,pmid,ti,ab,year,punchline_text,population,interventions,outcomes,population_mesh,interventions_mesh,outcomes_mesh,num_randomized,prob_low_rob,punchline_text,authors,journal,dois 0,32354652,Prospective randomized study to evaluate the efficacy and tolerability of Ectoin® containing Eye Spray (EES09) and comparison to the liposomal Eye Spray Tears Again® (TA) in the treatment of dry eye disease.,"PURPOSE To subjectively and objectively evaluate the efficacy and tolerability of preservative-free Ectoin ® Eye Spray - Colloidal (EES09) and Tears Again ® Eye Spray (TA) in subjects with mild-moderate dry eye disease (DED), and to compare efficacy of these two eye sprays with each other. METHODS Thirty-six volunteers (average age 32.3 ± 16.1 years; 26 females) were successfully recruited for this prospective double-blind study with between-subject design and randomly divided into two groups (gender and age balanced): Group A received EES09 and Group B received TA during the treatment phase. Inclusioncriteria were a minimum age of 18 years, a score of 18.0 or higher on the OSDI questionnaire, and a non-invasive tear break up time (NIKBUT, Oculus Keratograph M5, Oculus, Germany) of no more than 10s in at least one eye. The objective variables NIKBUT, conjunctival redness, lipid layer and osmolarity (TearLab Cooperation, USA) were assessed at baseline, 10 min. after spray application and after a treatment phase of 10±3 days (3x applications daily). Symptoms, tolerance and handling were evaluated with the OSDI and VAS questionnaires. RESULTS A statistically significant increase in NIKBUT and improvement in DED symptoms were obtained for the overall group (mean NIKBUT 7.7 ± 1.7s vs. 11.6 ± 4.6s, p<0.001; mean OSDI score: 36.1 ± 12.7 vs. 20. 7± 12.7, p<0.001) during course of treatment. No statistically significant effect was established for the variables lipid layer (p = 0.406), conjunctival redness (p = 0.766) and osmolarity (p = 0.378). No statistically significant differences were observed between the groups, for any variable. The noninferioritycriterion for EES09 towards TA could be shown for the scores of the dry eye symptoms via VAS questionnaire and the variable NIKBUT. CONCLUSIONS A beneficial treatment effect was confirmed for both, symptoms of DED and the objective variable NIKBUT. Both eye sprays were rated favourably in view of perceived tolerability and handling of the spray bottle.",2021,"No statistically significant effect was established for the variables lipid layer (p = 0.406), conjunctival redness (p = 0.766) and osmolarity (p = 0.378).","['Thirty-six volunteers (average age 32.3 ± 16.1 years; 26 females', 'subjects with mild-moderate dry eye disease (DED']","['preservative-free Ectoin ® Eye Spray - Colloidal (EES09) and Tears Again ® Eye Spray (TA', 'Ectoin® containing Eye Spray (EES09', 'liposomal Eye Spray Tears', 'EES09 and Group B received TA', 'Again® (TA']","['variables lipid layer', 'conjunctival redness', 'DED symptoms', 'Symptoms, tolerance and handling', 'efficacy and tolerability', 'OSDI and VAS questionnaires', 'OSDI questionnaire, and a non-invasive tear break up time (NIKBUT, Oculus Keratograph M5, Oculus, Germany', 'conjunctival redness, lipid layer and osmolarity (TearLab Cooperation, USA']","[{'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319689', 'cui_str': '16.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}]","[{'cui': 'C0033086', 'cui_str': 'Drug preservative'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0164311', 'cui_str': 'ectoine'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1761613', 'cui_str': 'Conjunctival hyperemia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0029387', 'cui_str': 'Osmolarity'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]",36.0,0.0518135,"No statistically significant effect was established for the variables lipid layer (p = 0.406), conjunctival redness (p = 0.766) and osmolarity (p = 0.378).","[{'ForeName': 'Daniela S', 'Initials': 'DS', 'LastName': 'Nosch', 'Affiliation': 'University of Applied Sciences (FHNW), Institute of Optometry, Olten, Switzerland. Electronic address: daniela.nosch@fhnw.ch.'}, {'ForeName': 'Roland E', 'Initials': 'RE', 'LastName': 'Joos', 'Affiliation': 'University of Applied Sciences (FHNW), Institute of Optometry, Olten, Switzerland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Job', 'Affiliation': 'University of Applied Sciences (FHNW), Institute of Optometry, Olten, Switzerland.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2020.04.003'] 1,32371165,Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials.,"BACKGROUND & AIMS Treatment of older patients (more than 60 years) with ulcerative colitis (UC) can be a challenge, because they might be more vulnerable to adverse events (AEs). We determined the effects of age on the safety and efficacy of anti-tumor necrosis factor (TNF) therapy in a pooled analysis of data from randomized trials. METHODS We obtained individual patient-level data from 4 trials of anti-TNF therapy for patients with UC from the Yale Open Data Access Project. Participants were assigned to groups of older age (60 years or older) and younger age (younger than 60 years). The primary outcome was difference in serious AEs (SAEs), defined as death, life-threatening event, hospitalization, and/or significant disability. Secondary outcomes were severe infections, non-severe infections, neoplasms, and achievement of clinical remission, defined by trial investigators as Mayo score ≤ 2 with no sub-score >1 at the end of induction or maintenance therapy. A random effects logistic regression model was fitted to estimate the effect of anti-TNF therapy on safety and efficacy by age, adjusting for confounders and trial-level effects. RESULTS The study cohort included 2257 patients (231 60 years or older). Higher proportions of older patients receiving anti-TNF therapy had SAEs (20%) and hospitalizations (14.4%), compared with younger patients (10.2% had SAEs and 5.2% were hospitalized); there were no significant differences between groups in proportions with severe or non-severe infections. Compared with placebo, there was no significant difference in safety risks associated with anti-TNF therapy (SAEs reduced by 5.4% in older patients vs reduction of 2.4% in younger patients; hospitalizations reduced by 6.7% in older patients vs reduction of 2.5% in younger patients; severe infections reduced by 3.1% vs increase of 0.7% in younger patients). There was no significant difference in between older vs younger patients in efficacy of anti-TNF therapy in inducing remission (odds risk ratio, 1.05, 95% CI, 0.33-3.39) or in maintaining remission (odds risk ratio, 0.49; 95% CI, 0.18-1.33). CONCLUSIONS In a pooled analysis of data from randomized trials, we found that older patients with UC have an increased baseline increased risk of SAEs, but no increase in risk can be attributed to anti-TNF therapy in older vs younger patients.",2021,"There was no significant difference in between older vs younger patients in efficacy of anti-TNF therapy in inducing remission (odds risk ratio, 1.05, 95% CI, 0.33-3.39) or in maintaining remission (odds risk ratio, 0.49; 95% CI, 0.18-1.33). ","['Participants were assigned to groups of older age (60 years or older) and younger age (younger than 60 years', 'Older Patients', 'patients with UC from the Yale Open Data Access Project', '2257 patients (231 60 years or older', 'older patients with UC', 'older patients (more than 60 years) with ulcerative colitis (UC', 'With Ulcerative Colitis']","['anti-TNF therapy', 'Tumor Necrosis Factor Antagonists', 'anti-tumor necrosis factor (TNF) therapy', 'placebo']","['proportions with severe or non-severe infections', 'severe infections, non-severe infections, neoplasms, and achievement of clinical remission, defined by trial investigators as Mayo score ≤ 2 with no sub-score >1 at the end of induction or maintenance therapy', 'severe infections', 'risk of SAEs', 'serious AEs (SAEs), defined as death, life-threatening event, hospitalization, and/or significant disability', 'safety and efficacy', 'safety risks associated with anti-TNF therapy (SAEs']","[{'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0231337', 'cui_str': 'Senility'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0439093', 'cui_str': '>'}]","[{'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3537192', 'cui_str': 'TNF Antagonists'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C4280965', 'cui_str': 'Greater than one'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",2257.0,0.224528,"There was no significant difference in between older vs younger patients in efficacy of anti-TNF therapy in inducing remission (odds risk ratio, 1.05, 95% CI, 0.33-3.39) or in maintaining remission (odds risk ratio, 0.49; 95% CI, 0.18-1.33). ","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cheng', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Massachusetts General Hospital, Division of Gastroenterology, Boston, Massachusetts.'}, {'ForeName': 'Kelly C', 'Initials': 'KC', 'LastName': 'Cushing', 'Affiliation': 'Massachusetts General Hospital, Division of Gastroenterology, Boston, Massachusetts; Harvard University, Boston, Massachusetts; University of Michigan, Division of Gastroenterology, Ann Arbor, Michigan.'}, {'ForeName': 'Tianxi', 'Initials': 'T', 'LastName': 'Cai', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Massachusetts General Hospital, Division of Gastroenterology, Boston, Massachusetts.'}, {'ForeName': 'Ashwin N', 'Initials': 'AN', 'LastName': 'Ananthakrishnan', 'Affiliation': 'Massachusetts General Hospital, Division of Gastroenterology, Boston, Massachusetts; Harvard University, Boston, Massachusetts. Electronic address: aananthakrishnan@mgh.harvard.edu.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2020.04.070'] 2,32359348,Comparison of ED95 of Butorphanol and Sufentanil for gastrointestinal endoscopy sedation: a randomized controlled trial.,"BACKGROUND Butorphanol, a synthetic opioid partial agonist analgesic, has been widely used to control perioperative pain. However, the ideal dose and availability of butorphanol for gastrointestinal (GI) endoscopy are not well known. The aim of this study was to evaluated the 95% effective dose (ED 95 ) of butorphanol and sufentanil in GI endoscopy and compared their clinical efficacy, especially regarding the recovery time. METHODS The study was divided into two parts. For the first part, voluntary patients who needed GI endoscopy anesthesia were recruited to measure the ED 95 of butorphanol and sufentanil needed to achieve successful sedation before GI endoscopy using the sequential method (the Dixon up-and-down method). The second part was a double-blind, randomized study. Two hundred cases of painless GI endoscopy patients were randomly divided into two groups (n = 100), including group B (butorphanol at the ED 95 dose) and group S (sufentanil at the ED 95 dose). Propofol was infused intravenously as the sedative in both groups. The recovery time, visual analogue scale (VAS) score, hand grip strength, fatigue severity scores, incidence of nausea and vomiting, and incidence of dizziness were recorded. RESULTS The ED 95 of butorphanol for painless GI endoscopy was 9.07 μg/kg (95% confidence interval: 7.81-19.66 μg/kg). The ED 95 of sufentanil was 0.1 μg/kg (95% CI, 0.079-0.422 μg/kg). Both butorphanol and sufentanil provided a good analgesic effect for GI endoscopy. However, the recovery time for butorphanol was significantly shorter than that for sufentanil (P < 0.05, group B vs. group S:21.26 ± 7.70 vs. 24.03 ± 7.80 min). CONCLUSIONS Butorphanol at 9.07 μg/kg was more effective than sufentanil for GI endoscopy sedation and notably reduced the recovery time. TRIAL REGISTRATION Chinese Clinical Trail Registry (Registration number # ChiCTR1900022780; Date of Registration on April 25rd, 2019).",2020,"The recovery time, visual analogue scale (VAS) score, hand grip strength, fatigue severity scores, incidence of nausea and vomiting, and incidence of dizziness were recorded. ","['Two hundred cases of painless', 'voluntary patients who needed GI endoscopy anesthesia', 'GI endoscopy patients', 'gastrointestinal endoscopy sedation']","['butorphanol', 'butorphanol and sufentanil', 'Butorphanol', 'ED95 of Butorphanol and Sufentanil', 'sufentanil', 'group B (butorphanol at the ED 95 dose) and group S (sufentanil', 'Propofol']","['recovery time', 'recovery time, visual analogue scale (VAS) score, hand grip strength, fatigue severity scores, incidence of nausea and vomiting, and incidence of dizziness', 'recovery time for butorphanol', 'GI endoscopy']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0234226', 'cui_str': 'Painless'}, {'cui': 'C0580276', 'cui_str': 'Informal patient'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0079278', 'cui_str': 'Gastrointestinal tract endoscopy'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}]","[{'cui': 'C0006491', 'cui_str': 'Butorphanol'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0441853', 'cui_str': 'Group S'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0006491', 'cui_str': 'Butorphanol'}, {'cui': 'C0079278', 'cui_str': 'Gastrointestinal tract endoscopy'}]",,0.25203,"The recovery time, visual analogue scale (VAS) score, hand grip strength, fatigue severity scores, incidence of nausea and vomiting, and incidence of dizziness were recorded. ","[{'ForeName': 'Xiaona', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, Wenzhou Medical University, Shangcai village, Nanbaixiang town, Ouhai District, Wenzhou City, 325000, Zhejiang Province, China.'}, {'ForeName': 'Limei', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, Wenzhou Medical University, Shangcai village, Nanbaixiang town, Ouhai District, Wenzhou City, 325000, Zhejiang Province, China.'}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Zheng', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, Wenzhou Medical University, Shangcai village, Nanbaixiang town, Ouhai District, Wenzhou City, 325000, Zhejiang Province, China.'}, {'ForeName': 'Linmin', 'Initials': 'L', 'LastName': 'Pan', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, Wenzhou Medical University, Shangcai village, Nanbaixiang town, Ouhai District, Wenzhou City, 325000, Zhejiang Province, China. panlinmina@163.com.'}]",BMC anesthesiology,['10.1186/s12871-020-01027-5'] 3,32359367,"Intraoperative dexmedetomidine attenuates norepinephrine levels in patients undergoing transsphenoidal surgery: a randomized, placebo-controlled trial.","BACKGROUND Dexmedetomidine has sympatholytic effects. We investigated whether dexmedetomidine could attenuate stress responses in patients undergoing endoscopic transnasal transseptal transsphenoidal surgery. METHODS Forty-six patients were randomized to receive a continuous infusion of 0.9% saline (n = 23) or dexmedetomidine (n = 23). Immediately after general anesthesia induction, the dexmedetomidine group received a loading dose of 1 mcg/kg dexmedetomidine over 10 min, followed by a maintenance dose of 0.2-0.7 mcg/kg/h and the control group received 0.9% saline at the same volume until 30 min before the end of surgery. Serum levels of epinephrine, norepinephrine, and glucose were assessed before surgery (T1) and the end of drug infusion (T2). The primary outcome was the change in norepinephrine levels between the two time points. RESULTS Changes (T2-T1 values) in perioperative serum norepinephrine levels were significantly greater in the dexmedetomidine group than in the control group (median difference, 56.9 pg/dL; 95% confidence interval, 20.7 to 83.8 pg/dL; P = 0.002). However, epinephrine level changes did not show significant intergroup differences (P = 0.208). Significantly fewer patients in the dexmedetomidine group than in the control group required rescue analgesics at the recovery area (4.3% vs. 30.4%, P = 0.047). CONCLUSIONS Intraoperative dexmedetomidine administration reduced norepinephrine release and rescue analgesic requirement. Dexmedetomidine might be used as an anesthetic adjuvant in patients undergoing transnasal transseptal transsphenoidal surgery. TRIAL REGISTRATION Clinical Trial Registry of Korea, identifier: KCT0003366; registration date: 21/11/2018; presenting author: Ji Seon Jeong.",2020,"Significantly fewer patients in the dexmedetomidine group than in the control group required rescue analgesics at the recovery area (4.3% vs. 30.4%, P = 0.047). ","['patients undergoing transnasal transseptal transsphenoidal surgery', 'Forty-six patients', 'patients undergoing endoscopic transnasal transseptal transsphenoidal surgery', 'patients undergoing transsphenoidal surgery']","['Dexmedetomidine', 'control group received 0.9% saline', 'Intraoperative dexmedetomidine', 'continuous infusion of 0.9% saline', 'dexmedetomidine', 'placebo']","['Serum levels of epinephrine, norepinephrine, and glucose', 'change in norepinephrine levels', 'perioperative serum norepinephrine levels', 'stress responses', 'norepinephrine levels', 'norepinephrine release and rescue analgesic requirement', 'rescue analgesics']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521131', 'cui_str': 'Transnasal approach'}, {'cui': 'C0442381', 'cui_str': 'Transseptal nasal approach'}, {'cui': 'C0205508', 'cui_str': 'Transsphenoidal approach'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1275471', 'cui_str': 'Serum norepinephrine measurement'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}]",46.0,0.659728,"Significantly fewer patients in the dexmedetomidine group than in the control group required rescue analgesics at the recovery area (4.3% vs. 30.4%, P = 0.047). ","[{'ForeName': 'RyungA', 'Initials': 'R', 'LastName': 'Kang', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon ro, Gangnam gu, Seoul, 06351, South Korea.'}, {'ForeName': 'Ji Seon', 'Initials': 'JS', 'LastName': 'Jeong', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon ro, Gangnam gu, Seoul, 06351, South Korea. jiseon78.jeong@samsung.com.'}, {'ForeName': 'Justin Sangwook', 'Initials': 'JS', 'LastName': 'Ko', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon ro, Gangnam gu, Seoul, 06351, South Korea.'}, {'ForeName': 'Soo-Youn', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jong Hwan', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon ro, Gangnam gu, Seoul, 06351, South Korea.'}, {'ForeName': 'Soo Joo', 'Initials': 'SJ', 'LastName': 'Choi', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon ro, Gangnam gu, Seoul, 06351, South Korea.'}, {'ForeName': 'Sungrok', 'Initials': 'S', 'LastName': 'Cha', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon ro, Gangnam gu, Seoul, 06351, South Korea.'}, {'ForeName': 'Jeong Jin', 'Initials': 'JJ', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon ro, Gangnam gu, Seoul, 06351, South Korea.'}]",BMC anesthesiology,['10.1186/s12871-020-01025-7'] 4,32363529,Linked Color Imaging Can Improve Detection Rate of Early Gastric Cancer in a High-Risk Population: A Multi-Center Randomized Controlled Clinical Trial.,"BACKGROUND Early diagnosis of gastric cancer is difficult in China due to the lack of a valid method for endoscopic screening. Early gastric cancer, especially flat gastric cancer, lacks specific endoscopic features. Many cases appear to be similar to ordinary gastritis cases under normal white light endoscopy, which can lead to misdiagnosis. AIMS In order to find a new method to improve detection rate of early gastric cancer in China, we designed a trial to validate linked color imaging (LCI) for screening of early gastric cancer in a high-risk population, as compared to white light imaging (WLI). METHOD Subjects were randomly allocated to either the LCI + WLI or WLI group and then subjected to gastroscopy and all endoscopies were made after special preparation. All endoscopists had knowledge of this experiment. The main indicator was the rate of detection of gastric neoplastic lesions. The difference in the detection rate between the two groups is reported. RESULTS The detection rate was 4.31% in the WLI group and 8.01% in the LCI + WLI group. This is a difference of 3.70% with a P value < 0.001 and an OR (95% CI) of 1.934 (1.362, 2.746). The lower limit of the 95% CI was greater than 0, and the superiority margin was 1%. CONCLUSION The detection rate of gastric neoplastic lesions was higher in the LCI + WLI group than in the WLI group, LCI might be an effective method for screening early gastric cancer.",2021,"The detection rate of gastric neoplastic lesions was higher in the LCI + WLI group than in the WLI group, LCI might be an effective method for screening early gastric cancer.","['early gastric cancer in China', 'Subjects', 'Early Gastric Cancer in a High-Risk Population']","['color imaging (LCI', 'LCI\u2009+\u2009WLI or WLI']","['rate of detection of gastric neoplastic lesions', 'detection rate of gastric neoplastic lesions', 'detection rate']","[{'cui': 'C0349530', 'cui_str': 'Early gastric cancer'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0563228', 'cui_str': 'White light'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",,0.0497281,"The detection rate of gastric neoplastic lesions was higher in the LCI + WLI group than in the WLI group, LCI might be an effective method for screening early gastric cancer.","[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Gao', 'Affiliation': 'Department of Gastroenterology, Changhai Hospital, The Second Military University, Shanghai, China.'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.""}, {'ForeName': 'Qianqian', 'Initials': 'Q', 'LastName': 'Meng', 'Affiliation': 'Department of Gastroenterology, Changhai Hospital, The Second Military University, Shanghai, China.'}, {'ForeName': 'Hangbin', 'Initials': 'H', 'LastName': 'Jin', 'Affiliation': ""Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.""}, {'ForeName': 'Zhenhua', 'Initials': 'Z', 'LastName': 'Zhu', 'Affiliation': 'The First Affiliated Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Zhijie', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology, Changhai Hospital, The Second Military University, Shanghai, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Qian', 'Affiliation': 'Department of Gastroenterology, Changhai Hospital, The Second Military University, Shanghai, China.'}, {'ForeName': 'Luoman', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Gastroenterology, Changhai Hospital, The Second Military University, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Gastroenterology, The Fifth Medical Centre, Chinese PLA General Hospital (Former 307th Hospital of the PLA), Beijing, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Min', 'Affiliation': 'Department of Gastroenterology, The Fifth Medical Centre, Chinese PLA General Hospital (Former 307th Hospital of the PLA), Beijing, China.'}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Endoscopy Center, Shanxi Cancer Hospital, Taiyuan, China.'}, {'ForeName': 'Haihua', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Endoscopy Center, Shanxi Cancer Hospital, Taiyuan, China.'}, {'ForeName': 'Shutang', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': 'Jiangsu Province Hospital of TCM and Affiliated Hospital of Nanjing University of TCM, Nanjing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Xiao', 'Affiliation': 'Jiangsu Province Hospital of TCM and Affiliated Hospital of Nanjing University of TCM, Nanjing, China.'}, {'ForeName': 'Yalei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'The First Affiliated Hospital of Anhui Medical University, Hefei, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Han', 'Affiliation': 'The First Affiliated Hospital of Anhui Medical University, Hefei, China.'}, {'ForeName': 'Yapi', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, China.'}, {'ForeName': 'Shuntian', 'Initials': 'S', 'LastName': 'Cai', 'Affiliation': 'Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, China.'}, {'ForeName': 'Weiqing', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Ji', 'Affiliation': 'Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China.'}, {'ForeName': 'Xuhua', 'Initials': 'X', 'LastName': 'Xiao', 'Affiliation': 'Affiliated Hospital of Guilin Medical University, Guilin, China.'}, {'ForeName': 'Qinghua', 'Initials': 'Q', 'LastName': 'Zheng', 'Affiliation': 'Affiliated Hospital of Guilin Medical University, Guilin, China.'}, {'ForeName': 'Beiping', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Guangdong Provincial TCM Hospital, Guangzhou, China.'}, {'ForeName': 'Wenbin', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': 'Guangdong Provincial TCM Hospital, Guangzhou, China.'}, {'ForeName': 'Guanghui', 'Initials': 'G', 'LastName': 'Lian', 'Affiliation': 'Gastroenterology Department of Xiangya Hospital, CSU, Changsha, China.'}, {'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Gastroenterology Department of Xiangya Hospital, CSU, Changsha, China.'}, {'ForeName': 'Qiu', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'Zhongnan Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'Zhongnan Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Zhuang', 'Affiliation': ""Xi'an Central Hospital, Xi'an, China.""}, {'ForeName': 'Wangli', 'Initials': 'W', 'LastName': 'Si', 'Affiliation': ""Xi'an Central Hospital, Xi'an, China.""}, {'ForeName': 'Xingang', 'Initials': 'X', 'LastName': 'Shi', 'Affiliation': 'Department of Gastroenterology, Changhai Hospital, The Second Military University, Shanghai, China.'}, {'ForeName': 'Youxiang', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'The First Affiliated Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Zhaoshen', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology, Changhai Hospital, The Second Military University, Shanghai, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology, Changhai Hospital, The Second Military University, Shanghai, China. dongwang0901@sina.com.'}]",Digestive diseases and sciences,['10.1007/s10620-020-06289-0'] 5,32379303,Personalised Adherence Support for Maintenance Treatment of Inflammatory Bowel Disease: A Tailored Digital Intervention to Change Adherence-related Beliefs and Barriers.,"BACKGROUND AND AIMS Interventions to improve adherence to medication may be more effective if tailored to the individual, addressing adherence-related beliefs about treatment and overcoming practical barriers to daily use. We evaluated whether an algorithm, tailoring support to address perceptual and practical barriers to adherence, reduced barriers and was acceptable to patients with inflammatory bowel disease [IBD]. METHODS Participants with IBD, prescribed azathioprine and/or mesalazine, were recruited via patient groups, social media, and hospital clinics and allocated to Intervention or Control Groups. The online intervention comprised messages tailored to address beliefs about IBD and maintenance treatment and to provide advice on overcoming practical difficulties with taking regular medication. The content was personalised to address specific perceptual and practical barriers identified by a pre-screening tool. Validated questionnaires assessed barriers to adherence and related secondary outcomes at baseline and at 1 and 3 months of follow-up. RESULTS A total of 329 participants were allocated to the Intervention [n = 153] and Control [n = 176] Groups; just under half [46.2%] completed follow-up. At 1 and 3 months, the Intervention Group had significantly fewer concerns about IBD medication [p ≤0.01]; and at three months, fewer doubts about treatment necessity, fewer reported practical barriers, and higher reported adherence [p <0.05]. Relative to controls at follow-up, the Intervention Group were more satisfied with information about IBD medicines, and viewed pharmaceuticals in general more positively. Questionnaires, interviews, and intervention usage indicated that the intervention was acceptable. CONCLUSIONS Personalised adherence support using a digital algorithm can help patients overcome perceptual barriers [doubts about treatment necessity and medication concerns] and practical barriers to adherence.",2020,"At 1 and 3 months, the Intervention Group had significantly fewer concerns about IBD medication [p ≤0.01]; and at three months, fewer doubts about treatment necessity, fewer reported practical barriers, and higher reported adherence [p <0.05].","['329 participants were allocated to the Intervention [n = 153] and Control [n = 176', 'Inflammatory Bowel Disease', 'patients with inflammatory bowel disease [IBD', 'Participants with IBD, prescribed']","['azathioprine', 'mesalazine']",['concerns about IBD medication'],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}]","[{'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C0127615', 'cui_str': 'mesalamine'}]","[{'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",329.0,0.0254986,"At 1 and 3 months, the Intervention Group had significantly fewer concerns about IBD medication [p ≤0.01]; and at three months, fewer doubts about treatment necessity, fewer reported practical barriers, and higher reported adherence [p <0.05].","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Chapman', 'Affiliation': 'UCL School of Pharmacy, Centre for Behavioural Medicine, London, UK.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Sibelli', 'Affiliation': 'UCL School of Pharmacy, Centre for Behavioural Medicine, London, UK.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'St-Clair Jones', 'Affiliation': 'Brighton and Sussex University Hospitals NHS Trust, Royal Sussex County Hospital, Pharmacy Department, Brighton, UK.'}, {'ForeName': 'Alastair', 'Initials': 'A', 'LastName': 'Forbes', 'Affiliation': 'Institute for Digestive Diseases, University College London, London, UK.'}, {'ForeName': 'Angel', 'Initials': 'A', 'LastName': 'Chater', 'Affiliation': 'UCL School of Pharmacy, Centre for Behavioural Medicine, London, UK.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Horne', 'Affiliation': 'UCL School of Pharmacy, Centre for Behavioural Medicine, London, UK.'}]",Journal of Crohn's & colitis,['10.1093/ecco-jcc/jjz034'] 6,32361875,Superior early and long-term continence following early micturition on day 2 after robot-assisted radical prostatectomy: a randomized prospective trial.,"PURPOSE To elucidate early and long-term continence and patient comfort depending on type and duration of catheterization after robot-assisted radical prostatectomy. METHODS 198 patients were randomized prospectively into three groups (May 2016-July 2017): A transurethral catheter with micturition on postoperative day (POD) 5 was placed in the control group (TD5); a suprapubic tube (SPT) with micturition on POD 5 was placed in the group SD5 or with micturition on POD 2 in group SD2, respectively. Questionnaires were used for catheter-related satisfaction. Functional outcome analysis included residual volume analysis, uroflowmetry, IPSS, 12-h pad test, and daily pad use. Follow-up was conducted up to 12 months. RESULTS Postoperative comfort and catheter-related complications were similar in the three groups. However, on the day of catheter removal, continence was significantly better in the 12-h pad test for the SD2 group with 14 ml vs. 30 ml (TD5) and 24 ml (SD5), p = 0.007. Median residual urine volume between the groups was comparable with 17 ml in TD5, 7 ml in SD5, and 11 ml in SD2, (p = 0.07). Postoperative IPSS did not differ significantly in the follow-up period. After 4 weeks, 63% of the patients in SD2 were continent (no pad/day) compared to 33% in TD5 and 41% in SD5, p = 0.004. After 12 months, 76% were continent in TD5, 87% in SD5, and 94% in SD2, p = 0.023. CONCLUSIONS Early micturition after SPT placement in robotic radical prostatectomy seems to be beneficial without an increased risk of complications.",2021,Early micturition after SPT placement in robotic radical prostatectomy seems to be beneficial without an increased risk of complications.,['198 patients were randomized prospectively into three groups (May 2016-July 2017'],"['robot-assisted radical prostatectomy', 'catheterization after robot-assisted radical prostatectomy']","['catheter removal, continence', 'residual volume analysis, uroflowmetry, IPSS, 12-h pad test, and daily pad use', 'Postoperative comfort and catheter-related complications', 'risk of complications', 'Postoperative IPSS', 'Median residual urine volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}]","[{'cui': 'C0394884', 'cui_str': 'Removal of catheter'}, {'cui': 'C0035190', 'cui_str': 'Residual respiratory volume'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0200008', 'cui_str': 'Uroflowmetry'}, {'cui': 'C1504431', 'cui_str': 'Idiopathic pneumonia syndrome'}, {'cui': 'C0332568', 'cui_str': 'Pad'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0948806', 'cui_str': 'Catheter related complication'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0429774', 'cui_str': 'Residual urine volume'}]",198.0,0.0340462,Early micturition after SPT placement in robotic radical prostatectomy seems to be beneficial without an increased risk of complications.,"[{'ForeName': 'Nina Natascha', 'Initials': 'NN', 'LastName': 'Harke', 'Affiliation': 'Department of Urology, Pediatric Urology and Urologic Oncology, Prostate Center Northwest, St. Antonius Hospital, Moellenweg 22, 48599, Gronau, Germany. harkenina@gmail.com.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Wagner', 'Affiliation': 'Department of Urology, Pediatric Urology and Urologic Oncology, Prostate Center Northwest, St. Antonius Hospital, Moellenweg 22, 48599, Gronau, Germany.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Liakos', 'Affiliation': 'Department of Urology, Pediatric Urology and Urologic Oncology, Prostate Center Northwest, St. Antonius Hospital, Moellenweg 22, 48599, Gronau, Germany.'}, {'ForeName': 'Katarina', 'Initials': 'K', 'LastName': 'Urbanova', 'Affiliation': 'Department of Urology, Pediatric Urology and Urologic Oncology, Prostate Center Northwest, St. Antonius Hospital, Moellenweg 22, 48599, Gronau, Germany.'}, {'ForeName': 'Mustapha', 'Initials': 'M', 'LastName': 'Addali', 'Affiliation': 'Department of Urology, Pediatric Urology and Urologic Oncology, Prostate Center Northwest, St. Antonius Hospital, Moellenweg 22, 48599, Gronau, Germany.'}, {'ForeName': 'Boris A', 'Initials': 'BA', 'LastName': 'Hadaschik', 'Affiliation': 'Department of Urology, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Jorn H', 'Initials': 'JH', 'LastName': 'Witt', 'Affiliation': 'Department of Urology, Pediatric Urology and Urologic Oncology, Prostate Center Northwest, St. Antonius Hospital, Moellenweg 22, 48599, Gronau, Germany.'}]",World journal of urology,['10.1007/s00345-020-03225-9'] 7,32370612,Effectiveness of a crossover prosthetic foot in active children with a congenital lower limb deficiency: an explorative study.,"BACKGROUND Children with lower limb prostheses cannot always keep up with their peers during active play. A pediatric crossover foot may be a promising prosthetic alternative for children engaging in high-intensity movements necessary for active play. OBJECTIVES To compare children's walking performance, running performance, experienced competence, and cosmesis using their prescribed prosthesis compared with the crossover foot. STUDY DESIGN Pretest-posttest study. METHODS Children with lower limb amputation or deficiency were recruited. Measurements were taken at baseline with the prescribed prosthesis and 6 weeks later with the crossover foot. Walking speed, energy cost of walking, anaerobic muscle power, stair climbing speed, ankle power, and cosmesis were evaluated. RESULTS Four children participated in the study. Two children had increased walking speed with the same energy cost, one child had decreased speed with increased energy cost, and one child had the same speed with decreased energy cost. Muscle power increased for three of the four children and ankle power increased for all children while using the crossover foot compared to the prescribed prosthesis. Two children reported knee pain or feeling excessive knee flexion when running with the crossover foot. One child reported negative feelings toward cosmesis of the crossover foot. CONCLUSIONS This study suggests crossover foot may benefit active children by improving walking and running performance, and decreasing energy cost. However, knee pain reports or negative feelings toward the atypical design suggest the crossover foot may not be ideal for every child. Further research is needed to determine which pediatric users would benefit from this type of prosthetic foot. CLINICAL RELEVANCE Children with lower limb deficiencies are active prosthetic users who often switch between low- and high-intensity movements in their daily activities. Therefore, they might benefit from a crossover prosthetic design. The preliminary findings of this study suggest the crossover foot (XF) may be a promising foot for active children.",2020,Muscle power increased for three of the four children and ankle power increased for all children while using the crossover foot compared to the prescribed prosthesis.,"['Children with lower limb amputation or deficiency were recruited', 'active children with a congenital lower limb deficiency', 'Children with lower limb deficiencies', 'Children with lower limb prostheses', 'Four children participated in the study']",[],"['Muscle power', 'energy cost', 'Walking speed, energy cost of walking, anaerobic muscle power, stair climbing speed, ankle power, and cosmesis', 'ankle power', 'knee pain or feeling excessive knee flexion', 'walking speed', ""children's walking performance, running performance, experienced competence, and cosmesis""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0337308', 'cui_str': 'Amputation of lower limb'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009678', 'cui_str': 'congenital'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0524491', 'cui_str': 'Leg prosthesis'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C1290942', 'cui_str': 'Climbing stairs'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0442802', 'cui_str': 'Excessive'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0086035', 'cui_str': 'Competence'}]",2.0,0.0342065,Muscle power increased for three of the four children and ankle power increased for all children while using the crossover foot compared to the prescribed prosthesis.,"[{'ForeName': 'Floor Jacoba Marie-Georgette', 'Initials': 'FJM', 'LastName': 'Verheul', 'Affiliation': 'Pediatric Department, De Hoogstraat Revalidatie, Utrecht, The Netherlands.'}, {'ForeName': 'Olaf', 'Initials': 'O', 'LastName': 'Verschuren', 'Affiliation': 'Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center, University Medical Center Utrecht, The Netherlands.'}, {'ForeName': 'Maremka', 'Initials': 'M', 'LastName': 'Zwinkels', 'Affiliation': 'Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center, University Medical Center Utrecht, The Netherlands.'}, {'ForeName': 'Mariska', 'Initials': 'M', 'LastName': 'Herwegh', 'Affiliation': 'Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center, University Medical Center Utrecht, The Netherlands.'}, {'ForeName': 'Anka', 'Initials': 'A', 'LastName': 'Michielsen', 'Affiliation': 'Pediatric Department, De Hoogstraat Revalidatie, Utrecht, The Netherlands.'}, {'ForeName': 'Marieke', 'Initials': 'M', 'LastName': 'de Haan', 'Affiliation': 'Pediatric Department, De Hoogstraat Revalidatie, Utrecht, The Netherlands.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'van Wijk', 'Affiliation': 'Pediatric Department, De Hoogstraat Revalidatie, Utrecht, The Netherlands.'}]",Prosthetics and orthotics international,['10.1177/0309364620912063'] 8,32383352,Phase I Single-Blinded Randomized Controlled Trial Comparing Balance and Aerobic Training in Degenerative Cerebellar Disease.,"INTRODUCTION Primary deficits in individuals with cerebellar degeneration include ataxia, unstable gait, and incoordination. Balance training is routinely recommended to improve function whereas little is known regarding aerobic training. OBJECTIVE To determine the feasibility of conducting a randomized trial comparing balance and aerobic training in individuals with cerebellar degeneration. DESIGN Assessor blinded randomized control phase I trial. SETTING Assessments in medical center, home training. PARTICIPANTS Twenty participants with cerebellar degeneration were randomized to home balance or aerobic training. INTERVENTION Aerobic training consisted of 4 weeks of stationary bicycle training, five times per week for 30-minute sessions. Home balance training consisted of performing the same duration of easy, moderate, and/or hard exercises. OUTCOME MEASURES Scale for the Assessment and Rating of Ataxia (SARA), maximal oxygen consumption (VO 2 max), Dynamic Gait Index, Timed Up and Go, gait speed. RESULTS All 20 participants completed assigned training with no major adverse events. Seven of each group attained target training duration, frequency, and intensity. Although both groups had significant improvements in ataxia severity, balance, and gait measures, there were greater improvements in individuals who performed aerobic training in ataxia severity and maximal oxygen consumption when compared to balance training. The effect size for these outcome measures was determined to be large, indicating a phase II trial comparing the benefits of aerobic and balance training was feasible and required 26 participants per group. Improvements in SARA score and VO 2 max remained in the aerobic training group at 3 months posttraining, but these improvements were trending back to baseline. In contrast, all balance group measures for pretraining and 3 months posttraining were statistically similar. CONCLUSIONS A phase II trial comparing balance and aerobic training in individuals with cerebellar degeneration is feasible. Benefits trended back toward baseline after training stopped, although benefits of longer duration exercise programs still need to be determined.",2021,"Improvements in SARA score and VO 2 max remained in the aerobic training group at 3 mo post-training, but these improvements were trending back to baseline.","['Assessments in medical center, home-training', 'individuals with cerebellar degeneration', 'individuals with cerebellar degeneration is feasible', 'individuals with cerebellar degeneration include ataxia, unstable gait, and incoordination', '20 participants with cerebellar degeneration', 'Degenerative Cerebellar Disease']","['Aerobic training consisted of four-weeks of stationary bicycle training', 'aerobic and balance training', 'Balance training', 'aerobic training', 'home balance or aerobic training', 'Balance and Aerobic Training', 'balance and aerobic training']","['SARA score and VO 2 max', 'Scale for the Assessment and Rating of Ataxia (SARA), maximal oxygen consumption (VO2max), Dynamic Gait Index (DGI), Timed up and Go (TUG), gait speed', 'ataxia severity and maximal oxygen consumption', 'ataxia severity, balance, and gait measures']","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0262404', 'cui_str': 'Cerebellar degeneration'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0004134', 'cui_str': 'Ataxia'}, {'cui': 'C0231686', 'cui_str': 'Unsteady gait'}, {'cui': 'C0520966', 'cui_str': 'Incoordination'}, {'cui': 'C0011164', 'cui_str': 'Degeneration'}, {'cui': 'C0007760', 'cui_str': 'Cerebellar disorder'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0392218', 'cui_str': 'Bicycle exerciser'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C4760258', 'cui_str': 'Ataxia assessment scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C2919794', 'cui_str': 'Dynamic gait index'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0004134', 'cui_str': 'Ataxia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",20.0,0.0295574,"Improvements in SARA score and VO 2 max remained in the aerobic training group at 3 mo post-training, but these improvements were trending back to baseline.","[{'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Barbuto', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Martelli', 'Affiliation': 'Department of Engineering, Columbia University, New York, NY, USA.'}, {'ForeName': 'Omofuma', 'Initials': 'O', 'LastName': 'Isirame', 'Affiliation': 'Department of Engineering, Columbia University, New York, NY, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Bishop', 'Affiliation': 'Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Sheng-Han', 'Initials': 'SH', 'LastName': 'Kuo', 'Affiliation': 'Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Agrawal', 'Affiliation': 'Department of Engineering, Columbia University, New York, NY, USA.'}, {'ForeName': 'Seonjoo', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Biostatistics, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': ""O'Dell"", 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Stein', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.'}]","PM & R : the journal of injury, function, and rehabilitation",['10.1002/pmrj.12401'] 9,32385765,"In shoulder adhesive capsulitis, ultrasound-guided anterior hydrodilatation in rotator interval is more effective than posterior approach: a randomized controlled study.","Shoulder adhesive capsulitis, also called frozen shoulder, is a musculoskeletal disorder associated with pain and functional disability. This study aimed to compare the effectiveness of shoulder ultrasound-guided hydrodilatation with corticosteroid, via rotator interval (RI) anteriorly, versus posterior approach, in adhesive capsulitis patients. All patients received exercise program following injection. PATIENTS AND METHODS A prospective randomized controlled study among 60 consecutive adhesive capsulitis patients was randomized into two equal groups. Group I received ultrasound-guided hydrodilatation with corticosteroid, saline, and local anesthetic via posterior intra-articular approach; group II received the same ultrasound-guided hydrodilatation via anterior rotator interval approach. Both groups received guided stretching exercises for 3 months after injection. Baseline and 3 months evaluation of pain by visual analogue scale (VAS), shoulder pain and disability index (SPADI), and range of motion (ROM) had been recorded for all patients. RESULTS Both groups showed significant improvement 3 months after hydrodilatation regarding VAS pain, external rotation, and SPADI. Only in group II (RI anterior approach) improvement was observed regarding flexion and abduction. There was no improvement regarding extension or internal rotation in either group. When comparing the improvement in both groups after hydrodilatation, group II (anterior approach) showed a statistically significant higher level of improvement regarding VAS pain (p = 0.003), SPADI, flexion, abduction, and external rotation, compared to group I (p < 0.001). Extension, internal rotation, and adduction were not different. CONCLUSIONS Ultrasound-guided anterior rotator interval hydrodilatation for adhesive capsulitis, followed by guided exercise, is clinically and functionally more effective than the conventional posterior approach.",2020,There was no improvement regarding extension or internal rotation in either group.,"['60 consecutive adhesive capsulitis patients', 'adhesive capsulitis patients']","['guided stretching exercises', 'exercise program following injection', 'ultrasound-guided hydrodilatation with corticosteroid, saline, and local anesthetic via posterior intra-articular approach; group II received the same ultrasound-guided hydrodilatation via anterior rotator interval approach', 'shoulder ultrasound-guided hydrodilatation with corticosteroid, via rotator interval (RI) anteriorly, versus posterior approach']","['SPADI, flexion, abduction, and external rotation', 'flexion and abduction', 'VAS pain, external rotation, and SPADI', 'pain by visual analogue scale (VAS), shoulder pain and disability index (SPADI), and range of motion (ROM', 'Extension, internal rotation, and adduction', 'extension or internal rotation', 'VAS pain']","[{'cui': 'C0158300', 'cui_str': 'Capsulitis, Adhesive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0442108', 'cui_str': 'Intra-articular'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0205512', 'cui_str': 'Posterior approach'}]","[{'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0086505', 'cui_str': 'Kidnapping'}, {'cui': 'C0231462', 'cui_str': 'External rotation'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0231459', 'cui_str': 'Internal rotation'}, {'cui': 'C0231457', 'cui_str': 'Adduction'}]",60.0,0.0893016,There was no improvement regarding extension or internal rotation in either group.,"[{'ForeName': 'Basant', 'Initials': 'B', 'LastName': 'Elnady', 'Affiliation': 'Department of Rheumatology, Rehabilitation and Physical Medicine, Benha University, Benha, Egypt.'}, {'ForeName': 'Elsayed M', 'Initials': 'EM', 'LastName': 'Rageh', 'Affiliation': 'Department of Rheumatology, Rehabilitation and Physical Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Manal Shawky', 'Initials': 'MS', 'LastName': 'Hussein', 'Affiliation': 'Department of Rheumatology, Rehabilitation and Physical Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Mohammed Hassan', 'Initials': 'MH', 'LastName': 'Abu-Zaid', 'Affiliation': 'Department of Rheumatology, Rehabilitation and Physical Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Dalia El-Sayed', 'Initials': 'DE', 'LastName': 'Desouky', 'Affiliation': 'Department of public health and community medicine, Menoufia University, Shibin Al Kawm, Egypt.'}, {'ForeName': 'Tohamy', 'Initials': 'T', 'LastName': 'Ekhouly', 'Affiliation': 'Department of Radiology, Benha University, Benha, Egypt.'}, {'ForeName': 'Johannes J', 'Initials': 'JJ', 'LastName': 'Rasker', 'Affiliation': 'Faculty of Behavioral, Management and Social sciences, Department Psychology, Health and Technology, University of Twente, PO box 217, 7500 AE, Enschede, Netherlands. j.j.rasker@utwente.nl.'}]",Clinical rheumatology,['10.1007/s10067-020-05131-2'] 10,32380954,Correlation and variation of cuff inflating volumes and pressures in different adult models of laryngeal mask: a prospective randomized trial.,"BACKGROUND Hyperinflation of laryngeal mask cuffs may carry the risk of airway complications. The manufacturer recommends inflating cuff until the intracuff pressure reaches 60 cmH 2 O, or inflate with the volume of air to not exceed the maximum recommended volume. We prospectively assessed the correlation of cuff inflating volumes and pressures, and the appropriated the cuff inflating volumes to generate an intracuff pressure of 60 cmH 2 O in the adult laryngeal masks from different manufacturers. METHODS Two groups of 80 patients requiring laryngeal mask size 3 and 4 during general anesthesia were randomized into 4 subgroups for each size of the laryngeal mask: Soft Seal® (Portex®), AuraOnce™ (Ambu®), LMA-Classic™ (Teleflex®) and LMA-ProSeal™ (Teleflex®). After insertion, the cuff was inflated with 5-ml increments of air up to the maximum recommended volume. After each 5-ml intracuff pressure was measured, the volume of air that generated the intracuff pressure of 60 cmH 2 O was recorded. RESULTS Mean (SD) volume of air required to achieve the intracuff pressure of 60 cmH 2 O in Soft Seal®, AuraOnce™, LMA-Classic™, LMA-ProSeal™ laryngeal mask size 3 were 11.80(1.88), 9.20(1.88), 8.95(1.50) and 13.50(2.48) ml, respectively, and these volumes in laryngeal mask size 4 were 14.45(4.12), 12.55(1.85), 11.30(1.95) and 18.20(3.47) ml, respectively. The maximum recommended volume resulted in high intracuff pressures (> 60 cmH 2 O) in all laryngeal mask types and sizes studied. CONCLUSION Pressure-volume curves of adult laryngeal masks are all in sigmoidal shape. Cuff designs and materials can effect pressure and volume correlation. Approximately half of the maximum recommended volume is required to achieve the intracuff pressure of 60 cmH 2 O except LMA-ProSeal™ which required two-thirds of the maximum recommended volume. TRIAL REGISTRATION Thai Clinical Trials Registry, TCTR20150602001, May 28, 2015.",2020,"The maximum recommended volume resulted in high intracuff pressures (> 60 cmH 2 O) in all laryngeal mask types and sizes studied. CONCLUSION Pressure-volume curves of adult laryngeal masks are all in sigmoidal shape.","['different adult models of laryngeal mask', 'Two groups of 80 patients requiring laryngeal mask size 3 and 4 during general anesthesia']","['laryngeal mask: Soft Seal® (Portex®), AuraOnce™ (Ambu®), LMA-Classic™ (Teleflex®) and LMA-ProSeal™ (Teleflex®']",['Mean (SD) volume of air required to achieve the intracuff pressure'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}, {'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0439658', 'cui_str': 'Classic'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",,0.0560544,"The maximum recommended volume resulted in high intracuff pressures (> 60 cmH 2 O) in all laryngeal mask types and sizes studied. CONCLUSION Pressure-volume curves of adult laryngeal masks are all in sigmoidal shape.","[{'ForeName': 'Narut', 'Initials': 'N', 'LastName': 'Ruananukun', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Rajchathewi, Bangkok, 10400, Thailand. aek_narut@hotmail.com.'}, {'ForeName': 'Jittiya', 'Initials': 'J', 'LastName': 'Watcharotayangul', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Rajchathewi, Bangkok, 10400, Thailand.'}, {'ForeName': 'Suchaya', 'Initials': 'S', 'LastName': 'Jeeranukosol', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Rajchathewi, Bangkok, 10400, Thailand.'}, {'ForeName': 'Rojnarin', 'Initials': 'R', 'LastName': 'Komonhirun', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Rajchathewi, Bangkok, 10400, Thailand.'}]",BMC anesthesiology,['10.1186/s12871-020-01028-4'] 11,32383634,Effects of Kinesiotape vs Soft and Semirigid Ankle Orthoses on Balance in Patients With Chronic Ankle Instability: A Randomized Controlled Trial.,"BACKGROUND Chronic ankle instability (CAI) is a frequent complication of ankle sprain that may be associated with long-term consequences. Although taping and bracing are common interventions that are widely used by clinicians and athletic trainers for patients with CAI, no studies have compared the effects of kinesiotaping and bracing on balance performance in these patients. The present study aimed to compare the effects of ankle kinesiotaping, a soft ankle orthosis, and a semirigid ankle orthosis on balance performance in patients with CAI. METHODS Sixty patients with CAI were randomly assigned to 4 groups that received kinesiotaping, a soft orthosis, a semirigid orthosis, or no treatment (control group). Dynamic and static balance were measured with the modified Star Excursion Balance Test, single leg hop test, and single leg stance test before and after a 4-week intervention period. RESULTS Significant between-group differences were seen in all evaluated outcomes ( P ≤ .003). The lowest reach distances in all directions in the modified Star Excursion Balance Test were found in the control group, and these patients also had a significantly shorter measured distance in the single leg hop test, and more errors in the single leg stance test compared with the 3 intervention groups. No significant differences were found among the 3 intervention groups. CONCLUSION Use of kinesiotaping and a soft or a semirigid ankle brace for 4 weeks were all beneficial in improving static and dynamic balance in individuals with CAI. None of the interventions was superior to the other 2. LEVEL OF EVIDENCE Level I, randomized controlled trial.",2020,"The lowest reach distances in all directions in the modified Star Excursion Balance Test were found in the control group, and these patients also had a significantly shorter measured distance in the single leg hop test, and more errors in the single leg stance test compared with the 3 intervention groups.","['individuals with CAI', 'patients with CAI', 'Patients With Chronic Ankle Instability', 'Sixty patients with CAI']","['kinesiotaping, a soft orthosis, a semirigid orthosis, or no treatment (control group', 'Kinesiotape vs Soft and Semirigid Ankle Orthoses']","['Dynamic and static balance', 'balance performance', 'static and dynamic balance']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3840097', 'cui_str': 'Chronic ankle instability'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4505491', 'cui_str': 'Kinesiotape'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",60.0,0.0598824,"The lowest reach distances in all directions in the modified Star Excursion Balance Test were found in the control group, and these patients also had a significantly shorter measured distance in the single leg hop test, and more errors in the single leg stance test compared with the 3 intervention groups.","[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Hadadi', 'Affiliation': 'Department of Orthotics and Prosthetics, School of Rehabilitation Sciences, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.'}, {'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Haghighat', 'Affiliation': 'Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Navid', 'Initials': 'N', 'LastName': 'Mohammadpour', 'Affiliation': 'Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Sobhan', 'Initials': 'S', 'LastName': 'Sobhani', 'Affiliation': 'Physical Therapy, School of Rehabilitation Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Foot & ankle international,['10.1177/1071100720917181'] 12,32380566,Randomized Trials of Retosiban Versus Placebo or Atosiban in Spontaneous Preterm Labor.,"OBJECTIVE The aim of this study is to assess the efficacy and safety of retosiban in spontaneous preterm labor (sPTL). STUDY DESIGN Two multicenter, randomized, and double-blind trials compared retosiban with placebo and retosiban with atosiban in women with a singleton pregnancy and intact membranes in sPTL at 24 to 33 6/7 weeks' gestation. Coprimary endpoints in the placebo-controlled trial were time to delivery (TTD) or treatment failure (whichever occurred first) and neonatal composite morbidity and mortality. The primary endpoint of the atosiban comparator trial was TTD. RESULTS The trials were terminated early because of slow recruitment. The placebo-controlled trial enrolled 23 participants (February 2016-July 2017; 2.6% of target);the atosiban-comparator trial enrolled 97 (March 2015-August 2017; 29% of target). Baseline participant characteristics were similar between treatments. In the placebo-controlled trial, mean gestational ages at randomization were 30.8 (retosiban, n  = 10) and 30.5 weeks (placebo, n  = 13), and mean times to delivery/treatment failure were 18.9 days (retosiban) and 11.1 days (placebo). Two and four neonates in the retosiban and placebo groups, respectively, had ≥1 component of the neonatal composite endpoint. In the atosiban-comparator trial, mean gestational age at randomization was 31.5 weeks (for both retosiban, n  = 47, and atosiban, n  = 50), and adjusted mean TTDs were 32.51 days (retosiban) and 33.71 days (atosiban; p  > 0.05). Adverse events were no more common with retosiban than placebo or atosiban. CONCLUSION Despite considerable efforts to conduct two adequate and well-controlled studies in patients with sPTL, both studies were unable to recruit effectively and consequently terminated prematurely. Key factors negatively affecting participation were patient and physician resistance to use of a placebo comparator, lack of investigator consensus on diagnostic criteria and acceptance of protocol procedures, and ethics committee decisions. Meaningful cooperation between pharmaceutical companies, regulatory authorities, and the obstetric community is essential for future development of drugs to treat sPTL.",2020,"Adverse events were no more common with retosiban than placebo or atosiban. ","[""women with a singleton pregnancy and intact membranes in sPTL at 24 to 33 6/7 weeks' gestation"", 'Spontaneous Preterm Labor', '23 participants (February 2016-July 2017; 2.6% of target);the atosiban-comparator trial enrolled 97 (March 2015-August 2017; 29% of target', 'patients with sPTL', 'spontaneous preterm labor (sPTL']","['retosiban', 'Retosiban Versus Placebo or Atosiban', 'retosiban with placebo and retosiban with atosiban', 'placebo']","['efficacy and safety', 'mean times to delivery/treatment failure', 'time to delivery (TTD) or treatment failure (whichever occurred first) and neonatal composite morbidity and mortality', 'Adverse events']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0426199', 'cui_str': 'Intact membranes'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0022876', 'cui_str': 'Premature labor'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4517633', 'cui_str': '2.6'}, {'cui': 'C0164398', 'cui_str': 'Atosiban'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0164398', 'cui_str': 'Atosiban'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",23.0,0.694512,"Adverse events were no more common with retosiban than placebo or atosiban. ","[{'ForeName': 'George', 'Initials': 'G', 'LastName': 'Saade', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Shennan', 'Affiliation': ""Department of Women and Children's Health, King's College London, St Thomas' Hospital, London, UK.""}, {'ForeName': 'Kathleen J', 'Initials': 'KJ', 'LastName': 'Beach', 'Affiliation': 'Department of Maternal and Fetal Medicine, GSK, Research Triangle Park, North Carolina.'}, {'ForeName': 'Eran', 'Initials': 'E', 'LastName': 'Hadar', 'Affiliation': 'Helen Schneider Hospital for Women, Rabin Medical Center, Petach-Tikva, Israel.'}, {'ForeName': 'Barbara V', 'Initials': 'BV', 'LastName': 'Parilla', 'Affiliation': 'Department of Obstetrics and Gynecology, Advocate Lutheran General Hospital, Park Ridge, Illinois.'}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Snidow', 'Affiliation': 'Alternative Discovery and Development, GSK, Research Triangle Park, North Carolina.'}, {'ForeName': 'Marcy', 'Initials': 'M', 'LastName': 'Powell', 'Affiliation': 'Central Safety Department, GSK, Research Triangle Park, North Carolina.'}, {'ForeName': 'Timothy H', 'Initials': 'TH', 'LastName': 'Montague', 'Affiliation': 'Clinical Statistics, Quantitative Sciences, GSK, Collegeville, Pennsylvania.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Clinical Statistics, Quantitative Sciences, GSK, Collegeville, Pennsylvania.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Komatsu', 'Affiliation': 'Maternal and Neonatal Health Unit, Alternative Discovery & Development, R&D, GSK, Research Triangle Park, North Carolina.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'McKain', 'Affiliation': 'Pharmacovigilance, PPD, Wilmington, North Carolina.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Thornton', 'Affiliation': 'Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}]",American journal of perinatology,['10.1055/s-0040-1710034'] 13,32386082,Long-term mortality in the Intermediate care after emergency abdominal surgery (InCare) trial-A post-hoc follow-up study.,"BACKGROUND Patients undergoing emergency abdominal surgery are at high risk of post-operative complications. Although post-operative treatment at an intermediate care unit may improve early outcome, there is a lack of studies on the long-term effects of such therapy. The aim of this study was to assess the long-term effect of intermediate care versus standard surgical ward care on mortality in the Intermediate Care After Emergency Abdominal Surgery (InCare) trial. METHODS We included adult patients undergoing emergency major laparoscopy or laparotomy with an Acute Physiology and Chronic Health Evaluation (APACHE) II score of 10 or more, who participated in the InCare trial from October 2010 to November 2012. In the InCare trial, patients were randomized to either post-operative intermediate care or standard surgical ward care. The primary outcome was time to death within 6 years after surgery. We assessed mortality with Coxregression analysis. RESULTS A total of 286 patients were included. The all-cause 6-year landmark mortality was 52.8% (76 of 144 patients) in the intermediate care group and 47.9% (68 of 142 patients) in the ward care group. There was no statistically significant difference in mortality risk between the two groups (hazard ratio 1.06 (95% confidence interval 0.76-1.47), P = .73). CONCLUSION We found no statistically significant difference in 6-year mortality between patients randomized to post-operative intermediate care or ward care after emergency abdominal surgery. However, we detected an absolute mortality risk reduction of 5% in favour of ward care, possibly due to random error.",2020,We found no statistically significant difference in six-year mortality between patients randomised to postoperative intermediate care or ward care afteremergency abdominal surgery.,"['A total of 286 patients were included', 'Patients undergoing emergency abdominal surgeryare at high risk of postoperative complications', 'After Emergency Abdominal Surgery (InCare) trial', 'adult patients undergoingemergency major laparoscopy or laparotomy with an Acute Physiology and Chronic Health Evaluation (APACHE) II score of 10 or more, who participated in the InCare trial from October 2010 to November 2012']","['postoperative intermediate care or standard surgical ward care', 'intermediate care versus standard surgical ward care']","['six-year mortality', 'cause six-year landmark mortality', 'mortality risk', 'time to death within six years after surgery']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0023038', 'cui_str': 'Laparotomy'}, {'cui': 'C0243030', 'cui_str': 'Acute physiology and chronic health evaluation'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1305702', 'cui_str': 'Ward'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",286.0,0.118646,We found no statistically significant difference in six-year mortality between patients randomised to postoperative intermediate care or ward care afteremergency abdominal surgery.,"[{'ForeName': 'Anna K', 'Initials': 'AK', 'LastName': 'Hansted', 'Affiliation': 'Herlev Anaesthesia Critical and Emergency Care Science Unit (ACES), Department of Anaesthesiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'Morten H', 'Initials': 'MH', 'LastName': 'Møller', 'Affiliation': 'Department of Intensive Care 4131, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Ann M', 'Initials': 'AM', 'LastName': 'Møller', 'Affiliation': 'Herlev Anaesthesia Critical and Emergency Care Science Unit (ACES), Department of Anaesthesiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'Jørn', 'Initials': 'J', 'LastName': 'Wetterslev', 'Affiliation': 'Copenhagen Trial Unit Dpt. 7812, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Rosenberg', 'Affiliation': 'Department of Surgery, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lars N', 'Initials': 'LN', 'LastName': 'Jorgensen', 'Affiliation': 'Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Waldau', 'Affiliation': 'Department of Intensive Care, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Vester-Andersen', 'Affiliation': 'Herlev Anaesthesia Critical and Emergency Care Science Unit (ACES), Department of Anaesthesiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13613'] 14,32384175,Testosterone replacement therapy: Pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups.,"BACKGROUND Testosterone replacement therapy (TRT) improves health in some but not all men with type 2 diabetes (T2DM) and adult-onset testosterone deficiency (TD). Such heterogeneity is compatible with the concept of patient subgroups that respond differently to therapy. OBJECTIVES Use baseline SHBG and age to identify putative subgroups that demonstrate different responses in variables such as waist circumference and HbA1c following TRT. MATERIALS AND METHODS A randomized double-blind trial approach was used to recruit and randomize men with T2DM and adult-onset TD into placebo and TRT-treated groups. Multiple regression was used to study differences between groups. RESULTS Baseline SHBG and change in SHBG (∆SHBG) were inversely related in the TRT group. Both median values of SHBG and age mediated the effect of TRT on ∆SHBG depending on whether baseline values were ≤ or>median (28.1 nmol/L, 63 years, respectively). In men with both SHBG ≤ 28.1 nmol/L and age ≤ 63 years (subgroup 1), TRT was positively associated with ∆SHBG (c = 4.67, 95%CI 1.17-8.16, P = .010) while in those with SHBG > 28.1 nmol/L and age > 63.1 years (subgroup 4) the association was inverse (c = -7.07, 95%CI -11.64 to -2.49, P = .003). The association between TRT and change (∆) in waist circumference, HbA1c and International Index of Erectile Function (IIEF) score differed between subgroups; in subgroup 4 but not subgroup 1, the therapy was significantly associated with ∆waist circumference, ∆HbA1c and ∆IIEF. DISCUSSION Though the mechanism remains unclear, our finding of different responses to TRT in terms of change in waist circumference, HbA1c and IIEF score supports the concept of subgroups in men with T2DM and adult-onset TD. CONCLUSION Our approach may provide a basis for identifying men who will or will not derive benefit from TRT though a larger study is required.",2020,"Both median values of SHBG and age mediated the effect of TRT on ∆SHBG depending on whether baseline values were ≤ or >median (28.1nmol/l, 63 years respectively).","['randomise men with T2DM and adult onset TD into placebo and TRT treated groups', 'men with type 2 diabetes (T2DM) and adult onset testosterone deficiency (TD']","['Testosterone replacement therapy (TRT', 'Testosterone replacement therapy: Pre-treatment sex hormone binding globulin levels', 'TRT']","['TRT and change (∆) in waist circumference, HbA1c and International Index of Erectile Function (IIEF) score', 'waist circumference, HbA1c and IIEF score', 'Baseline SHBG and change in SHBG (∆SHBG']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C1963961', 'cui_str': 'Testosterone deficiency'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4510497', 'cui_str': 'Testosterone replacement therapy'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C4510497', 'cui_str': 'Testosterone replacement therapy'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0202218', 'cui_str': 'Sex hormone binding globulin measurement'}]","[{'cui': 'C4510497', 'cui_str': 'Testosterone replacement therapy'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C2959364', 'cui_str': 'International index of erectile function score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0036883', 'cui_str': 'Sex steroid binding globulin'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",,0.239468,"Both median values of SHBG and age mediated the effect of TRT on ∆SHBG depending on whether baseline values were ≤ or >median (28.1nmol/l, 63 years respectively).","[{'ForeName': 'Sudarshan', 'Initials': 'S', 'LastName': 'Ramachandran', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Health Sciences, University Hospitals of North Midlands, Staffordshire University, Stoke-on-Trent, UK.'}, {'ForeName': 'Geoffrey I', 'Initials': 'GI', 'LastName': 'Hackett', 'Affiliation': 'School of Health and Life Sciences, Aston University, Birmingham, UK.'}, {'ForeName': 'Richard C', 'Initials': 'RC', 'LastName': 'Strange', 'Affiliation': 'Institute for Science and Technology in Medicine, Keele University, Keele, UK.'}]",Andrology,['10.1111/andr.12813'] 15,31309919,Long-term vitamin D and high-dose n -3 fatty acids' supplementation improve markers of cardiometabolic risk in type 2 diabetic patients with CHD.,"This study was performed to evaluate the effects of vitamin D and n-3 fatty acids' co-supplementation on markers of cardiometabolic risk in diabetic patients with CHD. This randomised, double-blinded, placebo-controlled trial was conducted among sixty-one vitamin D-deficient diabetic patients with CHD. At baseline, the range of serum 25-hydroxyvitamin D levels in study participants was 6·3-19·9 ng/ml. Subjects were randomly assigned into two groups either taking 50 000 IU vitamin D supplements every 2 weeks plus 2× 1000 mg/d n-3 fatty acids from flaxseed oil (n 30) or placebo (n 31) for 6 months. Vitamin D and n-3 fatty acids' co-supplementation significantly reduced mean (P = 0·01) and maximum levels of left carotid intima-media thickness (CIMT) (P = 0·004), and mean (P = 0·02) and maximum levels of right CIMT (P = 0·003) compared with the placebo. In addition, co-supplementation led to a significant reduction in fasting plasma glucose (β -0·40 mmol/l; 95 % CI -0·77, -0·03; P = 0·03), insulin (β -1·66 μIU/ml; 95 % CI -2·43, -0·89; P < 0·001), insulin resistance (β -0·49; 95 % CI -0·72, -0·25; P < 0·001) and LDL-cholesterol (β -0·21 mmol/l; 95 % CI -0·41, -0·01; P = 0·04), and a significant increase in insulin sensitivity (β +0·008; 95 % CI 0·004, 0·01; P = 0·001) and HDL-cholesterol (β +0·09 mmol/l; 95 % CI 0·01, 0·17; P = 0·02) compared with the placebo. Additionally, high-sensitivity C-reactive protein (β -1·56 mg/l; 95 % CI -2·65, -0·48; P = 0·005) was reduced in the supplemented group compared with the placebo group. Overall, vitamin D and n-3 fatty acids' co-supplementation had beneficial effects on markers of cardiometabolic risk.",2019,"' co-supplementation significantly reduced mean (P = 0·01) and maximum levels of left carotid intima-media thickness (CIMT) (P = 0·004), and mean (P = 0·02) and maximum levels of right CIMT (P = 0·003) compared with the placebo.","['0·17', 'type 2 diabetic patients with CHD', 'diabetic patients with CHD', 'sixty-one vitamin D-deficient diabetic patients with CHD']","['n-3 fatty acids from flaxseed oil (n 30) or placebo', 'placebo', ""Long-term vitamin D and high-dose n-3 fatty acids' supplementation"", ""vitamin D and n-3 fatty acids' co-supplementation"", 'Vitamin D and n-3 fatty acids', 'IU vitamin D supplements']","['HDL-cholesterol', 'maximum levels of left carotid intima-media thickness (CIMT', 'LDL-cholesterol', 'insulin sensitivity', 'cardiometabolic risk', 'insulin resistance', 'fasting plasma glucose', 'maximum levels of right CIMT', 'range of serum 25-hydroxyvitamin D levels']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517832', 'cui_str': 'Sixty-one'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0011155', 'cui_str': 'Deficient (qualifier value)'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0023754', 'cui_str': 'flaxseed oil'}, {'cui': 'C0632490', 'cui_str': 'N 30'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C3541352', 'cui_str': 'Vitamin D supplement (substance)'}]","[{'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0535968', 'cui_str': '25-hydroxyvitamin D'}]",61.0,0.769996,"' co-supplementation significantly reduced mean (P = 0·01) and maximum levels of left carotid intima-media thickness (CIMT) (P = 0·004), and mean (P = 0·02) and maximum levels of right CIMT (P = 0·003) compared with the placebo.","[{'ForeName': 'Hamid Reza', 'Initials': 'HR', 'LastName': 'Talari', 'Affiliation': 'Department of Radiology, Kashan University of Medical Sciences, Kashan, I.R. Iran.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Najafi', 'Affiliation': 'Department of Radiology, Kashan University of Medical Sciences, Kashan, I.R. Iran.'}, {'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Raygan', 'Affiliation': 'Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, I.R. Iran.'}, {'ForeName': 'Naghmeh', 'Initials': 'N', 'LastName': 'Mirhosseini', 'Affiliation': 'School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Vahidreza', 'Initials': 'V', 'LastName': 'Ostadmohammadi', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.'}, {'ForeName': 'Elaheh', 'Initials': 'E', 'LastName': 'Amirani', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Taghizadeh', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Hajijafari', 'Affiliation': 'Trauma Research Center, Kashan University of Medical Sciences, Kashan, I.R. Iran.'}, {'ForeName': 'Rana', 'Initials': 'R', 'LastName': 'Shafabakhsh', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.'}]",The British journal of nutrition,['10.1017/S0007114519001132'] 16,32393169,Does the revised intubating laryngeal tube (ILTS-D2) perform better than the intubating laryngeal mask (Fastrach)? - a randomised simulation research study.,"BACKGROUND The intubating laryngeal tube (ILTS-D™) and the intubating laryngeal mask (Fastrach™) are devices that facilitate both extraglottic application and blind tracheal intubation. A revised model of the iLTS-D (for scientific reasons called ILTS-D2) has been designed but not yet evaluated. Therefore, we compared the ILTS-D2 with the established Fastrach under controlled conditions in a prospective randomised controlled simulation research study. METHODS After ethical approval, we randomised 126 medical students into two groups. Each participant received either Fastrach or ILTS-D2 to perform five consecutive ventilation attempts in a manikin. The primary endpoint was the time to ventilation in the last attempt of using the devices as extraglottic devices. Secondary endpoints were the time to tracheal intubation and the success rates. RESULTS There was no relevant difference between the two devices in the time to ventilation in the last of five attempts (Fastrach: median 14 s [IQR: 12-15]; ILTS-D2: median 13 s [IQR: 12-15], p = 0.592). Secondary endpoints showed a 2 s faster blind tracheal intubation using the Fastrach than using the ILTS-D2 (Fastrach: median 14 s [IQR: 13-17]; ILTS-D2: median 16 s [IQR: 15-20] p < 0.001). For both devices, the success rates were 100% in the last attempt. CONCLUSIONS Concerning extraglottic airway management, we could not detect a relevant difference between the revised ILTS-D2 and the Fastrach under laboratory conditions. We advocate for an evaluation of the ILTS-D2 in randomised controlled clinical trials. TRIAL REGISTRATION Identifier at clinicaltrials.gov: NCT03542747. May 31, 2018.",2020,Secondary endpoints showed a 2 s faster blind tracheal intubation using the Fastrach than using the ILTS-D2 (Fastrach: median 14 s [IQR: 13-17]; ILTS-D2: median 16 s [IQR: 15-20] p < 0.001).,['126 medical students into two groups'],"['intubating laryngeal tube (ILTS-D™) and the intubating laryngeal mask (Fastrach™', 'Fastrach or ILTS-D2']","['2\u2009s faster blind tracheal intubation using the Fastrach', 'time to tracheal intubation and the success rates', 'time to ventilation', 'time to ventilation in the last attempt of using the devices as extraglottic devices', 'success rates']","[{'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0023078', 'cui_str': 'Laryngeal'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}]","[{'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]",,0.115281,Secondary endpoints showed a 2 s faster blind tracheal intubation using the Fastrach than using the ILTS-D2 (Fastrach: median 14 s [IQR: 13-17]; ILTS-D2: median 16 s [IQR: 15-20] p < 0.001).,"[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Ott', 'Affiliation': 'Department of Anaesthesiology, Medical Centre of the Johannes Gutenberg University, Langenbeckstr. 1, 55131, Mainz, Germany. ottth@uni-mainz.de.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Tschöpe', 'Affiliation': 'Department of Anaesthesiology, Medical Centre of the Johannes Gutenberg University, Langenbeckstr. 1, 55131, Mainz, Germany.'}, {'ForeName': 'Gerrit', 'Initials': 'G', 'LastName': 'Toenges', 'Affiliation': 'Institute of Medical Biostatistics, Epidemiology, and Informatics, Medical Centre of the Johannes Gutenberg University, Mainz, Germany.'}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Buggenhagen', 'Affiliation': 'Rudolf-Frey Lernklinik Central Education Platform, Medical Centre of the Johannes Gutenberg University, Mainz, Germany.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Engelhard', 'Affiliation': 'Department of Anaesthesiology, Medical Centre of the Johannes Gutenberg University, Langenbeckstr. 1, 55131, Mainz, Germany.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Kriege', 'Affiliation': 'Department of Anaesthesiology, Medical Centre of the Johannes Gutenberg University, Langenbeckstr. 1, 55131, Mainz, Germany.'}]",BMC anesthesiology,['10.1186/s12871-020-01029-3'] 17,32389050,Necessity of Interfragmentary Lag Screws in Precontoured Lateral Locking Plate Fixation for Supination-External Rotation Lateral Malleolar Fractures.,"BACKGROUND Interfragmentary lag screws, protected by a plate, have been applied for many years in the treatment of supination-external rotation (SER) ankle fractures. Recently, similar biomechanical stability was found between fixation completed with a plate and lag screw and a plate alone. The aim of this study was to determine whether interfragmentary lag screws are necessary during precontoured lateral locking plate fixation for SER lateral malleolar fractures. METHODS A prospective randomized controlled trial of 76 patients with unilateral Lauge-Hansen SER lateral malleolar fractures was conducted. The patients were randomly treated either with or without the use of interfragmentary lag screws with precontoured lateral locking plate fixation. Clinical outcomes were assessed using the Olerud-Molander Ankle Score and a visual analog scale for pain. Radiologic outcomes were assessed based on the Kellgren and Lawrence scale score, incongruity of the ankle joint, and type of fracture healing. Sixty-nine patients completed 12 months of follow-up. RESULTS There was no significant difference between the 2 groups with regard to clinical outcomes at 3 and 12 months after surgery and radiologic outcomes at 12 months after surgery. All patients in both groups achieved primary bone healing. CONCLUSION The results of this study suggest that with precontoured lateral locking plate fixation, the use of interfragmentary lag screw is not essential in the treatment SER lateral malleolar fractures. LEVEL OF EVIDENCE Level I, prospective randomized study.",2020,There was no significant difference between the 2 groups with regard to clinical outcomes at 3 and 12 months after surgery and radiologic outcomes at 12 months after surgery.,"['76 patients with unilateral Lauge-Hansen SER lateral malleolar fractures', 'Sixty-nine patients completed 12 months of follow-up', 'Supination-External Rotation Lateral Malleolar Fractures']","['precontoured lateral locking plate fixation', 'Interfragmentary Lag Screws in Precontoured Lateral Locking Plate Fixation', 'interfragmentary lag screws with precontoured lateral locking plate fixation']","['Radiologic outcomes', 'biomechanical stability', 'Olerud-Molander Ankle Score and a visual analog scale for pain', 'Kellgren and Lawrence scale score, incongruity of the ankle joint, and type of fracture healing', 'primary bone healing']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0023343', 'cui_str': 'Leprosy'}, {'cui': 'C0038845', 'cui_str': 'Supination'}, {'cui': 'C0231462', 'cui_str': 'External rotation'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C1096630', 'cui_str': 'Malleolar fracture'}, {'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}]","[{'cui': 'C0034599', 'cui_str': 'Radiology - specialty'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003087', 'cui_str': 'Ankle joint structure'}, {'cui': 'C0457357', 'cui_str': 'Type of fracture'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1321023', 'cui_str': 'Bone healing status'}]",76.0,0.0331161,There was no significant difference between the 2 groups with regard to clinical outcomes at 3 and 12 months after surgery and radiologic outcomes at 12 months after surgery.,"[{'ForeName': 'Young Hwan', 'Initials': 'YH', 'LastName': 'Park', 'Affiliation': 'Department of Orthopaedic Surgery, Korea University Guro Hospital, Seoul, Korea.'}, {'ForeName': 'Hyun Woo', 'Initials': 'HW', 'LastName': 'Cho', 'Affiliation': 'Department of Orthopaedic Surgery, Korea University Guro Hospital, Seoul, Korea.'}, {'ForeName': 'Gi Won', 'Initials': 'GW', 'LastName': 'Choi', 'Affiliation': 'Department of Orthopaedic Surgery, Korea University Ansan Hospital, Seoul, Korea.'}, {'ForeName': 'Hak Jun', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopaedic Surgery, Korea University Guro Hospital, Seoul, Korea.'}]",Foot & ankle international,['10.1177/1071100720917645'] 18,32389076,Biomechanical responses of young adults with unilateral transfemoral amputation using two types of mechanical stance control prosthetic knee joints.,"BACKGROUND Prosthetic knee joint function is important in the rehabilitation of individuals with transfemoral amputation. OBJECTIVES The objective of this study was to assess the gait patterns associated with two types of mechanical stance control prosthetic knee joints-weight-activated braking knee and automatic stance-phase lock knee. It was hypothesized that biomechanical differences exist between the two knee types, including a prolonged swing-phase duration and exaggerated pelvic movements for the weight-activated braking knee during gait. STUDY DESIGN Prospective crossover study. METHODS Spatiotemporal, kinematic, and kinetic parameters were obtained via instrumented gait analysis for 10 young adults with a unilateral transfemoral amputation. Discrete gait parameters were extracted based on their magnitudes and timing. RESULTS A 1.01% ± 1.14% longer swing-phase was found for the weight-activated braking knee (p < 0.05). The prosthetic ankle push-off also occurred earlier in the gait cycle for the weight-activated braking knee. Anterior pelvic tilt was 3.3 ± 3.0 degrees greater for the weight-activated braking knee. This range of motion was also higher (p < 0.05) and associated with greater hip flexion angles. CONCLUSIONS Stance control affects biomechanics primarily in the early and late stance associated with prosthetic limb loading and unloading. The prolonged swing-phase time for the weight-activated braking knee may be associated with the need for knee unloading to initiate knee flexion during gait. The differences in pelvic tilt may be related to knee stability and possibly the different knee joint stance control mechanisms. CLINICAL RELEVANCE Understanding the influence of knee function on gait biomechanics is important in selecting and improving treatments and outcomes for individuals with lower-limb amputations. Weight-activated knee joints may result in undesired gait deviations associated with stability in early stance-phase, and swing-phase initiation in the late stance-phase of gait.",2020,A 1.01% ± 1.14% longer swing-phase was found for the weight-activated braking knee (p < 0.05).,"['individuals with lower-limb amputations', 'individuals with transfemoral amputation', '10 young adults with a unilateral transfemoral amputation', 'young adults with unilateral transfemoral amputation using two types of mechanical stance control prosthetic knee joints']",['mechanical stance control prosthetic knee joints-weight-activated braking knee and automatic stance-phase lock knee'],"['prolonged swing-phase duration and exaggerated pelvic movements', 'hip flexion angles', 'Biomechanical responses', 'weight-activated braking knee']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0337308', 'cui_str': 'Amputation of lower limb'}, {'cui': 'C0002691', 'cui_str': 'Amputation above-knee'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}]","[{'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0337108', 'cui_str': 'Brake'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0231753', 'cui_str': 'Knee locking'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0442801', 'cui_str': 'Exaggerated'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0337108', 'cui_str': 'Brake'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}]",10.0,0.0173578,A 1.01% ± 1.14% longer swing-phase was found for the weight-activated braking knee (p < 0.05).,"[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Andrysek', 'Affiliation': 'Holland Bloorview Kids Rehabilitation Hospital and Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'García', 'Affiliation': 'Instituto Teleton, Santiago, Chile.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Rozbaczylo', 'Affiliation': 'Instituto Teleton, Santiago, Chile.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Alvarez-Mitchell', 'Affiliation': 'Escuela de Kinesiologia, Universidad Andres Bello, Santiago, Chile.'}, {'ForeName': 'Rebeca', 'Initials': 'R', 'LastName': 'Valdebenito', 'Affiliation': 'Instituto Teleton, Santiago, Chile.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Rotter', 'Affiliation': 'Instituto Teleton, Santiago, Chile.'}, {'ForeName': 'F Virginia', 'Initials': 'FV', 'LastName': 'Wright', 'Affiliation': 'Holland Bloorview Kids Rehabilitation Hospital and Department of Physical Therapy, University of Toronto, Toronto, ON, Canada.'}]",Prosthetics and orthotics international,['10.1177/0309364620916385'] 19,32269052,"Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8 + Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.","PURPOSE In oropharyngeal squamous cell carcinoma (OPC), high CD8 + tumor-infiltrating lymphocyte (CD8 + TIL) density confers improved prognosis. We compared neoadjuvant durvalumab (PD-L1 inhibitor) with durvalumab + tremelimumab (CTLA-4 inhibitor) in terms of impact on CD8 + TIL density, safety, and efficacy in patients with OPC. PATIENTS AND METHODS Patients with newly diagnosed stage II-IVA OPC or locoregionally recurrent OPC amenable to resection were included. Patients were randomized to two cycles of durvalumab or durvalumab + tremelimumab before surgery. The primary endpoint was change between baseline and resection specimen in CD8 + TIL density between arms. Secondary endpoints included safety, response rate per RECIST, major pathologic response (MPR; ≤10% viable tumor cells) rate, and patient-reported outcomes. RESULTS Of 28 eligible patients (14/arm), 20 (71%) had newly diagnosed OPC, and 24 (86%) were p16-positive. The posttreatment to pretreatment median CD8 + TIL density ratio was 1.31 for durvalumab and 1.15 for combination treatment ( P = 0.97; 95% CI: -1.07-2.28). In each group, 6 patients (43%, 95% CI: 17.66-71.14) had a response. Eight patients (29%) had a MPR at the primary tumor and/or nodal metastases. Neither baseline CD8 + TIL density nor PD-L1 expression level correlated with overall response, but a trend toward greater CD8 + TIL change in patients with a MPR was seen ( P = 0.059; 95% CI: -0.33-3.46). Four patients (14%) had grade ≥3 adverse events. At median follow-up time of 15.79 months, all patients were alive, and one had an additional recurrence. CONCLUSIONS Durvalumab + tremelimumab did not increase CD8 + TIL density more than durvalumab alone did. The observed safety and activity support further investigation of neoadjuvant checkpoint inhibitor for OPC.",2020,"The posttreatment to pretreatment median CD8 + TIL density ratio was 1.31 for durvalumab and 1.15 for combination treatment ( P =.97, 95%CI:(-1.07,2.28)).","['Patients with newly diagnosed stage II-IVA OPC or locoregionally-recurrent OPC amenable to resection were included', 'OPC patients', 'patients with oropharynx cancer', '28 eligible patients (14 per arm), 20 (71%) had newly diagnosed OPC, and 24 (86%) were p16-positive', 'oropharyngeal squamous cell carcinoma (OPC']","['durvalumab or durvalumab plus tremelimumab', 'neoadjuvant durvalumab (PD-L1 inhibitor) with durvalumab plus tremelimumab (CTLA-4 inhibitor', 'neoadjuvant durvalumab with or without tremelimumab']","['change between baseline and resection specimen in CD8 + TIL density', 'CD8+ tumor lymphocyte density, safety, and efficacy', 'median CD8 + TIL density ratio', 'CD8 + TIL density', 'safety, response rate per RECIST, major pathologic response (MPR; ≤10% viable tumor cells) rate, and patient-reported outcomes', 'additional recurrence', 'CD8 + TIL density, safety, and efficacy', 'CD8 + TIL change', 'baseline CD8 + TIL density nor PD-L1 expression level', 'grade ≥3 adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0268575', 'cui_str': 'Isovaleryl-CoA dehydrogenase deficiency'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0153382', 'cui_str': 'Malignant tumor of oropharynx'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0249880', 'cui_str': 'Cdk4-Associated Protein p16'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0280313', 'cui_str': 'Squamous cell carcinoma of oropharynx'}]","[{'cui': 'C4055109', 'cui_str': 'durvalumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2351038', 'cui_str': 'tremelimumab'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0111208', 'cui_str': 'Cytotoxic T-Lymphocyte Antigen 4'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0079722', 'cui_str': 'Tumor-Infiltrating Lymphocytes'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C1431543', 'cui_str': 'PGRMC1 protein, human'}, {'cui': 'C0443348', 'cui_str': 'Viable'}, {'cui': 'C0431085', 'cui_str': 'Tumor cells, uncertain whether benign or malignant'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",28.0,0.159168,"The posttreatment to pretreatment median CD8 + TIL density ratio was 1.31 for durvalumab and 1.15 for combination treatment ( P =.97, 95%CI:(-1.07,2.28)).","[{'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Ferrarotto', 'Affiliation': 'Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. rferrarotto@mdanderson.org.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Bell', 'Affiliation': 'Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Maria L', 'Initials': 'ML', 'LastName': 'Rubin', 'Affiliation': 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Hutcheson', 'Affiliation': 'Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Jason M', 'Initials': 'JM', 'LastName': 'Johnson', 'Affiliation': 'Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Ryan P', 'Initials': 'RP', 'LastName': 'Goepfert', 'Affiliation': 'Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Phan', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Yasir Y', 'Initials': 'YY', 'LastName': 'Elamin', 'Affiliation': 'Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Danice K', 'Initials': 'DK', 'LastName': 'Torman', 'Affiliation': 'Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Carla L', 'Initials': 'CL', 'LastName': 'Warneke', 'Affiliation': 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Amy C', 'Initials': 'AC', 'LastName': 'Hessel', 'Affiliation': 'Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Adam S', 'Initials': 'AS', 'LastName': 'Garden', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Jeffrey N', 'Initials': 'JN', 'LastName': 'Myers', 'Affiliation': 'Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Faye M', 'Initials': 'FM', 'LastName': 'Johnson', 'Affiliation': 'Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'J Jack', 'Initials': 'JJ', 'LastName': 'Lee', 'Affiliation': 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Andrew G', 'Initials': 'AG', 'LastName': 'Sikora', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Maura L', 'Initials': 'ML', 'LastName': 'Gillison', 'Affiliation': 'Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Bonnie S', 'Initials': 'BS', 'LastName': 'Glisson', 'Affiliation': 'Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Neil D', 'Initials': 'ND', 'LastName': 'Gross', 'Affiliation': 'Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-19-3977'] 20,32330373,"Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study.","OBJECTIVE To study the influence of a multi-component nutrient dietary supplement on sperm parameters and pregnancy rates in idiopathic male infertility (IMI) with oligo-, astheno-, and teratozoospermia. DESIGN A randomized, double-blind, placebo-controlled, prospective, parallel arms (1:1 allocation ratio), multi-center clinical trial. SETTINGS Eight urology/reproductive health clinical centers located in Ukraine. PATIENTS Eighty-three males aged 21-50 years with IMI and at least 1 of 3 abnormal values: total sperm concentration < 15 million/ml or/and spermatozoa progressive motility < 32% or/and forms with normal morphology < 4%. INTERVENTION(S) Patients were randomly allocated verum test dietary supplement (TDS) containing l-carnitine/acetyl-l-carnitine, l-arginine, glutathione, co-enzyme Q10, zinc, vitamin B 9 , vitamin B 12 , selenium, or placebo 1 time daily for 6 months. MAIN OUTCOME(S) The primary outcome measure was the percentage of normal spermiograms (concentration ≥ 15 million/ml and ≥ 32% of spermatozoa with progressive motility and ≥ 4% of normal forms) at month 0, 2, and 4. The percentage of pregnancies served the secondary outcome endpoint. Differences between the groups were assessed in z-test for proportions. RESULTS All males finished the study. At month 4, 29/42 (69.0%) males in the verum and 9/41 (22.0%) had normal spermiograms (P < .001). The percentage of spontaneous pregnancies in the verum group was greater than in the placebo group (10/42, 23.8% vs. 2/41, 4.9%, respectively, P = .017). There were no reportable supplement-associated adverse events. CONCLUSION Specific multi-nutrient combination l-carnitine/l-acetyl-carnitine, l-arginine, glutathione, co-enzyme-Q, zinc, folic acid, cyanocobalamin, and selenium can improve sperm quality in males with IMI and increase pregnancy rates.",2020,"Percent of spontaneous pregnancies in the verum group was greater than in the placebo group (10/42, 23.8% vs. 2/41, 4.9%, respectively, P = 0.017).","['Eight urology/reproductive health clinical centers located in Ukraine', 'males with IMI and increase pregnancy rates', 'idiopathic male subfertility involving oligo-, astheno-, teratozoospermia', 'Eighty-three males aged 21-50 years with IMI and at least 1 of 3 abnormal values: total sperm concentration < 15 million/ml or/and spermatozoa progressive motility < 32% or/and forms with normal morphology <4', 'idiopathic male infertility (IMI) with oligo-, astheno-, teratozoospermia']","['Specific multi-nutrient combination L-carnitine/ L-acetyl-carnitine, L-arginine, glutathione, co-enzyme-Q, zinc, folic acid, cyanocobalamin, and selenium', 'multicomponent nutrient dietary supplement', 'placebo', 'Dietary supplementation with a novel L-carnitine multi-micronutrient', 'verum test dietary supplement (TDS) containing L-carnitine/acetyl-L-carnitine, L-arginine, glutathione, co-enzyme-Q10, zinc, vitamin B 9 , vitamin B 12 , selenium or placebo']","['normal spermiograms', 'sperm parameters and pregnancy rates', 'spontaneous pregnancies', 'sperm quality', 'percentage of normal spermiograms (concentration ≥ 15 million/ml and ≥ 32% of spermatozoa with progressive motility and ≥ 4% of normal forms']","[{'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C0242667', 'cui_str': 'Reproductive Health'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0041580', 'cui_str': 'Ukraine'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0021364', 'cui_str': 'Male infertility'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0848676', 'cui_str': 'Sub-Fertility, Male'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0028953', 'cui_str': 'Oligonucleotide'}, {'cui': 'C0403824', 'cui_str': 'Teratozoospermia'}, {'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0429845', 'cui_str': 'Sperm concentration measurement'}, {'cui': 'C1960956', 'cui_str': 'Million/milliliter'}, {'cui': 'C3854382', 'cui_str': 'Spermatozoa progressive motility'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0332437', 'cui_str': 'Associated morphology'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0001040', 'cui_str': 'Acetylcarnitine'}, {'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0085798', 'cui_str': 'Glycogen Branching Enzyme'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0087163', 'cui_str': 'Levocarnitine'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0056077', 'cui_str': 'Ubiquinone'}, {'cui': 'C0042849', 'cui_str': 'Vitamin B Complex'}]","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0037868', 'cui_str': 'Spermatozoa'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1960956', 'cui_str': 'Million/milliliter'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0205431', 'cui_str': 'Formed'}]",83.0,0.423096,"Percent of spontaneous pregnancies in the verum group was greater than in the placebo group (10/42, 23.8% vs. 2/41, 4.9%, respectively, P = 0.017).","[{'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Kopets', 'Affiliation': 'Medical Center ""Astar"", Lviv, Ukraine.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Kuibida', 'Affiliation': 'Precarpathian Center of Reproductive Health, Ivano-Frankivsk, Ukraine.'}, {'ForeName': 'Iryna', 'Initials': 'I', 'LastName': 'Chernyavska', 'Affiliation': 'Mykolaiv State Clinical Hospital, Mykolaiv, Ukraine.'}, {'ForeName': 'Vasyl', 'Initials': 'V', 'LastName': 'Cherepanyn', 'Affiliation': 'Lviv State Center for the Reproductive Health, Lviv, Ukraine.'}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Mazo', 'Affiliation': 'Private Urologic Practice, Mykolaiv, Ukraine.'}, {'ForeName': 'Vitaliy', 'Initials': 'V', 'LastName': 'Fedevych', 'Affiliation': 'Lviv State Hospital, Lviv, Ukraine.'}, {'ForeName': 'Sergiy', 'Initials': 'S', 'LastName': 'Gerasymov', 'Affiliation': 'MedianaStatistics, Lviv, Ukraine.'}]",Andrology,['10.1111/andr.12805'] 21,32319087,The effect of rocuronium on ventilatory leak and sealing pressure using a supraglottic airway device: A randomized clinical trial.,"BACKGROUND The transition of ventilatory leak and sealing pressure in supraglottic airway devices after administration of neuromuscular blocking agents is unclear. We hypothesized that ventilatory leak would decrease due to the increase in sealing pressure after administration of 0.15 and 0.30 mg/kg rocuronium iv. METHODS Forty patients were randomly assigned to a control group or one of two rocuronium groups. After induction of general anaesthesia, an i-gel ® was inserted before rocuronium administration. The ventilatory leak and sealing pressure were measured immediately. Then, 0.15 mg/kg or 0.30 mg/kg rocuronium iv was administered and the ventilatory leak and sealing pressure were measured again. In the control group, measurements were obtained just after insertion of the supraglottic airway device and 5 minutes later, without any additional drug administration. RESULTS Similar decrements in ventilatory leak of approximately 3% were registered in all three groups. There were no changes in sealing pressure in any of the groups. However, multiple logistic regression analysis demonstrated that the reduced height of the first twitch response to train-of-four stimulation after administration of rocuronium was a determinant of a decrease in sealing pressure (odds ratio: 0.97, 95% confidence interval: 0.95-0.99, P = .04). CONCLUSIONS Our results suggest that ventilatory leak with a supraglottic airway device decreases independently of neuromuscular blockade, although the neuromuscular blockade may potentially decrease sealing pressure. Registration of Clinical trials: UMIN Clinical Trials Registry (registration ID: UMIN000027061, URL: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000031018).",2020,There were no changes in sealing pressure in any of the groups.,['Forty patients'],['rocuronium'],"['sealing pressure', 'ventilatory leak', 'ventilatory leak and sealing pressure', 'sealing pressure (odds ratio']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0209337', 'cui_str': 'Rocuronium'}]","[{'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0332234', 'cui_str': 'Leaking'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",40.0,0.193245,There were no changes in sealing pressure in any of the groups.,"[{'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Fujimoto', 'Affiliation': 'Department of Anesthesiology, Nishinihon Hospital, Kumamoto-City, Kumamoto, Japan.'}, {'ForeName': 'Fumiyo', 'Initials': 'F', 'LastName': 'Kubota', 'Affiliation': 'Department of Anesthesiology, Nishinihon Hospital, Kumamoto-City, Kumamoto, Japan.'}, {'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Anesthesiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto University Hospital, Kumamoto-City, Kumamoto, Japan.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13608'] 22,32297945,Effect of Treatment Expectation on Placebo Response and Analgesic Efficacy: A Secondary Aim in a Randomized Clinical Trial.,,2020,,[],[],['Placebo Response and Analgesic Efficacy'],[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.420829,,"[{'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Sanders', 'Affiliation': 'Division of Pediatric and Public Health, Adams School of Dentistry, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Gary D', 'Initials': 'GD', 'LastName': 'Slade', 'Affiliation': 'Division of Pediatric and Public Health, Adams School of Dentistry, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': 'Department of Community Dentistry and Behavioral Science, University of Florida, Gainesville.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Ohrbach', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University at Buffalo, State University of New York, Buffalo.'}, {'ForeName': 'Samuel J', 'Initials': 'SJ', 'LastName': 'Arbes', 'Affiliation': 'Rho Inc, Durham, North Carolina.'}, {'ForeName': 'Inna E', 'Initials': 'IE', 'LastName': 'Tchivileva', 'Affiliation': 'Division of Oral and Craniofacial Health Sciences, Adams School of Dentistry, University of North Carolina at Chapel Hill.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.2907'] 23,32308074,Effect of Light-Emitting Diode Irradiation on Chronic Nonhealed Wound After Below-Knee Amputation.,"Chronic nonhealed wound after below-knee amputation is a serious problem that is faced by the health care team; therefore, there is a need to find an adjuvant therapy to address this problem. The aim of the study is to evaluate the therapeutic efficacy of light-emitting diode (LED) irradiation on chronic nonhealed wound after below-knee amputation using a digitalized method of evaluation by Adobe Photoshop CS5 aided by magnetic lasso tool. Thirty patients with chronic nonhealed wound (≥4 weeks) after below-knee amputation were randomly divided into 2 equal groups, with 15 participants in each. Group A received the LED irradiation for 24 sessions (3 sessions per week) in addition to the standard medical treatment, and the second experimental group (group B) received the standard medical treatment for 8 weeks. Methods of evaluation included the wound surface area: for tracing the wound perimeter using a computerized software. Results showed that both LED irradiation therapy and standard medical treatment were effective in healing the chronic nonhealed wound, but the LED was more effective than standard medical treatment alone. A clear improvement in the results of wound healing surface area was found in group A, with an improvement percentage of 50.63%, when compared with group B, which used the standard medical treatment alone, with an improvement percentage of 43.96%.",2021,"A clear improvement in the results of wound healing surface area was found in group A, with an improvement percentage of 50.63%, when compared with group B, which used the standard medical treatment alone, with an improvement percentage of 43.96%.",['Thirty patients with chronic nonhealed wound (≥4 weeks) after below-knee amputation'],"['Light-Emitting Diode Irradiation', 'LED irradiation', 'light-emitting diode (LED) irradiation']","['Chronic Nonhealed Wound', 'wound healing surface area']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0002692', 'cui_str': 'Amputation of leg through tibia and fibula'}]","[{'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0162676', 'cui_str': 'Enzyme-multiplied immunoassay technique'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}]","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]",30.0,0.0172923,"A clear improvement in the results of wound healing surface area was found in group A, with an improvement percentage of 50.63%, when compared with group B, which used the standard medical treatment alone, with an improvement percentage of 43.96%.","[{'ForeName': 'Haitham Amin', 'Initials': 'HA', 'LastName': 'Elessawy', 'Affiliation': 'Pharos University in Alexandria, Alexandria, Egypt.'}, {'ForeName': 'Wafaa Hussein', 'Initials': 'WH', 'LastName': 'Borhan', 'Affiliation': 'Cairo University, Giza, Egypt.'}, {'ForeName': 'Nasser Ahmed', 'Initials': 'NA', 'LastName': 'Ghozlan', 'Affiliation': 'Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Samah Hosny', 'Initials': 'SH', 'LastName': 'Nagib', 'Affiliation': 'Cairo University, Giza, Egypt.'}]",The international journal of lower extremity wounds,['10.1177/1534734620915108'] 24,31958526,"Buffered lidocaine 1%/epinephrine 1:100,000 with sodium bicarbonate (sodium hydrogen carbonate) in a 3:1 ratio is less painful than a 9:1 ratio: A double-blind, randomized, placebo-controlled, crossover trial.","BACKGROUND Neutralizing (buffering) lidocaine 1%/epinephrine 1:100,000 solution (Lido/Epi) with sodium hydrogen carbonate (NaHCO 3 ) (also called sodium bicarbonate) is widely used to reduce burning sensations during infiltration of Lido/Epi. Optimal mixing ratios have not been systematically investigated. OBJECTIVES To determine whether a Lido/Epi:NaHCO 3 mixing ratio of 3:1 (investigational medicinal product 1) causes less pain during infiltration than a mixing ratio of 9:1 (IMP2) or unbuffered Lido/Epi (IMP3). METHODS Double-blind, randomized, placebo-controlled, crossover trial (n = 2 × 24) with 4 investigational medicinal products (IMP1-4). RESULTS The 3:1 mixing ratio was significantly less painful than the 9:1 ratio (P = .044). Unbuffered Lido/Epi was more painful than the buffered Lido/Epi (P = .001 vs IMP1; P = .033 vs IMP2). IMP4 (NaCl 0.9% [placebo]) was more painful than any of the anesthetic solutions (P = .001 vs IMP1; P = .001 vs IMP2; P = .016 vs IMP3). In all cases, the anesthesia was effective for at least 3 hours. LIMITATIONS Results of this trial cannot be generalized to other local anesthetics such as prilocaine, bupivacaine, or ropivacaine, which precipitate with NaHCO 3 admixtures. CONCLUSIONS Lido/Epi-NaHCO 3 mixtures effectively reduce burning pain during infiltration. The 3:1 mixing ratio is significantly less painful than the 9:1 ratio. Reported findings are of high practical relevance, given the extensive use of local anesthesia today.",2020,The 3:1 mixing ratio was significantly less painful than the 9:1 ratio (p = 0.044).,[],"['lidocaine', 'prilocaine, bupivacaine', 'Lido/Epi-NaHCO 3 mixing ratio 3:1 (IMP1', 'IMP2) or unbuffered Lido/Epi (IMP3', '4 investigational medicinal products (IMP1-4', 'ropivacaine', 'epinephrine 1:100,000 solutions (Lido/Epi) with sodium hydrogen carbonate (NaHCO 3 ) (bicarbonate', 'placebo', 'IMP4 (NaCl 0.9%=placebo', 'Unbuffered Lido/Epi', 'sodium bicarbonate (hydrogen carbonate', 'epinephrine']",['burning pain'],[],"[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0033124', 'cui_str': 'Prilocaine'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0267963', 'cui_str': 'Pancreatic Insufficiency'}, {'cui': 'C1720722', 'cui_str': 'Mix'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C0005367', 'cui_str': 'Hydrogen Carbonates'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}]","[{'cui': 'C0234230', 'cui_str': 'Pain, Burning'}]",,0.596982,The 3:1 mixing ratio was significantly less painful than the 9:1 ratio (p = 0.044).,"[{'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Vent', 'Affiliation': 'Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Surber', 'Affiliation': 'Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Nicole Tracy', 'Initials': 'NT', 'LastName': 'Graf Johansen', 'Affiliation': 'Graf Biostatistics, Winterthur, Switzerland.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Figueiredo', 'Affiliation': 'Hospital Pharmacy of the University Hospital Zurich, Schlieren, Switzerland.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Schönbächler', 'Affiliation': 'Institute of Psychology, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Imhof', 'Affiliation': 'Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Buset', 'Affiliation': 'Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Jürg', 'Initials': 'J', 'LastName': 'Hafner', 'Affiliation': 'Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland. Electronic address: juerg.hafner@usz.ch.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.09.088'] 25,31968207,Effects of the Carrier Phrase on Word Recognition Performances by Younger and Older Listeners Using Two Stimulus Paradigms.,"BACKGROUND In the 1950s, with monitored live voice testing, the vu meter time constant and the short durations and amplitude modulation characteristics of monosyllabic words necessitated the use of the carrier phrase amplitude to monitor (indirectly) the presentation level of the words. This practice continues with recorded materials. To relieve the carrier phrase of this function, first the influence that the carrier phrase has on word recognition performance needs clarification, which is the topic of this study. PURPOSE Recordings of Northwestern University Auditory Test No. 6 by two female speakers were used to compare word recognition performances with and without the carrier phrases when the carrier phrase and test word were (1) in the same utterance stream with the words excised digitally from the carrier (VA-1 speaker) and (2) independent of one another (VA-2 speaker). The 50-msec segment of the vowel in the target word with the largest root mean square amplitude was used to equate the target word amplitudes. RESEARCH DESIGN A quasi-experimental, repeated measures design was used. STUDY SAMPLE Twenty-four young normal-hearing adults (YNH; M  = 23.5 years; pure-tone average [PTA] = 1.3-dB HL) and 48 older hearing loss listeners (OHL; M  = 71.4 years; PTA = 21.8-dB HL) participated in two, one-hour sessions. DATA COLLECTION AND ANALYSES Each listener had 16 listening conditions (2 speakers × 2 carrier phrase conditions × 4 presentation levels) with 100 randomized words, 50 different words by each speaker. Each word was presented 8 times (2 carrier phrase conditions × 4 presentation levels [YNH, 0- to 24-dB SL; OHL, 6- to 30-dB SL]). The 200 recorded words for each condition were randomized as 8, 25-word tracks. In both test sessions, one practice track was followed by 16 tracks alternated between speakers and randomized by blocks of the four conditions. Central tendency and repeated measures analyses of variance statistics were used. RESULTS With the VA-1 speaker, the overall mean recognition performances were 6.0% (YNH) and 8.3% (OHL) significantly better with the carrier phrase than without the carrier phrase. These differences were in part attributed to the distortion of some words caused by the excision of the words from the carrier phrases. With the VA-2 speaker, recognition performances on the with and without carrier phrase conditions by both listener groups were not significantly different, except for one condition (YNH listeners at 8-dB SL). The slopes of the mean functions were steeper for the YNH listeners (3.9%/dB to 4.8%/dB) than for the OHL listeners (2.4%/dB to 3.4%/dB) and were <1%/dB steeper for the VA-1 speaker than for the VA-2 speaker. Although the mean results were clear, the variability in performance differences between the two carrier phrase conditions for the individual participants and for the individual words was striking and was considered in detail. CONCLUSION The current data indicate that word recognition performances with and without the carrier phrase (1) were different when the carrier phrase and target word were produced in the same utterance with poorer performances when the target words were excised from their respective carrier phrases (VA-1 speaker), and (2) were the same when the carrier phrase and target word were produced as independent utterances (VA-2 speaker).",2020,"With the VA-2 speaker, recognition performances on the with and without carrier phrase conditions by both listener groups were not significantly different, except for one condition (YNH listeners at 8-dB SL).","['SAMPLE\n\n\nTwenty-four young normal-hearing adults (YNH; M = 23.5 years; pure-tone average [PTA] = 1.3-dB HL) and 48 older hearing loss listeners (OHL; M = 71.4 years; PTA = 21.8-dB HL', 'Northwestern University Auditory Test No. 6 by two female speakers', 'Younger and Older Listeners']","['Carrier Phrase', 'VA-1 speaker']","['Word Recognition Performances', 'overall mean recognition performances']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517499', 'cui_str': '1.3 (qualifier value)'}, {'cui': 'C0439498', 'cui_str': 'decibel hearing level'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0015522', 'cui_str': 'Factor Eleven'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0560175', 'cui_str': 'Carrier State'}, {'cui': 'C0600665', 'cui_str': 'Phrase'}]","[{'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",24.0,0.0220376,"With the VA-2 speaker, recognition performances on the with and without carrier phrase conditions by both listener groups were not significantly different, except for one condition (YNH listeners at 8-dB SL).","[{'ForeName': 'Richard H', 'Initials': 'RH', 'LastName': 'Wilson', 'Affiliation': 'Department of Speech and Hearing Sciences, Arizona State University, Tempe, AZ.'}, {'ForeName': 'Victoria A', 'Initials': 'VA', 'LastName': 'Sanchez', 'Affiliation': 'Department of Otolaryngology-Head & Neck Surgery, University of South Florida, Tampa, FL.'}]",Journal of the American Academy of Audiology,['10.3766/jaaa.19061'] 26,32321301,Effects of diabetes duration and HgA1C level on corneal endothelial morphology.,"OBJECTIVE The aim of this study is to investigate the effects of the HbA1c level and the duration of diabetes mellitus on the corneal endothelium morphology and to compare between healthy individuals and diabetes mellitus patients with non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. MATERIAL AND METHODS Ninety patients who applied to the Health Sciences University Ulucanlar Eye Training and Research Hospital between January 2016 and January 2017 were included in this prospective randomized study. In the study, 45 diabetes mellitus patients and 45 healthy individuals were evaluated. The diabetes patients were compared in terms of HbA1c level, diabetes mellitus duration, corneal endothelial cell density, coefficient of variation, standard deviation, and hexagonality with healthy control group. RESULTS A statistically significant difference was found in the endothelial cell densitometer, coefficient of variation, and standard deviation measurements between the diabetes mellitus patients and the control (healthy) group. But, there was no statistically significant difference between 6A (hexagonality) and central corneal thickness measurements. There was a negative correlation between HbA1c levels and diabetes mellitus times and endothelial cell densitometer values in the patients with diabetes mellitus diagnosis and standard deviation values in the positive direction. There was a statistically significant difference between diabetes mellitus patients with the diagnosis of non-proliferative diabetic retinopathy and proliferative diabetic retinopathy in the endothelial cell densitometer and standard deviation values. But there was not any statistically significant difference between coefficient of variation, 6A, and central corneal thickness values. CONCLUSION The endothelial cell densitometer in diabetes mellitus patients with retinopathy is lower than that in healthy individuals. There is a negative correlation between retinopathy severity and corneal endothelial cell density. Diabetes affects negatively not only vascular tissues but also avascular cornea.",2021,There was a statistically significant difference between diabetes mellitus patients with the diagnosis of non-proliferative diabetic retinopathy and proliferative diabetic retinopathy in the endothelial cell densitometer and standard deviation values.,"['45 diabetes mellitus patients and 45 healthy individuals', 'Ninety patients who applied to the Health Sciences University Ulucanlar Eye Training and Research Hospital between January 2016 and January 2017', 'diabetes mellitus patients with retinopathy', 'healthy individuals and diabetes mellitus patients with non-proliferative diabetic retinopathy and proliferative diabetic retinopathy']",[],"['HbA1c levels and diabetes mellitus times and endothelial cell densitometer values', 'coefficient of variation, 6A, and central corneal thickness values', 'HbA1c level, diabetes mellitus duration, corneal endothelial cell density, coefficient of variation, standard deviation, and hexagonality', 'endothelial cell densitometer, coefficient of variation, and standard deviation measurements', 'endothelial cell densitometer', 'corneal endothelial morphology', '6A (hexagonality) and central corneal thickness measurements', 'retinopathy severity and corneal endothelial cell density']","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0035309', 'cui_str': 'Retinal disorder'}, {'cui': 'C0004606', 'cui_str': 'Nonproliferative diabetic retinopathy'}, {'cui': 'C0154830', 'cui_str': 'Proliferative retinopathy with diabetes mellitus'}]",[],"[{'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0225336', 'cui_str': 'Endothelial cell'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C1720164', 'cui_str': 'Central corneal thickness'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell density'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0332437', 'cui_str': 'Associated morphology'}, {'cui': 'C0035309', 'cui_str': 'Retinal disorder'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",90.0,0.0163855,There was a statistically significant difference between diabetes mellitus patients with the diagnosis of non-proliferative diabetic retinopathy and proliferative diabetic retinopathy in the endothelial cell densitometer and standard deviation values.,"[{'ForeName': 'Salih', 'Initials': 'S', 'LastName': 'Çolak', 'Affiliation': 'Ministry of Health, Osmaniye Government Hospital, Osmaniye, Turkey.'}, {'ForeName': 'Burcu', 'Initials': 'B', 'LastName': 'Kazanci', 'Affiliation': 'Ministry of Health, Ulucanlar Eye Research and Education Hospital, Ankara, Turkey.'}, {'ForeName': 'Dilek', 'Initials': 'D', 'LastName': 'Ozçelik Soba', 'Affiliation': 'Ministry of Health, Ulucanlar Eye Research and Education Hospital, Ankara, Turkey.'}, {'ForeName': 'Yasemin', 'Initials': 'Y', 'LastName': 'Ozdamar Erol', 'Affiliation': 'Ministry of Health, Ulucanlar Eye Research and Education Hospital, Ankara, Turkey.'}, {'ForeName': 'Pelin', 'Initials': 'P', 'LastName': 'Yilmazbas', 'Affiliation': 'Ministry of Health, Ulucanlar Eye Research and Education Hospital, Ankara, Turkey.'}]",European journal of ophthalmology,['10.1177/1120672120914812'] 27,32275060,"Implementation of a Transitional Care Model for Stroke: Perspectives From Frontline Clinicians, Administrators, and COMPASS-TC Implementation Staff.","BACKGROUND AND OBJECTIVES Stroke is a chronic, complex condition that disproportionally affects older adults. Health systems are evaluating innovative transitional care (TC) models to improve outcomes in these patients. The Comprehensive Post-Acute Stroke Services (COMPASS) Study, a large cluster-randomized pragmatic trial, tested a TC model for patients with stroke or transient ischemic attack discharged home from the hospital. The implementation of COMPASS-TC in complex real-world settings was evaluated to identify successes and challenges with integration into the clinical workflow. RESEARCH DESIGN AND METHODS We conducted a concurrent process evaluation of COMPASS-TC implementation during the first year of the trial. Qualitative data were collected from 4 sources across 19 intervention hospitals. We analyzed transcripts from 43 conference calls with hospital clinicians, individual and group interviews with leaders and clinicians from 9 hospitals, and 2 interviews with the COMPASS-TC Director of Implementation using iterative thematic analysis. Themes were compared to the domains of the RE-AIM framework. RESULTS Organizational, individual, and community factors related to Reach, Adoption, and Implementation were identified. Organizational readiness was an additional key factor to successful implementation, in that hospitals that were not ""organizationally ready"" had more difficulty addressing implementation challenges. DISCUSSION AND IMPLICATIONS Multifaceted TC models are challenging to implement. Facilitators of implementation were organizational commitment and capacity, prioritizing implementation of innovative delivery models to provide comprehensive care, being able to address challenges quickly, implementing systems for tracking patients throughout the intervention, providing clinicians with autonomy and support to address challenges, and adequately resourcing the intervention. CLINICAL TRIAL REGISTRATION NCT02588664.",2020,"The implementation of COMPASS-TC in complex real-world settings was evaluated to identify successes and challenges with integration into the clinical workflow. ","['43 conference calls with hospital clinicians, individual and group interviews with leaders and clinicians from 9 hospitals, and 2 interviews with the COMPASS-TC Director of Implementation using iterative thematic analysis', 'older adults', 'patients with stroke or transient ischemic attack discharged home from the hospital']","['COMPASS-TC implementation', 'TC model']",[],"[{'cui': 'C0086047', 'cui_str': 'Conferences'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0018260', 'cui_str': 'Group Interviews'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]",[],,0.0397485,"The implementation of COMPASS-TC in complex real-world settings was evaluated to identify successes and challenges with integration into the clinical workflow. ","[{'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Lutz', 'Affiliation': 'School of Nursing, University of North Carolina at Wilmington.'}, {'ForeName': 'Alexandria E', 'Initials': 'AE', 'LastName': 'Reimold', 'Affiliation': 'School of Nursing, University of North Carolina at Wilmington.'}, {'ForeName': 'Sylvia W', 'Initials': 'SW', 'LastName': 'Coleman', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Amy K', 'Initials': 'AK', 'LastName': 'Guzik', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Laurie P', 'Initials': 'LP', 'LastName': 'Russell', 'Affiliation': 'Division of Public Health Sciences, Wake Forest University Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Meghan D', 'Initials': 'MD', 'LastName': 'Radman', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Johnson', 'Affiliation': 'Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Pamela W', 'Initials': 'PW', 'LastName': 'Duncan', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Cheryl D', 'Initials': 'CD', 'LastName': 'Bushnell', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Wayne D', 'Initials': 'WD', 'LastName': 'Rosamond', 'Affiliation': 'Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Sabina B', 'Initials': 'SB', 'LastName': 'Gesell', 'Affiliation': 'Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}]",The Gerontologist,['10.1093/geront/gnaa029'] 28,32275352,Oral consumption of Garcinia kola(Bitter kola) lowers intraocular pressure.,"PURPOSE Garcinia kola (bitter kola) is locally ingested across the West African subregion. It has ocular hypotensive effects similar to some commonly used glaucoma medications when administered topically. The study assessed the effect of oral ingestion of G. kola on intraocular pressure (IOP). METHOD A randomized, single-blind, placebo-controlled, cross-over design was used in this study. Forty-six healthy subjects, aged between 19 and 27 years were recruited and randomized into two groups (A and B). Subjects in group A ingested 100 mg/kg body weight bitter kola in a 200 ml solution on their first visit and group B ingested 200 ml of water. On the second visit, the order of treatment was reversed, IOP was measured at baseline and every 45 min interval for 135 min. The mean difference between the baseline and post-treatment IOP measurements were tested for statistical significance using repeated-measures analysis of variance (95% confidence intervals [CIs]). RESULTS Mean IOP measurements decreased by 7.9, 18.2 and 20.6% at 45, 90 and 135 min, respectively, after G. kola treatment. The reduction, though variable across subjects, was statistically significant (F [2.13, 95.62] = 90.35, p < 0.0001) across the respective time points. Repetition of an identical protocol without G. kola caused clinically negligible changes in IOP. There was no statistically significant influence of gender or age in G. kola effect on IOP reading. CONCLUSION Oral ingestion of G. kola lowered the intraocular pressure of healthy young adults by 21%. Such an effect may be of therapeutic benefit to patients with POAG or ocular hypertension in low-income settings.",2020,"Mean IOP measurements decreased by 7.9, 18.2 and 20.6% at 45, 90 and 135 min, respectively, after G. kola treatment.","['Forty-six healthy subjects, aged between 19 and 27\xa0years', 'healthy young adults by 21', 'patients with POAG or ocular hypertension in low-income settings']","['oral ingestion of G.\xa0kola', 'Oral consumption of Garcinia kola (Bitter kola', 'placebo', 'Oral ingestion of G.\xa0kola']","['IOP', 'Mean IOP measurements', 'intraocular pressure', 'intraocular pressure (IOP']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0339573', 'cui_str': 'Primary open angle glaucoma'}, {'cui': 'C0028840', 'cui_str': 'Ocular hypertension'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0684195', 'cui_str': 'Cola'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0969734', 'cui_str': 'Kola, Bitter'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040420', 'cui_str': 'Tonometry'}]",46.0,0.221372,"Mean IOP measurements decreased by 7.9, 18.2 and 20.6% at 45, 90 and 135 min, respectively, after G. kola treatment.","[{'ForeName': 'Alex A', 'Initials': 'AA', 'LastName': 'Ilechie', 'Affiliation': 'Department of Optometry and Vision Science, University of Cape Coast, Cape Coast, Ghana.'}, {'ForeName': 'Mohammed M', 'Initials': 'MM', 'LastName': 'Jeduah', 'Affiliation': 'Department of Optometry and Vision Science, University of Cape Coast, Cape Coast, Ghana.'}, {'ForeName': 'Carl H', 'Initials': 'CH', 'LastName': 'Abraham', 'Affiliation': 'Department of Optometry and Vision Science, University of Cape Coast, Cape Coast, Ghana.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Ocansey', 'Affiliation': 'Department of Optometry and Vision Science, University of Cape Coast, Cape Coast, Ghana.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Abu', 'Affiliation': 'Department of Optometry and Vision Science, University of Cape Coast, Cape Coast, Ghana.'}, {'ForeName': 'Theophilus', 'Initials': 'T', 'LastName': 'Okyere', 'Affiliation': 'Department of Optometry and Vision Science, University of Cape Coast, Cape Coast, Ghana.'}, {'ForeName': 'Obarijima', 'Initials': 'O', 'LastName': 'Ngosaro', 'Affiliation': 'Department of Optometry, Madonna University, Okija, Nigeria.'}]",Acta ophthalmologica,['10.1111/aos.14440'] 29,32297653,Transmuscular quadratus lumborum block for percutaneous nephrolithotomy: Study protocol for a dose-finding trial.,"BACKGROUND The objective of this trial is to optimize the transmuscular quadratus lumborum (TQL) block, by investigating the minimal effective volume (MEV 90 ) of ropivacaine 0.75% for single-shot TQL block in percutaneous nephrolithotomy (PNL) patients. METHODS This double-blind, randomized and controlled dose-finding trial is based on a biased coin up-and-down sequential design, where the volume of local anaesthetic administered to each patient depends on the response from the previous one. Investigating the TQL block, the first patient recruited receives 20 ml ropivacaine 0.75% preoperatively. In case of block failure, the next patient will receive the same volume with an increment of 2 ml. Given a successful block for the first patient, the next patient will be randomized to either a lower volume (previous volume with a reduction of 2 ml), or the same volume as the previous patient. The respective probabilities being b = 0.11 for a reduced volume and 1-b = 0.89 for the same volume. Block success is defined as patient reported pain score numeric rated scale (NRS) ≤3 (0-10/10) 30 minutes after arrival in the post anaesthesia care unit (PACU). The NRS pain score is our primary and only outcome for block success. A minimum of 25 eligible patients are needed to achieve precise estimation of MEV 90 with narrow 95% confidence intervals derived by bootstrapping. DISCUSSION Recruiting will begin June 2020 and is expected to finish November 2020. Data analysis will be performed at interims during and after the study. Results will be published in an international peer-reviewed medical journal.",2020,The respective probabilities being b=0.11 for a reduced volume and 1-b=0.89 for the same volume.,"['25 eligible patients', 'percutaneous nephrolithotomy (PNL) patients']",['ropivacaine'],"['NRS pain score', 'pain score numeric rated scale (NRS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",,0.09871,The respective probabilities being b=0.11 for a reduced volume and 1-b=0.89 for the same volume.,"[{'ForeName': 'Christian H S', 'Initials': 'CHS', 'LastName': 'Andersen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Gunnar H', 'Initials': 'GH', 'LastName': 'Laier', 'Affiliation': 'Production, Research and Innovation, Region Sjaelland, Soro, Denmark.'}, {'ForeName': 'Martin V', 'Initials': 'MV', 'LastName': 'Nielsen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Dam', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Christian K', 'Initials': 'CK', 'LastName': 'Hansen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Katrine', 'Initials': 'K', 'LastName': 'Tanggaard', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Børglum', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13605'] 30,32297782,Influence of menthol and green apple e-liquids containing different nicotine concentrations among youth e-cigarette users.,"E-cigarettes are popular among adolescents. Given that flavors enhance e-cigarette appeal, this study examined the influence of flavors on nicotine in e-cigarettes. Youth e-cigarette users (average 26.2 days [SD = 3.6] in past 28 days) were randomized to use e-cigarettes containing 6 or 12 mg/mL of freebase nicotine and completed 4 test sessions. During the first 3 test sessions, participants completed 3 fixed puffing bouts (1 puffing bout = 10 puffs, 3 s each, 30-s interval), using menthol, green-apple, and unflavored e-liquids (50 propylene glycol [PG]/50 vegetable glycerin [VG]) with their assigned nicotine concentration in a random order using a ∼5.5-W V2 e-cigarette device. After each puffing bout, participants assessed subjective effects of nicotine and flavor. In the 4th test session, participants used any of the e-liquids they had tried in the earlier sessions, ad libitum for 60 min and the amount of e-liquid used for each flavor and the number of puffs was assessed. Participants (n = 49; 6 mg/mL [n = 24]; 12 mg/mL [n = 25]) were 63.3% male, 65.3% non-Hispanic White with an average age of 18.7 (SD = 0.9). Mixed models analysis revealed that green apple and 6 mg/mL of nicotine independently increased liking of e-cigarette taste. In addition, green apple produced higher ratings of fruitiness, sourness, sweetness, and menthol produced higher ratings of coolness. We did not observe any interactions between nicotine and flavor. Youth liked the taste of e-liquids containing green-apple flavor or low nicotine concentration which highlights the appeal of fruit flavors in e-cigarettes to adolescents. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,Mixed models analysis revealed that green apple and 6 mg/mL of nicotine independently increased liking of e-cigarette taste.,"['Youth e-cigarette users (average 26.2 days [SD = 3.6] in past 28 days', 'n = 25]) were 63.3% male, 65.3% non-Hispanic White with an average age of 18.7 (SD = 0.9', 'youth e-cigarette users']","['e-cigarettes containing 6 or 12 mg/mL of freebase nicotine', 'nicotine', 'menthol, green-apple, and unflavored e-liquids (50 propylene glycol [PG]/50 vegetable glycerin [VG]) with their assigned nicotine concentration', 'menthol and green apple e-liquids']",['liking of e-cigarette taste'],"[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C4505216', 'cui_str': 'Electronic cigarette user'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4068881', 'cui_str': '0.9'}]","[{'cui': 'C3849993', 'cui_str': 'Electronic cigarette'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0003625', 'cui_str': 'Malus'}, {'cui': 'C4543628', 'cui_str': 'Electronic cigarette liquid'}, {'cui': 'C0033437', 'cui_str': 'Propanediols'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]","[{'cui': 'C3849993', 'cui_str': 'Electronic cigarette'}, {'cui': 'C0039336', 'cui_str': 'Finding of sense of taste'}]",,0.0546791,Mixed models analysis revealed that green apple and 6 mg/mL of nicotine independently increased liking of e-cigarette taste.,"[{'ForeName': 'Asti', 'Initials': 'A', 'LastName': 'Jackson', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Green', 'Affiliation': 'Department of Surgery.'}, {'ForeName': 'Hanno C', 'Initials': 'HC', 'LastName': 'Erythropel', 'Affiliation': 'Department of Chemical and Environmental Engineering.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Kong', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Dana A', 'Initials': 'DA', 'LastName': 'Cavallo', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Tore', 'Initials': 'T', 'LastName': 'Eid', 'Affiliation': 'Department of Laboratory Medicine.'}, {'ForeName': 'Ralitza', 'Initials': 'R', 'LastName': 'Gueorguieva', 'Affiliation': 'Department of Biostatistics.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Buta', 'Affiliation': 'Department of Biostatistics.'}, {'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': ""O'Malley"", 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Suchitra', 'Initials': 'S', 'LastName': 'Krishnan-Sarin', 'Affiliation': 'Department of Psychiatry.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000368'] 31,32275468,Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.,"PURPOSE Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent EOC. METHODS Eligibility criteria included measurable disease, 1-3 prior regimens, and platinum-free interval (PFI) < 12 months. Participants were randomly allocated to intravenous nivolumab (every 2 weeks) or induction with nivolumab plus ipilimumab for 4 doses (every 3 weeks), followed by every-2-week maintenance nivolumab for a maximum of 42 doses. The primary null hypothesis was equal probability of objective response within 6 months of random allocation in each arm. RESULTS One hundred patients were allocated to receive either nivolumab (n = 49), or nivolumab plus ipilimumab (n = 51), with PFI of < 6 months in 62%. Six (12.2%) responses occurred within 6 months in the nivolumab group and 16 (31.4%) in the nivolumab plus ipilimumab group (odds ratio, 3.28; 85% CI, 1.54 to infinity; P = .034). The median progression-free survival (PFS) was 2 and 3.9 months in the nivolumab and nivolumab plus ipilimumab groups, respectively, with a PFI-stratified hazard ratio of 0.53 (95% CI, 0.34 to 0.82); the respective hazard ratio for death was 0.79 (95% CI, 0.44 to 1.42). Grade ≥ 3 related adverse events occurred in 33% of patients in the nivolumab group and 49% in the combination group, with no treatment-related deaths. PD-L1 expression was not significantly associated with response in either treatment group. CONCLUSION Compared with nivolumab alone, the combination of nivolumab and ipilimumab in EOC resulted in superior response rate and longer, albeit limited, PFS, with toxicity of the combination regimen comparable to prior reports. Additional combination studies to enhance durability of the dual regimen are warranted.",2020,"3 related adverse events occurred in 33% of patients in the nivolumab group and 49% in the combination group, with no treatment-related deaths.","['Recurrent or Persistent Ovarian Cancer', 'One hundred patients', 'epithelial ovarian cancer (EOC', 'Eligibility criteria included measurable disease, 1-3 prior regimens, and platinum-free interval (PFI) < 12 months', 'women with persistent or recurrent EOC']","['nivolumab', 'nivolumab plus ipilimumab', 'intravenous nivolumab (every 2 weeks) or induction with nivolumab plus ipilimumab', 'nivolumab alone', 'Nivolumab Versus Nivolumab and Ipilimumab']","['adverse events', 'Grade ≥', 'PD-L1 expression', 'median progression-free survival (PFS', 'respective hazard ratio for death']","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721610', 'cui_str': 'Epithelial Ovarian Carcinoma'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0585332', 'cui_str': 'Biweekly'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",100.0,0.189914,"3 related adverse events occurred in 33% of patients in the nivolumab group and 49% in the combination group, with no treatment-related deaths.","[{'ForeName': 'Dmitriy', 'Initials': 'D', 'LastName': 'Zamarin', 'Affiliation': 'Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Burger', 'Affiliation': 'Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Sill', 'Affiliation': 'Biostatistics and Bioinformatics, Clinical Trial Development Division, NRG Oncology, Roswell Park, Buffalo, NY.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Powell', 'Affiliation': 'Department of Pathology, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Heather A', 'Initials': 'HA', 'LastName': 'Lankes', 'Affiliation': ""NRG Oncology Biospecimen Bank-Columbus, Biopathology Center, The Research Institute at Nationwide Children's Hospital, Columbus, OH.""}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Feldman', 'Affiliation': 'Department of Pathology, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Zivanovic', 'Affiliation': 'Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Gunderson', 'Affiliation': 'Stephenson Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma; Oklahoma City, OK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Ko', 'Affiliation': 'Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Mathews', 'Affiliation': 'Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, RI.'}, {'ForeName': 'Sudarshan', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'AMITA Health Physicians, Hinsdale, IL.'}, {'ForeName': 'Andrea R', 'Initials': 'AR', 'LastName': 'Hagemann', 'Affiliation': 'Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, Saint Louis, MO.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Khleif', 'Affiliation': 'The Loop Immuno-oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington DC.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Aghajanian', 'Affiliation': 'Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.02059'] 32,30578883,Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.,"BACKGROUND In a recent phase III trial (NCT02020889) 53% of mepolizumab-treated versus 19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) achieved protocol-defined remission. OBJECTIVE We sought to investigate post hoc the clinical benefit of mepolizumab in patients with EGPA using a comprehensive definition of benefit encompassing remission, oral glucocorticoid (OGC) dose reduction, and EGPA relapses. METHODS The randomized, placebo-controlled, double-blind, parallel-group trial recruited patients with relapsing/refractory EGPA receiving stable OGCs (prednisolone/prednisone, ≥7.5-50 mg/d) for 4 or more weeks. Patients received 300 mg of subcutaneous mepolizumab or placebo every 4 weeks for 52 weeks. Clinical benefit was defined post hoc as follows: remission at any time (2 definitions used), 50% or greater OGC dose reduction during weeks 48 to 52, or no EGPA relapses. The 2 remission definitions were Birmingham Vasculitis Activity Score of 0 plus OGC dose of 4 mg/d or less (remission 1/clinical benefit 1) or 7.5 mg/d or less (remission 2/clinical benefit 2). Clinical benefit was assessed in all patients and among subgroups with a baseline blood eosinophil count of less than 150 cells/μL, baseline OGC dosage of greater than 20 mg/d, or weight of greater than 85 kg. RESULTS With mepolizumab versus placebo, 78% versus 32% of patients experienced clinical benefit 1, and 87% versus 53% of patients experienced clinical benefit 2 (both P < .001). Significantly more patients experienced clinical benefit 1 with mepolizumab versus placebo in the blood eosinophil count less than 150 cells/μL subgroup (72% vs 43%, P = .033) and weight greater than 85 kg subgroup (68% vs 23%, P = .005); in the OGC greater than 20 mg/d subgroup, results were not significant but favored mepolizumab (60% vs 36%, P = .395). CONCLUSION When a comprehensive definition of clinical benefit was applied to data from a randomized controlled trial, 78% to 87% of patients with EGPA experienced benefit with mepolizumab.",2019,"Significantly more patients experienced clinical benefit 1 with mepolizumab versus placebo in the blood eosinophil count less than 150 cells/μL subgroup (72% vs 43%, P = .033) and weight greater than 85 kg subgroup (68% vs 23%, P = .005); in the OGC greater than 20 mg/d subgroup, results were not significant but favored mepolizumab (60% vs 36%, P = .395). ","['treated patients with eosinophilic granulomatosis with polyangiitis (EGPA', ' ≥7.5-50\xa0mg/d) for 4 or more weeks', 'all patients and among subgroups with a baseline blood eosinophil count of less than 150\xa0cells/μL, baseline OGC dosage of greater than 20\xa0mg/d, or weight of greater than 85\xa0kg', 'patients with eosinophilic granulomatosis with polyangiitis', 'patients with EGPA using a comprehensive definition of benefit encompassing remission, oral glucocorticoid (OGC) dose reduction, and EGPA relapses', 'patients with relapsing/refractory EGPA receiving stable']","['mepolizumab', 'OGCs (prednisolone/prednisone', 'subcutaneous mepolizumab or placebo', 'placebo']","['Birmingham Vasculitis Activity Score', 'blood eosinophil count']","[{'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008728', 'cui_str': 'Allergic Granulomatosis'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0178602', 'cui_str': 'Dosages (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}]","[{'cui': 'C0969324', 'cui_str': 'mepolizumab'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2609436', 'cui_str': 'Vasculitis (SMQ)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}]",,0.433684,"Significantly more patients experienced clinical benefit 1 with mepolizumab versus placebo in the blood eosinophil count less than 150 cells/μL subgroup (72% vs 43%, P = .033) and weight greater than 85 kg subgroup (68% vs 23%, P = .005); in the OGC greater than 20 mg/d subgroup, results were not significant but favored mepolizumab (60% vs 36%, P = .395). ","[{'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Steinfeld', 'Affiliation': 'Respiratory TAU & Flexible Discovery Unit, GlaxoSmithKline, Philadelphia, Pa.'}, {'ForeName': 'Eric S', 'Initials': 'ES', 'LastName': 'Bradford', 'Affiliation': 'Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Brown', 'Affiliation': 'Research and Development, Immuno-Inflammation TAU, Uxbridge, United Kingdom.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Mallett', 'Affiliation': 'Research & Development, Statistics, Programming and Data Standards, GlaxoSmithKline, Stockley Park West, Uxbridge, United Kingdom.'}, {'ForeName': 'Steven W', 'Initials': 'SW', 'LastName': 'Yancey', 'Affiliation': 'Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC.'}, {'ForeName': 'Praveen', 'Initials': 'P', 'LastName': 'Akuthota', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, Calif.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Cid', 'Affiliation': ""Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Gerald J', 'Initials': 'GJ', 'LastName': 'Gleich', 'Affiliation': 'Departments of Dermatology and Medicine, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Jayne', 'Affiliation': 'Department of Medicine, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Paneez', 'Initials': 'P', 'LastName': 'Khoury', 'Affiliation': 'Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Langford', 'Affiliation': 'Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Merkel', 'Affiliation': 'Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pa.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Moosig', 'Affiliation': 'Rheumazentrum, Schleswig-Holstein Mitte, Neumünster, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Specks', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minn.'}, {'ForeName': 'Peter F', 'Initials': 'PF', 'LastName': 'Weller', 'Affiliation': 'Divisions of Allergy and Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Wechsler', 'Affiliation': 'Department of Medicine, National Jewish Health, Denver, Colo. Electronic address: wechslerm@njhealth.org.'}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2018.11.041'] 33,32297783,Efficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder.,"There has been a lack of research on the third area of impairment noted in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition -""occupational functioning."" It is important to understand the impact of common treatments for attention-deficit/hyperactivity disorder (ADHD) in occupational settings. Twenty individuals with ADHD between ages 16 and 25 participated in a double-blind, placebo controlled evaluation of 40 mg lisdexamfetamine dimesylate in a setting designed to approximate a restaurant workplace with associated, simulated food delivery. Outcome measures included ratings of performance, as well as behavioral productivity. Results indicated that participants completed more workplace tasks when on medication, relative to placebo. Ratings of job application quality, job interview performance, and delivery outcomes were not significantly different on medication versus placebo. These results suggest positive effects of medication in a workplace environment, but also a need for study of additional interventions to support workplace-related behavior and functioning. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Ratings of job application quality, job interview performance, and delivery outcomes were not significantly different on medication versus placebo.","['Twenty individuals with ADHD between ages 16 and 25 participated', 'adolescents and young adults with attention-deficit/hyperactivity disorder']","['lisdexamfetamine dimesylate', 'placebo']","['occupational success', 'ratings of performance, as well as behavioral productivity', 'workplace tasks', 'Ratings of job application quality, job interview performance, and delivery outcomes']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C1739826', 'cui_str': 'Lisdexamfetamine dimesylate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0521127', 'cui_str': 'Occupational'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0022395', 'cui_str': 'Employment Application'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",20.0,0.188748,"Ratings of job application quality, job interview performance, and delivery outcomes were not significantly different on medication versus placebo.","[{'ForeName': 'Chanelle T', 'Initials': 'CT', 'LastName': 'Gordon', 'Affiliation': 'Department of Counseling, School, and Educational Psychology, University at Buffalo-State University of New York.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Fabiano', 'Affiliation': 'Department of Counseling, School, and Educational Psychology, University at Buffalo-State University of New York.'}, {'ForeName': 'Kevin F', 'Initials': 'KF', 'LastName': 'Hulme', 'Affiliation': 'Department of Mechanical and Aerospace Engineering, University at Buffalo-State University of New York.'}, {'ForeName': 'Sandro M', 'Initials': 'SM', 'LastName': 'Sodano', 'Affiliation': 'Department of Counseling, School, and Educational Psychology, University at Buffalo-State University of New York.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Adragna', 'Affiliation': 'Jacobs School of Medicine and Biological Sciences, University at Buffalo-State University of New York.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Lim', 'Affiliation': 'Department of Mechanical and Aerospace Engineering, University at Buffalo-State University of New York.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Stanford', 'Affiliation': 'Department of Counseling, School, and Educational Psychology, University at Buffalo-State University of New York.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Janikowski', 'Affiliation': 'Department of Counseling, School, and Educational Psychology, University at Buffalo-State University of New York.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Bufalo', 'Affiliation': 'Department of Counseling, School, and Educational Psychology, University at Buffalo-State University of New York.'}, {'ForeName': 'Zulema', 'Initials': 'Z', 'LastName': 'Rodriguez', 'Affiliation': 'Department of Counseling, School, and Educational Psychology, University at Buffalo-State University of New York.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Swiatek', 'Affiliation': 'Department of Pharmacy Practice in the Clinical and Translational Research Center, University at Buffalo-State University of New York.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000365'] 34,32297784,Sleep moderates the relationship between stress and craving in individuals with opioid use disorder.,"Opioid use disorder (OUD) is a national public health concern. Craving, stress, and exposure to conditioned drug cues are implicated in risk of relapse to opioids. Although impaired sleep has been implicated in risk of relapse to other substances of misuse, little research to date has examined the relationship between sleep and craving in individuals with OUD. The present study examined sleep as a moderator of the relationship between craving and stress in a randomized controlled human laboratory study. Individuals with current OUD ( N = 39) completed a 1-night hospital stay to control for factors that may affect craving, stress, and sleep. Sleep was monitored via an actigraphy watch and the Pittsburgh Sleep Quality Index. The next morning, participants were randomized to a 15-min laboratory stress task or a no-stress condition. All participants were then exposed to a 15-min opioid cue paradigm, and craving was measured via self-report. Moderation models were conducted to evaluate whether the sleep indices moderated the relationship between stress condition (independent variable) and craving (dependent variable). Average self-reported nightly sleep duration moderated the relationship between stress condition and craving for participants in the no-stress condition ( b = 0.95, p < .05). Specifically, participants in the no-stress condition with lower average nightly sleep duration exhibited significantly greater craving following the opioid cue paradigm. Although preliminary, the findings add to the literature on craving, stress, and sleep among individuals with OUD. Sleep impairment may be an important target of a comprehensive, long-term treatment plan for some patients with OUD. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Average self-reported nightly sleep duration moderated the relationship between stress condition and craving for participants in the no-stress condition ( b = 0.95, p < .05).","['individuals with OUD', 'Individuals with current OUD ( N = 39', 'patients with OUD', 'individuals with opioid use disorder']",['15-min laboratory stress task or a no-stress condition'],"['Pittsburgh Sleep Quality Index', 'craving, stress, and sleep', 'Sleep']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",,0.0231032,"Average self-reported nightly sleep duration moderated the relationship between stress condition and craving for participants in the no-stress condition ( b = 0.95, p < .05).","[{'ForeName': 'Jenni B', 'Initials': 'JB', 'LastName': 'Teeters', 'Affiliation': 'Department of Psychological Sciences, Western Kentucky University.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Jones', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina.'}, {'ForeName': 'Amber M', 'Initials': 'AM', 'LastName': 'Jarnecke', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina.'}, {'ForeName': 'Sudie E', 'Initials': 'SE', 'LastName': 'Back', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000372'] 35,32297786,Baseline performance moderates stimulant effects on cognition in youth with ADHD.,"Attention-deficit/hyperactivity disorder is associated with impaired cognitive functioning and increased delay discounting (i.e., a stronger preference for immediate reward). At the group level, stimulant medication improves cognition and delay discounting, yet not all children exhibit problems in these domains, and previous work has not examined whether stimulant-induced improvements are moderated by baseline performance. To address this question in the current study, 82 children with attention-deficit/hyperactivity disorder (9-12 years old) attended a week-long research camp. On the baseline day (Monday), participants completed tasks of inhibitory control, visuospatial working memory, reaction time variability, and delay discounting. Children then completed a 3-day, randomized, double-blind, placebo-controlled trial of ∼1 mg/kg and 2 mg/kg long-acting methylphenidate (mean doses = 39.1 and 74.3 mg, respectively), during which they were readministered the battery of tasks. Cognitive composites (mean of inhibitory control, working memory, and reaction time variability performance) were created for the baseline and medication evaluation phases. As predicted, the extent to which cognition was improved with medication compared with placebo and with 2 mg/kg compared with 1 mg/kg was greatest among children with poorer baseline cognitive function. Children with stronger baseline cognition exhibited less improvement with methylphenidate compared with placebo and did not benefit from the 2 compared with the 1 mg/kg dose. In contrast, medication-related improvement in delay discounting was unrelated to baseline discounting. Given that improving cognitive function is one potential mechanisms by which stimulants exert their therapeutic effects, this study has significant implications for understanding how and for whom stimulant medication works. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,Children with stronger baseline cognition exhibited less improvement with methylphenidate compared with placebo and did not benefit from the 2 compared with the 1 mg/kg dose.,"['82 children with attention-deficit/hyperactivity disorder (9-12 years old) attended a week-long research camp', 'youth with ADHD']","['methylphenidate', '∼1 mg/kg and 2 mg/kg long-acting methylphenidate', 'placebo']","['Cognitive composites (mean of inhibitory control, working memory, and reaction time variability performance', 'cognition and delay discounting', 'delay discounting', 'inhibitory control, visuospatial working memory, reaction time variability, and delay discounting']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0001455', 'cui_str': 'Cyclic AMP'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]","[{'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}]",82.0,0.372394,Children with stronger baseline cognition exhibited less improvement with methylphenidate compared with placebo and did not benefit from the 2 compared with the 1 mg/kg dose.,"[{'ForeName': 'Whitney D', 'Initials': 'WD', 'LastName': 'Fosco', 'Affiliation': 'Center for Children and Families, Florida International University.'}, {'ForeName': 'Keri S', 'Initials': 'KS', 'LastName': 'Rosch', 'Affiliation': 'Center for Neurodevelopmental and Imaging Research, Kennedy Krieger Institute, Johns Hopkins University School of Medicine.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Waxmonsky', 'Affiliation': 'Department of Psychiatry, Pennsylvania State University College of Medicine.'}, {'ForeName': 'William E', 'Initials': 'WE', 'LastName': 'Pelham', 'Affiliation': 'Center for Children and Families and Department of Psychology, Florida International University.'}, {'ForeName': 'Larry W', 'Initials': 'LW', 'LastName': 'Hawk', 'Affiliation': 'Department of Psychology, University at Buffalo, State University of New York.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000374'] 36,32259412,Efficacy of laser application in dental bleaching: A randomized clinical controlled trial.,"PURPOSE To evaluate the bleaching efficacy of laser application with chemical treatment compared to chemical treatment alone. METHODS This was a randomized controlled trial (RCT), single blind (evaluator), in 24 patients randomized into two groups: Laser and chemical intervention (12) or chemical intervention alone without laser (12). The commercial products used were Whiteness HP 35% hydrogen peroxide gel and the Whitening Laser II of DCM equipment. The color was measured with a spectrophotometer before, immediately and 3 days after the bleaching procedure. The trial outcome measures were obtained using the Vita EasyShade spectrophotometer and the International CIELCh system. To establish differences before vs. after treatments and between groups, the T test and chi² tests were applied. The data was statistically analyzed with Student's T-test (P ≤ 0.05). RESULTS After applying the delta formula to measure the change in color, both groups gave clinically significant results before vs. after bleaching procedures ( P ≤ 0.05). The deltas for luminosity, chroma, and hue all showed significant improvements for baseline to 15 minutes post treatment (P ≤ 0.05), baseline to 3 days post treatment (P ≤ 0.05), but not for 15 minutes to 3 days post treatment (P ≥ 0.05). When comparing between groups applying T-test, no statistically significant differences were found (P ≥ 0.05) for all three deltas. When comparing sensitivity after bleaching, no differences were found between groups (P ≥ 0.05). CLINICAL SIGNIFICANCE The use of laser during bleaching treatment did not improve the results compared to not using laser.",2020,"When comparing between groups applying T-test, no statistically significant differences were found (P ≥ 0.05) for all three deltas.","['dental bleaching', '24 patients randomized into two groups']","['HP 35% hydrogen peroxide gel and the Whitening Laser II of DCM equipment', 'Laser and chemical intervention (12) or chemical intervention alone without laser (12', 'laser application']",['Vita EasyShade spectrophotometer and the International CIELCh system'],"[{'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0025748', 'cui_str': 'methylene chloride'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0220806', 'cui_str': 'Chemical'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0373745', 'cui_str': 'Vitamin A measurement'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",24.0,0.0307662,"When comparing between groups applying T-test, no statistically significant differences were found (P ≥ 0.05) for all three deltas.","[{'ForeName': 'Julieta M', 'Initials': 'JM', 'LastName': 'Méndez Romero', 'Affiliation': 'Faculty of Odontology, National University of Caaguazú, Coronel Oviedo, Paraguay, julieta_mendez92@hotmail.com.'}, {'ForeName': 'Ulises A', 'Initials': 'UA', 'LastName': 'Villasanti Torales', 'Affiliation': 'Dentistry Faculty, National University of Caaguazú, Coronel Oviedo, Paraguay.'}, {'ForeName': 'Carlos J', 'Initials': 'CJ', 'LastName': 'Villalba Martínez', 'Affiliation': 'Dentistry Faculty, National University of Caaguazú, Coronel Oviedo, Paraguay.'}]",American journal of dentistry,[] 37,32308128,"Clinical application of a new ternary polymer, SEC-1 coat™, for pediatric cardiopulmonary bypass circuits: a prospective randomized pilot study.","OBJECTIVE The use of biocompatible materials to reduce the systemic activation of inflammation and coagulation pathways is expanding rapidly. However, there have been few clinical studies of biocompatible circuits for pediatric cardiopulmonary bypass. This pilot study aimed to preliminarily evaluate the biocompatibility of SEC-1 coat™ (SEC) for cardiopulmonary bypass circuits in pediatric cardiac surgery. METHODS Twenty infants undergoing cardiac surgery for isolated ventricular septal defects at Kobe Children's Hospital were assigned randomly to an SEC-coated (SEC group, n = 10) or heparin-coated (control group, n = 10) circuit. Perioperative data and the following markers were prospectively analyzed: platelet counts and interleukin-6, interleukin-8, C3a, β-thromboglobulin, and thrombin-antithrombin complex levels. RESULTS Neither patient characteristics nor postoperative clinical outcomes differed significantly between the SEC and control groups. Platelet counts markedly decreased during cardiopulmonary bypass in both groups, but were significantly better preserved in the SEC group. Fewer patients needed postoperative platelet transfusions in the SEC group. After cardiopulmonary bypass termination, serum levels of β-thromboglobulin and thrombin-antithrombin complex were significantly lower in the SEC than in the control group. Although the differences were not statistically significant, serum levels of interleukin-6, interleukin-8, and C3a had a tendency toward being lower in the SEC group, with good preservation of leukocyte counts, fibrinogen, and antithrombin III. CONCLUSION SEC-1 coat™ for cardiopulmonary bypass circuits have good biocompatibility with regard to platelet preservation and in terms of attenuating inflammatory reaction or coagulation activation during pediatric cardiac surgery. It can be beneficial in pediatric as well as adult cardiac surgery.",2020,"Although the differences were not statistically significant, serum levels of interleukin-6, interleukin-8, and C3a had a tendency toward being lower in the SEC group, with good preservation of leukocyte counts, fibrinogen, and antithrombin III. CONCLUSION SEC-1 coat™ for cardiopulmonary bypass circuits have good biocompatibility with regard to platelet preservation and in terms of attenuating inflammatory reaction or coagulation activation during pediatric cardiac surgery.","['pediatric cardiac surgery', 'pediatric cardiopulmonary bypass circuits', 'pediatric cardiopulmonary bypass', ""Twenty infants undergoing cardiac surgery for isolated ventricular septal defects at Kobe Children's Hospital""]","['new ternary polymer, SEC-1 coat', 'SEC-1 coat™ (SEC', 'SEC-coated (SEC group, n\u2009=\u200910) or heparin-coated (control group, n\u2009=\u200910) circuit']","['serum levels of β-thromboglobulin and thrombin-antithrombin complex', 'platelet counts and interleukin-6, interleukin-8, C3a, β-thromboglobulin, and thrombin-antithrombin complex levels', 'serum levels of interleukin-6, interleukin-8, and C3a', 'postoperative platelet transfusions', 'postoperative clinical outcomes', 'Platelet counts']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0018830', 'cui_str': 'Cardiopulmonary bypass circuit'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0018818', 'cui_str': 'Ventricular septal defect'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0059387', 'cui_str': 'staphylococcal enterotoxin C'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0052128', 'cui_str': 'Thrombin-antithrombin complex'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0523338', 'cui_str': 'Complement C3a measurement'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0086818', 'cui_str': 'Platelet transfusion'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",20.0,0.0239215,"Although the differences were not statistically significant, serum levels of interleukin-6, interleukin-8, and C3a had a tendency toward being lower in the SEC group, with good preservation of leukocyte counts, fibrinogen, and antithrombin III. CONCLUSION SEC-1 coat™ for cardiopulmonary bypass circuits have good biocompatibility with regard to platelet preservation and in terms of attenuating inflammatory reaction or coagulation activation during pediatric cardiac surgery.","[{'ForeName': 'Tomomi', 'Initials': 'T', 'LastName': 'Hasegawa', 'Affiliation': ""Department of Pediatric Critical Care Medicine, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.""}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Oshima', 'Affiliation': ""Department of Cardiovascular Surgery, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.""}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Yokoyama', 'Affiliation': ""Department of Cardiovascular Surgery, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.""}, {'ForeName': 'Asuka', 'Initials': 'A', 'LastName': 'Akimoto', 'Affiliation': ""Department of Cardiovascular Surgery, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.""}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Misaka', 'Affiliation': ""Department of Cardiovascular Surgery, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.""}, {'ForeName': 'Shota', 'Initials': 'S', 'LastName': 'Akiyama', 'Affiliation': ""Department of Cardiovascular Surgery, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.""}]",Perfusion,['10.1177/0267659120915387'] 38,31957334,Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation.,"Optimal fludarabine exposure has been associated with improved treatment outcome in allogeneic hematopoietic cell transplantation, suggesting potential benefit of individualized dosing. A randomized controlled trial (RCT) comparing alternative fludarabine dosing strategies to current practice may be warranted, but should be sufficiently powered for a relevant end point, while still feasible to enroll. To find the optimal design, we simulated RCTs comparing current practice (160 mg/m 2 ) to either covariate-based or therapeutic drug monitoring (TDM)-guided dosing with potential outcomes being nonrelapse mortality (NRM), graft failure, or relapse, and ultimately overall survival (covering all three aforementioned outcomes). The inclusion in each treatment arm (n) required to achieve 80% power was calculated for all combinations of end points and dosing comparisons. The trial requiring the lowest n for sufficient power compared TDM-guided dosing to current practice with NRM as primary outcome (n = 70, NRM decreasing from 21% to 5.7%). We conclude that a superiority trial is feasible.",2020,The inclusion in each treatment arm (n) required to achieve 80% power was calculated for all combinations of endpoints and dosing comparisons.,"['allogeneic hematopoietic cell transplantation (HCT', 'allogeneic hematopoietic cell transplantation']",['fludarabine'],"['relapse mortality (NRM), graft failure, or relapse, and ultimately overall survival (OS']","[{'cui': 'C0206153', 'cui_str': 'Cell Transplantation'}]","[{'cui': 'C0059985', 'cui_str': 'fludarabine'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1262018', 'cui_str': 'Transplant failure'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.0895835,The inclusion in each treatment arm (n) required to achieve 80% power was calculated for all combinations of endpoints and dosing comparisons.,"[{'ForeName': 'Jurgen B', 'Initials': 'JB', 'LastName': 'Langenhorst', 'Affiliation': 'Pediatric Blood and Marrow Transplant Program, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.'}, {'ForeName': 'Thomas P C', 'Initials': 'TPC', 'LastName': 'Dorlo', 'Affiliation': 'Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'van Kesteren', 'Affiliation': 'Pediatric Blood and Marrow Transplant Program, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.'}, {'ForeName': 'Erik M', 'Initials': 'EM', 'LastName': 'van Maarseveen', 'Affiliation': 'Department of Clinical Pharmacy, University Medical Centre Utrecht (UMCU), Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Nierkens', 'Affiliation': 'Pediatric Blood and Marrow Transplant Program, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.'}, {'ForeName': 'Moniek A', 'Initials': 'MA', 'LastName': 'de Witte', 'Affiliation': 'Department of Hematology, University Medical Centre Utrecht (UMCU), Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Jaap Jan', 'Initials': 'JJ', 'LastName': 'Boelens', 'Affiliation': 'Pediatric Blood and Marrow Transplant Program, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.'}, {'ForeName': 'Alwin D R', 'Initials': 'ADR', 'LastName': 'Huitema', 'Affiliation': 'Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}]",CPT: pharmacometrics & systems pharmacology,['10.1002/psp4.12486'] 39,32053276,Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.,"BACKGROUND Anti-platelet antibody testing may be useful for the diagnosis and management of childhood immune thrombocytopenia (ITP). OBJECTIVES Here we aimed to assess the prevalence and prognostic significance of anti-platelet glycoprotein-specific IgM and IgG antibodies. METHODS Children with newly diagnosed ITP were included at diagnosis and randomized to an intravenous immunoglobulins (IVIg) or careful observation group (TIKI trial). In this well-defined and longitudinally followed cohort (N = 179), anti-platelet glycoprotein-specific IgM and IgG antibodies were determined by monoclonal antibody-immobilization of platelet antigens. RESULTS The dominant circulating anti-platelet antibody class in childhood ITP was IgM (62% of patients); but IgG antibodies were also found (10%). Children without IgM platelet antibodies were older and more often female. There was weak evidence for an association between IgM anti-GP IIb/IIIa antibodies and an increased bleeding severity (P = .03). The IgM and IgG anti-platelet responses partially overlapped, and reactivity was frequently directed against multiple glycoproteins. During 1-year follow-up, children with IgM antibodies in the observation group displayed a faster platelet recovery compared to children without, also after adjustment for age and preceding infections (P = 7.1 × 10 -5 ). The small group of patients with detectable IgG anti-platelet antibodies exhibited an almost complete response to IVIg treatment (N = 12; P = .02), suggesting that IVIg was particularly efficacious in these children. CONCLUSIONS Testing for circulating anti-platelet antibodies may be helpful for the clinical prognostication and the guidance of treatment decisions in newly diagnosed childhood ITP. Our data suggest that the development of even more sensitive tests may further improve the clinical value of antibody testing.",2020,"During one year follow-up, children with IgM antibodies in the observation group displayed a faster platelet recovery compared to children without IgM, also after adjustment for age and preceding infections (P=7.1x10 -5 ).","['Childhood Immune Thrombocytopenia', 'Children with newly diagnosed ITP were included at diagnosis and randomized to an']",['intravenous immunoglobulins (IVIg) or careful observation'],"['anti-platelet glycoprotein-specific IgM and IgG antibodies', 'IgM and IgG anti-platelet responses', 'bleeding severity', 'platelet recovery', 'IgG antibodies']","[{'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0272286', 'cui_str': 'Thrombocytopenia due to immune destruction'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021540', 'cui_str': 'ITP'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0085297', 'cui_str': 'Immunoglobulins, Intravenous'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]","[{'cui': 'C0086816', 'cui_str': 'Platelet Glycoproteins'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0020861', 'cui_str': 'IgM'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",179.0,0.0261397,"During one year follow-up, children with IgM antibodies in the observation group displayed a faster platelet recovery compared to children without IgM, also after adjustment for age and preceding infections (P=7.1x10 -5 ).","[{'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Schmidt', 'Affiliation': 'Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.'}, {'ForeName': 'Katja M J', 'Initials': 'KMJ', 'LastName': 'Heitink-Polle', 'Affiliation': 'Department of Pediatric Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Leendert', 'Initials': 'L', 'LastName': 'Porcelijn', 'Affiliation': 'Laboratory for Platelet and Leukocyte Serology, Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, the Netherlands.'}, {'ForeName': 'C Ellen', 'Initials': 'CE', 'LastName': 'van der Schoot', 'Affiliation': 'Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.'}, {'ForeName': 'Gestur', 'Initials': 'G', 'LastName': 'Vidarsson', 'Affiliation': 'Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.'}, {'ForeName': 'Marrie C A', 'Initials': 'MCA', 'LastName': 'Bruin', 'Affiliation': 'Department of Pediatric Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Masja', 'Initials': 'M', 'LastName': 'de Haas', 'Affiliation': 'Laboratory for Platelet and Leukocyte Serology, Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, the Netherlands.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14762'] 40,32270496,Noninterventional follow-up vs fluid bolus in RESPONSE to oliguria-The RESPONSE trial protocol and statistical analysis plan.,"BACKGROUND Oliguria is a frequent trigger for administering a fluid bolus, but the effect of fluid bolus in improving urine output is inadequately demonstrated. Here, we summarize the protocol and detailed statistical analysis plan of the randomized, controlled RESPONSE trial comparing follow-up as the experimental group and a 500 mL crystalloid fluid bolus as the control group for oliguria in critically ill oliguric patients. METHODS Our trial is an investigator-initiated, randomized, controlled, pilot trial conducted in three ICUs in two centers. We aim to randomize 1:1 altogether 130 hemodynamically stable oliguric patients either to a 2-hour follow-up without interventions or to receive a crystalloid bolus of 500 mL over 30 minutes. The primary outcome is the change in individual urine output during the 2-hour period compared to 2 hours preceding randomization. Doubling of the urine output is considered clinically significant. Additionally, we record the duration of oliguria, physiological and biochemical variables, adverse events, and the incidences of acute kidney injury and renal replacement therapy. CONCLUSIONS Oliguria is a frequent trigger for potentially harmful fluid loading. Therefore, the RESPONSE trial will give information of the potential effect of fluid bolus on oliguria in critically ill patients. TRIAL REGISTRATION clinical.trials.gov, NCT02860572.",2020,130 hemodynamically stable oliguric patients either to a 2-hour follow-up without interventions or to receive a crystalloid bolus of 500 mL over 30 minutes.,"['130 hemodynamically stable oliguric patients', 'critically ill patients', 'critically ill oliguric patients']",[],"['change in individual urine output', 'duration of oliguria, physiological and biochemical variables, adverse events, and the incidences of acute kidney injury and renal replacement therapy']","[{'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0578150', 'cui_str': 'Hemodynamically stable'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}]",[],"[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0028961', 'cui_str': 'Oliguria'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}]",130.0,0.334481,130 hemodynamically stable oliguric patients either to a 2-hour follow-up without interventions or to receive a crystalloid bolus of 500 mL over 30 minutes.,"[{'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Inkinen', 'Affiliation': 'Department of Anesthesia and Intensive Care, Central Finland Central Hospital, Central Finland Health Care District, Jyväskylä, Finland.'}, {'ForeName': 'Tuomas', 'Initials': 'T', 'LastName': 'Selander', 'Affiliation': 'Science Service Center, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Ville', 'Initials': 'V', 'LastName': 'Pettilä', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Miia', 'Initials': 'M', 'LastName': 'Valkonen', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Minna', 'Initials': 'M', 'LastName': 'Bäcklund', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Wennervirta', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Anni', 'Initials': 'A', 'LastName': 'Pulkkinen', 'Affiliation': 'Department of Anesthesia and Intensive Care, Central Finland Central Hospital, Central Finland Health Care District, Jyväskylä, Finland.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Hästbacka', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Suvi T', 'Initials': 'ST', 'LastName': 'Vaara', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13599'] 41,32270474,"Ultrasound-guided transmuscular quadratus lumborum catheters for elective caesarean section: A protocol for a single-centre, double-blind randomised trial.","BACKGROUND Management of moderate-to-severe post-operative pain after elective caesarean section (ECS) is internationally primarily based on either epidural catheters or opioids. However, both techniques are associated with some undesirable adverse events. Bilateral transmuscular quadratus lumborum (TQL) block has proven to reduce opioid consumption significantly in the first 24 post-operative hours following ECS and prolong time to first opioid (TFO) (Hansen CKD, Steingrimsdottir M, Laier GE, et al. Reg Anesth Pain Med. 2019; 10.1136/rapm-2019-100540). We present a randomised controlled trial aiming to investigate whether continuous analgesia via bilateral TQL catheters can prolong TFO after ECS. METHODS This study is a double-blind, randomised, placebo-controlled trial. Patients should be 18 years or older and scheduled for ECS under spinal anaesthesia to be included. Main exclusion criteria are inability to cooperate, excessive daily intake of opioids and difficult ultrasound visualisation of muscular and fascial structures. Participants are randomised to receive ultrasound-guided injection of either 30 mL ropivacaine 0.2% bilaterally and an elastomeric pump containing 0.2% ropivacaine, or 30 mL saline bilaterally and an elastomeric pump containing saline, 2 hours after catheter placement. The primary endpoint is TFO. Secondary outcomes include pain intensity on a numeric rating scale (NRS), accumulated morphine consumption during 24 hours, displacement frequency of catheters and morphine-related adverse events. RECRUITMENT PERIOD Four patients were included from September 2018 to November 2018. Inclusion was resumed in June 2019 and will continue until 24 patients with useful data have been included in the trial. Expected inclusion period is 10-14 months. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT03663478. EudraCT: 2017-003625-15.",2020,Bilateral transmuscular quadratus lumborum (TQL) block has proven to reduce opioid consumption significantly in the first 24 postoperative hours following ECS and prolong time to first opioid (TFO).,"['Patients should be 18 years or older and scheduled for ECS under spinal anaesthesia to be included', 'PERIOD\n\n\nFour patients were included from September 2018 - November 2018', 'elective caesarean section', '24 patients with useful data have been included in the trial', 'moderate to severe postoperative pain after elective caesarean section (ECS']","['Bilateral transmuscular quadratus lumborum (TQL) block', 'placebo', 'continuous analgesia via bilateral TQL catheters', 'ultrasound-guided injection of either 30 ml ropivacaine 0.2% bilaterally and an elastomeric pump containing 0.2% ropivacaine, or 30 ml saline bilaterally and an elastomeric pump containing saline', 'Ultrasound-guided transmuscular quadratus lumborum catheters']","['pain intensity on a numeric rating scale (NRS), accumulated morphine consumption during 24 hours, displacement frequency of catheters and morphine-related adverse events', 'TFO', 'opioid consumption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0224380', 'cui_str': 'Structure of quadratus lumborum muscle'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}]",4.0,0.736749,Bilateral transmuscular quadratus lumborum (TQL) block has proven to reduce opioid consumption significantly in the first 24 postoperative hours following ECS and prolong time to first opioid (TFO).,"[{'ForeName': 'Guðný E', 'Initials': 'GE', 'LastName': 'Steingrímsdóttir', 'Affiliation': 'Department of Anaesthesiology, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Christian K', 'Initials': 'CK', 'LastName': 'Hansen', 'Affiliation': 'Department of Anaesthesiology, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Børglum', 'Affiliation': 'Department of Anaesthesiology, Zealand University Hospital, Roskilde, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13601'] 42,32316886,Efficacy of Cognitive Behavioral Treatment for Insomnia: A Randomized Controlled Trial.,"This study examined the effects of cognitive behavioral treatment for insomnia. A randomized controlled trial was performed on 44 women. The intervention included one group session of sleep hygiene education and four individual sessions of counseling. The instruments included the Insomnia Severity Index, Pittsburgh Sleep Quality Index, the Center for Epidemiological Studies Depression Scale, and Menopausal quality of life. The data were analyzed using repeated measure MANOVA, followed by repeated measure ANOVA. Repeated measure MANOVA showed that time had a significant main effect on the anthropometric variables (body mass index, waist circumference, and blood pressures) and revealed significant main effects of the group and time on the psychosocial variables (sleep quality, insomnia, depressive symptoms, and quality of life) ( p < .05). Repeated measure ANOVA results indicated a significant effect of the group on insomnia and sleep quality ( p < .05). Overall, the intervention was effective in improving insomnia and poor sleep quality.",2020,Repeated measure ANOVA results indicated a significant effect of the group on insomnia and sleep quality ( p < .05).,"['44 women', 'Insomnia', 'insomnia']","['Cognitive Behavioral Treatment', 'sleep hygiene education and four individual sessions of counseling', 'cognitive behavioral treatment']","['Insomnia Severity Index, Pittsburgh Sleep Quality Index, the Center for Epidemiological Studies Depression Scale, and Menopausal quality of life', 'anthropometric variables (body mass index, waist circumference, and blood pressures', 'insomnia and sleep quality', 'psychosocial variables (sleep quality, insomnia, depressive symptoms, and quality of life', 'insomnia and poor sleep quality']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}]","[{'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C4277672', 'cui_str': 'Good Sleep Habits'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0002783', 'cui_str': 'Studies, Epidemiologic'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0033963', 'cui_str': 'Psychosocial Factors'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0235162', 'cui_str': 'Difficulty sleeping'}, {'cui': 'C0332306', 'cui_str': 'Quality'}]",44.0,0.0326915,Repeated measure ANOVA results indicated a significant effect of the group on insomnia and sleep quality ( p < .05).,"[{'ForeName': 'Ok Kyung', 'Initials': 'OK', 'LastName': 'Ham', 'Affiliation': 'Department of Nursing, Inha University, Incheon, Republic of Korea.'}, {'ForeName': 'Bo Gyeong', 'Initials': 'BG', 'LastName': 'Lee', 'Affiliation': 'College of Nursing, Daegu Catholic University, Daegu, Republic of Korea.'}, {'ForeName': 'Eunju', 'Initials': 'E', 'LastName': 'Choi', 'Affiliation': 'College of Nursing, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Su Jung', 'Initials': 'SJ', 'LastName': 'Choi', 'Affiliation': 'Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Suwon, Republic of Korea.'}]",Western journal of nursing research,['10.1177/0193945920914081'] 43,31514201,The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder.,"The current study aimed to explore the possible effect of stimulants on oxytocin (OT), a neuropeptide which regulates social behavior, as a mediator of the pro-social effect of methylphenidate (MPH) in children with attention deficit hyperactivity disorder (ADHD) compared to healthy controls (HCs). Utilizing a double-blind placebo-controlled design, we compared the performance of 50 children with ADHD and 40 HCs in ""theory of mind"" (ToM) tasks and examined the effect of a single dose of MPH/placebo on ToM and salivary OT levels in children with ADHD at baseline and following an interpersonal interaction. Children with ADHD displayed significantly poorer ToM performance; however, following MPH administration, their performance normalized and differences between children with ADHD and HC were no longer found. Salivary OT levels at baseline did not differ between children with ADHD and HCs. However, after a parent-child interaction, OT levels were significantly higher in the HC group compared to children with ADHD. Administration of MPH attenuated this difference such that after parent-child interaction differences in OT levels between children with ADHD and HC were no longer found. In the ADHD group, OT levels decreased from administration of placebo to the parent-child interaction. However, the administration of MPH to children with ADHD was associated with an increase in OT levels after the parent-child interaction. We conclude that OT might play a role as a mediator of social deficits in children with ADHD and that the reactivity of the OT system to social interaction in children with ADHD might be impaired. Stimulants may improve ToM and social functions in children with ADHD via its impact on the OT system. PRS: OT and Social Cognition in Children with ADHD: Impact of MPH.",2020,"However, after a parent-child interaction, OT levels were significantly higher in the HC group compared to children with ADHD.","['Children with ADHD', 'children with attention deficit hyperactivity disorder (ADHD', '50 children with ADHD and 40 HCs in ""theory of mind"" (ToM) tasks', 'children with ADHD at baseline and following an interpersonal interaction', 'children with attention deficit hyperactivity disorder', 'children with ADHD']","['methylphenidate', 'HC', 'MPH', 'MPH/placebo', 'oxytocin (OT', 'placebo', 'methylphenidate (MPH']","['ToM and social functions', 'poorer ToM performance', 'Salivary OT levels', 'social cognition and oxytocin', 'ToM and salivary OT levels', 'OT levels']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}, {'cui': 'C0935573', 'cui_str': 'Mentalizing'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}]","[{'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0048853', 'cui_str': 'MPH'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}]",50.0,0.04804,"However, after a parent-child interaction, OT levels were significantly higher in the HC group compared to children with ADHD.","[{'ForeName': 'Orit', 'Initials': 'O', 'LastName': 'Levi-Shachar', 'Affiliation': 'Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Hila Z', 'Initials': 'HZ', 'LastName': 'Gvirts', 'Affiliation': 'Department of Behavioral Sciences and Psychology, Ariel University, Ariel, Israel.'}, {'ForeName': 'Yiftach', 'Initials': 'Y', 'LastName': 'Goldwin', 'Affiliation': 'Shalvata Mental Health Center, Hod-Hasharon, Israel.'}, {'ForeName': 'Yuval', 'Initials': 'Y', 'LastName': 'Bloch', 'Affiliation': 'Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Shamay-Tsoory', 'Affiliation': 'Department of Psychology, Haifa University, Haifa, Israel.'}, {'ForeName': 'Orna', 'Initials': 'O', 'LastName': 'Zagoory-Sharon', 'Affiliation': 'Baruch Ivcher School of Psychology, Interdisciplinary Center, Herzlia, Israel.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Feldman', 'Affiliation': 'Baruch Ivcher School of Psychology, Interdisciplinary Center, Herzlia, Israel.'}, {'ForeName': 'Hagai', 'Initials': 'H', 'LastName': 'Maoz', 'Affiliation': 'Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. hagaima@gmail.com.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0522-5'] 44,32272171,Enhanced antimicrobial stewardship based on rapid phenotypic antimicrobial susceptibility testing for bacteraemia in patients with haematological malignancies: a randomized controlled trial.,"OBJECTIVES Recently, rapid phenotypic antimicrobial susceptibility testing (AST) based on microscopic imaging analysis has been developed. The aim of this study was to determine whether implementation of antimicrobial stewardship programmes (ASP) based on rapid phenotypic AST can increase the proportion of patients with haematological malignancies who receive optimal targeted antibiotics during early periods of bacteraemia. METHODS This randomized controlled trial enrolled patients with haematological malignancies and at least one positive blood culture. Patients were randomly assigned 1:1 to conventional (n = 60) or rapid phenotypic (n = 56) AST. The primary outcome was the proportion of patients receiving optimal targeted antibiotics 72 hr after blood collection for culture. RESULTS The percentage receiving optimal targeted antibiotics at 72 hr was significantly higher in the rapid phenotypic AST group (45/56, 80.4%) than in conventional AST group (34/60, 56.7%) (relative risk (RR) 1.42, 95% confidence interval (CI) 1.09-1.83). The percentage receiving unnecessary broad-spectrum antibiotics at 72 hr was significantly lower (7/26, 12.5% vs 18/60, 30.0%; RR 0.42, 95% CI 0.19-0.92) and the mean time to optimal targeted antibiotic treatment was significantly shorter (38.1, standard deviation (SD) 38.2 vs 72.8, SD 93.0 hr; p < 0.001) in the rapid phenotypic AST group. The mean time from blood collection to the AST result was significantly shorter in the rapid phenotypic AST group (48.3, SD 17.6 vs 83.1, SD 22.2 hr). DISCUSSION ASP based on rapid phenotypic AST can rapidly optimize antibiotic treatment for bacteraemia in patients with haematological malignancy. Rapid phenotypic AST can improve antimicrobial stewardship in immunocompromised patients.",2021,"The percentage receiving unnecessary broad-spectrum antibiotics at 72 hours was significantly lower (7/26, 12.5% vs. 18/60, 30.0%; RR 0.42, 95% CI 0.19 to 0.92) and the mean time to optimal targeted antibiotic treatment was significantly shorter (38.1, standard deviation (SD) 38.2 vs. 72.8, SD 93.0 hours; p <0.001) in the rapid phenotypic AST group.","['immunocompromised patients', 'patients with haematologic malignancies who receive optimal targeted antibiotics during early periods of bacteraemia', 'patients with haematologic malignancies and at least one positive blood culture', 'patients with haematologic malignancies', 'patients with haematologic malignancy']","['antimicrobial stewardship programs (ASP', 'rapid phenotypic (n = 56) AST', 'conventional AST', 'ASP', 'Rapid phenotypic AST']","['mean time to optimal targeted antibiotic treatment', 'percentage receiving optimal targeted antibiotics', 'percentage receiving unnecessary broad-spectrum antibiotics', 'proportion of patients receiving optimal targeted antibiotics 72\xa0hours after blood collection for culture', 'mean time from blood collection to the AST result']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376545', 'cui_str': 'Hematologic neoplasm'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0740299', 'cui_str': 'Blood culture positive for microorganism'}]","[{'cui': 'C4505099', 'cui_str': 'Antimicrobial Stewardship'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0427965', 'cui_str': 'Antimicrobial susceptibility - finding'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0427965', 'cui_str': 'Antimicrobial susceptibility - finding'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]",,0.161565,"The percentage receiving unnecessary broad-spectrum antibiotics at 72 hours was significantly lower (7/26, 12.5% vs. 18/60, 30.0%; RR 0.42, 95% CI 0.19 to 0.92) and the mean time to optimal targeted antibiotic treatment was significantly shorter (38.1, standard deviation (SD) 38.2 vs. 72.8, SD 93.0 hours; p <0.001) in the rapid phenotypic AST group.","[{'ForeName': 'J-H', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Kim', 'Affiliation': 'Division of Haematology-Oncology, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'C K', 'Initials': 'CK', 'LastName': 'Kang', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'K-I', 'Initials': 'KI', 'LastName': 'Jun', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Yoo', 'Affiliation': 'Division of Haematology-Oncology, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'J Y', 'Initials': 'JY', 'LastName': 'Chun', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Jung', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Y J', 'Initials': 'YJ', 'LastName': 'Kim', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'D Y', 'Initials': 'DY', 'LastName': 'Kim', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'H B', 'Initials': 'HB', 'LastName': 'Jo', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'D Y', 'Initials': 'DY', 'LastName': 'Kim', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Koh', 'Affiliation': 'Division of Haematology-Oncology, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'D-Y', 'Initials': 'DY', 'LastName': 'Shin', 'Affiliation': 'Division of Haematology-Oncology, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hong', 'Affiliation': 'Division of Haematology-Oncology, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'N J', 'Initials': 'NJ', 'LastName': 'Kim', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'S-S', 'Initials': 'SS', 'LastName': 'Yoon', 'Affiliation': 'Division of Haematology-Oncology, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'T S', 'Initials': 'TS', 'LastName': 'Kim', 'Affiliation': 'Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: kim.taeksoo@snu.ac.kr.'}, {'ForeName': 'W B', 'Initials': 'WB', 'LastName': 'Park', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea. Electronic address: wbpark1@snu.ac.kr.'}, {'ForeName': 'M-D', 'Initials': 'MD', 'LastName': 'Oh', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.'}]",Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,['10.1016/j.cmi.2020.03.038'] 45,32255178,PASS versus MBT™ for evaluation of anchorage control in three-dimensional measurements: a randomized controlled trial.,"BACKGROUND Growth and development might lead to anchorage loss during orthodontic treatment, such as the mesial drift of molars, the compensation characteristics of upper molars following mandibular growth, or the angulation of molars before treatment. Different anchorage reinforcement devices have been developed to prevent mechanical anchorage loss, but the anchorage loss resulting from physiological factors should also be taken into account. OBJECTIVE To explore the efficacy of a new strategy to control physiologic anchorage compared with that of the conventional straight-wire appliance. TRIAL DESIGN Randomized controlled trial (RCT). METHODS Participants of Han ethnicity were randomized into the physiologic anchorage spee-wire system (PASS) group or McLaughlin-Bennett-Trevisi (MBT™) straight-wire group by minimization random allocation. The eligibility criteria were patients with a Class I or II molar relationship, permanent dentition (11-35 years old), fixed appliances involving the extraction of at least two upper first premolars, and medium or maximum anchorage requirements. Pre-treatment and post-treatment dental casts were scanned into digital casts and measured using a blinded method. Mesial displacements of the upper first molars were considered as the primary outcome for evaluating anchorage control. Measurements were taken for subgroups based on age. RESULTS Data from 60 participants were analysed. The baseline characteristics were not significantly different between groups. Mesial displacement of the upper first molar (in mm) was 2.96 ± 1.52 in the PASS group and 2.70 ± 1.66 in the MBT group (P = 0.521). The variation in incisor torque was -6.94 ± 6.35 degree in the PASS group and -11.76 ± 7.65 degree in the MBT group (P = 0. 010). The incisor retraction (in mm) was 4.24 ± 1.99 and 5.67 ± 2.27 in the PASS and MBT groups, respectively (P = 0.012). Adverse effects were not documented in any patient. LIMITATION The study was a single-centre study. CONCLUSIONS Compared with the MBT group, the PASS group without additional anchorage devices could attain well anchorage control by considering the dentoalveolar compensation of anchor teeth. REGISTRATION This RCT was registered at the Chinese Clinical Trial Registry (Chictr.org.cn) ChiCTR-TRC-13003260.",2021,Mesial displacement of the upper first molar (in mm) was 2.96 ± 1.52 in the PASS group and 2.70 ± 1.66 in the MBT group (P = 0.521).,"['patients with a Class I or II molar relationship, permanent dentition (11-35 years old), fixed appliances involving the extraction of at least two upper first premolars, and medium or maximum anchorage requirements', 'Data from 60 participants were analysed', 'Participants of Han ethnicity']","['physiologic anchorage spee-wire system (PASS) group or McLaughlin-Bennett-Trevisi (MBT™) straight-wire group by minimization random allocation', 'PASS versus MBT', 'MBT', 'conventional straight-wire appliance']","['Adverse effects', 'incisor retraction', 'incisor torque']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441885', 'cui_str': 'Class 1'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0348070', 'cui_str': 'Structure of permanent tooth'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0441421', 'cui_str': 'Fixed orthodontic appliance'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0641339', 'cui_str': 'hexaaquanickel(II) chlorate'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}]","[{'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0005978', 'cui_str': 'Bone wire'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0559411', 'cui_str': ""Bennett's fracture""}, {'cui': 'C0054631', 'cui_str': '2-MERCAPTOBENZOTHIAZOLE'}, {'cui': 'C0019421', 'cui_str': 'Heterosexuality'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C1542418', 'cui_str': 'Appliance'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}, {'cui': 'C0332523', 'cui_str': 'Retraction'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}]",60.0,0.160756,Mesial displacement of the upper first molar (in mm) was 2.96 ± 1.52 in the PASS group and 2.70 ± 1.66 in the MBT group (P = 0.521).,"[{'ForeName': 'Huizhong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China.'}, {'ForeName': 'Ruoping', 'Initials': 'R', 'LastName': 'Jiang', 'Affiliation': 'Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Su', 'Affiliation': 'Department of Orthodontics, First Dental Center, Peking University School and Hospital of Stomatology, Beijing, China.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Feng', 'Affiliation': 'Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Teng', 'Affiliation': 'Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China.'}, {'ForeName': 'Tianmin', 'Initials': 'T', 'LastName': 'Xu', 'Affiliation': 'Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China.'}]",European journal of orthodontics,['10.1093/ejo/cjaa021'] 46,32264706,A randomized clinical trial comparing prompt photodynamic therapy with 3 months observation in patients with acute central serous chorioretinopathy with central macular leakage.,"PURPOSE The purpose of the study was to demonstrate whether photodynamic therapy in patients with acute central serous chorioretinopathy, with the leakage point within one optic disk diameter from the fovea, can be safely deferred. METHODS A single-center, randomized, controlled trial was conducted. Patients were randomized to photodynamic therapy within a week after presentation (Group I, 26 patients) or observation during 3 months (Group II, 26 patients). If leakage or subretinal fluid was observed during any control visit, photodynamic therapy was performed (again) within a week. PRIMARY OUTCOME Primary outcome was change of visual acuity (Early Treatment Diabetic Retinopathy Study) after 12 months. Secondary outcomes were visual acuity, central foveal thickness, metamorphopsia, and color discrimination. RESULTS Photodynamic therapy procedures: group I, 26 at baseline, 2 retreatments at 3 months; group II, 10 at 3 months, 1 at 6 months (2 subjects refusing treatment), 2 retreatments at 6 months. At 12 months, mean visual acuity of all patients had improved by 6.5 letters (P < 0.001), mean central foveal thickness was 172 µm less (P < 0.001). After photodynamic therapy, visual acuity recovered faster and metamorphopsia significantly improved (3 months, P < 0.001). Differences between groups at 12 months were not significant. CONCLUSION The (intended) number of photodynamic therapy (re)treatments in group II (n = 15) was 46% less than in group I (n = 28). Visual acuity and central foveal thickness at 12 months were similar. Therefore, the preferred management of acute central serous chorioretinopathy at presentation appears to be observation for 3 months.",2021,"At 12 months, mean visual acuity of all patients had improved by 6.5 letters (P < 0.001), mean central foveal thickness was 172 µm less (P < 0.001).","['patients with acute central serous chorioretinopathy, with the leakage point within one optic disk diameter from the fovea, can be safely deferred', 'patients with acute central serous chorioretinopathy with central macular leakage']",['photodynamic therapy'],"['change of visual acuity (Early Treatment Diabetic Retinopathy Study', 'Visual acuity and central foveal thickness', 'mean visual acuity', 'visual acuity, central foveal thickness, metamorphopsia, and color discrimination', 'mean central foveal thickness', 'visual acuity recovered faster and metamorphopsia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0730315', 'cui_str': 'Acute central serous chorioretinopathy'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0029127', 'cui_str': 'Optic disc structure'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0016622', 'cui_str': 'Structure of fovea centralis'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0271185', 'cui_str': 'Metamorphopsia'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}]",,0.228035,"At 12 months, mean visual acuity of all patients had improved by 6.5 letters (P < 0.001), mean central foveal thickness was 172 µm less (P < 0.001).","[{'ForeName': 'Tom Oar', 'Initials': 'TO', 'LastName': 'Missotten', 'Affiliation': 'The Rotterdam Eye Hospital, Rotterdam, The Netherlands.'}, {'ForeName': 'Johan G', 'Initials': 'JG', 'LastName': 'Hoddenbach', 'Affiliation': 'The Rotterdam Eye Hospital, Rotterdam, The Netherlands.'}, {'ForeName': 'Christine Ae', 'Initials': 'CA', 'LastName': 'Eenhorst', 'Affiliation': 'The Rotterdam Eye Hospital, Rotterdam, The Netherlands.'}, {'ForeName': 'L Ingeborgh', 'Initials': 'LI', 'LastName': 'van den Born', 'Affiliation': 'The Rotterdam Eye Hospital, Rotterdam, The Netherlands.'}, {'ForeName': 'José P', 'Initials': 'JP', 'LastName': 'Martinez Ciriano', 'Affiliation': 'The Rotterdam Eye Hospital, Rotterdam, The Netherlands.'}, {'ForeName': 'René J', 'Initials': 'RJ', 'LastName': 'Wubbels', 'Affiliation': 'The Rotterdam Eye Hospital, Rotterdam, The Netherlands.'}]",European journal of ophthalmology,['10.1177/1120672120915168'] 47,32255542,"Randomized, Double-Blind, Single-Dose, Placebo-Controlled Crossover Study to Evaluate the Effects of Esaxerenone on QTc Interval in Healthy Subjects.","This phase 1 single-center, single-dose, double-dummy, placebo-controlled, 4-period and 4-sequence crossover study assessed the potential of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker used to treat hypertension, to affect cardiac repolarization. In this double-blind study, 55 subjects were randomized to single doses of 10 mg esaxerenone (therapeutic dose), 40 mg esaxerenone (supratherapeutic dose), 400 mg moxifloxacin, or placebo. Serial electrocardiograms and pharmacokinetics (PK) were obtained over 24 and 168 hours, respectively. The primary end point was Fridericia-corrected QT interval (QTcF). Secondary end points included safety and PK. Assay sensitivity was confirmed as the lower limit of 90% confidence interval (90%CIs) for placebo-corrected change from baseline QTcF (∆∆QTcF) for moxifloxacin was >5 milliseconds at the prespecified times; mean ∆∆QTcF was 12.5 milliseconds at 3 and 4 hours postdose. The upper 90%CI limits of ∆∆QTcF were ≤0 milliseconds at all times for both doses of esaxerenone. No concentration-QTc relationship was identified. Therefore, esaxerenone had no potential to inhibit cardiac repolarization. No deaths or serious adverse events (AEs) occurred; 1 subject discontinued the study because of a treatment-emergent AE unrelated to esaxerenone. This clinical evaluation showed that esaxerenone has no QTc prolongation potential.",2020,The upper 90%CI limits of ∆∆QTcF were ≤0 milliseconds at all times for both doses of esaxerenone.,"['55 subjects', 'Healthy Subjects']","['esaxerenone', 'Placebo', 'esaxerenone (therapeutic dose), 40 mg esaxerenone (supratherapeutic dose), 400 mg moxifloxacin, or placebo', 'Esaxerenone', 'moxifloxacin']","['Assay sensitivity', 'concentration-QTc relationship', 'deaths or serious adverse events', 'Fridericia-corrected QT interval (QTcF', 'safety and PK', 'Serial electrocardiograms and pharmacokinetics (PK']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C5139864', 'cui_str': 'esaxerenone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",55.0,0.285919,The upper 90%CI limits of ∆∆QTcF were ≤0 milliseconds at all times for both doses of esaxerenone.,"[{'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Mendell', 'Affiliation': 'Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, USA.'}, {'ForeName': 'Fumiaki', 'Initials': 'F', 'LastName': 'Kobayashi', 'Affiliation': 'Daiichi Sankyo Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Takako', 'Initials': 'T', 'LastName': 'Shimizu', 'Affiliation': 'Daiichi Sankyo Co., Ltd., Tokyo, Japan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.794'] 48,32247709,The effects of watching comedy videos on anxiety and vital signs in surgical oncology patients.,"BACKGROUND Cancer, a disease as old as recorded human history, causes patients pain and psychological problems. Watching comedy videos can distract these patients, relieving psychological issues without causing any further harm. METHODS This randomized clinical trial was conducted on patients who were candidates for oncologic surgery at a university hospital in Turkey. The sample of the study consisted of 88 patients. Before surgery, patients in the experimental group (n = 44) watched comedy videos while those in the control group (n = 44) received no intervention. The Patient Introduction and Registration Form and the State and Trait Anxiety Inventory (STAI) were used as data collection tools. Anxiety, measured by the STAI, and vital signs (blood pressure, pulse, respiration, and oxygen saturation) were measured before and after the experimental protocol. Descriptive statistics, chi-square and t-test were used in the analysis of the data. RESULTS The pretest of STAI scores and vital signs were similar in both groups (p  >  0.05). After video watching, the mean state anxiety score of the patients was 43.36 ± 9.76 in the experimental group and 47.13 ± 5.76 in the control group. The difference between the mean anxiety scores of the two groups was statistically significant (p < 0.05). However, there were no significant differences in vital signs across groups (p > 0.05). Within group pre- versus post-treatment comparisons showed significant reduction in anxiety, diastolic and systolic blood pressures in the video group (p<0.05), while in controls, there was no significant improvement in anxiety and physiologic values. CONCLUSIONS The results suggest that watching comedy videos has a beneficial effect on pre-operative anxiety and blood pressure in surgical oncology patients.",2020,"Within group pre- versus post-treatment comparisons showed significant reduction in anxiety, diastolic and systolic blood pressures in the video group (p<0.05), while in controls, there was no significant improvement in anxiety and physiologic values. ","['88 patients', 'patients who were candidates for oncologic surgery at a university hospital in Turkey', 'surgical oncology patients']","['watching comedy videos', 'no intervention']","['vital signs', 'anxiety and vital signs', 'anxiety, diastolic and systolic blood pressures', 'Anxiety, measured by the STAI, and vital signs (blood pressure, pulse, respiration, and oxygen saturation', 'pre-operative anxiety and blood pressure', 'mean anxiety scores', 'anxiety and physiologic values', 'pretest of STAI scores and vital signs', 'mean state anxiety score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1515090', 'cui_str': 'Surgical oncology'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0041400', 'cui_str': 'Turkey - country'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}]",88.0,0.0432894,"Within group pre- versus post-treatment comparisons showed significant reduction in anxiety, diastolic and systolic blood pressures in the video group (p<0.05), while in controls, there was no significant improvement in anxiety and physiologic values. ","[{'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Genç', 'Affiliation': 'Department of Nursing, Dicle University, School of Health, Diyarbakir, Turkey.'}, {'ForeName': 'Serdar', 'Initials': 'S', 'LastName': 'Saritas', 'Affiliation': 'Department of Surgical Nursing, Inonu University, Fac.of Nursing Malatya, Malatya, Turkey,. Electronic address: serdar.saritas@inonu.edu.tr.'}]","Explore (New York, N.Y.)",['10.1016/j.explore.2020.02.009'] 49,32248857,Examining the Feasibility of a Mindfulness Intervention for the Prevention of Falls: A Pilot Study.,"This pilot study was designed to assess the feasibility of implementing a mindfulness intervention in the prevention of falls. We employed a quasi-experimental design consisting of 22 participants from two retirement homes in Ontario partaking in the regional falls prevention class. Participants were assigned to either an eight-week intervention, comprising mindfulness exercises incorporated into the standard falls prevention class, or to the standard falls prevention class. Participants were assessed using the Tinetti Balance and Gait Scale and the Timed Up and Go (TUG) test. The mindfulness intervention showed no significant effect on TUG or balance scores; however, there was a significant effect on assessments of gait. Given the ease of implementation of mindfulness-based interventions, further research may be warranted in mindfulness as a potential modality for falls prevention.",2020,"The mindfulness intervention showed no significant effect on TUG or balance scores; however, there was a significant effect on assessments of gait.",['22 participants from two retirement homes in Ontario partaking in the regional falls prevention class'],"['mindfulness intervention', 'mindfulness exercises incorporated into the standard falls prevention class, or to the standard falls prevention class', 'Mindfulness Intervention']","['Tinetti Balance and Gait Scale and the Timed Up and Go (TUG) test', 'assessments of gait', 'TUG or balance scores']","[{'cui': 'C0338046', 'cui_str': 'Residential home'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C2732846', 'cui_str': 'Tinetti balance and gait scale'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",22.0,0.0115415,"The mindfulness intervention showed no significant effect on TUG or balance scores; however, there was a significant effect on assessments of gait.","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hoang', 'Affiliation': 'McMaster University, Michael G. DeGroote School of Medicine.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Moore', 'Affiliation': 'McMaster University, Michael G. DeGroote School of Medicine.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Kwan', 'Affiliation': 'David Braley Health Sciences Centre.'}]",Canadian journal on aging = La revue canadienne du vieillissement,['10.1017/S0714980820000033'] 50,32171050,Implementation of a wound care education project to improve the wound care competency among psychiatric nurses: A quality improvement project and feasibility study.,"WHAT IS KNOWN ON THE SUBJECT?: Compared to the general population, people with mental illness die several years prematurely. The prevalence of chronic physical illnesses such as diabetes and cardiovascular disease is higher in people with mental health illnesses, putting them at increased risk of developing skin wounds. The majority of the studies on wound care education and management were carried out in acute care and long-term care settings. A very few addressed the wound care needs for psychiatric patients and the educational needs of nurses in the mental health setting. WHAT THE PAPER ADDS TO EXISTING KNOWLEDGE?: This study adds to the existing evidence by offering an evidence-based solution to equip Psychiatric and Mental Health Nurses (PMHNs) with the necessary knowledge and skills to provide high-quality wound care to patients. When a lack of wound care competency has been identified, it may be worth the effort to provide education and training to psychiatric nurses on wound care management. WHAT ARE THE IMPLICATIONS FOR PRACTICE?: This project has the potential benefit of healthcare cost savings, which can be further investigated in a future study, for instance, a pilot randomized controlled trial to estimate the parameters for a full-trial and cost-effectiveness study. Future mental health nursing practice and research need to focus on finding solutions to help support PMHNs improve their competence in caring for physical illnesses. ABSTRACT: Introduction People with mental illnesses are at increased risk of developing skin wounds. A very few studies addressed the wound care needs for psychiatric patients and the educational needs for psychiatric and mental health nurses (PMHNs). Aim A wound care education-feasibility and quality improvement project-was implemented to improve wound care competence among nurses on the Seniors' Mental Health Units at a psychiatric hospital. Methods A total of 36 nurses participated in wound care knowledge education and completed both the pretest and post-test. Four nurses participated in wound care skills training. Results The post-intervention mean score increase for wound care knowledge was 5.14 (178%) and for skills was 7(75.7%). The results were statistically significant (p < .001). Discussion This study adds to the existing evidence by offering an evidence-based solution to equip PMHNs with the necessary knowledge and skills to provide high-quality wound care to patients. Implications for Practice and Research Future mental health nursing practice and research need to focus on finding evidence-based practical solutions to help support PMHNs improve their ability to care for physical illnesses. A future pilot randomized controlled trial will be needed to estimate the parameters for a full-trial and cost-effectiveness study.",2020,The post-intervention mean score increase for wound care knowledge was 5.14 (178%) and for skills was 7 (75.7%).,"['psychiatric patients and the educational needs for psychiatric and mental health nurses (PMHNs', 'Psychiatric Nurses', ""nurses on the Seniors' Mental Health Units at a psychiatric hospital"", '36 nurses participated in wound care knowledge education and completed both the pretest and posttest', 'Four nurses participated in wound care skills training']",[],"['wound care knowledge', 'wound care competence']","[{'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C1964024', 'cui_str': 'Mental health nurse (occupation)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0020021', 'cui_str': 'Mental Hospitals'}, {'cui': 'C0886052', 'cui_str': 'Administers care to wound sites'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0559197', 'cui_str': 'Skills training (procedure)'}]",[],"[{'cui': 'C0886052', 'cui_str': 'Administers care to wound sites'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0086035', 'cui_str': 'Competence'}]",4.0,0.0594252,The post-intervention mean score increase for wound care knowledge was 5.14 (178%) and for skills was 7 (75.7%).,"[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Pirani', 'Affiliation': ""St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.""}]",Journal of psychiatric and mental health nursing,['10.1111/jpm.12629'] 51,32145713,Combined non-intubated anaesthesia and paravertebral nerve block in comparison with intubated anaesthesia in children undergoing video-assisted thoracic surgery.,"BACKGROUND This study is to investigate if non-intubated anaesthesia combined with paravertebral nerve block (PVNB) can enhance recovery in children undergoing video-assisted thoracic surgery (VATS). METHODS A randomized controlled trial including 60 patients aged 3 to 8 years old who underwent elective VATS was performed. They were randomly assigned to receive non-intubated anaesthesia combined with PVNB or general anaesthesia with tracheal intubation (1:1 ratio). The primary outcome was the length of postoperative in-hospital stay. The secondary outcomes included emergence time, the incidence of emergence delirium, time to first feeding, time to first out-of-bed activity, pain score and in-hospital complications. RESULTS The non-intubated group had shorter postoperative in-hospital stay than the control group (4 days [IQR, 4-6] vs 5 days [IQR, 5-8], 95% CI 0-2; P = .013). When compared to the control group, the incidence of emergence delirium (odds ratio [OR] 3.39, 95% CI 1.01-11.41; P = .043), emergence time, duration in the PACU, time to first eating food, first out-of-bed activity, pain score and consumption of sufentanil (at 6 and 12 hours after surgery) were decreased in the intervention group. In contrast, the incidence of airway complications was higher in the control than the intervention group (27.6% vs 6.9%, P = .037). There was no statistical significance in the occurrence of PONV, pneumothorax and other complications between the two groups. CONCLUSIONS Non-intubated anaesthesia combined with PVNB enhances recovery in paediatric patients for video-assisted thoracic surgery although further multi-centre study is needed.",2020,"When compared to the control group, the incidence of emergence delirium (odds ratio [OR] 3.39, 95% CI 1.01 - 11.41; P = 0.043), emergence time, duration in the PACU, time to first eating food, first out-of-bed activity, pain score and consumption of sufentanil (at 6 and 12 hours after surgery) were decreased in the intervention group.","['paediatric patients', '60 patients aged 3 to 8 years old who underwent elective VATS was performed', 'children undergoing video-assisted thoracic surgery (VATS', 'children undergoing video-assisted thoracic surgery']","['PVNB', 'Combined non-intubated anaesthesia and paravertebral nerve block', 'non-intubated anaesthesia combined with PVNB or general anaesthesia with tracheal intubation (1:1 ratio', 'intubated anaesthesia', 'intubated anaesthesia combined with paravertebral nerve block (PVNB']","['occurrence of PONV, pneumothorax and other complications', 'incidence of airway complications', 'shorter postoperative in-hospital stay', 'emergence time, duration in the PACU, time to first eating food, first out-of-bed activity, pain score and consumption of sufentanil', 'emergence time, the incidence of emergence delirium, time to first feeding, time to first out-of-bed activity, pain score and in-hospital complications', 'length of postoperative in-hospital stay', 'incidence of emergence delirium']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0752151', 'cui_str': 'VATS'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0198806', 'cui_str': 'Paravertebral anesthesia (procedure)'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0021932', 'cui_str': 'Intubation, Endotracheal'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]","[{'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0520909', 'cui_str': 'PONV'}, {'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0034871', 'cui_str': 'Hospital Recovery Rooms'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0004916', 'cui_str': 'Beds'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0920253', 'cui_str': 'Postanesthetic Excitement'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}]",60.0,0.135181,"When compared to the control group, the incidence of emergence delirium (odds ratio [OR] 3.39, 95% CI 1.01 - 11.41; P = 0.043), emergence time, duration in the PACU, time to first eating food, first out-of-bed activity, pain score and consumption of sufentanil (at 6 and 12 hours after surgery) were decreased in the intervention group.","[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wei', 'Affiliation': ""Department of Anaesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Yanting', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': ""Department of Anaesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': ""Department of Thoracic Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Tianyun', 'Initials': 'T', 'LastName': 'Zhao', 'Affiliation': ""Department of Anaesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Tian', 'Affiliation': ""Department of Anaesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Yingyi', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': ""Department of Anaesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Yonghong', 'Initials': 'Y', 'LastName': 'Tan', 'Affiliation': ""Department of Anaesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Xingrong', 'Initials': 'X', 'LastName': 'Song', 'Affiliation': ""Department of Anaesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Daqing', 'Initials': 'D', 'LastName': 'Ma', 'Affiliation': 'Anaethetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13572'] 52,32236718,Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial.,"AIMS In ENSURE-AF (NCT02072434), the oral Factor Xa inhibitor edoxaban showed similar efficacy and safety vs enoxaparin-warfarin in patients undergoing electrical cardioversion of nonvalvular atrial fibrillation (AF). This ancillary analysis compares primary efficacy and safety end points for patients receiving vs not receiving concomitant antiplatelet therapy (APT) in ENSURE-AF. METHODS The primary efficacy end point was a composite of stroke, systemic embolic events, myocardial infarction, and cardiovascular death during 28 days on study drug after cardioversion plus 30 days of follow-up. The primary safety end point was the composite of major and clinically relevant non-major bleeding occurring between the first and the last dose of study drug. RESULTS Of 2199 patients enrolled, 1095 were randomized to edoxaban and 1104 to enoxaparin-warfarin. Patients receiving concomitant APT were older; more naïve to vitamin K antagonist; had lower creatinine clearance; and more likely to have history of coronary artery disease, hypertension, diabetes, or ischemic stroke/transient ischemic attack. In patients receiving vs not receiving concomitant APT, primary efficacy event rate was numerically higher (0.92% vs 0.60%, p = 0.64) and primary safety event rate was significantly higher (3.21% vs 0.92%, p = 0.0096). Stepwise logistic regression analysis identified age and APT as covariates correlated with bleeding. There was a trend toward increased bleeding risk in elderly patients receiving vs not receiving concomitant APT. CONCLUSION In ENSURE-AF, thromboembolic events were rare and absolute bleeding event rates were higher with concomitant APT. These findings may be relevant for AF-patients considered for dual therapy; even for a short treatment duration of 1 month.",2020,"In patients receiving vs not receiving concomitant APT, primary efficacy event rate was numerically higher (0.92% vs 0.60%, p = 0.64) and primary safety event rate was significantly higher (3.21% vs 0.92%, p = 0.0096).","['patients receiving vs not receiving concomitant antiplatelet therapy (APT', 'elderly patients receiving vs not receiving concomitant APT', 'subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF', '2199 patients enrolled, 1095 were randomized to', 'patients undergoing electrical cardioversion of nonvalvular atrial fibrillation (AF']","['vitamin K antagonist', 'enoxaparin-warfarin', 'edoxaban vs warfarin', 'edoxaban']","['composite of stroke, systemic embolic events, myocardial infarction, and cardiovascular death', 'composite of major and clinically relevant non-major bleeding', 'primary safety event rate', 'creatinine clearance', 'bleeding risk', 'efficacy event rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0003645', 'cui_str': 'APT'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0013778', 'cui_str': 'Cardioversion'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]","[{'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C2975435', 'cui_str': 'edoxaban'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",2199.0,0.0331836,"In patients receiving vs not receiving concomitant APT, primary efficacy event rate was numerically higher (0.92% vs 0.60%, p = 0.64) and primary safety event rate was significantly higher (3.21% vs 0.92%, p = 0.0096).","[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Goette', 'Affiliation': 'Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital Paderborn, Am Busdorf 2, 33098, Paderborn, Germany. andreas.goette@vincenz.de.'}, {'ForeName': 'Jose L', 'Initials': 'JL', 'LastName': 'Merino', 'Affiliation': 'Hospital Universitario La Paz, IdiPaz, Universidad Europea, Madrid, Spain.'}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'De Caterina', 'Affiliation': 'University of Pisa, Pisa, Italy.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Huber', 'Affiliation': 'Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenspital, and Sigmund Freud University, Medical School, Vienna, Austria.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'Heidbuchel', 'Affiliation': 'Antwerp University and University Hospital, Cardiology, Antwerp, Belgium.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Jin', 'Affiliation': 'Daiichi Sankyo Pharma Development, Basking Ridge, NJ, USA.'}, {'ForeName': 'Gregory Y H', 'Initials': 'GYH', 'LastName': 'Lip', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK.'}]",Clinical research in cardiology : official journal of the German Cardiac Society,['10.1007/s00392-020-01635-8'] 53,31854069,Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs.,"We investigated the prevalence and impact of heavy alcohol use on the hepatitis C virus (HCV) care continuum amongst HIV/HCV co-infected persons who use drugs. In the CHAMPS study, 144 HIV/HCV co-infected persons were randomized to contingent cash incentives, peer mentors and usual care to evaluate the impact on HCV care. Alcohol use was ascertained using the 10-item AUDIT (hazardous: male ≥8, female ≥4) and phosphatidylethanol (PEth) (heavy: ≥50 ng/mL), an alcohol biomarker. Log binomial regression was used to evaluate the association between heavy alcohol use and failure to initiate treatment and to achieve sustained virologic response (SVR). Of the 135 participants with PEth data, median age was 55 years, 59% were male, 92% were Black, 91% reported a history of drug use, and 97% were on antiretroviral therapy. Hazardous drinking was reported on AUDIT by 28% of participants, and 35% had heavy alcohol use by PEth. Of the 47 individuals with a PEth ≥50 ng/mL, 23 (49%) reported no or minimal alcohol use by AUDIT. HCV treatment was initiated in 103 of 135 participants, and SVR was achieved in 92%. PEth ≥50 ng/mL (Relative Risk [RR] 0.72, 95% CI 0.35-1.48) was not significantly associated with failure to initiate HCV treatment or failure to achieve SVR (RR 0.85, 95% CI 0.46-1.57).In conclusion, alcohol use was common and frequently not detected by self-report. However, heavy alcohol use, even when measured objectively, was not associated with failure to initiate HCV treatment or to achieve cure.",2020,"0.72, 95% CI 0.35-1.48) was not significantly associated with failure to initiate HCV treatment or failure to achieve SVR (RR 0.85, 95% CI 0.46-1.57).","['144 HIV/HCV co-infected persons', 'HIV-Infected Persons', '135 participants with PEth data, median age was 55 years, 59% were male, 92% were Black, 91% reported a history of drug use, and 97% were on antiretroviral therapy', '47 individuals with a PEth ≥', 'HIV/HCV co-infected persons who use drugs']","['HCV', 'heavy alcohol']","['Hazardous drinking', 'sustained virologic response (SVR', 'failure to initiate HCV treatment or failure to achieve SVR']","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0907896', 'cui_str': 'preecdysis-triggering hormone'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0449889', 'cui_str': 'Drug used (attribute)'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0205466', 'cui_str': 'virology'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",144.0,0.038386,"0.72, 95% CI 0.35-1.48) was not significantly associated with failure to initiate HCV treatment or failure to achieve SVR (RR 0.85, 95% CI 0.46-1.57).","[{'ForeName': 'Risha', 'Initials': 'R', 'LastName': 'Irvin', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Geetanjali', 'Initials': 'G', 'LastName': 'Chander', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Ward', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Manogue', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Oluwaseun', 'Initials': 'O', 'LastName': 'Falade-Nwulia', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Juhi', 'Initials': 'J', 'LastName': 'Moon', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Catherine G', 'Initials': 'CG', 'LastName': 'Sutcliffe', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Sherilyn', 'Initials': 'S', 'LastName': 'Brinkley', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Taryn', 'Initials': 'T', 'LastName': 'Haselhuhn', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Katz', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Kayla', 'Initials': 'K', 'LastName': 'Herne', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Lilian', 'Initials': 'L', 'LastName': 'Arteaga', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Thomas', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Shruti H', 'Initials': 'SH', 'LastName': 'Mehta', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'Sulkowski', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}]",Journal of viral hepatitis,['10.1111/jvh.13251'] 54,32150651,Pre- and postnatal Lactobacillus reuteri treatment alters DNA methylation of infant T helper cells.,"BACKGROUND Perinatal childhood exposures, including probiotic supplementation, may affect epigenetic modifications and impact on immune maturation and allergy development. The aim of this study was to assess the effects of pre- and postnatal Lactobacillus reuteri supplementation on DNA methylation in relation to immune maturation and allergy development. METHODS DNA methylation patterns were investigated for allergy-related T helper subsets using a locus-specific method and at a genome-wide scale using the Illumina 450K array. From a randomised, double-blind, placebo-controlled allergy prevention trial with pre- and postnatal probiotic supplementation, CD4+ T helper cells were obtained at birth (from cord blood), and 12 and 24 months of age (total (placebo/probiotics); locus-specific method: CB = 32 (17/15), 12 months = 24 (9/15), 24 months = 35 (15/20); Illumina: CB = 19 (10/9), 12 months = 10 (6/4), 24 months = 19(11/8)). RESULTS Comparing probiotics to placebo, the greatest genome-wide differential DNA methylation was observed at birth, where the majority of sites were hypomethylated, indicating transcriptional accessibility in the probiotic group. Bioinformatic analyses, including network analyses, revealed a module containing 91 genes, enriched for immune-related pathways such as chemotaxis, PI3K-Akt, MAPK and TGF-β signalling. A majority of the module genes were associated with atopic manifestations (OR = 1.43, P = 2.4 × 10 -6 ), and a classifier built on this model could predict allergy development (AUC = 0.78, P = 3.0 × 10 e-3 ). Pathways such as IFN-γ signalling and T-cell activation were more hypermethylated at birth compared with later in life in both intervention groups over time, in line with DNA methylation patterns in the IFNG locus obtained by the locus-specific methodology. CONCLUSION Maternal L. reuteri supplementation during pregnancy alters DNA methylation patterns in CD4+ T cells towards enhanced immune activation at birth, which may affect immune maturation and allergy development.",2020,"Pathways such as IFN-γ signalling and T-cell activation were more hypermethylated at birth compared to later in life in both intervention groups over time, in line with DNA methylation patterns in the IFNG locus obtained by the locus-specific methodology. ",['DNA methylation patterns were investigated for allergy-related T helper subsets using a locus-specific method and at a genome-wide scale using the Illumina 450K array'],"['Maternal L. reuteri supplementation', 'placebo', 'Pre- and postnatal Lactobacillus reuteri treatment', 'pre-and postnatal Lactobacillus reuteri supplementation', 'pre- and postnatal probiotic supplementation, CD4+ T helper cells']","['greatest genome-wide differential DNA methylation', 'DNA methylation of infant T helper cells', 'atopic manifestations']","[{'cui': 'C0376452', 'cui_str': 'DNA Methylation'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0002111', 'cui_str': 'Allergy Specialty'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0222045'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0443281', 'cui_str': 'Postnatal (qualifier value)'}, {'cui': 'C0317625', 'cui_str': 'Lactobacillus reuteri'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0018894', 'cui_str': 'T-Lymphocytes, Helper'}]","[{'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0443199', 'cui_str': 'Differential (qualifier value)'}, {'cui': 'C0376452', 'cui_str': 'DNA Methylation'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0018894', 'cui_str': 'T-Lymphocytes, Helper'}, {'cui': 'C0392707', 'cui_str': 'Atopy (disorder)'}]",450.0,0.152078,"Pathways such as IFN-γ signalling and T-cell activation were more hypermethylated at birth compared to later in life in both intervention groups over time, in line with DNA methylation patterns in the IFNG locus obtained by the locus-specific methodology. ","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Forsberg', 'Affiliation': 'Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Huoman', 'Affiliation': 'Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Söderholm', 'Affiliation': 'Division of Molecular Medicine and Virology, Department of Biomedical and Clinical Sciences, Wallenberg Centre for Molecular Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Ratnesh', 'Initials': 'R', 'LastName': 'Bhai Mehta', 'Affiliation': 'Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Lennart', 'Initials': 'L', 'LastName': 'Nilsson', 'Affiliation': 'Allergy Center, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Abrahamsson', 'Affiliation': ""Crown Princess Victoria's Child and Youth Hospital, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.""}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Ernerudh', 'Affiliation': 'Department of Clinical Immunology and Transfusion Medicine, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Gustafsson', 'Affiliation': 'Department of Physics, Chemistry and Biology, Bioinformatics, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Jenmalm', 'Affiliation': 'Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}]",Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,['10.1111/pai.13240'] 55,30415602,Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.,"BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Secondary efficacy outcomes were a renal composite (≥40% decrease in estimated glomerular filtration rate to <60 ml per minute per 1.73 m 2 of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause. RESULTS We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years. In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE (upper boundary of the 95% confidence interval [CI], <1.3; P<0.001 for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8% in the dapagliflozin group and 9.4% in the placebo group; hazard ratio, 0.93; 95% CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; hazard ratio, 0.83; 95% CI, 0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88); there was no between-group difference in cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 1.17). A renal event occurred in 4.3% in the dapagliflozin group and in 5.6% in the placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any cause occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001). CONCLUSIONS In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 ClinicalTrials.gov number, NCT01730534 .).",2019,"Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001). ","['17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years', 'patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with', 'We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either', 'patients with type 2 diabetes', 'Type 2 Diabetes']","['dapagliflozin or placebo', 'placebo', 'dapagliflozin']","['estimated glomerular filtration rate', 'cardiovascular death or hospitalization for heart failure', 'rate of hospitalization for heart failure', 'rate of genital infections', 'death', 'renal composite', 'renal event', 'cardiovascular death', 'serious adverse events', 'body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause', 'Dapagliflozin and Cardiovascular Outcomes', 'MACE and a composite of cardiovascular death or hospitalization for heart failure', 'rate of MACE', 'composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke', 'Diabetic ketoacidosis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C4517758', 'cui_str': 'Four point two'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C3811844'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0729552', 'cui_str': 'Infectious disease of genitopelvic system'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0005902', 'cui_str': 'Body Surface Area'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0022661', 'cui_str': 'End-Stage Kidney Disease'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0011880', 'cui_str': 'Ketosis, Diabetic'}]",17160.0,0.638337,"Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001). ","[{'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Wiviott', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Itamar', 'Initials': 'I', 'LastName': 'Raz', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Marc P', 'Initials': 'MP', 'LastName': 'Bonaca', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Ofri', 'Initials': 'O', 'LastName': 'Mosenzon', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Eri T', 'Initials': 'ET', 'LastName': 'Kato', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Avivit', 'Initials': 'A', 'LastName': 'Cahn', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Silverman', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Zelniker', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Julia F', 'Initials': 'JF', 'LastName': 'Kuder', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Sabina A', 'Initials': 'SA', 'LastName': 'Murphy', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Lawrence A', 'Initials': 'LA', 'LastName': 'Leiter', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Darren K', 'Initials': 'DK', 'LastName': 'McGuire', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'John P H', 'Initials': 'JPH', 'LastName': 'Wilding', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Christian T', 'Initials': 'CT', 'LastName': 'Ruff', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Ingrid A M', 'Initials': 'IAM', 'LastName': 'Gause-Nilsson', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Fredriksson', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Johansson', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Langkilde', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Sabatine', 'Affiliation': ""From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1812389'] 56,32215700,Covariate adjusted reanalysis of the I-Preserve trial.,"BACKGROUND The CHARM-Preserved trial suggested that the renin-angiotensin system (RAS) inhibitor candesartan might have been beneficial in heart failure with preserved ejection fraction (HFpEF); however, this hypothesis was not supported by the findings of I-Preserve with irbesartan. AIMS To re-analyse the results of I-Preserve, adjusting for imbalances in baseline variables that may have influenced the trial outcomes. METHODS Cox proportional hazards models with covariate adjustment for baseline variables, including age, sex, medical history, physiological and laboratory variables. RESULTS In I-Preserve, 763 (37.0%) participants in the placebo group and 742 (35.9%) in the irbesartan group experienced the primary composite outcome (death from any cause or hospitalization for heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). The prespecified analysis of this outcome, stratifying for the use of ACEi at baseline, gave a hazard ratio (HR) of 0.95 (95% confidence interval, 0.86-1.05); p = 0.35. Adjusting the effect of treatment for key prognostic baseline variables, gave a HR of 0.89 (0.80-0.99); p = 0.033. Similar findings were observed for the composite of cardiovascular death or HF hospitalization. CONCLUSION Adjusting for imbalances in baseline variables that influence outcomes (or the response to therapy or both) can improve the power around the estimate of the effect of treatment and may alter its statistical significance. Along with the CHARM-Preserved results, these findings suggest that angiotensin-receptor blockers may have a modest effect in HFpEF.",2020,"In I-Preserve, 763 (37.0%) participants in the placebo group and 742 (35.9%) in the irbesartan group experienced the primary composite outcome (death from any cause or hospitalization for heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke).",[],['placebo'],"['composite of cardiovascular death or HF hospitalization', 'primary composite outcome (death from any cause or hospitalization for heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke']",[],"[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0002965', 'cui_str': 'Angina at Rest'}, {'cui': 'C0003811', 'cui_str': 'Arrhythmia'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]",,0.329686,"In I-Preserve, 763 (37.0%) participants in the placebo group and 742 (35.9%) in the irbesartan group experienced the primary composite outcome (death from any cause or hospitalization for heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke).","[{'ForeName': 'João Pedro', 'Initials': 'JP', 'LastName': 'Ferreira', 'Affiliation': 'BHF Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.'}, {'ForeName': 'Pooja', 'Initials': 'P', 'LastName': 'Dewan', 'Affiliation': 'BHF Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.'}, {'ForeName': 'Pardeep S', 'Initials': 'PS', 'LastName': 'Jhund', 'Affiliation': 'BHF Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Lorenzo-Almorós', 'Affiliation': 'Department of Internal Medicine. Renal, Vascular and Diabetes Laboratory, Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Kévin', 'Initials': 'K', 'LastName': 'Duarte', 'Affiliation': 'National Institute of Health and Medical Research (INSERM), Center for Clinical Multidisciplinary Research 1433, INSERM U1116, French Clinical Research Infrastructure Network (F-CRIN) Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (INI-CRCT), University of Lorraine, Regional University Hospital of Nancy, Nancy, France.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Petrie', 'Affiliation': 'BHF Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.'}, {'ForeName': 'Peter E', 'Initials': 'PE', 'LastName': 'Carson', 'Affiliation': 'Cardiovascular Division, Department of Cardiology, Washington Veterans Affairs Medical Center, Washington, DC, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'McKelvie', 'Affiliation': 'Department of Medicine, Western University, London, ON, Canada.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Komajda', 'Affiliation': 'Service de Cardiologie, Hôpital Saint Joseph, Paris, France.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Zile', 'Affiliation': 'Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina, USA.'}, {'ForeName': 'Faiez', 'Initials': 'F', 'LastName': 'Zannad', 'Affiliation': 'National Institute of Health and Medical Research (INSERM), Center for Clinical Multidisciplinary Research 1433, INSERM U1116, French Clinical Research Infrastructure Network (F-CRIN) Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (INI-CRCT), University of Lorraine, Regional University Hospital of Nancy, Nancy, France.'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'BHF Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK. john.mcmurray@glasgow.ac.uk.'}]",Clinical research in cardiology : official journal of the German Cardiac Society,['10.1007/s00392-020-01632-x'] 57,32196514,Results from a cluster-randomized trial to evaluate a microfinance and peer health leadership intervention to prevent HIV and intimate partner violence among social networks of Tanzanian men.,"Despite calls to engage men in HIV and intimate partner violence (IPV) prevention efforts, effective approaches to reach and engage men in low-resource, high-HIV prevalence settings are limited. We identified and engaged social networks of mostly young men in a study designed to evaluate the efficacy of a combined microfinance and peer health leadership intervention to prevent HIV and IPV. We conducted a cluster-randomized trial among 60 social networks locally referred to as ""camps"" within Dar es Salaam, Tanzania. Camps were randomly assigned (1:1) to a microfinance and peer health leadership intervention or a control condition that received a brief delayed intervention after the study's conclusion. Allocation was not masked to participants or researchers. Behavioral assessments were conducted at baseline and 30-months post-intervention launch, with biological samples drawn at 30-months to test for sexually-transmitted infections (STIs). Primary outcomes included prevalence of STIs and past-year IPV perpetration. Secondary outcomes included STI sexual risk behaviors and past-year HIV testing. Proximal intervention targets included inequitable gender norm attitudes and hope. A modified Poisson regression approach was used to estimate intention-to-treat intervention effects on outcomes assessed at the 30-month follow-up. We enrolled 1,258 men within 60 camps. Of these men, 1,029 (81.8%) completed the 30-month follow-up. There were no differences by condition in STI prevalence, IPV perpetration, or sexual risk behaviors at the 30-month follow-up. Intervention participants reported greater levels of past-year HIV testing, controlling for baseline testing (aRR 1.13 95% CI 1.005-1.28). They also reported significantly lower levels of inequitable gender norm attitudes (adjusted effect -0.11, 95% CI -0.21-0.003). We successfully engaged and retained social networks of men in this multilevel intervention study. While we did not see an effect on the primary outcomes, our intervention successfully improved HIV testing and reduced inequitable gender norm attitudes.",2020,"While we did not see an effect on the primary outcomes, our intervention successfully improved HIV testing and reduced inequitable gender norm attitudes.","['mostly young men', '60 social networks locally referred to as ""camps"" within Dar es Salaam, Tanzania', 'HIV and intimate partner violence among social networks of Tanzanian men', 'We enrolled 1,258 men within 60 camps']","['combined microfinance and peer health leadership intervention', 'microfinance and peer health leadership intervention or a control condition that received a brief delayed intervention', 'microfinance and peer health leadership intervention', 'Proximal intervention']","['greater levels of past-year HIV testing, controlling for baseline testing', 'HIV testing and reduced inequitable gender norm attitudes', 'STI prevalence, IPV perpetration, or sexual risk behaviors', 'prevalence of STIs and past-year IPV perpetration', 'STI sexual risk behaviors and past-year HIV testing', 'levels of inequitable gender norm attitudes']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0012054', 'cui_str': ""N',O'-Dibutyryl-cAMP""}, {'cui': 'C0039298', 'cui_str': 'United Republic of Tanzania'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0332285', 'cui_str': 'In (attribute)'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0023181', 'cui_str': 'Leadership'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}]","[{'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0036916', 'cui_str': 'STDs'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}]",1258.0,0.116286,"While we did not see an effect on the primary outcomes, our intervention successfully improved HIV testing and reduced inequitable gender norm attitudes.","[{'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Maman', 'Affiliation': 'Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Marta I', 'Initials': 'MI', 'LastName': 'Mulawa', 'Affiliation': 'Duke Global Health Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Balvanz', 'Affiliation': 'Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States of America.'}, {'ForeName': 'H Luz', 'Initials': 'HL', 'LastName': 'McNaughton Reyes', 'Affiliation': 'Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Mrema N', 'Initials': 'MN', 'LastName': 'Kilonzo', 'Affiliation': 'Department of Psychiatry and Mental Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.'}, {'ForeName': 'Thespina J', 'Initials': 'TJ', 'LastName': 'Yamanis', 'Affiliation': 'School of International Service, American University, Washington, DC, United States of America.'}, {'ForeName': 'Basant', 'Initials': 'B', 'LastName': 'Singh', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States of America.'}, {'ForeName': 'Lusajo J', 'Initials': 'LJ', 'LastName': 'Kajula', 'Affiliation': 'Department of Psychiatry and Mental Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.'}]",PloS one,['10.1371/journal.pone.0230371'] 58,27423055,Effect of moderately intense perioperative glucose control on renal allograft function: a pilot randomized controlled trial in renal transplantation.,"Recipient diabetes accounts for ~34% of end-stage renal disease in patients awaiting renal transplantation and has been linked to poor graft function. We conducted a single-center, open-label, randomized controlled trial to determine whether moderately intense glucose control during allograft reperfusion would reduce the incidence of poor graft function. Adult diabetics undergoing deceased donor renal transplant were randomized to moderately intense glucose control (n=30) or standard control (n=30). The primary outcome was poor graft function (dialysis within seven days of transplant or failure of serum creatinine to fall by 10% for three consecutive days). Recipients with moderately intense glucose control had less poor graft function in the intention-to-treat (43.3% vs 73.3%, P=.02) and per-protocol analysis (43.2% vs 81%, P<.01). Recipients with moderately intense control also had higher glomerular filtration rate (GFR) at 30 days after transplant in the per-protocol and intention-to-treat analyses. There were no episodes of severe hypoglycemia in either group and no differences in mortality, seizures, stroke, graft loss, or biopsy-proven rejection. Moderately intense glucose control at the time of allograft reperfusion reduces the incidence of poor graft function in diabetic renal transplant recipients and improves glomerular filtration rate at 30 days.",2016,"There were no episodes of severe hypoglycemia in either group and no differences in mortality, seizures, stroke, graft loss, or biopsy-proven rejection.","['Adult diabetics undergoing deceased donor renal transplant', 'diabetic renal transplant recipients', 'patients awaiting renal transplantation']",['moderately intense glucose control (n=30) or standard control'],"['severe hypoglycemia', 'renal allograft function', 'poor graft function (dialysis within seven days of transplant or failure of serum creatinine', 'glomerular filtration rate (GFR', 'incidence of poor graft function', 'mortality, seizures, stroke, graft loss, or biopsy-proven rejection', 'graft function', 'glomerular filtration rate']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0022671', 'cui_str': 'Grafting, Kidney'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0450127', 'cui_str': 'Allogeneic Grafts'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0017654', 'cui_str': 'Glomerular Filtration Rate'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0877042', 'cui_str': 'Graft loss'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C0035015', 'cui_str': 'Rejection'}]",,0.108288,"There were no episodes of severe hypoglycemia in either group and no differences in mortality, seizures, stroke, graft loss, or biopsy-proven rejection.","[{'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Parekh', 'Affiliation': 'Division of Transplantation, Department of Surgery, UT Southwestern Medical Center, Dallas, TX, USA. justin.parekh@utsouthwestern.edu.'}, {'ForeName': 'Garrett R', 'Initials': 'GR', 'LastName': 'Roll', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Wisel', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Rushakoff', 'Affiliation': 'Department of Endocrinology, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Ryutaro', 'Initials': 'R', 'LastName': 'Hirose', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.'}]",Clinical transplantation,['10.1111/ctr.12811'] 59,32208884,Predictors of Cognitive Improvement Following Treatment for Late-Life Depression.,"OBJECTIVE Cognitive impairment is frequently comorbid with late-life depression (LLD) and often persists despite remission of mood symptoms with antidepressant treatment. Increasing understanding of factors that predict improvement of cognitive symptoms in LLD is useful to inform treatment recommendations. METHODS We used data from 2 randomized clinical trials of geriatric depression to examine the relationships between sociodemographic factors (resilience, quality of life) and clinical factors (age of depression onset, severity of depression, apathy) with subsequent cognitive outcomes. One hundred sixty-five older adults with major depression who had completed one of 2 clinical trials were included: (1) methylphenidate plus placebo, citalopram plus placebo, and citalopram plus methylphenidate or (2) citalopram combined with Tai Chi or health education. A comprehensive neuropsychiatric battery was administered; 2 measures of cognitive improvement were examined, one defined as an increase in general cognitive performance score of at least 1 standard deviation and the other 0.5 standard deviation pre-post treatment. RESULTS At posttreatment, 59% of participants had remitted, but less than a third of those who remitted showed cognitive improvement (29%). Cognitive improvement was observed in 18% of nonremitters. Lower baseline depression severity, greater social functioning, and depression onset prior to 60 years of age were significantly associated with cognitive improvement. None of the other measures, including baseline apathy, resilience, and depression remission status, were significantly associated with cognitive improvement. CONCLUSIONS Lower severity of depression, earlier onset, and greater social functioning may predict improvement in cognitive functioning with treatment for depression in LLD.",2021,"None of the other measures, including baseline apathy, resilience, and depression remission status, were significantly associated with cognitive improvement. ",['One hundred sixty-five older adults with major depression who had completed one of 2 clinical trials were included: (1'],"['methylphenidate plus placebo, citalopram plus placebo, and citalopram plus methylphenidate or (2) citalopram combined with Tai Chi or health education']","['Cognitive improvement', 'Lower baseline depression severity, greater social functioning, and depression onset', 'general cognitive performance score', 'cognitive improvement', 'Cognitive Improvement', 'baseline apathy, resilience, and depression remission status']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0450385', 'cui_str': '65 (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0376403', 'cui_str': 'Taiji'}, {'cui': 'C0018701'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0085632', 'cui_str': 'Apathy'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",165.0,0.208231,"None of the other measures, including baseline apathy, resilience, and depression remission status, were significantly associated with cognitive improvement. ","[{'ForeName': 'Prabha', 'Initials': 'P', 'LastName': 'Siddarth', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at 8783UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Cynthia M', 'Initials': 'CM', 'LastName': 'Funes', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at 8783UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Kelsey T', 'Initials': 'KT', 'LastName': 'Laird', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at 8783UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Ercoli', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at 8783UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Lavretsky', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at 8783UCLA, Los Angeles, CA, USA.'}]",Journal of geriatric psychiatry and neurology,['10.1177/0891988720915515'] 60,31825248,Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.,"Background: The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product, United States-sourced insulin aspart (NovoLog ® ), and European Union-sourced insulin aspart (NovoRapid ® ). Materials and Methods: This was a single-center, randomized, double-blind, 3-treatment, 3-period, single-dose, crossover euglycemic study (NCT03202875) in 30 adult male subjects with type 1 diabetes (T1D). Subjects received 0.3 U/kg of each treatment under fasted conditions and underwent a 12-h euglycemic clamp technique to assess pharmacokinetic and pharmacodynamic activity for up to 12 h. Primary endpoints were area under the plasma insulin concentration-time curve from time zero to the last quantifiable concentration (INS-AUC last ), and extrapolated to infinity (INS-AUC inf ), maximum plasma insulin concentration (INS-C max ), and the area under the body weight-standardized glucose infusion rate (GIR)-time curve from 0 to 12 hours (GIR-AUC 0-12h ) among the three treatments. GIR max was the main secondary endpoint. Results: Of the 30 subjects randomized, 29 completed all 3 treatment periods. Pharmacokinetic and pharmacodynamic profiles were similar in all groups. The extent of exposure (INS-C max , INS-AUC last , and INS-AUC inf ) and glucodynamic activity (GIR-AUC 0-12h , GIR max ) was similar among the three treatments. The corresponding 90% confidence intervals for pairwise treatment ratios were completely contained within the limits of 80%-125%. SAR341402 was well tolerated. Conclusions: The present study demonstrated similar pharmacokinetic exposure profiles and glucodynamic potency among SAR341402, NovoLog, and NovoRapid in subjects with T1D, supporting further clinical evaluation of SAR341402 as a biosimilar/follow-on product.",2020,Pharmacokinetic and pharmacodynamic profiles were similar in all groups.,"['30 adult male subjects with type 1 diabetes (T1D', '30 subjects randomized, 29 completed all 3 treatment periods', 'subjects with T1D', 'Subjects with Type 1 Diabetes']","['euglycemic clamp technique', 'SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart', 'SAR341402 insulin aspart biosimilar/follow-on product, United States-sourced insulin aspart (NovoLog ® ), and European Union-sourced insulin aspart (NovoRapid ® ']","['plasma insulin concentration-time curve from time zero to the last quantifiable concentration (INS-AUC last ), and extrapolated to infinity (INS-AUC inf ), maximum plasma insulin concentration (INS-C max ), and the area under the body weight-standardized glucose infusion rate (GIR)-time curve', 'Pharmacokinetic and pharmacodynamic profiles', 'extent of exposure (INS-C max , INS-AUC last , and INS-AUC inf ) and glucodynamic activity (GIR-AUC 0-12h , GIR max ', 'pharmacokinetic and pharmacodynamic activity', 'tolerated']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0079318', 'cui_str': 'Glucose Clamp'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0123677', 'cui_str': 'Insulin, Aspart, Human'}, {'cui': 'C0205540', 'cui_str': 'Approved (qualifier value)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C4521696', 'cui_str': 'Source (property)'}, {'cui': 'C0939412', 'cui_str': 'NovoLog'}, {'cui': 'C0015179', 'cui_str': 'European Community'}]","[{'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0919414', 'cui_str': '0 (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",29.0,0.0795618,Pharmacokinetic and pharmacodynamic profiles were similar in all groups.,"[{'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Kapitza', 'Affiliation': 'Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany.'}, {'ForeName': 'Leszek', 'Initials': 'L', 'LastName': 'Nosek', 'Affiliation': 'Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Schmider', 'Affiliation': 'Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.'}, {'ForeName': 'Lenore', 'Initials': 'L', 'LastName': 'Teichert', 'Affiliation': 'Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Nowotny', 'Affiliation': 'Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.'}]",Diabetes technology & therapeutics,['10.1089/dia.2019.0351'] 61,32217042,The effect of different genres of music and silence on relaxation and anxiety: A randomized controlled trial.,"High stress and anxiety in healthy individuals may lead to use different pharmacological and non-pharmacological therapies. The study aimed to investigate the effect of different genres of music on anxiety and relaxation in healthy participants. This study was a randomized controlled trial with a cross-over design. Forty-six healthy undergraduates participated in the study and randomly received different genres of music (Pop, Rock, Western Classical, and Persian Traditional) and silence for five consecutive days between February and June 2018. Each participant was her/his own control. Relaxation and the State Anxiety were checked with Smith Relaxation States Inventory 3 and The State Anxiety Inventory before and after listening to 15 min of music or laying down in silence. None of the five procedures were preferred for a more relaxing effect (P > 0.05). Also, none of the interventions were preferred for reduction of the state anxiety (P > 0.05). Although different genres of music, i.e., Pop, Rock, Western Classical, Persian Traditional, could reduce state anxiety and improve relaxation, they had no extra effect compared to Silence.",2020,None of the five procedures were preferred for a more relaxing effect (P > 0.05).,"['healthy participants', 'Forty-six healthy undergraduates', 'healthy individuals']","['genres of music (Pop, Rock, Western Classical, and Persian Traditional']","['Relaxation and the State Anxiety', 'state anxiety', 'relaxing effect', 'relaxation and anxiety', 'state anxiety and improve relaxation']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0439820', 'cui_str': 'Popping sensation quality'}, {'cui': 'C0443177', 'cui_str': 'Classical (qualifier value)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}]","[{'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0542193', 'cui_str': 'Relaxed (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}]",46.0,0.0396863,None of the five procedures were preferred for a more relaxing effect (P > 0.05).,"[{'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Malakoutikhah', 'Affiliation': 'Student Research Committee, School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Mahlagha', 'Initials': 'M', 'LastName': 'Dehghan', 'Affiliation': 'Nursing Research Center, Kerman University of Medical Sciences, Kerman, Iran; Razi Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Haft-Bagh Highway, Kerman, Iran. Electronic address: m_dehghan@kmu.ac.ir.'}, {'ForeName': 'Asma', 'Initials': 'A', 'LastName': 'Ghonchehpoorc', 'Affiliation': 'Student Research Committee, School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Peiman', 'Initials': 'P', 'LastName': 'Parandeh Afshar', 'Affiliation': 'Student Research Committee, School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Honarmand', 'Affiliation': 'University of Tehran, Tehran, Iran. Electronic address: a.honarmand@ut.ac.ir.'}]","Explore (New York, N.Y.)",['10.1016/j.explore.2020.02.005'] 62,31657625,Improved Glycemic Control Through the Use of a Telehomecare Program in Patients with Diabetes Treated with Insulin.,"Background: With the drastic surge in the prevalence of diabetes, the use of medical resources for management of diabetic patients increased markedly. This study aimed to evaluate the impact of telehomecare (THC) use on clinical efficacy, nursing interventions, and medical visits compared with the standard care in insulin-treated diabetic patients. Materials and Methods: A prospective noninferiority clinical trial was designed. Participants were assigned to either an intervention group provided with a THC system during 3 months or to a control group. Main outcome was the difference in A1c at 3 months compared with baseline. Secondary outcomes were the difference in A1c at 6 months compared with baseline, the number of medical visits during the 6-month period of the study, and nursing interventions during the 3 months on THC. Results: A total of 92 participants completed the study. A significant decrease in A1c levels was observed in the THC group ( n  = 45) compared with the control group ( n  = 47) at 3 months (-0.61% vs. -0.06%, respectively, P  = 0.048) and at 6 months (-0.37% vs. -0.10%, respectively, P  = 0.036). The THC group had an average of 0.6 medical visit compared with 1.0 in the control group ( P  < 0.001). An increase in nursing interventions (mainly e-mails) was noted in THC group ( n  = 14.7) compared with control group ( n  = 1.1). Conclusions: This THC program demonstrates improvement in glycemic control and a decrease in the number of medical visits. However, it is important to consider an additional burden in nursing interventions when implementing a THC program.",2020,"A significant decrease in A1c levels was observed in the THC group (n=45) compared to the control group (n= 47) at 3 months (-0.61% vs -0.06%, respectively, p = 0.048) and at 6 months (-0.37% vs -0.10%, respectively, p = 0.036).","['Diabetic Patients Treated with Insulin', 'insulin-treated diabetic patients', '92 participants completed the study']","['intervention group provided with a THC system', 'THC', 'telehomecare (THC']","['glycemic control', 'number of medical visits', 'A1c levels', 'nursing interventions']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}]",92.0,0.0573843,"A significant decrease in A1c levels was observed in the THC group (n=45) compared to the control group (n= 47) at 3 months (-0.61% vs -0.06%, respectively, p = 0.048) and at 6 months (-0.37% vs -0.10%, respectively, p = 0.036).","[{'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Lemelin', 'Affiliation': ""Endocrinology Division, Medicine Department, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Ariane', 'Initials': 'A', 'LastName': 'Godbout', 'Affiliation': ""Endocrinology Division, Medicine Department, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Paré', 'Affiliation': 'Research Chair in Digital Health, HEC Montreal, Montreal, Canada.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Bernard', 'Affiliation': ""Endocrinology Division, Medicine Department, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.""}]",Diabetes technology & therapeutics,['10.1089/dia.2019.0324'] 63,32402650,"Task experience eliminates catecholaminergic effects on inhibitory control - A randomized, double-blind cross-over neurophysiological study.","Catecholaminergic neural transmission plays an important role during the inhibition of prepotent responses. Methylphenidate (MPH) is an important drug that modulates the catecholaminergic system. However, theoretical considerations suggest that the effects of drugs (e.g. MPH) on cognitive control may depend on prior learning effects. Here we investigate this in a conflict-modulated Go/Nogo task and evaluate neurophysiological processes associated with this dynamic using EEG signal decomposition methods and source localization analysis. The behavioral data show that prior learning experiences eliminate effects of MPH on response inhibition processes. On a neurophysiological level, we show that MPH modulates specific processes in medial frontal brain regions. Although MPH seems to consistently modulate neurophysiological processes associated with response inhibition, this is no longer sufficient to modulate behavioral performance once learning or task familiarization processes have taken place. An important consequence of this study finding is that it may be important to adjust MPH dosage depending on learning effects in a specific setting to constantly increase cognitive control functions in that setting. This has important implications for clinical practice, since MPH is the first-line pharmacological therapy in attention-deficit hyperactivity disorder (ADHD). Cross-over study designs with constant doses of MPH can mask effects on cognitive functions. The impact of learning needs careful consideration in cross-over study designs examining catecholaminergic drug effects.",2020,"Although MPH seems to consistently modulate neurophysiological processes associated with response inhibition, this is no longer sufficient to modulate behavioral performance once learning or task familiarization processes have taken place.",[],['Methylphenidate (MPH'],"['cognitive control functions', 'cognitive functions', 'catecholaminergic effects']",[],"[{'cui': 'C0025810', 'cui_str': 'Methylphenidate'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.0560393,"Although MPH seems to consistently modulate neurophysiological processes associated with response inhibition, this is no longer sufficient to modulate behavioral performance once learning or task familiarization processes have taken place.","[{'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Mückschel', 'Affiliation': 'Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine of the TU Dresden, Schubertstraße 42, D-01309 Dresden, Germany.'}, {'ForeName': 'Veit', 'Initials': 'V', 'LastName': 'Roessner', 'Affiliation': 'Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine of the TU Dresden, Schubertstraße 42, D-01309 Dresden, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Beste', 'Affiliation': 'Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine of the TU Dresden, Schubertstraße 42, D-01309 Dresden, Germany. Electronic address: christian.beste@uniklinikum-dresden.de.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2020.03.013'] 64,32216142,Combat-Related Posttraumatic Stress Disorder and Comorbid Major Depression in U.S. Veterans: The Role of Deployment Cycle Adversity and Social Support.,"Posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) commonly co-occur in combat veterans, and this comorbidity has been associated with higher levels of distress and more social and economic costs compared to one disorder alone. In a secondary analysis of a multisite randomized controlled trial of a sample of veterans with combat-related PTSD, we examined the associations among pre-, peri-, and postdeployment adversity, social support, and clinician-diagnosed comorbid MDD. Participants completed the Deployment Risk and Resilience Inventory and the Beck Depression Inventory-II as well as structured clinical interviews for diagnostic status. Among 223 U.S. veterans of the military operations in Iraq and Afghanistan (86.9% male) with primary combat-related PTSD, 69.5% had current comorbid MDD. After adjustment for sex, a linear regression model indicated that more concerns about family disruptions during deployment, f 2 = 0.065; more harassment during deployment, f 2 = 0.020; and lower ratings of postdeployment social support, f 2 = 0.154, were associated with more severe self-reported depression symptoms. Interventions that enhance social support as well as societal efforts to foster successful postdeployment reintegration are critical for reducing the mental health burden associated with this highly prevalent comorbidity in veterans with combat-related PTSD.",2020,"After adjustment for sex, a linear regression model indicated that more concerns about family disruptions during deployment, f 2 = 0.065; more harassment during deployment, f 2 = 0.020; and lower ratings of postdeployment social support, f 2 = 0.154, were associated with more severe self-reported depression symptoms.","['Posttraumatic stress disorder (PTSD) and major depressive disorder (MDD', 'Combat-Related Posttraumatic Stress Disorder and Comorbid Major Depression in U.S. Veterans', 'veterans with combat-related PTSD', '223 U.S. veterans of the military operations in Iraq and Afghanistan (86.9% male) with primary combat-related PTSD, 69.5% had current comorbid MDD']",[],"['Deployment Risk and Resilience Inventory and the Beck Depression Inventory-II', 'severe self-reported depression symptoms']","[{'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0026126', 'cui_str': 'Armed Forces Personnel'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0022066', 'cui_str': 'Republic of Iraq'}, {'cui': 'C0001732', 'cui_str': 'Afghanistan'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0161695,"After adjustment for sex, a linear regression model indicated that more concerns about family disruptions during deployment, f 2 = 0.065; more harassment during deployment, f 2 = 0.020; and lower ratings of postdeployment social support, f 2 = 0.154, were associated with more severe self-reported depression symptoms.","[{'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Goetter', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Susanne S', 'Initials': 'SS', 'LastName': 'Hoeppner', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Khan', 'Affiliation': 'San Francisco VA Medical Center, San Francisco, California, USA.'}, {'ForeName': 'Meredith E', 'Initials': 'ME', 'LastName': 'Charney', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Wieman', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Margaret R', 'Initials': 'MR', 'LastName': 'Venners', 'Affiliation': 'VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Kimberly M', 'Initials': 'KM', 'LastName': 'Avallone', 'Affiliation': 'Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Sheila A M', 'Initials': 'SAM', 'LastName': 'Rauch', 'Affiliation': 'VA Atlanta Healthcare System, Atlanta, Georgia, USA.'}, {'ForeName': 'Naomi M', 'Initials': 'NM', 'LastName': 'Simon', 'Affiliation': 'Department of Psychiatry, New York University School of Medicine, New York, New York, USA.'}]",Journal of traumatic stress,['10.1002/jts.22496'] 65,32036679,Adolescent Mothers' Perceptions of a Mobile Phone-Based Peer Support Intervention.,"BACKGROUND Postpartum depression (PPD) is prevalent among adolescent mothers and is associated with negative maternal and infant outcomes. Peer support can improve health outcomes among adult and adolescent populations and involves the provision of informational, emotional, and appraisal support delivered by a peer. PURPOSE To describe adolescent mothers' perceptions of a mobile phone-based peer support (MPPS) intervention designed to prevent PPD. METHODS This analysis draws on data from the MPPS intervention group of a pilot randomized controlled trial of pregnant adolescents 17 to 24 years old ( n  = 16). Maternal perceptions of the intervention were measured using the validated Peer Support Evaluation Inventory at 12 weeks postpartum. RESULTS Participants acknowledged receiving supportive actions including emotional (91%), informational (66%), and appraisal (64%) support. Participants perceived positive relationship qualities with their peer mentor such as trustworthiness (94%), acceptance (75%), empathy (81%), and commitment (81%) and felt their peer mentor possessed social competence (91%) and social skills (91%). Overall, 100% of participants were satisfied with their peer support experience and would recommend this type of support to a friend. CONCLUSION Participants perceived their experience with the MPPS intervention positively, which lends support to MPPS as an acceptable way to provide support to adolescent mothers.",2020,"Peer support can improve health outcomes among adult and adolescent populations and involves the provision of informational, emotional, and appraisal support delivered by a peer. ","[""Adolescent Mothers' Perceptions of a"", 'adult and adolescent populations', 'adolescent mothers', 'pregnant adolescents 17 to 24\u2009years old ( n \u2009=\u200916']","['mobile phone-based peer support (MPPS) intervention', 'MPPS intervention', 'Mobile Phone-Based Peer Support Intervention']","['social competence', 'social skills', 'health outcomes']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0679005', 'cui_str': 'Social Abilities'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0595357,"Peer support can improve health outcomes among adult and adolescent populations and involves the provision of informational, emotional, and appraisal support delivered by a peer. ","[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Chyzzy', 'Affiliation': 'Daphne Cockwell School of Nursing, Ryerson University, Toronto, ON, Canada.'}, {'ForeName': 'LaRon E', 'Initials': 'LE', 'LastName': 'Nelson', 'Affiliation': 'Yale University School of Nursing, New Haven, CT, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Stinson', 'Affiliation': 'The Hospital for Sick Children, Toronto, ON, Canada.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Vigod', 'Affiliation': ""Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Cindy-Lee', 'Initials': 'CL', 'LastName': 'Dennis', 'Affiliation': 'University of Toronto, Toronto, ON, Canada.'}]",The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres,['10.1177/0844562120904591'] 66,32216143,"Effects of Narrative Exposure Therapy on Posttraumatic Stress Disorder, Depression, and Insomnia in Traumatized North Korean Refugee Youth.","Refugees affected by multiple traumatic stressors are at high risk for developing trauma-related mental disorders, including posttraumatic stress disorder (PTSD), depression, and insomnia, which is sometimes overlooked. The present study examined the effectiveness of narrative exposure therapy (NET) on trauma-related symptoms in a sample of North Korean refugee youth. We focused on sleep patterns in addition to changes in symptom severity for PTSD, depression, and internalizing and externalizing symptoms. North Korean refugee youth (N = 20) with PTSD were assigned to either an NET-based treatment group or a control group, which consisted of treatment as usual (TAU). There were clinically significant reductions in PTSD, depression, and internalizing and externalizing symptoms for the NET group, Hedges' g = 3.6, but not the TAU group. The change in diagnostic status for PTSD was more notable for participants in the NET group compared to the TAU group. Of note, NET also produced a significant improvement in insomnia symptoms and sleep quality, Hedges' g = 2.1. The substantial recovery regarding overall posttraumatic symptoms in the NET group was observed 2 weeks after the end of treatment and remained stable at 6-month follow-up. The results of the present study suggest that NET may be a treatment option for traumatized North Korean refugee youth and may also be effective for the treatment of sleep problems that arise from traumatic experiences.",2020,"There were clinically significant reductions in PTSD, depression, and internalizing and externalizing symptoms for the NET group, Hedges' g = 3.6, but not the TAU group.","['Traumatized North Korean Refugee Youth', 'trauma-related symptoms in a sample of North Korean refugee youth', 'North Korean refugee youth (N = 20) with PTSD']","['NET', 'narrative exposure therapy (NET', 'NET-based treatment group or a control group, which consisted of treatment as usual (TAU', 'Narrative Exposure Therapy']","['symptom severity for PTSD, depression, and internalizing and externalizing symptoms', 'diagnostic status for PTSD', 'PTSD, depression, and internalizing and externalizing symptoms', 'Posttraumatic Stress Disorder, Depression, and Insomnia', 'overall posttraumatic symptoms', 'insomnia symptoms and sleep quality']","[{'cui': 'C1556095', 'cui_str': 'Koreans'}, {'cui': 'C0034961', 'cui_str': 'Refugees'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}]","[{'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1720655', 'cui_str': 'Tau'}]","[{'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",20.0,0.0228226,"There were clinically significant reductions in PTSD, depression, and internalizing and externalizing symptoms for the NET group, Hedges' g = 3.6, but not the TAU group.","[{'ForeName': 'Jinme K', 'Initials': 'JK', 'LastName': 'Park', 'Affiliation': 'Department of Psychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Jinah', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Department of Counseling, Kyonggy University, Suwon, Republic of Korea.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Elbert', 'Affiliation': 'Department of Psychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Seog Ju', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}]",Journal of traumatic stress,['10.1002/jts.22492'] 67,32216149,The Impact of Depression Severity on Treatment Outcomes Among Older Male Combat Veterans with Posttraumatic Stress Disorder.,"Posttraumatic stress disorder (PTSD) and depression are highly comorbid within the veteran population. Research studies have yielded divergent findings regarding the effect of depression on PTSD treatment outcomes. The present study investigated the influence of pretreatment depression severity on PTSD and depression symptom trajectories among 85 older (i.e., ≥ 60 years) male veterans with military-related PTSD who received either prolonged exposure or relaxation training as part of a randomized controlled trial. Participants were categorized as having no/mild depression (n = 23) or moderate/severe depression (n = 62). The PTSD Checklist (PCL-S) and Patient Health Questionnaire (PHQ-9) were completed at pretreatment, each of 12 therapy sessions, posttreatment, and 6-month follow-up, for a total of up to 15 data points per participant. Multilevel modeling (MLM) was used to evaluate the impact of pretreatment depression severity on piecewise symptom trajectories (i.e., active treatment and follow-up periods) over time and to determine whether treatment condition moderated the trajectories. The final MLM results showed significant main effects of depression severity on PCL-S scores, B = 10.84, p = .043 and PHQ-9 scores, B = 7.09, p = .001, over time. No significant interactions emerged for either the PCL-S or PHQ-9, indicating that although older veterans with more severe depression endorsed higher PTSD and depression scores across time, the symptom trajectories were not moderated by depression severity, treatment condition, or their interaction.",2020,"The final MLM results showed significant main effects of depression severity on PCL-S scores, B = 10.84, p = .043 and PHQ-9 scores, B = 7.09, p = .001, over time.","['Older Male Combat Veterans with Posttraumatic Stress Disorder', 'Participants were categorized as having no/mild depression (n = 23) or moderate/severe depression (n = 62', '85 older (i.e., ≥ 60 years) male veterans with military-related PTSD who received either']","['prolonged exposure or relaxation training', 'Multilevel modeling (MLM']","['depression severity on PCL-S scores', 'PTSD Checklist (PCL-S) and Patient Health Questionnaire (PHQ-9']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0588006', 'cui_str': 'Mild depression (disorder)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0588008', 'cui_str': 'Severe depression (disorder)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0026126', 'cui_str': 'Armed Forces Personnel'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0282333', 'cui_str': 'Relaxation Therapy'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C1879301', 'cui_str': 'Patient Health Questionnaire'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}]",85.0,0.00894826,"The final MLM results showed significant main effects of depression severity on PCL-S scores, B = 10.84, p = .043 and PHQ-9 scores, B = 7.09, p = .001, over time.","[{'ForeName': 'Kristen H', 'Initials': 'KH', 'LastName': 'Walter', 'Affiliation': 'Veterans Affairs (VA) San Diego Healthcare System, San Diego, California, USA.'}, {'ForeName': 'Lisa H', 'Initials': 'LH', 'LastName': 'Glassman', 'Affiliation': 'Veterans Medical Research Foundation, San Diego, California, USA.'}, {'ForeName': 'Stephanie Y', 'Initials': 'SY', 'LastName': 'Wells', 'Affiliation': 'Veterans Affairs (VA) San Diego Healthcare System, San Diego, California, USA.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Thorp', 'Affiliation': 'Veterans Affairs (VA) San Diego Healthcare System, San Diego, California, USA.'}, {'ForeName': 'Leslie A', 'Initials': 'LA', 'LastName': 'Morland', 'Affiliation': 'Veterans Affairs (VA) San Diego Healthcare System, San Diego, California, USA.'}]",Journal of traumatic stress,['10.1002/jts.22503'] 68,32216150,Posttraumatic Stress Disorder and Childhood Traumatic Loss: A Secondary Analysis of Symptom Severity and Treatment Outcome.,"Loss is a commonly experienced traumatic event among children. Although the experience of loss can potentially lead to posttraumatic stress symptoms (PTSS), little is known about PTSS levels after traumatic loss versus other traumatic events. We investigated data from a randomized controlled trial (RCT) on trauma-focused cognitive behavioral therapy (TF-CBT) versus a waitlist condition for children with PTSS. In a secondary analysis, we compared participants who reported traumatic loss as their index event (n = 23) to those who reported the two most frequently reported index events in the RCT: sexual abuse (SA; n = 59) and physical violence (PV; n = 55). The index event was rated according to the participants' most distressing traumatic event reported on the Clinician-Administered PTSD Scale for Children and Adolescents. Participants who experienced traumatic loss reported fewer PTSS and better general functioning than those who reported SA. A subgroup RCT (n = 19) revealed TF-CBT to be highly effective in reducing PTSS in cases of traumatic loss, d = 1.69. The effect sizes for PTSS indicated that all three trauma groups benefited from TF-CBT. In the waitlist group, PTSS symptoms improved for SA and PV, ds = 0.76 and 0.98, respectively, but not for traumatic loss, d = 0.23. These findings suggest that TF-CBT is a feasible and promising treatment for children who experience PTSS after traumatic loss. The results are limited by the post hoc quality of the analyses and lack of a measure of grief in the RCT.",2020,"In the waitlist group, PTSS symptoms improved for SA and PV, ds = 0.76 and 0.98, respectively, but not for traumatic loss, d = 0.23.","['children with PTSS', 'Posttraumatic Stress Disorder and Childhood Traumatic Loss', 'children who experience PTSS after traumatic loss']","['cognitive behavioral therapy (TF-CBT', 'TF-CBT']","['PTSS symptoms', 'traumatic loss']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0259766', 'cui_str': 'Traumatic acquired absence (morphologic abnormality)'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0259766', 'cui_str': 'Traumatic acquired absence (morphologic abnormality)'}]",59.0,0.0700977,"In the waitlist group, PTSS symptoms improved for SA and PV, ds = 0.76 and 0.98, respectively, but not for traumatic loss, d = 0.23.","[{'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Unterhitzenberger', 'Affiliation': 'Department of Psychology, Catholic University Eichstätt-Ingolstadt, Eichstätt, Germany.'}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Sachser', 'Affiliation': 'Clinic for Child and Adolescent Psychiatry/Psychotherapy, Ulm University, Ulm, Germany.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Rosner', 'Affiliation': 'Department of Psychology, Catholic University Eichstätt-Ingolstadt, Eichstätt, Germany.'}]",Journal of traumatic stress,['10.1002/jts.22499'] 69,31638433,The Effect of Acarbose on Glycemic Variability in Patients with Type 2 Diabetes Mellitus Using Premixed Insulin Compared to Metformin (AIM): An Open-Label Randomized Trial.,"Background: Acarbose (ACA) can effectively reduce the postprandial blood glucose and has similar antidiabetic effects as metformin (MET). To our knowledge, few studies have compared the effect of ACA or MET on glucose fluctuations. In the present study, we explored the effect of ACA or MET combined with premixed insulin (INS) on glycemic control and glycemic variability (GV). Methods: This was an open-label randomized trial that was conducted in type 2 diabetic patients taking premixed insulin. The patients were assigned to 12 weeks of MET ( n  = 62) or ACA ( n  = 62) treatment combined with INS. The main outcomes were changes in GV and glycosylated hemoglobin A1c (HbA1c) compared with baseline. Results: Compared with baseline, several GV indices (standard deviation [SD], mean amplitude of glycemic excursions [MAGE]) and blood glucose control indices (mean glucose [MG], time in range [TIR] and HbA1c) were both significantly improved in INS+ACA and INS+MET after 12-week therapy. However, coefficient of variation (CV) was significantly reduced in INS+ACA but not in INS+MET. Moreover, compared with INS+MET, INS+ACA led to a more pronounced percentage change from baseline in CV (26.3% [1.7%-44.6%] vs. 11.9% [-7.0% to 29.9%], P  = 0.022), MAGE (40.5% [20.1%-60.5%] vs. 25.2% [-2.1% to 43.4%], P  = 0.007) and SD (38.6% [25.2%-57.9%] vs. 30.1% [10.8%-46.5%], P  = 0.041). Conclusion: Both MET and ACE combined with INS effectively reduced blood glucose. Compared with MET, ACA combined with INS reduced GV.",2020,"However, coefficient of variation (CV) was significantly reduced in INS+ACA but not in INS+MET.","['patients with type 2 diabetes mellitus using', 'type 2 diabetic patients taking']","['INS+ACA', 'INS+MET, INS+ACA', 'Metformin', 'Acarbose', 'premixed Insulin', 'ACA or MET combined with premixed insulin (INS', ' Acarbose (ACA', 'premixed insulin', 'ACA (n=62) treatment combined with INS']","['glycemic variability', 'changes in GV and hemoglobin A1c (HbA1c', 'glycemic control and glycemic variability (GV', 'blood glucose', 'MAGE', 'several GV indices [standard deviation (SD), mean amplitude of glycemic excursions (MAGE)] and blood glucose control indices [mean glucose (MG), time in range (TIR) and HbA1c', 'coefficient of variation (CV', 'postprandial blood glucose']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0050393', 'cui_str': 'Acarbose'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}]",,0.185502,"However, coefficient of variation (CV) was significantly reduced in INS+ACA but not in INS+MET.","[{'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Gao', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Xiaojing', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Jiahui', 'Initials': 'J', 'LastName': 'Peng', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Jingyi', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Lu', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhu', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Yuqian', 'Initials': 'Y', 'LastName': 'Bao', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Vigersky', 'Affiliation': 'Diabetes Institute of the Walter Reed National Military Medical Center, Bethesda, Maryland.'}, {'ForeName': 'Weiping', 'Initials': 'W', 'LastName': 'Jia', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}]",Diabetes technology & therapeutics,['10.1089/dia.2019.0290'] 70,31910674,Promising Results From a Video-Feedback Interaction Guidance Intervention for Improving Maternal-Infant Interaction Quality of Depressed Mothers: A Feasibility Pilot Study.,"BACKGROUND Mothers and infants affected by postpartum depression are known to have (1) reduced quality interactions and (2) elevated cortisol levels, both of which are linked to negative developmental outcomes in children. Parent training promoting sensitive and responsive maternal-infant interactions may help optimize development in children of mothers with postpartum depression. OBJECTIVES This pilot study tested a video-feedback interaction guidance intervention designed to improve maternal-infant interaction, depressive symptoms, and cortisol patterns of depressed mothers and their infants. METHOD An experimental, pre-test, post-test design was employed to randomly assign mothers with postpartum depression to intervention ( n  = 6) and control ( n  = 6) conditions. Intervention mothers received three video-feedback sessions during home visits, provided at three-week intervals. Control participants received three home visits on the same schedule. RESULTS Significant differences favoring the intervention group were observed in maternal-infant interaction quality, especially maternal sensitivity and cognitive growth fostering activities, and in reduced infant diurnal cortisol. CONCLUSION Professionally guided video-feedback intervention appears to support improvements in interactions between depressed mothers and their infants and optimizes infants' diurnal cortisol patterns. The findings from this feasibility pilot study have been used to support a large-scale follow-up exploration.",2020,"RESULTS Significant differences favoring the intervention group were observed in maternal-infant interaction quality, especially maternal sensitivity and cognitive growth fostering activities, and in reduced infant diurnal cortisol. ","['depressed mothers and their infants', 'children of mothers with postpartum depression', 'Depressed Mothers']","['video-feedback interaction guidance intervention', 'Parent training promoting sensitive and responsive maternal-infant interactions', 'video-feedback sessions', 'Video-Feedback Interaction Guidance Intervention']","['maternal-infant interaction, depressive symptoms, and cortisol patterns', 'maternal-infant interaction quality, especially maternal sensitivity and cognitive growth fostering activities, and in reduced infant diurnal cortisol']","[{'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0205342', 'cui_str': 'Responsive'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0242298', 'cui_str': 'Fostering'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}]",,0.0234434,"RESULTS Significant differences favoring the intervention group were observed in maternal-infant interaction quality, especially maternal sensitivity and cognitive growth fostering activities, and in reduced infant diurnal cortisol. ","[{'ForeName': 'Panagiota D', 'Initials': 'PD', 'LastName': 'Tryphonopoulos', 'Affiliation': 'Arthur Labatt Family School of Nursing, Western University, FIMS and Nursing Building, London, Ontario, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Letourneau', 'Affiliation': 'Faculty of Nursing, Cumming School of Medicine (Pediatrics, Psychiatry & Community Health Sciences), University of Calgary, Calgary, Alberta, Canada.'}]",The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres,['10.1177/0844562119892769'] 71,32000509,Effect of the Attachment and Child Health Parent Training Program on Parent-Child Interaction Quality and Child Development.,"BACKGROUND Exposure to chronic stressors (poverty, addiction, family violence) in early life can derail children's development. Interventions focused on parental reflective function may promote parents' abilities to regulate their feelings and behaviors toward their children and buffer the impact of chronic stressors on children's development by nurturing high-quality parent-child interaction. PURPOSE To test the effectiveness of parental reflective function-focused intervention entitled Attachment and Child Health on parent-child interaction and child development. METHODS We conducted two pilots with vulnerable mothers and children <36 months. Randomized controlled trial (n = 20) and quasi-experimental (n = 10) methods tested the effect of Attachment and Child Health on parent-child interaction via Parent-Child Interaction Teaching Scale (PCITS) and on child development via Ages and Stages Questionnaire (ASQ-3) and Ages and Stages Questionnaire-Social Emotional (ASQSE). We employed analysis of covariance and t-tests to examine the outcomes. RESULTS For randomized controlled trial, we found significant improvements in PCITS parent total, combined total, and cognitive growth fostering scores, and ASQ-3 personal-social scores post-intervention. For quasi-experimental study, we found significant improvements in PCITS combined total, sensitivity to cues, response to child's distress, and responsiveness to caregiver scores. CONCLUSION Incorporating Attachment and Child Health contributed to effective programming for vulnerable families with young children.",2020,"For quasi-experimental study, we found significant improvements in PCITS combined total, sensitivity to cues, response to child's distress, and responsiveness to caregiver scores. ","['pilots with vulnerable mothers and children <36\u2009months', 'vulnerable families with young children']","['parental reflective function-focused intervention entitled Attachment and Child Health', 'Attachment and Child Health Parent Training Program']","['Parent-Child Interaction Quality and Child Development', ""PCITS combined total, sensitivity to cues, response to child's distress, and responsiveness to caregiver scores"", 'PCITS parent total, combined total, and cognitive growth fostering scores, and ASQ-3 personal-social scores', 'effect of Attachment and Child Health on parent-child interaction via Parent-Child Interaction Teaching Scale (PCITS) and on child development via Ages and Stages Questionnaire (ASQ-3) and Ages and Stages Questionnaire-Social Emotional (ASQSE']","[{'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0557118', 'cui_str': 'Family with young children'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0030542', 'cui_str': 'Parent-Child Relationship'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0008071', 'cui_str': 'Child Development'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0242298', 'cui_str': 'Fostering'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",,0.0304167,"For quasi-experimental study, we found significant improvements in PCITS combined total, sensitivity to cues, response to child's distress, and responsiveness to caregiver scores. ","[{'ForeName': 'Lubna', 'Initials': 'L', 'LastName': 'Anis', 'Affiliation': 'Faculty of Nursing, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Letourneau', 'Affiliation': 'Faculty of Nursing, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Benzies', 'Affiliation': 'Faculty of Nursing, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Ewashen', 'Affiliation': 'Faculty of Nursing, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Martha J', 'Initials': 'MJ', 'LastName': 'Hart', 'Affiliation': 'Faculty of Nursing, University of Calgary, Calgary, AB, Canada.'}]",The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres,['10.1177/0844562119899004'] 72,32401118,Benefits of a Self-Management Program for the Couple Living With Parkinson's Disease: A Pilot Study.,"The goal of this pilot study was to explore health benefits for couples participating together in an existing community-based self-management workshop for Parkinson's disease (PD). A quasi-experimental two-wave design explored the effects of the Strive to Thrive program in comparison to a wait-list control condition. Preliminary data ( n = 39 couples) showed that spouses in the intervention group had greater engagement in mental relaxation techniques at 7 weeks than those in the control condition (large effect size). Small effects were observed for increases in aerobic activity and mental relaxation for the adult with PD, increases in strength-based activities and self-efficacy for spouses, declines in depressive symptoms for spouses, and decreases in protective buffering for both adults with PD and spouses. The program showed potential for existing community-based programs to benefit couples living with chronic illness.",2021,Preliminary data ( n = 39 couples) showed that spouses in the intervention group had greater engagement in mental relaxation techniques at 7 weeks than those in the control condition (large effect size).,"[""couples participating together in an existing community-based self-management workshop for Parkinson's disease (PD"", ""Couple Living With Parkinson's Disease""]",['Self-Management Program'],"['aerobic activity and mental relaxation', 'health benefits', 'greater engagement in mental relaxation techniques', 'strength-based activities and self-efficacy']","[{'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0086387', 'cui_str': 'Health Benefits'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0035029', 'cui_str': 'Relaxation technique'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",39.0,0.0249277,Preliminary data ( n = 39 couples) showed that spouses in the intervention group had greater engagement in mental relaxation techniques at 7 weeks than those in the control condition (large effect size).,"[{'ForeName': 'Karen S', 'Initials': 'KS', 'LastName': 'Lyons', 'Affiliation': 'Boston College, Chestnut Hill, MA, USA.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Zajack', 'Affiliation': 'University of Nevada, Las Vegas, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Greer', 'Affiliation': ""Parkinson's Resources of Oregon, Beaverton, USA.""}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Chaimov', 'Affiliation': ""Parkinson's Resources of Oregon, Beaverton, USA.""}, {'ForeName': 'Nathan F', 'Initials': 'NF', 'LastName': 'Dieckmann', 'Affiliation': 'Oregon Health & Science University, Portland, USA.'}, {'ForeName': 'Julie H', 'Initials': 'JH', 'LastName': 'Carter', 'Affiliation': 'Oregon Health & Science University, Portland, USA.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464820918136'] 73,32404279,Stimulation of the vagus nerve reduces learning in a go/no-go reinforcement learning task.,"When facing decisions to approach rewards or to avoid punishments, we often figuratively go with our gut, and the impact of metabolic states such as hunger on motivation are well documented. However, whether and how vagal feedback signals from the gut influence instrumental actions is unknown. Here, we investigated the effect of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) vs. sham (randomized cross-over design) on approach and avoidance behavior using an established go/no-go reinforcement learning paradigm in 39 healthy human participants (23 female) after an overnight fast. First, mixed-effects logistic regression analysis of choice accuracy showed that taVNS acutely impaired decision-making, p = .041. Computational reinforcement learning models identified the cause of this as a reduction in the learning rate through taVNS (∆α = -0.092, p boot  = .002), particularly after punishment (∆α Pun = -0.081, p boot  = .012 vs. ∆α Rew =-0.031, p boot  = .22). However, taVNS had no effect on go biases, Pavlovian response biases or response time. Hence, taVNS appeared to influence learning rather than action execution. These results highlight a novel role of vagal afferent input in modulating reinforcement learning by tuning the learning rate according to homeostatic needs.",2020,"First, mixed-effects logistic regression analysis of choice accuracy showed that taVNS acutely impaired decision-making, p = .041.",['39 healthy human participants (23 female) after an overnight fast'],['non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) vs. sham (randomized cross-over design'],"['go biases, Pavlovian response biases or response time']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]","[{'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C1522191', 'cui_str': 'Otic route'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0242817', 'cui_str': 'Crossover Design'}]","[{'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",39.0,0.0349857,"First, mixed-effects logistic regression analysis of choice accuracy showed that taVNS acutely impaired decision-making, p = .041.","[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Kühnel', 'Affiliation': 'Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry and International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany. Electronic address: anne_kuehnel@psych.mpg.de.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Teckentrup', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstr. 14, 72076 Tübingen, Germany.'}, {'ForeName': 'Monja P', 'Initials': 'MP', 'LastName': 'Neuser', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstr. 14, 72076 Tübingen, Germany.'}, {'ForeName': 'Quentin J M', 'Initials': 'QJM', 'LastName': 'Huys', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom; Max Planck UCL Centre for Computational Psychiatry and Ageing Research, London, United Kingdom.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Burrasch', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstr. 14, 72076 Tübingen, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Walter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstr. 14, 72076 Tübingen, Germany; Otto-von-Guericke University Magdeburg, Department of Psychiatry and Psychotherapy, Magdeburg, Germany; Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany; Leibniz Institute for Neurobiology, Magdeburg, Germany.'}, {'ForeName': 'Nils B', 'Initials': 'NB', 'LastName': 'Kroemer', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstr. 14, 72076 Tübingen, Germany. Electronic address: nils.kroemer@uni-tuebingen.de.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2020.03.023'] 74,32274890,Comparison of two skin temperature assessment methods after the application of topical revulsive products: Conductive iButton data logger system vs contact-free infrared thermometry.,"BACKGROUND Skin temperature assessments comprise conductive and contact-free techniques. Comparison between conductive data loggers and contact-free thermometry after the application of revulsive products is scarce. This study aimed to compare iButton data loggers with an infrared thermometer after the application of two revulsive products. Secondly, the relation between skin temperature kinetics with skin's perfusion of microcirculation was investigated. MATERIALS AND METHODS Healthy females (n = 25) were randomly allocated to two groups, representing the products A and B. Skin temperature was measured with ""iButtons"" and an infrared pistol at baseline and up to 1 hour after application. Skin's perfusion of microcirculation was monitored with a laser speckle contrast imager. RESULTS Baseline ""iButton"" temperature values were significantly lower compared with infrared pistol values in both groups. After application of the products, skin temperature decreased as recorded with both devices followed by an increase to baseline values when measured with the pistol. The results obtained by the ""iButtons"" reached values above baseline in both products towards the end of the follow-up period. A moderate correlation was found between infrared pistol and ""iButton"" system in product A, with a weak negative correlation between skin's perfusion of microcirculation and temperature devices. For product B, the correlation between the devices was moderate and between skin's perfusion and temperature devices weak and positive. CONCLUSION Both devices produced similar kinetics, except at baseline, where they may differ as metallic loggers have been insufficiently adapted to skin temperature. Skin's perfusion of microcirculation could not explain skin temperature changes.",2020,"For product B, the correlation between the devices was moderate and between skin's perfusion and temperature devices weak and positive. ",['Healthy females (n\xa0=\xa025'],[],"['Baseline ""iButton"" temperature values', 'skin temperature']","[{'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}]",25.0,0.0531813,"For product B, the correlation between the devices was moderate and between skin's perfusion and temperature devices weak and positive. ","[{'ForeName': 'Rahel', 'Initials': 'R', 'LastName': 'Stoop', 'Affiliation': 'Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Landquart, Switzerland.'}, {'ForeName': 'Erich', 'Initials': 'E', 'LastName': 'Hohenauer', 'Affiliation': 'Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Landquart, Switzerland.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Aerenhouts', 'Affiliation': 'Department of Movement and Sport Sciences, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'André O', 'Initials': 'AO', 'LastName': 'Barel', 'Affiliation': 'Department of Movement and Sport Sciences, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Deliens', 'Affiliation': 'Department of Movement and Sport Sciences, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Clijsen', 'Affiliation': 'Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Landquart, Switzerland.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Clarys', 'Affiliation': 'Department of Movement and Sport Sciences, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium.'}]",Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI),['10.1111/srt.12847'] 75,31403596,"Small-Group, Community-Member Intervention for Urinary and Bowel Incontinence: A Randomized Controlled Trial.","OBJECTIVE To evaluate the effects of Mind Over Matter: Healthy Bowels, Healthy Bladder, a small-group intervention, on urinary and bowel incontinence symptoms among older women with incontinence. METHODS In this individually randomized group treatment trial, women aged 50 years and older with urinary, bowel incontinence, or both, were randomly allocated at baseline to participate in Mind Over Matter: Healthy Bowels, Healthy Bladder immediately (treatment group) or after final data collection (waitlist control group). The primary outcome was urinary incontinence (UI) improvement on the Patient Global Impression of Improvement at 4 months. Validated instruments assessed incontinence, self-efficacy, depression, and barriers to care-seeking. Intent-to-treat analyses compared differences between groups. Target sample size, based on an anticipated improvement rate of 45% in treated women vs 11% in the control group, 90% power, type I error of 0.05, with anticipated attrition of 25%, was 110. RESULTS Among 121 women randomized (62 treatment group; 59 control group), 116 (95%) completed the 4-month assessment. Most participants were non-Hispanic white (97%), with a mean age of 75 years (SD 9.2, range 51-98); 66% had attended some college. There were no significant between-group differences at baseline. At 4 months, 71% of treated women vs 23% of women in the control group reported improved UI on Patient Global Impression of Improvement (P<.001); 39% vs 5% were much improved (P<.001). Regarding bowel incontinence, 55% of treated women vs 27% of women in the control group improved on Patient Global Impression of Improvement (P<.005), with 35% vs 11% reporting much improvement (P<.005). Treated women improved significantly more than women in the control group on all validated instruments of incontinence severity, quality of life, and self-efficacy. Care-seeking rates were similar between groups. CONCLUSION Participation in a small-group intervention improves symptoms of both urinary and bowel incontinence in older women. Mind Over Matter is a feasible model with potential to bring effective behavioral solutions to the community. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT03140852.",2019,"Treated women improved significantly more than women in the control group on all validated instruments of incontinence severity, quality of life, and self-efficacy.","['women aged 50 years and older with urinary, bowel incontinence, or both, were randomly allocated at baseline to participate in Mind Over Matter', 'for Urinary and Bowel Incontinence', '121 women randomized (62 treatment group; 59 control group), 116 (95%) completed the 4-month assessment', 'older women', 'older women with incontinence', 'Most participants were non-Hispanic white (97%), with a mean age of 75 years (SD 9.2, range 51-98); 66% had attended some college']","['Small-Group, Community-Member Intervention', 'Mind Over Matter']","['symptoms of both urinary and bowel incontinence', 'incontinence severity, quality of life, and self-efficacy', 'bowel incontinence', 'urinary incontinence (UI) improvement on the Patient Global Impression of Improvement', 'Care-seeking rates', 'incontinence, self-efficacy, depression, and barriers to care-seeking', 'Patient Global Impression of Improvement']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0015732', 'cui_str': 'Bowel Incontinence'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517541', 'cui_str': '116 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0021167', 'cui_str': 'Incontinence (finding)'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015732', 'cui_str': 'Bowel Incontinence'}, {'cui': 'C0021167', 'cui_str': 'Incontinence (finding)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0042024', 'cui_str': 'Urinary Incontinence'}, {'cui': 'C4706333', 'cui_str': 'Patient Global Impression of Improvement (assessment scale)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}]",121.0,0.123771,"Treated women improved significantly more than women in the control group on all validated instruments of incontinence severity, quality of life, and self-efficacy.","[{'ForeName': 'Heidi W', 'Initials': 'HW', 'LastName': 'Brown', 'Affiliation': ""Departments of Obstetrics and Gynecology, Urology, Biostatistics, Population Health Sciences, and Medicine, University of Wisconsin-Madison School of Medicine and Public Health, the University of Wisconsin-Madison School of Pharmacy, Sonderegger Research Center, and the Wisconsin Institute for Healthy Aging, Community-Academic Aging Research Network, Madison, and the Medical College of Wisconsin, Milwaukee, Wisconsin; and the Department of Women's Health, Dell Medical School, the University of Texas at Austin, Austin, Texas.""}, {'ForeName': 'Emilie J', 'Initials': 'EJ', 'LastName': 'Braun', 'Affiliation': ''}, {'ForeName': 'Meg E', 'Initials': 'ME', 'LastName': 'Wise', 'Affiliation': ''}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Myers', 'Affiliation': ''}, {'ForeName': 'Zhanhai', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Sampene', 'Affiliation': ''}, {'ForeName': 'Sierra M', 'Initials': 'SM', 'LastName': 'Jansen', 'Affiliation': ''}, {'ForeName': 'D Paul', 'Initials': 'DP', 'LastName': 'Moberg', 'Affiliation': ''}, {'ForeName': 'Jane E', 'Initials': 'JE', 'LastName': 'Mahoney', 'Affiliation': ''}, {'ForeName': 'Rebecca G', 'Initials': 'RG', 'LastName': 'Rogers', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000003422'] 76,31523848,Repeat Annual Colorectal Cancer Screening in Rural Community Clinics: A Randomized Clinical Trial to Evaluate Outreach Strategies to Sustain Screening.,"PURPOSE The majority of colorectal cancer (CRC) research using the fecal immunochemical test (FIT) has studied short-term screening results in predominantly urban areas. The purpose of this study was to evaluate the effectiveness of 2 outreach strategies embedded in a health literacy intervention on repeat CRC screening in rural community clinics. METHODS A 2-arm randomized controlled trial was conducted in 4 rural clinics in Louisiana. During a regularly scheduled clinic visit, participants ages 50-75 received a FIT kit and brief educational intervention. Participants were randomized to receive an automated call or a personal call by a prevention counselor after 4 weeks and 8 weeks if FIT kits were not returned. In year 2, materials were mailed, and follow-up calls were conducted as in year 1. The primary outcome was repeat FIT-the return of the FIT kit in both years. PARTICIPANTS Of 568 eligible participants, 55% were female, 67% were African American, and 39% had low health literacy. FINDINGS Repeat FIT rates were 36.5% for those receiving the automated call and 33.6% for those receiving a personal call (P = .30). No annual FITs were returned in 30% of participants, while only 1 FIT was returned by 35% of participants (31% only year 1 and 4% only year 2). CONCLUSION Sustaining CRC screening with FIT is challenging in rural clinics. A lower cost automated call was just as effective as the personal call in promoting repeat annual screening. However, more intensive strategies are needed to improve long-term FIT screening among rural participants.",2020,Participants were randomized to receive an automated call or a personal call by a prevention counselor after 4 weeks and 8 weeks if FIT kits were not returned.,"['rural community clinics', '4 rural clinics in Louisiana', 'rural participants', 'Of 568 eligible participants, 55% were female, 67% were African American, and 39% had low health literacy', 'Rural Community Clinics']","['automated call or a personal call by a prevention counselor', 'health literacy intervention', 'FIT kit and brief educational intervention']","['annual FITs', 'repeat FIT-the return of the FIT kit in both years']","[{'cui': 'C0086944', 'cui_str': 'Rural Communities'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0024024', 'cui_str': 'Louisiana'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}]","[{'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C1571885', 'cui_str': 'Counselors'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C1690540', 'cui_str': 'Kit'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}]","[{'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C1690540', 'cui_str': 'Kit'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",568.0,0.0671545,Participants were randomized to receive an automated call or a personal call by a prevention counselor after 4 weeks and 8 weeks if FIT kits were not returned.,"[{'ForeName': 'Terry C', 'Initials': 'TC', 'LastName': 'Davis', 'Affiliation': 'Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, Louisiana.'}, {'ForeName': 'Alfred', 'Initials': 'A', 'LastName': 'Rademaker', 'Affiliation': 'Department of Preventive Medicine and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Morris', 'Affiliation': 'Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, Louisiana.'}, {'ForeName': 'Laurie Anne', 'Initials': 'LA', 'LastName': 'Ferguson', 'Affiliation': 'College of Nursing and Health, Loyola University, New Orleans, Louisiana.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Wiltz', 'Affiliation': 'Teche Action Clinic, Franklin, Louisiana.'}, {'ForeName': 'Connie L', 'Initials': 'CL', 'LastName': 'Arnold', 'Affiliation': 'Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, Louisiana.'}]",The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association,['10.1111/jrh.12399'] 77,32048478,Does spatial awareness training affect anatomy learning in medical students?,"Spatial ability (SA) is the cognitive capacity to understand and mentally manipulate concepts of objects, remembering relationships among their parts and those of their surroundings. Spatial ability provides a learning advantage in science and may be useful in anatomy and technical skills in health care. This study aimed to assess the relationship between SA and anatomy scores in first- and second-year medical students. The training sessions focused on the analysis of the spatial component of objects' structure and their interaction as applied to medicine; SA was tested using the Visualization of Rotation (ROT) test. The intervention group (n = 29) received training and their pre- and post-training scores for the SA tests were compared to a control group (n = 75). Both groups improved their mean scores in the follow-up SA test (P < 0.010). There was no significant difference in SA scores between the groups for either SA test (P = 0.31, P = 0.90). The SA scores for female students were significantly lower than for male students, both at baseline and follow-up (P < 0.010). Anatomy training and assessment were administered by the anatomy department of the medical school, and examination scores were not significantly different between the two groups post-intervention (P = 0.33). However, participants with scores in the bottom quartile for SA performed worse in the anatomy questions (P < 0.001). Spatial awareness training did not improve SA or anatomy scores; however, SA may identify students who may benefit from additional academic support.",2020,Both groups improved their mean scores in the follow-up SA test (P < 0.010).,"['first- and second-year medical students', 'medical students']","['Spatial awareness training', 'spatial awareness training', 'Spatial ability (SA', 'training and their pre- and post-training scores for the SA tests']","['mean scores', 'SA scores', 'SA or anatomy scores']","[{'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}]","[{'cui': 'C0584950', 'cui_str': 'Spatial awareness (observable entity)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0679024', 'cui_str': 'Spatial Ability'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}]",75.0,0.0139337,Both groups improved their mean scores in the follow-up SA test (P < 0.010).,"[{'ForeName': 'Rene A', 'Initials': 'RA', 'LastName': 'Gonzales', 'Affiliation': 'Department of Medical Education, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Ferns', 'Affiliation': 'Department of Medical Education, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom.'}, {'ForeName': 'Marc A T M', 'Initials': 'MATM', 'LastName': 'Vorstenbosch', 'Affiliation': 'Department of Anatomy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Claire F', 'Initials': 'CF', 'LastName': 'Smith', 'Affiliation': 'Department of Medical Education, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom.'}]",Anatomical sciences education,['10.1002/ase.1949'] 78,31403587,Gabapentin for Perioperative Pain Management for Uterine Aspiration: A Randomized Controlled Trial.,"OBJECTIVE To evaluate the effect of oral gabapentin in conjunction with usual oral pain management regimens of lorazepam, ibuprofen, oxycodone, and acetaminophen for surgical abortion on pain 5 minutes postprocedure. METHODS This was a randomized, double-blind, placebo-controlled trial of patients from 6 0/7-14 6/7 weeks of gestation scheduled to undergo surgical abortion at the Duke Family Planning Clinic. Participants were administered 600 mg of oral gabapentin compared with placebo with usual oral pain management. Pain score was assessed using a 100-mm visual analog scale, with the primary outcome being pain score 5 minutes after the procedure. The effect of gabapentin was assessed using a linear regression model controlling for baseline pain. We also measured pain perception 24 hours after the procedure. Secondary outcome measures included anxiety, side effects, and usage of opiate pain medication in the 24-hour postoperative period. RESULTS Out of 113 women screened for this study; 96 women were recruited, enrolled, and randomized to study treatment arm from August 2016 to June 2018. Pain at 5 minutes after the procedure was similar between the gabapentin and placebo groups ((Equation is included in full-text article.)=3.40; 95% CI -8.20 to 15.0; P=.56). Gabapentin and placebo were well tolerated, with no statistically significant difference in side effects or anxiety levels. Although prescription of opioids after the procedure was not standardized among patients, 73% of women received a short-term prescription for oxycodone. A lower percentage of women in the gabapentin group self-reported taking opioids in the 24 hours postprocedure (18% vs 47%; odds ratio 0.26; 95% CI 0.09-0.75). CONCLUSION The addition of gabapentin to usual oral pain management regimens with paracervical block did not reduce postoperative pain for patients undergoing outpatient surgical abortion. Although the addition of gabapentin was well tolerated and reduced oral opiate use 24 hours postprocedure, it did not affect the experience of pain during and immediately after the procedure. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02725710.",2019,"A lower percentage of women in the gabapentin group self-reported taking opioids in the 24 hours postprocedure (18% vs 47%; odds ratio 0.26; 95% CI 0.09-0.75). ","['Uterine Aspiration', '113 women screened for this study; 96 women were recruited, enrolled, and randomized to study treatment arm from August 2016 to June 2018', 'patients undergoing outpatient surgical abortion', 'patients from 6 0/7-14 6/7 weeks of gestation scheduled to undergo surgical abortion at the Duke Family Planning Clinic']","['Gabapentin', 'placebo', 'lorazepam, ibuprofen, oxycodone, and acetaminophen', 'oral gabapentin', 'gabapentin', 'oxycodone']","['pain 5 minutes postprocedure', 'postoperative pain', 'side effects or anxiety levels', 'Pain score', 'pain perception', 'tolerated', 'anxiety, side effects, and usage of opiate pain medication in the 24-hour postoperative period', 'Pain', 'experience of pain']","[{'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0392535', 'cui_str': 'Abortion, Induced'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C3840184', 'cui_str': 'Family planning clinic'}]","[{'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0024002', 'cui_str': 'Lorazepam'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety (observable entity)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C3714605', 'cui_str': 'Pain Perception'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0457083', 'cui_str': 'Usage (attribute)'}, {'cui': 'C0242401', 'cui_str': 'Opiates'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]",113.0,0.691935,"A lower percentage of women in the gabapentin group self-reported taking opioids in the 24 hours postprocedure (18% vs 47%; odds ratio 0.26; 95% CI 0.09-0.75). ","[{'ForeName': 'Beverly A', 'Initials': 'BA', 'LastName': 'Gray', 'Affiliation': 'Department of Obstetrics and Gynecology, Duke University Medical Center, and the Duke Office of Clinical Research and the Department of Biostatistics & Bioinformatics, BERD Methods Core, Duke University School of Medicine, Durham, North Carolina; and the Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Hagey', 'Affiliation': ''}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Crabtree', 'Affiliation': ''}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Wynn', 'Affiliation': ''}, {'ForeName': 'Jeremy M', 'Initials': 'JM', 'LastName': 'Weber', 'Affiliation': ''}, {'ForeName': 'Carl F', 'Initials': 'CF', 'LastName': 'Pieper', 'Affiliation': ''}, {'ForeName': 'Lisa B', 'Initials': 'LB', 'LastName': 'Haddad', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000003398'] 79,31977509,A Randomized Controlled Trial of Endovenous Laser Ablation Versus Mechanochemical Ablation With ClariVein in the Management of Superficial Venous Incompetence (LAMA Trial).,"OBJECTIVE This RCT compares the clinical, technical and quality of life outcomes after EVLA and MOCA. SUMMARY OF BACKGROUND DATA Thermal ablation is the current mainstay treatment for SVI. Newer nonthermal methods of treatment have been developed which do not require the use of tumescent anesthesia. The potential advantages of these newer methods should be tested in RCTs to ascertain their role in the future treatments of SVI. METHODS This single-center RCT enrolled patients with symptomatic, unilateral, single-axis SVI. Eligible patients were equally randomized to either EVLA or MOCA, both with concomitant phlebectomy when necessary. The joint primary outcomes were intraprocedural axial ablation pain scores and anatomical occlusion at 1 year. Secondary outcomes included postprocedural pain, venous clinical severity score (VCSS), quality of life (Aberdeen varicose veins questionnaire and EuroQol 5-domain utility index), patient satisfaction and complication rates. RESULTS One hundred fifty patients were randomized equally between the 2 interventions. Both groups reported low intraprocedural pain scores; on a 100 mm visual analog scale, pain during axial EVLA was 22 (9-44) compared to 15 (9-29) during MOCA; P = 0.210. At 1 year, duplex derived anatomical occlusion rates after EVLA were 63/69 (91%) compared to 53/69 (77%) in the MOCA group; P = 0.020. Both groups experienced significant improvement in VCSS and AVVQ after treatment, without a significant difference between groups. Median VCSS improved from 6 (5-8) to 0 (0-1) at one year; P < 0.001. Median AVVQ improved from 13.8 (10.0-17.7) to 2.0 (0.0-4.9); P < 0.001. One patient in the MOCA group experienced DVT. CONCLUSIONS Both EVLA and MOCA were highly efficacious in treating SVI; patients improved significantly in terms of disease severity, symptoms, and QoL. Both resulted in low procedural pain with a short recovery time. Axial occlusion rates were higher after EVLA. Long term follow-up is warranted to assess the effect of recanalization on the rate of clinical recurrence.",2021,"Both EVLA and MOCA were highly efficacious in treating SVI; patients improved significantly in terms of disease severity, symptoms, and QoL.","['One hundred fifty patients', 'This single-center RCT enrolled patients with symptomatic, unilateral, single-axis SVI', 'Eligible patients']","['Endovenous Laser Ablation Versus Mechanochemical Ablation With ClariVein', 'EVLA and MOCA', 'EVLA or MOCA, both with concomitant phlebectomy', 'MOCA']","['low intraprocedural pain scores', 'low procedural pain', 'Median AVVQ', 'intraprocedural axial ablation pain scores and anatomical occlusion at 1 year', 'Axial occlusion rates', 'visual analog scale, pain during axial EVLA', 'disease severity, symptoms, and QoL', 'postprocedural pain, venous clinical severity score (VCSS), quality of life (Aberdeen varicose veins questionnaire and EuroQol 5-domain utility index), patient satisfaction and complication rates', 'VCSS and AVVQ', 'duplex derived anatomical occlusion rates', 'Median VCSS']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0004457', 'cui_str': 'C2 Vertebra'}]","[{'cui': 'C0348007', 'cui_str': 'Pulsed Laser Tissue Ablation'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0191017', 'cui_str': 'Excision of vein (procedure)'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1619712', 'cui_str': 'Pain, Procedural'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0205131', 'cui_str': 'Axial (qualifier value)'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0220784', 'cui_str': 'Anatomic (qualifier value)'}, {'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0042345', 'cui_str': 'Varices'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0444916', 'cui_str': 'Duplex (qualifier value)'}]",150.0,0.215299,"Both EVLA and MOCA were highly efficacious in treating SVI; patients improved significantly in terms of disease severity, symptoms, and QoL.","[{'ForeName': 'Abduraheem Hussein', 'Initials': 'AH', 'LastName': 'Mohamed', 'Affiliation': 'Academic Vascular Surgical Unit, Hull York Medical School, Hull, HU3 2JZ, UK.'}, {'ForeName': 'Clement', 'Initials': 'C', 'LastName': 'Leung', 'Affiliation': ''}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Wallace', 'Affiliation': ''}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Carradice', 'Affiliation': ''}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Chetter', 'Affiliation': ''}]",Annals of surgery,['10.1097/SLA.0000000000003749'] 80,31977290,Effect of different forms of physical activity on balance in older women.,"The aim of this study was to analyze the effect of two types of physical activity, dance, and general exercises, on balance in older women. Study participants comprised two groups of women. The participants attended 45-min DMT ( n = 20) or GRE sessions ( n = 19) three times per week for 12 weeks. Before and after the training, the participants underwent the Postural Stability Test, the Limits of Stability Test, and the Fall Risk Test. Improvement of the balance was confirmed for only one test both for the dance group and the general exercises group.",2021,Improvement of the balance was confirmed for only one test both for the dance group and the general exercises group.,"['Study participants comprised two groups of women', 'older women']","['physical activity, dance, and general exercises', 'GRE sessions', 'physical activity']",[],"[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0010963', 'cui_str': 'Dancing'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}]",[],,0.0252853,Improvement of the balance was confirmed for only one test both for the dance group and the general exercises group.,"[{'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Filar-Mierzwa', 'Affiliation': 'Department of Occupational Therapy, University of Physical Education in Krakow, Krakow, Poland.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Długosz-Boś', 'Affiliation': 'University of Physical Education in Krakow, Krakow, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Marchewka', 'Affiliation': 'Department of Clinical Rehabilitation, University of Physical Education in Krakow, Krakow, Poland.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Aleksander-Szymanowicz', 'Affiliation': 'Department of Occupational Therapy, University of Physical Education in Krakow, Krakow, Poland.'}]",Journal of women & aging,['10.1080/08952841.2020.1718579'] 81,32052503,Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B.,"Hepatitis B virus (HBV) RNA in serum is a novel biomarker that reflects cccDNA activity. We investigated whether HBV RNA can predict serological response to peginterferon (PEG-IFN) treatment. Serum HBV RNA levels were retrospectively measured at weeks 0, 12, 24 and 52 of therapy and after treatment discontinuation (week 78) in 266 HBeAg-positive chronic HBV patients who had participated in a global randomized controlled trial (HBV99-01 study). Patients received 52 weeks PEG-IFN monotherapy (n = 136) or PEG-IFN and lamivudine (n = 130). The primary end point was HBeAg loss 24 weeks after PEG-IFN discontinuation. At baseline, the mean serum level of HBV RNA was 6.8 (SD 1.2) log c/mL. HBV RNA levels declined to 4.7 (1.7) log c/mL after one year of PEG-IFN therapy alone and to 3.3 (1.2)log c/mL after combination therapy. From week 12 onward, HBV RNA level was significantly lower in patients who achieved HBeAg loss at the end of follow-up as compared to those who did not, regardless of treatment allocation (week 12:4.4 vs 5.1 log c/mL, P = .01; week 24:3.7 vs 4.9 log c/mL, P < .001). The performance of a multivariable model based on HBV RNA level was comparable at week 12 (AUC 0.68) and 24 (AUC 0.72) of therapy. HBV RNA level above 5.5 log c/mL at week 12 showed negative predictive values of 93/67/90/64% for HBV genotypes A/B/C/D for the prediction of HBeAg loss. In conclusion, HBV RNA in serum declines profoundly during PEG-IFN treatment. Early on-treatment HBV RNA level may be used to predict nonresponse.",2020,HBV RNA level above 5.5 log c/mL at week 12 showed negative predictive values of 93/67/90/64% for HBV genotypes,"['266 HBeAg-positive chronic HBV patients who had participated', 'HBeAg-positive chronic hepatitis B']","['orPEG-IFN and lamivudine', 'peginterferon', 'Hepatitis B virus (HBV) RNA', 'HBV RNA', 'PEG-IFN monotherapy']","['Serum HBV RNA levels', 'mean serum level of HBV RNA', 'HBV RNA levelwas', 'HBeAg loss 24 weeks after PEG-IFN discontinuation', 'HBV RNA level', 'mL.HBV RNA levels']","[{'cui': 'C0019167', 'cui_str': 'e Antigens'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0524909', 'cui_str': 'Chronic Hepatitis B Virus Infection'}]","[{'cui': 'C0209738', 'cui_str': 'Lamivudine'}, {'cui': 'C0019169', 'cui_str': 'Hepatitis B Virus'}, {'cui': 'C0035668', 'cui_str': 'RNA'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0019167', 'cui_str': 'e Antigens'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]",,0.0431353,HBV RNA level above 5.5 log c/mL at week 12 showed negative predictive values of 93/67/90/64% for HBV genotypes,"[{'ForeName': 'Margo J H', 'Initials': 'MJH', 'LastName': 'van Campenhout', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'van Bömmel', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pfefferkorn', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'Janett', 'Initials': 'J', 'LastName': 'Fischer', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'Deichsel', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Boonstra', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Anneke J', 'Initials': 'AJ', 'LastName': 'van Vuuren', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Berg', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'Bettina E', 'Initials': 'BE', 'LastName': 'Hansen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Harry L A', 'Initials': 'HLA', 'LastName': 'Janssen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}]",Journal of viral hepatitis,['10.1111/jvh.13272'] 82,32172626,Dosage and Efficacy in Behavioral Interventions With Community Dwelling Older Adults: Lifestyle Redesign Revisited.,"Objectives: Behavioral interventions with community dwelling older adults often utilize multiple modes of treatment, which contributes to variation in participation and high rates of nonadherence. The objective of this report was to assess the treatment efficacy of one such study. Methods: We conducted an as-treated analysis of the Well Elderly II trial, where 322 individuals underwent 6 months of individual and group treatment and participated in community outings. We utilized inferential and graphical methods to assess the relationship between treatment received and depression change. Results: Individual treatment and community outings had similar small indirect effects on depressive symptoms, but a selection effect was present for individual treatment, where individuals with high baseline depression scores were the most likely to participate. Discussion: The results provide nuance that is unavailable using intent-to-treat. Future research should expand on our methods for as-treated analyses after intent-to-treat has shown aggregate improvements.",2021,"had similar small indirect effects on depressive symptoms, but a selection effect was present for individual treatment, where individuals with high baseline depression scores were the most likely to participate. ","['322 individuals underwent 6 months of individual and group treatment and participated in community outings', 'community dwelling older adults', 'Community Dwelling Older Adults']",['Behavioral interventions'],['depressive symptoms'],"[{'cui': 'C4517712', 'cui_str': 'Three hundred and twenty-two'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]",322.0,0.0232083,"had similar small indirect effects on depressive symptoms, but a selection effect was present for individual treatment, where individuals with high baseline depression scores were the most likely to participate. ","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Schelly', 'Affiliation': 'Clarkson University, Potsdam, NY, USA.'}, {'ForeName': 'Alisha', 'Initials': 'A', 'LastName': 'Ohl', 'Affiliation': 'Clarkson University, Potsdam, NY, USA.'}, {'ForeName': 'Ramona', 'Initials': 'R', 'LastName': 'Nadres', 'Affiliation': 'Clarkson University, Potsdam, NY, USA.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464820911335'] 83,31422134,Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque.,"OBJECTIVES The goal of this study was to determine whether ticagrelor reduces high-sensitivity troponin I concentrations in patients with established coronary artery disease and high-risk coronary plaque. BACKGROUND High-risk coronary atherosclerotic plaque is associated with higher plasma troponin concentrations suggesting ongoing myocardial injury that may be a target for dual antiplatelet therapy. METHODS In a randomized, double-blind, placebo-controlled trial, patients with multivessel coronary artery disease underwent coronary 18 F-fluoride positron emission tomography/coronary computed tomography scanning and measurement of high-sensitivity cardiac troponin I. Patients were randomized (1:1) to receive ticagrelor 90 mg twice daily or matched placebo. The primary endpoint was troponin I concentration at 30 days in patients with increased coronary 18 F-fluoride uptake. RESULTS In total, 202 patients were randomized to treatment, and 191 met the pre-specified criteria for inclusion in the primary analysis. In patients with increased coronary 18 F-fluoride uptake (120 of 191), there was no evidence that ticagrelor had an effect on plasma troponin concentrations at 30 days (ratio of geometric means for ticagrelor vs. placebo: 1.11; 95% confidence interval: 0.90 to 1.36; p = 0.32). Over 1 year, ticagrelor had no effect on troponin concentrations in patients with increased coronary 18 F-fluoride uptake (ratio of geometric means: 0.86; 95% confidence interval: 0.63 to 1.17; p = 0.33). CONCLUSIONS Dual antiplatelet therapy with ticagrelor did not reduce plasma troponin concentrations in patients with high-risk coronary plaque, suggesting that subclinical plaque thrombosis does not contribute to ongoing myocardial injury in this setting. (Dual Antiplatelet Therapy to Reduce Myocardial Injury [DIAMOND]; NCT02110303).",2020,"Over 1 year, ticagrelor had no effect on troponin concentrations in patients with increased coronary 18 F-fluoride uptake (ratio of geometric means: 0.86; 95% confidence interval: 0.63 to 1.17; p = 0.33). ","['Patients', 'patients with high-risk coronary plaque', '202 patients were randomized to treatment, and 191 met the pre-specified criteria for inclusion in the primary analysis', 'patients with established coronary artery disease and high-risk coronary plaque', 'patients with multivessel coronary artery disease underwent coronary 18 F-fluoride positron emission tomography/coronary computed tomography scanning and measurement of high-sensitivity cardiac troponin I. Patients']","['ticagrelor', 'placebo', 'Ticagrelor', 'ticagrelor 90\xa0mg twice daily or matched placebo']","['troponin concentrations', 'Myocardial Injury', 'plasma troponin concentrations', 'troponin I concentration', 'sensitivity troponin']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C0302995', 'cui_str': '18F radioisotope'}, {'cui': 'C0016327', 'cui_str': 'Fluorides'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C1096316', 'cui_str': 'Cardiac troponin'}]","[{'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3163568', 'cui_str': 'Ticagrelor 90 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0523952', 'cui_str': 'Troponin measurement'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0920210', 'cui_str': 'Troponin I measurement (procedure)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]",202.0,0.613089,"Over 1 year, ticagrelor had no effect on troponin concentrations in patients with increased coronary 18 F-fluoride uptake (ratio of geometric means: 0.86; 95% confidence interval: 0.63 to 1.17; p = 0.33). ","[{'ForeName': 'Alastair J', 'Initials': 'AJ', 'LastName': 'Moss', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: alastairmoss@gmail.com.'}, {'ForeName': 'Marc R', 'Initials': 'MR', 'LastName': 'Dweck', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Mhairi K', 'Initials': 'MK', 'LastName': 'Doris', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Jack P M', 'Initials': 'JPM', 'LastName': 'Andrews', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Bing', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Rachael O', 'Initials': 'RO', 'LastName': 'Forsythe', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Timothy R', 'Initials': 'TR', 'LastName': 'Cartlidge', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Tania A', 'Initials': 'TA', 'LastName': 'Pawade', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Marwa', 'Initials': 'M', 'LastName': 'Daghem', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Jennifer B', 'Initials': 'JB', 'LastName': 'Raftis', 'Affiliation': 'Medical Research Council Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Michelle C', 'Initials': 'MC', 'LastName': 'Williams', 'Affiliation': ""British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Imaging, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.""}, {'ForeName': 'Edwin J R', 'Initials': 'EJR', 'LastName': 'van Beek', 'Affiliation': ""British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Imaging, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Forsyth', 'Affiliation': 'Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Steff C', 'Initials': 'SC', 'LastName': 'Lewis', 'Affiliation': 'Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Lee', 'Affiliation': 'Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Anoop S V', 'Initials': 'ASV', 'LastName': 'Shah', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Nicholas L', 'Initials': 'NL', 'LastName': 'Mills', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Newby', 'Affiliation': ""British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Imaging, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.""}, {'ForeName': 'Philip D', 'Initials': 'PD', 'LastName': 'Adamson', 'Affiliation': 'British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.'}]",JACC. Cardiovascular imaging,['10.1016/j.jcmg.2019.05.023'] 84,31848678,"Comparison of Common Surgical Procedures in Non-complicated Pilonidal Sinus Disease, a 7-Year Follow-Up Trial.","BACKGROUND Pilonidal disease is a common problem in primary health care which may require immediate surgical referral. Although various management options have been proposed, so far there is no gold standard treatment. The aim of the present study was to determine which of the following techniques was superior as regards postoperative complications and recurrence, midline unshifted adipofascial turn-over flap, midline shifted adipofascial turn-over flap or Karydakis flap. METHODS A randomized clinical trial was conducted in the Department of General Surgery. Patients with non-complicated pilonidal sinus were enrolled in the study from April 2009 to January 2012. All patients were randomized the day of surgery at the coordinating center by means of a computer program. Patients were randomized to receive midline unshifted adipofascial turn-over flap, midline shifted adipofascial turn-over flap or Karydakis flap. All procedures were performed under local anesthesia and patients were discharged 6 h after surgery. Demographic characteristics, skin color, body hair type, family history, preoperative complaints and duration of symptoms, cyst size, intraoperative iatrogenic cyst rupture, the presence of a tuft of hairs in the cyst, surgical techniques, duration of drainage, length of hospital stay, postoperative complications and recurrence were evaluated. RESULTS One hundred and ninety-two patients with non-complicated pilonidal sinus were enrolled. Seventy-two patients were randomized to midline unshifted adipofascial turn-over flap, 67 patients to midline shifted adipofascial turn-over flap and 53 patients to Karydakis flap. The mean age was 25.66 ± 7.67 years. At 76-month follow-up, the overall complications and recurrence rates were not significantly different between groups (p > 0.05). CONCLUSION In cases of non-complicated pilonidal sinus, we recommend surgical management using local anesthesia, outpatient surgery and the surgical approach with which the surgeon is most familiar.",2020,"At 76-month follow-up, the overall complications and recurrence rates were not significantly different between groups (p > 0.05). ","['One hundred and ninety-two patients with non-complicated pilonidal sinus were enrolled', 'The mean age was 25.66\u2009±\u20097.67\xa0years', 'Patients with non-complicated pilonidal sinus were enrolled in the study from April 2009 to January 2012', 'Department of General Surgery']","['midline unshifted adipofascial turn-over flap, midline shifted adipofascial turn-over flap or Karydakis flap', 'midline unshifted adipofascial turn-over flap, 67 patients to midline shifted adipofascial turn-over flap and 53 patients to Karydakis flap']","['overall complications and recurrence rates', 'Demographic characteristics, skin color, body hair type, family history, preoperative complaints and duration of symptoms, cyst size, intraoperative iatrogenic cyst rupture, the presence of a tuft of hairs in the cyst, surgical techniques, duration of drainage, length of hospital stay, postoperative complications and recurrence']","[{'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0541749', 'cui_str': 'Does turn (finding)'}, {'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0037290', 'cui_str': 'Skin Tone'}, {'cui': 'C0018494', 'cui_str': 'Hair'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts (observable entity)'}, {'cui': 'C0010709', 'cui_str': 'Cyst'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0439669', 'cui_str': 'Iatrogenic (qualifier value)'}, {'cui': 'C0333140', 'cui_str': 'Ruptured cyst (morphologic abnormality)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}]",192.0,0.0452193,"At 76-month follow-up, the overall complications and recurrence rates were not significantly different between groups (p > 0.05). ","[{'ForeName': 'Mujgan', 'Initials': 'M', 'LastName': 'Caliskan', 'Affiliation': 'Department of General Surgery, Istanbul Medipol University, Istanbul, Turkey.'}, {'ForeName': 'Koray', 'Initials': 'K', 'LastName': 'Kosmaz', 'Affiliation': 'Department of General Surgery, Umraniye Education and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ismail Ege', 'Initials': 'IE', 'LastName': 'Subasi', 'Affiliation': 'Department of General Surgery, Umraniye Education and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Aylin', 'Initials': 'A', 'LastName': 'Acar', 'Affiliation': 'Department of General Surgery, Umraniye Education and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Evren', 'Affiliation': 'Department of Urology, Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Gurhan', 'Initials': 'G', 'LastName': 'Bas', 'Affiliation': 'Department of General Surgery, Medeniyet University, Istanbul, Turkey.'}, {'ForeName': 'Ali Timucin', 'Initials': 'AT', 'LastName': 'Atayoglu', 'Affiliation': 'Department of Family Medicine, Istanbul Medipol University, Istanbul, Turkey. atatayoglu@medipol.edu.tr.'}]",World journal of surgery,['10.1007/s00268-019-05331-1'] 85,31942918,Efficacy of an m-Health Physical Activity and Sleep Intervention to Improve Sleep Quality in Middle-Aged Adults: The Refresh Study Randomized Controlled Trial.,"BACKGROUND Poor sleep health is highly prevalent. Physical activity is known to improve sleep quality but not specifically targeted in sleep interventions. PURPOSE To compare the efficacy of a combined physical activity and sleep intervention with a sleep-only intervention and a wait-list control, for improving sleep quality in middle-aged adults without a diagnosed sleep disorder. METHODS Three-arm randomized controlled trial (Physical Activity and Sleep Health (PAS), Sleep Health Only (SO), Wait-list Control (CON) groups; 3-month primary time-point, 6-month follow-up) of 275 (PAS = 110, SO = 110, CON = 55) inactive adults (40-65 years) reporting poor sleep quality. The main intervention component was a smartphone/tablet ""app"" to aid goal setting and self-monitoring physical activity and/or sleep hygiene behaviors (including stress management), and a pedometer for PAS group. Primary outcome was Pittsburgh Sleep Quality Index (PSQI) global score. Secondary outcomes included several self-reported physical activity measures and PSQI subcomponents. Group differences were examined stepwise, first between pooled intervention (PI = PAS + SO) and CON groups, then between PAS and SO groups. RESULTS Compared with CON, PI groups significantly improved PSQI global and subcomponents scores at 3 and 6 months. There were no differences in sleep quality between PAS and SO groups. The PAS group reported significantly less daily sitting time at 3 months and was significantly more likely to report ≥2 days/week resistance training and meeting physical activity guidelines at 6 months than the SO group. CONCLUSIONS PIs had statistically significantly improved sleep quality among middle-aged adults with poor sleep quality without a diagnosed sleep disorder. The adjunctive physical activity intervention did not additionally improve sleep quality. CLINICAL TRIAL INFORMATION Australian New Zealand Clinical Trial Registry: ACTRN12617000680369; Universal Trial number: U1111-1194-2680; Human Research Ethics Committee, Blinded by request of journal: H-2016-0267.",2020,"The PAS group reported significantly less daily sitting time at 3 months and was significantly more likely to report ≥2 days/week resistance training and meeting physical activity guidelines at 6 months than the SO group. ","['Australian New Zealand Clinical Trial Registry', 'middle-aged adults with poor sleep quality without a diagnosed sleep disorder', 'middle-aged adults without a diagnosed sleep disorder', 'Middle-Aged Adults']","['combined physical activity and sleep intervention with a sleep-only intervention and a wait-list control', 'm-Health Physical Activity and Sleep Intervention', 'Physical Activity and Sleep Health (PAS), Sleep Health Only (SO', 'adjunctive physical activity intervention', 'Wait-list Control (CON', 'smartphone/tablet ""app"" to aid goal setting and self-monitoring physical activity and/or sleep hygiene behaviors (including stress management), and a pedometer for PAS group', 'CON']","['Pittsburgh Sleep Quality Index (PSQI) global score', 'poor sleep quality', 'Sleep Quality', 'several self-reported physical activity measures and PSQI subcomponents', 'sleep quality', 'PSQI global and subcomponents scores', 'daily sitting time']","[{'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0205847', 'cui_str': 'Middle Aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0235162', 'cui_str': 'Difficulty sleeping (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0851578', 'cui_str': 'Sleep Disorders'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0449435', 'cui_str': 'Aid (attribute)'}, {'cui': 'C0150598', 'cui_str': 'Goal setting (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C4277672', 'cui_str': 'Sleep Hygiene'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C3697468', 'cui_str': 'PSQI - Pittsburgh sleep quality index'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0235162', 'cui_str': 'Difficulty sleeping (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",,0.106602,"The PAS group reported significantly less daily sitting time at 3 months and was significantly more likely to report ≥2 days/week resistance training and meeting physical activity guidelines at 6 months than the SO group. ","[{'ForeName': 'Anna T', 'Initials': 'AT', 'LastName': 'Rayward', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, School of Medicine & Public Health, University of Newcastle, Callaghan, New South Wales, Australia.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Murawski', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, School of Medicine & Public Health, University of Newcastle, Callaghan, New South Wales, Australia.'}, {'ForeName': 'Mitch J', 'Initials': 'MJ', 'LastName': 'Duncan', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, School of Medicine & Public Health, University of Newcastle, Callaghan, New South Wales, Australia.'}, {'ForeName': 'Elizabeth G', 'Initials': 'EG', 'LastName': 'Holliday', 'Affiliation': 'School of Medicine & Public Health, University of Newcastle, Callaghan, New South Wales, Australia.'}, {'ForeName': 'Corneel', 'Initials': 'C', 'LastName': 'Vandelanotte', 'Affiliation': 'Physical Activity Research Group, School for Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, Queensland, Australia.'}, {'ForeName': 'Wendy J', 'Initials': 'WJ', 'LastName': 'Brown', 'Affiliation': 'School of Human Movement and Nutrition Sciences, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Ronald C', 'Initials': 'RC', 'LastName': 'Plotnikoff', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, School of Education, University of Newcastle, Callaghan, New South Wales, Australia.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaz064'] 86,32161949,Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme.,"BACKGROUND AND AIMS Oral systemic pan-Janus kinase [JAK] inhibition is effective for ulcerative colitis [UC] but is limited by toxicities. We describe preclinical to clinical translation of TD-1473-an oral gut-selective pan-JAK inhibitor-from in vitro characterization through a Phase 1b study in patients with UC. METHODS TD-1473 JAK inhibition potency was evaluated in vitro; plasma pharmacokinetics, safety and efficacy were assessed in mice. In a first-time-in-human study, plasma pharmacokinetics and safety were assessed after single and multiple [14 days] ascending doses administered orally to healthy subjects. The Phase 1b study randomized patients with moderately to severely active UC to receive once-daily oral TD-1473 20, 80 or 270 mg, or placebo for 28 days. Plasma and colonic tissue concentrations were measured; safety was assessed; and efficacy was evaluated by UC clinical parameters, disease-surrogate biomarkers, endoscopy, histology and colonic tissue JAK signalling. RESULTS TD-1473 exhibited potent pan-JAK inhibitory activity in vitro. Oral TD-1473 administration to mice achieved high, biologically active colonic tissue concentrations with low plasma exposure and decreased oxazolone-induced colitis activity without reducing blood cell counts vs placebo. TD-1473 administration in healthy human subjects and patients with UC yielded low plasma exposure and was generally well tolerated; treatment in patients with UC resulted in biologically active colonic tissue concentrations and descriptive trends toward reduced clinical, endoscopic and histological disease activity vs placebo. CONCLUSION Gut-selective pan-JAK inhibition with TD-1473 administration resulted in high intestinal vs plasma drug exposure, local target engagement, and trends toward reduced UC disease activity. [Clinicaltrials.gov NCT02657122, NCT02818686].",2020,"TD-1473 administration in healthy human subjects and patients with UC yielded low plasma exposure and was generally well tolerated; treatment in patients with UC resulted in biologically active colonic tissue concentrations and descriptive trends toward reduced clinical, endoscopic and histologic disease activity vs placebo. ","['healthy human subjects and patients with UC', 'patients with UC', 'ulcerative colitis']","['TD-1473', 'gut-selective pan-Janus kinase inhibitor', 'placebo', 'TD-1473-an oral gut-selective pan-JAK inhibitor']","['plasma pharmacokinetics and safety', 'biologically active colonic tissue concentrations', 'UC clinical parameters, disease-surrogate biomarkers, endoscopy, histology, and colonic tissue JAK signaling', 'vitro; plasma pharmacokinetics, safety, and efficacy', 'Plasma and colonic tissue concentrations']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009324', 'cui_str': 'Inflammatory Bowel Disease, Ulcerative Colitis Type'}]","[{'cui': 'C0085999', 'cui_str': 'Genus Pan (organism)'}, {'cui': 'C4521962', 'cui_str': 'Janus kinase inhibitor'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3854325', 'cui_str': 'JAK Inhibitors'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009368', 'cui_str': 'Colon'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0344441', 'cui_str': 'Histologic test (procedure)'}]",,0.069533,"TD-1473 administration in healthy human subjects and patients with UC yielded low plasma exposure and was generally well tolerated; treatment in patients with UC resulted in biologically active colonic tissue concentrations and descriptive trends toward reduced clinical, endoscopic and histologic disease activity vs placebo. ","[{'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Sandborn', 'Affiliation': 'Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Deanna D', 'Initials': 'DD', 'LastName': 'Nguyen', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Beattie', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Brassil', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Whitney', 'Initials': 'W', 'LastName': 'Krey', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Jacky', 'Initials': 'J', 'LastName': 'Woo', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Situ', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Reuben', 'Initials': 'R', 'LastName': 'Sana', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Sandvik', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'M Teresa', 'Initials': 'MT', 'LastName': 'Pulido-Rios', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Raj', 'Initials': 'R', 'LastName': 'Bhandari', 'Affiliation': 'Delta Research Partners, Monroe, LA, USA.'}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Leighton', 'Affiliation': 'Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Ganeshappa', 'Affiliation': 'Pinnacle Clinical Research, San Antonio, TX, USA.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Boyle', 'Affiliation': 'Biomarker Laboratory, University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Brihad', 'Initials': 'B', 'LastName': 'Abhyankar', 'Affiliation': 'Theravance Biopharma Ireland Limited, Dublin, Ireland.'}, {'ForeName': 'Melanie A', 'Initials': 'MA', 'LastName': 'Kleinschek', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Graham', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Panes', 'Affiliation': 'Department of Gastroenterology, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.'}]",Journal of Crohn's & colitis,['10.1093/ecco-jcc/jjaa049'] 87,32115967,Impedance therapy in rehabilitation of degenerative disc disease.,"AIM: The aim of this work was to investigate the effects of Impedance Therapy (IT) in the treatment of degenerative disc disease (DDD) by confirming the presence of the “disc grow-up” (DGU) phenomenon. METHOD: The set consisted of 55 patients with DDD with the average age of 51.3 years divided into two groups – the experimental group and the control group. The experimental group consisted of 29 patients with the average age of 56.7 years. The control group consisted of 26 patients with the average age of 45.8 years. RESULTS: In the experimental group of patients with DDD, who received IT, the DGU phenomenon with a success rate of 76 % was observed, with the average increase in the volume of the intervertebral disc of 31 % (p < 0.000). In the control group of patients receiving the standard electrotherapy, the DGU phenomenon was not proven – the DDD progressed normally with the mean volume reduction of 15 % (p < 0.000). CONCLUSIONS: Degenerative disc disease, as a disease of modern civilization, is treatable. It can be concluded that the theory that degenerative disc changes are irreversible was disproven by the impact of impedance therapy (Tab. 5, Ref. 14)",2020,"In the control group of patients receiving the standard electrotherapy, the DGU phenomenon was not proven - the DDD progressed normally with the mean volume reduction of 15 %       (p < 0.000). ","['29 patients with the average age of 56.7 years', '55 patients with DDD with the average age of 51.3 years', 'degenerative disc disease (DDD', '26 patients with the average age of 45.8\u2005years']","['Impedance therapy', 'Impedance Therapy (IT']","['success rate', 'volume of the intervertebral disc']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0011037', 'cui_str': 'Dichlorodiphenyldichloroethane'}, {'cui': 'C0158266', 'cui_str': 'Disc Degradation'}]","[{'cui': 'C0162537', 'cui_str': 'Electrical Impedance'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0021815', 'cui_str': 'Intervertebral Disc'}]",55.0,0.0127534,"In the control group of patients receiving the standard electrotherapy, the DGU phenomenon was not proven - the DDD progressed normally with the mean volume reduction of 15 %       (p < 0.000). ","[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Kostka', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Ziakova', 'Affiliation': ''}]",Bratislavske lekarske listy,['10.4149/BLL_2020_019'] 88,31982288,Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.,"INTRODUCTION Zonisamide is approved in Japan for treating motor dysfunction in Parkinson's disease, and might also be effective for parkinsonism in patients with dementia with Lewy bodies (DLB). Our study evaluated the safety and efficacy of zonisamide for treating parkinsonism in patients with DLB. METHODS This multicenter, randomized, double-blind, phase 3 trial was conducted in Japan between April 2015 and November 2017. Following a 4-week run-in period, outpatients diagnosed with probable DLB who had developed parkinsonism were randomized to receive oral zonisamide (25 or 50 mg/day) or placebo for 12 weeks, followed by a 40-week open-label extension. The primary endpoint was the change in Unified Parkinson's Disease Rating Scale (UPDRS) part III total score at Week 12. RESULTS Of 351 patients randomized, 346 (mean age, 77.2 years; 188 males) were included in the modified intention-to-treat population. At Week 12, the group difference (least squares mean ± SEM) for changes from baseline (vs placebo) in UPDRS part III total score was -2.7 ± 0.9 (95% confidence interval [CI]: -4.4, -0.9, P = 0.005) in the zonisamide 25-mg group and -2.6 ± 0.9 (95% CI: -4.4, -0.8, P = 0.005) in the zonisamide 50-mg group. Adverse events were reported in 47.1%, 48.7%, and 54.5% of patients in the placebo and zonisamide 25- and 50-mg groups, and led to treatment discontinuation in 5.0%, 4.3%, and 9.8% of patients, respectively. CONCLUSION Daily administration of 25- or 50-mg zonisamide significantly improved motor function compared with placebo; both doses were safe and well tolerated in patients with DLB.",2020,"CONCLUSION Daily administration of 25- or 50-mg zonisamide significantly improved motor function compared with placebo; both doses were safe and well tolerated in patients with DLB.","['patients with dementia with Lewy bodies (DLB', 'outpatients diagnosed with probable DLB who had developed parkinsonism', '351 patients randomized, 346', 'Japan between April 2015 and November 2017', 'patients with DLB', 'mean age, 77.2 years; 188 males) were included in the modified intention-to-treat population', 'patients with dementia with Lewy bodies']","['zonisamide', 'placebo', 'Zonisamide', 'oral zonisamide']","['safety and efficacy', 'Adverse events', 'motor function', 'safe and well tolerated', 'UPDRS part III total score', ""change in Unified Parkinson's Disease Rating Scale (UPDRS) part III total score""]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0752347', 'cui_str': 'Dementia, Lewy Body'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0242422', 'cui_str': 'Parkinsonism'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0078844', 'cui_str': 'zonisamide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0222045'}]",351.0,0.378219,"CONCLUSION Daily administration of 25- or 50-mg zonisamide significantly improved motor function compared with placebo; both doses were safe and well tolerated in patients with DLB.","[{'ForeName': 'Miho', 'Initials': 'M', 'LastName': 'Murata', 'Affiliation': 'Neurology, National Center Hospital, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8551, Japan.'}, {'ForeName': 'Toshinari', 'Initials': 'T', 'LastName': 'Odawara', 'Affiliation': 'Health Management Center, Yokohama City University, 22-2 Seto, Kanazawa-ku, Yokohama, Kanagawa, 236-0027, Japan.'}, {'ForeName': 'Kazuko', 'Initials': 'K', 'LastName': 'Hasegawa', 'Affiliation': 'Neurology, Sagamihara National Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara, Kanagawa, 252-0392, Japan.'}, {'ForeName': 'Ritsuko', 'Initials': 'R', 'LastName': 'Kajiwara', 'Affiliation': 'Sumitomo Dainippon Pharma Co., Ltd., 1-13-1 Kyobashi, Chuo-ku, Tokyo, 104-8356, Japan.'}, {'ForeName': 'Hisao', 'Initials': 'H', 'LastName': 'Takeuchi', 'Affiliation': 'Sumitomo Dainippon Pharma Co., Ltd., 1-13-1 Kyobashi, Chuo-ku, Tokyo, 104-8356, Japan.'}, {'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Tagawa', 'Affiliation': 'Sumitomo Dainippon Pharma Co., Ltd., 1-13-1 Kyobashi, Chuo-ku, Tokyo, 104-8356, Japan. Electronic address: masaaki-tagawa@ds-pharma.co.jp.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Kosaka', 'Affiliation': 'Shonan Inaho Clinic, 1-3-57 Shinomiya, Hiratsuka, Kanagawa, 254-0014, Japan.'}]",Parkinsonism & related disorders,['10.1016/j.parkreldis.2019.12.005'] 89,31968059,Effectiveness of Task-Shifted Trauma-Focused Cognitive Behavioral Therapy for Children Who Experienced Parental Death and Posttraumatic Stress in Kenya and Tanzania: A Randomized Clinical Trial.,"Importance Approximately 140 million children worldwide have experienced the death of one or both parents. These children, mostly in low- and middle-income countries, have higher rates of mental health problems than those who have not experienced parental death. Cognitive behavioral therapy (CBT) may improve the well-being of these children, but to our knowledge there have been no randomized clinical trials specifically focused on this population. Objectives To test the effectiveness of trauma-focused CBT (TF-CBT) for improving posttraumatic stress (PTS) in children in Kenya and Tanzania who have experienced parental death, to test the effects of TF-CBT on other mental health symptoms, and to examine the feasibility of task-shifting with greater reliance on experienced, local lay counselors as trainers and supervisors. Design, Setting, and Participants A randomized clinical trial conducted in urban and rural areas of Tanzania and Kenya compared TF-CBT and usual care (UC) for 640 children aged 7 to 13 years who were recruited from February 13, 2013, to July 24, 2015. All children had experienced the death of one or both parents and had elevated PTS and/or prolonged grief. Interviewers were masked to study condition. Participants were followed up for 12 months after the randomized clinical trial. Statistical analysis was performed from February 3, 2017, to August 26, 2019. All analyses were on an intent-to-treat basis. Interventions In the intervention condition, 320 children received 12 weeks of group TF-CBT delivered by lay counselors who were supervised weekly. In the UC condition, 320 children received community services typically offered to this population. Main Outcomes and Measures The primary outcome was PTS, evaluated using a continuous, standardized measure. Other mental health symptoms and child-guardian relationship were also measured. Results A total of 640 children (320 girls and 320 boys; mean [SD] age, 10.6 [1.6] years) were included in the study. Trauma-focused CBT was more effective than UC for PTS in 3 of 4 sites after treatment (end of 3-month randomized clinical trial): rural Kenya (Cohen d = 1.04 [95% CI, 0.72-1.36]), urban Kenya (Cohen d = 0.56 [95% CI, 0.29-0.83]), and urban Tanzania (Cohen d = 0.45 [95% CI, 0.10-0.80]). At 12-month follow-up, TF-CBT remained more effective than UC in both rural (Cohen d = 0.86 [95% CI, 0.64-1.07]) and urban (Cohen d = 0.99 [95% CI, 0.75-1.23]) Kenya. At 12-month follow-up in Tanzania, children who received TF-CBT and UC had comparable rates of improvement (rural Tanzania, Cohen d = 0.09 [95% CI, -0.08 to 0.26]; urban Tanzania, Cohen d = 0.11 [95% CI, -0.09 to 0.31]). A similar pattern was seen for secondary outcomes, with stronger effects observed in Kenya, where children experienced greater stress and adversity (eg, more food scarcity, poorer guardian health, and greater exposure to traumatic events). Conclusions and Relevance This study found that TF-CBT was more effective than UC in reducing PTS among children who experienced parental death in 3 of 4 sites in Kenya and Tanzania. At 12-month follow-up, TF-CBT was more effective in reducing PTS only among children in rural and urban Kenya. Trial Registration ClinicalTrials.gov identifier: NCT01822366.",2020,"At 12-month follow-up in Tanzania, children who received TF-CBT and UC had comparable rates of improvement (rural Tanzania, Cohen d = 0.09","['320 children', 'urban and rural areas of Tanzania and Kenya compared', '640 children aged 7 to 13 years who were recruited from February 13, 2013, to July 24, 2015', 'children in Kenya and Tanzania who have experienced parental death', 'children who experienced parental death in 3 of 4 sites in Kenya and Tanzania', '640 children (320 girls and 320 boys; mean [SD] age, 10.6 [1.6] years) were included in the study', 'Children Who Experienced Parental Death and Posttraumatic Stress in Kenya and Tanzania', '320 children received community services typically offered to this population']","['TF-CBT and usual care (UC', 'UC', 'trauma-focused CBT (TF-CBT', 'Cognitive behavioral therapy (CBT', 'Task-Shifted Trauma-Focused Cognitive Behavioral Therapy', 'TF-CBT']","['stress and adversity (eg, more food scarcity, poorer guardian health, and greater exposure to traumatic events', 'death of one or both parents and had elevated PTS and/or prolonged grief']","[{'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0039298', 'cui_str': 'United Republic of Tanzania'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C4708790', 'cui_str': '640'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0524342', 'cui_str': 'Parental Death'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517508', 'cui_str': '1.6 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0009482', 'cui_str': 'Services, Community'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C1274041', 'cui_str': 'Guardian'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0332663', 'cui_str': 'Traumatic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0018235', 'cui_str': 'Grief'}]",640.0,0.216778,"At 12-month follow-up in Tanzania, children who received TF-CBT and UC had comparable rates of improvement (rural Tanzania, Cohen d = 0.09","[{'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Dorsey', 'Affiliation': 'Department of Psychology, University of Washington, Seattle.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Lucid', 'Affiliation': 'Department of Psychology, University of Washington, Seattle.'}, {'ForeName': 'Prerna', 'Initials': 'P', 'LastName': 'Martin', 'Affiliation': 'Department of Psychology, University of Washington, Seattle.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'King', 'Affiliation': 'Department of Psychology, University of Washington, Seattle.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': ""O'Donnell"", 'Affiliation': 'Center for Child and Family Health, Duke University, Durham, North Carolina.'}, {'ForeName': 'Laura K', 'Initials': 'LK', 'LastName': 'Murray', 'Affiliation': 'Department of Mental Health and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Augustine I', 'Initials': 'AI', 'LastName': 'Wasonga', 'Affiliation': 'Ace Africa, Bungoma, Kenya.'}, {'ForeName': 'Dafrosa K', 'Initials': 'DK', 'LastName': 'Itemba', 'Affiliation': 'Tanzania Women Research Foundation, Moshi, Tanzania.'}, {'ForeName': 'Judith A', 'Initials': 'JA', 'LastName': 'Cohen', 'Affiliation': 'Department of Psychiatry, Allegheny Health Network, Drexel University College of Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Manongi', 'Affiliation': 'Institute of Public Health, Kilimanjaro Christian Medical University College, Moshi, Tanzania.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Whetten', 'Affiliation': 'Center for Health Policy and Inequalities Research, Sanford School of Public Policy and Duke Global Health Institute, Duke University, Durham, North Carolina.'}]",JAMA psychiatry,['10.1001/jamapsychiatry.2019.4475'] 90,32171028,Intervention fidelity and process outcomes of medication reviews including post-discharge follow-up in older hospitalized patients: Process evaluation of the MedBridge trial.,"WHAT IS KNOWN AND OBJECTIVE Drug-related problems (DRPs) are a growing healthcare burden worldwide. In an ongoing cluster-randomized controlled trial in Sweden (MedBridge), comprehensive medication reviews (CMRs) including post-discharge follow-up have been conducted in older hospitalized patients to prevent and solve DRPs. As part of a process evaluation of the MedBridge trial, this study aimed to assess the intervention fidelity and process outcomes of the trial's interventions. METHODS For intervention delivery, the percentage of patients that received intervention components was calculated per study group. Process outcomes, measured in about one-third of all intervention patients, included the following: the number of identified medication discrepancies, DRPs and recommendations to solve DRPs, correction rate of discrepancies, and implementation rate of recommendations. RESULTS AND DISCUSSION The MedBridge trial included 2637 patients (mean age: 81 years). The percentage of intervention patients (n = 1745) that received the intended intervention components was 94%-98% during admission, and 40%-81% upon and after discharge. The percentage of control patients (n = 892) that received at least one unintended intervention component was 15%. On average, 1.1 discrepancies and 2.0 DRPs were identified in 652 intervention patients. The correction and implementation rates were 79% and 73%, respectively. Stop medication was the most frequently implemented recommendation (n = 293) and 77% of the patients had at least one corrected discrepancy or implemented recommendation. WHAT IS NEW AND CONCLUSION The intervention fidelity within the MedBridge trial was high for CMRs during hospital stay and lower for intervention components upon and after discharge. The high prevalence of corrected discrepancies and implemented recommendations may explain potential effects of CMRs in the MedBridge trial.",2020,The intervention fidelity within the MedBridge trial was high for CMRs during hospital stay and lower for intervention components upon and after discharge.,"['652 intervention patients', 'older hospitalized patients', '2637 patients (mean age: 81\xa0years']",[],"['number of identified medication discrepancies, DRPs and recommendations to solve DRPs, correction rate of discrepancies, and implementation rate of recommendations', 'correction and implementation rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C1290905', 'cui_str': 'Discrepancy'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to (procedure)'}]",2637.0,0.0919464,The intervention fidelity within the MedBridge trial was high for CMRs during hospital stay and lower for intervention components upon and after discharge.,"[{'ForeName': 'Thomas G H', 'Initials': 'TGH', 'LastName': 'Kempen', 'Affiliation': 'Hospital Pharmacy Department, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Cam', 'Affiliation': 'Hospital Pharmacy Department, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Kälvemark', 'Affiliation': 'Hospital Pharmacy Department, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Karl-Johan', 'Initials': 'KJ', 'LastName': 'Lindner', 'Affiliation': 'Pharmacy Department, Region Västmanland, Västerås, Sweden.'}, {'ForeName': 'Håkan', 'Initials': 'H', 'LastName': 'Melhus', 'Affiliation': 'Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Elisabet I', 'Initials': 'EI', 'LastName': 'Nielsen', 'Affiliation': 'Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Sulku', 'Affiliation': 'Centre for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden.'}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Gillespie', 'Affiliation': 'Hospital Pharmacy Department, Uppsala University Hospital, Uppsala, Sweden.'}]",Journal of clinical pharmacy and therapeutics,['10.1111/jcpt.13128'] 91,32102725,Cognitive function after electroconvulsive therapy for depression: relationship to clinical response.,"BACKGROUND As uncertainty remains about whether clinical response influences cognitive function after electroconvulsive therapy (ECT) for depression, we examined the effect of remission status on cognitive function in depressed patients 4 months after a course of ECT. METHOD A secondary analysis was undertaken on participants completing a randomised controlled trial of ketamine augmentation of ECT for depression who were categorised by remission status (MADRS ⩽10 v. >10) 4 months after ECT. Cognition was assessed with self-rated memory and neuropsychological tests of anterograde verbal and visual memory, autobiographical memory, verbal fluency and working memory. Patients were assessed through the study, healthy controls on a single occasion, and compared using analysis of variance. RESULTS At 4-month follow-up, remitted patients (N = 18) had a mean MADRS depression score of 3.8 (95% CI 2.2-5.4) compared with 27.2 (23.0-31.5) in non-remitted patients (N = 19), with no significant baseline differences between the two groups. Patients were impaired on all cognitive measures at baseline. There was no deterioration, with some measures improving, 4-months after ECT, at which time remitted patients had significantly improved self-rated memory, anterograde verbal memory and category verbal fluency compared with those remaining depressed. Self-rated memory correlated with category fluency and autobiographical memory at follow-up. CONCLUSIONS We found no evidence of persistent impairment of cognition after ECT. Achieving remission improved subjective memory and verbal memory recall, but other aspects of cognitive function were not influenced by remission status. Self-rated memory may be useful to monitor the effects of ECT on longer-term memory.",2021,"Achieving remission improved subjective memory and verbal memory recall, but other aspects of cognitive function were not influenced by remission status.",[],"['ketamine augmentation of ECT', 'electroconvulsive therapy', 'electroconvulsive therapy (ECT']","['Cognitive function', 'cognitive function', 'Self-rated memory correlated with category fluency and autobiographical memory', 'subjective memory and verbal memory recall', 'mean MADRS depression score', 'self-rated memory, anterograde verbal memory and category verbal fluency', 'self-rated memory and neuropsychological tests of anterograde verbal and visual memory, autobiographical memory, verbal fluency and working memory']",[],"[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}, {'cui': 'C0013806', 'cui_str': 'Electroshock Therapy'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0561843', 'cui_str': 'Autobiographical Memory'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0589135', 'cui_str': 'Verbal memory recall (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0589502', 'cui_str': 'Antegrade direction (qualifier value)'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychologic Tests'}, {'cui': 'C0542316', 'cui_str': 'Visual memory (observable entity)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}]",,0.0786174,"Achieving remission improved subjective memory and verbal memory recall, but other aspects of cognitive function were not influenced by remission status.","[{'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Anderson', 'Affiliation': 'Neuroscience and Psychiatry Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.'}, {'ForeName': 'R Hamish', 'Initials': 'RH', 'LastName': 'McAllister-Williams', 'Affiliation': 'Newcastle University, Cumbria, Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'Darragh', 'Initials': 'D', 'LastName': 'Downey', 'Affiliation': 'Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Elliott', 'Affiliation': 'Neuroscience and Psychiatry Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Loo', 'Affiliation': 'University of New South Wales, Black Dog Institute & St George Hospital, Sydney, Australia.'}]",Psychological medicine,['10.1017/S0033291720000379'] 92,31970939,"Safety, Tolerability, Pharmacokinetics, and Food Effects on TAC-302 in Healthy Participants: Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Dose Studies.","TAC-302 stimulates neurite outgrowth activity and is expected to restore urinary function in patients with lower urinary tract dysfunction. We conducted 2 phase 1, randomized, placebo-controlled studies to confirm the safety and pharmacokinetics (PK) of TAC-302 in healthy adult Japanese male volunteers. In the first-in-human single-dose study (n = 60), TAC-302 was administered at doses from 100 to 1200 mg after an overnight fast. The effects of a meal on the PK of TAC-302 400 mg were also examined. A multiple-dose study (n = 36) evaluated the effects of meal fat content on the PK of single doses of TAC-302 (100, 200, or 400 mg) and multiple doses of TAC-302 administered for 5 days (100, 200, and 400 mg twice daily). TAC-302 showed linear PK up to doses of 1200 mg in the fasting state, and across the dose range of 100-400 mg in the fed state. No accumulation of TAC-302 was observed. Food, particularly with high fat content, increased TAC-302 plasma concentrations. No differences were observed in the adverse event incidence between the TAC-302 and placebo groups in either study. TAC-302 showed a wide safety margin.",2020,"TAC-302 showed linear PK up to doses of 1200 mg in the fasting state, and across the dose range of 100-400 mg in the fed state.","['healthy adult Japanese male volunteers', 'Healthy Participants', 'patients with lower urinary tract dysfunction']","['Placebo', 'placebo', 'TAC-302']","['Safety, Tolerability, Pharmacokinetics, and Food Effects', 'adverse event incidence', 'TAC-302 plasma concentrations', 'safety and pharmacokinetics (PK', 'accumulation of TAC-302']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0729866', 'cui_str': 'Lower urinary tract structure (body structure)'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",,0.0894403,"TAC-302 showed linear PK up to doses of 1200 mg in the fasting state, and across the dose range of 100-400 mg in the fed state.","[{'ForeName': 'Shogo', 'Initials': 'S', 'LastName': 'Sesoko', 'Affiliation': 'Sosenkai Clinic Edogawa, Mizue, Edogawa-ku, Tokyo, Japan.'}, {'ForeName': 'Jinhong', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Pharmacovigilance Department, Taiho Pharmaceutical Co., Ltd., Uchikanda, Chiyoda-ku, Tokyo, Japan.'}, {'ForeName': 'Takashige', 'Initials': 'T', 'LastName': 'Okayama', 'Affiliation': 'Pharmacokinetics Research Laboratories, Taiho Pharmaceutical Co., Ltd., Okubo, Tsukuba, Ibaraki, Japan.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Nishida', 'Affiliation': 'Clinical Development II Department, Taiho Pharmaceutical Co., Ltd., Uchikanda, Chiyoda-ku, Tokyo, Japan.'}, {'ForeName': 'Kazuhisa', 'Initials': 'K', 'LastName': 'Miyoshi', 'Affiliation': 'Clinical Development II Department, Taiho Pharmaceutical Co., Ltd., Uchikanda, Chiyoda-ku, Tokyo, Japan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.776'] 93,31960624,"A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men.","Tezepelumab, a human immunoglobulin G2 monoclonal antibody against thymic stromal lymphopoietin, is currently under clinical development for the treatment of severe, uncontrolled asthma. This phase 1, randomized, placebo-controlled, single-ascending-dose study assessed the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tezepelumab in healthy Japanese men. Participants were assigned to 1 of 3 tezepelumab dose cohorts (35, 105, or 280 mg; n = 8 per cohort) and randomized (6:2) to receive a single subcutaneous dose of tezepelumab or placebo, with a follow-up period of 84 to 112 days. The overall incidences and severities of treatment-emergent adverse events were similar across tezepelumab doses and between the tezepelumab and placebo groups. Tezepelumab was absorbed slowly, reaching a maximum serum concentration (mean, 5.2-39.7 µg/mL) after 7 to 10 days. Area under the concentration-time curve (mean, 207.2-1612.0 µg · day /mL) increased in an approximate dose-proportional manner. Tezepelumab had a long terminal serum half-life (mean, 23.9-26.3 days) and a small apparent distribution volume, suggesting limited distribution into peripheral tissues. No participants developed anti-tezepelumab antibodies. Single-dose, subcutaneous administration of tezepelumab 35 to 280 mg resulted in an acceptable safety profile with linear pharmacokinetics in healthy Japanese men. No clear differences in tezepelumab safety and pharmacokinetics between Japanese and non-Japanese populations were identified.",2020,The overall incidences and severities of treatment-emergent adverse events were similar across tezepelumab doses and between the tezepelumab and placebo groups.,"['healthy Japanese men', 'Healthy Japanese Men']","['Placebo', 'Tezepelumab', 'tezepelumab', 'tezepelumab or placebo', 'placebo', 'Subcutaneous Tezepelumab', 'subcutaneous tezepelumab']","['overall incidences and severities of treatment-emergent adverse events', 'anti-tezepelumab antibodies', 'tezepelumab safety and pharmacokinetics', 'Safety, Tolerability, Pharmacokinetics, and Immunogenicity', 'maximum serum concentration', 'concentration-time curve', 'safety, tolerability, pharmacokinetics, and immunogenicity']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4550163', 'cui_str': 'tezepelumab'}, {'cui': 'C1522438', 'cui_str': 'SC use'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4550163', 'cui_str': 'tezepelumab'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}]",,0.196404,The overall incidences and severities of treatment-emergent adverse events were similar across tezepelumab doses and between the tezepelumab and placebo groups.,"[{'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Sakamoto', 'Affiliation': 'AstraZeneca K.K., Ofuka-cho, Kita-ku, Osaka, Japan.'}, {'ForeName': 'Shunji', 'Initials': 'S', 'LastName': 'Matsuki', 'Affiliation': 'SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Irie', 'Affiliation': 'SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Uchida', 'Affiliation': 'Department of Pharmacology, Division of Clinical Pharmacology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Nobuya', 'Initials': 'N', 'LastName': 'Hayashi', 'Affiliation': 'AstraZeneca K.K., Ofuka-cho, Kita-ku, Osaka, Japan.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Horiuchi', 'Affiliation': 'AstraZeneca K.K., Ofuka-cho, Kita-ku, Osaka, Japan.'}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Ren', 'Affiliation': 'Quantitative Clinical Pharmacology, AstraZeneca, Gaithersburg, Maryland, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.775'] 94,31797570,"Pharmacokinetics, Bioequivalence, and Safety Studies of Prucalopride in Healthy Chinese Subjects.","The objectives of the present study were to evaluate the bioequivalence of 2 tablet formulations of prucalopride, generic and branded, and to investigate relevant pharmacokinetic and safety profiles. This study was designed as a randomized, open-label, fasting, single-dose, crossover, and dual-period trial. After overnight fasting, 12 subjects were given prucalopride tablets via oral administration, and blood specimens were obtained up to 96 hours after dosing. Prucalopride concentrations in plasma were measured using ultraprecision liquid chromatography-tandem mass spectrometry followed by calculation of pharmacokinetic parameters. The safety of prucalopride was assessed throughout the study. The pharmacokinetics of prucalopride can be defined as a 2-compartment model with a long elimination phase. No significant differences were observed between the pharmacokinetic profiles of the generic and branded prucalopride tablets. Bioequivalence was evaluated using 90%CIs for the ratio test/reference of log area under the concentration-time curve over 96 hours, log area under the concentration-time curve to infinity, and log peak concentration from generic and branded tablets, which were 100.06-109.94%, 100.63-110.32%, and 95.84-113.08%, respectively. During administration of the medication, there were 18 adverse events in 6 subjects in the test formulation group and 19 cases of adverse events in 6 subjects in the reference formulation group (P > .05). No severe adverse effects were detected. These results suggest that generic and branded prucalopride tablets are bioequivalent and show similar safety profiles.",2020,No significant differences were observed between the pharmacokinetic profiles of the generic and branded prucalopride tablets.,['Healthy Chinese Subjects'],['Prucalopride'],"['severe adverse effects', 'pharmacokinetic profiles of the generic and branded prucalopride tablets', 'adverse events']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}]","[{'cui': 'C0913506', 'cui_str': '4-amino-5-chloro-N-(1-(3-methoxypropyl)-4-piperidinyl)-2,3-dihydro-1-benzofuran-7-carboxamide'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0913506', 'cui_str': '4-amino-5-chloro-N-(1-(3-methoxypropyl)-4-piperidinyl)-2,3-dihydro-1-benzofuran-7-carboxamide'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",12.0,0.044,No significant differences were observed between the pharmacokinetic profiles of the generic and branded prucalopride tablets.,"[{'ForeName': 'Ziye', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Chenxiang', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Xuyong', 'Initials': 'X', 'LastName': 'Zheng', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Xuben', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Dongchuan', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Dikang Pharmaceutical Co, Ltd, Sichuan, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xia', 'Affiliation': 'Leeway Biological Technology Co, Ltd, Jiangsu, China.'}, {'ForeName': 'Huafang', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Office of Drug Clinical Trial Institution, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Xiaoxiao', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Office of Drug Clinical Trial Institution, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Xiuhua', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Office of Drug Clinical Trial Institution, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.754'] 95,31943717,The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial.,"BACKGROUND/OBJECTIVES Clinicians use validated scores to risk-stratify patients undergoing transcatheter aortic valve replacement (TAVR). However, evaluation by the Heart Team often deems patients to be at higher risk than their formal scores suggest. We sought to assess clinical outcomes of TAVR patients defined as high-risk by the Heart Team's assessment versus the patient's logistic EuroSCORE (LES). METHODS The BRAVO-3 trial randomized patients at high risk (LES ≥ 18, or deemed inoperable by the Heart Team) to TAVR with periprocedural anticoagulation with unfractionated heparin versus bivalirudin. Endpoints included net adverse cardiac events (NACE: the composite of all-cause mortality, MI, stroke, or bleeding), major adverse cardiovascular events (MACE: death, MI, or stroke), the individual components of MACE, major vascular complications, BARC ≥ 3b bleeding and VARC life-threatening bleeding at 30 days. We compared patients deemed high-risk based on LES ≥ 18 versus high-risk by the Heart Team despite lower LES. RESULTS A total of 467/800 (58.4%) patients were deemed high-risk by the Heart Team despite LES < 18. After multivariable analysis, there were no differences in the odds of endpoints between groups (NACE, OR LES≥18 : 1.32, 95% CI 0.86-2.02, p = .21; MACE, OR LES≥18 : 1.27, 95% CI 0.72-2.25, p = .41; major vascular complications, OR LES≥18 : 0.97, 95% CI 0.65-1.44, p = .88; BARC ≥3b, OR LES≥18 : 1.38, 95% CI 0.82-2.33, p = .23; and VARC life-threatening bleeding, OR LES≥18 : 0.99, 95% CI 0.69-1.41, p = .95). CONCLUSION Patients undergoing TAVR and labeled high-risk by LES ≥ 18 or Heart Team assessment despite LES < 18 have comparable short-term outcomes. Assignment of high-risk status to over 50% of patients is attributable to Heart Team's clinical assessment.",2020,"After multivariable analysis, there were no differences in the odds of endpoints between groups (NACE, OR LES≥18 : 1.32, 95% CI 0.86-2.02, p = .21; MACE, OR LES≥18 : 1.27, 95% CI 0.72-2.25, p = .41; major vascular complications, OR LES≥18 : 0.97, 95% CI 0.65-1.44, p = .88; BARC ≥3b, OR LES≥18 : 1.38, 95% CI 0.82-2.33, p = .23; and VARC life-threatening bleeding, OR LES≥18 : 0.99, 95% CI 0.69-1.41, p = .95). ","['patients at high risk (LES\u2009≥\u200918, or deemed inoperable by the Heart Team) to TAVR with periprocedural anticoagulation with', 'A total of 467/800 (58.4%) patients were deemed high-risk by the Heart Team despite LES\u2009<\u200918']","['unfractionated heparin versus bivalirudin', 'transcatheter aortic valve replacement', 'transcatheter aortic valve replacement (TAVR']","['net adverse cardiac events (NACE: the composite of all-cause mortality, MI, stroke, or bleeding), major adverse cardiovascular events (MACE: death, MI, or stroke), the individual components of MACE, major vascular complications, BARC\u2009≥\u20093b bleeding and VARC life-threatening bleeding', 'VARC life-threatening bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0205187', 'cui_str': 'Inoperable (qualifier value)'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]","[{'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0168273', 'cui_str': 'bivalirudin'}, {'cui': 'C2711836', 'cui_str': 'TAVR - Transcatheter aortic valve replacement'}]","[{'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}]",,0.242707,"After multivariable analysis, there were no differences in the odds of endpoints between groups (NACE, OR LES≥18 : 1.32, 95% CI 0.86-2.02, p = .21; MACE, OR LES≥18 : 1.27, 95% CI 0.72-2.25, p = .41; major vascular complications, OR LES≥18 : 0.97, 95% CI 0.65-1.44, p = .88; BARC ≥3b, OR LES≥18 : 1.38, 95% CI 0.82-2.33, p = .23; and VARC life-threatening bleeding, OR LES≥18 : 0.99, 95% CI 0.69-1.41, p = .95). ","[{'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Camaj', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Bimmer E', 'Initials': 'BE', 'LastName': 'Claessen', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Roxana', 'Initials': 'R', 'LastName': 'Mehran', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Matias B', 'Initials': 'MB', 'LastName': 'Yudi', 'Affiliation': 'Austin Health, Heidelberg, Victoria, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Power', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Usman', 'Initials': 'U', 'LastName': 'Baber', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Hengstenberg', 'Affiliation': 'DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany, and Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Lefevre', 'Affiliation': 'Institut Cardio Vasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Van Belle', 'Affiliation': 'Department of Cardiology and INSERM UMR 1011, University Hospital, and CHRU Lille, Lille, France.'}, {'ForeName': 'Gennaro', 'Initials': 'G', 'LastName': 'Giustino', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Guedeney', 'Affiliation': 'Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de cardiologie (AP-HP), Paris, France.'}, {'ForeName': 'Sabato', 'Initials': 'S', 'LastName': 'Sorrentino', 'Affiliation': 'Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Kupatt', 'Affiliation': 'LMU Munich, Munich, Germany.'}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Webb', 'Affiliation': ""St. Paul's Hospital, Vancouver, British Columbia, Canada.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Hildick-Smith', 'Affiliation': 'Sussex Cardiac Centre-Brighton & Sussex University Hospitals NHS Trust, Brighton, East Sussex, UK.'}, {'ForeName': 'Hans U', 'Initials': 'HU', 'LastName': 'Hink', 'Affiliation': 'Universitätsmedizin Mainz, Mainz, Germany.'}, {'ForeName': 'Efthymios N', 'Initials': 'EN', 'LastName': 'Deliargyris', 'Affiliation': 'Science and Strategy Consulting Group, Basking Ridge, New Jersey.'}, {'ForeName': 'Prodromos', 'Initials': 'P', 'LastName': 'Anthopoulos', 'Affiliation': 'Arena Pharmaceuticals, Inc., Zurich, Switzerland.'}, {'ForeName': 'Samin K', 'Initials': 'SK', 'LastName': 'Sharma', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Annapoorna', 'Initials': 'A', 'LastName': 'Kini', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Sartori', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jaya', 'Initials': 'J', 'LastName': 'Chandrasekhar', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'George D', 'Initials': 'GD', 'LastName': 'Dangas', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.28717'] 96,31595704,"Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions.","Olanzapine, a second-generation atypical antipsychotic drug, is widely used for schizophrenia and moderate to severe mania associated with bipolar disorders. This open-label, randomized, single-dose, 2-sequence, 2-period crossover, comparative pharmacokinetic study assessed the bioequivalence of 5 mg of olanzapine administered in tablet (R) or disintegrating tablet (T) formulation in healthy Chinese volunteers under both fasting and fed conditions. Numbers of enrolled subjects were 30 and 24 for fasting and fed treatments, respectively. Blood samples were drawn and collected predose as well as up to 144 hours postdose. The plasma concentration of olanzapine was quantitated by a robust, rapid, and sensitive liquid chromatography-tandem mass spectrometry method. The R was bioequivalent to T formulation under either fasting or fed conditions. The 90%CI for ratios of the geometric means observed maximum plasma concentration, area under the curve from time 0 extrapolated to last time point, and area under the curve from time 0 extrapolated to infinity were all within the allowed limit (80.0% to 125.0%). The pharmacokinetic profiles of T and R formulations were similar under fasting and fed conditions. Both formulations were well tolerated, with a similar incidence of treatment-emergent adverse events under fasting and fed conditions.",2020,"Both formulations were well tolerated, with a similar incidence of treatment-emergent adverse events under fasting and fed conditions.",['healthy Chinese volunteers under both fasting and fed conditions'],"['Olanzapine', 'olanzapine administered in tablet (R) or disintegrating tablet (T) formulation']",['plasma concentration of olanzapine'],"[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}]",,0.0149459,"Both formulations were well tolerated, with a similar incidence of treatment-emergent adverse events under fasting and fed conditions.","[{'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Du', 'Affiliation': 'Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China.'}, {'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China.'}, {'ForeName': 'Hongchuan', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Zhao', 'Affiliation': 'Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China.'}, {'ForeName': 'Zhixia', 'Initials': 'Z', 'LastName': 'Zhao', 'Affiliation': 'Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China.'}, {'ForeName': 'Weiyue', 'Initials': 'W', 'LastName': 'Yu', 'Affiliation': 'Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China.'}, {'ForeName': 'Lihong', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.743'] 97,31394283,Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis.,"BACKGROUND & AIMS We performed a randomized trial to determine whether albumin should be administered to patients with infections unrelated to spontaneous bacterial peritonitis (SBP). METHODS We performed a multicenter, open-label trial in which 118 patients with cirrhosis, non-SBP infections, and additional risk factors for poor outcome were randomly assigned to receive antibiotics plus albumin (study group; n = 61) or antibiotics alone (control group; n = 57). The primary outcome was in-hospital mortality; secondary outcomes were effect of albumin on disease course. RESULTS There were no significant differences at baseline between groups in results from standard laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity scores. However, the combined prevalence of acute on chronic liver failure (ACLF) and kidney dysfunction was significantly higher in the study group (44.3% vs 24.6% in the control group; P = .02), indicating greater baseline overall severity. There was no significant difference in the primary outcome between groups (13.1% in the study group vs 10.5% in the control group; P = .66). Circulatory and renal functions improved in only the study group. A significantly higher proportion of patients in the study group had resolution of ACLF (82.3% vs 33.3% in the control group; P = .03). A significantly lower proportion of patients in the study group developed nosocomial infections (6.6% vs 24.6% in the control group; P = .007). CONCLUSIONS In a randomized trial of patients with advanced cirrhosis and non-SBP infections, in-hospital mortality was similar between those who received albumin plus antibiotics vs those who received only antibiotics (controls). However, patients given albumin were sicker at baseline and, during the follow-up period, a higher proportion had ACLF resolution and a lower proportion had nosocomial infections. ClinicalTrials.gov no: NCT02034279.",2020,"There were no significant differences at baseline between groups in results from standard laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity scores.","['Patients with Cirrhosis and Infections', '118 patients with cirrhosis, non-SBP infections, and additional risk factors for poor outcome', 'patients with infections unrelated to spontaneous bacterial peritonitis (SBP', 'patients with advanced cirrhosis and non-SBP infections, in-hospital mortality was similar between those who received albumin plus antibiotics vs those who received only antibiotics (controls']","['antibiotics alone', 'antibiotics plus albumin', 'Albumin Treatment', 'albumin']","['standard laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity scores', 'nosocomial infections', 'ACLF resolution', 'chronic liver failure (ACLF) and kidney dysfunction', 'resolution of ACLF', 'Circulatory and renal functions', 'effect of albumin on disease course', 'hospital mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0445356', 'cui_str': 'Unrelated (finding)'}, {'cui': 'C0275551', 'cui_str': 'Primary bacterial peritonitis (disorder)'}, {'cui': 'C1263666', 'cui_str': 'Advanced cirrhosis'}, {'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0022885', 'cui_str': 'Laboratory test (procedure)'}, {'cui': 'C0162491', 'cui_str': 'Serum Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C0205721', 'cui_str': 'Infections, Hospital'}, {'cui': 'C2936476', 'cui_str': 'Chronic Liver Failure'}, {'cui': 'C0151746', 'cui_str': 'Abnormal renal function (finding)'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}]",118.0,0.156905,"There were no significant differences at baseline between groups in results from standard laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity scores.","[{'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Fernández', 'Affiliation': 'EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain; Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain. Electronic address: Jfdez@clinic.cat.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Angeli', 'Affiliation': 'EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain; University of Padua, Padua, Italy.'}, {'ForeName': 'Jonel', 'Initials': 'J', 'LastName': 'Trebicka', 'Affiliation': 'EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain; University Hospital of Bonn, Bonn, Germany; Hospital University of Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Merli', 'Affiliation': 'Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Gustot', 'Affiliation': 'Department of Gastroenterology, Erasme Hospital (ULB), Brussels, Belgium.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Alessandria', 'Affiliation': 'Division of Gastroenterology and Hepatology, Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy.'}, {'ForeName': 'Niels Kristian', 'Initials': 'NK', 'LastName': 'Aagaard', 'Affiliation': 'Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'de Gottardi', 'Affiliation': 'University of Berne, Berne, Switzerland.'}, {'ForeName': 'Tania M', 'Initials': 'TM', 'LastName': 'Welzel', 'Affiliation': 'Hospital University of Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Gerbes', 'Affiliation': 'University Medical School Munich, Munich, Germany.'}, {'ForeName': 'German', 'Initials': 'G', 'LastName': 'Soriano', 'Affiliation': 'Hospital of Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Vargas', 'Affiliation': ""Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona i CIBERehd, Barcelona, Spain.""}, {'ForeName': 'Agustin', 'Initials': 'A', 'LastName': 'Albillos', 'Affiliation': 'Hospital Universitario Ramon y Cajal, Madrid, Spain.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Salerno', 'Affiliation': 'Policlinico IRCCS San Donato, Milan, Italy.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Durand', 'Affiliation': ""Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France.""}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Bañares', 'Affiliation': 'Hospital Gregorio Marañon, Madrid, Spain.'}, {'ForeName': 'Rudolf', 'Initials': 'R', 'LastName': 'Stauber', 'Affiliation': 'Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Verónica', 'Initials': 'V', 'LastName': 'Prado', 'Affiliation': 'Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain.'}, {'ForeName': 'Mireya', 'Initials': 'M', 'LastName': 'Arteaga', 'Affiliation': 'Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Hernández-Tejero', 'Affiliation': 'Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain.'}, {'ForeName': 'Fátima', 'Initials': 'F', 'LastName': 'Aziz', 'Affiliation': 'Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Morando', 'Affiliation': 'University of Padua, Padua, Italy.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Jansen', 'Affiliation': 'University Hospital of Bonn, Bonn, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Lattanzi', 'Affiliation': 'Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Moreno', 'Affiliation': 'Department of Gastroenterology, Erasme Hospital (ULB), Brussels, Belgium.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Campion', 'Affiliation': 'Division of Gastroenterology and Hepatology, Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Gronbaek', 'Affiliation': 'Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Garcia', 'Affiliation': 'Hospital Gregorio Marañon, Madrid, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Sánchez', 'Affiliation': 'EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'García', 'Affiliation': 'EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Amorós', 'Affiliation': 'EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Pavesi', 'Affiliation': 'EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Clària', 'Affiliation': 'EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Moreau', 'Affiliation': ""EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain; Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France; Inserm, Université Paris Diderot-Paris 7, CNRS, Centre de Recherche sur l'Inflammation, Paris, France.""}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Arroyo', 'Affiliation': 'EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2019.07.055'] 98,32196954,Levocetirizine Oral Disintegrating Tablet: A Randomized Open-Label Crossover Bioequivalence Study in Healthy Japanese Volunteers.,"Levocetirizine is classified as a second-generation antihistamine. Levocetirizine is available for the treatment of allergic disorders such as allergic rhinitis and chronic idiopathic urticaria. This was a single-center, single-dose, open-label, randomized, 2-way crossover study in healthy Japanese male subjects consisting of 2 parts. Part 1 compared the bioavailability of levocetirizine oral disintegrating tablet (ODT) and levocetirizine immediate-release tablet (IRT) taken with water in the fasted state in 24 subjects; all subjects completed this part of the trial. In part 2, the bioavailability of levocetirizine ODT without water was compared with that of levocetirizine IRT with water in the fasted state in 48 subjects; 47 subjects completed this part of the trial. Bioequivalence was demonstrated between levocetirizine IRT 5 mg and ODT 5 mg. The safety profiles were generally similar between levocetirizine ODT and levocetirizine IRT, with no serious adverse events, deaths, or adverse events leading to withdrawal reported during the study.",2020,"The safety profiles were generally similar between levocetirizine ODT and levocetirizine IRT, with no serious adverse events, deaths, or adverse events leading to withdrawal reported during the study.","['Healthy Japanese Volunteers', '24 subjects', 'healthy Japanese male subjects consisting of 2 parts', '48 subjects; 47 subjects completed this part of the trial']","['levocetirizine ODT and levocetirizine IRT', 'levocetirizine ODT', 'Levocetirizine', 'Levocetirizine Oral Disintegrating Tablet', 'levocetirizine oral disintegrating tablet (ODT) and levocetirizine immediate-release tablet (IRT', 'levocetirizine IRT']","['serious adverse events, deaths, or adverse events']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0449719', 'cui_str': 'Part (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}]","[{'cui': 'C1174893', 'cui_str': 'levocetirizine'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",48.0,0.011894,"The safety profiles were generally similar between levocetirizine ODT and levocetirizine IRT, with no serious adverse events, deaths, or adverse events leading to withdrawal reported during the study.","[{'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Ino', 'Affiliation': 'Clinical Pharmacology Office, Japan Development Division, GlaxoSmithKline KK, Tokyo, Japan.'}, {'ForeName': 'Masanari', 'Initials': 'M', 'LastName': 'Shiramoto', 'Affiliation': 'Souseikai Hakata Clinic, Fukuoka, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Eto', 'Affiliation': 'Souseikai Hakata Clinic, Fukuoka, Japan.'}, {'ForeName': 'Miwa', 'Initials': 'M', 'LastName': 'Haranaka', 'Affiliation': 'Souseikai Hakata Clinic, Fukuoka, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Irie', 'Affiliation': 'Souseikai Hakata Clinic, Fukuoka, Japan.'}, {'ForeName': 'Takumi', 'Initials': 'T', 'LastName': 'Terao', 'Affiliation': 'Biomedical Data Sciences Department, Japan Development Division, GlaxoSmithKline KK, Tokyo, Japan.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Ogura', 'Affiliation': 'Clinical Pharmacology Office, Japan Development Division, GlaxoSmithKline KK, Tokyo, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Wakamatsu', 'Affiliation': 'Pre-Clinical Development Department, Japan Development Division, GlaxoSmithKline KK, Tokyo, Japan.'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Hoyano', 'Affiliation': 'Biomedical Data Sciences Department, Japan Development Division, GlaxoSmithKline KK, Tokyo, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Nakano', 'Affiliation': 'Immuno-Inflammation Therapeutic Office, Medicines Development, Japan Development, GlaxoSmithKline KK, Tokyo, Japan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.791'] 99,32196976,The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers.,"Tafamidis, a non-nonsteroidal anti-inflammatory benzoxazole derivative, acts as a transthyretin (TTR) stabilizer to slow progression of TTR amyloidosis (ATTR). Tafamidis meglumine, available as 20-mg capsules, is approved in more than 40 countries worldwide for the treatment of adults with early-stage symptomatic ATTR polyneuropathy. This agent, administered as an 80-mg, once-daily dose (4 × 20-mg capsules), is approved in the United States, Japan, Canada, and Brazil for the treatment of hereditary and wild-type ATTR cardiomyopathy in adults. An alternative single solid oral dosage formulation (tafamidis 61-mg free acid capsules) was developed and introduced for patient convenience (approved in the United States, United Arab Emirates, and European Union). In this single-center, open-label, randomized, 2-period, 2-sequence, crossover, multiple-dose phase 1 study, the rate and extent of absorption were compared between tafamidis 61-mg free acid capsules (test) and tafamidis meglumine 80-mg (4 × 20-mg) capsules (reference) after 7 days of repeated oral dosing under fasted conditions in 30 healthy volunteers. Ratios of adjusted geometric means (90%CI) for the test/reference formulations were 102.3 (98.0-106.8) for area under the concentration-time profile over the dosing interval and 94.1 (89.1-99.4) for the maximum observed concentration, satisfying prespecified bioequivalence acceptance criteria (90%CI, 80-125). Both tafamidis regimens had an acceptable safety/tolerability profile in this population.",2020,"Ratios of adjusted geometric means (90%CI) for the test/reference formulations were 102.3 (98.0-106.8) for area under the concentration-time profile over the dosing interval and 94.1 (89.1-99.4) for the maximum observed concentration, satisfying prespecified bioequivalence acceptance criteria (90%CI, 80-125).","['30 healthy volunteers', 'adults with early-stage symptomatic ATTR polyneuropathy', 'Healthy Volunteers']","['Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine', 'Tafamidis meglumine']","['acceptable safety/tolerability profile', 'Ratios of adjusted geometric means (90%CI']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0152025', 'cui_str': 'Polyneuropathy'}]","[{'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C2745275', 'cui_str': 'Tafamidis meglumine'}]","[{'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",30.0,0.0586977,"Ratios of adjusted geometric means (90%CI) for the test/reference formulations were 102.3 (98.0-106.8) for area under the concentration-time profile over the dosing interval and 94.1 (89.1-99.4) for the maximum observed concentration, satisfying prespecified bioequivalence acceptance criteria (90%CI, 80-125).","[{'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Lockwood', 'Affiliation': 'Pfizer, Groton, Connecticut, USA.'}, {'ForeName': 'Vu H', 'Initials': 'VH', 'LastName': 'Le', 'Affiliation': 'Pfizer, Groton, Connecticut, USA.'}, {'ForeName': 'Melissa T', 'Initials': 'MT', 'LastName': ""O'Gorman"", 'Affiliation': 'Pfizer, New York, New York, USA.'}, {'ForeName': 'Terrell A', 'Initials': 'TA', 'LastName': 'Patterson', 'Affiliation': 'Pfizer, Groton, Connecticut, USA.'}, {'ForeName': 'Marla B', 'Initials': 'MB', 'LastName': 'Sultan', 'Affiliation': 'Pfizer, New York, New York, USA.'}, {'ForeName': 'Ekaterina', 'Initials': 'E', 'LastName': 'Tankisheva', 'Affiliation': 'Pfizer, Brussels, Belgium.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Pfizer Beijing City, China.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Riley', 'Affiliation': 'Pfizer, Groton, Connecticut, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.789'] 100,28279433,"Patterns of Oxygenation, Mortality, and Growth Status in the Surfactant Positive Pressure and Oxygen Trial Cohort.","OBJECTIVE To characterize actual achieved patterns of oxygenation in infants born appropriate vs small for gestational age (SGA) randomized to a lower (85-89%) vs higher (91%-95%) oxygen saturation target in the Surfactant Positive Pressure and Oxygen Trial. To determine the association between achieved oxygen saturation levels and survival in infants born appropriate vs SGA enrolled in the Surfactant Positive Pressure and Oxygen Trial. STUDY DESIGN Median oxygen saturation and intermittent hypoxemia events (<80%, 20 seconds-5  minutes) were documented in 1054 infants of 24 0/7 -27 6/7  weeks of gestation while receiving supplemental oxygen during the first 3 days of life. RESULTS Lower target infants who were small for gestational age had the lowest oxygen saturation and highest incidence of intermittent hypoxemia during the first 3 days of life. The lowest quartile of oxygen saturation (≤92%) during the first 3 days of life was associated with lower 90-day survival for both infants born appropriate and SGA. An increased incidence of intermittent hypoxemia events during the first 3 days of life was associated with lower 90-day survival only in infants born SGA. CONCLUSION Lower achieved oxygen saturation during the first 3 days of life was associated with lower 90-day survival in extremely preterm infants. Infants born SGA had enhanced vulnerability to lower oxygen saturation targets as evidenced by lower achieved oxygen saturation and an association between increased intermittent hypoxemia events and lower survival. TRIAL REGISTRATION ClinicalTrials.gov: NCT00233324.",2017,"Infants born SGA had enhanced vulnerability to lower oxygen saturation targets as evidenced by lower achieved oxygen saturation and an association between increased intermittent hypoxemia events and lower survival. ","['1054 infants of 24 0/7 -27 6/7 \u2009weeks of gestation while receiving supplemental oxygen during the first 3 days of life', 'infants born appropriate vs small for gestational age', 'infants born appropriate vs SGA enrolled in the Surfactant Positive Pressure and Oxygen Trial']",[],"['intermittent hypoxemia events', 'lowest oxygen saturation and highest incidence of intermittent hypoxemia', 'Median oxygen saturation and intermittent hypoxemia events', 'Oxygenation, Mortality, and Growth Status', '90-day survival', 'lowest quartile of oxygen saturation', 'oxygen saturation', 'intermittent hypoxemia events and lower survival']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0235991', 'cui_str': 'Small for gestational age'}, {'cui': 'C4543209', 'cui_str': 'Surfactant'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}]",[],"[{'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range (finding)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]",,0.0648124,"Infants born SGA had enhanced vulnerability to lower oxygen saturation targets as evidenced by lower achieved oxygen saturation and an association between increased intermittent hypoxemia events and lower survival. ","[{'ForeName': 'Juliann M', 'Initials': 'JM', 'LastName': 'Di Fiore', 'Affiliation': ""Division of Neonatology, Rainbow Babies & Children's Hospital, Department of Pediatrics, Case Western Reserve University, Cleveland, OH. Electronic address: jmd3@case.edu.""}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Martin', 'Affiliation': ""Division of Neonatology, Rainbow Babies & Children's Hospital, Department of Pediatrics, Case Western Reserve University, Cleveland, OH.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Epidemiology & Biostatistics, Case Western Reserve University, Cleveland, OH.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Morris', 'Affiliation': 'Epidemiology & Biostatistics, Case Western Reserve University, Cleveland, OH.'}, {'ForeName': 'Waldemar A', 'Initials': 'WA', 'LastName': 'Carlo', 'Affiliation': 'Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Finer', 'Affiliation': 'Department of Pediatrics, University of California, San Diego, CA.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Walsh', 'Affiliation': ""Division of Neonatology, Rainbow Babies & Children's Hospital, Department of Pediatrics, Case Western Reserve University, Cleveland, OH.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of pediatrics,['10.1016/j.jpeds.2017.01.057'] 101,31896529,Distress and anhedonia as predictors of depression treatment outcome: A secondary analysis of a randomized clinical trial.,"Two core features of depression include depressed mood (heightened distress) and anhedonia (reduced pleasure). Despite their centrality to depression, studies have not examined their contribution to treatment outcomes in a randomized clinical trial providing mainstream treatments like antidepressant medications (ADM) and cognitive therapy (CT). We used baseline distress and anhedonia derived from a factor analysis of the Mood and Anxiety Symptom Questionnaire to predict remission and recovery in 433 individuals with recurrent/chronic major depressive disorder. Patients were provided with only ADM or both ADM and CT. Overall, higher baseline distress and anhedonia predicted longer times to remission within one year and recovery within three years. When controlling for treatment condition, distress improved prediction of outcomes over and above anhedonia, while anhedonia did not improve prediction of outcomes over and above distress. Interactions with treatment condition demonstrated that individuals with higher distress and anhedonia benefited from receiving CT in addition to ADM, whereas there was no added benefit of CT for individuals with lower distress and anhedonia. Assessing distress and anhedonia prior to treatment may help select patients who will benefit most from CT in addition to ADM. For the treatments and outcome measures tested, utilizing distress to guide treatment planning may yield the greatest benefit. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00057577.",2020,"Interactions with treatment condition demonstrated that individuals with higher distress and anhedonia benefited from receiving CT in addition to ADM, whereas there was no added benefit of CT for individuals with lower distress and anhedonia.",['433 individuals with recurrent/chronic major depressive disorder'],"['cognitive therapy (CT', 'CT']","['Distress and anhedonia', 'depressed mood (heightened distress) and anhedonia (reduced pleasure']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0344315', 'cui_str': 'Depressed'}, {'cui': 'C0442803', 'cui_str': 'Heightened (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}]",433.0,0.0961218,"Interactions with treatment condition demonstrated that individuals with higher distress and anhedonia benefited from receiving CT in addition to ADM, whereas there was no added benefit of CT for individuals with lower distress and anhedonia.","[{'ForeName': 'Gabriela K', 'Initials': 'GK', 'LastName': 'Khazanov', 'Affiliation': 'Department of Psychology, University of Pennsylvania, 425 S. University Avenue, Philadelphia, PA, 19104, USA. Electronic address: kattang@sas.upenn.edu.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Department of Psychology, University of Pennsylvania, 425 S. University Avenue, Philadelphia, PA, 19104, USA. Electronic address: colinxu@sas.upenn.edu.'}, {'ForeName': 'Barnaby D', 'Initials': 'BD', 'LastName': 'Dunn', 'Affiliation': 'Mood Disorders Centre, University of Exeter. Sir Henry Wellcome Building for Mood Disorders Research, University of Exeter, Perry Road, EX4 4QG, UK. Electronic address: B.D.Dunn@exeter.ac.uk.'}, {'ForeName': 'Zachary D', 'Initials': 'ZD', 'LastName': 'Cohen', 'Affiliation': 'Department of Psychology, University of Pennsylvania, 425 S. University Avenue, Philadelphia, PA, 19104, USA. Electronic address: zcohen@sas.upenn.edu.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'DeRubeis', 'Affiliation': 'Department of Psychology, University of Pennsylvania, 425 S. University Avenue, Philadelphia, PA, 19104, USA. Electronic address: derubeis@psych.upenn.edu.'}, {'ForeName': 'Steven D', 'Initials': 'SD', 'LastName': 'Hollon', 'Affiliation': 'Department of Psychology, Vanderbilt University. 2301 Vanderbilt Place, Nashville, TN, 37240, USA. Electronic address: steven.d.hollon@vanderbilt.edu.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103507'] 102,31747677,Adiponectin Gene Variant rs266729 Interacts with Different Macronutrient Distribution of Two Different Hypocaloric Diets.,"BACKGROUND The role of ADIPOQ gene variants in weight loss after different dietary fat amounts remains unclear. OBJECTIVE Our aim was to analyze the effects of ADIPOQ gene polymorphism rs266729 on metabolic changes after two different amounts of dietary fat in two hypocaloric diets. DESIGN A population of 283 obese patients was recruited in a randomized clinical trial with two diets: Diet HF (high-fat diet: 38% carbohydrates, 24% proteins, and 38% fats) versus Diet LF (low-fat diet: 53% carbohydrates, 20% proteins, and 27% fats). Before and after 3 months, an anthropometric evaluation, an assessment of nutritional intake, and a biochemical analysis were carried out. The variant of the ADIPOQgene was assessed by real-time PCR. RESULTS Weight loss was similar with both diets in both genotypes (CC vs. CG+GG). After dietary intervention with Diet HF, only subjects with CC genotype showed a significant improvement in insulin levels (-3.3 ± 0.6 vs. -1.8 ± 0.9 mU/L; p = 0.03) and the homeostasis model assessment for insulin resistance (HOMA-IR) (-1.3 ± 0.1 vs. -0.8 ± 0.2 units; p = 0.02). After Diet LF, subjects with CC genotype showed a significant improvement in total cholesterol levels (CC vs. CG+GG) (-15.3 ± 1.4 vs. -6.4 ± 1.3 mg/dL; p = 0.01), LDL cholesterol (-14.6 ± 1.8 vs. -6.4 ± 1.3 mg/dL; p = 0.01), insulin levels (-4.6 ± 1.0 vs. -1.6 ± 0.5 mU/L; p = 0.01), and HOMA-IR (-1.6 ± 0.1 vs. -1.0 ± 0.2 units; p = 0.02). Only subjects with CC genotype showed a significant increase of adiponectin levels after both diets (CC vs. CG+GG): Diet HF (10.6 ± 2.0 vs. 1.8 ± 1.0 ng/dL; p = 0.01) and Diet LF (16.1 ± 2.8 vs. 1.3 ± 1.0 ng/dL: p = 0.03). CONCLUSION CC genotype of ADIPOQgene variantrs266729 was associated with a better metabolic response after both diets. Additionally, Diet LF produced a significant improvement in lipid profile in noncarriers of allele G.",2020,Only subjects with CC genotype showed a significant increase of adiponectin levels after both diets (CC vs. CG+GG): Diet HF (10.6 ± 2.0 vs. 1.8 ± 1.0 ng/dL; p = 0.01) and Diet LF (16.1 ± 2.8 vs. 1.3,['283 obese patients'],"['Diet LF', 'diets: Diet HF (high-fat diet: 38% carbohydrates, 24% proteins, and 38% fats) versus Diet LF']","['lipid profile', 'insulin levels', 'homeostasis model assessment for insulin resistance (HOMA-IR', 'metabolic response', 'total cholesterol levels', 'adiponectin levels', 'Weight loss', 'LDL cholesterol']","[{'cui': 'C4708786', 'cui_str': 'Two hundred and eighty-three'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0521974', 'cui_str': 'Diet, High-Fat'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fats'}]","[{'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0428466', 'cui_str': 'Finding of cholesterol level (finding)'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}]",283.0,0.0224633,Only subjects with CC genotype showed a significant increase of adiponectin levels after both diets (CC vs. CG+GG): Diet HF (10.6 ± 2.0 vs. 1.8 ± 1.0 ng/dL; p = 0.01) and Diet LF (16.1 ± 2.8 vs. 1.3,"[{'ForeName': 'Daniel Antonio', 'Initials': 'DA', 'LastName': 'de Luis', 'Affiliation': 'Center of Investigation of Endocrinology and Nutrition, Medicine School and Department of Endocrinology and Investigation, Hospital Clinico Universitario, University of Valladolid, Valladolid, Spain, dadluis@yahoo.es.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Primo', 'Affiliation': 'Center of Investigation of Endocrinology and Nutrition, Medicine School and Department of Endocrinology and Investigation, Hospital Clinico Universitario, University of Valladolid, Valladolid, Spain.'}, {'ForeName': 'Olatz', 'Initials': 'O', 'LastName': 'Izaola', 'Affiliation': 'Center of Investigation of Endocrinology and Nutrition, Medicine School and Department of Endocrinology and Investigation, Hospital Clinico Universitario, University of Valladolid, Valladolid, Spain.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Aller', 'Affiliation': 'Center of Investigation of Endocrinology and Nutrition, Medicine School and Department of Endocrinology and Investigation, Hospital Clinico Universitario, University of Valladolid, Valladolid, Spain.'}]",Lifestyle genomics,['10.1159/000503863'] 103,31904292,Dexamethasone Addition to Popliteal Nerve Blocks: Effects on Duration of Analgesia and Incidence of Postoperative Nerve Complication.,"Background . The purpose of this prospective, double-blinded randomized control pilot study was to evaluate the effect of adjunctive dexamethasone on analgesia duration and the incidence of postoperative neuropathic complication. Peripheral nerve blocks are an effective adjunct to decrease postoperative pain in foot and ankle surgery, and any possible modalities to augment their efficacy is of clinical utility. Methods . Patients were randomly assigned to a control group (n = 25) receiving nerve blocks of bupivacaine and epinephrine or an experimental group (n = 24) with an adjunctive 8 mg dexamethasone. The patients, surgeons, and anesthesiologists were all blinded to allocation. Patients had a minimum 1 year postoperative follow-up. Results . Forty-nine patients completed the protocol. There was no statistically significant difference in analgesia duration ( P = .38) or postoperative neuropathic complication incidence ( P = .67) between the 2 groups. Conclusions . The addition of dexamethasone to popliteal nerve blocks does not appear to affect analgesia duration or incidence of postoperative neuropathic complications. However, our study was underpowered, and we recommend a larger scale prospective study for validation. Levels of Evidence: Level II: Prospective, randomized control pilot study.",2021,The addition of dexamethasone to popliteal nerve blocks does not appear to affect analgesia duration or incidence of postoperative neuropathic complications.,['Forty-nine patients completed the protocol'],"['adjunctive 8 mg dexamethasone', 'Dexamethasone', 'adjunctive dexamethasone', 'dexamethasone', 'control group (n = 25) receiving nerve blocks of bupivacaine and epinephrine']","['analgesia duration and the incidence of postoperative neuropathic complication', 'postoperative pain', 'analgesia duration', 'postoperative neuropathic complication incidence', 'Duration of Analgesia and Incidence of Postoperative Nerve Complication']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027741', 'cui_str': 'Nerve Blockade'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}]","[{'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0027740', 'cui_str': 'Nerve structure'}]",49.0,0.284825,The addition of dexamethasone to popliteal nerve blocks does not appear to affect analgesia duration or incidence of postoperative neuropathic complications.,"[{'ForeName': 'Naudereh', 'Initials': 'N', 'LastName': 'Noori', 'Affiliation': 'Cedars Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Kapil', 'Initials': 'K', 'LastName': 'Anand', 'Affiliation': 'Cedars Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Pfeffer', 'Affiliation': 'Cedars Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Thordarson', 'Affiliation': 'Cedars Sinai Medical Center, Los Angeles, California.'}]",Foot & ankle specialist,['10.1177/1938640019897224'] 104,31854112,Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.,"OBJECTIVE To investigate the impact of different anti-platelet strategies on outcomes after percutaneous coronary intervention (PCI) in patients with established cardiovascular disease (CVD). METHODS GLOBAL LEADERS was a randomized, superiority, all-comers trial comparing one-month dual anti-platelet therapy (DAPT) with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy (experimental treatment) with standard 12-month DAPT followed by 12-month aspirin monotherapy (reference treatment) in patients treated with a biolimus A9-eluting stent. Established CVD was defined as ≥1 prior myocardial infarction, PCI, coronary artery bypass operation, stroke, or established peripheral vascular disease. The primary endpoint was a composite of all-cause death or new Q-wave MI at 2-years. The secondary safety endpoint was BARC 3 or 5 bleeding. Exploratory secondary endpoints were the patient-orientated composite endpoint and net adverse clinical events. RESULTS Among the 15,761 patients in this cohort were 6,693 patients (42.5%) with established CVD. Compared to those without established CVD, these patients had significantly higher rates of the primary (5.1 vs. 3.3%, HR1.59[1.36-1.86], p < .001) and secondary composite endpoints with no significant differences in bleeding. There was a nonsignificant reduction in the primary endpoint in patients with established CVD receiving the experimental treatment (4.6 vs. 5.6%, HR0.82[0.66-1.02], p = .07). When comparing patients without CVD to those with one or three territories of CVD, the hazard ratio for the primary endpoint increased in unadjusted and adjusted models. CONCLUSIONS The poorer outcomes in patients with established CVD are not mitigated by prolonged monotherapy with a potent P2Y12 inhibitor suggesting a greater need to focus on modifiable risk factors.",2020,"Compared to those without established CVD, these patients had significantly higher rates of the primary (5.1 vs. 3.3%, HR1.59[1.36-1.86], p < .001) and secondary composite endpoints with no significant differences in bleeding.","['15,761 patients in this cohort were 6,693 patients (42.5%) with established CVD', 'patients with established cardiovascular disease (CVD', 'patients treated with a biolimus A9-eluting stent', 'patients with established CVD']","['percutaneous coronary intervention (PCI', 'dual anti-platelet therapy (DAPT) with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy (experimental treatment) with standard 12-month DAPT followed by 12-month aspirin monotherapy']","['bleeding', 'patient-orientated composite endpoint and net adverse clinical events', 'BARC 3 or 5 bleeding', 'composite of all-cause death or new Q-wave MI at 2-years']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C4310325', 'cui_str': 'Biolimus A9'}, {'cui': 'C0038257', 'cui_str': 'Stents'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0424013', 'cui_str': 'Orientated (finding)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0861151', 'cui_str': 'Q wave MI'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",,0.117965,"Compared to those without established CVD, these patients had significantly higher rates of the primary (5.1 vs. 3.3%, HR1.59[1.36-1.86], p < .001) and secondary composite endpoints with no significant differences in bleeding.","[{'ForeName': 'Scot', 'Initials': 'S', 'LastName': 'Garg', 'Affiliation': 'Royal Blackburn Hospital, East Lancashire Hospitals NHS Trust, Blackburn, UK.'}, {'ForeName': 'Ply', 'Initials': 'P', 'LastName': 'Chichareon', 'Affiliation': 'Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, Netherlands.'}, {'ForeName': 'Norihiro', 'Initials': 'N', 'LastName': 'Kogame', 'Affiliation': 'Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, Netherlands.'}, {'ForeName': 'Kuniaki', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, Netherlands.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Modolo', 'Affiliation': 'Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, Netherlands.'}, {'ForeName': 'Chun-Chin', 'Initials': 'CC', 'LastName': 'Chang', 'Affiliation': 'Erasmus Medical Center, Thoraxcenter, Rotterdam, Netherlands.'}, {'ForeName': 'Mariusz', 'Initials': 'M', 'LastName': 'Tomaniak', 'Affiliation': 'Erasmus Medical Center, Thoraxcenter, Rotterdam, Netherlands.'}, {'ForeName': 'Farzin', 'Initials': 'F', 'LastName': 'Fath-Ordoubadi', 'Affiliation': 'Manchester Heart Centre, Manchester Royal Infirmary, Manchester University Foundation Trust, Manchester, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Anderson', 'Affiliation': 'Department of Cardiology, University Hospital of Wales, Cardiff, UK.'}, {'ForeName': 'Keith G', 'Initials': 'KG', 'LastName': 'Oldroyd', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, UK.'}, {'ForeName': 'Rod H', 'Initials': 'RH', 'LastName': 'Stables', 'Affiliation': 'Liverpool Heart and Chest Hospital, Liverpool, UK.'}, {'ForeName': 'Neville', 'Initials': 'N', 'LastName': 'Kukreja', 'Affiliation': 'Department of Cardiology, East and North Hertfordshire NHS Trust, Hertfordshire, UK.'}, {'ForeName': 'Saqib', 'Initials': 'S', 'LastName': 'Chowdhary', 'Affiliation': 'Wythenshawe Hospital, Manchester University Foundation Trust, Manchester, UK.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Galasko', 'Affiliation': 'Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Hoole', 'Affiliation': 'Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, UK.'}, {'ForeName': 'Azfar', 'Initials': 'A', 'LastName': 'Zaman', 'Affiliation': 'Department of Cardiology, Freeman Hospital and Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK.'}, {'ForeName': 'Christian W', 'Initials': 'CW', 'LastName': 'Hamm', 'Affiliation': 'Kerckhoff Heart Center, Campus University of Giessen, Bad Nauheim, Germany.'}, {'ForeName': 'Philippe G', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'FACT, French Alliance for Cardiovascular Trials; Hôpital Bichat, AP-HP; Université Paris-Diderot; and INSERM U-1148, Paris, France.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Jüni', 'Affiliation': ""Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Valgimigli', 'Affiliation': 'Department of Cardiology, Bern University Hospital, Bern, Switzerland.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Windecker', 'Affiliation': 'Department of Cardiology, Bern University Hospital, Bern, Switzerland.'}, {'ForeName': 'Yoshinobu', 'Initials': 'Y', 'LastName': 'Onuma', 'Affiliation': 'Department of Cardiology, National University of Ireland Galway, Galway, Ireland.'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': 'Department of Cardiology, National University of Ireland Galway, Galway, Ireland.'}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.28649'] 105,31839571,"Effects of a high protein/low carbohydrate low-calorie diet versus a standard low-calorie diet on anthropometric parameters and cardiovascular risk factors, role of polymorphism rs3123554 in the cannabinoid receptor gene type 2 (CB2R).","BACKGROUND CB2R receptors has been referred to as the peripheral cannabinoid receptor isoform, and regulate inflammatory response in various settings. CB2R gene variants could play a role on metabolic changes after weight loss with different interventions. OBJECTIVE To assess the effect of the genetic variant (rs3123554) of the CB2R gene on anthropometric and biochemical changes after weight loss secondary to a high protein/low carbohydrate diet vs. a standard low-calorie diet during 9 months. DESIGN 268 obese subjects were randomly allocated to one of two diets for 9 months, Diet HP (high protein-low carbohydrate low-calorie diet) and Diet S (standard protein low-calorie diet). Biochemical and anthropometric parameters were measured at baseline and at 3 and 9 months. RESULTS Ninety-four patients (35.1%) had genotype GG and 174 (64.9%) subjects had the following genotypes; GA (115 patients, 42.9%) or AA (59 study subjects, 18.0%) (second group). After both diets, body mass index (BMI), fat mass, weight, waist circumference, and systolic blood pressure improved in both genotypes with no difference between diets. Before and after both low-calorie diets, body weight, BMI, fat mass, and waist circumference were higher in A allele carriers than in non-A allele carriers. After both diets (HP and S), levels of glucose, insulin, HOMA-IR, triglycerides, total cholesterol, and LDL cholesterol decreased in non-A allele carriers. These parameters remained unchanged in A allele carriers. Leptin levels decreased after HP and S diets in both genotypes. CONCLUSION Non-A allele carriers showed a better response of total cholesterol, LDL cholesterol, triglycerides, glucose, HOMA-IR, and insulin levels than allele A carriers with both low-calorie diets and with the same weight loss.",2020,"A allele carriers showed a better response of total cholesterol, LDL cholesterol, triglycerides, glucose, HOMA-IR, and insulin levels than allele A carriers with both low-calorie diets and with the same weight loss.",['268 obese subjects'],"['high protein/low carbohydrate diet vs. a standard low-calorie diet', 'Diet HP (high protein-low carbohydrate low-calorie diet) and Diet S (standard protein low-calorie diet', 'high protein/low carbohydrate low-calorie diet versus a standard low-calorie diet', 'genetic variant (rs3123554']","['Biochemical and anthropometric parameters', 'body mass index (BMI), fat mass, weight, waist circumference, and systolic blood pressure', 'total cholesterol, LDL cholesterol, triglycerides, glucose, HOMA-IR, and insulin levels', 'levels of glucose, insulin, HOMA-IR, triglycerides, total cholesterol, and LDL cholesterol', 'Leptin levels', 'body weight, BMI, fat mass, and waist circumference', 'anthropometric parameters and cardiovascular risk factors']","[{'cui': 'C4517673', 'cui_str': '268'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0259836', 'cui_str': 'Diet, Carbohydrate-Restricted'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2930544', 'cui_str': 'Low-Calorie Diet'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}]","[{'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",268.0,0.0171706,"A allele carriers showed a better response of total cholesterol, LDL cholesterol, triglycerides, glucose, HOMA-IR, and insulin levels than allele A carriers with both low-calorie diets and with the same weight loss.","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Primo', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición, Escuela de Medicina y Departamento dee Endocrinología y Nutrición, Hospital Clínico Universitario, Universidad de Valladolid, Valladolid, España.'}, {'ForeName': 'Olatz', 'Initials': 'O', 'LastName': 'Izaola', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición, Escuela de Medicina y Departamento dee Endocrinología y Nutrición, Hospital Clínico Universitario, Universidad de Valladolid, Valladolid, España.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'de Luis', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición, Escuela de Medicina y Departamento dee Endocrinología y Nutrición, Hospital Clínico Universitario, Universidad de Valladolid, Valladolid, España. Electronic address: dadluis@yahoo.es.'}]","Endocrinologia, diabetes y nutricion",['10.1016/j.endinu.2019.09.010'] 106,31219734,Treatment practices and lipid profile of patients with acute coronary syndrome: results from a tertiary care hospital.,"Background: Considering the increasing burden of cardiovascular risk factors and recent advances on the management of acute coronary syndromes (ACS), we studied the epidemiological characteristics and treatment strategies of patients presenting with ACS. We also evaluated the lipid profile and attainment of lipid goals in a 'real world' clinical setting. Methods: This was a substudy of IDEAL-LDL (Motivational interviewing to support low-density lipoprotein cholesterol (LDL-C) therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes), a single-centre, prospective, randomised controlled trial. Baseline data from a total of 357 ACS patients were gathered using standardised methods. Results: Median age of patients was 60 years and 81.2% were males. Arterial hypertension and smoking were the most prevalent risk factors for coronary artery disease (CAD). Patients with ST-elevation myocardial infarction (STEMI) were heavier smokers, but were younger and exercised more compared to those with non-ST-elevation acute coronary syndrome (NSTE-ACS). Conversely, more NSTE-ACS patients had arterial hypertension, dyslipidaemia and diabetes mellitus. One-fifth of ACS patients was treated conservatively without a percutaneous coronary intervention (PCI). A combination of statin, dual antiplatelet therapy and beta-blockers were prescribed to 79.6% of patients upon discharge. A renin-angiotensin-aldosterone system inhibitor and a beta-blocker were prescribed to 67.3 and 91.8% of patients with LVEF ≤40%, respectively. Of patients with prior history of CAD, 63.1%, 71.4% and 58.3% received regularly statins, antiplatelets and beta-blocker treatment, respectively. Only 22.3% of these CAD patients had an optimal LDL-C of <70 mg/dl at admission. Conclusions: In hospitalised patients with ACS, management practices differed by ACS type and discharge medication was, mostly, in line with the latest guidelines. However, medication adherence and lipid lowering goals of secondary CAD prevention were largely unachieved.",2020,Only 22.3% of these CAD patients had an optimal LDL-C of <70 mg/dl at admission. ,"['patients presenting with ACS', 'patients with acute coronary syndromes', 'Patients with ST-elevation myocardial infarction (STEMI) were heavier smokers', 'patients with acute coronary syndrome', 'hospitalised patients with ACS', 'Median age of patients was 60\xa0years and 81.2% were males', '357 ACS patients', 'acute coronary syndromes (ACS']","['percutaneous coronary intervention (PCI', 'statin, dual antiplatelet therapy and beta-blockers', 'LDL (Motivational interviewing to support low-density lipoprotein cholesterol (LDL-C) therapeutic goals and lipid-lowering therapy compliance']","['Arterial hypertension and smoking', 'ACS type and discharge medication', 'arterial hypertension, dyslipidaemia and diabetes mellitus', 'lipid profile and attainment of lipid goals']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0857118', 'cui_str': 'Heavy smoker'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0585943', 'cui_str': 'Lipid-lowering therapy (procedure)'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]","[{'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C1869029', 'cui_str': 'Dyslipidaemia (SMQ)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0018017', 'cui_str': 'Goals'}]",357.0,0.0374371,Only 22.3% of these CAD patients had an optimal LDL-C of <70 mg/dl at admission. ,"[{'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Farmakis', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Stefanos', 'Initials': 'S', 'LastName': 'Zafeiropoulos', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Anastasios', 'Initials': 'A', 'LastName': 'Kartas', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Aristi', 'Initials': 'A', 'LastName': 'Boulmpou', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Vasileios', 'Initials': 'V', 'LastName': 'Nevras', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Papadimitriou', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Athina', 'Initials': 'A', 'LastName': 'Tampaki', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Vlachou', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Eleftherios', 'Initials': 'E', 'LastName': 'Markidis', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Athanasios', 'Initials': 'A', 'LastName': 'Koutsakis', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Ziakas', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Haralambos', 'Initials': 'H', 'LastName': 'Karvounis', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Giannakoulas', 'Affiliation': 'Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}]",Acta cardiologica,['10.1080/00015385.2019.1626087'] 107,31782966,A randomized clinical trial of mobile phone motivational interviewing for alcohol use problems in Kenya.,"AIM To test the effectiveness of a motivational interviewing (MI) intervention using the mobile phone among adults with alcohol use problems. DESIGN A randomized clinical trial of mobile MI and standard in-person MI with 1- and 6-month follow-up, including a 1-month waitlist control followed by mobile MI. SETTING A primary health center in rural Kenya. PARTICIPANTS Three hundred adults screening positive for alcohol use problems were randomized and received immediate mobile MI (n = 89), in-person MI (n = 65) or delayed mobile MI (n = 76) for waiting-list controls 1 month after no treatment, with 70 unable to be reached for intervention. INTERVENTION AND COMPARATOR One MI session was provided either immediately by mobile phone, in-person at the health center or delayed by 1 month and then provided by mobile phone. MEASUREMENTS Alcohol use problems were repeatedly assessed using the Alcohol Use Disorder Identification Test (AUDIT) and the shorter AUDIT-C. The primary outcome was difference in alcohol score 1 month after no intervention for waiting-list control versus 1 month after MI for mobile MI. The secondary outcomes were difference in alcohol score for in-person MI versus mobile MI one and 6 months after MI. FINDINGS For our primary outcome, average AUDIT-C scores were nearly three points higher (difference = 2.88, 95% confidence interval = 2.11, 3.66) for waiting-list controls after 1 month of no intervention versus mobile MI 1 month after intervention. Results for secondary outcomes supported the null hypothesis of no difference between in-person and mobile MI at 1 month (Bayes factor = 0.22), but were inconclusive at 6 months (Bayes factor = 0.41). CONCLUSION Mobile phone-based motivational interviewing may be an effective treatment for alcohol use problems among adults visiting primary care in Kenya. Providing mobile motivational interviewing may help clinicians in rural areas to reach patients needing treatment for alcohol use problems.",2020,"CONCLUSION Mobile phone-based motivational interviewing may be an effective treatment for alcohol use problems among adults visiting primary care in Kenya.","['adults visiting primary care in Kenya', 'Three hundred adults screening positive for alcohol use problems', 'A primary health center in rural Kenya', 'adults with alcohol use problems', 'Alcohol Use Problems in Kenya']","['Mobile Phone Motivational Interviewing', 'mobile motivational interviewing', 'mobile MI and standard in-person MI with 1- and 6-month follow-up, including a one-month waitlist control followed by mobile MI', 'Mobile phone-based motivational interviewing', 'motivational interviewing (MI) intervention', 'immediate mobile MI (n=89), in-person MI (n=65), or delayed mobile MI']","['null hypothesis of no difference between in-person and mobile MI', 'alcohol score for in-person MI vs. mobile MI one and six months after MI', 'alcohol score', 'average AUDIT-C scores', 'Alcohol Use Disorder Identification Test (AUDIT) and the shorter AUDIT-C']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}]","[{'cui': 'C1136360', 'cui_str': 'Mobile Phone'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4082115', 'cui_str': 'One month (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}]","[{'cui': 'C0456148', 'cui_str': 'Null (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test (assessment scale)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}]",300.0,0.0830683,"CONCLUSION Mobile phone-based motivational interviewing may be an effective treatment for alcohol use problems among adults visiting primary care in Kenya.","[{'ForeName': 'Valerie S', 'Initials': 'VS', 'LastName': 'Harder', 'Affiliation': 'Departments of Pediatrics and Psychiatry, University of Vermont, Burlington, VT, USA.'}, {'ForeName': 'Abednego M', 'Initials': 'AM', 'LastName': 'Musau', 'Affiliation': 'Africa Mental Health Foundation, Nairobi, Kenya.'}, {'ForeName': 'Christine W', 'Initials': 'CW', 'LastName': 'Musyimi', 'Affiliation': 'Africa Mental Health Foundation, Nairobi, Kenya.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Ndetei', 'Affiliation': 'Africa Mental Health Foundation, Nairobi, Kenya.'}, {'ForeName': 'Victoria N', 'Initials': 'VN', 'LastName': 'Mutiso', 'Affiliation': 'Africa Mental Health Foundation, Nairobi, Kenya.'}]","Addiction (Abingdon, England)",['10.1111/add.14903'] 108,31056541,The role of the family in early intervention of preterm infants with abnormal general movements.,"OBJECTIVE To determine the effect of family-based intervention on motor function in preterm infants. METHODS This study was designed as a randomized controlled trial between August 2015 and September 2016. Forty-two preterm infants were randomized and split equally between the family-based intervention group, composed of a physiotherapeutic and a familial component (8 males, 8 females; mean age 91+/-3.09 days), and the traditional early intervention group (8 females, 8 males, mean age: 91.06+/-2.4 days). Both groups received a treatment program based on a neurodevelopmental approach during 3- to 12-months-old. The groups were evaluated at corrected ages of the third, sixth, ninth, twelfth, and 24th months using the Bayley Scale of Infant and Toddler Development, Third Edition (Bayley-III). RESULTS Within-group changes over time were statistically significant using multivariate tests of fine motor (Multivariate analysis of variance (MANOVA); F=1515.27, p less than 0.001) and gross motor (MANOVA; F=1950.59, p=0.001) development. However, there was no interaction between groups in fine (MANOVA; F=0.027, p=0.872) and gross motor development (MANOVA; F=0.022, p=0.883). CONCLUSION The early intervention approaches might support fine and gross motor function development in preterm infants in the first year of life.",2019,"However, there was no interaction between groups in fine (MANOVA; F=0.027, p=0.872) and gross motor development (MANOVA; F=0.022, p=0.883). ","['8 males, 8 females; mean age 91+/-3.09 days), and the traditional early intervention group (8 females, 8 males, mean age: 91.06+/-2.4 days', 'preterm infants in the first year of life', 'preterm infants with abnormal general movements', 'August 2015 and September 2016', 'preterm infants', 'Forty-two preterm infants']","['physiotherapeutic and a familial component', 'family-based intervention']",['motor function'],"[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0242687', 'cui_str': 'Early Intervention'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517631', 'cui_str': '2.4 (qualifier value)'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C4319566', 'cui_str': 'Forty-two'}]","[{'cui': 'C1611743', 'cui_str': 'Familial (FPAH)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}]",42.0,0.0405678,"However, there was no interaction between groups in fine (MANOVA; F=0.027, p=0.872) and gross motor development (MANOVA; F=0.022, p=0.883). ","[{'ForeName': 'Ozgun K', 'Initials': 'OK', 'LastName': 'Kara', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Hacettepe University, Ankara, Turkey. E-mail: ozgun_kaya@yahoo.com.'}, {'ForeName': 'Sedef', 'Initials': 'S', 'LastName': 'Sahin', 'Affiliation': ''}, {'ForeName': 'Bilge N', 'Initials': 'BN', 'LastName': 'Yardimci', 'Affiliation': ''}, {'ForeName': 'Akmer', 'Initials': 'A', 'LastName': 'Mutlu', 'Affiliation': ''}]","Neurosciences (Riyadh, Saudi Arabia)",['10.17712/nsj.2019.2.20180001'] 109,31121030,Physical Exercise Training Effect and Mediation Through Cardiorespiratory Fitness on Dual-Task Performances Differ in Younger-Old and Older-Old Adults.,"OBJECTIVE It has often been reported that dual-task (DT) performance declines with age. Physical exercise can help improve cognition, but these improvements could depend on cognitive functions and age groups. Moreover, the mechanisms supporting this enhancement are not fully elucidated. This study investigated the impacts of physical exercise on single- and dual-task performance in younger-old (<70) and older-old (70+) adults. The study also assessed whether the training effect on cognition was mediated by improvement in cardiorespiratory fitness. METHODS One hundred forty-three participants (65-89 years) took part in a physical exercise intervention for 3 months or were assigned to a control group. All participants completed a DT paradigm and an estimated measure of cardiorespiratory fitness. Regression models were used to test the training effect on these outcomes, and mediation analyses were used to determine whether the training-related cognitive changes were mediated by changes in cardiorespiratory fitness. RESULTS In 70+, training predicted improved processing speed (βc = -.33) and cardiorespiratory fitness (βa = .26) and the effect of training on processing speed was fully mediated by change in cardiorespiratory fitness (βab = -.12). In <70, training predicted improvement in task-set cost (βc = -.26) and change in cardiorespiratory fitness (βa = .30) but improvement in task-set cost was not entirely mediated by change in cardiorespiratory fitness. DISCUSSION Results are discussed in terms of the mechanisms supporting DT performance improvement following physical exercise training in older adults.",2021,"In 70+, training predicted improved processing speed (βc = - .33) and cardiorespiratory fitness (βa = .26) and the effect of training on processing speed was fully mediated by change in cardiorespiratory fitness (βab = -.12).","['younger-old and older-old adults', 'One-hundred forty-three participants (65 to 89 years) took part in a', 'younger-old (<70) and older-old (70+) adults']","['physical exercise', 'physical exercise intervention', 'Physical exercise training', 'Physical exercise']","['cardiorespiratory fitness', 'dual-task performances', 'task-set cost', 'processing speed (βc = - .33) and cardiorespiratory fitness']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001795', 'cui_str': 'Oldest Old'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0450368', 'cui_str': '43 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0582591', 'cui_str': 'Processing speed (observable entity)'}]",143.0,0.0164943,"In 70+, training predicted improved processing speed (βc = - .33) and cardiorespiratory fitness (βa = .26) and the effect of training on processing speed was fully mediated by change in cardiorespiratory fitness (βab = -.12).","[{'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Bherer', 'Affiliation': 'Department of Medicine, University of Montreal, Canada.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Langeard', 'Affiliation': 'Department of Medicine, University of Montreal, Canada.'}, {'ForeName': 'Navin', 'Initials': 'N', 'LastName': 'Kaushal', 'Affiliation': 'Department of Medicine, University of Montreal, Canada.'}, {'ForeName': 'Tudor', 'Initials': 'T', 'LastName': 'Vrinceanu', 'Affiliation': 'Department of Medicine, University of Montreal, Canada.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Desjardins-Crépeau', 'Affiliation': 'Research Centre, Montreal Heart Institute, Canada.'}, {'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Langlois', 'Affiliation': ""CIUSSS de l'Estrie, Centre Hospitalier Universitaire de Sherbrooke, Canada.""}, {'ForeName': 'Arthur F', 'Initials': 'AF', 'LastName': 'Kramer', 'Affiliation': 'Beckman Institute, University of Illinois, Urbana-Champaign, Illinois.'}]","The journals of gerontology. Series B, Psychological sciences and social sciences",['10.1093/geronb/gbz066'] 110,31892497,Evaluation of the Relationship Between the Required Pressure Level in Continuous Positive Airway Pressure Treatment and Voice in Patients With Obstructive Sleep Apnea Syndrome.,"OBJECTIVE The aim of this study was to investigate the effect of obstructive sleep apnea syndrome on voice, the relationship between the required pressure levels in continuous positive airway pressure (CPAP) and voice, and the effects of CPAP therapy on voice. MATERIAL AND METHODS A total of 73 subjects consisting of 53 patients and 20 control subjects were included in the study. The patient group was further divided into low- (Group A) and high- (Group B) pressure groups according to the required pressure level. All subjects underwent acoustic sound analysis to evaluate fundamental frequency (F0), jitter, shimmer, and noise-to-harmonics ratio (NHR). Acoustic voice analysis was repeated after 3 months of regular CPAP treatment in the patient group. The mean F0, jitter, shimmer, and NHR values of the patient group and control group were compared. Intergroup comparisons were also performed between Group A and the control group, and between Group B and the control group. Finally, before and after CPAP treatment values of mean F0, jitter, shimmer, and NHR were compared in Group A and Group B. RESULTS The mean shimmer and NHR values of the patient group were significantly higher than the control group (P = 0.01 and P = 0.023, respectively). The mean shimmer and NHR values of Group B were statistically higher than the control group (P = 0.002 and P < 0.001, respectively). The mean jitter, shimmer, and NHR values after CPAP treatment were significantly lower than those measured before CPAP treatment in Group B (P = 0.003, P = 0.001, and P = 0.001, respectively). CONCLUSION Voice is negatively affected in obstructive sleep apnea syndrome patients who require high pressure in CPAP treatment. CPAP treatment leads to improved voice in these patients.",2021,"The mean jitter, shimmer, and NHR values after CPAP treatment were significantly lower than those measured before CPAP treatment in Group B (P = 0.003, P = 0.001, and P = 0.001, respectively). ","['73 subjects consisting of 53 patients and 20 control subjects', 'Patients With Obstructive Sleep Apnea Syndrome', 'obstructive sleep apnea syndrome patients who require high pressure in CPAP treatment']","['CPAP therapy', 'CPAP', 'high- (Group B', 'Continuous Positive Airway Pressure Treatment and Voice']","['mean jitter, shimmer, and NHR values', 'mean F0, jitter, shimmer, and NHR', 'Acoustic voice analysis', 'mean F0, jitter, shimmer, and NHR values', 'mean shimmer and NHR values', 'fundamental frequency (F0), jitter, shimmer, and noise-to-harmonics ratio (NHR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C0042939', 'cui_str': 'Voice'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0001166', 'cui_str': 'Acoustics'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",73.0,0.0240367,"The mean jitter, shimmer, and NHR values after CPAP treatment were significantly lower than those measured before CPAP treatment in Group B (P = 0.003, P = 0.001, and P = 0.001, respectively). ","[{'ForeName': 'Süleyman Emre', 'Initials': 'SE', 'LastName': 'Karakurt', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Health Sciences University, Ankara Numune Training and Research Hospital, Ankara, Turkey. Electronic address: suleymanemrekarakurt@gmail.com.'}, {'ForeName': 'Mehmet Fatih', 'Initials': 'MF', 'LastName': 'Karakuş', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Health Sciences University, Ankara Numune Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Fakih Cihat', 'Initials': 'FC', 'LastName': 'Eravcı', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Health Sciences University, Ankara Numune Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Nurcan', 'Initials': 'N', 'LastName': 'Kum', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Health Sciences University, Ankara Numune Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Müge', 'Initials': 'M', 'LastName': 'Özcan', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Health Sciences University, Ankara Numune Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Kürşat Murat', 'Initials': 'KM', 'LastName': 'Özcan', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Health Sciences University, Ankara Numune Training and Research Hospital, Ankara, Turkey.'}]",Journal of voice : official journal of the Voice Foundation,['10.1016/j.jvoice.2019.12.007'] 111,31223067,"The relation between mortality salience, traffic locus of control, and risky driving behavior.","This study evaluated the direct relationships between mortality salience (MS), traffic locus of control (T-LOC), and risky driving behavior. The sample included 170 drivers. They completed scales measuring T-LOC, then they were randomly divided into one of the three condition groups: MS condition, traffic accidents MS condition, and the control condition. At the end, the participants completed a scale for measuring risky driving behavior. The results showed that MS interacts with the relevance of driving for self-esteem and with external T-LOC in determining risky driving. The implications of these results for safety and future research are discussed.",2021,The results showed that MS interacts with the relevance of driving for self-esteem and with external T-LOC in determining risky driving.,['The sample included 170 drivers'],[],"['mortality salience, traffic locus of control, and risky driving behavior', 'risky driving behavior', 'mortality salience (MS), traffic locus of control (T-LOC), and risky driving behavior']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4517599', 'cui_str': 'One hundred and seventy'}]",[],"[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0023953', 'cui_str': 'Locus of Control'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}]",170.0,0.0113052,The results showed that MS interacts with the relevance of driving for self-esteem and with external T-LOC in determining risky driving.,"[{'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Măirean', 'Affiliation': 'Faculty of Psychology and Educational Sciences, Alexandru Ioan Cuza University, Iasi, Romania.'}, {'ForeName': 'Corneliu-Eugen', 'Initials': 'CE', 'LastName': 'Havârneanu', 'Affiliation': 'Faculty of Psychology and Educational Sciences, Alexandru Ioan Cuza University, Iasi, Romania.'}]",Death studies,['10.1080/07481187.2019.1626935'] 112,31786954,"The association between trunk muscle endurance, balance and falls self-efficacy in women with osteoporotic vertebral fractures: an exploratory analysis from a pilot randomized controlled trial.","BACKGROUND Trunk muscle endurance may be associated with balance and falls self-efficacy for people with osteoporosis. However, all previous studies have examined trunk muscle strength rather than endurance. PURPOSE To explore the relationships between trunk muscle endurance and standing balance and falls self-efficacy for women with vertebral fractures. MATERIALS AND METHODS This is an exploratory, secondary analysis of baseline data of a pilot randomized controlled trial in Ontario, Canada. Thirty-one women with osteoporosis, aged 65 years or older, with at least one vertebral fracture were included. The associations between balance (Balance Outcome Measure for Elder Rehabilitation) and trunk muscle endurance (Timed Loaded Standing Test) and falls self-efficacy (Falls Efficacy Scale International) and trunk muscle endurance were tested via Spearman rank order correlation with Fisher's z transformations. RESULTS Trunk muscle endurance was correlated with better balance performance on the Balance Outcome Measure for Elder Rehabilitation [Spearman correlation coefficient, 0.71; 95% confidence interval: 0.47-0.85; p  < 0.001], but not with falls self efficacy (Spearman correlation coefficient; -0.22; 95% confidence interval: -0.53 to 0.14; p  = 0.23). CONCLUSIONS Trunk muscle endurance was moderately associated with better standing balance performance but not falls self-efficacy, highlighting the importance of trunk muscle endurance for standing balance for older adults with osteoporosis and vertebral fractures.Implications for RehabilitationOlder adults with osteoporosis and vertebral fractures who have better trunk muscle endurance may also have better standing balance.There was no association between trunk muscle endurance and how confident a person is that they will not fall while completing various activities of daily living.Trunk muscle endurance training could be included as part of a standing balance rehabilitation program for this population.",2021,There was no association between trunk muscle endurance and how confident a person is that they will not fall while completing various activities of daily living.,"['Thirty-one women with osteoporosis, aged 65\u2009years or older, with at least one vertebral fracture were included', 'women with osteoporotic vertebral fractures', 'people with osteoporosis', 'RehabilitationOlder adults with osteoporosis and vertebral fractures', 'women with vertebral fractures', 'older adults with osteoporosis and vertebral fractures']","['Trunk muscle endurance training', 'trunk muscle endurance']","['Trunk muscle endurance', 'standing balance performance', 'trunk muscle endurance, balance and falls self-efficacy', 'balance (Balance Outcome Measure for Elder Rehabilitation) and trunk muscle endurance (Timed Loaded Standing Test) and falls self-efficacy (Falls Efficacy Scale International) and trunk muscle endurance']","[{'cui': 'C0450355', 'cui_str': '31 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0080179', 'cui_str': 'Spinal Fractures'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}]","[{'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0331055', 'cui_str': 'Elder Plant'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0222045'}]",31.0,0.0545822,There was no association between trunk muscle endurance and how confident a person is that they will not fall while completing various activities of daily living.,"[{'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'McArthur', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Jenna C', 'Initials': 'JC', 'LastName': 'Gibbs', 'Affiliation': 'Department of Kinesiology and Physical Activity, McGill University, Montreal, Canada.'}, {'ForeName': 'Maureen C', 'Initials': 'MC', 'LastName': 'Ashe', 'Affiliation': 'Department of Family Medicine, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Cheung', 'Affiliation': 'Department of Medicine, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Keith D', 'Initials': 'KD', 'LastName': 'Hill', 'Affiliation': 'Department of Rehabilitation, Ageing and Independent Living, Curtin University, Victoria, Australia.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Kendler', 'Affiliation': 'Department of Medicine, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Aliya', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Sadhana', 'Initials': 'S', 'LastName': 'Prasad', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Canada.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Wark', 'Affiliation': 'Department of Medicine, University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Lora M', 'Initials': 'LM', 'LastName': 'Giangregorio', 'Affiliation': 'Department of Kinesiology, University of Waterloo, Waterloo, Canada.'}]",Disability and rehabilitation,['10.1080/09638288.2019.1696418'] 113,31204839,Therapist-assisted online treatment for child conduct problems in rural and urban families: Two randomized controlled trials.,"OBJECTIVE We examined the relative efficacy of an online versus face-to-face (FTF) parenting intervention for reducing the severity of child conduct problems and related parent and child outcomes in 2 randomized controlled trials. METHOD In Study 1, rural families ( n = 133) with a child 3-9 years of age with a full or subclinical primary diagnosis of oppositional defiant or conduct disorder traveled to Sydney, Australia for a comprehensive assessment and randomization to receive either AccessEI, a 6-10 week online therapist-assisted parenting program, or FTF treatment, whereby they received the same program presented FTF during a 1-week treatment. To control for unavoidable treatment dosage differences in the first study, Study 2 was conducted in which urban families ( n = 73) with a child aged 3 to 14 years meeting similar criteria as Study 1 were randomized to receive AccessEI versus FTF treatment. RESULTS In both studies, improvements in severity of child diagnoses and maternal measures of child behavior showed very large effect sizes for both treatments at posttreatment and 3-month follow-up and did not differ across treatment conditions. There were moderate effect sizes for improvements in parent mental health and no differences across treatment conditions. CONCLUSIONS It is concluded that the effects of the therapist-assisted online parenting interventions for the treatment of child conduct problems were similar to a FTF intervention, providing evidence for the effectiveness of an accessible treatment for rural and remote families. (PsycINFO Database Record (c) 2019 APA, all rights reserved).",2019,"It is concluded that the effects of the therapist-assisted online parenting interventions for the treatment of child conduct problems were similar to a FTF intervention, providing evidence for the effectiveness of an accessible treatment for rural and remote families.","['rural families ( n = 133) with a child 3-9 years of age with a full or subclinical primary diagnosis of oppositional defiant or conduct disorder traveled to Sydney, Australia for a comprehensive assessment and randomization to receive either AccessEI, a 6-10 week', 'urban families ( n = 73) with a child aged 3 to 14 years meeting similar criteria as Study 1', 'child conduct problems in rural and urban families']","['Therapist-assisted online treatment', 'online versus face-to-face (FTF) parenting intervention', 'FTF treatment', 'online therapist-assisted parenting program, or FTF treatment, whereby they received the same program presented FTF', 'therapist-assisted online parenting interventions']","['severity of child diagnoses and maternal measures of child behavior', 'parent mental health']","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205211', 'cui_str': 'Subclinical (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0860661', 'cui_str': 'Oppositional'}, {'cui': 'C0149654', 'cui_str': 'Conduct Disorder'}, {'cui': 'C0040802', 'cui_str': 'Travel (event)'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}]","[{'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]","[{'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0008065', 'cui_str': 'Child Behavior'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",,0.122302,"It is concluded that the effects of the therapist-assisted online parenting interventions for the treatment of child conduct problems were similar to a FTF intervention, providing evidence for the effectiveness of an accessible treatment for rural and remote families.","[{'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Dadds', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Thai', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Mendoza Diaz', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Broderick', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Moul', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'Lucy A', 'Initials': 'LA', 'LastName': 'Tully', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Hawes', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Davies', 'Affiliation': 'Royal Far West.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Burchfield', 'Affiliation': 'Royal Far West.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Cane', 'Affiliation': 'Royal Far West.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000419'] 114,31841037,Combining transcutaneous electrical nerve stimulation with therapeutic exercise to reduce pain in an elderly population: a pilot study.,"PURPOSE Chronic pain is a highly prevalent and debilitating condition, and there is a pressing need to find safe, effective and affordable treatments to tackle this public health issue. This pilot study aimed to assess whether therapeutic exercises supplemented by transcutaneous electrical nerve stimulation induces a greater hypoalgesic effect than therapeutic exercises supplemented by sham transcutaneous electrical nerve stimulation, in an elderly population suffering from chronic pain. MATERIALS AND METHODS Eighteen elderly participants suffering from chronic pain completed a therapeutic exercise program consisting of 45-min group sessions administered twice a week for 4 weeks. Half of the participants received real transcutaneous electrical nerve stimulation during the exercise sessions, while the others received sham transcutaneous electrical nerve stimulation. Participants completed pain questionnaires (McGill Pain Questionnaire, Brief Pain Inventory, Beck Depression Index) before and after the intervention, and recorded their pain levels on an 11-point numerical rating scale before and after each session (Clinical Trial.Gov ID: NCT02445677). RESULTS AND CONCLUSION Our results suggest that supplementing exercise sessions with transcutaneous electrical nerve stimulation does not improve the long-term outcomes of elderly patients suffering from chronic pain, but does induce short-term hypoalgesia during exercise sessions. Our study also offers valuable guidelines for the implementation of a future and adequately powered study looking at this research question.Implications for rehabilitationThe application of transcutaneous electrical nerve stimulation during exercises is well tolerated by elderly individuals suffering from chronic pain.Supplementing exercises with transcutaneous electrical nerve stimulation does not seem to improve general outcome in elderly suffering from chronic pain.Notwithstanding, the addition of transcutaneous electrical nerve stimulation tends to produce a marked hypoalgesic effect during the exercise sessions, an effect that could prompt indirect benefits for pain patients.",2021,"Participants completed pain questionnaires (McGill Pain Questionnaire, Brief Pain Inventory, Beck Depression Index) before and after the intervention, and recorded their pain levels on an 11-point numerical rating scale before and after each session (Clinical Trial.","['elderly patients suffering from chronic pain', 'elderly population', 'elderly individuals suffering from chronic pain', 'pain patients', 'elderly suffering from chronic pain', 'elderly population suffering from chronic pain', 'Eighteen elderly participants suffering from chronic pain completed a']","['Supplementing exercises with transcutaneous electrical nerve stimulation', 'therapeutic exercises supplemented by transcutaneous electrical nerve stimulation', 'therapeutic exercises supplemented by sham transcutaneous electrical nerve stimulation', 'transcutaneous electrical nerve stimulation with therapeutic exercise', 'therapeutic exercise program consisting of 45-min group sessions', 'transcutaneous electrical nerve stimulation during exercises', 'supplementing exercise sessions with transcutaneous electrical nerve stimulation', 'real transcutaneous electrical nerve stimulation during the exercise sessions, while the others received sham transcutaneous electrical nerve stimulation']","['pain questionnaires (McGill Pain Questionnaire, Brief Pain Inventory, Beck Depression Index', 'pain']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0040654', 'cui_str': 'Electric Stimulation, Transcutaneous'}, {'cui': 'C0452240', 'cui_str': 'Rehabilitation Exercise'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0587107', 'cui_str': 'During exercise (qualifier value)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0024985', 'cui_str': 'McGill Pain Questionnaire'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",18.0,0.0320347,"Participants completed pain questionnaires (McGill Pain Questionnaire, Brief Pain Inventory, Beck Depression Index) before and after the intervention, and recorded their pain levels on an 11-point numerical rating scale before and after each session (Clinical Trial.","[{'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Vaillancourt', 'Affiliation': 'School of Rehabilitation, Université de Sherbrooke, Sherbrooke, Canada.'}, {'ForeName': 'Alexia', 'Initials': 'A', 'LastName': 'Coulombe-Lévêque', 'Affiliation': 'School of Rehabilitation, Université de Sherbrooke, Sherbrooke, Canada.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Fradette', 'Affiliation': 'School of Rehabilitation, Université de Sherbrooke, Sherbrooke, Canada.'}, {'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Martel', 'Affiliation': 'School of Rehabilitation, Université de Sherbrooke, Sherbrooke, Canada.'}, {'ForeName': 'Wafaa', 'Initials': 'W', 'LastName': 'Naour', 'Affiliation': 'School of Rehabilitation, Université de Sherbrooke, Sherbrooke, Canada.'}, {'ForeName': 'Rubens A', 'Initials': 'RA', 'LastName': 'da Silva', 'Affiliation': 'Health Sciences Department, CUpht and LabBioNR, Université du Québec à Chicoutimi, Chicoutimi, Canada.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Léonard', 'Affiliation': 'School of Rehabilitation, Université de Sherbrooke, Sherbrooke, Canada.'}]",Disability and rehabilitation,['10.1080/09638288.2019.1693639'] 115,31227390,Impact of Adrenal Hormone Supplementation on Bone Geometry in Growing Teens With Anorexia Nervosa.,"PURPOSE Adolescents with anorexia nervosa (AN) have decreased dehydroepiandrosterone (DHEA) and estrogen concentrations that may contribute to skeletal deficits. We sought to determine whether DHEA + estrogen replacement (ERT) prevented bone loss in young adolescents with AN. METHODS We recruited females with AN (n = 70, ages 11-18 years) into a 12-month, randomized, double-blind placebo-controlled trial. Participants were randomized to oral micronized DHEA 50 mg + 20 mcg ethinyl estradiol/.1 mg levonorgestrel daily (n = 35) or placebo (n = 35). Outcomes included serial measures of bone mineral density (BMD) by dual-energy X-ray absorptiometry (total body, hip, spine) and peripheral quantitative computed tomography (pQCT; tibia). Magnetic resonance imaging of T1-weighted images of the left knee determined physeal status (open/closed). RESULTS Sixty-two subjects completed the trial. Physeal closure status was the strongest predictor of aBMD changes. Among girls with open physes, those who received DHEA + ERT showed a decline in BMD Z-scores compared with those receiving placebo, whereas there was no effect in those with at least one closed physis. Treatment did not affect any pQCT measures, regardless of physeal closure status. CONCLUSIONS Combined DHEA + ERT did not significantly improve dual-energy X-ray absorptiometry or pQCT BMD measurements in young adolescent girls with AN, in contrast to an earlier trial showing benefit in older adolescents and young women. In girls with open physes, the mean change in the placebo arm was greater than that of the DHEA + ERT group. We conclude that DHEA + ERT is ineffective for preserving bone health in growing young adolescents with AN at the dose and route of administration described in this report.",2019,"Combined DHEA + ERT did not significantly improve dual-energy X-ray absorptiometry or pQCT BMD measurements in young adolescent girls with AN, in contrast to an earlier trial showing benefit in older adolescents and young women.","['Sixty-two subjects completed the trial', 'Growing Teens With Anorexia Nervosa', 'young adolescent girls', 'Adolescents with anorexia nervosa (AN', 'older adolescents and young women', 'young adolescents with AN.\nMETHODS\n\n\nWe recruited females with AN (n\xa0= 70, ages 11-18\xa0years']","['ethinyl estradiol/.1\xa0mg levonorgestrel', 'placebo', 'DHEA\xa0+\xa0ERT', 'oral micronized DHEA 50\xa0mg\xa0', 'Combined DHEA\xa0+ ERT', 'Adrenal Hormone Supplementation', 'DHEA\xa0+ estrogen replacement (ERT']","['BMD Z-scores', 'pQCT measures, regardless of physeal closure status', 'bone loss', 'dual-energy X-ray absorptiometry or pQCT BMD measurements', 'serial measures of bone mineral density (BMD) by dual-energy X-ray absorptiometry (total body, hip, spine) and peripheral quantitative computed tomography (pQCT; tibia']","[{'cui': 'C4517835', 'cui_str': '62 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1521910', 'cui_str': 'Teens'}, {'cui': 'C0003125', 'cui_str': 'Anorexia Nervosas'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0023566', 'cui_str': 'Levonorgestrel'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1445654', 'cui_str': 'Adrenal hormone agent'}, {'cui': 'C0086258', 'cui_str': 'Estrogen Replacements'}]","[{'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0037949', 'cui_str': 'Spinal Column'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C0040184', 'cui_str': 'Tibia'}]",,0.498502,"Combined DHEA + ERT did not significantly improve dual-energy X-ray absorptiometry or pQCT BMD measurements in young adolescent girls with AN, in contrast to an earlier trial showing benefit in older adolescents and young women.","[{'ForeName': 'Amy D', 'Initials': 'AD', 'LastName': 'DiVasta', 'Affiliation': ""Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts; Division of Gynecology, Boston Children's Hospital, Boston, Massachusetts. Electronic address: amy.divasta@childrens.harvard.edu.""}, {'ForeName': 'Henry A', 'Initials': 'HA', 'LastName': 'Feldman', 'Affiliation': ""Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts; Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': ""O'Donnell"", 'Affiliation': 'Rutgers-Robert Wood Johnson Medical School, Piscataway, New Jersey.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Long', 'Affiliation': 'Division of Pediatric Nephrology, Stanford University School of Medicine, Palo Alto, California.'}, {'ForeName': 'Mary B', 'Initials': 'MB', 'LastName': 'Leonard', 'Affiliation': 'Division of Pediatric Nephrology, Stanford University School of Medicine, Palo Alto, California.'}, {'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Gordon', 'Affiliation': ""Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts; Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts.""}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2019.04.003'] 116,31790343,"Detecting noncredible performance with the neuropsychological assessment battery, screening module: A simulation study.","OBJECTIVE While the Neuropsychological Assessment Battery, Screening Module (S-NAB) is a commonly used cognitive screening measure, no composite embedded performance validity test (PVT) formula has yet been described within it. This study sought to empirically derive PVT formulas within the S-NAB using an analog simulation paradigm. METHOD Seventy-two university students ( M age = 18.92) were randomly assigned to either an Asymptomatic (AS) or simulated mild traumatic brain injury (S-mTBI) group and were administered a neuropsychological test battery that included the S-NAB and standalone and embedded PVTs. The AS group was instructed to perform optimally, and the S-mTBI group received symptom and test coaching to help simulate mTBI-related impairment. Both groups received warnings regarding the presence of PVTs throughout the test battery. RESULTS Groups showed significant differences (all p s < .001) on all S-NAB domain scores and PVTs. In the S-NAB, the Attention (S-ATT) and Executive Function (S-EXE) domains showed the largest effect sizes (Cohen's d s = 2.02 and 1.79, respectively). Seven raw scores from S-ATT and S-EXE subtests were entered as predictor variables in a direct logistic regression (LR). The model accurately classified 90.3% of cases. Two PVT formulas were described: (1) an exponentiated equation from LR results and (2) an arithmetic formula using four individually meaningful variables. Both formulas demonstrated outstanding discriminability between groups (AUCs = .96-.97) and yielded good classification statistics compared to other PVTs. CONCLUSIONS This study is the first to describe composite, embedded PVT formulas within the S-NAB. Implications, limitations, and appropriate future directions of inquiry are discussed.",2021,Groups showed significant differences (all p s < .001) on all S-NAB domain scores and PVTs.,['Method: Seventy-two university students ( M age\u2009=\u200918.92'],"['neuropsychological assessment battery, screening module', 'Asymptomatic (AS) or simulated mild traumatic brain injury (S-mTBI) group and were administered a neuropsychological test battery that included the S-NAB and standalone and embedded PVTs']",[],"[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0542351', 'cui_str': 'Battery (event)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C3508472', 'cui_str': 'Mild Traumatic Brain Injury'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychologic Tests'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]",[],7.0,0.0306443,Groups showed significant differences (all p s < .001) on all S-NAB domain scores and PVTs.,"[{'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Lace', 'Affiliation': 'Department of Psychology, Saint Louis University, St. Louis, MO, USA.'}, {'ForeName': 'Alex F', 'Initials': 'AF', 'LastName': 'Grant', 'Affiliation': 'Department of Psychology, Saint Louis University, St. Louis, MO, USA.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Ruppert', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO, USA.'}, {'ForeName': 'David A S', 'Initials': 'DAS', 'LastName': 'Kaufman', 'Affiliation': 'Department of Psychology, Saint Louis University, St. Louis, MO, USA.'}, {'ForeName': 'Carson L', 'Initials': 'CL', 'LastName': 'Teague', 'Affiliation': 'Department of Psychology, Saint Louis University, St. Louis, MO, USA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Lowell', 'Affiliation': 'Department of Psychology, Saint Louis University, St. Louis, MO, USA.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Gfeller', 'Affiliation': 'Department of Psychology, Saint Louis University, St. Louis, MO, USA.'}]",The Clinical neuropsychologist,['10.1080/13854046.2019.1694703'] 117,31181022,Cold Vibration (Buzzy) Versus Anesthetic Patch (EMLA) for Pain Prevention During Cannulation in Children: A Randomized Trial.,"INTRODUCTION The purpose of this study was to assess differences in observed pain-related behaviors during cannulation between a device combining cold and vibration (Buzzy) and the standard care (EMLA patch). METHODS Patients 18 months to 6 years old, requiring venous access in a pediatric emergency department, received either the Buzzy device or the EMLA patch. Predefined week randomization ensured equal allocation to the 2 intervention groups. Pain during cannulation was measured using the Children's Hospital of Eastern Ontario Pain Scale. Parent and nurse reports, cannulation success, and venous access times were also assessed. RESULTS In total, 607 included patients were randomized into the Buzzy group (n = 302) or the EMLA group (n = 305). Observed pain-related behaviors scores, parent-assessed pain scores, and nurse-reported pain ratings were higher with Buzzy. CONCLUSIONS Pain relief by a combination of cold and vibration during cannulation is not as effective as the standard-care method in children 18 months to 6 years old.",2021,"Observed pain-related behaviors scores, parent-assessed pain scores, and nurse-reported pain ratings were higher with Buzzy. ","['Children', 'Patients 18 months to 6 years old, requiring venous access in a pediatric emergency department, received either the']","['device combining cold and vibration (Buzzy) and the standard care (EMLA patch', 'Cold Vibration (Buzzy) Versus Anesthetic Patch (EMLA', 'EMLA', 'Buzzy device or the EMLA patch', 'Buzzy']","['cannulation success, and venous access times', 'Observed pain-related behaviors scores, parent-assessed pain scores, and nurse-reported pain ratings', 'Pain', ""Children's Hospital of Eastern Ontario Pain Scale"", 'Pain Prevention']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0059079', 'cui_str': 'EMLA'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C0002930', 'cui_str': 'Anesthesiology'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C3875135', 'cui_str': 'Observes (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}]",607.0,0.052218,"Observed pain-related behaviors scores, parent-assessed pain scores, and nurse-reported pain ratings were higher with Buzzy. ","[{'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Bourdier', 'Affiliation': 'From the CHU Clermont-Ferrand, Urgences Pédiatriques, Hôpital Estaing.'}, {'ForeName': 'Nedjoua', 'Initials': 'N', 'LastName': 'Khelif', 'Affiliation': 'From the CHU Clermont-Ferrand, Urgences Pédiatriques, Hôpital Estaing.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Velasquez', 'Affiliation': 'From the CHU Clermont-Ferrand, Urgences Pédiatriques, Hôpital Estaing.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Usclade', 'Affiliation': ''}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Rochette', 'Affiliation': ''}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Pereira', 'Affiliation': 'CHU Clermont-Ferrand, Biostatistics Unit, Délégation Recherche Clinique et Innovation, Clermont-Ferrand, France.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Favard', 'Affiliation': 'CHU Clermont-Ferrand, Pédiatrie, Hôpital Estaing.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Merlin', 'Affiliation': ''}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Labbé', 'Affiliation': 'From the CHU Clermont-Ferrand, Urgences Pédiatriques, Hôpital Estaing.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Sarret', 'Affiliation': 'From the CHU Clermont-Ferrand, Urgences Pédiatriques, Hôpital Estaing.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Michaud', 'Affiliation': 'From the CHU Clermont-Ferrand, Urgences Pédiatriques, Hôpital Estaing.'}]",Pediatric emergency care,['10.1097/PEC.0000000000001867'] 118,31883294,Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study.,"BACKGROUND Residual stent strut thrombosis after primary percutaneous coronary intervention (PCI), negatively affects myocardial perfusion, may increase stent thrombosis risk, and it is associated with neointima hyperplasia at follow-up. OBJECTIVES To study the effectiveness of any bivalirudin infusion versus unfractionated heparin (UFH) infusion in reducing residual stent strut thrombosis in patients with ST-elevation myocardial infarction (STEMI). METHODS Multi-vessel STEMI patients undergoing primary PCI and requiring staged intervention were selected among those randomly allocated to two different bivalirudin infusion regimens in the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) Treatment-Duration study. Those receiving heparin only were enrolled into a registry arm. Optical coherence tomography (OCT) of the infarct-related artery was performed at the end of primary PCI and 3-5 days thereafter during a staged intervention. The primary endpoint was the change in minimum flow area (ΔMinFA) defined as (stent area + incomplete stent apposition [ISA] area) - (intraluminal defect + tissue prolapsed area) between the index and staged PCI. RESULTS 123 patients in bivalirudin arm and 28 patients in the UFH arm were included. Mean stent area, percentage of malapposed struts, and mean percent thrombotic area were comparable after index or staged PCI. The ΔMinFA in the bivalirudin group was 0.25 versus 0.05 mm 2 in the UFH group, which resulted in a between-group significant difference of 0.36 [95% CI: (0.05, 0.71); p = .02]. This was mostly related to a decrease in tissue protrusion in the bivalirudin group (p = .03). There was a trend towards more patients in the bivalirudin group who achieved a 5% difference in the percentage of OCT frames with the area >5% (p = .057). CONCLUSIONS The administration of bivalirudin after primary PCI significantly reduces residual stent strut thrombosis when compared to UFH. This observation should be considered hypothesis-generating since the heparin-treated patients were not randomly allocated.",2020,This was mostly related to a decrease in tissue protrusion in the bivalirudin group (p = .03).,"['Multi-vessel STEMI patients undergoing primary PCI and requiring staged intervention', '123 patients in bivalirudin arm and 28 patients in the UFH arm were included', 'patients with ST-elevation myocardial infarction (STEMI', 'patients with ST-segment elevation myocardial infarction undergoing']","['bivalirudin infusion regimens in the MATRIX', 'bivalirudin', 'bivalirudin infusion versus unfractionated heparin (UFH) infusion', 'bivalirudin versus unfractionated heparin infusion', 'heparin']","['change in minimum flow area (ΔMinFA) defined as (stent area\u2009+\u2009incomplete stent apposition [ISA] area)\u2009-\u2009(intraluminal defect\u2009+\u2009tissue prolapsed area) between the index and staged PCI', 'tissue protrusion', 'Optical coherence tomography (OCT', 'percentage of OCT frames', 'Mean stent area, percentage of malapposed struts, and mean percent thrombotic area', 'residual stent strut thrombosis']","[{'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0168273', 'cui_str': 'bivalirudin'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0168273', 'cui_str': 'bivalirudin'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C4319583', 'cui_str': 'Matrix'}, {'cui': 'C0019134', 'cui_str': 'heparin'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C1443259', 'cui_str': 'Incomplete stent apposition'}, {'cui': 'C0442115', 'cui_str': 'Intraluminal (qualifier value)'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0333056', 'cui_str': 'Protrusion (morphologic abnormality)'}, {'cui': 'C0920367', 'cui_str': 'Tomography, Optical Coherence'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0441295', 'cui_str': 'Strut (physical object)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}]",123.0,0.116703,This was mostly related to a decrease in tissue protrusion in the bivalirudin group (p = .03).,"[{'ForeName': 'Hector M', 'Initials': 'HM', 'LastName': 'Garcia-Garcia', 'Affiliation': 'MedStar Washington Hospital Center, Washington, District of Columbia.'}, {'ForeName': 'Marianna', 'Initials': 'M', 'LastName': 'Adamo', 'Affiliation': 'Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Cardio-Thoracic Department, Civil Hospitals, Brescia, Italy.'}, {'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Soud', 'Affiliation': 'Rutgers New Jersey Medical School, Newark, New Jersey.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Yacob', 'Affiliation': 'MedStar Washington Hospital Center, Washington, District of Columbia.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Picchi', 'Affiliation': 'Cardiovascular and Neurologic Department, Misericordia Hospital, Grosseto, Italy.'}, {'ForeName': 'Gennaro', 'Initials': 'G', 'LastName': 'Sardella', 'Affiliation': 'Department of Cardiology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Frigoli', 'Affiliation': 'Clinical Trials Unit, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Ugo', 'Initials': 'U', 'LastName': 'Limbruno', 'Affiliation': 'Cardiovascular and Neurologic Department, Misericordia Hospital, Grosseto, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Rigattieri', 'Affiliation': ""Division of Cardiology, Sant'Andrea Hospital, Rome, Italy.""}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Diletti', 'Affiliation': 'Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Boccuzzi', 'Affiliation': 'Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Zimarino', 'Affiliation': 'Institute of Cardiology ""G. d\'Annunzio"" University, Chieti, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Contarini', 'Affiliation': 'Interventional Cardiology Unit Umberto I Hospital, Syracuse, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Russo', 'Affiliation': 'Interventional Cardiology Unit, Cardio-thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Calabrò', 'Affiliation': 'Division of Cardiology, Department of Cardiothoracic and Respiratory Sciences, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Andò', 'Affiliation': 'Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.'}, {'ForeName': 'Ferdinando', 'Initials': 'F', 'LastName': 'Varbella', 'Affiliation': 'Cardiology Unit, Ospedali Riuniti di Rivoli, Turin, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Garducci', 'Affiliation': ""Unita' Operativa Complessa di Cardiologia ASST di Vimercate (MB), Vimercate, Italy.""}, {'ForeName': 'Cataldo', 'Initials': 'C', 'LastName': 'Palmieri', 'Affiliation': 'Fondazione Toscana G. Monasterio - Ospedale del Cuore G. Pasquinucci, Pisa/Massa, Massa, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Briguori', 'Affiliation': 'Department of Cardiology, Interventional Cardiology, Mediterranea Cardiocentro, Naples, Italy.'}, {'ForeName': 'Alexios', 'Initials': 'A', 'LastName': 'Karagiannis', 'Affiliation': 'Clinical Trials Unit, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Valgimigli', 'Affiliation': 'Swiss Cardiovascular Center Bern, University of Bern, Bern, Switzerland.'}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.28661'] 119,31256309,Detection of gastric inflation using transesophageal echocardiography after different level of pressure-controlled mask ventilation: a prospective randomized trial.,"This study aimed to assess the technique of using transesophageal echocardiography (TEE) to detect gastric inflation and to determine the optimal level of inspiratory pressure during face mask ventilation (FMV). In this prospective and randomized trial, seventy-five adults scheduled for cardiac surgery were enrolled to one of the three groups (P 12 , P 15 , P 20 ) defined by the applied inspiratory pressure during FMV. After induction, mask ventilation was performed with the corresponding level of pressure-control ventilation for 2 min in each patient. Respiratory and hemodynamic parameters were recorded every 15 s. Arterial blood gases were tested before induction and at the time of intubation. Gastric cross-section area was detected using transesophageal echocardiography after intubation. The gastric cross-section areas were 3.1 ± 0.81, 3.8 ± 1.37 and 4.8 ± 2.29 cm 2 respectively. It statistically increased in group P 20 compared with group P 12 and P 15 . PaCO 2 before intubation statistically increased compared with the baseline in groups P 12 and P 15 , while decreased in group P 20 . The mean values of PaCO 2 equaled to 44.4 mmHg (40-51.5), 42.9 mmHg (34-50.5) and 36.9 mmHg (30.9-46) respectively in three groups. Peak airway pressure of 12-20 cmH 2 O could provide acceptable sufficient ventilation during mask ventilation, but 20 cmH 2 O result in higher incidence of gastric inflation. TEE is useful to detect the gastric inflation related to the entry of air into the stomach during pressure-controlled face mask ventilation.Trial Registration Number ChiCTR-IOR-14005325.",2020,"It statistically increased in group P 20 compared with group P 12 and P 15 . PaCO 2 before intubation statistically increased compared with the baseline in groups P 12 and P 15 , while decreased in group P 20 .",['seventy-five adults scheduled for cardiac surgery'],"['inspiratory pressure during face mask ventilation (FMV', 'transesophageal echocardiography after different level of pressure-controlled mask ventilation', 'TEE', 'transesophageal echocardiography (TEE']","['Respiratory and hemodynamic parameters', 'mean values of PaCO', 'Peak airway pressure', 'Gastric cross-section area']","[{'cui': 'C4319621', 'cui_str': 'Seventy-five'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}]","[{'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0180823', 'cui_str': 'Face mask (physical object)'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0206054', 'cui_str': 'Echocardiography, Transesophageal'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0024861', 'cui_str': 'Masks'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}]",75.0,0.0248302,"It statistically increased in group P 20 compared with group P 12 and P 15 . PaCO 2 before intubation statistically increased compared with the baseline in groups P 12 and P 15 , while decreased in group P 20 .","[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zeng', 'Affiliation': 'Department of Anesthesiology, West China Hospital, Sichuan University, 37# GuoXue Xiang, Chengdu, 610041, Sichuan, China.'}, {'ForeName': 'Zhi-Jie', 'Initials': 'ZJ', 'LastName': 'Jia', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of XinXiang Medical University, Henan, 453100, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Peng', 'Affiliation': 'Department of Anesthesiology, West China Hospital, Sichuan University, 37# GuoXue Xiang, Chengdu, 610041, Sichuan, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wei', 'Affiliation': 'Department of Anesthesiology, West China Hospital, Sichuan University, 37# GuoXue Xiang, Chengdu, 610041, Sichuan, China. weiw@scu.edu.cn.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-019-00340-w'] 120,31867778,A randomized controlled trial on the effectiveness of a portable patient education video prior to coronary angiography and angioplasty.,"INTRODUCTION Time limitations in busy clinical settings may impede adequate explanation of coronary angiography/angioplasty. We aim to evaluate the effectiveness of a portable patient education video in improving knowledge and allaying patient's anxiety. METHODS Consecutive patients undergoing coronary angiography/angioplasty were prospectively recruited over 1 year from a tertiary cardiac institution. A 3-min animated patient education video on the procedure was developed to be shown on a tablet. Patients were randomized 3:1 into an intervention group (video plus routine care) versus a control group (routine care). Before the procedure, a self-administered questionnaire was conducted in both groups. The questionnaire was repeated post-video in the intervention group. RESULTS A total of 332 patients (252 intervention groups, 80 controls) were recruited. At baseline, the intervention group had lower knowledge scores (p = .022) and similar anxiety scores (p = .323) compared with the control group. After the video, the intervention group had significantly higher knowledge scores (p ≤ .001) and lower anxiety scores (p ≤ .001). Within the intervention group, there was a significant increase in knowledge scores (p ≤ .001) and reduction in anxiety scores (p ≤ .001) before versus after watching the video. In the subset of patients who had previously undergone a similar procedure (n = 131), there was also significant improvement in knowledge scores and reduction in anxiety scores (p < .001). The video is accessible at https://youtu.be/R8AdaIbNq7Y. CONCLUSION The video improved knowledge and reduced anxiety in patients undergoing coronary angiography and angioplasty. This is a useful adjunct to incorporate into existing workflows to improve patient care.",2020,"After the video, the intervention group had significantly higher knowledge scores (p ≤ .001) and lower anxiety scores (p ≤ .001).","['patients undergoing coronary angiography and angioplasty', '332 patients (252 intervention groups, 80 controls) were recruited', 'Consecutive patients undergoing coronary angiography/angioplasty were prospectively recruited over 1 year from a tertiary cardiac institution']","['intervention group (video plus routine care) versus a control group (routine care', 'portable patient education video', 'portable patient education video prior to coronary angiography and angioplasty']","['similar anxiety scores', 'knowledge scores', 'knowledge scores and reduction in anxiety scores', 'anxiety scores', 'knowledge and reduced anxiety', 'lower anxiety scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085532', 'cui_str': 'Angiography of coronary arteries'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0085532', 'cui_str': 'Angiography of coronary arteries'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]",332.0,0.0621266,"After the video, the intervention group had significantly higher knowledge scores (p ≤ .001) and lower anxiety scores (p ≤ .001).","[{'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Yap', 'Affiliation': 'National Heart Center Singapore, Singapore.'}, {'ForeName': 'Tse Y', 'Initials': 'TY', 'LastName': 'Teo', 'Affiliation': 'National Heart Center Singapore, Singapore.'}, {'ForeName': 'Priscilla', 'Initials': 'P', 'LastName': 'Foong', 'Affiliation': 'National Heart Center Singapore, Singapore.'}, {'ForeName': 'Norwati', 'Initials': 'N', 'LastName': 'Binte Hussin', 'Affiliation': 'National Heart Center Singapore, Singapore.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'National Heart Center Singapore, Singapore.'}, {'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Shen', 'Affiliation': 'National Heart Center Singapore, Singapore.'}, {'ForeName': 'Khung K', 'Initials': 'KK', 'LastName': 'Yeo', 'Affiliation': 'National Heart Center Singapore, Singapore.'}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.28655'] 121,31756300,Efficacy of custom-fitted footwear to increase physical activity in children and adolescents with Down syndrome (ShoeFIT): randomised pilot study.,"PURPOSE To determine the feasibility of conducting a definitive randomised trial to evaluate the efficacy of custom-fitted footwear for increasing physical activity in children and adolescents with Down syndrome. METHODS Assessor-blinded, parallel-group randomised pilot study. Thirty-three children and adolescents with Down syndrome were randomly allocated to a custom-fitted footwear group (Clarks ® footwear) or a wait-list control group. Six feasibility domains were evaluated at baseline, 6 and 12 weeks; demand (recruitment), implementation (co-interventions and adherence), acceptability, practicality (adverse events), limited efficacy testing (physical activity, disability associated with foot and ankle problems, and gait parameters), and adaptation (shoe-fit). RESULTS Three participants were recruited per month. The use of co-interventions was common with six control group participants purchasing new footwear during the study. Mean adherence was 35 h/week in the custom-fitted footwear group, and there were few minor adverse events. There were trends for differences in physical activity favouring the custom-fitted footwear, but no trends for differences in disability associated with foot and ankle problems or gait parameters. The fit of the custom-fitted footwear was no better than participants' regular footwear. CONCLUSIONS A definitive randomised trial is feasible. However, recruitment, use of co-interventions and footwear fit need further consideration.Implications for rehabilitationConducting a definitive randomised trial to determine the efficacy of custom-fitted footwear in increasing physical activity in children and adolescents with Down syndrome is feasible.Custom-fitted footwear may improve physical activity in children and adolescents with Down syndrome.Commercially available footwear may not be suitable for children and adolescents with Down syndrome due to their unique foot shape.",2021,"There were trends for differences in physical activity favouring the custom-fitted footwear, but no trends for differences in disability associated with foot and ankle problems or gait parameters.","['Thirty-three children and adolescents with Down syndrome', 'children and adolescents with Down syndrome', 'children and adolescents with Down syndrome (ShoeFIT']","['custom-fitted footwear', 'custom-fitted footwear group (Clarks ® footwear) or a wait-list control group']","['demand (recruitment), implementation (co-interventions and adherence), acceptability, practicality (adverse events), limited efficacy testing (physical activity, disability associated with foot and ankle problems, and gait parameters), and adaptation (shoe-fit', 'physical activity', 'Mean adherence']","[{'cui': 'C0450358', 'cui_str': '33 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0013080', 'cui_str': '47,XY,+21'}]","[{'cui': 'C0162343', 'cui_str': 'Customs'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0336894', 'cui_str': 'Footwear (physical object)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0016504', 'cui_str': 'Foot'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}, {'cui': 'C0185506', 'cui_str': 'Shoeing'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",33.0,0.120227,"There were trends for differences in physical activity favouring the custom-fitted footwear, but no trends for differences in disability associated with foot and ankle problems or gait parameters.","[{'ForeName': 'Nirmeen M', 'Initials': 'NM', 'LastName': 'Hassan', 'Affiliation': 'Discipline of Podiatry, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Shields', 'Affiliation': 'Living with Disability Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Karl B', 'Initials': 'KB', 'LastName': 'Landorf', 'Affiliation': 'Discipline of Podiatry, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Andrew K', 'Initials': 'AK', 'LastName': 'Buldt', 'Affiliation': 'Discipline of Podiatry, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Nicholas F', 'Initials': 'NF', 'LastName': 'Taylor', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Evans', 'Affiliation': 'Discipline of Podiatry, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Cylie M', 'Initials': 'CM', 'LastName': 'Williams', 'Affiliation': 'Physiotherapy Department, School of Primary and Allied Health Care, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Hylton B', 'Initials': 'HB', 'LastName': 'Menz', 'Affiliation': 'Discipline of Podiatry, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Shannon E', 'Initials': 'SE', 'LastName': 'Munteanu', 'Affiliation': 'Discipline of Podiatry, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.'}]",Disability and rehabilitation,['10.1080/09638288.2019.1692380'] 122,30930133,"Regular insulin added to total parenteral nutrition vs subcutaneous glargine in non-critically ill diabetic inpatients, a multicenter randomized clinical trial: INSUPAR trial.","BACKGROUND There is no established insulin regimen in T2DM patients receiving parenteral nutrition. AIMS To compare the effectiveness (metabolic control) and safety of two insulin regimens in patients with diabetes receiving TPN. DESIGN Prospective, open-label, multicenter, clinical trial on adult inpatients with type 2 diabetes on a non-critical setting with indication for TPN. Patients were randomized on one of these two regimens: 100% of RI on TPN or 50% of Regular insulin added to TPN bag and 50% subcutaneous GI. Data were analyzed according to intention-to-treat principle. RESULTS 81 patients were on RI and 80 on GI. No differences were observed in neither average total daily dose of insulin, programmed or correction, nor in capillary mean blood glucose during TPN infusion (165.3 ± 35.4 in RI vs 172.5 ± 43.6 mg/dL in GI; p = 0.25). Mean capillary glucose was significantly lower in the GI group within two days after TPN interruption (160.3 ± 45.1 in RI vs 141.7 ± 43.8 mg/dL in GI; p = 0.024). The percentage of capillary glucose above 180 mg/dL was similar in both groups. The rate of capillary glucose ≤70 mg/dL, the number of hypoglycemic episodes per 100 days of TPN, and the percentage of patients with non-severe hypoglycemia were significantly higher on GI group. No severe hypoglycemia was detected. No differences were observed in length of stay, infectious complications, or hospital mortality. CONCLUSION Effectiveness of both regimens was similar. GI group achieved better metabolic control after TPN interruption but non-severe hypoglycemia rate was higher in the GI group. CLINICAL TRIAL REGISTRY This trial is registered at clinicaltrials.gov as NCT02706119.",2020,"No differences were observed in neither average total daily dose of insulin, programmed or correction, nor in capillary mean blood glucose during TPN infusion (165.3 ± 35.4 in RI vs 172.5 ± 43.6 mg/dL in GI; p = 0.25).","['T2DM patients receiving parenteral nutrition', '81 patients were on RI and 80 on GI', 'non-critically ill diabetic inpatients', 'patients with diabetes receiving TPN', 'adult inpatients with type 2 diabetes on a non-critical setting with indication for TPN']","['Regular insulin added to total parenteral nutrition vs subcutaneous glargine', 'RI on TPN or 50% of Regular insulin added to TPN bag and 50% subcutaneous GI']","['percentage of capillary glucose', 'number of hypoglycemic episodes', 'average total daily dose of insulin, programmed or correction, nor in capillary mean blood glucose', 'rate of capillary glucose', 'percentage of patients with non-severe hypoglycemia', 'metabolic control', 'severe hypoglycemia', 'severe hypoglycemia rate', 'Mean capillary glucose', 'length of stay, infectious complications, or hospital mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030547', 'cui_str': 'Parenteral Nutrition'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0030548', 'cui_str': 'Parenteral Hyperalimentation'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin, Regular'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0030548', 'cui_str': 'Parenteral Hyperalimentation'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C1706249', 'cui_str': 'Bag - unit of product usage (qualifier value)'}]","[{'cui': 'C0006901', 'cui_str': 'Capillaries'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0745153', 'cui_str': 'Hypoglycemic attack'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}]",81.0,0.0732609,"No differences were observed in neither average total daily dose of insulin, programmed or correction, nor in capillary mean blood glucose during TPN infusion (165.3 ± 35.4 in RI vs 172.5 ± 43.6 mg/dL in GI; p = 0.25).","[{'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Olveira', 'Affiliation': 'Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Spain; Universidad de Málaga, Spain; CIBERDEM (CB07/08/0019), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: gabrielm.olveira.sspa@juntadeandalucia.es.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Abuín', 'Affiliation': 'Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Spain; Universidad de Málaga, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'López', 'Affiliation': ""Servicio de Endocrinología y Nutrición, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain.""}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Herranz', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario de Guadalajara, Guadalajara, Spain.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'García-Almeida', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'García-Malpartida', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario y Politécnico La Fe, Valencia, Spain.'}, {'ForeName': 'Mercedes', 'Initials': 'M', 'LastName': 'Ferrer', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Cancer', 'Affiliation': 'Sección de Endocrinología y Nutrición, Hospital Universitario de Fuenlabrada, Madrid, Spain.'}, {'ForeName': 'Luis M', 'Initials': 'LM', 'LastName': 'Luengo-Pérez', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario de Badajoz, Badajoz, Spain.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Álvarez', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario Príncipe de Asturias, Madrid, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Aragón', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.'}, {'ForeName': 'María J', 'Initials': 'MJ', 'LastName': 'Ocón', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario Lozano Blesa, Zaragoza, Spain.'}, {'ForeName': 'Álvaro', 'Initials': 'Á', 'LastName': 'García-Manzanares', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital General La Mancha Centro, Alcázar de San Juan, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Bretón', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario Gregorio Marañón, Madrid, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Serrano-Aguayo', 'Affiliation': 'Unidad de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Pérez-Ferre', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Juan J', 'Initials': 'JJ', 'LastName': 'López-Gómez', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.'}, {'ForeName': 'Josefina', 'Initials': 'J', 'LastName': 'Olivares', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario Son Llatzer, Illes Balears, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Arraiza', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Complejo Hospitalario de Jaén, Jaén, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Tejera', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain.'}, {'ForeName': 'Jorge D', 'Initials': 'JD', 'LastName': 'Martín', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'García', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Complejo Asistencial Universitario de León, León, Spain.'}, {'ForeName': 'Ángel L', 'Initials': 'ÁL', 'LastName': 'Abad', 'Affiliation': 'Unidad de Nutrición - Sección de Endocrinología, Hospital General Universitario de Alicante, Alicante, Spain.'}, {'ForeName': 'María R', 'Initials': 'MR', 'LastName': 'Alhambra', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital Universitario Reina Sofía, Córdoba, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Zugasti', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Complejo Hospitalario de Navarra, Navarra, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Parra', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital de Mérida, Badajoz, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Torrejón', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain.'}, {'ForeName': 'María J', 'Initials': 'MJ', 'LastName': 'Tapia', 'Affiliation': 'Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Spain.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.02.036'] 123,31793231,Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects.,"Rezafungin is a new echinocandin in development for treatment of candidemia and invasive candidiasis, and for prophylaxis of invasive fungal infections. Rezafungin is the first echinocandin to undergo definitive QT/QTc study. This phase 1, single-center, randomized, double-blind trial was conducted to assess effects of intravenous rezafungin vs intravenous placebo (with moxifloxacin as positive control) on the QT interval of the electrocardiogram, corrected for heart rate by Fridericia's formula (QTcF), in healthy adults. Therapeutic (600 mg) and supratherapeutic (1400 mg) rezafungin doses were selected to achieve exposures 2.5-fold higher than produced by the highest dose used in a phase 2 trial (400 mg once weekly). The primary end point was change in QTcF from baseline (ΔQTcF) as a function of plasma concentration, assessed by comparing upper bounds of the 2-sided 90% confidence interval. The estimated mean ΔΔQTcF at the mean plasma concentrations for the rezafungin doses had upper bounds <10 milliseconds, within the upper bound of the 2-sided 90% confidence interval. Intravenous rezafungin up to 1400 mg in a single dose did not prolong QT interval and had no apparent effect on repolarization or QRS duration. Electrocardiogram results showed no clinically significant effects of concern. These findings support the continued development of rezafungin.",2020,Intravenous rezafungin up to 1400 mg in a single dose did not prolong QT interval and had no apparent effect on repolarization or QRS duration.,"['Healthy Subjects', 'healthy adults']","['Intravenous rezafungin', 'Rezafungin', 'rezafungin vs intravenous placebo (with moxifloxacin', 'supratherapeutic (1400\xa0mg) rezafungin']","['mean plasma concentrations', 'QT interval', 'change in QTcF from baseline (ΔQTcF) as a function of plasma concentration', 'repolarization or QRS duration']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]",,0.104894,Intravenous rezafungin up to 1400 mg in a single dose did not prolong QT interval and had no apparent effect on repolarization or QRS duration.,"[{'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Flanagan', 'Affiliation': 'Cidara Therapeutics Inc., San Diego, California, USA.'}, {'ForeName': 'Daniel B', 'Initials': 'DB', 'LastName': 'Goodman', 'Affiliation': 'BioTelemetry Research, Rockville, Maryland, USA.'}, {'ForeName': 'Alena', 'Initials': 'A', 'LastName': 'Jandourek', 'Affiliation': 'Cidara Therapeutics Inc., San Diego, California, USA.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': ""O'Reilly"", 'Affiliation': 'Celerion, Inc., Tempe, Arizona, USA.'}, {'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Sandison', 'Affiliation': 'Cidara Therapeutics Inc., San Diego, California, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.757'] 124,31713464,Shifting Maladaptive Fall Risk Appraisal in Older Adults through an in-Home Physio-fEedback and Exercise pRogram (PEER): A Pilot Study.,"OBJECTIVES 1) examine the preliminary effectiveness of the P hysio-fe E dback and E xercise p R ogram (PEER) for shifting maladaptive to adaptive fall risk appraisal and reducing fall risk, 2) determine the participants' feedback and acceptability of the program. METHODS Forty-one older adults were assigned to either PEER intervention or attention control group. The 8-week PEER intervention consists of a visual physio-feedback, cognitive reframing, and combined group and home-based exercise led by a trained peer coach. The attention control group read fall prevention brochures and continued their normal activities. BTrackS Balance Test (BBT), short version of Fall Efficacy Scale International (short FES-I) and CDC fall risk checklist were measured from pre- to post-intervention. The feedback and acceptability were conducted at the program conclusion. RESULTS About 11% of participants in the PEER group had positive shifting but none in the attention control group. Up to 32% of the participants in attention control had negative shifting compared to 5.3% in the PEER group. PEER group reported significant decreases in fall risk and high acceptability of the program. CONCLUSIONS PEER intervention facilitates a shift from maladaptive to adaptive fall risk appraisal and reduces fall risk. CLINICAL IMPLICATIONS Preventive interventions promoting alignment between perceive and physiological fall risk may contribute to reducing falls and increasing exercise adherence.",2020,Up to 32% of the participants in attention control had negative shifting compared to 5.3% in the PEER group.,"['Older Adults', 'Forty-one older adults']","['Exercise pRogram (PEER', 'PEER intervention consists of a visual physio-feedback, cognitive reframing, and combined group and home-based exercise led by a trained peer coach', 'P hysio-fe E dback and E xercise p R ogram (PEER', 'PEER intervention or attention control group']","['negative shifting', 'feedback and acceptability', 'fall risk and high acceptability', 'BTrackS Balance Test (BBT), short version of Fall Efficacy Scale International (short FES-I) and CDC fall risk checklist']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1268740', 'cui_str': 'Fall risk'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0222045'}, {'cui': 'C0674267', 'cui_str': 'greigite'}, {'cui': 'C0007670', 'cui_str': 'CDC'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}]",41.0,0.0181214,Up to 32% of the participants in attention control had negative shifting compared to 5.3% in the PEER group.,"[{'ForeName': 'Ladda', 'Initials': 'L', 'LastName': 'Thiamwong', 'Affiliation': 'College of Nursing, University of Central Florida , Orlando, Florida, USA.'}, {'ForeName': 'Helen J', 'Initials': 'HJ', 'LastName': 'Huang', 'Affiliation': 'Disability, Aging, and Technology Cluster, University of Central Florida , Orlando, Florida, USA.'}, {'ForeName': 'Boon Peng', 'Initials': 'BP', 'LastName': 'Ng', 'Affiliation': 'College of Nursing, University of Central Florida , Orlando, Florida, USA.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Yan', 'Affiliation': 'Department of Statistics and Data Science, College of Science, University of Central Florida , Orlando, Florida, USA.'}, {'ForeName': 'Mary Lou', 'Initials': 'ML', 'LastName': 'Sole', 'Affiliation': 'College of Nursing, University of Central Florida , Orlando, Florida, USA.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Stout', 'Affiliation': 'School of Kinesiology and Physical Therapy, College of Health Professions and Sciences, University of Central Florida , Orlando, Florida, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Talbert', 'Affiliation': 'College of Nursing, University of Central Florida , Orlando, Florida, USA.'}]",Clinical gerontologist,['10.1080/07317115.2019.1692120'] 125,26087985,The Good School Toolkit for reducing physical violence from school staff to primary school students: a cluster-randomised controlled trial in Uganda.,"BACKGROUND Violence against children from school staff is widespread in various settings, but few interventions address this. We tested whether the Good School Toolkit-a complex behavioural intervention designed by Ugandan not-for-profit organisation Raising Voices-could reduce physical violence from school staff to Ugandan primary school children. METHODS We randomly selected 42 primary schools (clusters) from 151 schools in Luwero District, Uganda, with more than 40 primary 5 students and no existing governance interventions. All schools agreed to be enrolled. All students in primary 5, 6, and 7 (approximate ages 11-14 years) and all staff members who spoke either English or Luganda and could provide informed consent were eligible for participation in cross-sectional baseline and endline surveys in June-July 2012 and 2014, respectively. We randomly assigned 21 schools to receive the Good School Toolkit and 21 to a waitlisted control group in September, 2012. The intervention was implemented from September, 2012, to April, 2014. Owing to the nature of the intervention, it was not possible to mask assignment. The primary outcome, assessed in 2014, was past week physical violence from school staff, measured by students' self-reports using the International Society for the Prevention of Child Abuse and Neglect Child Abuse Screening Tool-Child Institutional. Analyses were by intention to treat, and are adjusted for clustering within schools and for baseline school-level means of continuous outcomes. The trial is registered at clinicaltrials.gov, NCT01678846. FINDINGS No schools left the study. At 18-month follow-up, 3820 (92·4%) of 4138 randomly sampled students participated in a cross-sectional survey. Prevalence of past week physical violence was lower in the intervention schools (595/1921, 31·0%) than in the control schools (924/1899, 48·7%; odds ratio 0·40, 95% CI 0·26-0·64, p<0·0001). No adverse events related to the intervention were detected, but 434 children were referred to child protective services because of what they disclosed in the follow-up survey. INTERPRETATION The Good School Toolkit is an effective intervention to reduce violence against children from school staff in Ugandan primary schools. FUNDING MRC, DfID, Wellcome Trust, Hewlett Foundation.",2015,"Prevalence of past week physical violence was lower in the intervention schools (595/1921, 31·0%) than in the control schools (924/1899, 48·7%; odds ratio 0·40, 95% CI 0·26-0·64, p<0·0001).","['primary school students', 'Ugandan primary school children', 'All students in primary 5, 6, and 7 (approximate ages 11-14 years) and all staff members who spoke either English or Luganda and could provide informed consent were eligible for participation in cross-sectional baseline and endline surveys in June-July 2012 and 2014, respectively', '4138 randomly sampled students participated in a cross-sectional survey', 'violence against children from school staff in Ugandan primary schools', '42 primary schools (clusters) from 151 schools in Luwero District, Uganda, with more than 40 primary 5 students and no existing governance interventions', 'Violence against children from school staff', '434 children']","['Good School Toolkit', 'Good School Toolkit-a complex behavioural intervention designed by Ugandan not-for-profit organisation Raising Voices']","[""physical violence from school staff, measured by students' self-reports using the International Society for the Prevention of Child Abuse and Neglect Child Abuse Screening Tool-Child Institutional"", 'Prevalence of past week physical violence', 'physical violence']","[{'cui': 'C0033145', 'cui_str': 'Primary Schools'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0241520', 'cui_str': 'Ugandans (ethnic group)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205155', 'cui_str': 'Sectional (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0010362', 'cui_str': 'Disease Frequency Surveys'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0041573', 'cui_str': 'Republic of Uganda'}]","[{'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0241520', 'cui_str': 'Ugandans (ethnic group)'}, {'cui': 'C0029237', 'cui_str': 'Organization (morphologic abnormality)'}, {'cui': 'C0042939', 'cui_str': 'Voice'}]","[{'cui': 'C0476480', 'cui_str': 'Physical violence'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0008060', 'cui_str': 'Child Maltreatment'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]",4138.0,0.0363562,"Prevalence of past week physical violence was lower in the intervention schools (595/1921, 31·0%) than in the control schools (924/1899, 48·7%; odds ratio 0·40, 95% CI 0·26-0·64, p<0·0001).","[{'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Devries', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK. Electronic address: karen.devries@lshtm.ac.uk.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Knight', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Child', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Angel', 'Initials': 'A', 'LastName': 'Mirembe', 'Affiliation': 'Raising Voices, Kampala, Uganda.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Nakuti', 'Affiliation': 'Raising Voices, Kampala, Uganda.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Sturgess', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Allen', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Nambusi', 'Initials': 'N', 'LastName': 'Kyegombe', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Parkes', 'Affiliation': 'Institute of Education, University College London, London, UK.'}, {'ForeName': 'Eddy', 'Initials': 'E', 'LastName': 'Walakira', 'Affiliation': 'Makerere University, Kampala, Uganda.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Elbourne', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Watts', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Dipak', 'Initials': 'D', 'LastName': 'Naker', 'Affiliation': 'Raising Voices, Kampala, Uganda.'}]",The Lancet. Global health,['10.1016/S2214-109X(15)00060-1'] 126,30912222,"Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.","OBJECTIVE The efficacy and safety of lurasidone in schizophrenia has been demonstrated in multiple controlled trials, primarily in US and European populations. The aim of the current study was To evaluate lurasidone for the treatment of schizophrenia among patients in Japan, Korea, and Taiwan. METHODS Hospitalized patients (N = 460) with schizophrenia were randomized to 6 weeks of fixed-dose lurasidone 40 mg/d, lurasidone 80 mg/d, risperidone 4 mg/d, or placebo. Efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). RESULTS No significant endpoint differences in PANSS total score were found for lurasidone or risperidone vs placebo. Lurasidone was safe and well tolerated, with minimal effects on weight and metabolic parameters. DISCUSSION The current study was inconclusive regarding the efficacy of lurasidone in schizophrenia but further confirmed its safety and tolerability.",2019,No significant endpoint differences in PANSS total score were found for lurasidone or risperidone vs placebo.,"['schizophrenia', 'schizophrenia among patients in Japan, Korea, and Taiwan', 'Hospitalized patients (N\xa0=\xa0460) with schizophrenia']","['placebo', 'Lurasidone', 'lurasidone', 'risperidone', 'placebo, and risperidone', 'lurasidone 40\xa0mg/d, lurasidone 80\xa0mg']","['Efficacy', 'safe and well tolerated', 'safety and tolerability', 'Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S', 'PANSS total score', 'weight and metabolic parameters']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0022771', 'cui_str': 'Korea'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2003424', 'cui_str': 'lurasidone'}, {'cui': 'C0073393', 'cui_str': 'Risperidone'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",460.0,0.095896,No significant endpoint differences in PANSS total score were found for lurasidone or risperidone vs placebo.,"[{'ForeName': 'Teruhiko', 'Initials': 'T', 'LastName': 'Higuchi', 'Affiliation': 'Japan Depression Center, Tokyo, Japan.'}, {'ForeName': 'Masaomi', 'Initials': 'M', 'LastName': 'Iyo', 'Affiliation': 'Department of Psychiatry, National University Corporation Chiba University, Chiba, Japan.'}, {'ForeName': 'Jun Soo', 'Initials': 'JS', 'LastName': 'Kwon', 'Affiliation': 'Department of Psychiatry, College of Medicine, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Yuan-Hwa', 'Initials': 'YH', 'LastName': 'Chou', 'Affiliation': 'Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Hsing-Kang', 'Initials': 'HK', 'LastName': 'Chen', 'Affiliation': 'Department of General Psychiatry, Yu-Li Hospital, Hualien, Taiwan.'}, {'ForeName': 'Jen-Yeu', 'Initials': 'JY', 'LastName': 'Chen', 'Affiliation': 'Yu-Li Veterans Hospital, Hualien, Taiwan.'}, {'ForeName': 'Tzu-Ting', 'Initials': 'TT', 'LastName': 'Chen', 'Affiliation': 'National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.'}, {'ForeName': 'San-Yuan', 'Initials': 'SY', 'LastName': 'Huang', 'Affiliation': 'Tri-service General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Jung-Sik', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Yongin Mental Hospital, Seoul, South Korea.'}, {'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Saeki', 'Affiliation': 'Gannosu hospital, Fukuoka, Japan.'}, {'ForeName': 'Hisashi', 'Initials': 'H', 'LastName': 'Tanaka', 'Affiliation': 'Tanaka Hospital, Gunma, Japan.'}, {'ForeName': 'Tzong-Shi', 'Initials': 'TS', 'LastName': 'Wang', 'Affiliation': 'Department of Psychiatry, Taipei Tzu Chi Hospital, Taipei, Taiwan.'}, {'ForeName': 'Bo-Jian', 'Initials': 'BJ', 'LastName': 'Wu', 'Affiliation': 'Department of General Psychiatry, Yu-Li Hospital, Hualien, Taiwan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Katoh', 'Affiliation': 'Department of Internal Medicine, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ishigouoka', 'Affiliation': 'Institute of CNS Pharmacology, Tokyo, Japan.'}]",Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists,['10.1111/appy.12354'] 127,30907929,Effect of Wearable Digital Intervention for Improving Socialization in Children With Autism Spectrum Disorder: A Randomized Clinical Trial.,"Importance Autism behavioral therapy is effective but expensive and difficult to access. While mobile technology-based therapy can alleviate wait-lists and scale for increasing demand, few clinical trials exist to support its use for autism spectrum disorder (ASD) care. Objective To evaluate the efficacy of Superpower Glass, an artificial intelligence-driven wearable behavioral intervention for improving social outcomes of children with ASD. Design, Setting, and Participants A randomized clinical trial in which participants received the Superpower Glass intervention plus standard of care applied behavioral analysis therapy and control participants received only applied behavioral analysis therapy. Assessments were completed at the Stanford University Medical School, and enrolled participants used the Superpower Glass intervention in their homes. Children aged 6 to 12 years with a formal ASD diagnosis who were currently receiving applied behavioral analysis therapy were included. Families were recruited between June 2016 and December 2017. The first participant was enrolled on November 1, 2016, and the last appointment was completed on April 11, 2018. Data analysis was conducted between April and October 2018. Interventions The Superpower Glass intervention, deployed via Google Glass (worn by the child) and a smartphone app, promotes facial engagement and emotion recognition by detecting facial expressions and providing reinforcing social cues. Families were asked to conduct 20-minute sessions at home 4 times per week for 6 weeks. Main Outcomes and Measures Four socialization measures were assessed using an intention-to-treat analysis with a Bonferroni test correction. Results Overall, 71 children (63 boys [89%]; mean [SD] age, 8.38 [2.46] years) diagnosed with ASD were enrolled (40 [56.3%] were randomized to treatment, and 31 (43.7%) were randomized to control). Children receiving the intervention showed significant improvements on the Vineland Adaptive Behaviors Scale socialization subscale compared with treatment as usual controls (mean [SD] treatment impact, 4.58 [1.62]; P = .005). Positive mean treatment effects were also found for the other 3 primary measures but not to a significance threshold of P = .0125. Conclusions and Relevance The observed 4.58-point average gain on the Vineland Adaptive Behaviors Scale socialization subscale is comparable with gains observed with standard of care therapy. To our knowledge, this is the first randomized clinical trial to demonstrate efficacy of a wearable digital intervention to improve social behavior of children with ASD. The intervention reinforces facial engagement and emotion recognition, suggesting either or both could be a mechanism of action driving the observed improvement. This study underscores the potential of digital home therapy to augment the standard of care. Trial Registration ClinicalTrials.gov identifier: NCT03569176.",2019,"Children receiving the intervention showed significant improvements on the Vineland Adaptive Behaviors Scale socialization subscale compared with treatment as usual controls (mean [SD] treatment impact, 4.58 [1.62]; P = .005).","['Spectrum Disorder', 'children with ASD', 'Children aged 6 to 12 years with a formal ASD diagnosis who were currently receiving applied behavioral analysis therapy were included', '71 children (63 boys [89%]; mean [SD] age, 8.38 [2.46] years) diagnosed with ASD were enrolled (40 [56.3', 'Families were recruited between June 2016 and December 2017', 'Children With Autism']","['Superpower Glass intervention', 'Superpower Glass, an artificial intelligence-driven wearable behavioral intervention', 'Wearable Digital Intervention', 'wearable digital intervention', 'Superpower Glass intervention plus standard of care applied behavioral analysis therapy and control participants received only applied behavioral analysis therapy']","['Vineland Adaptive Behaviors Scale socialization subscale', 'social behavior']","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C1160858', 'cui_str': 'Behavior care assessment'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}]","[{'cui': 'C0017596', 'cui_str': 'Glass'}, {'cui': 'C0003916', 'cui_str': 'AI (Artificial Intelligence)'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C1160858', 'cui_str': 'Behavior care assessment'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0582680', 'cui_str': 'Vineland adaptive behavior scales (assessment scale)'}, {'cui': 'C0037447', 'cui_str': 'Socialization'}, {'cui': 'C0037397', 'cui_str': 'Social Behavior'}]",,0.0740403,"Children receiving the intervention showed significant improvements on the Vineland Adaptive Behaviors Scale socialization subscale compared with treatment as usual controls (mean [SD] treatment impact, 4.58 [1.62]; P = .005).","[{'ForeName': 'Catalin', 'Initials': 'C', 'LastName': 'Voss', 'Affiliation': 'Department of Computer Science, Stanford University, Stanford, California.'}, {'ForeName': 'Jessey', 'Initials': 'J', 'LastName': 'Schwartz', 'Affiliation': 'Department of Pediatrics (Systems Medicine), Stanford University, Stanford, California.'}, {'ForeName': 'Jena', 'Initials': 'J', 'LastName': 'Daniels', 'Affiliation': 'Department of Pediatrics (Systems Medicine), Stanford University, Stanford, California.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Kline', 'Affiliation': 'Department of Pediatrics (Systems Medicine), Stanford University, Stanford, California.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Haber', 'Affiliation': 'Department of Pediatrics (Systems Medicine), Stanford University, Stanford, California.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Washington', 'Affiliation': 'Department of Pediatrics (Systems Medicine), Stanford University, Stanford, California.'}, {'ForeName': 'Qandeel', 'Initials': 'Q', 'LastName': 'Tariq', 'Affiliation': 'Department of Pediatrics (Systems Medicine), Stanford University, Stanford, California.'}, {'ForeName': 'Thomas N', 'Initials': 'TN', 'LastName': 'Robinson', 'Affiliation': 'Department of Pediatrics (Systems Medicine), Stanford University, Stanford, California.'}, {'ForeName': 'Manisha', 'Initials': 'M', 'LastName': 'Desai', 'Affiliation': 'Department of Pediatrics (Systems Medicine), Stanford University, Stanford, California.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Phillips', 'Affiliation': 'Departments of Pediatrics (Stanford Solutions Science Lab) and Medicine, Stanford University, Stanford, California.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Feinstein', 'Affiliation': 'Departments of Pediatrics (Stanford Solutions Science Lab) and Medicine, Stanford University, Stanford, California.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Winograd', 'Affiliation': 'Department of Computer Science, Stanford University, Stanford, California.'}, {'ForeName': 'Dennis P', 'Initials': 'DP', 'LastName': 'Wall', 'Affiliation': 'Department of Pediatrics (Systems Medicine), Stanford University, Stanford, California.'}]",JAMA pediatrics,['10.1001/jamapediatrics.2019.0285'] 128,30844992,Eliciting Postactivation Potentiation With Hang Cleans Depends on the Recovery Duration and the Individual's 1 Repetition Maximum Strength.,"ABSTRACT Dinsdale, AJ and Bissas, A. Eliciting postactivation potentiation with hang cleans depends on the recovery duration and the individual's 1 repetition maximum strength. J Strength Cond Res 35(7): 1817-1824, 2021-Acutely coupling biomechanically similar resistance exercises (e.g., back squats) with subsequent explosive movements (e.g., countermovement jumps [CMJs]) can elicit an enhancement in explosive force and power production, which is known as postactivation potentiation (PAP). However, limited information exists with regard to the coupling of hang cleans with the CMJ. The purpose of this study was to determine the effectiveness of the hang clean at eliciting PAP through the systematic appraisal of the implemented recovery interval. Twelve explosively trained male track and field athletes completed 8 randomized protocols. These consisted of a structured warm-up, 3 baseline CMJs performed on a force platform, 3 reps of hang cleans set at 90% of 1 repetition maximum (1RM), a randomized rest, and 3 post-CMJs. The rest intervals were set at 0 (T0), 1 (T1), 2 (T2), 3 (T3), 4 (T4), 5 (T5), and 6 (T6) minutes after completing the hang cleans. A repeated-measures analysis of variance showed that the hang cleans did not elicit PAP, although there were significant (p < 0.05) decreases in jump height (JH) for T0 (-4%), T2 (-3%), and T3 (-3.3%). Interestingly, when splitting the subjects based on absolute 1RM hang clean (above 80 kg = strong and below 80 kg = weak), significant differences (p < 0.05) in JH were observed between the groups at T1 (strong -1.2% and weak +3.8%) and T5 (strong +5.1% and weak -1.9%). Our results suggest that to elicit PAP when using hang-clean protocols, it is important to establish first the function between individual strength levels and recovery duration as this may lead to contrasting optimal performance windows for different explosively trained athletes.",2021,"A repeated-measures analysis of variance showed that the hang cleans did not elicit PAP, although there were significant (p < 0.05) decreases in jump height (JH) for T0 (-4%), T2 (-3%), and T3 (-3.3%).",['Twelve explosively trained male track and field athletes completed 8 randomized protocols'],"['J Strength Cond Res XX(X', '2019-Acutely coupling biomechanically similar resistance exercises (e.g., back squats) with subsequent explosive movements (e.g., countermovement jumps [CMJs']","['Eliciting Postactivation Potentiation', 'JH', 'jump height (JH', 'absolute 1RM hang clean', 'Dinsdale, AJ and Bissas, A. Eliciting Postactivation Potentiation']","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0040595', 'cui_str': 'Track and Field'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0241236', 'cui_str': 'Does squat (finding)'}, {'cui': 'C1721090', 'cui_str': 'Explosives'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0560453', 'cui_str': 'Does jump (finding)'}]","[{'cui': 'C0560453', 'cui_str': 'Does jump (finding)'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0544691', 'cui_str': 'Hanging'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}]",,0.0211012,"A repeated-measures analysis of variance showed that the hang cleans did not elicit PAP, although there were significant (p < 0.05) decreases in jump height (JH) for T0 (-4%), T2 (-3%), and T3 (-3.3%).","[{'ForeName': 'Alexander J', 'Initials': 'AJ', 'LastName': 'Dinsdale', 'Affiliation': 'Carnegie School of Sport, Leeds Beckett University, Leeds, United Kingdom.'}, {'ForeName': 'Athanassios', 'Initials': 'A', 'LastName': 'Bissas', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003085'] 129,31823527,"Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects.","A rasagiline transdermal patch can be used to offer continuous rasagiline to patients with Parkinson's disease who cannot take their usual oral medications. This was the first study to investigate the pharmacokinetics, pharmacodynamics, and safety of the rasagiline transdermal patch in healthy Chinese subjects. Thirty subjects were randomized to 3 groups with 10 subjects in each group. The 10 subjects of group 1 received a single 1-mg dose of rasagiline as a tablet; the 20 subjects of groups 2 and 3 received a single transdermal patch (48-hour patch-on period) containing 1.25 mg and 2.5 mg rasagiline, respectively. After a 2-week washout period, the subjects of group 1 were assigned to receive 1 mg of rasagiline tablets every 24 hours for 7 days, and the subjects of group 2 were assigned to receive 1.25-mg rasagiline transdermal patches (48-hour patch-on period) every 72 hours for 5 time periods. The absorption of rasagiline from the transdermal patch was significantly improved, although the peak plasma concentration was obviously reduced. There was slight accumulation of rasagiline dose after multiple administrations. Inhibition of platelet monoamine oxidase-B (MAO-B) activity was dose dependent. The 80% inhibition maintained for at least 48 hours after multiple-dose administration of 1 mg tablets, and for 72 hours after multiple-dose administration of 1.25 mg/48 h patch. Compared with rasagiline tablets, the transdermal patch had a prolonged duration of 80% inhibition and increased maximal inhibition of MAO-B activity. These characteristics permitted an interval of 3 days of dosing, which was convenient for patients to use.",2020,"Compared with rasagiline tablets, the transdermal patch had a prolonged duration of 80% inhibition and increased maximal inhibition of MAO-B activity.","['Healthy Chinese Subjects', 'Thirty subjects were randomized to 3 groups with 10 subjects in each group', ""patients with Parkinson's disease who cannot take their usual oral medications"", 'healthy Chinese subjects']","['single transdermal patch (48-hour patch-on period) containing 1.25 mg and 2.5\xa0mg rasagiline', 'single 1-mg dose of rasagiline', 'platelet monoamine oxidase-B', '1.25-mg rasagiline transdermal patches', 'rasagiline tablets', 'Rasagiline Transdermal Patch', 'rasagiline transdermal patch']","['absorption of rasagiline', 'peak plasma concentration', 'maximal inhibition of MAO-B activity', 'MAO-B) activity', 'pharmacokinetics, pharmacodynamics, and safety', 'Pharmacokinetics, Pharmacodynamics, and Safety']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0991556', 'cui_str': 'Transdermal System'}, {'cui': 'C0439586', 'cui_str': '48 hours (qualifier value)'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4517497', 'cui_str': '1.25 (qualifier value)'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0525678', 'cui_str': 'rasagiline'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0026456', 'cui_str': 'MAO-B'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0525678', 'cui_str': 'rasagiline'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0026456', 'cui_str': 'MAO-B'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",30.0,0.0256371,"Compared with rasagiline tablets, the transdermal patch had a prolonged duration of 80% inhibition and increased maximal inhibition of MAO-B activity.","[{'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Clinical Pharmacology Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, China.'}, {'ForeName': 'Wenjia', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': 'Clinical Pharmacology Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, China.'}, {'ForeName': 'Quanying', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Clinical Pharmacology Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, China.'}, {'ForeName': 'Shunlin', 'Initials': 'S', 'LastName': 'Zong', 'Affiliation': 'Clinical Pharmacology Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, China.'}, {'ForeName': 'Chengzhe', 'Initials': 'C', 'LastName': 'Lv', 'Affiliation': ""Department of Pharmaceutics, Children's Hospital of Soochow University, Suzhou City, Jiangsu Province, China.""}]",Clinical pharmacology in drug development,['10.1002/cpdd.761'] 130,30853645,Efficacy of Anise (Pimpinella anisum L.) oil for migraine headache: A pilot randomized placebo-controlled clinical trial.,"Seyed Hamdollah Mosavat has made substantial contributions in conception, designing, acquisition of data and preformed clinical trial., Amin Moayedfard and Abbas Rahimi Jaberi had contribution in designing and preformed clinical trial. Zahra Sobhani and Maryam Mosaffa-Jahromi designed and prepared drugs of study. Aida Iraji has made drug biochemical assay. Seyed Hamdollah Mosavat had contribution in designing and revised the manuscript critically for important intellectual content and had contribution in designing and analyzing of data. Seyed Hamdollah Mosavat, Amin Moayedfard and Abbas Rahimi Jaberi had contribution in conception and designing and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.",2019,Seyed Hamdollah Mosavat had contribution in designing and revised the manuscript critically for important intellectual content and had contribution in designing and analyzing of data.,['migraine headache'],"['Anise (Pimpinella anisum L.) oil', 'Zahra Sobhani and Maryam', 'placebo']",[],"[{'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}]","[{'cui': 'C1138839', 'cui_str': 'Anise Seed Extract'}, {'cui': 'C1135879', 'cui_str': 'Pimpinella anisum'}, {'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.0421377,Seyed Hamdollah Mosavat had contribution in designing and revised the manuscript critically for important intellectual content and had contribution in designing and analyzing of data.,"[{'ForeName': 'Seyed Hamdollah', 'Initials': 'SH', 'LastName': 'Mosavat', 'Affiliation': 'Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Abbas Rahimi', 'Initials': 'AR', 'LastName': 'Jaberi', 'Affiliation': 'Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: rahimeia@sums.ac.ir.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Sobhani', 'Affiliation': 'Quality Control Department, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Mosaffa-Jahromi', 'Affiliation': 'Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Iraji', 'Affiliation': 'Central Research Laboratory, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Moayedfard', 'Affiliation': 'Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: mosavath@sums.ac.ir.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2019.01.047'] 131,28880260,Barriers to enrollment in a randomized controlled trial of hydrocortisone for cardiovascular insufficiency in term and late preterm newborn infants.,"OBJECTIVE To analyze reasons for low enrollment in a randomized controlled trial (RCT) of the effect of hydrocortisone for cardiovascular insufficiency on survival without neurodevelopmental impairment (NDI) in term/late preterm newborns. STUDY DESIGN The original study was a multicenter RCT. Eligibility: ⩾34 weeks' gestation, <72 h old, mechanically ventilated, receiving inotrope. Primary outcome was NDI at 2 years; infants with diagnoses at high risk for NDI were excluded. This paper presents an analysis of reasons for low patient enrollment. RESULTS Two hundred and fifty-seven of the 932 otherwise eligible infants received inotropes; however, 207 (81%) had exclusionary diagnoses. Only 12 infants were randomized over 10 months; therefore, the study was terminated. Contributing factors included few eligible infants after exclusions, open-label steroid therapy and a narrow enrollment window. CONCLUSION Despite an observational study to estimate the population, very few infants were enrolled. Successful RCTs of emergent therapy may require fewer exclusions, a short-term primary outcome, waiver of consent and/or other alternatives.",2017,"OBJECTIVE To analyze reasons for low enrollment in a randomized controlled trial (RCT) of the effect of hydrocortisone for cardiovascular insufficiency on survival without neurodevelopmental impairment (NDI) in term/late preterm newborns. ","['term and late preterm newborn infants', 'Two hundred and fifty-seven of the 932 otherwise eligible infants received inotropes; however, 207 (81%) had exclusionary diagnoses']",['hydrocortisone'],"['NDI at 2 years; infants with diagnoses at high risk for NDI', 'survival without neurodevelopmental impairment (NDI']","[{'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}]",932.0,0.467165,"OBJECTIVE To analyze reasons for low enrollment in a randomized controlled trial (RCT) of the effect of hydrocortisone for cardiovascular insufficiency on survival without neurodevelopmental impairment (NDI) in term/late preterm newborns. ","[{'ForeName': 'K L', 'Initials': 'KL', 'LastName': 'Watterberg', 'Affiliation': ""Department of Pediatrics/Neonatology, Children's Hospital of New Mexico, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Fernandez', 'Affiliation': ""Department of Pediatrics/Neonatology, Children's Hospital of New Mexico, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.""}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Walsh', 'Affiliation': ""Department of Pediatrics, Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, OH, USA.""}, {'ForeName': 'W E', 'Initials': 'WE', 'LastName': 'Truog', 'Affiliation': ""Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.""}, {'ForeName': 'B J', 'Initials': 'BJ', 'LastName': 'Stoll', 'Affiliation': ""Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA.""}, {'ForeName': 'G M', 'Initials': 'GM', 'LastName': 'Sokol', 'Affiliation': 'Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Kennedy', 'Affiliation': 'Department of Pediatrics, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'M V', 'Initials': 'MV', 'LastName': 'Fraga', 'Affiliation': ""Department of Pediatrics, The Children's Hospital of Philadelphia and The University of Pennsylvania, Philadelphia, PA, USA.""}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Beauman', 'Affiliation': ""Department of Pediatrics/Neonatology, Children's Hospital of New Mexico, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.""}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Carper', 'Affiliation': 'Social, Statistical and Environmental Sciences Unit, RTI International, Research Triangle Park, NC, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'Social, Statistical and Environmental Sciences Unit, RTI International, Rockville, MD, USA.'}, {'ForeName': 'A F', 'Initials': 'AF', 'LastName': 'Duncan', 'Affiliation': 'Department of Pediatrics, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'W F', 'Initials': 'WF', 'LastName': 'Buss', 'Affiliation': 'Department of Pharmacy, Indiana University Health, Indianapolis, IN, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Gauldin', 'Affiliation': ""Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.""}, {'ForeName': 'C B', 'Initials': 'CB', 'LastName': 'Lacy', 'Affiliation': ""Department of Pediatrics/Neonatology, Children's Hospital of New Mexico, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.""}, {'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'Sanchez', 'Affiliation': ""Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chawla', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Lakshminrusimha', 'Affiliation': ""Department of Pediatrics, University of Buffalo Women's and Children's Hospital of Buffalo, Buffalo, NY, USA.""}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Cotten', 'Affiliation': 'Department of Pediatrics, Duke University, Durham, NC, USA.'}, {'ForeName': 'K P', 'Initials': 'KP', 'LastName': 'Van Meurs', 'Affiliation': ""Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'B B', 'Initials': 'BB', 'LastName': 'Poindexter', 'Affiliation': ""Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'E F', 'Initials': 'EF', 'LastName': 'Bell', 'Affiliation': 'Department of Pediatrics, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'W A', 'Initials': 'WA', 'LastName': 'Carlo', 'Affiliation': 'Division of Neonatology, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Devaskar', 'Affiliation': 'Department of Pediatrics, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Wyckoff', 'Affiliation': 'Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'R D', 'Initials': 'RD', 'LastName': 'Higgins', 'Affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.'}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/jp.2017.131'] 132,30890339,A randomized comparative study of the effect of betamethasone oral mini-pulse therapy versus oral azathioprine in progressive nonsegmental vitiligo.,,2021,,['progressive non-segmental vitiligo'],"['azathioprine', 'betamethasone oral mini-pulse therapy']",[],"[{'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C1274648', 'cui_str': 'Segmental vitiligo'}]","[{'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0445542', 'cui_str': 'Mini (qualifier value)'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],,0.0234567,,"[{'ForeName': 'Suman', 'Initials': 'S', 'LastName': 'Patra', 'Affiliation': 'Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Binod K', 'Initials': 'BK', 'LastName': 'Khaitan', 'Affiliation': 'Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: binodkhaitan@hotmail.com.'}, {'ForeName': 'Vinod K', 'Initials': 'VK', 'LastName': 'Sharma', 'Affiliation': 'Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Neena', 'Initials': 'N', 'LastName': 'Khanna', 'Affiliation': 'Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.03.025'] 133,30879735,Effect of an alcohol-free beer enriched with isomaltulose and a resistant dextrin on insulin resistance in diabetic patients with overweight or obesity.,"BACKGROUND & AIMS The quality of carbohydrates has an essential role in nutritional management of type 2 diabetes mellitus (T2DM) because of its substantial impact on glucose homeostasis. Alcohol-free beer has beneficial bioactive components but it has a relatively high glycemic-index so its consumption is restricted in diabetic subjects. We aimed to explore the effect of an alcohol-free beer with modified carbohydrate composition almost completely eliminating maltose and adding isomaltulose (16.5 g/day) and a resistant maltodextrin (5.28 g/day) in comparison to a regular alcohol-free beer on glycemic control of diabetic subjects with overweight or obesity. DESIGN We randomized 41 subjects into two groups: a) consumption of 66 cL/day of; regular alcohol-free beer for the first 10 weeks and 66 cL/day of alcohol-free beer with modified carbohydrate composition for the next 10 weeks; b) the same described intervention in opposite order. There was a washout period for 6-8 weeks between the two interventions. Participants were counseled to adhere to a healthy diet for cardiovascular health and to increase physical activity. Clinical, biochemical, anthropometric, lifestyle and satiety assessments were performed at the beginning and at the end of each period. RESULTS Subjects showed significantly weight loss after the two ten weeks periods (-1.69 ± 3.21% and -1.77 ± 3.70% after experimental and regular alcohol-free beers, respectively, P = 0.881). Glucose and glycated hemoglobin did not significantly change after any period. Insulin concentrations and HOMA-IR significantly decreased (-11.1 [-21.3-4.64]% and -1.92 ± 32.8% respectively) after the intake of experimental alcohol-free beer but not after regular alcohol-free beer. Reductions remained statistically significant after adjusting for weight loss, energy intake, physical activity and intervention order. Subjects reported higher satiety scores after consuming experimental alcohol-free beer. CONCLUSIONS An alcohol-free beer including the substitution of regular carbohydrates for low doses of isomaltulose and the addition of a resistant maltodextrin within meals led to an improvement in insulin resistance in subjects with T2DM and overweight or obesity. CLINICAL TRIAL REGISTRATION The clinical trial has been registered in ClinicalTrials.gov (Identifier: NCT03337828).",2020,Insulin concentrations and HOMA-IR significantly decreased (-11.1,"['41 subjects into two groups: a', 'diabetic subjects with overweight or obesity', 'diabetic subjects', 'diabetic patients with overweight or obesity', 'subjects with T2DM and overweight or obesity']","['alcohol-free beer with modified carbohydrate composition', 'resistant maltodextrin', 'alcohol-free beer enriched with isomaltulose and a resistant dextrin', 'consumption of 66\xa0cL/day of; regular alcohol-free beer for the first 10 weeks and 66\xa0cL/day of alcohol-free beer with modified carbohydrate composition', 'regular alcohol-free beer']","['weight loss', 'weight loss, energy intake, physical activity and intervention order', 'insulin resistance', 'Clinical, biochemical, anthropometric, lifestyle and satiety assessments', 'Glucose and glycated hemoglobin', 'satiety scores', 'Insulin concentrations and HOMA-IR']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0004922', 'cui_str': 'Beer'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0064002', 'cui_str': 'isomaltulose anhydrous'}, {'cui': 'C0054527', 'cui_str': 'caloreen'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}]",41.0,0.0220514,Insulin concentrations and HOMA-IR significantly decreased (-11.1,"[{'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Mateo-Gallego', 'Affiliation': 'Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain; Universidad de Zaragoza, Zaragoza, Spain.'}, {'ForeName': 'Sofía', 'Initials': 'S', 'LastName': 'Pérez-Calahorra', 'Affiliation': 'Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain.'}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Lamiquiz-Moneo', 'Affiliation': 'Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain. Electronic address: itziarlamiquiz@gmail.com.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Marco-Benedí', 'Affiliation': 'Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain.'}, {'ForeName': 'Ana M', 'Initials': 'AM', 'LastName': 'Bea', 'Affiliation': 'Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain.'}, {'ForeName': 'Antonio J', 'Initials': 'AJ', 'LastName': 'Fumanal', 'Affiliation': 'Grupo Ágora - La Zaragozana S.A., Zaragoza, Spain.'}, {'ForeName': 'Ascensión', 'Initials': 'A', 'LastName': 'Prieto-Martín', 'Affiliation': 'Grupo Ágora - La Zaragozana S.A., Zaragoza, Spain.'}, {'ForeName': 'Martín', 'Initials': 'M', 'LastName': 'Laclaustra', 'Affiliation': 'Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain; Fundación Aragón Investigación y Desarrollo (ARAID), Zaragoza, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Cenarro', 'Affiliation': 'Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Civeira', 'Affiliation': 'Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain; Universidad de Zaragoza, Zaragoza, Spain.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.02.025'] 134,29543704,Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.,"In the current era of checkpoint inhibitors, some patients with metastatic melanoma have shown a significant improvement in survival. However, optimization of immunotherapy is an ongoing effort. Monocyte-derived dendritic cell (MODC) vaccines have been shown in clinical trials to be safe and capable of inducing tumor-specific immunity as well as occasional objective clinical responses. Here, we conducted a three-arm pilot clinical study in 15 patients with metastatic melanoma to evaluate three types of MODC vaccines, differing only by strategies of tumor antigen delivery. MODCs were isolated from each patient and loaded with patients' own melanoma cells as sources of antigens. Antigen loading was achieved ex vivo by fusing melanoma cells with MODCs, co-culturing melanoma cells with MODCs, or by pulsing MODCs with melanoma cell lysates. The vaccines were then injected into superficial lymph nodes using high-resolution ultrasound guidance. Primary end points included delayed-type hypersensitivity responses and positive ELISpot result, which measures interferon-γ production. Five of 15 patients achieved delayed-type hypersensitivity responses and six of 15 patients had positive ELISpot results. We demonstrated that the vaccines were safe and well-tolerated by all patients and produced immunological responses in all arms. Although MODC vaccine monotherapy has limited efficacy, combining this vaccine with other immunotherapies, such as checkpoint inhibitors, to engage multiple components of the immune system may be an effective and viable future approach.",2018,"Primary end points included delayed-type hypersensitivity responses and positive ELISpot result, which measures interferon-γ production.","['15 patients with metastatic melanoma to evaluate three types of MODC vaccines, differing only by strategies of tumor antigen delivery', 'patients with metastatic melanoma', 'metastatic melanoma']","['Monocyte-derived dendritic cell (MODC) vaccines', 'MODC vaccine monotherapy']","['delayed-type hypersensitivity responses and positive ELISpot result, which measures interferon-γ production', 'survival', 'safe and well-tolerated', 'delayed-type hypersensitivity responses']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0278883', 'cui_str': 'Metastatic melanoma'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0041361', 'cui_str': 'Tumor Antigens'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}]","[{'cui': 'C0026473', 'cui_str': 'Monocytes'}, {'cui': 'C0011306', 'cui_str': 'Dendritic Cells'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}]","[{'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C3544362', 'cui_str': 'Hypersensitivity (SMQ)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0920508', 'cui_str': 'ELISPOT'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0021747', 'cui_str': 'Interferons'}, {'cui': 'C0033268'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",15.0,0.149151,"Primary end points included delayed-type hypersensitivity responses and positive ELISpot result, which measures interferon-γ production.","[{'ForeName': 'Larisa J', 'Initials': 'LJ', 'LastName': 'Geskin', 'Affiliation': 'Department of Dermatology, Columbia University Medical Center, New York City, New York.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Damiano', 'Affiliation': 'Department of Dermatology, Columbia University Medical Center, New York City, New York.'}, {'ForeName': 'Christina C', 'Initials': 'CC', 'LastName': 'Patrone', 'Affiliation': 'Department of Dermatology, Columbia University Medical Center, New York City, New York.'}, {'ForeName': 'Lisa H', 'Initials': 'LH', 'LastName': 'Butterfield', 'Affiliation': 'Department of Medicine, Surgery, and Immunology, University of Pittsburgh Cancer Institute.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Kirkwood', 'Affiliation': 'Department of Medicine, University of Pittsburgh Medical Center.'}, {'ForeName': 'Louis D', 'Initials': 'LD', 'LastName': 'Falo', 'Affiliation': 'Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.'}]",Melanoma research,['10.1097/CMR.0000000000000441'] 135,30789580,Compression Stockings Used During Two Soccer Matches Improve Perceived Muscle Soreness and High-Intensity Performance.,"ABSTRACT Gimenes, SV, Marocolo, M, Pavin, LN, Pagoto Spigolon, LM, Neto, OB, Côrrea da Silva, BV, Duffield, R, and Ribeiro da Mota, G. Compression stockings used during two soccer matches improve perceived muscle soreness and high-intensity performance. J Strength Cond Res 35(7): 2010-2017, 2021-Evidence on the use of compression stockings (CS) during soccer matches is limited. Thus, we evaluated the acute effects of CS on match-based physical performance indicators and perceptual responses during 2 consecutive soccer matches with 72-hour recovery. Twenty outfield players were randomly allocated to the CS group (20-30 mm Hg) or control group (non-CS) and performed 2 matches (5 players using CS or regular socks per team/match). Match loads {rating of perceived exertion × minutes; CS ∼830 vs. control 843 (arbitrary units [AU])} and heart rate (HR) responses (both CS and control ∼86% HRpeak) did not differ (p > 0.05) between CS and control groups. Although total distance covered did not differ (p > 0.05) between groups, CS increased distances (effect size [ES] = 0.9-1.32) in higher-speed zones (>19 km·h-1 CS ∼550 m vs. control ∼373 m) alongside an increased number of accelerations (-50.0 to -3.0 m·s-2) than control (CS: 33.7 ± 11.2 vs. control: 23.8 ± 7.9; p = 0.003; ES = 1.04). Perceived recovery did not differ (p > 0.05) between groups for either match but was worse in the second match for both groups. Perceived muscle soreness increased in control after match 2 (from 3.1 ± 1.9 to 6.3 ± 1.6 AU; p < 0.0010) but did not in CS (from 2.8 ± 1.4 to 4.1 ± 1.9 AU; p = 0.6275; ES = 1.24 CS vs. control after match). Accordingly, CS use during 2 soccer matches with 72-hour recovery reduces perceived muscle soreness in the second match and increases higher-speed match running performance.",2021,"Although total distance covered did not differ (p > 0.05) between groups, CS increased distances (effect size [ES] = 0.9-1.32) in higher-speed zones (>19 km·h CS","['2 consecutive soccer matches with 72-hour recovery', 'Twenty outfield players']","['CS', 'Compression Stockings', 'control group (non-CS', 'control', 'compression stockings (CS']","['number of accelerations ', 'higher-speed match running performance', 'muscle soreness and high-intensity performance', 'Gimenes, SV, Marocolo, M, Pavin, LN, Pagoto Spigolon, LM, Neto, OB, Côrrea da Silva, BV, Duffield, R, and Ribeiro da Mota, G. Compression stockings', 'muscle soreness', 'Perceived muscle soreness', 'Muscle Soreness and High-Intensity Performance', 'Perceived recovery', 'Match loads {rating of perceived exertion × minutes; CS ∼830 vs. control 843 (arbitrary units [AU])} and heart rate (HR) responses']","[{'cui': 'C0037393', 'cui_str': 'Soccers'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1292423', 'cui_str': '72 hours (qualifier value)'}]","[{'cui': 'C0038348', 'cui_str': 'Compression Stockings'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0231528', 'cui_str': 'Muscle Pain'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0038348', 'cui_str': 'Compression Stockings'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439183', 'cui_str': 'Arbitrary unit (qualifier value)'}, {'cui': 'C1997337', 'cui_str': 'Speed of heart rate response'}]",,0.047621,"Although total distance covered did not differ (p > 0.05) between groups, CS increased distances (effect size [ES] = 0.9-1.32) in higher-speed zones (>19 km·h CS","[{'ForeName': 'Samuel Valencia', 'Initials': 'SV', 'LastName': 'Gimenes', 'Affiliation': 'Human Performance and Sports Research Group, Department of Sport Sciences, Institute of Health Sciences, Federal University of Triangulo Mineiro (UFTM), Uberaba, Brazil.'}, {'ForeName': 'Moacir', 'Initials': 'M', 'LastName': 'Marocolo', 'Affiliation': 'Physiology and Human Performance Research Group, Department of Physiology, Federal University of Juiz de Fora, Juiz de Fora, Brazil.'}, {'ForeName': 'Larissa Neves', 'Initials': 'LN', 'LastName': 'Pavin', 'Affiliation': 'Human Performance and Sports Research Group, Department of Sport Sciences, Institute of Health Sciences, Federal University of Triangulo Mineiro (UFTM), Uberaba, Brazil.'}, {'ForeName': 'Leandro Mateus Pagoto', 'Initials': 'LMP', 'LastName': 'Spigolon', 'Affiliation': 'School of Physical Education, Campinas State University FEF/UNICAMP, Campinas, Brazil.'}, {'ForeName': 'Octávio', 'Initials': 'O', 'LastName': 'Barbosa Neto', 'Affiliation': 'Human Performance and Sports Research Group, Department of Sport Sciences, Institute of Health Sciences, Federal University of Triangulo Mineiro (UFTM), Uberaba, Brazil.'}, {'ForeName': 'Bruno Victor Côrrea', 'Initials': 'BVC', 'LastName': 'da Silva', 'Affiliation': 'Department of Environmental, Biological and Health Sciences, University Center of Belo Horizonte (Uni-BH), Belo Horizonte, Brazil; and.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Duffield', 'Affiliation': 'Sport and Exercise Discipline Group, Faculty of Health, University of Technology Sydney (UTS), Sydney, Australia.'}, {'ForeName': 'Gustavo Ribeiro', 'Initials': 'GR', 'LastName': 'da Mota', 'Affiliation': 'Human Performance and Sports Research Group, Department of Sport Sciences, Institute of Health Sciences, Federal University of Triangulo Mineiro (UFTM), Uberaba, Brazil.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003048'] 136,30739626,"Effects of magnesium supplementation on carotid intima-media thickness and metabolic profiles in diabetic haemodialysis patients: a randomised, double-blind, placebo-controlled trial.","This study evaluated the effects of Mg administration on carotid intima-media thickness (CIMT), glycaemic control and markers of cardio-metabolic risk in diabetic haemodialysis (HD) patients. This randomised, double-blind, placebo-controlled clinical trial was conducted in fifty-four diabetic HD patients. Participants were randomly divided into two groups to take either 250 mg/d Mg as magnesium oxide (n 27) or placebo (n 27) for 24 weeks. Mg supplementation resulted in a significant reduction in mean (P<0·001) and maximum levels of left CIMT (P=0·02) and mean levels of right CIMT (P=0·004) compared with the placebo. In addition, taking Mg supplements significantly reduced serum insulin levels (β=-9·42 pmol/l; 95% CI -14·94, -3·90; P=0·001), homoeostasis model of assessment-insulin resistance (β=-0·56; 95 % CI -0·89, -0·24; P=0·001) and HbA1c (β=-0·74 %; 95 % CI -1·10, -0·39; P<0·001) and significantly increased the quantitative insulin sensitivity check index (β=0·008; 95 % CI 0·002, 0·01; P=0·002) compared with the placebo. In addition, Mg administration led to a significant reduction in serum total cholesterol (β=-0·30 mmol/l; 95% CI -0·56, -0·04; P=0·02), LDL-cholesterol (β=-0·29 mmol/l; 95% CI -0·52, -0·05; P=0·01), high-sensitivity C-reactive protein (hs-CRP) (P<0·001) and plasma malondialdehyde (MDA) (P=0·04) and a significant rise in plasma total antioxidant capacity (TAC) levels (P<0·001) compared with the placebo. Overall, we found that taking Mg for 24 weeks by diabetic HD patients significantly improved mean and maximum levels of left and mean levels of right CIMT, insulin metabolism, HbA1c, total cholesterol and LDL-cholesterol, hs-CRP, TAC and MDA levels.",2019,Mg supplementation resulted in a significant reduction in mean (P<0·001) and maximum levels of left CIMT (P=0·02) and mean levels of right CIMT (P=0·004) compared with the placebo.,"['diabetic haemodialysis (HD) patients', 'diabetic haemodialysis patients', 'fifty-four diabetic HD patients']","['magnesium oxide', 'placebo', 'magnesium supplementation']","['high-sensitivity C-reactive protein (hs-CRP', 'serum insulin levels', 'quantitative insulin sensitivity check index', 'plasma total antioxidant capacity (TAC) levels', 'mean and maximum levels of left and mean levels of right CIMT, insulin metabolism, HbA1c, total cholesterol and LDL-cholesterol, hs-CRP, TAC and MDA levels', 'LDL-cholesterol', 'serum total cholesterol', 'carotid intima-media thickness (CIMT), glycaemic control and markers of cardio-metabolic risk', 'carotid intima-media thickness and metabolic profiles', 'maximum levels of left CIMT (P=0·02) and mean levels of right CIMT', 'homoeostasis model of assessment-insulin resistance', 'plasma malondialdehyde (MDA']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517807', 'cui_str': 'Fifty-four'}]","[{'cui': 'C0024477', 'cui_str': 'Magnesium Oxide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1096534', 'cui_str': 'Providing magnesium based on suboptimal food or fluid intake, iatrogenic deficiency or medical diagnosis. (Source: IDNT Reference Manual, edition 4; ISBN #978-0-88091-467-3)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C3853758', 'cui_str': 'Metabolic Profile'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}]",54.0,0.55274,Mg supplementation resulted in a significant reduction in mean (P<0·001) and maximum levels of left CIMT (P=0·02) and mean levels of right CIMT (P=0·004) compared with the placebo.,"[{'ForeName': 'Hamid Reza', 'Initials': 'HR', 'LastName': 'Talari', 'Affiliation': '1Department of Radiology,Kashan University of Medical Sciences,Kashan,PO Box 87159-81151,Iran.'}, {'ForeName': 'Mehrafrouz', 'Initials': 'M', 'LastName': 'Zakizade', 'Affiliation': '1Department of Radiology,Kashan University of Medical Sciences,Kashan,PO Box 87159-81151,Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Soleimani', 'Affiliation': '2Department of Internal Medicine,Kashan University of Medical Sciences,Kashan,PO Box 87159-81151,Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': '3Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan,PO Box 87159-81151,Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Ghaderi', 'Affiliation': '4Department of Addiction Studies,School of Medicine,Kashan University of Medical Sciences,Kashan,PO Box 87159-81151,Iran.'}, {'ForeName': 'Naghmeh', 'Initials': 'N', 'LastName': 'Mirhosseini', 'Affiliation': '5School of Public Health,University of Saskatchewan,Saskatoon,SK S7N 2Z4,Canada.'}, {'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Eslahi', 'Affiliation': '3Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan,PO Box 87159-81151,Iran.'}, {'ForeName': 'Mahtab', 'Initials': 'M', 'LastName': 'Babadi', 'Affiliation': '3Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan,PO Box 87159-81151,Iran.'}, {'ForeName': 'Mohammad Ali', 'Initials': 'MA', 'LastName': 'Mansournia', 'Affiliation': '6Department of Epidemiology and Biostatistics,School of Public Health,Tehran University of Medical Sciences,Tehran 1417653761,Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': '3Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan,PO Box 87159-81151,Iran.'}]",The British journal of nutrition,['10.1017/S0007114519000163'] 137,30710258,Intraoperative use of dexmedetomidine for the prevention of emergence agitation and postoperative delirium in thoracic surgery: a randomized-controlled trial.,"PURPOSE We investigated whether preventive use of dexmedetomidine during surgery was effective for reducing emergence agitation and postoperative delirium. METHODS In this double-blind randomized-controlled trial, 143 patients undergoing thoracoscopic lung resection surgery were randomly assigned to the dexmedetomidine-sevoflurane (DEX-Sevo, n = 73) or sevoflurane (Sevo, n = 70) groups. Dexmedetomidine or saline administration was started after inducing anesthesia and continued until the end of surgery at a fixed dose (0.5 µg·kg -1 ·hr -1 ). The primary endpoint was the incidence of delirium up until the end of postoperative day 3. Emergence agitation and postoperative delirium were measured with the Riker sedation agitation scale and the confusion assessment method, respectively. The secondary endpoints were serum cytokine and catecholamine levels. RESULTS The DEX-Sevo group showed less frequent emergence agitation than the Sevo group (13% vs 35%, respectively; relative risk, 0.38; 95% confidence interval [CI], 0.18 to 0.79; P = 0.011) but the incidence of delirium after discharge from the postanesthesia care unit was not different (25% vs 25%, DEX-Sevo vs Sevo). Both pro- and anti-inflammatory cytokines were lower in the DEX-Sevo group than in the Sevo group. Nevertheless, the interleukin (IL)6/IL10 ratio (median difference, 5.8; 95% CI,1.8 to 10.0; P = 0.012) and IL8/IL10 ratio (median difference, 0.8; 95% CI, 0.2 to 1.3; P = 0.007) were higher in the DEX-Sevo group than in the Sevo group, indicating a pro-inflammatory cytokine balance in the DEX-Sevo group. Norepinephrine and epinephrine levels were lower in the DEX-Sevo group than in the Sevo group (both, P < 0.001). CONCLUSIONS Intraoperative dexmedetomidine reduced emergence agitation but not postoperative delirium in patients undergoing thoracic surgery. Dexmedetomidine seemed to affect emergence agitation through catecholamines, but not through an anti-inflammatory action. Trial registration Clinical Research Information Service (KCT 0001877); registered 7 April, 2016.",2019,Both pro- and anti-inflammatory cytokines were lower in the DEX-Sevo group than in the Sevo group.,"['143 patients undergoing thoracoscopic lung resection surgery', 'patients undergoing thoracic surgery', 'thoracic surgery']","['dexmedetomidine', 'Dexmedetomidine or saline', 'Dexmedetomidine', 'dexmedetomidine-sevoflurane (DEX-Sevo, n = 73) or sevoflurane']","['emergence agitation', 'interleukin (IL)6/IL10 ratio', 'incidence of delirium up until the end of postoperative day 3', 'pro-inflammatory cytokine balance', 'IL8/IL10 ratio', 'Norepinephrine and epinephrine levels', 'frequent emergence agitation', 'Riker sedation agitation scale', 'Emergence agitation and postoperative delirium', 'serum cytokine and catecholamine levels']","[{'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0039986', 'cui_str': 'Thoracic Surgery'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0920253', 'cui_str': 'Postanesthetic Excitement'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0202145', 'cui_str': 'Norepinephrine measurement (procedure)'}, {'cui': 'C0201998', 'cui_str': 'Adrenaline measurement'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0222045'}, {'cui': 'C1319200', 'cui_str': 'Postoperative confusion'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0546632', 'cui_str': 'Catecholamine measurement (procedure)'}]",143.0,0.644234,Both pro- and anti-inflammatory cytokines were lower in the DEX-Sevo group than in the Sevo group.,"[{'ForeName': 'Jie Ae', 'Initials': 'JA', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Gangnam-Gu, Seoul, 135-710, South Korea.'}, {'ForeName': 'Hyun Joo', 'Initials': 'HJ', 'LastName': 'Ahn', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Gangnam-Gu, Seoul, 135-710, South Korea. hyunjooahn@skku.edu.'}, {'ForeName': 'Mikyung', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Gangnam-Gu, Seoul, 135-710, South Korea.'}, {'ForeName': 'Sang Hyun', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Gangnam-Gu, Seoul, 135-710, South Korea.'}, {'ForeName': 'Heejoon', 'Initials': 'H', 'LastName': 'Jeong', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Gangnam-Gu, Seoul, 135-710, South Korea.'}, {'ForeName': 'Bong Gyu', 'Initials': 'BG', 'LastName': 'Seong', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Gangnam-Gu, Seoul, 135-710, South Korea.'}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-019-01299-7'] 138,30853262,Effects of macronutrient manipulation on postprandial metabolic responses in overweight males with high fasting lipids during simulated shift work: A randomized crossover trial.,"BACKGROUND & AIMS Meals consumed out of synchronisation with normal circadian rhythms are associated with metabolic dysregulation. Changes in macronutrient composition of meals can improve metabolic responses during the day. Therefore, we aimed to investigate whether macronutrient manipulation of meals alters postprandial glucose and lipid responses and the expression of circadian genes during the night. METHODS In a randomised crossover trial, 16 overweight males with high fasting lipids were fed isocaloric meals (2.7 MJ) at 0000 h. The meals differed primarily in total fat and total sugars content (control (8% total sugar, 5% saturated fat) vs test (16% total sugar, 26% saturated fat)). Postprandial blood samples were collected for glucose, insulin (3 h) and triglycerides (6 h) and analysed as incremental area under the curve (iAUC). RNA was extracted at 0 h, 2 h and 4 h and changes in expressions of the circadian genes clock and Per 1-3 analysed. RESULTS Postprandial glucose (p = 0.04) and insulin iAUC (p = 0.02) were significantly higher after consumption of the test meal compared to the control meal. Postprandial triglyceride iAUC was not statistically different between the two meal types (p = 0.72). No change in circadian gene expression was observed after the two meals. CONCLUSIONS Our results showed that macronutrient composition affects postprandial metabolic response at night. It emphasizes the need to consider the role and effects of night time eating, when developing metabolic disease prevention strategies for shift workers. STUDY ID NUMBER ACTRN12618001115224. WEBSITE OF TRIAL REGISTRY: http://www.anzctr.org.au/. Retrospectively registered after data collection.",2020,Postprandial glucose (p = 0.04) and insulin iAUC (p = 0.02) were significantly higher after consumption of the test meal compared to the control meal.,"['overweight males with high fasting lipids during simulated shift work', '16 overweight males with high fasting lipids were fed isocaloric meals (2.7\xa0MJ) at 0000']",['macronutrient manipulation'],"['total fat and total sugars content', 'circadian gene expression', 'insulin iAUC', 'Postprandial triglyceride iAUC', 'glucose, insulin (3\xa0h) and triglycerides (6\xa0h) and analysed as incremental area under the curve (iAUC', 'RNA', 'postprandial metabolic response', 'postprandial metabolic responses', 'metabolic responses', 'Postprandial glucose', 'Postprandial blood samples']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C4517635', 'cui_str': '2.7'}]","[{'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0041119', 'cui_str': 'Hydrogen-3'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}]",16.0,0.0731507,Postprandial glucose (p = 0.04) and insulin iAUC (p = 0.02) were significantly higher after consumption of the test meal compared to the control meal.,"[{'ForeName': 'Maxine P', 'Initials': 'MP', 'LastName': 'Bonham', 'Affiliation': 'Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, 3168, Australia. Electronic address: maxine.bonham@monash.edu.'}, {'ForeName': 'Elleni', 'Initials': 'E', 'LastName': 'Kaias', 'Affiliation': 'Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, 3168, Australia. Electronic address: elleni_kaias@hotmail.com.'}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Huggins', 'Affiliation': 'Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, 3168, Australia. Electronic address: catherine.huggins@monash.edu.'}, {'ForeName': 'Rochelle', 'Initials': 'R', 'LastName': 'Davis', 'Affiliation': 'Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, 3168, Australia. Electronic address: rochelle.davis@monash.edu.'}, {'ForeName': 'Gloria Kw', 'Initials': 'GK', 'LastName': 'Leung', 'Affiliation': 'Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, 3168, Australia. Electronic address: gloria.leung@monash.edu.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Eikelis', 'Affiliation': 'Iverson Health Innovation Research Institute, Swinburne University of Technology, Hawthorn, Victoria, Australia; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. Electronic address: neikelis@swin.edu.au.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Shaw', 'Affiliation': 'Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, 3168, Australia. Electronic address: emmacshaw@hotmail.co.uk.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Murgia', 'Affiliation': 'Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, 3168, Australia. Electronic address: chiara.murgia@monash.edu.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.02.018'] 139,29201994,Speed of processing training results in lower risk of dementia.,"Introduction Cognitive training improves cognitive performance and delays functional impairment, but its effects on dementia are not known. We examined whether three different types of cognitive training lowered the risk of dementia across 10 years of follow-up relative to control and if greater number of training sessions attended was associated with lower dementia risk. Methods The Advanced Cognitive Training in Vital Elderly (NCT00298558) study was a randomized controlled trial (N = 2802) among initially healthy older adults, which examined the efficacy of three cognitive training programs (memory, reasoning, or speed of processing) relative to a no-contact control condition. Up to 10 training sessions were delivered over 6 weeks with up to four sessions of booster training delivered at 11 months and a second set of up to four booster sessions at 35 months. Outcome assessments were taken immediately after intervention and at intervals over 10 years. Dementia was defined using a combination of interview- and performance-based methods. Results A total of 260 cases of dementia were identified during the follow-up. Speed training resulted in reduced risk of dementia (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.50-0.998, P  = .049) compared to control, but memory and reasoning training did not (HR 0.79, 95% CI 0.57-1.11, P  = .177 and HR 0.79, 95% CI 0.56-1.10, P  = .163, respectively). Each additional speed training session was associated with a 10% lower hazard for dementia (unadjusted HR, 0.90; 95% CI, 0.85-0.95, P  < .001). Discussion Initially, healthy older adults randomized to speed of processing cognitive training had a 29% reduction in their risk of dementia after 10 years of follow-up compared to the untreated control group.",2017,"Speed training resulted in reduced risk of dementia (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.50-0.998, P  = .049) compared to control, but memory and reasoning training did not (HR 0.79, 95% CI 0.57-1.11, P  = .177 and HR 0.79, 95% CI 0.56-1.10, P  = .163, respectively).","['healthy older adults', 'N\xa0=\xa02802) among initially healthy older adults']","['Speed training', 'Introduction\n\n\nCognitive training', 'cognitive training programs (memory, reasoning, or speed of processing) relative to a no-contact control condition', 'Advanced Cognitive Training', 'Speed of processing training', 'cognitive training', 'speed of processing cognitive training']","['cognitive performance and delays functional impairment', 'reduced risk of dementia']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1293116', 'cui_str': 'Introduction'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C3875154', 'cui_str': 'Relative to (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}]","[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}]",,0.0347415,"Speed training resulted in reduced risk of dementia (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.50-0.998, P  = .049) compared to control, but memory and reasoning training did not (HR 0.79, 95% CI 0.57-1.11, P  = .177 and HR 0.79, 95% CI 0.56-1.10, P  = .163, respectively).","[{'ForeName': 'Jerri D', 'Initials': 'JD', 'LastName': 'Edwards', 'Affiliation': 'Department of Psychiatry and Behavioral Neurosciences, University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Huiping', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Department of Biostatistics, The Richard M. Fairbanks School of Public Health and School of Medicine, Indiana University, Indianapolis, IN, USA.'}, {'ForeName': 'Daniel O', 'Initials': 'DO', 'LastName': 'Clark', 'Affiliation': 'Department of Medicine, Indiana University Center for Aging Research, Regenstrief Institute, Inc., Indianapolis, IN, USA.'}, {'ForeName': 'Lin T', 'Initials': 'LT', 'LastName': 'Guey', 'Affiliation': 'Moderna Therapeutics, Cambridge, MA, USA.'}, {'ForeName': 'Lesley A', 'Initials': 'LA', 'LastName': 'Ross', 'Affiliation': 'Department of Human Development and Family Studies, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Frederick W', 'Initials': 'FW', 'LastName': 'Unverzagt', 'Affiliation': 'Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.'}]","Alzheimer's & dementia (New York, N. Y.)",['10.1016/j.trci.2017.09.002'] 140,31645162,Neonatal morbidity in late preterm small for gestational age neonates.,"INTRODUCTION To compare neonatal respiratory morbidity among small for gestational age (SGA; birth weight less than 10th percentile for gestational age) versus appropriate for gestational age (AGA; BW at 10-90th percentile) neonates born in the late preterm period. METHODS A secondary analysis of a multicenter randomized trial of antenatal corticosteroids for women at risk for late preterm birth. Singleton, nonanomalous, AGA or SGA births that delivered at 34-36 weeks were included. Women were excluded if they delivered after 37 weeks or had a large for gestational age baby (LGA; weight over 90th for gestational age). The primary outcome was a composite of any of the following: respiratory support by 72 h (continuous positive airway pressure or high flow nasal cannula ≥2 h, oxygen with a fraction of inspired oxygen of ≥30% for ≥4 h, extra corporeal membrane oxygenation or mechanical ventilation) or neonatal death. The secondary outcomes included several neonatal and maternal morbidities. Multivariable Poisson regression models were used to examine the association between neonatal weight and outcomes (using adjusted relative risk [aRR] and 95% confidence intervals [CI]). RESULTS Of the 2831 women in the parent trial, 2315 (82%) women met inclusion criteria; among them, 426 (18%) of the neonates were SGA. There was no significant difference in the risk of the primary outcome between SGA and AGA (13.1 versus 15.1%, aRR 0.85, 95% CI 0.66-1.10). SGA, however, was associated with an increased risk for neonatal intensive care unit admission (68 versus 45%, aRR 1.60, 95% CI 1.47-1.74), hypothermia (12.2 versus 8.8%, aRR 1.36, 95% CI 1.01-1.83), feeding problems (47.2 versus 36.9%, aRR 1.24, 95% CI 1.07-1.45) and a decreased risk of neonatal hyperbilirubinemia (7.5 versus 12.7%, aRR 0.59, 95% CI 0.41-0.84), when compared to AGA. CONCLUSION In this cohort of late preterm birth, there was no significant difference in the rate of composite respiratory morbidity between SGA and AGA newborns.",2021,"In this cohort of late preterm birth, there was no significant difference in the rate of composite respiratory morbidity between SGA and AGA newborns.","['Singleton, nonanomalous, AGA or SGA births that delivered at 34-36\u2009weeks were included', 'small for gestational age (SGA; birth weight less than 10th percentile for gestational age) versus appropriate for gestational age (AGA; BW at 10-90th percentile) neonates born in the late preterm period', '2831 women in the parent trial, 2315 (82', 'late preterm small for gestational age neonates', 'women at risk for late preterm birth', 'Women were excluded if they delivered after 37\u2009weeks or had a large for gestational age baby (LGA; weight over 90th for gestational age']",['antenatal corticosteroids'],"['risk for neonatal intensive care unit admission', 'hypothermia', 'several neonatal and maternal morbidities', 'SGA and AGA', 'composite of any of the following: respiratory support by 72\u2009h (continuous positive airway pressure or high flow nasal cannula ≥2\u2009h, oxygen with a fraction of inspired oxygen of ≥30% for ≥4\u2009h, extra corporeal membrane oxygenation or mechanical ventilation) or neonatal death', 'risk of neonatal hyperbilirubinemia', 'feeding problems', 'rate of composite respiratory morbidity', 'neonatal respiratory morbidity', 'Neonatal morbidity']","[{'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0235991', 'cui_str': 'Small for gestational age'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0591126', 'cui_str': 'AT 10'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}, {'cui': 'C1848395', 'cui_str': 'Large for gestational age'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0205136', 'cui_str': 'Over (qualifier value)'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}]","[{'cui': 'C2828394', 'cui_str': 'Antenatal (qualifier value)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0413252', 'cui_str': 'Hypothermia due to exposure'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0410916', 'cui_str': 'Neonatal Death'}, {'cui': 'C0857007', 'cui_str': 'Hyperbilirubinemia, Neonatal'}, {'cui': 'C0232466', 'cui_str': 'Feeding problem (finding)'}, {'cui': 'C1301752', 'cui_str': 'Respiratory morbidity'}]",2831.0,0.264091,"In this cohort of late preterm birth, there was no significant difference in the rate of composite respiratory morbidity between SGA and AGA newborns.","[{'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Fishel Bartal', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Han-Yang', 'Initials': 'HY', 'LastName': 'Chen', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Sean C', 'Initials': 'SC', 'LastName': 'Blackwell', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Suneet P', 'Initials': 'SP', 'LastName': 'Chauhan', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Baha M', 'Initials': 'BM', 'LastName': 'Sibai', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA.'}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2019.1680630'] 141,30779716,Evidence for an Upper Threshold for Resistance Training Volume in Trained Women.,"INTRODUCTION The purpose of the present study was to compare the effects of different volumes of resistance training (RT) on muscle performance and hypertrophy in trained women. METHODS The study included 40 volunteers that performed RT for 24 wk divided into groups that performed 5 (G5), 10 (G10), 15 (G15), and 20 (G20) sets per muscle group per session. Ten-repetition maximum (10RM) tests were performed for the bench press, lat pulldown, 45° leg press, and stiff-legged deadlift. Muscle thickness (MT) was measured using ultrasound at biceps brachii, triceps brachii, pectoralis major, quadriceps femoris, and gluteus maximus. RESULTS All groups significantly increased all MT measures and 10RM tests after 24 wk of RT (P < 0.05). Between-group comparisons revealed no differences in any 10RM test between G5 and G10 (P > 0.05). G5 and G10 showed significantly greater 10RM increases than G15 for lat pulldown, leg press, and stiff-legged deadlift. 10RM changes for G20 were lower than all other groups for all exercises (P < 0.05). G5 and G10 showed significantly greater MT increases than G15 and G20 in all sites (P < 0.05). MT increased more in G15 than G20 in all sites (P < 0.05). G5 increases were higher than G10 for pectoralis major MT, whereas G10 showed higher increases in quadriceps MT than G5 (P < 0.05). CONCLUSIONS Five to 10 sets per week might be sufficient for attaining gains in muscle size and strength in trained women during a 24-wk RT program. There appears no further benefit by performing higher exercise volumes. Because lack of time is a commonly cited barrier to exercise adoption, our data support RT programs that are less time consuming, which might increase participation and adherence.",2019,All groups significantly increased all MT measures and 10RM tests after 24 wk of RT (P < 0.05).,"['trained women', 'Trained Women', '40 volunteers that performed RT for 24 wk divided into groups that performed 5 (G5), 10 (G10), 15 (G15), and 20 (G20) sets per muscle group per session']",['resistance training (RT'],"['10RM', 'Muscle thickness (MT', 'MT', '10RM test', 'MT measures and 10RM tests', 'quadriceps MT', '10RM changes for G20', 'muscle performance and hypertrophy']","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0020564', 'cui_str': 'Hypertrophy'}]",40.0,0.0186444,All groups significantly increased all MT measures and 10RM tests after 24 wk of RT (P < 0.05).,"[{'ForeName': 'Matheus', 'Initials': 'M', 'LastName': 'Barbalho', 'Affiliation': 'Department of Biological Science and Health, University of Amazonia, Belém, Pará, BRAZIL.'}, {'ForeName': 'Victor Silveira', 'Initials': 'VS', 'LastName': 'Coswig', 'Affiliation': 'College of Physical Education, Federal University of Pará, Castanhal, Pará, BRAZIL.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Steele', 'Affiliation': 'School of Sport, Health and Social Sciences, Southampton Solent University, Southampton, UNITED KINGDOM.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Fisher', 'Affiliation': 'School of Sport, Health and Social Sciences, Southampton Solent University, Southampton, UNITED KINGDOM.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Paoli', 'Affiliation': 'Department of Biomedical Sciences, Physiological Laboratory, University of Padova, Padova, ITALY.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Gentil', 'Affiliation': 'College of Physical Education and Dance, Federal University of Goiás, Goiânia, Goiás, BRAZIL.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000001818'] 142,29016190,Effect of flapless osteoperforation-assisted tooth movement on atrophic alveolar ridge: Histomorphometric and gene-enrichment analysis.,"OBJECTIVE To investigate the effect of flapless osteoperforation on the tissue response of the atrophic alveolar ridge affected by orthodontic tooth movement (OTM). MATERIALS AND METHODS An atrophic alveolar ridge model was established in the mandibular quadrants of eight beagle dogs. As a split-mouth design, the quadrants were randomly divided into group C (OTM only) and group OP (OTM with flapless osteoperforation). The rate of OTM for 10 weeks was compared between groups, and micro-CT-based histomorphometric analysis and RNA-sequencing-based gene-enrichment analysis were performed targeting the atrophic ridge. RESULTS Group OP displayed more rapid tooth movement with lower bone mineral density and higher trabecular fraction in the atrophic ridge than did group C, showing no intergroup difference of total ridge volume. As contributing biological functional pathways in group OP, the genes related to osteoclast differentiation and TNF signaling pathway were up-regulated and those associated with Wnt signaling pathway and AMPK signaling pathway were down-regulated. CONCLUSIONS Flapless osteoperforation facilitated the rate of OTM toward the atrophic ridge, maintaining low bone density, whereas it did not increase the volume of the atrophic ridge.",2018,"RESULTS Group OP displayed more rapid tooth movement with lower bone mineral density and higher trabecular fraction in the atrophic ridge than did group C, showing no intergroup difference of total ridge volume.","['atrophic alveolar ridge', 'mandibular quadrants of eight beagle dogs']","['C (OTM only) and group OP (OTM with flapless osteoperforation', 'flapless osteoperforation-assisted tooth movement']","['total ridge volume', 'rate of OTM', 'rapid tooth movement with lower bone mineral density and higher trabecular fraction', 'volume of the atrophic ridge', 'atrophic alveolar ridge model']","[{'cui': 'C0333641', 'cui_str': 'Atrophy'}, {'cui': 'C0447411', 'cui_str': 'Alveolar ridge structure (body structure)'}, {'cui': 'C0324306', 'cui_str': 'Beagle (organism)'}, {'cui': 'C0012984', 'cui_str': 'Canis familiaris'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332243', 'cui_str': 'Ridging (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}, {'cui': 'C0447411', 'cui_str': 'Alveolar ridge structure (body structure)'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}]",,0.0241267,"RESULTS Group OP displayed more rapid tooth movement with lower bone mineral density and higher trabecular fraction in the atrophic ridge than did group C, showing no intergroup difference of total ridge volume.","[{'ForeName': 'Ji-Won', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Jung-Yul', 'Initials': 'JY', 'LastName': 'Cha', 'Affiliation': ''}, {'ForeName': 'Ki-Ho', 'Initials': 'KH', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'Yoon-Goo', 'Initials': 'YG', 'LastName': 'Kang', 'Affiliation': ''}, {'ForeName': 'Su-Jung', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': ''}]",The Angle orthodontist,['10.2319/061217-388.1'] 143,32408862,Comparison of C-MAC D-blade videolaryngoscope and McCoy laryngoscope efficacy for nasotracheal intubation in simulated cervical spinal injury: a prospective randomized comparative study.,"BACKGROUND Immobilization with cervical spine worsens endotracheal intubation condition. Though various intubation devices have been demonstrated to perform well in oral endotracheal intubation, limited information is available concerning nasotracheal intubation (NTI) in patients with cervical spine immobilization. The present study compared the performance of the C-MAC D-Blade videolaryngoscope with the McCoy laryngoscope for NTI in patients with simulated cervical spine injuries. METHODS This was a prospective, randomized, controlled, study done in a tertiary hospital. Ninety-five patients requiring NTI were included in data analysis: McCoy group (group M, n = 47) or C-MAC D-Blade videolaryngoscope group (group C, n = 48). A Philadelphia neck collar was applied before anesthetic induction to immobilize the cervical spine. Single experienced anesthesiologist performed NTI. The primary outcome was duration of intubation divided by three steps: nose to oropharynx; oropharynx into glottic inlet; and glottic inlet to trachea. Secondary outcomes included glottic view as percentage of glottis opening (POGO) score and Cormack-Lehance (CL) grade, modified nasal intubation-difficulty scale (NIDS) rating, hemodynamic changes before and after intubation, and complications. RESULTS Total intubation duration was significantly shorter in group C (39.5 ± 11.4 s) compared to group M (48.1 ± 13.9 s). Group C required significantly less time for glottic visualization and endotracheal tube placement in the trachea. More patients in group C had CL grade I and higher POGO scores (P <  0.001, for both measures). No difficulty in NTI (modified NIDS = 0) was more in group C than group M. Hemodynamic changes and incidence of complications were comparable between groups. CONCLUSION The C-MAC D-Blade videolaryngoscope is an effective tool for NTI in a simulated difficult airway, which improves glottic visualization and shortens intubation time relative to those with McCoy laryngoscope. TRIAL REGISTRATION Clinical Research Information Service of the Korea National Institute of Health, Identification number: KCT 0004535, Registered December 10, 2019, Retrospectively registered, http://cris.nih.go.kr.",2020,"RESULTS Total intubation duration was significantly shorter in group C (39.5 ± 11.4 s) compared to group M (48.1 ± 13.9 s).","['patients with simulated cervical spine injuries', 'Immobilization with cervical spine worsens endotracheal intubation condition', 'simulated cervical spinal injury', 'patients with cervical spine immobilization', 'Ninety-five patients requiring NTI were included in data analysis']","['nasotracheal intubation', 'C-MAC D-Blade videolaryngoscope with the McCoy laryngoscope for NTI', 'McCoy', 'C-MAC D-Blade videolaryngoscope group', 'C-MAC D-blade videolaryngoscope and McCoy laryngoscope efficacy']","['Hemodynamic changes and incidence of complications', 'duration of intubation divided by three steps', 'time for glottic visualization and endotracheal tube placement', 'CL grade', 'Total intubation duration', 'POGO scores', 'glottic view as percentage of glottis opening (POGO) score and Cormack-Lehance (CL) grade, modified nasal intubation-difficulty scale (NIDS) rating, hemodynamic changes before and after intubation, and complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0432666', 'cui_str': 'Injury of cervical spine'}, {'cui': 'C0020944', 'cui_str': 'Immobilization - action'}, {'cui': 'C0728985', 'cui_str': 'Structure of cervical vertebral column'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0037937', 'cui_str': 'Spinal injury'}, {'cui': 'C1301792', 'cui_str': 'Cervical spine immobilization'}, {'cui': 'C4517906', 'cui_str': '95'}, {'cui': 'C0396625', 'cui_str': 'Nasotracheal intubation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0396625', 'cui_str': 'Nasotracheal intubation'}, {'cui': 'C0009545', 'cui_str': 'Active C5b6789'}, {'cui': 'C2948008', 'cui_str': 'Blade'}, {'cui': 'C3164607', 'cui_str': 'Videolaryngoscope'}, {'cui': 'C0180453', 'cui_str': 'Laryngoscope'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0017681', 'cui_str': 'Glottis structure'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0336630', 'cui_str': 'Endotracheal tube'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0396625', 'cui_str': 'Nasotracheal intubation'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.119102,"RESULTS Total intubation duration was significantly shorter in group C (39.5 ± 11.4 s) compared to group M (48.1 ± 13.9 s).","[{'ForeName': 'Kwon Hui', 'Initials': 'KH', 'LastName': 'Seo', 'Affiliation': 'Department of anesthesiology and pain medicine, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, 22, Gwanpyeong-ro 170 beon-gil, Dong-gu, Anyang-si, Gyeonggi-do, 14068, Republic of Korea.'}, {'ForeName': 'Kyung Mi', 'Initials': 'KM', 'LastName': 'Kim', 'Affiliation': 'Clinical assistant professor, Department of anesthesiology and pain medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. sumsonyo@gmail.com.'}, {'ForeName': 'Hyunji', 'Initials': 'H', 'LastName': 'John', 'Affiliation': 'Department of anesthesiology and pain medicine, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, 22, Gwanpyeong-ro 170 beon-gil, Dong-gu, Anyang-si, Gyeonggi-do, 14068, Republic of Korea.'}, {'ForeName': 'Joo Hyun', 'Initials': 'JH', 'LastName': 'Jun', 'Affiliation': 'Department of anesthesiology and pain medicine, Kangnam Sacred Heart Hospital, Hallym University School of Medicine, 12, Siheung-daero 187-gil, Yeongdeungpo-gu, Seoul, 07441, Republic of Korea.'}, {'ForeName': 'Minsoo', 'Initials': 'M', 'LastName': 'Han', 'Affiliation': 'Department of anesthesiology and pain medicine, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, 22, Gwanpyeong-ro 170 beon-gil, Dong-gu, Anyang-si, Gyeonggi-do, 14068, Republic of Korea.'}, {'ForeName': 'Soyoun', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of anesthesiology and pain medicine, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, 22, Gwanpyeong-ro 170 beon-gil, Dong-gu, Anyang-si, Gyeonggi-do, 14068, Republic of Korea.'}]",BMC anesthesiology,['10.1186/s12871-020-01021-x'] 144,30247454,Estimating the Weight of Children During Simulated Emergency Situations Using the Broselow Tape: Are We Underestimating the Risks of Errors?,"OBJECTIVE The objective of this study was to evaluate whether residents can accurately estimate children's weight using the Broselow tape. METHOD We conducted a preplanned secondary analysis from an experimental trial. Participants were residents in pediatrics, family medicine, and emergency medicine rotating in the ED. Residents were randomly assigned to 2 sets of paired scenarios during 2 sessions. They were asked to estimate the weight of a manikin using the Broselow tape at the beginning of each scenario. The first scenario from the initial session and the last scenario from the second session were used for the current study. The primary analysis was the proportion of participants who accurately estimated manikin weight within a 10% margin of error. RESULTS Forty residents were recruited. Thirty-two (80%) reported knowledge of the Broselow tape and 13 (32.5%) reported previous use. Weight estimation was accurate in 60% (24/40; 95% confidence interval [CI], 45%-74%) during the first scenarios. Error in weight estimation differed by greater than 25% in 28% (11/40). Error in estimation was not associated with previous knowledge (odds ratio, 6.2; 95% CI, 0.68-56) or previous use (odds ratio, 0.9; 95% CI, 0.23-3.5) of the Broselow tape. In the last scenario, 88% accurately estimated manikin weight (35/40; 95% CI, 73%-95%). CONCLUSIONS Although most residents reported knowledge of the Broselow tape, 40% made erroneous weight estimations by at least 10% with the first use in this simulation study. With repeated use, they improved significantly over time. Teaching appropriate use of the Broselow tape should be part of residency-training curricula and pediatric advanced life support course.",2020,"Error in estimation was not associated with previous knowledge (odds ratio, 6.2; 95% CI, 0.68-56) or previous use (odds ratio, 0.9; 95% CI, 0.23-3.5) of the Broselow tape.","['Forty residents were recruited', 'Participants were residents in pediatrics, family medicine, and emergency medicine rotating in the ED']",['Broselow Tape'],"['erroneous weight estimations', 'manikin weight', 'Weight estimation', 'proportion of participants who accurately estimated manikin weight', 'knowledge of the Broselow tape', 'Error in weight estimation', 'Weight of Children']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0015607', 'cui_str': 'Family Practice'}, {'cui': 'C0013964', 'cui_str': 'Emergency Medicine'}, {'cui': 'C0231458', 'cui_str': 'Rotated (qualifier value)'}]","[{'cui': 'C1704747', 'cui_str': 'Tape (basic dose form)'}]","[{'cui': 'C3541364', 'cui_str': 'Erroneous component'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0024722', 'cui_str': 'Mannequins'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1704747', 'cui_str': 'Tape (basic dose form)'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",40.0,0.0522277,"Error in estimation was not associated with previous knowledge (odds ratio, 6.2; 95% CI, 0.68-56) or previous use (odds ratio, 0.9; 95% CI, 0.23-3.5) of the Broselow tape.","[{'ForeName': 'Guylaine', 'Initials': 'G', 'LastName': 'Larose', 'Affiliation': 'From the Division of Emergency Medicine, Department of Pediatrics.'}, {'ForeName': 'Arielle', 'Initials': 'A', 'LastName': 'Levy', 'Affiliation': 'From the Division of Emergency Medicine, Department of Pediatrics.'}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Bailey', 'Affiliation': 'From the Division of Emergency Medicine, Department of Pediatrics.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Cummins-McManus', 'Affiliation': 'From the Division of Emergency Medicine, Department of Pediatrics.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Lebel', 'Affiliation': 'Department of Pharmacy, Faculty of Medicine, CHU Sainte-Justine, Université de Montreal, Montreal, Quebec, Canada.'}, {'ForeName': 'Jocelyn', 'Initials': 'J', 'LastName': 'Gravel', 'Affiliation': 'From the Division of Emergency Medicine, Department of Pediatrics.'}]",Pediatric emergency care,['10.1097/PEC.0000000000001581'] 145,29099236,Effect of incisal loading during orthodontic treatment in adults: A randomized control trial.,"OBJECTIVE To measure the changes in tooth mobility, alveolar bone, and receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) in the gingival crevicular fluid (GCF) during orthodontic treatment to regain incisal function in the presence and absence of biting exercises. MATERIALS AND METHODS Thirty-six females (42.3 ± 6.5 years old) with periodontally compromised upper incisors received orthodontic treatment to obtain ideal incisor relationships. Eighteen subjects in the experimental biting exercise group were instructed to bite a soft plastic roll for 5 min/d; the 18 control subjects were not given plastic rolls. Alveolar bone thickness, height, and density around the upper incisors were assessed at three root levels using cone-beam computed tomography. GCF was collected at the labial and palatal sites of the upper incisors at pretreatment (T0), end of treatment (T1), 1 month after T1 (T2), and 7 months after T1 (T3). RANKL/OPG was determined using enzyme-linked immunosorbent assays. RESULTS Labial and palatal bone thickness significantly increased (>twofold) from T1 to T3 in the experimental group at all three root levels (all P < .05). Bone thickness correlated negatively with RANKL/OPG ratio between T1 and T2 ( P < .05). Tooth mobility, bone height, and density were not significantly different between T1 and T3. CONCLUSIONS Biting exercises significantly increased bone thickness but did not affect tooth mobility, bone height, or density. The RANKL/OPG ratio decreased 1 month after treatment (T2) and correlated with increased bone thickness. ( ClinicalTrials.in.th TCTR20170625001).",2018,Bone thickness correlated negatively with RANKL/OPG ratio between T1 and T2 ( P < .05).,"['Eighteen subjects in the experimental biting exercise group', 'Thirty-six females (42.3 ± 6.5 years old) with periodontally compromised upper incisors received', 'adults']","['orthodontic treatment to obtain ideal incisor relationships', 'RANKL)/osteoprotegerin', 'incisal loading', 'bite a soft plastic roll for 5 min/d; the 18 control subjects were not given plastic rolls', 'Biting exercises']","['Bone thickness', 'Tooth mobility, bone height, and density', 'Labial and palatal bone thickness', 'bone thickness', 'Alveolar bone thickness, height, and density around the upper incisors', 'tooth mobility, bone height, or density', 'OPG ratio', 'tooth mobility, alveolar bone, and receptor activator of nuclear factor kappa-B ligand ', 'GCF']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4319606', 'cui_str': 'Thirty-six'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0021156', 'cui_str': 'Incisor'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0029335', 'cui_str': 'Orthodontics'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0021156', 'cui_str': 'Incisor'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C4040028', 'cui_str': 'Incisal'}, {'cui': 'C0005658', 'cui_str': 'Bites'}, {'cui': 'C0205358', 'cui_str': 'Soft (qualifier value)'}, {'cui': 'C0032167', 'cui_str': 'Plastics'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0040445', 'cui_str': 'Tooth Mobility'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0023759', 'cui_str': 'Lip'}, {'cui': 'C0700374', 'cui_str': 'Palate'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0021156', 'cui_str': 'Incisor'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0666364', 'cui_str': 'CD254 Antigen'}]",36.0,0.0228137,Bone thickness correlated negatively with RANKL/OPG ratio between T1 and T2 ( P < .05).,"[{'ForeName': 'Pornputthi', 'Initials': 'P', 'LastName': 'Puttaravuttiporn', 'Affiliation': ''}, {'ForeName': 'Mutita', 'Initials': 'M', 'LastName': 'Wongsuwanlert', 'Affiliation': ''}, {'ForeName': 'Chairat', 'Initials': 'C', 'LastName': 'Charoemratrote', 'Affiliation': ''}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Lindauer', 'Affiliation': ''}, {'ForeName': 'Chidchanok', 'Initials': 'C', 'LastName': 'Leethanakul', 'Affiliation': ''}]",The Angle orthodontist,['10.2319/071017-456.1'] 146,31675086,"Effectiveness of Universal School-Based Screening vs Targeted Screening for Major Depressive Disorder Among Adolescents: A Trial Protocol for the Screening in High Schools to Identify, Evaluate, and Lower Depression (SHIELD) Randomized Clinical Trial.","Importance The prevalence of annual major depressive disorder (MDD) episodes among adolescents in the United States rose from 8.3% in 2008 to 12.8% in 2016. Despite the US Preventive Services Task Force 2009 endorsement and 2016 reaffirmation of universal adolescent MDD screening in primary care, many adolescents are missed, as more than 60% lack annual preventive health visits and MDD screening remains inconsistent. Objective To compare the effectiveness of universal school-based screening for adolescent MDD vs the existing process of targeted screening based on observable behavior. Design, Setting, and Participants Screening in High Schools to Identify, Evaluate, and Lower Depression (SHIELD) is a randomized clinical trial that will take place in at least 8 Pennsylvania public high schools among at least 9650 students enrolled in 9th through 12th grade. Students will be randomized by grade to either targeted screening (current process) or universal screening (intervention). Students in the targeted screening arm will complete mandated school health screenings, which do not include an MDD screening. These students will be observed through the academic year for referral to the Student Assistance Program (SAP), required in all Pennsylvania schools. If a student exhibits behavior concerning for MDD raised by any contact (eg, teacher, parent, peer, or self-referral), SAP will triage the student and provide follow-up recommendations. Students in the universal screening arm will complete the validated Patient Health Questionnaire-9 (PHQ-9) from September through December of the academic year. The PHQ-9 includes 9 close-ended questions and is scored from 0 to 27. Students with a positive result (ie, score >10) will proceed to SAP triage. Students in the intervention arm will also be observed for behavior concerning for MDD during the school year, potentially prompting SAP triage referral. The primary outcome will be the proportion of adolescents referred to SAP triage who are recommended for additional MDD-related services and successfully engage with at least 1 SAP recommendation. Observers will not be blinded to patient groups, and an intention-to-treat analysis will be used. Discussion The SHIELD trial began with 3 schools during the 2018-2019 academic year. Screening in the intervention arm with the PHQ-9 is currently underway for the remaining schools, with a goal of completion of all PHQ-9 screenings by December 2019. This trial addresses the US Preventive Services Task Force call for large, high-quality randomized clinical trials to better understand the effects of MDD screening and quantify the proportion of adolescents with screen-detected MDD successfully referred and treated. Trial Registration ClinicalTrials.gov identifier: NCT03716869.",2019,The primary outcome will be the proportion of adolescents referred to SAP triage who are recommended for additional MDD-related services and successfully engage with at least 1 SAP recommendation.,"['Students with a positive result', 'least 8 Pennsylvania public high schools among at least 9650 students enrolled in 9th through 12th grade', '3 schools during the 2018-2019 academic year', 'Major Depressive Disorder', 'Adolescents', 'adolescents in the United States rose from 8.3% in 2008 to 12.8% in 2016', 'adolescents with screen-detected MDD successfully referred and treated']","['targeted screening (current process) or universal screening (intervention', 'Universal School-Based Screening vs Targeted Screening', 'universal school-based screening', 'universal adolescent MDD screening']","['prevalence of annual major depressive disorder (MDD) episodes', 'proportion of adolescents referred to SAP triage who are recommended for additional MDD-related services and successfully engage with at least 1 SAP recommendation']","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C4517547', 'cui_str': '12.8'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}]","[{'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}, {'cui': 'C0175671', 'cui_str': 'Universal (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0040861', 'cui_str': 'Triage'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}]",2009.0,0.132386,The primary outcome will be the proportion of adolescents referred to SAP triage who are recommended for additional MDD-related services and successfully engage with at least 1 SAP recommendation.,"[{'ForeName': 'Deepa L', 'Initials': 'DL', 'LastName': 'Sekhar', 'Affiliation': 'Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'Krista L', 'Initials': 'KL', 'LastName': 'Pattison', 'Affiliation': 'Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Confair', 'Affiliation': 'Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'Alissa', 'Initials': 'A', 'LastName': 'Molinari', 'Affiliation': 'Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'Eric W', 'Initials': 'EW', 'LastName': 'Schaefer', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Waxmonsky', 'Affiliation': 'Department of Psychiatry, Penn State College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'Leslie R', 'Initials': 'LR', 'LastName': 'Walker-Harding', 'Affiliation': ""Department of Pediatrics, Seattle Children's, Seattle, Washington.""}, {'ForeName': 'Perri', 'Initials': 'P', 'LastName': 'Rosen', 'Affiliation': 'Garrett Lee Smith Youth Suicide Prevention Grant, Harrisburg, Pennsylvania.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Kraschnewski', 'Affiliation': 'Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania.'}]",JAMA network open,['10.1001/jamanetworkopen.2019.14427'] 147,29083225,Alveolar bone response to light-force tipping and bodily movement in maxillary incisor advancement: A prospective randomized clinical trial.,"OBJECTIVE To compare alveolar bone thickness and height changes between untreated incisors (control), incisors advanced with light-force tipping, and incisors advanced with bodily movement mechanics. MATERIALS AND METHODS Forty-three subjects (aged 9.49 ± 1.56 years) with anterior crossbite were allocated into an untreated group (control), tipping group, or bodily movement group. Lateral cephalograms were taken before advancement (T 0 ) and after obtaining normal overjet (T 1 ). Changes in labial and palatal alveolar bone thickness and height surrounding maxillary incisors were evaluated with limited field-of-view cone-beam computed tomography before advancement (CT 0 ) and 4 months after normal overjet was obtained (CT 1 ). Wilcoxon matched-pairs signed-rank and Kruskal-Wallis one-way ANOVA tests were used to compare changes within and between groups, as appropriate. The significance level was set at .05. RESULTS Labial alveolar bone thickness at the midroot and apical levels were significantly decreased in the bodily movement group ( P < .05). However, between groups, there was no statistically significant difference in labial bone thickness changes at any level. Palatal and total alveolar bone thickness at the midroot and apical levels were significantly decreased in the tipping group compared with the control and bodily movement groups ( P < .05). Neither labial nor palatal bone height changes were significantly different among groups. CONCLUSIONS Maxillary incisor advancement with light-force tipping and bodily movement in growing patients resulted in labial alveolar bone thickness and labial and palatal alveolar bone height changes that were similar to the untreated group.",2018,Palatal and total alveolar bone thickness at the midroot and apical levels were significantly decreased in the tipping group compared with the control and bodily movement groups ( P < .05).,"['maxillary incisor advancement', 'Forty-three subjects (aged 9.49 ± 1.56 years) with anterior crossbite', 'untreated incisors (control), incisors advanced with light-force tipping, and incisors advanced with bodily movement mechanics']","['untreated group (control), tipping group, or bodily movement group']","['Palatal and total alveolar bone thickness at the midroot and apical levels', 'labial bone thickness changes', 'labial nor palatal bone height changes', 'labial alveolar bone thickness and labial and palatal alveolar bone height changes', 'Labial alveolar bone thickness at the midroot and apical levels', 'alveolar bone thickness and height changes', 'Alveolar bone response', 'Changes in labial and palatal alveolar bone thickness and height surrounding maxillary incisors']","[{'cui': 'C0021156', 'cui_str': 'Incisor'}, {'cui': 'C0441478', 'cui_str': 'Surgical advancement - action'}, {'cui': 'C0450368', 'cui_str': '43 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517507', 'cui_str': 'One point five six'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0266058', 'cui_str': 'Anterior crossbite (disorder)'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]","[{'cui': 'C0700374', 'cui_str': 'Palate'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0205111', 'cui_str': 'Apical (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0023759', 'cui_str': 'Lip'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1282914', 'cui_str': 'Surrounding (qualifier value)'}, {'cui': 'C0021156', 'cui_str': 'Incisor'}]",43.0,0.030179,Palatal and total alveolar bone thickness at the midroot and apical levels were significantly decreased in the tipping group compared with the control and bodily movement groups ( P < .05).,"[{'ForeName': 'Priyakorn', 'Initials': 'P', 'LastName': 'Chaimongkol', 'Affiliation': ''}, {'ForeName': 'Udom', 'Initials': 'U', 'LastName': 'Thongudomporn', 'Affiliation': ''}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Lindauer', 'Affiliation': ''}]",The Angle orthodontist,['10.2319/070717-449.1'] 148,28600154,"Markers of Successful Extubation in Extremely Preterm Infants, and Morbidity After Failed Extubation.","OBJECTIVES To identify variables associated with successful elective extubation, and to determine neonatal morbidities associated with extubation failure in extremely preterm neonates. STUDY DESIGN This study was a secondary analysis of the National Institute of Child Health and Human Development Neonatal Research Network's Surfactant, Positive Pressure, and Oxygenation Randomized Trial that included extremely preterm infants born at 24 0/7 to 27 6/7 weeks' gestation. Patients were randomized either to a permissive ventilatory strategy (continuous positive airway pressure group) or intubation followed by early surfactant (surfactant group). There were prespecified intubation and extubation criteria. Extubation failure was defined as reintubation within 5 days of extubation. RESULTS Of 1316 infants in the trial, 1071 were eligible; 926 infants had data available on extubation status; 538 were successful and 388 failed extubation. The rate of successful extubation was 50% (188/374) in the continuous positive airway pressure group and 63% (350/552) in the surfactant group. Successful extubation was associated with higher 5-minute Apgar score, and pH prior to extubation, lower peak fraction of inspired oxygen within the first 24 hours of age and prior to extubation, lower partial pressure of carbon dioxide prior to extubation, and non-small for gestational age status after adjustment for the randomization group assignment. Infants who failed extubation had higher adjusted rates of mortality (OR 2.89), bronchopulmonary dysplasia (OR 3.06), and death/ bronchopulmonary dysplasia (OR 3.27). CONCLUSIONS Higher 5-minute Apgar score, and pH prior to extubation, lower peak fraction of inspired oxygen within first 24 hours of age, lower partial pressure of carbon dioxide and fraction of inspired oxygen prior to extubation, and nonsmall for gestational age status were associated with successful extubation. Failed extubation was associated with significantly higher likelihood of mortality and morbidities. TRIAL REGISTRATION ClinicalTrials.gov: NCT00233324.",2017,The rate of successful extubation was 50% (188/374) in the continuous positive airway pressure group and 63% (350/552) in the surfactant group.,"['extremely preterm neonates', '1316 infants in the trial, 1071 were eligible; 926 infants had data available on extubation status; 538 were successful and 388 failed extubation', ""National Institute of Child Health and Human Development Neonatal Research Network's Surfactant, Positive Pressure, and Oxygenation Randomized Trial that included extremely preterm infants born at 24 0/7 to 27 6/7 weeks' gestation""]",['permissive ventilatory strategy (continuous positive airway pressure group) or intubation followed by early surfactant (surfactant group'],"['5-minute Apgar score, and pH prior to extubation, lower peak fraction of inspired oxygen', '5-minute Apgar score, and pH', 'partial pressure of carbon dioxide prior to extubation, and non-small for gestational age status', 'partial pressure of carbon dioxide and fraction of inspired oxygen prior to extubation, and nonsmall for gestational age status', 'Extubation failure', 'mortality and morbidities', 'rate of successful extubation', 'mortality', 'Morbidity']","[{'cui': 'C0205403', 'cui_str': 'Extreme (qualifier value)'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C1513896', 'cui_str': 'National Institute of Child Health and Human Development'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0035168'}, {'cui': 'C4543209', 'cui_str': 'Surfactant'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C3494262', 'cui_str': 'Extremely Preterm Infants'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C4543209', 'cui_str': 'Surfactant'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0003533', 'cui_str': 'Apgar Score'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C0030604', 'cui_str': 'Partial Pressure'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0235991', 'cui_str': 'Small for gestational age'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C1272703', 'cui_str': 'Successful'}]",1071.0,0.151987,The rate of successful extubation was 50% (188/374) in the continuous positive airway pressure group and 63% (350/552) in the surfactant group.,"[{'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Chawla', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, MI. Electronic address: schawla@dmc.org.'}, {'ForeName': 'Girija', 'Initials': 'G', 'LastName': 'Natarajan', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, MI.'}, {'ForeName': 'Seetha', 'Initials': 'S', 'LastName': 'Shankaran', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, MI.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Carper', 'Affiliation': 'Social, Statistical and Environmental Sciences Unit, Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC.'}, {'ForeName': 'Luc P', 'Initials': 'LP', 'LastName': 'Brion', 'Affiliation': 'Department of Pediatrics, University of Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Keszler', 'Affiliation': 'Department of Pediatrics, Women and Infant Hospital of Rhode Island, Alpert Medical School of Brown University, Providence, RI.'}, {'ForeName': 'Waldemar A', 'Initials': 'WA', 'LastName': 'Carlo', 'Affiliation': 'Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Namasivayam', 'Initials': 'N', 'LastName': 'Ambalavanan', 'Affiliation': 'Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Marie G', 'Initials': 'MG', 'LastName': 'Gantz', 'Affiliation': 'Social, Statistical and Environmental Sciences Unit, Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC.'}, {'ForeName': 'Abhik', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'Social, Statistical, and Environmental Sciences Unit, RTI International, Rockville, MD.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Finer', 'Affiliation': 'Department of Pediatrics, UC San Diego Medical Center, UC San Diego School of Medicine, San Diego, CA.'}, {'ForeName': 'Ronald N', 'Initials': 'RN', 'LastName': 'Goldberg', 'Affiliation': 'Department of Pediatrics, Duke University School of Medicine, Durham, NC.'}, {'ForeName': 'C Michael', 'Initials': 'CM', 'LastName': 'Cotten', 'Affiliation': 'Department of Pediatrics, Duke University School of Medicine, Durham, NC.'}, {'ForeName': 'Rosemary D', 'Initials': 'RD', 'LastName': 'Higgins', 'Affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of pediatrics,['10.1016/j.jpeds.2017.04.050'] 149,30550415,Effective But Not Adhered to: How Can We Improve Adherence to Evidence-Based Hamstring Injury Prevention in Amateur Football?,"OBJECTIVES To investigate adherence to a Nordic hamstring exercise (NHE) program in a real-world context of male amateur football, and the perceptions of end users (players) and intervention deliverers (coaches and medical staff) about adherence to this proven effective program. DESIGN Retrospective cohort study. SETTING Dutch amateur football. PARTICIPANTS Two hundred sixty-four players, 23 coaches, and 29 medical staff from Dutch amateur football teams that participated in a national randomized controlled trial 2 years earlier. INDEPENDENT VARIABLES Nordic hamstring exercise program. MAIN OUTCOME MEASURES Nordic hamstring exercise program adherence during 2014 and 2015. Intervention or control group allocation during the trial, transfers, and personal perception about adherence to the program were also examined. RESULTS Of all players, 69% reported never, 16% sometimes, 6% frequently, 5% often, and 4% always performing exercises of the NHE program. Adherence to the NHE program was higher among players who had been in the NHE arm of the previous trial and among players who had not been transferred to another club compared with players who had been transferred. Key factors in stimulating players to adhere to the NHE program were knowledge of the NHE and personal motivation. Coaches and medical staff members also mentioned personal motivation and consensus with team staff as key factors to encourage NHE adherence. CONCLUSIONS Among high-level male amateur football players, adherence to an evidence-based hamstring injury-prevention program was very low. It is essential to recognize factors that stimulate or limit adherence to injury-prevention programs for effective programs to actually lead to a reduction in hamstring injuries in a real-world context.",2021,"Among high-level male amateur football players, adherence to an evidence-based hamstring injury-prevention program was very low.","['players who had been in the NHE arm of the previous trial and among players who had not been transferred to another club compared with players who had been transferred', 'Two hundred sixty-four players, 23 coaches, and 29 medical staff from Dutch amateur football teams that participated in a national randomized controlled trial 2 years earlier', 'Dutch amateur football']",['Nordic hamstring exercise (NHE) program'],[],"[{'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C0149651', 'cui_str': 'Clubbing (morphologic abnormality)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C0025106', 'cui_str': 'Medical Staff'}, {'cui': 'C0013331', 'cui_str': 'Dutch (ethnic group)'}, {'cui': 'C0336986', 'cui_str': 'Football'}, {'cui': 'C1096777', 'cui_str': 'Randomized Controlled Trial'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",[],,0.0341895,"Among high-level male amateur football players, adherence to an evidence-based hamstring injury-prevention program was very low.","[{'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'van der Horst', 'Affiliation': 'Department of Rehabilitation, Physical Therapy Science and Sports, Rudolf Magnus Institute of Neurosciences, University Medical Center Utrecht, Utrecht, the Netherlands; and.'}, {'ForeName': 'Sander van de', 'Initials': 'SV', 'LastName': 'Hoef', 'Affiliation': 'Department of Rehabilitation, Physical Therapy Science and Sports, Rudolf Magnus Institute of Neurosciences, University Medical Center Utrecht, Utrecht, the Netherlands; and.'}, {'ForeName': 'Paul van', 'Initials': 'PV', 'LastName': 'Otterloo', 'Affiliation': 'Department of Rehabilitation, Physical Therapy Science and Sports, Rudolf Magnus Institute of Neurosciences, University Medical Center Utrecht, Utrecht, the Netherlands; and.'}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Klein', 'Affiliation': 'Department of Rehabilitation, Physical Therapy Science and Sports, Rudolf Magnus Institute of Neurosciences, University Medical Center Utrecht, Utrecht, the Netherlands; and.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Brink', 'Affiliation': 'Department of Rehabilitation, Physical Therapy Science and Sports, Rudolf Magnus Institute of Neurosciences, University Medical Center Utrecht, Utrecht, the Netherlands; and.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Backx', 'Affiliation': 'Department of Rehabilitation, Physical Therapy Science and Sports, Rudolf Magnus Institute of Neurosciences, University Medical Center Utrecht, Utrecht, the Netherlands; and.'}]",Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine,['10.1097/JSM.0000000000000710'] 150,30439725,Can Exercise Targeting Mid-Thoracic Spine Segmental Movement Reduce Back Pain and Improve Sensory Perception in Cross-Country Skiers?,"OBJECTIVE To assess the role of exercise targeting proper trunk stabilization and segmental spinal movement in back pain and sensory perception among cross-country skiers. DESIGN Randomized, controlled trial with blinded outcome assessors. SETTING University Hospital, Department of Rehabilitation and Sports Medicine. PARTICIPANTS Twenty elite cross-country skiers aged 17 to 27 years. INTERVENTIONS Ten cross-country skiers integrated 3 types of exercise targeting segmental motion in mid-thoracic spine into their routine training practice for 2 months. The 10 controls performed routine athletic training. MAIN OUTCOME MEASURES The Young Spine Questionnaire to measure intensity and frequency of back pain was completed at the start and end of study. Tactile sensory perception using 10-g Semmes-Weinstein monofilament, thermic perception using TIP THERM device, graphesthesia assessed by a touch monitor pencil, 2-point discrimination assessed by a digital caliper, and vibration perception assessed by a 128-Hz tuning fork measured in mid-thoracic spine 5 times. RESULTS No significant group differences in pain and sensory perception were identified at baseline. Over the 2-month study interval, repeated-measures analysis of variance revealed that the experimental group improved significantly relative to the control group on pain intensity (P = 0.005 for cervical, P = 0.004 for thoracic, and P = 0.014 for lumbar) and frequency of pain in the thoracic area only (P = 0.011). Improvements were also observed in the experimental relative to control group on graphesthesia (P < 0.001), vibration perception (P = 0.002), and 2-point discrimination (P < 0.001). CONCLUSIONS Exercise targeting the mid-thoracic spine may decrease back pain and improve sensory perception in cross-country skiers. LEVEL OF EVIDENCE Original research, level I.",2021,"Improvements were also observed in the experimental relative to control group on graphesthesia (P < 0.001), vibration perception (P = 0.002), and 2-point discrimination (P < 0.001). ","['Twenty elite cross-country skiers aged 17 to 27 years', 'University Hospital, Department of Rehabilitation and Sports Medicine']","['Ten cross-country skiers integrated 3 types of exercise targeting segmental motion in mid-thoracic spine into their routine training practice', 'routine athletic training', 'exercise targeting proper trunk stabilization and segmental spinal movement']","['frequency of pain', 'sensory perception', 'vibration perception', 'Tactile sensory perception', 'Young Spine Questionnaire to measure intensity and frequency of back pain', 'pain and sensory perception', 'pain intensity']","[{'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0425040', 'cui_str': 'Skier (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0038040', 'cui_str': 'Sports Medicine'}]","[{'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0425040', 'cui_str': 'Skier (finding)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205122', 'cui_str': 'Segmental (qualifier value)'}, {'cui': 'C0687704', 'cui_str': 'Motions (qualifier value)'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0581269', 'cui_str': 'Thoracic spine structure (body structure)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C1510656', 'cui_str': 'Athletics'}, {'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0036658', 'cui_str': 'Sensory Function'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0439815', 'cui_str': 'Tactile (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0037949', 'cui_str': 'Spinal Column'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",,0.0385444,"Improvements were also observed in the experimental relative to control group on graphesthesia (P < 0.001), vibration perception (P = 0.002), and 2-point discrimination (P < 0.001). ","[{'ForeName': 'Alena', 'Initials': 'A', 'LastName': 'Kobesova', 'Affiliation': 'Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Andel', 'Affiliation': 'School of Aging Studies, University of South Florida, Tampa, Florida; and.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Cizkova', 'Affiliation': 'Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Kolar', 'Affiliation': 'Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Kriz', 'Affiliation': 'Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.'}]",Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine,['10.1097/JSM.0000000000000699'] 151,31630600,"Alalfy modified cervical inversion technique as a tamponade in controlling PPH in placenta previa, a multicentric double blind randomized controlled trial.","INTRODUCTION Postpartum hemorrhage that occurs frequently with placenta previa is one of the causes of maternal mortality in 14% in developing countries. OBJECTIVE To assess efficacy of cervical inversion as a tamponade in controlling bed of placenta in cases of placenta previa. PATIENTS AND METHOD A prospective randomized controlled study was conducted among a total of 240 pregnant women with placenta previa (120 subjected to Alalfy modified cervical inversion technique plus hemostatic sutures and 120 was not subjected cervical inversion and only was subjected to hemostatic sutures in Obstetrics and Gynecology Department at Suez Canal University hospital, Helwan University and Algezeerah hospital for a planned cesarean section). RESULTS The mean intraoperative blood loss, the intraoperative time, and the postoperative hemoglobin show a statistically significant difference between cases with placenta previa who were exposed to cervical inversion in comparison to cases that had no cervical inversion with a p -value <.001. CONCLUSION Modified cervical inversion (Alalfy technique) as a tamponade when added to hemostatic sutures to the placental bed is an easy, rapid, and efficient procedure that can decrease the amount of blood loss, time needed to stop bleeding per bed, total operative time, also it can decrease the need for blood transfusion.",2021,"The mean intraoperative blood loss, the intraoperative time, and the postoperative hemoglobin show a statistically significant difference between cases with placenta previa who were exposed to cervical inversion in comparison to cases that had no cervical inversion with a p -value <.001. ","['240 pregnant women with placenta previa (120 subjected to Alalfy modified cervical inversion technique plus hemostatic sutures and 120 was not subjected cervical inversion and only was subjected to hemostatic sutures in Obstetrics and Gynecology Department at Suez Canal University hospital, Helwan University hospitals, Kasralainy Hospital, Ain Shams University Hospital, and Algezeerah hospital for a planned cesarean section']","['Modified cervical inversion (Alalfy technique', 'Alalfy modified cervical inversion technique']","['maternal mortality', 'mean intraoperative blood loss, the intraoperative time, and the postoperative hemoglobin']","[{'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0032046', 'cui_str': 'Placenta Previa'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C0021945', 'cui_str': 'Inversion (morphologic abnormality)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0019120', 'cui_str': 'Hemostatics'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0587480', 'cui_str': 'Obstetrics and gynecology department (environment)'}, {'cui': 'C0442636', 'cui_str': 'Canal (environment)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0007876', 'cui_str': 'C-Section (OB)'}]","[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C0021945', 'cui_str': 'Inversion (morphologic abnormality)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}]","[{'cui': 'C0024923', 'cui_str': 'Maternal Mortality'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",240.0,0.130663,"The mean intraoperative blood loss, the intraoperative time, and the postoperative hemoglobin show a statistically significant difference between cases with placenta previa who were exposed to cervical inversion in comparison to cases that had no cervical inversion with a p -value <.001. ","[{'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Alalfy', 'Affiliation': 'Reproductive Health and Family Planning Department, National Research Centre, Giza, Egypt.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Hussein', 'Affiliation': 'Obstetrics and Gynecology Department, Suez Canal University, Al Ismailia, Egypt.'}, {'ForeName': 'Waled', 'Initials': 'W', 'LastName': 'Saber', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Elsharkawy', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Sameh', 'Initials': 'S', 'LastName': 'Salama', 'Affiliation': 'Reproductive Health and Family Planning Department, National Research Centre, Giza, Egypt.'}, {'ForeName': 'Yossra', 'Initials': 'Y', 'LastName': 'Lasheen', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Doaa', 'Initials': 'D', 'LastName': 'Elshafey', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Taher', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Dalia', 'Initials': 'D', 'LastName': 'Farouk', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Eltaieb', 'Affiliation': 'Obstetrics and Gynecology Department, Ainshams Faculty of Medicine, Cairo, Egypt.'}, {'ForeName': 'Sherif', 'Initials': 'S', 'LastName': 'Elsirgany', 'Affiliation': 'Reproductive Health and Family Planning Department, National Research Centre, Giza, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Hussein', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Fikry', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Hatem', 'Initials': 'H', 'LastName': 'Hassan', 'Affiliation': 'Reproductive Health and Family Planning Department, National Research Centre, Giza, Egypt.'}, {'ForeName': 'Jehan', 'Initials': 'J', 'LastName': 'Sadek', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Doaa', 'Initials': 'D', 'LastName': 'Alaa', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Hesham', 'Initials': 'H', 'LastName': 'Torad', 'Affiliation': 'Urology Department, Kasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Rana', 'Initials': 'R', 'LastName': 'Abdella', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Sief', 'Initials': 'S', 'LastName': 'Ali', 'Affiliation': 'Obstetrics and Gynecology Department, Faculty of Medicine, Assuit University, Assuit, Egypt.'}, {'ForeName': 'Amera', 'Initials': 'A', 'LastName': 'Yehia', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Rehab', 'Initials': 'R', 'LastName': 'Lotfy', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Amal', 'Initials': 'A', 'LastName': 'Hanafy', 'Affiliation': 'Obstetrics and Gynecology Department, Kasr alainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Hassan', 'Affiliation': 'Obstetrics and Gynecology Department, Helwan Faculty of Medicine, Helwan University, Helwan, Egypt.'}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2019.1678140'] 152,31642725,The impact of exercise therapy and abdominal binding in the management of diastasis recti abdominis in the early post-partum period: a pilot randomized controlled trial.,"Purpose : To explore the feasibility of two physiotherapy interventions for the management of diastasis recti abdominis (DrA): abdominal binding and targeting trunk exercises. Methods : A pilot randomized controlled trial (RCT) design was used to compare the effectiveness of exercise therapy and/or abdominal binding to no intervention on thirty-two primiparous women who presented with DrA in the early post-partum period. Feasibility was determined based on study recruitment, compliance, and attrition rates as well as through computation of treatment effect sizes associated with each intervention compared to no intervention. Outcomes included inter-rectus distance measured using ultrasound, body image, pain, urogynecological symptoms, and function measured using questionnaires, and trunk flexion strength and endurance measured using clinical tests. Results : The recruitment rate was 3 participants/month. Intervention adherence rates were >50% and the attrition rate was 16%. After 6 months, positive effects (Cohen's d (d) = 0.2-0.5) on body image were observed in both the abdominal binding alone and combination therapy groups. A positive effect on trunk flexion strength (d = 0.7) was observed in the combination therapy group. Conclusion : The effect sizes suggest that physiotherapy interventions can positively impact body image and trunk flexion strength. While a clinical trial investigating these interventions is feasible, further preliminary investigation is recommended.",2021,"After 6 months, positive effects (Cohen's d (d) = 0.2-0.5) on body image were observed in both the abdominal binding alone and combination therapy groups.","['thirty-two primiparous women who presented with DrA in the early post-partum period', 'diastasis recti abdominis (DrA']","['exercise therapy and abdominal binding', 'exercise therapy and/or abdominal binding to no intervention', 'physiotherapy interventions']","['trunk flexion strength', 'impact body image and trunk flexion strength', 'attrition rate', 'compliance, and attrition rates', 'Intervention adherence rates', 'inter-rectus distance measured using ultrasound, body image, pain, urogynecological symptoms, and function measured using questionnaires, and trunk flexion strength and endurance measured using clinical tests', 'body image']","[{'cui': 'C0450357', 'cui_str': '32 (qualifier value)'}, {'cui': 'C0033150', 'cui_str': 'Primiparity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0221766', 'cui_str': 'Diastasis recti (disorder)'}]","[{'cui': 'C0452240', 'cui_str': 'Rehabilitation Exercise'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C1145667', 'cui_str': 'Binding - action (qualifier value)'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}]","[{'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0005891', 'cui_str': 'Body Image'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",,0.173037,"After 6 months, positive effects (Cohen's d (d) = 0.2-0.5) on body image were observed in both the abdominal binding alone and combination therapy groups.","[{'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Keshwani', 'Affiliation': 'School of Rehabilitation Therapy, Queens University, Kingston, ON, Canada.'}, {'ForeName': 'Sunita', 'Initials': 'S', 'LastName': 'Mathur', 'Affiliation': 'Department of Physical Therapy, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'McLean', 'Affiliation': 'School of Rehabilitation Sciences, University of Ottawa, Ottawa, ON, Canada.'}]",Physiotherapy theory and practice,['10.1080/09593985.2019.1675207'] 153,30786186,Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.,"BACKGROUND Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. METHODS In this double-blind, randomized trial involving high-risk ambulatory patients with cancer (Khorana score of ≥2, on a scale from 0 to 6, with higher scores indicating a higher risk of venous thromboembolism), we randomly assigned patients without deep-vein thrombosis at screening to receive rivaroxaban (at a dose of 10 mg) or placebo daily for up to 180 days, with screening every 8 weeks. The primary efficacy end point was a composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism and was assessed up to day 180. In a prespecified supportive analysis involving the same population, the same end point was assessed during the intervention period (first receipt of trial agent to last dose plus 2 days). The primary safety end point was major bleeding. RESULTS Of 1080 enrolled patients, 49 (4.5%) had thrombosis at screening and did not undergo randomization. Of the 841 patients who underwent randomization, the primary end point occurred in 25 of 420 patients (6.0%) in the rivaroxaban group and in 37 of 421 (8.8%) in the placebo group (hazard ratio, 0.66; 95% confidence interval [CI], 0.40 to 1.09; P = 0.10) in the period up to day 180. In the prespecified intervention-period analysis, the primary end point occurred in 11 patients (2.6%) in the rivaroxaban group and in 27 (6.4%) in the placebo group (hazard ratio, 0.40; 95% CI, 0.20 to 0.80). Major bleeding occurred in 8 of 405 patients (2.0%) in the rivaroxaban group and in 4 of 404 (1.0%) in the placebo group (hazard ratio, 1.96; 95% CI, 0.59 to 6.49). CONCLUSIONS In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period. During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding. (Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.).",2019,"The primary efficacy end point was a composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism and was assessed up to day 180.","['high-risk ambulatory patients with cancer (Khorana score of ≥2, on a scale from 0 to 6, with higher scores indicating a higher risk of venous thromboembolism', 'High-Risk Ambulatory Patients with Cancer', '1080 enrolled patients, 49 (4.5%) had thrombosis at screening and did not undergo randomization', 'high-risk ambulatory patients with cancer', 'Ambulatory patients receiving']","['rivaroxaban', 'systemic cancer therapy', 'placebo', 'Rivaroxaban']","['Major bleeding', 'major bleeding', 'composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism', 'venous thromboembolism or death']","[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary Embolism'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}]",1080.0,0.530441,"The primary efficacy end point was a composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism and was assessed up to day 180.","[{'ForeName': 'Alok A', 'Initials': 'AA', 'LastName': 'Khorana', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Gerald A', 'Initials': 'GA', 'LastName': 'Soff', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Ajay K', 'Initials': 'AK', 'LastName': 'Kakkar', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Saroj', 'Initials': 'S', 'LastName': 'Vadhan-Raj', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Hanno', 'Initials': 'H', 'LastName': 'Riess', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Ted', 'Initials': 'T', 'LastName': 'Wun', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Streiff', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Garcia', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Howard A', 'Initials': 'HA', 'LastName': 'Liebman', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Chandra P', 'Initials': 'CP', 'LastName': 'Belani', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Jai N', 'Initials': 'JN', 'LastName': 'Patel', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Habte A', 'Initials': 'HA', 'LastName': 'Yimer', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Wildgoose', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Burton', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Ujjwala', 'Initials': 'U', 'LastName': 'Vijapurkar', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Simrati', 'Initials': 'S', 'LastName': 'Kaul', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Eikelboom', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'McBane', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Kenneth A', 'Initials': 'KA', 'LastName': 'Bauer', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Kuderer', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Gary H', 'Initials': 'GH', 'LastName': 'Lyman', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1814630'] 154,31584944,Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial.,"BACKGROUND Excellent adherence to tuberculosis (TB) treatment is critical to cure TB and avoid the emergence of resistance. Wirelessly observed therapy (WOT) is a novel patient self-management system consisting of an edible ingestion sensor (IS), external wearable patch, and paired mobile device that can detect and digitally record medication ingestions. Our study determined the accuracy of ingestion detection in clinical and home settings using WOT and subsequently compared, in a randomized control trial (RCT), confirmed daily adherence to medication in persons using WOT or directly observed therapy (DOT) during TB treatment. METHODS AND FINDINGS We evaluated WOT in persons with active Mycobacterium tuberculosis complex disease using IS-enabled combination isoniazid 150 mg/rifampin 300 mg (IS-Rifamate). Seventy-seven participants with drug-susceptible TB in the continuation phase of treatment, prescribed daily isoniazid 300 mg and rifampin 600 mg, used IS-Rifamate. The primary endpoints of the trial were determination of the positive detection accuracy (PDA) of WOT, defined as the percentage of ingestions detected by WOT administered under direct observation, and subsequently the proportion of prescribed doses confirmed by WOT compared to DOT. Initially participants received DOT and WOT simultaneously for 2-3 weeks to allow calculation of WOT PDA, and the 95% confidence interval (CI) was estimated using the bootstrap method with 10,000 samples. Sixty-one participants subsequently participated in an RCT to compare the proportion of prescribed doses confirmed by WOT and DOT. Participants were randomized 2:1 to receive WOT or maximal in-person DOT. In the WOT arm, if ingestions were not remotely confirmed, the participant was contacted within 24 hours by text or cell phone to provide support. The number of doses confirmed was collected, and nonparametric methods were used for group and individual comparisons to estimate the proportions of confirmed doses in each randomized arm with 95% CIs. Sensitivity analyses, not prespecified in the trial registration, were also performed, removing all nonworking (weekend and public holiday) and held-dose days. Participants, recruited from San Diego (SD) and Orange County (OC) Divisions of TB Control and Refugee Health, were 43.1 (range 18-80) years old, 57% male, 42% Asian, and 39% white with 49% Hispanic ethnicity. The PDA of WOT was 99.3% (CI 98.1; 100). Intent-to-treat (ITT) analysis within the RCT showed WOT confirmed 93% versus 63% DOT (p < 0.001) of daily doses prescribed. Secondary analysis removing all nonworking days (weekends and public holidays) and held doses from each arm showed WOT confirmed 95.6% versus 92.7% (p = 0.31); WOT was non-inferior to DOT (difference 2.8% CI [-1.8%, 9.1%]). One hundred percent of participants preferred using WOT. WOT associated adverse events were <10%, consisting of minor skin rash and pruritus associated with the patch. WOT provided longitudinal digital reporting in near real time, supporting patient self-management and allowing rapid remote identification of those who needed more support to maintain adherence. This study was conducted during the continuation phase of TB treatment, limiting its generalizability to the entire TB treatment course. CONCLUSIONS In terms of accuracy, WOT was equivalent to DOT. WOT was superior to DOT in supporting confirmed daily adherence to TB medications during the continuation phase of TB treatment and was overwhelmingly preferred by participants. WOT should be tested in high-burden TB settings, where it may substantially support low- and middle-income country (LMIC) TB programs. TRIAL REGISTRATION ClinicalTrials.gov NCT01960257.",2019,"Wirelessly observed therapy (WOT) is a novel patient self-management system consisting of an edible ingestion sensor (IS), external wearable patch, and paired mobile device that can detect and digitally record medication ingestions.","['Seventy-seven participants with drug-susceptible TB in the continuation phase of treatment, prescribed daily', 'Participants, recruited from San Diego (SD) and Orange County (OC) Divisions of TB Control and Refugee Health, were 43.1 (range 18-80) years old, 57% male, 42% Asian, and 39% white with 49% Hispanic ethnicity', 'persons using WOT or directly observed therapy (DOT) during TB treatment', 'persons with active Mycobacterium tuberculosis complex disease using IS-enabled combination']","['isoniazid 300 mg and rifampin 600 mg, used IS-Rifamate', 'isoniazid', 'rifampin', 'WOT or maximal in-person DOT', 'Wirelessly observed therapy (WOT']","['proportion of prescribed doses confirmed by WOT and DOT', 'adverse events', 'positive detection accuracy (PDA) of WOT, defined as the percentage of ingestions detected by WOT administered under direct observation, and subsequently the proportion of prescribed doses confirmed by WOT compared to DOT']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0231204', 'cui_str': 'Susceptible (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0440277', 'cui_str': 'Oranges'}, {'cui': 'C1293097', 'cui_str': 'Division - action (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0034961', 'cui_str': 'Refugees'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0872145', 'cui_str': 'Directly Observed Therapy'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1032649', 'cui_str': 'Mycobacterium tuberculosis complex (organism)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0562342', 'cui_str': 'Empowered (finding)'}]","[{'cui': 'C0992473', 'cui_str': 'isoniazid 300 MG'}, {'cui': 'C4301185', 'cui_str': 'Rifampin 600 MG [Rifadin]'}, {'cui': 'C0723085', 'cui_str': 'Rifamate'}, {'cui': 'C0022209', 'cui_str': 'isoniazid'}, {'cui': 'C0035608', 'cui_str': 'rifampicin'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C1720485', 'cui_str': 'Corneal epithelial microcysts'}, {'cui': 'C3875135', 'cui_str': 'Observes (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by (contextual qualifier) (qualifier value)'}, {'cui': 'C1720485', 'cui_str': 'Corneal epithelial microcysts'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]",77.0,0.226502,"Wirelessly observed therapy (WOT) is a novel patient self-management system consisting of an edible ingestion sensor (IS), external wearable patch, and paired mobile device that can detect and digitally record medication ingestions.","[{'ForeName': 'Sara H', 'Initials': 'SH', 'LastName': 'Browne', 'Affiliation': 'University of California San Diego, La Jolla, California, United States of America.'}, {'ForeName': 'Anya', 'Initials': 'A', 'LastName': 'Umlauf', 'Affiliation': 'University of California San Diego, La Jolla, California, United States of America.'}, {'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Tucker', 'Affiliation': 'University of California San Diego, La Jolla, California, United States of America.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Low', 'Affiliation': 'Orange County Health Care Agency, Santa Ana, California, United States of America.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Moser', 'Affiliation': 'Health and Human Services Agency, San Diego, California, United States of America.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Gonzalez Garcia', 'Affiliation': 'University of California San Diego, La Jolla, California, United States of America.'}, {'ForeName': 'Charles A', 'Initials': 'CA', 'LastName': 'Peloquin', 'Affiliation': 'University of Florida, Gainesville, Florida, United States of America.'}, {'ForeName': 'Terrence', 'Initials': 'T', 'LastName': 'Blaschke', 'Affiliation': 'Stanford University, Stanford, California, United States of America.'}, {'ForeName': 'Florin', 'Initials': 'F', 'LastName': 'Vaida', 'Affiliation': 'University of California San Diego, La Jolla, California, United States of America.'}, {'ForeName': 'Constance A', 'Initials': 'CA', 'LastName': 'Benson', 'Affiliation': 'University of California San Diego, La Jolla, California, United States of America.'}]",PLoS medicine,['10.1371/journal.pmed.1002891'] 155,28985106,"A comparative study of the effect of the intrusion arch and straight wire mechanics on incisor root resorption: A randomized, controlled trial.","OBJECTIVE To analyze and compare external apical root resorption (EARR) of maxillary incisors treated by intrusion arch or continuous archwire mechanics. MATERIALS AND METHODS This cone-beam computed tomography (CBCT) study analyzed 28 deep bite patients in the permanent dentition who were randomly divided into two groups: Group 1, 12 patients with initial mean age of 15.1 ± 1.6 years and mean overbite of 4.6 ± 1.2 mm treated with the Connecticut intrusion arch (CIA) in the upper arch (Ortho Organizers, Carlsbad, Calif) for a mean period of 5.8 ± 1.27 months. Group 2, 16 patients with initial mean age of 22.1 ± 5.7 years and mean overbite of 4.1 ± 1.1 mm treated with conventional leveling and alignment using continuous archwire mechanics for 6.1 ± 0.81 months. The degree of EARR was detected in 112 maxillary incisors by using CBCT scans and a three-dimensional program (Dolphin 11.7, Dolphin Imaging & Management Solutions, Chatsworth, Calif). The CBCT scans were obtained before (T1) and 6 months after initiation of treatment (T2). Differences between and within groups were assessed by nonpaired and paired t-tests, respectively, with a 5% significance level. RESULTS Significant differences were found for both groups between T1 and T2 ( P < .05) indicating that EARR occurred in both groups. However, there were no significant differences when EARR was compared between group 1 (-0.76 mm) and group 2 (-0.59 mm). CONCLUSIONS The Connecticut intrusion arch did not lead to greater EARR of maxillary incisors when compared with conventional orthodontic mechanics.",2018,The Connecticut intrusion arch did not lead to greater EARR of maxillary incisors when compared with conventional orthodontic mechanics.,"['16 patients with initial mean age of 22.1 ± 5.7 years and mean overbite of 4.1 ± 1.1 mm treated with conventional leveling and alignment using continuous archwire mechanics for 6.1 ± 0.81 months', 'incisor root resorption', '28 deep bite patients in the permanent dentition who were randomly divided into two groups: Group 1, 12 patients with initial mean age of 15.1 ± 1.6 years and mean overbite of 4.6 ± 1.2 mm treated with the']","['Connecticut intrusion arch (CIA', 'intrusion arch and straight wire mechanics', 'external apical root resorption (EARR) of maxillary incisors treated by intrusion arch or continuous archwire mechanics', 'cone-beam computed tomography (CBCT']","['EARR of maxillary incisors', 'EARR', 'degree of EARR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517795', 'cui_str': 'Five point seven'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1305740', 'cui_str': 'Over Bite'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C4517491', 'cui_str': 'One point one'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0021156', 'cui_str': 'Incisor'}, {'cui': 'C0035851', 'cui_str': 'Root Resorption'}, {'cui': 'C0348070', 'cui_str': 'Dentition, Adult'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C4517508', 'cui_str': '1.6 (qualifier value)'}, {'cui': 'C4517764', 'cui_str': 'Four point six'}, {'cui': 'C4068880', 'cui_str': 'One point two'}]","[{'cui': 'C0009778', 'cui_str': 'Connecticut'}, {'cui': 'C1527360', 'cui_str': 'Heterosexuals'}, {'cui': 'C0005978', 'cui_str': 'Bone Wires'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C1290638', 'cui_str': 'Apical root resorption'}, {'cui': 'C0021156', 'cui_str': 'Incisor'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C1956110', 'cui_str': 'Cone-Beam Computerized Tomography'}]","[{'cui': 'C0021156', 'cui_str': 'Incisor'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}]",112.0,0.0253138,The Connecticut intrusion arch did not lead to greater EARR of maxillary incisors when compared with conventional orthodontic mechanics.,"[{'ForeName': 'Marcio Rodrigues', 'Initials': 'MR', 'LastName': 'de Almeida', 'Affiliation': ''}, {'ForeName': 'Aline Siqueira Butzke', 'Initials': 'ASB', 'LastName': 'Marçal', 'Affiliation': ''}, {'ForeName': 'Thais Maria Freire', 'Initials': 'TMF', 'LastName': 'Fernandes', 'Affiliation': ''}, {'ForeName': 'Juliana Brito', 'Initials': 'JB', 'LastName': 'Vasconcelos', 'Affiliation': ''}, {'ForeName': 'Renato Rodrigues', 'Initials': 'RR', 'LastName': 'de Almeida', 'Affiliation': ''}, {'ForeName': 'Ravindra', 'Initials': 'R', 'LastName': 'Nanda', 'Affiliation': ''}]",The Angle orthodontist,['10.2319/06417-424R'] 156,29214923,Creatine supplementation elicits greater muscle hypertrophy in upper than lower limbs and trunk in resistance-trained men.,"BACKGROUND Creatine (Cr) supplementation associated with resistance training produces greater muscular strength improvements in the upper compared with the lower body; however, no study has investigated if such region-specific results are seen with gains in muscle mass. AIM We aimed to evaluate the effect of Cr supplementation in combination with resistance training on lean soft tissue changes in the upper and lower limbs and trunk in resistance-trained young adult men. METHODS In a randomized, double-blind and placebo-controlled design, 43 resistance-trained men (22.7 ± 3.0 years, 72.9 ± 8.7 kg, 177.9 ± 5.7 cm, 23.0 ± 2.5 kg/m 2 ) received either creatine (Cr, n = 22) or placebo (PLA, n = 21) over an 8-week study period. The supplementation protocol included a loading phase (7 days, four doses of 0.3 g/kg per day) and a maintenance phase (7 weeks, single dose of 0.03 g/kg per day). During the same period, subjects performed resistance training four times per week using the following two-way split routine: Monday and Thursday = pectoral, shoulders, triceps, and abdomen, Tuesday and Friday = back, biceps, thighs, and calves. Lean soft tissue of the upper limbs (ULLST), lower limbs (LLLST), and trunk (TLST) was assessed by dual-energy X-ray absorptiometry before and after the intervention. RESULTS Both groups showed significant ( p < 0.001) improvements in ULLST, LLLST, TLST, and the Cr group achieved greater ( p < 0.001) increases in these outcomes compared with PLA. For the Cr group, improvements in ULLST (7.1 ± 2.9%) were higher than those observed in LLLST (3.2 ± 2.1%) and TLST (2.1 ± 2.2%). Otherwise, for PLA group there was no significant difference in the magnitude of segmental muscle hypertrophy (ULLST = 1.6 ± 3.0%; LLLST = 0.7 ± 2.8%; TLST = 0.7 ± 2.8%). CONCLUSION Our results suggest that Cr supplementation can positively augment muscle hypertrophy in resistance-trained young adult men, particularly in the upper limbs.",2017,"Both groups showed significant ( p < 0.001) improvements in ULLST, LLLST, TLST, and the Cr group achieved greater ( p < 0.001) increases in these outcomes compared with PLA.","['43 resistance-trained men (22.7 ± 3.0 years, 72.9 ± 8.7 kg, 177.9 ± 5.7 cm, 23.0 ± 2.5 kg/m 2 ) received either', 'resistance-trained young adult men', 'upper than lower limbs and trunk in resistance-trained men']","['placebo', 'Cr supplementation', 'Creatine supplementation', 'creatine (Cr, n = 22) or placebo', 'resistance training', 'Creatine (Cr) supplementation']","['muscle hypertrophy', 'ULLST', 'Lean soft tissue of the upper limbs (ULLST), lower limbs (LLLST), and trunk (TLST', 'muscular strength improvements', 'magnitude of segmental muscle hypertrophy', 'lean soft tissue changes']","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517880', 'cui_str': '8.7 (qualifier value)'}, {'cui': 'C4517795', 'cui_str': 'Five point seven'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0460005', 'cui_str': 'Torso'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0236033', 'cui_str': 'Muscle hypertrophy (finding)'}, {'cui': 'C0225317', 'cui_str': 'Soft tissues (body structure)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C1704240', 'cui_str': 'Magnitudes (qualifier value)'}, {'cui': 'C0205122', 'cui_str': 'Segmental (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",43.0,0.131973,"Both groups showed significant ( p < 0.001) improvements in ULLST, LLLST, TLST, and the Cr group achieved greater ( p < 0.001) increases in these outcomes compared with PLA.","[{'ForeName': 'João Pedro', 'Initials': 'JP', 'LastName': 'Nunes', 'Affiliation': '1 Study and Research Group in Metabolism, Nutrition, and Exercise. Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Alex S', 'Initials': 'AS', 'LastName': 'Ribeiro', 'Affiliation': '1 Study and Research Group in Metabolism, Nutrition, and Exercise. Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Brad J', 'Initials': 'BJ', 'LastName': 'Schoenfeld', 'Affiliation': '3 Exercise Science Department, CUNY Lehman College, USA.'}, {'ForeName': 'Crisieli M', 'Initials': 'CM', 'LastName': 'Tomeleri', 'Affiliation': '1 Study and Research Group in Metabolism, Nutrition, and Exercise. Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Ademar', 'Initials': 'A', 'LastName': 'Avelar', 'Affiliation': '4 Department of Physical Education, Maringá State University, Brazil.'}, {'ForeName': 'Michele Cc', 'Initials': 'MC', 'LastName': 'Trindade', 'Affiliation': '4 Department of Physical Education, Maringá State University, Brazil.'}, {'ForeName': 'Hellen Cg', 'Initials': 'HC', 'LastName': 'Nabuco', 'Affiliation': '1 Study and Research Group in Metabolism, Nutrition, and Exercise. Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Edilaine F', 'Initials': 'EF', 'LastName': 'Cavalcante', 'Affiliation': '1 Study and Research Group in Metabolism, Nutrition, and Exercise. Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Paulo Sugihara', 'Initials': 'PS', 'LastName': 'Junior', 'Affiliation': '1 Study and Research Group in Metabolism, Nutrition, and Exercise. Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Rodrigo R', 'Initials': 'RR', 'LastName': 'Fernandes', 'Affiliation': '1 Study and Research Group in Metabolism, Nutrition, and Exercise. Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Ferdinando O', 'Initials': 'FO', 'LastName': 'Carvalho', 'Affiliation': '5 Federal University of the Vale do São Francisco, Petrolina, Brazil.'}, {'ForeName': 'Edilson S', 'Initials': 'ES', 'LastName': 'Cyrino', 'Affiliation': '1 Study and Research Group in Metabolism, Nutrition, and Exercise. Londrina State University, Londrina, Brazil.'}]",Nutrition and health,['10.1177/0260106017737013'] 157,31617447,Mastery versus self-directed blended learning in basic life support: a randomised controlled trial.,"Background: Blended learning combines online learning with face-to-face learning. Research investigating the effect of different blended learning models to teach basic life support (BLS) is lacking. Objectives: To investigate the effect of a mastery learning (ML) versus a self-directed learning (SDL) blend on students' BLS performance. In ML, students learn BLS as a linear sequence meaning each step should be 'mastered' prior to advancing to the next. In SDL, students' autonomy is increased for his or her learning trajectory leading to non-linear, user driven learning paths. Methods: A randomised controlled trial. Four conditions were created by combining two learning models (SDL and ML) in two learning phases (online and face to face). Bachelor students ( n  = 145) were randomised over these four conditions. In all blends, an online learning module was available for one week prior to a face-to-face learning component of which the duration was 45 minutes. All learners' BLS performance was assessed individually and unannounced one week following blended learning. An individual BLS score was calculated combining cardiopulmonary resuscitation (CPR) variables reported by a Laerdal ResusciAnne Manikin and qualitative observations by two trained researchers. Results: Students' CPR performance adhered to international 2015 guidelines for all groups. Median BLS-performance was 83.0% (interquartile range 13.2%). No statistical differences between groups were found for BLS performance or CPR variables. Conclusions: All blended learning models were highly time-effective since the face-to-face component only took 45 minutes and learning outcomes adhered to guidelines.",2020,No statistical differences between groups were found for BLS performance or CPR variables. ,"[""students' BLS performance"", 'Bachelor students ( n \u2009=\u2009145']","['Mastery versus self-directed blended learning', ': Blended learning combines online learning with face-to-face learning', 'blended learning models to teach basic life support (BLS', 'mastery learning (ML) versus a self-directed learning (SDL']","['Median BLS-performance', 'BLS performance or CPR variables']","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0337600', 'cui_str': 'Bachelor (finding)'}, {'cui': 'C4517577', 'cui_str': '145'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0085873', 'cui_str': 'Basic life support (procedure)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}]",2015.0,0.0349064,No statistical differences between groups were found for BLS performance or CPR variables. ,"[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Madou', 'Affiliation': 'Vives University College, Torhout, Belgium.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Iserbyt', 'Affiliation': 'Department of Kinesiology, Physical Activity, Sport and Health Research Group, KU Leuven, Leuven, Belgium.'}]",Acta cardiologica,['10.1080/00015385.2019.1677374'] 158,32131656,Comparative Evaluation of Clinical Efficacy and Safety of Collagen Laminin-Based Dermal Matrix Combined With Resveratrol Microparticles (Dermalix) and Standard Wound Care for Diabetic Foot Ulcers.,"This is an open, prospective, comparative parallel-arm medical device clinical study of Dermalix (Dx) in diabetic foot wounds. Dx is a 3-dimensional collagen-laminin porous-structured dermal matrix prepared and additionally impregnated with resveratrol-loaded hyaluronic acid and dipalmitoylphosphatidylcholine-based microparticles. The aim was to evaluate the efficacy and safety of Dx, an investigational medical device, in Wagner 1 and 2 wounds in comparison to a standard wound care (SWC) that consists of irrigation and cleaning with sterile saline solution. Forty-eight patients were randomized to receive either SWC or SWC + Dx. A 4-week treatment period was followed by a 2-month follow-up without treatment. The wound area measurement, total collagen, vascular epidermal growth factor, tumor necrosis factor, interleukin 1, caspase 3, glutathione, reduced/oxidized glutathione, and lipid peroxidation levels were evaluated. At the end of 4 weeks, the percentage closures of wounds were determined as 57.82% for Dx, and 26.63% for SWC groups. Dx had a significant effect on tumor necrosis factor, caspase 3, and reduced/oxidized glutathione levels. Dx provided 2 times faster wound healing and decreased oxidative stress. Application of Dx in the first phase of wound would help the wound area heal faster with a safe profile.",2021,"The wound area measurement, total collagen, vascular epidermal growth factor, tumor necrosis factor, interleukin 1, caspase 3, glutathione, reduced/oxidized glutathione, and lipid peroxidation levels were evaluated.","['Forty-eight patients', 'Diabetic Foot Ulcers', 'diabetic foot wounds']","['irrigation and cleaning with sterile saline solution', 'SWC or SWC + Dx', 'standard wound care (SWC', 'Dermalix (Dx', 'Collagen Laminin-Based Dermal Matrix Combined With Resveratrol Microparticles (Dermalix) and Standard Wound Care']","['percentage closures of wounds', 'wound area measurement, total collagen, vascular epidermal growth factor, tumor necrosis factor, interleukin 1, caspase 3, glutathione, reduced/oxidized glutathione, and lipid peroxidation levels', 'tumor necrosis factor, caspase 3, and reduced/oxidized glutathione levels', 'wound healing and decreased oxidative stress']","[{'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer (disorder)'}, {'cui': 'C0206172', 'cui_str': 'Diabetic Foot'}, {'cui': 'C0021501', 'cui_str': 'wounds'}]","[{'cui': 'C0022100', 'cui_str': 'Lavage'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0232920', 'cui_str': 'Sterile (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0886052', 'cui_str': 'Administers care to wound sites'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0022984', 'cui_str': 'Glycoprotein GP-2'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C4319583', 'cui_str': 'Matrix'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C2930481', 'cui_str': 'cis-Resveratrol'}]","[{'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0242275', 'cui_str': 'Epidermal Growth Factor'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0021755', 'cui_str': 'T Helper Factor'}, {'cui': 'C0291573', 'cui_str': 'CASP3'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0061516', 'cui_str': 'Glutathione Disulfide'}, {'cui': 'C0023775', 'cui_str': 'Lipid Peroxidation'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}]",48.0,0.0262607,"The wound area measurement, total collagen, vascular epidermal growth factor, tumor necrosis factor, interleukin 1, caspase 3, glutathione, reduced/oxidized glutathione, and lipid peroxidation levels were evaluated.","[{'ForeName': 'Şevki', 'Initials': 'Ş', 'LastName': 'Çetinkalp', 'Affiliation': 'Ege University, Izmir, Turkey.'}, {'ForeName': 'Evren Homan', 'Initials': 'EH', 'LastName': 'Gökçe', 'Affiliation': 'Ege University, Izmir, Turkey.'}, {'ForeName': 'IlgınYıldırım', 'Initials': 'I', 'LastName': 'Şimşir', 'Affiliation': 'Ege University, Izmir, Turkey.'}, {'ForeName': 'Sakine', 'Initials': 'S', 'LastName': 'Tuncay Tanrıverdi', 'Affiliation': 'Ege University, Izmir, Turkey.'}, {'ForeName': 'Fatma', 'Initials': 'F', 'LastName': 'Doğan', 'Affiliation': 'Ege University, Izmir, Turkey.'}, {'ForeName': 'Çığır', 'Initials': 'Ç', 'LastName': 'Biray Avcı', 'Affiliation': 'Ege University, Izmir, Turkey.'}, {'ForeName': 'İpek', 'Initials': 'İ', 'LastName': 'Eroğlu', 'Affiliation': 'Hacettepe University, Ankara, Turkey.'}, {'ForeName': 'Tülün', 'Initials': 'T', 'LastName': 'Utku', 'Affiliation': 'Ege University, Izmir, Turkey.'}, {'ForeName': 'Cumhur', 'Initials': 'C', 'LastName': 'Gündüz', 'Affiliation': 'Ege University, Izmir, Turkey.'}, {'ForeName': 'Özgen', 'Initials': 'Ö', 'LastName': 'Özer', 'Affiliation': 'Ege University, Izmir, Turkey.'}]",The international journal of lower extremity wounds,['10.1177/1534734620907773'] 159,29375633,Open Trial of Family-Based Treatment of Anorexia Nervosa for Transition Age Youth.,"Objective This pilot study conducted an open trial of a manualized adaptation to Family-Based Treatment for Transition Age Youth (FBT-TAY) for Anorexia Nervosa (AN). The aims were: (1) determine the acceptability of FBT for TAY; and, (2) establish preliminary effect sizes for the impact of FBT-TAY on eating disorder behaviour and weight restoration. Method Twenty-six participants across two paediatric and one adult hospital site were recruited to participate. Participants completed the Eating Disorder Examination Questionnaire (EDE-Q) at the start of treatment, the end-of-treatment, and three-month follow-up. Results FBT-TAY is an acceptable and feasible treatment to all study therapists as evidenced by their fidelity to the model. FBT-TAY is a feasible and acceptable intervention to transition age youth, given only 27.27% chose treatment as usual over FBT-TAY. Participants presented significant improvement at end-of-treatment and three-months post-treatment (p < .001; ES = 0.34) from baseline on the EDE-Q Global Score. Participants also achieved and maintained weight restoration at the end-of-treatment and three-months post-treatment when compared to baseline (p < .0001, ES = 0.54). Conclusions FBT-TAY, the first manualized AN treatment for TAY, demonstrated feasibility and acceptability with therapists and participants as well as improvement for participants in EDE-Q global score and weight. Given the current dearth of effective treatments for TAY with AN, FBT-TAY is a promising adaptation of FBT. A larger clinical trial with a 12-month follow-up is recommended.",2018,FBT-TAY is an acceptable and feasible treatment to all study therapists as evidenced by their fidelity to the model.,"['Anorexia Nervosa for Transition Age Youth', 'Transition Age Youth (FBT-TAY) for Anorexia Nervosa (AN', 'Method\n\n\nTwenty-six participants across two paediatric and one adult hospital site were recruited to participate']","['FBT-TAY', 'manualized adaptation to Family-Based Treatment']","['Eating Disorder Examination Questionnaire (EDE-Q', 'maintained weight restoration']","[{'cui': 'C0003125', 'cui_str': 'Anorexia Nervosas'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C2960501', 'cui_str': 'Eating disorder examination questionnaire (assessment scale)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration (attribute)'}]",26.0,0.0412649,FBT-TAY is an acceptable and feasible treatment to all study therapists as evidenced by their fidelity to the model.,"[{'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Dimitropoulos', 'Affiliation': 'Faculty of Social Work, University of Calgary, Calgary, Alberta.'}, {'ForeName': 'Ashley L', 'Initials': 'AL', 'LastName': 'Landers', 'Affiliation': 'Virginia Polytechnic Institute & State University, Virginia USA.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Freeman', 'Affiliation': 'Eating Disorders Program, Toronto General Hospital, Toronto, Ontario.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Novick', 'Affiliation': 'Department of Sociology, University of Calgary, Calgary, Alberta.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Garber', 'Affiliation': 'Department of Psychiatry, University of California, San Francisco, California, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Le Grange', 'Affiliation': 'Department of Psychiatry, University of California, San Francisco, California, USA.'}]",Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent,[] 160,29095725,Audiologist-Guided Internet-Based Cognitive Behavior Therapy for Adults With Tinnitus in the United Kingdom: A Randomized Controlled Trial.,"OBJECTIVES Specialist tinnitus services are in high demand as a result of the negative effect tinnitus may have on quality of life. Additional clinically and cost-effective tinnitus management routes are needed. One potential route is providing Cognitive Behavioural Therapy for tinnitus via the Internet (iCBT). This study aimed to determine the efficacy of guided iCBT, using audiological support, on tinnitus distress and tinnitus-related comorbidities, in the United Kingdom. A further aim was to establish the stability of intervention effects 2-months postintervention. The hypothesis was that iCBT for tinnitus would be more effective at reducing tinnitus distress than weekly monitoring. DESIGN A randomized, delayed intervention efficacy trial, with a 2-month follow-up was implemented to evaluate the efficacy of iCBT in the United Kingdom. Participants were randomly assigned to the experimental (n = 73) or weekly monitoring control group (n = 73) after being stratified for tinnitus severity and age. After the experimental group completed the 8-week long iCBT intervention, the control group undertook the same intervention. Intervention effects were, therefore, evaluated in two independent groups at two time points. The primary outcome was a change in tinnitus distress between the groups as assessed by the Tinnitus Functional Index. Secondary assessment measures were included for insomnia, anxiety, depression, hearing disability, hyperacusis, cognitive failures, and satisfaction with life. These were completed at baseline, postintervention, and at a 2-month postintervention follow-up. RESULTS After undertaking the iCBT intervention, the experimental group had a greater reduction in tinnitus distress when compared with the control group. This reduction was statistically significant (Cohen's d = 0.7) and was clinically significant for 51% of the experimental group and 5% of the control group. This reduction was evident 4 weeks after commencing the iCBT intervention. Furthermore, the experimental group had a greater reduction in insomnia, depression, hyperacusis, cognitive failures, and a greater improvement in quality of life, as evidenced by the significant differences in these assessment measures postintervention. Results were maintained 2 months postintervention. CONCLUSIONS Guided (using audiological support) iCBT for tinnitus resulted in statistically significant reductions in tinnitus distress and comorbidities (insomnia, depression, hyperacusis, cognitive failures) and a significant increase in quality of life. These effects remained stable at 2-months postintervention. Further trials to determine the longer term efficacy of iCBT to investigate predictors of outcome and to compare iCBT with standard clinical care in the United Kingdom are required.Registered at clinicaltrials.gov: NCT02370810 on 5/03/2015.",2018,"After undertaking the iCBT intervention, the experimental group had a greater reduction in tinnitus distress when compared with the control group.",['Adults With Tinnitus in the United Kingdom'],"['iCBT intervention', 'guided iCBT', 'Audiologist-Guided Internet-Based Cognitive Behavior Therapy', 'iCBT']","['insomnia, depression, hyperacusis, cognitive failures', 'Tinnitus Functional Index', 'change in tinnitus distress', 'quality of life', 'insomnia, anxiety, depression, hearing disability, hyperacusis, cognitive failures, and satisfaction with life', 'tinnitus distress', 'tinnitus distress and comorbidities (insomnia, depression, hyperacusis, cognitive failures']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}]","[{'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0175838', 'cui_str': 'Audiologist'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0034880', 'cui_str': 'Recruitment, Loudness'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0040264', 'cui_str': 'Ringing-Buzzing-Tinnitus'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0034380'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0848765', 'cui_str': 'Hearing disability'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",73.0,0.0906811,"After undertaking the iCBT intervention, the experimental group had a greater reduction in tinnitus distress when compared with the control group.","[{'ForeName': 'Eldré W', 'Initials': 'EW', 'LastName': 'Beukes', 'Affiliation': 'Department of Vision and Hearing Sciences, Anglia Ruskin University, Cambridge, United Kingdom.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Baguley', 'Affiliation': 'Department of Vision and Hearing Sciences, Anglia Ruskin University, Cambridge, United Kingdom.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Allen', 'Affiliation': 'Department of Vision and Hearing Sciences, Anglia Ruskin University, Cambridge, United Kingdom.'}, {'ForeName': 'Vinaya', 'Initials': 'V', 'LastName': 'Manchaiah', 'Affiliation': 'Department of Vision and Hearing Sciences, Anglia Ruskin University, Cambridge, United Kingdom.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Andersson', 'Affiliation': 'Department of Vision and Hearing Sciences, Anglia Ruskin University, Cambridge, United Kingdom.'}]",Ear and hearing,['10.1097/AUD.0000000000000505'] 161,28753032,"Discomfort associated with Invisalign and traditional brackets: A randomized, prospective trial.","OBJECTIVE To evaluate differences in discomfort levels between patients treated with aligners and traditional fixed orthodontic appliances. MATERIALS AND METHODS This blinded, prospective, randomized equivalence two-arm parallel trial allocated 41 adult Class I nonextraction patients to either traditional fixed appliance (6 males and 12 females) or aligner (11 males and 12 females) treatment. Patients completed daily discomfort diaries following their initial treatment appointment, after 1 month and after 2 months. They recorded their levels of discomfort at rest, while chewing, and while biting, as well as their analgesic consumption and sleep disturbances. RESULTS Both treatment modalities demonstrated similar levels of initial discomfort. There were no significant sex differences. Patients in the traditional fixed appliances group reported significantly (P < .05) greater discomfort than patients in the aligner group during the first week of active treatment. There was significantly more discomfort while chewing than when at rest. Traditional patients also reported significantly more discomfort than aligner patients after the first and second monthly adjustment appointments. Discomfort after the subsequent adjustments was consistently lower than after the initial bonding or aligner delivery appointments. A higher percentage of patients in the fixed-appliance group reported taking analgesics during the first week for dental pain, but only the difference on day 2 was statistically significant. CONCLUSIONS Patients treated with traditional fixed appliances reported greater discomfort and consumed more analgesics than patients treated with aligners. This trial was not registered.",2017,Patients in the traditional fixed appliances group reported significantly (P < .05) greater discomfort than patients in the aligner group during the first week of active treatment.,"['6 males and 12 females) or aligner (11 males and 12 females) treatment', 'patients treated with aligners and traditional fixed orthodontic appliances', '41 adult Class I nonextraction patients to either']",['traditional fixed appliance'],"['levels of initial discomfort', 'discomfort levels', 'daily discomfort diaries', 'Discomfort', 'discomfort', 'levels of discomfort at rest, while chewing, and while biting, as well as their analgesic consumption and sleep disturbances', 'taking analgesics']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0441421', 'cui_str': 'Permanent Retainer'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0441885', 'cui_str': 'Class 1 (qualifier value)'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0441421', 'cui_str': 'Permanent Retainer'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0443144', 'cui_str': 'At rest (qualifier value)'}, {'cui': 'C0699816', 'cui_str': 'Does chew (finding)'}, {'cui': 'C0005658', 'cui_str': 'Bites'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnias'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}]",41.0,0.0560618,Patients in the traditional fixed appliances group reported significantly (P < .05) greater discomfort than patients in the aligner group during the first week of active treatment.,"[{'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'White', 'Affiliation': ''}, {'ForeName': 'Katie C', 'Initials': 'KC', 'LastName': 'Julien', 'Affiliation': ''}, {'ForeName': 'Helder', 'Initials': 'H', 'LastName': 'Jacob', 'Affiliation': ''}, {'ForeName': 'Phillip M', 'Initials': 'PM', 'LastName': 'Campbell', 'Affiliation': ''}, {'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': 'Buschang', 'Affiliation': ''}]",The Angle orthodontist,['10.2319/091416-687.1'] 162,28822518,Clinical Outcomes of patients with coronary artery disease who underwent FFR evaluation of intermediate coronary lesionS- COFFRS study.,"BACKGROUND We undertook this study to validate the impact of FFR-guided coronary interventions among Indian patients, which is not readily available as of date. Our patients differ from their western counterparts, both in terms of risk profile (younger, more metabolic syndrome, lipid rich diet) as well as their coronary size. METHODS We retrospectively evaluated 282 patients with intermediate stenosis in their coronary arteries, who underwent FFR to assess the functional severity of the lesion. There were 3 groups: Group 1-FFR>0.8 and kept on medical follow-up; Group 2-FFR≤0.8 and underwent revascularisation; and Group 3-FFR≤0.8 and refused to undergo revascularization. 281(99.6%) patients had regular follow-up in our clinic. RESULTS Median age-57 years (range=28-78). Males=230, 90 patients were in Group 1, 175 in group 2 (PCI in 144 & CABG in 31) and 17 in group 3. Median follow-up of patients was 17.9 months (2 to 56 months). Three patients(3.4%) in Group 1 had MACE (1 STEMI, 2 UA); 4 patients (2.3%) in Group 2 had Non-STE-ACS; 7 patients (41%) in Group 3 had MACE (3 deaths with acute LVF, 2 NSTEMI, 2 STEMI) CONCLUSION: In our experience, MACE events were not higher in patients with FFR>0.8 and kept under medical therapy and were similarly lower in patients with FFR ≤0.8 and underwent revascularisation (p=0.73). Also MACE events were higher in patients with FFR≤0.8 and did not undergo revascularisation compared to other two appropriately treated groups (p=0.03). FFR based revascularization decision appears to be a safe strategy in Indian patients.",2017,Also MACE events were higher in patients with FFR≤0.8 and did not undergo revascularisation compared to other two appropriately treated groups (p=0.03).,"['patients with coronary artery disease who underwent FFR evaluation of intermediate coronary lesionS- COFFRS study', 'Indian patients', '282 patients with intermediate stenosis in their coronary arteries, who underwent FFR to assess the functional severity of the lesion', '281(99.6%) patients had regular follow-up in our clinic']","['FFR-guided coronary interventions', 'Group 1-FFR>0.8 and kept on medical follow-up; Group 2-FFR≤0.8 and underwent revascularisation; and Group 3-FFR≤0.8 and refused to undergo revascularization']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}, {'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0441869', 'cui_str': 'Group 3 (qualifier value)'}, {'cui': 'C1705116', 'cui_str': 'Refused (qualifier value)'}]",[],282.0,0.0145643,Also MACE events were higher in patients with FFR≤0.8 and did not undergo revascularisation compared to other two appropriately treated groups (p=0.03).,"[{'ForeName': 'Srinivasa', 'Initials': 'S', 'LastName': 'Prasad', 'Affiliation': 'Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Harikrishnan', 'Affiliation': 'Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Sanjay', 'Affiliation': 'Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India. Electronic address: drsanjayganesh@gmail.com.'}, {'ForeName': 'S P', 'Initials': 'SP', 'LastName': 'Abhilash', 'Affiliation': 'Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bijulal', 'Affiliation': 'Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India.'}, {'ForeName': 'Mohanan Nair', 'Initials': 'MN', 'LastName': 'Krishna Kumar', 'Affiliation': 'Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India.'}, {'ForeName': 'Jaganmohan', 'Initials': 'J', 'LastName': 'Tharakan', 'Affiliation': 'Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India.'}, {'ForeName': 'V K', 'Initials': 'VK', 'LastName': 'Ajit Kumar', 'Affiliation': 'Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India.'}]",Indian heart journal,['10.1016/j.ihj.2016.12.007'] 163,28885034,Treatment outcomes of Class II malocclusion cases treated with miniscrew-anchored Forsus Fatigue Resistant Device: A randomized controlled trial.,"OBJECTIVE To evaluate the skeletal, dental, and soft tissue effects of the Forsus Fatigue Resistant Device (FRD) used with miniscrew anchorage and compare them with those of the conventional Forsus FRD. MATERIALS AND METHODS This study was carried out on 38 patients. These patients were randomly allocated into three groups. The 14 patients in group 1 (aged 12.76 ± 1.0 years) were treated with the FRD appliance. In group 2, the 15 patients (aged 12.52 ± 1.12 years) received treatment with FRD using miniscrew anchorage, and the 9 patients in group 3 (aged 12.82 ± 0.9 years) received no treatment as a control group. Linear and angular measurements were made on lateral cephalograms before and immediately after Forsus treatment. Data were analyzed statistically using paired t-, ANOVA, and Tukey tests. RESULTS Class I molar relationship and overjet correction were achieved in both treatment groups. Although mandibular growth was statistically nonsignificant, there was a significant headgear effect on the maxilla. Mandibular incisor proclination, maxillary incisor retroclination, and distalization of maxillary molars were significant in both treatment groups. However, no significant differences were found between the treatment groups. CONCLUSIONS Class II correction was mainly dentoalveolar in both treatment groups. Use of miniscrews with Forsus did not enhance mandibular forward growth nor prevent labial tipping of the mandibular incisors.",2017,Use of miniscrews with Forsus did not enhance mandibular forward growth nor prevent labial tipping of the mandibular incisors.,"['38 patients', '14 patients in group 1 (aged 12.76 ± 1.0 years', '15 patients (aged 12.52 ± 1.12 years) received treatment with FRD using miniscrew anchorage, and the 9 patients in group 3 (aged 12.82 ± 0.9 years) received', 'Class II malocclusion cases treated with']","['no treatment as a control group', 'miniscrew-anchored Forsus Fatigue Resistant Device', 'FRD appliance', 'Forsus Fatigue Resistant Device (FRD']","['Mandibular incisor proclination, maxillary incisor retroclination, and distalization of maxillary molars']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0441869', 'cui_str': 'Group 3 (qualifier value)'}, {'cui': 'C4068881', 'cui_str': 'Zero point nine'}, {'cui': 'C0399524', 'cui_str': 'Malocclusion, Angle Class II, Division 1'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1293132', 'cui_str': 'Anchoring'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0243112'}]","[{'cui': 'C0021156', 'cui_str': 'Incisor'}, {'cui': 'C0026367', 'cui_str': 'Molar'}]",38.0,0.0275757,Use of miniscrews with Forsus did not enhance mandibular forward growth nor prevent labial tipping of the mandibular incisors.,"[{'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Eissa', 'Affiliation': ''}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'El-Shennawy', 'Affiliation': ''}, {'ForeName': 'Safaa', 'Initials': 'S', 'LastName': 'Gaballah', 'Affiliation': ''}, {'ForeName': 'Ghada', 'Initials': 'G', 'LastName': 'El-Meehy', 'Affiliation': ''}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'El Bialy', 'Affiliation': ''}]",The Angle orthodontist,['10.2319/032717-214.1'] 164,28868603,Proliferative retinopathy during hyperbaric oxygen treatment.,"A 43-year-old male with type 2 diabetes mellitus, treated with insulin for 28 years and with an HbA1c of 7.9% six months prior, suffered from bilateral plantar ulcers refractory to specialised wound care. He underwent a planned 40 sessions of hyperbaric oxygen treatment (HBOT) at 243 kPa for 90 minutes. Consent was given for this report. The patient's ophthalmic history included bilateral proliferative diabetic retinopathy (PDR) identified on routine diabetic eye screening three years previously. This was treated with pan-retinal photocoagulation (PRP). Three months before starting HBOT, he underwent phacoemulsification and intra-ocular lens insertion of his left eye, having had the same procedure done to his right eye a year prior, without complication. He was reviewed again one week prior to his first HBOT and fundoscopy confirmed non-proliferative diabetic retinopathy (NPDR) without evidence of PDR. The patient had a routine follow up by the ophthalmologist following his fifth HBOT when fundoscopic examination revealed pre-retinal haemorrhage, a form of PDR, in his left eye. This was treated with PRP at the time. His visual acuity, 6⁄9 bilaterally, had not changed, nor did he describe any changes in his visual field despite these findings. He was seen three weeks later (following 12 further HBOT) when fundoscopy showed worsening proliferative changes, this time in both eyes. Bevacizumab was injected at the time and fill-in PRP performed the following week. His visual acuity remained unchanged in both eyes. At this point, HBOT was withheld to allow the proliferative phase of the patients' retinopathy to remit. The potentially adverse effects of hyperbaric oxygen to the retinal vasculature of diabetic patients was postulated in 1994 following a similar experience, albeit without a baseline fundoscopic examination. In particular, the concern was of accelerating the proliferative process of retinopathy with subsequent irreversible loss of vision. Thereafter, routine screening and treatment of all diabetic patients for PDR was adopted at our facility. Until now, there have been no further cases of NPDR evolving into PDR at three-month review following HBOT. Indeed, a brief literature search using the terms ""retinopathy"", ""complications"", ""adverse effects"", ""vitreous"", ""hemorrhage"", ""haemorrhage"", ""hyperbaric"" and ""oxygen"" has not found any other cases described. In a double blind, randomised trial (meeting abstract only) of 15 diabetic patients with both NPDR and PDR, patients in neither the HBOT (243 kPa for 90 min) nor the control arm had evidence of neovascularisation nor worsening of their proliferative retinopathy at three-month follow up. The significance of PDR following cataract surgery has also been considered. A review article consistently found that NPDR progression occurred in up to a third of such patients. Despite this, there were no cases of NPDR progressing to PDR at 12-month follow up. Whether this patient's sudden progression to PDR was related to HBOT, recent cataract surgery or another unknown factor is unclear. However, the temporal relationship to 17 HBOT is difficult to explain and appears more rapid than available data regarding vascular regrowth in wound healing would suggest.",2017,"His visual acuity, 6⁄9 bilaterally, had not changed, nor did he describe any changes in his visual field despite these findings.","['15 diabetic patients with both NPDR and PDR, patients in neither the HBOT (243 kPa for 90 min) nor the control arm had evidence of neovascularisation nor worsening of their proliferative retinopathy at three-month follow up', 'A 43-year-old male with type 2 diabetes mellitus, treated with insulin for 28 years and with an HbA1c of 7.9% six months prior, suffered from bilateral plantar ulcers refractory to specialised wound care', 'diabetic patients']","['hyperbaric oxygen treatment (HBOT', 'Bevacizumab', 'hyperbaric oxygen', 'pan-retinal photocoagulation (PRP']","['bilateral proliferative diabetic retinopathy (PDR', 'His visual acuity', 'NPDR progression', 'Proliferative retinopathy', 'pre-retinal haemorrhage']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439474', 'cui_str': 'kPa'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0332120', 'cui_str': 'Evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C0027686', 'cui_str': 'Pathologic Neovascularization'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0339467', 'cui_str': 'Proliferative retinopathy'}, {'cui': 'C4082119', 'cui_str': 'Three months (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0086815', 'cui_str': 'Plantar Ulcer'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0886052', 'cui_str': 'Administers care to wound sites'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0085999', 'cui_str': 'Genus Pan (organism)'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0023694', 'cui_str': 'Photocoagulation'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0154830', 'cui_str': 'PDR - proliferative diabetic retinopathy'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0339467', 'cui_str': 'Proliferative retinopathy'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0035317', 'cui_str': 'Retinal Hemorrhage'}]",15.0,0.0428016,"His visual acuity, 6⁄9 bilaterally, had not changed, nor did he describe any changes in his visual field despite these findings.","[{'ForeName': 'Viet', 'Initials': 'V', 'LastName': 'Tran', 'Affiliation': 'Hyperbaric Medicine Unit, Royal Hobart Hospital, Tasmania, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Smart', 'Affiliation': 'Hyperbaric Medicine Unit, Royal Hobart Hospital, Tasmania, Australia.'}]",Diving and hyperbaric medicine,[] 165,23146065,Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy.,"BACKGROUND AND PURPOSE Injectable botulinum neurotoxin (BoNT) is the principal effective treatment for blepharospasm (BSP). This trial explores the safety and efficacy of topical acetyl hexapeptide-8 (AH8), a competitive SNAP25 inhibitor, as a potential new therapy in BSP. METHODS Double-blind, placebo-controlled, randomized trial of daily topical application of AH8 in 24 patients with BSP. The primary outcome was time to return to baseline Jankovic Blepharospasm Rating Scale (JBRS) after a BoNT injection simultaneously with the initiation of AH8. Patients displaying a strictly regular pattern of response to 3-monthly injections of BoNT were included. RESULTS There were no significant adverse events. There was a trend for longer time until return to baseline JBRS after injection in the active group compared to placebo (3.7 months vs. 3.0 months), and for better scores in the active group. One-third (4/12) of the patients in the active group had a considerable extension of symptom control after BoNT (range: 3.3-7.1 months). CONCLUSIONS Topical AH8 is safe and promising for extending the duration of action of BoNT therapy for BSP.",2013,There were no significant adverse events.,"['patients receiving botulinum toxin therapy', 'Patients displaying a strictly regular pattern of response to 3-monthly injections of BoNT were included', '24 patients with BSP']","['topical acetyl hexapeptide-8', 'Topical AH8', 'placebo', 'botulinum neurotoxin (BoNT']","['considerable extension of symptom control', 'time to return to baseline Jankovic Blepharospasm Rating Scale (JBRS', 'longer time until return to baseline JBRS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0006055', 'cui_str': 'Botulin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C3495674', 'cui_str': 'acetyl hexapeptide-8'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1295507', 'cui_str': 'Botulinum neurotoxin'}]","[{'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C1274136', 'cui_str': 'Symptom control'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332156', 'cui_str': 'Return to (contextual qualifier) (qualifier value)'}, {'cui': 'C0005747', 'cui_str': 'Blepharospasm'}, {'cui': 'C0222045'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}]",24.0,0.382953,There were no significant adverse events.,"[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lungu', 'Affiliation': 'Office of the Clinical Director, NINDS, NIH, Bethesda, MD, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Considine', 'Affiliation': 'Human Motor Control Section, Medical Neurology Branch, NINDS, NIH, Bethesda, MD, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Zahir', 'Affiliation': 'Office of the Clinical Director, NINDS, NIH, Bethesda, MD, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Ponsati', 'Affiliation': 'BCN Peptides S.A., Barcelona, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Arrastia', 'Affiliation': 'BCN Peptides S.A., Barcelona, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hallett', 'Affiliation': 'Human Motor Control Section, Medical Neurology Branch, NINDS, NIH, Bethesda, MD, USA.'}]",European journal of neurology,['10.1111/ene.12009'] 166,31547754,Impact of exercise training program attendance and physical activity participation on six minute walk distance in patients with heart failure.,"Background : Exercise training is recommended for all people with stable heart failure (HF) however adherence is poor. This study sought to describe exercise participation in recently hospitalized HF patients who participated in a 12-week exercise training program. The association between exercise training variables and improvement in 6-min walk distance (6MWD) was also investigated. Methods : This study is a secondary analysis of results from the intervention arm of the EJECTION-HF trial (ACTRN12608000263392), (n = 140). Exercise program attendance was defined according to session frequency (< 12 sessions vs ≥ 12 sessions) and attendance duration (< 6 weeks attendance vs ≥ 6 weeks) over the 12 weeks. Physical activity at baseline and follow up were reported according to self-report of 150 min of moderate intensity exercise per week. Primary outcome was change in 6MWD at 12 weeks. Results : Being physically active (OR 3.8, CI 1.3-11.5) and frequent program attendance (OR 2.7, CI 1.2-5.9) were associated with significant improvements in 6MWD. Program duration and baseline physical activity were not significantly associated with the outcome. Conclusions : Attainment of 150 min of moderate intensity exercise per week and at least weekly attendance at the program, were associated with significant improvements in 6MWD at follow up. Efforts should be made to assist patients with HF to achieve these targets.",2021,"OR 2.7, CI 1.2-5.9) were associated with significant improvements in 6MWD.","['patients with heart failure', 'all people with stable heart failure (HF', 'hospitalized HF patients who participated in a 12-week']","['exercise training program', ' : Exercise training', 'exercise training program attendance and physical activity participation']","['frequent program attendance', 'attendance duration', 'change in 6MWD', '6MWD', 'Program duration and baseline physical activity', 'Physical activity', '6-min walk distance (6MWD']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0429886', 'cui_str': 'Walking distance (observable entity)'}]",150.0,0.0275743,"OR 2.7, CI 1.2-5.9) were associated with significant improvements in 6MWD.","[{'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Adsett', 'Affiliation': ""Heart Support Service, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.""}, {'ForeName': 'Norman R', 'Initials': 'NR', 'LastName': 'Morris', 'Affiliation': 'School of Allied Health Sciences, Griffith University, Gold Coast, Queensland, Australia.'}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Mudge', 'Affiliation': ""Department of Internal Medicine and Aged Care, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.""}]",Physiotherapy theory and practice,['10.1080/09593985.2019.1669232'] 167,32412917,Effect of Prescription Tongxin on Endothelial Progenitor Cells in Peripheral Blood.,"Context Coronary heart disease (CHD) refers to a disease where coronary atherosclerosis induces stenosis or obstruction of the blood vessels. Endothelial progenitor cells (EPCs) function to protect and repair the vascular endothelium, and their functional activity state reflects the ability of the body to repair vascular damage. In the peripheral blood of patients with CHD, the density of EPCs decreases, and the function of EPCs is low. Objective This study aimed to investigate the effects of a China Food and Drug Administration (CFDA)-approved prescription medicine, Tongxin, on the density and function of endothelial progenitor cells (EPCs) in peripheral blood. Design In this study, a randomized, single blind, parallel controlled clinical trial was used. The single blind subjects were subjects. Setting The study took place in the Cardiology and Emergency Departments at Shanghai Municipal Hospital of Traditional Chinese Medicine in Shanghai, China. Participants Participants were 48 patients with coronary heart disease at the hospital. Intervention Participants were randomly divided into 2 groups (n = 24 each): a control group and an intervention group. Both groups received routine drug treatments, such as platelet inhibitors, nitrates, β-receptor blockers, statins, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), and calcium blockers. The control group was treated with the Shexiang Baoxin Pill, while the intervention group was treated with prescription Tongxin. The course of treatment was 3 months for both groups. Outcome Measures Changes in the density and function of EPCs in the peripheral blood of the 2 groups were measured at baseline and postintervention, and the clinical efficacy of the 2 treatments was statistically analyzed. Results The density of EPCs was significantly higher in both groups after 3 months of treatment, compared to the densities at baseline (P < .05). The change in density between baseline and postintervention was significantly greater for the intervention group than for the control group (P < .05). For the control group, the proliferative vitality [optical density (OD)] value of the EPCs was significantly higher than that at baseline from the fourth day of treatment (P < .05). In the intervention group, the OD value was significantly higher than that at baseline from the first day of treatment (P < .05). Furthermore, the intervention group's cells began to enter the logarithmic growth phase of increase from the fifth day of treatment, and the group's increase as significantly higher than the control group's from the fifth to the seventh dayof treatment (P < .05 for all 3 days). Moreover, the total effective rate was higher in the intervention group than in the control group (P < .05). Conclusions Prescription Tongxin can stimulate the release of EPCs from the bone marrow to the peripheral blood of patients with CHD, can significantly increase the proliferation of EPCs in the peripheral blood, and can improve the clinical symptoms of patients. Its curative effect was greater than that of the control treatment.",2021,"Moreover, the total effective rate was higher in the intervention group than in the control group (P < .05). ","['Participants\n\n\nParticipants were 48 patients with coronary heart disease at the hospital', 'Setting\n\n\nThe study took place in the Cardiology and Emergency Departments at Shanghai Municipal Hospital of Traditional Chinese Medicine in Shanghai, China', 'Peripheral Blood']","['Shexiang Baoxin Pill', 'Prescription Tongxin', 'prescription Tongxin', 'control group and an intervention group', 'China Food and Drug Administration (CFDA)-approved prescription medicine, Tongxin', 'routine drug treatments, such as platelet inhibitors, nitrates, β-receptor blockers, statins, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), and calcium blockers']","['proliferative vitality [optical density (OD)] value of the EPCs', 'OD value', 'change in density', 'total effective rate', 'clinical efficacy', 'density and function of EPCs in the peripheral blood', 'Endothelial Progenitor Cells', 'density of EPCs', 'proliferation of EPCs', 'Endothelial progenitor cells (EPCs) function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0020013', 'cui_str': 'Municipal Hospitals'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}]","[{'cui': 'C2351547', 'cui_str': 'shexiang baoxin'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0041714', 'cui_str': 'United States Food, Drug Administration'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032188', 'cui_str': 'Platelet Inhibitors'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0022709', 'cui_str': 'Dipeptidyl carboxypeptidase I'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}]","[{'cui': 'C0334094', 'cui_str': 'Proliferation'}, {'cui': 'C0439164', 'cui_str': 'OD units'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C3850017', 'cui_str': 'Circulating Endothelial Progenitor Cells'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}]",48.0,0.0159673,"Moreover, the total effective rate was higher in the intervention group than in the control group (P < .05). ","[{'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Xue-Qin', 'Initials': 'XQ', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Fan', 'Affiliation': ''}, {'ForeName': 'Xiao-Zhen', 'Initials': 'XZ', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'Yi-Sheng', 'Initials': 'YS', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Qi-Mao', 'Initials': 'QM', 'LastName': 'Feng', 'Affiliation': ''}, {'ForeName': 'Li-Hua', 'Initials': 'LH', 'LastName': 'Lu', 'Affiliation': ''}]",Alternative therapies in health and medicine,[] 168,27647263,"The effects of selenium supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy: a randomised, double-blind, placebo-controlled trial.","This study was carried out to assess the effects of Se supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy (DN). This randomised, double-blind, placebo-controlled clinical trial was conducted among sixty patients with DN. Patients were randomly divided into two groups to take either 200 µg/d Se supplements as Se yeast (n 30) or placebo (n 30) for 12 weeks. In unadjusted analyses, compared with the placebo, Se supplementation led to a significant reduction in high-sensitivity C-reactive protein (hs-CRP) (-1069·2 (sd 1752·2) v. -135·3 (sd 1258·9) ng/ml, P=0·02), matrix metalloproteinase-2 (MMP-2) (-612·3 (sd 679·6) v. +76·0 (sd 309·1) ng/ml, P<0·001) and plasma malondialdehyde (MDA) concentrations (-0·1 (sd 0·7) v. +0·4 (sd 0·9) µmol/l, P=0·01). In addition, a significant increase in plasma total antioxidant capacity (TAC) (+174·9 (sd 203·9) v. +15·8 (sd 382·2) mmol/l, P=0·04) was observed following supplementation with Se compared with the placebo. Subjects who received Se supplements experienced a borderline statistically significant decrease in serum protein carbonyl (PCO) levels (P=0·06) compared with the placebo. When we adjusted the analysis for baseline values of biochemical parameters, age and BMI, serum hs-CRP (P=0·14) and MDA levels (P=0·16) became non-significant, whereas plasma nitric oxide (NO) (P=0·04) and glutathione (GSH) (P<0·001) became statistically significant, and other findings did not change. Supplementation with Se had no significant effect on NO, transforming growth factor β (TGF-β), advanced glycation end products (AGE), PCO and GSH compared with the placebo. Overall, our study demonstrated that Se supplementation among DN patients had favourable effects on serum MMP-2, plasma NO, TAC and GSH, but did not affect hs-CRP, TGF-β, AGE, PCO and MDA.",2016,"NO, TAC and GSH, but did not affect hs-CRP, TGF-β, AGE, PCO and MDA.","['patients with diabetic nephropathy', 'patients with diabetic nephropathy (DN', 'sixty patients with DN']","['selenium supplementation', 'placebo', '200 µg/d Se supplements as Se yeast (n 30) or placebo', 'Se supplementation', 'matrix metalloproteinase-2']","['hs-CRP, TGF-β, AGE, PCO and MDA', 'biochemical parameters, age and BMI, serum hs-CRP (P=0·14) and MDA levels', '612·3 (sd 679·6', 'plasma malondialdehyde (MDA) concentrations (-0·1 (sd 0·7', 'plasma nitric oxide (NO) (P=0·04) and glutathione (GSH', 'serum MMP-2, plasma', 'biomarkers of inflammation and oxidative stress', 'plasma total antioxidant capacity (TAC', 'serum protein carbonyl (PCO) levels', 'NO, transforming growth factor β (TGF-β), advanced glycation end products (AGE), PCO and GSH', 'high-sensitivity C-reactive protein (hs-CRP) (-1069·2 (sd 1752·2) v. -135·3']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011881', 'cui_str': 'Diabetic Nephropathy'}]","[{'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0043393', 'cui_str': 'Yeasts'}, {'cui': 'C0632490', 'cui_str': 'N 30'}, {'cui': 'C0172537', 'cui_str': '72-kDa Type IV Collagenase'}]","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0623362', 'cui_str': 'MMPs'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0036825', 'cui_str': 'Serum Proteins'}, {'cui': 'C0040691', 'cui_str': 'Animal growth regulators, transforming growth factors'}, {'cui': 'C0162574', 'cui_str': 'Advanced Glycation Endproducts'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}]",60.0,0.554735,"NO, TAC and GSH, but did not affect hs-CRP, TGF-β, AGE, PCO and MDA.","[{'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': '1Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,PO Box 8715988141, Kashan,Iran.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Kia', 'Affiliation': '1Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,PO Box 8715988141, Kashan,Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Soleimani', 'Affiliation': '2Department of Internal Medicine,Kashan University of Medical Sciences,PO Box 8715988141, Kashan,Iran.'}, {'ForeName': 'Ali Akbar', 'Initials': 'AA', 'LastName': 'Mohammadi', 'Affiliation': '3Petroleum Industry Health Organization,PO Box 83121625, Tehran,Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': '1Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,PO Box 8715988141, Kashan,Iran.'}]",The British journal of nutrition,[] 169,31567176,Role of Potassium-Sparing Diuretics in the Management of Hypokalemia in Peritoneal Dialysis.,"BACKGROUND Patients with kidney disease are at a higher risk of experiencing potassium imbalance. The kidney plays an important role in maintaining potassium homeostasis. A common dyskalemia that peritoneal dialysis (PD) patients experience is hypokalemia. AREAS OF UNCERTAINTY Potassium-sparing diuretics such as spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Owing to its potassium-sparing effects, it may correct hypokalemia that PD patients experience. The proper usage of potassium-sparing diuretics in PD patients and data on the efficacy and safety are being explored. DATA SOURCES Four relevant trials were identified. One randomized double-blind placebo-controlled cross-over study (n = 20), one interventional study without the control group (n = 20), one retrospective single-center chart review (n = 53), and one cross-sectional review (n = 75) trial. The randomized controlled trial did not note a statistically significant change in K levels (P > 0.05); the other 3 trials observed an increase in potassium levels in the potassium-sparing diuretics groups, but trials contained small participants and inadequate statistic rigor. THERAPEUTIC OPINIONS The role of potassium-sparing diuretics use for hypokalemia management in PD patients remains unclear.",2021,"The randomized controlled trial did not note a statistically significant change in K levels (P > 0.05); the other 3 trials observed an increase in potassium levels in the potassium-sparing diuretics groups, but trials contained small participants and inadequate statistic rigor. ","['n = 20), one interventional study without the control group (n = 20), one retrospective single-center chart review (n = 53), and one cross-sectional review (n = 75) trial', 'Patients with kidney disease', 'Hypokalemia in Peritoneal Dialysis', 'PD patients']","['Potassium-Sparing Diuretics', 'placebo-controlled cross-over study', 'potassium-sparing diuretics']","['efficacy and safety', 'potassium levels', 'K levels']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0541653', 'cui_str': 'Chart review'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205155', 'cui_str': 'Sectional (qualifier value)'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C0020621', 'cui_str': 'Hypopotassemia'}, {'cui': 'C0031139', 'cui_str': 'Peritoneal Dialysis'}]","[{'cui': 'C0304475', 'cui_str': 'Potassium supplement'}, {'cui': 'C0012798', 'cui_str': 'Diuretics'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0428289', 'cui_str': 'Finding of potassium level (finding)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",4.0,0.178401,"The randomized controlled trial did not note a statistically significant change in K levels (P > 0.05); the other 3 trials observed an increase in potassium levels in the potassium-sparing diuretics groups, but trials contained small participants and inadequate statistic rigor. ","[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Nguyen', 'Affiliation': 'Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brookville, NY.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Ren', 'Affiliation': ''}, {'ForeName': 'Jaweria', 'Initials': 'J', 'LastName': 'Hussain', 'Affiliation': ''}, {'ForeName': 'Jessica J', 'Initials': 'JJ', 'LastName': 'Balaoro', 'Affiliation': ''}]",American journal of therapeutics,['10.1097/MJT.0000000000001090'] 170,32492293,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.,"BACKGROUND Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown. METHODS We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days. RESULTS We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was -2.4 percentage points (95% confidence interval, -7.0 to 2.2; P = 0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. CONCLUSIONS After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668.).",2020,"Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. ","['United States and parts of Canada testing', '821 asymptomatic participants', 'enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure']","['placebo', 'Hydroxychloroquine', 'placebo or hydroxychloroquine', 'hydroxychloroquine']","['Side effects', 'incidence of new illness compatible with Covid-19', 'incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days', 'serious adverse reactions']","[{'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0454979', 'cui_str': 'Part of Canada'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0028798', 'cui_str': 'Exposure, Occupational'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0183251', 'cui_str': 'Shield'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",821.0,0.751633,"Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. ","[{'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Pullen', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Pastick', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Lofgren', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Okafor', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Alanna A', 'Initials': 'AA', 'LastName': 'Nascene', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Melanie R', 'Initials': 'MR', 'LastName': 'Nicol', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Abassi', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Nicole W', 'Initials': 'NW', 'LastName': 'Engen', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Cheng', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'LaBar', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'MacKenzie', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Drobot', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marten', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kelly', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ilan S', 'Initials': 'IS', 'LastName': 'Schwartz', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Kathy H', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}]",The New England journal of medicine,['10.1056/NEJMoa2016638'] 171,28322590,Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.,"Despite improvements in drug and device therapy for heart failure, hospitalization rates and mortality have changed little in the past decade. Randomized clinical trials using gene transfer to improve function of the failing heart are the focus of this review. Four randomized clinical trials of gene transfer in heart failure with reduced ejection fraction (HFrEF) have been published. Each enrolled patients with stable symptomatic HFrEF and used either intracoronary delivery of a virus vector or endocardial injection of a plasmid. The initial CUPID trial randomized 14 subjects to placebo and 25 subjects to escalating doses of adeno-associated virus type 1 encoding sarcoplasmic reticulum calcium ATPase (AAV1.SERCA2a). AAV1.SERCA2a was well tolerated, and the high-dose group met a 6 month composite endpoint. In the subsequent CUPID-2 study, 243 subjects received either placebo or the high dose of AAV1.SERCA2a. AAV1.SERCA2a administration, while safe, failed to meet the primary or any secondary endpoints. STOP-HF used plasmid endocardial injection of stromal cell-derived factor-1 to promote stem-cell recruitment. In a 93-subject trial of patients with ischemic etiology heart failure, the primary endpoint (symptoms and 6 min walk distance) failed, but subgroup analyses showed improvements in subjects with the lowest ejection fractions. A fourth trial randomized 14 subjects to placebo and 42 subjects to escalating doses of adenovirus-5 encoding adenylyl cyclase 6 (Ad5.hAC6). There were no safety concerns, and patients in the two highest dose groups (combined) showed improvements in left ventricular function (left ventricular ejection fraction and -dP/dt). The safety data from four randomized clinical trials of gene transfer in patients with symptomatic HFrEF suggest that this approach can be conducted with acceptable risk, despite invasive delivery techniques in a high-risk population. Additional trials are necessary before the approach can be endorsed for clinical practice.",2017,"There were no safety concerns, and patients in the two highest dose groups (combined) showed improvements in left ventricular function (left ventricular ejection fraction and -dP/dt).","['patients with symptomatic HFrEF', 'patients with ischemic etiology heart failure', '243 subjects received either', 'Each enrolled patients with stable symptomatic HFrEF and used either intracoronary delivery of a virus vector or endocardial injection of a plasmid', 'and 25 subjects to escalating doses of adeno-associated virus type 1 encoding sarcoplasmic reticulum calcium ATPase (AAV1.SERCA2a', 'and 42 subjects to', 'heart failure with reduced ejection fraction (HFrEF']","['escalating doses of adenovirus-5 encoding adenylyl cyclase 6 (Ad5.hAC6', 'AAV1.SERCA2a', 'placebo']","['heart failure, hospitalization rates and mortality', 'left ventricular function (left ventricular ejection fraction and -dP/dt']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0015127', 'cui_str': 'causes'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0442335', 'cui_str': 'Vectors (qualifier value)'}, {'cui': 'C0014124', 'cui_str': 'Endocardium'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0032136', 'cui_str': 'Plasmids'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0449572', 'cui_str': 'Virus type (attribute)'}, {'cui': 'C0916181', 'cui_str': 'Sarcoplasmic Reticulum Calcium ATPase'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]","[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0001483', 'cui_str': 'Adenoviruses'}, {'cui': 'C0908604', 'cui_str': 'type VI adenylyl cyclase'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0080309', 'cui_str': 'Ventricular Function'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}]",14.0,0.313564,"There were no safety concerns, and patients in the two highest dose groups (combined) showed improvements in left ventricular function (left ventricular ejection fraction and -dP/dt).","[{'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Penny', 'Affiliation': '1 VA San Diego Healthcare System, San Diego, California.'}, {'ForeName': 'H Kirk', 'Initials': 'HK', 'LastName': 'Hammond', 'Affiliation': '1 VA San Diego Healthcare System, San Diego, California.'}]",Human gene therapy,['10.1089/hum.2016.166'] 172,27836532,Controlled Pilot Study of High-Impact Low-Frequency Exercise on Bone Loss and Vital-Sign Stabilization in Adolescents With Eating Disorders.,"PURPOSE Adolescents with anorexia nervosa (AN) face an increased lifetime risk of bone fragility. This randomized controlled study examined the efficacy and safety of a high-impact activity program on markers of bone turnover and stabilization of vital signs (VSS). METHODS Forty-one hospitalized adolescents with AN were randomly assigned to routine care or routine care plus 20 jumps twice daily. Bone markers were measured at baseline days 1-3 (T1), days 4-6 (T2), and days 7-9 (T3). The primary outcome was change in bone-specific alkaline phosphatase (BSAP) at T3 adjusted for BSAP and % median body mass index at T1. Secondary outcomes were serum N-telopeptide (NTX) and osteocalcin at T3. Safety was determined by comparing weight gain, time to VSS and length of stay for each group. RESULTS BSAP, NTX, or osteocalcin did not differ between groups at baseline or at T3. BSAP and NTX at T3 were not associated with group of enrollment or % median body mass index. VSS was significantly reduced in the intervention group compared with the control group (11.6 ± 5.7 days vs. 17 ± 10.5 days, p = .049). There was no significant difference in weight gain or length of stay between groups. CONCLUSIONS Twice-daily jumping activity failed to influence markers of bone turnover in adolescents with AN but was well tolerated, shortened time to vital-sign stabilization and did not slow weight gain.",2017,"VSS was significantly reduced in the intervention group compared with the control group (11.6 ± 5.7 days vs. 17 ± 10.5 days, p = .049).","['Adolescents With Eating Disorders', 'Adolescents with anorexia nervosa (AN', 'Forty-one hospitalized adolescents with AN']","['high-impact activity program', 'High-Impact Low-Frequency Exercise', 'routine care or routine care plus 20 jumps twice daily']","['lifetime risk of bone fragility', 'bone turnover and stabilization of vital signs (VSS', 'change in bone-specific alkaline phosphatase (BSAP) at T3 adjusted for BSAP and % median body mass index', 'Bone markers', 'serum N-telopeptide (NTX) and osteocalcin at T3', 'weight gain or length of stay', 'weight gain, time to VSS and length of stay', 'Bone Loss and Vital-Sign Stabilization', 'BSAP, NTX, or osteocalcin', 'bone turnover', 'efficacy and safety', 'VSS']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0013473', 'cui_str': 'Eating Disorders'}, {'cui': 'C0003125', 'cui_str': 'Anorexia Nervosas'}, {'cui': 'C0001585', 'cui_str': 'Adolescent, Hospitalized'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205213', 'cui_str': 'Low frequency (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0560453', 'cui_str': 'Does jump (finding)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0302113', 'cui_str': 'Fragility, function (observable entity)'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0518766'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0002059', 'cui_str': 'Orthophosphoric-monoester phosphohydrolase (alkaline optimum)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1868706', 'cui_str': 'N-telopeptide'}, {'cui': 'C0373691', 'cui_str': 'Osteocalcin measurement (procedure)'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",41.0,0.107234,"VSS was significantly reduced in the intervention group compared with the control group (11.6 ± 5.7 days vs. 17 ± 10.5 days, p = .049).","[{'ForeName': 'Susanne P K', 'Initials': 'SPK', 'LastName': 'Martin', 'Affiliation': 'Division of Adolescent Medicine, Stanford University School of Medicine, Palo Alto, California. Electronic address: susannepkmartin@gmail.com.'}, {'ForeName': 'Laura K', 'Initials': 'LK', 'LastName': 'Bachrach', 'Affiliation': 'Division of Pediatric Endocrinology, Stanford University School of Medicine, Palo Alto, California.'}, {'ForeName': 'Neville H', 'Initials': 'NH', 'LastName': 'Golden', 'Affiliation': 'Division of Adolescent Medicine, Stanford University School of Medicine, Palo Alto, California.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2016.08.028'] 173,27681077,"The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial.","To the best of our knowledge, data on the effects of synbiotic supplementation on markers of insulin metabolism and lipid concentrations in patients with gestational diabetes mellitus (GDM) are scarce. The aim of the current study was to determine the effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in GDM patients. In total, seventy patients with GDM aged 18-40 years were assigned to two groups - the synbiotic group (n 35) and the placebo group (n 35) - in this randomised, double-blind, placebo-controlled trial. Patients in the synbiotic group received a daily capsule that contained three viable and freeze-dried strains: Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium bifidum (2×109 colony-forming units/g each) plus 800 mg inulin for 6 weeks. Fasting blood samples were collected at the beginning and week 6 to quantify related markers. After 6 weeks of intervention, compared with the placebo, synbiotic supplementation led to a significant decrease in serum insulin levels (-1·5 (sd 5·9) v. +4·8 (sd 11·5) µIU/ml, P=0·005), homoeostatic model assessment for insulin resistance (-0·4 (sd 1·3) v. +1·1 (sd 2·7), P=0·003) and homoeostatic model assessment for β cell function (-5·1 (sd 24·2) v. +18·9 (sd 45·6), P=0·008) and a significant increase in quantitative insulin sensitivity check index (+0·01 (sd 0·01) v. -0·007 (sd 0·02), P=0·02). In addition, synbiotic intake significantly decreased serum TAG (-14·8 (sd 56·5) v. +30·4 (sd 37·8) mg/dl, P<0·001) and VLDL-cholesterol concentrations (-3·0 (sd 11·3) v. +6·1 (sd 7·6) mg/dl, P<0·001) compared with the placebo. Overall, the results of this study demonstrate that taking synbiotic supplements for 6 weeks among patients with GDM had beneficial effects on markers of insulin metabolism, TAG and VLDL-cholesterol concentrations.",2016,"After 6 weeks of intervention, compared with the placebo, synbiotic supplementation led to a significant decrease in serum insulin levels (-1·5 (sd 5·9)","['seventy patients with GDM aged 18-40 years', 'gestational diabetes', 'GDM patients', 'patients with gestational diabetes mellitus (GDM']","['daily capsule that contained three viable and freeze-dried strains: Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium bifidum', 'synbiotic supplementation', 'placebo', 'placebo, synbiotic supplementation']","['homoeostatic model assessment for insulin resistance (-0·4', 'markers of insulin metabolism, TAG and VLDL-cholesterol concentrations', 'quantitative insulin sensitivity check index', 'homoeostatic model assessment for β cell function (-5·1 (sd 24·2', 'serum insulin levels (-1·5 (sd 5·9', 'serum TAG', 'insulin metabolism and lipid concentrations', 'Fasting blood samples', 'insulin metabolism and lipid profiles', 'VLDL-cholesterol concentrations']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0443348', 'cui_str': 'Viable (qualifier value)'}, {'cui': 'C0016698', 'cui_str': 'Lyophilization'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0022939', 'cui_str': 'Lactobacillus acidophilus'}, {'cui': 'C0022940', 'cui_str': 'Lactobacillus casei'}, {'cui': 'C0314974', 'cui_str': 'Bifidobacterium bifidum'}, {'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0037293', 'cui_str': 'Tag (morphologic abnormality)'}, {'cui': 'C0023826', 'cui_str': 'Pre-beta-Lipoprotein Cholesterol'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}]",70.0,0.553667,"After 6 weeks of intervention, compared with the placebo, synbiotic supplementation led to a significant decrease in serum insulin levels (-1·5 (sd 5·9)","[{'ForeName': 'Shahnaz', 'Initials': 'S', 'LastName': 'Ahmadi', 'Affiliation': '1Department of Gynecology and Obstetrics,School of Medicine,Iran University of Medical Sciences,PO Box 83121625, Tehran,Iran.'}, {'ForeName': 'Mehri', 'Initials': 'M', 'LastName': 'Jamilian', 'Affiliation': '3Department of Gynecology and Obstetrics,School of Medicine,Endocrinology and Metabolism Research Center,Arak University of Medical Sciences,PO Box 6618634683, Arak,Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Tajabadi-Ebrahimi', 'Affiliation': '4Science Department, Science Faculty,Islamic Azad University,Tehran Central Branch,PO Box 83121625, Tehran,Iran.'}, {'ForeName': 'Parvaneh', 'Initials': 'P', 'LastName': 'Jafari', 'Affiliation': '5Department of Microbiology, Science Faculty,Islamic Azad University,Arak Branch,PO Box 6618634683, Arak,Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': '6Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,PO Box 8715988141, Kashan,Iran.'}]",The British journal of nutrition,[] 174,27198036,"The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD.","This study was conducted to examine the effects of vitamin D, K and Ca co-supplementation on carotid intima-media thickness (CIMT) and metabolic status in overweight diabetic patients with CHD. This randomised, double-blind, placebo-controlled trial was conducted among sixty-six diabetic patients with CHD. Participants were randomly allocated into two groups to take either 5µg vitamin D, 90 µg vitamin K plus 500 mg Ca supplements (n 33) or placebo (n 33) twice a day for 12 weeks. Fasting blood samples were obtained at the beginning of the study and after the 12-week intervention period to determine related markers. Vitamin D, K and Ca co-supplementation resulted in a significant reduction in maximum levels of left CIMT (-0·04 (sd 0·22) v. +0·04 (sd 0·09) mm, P=0·02). Changes in serum vitamin D (+6·5 (sd 7·8) v. +0·4 (sd 2·2) ng/ml, P<0·001), Ca (+0·6 (sd 0·3) v. +0·1 (sd 0·1) mg/dl, P<0·001) and insulin concentrations (-0·9 (sd 3·1) v. +2·6 (sd 7·2) µIU/ml, P=0·01), homoeostasis model for assessment of estimated insulin resistance (-0·4 (sd 1·2) v. +0·7 (sd 2·3), P=0·01), β-cell function (-2·1 (sd 9·0) v. +8·9 (sd 23·7), P=0·01) and quantitative insulin sensitivity check index (+0·007 (sd 0·01) v. -0·006 (sd 0·02), P=0·01) in supplemented patients were significantly different from those in patients in the placebo group. Supplementation resulted in significant changes in HDL-cholesterol (+2·7 (sd 7·0) v. -2·5 (sd 5·7) mg/dl, P=0·002), high-sensitivity C-reactive protein (-1320·1 (sd 3758·3) v. +464·0 (sd 3053·3) ng/ml, P=0·03) and plasma malondialdehyde concentrations (-0·4 (sd 0·5) v. -1·0 (sd 1·1) µmol/l, P=0·007) compared with placebo. Overall, vitamin D, K and Ca co-supplementation for 12 weeks among diabetic patients with CHD had beneficial effects on maximum levels of left CIMT and metabolic status. The effect of vitamin D, K and Ca co-supplementation on maximum levels of left CIMT could be a chance finding.",2016,"Vitamin D, K and Ca co-supplementation resulted in a significant reduction in maximum levels of left CIMT (-0·04 (","['sd 7·2', 'sd 0·22', 'sixty-six diabetic patients with CHD', 'overweight type 2 diabetic patients with CHD', 'diabetic patients with CHD', 'overweight diabetic patients with CHD']","['placebo', 'vitamin D, K and Ca co-supplementation', 'Vitamin D, K and Ca co-supplementation', '5µg vitamin D, 90 µg vitamin K plus 500 mg', 'Ca ', 'vitamin D, K and calcium co-supplementation', 'Ca supplements']","['serum vitamin D', 'carotid intima-media thickness (CIMT) and metabolic status', 'Overall, vitamin D, K and Ca co-supplementation', 'maximum levels of left CIMT and metabolic status', 'β-cell function (-2·1 (sd 9·0', 'maximum levels of left CIMT (-0·04 ', 'Fasting blood samples', 'quantitative insulin sensitivity check index (+0·007 (sd 0·01', 'insulin concentrations (-0·9 (sd 3·1', 'plasma malondialdehyde concentrations ', '0·4 (sd 0·5', 'high-sensitivity C-reactive protein (-1320·1 (sd 3758·3', 'HDL-cholesterol (+2·7 (sd 7·0) v. -2·5 (sd 5·7', 'carotid intima-media thickness and metabolic status']","[{'cui': 'C4517841', 'cui_str': 'Sixty-six'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0042879', 'cui_str': 'Vitamin K measurement (procedure)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}]",66.0,0.40056,"Vitamin D, K and Ca co-supplementation resulted in a significant reduction in maximum levels of left CIMT (-0·04 (","[{'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': '1Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Raygan', 'Affiliation': '2Department of Cardiology,School of Medicine,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': '1Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Rezavandi', 'Affiliation': '2Department of Cardiology,School of Medicine,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Hamid Reza', 'Initials': 'HR', 'LastName': 'Talari', 'Affiliation': '3Department of Radiology,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Motahereh', 'Initials': 'M', 'LastName': 'Rafiee', 'Affiliation': '3Department of Radiology,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Somayyeh', 'Initials': 'S', 'LastName': 'Poladchang', 'Affiliation': '3Department of Radiology,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Manijeh', 'Initials': 'M', 'LastName': 'Darooghegi Mofrad', 'Affiliation': '1Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Taheri', 'Affiliation': '1Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Ali Akbar', 'Initials': 'AA', 'LastName': 'Mohammadi', 'Affiliation': '1Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan,Islamic Republic of Iran.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Esmaillzadeh', 'Affiliation': '4Food Security Research Center,Isfahan University of Medical Sciences,Isfahan,Islamic Republic of Iran.'}]",The British journal of nutrition,['10.1017/S0007114516001847'] 175,26947279,Safety and Immunogenicity of Cuban Antipneumococcal Conjugate Vaccine PCV7-TT in Healthy Adults.,"INTRODUCTION Pneumococcal infections are a major cause of morbidity and mortality and are associated with considerable economic burden on health systems. To prevent pneumococcal infections, 7-valent conjugate vaccines have been available for over a decade; more recently, 10- and 13-valent conjugate vaccines have been formulated, which are more immunogenic than vaccines with capsular polysaccharides only. In Cuba, a new vaccine candidate has been developed, PCV7-TT, a conjugate of tetanus toxoid with antigens of seven of the serotypes of Streptococcus pneumoniae with highest circulation in Cuba and in the world: 1, 5, 6B, 14, 18C, 19F and 23F. OBJECTIVE Assess the safety of the vaccine candidate PCV7-TT in healthy adults and conduct a preliminary assessment of its immunogenicity. METHODS A phase I, double-blind clinical trial was performed at the National Toxicology Center in Havana, Cuba. Healthy male volunteers aged 18-35 years were randomly assigned to two groups: 20 received the vaccine candidate PCV7-TT and 20 the polyvalent antipneumococcal vaccine PNEUMO-23 used as control, each in a single intramuscular dose. To assess safety, the occurrence of adverse events was monitored for 30 days following inoculation. To explore immunogenicity, concentrations of serotype-specific antibodies was quantified before and 30 days after inoculation, as well titers of opsonophagocytic antibodies. (National Clinical Trial Registry RPCEC00000133) RESULTS Local adverse events were pain, redness, induration, increased sensitivity to touch, and warmth in the injection area. Pain was registered in 70% of individuals who received PCV7-TT and in 75% of those vaccinated with PNEUMO-23. Reported systemic adverse events were general malaise, headache and drowsiness. All adverse events appeared in the first 72 hours post inoculation and lasted no longer than 3 days. One event was reported that was classified as severe in intensity and serious in consequences, but it was unrelated to vaccination appendicitis in one individual inoculated with the control vaccine. Before vaccination, all participants but one had antibody concentrations =0.20 µg/ml against the vaccine strains; after vaccination 100% of individuals were positive and the concentrations of antibodies increased in previously positive volunteers. Some individuals had opsonophagocytic antibodies against serotypes 1, 14, 19F and 23F before vaccination, with highest concentrations against serotypes 14 and 19F. After vaccination, the percent of individuals with opsonophagocytic titers >1:8 for all serotypes in the vaccine was >50% in both groups. CONCLUSIONS A single dose of candidate vaccine PCV7-TT was safe when used in healthy adults. Preliminary results showed that it was able to activate an immune response against the serotypes of Streptococcus pneumoniae used. KEYWORDS Invasive pneumococcal diseases, pneumococcal vaccines, conjugate vaccines, immunization, randomized clinical trial, safety, Cuba.",2015,"After vaccination, the percent of individuals with opsonophagocytic titers >1:8 for all serotypes in the vaccine was >50% in both groups.","['Healthy male volunteers aged 18-35 years', 'National Toxicology Center in Havana, Cuba', 'Healthy Adults', 'healthy adults']","['Cuban Antipneumococcal Conjugate Vaccine PCV7-TT', 'candidate vaccine PCV7-TT', 'vaccine candidate PCV7-TT and 20 the polyvalent antipneumococcal vaccine PNEUMO-23', 'vaccine candidate PCV7-TT', 'PCV7-TT']","['general malaise, headache and drowsiness', 'immunogenicity, concentrations of serotype-specific antibodies', 'Pain', 'concentrations of antibodies', 'pain, redness, induration, increased sensitivity to touch, and warmth in the injection area', 'adverse events', 'Safety and Immunogenicity']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0040541', 'cui_str': 'Toxicology'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0010435', 'cui_str': 'Cuba'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1608615', 'cui_str': 'Pneumo-23'}]","[{'cui': 'C0231218', 'cui_str': 'Undifferentiated illness: Vague ill health'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0013144', 'cui_str': 'Drowsy (finding)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0449550', 'cui_str': 'Serotype (UK)'}, {'cui': 'C0443640', 'cui_str': 'Specific antibody (substance)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C0332534', 'cui_str': 'Induration (morphologic abnormality)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0152054', 'cui_str': 'Therapeutic Touch'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.201135,"After vaccination, the percent of individuals with opsonophagocytic titers >1:8 for all serotypes in the vaccine was >50% in both groups.","[{'ForeName': 'Nadezhda', 'Initials': 'N', 'LastName': 'González', 'Affiliation': 'Biomolecular Chemistry Center, Havana, Cuba. ngonzalez@finlay.edu.cu.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Paredes', 'Affiliation': ''}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Pérez', 'Affiliation': ''}, {'ForeName': 'Mayelín', 'Initials': 'M', 'LastName': 'Mirabal', 'Affiliation': ''}, {'ForeName': 'Ivonne', 'Initials': 'I', 'LastName': 'Rivero', 'Affiliation': ''}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'González', 'Affiliation': ''}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Díaz', 'Affiliation': ''}, {'ForeName': 'Dagmar', 'Initials': 'D', 'LastName': 'García', 'Affiliation': ''}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Rodríguez', 'Affiliation': ''}, {'ForeName': 'Amarilis', 'Initials': 'A', 'LastName': 'Pérez', 'Affiliation': ''}, {'ForeName': 'Yamilka', 'Initials': 'Y', 'LastName': 'Soroa', 'Affiliation': ''}, {'ForeName': 'Darielis', 'Initials': 'D', 'LastName': 'Santana', 'Affiliation': ''}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Alvarez', 'Affiliation': 'Biomolecular Chemistry Center, Havana, Cuba.'}, {'ForeName': 'Yury', 'Initials': 'Y', 'LastName': 'Valdés', 'Affiliation': ''}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Vérez', 'Affiliation': ''}]",MEDICC review,['10.37757/MR2015.V17.N4.7'] 176,31848062,The Use of Inhaled N-Acetylcysteine for Laryngopharyngeal Reflux Disease: A Randomized Controlled Trial.,"OBJECTIVES Proton pump inhibitors (PPIs) are the mainstay of the medical treatment for laryngopharyngeal reflux disease (LPRD). However, extraesophageal symptoms of LPRD, such as globus, are often refractory to PPI treatment. Many kinds of adjunctive medications have been attempted to address those refractory cases. We aimed to study whether inhaled N-acetylcysteine (NAC), a mucolytic agent, has additive effects for the treatment of LPRD when used in conjunction with PPIs. METHODS Patients with reflux symptom index (RSI) greater than 13 and reflux finding scores (RFS) greater than 7 were prospectively enrolled and were randomly assigned to control or study group. Patients were treated with oral rabeprazole in the control group and with oral rabeprazole and inhaled NAC in the study group. Patients were followed once a month for 2 months with questionnaires and stroboscopic examination. At every follow-up, RSI and RFS were checked. The extent of improvements of RSI and RFS were evaluated and compared between two groups. RESULTS With treatment, the mean RSI changed from 21.0 to 7.6 (P < 0.001) in control group and from 19.7 to 4.5 (P < 0.001) in study group. The mean RFS also changed from 12.9 to 7.1 (P < 0.001) in control group and from 13.5 to 6.9 (P < 0.001) in study group. For both RSI and RFS, the extents of improvement were not significantly different between two groups. In patients whose RSI improved less than nine at the first follow-up (poor early responders), RSI became significantly lower in the study group (4.6 ± 2.0) than in the control group (9.5 ± 4.6) at second follow-up (P = 0.019). In good early responders, however, RSI was not significantly different between the two groups in the second follow-up. CONCLUSIONS In this study, there were no significant differences in the overall outcome between patients treated with inhaled NAC and PPI and those with PPI alone. Interestingly, some additional therapeutic effect of NAC appeared late for the patients with poor early response. Further studies are required to investigate the underlying mechanism for this.",2021,"In good early responders, however, RSI was not significantly different between the two groups in the second follow-up. ","['Laryngopharyngeal Reflux Disease', 'laryngopharyngeal reflux disease (LPRD', 'Patients with reflux symptom index (RSI) greater than 13 and reflux finding scores (RFS) greater than 7 were prospectively enrolled']","['oral rabeprazole', 'Proton pump inhibitors (PPIs', 'inhaled N-acetylcysteine (NAC', 'oral rabeprazole and inhaled NAC', 'Inhaled N-Acetylcysteine', 'NAC']","['mean RSI', 'RSI', 'RSI and RFS', 'mean RFS']","[{'cui': 'C1168250', 'cui_str': 'Laryngopharyngeal Reflux'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0303134', 'cui_str': '7Be radioisotope'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0378482', 'cui_str': 'rabeprazole'}, {'cui': 'C4521480', 'cui_str': 'Hydrogen/potassium adenosine triphosphatase enzyme system inhibitor (disposition)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.0260628,"In good early responders, however, RSI was not significantly different between the two groups in the second follow-up. ","[{'ForeName': 'Yong Seok', 'Initials': 'YS', 'LastName': 'Jo', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea.'}, {'ForeName': 'Ick Soo', 'Initials': 'IS', 'LastName': 'Choi', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea.'}, {'ForeName': 'Yoon Kyoung', 'Initials': 'YK', 'LastName': 'So', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea. Electronic address: hn0131@paik.ac.kr.'}]",Journal of voice : official journal of the Voice Foundation,['10.1016/j.jvoice.2019.11.017'] 177,30007996,Sensorimotor integration training in Parkinson`s disease.,"OBJECTIVE To determine the effects of sensorimotor integration training on postural control in Parkinson`s disease. METHODS This prospective, randomized controlled trial was conducted at Hacettepe University (Ankara, Turkey). The study was carried out from August 2012 until March 2015 and included 24 Parkinson`s patients with stage 2-3 according to the Modified Hoehn&Yahr Rating Scale. The patients were divided into 2 groups (control and study). The control group received conventional physiotherapy; the study group received sensorimotor integration training combined with conventional physiotherapy, 2 times per week for 6 weeks. We assessed the patients with clinical balance tests and computerized dynamic posturography. Assessments were performed at baseline, 7- and 12-weeks follow-up. RESULTS Computerized dynamic posturography posturography values (5th and 6th positions, composite balance, and vestibular system scores) were higher in the study group than in the control group. The improvements were maintained at the 12-week follow up except 6th positions scores (p<0.05). CONCLUSION Sensorimotor integration training combined with conventional physiotherapy approach ameliorated postural control by improving vestibular system in patients with Parkinson`s disease by improving sensory processes.",2018,"The improvements were maintained at the 12-week follow up except 6th positions scores (p<0.05). ","['August 2012 until March 2015 and included 24 Parkinson`s patients with stage 2-3 according to the Modified Hoehn&Yahr Rating Scale', 'patients with Parkinson`s disease by improving sensory processes', 'patients with clinical balance tests and computerized dynamic posturography', 'Hacettepe University (Ankara, Turkey', 'Parkinson`s disease']","['Sensorimotor integration training combined with conventional physiotherapy approach', 'Sensorimotor integration training', 'conventional physiotherapy', 'sensorimotor integration training combined with conventional physiotherapy', 'sensorimotor integration training']","['vestibular system', 'composite balance, and vestibular system scores']","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0919611', 'cui_str': 'Posturography'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0041400', 'cui_str': 'Turkey'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C0682674', 'cui_str': 'Structure of vestibular system'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",24.0,0.0147967,"The improvements were maintained at the 12-week follow up except 6th positions scores (p<0.05). ","[{'ForeName': 'Ayla', 'Initials': 'A', 'LastName': 'Fil-Balkan', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Hacettepe University, Ankara, Turkey. E-mail: aylafil@gmail.com.'}, {'ForeName': 'Yeliz', 'Initials': 'Y', 'LastName': 'Salci', 'Affiliation': ''}, {'ForeName': 'Hilal', 'Initials': 'H', 'LastName': 'Keklicek', 'Affiliation': ''}, {'ForeName': 'Kadriye', 'Initials': 'K', 'LastName': 'Armutlu', 'Affiliation': ''}, {'ForeName': 'Songul', 'Initials': 'S', 'LastName': 'Aksoy', 'Affiliation': ''}, {'ForeName': 'Hulya', 'Initials': 'H', 'LastName': 'Kayihan', 'Affiliation': ''}, {'ForeName': 'Bulent', 'Initials': 'B', 'LastName': 'Elibol', 'Affiliation': ''}]","Neurosciences (Riyadh, Saudi Arabia)",['10.17712/nsj.2018.3.20180021'] 178,28490394,"Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial.","Synbiotic intake may be associated with reduced inflammation in patients with rheumatoid arthritis (RA) due to optimised inflammatory markers, oxidative stress and insulin resistance. This research was conducted to assess the effects of synbiotic supplementation on the clinical and metabolic parameters of patients with RA. A total of fifty-four patients with RA were allocated into two groups to receive either a synbiotic capsule (n 27) or a placebo (n 27) for 8 weeks in this randomised, double-blind, placebo-controlled trial. Fasting blood samples were taken at baseline and week 8 of the study to quantify related markers. After the 8-week intervention, compared with the placebo, synbiotic supplementation resulted in a significant reduction in serum high-sensitivity C-reactive protein (hs-CRP) levels (-1427·8 (sd 3267·2) v. +2833·4 (sd 5639·7) ng/ml, P=0·001). In addition, compared with the placebo, synbiotic supplementation improved disease activity score-28 joints (DAS-28) (-1·6 (sd 0·8) v. -0·3 (sd 0·5), P<0·001) and visual analogue scales (VAS) pain (-30·4 (sd 18·7) v. -11·5 (sd 15·9), P<0·001). In addition, a significant elevation in plasma nitric oxide (NO) (+0·8 (sd 4·4) v. -2·6 (sd 4·5) µmol/l, P=0·008), and significant reductions in insulin values (-13·8 (sd 26·4) v. +4·2 (sd 28·2) pmol/l, P=0·01), homoeostasis model of assessment-estimated insulin resistance (HOMA-IR) (-0·5 (sd 1·0) v.+0·1 (sd 1·1), P=0·03) and homoeostatic model assessment-β-cell function (HOMA-B) (-9·4 (sd 17·9) v. +3·3 (sd 18·9), P=0·01) following supplementation with the synbiotic compared with the placebo. Compared with the placebo, synbiotic supplementation also resulted in a significant increase in plasma GSH (+36·6 (sd 63·5) v. -58·5 (sd 154·4) µmol/l, P=0·005). Overall, our study demonstrated that synbiotic supplementation for 8 weeks among patients with RA had beneficial effects on hs-CRP, DAS-28, VAS, NO, insulin levels, HOMA-IR, HOMA-B and GSH levels.",2017,"In addition, compared with the placebo, synbiotic supplementation improved disease activity score-28 joints (DAS-28) (-1·6 (sd 0·8) v. -0·3 (sd 0·5), P<0·001) and visual analogue scales (VAS) pain (-30·4 (","['patients with rheumatoid arthritis', 'patients with rheumatoid arthritis (RA', 'sd 18·7', 'patients with RA', 'sd 26·4', 'A total of fifty-four patients with RA']","['placebo', 'Synbiotic supplementation', 'synbiotic capsule', 'placebo, synbiotic supplementation', '0·5', 'synbiotic supplementation']","['plasma GSH', 'homoeostasis model of assessment-estimated insulin resistance (HOMA-IR) ', 'beneficial effects on hs-CRP, DAS-28, VAS, NO, insulin levels, HOMA-IR, HOMA-B and GSH levels', 'clinical and metabolic responses', 'disease activity score-28 joints (DAS-28) (-1·6 (sd 0·8) v. -0·3 (sd 0·5), P<0·001) and visual analogue scales (VAS) pain (-30·4 ', 'plasma nitric oxide (NO', 'Fasting blood samples', 'insulin values (-13·8 ', 'serum high-sensitivity C-reactive protein (hs-CRP) levels', 'homoeostatic model assessment-β-cell function (HOMA-B) ']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517807', 'cui_str': 'Fifty-four'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0051767', 'cui_str': 'DASD'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C4706353', 'cui_str': 'Disease Activity Score'}, {'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031843', 'cui_str': 'function'}]",54.0,0.614307,"In addition, compared with the placebo, synbiotic supplementation improved disease activity score-28 joints (DAS-28) (-1·6 (sd 0·8) v. -0·3 (sd 0·5), P<0·001) and visual analogue scales (VAS) pain (-30·4 (","[{'ForeName': 'Batol', 'Initials': 'B', 'LastName': 'Zamani', 'Affiliation': '1Department of Gastroenterology,Kashan University of Medical Sciences,Kashan PO Box 8715988141,Iran.'}, {'ForeName': 'Shima', 'Initials': 'S', 'LastName': 'Farshbaf', 'Affiliation': '2Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan PO Box 8715988141,Iran.'}, {'ForeName': 'Hamid R', 'Initials': 'HR', 'LastName': 'Golkar', 'Affiliation': '1Department of Gastroenterology,Kashan University of Medical Sciences,Kashan PO Box 8715988141,Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': '2Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan PO Box 8715988141,Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': '2Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan PO Box 8715988141,Iran.'}]",The British journal of nutrition,['10.1017/S000711451700085X'] 179,32413238,Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions.,"To assess the bioequivalence of two 5-mg olanzapine orally disintegrating tablet (ODT) products, 2 randomized, open-label, single-dose, 2-way crossover studies were carried out under fasting or fed conditions. Blood samples were collected at scheduled times according to the study protocol. Statistical analysis of area under the concentration-time curve from time 0 to 168 hours (AUC 0-t ), area under the curve from time zero to infinity (AUC 0-∞ ), and peak plasma concentration (C max ) was conducted. Two formulations were considered bioequivalent if the 90% confidence intervals (CIs) of the geometric mean ratios for AUC 0-t, AUC 0-∞ , and C max were within the range of 0.80-1.25. Adverse events were recorded and evaluated throughout the studies. A total of 48 subjects with 24 in each study completed the 2 studies. In fasted subjects, the 90%CIs for the test product versus the reference product were 97.28%-105.13% for AUC 0-t , 97.57%-105.54% for AUC 0-∞ , and 90.94%-103.97% for C max . In fed subjects, the 90%CIs for AUC 0-t , AUC 0-∞ and C max were 99.73%-122.63%, 99.56%-121.75%, and 99.46%-120.46%, respectively. No serious adverse events were reported in the studies. The reference and the test product of 5-mg olanzapine ODT show comparable pharmacokinetic profiles under both fed and fasted conditions and were considered bioequivalent.",2020,No serious adverse events were reported in the studies.,"['48 subjects with 24 in each study completed the 2 studies', 'Healthy Chinese Subjects Under Fed and Fasting Conditions']","['olanzapine', 'Olanzapine Orally Disintegrating Tablet Products', 'olanzapine ODT']","['serious adverse events', 'peak plasma concentration', '90%CIs for AUC 0-t , AUC 0-∞ and C max', 'Adverse events']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0342895', 'cui_str': 'Fish-eye disease'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C1248714', 'cui_str': 'olanzapine Disintegrating Oral Tablet'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C4319556', 'cui_str': '168'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",48.0,0.0358422,No serious adverse events were reported in the studies.,"[{'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Fan', 'Affiliation': 'Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Lizhi', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'QILU Pharmaceutical, Jinan, Shandong, China.'}, {'ForeName': 'Hongquan', 'Initials': 'H', 'LastName': 'Zheng', 'Affiliation': 'Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Junlin', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Yunfang', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Jianghui', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Fan', 'Affiliation': 'Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.765'] 180,32419688,Dietary intake and processes of behaviour change in a nutrition education intervention for pregnant women in rural Malawi: a cluster-randomised controlled trial.,"OBJECTIVE To examine if increased intake of locally available nutrient-dense foods among pregnant women improved the quality of their dietary intake and if use of the Theory of Planned Behaviour could explain changes in their dietary behaviour. DESIGN We used data from a randomised controlled trial where the intervention group received nutrition education and dietary counselling. We promoted the use of recipes that utilised powders to enhance dietary diversity. We examined how the intervention achieved changes in dietary intakes and used mixed effects logistic regression models with random effects at village level to explore changes over time of the outcomes, adjusted for selected explanatory variables. SETTING The study was conducted in twenty villages in rural Malawi. PARTICIPANTS Data from 257 pregnant women who were enrolled during late first trimester and followed until birth. RESULTS The intervention achieved improvements in the Dietary Diversity Score (DDS) and the Six Food Group Pyramid (SFG) score, especially in intakes of micronutrient-rich foods. A third of the women in the intervention group attained optimal DDS, whereas about 50 % attained optimal SFG. The theorised behaviour mediators (i.e. nutrition attitudes, nutrition behaviour control and subjective norm) that had improved were also significantly associated with high DDS. CONCLUSIONS Improved dietary intakes were achieved through promoting the use of locally available nutrient-dense foods. Attainment of high DDS was a consequence of the women's belief in the effectiveness of the proposed nutrition recommendations. We identified critical personal and environmental constraints related to dietary intakes during pregnancy in a low-resource setting.",2020,"The intervention achieved improvements in the Dietary Diversity Score (DDS) and the Six Food Group Pyramid (SFG) score, especially in intakes of micronutrient-rich foods.","['twenty villages in rural Malawi', 'Data from 257 pregnant women who were enrolled during late first trimester and followed until birth', 'pregnant women in rural Malawi', 'pregnant women']","['nutrition education and dietary counselling', 'nutrition education intervention']","['Dietary Diversity Score (DDS) and the Six Food Group Pyramid (SFG) score, especially in intakes of micronutrient-rich foods', 'optimal DDS']","[{'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0032979', 'cui_str': 'First trimester pregnancy'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]","[{'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034229', 'cui_str': 'Pyramidal tract structure'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0453861', 'cui_str': 'Rich food'}]",257.0,0.0758828,"The intervention achieved improvements in the Dietary Diversity Score (DDS) and the Six Food Group Pyramid (SFG) score, especially in intakes of micronutrient-rich foods.","[{'ForeName': 'Lillian', 'Initials': 'L', 'LastName': 'Ziyenda Katenga-Kaunda', 'Affiliation': 'Department of Nutrition, University of Oslo, PO Box 1046 Blindern, 0316Oslo, Norway.'}, {'ForeName': 'Per Ole', 'Initials': 'PO', 'LastName': 'Iversen', 'Affiliation': 'Department of Nutrition, University of Oslo, PO Box 1046 Blindern, 0316Oslo, Norway.'}, {'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Holmboe-Ottesen', 'Affiliation': 'Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Fjeld', 'Affiliation': 'Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Ibrahimu', 'Initials': 'I', 'LastName': 'Mdala', 'Affiliation': 'Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Penjani Rhoda', 'Initials': 'PR', 'LastName': 'Kamudoni', 'Affiliation': 'Department of Nutrition, University of Oslo, PO Box 1046 Blindern, 0316Oslo, Norway.'}]",Public health nutrition,['10.1017/S1368980020000294'] 181,32053243,Randomised simulation trial found an association between rescuers' height and weight and chest compression quality during paediatric resuscitation.,"AIM Our aim was to examine the relationship between rescuers' anthropometric data and chest compression quality during paediatric resuscitation training. METHODS This study focused on 224 medical students (53% women) who performed 2 minutes of paediatric resuscitation at the Medical University of Vienna, Austria: 116 on a baby manikin and 108 on an adolescent manikin. Skill Reporter software measured chest compression quality by recording compression depth, frequency, hand position and complete recoil. The participants' height, weight and body mass index (BMI) were recorded. RESULTS Participants with a lower BMI achieved higher total chest compression scores on both the baby and adolescent manikins than participants with a higher BMI. The latter were more likely to exceed the correct compression depth and not achieve complete chest recoil in the adolescent manikin. When it came to the baby manikin, the female participants achieved better chest recoil and the males achieved a higher number of compressions at the correct rate. Males also achieved better chest recoil with the adolescent manikins. Being tall only correlated with incomplete recoil in the adolescent manikin. CONCLUSION The results indicate that anthropometric variables were associated with chest compression quality in paediatric patients and should be considered by future education programmes.",2020,"RESULTS Participants with a lower BMI achieved higher total chest compression scores on both the baby and adolescent manikins than participants with a higher BMI.","['paediatric resuscitation', 'paediatric patients', '224 medical students (53% women) who performed two minutes of paediatric resuscitation at the Medical University of Vienna, Austria: 116 on a baby manikin and 108 on an adolescent manikin']",[],"['correct compression depth', 'chest compression quality by recording compression depth, frequency, hand position and complete recoil', 'total chest compression scores', 'height, weight and body mass index (BMI', 'chest compression quality']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319560', 'cui_str': '224'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0004348', 'cui_str': 'Austria'}, {'cui': 'C4517541', 'cui_str': '116 (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0024722', 'cui_str': 'Mannequins'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]",[],"[{'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",224.0,0.0156304,"RESULTS Participants with a lower BMI achieved higher total chest compression scores on both the baby and adolescent manikins than participants with a higher BMI.","[{'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Bibl', 'Affiliation': 'Division of Neonatology, Paediatric Intensive Care and Neuropaediatrics, Department of Paediatrics, Comprehensive Center for Paediatrics, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Gröpel', 'Affiliation': 'Department of Applied Psychology: Work, Education and Economy, University of Vienna, Vienna, Austria.'}, {'ForeName': 'Angelika', 'Initials': 'A', 'LastName': 'Berger', 'Affiliation': 'Division of Neonatology, Paediatric Intensive Care and Neuropaediatrics, Department of Paediatrics, Comprehensive Center for Paediatrics, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Georg M', 'Initials': 'GM', 'LastName': 'Schmölzer', 'Affiliation': 'Neonatal Research Unit, Centre for the Studies of Asphyxia and Resuscitation, Royal Alexandra Hospital, Alberta Health Services, Edmonton, AB, Canada.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Olischar', 'Affiliation': 'Division of Neonatology, Paediatric Intensive Care and Neuropaediatrics, Department of Paediatrics, Comprehensive Center for Paediatrics, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wagner', 'Affiliation': 'Division of Neonatology, Paediatric Intensive Care and Neuropaediatrics, Department of Paediatrics, Comprehensive Center for Paediatrics, Medical University of Vienna, Vienna, Austria.'}]","Acta paediatrica (Oslo, Norway : 1992)",['10.1111/apa.15229'] 182,26439877,"The favourable effects of long-term selenium supplementation on regression of cervical tissues and metabolic profiles of patients with cervical intraepithelial neoplasia: a randomised, double-blind, placebo-controlled trial.","This study was conducted to assess the effects of long-term Se administration on the regression and metabolic status of patients with cervical intraepithelial neoplasia grade 1 (CIN1). This randomised, double-blind, placebo-controlled trial was carried out among fifty-eight women diagnosed with CIN1. To diagnose CIN1, we used specific diagnostic procedures of biopsy, pathological diagnosis and colposcopy. Patients were randomly assigned to two groups to receive 200 μg Se supplements as Se yeast (n 28) or placebo (n 28) daily for 6 months. After 6 months of taking Se supplements, a greater percentage of women in the Se group had regressed CIN1 (88·0 v. 56·0 %; P=0·01) compared with those in the placebo group. Long-term Se supplementation, compared with the placebo, resulted in significant decreases in fasting plasma glucose levels (-0·37 (sd 0·32) v. +0·07 (sd 0·63) mmol/l; P=0·002), serum insulin levels (-28·8 (sd 31·2) v. +13·2 (sd 40·2) pmol/l; P<0·001), homeostatic model assessment of insulin resistance values (-1·3 (se 1·3) v. +0·5 (se 1·4); P<0·001) and a significant elevation in quantitative insulin sensitivity check index (+0·03 (sd 0·03) v. -0·01 (sd 0·01); P<0·001). In addition, patients who received Se supplements had significantly decreased serum TAG (-0·14 (sd 0·55) v. +0·15 (sd 0·38) mmol/l; P=0·02) and increased HDL-cholesterol levels (+0·13 (sd 0·21) v. -0·01 (sd 0·15) mmol/l; P=0·003). In addition, compared with the placebo group, there were significant rises in plasma total antioxidant capacity (+186·1 (sd 274·6) v. +42·8 (sd 180·4) mmol/l; P=0·02) and GSH levels (+65·0 (sd 359·8) v. -294·2 (sd 581·8) μmol/l; P=0·007) and a significant decrease in malondialdehyde levels (-1·5 (sd 2·1) v. +0·1 (sd 1·4) μmol/l; P=0·001) among those who took Se supplements. Overall, taking Se supplements among patients with CIN1 led to its regression and had beneficial effects on their metabolic profiles.",2015,(88·0 v. 56·0 %; P=0·01) compared with those in the placebo group.,"['fifty-eight women diagnosed with CIN1', 'patients with cervical intraepithelial neoplasia', 'patients with cervical intraepithelial neoplasia grade 1 (CIN1']","['selenium supplementation', 'placebo', '200 μg Se supplements as Se yeast (n 28) or placebo']","['fasting plasma glucose levels (-0·37 (sd 0·32', 'serum TAG (-0·14 (sd 0·55', 'serum insulin levels (-28·8 (sd 31·2', 'regressed CIN1', 'malondialdehyde levels', 'plasma total antioxidant capacity', 'quantitative insulin sensitivity check index (+0·03 (sd 0·03) v. -0·01', 'HDL-cholesterol levels ', 'GSH levels', 'insulin resistance values (-1·3 (se 1·3']","[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0206708', 'cui_str': 'Cervical Intraepithelial Neoplasms'}, {'cui': 'C0349458', 'cui_str': 'Cervical intraepithelial neoplasia grade 1 (disorder)'}]","[{'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0043393', 'cui_str': 'Yeasts'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0037293', 'cui_str': 'Tag (morphologic abnormality)'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",58.0,0.650458,(88·0 v. 56·0 %; P=0·01) compared with those in the placebo group.,"[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Karamali', 'Affiliation': '1Department of Gynecology and Obstetrics,School of Medicine,Arak University of Medical Sciences,PO Box 3819693345,Arak,Iran.'}, {'ForeName': 'Sepideh', 'Initials': 'S', 'LastName': 'Nourgostar', 'Affiliation': '1Department of Gynecology and Obstetrics,School of Medicine,Arak University of Medical Sciences,PO Box 3819693345,Arak,Iran.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Zamani', 'Affiliation': '1Department of Gynecology and Obstetrics,School of Medicine,Arak University of Medical Sciences,PO Box 3819693345,Arak,Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Vahedpoor', 'Affiliation': '3Department of Gynecology and Obstetrics,School of Medicine,Kashan University of Medical Sciences,PO Box 8715988141,Kashan,Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': '4Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,PO Box 8715988141,Kashan,Iran.'}]",The British journal of nutrition,['10.1017/S0007114515003852'] 183,24284287,"Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial.","BACKGROUND Melioidosis, an infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, is difficult to cure. Antimicrobial treatment comprises intravenous drugs for at least 10 days, followed by oral drugs for at least 12 weeks. The standard oral regimen based on trial evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline. This regimen is used in Thailand but is associated with side-effects and poor adherence by patients, and TMP-SMX alone is recommended in Australia. We compared the efficacy and side-effects of TMP-SMX with TMP-SMX plus doxycycline for the oral phase of melioidosis treatment. METHODS For this multi-centre, double-blind, non-inferiority, randomised placebo-controlled trial, we enrolled patients (aged ≥15 years) from five centres in northeast Thailand with culture-confirmed melioidosis who had received a course of parenteral antimicrobial drugs. Using a computer-generated sequence, we randomly assigned patients to receive TMP-SMX plus placebo or TMP-SMX plus doxycycline for 20 weeks (1:1; block size of ten, stratified by study site). We followed patients up every 4 months for 1 year and annually thereafter to the end of the study. The primary endpoint was culture-confirmed recurrent melioidosis, and the non-inferiority margin was a hazard ratio (HR) of 1.7. This study is registered with www.controlled-trials.com, number ISRCTN86140460. FINDINGS We enrolled and randomly assigned 626 patients: 311 to TMP-SMX plus placebo and 315 to TMP-SMX plus doxycycline. 16 patients (5%) in the TMP-SMX plus placebo group and 21 patients (7%) in the TMP-SMX plus doxycycline group developed culture-confirmed recurrent melioidosis (HR 0.81; 95% CI 0.42-1.55). The criterion for non-inferiority was met (p=0.01). Adverse drug reactions were less common in the TMP-SMX plus placebo group than in the TMP-SMX plus doxycycline group (122 [39%] vs 167 [53%]). INTERPRETATION Our findings suggest that TMP-SMX is not inferior to TMP-SMX plus doxycycline for the oral phase of melioidosis treatment, and is preferable on the basis of safety and tolerance by patients. FUNDING Thailand Research Fund, the Melioidosis Research Center, the Center of Excellence in Specific Health Problems in Greater Mekong Sub-region cluster, and the Wellcome Trust.",2014,"Adverse drug reactions were less common in the TMP-SMX plus placebo group than in the TMP-SMX plus doxycycline group (122 [39%] vs 167 [53%]). ","['enrolled patients (aged ≥15 years) from five centres in northeast Thailand with culture-confirmed melioidosis who had received a course of parenteral antimicrobial drugs', 'We enrolled and randomly assigned 626 patients: 311 to']","['doxycycline', 'placebo', 'TMP-SMX plus placebo', 'TMP-SMX plus placebo or TMP-SMX plus doxycycline', 'TMP-SMX with TMP-SMX plus doxycycline', 'trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline', 'TMP-SMX', 'Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline', 'TMP-SMX plus doxycycline']","['culture-confirmed recurrent melioidosis', 'culture-confirmed recurrent melioidosis, and the non-inferiority margin', 'Adverse drug reactions']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0039725', 'cui_str': 'Kingdom of Thailand'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0025229', 'cui_str': 'Burkholderia pseudomallei Infection'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C4522267', 'cui_str': 'Parenteral (intended site)'}, {'cui': 'C1136254', 'cui_str': 'Microbicides'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0041044', 'cui_str': 'Sulfamethoxazole / Trimethoprim'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0041041', 'cui_str': 'Trimethoprim'}]","[{'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0025229', 'cui_str': 'Burkholderia pseudomallei Infection'}, {'cui': 'C0205284', 'cui_str': 'Marginal (qualifier value)'}, {'cui': 'C0041755', 'cui_str': 'Drug Side Effects'}]",626.0,0.709392,"Adverse drug reactions were less common in the TMP-SMX plus placebo group than in the TMP-SMX plus doxycycline group (122 [39%] vs 167 [53%]). ","[{'ForeName': 'Ploenchan', 'Initials': 'P', 'LastName': 'Chetchotisakd', 'Affiliation': 'Faculty of Medicine, Khon Kaen University, Thailand; Melioidosis Research Centre, Khon Kaen University, Thailand.'}, {'ForeName': 'Wirongrong', 'Initials': 'W', 'LastName': 'Chierakul', 'Affiliation': 'Faculty of Tropical Medicine, Mahidol University, Thailand.'}, {'ForeName': 'Wipada', 'Initials': 'W', 'LastName': 'Chaowagul', 'Affiliation': 'Sappasithiprasong Hospital, Ubon Ratchathani, Thailand.'}, {'ForeName': 'Siriluck', 'Initials': 'S', 'LastName': 'Anunnatsiri', 'Affiliation': 'Faculty of Medicine, Khon Kaen University, Thailand; Melioidosis Research Centre, Khon Kaen University, Thailand.'}, {'ForeName': 'Kriangsak', 'Initials': 'K', 'LastName': 'Phimda', 'Affiliation': 'Udon Thani Hospital, Udon Thani, Thailand.'}, {'ForeName': 'Piroon', 'Initials': 'P', 'LastName': 'Mootsikapun', 'Affiliation': 'Faculty of Medicine, Khon Kaen University, Thailand.'}, {'ForeName': 'Seksan', 'Initials': 'S', 'LastName': 'Chaisuksant', 'Affiliation': 'Khon Kaen Hospital, Khon Kaen, Thailand.'}, {'ForeName': 'Jiraporn', 'Initials': 'J', 'LastName': 'Pilaikul', 'Affiliation': 'Mahasarakam Hospital, Mahasarakam, Thailand.'}, {'ForeName': 'Bandit', 'Initials': 'B', 'LastName': 'Thinkhamrop', 'Affiliation': 'Faculty of Public Health, Khon Kaen University, Thailand.'}, {'ForeName': 'Sunchai', 'Initials': 'S', 'LastName': 'Phiphitaporn', 'Affiliation': 'Udon Thani Hospital, Udon Thani, Thailand.'}, {'ForeName': 'Wattanachai', 'Initials': 'W', 'LastName': 'Susaengrat', 'Affiliation': 'Khon Kaen Hospital, Khon Kaen, Thailand.'}, {'ForeName': 'Chalongchai', 'Initials': 'C', 'LastName': 'Toondee', 'Affiliation': 'Mahasarakam Hospital, Mahasarakam, Thailand.'}, {'ForeName': 'Surasakdi', 'Initials': 'S', 'LastName': 'Wongrattanacheewin', 'Affiliation': 'Faculty of Medicine, Khon Kaen University, Thailand; Melioidosis Research Centre, Khon Kaen University, Thailand.'}, {'ForeName': 'Vanaporn', 'Initials': 'V', 'LastName': 'Wuthiekanun', 'Affiliation': 'Faculty of Tropical Medicine, Mahidol University, Thailand.'}, {'ForeName': 'Narisara', 'Initials': 'N', 'LastName': 'Chantratita', 'Affiliation': 'Faculty of Tropical Medicine, Mahidol University, Thailand.'}, {'ForeName': 'Janjira', 'Initials': 'J', 'LastName': 'Thaipadungpanit', 'Affiliation': 'Faculty of Tropical Medicine, Mahidol University, Thailand.'}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Day', 'Affiliation': 'Faculty of Tropical Medicine, Mahidol University, Thailand; University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Direk', 'Initials': 'D', 'LastName': 'Limmathurotsakul', 'Affiliation': 'Faculty of Tropical Medicine, Mahidol University, Thailand. Electronic address: direk@tropmedres.ac.'}, {'ForeName': 'Sharon J', 'Initials': 'SJ', 'LastName': 'Peacock', 'Affiliation': ""Faculty of Tropical Medicine, Mahidol University, Thailand; University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom.""}]","Lancet (London, England)",['10.1016/S0140-6736(13)61951-0'] 184,25536254,Effect of depth and duration of cooling on deaths in the NICU among neonates with hypoxic ischemic encephalopathy: a randomized clinical trial.,"IMPORTANCE Hypothermia at 33.5°C for 72 hours for neonatal hypoxic ischemic encephalopathy reduces death or disability to 44% to 55%; longer cooling and deeper cooling are neuroprotective in animal models. OBJECTIVE To determine if longer duration cooling (120 hours), deeper cooling (32.0°C), or both are superior to cooling at 33.5°C for 72 hours in neonates who are full-term with moderate or severe hypoxic ischemic encephalopathy. DESIGN, SETTING, AND PARTICIPANTS A randomized, 2 × 2 factorial design clinical trial performed in 18 US centers in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network between October 2010 and November 2013. INTERVENTIONS Neonates were assigned to 4 hypothermia groups; 33.5°C for 72 hours, 32.0°C for 72 hours, 33.5°C for 120 hours, and 32.0°C for 120 hours. MAIN OUTCOMES AND MEASURES The primary outcome of death or disability at 18 to 22 months is ongoing. The independent data and safety monitoring committee paused the trial to evaluate safety (cardiac arrhythmia, persistent acidosis, major vessel thrombosis and bleeding, and death in the neonatal intensive care unit [NICU]) after the first 50 neonates were enrolled, then after every subsequent 25 neonates. The trial was closed for emerging safety profile and futility analysis after the eighth review with 364 neonates enrolled (of 726 planned). This report focuses on safety and NICU deaths by marginal comparisons of 72 hours' vs 120 hours' duration and 33.5°C depth vs 32.0°C depth (predefined secondary outcomes). RESULTS The NICU death rates were 7 of 95 neonates (7%) for the 33.5°C for 72 hours group, 13 of 90 neonates (14%) for the 32.0°C for 72 hours group, 15 of 96 neonates (16%) for the 33.5°C for 120 hours group, and 14 of 83 neonates (17%) for the 32.0°C for 120 hours group. The adjusted risk ratio (RR) for NICU deaths for the 120 hours group vs 72 hours group was 1.37 (95% CI, 0.92-2.04) and for the 32.0°C group vs 33.5°C group was 1.24 (95% CI, 0.69-2.25). Safety outcomes were similar between the 120 hours group vs 72 hours group and the 32.0°C group vs 33.5°C group, except major bleeding occurred among 1% in the 120 hours group vs 3% in the 72 hours group (RR, 0.25 [95% CI, 0.07-0.91]). Futility analysis determined that the probability of detecting a statistically significant benefit for longer cooling, deeper cooling, or both for NICU death was less than 2%. CONCLUSIONS AND RELEVANCE Among neonates who were full-term with moderate or severe hypoxic ischemic encephalopathy, longer cooling, deeper cooling, or both compared with hypothermia at 33.5°C for 72 hours did not reduce NICU death. These results have implications for patient care and design of future trials. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01192776.",2014,"Safety outcomes were similar between the 120 hours group vs 72 hours group and the 32.0°C group vs 33.5°C group, except major bleeding occurred among 1% in the 120 hours group vs 3% in the 72 hours group (RR, 0.25 [95% CI, 0.07-0.91]).","['neonates who were full-term with moderate or severe hypoxic ischemic encephalopathy', '364 neonates enrolled (of 726 planned', '18 US centers in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network between October 2010 and November 2013', '50 neonates were enrolled, then after every subsequent 25 neonates', 'neonates with hypoxic ischemic encephalopathy', 'neonates who are full-term with moderate or severe hypoxic ischemic encephalopathy']",['depth and duration of cooling'],"['except major bleeding', 'Safety outcomes', 'adjusted risk ratio (RR) for NICU deaths', 'death or disability', 'safety (cardiac arrhythmia, persistent acidosis, major vessel thrombosis and bleeding, and death', 'NICU death', 'NICU death rates']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C2712360', 'cui_str': 'Severe hypoxic ischemic encephalopathy (disorder)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1513896', 'cui_str': 'National Institute of Child Health and Human Development'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0035168'}, {'cui': 'C0752304', 'cui_str': 'Hypoxic-Ischemic Encephalopathy'}]","[{'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C1869051', 'cui_str': 'Cardiac arrhythmias (SMQ)'}, {'cui': 'C0001122', 'cui_str': 'Acidosis'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}]",50.0,0.186228,"Safety outcomes were similar between the 120 hours group vs 72 hours group and the 32.0°C group vs 33.5°C group, except major bleeding occurred among 1% in the 120 hours group vs 3% in the 72 hours group (RR, 0.25 [95% CI, 0.07-0.91]).","[{'ForeName': 'Seetha', 'Initials': 'S', 'LastName': 'Shankaran', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Abbot R', 'Initials': 'AR', 'LastName': 'Laptook', 'Affiliation': 'Department of Pediatrics, Women and Infants Hospital, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Athina', 'Initials': 'A', 'LastName': 'Pappas', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'McDonald', 'Affiliation': 'Social, Statistical, and Environmental Sciences Unit, RTI International, Research Triangle Park, North Carolina.'}, {'ForeName': 'Abhik', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'Social, Statistical, and Environmental Sciences Unit, RTI International, Rockville, Maryland.'}, {'ForeName': 'Jon E', 'Initials': 'JE', 'LastName': 'Tyson', 'Affiliation': 'Department of Pediatrics, University of Texas Medical School at Houston.'}, {'ForeName': 'Brenda B', 'Initials': 'BB', 'LastName': 'Poindexter', 'Affiliation': 'Department of Pediatrics, Indiana University School of Medicine, Indianapolis.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Schibler', 'Affiliation': ""Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Edward F', 'Initials': 'EF', 'LastName': 'Bell', 'Affiliation': 'Department of Pediatrics, University of Iowa, Iowa City.'}, {'ForeName': 'Roy J', 'Initials': 'RJ', 'LastName': 'Heyne', 'Affiliation': 'Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Pedroza', 'Affiliation': ""Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Bara', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Krisa P', 'Initials': 'KP', 'LastName': 'Van Meurs', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, Lucile Packard Children's Hospital, Stanford University School of Medicine, Palo Alto, California.""}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Grisby', 'Affiliation': ""Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Carolyn M Petrie', 'Initials': 'CM', 'LastName': 'Huitema', 'Affiliation': 'Social, Statistical, and Environmental Sciences Unit, RTI International, Rockville, Maryland.'}, {'ForeName': 'Meena', 'Initials': 'M', 'LastName': 'Garg', 'Affiliation': 'Department of Pediatrics, University of California, Los Angeles.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Ehrenkranz', 'Affiliation': 'Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Edward G', 'Initials': 'EG', 'LastName': 'Shepherd', 'Affiliation': ""Department of Pediatrics, Nationwide Children's Hospital, Ohio State University, Columbus.""}, {'ForeName': 'Lina F', 'Initials': 'LF', 'LastName': 'Chalak', 'Affiliation': 'Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Shannon E G', 'Initials': 'SE', 'LastName': 'Hamrick', 'Affiliation': ""Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia.""}, {'ForeName': 'Amir M', 'Initials': 'AM', 'LastName': 'Khan', 'Affiliation': 'Department of Pediatrics, University of Texas Medical School at Houston.'}, {'ForeName': 'Anne Marie', 'Initials': 'AM', 'LastName': 'Reynolds', 'Affiliation': 'Department of Pediatrics, University at Buffalo, Buffalo, New York.'}, {'ForeName': 'Matthew M', 'Initials': 'MM', 'LastName': 'Laughon', 'Affiliation': 'Division of Neonatal/Perinatal Medicine, Department of Pediatrics, University of North Carolina, Chapel Hill.'}, {'ForeName': 'William E', 'Initials': 'WE', 'LastName': 'Truog', 'Affiliation': ""Department of Pediatrics, Children's Mercy Hospital, Kansas City School of Medicine, University of Missouri.""}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Dysart', 'Affiliation': ""Department of Pediatrics, Perelman School of Medicine, Children's Hospital of Philadelphia, University of Pennsylvania.""}, {'ForeName': 'Waldemar A', 'Initials': 'WA', 'LastName': 'Carlo', 'Affiliation': 'Division of Neonatology, University of Alabama at Birmingham.'}, {'ForeName': 'Michele C', 'Initials': 'MC', 'LastName': 'Walsh', 'Affiliation': ""Department of Pediatrics, Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, Ohio.""}, {'ForeName': 'Kristi L', 'Initials': 'KL', 'LastName': 'Watterberg', 'Affiliation': 'University of New Mexico Health Sciences Center, Albuquerque, New Mexico.'}, {'ForeName': 'Rosemary D', 'Initials': 'RD', 'LastName': 'Higgins', 'Affiliation': 'Pregnancy and Perinatology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2014.16058'] 185,24612754,Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial.,"BACKGROUND Observational evidence suggests that community-based services for people with schizophrenia can be successfully provided by community health workers, when supervised by specialists, in low-income and middle-income countries. We did the COmmunity care for People with Schizophrenia in India (COPSI) trial to compare the effectiveness of a collaborative community-based care intervention with standard facility-based care. METHODS We did a multicentre, parallel-group, randomised controlled trial at three sites in India between Jan 1, 2009 and Dec 31, 2010. Patients aged 16-60 years with a primary diagnosis of schizophrenia according to the tenth edition of the International Classification of Diseases, Diagnostic Criteria for Research (ICD-10-DCR) were randomly assigned (2:1), via a computer-generated randomisation list with block sizes of three, six, or nine, to receive either collaborative community-based care plus facility-based care or facility-based care alone. Randomisation was stratified by study site. Outcome assessors were masked to group allocation. The primary outcome was a change in symptoms and disabilities over 12 months, as measured by the positive and negative syndrome scale (PANSS) and the Indian disability evaluation and assessment scale (IDEAS). Analysis was by modified intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN 56877013. FINDINGS 187 participants were randomised to the collaborative community-based care plus facility-based care group and 95 were randomised to the facility-based care alone group; 253 (90%) participants completed follow-up to month 12. At 12 months, total PANSS and IDEAS scores were lower in patients in the intervention group than in those in the control group (PANSS adjusted mean difference -3.75, 95% CI -7.92 to 0.42; p=0.08; IDEAS -0.95, -1.68 to -0.23; p=0.01). However, no difference was shown in the proportion of participants who had a reduction of more than 20% in overall symptoms (PANSS 85 [51%] in the intervention group vs 44 [51%] in the control group; p=0.89; IDEAS 75 [48%] vs 28 [35%]). We noted a significant reduction in symptom and disability outcomes at the rural Tamil Nadu site (-9.29, -15.41 to -3.17; p=0.003). Two patients (one in each group) died by suicide during the study, and two patients died because of complications of a road traffic accident and pre-existing cardiac disease. 18 (73%) patients (17 in the intervention group) were admitted to hospital during the course of the trial, of whom seven were admitted because of physical health problems, such as acute gastritis and vomiting, road accident, high fever, or cardiovascular disease. INTERPRETATION The collaborative community-based care plus facility-based care intervention is modestly more effective than facility-based care, especially for reducing disability and symptoms of psychosis. Our results show that the study intervention is best implemented as an initial service in settings where services are scarce, for example in rural areas. FUNDING Wellcome Trust.",2014,"The collaborative community-based care plus facility-based care intervention is modestly more effective than facility-based care, especially for reducing disability and symptoms of psychosis.","['people with schizophrenia', 'Patients aged 16-60 years with a primary diagnosis of schizophrenia according to the tenth edition of the International Classification of Diseases, Diagnostic Criteria for Research (ICD-10-DCR', '18 (73%) patients (17 in the intervention group) were admitted to hospital during the course of the trial, of whom seven were admitted because of physical health problems, such as acute gastritis and vomiting, road accident, high fever, or cardiovascular disease', 'people with schizophrenia and their caregivers in India (COPSI', 'three sites in India between Jan 1, 2009 and Dec 31, 2010', '187 participants', 'People with Schizophrenia in India (COPSI']","['collaborative community-based care plus facility-based care intervention', 'collaborative community-based care plus facility-based care group and 95 were randomised to the facility-based care alone', 'collaborative community-based care plus facility-based care or facility-based care alone', 'community-based intervention', 'collaborative community-based care intervention with standard facility-based care']","['complications of a road traffic accident and pre-existing cardiac disease', 'overall symptoms', 'change in symptoms and disabilities over 12 months, as measured by the positive and negative syndrome scale (PANSS) and the Indian disability evaluation and assessment scale (IDEAS', 'symptom and disability outcomes', 'total PANSS and IDEAS scores']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0205444', 'cui_str': 'Tenth (qualifier value)'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C0870733', 'cui_str': 'International Statistical Classification of Diseases and Related Health Problems'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0035168'}, {'cui': 'C1137110', 'cui_str': 'ICD-10'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C1446390', 'cui_str': 'Physical health problems'}, {'cui': 'C0149518', 'cui_str': 'Acute gastritis (disorder)'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0442650', 'cui_str': 'Road (environment)'}, {'cui': 'C1961149', 'cui_str': 'Accidental physical contact (event)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C4517618', 'cui_str': '187 (qualifier value)'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0221706', 'cui_str': 'Traffic accident on public road (event)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0018799', 'cui_str': 'Cardiac Diseases'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}, {'cui': 'C0012605', 'cui_str': 'Disability Evaluation'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales (assessment scale)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",187.0,0.177532,"The collaborative community-based care plus facility-based care intervention is modestly more effective than facility-based care, especially for reducing disability and symptoms of psychosis.","[{'ForeName': 'Sudipto', 'Initials': 'S', 'LastName': 'Chatterjee', 'Affiliation': 'Sangath, Goa, India.'}, {'ForeName': 'Smita', 'Initials': 'S', 'LastName': 'Naik', 'Affiliation': 'Sangath, Goa, India.'}, {'ForeName': 'Sujit', 'Initials': 'S', 'LastName': 'John', 'Affiliation': 'Schizophrenia Research Foundation, Chennai, India.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Dabholkar', 'Affiliation': 'Parivartan, Satara, India.'}, {'ForeName': 'Madhumitha', 'Initials': 'M', 'LastName': 'Balaji', 'Affiliation': 'Sangath, Goa, India.'}, {'ForeName': 'Mirja', 'Initials': 'M', 'LastName': 'Koschorke', 'Affiliation': ""King's College London, Institute of Psychiatry, Health Service and Population Research Department, London, UK.""}, {'ForeName': 'Mathew', 'Initials': 'M', 'LastName': 'Varghese', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, India.'}, {'ForeName': 'Rangaswamy', 'Initials': 'R', 'LastName': 'Thara', 'Affiliation': 'Schizophrenia Research Foundation, Chennai, India.'}, {'ForeName': 'Helen A', 'Initials': 'HA', 'LastName': 'Weiss', 'Affiliation': 'Medical Research Council Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Williams', 'Affiliation': 'Centre for Global Mental Health, Health Service and Population Research Department, London, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'McCrone', 'Affiliation': 'Centre for Global Mental Health, Health Service and Population Research Department, London, UK.'}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Patel', 'Affiliation': 'Sangath, Goa, India; Centre for Global Mental Health, London School of Hygiene & Tropical Medicine, London, UK; Public Health Foundation of India, New Delhi, India.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Thornicroft', 'Affiliation': ""King's College London, Institute of Psychiatry, Health Service and Population Research Department, London, UK. Electronic address: graham.thornicroft@kcl.ac.uk.""}]","Lancet (London, England)",['10.1016/S0140-6736(13)62629-X'] 186,24314909,Characterizing the mechanisms of central and peripheral forms of neurostimulation in chronic dysphagic stroke patients.,"BACKGROUND Swallowing problems following stroke may result in increased risk of aspiration pneumonia, malnutrition, and dehydration. OBJECTIVE/HYPOTHESIS Our hypothesis was that three neurostimulation techniques would produce beneficial effects on chronic dysphagia following stroke through a common brain mechanism that would predict behavioral response. METHODS In 18 dysphagic stroke patients (mean age: 66 ± 3 years, 3 female, time-post-stroke: 63 ± 15 weeks [±SD]), pharyngeal electromyographic responses were recorded after single-pulse transcranial magnetic stimulation (TMS) over the pharyngeal motor cortex, to measure corticobulbar excitability before, immediately, and 30 min, after real and sham applications of neurostimulation. Patients were randomized to a single session of either: pharyngeal electrical stimulation (PES), paired associative stimulation (PAS) or repetitive TMS (rTMS). Penetration-aspiration scores and bolus transfer timings were assessed before and after both real and sham interventions using videofluoroscopy. RESULTS Corticobulbar excitability of pharyngeal motor cortex was beneficially modulated by PES, PAS and to a lesser extent by rTMS, with functionally relevant changes in the unaffected hemisphere. Following combining the results of real neurostimulation, an overall increase in corticobulbar excitability in the unaffected hemisphere (P = .005, F1,17 = 10.6, ANOVA) with an associated 15% reduction in aspiration (P = .005, z = -2.79) was observed compared to sham. CONCLUSIONS In this mechanistic study, an increase in corticobulbar excitability the unaffected projection was correlated with the improvement in swallowing safety (P = .001, rho = -.732), but modality-specific differences were observed. Paradigms providing peripheral input favored change in neurophysiological and behavioral outcome measures in chronic dysphagia patients. Further larger cohort studies of neurostimulation in chronic dysphagic stroke are imperative.",2014,"Penetration-aspiration scores and bolus transfer timings were assessed before and after both real and sham interventions using videofluoroscopy. ","['18 dysphagic stroke patients (mean age: 66 ± 3 years, 3 female, time-post-stroke: 63 ± 15 weeks [±SD', 'chronic dysphagia patients', 'chronic dysphagic stroke patients']","['pulse transcranial magnetic stimulation (TMS', 'videofluoroscopy', 'pharyngeal electrical stimulation (PES), paired associative stimulation (PAS) or repetitive TMS (rTMS']","['pharyngeal electromyographic responses', 'swallowing safety', 'corticobulbar excitability', 'Penetration-aspiration scores and bolus transfer timings']","[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation (procedure)'}, {'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]","[{'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0235169', 'cui_str': 'Excitability (finding)'}, {'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C0449243', 'cui_str': 'Timing (attribute)'}]",,0.120098,"Penetration-aspiration scores and bolus transfer timings were assessed before and after both real and sham interventions using videofluoroscopy. ","[{'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Michou', 'Affiliation': 'Gastrointestinal Centre, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, University of Manchester (Part of the Manchester Academic Health Sciences Centre [MAHSC]), Salford Royal Hospital, Clinical Sciences Building, Salford M6 8HD, UK.'}, {'ForeName': 'Satish', 'Initials': 'S', 'LastName': 'Mistry', 'Affiliation': 'Gastrointestinal Centre, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, University of Manchester (Part of the Manchester Academic Health Sciences Centre [MAHSC]), Salford Royal Hospital, Clinical Sciences Building, Salford M6 8HD, UK.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Jefferson', 'Affiliation': 'Gastrointestinal Centre, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, University of Manchester (Part of the Manchester Academic Health Sciences Centre [MAHSC]), Salford Royal Hospital, Clinical Sciences Building, Salford M6 8HD, UK.'}, {'ForeName': 'Pippa', 'Initials': 'P', 'LastName': 'Tyrrell', 'Affiliation': 'Stroke Medicine, Institute of Cardiovascular Sciences, University of Manchester (Part of the Manchester Academic Health Sciences Centre [MAHSC]), Salford Royal Hospital Foundation Trust, Salford M6 8HD, UK.'}, {'ForeName': 'Shaheen', 'Initials': 'S', 'LastName': 'Hamdy', 'Affiliation': 'Gastrointestinal Centre, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, University of Manchester (Part of the Manchester Academic Health Sciences Centre [MAHSC]), Salford Royal Hospital, Clinical Sciences Building, Salford M6 8HD, UK. Electronic address: shaheen.hamdy@manchester.ac.uk.'}]",Brain stimulation,['10.1016/j.brs.2013.09.005'] 187,31821750,"Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.","Itacitinib is a JAK1-selective inhibitor in phase 3 development in graft-versus-host disease. A post hoc electrocardiogram (ECG) analysis and a plasma concentration-QTc (C-QTc) analysis were performed to assess cardiac safety using data from the first-in-human itacitinib study. The study included 2 cohorts of 12 healthy participants each in an interleaving dosing design with single doses of 10-300 mg or placebo; 500 and 1000 mg doses were subsequently added with 12 participants randomized to itacitinib or placebo. Continuous Holter recordings were collected from 1 hour predose to 8 hours postdose on each dosing day, and ECG intervals were blindly extracted to match timed pharmacokinetic samples. Data showed no hysteresis, and a prespecified linear mixed-effects C-QTc model was used with change-from-baseline QTcF (QT interval corrected for heart rate by Fridericia's method) as the dependent variable, plasma itacitinib concentrations and centered baseline QTcF as continuous covariates, treatment and time as categorical factors, and a random intercept per participant. The estimated slope of the C-QTc relationship was not significantly different from zero: 0.0002 milliseconds per nM (90%CI, -0.00019 to 0.00054 milliseconds). No clinically meaningful effects on cardiac conduction (PR and QRS intervals) or any categorical PR or QRS outliers were observed. A QTc effect exceeding the threshold of concern (10 milliseconds) can be excluded for itacitinib plasma concentrations up to ∼13 000 nM (∼7200 ng/mL), which is well above the maximum concentration expected with the highest proposed therapeutic dose of itacitinib either with concomitant use of cytochrome P450 3A4 inhibitors or in patients with impaired hepatic function.",2020,No clinically meaningful effects on cardiac conduction (PR and QRS intervals) or any categorical PR or QRS outliers were observed.,"['patients with impaired hepatic function', '12 healthy participants each in an interleaving dosing design with single doses of 10-300 mg or', 'Healthy Participants']","['Itacitinib, a JAK1 Inhibitor', 'placebo', 'itacitinib or placebo']","['estimated slope of the C-QTc relationship', 'plasma concentration-QTc (C-QTc) analysis', 'cardiac conduction (PR and QRS intervals) or any categorical PR or QRS outliers']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0232741', 'cui_str': 'Liver function (observable entity)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0232217', 'cui_str': 'Cardiac conduction (observable entity)'}, {'cui': 'C0520880', 'cui_str': 'QRS interval'}]",,0.157254,No clinically meaningful effects on cardiac conduction (PR and QRS intervals) or any categorical PR or QRS outliers were observed.,"[{'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Gong', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Borje', 'Initials': 'B', 'LastName': 'Darpo', 'Affiliation': 'eRT/iCardiac Technologies, Rochester, New York, USA.'}, {'ForeName': 'Hongqi', 'Initials': 'H', 'LastName': 'Xue', 'Affiliation': 'eRT/iCardiac Technologies, Rochester, New York, USA.'}, {'ForeName': 'Naresh', 'Initials': 'N', 'LastName': 'Punwani', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'He', 'Affiliation': 'Incyte Corporation, Wilmington, Delaware, USA.'}, {'ForeName': 'April M', 'Initials': 'AM', 'LastName': 'Barbour', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Noam', 'Initials': 'N', 'LastName': 'Epstein', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Landman', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Xuejun', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Swamy', 'Initials': 'S', 'LastName': 'Yeleswaram', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.758'] 188,25442690,Effect of antenatal multiple micronutrient supplementation on anthropometry and blood pressure in mid-childhood in Nepal: follow-up of a double-blind randomised controlled trial.,"BACKGROUND In 2002-04, we did a randomised controlled trial in southern Nepal, and reported that children born to mothers taking multiple micronutrient supplements during pregnancy had a mean birthweight 77 g greater than children born to mothers taking iron and folic acid supplements. Children born to mothers in the study group were a mean 204 g heavier at 2·5 years of age and their systolic blood pressure was a mean 2·5 mm Hg lower than children born to mothers in the control group. We aimed to follow up the same children to mid-childhood (age 8·5 years) to investigate whether these differences would be sustained. METHODS For this follow-up study, we identified children from the original trial and measured anthropometry, body composition with bioelectrical impedance (with population-specific isotope calibration), blood pressure, and renal dimensions by ultrasound. We documented socioeconomic status, household food security, and air pollution. Main outcomes of the follow-up at 8 years were Z scores for weight-for-age, height-for-age, and body-mass index (BMI)-for-age according to WHO Child Growth Standards for children aged 5-19 years, and blood pressure. This study is registered with the International Standard Randomised Controlled Trial register, number ISRCTN88625934. FINDINGS Between Sept 21, 2011, and Dec 7, 2012, we assessed 841 children (422 in the control group and 419 in the intervention group). Unadjusted differences (intervention minus control) in Z scores were 0·05 for weight-for-age (95% CI -0·09 to 0·19), 0·02 in height-for-age (-0·10 to 0·15), and 0·04 in BMI-for-age (-0·09 to 0·18). We recorded no difference in blood pressure. Adjusted differences were similar for all outcomes. INTERPRETATION We recorded no differences in phenotype between children born to mothers who received antenatal multiple micronutrient or iron and folate supplements at age 8·5 years. Our findings did not extend to physiological differences or potential longer-term effects. FUNDING The Wellcome Trust.",2014,We recorded no differences in phenotype between children born to mothers who received antenatal multiple micronutrient or iron and folate supplements at age 8·5 years.,"['841 children (422 in the control group and 419 in the intervention group', 'Children born to mothers in the study group were a mean', 'children born to mothers taking multiple micronutrient supplements during pregnancy had a mean birthweight 77 g greater than children born to mothers taking iron and folic acid supplements', 'children born to mothers who received', '204', 'mid-childhood in Nepal', 'same children to mid-childhood (age 8·5 years']","['antenatal multiple micronutrient or iron and folate supplements', 'antenatal multiple micronutrient supplementation']","['anthropometry, body composition with bioelectrical impedance (with population-specific isotope calibration), blood pressure, and renal dimensions by ultrasound', 'systolic blood pressure', 'anthropometry and blood pressure', 'socioeconomic status, household food security, and air pollution', 'blood pressure']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0027689', 'cui_str': 'Federal Democratic Republic of Nepal'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C2828394', 'cui_str': 'Antenatal (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C3661616', 'cui_str': 'Folate supplement'}]","[{'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0162536', 'cui_str': 'Bioelectrical Impedance'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0022262', 'cui_str': 'Isotopes'}, {'cui': 'C0006751', 'cui_str': 'Calibration'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C3178753', 'cui_str': 'Food Security'}, {'cui': 'C0001873', 'cui_str': 'Air Pollution'}]",841.0,0.177378,We recorded no differences in phenotype between children born to mothers who received antenatal multiple micronutrient or iron and folate supplements at age 8·5 years.,"[{'ForeName': 'Delan', 'Initials': 'D', 'LastName': 'Devakumar', 'Affiliation': 'Institute for Global Health, University College London, London, UK. Electronic address: d.devakumar@ucl.ac.uk.'}, {'ForeName': 'Shiva Shankar', 'Initials': 'SS', 'LastName': 'Chaube', 'Affiliation': 'Mother and Infant Research Activities, Kathmandu, Nepal.'}, {'ForeName': 'Jonathan C K', 'Initials': 'JC', 'LastName': 'Wells', 'Affiliation': 'Institute of Child Health, University College London, London, UK.'}, {'ForeName': 'Naomi M', 'Initials': 'NM', 'LastName': 'Saville', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'Jon G', 'Initials': 'JG', 'LastName': 'Ayres', 'Affiliation': 'Institute of Occupational and Environmental Medicine, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Dharma S', 'Initials': 'DS', 'LastName': 'Manandhar', 'Affiliation': 'Mother and Infant Research Activities, Kathmandu, Nepal.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Costello', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Osrin', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}]",The Lancet. Global health,['10.1016/S2214-109X(14)70314-6'] 189,32096313,Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants.,"Single-visit cures for chronic hepatitis C are lacking. We conducted two clinical studies towards the goal of developing a regimen for single-visit cure. In a randomized, open-label, Phase 2 study (RG101-04), investigators enrolled 26 adult chronic hepatitis C patients to evaluate safety and efficacy of single subcutaneous injection of RG-101 (4 mg/kg) and daily oral tablets of GSK2878175 (20 mg) for 6, 9 or 12 weeks. In another randomized, double-blind, single dose Phase 1 study (RG101-06), investigators enrolled 18 healthy men to assess safety and PK of GSK2878175 long-acting injectable at 100, 200 or 400 mg. In RG101-04, SVR48 rates were 50%, 56% and 89%, for the 6, 9 and 12 weeks treatment arms, respectively. All AEs were mild or moderate in severity (≤Grade 2). In RG101-06 at 400 mg, the mean duration of GSK2878175 plasma levels above in vitro therapeutic concentrations for GT1b was 41 days. All AEs were Grade 2 or less. In conclusion, single injection of RG-101 combined with 12 weeks of GSK2878175 oral tablets was generally well tolerated and resulted in high SVR rates in chronic hepatitis C patients. Single injections of GSK2878175 long-acting injectable were also well tolerated; however, higher doses would be required if used in combination with RG-101 to achieve the SVR rates observed in the oral combination study to enable a single-visit curative regimen.",2020,"In RG101-06 at 400 mg, the mean duration of GSK2878175 plasma levels above in vitro therapeutic concentrations for GT1b was 41 days.","['18 healthy men', 'Chronic Hepatitis C Patients and Long-Acting Injectable GSK2878175 in Healthy Participants', '26 adult chronic hepatitis C patients', 'chronic hepatitis C patients']",['RG-101 (4 mg/kg) and daily oral tablets of GSK2878175'],"['SVR rates', 'SVR48 rates', 'high SVR rates', 'mean duration of GSK2878175 plasma levels']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0524910', 'cui_str': 'Hepatitis C, Chronic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0993159', 'cui_str': 'Oral Tablet'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",26.0,0.188458,"In RG101-06 at 400 mg, the mean duration of GSK2878175 plasma levels above in vitro therapeutic concentrations for GT1b was 41 days.","[{'ForeName': 'Yanli', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Campbell', 'Affiliation': 'GlaxoSmithKline, Stockley Park, Middlesex, UK.'}, {'ForeName': 'Kelong', 'Initials': 'K', 'LastName': 'Han', 'Affiliation': 'GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Dickens', 'Initials': 'D', 'LastName': 'Theodore', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Deeg', 'Affiliation': 'Regulus Therapeutics Inc., San Diego, California, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Huang', 'Affiliation': 'Regulus Therapeutics Inc., San Diego, California, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hamatake', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Soumi', 'Initials': 'S', 'LastName': 'Lahiri', 'Affiliation': 'GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Shuguang', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Gabor', 'Initials': 'G', 'LastName': 'Horvath', 'Affiliation': 'Buda Hepatology Center, Budapest, Hungary.'}, {'ForeName': 'Spilios', 'Initials': 'S', 'LastName': 'Manolakopoulos', 'Affiliation': '2nd Department of Internal Medicine, GI-Liver Unit, Hippocratio General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'George N', 'Initials': 'GN', 'LastName': 'Dalekos', 'Affiliation': 'Department of Medicine and Research Laboratory of Internal Medicine, Institute of Internal Medicine and Hepatology, University Hospital of Larisa, Larisa, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Papatheodoridis', 'Affiliation': '2nd Department of Internal Medicine, GI-Liver Unit, Hippocratio General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Goulis', 'Affiliation': 'Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Tivadar', 'Initials': 'T', 'LastName': 'Banyai', 'Affiliation': 'Bekes County Pandy Kalman Hospital, Gyula, Hungary.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Jilma', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Leivers', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, North Carolina, USA.'}]",Journal of viral hepatitis,['10.1111/jvh.13282'] 190,24703531,Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.,"BACKGROUND Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. However, how best to minimise the time spent taking cytotoxic drugs and whether molecular selection can refine this further is unknown. The primary aim of this study was to establish how cetuximab might be safely and effectively added to intermittent chemotherapy. METHODS COIN-B was an open-label, multicentre, randomised, exploratory phase 2 trial done at 30 hospitals in the UK and one in Cyprus. We enrolled patients with advanced colorectal cancer who had received no previous chemotherapy for metastases. Randomisation was done centrally (by telephone) by the Medical Research Council Clinical Trials Unit using minimisation with a random element. Treatment allocation was not masked. Patients were assigned (1:1) to intermittent chemotherapy plus intermittent cetuximab or to intermittent chemotherapy plus continuous cetuximab. Chemotherapy was FOLFOX (folinic acid and oxaliplatin followed by bolus and infused fluorouracil). Patients in both groups received FOLFOX and weekly cetuximab for 12 weeks, then either had a planned interruption (those taking intermittent cetuximab) or planned maintenance by continuing on weekly cetuximab (continuous cetuximab). On RECIST progression, FOLFOX plus cetuximab or FOLFOX was recommenced for 12 weeks followed by further interruption or maintenance cetuximab, respectively. The primary outcome was failure-free survival at 10 months. The primary analysis population consisted of patients who completed 12 weeks of treatment without progression, death, or leaving the trial. We tested BRAF and NRAS status retrospectively. The trial was registered, ISRCTN38375681. FINDINGS We registered 401 patients, 226 of whom were enrolled. Results for 169 with KRAS wild-type are reported here, 78 (46%) assigned to intermittent cetuximab and 91 (54%) to continuous cetuximab. 64 patients assigned to intermittent cetuximab and 66 of those assigned to continuous cetuximab were included in the primary analysis. 10-month failure-free survival was 50% (lower bound of 95% CI 39) in the intermittent group versus 52% (lower bound of 95% CI 41) in the continuous group; median failure-free survival was 12.2 months (95% CI 8.8-15.6) and 14.3 months (10.7-20.4), respectively. The most common grade 3-4 adverse events were skin rash (21 [27%] of 77 patients vs 20 [22%] of 92 patients), neutropenia (22 [29%] vs 30 [33%]), diarrhoea (14 [18%] vs 23 [25%]), and lethargy (20 [26%] vs 19 [21%]). INTERPRETATION Cetuximab was safely incorporated in two first-line intermittent chemotherapy strategies. Maintenance of biological monotherapy, with less cytotoxic chemotherapy within the first 6 months, in molecularly selected patients is promising and should be validated in phase 3 trials.",2014,"10-month failure-free survival was 50% (lower bound of 95% CI 39) in the intermittent group versus 52% (lower bound of 95% CI 41) in the continuous group; median failure-free survival was 12.2 months (95% CI 8.8-15.6) and 14.3 months (10.7-20.4), respectively.","['enrolled patients with advanced colorectal cancer who had received no previous chemotherapy for metastases', '401 patients, 226 of whom were enrolled', '64 patients assigned to', '30 hospitals in the UK and one in Cyprus', 'Advanced colorectal cancer', 'patients with KRAS wild-type advanced colorectal cancer (COIN-B']","['Intermittent chemotherapy plus either intermittent or continuous cetuximab', 'intermittent cetuximab', 'FOLFOX', 'FOLFOX and weekly cetuximab', 'planned interruption (those taking intermittent cetuximab) or planned maintenance by continuing on weekly cetuximab (continuous cetuximab', 'Chemotherapy was FOLFOX (folinic acid and oxaliplatin followed by bolus and infused fluorouracil', 'intermittent chemotherapy plus intermittent cetuximab or to intermittent chemotherapy plus continuous cetuximab', 'continuous cetuximab', 'cetuximab', 'cytotoxic chemotherapy']","['lethargy', 'diarrhoea', 'failure-free survival', 'neutropenia', 'median failure-free survival', 'skin rash', '10-month failure-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0010622', 'cui_str': 'Cyprus'}, {'cui': 'C0445392', 'cui_str': 'Wild (qualifier value)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0524669', 'cui_str': 'Coins'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C4707055', 'cui_str': 'Infuse'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C4521706', 'cui_str': 'Cytotoxic'}]","[{'cui': 'C0023380', 'cui_str': 'Lethargy'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]",401.0,0.101035,"10-month failure-free survival was 50% (lower bound of 95% CI 39) in the intermittent group versus 52% (lower bound of 95% CI 41) in the continuous group; median failure-free survival was 12.2 months (95% CI 8.8-15.6) and 14.3 months (10.7-20.4), respectively.","[{'ForeName': 'Harpreet', 'Initials': 'H', 'LastName': 'Wasan', 'Affiliation': 'Imperial College Healthcare NHS Trust, London, UK.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Meade', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, UK. Electronic address: a.meade@ucl.ac.uk.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Adams', 'Affiliation': 'Cardiff University, Cardiff, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Wilson', 'Affiliation': ""Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Pugh', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fisher', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, UK.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Sydes', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, UK.'}, {'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Madi', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, UK.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Sizer', 'Affiliation': 'Essex County Hospital, Colchester, UK.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Lowdell', 'Affiliation': 'Imperial College Healthcare NHS Trust, London, UK.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Middleton', 'Affiliation': 'University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Butler', 'Affiliation': 'University Hospital of Wales, Cardiff, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kaplan', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Maughan', 'Affiliation': 'Cancer Research UK-MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(14)70106-8'] 191,24461758,Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.,"BACKGROUND Recurrence of tuberculosis after treatment makes management difficult and is a key factor for determining treatment efficacy. Two processes can cause recurrence: relapse of the primary infection or re-infection with an exogenous strain. Although re-infection can and does occur, its importance to tuberculosis epidemiology and its biological basis is still debated. We used whole-genome sequencing-which is more accurate than conventional typing used to date-to assess the frequency of recurrence and to gain insight into the biological basis of re-infection. METHODS We assessed patients from the REMoxTB trial-a randomised controlled trial of tuberculosis treatment that enrolled previously untreated participants with Mycobacterium tuberculosis infection from Malaysia, South Africa, and Thailand. We did whole-genome sequencing and mycobacterial interspersed repetitive unit-variable number of tandem repeat (MIRU-VNTR) typing of pairs of isolates taken by sputum sampling: one from before treatment and another from either the end of failed treatment at 17 weeks or later or from a recurrent infection. We compared the number and location of SNPs between isolates collected at baseline and recurrence. FINDINGS We assessed 47 pairs of isolates. Whole-genome sequencing identified 33 cases with little genetic distance (0-6 SNPs) between strains, deemed relapses, and three cases for which the genetic distance ranged from 1306 to 1419 SNPs, deemed re-infections. Six cases of relapse and six cases of mixed infection were classified differently by whole-genome sequencing and MIRU-VNTR. We detected five single positive isolates (positive culture followed by at least two negative cultures) without clinical evidence of disease. INTERPRETATION Whole-genome sequencing enables the differentiation of relapse and re-infection cases with greater resolution than do genotyping methods used at present, such as MIRU-VNTR, and provides insights into the biology of recurrence. The additional clarity provided by whole-genome sequencing might have a role in defining endpoints for clinical trials. FUNDING Wellcome Trust, European Union, Medical Research Council, Global Alliance for TB Drug Development, European and Developing Country Clinical Trials Partnership.",2013,"Whole-genome sequencing identified 33 cases with little genetic distance (0-6 SNPs) between strains, deemed relapses, and three cases for which the genetic distance ranged from 1306 to 1419 SNPs, deemed re-infections.","['enrolled previously untreated participants with Mycobacterium tuberculosis infection from Malaysia, South Africa, and Thailand', '47 pairs of isolates']",[],[],"[{'cui': 'C0041296', 'cui_str': 'Mycobacterium tuberculosis Infection'}, {'cui': 'C0024552', 'cui_str': 'Federation of Malaya'}, {'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C0039725', 'cui_str': 'Kingdom of Thailand'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}]",[],[],,0.085275,"Whole-genome sequencing identified 33 cases with little genetic distance (0-6 SNPs) between strains, deemed relapses, and three cases for which the genetic distance ranged from 1306 to 1419 SNPs, deemed re-infections.","[{'ForeName': 'Josephine M', 'Initials': 'JM', 'LastName': 'Bryant', 'Affiliation': 'Wellcome Trust Sanger Institute, Hinxton, UK.'}, {'ForeName': 'Simon R', 'Initials': 'SR', 'LastName': 'Harris', 'Affiliation': 'Wellcome Trust Sanger Institute, Hinxton, UK.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Parkhill', 'Affiliation': 'Wellcome Trust Sanger Institute, Hinxton, UK.'}, {'ForeName': 'Rodney', 'Initials': 'R', 'LastName': 'Dawson', 'Affiliation': 'Division of Pulmonology, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Andreas H', 'Initials': 'AH', 'LastName': 'Diacon', 'Affiliation': 'DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg, South Africa.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'van Helden', 'Affiliation': 'DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg, South Africa.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Pym', 'Affiliation': 'South African Medical Research Council and KwaZulu Research Institute for TB and HIV, Durban, South Africa.'}, {'ForeName': 'Aziah A', 'Initials': 'AA', 'LastName': 'Mahayiddin', 'Affiliation': 'Institute of Respiratory Medicine, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Charoen', 'Initials': 'C', 'LastName': 'Chuchottaworn', 'Affiliation': 'Chest Disease Institute, Muang, Nothaburi, Thailand.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Sanne', 'Affiliation': 'Clinical HIV Research Unit, Helen Joseph Hospital, Westdene, Johannesburg, South Africa.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Louw', 'Affiliation': 'Madibeng Centre for Research, Brits, South Africa.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'Boeree', 'Affiliation': 'Radboud MD University Nijmegen Medical Centre/UCCZ Dekkerswald, Nijmegen, Netherlands.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hoelscher', 'Affiliation': 'Department of Infectious Diseases and Tropical Medicine, Klinikum, Ludwig-Maximilians-University, Munich, Germany; DZIF German Centre for Infection Research, Munich, Germany.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'McHugh', 'Affiliation': 'Centre for Clinical Microbiology, Royal Free Campus, University College London, London, UK.'}, {'ForeName': 'Anna L C', 'Initials': 'AL', 'LastName': 'Bateson', 'Affiliation': 'Centre for Clinical Microbiology, Royal Free Campus, University College London, London, UK.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Hunt', 'Affiliation': 'Centre for Clinical Microbiology, Royal Free Campus, University College London, London, UK.'}, {'ForeName': 'Solomon', 'Initials': 'S', 'LastName': 'Mwaigwisya', 'Affiliation': 'Centre for Clinical Microbiology, Royal Free Campus, University College London, London, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Wright', 'Affiliation': 'Centre for Clinical Microbiology, Royal Free Campus, University College London, London, UK.'}, {'ForeName': 'Stephen H', 'Initials': 'SH', 'LastName': 'Gillespie', 'Affiliation': 'School of Medicine, University of St Andrews, St Andrews, UK. Electronic address: shg3@st-andrews.ac.uk.'}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Bentley', 'Affiliation': 'Wellcome Trust Sanger Institute, Hinxton, UK.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(13)70231-5'] 192,18519778,A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.,"PURPOSE Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical models. A phase I study of recombinant human IL-18 (rhIL-18) was done to determine the toxicity, pharmacokinetics, and biological activities of rhIL-18 administered at different doses in two different schedules to patients with advanced cancer. EXPERIMENTAL DESIGN Cohorts of three to four patients were given escalating doses of rhIL-18 as a 2-h i.v. infusion either on 5 consecutive days repeated every 28 days (group A) or once a week (group B) for up to 6 months. Toxicities were graded using standard criteria. Blood samples were obtained for safety, pharmacokinetic, and pharmacodynamic measurements. RESULTS Nineteen patients (10 melanoma and 9 renal cell cancer) were given rhIL-18 in doses of 100, 500, or 1,000 microg/kg (group A) or 100, 1,000, or 2,000 microg/kg (group B). Common side effects included chills, fever, headache, fatigue, and nausea. Common laboratory abnormalities included transient, asymptomatic grade 1 to 3 lymphopenia, grade 1 to 4 hyperglycemia, grade 1 to 2 anemia, neutropenia, hypoalbuminemia, liver enzyme elevations, and serum creatinine elevations. No dose-limiting toxicities were observed. Biological effects of rhIL-18 included transient lymphopenia and increased expression of activation antigens on lymphocytes. Increases in serum concentrations of IFN-gamma, granulocyte macrophage colony-stimulating factor, and IL-18-binding protein were observed following dosing. CONCLUSIONS rhIL-18 can be given in biologically active doses by either weekly infusions or daily infusions for 5 days repeated every 28 days to patients with advanced cancer. Toxicity was generally mild to moderate, and a maximum tolerated dose of rhIL-18 by either schedule was not determined.",2008,"Increases in serum concentrations of IFN-gamma, granulocyte macrophage colony-stimulating factor, and IL-18-binding protein were observed following dosing. ","['Nineteen patients (10 melanoma and 9 renal cell cancer', 'patients with advanced cancer', 'patients with cancer']","['recombinant human interleukin-18', 'recombinant human IL-18 (rhIL-18']","['Toxicities', 'serum concentrations of IFN-gamma, granulocyte macrophage colony-stimulating factor, and IL-18-binding protein', 'toxicity, pharmacokinetics, and biological activities of rhIL-18', 'No dose-limiting toxicities', 'safety, pharmacokinetic, and pharmacodynamic measurements', 'transient, asymptomatic grade 1 to 3 lymphopenia, grade 1 to 4 hyperglycemia, grade 1 to 2 anemia, neutropenia, hypoalbuminemia, liver enzyme elevations, and serum creatinine elevations', 'Toxicity', 'chills, fever, headache, fatigue, and nausea']","[{'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0007134', 'cui_str': 'Nephroid Carcinoma'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0383327', 'cui_str': 'Interferon-gamma-Inducing Factor'}, {'cui': 'C3849701', 'cui_str': 'interleukin 18 protein, human'}]","[{'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1552644', 'cui_str': 'Greek letter gamma'}, {'cui': 'C0079460', 'cui_str': 'Tumor-Cell Human GM Colony-Stimulating Factor'}, {'cui': 'C0383327', 'cui_str': 'Interferon-gamma-Inducing Factor'}, {'cui': 'C0242210', 'cui_str': 'Binding Proteins'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0024312', 'cui_str': 'Lymphocytopenia'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0239981', 'cui_str': 'Hypoalbuminemia'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme (substance)'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0085593', 'cui_str': 'Chills'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",4.0,0.190735,"Increases in serum concentrations of IFN-gamma, granulocyte macrophage colony-stimulating factor, and IL-18-binding protein were observed following dosing. ","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Robertson', 'Affiliation': 'Lymphoma Program, Indiana University School of Medicine, 535 Barnhill Drive, Indianapolis, IN 46202, USA. mjrobert@iupui.edu'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Kirkwood', 'Affiliation': ''}, {'ForeName': 'Theodore F', 'Initials': 'TF', 'LastName': 'Logan', 'Affiliation': ''}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Koch', 'Affiliation': ''}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Kathman', 'Affiliation': ''}, {'ForeName': 'Lyndon C', 'Initials': 'LC', 'LastName': 'Kirby', 'Affiliation': ''}, {'ForeName': 'William N', 'Initials': 'WN', 'LastName': 'Bell', 'Affiliation': ''}, {'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Thurmond', 'Affiliation': ''}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Weisenbach', 'Affiliation': ''}, {'ForeName': 'Mohammed M', 'Initials': 'MM', 'LastName': 'Dar', 'Affiliation': ''}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-07-4740'] 193,22913655,Derivation and validation of a Short Form of the Mini-Mental State Examination for the screening of dementia in older adults with a memory complaint.,"BACKGROUND AND PURPOSE To validate a Short Form of the Mini-Mental State Examination (SMMSE) as a screening test for dementia in older ambulatory individuals followed in a memory clinic for a memory complaint. METHODS A total of 202 cognitively healthy individuals, 100 individuals with a mild cognitive impairment and 304 demented individuals sent for a memory complaint by their primary care physician to a memory clinic were prospectively included in this cross-sectional study. They were randomized into derivation (n = 303) and validation (n = 303) groups. The SMMSE score was built from six memory items of MMSE, with a score ranging from 0 to 6 (i.e. best performance). RESULTS The receiver operating characteristic curve showed an area under the curve of 0.98 for the derivation group and 0.97 for the validation group without differences between curves (P = 0.254). The cut-off between the sensitivity and the specificity of the SMMSE score for clinically diagnosed dementia was ≤4. The performance of the SMMSE for the diagnosis of dementia was high in the derivation and validation groups: sensitivity at 93.1% and 93.8%, specificity at 93.8% and 90.5%, positive predictive value at 94.3% and 90.1%, negative predictive value at 92.5% and 94.0%, likelihood ratio of positive test at 14.9 and 9.8 and of negative test at 0.07 and 0.07, respectively. CONCLUSIONS The Short Form of the Mini-Mental State Examination was a good screening test for dementia in older individuals followed in a memory clinic for a memory complaint. The next step should be the confirmation of its discriminative value in older primary care patients.",2013,The Short Form of the Mini-Mental State Examination was a good screening test for dementia in older individuals followed in a memory clinic for a memory complaint.,"['older ambulatory individuals followed in a memory clinic for a memory complaint', '202 cognitively healthy individuals, 100 individuals with a mild cognitive impairment and 304 demented individuals sent for a memory complaint by their primary care physician to a memory clinic were prospectively included in this cross-sectional study', 'older adults with a memory complaint', 'older primary care patients']","['Mini-Mental State Examination', 'Mini-Mental State Examination (SMMSE']",['negative predictive value'],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0860630', 'cui_str': 'Demented'}, {'cui': 'C0033131', 'cui_str': 'Primary Care Physicians'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0010362', 'cui_str': 'Disease Frequency Surveys'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}]","[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",202.0,0.0774533,The Short Form of the Mini-Mental State Examination was a good screening test for dementia in older individuals followed in a memory clinic for a memory complaint.,"[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Haubois', 'Affiliation': 'Department of Neuroscience, Division of Geriatric Medicine, Angers University Hospital, Angers, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'de Decker', 'Affiliation': 'Department of Neuroscience, Division of Geriatric Medicine, Angers University Hospital, Angers, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Annweiler', 'Affiliation': 'Department of Neuroscience, Division of Geriatric Medicine, Angers University Hospital, Angers, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Launay', 'Affiliation': 'Department of Neuroscience, Division of Geriatric Medicine, Angers University Hospital, Angers, France.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Allali', 'Affiliation': 'Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals and Geneva University, Geneva.'}, {'ForeName': 'F R', 'Initials': 'FR', 'LastName': 'Herrmann', 'Affiliation': 'Department of Rehabillitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Beauchet', 'Affiliation': 'Department of Neuroscience, Division of Geriatric Medicine, Angers University Hospital, Angers, France.'}]",European journal of neurology,['10.1111/j.1468-1331.2012.03830.x'] 194,31916704,Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL-1 to Healthy Volunteers.,"NRL-1 is a novel intranasal formulation of diazepam that is being evaluated as rescue medication in patients with epilepsy who experience bouts of increased seizure activity despite stable regimens of antiepileptic drugs. This phase 1, open-label, randomized, crossover study in healthy adult volunteers consisted of 3 single-dose periods (5, 10, and 20 mg) followed by a 2-dose period (2 × 10 mg) with a minimum 28-day washout between treatments. Blood samples were taken at prespecified time points after intranasal dosing, and bioanalytic analysis of diazepam and nordiazepam was conducted using a validated liquid chromatography-tandem mass spectrometry method. Plasma pharmacokinetic parameters were summarized using descriptive statistics, and dose proportionality (peak concentration [C max ] and area under the plasma concentration-time curve [AUC 0-∞ ]) was evaluated based on a power model within a 90%CI of 0.84 to 1.16. Comparisons were also conducted between single 10-mg dose and multidose (2 × 10 mg) treatments. NRL-1 administration resulted in rapid diazepam absorption (median time to peak concentration 1.4-1.5 hours). Plasma concentration-time profiles showed similar patterns of exposure that appeared to be dose dependent, with C max of 85.6, 133.6, and 235.3 ng/mL for the 5-, 10-, and 20-mg doses, respectively, although the lower 90%CI for C max and AUC 0-∞ exceeded dose proportionality criteria. The coefficient of variation ranged from 59% to 67% for C max and 48% to 56% for AUC parameters. Dose-normalized AUC 0-∞ values were comparable between the 2 × 10-mg and single 10-mg doses. Treatment-emergent adverse events were consistent with those expected for diazepam, with transient somnolence the most frequent adverse event (94.4%). These results support NRL-1 as a potential therapy for managing seizure emergencies.",2020,NRL-1 administration resulted in rapid diazepam absorption (median time to peak concentration 1.4-1.5 hours).,"['Healthy Volunteers', 'patients with epilepsy who experience bouts of increased seizure activity despite stable regimens of antiepileptic drugs', 'healthy adult volunteers']","['diazepam and nordiazepam', 'Diazepam', 'NRL-1', 'diazepam']","['rapid diazepam absorption', 'Plasma pharmacokinetic parameters', 'dose proportionality (peak concentration [C max ] and area under the plasma concentration-time curve [AUC 0-∞ ']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0003299', 'cui_str': 'Antiepileptic Agents'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0012010', 'cui_str': 'Diazepam'}, {'cui': 'C0011279', 'cui_str': 'Nordazepam'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0012010', 'cui_str': 'Diazepam'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",,0.0330675,NRL-1 administration resulted in rapid diazepam absorption (median time to peak concentration 1.4-1.5 hours).,"[{'ForeName': 'Sarina', 'Initials': 'S', 'LastName': 'Tanimoto', 'Affiliation': 'Pacific Link Consulting, San Diego, California, USA.'}, {'ForeName': 'Luana', 'Initials': 'L', 'LastName': 'Pesco Koplowitz', 'Affiliation': 'DUCK FLATS Pharma, Elbridge, New York, USA.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Lowenthal', 'Affiliation': 'Pacific Link Consulting, San Diego, California, USA.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Koplowitz', 'Affiliation': 'DUCK FLATS Pharma, Elbridge, New York, USA.'}, {'ForeName': 'Adrian L', 'Initials': 'AL', 'LastName': 'Rabinowicz', 'Affiliation': 'Neurelis, Inc, San Diego, California, USA.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Carrazana', 'Affiliation': 'Neurelis, Inc, San Diego, California, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.767'] 195,24047926,Diabetes self-management and leptin in Mexican Americans with type 2 diabetes: the Starr County border health initiative.,"PURPOSE The purpose of the study was to (1) characterize leptin in Mexican Americans with poorly controlled type 2 diabetes, (2) examine relationships among leptin and indicators of diabetes status (body mass index and A1C), and (3) explore the effects of a culturally tailored diabetes self-management education intervention on leptin. METHODS In Starr County, an impoverished Texas-Mexico border community, 252 Mexican Americans with type 2 diabetes were recruited to test a diabetes self-management education intervention culturally tailored in terms of language, dietary recommendations, social emphasis, family participation, and incorporation of cultural health beliefs. Groups of 8 participants were randomized to experimental or wait-listed control conditions. Outcomes were measured at 3, 6, and 12 months; by 12 months, 109 had complete leptin data. RESULTS Most participants were women and, on average, 55 years of age, diagnosed with diabetes for 8 years, obese, and in poor glycemic control. Three variables-body mass index, sex, A1C-explained 36% of the variance in baseline leptin; there were no intervention effects on leptin. Sex, time, and gender × time interaction effects on leptin were statistically significant; greater increases in leptin over time occurred in women compared to men. In women, fasting blood glucose changes from baseline to 12 months significantly predicted leptin changes from baseline to 12 months; in men, body mass index changes predicted leptin change. CONCLUSIONS With increasing obesity rates, further research is warranted to determine if leptin is a useful intervention target in type 2 diabetes.",2013,"Sex, time, and gender × time interaction effects on leptin were statistically significant; greater increases in leptin over time occurred in women compared to men.","['252 Mexican Americans with type 2 diabetes', 'Mexican Americans with type 2 diabetes', 'Most participants were women and, on average, 55 years of age, diagnosed with diabetes for 8 years, obese, and in poor glycemic control', 'Mexican Americans with poorly controlled type 2 diabetes']",['culturally tailored diabetes self-management education intervention'],"['leptin over time', 'leptin', 'fasting blood glucose changes', 'leptin changes']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0342299', 'cui_str': 'Poor glycemic control (disorder)'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}]","[{'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",8.0,0.0233174,"Sex, time, and gender × time interaction effects on leptin were statistically significant; greater increases in leptin over time occurred in women compared to men.","[{'ForeName': 'Sharon A', 'Initials': 'SA', 'LastName': 'Brown', 'Affiliation': 'School of Nursing, The University of Texas at Austin, TX, USA (Dr Brown, Prof García)'}, {'ForeName': 'Kamiar', 'Initials': 'K', 'LastName': 'Kouzekanani', 'Affiliation': 'Texas A&M University, Corpus Christi, TX, USA (Dr Kouzekanani)'}, {'ForeName': 'Alexandra A', 'Initials': 'AA', 'LastName': 'García', 'Affiliation': 'School of Nursing, The University of Texas at Austin, TX, USA (Dr Brown, Prof García)'}, {'ForeName': 'Philip R', 'Initials': 'PR', 'LastName': 'Orlander', 'Affiliation': 'The University of Texas Medical School at Houston, TX, USA (Dr Orlander)'}, {'ForeName': 'Craig L', 'Initials': 'CL', 'LastName': 'Hanis', 'Affiliation': 'The University of Texas Health Science Center at Houston, TX, USA (Prof Hanis)'}]",The Diabetes educator,['10.1177/0145721713505153'] 196,23080477,Brain injury following trial of hypothermia for neonatal hypoxic-ischaemic encephalopathy.,"OBJECTIVE The objective of our study was to examine the relationship between brain injury and outcome following neonatal hypoxic-ischaemic encephalopathy treated with hypothermia. DESIGN AND PATIENTS Neonatal MRI scans were evaluated in the National Institute of Child Health and Human Development (NICHD) randomised controlled trial of whole-body hypothermia and each infant was categorised based upon the pattern of brain injury on the MRI findings. Brain injury patterns were assessed as a marker of death or disability at 18-22 months of age. RESULTS Scans were obtained on 136 of 208 trial participants (65%); 73 in the hypothermia and 63 in the control group. Normal scans were noted in 38 of 73 infants (52%) in the hypothermia group and 22 of 63 infants (35%) in the control group. Infants in the hypothermia group had fewer areas of infarction (12%) compared to infants in the control group (22%). Fifty-one of the 136 infants died or had moderate or severe disability at 18 months. The brain injury pattern correlated with outcome of death or disability and with disability among survivors. Each point increase in the severity of the pattern of brain injury was independently associated with a twofold increase in the odds of death or disability. CONCLUSIONS Fewer areas of infarction and a trend towards more normal scans were noted in brain MRI following whole-body hypothermia. Presence of the NICHD pattern of brain injury is a marker of death or moderate or severe disability at 18-22 months following hypothermia for neonatal encephalopathy.",2012,Infants in the hypothermia group had fewer areas of infarction (12%) compared to infants in the control group (22%).,"['Scans were obtained on 136 of 208 trial participants (65%); 73 in the hypothermia and 63 in the control group', 'Fifty-one of the 136 infants died or had moderate or severe disability at 18 months', 'Neonatal MRI scans were evaluated in the National Institute of Child Health and Human Development (NICHD', 'neonatal hypoxic-ischaemic encephalopathy']",['hypothermia'],"['severity of the pattern of brain injury', 'death or disability', 'Normal scans', 'infarction', 'death or moderate or severe disability', 'odds of death or disability', 'normal scans']","[{'cui': 'C0441633'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C4517568', 'cui_str': 'One hundred and thirty-six'}, {'cui': 'C0413252', 'cui_str': 'Hypothermia due to exposure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0917711', 'cui_str': 'MRI Scans'}, {'cui': 'C1513896', 'cui_str': 'National Institute of Child Health and Human Development'}, {'cui': 'C0752304', 'cui_str': 'Hypoxic-Ischemic Encephalopathy'}]","[{'cui': 'C0413252', 'cui_str': 'Hypothermia due to exposure'}]","[{'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0270611', 'cui_str': 'Brain Injuries'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0441633'}, {'cui': 'C0021308', 'cui_str': 'Infarction'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]",,0.077706,Infants in the hypothermia group had fewer areas of infarction (12%) compared to infants in the control group (22%).,"[{'ForeName': 'Seetha', 'Initials': 'S', 'LastName': 'Shankaran', 'Affiliation': ""Department of Pediatrics/Neonatology, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, MI 48201, USA. sshankar@med.wayne.edu""}, {'ForeName': 'Patrick D', 'Initials': 'PD', 'LastName': 'Barnes', 'Affiliation': ''}, {'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Hintz', 'Affiliation': ''}, {'ForeName': 'Abbott R', 'Initials': 'AR', 'LastName': 'Laptook', 'Affiliation': ''}, {'ForeName': 'Kristin M', 'Initials': 'KM', 'LastName': 'Zaterka-Baxter', 'Affiliation': ''}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'McDonald', 'Affiliation': ''}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Ehrenkranz', 'Affiliation': ''}, {'ForeName': 'Michele C', 'Initials': 'MC', 'LastName': 'Walsh', 'Affiliation': ''}, {'ForeName': 'Jon E', 'Initials': 'JE', 'LastName': 'Tyson', 'Affiliation': ''}, {'ForeName': 'Edward F', 'Initials': 'EF', 'LastName': 'Donovan', 'Affiliation': ''}, {'ForeName': 'Ronald N', 'Initials': 'RN', 'LastName': 'Goldberg', 'Affiliation': ''}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Bara', 'Affiliation': ''}, {'ForeName': 'Abhik', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': ''}, {'ForeName': 'Neil N', 'Initials': 'NN', 'LastName': 'Finer', 'Affiliation': ''}, {'ForeName': 'Pablo J', 'Initials': 'PJ', 'LastName': 'Sanchez', 'Affiliation': ''}, {'ForeName': 'Brenda B', 'Initials': 'BB', 'LastName': 'Poindexter', 'Affiliation': ''}, {'ForeName': 'Krisa P', 'Initials': 'KP', 'LastName': 'Van Meurs', 'Affiliation': ''}, {'ForeName': 'Waldemar A', 'Initials': 'WA', 'LastName': 'Carlo', 'Affiliation': ''}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Stoll', 'Affiliation': ''}, {'ForeName': 'Shahnaz', 'Initials': 'S', 'LastName': 'Duara', 'Affiliation': ''}, {'ForeName': 'Ronnie', 'Initials': 'R', 'LastName': 'Guillet', 'Affiliation': ''}, {'ForeName': 'Rosemary D', 'Initials': 'RD', 'LastName': 'Higgins', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Archives of disease in childhood. Fetal and neonatal edition,['10.1136/archdischild-2011-301524'] 197,32493211,"Dural sac cross-sectional area is a highly effective parameter for spinal anesthesia in geriatric patients undergoing transurethral resection of the prostate: a prospective, double blinded, randomized study.","BACKGROUND Spinal anesthesia is optimal choice for transurethral resection of the prostate (TURP), but the sensory block should not cross the T10 level. With advancing age, the sensory blockade level increases after spinal injection in some patients with spinal canal stenosis. We optimize the dose of spinal anesthesia according to the decreased ratio of the dural sac cross-sectional area (DSCSA), the purpose of this study is to hypothesis that if DSCSA is an effective parameter to modify the dosage of spinal anesthetics to achieve a T10 blockade in geriatric patients undergoing TURP. METHODS Sixty geriatric patients schedule for TURP surgery were enrolled in this study. All subjects were randomized divided into two groups, the ultrasound (group U) and the control (group C) groups, patient receive either a dose of 2 ml of 0.5% isobaric bupivacaine in group C, or a modified dose of 0.5% isobaric bupivacaine in group U. We measured the sagittal anteroposterior diameter (D) of the dural sac at the L3-4 level with ultrasound, and calculated the approximate DSCSA (A) according to the following formula: A = π(D/2) 2 , ( π = 3.14). The modified dosage of bupivacaine was adjusted according to the decreased ratio of the DSCSA. RESULTS The cephalad spread of the sensory blockade level was significantly lower (P < 0.001) in group U (T10, range T7-T12) compared with group C (T3, range T2-T9). The dosage of bupivacaine was significantly decreased in group U compared with group C (P < 0.001). The regression times of the two segments were delay in group U compared with group C (P < 0.001). The maximal decrease in MAP was significantly higher in the group C than in group U after spinal injection (P < 0.001), without any modifications HR in either group. Eight patients in group C and two patients in group U required ephedrine (P = 0.038). CONCLUSIONS The DSCSA is a highly effective parameter for spinal anesthesia in geriatric patients undergoing TURP, a modified dose of local anesthetic is a critical factor for controlling the sensory level. TRIAL REGISTRATION This study was registered in the Chinese Clinical Trial Registry (Registration number: ChiCTR1800015566).on 8, April, 2018.",2020,"The cephalad spread of the sensory blockade level was significantly lower (P < 0.001) in group U (T10, range T7-T12) compared with group C (T3, range T2-T9).","['Sixty geriatric patients schedule for TURP surgery were enrolled in this study', 'geriatric patients undergoing transurethral resection of the prostate', 'geriatric patients undergoing TURP', 'geriatric patients undergoing', 'patients with spinal canal stenosis']","['TURP', 'bupivacaine', 'DSCSA', 'modified dose of 0.5% isobaric bupivacaine', 'patient receive either a dose of 2\u2009ml of 0.5% isobaric bupivacaine', 'spinal anesthesia', 'ephedrine']","['sagittal anteroposterior diameter (D) of the dural sac', 'cephalad spread of the sensory blockade level', 'maximal decrease in MAP']","[{'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0040771', 'cui_str': 'Transurethral prostatectomy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1861329', 'cui_str': 'Spinal canal stenosis'}]","[{'cui': 'C0040771', 'cui_str': 'Transurethral prostatectomy'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0014479', 'cui_str': 'Ephedrine'}]","[{'cui': 'C0205129', 'cui_str': 'Sagittal'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0205096', 'cui_str': 'Cephalic'}, {'cui': 'C0332261', 'cui_str': 'Spreading'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0024779', 'cui_str': 'Maps'}]",60.0,0.0363662,"The cephalad spread of the sensory blockade level was significantly lower (P < 0.001) in group U (T10, range T7-T12) compared with group C (T3, range T2-T9).","[{'ForeName': 'Wei Bing', 'Initials': 'WB', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, The Affiliated AnQing Hospitals of Anhui Medical University, 352th, Renming Road, AnQing, 246003, AnHui province, China. w2bwang@sina.com.'}, {'ForeName': 'Ai Jiao', 'Initials': 'AJ', 'LastName': 'Sun', 'Affiliation': 'Department of Anesthesiology, The Affiliated AnQing Hospitals of Anhui Medical University, 352th, Renming Road, AnQing, 246003, AnHui province, China.'}, {'ForeName': 'Hong Ping', 'Initials': 'HP', 'LastName': 'Yu', 'Affiliation': 'Department of Anesthesiology, The Affiliated AnQing Hospitals of Anhui Medical University, 352th, Renming Road, AnQing, 246003, AnHui province, China.'}, {'ForeName': 'Jing Chun', 'Initials': 'JC', 'LastName': 'Dong', 'Affiliation': 'Department of Anesthesiology, The Affiliated AnQing Hospitals of Anhui Medical University, 352th, Renming Road, AnQing, 246003, AnHui province, China.'}, {'ForeName': 'Huang', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesiology, The Affiliated AnQing Hospitals of Anhui Medical University, 352th, Renming Road, AnQing, 246003, AnHui province, China.'}]",BMC anesthesiology,['10.1186/s12871-020-01059-x'] 198,23148885,Favourable effects of the Dietary Approaches to Stop Hypertension diet on glucose tolerance and lipid profiles in gestational diabetes: a randomised clinical trial.,"Although gestational diabetes mellitus (GDM) is associated with an increased risk of maternal and neonatal morbidity, there is no consensus as to the optimal approach of nutritional management in these patients. The present study was designed to assess the effect of the Dietary Approaches to Stop Hypertension (DASH) eating plan on glucose tolerance and lipid profiles of pregnant women with GDM. The present randomised controlled clinical trial was performed among thirty-four women diagnosed with GDM at 24-28 weeks of gestation. Subjects were randomly assigned to consume either the control diet (n 17) or the DASH eating pattern (n 17) for 4 weeks. The control diet was designed to contain 45-55% carbohydrates, 15-20% protein and 25-30% total fat. The macronutrient composition of the DASH diet was similar to the control diet; however, the DASH diet was rich in fruits, vegetables, whole grains and low-fat dairy products, and contained lower amounts of saturated fats, cholesterol and refined grains with a total of 2400 mg Na/d. Fasting blood samples were taken at baseline and after 4 weeks of intervention to measure fasting plasma glucose, glycated Hb (HbA1c) and lipid profiles. Participants underwent a 3 h oral glucose tolerance tests and blood samples were collected at 60, 120 and 180 min to measure plasma glucose levels. Adherence to the DASH eating pattern, compared with the control diet, resulted in improved glucose tolerance such that plasma glucose levels reduced at 60 (21·86 v. 20·45 mmol/l, Pgroup = 0·02), 120 (22·3 v. 0·2 mmol/l, Pgroup = 0·001) and 180 min (21·7 v. 0·22 mmol/l, Pgroup = 0·002) after the glucose load. Decreased HbA1c levels (20·2 v. 0·05 %, Pgroup = 0·001) was also seen in the DASH group compared with the control group. Mean changes for serum total (20·42 v. 0·31 mmol/l, Pgroup = 0·01) and LDL-cholesterol (20·47 v. 0·22 mmol/l, Pgroup = 0·005), TAG (20·17 v. 0·34 mmol/l, Pgroup = 0·01) and total:HDL-cholesterol ratio (20·6 (SD 0·9) v. 0·3 (SD 0·8), Pgroup = 0·008) were significantly different between the two diets. Additionally, consumption of the DASH diet favourably influenced systolic blood pressure (22·6 v. 1·7 mmHg, Pgroup = 0·001). Mean changes of fasting plasma glucose (20·29 v. 0·15 mmol/l, Pgroup = 0·09) were nonsignificant comparing the DASH diet with the control diet. In conclusion, consumption of the DASH eating pattern for 4 weeks among pregnant women with GDM resulted in beneficial effects on glucose tolerance and lipid profiles compared with the control diet.",2013,"Decreased HbA1c levels (20·2 v. 0·05 %, Pgroup = 0·001) was also seen in the DASH group compared with the control group.","['pregnant women with', 'thirty-four women diagnosed with GDM at 24-28 weeks of gestation', 'gestational diabetes mellitus (GDM', 'gestational diabetes', 'pregnant women with GDM']","['control diet (n 17) or the DASH eating pattern', 'Dietary Approaches to Stop Hypertension diet', 'Dietary Approaches to Stop Hypertension (DASH) eating plan', 'GDM']","['total:HDL-cholesterol ratio', 'glucose tolerance and lipid profiles', 'systolic blood pressure', 'Decreased HbA1c levels', 'Fasting blood samples', 'LDL-cholesterol', 'plasma glucose levels', 'fasting plasma glucose, glycated Hb (HbA1c) and lipid profiles', 'glucose tolerance such that plasma glucose levels', 'Mean changes of fasting plasma glucose']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C4053458', 'cui_str': 'Dietary Approaches To Stop Hypertension Diet'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",34.0,0.0357797,"Decreased HbA1c levels (20·2 v. 0·05 %, Pgroup = 0·001) was also seen in the DASH group compared with the control group.","[{'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Tabassi', 'Affiliation': ''}, {'ForeName': 'Mansooreh', 'Initials': 'M', 'LastName': 'Samimi', 'Affiliation': ''}, {'ForeName': 'Taherh', 'Initials': 'T', 'LastName': 'Fahiminejad', 'Affiliation': ''}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Esmaillzadeh', 'Affiliation': ''}]",The British journal of nutrition,['10.1017/S0007114512004242'] 199,32493213,Comparison of gastric insufflation using LMA-supreme and I-gel versus tracheal intubation in laparoscopic gynecological surgery by ultrasound: a randomized observational trial.,"BACKGROUND The application of bedside ultrasound to evaluate gastric content and volume can assist in determining aspiration risk. Applying positive pressure ventilation via supraglottic airway devices (SAD) can result in a degree of gastric insufflation. This study assessed and compared the antral cross-sectional area (CSA) in patients undergoing laparoscopic gynecological surgery when managed with different SAD. METHODS One hundred American Society of Anesthesiologists I or II female patients were assessed for inclusion in this study and divided into three groups of different ventilation devices. Patients were randomly allocated into three groups to receive LMA-Supreme (Group S), I-gel (Group I) or tracheal tube (Group T). The primary outcome was the antral cross-sectional area and secondary outcomes included haemodynamic parameters and postoperative morbidity such as sore throat, hoarseness, dry throat, nausea and vomiting. RESULTS The antral CSA was not significantly different among three groups before induction (P = 0.451), after induction (P = 0.456) and at the end of surgery (P = 0.195). The haemodynamic variables were significantly higher in the tracheal tube group than in the LMA-Supreme and I-gel groups after insertion (P < 0.0001) and after removal (P < 0.01). Sore throat was detected in none in the I-gel group compare to two patients (6.7%) in the LMA-Supreme group and fifteen patients (50%) in the tracheal tube group. Hoareness was detected in one (3.3%) in the I-gel group compare to two patients (6.7%) in the LMA-Supreme group and eleven patients (36.7%) in the tracheal tube group. CONCLUSIONS The SADs do not cause obvious gastric insufflation. Thus, LMA-Supreme and I-gel can be widely used as alternative to endotracheal intubation for the short laparoscopic gynecological surgery. TRIAL REGISTRATION This trial was registered at the Chinese Clinical Trial Registry (ChiCTR1800018212, data of registration, September 2018).",2020,The haemodynamic variables were significantly higher in the tracheal tube group than in the LMA-Supreme and I-gel groups after insertion (P < 0.0001) and after removal (P < 0.01).,"['One hundred American Society of Anesthesiologists', 'laparoscopic gynecological surgery by ultrasound', 'I or II female patients', 'patients undergoing laparoscopic gynecological surgery when managed with different SAD']","['LMA-Supreme (Group S), I-gel (Group I) or tracheal tube', 'positive pressure ventilation via supraglottic airway devices (SAD', 'LMA-supreme and I-gel versus tracheal intubation']","['antral cross-sectional area and secondary outcomes included haemodynamic parameters and postoperative morbidity such as sore throat, hoarseness, dry throat, nausea and vomiting', 'haemodynamic variables', 'Hoareness', 'Sore throat', 'antral CSA']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0038902', 'cui_str': 'Operation on female genital organs'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C4076036', 'cui_str': 'Supraglottic airway'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}, {'cui': 'C3282376', 'cui_str': 'Supreme'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0441843', 'cui_str': 'Group I'}, {'cui': 'C1260970', 'cui_str': 'Tracheal tube'}, {'cui': 'C0021778', 'cui_str': 'Intermittent positive pressure ventilation'}, {'cui': 'C4076036', 'cui_str': 'Supraglottic airway'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C0293352', 'cui_str': 'Antral'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C0235234', 'cui_str': 'Pharyngeal dryness'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0439828', 'cui_str': 'Variable'}]",100.0,0.131033,The haemodynamic variables were significantly higher in the tracheal tube group than in the LMA-Supreme and I-gel groups after insertion (P < 0.0001) and after removal (P < 0.01).,"[{'ForeName': 'Qiuping', 'Initials': 'Q', 'LastName': 'Ye', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital of Anhui Medical University, No.218 Jixi Road, Hefei, 230022, Anhui Province, People's Republic of China.""}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital of Anhui Medical University, No.218 Jixi Road, Hefei, 230022, Anhui Province, People's Republic of China.""}, {'ForeName': 'Weiping', 'Initials': 'W', 'LastName': 'Fang', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital of Anhui Medical University, No.218 Jixi Road, Hefei, 230022, Anhui Province, People's Republic of China.""}, {'ForeName': 'Gordon Tin Chun', 'Initials': 'GTC', 'LastName': 'Wong', 'Affiliation': ""Department of Anesthesiology, The University of Hong Kong, Hong Kong SAR, People's Republic of China.""}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital of Anhui Medical University, No.218 Jixi Road, Hefei, 230022, Anhui Province, People's Republic of China. luyao-mz@163.com.""}]",BMC anesthesiology,['10.1186/s12871-020-01057-z'] 200,24012740,Invalidation of a commercially available human 5α-dihydrotestosterone immunoassay.,"Enzyme immunoassays (EIA) are commonly utilized for the evaluation of androgens in biological fluids; however, careful consideration must be given to cross-reactivity with other endogenous sex-steroid hormones. Our purpose was to determine the validity of a commonly-utilized commercially-available dihydrotestosterone (DHT) EIA. Serum samples obtained from older hypogonadal men who participated in a 12-month randomized controlled trial evaluating the effects of testosterone-enanthate (125 mg/week) or vehicle in combination with finasteride (5mg/day) or placebo were assayed for DHT via EIA and using a validated gold-standard LC-MS/MS approach. Additionally, commercially-available (DHT-free) buffer containing graded testosterone doses was evaluated by DHT immunoassay. DHT concentrations measured via EIA were 79% to >1000% higher than values obtained by LC-MS/MS (p<0.05), with the largest differences (415-1128%) occuring in groups receiving finasteride. Both LC-MS/MS and EIA indicated that testosterone-enanthate increased serum DHT to a similar magnitude. In contrast, finasteride-induced reductions in DHT were detected by LC-MS/MS, but not EIA (p<0.05). No significant associations were present for DHT concentrations between measurement techniques. Cross-reactivity of testosterone with the immunoassay ranged from 18% to 99% and DHT concentrations measured by EIA were highly associated with the spiked testosterone concentrations in DHT-free buffer (r=0.885, p<0.001). In conclusion, we provide evidence invalidating a commonly-utilized commercially-available DHT immunoassay because significant cross-reactivity exists between testosterone and the EIA and because the changes in DHT observed via EIA were not associated with a validated gold-standard measurement technique. The cross-reactivity of testosterone is particularly concerning because testsoterone is present in 100-fold greater concentrations than is DHT within the circulation.",2013,"Cross-reactivity of testosterone with the immunoassay ranged from 18% to 99% and DHT concentrations measured by EIA were highly associated with the spiked testosterone concentrations in DHT-free buffer (r=0.885, p<0.001).",['older hypogonadal men'],"['commonly-utilized commercially-available dihydrotestosterone (DHT) EIA', 'testosterone-enanthate', 'vehicle in combination with finasteride (5mg/day) or placebo', 'finasteride']","['DHT concentrations measured via EIA', 'serum DHT', 'DHT concentrations', 'DHT']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0038148', 'cui_str': 'Dihydrotestosterone'}, {'cui': 'C0076189', 'cui_str': 'testosterone enanthate'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}, {'cui': 'C0060389', 'cui_str': 'Finasteride'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.0747809,"Cross-reactivity of testosterone with the immunoassay ranged from 18% to 99% and DHT concentrations measured by EIA were highly associated with the spiked testosterone concentrations in DHT-free buffer (r=0.885, p<0.001).","[{'ForeName': 'Joshua F', 'Initials': 'JF', 'LastName': 'Yarrow', 'Affiliation': 'VA Medical Center, Gainesville, FL 32608, United States; Department of Applied Physiology & Kinesiology, University of Florida, Gainesville, FL 32611, United States. Electronic address: jfyarrow@ufl.edu.'}, {'ForeName': 'Darren T', 'Initials': 'DT', 'LastName': 'Beck', 'Affiliation': ''}, {'ForeName': 'Christine F', 'Initials': 'CF', 'LastName': 'Conover', 'Affiliation': ''}, {'ForeName': 'Luke A', 'Initials': 'LA', 'LastName': 'Beggs', 'Affiliation': ''}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Goldberger', 'Affiliation': ''}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Borst', 'Affiliation': ''}]",Steroids,['10.1016/j.steroids.2013.08.013'] 201,20402755,Repetitive transcranial magnetic stimulation at 1Hz and 5Hz produces sustained improvement in motor function and disability after ischaemic stroke.,"BACKGROUND Repetitive transcranial magnetic stimulation (rTMS) is a simple and non-invasive method of augmenting motor recovery after stroke, probably mediated by restoring inter-hemispheric activation balance. This placebo-controlled pilot study examined the possible benefit of stimulating the lesioned hemisphere (5-Hz rTMS) or inhibiting the contra-lesional hemisphere (1-Hz rTMS) on clinical recovery of motor function in patients with ischaemic stroke and assessed the sustainability of the response. METHODS Sixty patients with ischaemic stroke (>1 month from onset) with mild-to-moderate hemiparesis were randomized to receive 10 daily sessions of either sham rTMS, 5-Hz ipsi-lesional rTMS or 1-Hz contra-lesional rTMS, in addition to a standard physical therapy protocol. Serial assessments were made over a period of 12 weeks by the thumb-index finger tapping test (FT), Activity Index (AI) score and the modified Rankin Scale (mRS). RESULTS In contrast to control patients, those receiving active rTMS as ipsi-lesional 5-Hz stimulation or 1-Hz contra-lesional stimulation showed statistically significant improvement on the FT test, AI scores and mRS score at 2 weeks, and the effect was sustained over the 12-week observation period. No significant adverse events were observed during treatment in either group. CONCLUSIONS Repetitive TMS has beneficial effects on motor recovery that can be translated to clinically meaningful improvement in disability in patients with post-stroke hemiparesis, with a well-sustained effect. The similarity of inhibitory and stimulatory rTMS in producing these effects supports the inter-hemispheric balance hypothesis and encourages further research into their use in long-term neurorehabilitation programmes of patients with stroke.",2010,"CONCLUSIONS Repetitive TMS has beneficial effects on motor recovery that can be translated to clinically meaningful improvement in disability in patients with post-stroke hemiparesis, with a well-sustained effect.","['Sixty patients with ischaemic stroke (>1 month from onset) with mild-to-moderate hemiparesis', 'patients with stroke', 'patients with ischaemic stroke']","['placebo', 'Repetitive transcranial magnetic stimulation (rTMS', 'sham rTMS, 5-Hz ipsi-lesional rTMS or 1-Hz contra-lesional rTMS, in addition to a standard physical therapy protocol', 'Repetitive transcranial magnetic stimulation at 1Hz and 5Hz', 'Repetitive TMS', 'stimulating the lesioned hemisphere (5-Hz rTMS) or inhibiting the contra-lesional hemisphere (1-Hz rTMS']","['thumb-index finger tapping test (FT), Activity Index (AI) score and the modified Rankin Scale (mRS', 'adverse events', 'motor function and disability', 'FT test, AI scores and mRS score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C4280965', 'cui_str': '>1'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0457436', 'cui_str': 'Left hemiparesis (disorder)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C0040067', 'cui_str': 'Thumb'}, {'cui': 'C0230388', 'cui_str': 'Index finger structure'}, {'cui': 'C0034115', 'cui_str': 'Puncture and Drainage'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}]",60.0,0.0417162,"CONCLUSIONS Repetitive TMS has beneficial effects on motor recovery that can be translated to clinically meaningful improvement in disability in patients with post-stroke hemiparesis, with a well-sustained effect.","[{'ForeName': 'T H', 'Initials': 'TH', 'LastName': 'Emara', 'Affiliation': 'Department of Neurology and Psychiatry.'}, {'ForeName': 'R R', 'Initials': 'RR', 'LastName': 'Moustafa', 'Affiliation': 'Department of Neurology and Psychiatry.'}, {'ForeName': 'N M', 'Initials': 'NM', 'LastName': 'ElNahas', 'Affiliation': 'Department of Neurology and Psychiatry.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'ElGanzoury', 'Affiliation': 'Department of Physical Medicine, Rheumatology and Rehabilitation, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'T A', 'Initials': 'TA', 'LastName': 'Abdo', 'Affiliation': 'Department of Neurology and Psychiatry.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Mohamed', 'Affiliation': 'Department of Neurology and Psychiatry.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'ElEtribi', 'Affiliation': 'Department of Neurology and Psychiatry.'}]",European journal of neurology,['10.1111/j.1468-1331.2010.03000.x'] 202,32133778,"Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers.","Antihistamines have been in clinical use for more than 70 years to treat allergic and nonallergic symptoms including relief from cold and flu symptoms. Despite their widespread use, pharmacokinetic (PK) data are sparse for older, first-generation antihistamines. This phase 1 single-center open-label, randomized, single-dose, 3-way crossover trial evaluated the PK profiles of 2 doses of film-coated triprolidine caplets (2.5 and 5 mg) compared with a reference combination tablet (triprolidine 2.5 mg + pseudoephedrine 60 mg) in 24 healthy adults. Blood samples were collected predose and at specified intervals across a 24-hour period after administration, and triprolidine was quantified using liquid chromatography-tandem mass spectrometry. Maximum plasma concentration of triprolidine for the 2.5 mg and dose-normalized 5 mg single-agent tablets were comparable (8.4 versus 7.1 ng/mL, respectively) and higher for the combination tablet (9.5 ng/mL). PK parameters, including time to maximum plasma concentration (∼1.5 hours) and elimination half-life (∼4 hours), were comparable between the 3 treatment arms. The safety profile of this sedating antihistamine was as expected; however, adverse effects were reported in a markedly higher proportion of women than men. There were no significant sex differences in any of the measured PK parameters.",2020,There were no significant sex differences in any of the measured PK parameters.,"['Healthy Volunteers', '24 healthy adults']","['sedating antihistamine', 'Antihistamines', 'Pseudoephedrine', 'Triprolidine', 'reference combination tablet (triprolidine 2.5\xa0mg + pseudoephedrine', 'film-coated triprolidine caplets']","['time to maximum plasma concentration', 'adverse effects', 'Bioavailability', 'Maximum plasma concentration of triprolidine']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C1955826', 'cui_str': 'Antihistamines, Sedating'}, {'cui': 'C0019590', 'cui_str': 'Antihistamines'}, {'cui': 'C0033798', 'cui_str': 'Pseudoephedrine'}, {'cui': 'C0041098', 'cui_str': 'Triprolidine'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0453946', 'cui_str': 'Coat (physical object)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0041098', 'cui_str': 'Triprolidine'}]",24.0,0.110154,There were no significant sex differences in any of the measured PK parameters.,"[{'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Febbraro', 'Affiliation': 'PRA Health Sciences, Reading, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Shea', 'Affiliation': 'Reckitt Benckiser Health LLC, Parsippany, New Jersey, USA.'}, {'ForeName': 'Ana Santos', 'Initials': 'AS', 'LastName': 'Cravo', 'Affiliation': 'Reckitt Benckiser Healthcare Ltd, Slough, UK.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.777'] 203,32126336,Typical symptom change patterns and their predictors in patients with social anxiety disorder: A latent class analysis.,"OBJECTIVES The use of trajectories and analysis of change patterns is a promising way toward better differentiation of subgroups in psychotherapy studies. Research on change patterns in social anxiety disorder (SAD) are still rare, although SAD is one of the most common mental disorders. In a secondary analysis of data from the SOPHO-NET-trial (ISRCTN53517394) this study aimed to investigate change patterns and their predictors in a sample of SAD patients. METHODS Patients with SAD (N = 357) were randomly assigned to cognitive-behavioral or psychodynamic therapy. The Liebowitz Social Anxiety Scale (LSAS) was assessed at 1 st session (pre), 8th session, 15th session and at the end of treatment (post). We used latent state variables and latent class analysis for the classification of change patterns and logistic regression for the identification of different predictors. RESULTS Analyses revealed three typical patterns: (i.) responders with a high initial impairment (N = 57), (ii.) responders with a moderate initial impairment (N = 225), and (iii.) patients with a high initial impairment and no remission (N = 75). Among other significant predicators, patient´s attachment anxiety and therapeutic alliance at session eight contributed to the prediction of change patterns. DISCUSSION Psychotherapy of SAD should consider patient's attachment and focus on the establishment of a solid therapeutic alliance in an early therapy stage.",2020,"Among other significant predicators, patient´s attachment anxiety and therapeutic alliance at session eight contributed to the prediction of change patterns. ","['patients with social anxiety disorder', 'responders with a moderate initial impairment (N = 225), and (iii', 'patients with a high initial impairment and no remission (N = 75', 'Patients with SAD (N = 357']",['cognitive-behavioral or psychodynamic therapy'],"['Liebowitz Social Anxiety Scale (LSAS', 'social anxiety disorder (SAD', 'patient´s attachment anxiety and therapeutic alliance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031572', 'cui_str': 'Social Anxiety Disorder'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C4517652', 'cui_str': '225 (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C0222045'}, {'cui': 'C0031572', 'cui_str': 'Social Anxiety Disorder'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0814487', 'cui_str': 'Therapeutic Alliance'}]",357.0,0.0199963,"Among other significant predicators, patient´s attachment anxiety and therapeutic alliance at session eight contributed to the prediction of change patterns. ","[{'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Altmann', 'Affiliation': 'Universitätsklinikum Jena, Institute of Psychosocial Medicine and Psychotherapy, Stoystr. 3, 07740 Jena Germany. Electronic address: uwe.altmann@med.uni-jena.de.'}, {'ForeName': 'Romina', 'Initials': 'R', 'LastName': 'Gawlytta', 'Affiliation': 'Universitätsklinikum Jena, Institute of Psychosocial Medicine and Psychotherapy, Stoystr. 3, 07740 Jena Germany. Electronic address: romina.gawlytta@med.uni-jena.de.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Hoyer', 'Affiliation': 'Technische Universität Dresden, Institute of Clinical Psychology and Psychotherapy, Hohe Straße 53, 01187 Dresden Germany. Electronic address: Juergen.Hoyer@tu-dresden.de.'}, {'ForeName': 'Falk', 'Initials': 'F', 'LastName': 'Leichsenring', 'Affiliation': 'Universitätsklinikum Giessen, Clinic of Psychosomatic and Psychotherapy, Friedrichstr. 33, 35392 Gießen Germany. Electronic address: falk.leichsenring@psycho.med.uni-giessen.de.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Leibing', 'Affiliation': 'Universitätsmedizin Göttingen Clinic of Psychosomatic Medicine and Psychotherapy Von-Siebold-Str. 5, 37075 Göttingen Germany. Electronic address: eleibin@gwdg.de.'}, {'ForeName': 'Manfred', 'Initials': 'M', 'LastName': 'Beutel', 'Affiliation': 'Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Clinic and Polyclinic for Psychosomatic Medicine and Psychotherapy, Untere Zahlbacher Strasse 8, 55131 Mainz Germany. Electronic address: Manfred.Beutel@unimedizin-mainz.de.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Willutzki', 'Affiliation': 'Universität Witten/Herdecke, Department of Psychology and Psychotherapy, Alfred-Herrhausen-Straße 44, 58455 Witten Germany. Electronic address: Ulrike.Willutzki@uni-wh.de.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Herpertz', 'Affiliation': 'LWL-Universitätsklinikum der Ruhr-Universität Bochum Clinic of Psychosomatic Medicine and Psychotherapy Alexandrinenstr. 1-3, 44791 Bochum Germany. Electronic address: stephan.herpertz@ruhr-uni-bochum.de.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Strauss', 'Affiliation': 'Universitätsklinikum Jena, Institute of Psychosocial Medicine and Psychotherapy, Stoystr. 3, 07740 Jena Germany. Electronic address: bernhard.strauss@med.uni-jena.de.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2020.102200'] 204,32428959,Dresdener Network Osteoporosis.,"PURPOSE On a global scale the main focus of traumatological therapy lies in the treatment of unintentional injuries or victims of violence. People of all ages and through all economic groups can be affected. Due to demographic change in Western industrial countries, however, this focus increasingly shifts towards fragility fractures. In Europe osteoporosis is the most common bone disease in advanced age. Secondary prevention programs like the Fracture Liaison Service (FLS) are becoming increasingly prevalent, especially in Anglo-American health care systems. In German orthopedic and trauma wards and hospitals, however, the FLS is still relatively uncommon. This article will examine the question whether secondary prevention programs like FLS need to be established in the German health care system. This study aims at finding out, whether in the area of a medium sized German city there is a difference regarding the initiation of osteoporosis diagnosis and therapy between the regular aftercare by the general practitioner or the orthopedic surgeon and the aftercare by a specialist trained in osteology (Osteologe). MATERIALS AND METHODS For the open, randomized prospective study 70 patients with low energy fractures were recruited, who were older than 60 years and have been treated in our department. RESULTS 58 out of 70 patients have completed the study, which amounts to a follow-up of 82.9%. Limited mobility and a high degree of organizational effort were the main reasons for early termination of the study. While in the group with regular aftercare, only 2 out of 29 patients received a specific osteoporosis treatment, in group who were directly transferred to a specialist trained in osteology 17 out of 29 patients received specific treatment. After re-evaluation of group with regular aftercare in 21 out of 29 cases a specific osteoporosis treatment was recommended. CONCLUSIONS It could be established that there is a significant diagnosis and treatment gap regarding the aftercare of patients with fractures caused by osteoporosis between general practitioners or orthopedic surgeons on the one hand and the specialists trained in osteology on the other hand. To improve the aftercare of fracture patients, cross sectoral networks with a background in geriatrics and orthopedic-trauma surgery like a FLS need to be established in the German healthcare system.",2021,"Secondary prevention programs like the Fracture Liaison Service (FLS) are becoming increasingly prevalent, especially in Anglo-American health care systems.","['70 patients with low energy fractures were recruited, who were older than 60 years and have been treated in our department', '58 out of 70 patients', 'unintentional injuries or victims of violence']","['Fracture Liaison Service (FLS', 'specific treatment', 'specific osteoporosis treatment']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0151736', 'cui_str': 'Accidental injury'}, {'cui': 'C0042693', 'cui_str': 'Violence'}]","[{'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4303745', 'cui_str': 'Treatment for osteoporosis'}]",[],70.0,0.0352955,"Secondary prevention programs like the Fracture Liaison Service (FLS) are becoming increasingly prevalent, especially in Anglo-American health care systems.","[{'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Fülling', 'Affiliation': 'Department of Trauma, Reconstructive and Hand Surgery, Dresden Municipal Hospital.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Bula', 'Affiliation': 'Department of Trauma and Reconstructive Surgery, Orthopaedic, Plastic, Aesthetic and Hand Surgery, Gutersloh Municipal Hospital.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Defèr', 'Affiliation': 'General Medicine, Private Practice, Dresden.'}, {'ForeName': 'Felix Alois', 'Initials': 'FA', 'LastName': 'Bonnaire', 'Affiliation': 'Department of Trauma, Reconstructive and Hand Surgery, Dresden Municipal Hospital.'}]",Zeitschrift fur Orthopadie und Unfallchirurgie,['10.1055/a-1149-9588'] 205,32434470,"GlideScope® versus C-MAC®(D) videolaryngoscope versus Macintosh laryngoscope for double lumen endotracheal intubation in patients with predicted normal airways: a randomized, controlled, prospective trial.","BACKGROUND The double lumen endotracheal tube (DLT) is the most widely-used device for single lung ventilation in current thoracic anesthesia practice. In recent years, the routine application of the videolaryngoscope for single lumen endotracheal intubation has increased; nevertheless there are few studies of the use of the videolaryngoscope for DLT. We wondered whether there were benefits to using the videolaryngoscope for DLT placement in patients with predicted normal airways. Therefore, this study was designed to compare the performances of the GlideScope®, the C-MAC®(D) videolaryngoscope and the Macintosh laryngoscope in DLT intubation. METHODS This was a randomized, controlled, prospective study. We randomly allocated 90 adult patients with predicted normal airways into three groups. All patients underwent routine anesthesia using different laryngoscopes according to group allocation. We compared DLT insertion times, first-pass success rates, numerical rating scales (NRS) of DLT delivery and DLT insertion, Cormack-Lehane degrees (C/L), hemodynamic changes and incidences of intubation complications. All outcomes were analyzed using SPSS13.0. RESULTS Compared with the GlideScope, the Macintosh gave shorter times for DLT insertion (median: 96 (IQR: 51 [min-max: 62-376] s vs 73 (26 [48-419] s, p = 0.003); however, there was no difference between the Macintosh and C-MAC(D) (p = 0.610). The Macintosh had a significantly higher successful first attempt rate than did the GlideScope or C-MAC(D) (p = 0.001, p = 0.028, respectively). NRS of DLT delivery and insertion were significantly lower in the Macintosh than in the others (p < 0.001). However, the C/L degree in the Macintosh was significantly higher than in the others (p < 0.001). The incidences of oral bleeding, hoarseness, sore throat and dental trauma were low in all groups (p > 0.05). There were no significant differences in DLT misplacement, fiberoptic time or hemodynamic changes among the groups. CONCLUSIONS Compared with the Macintosh laryngoscope, the GlideScope® and C-MAC®(D) videolaryngoscopes may not be recommended as the first choice for routine DLT intubation in patients with predicted normal airways. TRIAL REGISTRATION The study was prospectively registered at the Chinese Clinical Trial Registry (no. ChiCTR1900025718); principal investigator: Z.L.H.; date of registration: September 6, 2019.",2020,The Macintosh had a significantly higher successful first attempt rate than did the GlideScope or C-MAC(D),"['90 adult patients with predicted normal airways into three groups', 'patients with predicted normal airways']","['C-MAC®(D', 'routine anesthesia', 'GlideScope® versus C-MAC®(D) videolaryngoscope versus Macintosh laryngoscope', 'double lumen endotracheal tube (DLT']","['incidences of oral bleeding, hoarseness, sore throat and dental trauma', 'DLT misplacement, fiberoptic time or hemodynamic changes', 'DLT insertion times, first-pass success rates, numerical rating scales (NRS) of DLT delivery and DLT insertion, Cormack-Lehane degrees (C/L), hemodynamic changes and incidences of intubation complications', 'NRS of DLT delivery and insertion', 'successful first attempt rate']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0009545', 'cui_str': 'Active C5b6789'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C3164607', 'cui_str': 'Videolaryngoscope'}, {'cui': 'C0180453', 'cui_str': 'Laryngoscope'}, {'cui': 'C2584423', 'cui_str': 'Double lumen tracheobronchial tube'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0029163', 'cui_str': 'Bleeding from mouth'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}, {'cui': 'C1301685', 'cui_str': 'Dental trauma'}, {'cui': 'C2584423', 'cui_str': 'Double lumen tracheobronchial tube'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0444693', 'cui_str': 'First pass'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1504364', 'cui_str': 'Intubation complication'}, {'cui': 'C1272703', 'cui_str': 'Successful'}]",90.0,0.0618911,The Macintosh had a significantly higher successful first attempt rate than did the GlideScope or C-MAC(D),"[{'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.'}, {'ForeName': 'Renlong', 'Initials': 'R', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.'}, {'ForeName': 'Zhixing', 'Initials': 'Z', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.'}, {'ForeName': 'Yannan', 'Initials': 'Y', 'LastName': 'Hang', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.'}, {'ForeName': 'Shanjuan', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China. Shanjuanwang@shsmu.edu.cn.'}, {'ForeName': 'Zhenling', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China. Zhenlinghuang@shsmu.edu.cn.'}]",BMC anesthesiology,['10.1186/s12871-020-01012-y'] 206,32045616,Predictors of overall and test-specific colorectal Cancer screening adherence.,"This study investigated predictors of overall and test-specific colorectal cancer screening (CRCS). Stool blood test (SBT) and/or colonoscopy screening were offered to primary care patients in two randomized controlled trials which assessed the impact of behavioral interventions on screening. Data were obtained through surveys and electronic medical records. Among 1942 participants, 646 (33%) screened. Exposure to interventions was associated with higher overall CRCS by twofold to threefold; older age, African American race, being married, and having a higher screening decision stage were also associated with higher overall CRCS (odds ratios = 1.30, 1.31, 1.34, and 5.59, respectively). Intervention, older age, female gender, and being married were associated with higher SBT adherence, while preference for colonoscopy was associated with lower SBT adherence. Intervention and higher decision stage were associated with higher colonoscopy adherence, while preference for SBT was associated with lower colonoscopy adherence. Among older individuals, African Americans had higher overall CRCS than whites, but this was not true among younger individuals (interaction p = .041). The higher screening adherence of African Americans over whites was due to stronger screening with a non-preferred test, i.e., higher SBT adherence only among individuals who preferred colonoscopy and higher colonoscopy adherence only among individuals who preferred SBT. Intervention exposure, sociodemographic background, and screening decision stage predicted overall CRCS adherence. Gender and test preference also affected test-specific screening adherence. Interactions involving race and test preference suggest that it is important to provide both colonoscopy and SBT screening options to patients, particularly African Americans.",2020,"Intervention and higher decision stage were associated with higher colonoscopy adherence, while preference for SBT was associated with lower colonoscopy adherence.","['1942 participants, 646 (33%) screened', 'patients, particularly African Americans', 'older individuals, African Americans', 'African Americans over whites']","['specific colorectal cancer screening (CRCS', 'Stool blood test (SBT) and/or colonoscopy screening']","['SBT adherence', 'overall CRCS', 'overall CRCS adherence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0018941', 'cui_str': 'Blood Tests'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0329383,"Intervention and higher decision stage were associated with higher colonoscopy adherence, while preference for SBT was associated with lower colonoscopy adherence.","[{'ForeName': 'Constantine', 'Initials': 'C', 'LastName': 'Daskalakis', 'Affiliation': 'Thomas Jefferson University, Department of Pharmacology & Experimental Therapeutics, Division of Biostatistics, United States of America. Electronic address: constantine.daskalakis@jefferson.edu.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'DiCarlo', 'Affiliation': 'Thomas Jefferson University, Department of Medical Oncology, Division of Population Science, United States of America.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Hegarty', 'Affiliation': 'Thomas Jefferson University, Department of Pharmacology & Experimental Therapeutics, Division of Biostatistics, United States of America.'}, {'ForeName': 'Anuragh', 'Initials': 'A', 'LastName': 'Gudur', 'Affiliation': 'Drexel University College of Medicine, United States of America.'}, {'ForeName': 'Sally W', 'Initials': 'SW', 'LastName': 'Vernon', 'Affiliation': 'University of Texas School of Public Health, Center for Health Promotion and Prevention Research, Division of Health Promotion and Behavioral Sciences, United States of America.'}, {'ForeName': 'Ronald E', 'Initials': 'RE', 'LastName': 'Myers', 'Affiliation': 'Thomas Jefferson University, Department of Medical Oncology, Division of Population Science, United States of America.'}]",Preventive medicine,['10.1016/j.ypmed.2020.106022'] 207,31508861,An Evidence-Based Model for Disseminating-Implementing Coordinated Anxiety Learning and Management in Department of Veterans Affairs' Community-Based Outpatient Clinics.,"PURPOSE To explore the feasibility and utility of using a workshop, and supervision-consultation plus external facilitation to disseminate and implement cognitive-behavioral therapy in Veterans Affairs (VA) community-based outpatient clinics (CBOCs). METHODS This study occurred in the context of a randomized controlled trial aimed at comparing 2 methods for implementing Coordinated Anxiety Learning Management (CALM) in VA CBOCs. A 3-phase (workshop, supervision-consultation, external facilitation) model was used to support 32 VA CBOC mental health providers in learning and adopting CALM in their clinical practice. Qualitative data describe training activities and the feasibility and utility of each training phase in addressing challenges to adopting CALM. FINDINGS All 3 phases of the model were feasible to use with our sample of CBOC mental health providers. Providers reported challenges learning CALM during the workshop and concerns about not having enough training post-workshop to use CALM in practice. Providers primarily utilized supervision-consultation to tailor CALM to their practice, including learning how to prioritize a target disorder, ""switch"" the focus of treatment to a different disorder when comorbidities were present, and modify CALM sessions to fit shorter treatment visits. Providers primarily utilized external facilitation to further tailor CALM to their practice through implementation (eg, concrete help) and support-oriented help. Key lessons for implementing CALM in CBOCs are presented and discussed. CONCLUSIONS Findings provide initial evidence for the feasibility and utility of using each component of a facilitation-enhanced training model to promote CBOC VA providers' implementation of a computer and manual version of CALM in their practice.",2020,"A 3-phase (workshop, supervision-consultation, external facilitation) model was used to support 32 VA CBOC mental health providers in learning and adopting CALM in their clinical practice.",['Veterans Affairs (VA) community-based outpatient clinics (CBOCs'],"['implementing Coordinated Anxiety Learning Management (CALM', 'workshop, and supervision-consultation plus external facilitation to disseminate and implement cognitive-behavioral therapy']",[],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}]","[{'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0234112', 'cui_str': 'Facilitation, function (observable entity)'}, {'cui': 'C0205221', 'cui_str': 'Disseminated (qualifier value)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]",[],,0.0174379,"A 3-phase (workshop, supervision-consultation, external facilitation) model was used to support 32 VA CBOC mental health providers in learning and adopting CALM in their clinical practice.","[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Cucciare', 'Affiliation': 'Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Affairs Healthcare System, North Little Rock, Arkansas.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Marchant', 'Affiliation': 'Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Affairs Healthcare System, North Little Rock, Arkansas.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Lindsay', 'Affiliation': 'Houston Veterans Affairs Health Services Research and Development Service Center for Innovations in Quality, Effectiveness, and Safety, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas.'}, {'ForeName': 'Michelle G', 'Initials': 'MG', 'LastName': 'Craske', 'Affiliation': 'Department of Psychology, University of California-Los Angeles, Los Angeles, California.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Ecker', 'Affiliation': 'Houston Veterans Affairs Health Services Research and Development Service Center for Innovations in Quality, Effectiveness, and Safety, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Day', 'Affiliation': 'Houston Veterans Affairs Health Services Research and Development Service Center for Innovations in Quality, Effectiveness, and Safety, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas.'}, {'ForeName': 'Julianna', 'Initials': 'J', 'LastName': 'Hogan', 'Affiliation': 'Houston Veterans Affairs Health Services Research and Development Service Center for Innovations in Quality, Effectiveness, and Safety, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Henn', 'Affiliation': 'VA Texas Valley Coastal Bend Health Care System, Harlingen, Texas.'}, {'ForeName': 'Richard T', 'Initials': 'RT', 'LastName': 'LeBeau', 'Affiliation': 'Department of Psychology, University of California-Los Angeles, Los Angeles, California.'}, {'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Rabalais', 'Affiliation': 'VA North Texas Health Care System, Dallas, Texas.'}, {'ForeName': 'Raphael D', 'Initials': 'RD', 'LastName': 'Rose', 'Affiliation': 'Department of Psychology, University of California-Los Angeles, Los Angeles, California.'}, {'ForeName': 'Mason', 'Initials': 'M', 'LastName': 'Qualls', 'Affiliation': 'Harvard South Shore Psychiatry Residency Training Program, Brockton, Massachusetts.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Treanor', 'Affiliation': 'Department of Psychology, Anxiety and Depression Research Center, University of California-Los Angeles, Los Angeles, California.'}, {'ForeName': 'Traci H', 'Initials': 'TH', 'LastName': 'Abraham', 'Affiliation': 'Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Affairs Healthcare System, North Little Rock, Arkansas.'}]",The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association,['10.1111/jrh.12398'] 208,32434495,Effect of sevoflurane and propofol on tourniquet-induced endothelial damage: a pilot randomized controlled trial for knee-ligament surgery.,"BACKGROUND The glycocalyx layer is a key structure in the endothelium. Tourniquet-induced ischemic periods are used during orthopedic surgery, and the reactive oxygen species generated after ischemia-reperfusion may mediate the shedding of the glycocalyx. Here, we describe the effects of tourniquet-induced ischemia-reperfusion and compare the effects of sevoflurane and propofol on the release of endothelial biomarkers after ischemia-reperfusion in knee-ligament surgery. METHODS This pilot, single-center, blinded, randomized, controlled trial included 16 healthy patients. After spinal anesthesia, hypnosis was achieved with sevoflurane or propofol according to randomization. During the perioperative period, five venous blood samples were collected for quantification of syndecan-1, heparan sulfate, and thrombomodulin from blood serum by using ELISA assays kits. Sample size calculation was performed to detect a 25% change in the mean concentration of syndecan-1 with an alpha of 0.05 and power of 80%. RESULTS For our primary outcome, a two-way ANOVA with post-hoc Bonferroni correction analysis showed no differences in syndecan-1 concentrations between the sevoflurane and propofol groups at any time point. In the sevoflurane group, we noted an increase in syndecan-1 concentrations 90 min after tourniquet release in the sevoflurane group from 34.6 ± 24.4 ng/mL to 47.9 ± 29.8 ng/mL (Wilcoxon test, p < 0.01) that was not observed in patients randomized to the propofol group. The two-way ANOVA showed no intergroup differences in heparan sulfate and thrombomodulin levels. CONCLUSIONS Superficial endothelial damage without alterations in the cell layer integrity was observed after tourniquet knee-ligament surgery. There was no elevation in serum endothelial biomarkers in the propofol group patients. Sevoflurane did not show the protective effect observed in in vitro and in vivo studies. TRIAL REGISTRATION The trial was registered in www.clinicaltrials.gov (ref: NCT03772054, Registered 11 December 2018).",2020,"In the sevoflurane group, we noted an increase in syndecan-1 concentrations 90 min after tourniquet release in the sevoflurane group from 34.6 ± 24.4 ng/mL to 47.9 ± 29.8 ng/mL (Wilcoxon test, p < 0.01) that was not observed in patients randomized to the propofol group.","['16 healthy patients', 'knee-ligament surgery']","['sevoflurane and propofol', 'tourniquet-induced ischemia-reperfusion', 'sevoflurane', 'propofol', 'sevoflurane or propofol', 'Sevoflurane']","['syndecan-1 concentrations 90\u2009min after tourniquet release', 'endothelial biomarkers', 'cell layer integrity', 'syndecan-1 concentrations', 'serum endothelial biomarkers', 'heparan sulfate and thrombomodulin levels', 'tourniquet-induced endothelial damage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0023685', 'cui_str': 'Structure of ligament'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}]","[{'cui': 'C0753253', 'cui_str': 'SDC1 protein, human'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0412803', 'cui_str': 'Tourniquet release'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0019143', 'cui_str': 'Heparan sulfate'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0010957', 'cui_str': 'Damage'}]",16.0,0.215818,"In the sevoflurane group, we noted an increase in syndecan-1 concentrations 90 min after tourniquet release in the sevoflurane group from 34.6 ± 24.4 ng/mL to 47.9 ± 29.8 ng/mL (Wilcoxon test, p < 0.01) that was not observed in patients randomized to the propofol group.","[{'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Maldonado', 'Affiliation': 'Department of Anesthesia and Perioperative Medicine. Hospital Clínico de la Universidad de Chile. Faculty of Medicine, Universidad de Chile, Santiago, Chile.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Morales', 'Affiliation': 'Program of Cellular and Molecular Biology, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, Universidad de Chile, Santiago, Chile.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Gutiérrez', 'Affiliation': 'Department of Anesthesia and Perioperative Medicine. Hospital Clínico de la Universidad de Chile. Faculty of Medicine, Universidad de Chile, Santiago, Chile.'}, {'ForeName': 'Maximiliano', 'Initials': 'M', 'LastName': 'Barahona', 'Affiliation': 'Department of Orthopaedic Surgery, Faculty of Medicine, Universidad de Chile, Santiago, Chile.'}, {'ForeName': 'Oscar', 'Initials': 'O', 'LastName': 'Cerda', 'Affiliation': 'Program of Cellular and Molecular Biology, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, Universidad de Chile, Santiago, Chile.'}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'Cáceres', 'Affiliation': 'Program of Cellular and Molecular Biology, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, Universidad de Chile, Santiago, Chile. monicacaceres@med.uchile.cl.'}]",BMC anesthesiology,['10.1186/s12871-020-01030-w'] 209,29936923,"Selenium supplementation lowers insulin resistance and markers of cardio-metabolic risk in patients with congestive heart failure: a randomised, double-blind, placebo-controlled trial.","This study was carried out to evaluate the effects of Se supplementation on metabolic profiles in patients with congestive heart failure (CHF). This randomised double-blind, placebo-controlled trial was performed among fifty-three subjects with CHF, aged 45-85 years old. Subjects were randomly allocated into two groups to take either 200 µg/d of Se as Se yeast (n 26) or placebo (n 27) for 12 weeks. Metabolic profiles were assessed at baseline and at the end of trial. Compared with the placebo, Se supplementation led to significant reductions in serum insulin (-18·41 (sd 27·53) v. +13·73 (sd 23·63) pmol/l, P<0·001), homoeostatic model of assessment for insulin resistance (-1·01 (sd 1·61) v. +0·55 (sd 1·20), P<0·001) and a significant increase in quantitative insulin sensitivity check index (QUICKI) (+0·007 (sd 0·03) v. -0·01 (sd 0·01), P=0·007). In addition, Se supplementation significantly decreased LDL-cholesterol (-0·23 (sd 0·29) v. -0·04 (sd 0·28) mmol/l, P=0·03) and total-:HDL-cholesterol ratio (-0·47 (sd 0·31) v. -0·06 (sd 0·42), P<0·001), and significantly increased HDL-cholesterol levels (+0·18 (sd 0·19) v. +0·02 (sd 0·13) mmol/l, P=0·001) compared with the placebo. In addition, taking Se supplements was associated with a significant reduction in high-sensitivity C-reactive protein (hs-CRP) (-1880·8 (sd 3437·5) v. +415·3 (sd 2116·5) ng/ml, P=0·01), and a significant elevation in plasma total antioxidant capacity (TAC) (+30·9 (sd 118·0) v. -187·9 (sd 412·7) mmol/l, P=0·004) and total glutathione levels (+33·7 (sd 130·4) v. -39·2 (sd 132·8) µmol/l, P=0·003) compared with the placebo. When we applied Bonferroni correction for multiple outcome testing, QUICKI (P=0·11), LDL-cholesterol (P=0·51), hs-CRP (P=0·17), TAC (P=0·06) and GSH (P=0·05) became non-significant, and other metabolic profiles did not alter. Overall, our study supported that Se supplementation for 12 weeks to patients with CHF had beneficial effects on insulin metabolism and few markers of cardio-metabolic risk.",2018,"ng/ml, P=0·01), and a significant elevation in plasma total antioxidant capacity (TAC) (","['patients with congestive heart failure', 'fifty-three subjects with CHF, aged 45-85 years old', 'patients with congestive heart failure (CHF']","['Se supplementation', 'Selenium supplementation', 'placebo', 'placebo, Se supplementation']","['total glutathione levels', 'quantitative insulin sensitivity check index (QUICKI) ', 'high-sensitivity C-reactive protein (hs-CRP) (-1880·8 (sd 3437·5', 'serum insulin (-18·41 (sd 27·53', 'total-:HDL-cholesterol ratio', 'QUICKI (P=0·11), LDL-cholesterol (P=0·51), hs-CRP (P=0·17), TAC (P=0·06) and GSH', 'LDL-cholesterol', 'Metabolic profiles', 'insulin resistance and markers of cardio-metabolic risk', 'metabolic profiles', 'plasma total antioxidant capacity (TAC) ', 'HDL-cholesterol levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure (disorder)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}]",53.0,0.613225,"ng/ml, P=0·01), and a significant elevation in plasma total antioxidant capacity (TAC) (","[{'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Raygan', 'Affiliation': '1Department of Cardiology,School of Medicine,Kashan University of Medical Sciences,Kashan, PO Box 8715988141,Iran.'}, {'ForeName': 'Milad', 'Initials': 'M', 'LastName': 'Behnejad', 'Affiliation': '1Department of Cardiology,School of Medicine,Kashan University of Medical Sciences,Kashan, PO Box 8715988141,Iran.'}, {'ForeName': 'Vahidreza', 'Initials': 'V', 'LastName': 'Ostadmohammadi', 'Affiliation': '2Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan, PO Box 8715988141,Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': '2Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan, PO Box 8715988141,Iran.'}, {'ForeName': 'Mohammad A', 'Initials': 'MA', 'LastName': 'Mansournia', 'Affiliation': '3Department of Epidemiology and Biostatistics,School of Public Health,Tehran University of Medical Sciences,Tehran, PO Box 141556446,Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Karamali', 'Affiliation': '2Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan, PO Box 8715988141,Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': '2Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan, PO Box 8715988141,Iran.'}]",The British journal of nutrition,['10.1017/S0007114518001253'] 210,31518174,Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.,"PURPOSE The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy. PATIENTS AND METHODS We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor-positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy. Ovarian function was assessed every 6 months for 2 years since enrollment on the basis of follicular-stimulating hormone levels and vaginal bleeding history. If ovarian function was confirmed to be premenopausal at each visit, the patient was randomly assigned to complete 5 years of TAM alone (TAM-only) group or 5 years of TAM with OFS for 2 years that involved monthly goserelin administration (TAM + OFS) group. DFS was defined from the time of enrollment to the time of the first event. RESULTS A total of 1,293 patients were randomly assigned, and 1,282 patients were eligible for analysis. The estimated 5-year DFS rate was 91.1% in the TAM + OFS group and 87.5% in the TAM-only group (hazard ratio, 0.69; 95% CI, 0.48 to 0.97; P = .033). The estimated 5-year overall survival rate was 99.4% in the TAM + OFS group and 97.8% in the TAM-only group (hazard ratio, 0.31; 95% CI, 0.10 to 0.94; P = .029). CONCLUSION The addition of 2 years of OFS to TAM significantly improved DFS compared with TAM alone in patients who remained premenopausal or resumed ovarian function after chemotherapy.",2020,"The estimated 5-year DFS rate was 91.1% in the TAM + OFS group and 87.5% in the TAM-only group (hazard ratio, 0.69; 95% CI, 0.48 to 0.97; P = .033).","['Premenopausal Breast Cancer', 'patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy', 'patients who remained premenopausal or resumed ovarian function after chemotherapy', 'We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor-positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy', '1,293 patients were randomly assigned, and 1,282 patients were eligible for analysis', 'premenopausal patients with breast cancer after completion of']","['ovarian function suppression (OFS', 'TAM alone (TAM-only) group or 5 years of TAM with OFS for 2 years that involved monthly goserelin administration (TAM + OFS', 'TAM + OFS', 'OFS to TAM', 'chemotherapy', 'TAM', 'Tamoxifen', 'tamoxifen (TAM']","['disease-free survival (DFS', '5-year DFS rate', '5-year overall survival rate', 'DFS', 'Ovarian function']","[{'cui': 'C0741682', 'cui_str': 'Premenopausal breast cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2938924', 'cui_str': 'Oestrogen receptor positive breast cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}, {'cui': 'C0016712', 'cui_str': ""Freund's Adjuvant""}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0120107', 'cui_str': 'Goserelin'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}]","[{'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0031843', 'cui_str': 'function'}]",1293.0,0.181147,"The estimated 5-year DFS rate was 91.1% in the TAM + OFS group and 87.5% in the TAM-only group (hazard ratio, 0.69; 95% CI, 0.48 to 0.97; P = .033).","[{'ForeName': 'Hyun-Ah', 'Initials': 'HA', 'LastName': 'Kim', 'Affiliation': 'Korea Cancer Center Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Jong Won', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': 'Asan Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Seok Jin', 'Initials': 'SJ', 'LastName': 'Nam', 'Affiliation': 'Samsung Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Byeong-Woo', 'Initials': 'BW', 'LastName': 'Park', 'Affiliation': 'Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Seock-Ah', 'Initials': 'SA', 'LastName': 'Im', 'Affiliation': 'Seoul National University Hospital Seoul, Republic of Korea.'}, {'ForeName': 'Eun Sook', 'Initials': 'ES', 'LastName': 'Lee', 'Affiliation': 'National Cancer Center, Goyang, Republic of Korea.'}, {'ForeName': 'Yong Sik', 'Initials': 'YS', 'LastName': 'Jung', 'Affiliation': 'Ajou University, Suwon, Republic of Korea.'}, {'ForeName': 'Jung Han', 'Initials': 'JH', 'LastName': 'Yoon', 'Affiliation': 'Chonnam National University Hwasun Hospital, Gwangju, Republic of Korea.'}, {'ForeName': 'Sung Soo', 'Initials': 'SS', 'LastName': 'Kang', 'Affiliation': ""Cheil General Hospital and Women's Healthcare Center, Seoul, Republic of Korea.""}, {'ForeName': 'Soo-Jung', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Yeungnam University Hospital, Daegu, Republic of Korea.'}, {'ForeName': 'Kyong Hwa', 'Initials': 'KH', 'LastName': 'Park', 'Affiliation': 'Korea University Anam Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Joon', 'Initials': 'J', 'LastName': 'Jeong', 'Affiliation': 'Gangnam Severance Hospital, Seoul, Republic or Korea.'}, {'ForeName': 'Se-Heon', 'Initials': 'SH', 'LastName': 'Cho', 'Affiliation': 'Dong-A University Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Sung Yong', 'Initials': 'SY', 'LastName': 'Kim', 'Affiliation': 'Soonchunhyang University College of Medicine, Cheonan, Republic of Korea.'}, {'ForeName': 'Lee Su', 'Initials': 'LS', 'LastName': 'Kim', 'Affiliation': 'Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.'}, {'ForeName': 'Byung-In', 'Initials': 'BI', 'LastName': 'Moon', 'Affiliation': ""Ewha Woman's University Mokdong Hospital, Seoul, Republic of Korea.""}, {'ForeName': 'Min Hyuk', 'Initials': 'MH', 'LastName': 'Lee', 'Affiliation': 'Soonchunhyang University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Tae Hyun', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': 'Inje University Busan Paik Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Chanheun', 'Initials': 'C', 'LastName': 'Park', 'Affiliation': 'Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sung Hoo', 'Initials': 'SH', 'LastName': 'Jung', 'Affiliation': 'Chonbuk National University Medical School, Jeonju, Republic of Korea.'}, {'ForeName': 'Geumhee', 'Initials': 'G', 'LastName': 'Gwak', 'Affiliation': 'Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Jeryong', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Chungnam National University Hospital, Daejeon, Republic of Korea.'}, {'ForeName': 'Sun Hee', 'Initials': 'SH', 'LastName': 'Kang', 'Affiliation': 'Keimyung University School of Medicine, Daegu, Republic of Korea.'}, {'ForeName': 'Young Woo', 'Initials': 'YW', 'LastName': 'Jin', 'Affiliation': 'Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.'}, {'ForeName': 'Hee Jeong', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Asan Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Se-Hwan', 'Initials': 'SH', 'LastName': 'Han', 'Affiliation': 'Ajou University, Suwon, Republic of Korea.'}, {'ForeName': 'Wonshik', 'Initials': 'W', 'LastName': 'Han', 'Affiliation': 'Seoul National University, Seoul, Republic of Korea.'}, {'ForeName': 'Min Hee', 'Initials': 'MH', 'LastName': 'Hur', 'Affiliation': 'Inha University, Incheon, Republic of Korea.'}, {'ForeName': 'Woo Chul', 'Initials': 'WC', 'LastName': 'Noh', 'Affiliation': 'Korea Cancer Center Hospital, Seoul, Republic of Korea.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.00126'] 211,32062872,Are People Sensitive to Problems in Communication?,"Recent research indicates that interpersonal communication is noisy, and that people exhibit considerable insensitivity to problems in communication. Using a dyadic referential communication task, the goal of which is accurate information transfer, this study examined the extent to which interlocutors are sensitive to problems in communication and use other-initiated repairs (OIRs) to address them. Participants were randomly assigned to dyads (N = 88 participants, or 44 dyads) and tried to communicate a series of recurring abstract geometric shapes to a partner across a text-chat interface. Participants alternated between directing (describing shapes) and matching (interpreting shape descriptions) roles across 72 trials of the task. Replicating prior research, over repeated social interactions communication success improved and the shape descriptions became increasingly efficient. In addition, confidence in having successfully communicated the different shapes increased over trials. Importantly, matchers were less confident on trials in which communication was unsuccessful, communication success was lower on trials that contained an OIR compared to those that did not contain an OIR, and OIR trials were associated with lower Director Confidence. This pattern of results demonstrates that (a) interlocutors exhibit (a degree of) sensitivity to problems in communication, (b) they appropriately use OIRs to address problems in communication, and (c) OIRs signal problems in communication.",2020,Participants alternated between directing (describing shapes) and matching (interpreting shape descriptions) roles across 72 trials of the task.,[],[],['communication success'],[],[],"[{'cui': 'C0009452', 'cui_str': 'Communication'}]",88.0,0.0499751,Participants alternated between directing (describing shapes) and matching (interpreting shape descriptions) roles across 72 trials of the task.,"[{'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Micklos', 'Affiliation': 'Language and Cognition Department, Max Planck Institute for Psycholinguistics.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Walker', 'Affiliation': 'School of Psychological Sciences, University of Western Australia.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Fay', 'Affiliation': 'School of Psychological Sciences, University of Western Australia.'}]",Cognitive science,['10.1111/cogs.12816'] 212,32429839,Sevoflurane versus PRopofol combined with Remifentanil anesthesia Impact on postoperative Neurologic function in supratentorial Gliomas (SPRING): protocol for a randomized controlled trial.,"BACKGROUND Patients with intracranial tumors are more sensitive to anesthetics than the general population and are therefore more susceptible to postoperative neurologic and neurocognitive dysfunction. Sevoflurane or propofol combined with remifentanil are widely used general anesthetic regimens for craniotomy, with neither regimen shown to be superior to the other in terms of neuroprotective efficacy and anesthesia quality. There is no evidence regarding the variable effects on postoperative neurologic and neurocognitive functional outcome under these two general anesthetic regimens. This trial will compare inhalational sevoflurane or intravenous propofol combined with remifentanil anesthesia in patients with supratentorial gliomas and test the hypothesis that postoperative neurologic function is equally affected between the two regimens. METHODS This is a prospective, single-center, randomized parallel arm equivalent clinical trial, which is approved by China Ethics Committee of Registering Clinical Trials (ChiECRCT-20,160,051). Patients with supratentorial gliomas diagnosed by magnetic resonance imaging will be eligible for the trial. Written informed consent will be obtained before randomly assigning each subject to either the sevoflurane-remifentanil or propofol-remifentanil group for anesthesia maintenance to achieve an equal-desired depth of anesthesia. Intraoperative intervention and monitoring will follow a standard anesthetic management protocol. All of the physiological parameters and other medications administered during the intervention will be recorded. The primary outcome will be neurologic function change assessed by National Institute of Health Stroke Scale (NIHSS) within 4 h after general anesthesia when observer's assessment of alertness/sedation (OAA/S) reaches 4. Secondary outcomes will include NIHSS and modified NIHSS change 1 and 2 days after general anesthesia, hemodynamic stability, intraoperative brain relaxation, quality of anesthesia emergence, quality of anesthesia recovery, postoperative cognitive function, postoperative pain, postoperative neurologic complications, as well as perioperative medical expense. DISCUSSION This randomized equivalency trial will primarily compare the impacts of sevoflurane-remifentanil and propofol-remifentanil anesthesia on short-term postoperative neurologic function in patients with supratentorial gliomas undergoing craniotomy. The exclusion criteria are strict to ensure that the groups are comparable in all aspects. Repeated and routine neurologic evaluations after operation are always important to evaluate neurosurgical patients' recovery and any newly presenting complications. The results of this trial would help specifically to interpret anesthetic residual effects on postoperative outcomes, and perhaps would help the anesthesiologist to select the optimal anesthetic regimen to minimize its impact on neurologic function in this specific patient population. TRIAL REGISTRATION The study was registered and approved by the Chinese Clinical Trial Registry (Chinese Clinical Trial Registry, ChiCTR-IOR-16009177). Principle investigator: Nan Lin (email address: linnan127@gmail.com) and Ruquan Han (email address: hanrq666@aliyun.com) Date of Registration: September 8th, 2016. Country of recruitment: China.",2020,The primary outcome will be neurologic function change assessed by National Institute of Health Stroke Scale (NIHSS) within 4 h after general anesthesia when observer's assessment of alertness/sedation (OAA/S) reaches 4.,"['patients with supratentorial gliomas', 'patients with supratentorial gliomas undergoing craniotomy', 'supratentorial Gliomas (SPRING', 'Patients with supratentorial gliomas diagnosed by', 'Patients with intracranial tumors']","['Intraoperative intervention', 'propofol combined with remifentanil anesthesia', 'hanrq666@aliyun.com', 'Sevoflurane', 'inhalational sevoflurane', 'Remifentanil anesthesia', 'sevoflurane-remifentanil or propofol-remifentanil', 'magnetic resonance imaging', 'sevoflurane-remifentanil and propofol-remifentanil anesthesia', 'Lin (email address: linnan127@gmail.com) and Ruquan Han (email address', 'PRopofol', 'Sevoflurane or propofol combined with remifentanil']","['postoperative Neurologic function', ""neurologic function change assessed by National Institute of Health Stroke Scale (NIHSS) within 4\u2009h after general anesthesia when observer's assessment of alertness/sedation (OAA/S) reaches 4"", 'postoperative neurologic function', 'postoperative neurologic and neurocognitive functional outcome', 'NIHSS and modified NIHSS change 1 and 2 days after general anesthesia, hemodynamic stability, intraoperative brain relaxation, quality of anesthesia emergence, quality of anesthesia recovery, postoperative cognitive function, postoperative pain, postoperative neurologic complications, as well as perioperative medical expense']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441938', 'cui_str': 'Supratentorial'}, {'cui': 'C0017638', 'cui_str': 'Glioma'}, {'cui': 'C0010280', 'cui_str': 'Craniotomy'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1527390', 'cui_str': 'Intracranial tumor'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0574448', 'cui_str': 'Lingala language'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0641339', 'cui_str': 'hexaaquanickel(II) chlorate'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}]",,0.123406,The primary outcome will be neurologic function change assessed by National Institute of Health Stroke Scale (NIHSS) within 4 h after general anesthesia when observer's assessment of alertness/sedation (OAA/S) reaches 4.,"[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xing', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Lin', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China. linnan127@gmail.com.'}, {'ForeName': 'Ruquan', 'Initials': 'R', 'LastName': 'Han', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China. Hanrq666@aliyun.com.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Bebawy', 'Affiliation': 'Departments of Anesthesiology & Neurological Surgery, Northwestern University Feinberg School of Medicine, 251 E. Huron St., F5-704, Chicago, IL, 60611, USA.'}, {'ForeName': 'Yuming', 'Initials': 'Y', 'LastName': 'Peng', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China.'}, {'ForeName': 'Jiaxin', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China.'}, {'ForeName': 'Xiaoyuan', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Dong', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zeng', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China.'}, {'ForeName': 'Manyu', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China.'}, {'ForeName': 'Lanyi', 'Initials': 'L', 'LastName': 'Nie', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, China.'}]",BMC anesthesiology,['10.1186/s12871-020-01035-5'] 213,32493276,The effect of intraoperative lidocaine infusion on opioid consumption and pain after totally extraperitoneal laparoscopic inguinal hernioplasty: a randomized controlled trial.,"BACKGROUND As a component of multimodal analgesia, the administration of systemic lidocaine is a well-known technique. We aimed to evaluate the efficacy of lidocaine infusion on postoperative pain-related outcomes in patients undergoing totally extraperitoneal (TEP) laparoscopies inguinal hernioplasty. METHODS In this randomized controlled double-blind study, we recruited 64 patients to receive either lidocaine 2% (intravenous bolus 1.5 mg. kg - 1 followed by an infusion of 2 mg. kg - 1 . h - 1 ), or an equal volume of normal saline. The infusion was initiated just before the induction of anesthesia and discontinued after tracheal extubation. The primary outcome of the study was postoperative morphine equivalent consumption up to 24 h after surgery. Secondary outcomes included postoperative pain scores, nausea/vomiting (PONV), sedation, quality of recovery (scores based on QoR-40 questionnaire), patient satisfaction, and the incidence of chronic pain. RESULTS The median (IQR) cumulative postoperative morphine equivalent consumption in the first 24 h was 0 (0-1) mg in the lidocaine group and 4 [1-8] mg in the saline group (p < 0.001). Postoperative pain intensity at rest and during movement at various time points in the first 24 h were significantly lower in the lidocaine group compared with the saline group (p < 0.05). Fewer patients reported PONV in the lidocaine group than in the saline group (p < 0.05). Median QoR scores at 24 h after surgery were significantly better in the lidocaine group (194 (194-196) than saline group 184 (183-186) (p < 0.001). Patients receiving lidocaine were more satisfied with postoperative analgesia than those receiving saline (p = 0.02). No difference was detected in terms of postoperative sedation and chronic pain after surgery. CONCLUSIONS Intraoperative lidocaine infusion for laparoscopic TEP inguinal hernioplasty reduces opioid consumption, pain intensity, PONV and improves the quality of recovery and patient satisfaction. TRIAL REGISTRATION ClinicalTrials.gov- NCT02601651. Date of registration: November 10, 2015.",2020,Median QoR scores at 24 h after surgery were significantly better in the lidocaine group (194 (194-196) than saline group 184 (183-186) (p < 0.001).,"['patients undergoing totally extraperitoneal (TEP) laparoscopies inguinal hernioplasty', '64 patients to receive either', 'after totally extraperitoneal laparoscopic inguinal hernioplasty']","['lidocaine infusion', 'lidocaine', 'intraoperative lidocaine infusion', 'lidocaine 2% (intravenous bolus 1.5\u2009mg']","['postoperative morphine equivalent consumption', 'satisfied with postoperative analgesia', 'postoperative pain scores, nausea/vomiting (PONV), sedation, quality of recovery (scores based on QoR-40 questionnaire), patient satisfaction, and the incidence of chronic pain', 'median (IQR) cumulative postoperative morphine', 'postoperative pain-related outcomes', 'PONV', 'opioid consumption, pain intensity, PONV and improves the quality of recovery and patient satisfaction', 'Median QoR scores', 'opioid consumption and pain', 'Postoperative pain intensity', 'equivalent consumption', 'postoperative sedation and chronic pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442090', 'cui_str': 'Extraperitoneal'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C4284593', 'cui_str': 'Inguinal hernioplasty'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C3844012', 'cui_str': '1.5'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",,0.699271,Median QoR scores at 24 h after surgery were significantly better in the lidocaine group (194 (194-196) than saline group 184 (183-186) (p < 0.001).,"[{'ForeName': 'Anup', 'Initials': 'A', 'LastName': 'Ghimire', 'Affiliation': 'Department of Anesthesiology, Nepal Mediciti Hospital, Lalitpur, Nepal.'}, {'ForeName': 'Asish', 'Initials': 'A', 'LastName': 'Subedi', 'Affiliation': 'Department of Anesthesiology & Critical Care Medicine, BP Koirala Institute of Health Sciences, Dharan, Nepal. asishsubedi19@gmail.com.'}, {'ForeName': 'Balkrishna', 'Initials': 'B', 'LastName': 'Bhattarai', 'Affiliation': 'Department of Anesthesiology & Critical Care Medicine, BP Koirala Institute of Health Sciences, Dharan, Nepal.'}, {'ForeName': 'Birendra Prasad', 'Initials': 'BP', 'LastName': 'Sah', 'Affiliation': 'Department of Anesthesiology & Critical Care Medicine, BP Koirala Institute of Health Sciences, Dharan, Nepal.'}]",BMC anesthesiology,['10.1186/s12871-020-01054-2'] 214,31859438,Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial.,"AIMS We compared long-term clinical outcomes between patients treated with Orsiro sirolimus-eluting stent (O-SES) and those treated with durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent (R-ZES). METHODS AND RESULTS The ORIENT trial was a randomized controlled noninferiority trial to compare angiographic outcomes between O-SES and R-ZES. We performed a post hoc analysis of 3-year clinical outcomes and included 372 patients who were prospectively enrolled and randomly assigned to O-SES (n = 250) and R-ZES (n = 122) groups in a 2:1 ratio. The primary endpoint was target lesion failure defined as a composite of cardiac death, nonfatal myocardial infarction, and target lesion revascularization. At 3 years, target lesion failure occurred in 4.7% and 7.8% of O-SES and R-ZES groups, respectively (hazard ratio, 0.58; 95% confidence intervals, 0.24-1.41; p = .232 by log-rank test). Secondary endpoints including cardiac death, myocardial infarction, and target lesion revascularization showed no significant differences between the groups. Stent thrombosis occurred in two patients in R-ZES group (0.0% vs. 1.6%, p = .040). CONCLUSION This study confirms long-term safety and efficacy of the two stents. We found a trend for lower target lesion failure with O-SES compared to R-ZES, although statistically insignificant.",2020,"We found a trend for lower target lesion failure with O-SES compared to R-ZES, although statistically insignificant.","['372 patients who were prospectively enrolled and randomly assigned to', 'patients treated with']","['durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent (R-ZES', 'O-SES', 'R-ZES', 'Orsiro sirolimus-eluting stent (O-SES', 'O-SES and R-ZES', 'biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent']","['cardiac death, myocardial infarction, and target lesion revascularization', 'target lesion failure defined as a composite of cardiac death, nonfatal myocardial infarction, and target lesion revascularization', 'Stent thrombosis', 'target lesion failure']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0032521', 'cui_str': 'Polymers'}, {'cui': 'C1947912', 'cui_str': 'Integrity (attribute)'}, {'cui': 'C1700035', 'cui_str': 'zotarilumus'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0020205', 'cui_str': 'Hybrids'}]","[{'cui': 'C0376297', 'cui_str': 'Cardiac Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}]",372.0,0.14226,"We found a trend for lower target lesion failure with O-SES compared to R-ZES, although statistically insignificant.","[{'ForeName': 'Soo-Hyun', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Si-Hyuck', 'Initials': 'SH', 'LastName': 'Kang', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Joo Myung', 'Initials': 'JM', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Woo-Young', 'Initials': 'WY', 'LastName': 'Chung', 'Affiliation': 'Department of Internal Medicine, Boramae Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Jin Joo', 'Initials': 'JJ', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Chang-Hwan', 'Initials': 'CH', 'LastName': 'Yoon', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Jung-Won', 'Initials': 'JW', 'LastName': 'Suh', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Young-Seok', 'Initials': 'YS', 'LastName': 'Cho', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Joon-Hyung', 'Initials': 'JH', 'LastName': 'Doh', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Jin Man', 'Initials': 'JM', 'LastName': 'Cho', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.'}, {'ForeName': 'Jang-Whan', 'Initials': 'JW', 'LastName': 'Bae', 'Affiliation': 'Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Republic of Korea.'}, {'ForeName': 'Tae-Jin', 'Initials': 'TJ', 'LastName': 'Youn', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'In-Ho', 'Initials': 'IH', 'LastName': 'Chae', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.'}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.28654'] 215,30962103,"A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.","BACKGROUND & AIMS Despite the wide spectrum of experimental compounds tested in clinical trials, there is still no proven pharmacological treatment available for Fragile-X syndrome (FXS), since several targeted clinical trials with high expectations of success have failed to demonstrate significant improvements. Here we tested epigallocatechin-3-gallate (EGCG) as a treatment option for ameliorating core cognitive and behavioral features in FXS. METHODS We conducted preclinical studies in Fmr1 knockout mice (Fmr1-/y) using novel object-recognition memory paradigm upon acute EGCG (10 mg/kg) administration. Furthermore we conducted a double-blind placebo-controlled phase I clinical trial (TESXF; NCT01855971). Twenty-seven subjects with FXS (18-55 years) were administered of EGCG (5-7 mg/kg/day) combined with cognitive training (CT) during 3 months with 3 months of follow-up after treatment discontinuation. RESULTS Preclinical studies showed an improvement in memory using the Novel Object Recognition paradigm. We found that FXS patients receiving EGCG + CT significantly improved cognition (visual episodic memory) and functional competence (ABAS II-Home Living skills) in everyday life compared to subjects receiving Placebo + CT. CONCLUSIONS Phase 2 clinical trials in larger groups of subjects are necessary to establish the therapeutic potential of EGCG for the improvement of cognition and daily life competences in FXS.",2020,"We found that FXS patients receiving EGCG + CT significantly improved cognition (visual episodic memory) and functional competence (ABAS II-Home Living skills) in everyday life compared to subjects receiving Placebo + CT. ","['Twenty-seven subjects with FXS (18-55 years', 'adults with Fragile X syndrome']","['placebo', 'EGCG\xa0+\xa0CT', 'Placebo', 'epigallocatechin-3-gallate (EGCG', 'epigallocatechin-3-gallate and cognitive training', 'cognitive training (CT', 'EGCG']","['safety and efficacy', 'cognition (visual episodic memory) and functional competence (ABAS II-Home Living skills) in everyday life']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0016667', 'cui_str': 'X-Linked Mental Retardation and Macroorchidism'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0059438', 'cui_str': 'epigallocatechin gallate'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0561843', 'cui_str': 'Autobiographical Memory'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",27.0,0.363616,"We found that FXS patients receiving EGCG + CT significantly improved cognition (visual episodic memory) and functional competence (ABAS II-Home Living skills) in everyday life compared to subjects receiving Placebo + CT. ","[{'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'de la Torre', 'Affiliation': 'IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain; CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN), E-08003 Barcelona, Spain; University Pompeu Fabra (CEXS-UPF), E-08003 Barcelona, Spain. Electronic address: rtorre@imim.es.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'de Sola', 'Affiliation': 'IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain; CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN), E-08003 Barcelona, Spain.'}, {'ForeName': 'Magí', 'Initials': 'M', 'LastName': 'Farré', 'Affiliation': 'Autonomous University of Barcelona (UDIMAS-UAB), E-08003 Barcelona, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Xicota', 'Affiliation': 'IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain; CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN), E-08003 Barcelona, Spain.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Cuenca-Royo', 'Affiliation': 'IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain; CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN), E-08003 Barcelona, Spain.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Rodriguez', 'Affiliation': 'IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain; CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN), E-08003 Barcelona, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'León', 'Affiliation': 'Neurofunctionality of Brain and Language Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Langohr', 'Affiliation': 'IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain; Polytechnic University of Catalonia, E-08034 Barcelona, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Gomis-González', 'Affiliation': 'University Pompeu Fabra (CEXS-UPF), E-08003 Barcelona, Spain.'}, {'ForeName': 'Gimena', 'Initials': 'G', 'LastName': 'Hernandez', 'Affiliation': 'IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain; CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN), E-08003 Barcelona, Spain.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Esteba', 'Affiliation': ""Parc Hospitalari Martí í Julià-Institut d'Assistència Sanitària, E-17190 Salt, Spain.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Del Hoyo', 'Affiliation': 'IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain; CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN), E-08003 Barcelona, Spain.'}, {'ForeName': 'Júdit', 'Initials': 'J', 'LastName': 'Sánchez-Gutiérrez', 'Affiliation': 'Fundació Privada Espai Salut, Corporación Fisiogestión, E-08009 Barcelona, Spain.'}, {'ForeName': 'Maria José', 'Initials': 'MJ', 'LastName': 'Cortés', 'Affiliation': 'Intellectual Disabilities and Developmental Disorders Research Unit (UNIVIDD), Fundació Villablanca, IISPV, URV, CIBERSAM, E-43206, Reus, Spain.'}, {'ForeName': 'Andrés', 'Initials': 'A', 'LastName': 'Ozaita', 'Affiliation': 'University Pompeu Fabra (CEXS-UPF), E-08003 Barcelona, Spain.'}, {'ForeName': 'Josep María', 'Initials': 'JM', 'LastName': 'Espadaler', 'Affiliation': 'Neurofunctionality of Brain and Language Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Novell', 'Affiliation': ""Parc Hospitalari Martí í Julià-Institut d'Assistència Sanitària, E-17190 Salt, Spain.""}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Martínez-Leal', 'Affiliation': 'Intellectual Disabilities and Developmental Disorders Research Unit (UNIVIDD), Fundació Villablanca, IISPV, URV, CIBERSAM, E-43206, Reus, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Milá', 'Affiliation': 'Biochemistry and Molecular Genetics Department, Hospital Clínic I Provincial de Barcelona, E-08036, Spain.'}, {'ForeName': 'Mara', 'Initials': 'M', 'LastName': 'Dierssen', 'Affiliation': 'IMIM-Hospital del Mar Medical Research Institute, E-08003 Barcelona, Spain; University Pompeu Fabra (CEXS-UPF), E-08003 Barcelona, Spain; Center for Genomic Regulation (CRG), E-08003 Barcelona, Spain; CIBER of Rare Diseases (CIBERER), E-08003 Barcelona, Spain; The Barcelona Institute of Science and Technology, E-08003 Barcelona, Spain. Electronic address: mara.dierssen@crg.eu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.02.028'] 216,32434204,"A Prospective, Randomized, Open-Label Trial of Atorvastatin versus Rosuvastatin in the Prevention of Contrast-Induced Acute Kidney Injury, Worsened Renal Function at 30 Days, and Clinical Events After Acute Coronary Angiography: the PRATO-ACS-2 Study.","BACKGROUND/AIMS Both high-dose atorvastatin and rosuvastatin have been shown to reduce contrast-induced acute kidney injury (AKI) occurrence and improve clinical outcomes in high-risk coronary patients undergoing angiographic procedures. However, there is a lack of head-to-head comparative studies on the effects of atorvastatin or rosuvastatin administered upon hospital admission in statin-naive patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS). METHODS In this open-label, noninferiority study, we compared changes in renal function in 709 NSTE-ACS patients randomized to atorvastatin (80 mg upon admission followed by 40 mg/day) or rosuvastatin (40 mg upon admission followed by 20 mg/day). The primary end point was AKI (increase in serum creatinine ≥0.5 mg/dL or ≥25% above baseline within 72 h). Worsening renal function (WRF) (decrease of ≥25% in the glomerular filtration rate from baseline to 30 days), 30-day major adverse cardiovascular events, and 12-month myocardial infarction (MI) or death were also evaluated. RESULTS The AKI incidence was similar in the 2 groups (i.e., 8.2% with rosuvastatin and 7.6% with atorvastatin; absolute risk difference = 0.54; 90% CI -3.9 to 2.8), satisfying the noninferiority criteria. WRF occurred in 53 (7.5%) patients, 19 (34%) of whom had developed AKI. The rates of WRF and adverse events at 30 days and at 12 months did not differ significantly between the 2 groups. Both AKI and WRF were found to be closely associated with the 12-month cardiovascular outcome irrespectively of statin choice. CONCLUSIONS High-dose rosuvastatin or atorvastatin started upon hospital admission led to similar rates of AKI, 30-day renal function changes, and 12-month death or MI in NSTE-ACS patients who underwent an early invasive strategy (clinical trial registration: https://www.clinicaltrials.gov; unique identifier: NCT01870804).",2020,The rates of WRF and adverse events at 30 days and at 12 months did not differ significantly between the 2 groups.,"['709 NSTE-ACS patients randomized to', 'statin-naive patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS', 'high-risk coronary patients undergoing angiographic procedures']","['Atorvastatin versus Rosuvastatin', 'atorvastatin', 'rosuvastatin', 'rosuvastatin or atorvastatin', 'atorvastatin and rosuvastatin', 'atorvastatin or rosuvastatin']","['Worsening renal function (WRF', 'rates of AKI, 30-day renal function changes, and 12-month death or MI', '30-day major adverse cardiovascular events, and 12-month myocardial infarction (MI) or death', 'rates of WRF and adverse events', 'AKI (increase in serum creatinine ≥0.5', 'WRF', 'AKI incidence']","[{'cui': 'C3160886', 'cui_str': 'Non ST segment elevation acute coronary syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}]","[{'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",,0.044536,The rates of WRF and adverse events at 30 days and at 12 months did not differ significantly between the 2 groups.,"[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Toso', 'Affiliation': 'Division of Cardiology, Santo Stefano Hospital, Prato, Italy, anna.toso@libero.it.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Leoncini', 'Affiliation': 'Division of Cardiology, Santo Stefano Hospital, Prato, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Maioli', 'Affiliation': 'Division of Cardiology, Santo Stefano Hospital, Prato, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Tropeano', 'Affiliation': 'Division of Cardiology, Santo Stefano Hospital, Prato, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Villani', 'Affiliation': 'Section of Biostatistics and Clinical Epidemiology, Department of Public Health, Neurosciences, Experimental and Forensic Medicine, Pavia University, Pavia, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Bellandi', 'Affiliation': 'Division of Cardiology, Santo Stefano Hospital, Prato, Italy.'}]",Cardiorenal medicine,['10.1159/000506857'] 217,31453826,Electronic interventions aimed at increasing self-worth in mild dementia may not be feasible.,"ABSTRACT Alzheimer disease (AD) is a devastating diagnosis. Milieu therapy and memory activities have been shown to improve self-worth and improve mood in AD patients, but adherence to these activities is challenging. This prospective randomized pilot study examined adherence to memory recall activities using positive reinforcement and explored the impact on self-worth and depression. Pretest-posttest scores and data abstraction were used to measure protocol adherence, self-worth (Rosenberg Self-Esteem Scale), cognitive decline (Mini-Mental Status Examination), and symptoms of depression (Geriatric Depression Scale). Among 22 mild AD participants, there were no statistically significant differences in pretest versus posttest scores for all measures. The results suggest that the intervention of memory recall did not enhance self-worth, improve the status of memory recall, or lower symptoms of depression. Additionally, positive reinforcement did not play a role in adherence to accessing the tasks.",2021,"The results suggest that the intervention of memory recall did not enhance self-worth, improve the status of memory recall, or lower symptoms of depression.",['22 mild AD participants'],[],"['protocol adherence, self-worth (Rosenberg Self-Esteem Scale), cognitive decline (Mini-Mental Status Examination), and symptoms of depression (Geriatric Depression Scale', 'status of memory recall, or lower symptoms of depression']","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}]",[],"[{'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0582666', 'cui_str': 'Rosenberg self-esteem scale (assessment scale)'}, {'cui': 'C0234985', 'cui_str': 'Cognitive Decline'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0451184', 'cui_str': 'Geriatric depression scale (assessment scale)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0679063', 'cui_str': 'Memory recall'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]",,0.0407177,"The results suggest that the intervention of memory recall did not enhance self-worth, improve the status of memory recall, or lower symptoms of depression.","[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Martinez', 'Affiliation': 'Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Sonja E', 'Initials': 'SE', 'LastName': 'Stutzman', 'Affiliation': ""O'Donnell Brain Institute, The University of Texas Southwestern Medical Center, Dallas, Texas.""}, {'ForeName': 'DaiWai M', 'Initials': 'DM', 'LastName': 'Olson', 'Affiliation': 'Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, Texas.'}]",Journal of the American Association of Nurse Practitioners,['10.1097/JXX.0000000000000280'] 218,32498637,Influence of an Exergaming Training Program on Reducing the Expression of IL-10 and TGF-β in Cancer Patients.,"Objective: To evaluate the effect of exergaming in the plasma levels of adipokines (interleukin [IL]-1β, IL-6, IL-8, and tumor necrosis factor-alpha [TNF-α]), Th1 (IL-2, IL-12, and interferon gamma [IFN-γ]), Th2 (IL-4 and IL-33), Th17 (IL-17 and IL-23), and regulatory T (Treg) (IL-10 and transforming growth factor-beta [TGF-β]) in cancer patients undergoing treatment. Materials and Methods: We conducted a quasi-experimental control clinical trial using exergaming in all groups through the Xbox 360 Kinect™. The game used in this study was called Your Shape Fitness Evolved 2012 . The volunteer participants played the game two to three times per week, for a total of 20 sessions. Forty-five volunteer participants were divided into 3 groups: cancer patients undergoing chemotherapy and/or radiotherapy treatment (chemotherapy and/or radiotherapy group CRG; n  = 15); cancer patients who finished chemotherapy and/or radiotherapy treatment (cancer accompaniment group CAG; n  = 15); and the control group (volunteers without a cancer diagnosis CG; n  = 15). In the pre- and post-training period, all volunteers submitted to blood collection procedures using the enzyme-linked immunosorbent assay (ELISA). This test was used to obtain the levels of adipokines expression (IL-1β, IL-6, IL-8, and TNF-α) and the cytokine profiles Th1 (IL-2, IL-12, and IFN-γ), Th2 (IL-4 and IL-33), Th17 (IL-17 and IL-23), and Treg (IL-10 and TGF-β). Results: After exergaming, the CRG showed significant reductions in proinflammatory cytokines (IL-6: P  < 0.05; IL-10: P  = 0.038; TGF-β: P  = 0.049) and for CAG (IL-10: P  = 0.034), as well as a reduction in the expression of cytokines related to the action of T lymphocytes. Conclusion: Exergaming promoted changes in the expression of cytokine profiles IL-6, IL-10, and TGF-β, which correlated with the action profiles of CD4 + T lymphocytes.",2020,"Exergaming promoted changes in the expression of cytokine profiles IL-6, IL-10, and TGF-β, which correlated with the action profiles of CD4 + T lymphocytes.","['Cancer Patients', 'Forty-five volunteer participants were divided into 3 groups: cancer patients undergoing', 'all groups through the Xbox 360 Kinect™', 'cancer patients undergoing treatment']","['chemotherapy and/or radiotherapy treatment (chemotherapy and/or radiotherapy group CRG; n \u2009=\u200915); cancer patients who finished chemotherapy and/or radiotherapy treatment (cancer accompaniment group CAG; n \u2009=\u200915); and the control group (volunteers without a cancer diagnosis CG', 'Exergaming Training Program', 'IL-10 and transforming growth factor-beta [TGF-β']","['expression of cytokine profiles IL-6, IL-10, and TGF-β', 'levels of adipokines expression (IL-1β, IL-6, IL-8, and TNF-α) and the cytokine profiles Th1 (IL-2, IL-12, and IFN-γ), Th2 (IL-4 and IL-33), Th17 (IL-17 and IL-23), and Treg (IL-10 and TGF-β', 'plasma levels of adipokines (interleukin [IL]-1β, IL-6, IL-8, and tumor necrosis factor-alpha [TNF-α]), Th1 (IL-2, IL-12, and interferon gamma [IFN-γ', 'IL-4 and IL-33), Th17 (IL-17 and IL-23), and regulatory T (Treg', 'proinflammatory cytokines', 'Expression of IL-10 and TGF-β']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1706059', 'cui_str': 'Finish'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0040690', 'cui_str': 'Platelet Transforming Growth Factor'}, {'cui': 'C0040691', 'cui_str': 'Transforming Growth Factor'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0040691', 'cui_str': 'Transforming Growth Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1955907', 'cui_str': 'Adipokine'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021756', 'cui_str': 'Interleukin-2'}, {'cui': 'C0123759', 'cui_str': 'Interleukin-12'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C1667752', 'cui_str': 'IL33 protein, human'}, {'cui': 'C2936411', 'cui_str': 'T Helper 17 Cells'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0963088', 'cui_str': 'IL-23'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0021745', 'cui_str': 'Interferon Type II'}, {'cui': 'C0220905', 'cui_str': 'regulations'}]",45.0,0.0339559,"Exergaming promoted changes in the expression of cytokine profiles IL-6, IL-10, and TGF-β, which correlated with the action profiles of CD4 + T lymphocytes.","[{'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'da Silva Alves', 'Affiliation': 'Bioscience Program, Federal University of Alfenas, Alfenas, Brazil.'}, {'ForeName': 'Douglas Reis', 'Initials': 'DR', 'LastName': 'Abdalla', 'Affiliation': 'Health Sciences, Humans Talents Faculty and University of Uberaba, Uberaba, Brazil.'}, {'ForeName': 'Denise Hollanda', 'Initials': 'DH', 'LastName': 'Iunes', 'Affiliation': 'Motricity Science Institute, and Federal University of Alfenas, Alfenas, Brazil.'}, {'ForeName': 'Karina Oliveira Prado', 'Initials': 'KOP', 'LastName': 'Mariano', 'Affiliation': 'Rehabilitation Science Program, Federal University of Alfenas, Alfenas, Brazil.'}, {'ForeName': 'Juliana Bassalobre Carvalho', 'Initials': 'JBC', 'LastName': 'Borges', 'Affiliation': 'Motricity Science Institute, and Federal University of Alfenas, Alfenas, Brazil.'}, {'ForeName': 'Eddie Fernando Cândido', 'Initials': 'EFC', 'LastName': 'Murta', 'Affiliation': 'Institute of Oncology Research, Federal University of Triângulo Mineiro, Uberaba, Brazil.'}, {'ForeName': 'Márcia Antoniazi', 'Initials': 'MA', 'LastName': 'Michelin', 'Affiliation': 'Institute of Oncology Research, Federal University of Triângulo Mineiro, Uberaba, Brazil.'}, {'ForeName': 'Leonardo César', 'Initials': 'LC', 'LastName': 'Carvalho', 'Affiliation': 'Bioscience Program, Federal University of Alfenas, Alfenas, Brazil.'}]",Games for health journal,['10.1089/g4h.2020.0022'] 219,32493372,Comparison of intrathecal morphine with continuous patient-controlled epidural anesthesia versus intrathecal morphine alone for post-cesarean section analgesia: a randomized controlled trial.,"BACKGROUND Several neuraxial techniques have demonstrated effective post-cesarean section analgesia. According to previous reports, it is likely that patient-controlled epidural analgesia (PCEA) without opioids is inferior to intrathecal morphine (IM) alone for post-cesarean section analgesia. However, little is known whether adding PCEA to IM is effective or not. The aim of this study was to compare post-cesarean section analgesia between IM with PCEA and IM alone. METHODS Fifty patients undergoing elective cesarean section were enrolled in this prospective randomized study. Patients were randomized to one of two groups: IM group and IM + PCEA group. All patients received spinal anesthesia with 12 mg of 0.5% hyperbaric bupivacaine, 10 μg of fentanyl, and 150 μg of morphine. Patients in IM + PCEA group received epidural catheterization through Th11-12 or Th12-L1 before spinal anesthesia and PCEA (basal 0.167% levobupivacaine infusion rate of 6 mL/h, bolus dose of 3 mL in lockout interval of 30 min) was commenced at the end of surgery. A numerical rating scale (NRS) at rest and on movement at 4,8,12,24,48 h after the intrathecal administration of morphine were recorded. In addition, we recorded the incidence of delayed ambulation and the number of patients who requested rescue analgesics. We examined NRS using Bonferroni's multiple comparison test following repeated measures analysis of variance; p < 0.05 was considered as statistically significant. RESULTS Twenty-three patients in each group were finally analyzed. Mean NRS at rest was significantly higher in IM group than in IM + PCEA group at 4 (2.7 vs 0.6), 8 (2.2 vs 0.6), and 12 h (2.5 vs 0.7), and NRS during mobilization was significantly higher in IM group than in IM + PCEA group at 4 (4.9 vs 1.5), 8 (4.8 vs 1.9), 12 (4.9 vs 2), and 24 h (5.7 vs 3.5). The number of patients who required rescue analgesics during the first 24 h was significantly higher in IM group compared to IM + PCEA group. No significant difference was observed between the groups in incidence of delayed ambulation. CONCLUSIONS The combined use of PCEA with IM provided better post-cesarean section analgesia compared to IM alone. TRIAL REGISTRATION UMIN-CTR (Registration No. UMIN000032475). Registered 6 May 2018 - Retrospectively registered.",2020,The number of patients who required rescue analgesics during the first 24 h was significantly higher in IM group compared to IM + PCEA group.,"['Fifty patients undergoing elective cesarean section', 'post-cesarean section analgesia']","['PCEA and IM alone', 'PCEA', 'IM group and IM\u2009+\u2009PCEA', 'morphine', 'intrathecal morphine alone', 'epidural catheterization through Th11-12 or Th12-L1 before spinal anesthesia and PCEA (basal 0.167% levobupivacaine', 'intrathecal morphine', 'IM\u2009+\u2009PCEA', 'spinal anesthesia with 12\u2009mg of 0.5% hyperbaric bupivacaine']","['numerical rating scale (NRS', 'Mean NRS at rest', 'incidence of delayed ambulation', 'NRS during mobilization', 'delayed ambulation and the number of patients who requested rescue analgesics']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C1301707', 'cui_str': 'Patient controlled epidural analgesia'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}]",50.0,0.0935582,The number of patients who required rescue analgesics during the first 24 h was significantly higher in IM group compared to IM + PCEA group.,"[{'ForeName': 'Izumi', 'Initials': 'I', 'LastName': 'Sato', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Asahikawa Medical University, Midorigaoka-higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Iwasaki', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Asahikawa Medical University, Midorigaoka-higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan. iwasakih@asahikawa-med.ac.jp.'}, {'ForeName': 'Sarah Kyuragi', 'Initials': 'SK', 'LastName': 'Luthe', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Asahikawa Medical University, Midorigaoka-higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Iida', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Asahikawa Medical University, Midorigaoka-higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Hirotsugu', 'Initials': 'H', 'LastName': 'Kanda', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Asahikawa Medical University, Midorigaoka-higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan.'}]",BMC anesthesiology,['10.1186/s12871-020-01050-6'] 220,32498606,Non-invasive brain stimulation in Stroke patients (NIBS): A prospective randomized open blinded end-point (PROBE) feasibility trial using transcranial direct current stimulation (tDCS) in post-stroke hemispatial neglect.,"Up to 80% of people who experience a right-hemisphere stroke suffer from hemispatial neglect. This syndrome is debilitating and impedes rehabilitation. We carried out a clinical feasibility trial of transcranial direct current stimulation (tDCS) and a behavioural rehabilitation programme, alone or in combination, in patients with neglect. Patients >4 weeks post right hemisphere stroke were randomized to 10 sessions of tDCS, 10 sessions of a behavioural intervention, combined intervention, or a control task. Primary outcomes were recruitment and retention rates, with secondary outcomes effect sizes on measures of neglect and quality of life, assessed directly after the interventions, and at 6 months follow up. Of 288 confirmed stroke cases referred (representing 7% of confirmed strokes), we randomized 8% (0.6% of stroke cases overall). The largest number of exclusions (91/288 (34%)) were due to medical comorbidities that prevented patients from undergoing 10 intervention sessions. We recruited 24 patients over 29 months, with 87% completing immediate post-intervention and 67% 6 month evaluations. We established poor feasibility of a clinical trial requiring repeated hospital-based tDCS within a UK hospital healthcare setting, either with or without behavioural training, over a sustained time period. Future trials should consider intensity, duration and location of tDCS neglect interventions. Trial registration: ClinicalTrials.gov identifier: NCT02401724.",2021,"Patients >4 weeks post right hemisphere stroke were randomized to 10 sessions of tDCS, 10 sessions of a behavioural intervention, combined intervention, or a control task.","['24 patients over 29 months, with 87% completing immediate post-intervention and 67% 6 month evaluations', 'Patients >4 weeks post right hemisphere stroke', 'post-stroke hemispatial neglect', 'patients with neglect', 'Stroke patients (NIBS']","['transcranial direct current stimulation (tDCS', 'tDCS, 10 sessions of a behavioural intervention, combined intervention, or a control task']","['recruitment and retention rates, with secondary outcomes effect sizes on measures of neglect and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0228175', 'cui_str': 'Right cerebral hemisphere structure'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0751421', 'cui_str': 'Hemispatial Neglect'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",8.0,0.110521,"Patients >4 weeks post right hemisphere stroke were randomized to 10 sessions of tDCS, 10 sessions of a behavioural intervention, combined intervention, or a control task.","[{'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Learmonth', 'Affiliation': 'Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Christopher S Y', 'Initials': 'CSY', 'LastName': 'Benwell', 'Affiliation': 'School of Psychology, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Gesine', 'Initials': 'G', 'LastName': 'Märker', 'Affiliation': 'School of Psychology, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Dascalu', 'Affiliation': 'School of Psychology, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Checketts', 'Affiliation': 'School of Psychology, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Celestine', 'Initials': 'C', 'LastName': 'Santosh', 'Affiliation': 'Queen Elizabeth University Hospital, Glasgow, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Barber', 'Affiliation': 'University Hospital Monklands, Lanarkshire, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Walters', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Keith W', 'Initials': 'KW', 'LastName': 'Muir', 'Affiliation': 'Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Harvey', 'Affiliation': 'School of Psychology, University of Glasgow, Glasgow, UK.'}]",Neuropsychological rehabilitation,['10.1080/09602011.2020.1767161'] 221,32243493,The fallacy of indexed effective orifice area charts to predict prosthesis-patient mismatch after prosthesis implantation.,"AIMS Indexed effective orifice area (EOAi) charts are used to determine the likelihood of prosthesis-patient mismatch (PPM) after aortic valve replacement (AVR). The aim of this study is to validate whether these EOAi charts, based on echocardiographic normal reference values, can accurately predict PPM. METHODS AND RESULTS In the PERIcardial SurGical AOrtic Valve ReplacemeNt (PERIGON) Pivotal Trial, 986 patients with aortic valve stenosis/regurgitation underwent AVR with an Avalus valve. Patients were randomly split (50:50) into training and test sets. The mean measured EOAs for each valve size from the training set were used to create an Avalus EOAi chart. This chart was subsequently used to predict PPM in the test set and measures of diagnostic accuracy (sensitivity, specificity, and negative and positive predictive value) were assessed. PPM was defined by an EOAi ≤0.85 cm2/m2, and severe PPM was defined as EOAi ≤0.65 cm2/m2. The reference values obtained from the training set ranged from 1.27 cm2 for size 19 mm up to 1.81 cm2 for size 27 mm. The test set had an incidence of 66% of PPM and 24% of severe PPM. The EOAi chart inaccurately predicted PPM in 30% of patients and severe PPM in 22% of patients. For the prediction of PPM, the sensitivity was 87% and the specificity 37%. For the prediction of severe PPM, the sensitivity was 13% and the specificity 98%. CONCLUSION The use of echocardiographic normal reference values for EOAi charts to predict PPM is unreliable due to the large proportion of misclassifications.",2020,The EOAi chart inaccurately predicted PPM in 30% of patients and severe PPM in 22% of patients.,"['prosthesis-patient mismatch (PPM) after aortic valve replacement (AVR', '986 patients with aortic valve stenosis/regurgitation underwent AVR with an Avalus valve']",[],"['diagnostic accuracy (sensitivity, specificity, and negative and positive predictive value', 'PPM', 'severe PPM']","[{'cui': 'C0175649', 'cui_str': 'Prosthesis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0449217', 'cui_str': 'aVR'}, {'cui': 'C0003507', 'cui_str': 'Aortic valve stenosis'}, {'cui': 'C0232605', 'cui_str': 'Regurgitates after swallowing'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}]",[],"[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439187', 'cui_str': 'ppm'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",986.0,0.0267809,The EOAi chart inaccurately predicted PPM in 30% of patients and severe PPM in 22% of patients.,"[{'ForeName': 'Michiel D', 'Initials': 'MD', 'LastName': 'Vriesendorp', 'Affiliation': 'Cardiothoracic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands.'}, {'ForeName': 'Rob A F', 'Initials': 'RAF', 'LastName': 'De Lind Van Wijngaarden', 'Affiliation': 'Cardiothoracic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Head', 'Affiliation': 'Global Clinical Operations, Coronary and Structural Heart, Medtronic, Endepolsdomein 5, 6229 GW, Maastricht, Netherlands.'}, {'ForeName': 'Arie-Pieter', 'Initials': 'AP', 'LastName': 'Kappetein', 'Affiliation': 'Global Clinical Operations, Coronary and Structural Heart, Medtronic, Endepolsdomein 5, 6229 GW, Maastricht, Netherlands.'}, {'ForeName': 'Graeme L', 'Initials': 'GL', 'LastName': 'Hickey', 'Affiliation': 'Global Clinical Operations, Coronary and Structural Heart, Medtronic, Endepolsdomein 5, 6229 GW, Maastricht, Netherlands.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Rao', 'Affiliation': 'Cardiovascular Surgery, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, Canada.'}, {'ForeName': 'Neil J', 'Initials': 'NJ', 'LastName': 'Weissman', 'Affiliation': 'Cardiovascular Core Laboratories, MedStar Health Research Institute, 6525 Belcrest Road, Suite 700, Hyattsville, MD 20782, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Reardon', 'Affiliation': 'Cardiovascular Surgery, Houston Methodist Debakey Heart and Vascular Center, 6550 Fannin Street, Houston, TX 77030, USA.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Moront', 'Affiliation': 'Cardiothoracic Surgery, ProMedica Toledo Hospital, 2109 Hughes Drive, Suite 720, Toledo, OH 43606, USA.'}, {'ForeName': 'Joseph F', 'Initials': 'JF', 'LastName': 'Sabik', 'Affiliation': 'Cardiac Surgery, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Lakeside 7, Cleveland, OH 44106-7060, USA.'}, {'ForeName': 'Robert J M', 'Initials': 'RJM', 'LastName': 'Klautz', 'Affiliation': 'Cardiothoracic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands.'}]",European heart journal. Cardiovascular Imaging,['10.1093/ehjci/jeaa044'] 222,32496902,Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.,"PURPOSE The high-risk stratum of Children's Oncology Group Study AALL1131 was designed to test the hypothesis that postinduction CNS prophylaxis with intrathecal triple therapy (ITT) including methotrexate, hydrocortisone, and cytarabine would improve the postinduction 5-year disease-free survival (DFS) compared with intrathecal methotrexate (IT MTX), when given on a modified augmented Berlin-Frankfurt-Münster backbone. PATIENTS AND METHODS Children with newly diagnosed National Cancer Institute (NCI) high-risk B-cell acute lymphoblastic leukemia (HR B-ALL) or NCI standard-risk B-ALL with defined minimal residual disease thresholds during induction were randomly assigned to receive postinduction IT MTX or ITT. Patients with CNS3-status disease were not eligible. Postinduction IT therapy was given for a total of 21 to 26 doses. Neurocognitive assessments were performed during therapy and during 1 year off therapy. RESULTS Random assignment was closed to accrual in March 2018 after a futility boundary had been crossed, concluding that ITT could not be shown to be superior to IT MTX. The 5-year postinduction DFS and overall survival rates (± SE) of children randomly assigned to IT MTX versus ITT were 93.2% ± 2.1% v 90.6% ± 2.3% ( P = .85), and 96.3% ± 1.5% v 96.7% ± 1.4% ( P = .77), respectively. There were no differences in the cumulative incidence of isolated bone marrow relapse, isolated CNS relapse, or combined bone marrow and CNS relapse rates, or in toxicities observed for patients receiving IT MTX compared with ITT. There were no significant differences in neurocognitive outcomes for patients receiving IT MTX compared with ITT. CONCLUSION Postinduction CNS prophylaxis with ITT did not improve 5-year DFS for children with HR B-ALL. The standard of care for CNS prophylaxis for children with B-ALL and no overt CNS involvement remains IT MTX.",2020,"There were no differences in the cumulative incidence of isolated bone marrow relapse, isolated CNS relapse, or combined bone marrow and CNS relapse rates, or in toxicities observed for patients receiving IT MTX compared with ITT.","['children with B-ALL and no overt CNS involvement remains IT MTX', 'Patients with CNS3-status disease', 'Children with newly diagnosed National Cancer Institute (NCI) high-risk B-cell acute lymphoblastic leukemia (HR B-ALL) or NCI standard-risk B-ALL with defined minimal residual disease thresholds during induction']","['Intrathecal Methotrexate', 'postinduction IT MTX or ITT', 'IT MTX', 'Intrathecal Triple Therapy', 'intrathecal triple therapy (ITT) including methotrexate, hydrocortisone, and cytarabine', 'intrathecal methotrexate (IT MTX']","['cumulative incidence of isolated bone marrow relapse, isolated CNS relapse, or combined bone marrow and CNS relapse rates, or in toxicities', 'neurocognitive outcomes', '5-year DFS', 'postinduction 5-year disease-free survival (DFS', '5-year postinduction DFS and overall survival rates (± SE']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1292769', 'cui_str': 'Precursor B-cell lymphoblastic leukemia'}, {'cui': 'C0686377', 'cui_str': 'Secondary malignant neoplasm of central nervous system'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0242596', 'cui_str': 'Minimal residual disease'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0028654', 'cui_str': 'Clinical nurse specialist'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",,0.0503645,"There were no differences in the cumulative incidence of isolated bone marrow relapse, isolated CNS relapse, or combined bone marrow and CNS relapse rates, or in toxicities observed for patients receiving IT MTX compared with ITT.","[{'ForeName': 'Wanda L', 'Initials': 'WL', 'LastName': 'Salzer', 'Affiliation': 'Uniformed Services University, Bethesda, MD.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Burke', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI.""}, {'ForeName': 'Meenakshi', 'Initials': 'M', 'LastName': 'Devidas', 'Affiliation': ""Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN.""}, {'ForeName': 'Yunfeng', 'Initials': 'Y', 'LastName': 'Dai', 'Affiliation': 'Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL.'}, {'ForeName': 'Kristina K', 'Initials': 'KK', 'LastName': 'Hardy', 'Affiliation': ""Children's National Medical Center, Washington, DC.""}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Kairalla', 'Affiliation': 'Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL.'}, {'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Gore', 'Affiliation': ""Department of Pediatrics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO.""}, {'ForeName': 'Joanne M', 'Initials': 'JM', 'LastName': 'Hilden', 'Affiliation': ""Department of Pediatrics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Larsen', 'Affiliation': ""Department of Pediatrics, Maine Children's Cancer Program, Scarborough, ME.""}, {'ForeName': 'Karen R', 'Initials': 'KR', 'LastName': 'Rabin', 'Affiliation': 'Department of Pediatrics, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Patrick A', 'Initials': 'PA', 'LastName': 'Zweidler-McKay', 'Affiliation': 'ImmunoGen, Inc, Waltham, MA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Borowitz', 'Affiliation': 'Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD.'}, {'ForeName': 'Brent', 'Initials': 'B', 'LastName': 'Wood', 'Affiliation': 'Department of Laboratory Medicine, University of Washington, Seattle, WA.'}, {'ForeName': 'Nyla A', 'Initials': 'NA', 'LastName': 'Heerema', 'Affiliation': 'Department of Pathology, The Ohio State University School of Medicine, Columbus, OH.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Carroll', 'Affiliation': 'Department of Genetics, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Winick', 'Affiliation': 'Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'William L', 'Initials': 'WL', 'LastName': 'Carroll', 'Affiliation': 'Department of Pediatrics, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Raetz', 'Affiliation': 'Department of Pediatrics, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY.'}, {'ForeName': 'Mignon L', 'Initials': 'ML', 'LastName': 'Loh', 'Affiliation': ""Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.""}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Hunger', 'Affiliation': ""Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.""}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.02892'] 223,32501541,"Pharmacokinetics, safety and tolerability of long-acting parenteral intramuscular injection formulations of doravirine.","WHAT IS KNOWN AND OBJECTIVE Doravirine is a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus (HIV)-1 infection. This phase 1 study in healthy adults investigated the pharmacokinetics, safety and tolerability of long-acting parenteral (LAP) microsuspension formulations of doravirine administered as an intramuscular (IM) injection. METHODS After confirmation of tolerability and safety of oral doravirine, 36 participants were randomized 1:1:1 to receive IM doravirine 200 mg as Treatment A (1 × 1 mL, 20% [200 mg/mL] suspension), B (1 × 0.66 mL, 30% [300 mg/mL] suspension) or C (2 × 0.5 mL, 20% suspension). Blood samples were taken as venous plasma, venous dried blood spots (DBS) and fingerstick DBS. RESULTS AND DISCUSSION Plasma concentration-time profiles following IM treatments demonstrated rapid initial doravirine release, with initial peak ~4 days post-injection, followed by decline over the next ~6 days; a second peak was reached at ~24-36 days, corresponding to prolonged and sustained release, with measurable concentrations up to Day 183. Treatment C was associated with highest peak concentrations and shortest time to maximum concentration. Elimination half-lives for all IM formulations were prolonged versus oral administration (~46-58 days vs ~11-15 hours). Oral doravirine and IM doravirine were generally well tolerated; injection-site pain was the most common adverse event for IM doravirine. Doravirine concentrations from DBS samples showed strong correlations to venous plasma concentrations. WHAT IS NEW AND CONCLUSIONS Novel doravirine LAP IM injection formulations investigated in this study demonstrated sustained plasma doravirine concentrations over a course of >20 weeks.",2020,Oral doravirine and IM doravirine were generally well tolerated; injection-site pain was the most common adverse event for IM doravirine.,"['36 participants', 'human immunodeficiency virus (HIV)-1 infection', 'healthy adults']","['IM doravirine 200\xa0mg as Treatment', 'doravirine', 'oral doravirine', 'Oral doravirine and IM doravirine']","['Pharmacokinetics, safety and tolerability', 'venous plasma, venous dried blood spots (DBS) and fingerstick DBS', 'tolerated; injection-site pain', 'pharmacokinetics, safety and tolerability', 'sustained plasma doravirine concentrations', 'rapid initial doravirine release']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C4045491', 'cui_str': 'DORAVIRINE'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3838734', 'cui_str': 'Venous plasma'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0151828', 'cui_str': 'Injection site pain'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C4045491', 'cui_str': 'DORAVIRINE'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}]",36.0,0.0348717,Oral doravirine and IM doravirine were generally well tolerated; injection-site pain was the most common adverse event for IM doravirine.,"[{'ForeName': 'Ka Lai', 'Initials': 'KL', 'LastName': 'Yee', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Sachin', 'Initials': 'S', 'LastName': 'Mittal', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Fan', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Ilias', 'Initials': 'I', 'LastName': 'Triantafyllou', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Marissa F', 'Initials': 'MF', 'LastName': 'Dockendorf', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Paul H', 'Initials': 'PH', 'LastName': 'Fackler', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'S Aubrey', 'Initials': 'SA', 'LastName': 'Stoch', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Sauzanne G', 'Initials': 'SG', 'LastName': 'Khalilieh', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Iwamoto', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}]",Journal of clinical pharmacy and therapeutics,['10.1111/jcpt.13182'] 224,32502991,RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study (REDIRECT): a prospective randomized controlled trial.,"OBJECTIVE The RECO flow restoration (FR) device is a new stent retriever designed for rapid flow restoration in acute ischemic stroke (AIS) caused by large vessel occlusion (LVO). Here, the authors compared the efficacy and safety of the RECO device with the predicate Solitaire FR stent retriever. METHODS The RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study (REDIRECT) was a multicenter, prospective, open randomized controlled trial. Patients with acute LVO at 7 Chinese stroke centers participated in the study. The primary efficacy endpoint was defined as a modified thrombolysis in cerebral infarction (mTICI) reperfusion grade ≥ 2 within three passes. The primary safety endpoint comprised any serious adverse device effect, symptomatic intracerebral hemorrhage (sICH), and any serious adverse event (SAE; defined as cerebral palsy or death) within 24 hours after the procedure. The secondary efficacy endpoints consisted of functional independence (modified Rankin Scale score 0-2), procedure duration, and 90-day all-cause mortality. RESULTS Between January 2014 and August 2016, 67 patients were randomly allocated to the RECO group and 69 patients to the Solitaire FR group. The primary efficacy endpoint (mTICI grade ≥ 2 within three passes) was similar in the two treatment groups (91% vs 87%, respectively, p = 0.5861), and the rate of reperfusion with an mTICI grade 2b/3 was 87% versus 75% (p = 0.1272). There were no serious adverse device effects in any patient. The rates of sICH (1.5% vs 7.2%, p = 0.1027) and SAEs (6.0% vs 1.4%, p = 0.2050) within 24 hours after the procedure were similar in the two treatment groups. There was no significant difference in the rate of functional independence (63% vs 46%, p = 0.0609) or 90-day all-cause mortality (13% vs 23%, p = 0.1848) or in procedure duration (85.39 ± 47.01 vs 89.94 ± 53.34 minutes, p = 0.5986) between the two groups. CONCLUSIONS The RECO stent retriever is effective and safe as a mechanical thrombectomy device for AIS due to LVO. Clinical trial registration no.: NCT01983644 (clinicaltrials.gov).",2020,"There was no significant difference in the rate of functional independence (63% vs 46%, p = 0.0609) or 90-day all-cause mortality (13% vs 23%, p = 0.1848) or in procedure duration (85.39 ± 47.01 vs 89.94 ± 53.34 minutes, p = 0.5986) between the two groups. ","['Patients with acute LVO at 7 Chinese stroke centers participated in the study', 'group and 69 patients to the Solitaire FR group', 'Between January 2014 and August 2016, 67 patients']","['RECO', 'RECO flow restoration (FR) device', 'RECO Flow Restoration Device Versus Solitaire FR']","['rate of functional independence', 'rate of reperfusion with an mTICI grade', '90-day all-cause mortality', 'efficacy and safety', 'primary efficacy endpoint (mTICI grade ≥ 2 within three passes', 'functional independence (modified Rankin Scale score 0-2), procedure duration, and 90-day all-cause mortality', 'serious adverse device effects', 'SAEs', 'serious adverse device effect, symptomatic intracerebral hemorrhage (sICH), and any serious adverse event (SAE; defined as cerebral palsy or death', 'rates of sICH', 'modified thrombolysis in cerebral infarction (mTICI) reperfusion grade ≥ 2 within three passes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0225990', 'cui_str': 'Large blood vessel structure'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0326603', 'cui_str': 'Solitaire'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}]","[{'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0326603', 'cui_str': 'Solitaire'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",67.0,0.109286,"There was no significant difference in the rate of functional independence (63% vs 46%, p = 0.0609) or 90-day all-cause mortality (13% vs 23%, p = 0.1848) or in procedure duration (85.39 ± 47.01 vs 89.94 ± 53.34 minutes, p = 0.5986) between the two groups. ","[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Cao', 'Affiliation': ""1Department of Neurosurgery, The First People's Hospital of Changzhou/The Third Affiliated Hospital of Soochow University, Changzhou.""}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': '2Department of Neurology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': '2Department of Neurology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou.'}, {'ForeName': 'Kaifu', 'Initials': 'K', 'LastName': 'Ke', 'Affiliation': '3Department of Neurology, The Affiliated Hospital of Nantong University, Nantong.'}, {'ForeName': 'Yunfeng', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': '3Department of Neurology, The Affiliated Hospital of Nantong University, Nantong.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': '4Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao.'}, {'ForeName': 'Weihong', 'Initials': 'W', 'LastName': 'Zheng', 'Affiliation': '5Department of Neurology, Zhongshan Hospital of Xiamen University, Xiamen.'}, {'ForeName': 'Xingyu', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': '5Department of Neurology, Zhongshan Hospital of Xiamen University, Xiamen.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""6Department of Imaging, Yangzhou No. 1 People's Hospital, Yangzhou; and.""}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': ""7Department of CCU, Daping Hospital, Chongqing, People's Republic of China.""}, {'ForeName': 'Jinggang', 'Initials': 'J', 'LastName': 'Xuan', 'Affiliation': ""1Department of Neurosurgery, The First People's Hospital of Changzhou/The Third Affiliated Hospital of Soochow University, Changzhou.""}, {'ForeName': 'Ya', 'Initials': 'Y', 'LastName': 'Peng', 'Affiliation': ""1Department of Neurosurgery, The First People's Hospital of Changzhou/The Third Affiliated Hospital of Soochow University, Changzhou.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of neurosurgery,['10.3171/2020.3.JNS193356'] 225,32686440,[Effect of a Mediterranean-pattern diet on the metabolic response secondary to weight loss; role of the single nucleotide polymorphism (rs16147) of neuropeptide Y].,"Introduction Background and aims: intervention studies that evaluate the effect of rs16147 on metabolic response and weight change after dietary intervention are scarce. We propose to evaluate the role of the rs16147 genetic variant in the metabolic effects produced by a hypocaloric Mediterranean-pattern diet with high content of omega-9. Material and methods: a sample of 363 obese subjects was recruited. At the baseline visit the patients were randomly assigned to one of two hypocaloric diets for 12 weeks (diet M, Mediterranean pattern; diet C, standard hypocaloric). All patients, at baseline and at 12 weeks, had biochemical and anthropometric variables measured, and genotyping performed for the rs16147 variant. Results: in all subjects, and with both diets, the parameters of adiposity, blood pressure, and circulating leptin improved. In obese subjects with allele (A) insulin levels (GG vs. GA + AA) (-0.9 ± 1.1 IU/L vs. -4.4 ± 1.0 IU/L; p = 0.01) and HOMA-IR (-0.3 ± 0.1 units vs. -1.2 ± 0.3 units; p = 0.02) decreased significantly with diet M. Subjects carrying the minor allele showed a significant decrease in basal insulin levels (GG vs. GA + AA) (0.7 ± 0.3 IU/L vs. -2.2 ± 0.9 IU/L: p = 0.02) and HOMA-IR (-0.3 ± 0.2 units vs. -0.7 ± 0.1 units: p = 0.01) after diet C. This decrease in circulating insulin and HOMA-IR levels in patients with allele A was significantly higher with diet M than with diet C. Conclusions: the A allele of the rs16147 variant produces a better metabolic response in terms of insulin resistance and basal insulin secondary to weight loss with two different hypocaloric diets in obese subjects, with improvement being higher with the Mediterranean diet.",2020,"This decrease in circulating insulin and HOMA-IR levels in patients with allele A was significantly higher with diet M than with diet C. CONCLUSIONS the A allele of the rs16147 variant produces a better metabolic response in terms of insulin resistance and basal insulin secondary to weight loss with two different hypocaloric diets in obese subjects, with improvement being higher with the Mediterranean diet.","['obese subjects', 'a sample of 363 obese subjects was recruited']","['Mediterranean-pattern diet', 'hypocaloric Mediterranean-pattern diet with high content of omega-9', 'hypocaloric diets for 12 weeks (diet M, Mediterranean pattern; diet C, standard hypocaloric']","['circulating insulin and HOMA-IR levels', 'adiposity, blood pressure, and circulating leptin improved', 'basal insulin levels', 'metabolic response and weight change']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C1719844', 'cui_str': 'Omega'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",363.0,0.0271651,"This decrease in circulating insulin and HOMA-IR levels in patients with allele A was significantly higher with diet M than with diet C. CONCLUSIONS the A allele of the rs16147 variant produces a better metabolic response in terms of insulin resistance and basal insulin secondary to weight loss with two different hypocaloric diets in obese subjects, with improvement being higher with the Mediterranean diet.","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Primo Martín', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Olatz', 'Initials': 'O', 'LastName': 'Izaola Jáuregui', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Juan José', 'Initials': 'JJ', 'LastName': 'López Gómez', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Gómez Hoyos', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Ortolá Buigues', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Delgado', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Díaz', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Torres Torres', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'de Luis Román', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}]",Nutricion hospitalaria,['10.20960/nh.02941'] 226,32686444,ACYL-CoA synthetase long-chain 5 polymorphism is associated with weight loss and metabolic changes in response to a partial meal-replacement hypocaloric diet.,"Introduction Aims:to analyze the effects of the rs2419621 genetic variant of the ACSL5 gene on weight change and metabolic parameters after a partial meal-replacement hypocaloric diet. Methods: this was a non-randomized, single-treatment study with a formula-diet in 44 obese subjects with body mass index (BMI) greater than 35 kg/m2. Patients received nutritional education and a modified diet with two intakes of a normocaloric hyperproteic formula during 3 months. Anthropometric parameters and biochemical profile were measured at baseline and after 3 months. The rs2419621 variant of the ACSL5 gene was assessed using real-time polymerase chain reaction. Results: T-allele carriers showed greater improvement in body weight (CC vs. CT + TT; -7.4 ± 2.1 kg vs. -9.3 ± 1.8 kg; p = 0.01), body mass index (-3.1 ± 0.4 kg/m2 vs. -3.4 ± 0.5 kg/m2; p = 0.02), fat mass (-5.2 ± 1.4 kg vs. -6.4 ± 1.2 kg; p = 0.01) and waist circumference (-6.1 ± 1.1 cm vs. -8.6 ± 0.8 cm; p = 0.02) than non-T-allele carriers. Only subjects with the T allele showed significant improvement in triglyceride levels (-4.6 ± 2.4 md/dL vs. -14.4 ± 2.3 mg/dL; p = 0.01). Finally, improvements in insulin (-2.0 ± 0.3 mU/L vs. -4.5 ± 0.5 mU/L; p = 0.01) and HOMA-IR (-0.4 ± 0.2 units vs. -1.3 ± 0.3 units; p = 0.02) were higher in T-allele carriers than in non-T-allele carriers. Conclusions: our data suggest that the genetic variant (rs2419621) of the ACSL5 gene is associated with diet response after a partial-meal replacement intervention, with greater improvements in adiposity and biochemical parameters in subjects with the T allele.",2020,"RESULTS T-allele carriers showed greater improvement in body weight (CC vs. CT + TT; -7.4 ± 2.1 kg vs. -9.3 ± 1.8 kg; p = 0.01), body mass index (-3.1 ± 0.4 kg/m2 vs. -3.4 ± 0.5 kg/m2; p = 0.02), fat mass (-5.2 ± 1.4 kg vs. -6.4 ± 1.2 kg; p = 0.01) and waist circumference (-6.1 ± 1.1 cm vs. -8.6 ± 0.8 cm; p = 0.02) than non-T-allele carriers.","['44 obese subjects with body mass index (BMI) greater than 35 kg/m2', 'subjects with the T allele']","['formula-diet', 'nutritional education and a modified diet with two intakes of a normocaloric hyperproteic formula']","['waist circumference', 'Anthropometric parameters and biochemical profile', 'body mass index', 'body weight', 'triglyceride levels', 'HOMA-IR', 'adiposity and biochemical parameters', 'weight change and metabolic parameters']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0002085', 'cui_str': 'Genetic alleles'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0204934', 'cui_str': 'Nutrition education'}, {'cui': 'C0452264', 'cui_str': 'Therapeutic diet'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",44.0,0.114747,"RESULTS T-allele carriers showed greater improvement in body weight (CC vs. CT + TT; -7.4 ± 2.1 kg vs. -9.3 ± 1.8 kg; p = 0.01), body mass index (-3.1 ± 0.4 kg/m2 vs. -3.4 ± 0.5 kg/m2; p = 0.02), fat mass (-5.2 ± 1.4 kg vs. -6.4 ± 1.2 kg; p = 0.01) and waist circumference (-6.1 ± 1.1 cm vs. -8.6 ± 0.8 cm; p = 0.02) than non-T-allele carriers.","[{'ForeName': 'Olatz', 'Initials': 'O', 'LastName': 'Izaola Jáuregui', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Juan José', 'Initials': 'JJ', 'LastName': 'López Gómez', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Primo Martín', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Torres Torres', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Gómez Hoyos', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Ortolá Buigues', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Delgado', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'de Luis Román', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}]",Nutricion hospitalaria,['10.20960/nh.03019'] 227,32496865,Socioecological determinants of community resource utilisation among low-income women in Mexico City who experienced male-to-female intimate partner violence.,"Women who experience intimate partner violence (IPV) face multiple barriers to seeking help from community resources, but little research has examined the impact of ecological influences on community resource utilisation among women living in low- and middle-income countries. The current study investigated individual-, relationship-, family-, and community-level influences on community resource utilisation among Mexican women experiencing IPV. Using baseline data from 950 women in Mexico City enrolled in a clinic-based randomised controlled trial, multilevel regressions were performed to assess associations between socioecological factors and women's community resource utilisation. 41.3% women used at least one resource. At the individual-level, every additional resource that women were aware of, was associated with a 20% increase in the total number of resources used ( p  < .001). Every additional lethal risk factor was associated with a 5% increase in the total number of resources used ( p  = .004). At the family-level, women who reported having an in-law encourage IPV used 46% more resources ( p  < .001). At the community-level, stronger supportive norms around community resource utilisation was associated with a 6% increase in the total number of resources ( p  = .01). These findings suggest the importance of addressing family and community factors in the broader ecological context of Mexican women's help-seeking behaviours.",2020,Every additional lethal risk factor was associated with a 5% increase in the total number of resources used ( p  = .004).,"['low-income women in Mexico City who experienced male-to-female intimate partner violence', 'Mexican women experiencing IPV', 'Women who experience intimate partner violence (IPV', '950 women in Mexico City enrolled in a clinic', 'women living in low- and middle-income countries']",[],"['total number of resources', 'total number of resources used']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C4708800', 'cui_str': '950'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0454664', 'cui_str': 'Country'}]",[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0035201', 'cui_str': 'Resources'}]",950.0,0.0384717,Every additional lethal risk factor was associated with a 5% increase in the total number of resources used ( p  = .004).,"[{'ForeName': 'Tiara C', 'Initials': 'TC', 'LastName': 'Willie', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Bastida', 'Affiliation': 'Department of Psychiatry, University of California, Davis, CA, USA.'}, {'ForeName': 'Claudia Diaz', 'Initials': 'CD', 'LastName': 'Olavarrieta', 'Affiliation': 'Research Division, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Scolese', 'Affiliation': 'Department of Global and Community Health, George Mason University, Fairfax, VA, USA.'}, {'ForeName': 'Paola Abril', 'Initials': 'PA', 'LastName': 'Campos', 'Affiliation': 'Harvard TH Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Kathryn L', 'Initials': 'KL', 'LastName': 'Falb', 'Affiliation': 'International Rescue Committee, Washington, DC, USA.'}, {'ForeName': 'Jhumka', 'Initials': 'J', 'LastName': 'Gupta', 'Affiliation': 'Department of Global and Community Health, George Mason University, Fairfax, VA, USA.'}]",Global public health,['10.1080/17441692.2020.1775868'] 228,32505171,The effect of 1% glucose loading on metabolism in the elderly patients during remifentanil-induced anesthesia: a randomized controlled trial.,"BACKGROUND Previous studies showed that remifentanil-induced anesthesia can inhibit surgical stress response in non-diabetic adult patients and that low-dose glucose loading during anesthesia may attenuate fat catabolism. However, little is known about the influence of glucose loading on metabolism in elderly patients, whose condition may be influenced by decreased basal metabolism and increased insulin resistance. We hypothesized that, in elderly patients, intraoperative low glucose infusion may attenuate the catabolism of fat without causing harmful hyperglycemia during remifentanil-induced anesthesia. METHODS Elderly, non-diabetic patients scheduled to undergo elective surgery were enrolled and randomized to receive no glucose (0G group) or low-dose glucose infusion (0.1 g/kg/hr. for 1 h followed by 0.05 g/kg/hr. for 1 h; LG group) during surgery. Glucose, adrenocorticotropic hormone (ACTH), 3-methylhistidine (3-MH), insulin, cortisol, free fatty acid (FFA), creatinine (Cr), and ketone body levels were measured pre-anesthesia, 1 h post-glucose infusion, at the end of surgery, and on the following morning. RESULTS A total of 31 patients (aged 75-85) were included (0G, n = 16; LG, n = 15). ACTH levels during anesthesia decreased significantly in both groups. In the LG group, glucose levels increased significantly after glucose loading but hyperglycemia was not observed. During surgery, ketone bodies and FFA were significantly lower in the LG group than the 0G group. There were no significant differences in insulin, Cr, 3-MH, and 3-MH/Cr between the two groups. CONCLUSION Remifentanil-induced anesthesia inhibited surgical stress response in elderly patients. Intraoperative low-dose glucose infusion attenuated catabolism of fat without inducing hyperglycemia. TRIAL REGISTRATION This study has been registered with the University hospital Medical Information Network Center (http://www.umin.ac.jp/english/). TRIAL REGISTRATION NUMBER UMIN000016189. The initial registration date: January 12th 2015.",2020,"There were no significant differences in insulin, Cr, 3-MH, and 3-MH/Cr between the two groups. ","['31 patients (aged 75-85', 'elderly patients during remifentanil-induced anesthesia', 'Elderly, non-diabetic patients scheduled to undergo elective surgery', 'elderly patients', 'non-diabetic adult patients']","['Remifentanil-induced anesthesia', 'remifentanil-induced anesthesia', 'no glucose (0G group) or low-dose glucose infusion', 'glucose loading']","['Glucose, adrenocorticotropic hormone (ACTH), 3-methylhistidine (3-MH), insulin, cortisol, free fatty acid (FFA), creatinine (Cr), and ketone body levels', 'insulin, Cr, 3-MH, and 3-MH/Cr', 'glucose levels', 'ACTH levels during anesthesia', 'surgical stress response', 'hyperglycemia', 'ketone bodies and FFA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0047600', 'cui_str': '3-methyl histidine'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0022631', 'cui_str': 'Ketone body'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C0201835', 'cui_str': 'Adrenocorticotropic hormone measurement'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}]",31.0,0.0680124,"There were no significant differences in insulin, Cr, 3-MH, and 3-MH/Cr between the two groups. ","[{'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Fukuta', 'Affiliation': 'Department of Anesthesiology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan. kouhei_f_1983@yahoo.co.jp.'}, {'ForeName': 'Asuka', 'Initials': 'A', 'LastName': 'Kasai', 'Affiliation': 'Department of Anesthesiology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Niki', 'Affiliation': 'Department of Anesthesiology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Ishikawa', 'Affiliation': 'Department of Anesthesiology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.'}, {'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Kawanishi', 'Affiliation': 'Department of Anesthesiology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.'}, {'ForeName': 'Nami', 'Initials': 'N', 'LastName': 'Kakuta', 'Affiliation': 'Department of Anesthesiology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.'}, {'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Sakai', 'Affiliation': 'Department of Anesthesiology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.'}, {'ForeName': 'Yasuo M', 'Initials': 'YM', 'LastName': 'Tsutsumi', 'Affiliation': 'Department of Anesthesiology and Critical Care, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami, Hiroshima, 774-8551, Japan.'}, {'ForeName': 'Katsuya', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': 'Department of Anesthesiology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.'}]",BMC anesthesiology,['10.1186/s12871-020-01061-3'] 229,32505177,Effects of dexmedetomidine on stress hormones in patients undergoing cardiac valve replacement: a randomized controlled trial.,"BACKGROUND Stress response always occurs in cardiac valve replacement patients undergoing cardiopulmonary bypass (CPB). METHODS 60 patients undergoing cardiac valve replacement were recruited and randomized into control and Dex groups. Dex group received 1.0 μg·kg-1 of Dex for 10 min intravenously before anesthesia, followed by 0.5 μg·kg-1·h-1 of Dex, steadily administered throughout the procedure. And controlled group received the identical velocity of saline as Dex group. Plasma level of cortisol (Cor), epinephrine (E), norepinephrine (NE), and serotonin (5-HT) were evaluated at four timepoints: Before administration (T0), sawn sternum (T1), end of extracorporeal circulation (T2), and 24 h post operation (T3). General data of operation and recovery such as heart rate (HR), mean arterial pressure (MAP), intraoperative bispectral index (BIS), and hospitalization time in the intensive care unit (ICU) were also compared. RESULTS Increase of Cor, E, NE, and 5-HT for the Dex group was significant lesser than that in the control group (P < 0.05), and ICU hospitalization time and ventilator support time was significantly shorter in the Dex group. The proportion of patients discharged from the hospital with better prognosis was significantly higher than that in the control group, while there were no significant differences in hospitalization costs and vasoactive drugs use between the two groups. CONCLUSIONS Dex reduces plasma Cor, E and NE elevations in patients after CPB, alleviates the stress reaction of the body, shortens the hospitalization time and ventilator support time in ICU, and plays a positive role in the rehabilitation of patients undergoing cardiac valve replacement. TRIAL REGISTRATION China Clinical Trial Registry (No. ChiCTR-IPR-17010954) March 22rd, 2017.",2020,"Dex reduces plasma Cor, E and NE elevations in patients after CPB, alleviates the stress reaction of the body, shortens the hospitalization time and ventilator support time in ICU, and plays a positive role in the rehabilitation of patients undergoing cardiac valve replacement. ","['cardiac valve replacement patients undergoing cardiopulmonary bypass (CPB', 'patients undergoing cardiac valve replacement', '60 patients undergoing cardiac valve replacement']","['1.0\u2009μg·kg-1 of Dex', 'dexmedetomidine', 'Dex']","['heart rate (HR), mean arterial pressure (MAP), intraoperative bispectral index (BIS), and hospitalization time in the intensive care unit (ICU', 'Cor, E, NE, and 5-HT', 'proportion of patients discharged from the hospital with better prognosis', 'ICU hospitalization time and ventilator support time', 'Plasma level of cortisol (Cor), epinephrine (E), norepinephrine (NE), and serotonin (5-HT', 'hospitalization costs and vasoactive drugs use', 'plasma Cor, E and NE elevations', 'stress hormones']","[{'cui': 'C0018825', 'cui_str': 'Cardiac valve prosthesis'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}]","[{'cui': 'C0011816', 'cui_str': 'Dextromethorphan'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0278250', 'cui_str': 'Prognosis good'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C1281899', 'cui_str': 'Plasma cortisol measurement'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}]",60.0,0.070869,"Dex reduces plasma Cor, E and NE elevations in patients after CPB, alleviates the stress reaction of the body, shortens the hospitalization time and ventilator support time in ICU, and plays a positive role in the rehabilitation of patients undergoing cardiac valve replacement. ","[{'ForeName': 'Hanhua', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, No. 149 Dalian Road, Huichuan District, Zunyi, 563003, Guizhou Province, China.'}, {'ForeName': 'Jinqing', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Department of Anesthesiology, Third Affiliated Hospital of Zunyi Medical University, Zunyi, 563003, Guizhou Province, China.'}, {'ForeName': 'Jiamei', 'Initials': 'J', 'LastName': 'Pan', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, No. 149 Dalian Road, Huichuan District, Zunyi, 563003, Guizhou Province, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Han', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, No. 149 Dalian Road, Huichuan District, Zunyi, 563003, Guizhou Province, China.'}, {'ForeName': 'Huijun', 'Initials': 'H', 'LastName': 'Cai', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, No. 149 Dalian Road, Huichuan District, Zunyi, 563003, Guizhou Province, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, No. 149 Dalian Road, Huichuan District, Zunyi, 563003, Guizhou Province, China. zhzmcc@sina.com.'}]",BMC anesthesiology,['10.1186/s12871-020-00993-0'] 230,32034876,A Hands-On Organ-Slicing Activity to Teach the Cross-Sectional Anatomy.,"The presentation of pre-sliced specimens is a frequently used method in the laboratory teaching of cross-sectional anatomy. In the present study, a new teaching method based on a hands-on slicing activity was introduced into the teaching of brain, heart, and liver cross-sectional anatomy. A randomized, controlled trial was performed. A total of 182 third-year medical students were randomized into a control group taught with the prosection mode (pre-sliced organ viewing) and an experimental group taught with the dissection mode (hands-on organ slicing). These teaching methods were assessed by testing the students' knowledge of cross-sectional specimens and cross-sectional radiological images, and analyzing students' feedback. Using a specimen test on three organs (brain, heart, and liver), significant differences were observed in the mean scores of the control and experimental groups: for brain 59.6% (±14.2) vs. 70.1% (±15.5), (P < 0.001, Cohen's d = 0.17); for heart: 57.6% (±12.5) vs. 75.6% (±15.3), (P < 0.001, d = 0.30); and for liver: 60.4% (±14.5) vs. 81.7% (±14.2), (P < 0.001, d = 0.46). In a cross-sectional radiological image test, better performance was also found in the experimental group (P < 0.001). The mean scores of the control vs. experimental groups were as follows: for brain imaging 63.9% (±15.1) vs. 71.1% (±16.1); for heart imaging 64.7% (±14.5) vs. 75.2% (±15.5); and for liver imaging 61.1% (±15.5) vs. 81.2% (±14.6), respectively. The effect sizes (Cohen's d) were 0.05, 0.23, and 0.52, respectively. Students in the lower tertile benefited the most from the slicing experiences. Students' feedback was generally positive. Hands-on slicing activity can increase the effectiveness of anatomy teaching and increase students' ability to interpret radiological images.",2020,"In a cross-sectional radiological image test, better performance was also found in the experimental group (P < 0.001).",['A total of 182 third-year medical students'],['control group taught with the prosection mode (pre-sliced organ viewing) and an experimental group taught with the dissection mode (hands-on organ slicing'],['mean scores'],"[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0012737', 'cui_str': 'Dissection'}, {'cui': 'C0018563', 'cui_str': 'Hand'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0196539,"In a cross-sectional radiological image test, better performance was also found in the experimental group (P < 0.001).","[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': ""Department of Anatomy, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': ""Department of Anatomy, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'ForeName': 'Yizhi', 'Initials': 'Y', 'LastName': 'Zuo', 'Affiliation': ""Department of Anatomy, Nanjing Medical University, Nanjing, People's Republic of China.""}]",Anatomical sciences education,['10.1002/ase.1947'] 231,32180266,Combination of minimum wiping pressure and number of wipings that can remove pseudo-skin dirt: A digital image color analysis.,"BACKGROUND Excessive wiping friction in skin care may lead to skin damage. Bed baths are required to remove skin dirt without affecting the skin barrier function; the wiping pressure and number of wipings that satisfy these two requirements have not been clarified. This study aimed to determine the minimum wiping pressure and number of wipings that can remove skin dirt. MATERIALS AND METHODS In this quasi-experimental study, 50 healthy adults received an adhesion of pseudo-oily and aqueous dirt, randomly assigned to the left and right forearms. Each participant was wiped three times with wiping pressure classified into six randomly assigned categories. The dirt removal rate was calculated by color-analyzing images captured before and after each wiping, and its dependence on the combination of wiping pressure and number of wipings was assessed using a linear mixed model. RESULTS The combinations achieving oily dirt removal rates of 80% or more were wiping once and pressure ≥50 mmHg, wiping twice and pressure ≥40 mmHg, and wiping thrice and pressure ≥10 mmHg. Aqueous dirt was removed almost completely by wiping once, even with pressure ≥5 mmHg. CONCLUSION Wiping with at least 10 mmHg or more three times can sufficiently remove both oily and aqueous dirt. Dirt removal rates with weak pressure can be made about as effective as those achieved with strong pressure by increasing the number of wipings. This result can be applied to daily nursing, home care, and long-term care health facilities.",2020,Dirt removal rates with weak pressure can be made about as effective as those achieved with strong pressure by increasing the number of wipings.,['50 healthy adults'],['adhesion of pseudo-oily and aqueous dirt'],['dirt removal rate'],"[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0001511', 'cui_str': 'Tissue Adhesions'}, {'cui': 'C0205237', 'cui_str': 'False (qualifier value)'}, {'cui': 'C1563093', 'cui_str': 'Distal intermedial ridge of tibia'}]","[{'cui': 'C1563093', 'cui_str': 'Distal intermedial ridge of tibia'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}]",50.0,0.0278862,Dirt removal rates with weak pressure can be made about as effective as those achieved with strong pressure by increasing the number of wipings.,"[{'ForeName': 'Issei', 'Initials': 'I', 'LastName': 'Konya', 'Affiliation': 'Graduate School of Health Sciences, Hokkaido University, Hokkaido, Japan.'}, {'ForeName': 'Inaho', 'Initials': 'I', 'LastName': 'Shishido', 'Affiliation': 'Graduate School of Health Sciences, Hokkaido University, Hokkaido, Japan.'}, {'ForeName': 'Yoichi M', 'Initials': 'YM', 'LastName': 'Ito', 'Affiliation': 'Research Center for Medical and Health Data Science, Institute of Statistical Mathematics, Tokyo, Japan.'}, {'ForeName': 'Rika', 'Initials': 'R', 'LastName': 'Yano', 'Affiliation': 'Faculty of Health Sciences, Hokkaido University, Hokkaido, Japan.'}]",Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI),['10.1111/srt.12844'] 232,25281353,Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study.,"BACKGROUND Low circulating concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, are associated with an increased risk of type 2 diabetes, but whether this association is causal remains unclear. We aimed to estimate the unconfounded, causal association between 25(OH)D concentration and risk of type 2 diabetes using a mendelian randomisation approach. METHODS Using several data sources from populations of European descent, including type 2 diabetes cases and non-cases, we did a mendelian randomisation analysis using single nucleotide polymorphisms (SNPs) within or near four genes related to 25(OH)D synthesis and metabolism: DHCR7 (related to vitamin D synthesis), CYP2R1 (hepatic 25-hydroxylation), DBP (also known as GC; transport), and CYP24A1 (catabolism). We assessed each SNP for an association with circulating 25(OH)D concentration (5449 non-cases; two studies), risk of type 2 diabetes (28 144 cases, 76 344 non-cases; five studies), and glycaemic traits (concentrations of fasting glucose, 2-h glucose, fasting insulin, and HbA1c; 46 368 non-cases; study consortium). We combined these associations in a likelihood-based mendelian randomisation analysis to estimate the causal association of 25(OH)D concentration with type 2 diabetes and the glycaemic traits, and compared them with that from a meta-analysis of data from observational studies (8492 cases, 89 698 non-cases; 22 studies) that assessed the association between 25(OH)D concentration and type 2 diabetes. FINDINGS All four SNPs were associated with 25(OH)D concentrations (p<10(-6)). The mendelian randomisation-derived unconfounded odds ratio for type 2 diabetes was 1·01 (95% CI 0·75-1·36; p=0·94) per 25·0 nmol/L (1 SD) lower 25(OH)D concentration. The corresponding (potentially confounded) relative risk from the meta-analysis of data from observational studies was 1·21 (1·16-1·27; p=7·3 × 10(-19)). The mendelian randomisation-derived estimates for glycaemic traits were not significant (p>0·25). INTERPRETATION The association between 25(OH)D concentration and type 2 diabetes is unlikely to be causal. Efforts to increase 25(OH)D concentrations might not reduce the risk of type 2 diabetes as would be expected on the basis of observational evidence. These findings warrant further investigations to identify causal factors that might increase 25(OH)D concentration and also reduce the risk of type 2 diabetes. FUNDING UK Medical Research Council Epidemiology Unit and European Union Sixth Framework Programme.",2015,"The mendelian randomisation-derived estimates for glycaemic traits were not significant (p>0·25). ","['5449 non-cases; two studies), risk of type 2 diabetes (28\u2008144 cases, 76\u2008344 non-cases; five studies), and glycaemic traits (concentrations of fasting glucose, 2-h glucose, fasting insulin, and HbA1c; 46\u2008368 non-cases; study consortium']",[],"['circulating 25(OH)D concentration', 'DHCR7 (related to vitamin D synthesis), CYP2R1 (hepatic 25-hydroxylation), DBP', '25(OH)D synthesis and metabolism']","[{'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0011744', 'cui_str': 'Hydrogen-2'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}]",[],"[{'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C1827418', 'cui_str': 'CYP2R1'}, {'cui': 'C0020365', 'cui_str': 'Hydroxylation'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}]",,0.023023,"The mendelian randomisation-derived estimates for glycaemic traits were not significant (p>0·25). ","[{'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Ye', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Sharp', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Burgess', 'Affiliation': 'Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Scott', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.'}, {'ForeName': 'Fumiaki', 'Initials': 'F', 'LastName': 'Imamura', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Langenberg', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Wareham', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.'}, {'ForeName': 'Nita G', 'Initials': 'NG', 'LastName': 'Forouhi', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK. Electronic address: nita.forouhi@mrc-epid.cam.ac.uk.'}]",The lancet. Diabetes & endocrinology,['10.1016/S2213-8587(14)70184-6'] 233,31026216,Why Does Prevention of Recurrent Urinary Tract Infection not Result in Less Renal Scarring? A Deeper Dive into the RIVUR Trial.,"PURPOSE The RIVUR (Randomized Intervention for Children with Vesicoureteral Reflux) trial reported that antibiotic prophylaxis reduced recurrent urinary tract infection but antibiotic prophylaxis was not associated with decreased new renal scarring. However, the original reports did not assess the relationship among recurrent urinary tract infection, new renal scarring and antibiotic prophylaxis in detail. Therefore, we investigated the relationship among these issues. MATERIALS AND METHODS We included subjects with dimercaptosuccinic acid scan within 6 months of enrollment and at least 1 followup dimercaptosuccinic acid scan from the RIVUR trial. The primary outcome was recurrent urinary tract infection associated new renal scarring, defined as recurrent urinary tract infection and new changes on dimercaptosuccinic acid scan. Due to a low number of events, propensity score was used to adjust for confounders. Multivariate logistic regression was fitted to investigate the associations between the covariates and the outcome. RESULTS A total of 489 patients (91% female, mean age 20.3 months) were included in the study. Any new renal scarring was more common among those with recurrent urinary tract infection (OR 4.1, 95% CI 2.0-8.5, p <0.01) after adjusting for age, sex, index urinary tract infection, duplication, bowel bladder dysfunction and antibiotic prophylaxis. Recurrent urinary tract infection associated new renal scarring occurred in 5 of 244 (2%) patients on antibiotic prophylaxis and 13 of 245 (5%) on placebo. Compared to antibiotic prophylaxis, placebo was associated with a higher risk of recurrent urinary tract infection associated new renal scarring (OR 3.1, 95% CI 1.0-8.8, p=0.04) after adjusting for age, sex, race, index urinary tract infection, bowel bladder dysfunction, duplication, hydronephrosis, vesicoureteral reflux grade and baseline renal scarring. There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. CONCLUSIONS Recurrent urinary tract infection was associated with new renal scarring in the RIVUR trial. When limited to recurrent urinary tract infection associated new renal scarring, antibiotic prophylaxis was associated with a decreased risk of this outcome. It remains unclear why new renal scarring developed in a proportion of subjects without recurrent urinary tract infection. The results should be carefully interpreted due to the inherent limitations.",2019,"There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. ","['Children with Vesicoureteral Reflux', 'We included subjects with dimercaptosuccinic acid scan within 6 months of enrollment and at least 1 followup dimercaptosuccinic acid scan from the RIVUR trial', '489 patients (91% female, mean age 20.3 months) were included in the study']","['antibiotic prophylaxis', 'antibiotic prophylaxis, placebo', 'placebo']","['higher risk of recurrent urinary tract infection associated new renal scarring', 'index urinary tract infection, bowel bladder dysfunction, duplication, hydronephrosis, vesicoureteral reflux grade and baseline renal scarring', 'recurrent urinary tract infection associated new renal scarring, defined as recurrent urinary tract infection and new changes on dimercaptosuccinic acid scan', 'scar severity at final dimercaptosuccinic acid scan', 'Recurrent urinary tract infection associated new renal scarring']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0042580', 'cui_str': 'Vesicoureteral Reflux'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1875873', 'cui_str': '2,3-Dimercaptosuccinic Acid'}, {'cui': 'C0441633'}, {'cui': 'C0332285', 'cui_str': 'In (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0262655', 'cui_str': 'Recurrent urinary tract infection (disorder)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C1700247', 'cui_str': 'Renal scarring'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0232841', 'cui_str': 'Bladder dysfunction (finding)'}, {'cui': 'C0332597', 'cui_str': 'Duplication (finding)'}, {'cui': 'C0020295', 'cui_str': 'Hydronephrosis'}, {'cui': 'C0042580', 'cui_str': 'Vesicoureteral Reflux'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1875873', 'cui_str': '2,3-Dimercaptosuccinic Acid'}, {'cui': 'C0441633'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}]",489.0,0.0321717,"There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. ","[{'ForeName': 'Hsin-Hsiao', 'Initials': 'HH', 'LastName': 'Wang', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kurtz', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Logvinenko', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}, {'ForeName': 'Caleb', 'Initials': 'C', 'LastName': 'Nelson', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}]",The Journal of urology,['10.1097/JU.0000000000000292'] 234,32504701,Propofol compared with bolus and titrated midazolam for sedation in outpatient colonoscopy: a prospective randomized double-blind study.,"BACKGROUND AND AIMS The safest and most efficient method of sedation for outpatient colonoscopy remains unclear. This study aimed to compare the efficiency and safety of bolus administration of midazolam compared with titrated administration and propofol administration for patients undergoing outpatient colonoscopy. METHODS We randomly divided patients undergoing colonoscopy into the propofol group, bolus midazolam group, and titrated midazolam group. We compared total procedure time, induction time, recovery time, and discharge time among the 3 groups. We also compared patient satisfaction and the incidence of adverse events. RESULTS In total, 267 patients (89 in each study group) were enrolled during the study period. Patients in the propofol group had a shorter total procedure time (39.5 vs 59.4 vs 58.1 minutes; P < .001), induction time (4.6 vs 6.3 vs 7.6 minutes; P < .001), recovery time (11.5 vs 29.5 vs 29.2 minutes; P < .001), and discharge time (20.6 vs 34.9 vs 34.7 minutes; P < .001) than patients in the bolus midazolam group and titrated midazolam group. Patients in the propofol group reported higher degrees of satisfaction than patients in the bolus or titrated midazolam plus meperidine groups (9.9 vs 9.6 vs 9.6 [P = .007] and 4.9 vs 4.7 vs 4.8 [P = .008], respectively). Adverse events were not significantly different between groups. CONCLUSIONS In this randomized trial, propofol was superior to bolus or titrated midazolam in terms of endoscopy unit efficiency and patient satisfaction during outpatient colonoscopy. (Clinical trial registration number: KCT0002805.).",2021,"Patients in the propofol group reported higher degrees of satisfaction than patients in the bolus or titrated midazolam plus meperidine groups (9.9 vs 9.6 vs 9.6; P = 0.007, 4.9 vs 4.7 vs 4.8; P = .008).","['We randomly divided patients undergoing', '267 patients (89 in each study group) were enrolled during the study period', 'patients undergoing outpatient colonoscopy', 'outpatient colonoscopy']","['bolus and titrated midazolam', 'midazolam plus meperidine', 'midazolam', 'Propofol', 'colonoscopy into the propofol group, bolus midazolam', 'propofol']","['discharge time', 'Adverse events', 'efficiency and safety', 'recovery time', 'induction time', 'higher degrees of satisfaction', 'shorter total procedure time', 'total procedure time, induction time, recovery time, and discharge time']","[{'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517672', 'cui_str': '267'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}]","[{'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025376', 'cui_str': 'Meperidine'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",267.0,0.230232,"Patients in the propofol group reported higher degrees of satisfaction than patients in the bolus or titrated midazolam plus meperidine groups (9.9 vs 9.6 vs 9.6; P = 0.007, 4.9 vs 4.7 vs 4.8; P = .008).","[{'ForeName': 'Dae Bum', 'Initials': 'DB', 'LastName': 'Kim', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, St Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Joon Sung', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Cheal Wung', 'Initials': 'CW', 'LastName': 'Huh', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Dae Won', 'Initials': 'DW', 'LastName': 'Ma', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Jeong-Seon', 'Initials': 'JS', 'LastName': 'Ji', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Byung-Wook', 'Initials': 'BW', 'LastName': 'Kim', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Hwang', 'Initials': 'H', 'LastName': 'Choi', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}]",Gastrointestinal endoscopy,['10.1016/j.gie.2020.05.045'] 235,32497693,Habit tracking of sunscreen use in National Collegiate Athletics Association cross country athletes: A randomized pilot study.,,2021,,['NCAA Cross Country Athletes'],[],[],"[{'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]",[],[],,0.030267,,"[{'ForeName': 'Mary P', 'Initials': 'MP', 'LastName': 'List', 'Affiliation': 'Department of Internal Medicine, The Christ Hospital, Cincinnati, Ohio. Electronic address: marylist23@gmail.com.'}, {'ForeName': 'Mary B', 'Initials': 'MB', 'LastName': 'Carter', 'Affiliation': 'Department of Global Education, School of Medicine, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Brian B', 'Initials': 'BB', 'LastName': 'Adams', 'Affiliation': 'Department of Dermatology, College of Medicine, University of Cincinnati, Cincinnati, Ohio.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.05.108'] 236,32515156,A 12-month pilot study outcomes of vagus nerve stimulation in Crohn's disease.,"BACKGROUND The vagus nerve has anti-inflammatory properties. We aimed to investigate vagus nerve stimulation (VNS) as a new therapeutic strategy targeting an intrinsic anti-inflammatory pathway in a pilot study in Crohn's disease patients. The main objectives addressed the questions of long-term safety, tolerability, and anti-inflammatory effects of this therapy. This study is the continuation of previous reported findings at 6 months. METHODS Nine patients with moderate active disease underwent VNS. An electrode wrapped around the left cervical vagus nerve was continuously stimulated over 1 year. Clinical, biological, endoscopic parameters, cytokines (plasma, gut), and mucosal metabolites were followed-up. KEY RESULTS After 1 year of VNS, five patients were in clinical remission and six in endoscopic remission. C-reactive protein (CRP) and fecal calprotectin decreased in six and five patients, respectively. Seven patients restored their vagal tone and decreased their digestive pain score. The patients' cytokinergic profile evolved toward a more ""healthy profile"": Interleukins 6, 23, 12, tumor necrosis factor α, and transforming growth factorβ1 were the most impacted cytokines. Correlations were observed between CRP and tumor necrosis factor α, and some gut mucosa metabolites as taurine, lactate, alanine, and beta-hydroxybutyrate. VNS was well tolerated. CONCLUSION & INFERENCES Vagus nerve stimulation appears as an innovative and well-tolerated treatment in moderate Crohn's disease. After 12 months, VNS has restored a homeostatic vagal tone and reduced the inflammatory state of the patients. VNS has probably a global modulatory effect on the immune system along with gut metabolic regulations. This pilot study needs replication in a larger randomized double-blinded control study.",2020,"Correlations were observed between CRP and tumor necrosis factor α, and some gut mucosa metabolites as taurine, lactate, alanine, and beta-hydroxybutyrate.","['patients\' cytokinergic profile evolved toward a more ""healthy profile', ""Crohn's disease patients"", ""Crohn's disease"", 'Nine patients with moderate active disease underwent VNS']","['vagus nerve stimulation', 'vagus nerve stimulation (VNS']","['vagal tone', 'clinical remission and six in endoscopic remission', 'tolerated', 'CRP and tumor necrosis factor α, and some gut mucosa metabolites as taurine, lactate, alanine, and beta-hydroxybutyrate', 'C-reactive protein (CRP) and fecal calprotectin', 'digestive pain score', 'tumor necrosis factor α, and transforming growth factorβ1', 'homeostatic vagal tone', 'Clinical, biological, endoscopic parameters, cytokines (plasma, gut), and mucosal metabolites']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332253', 'cui_str': 'Evolving'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}]","[{'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0039350', 'cui_str': 'Taurine'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}, {'cui': 'C0106006', 'cui_str': '3-hydroxybutyrate'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0012238', 'cui_str': 'Digestive system function'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]",5.0,0.0874017,"Correlations were observed between CRP and tumor necrosis factor α, and some gut mucosa metabolites as taurine, lactate, alanine, and beta-hydroxybutyrate.","[{'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Sinniger', 'Affiliation': 'Inserm, U1216, Grenoble Institute Neurosciences, University of Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Pellissier', 'Affiliation': 'University of Grenoble Alpes, University of Savoie Mont Blanc and LIP/PC2S, Grenoble, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Fauvelle', 'Affiliation': 'Inserm, U1216, Grenoble Institute Neurosciences, University of Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Candice', 'Initials': 'C', 'LastName': 'Trocmé', 'Affiliation': 'BEP Laboratory Building, University of Grenoble Alpes Hospital, Grenoble, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Hoffmann', 'Affiliation': 'Neurosurgery Department, Grenoble Alpes Hospital, University of Grenoble Alpes Hospital, Grenoble, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Vercueil', 'Affiliation': 'Inserm, U1216, Grenoble Institute Neurosciences, University of Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Cracowski', 'Affiliation': 'INSERM CIC1406, University of Grenoble Alpes Hospital, Grenoble, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'David', 'Affiliation': 'Inserm, U1216, Grenoble Institute Neurosciences, University of Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Bonaz', 'Affiliation': 'Inserm, U1216, Grenoble Institute Neurosciences, University of Grenoble Alpes, Grenoble, France.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13911'] 237,31272294,Embodying the Police: The Effects of Enclothed Cognition on Shooting Decisions.,"The theory of enclothed cognition proposes that wearing physical articles of clothing can trigger psychological processes and behavioral tendencies connected to their symbolic meaning. Furthermore, past research has found that increases in power are associated with greater approach orientation and action tendencies. In this study, we integrate these two literatures to examine how embodying the role of a police officer through wearing a uniform would affect responses on a reaction-time measure known as the Shooter Task. This first-person video game simulation requires participants to shoot or not shoot targets holding guns or objects. The task typically elicits a stereotypical pattern of responses, such that unarmed Black versus White targets are more likely to be mistakenly shot and armed Black versus White targets are more likely to be correctly shot. Based on the relationship between power and action, we hypothesized that participants who were randomly assigned to wear a police uniform would show more shooting errors, particularly false alarms, than control participants. Consistent with our hypotheses, participants in uniform were more likely to shoot unarmed targets, regardless of their race. Moreover, this pattern was partially moderated by attitudes about the police and their abuse of power. Specifically, uniformed participants who justified police use of power were more likely to shoot innocent targets than those who were wary of it. We discuss implications for police perceptions and the theory of enclothed cognition more broadly.",2020,"Specifically, uniformed participants who justified police use of power were more likely to shoot innocent targets than those who were wary of it.",[],[],[],[],[],[],,0.0167261,"Specifically, uniformed participants who justified police use of power were more likely to shoot innocent targets than those who were wary of it.","[{'ForeName': 'Saaid A', 'Initials': 'SA', 'LastName': 'Mendoza', 'Affiliation': 'Providence College, Providence, RI, USA.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Parks-Stamm', 'Affiliation': 'University of Southern Maine, Portland, ME, USA and Grand Canyon University, Phoenix, AZ, USA.'}]",Psychological reports,['10.1177/0033294119860261'] 238,32517497,Icare versus Goldmann in a randomised middle-aged population : The influence of central corneal thickness and refractive errors.,"PURPOSE The aim of this study was to compare the measurements of intraocular pressure by two tonometers, the Icare rebound tonometer and the Goldmann applanation tonometer, in a randomised screening study. The influence of refraction and central corneal thickness on the measurements was also evaluated. METHODS Intraocular pressure was measured with rebound tonometer and Goldmann applanation tonometer in 1266 participants; refraction and central corneal thickness were also determined. One randomised eye of each participant was selected for this report's analysis. A Bland-Altman plot was used to compare the values obtained with the two devices. RESULTS The correlation between rebound tonometer and Goldmann applanation tonometer was good: the intraclass correlation coefficient (r) between the two methods was 0.735 ( p  < 0.001). The mean difference (rebound tonometer-Goldmann applanation tonometer) was 0.11 ± 2.3 mmHg. The difference was not statistically significant (95% confidence interval: 0.11 to 0.13, p  = 0.09). With increasing central corneal thickness, not only did intraocular pressure values with both devices increase, but the difference between them also increased. Refraction (spherical equivalent) did not influence intraocular pressure or the rebound tonometer-Goldmann applanation tonometer difference. However, high astigmatism (≥2D) exerted an influence on intraocular pressure values taken with Goldmann applanation tonometer. CONCLUSION Measurements with rebound tonometer and Goldmann applanation tonometer are relatively uniform although rebound tonometer slightly overestimated intraocular pressure. Both rebound tonometer and Goldmann applanation tonometer and the difference between these devices were affected by central corneal thickness but not by refraction. Higher astigmatism affected Goldmann applanation tonometer more than rebound tonometer. It is concluded that rebound tonometer is a reliable method for measuring intraocular pressure in a population-based screening study.",2021,The correlation between rebound tonometer and Goldmann applanation tonometer was good: the intraclass correlation coefficient (r) between the two methods was 0.735 (,['1266 participants'],"['Icare versus Goldmann', 'Icare rebound tonometer and the Goldmann applanation tonometer', 'rebound tonometer and Goldmann applanation tonometer']","['Goldmann applanation tonometer', 'intraocular pressure or the rebound tonometer-Goldmann applanation tonometer difference', 'mean difference (rebound tonometer-Goldmann applanation tonometer', 'intraocular pressure values', 'rebound tonometer and Goldmann applanation tonometer', 'intraocular pressure', 'central corneal thickness', 'refraction and central corneal thickness']",[],"[{'cui': 'C0183969', 'cui_str': 'Tonometer'}, {'cui': 'C1271528', 'cui_str': 'Goldmann applanation tonometer'}]","[{'cui': 'C1271528', 'cui_str': 'Goldmann applanation tonometer'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0183969', 'cui_str': 'Tonometer'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1720164', 'cui_str': 'Central corneal thickness'}, {'cui': 'C0429585', 'cui_str': 'Refraction measurement - finding'}]",1266.0,0.0730484,The correlation between rebound tonometer and Goldmann applanation tonometer was good: the intraclass correlation coefficient (r) between the two methods was 0.735 (,"[{'ForeName': 'Katri', 'Initials': 'K', 'LastName': 'Stoor', 'Affiliation': 'Department of Ophthalmology, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'Elina', 'Initials': 'E', 'LastName': 'Karvonen', 'Affiliation': 'Department of Ophthalmology, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'Pasi', 'Initials': 'P', 'LastName': 'Ohtonen', 'Affiliation': 'Medical Research Center Oulu, University of Oulu, Oulu, Finland.'}, {'ForeName': 'M Johanna', 'Initials': 'MJ', 'LastName': 'Liinamaa', 'Affiliation': 'Department of Ophthalmology, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'Ville', 'Initials': 'V', 'LastName': 'Saarela', 'Affiliation': 'Department of Ophthalmology, Oulu University Hospital, Oulu, Finland.'}]",European journal of ophthalmology,['10.1177/1120672120921380'] 239,32513111,Effect of caudal ketamine on minimum local anesthetic concentration of ropivacaine in children: a prospective randomized trial.,"BACKGROUND Caudal ketamine has been shown to provide an effective and prolonged post-operative analgesia with few adverse effects. However, the effect of caudal ketamine on the minimum local anesthetic concentration (MLAC) of ropivacaine for intra-operative analgesia is unclear. METHODS One hundred and sixty-nine children were randomized to five groups: Group C (caudal ropivacaine only), Group K 0.25 (caudal ropivacaine plus 0.25 mg/kg ketamine), Group K 0.5 (caudal ropivacaine plus 0.5 mg/kg ketamine), Group K 0.75 (caudal ropivacaine plus 0.75 mg/kg ketamine), and Group K 1.0 (caudal ropivacaine plus 1.0 mg/kg ketamine). The primary outcome was the MLAC values of ropivacaine with/without ketamine for caudal block. RESULTS The MLAC values of ropivacaine were 0.128% (0.028%) in the control group, 0.112% (0.021%) in Group K 0.25 , 0.112% (0.018%) in Group K 0.5 , 0.110% (0.019%) in Group K 0.75 , and 0.110% (0.020%) in Group K 1.0 . There were no significant differences among the five groups for the MLAC values (p = 0.11). During the post-operative period the mean durations of analgesia were 270, 381, 430, 494, and 591 min in the control, K 0.25 , K 0. 5 , K 0.75 , and K 1.0 groups respectively, which shown that control group is significantly different from all ketamine groups. Also there were significant differences between K 0.25 and K 0.75 groups, and between K 1.0 groups and the other ketamine groups. CONCLUSIONS Adding caudal ketamine to ropivacaine prolong the duration of post-operative analgesia; however, it does not decrease the MLAC of caudal ropivacaine for intra-operative analgesia in children. CLINICAL TRIAL REGISTRATION ChiCTR-TRC-13003492. Registered on 13 August 2013.",2020,There were no significant differences among the five groups for the MLAC values (p = 0.11).,"['One hundred and sixty-nine children', 'children']","['Group C (caudal ropivacaine only), Group K 0.25 (caudal ropivacaine plus 0.25\u2009mg/kg ketamine), Group K 0.5 (caudal ropivacaine plus 0.5\u2009mg/kg ketamine), Group K 0.75 (caudal ropivacaine plus 0.75\u2009mg/kg ketamine), and Group K 1.0 (caudal ropivacaine plus 1.0\u2009mg/kg ketamine', 'ropivacaine', 'caudal ketamine']","['MLAC values of ropivacaine with/without ketamine for caudal block', 'mean durations of analgesia', 'MLAC values of ropivacaine', 'duration of post-operative analgesia', 'minimum local anesthetic concentration', 'MLAC values']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0205097', 'cui_str': 'Caudal'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0441845', 'cui_str': 'Group K'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C4068882', 'cui_str': '0.75'}]","[{'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0205097', 'cui_str': 'Caudal'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}]",169.0,0.0585345,There were no significant differences among the five groups for the MLAC values (p = 0.11).,"[{'ForeName': 'Huai-Zhen', 'Initials': 'HZ', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510623, China.""}, {'ForeName': 'Ling-Yu', 'Initials': 'LY', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510623, China.""}, {'ForeName': 'Hui-Hong', 'Initials': 'HH', 'LastName': 'Liang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510623, China.""}, {'ForeName': 'Yan-Ting', 'Initials': 'YT', 'LastName': 'Fan', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510623, China.""}, {'ForeName': 'Xing-Rong', 'Initials': 'XR', 'LastName': 'Song', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510623, China.""}, {'ForeName': 'Ying-Jun', 'Initials': 'YJ', 'LastName': 'She', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510623, China. yjsheh@yeah.net.""}]",BMC anesthesiology,['10.1186/s12871-020-01058-y'] 240,31570034,Evaluation of telemonitoring of continuous positive airway pressure therapy in obstructive sleep apnoea syndrome: TELEPAP pilot study.,"INTRODUCTION Continuous positive airway pressure is an effective treatment for obstructive sleep apnoea syndrome. However, positive airway pressure compliance rates are disappointingly low, so effective interventions are needed to improve compliance in sleep apnoea. Telemonitoring has been used to improve compliance, but results have been inconsistent. This study aimed to determine outcomes of telemonitoring positive airway pressure compliance and efficacy data compared to usual care and phone-call care. METHODS Randomized controlled study in which 51 patients (82.4% male; between 25 and 78 years), diagnosed with moderate to severe obstructive sleep apnoea were consecutively randomized to usual care, weekly phone-call care or telemonitored care with the use of Restraxx™. All patients were submitted to a comprehensive educational programme during positive airway pressure adaptation. Patients were followed for the first four weeks of treatment with automatic positive airway pressure (AutoSet Spirit S8®; ResMed), and compliance and efficacy data were analyzed. RESULTS Telemonitored care group used automatic positive airway pressure an average of 5.0 ± 1.8 hours/night, usual care patients 5.1 ± 2.5 hours and phone-call care patients 3.9 ± 2.6 hours. The residual Apnoea--Hypopnoea Index was 5.3 ± 3.0 in telemonitored care, 5.0 ± 2.5 in usual care and 5.6 ± 3.8 in phone-call care. No statistically significant differences were found between groups regarding positive airway pressure compliance or efficacy ( p  = 0.296 and p  = 0.825, respectively). DISCUSSION In the presence of a comprehensive educational programme during positive airway pressure adaptation, telemonitoring patients did not show benefits concerning compliance and efficacy. A larger follow-up period is needed to evaluate the long-term results of a telemonitoring programme.",2021,"No statistically significant differences were found between groups regarding positive airway pressure compliance or efficacy ( p  = 0.296 and p  = 0.825, respectively). ","['obstructive sleep apnoea syndrome', '51 patients (82.4% male; between 25 and 78 years), diagnosed with moderate to severe obstructive sleep apnoea']","['usual care, weekly phone-call care or telemonitored care with the use of Restraxx™', 'usual care and phone-call care', 'comprehensive educational programme', 'Continuous positive airway pressure', 'telemonitoring of continuous positive airway pressure therapy']","['automatic positive airway pressure', 'positive airway pressure compliance or efficacy', 'residual Apnoea--Hypopnoea Index']","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C4761101', 'cui_str': 'Automatic positive airway pressure'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}]",,0.0223554,"No statistically significant differences were found between groups regarding positive airway pressure compliance or efficacy ( p  = 0.296 and p  = 0.825, respectively). ","[{'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Fernandes', 'Affiliation': 'Sleep and Non-Invasive Ventilation Unit, Thorax Department, Centro Hospitalar Universitário Lisboa Norte, Portugal.'}, {'ForeName': 'Catarina', 'Initials': 'C', 'LastName': 'Antunes', 'Affiliation': 'Sleep and Non-Invasive Ventilation Unit, Thorax Department, Centro Hospitalar Universitário Lisboa Norte, Portugal.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Martinho', 'Affiliation': 'Sleep and Non-Invasive Ventilation Unit, Thorax Department, Centro Hospitalar Universitário Lisboa Norte, Portugal.'}, {'ForeName': 'João', 'Initials': 'J', 'LastName': 'Carvalho', 'Affiliation': 'Sleep and Non-Invasive Ventilation Unit, Thorax Department, Centro Hospitalar Universitário Lisboa Norte, Portugal.'}, {'ForeName': 'Tiago', 'Initials': 'T', 'LastName': 'Abreu', 'Affiliation': 'Sleep and Non-Invasive Ventilation Unit, Thorax Department, Centro Hospitalar Universitário Lisboa Norte, Portugal.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Oliveira', 'Affiliation': 'Sleep and Non-Invasive Ventilation Unit, Thorax Department, Centro Hospitalar Universitário Lisboa Norte, Portugal.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Pinto', 'Affiliation': 'Sleep and Non-Invasive Ventilation Unit, Thorax Department, Centro Hospitalar Universitário Lisboa Norte, Portugal.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Bárbara', 'Affiliation': 'Sleep and Non-Invasive Ventilation Unit, Thorax Department, Centro Hospitalar Universitário Lisboa Norte, Portugal.'}]",Journal of telemedicine and telecare,['10.1177/1357633X19875850'] 241,32522156,Efficacy of electrical stimulation on epidural anesthesia for cesarean section: a randomized controlled trial.,"BACKGROUND Loss of resistance (LOR) technique is a widely used method to identify the epidural space. However, cases of inadequate epidural anesthesia in cesarean section were frequently reported. Also, the success rate of epidural anesthesia with LOR technique varied depending on the proficiency of the practitioner. The purpose of this study was to assess the efficacy and safety of electrical stimulation to identify epidural spaces in cesarean section for novices or clinicians with recent gap in experience. METHODS Pregnant women scheduled for elective cesarean section were randomly allocated to two groups. Groups were classified based on the methods used for identifying the epidural space: the LOR group (group L) and the LOR with epidural electrical stimulation group (group E). Clinicians with less than 10 epidural cesarean section experiences in the recent year performed epidural anesthesia for cesarean section. In the group E, a RegionalStim® conductive catheter was inserted through the Tuohy needle, and the guidewire passing through the catheter was connected to a peripheral nerve stimulator. The intensity of the stimulation was gradually increased from 0.25 mA to 1.5 mA until paresthesia was elicited and radiated. We assessed the success of epidural anesthesia (complete success, partial success or failure). Other clinical parameters including maternal satisfaction, time required for epidural anesthesia, neonatal Apgar scores, pain scores and adverse events were compared between the two groups. RESULTS Except for 6 patients who withdrew consent, 54 patients were enrolled in this study (28 for the group L and 26 for the group E). The demographic data showed no difference between the two groups. There was no adverse event resulted from electrical stimulation. The group E showed higher rate of complete success, sensitivity in finding epidural space and maternal satisfaction compared to the group L (21/26 vs. 15/28, p = 0.034, 0.96 vs. 0.68, p = 0.012 and 4.04 vs. 3.39, p = 0.02, respectively). The other clinical parameters showed no differences between the two groups. CONCLUSION In addition to the conventional LOR technique, identifying epidural spaces using electrical stimulation led to better outcomes without additional risks for novices as well as clinicians with recent gap in experience. TRIAL REGISTRATION This study was retrospectively registered in the ClinicalTrials.gov Registry (NCT03443466) on February 23, 2018.",2020,"The group E showed higher rate of complete success, sensitivity in finding epidural space and maternal satisfaction compared to the group L (21/26 vs. 15/28, p = 0.034, 0.96 vs. 0.68, p = 0.012 and 4.04 vs. 3.39, p = 0.02, respectively).","['Clinicians with less than 10 epidural cesarean section experiences in the recent year performed epidural anesthesia for cesarean section', '6 patients who withdrew consent, 54 patients were enrolled in this study (28 for the group L and 26 for the group E', 'cesarean section for novices or clinicians with recent gap in experience', 'epidural anesthesia for cesarean section', 'Pregnant women scheduled for elective cesarean section']","['electrical stimulation', 'conventional LOR technique', 'LOR with epidural electrical stimulation']","['higher rate of complete success, sensitivity in finding epidural space and maternal satisfaction', 'success of epidural anesthesia (complete success, partial success or failure', 'efficacy and safety', 'intensity of the stimulation', 'maternal satisfaction, time required for epidural anesthesia, neonatal Apgar scores, pain scores and adverse events']","[{'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0441846', 'cui_str': 'Group L'}, {'cui': 'C0441839', 'cui_str': 'Group E'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0587268', 'cui_str': 'Loss of resistance technique'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0014537', 'cui_str': 'Structure of epidural space'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0003533', 'cui_str': 'Finding of Apgar score'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",54.0,0.087104,"The group E showed higher rate of complete success, sensitivity in finding epidural space and maternal satisfaction compared to the group L (21/26 vs. 15/28, p = 0.034, 0.96 vs. 0.68, p = 0.012 and 4.04 vs. 3.39, p = 0.02, respectively).","[{'ForeName': 'Young Sung', 'Initials': 'YS', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul, 08308, South Korea.'}, {'ForeName': 'Hyo Sung', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul, 08308, South Korea.'}, {'ForeName': 'Hyerim', 'Initials': 'H', 'LastName': 'Jeong', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul, 08308, South Korea.'}, {'ForeName': 'Chung Hun', 'Initials': 'CH', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul, 08308, South Korea.'}, {'ForeName': 'Mi Kyoung', 'Initials': 'MK', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul, 08308, South Korea.'}, {'ForeName': 'Sang Sik', 'Initials': 'SS', 'LastName': 'Choi', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul, 08308, South Korea. clonidine@empal.com.'}]",BMC anesthesiology,['10.1186/s12871-020-01063-1'] 242,32524538,Upper extremity rehabilitation using video games in cerebral palsy: a randomized clinical trial.,"INTRODUCTION The aim of the present study was to compare the effects of neurodevelopmental therapy (NDT)-based upper extremity rehabilitation and video game-based therapy (VGBT) using Nintendo ® wii and leap motion controller (LMC) games on upper extremity function in patients with cerebral palsy (CP). The 30 patients included in the present study were randomized to two groups: VGBT group (VGBT using Nintendo® Wii and LMC games) and control group (NDT-based upper extremity rehabilitation). Both groups trained 3 days a week for 8 weeks. Manual dexterity was evaluated using the ""Minnesota Manual Dexterity Test (MMDT)"", functional ability using the ""Childhood Health Assessment Questionnaire (CHAQ)"" and the ""Duruoz Hand Index (DEI)"" and grip and pinch strengths using a dynamometer. Following treatment, significant changes were found, MMDT, grip and pinch strength, CHAQ, and DHI scores in both groups (p < 0.05); however, VGBT group was statistically superior to group II with respect to changes in MMDT (p < 0.05). VGBT using Nintendo ® Wii and LMC games had slightly superior effects on manual dexterity in patients with CP while compared with NDT-based upper extremity rehabilitation. Futhermore, the effects of both treatment programs on grip strengths and functional ability were similar beneficial.",2021,"Following treatment, significant changes were found, MMDT, grip and pinch strength, CHAQ, and DHI scores in both groups (p < 0.05); however, VGBT group was statistically superior to group II with respect to changes in MMDT (p < 0.05).","['patients with cerebral palsy (CP', 'cerebral palsy', 'patients with CP while compared with NDT-based upper extremity rehabilitation', '30 patients included in the present study']","['neurodevelopmental therapy (NDT)-based upper extremity rehabilitation and video game-based therapy (VGBT) using Nintendo ® wii and leap motion controller (LMC) games', 'VGBT using Nintendo ® Wii and LMC games', 'VGBT', 'Upper extremity rehabilitation using video games', 'VGBT group (VGBT using Nintendo® Wii and LMC games) and control group (NDT-based upper extremity rehabilitation']","['Minnesota Manual Dexterity Test (MMDT)"", functional ability using the ""Childhood Health Assessment Questionnaire (CHAQ)"" and the ""Duruoz Hand Index (DEI)"" and grip and pinch strengths', 'manual dexterity', 'MMDT, grip and pinch strength, CHAQ, and DHI scores', 'grip strengths and functional ability', 'Manual dexterity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0026183', 'cui_str': 'Minnesota'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C2732494', 'cui_str': 'Childhood health assessment questionnaire'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C1720876', 'cui_str': 'Pinch Strength'}, {'cui': 'C0527811', 'cui_str': 'bakumondo-to'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}]",30.0,0.0243632,"Following treatment, significant changes were found, MMDT, grip and pinch strength, CHAQ, and DHI scores in both groups (p < 0.05); however, VGBT group was statistically superior to group II with respect to changes in MMDT (p < 0.05).","[{'ForeName': 'Eren', 'Initials': 'E', 'LastName': 'Avcil', 'Affiliation': 'Institute of Health Sciences, Istanbul Medipol University, Istanbul, Turkey.'}, {'ForeName': 'Devrim', 'Initials': 'D', 'LastName': 'Tarakci', 'Affiliation': 'Department of Ergotherapy, Faculty of Health Sciences, Istanbul Medipol University, Istanbul, Turkey.'}, {'ForeName': 'Nilay', 'Initials': 'N', 'LastName': 'Arman', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey. saimenilayarman@istanbul.edu.tr.'}, {'ForeName': 'Ela', 'Initials': 'E', 'LastName': 'Tarakci', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey.'}]",Acta neurologica Belgica,['10.1007/s13760-020-01400-8'] 243,32524934,"Examining child intake frequency, mothers' own liking and child early exposure as potential predictors of child liking for restricted foods and drinks at 5 years old.","OBJECTIVE To examine longitudinal patterns of child introduction to foods and drinks targeted for restriction by parents and associations between child intake frequency, mother's own liking, child early exposure and child liking for restricted foods and drinks at 5 years old. DESIGN The study involved secondary analyses of longitudinal data from mothers and children participating in the NOURISH randomised controlled trial. Patterns of descriptive data were examined, and a binary logistic regression model tested for prediction of child liking of a selection of restricted foods and drinks. SETTING Brisbane and Adelaide, Australia. PARTICIPANTS Two hundred and eleven mothers and their first born 5-year-old children. RESULTS The proportion of children who had tried the selected restricted foods and drinks progressively increased from 14 months to 5 years old. Mothers' own high liking for both sweet and savoury restricted foods and drinks predicted child high liking for the same items at 5 years old. Child high intake frequency at 5 years old also predicted child high liking for sweet foods and drinks, but child early exposure did not predict child liking for the restricted items examined. CONCLUSIONS These results challenge the belief that limiting children's intake of foods high in sugar, fat and/or salt will increase their liking for them. Findings instead suggest that restricting children's access to such foods may be beneficial. While further research is required, mothers should be made aware that their own food preferences may inadvertently influence their child's liking for the very foods they are trying to restrict.",2020,Mothers' own high liking for both sweet and savoury restricted foods and drinks predicted child high liking for the same items at 5 years old.,"['Two hundred and eleven mothers and their first born 5-year-old children', 'Brisbane and Adelaide, Australia', 'mothers and children participating in the NOURISH randomised controlled trial']",[],[],"[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],[],211.0,0.0156282,Mothers' own high liking for both sweet and savoury restricted foods and drinks predicted child high liking for the same items at 5 years old.,"[{'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Jackson', 'Affiliation': 'School of Exercise and Nutrition Sciences, Queensland University of Technology, Brisbane, Queensland4059, Australia.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Jansen', 'Affiliation': 'School of Exercise and Nutrition Sciences, Queensland University of Technology, Brisbane, Queensland4059, Australia.'}, {'ForeName': 'Kimberley M', 'Initials': 'KM', 'LastName': 'Mallan', 'Affiliation': 'School of Behavioural and Health Sciences, Australian Catholic University, Brisbane, Queensland, Australia.'}]",Public health nutrition,['10.1017/S1368980020000312'] 244,31771410,Does telerehabilitation result in inferior clinical outcomes compared with in-person care for the management of chronic musculoskeletal spinal conditions in the tertiary hospital setting? A non-randomised pilot clinical trial.,"INTRODUCTION Clinical guidelines recommend multidisciplinary non-surgical management for most musculoskeletal spinal conditions. Access to such services continues to be a barrier for many individuals residing outside metropolitan regions. The primary aim of this study was to determine whether clinical outcomes achieved via telerehabilitation are as good as those achieved via in-person care. METHODS A non-randomised pilot clinical trial was undertaken where eligible patients chose to access treatment either via telerehabilitation or in-person (control group). Outcome measures for pain-related disability, pain severity and health-related quality of life were recorded at baseline, 3-, 6- and 9-months. Secondary outcomes included patient satisfaction and technical disruptions. RESULTS Seventy-one patients were recruited (telerehabilitation, n  = 51; control group, n  = 20). Patient characteristics did not differ at baseline and clinically meaningful improvements for pain-related disability and health-related quality of life were observed in both groups. Non-inferiority of telerehabilitation could not be claimed for any clinical outcome measure. There were no significant group-by-time interactions observed for either pain-related disability ( p  = 0.706), pain severity ( p  = 0.187) or health-related quality of life ( p  = 0.425) measures. The telerehabilitation group reported significantly higher levels of treatment satisfaction (median: 97 vs. 76.5; p  = 0.021); 7.9% of telerehabilitation appointments were not completed due to technical disruptions. DISCUSSION Findings indicate patients with chronic musculoskeletal spinal conditions can achieve clinically meaningful improvements in their condition when accessing care via telerehabilitation. Telerehabilitation should be considered for individuals unable to access relevant in-person services; however non-inferiority remains inconclusive and requires further exploration.",2021,Patient characteristics did not differ at baseline and clinically meaningful improvements for pain-related disability and health-related quality of life were observed in both groups.,"['eligible patients chose to access treatment either via telerehabilitation or in-person (control group', 'Seventy-one patients were recruited (telerehabilitation, n \u2009=\u200951; control group, n \u2009=\u200920', 'patients with chronic musculoskeletal spinal conditions']",[],"['health-related quality of life', 'pain-related disability and health-related quality of life', 'patient satisfaction and technical disruptions', 'levels of treatment satisfaction', 'pain severity', 'pain-related disability, pain severity and health-related quality of life', 'pain-related disability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4042802', 'cui_str': 'Remote Rehabilitation'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0450389', 'cui_str': '71'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",[],"[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",71.0,0.266307,Patient characteristics did not differ at baseline and clinically meaningful improvements for pain-related disability and health-related quality of life were observed in both groups.,"[{'ForeName': 'Michelle A', 'Initials': 'MA', 'LastName': 'Cottrell', 'Affiliation': 'School of Health & Rehabilitation Sciences, University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Shaun P', 'Initials': 'SP', 'LastName': ""O'Leary"", 'Affiliation': 'School of Health & Rehabilitation Sciences, University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Maree', 'Initials': 'M', 'LastName': 'Raymer', 'Affiliation': ""Statewide Neurosurgical and Orthopaedic Physiotherapy Screening Clinic & Multidisciplinary Service, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia.""}, {'ForeName': 'Anne J', 'Initials': 'AJ', 'LastName': 'Hill', 'Affiliation': 'School of Health & Rehabilitation Sciences, University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Comans', 'Affiliation': 'Centre for Health Services Research, University of Queensland, Queensland, Australia.'}, {'ForeName': 'Trevor G', 'Initials': 'TG', 'LastName': 'Russell', 'Affiliation': 'School of Health & Rehabilitation Sciences, University of Queensland, St Lucia, Queensland, Australia.'}]",Journal of telemedicine and telecare,['10.1177/1357633X19887265'] 245,32534584,Effect of continuous intraoperative infusion of methoxamine on renal function in elderly patients undergoing gastrointestinal tumor surgery: a randomized controlled trial.,"BACKGROUND Acute renal injury (AKI) caused by hypotension often occurs in elderly patients after gastrointestinal tumor surgery. Although vasoactive drugs can increase effective filtration pressure, they may increase renal vascular resistance and reduce renal blood flow. The effect of methoxamine on renal function is not clear. METHODS After obtaining written informed consent, 180 elderly patients undergoing elective gastrointestinal tumor surgery were randomly allocated into two groups: M group (continuous infusion of methoxamine at 2 μg/kg/min) and N group (continuous infusion of normal saline). The patients' mean arterial pressure was maintained within 20% of baseline by a continuous infusion of methoxamine or normal saline. Maintenance fluid was kept at 5 mL/kg/h. According to Kidney disease improve global outcome (KDIGO) guidelines, creatinine was measured at 1, 2 and 7 days after operation, and urine volume at 6, 12 and 24 h after operation was measured to evaluate the occurrence of AKI. 162 patients were included in the final data analysis. RESULTS Significant differences in the incidence of postoperative Acute kidney injury (M group: 7.5%; N group: 18.3%; P < 0.05), the frequency of hypotension (M group: 1 [1-3]; N group: 3 [1-5]; P < 0.05), and the duration of intraoperative hypotension (M group: 2[0-10]; N group: 10 [5-16]; P < 0.05) were identified between the groups. Multivariate logistic regression analyses demonstrated that preoperative creatinine and the frequency of intraoperative hypotension were the common factors leading to the occurrence of postoperative AKI. The results of Cox multivariate analysis showed that age and AKI were independent risk factors for 30-day death. CONCLUSION Compared with the intraoperative continuous infusion of placebo and methoxamine, continuous infusion of 2 μg/kg/min methoxamine reduced the incidence of postoperative AKI and other clinical complications in elderly patients undergoing gastrointestinal surgery by raising blood pressure and improved the prognosis of patients. TRIAL REGISTRATION Trial registration: Chinese Clinical Trial Registry, ChiCTR1900020536, registered 7 January, 2019.",2020,"RESULTS Significant differences in the incidence of postoperative Acute kidney injury (M group: 7.5%; N group: 18.3%; P < 0.05), the frequency of hypotension (M group: 1 [1-3]; N group: 3 [1-5]; P < 0.05), and the duration of intraoperative hypotension (M group: 2[0-10]; N group: 10 [5-16]; P < 0.05) were identified between the groups.","['elderly patients after gastrointestinal tumor surgery', 'elderly patients undergoing gastrointestinal tumor surgery', 'elderly patients undergoing gastrointestinal surgery', '180 elderly patients undergoing elective gastrointestinal tumor surgery', '162 patients were included in the final data analysis']","['placebo and methoxamine', 'M group (continuous infusion of methoxamine at 2\u2009μg/kg/min) and N group (continuous infusion of normal saline', 'methoxamine or normal saline', 'continuous intraoperative infusion of methoxamine', 'methoxamine']","['renal function', 'incidence of postoperative AKI', 'renal vascular resistance and reduce renal blood flow', 'frequency of hypotension', 'effective filtration pressure', 'mean arterial pressure', 'global outcome (KDIGO) guidelines, creatinine', 'duration of intraoperative hypotension', 'occurrence of AKI', 'incidence of postoperative Acute kidney injury']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017185', 'cui_str': 'Neoplasm of gastrointestinal tract'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0524722', 'cui_str': 'Gastrointestinal surgery'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C5191360', 'cui_str': '162'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025681', 'cui_str': 'Methoxamine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion'}, {'cui': 'C1532757', 'cui_str': 'kg/min'}, {'cui': 'C1278442', 'cui_str': 'Continuous infusion of normal saline'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0042380', 'cui_str': 'Vascular resistance, function'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0035070', 'cui_str': 'Circulation, Renal'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0016107', 'cui_str': 'Filtration'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1112259', 'cui_str': 'Intraoperative hypotension'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}]",162.0,0.272553,"RESULTS Significant differences in the incidence of postoperative Acute kidney injury (M group: 7.5%; N group: 18.3%; P < 0.05), the frequency of hypotension (M group: 1 [1-3]; N group: 3 [1-5]; P < 0.05), and the duration of intraoperative hypotension (M group: 2[0-10]; N group: 10 [5-16]; P < 0.05) were identified between the groups.","[{'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University, Key Laboratory of Anesthesia and Analgesia, Xuzhou Medical University, Xuzhou, Jangsu, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Xuzhou Medical University and Department of Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jangsu, China.'}, {'ForeName': 'Hanbing', 'Initials': 'H', 'LastName': 'Xiao', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University, Key Laboratory of Anesthesia and Analgesia, Xuzhou Medical University, Xuzhou, Jangsu, China.'}, {'ForeName': 'Tianyu', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University, Key Laboratory of Anesthesia and Analgesia, Xuzhou Medical University, Xuzhou, Jangsu, China.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Niu', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University, Key Laboratory of Anesthesia and Analgesia, Xuzhou Medical University, Xuzhou, Jangsu, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University, Key Laboratory of Anesthesia and Analgesia, Xuzhou Medical University, Xuzhou, Jangsu, China.'}, {'ForeName': 'Dunyi', 'Initials': 'D', 'LastName': 'Qi', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University, Key Laboratory of Anesthesia and Analgesia, Xuzhou Medical University, Xuzhou, Jangsu, China. qdy6808@163.com.'}]",BMC anesthesiology,['10.1186/s12871-020-01064-0'] 246,32543247,Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention.,"A novel enoxaparin regimen consisting of intra-arterial bolus (0.75 mg/kg) followed by intravenous infusion (0.75 mg/kg/6 hours) has been developed as a possible solution to the delayed absorption of oral P2Y 12 inhibitors in opiate-treated ST-elevation myocardial infarction (STEMI) patients undergoing primary angioplasty. We aimed to study the feasibility of this regimen as an alternative to standard-of-care treatment (SOC) with unfractionated heparin ± glycoprotein IIb/IIIa antagonist (GPI). One hundred opiate-treated patients presenting with STEMI and accepted for primary angioplasty were randomized (1:1) to either enoxaparin or SOC. Fifty patients were allocated enoxaparin (median age 61, 40% females) and 49 allocated SOC (median age 62, 22% females). One developed stroke before angiography and was withdrawn. One SOC patient had a gastrointestinal bleed resulting in 1 g drop in hemoglobin and early cessation of GPI infusion. Two enoxaparin patients had transient minor bleeding: one transient gingival bleed and one episode of coffee ground vomit with no hemoglobin drop or hemodynamic instability. Two SOC and no enoxaparin group patients had acute stent thrombosis. These preliminary data support further study of this novel 6-hour enoxaparin regimen in opiate-treated PPCI patients.",2021,Two SOC and no enoxaparin group patients had acute stent thrombosis.,"['One hundred opiate-treated patients presenting with STEMI and accepted for primary angioplasty', 'Fifty patients were allocated', 'opiate-treated PPCI patients', 'median age 61, 40% females) and 49 allocated SOC (median age 62, 22% females', 'opiate-treated patients undergoing primary percutaneous coronary intervention']","['standard-of-care treatment (SOC) with unfractionated heparin ± glycoprotein IIb/IIIa antagonist (GPI', 'enoxaparin or SOC', 'enoxaparin therapy', 'standard-of-care antithrombotic therapy', 'enoxaparin']","['transient minor bleeding: one transient gingival bleed and one episode of coffee ground vomit with no hemoglobin drop or hemodynamic instability', 'gastrointestinal bleed', 'acute stent thrombosis']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0242401', 'cui_str': 'Opiates'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty of blood vessel'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0016011', 'cui_str': 'Glycoproteins IIb-IIIa'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0017759', 'cui_str': 'Glucose-6-phosphate isomerase'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0009237', 'cui_str': 'Coffee'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0162119', 'cui_str': 'Hemoglobin low'}, {'cui': 'C0948268', 'cui_str': 'Hemodynamic instability'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal hemorrhage'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}]",50.0,0.0391926,Two SOC and no enoxaparin group patients had acute stent thrombosis.,"[{'ForeName': 'Wael', 'Initials': 'W', 'LastName': 'Sumaya', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'William A E', 'Initials': 'WAE', 'LastName': 'Parker', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Heather M', 'Initials': 'HM', 'LastName': 'Judge', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Ian R', 'Initials': 'IR', 'LastName': 'Hall', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Rachel C', 'Initials': 'RC', 'LastName': 'Orme', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Zulfiquar', 'Initials': 'Z', 'LastName': 'Adam', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Richardson', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Alexander M K', 'Initials': 'AMK', 'LastName': 'Rothman', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Kenneth P', 'Initials': 'KP', 'LastName': 'Morgan', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Julian P', 'Initials': 'JP', 'LastName': 'Gunn', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Robert F', 'Initials': 'RF', 'LastName': 'Storey', 'Affiliation': 'Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.'}]",Platelets,['10.1080/09537104.2020.1779925'] 247,32536023,"Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study.","OBJECTIVES Human milk oligosaccharides safely and beneficially impact bifidobacteria abundance in healthy adults, while their effects in patients with irritable bowel syndrome (IBS) are unknown. Hence, we aimed to determine the dose of 4:1 mix of 2'-O-fucosyllactose and Lacto-N-neotetraose (2'FL/LNnT) that increases fecal bifidobacteria abundance without aggravating overall gastrointestinal symptoms in IBS patients in a randomized, double-blind, controlled study. Additionally, the impact of 2'FL/LNnT on the fecal bacterial profile was assessed. METHODS Irritable bowel syndrome patients diagnosed according to the Rome IV criteria received placebo (glucose), or 5 g or 10 g 2'FL/LNnT for 4 weeks followed by a four-week follow-up period. Gastrointestinal Symptom Rating Scale-IBS was used to assess gastrointestinal symptom severity; fecal microbiota composition was evaluated by GA-map™ Dysbiosis Test. RESULTS Of the included 60 patients, two (one placebo and one 10 g) discontinued prematurely. Fecal bifidobacteria abundance was increased at week 4, but not at week 8, in the 10 g group compared to the other groups. Severity of overall or individual gastrointestinal symptoms did not differ between the groups at week 4 or 8, and no symptom deterioration was seen in any of the groups. The 10 g dose influenced overall fecal microbiota composition, and responders-defined as bifidobacteria increase ≥50%-could be discriminated from non-responders based on fecal microbiota modulation. CONCLUSIONS The 10 g dose of 2'FL/LNnT induced an increase in the beneficial Bifidobacterium spp. without aggravating gastrointestinal symptoms in patients with IBS. This approach may be worthwhile to modulate gut microbiota of IBS patients toward a healthier profile.",2020,"Severity of overall or individual gastrointestinal symptoms did not differ between the groups at week 4 or 8, and no symptom deterioration was seen in any of the groups.","['Irritable bowel syndrome patients diagnosed according to the Rome IV criteria received', 'IBS patients', 'patients with irritable bowel syndrome (IBS', 'healthy adults', 'irritable bowel syndrome patients', 'patients with IBS']","['Human milk oligosaccharide supplementation', ""placebo (glucose), or 5\xa0g or 10\xa0g 2'FL/LNnT"", ""2'-O-fucosyllactose and Lacto-N-neotetraose (2'FL/LNnT"", ""2'FL/LNnT"", 'placebo']","['gastrointestinal symptom severity; fecal microbiota composition', 'Fecal bifidobacteria abundance', 'Severity of overall or individual gastrointestinal symptoms', 'fecal bifidobacteria abundance', 'fecal bacterial profile', 'overall fecal microbiota composition', 'symptom deterioration', 'Gastrointestinal Symptom Rating Scale-IBS']","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0026140', 'cui_str': 'Breast milk'}, {'cui': 'C0028959', 'cui_str': 'Oligosaccharide'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1318182', 'cui_str': '10G'}, {'cui': 'C0064595', 'cui_str': 'lacto-N-neotetraose'}]","[{'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}]",60.0,0.247149,"Severity of overall or individual gastrointestinal symptoms did not differ between the groups at week 4 or 8, and no symptom deterioration was seen in any of the groups.","[{'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Iribarren', 'Affiliation': 'Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Törnblom', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Imran', 'Initials': 'I', 'LastName': 'Aziz', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Maria K', 'Initials': 'MK', 'LastName': 'Magnusson', 'Affiliation': 'Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Sundin', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Louise K', 'Initials': 'LK', 'LastName': 'Vigsnaes', 'Affiliation': 'Glycom A/S, Hørsholm, Denmark.'}, {'ForeName': 'Ingvild Dybdrodt', 'Initials': 'ID', 'LastName': 'Amundsen', 'Affiliation': 'Glycom A/S, Hørsholm, Denmark.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'McConnell', 'Affiliation': 'Glycom A/S, Hørsholm, Denmark.'}, {'ForeName': 'Dorthe', 'Initials': 'D', 'LastName': 'Seitzberg', 'Affiliation': 'Glycom A/S, Hørsholm, Denmark.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Öhman', 'Affiliation': 'Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Simrén', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13920'] 248,32682994,Time limited eating in adolescents with obesity (time LEAd): Study protocol.,"BACKGROUND Time limited eating (TLE) has been shown to be effective for weight loss and improvement of glycemic control in adults with obesity and type 2 diabetes (T2D), but has not been well studied in adolescents. TLE may be a more feasible, flexible and effective dietary intervention for adolescents because it removes the need for intensive counting of calories or macronutrients, and emphasizes eating during a specified time period. OBJECTIVES The aim of this study is to assess the feasibility of a TLE approach in adolescents with obesity using a continuous glucose monitor (CGM) to promote adherence to the intervention. METHODS We propose a prospective, randomized controlled trial, in 60 adolescents (ages 14-18) with obesity (BMI% ≥ 95th percentile). Youth will be randomized to one of three treatment groups for a 12-week intervention: Group 1) Low sugar and carbohydrate education (LSC, 5% of total daily calories from sugar (<35 g)/day; <90 g carbohydrate (CHO)/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback), Group 2) LSC + TLE (16-h fast/8-h feed for 5 days per week) + blinded CGM, and Group 3) LSC + TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy). Outcomes will include change in total body fat (TBF) percentage measured on DEXA scan, BMI status and fasting blood glucose at 12 weeks compared to baseline. CONCLUSIONS TLE is a potentially powerful lifestyle intervention that could be readily integrated into pediatric weight management programs to optimize their impact and accelerate healthy changes. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT03954223.",2020,"TLE may be a more feasible, flexible and effective dietary intervention for adolescents because it removes the need for intensive counting of calories or macronutrients, and emphasizes eating during a specified time period. ","['60 adolescents (ages 14-18) with obesity (BMI%\u202f≥\u202f95th percentile', 'adolescents with obesity (time LEAd', 'adolescents with obesity using a', 'adults with obesity and type 2 diabetes (T2D']","['TLE approach', 'LSC\u202f+\u202fTLE', 'TLE', 'Low sugar and carbohydrate education (LSC, 5% of total daily calories from sugar (<35\u202fg)/day; <90\u202fg carbohydrate (CHO)/day)\u202f+\u202fblinded CGM', 'continuous glucose monitor (CGM']","['total body fat (TBF) percentage measured on DEXA scan, BMI status and fasting blood glucose']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332186', 'cui_str': 'Definite time'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439175', 'cui_str': '% of total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0439087', 'cui_str': '<90'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}]","[{'cui': 'C0424677', 'cui_str': 'Total body fat'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}]",,0.0740017,"TLE may be a more feasible, flexible and effective dietary intervention for adolescents because it removes the need for intensive counting of calories or macronutrients, and emphasizes eating during a specified time period. ","[{'ForeName': 'Alaina P', 'Initials': 'AP', 'LastName': 'Vidmar', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America. Electronic address: avidmar@chla.usc.edu.""}, {'ForeName': 'Michael I', 'Initials': 'MI', 'LastName': 'Goran', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Naguib', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'Fink', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Choo Phei', 'Initials': 'CP', 'LastName': 'Wee', 'Affiliation': 'CTSI Biostatics Core, Saban Research Institute, Los Angeles, CA, United States of America.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Hegedus', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Kelleen', 'Initials': 'K', 'LastName': 'Lopez', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Janelle', 'Initials': 'J', 'LastName': 'Gonzalez', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Raymond', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106082'] 249,32443961,Primary Care Clinic Nurse Activities with a Telehealth Monitoring System.,"The purpose of this study was to evaluate differences in the types of nursing activities and communication processes reported in a primary care clinic between patients who used a home-based monitoring system to electronically communicate self-monitored blood glucose and blood pressure values and those who assumed usual care. Data were extracted from electronic medical records from individuals who participated in a randomized controlled trial comparing in-home monitoring and usual care in patients with Type 2 diabetes and hypertension being treated in a primary care clinic. Data about nursing activities initiated by primary care clinic nurses were compared between groups using descriptive statistics and independent t -tests. Significant differences between groups were identified for the direct care nursing activities of providing lifestyle and health education, medication adjustments, and patient follow-up. This study provides evidence of greater nursing activity reported in a primary care clinic in patients who utilized a home-based monitoring system.",2020,"Significant differences between groups were identified for the direct care nursing activities of providing lifestyle and health education, medication adjustments, and patient follow-up.","['patients with Type 2 diabetes and hypertension being treated in a primary care clinic', 'patients who utilized a home-based monitoring system', 'patients who used a home-based monitoring system to electronically communicate self-monitored blood glucose and blood pressure values and those who assumed usual care']",[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205196', 'cui_str': 'Communicating'}, {'cui': 'C0005803', 'cui_str': 'Self-monitoring of blood glucose'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",[],[],,0.0129672,"Significant differences between groups were identified for the direct care nursing activities of providing lifestyle and health education, medication adjustments, and patient follow-up.","[{'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Howland', 'Affiliation': 'Sinclair School of Nursing, University of Missouri, Columbia, MO, USA.'}, {'ForeName': 'Laurel', 'Initials': 'L', 'LastName': 'Despins', 'Affiliation': 'Sinclair School of Nursing, University of Missouri, Columbia, MO, USA.'}, {'ForeName': 'Jeri', 'Initials': 'J', 'LastName': 'Sindt', 'Affiliation': 'Sinclair School of Nursing, University of Missouri, Columbia, MO, USA.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Wakefield', 'Affiliation': 'Sinclair School of Nursing, University of Missouri, Columbia, MO, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Mehr', 'Affiliation': 'Curtis W. and Ann H. Long Department of Family and Community Medicine, School of Medicine, University of Missouri, Columbia, MO, USA.'}]",Western journal of nursing research,['10.1177/0193945920923082'] 250,32546128,Videolaryngoscopy versus direct laryngoscopy for double-lumen endotracheal tube intubation in thoracic surgery - a randomised controlled clinical trial.,"BACKGROUND Double-lumen tube (DLT) intubation is necessary for thoracic surgery and other operations with the need for lung separation. However, DLT insertion is complex and might result in airway trauma. A new videolaryngoscopy (GVL) with a thin blade might improve the intubation time and reduce complexity as well as iatrogenic airway complications compared to conventional direct laryngoscopy (DL) for DLT intubation. METHODS A randomised, controlled trial was conducted in 70 patients undergoing elective thoracic surgery using DLT for lung separation. Primary endpoint was time to successful intubation. The secondary endpoints of this study were number of intubation attempts, the assessment of difficulty, any complications during DLT intubation and the incidence of objective trauma of the oropharynx and supraglottic space and intubation-related subjective symptoms. RESULTS 65 patients were included (DL group [n  =  31], GVL group [n  =  34]). Median intubation time (25th-75th percentiles) in GVL group was 93 s (63-160) versus 74 (58-94) in DL group [p = 0.044]. GVL resulted in significantly improved visualisation of the larynx (Cormack and Lehane grade of 1 in GVL group was 97% vs. 74% in DL Group [p = 0.008]). Endoscopic examinations revealed significant differences in GVL group compared to DL group showing less red-blooded vocal cord [p = 0.004], vocal cord haematoma [p = 0.022] and vocal cord haemorrhage [p = 0.002]. No significant differences regarding the postoperative subjective symptoms of airway were found. CONCLUSIONS Videolaryngoscopy using the GlideScope®-Titanium shortly prolongs DLT intubation duration compared to direct laryngoscopy but improves the view. Objective intubation trauma but not subjective complaints are reduced. TRIAL REGISTRATION German Clinical Trial Register DRKS00020978, retrospectively registered on 09. March 2020.",2020,"Endoscopic examinations revealed significant differences in GVL group compared to DL group showing less red-blooded vocal cord [p = 0.004], vocal cord haematoma [p = 0.022] and vocal cord haemorrhage [p = 0.002].","['70 patients undergoing elective thoracic surgery using DLT for lung separation', '65 patients were included (DL group [n\u200a\u2009=\u2009\u200a31], GVL group [n\u200a\u2009=\u2009\u200a34']","['conventional direct laryngoscopy (DL', 'Double-lumen tube (DLT) intubation', 'Videolaryngoscopy versus direct laryngoscopy for double-lumen endotracheal tube intubation', 'videolaryngoscopy (GVL', 'GVL']","['postoperative subjective symptoms of airway', 'number of intubation attempts, the assessment of difficulty, any complications during DLT intubation and the incidence of objective trauma of the oropharynx and supraglottic space and intubation-related subjective symptoms', 'vocal cord haematoma', 'Median intubation time', 'DLT intubation duration', 'time to successful intubation', 'visualisation of the larynx (Cormack and Lehane grade', 'vocal cord haemorrhage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0039986', 'cui_str': 'Thoracic surgery'}, {'cui': 'C0441299', 'cui_str': 'Double lumen tube'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0036679', 'cui_str': 'Separation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0392823', 'cui_str': 'Direct laryngoscopy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0600554', 'cui_str': 'Graft-vs-Leukemia Effect'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0392823', 'cui_str': 'Direct laryngoscopy'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C2584423', 'cui_str': 'Double lumen tracheobronchial tube'}, {'cui': 'C0600554', 'cui_str': 'Graft-vs-Leukemia Effect'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0441299', 'cui_str': 'Double lumen tube'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0225574', 'cui_str': 'Structure of supraglottic space'}, {'cui': 'C0344369', 'cui_str': 'Vocal cord hematoma'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0336630', 'cui_str': 'Endotracheal tube'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0023051', 'cui_str': 'Disorder of the larynx'}, {'cui': 'C0456719', 'cui_str': 'Cormack and Lehane grade'}]",70.0,0.326676,"Endoscopic examinations revealed significant differences in GVL group compared to DL group showing less red-blooded vocal cord [p = 0.004], vocal cord haematoma [p = 0.022] and vocal cord haemorrhage [p = 0.002].","[{'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Risse', 'Affiliation': 'Center of Emergency Medicine, University Hospital Essen, Hufelandstrasse 55, 45122, Essen, Germany. joachim.risse@uk-essen.de.'}, {'ForeName': 'Ann-Kristin', 'Initials': 'AK', 'LastName': 'Schubert', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Philipps-University Marburg, Baldingerstraße, 35033, Marburg, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Wiesmann', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Philipps-University Marburg, Baldingerstraße, 35033, Marburg, Germany.'}, {'ForeName': 'Ansgar', 'Initials': 'A', 'LastName': 'Huelshoff', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Philipps-University Marburg, Baldingerstraße, 35033, Marburg, Germany.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Stay', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Philipps-University Marburg, Baldingerstraße, 35033, Marburg, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Zentgraf', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Philipps-University Marburg, Baldingerstraße, 35033, Marburg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Kirschbaum', 'Affiliation': 'Visceral, Thoracic and Vascular Surgery Clinic, University Hospital Giessen and Marburg GmbH, Baldingerstraße, 35033, Marburg, Germany.'}, {'ForeName': 'Hinnerk', 'Initials': 'H', 'LastName': 'Wulf', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Philipps-University Marburg, Baldingerstraße, 35033, Marburg, Germany.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Feldmann', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Philipps-University Marburg, Baldingerstraße, 35033, Marburg, Germany.'}, {'ForeName': 'Karl Matteo', 'Initials': 'KM', 'LastName': 'Meggiolaro', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Philipps-University Marburg, Baldingerstraße, 35033, Marburg, Germany.'}]",BMC anesthesiology,['10.1186/s12871-020-01067-x'] 251,32557665,Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study.,"We describe outcomes from the first-in-human study of garetosmab (a fully human monoclonal antibody that inhibits activin A) under development for the treatment of fibrodysplasia ossificans progressiva (FOP). In a double-blind, placebo-controlled phase 1 study, 40 healthy women of nonchildbearing potential were randomized to receive a single dose of intravenous garetosmab 0.3, 1, 3, or 10 mg/kg; subcutaneous garetosmab 300 mg; or placebo. Serum concentrations of functional garetosmab (with ≥1 arm free to bind to target), total activin A, and antidrug antibodies were measured predose and up to 113 days post-first dose. Garetosmab demonstrated an acceptable safety profile with no dose-limiting toxicities. Garetosmab displayed nonlinear pharmacokinetics with target-mediated elimination. With increasing doses of intravenous garetosmab, mean peak concentration increased in a dose-proportional manner; mean steady-state estimates ranged from 41.4 to 47.8 mL/kg. A greater than dose-proportional increase in mean area under the concentration-time curve from time zero extrapolated to infinity (range, 72.2-7520 mg*day/L) was observed, consistent with decreasing mean clearance (range, 4.35-1.34 mL/day/kg). Following administration of intravenous garetosmab, mean concentrations of total activin A increased in a dose-dependent manner. At 10 mg/kg, total activin A levels reached a state of little or no change between weeks 4 and 12, suggesting saturation of the target-mediated pathway. No safety signals were seen in this study to preclude investigation in patients. Following intravenous administration, garetosmab concentrations decreased quickly, then decreased over time (reflecting linear elimination), and finally decreased in a nonlinear phase, reflecting target-mediated elimination. Results here support further investigation. Garetosmab 10 mg/kg every 4 weeks intravenously is being evaluated in patients with FOP (NCT03188666).",2020,"Following administration of intravenous garetosmab, mean concentrations of total activin A increased in a dose-dependent manner.",['40 healthy women of nonchildbearing potential'],"['placebo', 'intravenous garetosmab 0.3, 1, 3, or 10 mg/kg; subcutaneous garetosmab 300 mg; or placebo', 'Garetosmab (Anti-Activin A']","['mean concentrations of total activin A', 'total activin', 'mean peak concentration', 'Serum concentrations of functional garetosmab (with ≥1 arm free to bind to target), total activin A, and antidrug antibodies', 'mean clearance']","[{'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0100748', 'cui_str': 'Activin A'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0100748', 'cui_str': 'Activin A'}, {'cui': 'C0050668', 'cui_str': 'Activin hormone'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}]",40.0,0.164094,"Following administration of intravenous garetosmab, mean concentrations of total activin A increased in a dose-dependent manner.","[{'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Vanhoutte', 'Affiliation': 'SGS Clinical Pharmacology Unit, Antwerp, Belgium.'}, {'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Liang', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Marcella', 'Initials': 'M', 'LastName': 'Ruddy', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'An', 'Initials': 'A', 'LastName': 'Zhao', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Tiera', 'Initials': 'T', 'LastName': 'Drewery', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Yuhuan', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'DelGizzi', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Forleo-Neto', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Manoj', 'Initials': 'M', 'LastName': 'Rajadhyaksha', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Herman', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Davis', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1638'] 252,32444343,"The effect of acute aerobic exercise on central arterial stiffness, wave reflections, and hemodynamics in adults with diabetes: A randomized cross-over design.","BACKGROUND Individuals with diabetes have greater central arterial stiffness, wave reflections, and hemodynamics, all of which promote the accelerated cardiovascular pathology seen in this population. Acute aerobic exercise has been shown to be an effective strategy for reducing central arterial stiffness, wave reflections, and hemodynamics in healthy individuals; however, the effects of acute aerobic exercise in reducing these outcomes is not well established in people with diabetes. Recently, implementation of high-intensity interval exercise (HIIE) has shown superior improvements in cardiovascular health outcomes when compared to traditional aerobic exercise. Yet, the effect of HIIE on the aforementioned outcomes in people with diabetes is not known. The purpose of this study was to (i) describe the central arterial stiffness, wave reflections, and hemodynamic responses to a bout of HIIE and moderate-intensity continuous exercise (MICE) in adults with diabetes; and (ii) compare the effects of HIIE and MICE on the aforementioned outcomes. METHODS A total of 24 adult men and women (aged 29-59 years old) with type 1 (n = 12) and type 2 (n = 12) diabetes participated in a randomized cross-over study. All participants completed the following protocols: (i) HIIE: cycling for 4 × 4 min at 85%-95% of heart rate peak (HR peak ), interspersed with 3 min of active recovery at 60%-70%HR peak ; (ii) MICE: 33 min of continuous cycling at 60%-70%HR peak ; and (iii) control (CON): lying quietly in a supine position for 30 min. RESULTS A significant group × time effect was found for changes in central systolic blood pressure (F = 3.20, p = 0.01) with a transient reduction for the HIIE group but not for the MICE or CON groups. There was a significant group × time effect for changes in augmentation index at a heart rate of 75 beats/min (F = 2.32, p = 0.04) with a decrease following for HIIE and MICE but not for CON. For all other measures of central arterial stiffness and hemodynamics, no significant changes were observed (p > 0.05). CONCLUSION A bout of HIIE appears to lead to a greater transient reduction in central systolic blood pressure than the reduction observed following MICE; however, both HIIE and MICE improved augmentation index at a heart rate of 75 beats/min in people with diabetes. There was no significant difference in response to HIIE and MICE in all outcomes. This provides preliminary evidence on the role of HIIE on such outcomes in people with diabetes.",2021,"For all other measures of central arterial stiffness and hemodynamics, no significant changes were observed (p > 0.05). ","['people with diabetes', '24 adult men and women (aged 29-59 years old) with type 1 (n\u202f=\u202f12) and type 2 (n\u202f=\u202f12) diabetes participated in a randomized cross-over study', 'healthy individuals', 'adults with diabetes', 'Individuals with diabetes']","['MICE', 'HIIE and moderate-intensity continuous exercise (MICE', 'Acute aerobic exercise', 'acute aerobic exercise', 'HIIE and MICE']","['central arterial stiffness, wave reflections, and hemodynamic responses', 'central arterial stiffness and hemodynamics', 'cardiovascular health outcomes', 'response to HIIE and MICE', 'augmentation index', 'central systolic blood pressure', 'augmentation index at a heart rate', 'central arterial stiffness, wave reflection and hemodynamics']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",24.0,0.0774815,"For all other measures of central arterial stiffness and hemodynamics, no significant changes were observed (p > 0.05). ","[{'ForeName': 'Kimberley L', 'Initials': 'KL', 'LastName': 'Way', 'Affiliation': 'Faculty of Medicine and Health, Discipline of Exercise and Sports Science, University of Sydney, Lidcombe, NSW 2141, Australia; Charles Perkins Centre, University of Sydney, Camperdown, NSW 2006, Australia; Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Camperdown, NSW 2006, Australia. Electronic address: KWay@ottawaheart.ca.'}, {'ForeName': 'Angela S', 'Initials': 'AS', 'LastName': 'Lee', 'Affiliation': 'Charles Perkins Centre, University of Sydney, Camperdown, NSW 2006, Australia; Faculty of Medicine and Health, Central Clinical School, University of Sydney, Camperdown, NSW 2006, Australia; Department of Endocrinology, Diabetes Centre, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.'}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Twigg', 'Affiliation': 'Charles Perkins Centre, University of Sydney, Camperdown, NSW 2006, Australia; Faculty of Medicine and Health, Central Clinical School, University of Sydney, Camperdown, NSW 2006, Australia; Department of Endocrinology, Diabetes Centre, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.'}, {'ForeName': 'Nathan A', 'Initials': 'NA', 'LastName': 'Johnson', 'Affiliation': 'Faculty of Medicine and Health, Discipline of Exercise and Sports Science, University of Sydney, Lidcombe, NSW 2141, Australia; Charles Perkins Centre, University of Sydney, Camperdown, NSW 2006, Australia; Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Camperdown, NSW 2006, Australia.'}]",Journal of sport and health science,['10.1016/j.jshs.2020.02.009'] 253,32446304,Effectivity of benzydamine hydrochloride gargle to reduce propofol consumption in endoscopic retrograde cholangiopancreatography procedure: a randomized controlled trial.,"BACKGROUND Endoscopic Retrograde Cholangiopancreatography (ERCP) is a complex endoscopic procedure that requires moderate to deep sedation. Propofol is the sedative agent of choice for sedation in ERCP due to its fast distribution and fast elimination time without a cumulative effect after infusion, resulting in shorter recovery time. Benzydamine hydrochloride is a topical non-steroidal anti-inflammatory drug that has analgesic, local anesthetic, and anti-inflammatory effects that have been known to be effective in reducing postoperative sore throat. Combination of propofol and topical analgesic may provide adequate sedation and reduce propofol consumption. This study aimed to determine the effectivity of benzydamine hydrochloride gargling in reducing propofol consumption in the ERCP procedure. METHODS This study was a single-blind randomized controlled trial for patients undergoing ERCP procedures at Cipto Mangunkusumo Hospital from August to September 2018. A total of 72 subjects were recruited consecutively and randomly assigned into two groups. The first group received 15 mL of 0.15% benzydamine hydrochloride mouthwash prior to the procedure, whereas the second group received 15 mL of water mouthwash. Additional propofol was administered when patient moved or Ramsay Sedation Scale rose above 4. Cumulative propofol consumption per kg body weight per minute and incidence of postoperative sore throat were recorded in each group. Incidence of desaturation, postoperative nausea vomitting, and dysphagia were also recorded. Data analysis was performed with Statistical Package for the Social Sciences. RESULTS Cumulative propofol consumption per minute per kg body weight in the benzydamine hydrochloride group was 152.7 (91.9-238.8) mcg/kg/minute, while in the control group was 200.05 (114.4-380.2) mcg/kg/ minute (p = < 0.001). The incidence of sore throat on the 0th, 2nd, and 4th hour for the benzydamine hydrochloride group was 11.4, 11.4, and 5.7%, while in the control group was 50, 52.8, and 36.1% (p = < 0.001, < 0.001, 0.003). Desaturation was found in control group whereas none in benzydamine hydrochloride group. Complaints of nausea and vomiting were comparable in both groups. CONCLUSION Benzydamine hydrochloride gargling was effective in reducing cumulative propofol consumption in the ERCP procedure. TRIAL REGISTRATION Study was registered retrospectively in ClinicalTrials.gov with NCT04167592 on November 8th 2019.",2020,"Complaints of nausea and vomiting were comparable in both groups. ","['endoscopic retrograde cholangiopancreatography procedure', 'A total of 72 subjects', 'patients undergoing ERCP procedures at Cipto Mangunkusumo Hospital from August to September 2018']","['Benzydamine hydrochloride', '15\u2009mL of 0.15% benzydamine hydrochloride', 'propofol', 'propofol and topical analgesic', 'Endoscopic Retrograde Cholangiopancreatography (ERCP', 'benzydamine hydrochloride', 'Propofol', '15\u2009mL of water mouthwash', 'benzydamine hydrochloride gargle']","['Incidence of desaturation, postoperative nausea vomitting, and dysphagia', 'Cumulative propofol consumption per minute per kg body weight', 'cumulative propofol consumption', 'Desaturation', 'Complaints of nausea and vomiting', 'Cumulative propofol consumption per kg body weight per minute and incidence of postoperative sore throat', 'propofol consumption', 'incidence of sore throat']","[{'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0282070', 'cui_str': 'Benzydamine hydrochloride'}, {'cui': 'C4068886', 'cui_str': '0.15'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0026647', 'cui_str': 'Oromucosal solution for gargle'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0520904', 'cui_str': 'Postoperative nausea'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0702093', 'cui_str': '/minute'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}]",72.0,0.100761,"Complaints of nausea and vomiting were comparable in both groups. ","[{'ForeName': 'Adhrie', 'Initials': 'A', 'LastName': 'Sugiarto', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo General Hospital, Pangeran Diponegoro Street No. 71, Jakarta, Indonesia. adhrie@gmail.com.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Kapuangan', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo General Hospital, Pangeran Diponegoro Street No. 71, Jakarta, Indonesia.'}, {'ForeName': 'Aida Rosita', 'Initials': 'AR', 'LastName': 'Tantri', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo General Hospital, Pangeran Diponegoro Street No. 71, Jakarta, Indonesia.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Chrisnata', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo General Hospital, Pangeran Diponegoro Street No. 71, Jakarta, Indonesia.'}]",BMC anesthesiology,['10.1186/s12871-020-00996-x'] 254,32544925,Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).,"Anhedonia remains a major clinical issue for which there is few effective interventions. Untreated or poorly controlled anhedonia has been linked to worse disease course and increased suicidal behavior across disorders. Taking a proof-of-mechanism approach under the auspices of the National Institute of Mental Health FAST-FAIL initiative, we were the first to show that, in a transdiagnostic sample screened for elevated self-reported anhedonia, 8 weeks of treatment with a kappa-opioid receptor (KOR) antagonist resulted in significantly higher reward-related activation in one of the core hubs of the brain reward system (the ventral striatum), better reward learning in the Probabilistic Reward Task (PRT), and lower anhedonic symptoms, relative to 8 weeks of placebo. Here, we performed secondary analyses of the PRT data to investigate the putative effects of KOR antagonism on anhedonic behavior with more precision by using trial-level model-based Bayesian computational modeling and probability analyses. We found that, relative to placebo, KOR antagonism resulted in significantly higher learning rate (i.e., ability to learn from reward feedback) and a more sustained preference toward the more frequently rewarded stimulus, but unaltered reward sensitivity (i.e., the hedonic response to reward feedback). Collectively, these findings provide novel evidence that in a transdiagnostic sample characterized by elevated anhedonia, KOR antagonism improved the ability to modulate behavior as a function of prior rewards. Together with confirmation of target engagement in the primary report (Krystal et al., Nat Med, 2020), the current findings suggest that further transdiagnostic investigation of KOR antagonism for anhedonia is warranted.",2020,"We found that, relative to placebo, KOR antagonism resulted in significantly higher learning rate (i.e., ability to learn from reward feedback) and a more sustained preference toward the more frequently rewarded stimulus, but unaltered reward sensitivity (i.e., the hedonic response to reward feedback).",[],"['placebo, KOR antagonism', 'KOR antagonism', 'placebo']","['learning rate (i.e., ability to learn from reward feedback']",[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0064239', 'cui_str': 'kappa Opioid Receptor'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0233832', 'cui_str': 'Learning ability'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]",,0.0633681,"We found that, relative to placebo, KOR antagonism resulted in significantly higher learning rate (i.e., ability to learn from reward feedback) and a more sustained preference toward the more frequently rewarded stimulus, but unaltered reward sensitivity (i.e., the hedonic response to reward feedback).","[{'ForeName': 'Diego A', 'Initials': 'DA', 'LastName': 'Pizzagalli', 'Affiliation': 'McLean Hospital, Harvard Medical School, Belmont, MA, USA. dap@mclean.harvard.edu.'}, {'ForeName': 'Moria', 'Initials': 'M', 'LastName': 'Smoski', 'Affiliation': 'Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Yuen-Siang', 'Initials': 'YS', 'LastName': 'Ang', 'Affiliation': 'McLean Hospital, Harvard Medical School, Belmont, MA, USA.'}, {'ForeName': 'Alexis E', 'Initials': 'AE', 'LastName': 'Whitton', 'Affiliation': 'School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Sanacora', 'Affiliation': 'Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Sanjay J', 'Initials': 'SJ', 'LastName': 'Mathew', 'Affiliation': 'Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Nurnberger', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'Sarah H', 'Initials': 'SH', 'LastName': 'Lisanby', 'Affiliation': 'National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'Dan V', 'Initials': 'DV', 'LastName': 'Iosifescu', 'Affiliation': 'New York University School of Medicine, New York, NY, USA.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Murrough', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Hongqiu', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Richard D', 'Initials': 'RD', 'LastName': 'Weiner', 'Affiliation': 'Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Joseph R', 'Initials': 'JR', 'LastName': 'Calabrese', 'Affiliation': 'Case Western Reserve School of Medicine, Cleveland, OH, USA.'}, {'ForeName': 'Wayne', 'Initials': 'W', 'LastName': 'Goodman', 'Affiliation': 'Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'William Z', 'Initials': 'WZ', 'LastName': 'Potter', 'Affiliation': 'National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Krystal', 'Affiliation': 'Duke University School of Medicine, Durham, NC, USA.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0738-4'] 255,32552138,Community Targeting of Uncontrolled Hypertension: Results of a Hypertension Screening and Education Intervention in Community Churches Serving Predominantly Racial/Ethnic Minority Populations.,"Background. Uncontrolled hypertension is the primary risk factor for the development of cardiovascular complications and particularly burdens racial/ethnic minority populations. Aim. To determine the effectiveness of a community hypertension screening, education, and empowerment intervention on blood pressure (BP) improvement. Method . We screened 152 participants across four churches in predominantly racial/ethnic minority neighborhoods for elevated BP. During this visit, those with BP ≥ 140/90 mmHg were enrolled in the study and completed interventions. Individuals with moderately elevated BP (≥140/90 and <160/100 mmHg; Group 1) viewed a 3-minute hypertension education video. Individuals with severely elevated BP (≥160/100 mmHg; Group 2) additionally viewed echocardiograms images with subclinical changes from uncontrolled hypertension and had a brief on-site medication review with a pharmacist. Both groups received automated BP monitors and information on neighborhood federally qualified health centers for primary care. Participants returned to each church for follow-up 3 months later. We analyzed BP difference at 3 months and percentage with controlled BP for each group. Results . For Group 1, mean baseline and follow-up BPs were 143.5/88.0 mmHg and 138.5/85.8 mmHg, respectively. For Group 2, BPs significantly decreased from 165.4/98.3 mmHg to 150.4/90.8 mmHg. After the intervention, participants with controlled BP for Groups 1 and 2 were 35.5% and 55.2%, respectively. Discussion . Participants in both groups had BP improvements. Greater improvements were in individuals at higher cardiovascular risk due to severely elevated BPs (≥160/100 mmHg). Conclusion . This pilot highlights the impact that streamlined empowerment interventions with dedicated health personnel can have in high-risk communities with elevated BPs.",2021,Individuals with severely elevated BP (≥160/100 mmHg; Group 2) additionally viewed echocardiograms images with subclinical changes from uncontrolled hypertension and had a brief on-site medication review with a pharmacist.,"['140/90 mmHg were enrolled in the study and completed interventions', '152 participants across four churches in predominantly racial/ethnic minority neighborhoods for elevated BP', 'Individuals with severely elevated BP (≥160/100 mmHg; Group 2) additionally viewed echocardiograms images with subclinical changes from uncontrolled hypertension and had a brief on-site medication review with a pharmacist', 'Individuals with moderately elevated BP (≥140/90 and <160/100 mmHg; Group 1) viewed a 3-minute hypertension education video', 'Uncontrolled Hypertension']","['community hypertension screening, education, and empowerment intervention', 'Hypertension Screening and Education Intervention']","['blood pressure (BP) improvement', 'BP improvements']","[{'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0562324', 'cui_str': 'Church'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0027569', 'cui_str': 'Neighborhood'}, {'cui': 'C0497247', 'cui_str': 'Elevated blood pressure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1868885', 'cui_str': 'Uncontrolled hypertension'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0560023', 'cui_str': 'Review of medication'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0204946', 'cui_str': 'Hypertension education'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0740221', 'cui_str': 'Hypertension screening'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",152.0,0.0420355,Individuals with severely elevated BP (≥160/100 mmHg; Group 2) additionally viewed echocardiograms images with subclinical changes from uncontrolled hypertension and had a brief on-site medication review with a pharmacist.,"[{'ForeName': 'Heather M', 'Initials': 'HM', 'LastName': 'Prendergast', 'Affiliation': 'University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Escobar-Schulz', 'Affiliation': 'University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Del Rios', 'Affiliation': 'University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Petzel-Gimbar', 'Affiliation': 'University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'McPherson', 'Affiliation': 'University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Jackson', 'Affiliation': 'University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'KaLynn', 'Initials': 'K', 'LastName': 'Terrell', 'Affiliation': 'Marian University, Indianapolis, IN, USA.'}, {'ForeName': 'Sara W', 'Initials': 'SW', 'LastName': 'Heinert', 'Affiliation': 'University of Illinois at Chicago, Chicago, IL, USA.'}]",Health promotion practice,['10.1177/1524839920933897'] 256,32448972,Comparison between shockpulse and pneumatic lithotripsy in percutaneous nephrolithotomy.,"PURPOSE To compare the effectiveness and safety of shockpulse with pneumatic lithotripsy in percutaneous nephrolithotomy. METHODS A prospective randomized comparative study was performed in Department of Urology, Bir Hospital for 1-year duration with 61 patients in shockpulse (Group 1) and 58 patients in pneumatic lithoclast (Group 2) groups, respectively. Patient's demographics, stone characteristics, hemoglobin drop, hospital stay, operative duration, stone fragmentation time and postoperative complications were compared. RESULTS The two groups did not differ significantly in terms of patient's demographic and stone characteristics. The mean hemoglobin drop was 1.96 ± 1.48 g/dl in Group 1 and 2.32 ± 1.38 g/dl in Group 2 (p = 0.16) and hospital stay was 3.14 ± 1.42 days in Group 1 and 3.29 ± 1.82 days in Group 2 (p = 0.62). The number of cases that required multiple tracts were six (9.8%) in Group 1 and 12 (20.68%) in Group 2 (p = 0.12). The stone-free rates were 78.69% in Group 1 and 74.13% in Group 2 (p = 0.66). Mean total operation time was 43.23 ± 18.49 min in Group 1 as compared to 51.53 ± 19.48 min in Group 2 (p = 0.0188). Mean stone fragmentation time was 17.95 ± 15.25 min in Group 1 and 24.37 ± 11.12 min in Group 2 (p = 0.0096). Overall complications were not significant between the two Groups (p = 0.58). On sub-analysis of the patients with single tracts in both groups the results were comparable to patients with single and multiple tracts combined. CONCLUSIONS Despite similar stone-free rates and complications between the two Groups, shockpulse has significantly lower stone fragmentation time and total operation time as compared to pneumatic lithotripsy.",2021,"Despite similar stone-free rates and complications between the two Groups, shockpulse has significantly lower stone fragmentation time and total operation time as compared to pneumatic lithotripsy.","['Department of Urology, Bir Hospital for 1-year duration with 61 patients in shockpulse (Group 1) and 58 patients in pneumatic lithoclast (Group 2) groups, respectively', 'percutaneous nephrolithotomy']","['shockpulse and pneumatic lithotripsy', 'pneumatic lithotripsy']","['Mean stone fragmentation time', 'stone-free rates', 'Mean total operation time', ""Patient's demographics, stone characteristics, hemoglobin drop, hospital stay, operative duration, stone fragmentation time and postoperative complications"", 'stone fragmentation time and total operation time', 'mean hemoglobin drop', 'Overall complications', ""patient's demographic and stone characteristics"", 'hospital stay']","[{'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0441577', 'cui_str': 'Ballistic fragmentation'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}]","[{'cui': 'C0023878', 'cui_str': 'Lithotripsy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0332472', 'cui_str': 'Fragmentation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0162119', 'cui_str': 'Hemoglobin low'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.0275498,"Despite similar stone-free rates and complications between the two Groups, shockpulse has significantly lower stone fragmentation time and total operation time as compared to pneumatic lithotripsy.","[{'ForeName': 'Birendra Kumar', 'Initials': 'BK', 'LastName': 'Yadav', 'Affiliation': 'Deparment of Urology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal. ucmsbirendra@gmail.com.'}, {'ForeName': 'Robin Bahadur', 'Initials': 'RB', 'LastName': 'Basnet', 'Affiliation': 'Deparment of Urology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal.'}, {'ForeName': 'Anil', 'Initials': 'A', 'LastName': 'Shrestha', 'Affiliation': 'Deparment of Urology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal.'}, {'ForeName': 'Parash Mani', 'Initials': 'PM', 'LastName': 'Shrestha', 'Affiliation': 'Deparment of Urology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal.'}]",World journal of urology,['10.1007/s00345-020-03239-3'] 257,32552691,Modified-ramped position: a new position for intubation of obese females: a randomized controlled pilot study.,"BACKGROUND Endotracheal intubation requires optimum position of the head and neck. In obese females, the usual ramped position might not provide adequate intubating conditions. We hypothesized that a new position, termed modified-ramped position, during induction of anesthesia would facilitate endotracheal intubation through bringing the breasts away from the laryngoscope and would also improve the laryngeal visualization. METHODS Sixty obese female patients scheduled for general anesthesia were randomly assigned into either ramped or modified-ramped position during induction of anesthesia. In the ramped position (n = 30), the patient head and shoulders were elevated to achieve alignment of the sternal notch and the external auditory meatus; while in the modified-ramped position (n = 30), the patient shoulders were elevated using a special pillow, and the head was extended to the most possible range. Our primary outcome was the incidence of failed laryngoscopic insertion in the oral cavity (the need for patient repositioning). Other outcomes included time till vocal cord visualization, time till successful endotracheal intubation, difficulty of the mask ventilation, and Cormack-Lehane grade for laryngeal view. RESULTS Fourteen patients (47%) in ramped group required repositioning to facilitate introduction of the laryngoscope in the oral cavity in comparison to one patient (3%) in the modified-ramped position (p < 0.001). Modified-ramped position showed lower incidence of difficult mask ventilation, shorter time for glottic visualization, and shorter time for endotracheal tube insertion compared to the ramped position. The Cormack-Lehane grade was better in the modified-ramped position. CONCLUSION Modified-ramped position provided better intubating conditions, improved the laryngeal view, and eliminated the need for repositioning of obese female patients during insertion of the laryngoscope compared to ramped position. CLINICAL TRIAL REGISTRATION Identifier: NCT03640442. Date: August 2018.",2020,"RESULTS Fourteen patients (47%) in ramped group required repositioning to facilitate introduction of the laryngoscope in the oral cavity in comparison to one patient (3%) in the modified-ramped position (p < 0.001).","['obese females', 'obese female patients', 'Sixty obese female patients scheduled for general anesthesia']","['ramped or modified-ramped position during induction of anesthesia', 'Modified-ramped position']","['time till vocal cord visualization, time till successful endotracheal intubation, difficulty of the mask ventilation, and Cormack-Lehane grade for laryngeal view', 'incidence of failed laryngoscopic insertion in the oral cavity (the need for patient repositioning', 'incidence of difficult mask ventilation, shorter time for glottic visualization, and shorter time for endotracheal tube insertion']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0034646', 'cui_str': 'Ramp'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0853212', 'cui_str': 'Induction of anaesthesia'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042930', 'cui_str': 'Vocal cord structure'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0023078', 'cui_str': 'Laryngeal'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C2362912', 'cui_str': 'Patient Moving and Lifting'}, {'cui': 'C4706398', 'cui_str': 'Difficult mask ventilation'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0017681', 'cui_str': 'Glottis structure'}]",60.0,0.0652977,"RESULTS Fourteen patients (47%) in ramped group required repositioning to facilitate introduction of the laryngoscope in the oral cavity in comparison to one patient (3%) in the modified-ramped position (p < 0.001).","[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Hasanin', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt. ahmedmohamedhasanin@gmail.com.'}, {'ForeName': 'Hager', 'Initials': 'H', 'LastName': 'Tarek', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt.'}, {'ForeName': 'Maha M A', 'Initials': 'MMA', 'LastName': 'Mostafa', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt.'}, {'ForeName': 'Amany', 'Initials': 'A', 'LastName': 'Arafa', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt.'}, {'ForeName': 'Ahmed G', 'Initials': 'AG', 'LastName': 'Safina', 'Affiliation': 'Department of surgery, Cairo university, Giza, Egypt.'}, {'ForeName': 'Mona H', 'Initials': 'MH', 'LastName': 'Elsherbiny', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt.'}, {'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Hosny', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Gado', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt.'}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'Almenesey', 'Affiliation': 'Department of anesthesia and critical care medicine, Beni suef university, Beni suef, Egypt.'}, {'ForeName': 'Ghada Adel', 'Initials': 'GA', 'LastName': 'Hamden', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Mahmoud', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Amin', 'Affiliation': 'Department of anesthesia and critical care medicine, Cairo university, Giza, Egypt.'}]",BMC anesthesiology,['10.1186/s12871-020-01070-2'] 258,32446706,A role for the right dorsolateral prefrontal cortex in enhancing regulation of both craving and negative emotions in internet gaming disorder: A randomized trial.,"Reward-seeking and relief from negative emotions are two central motivational drives underlying addictions. Impaired executive control over craving and negative emotions contributes to compulsive addictive behaviors. Neuroimaging evidence has implicated the prefrontal cortex (PFC) in regulating craving or emotions. This study aims at examining whether anodal transcranial direct current stimulation (tDCS) over a specific region of the PFC would enhance both regulation processes. Thirty-three men with internet gaming disorder received active (1.5 mA for 20 minutes) and sham tDCS over the right dorsolateral PFC (dlPFC) one week apart in a randomized order. During each stimulation session, participants regulated craving for gaming during a regulation of craving (ROC) task and negative emotions during an emotion regulation (ER) task using cognitive reappraisal. Subjective ratings of craving and negative emotions and skin conductance responses (SCRs) were recorded. For both craving and negative emotions, tDCS of the right dlPFC facilitated downregulation and upregulation: active relative to sham tDCS decreased ratings (ROC: 95% CI of difference -1.38 to -0.56, p < 0.001; ER: -1.65 to -0.70, p < 0.001) and/or SCRs (ROC: -1.99 to -0.41 μs, p = 0.004) for downregulation, and increased ratings (ROC: 0.24 to 0.82, p = 0.001; ER: 0.26 to 0.72, p < 0.001) for upregulation. These findings provide the first experimental evidence confirming that tDCS of the right dlPFC enhances both craving- and negative-emotion-regulation. This suggests a promising approach for concurrently enhancing executive control over two central motivational drives underlying addictions.",2020,"and/or SCRs (ROC: -1.99 to -0.41 μs, p = 0.004) for downregulation, and increased ratings (ROC: 0.24 to 0.82, p = 0.001; ER: 0.26 to 0.72, p < 0.001) for upregulation.","['Thirty-three men with internet gaming disorder received', 'internet gaming disorder']","['participants regulated craving for gaming during a regulation of craving (ROC) task and negative emotions during an emotion regulation (ER) task using cognitive reappraisal', 'anodal transcranial direct current stimulation (tDCS', 'active (1.5 mA for 20 minutes) and sham tDCS over the right dorsolateral PFC (dlPFC']",['Subjective ratings of craving and negative emotions and skin conductance responses (SCRs'],"[{'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4760905', 'cui_str': 'Internet gaming disorder'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C2983598', 'cui_str': 'Dorsolateral'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]",33.0,0.110968,"and/or SCRs (ROC: -1.99 to -0.41 μs, p = 0.004) for downregulation, and increased ratings (ROC: 0.24 to 0.82, p = 0.001; ER: 0.26 to 0.72, p < 0.001) for upregulation.","[{'ForeName': 'Lu-Lu', 'Initials': 'LL', 'LastName': 'Wu', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, No. 19 XieJieKouWai Street, Haidian Strict 100875, Beijing, China.'}, {'ForeName': 'Marc N', 'Initials': 'MN', 'LastName': 'Potenza', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Child Study Center, Yale University School of Medicine, New Haven, CT, USA; Department of Neuroscience, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, Connecticut Council on Problem Gambling, Wethersfield, CT, USA; Connecticut Council on Problem Gambling, Wethersfield, CT, USA; Connecticut Mental Health Center, New Haven, CT, USA.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Zhou', 'Affiliation': 'Faculty of Education, Beijing Normal University, Beijing 100875, China.'}, {'ForeName': 'Hedy', 'Initials': 'H', 'LastName': 'Kober', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Department of Psychology, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Xin-Hui', 'Initials': 'XH', 'LastName': 'Shi', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, No. 19 XieJieKouWai Street, Haidian Strict 100875, Beijing, China.'}, {'ForeName': 'Sarah W', 'Initials': 'SW', 'LastName': 'Yip', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Child Study Center, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Jia-Hua', 'Initials': 'JH', 'LastName': 'Xu', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, No. 19 XieJieKouWai Street, Haidian Strict 100875, Beijing, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, No. 19 XieJieKouWai Street, Haidian Strict 100875, Beijing, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, No. 19 XieJieKouWai Street, Haidian Strict 100875, Beijing, China.'}, {'ForeName': 'Guan-Qun', 'Initials': 'GQ', 'LastName': 'Liu', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, No. 19 XieJieKouWai Street, Haidian Strict 100875, Beijing, China.'}, {'ForeName': 'Jin-Tao', 'Initials': 'JT', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, No. 19 XieJieKouWai Street, Haidian Strict 100875, Beijing, China; Beijing Key Lab of Applied Experimental Psychology, School of Psychology, Beijing Normal University, Beijing, China. Electronic address: zhangjintao@bnu.edu.cn.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2020.04.003'] 259,32452659,"Pharmacokinetics and Bioequivalence of Clopidogrel Hydrogen Sulfate Tablets in Fed and Fasted Conditions: An Open-Label, Randomized, Semireplicated Crossover Study in Healthy Chinese Volunteers.","Clopidogrel is an antiplatelet drug with high intraindividual variability in systemic exposure and efficacy. It has been used for treating atherosclerosis and acute coronary syndrome and in preventing stent restenosis and thrombotic complications after stent implantation in clinical practice for nearly 20 years. In this study we aimed to evaluate the bioequivalence of 2 clopidogrel hydrogen sulfate formulations (75-mg tablets) under fed (n = 66) and fasted (n = 66) conditions by using the reference-scaled average bioequivalence method. An open-label, randomized, 3-sequence and 3-period crossover (3×3), semireplicated study was designed and conducted. Clopidogrel concentration of plasma samples was measured by high-precision liquid chromatography and tandem mass spectrometry. The pharmacokinetic parameters were derived by a noncompartmental model. In the fed condition the geometric least-squares mean ratios of peak concentration (C max ) and area under the concentration-time curve (AUC 0-t ) were, respectively, 103.38% and 98.97%, and the corresponding 90%CIs were 95.68% to 111.70% and 94.67% to 103.47%. In the fasted condition the geometric least squares mean ratios of C max and AUC 0-t were, respectively, 106.53% and 105.77%, and the corresponding 90%CIs were 97.62% to 116.25% and 96.96% to 115.38%. According to the criteria for bioequivalence (80.00% to 125.00%), the test formulations of clopidogrel and Plavix were determined to be bioequivalent.",2020,"According to the criteria for bioequivalence (80.00% to 125.00%), the test formulations of clopidogrel and Plavix were determined to be bioequivalent.","['Fed and Fasted Conditions', 'Healthy Chinese Volunteers']","['clopidogrel hydrogen sulfate formulations', 'Clopidogrel Hydrogen Sulfate Tablet', 'Clopidogrel']","['geometric least squares mean ratios of C max and AUC 0-t', 'Clopidogrel concentration of plasma samples', 'geometric least-squares mean ratios of peak concentration (C max ) and area under the concentration-time curve (AUC 0-t ']","[{'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0772326', 'cui_str': 'Clopidogrel bisulfate'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}]","[{'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",66.0,0.0275802,"According to the criteria for bioequivalence (80.00% to 125.00%), the test formulations of clopidogrel and Plavix were determined to be bioequivalent.","[{'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Pei', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Chaoying', 'Initials': 'C', 'LastName': 'Hu', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Shili', 'Initials': 'S', 'LastName': 'Gong', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital Capital Medical University, Beijing, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.804'] 260,32458093,Enhanced super-mini-PCNL (eSMP): low renal pelvic pressure and high stone removal efficiency in a prospective randomized controlled trial.,"OBJECTIVE In the present prospective randomized controlled trial (RCT), enhanced-SMP (eSMP) and conventional Chinese mini-PCNL (mPCNL) were compared to test the low renal pelvic pressure (RPP) and high stone removal efficiency in eSMP. MATERIALS AND METHODS Hundred patients with 2-5 cm renal calculus were enrolled. Renal pelvic pressure, operation time, lithotripsy time, removed stone volume, and complications were compared between eSMP and mPCNL statistically. RESULTS There was no significant difference in removed stone volume between mPCNL and eSMP (8.09 ± 3.36 vs. 7.88 ± 3.07 mm 3 , t = 0.320, p = 0.750), lithotripsy time in mPCNL was longer than eSMP (49.6 ± 19.5 vs. 34.9 ± 14.2 min, t = 4.152, p < 0.001), thus stone removal efficiency was higher in eSMP (13.71 ± 1.18 vs. 9.82 ± 1.24 mm 3 /h, t = 15.499, p < 0.001). Intra-operative RPP in mPCNL was higher than eSMP (17.72 ± 3.33 vs. 12.03 ± 2.37 mmHg, t = 9.524, p < 0.001); accumulated time of backflow status (RPP > 30 mmHg) in mPCNL was longer than eSMP (23.3 ± 16.9 vs. 3.7 ± 4.2 s, t = 7.710, p < 0.001). There was no significant difference in postoperative fever rate between mPCNL and eSMP (12.77% vs. 4.34%, χ 2  = 2.095, p = 0.148), nor final stone-free rate (87.2% vs. 91.3%, χ 2  = 0.401, p = 0.526). Hospital stay in eSMP was shorter than mPCNL (2.54 ± 0.72 vs. 3.00 ± 0.88, t = 2.724, p = 0.008). CONCLUSION Enhanced SMP (eSMP) was safe and effective in the management of 2-5 cm renal calculus. It can keep a lower renal pelvic pressure and a higher stone removal efficiency when compared to conventional Chinese mini-PCNL. CLINICAL TRIAL REGISTRATION NC03206515.",2021,"It can keep a lower renal pelvic pressure and a higher stone removal efficiency when compared to conventional Chinese mini-PCNL. CLINICAL TRIAL REGISTRATION NC03206515.",['Hundred patients with 2-5\xa0cm renal calculus were enrolled'],"['enhanced-SMP (eSMP) and conventional Chinese mini-PCNL (mPCNL', 'Enhanced super-mini-PCNL (eSMP', 'SMP (eSMP']","['removed stone volume', 'stone removal efficiency', 'Hospital stay in eSMP', 'renal pelvic pressure', 'lithotripsy time in mPCNL', 'final stone-free rate', 'postoperative fever rate', 'time of backflow status', 'low renal pelvic pressure (RPP', 'Renal pelvic pressure, operation time, lithotripsy time, removed stone volume, and complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022650', 'cui_str': 'Kidney stone'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0445542', 'cui_str': 'Mini'}]","[{'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0227666', 'cui_str': 'Renal pelvis structure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0023878', 'cui_str': 'Lithotripsy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0424786', 'cui_str': 'Postoperative fever'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",0.0,0.0398232,"It can keep a lower renal pelvic pressure and a higher stone removal efficiency when compared to conventional Chinese mini-PCNL. CLINICAL TRIAL REGISTRATION NC03206515.","[{'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zhong', 'Affiliation': 'Department of Urology, Minimally Invasive Surgery Center, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, 1 Kangda Road, Haizhu District, Guangzhou, 510230, Guangdong, China.'}, {'ForeName': 'Junjun', 'Initials': 'J', 'LastName': 'Wen', 'Affiliation': 'Department of Urology, Minimally Invasive Surgery Center, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, 1 Kangda Road, Haizhu District, Guangzhou, 510230, Guangdong, China.'}, {'ForeName': 'Linjie', 'Initials': 'L', 'LastName': 'Peng', 'Affiliation': 'Department of Urology, Minimally Invasive Surgery Center, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, 1 Kangda Road, Haizhu District, Guangzhou, 510230, Guangdong, China.'}, {'ForeName': 'Guohua', 'Initials': 'G', 'LastName': 'Zeng', 'Affiliation': 'Department of Urology, Minimally Invasive Surgery Center, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, 1 Kangda Road, Haizhu District, Guangzhou, 510230, Guangdong, China. gzgyzgh@vip.sina.com.'}]",World journal of urology,['10.1007/s00345-020-03263-3'] 261,32553680,Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.,,2021,,['postmenopausal women with osteoporosis'],[],['Morphea-like skin lesions'],"[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}]",[],"[{'cui': 'C0036420', 'cui_str': 'Localized scleroderma'}, {'cui': 'C0037284', 'cui_str': 'Skin lesion'}]",,0.0179395,,"[{'ForeName': 'Kenneth G', 'Initials': 'KG', 'LastName': 'Saag', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Tobias J', 'Initials': 'TJ', 'LastName': 'de Villiers', 'Affiliation': 'Mediclinic Panorama and Department of Obstetrics and Gynaecology, University of Stellenbosch, Cape Town, South Africa.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Alexandersen', 'Affiliation': 'Center for Clinical and Basic Research, Vejle, Denmark.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Jacobe', 'Affiliation': 'Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Carrie', 'Initials': 'C', 'LastName': 'Kovarik', 'Affiliation': 'Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Victoria P', 'Initials': 'VP', 'LastName': 'Werth', 'Affiliation': 'Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Leung', 'Affiliation': 'Merck & Co, Inc, Kenilworth, New Jersey.'}, {'ForeName': 'Avani', 'Initials': 'A', 'LastName': 'Desai-Merchant', 'Affiliation': 'Merck & Co, Inc, Kenilworth, New Jersey.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Mattaliano', 'Affiliation': 'Merck & Co, Inc, Kenilworth, New Jersey.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Gurner', 'Affiliation': 'Merck & Co, Inc, Kenilworth, New Jersey. Electronic address: deborah_gurner@merck.com.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.06.036'] 262,32553717,Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.,"OBJECTIVES The aim was to fully characterize the plasma and urine washout pharmacokinetics of tenofovir (TFV) in adults following 6 weeks of controlled levels of tenofovir disoproxil fumarate (TDF) adherence, in order to inform the utility of clinic-based adherence testing. DESIGN This was a three-arm, randomized, open-label study in adult volunteers. Participants were randomized to receive TDF 300 mg/emtricitabine (FTC) 200 mg as (1) 7 doses/week (perfect adherence), (2) 4 doses/week (moderate adherence), or (3) 2 doses/week (low adherence). Plasma and urine samples were collected regularly during the 6-week dosing phase and for 4 weeks following drug cessation. RESULTS Twenty-eight adults were included in this analysis. Median (range) age was 33 (20-49) years. No differences in TFV pharmacokinetic parameters during the washout were observed across the study arms. Small differences in TFV plasma concentrations occurred across arms between 4 and 10 h post-dose. The cumulative amount of TFV excreted in urine was not different at 24 h post-dose, but at 148 h it was 24.8 mg, 21.0 mg, and 17.2 mg for the perfect, moderate, and low adherence arms, respectively (p = 0.043). CONCLUSIONS Among adults with different TDF adherence patterns, relative differences in plasma concentrations and cumulative urine extraction of TFV were minor following cessation. TFV measurement in plasma or urine is more indicative of last drug ingestion, rather than prior dose patterns.",2020,"The cumulative amount of TFV excreted in urine was not different 24 hours post-dose, but at 148 hours was 24.8, 21.0 and 17.2 mg for the Perfect, Moderate and Low Adherence arms, respectively (p = 0.043). ","['Adults with Controlled Levels of Adherence to', 'adult volunteers', 'adults with different TDF adherence patterns', 'Median (range) age was 33 (20-49) years', 'Twenty-eight adults']","['Tenofovir Disoproxil Fumarate', 'TDF 300\u2009mg/emtricitabine (FTC']","['Plasma and urine samples', 'cumulative amount of TFV excreted in urine', 'TFV PK parameters', 'Plasma Pharmacokinetics and Urinary Excretion of Tenofovir', 'plasma concentrations and cumulative urine extraction of TFV', 'TFV measurement in plasma or urine', 'TFV plasma concentrations']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0619283', 'cui_str': 'IS 33'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4283787', 'cui_str': '28'}]","[{'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0206682', 'cui_str': 'Follicular thyroid carcinoma'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",28.0,0.0747984,"The cumulative amount of TFV excreted in urine was not different 24 hours post-dose, but at 148 hours was 24.8, 21.0 and 17.2 mg for the Perfect, Moderate and Low Adherence arms, respectively (p = 0.043). ","[{'ForeName': 'Tim R', 'Initials': 'TR', 'LastName': 'Cressey', 'Affiliation': 'PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Immunology and Infectious Diseases, Boston, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. Electronic address: tim.cressey@phpt.org.'}, {'ForeName': 'Oraphan', 'Initials': 'O', 'LastName': 'Siriprakaisil', 'Affiliation': 'Sanpatong Hospital, Chiang Mai, Thailand.'}, {'ForeName': 'Rachel W', 'Initials': 'RW', 'LastName': 'Kubiak', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Virat', 'Initials': 'V', 'LastName': 'Klinbuayaem', 'Affiliation': 'Sanpatong Hospital, Chiang Mai, Thailand.'}, {'ForeName': 'Pra-Ornsuda', 'Initials': 'PO', 'LastName': 'Sukrakanchana', 'Affiliation': 'PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Justice', 'Initials': 'J', 'LastName': 'Quame-Amaglo', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Okochi', 'Affiliation': 'Department of Medicine, University of California-San Francisco (UCSF), San Francisco, CA, USA.'}, {'ForeName': 'Yardpiroon', 'Initials': 'Y', 'LastName': 'Tawon', 'Affiliation': 'PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Ratchada', 'Initials': 'R', 'LastName': 'Cressey', 'Affiliation': 'Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Jared M', 'Initials': 'JM', 'LastName': 'Baeten', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, USA.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Gandhi', 'Affiliation': 'Department of Medicine, University of California-San Francisco (UCSF), San Francisco, CA, USA.'}, {'ForeName': 'Paul K', 'Initials': 'PK', 'LastName': 'Drain', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, USA.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.06.037'] 263,32559794,Preoperative Fasting Abbreviation and its Effects on Postoperative Nausea and Vomiting Incidence in Gynecological Surgery Patients.,"OBJECTIVE To investigate the effects of preoperative fasting abbreviation with a carbohydrate and protein-enriched solution, on postoperative nausea and vomiting (PONV) incidence in gynecological surgery patients, a population naturally at risk for such unpleasant episodes. METHODS The present prospective double-blind randomized study was performed at The Hospital Municipal e Maternidade Dr. Odelmo Leão Carneiro (HMMOLC, in the Portuguese acronym), in Uberlândia, state of Minas Gerais, Brazil, in partnership with the Gynecology Department of the Universidade Federal de São Paulo (UNIFESP), approved by the Human Research Ethics Committee of UNIFESP and the board of HMMOLC, and included in the Brazil Platform and in the Brazilian Clinical Trial Registry. After signing the consent form, 80 women, who were submitted to gynecological surgery in the period from January to June 2016, were randomized into 2 groups: control group ( n  = 42) and juice group ( n  = 38). They received, respectively, 200 mL of inert solution or liquid enriched with carbohydrate and protein 4 hours presurgery. The incidence, frequency and intensity of PONV were studied using the Visual Analogue Scale (VAS), with statistical analysis performed by the software IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp, Armonk, NY, USA). RESULTS The incidence of nausea and vomiting was lower than in the literature, to this population, with 18.9% (14/74) for the control group and 10.8% (8/74) for the juice group, respectively, with no statistically significant difference between the groups. CONCLUSION The incidence of nausea and vomiting was lower than in the literature, but it cannot be said that this is due to the abbreviation of fasting. It can provide greater comfort, with the possibility of PONV prevention in patients at risk for these episodes.",2020,"The incidence, frequency and intensity of PONV were studied using the Visual Analogue Scale (VAS), with statistical analysis performed by the software IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp, Armonk, NY, USA). ","['Hospital Municipal e Maternidade Dr. Odelmo Leão Carneiro (HMMOLC, in the Portuguese acronym), in Uberlândia, state of Minas Gerais, Brazil, in partnership with the Gynecology Department of the Universidade Federal de São Paulo (UNIFESP', '80 women, who were submitted to gynecological surgery in the period from January to June 2016', 'Gynecological Surgery Patients', 'gynecological surgery patients, a population naturally at risk for such unpleasant episodes']","['inert solution or liquid enriched with carbohydrate and protein 4\u2009hours presurgery', 'preoperative fasting abbreviation with a carbohydrate and protein-enriched solution', 'control group ( n \u2009=\u200942) and juice group']","['incidence, frequency and intensity of PONV', 'nausea and vomiting', 'Postoperative Nausea and Vomiting Incidence', 'Visual Analogue Scale (VAS', 'postoperative nausea and vomiting (PONV) incidence']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0032730', 'cui_str': 'Portuguese'}, {'cui': 'C1956259', 'cui_str': 'Acronyms'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C0587481', 'cui_str': 'Gynecology department'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038902', 'cui_str': 'Operation on female genital organs'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}]","[{'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1292426', 'cui_str': '4 hours'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0000723', 'cui_str': 'Abbreviation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1268568', 'cui_str': 'Juice'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",,0.0588202,"The incidence, frequency and intensity of PONV were studied using the Visual Analogue Scale (VAS), with statistical analysis performed by the software IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp, Armonk, NY, USA). ","[{'ForeName': 'Gisele Vissoci', 'Initials': 'GV', 'LastName': 'Marquini', 'Affiliation': 'Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Francisco Edes da Silva', 'Initials': 'FEDS', 'LastName': 'Pinheiro', 'Affiliation': 'Department of Gynecology, Hospital Municipal Maternidade Dr. Odelmo Leão Carneiro, Uberlândia, MG, Brazil.'}, {'ForeName': 'Alfredo Urbano da Costa', 'Initials': 'AUDC', 'LastName': 'Vieira', 'Affiliation': 'Department of Gynecology, Hospital Municipal Maternidade Dr. Odelmo Leão Carneiro, Uberlândia, MG, Brazil.'}, {'ForeName': 'Rogério Melo da Costa', 'Initials': 'RMDC', 'LastName': 'Pinto', 'Affiliation': 'Faculty of Mathematics, Universidade Federal de Uberlândia, Uberlândia, MG, Brazil.'}, {'ForeName': 'Maria Gabriela Baumgarten Kuster', 'Initials': 'MGBK', 'LastName': 'Uyeda', 'Affiliation': 'Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Manoel João Batista Castello', 'Initials': 'MJBC', 'LastName': 'Girão', 'Affiliation': 'Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Marair Gracio Ferreira', 'Initials': 'MGF', 'LastName': 'Sartori', 'Affiliation': 'Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}]",Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia,['10.1055/s-0040-1712994'] 264,32576151,Intravenous lidocaine to prevent endothelial dysfunction after major abdominal surgery: a randomized controlled pilot trial.,"BACKGROUND Major abdominal surgery is associated with endothelial glycocalyx disruption. The anti-inflammatory effects of lidocaine were recently associated with endothelial barrier protection. METHODS This was a single-centre, parallel group, randomized, controlled, double blind, pilot trial. Forty adult patients scheduled for major abdominal surgery were included between December 2016 and March 2017 in the setting of a University Hospital in Brussels (Belgium); reasons for non-inclusion were planned liver resection and conditions associated to increased risk of local anesthetics systemic toxicity. Patients were randomized to receive either lidocaine by continuous intravenous administration or an equivalent volume of 0.9% saline. The primary endpoint was the postoperative syndecan-1 concentration (difference between groups). Near-infrared spectroscopy of the thenar eminence in association with the vascular occlusion test, and contemporary analysis of flow-mediated dilation of the brachial artery were the secondary outcomes, along with haemodynamic data. Blood samples and data were collected before surgery (T0), and at 1-3 h (T1) and 24 h (T2) post-surgery. RESULTS Syndecan-1 concentration increased significantly post-surgery (P < 0.001), but without any difference between groups. The near-infrared spectroscopy-derived and flow-mediated dilation-derived variables showed minor changes unrelated to group assignment. Compared with the placebo group, the intervention group had a significantly lower peri-operative mean arterial pressure and cardiac index, despite equally conducted goal-directed haemodynamic management. Postoperative lactate concentrations were similar between groups. CONCLUSIONS Lidocaine failed to have any effect on endothelial function. Since in comparisons to other types of clinical situations, syndecan-1 was only slightly upregulated, endothelial dysfunction after major abdominal surgery might be overestimated. TRIAL REGISTRATION « ISRCTN Registry » identifier: ISRCTN63417725. Date: 15/06/2020. Retrospectively registered.",2020,"Compared with the placebo group, the intervention group had a significantly lower peri-operative mean arterial pressure and cardiac index, despite equally conducted goal-directed haemodynamic management.","['after major abdominal surgery', 'Forty adult patients scheduled for major abdominal surgery were included between December 2016 and March 2017 in the setting of a University Hospital in Brussels (Belgium); reasons for non-inclusion were planned liver resection and conditions associated to increased']","['Intravenous lidocaine', 'Lidocaine', 'lidocaine by continuous intravenous administration or an equivalent volume of 0.9% saline', 'lidocaine', 'placebo']","['endothelial function', 'peri-operative mean arterial pressure and cardiac index', 'Postoperative lactate concentrations', 'Syndecan-1 concentration', 'postoperative syndecan-1 concentration', 'risk of local anesthetics systemic toxicity', 'endothelial dysfunction']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0019144', 'cui_str': 'Liver excision'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0021440', 'cui_str': 'Intravenous infusion'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0753253', 'cui_str': 'SDC1 protein, human'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C4761262', 'cui_str': 'Local anaesthetic systemic toxicity'}, {'cui': 'C0856169', 'cui_str': 'Endothelial dysfunction'}]",40.0,0.615618,"Compared with the placebo group, the intervention group had a significantly lower peri-operative mean arterial pressure and cardiac index, despite equally conducted goal-directed haemodynamic management.","[{'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Pustetto', 'Affiliation': 'Department of Anesthesiology, Centre Hospitalier Universitaire Grenoble-Alpes, Boulevard de la Chantourne, 38700, Grenoble, France. marco.pustetto@gmail.com.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Goldsztejn', 'Affiliation': 'Department of Anesthesiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Touihri', 'Affiliation': 'Department of Anesthesiology, CHIREC Hospital group, Brussels, Belgium.'}, {'ForeName': 'Edgard', 'Initials': 'E', 'LastName': 'Engelman', 'Affiliation': 'Department of Anesthesiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Ickx', 'Affiliation': 'Department of Anesthesiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.'}, {'ForeName': 'Luc', 'Initials': 'L', 'LastName': 'Van Obbergh', 'Affiliation': 'Department of Anesthesiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.'}]",BMC anesthesiology,['10.1186/s12871-020-01075-x'] 265,32446787,"Individualized target fortification of breast milk with protein, carbohydrates, and fat for preterm infants: A double-blind randomized controlled trial.","BACKGROUND & AIMS In preterm infants, natural variation of breast milk composition makes it difficult to achieve recommended macronutrient intakes with standard fortification. Evidence suggests that nutritional deficiency induces poor postnatal growth. This study investigates impacts of target fortification on preterm growth and metabolism by adjusting breast milk macronutrients. METHODS This study was conducted as a single-centre, double-blind, randomized controlled trial for infants <30 gestational weeks. The control group received standard fortification and the intervention group received standard plus target fortification adding modular protein, lipids, and carbohydrates. Breast milk content was measured 3x/week using a validated near-infrared bedside spectrometer (NIRS). Modulars were added to achieve recommended values. To assess total nutrient intake, all 2810 native breast milk samples were analyzed - protein and fat using bedside-NIRS, lactose using tandem mass spectrometry (UPLC-MS/MS). Body composition was measured using air displacement plethysmography. Primary outcome was weight gain during the first 21 days of intervention. RESULTS Baseline characteristics, morbidities, and total fluid intake were not different between groups (intervention n = 52, control n = 51). The intervention group infants had higher macronutrient intakes, weight gain (21.2 ± 2.5 vs 19.3 ± 2.4 g/kg/d, mean difference: 1.9 g/kg/d, 95% CI: 0.9 - 2.9), and body weight. Infants in the intervention group from mothers with below-average breast milk protein content showed greatest impact on weight at 36 weeks (2580 ± 280 g vs 2210 ± 300 g), length, head circumference, fat, and fat-free mass. Also, feeding intolerance was less frequent, blood urea was higher, and triglycerides were lower. CONCLUSIONS This study provides evidence that target fortification of breast milk with low macronutrient content enhances the quality of nutrition and growth and is feasible in clinical routine.",2021,"Infants in the intervention group from mothers with below-average breast milk protein content showed greatest impact on weight at 36 weeks (2580 ± 280 g vs 2210 ± 300 g), length, head circumference, fat, and fat-free mass.","['21.2\xa0±\xa02.5 vs 19.3\xa0±\xa02.4\xa0g/kg/d, mean difference', '2810 native breast milk samples', 'infants <30 gestational weeks', 'preterm infants']","['standard fortification and the intervention group received standard plus target fortification adding modular protein, lipids, and carbohydrates']","['blood urea', 'Body composition', 'higher macronutrient intakes, weight gain', 'body weight', 'weight gain', 'morbidities, and total fluid intake', 'preterm growth and metabolism']","[{'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C4517631', 'cui_str': '2.4'}, {'cui': 'C1532536', 'cui_str': 'g/kg/day'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}]","[{'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0429791', 'cui_str': 'Fluid intake'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}]",,0.415734,"Infants in the intervention group from mothers with below-average breast milk protein content showed greatest impact on weight at 36 weeks (2580 ± 280 g vs 2210 ± 300 g), length, head circumference, fat, and fat-free mass.","[{'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Rochow', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics, Paracelsus Medical School, General Hospital of Nuremberg, Nuremberg, Germany.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Fusch', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Anaam', 'Initials': 'A', 'LastName': 'Ali', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Akshdeep', 'Initials': 'A', 'LastName': 'Bhatia', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Hon Yiu', 'Initials': 'HY', 'LastName': 'So', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Iskander', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Chessell', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Salhab', 'Initials': 'S', 'LastName': 'El Helou', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Fusch', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics, Paracelsus Medical School, General Hospital of Nuremberg, Nuremberg, Germany. Electronic address: christoph.fusch@klinikum-nuernberg.de.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.04.031'] 266,32459282,"Resistant starch supplementation effects on plasma indole 3-acetic acid and aryl hydrocarbon receptor mRNA expression in hemodialysis patients: Randomized, double blind and controlled clinical trial.","INTRODUCTION Gut microbiota imbalance is linked to high uremic toxins production such as indole-3-acetic acid (IAA) in chronic kidney disease patients. This toxin can activate the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor involved with inflammation. Strategies to restore gut microbiota balance can be associated with reduced production of IAA and its deleterious effects. This study aimed to evaluate prebiotic resistant starch (RS) supplementation effects on IAA plasma levels and AhR mRNA expression in CKD patients on hemodialysis (HD). METHODS This randomized, double-blind and placebo-controlled clinical trial evaluated forty-two stable HD patients allocated in RS (n=22) or placebo (n=20) groups. Patients received, alternately, cookies and sachets containing 16 g/day of RS (Hi-Maize 260®) or manioc flour for four weeks. Fasting pre-dialysis blood samples were collected and IAA plasma levels measured by high performance liquid chromatography. Peripheral blood mononuclear cells were isolated and processed for AhR and nuclear factor kappa B (NF-κB) mRNA expression analyzes by quantitative real-time PCR. Anthropometric and biochemical parameters, as well as food intake were also evaluated. RESULTS Thirty-one patients completed the study, 15 in the RS group and 16 in the placebo group. Although there was no significant alteration in IAA plasma levels, neither in AhR mRNA expression and NF-κB mRNA expression after RS supplementation, a positive correlation (r=0.48; p=0.03) was observed between IAA plasma levels and AhR expression at baseline. CONCLUSION Even though prebiotic RS supplementation did not influence IAA levels or AhR expression, their positive association reinforces a possible interaction between them.",2020,"Although there was no significant alteration in IAA plasma levels, neither in AhR mRNA expression and NF-κB mRNA expression after RS supplementation, a positive correlation (r=0.48; p=0.03) was observed between IAA plasma levels and AhR expression at baseline. ","['CKD patients on hemodialysis (HD', 'forty-two stable HD patients allocated in RS (n=22) or', 'chronic kidney disease patients', 'n=20) groups', 'hemodialysis patients']","['placebo', 'prebiotic RS supplementation', 'Resistant starch supplementation', 'prebiotic resistant starch (RS) supplementation']","['Peripheral blood mononuclear cells', 'IAA plasma levels', 'IAA plasma levels and AhR expression', 'AhR mRNA expression and NF-κB mRNA expression', 'IAA plasma levels and AhR mRNA expression']","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0936060', 'cui_str': 'Indoleacetic acid'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0052441', 'cui_str': 'Aryl Hydrocarbon Receptor'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}]",42.0,0.14231,"Although there was no significant alteration in IAA plasma levels, neither in AhR mRNA expression and NF-κB mRNA expression after RS supplementation, a positive correlation (r=0.48; p=0.03) was observed between IAA plasma levels and AhR expression at baseline. ","[{'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Azevedo', 'Affiliation': 'Universidade Federal Fluminense, Programa de Pós-graduação em Ciências Cardiovasculares, Niterói, RJ, Brazil.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Esgalhado', 'Affiliation': 'Universidade Federal Fluminense, Programa de Pós-graduação em Ciências Cardiovasculares, Niterói, RJ, Brazil.'}, {'ForeName': 'Julie Ann', 'Initials': 'JA', 'LastName': 'Kemp', 'Affiliation': 'Universidade Federal Fluminense, Programa de Pós-graduação em Ciências Médicas, Niterói, RJ, Brazil.'}, {'ForeName': 'Bruna', 'Initials': 'B', 'LastName': 'Regis', 'Affiliation': 'Universidade Federal Fluminense, Programa de Pós-graduação em Ciências Médicas, Niterói, RJ, Brazil.'}, {'ForeName': 'Ludmila Fmf', 'Initials': 'LF', 'LastName': 'Cardozo', 'Affiliation': 'Universidade Federal Fluminense, Programa de Pós-graduação em Ciências Cardiovasculares, Niterói, RJ, Brazil.'}, {'ForeName': 'Lia S', 'Initials': 'LS', 'LastName': 'Nakao', 'Affiliation': 'Universidade Federal do Paraná, Programa de Pós-graduação em Ciências Médicas, Curitiba, PR, Brazil.'}, {'ForeName': 'Jessyca Sousa de', 'Initials': 'JS', 'LastName': 'Brito', 'Affiliation': 'Universidade Federal Fluminense, Programa de Pós-graduação em Ciências Médicas, Niterói, RJ, Brazil.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Mafra', 'Affiliation': 'Universidade Federal Fluminense, Programa de Pós-graduação em Ciências Cardiovasculares, Niterói, RJ, Brazil.'}]",Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia,['10.1590/2175-8239-JBN-2020-0003'] 267,32461053,Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: A randomized clinical trial.,"PURPOSE To evaluate the efficacy of topical ivermectin-metronidazole combined therapy in the management of Demodex-associatedblepharitis. METHODS Sixty patients with a diagnosis of Demodex-associatedblepharitis were recruited in a randomized clinical trial. Thirty receiving topical ivermectin (0.1%)-metronidazole (1%) gel treatment on days 0, 15 and 30. Thirty additional patients were used as a control group receiving vehicle on days 0, 15 and 30. The primary efficacy measure was the number of Demodex spp. mitesin the eyelashes of patients. The secondary outcomes included clinical improvement of signs and adverse events. RESULTS Complete eradication of Demodex spp. was found in 96.6% of patients in the treatment group. Furthermore, a significant reduction of inflammation signs were found in all treated patients versus controls. None of the patients experienced any adverse effects associated with the treatment. CONCLUSION Demodex infection was controlled satisfactorily with the ivermectin (0.1%)-metronidazole (1%) gel, and no adverse effects were observed. Application of this gel for the treatment of different parasitic infections of the eyelids could be feasible, and this requires further exploration.",2021,"RESULTS Complete eradication of Demodex spp. was found in 96.6% of patients in the treatment group.","['Sixty patients with a diagnosis of Demodex-associatedblepharitis', 'blepharitis caused by Demodex spp']","['Topical ivermectin-metronidazole gel therapy', 'topical ivermectin (0.1%)-metronidazole (1%) gel treatment', 'ivermectin (0.1%)-metronidazole', 'topical ivermectin-metronidazole combined therapy']","['adverse effects', 'clinical improvement of signs and adverse events', 'inflammation signs', 'number of Demodex spp']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0323683', 'cui_str': 'Demodex'}, {'cui': 'C0005741', 'cui_str': 'Blepharitis'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0022322', 'cui_str': 'Ivermectin'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0033972', 'cui_str': 'Combined therapy'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0323683', 'cui_str': 'Demodex'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}]",30.0,0.0437704,"RESULTS Complete eradication of Demodex spp. was found in 96.6% of patients in the treatment group.","[{'ForeName': 'Marcel Y', 'Initials': 'MY', 'LastName': 'Ávila', 'Affiliation': 'Department of Ophthalmology, School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia. Electronic address: myavilac@unal.edu.co.'}, {'ForeName': 'Dayron F', 'Initials': 'DF', 'LastName': 'Martínez-Pulgarín', 'Affiliation': 'Department of Ophthalmology, School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Rizo Madrid', 'Affiliation': 'Department of Ophthalmology, School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2020.04.011'] 268,32552828,Conversion of I-gel to definitive airway in a cervical immobilized manikin: Aintree intubation catheter vs long endotracheal tube.,"BACKGROUND After prehospital insertion of i-gel, a popular supraglottic airway (SGA), fiberoptic-guided intubation through i-gel is often required to switch the i-gel to a definitive airway for anticipated difficult airway. The Aintree intubation catheter (AIC) was developed for this purpose yet it requires many procedural steps during which maintenance of adequate ventilation is difficult. We custom-made a long endotracheal tube (LET) which may facilitate this procedure and compared the efficacy of the AIC and LET in a cervical immobilized manikin. METHODS In this 2 × 2 crossover manikin-based trial, 20 anaesthesiologists and residents performed both methods in random order. Total intubation time, fiberoptic time, and procedure time were recorded. The ease of insertion, procedure failure rate, difficulty score, and participants' preference were recorded. RESULTS Total intubation time was significantly shorter for the LET than the AIC group (70.8 ± 16.4 s vs 94.0 ± 28.4 s, P = 0.001). The procedure time was significantly shorter in the LET group (51.9 ± 13.8 s vs 76.5 ± 25.4 s, P <  0.001). The ease of insertion score was lower, i.e., easier, in the AIC than the LET group (2.0 [1.0-2.75] vs 1.0 [1.0-1.0], P <  0.001). Fiberoptic time (19.0 ± 6.9 s vs 17.5 ± 12.3 s) and subjective difficulty (4.0 [3.0-6.0] vs 4.0 [3.0-5.75]) were similar between groups. Fourteen participants preferred the LET method (70%) due to its fewer procedural steps. CONCLUSIONS LET resulted in a shorter intubation time than the AIC during fiberoptic-guided intubation through the i-gel, possibly due to the less procedural steps compared to AIC. TRIAL REGISTRATION NCT03645174 (ClinicalTrials.gov, Aug 22, 2018).",2020,"RESULTS Total intubation time was significantly shorter for the LET than the AIC group (70.8 ± 16.4 s vs 94.0 ± 28.4 s, P = 0.001).",[],"['custom-made a long endotracheal tube (LET', 'LET', 'Aintree intubation catheter (AIC']","['Fiberoptic time', 'procedure time', 'subjective difficulty', 'Total intubation time', 'shorter intubation time', 'ease of insertion score', 'Total intubation time, fiberoptic time, and procedure time']",[],"[{'cui': 'C0162343', 'cui_str': 'Customs'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0336630', 'cui_str': 'Endotracheal tube'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",20.0,0.129802,"RESULTS Total intubation time was significantly shorter for the LET than the AIC group (70.8 ± 16.4 s vs 94.0 ± 28.4 s, P = 0.001).","[{'ForeName': 'Yun Jeong', 'Initials': 'YJ', 'LastName': 'Chae', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, 16499, South Korea.'}, {'ForeName': 'Heirim', 'Initials': 'H', 'LastName': 'Lee', 'Affiliation': 'Office of Biostatics, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, 164, World cup-ro, Yeongtong-gu, Suwon, 16499, South Korea.'}, {'ForeName': 'Bokyeong', 'Initials': 'B', 'LastName': 'Jun', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, 16499, South Korea.'}, {'ForeName': 'In Kyong', 'Initials': 'IK', 'LastName': 'Yi', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, 16499, South Korea. lyrin01@gmail.com.'}]",BMC anesthesiology,['10.1186/s12871-020-01069-9'] 269,32567217,"Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.","Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF, pegfilgrastim) is a long-acting derivative of recombinant human granulocyte colony-stimulating factor with limited renal clearance and a longer half-life. It is used for the prevention of febrile neutropenia, owing to its capacity to promote neutrophil recovery. In this study, the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of 2 formulations of PEG-rhG-CSF were evaluated in healthy Chinese subjects. Twenty-four male subjects who received a single dose of subcutaneous PEG-rhG-CSF 100 µg/kg were randomized to either treatment A (3 mg/mL) or treatment B (1 mg/mL). Noncompartmental pharmacokinetic parameters of PEG-rhG-CSF were derived from serum concentration-time data. In addition, absolute neutrophil count (ANC) as a pharmacodynamic maker, immunogenicity through antidrug antibody testing, and safety were evaluated. The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC 0-t ) and the mean maximum concentration (C max ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively). The mean value of area under the △ANC (baseline-adjusted ANC)-time curve and the maximum △ANC values were 4380 × 10 9  h/L and 33.1 × 10 9 /L, respectively, in the treatment A group, and 5170 × 10 9  h/L and 38.6 × 10 9 /L, respectively, in the treatment B group. The pharmacokinetic and pharmacodynamic profiles were similar for the 2 PEG-rhG-CSF formulations following a single dose of 100 µg/kg. The safety and immunogenicity profiles were also similar, with no significant differences. The dose adjustment of PEG-rhG-CSF was not considered necessary for formulation transformation.",2021,"The safety and immunogenicity profiles were also similar, with no significant differences.","['Twenty-four male subjects who received a single dose of subcutaneous PEG-rhG-CSF 100\xa0µg/kg', 'Healthy Chinese Subjects', 'healthy Chinese subjects']","['PEG-rhG-CSF', 'Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF, pegfilgrastim', 'Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor']","['absolute neutrophil count (ANC', 'mean area under the concentration-time curve', 'mean value of area under the △ANC', 'safety and immunogenicity profiles', 'pharmacokinetic and pharmacodynamic profiles', 'pharmacokinetics, pharmacodynamics, safety, and immunogenicity', 'mean maximum concentration (C max ) of PEG-rhG-CSF']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C3852764', 'cui_str': 'PEG-rhG-CSF'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C3852764', 'cui_str': 'PEG-rhG-CSF'}, {'cui': 'C1271481', 'cui_str': 'Recombinant human granulocyte colony stimulating factor'}, {'cui': 'C1136535', 'cui_str': 'pegfilgrastim'}]","[{'cui': 'C0948762', 'cui_str': 'Absolute neutrophil count'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C3852764', 'cui_str': 'PEG-rhG-CSF'}]",24.0,0.0294381,"The safety and immunogenicity profiles were also similar, with no significant differences.","[{'ForeName': 'Chaoying', 'Initials': 'C', 'LastName': 'Hu', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.'}, {'ForeName': 'Bingxin', 'Initials': 'B', 'LastName': 'Ji', 'Affiliation': 'Department of Hematology, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.'}, {'ForeName': 'Cuicui', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.'}, {'ForeName': 'Wanling', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': 'Department of Hematology, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.'}, {'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.'}, {'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Medical Affair Office, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.819'] 270,32567233,Effects of Oxycodone Combined With Flurbiprofen Axetil on Postoperative Analgesia and Immune Function in Patients Undergoing Radical Resection of Colorectal Cancer.,"The influence of surgery and anesthesia on immune function during the perioperative period should not be neglected. In this study, we evaluated the effects of oxycodone combined with flurbiprofen axetil on postoperative analgesia and immune function in patients undergoing radical resection of colorectal cancer (CRC). One hundred and thirty-three were randomized into the oxycodone combined with flurbiprofen axetil (OF) group or the sufentanil combined with flurbiprofen axetil (SF) group. Patients in the OF group were prescribed oxycodone hydrochloride 0.1 mg/kg combined with flurbiprofen axetil 3 mg/kg for postoperative analgesia, whereas the SF group received sufentanil 0.1 μg/kg combined with flurbiprofen axetil 3 mg/kg. The primary outcome was visual analog scale (VAS) score. Secondary outcomes included the quantities of CD4 + , CD8 + , and natural killer (NK) T cells, tumor necrosis factor (TNF)-α level, and interleukin (IL)-6 in peripheral blood, the consumption of analgesics, and the incidence of adverse reactions, and so forth. The VAS scores at rest were similar in both group. However, the VAS scores at cough in the OF group at 8, 12, and 24 hours postsurgery were lower than those in the SF group. Compared with the SF group, the count of CD4 + T cells and ratio of CD4 + /CD8 + were higher in the OF group at 12, 24, 48, and 72 hours postsurgery, although the count of CD8 + and NK T cells was higher than that in the SF group at 48 and 72 hours postsurgery. In addition, the serum level of TNF-α and IL-6 at 12, 24, 48, and 72 hours postsurgery in the OF group was lower than that in the SF group. In addition, the incidence of postoperative nausea, postoperative vomiting, and pruritus was lower, the time to first flatus and bowel movement was earlier in the OF group. Oxycodone combined with flurbiprofen axetil applied for patient-controlled intravenous analgesia could effectively reduce pain intensity, particularly for visceral pain, and help to reverse the status of immunosuppression during radical resection of CRC.",2021,"However, the VAS scores at cough in the OF group at 8, 12, and 24 hours postsurgery were lower than those in the SF group.","['patients undergoing radical resection of colorectal cancer (CRC', 'One hundred and thirty-three', 'Patients Undergoing Radical Resection of Colorectal Cancer']","['oxycodone hydrochloride', 'flurbiprofen axetil', 'oxycodone combined with flurbiprofen axetil (OF', 'SF', 'surgery and anesthesia', 'sufentanil 0.1 μg/kg combined with flurbiprofen axetil', 'Oxycodone', 'sufentanil combined with flurbiprofen axetil (SF', 'Oxycodone Combined With Flurbiprofen Axetil', 'oxycodone']","['visual analog scale (VAS) score', 'time to first flatus and bowel movement', 'quantities of CD4 + , CD8 + , and natural killer (NK) T cells, tumor necrosis factor (TNF)-α level, and interleukin (IL)-6 in peripheral blood, the consumption of analgesics, and the incidence of adverse reactions, and so forth', 'pain intensity', 'postoperative analgesia and immune function', 'VAS scores at cough', 'postoperative nausea, postoperative vomiting, and pruritus', 'count of CD4 + T cells and ratio of CD4 + /CD8 ', 'serum level of TNF-α and IL-6', 'count of CD8 + and NK T cells', 'Postoperative Analgesia and Immune Function', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C4517563', 'cui_str': '133'}]","[{'cui': 'C0282274', 'cui_str': 'Oxycodone hydrochloride'}, {'cui': 'C1610514', 'cui_str': 'flurbiprofen axetil'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C4517420', 'cui_str': '0.1'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C2350466', 'cui_str': 'Natural Killer T-Cell'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C1817756', 'cui_str': 'Immunologic function'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0520904', 'cui_str': 'Postoperative nausea'}, {'cui': 'C0520905', 'cui_str': 'Postoperative vomiting'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",133.0,0.043884,"However, the VAS scores at cough in the OF group at 8, 12, and 24 hours postsurgery were lower than those in the SF group.","[{'ForeName': 'Zhengzuo', 'Initials': 'Z', 'LastName': 'Wan', 'Affiliation': 'Department of Anesthesiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China.'}, {'ForeName': 'Chunhua', 'Initials': 'C', 'LastName': 'Chu', 'Affiliation': ""Department of Acupuncture and Massage, Zhejiang Provincial People's Hospital, Hangzhou, China.""}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Que', 'Affiliation': 'Department of Anesthesiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.818'] 271,32442971,Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage.,"OBJECTIVE Aneurysmal subarachnoid hemorrhage (aSAH) is associated with significant morbidity and mortality. The presence of thick, diffuse subarachnoid blood may portend a worse clinical course and outcome, independently of other known prognostic factors such as age, aneurysm size, and initial clinical grade. METHODS In this post hoc analysis, patients with aSAH undergoing surgical clipping (n = 383) or endovascular coiling (n = 189) were pooled from the placebo arms of the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS)-2 and CONSCIOUS-3 randomized, double-blind, placebo-controlled phase 3 studies, respectively. Patients without and with thick, diffuse SAH (≥ 4 mm thick and involving ≥ 3 basal cisterns) on admission CT scans were compared. Clot size was centrally adjudicated. All-cause mortality and vasospasm-related morbidity at 6 weeks and Glasgow Outcome Scale-Extended (GOSE) scores at 12 weeks after aSAH were assessed. The effect of the thick and diffuse cisternal aSAH on vasospasm-related morbidity and mortality, and on poor clinical outcome at 12 weeks, was evaluated using logistic regression models. RESULTS Overall, 294 patients (51.4%) had thick and diffuse aSAH. Compared to patients with less hemorrhage burden, these patients were older (median age 55 vs 50 years) and more often had World Federation of Neurosurgical Societies (WFNS) grade III-V SAH at admission (24.1% vs 16.5%). At 6 weeks, all-cause mortality and vasospasm-related morbidity occurred in 36.1% (95% CI 30.6%-41.8%) of patients with thick, diffuse SAH and in 14.7% (95% CI 10.8%-19.5%) of those without thick, diffuse SAH. Individual event rates were 7.5% versus 2.5% for all-cause death, 19.4% versus 6.8% for new cerebral infarct, 28.2% versus 9.4% for delayed ischemic neurological deficit, and 24.8% versus 10.8% for rescue therapy due to cerebral vasospasm, respectively. Poor clinical outcome (GOSE score ≥ 4) was observed in 32.7% (95% CI 27.3%-38.3%) and 16.2% (95% CI 12.1%-21.1%) of patients with and without thick, diffuse SAH, respectively. CONCLUSIONS In a large, centrally adjudicated population of patients with aSAH, WFNS grade at admission and thick, diffuse SAH independently predicted vasospasm-related morbidity and poor 12-week clinical outcome. Patients with thick, diffuse cisternal SAH may be an important cohort to target in future clinical trials of treatment for vasospasm.",2020,All-cause mortality and vasospasm-related morbidity at 6 weeks and Glasgow Outcome Scale-Extended (GOSE) scores at 12 weeks after aSAH were assessed.,"['After Subarachnoid Hemorrhage', 'Patients with thick, diffuse cisternal', 'patients with aSAH undergoing surgical clipping (n = 383) or', '294 patients (51.4%) had thick and diffuse aSAH']","['Clazosentan', 'endovascular coiling', 'placebo']","['Clot size', 'Individual event rates', 'World Federation of Neurosurgical Societies (WFNS) grade III-V SAH at admission', 'Neurological Ischemia and Infarction Occurring', 'All-cause mortality and vasospasm-related morbidity at 6 weeks and Glasgow Outcome Scale-Extended (GOSE) scores', 'mortality and vasospasm-related morbidity', 'delayed ischemic neurological deficit', 'admission CT scans']","[{'cui': 'C0038525', 'cui_str': 'Subarachnoid hemorrhage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C1721268', 'cui_str': 'clazosentan'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009074', 'cui_str': 'Clotrimazole'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0036001', 'cui_str': 'S-Adenosyl homocysteine'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0042396', 'cui_str': 'Vascular constriction'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0701887', 'cui_str': 'Glasgow outcome scale'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4285772', 'cui_str': 'Delayed ischaemic neurological deficit'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}]",189.0,0.207046,All-cause mortality and vasospasm-related morbidity at 6 weeks and Glasgow Outcome Scale-Extended (GOSE) scores at 12 weeks after aSAH were assessed.,"[{'ForeName': 'E François', 'Initials': 'EF', 'LastName': 'Aldrich', 'Affiliation': '1Department of Neurosurgery, University of Maryland, Baltimore, Maryland.'}, {'ForeName': 'Randall', 'Initials': 'R', 'LastName': 'Higashida', 'Affiliation': '2Department of Neurointerventional Radiology, University of California San Francisco Medical Center, San Francisco, California.'}, {'ForeName': 'Abdel', 'Initials': 'A', 'LastName': 'Hmissi', 'Affiliation': '3Global Clinical Development, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Le', 'Affiliation': '1Department of Neurosurgery, University of Maryland, Baltimore, Maryland.'}, {'ForeName': 'R Loch', 'Initials': 'RL', 'LastName': 'Macdonald', 'Affiliation': '4Department of Neurological Surgery, University of California San Francisco, Fresno, California.'}, {'ForeName': 'Angelina', 'Initials': 'A', 'LastName': 'Marr', 'Affiliation': '3Global Clinical Development, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.'}, {'ForeName': 'Stephan A', 'Initials': 'SA', 'LastName': 'Mayer', 'Affiliation': '6Department of Neurology, Henry Ford Neuroscience Institute, Wayne State School of Medicine, Detroit, Michigan; and.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Roux', 'Affiliation': '3Global Clinical Development, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Bruder', 'Affiliation': '7Department of Anesthesia and Critical Care, Hôpital de la Timone, Aix-Marseille Université, Marseille, France.'}]",Journal of neurosurgery,['10.3171/2020.3.JNS193400'] 272,32445277,Exhalation delivery system with fluticasone improves quality of life and health status: pooled analysis of phase 3 trials NAVIGATE I and II.,"BACKGROUND Chronic rhinosinusitis with or without nasal polyps (CRSwNP/CRSsNP) seriously impairs health-related quality of life (HRQoL). This analysis describes the impact of the exhalation delivery system with fluticasone (EDS-FLU) on HRQoL, assessed by the 36-item Short-Form Health Survey version 2 (SF-36v2), and on utilities, assessed via the Short-Form 6-Dimension (SF-6D), in patients with CRSwNP. METHODS Post hoc analysis of pooled randomized clinical trial data (NAVIGATE I and II; N = 643) to examine change from baseline in SF-36v2 and SF-6D at end-of-double-blind (EODB: 16 weeks) and end-of-open-label (EOOL: 24 weeks; following 8 weeks of open-label treatment) for EDS-FLU vs placebo (EDS-PBO). Baseline characteristics predictive of change in SF-36 and SF-6D scores were assessed. RESULTS Mean baseline SF-36v2 scores were below population norms. At EODB, mean improvement was greater for all SF-36v2 domain and component scores with EDS-FLU (range: 2.9 [physical functioning] to 5.11 [bodily pain {BP}]) vs EDS-PBO (range: 0.81 [mental health] to 2.87 [BP]) (each comparison p < 0.01); physical and mental component score improvements within the EDS-FLU group exceeded the minimal clinically important difference (MCID). Clinically meaningful and statistically significant improvements in SF-6D utility scores were seen in EDS-FLU-treated patients compared to EDS-PBO-treated patients (0.058 vs 0.023, respectively, p < 0.001). At EOOL, SF-36v2 and SF-6D mean scores were at or above population norms, with clinically meaningful and statistically significant improvements from baseline. CONCLUSION In this pooled analysis of 2 large pivotal EDS-FLU trials, health domain and health utilities improvements were significantly greater with EDS-FLU than EDS-PBO and were comparable to population norms.",2020,"Clinically meaningful and statistically significant improvements in SF-6D utility scores were seen in EDS-FLU-treated patients compared to EDS-PBO-treated patients (0.058 vs 0.023, respectively, p < 0.001).",['patients with CRSwNP'],"['nasal polyps (CRSwNP/CRSsNP', 'EDS-FLU vs placebo (EDS-PBO', 'fluticasone (EDS-FLU', 'fluticasone']","['SF-6D utility scores', 'quality of life and health status', 'At EOOL, SF-36v2 and SF-6D mean scores', 'SF-36 and SF-6D scores', 'Mean baseline SF-36v2 scores', 'physical and mental component score improvements']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0449914', 'cui_str': 'Delivery system'}, {'cui': 'C0082607', 'cui_str': 'fluticasone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",,0.118395,"Clinically meaningful and statistically significant improvements in SF-6D utility scores were seen in EDS-FLU-treated patients compared to EDS-PBO-treated patients (0.058 vs 0.023, respectively, p < 0.001).","[{'ForeName': 'Zachary M', 'Initials': 'ZM', 'LastName': 'Soler', 'Affiliation': 'Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Colman', 'Affiliation': 'OptiNose US, Inc., Yardley, PA.'}, {'ForeName': 'Fulton F', 'Initials': 'FF', 'LastName': 'Velez', 'Affiliation': 'Covance Market Access Services Inc, Gaithersburg, MD.'}, {'ForeName': 'Rodney J', 'Initials': 'RJ', 'LastName': 'Schlosser', 'Affiliation': 'Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC.'}]",International forum of allergy & rhinology,['10.1002/alr.22573'] 273,32463281,"Impact of smoked cannabis on tobacco cigarette smoking intensity and subjective effects: A placebo-controlled, double-blind, within-subjects human laboratory study.","Co-users of cannabis and tobacco frequently use cannabis, then tobacco cigarettes, in a sequential pattern within an occasion, that is, they ""chase"" smoked cannabis with a tobacco cigarette. The objective of this placebo-controlled, double-blind, within-subjects human laboratory study was to gather preliminary data on how smoking active versus placebo cannabis impacts tobacco cigarette smoking behavior, craving, and subjective effects. Adult daily cannabis and tobacco co-users ( N = 9) were randomly assigned to two experimental visit orders (i.e., active cannabis (5.2% THC) first visit and placebo cannabis second visit, or vice versa). Participants smoked one cannabis cigarette, and approximately 30 min later were given a 5-min ad libitum period to smoke one of their own brand of tobacco cigarette. As expected, boost in plasma THC levels and cannabis-related subjective effects differed between active and placebo cannabis conditions. Tobacco cigarette puff topography measures and tobacco craving did not differ between cannabis conditions, but there appeared to be between-participants heterogeneity in cumulative total puff volume. After smoking active versus placebo cannabis, the changes in subjective effects of tobacco smoking after adjusting for pretobacco smoking levels were not significant. Results do not support the notion that immediate effects of smoked cannabis change the behavior of tobacco smoking. The strong overlap between cannabis and tobacco smoking may not be explained by primarily pharmacological factors, but may be driven by more nuanced and complex mechanisms involving pharmacological processes as well as learning factors. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"After smoking active versus placebo cannabis, the changes in subjective effects of tobacco smoking after adjusting for pretobacco smoking levels were not significant.",['Adult daily cannabis and tobacco co-users ( N = 9'],"['smoked cannabis', 'placebo cannabis', 'placebo']","['behavior of tobacco smoking', 'plasma THC levels and cannabis-related subjective effects', 'pretobacco smoking levels', 'tobacco cigarette smoking intensity and subjective effects', 'Tobacco cigarette puff topography measures and tobacco craving']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}]","[{'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0453996', 'cui_str': 'Tobacco smoking behavior - finding'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C1533107', 'cui_str': 'Puff - unit of product usage'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0870371', 'cui_str': 'Craving'}]",9.0,0.19476,"After smoking active versus placebo cannabis, the changes in subjective effects of tobacco smoking after adjusting for pretobacco smoking levels were not significant.","[{'ForeName': 'Erica N', 'Initials': 'EN', 'LastName': 'Peters', 'Affiliation': 'Public Health Business Line, Battelle.'}, {'ForeName': 'Evan S', 'Initials': 'ES', 'LastName': 'Herrmann', 'Affiliation': 'Public Health Business Line, Battelle.'}, {'ForeName': 'Carson', 'Initials': 'C', 'LastName': 'Smith', 'Affiliation': 'Public Health Business Line, Battelle.'}, {'ForeName': 'Jess Alan', 'Initials': 'JA', 'LastName': 'Wilhelm', 'Affiliation': 'Public Health Business Line, Battelle.'}, {'ForeName': 'Bartosz', 'Initials': 'B', 'LastName': 'Koszowski', 'Affiliation': 'Public Health Business Line, Battelle.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Halquist', 'Affiliation': 'Department of Pharmaceutics, Virginia Commonwealth University.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Kosmider', 'Affiliation': 'Department of Pharmaceutics, Virginia Commonwealth University.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Poklis', 'Affiliation': 'Department of Pharmacology and Toxicology, Virginia Commonwealth University.'}, {'ForeName': 'Sage', 'Initials': 'S', 'LastName': 'Roth', 'Affiliation': 'Public Health Business Line, Battelle.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Bart', 'Affiliation': 'Public Health Business Line, Battelle.'}, {'ForeName': 'Wallace B', 'Initials': 'WB', 'LastName': 'Pickworth', 'Affiliation': 'Public Health Business Line, Battelle.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000391'] 274,32466746,Infraclavicular nerve block reduces postoperative pain after distal radial fracture fixation: a randomized controlled trial.,"BACKGROUND It is unclear whether regional anesthesia with infraclavicular nerve block or general anesthesia provides better postoperative analgesia after distal radial fracture fixation, especially when combined with regular postoperative analgesic medications. The aim of this study was to compare the postoperative analgesic effects of regional versus general anesthesia. METHODS In this prospective, observer blinded, randomized controlled trial, 52 patients undergoing distal radial fracture fixation received either general anesthesia (n = 26) or regional anesthesia (infraclavicular nerve block, n = 26). Numerical rating scale pain scores, analgesic consumption, patient satisfaction, adverse effects, upper limb functional scores (Patient-Rated Wrist Evaluation, QuickDASH), health related quality of life (SF12v2), and psychological status were evaluated after surgery. RESULT Regional anesthesia was associated with significantly lower pain scores both at rest and with movement on arrival to the post-anesthetic care unit; and at 1, 2, 24 and 48 h after surgery (p ≤ 0.001 at rest and with movement). Morphine consumption in the post-anesthetic care unit was significantly lower in the regional anesthesia group (p<0.001). There were no differences in oral analgesic consumption. Regional anesthesia was associated with lower incidences of nausea (p = 0.004), and vomiting (p = 0.050). Patient satisfaction was higher in the regional anesthesia group (p = 0.003). There were no long-term differences in pain scores and other patient outcomes. CONCLUSION Regional anesthesia with ultrasound guided infraclavicular nerve block was associated with better acute pain relief after distal radial fracture fixation, and may be preferred over general anesthesia. TRIAL REGISTRATION Before subject enrollment, the study was registered at ClinicalTrials.gov (NCT03048214) on 9th February 2017.",2020,"Regional anesthesia with ultrasound guided infraclavicular nerve block was associated with better acute pain relief after distal radial fracture fixation, and may be preferred over general anesthesia. ","['after distal radial fracture fixation', '52 patients undergoing distal radial fracture fixation received either']","['Regional anesthesia with ultrasound guided infraclavicular nerve block', 'general anesthesia (n\u2009=\u200926) or regional anesthesia (infraclavicular nerve block, n\u2009=\u200926', 'Infraclavicular nerve block']","['Patient satisfaction', 'pain scores', 'postoperative pain', 'Numerical rating scale pain scores, analgesic consumption, patient satisfaction, adverse effects, upper limb functional scores (Patient-Rated Wrist Evaluation, QuickDASH), health related quality of life (SF12v2), and psychological status', 'vomiting', 'acute pain relief', 'oral analgesic consumption', 'Morphine consumption', 'nausea', 'postoperative analgesic effects']","[{'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0034628', 'cui_str': 'Fracture of radius'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0230108', 'cui_str': 'Infraclavicular region structure'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0184567', 'cui_str': 'Acute pain'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}]",52.0,0.47479,"Regional anesthesia with ultrasound guided infraclavicular nerve block was associated with better acute pain relief after distal radial fracture fixation, and may be preferred over general anesthesia. ","[{'ForeName': 'Stanley S', 'Initials': 'SS', 'LastName': 'Wong', 'Affiliation': 'Laboratory and Clinical Research Institute for Pain, Department of Anaesthesiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Room 424, Block K, 102, Pokfulam Road, Hong Kong SAR, China. wongstan@hku.hk.'}, {'ForeName': 'Wing S', 'Initials': 'WS', 'LastName': 'Chan', 'Affiliation': 'Laboratory and Clinical Research Institute for Pain, Department of Anaesthesiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Room 424, Block K, 102, Pokfulam Road, Hong Kong SAR, China.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Fang', 'Affiliation': 'Department of Orthopaedics and Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.'}, {'ForeName': 'Chi W', 'Initials': 'CW', 'LastName': 'Chan', 'Affiliation': 'Department of Anaesthesiology, Queen Mary Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Tak W', 'Initials': 'TW', 'LastName': 'Lau', 'Affiliation': 'Department of Orthopaedics and Traumatology, Queen Mary Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Frankie', 'Initials': 'F', 'LastName': 'Leung', 'Affiliation': 'Department of Orthopaedics and Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.'}, {'ForeName': 'Chi W', 'Initials': 'CW', 'LastName': 'Cheung', 'Affiliation': 'Laboratory and Clinical Research Institute for Pain, Department of Anaesthesiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Room 424, Block K, 102, Pokfulam Road, Hong Kong SAR, China.'}]",BMC anesthesiology,['10.1186/s12871-020-01044-4'] 275,32468955,Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.,"PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy and survival in participants with BMs. PATIENTS AND METHODS Patients were randomly assigned 2:1 to tucatinib or placebo, in combination with trastuzumab and capecitabine. All patients underwent baseline brain magnetic resonance imaging; those with BMs were classified as active or stable. Efficacy analyses were performed by applying RECIST 1.1 criteria to CNS target lesions by investigator assessment. CNS-PFS (intracranial progression or death) and overall survival (OS) were evaluated in all patients with BMs. Confirmed intracranial objective response rate (ORR-IC) was evaluated in patients with measurable intracranial disease. RESULTS There were 291 patients with BMs: 198 (48%) in the tucatinib arm and 93 (46%) in the control arm. The risk of intracranial progression or death was reduced by 68% in the tucatinib arm (hazard ratio [HR], 0.32; 95% CI, 0.22 to 0.48; P < .0001). Median CNS-PFS was 9.9 months in the tucatinib arm versus 4.2 months in the control arm. Risk of death was reduced by 42% in the tucatinib arm (OS HR, 0.58; 95% CI, 0.40 to 0.85; P = .005). Median OS was 18.1 versus 12.0 months. ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P = .03). CONCLUSION In patients with HER2-positive breast cancer with BMs, the addition of tucatinib to trastuzumab and capecitabine doubled ORR-IC, reduced risk of intracranial progression or death by two thirds, and reduced risk of death by nearly half. To our knowledge, this is the first regimen to demonstrate improved antitumor activity against BMs in patients with HER2-positive breast cancer in a randomized, controlled trial.",2020,"ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P = .03). ","['patients with HER2-positive breast cancer', 'Patients', 'Previously Treated HER2-Positive Breast Cancer', 'participants with BMs', 'patients with HER2-positive breast cancer with BMs', '291 patients with BMs: 198 (48%) in the tucatinib arm and 93 (46%) in the control arm', 'patients with measurable intracranial disease', 'patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs']","['baseline brain magnetic resonance imaging', 'Tucatinib Plus Trastuzumab and Capecitabine', 'tucatinib or placebo, in combination with trastuzumab and capecitabine']","['risk of intracranial progression or death', 'Risk of death', 'ORR-IC', 'Median OS', 'risk of death', 'intracranial efficacy and survival', 'Median CNS-PFS', 'Intracranial Efficacy and Survival', 'intracranial objective response rate (ORR-IC', 'antitumor activity against BMs', 'CNS-PFS (intracranial progression or death) and overall survival (OS', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0028654', 'cui_str': 'Clinical nurse specialist'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}]",291.0,0.139198,"ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P = .03). ","[{'ForeName': 'Nancy U', 'Initials': 'NU', 'LastName': 'Lin', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Borges', 'Affiliation': 'University of Colorado Cancer Center, Aurora, CO.'}, {'ForeName': 'Carey', 'Initials': 'C', 'LastName': 'Anders', 'Affiliation': 'Duke Cancer Institute, Durham, NC.'}, {'ForeName': 'Rashmi K', 'Initials': 'RK', 'LastName': 'Murthy', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Elisavet', 'Initials': 'E', 'LastName': 'Paplomata', 'Affiliation': 'Carbone Cancer Center/University of Wisconsin, Madison, WI.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Hamilton', 'Affiliation': 'Sarah Cannon Research Institute/Tennessee Oncology-Nashville, Nashville, TN.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Hurvitz', 'Affiliation': 'University of California Los Angeles Medical Center/Jonsson Comprehensive Cancer Center, Los Angeles, CA.'}, {'ForeName': 'Sherene', 'Initials': 'S', 'LastName': 'Loi', 'Affiliation': 'Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Okines', 'Affiliation': 'Royal Marsden National Health Service (NHS) Foundation Trust, London, United Kingdom.'}, {'ForeName': 'Vandana', 'Initials': 'V', 'LastName': 'Abramson', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Philippe L', 'Initials': 'PL', 'LastName': 'Bedard', 'Affiliation': 'University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada.'}, {'ForeName': 'Mafalda', 'Initials': 'M', 'LastName': 'Oliveira', 'Affiliation': ""Hospital Universitario Vall D'Hebron, Barcelona, Spain.""}, {'ForeName': 'Volkmar', 'Initials': 'V', 'LastName': 'Mueller', 'Affiliation': 'Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Zelnak', 'Affiliation': 'Northside Hospital, Atlanta, GA.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'DiGiovanna', 'Affiliation': 'Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bachelot', 'Affiliation': 'Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'A Jo', 'Initials': 'AJ', 'LastName': 'Chien', 'Affiliation': 'University of California at San Francisco, San Francisco, CA.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': ""O'Regan"", 'Affiliation': 'Carbone Cancer Center/University of Wisconsin, Madison, WI.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wardley', 'Affiliation': 'Christie NHS Foundation Trust, Manchester Academic Health Science Centre & Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Conlin', 'Affiliation': 'Providence Cancer Institute, Portland, OR.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cameron', 'Affiliation': 'Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Carey', 'Affiliation': 'University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Curigliano', 'Affiliation': 'Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, University of Milano, Milan, Italy.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Gelmon', 'Affiliation': 'British Columbia Cancer-Vancouver Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Sibylle', 'Initials': 'S', 'LastName': 'Loibl', 'Affiliation': 'German Breast Group, Neu-Isenburg, Germany.'}, {'ForeName': 'JoAl', 'Initials': 'J', 'LastName': 'Mayor', 'Affiliation': 'Seattle Genetics, Bothell, WA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'McGoldrick', 'Affiliation': 'Seattle Genetics, Bothell, WA.'}, {'ForeName': 'Xuebei', 'Initials': 'X', 'LastName': 'An', 'Affiliation': 'Seattle Genetics, Bothell, WA.'}, {'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Winer', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.00775'] 276,32488885,Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects.,"This study evaluated the effect of 3 doses of a trazodone hydrochloride 6% oral drops solution on the QT interval of healthy volunteers. Subjects were randomly assigned to receive a single dose of trazodone 20 mg, 60 mg, and 140 mg, moxifloxacin 400 mg, and trazodone-matched placebo in 5 periods separated by 7-day washouts, according to a double-blind, crossover study design. Subjects were monitored continuously, and triplicate ECGs were extracted from baseline (predose) until 24 hours postdose. Blood samples for trazodone and moxifloxacin analyses were collected at the same time points. The concentration-QTc relationship assessed on placebo-adjusted change from baseline for Fridericia-corrected QT (ΔΔQTcF) was the primary end point. ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations. The upper bound of the 90%CI exceeded 10 ms for the 60- and the 140-mg doses. Time-matched analysis results were in line with these findings. No significant trazodone effect on heart rate or PR or QRS intervals and no clinically significant new morphological changes were present. In this moxifloxacin-validated ECG trial, trazodone had a modest, dose-dependent effect on cardiac repolarization, with no QTc prolongation observed with the 20-mg dose and an effect exceeding the values set in E14 guideline with the 60- and 140-mg doses. The effect on cardiac repolarization is unlikely to represent a clinical risk for ventricular proarrhythmia, but caution should be used with concomitant use of other medications that prolong QT or increase trazodone exposure.",2020,No significant trazodone effect on heart rate or PR or QRS intervals and no clinically significant new morphological changes were present.,"['healthy volunteers', 'Healthy Subjects']","['trazodone 20\xa0mg, 60\xa0mg, and 140\xa0mg, moxifloxacin 400\xa0mg, and trazodone-matched placebo', 'trazodone', 'trazodone hydrochloride 6% oral drops solution', 'Trazodone', 'moxifloxacin']","['concentration-QTc relationship', 'ΔΔQTcF values', 'heart rate or PR or QRS intervals', 'cardiac repolarization']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0040805', 'cui_str': 'Trazodone'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C1126029', 'cui_str': 'moxifloxacin 400 MG'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0282369', 'cui_str': 'Trazodone hydrochloride'}, {'cui': 'C1273616', 'cui_str': 'Oral drops solution'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0520880', 'cui_str': 'QRS interval'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}]",,0.0666214,No significant trazodone effect on heart rate or PR or QRS intervals and no clinically significant new morphological changes were present.,"[{'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Tellone', 'Affiliation': 'Angelini SpA, Piazzale della Stazione, Pomezia, Italy.'}, {'ForeName': 'Maria Teresa', 'Initials': 'MT', 'LastName': 'Rosignoli', 'Affiliation': 'Angelini SpA, Piazzale della Stazione, Pomezia, Italy.'}, {'ForeName': 'Rossella', 'Initials': 'R', 'LastName': 'Picollo', 'Affiliation': 'Angelini SpA, Piazzale della Stazione, Pomezia, Italy.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Dragone', 'Affiliation': 'Angelini SpA, Piazzale della Stazione, Pomezia, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Del Vecchio', 'Affiliation': 'Angelini SpA, Piazzale della Stazione, Pomezia, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Comandini', 'Affiliation': 'Angelini SpA, Piazzale della Stazione, Pomezia, Italy.'}, {'ForeName': 'Milko', 'Initials': 'M', 'LastName': 'Radicioni', 'Affiliation': 'Cross Research SA, Arzo, Switzerland.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Leuratti', 'Affiliation': 'Cross Research SA, Arzo, Switzerland.'}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Calisti', 'Affiliation': 'Angelini SpA, Piazzale della Stazione, Pomezia, Italy.'}]",Journal of clinical pharmacology,['10.1002/jcph.1640'] 277,32565243,"Six high-intensity interval training sessions over 5 days increases maximal oxygen uptake, endurance capacity, and sub-maximal exercise fat oxidation as much as 6 high-intensity interval training sessions over 2 weeks.","BACKGROUND High-intensity interval training (HIIT) induces similar or even superior adaptations compared to continuous endurance training. Indeed, just 6 HIIT sessions over 2 weeks significantly improves maximal oxygen uptake (VO 2max ), submaximal exercise fat oxidation, and endurance performance. Whether even faster adaptations can be achieved with HIIT is not known. Thus, we aimed to determine whether 2 sessions of HIIT per day, separated by 3 h, every other day for 5 days (double HIIT (HIIT-D), n = 15) could increase VO 2max , submaximal exercise fat oxidation, and endurance capacity as effectively as 6 sessions of HIIT over 2 weeks (single HIIT (HIIT-S), n = 13). METHODS Each training session consisted of 10 × 60 s of cycling at 100% of VO 2max interspersed with 75 s of low-intensity cycling at 60 watt (W). Pre- and post-training assessments included VO 2max , time to exhaustion at ∼80% of VO 2max , and 60-min cycling trials at ∼67% of VO 2max . RESULTS Similar increases (p < 0.05) in VO 2max (HIIT-D: 7.7% vs. HIIT-S: 6.0%, p > 0.05) and endurance capacity (HIIT-D: 80.1% vs. HIIT-S: 79.2%, p > 0.05) were observed. Submaximal exercise carbohydrate oxidation was reduced in the 2 groups after exercise training (HIIT-D: 9.2%, p = 0.014 vs. HIIT-S: 18.8%, p = 0.012) while submaximal exercise fat oxidation was significantly increased in HIIT-D (15.5%, p = 0.048) but not in HIIT-S (9.3%, p = 0.290). CONCLUSION Six HIIT sessions over 5 days was as effective in increasing VO 2max and endurance capacity and was more effective in improving submaximal exercise fat oxidation than 6 HIIT sessions over 2 weeks.",2021,"Submaximal exercise carbohydrate oxidation was reduced in the 2 groups after exercise training (HIIT-D 9.2%, p = 0.14 vs. HIIT-S 18.8%, p = 0.14) while submaximal exercise fat oxidation was significantly increased in HIIT-D (15.5%; p = 0.048) but not in HIIT-S (9.3%; p = 0.290). ",[],"['High-intensity interval training (HIIT', 'VO 2max interspersed with 75 s of low-intensity cycling at 60 W. Pre- and post-training assessments included VO 2max , time to exhaustion at ∼80% of VO 2max and 60-min cycling trials at ∼67% of VO 2max ']","['submaximal exercise fat oxidation', 'VO 2max', 'VO 2max and endurance capacity', 'endurance capacity', 'maximal oxygen uptake, endurance capacity and sub-maximal exercise fat oxidation', 'VO 2max , submaximal exercise fat oxidation and endurance capacity', 'maximal oxygen uptake (VO 2max ), submaximal exercise fat oxidation and endurance performance', 'Submaximal exercise carbohydrate oxidation']",[],"[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}]",,0.049312,"Submaximal exercise carbohydrate oxidation was reduced in the 2 groups after exercise training (HIIT-D 9.2%, p = 0.14 vs. HIIT-S 18.8%, p = 0.14) while submaximal exercise fat oxidation was significantly increased in HIIT-D (15.5%; p = 0.048) but not in HIIT-S (9.3%; p = 0.290). ","[{'ForeName': 'Muhammed M', 'Initials': 'MM', 'LastName': 'Atakan', 'Affiliation': 'Division of Nutrition and Metabolism in Exercise, Faculty of Sport Sciences, Hacettepe University, Ankara 06690, Turkey; Institute for Health and Sport, Victoria University, Melbourne, VIA 3011, Australia.'}, {'ForeName': 'Yasemin', 'Initials': 'Y', 'LastName': 'Güzel', 'Affiliation': 'Division of Nutrition and Metabolism in Exercise, Faculty of Sport Sciences, Hacettepe University, Ankara 06690, Turkey.'}, {'ForeName': 'Süleyman', 'Initials': 'S', 'LastName': 'Bulut', 'Affiliation': 'Division of Nutrition and Metabolism in Exercise, Faculty of Sport Sciences, Hacettepe University, Ankara 06690, Turkey.'}, {'ForeName': 'Şükran N', 'Initials': 'ŞN', 'LastName': 'Koşar', 'Affiliation': 'Division of Nutrition and Metabolism in Exercise, Faculty of Sport Sciences, Hacettepe University, Ankara 06690, Turkey.'}, {'ForeName': 'Glenn K', 'Initials': 'GK', 'LastName': 'McConell', 'Affiliation': 'Institute for Health and Sport, Victoria University, Melbourne, VIA 3011, Australia. Electronic address: glenn.mcconell@vu.edu.au.'}, {'ForeName': 'Hüseyin H', 'Initials': 'HH', 'LastName': 'Turnagöl', 'Affiliation': 'Division of Nutrition and Metabolism in Exercise, Faculty of Sport Sciences, Hacettepe University, Ankara 06690, Turkey. Electronic address: deniz@hacettepe.edu.tr.'}]",Journal of sport and health science,['10.1016/j.jshs.2020.06.008'] 278,32623812,Effects of Vitamin D Supplementation on Disabling Foot Pain in Patients With Symptomatic Knee Osteoarthritis.,"OBJECTIVE The present study was undertaken to determine whether vitamin D supplementation or maintaining sufficient vitamin D level reduces foot pain over 2 years in patients with symptomatic knee osteoarthritis (OA). METHODS A post hoc study was conducted from a randomized, double-blind, placebo-controlled trial named the Vitamin D Effect on Osteoarthritis (VIDEO) study. Symptomatic knee OA patients with serum 25-hydroxyvitamin D levels between 12.5 nmoles/liter and 60 nmoles/liter were included and randomly allocated to either monthly vitamin D 3 or placebo treatment (1:1) for 2 years. Manchester Foot Pain and Disability Index (MFPDI) was used to evaluate foot pain and disabling foot pain was defined as at least 1 of the 10 functional limitation items (items 1-9 and 11) being documented as on ""most/every day(s)"" in the last month. A repeated-measures, mixed-effects model was used to analyze the change of MFPDI scores between groups adjusting for potential confounders. RESULTS A total of 413 patients with a mean age of 63.2 years (49.7% males) were enrolled and 340 completed the study. The mean MFPDI score was 22.8 ± 7.3, with 23.7% of participants having disabling foot pain at baseline. There were significant differences in MFPDI scores change between groups over 2 years, with more improvements in the vitamin D group than in the placebo group (-0.03 versus 1.30; P = 0.013) and more improvement in those maintaining sufficient vitamin D levels (n = 226) than those who did not (n = 114) (-0.09 versus 2.19; P = 0.001). CONCLUSION Vitamin D supplementation and maintenance of sufficient vitamin D levels may improve foot pain in those with knee OA.",2021,"There were significant differences in MFPDI scores change between groups over 2 years, with more improvements in vitamin D group than in placebo group (-0.03 vs. 1.30, P=0.013) and more improvement in those maintaining sufficient vitamin D levels (n=226) than those who did not (n=114) (-0.09 vs. 2.19, P=0.001). ","['413 patients with a mean age of 63.2 years (49.7% males) were enrolled and 340 completed the study', 'those with knee OA', 'patients with symptomatic knee osteoarthritis', 'Symptomatic knee OA patients with serum 25-hydroxyvitamin D levels between 12.5 nmol/L to 60 nmol/L', 'patients with symptomatic knee OA']","['vitamin D supplementation or maintaining sufficient vitamin D level', 'placebo', 'Vitamin D supplementation', 'vitamin D', 'VItamin D', 'vitamin D supplementation', 'vitamin D3 or placebo']","['vitamin D levels', 'Manchester Foot Pain and Disability Index (MFPDI', 'MFPDI scores change', 'disabling foot pain', 'mean MFPDI score', 'MFPDI scores', 'foot pain and Disabling foot pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517730', 'cui_str': '340'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0439282', 'cui_str': 'nmol/L'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0016512', 'cui_str': 'Foot pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2960415', 'cui_str': 'Manchester foot pain and disability index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2960416', 'cui_str': 'Manchester foot pain and disability index score'}]",413.0,0.502134,"There were significant differences in MFPDI scores change between groups over 2 years, with more improvements in vitamin D group than in placebo group (-0.03 vs. 1.30, P=0.013) and more improvement in those maintaining sufficient vitamin D levels (n=226) than those who did not (n=114) (-0.09 vs. 2.19, P=0.001). ","[{'ForeName': 'Liudan', 'Initials': 'L', 'LastName': 'Tu', 'Affiliation': 'The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, and University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Zheng', 'Affiliation': 'University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Flavia', 'Initials': 'F', 'LastName': 'Cicuttini', 'Affiliation': 'Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Xingzhong', 'Initials': 'X', 'LastName': 'Jin', 'Affiliation': 'University of Tasmania, Hobart, Tasmania, and the University of Sydney, New South Wales, Australia.'}, {'ForeName': 'Weiyu', 'Initials': 'W', 'LastName': 'Han', 'Affiliation': 'University of Tasmania, Hobart, Tasmania, Australia, and Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Zhaohua', 'Initials': 'Z', 'LastName': 'Zhu', 'Affiliation': 'University of Tasmania, Hobart, Tasmania, Australia, and Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Benny', 'Initials': 'B', 'LastName': 'Antony', 'Affiliation': 'University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Winzenberg', 'Affiliation': 'University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Jones', 'Affiliation': 'University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Jieruo', 'Initials': 'J', 'LastName': 'Gu', 'Affiliation': 'The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Anita E', 'Initials': 'AE', 'LastName': 'Wluka', 'Affiliation': 'Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Changhai', 'Initials': 'C', 'LastName': 'Ding', 'Affiliation': 'The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, University of Tasmania, Hobart, Tasmania, Australia, Monash University, Melbourne, Victoria, Australia, and Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.'}]",Arthritis care & research,['10.1002/acr.24371'] 279,32634624,Effects of Screening Compliance on Long-term Reductions in All-Cause and Colorectal Cancer Mortality.,"BACKGROUND & AIMS Randomized trials have shown that biennial fecal occult blood test (FOBT) screening reduces mortality from colorectal cancer (CRC), but not overall mortality. Differences in benefit for men vs women, and by age, are unknown. We sought to evaluate long-term reduction in all-cause and CRC-specific mortality in men and women who comply with offered screening, and in different age groups, using individual participant data from 2 large randomized trials of biennial FOBT screening, compared with an intention to treat analysis. METHODS We updated the CRC and all-cause mortality from the Danish CRC screening trial (n = 61,933) through 30 years of follow up and pooled individual participant data with individual 30-year follow-up data from the Minnesota Colon Cancer Control trial (n = 46,551). We compared the biennial screening groups to usual care (controls) in individuals 50-80 years old using Kaplan Meier estimates of relative risks and risk differences, adjusted for study differences in age, sex, and compliance. RESULTS Through 30 years of follow up, there were 33,478 (71.9%) and 33,479 (72.2%) total deaths and 1023 (2.2%) and 1146 (2.5%) CRC deaths in the biennial screening (n = 46,553) and control groups (n = 46,358), respectively. Among compliers, biennial FOBT screening significantly reduced CRC mortality by 16% (relative risk [RR], 0.84; 95% CI, 0.74-0.96) and all-cause mortality by 2% (RR, 0.98; 95% CI, 0.97-0.99). Among compliers, the reduction in CRC mortality was larger for men (RR, 0.75; 95% CI, 0.62-0.90) than women (RR, 0.91; 95% CI, 0.75-1.09). The largest reduction in CRC mortality was in compliant men 60-69 years old (RR, 0.59; 95% CI, 0.42-0.81) and women 70 years and older (RR, 0.53; 95% CI, 0.30-0.94). CONCLUSIONS Long-term CRC mortality outcomes of screening among compliers using biennial FOBT are sustained, with a statistically significant reduction in all-cause mortality. The reduction in CRC mortality is greater in men than women-the benefit in women lags that of men by about 10 years.",2021,"Among compliers, the reduction in CRC mortality was larger for men (RR, 0.75; 95% CI, 0.62-0.90) than women (RR, 0.91; 95% CI, 0.75-1.09).","['men and women who comply with offered screening, and in different age groups']","['biennial screening groups to usual care (controls', 'biennial FOBT screening']","['total deaths', 'CRC mortality', 'CRC deaths', 'cause mortality', 'Colorectal Cancer Mortality']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}]","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0201811', 'cui_str': 'Screening for occult blood in feces'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",61933.0,0.195055,"Among compliers, the reduction in CRC mortality was larger for men (RR, 0.75; 95% CI, 0.62-0.90) than women (RR, 0.91; 95% CI, 0.75-1.09).","[{'ForeName': 'Aasma', 'Initials': 'A', 'LastName': 'Shaukat', 'Affiliation': 'Division of Gastroenterology, Minneapolis Veterans Affairs Healthcare System Minneapolis, Minnesota; Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota; Division of Environmental Health Sciences, University of Minnesota School of Public Health, Minneapolis, Minnesota. Electronic address: shaukat@umn.edu.'}, {'ForeName': 'Lasse', 'Initials': 'L', 'LastName': 'Kaalby', 'Affiliation': 'Open Patient Data Explorative Network, Odense University Hospital and University of Southern Denmark, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Surgery, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Baatrup', 'Affiliation': 'Open Patient Data Explorative Network, Odense University Hospital and University of Southern Denmark, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Surgery, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Kronborg', 'Affiliation': 'Open Patient Data Explorative Network, Odense University Hospital and University of Southern Denmark, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Surgery, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Duval', 'Affiliation': 'Cardiovascular Division, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Shyne', 'Affiliation': 'Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, Minnesota.'}, {'ForeName': 'Jack S', 'Initials': 'JS', 'LastName': 'Mandel', 'Affiliation': 'Division of Environmental Health Sciences, University of Minnesota School of Public Health, Minneapolis, Minnesota.'}, {'ForeName': 'Timothy R', 'Initials': 'TR', 'LastName': 'Church', 'Affiliation': 'Division of Environmental Health Sciences, University of Minnesota School of Public Health, Minneapolis, Minnesota.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2020.06.019'] 280,32649011,Early-term elective Caesarean sections did not increase the risk of behavioural problems at six to eight years of age.,"AIM Our aim was to explore the under-researched associations between an elective Caesarean section (C-section) at early-term or full-term gestation and behaviour at 6-8 years of age. METHODS We identified 1220 eligible children born by elective C-sections at Danish hospital from 2009 to 2011. Their mothers were randomised to elective C-sections at either 38+3 (early-term) or 39+3 (full-term) weeks of gestation. From December 2017 to August 2018, the parents completed the Strengths and Difficulties Questionnaire. The results were adjusted for maternal education, parity and the child's sex. RESULTS Of the 574 (45%) children followed up, 288 were delivered early-term and 286 were delivered full-term. The groups had similar baseline characteristics. There were no differences in the total difficulties score, subscale scores or the risk of being classified as having a possible or probable psychiatric disorder. Early-term boys had a lower risk of being classified as having a possible or probable psychiatric disorder and early-term girls had higher risk, but the results were not statistically significant. CONCLUSION We found no difference in behaviour at 6-8 years of age between children born by elective C-section at early- versus full-term gestation.",2021,We found no difference in behaviour at 6-8 years of age between children born by elective C-section at early versus full term gestation.,"['Of the 574 (45%) children followed up, 288 were delivered early term and 286 were delivered full term', '1220 eligible children born by elective C-sections at Danish hospital from 2009-2011']",['elective Caesarean section (C-section'],"['risk of behavioural problems', 'behaviour', 'lower risk of being classified as having a possible or probable psychiatric disorder', 'total difficulties score, subscale scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0010969', 'cui_str': 'Danish language'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0332149', 'cui_str': 'Possible'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0459443', 'cui_str': 'Subscale score'}]",,0.0627165,We found no difference in behaviour at 6-8 years of age between children born by elective C-section at early versus full term gestation.,"[{'ForeName': 'Trine Muhs', 'Initials': 'TM', 'LastName': 'Nielsen', 'Affiliation': 'Perinatal Epidemiology Research Unit, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Glavind', 'Affiliation': 'Perinatal Epidemiology Research Unit, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Ioanna', 'Initials': 'I', 'LastName': 'Milidou', 'Affiliation': 'Perinatal Epidemiology Research Unit, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Tine Brink', 'Initials': 'TB', 'LastName': 'Henriksen', 'Affiliation': 'Perinatal Epidemiology Research Unit, Aarhus University, Aarhus, Denmark.'}]","Acta paediatrica (Oslo, Norway : 1992)",['10.1111/apa.15468'] 281,32657437,Niacinamide mitigates SASP-related inflammation induced by environmental stressors in human epidermal keratinocytes and skin.,"OBJECTIVE To evaluate whether niacinamide (Nam) can mitigate production of inflammatory and senescence-related biomarkers induced by environmental stressors. METHODS Human epidermal keratinocytes were exposed to UVB, urban dust, diesel exhaust and cigarette smoke extract and treated with Nam or vehicle control. Full thickness 3-D skin organotypic models were exposed to a combination of UVB and PM 2.5 and treated with Nam or vehicle control. Quantitation of the SASP-related inflammatory mediators PGE 2 , IL-6 and IL-8 was performed on cultured media. UVB-exposed keratinocytes treated with and without Nam were immunostained for the senescence biomarker Lamin B1 (LmnB1). Transcriptomics profiling of cigarette smoke extract effects on keratinocytes was performed. A double-blind, placebo-controlled clinical was conducted on 40 female panellists that were pretreated on back sites for two weeks with 5% Nam or vehicle and then exposed to 1.5 minimal erythemal dose (MED) solar-simulated radiation (SSR). Treated sites were compared with non-treated exposed sites for erythema and the skin surface IL-1αRA/IL-1α inflammatory biomarkers. RESULTS Ultraviolet B induced synthesis of PGE 2 , IL-8 and IL-6 and reduced LmnB1 levels in keratinocytes. Urban dust and diesel exhaust only stimulated synthesis of IL-8 whereas cigarette smoke extract only stimulated levels of PGE 2 . In all exposures, treatment with Nam significantly mitigated synthesis of the inflammatory mediators and restored levels of UVB-reduced LmnB1. In the 3D skin equivalent model, Nam reduced IL-8 levels stimulated by a combination of topical PM 2.5 and UV exposure. In a UV challenge clinical, pretreatment with 5% Nam reduced erythema and skin surface IL-1αRA/IL-1α inflammatory biomarkers that were induced by SSR. CONCLUSION Since it is known that Nam has anti-inflammatory properties, we tested whether Nam can inhibit environmental stress-induced inflammation and senescence-associated secretory phenotype (SASP) biomarkers. We show Nam can reduce PGE 2 , IL-6 and IL-8 levels induced by environmental stressors. Additionally, in vivo pretreatment with Nam can reduce UV-induced erythema and skin surface inflammatory biomarkers. These findings add to the body of evidence that Nam can mitigate the skin's inflammatory response elicited by environmental stressors. This supports Nam can potentially inhibit senescence and premature ageing and thereby maintain skin's functionality and appearance.",2020,"RESULTS UVB induced synthesis of PGE 2 , IL-8 and IL-6 and reduced LmnB1 levels in keratinocytes.","['40 female panelists that were pretreated on back sites for two weeks with', 'Human epidermal keratinocytes were exposed to UVB, urban dust, diesel exhaust, and']","['niacinamide (Nam', 'cigarette smoke extract and treated with Nam or vehicle control', 'UVB and PM 2.5 and treated with Nam or vehicle control', '5% Nam or vehicle and then exposed to 1.5 minimal erythemal dose (MED) solar simulated radiation (SSR', 'placebo']","['synthesis of PGE 2 , IL-8 and IL-6 and reduced LmnB1 levels', 'PGE 2 , IL-6, and IL-8 levels', 'mitigated synthesis of the inflammatory mediators and restored levels of UVB-reduced LmnB1', 'IL-8 levels', 'erythema and skin surface IL-1αRA/IL-1α inflammatory biomarkers', 'UV-induced erythema and skin surface inflammatory biomarkers']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C4082118', 'cui_str': 'Two weeks'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0014520', 'cui_str': 'Epidermis structure'}, {'cui': 'C0022567', 'cui_str': 'Keratinocyte'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0454530', 'cui_str': 'Ultraviolet B therapy'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0013330', 'cui_str': 'Dust'}, {'cui': 'C0012151', 'cui_str': 'Diesel Exhaust'}]","[{'cui': 'C0028027', 'cui_str': 'Niacinamide'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0454530', 'cui_str': 'Ultraviolet B therapy'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0033559', 'cui_str': 'E series prostaglandin'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0454530', 'cui_str': 'Ultraviolet B therapy'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]",40.0,0.0491362,"RESULTS UVB induced synthesis of PGE 2 , IL-8 and IL-6 and reduced LmnB1 levels in keratinocytes.","[{'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Bierman', 'Affiliation': 'The Procter & Gamble Company, Mason, OH, 45040, USA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Laughlin', 'Affiliation': 'The Procter & Gamble Company, Mason, OH, 45040, USA.'}, {'ForeName': 'Makio', 'Initials': 'M', 'LastName': 'Tamura', 'Affiliation': 'The Procter & Gamble Company, Mason, OH, 45040, USA.'}, {'ForeName': 'Ben C', 'Initials': 'BC', 'LastName': 'Hulette', 'Affiliation': 'The Procter & Gamble Company, Mason, OH, 45040, USA.'}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Mack', 'Affiliation': 'The Procter & Gamble Company, Mason, OH, 45040, USA.'}, {'ForeName': 'Joseph D', 'Initials': 'JD', 'LastName': 'Sherrill', 'Affiliation': 'The Procter & Gamble Company, Mason, OH, 45040, USA.'}, {'ForeName': 'Christina Y R', 'Initials': 'CYR', 'LastName': 'Tan', 'Affiliation': 'Skin Research Institute of Singapore, A*STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore, 138648, Singapore.'}, {'ForeName': 'Malgorzata', 'Initials': 'M', 'LastName': 'Morenc', 'Affiliation': 'Skin Research Institute of Singapore, A*STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore, 138648, Singapore.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Bellanger', 'Affiliation': 'Skin Research Institute of Singapore, A*STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore, 138648, Singapore.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Oblong', 'Affiliation': 'The Procter & Gamble Company, Mason, OH, 45040, USA.'}]",International journal of cosmetic science,['10.1111/ics.12651'] 282,32654080,"Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.","OBJECTIVES To assess the efficacy and safety of the commonly used urate-lowering therapies (ULTs): febuxostat, allopurinol, and lesinurad in hyperuricemic patients with gout. METHODS We included all randomized controlled trials (RCTs) that compared ULTs with placebo or head to head. The primary efficacy endpoint was the proportion of subjects achieving the target serum urate (SU) level at month 6. Safety outcomes included total adverse events (AEs), serious AEs, withdrawals due to AEs, and AEs per organ system. A Bayesian network model was used to compare all ULTs with placebo and among themselves. RESULTS Fifteen RCTs were included for the analysis, in which 7968 patients were randomly assigned to take either placebo or one of 11 ULTs: allopurinol, febuxostat 40/80/120/240 mg/day, lesinurad 400 mg/day, lesinurad 200/400/600 mg/day plus allopurinol, and lesinurad 200/400 mg/day plus febuxostat. All ULTs were effective in achieving the target SU level at month 6 compared with placebo (ORs between 26.81 and 1928). Febuxostat 80/120/240 mg/day was superior to allopurinol and well tolerated for urate reduction. And as febuxostat dosage increased, more patients achieved the target SU level. Furthermore, the lesinurad combination with xanthine oxidase inhibitor (XOI) groups had a higher proportion of patients achieving the target SU level than the febuxostat 40 mg/day group (ORs between 2.89 and 9.17), the allopurinol group (ORs between 3.56 and 11.27), or the lesinurad 400 mg/day monotherapy group (ORs between 12.30 and 39.17) but might have a high risk of AEs. CONCLUSIONS All ULTs are effective in achieving the target SU level compared with placebo in hyperuricemic patients with gout. Lesinurad in combination with febuxostat or allopurinol is effective in urate lowering, especially for patients with inadequate response to XOI monotherapy. Key Points • All urate-lowering therapies (ULTs) were effective in achieving the target serum urate (SU) level at month 6 compared with placebo in hyperuricemic patients with gout. • Febuxostat 80/120/240 mg/day was superior to allopurinol and well tolerated for urate reduction. And as febuxostat dosage increased, more patients achieved the target SU level. • Lesinurad in combination with febuxostat or allopurinol was effective in urate lowering, especially for patients with inadequate response to xanthine oxidase inhibitor monotherapy, but might have a high risk of AEs.",2021,All urate-lowering therapies (ULTs) were effective in achieving the target serum urate (SU) level at month 6 compared with placebo in hyperuricemic patients with gout.,"['hyperuricemic patients with gout', 'Fifteen RCTs were included for the analysis, in which 7968 patients', 'patients with inadequate response to XOI monotherapy']","['urate-lowering therapies', 'xanthine oxidase inhibitor (XOI', 'All urate-lowering therapies (ULTs', 'ULTs with placebo', 'Febuxostat', 'febuxostat or allopurinol', 'urate-lowering therapies (ULTs): febuxostat, allopurinol', 'allopurinol', 'allopurinol, febuxostat 40/80/120/240', 'allopurinol, and lesinurad 200/400\xa0mg/day plus febuxostat', 'placebo']","['total adverse events (AEs), serious AEs, withdrawals due to AEs, and AEs per organ system', 'target serum urate (SU) level', 'proportion of subjects achieving the target serum urate (SU) level', 'efficacy and safety', 'target SU level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018099', 'cui_str': 'Gout'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0302609', 'cui_str': 'Xanthine oxidase inhibitor'}]","[{'cui': 'C0202239', 'cui_str': 'Uric acid measurement'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0302609', 'cui_str': 'Xanthine oxidase inhibitor'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0249529', 'cui_str': 'febuxostat'}, {'cui': 'C0002144', 'cui_str': 'Allopurinol'}, {'cui': 'C3886073', 'cui_str': 'lesinurad'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0460002', 'cui_str': 'Body system structure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0202239', 'cui_str': 'Uric acid measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0455272', 'cui_str': 'Serum urate measurement'}]",7968.0,0.223971,All urate-lowering therapies (ULTs) were effective in achieving the target serum urate (SU) level at month 6 compared with placebo in hyperuricemic patients with gout.,"[{'ForeName': 'Meida', 'Initials': 'M', 'LastName': 'Fan', 'Affiliation': ""Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.""}, {'ForeName': 'Bingcheng', 'Initials': 'B', 'LastName': 'Zhao', 'Affiliation': ""Department of Anesthesiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.""}, {'ForeName': 'Xinyu', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': ""Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Tianhe, Guangzhou, 510630, People's Republic of China.""}, {'ForeName': 'Xuefeng', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ""The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Xinzao, Panyu, Guangzhou, 511436, Guangdong, People's Republic of China. xuefengli@gzhmu.edu.cn.""}, {'ForeName': 'Jieruo', 'Initials': 'J', 'LastName': 'Gu', 'Affiliation': ""Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Tianhe, Guangzhou, 510630, People's Republic of China. gujieruo@163.com.""}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Schlesinger', 'Affiliation': 'Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, 08901, USA. schlesna@aol.com.'}]",Clinical rheumatology,['10.1007/s10067-020-05272-4'] 283,32463593,Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects.,"Sildenafil citrate is approved to treat erectile dysfunction. An orally disintegrating tablet (ODT) of sildenafil citrate that does not require swallowing or administration with fluids has been developed. The bioequivalence and bioavailability of sildenafil citrate ODT (50 mg) without and with water were compared with conventional sildenafil citrate tablets (50 mg) in an open-label, randomized crossover study. Healthy Chinese male subjects (n = 36) were allocated to 1 of 6 sildenafil citrate treatment sequences under fasted conditions, and plasma samples for determination of sildenafil concentrations were collected predose through 14 hours postdose. Bioequivalence was demonstrated for sildenafil citrate ODT administered without water relative to the sildenafil citrate tablet administered with water; 90%CIs for the ratios of adjusted geometric means for sildenafil AUC last , C max , and AUC inf (ratio, 101.41%; 90%CI, 95.49%-107.70%; ratio, 93.55%; 90%CI, 84.15%-104.00%; and ratio, 101.03%; 90%CI, 94.80%-107.66%; respectively) were wholly contained within the bioequivalence acceptance range of 80% to 125%, indicating bioequivalence criteria were met. Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUC last , C max , and AUC inf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively). Both sildenafil citrate formulations were generally well tolerated in healthy Chinese men. Sildenafil citrate ODT administered without or with water was bioequivalent to or met bioequivalence criteria compared with conventional sildenafil citrate tablets administered with water under fasted conditions in healthy Chinese men, thus offering a convenient alternative method of oral administration.",2020,Bioequivalence was demonstrated for sildenafil citrate ODT administered without water relative to the sildenafil citrate tablet administered with water; 90%CIs for the ratios of adjusted geometric means for sildenafil,"['Healthy Chinese male subjects (n = 36', 'healthy Chinese men', 'Healthy Chinese Male Subjects']","['sildenafil citrate tablet', 'sildenafil citrate ODT', 'Sildenafil citrate ODT', 'conventional sildenafil citrate tablets', 'sildenafil AUC', 'sildenafil citrate ODT (50 mg) without and with water were compared with conventional sildenafil citrate tablets', 'sildenafil citrate formulations', 'Sildenafil citrate', 'sildenafil citrate', 'Sildenafil Citrate', 'sildenafil']","['Relative bioavailability', 'AUC last , C max , and AUC inf', 'Bioequivalence and Bioavailability', 'last , C max , and AUC inf']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0724693', 'cui_str': 'Sildenafil citrate'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C2960508', 'cui_str': 'Orodispersible tablet'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0529793', 'cui_str': 'sildenafil'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0039789', 'cui_str': 'Equivalencies, Therapeutic'}]",36.0,0.0744477,Bioequivalence was demonstrated for sildenafil citrate ODT administered without water relative to the sildenafil citrate tablet administered with water; 90%CIs for the ratios of adjusted geometric means for sildenafil,"[{'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Lv', 'Affiliation': 'Peking University First Hospital, Institute of Clinical Pharmacology, Beijing, China.'}, {'ForeName': 'Bin-Yu', 'Initials': 'BY', 'LastName': 'Luo', 'Affiliation': 'Pfizer Inc, Shanghai, China.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'LaBadie', 'Affiliation': 'Pfizer Inc, Groton, Connecticut, USA.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'Pfizer Inc, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Feng', 'Affiliation': 'Pfizer Inc, Beijing, China.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Ernst', 'Affiliation': 'ExecuPharm, King of Prussia, Pennsylvania, USA.'}, {'ForeName': 'Penelope H', 'Initials': 'PH', 'LastName': 'Crownover', 'Affiliation': 'Pfizer Inc, Groton, Connecticut, USA.'}, {'ForeName': 'Yali', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Pfizer Inc, Groton, Connecticut, USA.'}, {'ForeName': 'Qinying', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'Pfizer Inc, Groton, Connecticut, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.806'] 284,32463599,"A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.","A comparison of the immunogenicity, safety, and pharmacokinetic properties of HS016 and its originator, adalimumab, was conducted in Chinese healthy male subjects. This was a phase 1 single-center, randomized, parallel-group double-blind clinical trial. Chinese healthy male subjects (1:1) allocated to HS016 and adalimumab groups were treated with single subcutaneous injections (40 mg/0.8 mL). The pharmacokinetic equivalence of HS016 and adalimumab was assessed by (1) the area under the plasma concentration-time curve (AUC) from time 0 to the last detectable drug concentration (AUC 0-t ), (2) the AUC from time 0 extrapolated to infinity (AUC 0-∞ ), and (3) the maximum plasma concentration (C max ). Other pharmacokinetic parameters (time to C max , apparent clearance, and half-life), safety, and immunogenicity were also evaluated. A total of 136 subjects were randomly divided into HS016 (n = 68) or adalimumab (n = 68) groups. The geometric means of AUC 0-t , AUC 0-∞ , and C max were similar for HS016 and adalimumab. The 90%CIs of AUC 0-t (87.2% to 106.1%), AUC 0-∞ (87.4% to 108.4%), and C max (98.6% to 113.6%) were all within the prespecified bioequivalence criteria (80% to 125%). The incidence of treatment-emergent adverse events (TEAEs) was similar in both groups, with most TEAEs being mild; only 3 (4.4%) subjects in the HS016 group experienced moderate TEAEs. No significant differences in the time to C max , apparent clearance, half-life, and immunogenicity were detected. The pharmacokinetic profile of HS016 was equivalent to that of the originator, adalimumab, with similar safety and immunogenicity profiles. HS016 may be considered for assessment in the treatment of patients with ankylosing spondylitis.",2021,"The 90%CIs of AUC 0-t (87.2% to 106.1%), AUC 0-∞ (87.4% to 108.4%), and C max (98.6% to 113.6%) were all within the prespecified bioequivalence criteria (80% to 125%).","['Chinese healthy male subjects', 'patients with ankylosing spondylitis', 'Chinese Healthy Male Subjects', '136 subjects', 'Chinese healthy male subjects (1:1) allocated to']","['adalimumab', 'Biosimilar HS016 and the Originator Adalimumab', 'HS016 and adalimumab', 'HS016', 'single subcutaneous injections', 'HS016 and its originator, adalimumab']","['time to C max , apparent clearance, half-life, and immunogenicity', 'maximum plasma concentration (C max ', 'plasma concentration-time curve (AUC', '90%CIs of AUC 0-t', 'pharmacokinetic parameters (time to C max , apparent clearance, and half-life), safety, and immunogenicity', 'incidence of treatment-emergent adverse events (TEAEs', 'immunogenicity, safety, and pharmacokinetic properties', 'geometric means of AUC 0-t , AUC 0-∞ , and C max']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038013', 'cui_str': 'Ankylosing spondylitis'}, {'cui': 'C4517568', 'cui_str': '136'}]","[{'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous injection'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",136.0,0.110923,"The 90%CIs of AUC 0-t (87.2% to 106.1%), AUC 0-∞ (87.4% to 108.4%), and C max (98.6% to 113.6%) were all within the prespecified bioequivalence criteria (80% to 125%).","[{'ForeName': 'Guoying', 'Initials': 'G', 'LastName': 'Cao', 'Affiliation': 'Phase I Clinical Trial Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jicheng', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Phase I Clinical Trial Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jufang', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Phase I Clinical Trial Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Phase I Clinical Trial Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Xue', 'Affiliation': 'Phase I Clinical Trial Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Phase I Clinical Trial Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Phase I Clinical Trial Center, Huashan Hospital, Fudan University, Shanghai, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.816'] 285,32476640,"Effects of the Rango Cards game intervention on food consumption, nutritional knowledge and self-efficacy in the adoption of healthy eating practices of high school students: a cluster randomised controlled trial.","OBJECTIVE The study aimed to assess the impact of a game-based nutritional intervention on food consumption, nutritional knowledge and self-efficacy in the adoption of healthy eating practices. DESIGN This cluster randomised controlled trial included both male and female high school students from private schools in the Federal District, Brazil. Four schools were randomly selected for each group. Investigated variables were age, sex, monthly family income, maternal education level, dietary perceptions and practices, nutritional knowledge and self-efficacy in the adoption of healthy eating practices. SETTING Intervention group participants were instructed to play Rango Cards, a digital game developed for the study, on their own, for a period of 7-17 d, while the control group was not provided with any game or material during the study. PARTICIPANTS The study included 319 adolescents (mean age = 15·8 (sd 0·7) years). RESULTS Significant reductions were observed in the intervention group compared with the control group for the following variables: habit of eating while watching TV or studying and having meals at fast food restaurants. The intervention group showed increased knowledge of the effects of fruit and vegetable consumption as well as improved self-efficacy in the adoption of healthy eating practices such as reducing Na intake and preparing healthy meals. CONCLUSIONS The design of Rango Cards is potentially capable of effecting positive changes. Therefore, the digital game promotes autonomy and self-care among adolescents with regard to healthy eating.",2020,"RESULTS Significant reductions were observed in the intervention group compared with the control group for the following variables: habit of eating while watching TV or studying and having meals at fast food restaurants.","['The study included 319 adolescents (mean age = 15·8', 'healthy eating practices', 'adolescents with regard to healthy eating', 'healthy eating practices of high school students', 'male and female high school students from private schools in the Federal District, Brazil']","['play Rango Cards, a digital game', 'game-based nutritional intervention', 'Rango Cards game intervention']","['knowledge of the effects of fruit and vegetable consumption', 'food consumption, nutritional knowledge and self-efficacy', 'self-efficacy']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0567466', 'cui_str': 'Eating practice'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",319.0,0.0509513,"RESULTS Significant reductions were observed in the intervention group compared with the control group for the following variables: habit of eating while watching TV or studying and having meals at fast food restaurants.","[{'ForeName': 'Carolina Martins Dos Santos', 'Initials': 'CMDS', 'LastName': 'Chagas', 'Affiliation': 'Federal University of Lavras, Department of Nutrition,\xa0Minas Gerais37200-000, Brazil.'}, {'ForeName': 'Giselle Rhai-Sa', 'Initials': 'GR', 'LastName': 'Melo', 'Affiliation': 'University of Brasilia, School of Health Sciences, Graduate Program in Human Nutrition, Federal District, Brazil.'}, {'ForeName': 'Raquel Braz Assunção', 'Initials': 'RBA', 'LastName': 'Botelho', 'Affiliation': 'University of Brasilia, School of Health Sciences, Post-Graduate Program in Human Nutrition, Federal District, Brazil.'}, {'ForeName': 'Natacha', 'Initials': 'N', 'LastName': 'Toral', 'Affiliation': 'University of Brasilia, School of Health Sciences, Post-Graduate Program in Human Nutrition, Federal District, Brazil.'}]",Public health nutrition,['10.1017/S1368980020000531'] 286,32479220,Maternal Cash Transfers Led To Increases In Facility Deliveries And Improved Quality Of Delivery Care In Nigeria.,"Ninety-nine percent of global maternal deaths occur in low- and middle-income countries. The high mortality rates are often attributed to a large portion of births occurring outside of formal health care facilities. This has prompted the creation of programs to promote the use of formal delivery care. However, poor-quality care in health facilities in low- and middle-income countries is well documented. It is not clear that shifting births into health facilities in these settings necessarily leads to better-quality care. We present results from a randomized controlled trial in Nigeria that evaluated a conditional cash transfer intervention that paid pregnant women to deliver in a health facility. We found that the intervention led to a 41 percent increase in facility deliveries. We also found improvements in the quality of delivery care (as a result of more births taking place in formal health care settings) and in overall satisfaction with care. We found no evidence of a reduction in preventable complications that led to maternal deaths, though we found some improvements in self-reported health. Our results indicate that promoting facility deliveries can improve the quality of care received, even in settings where formal care quality is poor. However, modest quality improvements might not be sufficient to substantially improve health outcomes.",2020,"We found no evidence of a reduction in preventable complications that led to maternal deaths, though we found some improvements in self-reported health.","['paid pregnant women to deliver in a health facility', 'Facility Deliveries']",['conditional cash transfer intervention'],"['facility deliveries', 'quality of delivery care', 'health outcomes', 'global maternal deaths']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]","[{'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1171257', 'cui_str': 'Delivery care'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0024923', 'cui_str': 'Maternal death'}]",,0.022662,"We found no evidence of a reduction in preventable complications that led to maternal deaths, though we found some improvements in self-reported health.","[{'ForeName': 'Edward N', 'Initials': 'EN', 'LastName': 'Okeke', 'Affiliation': 'Edward N. Okeke (eokeke@rand.org) is a senior policy researcher in the Department of Economics, Sociology, and Statistics, RAND Corporation, in Arlington, Virginia, and a professor of policy analysis in the Pardee RAND Graduate School, in Santa Monica, California.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Wagner', 'Affiliation': 'Zachary Wagner is an associate policy researcher in the Department of Economics, Sociology, and Statistics, RAND Corporation, in Santa Monica, California.'}, {'ForeName': 'Isa S', 'Initials': 'IS', 'LastName': 'Abubakar', 'Affiliation': 'Isa S. Abubakar is a professor of community medicine at Bayero University and Aminu Kano Teaching Hospital, both in Kano, Nigeria.'}]",Health affairs (Project Hope),['10.1377/hlthaff.2019.00893'] 287,32609651,Can insights from placebo and nocebo mechanisms studies improve the randomized controlled trial?,"Background and aims The randomized controlled trial (RCT) is currently facing several challenges, one of these being that the placebo response appears to be increasing in RCTs, thereby making it difficult to demonstrate an effect of potentially new treatments over placebo. This problem has primarily been approached by predicting the magnitude of the placebo response via stable factors, such as demographic variables, and/or by developing complex designs aimed at reducing the placebo response in the hope that it will improve the test of the active treatment. Yet, the success of this approach has so far been limited. Methods A new approach toward improving the RCT is put forward based on placebo and nocebo mechanism studies, i.e. studies that investigate the mechanisms underlying placebo analgesia and nocebo hyperalgesia. In a series of meta-analyses the magnitude of placebo and nocebo effects were determined. Experimental studies across nociplastic and neuropathic pain conditions and across pharmacological and acupuncture treatments investigated psychological and neurobiological mechanisms underlying these effects. The obtained results were used to make approximations of expectations to see if that could predict the placebo response in RCTs and function as a new way of tapping into the placebo component of treatment effects. Results The magnitude of placebo and nocebo effects is large and highly variable. Placebo effects exist across chronic pain conditions with varying degrees of known etiology as well as across pharmacological and non-pharmacological treatments. Patients' perception of the treatment, the verbal suggestions given for pain relief, and the patients' expectations toward pain relief contribute to the magnitude of the placebo effect and to pain relief following placebo interventions. Also, unintentional unblinding and patients' perception of a treatment markedly influence the treatment outcome. By making approximations of expectations toward treatment effects it was possible to predict the magnitude of the placebo response in RCTs. Conclusions and implications The new approach of tapping into or directly asking patients about their perception and expectations toward a treatment, along with the account of the natural history of pain, has the potential to improve the information that can be obtained from RCTs. Thus, by interfacing insights from placebo and nocebo mechanism studies, it may be possible to enhance the information that can be obtained from RCTs and to account for a large part of the variability in the placebo component of the overall treatment effect. This approach has the potential to improve the scientific evaluation of treatments, as well as to illustrate how the effect of treatments can be optimized in clinical practice, which is the crux of evidence-based medicine.",2020,"Patients' perception of the treatment, the verbal suggestions given for pain relief, and the patients' expectations toward pain relief contribute to the magnitude of the placebo effect and to pain relief following placebo interventions.",[],"['acupuncture', 'Placebo', 'placebo']",['pain relief'],[],"[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}]",,0.289856,"Patients' perception of the treatment, the verbal suggestions given for pain relief, and the patients' expectations toward pain relief contribute to the magnitude of the placebo effect and to pain relief following placebo interventions.","[{'ForeName': 'Lene', 'Initials': 'L', 'LastName': 'Vase', 'Affiliation': 'Department of Psychology and Behavioural Sciences, Aarhus University, Bartholins Allé 11, Building 1350, DK-8000 Aarhus C, Denmark.'}]",Scandinavian journal of pain,['10.1515/sjpain-2019-0183'] 288,32617960,"Modeling the Effect of DAV132, a Novel Colon-Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers.","To prevent antibiotic-induced perturbations on gut microbiota, DAV132, a novel colon-targeted adsorbent, which sequesters antibiotic residues in the lower gastrointestinal tract, was developed. We built an integrated pharmacological model of how DAV132 reduces fecal free moxifloxacin and preserves gut microbiota. We used plasma and fecal free moxifloxacin concentrations, and Shannon diversity index from 16S ribosomal RNA gene metagenomics analysis of fecal microbiota, of 143 healthy volunteers assigned randomly to receive moxifloxacin only, or with 10 DAV132 dose regimens, or to a control group. We modeled reduced fecal moxifloxacin concentrations using a transit model for DAV132 kinetics and a Michaelis-Menten model with an effect of the amount of activated charcoal on adsorption efficacy. Changes in moxifloxacin-induced perturbations on gut microbiota diversity were then quantified through a turnover model with the Emax model. With the developed model, the efficiency of pharmacokinetic antagonism and its consequences on gut microbiota diversity were quantified.",2021,We built an integrated pharmacological model of how DAV132 reduces fecal free moxifloxacin (MXF) and preserves gut microbiota.,"['healthy volunteers', '143 healthy volunteers assigned randomly to receive']","['DAV132', 'moxifloxacin (MXF', 'moxifloxacin', 'MXF']","['fecal MXF concentrations', 'gut microbiota diversity']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}]",143.0,0.0162659,We built an integrated pharmacological model of how DAV132 reduces fecal free moxifloxacin (MXF) and preserves gut microbiota.,"[{'ForeName': 'Jinju', 'Initials': 'J', 'LastName': 'Guk', 'Affiliation': 'Université de Paris, IAME, INSERM, Paris, France.'}, {'ForeName': 'Jérémie', 'Initials': 'J', 'LastName': 'Guedj', 'Affiliation': 'Université de Paris, IAME, INSERM, Paris, France.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Burdet', 'Affiliation': 'Université de Paris, IAME, INSERM, Paris, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Andremont', 'Affiliation': 'Université de Paris, IAME, INSERM, Paris, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'de Gunzburg', 'Affiliation': 'Da Volterra, Paris, France.'}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Ducher', 'Affiliation': 'Da Volterra, Paris, France.'}, {'ForeName': 'France', 'Initials': 'F', 'LastName': 'Mentré', 'Affiliation': 'Université de Paris, IAME, INSERM, Paris, France.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.1977'] 289,32620344,Short-term effects of atropine combined with orthokeratology (ACO) on choroidal thickness.,"PURPOSE To analyse the one-month change in subfoveal choroidal thickness (SFChT) of myopic children treated with 0.01 % atropine, orthokeratology (OK), or their combination. METHODS This is a prospective, randomized controlled trial. One hundred fifty-four children aged between 8 and 12 years with a spherical equivalent (SE) of -1.00 to -6.00 diopters were enrolled. Subjects were randomly assigned to receive 0.01 % atropine and orthokeratology (ACO, n = 39), 0.01 % atropine and single vision glasses (atropine, n = 42), orthokeratology and placebo (OK, n = 36), or placebo and single vision glasses (control, n = 37). SFChT was assessed using optical coherence tomography (OCT). Ocular parameters, including axial length (AL), were measured using a Lenstar LS 900. RESULTS SFChT significantly increased in the ACO (14.12 ± 12.88 μm, p < 0.001), OK (9.43 ± 9.14 μm, p < 0.001) and atropine (5.49 ± 9.38 μm, p < 0.001) groups, while it significantly decreased in the control group (-4.81 ± 9.93 μm, p = 0.006). The one-month change in SFChT was significantly different between the control and treatment groups (p < 0.001). The results of pairwise comparisons among the treatment groups showed that the magnitude of the SFChT change was larger in the ACO group than in the atropine group (p = 0.002). The changes in the ACO and OK groups were not significantly different (p = 0.326). CONCLUSION The combination of OK and atropine induced a greater increase in SFChT than monotherapy with atropine, which might indicate a better treatment effect for childhood myopia control.",2021,The one-month change in SFChT was significantly different between the control and treatment groups (p < 0.001).,['One hundred fifty-four children aged between 8 and 12 years with a spherical equivalent (SE) of -1.00 to -6.00 diopters were enrolled'],"['OK and atropine', 'SFChT', 'atropine and orthokeratology (ACO, n\u2009=\u200939), 0.01 % atropine and single vision glasses (atropine, n\u2009=\u200942), orthokeratology and placebo (OK, n\u2009=\u200936), or placebo and single vision glasses (control, n\u2009=\u200937', 'atropine, orthokeratology (OK), or their combination', 'atropine combined with orthokeratology (ACO', 'atropine']","['subfoveal choroidal thickness (SFChT', 'SFChT', 'Ocular parameters, including axial length (AL', 'OK', 'SFChT change', 'choroidal thickness', 'ACO']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0439484', 'cui_str': 'Diopters'}]","[{'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0004259', 'cui_str': 'Atropine'}, {'cui': 'C0442185', 'cui_str': 'Subfoveal'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0054889', 'cui_str': 'CAV protocol'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C1275648', 'cui_str': 'Single vision glasses'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0442185', 'cui_str': 'Subfoveal'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205131', 'cui_str': 'Axial'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0054889', 'cui_str': 'CAV protocol'}]",154.0,0.138539,The one-month change in SFChT was significantly different between the control and treatment groups (p < 0.001).,"[{'ForeName': 'Wenchen', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Zhouyue', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Jinyun', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Long', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Dongmei', 'Initials': 'D', 'LastName': 'Cui', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Weiyin', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China. Electronic address: Yangx_zoc@163.com.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2020.06.006'] 290,32620345,"Efficacy of a novel water propelled, heating eye mask massager on tear film and ocular adnexa.","PURPOSE To determine the effectiveness of the Aurai water propelled, heating Eye Massager (AEM) in managing dry eye disease and its effects on the ocular adnexa. METHODS This prospective, randomised cross-over study enrolled 15 participants (aged 25.8 ± 5.45 years, 5 male). Participants wore a smart watch 24 h a day to track their sleeping cycle and heart rate for 4 weeks, using the AEM twice a day for 2 of those weeks. A cycle of 6 min of a controlled heat and vibration pattern in the morning and another cycle in the evening were applied with the AEM. Primary outcomes of symptomatology (Ocular Surface Disease Index (OSDI) and Symptom Assessment iN Dry Eye (SANDE)), tear film and ocular surface homeostasis markers (osmolarity, non-invasive breakup time (NIKBUT), tear meniscus height (TMH), lipid layer thickness and ocular staining) and safety measures (ocular redness and intraocular pressure), were assessed at baseline, after 2 weeks of AEM use and after 2 weeks of no treatment (in random-sequence). Sleeping tracking (ST) and heart rate/blood oxygen detection over these periods was also assessed. RESULTS There was a significant change in OSDI score from 34.3 ± 19.5 at baseline to 18.8 ± 17.5 after treatment (p = 0.001) and also for the SANDE (5.7 ± 2.4 vs 3.7 ± 2.1; p = 0.001). Heart rate was not affected by treatment (p = 0.956), nor sleep pattern (p = 0.529), but this varied by day (p = 0.001). Tear film and ocular surface homeostasis, the ocular adnexia and safety measures were not affected by treatment (p > 0.05). CONCLUSION The Aurai water propelled Eye Massager may reduce the severity of symptoms of dry eye, but there were no detectable effects on tear stability and ocular surface disease from two weeks use.",2021,"Tear film and ocular surface homeostasis, the ocular adnexia and safety measures were not affected by treatment (p > 0.05). ","['15 participants (aged 25.8 ± 5.45 years, 5 male']","['novel water propelled, heating eye mask massager', 'Aurai water propelled, heating Eye Massager (AEM']","['Tear film and ocular surface homeostasis, the ocular adnexia and safety measures', 'OSDI score', 'tear stability and ocular surface disease', 'Heart rate', 'symptomatology (Ocular Surface Disease Index (OSDI) and Symptom Assessment iN Dry Eye (SANDE)), tear film and ocular surface homeostasis markers (osmolarity, non-invasive breakup time (NIKBUT), tear meniscus height (TMH), lipid layer thickness and ocular staining) and safety measures (ocular redness and intraocular pressure', 'sleep pattern', 'tear film and ocular adnexa', 'Sleeping tracking (ST) and heart rate/blood oxygen detection']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C3204590', 'cui_str': 'Propel'}, {'cui': 'C0018851', 'cui_str': 'Heating'}, {'cui': 'C0181752', 'cui_str': 'Eye mask'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}]","[{'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0029387', 'cui_str': 'Osmolarity'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1827565', 'cui_str': 'Tear meniscus height'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0038128', 'cui_str': 'Stain'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0474396', 'cui_str': 'Sleep behavior finding'}, {'cui': 'C0229243', 'cui_str': 'Ocular adnexa structure'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",15.0,0.0368583,"Tear film and ocular surface homeostasis, the ocular adnexia and safety measures were not affected by treatment (p > 0.05). ","[{'ForeName': 'Sònia', 'Initials': 'S', 'LastName': 'Travé-Huarte', 'Affiliation': 'Aston University, Birmingham, B4 7ET, UK. Electronic address: traveuhs@aston.ac.uk.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Wolffsohn', 'Affiliation': 'Aston University, Birmingham, B4 7ET, UK. Electronic address: j.s.w.wolffsohn@aston.ac.uk.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2020.06.002'] 291,32624568,Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children.,"Childhood obesity has reached epidemic levels and is a serious health concern associated with metabolic syndrome, nonalcoholic fatty liver disease, and gut microbiota alterations. Physical exercise is known to counteract obesity progression and modulate the gut microbiota composition. This study aims to determine the effect of a 12-week strength and endurance combined training program on gut microbiota and inflammation in obese pediatric patients. Thirty-nine obese children were assigned randomly to the control or training group. Anthropometric and biochemical parameters, muscular strength, and inflammatory signaling pathways in mononuclear cells were evaluated. Bacterial composition and functionality were determined by massive sequencing and metabolomic analysis. Exercise reduced plasma glucose levels and increased dynamic strength in the upper and lower extremities compared with the obese control group. Metagenomic analysis revealed a bacterial composition associated with obesity, showing changes at the phylum, class, and genus levels. Exercise counteracted this profile, significantly reducing the Proteobacteria phylum and Gammaproteobacteria class. Moreover, physical activity tended to increase some genera, such as Blautia, Dialister, and Roseburia, leading to a microbiota profile similar to that of healthy children. Metabolomic analysis revealed changes in short-chain fatty acids, branched-chain amino acids, and several sugars in response to exercise, in correlation with a specific microbiota profile. Finally, the training protocol significantly inhibited the activation of the obesity-associated NLRP3 signaling pathway. Our data suggest the existence of an obesity-related deleterious microbiota profile that is positively modified by physical activity intervention. Exercise training could be considered an efficient nonpharmacological therapy, reducing inflammatory signaling pathways induced by obesity in children via microbiota modulation.",2020,Exercise reduced plasma glucose levels and increased dynamic strength in the upper and lower extremities compared with the obese control group.,"['children via microbiota modulation', 'obese children', 'obese pediatric patients', 'Thirty-nine obese children']","['control or training group', 'Exercise training', 'strength and endurance combined training program', 'Physical exercise']","['plasma glucose levels', 'gut microbiota and inflammation', 'Bacterial composition and functionality', 'activation of the obesity-associated NLRP3 signaling pathway', 'Anthropometric and biochemical parameters, muscular strength, and inflammatory signaling pathways in mononuclear cells', 'Proteobacteria phylum and Gammaproteobacteria class', 'dynamic strength']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816447', 'cui_str': '39'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C1294062', 'cui_str': 'Mononuclear cell count'}, {'cui': 'C0751985', 'cui_str': 'Proteobacteria'}, {'cui': 'C0751988', 'cui_str': 'Gammaproteobacteria'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}]",39.0,0.0202337,Exercise reduced plasma glucose levels and increased dynamic strength in the upper and lower extremities compared with the obese control group.,"[{'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Quiroga', 'Affiliation': 'Complejo Asistencial Universitario (CAULE), León, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Nistal', 'Affiliation': 'Complejo Asistencial Universitario (CAULE), León, Spain.'}, {'ForeName': 'Brisamar', 'Initials': 'B', 'LastName': 'Estébanez', 'Affiliation': 'Institute of Biomedicine (IBIOMED), León, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Porras', 'Affiliation': 'Institute of Biomedicine (IBIOMED), León, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Juárez-Fernández', 'Affiliation': 'Institute of Biomedicine (IBIOMED), León, Spain.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Martínez-Flórez', 'Affiliation': 'Institute of Biomedicine (IBIOMED), León, Spain.'}, {'ForeName': 'María Victoria', 'Initials': 'MV', 'LastName': 'García-Mediavilla', 'Affiliation': 'Institute of Biomedicine (IBIOMED), León, Spain.'}, {'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'de Paz', 'Affiliation': 'Institute of Biomedicine (IBIOMED), León, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'González-Gallego', 'Affiliation': 'Institute of Biomedicine (IBIOMED), León, Spain.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Sánchez-Campos', 'Affiliation': 'Institute of Biomedicine (IBIOMED), León, Spain. ssanc@unileon.es.'}, {'ForeName': 'María J', 'Initials': 'MJ', 'LastName': 'Cuevas', 'Affiliation': 'Institute of Biomedicine (IBIOMED), León, Spain.'}]",Experimental & molecular medicine,['10.1038/s12276-020-0459-0'] 292,32684633,"Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.","Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted to patients up to 65 years of age. Prospective phase III trial data in the era of novel agents for patients up to 70 years of age are not available. The GMMG-MM5 trial included 601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n = 353), 61-65 years (S2, n = 107) and 66-70 years (S3, n = 141). Treatment consisted of a bortezomib-containing IT, MEL200/ASCT, consolidation, and maintenance with lenalidomide. Adherence to treatment was similar among patients of the three age groups. Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p = 0.05/<0.001). With respect to progression-free survival (log-rank p = 0.73), overall survival (log-rank p = 0.54) as well as time-to-progression (Gray's p = 0.83) and non-relapse mortality (Gray's p = 0.25), no differences were found between the three age groups. Our results imply that an intensive upfront therapy with a bortezomib-containing IT, MEL200/ASCT, lenalidomide consolidation, and maintenance should be applied to transplant-eligible MM patients up to 70 years of age.",2021,"Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p = 0.05/<0.001).","['601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n\u2009=\u2009353), 61-65 years (S2, n\u2009=\u2009107) and 66-70 years (S3, n\u2009=\u2009141', 'patients up to 70 years of age are not available', 'myeloma up to 70 years of age', 'newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose']","['bortezomib-containing IT, MEL200/ASCT, consolidation, and maintenance with lenalidomide', 'Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance', 'bortezomib-containing IT, MEL200/ASCT, lenalidomide consolidation', 'melphalan (MEL200), and autologous blood stem cell transplantation (ASCT', 'Intensive upfront therapy']","['progression-free survival', 'overall survival', 'Overall toxicity', 'non-relapse mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0686905', 'cui_str': 'Unavailability'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0444956', 'cui_str': 'High dose'}]","[{'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0521530', 'cui_str': 'Lung consolidation'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0025241', 'cui_str': 'Melphalan'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",601.0,0.0313945,"Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p = 0.05/<0.001).","[{'ForeName': 'Elias K', 'Initials': 'EK', 'LastName': 'Mai', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Kaya', 'Initials': 'K', 'LastName': 'Miah', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Uta', 'Initials': 'U', 'LastName': 'Bertsch', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Dürig', 'Affiliation': 'Department of Hematology, University Clinic Essen, Essen, Germany.'}, {'ForeName': 'Christof', 'Initials': 'C', 'LastName': 'Scheid', 'Affiliation': 'Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.'}, {'ForeName': 'Katja C', 'Initials': 'KC', 'LastName': 'Weisel', 'Affiliation': 'Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Kunz', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Munder', 'Affiliation': 'Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Hans-Walter', 'Initials': 'HW', 'LastName': 'Lindemann', 'Affiliation': 'Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.'}, {'ForeName': 'Maximilian', 'Initials': 'M', 'LastName': 'Merz', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Hose', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Jauch', 'Affiliation': 'Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Seckinger', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Luntz', 'Affiliation': 'Coordination Centre for Clinical Trials, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Sauer', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Fuhrmann', 'Affiliation': 'Department of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Brossart', 'Affiliation': 'University Hospital Bonn, Bonn, Germany.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Elmaagacli', 'Affiliation': 'Department of Hematology and Oncology, Asklepios Hospital Hamburg St. Georg, Hamburg, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Goerner', 'Affiliation': 'Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, Bielefeld, Germany.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Bernhard', 'Affiliation': 'Department of Internal Medicine V, Klinikum Darmstadt, Darmstadt, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hoffmann', 'Affiliation': 'Medical Clinic A, Klinikum Ludwigshafen, Ludwigshafen, Germany.'}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Raab', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Igor W', 'Initials': 'IW', 'LastName': 'Blau', 'Affiliation': 'Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Hänel', 'Affiliation': 'Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Benner', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Hans J', 'Initials': 'HJ', 'LastName': 'Salwender', 'Affiliation': 'Department of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Goldschmidt', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. hartmut.goldschmidt@med.uni-heidelberg.de.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Leukemia,['10.1038/s41375-020-0976-9'] 293,32646228,Electroacupuncture for post-stroke overactive bladder: a multi-centre pilot randomized controlled trial.,"BACKGROUND Although acupuncture has been shown to be effective at treating overactive bladder (OAB) following stroke, to our knowledge, no randomized controlled trial (RCT) examining the effects of acupuncture on patients with post-stroke OAB has been conducted. The aim of this preliminary study was to explore the effects of electroacupuncture (EA) in the treatment of post-stroke OAB. METHODS This study was a multi-site randomized, assessor-blind, controlled pilot trial of patients with post-stroke OAB. In all, 34 post-stroke subjects (mean age: 71.0 years; 32.4% female) with OAB symptoms were randomly assigned to the treatment group or control group in a 1:1 ratio. The subjects in the treatment group were treated with six sessions of EA for 4 weeks, while the subjects in the control group received usual care. The primary outcome measure was the overactive bladder symptom scale (OABSS). Secondary outcome measures included a three day bladder diary and the stroke-specific quality-of-life scale (SSQoL). RESULTS EA showed a moderate effect size (ES) on the perceived severity of OAB symptoms as measured by the OABSS at week 5 (one week post-treatment, ES 0.57; p = 0.034) and week 8 (three weeks post-treatment, ES 0.60; p = 0.021), although the results did not remain statistically significant after Bonferroni correction for multiple testing. No significant differences in bladder diary parameters or SSQoL score were found. The EA treatment was well tolerated by the post-stroke subjects. CONCLUSION A six-session EA treatment was feasible and appeared to reduce OAB symptoms in post-stroke patients. Further fully powered trials are warranted to confirm the efficacy of EA for those with post-stroke OAB.",2021,No significant differences in bladder diary parameters or SSQoL score were found.,"['34 post-stroke subjects (mean age: 71.0 years; 32.4% female) with OAB symptoms', 'post-stroke overactive bladder', 'patients with post-stroke OAB']","['electroacupuncture (EA', 'acupuncture', 'Electroacupuncture', 'control group received usual care']","['tolerated', 'severity of OAB symptoms', 'bladder diary parameters or SSQoL score', 'OAB symptoms', 'overactive bladder symptom scale (OABSS', 'moderate effect size (ES', 'three day bladder diary and the stroke-specific quality-of-life scale (SSQoL']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517709', 'cui_str': '32.4'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0430970', 'cui_str': 'Urinary frequency volume chart'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}]",34.0,0.112619,No significant differences in bladder diary parameters or SSQoL score were found.,"[{'ForeName': 'Haiyong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Changde', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Shanghai TCM-integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Minjie', 'Initials': 'M', 'LastName': 'Zhou', 'Affiliation': 'Shanghai TCM-integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Pui', 'Initials': 'P', 'LastName': 'Yan Chan', 'Affiliation': 'School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Lo', 'Initials': 'L', 'LastName': 'Lo Yam', 'Affiliation': 'School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Wing', 'Initials': 'W', 'LastName': 'Lok Lam', 'Affiliation': 'School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Kwok-Pui', 'Initials': 'KP', 'LastName': 'Leung', 'Affiliation': 'Rehabilitation Unit, Department of Medicine, Tung Wah Hospital, Hong Kong, China.'}, {'ForeName': 'Sheung-Wai', 'Initials': 'SW', 'LastName': 'Li', 'Affiliation': 'Rehabilitation Unit, Department of Medicine, Tung Wah Hospital, Hong Kong, China.'}, {'ForeName': 'Wai-Yin', 'Initials': 'WY', 'LastName': 'Tsang', 'Affiliation': 'Department of Geriatrics and Rehabilitative Medicine, Tung Wah Eastern Hospital, Hong Kong, China.'}, {'ForeName': 'Bacon', 'Initials': 'B', 'LastName': 'Fung-Leung Ng', 'Affiliation': 'The Chinese Medicine Department, Hospital Authority, Hong Kong, China.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Tat-Chi Ziea', 'Affiliation': 'The Chinese Medicine Department, Hospital Authority, Hong Kong, China.'}, {'ForeName': 'Wing-Fai', 'Initials': 'WF', 'LastName': 'Yeung', 'Affiliation': 'School of Nursing, the Hong Kong Polytechnic University, Hong Kong, China.'}, {'ForeName': 'Lixing', 'Initials': 'L', 'LastName': 'Lao', 'Affiliation': 'School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.'}]",Acupuncture in medicine : journal of the British Medical Acupuncture Society,['10.1177/0964528420925488'] 294,32656799,"Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.","Second-generation immunomodulatory agents, such as lenalidomide, have a more favourable side-effect profile than the first-generation thalidomide, but their optimum combination and duration for patients with newly diagnosed transplant-ineligible myeloma (ND-TNE-MM) has not been defined. The most appropriate delivery and dosing regimens of these therapies for patients at advanced age and frailty status is also unclear. The Myeloma XI study compared cyclophosphamide, thalidomide and dexamethasone (CTDa) to cyclophosphamide, lenalidomide and dexamethasone (CRDa) as induction therapy, followed by a maintenance randomisation between ongoing therapy with lenalidomide or observation for patients with ND-TNE-MM. CRDa deepened response but did not improve progression-free (PFS) or overall survival (OS) compared to CTDa. However, analysis by age group highlighted significant differences in tolerability in older, frailer patients that may have limited treatment delivery and impacted outcome. Deeper responses and PFS and OS benefits with CRDa over CTDs were seen in patients aged ≤70 years, with an increase in toxicity and discontinuation observed in older patients. Our results highlight the importance of considering age and frailty in the approach to therapy for patients with ND-TNE-MM, highlighting the need for prospective validation of frailty adapted therapy approaches, which may improve outcomes by tailoring treatment to the individual.",2021,CRDa deepened response but did not improve progression-free (PFS) or overall survival (OS) compared to CTDa.,"['transplant ineligible patients with newly diagnosed multiple myeloma', 'patients with newly diagnosed transplant-ineligible myeloma (ND-TNE-MM', 'patients at advanced age and frailty status', 'patients with ND-TNE-MM', 'patients aged ≤70\xa0years']","['cyclophosphamide, thalidomide and dexamethasone (CTDa) to cyclophosphamide, lenalidomide and dexamethasone (CRDa']","['progression-free (PFS) or overall survival (OS', 'tolerability', 'toxicity and discontinuation']","[{'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0039736', 'cui_str': 'Thalidomide'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}]","[{'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]",,0.0419444,CRDa deepened response but did not improve progression-free (PFS) or overall survival (OS) compared to CTDa.,"[{'ForeName': 'Graham H', 'Initials': 'GH', 'LastName': 'Jackson', 'Affiliation': 'Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Pawlyn', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Cairns', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Striha', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Collett', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Waterhouse', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Jones', 'Affiliation': 'Kings College Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Wilson', 'Affiliation': 'Western Sussex Hospitals NHS Foundation Trust, Chichester, UK.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Taylor', 'Affiliation': 'Russells Hall Hospital, Dudley, UK.'}, {'ForeName': 'Bhuvan', 'Initials': 'B', 'LastName': 'Kishore', 'Affiliation': 'University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Mamta', 'Initials': 'M', 'LastName': 'Garg', 'Affiliation': 'Leicester Royal Infirmary, Leicester, UK.'}, {'ForeName': 'Cathy D', 'Initials': 'CD', 'LastName': 'Williams', 'Affiliation': 'Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.'}, {'ForeName': 'Kamaraj', 'Initials': 'K', 'LastName': 'Karunanithi', 'Affiliation': 'University Hospital of North Midlands, Stoke-on-Trent, UK.'}, {'ForeName': 'Jindriska', 'Initials': 'J', 'LastName': 'Lindsay', 'Affiliation': 'E1ast Kent Hospitals University NHS Foundation Trust, Canterbury, UK.'}, {'ForeName': 'Matthew W', 'Initials': 'MW', 'LastName': 'Jenner', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Cook', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Nigel H', 'Initials': 'NH', 'LastName': 'Russell', 'Affiliation': 'Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.'}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Drayson', 'Affiliation': 'Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Martin F', 'Initials': 'MF', 'LastName': 'Kaiser', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Roger G', 'Initials': 'RG', 'LastName': 'Owen', 'Affiliation': ""Haematological Malignancy Diagnostic Service (HMDS), St James's University Hospital, Leeds, UK.""}, {'ForeName': 'Walter M', 'Initials': 'WM', 'LastName': 'Gregory', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Faith E', 'Initials': 'FE', 'LastName': 'Davies', 'Affiliation': 'Perlmutter Cancer Center, NY Langone Health, New York, NY, USA.'}, {'ForeName': 'Gareth J', 'Initials': 'GJ', 'LastName': 'Morgan', 'Affiliation': 'Perlmutter Cancer Center, NY Langone Health, New York, NY, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of haematology,['10.1111/bjh.16945'] 295,32680773,Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine.,"BACKGROUND Vaccine-induced mucosal immune responses may be critical for protection against HIV infection, but may also result in short or long-term changes that enhance susceptibility to infection in some individuals, such as those with baseline seroreactivity to vaccine vector antigens. We examined cellular immune responses in blood and gut mucosal tissue roughly two years following vaccination with placebo or the Step study vaccine MRKAd5/HIV-1. METHODS Participants vaccinated with either placebo or MRKAd5/HIV-1 during participation in HVTN 071, and HVTN 502/Merck 023 underwent phlebotomy and colonic mucosal biopsies via flexible sigmoidoscopy at two timepoints roughly six months apart. After isolation of mononuclear cells, we compared cellular phenotypes and intracellular cytokine responses in vaccine and placebo recipients with and without baseline serological reactivity to Ad5. RESULTS Surface expression of activation and gut-homing markers were elevated on CD4 + and CD8 + gut mucosal mononuclear cells (GMMC) in comparison with PBMC (p < 0.01), but were not significantly affected by baseline Ad5 serostatus or receipt of MRKAd5/HIV-1. ICS responses to stimulation with vaccine antigens were of low frequency and magnitude. Ad5 vector responses were seen in vaccinees and baseline seropositive individuals. CD4 + responses to vector antigens were more common in GMMC than PBMC (p < 0.01) and CD8 + responses to HIV gag insert antigens were more frequent in Ad5 seropositive than Ad5 seronegative individuals (p = 0.03). CONCLUSION Vaccination with the Ad5 vectored candidate HIV vaccine MRKAd5/HIV-1 does not lead to long-term changes in the activation state of mucosal CD4 + or CD8 + T lymphocytes regardless of baseline Ad5 serostatus. The findings of this study do not reveal a basis for enhanced susceptibility to HIV infection two years post vaccination.",2020,"CD4 + responses to vector antigens were more common in GMMC than PBMC (p < 0.01) and CD8 + responses to HIV gag insert antigens were more frequent in Ad5 seropositive than Ad5 seronegative individuals (p = 0.03). ","['Participants vaccinated with either', 'recipients of an Ad5-vectored HIV vaccine', 'during participation in HVTN 071, and HVTN 502/Merck 023 underwent']","['phlebotomy and colonic mucosal biopsies via flexible sigmoidoscopy', 'placebo or MRKAd5/HIV-1', 'placebo']","['CD4\xa0+\xa0and CD8\xa0+\xa0gut mucosal mononuclear cells (GMMC', 'cellular phenotypes and intracellular cytokine responses', 'Ad5 vector responses']","[{'cui': 'C0528480', 'cui_str': 'Presenilin 2'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0190979', 'cui_str': 'Phlebotomy'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0852695', 'cui_str': 'Mucosal biopsy'}, {'cui': 'C0016234', 'cui_str': 'Flexible fiberoptic sigmoidoscopy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C1294062', 'cui_str': 'Mononuclear cell count'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C0175996', 'cui_str': 'Protoplasm'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0528480', 'cui_str': 'Presenilin 2'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}]",,0.146174,"CD4 + responses to vector antigens were more common in GMMC than PBMC (p < 0.01) and CD8 + responses to HIV gag insert antigens were more frequent in Ad5 seropositive than Ad5 seronegative individuals (p = 0.03). ","[{'ForeName': 'Marcel E', 'Initials': 'ME', 'LastName': 'Curlin', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Electronic address: curlin@ohsu.edu.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Shao', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Diaz', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Paul T', 'Initials': 'PT', 'LastName': 'Edlefsen', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Novak', 'Affiliation': 'Division of Infectious Diseases, University of Illinois, Chicago, USA.'}, {'ForeName': 'Kenneth H', 'Initials': 'KH', 'LastName': 'Mayer', 'Affiliation': 'Fenway Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Allen', 'Affiliation': 'Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Morgan', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Maenza', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Buchbinder', 'Affiliation': 'Bridge HIV, San Francisco Department of Public Health, San Francisco, CA, USA.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Keefer', 'Affiliation': 'Department of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, NY, USA.'}, {'ForeName': 'Stephen C De', 'Initials': 'SC', 'LastName': 'Rosa', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Corey', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Duerr', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Vaccine,['10.1016/j.vaccine.2020.06.043'] 296,32473649,"The propofol-sparing effect of intravenous lidocaine in elderly patients undergoing colonoscopy: a randomized, double-blinded, controlled study.","BACKGROUND Propofol provides a prominent sedation effect in colonoscopy. However, anesthesia and sedation induced with propofol in the elderly might result in cardiopulmonary complications, especially when it is combined with opoids in the regimen. This study aimed to test the hypothesis that the addition of intravenous lidocaine to propofol-based sedation could decrease the overall propofol requirement in elderly patients during colonoscopy while the procedural sedation satisfaction and the hemodynamic stability were not compromised. METHODS Ninety-two patients undergoing colonoscopy were randomly enrolled into lidocaine+propofol (L + P) group or normal saline+propofol (NS + P) groups. Subjects received intravenous bolus of 1.5 mg/kg lidocaine followed by 4 mg kg - 1  h - 1 lidocaine continuous infusion in L + P group or equivalent volumes of normal saline for boluses and infusion in NS + P group. Anesthesia was induced with 2.5 μg sufentanil followed by injection of 1.2 mg kg - 1 propofol in all patients. A single supplemental bolus of 0.6 mg kg - 1 propofol was administered whenever MOAA/S score > 1 or had body movement during the colonoscopy. The recorded primary endpoints included: the total amount of propofol administered during entire procedure, the supplemental amount of propofol after induction, and the frequencies of boluses of supplemental propofol. RESULTS A total of 79 patients were included in the final analysis. Compared with NS + P group, the total amounts of propofol (induction plus supplemental) were no significant differences in L + P group; however, the required supplemental propofol was less (69.9 ± 39.2 mg vs. 51.5 ± 38.6 mg) (P = 0.039); the average frequencies of boluses of supplemental propofol given after induction were lower (2.1 ± 1.1 vs. 1.4 ± 0.9) (P = 0.003); the calculated ""unit propofol"" infusion rate was lower (0.18 ± 0.05 vs. 0.14 ± 0.04 mg kg - 1  min - 1 ) (P = 0.002). CONCLUSIONS The addition of intravenous lidocaine to propofol-based sedation resulted in a remarked reduction of supplemental propofol in the elderly during colonoscopy. TRIAL REGISTRATION The present clinical trial was registered at http://www.chictr.org.cn on 11th March 2019 (registration No. ChiCTR1900021818).",2020,"Compared with NS + P group, the total amounts of propofol (induction plus supplemental) were no significant differences in L + P group; however, the required supplemental propofol was less (69.9 ± 39.2 mg vs. 51.5 ± 38.6 mg) (P = 0.039); the average frequencies of boluses of supplemental propofol given after induction were lower (2.1 ± 1.1 vs. 1.4 ± 0.9) (P = 0.003); the calculated ""unit propofol"" infusion rate was lower (0.18 ± 0.05 vs. 0.14 ± 0.04 mg kg - 1  min - 1 ) (P = 0.002). ","['elderly patients during colonoscopy', 'A total of 79 patients were included in the final analysis', 'Ninety-two patients undergoing colonoscopy', 'elderly patients undergoing colonoscopy']","['lidocaine+propofol (L\u2009+\u2009P) group or normal saline+propofol (NS\u2009+\u2009P', 'lidocaine', 'intravenous lidocaine', 'propofol-based sedation', 'intravenous bolus of 1.5\u2009mg/kg lidocaine', 'lidocaine continuous infusion in L\u2009+\u2009P group or equivalent volumes of normal saline for boluses and infusion in NS\u2009+\u2009P group', 'Propofol', 'propofol']","['calculated ""unit propofol"" infusion rate', 'overall propofol requirement', 'total amount of propofol administered during entire procedure, the supplemental amount of propofol after induction, and the frequencies of boluses of supplemental propofol', 'total amounts of propofol']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C3816959', 'cui_str': '90'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}]",79.0,0.134813,"Compared with NS + P group, the total amounts of propofol (induction plus supplemental) were no significant differences in L + P group; however, the required supplemental propofol was less (69.9 ± 39.2 mg vs. 51.5 ± 38.6 mg) (P = 0.039); the average frequencies of boluses of supplemental propofol given after induction were lower (2.1 ± 1.1 vs. 1.4 ± 0.9) (P = 0.003); the calculated ""unit propofol"" infusion rate was lower (0.18 ± 0.05 vs. 0.14 ± 0.04 mg kg - 1  min - 1 ) (P = 0.002). ","[{'ForeName': 'Mengmeng', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou, 325027, China.""}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou, 325027, China.""}, {'ForeName': 'Haoran', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou, 325027, China.""}, {'ForeName': 'Qingxia', 'Initials': 'Q', 'LastName': 'Fu', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou, 325027, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou, 325027, China.""}, {'ForeName': 'Junzheng', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesia and Pediatrics, Cincinnati Children Hospital Medical Center, Cincinnati, OH, USA.'}, {'ForeName': 'Wangning', 'Initials': 'W', 'LastName': 'Shangguan', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou, 325027, China. sgwning@163.com.""}]",BMC anesthesiology,['10.1186/s12871-020-01049-z'] 297,32597373,Testing the Effectiveness of a Strengths-Based Intervention Targeting All 24 Strengths: Results From a Randomized Controlled Trial.,"This study assessed the effectiveness of a strengths-based randomized controlled trial focused on fostering all 24 character strengths in a group of 75 participants from a University in Tunisia. Participants randomly assigned to the challenge condition (n = 40) received an email each day for 24 days, that highlighted a particular strength of the day including why the strength is valuable, how to implement the strength behaviourally, and a motto related to that strength. Those in the control condition (n = 35) simply received emails containing the motto for each strength daily for 24 days. We assessed all participants' levels of happiness before the experiment (T0), the day following the experiment (T1), and one-month following the experiment (T2). Results from a 2 (group) X 3 (time) split plot ANOVA revealed a significant group-by-time interaction, such that at T2 the experimental group had greater happiness scores than the control group. These findings provide some evidence that even ""minimalist"" interventions (involving the receipt of emails encouraging character-strength development), might be effective for promoting gains in happiness even one month after the intervention.",2021,"We assessed all participants' levels of happiness before the experiment (T0), the day following the experiment (T1), and one-month following the experiment (T2).",['fostering all 24 character strengths in a group of 75 participants from a University in Tunisia'],[],['happiness scores'],"[{'cui': 'C0242298', 'cui_str': 'Fostering'}, {'cui': 'C0007952', 'cui_str': 'Character'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0041388', 'cui_str': 'Tunisia'}]",[],"[{'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",75.0,0.0324202,"We assessed all participants' levels of happiness before the experiment (T0), the day following the experiment (T1), and one-month following the experiment (T2).","[{'ForeName': 'Lobna', 'Initials': 'L', 'LastName': 'Chérif', 'Affiliation': 'Royal Military College of Canada, Kingston, Ontario, Canada.'}, {'ForeName': 'Valerie M', 'Initials': 'VM', 'LastName': 'Wood', 'Affiliation': ""Queen's University, Kingston, Ontario, Canada.""}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Watier', 'Affiliation': 'Lanla Mesure\u2009+\u2009Gestion, Montreal, Québec, Canada.'}]",Psychological reports,['10.1177/0033294120937441'] 298,32614141,Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination.,"PURPOSE The rs17632542 single nucleotide polymorphism (SNP) results in lower serum prostate specific antigen (PSA) levels which may further mitigate against its clinical utility as a prostate cancer biomarker. Post-digital rectal exam (post-DRE) urine is a minimally invasive fluid that is currently utilized in prostate cancer diagnosis. To detect and quantitate the variant protein in urine. EXPERIMENTAL DESIGN Fifty-three post-DRE urines from rs17632542 genotyped individuals processed and analyzed by liquid chromatography/mass spectrometry (LC-MS) in a double-blinded randomized study. The ability to distinguish between homozygous wild-type, heterozygous, or homozygous variant is examined before unblinding. RESULTS Stable-isotope labeled peptides are used in the detection and quantitation of three peptides of interest in each sample using parallel reaction monitoring (PRM). Using these data, groupings are predicted using hierarchical clustering in R. Accuracy of the predictions show 100% concordance across the 53 samples, including individuals homozygous and heterozygous for the SNP. CONCLUSIONS AND CLINICAL RELEVANCE The study demonstrates that MS based peptide variant quantitation in urine could be useful in determining patient genotype expression. This assay provides a tool to evaluate the utility of PSA variant (rs17632542) in parallel with current and forthcoming urine biomarker panels.",2020,"Using these data, groupings were predicted using hierarchical clustering in R. Accuracy of the predictions showed 100% concordance across the 53 samples, including individuals homozygous and heterozygous for the SNP. ",['Fifty-three post-DRE urines from rs17632542 genotyped individuals'],[],"['peak detection and area extraction', 'serum PSA levels']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1384593', 'cui_str': 'Digital examination of rectum'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",[],"[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement'}]",,0.0364145,"Using these data, groupings were predicted using hierarchical clustering in R. Accuracy of the predictions showed 100% concordance across the 53 samples, including individuals homozygous and heterozygous for the SNP. ","[{'ForeName': 'Joseph J', 'Initials': 'JJ', 'LastName': 'Otto', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Vanessa L', 'Initials': 'VL', 'LastName': 'Correll', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Hampus A', 'Initials': 'HA', 'LastName': 'Engstroem', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Naomi L', 'Initials': 'NL', 'LastName': 'Hitefield', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Brian P', 'Initials': 'BP', 'LastName': 'Main', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Brenna', 'Initials': 'B', 'LastName': 'Albracht', 'Affiliation': 'Department of Urology, The University of Texas Health San Antonio, San Antonio, TX, 78229, USA.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Johnson-Pais', 'Affiliation': 'Department of Urology, The University of Texas Health San Antonio, San Antonio, TX, 78229, USA.'}, {'ForeName': 'Li Fang', 'Initials': 'LF', 'LastName': 'Yang', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Liss', 'Affiliation': 'Department of Urology, The University of Texas Health San Antonio, San Antonio, TX, 78229, USA.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Boutros', 'Affiliation': 'Departments of Human Genetics and Urology, Jonsson Comprehensive Cancer Center, Institute for Precision Health University of California Los Angeles, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kislinger', 'Affiliation': 'University of Toronto, Department of Medical Biophysics, Toronto, ON M5G 1L7, Canada.'}, {'ForeName': 'Robin J', 'Initials': 'RJ', 'LastName': 'Leach', 'Affiliation': 'Department of Urology, The University of Texas Health San Antonio, San Antonio, TX, 78229, USA.'}, {'ForeName': 'Oliver J', 'Initials': 'OJ', 'LastName': 'Semmes', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Julius O', 'Initials': 'JO', 'LastName': 'Nyalwidhe', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}]",Proteomics. Clinical applications,['10.1002/prca.202000012'] 299,32615054,Implementation of an attention training programme with a sample of children who have sustained traumatic brain injuries in South Africa: A pilot study.,"This pilot study evaluated the feasibility of implementing an attention-training programme for children who have sustained moderate-to-severe traumatic brain injuries (TBIs) in a South African context. We compared the performance on the programme of children with TBI (TBI Intervention Group) to children who had been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD Intervention Group), a TBI Art group and a TBI No-intervention Group ( n =5 in each group) in this preliminary study. Children in the two Intervention Groups participated in the ""Pay Attention!"" programme for 45 minutes twice a week for 12 weeks. All children were aged 6-8 years and underwent neuropsychological testing pre- and post-intervention. Behavioural data were collected from parents. Children in the ADHD Intervention Group showed individual clinically significant attentional improvements on measures of the Conners' Continuous Performance Test II using the Reliable Change Index (≥ 2.58 SD). Despite mixed results, the pilot study demonstrates that implementing a cognitive rehabilitation programme in South Africa is feasible and necessary, despite limited infrastructure and access to resources.",2021,Children in the ADHD Intervention Group showed individual clinically significant attentional improvements on measures of the Conners' Continuous Performance Test II using the Reliable Change Index (≥ 2.58 SD).,"['children who have sustained traumatic brain injuries in South Africa', 'children who have sustained moderate-to-severe traumatic brain injuries (TBIs) in a South African context', 'All children were aged 6-8 years and underwent neuropsychological testing pre- and post-intervention', 'children with TBI (TBI Intervention Group) to children who had been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD Intervention Group), a']","['cognitive rehabilitation programme', 'attention training programme', 'Pay Attention', 'TBI Art group and a TBI No-intervention Group', 'attention-training programme']","[""individual clinically significant attentional improvements on measures of the Conners' Continuous Performance Test II using the Reliable Change Index""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0449255', 'cui_str': 'Context'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043162', 'cui_str': 'Total body irradiation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}]","[{'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0556509', 'cui_str': 'Attention training'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0043162', 'cui_str': 'Total body irradiation'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0690508,Children in the ADHD Intervention Group showed individual clinically significant attentional improvements on measures of the Conners' Continuous Performance Test II using the Reliable Change Index (≥ 2.58 SD).,"[{'ForeName': 'Talia H', 'Initials': 'TH', 'LastName': 'Lanesman', 'Affiliation': 'ACSENT Laboratory, Department of Psychology, University of Cape Town, Rondebosch, South Africa.'}, {'ForeName': 'Leigh E', 'Initials': 'LE', 'LastName': 'Schrieff', 'Affiliation': 'ACSENT Laboratory, Department of Psychology, University of Cape Town, Rondebosch, South Africa.'}]",Neuropsychological rehabilitation,['10.1080/09602011.2020.1782233'] 300,32618438,"The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.","The marketed tablet formulation of peficitinib differs from the tablet used during the clinical trials. The bioequivalence of the marketed formulation and developmental tablet, and the food effect on the marketed formulation, were analyzed in 2 Japanese open-label, randomized, 2-way crossover studies in healthy male volunteers. Volunteers received a single oral dose of the marketed 150-mg peficitinib tablet under fasted conditions (bioequivalence), and under fed or fasted conditions (food effect). Bioequivalence was compared with the developmental 150-mg tablet. Samples for pharmacokinetic analysis were collected before dose and ≤72 hours after dose. Safety assessments included adverse events, vital signs, and laboratory variables. In total, 40 and 18 subjects were randomized to the bioequivalence and food effect studies, respectively. The 2 peficitinib formulations were bioequivalent (90% confidence intervals of the geometric mean ratios for C max and AUC t of peficitinib were within predefined limits of 0.8 to 1.25). The AUC last and the C max of the marketed tablet were 36.8% and 56.4% higher, respectively, under fed versus fasted conditions. Peficitinib was well tolerated. The marketed 150-mg tablet formulation of peficitinib was bioequivalent to the developmental 150-mg formulation, with no discernible safety differences. Bioavailability increased under fed conditions with the marketed tablet formulation.",2021,"The marketed 150-mg tablet formulation of peficitinib was bioequivalent to the developmental 150-mg formulation, with no discernible safety differences.","['Healthy Volunteers', 'healthy male volunteers', 'In total, 40 and 18 subjects']",['Peficitinib'],"['adverse events, vital signs, and laboratory variables', 'Bioavailability', 'tolerated']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C4505522', 'cui_str': 'peficitinib'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}]",,0.0296822,"The marketed 150-mg tablet formulation of peficitinib was bioequivalent to the developmental 150-mg formulation, with no discernible safety differences.","[{'ForeName': 'Mai', 'Initials': 'M', 'LastName': 'Shibata', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Junko', 'Initials': 'J', 'LastName': 'Toyoshima', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Kaneko', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Oda', 'Affiliation': 'Astellas Research Institute of America LLC, Northbrook, Illinois, USA.'}, {'ForeName': 'Tsuyoshi', 'Initials': 'T', 'LastName': 'Kiyota', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Kambayashi', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Nishimura', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.843'] 301,32638392,The impact of different hair-removal behaviours on the biophysical and biochemical characteristics of female axillary skin.,"OBJECTIVE The impact of hair removal on the biophysical and biochemical characteristics of human axillary skin is not fully understood. This study investigated the effect of different hair-removal techniques on biophysical parameters and the concentrations of key inflammatory biomarkers in the axillae of female Thai subjects. Axillary hair was removed by shaving, plucking or waxing. METHODS Following a 2-week washout phase without hair removal, subjects underwent visual assessment for erythema and skin dryness in one (randomized) axilla, then, hair was removed from the axilla by shaving, plucking or waxing according to each subject's established habit. Erythema and dryness were assessed again 30 min after hair removal, and buffer scrubs collected from depilated and non-depilated axillae and analysed for inflammatory cytokines; after a further 48 h, erythema, dryness and post-inflammatory hyperpigmentation (PIHP) were assessed in the depilated axilla. Biophysical assessments (skin hydration, barrier integrity, elasticity and roughness) were made in depilated and non-depilated axillae. RESULTS All three hair-removal techniques induced an increase in axillary erythema and skin dryness. Shaving was associated with significantly less erythema (P < 0.01), but significantly greater skin dryness (P < 0.05) versus the other techniques 30 min after hair removal. There were no between-technique differences in PIHP or biophysical parameters. Interleukins IL-1α and IL-1RA concentrations increased, and IL-8 concentration decreased following hair removal by each technique. CONCLUSION This is the first study to identify the principal cytokines associated with the inflammatory process triggered by axillary hair removal. A single hair-removal treatment did not appear to induce PIHP or further biophysical changes to the skin.",2020,"Interleukins IL-1α and IL-1RA concentrations increased, and IL-8 concentration decreased following hair removal by each technique. ","['female axillary skin', 'female Thai subjects']",['hair-removal techniques'],"['IL-8 concentration', 'Interleukins IL-1α and IL-1RA concentrations', 'axillary erythema and skin dryness', 'Biophysical assessments (skin hydration, barrier integrity, elasticity and roughness', 'Erythema and dryness', 'PIHP or biophysical parameters', 'erythema, dryness and post-inflammatory hyperpigmentation (PIHP', 'skin dryness', 'erythema']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0222146', 'cui_str': 'Skin structure of axilla'}, {'cui': 'C0039724', 'cui_str': 'Thai language'}]","[{'cui': 'C0018504', 'cui_str': 'Epilation'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0245109', 'cui_str': 'anakinra'}, {'cui': 'C0004454', 'cui_str': 'Axillary'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0151908', 'cui_str': 'Dry skin'}, {'cui': 'C0005553', 'cui_str': 'Biophysics'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0333616', 'cui_str': 'Postinflammatory hyperpigmentation'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",,0.0592639,"Interleukins IL-1α and IL-1RA concentrations increased, and IL-8 concentration decreased following hair removal by each technique. ","[{'ForeName': 'R L', 'Initials': 'RL', 'LastName': 'Evans', 'Affiliation': 'Unilever Research & Development, Port Sunlight Laboratory, Quarry Road East, Bebington, Wirral, Merseyside, CH63 3JW, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bates', 'Affiliation': 'Unilever Research & Development, Port Sunlight Laboratory, Quarry Road East, Bebington, Wirral, Merseyside, CH63 3JW, UK.'}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Marriott', 'Affiliation': 'Unilever Research & Development, Port Sunlight Laboratory, Quarry Road East, Bebington, Wirral, Merseyside, CH63 3JW, UK.'}, {'ForeName': 'D S', 'Initials': 'DS', 'LastName': 'Arnold', 'Affiliation': 'Unilever Research & Development, Port Sunlight Laboratory, Quarry Road East, Bebington, Wirral, Merseyside, CH63 3JW, UK.'}]",International journal of cosmetic science,['10.1111/ics.12648'] 302,32672635,"Treatment Outcomes of Mitomycin C-Augmented Trabeculectomy, Sub-Tenon Injection versus Soaked Sponges, after 3 Years of Follow-up: A Randomized Clinical Trial.","PURPOSE To report the 3-year outcome of trabeculectomy with mitomycin C (MMC)-soaked sponges versus intra-Tenon injection of MMC in eyes with uncontrolled primary open-angle glaucoma. DESIGN Randomized clinical trial. PARTICIPANTS Eighty-two consecutive patients with uncontrolled primary open-angle glaucoma. METHODS Participants were randomized either to intra-Tenon injection of 0.1 ml of 0.01% MMC (TI group) or 0.02% subconjunctival application of MMC-soaked sponges (TS group). Patients were followed up for 3 years after surgery. The data for 73 eyes were included in the final analysis. MAIN OUTCOME MEASURES The primary outcome measure was the surgical success, defined as intraocular pressure (IOP) more than 5 mmHg and <21 mmHg, and IOP reduction of 20% or more from baseline, no reoperation for glaucoma, and no loss of light perception vision. Secondary outcome measures were IOP, glaucoma medications, best-corrected visual acuity (VA), bleb morphologic features according to the Indiana Bleb Appearance Grading Scale, complications, and endothelial cell count changes. RESULTS The cumulative probability of success at 3-year follow-up was 72.2% in the TI group and 65.1% in the TS group (P = 0.30). Uncontrolled IOP was the most common reason for failure. The mean preoperative IOP was 22.4±4.6 mmHg with an average of 3.1±1.0 medications. At 3 years, final IOP was 15.3±3.7 mmHg in the TI group and 16.4±3.5 mmHg in the TS group (P = 0.55). Mean glaucoma number of medications was 0.9±1.1 and 1.1±1.1 in the TI and TS groups, respectively (P = 0.54). Blebs tended to be more diffuse (P = 0.032), less vascularized (P = 0.013), and more shallow (P = 0.012) after intra-Tenon injection. Visual outcomes and endothelial cell changes were similar in both groups (P = 0.47 and P = 0.94, respectively). CONCLUSIONS Although the success rate and IOP reduction were comparable with both techniques, bleb morphologic parameters were more favorable after intra-Tenon injection of 0.1 ml of 0.01% MMC.",2018,"Visual outcomes and endothelial cell changes were similar in both groups (P = 0.47 and P = 0.94, respectively). ","['Participants', 'eyes with uncontrolled primary open-angle glaucoma', 'Eighty-two consecutive patients with uncontrolled primary open-angle glaucoma', '73 eyes were included in the final analysis']","['intra-Tenon injection of 0.1 ml of 0.01% MMC (TI group) or 0.02% subconjunctival application of MMC-soaked sponges (TS group', 'Mitomycin C-Augmented Trabeculectomy, Sub-Tenon Injection versus Soaked Sponges', 'trabeculectomy with mitomycin C (MMC)-soaked sponges versus intra-Tenon injection of MMC']","['final IOP', 'surgical success, defined as intraocular pressure (IOP', 'success rate and IOP reduction', 'Mean glaucoma number of medications', 'cumulative probability of success', 'Visual outcomes and endothelial cell changes', 'bleb morphologic parameters', 'mean preoperative IOP', 'IOP, glaucoma medications, best-corrected visual acuity (VA), bleb morphologic features according to the Indiana Bleb Appearance Grading Scale, complications, and endothelial cell count changes', 'reoperation for glaucoma, and no loss of light perception vision', 'IOP reduction']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0339573', 'cui_str': 'Primary open angle glaucoma'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517398', 'cui_str': '0.02'}, {'cui': 'C0442183', 'cui_str': 'Subconjunctival'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0204774', 'cui_str': 'Soak'}, {'cui': 'C0032699', 'cui_str': 'Phylum Porifera'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0040574', 'cui_str': 'Trabeculoplasty'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}]","[{'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0225336', 'cui_str': 'Endothelial cell'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0005758', 'cui_str': 'Blister'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0021206', 'cui_str': 'Indiana'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell density'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}]",82.0,0.17897,"Visual outcomes and endothelial cell changes were similar in both groups (P = 0.47 and P = 0.94, respectively). ","[{'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Esfandiari', 'Affiliation': 'Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Pakravan', 'Affiliation': 'Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Yazdani', 'Affiliation': 'Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Azadeh', 'Initials': 'A', 'LastName': 'Doozandeh', 'Affiliation': 'Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Yaseri', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ian P', 'Initials': 'IP', 'LastName': 'Conner', 'Affiliation': 'Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: connerip@upmc.edu.'}]",Ophthalmology. Glaucoma,['10.1016/j.ogla.2018.06.003'] 303,32674009,Extracorporeal shockwave therapy in the management of plantar fasciitis: A randomized controlled trial.,"BACKGROUND This study aimed at estimating the extent to which a combination therapy of extracorporeal shockwave therapy (ESWT) with usual care (exercise and orthotic support) improve functional ability in the patient with plantar fasciitis when compared to usual care alone. METHODS Participants with plantar fasciitis were randomly allocated into two groups: ESWT (n=23), and control (n=21). All participants received home exercise program with orthotic support. In addition, ESWT group received 2000 shock waves with 0.02 mJ/mm 2 for three sessions. Functional outcomes were measured by function subscale of American orthopedic foot and ankle society (AOFAS-F) score and 12 minutes walking test including walking speed, cadence. The scores were recorded at baseline, third week and third month after the treatment. Analysis was performed using repeated measures ANOVA, and an intention to treat approach using multiple imputations. RESULTS Results showed that there was a significant improvement in AOFAS-F total score and walking speed over three months in both groups (p<0.001, p=0.04 respectively); improvements in AOFAS-F were particularly in activity limitation (p=0.001), walking distance (p=0.02) and walking surface (p=0.02). Groups were comparable with each other for both walking speed and AOFAS-F in any assessment time (p>0.05). However, groups performed differently in cadence where there was an increase in cadence in ESWT group whereas a decline in control at the third month (p=0.07). CONCLUSION The results revealed that ESWT did not have an additive benefit over usual care to improve foot function and walking performance in patient with plantar fasciitis over three months post-treatment.",2020,Groups were comparable with each other for both walking speed and AOFAS-F in any assessment time (p>0.05).,"['Participants with plantar fasciitis', 'plantar fasciitis', 'patient with plantar fasciitis']","['ESWT', 'extracorporeal shockwave therapy (ESWT) with usual care (exercise and orthotic support', 'Extracorporeal shockwave therapy', 'home exercise program with orthotic support']","['foot function and walking performance', 'walking surface', 'AOFAS-F total score and walking speed', 'AOFAS-F', 'function subscale of American orthopedic foot and ankle society (AOFAS-F) score and 12 minutes walking test including walking speed, cadence', 'cadence', 'walking distance', 'activity limitation', 'functional ability']","[{'cui': 'C0149756', 'cui_str': 'Plantar fasciitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1737238', 'cui_str': 'Extracorporeal shock wave therapy'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0029365', 'cui_str': 'Orthotic device'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0430516', 'cui_str': '12-minute walk test'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}]",,0.0431827,Groups were comparable with each other for both walking speed and AOFAS-F in any assessment time (p>0.05).,"[{'ForeName': 'Eda', 'Initials': 'E', 'LastName': 'Cinar', 'Affiliation': 'School of Physical and Occupational Therapy, McGill University, 8852 Saint Hubert, Montreal, QC, H2M 1Y5, Canada. Electronic address: edaccinar@gmail.com.'}, {'ForeName': 'Shikha', 'Initials': 'S', 'LastName': 'Saxena', 'Affiliation': 'School of Physical and Occupational Therapy, McGill University, 8852 Saint Hubert, Montreal, QC, H2M 1Y5, Canada. Electronic address: shikha.saxena@mail.mcgill.ca.'}, {'ForeName': 'Halil Ekrem', 'Initials': 'HE', 'LastName': 'Akkurt', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Konya Training and Research Hospital, Konya Eğitim ve Araştırma Hastanesi Fiziksel Tıp ve Rehabilitasyon Kliniği, Meram, Konya, 42090, Turkey. Electronic address: ekremakkurt@yahoo.com.'}, {'ForeName': 'Fatma', 'Initials': 'F', 'LastName': 'Uygur', 'Affiliation': 'Department of Physical Therapy and Rehabilitation, Faculty of Health Science Cyprus International University, via Mersin 10, 99258 Lefkoşa, Turkey. Electronic address: fztuygur@yahoo.com.'}]","Foot (Edinburgh, Scotland)",['10.1016/j.foot.2020.101679'] 304,33071262,Effects of Active Learning Education on Arterial Stiffness of Older Adults with Low Health Literacy: A Randomized Controlled Trial.,"AIM We examined the effects of active learning education on arterial stiffness and physical activity of community-dwelling older adults with low health literacy. METHODS This study is a secondary analysis of randomized controlled trial of 60 participants aged 65 and older with low health literacy. The intervention group (n=30) participated in a weekly 90-minute active learning program session for 24 weeks, which addressed health promotion in older age. The control group (n=30) attended a 90-minute health education class in a didactic manner. The outcomes were measured at baseline and in week 24. The degree of arterial stiffness was assessed based on the cardio-ankle vascular index (CAVI) using the VS-1500 device (Fukuda Denshi Co., Ltd., Tokyo, Japan). The shortened version of the self-reported International Physical Activity Questionnaire was used to assess the amount of total physical activity determined by the metabolic equivalent hours per week. We used analysis by intention-to-treat, with multiple imputation for missing data. RESULTS Seven participants (11.7%) dropped out prior to the post-intervention assessment. The multiple imputation analysis revealed that the intervention group showed significant improvement in CAVI [between-groups difference (95% confidence interval)=-0.78 (-1.25 to -0.31), Cohen's d=0.82] and physical activity [32.5 (0.3 to 64.7), Cohen's d=0.57] as compared with the control group. The sensitivity analysis for the complete cases showed similar results. CONCLUSION Active learning health education may be effective in improving arterial stiffness and physical activity in older adults with low health literacy.",2021,"The sensitivity analysis for the complete cases showed similar results. ","['60 participants aged 65 and older with low health literacy', 'community-dwelling older adults with low health literacy', 'older adults with low health literacy', 'Older Adults with Low Health Literacy']","['active learning education', 'Active Learning Education', '90-minute health education class in a didactic manner', '90-minute active learning program session']","['CAVI', 'cardio-ankle vascular index (CAVI', 'physical activity', 'degree of arterial stiffness', 'total physical activity', 'arterial stiffness and physical activity']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0243012', 'cui_str': 'Active Learning'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C4034558', 'cui_str': 'Cardio-ankle vascular index'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",60.0,0.0732693,"The sensitivity analysis for the complete cases showed similar results. ","[{'ForeName': 'Kazuki', 'Initials': 'K', 'LastName': 'Uemura', 'Affiliation': 'Center for Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University.'}, {'ForeName': 'Minoru', 'Initials': 'M', 'LastName': 'Yamada', 'Affiliation': 'Graduate School of Comprehensive Human Sciences, University of Tsukuba.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Kuzuya', 'Affiliation': 'Institutes of Innovation for Future Society, Nagoya University.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Okamoto', 'Affiliation': 'Center for Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University.'}]",Journal of atherosclerosis and thrombosis,['10.5551/jat.58354'] 305,32470147,Effect of non-sedation on post-traumatic stress and psychological health in survivors of critical illness-A substudy of the NONSEDA randomized trial.,"BACKGROUND Critical illness can cause post-traumatic stress and impaired mental health. The NONSEDA trial was a Scandinavian multicenter RCT, assessing non-sedation versus sedation with a daily wake-up call during mechanical ventilation in critically ill adults. The aim of this substudy was to assess the effect of non-sedation on post-traumatic stress and mental health. METHODS This substudy is based on all participating patients from a single NONSEDA trial site (Kolding, Denmark). Patients were randomized to sedation or non-sedation within the first 24 hours of mechanical ventilation. Three months after ICU discharge survivors were examined by a neuropsychologist for post-traumatic stress, anxiety and depression, and filled out the SF-36 questionnaire regarding quality of life. RESULTS The two groups of survivors were similar with regard to baseline characteristics, length of admission and mechanical ventilation. Sedated patients received more propofol and midazolam. Doses of morphine and haloperidole were equal. PRIMARY OUTCOME the number of patients with post-traumatic stress disorder did not differ between groups (non-sedated: 2 patients vs sedated: 0, P = .23). SECONDARY OUTCOMES there were no differences between groups in Beck Anxiety Index (median, non-sedated: 0 vs sedated: 0, P = .62), Beck Depression Index (median, non-sedated: 7 vs sedated: 4, P = .24), SF-36 mental component score (mean, non-sedated: 46.7 vs sedated: 47.5, P = .73) or number of patients with symptoms of post-traumatic stress (8 in both groups, P = .89). CONCLUSION Levels of PTSD, anxiety and depression and quality of life regarding mental health were similar between the non-sedated and sedated group.",2020,"There were no differences between groups in either Beck Anxiety Index (median, non-sedated: 0 vs sedated: 0, p=0.62), Beck Depression Index (median, non-sedated: 7 vs sedated: 4, p=0.24), SF-36 mental component score (mean, non-sedated: 46.7 vs sedated: 47.5, p=0.73) or number of patients with symptoms of posttraumatic stress (8 in both groups, p=0.89). ","['survivors of critical illness', 'critically ill adults', 'participating patients from a single NONSEDA trial-site (Kolding, Denmark']","['propofol and midazolam', 'morphine', 'non-sedation', 'sedation or non-sedation']","['Beck Anxiety Index', 'number of patients with symptoms of posttraumatic stress', 'Beck Depression Index', 'number of patients with posttraumatic stress disorder', 'PTSD, anxiety and depression and quality of life regarding mental health', 'posttraumatic stress and psychological health', 'SF-36 mental component score']","[{'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0854969,"There were no differences between groups in either Beck Anxiety Index (median, non-sedated: 0 vs sedated: 0, p=0.62), Beck Depression Index (median, non-sedated: 7 vs sedated: 4, p=0.24), SF-36 mental component score (mean, non-sedated: 46.7 vs sedated: 47.5, p=0.73) or number of patients with symptoms of posttraumatic stress (8 in both groups, p=0.89). ","[{'ForeName': 'Helene K', 'Initials': 'HK', 'LastName': 'Nedergaard', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Lillebaelt Hospital Kolding, University Hospital of Southern Denmark, Kolding, Denmark.'}, {'ForeName': 'Hanne I', 'Initials': 'HI', 'LastName': 'Jensen', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Lillebaelt Hospital Kolding, University Hospital of Southern Denmark, Kolding, Denmark.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Stylsvig', 'Affiliation': 'Clinic of Neuropsychology, Odense, Denmark.'}, {'ForeName': 'Hanne T', 'Initials': 'HT', 'LastName': 'Olsen', 'Affiliation': 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Strøm', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Palle', 'Initials': 'P', 'LastName': 'Toft', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13648'] 306,32475294,Sixth-year follow-up of the effects of recreational activities found to eliminate the symptoms of social phobia and shyness.,"BACKGROUND The lack of 6-year follow-up studies that test the effect of recreational activities in the recovery of social phobia and shyness symptoms is the reason to conduct this study. AIM The purpose is to follow the effect of the 12-week recreational activity program found to eliminate social phobia and shyness symptoms after the completion of university studies in its sixth year. METHODS At the end of the 12-week recreational activity program that treats the symptoms of social phobia and shyness in university prep school students, 83 students who participated in the posttest both from intervention and control groups were invited to the study. In the sixth-year follow-up study, a total of 51 voluntary students - 32 from the intervention group and 19 from the control group - were administered the Liebowitz Social Anxiety Scale, the Shyness Scale and the Coopersmith Self-Esteem Inventory. RESULTS When the pretests and the sixth-year scores are compared, it is seen that it still has an improving effect on social phobia and shyness; when the posttests and the sixth-year tests are compared, no difference is seen regarding social phobia whereas it is seen that recovery still continues regarding the symptoms of shyness, and a decrease is seen in self-esteem. DISCUSSION While the improving effect of recreational activities on shyness and social phobia symptoms still continues, their effect on self-esteem decreases. CONCLUSION It is suggested that recreational activities should be included in the programs at universities regarding personal and professional development, and the reasons for the decrease in self-esteem scores should be determined through more detailed studies.",2020,"When the pretests and the sixth-year scores are compared, it is seen that it still has an improving effect on social phobia and shyness; when the posttests and the sixth-year tests are compared, no difference is seen regarding social phobia whereas it is seen that recovery still continues regarding the symptoms of shyness, and a decrease is seen in self-esteem. ","['university prep school students, 83 students who participated in the posttest both from intervention and control groups were invited to the study']","['recreational activities', 'recreational activity program']","['Liebowitz Social Anxiety Scale', 'social phobia and shyness symptoms']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0034872', 'cui_str': 'Recreation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0037020', 'cui_str': 'Shyness'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",83.0,0.0164186,"When the pretests and the sixth-year scores are compared, it is seen that it still has an improving effect on social phobia and shyness; when the posttests and the sixth-year tests are compared, no difference is seen regarding social phobia whereas it is seen that recovery still continues regarding the symptoms of shyness, and a decrease is seen in self-esteem. ","[{'ForeName': 'Elif', 'Initials': 'E', 'LastName': 'Karagün', 'Affiliation': 'Faculty of Sports Science, Department of Recreation, Kocaeli University, Kocaeli, Turkey.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Yildiz', 'Affiliation': 'Faculty of Medicine, Department of Psychiatry, Kocaeli University, Kocaeli, Turkey.'}, {'ForeName': 'Çiğdem', 'Initials': 'Ç', 'LastName': 'Çağlayan', 'Affiliation': 'Faculty of Medicine, Department of Public Health, Kocaeli University, Kocaeli, Turkey.'}, {'ForeName': 'Zekiye', 'Initials': 'Z', 'LastName': 'Başaran', 'Affiliation': 'Faculty of Sports Sciences, Kocaeli University, Kocaeli, Turkey.'}]",The International journal of social psychiatry,['10.1177/0020764020924702'] 307,32593287,High-flow nasal cannula improves clinical efficacy of airway management in patients undergoing awake craniotomy.,"BACKGROUND Awake craniotomy requires specific sedation procedure in an awake patient who should be able to cooperate during the intraoperative neurological assessment. Currently, limited number of literatures on the application of high-flow nasal cannula (HFNC) in the anesthetic management for awake craniotomy has been reported. Hence, we carried out a prospective study to assess the safety and efficacy of humidified high-flow nasal cannula (HFNC) airway management in the patients undergoing awake craniotomy. METHODS Sixty-five patients who underwent awake craniotomy were randomly assigned to use HFNC with oxygen flow rate at 40 L/min or 60 L/min, or nasopharynx airway (NPA) device in the anesthetic management. Data regarding airway management, intraoperative blood gas analysis, intracranial pressure, gastric antral volume, and adverse events were collected and analyzed. RESULTS Patients using HFNC with oxygen flow rate at 40 or 60 L/min presented less airway obstruction and injuries. Patients with HFNC 60 L/min maintained longer awake time than the patients with NPA. While the intraoperative PaO 2 and SPO 2 were not significantly different between the HFNC and NPA groups, HFNC patients achieved higher PaO 2 /FiO 2 than patients with NPA. There were no differences in Brain Relaxation Score and gastric antral volume among the three groups as well as before and after operation in any of the three groups. CONCLUSION HFNC was safe and effective for the patients during awake craniotomy. TRIAL REGISTRATION Chinese Clinical Trial Registry, CHiCTR1800016621 . Date of Registration: 12 June 2018.",2020,"There were no differences in Brain Relaxation Score and gastric antral volume among the three groups as well as before and after operation in any of the three groups. ","['Sixty-five patients who underwent awake craniotomy', 'patients undergoing awake craniotomy']","['humidified high-flow nasal cannula (HFNC) airway management', 'HFNC with oxygen flow rate at 40\u2009L/min or 60\u2009L/min, or nasopharynx airway (NPA) device', 'HFNC', 'High-flow nasal cannula']","['Brain Relaxation Score and gastric antral volume', 'safety and efficacy', 'intraoperative blood gas analysis, intracranial pressure, gastric antral volume, and adverse events', 'oxygen flow rate', 'airway obstruction and injuries']","[{'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0010280', 'cui_str': 'Craniotomy'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0150126', 'cui_str': 'Airway management'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0439393', 'cui_str': 'L/min'}, {'cui': 'C0027442', 'cui_str': 'Nasopharyngeal'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0293352', 'cui_str': 'Antral'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0021880', 'cui_str': 'Intracranial pressure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0001883', 'cui_str': 'Respiratory obstruction'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]",65.0,0.0784692,"There were no differences in Brain Relaxation Score and gastric antral volume among the three groups as well as before and after operation in any of the three groups. ","[{'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Yi', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital, Fudan University, No.12 Wulumuqi Zhong Road, Shanghai, 200040, China.'}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Shanghai Jiahui International Hospital, Shanghai, 200000, China.'}, {'ForeName': 'Zhoujing', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital, Fudan University, No.12 Wulumuqi Zhong Road, Shanghai, 200040, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Cao', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital, Fudan University, No.12 Wulumuqi Zhong Road, Shanghai, 200040, China.'}, {'ForeName': 'Xiaobing', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital, Fudan University, No.12 Wulumuqi Zhong Road, Shanghai, 200040, China.'}, {'ForeName': 'Huahua', 'Initials': 'H', 'LastName': 'Gu', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital, Fudan University, No.12 Wulumuqi Zhong Road, Shanghai, 200040, China. ghhmzk@sina.com.'}]",BMC anesthesiology,['10.1186/s12871-020-01073-z'] 308,32603526,Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.,"Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, was evaluated in a phase 1b study in patients with end-stage renal disease with anemia on hemodialysis. Seventeen patients, on epoetin-alfa maintenance therapy with stable hemoglobin levels ≥10 g/dL, had epoetin-alfa discontinued on day 3 and were enrolled in this double-blind placebo-controlled study. Two cohorts were randomized 3:1 (roxadustat: placebo). Patients received single doses of roxadustat (1 or 2 mg/kg) or placebo 1 hour after hemodialysis on day 1 and 2 hours before dialysis on day 8. Maximum plasma concentration and area under the plasma concentration-time curve for patients receiving roxadustat were slightly more than dose proportional and elimination half-life ranged from 14.7 to 19.4 hours. Roxadustat was highly protein bound (99%) in plasma, and dialysis contributed a small fraction of the total clearance: only 4.56% and 3.04% of roxadustat recovered from the 1 and 2 mg/kg dose groups, respectively. Roxadustat induced transient elevations of endogenous erythropoietin that peaked between 7 and 14 hours after dosing and returned to baseline by 48 hours after dosing. Peak median endogenous erythropoietin levels were 96 mIU/mL and 268 mIU/mL for the 1- and 2-mg/kg doses, respectively, within physiologic range of endogenous erythropoietin responses to hypoxia at high altitude or after blood loss. No serious adverse events were reported, and there were no treatment- or dose-related trends in adverse event incidence.",2020,"No serious adverse events were reported, and there were no treatment- or dose-related trends in adverse event incidence.","['Chronic Kidney Disease', 'Hemodialysis Patients', 'patients with end-stage renal disease with anemia on hemodialysis', 'Seventeen patients, on epoetin-alfa maintenance therapy with stable hemoglobin levels ≥10\xa0g/dL, had epoetin-alfa discontinued on day 3 and were enrolled in this double-blind']","['Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor', 'Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592', 'Placebo', 'placebo']","['Peak median endogenous erythropoietin levels', 'serious adverse events', 'transient elevations of endogenous erythropoietin', 'Maximum plasma concentration and area under the plasma concentration-time curve']","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0357126', 'cui_str': 'Epoetin Alfa'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0439267', 'cui_str': 'g/dL'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}]","[{'cui': 'C3713379', 'cui_str': 'FG-4592'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C3658210', 'cui_str': 'Proline Hydroxylase Inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0202001', 'cui_str': 'Erythropoietin measurement'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",2.0,0.0875764,"No serious adverse events were reported, and there were no treatment- or dose-related trends in adverse event incidence.","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Provenzano', 'Affiliation': 'Department of Medicine, Wayne State University, Detroit, Michigan, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Tumlin', 'Affiliation': 'Southeast Renal Research Institute, Chattanooga, Tennessee, USA.'}, {'ForeName': 'Raja', 'Initials': 'R', 'LastName': 'Zabaneh', 'Affiliation': 'Northwest Louisiana Nephrology Research, Shreveport, Louisiana, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Chou', 'Affiliation': 'FibroGen, Inc., San Francisco, California, USA.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Hemmerich', 'Affiliation': 'FibroGen, Inc., San Francisco, California, USA.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Neff', 'Affiliation': 'FibroGen, Inc., San Francisco, California, USA.'}, {'ForeName': 'K-H Peony', 'Initials': 'KP', 'LastName': 'Yu', 'Affiliation': 'FibroGen, Inc., San Francisco, California, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1648'] 309,32460699,"Dexmedetomidine for prevention of postoperative pulmonary complications in patients after oral and maxillofacial surgery with fibular free flap reconstruction:a prospective, double-blind, randomized, placebo-controlled trial.","BACKGROUND Postoperative pulmonary complications (PPCs) are common and significant problems for oral and maxillofacial surgery patients. Dexmedetomidine (DEX), an α 2 -adrenoreceptor agonist, has been proven having lung protection effects. However, since now, there has not been final conclusion about whether DEX can reduce the incidence of PPCs. We hypothesize that, in oral and maxillofacial surgery with fibular free flap reconstruction patients, DEX may decrease the incidence of PPCs. METHODS This was a prospective, double-blind, randomized, placebo-controlled, single-centered trial with two parallel arms. A total of 160 patients at intermediate-to-high risk of PPCs undergoing oral and maxillofacial surgery with fibular free flap reconstruction and tracheotomy were enrolled and randomized to receive continuous infusion of either DEX or placebo (normal saline). 0.4 μg/kg of DEX was given over 10mins as an initial dose followed by a maintaining dose of 0.4 μg/kg/h till the second day morning after surgery. At the same time, the normal saline was administered a similar quantity. The primary outcome was the incidence of PPCs according to Clavien-Dindo score within 7 days after surgery. RESULTS The two groups had similar characteristics at baseline. 18(22.5%) of 80 patients administered DEX, and 32(40.0%) of 80 patient administered placebo experienced PPCs within the first 7 days after surgery (relative risk [RR] 0.563,95% confidence interval [CI] 0.346-0.916; P = 0.017). In the first 7 days after surgery, the DEX group had a lower incidence of PPCs and a better postoperative survival probability (Log-rank test, P = 0.019), and was less prone to occur PPCs (Cox regression, P = 0.025, HR = 0.516). When the total dose of DEX was more than 328 μg, the patients were unlikely to have PPCs (ROC curve, AUC = 0.614, P = 0.009). CONCLUSIONS For patients undergoing oral and maxillofacial surgery with fibular free flap reconstruction and tracheotomy who were at intermediate or high risk of developing PPCs, continuous infusion of DEX could decrease the occurrence of PPCs during the first 7 days after surgery and shorten the length of hospital stay after surgery, but did not increase the prevalence of bradycardia or hypotension. TRIAL REGISTRATION Chinese Clinical Trial Registry, www.chictr.org.cn, number: ChiCTR1800016153; Registered on May 15, 2018.",2020,"In the first 7 days after surgery, the DEX group had a lower incidence of PPCs and a better postoperative survival probability (Log-rank test, P = 0.019), and was less prone to occur PPCs (Cox regression, P = 0.025, HR = 0.516).","['160 patients at intermediate-to-high risk of PPCs undergoing oral and maxillofacial surgery with fibular free flap reconstruction and tracheotomy', 'number', 'patients after oral and maxillofacial surgery with fibular free flap reconstruction']","['DEX or placebo (normal saline', 'DEX', 'Dexmedetomidine', 'Dexmedetomidine (DEX', 'maxillofacial surgery with fibular free flap reconstruction and tracheotomy', 'placebo']","['postoperative pulmonary complications', 'incidence of PPCs according to Clavien-Dindo score', 'length of hospital stay', 'occurrence of PPCs', 'prevalence of bradycardia or hypotension', 'incidence of PPCs', 'postoperative survival probability']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0812928', 'cui_str': 'Oral and maxillofacial surgery'}, {'cui': 'C0016068', 'cui_str': 'Bone structure of fibula'}, {'cui': 'C0411582', 'cui_str': 'Reconstruction with free flap'}, {'cui': 'C0040590', 'cui_str': 'Tracheostomy'}, {'cui': 'C0237753', 'cui_str': 'Number'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0038908', 'cui_str': 'Oral surgery'}, {'cui': 'C0016068', 'cui_str': 'Bone structure of fibula'}, {'cui': 'C0411582', 'cui_str': 'Reconstruction with free flap'}, {'cui': 'C0040590', 'cui_str': 'Tracheostomy'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",160.0,0.736349,"In the first 7 days after surgery, the DEX group had a lower incidence of PPCs and a better postoperative survival probability (Log-rank test, P = 0.019), and was less prone to occur PPCs (Cox regression, P = 0.025, HR = 0.516).","[{'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Department of Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China. 3917798@qq.com.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Peking University Hospital of Stomatology, Beijing, 100081, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Han', 'Affiliation': 'Department of Anesthesiology, Peking University Hospital of Stomatology, Beijing, 100081, China.'}, {'ForeName': 'Xudong', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Peking University Hospital of Stomatology, Beijing, 100081, China. kqyangxudong@163.com.'}]",BMC anesthesiology,['10.1186/s12871-020-01045-3'] 310,32468719,Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design).,"Fingolimod is indicated for the treatment of patients with the relapsing-remitting form of multiple sclerosis. The primary study objective was to evaluate the bioequivalence of a test formulation, 0.5 mg fingolimod HCl capsule (Lebrina, Asofarma Sociedad Anónima Industrial y Comercial, Argentina) relative to a reference formulation, 0.5 mg fingolimod capsule (Gilenya, Novartis Pharmaceutical, Australia). In a single-center, randomized, single-dose, single-blinded, 2-way crossover study, 33 New Zealand healthy subjects of both sexes were enrolled to receive a 0.5-mg dose of 3 capsules of each fingolimod formulation under fasting conditions, with a 42-day washout period between administrations. Additional pharmacokinetic information regarding its main active metabolite, fingolimod phosphate, was also provided. The point estimate and 90% confidence intervals of the ratios of maximum concentration and area under the plasma concentration-time curve from time 0 to 72 hours were 99.07 (95.83-102.41) and 97.64 (95.33-100.00) for fingolimod, and 95.60 (90.95-100.49) and 98.54 (96.19-100.96), for fingolimod phosphate. Primary parameters, maximum concentration and area under the plasma concentration-time curve from time 0 to 72 hours for fingolimod and fingolimod phosphate were found to have no significant difference when test and reference formulations were compared. Fingolimod and fingolimod phosphate of both formulations were within the accepted 90% confidence interval limits of 80.00% and 125.00%. No significant differences between the test and reference drug products were detected in any of the pharmacokinetic parameters estimated. Notwithstanding the primary conclusion of bioequivalence is focused on the measurement of the parent compound, compliance with the same criteria by the active metabolite reinforces the comparability between the pharmacokinetic profiles of both formulations (ClinicalTrials.gov Identifier: NCT03757338).",2020,No significant differences between the test and reference drug products were detected in any of the pharmacokinetic parameters estimated.,"['patients with the relapsing-remitting form of multiple sclerosis', '33 New Zealand healthy subjects of both sexes', 'New Zealand Healthy Subjects (Truncated Design']","['Fingolimod', '0.5 mg Assessing Both Parent Drug and Active Metabolite', 'fingolimod HCl capsule ']","['maximum concentration and area under the plasma concentration-time curve from time 0 to 72 hours for fingolimod and fingolimod phosphate', 'ratios of maximum concentration and area under the plasma concentration-time curve']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0439600', 'cui_str': 'Remitting'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C1699926', 'cui_str': 'fingolimod'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0388087', 'cui_str': 'Fingolimod hydrochloride'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C1699926', 'cui_str': 'fingolimod'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",33.0,0.0636992,No significant differences between the test and reference drug products were detected in any of the pharmacokinetic parameters estimated.,"[{'ForeName': 'Noelyn Anne', 'Initials': 'NA', 'LastName': 'Hung', 'Affiliation': 'Zenith Technology Corporation Ltd, Dunedin, New Zealand.'}, {'ForeName': 'Fernando Guillermo', 'Initials': 'FG', 'LastName': 'Costa', 'Affiliation': 'Asofarma S.A.I y C. (Asofarma Sociedad Anónima Industrial y Comercial), Buenos Aires, Argentina.'}, {'ForeName': 'Cheung-Tak', 'Initials': 'CT', 'LastName': 'Hung', 'Affiliation': 'Zenith Technology Corporation Ltd, Dunedin, New Zealand.'}, {'ForeName': 'Mónica Esther', 'Initials': 'ME', 'LastName': 'Rosenberg', 'Affiliation': 'Asofarma S.A.I y C. (Asofarma Sociedad Anónima Industrial y Comercial), Buenos Aires, Argentina.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.813'] 311,32473046,"A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.","BACKGROUND The risk of invasive pneumococcal disease is significant among solid organ transplant (SOT) recipients. The optimal pneumococcal vaccination strategy for SOT patients is not known. METHODS The potential kidney transplant recipients in dialysis were randomized into two arms: to receive a 23-valent pneumococcal polysaccharide vaccine (PPV23) before transplantation or to receive a 13-valent pneumococcal conjugate vaccine (PCV13) before transplantation and a second dose of PCV13 six months after the transplantation. Serotype-specific antibody concentrations and opsonophagocytic activity (OPA) were measured before and after the first vaccination (visits V1,V2) and six and seven months after the transplantation, for example, before and after the second PCV13 (visits V3,V4). RESULTS Out of 133 participants, 48 (PCV13 arm) and 46 (PPV23 arm) received a kidney transplant, and 37 + 37 in both arms completed the study. After the first vaccination, the geometric mean concentrations (GMCs) in the PCV13 arm were significantly higher for 9/13 serotypes and the OPA geometric mean titers (GMTs) were significantly higher for 4/13 serotypes. At V3, the antibody levels had declined but OPA remained significantly higher for 7/13 (PCV13) vs 4/13 (PPV23) serotypes. At V4, the GMCs for 9/13 serotypes and the GMTs for 12/13 serotypes were significantly higher in the PCV13 arm. The GMCs but not GMTs were lower than at V2. There was no difference in adverse effects. No vaccine-related allograft rejection was detected. CONCLUSIONS The immunogenicity of PCV13 was better in dialysis patients, and revaccination with PCV13 was immunogenic and safe.",2020,"The immunogenicity of PCV13 was better in dialysis patients, and revaccination with PCV13 was immunogenic and safe .","['kidney transplant recipients in dialysis', 'Out of 133 participants, 48 (PCV13 arm) and 46 (PPV23 arm) received a kidney transplant, and 37 + 37 in both arms completed the study', 'kidney transplant recipients', 'solid organ transplant (SOT) recipients', 'SOT patients']","['23-valent pneumococcal polysaccharide vaccine (PPV23) before transplantation or to receive a 13-valent pneumococcal conjugate vaccine (PCV13', '23-valent pneumococcal polysaccharide vaccination']","['geometric mean concentrations (GMCs', 'allograft rejection', 'immunogenicity of PCV13', 'OPA', 'adverse effects', 'antibody levels', 'OPA geometric mean titres (GMTs', 'Serotype-specific antibody concentrations and opsonophagocytic activity (OPA']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0230348', 'cui_str': 'Both upper arms'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0730400', 'cui_str': 'Solid organ transplant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0961101', 'cui_str': '23-valent pneumococcal capsular polysaccharide vaccine'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C3152625', 'cui_str': 'Pneumococcal 13-valent conjugate vaccine'}, {'cui': 'C0038410', 'cui_str': 'Streptococcus pneumoniae'}, {'cui': 'C0032594', 'cui_str': 'Polysaccharide'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0035015', 'cui_str': 'Rejection (Psychology)'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0036759', 'cui_str': 'Serotyping'}, {'cui': 'C0443640', 'cui_str': 'Specific antibody'}]",133.0,0.0617085,"The immunogenicity of PCV13 was better in dialysis patients, and revaccination with PCV13 was immunogenic and safe .","[{'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Eriksson', 'Affiliation': 'HUH Inflammation Center, Division of Infectious Diseases of Helsinki University Hospital, Helsinki University, Helsinki, Finland.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Käyhty', 'Affiliation': 'National Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Saha', 'Affiliation': 'Division of Nephrology, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Lahdenkari', 'Affiliation': 'National Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Petri', 'Initials': 'P', 'LastName': 'Koskinen', 'Affiliation': 'HUH Abdominal Center, Division of Nephrology, Helsinki University Hospital and Helsinki University, Helsinki, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Mäkisalo', 'Affiliation': 'HUH Abdominal Center, Division of Liver Diseases and Transplantation, Helsinki University Hospital and Helsinki University, Helsinki, Finland.'}, {'ForeName': 'Veli-Jukka', 'Initials': 'VJ', 'LastName': 'Anttila', 'Affiliation': 'HUH Inflammation Center, Division of Infectious Diseases of Helsinki University Hospital, Helsinki University, Helsinki, Finland.'}]",Transplant infectious disease : an official journal of the Transplantation Society,['10.1111/tid.13343'] 312,32476236,Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease.,"BACKGROUND Butyrate has shown anti-inflammatory and regenerative properties, providing symptomatic relief when orally supplemented in patients suffering from various colonic diseases. We investigated the effect of a colonic-delivery formulation of butyrate on the fecal microbiota of patients with inflammatory bowel diseases (IBDs). METHODS In this double-blind, placebo-controlled, pilot study, 49 IBD patients (n = 19 Crohn's disease, CD and n = 30 ulcerative colitis, UC) were randomized to oral administration of microencapsulated-sodium-butyrate (BLM) or placebo for 2 months, in addition to conventional therapy. Eighteen healthy volunteers (HVs) were recruited to provide a healthy microbiota model of the local people. Fecal microbiota from stool samples was assessed by 16S sequencing. Clinical disease activity and quality of life (QoL) were evaluated before and after treatment. KEY RESULTS At baseline, HVs showed a different microbiota composition compared with IBD patients. Sodium-butyrate altered the gut microbiota of IBD patients by increasing bacteria able to produce SCFA in UC patients (Lachnospiraceae spp.) and the butyrogenic colonic bacteria in CD patients (Butyricicoccus). In UC patients, QoL was positively affected by treatment. CONCLUSIONS AND INFERENCES Sodium-butyrate supplementation increases the growth of bacteria able to produce SCFA with potentially anti-inflammatory action. The clinical impact of this finding requires further investigation.",2020,"At baseline, HVs showed a different microbiota composition compared with IBD patients.","[""49 IBD patients (n\xa0=\xa019 Crohn's disease, CD and n\xa0=\xa030 ulcerative colitis, UC"", 'patients with inflammatory bowel diseases (IBDs', 'patients suffering from various colonic diseases', 'patients with inflammatory bowel disease', 'Eighteen healthy volunteers (HVs']","['Sodium-butyrate', 'microencapsulated-sodium-butyrate (BLM) or placebo', 'butyrate', 'microencapsulated sodium butyrate', 'placebo']","['Clinical disease activity and quality of life (QoL', 'QoL']","[{'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0009373', 'cui_str': 'Disorder of colon'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0142812', 'cui_str': 'Butyric Acid, Sodium Salt'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006521', 'cui_str': 'Butyrates'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",49.0,0.0508898,"At baseline, HVs showed a different microbiota composition compared with IBD patients.","[{'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Facchin', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Vitulo', 'Affiliation': 'Department of Biotechnology, University of Verona, Verona, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Calgaro', 'Affiliation': 'Department of Biotechnology, University of Verona, Verona, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Buda', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Romualdi', 'Affiliation': 'Department of Biology, University of Padua, Padua, Italy.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pohl', 'Affiliation': 'Department of Gastroenterology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Perini', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.'}, {'ForeName': 'Greta', 'Initials': 'G', 'LastName': 'Lorenzon', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Marinelli', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': ""D'Incà"", 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.'}, {'ForeName': 'Giacomo Carlo', 'Initials': 'GC', 'LastName': 'Sturniolo', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.'}, {'ForeName': 'Edoardo Vincenzo', 'Initials': 'EV', 'LastName': 'Savarino', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13914'] 313,32485095,"Differential effects of testosterone on circulating neutrophils, monocytes, and platelets in men: Findings from two trials.","BACKGROUND Testosterone treatment increases erythrocytes in men, but its effects on leukocyte and platelet counts are unknown and could affect its safety. OBJECTIVE To determine whether testosterone affects circulating leukocytes and platelets in men. METHODS Secondary analyses of two randomized testosterone trials were performed: the 5α-reductase (5aR) and OPTIMEN trials. In 5aR trial, 102 healthy men, 21-50 years (mean age 38), received a long-acting GnRH agonist, and 50, 125, 300, or 600 mg/week testosterone enanthate (TE) plus placebo or 2.5 mg / day dutasteride for 20 weeks. In OPTIMEN, 78 functionally limited men, ≥65 years (mean age 72) with protein intake ≤ 0.83 g kg -1  day -1 , were randomized to controlled diets with 0.8 g kg -1  day -1 protein or 1.3 g kg -1  day -1 protein plus placebo or TE (100 mg/week) for 6 months. Changes from baseline in total and differential leukocyte count, and platelet count were evaluated. RESULTS In 5aR, testosterone administration was associated with increases in total leukocyte (estimated change from baseline 40, 490, 1230, and 1280 cells/µL, P < .001), neutrophil (65.1, 436.1, 1177.2, and 1192.2 cells/µL, P < .001), monocyte (-20.2, 24.5, 90.6, and 143.9 cells/µL, P < .001), platelet (-7.3, 8.4, 8.7, and 8.9 × 10 3 cells/µL, P = .033), and erythrocyte counts. Testosterone did not affect absolute lymphocyte count. Similar increase in total leukocyte count was observed with testosterone treatment in OPTIMEN (change 0.77 × 10 3 cells/µL, P vs placebo = 0.004). CONCLUSIONS Testosterone administration in men differentially increases neutrophil and monocyte counts. These findings, together with its erythropoietic effects, suggest that testosterone promotes the differentiation of hematopoietic progenitors into the myeloid lineage. These findings have potential mechanistic, therapeutic, and safety implications.",2020,Similar increase in total leukocyte count was observed with testosterone treatment in OPTIMEN (change 0.77,"['78 functionally-limited men, ≥65 years (mean age 72) with protein intake ≤0.83 g * kg -1 * day -1', 'men', '102 healthy men, 21-50 years (mean age 38', 'Men']","['controlled diets with 0.8 g * kg -1 * day -1 protein or 1.3 g * kg -1 * day -1 protein plus placebo or TE', 'testosterone', 'Testosterone', 'enanthate (TE) plus placebo', '5α-Reductase (5aR']","['total and differential leukocyte count, and platelet count', 'monocyte', 'total leukocyte', 'total leukocyte count', 'Peripheral Neutrophils, Monocytes and Platelets', 'platelet', 'neutrophil and monocyte counts', 'absolute lymphocyte count', 'neutrophil', 'erythrocyte counts']","[{'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0743195', 'cui_str': 'Dietary control'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0019226', 'cui_str': 'Enanthates'}, {'cui': 'C0030016', 'cui_str': 'Oxidoreductase'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0162401', 'cui_str': 'Differential white blood cell count procedure'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0026473', 'cui_str': 'Monocyte'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0200637', 'cui_str': 'Monocyte count'}, {'cui': 'C3544087', 'cui_str': 'Absolute lymphocyte count'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}]",102.0,0.505029,Similar increase in total leukocyte count was observed with testosterone treatment in OPTIMEN (change 0.77,"[{'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'Gagliano-Jucá', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Karol M', 'Initials': 'KM', 'LastName': 'Pencina', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Guo', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Zhuoying', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Huang', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Shehzad', 'Initials': 'S', 'LastName': 'Basaria', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Shalender', 'Initials': 'S', 'LastName': 'Bhasin', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}]",Andrology,['10.1111/andr.12834'] 314,32585278,"Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study.","BACKGROUND Onychomycosis is a recalcitrant fungal nail infection. Topical antifungal agents may be preferred over systemic agents due to lack of systemic adverse effects. OBJECTIVE To investigate the efficacy and safety of topical terbinafine 10% solution (MOB-015) for the treatment of distal and lateral subungual onychomycosis. METHODS In a multicenter, double-blind, phase III, North American study, patients with mild to moderate distal and lateral subungual onychomycosis involving 20% to 60% of at least 1 great toenail were randomized to once daily application of MOB-015 or matching vehicle for 48 weeks. The primary efficacy variable was complete cure, while the secondary efficacy variables were mycological cure and treatment success. Safety evaluations were also performed. RESULTS At week 52, the mycological cure (negative culture and potassium hydroxide microscopy) rate in the MOB-015 and vehicle groups was 69.9% and 27.7%, respectively (P < .001), and complete cure (0% clinical disease involvement and mycological cure) was achieved in 4.5% and 0% of patients, respectively (P = .0195). At least 1 adverse event leading to discontinuation of treatment occurred in 2.8% of patients in the MOB-015 group and in 4.2% in the vehicle group. LIMITATION The follow-up period after end of treatment may not be sufficient to accurately reflect cure in distal and lateral subungual onychomycosis. CONCLUSIONS MOB-015 is a treatment option for onychomycosis with an adverse event profile similar to vehicle.",2021,"Complete cure (0% clinical disease involvement and mycological cure) was achieved in 4.5% and 0% subjects, respectively (P=0.0195).","['North American study subjects with mild to moderate DSO involving 20-60% of at least one great toenail', 'distal and lateral subungual onychomycosis (DSO', 'mild-to-moderate distal subungual onychomycosis']","['MOB-015 or matching vehicle', 'topical terbinafine 10% solution (MOB-015']","['adverse event (AE) leading to discontinuation', 'Efficacy and safety', 'complete and mycological cure', 'efficacy and safety', 'mycological cure (negative culture and KOH) rate', 'Complete cure', 'mycological cure']","[{'cui': 'C0425358', 'cui_str': 'North American origin'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C1274513', 'cui_str': 'Distal and lateral subungual onychomycosis'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0222007', 'cui_str': 'Toenails'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0040261', 'cui_str': 'Onychomycosis'}]","[{'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0076110', 'cui_str': 'terbinafine'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205467', 'cui_str': 'Mycologic'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0071767', 'cui_str': 'Potassium Hydroxide'}]",,0.185955,"Complete cure (0% clinical disease involvement and mycological cure) was achieved in 4.5% and 0% subjects, respectively (P=0.0195).","[{'ForeName': 'Aditya K', 'Initials': 'AK', 'LastName': 'Gupta', 'Affiliation': 'Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Mediprobe Research Inc, London, Ontario, Canada. Electronic address: agupta@execulink.com.'}, {'ForeName': 'Maria S', 'Initials': 'MS', 'LastName': 'Surprenant', 'Affiliation': 'Doctors Research Network, Miami, Florida.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Kempers', 'Affiliation': 'Minnesota Clinical Study Center, Fridley, Minnesota.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Pariser', 'Affiliation': 'Department of Dermatology, Eastern Virginia Medical School and Virginia Clinical Research, Inc, Norfolk, Virginia.'}, {'ForeName': 'Kjell', 'Initials': 'K', 'LastName': 'Rensfeldt', 'Affiliation': 'currently retired, Stockholm, Sweden.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Tavakkol', 'Affiliation': 'Moberg Pharma AB (publ), Bromma, Sweden. Electronic address: amir.tavakkol@mobergpharma.se.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.06.055'] 315,32600489,Volunteers' experiences of providing telephone-based breast-feeding peer support in the RUBY randomised controlled trial.,"OBJECTIVE The Ringing Up About Breastfeeding earlY (RUBY) randomised controlled trial (RCT) found that a telephone-based peer volunteer support intervention increased breast-feeding duration in a setting with high breast-feeding initiation. This sub-study of the RUBY RCT describes the motivation, preparation and experiences of volunteers who provided the peer support intervention. DESIGN An online survey was completed by 154 (67 %) volunteers after ceasing volunteering. SETTING Volunteers provided peer support to primiparous women (n 574) who birthed at one of three public hospitals in Melbourne, Australia, between February 2013 and December 2015. PARTICIPANTS Volunteers (n 230) had themselves breastfed for at least 6 months and received 4 h of training for the role. RESULTS The median number of mothers supported was two (range 1-11), and two-thirds of respondents supported at least one mother for 6 months. Volunteers were motivated by a strong desire to support new mothers to establish and continue breast-feeding. Most (93 %) considered the training session adequate. The majority (60 %) reported following the call schedule 'most of the time', but many commented that 'it depends on the mother'. Overall, 84 % of volunteers were satisfied with the role and reported that the experience was enjoyable (85 %) and worthwhile (90 %). Volunteers agreed that telephone support for breast-feeding was valued by women (88 %) and that the programme would be effective in helping women to breastfeed (93 %). CONCLUSIONS These findings are important for those developing similar peer support programmes in which recruiting volunteers and developing training requirements are an integral and recurrent part of volunteer management.",2020,found that a telephone-based peer volunteer support intervention increased breast-feeding duration in a setting with high breast-feeding initiation.,"['Volunteers provided peer support to primiparous women (n 574) who birthed at one of three public hospitals in Melbourne, Australia, between February 2013 and December 2015', 'Volunteers (n 230) had themselves breastfed for at least 6 months and received 4 h of training for the role']","['RUBY RCT', 'telephone-based breast-feeding peer support', 'telephone-based peer volunteer support intervention', 'Ringing Up']","['breast-feeding duration', 'median number of mothers']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0033150', 'cui_str': 'Para 1'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0020022', 'cui_str': 'Public Hospitals'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0035820', 'cui_str': 'Role'}]","[{'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]",,0.031904,found that a telephone-based peer volunteer support intervention increased breast-feeding duration in a setting with high breast-feeding initiation.,"[{'ForeName': 'H A', 'Initials': 'HA', 'LastName': 'Grimes', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Melbourne, Victoria3000, Australia.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Shafiei', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Melbourne, Victoria3000, Australia.'}, {'ForeName': 'H L', 'Initials': 'HL', 'LastName': 'McLachlan', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Melbourne, Victoria3000, Australia.'}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Forster', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Melbourne, Victoria3000, Australia.'}]",Public health nutrition,['10.1017/S136898002000124X'] 316,32609412,"Multifactorial Intervention on Type 2 Diabetes (MIDiab) Study: A multicenter, open-label, randomized, parallel controlled, community trial.",,2020,,[],['Multifactorial Intervention'],[],[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0248914,,"[{'ForeName': 'Yupeng', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Qingbo', 'Initials': 'Q', 'LastName': 'Guan', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Hou', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Haiqing', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Jing', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Shizhan', 'Initials': 'S', 'LastName': 'Ma', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Shanshan', 'Initials': 'S', 'LastName': 'Shao', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Qingling', 'Initials': 'Q', 'LastName': 'Guo', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Zhong', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Gao', 'Affiliation': 'Shandong Provincial Key Laboratory of Endocrinology and Lipid Metabolism, Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine, Jinan, China.'}, {'ForeName': 'Jiajun', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of diabetes,['10.1111/1753-0407.13081'] 317,32615179,Early precut versus primary precut sphincterotomy to reduce post-ERCP pancreatitis: randomized controlled trial (with videos).,"BACKGROUND AND AIMS Precut sphincterotomy, usually performed after prolonged and failed cannulation, is considered a risk factor for post-ERCP pancreatitis (PEP). There are limited studies on primary needle-knife precut for the prevention of PEP. The aim of this study was to assess the safety and efficacy of primary precut. METHODS A randomized controlled trial was conducted in a tertiary care setting on patients who underwent ERCP. Patients were randomized to very early precut (group A, precut after 2 failed attempts of wire-guided sphincterotome cannulation) and primary precut (group B, direct needle-knife precut). All procedures were done by an experienced endoscopist. The primary outcome of the study was to compare the incidence of PEP between the 2 groups. RESULTS Three hundred three patients were randomized to group A (n = 152, age 48.2 ± 15.4 years, 61 men) and group B (n = 151, age 46.7 ± 13.8 years, 65 men). There was no significant difference in baseline characteristics and indications for ERCP between the 2 groups. Development of PEP (5.2% vs .67%; P = .04) and asymptomatic hyperamylasemia (12.5% vs 2.6%; P = .01) were lower in group B compared with group A. The bile duct cannulation time (13.8 ± 2.2 vs 7.2 ± 1.7 minutes; P = .001) was lower in group B, whereas the overall cannulation success rate (98% vs 98.6%; P = 1.0) was similar in both the groups. CONCLUSIONS Primary precut by an experienced endoscopist results in low risk of PEP. (Clinical trial registration number: CTRI/2017/08/009510.).",2021,Development of PEP (5.2% vs 0.67%; p = 0.04) and asymptomatic hyperamylasemia (12.5% vs 2.6%; p = 0.01) were lower in group B compared with group A.,"['patients who underwent ERCP', 'Three hundred three patients were randomized to group A (n= 152, age 48.2±15.4 years, 61 men) and group B (n= 151, age 46.7±13.8 years, 65 men']","['wire guided sphincterotome cannulation) and primary precut (group B: direct needle-knife precut', 'Early precut versus primary precut sphincterotomy']","['asymptomatic hyperamylasemia', 'safety and efficacy', 'bile duct cannulation time', 'incidence of PEP', 'low risk of PEP', 'overall cannulation success rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0181089', 'cui_str': 'Guide wire'}, {'cui': 'C0183424', 'cui_str': 'Sphincterotome'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0441189', 'cui_str': 'Direct needle'}, {'cui': 'C0181467', 'cui_str': 'Knife'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0177047', 'cui_str': 'Sphincterotomy (bladder)'}]","[{'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0221773', 'cui_str': 'Hyperamylasaemia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0005400', 'cui_str': 'Bile duct structure'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0030305', 'cui_str': 'Pancreatitis'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",303.0,0.106841,Development of PEP (5.2% vs 0.67%; p = 0.04) and asymptomatic hyperamylasemia (12.5% vs 2.6%; p = 0.01) were lower in group B compared with group A.,"[{'ForeName': 'Sudhir', 'Initials': 'S', 'LastName': 'Maharshi', 'Affiliation': 'Department of Gastroenterology, SMS Medical College and Hospitals, Jaipur, India.'}, {'ForeName': 'Shyam Sunder', 'Initials': 'SS', 'LastName': 'Sharma', 'Affiliation': 'Department of Gastroenterology, SMS Medical College and Hospitals, Jaipur, India.'}]",Gastrointestinal endoscopy,['10.1016/j.gie.2020.06.064'] 318,32632523,Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity.,"BACKGROUND Due to the SARS-CoV2 pandemic, medical face masks are widely recommended for a large number of individuals and long durations. The effect of wearing a surgical and a FFP2/N95 face mask on cardiopulmonary exercise capacity has not been systematically reported. METHODS This prospective cross-over study quantitated the effects of wearing no mask (nm), a surgical mask (sm) and a FFP2/N95 mask (ffpm) in 12 healthy males (age 38.1 ± 6.2 years, BMI 24.5 ± 2.0 kg/m 2 ). The 36 tests were performed in randomized order. The cardiopulmonary and metabolic responses were monitored by ergo-spirometry and impedance cardiography. Ten domains of comfort/discomfort of wearing a mask were assessed by questionnaire. RESULTS The pulmonary function parameters were significantly lower with mask (forced expiratory volume: 5.6 ± 1.0 vs 5.3 ± 0.8 vs 6.1 ± 1.0 l/s with sm, ffpm and nm, respectively; p = 0.001; peak expiratory flow: 8.7 ± 1.4 vs 7.5 ± 1.1 vs 9.7 ± 1.6 l/s; p < 0.001). The maximum power was 269 ± 45, 263 ± 42 and 277 ± 46 W with sm, ffpm and nm, respectively; p = 0.002; the ventilation was significantly reduced with both face masks (131 ± 28 vs 114 ± 23 vs 99 ± 19 l/m; p < 0.001). Peak blood lactate response was reduced with mask. Cardiac output was similar with and without mask. Participants reported consistent and marked discomfort wearing the masks, especially ffpm. CONCLUSION Ventilation, cardiopulmonary exercise capacity and comfort are reduced by surgical masks and highly impaired by FFP2/N95 face masks in healthy individuals. These data are important for recommendations on wearing face masks at work or during physical exercise.",2020,"The pulmonary function parameters were significantly lower with mask (forced expiratory volume: 5.6 ± 1.0 vs 5.3 ± 0.8 vs 6.1 ± 1.0 l/s with sm, ffpm and nm, respectively; p = 0.001; peak expiratory flow: 8.7 ± 1.4 vs 7.5 ± 1.1 vs 9.7 ± ","['12 healthy males (age 38.1\u2009±\u20096.2\xa0years, BMI 24.5\u2009±\u20092.0\xa0kg/m 2 ', 'healthy individuals']","['wearing a surgical and a FFP2/N95 face mask', 'wearing no mask (nm), a surgical mask (sm) and a FFP2/N95 mask', 'surgical and FFP2/N95 face masks']","['Cardiac output', 'Peak blood lactate response', 'ventilation', 'pulmonary function parameters', 'cardiopulmonary exercise capacity', 'cardiopulmonary and metabolic responses']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0181758', 'cui_str': 'Surgical face mask'}]","[{'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",12.0,0.0184074,"The pulmonary function parameters were significantly lower with mask (forced expiratory volume: 5.6 ± 1.0 vs 5.3 ± 0.8 vs 6.1 ± 1.0 l/s with sm, ffpm and nm, respectively; p = 0.001; peak expiratory flow: 8.7 ± 1.4 vs 7.5 ± 1.1 vs 9.7 ± ","[{'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Fikenzer', 'Affiliation': 'Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Germany. sven.fikenzer@medizin.uni-leipzig.de.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Uhe', 'Affiliation': 'Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Germany.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Lavall', 'Affiliation': 'Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Germany.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Rudolph', 'Affiliation': 'Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Germany.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Falz', 'Affiliation': 'Institut für Sportmedizin und Prävention, Universität Leipzig, Marschner Str. 29, 04109, Leipzig, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Busse', 'Affiliation': 'Institut für Sportmedizin und Prävention, Universität Leipzig, Marschner Str. 29, 04109, Leipzig, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Hepp', 'Affiliation': 'Klinik für Orthopädie, Unfallchirurgie und Plastische Chirurgie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Germany.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Laufs', 'Affiliation': 'Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Germany.'}]",Clinical research in cardiology : official journal of the German Cardiac Society,['10.1007/s00392-020-01704-y'] 319,32640854,Modulation of the prefrontal blood oxygenation response to intermittent theta-burst stimulation in depression: A sham-controlled study with functional near-infrared spectroscopy.,"OBJECTIVE To better understand the neural mechanisms behind the effect of intermittent theta-burst stimulation (iTBS), we investigated how the prefrontal blood oxygenation response measured by changes in oxygenated haemoglobin (oxy-Hb) was modulated during a sham-controlled iTBS treatment course, and whether this was related to depressive symptom change. METHODS In this randomised, double-blind study, patients with ongoing treatment-resistant depression received either active ( n  = 18) or sham ( n  = 21) iTBS over the dorsomedial prefrontal cortex for ten to fifteen days with two sessions daily. Event-related functional near-infrared spectroscopy (fNIRS) was measured during each iTBS train, and resting-state oxy-Hb was compared before and after each iTBS session at the first, fifth, and last treatment day. RESULTS Patients receiving active iTBS had an increase of the event-related oxy-Hb response compared to the sham group on the fifth (bilateral prefrontal cortices p  < .001) and last (left prefrontal p  = .007, right prefrontal p  = .025) treatment day. Resting-state analysis showed suppressed oxy-Hb change in active iTBS compared to sham iTBS on the last treatment day ( p  = .024). Oxy-Hb change was unrelated to depressive symptom change ( p  = .474). CONCLUSIONS This study describes a modulation of the blood oxygenation response over the prefrontal cortex that was built up during the course of active iTBS treatment in depression.",2021,"RESULTS Patients receiving active iTBS had an increase of the event-related oxy-Hb response compared to the sham group on the fifth (bilateral prefrontal cortices p  < .001) and last (left prefrontal p  = .007, right prefrontal p  = .025) treatment day.","['patients with ongoing treatment-resistant depression received either', 'depression']","['active ( n \u2009=\u200918) or sham ( n \u2009=\u200921) iTBS', 'intermittent theta-burst stimulation (iTBS', 'intermittent theta-burst stimulation']","['blood oxygenation response', 'depressive symptom change', 'oxy-Hb change in active iTBS', 'event-related oxy-Hb response', 'prefrontal blood oxygenation response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",,0.141215,"RESULTS Patients receiving active iTBS had an increase of the event-related oxy-Hb response compared to the sham group on the fifth (bilateral prefrontal cortices p  < .001) and last (left prefrontal p  = .007, right prefrontal p  = .025) treatment day.","[{'ForeName': 'Wiebke', 'Initials': 'W', 'LastName': 'Struckmann', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Persson', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Weigl', 'Affiliation': 'Department of Surgical Science, Anaesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Malin', 'Initials': 'M', 'LastName': 'Gingnell', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Bodén', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.'}]",The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry,['10.1080/15622975.2020.1785007'] 320,32646379,90 days impacts of remote ischemic preconditioning on patients undergoing open total aortic arch replacement: a post-hoc analysis of previous trial.,"BACKGROUND In the previous randomized controlled trial by our research group, we evaluated the effect of remote ischemic preconditioning (RIPC) in 130 patients (65 per arm) on acute kidney injury (AKI) within 7 days of open total aortic arch replacement. Significantly fewer RIPC-treated patients than sham-treated patients developed postoperative AKI, and, epically, RIPC significantly reduced serious AKI (stage II-III). However, the long-term effect of RIPC in patients undergoing open total aortic arch replacement is unclear. METHODS This study was a post-hoc analysis. We aimed to assess the roles of RIPC in major adverse kidney events (MAKE), defined as consisting persistent renal dysfunction, renal replacement therapy and mortality, within 90 days after surgery in patients receiving open total aortic arch replacement. RESULTS In this 90-day follow-up study, data were available for all study participants. We found that RIPC failed to improve the presence of MAKE within 90 days after surgery (RIPC: 7 of 65[10.8%]) vs sham: 15 of 65[23.1%]; P = 0.061). In those patients who developed AKI after surgery, we found that the rate of MAKE within 90 days after surgery differed between the RIPC group and the sham group (RIPC: 4 of 36[11.2%]; sham: 14 of 48[29.2%]; P = 0.046). CONCLUSIONS At 90 days after open total aortic arch replacement, we failed to find a difference between the renoprotective effects of RIPC and sham treatment. The effectiveness or ineffectiveness of RIPC should be further investigated in a large randomized sham-controlled trial. TRIAL REGISTRATION This study was approved by the Ethics Committee of Fuwai Hospital (No. 2016-835) and our previous study was registered at clinicaltrials.gov before patient enrollment ( NCT03141385 ; principal investigator: G.W.; date of registration: March 5, 2017).",2020,"Significantly fewer RIPC-treated patients than sham-treated patients developed postoperative AKI, and, epically, RIPC significantly reduced serious AKI (stage II-III).","['130 patients (65 per arm) on acute kidney injury (AKI) within 7\u2009days of open total aortic arch replacement', 'patients undergoing open total aortic arch replacement', 'patients receiving open total aortic arch replacement']","['remote ischemic preconditioning', 'RIPC', 'remote ischemic preconditioning (RIPC']",['postoperative AKI'],"[{'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3697092', 'cui_str': 'Aortic arch replacement'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0376466', 'cui_str': 'Ischemic Pre-Conditioning'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}]",,0.491524,"Significantly fewer RIPC-treated patients than sham-treated patients developed postoperative AKI, and, epically, RIPC significantly reduced serious AKI (stage II-III).","[{'ForeName': 'Yimeng', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng District, Beijing, 100037, China.'}, {'ForeName': 'Guyan', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng District, Beijing, 100037, China. guyanwang2006@163.com.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Lijing', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng District, Beijing, 100037, China.'}, {'ForeName': 'Congya', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng District, Beijing, 100037, China.'}, {'ForeName': 'Xiying', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng District, Beijing, 100037, China.'}, {'ForeName': 'Guiyu', 'Initials': 'G', 'LastName': 'Lei', 'Affiliation': 'Department of Anesthesiology, Beijng Tongren Hospital, Capital Medical University, No. 1 Dongjiaominxiang, Dongcheng District, Beijing, 100730, China.'}]",BMC anesthesiology,['10.1186/s12871-020-01085-9'] 321,32649961,The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial.,"BACKGROUND Platelet-rich plasma (PRP) may be a useful treatment for androgenetic alopecia (AGA), although objective studies are needed. OBJECTIVE To determine whether PRP injections improve female AGA. METHOD Prospective randomized controlled trial of 30 women diagnosed with AGA. Patients received subdermal scalp injections of Eclipse system PRP or placebo saline at weeks 0, 4, and 8. Outcome measures were changes in hair density (hair/cm 2 ), hair caliber (mm), and blinded global photographic assessment (improved or not improved) at week 24. RESULTS Blinded global photographic assessment indicated that 57% of patients receiving PRP versus 7% of patients receiving saline improved at week 24 from baseline (P < .01). Compared to baseline, there was improvement in mean density in the PRP group versus the placebo group at week 8 (+71.1 vs -26.7 hairs/cm 2 ; P < .01) and week 24 (+105.9 vs -52.4 hairs/cm 2 ; P < .01). Compared to baseline, there was improvement in mean caliber in the PRP group versus the placebo group at week 8 (+0.0043 vs -0.0034 mm; P < .01) and week 24 (+0.0053 vs -0.0060 mm; P < .01). Adverse effects included headache, scalp tightness, swelling, redness, and postinjection bleeding. LIMITATIONS Two patients lost to follow-up. CONCLUSIONS PRP with the Eclipse system is a safe and effective intervention for female AGA.",2020,"Compared to baseline, there was improvement in mean caliber in the PRP group vs. the placebo group at week 8 (+0.0043 vs. -0.0034 mm, p<0.01) and week 24 (+0.0053 vs. -0.0060 mm, p<0.01).","['30 females diagnosed with AGA', 'female androgenetic alopecia', 'androgenetic alopecia (AGA']","['subdermal scalp injections of Eclipse system PRP or placebo saline', 'PRP injections', 'platelet-rich plasma', 'placebo']","['mean caliber', 'headache, scalp tightness, swelling, redness, and post-injection bleeding', 'mean density', 'changes in hair density (hair/cm 2 ), hair caliber (mm), and blinded global photographic assessment']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}]","[{'cui': 'C0036270', 'cui_str': 'Scalp structure'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0036270', 'cui_str': 'Scalp structure'}, {'cui': 'C0439816', 'cui_str': 'Tightness sensation quality'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",30.0,0.356908,"Compared to baseline, there was improvement in mean caliber in the PRP group vs. the placebo group at week 8 (+0.0043 vs. -0.0034 mm, p<0.01) and week 24 (+0.0053 vs. -0.0060 mm, p<0.01).","[{'ForeName': 'Danielle P', 'Initials': 'DP', 'LastName': 'Dubin', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: DPDubin121@gmail.com.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Lin', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Hayley M', 'Initials': 'HM', 'LastName': 'Leight', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Aaron S', 'Initials': 'AS', 'LastName': 'Farberg', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; Arkansas Dermatology, Little Rock, Arkansas.'}, {'ForeName': 'Richard L', 'Initials': 'RL', 'LastName': 'Torbeck', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'William B', 'Initials': 'WB', 'LastName': 'Burton', 'Affiliation': 'Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Hooman', 'Initials': 'H', 'LastName': 'Khorasani', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.06.1021'] 322,32668005,Effectiveness of a Technology-Enhanced Integrated Care Model for Frail Older People: A Stepped-Wedge Cluster Randomized Trial in Nursing Homes.,"BACKGROUND AND OBJECTIVES The objective of this study was to evaluate the impact of an information and communication technologies (ICT)-enhanced, multidisciplinary integrated care model, called Systems for Person-centered Elder Care (SPEC), on frail older adults at nursing homes. RESEARCH DESIGN AND METHODS SPEC was implemented at 10 nursing homes in South Korea in random order using a stepped-wedge design. Data were collected on all participating older residents in the homes before the first implementation and until 6 months after the last implementation. The 21-month SPEC intervention guided by the chronic care model (CCM) consists of 5 strategies: comprehensive geriatric assessment, care planning, optional interdisciplinary case conferences, care coordination, and a cloud-based ICT tool along with a free messaging app. The primary outcome was quality of care measured by a composite quality indicator (QI) from the interRAI assessment system. Usual care continued over the control periods. Nursing home staff were not blinded to the intervention. RESULTS There were a total of 482 older nursing home residents included in the analysis. Overall quality of care measured by the composite QI was significantly improved (adjusted mean difference: -0.025 [95% CI: -0.037 to -0.014, p < .0001]). The intervention effect was consistent in the subgroup analysis by cognition and activities of daily living. There were no important adverse events or side effects. DISCUSSION AND IMPLICATIONS The SPEC, a CCM-guided, ICT-supported, multidisciplinary integrated care management intervention, can improve the quality of care measured by health and functional outcomes for frail older persons residing in nursing homes with limited health care provision. CLINICAL TRIALS REGISTRATION NUMBER ISRCTN11972147.",2021,Overall quality of care measured by the composite QI was significantly improved (adjusted mean difference: -0.025,"['SPEC was implemented at ten nursing homes in South Korea in random order using a stepped-wedge design', 'participating older residents in the homes before the first implementation and until six months after the last implementation', 'frail older persons residing in nursing homes with limited healthcare provision', 'Frail Older People', '482 older nursing home residents included in the analysis', 'Nursing Homes', 'frail older adults at nursing homes']","['information and communication technologies', 'multidisciplinary integrated care model, called Systems for Person-centered Elder Care (SPEC', 'SPEC intervention guided by the chronic care model (CCM) consists of five strategies: comprehensive geriatric assessment, care planning, optional interdisciplinary case conferences, care coordination, and a cloud-based ICT tool along with free messaging app', 'Technology-Enhanced Integrated Care Model']","['Overall quality of care measured by the composite QI', 'cognition and activities of daily living', 'quality of care measured by a composite quality indicator (QI) from the interRAI assessment system']","[{'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439639', 'cui_str': 'Wedge'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}]","[{'cui': 'C0683867', 'cui_str': 'Information Technology'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0419193', 'cui_str': 'Care of aged'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0017463', 'cui_str': 'Geriatric screening'}, {'cui': 'C0178916', 'cui_str': 'Care plan'}, {'cui': 'C0556657', 'cui_str': 'Case conference'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",482.0,0.0605142,Overall quality of care measured by the composite QI was significantly improved (adjusted mean difference: -0.025,"[{'ForeName': 'Hongsoo', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, South Korea.'}, {'ForeName': 'Young-Il', 'Initials': 'YI', 'LastName': 'Jung', 'Affiliation': 'Department of Environmental Health, Korea National Open University, Seoul, South Korea.'}, {'ForeName': 'Gi-Soo', 'Initials': 'GS', 'LastName': 'Kim', 'Affiliation': 'Department of Statistics, Seoul National University, South Korea.'}, {'ForeName': 'Hyoungshim', 'Initials': 'H', 'LastName': 'Choi', 'Affiliation': 'College of Nursing, Hansei University, Gunpo, South Korea.'}, {'ForeName': 'Yeon-Hwan', 'Initials': 'YH', 'LastName': 'Park', 'Affiliation': 'College of Nursing, Research Institute of Nursing Science, Seoul National University, South Korea.'}]",The Gerontologist,['10.1093/geront/gnaa090'] 323,33068792,Impact of Treating Physician on Radiation Therapy Related Severe Toxicities in Men with Prostate Cancer.,"PURPOSE The impact of treating physician on radiation therapy (RT) related toxicity is unclear. We carried out a secondary analysis of a randomized controlled study to determine whether the risk of RT-related late toxicities in patients with prostate cancer varies depending on the treating radiation oncologist. METHODS AND MATERIALS This is a secondary analysis of a phase 3 randomized controlled study in which patients with prostate cancer with Gleason score ≤7, clinical stage T1b-T3a, and prostate-specific antigen <30 ng/mL were randomized to receive androgen suppression for 6 months, starting either 4 months before or concurrently with definitive prostate radiation therapy. Incidence of late RT-related toxicity was estimated using Kaplan-Meier methods. We applied multivariable semiparametric shared frailty models with gamma distribution to determine the between-physician variation in the hazard of late RT-related grade ≥3 gastrointestinal, genitourinary, or overall toxicity. Patient level covariables included age, risk group, year of enrollment, and treatment regimen. Frailty variance, a measure of unexplained heterogeneity, was estimated with 95% confidence intervals (CIs). Statistical significance was suggested when the lower limit of the 95% CI for the frailty variance was >0. The Commenges-Andersen test was used for P value estimation. RESULTS Overall, 426 patients were treated by 9 radiation oncologists. On log-rank test, there was a significant difference in the cumulative incidence of overall grade ≥3 toxicities (P = .001) and grade ≥3 gastrointestinal toxicity (P = .01) among the physician-based clusters. The frailty variance for overall late grade ≥3 toxicity was 0.31 (95% CI, 0.02-1.39; P = .01). The frailty variance for the grade ≥3 gastrointestinal and genitourinary toxicity was 0.84 (95% CI, 0.00-4.20; P = .11) and 0.11 (95% CI, 0.00-1.13; P = .31), respectively. CONCLUSIONS In our study, the hazard of overall RT-related late grade ≥3 toxicity varied significantly depending on treating radiation oncologist. Further studies are required to explore the underlying processes that lead to such variations in clinical trials involving radiation therapy in prostate cancer.",2021,The frailty variance for the grade ≥3 gastrointestinal and genitourinary toxicity was 0.84,"['prostate cancer (PCa) patients', 'Men with Prostate Cancer', 'PCa patients with Gleason score ≤7, clinical stage T1b-T3a and prostate-specific', '426 patients were treated by 9 radiation oncologists']","['androgen suppression', 'definitive prostate radiotherapy', 'radiotherapy', 'Radiotherapy']","['grade ≥3 gastrointestinal', 'grade ≥3 gastrointestinal and genitourinary toxicity', 'hazard of overall radiotherapy-related late grade ≥3 toxicity', 'Incidence of late radiotherapy-related toxicity', 'cumulative incidence of overall grade ≥3 toxicities', 'Frailty variance', 'frailty variance for overall late grade ≥3 toxicity']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332326', 'cui_str': 'Gleason grading system for prostatic cancer'}, {'cui': 'C0205563', 'cui_str': 'Clinical stage finding'}, {'cui': 'C0475385', 'cui_str': 'Tumor stage T1b'}, {'cui': 'C0475390', 'cui_str': 'Tumor stage T3a'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C1514693', 'cui_str': 'Radiation oncologist'}]","[{'cui': 'C0002844', 'cui_str': 'Androgen'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0443196', 'cui_str': 'Definitive'}, {'cui': 'C0948317', 'cui_str': 'Radiotherapy to prostate'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0042066', 'cui_str': 'Structure of genitourinary system'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}]",426.0,0.201391,The frailty variance for the grade ≥3 gastrointestinal and genitourinary toxicity was 0.84,"[{'ForeName': 'Soumyajit', 'Initials': 'S', 'LastName': 'Roy', 'Affiliation': 'New York Medical College, New York, New York; The Ottawa Hospital Cancer Centre, Ottawa, Canada; Division of Radiation Oncology, Department of Radiology, University of Ottawa, Ontario, Canada.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Grimes', 'Affiliation': 'The Ottawa Hospital Cancer Centre, Ottawa, Canada.'}, {'ForeName': 'Scott C', 'Initials': 'SC', 'LastName': 'Morgan', 'Affiliation': 'The Ottawa Hospital Cancer Centre, Ottawa, Canada; Division of Radiation Oncology, Department of Radiology, University of Ottawa, Ontario, Canada.'}, {'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Spratt', 'Affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Libni', 'Initials': 'L', 'LastName': 'Eapen', 'Affiliation': 'The Ottawa Hospital Cancer Centre, Ottawa, Canada; Division of Radiation Oncology, Department of Radiology, University of Ottawa, Ontario, Canada.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Mac Rae', 'Affiliation': 'The Ottawa Hospital Cancer Centre, Ottawa, Canada; Division of Radiation Oncology, Department of Radiology, University of Ottawa, Ontario, Canada.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Malone', 'Affiliation': 'The Ottawa Hospital Cancer Centre, Ottawa, Canada.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Craig', 'Affiliation': 'The Ottawa Hospital Cancer Centre, Ottawa, Canada.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Malone', 'Affiliation': 'The Ottawa Hospital Cancer Centre, Ottawa, Canada; Division of Radiation Oncology, Department of Radiology, University of Ottawa, Ontario, Canada. Electronic address: smalone@toh.ca.'}]",Practical radiation oncology,['10.1016/j.prro.2020.09.013'] 324,33087250,Metabolomic basis for response to high dose vitamin D in critical illness.,"BACKGROUND & AIMS It is unclear if intervention can mitigate the dramatic alterations of metabolic homeostasis present in critical illness. Our objective was to determine the associations between increased 25-hydroxyvitamin D levels following high dose vitamin D 3 and more favorable metabolomic profiles in critical illness. METHODS We performed a post-hoc metabolomics study of the VITdAL-ICU randomized double-blind, placebo-controlled trial. Trial patients from Medical and Surgical Intensive Care Units at a tertiary university hospital with 25-hydroxyvitamin D level ≤20 ng/mL received either high dose oral vitamin D 3 (540,000 IU) or placebo. We performed an analysis of 578 metabolites from 1215 plasma samples from 428 subjects at randomization (day 0), day 3 and 7. Using mixed-effects modeling, we studied changes in metabolite profiles in subjects receiving intervention or placebo relative to absolute increases in 25-hydroxyvitamin D levels from day 0 to day 3. RESULTS 55.2% of subjects randomized to high dose vitamin D 3 demonstrated an absolute increase in 25-hydroxyvitamin D ≥ 15 ng/ml from day 0 to day 3. With an absolute increase in 25-hydroxyvitamin D ≥ 15 ng/ml, multiple members of the sphingomyelin, plasmalogen, lysoplasmalogen and lysophospholipid metabolite classes had significantly positive Bonferroni corrected associations over time. Further, multiple representatives of the acylcarnitine and phosphatidylethanolamine metabolite classes had significantly negative Bonferroni corrected associations over time with an absolute increase in 25-hydroxyvitamin D ≥ 15 ng/ml. Changes in these highlighted metabolite classes were associated with decreased 28-day mortality. CONCLUSIONS Increases in 25-hydroxyvitamin D following vitamin D 3 intervention are associated with favorable changes in metabolites involved in endothelial protection, enhanced innate immunity and improved mitochondrial function.",2021,55.2% of subjects randomized to high dose vitamin D 3 demonstrated an absolute increase in 25-hydroxyvitamin D ≥ ,"['Trial patients from Medical and Surgical Intensive Care Units at a tertiary university hospital with 25-hydroxyvitamin D level ≤20\xa0ng/mL received either', '578 metabolites from 1215 plasma samples from 428 subjects at randomization (day 0), day 3 and 7', 'subjects receiving intervention or', '15']","['placebo', 'high dose oral vitamin D 3 (540,000 IU) or placebo']","['28-day mortality', '25-hydroxyvitamin D levels', '25-hydroxyvitamin D\xa0≥', 'metabolite profiles']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1948041', 'cui_str': 'Surgical and medical procedures'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C4517775', 'cui_str': '428'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}]",,0.65149,55.2% of subjects randomized to high dose vitamin D 3 demonstrated an absolute increase in 25-hydroxyvitamin D ≥ ,"[{'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Amrein', 'Affiliation': 'Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Lasky-Su', 'Affiliation': ""Channing Division of Network Medicine, Brigham and Women's Hospital, USA.""}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Dobnig', 'Affiliation': 'Thyroid Endocrinology Osteoporosis Institute Dobnig, Graz, Austria.'}, {'ForeName': 'Kenneth B', 'Initials': 'KB', 'LastName': 'Christopher', 'Affiliation': ""Division of Renal Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital, USA. Electronic address: kbchristopher@bwh.harvard.edu.""}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.09.028'] 325,33087330,Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial.,"PURPOSE Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab efficacy in optimally selected patients using highly sensitive beads, emulsion, amplification, and magnetics (BEAMing) analysis, capable of detecting alterations below standard clinical assays. PATIENTS AND METHODS CO.17 trial compared cetuximab versus best supportive care (BSC) in RAS/BRAF -unselected mCRC. We performed RAS/BRAF analysis on microdissected tissue of 242 patients in CO.17 trial using BEAMing for KRAS/NRAS (codons 12/13/59/61/117/146) and BRAF V600E. Patients without BEAMing but with previous Sanger sequencing-detected mutations were included. RESULTS KRAS, NRAS , and BRAF mutations were present in 53%, 4%, and 3% of tumors, respectively. Cetuximab improved overall survival [OS; HR, 0.51; 95% confidence interval (CI), 0.32-0.81; P = 0.004] and progression-free survival (PFS; HR, 0.25; 95% CI, 0.15-0.41; P < 0.0001) compared with BSC in RAS/BRAF wild-type patients. Cetuximab did not improve OS/PFS for KRAS-, NRAS- , or BRAF- mutated tumors, and tests of interaction confirmed expanded KRAS ( P = 0.0002) and NRAS ( P = 0.006) as predictive, while BRAF mutations were not ( P = 0.089). BEAMing identified 14% more tumors as RAS mutant than Sanger sequencing, and cetuximab lacked activity in these patients. Mutations at MAF < 5% were noted in 6 of 242 patients (2%). One patient with a KRAS A59T mutation (MAF = 2%) responded to cetuximab. More NRAS than KRAS mutations were low MAF (OR, 20.50; 95% CI, 3.88-96.85; P = 0.0038). CONCLUSIONS We establish single-agent cetuximab efficacy in optimally selected patients and show that subclonal RAS/BRAF alterations are uncommon and remain of indeterminate significance.",2021,"Cetuximab improved overall survival (OS) (HR 0.51, 95% CI 0.32-0.81, P=0.004) and progression free survival (PFS) (HR 0.25, 95% CI 0.15-0.41, P<0.0001) compared to BSC in RAS/BRAF wild type patients.",['metastatic colorectal cancer (mCRC) and'],"['Cetuximab', 'cetuximab versus best supportive care (BSC', 'cetuximab']","['overall survival (OS', 'KRAS, NRAS, and BRAF mutations', 'progression free survival (PFS', 'NRAS', 'OS/PFS for KRAS, NRAS, or BRAF mutated tumors and tests of interaction confirmed expanded KRAS']","[{'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}]","[{'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0344211', 'cui_str': 'Support'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1259929', 'cui_str': 'BRAF protein, human'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}]",242.0,0.136332,"Cetuximab improved overall survival (OS) (HR 0.51, 95% CI 0.32-0.81, P=0.004) and progression free survival (PFS) (HR 0.25, 95% CI 0.15-0.41, P<0.0001) compared to BSC in RAS/BRAF wild type patients.","[{'ForeName': 'Jonathan M', 'Initials': 'JM', 'LastName': 'Loree', 'Affiliation': 'BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Dowers', 'Affiliation': 'The University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Dongsheng', 'Initials': 'D', 'LastName': 'Tu', 'Affiliation': 'Canadian Cancer Trials Group, Kingston, Ontario, Canada.'}, {'ForeName': 'Derek J', 'Initials': 'DJ', 'LastName': 'Jonker', 'Affiliation': 'The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Daniel L', 'Initials': 'DL', 'LastName': 'Edelstein', 'Affiliation': 'Sysmex-Inostics, Baltimore, Maryland.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Quinn', 'Affiliation': 'Sysmex-Inostics, Baltimore, Maryland.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Holtrup', 'Affiliation': 'Sysmex-Inostics, Baltimore, Maryland.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Price', 'Affiliation': 'Queen Elizabeth Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Zalcberg', 'Affiliation': 'Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Malcolm J', 'Initials': 'MJ', 'LastName': 'Moore', 'Affiliation': 'BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Christos S', 'Initials': 'CS', 'LastName': 'Karapetis', 'Affiliation': 'Flinders University, Adelaide, South Australia, Australia.'}, {'ForeName': 'Chris J', 'Initials': 'CJ', 'LastName': ""O'Callaghan"", 'Affiliation': 'Canadian Cancer Trials Group, Kingston, Ontario, Canada.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Waring', 'Affiliation': 'The University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Hagen F', 'Initials': 'HF', 'LastName': 'Kennecke', 'Affiliation': 'Virginia Mason Cancer Institute, Seattle, Washington.'}, {'ForeName': 'Stanley R', 'Initials': 'SR', 'LastName': 'Hamilton', 'Affiliation': 'City of Hope, Los Angeles, California.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Kopetz', 'Affiliation': 'University of Texas, MD Anderson Cancer Center, Houston, Texas. skopetz@mdanderson.org.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-2710'] 326,32618538,Influence of pre-schooler and parent nutrition education on carotenoid levels of Mexican-heritage children.,"OBJECTIVE To determine the mediating effect of direct preschool and parent nutrition education on changes in skin carotenoids scores over 2 years in children of Mexican heritage. DESIGN In a quasi-experimental, community-based study, two school districts were randomly assigned to either a comparison group (parent workshops unrelated to nutrition) or a childhood obesity prevention intervention group which included nutrition education at family nights for parents and at school for children. Changes in skin carotenoid intensity scores (diffCAROT, year 2015 minus 2013) were measured in children as a proxy for fruit and vegetable consumption using Resonance Raman Spectroscopy. SETTING Two rural, low-income, school districts from a county in California's Central Valley. PARTICIPANTS 316 Mexican heritage families with children aged 3-8 years. RESULTS Intervention group children improved over 2 years in skin carotenoid scores relative to comparison group children (diffCAROT mean +1419 (sd 9540) v. -3473 (sd 9272), P = 0·0001). Parent attendance at nutrition education classes partially mediated the intervention effect on diffCAROT (P = 0·02). Controlling for child's age and other covariates, participation in preschool during the study had a significant positive effect on diffCAROT among intervention children compared with controls (P < 0·03), whereas no significant difference by group was observed among those not enrolled in preschool or already enrolled in elementary school. CONCLUSIONS Programmes that combine direct parent and preschool nutrition education may be effective in low-income Mexican heritage families to improve children's intake of fruit and vegetables.",2020,"RESULTS Intervention group children improved over 2 years in skin carotenoid scores relative to comparison group children (diffCAROT mean +1419 (sd 9540) v. -3473 (sd 9272), P = 0·0001).","['316 Mexican heritage families with children aged 3-8 years', ""Two rural, low-income, school districts from a county in California's Central Valley"", 'In a quasi-experimental, community-based study, two school districts', 'children of Mexican heritage', 'Mexican-heritage children']","['direct preschool and parent nutrition education', 'pre-schooler and parent nutrition education', 'comparison group (parent workshops unrelated to nutrition) or a childhood obesity prevention intervention group which included nutrition education at family nights for parents and at school for children']","['skin carotenoid scores', 'skin carotenoid intensity scores', 'skin carotenoids scores']","[{'cui': 'C0450356', 'cui_str': '316'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0563004', 'cui_str': 'Valley'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0680063', 'cui_str': 'Child of'}]","[{'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0445356', 'cui_str': 'Unrelated'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C2362324', 'cui_str': 'Childhood obesity'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",,0.0238306,"RESULTS Intervention group children improved over 2 years in skin carotenoid scores relative to comparison group children (diffCAROT mean +1419 (sd 9540) v. -3473 (sd 9272), P = 0·0001).","[{'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Horowitz', 'Affiliation': 'University of California Cooperative Extension, Yolo County, Woodland, CA95695, USA.'}, {'ForeName': 'Lucia L', 'Initials': 'LL', 'LastName': 'Kaiser', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Rosa D', 'Initials': 'RD', 'LastName': 'Manzo', 'Affiliation': 'Health Sciences Research Institute, University of California, Merced, CA, USA.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Aguilera', 'Affiliation': 'Department of Public Health, University of California, Merced, CA, USA.'}, {'ForeName': 'L Karina', 'Initials': 'LK', 'LastName': 'Diaz Rios', 'Affiliation': 'Division of Agriculture and Natural Resources, University of California, Merced, CA, USA.'}, {'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'Macias', 'Affiliation': 'University of California Cooperative Extension, Fresno County, CA, USA.'}]",Public health nutrition,['10.1017/S1368980019004579'] 327,32619612,"Comparison of different incremental dose regimens of narrow-band ultraviolet B in skin types III to V: A prospective, randomized, single-blind, parallel study in patients with psoriasis.",,2021,,['patients with psoriasis'],['narrow-band ultraviolet B'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C1532472', 'cui_str': 'Ultra-violet'}]",[],,0.0136611,,"[{'ForeName': 'Yingyuan', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, and the Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xuemei', 'Initials': 'X', 'LastName': 'Yi', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, and the Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, and the Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Yu', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, and the Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Yu', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, and the Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Qianlian', 'Initials': 'Q', 'LastName': 'Le', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, and the Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Zeyu', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, and the Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yangfeng', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, and the Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China. Electronic address: dingyangfeng@hotmail.com.'}, {'ForeName': 'Yuling', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, and the Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China. Electronic address: shiyuling1973@tongji.edu.cn.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.06.993'] 328,32621543,Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.,"MHAA4549A is a human anti-influenza A monoclonal antibody developed to treat influenza A. We report MHAA4549A serum, nasopharyngeal, and tracheal aspirate pharmacokinetics from a phase 2b study in hospitalized patients with severe influenza A. Patients were randomized 1:1:1 into 3 groups receiving single intravenous doses of 3600 mg (n = 55) or 8400 mg (n = 47) MHAA4549A or placebo (n = 56). Patients also received oral oseltamivir twice daily for ≥5 days. Serum, nasopharyngeal, and tracheal aspirate pharmacokinetic samples were collected on days 1-60 from MHAA4549A-treated groups. Day 5 plasma samples from all groups were collected for assessing the pharmacokinetics of oseltamivir and its active metabolite, oseltamivir carboxylate. Noncompartmental pharmacokinetic analysis was performed using Phoenix WinNonlin. Data were collected during a preplanned interim analysis that became final when the trial terminated because of a lack of efficacy. Serum MHAA4549A concentrations were dose-proportional and biphasic. Mean MHAA4549A clearance was 288-350 mL/day, and mean half-life was 17.8-19.0 days. Nasopharyngeal MHAA4549A concentrations were non-dose-proportional. We detected MHAA4549A in tracheal aspirate samples, but intersubject variability was high. MHAA4549A serum and nasopharyngeal exposures were confirmed in all MHAA4549A-treated patients. Serum MHAA4549A had faster clearance and a shorter half-life in influenza A-infected patients compared with healthy subjects. MHAA4549A detection in tracheal aspirate samples indicated exposure in the lower respiratory tract. Oseltamivir and oseltamivir carboxylate exposures were similar between MHAA4549A-treated and placebo groups, suggesting a lack of MHAA4549A interference with oseltamivir pharmacokinetics.",2020,Serum MHAA4549A had faster clearance and a shorter half-life in influenza A-infected patients compared with healthy subjects.,"['Patients Hospitalized With Severe Influenza A Infection', 'hospitalized patients with severe influenza A. Patients']","['MHAA4549A-treated and placebo', 'oral oseltamivir', 'Monoclonal Antibody MHAA4549A', 'MHAA4549A', 'MHAA4549A or placebo']","['Serum, nasopharyngeal, and tracheal aspirate pharmacokinetic samples', 'MHAA4549A serum and nasopharyngeal exposures', 'Serum MHAA4549A concentrations', 'Mean MHAA4549A clearance', 'Nasopharyngeal MHAA4549A concentrations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1615607', 'cui_str': 'Influenza A virus subtype H1N1'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}]","[{'cui': 'C5139963', 'cui_str': 'MHAA4549A'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0874161', 'cui_str': 'Oseltamivir'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027442', 'cui_str': 'Nasopharyngeal'}, {'cui': 'C2919642', 'cui_str': 'Specimen from trachea obtained by aspiration'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C5139963', 'cui_str': 'MHAA4549A'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}]",,0.04558,Serum MHAA4549A had faster clearance and a shorter half-life in influenza A-infected patients compared with healthy subjects.,"[{'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Deng', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Gaohong', 'Initials': 'G', 'LastName': 'She', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Mauricio', 'Initials': 'M', 'LastName': 'Maia', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Jeremy J', 'Initials': 'JJ', 'LastName': 'Lim', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Melicent C', 'Initials': 'MC', 'LastName': 'Peck', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Jacqueline M', 'Initials': 'JM', 'LastName': 'McBride', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Priya', 'Initials': 'P', 'LastName': 'Kulkarni', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Priscilla', 'Initials': 'P', 'LastName': 'Horn', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Aide', 'Initials': 'A', 'LastName': 'Castro', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Newton', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'Jorge A', 'Initials': 'JA', 'LastName': 'Tavel', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Hanley', 'Affiliation': 'Genentech, Inc, South San Francisco, California, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1652'] 329,32631301,"The clinical effect of dexmedetomidine combined with parecoxib sodium on sedation, antianxiety and prevention of intubation stress in patients undergoing functional endoscopic sinus surgery: a randomised controlled trial.","BACKGROUND To investigate the effect of intravenous injection of dexmedetomidine combined with parecoxib sodium on sedation and anxiety and stress response of tracheal intubation in patients undergoing functional endoscopic sinus surgery. METHODS One hundred twenty patients undergoing endoscopic sinus surgery were randomly divided into four groups: group DP, group D, group P and group N. The blood pressure (BP), heart rate (HR), blood oxygen saturation (SPO2), EEG, bispectral index (BIS), Ramsay sedation score and state anxiety questionnaire (SAI) were recorded before administration (T0), 10 min (T1), 20 min (T2) and 30 min (T3) after administration. After 30 min, endotracheal intubation was performed after anesthesia induction. The BP, HR, SPO2 were recorded 1 min before intubation (T4), intubation (T5), 3 min (T6) after intubation, 5 min (T7) after intubation, and blood samples were collected from patients before administration and after intubation 2 min to detect serum cortisol (Cor), adrenalin (E) norepinephrine (NE) and blood glucose (BS). RESULTS There was no significant difference in Ramsay sedation score before anesthesia, but the Ramsay sedation score in group D、DP was significantly higher than that in group P and group N, the BIS, BP, HR and anxiety scores were significantly lower than those in the group P and group N (p < 0.05). There was no significant difference in Ramsay sedation score, BIS value, anxiety score and BP, HR between group D and group DP (p > 0.05). Compared with T4, there was no significant difference in BIS and BP, HR in group D, group DP and group P (p > 0.05), but the BIS, BP and HR in group N were significantly higher than T4, (p < 0.05). Three minutes after intubation there was no statistical difference in the changes of Cor, E, NE and BS values compared with before intubation in group P and group DP (p > 0.05), but the changes of Cor, E, NE and BS values were significantly lower than that in group N (p < 0.05). Compared with T0, the values of NE, E, Cor, BS decreased in group D, DP and P at T4, group DP decreased more significantly than group D (p < 0.05). while the NE, E, Cor, BS of T6 are at the same level as the base value. In group N, the NE, E, Cor, BS of T4 were at the same level of T0, but significantly higher at T6.And at T6, NE and E in group D, P and N were significantly different from those in group DP (p < 0.05). CONCLUSION Preoperative intravenous infusion of dexmedetomidine combined with parecoxib sodium by functional nasal endoscopy can not only calm and resist anxiety, but also better prevent stress response of endotracheal intubation, which is a safe and effective way of preoperative medication. TRIAL REGISTRATION ChiCTR-OPN-17010444 . Prospectively registered on 16 January 2017.",2020,"Compared with T0, the values of NE, E, Cor, BS decreased in group D, DP and P at T4, group DP decreased more significantly than group D (p < 0.05).","['Prospectively registered on 16 January 2017', 'patients undergoing functional endoscopic sinus surgery', 'One hundred twenty patients undergoing endoscopic sinus surgery']","['endotracheal intubation', 'dexmedetomidine', 'parecoxib sodium']","['BIS and BP, HR', 'BIS, BP and HR', 'sedation, antianxiety and prevention of intubation stress', 'Ramsay sedation score, BIS value, anxiety score and BP, HR', 'BIS, BP, HR and anxiety scores', 'serum cortisol (Cor), adrenalin (E) norepinephrine (NE) and blood glucose (BS', 'sedation and anxiety and stress response', 'values of NE, E, Cor, BS', 'BP, HR, SPO2', 'changes of Cor, E, NE and BS values', 'blood pressure (BP), heart rate (HR), blood oxygen saturation (SPO2), EEG, bispectral index (BIS), Ramsay sedation score and state anxiety questionnaire (SAI', 'Ramsay sedation score']","[{'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442968', 'cui_str': 'Functional endoscopic sinus surgery'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0748725', 'cui_str': 'Sinus operation'}]","[{'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0915144', 'cui_str': 'Parecoxib sodium'}]","[{'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0236396', 'cui_str': 'Serum cortisol measurement'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",120.0,0.034208,"Compared with T0, the values of NE, E, Cor, BS decreased in group D, DP and P at T4, group DP decreased more significantly than group D (p < 0.05).","[{'ForeName': 'Xiaoxia', 'Initials': 'X', 'LastName': 'Gu', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital, Jinan University, No. 601 West Huangpu Avenue, Tianhe District, Guangzhou City, 510632, Guangdong Province, China.'}, {'ForeName': 'Xiujuan', 'Initials': 'X', 'LastName': 'Tan', 'Affiliation': ""Department of Anesthesiology, the Affiliated Hospital of Guangdong Medical University, No. 57 South People's Avenue, Xiashan District, Zhanjiang City, 524001, Guangdong Province, China.""}, {'ForeName': 'Jinxian', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Department of Anesthesiology, the Affiliated Hospital of Guangdong Medical University, No. 57 South People's Avenue, Xiashan District, Zhanjiang City, 524001, Guangdong Province, China.""}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, the Affiliated Hospital of Guangdong Medical University, No. 57 South People's Avenue, Xiashan District, Zhanjiang City, 524001, Guangdong Province, China.""}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': ""Department of Anesthesiology, the Affiliated Hospital of Guangdong Medical University, No. 57 South People's Avenue, Xiashan District, Zhanjiang City, 524001, Guangdong Province, China.""}, {'ForeName': 'Liangqing', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, the Affiliated Hospital of Guangdong Medical University, No. 57 South People's Avenue, Xiashan District, Zhanjiang City, 524001, Guangdong Province, China. gu7450210@163.com.""}]",BMC anesthesiology,['10.1186/s12871-020-01080-0'] 330,32656955,High-Resolution Breast MRI Reconstruction Using a Deep Convolutional Generative Adversarial Network.,"BACKGROUND A generative adversarial network could be used for high-resolution (HR) medical image synthesis with reduced scan time. PURPOSE To evaluate the potential of using a deep convolutional generative adversarial network (DCGAN) for generating HR pre and HR post images based on their corresponding low-resolution (LR) images (LR pre and LR post ). STUDY TYPE This was a retrospective analysis of a prospectively acquired cohort. POPULATION In all, 224 subjects were randomly divided into 200 training subjects and an independent 24 subjects testing set. FIELD STRENGTH/SEQUENCE Dynamic contrast-enhanced (DCE) MRI with a 1.5T scanner. ASSESSMENT Three breast radiologists independently ranked the image datasets, using the DCE images as the ground truth, and reviewed the image quality of both the original LR images and the generated HR images. The BI-RADS category and conspicuity of lesions were also ranked. The inter/intracorrelation coefficients (ICCs) of mean image quality scores, lesion conspicuity scores, and Breast Imaging Reporting and Data System (BI-RADS) categories were calculated between the three readers. STATISTICAL TEST Wilcoxon signed-rank tests evaluated differences among the multireader ranking scores. RESULTS The mean overall image quality scores of the generated HR pre and HR post were significantly higher than those of the original LR pre and LR post (4.77 ± 0.41 vs. 3.27 ± 0.43 and 4.72 ± 0.44 vs. 3.23 ± 0.43, P < 0.0001, respectively, in the multireader study). The mean lesion conspicuity scores of the generated HR pre and HR post were significantly higher than those of the original LR pre and LR post (4.18 ± 0.70 vs. 3.49 ± 0.58 and 4.35 ± 0.59 vs. 3.48 ± 0.61, P < 0.001, respectively, in the multireader study). The ICCs of the image quality scores, lesion conspicuity scores, and BI-RADS categories had good agreements among the three readers (all ICCs >0.75). DATA CONCLUSION DCGAN was capable of generating HR of the breast from fast pre- and postcontrast LR and achieved superior quantitative and qualitative performance in a multireader study. LEVEL OF EVIDENCE 3 TECHNICAL EFFICACY STAGE: 2 J. MAGN. RESON. IMAGING 2020;52:1852-1858.",2020,"The mean overall image quality scores of the generated HR pre and HR post were significantly higher than those of the original LR pre and LR post (4.77 ± 0.41 vs. 3.27 ± 0.43 and 4.72 ± 0.44 vs. 3.23 ± 0.43, P < 0.0001, respectively, in the multireader study).",['224 subjects were randomly divided into 200 training subjects and an independent 24 subjects testing set'],['deep convolutional generative adversarial network (DCGAN'],"['intracorrelation coefficients (ICCs) of mean image quality scores, lesion conspicuity scores, and Breast Imaging Reporting and Data System (BI-RADS) categories', 'ICCs of the image quality scores, lesion conspicuity scores, and BI-RADS categories', 'mean lesion conspicuity scores of the generated HR pre and HR post', 'mean overall image quality scores of the generated HR pre and HR post']","[{'cui': 'C4319560', 'cui_str': '224'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]","[{'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C1622900', 'cui_str': 'Data Systems'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",224.0,0.0301274,"The mean overall image quality scores of the generated HR pre and HR post were significantly higher than those of the original LR pre and LR post (4.77 ± 0.41 vs. 3.27 ± 0.43 and 4.72 ± 0.44 vs. 3.23 ± 0.43, P < 0.0001, respectively, in the multireader study).","[{'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Sun', 'Affiliation': 'Department of Radiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Liangqiong', 'Initials': 'L', 'LastName': 'Qu', 'Affiliation': 'Department of Radiology and BRIC, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Chunfeng', 'Initials': 'C', 'LastName': 'Lian', 'Affiliation': 'Department of Radiology and BRIC, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Yongsheng', 'Initials': 'Y', 'LastName': 'Pan', 'Affiliation': 'Department of Radiology and BRIC, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Hu', 'Affiliation': 'Department of Radiology and BRIC, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Bingqing', 'Initials': 'B', 'LastName': 'Xia', 'Affiliation': 'Department of Radiology, International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xinyue', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Radiology, Ruijin Hospital Luwan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Weimin', 'Initials': 'W', 'LastName': 'Chai', 'Affiliation': 'Department of Radiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Fuhua', 'Initials': 'F', 'LastName': 'Yan', 'Affiliation': 'Department of Radiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Dinggang', 'Initials': 'D', 'LastName': 'Shen', 'Affiliation': 'Department of Research and Development, Shanghai United Imaging Intelligence Co.,Ltd., Shanghai, China.'}]",Journal of magnetic resonance imaging : JMRI,['10.1002/jmri.27256'] 331,32666831,Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.,"BACKGROUND/AIMS Standard approaches to trial design and analyses can be inefficient and non-pragmatic. Failure to consider a range of outcomes impedes evidence-based interpretation and reduces power. Traditional approaches synthesizing information obtained from separate analysis of each outcome fail to incorporate associations between outcomes and recognize the cumulative nature of outcomes in individual patients, suffer from competing risk complexities during interpretation, and since efficacy and safety analyses are often conducted on different populations, generalizability is unclear. Pragmatic and efficient approaches to trial design and analyses are needed. METHODS Approaches providing a pragmatic assessment of benefits and harms of interventions, summarizing outcomes experienced by patients, and providing sample size efficiencies are described. Ordinal outcomes recognize finer gradations of patient responses. Desirability of outcome ranking is an ordinal outcome combining benefits and harms within patients. Analysis of desirability of outcome ranking can be based on rank-based methodologies including the desirability of outcome ranking probability, the win ratio, and the proportion in favor of treatment. Partial credit analyses, involving grading the levels of the desirability of outcome ranking outcome similar to an academic test, provides an alternative approach. The methodologies are demonstrated using the acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes study (SOCRATES; NCT01994720), a randomized clinical trial. RESULTS Two 5-level ordinal outcomes were developed for SOCRATES. The first was based on a modified Rankin scale. The odds ratio is 0.86 (95% confidence interval = 0.75, 0.99; p = 0.04) indicating that the odds of worse stroke categorization for a trial participant assigned to ticagrelor is 0.86 times that of a trial participant assigned to aspirin. The 5-level desirability of outcome ranking outcome incorporated and prioritized survival; the number of strokes, myocardial infarction, and major bleeding events; and whether a stroke event was disabling. The desirability of outcome ranking probability and win ratio are 0.504 (95% confidence interval = 0.499, 0.508; p = 0.10) and 1.11 (95% confidence interval = 0.98, 1.26; p = 0.10), respectively, implying that the probability of a more desirable result with ticagrelor is 50.4% and that a more desirable result occurs 1.11 times more frequently on ticagrelor versus aspirin. CONCLUSION Ordinal outcomes can improve efficiency through required pre-specification, careful construction, and analyses. Greater pragmatism can be obtained by composing outcomes within patients. Desirability of outcome ranking provides a global assessment of the benefits and harms that more closely reflect the experience of patients. The desirability of outcome ranking probability, the proportion in favor of treatment, the win ratio, and partial credit can more optimally inform patient treatment, enhance the understanding of the totality of intervention effects on patients, and potentially provide efficiencies over standard analyses. The methods provide the infrastructure for incorporating patient values and estimating personalized effects.",2020,"The odds ratio is 0.86 (95% confidence interval = 0.75, 0.99; p = 0.04) indicating that the odds of worse stroke categorization for a trial participant assigned to ticagrelor is 0.86 times that of a trial participant assigned to aspirin.",[],"['aspirin', 'aspirin or ticagrelor', 'ticagrelor']","['prioritized survival; the number of strokes, myocardial infarction, and major bleeding events; and whether a stroke event was disabling']",[],"[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",,0.138628,"The odds ratio is 0.86 (95% confidence interval = 0.75, 0.99; p = 0.04) indicating that the odds of worse stroke categorization for a trial participant assigned to ticagrelor is 0.86 times that of a trial participant assigned to aspirin.","[{'ForeName': 'Scott R', 'Initials': 'SR', 'LastName': 'Evans', 'Affiliation': 'Biostatistics Center, George Washington University, Washington, DC, USA.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Knutsson', 'Affiliation': 'AstraZeneca, Research and Development, Gothenburg, Sweden.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Amarenco', 'Affiliation': 'Department of Neurology and Stroke Centre, Bichat Hospital, Paris University, Paris, France.'}, {'ForeName': 'Gregory W', 'Initials': 'GW', 'LastName': 'Albers', 'Affiliation': 'Stanford Stroke Center, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Bath', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Denison', 'Affiliation': 'AstraZeneca, Research and Development, Gothenburg, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Ladenvall', 'Affiliation': 'AstraZeneca, Research and Development, Gothenburg, Sweden.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Jonasson', 'Affiliation': 'AstraZeneca, Research and Development, Gothenburg, Sweden.'}, {'ForeName': 'J Donald', 'Initials': 'JD', 'LastName': 'Easton', 'Affiliation': 'Department of Neurology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Minematsu', 'Affiliation': 'National Cerebral and Cardiovascular Center, Osaka, Japan.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Molina', 'Affiliation': ""Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Beijing Tiantan Hospital, Beijing, China.'}, {'ForeName': 'Ks Lawrence', 'Initials': 'KL', 'LastName': 'Wong', 'Affiliation': 'Department of Medicine & Therapeutics, Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'S Claiborne', 'Initials': 'SC', 'LastName': 'Johnston', 'Affiliation': ""Dean's Office, Dell Medical School, University of Texas at Austin, Austin, TX, USA.""}]","Clinical trials (London, England)",['10.1177/1740774520941441'] 332,32673049,An evaluation of fixed and randomized price sequence on the alcohol purchase task.,"Factors influencing drug consumption can be effectively evaluated in the context of behavioral economic demand. Specifically, hypothetical purchase tasks (HPTs) allow for estimated drug consumption at a range of prices in which drug administration is not ethically or feasibly possible. With the marked increase of HPTs in behavioral research, understanding methodological influences on responding is paramount. One such methodological consideration is the price sequence, which can be presented in a fixed, ascending order or a randomized sequence. This study compared fixed and fully randomized sequence order with college student drinkers using a within-subjects design. Self-reported consumption revealed that despite some small differences between the fixed and random sequences, consumption preferences were highly similar, regardless of presentation order. These results suggest participants are likely not anchoring their responses to the prior price on a fixed-order sequence. We conclude with a discussion on how these findings provide implications for HPTs and future research. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Self-reported consumption revealed that despite some small differences between the fixed and random sequences, consumption preferences were highly similar, regardless of presentation order.",['college student drinkers using a within-subjects design'],['hypothetical purchase tasks (HPTs'],[],"[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]",[],[],,0.0361818,"Self-reported consumption revealed that despite some small differences between the fixed and random sequences, consumption preferences were highly similar, regardless of presentation order.","[{'ForeName': 'Allyson R', 'Initials': 'AR', 'LastName': 'Salzer', 'Affiliation': 'Department of Applied Behavioral Science, University of Kansas.'}, {'ForeName': 'Justin C', 'Initials': 'JC', 'LastName': 'Strickland', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.'}, {'ForeName': 'William W', 'Initials': 'WW', 'LastName': 'Stoops', 'Affiliation': 'Department of Behavioral Science, University of Kentucky Medical Center.'}, {'ForeName': 'Derek D', 'Initials': 'DD', 'LastName': 'Reed', 'Affiliation': 'Department of Applied Behavioral Science, University of Kansas.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000421'] 333,32673102,Effects of the Interactive Videogame Nintendo Wii Sports on Upper Limb Motor Function of Individuals with Post-Polio Syndrome: A Randomized Clinical Trial.,"Objective: To compare the effects of an upper limb videogame-based training with a training based on similar motor demands on upper limb function, dexterity, functionality, balance, fatigue, and pain in post-polio syndrome (PPS) and to assess the acceptability, feasibility, and safety of the intervention. Materials and Methods: This is a randomized, parallel, single-blind clinical trial. Thirty-nine individuals were randomized into Interactive Videogames Group (IVG, n  = 19) and Active Exercises Group (AEG, n  = 20). Participants performed two weekly sessions (50 minutes each), totaling 14 sessions with the aim of providing mild to moderate intensity. IVG practiced four Nintendo Wii Sport games (tennis, golf, boxing, and bowling). The AEG performed similar movements required for IVG. Primary outcome: upper limb motor function-Motor Function Measure-32. Secondary outcomes: dexterity-Box and Block test; functionality-Functional Independence Measure; balance-Functional Reach Test, muscle fatigue-Fatigue Severity Scale, upper limb pain-Visual Analogue Scale for pain, acceptability, applicability, and safety. Analysis of group, time, interaction between groups, and time effects was performed through repeated-measures analysis of variance (2 × 3) and Bonferroni post hoc test with alpha of 0.05. Results: Interactive videogames were safe, feasible, and acceptable. Both groups showed similar postintervention improvement on motor function, functionality, balance, pain, and fatigue, with maintenance over the follow-up period. There was an interaction effect between the groups on dexterity and the IVG demonstrated better performance compared with the AEG. Final Considerations: The similar positive clinical effects of the interactive video games on PPS upper limb function and its superior effects on dexterity support its use as a safe and feasible intervention. Particularly when it comes to chronic patients, who require long-term physical therapy, new and stimulating interventions may contribute to the rehabilitation process and improve their engagement in the treatment. Registered on the Brazilian Clinical Trials platform under number RBR-8S2NBF.",2020,There was an interaction effect between the groups on dexterity and the IVG demonstrated better performance compared with the AEG. Final Considerations: The similar positive clinical effects of the interactive video games on PPS upper limb function and its superior effects on dexterity support its use as a safe and feasible intervention.,"['Individuals with Post-polio Syndrome', 'Thirty-nine individuals']","['Interactive Videogames Group (IVG, n \u2009=\u200919) and Active Exercises Group (AEG, n \u2009=\u200920', 'Interactive Videogame Nintendo Wii Sports', 'upper limb videogame-based training with a training based on similar motor demands']","['dexterity-Box and Block test; functionality-Functional Independence Measure; balance-Functional Reach Test, muscle fatigue-Fatigue Severity Scale, upper limb pain-Visual Analogue Scale for pain, acceptability, applicability, and safety', 'acceptability, feasibility, and safety', 'upper limb motor function-Motor Function Measure-32', 'Upper Limb Motor Function', 'motor function, functionality, balance, pain, and fatigue, with maintenance', 'upper limb function, dexterity, functionality, balance, fatigue, and pain in post-polio syndrome (PPS']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0080040', 'cui_str': 'Post poliomyelitis syndrome'}, {'cui': 'C3816447', 'cui_str': '39'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0419117', 'cui_str': 'Active exercise'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C1998271', 'cui_str': 'Functional reach test'}, {'cui': 'C0242979', 'cui_str': 'Muscle fatigue'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0239377', 'cui_str': 'Pain in upper limb'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0080040', 'cui_str': 'Post poliomyelitis syndrome'}, {'cui': 'C0265259', 'cui_str': 'Popliteal pterygium syndrome'}]",39.0,0.0432868,There was an interaction effect between the groups on dexterity and the IVG demonstrated better performance compared with the AEG. Final Considerations: The similar positive clinical effects of the interactive video games on PPS upper limb function and its superior effects on dexterity support its use as a safe and feasible intervention.,"[{'ForeName': 'Erika Christina', 'Initials': 'EC', 'LastName': 'Gouveia E Silva', 'Affiliation': 'Neuroscience and Behaviour post graduation program of the Institute of Psicology of the University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Lange', 'Affiliation': 'College of Nursing & Health Sciences, Flinders University, Adelaide, Australia.'}, {'ForeName': 'Jéssica Maria Ribeiro', 'Initials': 'JMR', 'LastName': 'Bacha', 'Affiliation': 'Rehabilitation Science Post Graduation Program of the Department of Physical Therapy, Speech and Occupational Therapy of the School of Medicine of the University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'José Eduardo', 'Initials': 'JE', 'LastName': 'Pompeu', 'Affiliation': 'Department of Physical Therapy, Speech and Occupational Therapy of the School of Medicine of the University of Sao Paulo, Sao Paulo, Brazil.'}]",Games for health journal,['10.1089/g4h.2019.0192'] 334,32679537,Blood pressure postpartum (BP 2 ) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy.,"OBJECTIVES Women who had hypertensive disorders of pregnancy (HDP) are twice as likely to experience maternal cardiovascular disease later in life. The primary aim of this study (BP 2 ) is to compare outcomes of 3 different management strategies, including lifestyle behaviour change (LBC), in the first 12 months postpartum in women who had HDP in their preceding pregnancy. Secondary aims include assessing the effects on other cardiometabolic parameters. STUDY DESIGN Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480. Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2) Brief intervention: information package as per group 1, plus assessment and brief LBC counselling at a specialised clinic with an obstetric physician and dietitian 6 months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6 month telephone-based LBC program from 6 to 12 months postpartum. All women have an outcome assessment at 12 months. MAIN OUTCOME MEASURES Primary outcomes: (a) BP change or (b) weight change and/or waist circumference change. SECONDARY OUTCOMES maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios. The study is powered to detect a 4 mmHg difference in systolic BP between groups, or a 4 kg weight loss difference/2cm waist circumference change. CONCLUSIONS BP 2 will provide evidence regarding the feasibility and effectiveness of postpartum LBC interventions and structured clinical follow-up in improving cardiovascular health markers after HDP.",2020,Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2),"['women who had HDP in their preceding pregnancy', 'Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480', 'Women who had hypertensive disorders of pregnancy (HDP']","['LBC counselling at a specialised clinic with an obstetric physician and dietitian 6\xa0months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6\xa0month telephone-based LBC program', 'Optimised usual care: information package and family doctor follow-up 6\xa0months postpartum 2']","['Blood pressure postpartum (BP 2 ', 'BP change or (b) weight change and/or waist circumference change', 'maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios', 'systolic BP', 'lifestyle behaviour change (LBC']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0852260', 'cui_str': 'Hypertension associated disorders of pregnancy'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C4319609', 'cui_str': '480'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general)'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C1704221', 'cui_str': 'Family medicine specialist'}, {'cui': 'C0589124', 'cui_str': 'Follow-up 6 months'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0024921', 'cui_str': 'Maternal Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4704805', 'cui_str': 'Weight Trajectory'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",480.0,0.118249,Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2),"[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Henry', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia; The George Institute for Global Health, Sydney, Australia. Electronic address: Amanda.Henry@unsw.edu.au.""}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Arnott', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Faculty of Medicine, University of New South Wales, Sydney, Australia; Sydney Medical School, University of Sydney, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Makris', 'Affiliation': 'Faculty of Medicine, University of New South Wales, Sydney, Australia; School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Davis', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Annemarie', 'Initials': 'A', 'LastName': 'Hennessy', 'Affiliation': 'School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Beech', 'Affiliation': 'Royal Hospital for Women, Randwick, New South Wales, Australia.'}, {'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Pettit', 'Affiliation': 'Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Se Homer', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia; Faculty of Health, University of Technology, Sydney, New South Wales, Australia.'}, {'ForeName': 'Maria E', 'Initials': 'ME', 'LastName': 'Craig', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Roberts', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.""}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Hyett', 'Affiliation': 'Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Sydney Medical School, University of Sydney, Australia.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Chambers', 'Affiliation': ""National Perinatal Epidemiology and Statistics Unit, School of Women's and Children's Health and Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Oisin', 'Initials': 'O', 'LastName': 'Fitzgerald', 'Affiliation': ""National Perinatal Epidemiology and Statistics Unit, School of Women's and Children's Health and Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Gow', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Mann', 'Affiliation': 'General Practitioner, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Challis', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Royal Hospital for Women, Randwick, New South Wales, Australia.""}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Gale', 'Affiliation': 'New South Wales Ministry of Health, North Sydney, New South Wales, Australia.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Ruhotas', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Emilee', 'Initials': 'E', 'LastName': 'Kirwin', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Denney-Wilson', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Brown', 'Affiliation': 'Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.'}]",Pregnancy hypertension,['10.1016/j.preghy.2020.07.001'] 335,32682347,A PERIOD3 variable number tandem repeat polymorphism modulates melatonin treatment response in delayed sleep-wake phase disorder.,"We examined whether a polymorphism of the PERIOD3 gene (PER3; rs57875989) modulated the sleep-promoting effects of melatonin in Delayed Sleep-Wake Phase Disorder (DSWPD). One hundred and four individuals (53 males; 29.4 ±10.0 years) with DSWPD and a delayed dim light melatonin onset (DLMO) collected buccal swabs for genotyping (PER3 4/4 n = 43; PER3 5 allele [heterozygous and homozygous] n = 60). Participants were randomised to placebo or 0.5 mg melatonin taken 1 hour before desired bedtime (or ~1.45 hours before DLMO), with sleep attempted at desired bedtime (4 weeks; 5-7 nights/week). We assessed sleep (diary and actigraphy), Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Patient-Reported Outcomes Measurement Information System (PROMIS: Sleep Disturbance, Sleep-Related Impairment), Sheehan Disability Scale (SDS) and Patient- and Clinician-Global Improvement (PGI-C, CGI-C). Melatonin treatment response on actigraphic sleep onset time did not differ between genotypes. For PER3 4/4 carriers, self-reported sleep onset time was advanced by a larger amount and sleep onset latency (SOL) was shorter in melatonin-treated patients compared to those receiving placebo (P = .008), while actigraphic sleep efficiency in the first third of the sleep episode (SE T1) did not differ. For PER3 5 carriers, actigraphic SOL and SE T1 showed a larger improvement with melatonin (P < .001). Melatonin improved ISI (P = .005), PROMIS sleep disturbance (P < .001) and sleep-related impairment (P = .017), SDS (P = .019), PGI-C (P = .028) and CGI-C (P = .016) in PER3 4/4 individuals only. Melatonin did not advance circadian phase. Overall, PER3 4/4 DSWPD patients have a greater response to melatonin treatment. PER3 genotyping may therefore improve DSWPD patient outcomes.",2020,"Melatonin improved ISI (P=0.005), PROMIS Sleep Disturbance (P<0.001) and Sleep-Related Impairment (P=0.017), SDS (P=0.019), PGI-C (P=0.028), and CGI-C (P=0.016) in PER3 4/4 individuals only.","['Delayed Sleep-Wake Phase Disorder', 'Delayed Sleep-Wake Phase Disorder (DSWPD', 'One hundred and four individuals (53 males; 29.4±10.0 years) with DSWPD and a delayed dim light melatonin onset (DLMO) collected buccal swabs for genotyping (PER3 4/4 n=43']","['placebo or 0.5mg melatonin', 'melatonin', 'Melatonin', 'placebo']","['sleep (diary and actigraphy), Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Patient-Reported Outcomes Measurement Information System (PROMIS: Sleep Disturbance, Sleep-Related Impairment), Sheehan Disability Scale (SDS), and Patient- and Clinician-Global Improvement (PGI-C, CGI-C', 'sleep onset latency (SOL', 'ISI', 'actigraphic sleep efficiency', 'Sleep-Related Impairment', 'PGI-C', 'actigraphic sleep onset time', 'PROMIS Sleep Disturbance']","[{'cui': 'C0393770', 'cui_str': 'Sleep-wake schedule disorder, delayed phase type'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0114346', 'cui_str': 'dimesna'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0581714', 'cui_str': 'Buccal smear procedure'}, {'cui': 'C0017337', 'cui_str': 'Gene'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0021428', 'cui_str': 'Information system'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C4720840', 'cui_str': 'Sheehan disability scale'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0523816', 'cui_str': 'Pepsinogen I measurement'}, {'cui': 'C4505222', 'cui_str': 'Sleep Onset Latency'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0449244', 'cui_str': 'Time of onset'}]",104.0,0.188696,"Melatonin improved ISI (P=0.005), PROMIS Sleep Disturbance (P<0.001) and Sleep-Related Impairment (P=0.017), SDS (P=0.019), PGI-C (P=0.028), and CGI-C (P=0.016) in PER3 4/4 individuals only.","[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Magee', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Tracey L', 'Initials': 'TL', 'LastName': 'Sletten', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Jade M', 'Initials': 'JM', 'LastName': 'Murray', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Gordon', 'Affiliation': 'Cooperative Research Centre for Alertness, Safety and Productivity, Clayton, Victoria, Australia.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Lovato', 'Affiliation': 'Cooperative Research Centre for Alertness, Safety and Productivity, Clayton, Victoria, Australia.'}, {'ForeName': 'Delwyn J', 'Initials': 'DJ', 'LastName': 'Bartlett', 'Affiliation': 'Cooperative Research Centre for Alertness, Safety and Productivity, Clayton, Victoria, Australia.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Kennaway', 'Affiliation': 'Robinson Research Institute, Adelaide School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Steven W', 'Initials': 'SW', 'LastName': 'Lockley', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Leon C', 'Initials': 'LC', 'LastName': 'Lack', 'Affiliation': 'Adelaide Institute for Sleep Health: A Flinders Centre of Research Excellence, School of Medicine, Flinders University, Adelaide, South Australia, Australia.'}, {'ForeName': 'Ronald R', 'Initials': 'RR', 'LastName': 'Grunstein', 'Affiliation': 'Cooperative Research Centre for Alertness, Safety and Productivity, Clayton, Victoria, Australia.'}, {'ForeName': 'Simon N', 'Initials': 'SN', 'LastName': 'Archer', 'Affiliation': 'Surrey Sleep Research Centre, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.'}, {'ForeName': 'Shantha M W', 'Initials': 'SMW', 'LastName': 'Rajaratnam', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of pineal research,['10.1111/jpi.12684'] 336,33069172,Intensive versus guideline-recommended blood pressure reduction in acute lacunar stroke with intravenous thrombolysis therapy: The ENCHANTED trial.,"BACKGROUND AND PURPOSE This was an investigation of the differential effects of early intensive versus guideline-recommended blood pressure (BP) lowering between lacunar and non-lacunar acute ischaemic stroke (AIS) in the BP arm of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED). METHODS In 1,632 participants classified as having definite or probable lacunar (n = 454 [27.8%]) or non-lacunar AIS according to pre-specified definitions based upon clinical and adjudicated imaging findings, mean BP changes over days 0-7 were plotted, and systolic BP differences by treatment between subgroups were estimated in generalized linear models. Logistic regression models were used to estimate the BP treatment effects on 90-day outcomes (primary, an ordinal shift of modified Rankin scale scores) across lacunar and non-lacunar AIS after adjustment for baseline covariables. RESULTS Most baseline characteristics, acute BP and other management differed between lacunar and non-lacunar AIS, but mean systolic BP differences by treatment were comparable at each time point (all p interaction  > 0.12) and over 24 h post-randomization (-5.5, 95% CI -6.5, -4.4 mmHg in lacunar AIS vs. -5.6, 95% CI -6.3, -4.8 mmHg in non-lacunar AIS, p interaction  = 0.93). The neutral effect of intensive BP lowering on functional outcome and the beneficial effect on intracranial haemorrhage were similar for the two subgroups (all p interaction  > 0.19). CONCLUSIONS There were no differences in the treatment effect of early intensive versus guideline-recommended BP lowering across lacunar and non-lacunar AIS.",2021,There were no differences in the treatment effect of early intensive versus guideline-recommended BP lowering across lacunar and non-lacunar AIS.,"['1632 participants classified as having definite or probable lacunar (n=454 [27.8%]) or non-lacunar AIS', 'acute lacunar stroke with intravenous thrombolysis therapy']","['Intensive versus guideline-recommended blood pressure reduction', 'early intensive versus guideline-recommended blood pressure (BP) lowering between lacunar']","['ordinal shift of modified Rankin scale [mRS] scores) across lacunar and non-lacunar AIS', 'mean systolic BP difference', 'intracranial hemorrhage']","[{'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0439544', 'cui_str': 'Definite'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C3178801', 'cui_str': 'Lacunar stroke'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0441994', 'cui_str': 'Lower'}]","[{'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0151699', 'cui_str': 'Intracranial hemorrhage'}]",1632.0,0.0837521,There were no differences in the treatment effect of early intensive versus guideline-recommended BP lowering across lacunar and non-lacunar AIS.,"[{'ForeName': 'Zien', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Xia', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Carcel', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Sohei', 'Initials': 'S', 'LastName': 'Yoshimura', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Candice', 'Initials': 'C', 'LastName': 'Delcourt', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'Malavera', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Grant', 'Initials': 'G', 'LastName': 'Mair', 'Affiliation': 'Division of Neuroimaging Sciences, Edinburgh Imaging and Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Woodward', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Chalmers', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Demchuk', 'Affiliation': 'Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Richard I', 'Initials': 'RI', 'LastName': 'Lindley', 'Affiliation': 'The George Institute for Global Health and University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Thompson G', 'Initials': 'TG', 'LastName': 'Robinson', 'Affiliation': 'Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Center, University of Leicester, Leicester, UK.'}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Parsons', 'Affiliation': 'South Western Clinical School, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Joanna M', 'Initials': 'JM', 'LastName': 'Wardlaw', 'Affiliation': 'Division of Neuroimaging Sciences, Edinburgh Imaging and Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Craig S', 'Initials': 'CS', 'LastName': 'Anderson', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}]",European journal of neurology,['10.1111/ene.14598'] 337,33074282,Short-term Outcomes of the Study of Refeeding to Optimize Inpatient Gains for Patients With Anorexia Nervosa: A Multicenter Randomized Clinical Trial.,"Importance The standard of care for refeeding inpatients with anorexia nervosa, starting with low calories and advancing cautiously, is associated with slow weight gain and protracted hospital stay. Limited data suggest that higher-calorie refeeding improves these outcomes with no increased risk of refeeding syndrome. Objective To compare the short-term efficacy, safety, and cost of lower-calorie vs higher-calorie refeeding for malnourished adolescents and young adults with anorexia nervosa. Design, Setting, and Participants In this multicenter randomized clinical trial with prospective follow-up conducted at 2 inpatient eating disorder programs at large tertiary care hospitals, 120 adolescents and young adults aged 12 to 24 years hospitalized with anorexia nervosa or atypical anorexia nervosa and 60% or more of median body mass index were enrolled from February 8, 2016, to March 7, 2019. The primary analysis was a modified intent-to-treat approach. Interventions Higher-calorie refeeding, beginning at 2000 kcal/d and increasing by 200 kcal/d vs lower-calorie refeeding, beginning at 1400 k/cal and increasing by 200 kcal every other day. Main Outcomes and Measures Main outcomes were end-of-treatment outcomes; the primary end point of this trial will be clinical remission over 12 months. Short-term efficacy was defined a priori as time to restore medical stability in the hospital, measured by the following 6 indices: 24-hour heart rate of 45 beats/min or more, systolic blood pressure of 90 mm Hg or more, temperature of 35.6 °C or more, orthostatic increase in heart rate of 35 beats/min or less, orthostatic decrease in systolic blood pressure of 20 mm Hg or less, and 75% or more of median body mass index for age and sex. The prespecified safety outcome was incidence of electrolyte abnormalities; cost efficacy was defined as savings associated with length of stay. Results Because 9 participants withdrew prior to treatment, the modified intention-to-treat analyses included 111 participants (93%; 101 females [91%]; mean [SD] age, 16.4 [2.5] years). Higher-calorie refeeding restored medical stability significantly earlier than lower-calorie refeeding (hazard ratio, 1.67 [95% CI, 1.10-2.53]; P = .01). Electrolyte abnormalities and other adverse events did not differ by group. Hospital stay was 4.0 days shorter (95% CI, -6.1 to -1.9 days) among the group receiving higher-calorie refeeding, which was associated with a savings of $19 056 (95% CI, -$28 819 to -$9293) in hospital charges per participant. Conclusions and Relevance In the first randomized clinical trial in the US to compare refeeding approaches in patients with anorexia nervosa and atypical anorexia nervosa, higher-calorie refeeding demonstrated short-term efficacy with no increase in safety events during hospitalization. Trial Registration ClinicalTrials.gov Identifier: NCT02488109.",2021,"Hospital stay was 4.0 days shorter (95% CI, -6.1 to -1.9 days) among the group receiving higher-calorie refeeding, which was associated with a savings of $19 056 (95% CI, -$28 819 to -$9293) in hospital charges per participant. ","['refeeding inpatients with anorexia nervosa', 'malnourished adolescents and young adults with anorexia nervosa', 'participants withdrew prior to treatment, the modified intention-to-treat analyses included 111 participants (93%; 101 females [91%]; mean [SD] age, 16.4 [2.5] years', 'Patients With Anorexia Nervosa', 'patients with anorexia nervosa and atypical anorexia nervosa', '2 inpatient eating disorder programs at large tertiary care hospitals, 120 adolescents and young adults aged 12 to 24 years hospitalized with anorexia nervosa or atypical anorexia nervosa and 60% or more of median body mass index were enrolled from February 8, 2016, to March 7, 2019']",['lower-calorie vs higher-calorie refeeding'],"['incidence of electrolyte abnormalities; cost efficacy', 'savings associated with length of stay', 'orthostatic increase in heart rate', 'clinical remission', '24-hour heart rate of 45 beats/min or more, systolic blood pressure', 'risk of refeeding syndrome', 'safety events', 'orthostatic decrease in systolic blood pressure', 'Hospital stay', 'Electrolyte abnormalities and other adverse events']","[{'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0338959', 'cui_str': 'Atypical anorexia nervosa'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0151613', 'cui_str': 'Electrolytes abnormal'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036245', 'cui_str': 'Savings'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0860549', 'cui_str': 'Refeeding syndrome'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.187957,"Hospital stay was 4.0 days shorter (95% CI, -6.1 to -1.9 days) among the group receiving higher-calorie refeeding, which was associated with a savings of $19 056 (95% CI, -$28 819 to -$9293) in hospital charges per participant. ","[{'ForeName': 'Andrea K', 'Initials': 'AK', 'LastName': 'Garber', 'Affiliation': 'Division of Adolescent and Young Adult Medicine, Department of Pediatrics, University of California, San Francisco.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, University of California, San Francisco.'}, {'ForeName': 'Erin C', 'Initials': 'EC', 'LastName': 'Accurso', 'Affiliation': 'Department of Psychiatry and Behavioral Medicine, University of California, San Francisco.'}, {'ForeName': 'Sally H', 'Initials': 'SH', 'LastName': 'Adams', 'Affiliation': 'Division of Adolescent and Young Adult Medicine, Department of Pediatrics, University of California, San Francisco.'}, {'ForeName': 'Sara M', 'Initials': 'SM', 'LastName': 'Buckelew', 'Affiliation': 'Division of Adolescent and Young Adult Medicine, Department of Pediatrics, University of California, San Francisco.'}, {'ForeName': 'Cynthia J', 'Initials': 'CJ', 'LastName': 'Kapphahn', 'Affiliation': 'Division of Adolescent Medicine, Department of Pediatrics, Stanford University, Stanford, California.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Kreiter', 'Affiliation': 'Division of Adolescent Medicine, Department of Pediatrics, Stanford University, Stanford, California.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Le Grange', 'Affiliation': 'Division of Adolescent and Young Adult Medicine, Department of Pediatrics, University of California, San Francisco.'}, {'ForeName': 'Vanessa I', 'Initials': 'VI', 'LastName': 'Machen', 'Affiliation': 'Division of Adolescent and Young Adult Medicine, Department of Pediatrics, University of California, San Francisco.'}, {'ForeName': 'Anna-Barbara', 'Initials': 'AB', 'LastName': 'Moscicki', 'Affiliation': 'Division of Adolescent and Young Adult Medicine, Department of Pediatrics, University of California, Los Angeles.'}, {'ForeName': 'Allyson', 'Initials': 'A', 'LastName': 'Sy', 'Affiliation': 'Division of Adolescent Medicine, Department of Pediatrics, Stanford University, Stanford, California.'}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Wilson', 'Affiliation': 'Department of Clinical Pharmacy, University of California, San Francisco.'}, {'ForeName': 'Neville H', 'Initials': 'NH', 'LastName': 'Golden', 'Affiliation': 'Division of Adolescent Medicine, Department of Pediatrics, Stanford University, Stanford, California.'}]",JAMA pediatrics,['10.1001/jamapediatrics.2020.3359'] 338,33070698,Acute effect of resistance exercise on cognitive function in people living with HIV.,"People living with HIV are at an increased risk of developing cognitive deficits. Physical exercise is an important strategy to improve the brain health of people living with HIV. This randomized, controlled study aimed to investigate the acute effect of a single resistance exercise session on the cognitive function of people living with HIV. Twenty-three people living with HIV were randomized (1:1) to a control group (n = 12) or the exercise group (n = 11). Cognitive function was assessed by the Stroop test and the Trail Making Test. The exercise group was evaluated before and after the exercise session; meanwhile, the control group was evaluated before and after a 40-minute rest period. No statistical difference was found on the effect of exercise on cognitive function ( p  > 0.05). This result suggests that one session of resistance exercise was not capable of improving the cognitive function of people with HIV.",2021,No statistical difference was found on the effect of exercise on cognitive function ( p  > 0.05).,"['Twenty-three people living with HIV', 'people with HIV', 'People living with HIV', 'people living with HIV']","['single resistance exercise session', 'Physical exercise', 'resistance exercise']","['Cognitive function', 'cognitive function']","[{'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",23.0,0.0426023,No statistical difference was found on the effect of exercise on cognitive function ( p  > 0.05).,"[{'ForeName': 'Dayane C', 'Initials': 'DC', 'LastName': 'de Souza', 'Affiliation': 'Department of Physical Education, Western State University of Parana, Marechal Cândido Rondon, Brazil.'}, {'ForeName': 'Wagner Jr', 'Initials': 'WJ', 'LastName': 'Domingues', 'Affiliation': 'Collegiate of Physical Education, Institute of Social Sciences, Education and Zootechnics, Federal University of Amazonas, Parintins, Brazil.'}, {'ForeName': 'Kauana B', 'Initials': 'KB', 'LastName': 'Marchini', 'Affiliation': 'Department of Physical Education, State University of Maringa, Maringa, Brazil.'}, {'ForeName': 'Pollyana M', 'Initials': 'PM', 'LastName': 'Nunhes', 'Affiliation': 'Department of Physical Education, State University of Maringa, Maringa, Brazil.'}, {'ForeName': 'Alesandro', 'Initials': 'A', 'LastName': 'Garcia', 'Affiliation': 'Maringá University Center, Maringa, Brazil.'}, {'ForeName': 'Lucas F', 'Initials': 'LF', 'LastName': 'Hey', 'Affiliation': 'Department of Physical Education, State University of Maringa, Maringa, Brazil.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Ardengue', 'Affiliation': 'Department of Physical Education, State University of Maringa, Maringa, Brazil.'}, {'ForeName': 'Isabela', 'Initials': 'I', 'LastName': 'Pasinato', 'Affiliation': 'Department of Physical Education, State University of Maringa, Maringa, Brazil.'}, {'ForeName': 'Ademar', 'Initials': 'A', 'LastName': 'Avelar', 'Affiliation': 'Department of Physical Education, State University of Maringa, Maringa, Brazil.'}]",International journal of STD & AIDS,['10.1177/0956462420958578'] 339,33079803,The Effects of an Infant Calming Intervention on Mothers' Parenting Self-Efficacy and Satisfaction During the Postpartum Period: A Randomized Controlled Trial.,"The aim of this study was to evaluate the effects of a behavioral infant calming technique to support mothers' parenting self-efficacy and parenting satisfaction. The methods of this randomized controlled trial are based on the CONSORT guidelines. Data were collected during March 1 to May 20, 2019, from 3 postpartum units in 1 university-level hospital in Finland. A total of 250 mothers agreed to participate, of which 120 were randomly allocated to the intervention group and 130 to the control group. All mothers completed a baseline questionnaire before randomization. Mothers in the intervention group were taught the 5 S's infant calming technique. The control group received standard care. Follow-up data were collected 6 to 8 weeks postpartum. The primary outcome measure was the change in parenting self-efficacy and parenting satisfaction scores over the follow-up period. The intervention group showed significantly larger improvements in parenting self-efficacy scores. There were no statistically significant differences in median improvements in parenting satisfaction. The 5 S's infant calming technique is feasible. These study findings may assist midwifery and neonatal nursing staff to support mothers and families during the postpartum period, whether the infants are fussy or not.",2020,The intervention group showed significantly larger improvements in parenting self-efficacy scores.,"['250 mothers agreed to participate, of which 120 were randomly allocated to the intervention group and 130 to the control group']","['Infant Calming Intervention', 'standard care', 'behavioral infant calming technique']","['median improvements in parenting satisfaction', ""Mothers' Parenting Self-Efficacy and Satisfaction"", 'change in parenting self-efficacy and parenting satisfaction scores', 'parenting self-efficacy scores']","[{'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",250.0,0.0876972,The intervention group showed significantly larger improvements in parenting self-efficacy scores.,"[{'ForeName': 'Elina', 'Initials': 'E', 'LastName': 'Botha', 'Affiliation': 'Faculty of Social Sciences, Health Sciences, Tampere University, Tampere, Finland (Ms Botha, Mr Helminen, and Drs Kaunonen and Joronen); Research, Development and Innovation Centre, Tampere University Hospital, Tampere, Finland (Mr Helminen); General Administration, Pirkanmaa Hospital District, Tampere University, Tampere, Finland (Dr Kaunonen); and School of Nursing Science/NuMIQ Research Unit, North-West University, Potchefstroom, South Africa (Dr Lubbe).'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Helminen', 'Affiliation': ''}, {'ForeName': 'Marja', 'Initials': 'M', 'LastName': 'Kaunonen', 'Affiliation': ''}, {'ForeName': 'Welma', 'Initials': 'W', 'LastName': 'Lubbe', 'Affiliation': ''}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Joronen', 'Affiliation': ''}]",The Journal of perinatal & neonatal nursing,['10.1097/JPN.0000000000000510'] 340,33100187,Effect of Group Cognitive Behavioural Therapy on Loneliness in a Community Sample of Older Adults: A Secondary Analysis of a Randomized Controlled Trial.,"OBJECTIVES Research suggests a link between loneliness, depression, and anxiety. Multiple studies have examined treatment programs for loneliness; however, none have examined the efficacy of Cognitive Behavioral Therapy (CBT) for depression and anxiety in reducing loneliness. METHODS Change in loneliness in sixty-two older adults (≥60 yrs; 65% female) who took part in a previously reported randomized controlled trial for the treatment of comorbid depression and anxiety was examined. Older adults were randomized to a 12-week group CBT or waitlist control condition. Participants who took part in CBT were followed-up three months later. RESULTS Linear Mixed Model analyses indicated that after controlling for baseline cognition, depression, and anxiety, participants who completed CBT experienced a significant decrease in loneliness while the control group did not. This reduction was maintained at follow-up. CONCLUSIONS CBT programs for depression and anxiety are likely to be effective at reducing loneliness. This may be due to shared underlying cognitive and behavioral mechanisms between loneliness, depression, and anxiety such as sensitivity to perceived threat and social withdrawal. Further research is needed to understand if specific loneliness interventions are more effective. CLINICAL IMPLICATIONS CBT may be effective at reducing loneliness among older adults with depression and anxiety.",2021,"RESULTS Linear Mixed Model analyses indicated that after controlling for baseline cognition, depression, and anxiety, participants who completed CBT experienced a significant decrease in loneliness while the control group did not.","['Change in loneliness in sixty-two older adults (≥60\xa0yrs; 65% female', 'Loneliness in a Community Sample of Older Adults', 'Older adults', 'older adults with depression and anxiety']","['Cognitive Behavioral Therapy (CBT', 'CBT or waitlist control condition', 'CBT programs', 'Group Cognitive Behavioural Therapy']","['loneliness', 'baseline cognition, depression, and anxiety']","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0023974', 'cui_str': 'Feeling lonely'}, {'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0023974', 'cui_str': 'Feeling lonely'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",62.0,0.0408848,"RESULTS Linear Mixed Model analyses indicated that after controlling for baseline cognition, depression, and anxiety, participants who completed CBT experienced a significant decrease in loneliness while the control group did not.","[{'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Smith', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, Australia.'}, {'ForeName': 'Viviana', 'Initials': 'V', 'LastName': 'Wuthrich', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, Australia.'}, {'ForeName': 'Carly', 'Initials': 'C', 'LastName': 'Johnco', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, Australia.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Belcher', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, Australia.'}]",Clinical gerontologist,['10.1080/07317115.2020.1836105'] 341,33106180,"PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke-statistical analysis plan of a randomised, open, phase III, clinical trial with blinded outcome assessment.","RATIONALE Aspiration, infections, and fever are common in the first days after stroke, especially in older patients. The occurrence of these complications has been associated with an increased risk of death or dependency. AIMS AND DESIGN PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke (PRECIOUS) is an international, multi-centre, 3 × 2 factorial, randomised, controlled, open-label clinical trial with blinded outcome assessment, which will assess whether prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, respectively, or any combination of these in the first 4 days after stroke onset improves functional outcome at 90 days in elderly patients with acute stroke. DISCUSSION This statistical analysis plan provides a technical description of the statistical methodology and unpopulated tables and figures. The paper is written prior to data lock and unblinding of treatment allocation. TRIAL REGISTRATION ISRCTN registry ISRCTN82217627 . Registered on 22 September 2015. The trial was prospectively registered.",2020,"AIMS AND DESIGN PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke (PRECIOUS) is an international, multi-centre, 3 × 2 factorial, randomised, controlled, open-label clinical trial with blinded outcome assessment, which will assess whether prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, respectively, or any combination of these in the first 4 days after stroke onset improves functional outcome at 90 days in elderly patients with acute stroke. ","['older patients', 'elderly patients with acute Stroke-statistical analysis plan', 'elderly patients with acute Stroke (PRECIOUS', 'elderly patients with acute stroke']","['metoclopramide, ceftriaxone, paracetamol']",['functional outcome'],"[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0025853', 'cui_str': 'Metoclopramide'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.155944,"AIMS AND DESIGN PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke (PRECIOUS) is an international, multi-centre, 3 × 2 factorial, randomised, controlled, open-label clinical trial with blinded outcome assessment, which will assess whether prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, respectively, or any combination of these in the first 4 days after stroke onset improves functional outcome at 90 days in elderly patients with acute stroke. ","[{'ForeName': 'Jeroen C', 'Initials': 'JC', 'LastName': 'de Jonge', 'Affiliation': 'Department of Neurology and Neurosurgery, Brain Center, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.'}, {'ForeName': 'Lisa J', 'Initials': 'LJ', 'LastName': 'Woodhouse', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Hendrik', 'Initials': 'H', 'LastName': 'Reinink', 'Affiliation': 'Department of Neurology and Neurosurgery, Brain Center, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.'}, {'ForeName': 'H Bart', 'Initials': 'HB', 'LastName': 'van der Worp', 'Affiliation': 'Department of Neurology and Neurosurgery, Brain Center, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. H.B.vanderWorp@umcutrecht.nl.'}, {'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Bath', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Trials,['10.1186/s13063-020-04717-0'] 342,33069511,Lower nocturnal blood glucose response to a potato-based mixed evening meal compared to rice in individuals with type 2 diabetes.,"BACKGROUND & AIMS Guidelines for reducing postprandial blood glucose concentrations include avoiding high glycemic index (GI) foods, such as white potatoes. However, GI testing is often undertaken in the morning with foods consumed in isolation by non-clinical cohorts. We investigated the impact of potato preparation and consumption as part of a mixed-evening meal on postprandial and nocturnal glycemic responses, and postprandial insulin response, in individuals with Type 2 Diabetes Mellitus (T2DM). METHODS In a randomized, cross-over design, 24 males and females (age 58.3 ± 9.3 y; BMI: 31.7 ± 6.8 kg/m 2 ) with T2DM (diet or metformin controlled) completed four experimental trials after consuming a standardized breakfast (25% daily energy intake (EI)) and lunch (35% EI). Dinner (40% EI) was consumed at 1800 h being either: 1) boiled potato (BOIL); 2) roasted potato (ROAST); 3) boiled potato cooled for 24 h (COOLED); or 4) basmati rice (CONTROL). Each meal contained 50% carbohydrate, 30% fat and 20% protein. Blood samples were collected prior to, immediately post meal and at 30-min intervals for a further 120 min. A continuous glucose monitor was worn to assess nocturnal interstitial glucose concentrations. RESULTS No differences were detected in postprandial venous glucose area under the curve (iAUC) between CONTROL and all three potato conditions. Postprandial insulin iAUC was greater following COOLED compared to CONTROL (P = 0.003; 95% CI: 18.9-111.72 miU/mL). No significant differences between CONTROL and BOIL or ROAST were detected for postprandial insulin concentrations. All potato meals resulted in lower nocturnal glucose AUC than CONTROL (P < 0.001; 95% CI 4.15-15.67 mmol/L x h). CONCLUSION Compared to an isoenergetic rice meal, boiled, roasted or boiled then cooled potato-based meals were not associated with unfavourable postprandial glucose responses or nocturnal glycemic control, and can be considered suitable for individuals with T2DM when consumed as part of a mixed-evening meal. CLINICAL TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry https://www.anzctr.org.au/, ACTRN 12618000480280.",2021,No differences were detected in postprandial venous glucose area under the curve (iAUC) between CONTROL and all three potato conditions.,"['24 males and females (age 58.3\xa0±\xa09.3\xa0y; BMI: 31.7\xa0±\xa06.8\xa0kg/m 2 ) with', 'individuals with type 2 diabetes', 'individuals with Type 2 Diabetes Mellitus (T2DM']","['boiled potato (BOIL); 2) roasted potato (ROAST); 3) boiled potato cooled for 24\xa0h (COOLED); or 4) basmati rice', 'potato-based mixed evening meal', 'T2DM (diet or metformin', 'isoenergetic rice meal, boiled, roasted or boiled then cooled potato-based meals']","['Postprandial insulin iAUC', 'postprandial insulin concentrations', 'nocturnal blood glucose response', 'BOIL or ROAST', 'nocturnal glucose AUC', 'postprandial and nocturnal glycemic responses, and postprandial insulin response', 'nocturnal interstitial glucose concentrations', 'postprandial venous glucose area under the curve (iAUC']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4708784', 'cui_str': '31.7'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C0453152', 'cui_str': 'Boiled potato'}, {'cui': 'C0453170', 'cui_str': 'Roast potato'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C0032846', 'cui_str': 'Potato'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0585040', 'cui_str': 'Evening meal'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0242301', 'cui_str': 'Furuncle'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0242301', 'cui_str': 'Furuncle'}, {'cui': 'C1522203', 'cui_str': 'Interstitial route'}, {'cui': 'C0427743', 'cui_str': 'Glucose concentration, test strip measurement'}]",24.0,0.0221104,No differences were detected in postprandial venous glucose area under the curve (iAUC) between CONTROL and all three potato conditions.,"[{'ForeName': 'Brooke L', 'Initials': 'BL', 'LastName': 'Devlin', 'Affiliation': 'Exercise and Nutrition Research Program, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, 3000, Australia; Department of Dietetics, Nutrition and Sport, La Trobe University, Melbourne, Australia. Electronic address: b.devlin@latrobe.edu.au.'}, {'ForeName': 'Evelyn B', 'Initials': 'EB', 'LastName': 'Parr', 'Affiliation': 'Exercise and Nutrition Research Program, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, 3000, Australia.'}, {'ForeName': 'Bridget E', 'Initials': 'BE', 'LastName': 'Radford', 'Affiliation': 'Exercise and Nutrition Research Program, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, 3000, Australia.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Hawley', 'Affiliation': 'Exercise and Nutrition Research Program, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, 3000, Australia.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.09.049'] 343,33077275,"Increased bioavailability of phenolic acids and enhanced vascular function following intake of feruloyl esterase-processed high fibre bread: A randomized, controlled, single blind, crossover human intervention trial.","BACKGROUND & AIMS Clinical trial data have indicated an association between wholegrain consumption and a reduction in surrogate markers of cardiovascular disease. Phenolics present in wholegrain bound to arabinoxylan fibre may contribute these effects, particularly when released enzymatically from the fiber prior to ingestion. The aim of the present study was therefore to determine whether the intake of high fibre bread containing higher free ferulic acid (FA) levels (enzymatically released during processing) enhances human endothelium-dependent vascular function. METHODS A randomized, single masked, controlled, crossover, human intervention study was conducted on 19 healthy men. Individuals consumed either a high fibre flatbread with enzymatically released free FA (14.22 mg), an equivalent standard high fibre bread (2.34 mg), or a white bread control (0.48 mg) and markers of vascular function and plasma phenolic acid concentrations were measured at baseline, 2, 5 and 7 h post consumption. RESULTS Significantly increased brachial arterial dilation was observed following consumption of the high free FA ('enzyme-treated') high fibre bread verses both a white bread (2 h: p < 0.05; 5 h: p < 0.01) and a standard high fibre bread (5 h: p < 0.05). Concurrently, significant increases in plasma FA levels were observed, at 2 h (p < 0.01) after consumption of the enzyme-treated bread, relative to control treatments. Blood pressure, heart rate, DVP-SI and DVP-RI were not significantly altered following intake of any of the breads (p > 0.05). CONCLUSION Dietary intake of bread, processed enzymatically to release FA from arabinoxylan fiber during production increases the bioavailability of FA, and induces acute endothelium-dependent vasodilation. CLINICAL TRIAL REGISTRY NO: NCT03946293. WEBSITE: www.clinicaltrials.gov.",2021,"Concurrently, significant increases in plasma FA levels were observed, at 2 h (p < 0.01) after consumption of the enzyme-treated bread, relative to control treatments.",['19 healthy men'],['feruloyl esterase-processed high fibre bread'],"['Blood pressure, heart rate, DVP-SI and DVP-RI', 'bioavailability of phenolic acids and enhanced vascular function', 'free ferulic acid (FA) levels', 'vascular function and plasma phenolic acid concentrations', 'bioavailability of FA', 'brachial arterial dilation', 'plasma FA levels']","[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0117605', 'cui_str': 'feruloyl esterase'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0006138', 'cui_str': 'Bread'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0078144', 'cui_str': 'VDP protocol'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C2586298', 'cui_str': 'Hydroxybenzoic acid'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0060291', 'cui_str': 'ferulic acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}]",19.0,0.147132,"Concurrently, significant increases in plasma FA levels were observed, at 2 h (p < 0.01) after consumption of the enzyme-treated bread, relative to control treatments.","[{'ForeName': 'Alice L', 'Initials': 'AL', 'LastName': 'Turner', 'Affiliation': 'Department of Food and Nutritional Sciences, School of Chemistry, Food and Pharmacy, University of Reading, Reading, UK (ALT, JPES).'}, {'ForeName': 'Louise V', 'Initials': 'LV', 'LastName': 'Michaelson', 'Affiliation': 'Department of Plant Sciences, Rothamsted Research, Harpenden, UK (LVM, PRS, AL).'}, {'ForeName': 'Peter R', 'Initials': 'PR', 'LastName': 'Shewry', 'Affiliation': 'Department of Plant Sciences, Rothamsted Research, Harpenden, UK (LVM, PRS, AL).; School of Agriculture, Policy and Development, University of Reading, Reading, Berks, UK (PRS).'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Lovegrove', 'Affiliation': 'Department of Plant Sciences, Rothamsted Research, Harpenden, UK (LVM, PRS, AL).'}, {'ForeName': 'Jeremy P E', 'Initials': 'JPE', 'LastName': 'Spencer', 'Affiliation': 'Department of Food and Nutritional Sciences, School of Chemistry, Food and Pharmacy, University of Reading, Reading, UK (ALT, JPES).. Electronic address: j.p.e.spencer@reading.ac.uk.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.07.026'] 344,33075842,A Model to Predict Vaginal Delivery and Maternal and Neonatal Morbidity in Low-Risk Nulliparous Patients at Term.,"OBJECTIVE This study aimed to develop and validate a model to predict the probability of vaginal delivery (VD) in low-risk term nulliparous patients, and to determine whether it can predict the risk of severe maternal and neonatal morbidity. METHODS Secondary analysis of an obstetric cohort of patients and their neonates born in 25 hospitals across the United States ( n  = 115,502). Trained and certified research personnel abstracted the maternal and neonatal records. Nulliparous patients with singleton, nonanomalous vertex fetuses, admitted with an intent for VD ≥ 37 weeks were included in this analysis. Patients in active labor (cervical exam > 5 cm), those with prior cesarean and other comorbidities were excluded. Eligible patients were randomly divided into a training and test sets. Based on the training set, and using factors available at the time of admission for delivery, we developed and validated a logistic regression model to predict the probability of VD, and then estimated the prevalences of severe morbidity according to the predicted probability of VD. RESULTS A total of 19,611 patients were included. Based on the training set ( n  = 9,739), a logistic regression model was developed that included maternal age, body mass index (BMI), cervical dilatation, and gestational age on admission. The model was internally validated on the test set ( n  = 9,872 patients) and yielded a receiver operating characteristic-area under the curve (ROC-AUC) of 0.71 (95% confidence interval [CI]: 0.70-0.72). Based on a subset of 18,803 patients with calculated predicted probabilities, we demonstrated that the prevalences of severe morbidity decreased as the predicted probability of VD increased ( p  < 0.01). CONCLUSION In a large cohort of low-risk nulliparous patients in early labor or undergoing induction of labor, at term with singleton gestations, we developed and validated a model to calculate the probability of VD, and maternal and neonatal morbidity. If externally validated, this calculator may be clinically useful in helping to direct level of care, staffing, and adjustment for case-mix among various systems. KEY POINTS · A model to predict the probability of vaginal delivery in low-risk nulliparous patients at term.. · The model also predicts the risk of severe maternal and neonatal morbidity.. · The prevalences of severe morbidity decrease as the probability of vaginal delivery increases..",2020,"The model was internally validated on the test set ( n  = 9,872 patients) and yielded a receiver operating characteristic-area under the curve (ROC-AUC) of 0.71 (95% confidence interval [CI]: 0.70-0.72).","['low-risk term nulliparous patients', 'Nulliparous patients with singleton, nonanomalous vertex fetuses, admitted with an intent for VD\u2009≥\u200937 weeks', 'Eligible patients', 'Patients in active labor (cervical exam\u2009>\u20095\u2009cm), those with prior cesarean and other comorbidities were excluded', 'low-risk nulliparous patients at term.. ·', 'A total of 19,611 patients were included', 'Secondary analysis of an obstetric cohort of patients and their neonates born in 25 hospitals across the United States ( n \u2009=\u2009115,502', 'Low-Risk Nulliparous Patients at Term', 'low-risk nulliparous patients in early labor or undergoing induction of labor, at term with singleton gestations']",[],"['Vaginal Delivery and Maternal and Neonatal Morbidity', 'probability of vaginal delivery', 'probability of vaginal delivery (VD', 'probability of VD, and maternal and neonatal morbidity', 'probability of VD', 'severe morbidity']","[{'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0230003', 'cui_str': 'Vertex structure'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0233081', 'cui_str': 'Normal labor'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0439084', 'cui_str': '>5'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0022876', 'cui_str': 'Premature labor'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]",[],"[{'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",19611.0,0.0573934,"The model was internally validated on the test set ( n  = 9,872 patients) and yielded a receiver operating characteristic-area under the curve (ROC-AUC) of 0.71 (95% confidence interval [CI]: 0.70-0.72).","[{'ForeName': 'Maged M', 'Initials': 'MM', 'LastName': 'Costantine', 'Affiliation': 'Departments of Obstetrics and Gynecology of University of Texas Medical Branch, Galveston, Texas.'}, {'ForeName': 'Grecio', 'Initials': 'G', 'LastName': 'Sandoval', 'Affiliation': 'The George Washington University Biostatistics Center, Washington, Dist. of Columbia.'}, {'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Grobman', 'Affiliation': 'Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Bailit', 'Affiliation': 'Department of Obstetrics and Gynecology, MetroHealth Medical Center-Case Western Reserve University, Cleveland, Ohio.'}, {'ForeName': 'Uma M', 'Initials': 'UM', 'LastName': 'Reddy', 'Affiliation': 'Department of Obstetrics and Gynecology, The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.'}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Wapner', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University, New York, New York.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Varner', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Thorp', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Steve N', 'Initials': 'SN', 'LastName': 'Caritis', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Prasad', 'Affiliation': 'Department of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Alan T N', 'Initials': 'ATN', 'LastName': 'Tita', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Yoram', 'Initials': 'Y', 'LastName': 'Sorokin', 'Affiliation': 'Department of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Dwight J', 'Initials': 'DJ', 'LastName': 'Rouse', 'Affiliation': 'Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Sean C', 'Initials': 'SC', 'LastName': 'Blackwell', 'Affiliation': ""Department of Obstetrics and Gynecology, The University of Texas Health Science Center at Houston, McGovern Medical School-Children's Memorial Hermann Hospital, Houston, Texas.""}, {'ForeName': 'Jorge E', 'Initials': 'JE', 'LastName': 'Tolosa', 'Affiliation': 'Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon.'}]",American journal of perinatology,['10.1055/s-0040-1718704'] 345,33081982,"A plant-based meal affects thalamus perfusion differently than an energy- and macronutrient-matched conventional meal in men with type 2 diabetes, overweight/obese, and healthy men: A three-group randomized crossover study.","BACKGROUND & AIMS Reward circuitry in the brain plays a key role in weight regulation. We tested the effects of a plant-based meal on these brain regions. METHODS A randomized crossover design was used to test the effects of two energy- and macronutrient-matched meals: a vegan (V-meal) and a conventional meat (M-meal) on brain activity, gastrointestinal hormones, and satiety in participants with type 2 diabetes (T2D; n = 20), overweight/obese participants (O; n = 20), and healthy controls (H; n = 20). Brain perfusion was measured, using arterial spin labeling functional brain imaging; satiety was assessed using a visual analogue scale; and plasma concentrations of gut hormones were determined at 0 and 180 min. Repeated-measures ANOVA was used for statistical analysis. Bonferroni correction for multiple comparisons was applied. The Hedge's g statistic was used to measure the effect size for means of paired difference between the times (180-0 min) and meal types (M-V meal) for each group. RESULTS Thalamus perfusion was the highest in patients with T2D and the lowest in overweight/obese individuals (p = 0.001). Thalamus perfusion decreased significantly after ingestion of the M-meal in men with T2D (p = 0.04) and overweight/obese men (p = 0.004), and it decreased significantly after ingestion of the V-meal in healthy controls (p < 0.001; Group x Meal x Time: F = 3.4; p = 0.035). The effect size was -0.41 (95% CI, -1.14 to 0.31; p = 0.26) for men with diabetes; -0.72 (95% CI, -1.48 to 0.01; p = 0.05) for overweight/obese men; and 0.82 (95% CI, 0.09 to 1.59; p = 0.03) for healthy men. Postprandial secretion of active GLP-1 increased after the V-meal compared with the M-meal by 42% (95% CI 25-62%; p = 0.003) in men with T2D and by 41% (95% CI 24-61%; p = 0.002) in healthy controls. Changes in thalamus perfusion after ingestion of both test meals correlated with changes in satiety (r = +0.68; p < 0.01), fasting plasma insulin (r = +0.40; p < 0.01), C-peptide (r = +0.48; p < 0.01) and amylin (r = +0.55; p < 0.01), and insulin secretion at 5 mmol/l (r = +0.77; p < 0.05). CONCLUSIONS The higher postprandial GLP-1 secretion after the V-meal in men with T2D, with concomitant greater satiety and changes in thalamus perfusion, suggest a potential use of plant-based meals in addressing the key pathophysiologic mechanisms of food intake regulation. Trial registration ClinicalTrials.gov number, NCT02474147.",2021,"Thalamus perfusion decreased significantly after ingestion of the M-meal in men with T2D (p = 0.04) and overweight/obese men (p = 0.004), and it decreased significantly after ingestion of the V-meal in healthy controls (p < 0.001; Group x Meal x Time: F = ","['men with type 2 diabetes, overweight/obese, and healthy men', 'participants with type 2 diabetes (T2D; n\xa0=\xa020), overweight/obese participants (O; n\xa0=\xa020), and healthy controls (H; n\xa0=\xa020', 'men with diabetes;\xa0-0.72']","['plant-based meal', 'energy- and macronutrient-matched conventional meal', 'energy- and macronutrient-matched meals: a vegan (V-meal) and a conventional meat (M-meal']","['brain activity, gastrointestinal hormones, and satiety', 'visual analogue scale; and plasma concentrations of gut hormones', 'satiety', 'fasting plasma insulin', 'Thalamus perfusion', 'Brain perfusion', 'insulin secretion', 'higher postprandial GLP-1 secretion', 'Postprandial secretion of active GLP-1']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C4517475', 'cui_str': '0.72'}]","[{'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0344353', 'cui_str': 'Vegan'}, {'cui': 'C0025017', 'cui_str': 'Meat'}]","[{'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0017182', 'cui_str': 'Gastrointestinal hormone'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0205177', 'cui_str': 'Active'}]",,0.0847429,"Thalamus perfusion decreased significantly after ingestion of the M-meal in men with T2D (p = 0.04) and overweight/obese men (p = 0.004), and it decreased significantly after ingestion of the V-meal in healthy controls (p < 0.001; Group x Meal x Time: F = ","[{'ForeName': 'Hana', 'Initials': 'H', 'LastName': 'Kahleova', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Physicians Committee for Responsible Medicine, Washington, DC, USA. Electronic address: hkahleova@pcrm.org.'}, {'ForeName': 'Jaroslav', 'Initials': 'J', 'LastName': 'Tintera', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Lenka', 'Initials': 'L', 'LastName': 'Thieme', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Veleba', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Klementova', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Kudlackova', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Hana', 'Initials': 'H', 'LastName': 'Malinska', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Olena', 'Initials': 'O', 'LastName': 'Oliyarnyk', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Irena', 'Initials': 'I', 'LastName': 'Markova', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Haluzik', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Pavlovicova', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hill', 'Affiliation': 'Institute of Endocrinology, Prague, Czech Republic.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Tura', 'Affiliation': 'Metabolic Unit, CNR Institute of Neuroscience, Padua, Italy.'}, {'ForeName': 'Terezie', 'Initials': 'T', 'LastName': 'Pelikanova', 'Affiliation': 'Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.005'] 346,33081983,Effect of nutritional support in patients with lower respiratory tract infection: Secondary analysis of a randomized clinical trial.,"BACKGROUND In polymorbid patients with bronchopulmonary infection, malnutrition is an independent risk factor for mortality. There is a lack of interventional data investigating whether providing nutritional support during the hospital stay in patients at risk for malnutrition presenting with lower respiratory tract infection lowers mortality. METHODS For this secondary analysis of a randomized clinical trial (EFFORT), we analyzed data of a subgroup of patients with confirmed lower respiratory tract infection from an initial cohort of 2028 patients. Patients at nutritional risk (Nutritional Risk Screening [NRS] score ≥3 points) were randomized to receive protocol-guided individualized nutritional support to reach protein and energy goals (intervention group) or standard hospital food (control group). The primary endpoint of this analysis was all-cause 30-day mortality. RESULTS We included 378 of 2028 EFFORT patients (mean age 74.4 years, 24% with COPD) into this analysis. Compared to usual care hospital nutrition, individualized nutritional support to reach caloric and protein goals showed a similar beneficial effect of on the risk of mortality in the subgroup of respiratory tract infection patients as compared to the main EFFORT trial (odds ratio 0.47 [95%CI 0.17 to 1.27, p = 0.136] vs 0.65 [95%CI 0.47 to 0.91, p = 0.011]) with no evidence of a subgroup effect (p for interaction 0.859). Effects were also similar among different subgroups based on etiology and type of respiratory tract infection and for other secondary endpoints. CONCLUSION This subgroup analysis from a large nutrition support trial suggests that patients at nutritional risk as assessed by NRS 2002 presenting with bronchopulmonary infection to the hospital likely have a mortality benefit from individualized inhospital nutritional support. The small sample size and limited statistical power calls for larger nutritional studies focusing on this highly vulnerable patient population. CLINICAL TRIAL REGISTRATION Registered under ClinicalTrials.gov Identifier no. NCT02517476.",2021,p = 0.011]) with no evidence of a subgroup effect (p for interaction 0.859).,"['Patients at nutritional risk (Nutritional Risk Screening [NRS] score ≥3 points', '378 of 2028 EFFORT patients (mean age 74.4 years, 24% with COPD) into this analysis', 'patients with confirmed lower respiratory tract infection from an initial cohort of 2028 patients', 'patients with lower respiratory tract infection', 'patients at risk for malnutrition presenting with lower respiratory tract infection lowers mortality']","['protocol-guided individualized nutritional support to reach protein and energy goals (intervention group) or standard hospital food (control group', 'nutritional support']","['etiology and type of respiratory tract infection', 'cause 30-day mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0149725', 'cui_str': 'Lower respiratory tract infection'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0184549', 'cui_str': 'At risk for imbalanced nutrition, less than body requirements'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0035243', 'cui_str': 'Respiratory tract infection'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",2028.0,0.157558,p = 0.011]) with no evidence of a subgroup effect (p for interaction 0.859).,"[{'ForeName': 'Annic', 'Initials': 'A', 'LastName': 'Baumgartner', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.'}, {'ForeName': 'Flavia', 'Initials': 'F', 'LastName': 'Hasenboehler', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Cantone', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Hersberger', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Bargetzi', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Bargetzi', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Kaegi-Braun', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Tribolet', 'Affiliation': 'Internal Medicine, Spital Lachen, Switzerland; Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland.'}, {'ForeName': 'Filomena', 'Initials': 'F', 'LastName': 'Gomes', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; The New York Academy of Sciences, New York City, NY, USA.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Hoess', 'Affiliation': 'Internal Medicine, Kantonsspital Muensterlingen, Switzerland.'}, {'ForeName': 'Vojtech', 'Initials': 'V', 'LastName': 'Pavlicek', 'Affiliation': 'Internal Medicine, Kantonsspital Muensterlingen, Switzerland.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Bilz', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Sigrist', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Brändle', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Henzen', 'Affiliation': 'Internal Medicine, Kantonsspital Luzern, Switzerland.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Thomann', 'Affiliation': 'Department of Internal Medicine, Buergerspital Solothurn, Switzerland.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Rutishauser', 'Affiliation': 'Internal Medicine, Kantonsspital Baselland, Switzerland.'}, {'ForeName': 'Drahomir', 'Initials': 'D', 'LastName': 'Aujesky', 'Affiliation': 'Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Rodondi', 'Affiliation': 'Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Switzerland.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Donzé', 'Affiliation': ""Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Neuchâtel Hospital Network, Neuchâtel, Switzerland.""}, {'ForeName': 'Zeno', 'Initials': 'Z', 'LastName': 'Stanga', 'Affiliation': 'Division of Diabetology, Endocrinology, Nutritional Medicine & Metabolism, Inselspital, Bern University Hospital, University of Bern, Switzerland.'}, {'ForeName': 'Beat', 'Initials': 'B', 'LastName': 'Mueller', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Schuetz', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland. Electronic address: schuetzph@gmail.com.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.009'] 347,33085510,"Effect of a Novel Smartphone Application on Breastfeeding Rates Among Low-Income, First-Time Mothers Intending to Exclusively Breastfeed: Secondary Analysis of a Randomized Controlled Trial.","Objective: To examine the effect of a novel smartphone application (app)-BreastFeeding Friend (BFF)-on breastfeeding rates among low-income first-time mothers planning exclusive breastfeeding. Methods: A recent randomized controlled trial (RCT) randomized low-income first-time mothers to BFF or control app. BFF contained breastfeeding education and videos. The control app contained digital breastfeeding handouts. Outcomes included breastfeeding rates until 6 months postpartum and patient-reported best breastfeeding resource. After enrollment, nearly half the participants reported planning formula feeding after breastfeeding initiation, potentially confounding the RCT results. In this secondary analysis, women planning formula feeding were excluded. Outcomes between study groups were compared by intent-to-treat. Results: Of the original 170 participants, 41 in BFF and 46 in control group planned exclusively breastfeeding and were included. Exclusive breastfeeding rates were similar from 2 days postpartum (BFF: n  = 19 [48.7%] versus control app: n  = 21 [46.7%]; relative risk [RR] = 1.04, 95% confidence interval, CI = 0.67-1.63]) until 6 months postpartum. At 6 weeks postpartum, the majority of BFF users ( n  = 23 [62.2%]) believed an app provided the best breastfeeding support compared with 39% of control app users ( n  = 16; RR = 1.59 [95% CI = 1.01-2.52]). BFF users were 2.5 times more likely to deny having breastfeeding challenges compared with control app users ( n  = 12 [42.9%] versus n  = 6 [16.7%]; RR = 2.57 [95% CI = 1.10-6.00]). Conclusion: BFF reduced self-reported breastfeeding challenges and was perceived as the best breastfeeding resource at home but did not increase breastfeeding rates among low-income first-time mothers desiring to exclusively breastfeed. BFF shows promise but must be further optimized to ultimately impact breastfeeding rates. Trial Identification Number: NCT03167073.",2021,BFF users were 2.5 times more likely to deny having breastfeeding challenges compared with control app users ( n  = 12 [42.9%] versus n  = 6 [16.7%];,"['170 participants, 41 in BFF and 46 in control group planned exclusively breastfeeding and were included', 'rates among low-income first-time mothers planning exclusive breastfeeding', 'First-Time Mothers Intending to Exclusively Breastfeed']","['novel smartphone application (app)-BreastFeeding Friend (BFF)-on breastfeeding', 'Novel Smartphone Application']","['Exclusive breastfeeding rates', 'breastfeeding rates until 6 months postpartum and patient-reported best breastfeeding resource', 'Breastfeeding Rates', 'breastfeeding rates']","[{'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0242205', 'cui_str': 'Breastfeeding, Exclusive'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0079382', 'cui_str': 'Friend'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0035201', 'cui_str': 'Resources'}]",170.0,0.150521,BFF users were 2.5 times more likely to deny having breastfeeding challenges compared with control app users ( n  = 12 [42.9%] versus n  = 6 [16.7%];,"[{'ForeName': 'Adam K', 'Initials': 'AK', 'LastName': 'Lewkowitz', 'Affiliation': 'Department of Obstetrics and Gynecology, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.'}, {'ForeName': 'Julia D', 'Initials': 'JD', 'LastName': 'López', 'Affiliation': 'Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.'}, {'ForeName': 'Erika F', 'Initials': 'EF', 'LastName': 'Werner', 'Affiliation': 'Department of Obstetrics and Gynecology, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.'}, {'ForeName': 'Megan L', 'Initials': 'ML', 'LastName': 'Ranney', 'Affiliation': 'Department of Emergency Medicine, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Macones', 'Affiliation': ""Department of Women's Health, Dell Medical School, University of Texas at Austin, Austin, Texas, USA.""}, {'ForeName': 'Dwight J', 'Initials': 'DJ', 'LastName': 'Rouse', 'Affiliation': 'Department of Obstetrics and Gynecology, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Savitz', 'Affiliation': 'Department of Epidemiology, Brown School of Public Health, Providence, Rhode Island, USA.'}, {'ForeName': 'Alison G', 'Initials': 'AG', 'LastName': 'Cahill', 'Affiliation': 'Department of Emergency Medicine, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0240'] 348,33085532,A Randomized Controlled Trial: The Effect of Own Mother's Breast Milk Odor and Another Mother's Breast Milk Odor on Pain Level of Newborn Infants.,"Objective: Our research was conducted empirically to determine whether another mother's breast milk could be used to reduce the pain of newborns who were not able to access their own mother's milk for any reason. Materials and Methods: The sample group of the research included 90 newborns [smell of own mother's milk (30), smell of another mother's milk (30), and the control group (30)] hospitalized in the unit. A neonatal information form was used as the data collection tool, the Neonatal Pain, Agitation, and Sedation Scale (N-PASS) was used to assess the newborn's pain, and an evaluation form prepared by the researcher was used to record the findings. Results: The group which was exposed to their own mother's milk had a significantly lower N-PASS mean score compared to other groups and the group which was exposed to another mother's milk was observed to have a significantly lower N-PASS mean score compared to the control group ( p  < 0.05). While the median values for the total time spent crying of the ""own mother's milk"" group and the ""another mother's milk"" group were similar; the total time spent crying of the control group had a significantly higher median value. Conclusion: Our research determined that, while the most effective method for reducing pain in newborns was the smell of their own mother's breast milk, for newborns who were not able to access their own mother's breast milk, the smell of breast milk from a different mother could also be used.",2021,The group which was exposed to their own mothers' milk had a significantly lower N-PASS mean score compared to other groups and the group which was exposed to another mother's milk was observed to have a significantly lower N-PASS mean score compared to the control group ( p  < 0.05).,"['on Pain Level of Newborn Infants', ""90 newborns [smell of own mother's milk (30), smell of another mother's milk (30), and the control group (30)] hospitalized in the unit""]","[""Own Mother's Breast Milk Odor and Another Mother's Breast Milk Odor""]","['total time spent crying', 'Neonatal Pain, Agitation, and Sedation Scale (N-PASS', 'N-PASS mean score', 'pain']","[{'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0026140', 'cui_str': 'Breast milk'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0439148', 'cui_str': 'Unit'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0028884', 'cui_str': 'With odor'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",90.0,0.0206279,The group which was exposed to their own mothers' milk had a significantly lower N-PASS mean score compared to other groups and the group which was exposed to another mother's milk was observed to have a significantly lower N-PASS mean score compared to the control group ( p  < 0.05).,"[{'ForeName': 'Merve', 'Initials': 'M', 'LastName': 'Cakirli', 'Affiliation': 'Department of Child Health and Disease Nursing, Faculty of Health Sciences, Eskisehir Osmangazi University, Eskisehir, Turkey.'}, {'ForeName': 'Ayfer', 'Initials': 'A', 'LastName': 'Acikgoz', 'Affiliation': 'Department of Child Health and Disease Nursing, Faculty of Health Sciences, Eskisehir Osmangazi University, Eskisehir, Turkey.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0222'] 349,33091102,Screening for expired medications in automated dispensing cabinets.,"PURPOSE Results of a study to quantify rates of identification of expired medications in automated dispensing cabinets (ADCs) are reported. METHODS A pre-post analysis was conducted to determine the effect of various types of ADC audits on rates of finding expired medications in ADCs. For the experimental phase of the study, 4 ADCs at the main campus of an academic medical center were randomly assigned to receive one of 4 interventions: (1) monthly audits of all ADC pockets, (2) monthly audits of matrix (open pocket) drawers only, (3) monthly audits of unassigned pockets only, and (4) no additional intervention. RESULTS At baseline, rates of finding expired medication doses in the 4 ADCs ranged from 0.4% to 0.7%. During the 3-month experimental period, rates of finding expired medication doses ranged from 0.1% to 0.3%. During a final audit 1 month later, the ADC targeted for monthly audits of all pockets was found to contain no expired doses, with an overall improvement in expired-dose rates for all audited ADCs observed over the course of the 4-month study. The average time to perform a full audit for an ADC with about 340 pockets was 1 hour, or 15 seconds per pocket. The average time to perform matrix drawer-only audits averaged around 45 minutes, or 11 seconds per pocket. The average time to perform audits of unassigned matrix drawers averaged 30 minutes, or 10 seconds per pocket. CONCLUSION Auditing of all ADC pockets on a monthly basis appears to be an effective method of reducing the rate of identification of expired medications in ADC pockets.",2020,"The average time to perform audits of unassigned matrix drawers averaged 30 minutes, or 10 seconds per pocket. ",['4 ADCs at the main campus of an academic medical center'],"['matrix (open pocket) drawers only, (3) monthly audits of unassigned pockets only, and (4) no additional intervention']",['rates of finding expired medication doses'],"[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0179481', 'cui_str': 'Cabinet'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}]","[{'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0453897', 'cui_str': 'Drawers'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",,0.0354343,"The average time to perform audits of unassigned matrix drawers averaged 30 minutes, or 10 seconds per pocket. ","[{'ForeName': 'Alexis N', 'Initials': 'AN', 'LastName': 'Nanni', 'Affiliation': 'University of North Carolina Medical Center, Chapel Hill, NC.'}, {'ForeName': 'Trusha S', 'Initials': 'TS', 'LastName': 'Rana', 'Affiliation': 'University of North Carolina Medical Center, Chapel Hill, NC.'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Schenkat', 'Affiliation': 'University of North Carolina Medical Center, Chapel Hill, NC.'}]",American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,['10.1093/ajhp/zxaa318'] 350,33092901,Endoscopic intragastric injection of botulinum toxin A in obese patients on bariatric surgery waiting lists: A randomised double-blind study (IntraTox study).,"BACKGROUND & AIMS Several studies have evaluated the effect of intragastric injection of botulinum toxin A to treat obesity, achieving mixed results. Our objective is to determine the effect of intragastric botulinum toxin A on weight loss, satiety, biomarkers, and quality of life of obese patients prior bariatric surgery. METHODS Design: single-centre, randomised, double-blind, placebo-controlled clinical trial in 52 obese patients on bariatric surgery waiting lists. Two-arm parallel: the treatment group was administered intragastric botulinum toxin A by endoscopy, whereas the control group was administered physiological saline solution. Weight loss was evaluated at weeks 2, 4, 8, 16, and 24, as well as changes in body composition, satiety (Visual analogue scale (VAS) and GCSI questionnaire), quality of life (GIQLI questionnaire), and biomarkers of satiety and appetite. RESULTS Weight loss at weeks 2, 4, 8, 16, and 24 after the endoscopy, with respect to the basal visit, was 0.6 ± 2 kg, 0.4 ± 2.7 kg, 0.4 ± 3.1 kg, 0.2 ± 4.5 kg, and 0.6 ± 4.3 kg for the control group vs 1.9 ± 2.1 kg, 2 ± 2.6 kg, 2.8 ± 4.1 kg, 3.5 ± 5.3 kg, and 4.5 ± 7 kg for the treatment group, respectively, being differences between groups significant at all times (p = 0.016, 0.031, 0.014, 0.021, and 0.023, respectively). Treatment group patients obtained a significantly higher score for GIQLI questionnaire compared with baseline (104.4 ± 13.9 points vs 97.7 ± 15.6 points; p = 0.024), showing a significant improvement in the section of subjective physical capacity. No significant differences were found regarding perception of satiety, or biomarkers of satiety and appetite. CONCLUSIONS Intragastric injection of botulinum toxin A is an effective and safe procedure to achieve a moderate weight loss and improve quality of life. Registered under clinicaltrialsregister.eu Identifier EudraCT number 2015-004391-29 https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004391-29/ES.",2021,"Treatment group patients obtained a significantly higher score for GIQLI questionnaire compared with baseline (104.4 ± 13.9 points vs 97.7 ± 15.6 points; p = 0.024), showing a significant improvement in the section of subjective physical capacity.","['52 obese patients on bariatric surgery waiting lists', 'obese patients on bariatric surgery', 'obese patients prior bariatric surgery']","['botulinum toxin', 'botulinum toxin A', 'intragastric botulinum toxin', 'intragastric botulinum toxin A by endoscopy, whereas the control group was administered physiological saline solution', 'placebo', 'Endoscopic intragastric injection of botulinum toxin A']","['weight loss, satiety, biomarkers, and quality of life', 'moderate weight loss and improve quality of life', 'perception of satiety, or biomarkers of satiety and appetite', 'section of subjective physical capacity', 'score for GIQLI questionnaire', 'Weight loss', 'body composition, satiety (Visual analogue scale (VAS) and GCSI questionnaire), quality of life (GIQLI questionnaire), and biomarkers of satiety and appetite']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0332152', 'cui_str': 'Before'}]","[{'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1321035', 'cui_str': 'Injection of botulinum toxin'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0967114', 'cui_str': 'goblet cell silencer inhibitor'}]",52.0,0.19083,"Treatment group patients obtained a significantly higher score for GIQLI questionnaire compared with baseline (104.4 ± 13.9 points vs 97.7 ± 15.6 points; p = 0.024), showing a significant improvement in the section of subjective physical capacity.","[{'ForeName': 'Francisco José', 'Initials': 'FJ', 'LastName': 'Sánchez Torralvo', 'Affiliation': 'UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, S/N, 29009, Málaga, Spain; Universidad de Málaga, Málaga, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA), Spain. Electronic address: fransancheztorralvo@gmail.com.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Vázquez Pedreño', 'Affiliation': 'UGC Aparato Digestivo, Unidad de Endoscopias. Hospital Regional Universitario de Málaga, Málaga, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Gonzalo Marín', 'Affiliation': 'UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, S/N, 29009, Málaga, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA), Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Tapia', 'Affiliation': 'UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, S/N, 29009, Málaga, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA), Spain.'}, {'ForeName': 'Fuensanta', 'Initials': 'F', 'LastName': 'Lima', 'Affiliation': 'UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, S/N, 29009, Málaga, Spain.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'García Fuentes', 'Affiliation': 'Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA), Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'García', 'Affiliation': 'UGC Aparato Digestivo, Unidad de Endoscopias. Hospital Regional Universitario de Málaga, Málaga, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Moreno Ruiz', 'Affiliation': 'UGC Cirugía General y Digestiva, Hospital Regional Universitario de Málaga, Málaga, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Rodríguez Cañete', 'Affiliation': 'UGC Cirugía General y Digestiva, Hospital Regional Universitario de Málaga, Málaga, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Valdés', 'Affiliation': 'UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, S/N, 29009, Málaga, Spain; Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA), Spain.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Olveira', 'Affiliation': 'UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, S/N, 29009, Málaga, Spain; Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA), Spain.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.008'] 351,33103229,"Safety, Feasibility and Effectiveness of Pulse Methylprednisolone Therapy in Comparison with Intramuscular Adrenocorticotropic Hormone in Children with West Syndrome.","OBJECTIVE To assess the feasibility, effectiveness, and safety of pulse methylprednisolone in comparison with intramuscular adrenocorticotropic hormone (ACTH) therapy in children with West syndrome (WS). METHODS This open-label, pilot study with a parallel-group assignment included 44 recently diagnosed children with WS. Methylprednisolone therapy was given as intravenous infusion at a dose of 30 mg/kg/d for five days followed by oral steroids 1 mg/kg gradually tapered over 5-6 wk. The efficacy outcomes included a cessation of epileptic spasms (as per caregiver reporting) and resolution of hypsarrhythmia on electroencephalogram; safety outcome was the frequency of various adverse effects. RESULTS By day 14 of therapy, 6/18 (33.3%) children in the methylprednisolone group and 10/26 (38.5%) children in the ACTH group achieved cessation of epileptic spasms [group difference - 5.2%; confidence interval (CI) -30.7 to 22.8; p = 0.73]. However, by six weeks of therapy, 4/18 (22.2%) children in the methylprednisolone group and 11/26 (42.3%) children in the ACTH group had cessation of epileptic spasms (group difference - 20.1%; CI -43.0 to 8.4; p = 0.17). Hypertension was more commonly observed in the ACTH group (10 children) than in the methylprednisolone group (2 children; p = 0.046). Pulse methylprednisolone therapy was relatively safe. CONCLUSIONS The study observed limited effectiveness of both ACTH and pulse methylprednisolone therapy, which may partially be due to preponderance of structural etiology and a long treatment lag. However, pulse methylprednisolone therapy appeared to be safe, tolerable, and feasible for management of WS.",2021,"By day 14 of therapy, 6/18 (33.3%) children in the methylprednisolone group and 10/26 (38.5%) children in the ACTH group achieved cessation of epileptic spasms [group difference - 5.2%; confidence interval (CI) -30.7 to 22.8; p = 0.73].","['children with West syndrome (WS', '44 recently diagnosed children with WS', 'Children with West Syndrome']","['Pulse Methylprednisolone Therapy', 'Intramuscular Adrenocorticotropic Hormone', 'ACTH', 'Pulse methylprednisolone therapy', 'methylprednisolone', 'Methylprednisolone therapy', 'intramuscular adrenocorticotropic hormone (ACTH) therapy', 'pulse methylprednisolone therapy', 'pulse methylprednisolone', 'ACTH and pulse methylprednisolone therapy']","['safe, tolerable, and feasible for management of WS', 'cessation of epileptic spasms (as per caregiver reporting) and resolution of hypsarrhythmia on electroencephalogram; safety outcome', 'Hypertension', 'feasibility, effectiveness, and safety', 'frequency of various adverse effects', 'Safety, Feasibility and Effectiveness', 'cessation of epileptic spasms']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}]","[{'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C1527366', 'cui_str': 'Salaam Seizures'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",44.0,0.0682628,"By day 14 of therapy, 6/18 (33.3%) children in the methylprednisolone group and 10/26 (38.5%) children in the ACTH group achieved cessation of epileptic spasms [group difference - 5.2%; confidence interval (CI) -30.7 to 22.8; p = 0.73].","[{'ForeName': 'Madan', 'Initials': 'M', 'LastName': 'Rajpurohit', 'Affiliation': 'Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Anju', 'Initials': 'A', 'LastName': 'Gupta', 'Affiliation': 'Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Priyanka', 'Initials': 'P', 'LastName': 'Madaan', 'Affiliation': 'Pediatric Neurology Division, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Jitendra Kumar', 'Initials': 'JK', 'LastName': 'Sahu', 'Affiliation': 'Pediatric Neurology Division, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Pratibha', 'Initials': 'P', 'LastName': 'Singhi', 'Affiliation': 'Pediatric Neurology Division, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India. doctorpratibhasinghi@gmail.com.'}]",Indian journal of pediatrics,['10.1007/s12098-020-03521-7'] 352,33106609,Intensive treat-to-target statin therapy and severity of diabetic retinopathy complicated by hypercholesterolaemia.,"OBJECTIVES To compare the effects of intensive and standard statin therapy on severity of diabetic retinopathy (DR) complicated by hypercholesterolaemia in a prespecified substudy of the standard vs. intEnsive statin therapy for hypercholesteroleMic Patients with diAbetic retinopaTHY (EMPATHY) study. METHODS Among 5144 patients in the multicentre, prospective, randomized EMPATHY study, this substudy considered 157 patients with seven-field fundus photographs of sufficient quality taken during study enrolment and at the 3-year visit. Eighty-five and seventy-two patients received intensive and standard statin treatments, respectively, in a treat-to-target manner. The primary endpoint was a two-step change in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR severity scale at 36 months. Surrogate markers included changes in hard exudates, changes in visual acuity, and additional ocular treatments during study follow-up. RESULTS Intensive and standard treatment groups did not differ significantly in terms of changing two or more steps on the DR severity scale (P = 0.4380). In patients with severe DR, defined as ≥47 on the severity scale, exploratory analysis showed more frequent improvement of DR, by at least one step, with intensive vs. standard treatment (83.3% vs. 40.0%; P = 0.0346). The intensive and standard groups did not differ in changes on the hard exudates severity scale (P = 0.3460), logarithm of minimum angle of resolution visual acuity (P = 0.5500), or additional ocular treatment during follow-up. CONCLUSIONS Intensive and standard statin treatment may have similar effects on DR in the population of all patients with DR and hypercholesterolaemia, but intensive therapy may be more beneficial in patients with severe DR.",2021,"The intensive and standard groups did not differ in changes on the hard exudates severity scale (P = 0.3460), logarithm of minimum angle of resolution visual acuity (P = 0.5500), or additional ocular treatment during follow-up. ","['Eighty-five and seventy-two patients received', 'hypercholesteroleMic Patients with diAbetic retinopaTHY (EMPATHY) study', 'diabetic retinopathy complicated by hypercholesterolaemia', 'patients with severe DR', '157 patients with seven-field fundus photographs of sufficient quality taken during study enrolment and at the 3-year visit', '5144 patients']","['Intensive treat-to-target statin therapy', 'intensive and standard statin therapy', 'intensive and standard statin']","['logarithm of minimum angle of resolution visual acuity', 'hard exudates severity scale', 'DR severity scale', 'severity of diabetic retinopathy (DR', 'two-step change in the Early Treatment Diabetic Retinopathy Study (ETDRS']","[{'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0020443', 'cui_str': 'Hypercholesterolemia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0016823', 'cui_str': 'Structure of fundus of eye'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}]","[{'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0423410', 'cui_str': 'Retinal lipid deposits'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",157.0,0.0390123,"The intensive and standard groups did not differ in changes on the hard exudates severity scale (P = 0.3460), logarithm of minimum angle of resolution visual acuity (P = 0.5500), or additional ocular treatment during follow-up. ","[{'ForeName': 'Tomoaki', 'Initials': 'T', 'LastName': 'Murakami', 'Affiliation': 'Department of Ophthalmology, Kyoto University Graduate School of Medicine, Kyoto, Japan. mutomo@kuhp.kyoto-u.ac.jp.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Kato', 'Affiliation': 'Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Shigeeda', 'Affiliation': 'Ideta Eye Clinic, Kumamoto, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Itoh', 'Affiliation': 'Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Issei', 'Initials': 'I', 'LastName': 'Komuro', 'Affiliation': 'Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Takeuchi', 'Affiliation': 'Department of Clinical Medicine (Biostatistics and Pharmaceutical Medicine), School of Pharmacy, Kitasato University, Tokyo, Japan.'}, {'ForeName': 'Nagahisa', 'Initials': 'N', 'LastName': 'Yoshimura', 'Affiliation': 'Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Eye (London, England)",['10.1038/s41433-020-01202-5'] 353,33122344,"Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial.","PURPOSE A primary analysis of the ongoing NIVAHL trial demonstrated unexpectedly high interim complete response rates to nivolumab-based first-line treatment in early-stage unfavorable Hodgkin lymphoma. However, biomarkers such as metabolic tumor volume (MTV) or total lesion glycolysis (TLG) and their change under treatment (ΔMTV and ΔTLG), measured on PET, might provide additional relevant information for response assessment in this setting. Hence, the current analysis aimed to investigate early response to checkpoint inhibitor therapy beyond conventional criteria. PATIENTS AND METHODS NIVAHL is a prospective, randomized phase II trial that recruited between April 2017 and October 2018. Patients in arms A and B were assessed for early treatment response after two courses of doxorubicin, vinblastine, and dacarbazine with two concomitant nivolumab infusions per cycle (2 × N-AVD) and 4 × nivolumab, respectively. In the current analysis, we included all 59 individuals with PET images available to the central review panel for quantitative analysis before April 30, 2019. RESULTS At interim restaging, we determined a mean ΔMTV and ΔTLG of -99.8% each in arm A after 2 × N-AVD, compared with -91.4% and -91.9%, respectively, for treatment group B undergoing 4 × nivolumab. This high decrease in MTV and TLG was observed regardless of the initial lymphoma burden. CONCLUSIONS Our study showed that nivolumab-based first-line treatment leads to rapid, near-complete reduction of tumor metabolism in early-stage unfavorable Hodgkin lymphoma. Thus, PET-derived biomarkers might allow reduction or even omission of chemotherapy and radiotherapy. Furthermore, MTV and TLG could be also used to optimize immune checkpoint-targeting treatments in other cancers.",2021,"This high decrease in MTV and TLG was observed regardless of the initial lymphoma burden. ","['early-stage unfavorable Hodgkin lymphoma', '59 individuals with PET images available to the central review panel for quantitative analysis before April 30, 2019', 'recruited between April 2017 and October 2018', 'Hodgkin Lymphoma']","['doxorubicin, vinblastine, and dacarbazine', '4×nivolumab', 'nivolumab-based first-line treatment', 'First-Line Anti-PD-1 Treatment']","['MTV and TLG', 'mean ∆MTV and ∆TLG', 'positron emission tomography (PET', 'metabolic tumor volume (MTV) or total lesion glycolysis (TLG) and their change under treatment (∆MTV and ∆TLG']","[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0019829', 'cui_str': 'Hodgkin lymphoma'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0042670', 'cui_str': 'Vinblastine'}, {'cui': 'C0010927', 'cui_str': 'Dacarbazine'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0475276', 'cui_str': 'Tumor volume'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0017952', 'cui_str': 'Glycolysis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]",,0.0366924,"This high decrease in MTV and TLG was observed regardless of the initial lymphoma burden. ","[{'ForeName': 'Conrad-Amadeus', 'Initials': 'CA', 'LastName': 'Voltin', 'Affiliation': 'Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Mettler', 'Affiliation': 'Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Lutz', 'Initials': 'L', 'LastName': 'van Heek', 'Affiliation': 'Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Goergen', 'Affiliation': 'First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Horst', 'Initials': 'H', 'LastName': 'Müller', 'Affiliation': 'First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Baues', 'Affiliation': 'Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Keller', 'Affiliation': 'Department of Hematology, Oncology, and Tumor Immunology, Campus Benjamin Franklin, Charité - University Medicine Berlin, Berlin, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Meissner', 'Affiliation': 'Fifth Department of Internal Medicine, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Karolin', 'Initials': 'K', 'LastName': 'Trautmann-Grill', 'Affiliation': 'First Department of Internal Medicine, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Kerkhoff', 'Affiliation': 'Department of Medicine A - Hematology, Oncology, and Pneumology, University Hospital Münster, University of Münster, Münster, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Fuchs', 'Affiliation': 'First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Sasse', 'Affiliation': 'First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Bastian', 'Initials': 'B', 'LastName': 'von Tresckow', 'Affiliation': 'First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Dietlein', 'Affiliation': 'Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Borchmann', 'Affiliation': 'First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Engert', 'Affiliation': 'First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Kobe', 'Affiliation': 'Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. paul.broeckelmann@uk-koeln.de carsten.kobe@uk-koeln.de.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Bröckelmann', 'Affiliation': 'First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. paul.broeckelmann@uk-koeln.de carsten.kobe@uk-koeln.de.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-3303'] 354,33147665,"Efficacy and safety of ingenol disoxate gel in field treatment of actinic keratosis on full face, scalp or large area (250 cm2) on the chest: results of four phase 3 randomized controlled trials.","INTRODUCTION Actinic keratosis (AK) is a skin condition arising from chronic exposure to ultraviolet light and may lead to the development of malignancies. This trial aimed to evaluate efficacy and safety of ingenol disoxate gel (IngDsx, 0.018% for face/chest [FC]; 0.037% for scalp [S]), versus vehicle. METHODS Four identical phase 3 trials in patients with AK on the full face/up to 250cm2 of chest or full balding scalp, with an initial 8-week period and 12-month follow-up, were conducted. FC and S trials were pooled for analysis. The primary endpoint was complete clearance at Week 8. RESULTS Across trials, 616 patients were randomized to FC and 626 to S, with 410 and 420 assigned to receive IngDsx, respectively. In the FC and S trials, 25.9% and 24.5% of patients in the IngDsx group, respectively, achieved the primary endpoint. IngDsx was relatively well tolerated. During extended follow-up, there were more identified non-melanoma skin malignancies in the IngDsx group than vehicle group; HR: 2.38 (95% CI: 1.28, 4.41). CONCLUSION Treatment with IngDsx was superior to vehicle on all clinical endpoints, patient-reported and cosmetic outcomes. During the 12-month follow-up, slightly increased skin malignancies in the treatment area were identified, potentially due to unintentional detection bias.",2020,"During extended follow-up, there were more identified non-melanoma skin malignancies in the IngDsx group than vehicle group; HR: 2.38 (95% CI: 1.28, 4.41). ","['616 patients were randomized to FC and 626 to S, with 410 and 420 assigned to receive IngDsx, respectively', 'Four identical phase 3 trials in patients with AK on the full face/up to 250cm2 of chest or full balding scalp, with an initial 8-week period and 12-month follow-up, were conducted', 'actinic keratosis on full face, scalp or large area (250 cm2) on the chest']","['ingenol disoxate gel', 'ingenol disoxate gel (IngDsx']","['complete clearance', 'skin malignancies', 'Efficacy and safety', 'melanoma skin malignancies', 'tolerated']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517774', 'cui_str': '420'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0022602', 'cui_str': 'Actinic keratosis'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0002170', 'cui_str': 'Alopecia'}, {'cui': 'C0036270', 'cui_str': 'Scalp structure'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0439479', 'cui_str': 'sq. cm'}]","[{'cui': 'C0063537', 'cui_str': 'ingenol'}, {'cui': 'C0017243', 'cui_str': 'Gel'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0151779', 'cui_str': 'Malignant melanoma of skin'}]",616.0,0.0669167,"During extended follow-up, there were more identified non-melanoma skin malignancies in the IngDsx group than vehicle group; HR: 2.38 (95% CI: 1.28, 4.41). ","[{'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Berman', 'Affiliation': 'Center for Clinical and Cosmetic Research, Aventura, FL. bbmdphd@gmail.com.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bukhalo', 'Affiliation': ''}, {'ForeName': 'C William', 'Initials': 'CW', 'LastName': 'Hanke', 'Affiliation': ''}, {'ForeName': 'Mikala Fiig', 'Initials': 'MF', 'LastName': 'Jarner', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Larsson', 'Affiliation': ''}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Siegel', 'Affiliation': ''}, {'ForeName': 'Torsten', 'Initials': 'T', 'LastName': 'Skov', 'Affiliation': ''}, {'ForeName': 'Rolf-Markus', 'Initials': 'RM', 'LastName': 'Szeimies', 'Affiliation': ''}]",Dermatology online journal,[] 355,33070419,Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.,"AIMS Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). While ATTR-ACT was not designed for a dose-specific assessment, further analysis from ATTR-ACT and its long-term extension study (LTE) can guide determination of the optimal dose. METHODS AND RESULTS In ATTR-ACT, patients were randomized (2:1:2) to tafamidis 80 mg, 20 mg, or placebo for 30 months. Patients completing ATTR-ACT could enrol in the LTE (with placebo-treated patients randomized to tafamidis 80 or 20 mg; 2:1) and all patients were subsequently switched to high-dose tafamidis. All-cause mortality was assessed in ATTR-ACT combined with the LTE (median follow-up 51 months). In ATTR-ACT, the combination of all-cause mortality and cardiovascular-related hospitalizations over 30 months was significantly reduced with tafamidis 80 mg (P = 0.0030) and 20 mg (P = 0.0048) vs. placebo. All-cause mortality vs. placebo was reduced with tafamidis 80 mg [Cox hazards model (95% confidence interval): 0.690 (0.487-0.979), P = 0.0378] and 20 mg [0.715 (0.450-1.137), P = 0.1564]. The mean (standard error) change in N-terminal pro-B-type natriuretic peptide from baseline to Month 30 was -1170.51 (587.31) (P = 0.0468) with tafamidis 80 vs. 20 mg. In ATTR-ACT combined with the LTE there was a significantly greater survival benefit with tafamidis 80 vs. 20 mg [0.700 (0.501-0.979), P = 0.0374]. Incidence of adverse events in both tafamidis doses were comparable to placebo. CONCLUSION Tafamidis, both 80 and 20 mg, effectively reduced mortality and cardiovascular-related hospitalizations in patients with ATTR-CM. The longer-term survival data and the lack of dose-related safety concerns support tafamidis 80 mg as the optimal dose. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov NCT01994889; NCT02791230.",2021,"All-cause mortality vs. placebo was reduced with tafamidis 80mg (Cox hazards model [95% CI]: 0.690 [0.487-0.979], P=0.0378) and 20mg (0.715 [0.450-1.137], P=0.1564).",['patients with ATTR-CM'],['placebo'],"['Incidence of adverse events', 'longer-term survival data', 'Efficacy and safety', 'mortality and cardiovascular-related hospitalizations', 'mean (SE) change in NT-proBNP', 'survival benefit']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032923', 'cui_str': 'Prealbumin'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}]",,0.153542,"All-cause mortality vs. placebo was reduced with tafamidis 80mg (Cox hazards model [95% CI]: 0.690 [0.487-0.979], P=0.0378) and 20mg (0.715 [0.450-1.137], P=0.1564).","[{'ForeName': 'Thibaud', 'Initials': 'T', 'LastName': 'Damy', 'Affiliation': 'French Referral Center for Cardiac Amyloidosis, Amyloidosis Mondor Network, GRC Amyloid Research Institute and Department of Cardiology, all at APHP, CHU Henri Mondor; and INSERM U955, Clinical Investigation Center 006, and DHU ATVB, Créteil, France.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Garcia-Pavia', 'Affiliation': 'Hospital Universitario Puerta de Hierro Majadahonda, CIBERCV, Madrid, Spain.'}, {'ForeName': 'Mazen', 'Initials': 'M', 'LastName': 'Hanna', 'Affiliation': 'Amyloidosis Centre, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': 'Judge', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Giampaolo', 'Initials': 'G', 'LastName': 'Merlini', 'Affiliation': 'Amyloidosis Center, IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy.'}, {'ForeName': 'Balarama', 'Initials': 'B', 'LastName': 'Gundapaneni', 'Affiliation': 'Pfizer, Groton, CT, USA.'}, {'ForeName': 'Terrell A', 'Initials': 'TA', 'LastName': 'Patterson', 'Affiliation': 'Pfizer, Groton, CT, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Riley', 'Affiliation': 'Pfizer, Groton, CT, USA.'}, {'ForeName': 'Jeffrey H', 'Initials': 'JH', 'LastName': 'Schwartz', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Marla B', 'Initials': 'MB', 'LastName': 'Sultan', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Witteles', 'Affiliation': 'Stanford University School of Medicine, Stanford, CA, USA.'}]",European journal of heart failure,['10.1002/ejhf.2027'] 356,33084903,"Use of Smokeless Tobacco Before Conception and Its Relationship With Maternal and Fetal Outcomes of Pregnancy in Thatta, Pakistan: Findings From Women First Study.","INTRODUCTION Smokeless tobacco (SLT) consumption during pregnancy has adverse consequences for the mother and fetus. We aimed to investigate the effects of maternal pre-pregnancy SLT consumption on maternal and fetal outcomes in the district of Thatta, Pakistan. AIMS AND METHODS We conducted a secondary data analysis of an individual randomized controlled trial of preconception maternal nutrition. Study participants were women of reproductive age (WRA) residing in the district of Thatta, Pakistan. Participants were asked questions regarding the usage of commonly consumed SLT known as gutka (exposure variable). Study outcomes included maternal anemia, miscarriage, preterm births, stillbirths, and low birth weight. We performed a cox-regression analysis by controlling for confounders such as maternal age, education, parity, working status, body mass index, and geographic clusters. RESULTS The study revealed that 71.5% of the women reported using gutka, with a higher proportion residing in rural areas as compared with urban areas in the district of Thatta, Pakistan. In the multivariable analysis, we did not find a statistically significant association between gutka usage and anemia [(relative risk, RR: 1.04, 95% confidence interval, CI (0.92 to 1.16)], miscarriage [(RR: 1.08, 95% CI (0.75 to 1.54)], preterm birth [(RR: 1.37, 95% CI (0.64 to 2.93)], stillbirth [(RR: 1.02, 95% CI (0.39 to 2.61)], and low birth weight [(RR: 0.96, 95% CI (0.72 to 1.28)]. CONCLUSIONS The study did not find an association between gutka usage before pregnancy and adverse maternal and fetal outcomes. In the future, robust epidemiological studies are required to detect true differences with a dose-response relationship between gutka usage both before and during pregnancy and adverse fetomaternal outcomes. IMPLICATIONS While most epidemiological studies conducted in Pakistan have focused on smoking and its adverse outcomes among males, none of the studies have measured the burden of SLT among WRA and its associated adverse outcomes. In addition, previously conducted studies have primarily assessed the effect of SLT usage during pregnancy rather than before pregnancy on adverse fetal and maternal outcomes. The current study is unique because it provides an insight into the usage of SLT among WRA before pregnancy and investigates the association between pre-pregnancy SLT usage and its adverse fetomaternal outcomes in rural Pakistan.",2021,"In the multivariable analysis, we did not find a statistically significant association between gutka usage and anemia [(RR: 1.04, 95% CI (0.92-1.16)]; miscarriage [(RR: 1.08, 95% CI (0.75-1.54)]; preterm birth [(RR: 1.37, 95% CI (0.64-2.93)]; stillbirth [(RR: 1.02, 95% CI (0.39-2.61)] and low birth weight [(RR: 0.96, 95% CI (0.72-1.28)]. ","['Study participants were women of reproductive age residing in the district of Thatta, Pakistan', 'district of Thatta, Pakistan']","['maternal pre-pregnancy SLT consumption', 'preconception maternal nutrition', 'Smokeless tobacco (SLT) consumption']","['maternal anemia, miscarriage, preterm births, stillbirths, and low birth weight', 'gutka usage and anemia', 'stillbirth', 'preterm birth', 'low birth weight']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0040338', 'cui_str': 'Smokeless Tobacco'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1720845', 'cui_str': 'Maternal Nutritional Physiological Phenomenon'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C4289021', 'cui_str': 'Gutka Tobacco'}, {'cui': 'C0457083', 'cui_str': 'Usage'}]",,0.163725,"In the multivariable analysis, we did not find a statistically significant association between gutka usage and anemia [(RR: 1.04, 95% CI (0.92-1.16)]; miscarriage [(RR: 1.08, 95% CI (0.75-1.54)]; preterm birth [(RR: 1.37, 95% CI (0.64-2.93)]; stillbirth [(RR: 1.02, 95% CI (0.39-2.61)] and low birth weight [(RR: 0.96, 95% CI (0.72-1.28)]. ","[{'ForeName': 'Sumera', 'Initials': 'S', 'LastName': 'Aziz Ali', 'Affiliation': 'Department of Epidemiology, Columbia University New York, NY, USA.'}, {'ForeName': 'Umber', 'Initials': 'U', 'LastName': 'Khan', 'Affiliation': 'Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Farina', 'Initials': 'F', 'LastName': 'Abrejo', 'Affiliation': 'Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Brandi', 'Initials': 'B', 'LastName': 'Vollmer', 'Affiliation': 'Department of Epidemiology, Columbia University New York, NY, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Saleem', 'Affiliation': 'Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'K Michael', 'Initials': 'KM', 'LastName': 'Hambidge', 'Affiliation': 'Department of Pediatrics, Section of Nutrition, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Nancy F', 'Initials': 'NF', 'LastName': 'Krebs', 'Affiliation': 'Department of Pediatrics, Section of Nutrition, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Jamie E', 'Initials': 'JE', 'LastName': 'Westcott', 'Affiliation': 'Department of Pediatrics, Section of Nutrition, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Goldenberg', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University, New York, NY, USA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'McClure', 'Affiliation': 'RTI International, 3040 E. Cornwallis Road, Research Triangle Park, NC, USA.'}, {'ForeName': 'Omrana', 'Initials': 'O', 'LastName': 'Pasha', 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa215'] 357,33083790,Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.,"Background Various cardioprotective approaches have been evaluated to prevent chemotherapy-related cardiotoxicity; however, their overall utility remains uncertain. Objectives To assess the effects of neurohormonal therapies in preventing cardiotoxicity in patients receiving chemotherapy. Methods This meta-analysis included randomized clinical trials of adult patients that underwent chemotherapy and neurohormonal therapies (beta-blockers, mineralocorticoid receptor antagonists, or ACE inhibitors/ARBs) vs. placebo with follow-up ≥4 weeks. The primary outcome was change in left ventricular ejection fraction (LVEF) from baseline to the end of trial. Other outcomes of interest were measures of LV size, strain, and diastolic function. Pooled estimates for each outcome were reported as standardized mean difference (SMD) and weighted mean difference (WMD) between the neurohormonal therapy and placebo groups using random effects models. Results We included 17 trials, collectively enrolling 1,984 participants. In pooled analysis, neurohormonal therapy (vs. placebo) was associated with significantly higher LVEF on follow-up [SMD(95% CI): +1.04(0.57 to 1.50)] but with significant heterogeneity in the pooled estimate (I 2 = 96%). Compared with placebo-treated patients, those randomized to neurohormonal therapies experienced a 3.96% (95%CI: 2.9% to 5.0%) less decline in LVEF estimated by WMD, but with significant heterogeneity (I 2 = 98%). There was a trend towards lower adverse clinical events with neurohormonal therapy (vs. placebo) without statistical significance [risk ratio(95%CI): 0.80(0.53-1.20) I 2 = 71%]. Conclusions Neurohormonal therapies are associated with higher LVEF in follow-up among cancer patients receiving chemotherapy, although absolute changes in LVEF are small and may be within inter-test variability. Furthermore, significant heterogeneity is observed in the treatment effects across studies highlighting the need for larger trials of cardioprotective strategies.",2019,There was a trend towards lower adverse clinical events with neurohormonal therapy (vs. placebo) without statistical significance [risk ratio(95%CI): 0.80(0.53-1.20),"['cancer patients receiving', 'adult patients that underwent', '17 trials, collectively enrolling 1,984 participants', 'patients receiving chemotherapy', 'Patients with Cancer Undergoing Chemotherapy']","['chemotherapy', 'neurohormonal therapies', 'chemotherapy and neurohormonal therapies (beta-blockers, mineralocorticoid receptor antagonists, or ACE inhibitors/ARBs) vs. placebo', 'placebo', 'Neurohormonal Therapies', 'neurohormonal therapy (vs. placebo']","['Cardiotoxicity', 'change in left ventricular ejection fraction (LVEF', 'LV size, strain, and diastolic function']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0001645', 'cui_str': 'Beta adrenergic receptor antagonist'}, {'cui': 'C1579268', 'cui_str': 'Mineralocorticoid Antagonists'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0876994', 'cui_str': 'Cardiotoxicity'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",1984.0,0.517703,There was a trend towards lower adverse clinical events with neurohormonal therapy (vs. placebo) without statistical significance [risk ratio(95%CI): 0.80(0.53-1.20),"[{'ForeName': 'Muthiah', 'Initials': 'M', 'LastName': 'Vaduganathan', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center & Harvard Medical School, Boston, MA.""}, {'ForeName': 'Sameer A', 'Initials': 'SA', 'LastName': 'Hirji', 'Affiliation': ""Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.""}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Qamar', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.""}, {'ForeName': 'Navkaranbir', 'Initials': 'N', 'LastName': 'Bajaj', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Ankur', 'Initials': 'A', 'LastName': 'Gupta', 'Affiliation': 'Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Vlad', 'Initials': 'V', 'LastName': 'Zaha', 'Affiliation': 'Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Alvin', 'Initials': 'A', 'LastName': 'Chandra', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center & Harvard Medical School, Boston, MA.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Haykowsky', 'Affiliation': 'College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Ky', 'Affiliation': 'Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Javid', 'Initials': 'J', 'LastName': 'Moslehi', 'Affiliation': 'Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Anju', 'Initials': 'A', 'LastName': 'Nohria', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center & Harvard Medical School, Boston, MA.""}, {'ForeName': 'Javed', 'Initials': 'J', 'LastName': 'Butler', 'Affiliation': 'Department of Medicine, University of Mississippi, Jackson, MS.'}, {'ForeName': 'Ambarish', 'Initials': 'A', 'LastName': 'Pandey', 'Affiliation': 'Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX.'}]",JACC. CardioOncology,['10.1016/j.jaccao.2019.08.006'] 358,33121939,"Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. In press. https://doi.org/10.1158/1078-0432.ccr-20-2063.",,2020,,['Patients with Advanced Sarcomatoid Renal Cell Carcinoma'],['Nivolumab Plus Ipilimumab'],['Efficacy and Safety'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1266043', 'cui_str': 'Renal cell carcinoma, sarcomatoid'}]","[{'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0202491,,"[{'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Rizzo', 'Affiliation': 'Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Mollica', 'Affiliation': 'Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Massari', 'Affiliation': 'Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address: fmassari79@gmail.com.'}]",European urology oncology,['10.1016/j.euo.2020.10.005'] 359,33130093,"Does intensity really matter regarding aerobic exercise reductions in wave reflection and central hemodynamics? Commentary on ""The effect of acute aerobic exercise on central arterial stiffness, wave reflections, and hemodynamics in adults with diabetes: A randomized cross-over design"" by Way et al.",,2021,,['adults with diabetes'],['acute aerobic exercise'],"['central arterial stiffness, wave reflection and hemodynamics']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}]",,0.0689343,,"[{'ForeName': 'Wendell Arthur', 'Initials': 'WA', 'LastName': 'Lopes', 'Affiliation': 'Department of Physical Education, Center of Health Sciences, State University of Maringa, Maringa 87020-900, Brazil; Postgraduate in Physical Education Program, Center of Health Sciences, State University of Maringa, Maringa 87020-900, Brazil; Research Group on Systemic Arterial Hypertension, Arterial Stiffness and Vascular Aging (GPHARV), Maringa 87020-900, Brazil.'}, {'ForeName': 'João Carlos', 'Initials': 'JC', 'LastName': 'Locatelli', 'Affiliation': 'Postgraduate in Physical Education Program, Center of Health Sciences, State University of Maringa, Maringa 87020-900, Brazil; Research Group on Systemic Arterial Hypertension, Arterial Stiffness and Vascular Aging (GPHARV), Maringa 87020-900, Brazil. Electronic address: joao17_carlos@hotmail.com.'}, {'ForeName': 'Caroline Ferraz', 'Initials': 'CF', 'LastName': 'Simões', 'Affiliation': 'Department of Physical Education, Center of Health Sciences, State University of Maringa, Maringa 87020-900, Brazil; Postgraduate in Physical Education Program, Center of Health Sciences, State University of Maringa, Maringa 87020-900, Brazil; Research Group on Systemic Arterial Hypertension, Arterial Stiffness and Vascular Aging (GPHARV), Maringa 87020-900, Brazil.'}, {'ForeName': 'Rogério Toshiro Passos', 'Initials': 'RTP', 'LastName': 'Okawa', 'Affiliation': 'Research Group on Systemic Arterial Hypertension, Arterial Stiffness and Vascular Aging (GPHARV), Maringa 87020-900, Brazil; Department of Medicine, Center of Health Sciences, State University of Maringa, Maringa 87020-900, Brazil.'}]",Journal of sport and health science,['10.1016/j.jshs.2020.10.008'] 360,33136005,A randomised comparison of coronary stents according to short or prolonged durations of dual antiplatelet therapy in patients with acute coronary syndromes: a pre-specified analysis of the SMART-DATE trial.,"BACKGROUND Data on direct comparison between various drug-eluting stents with short duration dual antiplatelet therapy (DAPT) are limited, especially in patients with acute coronary syndrome (ACS). AIMS We sought to compare biodegradable polymer biolimus-eluting stents (BP-BES) with durable polymer everolimus-eluting (DP-EES) and zotarolimus-eluting stents (DP-ZES) in patients with ACS according to different durations of DAPT. METHODS In the SMART-DATE trial, 2,712 patients with ACS underwent randomisation for allocation of DAPT (6 months [n=1,357] or 12 months or longer [n=1,355]) and type of stent (BP-BES [n=901]), DP-EES [n=904], or DP-ZES [n=907]). The primary endpoint was a composite of cardiac death, myocardial infarction, or stent thrombosis. RESULTS At 18 months, the primary endpoint was attained by 2.6% with BP-BES, 2.0% with DP-EES, and 2.1% with DP-ZES (HR 1.29, 95% CI: 0.70-2.39, p=0.42 for BP-BES vs DP-EES and HR 1.23, 95% CI: 0.67-2.26, p=0.50 for BP-BES vs DP-ZES). The treatment effect of BP-BES for the primary endpoint was consistent among patients receiving 6-month DAPT as well as those receiving 12-month or longer DAPT (BP-BES vs. DP-EES, pinteraction=0.48 and BP-BES vs DP-ZES, pinteraction=0.87). After excluding 179 patients (101 in the BP-BES group) who did not receive allocated DES, the per-protocol analysis showed similar results. CONCLUSIONS The risk of a composite of cardiac death, myocardial infarction, or stent thrombosis was not significantly different between patients receiving BP-BES versus DP-EES or DP-ZES across a short or prolonged duration of DAPT after ACS.",2021,"The risk of a composite of cardiac death, myocardial infarction, or stent thrombosis was not significantly different between patients receiving BP-BES vs. DP-EES or DP-ZES across short or prolonged duration of DAPT after ACS.","['patients with Acute Coronary Syndromes', 'patients with acute coronary syndrome(ACS', '2712 patients with ACS underwent randomization for allocation of DAPT (6-month [n=1357] or 12-month or longer [n=1355]) and type of stents (BP-BES [n=901']","['DP-EES [n=904], or DP-ZES', 'Dual Antiplatelet Therapy', 'Coronary Stents', 'biodegradable-polymer biolimus-eluting stents(BP-BES) with durable-polymer everolimus-eluting(DP-EES) and zotarolimus-eluting stents(DP-ZES']","['composite of cardiac death, myocardial infarction, or stent thrombosis', 'risk of a composite of cardiac death, myocardial infarction, or stent thrombosis', 'BP-BES']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}]","[{'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0687568', 'cui_str': 'Coronary artery stent'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C1700035', 'cui_str': 'Zotarolimus'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0038257', 'cui_str': 'Stent'}]",2712.0,0.0722826,"The risk of a composite of cardiac death, myocardial infarction, or stent thrombosis was not significantly different between patients receiving BP-BES vs. DP-EES or DP-ZES across short or prolonged duration of DAPT after ACS.","[{'ForeName': 'Woo Jin', 'Initials': 'WJ', 'LastName': 'Jang', 'Affiliation': 'Ewha Womans University College of Medicine, Seoul Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Jin Bae', 'Initials': 'JB', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Young Bin', 'Initials': 'YB', 'LastName': 'Song', 'Affiliation': ''}, {'ForeName': 'Ki Hong', 'Initials': 'KH', 'LastName': 'Choi', 'Affiliation': ''}, {'ForeName': 'Seung-Hyuk', 'Initials': 'SH', 'LastName': 'Choi', 'Affiliation': ''}, {'ForeName': 'Woo Jung', 'Initials': 'WJ', 'LastName': 'Chun', 'Affiliation': ''}, {'ForeName': 'Ju Hyeon', 'Initials': 'JH', 'LastName': 'Oh', 'Affiliation': ''}, {'ForeName': 'Ik Hyun', 'Initials': 'IH', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'Joon-Hyung', 'Initials': 'JH', 'LastName': 'Doh', 'Affiliation': ''}, {'ForeName': 'Jin-Ok', 'Initials': 'JO', 'LastName': 'Jeong', 'Affiliation': ''}, {'ForeName': 'Jong-Seon', 'Initials': 'JS', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'Hyeon-Cheol', 'Initials': 'HC', 'LastName': 'Gwon', 'Affiliation': ''}, {'ForeName': 'Joo-Yong', 'Initials': 'JY', 'LastName': 'Hahn', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-20-00556'] 361,33148481,Interaction of serum calcium and folic acid treatment on first stroke in hypertensive males.,"BACKGROUND & AIMS The role of serum calcium on the risk of stroke is still uncertain. We aimed to evaluate the effect of serum calcium on first stroke risk, and on the efficacy of folic acid treatment in prevention of first stroke among hypertensive patients. METHODS Our analyses included a total of 19,644 eligible hypertensive adults from the China Stroke Primary Prevention Trial (CSPPT). In the CSPPT, a total of 20,702 hypertensive patients were randomly assigned to a double-blind, daily treatment with either 10 mg enalapril and 0.8 mg folic acid or 10 mg enalapril alone. The primary outcome was a first stroke. RESULTS Over a median of 4.5 years, among those not receiving folic acid, a significantly higher risk of first stroke was found in hypertensive males with baseline albumin-corrected serum calcium ≥2.43 mmol/L (median) (vs. <2.43 mmol/L; 6.5% vs. 2.3%; adjusted HR, 2.47; 95% CI: 1.72, 3.55). For those with enalapril and folic acid treatment, compared with the enalapril only group, the risk of first stroke was reduced from 6.5% to 3.0% (adjusted HR, 0.49; 95% CI: 0.35, 0.68) in hypertensive males with baseline albumin-corrected serum calcium ≥2.43 mmol/L, whereas there was no significant effect among hypertensive males with baseline albumin-corrected serum calcium <2.43 mmol/L. However, among hypertensive females, serum calcium did not significantly affect the first stroke risk and the efficacy of folic acid in prevention of first stroke. CONCLUSIONS Among Chinese hypertensive males, those with elevated serum calcium levels had increased risk of first stroke, and this risk was reduced by 51% with folic acid treatment.",2021,"However, among hypertensive females, serum calcium did not significantly affect the first stroke risk and the efficacy of folic acid in prevention of first stroke. ","['hypertensive males', '20,702 hypertensive patients', 'Chinese hypertensive males', 'hypertensive patients', '19,644 eligible hypertensive adults from the China Stroke Primary Prevention Trial (CSPPT']","['folic acid', 'folic acid treatment', 'enalapril and folic acid', 'serum calcium and folic acid treatment', 'serum calcium', 'enalapril and 0.8\xa0mg folic acid or 10\xa0mg enalapril alone', 'enalapril']","['first stroke', 'risk of first stroke']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0033144', 'cui_str': 'Primary prevention'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0014025', 'cui_str': 'Enalapril'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C4517481', 'cui_str': '0.8'}]","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",20702.0,0.0502796,"However, among hypertensive females, serum calcium did not significantly affect the first stroke risk and the efficacy of folic acid in prevention of first stroke. ","[{'ForeName': 'Hongxu', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; National Clinical Research Center for Kidney Disease, Guangzhou 510515, China; State Key Laboratory for Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou 510515, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510515, China; Institute for Biomedicine, Anhui Medical University, Hefei 230032, China.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; National Clinical Research Center for Kidney Disease, Guangzhou 510515, China; State Key Laboratory for Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou 510515, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510515, China.'}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; National Clinical Research Center for Kidney Disease, Guangzhou 510515, China; State Key Laboratory for Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou 510515, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510515, China.'}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, Peking University First Hospital, Beijing 100034, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Peking University First Hospital, Beijing 100034, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Liang', 'Affiliation': 'Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; National Clinical Research Center for Kidney Disease, Guangzhou 510515, China; State Key Laboratory for Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou 510515, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510515, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Nie', 'Affiliation': 'Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; National Clinical Research Center for Kidney Disease, Guangzhou 510515, China; State Key Laboratory for Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou 510515, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510515, China.'}, {'ForeName': 'Binyan', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Institute for Biomedicine, Anhui Medical University, Hefei 230032, China; Shenzhen Evergreen Medical Institute, Shenzhen 518057, China.'}, {'ForeName': 'Xiaobin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205-2179, USA.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Huo', 'Affiliation': 'Department of Cardiology, Peking University First Hospital, Beijing 100034, China.'}, {'ForeName': 'Fan Fan', 'Initials': 'FF', 'LastName': 'Hou', 'Affiliation': 'Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; National Clinical Research Center for Kidney Disease, Guangzhou 510515, China; State Key Laboratory for Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou 510515, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510515, China.'}, {'ForeName': 'Xiping', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; National Clinical Research Center for Kidney Disease, Guangzhou 510515, China; State Key Laboratory for Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou 510515, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510515, China. Electronic address: xipingxu126@126.com.'}, {'ForeName': 'Xianhui', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': 'Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; National Clinical Research Center for Kidney Disease, Guangzhou 510515, China; State Key Laboratory for Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou 510515, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510515, China. Electronic address: pharmaqin@126.com.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.033'] 362,33160147,Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial.,"BACKGROUND Studies in the adjuvant setting have shown that endocrine therapy related side effects predict breast cancer recurrence risk. Here, we assess the relationship between early reported side effects and incidence of breast cancer in women randomised to tamoxifen for cancer prevention in the International Breast Intervention Study (IBIS)-I trial. METHODS Women randomised to tamoxifen in the IBIS-I trial and for whom side effect status was known at the 6-month follow-up visit were included in this analysis. Side effects included in this analysis were hot flushes, vaginal discharge, and vaginal dryness. The primary endpoint was all breast cancer and secondary endpoint was oestrogen receptor (ER) positive breast cancer. Cox proportional hazard models were used to investigate breast cancer incidence in the tamoxifen group with and without side effects reported within 6 months of randomisation. RESULTS Women randomised to tamoxifen and reporting hot flushes at the 6-month follow-up visit had a non-statistically significant increase in breast cancer compared to those without hot flushes (HR = 1.26 (0.98-1.62), P = 0.08). A significant higher breast cancer risk was observed for postmenopausal women who reported hot flushes at the 6-month follow-up visit compared to those without hot flushes (HR = 1.59 (1.12-2.26), P = 0.01). A higher risk was observed for ER-positive breast cancer in postmenopausal women (HR = 1.81 (1.19-2.74), P = 0.01). No significant associations between gynaecological side effects and breast cancer occurrence was observed. CONCLUSIONS Overall, no association between side effects reported at 6 months and subsequent breast cancer occurrence was observed. Some side effects might be useful markers for breast cancer occurrence in postmenopausal women.",2020,"A significant higher breast cancer risk was observed for postmenopausal women who reported hot flushes at the 6-month follow-up visit compared to those without hot flushes (HR = 1.59 (1.12-2.26), P = 0.01).","['Women randomised to', 'postmenopausal women']","['tamoxifen', 'Tamoxifen']","['breast cancer incidence', 'breast cancer and secondary endpoint was oestrogen receptor (ER) positive breast cancer', 'gynaecological side effects and breast cancer occurrence', 'breast cancer occurrence', 'hot flushes, vaginal discharge, and vaginal dryness', 'breast cancer', 'breast cancer risk', 'hot flushes']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}]","[{'cui': 'C0039286', 'cui_str': 'Tamoxifen'}]","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0034804', 'cui_str': 'Estrogen receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0227791', 'cui_str': 'Vaginal discharge'}, {'cui': 'C0241633', 'cui_str': 'Vaginal dryness'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.0825288,"A significant higher breast cancer risk was observed for postmenopausal women who reported hot flushes at the 6-month follow-up visit compared to those without hot flushes (HR = 1.59 (1.12-2.26), P = 0.01).","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Hale', 'Affiliation': 'Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Charterhouse Square, Queen Mary University London, London, EC1M 6BQ, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Howell', 'Affiliation': 'Division of Cancer Sciences, University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK.'}, {'ForeName': 'Mitch', 'Initials': 'M', 'LastName': 'Dowsett', 'Affiliation': 'Ralph Lauren Centre for Breast Cancer Research, London, SW3 6JJ, UK.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Cuzick', 'Affiliation': 'Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Charterhouse Square, Queen Mary University London, London, EC1M 6BQ, UK.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Sestak', 'Affiliation': 'Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Charterhouse Square, Queen Mary University London, London, EC1M 6BQ, UK. Electronic address: i.sestak@qmul.ac.uk.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.10.015'] 363,33080088,Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study.,"BACKGROUND Atrial fibrillation/atrial flutter (AF/AFL) burden increases with increasing duration of AF/AFL history. HYPOTHESIS Outcomes with dronedarone may also be impacted by duration of AF/AFL history. METHODS In this post hoc analysis of ATHENA, efficacy and safety of dronedarone vs placebo were assessed in groups categorized by time from first known AF/AFL episode to randomization (ie, duration of AF/AFL history): <3 months (short), 3 to <24 months (intermediate), and ≥ 24 months (long). RESULTS Of 2859 patients with data on duration of AF/AFL history, 45.3%, 29.6%, and 25.1% had short, intermediate, and long histories, respectively. Patients in the long history group had the highest prevalence of structural heart disease and were more likely to be in AF/AFL at baseline. Placebo-treated patients in the long history group also had the highest incidence of AF/AFL recurrence and cardiovascular (CV) hospitalization during the study. The risk of first CV hospitalization/death from any cause was lower with dronedarone vs placebo in patients with short (hazard ratio, 0.79 [95% confidence interval: 0.65-0.96]) and intermediate (0.72 [0.56-0.92]) histories; a trend favoring dronedarone was also observed in patients with long history (0.84 [0.66-1.07]). A similar pattern was observed for first AF/AFL recurrence. No new drug-related safety issues were identified. CONCLUSIONS Patients with long AF/AFL history had the highest burden of AF/AFL at baseline and during the study. Dronedarone significantly improved efficacy vs placebo in patients with short and intermediate AF/AFL histories. While exploratory, these results support the potential value in initiating rhythm control treatment early in patients with AF/AFL.",2020,"The risk of first CV hospitalization/death from any cause was lower with dronedarone vs placebo in patients with short (hazard ratio, 0.79 [95% confidence interval: 0.65-0.96]) and intermediate (0.72 [0.56-0.92]) histories; a trend favoring dronedarone was also observed in patients with long history (0.84 [0.66-1.07]).","['groups categorized by time from first known AF/AFL episode to randomization (ie, duration of AF/AFL history', 'patients with AF/AFL', 'patients with short and intermediate AF/AFL histories', '2859 patients with data on duration of AF/AFL history, 45.3%, 29.6%, and 25.1% had short, intermediate, and long histories, respectively']","['Dronedarone', 'dronedarone', 'placebo', 'Placebo', 'dronedarone vs placebo']","['efficacy', 'highest prevalence of structural heart disease', 'highest burden of AF/AFL', 'efficacy and safety', 'Efficacy and safety', 'risk of first CV hospitalization/death', 'highest incidence of AF/AFL recurrence and cardiovascular (CV) hospitalization']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0205166', 'cui_str': 'Long'}]","[{'cui': 'C0766326', 'cui_str': 'dronedarone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",2859.0,0.0325847,"The risk of first CV hospitalization/death from any cause was lower with dronedarone vs placebo in patients with short (hazard ratio, 0.79 [95% confidence interval: 0.65-0.96]) and intermediate (0.72 [0.56-0.92]) histories; a trend favoring dronedarone was also observed in patients with long history (0.84 [0.66-1.07]).","[{'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Blomström-Lundqvist', 'Affiliation': 'Department of Medical Science and Cardiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Nassir', 'Initials': 'N', 'LastName': 'Marrouche', 'Affiliation': 'Section of Cardiology, Tulane University Heart and Vascular Institute, New Orleans, Louisiana, USA.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Connolly', 'Affiliation': 'Population Health Research Institute, Hamilton, Canada.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Corp Dit Genti', 'Affiliation': 'Sanofi-Aventis, Paris, France.'}, {'ForeName': 'Mattias', 'Initials': 'M', 'LastName': 'Wieloch', 'Affiliation': 'Sanofi-Aventis, Paris, France.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Koren', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, at the time of the study, USA.'}, {'ForeName': 'Stefan H', 'Initials': 'SH', 'LastName': 'Hohnloser', 'Affiliation': 'Department of Cardiology, Division of Clinical Electrophysiology, J. W. Goethe University, Frankfurt, Germany.'}]",Clinical cardiology,['10.1002/clc.23463'] 364,33085967,Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.,"AIMS The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). METHODS AND RESULTS We conducted a pre-specified subgroup analysis of The Ticagrelor With Aspirin or Alone in High Risk Patients After Coronary Intervention (TWILIGHT) trial, which enrolled 9006 patients with high-risk features undergoing PCI with DES. After 3 months of dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin, 7119 adherent and event-free patients were randomized in a double-blind manner to ticagrelor plus placebo versus ticagrelor plus aspirin for 12 months. The primary outcome was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding while the composite of all-cause death, myocardial infarction (MI), or stroke was the key secondary outcome. Among patients with NSTE-ACS (n = 4614), ticagrelor monotherapy reduced BARC 2, 3, or 5 bleeding by 53% [3.6% vs. 7.6%; hazard ratio (HR) 0.47; 95% confidence interval (CI) 0.36-0.61; P < 0.001) and in stable patients (n = 2503) by 24% (4.8% vs. 6.2%; HR 0.76; 95% CI 0.54-1.06; P = 0.11; nominal Pint = 0.03). Rates of all-cause death, MI, or stroke among those with (4.3% vs. 4.4%; HR 0.97; 95% CI 0.74-1.28; P = 0.84) and without (3.1% vs. 3.2%; HR 0.96; 95% CI 0.61-1.49; P = 0.85) NSTE-ACS were similar between treatment arms irrespective of clinical presentation (Pint = 0.96). CONCLUSION Among patients with or without NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT02270242.",2020,"The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS. ","['patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES', 'patients with or without NSTE-ACS', 'patients with non-ST-segment elevation acute coronary syndromes', 'High Risk Patients', '9006 patients with high-risk features undergoing PCI with DES', 'patients with NSTE-ACS']","['dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin', 'ticagrelor plus aspirin', 'Ticagrelor With Aspirin', 'Coronary Intervention (TWILIGHT', 'ticagrelor plus placebo versus ticagrelor plus aspirin', 'ticagrelor monotherapy', 'Ticagrelor alone vs. ticagrelor plus aspirin']","['bleeding events', 'meaningful bleeding events', 'Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding while the composite of all-cause death, myocardial infarction (MI), or stroke', 'Rates of all-cause death, MI, or stroke']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C3160886', 'cui_str': 'Non ST segment elevation acute coronary syndrome'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",9006.0,0.334593,"The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS. ","[{'ForeName': 'Usman', 'Initials': 'U', 'LastName': 'Baber', 'Affiliation': 'Department of Cardiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Dangas', 'Affiliation': 'Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.'}, {'ForeName': 'Dominick Joseph', 'Initials': 'DJ', 'LastName': 'Angiolillo', 'Affiliation': 'Department of Cardiology, University of Florida-Shands, Jacksonville, FL 32218, USA.'}, {'ForeName': 'David Joel', 'Initials': 'DJ', 'LastName': 'Cohen', 'Affiliation': 'Department of Cardiology, University of Missouri-Kansas CIty, Kansas City, MO 64110, USA.'}, {'ForeName': 'Samin Kumar', 'Initials': 'SK', 'LastName': 'Sharma', 'Affiliation': 'Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.'}, {'ForeName': 'Johny', 'Initials': 'J', 'LastName': 'Nicolas', 'Affiliation': 'Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Briguori', 'Affiliation': 'Department of Cardiology, Clinica Mediterranea, 80122 Napoli NA, Italy.'}, {'ForeName': 'Jin Yu', 'Initials': 'JY', 'LastName': 'Cha', 'Affiliation': 'Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Collier', 'Affiliation': 'Department of Cardiology, London School of Hygiene and Tropical Medicine, Keppel St, Bloomsbury, London WC1E 7HT, UK.'}, {'ForeName': 'Dariusz', 'Initials': 'D', 'LastName': 'Dudek', 'Affiliation': 'The 2nd Department of Cardiology Jagiellonian University Medical College, Swietej Anny 12, 31-008 Krakow, Poland.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Džavik', 'Affiliation': 'Department of Interventional Cardiology, Research and Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk Cardiac Centre, University Health Network, 200 Elizabeth St, Toronto, ON M5G 2CA, Canada.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Escaned', 'Affiliation': 'Department of Cardiology, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos and Complutense University, Calle del Prof Martin Lagos, s/n, 28040 Madrid, Spain.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Gil', 'Affiliation': 'Department of Invasive Cardiology, Center of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, 137 Woloska Str, 02-507 Warsaw, Poland.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Gurbel', 'Affiliation': 'Department of Cardiology, Sinai Hospital of Baltimore System, Baltimore, MD 21215, USA.'}, {'ForeName': 'Christian W', 'Initials': 'CW', 'LastName': 'Hamm', 'Affiliation': 'Department of Cardiology, Kerckhoff Clinic, Benekestrabe 2-8, 61231 Bad Nauheim, Germany.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Henry', 'Affiliation': 'Department of Cardiology, The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital, Cincinnati, OH 45219, USA.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Huber', 'Affiliation': 'Department of Cardiology, Wilhelminenhospital, Montleartstrabe 37, 1160 Wien, Austria.'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Kastrati', 'Affiliation': 'Department of Cardiology, Deutsches Herzzentrum Munchen, Lazarettstrabe 36, 80636 Munchen, Germany.'}, {'ForeName': 'Upendra', 'Initials': 'U', 'LastName': 'Kaul', 'Affiliation': 'Department of Cardiology, Batra Hospital and Medical Research Centre, New Delhi 110062, India.'}, {'ForeName': 'Ran', 'Initials': 'R', 'LastName': 'Kornowski', 'Affiliation': 'Department of Cardiology, Rabin Medical Center, Zeev Jabutinsky Rd 39, Petach Tikva 49100, Israel.'}, {'ForeName': 'Mitchell', 'Initials': 'M', 'LastName': 'Krucoff', 'Affiliation': 'Department of Cardiology, Duke University Medical Center-Duke Clinical Research Institute, Durham, NC 27710, USA.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Kunadian', 'Affiliation': 'Department of Cardiology, Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Freeman Road, High Heaton, NE7 7DN Newcastle upon Tyne, UK.'}, {'ForeName': 'Steven Owen', 'Initials': 'SO', 'LastName': 'Marx', 'Affiliation': 'Department of Cardiology, Columbia University Medical Center, New York, NY 10027, USA.'}, {'ForeName': 'Shamir', 'Initials': 'S', 'LastName': 'Mehta', 'Affiliation': 'Department of Cardiology, Hamilton Health Sciences, Hamilton, ON L8N 3Z5, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Moliterno', 'Affiliation': 'Department of Cardiology, University of Kentucky, Lexington, KY 40506, USA.'}, {'ForeName': 'Erik Magnus', 'Initials': 'EM', 'LastName': 'Ohman', 'Affiliation': 'Department of Cardiology, Duke University Medical Center-Duke Clinical Research Institute, Durham, NC 27710, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Oldroyd', 'Affiliation': 'Department of Cardiology, The West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Agamemnon St, Clydebank G81 4DY, UK.'}, {'ForeName': 'Gennaro', 'Initials': 'G', 'LastName': 'Sardella', 'Affiliation': 'Department of Cardiology, Policlinico Umberto I University, 00161 Roma, Italy.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Sartori', 'Affiliation': 'Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Shlofmitz', 'Affiliation': 'Department of Cardiology, St. Francis Hospital, Roslyn, 100 Port Washington Blvd, Roslyn, NY 11576, USA.'}, {'ForeName': 'Philippe Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'Department of Cardiology, Groupe Hospitalier Bichat-Claude-Bernard, 46 Rue Henri Huchard, 75018 Paris, France.'}, {'ForeName': 'Giora', 'Initials': 'G', 'LastName': 'Weisz', 'Affiliation': 'Department of Cardiology, Montefiore Medical Center, The Bronx, NY 10467, USA.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Witzenbichler', 'Affiliation': 'Department of Cardiology, Helios Amper-Klinikum, Krankenhausstrabe 15, 85221 Dachau, Germany.'}, {'ForeName': 'Ya-Ling', 'Initials': 'YL', 'LastName': 'Han', 'Affiliation': 'Department of Cardiology, Shenyang North Hospital, Huanggu Qu, Shenyang Shi, Liaoning Sheng, China.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Pocock', 'Affiliation': 'Department of Cardiology, London School of Hygiene and Tropical Medicine, Keppel St, Bloomsbury, London WC1E 7HT, UK.'}, {'ForeName': 'Charles Michael', 'Initials': 'CM', 'LastName': 'Gibson', 'Affiliation': 'Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.'}, {'ForeName': 'Roxana', 'Initials': 'R', 'LastName': 'Mehran', 'Affiliation': 'Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.'}]",European heart journal,['10.1093/eurheartj/ehaa670'] 365,33012041,The effect of non-surgical periodontal treatment on gingival crevicular fluid periostin levels in patients with gingivitis and periodontitis.,"OBJECTIVE The objective of the study was to evaluate the effect of non-surgical periodontal treatment on gingival crevicular fluid (GCF) periostin levels in patients with gingivitis (G) and periodontitis (P). SUBJECTS AND METHODS A total of 90 subjects, 30 patients with P, 30 with G, and 30 periodontally healthy (H) subjects were included. Patients with periodontal disease received non-surgical periodontal treatment. GCF periostin levels were assessed at baseline, at the 6th week, and the 3rd month after treatment. RESULTS It was found that GCF periostin level was the lowest in the H group (89.31[47.12] pg/30 sec), followed by the G group (132.82[145.14] pg/30 sec), and the highest in the P group (207.75[189.45] pg/30 sec). These differences were statistically significant between H and the other groups (p < .001). After treatment, GCF periostin levels significantly decreased at the 6th week and the 3rd month in the G group, at the 3rd month in the P group compared to baseline values (p < .05). CONCLUSION The results of this study suggest that GCF periostin plays a role as a reliable biological marker in the pathogenesis of periodontal disease and non-surgical periodontal treatment is effective in decreasing GCF periostin levels.",2021,"It was found that GCF periostin level was the lowest in the H group (89.31[47.12] pg/30 sec), followed by the G group (132.82[145.14]","['Patients with periodontal disease received non-surgical periodontal treatment', 'patients with gingivitis (G) and periodontitis (P', 'patients with gingivitis and periodontitis', '90 subjects, 30 patients with P, 30 with G, and 30 periodontally healthy (H) subjects were included']",['non-surgical periodontal treatment'],"['GCF periostin levels', 'gingival crevicular fluid (GCF) periostin levels', 'GCF periostin level', 'gingival crevicular fluid periostin levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031090', 'cui_str': 'Periodontal disease'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0017564', 'cui_str': 'Gingival Exudate'}, {'cui': 'C0219433', 'cui_str': 'POSTN protein, human'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",90.0,0.0322563,"It was found that GCF periostin level was the lowest in the H group (89.31[47.12] pg/30 sec), followed by the G group (132.82[145.14]","[{'ForeName': 'Rana', 'Initials': 'R', 'LastName': 'Arslan', 'Affiliation': 'Oral and Dental Health Center, Yozgat, Turkey.'}, {'ForeName': 'Meltem', 'Initials': 'M', 'LastName': 'Karsiyaka Hendek', 'Affiliation': 'Department of Periodontology, Faculty of Dentistry, Kirikkale University, Kirikkale, Turkey.'}, {'ForeName': 'Ucler', 'Initials': 'U', 'LastName': 'Kisa', 'Affiliation': 'Department of Biochemistry, Faculty of Medicine, Kirikkale University, Kirikkale, Turkey.'}, {'ForeName': 'Ebru', 'Initials': 'E', 'LastName': 'Olgun', 'Affiliation': 'Department of Periodontology, Faculty of Dentistry, Kirikkale University, Kirikkale, Turkey.'}]",Oral diseases,['10.1111/odi.13664'] 366,33103770,Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial.,"BACKGROUND Atrial fibrillation (AF) is a complex cardiac arrhythmia in clinical practice with increasing incidence. However, the effects of statins on patients with AF are not quite clear. HYPOTHESIS To investigate the protective effect of calcium channel blocker (CCB) and valsartan combined fluvastatin on hypertension (HTN) patients with nonpermanent AF. METHODS In three and a half years, 189 cases of patients diagnosed as HTN combining nonpermanent AF by eight medical centers, were recruited and randomly assigned to four groups with varied treatments: CCB group; CCB + statin group; valsartan group; and valsartan + statin group. The four groups were followed up for 24 months. The 7-day Holter ultrasound echocardiography (UCG) and biochemical indexes were completed at preset time nodes respectively. RESULTS After 24 months of follow-up, 178 patients completed the study. Compared with CCB group, the blood lipid level, inflammatory index, ultrasonic index and electrocardiographic measurement results of CCB + statin group, valsartan group and valsartan + statin group were improved in different degrees and had statistical significance (P < .05 or P < .01). Furthermore, the improvement trend of CCB + statin group and valsartan + statin group was more obvious. CONCLUSIONS The results indicated that valsartan can reduce AF load and recurrence rate, and delay the progression of nonpermanent AF to permanent AF in multiple ways, and the effect of combination of valsartan and fluvastatin is more significant. These results provide a new direction for the integrated upstream control strategy of AF.",2020,"Compared with CCB group, the blood lipid level, inflammatory index, ultrasonic index and electrocardiographic measurement results of CCB + statin group, valsartan group and valsartan + statin group were improved in different degrees and had statistical significance (P < .05 or P < .01).","['patients with AF', 'hypertension (HTN) patients with nonpermanent AF', '189 cases of patients diagnosed as HTN combining nonpermanent AF by eight medical centers', 'nonpermanent atrial fibrillation with hypertension', '178 patients completed the study']","['CCB', 'valsartan', 'valsartan\u2009+\u2009statin group', 'valsartan + statin', 'CCB\u2009+\u2009statin group; valsartan', 'calcium channel blocker (CCB) and valsartan combined fluvastatin', 'valsartan and fluvastatin']","['blood lipid level, inflammatory index, ultrasonic index and electrocardiographic measurement results of CCB', '7-day Holter ultrasound echocardiography (UCG) and biochemical indexes', 'AF load and recurrence rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0006684', 'cui_str': 'Calcium channel blocker'}, {'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0082608', 'cui_str': 'fluvastatin'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0428460', 'cui_str': 'Lipid level - finding'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0006684', 'cui_str': 'Calcium channel blocker'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",,0.0230172,"Compared with CCB group, the blood lipid level, inflammatory index, ultrasonic index and electrocardiographic measurement results of CCB + statin group, valsartan group and valsartan + statin group were improved in different degrees and had statistical significance (P < .05 or P < .01).","[{'ForeName': 'Zhiqiang', 'Initials': 'Z', 'LastName': 'Zhao', 'Affiliation': 'Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Jianwei', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Zhaojie', 'Initials': 'Z', 'LastName': 'Dong', 'Affiliation': 'Department of Cardiology, An Zhen Hospital affiliated to Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Niu', 'Affiliation': 'Department of Geriatrics, the first hospital of Shijiazhuang City, Hebei, China.'}, {'ForeName': 'Enzhao', 'Initials': 'E', 'LastName': 'Liu', 'Affiliation': 'Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Lifeng', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Yingzi', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Guangping', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.'}]",Clinical cardiology,['10.1002/clc.23487'] 367,33109739,Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR + Early-stage Breast Cancer for 10 Years of Endocrine Therapy.,"PURPOSE Individualized selection of patients with early-stage hormone receptor-positive (HR + ) breast cancer for extended endocrine therapy (EET) is required to balance modest gains in outcome with toxicities of prolonged use. This study examined the Breast Cancer Index [BCI; HOXB13/IL17BR ratio (H/I)] as a predictive biomarker of EET benefit in patients from the Investigation on the Duration of Extended Adjuvant Letrozole trial. EXPERIMENTAL DESIGN BCI was tested in primary tumor specimens from 908 patients randomized to receive 2.5 versus 5 years of extended letrozole. The primary endpoint was recurrence-free interval. Cox models and likelihood ratios tested the interaction between EET and BCI (H/I). RESULTS BCI (H/I)-high significantly predicted benefit from extended letrozole in the overall cohort [HR 0.42; 95% confidence interval (CI), 0.21-0.84; P = 0.011] and any aromatase inhibitor subset [HR 0.34; 95% CI, 0.16-0.73; P = 0.004), whereas BCI (H/I)-low patients did not derive significant benefit (HR 0.95; 95% CI, 0.58-1.56; P = 0.84 and HR 0.90; 95% CI, 0.53-1.55; P = 0.71, respectively) treatment to biomarker interaction was significant ( P = 0.045, P = 0.025, respectively). BCI identified approximately 50% of patients with clinically high-risk disease that did not benefit, and with clinically low-risk disease that derived significant benefit, from an additional 2.5 years of EET. CONCLUSIONS BCI (H/I) predicted preferential benefit from 5 versus 2.5 years of EET and identified patients with improved outcomes from completing 10 years of adjuvant endocrine therapy. Findings expand the clinical utility of BCI (H/I) to a broader range of patients and beyond prognostic risk factors as a predictive endocrine response biomarker for early-stage HR + breast cancer.",2021,Findings expand the clinical utility of BCI (H/I) to a broader range of patients and beyond prognostic risk factors as a predictive endocrine response biomarker for early stage HR+ breast cancer.,"['HR+ early stage breast cancer patients for 10 years of endocrine therapy', 'patients with early stage hormone receptor positive (HR+) breast cancer for extended', 'BCI was tested in primary tumor specimens from 908 patients randomized to receive 2.5 vs 5 years of', 'patients from the Investigation on the Duration of Extended Adjuvant Letrozole (IDEAL) trial']","['endocrine therapy (EET', 'letrozole', 'extended letrozole']","['HOXB13/IL17BR ratio (H/I', 'Breast Cancer Index (BCI', 'recurrence-free interval (RFI', 'BCI']","[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1321660', 'cui_str': 'Fosamprenavir calcium'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]",908.0,0.0385669,Findings expand the clinical utility of BCI (H/I) to a broader range of patients and beyond prognostic risk factors as a predictive endocrine response biomarker for early stage HR+ breast cancer.,"[{'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Noordhoek', 'Affiliation': 'Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Treuner', 'Affiliation': 'Biotheranostics, Inc., San Diego, California.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'Putter', 'Affiliation': 'Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Biotheranostics, Inc., San Diego, California.'}, {'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Wong', 'Affiliation': 'Biotheranostics, Inc., San Diego, California.'}, {'ForeName': 'Elma', 'Initials': 'E', 'LastName': 'Meershoek-Klein Kranenbarg', 'Affiliation': 'Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Marjolijn', 'Initials': 'M', 'LastName': 'Duijm-de Carpentier', 'Affiliation': 'Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Cornelis J H', 'Initials': 'CJH', 'LastName': 'van de Velde', 'Affiliation': 'Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Schnabel', 'Affiliation': 'Biotheranostics, Inc., San Diego, California.'}, {'ForeName': 'Gerrit-Jan', 'Initials': 'GJ', 'LastName': 'Liefers', 'Affiliation': 'Leiden University Medical Center, Leiden, the Netherlands. g.j.liefers@lumc.nl.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-2737'] 368,33115382,Encephaloduroarteriosynangiosis (EDAS) revascularization for symptomatic intracranial atherosclerotic steno-occlusive (ERSIAS) Phase-II objective performance criterion trial.,"BACKGROUND Intracranial atherosclerotic disease (ICAD) is one of the most challenging stroke etiologies, with frequent recurrences despite optimized medical management. Encephaloduroarteriosynangiosis (EDAS) is an indirect revascularization method that produces extra-cranial collaterals to intracranial vessels. We present the results of a phase-II trial of EDAS in intracranial atherosclerotic disease patients. AIMS To evaluate the feasibility, safety, and preliminary efficacy of EDAS in intracranial atherosclerotic disease patients. METHODS ERSIAS was a prospective objective-performance-criterion trial of EDAS plus intensive medical management (IMM) in intracranial atherosclerotic disease (ICAD) patients failing medical treatment. Primary endpoint was any stroke/death within 30-days post-surgery or stroke in the territory of the qualifying artery beyond 30 days. The primary analysis compared event rates through one year with an objective-performance-criterion based on a 10% reduction from the 20% rate in the intensive medical management arm of the stenting versus aggressive medical management for preventing recurrent stroke in intracranial stenosis trial (SAMMPRIS) in patients with poor collaterals. Event rates through two years were compared with propensity-score-matched (PSM) medically treated patients from SAMMPRIS and the carotid occlusion surgery study (COSS). RESULTS During a median follow-up of 24.5 months, 5 (9.6%) of 52 patients had a primary endpoint event. The primary endpoint rate at one year met the threshold for nonfutility and advancement to phase III (<10%). In the sensitivity analysis, primary endpoint event rate at two years was lower than in PSM controls, 9.6% versus 21.2% (p < 0.07). Overall, 86% of EDAS-plus-intensive medical management patients were functionally independent at last follow-up and 89% demonstrated neovascularization. There were two (3.8%) surgical complications and no intracranial hemorrhages. CONCLUSION ERSIAS phase II provides evidence of safety and strong signals of efficacy of EDAS-plus-intensive medical management, supporting advancement to a seamless phase-IIb/III trial. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov.NCT01819597.",2021,"In the sensitivity analysis, primary endpoint event rate at two years was lower than in PSM controls, 9.6% versus 21.2% (p < 0.07).","['intracranial atherosclerotic disease (ICAD) patients failing medical treatment', 'intracranial atherosclerotic disease patients', 'symptomatic intracranial atherosclerotic steno-occlusive (ERSIAS', 'patients with poor collaterals']","['EDAS plus intensive medical management (IMM', 'Encephaloduroarteriosynangiosis (EDAS) revascularization', 'Encephaloduroarteriosynangiosis (EDAS', 'EDAS']","['surgical complications and no intracranial hemorrhages', 'stroke/death within 30-days post-surgery or stroke in the territory of the qualifying artery beyond 30 days', 'primary endpoint rate at one year met the threshold for nonfutility and advancement to phase III', 'neovascularization']","[{'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0524571', 'cui_str': 'Steno bredanensis'}, {'cui': 'C1947917', 'cui_str': 'Occluded'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C1275670', 'cui_str': 'Collateral branch of vessel'}]","[{'cui': 'C1504429', 'cui_str': 'Encephalo-duro-arterio-synangiosis'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0151699', 'cui_str': 'Intracranial hemorrhage'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0441478', 'cui_str': 'Surgical advancement - action'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0027686', 'cui_str': 'Neovascularization'}]",,0.0658465,"In the sensitivity analysis, primary endpoint event rate at two years was lower than in PSM controls, 9.6% versus 21.2% (p < 0.07).","[{'ForeName': 'Nestor R', 'Initials': 'NR', 'LastName': 'Gonzalez', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Lyden', 'Affiliation': 'Department of Neurosurgery, First Affiliated Hospital of Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Shlee', 'Initials': 'S', 'LastName': 'Song', 'Affiliation': 'Department of Neurosurgery, First Affiliated Hospital of Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Konrad', 'Initials': 'K', 'LastName': 'Schlick', 'Affiliation': 'Department of Neurosurgery, First Affiliated Hospital of Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Oana', 'Initials': 'O', 'LastName': 'Dumitrascu', 'Affiliation': 'Department of Neurosurgery, First Affiliated Hospital of Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Miguel D', 'Initials': 'MD', 'LastName': 'Quintero-Consuegra', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Toscano', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Liebeskind', 'Affiliation': 'Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Restrepo', 'Affiliation': 'Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Rao', 'Affiliation': 'Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Hinman', 'Affiliation': 'Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Alexander', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Schievink', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Piantadosi', 'Affiliation': 'Department of Neurology, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Saver', 'Affiliation': 'Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}]",International journal of stroke : official journal of the International Stroke Society,['10.1177/1747493020967256'] 369,33131908,Dose-dependent reductions in plasma ceramides after anthocyanin supplementation are associated with improvements in plasma lipids and cholesterol efflux capacity in dyslipidemia: A randomized controlled trial.,"BACKGROUND & AIMS Plasma ceramides have been identified as novel risk factors for metabolic and cardiovascular diseases. We aimed to evaluate the effects of dietary anthocyanins on plasma ceramides and to disentangle whether the alterations in ceramides could be related with those in other cardiometabolic risk factors in the dyslipidemia. METHODS In a randomized double-blinded placebo-controlled trial, 176 eligible dyslipidemia subjects were randomly assigned into four groups receiving placebo, 40, 80, or 320 mg/day anthocyanins, respectively for 12 weeks. RESULTS A total of 169 subjects completed the study. After 12-week intervention, dietary anthocyanins dose-dependently reduced plasma concentrations of all six ceramide species in the dyslipidemia subjects (all P trend values < 0.05). Specifically, 320 mg/day anthocyanins effectively lowered plasma N-palmitoylsphingosine (Cer 16:0, mean change: -28.3 ± 41.2 versus 2.9 ± 38.2, nmol/L, P = 0.018) and N-tetracosanoylsphingosine (Cer 24:0, mean change: -157.1 ± 493.9 versus 10.7 ± 439.9, nmol/L, P = 0.002) compared with the placebo. The declines in plasma Cer 16:0 and Cer 24:0 were significantly correlated with the decreases in plasma non-high-density lipoprotein cholesterol (nonHDL-C, Spearman's r = 0.32, P = 0.040 for Cer 16:0; Spearman's r = 0.35, P = 0.026 for Cer 24:0), apolipoprotein B (Spearman's r = 0.33, P = 0.031 for Cer 16:0; Spearman's r = 0.48, P = 0.002 for Cer 24:0), and total cholesterol (Spearman's r = 0.34, P = 0.026 for Cer 16:0; Spearman's r = 0.31, P = 0.042 for Cer 24:0) after 12-week 320 mg/day anthocyanin administration. Besides, we found that anthocyanins at 320 mg/day also markedly enhanced cholesterol efflux capacity in the dyslipidemia, the changes of which were positively associated with the reductions in Cer 16:0 (Spearman's r = 0.42, P = 0.006) independent of HDL-C and apolipoprotein A-I. CONCLUSIONS Reductions in plasma Cer 16:0 and Cer 18:0 after 12-week anthocyanin intervention were dose-dependently associated with improvements in plasma lipids and cholesterol efflux capacity in the dyslipidemia. CLINICAL TRIAL REGISTRATION The study was registered at ClinicalTrials.gov with the identifier No. NCT03415503.",2021,"After 12-week intervention, dietary anthocyanins dose-dependently reduced plasma concentrations of all six ceramide species in the dyslipidemia subjects (all P trend values < 0.05).","['169 subjects completed the study', '176 eligible dyslipidemia subjects']","['anthocyanins', 'anthocyanin supplementation', 'placebo', 'dietary anthocyanins']","['plasma lipids and cholesterol efflux capacity', 'total cholesterol', 'plasma concentrations', 'plasma non-high-density lipoprotein cholesterol', 'plasma lipids and cholesterol efflux capacity in dyslipidemia', 'plasma N-palmitoylsphingosine', 'apolipoprotein B', 'cholesterol efflux capacity', 'plasma Cer']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}]","[{'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0386062', 'cui_str': 'N-palmitoylsphingosine'}, {'cui': 'C0003593', 'cui_str': 'Apolipoprotein B'}, {'cui': 'C0237504', 'cui_str': 'CER'}]",176.0,0.200688,"After 12-week intervention, dietary anthocyanins dose-dependently reduced plasma concentrations of all six ceramide species in the dyslipidemia subjects (all P trend values < 0.05).","[{'ForeName': 'Yimin', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Huihui', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Zezhong', 'Initials': 'Z', 'LastName': 'Tian', 'Affiliation': 'School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Kongyao', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': 'School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Die', 'Initials': 'D', 'LastName': 'Fan', 'Affiliation': 'Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Xilin', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': 'School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Wenhua', 'Initials': 'W', 'LastName': 'Ling', 'Affiliation': 'Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China. Electronic address: yangyan3@mail.sysu.edu.cn.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.014'] 370,33131909,The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids.,"BACKGROUND & AIMS Duodenal-jejunal bypass liners (DJBLs) prevent absorption in the proximal small intestine, the site of fatty acid absorption. We sought to investigate the effects of a DJBL on blood concentrations of essential fatty acids (EFAs) and bioactive polyunsaturated fatty acids (PUFAs). METHODS Sub-study of a multicentre, randomised, controlled trial with two treatment groups. Patients aged 18-65 years with type-2 diabetes mellitus and body mass index 30-50 kg/m 2 were randomised to receive a DJBL for 12 months or best medical therapy, diet and exercise. Whole plasma PUFA concentrations were determined at baseline, 10 days, 6 and 11.5 months; data were available for n = 70 patients per group. RESULTS Weight loss was significantly greater in the DJBL group compared to controls after 11.5 months: total body weight loss 11.3 ± 5.3% versus 6.0 ± 5.7% (mean difference [95% CI] = 5.27% [3.75, 6.80], p < 0.001). Absolute concentrations of both EFAs, linoleic acid and α-linolenic acid, and their bioactive derivatives, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, were significantly lower in the DJBL group than in the control group at 6 and 11.5 months follow-up. Total serum cholesterol, LDL-cholesterol and HDL-cholesterol were also significantly lower in the DJBL group. CONCLUSION One year of DJBL therapy is associated with superior weight loss and greater reductions in total serum cholesterol and LDL-cholesterol, but also depletion of EFAs and their longer chain derivatives. DJBL therapy may need to be offset by maintaining an adequate dietary intake of PUFAs or by supplementation. TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT02459561.",2021,"One year of DJBL therapy is associated with superior weight loss and greater reductions in total serum cholesterol and LDL-cholesterol, but also depletion of EFAs and their longer chain derivatives.","['70 patients per group', 'Patients aged 18-65 years with type-2 diabetes mellitus and body mass index 30-50\xa0kg/m 2']","['DJBL', 'DJBL for 12 months or best medical therapy, diet and exercise', 'Duodenal-jejunal bypass liners (DJBLs', 'duodenal-jejunal bypass liner']","['total serum cholesterol and LDL-cholesterol', 'total body weight loss', 'Total serum cholesterol, LDL-cholesterol and HDL-cholesterol', 'Whole plasma PUFA concentrations', 'superior weight loss', 'blood concentrations of essential fatty acids (EFAs) and bioactive polyunsaturated fatty acids (PUFAs', 'Absolute concentrations of both EFAs, linoleic acid and α-linolenic acid, and their bioactive derivatives, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid', 'Weight loss']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3880361', 'cui_str': 'Duodenal-jejunal bypass liner'}]","[{'cui': 'C1445957', 'cui_str': 'Serum total cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated fatty acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0427728', 'cui_str': 'Blood concentration, dipstick - finding'}, {'cui': 'C0015686', 'cui_str': 'Fatty Acids, Essential'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0023749', 'cui_str': 'Linoleic acid'}, {'cui': 'C0051405', 'cui_str': 'alpha-Linolenic Acid'}, {'cui': 'C0243072', 'cui_str': 'derivatives'}, {'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0058624', 'cui_str': 'docosapentaenoic acid'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}]",,0.104392,"One year of DJBL therapy is associated with superior weight loss and greater reductions in total serum cholesterol and LDL-cholesterol, but also depletion of EFAs and their longer chain derivatives.","[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Glaysher', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK. Electronic address: michaelglaysher@me.com.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Ward', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Madhawi', 'Initials': 'M', 'LastName': 'Aldhwayan', 'Affiliation': 'Imperial College London, London, UK; Department of Community Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Aruchuna', 'Initials': 'A', 'LastName': 'Ruban', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Christina Gabriele', 'Initials': 'CG', 'LastName': 'Prechtl', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Helena L', 'Initials': 'HL', 'LastName': 'Fisk', 'Affiliation': 'School of Human Development & Health, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Navpreet', 'Initials': 'N', 'LastName': 'Chhina', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Werd', 'Initials': 'W', 'LastName': 'Al-Najim', 'Affiliation': 'Imperial College London, London, UK; Diabetes Complications Research Centre, Conway Institute, School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Smith', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Klimowska-Nassar', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Johnson', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Emmanuela', 'Initials': 'E', 'LastName': 'Falaschetti', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Anthony P', 'Initials': 'AP', 'LastName': 'Goldstone', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Alexander Dimitri', 'Initials': 'AD', 'LastName': 'Miras', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Byrne', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Philip C', 'Initials': 'PC', 'LastName': 'Calder', 'Affiliation': 'School of Human Development & Health, Faculty of Medicine, University of Southampton, Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK.'}, {'ForeName': 'Julian P', 'Initials': 'JP', 'LastName': 'Teare', 'Affiliation': 'Imperial College London, London, UK.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.026'] 371,33131164,Effect of vitamin D and/or omega-3 fatty acid supplementation on stroke outcomes: A randomized trial.,"BACKGROUND AND PURPOSE Among stroke patients, low serum 25-hydroxyvitamin D predicts poor outcomes. In mice, higher omega-3 (n-3) fatty acid intake diminishes brain damage after stroke. In this study, we tested whether vitamin D or n-3 fatty acids supplementation prior to stroke reduces the risk of functional limitations and physical disability after stroke. METHODS We used data from VITAL (the VITamin D and OmegA-3 TriaL) which randomized middle-aged and older men and women without cardiovascular disease to vitamin D 3 (2000 IU/day) and/or marine n-3 fatty acids (1 g/day) and followed them for incident stroke events. Individuals experiencing a non-fatal stroke were mailed questionnaires assessing functional limitations (the physical performance scale adapted from Nagi) and physical disability (the modified Katz Activities of Daily Living and Rosow-Breslau Functional Health scales). We used logistic regression to analyze associations between randomized treatment and limitations on each scale. RESULTS A total of 290 individuals experienced their first stroke during the trial, of whom 197 stroke survivors completed the stroke outcomes questionnaire a median of 1.4 years after diagnosis. We observed no associations between randomized treatment to vitamin D and functional limitations (odds ratio [OR] 1.01, 95% confidence interval [CI] 0.52, 1.97) or physical disability (Rosow-Breslau scale: OR 0.92, 95% CI 0.50, 1.67; Katz scale: OR 1.03, 95% CI 0.31, 3.42). Those randomized to n-3 fatty acids had a non-significantly lower risk of functional limitations (OR 0.55, 95% CI 0.28, 1.09) and physical disability (Rosow-Breslau scale: OR 0.56, 95% CI 0.31, 1.02; Katz sclae: OR 0.32, 95% CI 0.50, 1.67). CONCLUSION Vitamin D or omega-3 fatty acid supplementation prior to stroke did not result in significantly improved post-stroke outcomes.",2021,Individuals experiencing a non-fatal stroke were mailed questionnaires assessing functional limitations (the physical performance scale adapted from Nagi) and physical disability (the modified Katz Activities of Daily Living and Rosow-Breslau Functional Health scales).,"['197 stroke survivors', 'Individuals experiencing a non-fatal stroke', '290 individuals experienced their first stroke during the trial', 'middle-aged and older men and women without cardiovascular disease to vitamin D 3 (2000 IU/day) and/or', '1 g/day) and followed them for incident stroke events']","['vitamin D and/or omega-3 fatty acid supplementation', 'omega-3 (n-3) fatty acid intake', 'Vitamin D or omega-3 fatty acids supplementation', 'VITamin D', 'marine n-3 fatty acids', 'vitamin D or n-3']","['physical disability (the modified Katz Activities of Daily Living and Rosow-Breslau Functional Health scales', 'risk of functional limitations', 'stroke outcomes questionnaire', 'stroke outcomes', 'physical disability']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C5191218', 'cui_str': '290'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0441471', 'cui_str': 'Event'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0561929', 'cui_str': 'N-3 fatty acid supplementation'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0524645', 'cui_str': 'Marines'}]","[{'cui': 'C0520817', 'cui_str': 'Physical handicap'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451239', 'cui_str': 'Katz activities of daily living'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",197.0,0.240013,Individuals experiencing a non-fatal stroke were mailed questionnaires assessing functional limitations (the physical performance scale adapted from Nagi) and physical disability (the modified Katz Activities of Daily Living and Rosow-Breslau Functional Health scales).,"[{'ForeName': 'Pamela M', 'Initials': 'PM', 'LastName': 'Rist', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Buring', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Nancy R', 'Initials': 'NR', 'LastName': 'Cook', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Rexrode', 'Affiliation': ""Division of Women's Health, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}]",European journal of neurology,['10.1111/ene.14623'] 372,33141616,Metabolomic Effects of Hormone Therapy and Associations With Coronary Heart Disease Among Postmenopausal Women.,"BACKGROUND In the WHI-HT trials (Women's Health Initiative Hormone Therapy), treatment with oral conjugated equine estrogens and medroxyprogesterone acetate (CEE+MPA) resulted in increased risk of coronary heart disease (CHD), whereas oral conjugated equine estrogens (CEE) did not. METHODS Four hundred eighty-one metabolites were measured at baseline and at 1-year in 503 and 431 participants in the WHI CEE and CEE+MPA trials, respectively. The effects of randomized HT on the metabolite profiles at 1-year was evaluated in linear models adjusting for baseline metabolite levels, age, body mass index, race, incident CHD, prevalent hypertension, and diabetes. Metabolites with discordant effects by HT type were evaluated for association with incident CHD in 944 participants (472 CHD cases) in the WHI-OS (Women's Health Initiative Observational Study), with replication in an independent cohort of 980 men and women at high risk for cardiovascular disease. RESULTS HT effects on the metabolome were profound; 62% of metabolites significantly changed with randomized CEE and 52% with CEE+MPA (false discovery rate-adjusted P value<0.05) in multivariable models. Concerted increases in abundance were seen within various metabolite classes including triacylglycerols, phosphatidylethanolamines, and phosphatidylcholines; decreases in abundance was observed for acylcarnitines, lysophosphatidylcholines, quaternary amines, and cholesteryl/cholesteryl esters. Twelve metabolites had discordant effects by HT type and were associated with incident CHD in the WHI-OS; a metabolite score estimated in a Least Absolute Shrinkage and Selection Operator regression was associated with CHD risk with an odds ratio of 1.47 per SD increase (95% CI, 1.27-1.70, P <10 -6 ). All twelve metabolites were altered in the CHD protective direction by CEE treatment. One metabolite (lysine) was significantly altered in the direction of increased CHD risk by CEE+MPA; the remaining 11 metabolites were not significantly changed by CEE+MPA. The CHD associations of a subset of 4 metabolites including C58:11 triacylglycerol, C54:9 triacylglycerol, C36:1 phosphatidylcholine and sucrose replicated in an independent dataset of 980 participants in the PREDIMED trial (Prevención con Dieta Mediterránea). CONCLUSIONS Randomized treatment with oral HT resulted in large metabolome shifts that generally favored CEE alone over CEE+MPA in term of CHD risk. Discordant metabolite effects between HT regimens may partially mediate the differences in CHD risk between the 2 WHI-HT trials.",2020,"Concerted increases in abundance were seen within various metabolite classes including triacylglycerols (TAG), phosphatidylethanolamines and phosphatidylcholines (PC); decreases in abundance was observed for acylcarnitines, lysophosphatidylcholines, quaternary amines and cholesteryl/cholesteryl esters.","['Postmenopausal Women', '944 participants (472 CHD cases) in the WHI Observational Study (WHI-OS), with replication in an independent cohort of 980 men and women at high risk for cardiovascular disease']","['oral HT', 'randomized HT', 'CEE+MPA', 'Hormone Therapy', 'oral conjugated equine estrogens and medroxyprogesterone acetate (CEE+MPA']","['triacylglycerols (TAG), phosphatidylethanolamines and phosphatidylcholines (PC); decreases in abundance', 'risk of coronary heart disease (CHD', 'CHD risk', 'acylcarnitines, lysophosphatidylcholines, quaternary amines and cholesteryl/cholesteryl esters']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}, {'cui': 'C0598312', 'cui_str': 'DNA replication'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0019944', 'cui_str': 'Equus caballus'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}]","[{'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0031618', 'cui_str': 'Phosphatidylethanolamines'}, {'cui': 'C1959616', 'cui_str': 'Lecithin'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C1282512', 'cui_str': 'At risk of coronary heart disease'}, {'cui': 'C0368608', 'cui_str': 'Acylcarnitine'}, {'cui': 'C0024360', 'cui_str': 'Lysolecithin'}, {'cui': 'C0002508', 'cui_str': 'Amine'}, {'cui': 'C0008387', 'cui_str': 'Cholesterol ester'}]",980.0,0.171214,"Concerted increases in abundance were seen within various metabolite classes including triacylglycerols (TAG), phosphatidylethanolamines and phosphatidylcholines (PC); decreases in abundance was observed for acylcarnitines, lysophosphatidylcholines, quaternary amines and cholesteryl/cholesteryl esters.","[{'ForeName': 'Raji', 'Initials': 'R', 'LastName': 'Balasubramanian', 'Affiliation': 'Department of Biostatistics & Epidemiology, University of Massachusetts-Amherst (R.B., R.S.).'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Demler', 'Affiliation': ""Division of Preventive Medicine (O.D., J.P.P., J.E.M.), Brigham and Women's Hospital, Harvard Medical School.""}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Guasch-Ferré', 'Affiliation': 'Department of Nutrition (M.G.-F., M.A.M.-G., F.B.H.).'}, {'ForeName': 'Nina P', 'Initials': 'NP', 'LastName': 'Paynter', 'Affiliation': ""Division of Preventive Medicine (O.D., J.P.P., J.E.M.), Brigham and Women's Hospital, Harvard Medical School.""}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Sheehan', 'Affiliation': 'Department of Biostatistics & Epidemiology, University of Massachusetts-Amherst (R.B., R.S.).'}, {'ForeName': 'Simin', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (S.L., J.E.M., F.B.H.).'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Division of Preventive Medicine (O.D., J.P.P., J.E.M.), Brigham and Women's Hospital, Harvard Medical School.""}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Salas-Salvadó', 'Affiliation': 'Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, Hospital Universitari San Joan de Reus (J.S.-S.).'}, {'ForeName': 'Miguel Á', 'Initials': 'MÁ', 'LastName': 'Martínez-Gonzalez', 'Affiliation': 'Department of Nutrition (M.G.-F., M.A.M.-G., F.B.H.).'}, {'ForeName': 'Frank B', 'Initials': 'FB', 'LastName': 'Hu', 'Affiliation': 'Department of Nutrition (M.G.-F., M.A.M.-G., F.B.H.).'}, {'ForeName': 'Clary', 'Initials': 'C', 'LastName': 'Clish', 'Affiliation': 'Broad Institute of the Massachusetts Institute of Technology & Harvard University, Cambridge, MA (C.C.).'}, {'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Rexrode', 'Affiliation': ""Division of Women's Health (K.M.R.), Brigham and Women's Hospital, Harvard Medical School.""}]",Circulation. Genomic and precision medicine,['10.1161/CIRCGEN.119.002977'] 373,33148023,Efficacy and safety of Nd:YAG laser vitreolysis for symptomatic vitreous floaters: A randomized controlled trial.,"BACKGROUND Vitreous floaters are a common and inconvenient phenomena. This study aims to examine the efficacy and safety in treating vitreous floaters using Nd:YAG laser vitreolysis. METHODS In this prospective double-blinded randomized clinical trial 24 eyes of twenty-four patients were randomized into intervention with YAG laser vitreolysis and control groups. Primary outcomes were visual disturbance on a 10-point scale, qualitative changes in a 4-level scale, contrast sensitivity measured with the Pelli-Robson table and the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25). Secondary results included objective change in vitreous opacities, best-corrected visual acuity (BCVA), variation in intraocular pressure (IOP) and other adverse events. RESULTS Twenty-one patients (21 eyes; 5 male, 16 female) were enrolled in this study (mean age 62 ± 7.9 years), three were lost during follow-up. In the YAG laser group, the 10-point visual disturbance score improved a mean of 4.7 points ( p  < 0.001) compared to the control group that improved 2.1 ( p  = 0.09). The YAG laser group reported greater subjectively symptomatic improvement (77%) than controls (25%). NEI VFQ-25 revealed improved general vision (75.8 versus 59.2; p  = 0.037) and in mental health at 6 months (84.3 versus 70.3; p  = 0.048). There was no significant difference in contrast sensitivity ( p  = 0.848) and in IOP ( p  = 0.505). No differences in adverse events between groups were identified. CONCLUSION Vitreolysis with Nd:YAG laser improves visual results in patients with symptomatic vitreous floaters, without adverse events considered clinically relevant. Other trials with a larger number of participants are required to corroborate these results.",2021,"Vitreolysis with Nd:YAG laser improves visual results in patients with symptomatic vitreous floaters, without adverse events considered clinically relevant.","['symptomatic vitreous floaters', 'patients with symptomatic vitreous floaters', '24 eyes of twenty-four patients', 'Twenty-one patients (21 eyes; 5 male, 16 female) were enrolled in this study (mean age 62\u2009±\u20097.9\u2009years']","['Vitreolysis with Nd:YAG laser', 'YAG laser', 'YAG laser vitreolysis and control groups', 'Nd:YAG laser vitreolysis']","['10-point visual disturbance score', 'mental health', 'efficacy and safety', 'visual results', 'general vision', 'objective change in vitreous opacities, best-corrected visual acuity (BCVA), variation in intraocular pressure (IOP) and other adverse events', 'adverse events', 'Efficacy and safety', 'contrast sensitivity', 'visual disturbance on a 10-point scale, qualitative changes in a 4-level scale, contrast sensitivity measured with the Pelli-Robson table and the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25', 'subjectively symptomatic improvement']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0016242', 'cui_str': 'Vitreous floaters'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0392276', 'cui_str': 'Neodymium-YAG laser'}, {'cui': 'C0587723', 'cui_str': 'YAG - laser'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0547030', 'cui_str': 'Visual disturbance'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0016242', 'cui_str': 'Vitreous floaters'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0009928', 'cui_str': 'Contrast sensitivity'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0456950', 'cui_str': 'Level 4'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0039224', 'cui_str': 'Table'}, {'cui': 'C1955969', 'cui_str': 'National Eye Institute'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}]",24.0,0.30993,"Vitreolysis with Nd:YAG laser improves visual results in patients with symptomatic vitreous floaters, without adverse events considered clinically relevant.","[{'ForeName': 'Gustavo D', 'Initials': 'GD', 'LastName': 'Ludwig', 'Affiliation': 'Ophthalmology Department, Instituto de Assistência Médica ao Servidor Publico Estadual de São Paulo (IAMSPE), São Paulo, SP, Brazil.'}, {'ForeName': 'Henrique', 'Initials': 'H', 'LastName': 'Gemelli', 'Affiliation': 'Ophthalmology Department, Instituto de Assistência Médica ao Servidor Publico Estadual de São Paulo (IAMSPE), São Paulo, SP, Brazil.'}, {'ForeName': 'Guilherme M', 'Initials': 'GM', 'LastName': 'Nunes', 'Affiliation': 'Ophthalmology Department, Instituto de Assistência Médica ao Servidor Publico Estadual de São Paulo (IAMSPE), São Paulo, SP, Brazil.'}, {'ForeName': 'Pedro D', 'Initials': 'PD', 'LastName': 'Serracarbassa', 'Affiliation': 'Ophthalmology Department, Instituto de Assistência Médica ao Servidor Publico Estadual de São Paulo (IAMSPE), São Paulo, SP, Brazil.'}, {'ForeName': 'Márgara', 'Initials': 'M', 'LastName': 'Zanotele', 'Affiliation': 'Ophthalmology Department, Instituto de Assistência Médica ao Servidor Publico Estadual de São Paulo (IAMSPE), São Paulo, SP, Brazil.'}]",European journal of ophthalmology,['10.1177/1120672120968762'] 374,33165078,PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color: Post Hoc Analyses of the US Phase III Clinical Study Data.,"BACKGROUND Limited US clinical data are available on the use of aesthetic products in patients with skin of color (SOC). OBJECTIVE To compare the efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in patients with and without SOC. METHODS AND MATERIALS Post hoc analyses were performed on the pooled population of all 492 patients treated with 20U prabotulinumtoxinA in the 2 US single-dose Phase III glabellar line clinical studies. Patients were grouped by Fitzpatrick skin Type: IV + V + VI (with SOC) versus I + II + III (without SOC). The primary efficacy end point was the proportion of responders with a ≥1-point improvement from baseline at maximum frown on the 4-point Glabellar Line Scale. Adverse events (AEs) were also summarized. RESULTS Responder rates among patients with SOC (n = 140) were lower than those without SOC (n = 352), by 5.9% on average across all visits; at no time point were differences statistically significant. At Day 30, responder rates were 94.0% and 96.0%, respectively (p = .401). Headache was the most common treatment-related AE, occurring in 12.1% and 8.2% of patients with and without SOC, respectively. CONCLUSION A single dose of 20U prabotulinumtoxinA was well tolerated and similar in effectiveness in patients with and without SOC for the treatment of glabellar lines.",2021,"Headache was the most common treatment-related AE, occurring in 12.1% and 8.2% of patients with and without SOC, respectively. ","['patients with and without SOC', 'Adult Patients With Skin of Color', 'Patients were grouped by Fitzpatrick skin Type', 'Post hoc analyses were performed on the pooled population of all 492 patients treated with 20U prabotulinumtoxinA in the 2 US single-dose Phase III glabellar line clinical studies', 'patients with skin of color (SOC']","['20U prabotulinumtoxinA', 'IV + V + VI (with SOC) versus I + II + III (without SOC', 'prabotulinumtoxinA', 'PrabotulinumtoxinA']","['efficacy and safety', 'proportion of responders with a ≥1-point improvement from baseline at maximum frown on the 4-point Glabellar Line Scale', 'responder rates', 'Headache']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0442019', 'cui_str': 'Glabellar'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0442019', 'cui_str': 'Glabellar'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0018681', 'cui_str': 'Headache'}]",140.0,0.0269578,"Headache was the most common treatment-related AE, occurring in 12.1% and 8.2% of patients with and without SOC, respectively. ","[{'ForeName': 'Susan C', 'Initials': 'SC', 'LastName': 'Taylor', 'Affiliation': 'Department of Dermatology, Perelman School of Medicine, Philadelphia, Pennsylvania.'}, {'ForeName': 'Pearl E', 'Initials': 'PE', 'LastName': 'Grimes', 'Affiliation': 'Vitiligo and Pigmentation Institute of Southern California, Los Angeles, California.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Joseph', 'Affiliation': 'Clinical Testing of Beverly Hills Inc., Encino, California.'}, {'ForeName': 'Anneke', 'Initials': 'A', 'LastName': 'Jonker', 'Affiliation': 'Medical Writing Associates, West Vancouver, British Columbia, Canada.'}, {'ForeName': 'Rui L', 'Initials': 'RL', 'LastName': 'Avelar', 'Affiliation': 'Evolus, Inc., Newport Beach, California.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002864'] 375,33160908,Opioid prescription for pain after osmotic dilator placement in abortion care: A randomized controlled trial.,"OBJECTIVE To compare the overnight maximum pain scores after osmotic dilator placement prior to a dilation and evacuation (D&E) procedure in participants assigned to a prescription for ibuprofen alone or to ibuprofen plus oxycodone. STUDY DESIGN We conducted a nonblinded pragmatic, randomized controlled trial to evaluate pain management among women undergoing osmotic dilator placement prior to D&E. We randomly assigned 70 participants at 12 weeks 6 days to 23 weeks 6 days gestation to receive a prescription for ibuprofen alone, or ibuprofen plus oxycodone. We assessed pain using a numeric rating scale (NRS; scale 0-10) at the following time points: Baseline, dilator placement, 2 and 6 hours, and preoperatively, where we also asked participants their maximum pain score. The primary outcome was mean individual NRS pain score change from baseline to maximum pain score. RESULTS Maximum mean pain score (change from baseline) was 4.7 ± 2.9 in the ibuprofen group, and 6.5 ± 2.5 in the ibuprofen plus oxycodone group (p < 0.01). Participants in both groups reported highest NRS pain scores 2 hours after dilator placement, 3.9 ± 2.5 and 5.3 ± 2.6 respectively (p = 0.02). Average ibuprofen use in both arms was similar, and 81% of participants used at least 1 dose of ibuprofen after dilator placement. Of those randomized to prescription to ibuprofen plus oxycodone, only 51% used a dose of oxycodone. CONCLUSIONS Compared to participants randomized to receive a prescription for ibuprofen, those randomized to receive a prescription for ibuprofen plus oxycodone reported higher maximum overnight pain scores. IMPLICATIONS Participants receiving a prescription for ibuprofen alone had lower maximum overnight pain scores following osmotic dilator placement. Given that opioid prescriptions did not appear to reduce overnight pain, minimizing these prescriptions would avoid opioid exposure for patients undergoing D&E.",2021,"RESULTS Maximum mean pain score (change from baseline) was 4.7± 2.9 in the ibuprofen group, and 6.5± 2.5 in the ibuprofen plus oxycodone group (p<0.01).","['participants assigned to a prescription for', 'pain after osmotic dilator placement in abortion care', 'women undergoing osmotic dilator placement prior to D&E']","['ibuprofen plus oxycodone', 'Opioid prescription', 'osmotic dilator placement prior to a dilation and evacuation (D&E) procedure', 'oxycodone', 'ibuprofen alone or to ibuprofen plus oxycodone', 'ibuprofen', 'ibuprofen alone, or ibuprofen plus oxycodone']","['maximum overnight pain scores', 'Maximum mean pain score', 'overnight maximum pain scores', 'highest NRS pain scores', 'maximum pain score', 'mean individual NRS pain score change from baseline to maximum pain score', 'pain using a numeric rating scale']","[{'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0029391', 'cui_str': 'Osmosis'}, {'cui': 'C0180431', 'cui_str': 'Dilator'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C1282573', 'cui_str': 'Evacuation procedure'}]","[{'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0029391', 'cui_str': 'Osmosis'}, {'cui': 'C0180431', 'cui_str': 'Dilator'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C1282573', 'cui_str': 'Evacuation procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",70.0,0.400701,"RESULTS Maximum mean pain score (change from baseline) was 4.7± 2.9 in the ibuprofen group, and 6.5± 2.5 in the ibuprofen plus oxycodone group (p<0.01).","[{'ForeName': 'Divyah', 'Initials': 'D', 'LastName': 'Nagendra', 'Affiliation': 'Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Sarita', 'Initials': 'S', 'LastName': 'Sonalkar', 'Affiliation': 'Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Schurr', 'Affiliation': 'Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Arden', 'Initials': 'A', 'LastName': 'McAllister', 'Affiliation': 'Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: arden.mcallister@pennmedicine.upenn.edu.'}, {'ForeName': 'Andrea H', 'Initials': 'AH', 'LastName': 'Roe', 'Affiliation': 'Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Jade M', 'Initials': 'JM', 'LastName': 'Shorter', 'Affiliation': 'Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Mary D', 'Initials': 'MD', 'LastName': 'Sammel', 'Affiliation': 'Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Courtney A', 'Initials': 'CA', 'LastName': 'Schreiber', 'Affiliation': 'Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.'}]",Contraception,['10.1016/j.contraception.2020.10.019'] 376,33168406,Comparison of the Effect of Laryngeal Mask Airway Versus Endotracheal Tube on Airway Management in Pediatric Patients with Tonsillar Hypertrophy.,"PURPOSE The laryngeal mask airway (LMA) has become an important choice in both routine and difficult airway management. We aimed to evaluate the safety and effectiveness of LMA use in pediatric patients with tonsillar hypertrophy. DESIGN This study was a randomized controlled trial. METHODS The study included 100 pediatric patients who had first or second degree tonsillar hypertrophy. Pediatric patients undergoing elective laparoscopic inguinal hernia repair were randomly divided into two groups (n = 50): LMA group and the endotracheal tube (ETT) group. The primary outcomes were ventilation leak volume, peak airway pressure, and partial pressure of end-tidal carbon dioxide (P ET co 2 ). Data for primary outcomes were collected before and 5-, 15-, and 25-minute after opening pneumoperitoneum, and on closing the pneumoperitoneum. Complications such as laryngospasm, bronchospasm, desaturation, severe coughing, blood on the device after removal, and sore throat were recorded. FINDINGS A total of 100 pediatric patients were assessed and 97 eligible patients were randomly assigned to receive an LMA (n = 49) or an ETT (n = 48). There was no statistically significant difference in ventilation leak volume and P ET co 2 between the LMA and ETT groups (P > .05). Compared with T 1-4 , peak airway pressure was significantly lower in T 0 (LMA group 12.6 ± 0.9, 95% confidence interval 12.2 to 13.0; ETT group 12.8 ± 1.2, 95% confidence interval 12.2 to 13.3; P < .05). The incidences of laryngospasm 11 (22.9%), desaturation 18 (37.5%), and severe coughing 13 (27%) were higher in the ETT group (11 [22.9%] vs 3 [6.1%], 18 [37.5%] vs 6 [12.2%], 13 [27%] vs 3 [6.1%]; P < .05). CONCLUSIONS The application of LMA has a lower incidence of complications. LMA as an airway device is effective and perhaps superior in appropriate patients.",2021,There was no statistically significant difference in ventilation leak volume and P ET co 2 between the LMA and ETT groups (P > .05).,"['100 pediatric patients were assessed and 97 eligible patients', '100 pediatric patients who had first or second degree tonsillar hypertrophy', 'pediatric patients with tonsillar hypertrophy', 'Pediatric patients undergoing elective laparoscopic inguinal hernia repair', 'Pediatric Patients with Tonsillar Hypertrophy']","['LMA', 'Laryngeal Mask Airway', 'laryngeal mask airway (LMA', 'LMA group and the endotracheal tube (ETT', 'Endotracheal Tube']","['peak airway pressure', 'Complications such as laryngospasm, bronchospasm, desaturation, severe coughing, blood on the device after removal, and sore throat', 'ventilation leak volume and P ET co 2', 'severe coughing', 'safety and effectiveness', 'ventilation leak volume, peak airway pressure, and partial pressure of end-tidal carbon dioxide (P ET co 2 ']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443298', 'cui_str': 'Second degree'}, {'cui': 'C0272386', 'cui_str': 'Hypertrophy of tonsils'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0021446', 'cui_str': 'Repair of inguinal hernia'}]","[{'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0336630', 'cui_str': 'Endotracheal tube'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0023066', 'cui_str': 'Laryngeal spasm'}, {'cui': 'C0006266', 'cui_str': 'Bronchospasm'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0332234', 'cui_str': 'Leaking'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030604', 'cui_str': 'Partial pressure'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}]",100.0,0.12356,There was no statistically significant difference in ventilation leak volume and P ET co 2 between the LMA and ETT groups (P > .05).,"[{'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': ""Department of Operating Room and Anesthesiology, Hebei Medical University Affiliated Children's Hospital of Hebei Province, Shijiazhuang, China.""}, {'ForeName': 'Hongyan', 'Initials': 'H', 'LastName': 'Cao', 'Affiliation': ""Department of Operating Room and Anesthesiology, Hebei Medical University Affiliated Children's Hospital of Hebei Province, Shijiazhuang, China.""}, {'ForeName': 'Xiaona', 'Initials': 'X', 'LastName': 'Tan', 'Affiliation': ""Department of Neurological Rehabilitation, Hebei Medical University Affiliated Children's Hospital of Hebei Province, Shijiazhuang, China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Qiao', 'Affiliation': ""Department of Operating Room and Anesthesiology, Hebei Medical University Affiliated Children's Hospital of Hebei Province, Shijiazhuang, China.""}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': ""Department of Operating Room and Anesthesiology, Hebei Medical University Affiliated Children's Hospital of Hebei Province, Shijiazhuang, China.""}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Shi', 'Affiliation': ""Department of Operating Room and Anesthesiology, Hebei Medical University Affiliated Children's Hospital of Hebei Province, Shijiazhuang, China. Electronic address: shileilx@163.com.""}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.06.020'] 377,33172506,A mycoprotein-based high-protein vegan diet supports equivalent daily myofibrillar protein synthesis rates compared with an isonitrogenous omnivorous diet in older adults: a randomised controlled trial.,"Animal-derived dietary protein ingestion and physical activity stimulate myofibrillar protein synthesis rates in older adults. We determined whether a non-animal-derived diet can support daily myofibrillar protein synthesis rates to the same extent as an omnivorous diet. Nineteen healthy older adults (aged 66 (sem 1) years; BMI 24 (sem 1) kg/m2; twelve males, seven females) participated in a randomised, parallel-group, controlled trial during which they consumed a 3-d isoenergetic high-protein (1·8 g/kg body mass per d) diet, where the protein was provided from predominantly (71 %) animal (OMNI; n 9; six males, three females) or exclusively vegan (VEG; n 10; six males, four females; mycoprotein providing 57 % of daily protein intake) sources. During the dietary control period, participants conducted a daily bout of unilateral resistance-type leg extension exercise. Before the dietary control period, participants ingested 400 ml of deuterated water, with 50-ml doses consumed daily thereafter. Saliva samples were collected throughout to determine body water 2H enrichments, and muscle samples were collected from rested and exercised muscle to determine daily myofibrillar protein synthesis rates. Deuterated water dosing resulted in body water 2H enrichments of approximately 0·78 (sem 0·03) %. Daily myofibrillar protein synthesis rates were 13 (sem 8) (P = 0·169) and 12 (sem 4) % (P = 0·016) greater in the exercised compared with rested leg (1·59 (sem 0·12) v. 1·77 (sem 0·12) and 1·76 (sem 0·14) v. 1·93 (sem 0·12) %/d) in OMNI and VEG groups, respectively. Daily myofibrillar protein synthesis rates did not differ between OMNI and VEG in either rested or exercised muscle (P > 0·05). Over the course of a 3-d intervention, omnivorous- or vegan-derived dietary protein sources can support equivalent rested and exercised daily myofibrillar protein synthesis rates in healthy older adults consuming a high-protein diet.",2021,Daily myofibrillar protein synthesis rates did not differ between OMNI and VEG in either rested or exercised muscle (P>0.05).,"['older adults', 'Nineteen healthy older adults (age 66±1', 'healthy older adults']","['unilateral resistance-type leg extension exercise', '3-day isocaloric high-protein (1.8 g·kg body mass-1·d-1) diet', 'isonitrogenous omnivorous diet', 'AbstractAnimal-derived dietary protein ingestion and physical activity']",['Daily myofibrillar protein synthesis rates'],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0012177', 'cui_str': 'Proteins, Dietary'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0597295', 'cui_str': 'Genetic translation'}]",19.0,0.0203003,Daily myofibrillar protein synthesis rates did not differ between OMNI and VEG in either rested or exercised muscle (P>0.05).,"[{'ForeName': 'Alistair J', 'Initials': 'AJ', 'LastName': 'Monteyne', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, ExeterEX1 2LU, UK.'}, {'ForeName': 'Mandy V', 'Initials': 'MV', 'LastName': 'Dunlop', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, ExeterEX1 2LU, UK.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Machin', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, ExeterEX1 2LU, UK.'}, {'ForeName': 'Mariana O C', 'Initials': 'MOC', 'LastName': 'Coelho', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, ExeterEX1 2LU, UK.'}, {'ForeName': 'George F', 'Initials': 'GF', 'LastName': 'Pavis', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, ExeterEX1 2LU, UK.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Porter', 'Affiliation': 'Department of Surgery, University of Texas Medical Branch, Galveston, TX77555, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Murton', 'Affiliation': 'Department of Surgery, University of Texas Medical Branch, Galveston, TX77555, USA.'}, {'ForeName': 'Doaa R', 'Initials': 'DR', 'LastName': 'Abdelrahman', 'Affiliation': 'Department of Surgery, University of Texas Medical Branch, Galveston, TX77555, USA.'}, {'ForeName': 'Marlou L', 'Initials': 'ML', 'LastName': 'Dirks', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, ExeterEX1 2LU, UK.'}, {'ForeName': 'Francis B', 'Initials': 'FB', 'LastName': 'Stephens', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, ExeterEX1 2LU, UK.'}, {'ForeName': 'Benjamin T', 'Initials': 'BT', 'LastName': 'Wall', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, ExeterEX1 2LU, UK.'}]",The British journal of nutrition,['10.1017/S0007114520004481'] 378,33170576,Two-Thumb Encircling Technique With a Novel Compression Assist Device Provides Safe and Effective Chest Compressions in Infants.,"OBJECTIVE Currently, 2-thumb encircling technique is recommended in 2-rescuer infant cardiopulmonary resuscitation (CPR). However, many complications can occur during CPR. Therefore, we developed a novel compression assist device (Reheart) that can reduce chest compression area and determined whether using our device provides better compression quality. METHODS A novel compression assist device consists of 2 parts. The upper part was designed to put 2 thumbs together in the thumb sleeves, and the lower part was designed based on a circular rubber plate with a 2.0-cm diameter to confine compression area. Infant manikin CPR simulations using the 2-thumb encircling technique with Reheart and without Reheart were sequentially performed by participants in randomized crossover fashion. RESULTS A total of 32 health care providers were included. The average age of the participants was 30.2 ± 3.5 years, and 21 participants (65.6%) were male. The accuracy in the Reheart group was better than that in the conventional group (proportion of compression on target area, 52.5% ± 13.2% vs 35.4% ± 17.6%; P < 0.001). The difference in the rates of chest compressions between the 2 groups was not significant (119.6 ± 14.4 vs 120.7 ± 14.0 compressions/min, P = 0.59). The depth of chest compressions was also not significantly different between the 2 groups (34.5 mm [33.6-34.9 mm] vs 34.2 mm [33.0-34.9 mm], P = 0.32). CONCLUSIONS Our new compression assist device can help provide safe and effective chest compressions during 2-rescuer infant CPR.",2020,"The accuracy in the Reheart group was better than that in the conventional group (proportion of compression on target area, 52.5% ± 13.2% vs 35.4% ± 17.6%; P < 0.001).","['32 health care providers', '2-rescuer infant cardiopulmonary resuscitation (CPR', 'The average age of the participants was 30.2 ± 3.5 years, and 21 participants (65.6%) were male', 'Infants']",[],"['depth of chest compressions', 'rates of chest compressions']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]",[],"[{'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0332459', 'cui_str': 'Compression'}]",,0.0341644,"The accuracy in the Reheart group was better than that in the conventional group (proportion of compression on target area, 52.5% ± 13.2% vs 35.4% ± 17.6%; P < 0.001).","[{'ForeName': 'Se Uk', 'Initials': 'SU', 'LastName': 'Lee', 'Affiliation': 'From the Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine.'}, {'ForeName': 'Do Kyun', 'Initials': 'DK', 'LastName': 'Kim', 'Affiliation': 'Department of Emergency Medicine, Seoul National University Hospital, Seoul.'}, {'ForeName': 'Ikwan', 'Initials': 'I', 'LastName': 'Chang', 'Affiliation': 'Department of Emergency Medicine, Seoul National University Hospital, Seoul.'}, {'ForeName': 'Jae Yun', 'Initials': 'JY', 'LastName': 'Jung', 'Affiliation': 'Department of Emergency Medicine, Seoul National University Hospital, Seoul.'}, {'ForeName': 'So Hyun', 'Initials': 'SH', 'LastName': 'Paek', 'Affiliation': 'Department of Emergency Medicine, Seoul National University Hospital, Seoul.'}, {'ForeName': 'Joong Wan', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Department of Emergency Medicine, Seoul National University Hospital, Seoul.'}, {'ForeName': 'Jin Hee', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Emergency Medicine, Seoul National University Bundang Hospital, Seong-nam, Korea.'}, {'ForeName': 'Young Ho', 'Initials': 'YH', 'LastName': 'Kwak', 'Affiliation': 'Department of Emergency Medicine, Seoul National University Hospital, Seoul.'}]",Pediatric emergency care,['10.1097/PEC.0000000000001738'] 379,33098852,"Ethinyl estradiol vs estradiol valerate in combined oral contraceptives - Effect on glucose tolerance: A randomized, controlled clinical trial.","OBJECTIVE To compare the effects of two formulations of combined oral contraceptives (COCs), estradiol valerate (EV) and ethinyl estradiol (EE) combined with dienogest (DNG), and DNG-only, on glucose tolerance. STUDY DESIGN We performed a randomized, controlled 9-week clinical trial. Inclusion criteria were: age 18-35 years, regular menstrual cycle (28 ± 7 days), no polycystic ovaries, non-smoking, no contraindications for COC use and a 2-month wash-out from hormonal contraceptive use. The women were randomized to EV + DNG (n = 20), EE + DNG (n = 20), and DNG-only (n = 19), and evaluated at baseline, at 4-5 weeks and 8-9 weeks of treatment. Study medications were used continuously for 63 days. Primary outcome measure was change in the whole-body insulin sensitivity index (Matsuda index) derived from the oral glucose tolerance test (OGTT) over the treatment period. Secondary outcome measures were area under curves (AUC) of glucose and insulin, homeostatic model assessment - insulin resistance (HOMA-IR) and Insulin Sensitivity Index (ISI). RESULTS Fifty-nine women enrolled, and 56 women completed the study. The Matsuda index changed from baseline as follows (mean percentage change, mean change [95%CI]): DNG-only -12%, -1.45 [95%CI -3.22-0.325] P = 0.10; EV + DNG + 2.7%, -0.10 [-1.34 to 1.14] P = 0.86; EE + DNG -5.5%, -1.02 [-2.51 to 0.46] P = 0.16, comparing the groups P = 0.27. There were no clinically significant differences in glucose tolerance between the COC groups, but the DNG-only group showed an improvement in the 2-h glucose levels (5.5 [95%CI 5.0-6.0] to 4.7 mmol/l [4.2-5.2], P = 0.001). CONCLUSION We found no clinically significant differences between EV and EE combined with DNG and DNG-only on glucose tolerance in healthy, young, normal-weight women, indicating that these preparations appear close to neutral regarding glucose metabolism when used continuously for nine weeks. IMPLICATIONS Combinations of both ethinyl estradiol and natural estradiol (estradiol valerate) with dienogest (DNG), as well as DNG-only, seem metabolically safe in young and healthy women in short-term continuous use.",2021,"We found no clinically significant differences between EV and EE combined with DNG and DNG-only on glucose tolerance in healthy, young, normal-weight women, indicating that these preparations appear close to neutral regarding glucose metabolism when used continuously for nine weeks.","['Inclusion criteria were: age 18-35 years, regular menstrual cycle (28±7 days), no polycystic ovaries, non-smoking, no contraindications for COC use and a 2-month wash-out from hormonal contraceptive use', 'young and healthy women in short-term continuous use', 'Fifty-nine women enrolled, and 56 women completed the study', 'healthy, young, normal-weight women']","['ethinyl estradiol and natural estradiol (estradiol valerate) with dienogest (DNG', 'Ethinyl Estradiol vs Estradiol Valerate', 'EV+DNG', 'combined oral contraceptives (COCs), estradiol valerate (EV) and ethinyl estradiol (EE) combined with dienogest (DNG), and DNG']","['change in the whole-body insulin sensitivity index (Matsuda index', 'area under curves (AUC) of glucose and insulin, homeostatic model assessment - insulin resistance (HOMA-IR) and Insulin Sensitivity Index (ISI', '2-hour glucose levels', 'oral glucose tolerance test (OGTT', 'glucose tolerance', 'Glucose Tolerance', 'Matsuda index']","[{'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0025329', 'cui_str': 'Normal menstrual cycle'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0009871', 'cui_str': 'Contraceptive agent'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C3830128', 'cui_str': '59'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}]","[{'cui': 'C0015011', 'cui_str': 'Ethinyl Estradiol'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0059623', 'cui_str': 'Estradiol valerate'}, {'cui': 'C0057916', 'cui_str': 'dienogest'}, {'cui': 'C0009906', 'cui_str': 'Oral Contraceptives, Combined'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}]",59.0,0.12365,"We found no clinically significant differences between EV and EE combined with DNG and DNG-only on glucose tolerance in healthy, young, normal-weight women, indicating that these preparations appear close to neutral regarding glucose metabolism when used continuously for nine weeks.","[{'ForeName': 'Annina', 'Initials': 'A', 'LastName': 'Haverinen', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 2, PO 140, 00029 Helsinki, Finland.'}, {'ForeName': 'Marika', 'Initials': 'M', 'LastName': 'Kangasniemi', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Oulu, Oulu University Hospital and Medical Research Centre PEDEGO Research Unit, Kajaanintie 50, PO 5000, 90014 Oulu, Finland.'}, {'ForeName': 'Kaisu', 'Initials': 'K', 'LastName': 'Luiro', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 2, PO 140, 00029 Helsinki, Finland.'}, {'ForeName': 'Terhi', 'Initials': 'T', 'LastName': 'Piltonen', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Oulu, Oulu University Hospital and Medical Research Centre PEDEGO Research Unit, Kajaanintie 50, PO 5000, 90014 Oulu, Finland.'}, {'ForeName': 'Oskari', 'Initials': 'O', 'LastName': 'Heikinheimo', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 2, PO 140, 00029 Helsinki, Finland.'}, {'ForeName': 'Juha S', 'Initials': 'JS', 'LastName': 'Tapanainen', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 2, PO 140, 00029 Helsinki, Finland; Department of Obstetrics and Gynecology, University of Oulu, Oulu University Hospital and Medical Research Centre PEDEGO Research Unit, Kajaanintie 50, PO 5000, 90014 Oulu, Finland. Electronic address: juha.tapanainen@helsinki.fi.'}]",Contraception,['10.1016/j.contraception.2020.10.014'] 380,33106087,"Risk Ladder, Table, or Bulleted List? Identifying Formats That Effectively Communicate Personalized Risk and Risk Reduction Information for Multiple Diseases.","BACKGROUND Personalized medicine may increase the amount of probabilistic information patients encounter. Little guidance exists about communicating risk for multiple diseases simultaneously or about communicating how changes in risk factors affect risk (hereafter ""risk reduction""). PURPOSE To determine how to communicate personalized risk and risk reduction information for up to 5 diseases associated with insufficient physical activity in a way laypeople can understand and that increases intentions. METHODS We recruited 500 participants with <150 min weekly of physical activity from community settings. Participants completed risk assessments for diabetes, heart disease, stroke, colon cancer, and breast cancer (women only) on a smartphone. Then, they were randomly assigned to view personalized risk and risk reduction information organized as a bulleted list, a simplified table, or a specialized vertical bar graph (""risk ladder""). Last, they completed a questionnaire assessing outcomes. Personalized risk and risk reduction information was presented as categories (e.g., ""very low""). Our analytic sample ( N = 372) included 41.3% individuals from underrepresented racial/ethnic backgrounds, 15.9% with vocational-technical training or less, 84.7% women, 43.8% aged 50 to 64 y, and 71.8% who were overweight/obese. RESULTS Analyses of covariance with post hoc comparisons showed that the risk ladder elicited higher gist comprehension than the bulleted list ( P = 0.01). There were no significant main effects on verbatim comprehension or physical activity intentions and no moderation by sex, race/ethnicity, education, numeracy, or graph literacy ( P > 0.05). Sequential mediation analyses revealed a small beneficial indirect effect of risk ladder versus list on intentions through gist comprehension and then through perceived risk ( b IndirectEffect = 0.02, 95% confidence interval: 0.00, 0.04). CONCLUSION Risk ladders can communicate the gist meaning of multiple pieces of risk information to individuals from many sociodemographic backgrounds and with varying levels of facility with numbers and graphs.",2021,"There were no significant main effects on verbatim comprehension or physical activity intentions and no moderation by sex, race/ethnicity, education, numeracy, or graph literacy ( P > 0.05).","['Our analytic sample ( N = 372) included 41.3% individuals from underrepresented racial/ethnic backgrounds, 15.9% with vocational-technical training or less, 84.7% women, 43.8% aged 50 to 64 y, and 71.8% who were overweight/obese', '500 participants with <150 min weekly of physical activity from community settings']",[],"['verbatim comprehension or physical activity intentions and no moderation by sex, race/ethnicity, education, numeracy, or graph literacy', 'gist comprehension', 'risk assessments for diabetes, heart disease, stroke, colon cancer, and breast cancer']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517770', 'cui_str': '41.3'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009462', 'cui_str': 'Community'}]",[],"[{'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0238198', 'cui_str': 'Gastrointestinal stromal tumor'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]",500.0,0.0321693,"There were no significant main effects on verbatim comprehension or physical activity intentions and no moderation by sex, race/ethnicity, education, numeracy, or graph literacy ( P > 0.05).","[{'ForeName': 'Erika A', 'Initials': 'EA', 'LastName': 'Waters', 'Affiliation': 'Department of Surgery, Division of Public Health Sciences, Washington University in St. Louis, Saint Louis, MO, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Maki', 'Affiliation': 'Department of Surgery, Division of Public Health Sciences, Washington University in St. Louis, Saint Louis, MO, USA.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Surgery, Division of Public Health Sciences, Washington University in St. Louis, Saint Louis, MO, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Ackermann', 'Affiliation': 'Department of Surgery, Division of Public Health Sciences, Washington University in St. Louis, Saint Louis, MO, USA.'}, {'ForeName': 'Chelsey R', 'Initials': 'CR', 'LastName': 'Carter', 'Affiliation': 'Department of Surgery, Division of Public Health Sciences, Washington University in St. Louis, Saint Louis, MO, USA.'}, {'ForeName': 'Hank', 'Initials': 'H', 'LastName': 'Dart', 'Affiliation': 'Department of Surgery, Division of Public Health Sciences, Washington University in St. Louis, Saint Louis, MO, USA.'}, {'ForeName': 'Deborah J', 'Initials': 'DJ', 'LastName': 'Bowen', 'Affiliation': 'University of Washington, Merced, CA, USA.'}, {'ForeName': 'Linda D', 'Initials': 'LD', 'LastName': 'Cameron', 'Affiliation': 'University of California, Merced, CA, USA.'}, {'ForeName': 'Graham A', 'Initials': 'GA', 'LastName': 'Colditz', 'Affiliation': 'Department of Surgery, Division of Public Health Sciences, Washington University in St. Louis, Saint Louis, MO, USA.'}]",Medical decision making : an international journal of the Society for Medical Decision Making,['10.1177/0272989X20968070'] 381,33115598,"The effect of dietary nitrate and vitamin C on endothelial function, oxidative stress and blood lipids in untreated hypercholesterolemic subjects: A randomized double-blind crossover study.","BACKGROUND Vitamin C may enhance nitric oxide (NO) production through stepwise reduction of dietary nitrate (NO 3 ) to nitrite (NO 2 ) to NO. The combined effect of vitamin C and NO 3 supplementation is relatively unexplored in untreated hypercholesterolemia. AIMS We aimed to examine whether co-administration of vitamin C and nitrate for 4-weeks would improve endothelial function (primary outcome), plasma NO metabolites, oxidative stress, and blood lipids (secondary outcomes). METHODS Subjects 50-70 years of age with low density lipoprotein (LDL) > 130 mg/dL and RHI ≤2 were enrolled in this randomized double-blind crossover study. Subjects were assigned to two 4-week supplementation treatments starting with 70 ml of concentrated beetroot juice (CBJ) with 1000 mg of vitamin C (NC) or CBJ with matched placebo (N), then switched to alternate treatment following 2-week washout. The change in reactive hyperemia index (RHI), sum of plasma NO metabolites (NO 2  + NO 3 (NOx)), oxidized LDL (oxLDL), and serum lipids were assessed at baseline and at 4-weeks of each treatment period. RESULTS Eighteen subjects (11M:7F) completed all study visits. No significant treatment differences were observed in RHI change (N: 0.21 ± 0.12; NC: 0.20 ± 0.17; p = 0.99). Secondary analysis revealed that a subgroup of NC subjects who started with a baseline RHI of <1.67 (threshold value for ED) had greater improvements in RHI compared to subjects with RHI >1.67 (1.23 ± 0.15 to 1.96 ± 0.19; n = 8 vs. 1.75 ± 0.11 to 1.43 ± 0.10; n = 8; p = 0.02). Compared to N, NC experienced a significant increase in plasma NOx (N: 94.2 ± 15.5 μmol/L; NC: 128.7 ± 29.1 μmol/L; p = 0.01). Although there was no significant difference in oxLDL change between treatments (N: -1.08 ± 9.8 U/L; NC: -6.07 ± 9.14 U/L; p = 0.19), NC elicited significant reductions in LDL (N: 2.2 ± 2; NC: -10.7 ± 23; p = 0.049), triglycerides (N: 14.6 ± 43; NC: -43.7 ± 45; p = 0.03), and no change in serum high density lipoprotein. Within treatment group comparisons showed that only NC reduced oxLDL significantly from baseline to 4 weeks (p = 0.01). CONCLUSIONS No between intervention differences were observed in RHI. RHI only improved in NC subjects with ED at intervention baseline. Four weeks of NC enriched the NO pool and promoted reduction of blood lipids and oxidative stress in subjects with hypercholesterolemia. These preliminary findings highlight a supplementation strategy that may reduce the progression of atherosclerotic disease and deserves further attention in studies using flow mediated dilation methods. CLINICAL TRIAL REGISTRATION www.clinicaltrials.gov (NCT04283630).",2021,"Within treatment group comparisons showed that only NC reduced oxLDL significantly from baseline to 4 weeks (p = 0.01). ","['Subjects 50-70 years of age with low density lipoprotein (LDL)\xa0', '130', 'untreated hypercholesterolemic subjects', 'subjects with hypercholesterolemia', 'Eighteen subjects (11M:7F) completed all study visits']","['vitamin C and NO 3 supplementation', 'vitamin C and nitrate', 'supplementation treatments starting with 70\xa0ml of concentrated beetroot juice (CBJ) with 1000\xa0mg of vitamin C (NC) or CBJ with matched placebo', 'dietary nitrate and vitamin C']","['NO 3 (NOx)), oxidized LDL (oxLDL), and serum lipids', 'endothelial function (primary outcome), plasma NO metabolites, oxidative stress, and blood lipids (secondary outcomes', 'reactive hyperemia index (RHI), sum of plasma', 'plasma NOx', 'RHI', 'RHI change', 'oxLDL change', 'endothelial function, oxidative stress and blood lipids', 'serum high density lipoprotein', 'blood lipids and oxidative stress', 'NC reduced oxLDL']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0020443', 'cui_str': 'Hypercholesterolemia'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0348035', 'cui_str': 'Oxidized low density lipoprotein'}, {'cui': 'C0428462', 'cui_str': 'Measurement of serum lipid level'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0178824', 'cui_str': 'Reactive Hyperemia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",,0.517327,"Within treatment group comparisons showed that only NC reduced oxLDL significantly from baseline to 4 weeks (p = 0.01). ","[{'ForeName': 'Reem', 'Initials': 'R', 'LastName': 'Basaqr', 'Affiliation': 'Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, USA. Electronic address: reem.basaqr@uky.edu.'}, {'ForeName': 'Michealia', 'Initials': 'M', 'LastName': 'Skleres', 'Affiliation': 'Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, USA. Electronic address: michealia.skleres@uky.edu.'}, {'ForeName': 'Rani', 'Initials': 'R', 'LastName': 'Jayswal', 'Affiliation': 'Department of Biostatistics & Bioinformatics, University of Kentucky, USA. Electronic address: rani.jayswal@uky.edu.'}, {'ForeName': 'D Travis', 'Initials': 'DT', 'LastName': 'Thomas', 'Affiliation': 'Department of Athletic Training and Clinical Nutrition, College of Health Sciences, University of Kentucky, USA. Electronic address: dth225@uky.edu.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.012'] 382,33120862,"One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL).","Omega-3 (n-3) treatment may lower cardiovascular risk, yet its effects on the circulating lipidome and relation to cardiovascular risk biomarkers are unclear. We hypothesized that n-3 treatment is associated with favorable changes in downstream fatty acids (FAs), oxylipins, bioactive lipids, clinical lipid and inflammatory biomarkers. We examined these VITAL200, a nested substudy of 200 subjects balanced on demographics and treatment and randomly selected from the Vitamin D and Omega-3 Trial (VITAL). VITAL is a randomized double-blind trial of 840 mg/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) vs. placebo among 25,871 individuals. Small polar bioactive lipid features, oxylipins and FAs from plasma and red blood cells were measured using three independent assaying techniques at baseline and one year. The Women's Health Study (WHS) was used for replication with dietary n-3 intake. Randomized n-3 treatment led to changes in 143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR) < 0.05 in VITAL200, validated ( p -values < 0.05)) in WHS with increases in 95 including EPA, DHA, n-3 docosapentaenoic acid (DPA-n3), and decreases in 48 including DPA-n6, dihomo gamma linolenic (DGLA), adrenic and arachidonic acids. N-3 related changes in the bioactive lipidome were heterogeneously associated with changes in clinical lipid and inflammatory biomarkers. N-3 treatment significantly modulates the bioactive lipidome, which may contribute to its clinical benefits.",2020,"Randomized n-3 treatment led to changes in 143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR) < 0.05 in VITAL200, validated ( p -values < 0.05)) in WHS with increases in 95 including EPA, DHA, n-3 docosapentaenoic acid (DPA-n3), and decreases in 48 including DPA-n6, dihomo gamma linolenic (DGLA), adrenic and arachidonic acids.","['25,871 individuals', '200 subjects balanced on demographics and treatment and randomly selected from the Vitamin D and Omega-3 Trial (VITAL']","['n-3 treatment', 'Omega-3 Treatment', 'Omega-3 (n-3', 'N-3 treatment', 'eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) vs. placebo']","['downstream fatty acids (FAs), oxylipins, bioactive lipids, clinical lipid and inflammatory biomarkers', 'Fatty Acids, Oxylipins, and Related Bioactive Lipids', '143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR', 'EPA, DHA, n-3 docosapentaenoic acid (DPA-n3), and decreases in 48 including DPA-n6, dihomo gamma linolenic (DGLA), adrenic and arachidonic acids', 'Small polar bioactive lipid features, oxylipins and FAs from plasma and red blood cells']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0522506', 'cui_str': 'Downstream'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C1956100', 'cui_str': 'Oxylipins'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0205557', 'cui_str': 'False positive'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0058624', 'cui_str': 'docosapentaenoic acid'}, {'cui': 'C0042291', 'cui_str': 'valproic acid'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0017011', 'cui_str': 'Gamma radiation'}, {'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}]",,0.199205,"Randomized n-3 treatment led to changes in 143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR) < 0.05 in VITAL200, validated ( p -values < 0.05)) in WHS with increases in 95 including EPA, DHA, n-3 docosapentaenoic acid (DPA-n3), and decreases in 48 including DPA-n6, dihomo gamma linolenic (DGLA), adrenic and arachidonic acids.","[{'ForeName': 'Olga V', 'Initials': 'OV', 'LastName': 'Demler', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Luttmann-Gibson', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'Jeramie D', 'Initials': 'JD', 'LastName': 'Watrous', 'Affiliation': 'Department of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.'}, {'ForeName': 'Kim A', 'Initials': 'KA', 'LastName': 'Lagerborg', 'Affiliation': 'Department of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.'}, {'ForeName': 'Hesam', 'Initials': 'H', 'LastName': 'Dashti', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Giulianini', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'Mallory', 'Initials': 'M', 'LastName': 'Heath', 'Affiliation': ""Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Camargo', 'Affiliation': 'Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.'}, {'ForeName': 'William S', 'Initials': 'WS', 'LastName': 'Harris', 'Affiliation': 'OmegaQuant Analytics, Sioux Falls, SD 57106, USA.'}, {'ForeName': 'Jay G', 'Initials': 'JG', 'LastName': 'Wohlgemuth', 'Affiliation': 'Quest Diagnostics, San Juan Capistrano, CA 92673, USA.'}, {'ForeName': 'Allen M', 'Initials': 'AM', 'LastName': 'Andres', 'Affiliation': 'Department of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.'}, {'ForeName': 'Saumya', 'Initials': 'S', 'LastName': 'Tivari', 'Affiliation': 'Department of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Long', 'Affiliation': 'Department of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.'}, {'ForeName': 'Mahan', 'Initials': 'M', 'LastName': 'Najhawan', 'Affiliation': 'Department of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.'}, {'ForeName': 'Khoi', 'Initials': 'K', 'LastName': 'Dao', 'Affiliation': 'Department of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Prentice', 'Affiliation': 'Quest Diagnostics, San Juan Capistrano, CA 92673, USA.'}, {'ForeName': 'Julia A', 'Initials': 'JA', 'LastName': 'Larsen', 'Affiliation': 'Quest Diagnostics, San Juan Capistrano, CA 92673, USA.'}, {'ForeName': 'Olivia I', 'Initials': 'OI', 'LastName': 'Okereke', 'Affiliation': 'Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.'}, {'ForeName': 'Karen H', 'Initials': 'KH', 'LastName': 'Costenbader', 'Affiliation': ""Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Buring', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Cheng', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Ctr, Los Angeles, CA 90048, USA.'}, {'ForeName': 'Mohit', 'Initials': 'M', 'LastName': 'Jain', 'Affiliation': 'Department of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.'}, {'ForeName': 'Samia', 'Initials': 'S', 'LastName': 'Mora', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}]",Metabolites,['10.3390/metabo10110431'] 383,33123838,Randomized Controlled Trial of an Integrated Family-Based Treatment for Adolescents Presenting to Community Mental Health Centers.,"Most adolescents presenting to community mental health centers have one or more comorbidities (internalizing, externalizing, and substance use problems). We evaluated an integrated family-based outpatient treatment for adolescents (OPT-A) that can be delivered in a community mental health center by a single therapist. A sample of 134 youth/families were randomized to receive OPT-A or usual services, delivered at the same public sector mental health center. Repeated, multi-informant assessments occurred through 18-months post-baseline. At baseline, the sample displayed low internalizing symptoms, moderate substance use, and high externalizing problems. Compared to usual services, OPT-A had effects on abstinence rates, retention, motivation, parent involvement, and satisfaction, but not on internalizing or externalizing problems. While OPT-A achieved some key improvements for youth who present to community mental health centers, and families were satisfied with treatment, continued work is necessary to examine treatments for comorbidity while balancing treatment feasibility and complex strategies to boost treatment effectiveness.",2021,"Compared to usual services, OPT-A had effects on abstinence rates, retention, motivation, parent involvement, and satisfaction, but not on internalizing or externalizing problems.","['Most adolescents presenting to community mental health centers', 'Adolescents Presenting to Community Mental Health Centers', '134 youth/families']","['Integrated Family-Based Treatment', 'OPT-A or usual services, delivered at the same public sector mental health center']","['abstinence rates, retention, motivation, parent involvement, and satisfaction', 'internalizing or externalizing problems']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0009474', 'cui_str': 'CMHC'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0015576', 'cui_str': 'Family'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0034035', 'cui_str': 'Public Sector'}, {'cui': 'C0009474', 'cui_str': 'CMHC'}]","[{'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0033213', 'cui_str': 'Problem'}]",134.0,0.0905881,"Compared to usual services, OPT-A had effects on abstinence rates, retention, motivation, parent involvement, and satisfaction, but not on internalizing or externalizing problems.","[{'ForeName': 'Ashli J', 'Initials': 'AJ', 'LastName': 'Sheidow', 'Affiliation': 'Oregon Social Learning Center, 10 Shelton McMurphey Blvd., Eugene, OR, 97401, USA.'}, {'ForeName': 'Kristyn', 'Initials': 'K', 'LastName': 'Zajac', 'Affiliation': 'University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030, USA. zajac@uchc.edu.'}, {'ForeName': 'Jason E', 'Initials': 'JE', 'LastName': 'Chapman', 'Affiliation': 'Oregon Social Learning Center, 10 Shelton McMurphey Blvd., Eugene, OR, 97401, USA.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'McCart', 'Affiliation': 'Oregon Social Learning Center, 10 Shelton McMurphey Blvd., Eugene, OR, 97401, USA.'}, {'ForeName': 'Tess K', 'Initials': 'TK', 'LastName': 'Drazdowski', 'Affiliation': 'Oregon Social Learning Center, 10 Shelton McMurphey Blvd., Eugene, OR, 97401, USA.'}]",Community mental health journal,['10.1007/s10597-020-00735-z'] 384,33129819,Comparisons of Nonhyperemic Pressure Ratios: Predicting Functional Results of Coronary Revascularization Using Longitudinal Vessel Interrogation.,"OBJECTIVES The aim of this study was to investigate the accuracy of pre-percutaneous coronary intervention (PCI) predicted nonhyperemic pressure ratios (NHPRs) with actual post-PCI NHPRs and to assess the efficacy of PCI strategy using pre-PCI NHPR pullback. BACKGROUND Predicting the functional results of PCI is feasible using pre-PCI longitudinal vessel interrogation with the instantaneous wave-free ratio (iFR), a pressure-based, adenosine-free NHPR. However, the reliability of novel NHPRs (resting full-cycle ratio [RFR] and diastolic pressure ratio [dPR]) for this purpose remains uncertain. METHODS In this prospective, multicenter, randomized controlled trial, vessels were randomly assigned to receive pre-PCI iFR, RFR, or dPR pullback (50 vessels each). The pre-PCI predicted NHPRs were compared with actual NHPRs after contemporary PCI using intravascular imaging. The number and the total length of treated lesions were compared between NHPR pullback-guided and angiography-guided strategies. RESULTS The predicted NHPRs were strongly correlated with actual NHPRs: iFR, r = 0.83 (95% confidence interval: 0.72 to 0.90; p < 0.001); RFR, r = 0.84 (95% confidence interval: 0.73 to 0.91; p < 0.001), and dPR, r = 0.84 (95% confidence interval: 0.73 to 0.91; p < 0.001). The number and the total length of treated lesions were lower with the NHPR pullback strategy than with the angiography-guided strategy, leading to physiological improvement. CONCLUSIONS Predicting functional PCI results on the basis of pre-procedural RFR and dPR pullbacks yields similar results to iFR. Compared with an angiography-guided strategy, a pullback-guided PCI strategy with any of the 3 NHPRs reduced the number and the total length of treated lesions. (Study to Examine Correlation Between Predictive Value and Post PCI Value of iFR, RFR and dPR; UMIN000033534).",2020,"The number and the total length of treated lesions were lower with the NHPR pull back strategy than with the angiography-guided strategy, leading to physiological improvement. ",[],"['pre-PCI iFR, RFR, or dPR pull back', 'Coronary Revascularization Using Longitudinal Vessel Interrogation', 'pre-percutaneous coronary intervention (PCI']","['reliability of novel NHPRs (resting full-cycle ratio [RFR] and diastolic pressure ratio [dPR', 'number and the total length of treated lesions', 'nonhyperemic pressure ratios (NHPRs', 'Predictive Value and Post PCI Value of iFR, RFR and dPR']",[],"[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0406778', 'cui_str': 'Dermatopathia pigmentosa reticularis'}, {'cui': 'C0580846', 'cui_str': 'Does pull'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}]","[{'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1442095', 'cui_str': 'Pressure ratio'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0406778', 'cui_str': 'Dermatopathia pigmentosa reticularis'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",,0.097615,"The number and the total length of treated lesions were lower with the NHPR pull back strategy than with the angiography-guided strategy, leading to physiological improvement. ","[{'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Omori', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan. Electronic address: omori@heart-center.or.jp.'}, {'ForeName': 'Yoshiaki', 'Initials': 'Y', 'LastName': 'Kawase', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Mizukami', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Tanigaki', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Tetsuo', 'Initials': 'T', 'LastName': 'Hirata', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Kikuchi', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Ota', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Sobue', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Taiji', 'Initials': 'T', 'LastName': 'Miyake', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Itta', 'Initials': 'I', 'LastName': 'Kawamura', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Munenori', 'Initials': 'M', 'LastName': 'Okubo', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Kamiya', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Hirakawa', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Masanori', 'Initials': 'M', 'LastName': 'Kawasaki', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Masayasu', 'Initials': 'M', 'LastName': 'Nakagawa', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Kunihiko', 'Initials': 'K', 'LastName': 'Tsuchiya', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Yoriyasu', 'Initials': 'Y', 'LastName': 'Suzuki', 'Affiliation': 'Department of Cardiovascular Medicine, Nagoya Heart Center, Nagoya, Japan.'}, {'ForeName': 'Tatsuya', 'Initials': 'T', 'LastName': 'Ito', 'Affiliation': 'Department of Cardiovascular Medicine, Nagoya Heart Center, Nagoya, Japan.'}, {'ForeName': 'Mitsuyasu', 'Initials': 'M', 'LastName': 'Terashima', 'Affiliation': 'Department of Cardiovascular Medicine, Toyohashi Heart Center, Toyohashi, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kondo', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}, {'ForeName': 'Takahiko', 'Initials': 'T', 'LastName': 'Suzuki', 'Affiliation': 'Department of Cardiovascular Medicine, Toyohashi Heart Center, Toyohashi, Japan.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Escaned', 'Affiliation': 'Hospital Clinico San Carlos IDISSC and Universidad Complutense de Madrid, Madrid, Spain.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Matsuo', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.'}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2020.06.060'] 385,33161116,Infant Television Watching Predicts Toddler Television Watching in a Low-Income Population.,"OBJECTIVE This study examines the development of active television (TV) watching behaviors across the first 2 years of life in a racially and ethnically diverse, low-income cohort and identifies caregiver and child predictors of early TV watching. METHODS We used longitudinal data from infants enrolled in the active control group (N = 235; 39% Latino; 29% Black; 15% White) of Greenlight, a cluster randomized multisite trial to prevent childhood obesity. At preventive health visits from 2 months to 2 years, caregivers were asked: ""How much time does [child's first name] spend watching television each day?"" Proportional odds models and linear regression analyses were used to assess associations among TV introduction age, active TV watching amount at 2 years, and sociodemographic factors. RESULTS Sixty-eight percent of children watched TV by 6 months, and 88% by 2 years. Age of TV introduction predicted amount of daily active TV watching at 2 years, with a mean time of 93 minutes if starting at 2 months; 64 minutes if starting at 4 or 6 months; and 42 minutes if starting after 6 months. Factors predicting earlier introduction included lower income, fewer children in household, care away from home, male sex, and non-Latino ethnicity of child. CONCLUSIONS Many caregivers report that their infants actively watch TV in the first 6 months of life. Earlier TV watching is related to sociodemographic factors yet predicts more daily TV watching at 2 years even controlling those factors. Interventions to limit early TV watching should be initiated in infancy.",2021,"Age of TV introduction predicted amount of daily active TV watching at 2 years, with a mean time of 93 minutes if starting at 2 months; 64 minutes if starting at 4 or 6 months; and 42 minutes if starting after 6 months.","['infants enrolled in the active control group (N\u202f=\u202f235; 39% Latino; 29% black; 15% white) of Greenlight, a cluster randomized multi-site trial to prevent childhood obesity', 'first 2 years of life in a racially and ethnically diverse, low-income cohort and identifies caregiver and child predictors of early TV watching']","['watching television each day', 'active television (TV) watching behaviors', 'Infant television watching predicts toddler television watching']",[],"[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C2362324', 'cui_str': 'Childhood obesity'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0039461', 'cui_str': 'Television'}]","[{'cui': 'C0039461', 'cui_str': 'Television'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}]",[],235.0,0.061021,"Age of TV introduction predicted amount of daily active TV watching at 2 years, with a mean time of 93 minutes if starting at 2 months; 64 minutes if starting at 4 or 6 months; and 42 minutes if starting after 6 months.","[{'ForeName': 'Alexander J', 'Initials': 'AJ', 'LastName': 'Hish', 'Affiliation': 'Duke University School of Medicine (AJ Hish), Durham, NC.'}, {'ForeName': 'Charles T', 'Initials': 'CT', 'LastName': 'Wood', 'Affiliation': 'Department of Pediatrics, Duke University (CT Wood, JB Howard, and EM Perrin), Vienna, Austria; Duke Center for Childhood Obesity Research, Duke University School of Medicine (CT Wood, JB Howard, and EM Perrin), Durham, NC.'}, {'ForeName': 'Janna B', 'Initials': 'JB', 'LastName': 'Howard', 'Affiliation': 'Department of Pediatrics, Duke University (CT Wood, JB Howard, and EM Perrin), Vienna, Austria; Duke Center for Childhood Obesity Research, Duke University School of Medicine (CT Wood, JB Howard, and EM Perrin), Durham, NC.'}, {'ForeName': 'Kori B', 'Initials': 'KB', 'LastName': 'Flower', 'Affiliation': 'Division of General Pediatrics and Adolescent Medicine, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine (KB Flower).'}, {'ForeName': 'H Shonna', 'Initials': 'HS', 'LastName': 'Yin', 'Affiliation': 'Department of Pediatrics, School of Medicine/Bellevue Hospital Center, New York University (HS Yin), New York, NY.'}, {'ForeName': 'Russell L', 'Initials': 'RL', 'LastName': 'Rothman', 'Affiliation': 'Center for Health Services Research, Vanderbilt University Medical Center (RL Rothman), Nashville, Tenn.'}, {'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Delamater', 'Affiliation': 'University of Miami School of Medicine (AM Delamater), Miami, Fla.'}, {'ForeName': 'Lee M', 'Initials': 'LM', 'LastName': 'Sanders', 'Affiliation': 'Department of Pediatrics, Center for Policy, Outcomes and Prevention, Stanford University (LM Sanders), Stanford, Calif.'}, {'ForeName': 'Aihua', 'Initials': 'A', 'LastName': 'Bian', 'Affiliation': 'Department of Biostatistics, Vanderbilt University School of Medicine (A Bian and JS Schildcrout), Nashville, Tenn.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Schildcrout', 'Affiliation': 'Department of Biostatistics, Vanderbilt University School of Medicine (A Bian and JS Schildcrout), Nashville, Tenn.'}, {'ForeName': 'Eliana M', 'Initials': 'EM', 'LastName': 'Perrin', 'Affiliation': 'Department of Pediatrics, Duke University (CT Wood, JB Howard, and EM Perrin), Vienna, Austria; Duke Center for Childhood Obesity Research, Duke University School of Medicine (CT Wood, JB Howard, and EM Perrin), Durham, NC. Electronic address: eliana.perrin@duke.edu.'}]",Academic pediatrics,['10.1016/j.acap.2020.11.002'] 386,33179395,"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial.","BACKGROUND AND OBJECTIVE The efficacy of combination therapy with corticosteroids and CNI, TAC and CsA, for PM/DM-ILD has been described retrospectively. However, it remains unknown which CNI treatment regimens, TAC or CsA regimens, are more effective as initial treatments for patients with PM/DM-ILD. METHODS We conducted a prospective multicentre, open-label, randomized, 52-week phase 2 trial. Patients with PM/DM-ILD were randomly allocated to receive PSL plus TAC (TAC group) or PSL plus CsA (CsA group). The primary endpoint was PFS rate in the intention-to-treat population at 52 weeks. The secondary endpoints were OS rate at 52 weeks, changes in pulmonary function tests from baseline to 52 weeks and AE. RESULTS Fifty-eight patients were randomly assigned to the TAC group (n = 30) and the CsA group (n = 28). The PFS rates at 52 weeks were 87% in the TAC group and 71% in the CsA group (P = 0.16). The OS rates at 52 weeks were 97% in the TAC group and 93% in the CsA group (P = 0.50). The %FVC at 52 weeks in the per-protocol populations significantly increased in both groups. None of the patients discontinued the treatment due to AE. CONCLUSION PSL plus TAC treatment may achieve a better short-term PFS rate compared with PSL plus CsA treatment. Further studies must be conducted to evaluate the long-term efficacy and safety of such treatment.",2021,The PFS rates at 52 weeks were 87% in the TAC group and 71% in the CsA group (P = 0.16).,"['Fifty-eight patients', 'Patients with PM/DM-ILD', 'polymyositis/dermatomyositis-associated ILD']","['TAC', 'Prednisolone and tacrolimus versus prednisolone and cyclosporin', 'PSL plus TAC', 'PSL plus TAC (TAC group) or PSL plus CsA (CsA group', 'corticosteroids and CNI, TAC and CsA']","['PFS rates', 'OS rate at 52\u2009weeks, changes in pulmonary function tests', 'PFS rate', 'short-term PFS rate', 'OS rates']","[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0085655', 'cui_str': 'Polymyositis'}, {'cui': 'C0011633', 'cui_str': 'Dermatomyositis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]","[{'cui': 'C3489891', 'cui_str': 'TAC Alternate'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C1431767', 'cui_str': 'cni protein, Drosophila'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]",58.0,0.117115,The PFS rates at 52 weeks were 87% in the TAC group and 71% in the CsA group (P = 0.16).,"[{'ForeName': 'Tomoyuki', 'Initials': 'T', 'LastName': 'Fujisawa', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Hironao', 'Initials': 'H', 'LastName': 'Hozumi', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Kamiya', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Kaida', 'Affiliation': 'Department of Respiratory Medicine, Enshu Hospital, Hamamatsu, Japan.'}, {'ForeName': 'Taisuke', 'Initials': 'T', 'LastName': 'Akamatsu', 'Affiliation': 'Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Kusagaya', 'Affiliation': 'Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan.'}, {'ForeName': 'Yasuomi', 'Initials': 'Y', 'LastName': 'Satake', 'Affiliation': 'Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.'}, {'ForeName': 'Kazutaka', 'Initials': 'K', 'LastName': 'Mori', 'Affiliation': 'Department of Respiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Mikamo', 'Affiliation': 'Department of Respiratory Medicine, Hamamatsu Medical Center, Hamamatsu, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Matsuda', 'Affiliation': 'Department of Respiratory Medicine, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.'}, {'ForeName': 'Koshi', 'Initials': 'K', 'LastName': 'Yokomura', 'Affiliation': 'Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Koshimizu', 'Affiliation': 'Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan.'}, {'ForeName': 'Mikio', 'Initials': 'M', 'LastName': 'Toyoshima', 'Affiliation': 'Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.'}, {'ForeName': 'Shiro', 'Initials': 'S', 'LastName': 'Imokawa', 'Affiliation': 'Department of Respiratory Medicine, Iwata City Hospital, Iwata, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Yasui', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Yuzo', 'Initials': 'Y', 'LastName': 'Suzuki', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Karayama', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Kazuki', 'Initials': 'K', 'LastName': 'Furuhashi', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Noriyuki', 'Initials': 'N', 'LastName': 'Enomoto', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Yutaro', 'Initials': 'Y', 'LastName': 'Nakamura', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Inui', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Suda', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}]","Respirology (Carlton, Vic.)",['10.1111/resp.13978'] 387,33185716,Sun exposure reduction by melanoma survivors with wearable sensor providing real-time UV exposure and daily text messages with structured goal setting.,"Despite knowledge of subsequent melanoma risk and the benefit of sun protection in risk reduction, melanoma survivors often do not engage in adequate sun protection and continue to sunburn at rates similar to individuals without a history of skin cancer. This novel intensive intervention provided a wearable UV sensor delivering real-time UV exposure with a smartphone and daily text messages. On days 1-10 (period 1), behavioral facilitation and outcome expectancies messages were provided. On day 10, participants reviewed and reflected on their daily UV exposure on the previous 10 days and set goals for improving sun protection. Then on days 11-21 (period 2) self-efficacy and self-regulation messages were provided. Sixty melanoma survivors were randomized (1:1) to receive structured or unstructured goal setting queries on day 10. Controlling for cloudy/rain conditions with less UV due to weather, there was a time effect with a significant decrease in UV exposure from periods 1-2 [period 1-2, F (59) = 22.60, p < 0.0001]. In this short-term study, melanoma survivors managed their daily UV exposure to stay below their maximum tolerated UV dose. ClinicalTrials.gov Protocol Record NCT0334796, date of registration Nov 15, 2017.",2021,"Controlling for cloudy/rain conditions with less UV due to weather, there was a time effect with a significant decrease in UV exposure from periods 1-2 [period 1-2, F (59) = 22.60, p < 0.0001].",['Sixty melanoma survivors'],[],"['UV exposure', 'behavioral facilitation and outcome expectancies messages']","[{'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]",[],"[{'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}]",,0.206136,"Controlling for cloudy/rain conditions with less UV due to weather, there was a time effect with a significant decrease in UV exposure from periods 1-2 [period 1-2, F (59) = 22.60, p < 0.0001].","[{'ForeName': 'June K', 'Initials': 'JK', 'LastName': 'Robinson', 'Affiliation': 'Department of Dermatology, Feinberg School of Medicine, Northwestern University, 645 N Michigan Ave, Suite 1050, Chicago, IL, 60611, USA. june-robinson@northwestern.edu.'}, {'ForeName': 'Dalya A', 'Initials': 'DA', 'LastName': 'Durst', 'Affiliation': 'Department of Dermatology, Feinberg School of Medicine, Northwestern University, 645 N Michigan Ave, Suite 1050, Chicago, IL, 60611, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Gray', 'Affiliation': 'Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Kwasny', 'Affiliation': 'Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Seung Yun', 'Initials': 'SY', 'LastName': 'Heo', 'Affiliation': 'Department of Biomedical Engineering, Center for Bio-Integrated Electronics, Simpson Querrey Institute for Bionanotechnology, Northwestern University, Evanston, IL, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Banks', 'Affiliation': 'Department of Biomedical Engineering, Center for Bio-Integrated Electronics, Simpson Querrey Institute for Bionanotechnology, Northwestern University, Evanston, IL, USA.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Rogers', 'Affiliation': 'Department of Biomedical Engineering, Center for Bio-Integrated Electronics, Simpson Querrey Institute for Bionanotechnology, Northwestern University, Evanston, IL, USA.'}]",Archives of dermatological research,['10.1007/s00403-020-02163-1'] 388,33200213,Pulmonary vein isolation alone vs. more extensive ablation with defragmentation and linear ablation of persistent atrial fibrillation: the EARNEST-PVI trial.,"AIMS Previous studies could not demonstrate any benefit of more intensive ablation in addition to pulmonary vein isolation (PVI) including complex fractionated atrial electrogram (CFAE) and linear ablation for recurrence in the initial catheter ablation of persistent atrial fibrillation (AF). This study aimed to establish the non-inferiority of PVI alone to PVI plus these additional ablation strategies. METHODS AND RESULTS Patients with persistent AF who underwent an initial catheter ablation (n = 512, long-standing persistent AF; 128 cases) were randomly assigned in a 1:1 ratio to either PVI alone (PVI-alone group) or PVI plus CFAE and/or linear ablation (PVI-plus group). After excluding 15 cases who did not receive procedures, we analysed 249 and 248 patients, respectively. The primary endpoint was recurrence of AF, atrial flutter, and/or atrial tachycardia, and the non-inferior margin was set at a hazard ratio of 1.43. In the PVI-plus group, 85.1% of patients had linear ablation and 15.3% CFAE ablation. After 12 months, freedom from the primary endpoint occurred in 71.3% of patients in the PVI-alone group and in 78.3% in the PVI-plus group [hazard ratio = 1.56 (95% confidence interval: 1.10-2.24), non-inferior P = 0.3062]. The procedure-related complication rates were 2.0% in the PVI-alone group and 3.6% in the PVI-plus group (P = 0.199). CONCLUSION This randomized trial did not establish the non-inferiority of PVI alone to PVI plus linear ablation or CFAE ablation in patients with persistent AF, but implied that the PVI plus strategy was promising to improve the clinical efficacy (NCT03514693).",2021,"This randomized trial did not establish the non-inferiority of PVI alone to PVI plus linear ablation or CFAE ablation in patients with persistent AF, but implied that the PVI plus strategy was promising to improve the clinical efficacy (NCT03514693).","['patients with persistent AF', 'persistent atrial fibrillation', 'Patients with persistent AF who underwent an initial catheter ablation (n\u2009=\u2009512, long-standing persistent AF; 128 cases']","['Pulmonary vein isolation alone vs. more extensive ablation with defragmentation and linear ablation', 'complex fractionated atrial electrogram (CFAE) and linear ablation', 'PVI alone to PVI plus linear ablation or CFAE ablation', 'PVI alone (PVI-alone group) or PVI plus CFAE and/or linear ablation (PVI-plus group']","['procedure-related complication rates', 'recurrence of AF, atrial flutter, and/or atrial tachycardia, and the non-inferior margin']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0868928', 'cui_str': 'Case'}]","[{'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0205231', 'cui_str': 'Extensive'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C2350882', 'cui_str': 'Atrial Electrogram'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0004239', 'cui_str': 'Atrial flutter'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}]",,0.0893291,"This randomized trial did not establish the non-inferiority of PVI alone to PVI plus linear ablation or CFAE ablation in patients with persistent AF, but implied that the PVI plus strategy was promising to improve the clinical efficacy (NCT03514693).","[{'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Inoue', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Shungo', 'Initials': 'S', 'LastName': 'Hikoso', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Masaharu', 'Initials': 'M', 'LastName': 'Masuda', 'Affiliation': 'Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Yoshio', 'Initials': 'Y', 'LastName': 'Furukawa', 'Affiliation': 'Cardiovascular Center, Kansai Rosai Hospital, Amagasaki, Japan.'}, {'ForeName': 'Akio', 'Initials': 'A', 'LastName': 'Hirata', 'Affiliation': 'Division of Cardiology, Osaka General Medical Center, Osaka, Japan.'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Egami', 'Affiliation': 'Cardiovascular Division, Osaka Police Hospital, Osaka, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Watanabe', 'Affiliation': 'Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Minamiguchi', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Miwa', 'Initials': 'M', 'LastName': 'Miyoshi', 'Affiliation': 'Department of Cardiovascular Medicine, Yao Municipal Hospital, Yao, Japan.'}, {'ForeName': 'Nobuaki', 'Initials': 'N', 'LastName': 'Tanaka', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Oka', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Okada', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kanda', 'Affiliation': 'Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Matsuda', 'Affiliation': 'Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Kawasaki', 'Affiliation': 'Cardiovascular Center, Kansai Rosai Hospital, Amagasaki, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Hayashi', 'Affiliation': 'Department of Cardiology, Osaka Hospital, Japan Community Healthcare Organization, Osaka, Japan.'}, {'ForeName': 'Tetsuhisa', 'Initials': 'T', 'LastName': 'Kitamura', 'Affiliation': 'Division of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Tomoharu', 'Initials': 'T', 'LastName': 'Dohi', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Sunaga', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Hiroya', 'Initials': 'H', 'LastName': 'Mizuno', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Daisaku', 'Initials': 'D', 'LastName': 'Nakatani', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Sakata', 'Affiliation': 'Cardiovascular Center, Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa293'] 389,33197559,Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.,"BACKGROUND Large clinical trials established the benefits of sodium-glucose cotransporter 2 inhibitors in patients with diabetes and with heart failure with reduced ejection fraction (HFrEF). The early and significant improvement in clinical outcomes is likely explained by effects beyond a reduction in hyperglycemia. OBJECTIVES The purpose of this study was to assess the effect of empagliflozin on left ventricular (LV) function and volumes, functional capacity, and quality of life (QoL) in nondiabetic HFrEF patients. METHODS In this double-blind, placebo-controlled trial, nondiabetic HFrEF patients (n = 84) were randomized to empagliflozin 10 mg daily or placebo for 6 months. The primary endpoint was change in LV end-diastolic and -systolic volume assessed by cardiac magnetic resonance. Secondary endpoints included changes in LV mass, LV ejection fraction, peak oxygen consumption in the cardiopulmonary exercise test, 6-min walk test, and quality of life. RESULTS Empagliflozin was associated with a significant reduction of LV end-diastolic volume (-25.1 ± 26.0 ml vs. -1.5 ± 25.4 ml for empagliflozin vs. placebo, respectively; p < 0.001) and LV end-systolic volume (-26.6 ± 20.5 ml vs. -0.5 ± 21.9 ml for empagliflozin vs. placebo; p < 0.001). Empagliflozin was associated with reductions in LV mass (-17.8 ± 31.9 g vs. 4.1 ± 13.4 g, for empagliflozin vs. placebo, respectively; p < 0.001) and LV sphericity, and improvements in LV ejection fraction (6.0 ± 4.2 vs. -0.1 ± 3.9; p < 0.001). Patients who received empagliflozin had significant improvements in peak O 2 consumption (1.1 ± 2.6 ml/min/kg vs. -0.5 ± 1.9 ml/min/kg for empagliflozin vs. placebo, respectively; p = 0.017), oxygen uptake efficiency slope (111 ± 267 vs. -145 ± 318; p < 0.001), as well as in 6-min walk test (81 ± 64 m vs. -35 ± 68 m; p < 0.001) and quality of life (Kansas City Cardiomyopathy Questionnaire-12: 21 ± 18 vs. 2 ± 15; p < 0.001). CONCLUSIONS Empagliflozin administration to nondiabetic HFrEF patients significantly improves LV volumes, LV mass, LV systolic function, functional capacity, and quality of life when compared with placebo. Our observations strongly support a role for sodium-glucose cotransporter 2 inhibitors in the treatment of HFrEF patients independently of their glycemic status. (Are the ""Cardiac Benefits"" of Empagliflozin Independent of Its Hypoglycemic Activity? [ATRU-4] [EMPA-TROPISM]; NCT03485222).",2021,"Patients who received empagliflozin had significant improvements in peak O2 consumption (1.1±2.6 vs -0.5±1.9mL/min/kg for empagliflozin vs placebo, respectively, p=0.017), oxygen uptake efficiency slope (111±267 vs -146±318, p<0.001), as well as in 6-minute walk test (81±64 vs -35±68 meters, p<0.001) and quality of life (KCCQ-12: 21±18 vs 2±15, p<0.001). ","['HFrEF patients independently of their diabetic status', 'Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction', 'non-diabetic HFrEF patients (n=84', 'patients with diabetes and with heart failure with reduced ejection fraction (HFrEF', 'non-diabetic HFrEF patients']","['empagliflozin', 'SGLT2 inhibitors', 'Empagliflozin', 'placebo', 'empagliflozin or placebo', 'empagliflozin vs placebo']","['changes in LV mass, LVEF, peak oxygen consumption in the cardiopulmonary exercise test, 6-minute walk test, and quality of life RESULTS', 'oxygen uptake efficiency slope', '6-minute walk test', 'LVEF', 'LV volumes, LV mass, LV systolic function, functional capacity, and quality of life', 'cardiac remodeling, reduced LV volumes, decreased LV mass, increased LV systolic function, enhanced functional capacity (both peak oxygen consumption and 6-minute walk test), and improved quality of life', 'LVESV', 'peak O2 consumption', 'change in left ventricle end-diastolic volume (LVEDV) and left ventricle end-systolic volume (LVESV) assessed by cardiac magnetic resonance', 'LVEDV', 'quality of life', 'LV function and volumes, functional capacity and quality of life (QoL', 'LV mass ']","[{'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C3273807', 'cui_str': 'SGLT2 Inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0455825', 'cui_str': 'Left ventricular mass'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0007799', 'cui_str': 'Brain ventricle structure'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0225897', 'cui_str': 'Left cardiac ventricular structure'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}]",84.0,0.535117,"Patients who received empagliflozin had significant improvements in peak O2 consumption (1.1±2.6 vs -0.5±1.9mL/min/kg for empagliflozin vs placebo, respectively, p=0.017), oxygen uptake efficiency slope (111±267 vs -146±318, p<0.001), as well as in 6-minute walk test (81±64 vs -35±68 meters, p<0.001) and quality of life (KCCQ-12: 21±18 vs 2±15, p<0.001). ","[{'ForeName': 'Carlos G', 'Initials': 'CG', 'LastName': 'Santos-Gallego', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Ariana P', 'Initials': 'AP', 'LastName': 'Vargas-Delgado', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Juan Antonio', 'Initials': 'JA', 'LastName': 'Requena-Ibanez', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Garcia-Ropero', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Mancini', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Pinney', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Macaluso', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Sartori', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Merce', 'Initials': 'M', 'LastName': 'Roque', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Sabatel-Perez', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Anderly', 'Initials': 'A', 'LastName': 'Rodriguez-Cordero', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'M Urooj', 'Initials': 'MU', 'LastName': 'Zafar', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Icilma', 'Initials': 'I', 'LastName': 'Fergus', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Atallah-Lajam', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Johanna P', 'Initials': 'JP', 'LastName': 'Contreras', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Cathleen', 'Initials': 'C', 'LastName': 'Varley', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Pedro R', 'Initials': 'PR', 'LastName': 'Moreno', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Vivian M', 'Initials': 'VM', 'LastName': 'Abascal', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Anuradha', 'Initials': 'A', 'LastName': 'Lala', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Tamler', 'Affiliation': 'Division of Endocrinology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Sanz', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Valentin', 'Initials': 'V', 'LastName': 'Fuster', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain.'}, {'ForeName': 'Juan J', 'Initials': 'JJ', 'LastName': 'Badimon', 'Affiliation': 'Cardiology Department, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA; AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: juan.badimon@mssm.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2020.11.008'] 390,33197560,Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.,"OBJECTIVES This study sought to evaluate the ability of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to reduce the risk of complex coronary atherosclerosis requiring revascularization. BACKGROUND PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall. METHODS FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) was a randomized trial of the PCSK9 inhibitor evolocumab versus placebo in 27,564 patients with stable atherosclerotic cardiovascular disease on statin therapy followed for a median of 2.2 years. Clinical documentation of revascularization events was blindly reviewed to assess coronary anatomy and procedural characteristics. Complex revascularization was the composite of complex percutaneous coronary intervention (PCI) (as per previous analyses, ≥1 of: multivessel PCI, ≥3 stents, ≥3 lesions treated, bifurcation PCI, or total stent length >60 mm) or coronary artery bypass grafting surgery (CABG). RESULTS In this study, 1,724 patients underwent coronary revascularization, including 1,482 who underwent PCI, 296 who underwent CABG, and 54 who underwent both. Complex revascularization was performed in 632 (37%) patients. Evolocumab reduced the risk of any coronary revascularization by 22% (hazard ratio [HR]: 0.78; 95% CI: 0.71 to 0.86; p < 0.001), simple PCI by 22% (HR: 0.78; 95% CI: 0.70 to 0.88; p < 0.001), complex PCI by 33% (HR: 0.67; 95% CI: 0.54 to 0.84; p < 0.001), CABG by 24% (HR: 0.76; 95% CI: 0.60 to 0.96; p = 0.019), and complex revascularization by 29% (HR: 0.71; 95% CI: 0.61 to 0.84; p < 0.001). The magnitude of the risk reduction with evolocumab in complex revascularization tended to increase over time (20%, 36%, and 41% risk reductions in the first, second, and beyond second years). CONCLUSIONS Adding evolocumab to statin therapy significantly reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER); NCT01764633.).",2021,"Evolocumab reduced the risk of any coronary revascularization by 22% (HR 0.78 [0.71-0.86]; P<0.001), simple PCI by 22% (HR 0.78, [0.70-0.88]; P<0.001), complex PCI by 33% (HR 0.67 [0.54-0.84]; P<0.001), CABG by 24% (HR 0.76 [0.60-0.96]; P=0.019), and complex revascularization by 29% (HR 0.71 [0.61-0.84]; P<0.001).","['27,564 patients with stable atherosclerosis on statin therapy followed for a median of 2.2 years', '1,724 patients underwent coronary revascularization, including 1482 who underwent PCI, 296 who underwent CABG, and 54 both']","['Evolocumab', 'coronary artery bypass grafting surgery (CABG', 'PCSK9 inhibitor evolocumab vs. placebo', 'PCSK9 inhibitors', 'complex percutaneous coronary intervention (PCI']","['Complex Coronary Disease Requiring Revascularization', 'simple PCI', 'Complex revascularization', 'risk of any coronary revascularization', 'risk of developing complex coronary disease requiring revascularization', 'complex PCI', 'complex revascularization']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}]","[{'cui': 'C3529352', 'cui_str': 'evolocumab'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C4522007', 'cui_str': 'PCSK9 inhibitor'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0010068', 'cui_str': 'Coronary Heart Disease'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}]",27564.0,0.0465221,"Evolocumab reduced the risk of any coronary revascularization by 22% (HR 0.78 [0.71-0.86]; P<0.001), simple PCI by 22% (HR 0.78, [0.70-0.88]; P<0.001), complex PCI by 33% (HR 0.67 [0.54-0.84]; P<0.001), CABG by 24% (HR 0.76 [0.60-0.96]; P=0.019), and complex revascularization by 29% (HR 0.71 [0.61-0.84]; P<0.001).","[{'ForeName': 'Kazuma', 'Initials': 'K', 'LastName': 'Oyama', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.""}, {'ForeName': 'Remo H M', 'Initials': 'RHM', 'LastName': 'Furtado', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Hospital Israelita Albert Einsteinand Instituto do Coraçao da Faculdade de Medicina da USP, Sao Paulo, Brazil.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Fagundes', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Zelniker', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiology, Vienna General Hospital and Medical University of Vienna, Vienna, Austria.""}, {'ForeName': 'Minao', 'Initials': 'M', 'LastName': 'Tang', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Kuder', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Sabina A', 'Initials': 'SA', 'LastName': 'Murphy', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Hamer', 'Affiliation': 'Amgen, Thousand Oaks, California, USA.'}, {'ForeName': 'Huei', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Amgen, Thousand Oaks, California, USA.'}, {'ForeName': 'Anthony C', 'Initials': 'AC', 'LastName': 'Keech', 'Affiliation': 'National Health and Medical Research Council Clinical Trials Centre, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Giugliano', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Sabatine', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Brian A', 'Initials': 'BA', 'LastName': 'Bergmark', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: bbergmark@bwh.harvard.edu.""}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2020.11.011'] 391,33213185,Analgesic and Opioid Use for Patients Discharged from the Emergency Department with Ureteral Stones.,"Objective: The aim of this study was to describe and characterize the analgesic and opioid use for patients discharged from the emergency department (ED) with renal colic due to ureteral stone. Methods: This is a secondary analysis of a multicenter prospective trial of ED patients diagnosed by CT scan as having a symptomatic ureteral stone <9 mm in diameter. Participants were contacted after randomization on days 2, 7, 15, 20, and 29 and reported opioid and nonopioid analgesic use and stone passage. CT scan was repeated on day 29 to 36 to confirm passage. Results: Of 403 participants, 314 (77.9%) took an analgesic after discharge and 199 (49.4%) took opioids. Opioids were more commonly used by younger patients ( p  = 0.04) and those with a family history of stones ( p  = 0.003). Stone size and tamsulosin use were not associated with analgesic utilization. Shorter time to passage and more distal stone location were associated with less analgesic and opioid use. For those who did not expel a stone, 55.0% took opioids at any time, and for those who did expel a stone, 31.9% took opioids before the stone was expelled and 15.7% took opioids at any time after the stone was expelled. Conclusions: Factors associated with increased use of analgesics in patients discharged from the ED include a longer time to stone passage, no spontaneous passage, and proximal position of the stone in the ureter. Some patients continued to use analgesics after the stone had passed, but most stopped using analgesics by day 29. The study has been registered at https://clinicaltrials.gov (NCT00382265).",2021,Opioids were more commonly used in younger patients (p=0.04) and in those with a family history of stones (p=0.003).,"['Out of 403 participants, 314 (77.9%) took any analgesic after discharge and 199 (49.4%) took opioids', 'patients discharged from the Emergency Department with ureteral stones', 'patients discharged from the emergency department with renal colic due to ureteral stone', 'emergency department patients diagnosed by computed tomography (CT) scan with a symptomatic ureteral stone < 9 mm in diameter']",['opioid and non-opioid analgesic use and stone passage'],"['Shorter time to passage and more distal stone location', 'CT scan']","[{'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0041952', 'cui_str': 'Ureteric stone'}, {'cui': 'C0152169', 'cui_str': 'Renal colic'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0242937', 'cui_str': 'Non-opioid analgesic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0439799', 'cui_str': 'Channel'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439799', 'cui_str': 'Channel'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}]",403.0,0.0532764,Opioids were more commonly used in younger patients (p=0.04) and in those with a family history of stones (p=0.003).,"[{'ForeName': 'Andrew C', 'Initials': 'AC', 'LastName': 'Meltzer', 'Affiliation': 'Department of Emergency Medicine, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USA.'}, {'ForeName': 'Allan B', 'Initials': 'AB', 'LastName': 'Wolfson', 'Affiliation': 'Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Mufarrij', 'Affiliation': 'Department of Urology, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USA.'}, {'ForeName': 'Cora', 'Initials': 'C', 'LastName': 'MacPherson', 'Affiliation': 'The George Washington University Biostatistics Center, Rockville, Maryland, USA.'}, {'ForeName': 'Nataly', 'Initials': 'N', 'LastName': 'Montano', 'Affiliation': 'Department of Emergency Medicine, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USA.'}, {'ForeName': 'Ziya', 'Initials': 'Z', 'LastName': 'Kirkali', 'Affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Pamela Katzen', 'Initials': 'PK', 'LastName': 'Burrows', 'Affiliation': 'The George Washington University Biostatistics Center, Rockville, Maryland, USA.'}, {'ForeName': 'Stephen V', 'Initials': 'SV', 'LastName': 'Jackman', 'Affiliation': 'Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.'}]",Journal of endourology,['10.1089/end.2020.0835'] 392,33229600,Three-dimensional versus two-dimensional ultrasound-guided embryo transfer: a randomised control study (abridged secondary publication).,,2020,,[],['dimensional ultrasound-guided embryo transfer'],[],[],"[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0013938', 'cui_str': 'Embryo transfer'}]",[],,0.0438967,,"[{'ForeName': 'T C', 'Initials': 'TC', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Saravelos', 'Affiliation': 'Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong.'}, {'ForeName': 'W S', 'Initials': 'WS', 'LastName': 'Kong', 'Affiliation': 'Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong.'}]",Hong Kong medical journal = Xianggang yi xue za zhi,[] 393,33229602,Bilateral movement computer games to improve motor function of upper limb and quality of life in patients with sub-acute stroke: a randomised controlled trial: abridged secondary publication.,,2020,,['patients with sub-acute stroke'],['Bilateral movement computer games'],['motor function of upper limb and quality of life'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0870328', 'cui_str': 'Computer Games'}]","[{'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0968075,,"[{'ForeName': 'S S L', 'Initials': 'SSL', 'LastName': 'Lam', 'Affiliation': 'Physiotherapy Department, Shatin Hospital.'}, {'ForeName': 'S S M', 'Initials': 'SSM', 'LastName': 'Ng', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University.'}, {'ForeName': 'C W K', 'Initials': 'CWK', 'LastName': 'Lai', 'Affiliation': 'Physiotherapy Department, Shatin Hospital.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Woo', 'Affiliation': 'Department of Medicine & Therapeutics, The Chinese University of Hong Kong.'}]",Hong Kong medical journal = Xianggang yi xue za zhi,[] 394,33229604,Rapid movement therapy to improve balance recovery in stroke survivors: a randomised controlled trial: abridged secondary publication.,,2020,,['stroke survivors'],['Rapid movement therapy'],[],"[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0454279', 'cui_str': 'Movement therapy'}]",[],,0.238117,,"[{'ForeName': 'R K Y', 'Initials': 'RKY', 'LastName': 'Tong', 'Affiliation': 'Department of Biomedical Engineering, Faculty of Engineering, The Chinese University of Hong Kong.'}, {'ForeName': 'K C C', 'Initials': 'KCC', 'LastName': 'Cheng', 'Affiliation': 'Department of Sports Science and Physical Education, Faculty of Education, The Chinese University of Hong Kong.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Junata', 'Affiliation': 'Department of Biomedical Engineering, Faculty of Engineering, The Chinese University of Hong Kong.'}, {'ForeName': 'H S', 'Initials': 'HS', 'LastName': 'Man', 'Affiliation': 'Department of Biomedical Engineering, Faculty of Engineering, The Chinese University of Hong Kong.'}]",Hong Kong medical journal = Xianggang yi xue za zhi,[] 395,33121228,Hemodynamic effects of norepinephrine versus phenylephrine infusion for prophylaxis against spinal anesthesia-induced hypotension in the elderly population undergoing hip fracture surgery: a randomized controlled trial.,"BACKGROUND Elderly population are at increased risk of spinal anesthesia-induced hypotension increasing their risk for postoperative morbidity and mortality. This study aimed to compare the hemodynamic effects of prophylactic infusion of norepinephrine (NE) versus phenylephrine (PE) in elderly patients undergoing hip fracture surgery under spinal anesthesia. METHODS Elderly patients scheduled for hip fracture surgery were randomized to receive either NE infusion (8 µg/min) (NE group, n = 31) or PE infusion (100 µg/min) (PE group, n = 31) after spinal anesthesia. Outcomes included mean heart rate, mean blood pressure, cardiac output, incidence of spinal anesthesia-induced hypotension, incidence of bradycardia, and incidence of hypertension. RESULTS Sixty-two patients with a mean age of 71 ± 6 years were included in the final analysis (31 patients in each group). The NE group showed a higher mean heart rate and cardiac output than the PE group. The NE group had a lower incidence of reactive bradycardia (10% vs. 36%, P = 0.031) and hypertension (3% vs. 36%, P = 0.003) than the PE group. No study participant developed hypotension, and the mean blood pressure was comparable between the two groups. CONCLUSIONS Both NE and PE infusions effectively prevented spinal anesthesia-induced hypotension in elderly patients undergoing hip fracture surgery. However, NE provided more hemodynamic stability than PE; maintaining the heart rate, higher cardiac output, less reactive bradycardia, and hypertension.",2021,"The NE group had a lower incidence of reactive bradycardia (10% vs. 36%, P=0.03) and hypertension (3% vs. 36%, P=0.003) than the PE group.","['Elderly patients scheduled for hip fracture surgery', 'elderly patients undergoing hip fracture surgery', 'elderly population undergoing hip fracture surgery']","['norepinephrine', 'phenylephrine (PE', 'norepinephrine (NE', 'NE', 'NE infusion (8 mcg/min) (NE group, n=31) or PE infusion', 'NE and PE', 'phenylephrine infusion']","['hypotension', 'mean blood pressure', 'spinal anesthesia-induced hypotension', 'mean heart rate and cardiac output', 'reactive bradycardia', 'heart rate, mean blood pressure, cardiac output, incidence of spinal anesthesia-induced hypotension, incidence of bradycardia, and incidence of hypertension', 'hemodynamic stability', 'Efficacy and safety', 'heart rate, higher cardiac output, less reactive bradycardia, and hypertension', 'hypertension']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0439424', 'cui_str': 'ug/min'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0085128', 'cui_str': 'Increased cardiac output'}]",62.0,0.103337,"The NE group had a lower incidence of reactive bradycardia (10% vs. 36%, P=0.03) and hypertension (3% vs. 36%, P=0.003) than the PE group.","[{'ForeName': 'Maha', 'Initials': 'M', 'LastName': 'Mostafa', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Hasanin', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Mostafa', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mai Y', 'Initials': 'MY', 'LastName': 'Taha', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Elsayad', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Fatma Alzahraa', 'Initials': 'FA', 'LastName': 'Haggag', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Taalab', 'Affiliation': 'Department of Orthopedic Surgery, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Rady', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Bassant', 'Initials': 'B', 'LastName': 'Abdelhamid', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Cairo University, Cairo, Egypt.'}]",Korean journal of anesthesiology,['10.4097/kja.20519'] 396,33130107,Effects of clinic-level implementation of One Key Question® on reproductive health counseling and patient satisfaction.,"OBJECTIVE We evaluated the effect of clinic level implementation of the One Key Question (OKQ) intervention, including physician and staff training and workflow adjustments, on reproductive counseling and patient satisfaction in primary care and ob/gyn. STUDY DESIGN We implemented the OKQ intervention in one primary care and one ob/gyn practice, while observing another primary care and ob/gyn practice that each provided usual care (control practices). We surveyed separate patient cohorts at two time points: 26 before and 33 after the primary care practice implemented OKQ, 38 before and 36 after the ob/gyn practice implemented OKQ, 26 and 37 at the primary care control practice, and 31 and 37 at the ob/gyn control practice. We used chi square tests to assess OKQ's effects on counseling rates and patient satisfaction, comparing intervention to control practices across time points. RESULTS In primary care, from before to after implementation, the intervention practice did not significantly increase reproductive counseling (69-76%, p = 0.58), but increased patient satisfaction (81-97%, p = 0.04) while the control practice demonstrated a decrease in patient satisfaction over the same time periods. In the ob/gyn clinics, no significant change in reproductive counseling or patient satisfaction was seen in the intervention practice, while the control practice demonstrated a decrease in patient satisfaction. CONCLUSIONS Implementing OKQ appears to increase patient satisfaction. Larger studies are needed to assess whether this clinic-level intervention may increase reproductive counseling. IMPLICATIONS Further studies of the impact of clinic-level implementation of OKQ are needed.",2021,"In the ob/gyn clinics, no significant change in reproductive counseling or patient satisfaction was seen in the intervention practice, while the control practice demonstrated a decrease in patient satisfaction. ","['surveyed separate patient cohorts at two time points: 26 before and 33 after the primary care practice implemented OKQ, 38 before and 36 after the ob/gyn practice implemented OKQ, 26 and 37 at the primary care control practice, and 31 and 37 at the ob/gyn control practice']","['OKQ intervention in one primary care and one ob/gyn practice, while observing another primary care and ob/gyn practice that each provided usual care (control practices']","['reproductive counseling or patient satisfaction', 'Reproductive Health Counseling and Patient Satisfaction', 'reproductive counseling', 'patient satisfaction']","[{'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0474170', 'cui_str': 'Reproductive education'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0242667', 'cui_str': 'Reproductive Health'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]",,0.0306413,"In the ob/gyn clinics, no significant change in reproductive counseling or patient satisfaction was seen in the intervention practice, while the control practice demonstrated a decrease in patient satisfaction. ","[{'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Song', 'Affiliation': 'Pritzker School of Medicine, University of Chicago, 924 E 57th St, Ste #104, Chicago, IL 60637, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'White VanGompel', 'Affiliation': 'Pritzker School of Medicine, University of Chicago, 924 E 57th St, Ste #104, Chicago, IL 60637, USA; Department of Family Medicine, University of Chicago, 5841 S Maryland Ave., MC 7110, Chicago, IL 60637, USA; NorthShore University HealthSystem (NSUHS) Research Institute, 1001 University Pl, Evanston, IL, 60201, USA.'}, {'ForeName': 'Chi', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'NorthShore University HealthSystem (NSUHS) Research Institute, 1001 University Pl, Evanston, IL, 60201, USA.'}, {'ForeName': 'Suzette', 'Initials': 'S', 'LastName': 'Guzman', 'Affiliation': 'Pritzker School of Medicine, University of Chicago, 924 E 57th St, Ste #104, Chicago, IL 60637, USA.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Carlock', 'Affiliation': 'NorthShore University HealthSystem (NSUHS) Research Institute, 1001 University Pl, Evanston, IL, 60201, USA.'}, {'ForeName': 'Kellie', 'Initials': 'K', 'LastName': 'Schueler', 'Affiliation': 'Pritzker School of Medicine, University of Chicago, 924 E 57th St, Ste #104, Chicago, IL 60637, USA.'}, {'ForeName': 'Debra B', 'Initials': 'DB', 'LastName': 'Stulberg', 'Affiliation': 'Pritzker School of Medicine, University of Chicago, 924 E 57th St, Ste #104, Chicago, IL 60637, USA; Department of Family Medicine, University of Chicago, 5841 S Maryland Ave., MC 7110, Chicago, IL 60637, USA. Electronic address: stulberg@uchicago.edu.'}]",Contraception,['10.1016/j.contraception.2020.10.018'] 397,33133403,Are Three Doses of Intravenous Tranexamic Acid more Effective than Single Dose in Reducing Blood Loss During Bilateral Total Knee Arthroplasty?,"Purpose Tranexamic acid (TXA) has shown to reduce perioperative blood loss after bilateral total knee arthroplasty (TKA). But dosage and schedule of administration are not clear in literature. This study was aimed to compare prospectively blood loss and transfusion requirement in bilateral TKA with 3-dose regimen versus a single intra-operative dose of intravenous TXA. Methods This prospective non-randomised controlled trial included 25 patients undergoing bilateral simultaneous TKA who received three doses of 1 g intravenous TXA (group 1). First dose was given prior to deflation of the tourniquet, followed by two more doses 6 h apart. The control group included 25 matched patients (group 2) receiving a single dose of 1 g intravenous TXA just prior to deflation of the tourniquet. Results Mean drop in haemoglobin was less in group 1 as compared to group 2, but this difference was not statistically significant (2.51 vs 2.93 g/dL, p  = 0.210). Similarly mean drop in haematocrit was more in group 2 as compared to group 1, though it was not statistically significant (9.34 vs. 9.18, p  = 0.868). The need for blood transfusions was more in group 2 compared to group 1, but this difference was not statistically significant ( p  = 0.601). Higher frequency of ecchymosis around the surgical site was noted in group 2 as compared to group 1, for which prophylactic low-molecular-weight heparin had to be stopped post-operatively, but this difference was not statistically significant ( p  = 0.065). Conclusion The study has failed to show any significant beneficial effect of three doses of TXA in TKA as compared to a single dose. Though a trend towards reduction in mean haemoglobin drop and decreased need for stopping LMWH in post-operative period was seen, the results were not statistically significant. Level of Evidence II, prospective non-randomised controlled trial.",2020,"Similarly mean drop in haematocrit was more in group 2 as compared to group 1, though it was not statistically significant (9.34 vs. 9.18, p  = 0.868).","['25 patients undergoing bilateral simultaneous TKA who received three doses of 1 g', 'after bilateral total knee arthroplasty (TKA']","['Tranexamic acid (TXA', 'intravenous TXA', 'Tranexamic Acid', 'TXA', 'TXA just prior to deflation of the tourniquet']","['haematocrit', 'perioperative blood loss', 'mean haemoglobin', 'Higher frequency of ecchymosis', 'Mean drop in haemoglobin', 'Blood Loss', 'need for blood transfusions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0040519', 'cui_str': 'Tourniquet'}]","[{'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0013491', 'cui_str': 'Ecchymosis'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}]",25.0,0.18832,"Similarly mean drop in haematocrit was more in group 2 as compared to group 1, though it was not statistically significant (9.34 vs. 9.18, p  = 0.868).","[{'ForeName': 'Tarun', 'Initials': 'T', 'LastName': 'Goyal', 'Affiliation': 'Department of Orthopaedics, All India Institute of Medical Sciences, Bathinda, Punjab 151001 India.'}, {'ForeName': 'Arghya Kundu', 'Initials': 'AK', 'LastName': 'Choudhury', 'Affiliation': 'Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh, India.'}, {'ForeName': 'Tushar', 'Initials': 'T', 'LastName': 'Gupta', 'Affiliation': 'Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh, India.'}]",Indian journal of orthopaedics,['10.1007/s43465-020-00231-2'] 398,33135319,Analgesic effect of music during wound care among patients with diaphyseal tibial fractures: Randomized controlled trial.,"BACKGROUND Evidence is scarce regarding the analgesic effect of music for the relief of acute pain during the care of surgical tibial fracture wounds. OBJECTIVE To evaluate the analgesic effect of music on acute procedural pain during the care of surgical tibial fracture wounds. METHOD This was a randomized, controlled, blinded clinical trial with 70 patients in the immediate postoperative period for diaphyseal tibial fracture surgery. Participants were randomly allocated to two groups: a control group (CG), in which patients received only the institution's standard analgesia, and an intervention group (IG) composed of patients receiving a 30-min session of music of their own choice, as a complementary method to the institution's standard analgesia. Pain was evaluated during the first postoperative dressing change, using the Numerical Rating Scale (NRS). RESULTS The sample was homogeneously composed of men (91.4%), young adults (61.4%), without previous diseases (88.6%) and whose traumas were related to a motorcycle crash (84.3%). The main musical genres chosen by participants were the most popular in their region (61.4%). Those who listened to music presented lower pain scores when compared with those in the CG (IG:2.4 ± 2.4 versus CG:5.8 ± 2.7; p < 0.001; η 2  = 0.171; p < 0.001). CONCLUSION Listening to music is effective for relieving acute procedural pain during the first post-operative tibial fracture dressing change. Music should be incorporated into the multimodal analgesia protocols for management of orthopedic postoperative wound care-related pain. SIGNIFICANCE Patients with diaphyseal tibial fractures that listened to music before and during the wound dressing change showed less pain when compared to those who received the standardized pharmacologic analgesia alone.",2021,"Those who listened to music presented lower pain scores when compared to those in the CG (IG:2.4±2.4 vs. CG:5.8±2.7; p<0.001; ƞ 2 =0.171; p<0.001). ","['surgical tibial fracture wounds', '70 patients in the immediate postoperative period for diaphyseal tibial fracture surgery', 'patients with diaphyseal tibial fractures']","[""control group (CG), in which patients received only the institution's standard analgesia, and an intervention group (IG) composed of patients receiving a 30 minute session of music of their own choice, as a complementary method to the institution's standard analgesia""]","['Analgesic effect', 'Numerical Rating Scale (NRS', 'Pain', 'pain scores']","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0040185', 'cui_str': 'Fracture of tibia'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",70.0,0.124838,"Those who listened to music presented lower pain scores when compared to those in the CG (IG:2.4±2.4 vs. CG:5.8±2.7; p<0.001; ƞ 2 =0.171; p<0.001). ","[{'ForeName': 'Maria Cristina Leite', 'Initials': 'MCL', 'LastName': 'Ferraz', 'Affiliation': 'Graduate Program of Nursing, Federal University of Sergipe, São Cristóvão, Brazil.'}, {'ForeName': 'Eduesley', 'Initials': 'E', 'LastName': 'Santana-Santos', 'Affiliation': 'Graduate Program of Nursing, Federal University of Sergipe, São Cristóvão, Brazil.'}, {'ForeName': 'Jonas Santana', 'Initials': 'JS', 'LastName': 'Pinto', 'Affiliation': 'Health Science Graduate Program, Federal University of Sergipe, Aracaju, Brazil.'}, {'ForeName': 'Caíque Jordan', 'Initials': 'CJ', 'LastName': 'Nunes Ribeiro', 'Affiliation': 'Graduate Program of Nursing, Federal University of Sergipe, São Cristóvão, Brazil.'}, {'ForeName': 'Joyce Francielle Nei Bomfim', 'Initials': 'JFNB', 'LastName': 'Santana', 'Affiliation': 'Teaching Hospital, Federal University of Sergipe, Aracaju, Brazil.'}, {'ForeName': 'José Antonio Barreto', 'Initials': 'JAB', 'LastName': 'Alves', 'Affiliation': 'Department of Nursing, Federal University of Sergipe, Aracaju, Brazil.'}, {'ForeName': 'Maria do Carmo de Oliveira', 'Initials': 'MDCO', 'LastName': 'Ribeiro', 'Affiliation': 'Graduate Program of Nursing, Federal University of Sergipe, São Cristóvão, Brazil.'}]","European journal of pain (London, England)",['10.1002/ejp.1692'] 399,33136253,A randomised trial of pharmacist-led discharge prescribing in an Australian geriatric evaluation and management service.,"Background Prescribing discharge medications is a potential ""next step"" for pharmacists in Australian hospitals, however, safety must be demonstrated via a randomised controlled study. Objective To determine if a collaborative, pharmacist led discharge prescribing model results in less patients with medication errors than conventional prescribing for both handwritten and digital prescriptions. Setting Geriatric Medical ward in a quaternary hospital, Australia Methods A prospective, single-blinded randomised controlled study of patients randomised to conventional (control) or a pharmacist-led prescribing (intervention) arms at discharge from hospital. This study had 2 phases; (1) handwritten prescribing and (2) digital prescribing. In addition, the two prescribing methods were compared. Main outcome measures The primary outcome was the percentage of patients with a medication error on their discharge prescription. Results In phase 1, 45 patients were recruited; 21 (control) and 24 (intervention). 95% of control patients and 29% in the intervention arm had at least one medication error, p < 0.0002, relative risk (RR) 0.31, confidence interval (CI) 0.16-0.58. The number of items with at least 1 error reduced from 69 to 4%; p < 0.0001, RR 0.06, CI 0.03-0.11 and fewer items had at least 1 clinically significant error (11% vs 2%, p = 0.0004, RR 0.15, CI 0.04-0.30). In phase 2, 39 patients were recruited; 18 (control) and 21 (intervention). 100% of control patients and 62% in the intervention arm had at least one medication error (p = 0.005, RR 0.62, CI 0.44-0.87). Items with at least 1 error decreased from 21 to 7% (p < 0.0001, RR 0.34, CI 0.44-0.56), there were fewer items with at least 1 clinically significant error (13% vs 5%, p < 0.003, RR 0.4, CI 0.22-0.72). There was no significant change in the primary outcome between handwritten and digital (60% vs 79%, p < 0.055). Conclusion In a geriatric setting, pharmacist-led partnered discharge prescribing results in significantly less patients with medication errors than the conventional method for both handwritten and digital methods.",2021,"The number of items with at least 1 error reduced from 69 to 4%; p < 0.0001, RR 0.06, CI 0.03-0.11 and fewer items had at least 1 clinically significant error (11% vs 2%, p = 0.0004, RR 0.15, CI 0.04-0.30).","['45 patients were recruited; 21 (control) and 24 (intervention', '39 patients were recruited; 18 (control) and 21 (intervention', 'Australian geriatric evaluation and management service', 'less patients with medication errors than conventional prescribing for both handwritten and digital prescriptions']","['pharmacist-led discharge prescribing', 'conventional (control) or a pharmacist-led prescribing (intervention']","['percentage of patients with a medication error on their discharge prescription', 'medication error']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0025115', 'cui_str': 'Medication error'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}]","[{'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025115', 'cui_str': 'Medication error'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}]",,0.284538,"The number of items with at least 1 error reduced from 69 to 4%; p < 0.0001, RR 0.06, CI 0.03-0.11 and fewer items had at least 1 clinically significant error (11% vs 2%, p = 0.0004, RR 0.15, CI 0.04-0.30).","[{'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Finn', 'Affiliation': 'Royal Brisbane and Womens Hospital, Brisbane, Australia. shannon.finn@health.qld.gov.au.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': ""D'arcy"", 'Affiliation': ', Brisbane, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Donovan', 'Affiliation': 'Royal Brisbane and Womens Hospital, Brisbane, Australia.'}, {'ForeName': 'Shanthi', 'Initials': 'S', 'LastName': 'Kanagarajah', 'Affiliation': 'Royal Brisbane and Womens Hospital, Brisbane, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Barras', 'Affiliation': 'Princess Alexandra Hospital, Brisbane, Australia.'}]",International journal of clinical pharmacy,['10.1007/s11096-020-01184-0'] 400,33140199,"Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial.","BACKGROUND Adrenomedullin (AM) is a bioactive peptide having many pleiotropic effects, including mucosal healing and immunomodulation. AM has shown beneficial effects in rodent models and in preliminary study for patients with ulcerative colitis (UC). We performed a clinical trial to investigate the efficacy and safety of AM in patients with UC. METHODS This was a multi-center, double-blind, placebo-controlled phase-2a trial evaluating 28 patients in Japan with steroid-resistant UC. Patients were randomly assigned to four groups and given an infusion of 5, 10, 15 ng/kg/min of AM or placebo for 8 h per day for 14 days. The primary endpoint was the change in Mayo scores at 2 weeks. Main secondary endpoints included the change in Mayo scores and the rate of clinical remission at 8 weeks, defined as a Mayo score 0. RESULTS No differences in the primary or secondary endpoints were observed among the four groups at 2 weeks. Despite the insufficient tracking rate, the Mayo score at 8 weeks was only significantly decreased in the high-dose AM group (15 ng/kg/min) compared with the placebo group (- 9.3 ± 1.2 vs. - 3.0 ± 2.8, P = 0.035), with its rate of clinical remission at 8 weeks being significantly higher (3/3, 100% vs. 0/2, 0%, P = 0.025). We noted mild but no serious adverse events caused by the vasodilatory effect of AM. CONCLUSIONS In this double-blind randomized trial, we observed the complete remission at 8 weeks in patients with steroid-resistant UC receiving a high dose of AM. CLINICAL TRIAL REGISTRY JAPIC clinical trials information; Japic CTI-205255 (200410115290). https://www.clinicaltrials.jp/cti-user/trial/Search.jsp .",2021,"Despite the insufficient tracking rate, the Mayo score at 8 weeks was only significantly decreased in the high-dose AM group (15 ng/kg/min) compared with the placebo group (- 9.3 ± 1.2 vs. - 3.0 ± 2.8, P = 0.035), with its rate of clinical remission at 8 weeks being significantly higher (3/3, 100% vs. 0/2, 0%, P = 0.025).","['steroid-resistant ulcerative colitis', 'patients with ulcerative colitis (UC', 'patients with UC', '28 patients in Japan with steroid-resistant UC', 'patients with steroid-resistant UC receiving a high dose of AM']","['AM or placebo', 'placebo', 'AM']","['change in Mayo scores', 'efficacy and safety', 'change in Mayo scores and the rate of clinical remission at 8\xa0weeks, defined as a Mayo score 0', 'Mayo score', 'rate of clinical remission']","[{'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0215825', 'cui_str': 'ADM(1-52)'}]","[{'cui': 'C0215825', 'cui_str': 'ADM(1-52)'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C3539106', 'cui_str': 'Defined'}]",,0.734339,"Despite the insufficient tracking rate, the Mayo score at 8 weeks was only significantly decreased in the high-dose AM group (15 ng/kg/min) compared with the placebo group (- 9.3 ± 1.2 vs. - 3.0 ± 2.8, P = 0.035), with its rate of clinical remission at 8 weeks being significantly higher (3/3, 100% vs. 0/2, 0%, P = 0.025).","[{'ForeName': 'Toshihiro', 'Initials': 'T', 'LastName': 'Kita', 'Affiliation': 'Division of Circulatory and Body Fluid Regulation, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Miyazaki, Miyazaki, 889-1692, Japan. toshihiro_kita@med.miyazaki-u.ac.jp.'}, {'ForeName': 'Sinya', 'Initials': 'S', 'LastName': 'Ashizuka', 'Affiliation': 'Division of Circulatory and Body Fluid Regulation, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Miyazaki, Miyazaki, 889-1692, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Ohmiya', 'Affiliation': 'Department of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yamamoto', 'Affiliation': 'IBD Center, Yokkaichi Hazu Medical Center, Yokkaichi, Japan.'}, {'ForeName': 'Takanori', 'Initials': 'T', 'LastName': 'Kanai', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Motoya', 'Affiliation': 'IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan.'}, {'ForeName': 'Fumihito', 'Initials': 'F', 'LastName': 'Hirai', 'Affiliation': 'Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nakase', 'Affiliation': 'Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.'}, {'ForeName': 'Tomohiko', 'Initials': 'T', 'LastName': 'Moriyama', 'Affiliation': 'Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Masanao', 'Initials': 'M', 'LastName': 'Nakamura', 'Affiliation': 'Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Suzuki', 'Affiliation': 'Department of Gastroenterology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan.'}, {'ForeName': 'Shuji', 'Initials': 'S', 'LastName': 'Kanmura', 'Affiliation': 'Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.'}, {'ForeName': 'Taku', 'Initials': 'T', 'LastName': 'Kobayashi', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Hidehisa', 'Initials': 'H', 'LastName': 'Ohi', 'Affiliation': 'Department of Gastroenterology, Idzuro Imamura Hospital, Kagoshima, Japan.'}, {'ForeName': 'Ryoichi', 'Initials': 'R', 'LastName': 'Nozaki', 'Affiliation': 'Coloproctology Center Takano Hospital, Kumamoto, Japan.'}, {'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Mitsuyama', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.'}, {'ForeName': 'Shojiro', 'Initials': 'S', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.'}, {'ForeName': 'Haruhiko', 'Initials': 'H', 'LastName': 'Inatsu', 'Affiliation': 'Division of Circulatory and Body Fluid Regulation, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Miyazaki, Miyazaki, 889-1692, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Division of Circulatory and Body Fluid Regulation, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Miyazaki, Miyazaki, 889-1692, Japan.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Hibi', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Kitamura', 'Affiliation': 'Division of Circulatory and Body Fluid Regulation, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Miyazaki, Miyazaki, 889-1692, Japan.'}]",Journal of gastroenterology,['10.1007/s00535-020-01741-4'] 401,33145695,Delayed Visits for Contraception Due to Concerns Regarding Pelvic Examination Among Women with History of Intimate Partner Violence.,"BACKGROUND Concern regarding pelvic examinations may be more common among women experiencing intimate partner violence. OBJECTIVE We examined women's attitudes towards pelvic examination with history of intimate partner violence (pressured to have sex, or verbal, or physical abuse). DESIGN Secondary analysis of data from a cluster randomized trial on contraceptive access. PARTICIPANTS Women aged 18-25 were recruited at 40 reproductive health centers across the USA (2011-2013). MAIN MEASURES Delays in clinic visits for contraception and preference to avoid pelvic examinations, by history of ever experiencing pressured sex, verbal, or physical abuse from a sexual partner, reported by frequency (never, rarely, sometimes, often). We used multivariable logistic regression with generalized estimating equations for clustered data. KEY RESULTS A total of 1490 women were included. Ever experiencing pressured sex was reported by 32.4% of participants, with 16.5% reporting it rarely, 12.1% reporting it sometimes, and 3.8% reporting it often. Ever experiencing verbal abuse was reported by 19.4% and physical abuse by 10.2% of participants. Overall, 13.2% of participants reported ever having delayed going to the clinic for contraception to avoid having a pelvic examination, and 38.2% reported a preference to avoid pelvic examinations. In multivariable analysis, women reporting that they experienced pressured sex often had significantly higher odds of delaying a clinic visit for birth control (aOR 3.10 95% CI 1.39-6.84) and for reporting a preference to avoid pelvic examinations (aOR 2.91 95% CI 1.57-5.40). We found no associations between delay of clinic visits or preferences to avoid a pelvic examination and verbal or physical abuse. CONCLUSIONS History of pressured sex from an intimate partner is common. Among women who have experienced pressured sex, concern regarding pelvic examinations is a potential barrier to contraception. Communicating that routine pelvic examinations are no longer recommended by professional societies could potentially reduce barriers and increase preventive healthcare visits.",2021,"In multivariable analysis, women reporting that they experienced pressured sex often had significantly higher odds of delaying a clinic visit for birth control (aOR 3.10 95% CI 1.39-6.84) and for reporting a preference to avoid pelvic examinations (aOR 2.91 95% CI 1.57-5.40).","['A total of 1490 women were included', ""women's attitudes towards pelvic examination with history of intimate partner violence (pressured to have sex, or verbal, or physical abuse"", 'Women with History of Intimate Partner Violence', 'women experiencing intimate partner violence', 'Women aged 18-25 were recruited at 40 reproductive health centers across the USA (2011-2013']",[],"['Delays in clinic visits for contraception and preference to avoid pelvic examinations, by history of ever experiencing pressured sex, verbal, or physical abuse from a sexual partner, reported by frequency (never, rarely, sometimes, often', 'delaying a clinic visit for birth control']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0200045', 'cui_str': 'Manual pelvic examination'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C1621955', 'cui_str': 'Physical abuse'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0450335', 'cui_str': '18/25'}, {'cui': 'C0242667', 'cui_str': 'Reproductive Health'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]",[],"[{'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0700589', 'cui_str': 'Contraception'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0200045', 'cui_str': 'Manual pelvic examination'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C1621955', 'cui_str': 'Physical abuse'}, {'cui': 'C0036911', 'cui_str': 'Sexual partners'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0522498', 'cui_str': 'Rare'}]",1490.0,0.0624949,"In multivariable analysis, women reporting that they experienced pressured sex often had significantly higher odds of delaying a clinic visit for birth control (aOR 3.10 95% CI 1.39-6.84) and for reporting a preference to avoid pelvic examinations (aOR 2.91 95% CI 1.57-5.40).","[{'ForeName': 'Hunter K', 'Initials': 'HK', 'LastName': 'Holt', 'Affiliation': 'Department of Family and Community Medicine, University of California, San Francisco, CA, USA. Hunter.Holt@ucsf.edu.'}, {'ForeName': 'George F', 'Initials': 'GF', 'LastName': 'Sawaya', 'Affiliation': 'Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'El Ayadi', 'Affiliation': 'Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Jillian T', 'Initials': 'JT', 'LastName': 'Henderson', 'Affiliation': 'Kaiser Permanente Center for Health Research, Northwest, Portland, Oregon, USA.'}, {'ForeName': 'Corinne H', 'Initials': 'CH', 'LastName': 'Rocca', 'Affiliation': 'Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Carolyn L', 'Initials': 'CL', 'LastName': 'Westhoff', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Cynthia C', 'Initials': 'CC', 'LastName': 'Harper', 'Affiliation': 'Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, CA, USA.'}]",Journal of general internal medicine,['10.1007/s11606-020-06334-8'] 402,33158633,"The effectiveness of traditional corticotomy vs flapless corticotomy in miniscrew-supported en-masse retraction of maxillary anterior teeth in patients with Class II Division 1 malocclusion: A single-centered, randomized controlled clinical trial.","INTRODUCTION This single-centered, parallel-groups trial aimed to evaluate the efficacy of traditional corticotomy vs flapless corticotomy in accelerating en-masse retraction. In addition, to assess the skeletal, dental, and soft-tissue variables, as well as the external apical root resorption (EARR) of the maxillary anterior teeth. METHODS Forty patients with Class II Division 1 malocclusion aged >18 years at the beginning of treatment, requiring maxillary first premolar extractions, were randomly distributed into 2 groups (n = 20 each): 1 group was treated using traditional corticotomy, and the other group was treated with flapless corticotomy in en-masse retraction with anchorage based on miniscrews placed between maxillary second premolars and first molars bilaterally. Randomization was implemented with a computer-generated list of random numbers; allocation was concealed in sequentially numbered, opaque, sealed envelopes. The study was single-blinded (outcomes' assessor). The primary outcome was the en-masse retraction duration. Secondary outcomes were the skeletal, dental, and soft-tissue changes on lateral cephalometric and the EARR of maxillary anterior teeth on digital panoramic radiographs. RESULTS The en-masse retraction duration in the flapless corticotomy group was longer than the traditional corticotomy group. The average retraction duration was 4.04 ± 1.10 months for the flapless corticotomy group and 3.75 ± 2.14 months for the traditional corticotomy group, with no significant difference between the 2 groups (95% confidence interval [CI], -0.81 to 1.39; P = 0.59). No significant differences were observed between the 2 groups regarding changes in several lateral cephalometric variables (eg, SNA angle [95% CI, -2.55° to 1.66°; P = 0.67], SN-U1 angle [95% CI, -1.70° to 1.32°; P = 0.80], and UL-E [95% CI: -1.33 to 1.00 mm; P = 0.78]) or in the amount of EARR in the maxillary anterior teeth (P = 0.31). The proportion of the observed EARR ranged from 1% to 6% of root length in both corticotomy groups. No serious harms were observed in both groups. CONCLUSIONS No significant differences between the flapless and traditional corticotomies were found in terms of the skeletal, dental, and soft-tissue variables as well as in the amount of EARR. Corticotomy-assisted en-masse retraction led to improvements in skeletal structures and facial profile and resulted in sufficient retraction of maxillary anterior teeth, slight distal movement of maxillary first molars, and an intrusion movement for both anterior and posterior teeth. Both corticotomy techniques did not cause significant EARR. REGISTRATION ClinicalTrials.gov (Identifier: NCT03279042). PROTOCOL The protocol was not published before the trial commencement.",2020,"No significant differences were observed between the 2 groups regarding changes in several lateral cephalometric variables (eg, SNA angle [95% CI, -2.55° to 1.66°; P = 0.67], SN-U1 angle [95% CI, -1.70° to 1.32°; P = 0.80], and UL-E [95% CI: -1.33 to 1.00 mm; P = 0.78]) or in the amount of EARR in the maxillary anterior teeth (P = 0.31).","['18\xa0years at the beginning of treatment, requiring maxillary first premolar extractions', 'patients with Class II Division 1 malocclusion', 'Forty patients with Class II Division 1 malocclusion aged']","['traditional corticotomy vs flapless corticotomy', 'traditional corticotomy, and the other group was treated with flapless corticotomy in en-masse retraction with anchorage based on miniscrews placed between maxillary second premolars and first molars bilaterally', 'Corticotomy-assisted en-masse retraction']","['external apical root resorption (EARR) of the maxillary anterior teeth', 'average retraction duration', 'skeletal, dental, and soft-tissue variables', 'flapless and traditional corticotomies', 'skeletal structures and facial profile', 'en-masse retraction duration', 'skeletal, dental, and soft-tissue changes on lateral cephalometric and the EARR of maxillary anterior teeth on digital panoramic radiographs', 'several lateral cephalometric variables']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0399524', 'cui_str': 'Malocclusion, Angle class II, division 1'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332523', 'cui_str': 'Retraction'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0227056', 'cui_str': 'Structure of mandibular left first molar tooth'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C1290638', 'cui_str': 'Resorption of apex of tooth root'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0332523', 'cui_str': 'Retraction'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0424476', 'cui_str': 'Facial profile'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0034579', 'cui_str': 'Orthopantogram'}]",40.0,0.0473728,"No significant differences were observed between the 2 groups regarding changes in several lateral cephalometric variables (eg, SNA angle [95% CI, -2.55° to 1.66°; P = 0.67], SN-U1 angle [95% CI, -1.70° to 1.32°; P = 0.80], and UL-E [95% CI: -1.33 to 1.00 mm; P = 0.78]) or in the amount of EARR in the maxillary anterior teeth (P = 0.31).","[{'ForeName': 'Hanin Nizar', 'Initials': 'HN', 'LastName': 'Khlef', 'Affiliation': 'Department of Orthodontics, University of Damascus Dental School, Damascus University, Damascus, Syria.'}, {'ForeName': 'Mohammad Younis', 'Initials': 'MY', 'LastName': 'Hajeer', 'Affiliation': 'Department of Orthodontics, University of Damascus Dental School, Damascus University, Damascus, Syria. Electronic address: myhajeer@gmail.com.'}, {'ForeName': 'Mowaffak A', 'Initials': 'MA', 'LastName': 'Ajaj', 'Affiliation': 'Department of Orthodontics, University of Damascus Dental School, Damascus University, Damascus, Syria.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Heshmeh', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University of Damascus Dental School, Damascus University, Damascus, Syria.'}, {'ForeName': 'Nisreen', 'Initials': 'N', 'LastName': 'Youssef', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University of Damascus Dental School, Damascus University, Damascus, Syria.'}, {'ForeName': 'Luai', 'Initials': 'L', 'LastName': 'Mahaini', 'Affiliation': 'Department of Orthodontics, University of Damascus Dental School, Damascus University, Damascus, Syria.'}]","American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics",['10.1016/j.ajodo.2020.08.008'] 403,33160719,"Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.","STUDY OBJECTIVE Little is known about the cause or optimal treatment of hyperemesis in habitual cannabis users. Anecdotal evidence supports the use of haloperidol over traditional antiemetics for this newly recognized disorder. We compare haloperidol with ondansetron for cannabis hyperemesis syndrome. METHODS We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0.05 or 0.1 mg/kg) or ondansetron 8 mg intravenously in a triple-blind fashion. The primary outcome was the reduction from baseline in abdominal pain and nausea (each measured on a 10-cm visual analog scale) at 2 hours after treatment. Although the trial allowed for crossover, the primary analysis used only the first treatment period because few subjects crossed over. RESULTS We enrolled 33 subjects, of whom 30 (16 men, aged 29 years [SD 11 years] using 1.5 g/day [SD 0.9 g/day] since age 19 years [SD 2 years]) received at least 1 treatment (haloperidol 13, ondansetron 17). Haloperidol at either dose was superior to ondansetron (difference 2.3 cm [95% confidence interval 0.6 to 4.0 cm]; P=.01), with similar improvements in both pain and nausea, as well as less use of rescue antiemetics (31% versus 59%; difference -28% [95% confidence interval -61% to 13%]) and shorter time to emergency department (ED) departure (3.1 hours [SD 1.7] versus 5.6 hours [SD 4.5]; difference 2.5 hours [95% confidence interval 0.1 to 5.0 hours]; P=.03). There were 2 return visits for acute dystonia, both in the higher-dose haloperidol group. CONCLUSION In this clinical trial, haloperidol was superior to ondansetron for the acute treatment of cannabis-associated hyperemesis. The efficacy of haloperidol over ondansetron provides insight into the pathophysiology of this now common diagnosis in many EDs.",2021,"Haloperidol at either dose was superior to ondansetron (difference 2.3 cm [95% confidence interval 0.6 to 4.0 cm]; P=.01), with similar improvements in both pain and nausea, as well as less use of rescue antiemetics (31% versus 59%; difference -28% [95% confidence interval -61% to 13%]) and shorter time to emergency department (ED) departure (3.1 hours [SD 1.7] versus 5.6 hours [SD 4.5]; difference 2.5 hours [95% confidence interval 0.1 to 5.0 hours];","['Cannabis Hyperemesis Syndrome (HaVOC', 'We enrolled 33 subjects, of whom 30 (16 men, aged 29 years [SD 11 years] using 1.5 g/day [SD 0.9 g/day] since age 19 years [SD 2 years]) received at', 'habitual cannabis users']","['haloperidol', 'Haloperidol', 'haloperidol with ondansetron', 'Intravenous Haloperidol Versus Ondansetron', 'ondansetron', 'least 1 treatment (haloperidol 13, ondansetron']","['reduction from baseline in abdominal pain and nausea (each measured on a 10-cm visual analog scale', 'shorter time to emergency department (ED) departure', 'pain and nausea', 'rescue antiemetics']","[{'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0020450', 'cui_str': 'Hyperemesis gravidarum'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0019737', 'cui_str': 'HLA-B antigen'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}]","[{'cui': 'C0018546', 'cui_str': 'Haloperidol'}, {'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic agent'}]",33.0,0.420081,"Haloperidol at either dose was superior to ondansetron (difference 2.3 cm [95% confidence interval 0.6 to 4.0 cm]; P=.01), with similar improvements in both pain and nausea, as well as less use of rescue antiemetics (31% versus 59%; difference -28% [95% confidence interval -61% to 13%]) and shorter time to emergency department (ED) departure (3.1 hours [SD 1.7] versus 5.6 hours [SD 4.5]; difference 2.5 hours [95% confidence interval 0.1 to 5.0 hours];","[{'ForeName': 'Aaron J', 'Initials': 'AJ', 'LastName': 'Ruberto', 'Affiliation': ""Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada.""}, {'ForeName': 'Marco L A', 'Initials': 'MLA', 'LastName': 'Sivilotti', 'Affiliation': ""Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada. Electronic address: marco.sivilotti@queensu.ca.""}, {'ForeName': 'Savannah', 'Initials': 'S', 'LastName': 'Forrester', 'Affiliation': ""Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada.""}, {'ForeName': 'Andrew K', 'Initials': 'AK', 'LastName': 'Hall', 'Affiliation': ""Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada.""}, {'ForeName': 'Frances M', 'Initials': 'FM', 'LastName': 'Crawford', 'Affiliation': ""Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada.""}, {'ForeName': 'Andrew G', 'Initials': 'AG', 'LastName': 'Day', 'Affiliation': ""Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada.""}]",Annals of emergency medicine,['10.1016/j.annemergmed.2020.08.021'] 404,33169409,Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.,"BACKGROUND AND AIMS Advanced fibrosis attributable to NASH is a leading cause of end-stage liver disease. APPROACH AND RESULTS In this phase 2b trial, 392 patients with bridging fibrosis or compensated cirrhosis (F3-F4) were randomized to receive placebo, selonsertib 18 mg, cilofexor 30 mg, or firsocostat 20 mg, alone or in two-drug combinations, once-daily for 48 weeks. The primary endpoint was a ≥1-stage improvement in fibrosis without worsening of NASH between baseline and 48 weeks based on central pathologist review. Exploratory endpoints included changes in NAFLD Activity Score (NAS), liver histology assessed using a machine learning (ML) approach, liver biochemistry, and noninvasive markers. The majority had cirrhosis (56%) and NAS ≥5 (83%). The primary endpoint was achieved in 11% of placebo-treated patients versus cilofexor/firsocostat (21%; P = 0.17), cilofexor/selonsertib (19%; P = 0.26), firsocostat/selonsertib (15%; P = 0.62), firsocostat (12%; P = 0.94), and cilofexor (12%; P = 0.96). Changes in hepatic collagen by morphometry were not significant, but cilofexor/firsocostat led to a significant decrease in ML NASH CRN fibrosis score (P = 0.040) and a shift in biopsy area from F3-F4 to ≤F2 fibrosis patterns. Compared to placebo, significantly higher proportions of cilofexor/firsocostat patients had a ≥2-point NAS reduction; reductions in steatosis, lobular inflammation, and ballooning; and significant improvements in alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, bile acids, cytokeratin-18, insulin, estimated glomerular filtration rate, ELF score, and liver stiffness by transient elastography (all P ≤ 0.05). Pruritus occurred in 20%-29% of cilofexor versus 15% of placebo-treated patients. CONCLUSIONS In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, led to improvements in NASH activity, and may have an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.",2021,"Changes in hepatic collagen by morphometry were not significant, but CILO/FIR led to a significant decrease in ML NASH CRN fibrosis score (p=0.040) and a shift in biopsy area from F3-F4 to ≤F2 fibrosis patterns.","['patients with advanced fibrosis due to NASH', '392 patients with bridging fibrosis or compensated cirrhosis (F3-F4', 'Advanced fibrosis due to nonalcoholic steatohepatitis (NASH']","['placebo', 'placebo, selonsertib 18 mg (SEL), cilofexor 30 mg (CILO), or firsocostat 20 mg (FIR), alone or in two-drug combinations']","['≥1-stage improvement in fibrosis without worsening of NASH', 'NASH activity', 'FIR', 'CILO', 'CILO/FIR', 'FIR/SEL', 'Pruritus', 'NAFLD Activity Score (NAS), liver histology assessed using a machine learning (ML) approach, liver biochemistry, and noninvasive markers', 'CILO/SEL', 'ML NASH CRN fibrosis score', 'ALT, AST, bilirubin, bile acids, CK18, insulin, eGFR, ELF score, and liver stiffness', 'hepatic collagen']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}, {'cui': 'C0334160', 'cui_str': 'Bridging fibrosis'}, {'cui': 'C0205432', 'cui_str': 'Compensated'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4743336', 'cui_str': 'firsocostat'}, {'cui': 'C0013162', 'cui_str': 'Drug Combinations'}]","[{'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C4743336', 'cui_str': 'firsocostat'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0376284', 'cui_str': 'Machine Learning'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0010031', 'cui_str': 'Corneal structure'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0005390', 'cui_str': 'Bile acid'}, {'cui': 'C2363999', 'cui_str': 'Cytokeratin 18'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}]",392.0,0.360092,"Changes in hepatic collagen by morphometry were not significant, but CILO/FIR led to a significant decrease in ML NASH CRN fibrosis score (p=0.040) and a shift in biopsy area from F3-F4 to ≤F2 fibrosis patterns.","[{'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Loomba', 'Affiliation': 'NAFLD Research Center, University of California at San Diego, La Jolla, CA.'}, {'ForeName': 'Mazen', 'Initials': 'M', 'LastName': 'Noureddin', 'Affiliation': 'Fatty Liver Program, Cedars-Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Kris V', 'Initials': 'KV', 'LastName': 'Kowdley', 'Affiliation': 'Liver Institute Northwest, Seattle, WA.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Kohli', 'Affiliation': 'Arizona Liver Health, Chandler, AZ.'}, {'ForeName': 'Aasim', 'Initials': 'A', 'LastName': 'Sheikh', 'Affiliation': 'GI Specialists of Georgia, Marietta, GA.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Neff', 'Affiliation': 'Covenant Research, LLC, Sarasota, FL.'}, {'ForeName': 'Bal Raj', 'Initials': 'BR', 'LastName': 'Bhandari', 'Affiliation': 'Delta Research Partners, LLC, Bastrop, LA.'}, {'ForeName': 'Nadege', 'Initials': 'N', 'LastName': 'Gunn', 'Affiliation': 'Pinnacle Clinical Research, Austin, TX.'}, {'ForeName': 'Stephen H', 'Initials': 'SH', 'LastName': 'Caldwell', 'Affiliation': 'University of Virginia, Charlottesville, VA.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Goodman', 'Affiliation': 'Inova Fairfax Hospital, Falls Church, VA.'}, {'ForeName': 'Ilan', 'Initials': 'I', 'LastName': 'Wapinski', 'Affiliation': 'PathAI, Boston, MA.'}, {'ForeName': 'Murray', 'Initials': 'M', 'LastName': 'Resnick', 'Affiliation': 'PathAI, Boston, MA.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Beck', 'Affiliation': 'PathAI, Boston, MA.'}, {'ForeName': 'Dora', 'Initials': 'D', 'LastName': 'Ding', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Jia', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA.'}, {'ForeName': 'Jen-Chieh', 'Initials': 'JC', 'LastName': 'Chuang', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA.'}, {'ForeName': 'Ryan S', 'Initials': 'RS', 'LastName': 'Huss', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA.'}, {'ForeName': 'Chuhan', 'Initials': 'C', 'LastName': 'Chung', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA.'}, {'ForeName': 'G Mani', 'Initials': 'GM', 'LastName': 'Subramanian', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA.'}, {'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Myers', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA.'}, {'ForeName': 'Keyur', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': 'University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Brian B', 'Initials': 'BB', 'LastName': 'Borg', 'Affiliation': 'Southern Therapy and Advanced Research, Jackson, MS.'}, {'ForeName': 'Reem', 'Initials': 'R', 'LastName': 'Ghalib', 'Affiliation': 'Texas Clinical Research Institute, Arlington, TX.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Kabler', 'Affiliation': 'Jubilee Clinical Research, Las Vegas, NV.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Poulos', 'Affiliation': 'Cumberland Research Associates, Fayetteville, NC.'}, {'ForeName': 'Ziad', 'Initials': 'Z', 'LastName': 'Younes', 'Affiliation': 'Gastro One, Germantown, TN.'}, {'ForeName': 'Magdy', 'Initials': 'M', 'LastName': 'Elkhashab', 'Affiliation': 'Toronto Liver Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'Hassanein', 'Affiliation': 'Southern California Research Center, Coronado, CA.'}, {'ForeName': 'Rajalakshmi', 'Initials': 'R', 'LastName': 'Iyer', 'Affiliation': 'Iowa Digestive Disease Center, Clive, IA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Ruane', 'Affiliation': 'Ruane Medical and Liver Health Institute, Los Angeles, CA.'}, {'ForeName': 'Mitchell L', 'Initials': 'ML', 'LastName': 'Shiffman', 'Affiliation': 'Bon Secours Mercy Health, Richmond, VA.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Strasser', 'Affiliation': 'Royal Prince Alfred Hospital and The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Vincent Wai-Sun', 'Initials': 'VW', 'LastName': 'Wong', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Naim', 'Initials': 'N', 'LastName': 'Alkhouri', 'Affiliation': 'Texas Liver Institute, UT Health San Antonio, San Antonio, TX.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Hepatology (Baltimore, Md.)",['10.1002/hep.31622'] 405,33240572,Evaluation of the IOP-Lowering Effect of a Multi-Pressure Dial at Different Negative Pressure Settings.,"Purpose To evaluate the intraocular pressure (IOP)-lowering effect of a multi-pressure dial (MPD) at targeted negative pressure settings. Methods Prospective, intrasubject controlled study of 65 healthy subjects randomized to receive no negative pressure for 60 minutes or negative pressure application at designated levels of 25%, 50%, and 75% of baseline IOP for 20 minutes each. The main outcome measure was mean IOP with application of negative pressure. Results In the study eye group, from a baseline IOP of 15.8 ± 3.6 mm Hg, the mean IOP was 13.5 ± 3.4, 11.5 ± 3.1, and 10.2 ± 2.7 mm Hg with negative pressure settings of 25%, 50% and 75%, respectively. In the control eye group, from a baseline IOP of 15.5 ± 3.0 mm Hg, the mean IOP values at the same time points, without negative pressure, were 15.6 ± 3.0, 15.5 ± 2.5 and 15.3 ± 2.4 mm Hg. The difference between the mean IOPs of the two groups was significantly different at all negative pressure settings ( P < 0.001) in comparison with baseline. There was one minor adverse event, a corneal abrasion, that was unrelated to device wear. Conclusions Negative pressure application to the periocular space with a multi-pressure dial can produce titratable IOP reduction while the device is worn with active negative pressure. To our knowledge, this technology represents the first nonpharmacologic, nonlaser, nonsurgical method for IOP reduction. Translational Relevance This represents the first study demonstrating the IOP-lowering ability of the multi-pressure dial, a device that uses a novel IOP-lowering strategy by delivering negative pressure to the periocular region.",2020,The difference between the mean IOPs of the two groups was significantly different at all negative pressure settings ( P < 0.001) in comparison with baseline.,['65 healthy subjects randomized to'],"['multi-pressure dial (MPD', 'receive no negative pressure for 60 minutes or negative pressure application', 'Multi-Pressure Dial at Different Negative Pressure Settings']","['adverse event, a corneal abrasion', 'mean IOP with application of negative pressure', 'mean IOP values', 'mean IOPs', 'intraocular pressure']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0010032', 'cui_str': 'Corneal abrasion'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0578862', 'cui_str': 'Intraocular pressure finding'}]",65.0,0.0884468,The difference between the mean IOPs of the two groups was significantly different at all negative pressure settings ( P < 0.001) in comparison with baseline.,"[{'ForeName': 'Russell J', 'Initials': 'RJ', 'LastName': 'Swan', 'Affiliation': 'Vance Thompson Vision, Sioux Falls, South Dakota, USA.'}, {'ForeName': 'Tanner J', 'Initials': 'TJ', 'LastName': 'Ferguson', 'Affiliation': 'Cole Eye Institute, Cleveland Clinic, Cleveland Ohio, USA.'}, {'ForeName': 'Manjool', 'Initials': 'M', 'LastName': 'Shah', 'Affiliation': 'Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Kelly W', 'Initials': 'KW', 'LastName': 'Muir', 'Affiliation': 'Duke Eye Center, Durham, North Carolina, USA.'}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Samuelson', 'Affiliation': 'Minnesota Eye Consultants, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Iqbal Ike K', 'Initials': 'IIK', 'LastName': 'Ahmed', 'Affiliation': 'Prism Eye Institute, Mississauga, Ontario, Canada.'}, {'ForeName': 'Richard L', 'Initials': 'RL', 'LastName': 'Lindstrom', 'Affiliation': 'Minnesota Eye Consultants, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Nathan M', 'Initials': 'NM', 'LastName': 'Radcliffe', 'Affiliation': 'New York Eye and Ear Infirmary of Mount Sinai, New York, New York.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Berdahl', 'Affiliation': 'Vance Thompson Vision, Sioux Falls, South Dakota, USA.'}]",Translational vision science & technology,['10.1167/tvst.9.12.19'] 406,33185243,Impact of access route to the left ventricle on asymptomatic periprocedural brain injury: the results of a randomized trial in patients undergoing catheter ablation of ventricular tachycardia.,"AIMS Catheter ablation of ventricular tachycardia (VT) is an effective treatment in patients with structural heart disease (SHD) and recurrent arrhythmias. However, the procedure is associated with the risk of complications, including both manifest and asymptomatic cerebral thromboembolic events. We hypothesized that periprocedural asymptomatic brain injury (ABI) can be reduced by using transseptal instead of the retrograde access route to the left ventricle (LV). METHODS AND RESULTS Consecutive patients undergoing VT ablation for SHD were randomized 1:1 to either retrograde or transseptal LV access. All patients underwent radiofrequency ablation in conscious sedation with the use of an irrigated tip catheter. The degree of brain damage was evaluated by serum level of biomarker S100B. Significant ABI was defined as a post-ablation relative increase of S100B level >30%. A total of 144 patients (66 ± 9 years; 14 females; 90% coronary artery disease; LV ejection fraction: 30 ± 8%) were enrolled and 72 were allocated to each study groups. Symptomatic neurological complication of the procedure was not observed in any subject. A significant ABI was detected in 19.4% of patients. It was more commonly observed in subjects randomized to retrograde vs. transseptal LV access (26.4% vs. 12.5%, P = 0.04). In a multivariate analysis, only retrograde LV access and advanced age were independent determinants of significant ABI. CONCLUSION Significant ABI after ablation of VT in patients with SHD can be detected in one-fifth of subjects. Retrograde access to LV is associated with a two-fold higher probability of significant ABI.",2021,Symptomatic neurological complication of the procedure was not observed in any subject.,"['Consecutive patients undergoing VT ablation for SHD', 'patients with structural heart disease (SHD) and recurrent arrhythmias', 'patients undergoing catheter ablation of ventricular tachycardia', 'asymptomatic periprocedural brain injury', 'patients with SHD', '144 patients (66\u2009±\u20099\u2009years; 14 females; 90% coronary artery disease; LV ejection fraction: 30\u2009±\u20098%) were enrolled and 72']","['radiofrequency ablation', 'retrograde or transseptal LV access', 'Catheter ablation of ventricular tachycardia (VT']","['Symptomatic neurological complication', 'serum level of biomarker S100B. Significant ABI', 'ABI', 'degree of brain damage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042514', 'cui_str': 'Ventricular tachycardia'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0007799', 'cui_str': 'Brain ventricle structure'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]","[{'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0439784', 'cui_str': 'Retrograde direction'}, {'cui': 'C0442381', 'cui_str': 'Transseptal nasal approach'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0007799', 'cui_str': 'Brain ventricle structure'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0042514', 'cui_str': 'Ventricular tachycardia'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}]",144.0,0.0342564,Symptomatic neurological complication of the procedure was not observed in any subject.,"[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Borišincová', 'Affiliation': 'Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Peichl', 'Affiliation': 'Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wichterle', 'Affiliation': 'Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Šramko', 'Affiliation': 'Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic.'}, {'ForeName': 'Bashar', 'Initials': 'B', 'LastName': 'Aldhoon', 'Affiliation': 'Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic.'}, {'ForeName': 'Janka', 'Initials': 'J', 'LastName': 'Franeková', 'Affiliation': 'Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Čihák', 'Affiliation': 'Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Kautzner', 'Affiliation': 'Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa320'] 407,33190085,Patient experiences of as-needed budesonide-formoterol by Turbuhaler® for treatment of mild asthma; a qualitative study.,"BACKGROUND Combination low-dose budesonide-formoterol, taken as-needed for symptom relief reduces exacerbation risk and is recommended for treatment of mild asthma. The NovelQ qualitative study explored patients' attitudes toward using this novel therapy. METHODS Adults with mild asthma using reliever-only treatment were randomised to as-needed budesonide-formoterol Turbuhaler® in a multinational, 52-week open-label randomised controlled trial (NovelSTART-ACTRN12615000999538). A subgroup were interviewed to explore their attitudes to use of as-needed budesonide-formoterol after receiving it for ≥10 months. Semi-structured interviews were conducted until saturation, audio-recorded, and thematically analysed. RESULTS Analysis of 35 participants (66% female; mean age 43.5 [range 18-74]; mean Asthma Control Questionnaire score 1.09 ± SD0.55) interviews identified 5 themes, each including both barriers and facilitators to therapy use. Themes were: 'Treatment effectiveness' i.e. how well symptoms were relieved and/or prevented; 'Lifestyle fit of the regimen' e.g. the extent to which the treatment regimen integrated into the patient's daily life; 'Attitudes toward medication use and safety' e.g. openness for new reliever treatments, beliefs about treatment necessity or side effects; 'Device attributes' e.g. perceived ease of use; and 'Doctor-patient relationship' e.g. impact of health professional support on new treatment acceptance. CONCLUSIONS A wide range of factors seem to drive the opinions of mild asthma patients on as-needed budesonide-formoterol therapy. Many patients perceived both positive and negative treatment attributes, and their individual evaluation of these attributes determined their likelihood of using it after the study. Supportive patient-physician interactions appear key to addressing patient barriers. Recommendations for patient-centred discussions, developed from this research, are provided.",2020,"Many patients perceived both positive and negative treatment attributes, and their individual evaluation of these attributes determined their likelihood of using it after the study.","['mild asthma', '35 participants (66% female; mean age 43.5 [range 18-74', 'Adults with mild asthma using reliever-only treatment']","['budesonide-formoterol', 'budesonide-formoterol Turbuhaler®', 'budesonide-formoterol by Turbuhaler®']",['mean Asthma Control Questionnaire score'],"[{'cui': 'C0581124', 'cui_str': 'Mild asthma'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1276807', 'cui_str': 'formoterol and budesonide'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4706265', 'cui_str': 'Asthma Control Questionnaire score'}]",,0.0311362,"Many patients perceived both positive and negative treatment attributes, and their individual evaluation of these attributes determined their likelihood of using it after the study.","[{'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Foster', 'Affiliation': 'Clinical Management Group, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia. Electronic address: j.m.foster@woolcock.org.au.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Beasley', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand. Electronic address: richard.beasley@mrinz.ac.nz.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Braithwaite', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand. Electronic address: Irene.Braithwaite@mrinz.ac.nz.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Harrison', 'Affiliation': 'Nottingham Respiratory Medicine Unit and NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK. Electronic address: tim.harrison@nottingham.ac.uk.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Holliday', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand. Electronic address: Mark.Holliday@mrinz.ac.nz.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Pavord', 'Affiliation': 'Respiratory Medicine Unit, Oxford Respiratory NIHR Biomedical Research Centre, University of Oxford, Oxford, UK. Electronic address: ian.pavord@ndm.ox.ac.uk.'}, {'ForeName': 'H K', 'Initials': 'HK', 'LastName': 'Reddel', 'Affiliation': 'Clinical Management Group, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia. Electronic address: helen.reddel@sydney.edu.au.'}]",Respiratory medicine,['10.1016/j.rmed.2020.106154'] 408,32703038,Multiple functions of policosanol in elderly patients with dyslipidemia.,"OBJECTIVE To determine the multiple functions of policosanol in elderly dyslipidemia patients. Methodology: There were 294 elderly dyslipidemia patients enrolled into this clinical study. They were randomly divided into four groups, as follows: 20 mg policosanol (group A, n = 64); 10 mg policosanol (group B, n = 72); 20 mg atorvastatin (group C, n = 91); and 10 mg policosanol + 20 mg atorvastatin (group D, n = 62). Plasma platelet count, platelet aggregation rate, circulating endothelial cell (CEC) count, high sensitivity C-reactive protein (hs-CRP), and carotid intima-media thickness (IMT) were measured before the study (week 0) and at weeks 12, 24, and 52. RESULTS In group A, the platelet aggregation rate caused by adenosine diphosphate (ADP) after treatment was significantly decreased compared with before treatment (48.79% ± 20.29% vs. 40.37% ± 23.56%), but the arachidonic acid (AA)-induced platelet aggregation rates were similar. The platelet aggregation rates induced by AA and ADP in groups B, C, and D did not change significantly. CEC counts and hs-CRP and homocysteine levels in all groups after treatment were significantly lower compared with before treatment, but carotid IMTs were similar. CONCLUSION Policosanol regulates blood lipid levels and improves endothelial cell function, and it could delay the progress of atherosclerosis. Trial registration number: ChiCTR-RRC-17013396 (retrospectively registered).",2020,"In group A, the platelet aggregation rate caused by adenosine diphosphate (ADP) after treatment was significantly decreased compared with before treatment (48.79% ± 20.29% vs. 40.37% ± 23.56%), but the arachidonic acid (AA)-induced platelet aggregation rates were similar.","['elderly patients with dyslipidemia', '294 elderly dyslipidemia patients enrolled into this clinical study', 'elderly dyslipidemia patients']","['atorvastatin', 'policosanol', 'Policosanol', 'policosanol\u2009+\u200920\u2009mg atorvastatin']","['arachidonic acid (AA)-induced platelet aggregation rates', 'Plasma platelet count, platelet aggregation rate, circulating endothelial cell (CEC) count, high sensitivity C-reactive protein (hs-CRP), and carotid intima-media thickness (IMT', 'platelet aggregation rates', 'endothelial cell function', 'CEC counts and hs-CRP and homocysteine levels', 'carotid IMTs', 'platelet aggregation rate caused by adenosine diphosphate (ADP']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0215278', 'cui_str': 'policosanol'}]","[{'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C1268819', 'cui_str': 'Induced platelet aggregation'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0032176', 'cui_str': 'Platelet aggregation'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell density'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0334121', 'cui_str': 'Inflammatory myofibroblastic tumor'}, {'cui': 'C0225336', 'cui_str': 'Endothelial cell'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0318601', 'cui_str': 'Canine enteric calicivirus'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C2242817', 'cui_str': 'Homocysteine measurement'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0001459', 'cui_str': 'Adenosine diphosphate'}]",294.0,0.0213996,"In group A, the platelet aggregation rate caused by adenosine diphosphate (ADP) after treatment was significantly decreased compared with before treatment (48.79% ± 20.29% vs. 40.37% ± 23.56%), but the arachidonic acid (AA)-induced platelet aggregation rates were similar.","[{'ForeName': 'Chunlin', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Second Department of Internal Medicine, 316 Hospital of PLA, Beijing, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'First Department of Cardiovascular Diseases, South Building, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Quanjin', 'Initials': 'Q', 'LastName': 'Si', 'Affiliation': 'First Department of Cardiovascular Diseases, South Building, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Kailiang', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': 'First Department of Cardiovascular Diseases, South Building, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Xu', 'Affiliation': 'First Department of Cardiovascular Diseases, South Building, Chinese PLA General Hospital, Beijing, China.'}]",The Journal of international medical research,['10.1177/0300060520936082'] 409,33156688,Comparison of the Effect of Breast Milk and Sodium Bicarbonate Solution for Oral Care in Infants with Tracheal Intubation After Cardiothoracic Surgery.,"Background: This study aimed to explore the effect of breast milk and sodium bicarbonate solution used in oral care of infants with tracheal intubation after cardiothoracic surgery. Methods: A randomized clinical controlled trial was conducted in a provincial hospital in China. Fifty infantile patients were randomly divided into two groups: the patients in the study group ( n  = 25) used breast milk for oral care and the patients in the control group ( n  = 25) used sodium bicarbonate solution for oral care. The relevant clinical data were recorded, including the mechanical ventilation duration, length of intensive care unit (ICU) stay, length of hospital stay, and complications. Results: The length of ICU stay, length of hospital stay, and duration of mechanical ventilation were shorter in the study group, but the difference was not statistically significant ( p  > 0.05). However, the incidence of thrush and ventilator-associated pulmonary infection in the study group was significantly lower than that in the control group ( p  < 0.05). Conclusion: The use of breast milk for oral care has a positive effect on the prevention of thrush and ventilator-associated pulmonary infection in infants with tracheal intubation after cardiothoracic surgery.",2021,"The length of ICU stay, length of hospital stay, and duration of mechanical ventilation were shorter in the study group, but the difference was not statistically significant ( p  > 0.05).","['Fifty infantile patients', 'infants with tracheal intubation after cardiothoracic surgery', 'Infants with Tracheal Intubation', 'provincial hospital in China']","['Breast Milk and Sodium Bicarbonate Solution', 'breast milk for oral care and the patients in the control group ( n \u2009=\u200925) used sodium bicarbonate solution for oral care', 'breast milk and sodium bicarbonate solution']","['mechanical ventilation duration, length of intensive care unit (ICU) stay, length of hospital stay, and complications', 'length of ICU stay, length of hospital stay, and duration of mechanical ventilation', 'incidence of thrush and ventilator-associated pulmonary infection']","[{'cui': 'C0231330', 'cui_str': 'Infancy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C1274037', 'cui_str': 'Cardiothoracic surgery'}, {'cui': 'C3661820', 'cui_str': 'Provincial hospital'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0006840', 'cui_str': 'Candidiasis'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0876973', 'cui_str': 'Infectious disease of lung'}]",50.0,0.0395689,"The length of ICU stay, length of hospital stay, and duration of mechanical ventilation were shorter in the study group, but the difference was not statistically significant ( p  > 0.05).","[{'ForeName': 'Xian-Rong', 'Initials': 'XR', 'LastName': 'Yu', 'Affiliation': 'Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Shu-Ting', 'Initials': 'ST', 'LastName': 'Huang', 'Affiliation': 'Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Xu', 'Affiliation': 'Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Wang-Sheng', 'Initials': 'WS', 'LastName': 'Dai', 'Affiliation': 'Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Zeng-Chun', 'Initials': 'ZC', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Cao', 'Affiliation': 'Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0239'] 410,33166726,Short-interval intracortical inhibition as a function of inter-stimulus interval: Three methods compared.,"BACKGROUND Short-interval intracortical inhibition (SICI), as measured by threshold-tracking as a function of inter-stimulus interval (ISI), has been proposed as a useful biomarker for amyotrophic lateral sclerosis (ALS), but its relationship to conventional amplitude measurements has not been established. METHODS Serial tracking of SICI at increasing ISIs from 1 to 7 ms (T-SICIs) was compared in 50 healthy control subjects with the same ISIs tracked in parallel (T-SICIp), and with conventional amplitude measurements (A-SICI). For T-SICIp and A-SICI, pairs of conditioning and test stimuli with different ISIs were pseudo-randomised and interspersed with test-alone stimuli given at regular intervals. Thresholds were estimated by regression of log peak-to-peak amplitude on stimulus. RESULTS T-SICIp and A-SICI were closely related: a ten-fold reduction in amplitude corresponding to an approximately 18% increase in threshold. Threshold increases were greater for T-SICIs than for T-SICIp at 3.5-5 ms (P < 0.001). This divergence depended on the initial settings and whether ISIs were progressively increased or decreased, and was attributed to the limitations of the serial tracking protocol. SICI variability between subjects was greatest for T-SICIs estimates and least for A-SICI, and only A-SICI estimates revealed a significant decline in inhibition with age. CONCLUSIONS The serial tracking protocol did not accurately show the dependence of inhibition on ISI. Randomising ISIs gives corresponding SICI measures, whether tracking thresholds or measuring amplitude measurements. SICI variability suggested that A-SICI measurements may be the most sensitive to loss of inhibition.",2021,"SICI variability between subjects was greatest for T-SICIs estimates and least for A-SICI, and only A-SICI estimates revealed a significant decline in inhibition with age. ","['50 healthy control subjects with the same ISIs tracked in parallel (T-SICIp), and with conventional amplitude measurements (A-SICI']",[],['SICI variability'],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]",[],"[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]",50.0,0.0606434,"SICI variability between subjects was greatest for T-SICIs estimates and least for A-SICI, and only A-SICI estimates revealed a significant decline in inhibition with age. ","[{'ForeName': 'Hatice', 'Initials': 'H', 'LastName': 'Tankisi', 'Affiliation': 'Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Bülent', 'Initials': 'B', 'LastName': 'Cengiz', 'Affiliation': 'Department of Neurology, Gazi University Faculty of Medicine, Beşevler, 06500, Ankara, Turkey.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Howells', 'Affiliation': 'Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Gintaute', 'Initials': 'G', 'LastName': 'Samusyte', 'Affiliation': 'Department of Neurology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Koltzenburg', 'Affiliation': 'Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, Queen Square, WC1N 3BG, London, United Kingdom; Department of Clinical Neurophysiology, National Hospital for Neurology and Neurosurgery, Queen Square, WC1N 3BG, London, United Kingdom.'}, {'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Bostock', 'Affiliation': 'Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N 3BG, London, United Kingdom. Electronic address: H.Bostock@ucl.ac.uk.'}]",Brain stimulation,['10.1016/j.brs.2020.11.002'] 411,33177355,Feasibility and Safety of Laparoscopic Complete Mesocolic Excision (CME) for Right-sided Colon Cancer: Short-term Outcomes. A Randomized Clinical Study.,"OBJECTIVE The aim of this prospective clinical study is to compare short-term outcome of laparoscopic right hemicolectomy using the Complete Mesocolic Excision (CME group) with patients who underwent conventional right-sided colonic resection (NCME group). SUMMARY BACKGROUND DATA Although CME with central vascular ligation in laparoscopic right hemicolectomy is associated with a significant decrease in local recurrence rates and improvements in cancer-related 5-year survival, there may be additional risks associated with this technique because of increased surgical complications. As a result, there is controversy surrounding its use. METHODS In this randomized controlled trial, several primary endpoints (operative time, intraoperative blood loss, other complications, conversion rate, and anastomotic leak) and secondary endpoints (overall postoperative complications) were evaluated. In addition, we evaluated histopathologic data, including specimen length and the number of lymph nodes harvested, as objective signs of the quality of CME, related to oncological outcomes. RESULTS The CME group had a significantly longer mean operative time than the NCME group (216.3 minutes vs 191.5 minutes, P = 0.005). However, the CME group had a higher number of lymph nodes (23.8 vs 16.6; P < 0.001) and larger surgical specimens (34.3 cm vs 29.3 cm; P = 0.002). No differences were reported with respect to intraoperative blood loss, conversion rate, leakage, or other postoperative complications. CONCLUSIONS In this study laparoscopic CME were a safe and feasible technique with improvement in lymph nodes harvesting and length of surgical specimens with no increase of surgical intraoperative and postoperative complications.",2021,"Although CME with central vascular ligation in laparoscopic right hemicolectomy is associated with a significant decrease in local recurrence rates and improvements in cancer-related 5-year survival, there may be additional risks associated with this technique because of increased surgical complications.","['Right-Sided Colon Cancer', 'patients who underwent conventional right-sided colonic resection (NCME group']","['laparoscopic right hemicolectomy', 'Laparoscopic Complete Mesocolic Excision (CME', 'laparoscopic CME', 'CME', 'Complete Mesocolic Excision (CME group', 'NCME']","['mean operative time', 'number of lymph nodes', 'local recurrence rates', 'larger surgical specimens', 'operative time, intraoperative blood loss, other complications, conversion rate, and anastomotic leak) and secondary endpoints (overall postoperative complications', 'intraoperative blood loss, conversion rate, leakage, or other postoperative complications', 'surgical intraoperative and postoperative complications']","[{'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0641638', 'cui_str': 'NCME'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0585464', 'cui_str': 'Laparoscopic-assisted right colectomy'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0641638', 'cui_str': 'NCME'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0919691', 'cui_str': 'Anastomotic leak'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}]",,0.103298,"Although CME with central vascular ligation in laparoscopic right hemicolectomy is associated with a significant decrease in local recurrence rates and improvements in cancer-related 5-year survival, there may be additional risks associated with this technique because of increased surgical complications.","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Di Buono', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Buscemi', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Gianfranco', 'Initials': 'G', 'LastName': 'Cocorullo', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Sorce', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Amato', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Bonventre', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Maienza', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Galia', 'Affiliation': 'Department of Radiology, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Gulotta', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Romano', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Antonino', 'Initials': 'A', 'LastName': 'Agrusa', 'Affiliation': 'Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.'}]",Annals of surgery,['10.1097/SLA.0000000000004557'] 412,33184650,"Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.","STUDY OBJECTIVES Evaluate efficacy and safety of lower-sodium oxybate (LXB), a novel oxybate medication with 92% less sodium than sodium oxybate (SXB). METHODS Adults aged 18-70 years with narcolepsy with cataplexy were eligible. The study included a ≤30-day screening period; a 12-week, open-label, optimized treatment and titration period to transition to LXB from previous medications for the treatment of cataplexy; a 2-week stable-dose period (SDP); a 2-week, double-blind, randomized withdrawal period (DBRWP); and a 2-week safety follow-up. During DBRWP, participants were randomized 1:1 to placebo or to continue LXB treatment. RESULTS Efficacy was assessed in 134 participants who received randomized treatment, and safety was assessed in all enrolled participants (N = 201). Statistically significant worsening of symptoms was observed in participants randomized to placebo, with median (first quartile [Q1], third quartile [Q3]) change in weekly number of cataplexy attacks from SDP to DBRWP (primary efficacy endpoint) in the placebo group of 2.35 (0.00, 11.61) versus 0.00 (-0.49, 1.75) in the LXB group (p < 0.0001; mean [standard deviation, SD] change: 11.46 [24.751] vs 0.12 [5.772]), and median (Q1, Q3) change in Epworth Sleepiness Scale score (key secondary efficacy endpoint) of 2.0 (0.0, 5.0) in the placebo group versus 0.0 (-1.0, 1.0) in the LXB group (p < 0.0001; mean [SD] change: 3.0 [4.68] vs 0.0 [2.90]). The most common treatment-emergent adverse events with LXB were headache (20.4%), nausea (12.9%), and dizziness (10.4%). CONCLUSIONS Efficacy of LXB for the treatment of cataplexy and excessive daytime sleepiness was demonstrated. The safety profile of LXB was consistent with SXB. CLINICAL TRIAL REGISTRATION NCT03030599.",2021,"The most common treatment-emergent adverse events with LXB were headache (20.4%), nausea (12.9%), and dizziness (10.4%). ","['adults with narcolepsy with cataplexy', 'Adults aged 18-70 years with narcolepsy with cataplexy were eligible', '134 participants who received randomized treatment, and safety was assessed in all enrolled participants (N = 201']","['calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258', 'lower-sodium oxybate (LXB', 'placebo', 'LXB', 'sodium oxybate (SXB']","['headache', 'cataplexy and excessive daytime sleepiness', 'nausea', 'Efficacy', 'median (Q1, Q3) change in Epworth Sleepiness Scale score', 'dizziness']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0751362', 'cui_str': 'Cataplexy and narcolepsy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]","[{'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0037537', 'cui_str': 'Sodium Oxybate'}, {'cui': 'C0012169', 'cui_str': 'Low sodium diet'}, {'cui': 'C0673093', 'cui_str': '4-hydroxybutyric acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0007384', 'cui_str': 'Cataplexy'}, {'cui': 'C4551761', 'cui_str': 'Excessive daytime sleepiness'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4706348', 'cui_str': 'ESS (Epworth Sleepiness Scale) score'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}]",134.0,0.418502,"The most common treatment-emergent adverse events with LXB were headache (20.4%), nausea (12.9%), and dizziness (10.4%). ","[{'ForeName': 'Richard K', 'Initials': 'RK', 'LastName': 'Bogan', 'Affiliation': 'School of Medicine, University of South Carolina, Columbia, SC.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Thorpy', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Dauvilliers', 'Affiliation': 'Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France.'}, {'ForeName': 'Markku', 'Initials': 'M', 'LastName': 'Partinen', 'Affiliation': 'Helsinki Sleep Clinic, Vitalmed Research Center, Helsinki, Finland.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Del Rio Villegas', 'Affiliation': 'Neurophysiology and Sleep Disorders Unit, Hospital Vithas Nuestra Señora de America, Madrid, Spain.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Foldvary-Schaefer', 'Affiliation': 'Sleep Disorders Center, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Skowronski', 'Affiliation': 'Global Clinical Development, Jazz Pharmaceuticals, Inc., Palo Alto, CA.'}, {'ForeName': 'Lihua', 'Initials': 'L', 'LastName': 'Tang', 'Affiliation': 'Biostatistics, Jazz Pharmaceuticals, Inc., Palo Alto, CA.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Skobieranda', 'Affiliation': 'Global Clinical Development, Jazz Pharmaceuticals, Inc., Palo Alto, CA.'}, {'ForeName': 'Karel', 'Initials': 'K', 'LastName': 'Šonka', 'Affiliation': 'Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}]",Sleep,['10.1093/sleep/zsaa206'] 413,33181782,Use of a Procalcitonin-guided Antibiotic Treatment Algorithm in the Pediatric Intensive Care Unit.,"BACKGROUND The utility of procalcitonin testing in the pediatric intensive care unit (PICU) is not known. We sought to determine the impact of a procalcitonin-guided antibiotic treatment algorithm implemented with antibiotic stewardship (AS) guidance vs. usual care on antibiotic use in critically ill children. METHODS Single center, pragmatic, randomized prospective clinical trial of critically ill children admitted to an ICU setting and started on intravenous antibiotics from February 15, 2018, to April 11, 2019. Patients were assigned on a monthly basis to either the procalcitonin or usual care arm. The procalcitonin arm had procalcitonin testing on hospital days 0, 1, 2, and 4 and stewardship assistance with algorithm result interpretation. Both arms had routine AS audit and feedback. The primary outcome was median antibiotic days of therapy per patient in the first 14-days after enrollment. RESULTS Among 270 patients, 137 were in the procalcitonin arm and 133 in the usual care arm. Antibiotic days of therapy (DOT) were not significantly different between the procalcitonin arm (6.6, IQR: 3.1-10.9) and the usual care arm (7.6, IQR: 3-11.8; P = 0.37). More AS recommendations were made in the procalcitonin vs. control arm (54 vs. 37; P = 0.03). Adherence with algorithm-based antibiotic recommendations was high in the procalcitonin arm (70%). CONCLUSIONS We found no difference in antibiotic DOT between study arms. This trial was underpowered but demonstrates feasibility of using a procalcitonin-guided antibiotic treatment algorithm with AS audit and feedback in the PICU.",2021,"Antibiotic days of therapy (DOT) were not significantly different between the procalcitonin arm (6.6, IQR: 3.1-10.9) and the usual care arm (7.6, IQR: 3-11.8; P = 0.37).","['270 patients, 137 were in the procalcitonin arm and 133 in the usual care arm', 'Pediatric Intensive Care Unit', 'critically ill children', 'critically ill children admitted to an ICU setting and started on intravenous antibiotics from February 15, 2018, to April 11, 2019']","['procalcitonin or usual care arm', 'Procalcitonin-guided Antibiotic Treatment Algorithm', 'procalcitonin-guided antibiotic treatment algorithm implemented with antibiotic stewardship (AS) guidance vs. usual care']","['antibiotic DOT', 'median antibiotic days of therapy per patient in the first 14-days after enrollment', 'Antibiotic days of therapy (DOT']","[{'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0072027', 'cui_str': 'Procalcitonin'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0021710', 'cui_str': 'Pediatric intensive care unit'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0072027', 'cui_str': 'Procalcitonin'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C4505100', 'cui_str': 'Antibiotic Stewardship'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}]",,0.0832058,"Antibiotic days of therapy (DOT) were not significantly different between the procalcitonin arm (6.6, IQR: 3.1-10.9) and the usual care arm (7.6, IQR: 3-11.8; P = 0.37).","[{'ForeName': 'Sophie E', 'Initials': 'SE', 'LastName': 'Katz', 'Affiliation': 'From the Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Crook', 'Affiliation': 'From the Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Gillon', 'Affiliation': 'Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'J Eric', 'Initials': 'JE', 'LastName': 'Stanford', 'Affiliation': 'Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Biostatistics, Vanderbilt University, Nashville, TN.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Colby', 'Affiliation': 'Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Ritu', 'Initials': 'R', 'LastName': 'Banerjee', 'Affiliation': 'From the Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN.'}]",The Pediatric infectious disease journal,['10.1097/INF.0000000000002986'] 414,33183883,Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics.,"BACKGROUND AND AIMS Diet is both a modulator of the gastrointestinal microbiota and an important therapy in irritable bowel syndrome (IBS). We aimed to comprehensively (i) identify diet-microbiota associations in adults with IBS consuming habitual diet; (ii) assess the impact of two nutritional interventions on the microbiota; and (iii) determine whether baseline microbiota can predict clinical response to diet or probiotic intervention. METHODS Data were analyzed from 95 individuals with IBS participating in a previously published 4-week 2x2 factorial design randomized controlled trial investigating the impact of the low FODMAP diet (LFD) and co-administration of a probiotic. Diet was assessed at four hierarchical levels and partial 16S rRNA gene sequencing was used to profile the microbiota. RESULTS There were numerous diet-microbiota associations especially at the nutrient level, including a negative association between protein and Bifidobacterium abundance (r s  = -0.358, p < 0.001). After correction for multiple testing, the significance for this association (q = 0.237) and all others was lost. Low FODMAP diet led to changes in abundance of major saccharolytic genera compared with sham diet, including higher Bacteroides (LFD 34.1% (15.7%) vs sham 23.3% (15.2%), q = 0.01) and lower Bifidobacterium (0.9% (1.0%) vs 2.1%, (2.5%) q = 0.029). Compared with placebo, probiotic supplementation led to higher Lactobacillus (probiotic 0.08% (0.1%) vs placebo 0.03% (0.2%), q < 0.001), and Streptococcus abundance (2.0% (2.2%) vs 0.6% (1.2%), q = 0.001). The probiotic treatment buffered the impact of the low FODMAP diet on Bifidobacterium. Baseline microbiota did not predict clinical response to either intervention. CONCLUSIONS Although diet modifies the gut microbiota, bivariate correlation analysis may only provide a limited explanation of the complex diet interactions with individual gut bacteria in IBS. Some diet interventions modify the microbiota in IBS. TRIAL REGISTRY ISRCTN (http://www.isrctn.com) Registered under ISRCTN registry identifier no.ISRCTN02275221.",2021,"Compared with placebo, probiotic supplementation led to higher Lactobacillus (probiotic 0.08% (0.1%) vs placebo 0.03% (0.2%), q < 0.001), and Streptococcus abundance (2.0% (2.2%) vs 0.6% (1.2%), q = 0.001).","['irritable bowel syndrome (IBS', 'adults with IBS consuming habitual diet', 'Data were analyzed from 95 individuals with IBS participating']","['low FODMAP diet and probiotics', 'Low FODMAP diet', 'low FODMAP diet (LFD) and co-administration of a probiotic', 'placebo, probiotic supplementation', 'low FODMAP diet']","['abundance of major saccharolytic genera', 'Streptococcus abundance', 'lower Bifidobacterium']","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C4728066', 'cui_str': 'Low FODMAP diet'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}]",95.0,0.0386556,"Compared with placebo, probiotic supplementation led to higher Lactobacillus (probiotic 0.08% (0.1%) vs placebo 0.03% (0.2%), q < 0.001), and Streptococcus abundance (2.0% (2.2%) vs 0.6% (1.2%), q = 0.001).","[{'ForeName': 'Heidi M', 'Initials': 'HM', 'LastName': 'Staudacher', 'Affiliation': ""King's College London, Department of Nutritional Sciences, London, United Kingdom.""}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Scholz', 'Affiliation': 'Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.'}, {'ForeName': 'Miranda Ce', 'Initials': 'MC', 'LastName': 'Lomer', 'Affiliation': ""King's College London, Department of Nutritional Sciences, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, UK.""}, {'ForeName': 'Frances S', 'Initials': 'FS', 'LastName': 'Ralph', 'Affiliation': ""King's College London, Department of Nutritional Sciences, London, United Kingdom.""}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Irving', 'Affiliation': ""King's College London, Department of Nutritional Sciences, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, UK.""}, {'ForeName': 'James O', 'Initials': 'JO', 'LastName': 'Lindsay', 'Affiliation': 'Barts Health NHS Trust, Department of Gastroenterology, Royal London Hospital, London, UK; Queen Mary University of London, Centre for Immunobiology, London, UK.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Fava', 'Affiliation': 'Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.'}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': 'Tuohy', 'Affiliation': 'Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Whelan', 'Affiliation': ""King's College London, Department of Nutritional Sciences, London, United Kingdom. Electronic address: kevin.whelan@kcl.ac.uk.""}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.013'] 415,33199443,EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.,"OBJECTIVE Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome and EGFR copy number (CN) in pretreatment tissue and plasma cell-free DNA (cfDNA) of patients enrolled in a randomised first-line phase III clinical trial of chemotherapy or chemotherapy plus the anti-EGFR monoclonal antibody panitumumab in aGEA (NCT00824785). DESIGN EGFR CN by either fluorescence in situ hybridisation (n=114) or digital-droplet PCR in tissues (n=250) and plasma cfDNAs (n=354) was available for 474 (86%) patients in the intention-to-treat (ITT) population. Tissue and plasma low-pass whole-genome sequencing was used to screen for coamplifications in receptor tyrosine kinases. Interaction between chemotherapy and EGFR inhibitors was modelled in patient-derived organoids (PDOs) from aGEA patients. RESULTS EGFR amplification in cfDNA correlated with poor survival in the ITT population and similar trends were observed when the analysis was conducted in tissue and plasma by treatment arm. EGFR inhibition in combination with chemotherapy did not correlate with improved survival, even in patients with significant EGFR CN gains. Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin in PDOs, resulted in a paradoxical increase in viability and accelerated progression through the cell cycle, associated with p21 and cyclin B1 downregulation and cyclin E1 upregulation, selectively in organoids from EGFR -amplified aGEA. CONCLUSION EGFR CN can be accurately measured in tissue and liquid biopsies and may be used for the selection of aGEA patients. EGFR inhibitors may antagonise the antitumour effect of anthracyclines with important implications for the design of future combinatorial trials.",2021,"EGFR inhibition in combination with chemotherapy did not correlate with improved survival, even in patients with significant EGFR CN gains.","['advanced gastro-oesophageal cancers', 'advanced gastro-oesophageal adenocarcinoma (aGEA) patients', 'patients enrolled in a randomised first-line phase III clinical trial of', 'patient-derived organoids (PDOs) from aGEA patients']","['chemotherapy alone or chemotherapy plus panitumumab', 'chemotherapy or chemotherapy plus the anti-EGFR monoclonal antibody panitumumab']","['survival', 'EGFR inhibition']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0546837', 'cui_str': 'Malignant tumor of esophagus'}, {'cui': 'C0279628', 'cui_str': 'Adenocarcinoma of esophagus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0029250', 'cui_str': 'Organoids'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0879427', 'cui_str': 'panitumumab'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]",,0.0508792,"EGFR inhibition in combination with chemotherapy did not correlate with improved survival, even in patients with significant EGFR CN gains.","[{'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Smyth', 'Affiliation': 'Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Vlachogiannis', 'Affiliation': 'Molecular Pathology, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Somaieh', 'Initials': 'S', 'LastName': 'Hedayat', 'Affiliation': 'Molecular Pathology, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Harbery', 'Affiliation': 'Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Sanna', 'Initials': 'S', 'LastName': 'Hulkki-Wilson', 'Affiliation': 'Molecular Pathology, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Massimiliano', 'Initials': 'M', 'LastName': 'Salati', 'Affiliation': 'Molecular Pathology, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Kyriakos', 'Initials': 'K', 'LastName': 'Kouvelakis', 'Affiliation': 'Clinical Research & Development, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Fernandez-Mateos', 'Affiliation': 'Centre for Evolution and Cancer, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'George D', 'Initials': 'GD', 'LastName': 'Cresswell', 'Affiliation': 'Centre for Evolution and Cancer, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Fontana', 'Affiliation': 'Molecular Pathology, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Therese', 'Initials': 'T', 'LastName': 'Seidlitz', 'Affiliation': 'Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Germany.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Peckitt', 'Affiliation': 'Clinical Research & Development, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Jens C', 'Initials': 'JC', 'LastName': 'Hahne', 'Affiliation': 'Molecular Pathology, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Lampis', 'Affiliation': 'Molecular Pathology, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Ruwaida', 'Initials': 'R', 'LastName': 'Begum', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Watkins', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Sheela', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Naureen', 'Initials': 'N', 'LastName': 'Starling', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Waddell', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Okines', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Crosby', 'Affiliation': 'Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK.'}, {'ForeName': 'Was', 'Initials': 'W', 'LastName': 'Mansoor', 'Affiliation': 'Department of Medical Oncology, Christie Hospital, Manchester, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Wadsley', 'Affiliation': 'Cancer Clinical Trials Centre, Weston Park Cancer Centre, Sheffield, UK.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Middleton', 'Affiliation': 'Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Fassan', 'Affiliation': 'Department of Medicine (DIMED), University of Padua, Padova, Italy.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wotherspoon', 'Affiliation': 'Histopathology, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Braconi', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Chau', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Vivanco', 'Affiliation': 'Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Sottoriva', 'Affiliation': 'Centre for Evolution and Cancer, The Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Stange', 'Affiliation': 'Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Germany.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cunningham', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Valeri', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK nicola.valeri@icr.ac.uk.'}]",Gut,['10.1136/gutjnl-2020-322658'] 416,33201116,"Prophylactic Single-use Negative Pressure Dressing in Closed Surgical Wounds After Incisional Hernia Repair: A Randomized, Controlled Trial.","OBJECTIVE A randomized controlled trial (RCT) was undertaken to evaluate whether the prophylactic application of a specific single-use negative pressure (sNPWT) dressing on closed surgical incisions after incisional hernia (IH) repair decreases the risk of surgical site occurrences (SSOs) and the length of stay. BACKGROUND The sNPWT dressings have been associated to several advantages like cost savings and prevention of SSOs like seroma, hematoma, dehiscence, or wound infection (SSI) in closed surgical incisions. But this beneficious effect has not been previously studied in cases of close wounds after abdominal wall hernia repairs. METHODS An RCT was undertaken between May 2017 and January 2020 (ClinicalTrials.gov registration number NCT03576222). Participating patients, with IH type W2 or W3 according to European Hernia Society classification, were randomly assigned to receive intraoperatively either the sNPWT (PICO)(72 patients) or a conventional dressing at the end of the hernia repair (74 patients). The primary endpoint was the development of SSOs during the first 30 days after hernia repair. The secondary endpoint included length of hospital stay. Statistical analysis was performed using IBM SPSS Statistics Version 23.0. RESULTS At 30 days postoperatively, there was significatively higher incidence of SSOs in the control group compared to the treatment group (29.8% vs 16.6%, P < 0.042). There was no SSI in the treatment group and 6 cases in the control group (0% vs 8%, P < 0.002). No significant differences regarding seroma, hematoma, wound dehiscence, and length of stay were observed between the groups. CONCLUSION The use of prophylactic sNPWT PICO dressing for closed surgical incisions following IH repair reduces significatively the overall incidence of SSOs and the SSI at 30 days postoperatively.",2021,"No significant differences regarding seroma, hematoma, wound dehiscence, and length of stay were observed between the groups. ","['Participating patients, with IH type W2 or W3 according to European Hernia Society classification', 'After Incisional Hernia Repair', 'Closed Surgical Wounds']","['Prophylactic Single-use Negative Pressure Dressing', 'sNPWT (PICO)(72 patients) or a conventional dressing at the end of the hernia repair', 'specific single-use negative pressure (sNPWT) dressing', 'prophylactic sNPWT PICO dressing']","['development of SSOs', 'length of hospital stay', 'seroma, hematoma, wound dehiscence, and length of stay', 'incidence of SSOs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0267716', 'cui_str': 'Incisional hernia'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0342971', 'cui_str': 'Repair of incisional hernia'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0332803', 'cui_str': 'Surgical wound'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1956079', 'cui_str': 'Negative-Pressure Dressings'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0019328', 'cui_str': 'Hernia repair'}, {'cui': 'C0205369', 'cui_str': 'Specific'}]","[{'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0332850', 'cui_str': 'Operative site'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0259768', 'cui_str': 'Wound dehiscence'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",,0.157012,"No significant differences regarding seroma, hematoma, wound dehiscence, and length of stay were observed between the groups. ","[{'ForeName': 'José', 'Initials': 'J', 'LastName': 'Bueno-Lledó', 'Affiliation': 'Surgical Unit of Abdominal Wall. Department of Digestive Surgery, ""La Fe"" Hospital, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Ascensión', 'Initials': 'A', 'LastName': 'Franco-Bernal', 'Affiliation': ''}, {'ForeName': 'María Teresa', 'Initials': 'MT', 'LastName': 'Garcia-Voz-Mediano', 'Affiliation': ''}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Torregrosa-Gallud', 'Affiliation': ''}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Bonafé', 'Affiliation': ''}]",Annals of surgery,['10.1097/SLA.0000000000004310'] 417,33197654,No effect of anodal tDCS on motor cortical excitability and no evidence for responders in a large double-blind placebo-controlled trial.,"BACKGROUND Transcranial direct current stimulation (tDCS) has emerged as a non-invasive brain stimulation technique. Most studies show that anodal tDCS increases cortical excitability. However, this effect has been found to be highly variable. OBJECTIVE To test the effect of anodal tDCS on cortical excitability and the interaction effect of two participant-specific factors that may explain individual differences in sensitivity to anodal tDCS: the Brain Derived Neurotrophic Factor Val66Met polymorphism (BDNF genotype) and the latency difference between anterior-posterior and lateromedial TMS pulses (APLM latency). METHODS In 62 healthy participants, cortical excitability over the left motor cortex was measured before and after anodal tDCS at 2 mA for 20 min in a pre-registered, double-blind, randomized, placebo-controlled trial with repeated measures. RESULTS We did not find a main effect of anodal tDCS, nor an interaction effect of the participant-specific predictors. Moreover, further analyses did not provide evidence for the existence of responders and non-responders. CONCLUSION This study indicates that anodal tDCS at 2 mA for 20 min may not reliably affect cortical excitability.",2021,"We did not find a main effect of anodal tDCS, nor an interaction effect of the participant-specific predictors.",['62 healthy participants'],"['Transcranial direct current stimulation (tDCS', 'placebo', 'anodal tDCS']","['motor cortical excitability', 'cortical excitability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C4277734', 'cui_str': 'Cortical Excitability'}]",62.0,0.431948,"We did not find a main effect of anodal tDCS, nor an interaction effect of the participant-specific predictors.","[{'ForeName': 'Zeb D', 'Initials': 'ZD', 'LastName': 'Jonker', 'Affiliation': 'Department of Neuroscience, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Rehabilitation Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands; Rijndam Rehabilitation Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Gaiser', 'Affiliation': 'Department of Neuroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Joke H M', 'Initials': 'JHM', 'LastName': 'Tulen', 'Affiliation': 'Department of Psychiatry, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Gerard M', 'Initials': 'GM', 'LastName': 'Ribbers', 'Affiliation': 'Department of Rehabilitation Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands; Rijndam Rehabilitation Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Maarten A', 'Initials': 'MA', 'LastName': 'Frens', 'Affiliation': 'Department of Neuroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Ruud W', 'Initials': 'RW', 'LastName': 'Selles', 'Affiliation': 'Department of Rehabilitation Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Plastic and Reconstructive Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands. Electronic address: r.selles@erasmusmc.nl.'}]",Brain stimulation,['10.1016/j.brs.2020.11.005'] 418,33202169,"Effect of Domperidone on Breast Milk Production in Mothers of Sick Neonates: A Randomized, Double-Blinded, Placebo-Controlled Trial.","Objective: Mothers of many preterm babies are unable to produce sufficient milk for their babies during the prolonged hospitalization. Domperidone stimulates the release of prolactin, thereby increasing breast milk production. The primary outcome was to study the efficacy of domperidone in augmenting breast milk production in mothers with lactation failure (LF). The secondary outcomes included the effect of domperidone on prolactin levels, adverse effects of domperidone, and outcome on breastfeeding rates at discharge. Materials and Methods: This was a randomized, double-blinded, placebo-controlled trial where mothers with LF were either allocated domperidone (10 mg) or placebo, 2 tablets three times a day for 14 days. Milk volumes were recorded daily for 14 days. Serum prolactin levels were measured at the start and at day 7 of study. Results: Out of 166 women eligible for the study, 119 (71.7%) mothers were able to increase their breast milk production without pharmacological treatment after being counseled on the advantages of human milk and proper breastfeeding management. Forty-seven mothers were finally enrolled in the study; 24 in the domperidone group (DG) and 23 in the placebo group (PG). Breast milk production increased from a baseline of 156 + 141.1 to 400.9 + 239.2 mL in the DG and increased from a baseline of 175.8 + 150.7 to 260.5 + 237.5 mL in the PG, after 14 days ( p  < 0.01). The prolactin levels in the DG and PG increased from 72.85 (22.2-167.15) and 42.33 (14.02-93.54) ng/mL, respectively, to 223.4 (49.79-280.2) ng/mL ( p  = 0.005) in the DG and 60.08 (14.31-132.14) ng/mL ( p  = 0.232) in the PG on the 7th day of treatment. No adverse effects were recorded. Ninety-five percent of babies in the DG were exclusively breastfeeding at hospital discharge, compared with 52.4% in the PG ( p  = 0.008). Conclusion: Domperidone treatment can result in an increase in breast milk production with no adverse effects. The study was registered with the Thai Clinical Trials Registry ID TCTR2020091008.",2021,The prolactin levels in the DG and PG increased from 72.85 (22.2-167.15) and 42.33 (14.02-93.54),"['Forty-seven mothers were finally enrolled in the study; 24 in the domperidone group (DG) and 23 in the placebo group (PG', '166 women eligible for the study, 119 (71.7', 'mothers with LF', 'Mothers of many preterm babies', 'mothers with lactation failure (LF', 'Mothers of Sick Neonates']","['placebo', 'Domperidone', 'domperidone', 'Placebo']","['Breast milk production', 'prolactin levels', 'adverse effects', 'breast milk production', 'Serum prolactin levels', 'prolactin levels, adverse effects of domperidone, and outcome on breastfeeding rates at discharge', 'Milk volumes', 'Breast Milk Production']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013015', 'cui_str': 'Domperidone'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C5191361', 'cui_str': '166'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infants'}, {'cui': 'C0152158', 'cui_str': 'Failure of lactation'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013015', 'cui_str': 'Domperidone'}]","[{'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0033371', 'cui_str': 'Prolactin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1277972', 'cui_str': 'Serum prolactin measurement'}, {'cui': 'C0013015', 'cui_str': 'Domperidone'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",166.0,0.509817,The prolactin levels in the DG and PG increased from 72.85 (22.2-167.15) and 42.33 (14.02-93.54),"[{'ForeName': 'Meera', 'Initials': 'M', 'LastName': 'Khorana', 'Affiliation': 'Neonatal Unit, Department of Pediatrics, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand.'}, {'ForeName': 'Panrada', 'Initials': 'P', 'LastName': 'Wongsin', 'Affiliation': 'Neonatal Unit, Department of Pediatrics, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand.'}, {'ForeName': 'Roongrawee', 'Initials': 'R', 'LastName': 'Torbunsupachai', 'Affiliation': 'Neonatal Unit, Department of Pediatrics, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand.'}, {'ForeName': 'Wiboon', 'Initials': 'W', 'LastName': 'Kanjanapattanakul', 'Affiliation': 'Neonatal Unit, Department of Pediatrics, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0234'] 419,33205201,Randomized comparison of oesophageal protection with a temperature control device: results of the IMPACT study.,"AIMS Thermal injury to the oesophagus is an important cause of life-threatening complication after ablation for atrial fibrillation (AF). Thermal protection of the oesophageal lumen by infusing cold liquid reduces thermal injury to a limited extent. We tested the ability of a more powerful method of oesophageal temperature control to reduce the incidence of thermal injury. METHODS AND RESULTS A single-centre, prospective, double-blinded randomized trial was used to investigate the ability of the ensoETM device to protect the oesophagus from thermal injury. This device was compared in a 1:1 randomization with a control group of standard practice utilizing a single-point temperature probe. In the protected group, the device maintained the luminal temperature at 4°C during radiofrequency (RF) ablation for AF under general anaesthesia. Endoscopic examination was performed at 7 days post-ablation and oesophageal injury was scored. The patient and the endoscopist were blinded to the randomization. We recruited 188 patients, of whom 120 underwent endoscopy. Thermal injury to the mucosa was significantly more common in the control group than in those receiving oesophageal protection (12/60 vs. 2/60; P = 0.008), with a trend toward reduction in gastroparesis (6/60 vs. 2/60, P = 0.27). There was no difference between groups in the duration of RF or in the force applied (P value range= 0.2-0.9). Procedure duration and fluoroscopy duration were similar (P = 0.97, P = 0.91, respectively). CONCLUSION Thermal protection of the oesophagus significantly reduces ablation-related thermal injury compared with standard care. This method of oesophageal protection is safe and does not compromise the efficacy or efficiency of the ablation procedure.",2021,"Thermal injury to the mucosa was significantly more common in the control group than in those receiving oesophageal protection (12/60 vs. 2/60; P = 0.008), with a trend toward reduction in gastroparesis (6/60 vs. 2/60, P = 0.27).","['188 patients, of whom 120 underwent endoscopy']",['oesophageal protection with a temperature control device'],"['gastroparesis', 'Procedure duration and fluoroscopy duration', 'duration of RF']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}]","[{'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}]",188.0,0.07525,"Thermal injury to the mucosa was significantly more common in the control group than in those receiving oesophageal protection (12/60 vs. 2/60; P = 0.008), with a trend toward reduction in gastroparesis (6/60 vs. 2/60, P = 0.27).","[{'ForeName': 'Lisa W M', 'Initials': 'LWM', 'LastName': 'Leung', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Abhay', 'Initials': 'A', 'LastName': 'Bajpai', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Zia', 'Initials': 'Z', 'LastName': 'Zuberi', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Li', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Norman', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Riyaz A', 'Initials': 'RA', 'LastName': 'Kaba', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Zaki', 'Initials': 'Z', 'LastName': 'Akhtar', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Banu', 'Initials': 'B', 'LastName': 'Evranos', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Hanney', 'Initials': 'H', 'LastName': 'Gonna', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Idris', 'Initials': 'I', 'LastName': 'Harding', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Manav', 'Initials': 'M', 'LastName': 'Sohal', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}, {'ForeName': 'Nawaf', 'Initials': 'N', 'LastName': 'Al-Subaie', 'Affiliation': 'Anesthetic Department, Anesthesia and Intensive Care Medicine, Kuwait Oil Company Ahmadi Hospital, Kuwait.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Louis-Auguste', 'Affiliation': ""Department of Gastroenterology, St. George's University Hospitals NHS Foundation Trust, St. George's, London, UK.""}, {'ForeName': 'Jamal', 'Initials': 'J', 'LastName': 'Hayat', 'Affiliation': ""Department of Gastroenterology, St. George's University Hospitals NHS Foundation Trust, St. George's, London, UK.""}, {'ForeName': 'Mark M', 'Initials': 'MM', 'LastName': 'Gallagher', 'Affiliation': ""Cardiology Department, Cardiology Clinical Academic Group, St. George's NHS Foundation Trust, London SW17 0QT, UK.""}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa276'] 420,33212271,Relationship of Topographic Distribution of Geographic Atrophy to Visual Acuity in Nonexudative Age-Related Macular Degeneration.,"PURPOSE To investigate the topographic distribution of geographic atrophy (GA) and to identify an anatomic endpoint that correlates with visual acuity (VA) in eyes with GA. DESIGN Retrospective analysis of a multicenter, prospective, randomized controlled trial. PARTICIPANTS The Age-Related Eye Disease Study participants with GA secondary to nonexudative age-related macular degeneration. METHODS We manually delineated GA on 1654 fundus photographs of 365 eyes. We measured GA areas in 9 subfields on the Early Treatment Diabetic Retinopathy Study (ETDRS) grid and correlated them with VA via a mixed-effects model. We determined the optimal diameter for the central zone by varying the diameter from 0 to 10 mm until the highest r 2 between GA area in the central zone and VA was achieved. We estimated the VA decline rate over 8 years using a linear mixed model. MAIN OUTCOME MEASURES Geographic atrophy area in macular subfields and VA. RESULTS The percentage of area affected by GA declined as a function of retinal eccentricity. GA area was higher in the temporal than the nasal region (1.30 ± 1.75 mm 2 vs. 1.10 ± 1.62 mm 2 ; P = 0.005) and in the superior than the inferior region (1.26 ± 1.73 mm 2 vs. 1.03 ± 1.53 mm 2 ; P < 0.001). Total GA area correlated poorly with VA (r 2  = 0.07). Among GA areas in 9 subfields, only GA area in the central zone was associated independently with VA (P < 0.001). We determined 1 mm as the optimal diameter for the central zone in which GA area correlated best with VA (r 2  = 0.45). On average, full GA coverage of the central 1-mm diameter zone corresponded to 34.8 letters' decline in VA. The VA decline rate was comparable between eyes with initial noncentral and central GA before GA covered the entire central 1-mm diameter zone (2.7 letters/year vs. 2.8 letters/year; P = 0.94). CONCLUSIONS The prevalence of GA varies significantly across different macular regions. Although total GA area was associated poorly with VA, GA area in the central 1-mm diameter zone was correlated significantly with VA and may serve as a surrogate endpoint in clinical trials.",2021,"GA area was higher in the temporal than nasal region (1.30 ± 1.75 vs. 1.10 ± 1.62 mm 2 ; P = 0.005), and in the superior than inferior region (1.26 ± 1.73 vs. 1.03 ± 1.53 mm 2 ; P < 0.001).","['We manually delineated GA on 1654 fundus photographs of 365 eyes', 'The Age-Related Eye Disease Study (AREDS) participants with GA secondary to nonexudative age-related macular degeneration', 'eyes with GA', 'Nonexudative Age-Related Macular Degeneration']",[],"['VA decline rate', 'GA area', 'GA area in macular subfields and VA', 'Total GA']","[{'cui': 'C1536085', 'cui_str': 'Dry Macular Degeneration'}, {'cui': 'C0016823', 'cui_str': 'Structure of fundus of eye'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0015397', 'cui_str': 'Disorder of eye'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C0271083', 'cui_str': 'Nonexudative age-related macular degeneration'}]",[],"[{'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C1536085', 'cui_str': 'Dry Macular Degeneration'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",1654.0,0.152891,"GA area was higher in the temporal than nasal region (1.30 ± 1.75 vs. 1.10 ± 1.62 mm 2 ; P = 0.005), and in the superior than inferior region (1.26 ± 1.73 vs. 1.03 ± 1.53 mm 2 ; P < 0.001).","[{'ForeName': 'Liangbo L', 'Initials': 'LL', 'LastName': 'Shen', 'Affiliation': 'Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Mengyuan', 'Initials': 'M', 'LastName': 'Sun', 'Affiliation': 'Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut.'}, {'ForeName': 'Aneesha', 'Initials': 'A', 'LastName': 'Ahluwalia', 'Affiliation': 'Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Benjamin K', 'Initials': 'BK', 'LastName': 'Young', 'Affiliation': 'Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Park', 'Affiliation': 'Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Cynthia A', 'Initials': 'CA', 'LastName': 'Toth', 'Affiliation': 'Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina.'}, {'ForeName': 'Eleonora M', 'Initials': 'EM', 'LastName': 'Lad', 'Affiliation': 'Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Lucian V', 'Initials': 'LV', 'LastName': 'Del Priore', 'Affiliation': 'Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut. Electronic address: lucian.delpriore@yale.edu.'}]",Ophthalmology. Retina,['10.1016/j.oret.2020.11.003'] 421,33214162,Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial).,"BACKGROUND Longstanding colonic IBD increases the risk of developing colorectal cancer. The utility of chromoendoscopy with standard-definition white light technology has been established. However, the use of high-definition virtual chromoendoscopy (HDV) in colitis surveillance remains undefined. OBJECTIVE To compare the performance of HDV (i-scan OE mode 2) with high-definition white light (HDWL) for detection of neoplasia in patients with IBD undergoing surveillance colonoscopy. Additionally, we assessed the utility of protocol-guided quadrantic non-targeted biopsies. DESIGN A multioperator randomised controlled trial was carried out in two centres in the UK. Total of 188 patients (101 men, mean age 54) with longstanding ulcerative or Crohn's colitis were randomised, prior to starting the surveillance colonoscopy, to using either HDV (n=94) or HDWL (n=94) on withdrawal. Targeted and quadrantic non-targeted biopsies were taken in both arms per-randomisation protocol. The primary outcome was the difference in neoplasia detection rate (NDR) between HDV and HDWL. RESULTS There was no significant difference between HDWL and HDV for neoplasia detection. The NDR was not significantly different for HDWL (24.2%) and HDV (14.9%) (p=0.14). All intraepithelial neoplasia (IEN) detected contained low-grade dysplasia only. A total of 6751 non-targeted biopsies detected one IEN only. The withdrawal time was similar in both arms of the study; median of 24 min (HDWL) versus 25.5 min (HDV). CONCLUSION HDV and HDWL did not differ significantly in the detection of neoplasia. Almost all neoplasia were detected on targeted biopsy or resection. Quadrantic non-targeted biopsies have negligible additional gain. TRIAL REGISTRATION NUMBER Clinical Trial.gov ID NCT02822352.",2021,The NDR was not significantly different for HDWL (24.2%) and HDV (14.9%) (p=0.14).,"['patients with IBD undergoing surveillance colonoscopy', 'two centres in the UK', 'A total of 6751 non-targeted biopsies detected one IEN only', ""188 patients (101 men, mean age 54) with longstanding ulcerative or Crohn's colitis""]","['HDV (n=94) or HDWL', 'protocol-guided quadrantic non-targeted biopsies', 'chromoendoscopy with standard-definition white light technology', 'virtual chromoendoscopy', 'high-definition white light (HDWL']","['neoplasia detection rate (NDR) between HDV and HDWL', 'withdrawal time', 'HDWL and HDV for neoplasia detection', 'HDV and HDWL', 'NDR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0878500', 'cui_str': 'Epithelial dysplasia'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0156147', 'cui_str': ""Crohn's disease of large bowel""}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0563228', 'cui_str': 'White light'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]","[{'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0563228', 'cui_str': 'White light'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",6751.0,0.390479,The NDR was not significantly different for HDWL (24.2%) and HDV (14.9%) (p=0.14).,"[{'ForeName': 'Kesavan', 'Initials': 'K', 'LastName': 'Kandiah', 'Affiliation': 'Department of Gastroenterology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.'}, {'ForeName': 'Sharmila', 'Initials': 'S', 'LastName': 'Subramaniam', 'Affiliation': 'Department of Gastroenterology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.'}, {'ForeName': 'Sreedhari', 'Initials': 'S', 'LastName': 'Thayalasekaran', 'Affiliation': 'Department of Gastroenterology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.'}, {'ForeName': 'Fergus Jq', 'Initials': 'FJ', 'LastName': 'Chedgy', 'Affiliation': 'Department of Gastroenterology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.'}, {'ForeName': 'Gaius', 'Initials': 'G', 'LastName': 'Longcroft-Wheaton', 'Affiliation': 'Department of Gastroenterology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Fogg', 'Affiliation': 'Department of Gastroenterology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Brown', 'Affiliation': 'School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.'}, {'ForeName': 'Samuel Cl', 'Initials': 'SC', 'LastName': 'Smith', 'Affiliation': 'Institute of Immunology and Immunotherapy, NIHR Wellcome Trust Clinical Research Facilities, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Marietta', 'Initials': 'M', 'LastName': 'Iacucci', 'Affiliation': 'Institute of Immunology and Immunotherapy, NIHR Wellcome Trust Clinical Research Facilities, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Pradeep', 'Initials': 'P', 'LastName': 'Bhandari', 'Affiliation': 'Department of Gastroenterology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK pradeep.bhandari@porthosp.nhs.uk.'}]",Gut,['10.1136/gutjnl-2020-320980'] 422,33160281,Effect of hemodiafiltration on measured physical activity: primary results of the HDFIT randomized controlled trial.,"BACKGROUND Dialysis patients are typically inactive and their physical activity (PA) decreases over time. Uremic toxicity has been suggested as a potential causal factor of low PA in dialysis patients. Post-dilution high-volume online hemodiafiltration (HDF) provides greater higher molecular weight removal and studies suggest better clinical/patient-reported outcomes compared with hemodialysis (HD). METHODS HDFIT was a randomized controlled trial at 13 clinics in Brazil that aimed to investigate the effects of HDF on measured PA (step counts) as a primary outcome. Stable HD patients (vintage 3-24 months) were randomized to receive HDF or high-flux HD. Treatment effect of HDF on the primary outcome from baseline to 3 and 6 months was estimated using a linear mixed-effects model. RESULTS We randomized 195 patients (HDF 97; HD 98) between August 2016 and October 2017. Despite the achievement of a high convective volume in the majority of sessions and a positive impact on solute removal, the treatment effect HDF on the primary outcome was +538 [95% confidence interval (CI) -330 to 1407] steps/24 h after dialysis compared with HD, and was not statistically significant. Despite a lack of statistical significance, the observed size of the treatment effect was modest and driven by steps taken between 1.5 and 24.0 h after dialysis, in particular between 20 and 24 h (+197 steps; 95% CI -95 to 488). CONCLUSIONS HDF did not have a statistically significant treatment effect on PA 24 h following dialysis, albeit effect sizes may be clinically meaningful and deserve further investigation.",2021,"Post-dilution high-volume online hemodiafiltration (HDF) provides greater higher molecular weight removal and studies suggest better clinical/patient-reported outcomes compared with hemodialysis (HD). ","['dialysis patients', 'Stable HD patients (vintage 3-24\u2009months', '195 patients (HDF 97; HD 98) between August 2016 and October 2017', '13 clinics in Brazil']","['Post-dilution high-volume online hemodiafiltration (HDF', 'hemodiafiltration', 'HDF', 'HDF or high-flux HD']","['Uremic toxicity', 'physical activity']","[{'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0206075', 'cui_str': 'Hemodiafiltration'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0445431', 'cui_str': 'After the filter'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0206075', 'cui_str': 'Hemodiafiltration'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",195.0,0.266364,"Post-dilution high-volume online hemodiafiltration (HDF) provides greater higher molecular weight removal and studies suggest better clinical/patient-reported outcomes compared with hemodialysis (HD). ","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Pecoits-Filho', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Larkin', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.'}, {'ForeName': 'Carlos Eduardo', 'Initials': 'CE', 'LastName': 'Poli-de-Figueiredo', 'Affiliation': 'Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Américo Lourenço', 'Initials': 'AL', 'LastName': 'Cuvello-Neto', 'Affiliation': 'Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil.'}, {'ForeName': 'Ana Beatriz Lesqueves', 'Initials': 'ABL', 'LastName': 'Barra', 'Affiliation': 'Fresenius Medical Care, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Priscila Bezerra', 'Initials': 'PB', 'LastName': 'Gonçalves', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.'}, {'ForeName': 'Shimul', 'Initials': 'S', 'LastName': 'Sheth', 'Affiliation': 'Renal Research Institute, New York, NY,\xa0USA.'}, {'ForeName': 'Murilo', 'Initials': 'M', 'LastName': 'Guedes', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Han', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.'}, {'ForeName': 'Viviane', 'Initials': 'V', 'LastName': 'Calice-Silva', 'Affiliation': 'Fundação Pró Rim, Joinville, SC, Brazil.'}, {'ForeName': 'Manuel Carlos Martins', 'Initials': 'MCM', 'LastName': 'de Castro', 'Affiliation': 'Instituto de Nefrologia de Taubaté, Taubaté, SP, Brazil.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kotanko', 'Affiliation': 'Renal Research Institute, New York, NY,\xa0USA.'}, {'ForeName': 'Thyago Proenca', 'Initials': 'TP', 'LastName': 'de Moraes', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.'}, {'ForeName': 'Jochen G', 'Initials': 'JG', 'LastName': 'Raimann', 'Affiliation': 'Renal Research Institute, New York, NY,\xa0USA.'}, {'ForeName': 'Maria Eugenia F', 'Initials': 'MEF', 'LastName': 'Canziani', 'Affiliation': 'Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association",['10.1093/ndt/gfaa173'] 423,33164264,Pulmonary Daoyin as a traditional Chinese medicine rehabilitation programme for patients with IPF: A randomized controlled trial.,"BACKGROUND AND OBJECTIVE IPF is a chronic progressive lung disease in which PR provides benefit for patients. PD, a TCM PR programme, has known effectiveness in COPD, but its utility in IPF is unknown. We investigated its effectiveness and safety in patients with IPF. METHODS A 6-month randomized controlled trial (RCT) was conducted in three Chinese clinics. Ninety-six participants diagnosed with IPF were randomly assigned to one of the three groups: the PD group received a PD programme two times a day, 5 days/week for 2 months, and the exercise group exercised via a stationary cycle ergometer, 30 min/day, 5 days/week for 2 months. Volunteers in the control group were advised to maintain their usual activities. Primary outcomes were changes from baseline in the 6MWD and HRQoL score on the SGRQ-I at 1 and 2 months (at the end of the intervention) and at 6 months (4 months after the intervention). Secondary outcomes measures included FVC, DL CO (% predicted) and the changes in mMRC. RESULTS The 6MWD was increased in the PD group compared to exercise and control groups. 6MWD increased by 60.44 m in the PD group, 32.16 m in the exercise group and 12.42 m in controls after the 2 months of rehabilitation programme. The between-group differences in the change from baseline were 28.78 m (95% CI: 0.54 to 56.01; P = 0.044) and 48.02 m (95% CI: 23.04 to 73.00; P < 0.001) at 2 months, and 25.61 m (95% CI: -0.67 to 51.89; P = 0.058) and 50.93 m (95% CI: 25.47 to 76.40; P < 0.001) at 6 months, respectively, including a difference exceeding the MCID. There was no significant change in the SGRQ-I score, the mMRC dyspnoea score, FVC and DL CO (% predicted) in either the PD or exercise groups. CONCLUSION Two months after the intervention, a clinically meaningful difference in 6MWD was observed favouring the PD programme. The PD programme is safe and effective as a rehabilitation intervention designed to increase exercise tolerance and is an appropriate substitute for PR.",2021,The PD programme is safe and effective as a rehabilitation intervention designed to increase exercise tolerance and is an appropriate substitute for PR.,"['patients with IPF', 'Ninety-six participants diagnosed with IPF', 'three Chinese clinics']","['exercise group exercised via a stationary cycle ergometer', 'PD programme']","['effectiveness and safety', 'SGRQ', 'FVC, DL CO (% predicted) and the changes in mMRC', 'mMRC dyspnoea score, FVC and DL CO', 'exercise tolerance', '6MWD and HRQoL score on the SGRQ', '6MWD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034069', 'cui_str': 'Fibrosis of lung'}, {'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439835', 'cui_str': 'Stationary'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",96.0,0.111005,The PD programme is safe and effective as a rehabilitation intervention designed to increase exercise tolerance and is an appropriate substitute for PR.,"[{'ForeName': 'Miao', 'Initials': 'M', 'LastName': 'Zhou', 'Affiliation': 'Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan and Education Ministry of P.R. China, Henan University of Chinese Medicine, Zhengzhou, China.'}, {'ForeName': 'Hailong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan and Education Ministry of P.R. China, Henan University of Chinese Medicine, Zhengzhou, China.'}, {'ForeName': 'Fenglei', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Department of Respiratory, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.'}, {'ForeName': 'Zhefeng', 'Initials': 'Z', 'LastName': 'Yu', 'Affiliation': 'Department of Respiratory, Ruzhou Hospital of Chinese Medicine, Pingdingshan, China.'}, {'ForeName': 'Chengbo', 'Initials': 'C', 'LastName': 'Yuan', 'Affiliation': 'Department of Respiratory, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Oliver', 'Affiliation': 'School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Jiansheng', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan and Education Ministry of P.R. China, Henan University of Chinese Medicine, Zhengzhou, China.'}]","Respirology (Carlton, Vic.)",['10.1111/resp.13972'] 424,33164282,Climbing up or falling down: Narcissism predicts physiological sensitivity to social status in children and their parents.,"Children's narcissism may be rooted in sensitivity to social status (i.e., prominence, respect, and influence in a social group), and this sensitivity might be shared with parents. Testing this idea, a randomized experiment examined how children with high narcissism levels and their parents respond to gains and losses of social status. On a simulated social media platform, children (N = 123, ages 8-13) competed with fictitious peers for status and were randomly assigned to gain or lose status. Unbeknownst to children, parents viewed the course of the task. Children's and parents' affective reactions during the task were measured with facial electromyography, which detects spontaneous facial muscle activity linked to positive affect (i.e., zygomaticus major activity, involved in smiling) and negative affect (i.e., corrugator supercilii activity, involved in frowning). Children with higher narcissism levels showed steeper increases in negative affect during status loss and steeper increases in both positive and negative affect during status gain. Their parents mirrored the steeper increase in positive affect during their child's status gain, but they did not mirror the increase in negative affect. These results suggest that children with high narcissism levels and their parents show intensified affective-motivational responses to children's status-relevant experiences. These responses may be transmitted from one generation to the other (e.g., genetically or through parent-child socialization).",2021,"Children's and parents' affective reactions during the task were measured with facial electromyography, which detects spontaneous facial muscle activity linked to positive affect (i.e., zygomaticus major activity, involved in smiling) and negative affect (i.e., corrugator supercilii activity, involved in frowning).","['children (N = 123, ages 8-13) competed with fictitious peers for status', 'Children and Their Parents', 'children with high narcissism levels and their parents']",[],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0027401', 'cui_str': 'Narcissism'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",[],[],123.0,0.0138956,"Children's and parents' affective reactions during the task were measured with facial electromyography, which detects spontaneous facial muscle activity linked to positive affect (i.e., zygomaticus major activity, involved in smiling) and negative affect (i.e., corrugator supercilii activity, involved in frowning).","[{'ForeName': 'Stathis', 'Initials': 'S', 'LastName': 'Grapsas', 'Affiliation': 'Department of Developmental Psychology, Tilburg University, Tilburg, the Netherlands.'}, {'ForeName': 'Jaap J A', 'Initials': 'JJA', 'LastName': 'Denissen', 'Affiliation': 'Department of Developmental Psychology, Tilburg University, Tilburg, the Netherlands.'}, {'ForeName': 'Hae Yeon', 'Initials': 'HY', 'LastName': 'Lee', 'Affiliation': 'Department of Psychology, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Bos', 'Affiliation': 'Institute of Education and Child Studies, Leiden University, Leiden, the Netherlands.'}, {'ForeName': 'Eddie', 'Initials': 'E', 'LastName': 'Brummelman', 'Affiliation': 'Research Institute of Child Development and Education, University of Amsterdam, Amsterdam, the Netherlands.'}]",Developmental science,['10.1111/desc.13062'] 425,33161458,Task Sharing or Task Dumping: Counsellors Experiences of Delivering a Psychosocial Intervention for Mental Health Problems in South Africa.,"Given task-sharing mental health counselling to non-specialist providers is a recognised strategy to increase service capacity, ensuring that their training, supervision, and support needs are met is necessary to facilitate the sustainable delivery of a high-quality service. Using in-depth interviews, we qualitatively explored the experiences of 18 facility-based counsellors (FBCs) tasked with delivering a counselling intervention within chronic disease services offered within primary care facilities participating in the project MIND cluster randomised controlled trial. Findings show that project MIND training with a strong emphasis on role playing and skills rehearsal improved FBCs' confidence and competence, complemented by highly structured supervision and debriefing provided by a registered counsellor, were key strategies for supporting the implementation of task-shared mental health counselling. FBCs perceived many benefits to providing mental health counselling in primary healthcare but systemic interventions are needed for sustained implementation.",2021,"Findings show that project MIND training with a strong emphasis on role playing and skills rehearsal improved FBCs' confidence and competence, complemented by highly structured supervision and debriefing provided by a registered counsellor, were key strategies for supporting the implementation of task-shared mental health counselling.",['Mental Health Problems in South Africa'],"['18 facility-based counsellors (FBCs) tasked with delivering a counselling intervention', 'Psychosocial Intervention', 'Task Sharing or Task Dumping']",[],"[{'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0629928,"Findings show that project MIND training with a strong emphasis on role playing and skills rehearsal improved FBCs' confidence and competence, complemented by highly structured supervision and debriefing provided by a registered counsellor, were key strategies for supporting the implementation of task-shared mental health counselling.","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Jacobs', 'Affiliation': 'Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Myers', 'Affiliation': 'Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'van der Westhuizen', 'Affiliation': 'Alan J. Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Brooke-Sumner', 'Affiliation': 'Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Sorsdahl', 'Affiliation': 'Alan J. Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. katherine.sorsdahl@uct.ac.za.'}]",Community mental health journal,['10.1007/s10597-020-00734-0'] 426,33200217,"Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial.","OBJECTIVES Connective tissue disease-related thrombocytopenia (CTD-TP) is a problematic disorder in clinical practice. Because the first-line therapy of glucocorticoid and/or immunosuppressants is not effective for refractory cases, alternative treatment approaches are urgently needed. The present study investigated the efficacy and safety of sirolimus in refractory CTD-TP patients. METHODS This single-centre, single-arm, phase II study enrolled 20 refractory CTD-TP patients between September 2017 and September 2018 (registered on ClinicalTrials.gov: NCT03688191). Oral sirolimus administration was dose-adjusted to maintain a therapeutic range of 6-15 ng/ml for 6 months. The primary endpoints were partial and complete remission rates at 6 months. RESULTS Twelve (60%) patients achieved the primary end point with a 50% complete remission rate after 6 months. Among the 14 SLE patients, the overall response rate was 71.4%, with a complete remission rate of 64.3%. None of the primary Sjögren's syndrome cases responded to sirolimus. There was no significant difference in baseline clinical characteristics or lymphocyte subpopulations between responders and non-responders. No severe side effect was detected during the study. CONCLUSION Sirolimus is an effective and safe treatment option for refractory CTD-TP patients. TRIAL REGISTRATION https://clinicaltrials.gov, NCT03688191.",2021,"Among the 14 SLE patients, the overall response rate was 71.4%, with a complete remission rate of 64.3%.","['refractory CTD-TP patients', 'patients with connective tissue disease-related refractory thrombocytopenia']","['sirolimus', 'Oral sirolimus', 'Sirolimus']","['partial and complete remission rates', 'complete remission rate', 'severe side effect', 'efficacy and safety', 'overall response rate', 'baseline clinical characteristics or lymphocyte subpopulations']","[{'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0009782', 'cui_str': 'Disorder of connective tissue'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C2826321', 'cui_str': 'Refractory thrombocytopenia'}]","[{'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0079720', 'cui_str': 'Lymphocyte Subpopulations'}]",20.0,0.0661919,"Among the 14 SLE patients, the overall response rate was 71.4%, with a complete remission rate of 64.3%.","[{'ForeName': 'Chanyuan', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': 'Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Xu', 'Affiliation': 'Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China.'}, {'ForeName': 'Mengtao', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China.'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': 'Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa645'] 427,33201130,Intermittent Pneumatic Compression in Addition to Standard Prophylaxis of Postoperative Venous Thromboembolism in Extremely High-risk Patients (IPC SUPER): A Randomized Controlled Trial.,"OBJECTIVE To assess the efficacy of adjunctive IPC to standard prophylaxis of postoperative VTE in patients at extremely high-risk. SUMMARY OF BACKGROUND DATA The standard prophylaxis for postoperative VTE is insufficient in extremely high-risk patients. It is unclear whether an adjunctive use of IPC would result in a lower incidence of postoperative venous thrombosis. METHODS We randomly assigned patients who underwent major surgery and had a Caprini score of ≥11 to receive either IPC in addition to standard prophylaxis with anti-embolic stockings (pressure of 18-21 mm Hg at the ankle) and low-molecular-weight heparin (IPC group) or standard prophylaxis alone (control group). The primary outcome was an asymptomatic venous thrombosis of the lower limbs, as detected by duplex ultrasound scan performed before inclusion and every 3-5 days after surgery. RESULTS A total of 407 patients underwent randomization, of which 204 were assigned to the IPC group and 203 to the control group. The primary outcome occurred in 1 (0.5%) patient in the IPC group and 34 (16.7%) patients in the control group [relative risk, 0.03, 95% confidential interval (CI): 0.01-0.21]. Pulmonary embolism occurred in none of the 204 patients in the IPC group and in 5 (2.5%) patients in the control group (relative risk, 0.09; 95% CI, 0.01-1.63), and postoperative death occurred in 6 (2.9%) patients in the IPC group and 10 (4.9%) in the control group (relative risk, 0.50; 95% CI, 0.50-1.60). CONCLUSIONS Among patients with a Caprini score of ≥11 who received standard prophylaxis for VTE, adjunctive IPC resulted in a significantly lower incidence of asymptomatic venous thrombosis.",2021,"Pulmonary embolism occurred in none of the 204 patients in the IPC group and in 5 (2.5%) patients in the control group (relative risk, 0.09; 95% CI, 0.01-1.63), and postoperative death occurred in 6 (2.9%) patients in the IPC group and 10 (4.9%) in the control group (relative risk, 0.50; 95% CI, 0.50-1.60). ","['patients at extremely high-risk', 'A total of 407 patients underwent randomization, of which 204 were assigned to the IPC group and 203 to the control group', 'Extremely High-risk Patients (IPC SUPER', 'We randomly assigned patients who underwent major surgery and had a Caprini score of ≥11 to receive either', 'patients with a Caprini score of ≥11 who received']","['Intermittent Pneumatic Compression', 'adjunctive IPC', 'standard prophylaxis for VTE, adjunctive IPC', 'IPC', 'IPC in addition to standard prophylaxis with anti-embolic stockings (pressure of 18-21\u200amm Hg at the ankle) and low-molecular-weight heparin (IPC group) or standard prophylaxis alone (control group']","['Pulmonary embolism', 'asymptomatic venous thrombosis', 'asymptomatic venous thrombosis of the lower limbs', 'postoperative death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205403', 'cui_str': 'Extreme'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0630906', 'cui_str': 'vinyltriethoxysilane'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0445269', 'cui_str': 'Socks'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0019139', 'cui_str': 'Low molecular weight heparin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0277599', 'cui_str': 'Postoperative death'}]",407.0,0.212382,"Pulmonary embolism occurred in none of the 204 patients in the IPC group and in 5 (2.5%) patients in the control group (relative risk, 0.09; 95% CI, 0.01-1.63), and postoperative death occurred in 6 (2.9%) patients in the IPC group and 10 (4.9%) in the control group (relative risk, 0.50; 95% CI, 0.50-1.60). ","[{'ForeName': 'Kirill', 'Initials': 'K', 'LastName': 'Lobastov', 'Affiliation': 'Department of General Surgery and Radiology, Pirogov Russian National Research Medical University, Moscow, Russian Federation.'}, {'ForeName': 'Ekaterina', 'Initials': 'E', 'LastName': 'Sautina', 'Affiliation': 'Department of General Surgery and Radiology, Pirogov Russian National Research Medical University, Moscow, Russian Federation.'}, {'ForeName': 'Eleanora', 'Initials': 'E', 'LastName': 'Alencheva', 'Affiliation': 'Department of Surgery and Endoscopy, Central State Medical Academy of the Presidents Administration of the Russian Federation, Moscow, Russian Federation.'}, {'ForeName': 'Astanda', 'Initials': 'A', 'LastName': 'Bargandzhiya', 'Affiliation': 'Department of General Surgery and Radiology, Pirogov Russian National Research Medical University, Moscow, Russian Federation.'}, {'ForeName': 'Ilya', 'Initials': 'I', 'LastName': 'Schastlivtsev', 'Affiliation': 'Department of General Surgery and Radiology, Pirogov Russian National Research Medical University, Moscow, Russian Federation.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Barinov', 'Affiliation': 'Department of Surgery and Endoscopy, Central State Medical Academy of the Presidents Administration of the Russian Federation, Moscow, Russian Federation.'}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Laberko', 'Affiliation': 'Department of General Surgery and Radiology, Pirogov Russian National Research Medical University, Moscow, Russian Federation.'}, {'ForeName': 'Grigoriy', 'Initials': 'G', 'LastName': 'Rodoman', 'Affiliation': 'Department of General Surgery and Radiology, Pirogov Russian National Research Medical University, Moscow, Russian Federation.'}, {'ForeName': 'Valeriy', 'Initials': 'V', 'LastName': 'Boyarintsev', 'Affiliation': 'Department of Surgery and Endoscopy, Central State Medical Academy of the Presidents Administration of the Russian Federation, Moscow, Russian Federation.'}]",Annals of surgery,['10.1097/SLA.0000000000004556'] 428,33214000,Would creatine supplementation augment exercise performance during a low carbohydrate high fat diet?,"Low carbohydrate high fat (LCHF) diets are emerging in popularity. Several athletics have adopted LCHF diets in an attempt to improve exercise performance and body composition by enhancing fat utilization. However, these diets impair maximal and supramaximal exercise performance due to limited glycogen stores as well as increasing ratings of perceived exertion (RPE). All of these factors may impact training volume and compliance, leading to less optimal training adaptations over time. In contrast, LCHF diets is an effective strategy for weight and fat mass loss and is beneficial for a variety of metabolic processes. One potential nutritional strategy to off-set the negative aspects of a LCHF is creatine (Cr). Creatine supplementation has been shown to increase muscle power output and reduce the rate of fatigue; thereby allowing individuals to work at a higher intensity for a greater duration. Furthermore, Cr supplementation may positively enhance body composition (gains in muscle mass and possibly aid in fat mass loss). Despite the popularity of both LCHF and creatine supplementation, there is no data available investigating the effects of Cr supplementation on exercise performance and body composition during LCHF diets in humans. We would hypothesize that Cr supplementation may augment exercise performance (anerobic power and strength) during a LCHF diet compared to a LCHF diet and placebo. In addition, combining Cr with a LCHF diet would further increase body fat loss and improve body composition compared to a LCHF diet and/or low-fat diets (LFDs) placebo. Our hypotheses would be under the assumption that total caloric intake and protein intake are matched. Future research is warranted to examine chronic exercise with LCHF diets with and without creatine and compare performance and body composition changes to high carbohydrate diets.",2021,We would hypothesize that Cr supplementation may augment exercise performance (anerobic power and strength) during a LCHF diet compared to a LCHF diet and placebo.,['humans'],"['Low carbohydrate high fat (LCHF) diets', 'Creatine supplementation', 'LCHF diets', 'creatine supplementation', 'LCHF diet and placebo', 'Cr supplementation']","['exercise performance and body composition', 'exercise performance (anerobic power and strength', 'body fat loss and improve body composition']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0521974', 'cui_str': 'High fat diet'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0424630', 'cui_str': 'Loss of body fat - finding'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0248571,We would hypothesize that Cr supplementation may augment exercise performance (anerobic power and strength) during a LCHF diet compared to a LCHF diet and placebo.,"[{'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Kaviani', 'Affiliation': 'School of Nutrition and Dietetics, Faculty of Pure and Applied Science, Acadia University, Wolfville, Nova Scotia B4P 2R6, Canada. Electronic address: Mojtaba.kaviani@acadiau.ca.'}, {'ForeName': 'Azimeh', 'Initials': 'A', 'LastName': 'Izadi', 'Affiliation': 'Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: izadia@tbzmed.ac.ir.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Heshmati', 'Affiliation': 'Department of Nutritional Science, School of Nutritional Science and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]",Medical hypotheses,['10.1016/j.mehy.2020.110369'] 429,33214446,"Preoperative Hepatic and Regional Arterial Chemotherapy in Patients Who Underwent Curative Colorectal Cancer Resection: A Prospective, Multi-center, Randomized Controlled Trial.","OBJECTIVE To evaluate the effects of the addition of preoperative hepatic and regional arterial chemotherapy (PHRAC) on prognosis of stage II and III colorectal cancer (CRC) in a multicenter setting. SUMMARY OF BACKGROUND DATA Our previous single-center pilot trial suggested that PHRAC in combination with surgical resection could reduce the occurrence of liver metastasis (LM) and improve survival in CRC patients. METHODS A prospective multi-center randomized controlled trial was conducted from December 2008 to December 2012 at 5 hospitals in China. Eligible patients with clinical stage II or III CRC who underwent curative resection were randomized to receive PHRAC plus adjuvant therapy (PHRAC arm) or adjuvant therapy alone (control arm). The primary endpoint was DFS. Secondary endpoints were cumulative LM rates, overall survival (OS), and safety (NCT00643877). RESULTS A total of 688 patients from 5 centers in China were randomly assigned (1:1) to each arm. The five-year DFS rate was 77% in the PHRAC arm and 65% in the control arm (HR = 0.61, 95% CI 0.46-0.81; P = 0.001). The 5-year LM rates were 7% and 16% in the PHRAC and control arms, respectively (HR = 0.37, 95% CI 0.22-0.63; P < 0.001). The 5-year OS rate was 84% in the PHRAC arm and 76% in the control arm (HR = 0.61, 95% CI 0.43-0.86; P = 0.005). There were no significant differences regarding treatment related morbidity or mortality between the two arms. CONCLUSIONS The addition of PHRAC could improve DFS in patients with stage II and III CRC. It reduced the incidence of LM and improved OS without compromising patient safety. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT00643877.",2021,"There were no significant differences regarding treatment related morbidity or mortality between the two arms. ","['December 2008 to December 2012 at 5 hospitals in China', 'Patients', '688 patients from 5 centers in China', 'patients with stage II and III CRC', 'Eligible patients with clinical stage II or III CRC who underwent curative resection']","['Curative Colorectal Cancer Resection', 'PHRAC', 'preoperative hepatic and regional arterial chemotherapy (PHRAC', 'PHRAC plus adjuvant therapy (PHRAC arm) or adjuvant therapy alone (control arm', 'Preoperative Hepatic and Regional Arterial Chemotherapy']","['five-year OS rate', 'prognosis of stage II and III colorectal cancer (CRC', 'five-year LM rates', 'incidence of LM and improved OS', 'cumulative LM rates, overall survival (OS) and safety (NCT00643877', 'disease-free survival (DFS', 'morbidity or mortality', 'five-year DFS rate']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0205571', 'cui_str': 'Clinical stage II'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0494165', 'cui_str': 'Secondary malignant neoplasm of liver'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",688.0,0.242269,"There were no significant differences regarding treatment related morbidity or mortality between the two arms. ","[{'ForeName': 'Dexiang', 'Initials': 'D', 'LastName': 'Zhu', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jianguo', 'Initials': 'J', 'LastName': 'Xia', 'Affiliation': 'Department of General Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Gu', 'Affiliation': ""Department of General Surgery, The Affiliated Shanghai Ninth People's Hospital of Shanghai Jiao Tong University Medical School, Shanghai, China.""}, {'ForeName': 'Jianjiang', 'Initials': 'J', 'LastName': 'Lin', 'Affiliation': 'Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Kefeng', 'Initials': 'K', 'LastName': 'Ding', 'Affiliation': 'Department of Surgical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Zhou', 'Affiliation': 'Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Liang', 'Affiliation': 'Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Tianshu', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Chunzhi', 'Initials': 'C', 'LastName': 'Qin', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Ren', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yunshi', 'Initials': 'Y', 'LastName': 'Zhong', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Zhiping', 'Initials': 'Z', 'LastName': 'Yan', 'Affiliation': 'Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jiemin', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jingwen', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Wenju', 'Initials': 'W', 'LastName': 'Chang', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Shaokang', 'Initials': 'S', 'LastName': 'Zhan', 'Affiliation': 'Department of Statistics, School of Public Health, Fudan University, Shanghai, China.'}, {'ForeName': 'Yongbin', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Department of General Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Haizhong', 'Initials': 'H', 'LastName': 'Huo', 'Affiliation': ""Department of General Surgery, The Affiliated Shanghai Ninth People's Hospital of Shanghai Jiao Tong University Medical School, Shanghai, China.""}, {'ForeName': 'Fanlong', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Junhui', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Xinyu', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jianmin', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}]",Annals of surgery,['10.1097/SLA.0000000000004558'] 430,33218878,"The Effect of Preoperative Oral Versus Parenteral Dextrose Supplementation on Pain, Nausea, and Quality of Recovery After Laparoscopic Cholecystectomy.","PURPOSE Earlier studies suggest that carbohydrate loading is effective in reducing preoperative nausea. This study was conducted to investigate the effect of preoperative oral versus parenteral carbohydrate loading on the postoperative pain, nausea, and quality of recovery (QoR). DESIGN Three-arm randomized, single-blind clinical trial. METHODS In this study, 95 adult patients scheduled for elective laparoscopic cholecystectomy were randomly assigned into three groups of preoperative intravenous dextrose 10% infusion, oral carbohydrate (OCH)-rich drink, and control. The pain and nausea severity scores were measured during recovery, 6 hours, and 24 hours thereafter. The 40-item QoR score was evaluated the day after surgery. FINDINGS In recovery, nausea severity was comparable among three groups, whereas pain score in the OCH group was significantly less than the controls (P = .009). Pain score in patients who received intravenous dextrose was mediocre and not statistically different from two other groups. Six and 24 hours after surgery, nausea and pain scores in OCH and dextrose infusion groups were significantly lower than the control group (P < .05). The 40-item QoR score was significantly higher in intervention groups than control participants (P < .05). Blood glucose levels were comparable in three groups before and after surgery. CONCLUSIONS Preoperative carbohydrate loading significantly improves the QoR after laparoscopic cholecystectomy without significant effect on blood glucose levels. Oral route more effectively controls nausea and pain than parenteral dextrose administration.",2021,The 40-item QoR score was significantly higher in intervention groups than control participants (P < .05).,"['95 adult patients scheduled for elective laparoscopic cholecystectomy', 'After Laparoscopic Cholecystectomy']","['carbohydrate loading', 'preoperative intravenous dextrose 10% infusion, oral carbohydrate (OCH)-rich drink, and control', 'preoperative oral versus parenteral carbohydrate loading', 'Preoperative Oral Versus Parenteral Dextrose Supplementation', 'intravenous dextrose']","['pain and nausea severity scores', 'postoperative pain, nausea, and quality of recovery (QoR', 'Blood glucose levels', 'QoR', 'pain score', 'blood glucose levels', 'preoperative nausea', 'Pain, Nausea, and Quality of Recovery', 'Pain score', 'nausea severity', '40-item QoR score', 'nausea and pain scores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}]","[{'cui': 'C4277655', 'cui_str': 'Carbohydrate Loading Diet'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",95.0,0.0459098,The 40-item QoR score was significantly higher in intervention groups than control participants (P < .05).,"[{'ForeName': 'Seyed Hamzeh', 'Initials': 'SH', 'LastName': 'Mousavie', 'Affiliation': 'Department of Surgery, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Negahi', 'Affiliation': 'Department of Surgery, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Parisa', 'Initials': 'P', 'LastName': 'Hosseinpour', 'Affiliation': 'Department of Surgery, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Masood', 'Initials': 'M', 'LastName': 'Mohseni', 'Affiliation': 'Department of Anesthesiology, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Masood.mohseni@gmail.com.'}, {'ForeName': 'Shima', 'Initials': 'S', 'LastName': 'Movassaghi', 'Affiliation': 'Department of Anesthesiology, Iran University of Medical Sciences, Tehran, Iran.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.07.002'] 431,33217593,Effect of Toremifene on Endometrium and Neurocognitive Function in Patients with Breast Cancer Based on Resting-State Functional Magnetic Resonance Imaging.,"In this study, the characteristics of hemodynamic changes with use of toremifene before and after neoadjuvant chemotherapy in breast cancer treatment were analyzed using resting-state functional magnetic resonance imaging. Also, the effect of toremifene on the quality of life of patients with advanced breast cancer was analyzed. The study population comprised 100 patients who received endocrine therapy after breast cancer surgery in our hospital from January 2016 to January 2019. Patients were randomly divided into an observation group and a control group, with 50 cases in each group. The observation group was treated with tamoxifen combined with toremifene treatment; the control group was treated with toremifene. Before and after chemotherapy, the same scheme was used to perform dynamic contrast-enhanced imaging of the breast using a 1.5T superconducting scanner with 3 mL/second bolus injection of adiphenine meglumine 0.2 mmol/kg. Semiquantitative blood flow measurement was completed on the workstation and before and after chemotherapy to compare results. The patient's quality of life, progesterone and estrogen levels, social function, physical function, mental function, and material function were analyzed. The mean values of the early enhancement parameters Efirst, Vfirst, Ee, and Ve before chemotherapy were greater than in the residual lesions after chemotherapy (P < 0.5). The semiquantitative study of resting brain function before and after breast cancer neoadjuvant chemotherapy showed that the hemodynamics of the residual lesions were significantly reduced, and the blood flow rate was significantly reduced. Compared with the clinical effect of tamoxifen in the treatment of breast cancer after surgery, tamoxifen combined with toremifene has more advantages in improving quality of life, improving progesterone levels, and reducing estrogen levels, and it has no detrimental effects on the endometrium.",2021,"The mean values of the early enhancement parameters Efirst, Vfirst, Ee and Ve before chemotherapy were greater than the residual lesions after chemotherapy (P<0.5).","['advanced breast cancer', 'after breast cancer surgery in our hospital from January 2016 to January 2019 were collected as the research objects', '100 patients who received', 'Patients with Breast Cancer Based on Resting State Functional MRI']","['adiphenine meglumine', 'tamoxifen Combined toremifene', 'toremifene', 'endocrine therapy', 'Toremifene', 'tamoxifen']","['blood flow rate', 'mean values of the early enhancement parameters Efirst, Vfirst, Ee and Ve before chemotherapy', 'quality of life, progesterone, estrogenic levels, social function, physical function, mental function, and material function', 'Endometrium and Neurocognitive Function', 'hemodynamic of the residual lesions']","[{'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0001521', 'cui_str': 'adiphenine'}, {'cui': 'C0025179', 'cui_str': 'Meglumine'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}, {'cui': 'C0076836', 'cui_str': 'Toremifene'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}]","[{'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0563143', 'cui_str': 'Mental function'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0014180', 'cui_str': 'Endometrial structure'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",100.0,0.0129719,"The mean values of the early enhancement parameters Efirst, Vfirst, Ee and Ve before chemotherapy were greater than the residual lesions after chemotherapy (P<0.5).","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': ""Department of Obstetrics and Gynecology, Shanghai Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Yijin', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': ""Department of Obstetrics and Gynecology, Shanghai Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Ma', 'Affiliation': ""Department of Obstetrics and Gynecology, Shanghai Sixth People's Hospital, Shanghai, China. Electronic address: mali4541258@yeah.net.""}, {'ForeName': 'Joh', 'Initials': 'J', 'LastName': 'Nowen', 'Affiliation': 'Department of Electrical and Electronics Engineering, Istanbul University, Istanbul, Turkey.'}]",World neurosurgery,['10.1016/j.wneu.2020.11.051'] 432,33220115,Effectiveness of training stop-smoking advisers to deliver cessation support to the UK national proposed standard versus usual care in Malaysia: a two-arm cluster-randomized controlled trial.,"AIMS To assess the effectiveness of training stop smoking services providers in Malaysia to deliver support for smoking cessation based on the UK National Centre for Smoking Cessation and Training (NCSCT) standard treatment programme compared with usual care. DESIGN Two-arm cluster-randomized controlled effectiveness trial across 19 sites with follow-up at 4-week, 3-month, and 6-month. SETTING Stop smoking services operating in public hospitals in Malaysia. PARTICIPANTS Five hundred and two smokers [mean ± standard deviation (SD), age 45.6 (13.4) years; 97.4% male] attending stop smoking services in hospital settings in Malaysia: 330 in 10 hospitals in the intervention condition and 172 in nine hospitals in the control condition. INTERVENTION AND COMPARATOR The intervention consisted of training stop-smoking practitioners to deliver support and follow-up according to the NCSCT Standard Treatment Programme. The comparator was usual care (brief support and follow-up). MEASUREMENTS The primary outcome was continuous tobacco smoking abstinence up to 6 months in smokers who received smoking cessation treatment, verified by expired-air carbon monoxide (CO) concentration. Secondary outcomes were continuous CO-verified tobacco smoking abstinence up to 4 weeks and 3 months. RESULTS Follow-up rates at 4 weeks, 3 months and 6 months were 80.0, 70.6 and 53.3%, respectively, in the intervention group and 48.8, 30.8 and 23.3%, respectively, in the control group. At 6-month follow-up, 93 participants in the intervention group and 19 participants in the control group were abstinent from smoking, representing 28.2 versus 11.0% in an intention-to-treat (ITT) analysis assuming that participants with missing data had resumed smoking, and 52.8 versus 47.5% in a follow-up-only (FUO) analysis. Unadjusted odds ratios (accounting for clustering) were 5.04, (95% confidence interval (CI) = 1.22-20.77, P = 0.025) and 1.70, (95% CI = 0.25-11.53, P = 0.589) in the ITT and FUO analyses, respectively. Abstinence rates at 4 week and 3 month follow-ups were significantly higher in the intervention versus control group in the ITT but not the FUO analysis. CONCLUSIONS On an intention-to-treat analysis with missing-equals-smoking imputation, training Malaysian stop smoking service providers in the UK National Centre for Smoking Cessation and Training standard treatment programme appeared to increase 6 month continuous abstinence rates in smokers seeking help with stopping compared with usual care. However, the effect may have been due to increasing follow-up rates.",2021,"Abstinence rates at 4-week and 3-month follow-ups were significantly higher in the intervention versus control group in the ITT but not the FUO analysis. ","['Stop smoking services operating in public hospitals in Malaysia', 'Malaysia to deliver support for smoking cessation based on the UK National Centre for Smoking Cessation and Training (NCSCT', '502 smokers (mean[SD] age 45.6[13.4] years; 97.4% male) attending stop smoking services in hospital settings in Malaysia: 330 in 10 hospitals in the intervention condition and 172 in nine hospitals in the control condition', 'Malaysia']","['training stop-smoking practitioners to deliver support and follow-up according to the NCSCT Standard Treatment Programme', 'training stop-smoking advisers']","['continuous CO-verified tobacco smoking abstinence', 'Abstinence rates', 'continuous tobacco smoking abstinence up to 6 months in smokers who received smoking cessation treatment, verified by expired-air carbon monoxide (CO) concentration']","[{'cui': 'C0425310', 'cui_str': 'Stopped smoking'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0020022', 'cui_str': 'Public Hospitals'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4517719', 'cui_str': '330'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0425310', 'cui_str': 'Stopped smoking'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0453996', 'cui_str': 'Tobacco smoking behavior - finding'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0225387', 'cui_str': 'Exhaled air'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",502.0,0.049221,"Abstinence rates at 4-week and 3-month follow-ups were significantly higher in the intervention versus control group in the ITT but not the FUO analysis. ","[{'ForeName': 'Lei Hum', 'Initials': 'LH', 'LastName': 'Wee', 'Affiliation': 'Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'West', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Guat Hiong', 'Initials': 'GH', 'LastName': 'Tee', 'Affiliation': 'Ministry of Health, Institute for Public Health, Malaysia.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Yeap', 'Affiliation': 'Stats Consulting Sdn. Bhd, Malaysia.'}, {'ForeName': 'Caryn Mei Hsien', 'Initials': 'CMH', 'LastName': 'Chan', 'Affiliation': 'Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Bee Kiau', 'Initials': 'BK', 'LastName': 'Ho', 'Affiliation': 'Ministry of Health, Bandar Botanic Health Centre, Malaysia.'}, {'ForeName': 'Komathi', 'Initials': 'K', 'LastName': 'Perialathan', 'Affiliation': 'Ministry of Health, Institute of Health Behavioural Research, Malaysia.'}, {'ForeName': 'Mohamad Haniki', 'Initials': 'MH', 'LastName': 'Nik Mohamed', 'Affiliation': 'International Islamic University Malaysia, Malaysia.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Michie', 'Affiliation': 'Centre for Behaviour Change, University College London, London, UK.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Jackson', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}]","Addiction (Abingdon, England)",['10.1111/add.15346'] 433,33226176,The comparative study of efficacy between 1064-nm long-pulsed Nd:YAG laser and 595-nm pulsed dye laser for the treatment of acne vulgaris.,"BACKGROUND The popularity of laser therapy in acne treatment has been increasing recently due to its safety, effectiveness, and convenience. Both 595-nm pulsed dye laser (PDL) and 1064-nm long-pulsed neodymium:yttrium-aluminum-garnet laser (Nd:YAG) have been successful in treating inflammatory acne lesions. However, clinical data from controlled comparative studies are still lacking. AIMS To compare the clinical efficacy of 1064-nm Nd:YAG with 595-nm PDL for the treatment of acne vulgaris. METHODS Thirty-four participants with mild to moderate facial acne were enrolled and then randomized to receive three, 2-week interval treatments with 1064-nm Nd:YAG on one side of the face and 595-nm PDL on the other side. Clinical assessments including acne lesion counts, acne erythema grading, and erythema index were performed at baseline, 2nd, 4th, and 8th week. Participants' satisfaction, preference, and adverse effects were recorded. RESULTS As compared with baseline, the significant reduction of mean inflammatory acne lesion counts, acne erythema grading, and erythema index was demonstrated on 595-nm PDL-treated sides and 1064-nm Nd:YAG-treated sides. However, there were no significant differences between both sides. The participants were satisfied with both laser treatments, but the participants preferred 1064-nm Nd:YAG over 595-nm PDL treatment. The adverse effects were less on 1064 nm Nd: YAG-treated sides. CONCLUSIONS 1064-nm Nd:YAG and 595-nm PDL treatments are equally effective in reducing inflammatory acne lesions and acne erythema in mild to moderate facial acne vulgaris.",2021,The adverse effects were less on 1064 nm,"['acne vulgaris', 'Thirty-four participants with mild to moderate facial acne']","['Nd:YAG', '595-nm pulsed dye laser (PDL) and 1064-nm long-pulsed neodymium:yttrium-aluminum-garnet laser', '1064-nm long-pulsed Nd:YAG laser and 595-nm pulsed dye laser', '1064-nm Nd:YAG with 595-nm PDL']","['inflammatory acne lesions and acne erythema', 'satisfaction, preference, and adverse effects', 'acne lesion counts, acne erythema grading, and erythema index', 'mean inflammatory acne lesion counts, acne erythema grading, and erythema index', 'adverse effects']","[{'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}]","[{'cui': 'C0027599', 'cui_str': 'Neodymium'}, {'cui': 'C0587723', 'cui_str': 'YAG - laser'}, {'cui': 'C5191367', 'cui_str': '595'}, {'cui': 'C0392258', 'cui_str': 'Dye laser device'}, {'cui': 'C1289859', 'cui_str': 'Pulsed dye laser device'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}]","[{'cui': 'C1998083', 'cui_str': 'Inflammatory acne'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",34.0,0.0215656,The adverse effects were less on 1064 nm,"[{'ForeName': 'Napith', 'Initials': 'N', 'LastName': 'Chalermsuwiwattanakan', 'Affiliation': 'Skin Center, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.'}, {'ForeName': 'Salinee', 'Initials': 'S', 'LastName': 'Rojhirunsakool', 'Affiliation': 'Skin Center, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.'}, {'ForeName': 'Nanticha', 'Initials': 'N', 'LastName': 'Kamanamool', 'Affiliation': 'Department of Preventive and Social Medicine, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.'}, {'ForeName': 'Silada', 'Initials': 'S', 'LastName': 'Kanokrungsee', 'Affiliation': 'Skin Center, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.'}, {'ForeName': 'Montree', 'Initials': 'M', 'LastName': 'Udompataikul', 'Affiliation': 'Skin Center, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13832'] 434,33231771,Effect of standardized post-coercion review session on symptoms of PTSD: results from a randomized controlled trial.,"OBJECTIVE Post-coercion review is increasingly regarded as a mean to reduce the negative consequences of coercive interventions, including the development of posttraumatic symptoms. However, the efficacy of this intervention in preventing posttraumatic symptoms or PTSD has not been sufficiently studied. The objective of this study is to examine the influence of a single, standardized post-coercion review session on the development or exacerbation of PTSD symptoms in patients with psychotic disorders. METHODS In a multi-center, two-armed, randomized controlled trial, patients who experienced coercive interventions during current hospitalization were either randomized to standard treatment or an intervention group receiving a guideline-based, standardized reflecting review session. Factorial MANCOVA and subsequent ANCOVAs investigated the effects of the post-coercion reflecting review session on post-traumatic symptoms as measured by the subscales of the Impact of Events Scale-Revised (IES-R). Similarly, the effect of the intervention on the intensity of the peritraumatic reactions measured by the Peritraumatic Distress Inventory (PDI) was analyzed by conducting a factorial ANCOVA. RESULTS N = 82 patients were included in an intention-to-treat analysis. MANCOVA and post hoc ANCOVAs revealed a significant main effect of the intervention for the IES-R subscales intrusion and hyperarousal, when controlling for levels of peritraumatic distress, whereby intervention group participants presented lower respective mean scores. There was no significant difference regarding the intensity of the peritraumatic reaction. CONCLUSION Standardized post-coercion review contributes to a reduction of the burden of PTSD symptoms in patients with psychotic disorders experiencing coercive interventions in acute settings and shall be recommended as a measure of trauma-informed care. The trial was registered at ClinicalTrials.gov (ID NCT03512925) on 01/30/2018 (retrospectively registered).",2021,"MANCOVA and post hoc ANCOVAs revealed a significant main effect of the intervention for the IES-R subscales intrusion and hyperarousal, when controlling for levels of peritraumatic distress, whereby intervention group participants presented lower respective mean scores.","['patients with psychotic disorders experiencing coercive interventions in acute settings', 'patients who experienced coercive interventions during current hospitalization', 'patients with psychotic disorders', '82 patients were included in an intention-to-treat analysis', 'N\u2009']","['standardized post-coercion review session', 'intervention group receiving a guideline-based, standardized reflecting review session']","['levels of peritraumatic distress', 'symptoms of PTSD', 'IES-R subscales intrusion and hyperarousal', 'intensity of the peritraumatic reaction', 'intensity of the peritraumatic reactions', 'Peritraumatic Distress Inventory (PDI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0009236', 'cui_str': 'Coercion'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C3472482', 'cui_str': 'Impact of event scale revised'}, {'cui': 'C4552570', 'cui_str': 'Hyperarousal'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",82.0,0.1483,"MANCOVA and post hoc ANCOVAs revealed a significant main effect of the intervention for the IES-R subscales intrusion and hyperarousal, when controlling for levels of peritraumatic distress, whereby intervention group participants presented lower respective mean scores.","[{'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Wullschleger', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Campus Charité Mitte, Berlin, Germany. alexandre.wullschleger@hcuge.ch.'}, {'ForeName': 'Angelika', 'Initials': 'A', 'LastName': 'Vandamme', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Campus Charité Mitte, Berlin, Germany.'}, {'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Mielau', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Campus Charité Mitte, Berlin, Germany.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Renner', 'Affiliation': 'Steinbeis Transfer Institute Medical Psychology, Steinbeis-Hochschule Berlin, Berlin, Germany.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Bermpohl', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Campus Charité Mitte, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Heinz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Campus Charité Mitte, Berlin, Germany.'}, {'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Montag', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Campus Charité Mitte, Berlin, Germany.'}, {'ForeName': 'Lieselotte', 'Initials': 'L', 'LastName': 'Mahler', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Campus Charité Mitte, Berlin, Germany.'}]",European archives of psychiatry and clinical neuroscience,['10.1007/s00406-020-01215-x'] 435,33228654,Comparison of self-report and administrative data sources to capture health care resource use in people with chronic obstructive pulmonary disease following pulmonary rehabilitation.,"BACKGROUND The optimal method to collect accurate healthcare utilisation data in people with chronic obstructive pulmonary disease (COPD) is not well established. The aim of this study was to determine feasibility and compare self-report and administrative data sources to capture health care resource use in people with COPD for 12 months following pulmonary rehabilitation. METHODS This is a secondary analysis of a randomised controlled equivalence trial comparing centre-based and home-based pulmonary rehabilitation. Healthcare utilisation data were collected for 12 months following pulmonary rehabilitation from self-report (monthly telephone questionnaires and diaries) and administrative sources (Medicare Benefits Schedule, medical records). Feasibility was assessed by the proportion of self-reports completed and accuracy was established using month-by-month and per participant comparison of self-reports with administrative data. RESULTS Data were available for 145/163 eligible study participants (89%, mean age 69 (SD 9) years, mean forced expiratory volume in 1 s 51 (SD 19) % predicted; n = 83 male). For 1725 months where data collection was possible, 1160 (67%) telephone questionnaires and 331 (19%) diaries were completed. Accuracy of recall varied according to type of health care encounter and self-report method, being higher for telephone questionnaire report of emergency department presentation (Kappa 0.656, p < 0.001; specificity 99%, sensitivity 59%) and hospital admission (Kappa 0.669, p < 0.001; specificity 97%, sensitivity 68%) and lower for general practitioner (Kappa 0.400, p < 0.001; specificity 62%, sensitivity 78%) and medical specialist appointments (Kappa 0.458, p < 0.001; specificity 88%, sensitivity 58%). A wide variety of non-medical encounters were reported (allied health and nursing) which were not captured in administrative data. CONCLUSION For self-reported methods of healthcare utilisation in people with COPD following pulmonary rehabilitation, monthly telephone questionnaires were more frequently completed and more accurate than diaries. Compared to administrative records, self-reports of emergency department presentations and inpatient admissions were more accurate than for general practitioner and medical specialist appointments. TRIAL REGISTRATION NCT01423227 at clinicaltrials.gov.",2020,"Accuracy of recall varied according to type of health care encounter and self-report method, being higher for telephone questionnaire report of emergency department presentation (Kappa 0.656, p < 0.001; specificity 99%, sensitivity 59%) and hospital admission (Kappa 0.669,","['people with chronic obstructive pulmonary disease (COPD', 'people with COPD for 12\u2009months following pulmonary rehabilitation', 'people with chronic obstructive pulmonary disease following pulmonary rehabilitation', 'people with COPD following pulmonary rehabilitation, monthly telephone questionnaires', 'Data were available for 145/163 eligible study participants (89%, mean age 69 (SD 9) years, mean forced expiratory volume in 1\u2009s 51 (SD 19) % predicted; n\u2009=\u200983 male']",[],"['hospital admission', 'medical specialist appointments']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0086582', 'cui_str': 'Male'}]",[],"[{'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}]",,0.104907,"Accuracy of recall varied according to type of health care encounter and self-report method, being higher for telephone questionnaire report of emergency department presentation (Kappa 0.656, p < 0.001; specificity 99%, sensitivity 59%) and hospital admission (Kappa 0.669,","[{'ForeName': 'Chantal L', 'Initials': 'CL', 'LastName': 'Grimwood', 'Affiliation': 'Physiotherapy, The Alfred, PO Box 315, Prahran, VIC, 3181, Australia.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Holland', 'Affiliation': 'Physiotherapy, The Alfred, PO Box 315, Prahran, VIC, 3181, Australia.'}, {'ForeName': 'Christine F', 'Initials': 'CF', 'LastName': 'McDonald', 'Affiliation': 'Institute for Breathing and Sleep, Level 5, Harold Stokes Building, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia.'}, {'ForeName': 'Ajay', 'Initials': 'A', 'LastName': 'Mahal', 'Affiliation': 'The Nossal Institute for Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Hill', 'Affiliation': 'Institute for Breathing and Sleep, Level 5, Harold Stokes Building, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia.'}, {'ForeName': 'Annemarie L', 'Initials': 'AL', 'LastName': 'Lee', 'Affiliation': 'Physiotherapy, The Alfred, PO Box 315, Prahran, VIC, 3181, Australia.'}, {'ForeName': 'Narelle S', 'Initials': 'NS', 'LastName': 'Cox', 'Affiliation': 'La Trobe University Clinical School, Level 4 The Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.'}, {'ForeName': 'Rosemary', 'Initials': 'R', 'LastName': 'Moore', 'Affiliation': 'Institute for Breathing and Sleep, Level 5, Harold Stokes Building, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Nicolson', 'Affiliation': 'Physiotherapy, The Alfred, PO Box 315, Prahran, VIC, 3181, Australia.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': ""O'Halloran"", 'Affiliation': 'Public Health, La Trobe University, Bundoora, VIC, 3086, Australia.'}, {'ForeName': 'Aroub', 'Initials': 'A', 'LastName': 'Lahham', 'Affiliation': 'La Trobe University Clinical School, Level 4 The Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Gillies', 'Affiliation': 'La Trobe University Clinical School, Level 4 The Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.'}, {'ForeName': 'Angela T', 'Initials': 'AT', 'LastName': 'Burge', 'Affiliation': 'Physiotherapy, The Alfred, PO Box 315, Prahran, VIC, 3181, Australia. angela.burge@monash.edu.'}]",BMC health services research,['10.1186/s12913-020-05920-0'] 436,32707246,Integrating colocated behavioral health care into a dermatology clinic: A prospective randomized controlled treatment pilot study in patients with alopecia areata.,,2021,,['Patients with Alopecia Areata'],['Integrating Co-located Behavioral Healthcare'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002170', 'cui_str': 'Alopecia'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}]",[],,0.0112644,,"[{'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Gorbatenko-Roth', 'Affiliation': 'University of Wisconsin-Stout, Department of Psychology, Menomonie, Wisconsin; University of Minnesota, Department of Dermatology, Minneapolis, Minnesota. Electronic address: gorbatenkok@uwstout.edu.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Hodges', 'Affiliation': 'Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Dayna', 'Initials': 'D', 'LastName': 'Lifson', 'Affiliation': 'M Health Fairview, Minneapolis, Minnesota.'}, {'ForeName': 'Maribeth', 'Initials': 'M', 'LastName': 'Golm', 'Affiliation': 'University of Minnesota, Department of Dermatology, Minneapolis, Minnesota.'}, {'ForeName': 'Dory', 'Initials': 'D', 'LastName': 'Kranz', 'Affiliation': 'National Alopecia Areata Foundation, San Rafael, California.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Windenburg', 'Affiliation': 'University of Minnesota, Department of Dermatology, Minneapolis, Minnesota.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Hordinsky', 'Affiliation': 'University of Minnesota, Department of Dermatology, Minneapolis, Minnesota.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.07.070'] 437,33175638,Maximising the acceptability of extended time intervals between screens in the NHS Cervical Screening Programme: An online experimental study.,"OBJECTIVE The NHS Cervical Screening Programme plans to increase the screening interval from 3 to 5 years for women aged 25-49 who test negative for human papillomavirus (HPV). This exploratory cross-sectional online survey tested the impact of different levels of information about the proposed change on acceptability of a longer interval. METHODS Women aged 18-45 (n = 585) were individually randomised to one of three information exposure groups differing in the level of information provided about the screening interval change: (1) basic information; (2) basic information with additional detail about timeline of HPV infection; (3) as (2) but with the addition of a diagram. Acceptability of the change ( favourable and unfavourable attitudes ) was assessed post-exposure alongside HPV timeline beliefs. We used ANOVA and regression analyses to test for between-group differences. RESULTS Women in Group 3 had higher scores on the favourable attitudes sub-scale compared with Group 1. Women in Groups 2 and 3 had more accurate timeline beliefs than those in Group 1. There were no between-group differences in unfavourable attitudes . After adjusting for demographic factors, a higher favourable attitudes score was independently predicted by being in Group 3 compared to Group 1, more accurate HPV timeline beliefs, and previous irregular or non-attendance at screening. CONCLUSIONS Overall, acceptability of an increased screening interval was moderate, but providing women with information about the safety and rationale for this change may improve acceptability. In particular, communicating the long timeline from HPV exposure to cervical cancer may reassure women about the safety of the proposed changes.",2021,"After adjusting for demographic factors, a higher favourable attitudes score was independently predicted by being in Group 3 compared to Group 1, more accurate HPV timeline beliefs, and previous irregular or non-attendance at screening. ","['Women aged 18-45 (n\u2009=\u2009585', 'women aged 25-49 who test negative for human papillomavirus (HPV']","['NHS Cervical Screening Programme plans', 'information exposure groups differing in the level of information provided about the screening interval change: (1) basic information; (2) basic information with additional detail about timeline of HPV infection']","['accurate timeline beliefs', 'Acceptability of the change ( favourable and unfavourable attitudes ']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}]","[{'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0145943', 'cui_str': 'TimeLine'}, {'cui': 'C0343641', 'cui_str': 'Human papilloma virus infection'}]","[{'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0145943', 'cui_str': 'TimeLine'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}]",585.0,0.101047,"After adjusting for demographic factors, a higher favourable attitudes score was independently predicted by being in Group 3 compared to Group 1, more accurate HPV timeline beliefs, and previous irregular or non-attendance at screening. ","[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Hill', 'Affiliation': 'Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, UCL, London, UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Nemec', 'Affiliation': ""Cancer Prevention Group, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Marlow', 'Affiliation': 'Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, UCL, London, UK.'}, {'ForeName': 'Susan Mary', 'Initials': 'SM', 'LastName': 'Sherman', 'Affiliation': 'School of Psychology, Keele University, Keele, UK.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Waller', 'Affiliation': 'Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, UCL, London, UK.'}]",Journal of medical screening,['10.1177/0969141320970591'] 438,33201041,Perceptual Cognitive Training Does Not Improve Clinical Outcomes at 4 and 12 Weeks Following Concussion in Children and Adolescents: A Randomized Controlled Trial.,"OBJECTIVE To determine whether a perceptual-cognitive training program using 3D-multiple object tracking (3D-MOT) can improve symptoms following acute pediatric concussion. SETTING Research laboratory within a pediatric trauma center. PARTICIPANTS Children and adolescents (n = 62, age= 13.27 ± 2.50) with diagnosed concussion. DESIGN Randomized controlled trial. Children were randomized into either 3D-MOT, 2048 game, or standard care-only groups. Participants and parents completed the Post-Concussion Symptom Inventory (PCSI) at baseline, 4, 8, and 12 weeks postinjury. Intervention participants completed either the 3D-MOT protocol or the 2048 game at 6 sessions between the baseline and 4-week assessment. MAIN MEASURES A 3 (group) × 10 (time) mixed-model analysis of variance evaluated PCSI total scores. The rate of persistent postconcussive symptom (PPCS) was evaluated at 4 weeks using χ2 analysis. RESULTS Symptoms decreased throughout the study using both child-reported (F(9,374) = 22.03, P < .001) and parent-reported scores (F(9,370) = 28.06, P < .001). Twenty-four (44.4%) children met the study definition for PPCS using the child-reported PCSI, while 20 (37.7%) children had PPCS using parent reports. The intervention did not significantly affect symptom resolution or PPCS rates. CONCLUSION There is no benefit to prescribing 3D-MOT training for acute rehabilitation in pediatric patients with concussion and clinicians should instead focus on more effective programs.",2021,"RESULTS Symptoms decreased throughout the study using both child-reported (F(9,374) = 22.03, P < .001) and parent-reported scores (F(9,370) = 28.06, P < .001).","['Research laboratory within a pediatric trauma center', 'Children and adolescents (n = 62, age= 13.27 ± 2.50) with diagnosed concussion', 'pediatric patients with concussion and clinicians', 'Children and Adolescents']","['perceptual-cognitive training program using 3D-multiple object tracking (3D-MOT', 'Perceptual Cognitive Training', '3D-MOT protocol', 'MOT training']","['Post-Concussion Symptom Inventory (PCSI', 'rate of persistent postconcussive symptom (PPCS', 'symptom resolution or PPCS rates']","[{'cui': 'C0022886', 'cui_str': 'Laboratory Research'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0040786', 'cui_str': 'Trauma center'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0546983', 'cui_str': 'Postconcussion syndrome'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.131708,"RESULTS Symptoms decreased throughout the study using both child-reported (F(9,374) = 22.03, P < .001) and parent-reported scores (F(9,370) = 28.06, P < .001).","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Teel', 'Affiliation': ""School of Physical and Occupational Therapy, McGill University, Montreal, Quebec, Canada (Drs Teel, Marie Brossard-Racine, and Gagnon); Division of Neonatology (Dr Marie Brossard-Racine) and Division of Pediatric Emergency Medicine (Dr Gagnon), Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada; Department of Neurology and Neurosurgery, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada (Dr Marie Brossard-Racine); and Département des sciences de l'activité physique, Université du Québec à Trois-Rivières, Trois-Rivières, Quebec, Canada (Dr Corbin-Berrigan).""}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Brossard-Racine', 'Affiliation': ''}, {'ForeName': 'Laurie-Ann', 'Initials': 'LA', 'LastName': 'Corbin-Berrigan', 'Affiliation': ''}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Gagnon', 'Affiliation': ''}]",The Journal of head trauma rehabilitation,['10.1097/HTR.0000000000000633'] 439,33197271,Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.,"OBJECTIVE Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by recommending GLP-1 receptor agonists and SGLT-2 inhibitors as initial glucose-lowering therapy. This is questioned since outcome trials of these drug classes had metformin as background therapy. In this post hoc analysis, the effect of dulaglutide on CV events was investigated according to the baseline metformin therapy by means of a subgroup analysis of the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. RESEARCH DESIGN AND METHODS Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%). They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care. The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes. Key secondary outcomes included a microvascular composite endpoint, all-cause death, and heart failure. The effect of dulaglutide in patients with and without baseline metformin was evaluated by a Cox regression hazard model with baseline metformin, dulaglutide assignment, and their interaction as independent variables. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by a Cox regression model with adjustments for factors differing at baseline between people with vs. without metformin, identified using the backward selection. RESULTS Compared to patients with metformin at baseline (n = 8037; 81%), those without metformin (n = 1864; 19%) were older and slightly less obese and had higher proportions of women, prior CV events, heart failure, and renal disease. The primary outcome occurred in 976 (12%) participants with baseline metformin and in 281 (15%) without. There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81-1.05) vs. 0.78 (CI 0.61-0.99); interaction P = 0.18]. Findings for key secondary outcomes were similar in patients with and without baseline metformin. CONCLUSION This analysis suggests that the cardioprotective effect of dulaglutide is unaffected by the baseline use of metformin therapy.",2021,There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81-1.05) vs. 0.78 (CI 0.61-0.99); interaction P = 0.18].,"['patients with diabetes and established or high risk for coronary vascular disease treated with', 'Patients in REWIND (n\u2009=\u20099901; women: 46.3%; mean age: 66.2\u2009years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69', 'patients with and without baseline', 'patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease']","['placebo', 'dulaglutide with and without baseline metformin', 'dulaglutide', 'metformin']","['microvascular composite endpoint, all-cause death, and heart failure', 'Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs', 'CV events', 'first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes', 'higher proportions of women, prior CV events, heart failure, and renal disease']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0042373', 'cui_str': 'Vascular disorder'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C1562292', 'cui_str': 'Incretin'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3179549', 'cui_str': 'dulaglutide'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}]",9901.0,0.202898,There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81-1.05) vs. 0.78 (CI 0.61-0.99); interaction P = 0.18].,"[{'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Ferrannini', 'Affiliation': 'Department of Medicine K2, Karolinska Institutet, Solnavägen 1, Stockholm SE171 77, Sweden.'}, {'ForeName': 'Hertzel', 'Initials': 'H', 'LastName': 'Gerstein', 'Affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada.'}, {'ForeName': 'Helen Martina', 'Initials': 'HM', 'LastName': 'Colhoun', 'Affiliation': 'Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK.'}, {'ForeName': 'Gilles R', 'Initials': 'GR', 'LastName': 'Dagenais', 'Affiliation': 'Department of Medicine, Institut Universitaire de Cardiologie et Pneumologie, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Diaz', 'Affiliation': 'ECLA, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Paraguay 160, S2000 Rosario, Santa Fe, Argentina.'}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Dyal', 'Affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Lakshmanan', 'Affiliation': 'Eli Lilly and Company, 893 Delaware St, Indianapolis, IN 46225, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Mellbin', 'Affiliation': 'Department of Medicine K2, Karolinska Institutet, Solnavägen 1, Stockholm SE171 77, Sweden.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Probstfield', 'Affiliation': 'Department of Medicine, RR-512, Health Sciences Building, University of Washington, Box 356420, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA.'}, {'ForeName': 'Matthew Casey', 'Initials': 'MC', 'LastName': 'Riddle', 'Affiliation': 'Department of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.'}, {'ForeName': 'Jonathan Edward', 'Initials': 'JE', 'LastName': 'Shaw', 'Affiliation': 'Baker Heart and Diabetes Institute, 75 Commercial Rd, Melbourne VIC 3004, Australia.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Avezum', 'Affiliation': 'Instituto Dante Pazzanese de Cardiologia and University Santo Amaro, Av. Dr. Dante Pazzanese, 500 - Vila Mariana, São Paulo - SP, 04012-909, Brazil.'}, {'ForeName': 'Jan Neil', 'Initials': 'JN', 'LastName': 'Basile', 'Affiliation': 'Division of Cardiology, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC 29425, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Cushman', 'Affiliation': 'Memphis Veterans Affairs Medical Center, Preventive Medicine Section, 1030 Jefferson Ave, Memphis, TN 38104, USA.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Jansky', 'Affiliation': 'Department of Cardiovascular Surgery, University Hospital Motol, V Úvalu 84 150 06 Praha 5, Czech Republic.'}, {'ForeName': 'Mátyás', 'Initials': 'M', 'LastName': 'Keltai', 'Affiliation': 'Department of Cardiology, Semmelweis University, Hungarian Institute of Cardiology, Üllői út 26, 1085 Budapest, Hungary.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Lanas', 'Affiliation': 'Department of Internal Medicine, Universidad de La Frontera, Francisco Salazar 1145, Temuco, Araucanía, Chile.'}, {'ForeName': 'Lawrence Alan', 'Initials': 'LA', 'LastName': 'Leiter', 'Affiliation': ""Department of Medicine, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, 38 Shuter St, Toronto, ON M5B 1A6, Canada.""}, {'ForeName': 'Patricio', 'Initials': 'P', 'LastName': 'Lopez-Jaramillo', 'Affiliation': 'Masira Research Institute, Medical School, Universidad de Santander UDES, Calle 70 No 55-210 Bucaramanga, Colombia.'}, {'ForeName': 'Prem', 'Initials': 'P', 'LastName': 'Pais', 'Affiliation': ""Division of Clinical Research and Training, St. John's Research Institute, 100 Feet Rd, John Nagar, Koramangala, Bengaluru, Karnataka 560034, India.""}, {'ForeName': 'Valdis', 'Initials': 'V', 'LastName': 'Pīrāgs', 'Affiliation': 'Department of Internal Medicine, Latvijas Universitate, Raiņa bulvāris 19, Centra rajons, Riga LV-1586, Latvia.'}, {'ForeName': 'Nana', 'Initials': 'N', 'LastName': 'Pogosova', 'Affiliation': 'National Medical Research Center of Cardiology, Ulitsa Ostrovityanova, 1, Moscow 117997, Russian Federation.'}, {'ForeName': 'Peter Johann', 'Initials': 'PJ', 'LastName': 'Raubenheimer', 'Affiliation': 'Department of Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.'}, {'ForeName': 'Wayne Huey-Herng', 'Initials': 'WH', 'LastName': 'Sheu', 'Affiliation': 'Department of Medicine, Taichung Veterans General Hospital, Rongguang Road, Puli Township, Nantou County, Taichung 54552, Taiwan.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Rydén', 'Affiliation': 'Department of Medicine K2, Karolinska Institutet, Solnavägen 1, Stockholm SE171 77, Sweden.'}]",European heart journal,['10.1093/eurheartj/ehaa777'] 440,33206268,The Effects of Aquatic Versus Kata Techniques Training on Static and Dynamic Balance in Children with Autism Spectrum Disorder.,"The present study aimed to compare the effect of a land-based and a swimming-based exercise program on balance abilities in children with autism. Thirty children were voluntarily selected and randomly assigned to karate exercise, aquatic training and control groups. Participants practiced for 10 weeks, 2 sessions of 60 min per week. Before and after the 10-week intervention, static and dynamic balance tests were administered. The results showed that both interventions had a significant effect on balance abilities (p < 0.001); interestingly, we found the greater improvement in balance performance in kata techniques group. Due to the importance of balance performance on daily functions, communication and interaction skills, karate and swimming exercises can be the valuable interventions added to autism's daily programs. Iranian Registry of Clinical Trials number: IRCT20180626040242N1.",2021,"The results showed that both interventions had a significant effect on balance abilities (p < 0.001); interestingly, we found the greater improvement in balance performance in kata techniques group.","['Children with Autism Spectrum Disorder', 'children with autism', 'Thirty children']","['land-based and a swimming-based exercise program', 'Aquatic Versus Kata Techniques Training', 'karate exercise, aquatic training and control groups']","['balance performance', 'Static and Dynamic Balance', 'balance abilities']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039003', 'cui_str': 'Swimming'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0080236', 'cui_str': 'Training Technics'}, {'cui': 'C0079654', 'cui_str': 'Karate'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0560184', 'cui_str': 'Ability to balance'}]",30.0,0.0267585,"The results showed that both interventions had a significant effect on balance abilities (p < 0.001); interestingly, we found the greater improvement in balance performance in kata techniques group.","[{'ForeName': 'Soleyman', 'Initials': 'S', 'LastName': 'Ansari', 'Affiliation': 'PhD of Exercise Physiology, Department of Physical Education, Rasht Branch, Islamic Azad University, Rasht, Iran.'}, {'ForeName': 'Abbas Ali', 'Initials': 'AA', 'LastName': 'Hosseinkhanzadeh', 'Affiliation': 'Department of Psychology, Faculty of Literature and Humanities, University of Guilan, Rasht, Iran.'}, {'ForeName': 'Fahimeh', 'Initials': 'F', 'LastName': 'AdibSaber', 'Affiliation': 'Department of Physical Education, Rasht Branch, Islamic Azad University, Rasht, Iran. adibsaber@iaurasht.ac.ir.'}, {'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Shojaei', 'Affiliation': 'Department of Motor Behavior, Faculty of Physical Education and Sport Sciences, Alzahra University, Tehran, Iran.'}, {'ForeName': 'Afkham', 'Initials': 'A', 'LastName': 'Daneshfar', 'Affiliation': 'Department of Motor Behavior, Faculty of Physical Education and Sport Sciences, Alzahra University, Tehran, Iran.'}]",Journal of autism and developmental disorders,['10.1007/s10803-020-04785-w'] 441,33211886,"The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study.","OBJECTIVES To compare the efficacy and safety of citrate mixture and sodium bicarbonate on urine alkalization in gout patients under benzbromarone treatment. METHODS A prospective, randomized, parallel controlled trial was conducted among 200 gout patients in the dedicated gout clinic of the Affiliated Hospital of Qingdao University. The participants were randomly divided into two groups (1:1), sodium bicarbonate group (3 g/day) and citrate mixture group (7 g/day). All patients were prescribed with 25 mg/day benzbromarone at initiation and maintained at a dose of 50 mg/day. Clinical and biochemical data were collected at each follow-up time point (baseline, weeks 2, 4, 8 and 12). RESULTS A total of 182 patients completed the 12-week urine alkalization study. The urine pH value of both groups increased significantly from the baseline to the final follow-up time point (sodium bicarbonate group, 5.50-6.00, P < 0.05; citrate mixture group, 5.53-5.93, P < 0.05). While the comparisons regarding urine pH between treatment groups showed no significant differences for each time point. The estimated glomerular filtration rate (eGFR) dropped significantly after 12 weeks' trial in the sodium bicarbonate group (P < 0.01), while it was comparable between baseline and the last follow-up (P > 0.05) in the citrate mixture group. Results of urine analysis showed that the incident rate of occult blood in the sodium bicarbonate group was higher than that in the citrate mixture group (38 vs 24%, P < 0.05), accompanied by a similar occurrence of kidney stones. After 12-week follow-up, the frequency of twice gout flare in the citrate mixture group was significantly lower than that in sodium bicarbonate group (4 vs 12%, P = 0.037). No treatment-emergent adverse events occurred. CONCLUSION The efficacy of citrate mixture on urine alkalization is comparable to sodium bicarbonate under benzbromarone treatment without significant adverse events. Citrate mixture is superior to sodium bicarbonate in lowering the incidence of urine occult blood and the frequency of gout attacks. TRIAL REGISTRATION Registered with ChiCTR (http://www.chictr.org.cn), No. ChiCTR1800018518.",2021,"Citrate mixture is superior to sodium bicarbonate in lowering the incidence of urine occult blood and the frequency of gout attacks. ","['gout patients under benzbromarone treatment', '182 patients completed the 12-week urine alkalization study', '200 gout patients in the dedicated gout clinic of the Affiliated Hospital of Qingdao University', 'Chinese primary gout patients with benzbromarone']","['citrate mixture vs sodium bicarbonate', 'Citrate mixture', 'sodium bicarbonate', 'citrate mixture and sodium bicarbonate', 'citrate mixture']","['glomerular filtration rate (eGFR', 'urine pH', 'frequency of twice gout flare', 'kidney stones', 'urine pH value', 'efficacy and safety', 'incident rate of occult blood']","[{'cui': 'C0018099', 'cui_str': 'Gout'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005035', 'cui_str': 'Benzbromarone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0149896', 'cui_str': 'Primary gout'}]","[{'cui': 'C0008857', 'cui_str': 'Citrates'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}]","[{'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0042044', 'cui_str': 'Urine pH test'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0149896', 'cui_str': 'Primary gout'}, {'cui': 'C0022650', 'cui_str': 'Kidney stone'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0028792', 'cui_str': 'Occult blood screening'}]",200.0,0.03432,"Citrate mixture is superior to sodium bicarbonate in lowering the incidence of urine occult blood and the frequency of gout attacks. ","[{'ForeName': 'Xiaomei', 'Initials': 'X', 'LastName': 'Xue', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Xinde', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Xuefeng', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Ren', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Ruixia', 'Initials': 'R', 'LastName': 'Sun', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Zhaotong', 'Initials': 'Z', 'LastName': 'Jia', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Xiaopeng', 'Initials': 'X', 'LastName': 'Ji', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Yuwei', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Aichang', 'Initials': 'A', 'LastName': 'Ji', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Wenyan', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': 'Institute of Metabolic Diseases, Qingdao University, Qingdao, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Institute of Metabolic Diseases, Qingdao University, Qingdao, China.'}, {'ForeName': 'Tony R', 'Initials': 'TR', 'LastName': 'Merriman', 'Affiliation': 'Institute of Metabolic Diseases, Qingdao University, Qingdao, China.'}, {'ForeName': 'Changgui', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}, {'ForeName': 'Lingling', 'Initials': 'L', 'LastName': 'Cui', 'Affiliation': 'Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, Qingdao, China.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa668'] 442,33213378,Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.,"BACKGROUND To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics. METHODS In the present placebo-controlled, randomized, double-blinded, multicentre clinical trial, patients with cirrhotic ascites who failed to adequately respond to a combination of an aldosterone antagonist plus an orally administered loop diuretic were randomly placed at a 4:2:1 ratio into 3 groups [the 15 mg/day tolvaptan group (N = 301), 7.5 mg/day tolvaptan group (N = 153) and placebo group (N = 76)] for 7 days of treatment. The effects and safety were evaluated on days 4 and 7. A change in body weight from baseline on day 7 of treatment was the primary endpoint. RESULTS The administration of 7.5 or 15 mg/day tolvaptan significantly decreased body weight from baseline on day 7 of treatment compared to that with placebo treatment (P = 0.026; P = 0.001). For the secondary endpoints, changes in abdominal circumference from baseline and improvements in ascites were markedly different in the treatment groups and the placebo group on day 7 (P 7.5  = 0.05, P 15.0  = 0.002 and P 7.5  = 0.037, P 15.0  = 0.003), but there was no difference between the 7.5 mg/day and 15 mg/day dosage groups. The 24-h cumulative urine volume was higher in the 7.5 mg/day and 15 mg/day tolvaptan groups than the placebo group (P = 0.002, P < 0.001) and was greater in the 15 mg/day tolvaptan group than the 7.5 mg/day tolvaptan group (P = 0.004). Sodium serum concentrations were higher in patients with hyponatraemia after tolvaptan treatment, with no significant difference between the two dosage groups. The incidence of serious adverse drug reactions was not different between the groups (P = 0.543). CONCLUSIONS Tolvaptan treatment at 7.5 mg per day might be a good therapeutic choice for Chinese cirrhotic patients with ascites who did not achieve satisfactory clinical responses to previous treatment regimens with combination therapy with an aldosterone antagonist and an orally administered loop diuretic. TRIAL REGISTRATION NCT01349348. Retrospectively registered May 2011.",2020,"The incidence of serious adverse drug reactions was not different between the groups (P = 0.543). ","['Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses', 'patients with cirrhotic ascites who failed to adequately respond to a combination of an', 'Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics', 'Chinese cirrhotic patients with ascites']","['aldosterone antagonist', 'placebo', 'tolvaptan', 'Tolvaptan therapy', 'aldosterone antagonist plus an orally administered loop diuretic', 'tolvaptan group (N\u2009=\u2009301), 7.5\xa0mg/day tolvaptan']","['abdominal circumference from baseline and improvements in ascites', 'safety and efficacy', 'body weight', '24-h cumulative urine volume', 'Sodium serum concentrations', 'incidence of serious adverse drug reactions']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0439686', 'cui_str': 'Cirrhotic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003962', 'cui_str': 'Ascites'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0012798', 'cui_str': 'Diuretic'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C1319171', 'cui_str': 'Medication response'}, {'cui': 'C0020625', 'cui_str': 'Hyponatremia'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0002007', 'cui_str': 'Aldosterone receptor antagonist-containing product'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0354100', 'cui_str': 'Loop diuretic'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}]","[{'cui': 'C1300813', 'cui_str': 'Abdominal circumference'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0003962', 'cui_str': 'Ascites'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}]",,0.191226,"The incidence of serious adverse drug reactions was not different between the groups (P = 0.543). ","[{'ForeName': 'Jieting', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'School of Medicine Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, No. 145, Middle Shandong Road, Shanghai, 200001, China.'}, {'ForeName': 'Yongfeng', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'School of Medicine Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, No. 145, Middle Shandong Road, Shanghai, 200001, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Han', 'Affiliation': 'Tianjin Third Hospital, Tianjin, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Mao', 'Affiliation': 'Southwest Hospital, Chongqing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Huiguo', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': 'Beijing Youan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Shang', 'Affiliation': 'Henan Provincial Peoples Hospital, Zhengzhou, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Shanghai Public Health Clinical Center, Shanghai, China.'}, {'ForeName': 'Junqi', 'Initials': 'J', 'LastName': 'Niu', 'Affiliation': 'The First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Ji', 'Affiliation': 'The First Affiliated Hospital, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Chengwei', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': '85 Hospital of Peoples Liberation Army, Shanghai, China.'}, {'ForeName': 'Jidong', 'Initials': 'J', 'LastName': 'Jia', 'Affiliation': 'Beijing Friendship Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiangjun', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'Qingdao Municipal Hospital, Qingdao, China.'}, {'ForeName': 'Nonghua', 'Initials': 'N', 'LastName': 'Lv', 'Affiliation': 'The First Affiliated Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Yueqiu', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Shanghai Shuguang Hospital, Shanghai, China.'}, {'ForeName': 'Zhenghua', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'School of Medicine Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, No. 145, Middle Shandong Road, Shanghai, 200001, China.'}, {'ForeName': 'Zhong', 'Initials': 'Z', 'LastName': 'Wei', 'Affiliation': 'School of Medicine Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, No. 145, Middle Shandong Road, Shanghai, 200001, China.'}, {'ForeName': 'Yingxuan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'School of Medicine Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, No. 145, Middle Shandong Road, Shanghai, 200001, China.'}, {'ForeName': 'Minde', 'Initials': 'M', 'LastName': 'Zeng', 'Affiliation': 'School of Medicine Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, No. 145, Middle Shandong Road, Shanghai, 200001, China.'}, {'ForeName': 'Yimin', 'Initials': 'Y', 'LastName': 'Mao', 'Affiliation': 'School of Medicine Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, No. 145, Middle Shandong Road, Shanghai, 200001, China. 13003175438@163.com.'}]",BMC gastroenterology,['10.1186/s12876-020-01536-0'] 443,33217147,Blood markers in remote ischaemic conditioning for acute ischaemic stroke: data from the REmote ischaemic Conditioning After Stroke Trial.,"BACKGROUND AND PURPOSE Remote ischaemic per-conditioning (RIC) is neuroprotective in experimental ischaemic stroke. Several neurohumoral, vascular and inflammatory mediators are implicated. The effect of RIC on plasma biomarkers was assessed using clinical data from the REmote ischaemic Conditioning After Stroke Trial (RECAST-1). METHODS RECAST-1 was a pilot sham-controlled blinded trial in 26 patients with ischaemic stroke, randomized to receive four 5-min cycles of RIC within 24 h of ictus. Plasma taken pre-intervention, immediately post-intervention and on day 4 was analysed for nitric oxide (nitrate/nitrite) using chemiluminescence and all other biomarkers by multiplex analysis. Biomarkers were correlated with clinical outcome (day 90 National Institutes of Health Stroke Scale, modified Rankin Scale, Barthel index). RESULTS Remote ischaemic per-conditioning reduced serum amyloid protein (SAP) and tissue necrosis factor α (TNF-α) levels from pre- to post-intervention (n = 13, two-way ANOVA, p < 0.05). Overall (n = 26), increases in SAP pre- to post-intervention and pre-intervention to day 4 were moderately correlated with worse day 90 clinical outcomes. No consistent significant changes over time, or by treatment, or correlations with outcome were seen for other biomarkers. CONCLUSIONS Remote ischaemic per-conditioning reduced SAP and TNF-α levels from pre- to post-intervention. Increases in plasma levels of SAP were associated with worse clinical outcomes after ischaemic stroke. Larger studies assessing biomarkers and the safety and efficacy of RIC in acute ischaemic stroke are warranted to further understand these relationships.",2021,"RESULTS RIC reduced serum amyloid protein (SAP) and tissue necrosis factor-α (TNF-α) levels from pre- to post-intervention (n=13, 2-way ANOVA, p<0.05).","['acute ischaemic stroke', '26 patients with ischaemic stroke']","['Remote ischaemic per-conditioning (RIC', 'RIC']","['serum amyloid protein (SAP) and tissue necrosis factor-α (TNF-α) levels', 'plasma levels of SAP', 'SAP and TNF-α levels', 'Blood markers', 'Health Stroke Scale [NIHSS], modified Rankin scale [mRS], Barthel index [BI', 'SAP pre']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0311444', 'cui_str': 'Serum amyloid protein'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]",26.0,0.120839,"RESULTS RIC reduced serum amyloid protein (SAP) and tissue necrosis factor-α (TNF-α) levels from pre- to post-intervention (n=13, 2-way ANOVA, p<0.05).","[{'ForeName': 'Jason P', 'Initials': 'JP', 'LastName': 'Appleton', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Saoirse E', 'Initials': 'SE', 'LastName': ""O'Sullivan"", 'Affiliation': 'Division of Medical Sciences and GEM, School of Medicine, Vascular Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Hedstrom', 'Affiliation': 'Division of Medical Sciences and GEM, School of Medicine, Vascular Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Jane A', 'Initials': 'JA', 'LastName': 'May', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Donnelly', 'Affiliation': 'Division of Medical Sciences and GEM, School of Medicine, Vascular Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Nikola', 'Initials': 'N', 'LastName': 'Sprigg', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Bath', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'England', 'Affiliation': 'Division of Medical Sciences and GEM, School of Medicine, Vascular Medicine, University of Nottingham, Derby, UK.'}]",European journal of neurology,['10.1111/ene.14650'] 444,33217618,End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.,"PURPOSE To report the end-of-study results from the Ladder clinical trial of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD). DESIGN Multicenter, randomized, active treatment-controlled phase 2 clinical trial. PARTICIPANTS Patients diagnosed with nAMD with a documented response to anti-vascular endothelial growth factor treatment who received study treatment (N = 220). METHODS Patients were randomized 3:3:3:2 to treatment with the PDS filled with ranibizumab 10-mg/ml, 40-mg/ml, and 100-mg/ml formulations or monthly intravitreal ranibizumab 0.5-mg injections. MAIN OUTCOME MEASURES End-of-study results for the time to first meeting refill criteria (first refill), mean change from baseline for best-corrected visual acuity (BCVA) and central foveal thickness (CFT), and safety. RESULTS At study end, the mean time on study was 22.1 months (range, 10.8-37.6 months) for all PDS patients. Median time to first refill was 8.7 months, 13.0 months, and 15.8 months, and 28.9%, 56.0%, and 59.4% of patients went 12 months or longer without meeting refill criteria in the PDS 10-mg/ml, 40-mg/ml, and 100-mg/ml treatment arms, respectively. At month 22, the observed mean BCVA change from baseline was ‒4.6 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, ‒2.3 ETDRS letters, +2.9 ETDRS letters, and +2.7 ETDRS letters in the PDS 10-mg/ml, 40-mg/ml, 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg treatment arms, respectively. At month 22, the observed mean CFT change from baseline was similar in the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg treatment arms. No new safety signals were detected during the additional follow-up. CONCLUSIONS Over a mean of 22 months on study, vision and anatomic outcomes were comparable between the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg arms, with a lower total number of ranibizumab treatments with the PDS. The Ladder end-of-study findings were consistent with the primary analysis, and the PDS generally was well tolerated throughout the entire study period. The PDS has the potential to reduce treatment burden in patients with nAMD while maintaining vision.",2021,"No new safety signals were detected during the additional follow-up. ","['neovascular age-related macular degeneration (nAMD', 'Patients', 'patients with nAMD while maintaining vision', 'Neovascular Age-Related Macular Degeneration', 'Patients diagnosed with nAMD with a documented response to anti-vascular endothelial growth factor treatment who received study treatment (N = 220']","['Ranibizumab', 'ranibizumab (PDS', 'PDS filled with ranibizumab 10 mg/mL, 40 mg/mL, and 100 mg/mL formulations or monthly intravitreal ranibizumab 0.5 mg injections', 'ranibizumab']","['time to first meeting refill criteria (first refill), mean change from baseline for best-corrected visual acuity (BCVA) and central foveal thickness (CFT), and safety', 'new safety signals', 'vision and anatomic outcomes', 'mean CFT change', 'Median time to first refill', 'observed mean BCVA change']","[{'cui': 'C0271084', 'cui_str': 'Exudative age-related macular degeneration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517650', 'cui_str': '220'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0452253', 'cui_str': 'Port'}, {'cui': 'C0449914', 'cui_str': 'Delivery system'}, {'cui': 'C1724107', 'cui_str': 'ranibizumab 10 MG/ML'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",220.0,0.131031,"No new safety signals were detected during the additional follow-up. ","[{'ForeName': 'Arshad M', 'Initials': 'AM', 'LastName': 'Khanani', 'Affiliation': 'Sierra Eye Associates and the Reno School of Medicine, University of Nevada, Reno, Nevada. Electronic address: arshad.khanani@gmail.com.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Callanan', 'Affiliation': 'Texas Retina Associates, Arlington, Texas.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Dreyer', 'Affiliation': 'Retina Northwest, Portland, Oregon, and Baylor University, Waco, Texas.'}, {'ForeName': 'Sanford', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Orange County Retina, Santa Ana, California.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Howard', 'Affiliation': 'Retina Associates of Utah and the Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, Utah.'}, {'ForeName': 'J Jill', 'Initials': 'JJ', 'LastName': 'Hopkins', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Chin-Yu', 'Initials': 'CY', 'LastName': 'Lin', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Meike', 'Initials': 'M', 'LastName': 'Lorenz-Candlin', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Sneha', 'Initials': 'S', 'LastName': 'Makadia', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Shienal', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Tammy', 'Initials': 'T', 'LastName': 'Tam', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Shamika', 'Initials': 'S', 'LastName': 'Gune', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology. Retina,['10.1016/j.oret.2020.11.004'] 445,33179399,Focal and pseudo/rotational activations in human atrial fibrillation defined with automated periodicity mapping.,"INTRODUCTION Defining atrial fibrillation (AF) wave propagation is challenging unless local signal features are discrete or periodic. Periodic focal or rotational activity may identify AF drivers. Our objective was to characterize AF propagation at sites with periodic activation to evaluate the prevalence and relationship between focal and rotational activation. METHODS We included 80 patients (61 ± 10 years, persistent AF 49%) from the FaST randomized trial that compared the efficacy of adjunctive focal site ablation versus pulmonary vein isolation. Patients underwent left atrial (LA) activation mapping with a 20-pole circular catheter during spontaneous or induced AF. Five-second bipolar and unipolar electrograms in AF were analyzed. Periodic sites were identified by spectral analysis of the bipolar electrogram. Activation maps of periodic sites were constructed using an automated, validated tracking algorithm, and classified into three patterns: focal sites (FS), rotation (RO), or pseudo-rotation (pRO). RESULTS The most common propagation pattern at periodic sites was FS for 5-s in all patients (4.9 ± 1.9 per patient). RO and pRO were observed in two and seven patients, respectively, but were all transient (3-5 cycles). Activation from a FS evolved into transient RO/pRO in five patients. No patient had autonomous RO/pRO activations. Patients with RO/pRO had greater LA surface area with periodicity (78 ± 7 vs. 63 ± 16%, p = .0002) and shorter LA periodicity CL (166 ± 10 vs. 190±28 ms, p = .0001) than the rest. CONCLUSION Using automated, regional AF periodicity mapping, FS is more prevalent and temporally stable than RO/pRO. Most RO/pRO evolve from neighboring FS. These findings and their implications for AF maintenance require verification with global, panoramic mapping.",2021,"Patients with RO/pRO had greater LA surface area with periodicity (78 ± 7 vs. 63 ± 16%, p = .0002) and shorter LA periodicity CL (166 ± 10 vs. 190±28 ms, p = .0001) than the rest. ","['80 patients (61\u2009±\u200910\u2009years, persistent AF 49']","['left atrial (LA) activation mapping with a 20-pole circular catheter during spontaneous or induced AF', 'adjunctive focal site ablation versus pulmonary vein isolation']","['RO and pRO', 'focal sites (FS), rotation (RO), or pseudo-rotation (pRO', 'autonomous RO/pRO activations', 'LA surface area with periodicity', 'shorter LA periodicity CL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}]","[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C1283195', 'cui_str': 'Mapping - action'}, {'cui': 'C0337815', 'cui_str': 'Poles'}, {'cui': 'C1282913', 'cui_str': 'Circular'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}]","[{'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0205237', 'cui_str': 'False'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0031084', 'cui_str': 'Periodicities'}]",80.0,0.0219431,"Patients with RO/pRO had greater LA surface area with periodicity (78 ± 7 vs. 63 ± 16%, p = .0002) and shorter LA periodicity CL (166 ± 10 vs. 190±28 ms, p = .0001) than the rest. ","[{'ForeName': 'Sachin', 'Initials': 'S', 'LastName': 'Nayyar', 'Affiliation': 'Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Canada.'}, {'ForeName': 'Andrew C T', 'Initials': 'ACT', 'LastName': 'Ha', 'Affiliation': 'Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Canada.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Timmerman', 'Affiliation': 'Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Canada.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Suszko', 'Affiliation': 'Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Canada.'}, {'ForeName': 'Don', 'Initials': 'D', 'LastName': 'Ragot', 'Affiliation': 'Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Canada.'}, {'ForeName': 'Vijay S', 'Initials': 'VS', 'LastName': 'Chauhan', 'Affiliation': 'Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Canada.'}]",Journal of cardiovascular electrophysiology,['10.1111/jce.14812'] 446,33221515,Aqueous Chlorhexidine Compared with Povidone-Iodine as Ocular Antisepsis before Intravitreal Injection: A Randomized Clinical Trial.,"PURPOSE Topical povidone-iodine (PI) is widely used as an ocular surface antiseptic for intravitreal injections (IVIs). Although PI is generally well tolerated, it can be associated with significant ocular irritation. Aqueous chlorhexidine (AqCHX) has been described as a possibly better tolerated antimicrobial for ophthalmic procedures. We compared patient pain scores, ocular surface characteristics, and antimicrobial efficacy between PI 5% and AqCHX 0.1% during IVIs. DESIGN Prospective single-center, randomized clinical trial. PARTICIPANTS Patients receiving same-day bilateral intravitreal anti-vascular endothelial growth factor (VEGF) injections. METHODS Each patient had 1 eye randomized to PI or AqCHX, and the second eye received the other agent. Both eyes received topical proparacaine 0.5%. MAIN OUTCOME MEASURES After IVIs, participants rated their pain (Wong-Baker, scale 0-10) for each eye 1 minute after PI or AqCHX instillation and 1 day after the procedure. Each eye was assessed using a standardized quantitative grading system of corneal epitheliopathy (ocular staining score). Microbial swab cultures of the conjunctiva both before instillation of topical antisepsis and 10 minutes after IVIs were given. RESULTS A total of 100 eyes of 50 patients were included. The mean patient age was 68 years (range, 39-92), and 30 of 50 (60%) were male. Compared with AqCHX, eyes receiving PI had a greater mean pain score immediately after injection (1.44 vs. 0.44, P < 0.001) but not on postprocedure day 1 (1.04 vs. 0.48, P = 0.06). Eyes that received PI had a higher ocular staining score indicating worse corneal epitheliopathy (4.22 vs. 3.10, P < 0.001). There was no difference in rates of positive microbial cultures between groups. There was no difference in rates of adverse events between groups (P = 0.99), and no cases of endophthalmitis occurred. CONCLUSIONS Povidone-iodine demonstrated greater ocular surface discomfort and corneal epitheliopathy compared with AqCHX during same-day bilateral IVIs. The 2 agents otherwise demonstrated no difference in positive microbial cultures or adverse events. Aqueous chlorhexidine may be a better tolerated alternative to PI for antimicrobial prophylaxis during IVIs for some patients.",2021,"Compared to aqueous chlorhexidine, eyes receiving povidone iodine had a greater mean pain score immediately after injection (1.44 vs 0.44, p<0.001), but not on post-procedure day one (1.04 vs 0.48, p=0.06).","['One hundred eyes of 50 patients were included', 'The mean patient age was 68 years (range 39-92) and 30/50 (60%) were male']","['povidone iodine', 'Povidone Iodine', 'Aqueous chlorhexidine', 'Topical povidone iodine', 'povidone iodine 5% and aqueous chlorhexidine', 'Povidone iodine', 'topical antisepsis', 'chlorhexidine', 'povidone iodine or aqueous chlorhexidine', 'Aqueous Chlorhexidine', 'povidone iodine or aqueous chlorhexidine instillation', 'topical proparacaine', 'aqueous chlorhexidine']","['rates of adverse events', 'ocular surface discomfort and corneal epitheliopathy', 'rates of positive microbial cultures', 'ocular staining score', 'corneal epitheliopathy', 'positive microbial cultures or adverse events', 'corneal epitheliopathy (ocular staining score', 'mean pain score', 'patient pain scores, ocular surface characteristics, and antimicrobial efficacy']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0032857', 'cui_str': 'Povidone-Iodine'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0003424', 'cui_str': 'Antisepsis'}, {'cui': 'C0184959', 'cui_str': 'Instillation'}, {'cui': 'C0072510', 'cui_str': 'proparacaine'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C2242979', 'cui_str': 'Culture'}, {'cui': 'C0038128', 'cui_str': 'Stain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449588', 'cui_str': 'Surface characteristics'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",50.0,0.0462838,"Compared to aqueous chlorhexidine, eyes receiving povidone iodine had a greater mean pain score immediately after injection (1.44 vs 0.44, p<0.001), but not on post-procedure day one (1.04 vs 0.48, p=0.06).","[{'ForeName': 'Ferhina S', 'Initials': 'FS', 'LastName': 'Ali', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Jenkins', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Ranjodh S', 'Initials': 'RS', 'LastName': 'Boparai', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Obeid', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Martha E', 'Initials': 'ME', 'LastName': 'Ryan', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Turner D', 'Initials': 'TD', 'LastName': 'Wibblesman', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Chiang', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Sunir J', 'Initials': 'SJ', 'LastName': 'Garg', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania. Electronic address: sgarg@midatlanticretina.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}]",Ophthalmology. Retina,['10.1016/j.oret.2020.11.008'] 447,32697444,"HUMAN AMNIOTIC MEMBRANE TO TREAT MACULAR HOLES THAT FAILED TO CLOSE, SULFUR HEXAFLUORIDE ENDOTAMPONADE VERSUS AIR ENDOTAMPONADE: A Prospective Comparative Study.","BACKGROUND/PURPOSE To determinate the efficacy of the human amniotic membrane plugs with sulfur hexafluoride versus human amniotic membrane plug with air as endotamponade to treat macular holes that failed to close after vitrectomy plus internal limiting membrane peeling. Multimodal imaging was focused to evaluate preoperative features and postoperative changes. METHODS Prospective interventional comparative study. Twenty eyes of 20 patients affected with macular hole that failed to close were divided into 2 groups: 10 eyes received an amniotic membrane plug with 20% sulfur hexafluoride tamponade and 10 eyes received an amniotic membrane plug with air tamponade. All eyes were studied using multimodal advanced diagnostic tools, such as spectral-domain optical coherence tomography, optical coherence tomography angiography, microperimetry, and adaptive optics to investigate the postoperative results. RESULTS In both groups, all macular holes were found successfully closed after 12 months. Mean preoperative best-corrected visual acuity was 20/400 in the SF6 group and 20/250 in air group. Final mean best-corrected visual acuity was 20/63 in both groups. The superficial capillary plexus, studied using optical coherence tomography angiography, showed a statistically significant difference between the treated and the fellow eyes. Adaptive optics images revealed the presence of a photoreceptor cell mosaic in the area of the amniotic membrane plug. CONCLUSION The human amniotic membrane combined with air endotamponade demonstrated its effectiveness to seal macular holes that failed to close after vitrectomy plus internal limiting membrane peeling. Advanced multimodal diagnostic imaging helped us to better understand the modifications associated with the use of the amniotic membrane in these cases.",2021,"The superficial capillary plexus, studied using optical coherence tomography angiography, showed a statistically significant difference between the treated and the fellow eyes.",['Twenty eyes of 20 patients affected by macular hole that failed to close were divided into 2 groups: 10 eyes received an'],"['amniotic membrane plug with 20% sulfur hexafluoride tamponade and 10 eyes received an amniotic membrane plug with air tamponade', 'sulfur hexafluoride versus human amniotic membrane plug with air as endotamponade', 'Sulfur Hexafluoride endotamponade versus air endotamponade']","['Mean pre-operative BCVA', 'Final mean BCVA']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0024441', 'cui_str': 'Macular hole'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0002630', 'cui_str': 'Structure of amnion'}, {'cui': 'C0182324', 'cui_str': 'Plug'}, {'cui': 'C0038779', 'cui_str': 'Sulfur Hexafluoride'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C2936394', 'cui_str': 'Endotamponade'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}]",20.0,0.0285286,"The superficial capillary plexus, studied using optical coherence tomography angiography, showed a statistically significant difference between the treated and the fellow eyes.","[{'ForeName': 'Tomaso', 'Initials': 'T', 'LastName': 'Caporossi', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence-Careggi, Florence, Italy; and.'}, {'ForeName': 'Ruggero', 'Initials': 'R', 'LastName': 'Tartaro', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence-Careggi, Florence, Italy; and.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Finocchio', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence-Careggi, Florence, Italy; and.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Pacini', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence-Careggi, Florence, Italy; and.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'De Angelis', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence-Careggi, Florence, Italy; and.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Bacherini', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence-Careggi, Florence, Italy; and.'}, {'ForeName': 'Stanislao', 'Initials': 'S', 'LastName': 'Rizzo', 'Affiliation': 'Department of Ophthalmology, Catholic University of Sacred Hearth-Foundation ""Policlinico Universitario A. Gemelli""-IRCCS, Rome, Italy.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002913'] 448,32694318,"Mechanisms of Mindfulness Meditation, Cognitive Therapy, and Mindfulness-based Cognitive Therapy for Chronic Low Back Pain.","OBJECTIVES This study evaluated theoretically derived mechanisms and common therapeutic factors to test their role in accounting for pain-related outcome change during group-delivered cognitive therapy, mindfulness meditation, and mindfulness-based cognitive therapy for chronic low back pain. METHODS A secondary analysis of a pilot randomized controlled trial was used to explore the primary mechanisms of pretreatment to posttreatment changes in pain control beliefs, mindful observing, and pain catastrophizing, and the secondary common factor mechanisms of therapeutic alliance, group cohesion, and amount of at-home skill practice during treatment. The primary outcome was pain interference; pain intensity was a secondary outcome. RESULTS Large effect size changes in the 3 primary mechanisms and the outcome variables were found across the conditions. Across all 3 treatment conditions, change in pain control beliefs and pain catastrophizing were significantly associated with improved pain interference, but not pain intensity. Therapeutic alliance was significantly associated with pain intensity improvement and change in the therapy-specific mechanisms across the 3 conditions. Mindful observing, group cohesion, and amount of at-home practice were not significantly associated with changes in the outcomes. DISCUSSION Cognitive therapy, mindfulness meditation, and mindfulness-based cognitive therapy for chronic low back pain were all associated with significant changes in the primary mechanisms to a similar degree. Change in perceived pain control and pain catastrophizing emerged as potential ""meta-mechanisms"" that might be a shared pathway that contributes to improved pain-related outcomes across treatments. Further, strong working alliance may represent a critical therapeutic process that both promotes and interacts with therapeutic techniques to influence outcome.",2020,"Across all three treatment conditions, change in pain control beliefs and pain catastrophizing were significantly associated with improved pain interference, but not pain intensity.",['Chronic Low Back Pain'],"['cognitive therapy (CT), mindfulness meditation (MM) and mindfulness-based cognitive therapy (MBCT', 'Mindfulness Meditation, Cognitive Therapy, and Mindfulness-based Cognitive Therapy']","['pain control beliefs, mindful observing, and pain catastrophizing', 'pain intensity', 'pain interference; pain intensity', 'pain control beliefs and pain catastrophizing', 'pain interference']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}]",3.0,0.0798335,"Across all three treatment conditions, change in pain control beliefs and pain catastrophizing were significantly associated with improved pain interference, but not pain intensity.","[{'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Day', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'L Charles', 'Initials': 'LC', 'LastName': 'Ward', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'Beverly E', 'Initials': 'BE', 'LastName': 'Thorn', 'Affiliation': 'Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Burns', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, WA.'}, {'ForeName': 'Dawn M', 'Initials': 'DM', 'LastName': 'Ehde', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, AL.'}, {'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Barnier', 'Affiliation': 'Department of Cognitive Science, Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'Jason B', 'Initials': 'JB', 'LastName': 'Mattingley', 'Affiliation': 'School of Psychology.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Jensen', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, AL.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000862'] 449,32725609,A significant increase in exercise test performance with virtual group motivation: a randomised open-label controlled trial.,"AIMS Exercise stress testing is frequently used for the assessment of coronary artery disease. As the validity of the test result is highly dependent on the patient’s cooperation and motivation, we hypothesised that virtual group motivation would result in a higher exercise capacity and may increase the test’s validity. METHODS 108 patients at a Swiss teaching hospital with an indication for exercise testing were included in a controlled, open-label trial and randomised 1:1 to treadmill exercise testing whilst either watching a video of a walking group (video group, n = 43), or watching a static image of flowers (image group, n = 43). The video showed a group of five amateur runners, giving the patients the impression of running within the group. As primary outcomes, the performance achieved and the perceived level of comfort during the test were analysed. RESULTS The video group achieved significantly higher percentages of their age-predicted METs (149 ± 32% vs 135 ± 29%, p = 0.041) and longer exercise durations (11:12 ± 2:54 min vs 08:54 ± 02:39 min, p <0.001). Levels of comfort (8.4 ± 1.4 vs 7.5 ± 1.7 analogue scale, p = 0.011) and closeness to their physical limits (8.9 ± 0.8 vs 8.1 ± 1.5, p = 0.005) were rated significantly higher by patients in the video group. CONCLUSIONS Patients watching a video of a running group achieved significantly higher maximum exercise levels and longer test durations. This may have implications for the test’s validity. Furthermore, the virtual setting enhanced patient comfort. (This trial was formally registered at clinicaltrials.gov: trial ID NCT03704493.).",2020,"Levels of comfort (8.4 ± 1.4 vs 7.5 ± 1.7 analogue scale, p = 0.011) and closeness to their physical limits (8.9 ± 0.8 vs 8.1 ± 1.5, p = 0.005) were rated significantly higher by patients in the video group. ",['108 patients at a Swiss teaching hospital with an indication for exercise testing'],"['treadmill exercise testing whilst either watching a video of a walking group (video group, n = 43), or watching a static image of flowers (image group']","['performance achieved and the perceived level of comfort', 'closeness to their physical limits', 'exercise test performance', 'maximum exercise levels', 'Levels of comfort', 'longer exercise durations']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0241315', 'cui_str': 'Swiss'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0330090', 'cui_str': 'Flowers'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0517225', 'cui_str': 'Comfort level'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",,0.11557,"Levels of comfort (8.4 ± 1.4 vs 7.5 ± 1.7 analogue scale, p = 0.011) and closeness to their physical limits (8.9 ± 0.8 vs 8.1 ± 1.5, p = 0.005) were rated significantly higher by patients in the video group. ","[{'ForeName': 'Verena C', 'Initials': 'VC', 'LastName': 'Wilzeck', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland.'}, {'ForeName': 'Janik', 'Initials': 'J', 'LastName': 'Hufschmid', 'Affiliation': 'Old Cantonal High School, Aarau, Switzerland.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Bischof', 'Affiliation': 'Old Cantonal High School, Aarau, Switzerland.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Hansi', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland.'}, {'ForeName': 'Matthias P', 'Initials': 'MP', 'LastName': 'Nägele', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland.'}, {'ForeName': 'Juerg H', 'Initials': 'JH', 'LastName': 'Beer', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland / Centre of Molecular Cardiology, University of Zurich, Switzerland.'}, {'ForeName': 'Urs', 'Initials': 'U', 'LastName': 'Hufschmid', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland / 0041564862637 | 00414862636.'}]",Swiss medical weekly,['10.4414/smw.2020.20287'] 450,32611638,Minimal manifestation status and prednisone withdrawal in the MGTX trial.,"OBJECTIVE To examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG). METHODS This study is a post hoc analysis of data from a randomized trial of thymectomy in MG (Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy [MGTX]). MGTX was a multicenter, randomized, rater-blinded 3-year trial that was followed by a voluntary 2-year extension for patients with acetylcholine receptor (AChR) antibody-positive MG without thymoma. Patients were randomized 1:1 to thymectomy plus prednisone vs prednisone alone. Participants were age 18-65 years at enrollment with disease duration less than 5 years. All patients received oral prednisone titrated up to 100 mg on alternate days until they achieved MMS, which prompted a standardized prednisone taper as long as MMS was maintained. The achievement rate of sustained MMS (no symptoms of MG for 6 months) with complete withdrawal of prednisone was compared between the thymectomy plus prednisone and prednisone alone groups. RESULTS Patients with MG in the thymectomy plus prednisone group achieved sustained MMS with complete withdrawal of prednisone more frequently (64% vs 38%) and quickly compared to the prednisone alone group (median time 30 months vs no median time achieved, p < 0.001) over the 5-year study period. Prednisone-associated adverse symptoms were more frequent in the prednisone alone group and distress level increased with higher doses of prednisone. CONCLUSIONS Thymectomy benefits patients with MG by increasing the likelihood of achieving sustained MMS with complete withdrawal of prednisone. CLINICALTRIALSGOV IDENTIFIER NCT00294658. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that for patients with generalized MG with AChR antibody, those receiving thymectomy plus prednisone are more likely to attain sustained MMS and complete prednisone withdrawal than those on prednisone alone.",2020,"Prednisone associated adverse symptoms were more frequent in the prednisone alone group and distress level increased with higher doses of prednisone. ","['generalized MG patients with AChR antibody, those receiving', 'thymectomized myasthenia gravis (MG) patients', 'patients with acetylcholine receptor (AChR) antibody positive MG without thymoma', 'Participants were age 18-65 years at enrollment with disease duration less than 5 years', 'myasthenia gravis (MGTX']","['prednisone', 'thymectomy plus prednisone', 'Prednisone', 'MGTX', 'thymectomy', 'oral prednisone', 'thymectomy plus prednisone versus prednisone alone']","['achievement rate of sustained MMS', 'distress level', 'sustained MMS', 'adverse symptoms']","[{'cui': 'C0472367', 'cui_str': 'Generalized myasthenia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0236516', 'cui_str': 'Acetylcholine receptor antibody'}, {'cui': 'C0026896', 'cui_str': 'Myasthenia gravis'}, {'cui': 'C0034792', 'cui_str': 'Cholinergic receptor'}, {'cui': 'C0741132', 'cui_str': 'Antibody test positive'}, {'cui': 'C0040100', 'cui_str': 'Thymoma'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0174725', 'cui_str': 'margatoxin'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0040071', 'cui_str': 'Excision of thymus'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0174725', 'cui_str': 'margatoxin'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.173208,"Prednisone associated adverse symptoms were more frequent in the prednisone alone group and distress level increased with higher doses of prednisone. ","[{'ForeName': 'Ikjae', 'Initials': 'I', 'LastName': 'Lee', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY. leeij15@gmail.com.'}, {'ForeName': 'Hui-Chien', 'Initials': 'HC', 'LastName': 'Kuo', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Inmaculada B', 'Initials': 'IB', 'LastName': 'Aban', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Cutter', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Tarrant', 'Initials': 'T', 'LastName': 'McPherson', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Henry J', 'Initials': 'HJ', 'LastName': 'Kaminski', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Sussman', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Ströbel', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Oger', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Cea', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Jeannine M', 'Initials': 'JM', 'LastName': 'Heckmann', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Evoli', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Wilfred', 'Initials': 'W', 'LastName': 'Nix', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Ciafaloni', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Antonini', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Rawiphan', 'Initials': 'R', 'LastName': 'Witoonpanich', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'John O', 'Initials': 'JO', 'LastName': 'King', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Said R', 'Initials': 'SR', 'LastName': 'Beydoun', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Colin H', 'Initials': 'CH', 'LastName': 'Chalk', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Alexandru C', 'Initials': 'AC', 'LastName': 'Barboi', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Anthony A', 'Initials': 'AA', 'LastName': 'Amato', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Aziz I', 'Initials': 'AI', 'LastName': 'Shaibani', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Bashar', 'Initials': 'B', 'LastName': 'Katirji', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Bryan R F', 'Initials': 'BRF', 'LastName': 'Lecky', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Buckley', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Vincent', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Elza', 'Initials': 'E', 'LastName': 'Dias-Tosta', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Yoshikawa', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Marcia', 'Initials': 'M', 'LastName': 'Waddington-Cruz', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Pulley', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Rivner', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Kostera-Pruszczyk', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Pascuzzi', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Carlayne E', 'Initials': 'CE', 'LastName': 'Jackson', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Jan J G', 'Initials': 'JJG', 'LastName': 'Verschuuren', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Massey', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'John T', 'Initials': 'JT', 'LastName': 'Kissel', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Lineu C', 'Initials': 'LC', 'LastName': 'Werneck', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Benatar', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Barohn', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Rup', 'Initials': 'R', 'LastName': 'Tandan', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Tahseen', 'Initials': 'T', 'LastName': 'Mozaffar', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Conwit', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Minisman', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Joshua R', 'Initials': 'JR', 'LastName': 'Sonett', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': 'Gil I', 'Initials': 'GI', 'LastName': 'Wolfe', 'Affiliation': 'From the Departments of Neurology (I.L.) and Biostatistics (H.-C.K., I.B.A., G.R.C., T.M., G.M.), University of Alabama at Birmingham; Department of Neurology (H.J.K.), George Washington University School of Medicine and Health Sciences, Washington, DC; Department of Neurology (J.S.), Greater Manchester Neuroscience Center, Salford, Greater Manchester, UK; Institute of Pathology (P.S.), University Medical Center Göttingen; Division of Neurology (J.O.), University of British Columbia, Vancouver, Canada; Department of Neurology (G.C.), University of Chile, Santiago; Division of Neurology (J.M.H.), Department of Medicine, University of Cape Town, South Africa; Department of Neurology (A.E.), Catholic University, Rome, Italy; Department of Neurology (W.N.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (E.C.), University of Rochester Medical Center, NY; Department of Neurosciences (G.A.), Mental Health and Sensory Organs, Sapienza University of Rome, Italy; Division of Neurology (R.W.), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (J.O.K.), Royal Melbourne Hospital, Victoria, Australia; Department of Neurology (S.R.B.), University of Southern California, Los Angeles; Department of Neurology (C.H.C.), McGill University, Montreal, Canada; Department of Neurology (A.C.B.), Medical College of Wisconsin, Milwaukee; Department of Neurology (A.A.A.), Harvard Medical School, Boston, MA; Nerve and Muscle Center of Texas (A.I.S.), Houston; Department of Neurology (B.K.), Case Western Reserve University, Cleveland, OH; Walton Centre for Neurology and Neurosurgery (B.R.F.L.), Liverpool; Nuffield Department of Clinical Neurosciences (C.B., A.V.), Oxford University, UK; Unit of Neurology (E.D.-T.), University of Brasilia, Brazil; Department of Neurology (H.Y.), Kanazawa University, Japan; Department of Neurology (M.W.-C.), Federal University, Rio de Janeiro, Brazil; Department of Neurology (M.T.P.), University of Florida, Jacksonville; Department of Neurology (M.H.R.), Augusta University, GA; Department of Neurology (A.K.-P.), Medical University of Warsaw, Poland; Department of Neurology (R.M.P.), Indiana School of Medicine, Indianapolis; Department of Neurology (C.E.J.), University of Texas Health Science Center, San Antonio; Department of Neurology (J.J.G.V.), Leiden University Medical Center, the Netherlands; Department of Neurology (J.M.M.), Duke University Medical Center, Durham, NC; Department of Neurology (J.T.K.), Ohio State University Wexner Medical Center, Columbus; Department of Neurology (L.C.W.), Universidade Federal do Parana, Curitiba, Brazil; Department of Neurology (M.B.), University of Miami, FL; Department of Neurology (R.J.B.), University of Kansas Medical Center, Kansas City; Department of Neurological Sciences (R.T.), University of Vermont College of Medicine, Burlington; Department of Neurology (T.M.), University of California Irvine Medical Center, Orange; Division of Extramural Research (R.C.), NIH, National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of General Thoracic Surgery (J.R.S.), Columbia University Medical Center, New York; and Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neurology,['10.1212/WNL.0000000000010031'] 451,33185570,"The effects of rudeness, experience, and perspective-taking on challenging premature closure after pediatric ICU physicians receive hand-off with the wrong diagnosis: a randomized controlled simulation trial.","OBJECTIVES Rudeness exposure has been shown to inhibit diagnostic performance. The effects of rudeness on challenging a handed-off diagnostic error has not been studied. METHODS This was a randomized controlled study of attending, fellow, and resident physicians in a tertiary care pediatric ICU. Participants underwent a standardized simulation that started with the wrong diagnosis in hand-off. The hand-off was randomized to neutral vs. rude. Participants were not informed of the randomization nor diagnostic error prior to the simulation. Perspective taking questionnaires were administrated for each participant. Primary outcome was challenging diagnostic error post-simulation. Secondary outcomes included rate and frequency of diagnostic error challenge during simulation. RESULTS Among 41 simulations (16 residents, 14 fellows, and 11 attendings), the neutral group challenged the diagnostic error more than the rude group (neutral: 71%, rude: 55%, p=0.28). The magnitude of this trend was larger among resident physicians only, although not statistically significant (neutral: 50%, rude: 12.5%, p=0.11). Experience was associated with a higher percentage of challenging diagnostic error (residents: 31%, fellows: 86%, attendings: 82%, p=0.003). Experienced physicians were faster to challenge diagnostic error (p<0.0003), and experience was associated with a greater frequency of diagnostic error challenges (p<0.0001). High perspective taking scores were also associated with 1.63 times more diagnostic error challenges (p=0.007). CONCLUSIONS Experience was strongly associated with likelihood to challenge diagnostic error. Rudeness may disproportionally hinder diagnostic performance among less experienced physicians. Perspective taking merits further research in possibly reducing diagnostic error momentum.",2021,High perspective taking scores were also associated with 1.63 times more diagnostic error challenges (p=0.007).,"['41 simulations (16 residents, 14 fellows, and 11 attendings', 'attending, fellow, and resident physicians in a tertiary care pediatric ICU']",[],"['diagnostic error', 'challenge diagnostic error', 'diagnostic error post-simulation', 'diagnostic error challenges', 'rate and frequency of diagnostic error challenge during simulation', 'diagnostic performance']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]",[],"[{'cui': 'C0011922', 'cui_str': 'Errors, Diagnostic'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]",,0.0915778,High perspective taking scores were also associated with 1.63 times more diagnostic error challenges (p=0.007).,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Avesar', 'Affiliation': ""Loma Linda University Children's Hospital, Loma Linda CA, USA.""}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Erez', 'Affiliation': 'University of Florida, Gainesville, Fl, USA.'}, {'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Essakow', 'Affiliation': ""Children's Hospital Los Angeles, Los Angeles, CA, USA.""}, {'ForeName': 'Caulette', 'Initials': 'C', 'LastName': 'Young', 'Affiliation': ""Children's Hospital Los Angeles, Los Angeles, CA, USA.""}, {'ForeName': 'Binyamin', 'Initials': 'B', 'LastName': 'Cooper', 'Affiliation': 'Carnegie Mellon University, Pittsburg, PA, USA.'}, {'ForeName': 'Denizhan', 'Initials': 'D', 'LastName': 'Akan', 'Affiliation': ""Children's Hospital Los Angeles, Los Angeles, CA, USA.""}, {'ForeName': 'Margaret J', 'Initials': 'MJ', 'LastName': 'Klein', 'Affiliation': ""Children's Hospital Los Angeles, Los Angeles, CA, USA.""}, {'ForeName': 'Todd P', 'Initials': 'TP', 'LastName': 'Chang', 'Affiliation': ""Children's Hospital Los Angeles, Los Angeles, CA, USA.""}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Rake', 'Affiliation': ""Children's Hospital Los Angeles, Los Angeles, CA, USA.""}]","Diagnosis (Berlin, Germany)",['10.1515/dx-2020-0083'] 452,33188692,Multi-catheter cryotherapy compared with radiofrequency ablation in long-standing persistent atrial fibrillation: a randomized clinical trial.,"AIMS Restoring sinus rhythm (SR) by ablation alone is an endpoint used in radiofrequency (RF) ablation for long-standing persistent atrial fibrillation (AF) but not with cryotherapy. The simultaneous use of two cryotherapy catheters can improve ablation efficiency; we compared this with RF ablation in chronic persistent AF aiming for termination to SR by ablation alone. METHODS AND RESULTS Consecutive patients undergoing their first ablation for persistent AF of >6 months duration were screened. A total of 100 participants were randomized 1:1 to multi-catheter cryotherapy or RF. For cryotherapy, a 28-mm Arctic Front Advance was used in tandem with focal cryoablation catheters. Open-irrigated, non-force sensing catheters were used in the RF group with a 3D mapping system. Pulmonary vein (PV) isolation and non-PV triggers were targeted. Participants were followed up at 6 and 12 months, then yearly. Acute PVI was achieved in all cases. More patients in the multi-catheter cryotherapy group were restored to SR by ablation alone, with a shorter procedure duration. Sinus rhythm continued to the last available follow-up in 16/49 patients (33%) in the multi-catheter at 3.0 ± 1.6 years post-ablation and in 12/50 patients (24%) in the RF group at 4.0 ± 1.2 years post-ablation. The yearly rate of arrhythmia recurrence was similar. CONCLUSION Multi-catheter cryotherapy can restore SR by ablation alone in more cases and more quickly than RF ablation. Long-term success is difficult to achieve by either methods and is similar with both.",2021,"More patients in the multi-catheter cryotherapy group were restored to SR by ablation alone, with a shorter procedure duration.","['long-standing persistent atrial fibrillation', 'Consecutive patients undergoing their first ablation for persistent AF of >6\u2009months duration were screened', '100 participants']","['radiofrequency ablation', 'Multi-catheter cryotherapy', 'cryotherapy catheters', 'multi-catheter cryotherapy or RF', 'AIMS\n\n\nRestoring sinus rhythm (SR) by ablation alone', 'radiofrequency (RF) ablation', 'RF ablation']","['Sinus rhythm', 'Acute PVI', 'yearly rate of arrhythmia recurrence', 'ablation efficiency']","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0232201', 'cui_str': 'Sinus rhythm'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}]","[{'cui': 'C0232201', 'cui_str': 'Sinus rhythm'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}]",100.0,0.0199521,"More patients in the multi-catheter cryotherapy group were restored to SR by ablation alone, with a shorter procedure duration.","[{'ForeName': 'Mark M', 'Initials': 'MM', 'LastName': 'Gallagher', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Yi', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Hanney', 'Initials': 'H', 'LastName': 'Gonna', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Lisa W M', 'Initials': 'LWM', 'LastName': 'Leung', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Idris', 'Initials': 'I', 'LastName': 'Harding', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Banu', 'Initials': 'B', 'LastName': 'Evranos', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Bastiaenen', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Rajan', 'Initials': 'R', 'LastName': 'Sharma', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Wright', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Norman', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'Zia', 'Initials': 'Z', 'LastName': 'Zuberi', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}, {'ForeName': 'A John', 'Initials': 'AJ', 'LastName': 'Camm', 'Affiliation': ""Cardiology Clinical Academic Group, St. George's University Hospitals NHS Foundation Trust, St. George's University of London, Blackshaw Road, London SW17 0QT, UK.""}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa289'] 453,32729416,Development and Validation of a Five-immune Gene Pair Signature in Endometrial Carcinoma.,"BACKGROUND Endometrial cancer (EC) is a common gynecological malignancy worldwide. Immunity is closely related to the occurrence and prognosis of EC. At the same time, immune-related genes have great potential as prognostic markers in many types of cancer. OBJECTIVE Therefore, we attempt to develop immune-related gene markers to enhance prognosis prediction of EC. METHODS 542 samples of EC gene expression data and clinical follow-up information were downloaded from The Cancer Genome Atlas (TCGA). The samples were randomly divided into two groups, one group as a training set (N=271), and one set as a validation set. (N=271). In the training set, the gene pairs were established based on the relative expression levels of 271 immune genes, and the prognosis-related gene pairs were screened. The lasso was used to select the features, and finally, the robust biomarkers were screened. Finally, the prognostic model of the immune gene pair was established and verified by the validation data set. RESULTS 10030 immune gene pair (IRGPs) were obtained, and univariate survival analysis was used to identify 1809 prognostic-related IRGPs (p<0.05). 5-IRGPs were obtained by lasso regression feature selection, and multivariate regression was used to establish 5-IRGPs signature, 5-IRGPs signature is an independent prognostic factor for EC patients, and could be risk stratified in patients with TCGA datasets, age, ethnicity, stage, and histological classification (p<0.05). The mean AUC of survival in both the training set and the validation set was greater than 0.7, indicating that 5-IRGPs signature has superior classification performance in patients with EC. In addition, 5-IRGPs have the highest average C index (0.795) compared to the prognostic characteristics of the three endometrial cancers reported in the past and Stage and Age. CONCLUSION This study constructed a 5-IRGPs signature as a novel prognostic marker for predicting survival in patients with EC.",2021,"In addition, 5-IRGPs have the highest average C index (0.795) compared to the prognostic characteristics of the three endometrial cancers reported in the past and Stage and Age. ","['Endometrial carcinoma', '542 samples of EC gene expression data and clinical follow-up information from were downloaded from The Cancer Genome Atlas (TCGA', 'patients with EC']",[],"['highest average C index', 'mean AUC of survival']","[{'cui': 'C0476089', 'cui_str': 'Endometrial carcinoma'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0007103', 'cui_str': 'Endometrial neoplasms malignant'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",10030.0,0.038112,"In addition, 5-IRGPs have the highest average C index (0.795) compared to the prognostic characteristics of the three endometrial cancers reported in the past and Stage and Age. ","[{'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Reproductive Medicine Center, Liuzhou Maternity and Child Health Care Hospital, Liuzhou, Guangxi Autonomous Region, 545001, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Yu', 'Affiliation': 'College of Life Science and Technology, Guangxi University, Nanning, 530004, China.'}, {'ForeName': 'Zhong', 'Initials': 'Z', 'LastName': 'Lin', 'Affiliation': 'Reproductive Medicine Center, Liuzhou Maternity and Child Health Care Hospital, Liuzhou, Guangxi Autonomous Region, 545001, China.'}, {'ForeName': 'Dingyuan', 'Initials': 'D', 'LastName': 'Zeng', 'Affiliation': 'Department of Obstetrics and Gynecology, China.'}]",Combinatorial chemistry & high throughput screening,['10.2174/1386207323999200729113641'] 454,32701012,"Novel Cross-Linked Ocular Bandage Gel Improves Reepithelialization After Photorefractive Keratectomy: A Randomized, Masked Prospective Study.","Purpose: To compare, in a masked manner, a novel cross-linked hyaluronic acid ocular bandage gel (OBG) versus standard-of-care bandage contact lens (BCL) plus artificial tears with respect to safety and effectiveness in healing epithelial defects created for photorefractive keratectomy (PRK). Methods: This was a randomized, reading center-masked, exploratory study. Forty-five patients (myopic without significant anisometropia) scheduled for bilateral PRK (9-mm epithelial defect) were randomized post-PRK to treatment with OBG 8 times daily for 3 days, followed by 4 times daily for 11 days (Group 1); OBG 4 times daily for 14 days (Group 2); or BCL and artificial tears (Control). A masked reading center used image analysis of digital slit lamp photos of the fluorescein-stained cornea to evaluate defect size during the 14-day postoperative follow-up period. Effectiveness endpoints were (1) time to complete closure of the corneal defect and (2) proportion of patients with complete healing on day 3 postoperatively, whose defect remained closed. Safety assessments included findings for adverse events and vision, Standard Patient Evaluation of Eye Dryness (SPEED ™ ) Questionnaire, slit lamp, intraocular pressure, and fundus examinations. Results: The proportion of patients with complete healing at 3 days was 73.3%, 86.7%, and 66.7% of patients in Groups 1, 2, and Control, respectively. On day 2, the mean wound size was 6%-26% smaller in Groups 1 and 2 compared with Control. No safety concern arose. SPEED scores were not significantly different across groups. Conclusion: OBG offers a well-tolerated and effective therapy for quickly reepithelializing the cornea following trauma, disease, or surgery.",2020,"On day 2, the mean wound size was 6%-26% smaller in Groups 1 and 2 compared with Control.","['Forty-five patients (myopic without significant anisometropia) scheduled for bilateral PRK (9-mm epithelial defect', 'After Photorefractive Keratectomy']","['OBG', 'hyaluronic acid ocular bandage gel (OBG) versus standard-of-care bandage contact lens (BCL) plus artificial tears', 'Novel Cross-Linked Ocular Bandage Gel Improves Reepithelialization']","['proportion of patients with complete healing', 'Effectiveness endpoints were (1) time to complete closure of the corneal defect and (2) proportion of patients with complete healing', 'SPEED scores', 'adverse events and vision, Standard Patient Evaluation of Eye Dryness (SPEED ™ ) Questionnaire, slit lamp, intraocular pressure, and fundus examinations', 'mean wound size']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027092', 'cui_str': 'Myopia'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0003081', 'cui_str': 'Anisometropia'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0022772', 'cui_str': ""Democratic people's republic of Korea""}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0395416', 'cui_str': 'Refractive keratoplasty by laser surgery'}]","[{'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0004726', 'cui_str': 'Bandage'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2608262', 'cui_str': 'Artificial Tears'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0332220', 'cui_str': 'Cross-linking'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0948085', 'cui_str': 'Corneal defect'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0314719', 'cui_str': 'Dry eyes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0183355', 'cui_str': 'Slit lamp biomicroscope'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0016823', 'cui_str': 'Structure of fundus of eye'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",45.0,0.061894,"On day 2, the mean wound size was 6%-26% smaller in Groups 1 and 2 compared with Control.","[{'ForeName': 'Darcy', 'Initials': 'D', 'LastName': 'Wolsey', 'Affiliation': 'The Eye Institute of Utah, Salt Lake City, Utah, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Slade', 'Affiliation': 'Slade & Baker Vision Center, Houston, Texas, USA.'}, {'ForeName': 'Barbara M', 'Initials': 'BM', 'LastName': 'Wirostko', 'Affiliation': 'EyeGate Pharmaceuticals, Inc., Salt Lake City, Utah, USA.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Brandano', 'Affiliation': 'EyeGate Pharmaceuticals, Inc., Waltham, Massachusetts, USA.'}, {'ForeName': 'Brenda K', 'Initials': 'BK', 'LastName': 'Mann', 'Affiliation': 'EyeGate Pharmaceuticals, Inc., Salt Lake City, Utah, USA.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Durrie', 'Affiliation': 'Durrie Vision, Overland Park, Kansas, USA.'}, {'ForeName': 'Vance', 'Initials': 'V', 'LastName': 'Thompson', 'Affiliation': 'Vance Thompson Vision, Sioux Falls, South Dakota, USA.'}]",Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,['10.1089/jop.2019.0156'] 455,32697858,Topical application of autophagy-activating peptide improved skin barrier function and reduced acne symptoms in acne-prone skin.,"BACKGROUND Recent studies about the important roles of autophagy signaling in sebaceous lipogenesis and epidermal differentiation suggest potential benefits of autophagy activation in acne. AIMS To investigate the effects of an autophagy activator on acne-prone skin. METHODS Autophagy signaling in human immortalized SZ95 sebocytes, normal human epidermal keratinocytes, and 3D reconstituted skin was examined. Effects of an autophagy-activating peptide on sebaceous lipogenesis were measured by fluorescence microscopic analysis. The clinical efficacy in acne-prone skin was evaluated through an eight-week, double-blind, randomized, vehicle-controlled study. Changes in skin surface lipid compositions were further analyzed. RESULTS In cultured sebocytes and keratinocytes, the investigated autophagy-activating peptide increased LC3-II expression, indicating a stimulation of autophagy signaling. Testosterone and linoleic acid treatment induced lipogenesis in cultured sebocytes and is further inhibited by the autophagy activator peptide treatment. Increased expression of differentiation marker proteins in cultured keratinocytes was also observed by autophagy-activating peptide. In clinical study, reduction of closed comedones and the amount of skin surface lipids as well as of trans-epidermal water loss (TEWL) were observed in acne-prone skin after autophagy-activating peptide application. In addition, reduction of squalene and increase in cholesterol were observed after an 8-week application. CONCLUSIONS Topical application of an autophagy activator downregulated sebaceous lipogenesis and improved the skin barrier function. Considering the important roles of sebum and skin barrier function in acne pathogenesis, autophagy activation might represent a new therapeutic option in early forms of acne.",2021,"In cultured sebocytes and keratinocytes, the investigated autophagy-activating peptide increased LC3-II expression, indicating a stimulation of autophagy signaling.",['acne-prone skin'],"['autophagy-activating peptide', 'autophagy activator', 'Testosterone and linoleic acid']","['reduction of squalene and increase of cholesterol', 'Increased expression of differentiation marker proteins', 'skin barrier function', 'sebaceous lipogenesis']","[{'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]","[{'cui': 'C0004391', 'cui_str': 'Autophagocytosis'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0023749', 'cui_str': 'Linoleic acid'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0038071', 'cui_str': 'Squalene'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0007589', 'cui_str': 'Differentiation, Cell'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0596843', 'cui_str': 'Adipogenesis'}]",,0.0186451,"In cultured sebocytes and keratinocytes, the investigated autophagy-activating peptide increased LC3-II expression, indicating a stimulation of autophagy signaling.","[{'ForeName': 'Yoonjin', 'Initials': 'Y', 'LastName': 'Lee', 'Affiliation': 'College of Life Science and Biotechnology, Korea University, Seoul, South Korea.'}, {'ForeName': 'Kayoung', 'Initials': 'K', 'LastName': 'Shin', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Kyong-Oh', 'Initials': 'KO', 'LastName': 'Shin', 'Affiliation': 'Department of Food Science and Nutrition, Hallym University, Chuncheon, South Korea.'}, {'ForeName': 'Seokjeong', 'Initials': 'S', 'LastName': 'Yoon', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Juyeon', 'Initials': 'J', 'LastName': 'Jung', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Eojin', 'Initials': 'E', 'LastName': 'Hwang', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Hwa-Jee', 'Initials': 'HJ', 'LastName': 'Chung', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Amir M', 'Initials': 'AM', 'LastName': 'Hossini', 'Affiliation': 'Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany.'}, {'ForeName': 'Christos C', 'Initials': 'CC', 'LastName': 'Zouboulis', 'Affiliation': 'Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany.'}, {'ForeName': 'Min Jeong', 'Initials': 'MJ', 'LastName': 'Baek', 'Affiliation': 'Dermapro Skin Research Center, DERMAPRO Ltd., Seoul, South Korea.'}, {'ForeName': 'Ji Hwoon', 'Initials': 'JH', 'LastName': 'Baek', 'Affiliation': 'Dermapro Skin Research Center, DERMAPRO Ltd., Seoul, South Korea.'}, {'ForeName': 'Young Min', 'Initials': 'YM', 'LastName': 'Chi', 'Affiliation': 'College of Life Science and Biotechnology, Korea University, Seoul, South Korea.'}, {'ForeName': 'Sangeun', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.'}, {'ForeName': 'Sekyoo', 'Initials': 'S', 'LastName': 'Jeong', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13636'] 456,32703270,The effect of blue dishware versus white dishware on food intake and eating challenges among residents living with dementia: a crossover trial.,"OBJECTIVE Residents living with dementia (RLWD) often experience changes in their visual perception, which could reduce food intake. Inadequate food intake is known to cause malnutrition, which increases the risk of hospitalization, morbidity, and mortality. This study evaluated the effectiveness of using blue dishware compared to white dishware to improve food intake and mitigate eating challenges among 18 RLWD (mean age 84.6 ± 7.9 years, 72.2% female). RESULTS A within-within person crossover design determined differences in food intake and eating challenges between blue and white dishware conditions. Five participants responded to the blue dishware and increased their average food intake by ≥ 10%. Responders were not different from non-responders in terms of demographic or health characteristics. The proportion of eating challenges experienced was not significantly different between the blue and white dishware conditions. Percent food intake was significantly greater at lunch (83.5 ± 19.0%) compared to dinner (75.8 ± 22.1%; p < 0.0001), regardless of dishware condition. However, there were no significant differences for food intake between the dishware conditions, even after matching food choices. Promoting food intake and reducing eating challenges in RLWD likely needs multi-component interventions targeting meal quality, meal access, and mealtime experience. Trial registration ClincialTrials.gov Identifier: NCT04298788. Retrospectively registered: 6 March 2020, https://clinicaltrials.gov/ct2/show/NCT04298788?term=NCT04298788&draw=2&rank=1 .",2020,"Percent food intake was significantly greater at lunch (83.5 ± 19.0%) compared to dinner (75.8 ± 22.1%; p < 0.0001), regardless of dishware condition.","['18 RLWD (mean age 84.6\u2009±\u20097.9\xa0years, 72.2% female', 'Residents living with dementia (RLWD', 'residents living with dementia']",['blue dishware versus white dishware'],"['Percent food intake', 'food intake and eating challenges', 'proportion of eating challenges', 'food intake', 'food intake and mitigate eating challenges', 'risk of hospitalization, morbidity, and mortality', 'average food intake']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",5.0,0.0765427,"Percent food intake was significantly greater at lunch (83.5 ± 19.0%) compared to dinner (75.8 ± 22.1%; p < 0.0001), regardless of dishware condition.","[{'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Donnelly', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Wei', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Morrison-Koechl', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Keller', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada. hkeller@uwaterloo.ca.'}]",BMC research notes,['10.1186/s13104-020-05195-y'] 457,32703721,Effects of Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial.,"BACKGROUND Ketogenic metabolic therapy (KMT) using ketogenic diets (KD) is emerging as viable alternative or complementary strategy for managing cancer; however, few clinical trials have been reported. The present study aimed to evaluate the effects of a KD in patients with locally advanced and metastatic breast cancer receiving chemotherapy. METHODS A total of 80 patients undergoing treatment with chemotherapy were randomly assigned to KD or control group for 12 weeks. Concurrent with the admission, midway point, and at 12 weeks, fasting blood samples were collected for evaluation of insulin, IGF-1, CEA, CA15-3, ESR, CRP, IL-10, and TNF-α. Sonography for patients with locally advanced disease and CT or MRI scans for patients with metastatic disease were done on admission and at 12 weeks. At the completion of the chemotherapy, patients with locally advanced disease underwent surgery and stage was recalculated. Also patients with metastases were evaluated for response rate. RESULTS TNF-α decreased significantly after 12 weeks of treatment (MD: 0.64 [CI 95%: -3.7, 5] P < 0.001), while IL-10 increased (MD: 0.95 [CI 95%: -1,3] P < 0.001) in the intervention compared to the control group. Patients in the KD group had lower adjusted serum insulin compared to the control group (MD:-1.1 [CI 95%: -3,1] p < 0.002). KD lead to a reduction in tumor size in the KD compared to the control (27 vs 6 mm, P = 0.01). Stage decreased significantly in patients with locally advanced disease in the KD group after 12 weeks (P < 0.01). No significant differences in response rate were observed in patients with metastatic disease. CONCLUSIONS KMT in breast cancer patients might exert beneficial effects through decreasing TNF-α and insulin and increasing IL-10. KD may result in a better response through reductions in tumor size and downstaging in patients with locally advanced disease; however, more studies are needed to elucidate the potential beneficial effects of KD in patients with metastases. TRIAL REGISTRATION This trial has been registered on Iranian Registry of Clinical Trials (IRCT) under the identification code: IRCT20171105037259N2. https://www.irct.ir/trial/30755.",2021,Stage decreased significantly in patients with locally advanced disease in the KD group after 12 weeks (P < 0.01).,"['80 patients undergoing treatment with', 'patients with locally advanced disease underwent surgery and stage was recalculated', 'patients with locally advanced disease', 'patients with metastases', 'breast cancer patients', 'patients with metastatic disease', 'patients with locally advanced and metastatic breast cancer receiving chemotherapy', 'patients with breast cancer']","['chemotherapy', 'KD', 'Ketogenic metabolic therapy (KMT) using ketogenic diets (KD', 'Ketogenic metabolic therapy']","['insulin, IGF-1, CEA, CA15-3, ESR, CRP, IL-10, and TNF-α. Sonography', 'TNF-α', 'fasting blood samples', 'lower adjusted serum insulin', 'tumor size', 'response rate', 'IL-10']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0730490', 'cui_str': 'Stage 1S'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0259972', 'cui_str': 'Ketogenic diet'}, {'cui': 'C0587059', 'cui_str': 'Metabolic therapy'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0007082', 'cui_str': 'Carcinoembryonic antigen'}, {'cui': 'C0006611', 'cui_str': 'Cancer antigen 15-3'}, {'cui': 'C0013845', 'cui_str': 'Electron spin resonance measurement'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0475440', 'cui_str': 'Tumor size'}]",80.0,0.11375,Stage decreased significantly in patients with locally advanced disease in the KD group after 12 weeks (P < 0.01).,"[{'ForeName': 'Adeleh', 'Initials': 'A', 'LastName': 'Khodabakhshi', 'Affiliation': 'Department of Nutrition, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Esmaeil', 'Initials': 'ME', 'LastName': 'Akbari', 'Affiliation': 'Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hamid Reza', 'Initials': 'HR', 'LastName': 'Mirzaei', 'Affiliation': 'Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Thomas N', 'Initials': 'TN', 'LastName': 'Seyfried', 'Affiliation': 'Department of Biology, Boston College, Chestnut Hill, MA, United States.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Kalamian', 'Affiliation': 'Dietary Therapies LLLC, Hamilton, MT, United States.'}, {'ForeName': 'Sayed Hossein', 'Initials': 'SH', 'LastName': 'Davoodi', 'Affiliation': 'Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Cellular and Molecular Nutrition, Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: khodabakhshiadeleh@yahoo.com.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.06.028'] 458,32705473,12-Month Evaluation of an EHR-Supported Staff Role Change for Provision of Tobacco Cessation Care in 8 Primary Care Safety-Net Clinics.,"SIGNIFICANCE Guidelines urge primary care practices to routinely provide tobacco cessation care (i.e., assess tobacco use, provide brief cessation advice, and refer to cessation support). This study evaluates the impact of a systems-based strategy to provide tobacco cessation care in eight primary care clinics serving low-income patients. METHODS A non-randomized stepped wedge study design was used to implement an intervention consisting of (1) changes to the electronic health record (EHR) referral functionality and (2) expansion of staff roles to provide brief advice to quit; assess readiness to quit; offer a referral to tobacco cessation counseling; and sign the referral order. Outcomes assessed from the EHR include performance of tobacco cessation care tasks, referral contact, and enrollment rates for the quitline (QL) and in-house Freedom from Smoking (FFS) program. Generalized estimating equations (GEE) methods were used to compute odds ratios contrasting the pre-implementation vs. 1-, 3-, 6-, and 12-month post-implementation periods. RESULTS Of the 176,061 visits, 26.1% were by identified tobacco users. All indicators significantly increased at each time period evaluated post-implementation. In comparison with the pre-intervention period, assessing smoking status (26.6% vs. 55.7%; OR = 3.7, CI = 3.6-3.9), providing advice (44.8% vs. 88.7%; OR = 7.8, CI = 6.6-9.1), assessing readiness to quit (15.8% vs. 55.0%; OR = 6.2, CI = 5.4-7.0), and acceptance of a referral to tobacco cessation counseling (0.5% vs. 30.9%; OR = 81.0, CI = 11.4-575.8) remained significantly higher 12 months post-intervention. For the QL and FFS, respectively, there were 1223 and 532 referrals; 324 (31.1%) and 103 (24.7%) were contacted; 241 (74.4%) and 72 (69.6%) enrolled; and 195 (80.9%) and 14 (19.4%) received at least one counseling session. CONCLUSIONS This system change intervention that includes an EHR-supported role expansion substantially increased the provision of tobacco cessation care and improvements were sustained beyond 1 year. This approach has the potential to greatly increase the number of individuals referred for tobacco cessation counseling.",2020,This system change intervention that includes an EHR-supported role expansion substantially increased the provision of tobacco cessation care and improvements were sustained beyond 1 year.,['eight primary care clinics serving low-income patients'],"['systems-based strategy to provide tobacco cessation care', 'EHR-Supported Staff Role Change for Provision of Tobacco Cessation Care', 'electronic health record (EHR) referral functionality and (2) expansion of staff roles to provide brief advice to quit; assess readiness to quit']","['assessing readiness to quit', 'acceptance of a referral to tobacco cessation counseling', 'smoking status', 'EHR include performance of tobacco cessation care tasks, referral contact, and enrollment rates for the quitline (QL) and in-house Freedom from Smoking (FFS) program']","[{'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0600549', 'cui_str': 'Tobacco Cessation'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0237102', 'cui_str': 'Role change'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}]","[{'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0600549', 'cui_str': 'Tobacco Cessation'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]",,0.075455,This system change intervention that includes an EHR-supported role expansion substantially increased the provision of tobacco cessation care and improvements were sustained beyond 1 year.,"[{'ForeName': 'Susan A', 'Initials': 'SA', 'LastName': 'Flocke', 'Affiliation': 'Department of Family Medicine, Oregon Health & Science University, Portland, OR, USA. flocke@ohsu.edu.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Seeholzer', 'Affiliation': 'Center for Health Care Research and Policy, The MetroHealth System, Cleveland, OH, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Lewis', 'Affiliation': 'Center for Health Care Research and Policy, The MetroHealth System, Cleveland, OH, USA.'}, {'ForeName': 'India J', 'Initials': 'IJ', 'LastName': 'Gill', 'Affiliation': 'Center for Community Health Integration, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Jeanmarie C', 'Initials': 'JC', 'LastName': 'Rose', 'Affiliation': 'Center for Community Health Integration, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Albert', 'Affiliation': 'Center for Community Health Integration, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Love', 'Affiliation': 'Center for Health Care Research and Policy, The MetroHealth System, Cleveland, OH, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kaelber', 'Affiliation': 'Center for Health Care Research and Policy, The MetroHealth System, Cleveland, OH, USA.'}]",Journal of general internal medicine,['10.1007/s11606-020-06030-7'] 459,32722801,Intensive vs. standard blood pressure control and vascular procedures: insights from the Systolic Blood Pressure Intervention Trial (SPRINT).,,2021,,[],['Intensive versus standard blood pressure control and vascular procedures'],[],[],"[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",[],,0.0251511,,"[{'ForeName': 'Maria Lukács', 'Initials': 'ML', 'LastName': 'Krogager', 'Affiliation': 'Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Manan', 'Initials': 'M', 'LastName': 'Pareek', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Kristian Hay', 'Initials': 'KH', 'LastName': 'Kragholm', 'Affiliation': 'Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Byrne', 'Affiliation': 'Department of Cardiology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Muthiah', 'Initials': 'M', 'LastName': 'Vaduganathan', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Tor', 'Initials': 'T', 'LastName': 'Biering-Sørensen', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Dragana', 'Initials': 'D', 'LastName': 'Rujic', 'Affiliation': 'Department of Cardiology, Herlev and Gentofte Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Thomas Bastholm', 'Initials': 'TB', 'LastName': 'Olesen', 'Affiliation': 'Department of Internal Medicine, Hospital of Little Belt, Kolding, Denmark.'}, {'ForeName': 'Michael Hecht', 'Initials': 'MH', 'LastName': 'Olsen', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Holbæk Hospital, Holbæk, Denmark.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.""}]",European heart journal. Cardiovascular pharmacotherapy,['10.1093/ehjcvp/pvaa093'] 460,32737814,Examining Change in Self-Reported Gambling Measures Over Time as Related to Socially Desirable Responding Bias.,"Socially desirable responding is a response bias that can affect the accuracy of self-reports. It is especially likely when questions address sensitive topics, such as gambling attitudes, problems and behaviours. A sample of 321 participants were recruited from Amazon's mTurk crowdsourcing platform for a randomized controlled trial investigating an online gambling intervention. Data from this study was used to examine the influence of socially desirable responding on gambling self-report measures over time. At baseline, self-deception (SD), a factor of socially desirable responding, was significantly higher among males than females and among those with household incomes greater than $20,000 per year. Controlling for demographic variability, mixed effects models examining the relationship between socially desirable responding factors [SD and impression management (IM)] and time were conducted. Among males, there were significant interactions between IM with the NORC DSM-IV screen for gambling problems (NODS) and the gambling symptom assessment scale (G-SAS) scores respectively, over time. In other words, males with higher IM scores, demonstrated less change in NODS and G-SAS scores from baseline to 6-month follow-up compared to males with lower IM scores. There were no significant interactions in any models among females or among the full sample. Controlling the well-documented effect of socially desirable responding on self-reported measures in addictions research should be considered as a method to help reduce error and improve validity. Future research should continue to examine the effect of this bias on gambling measures over time and in each gender.Trial registration: https://ClinicalTrials.gov/NCT03124589 , registered 19 January 2017.",2021,"At baseline, self-deception (SD), a factor of socially desirable responding, was significantly higher among males than females and among those with household incomes greater than $20,000 per year.","[""321 participants were recruited from Amazon's mTurk crowdsourcing platform"", 'registered 19 January 2017']",['online gambling intervention'],"['NODS and G-SAS scores', 'Self-Reported Gambling Measures', 'self-deception (SD), a factor of socially desirable responding', 'gambling symptom assessment scale (G-SAS) scores']","[{'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C3494386', 'cui_str': 'Crowd Sourcing'}, {'cui': 'C0600375', 'cui_str': 'Registers'}]","[{'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0220952', 'cui_str': 'DSM-IV'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0024195', 'cui_str': 'Deception'}, {'cui': 'C0050325', 'cui_str': 'A-factor (Streptomyces)'}]",321.0,0.0618734,"At baseline, self-deception (SD), a factor of socially desirable responding, was significantly higher among males than females and among those with household incomes greater than $20,000 per year.","[{'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Schell', 'Affiliation': 'Institute of Mental Health and Policy Research, Centre for Addiction and Mental Health, 33 Russell St., Toronto, ON, M5S 2S1, Canada.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Godinho', 'Affiliation': 'Institute of Mental Health and Policy Research, Centre for Addiction and Mental Health, 33 Russell St., Toronto, ON, M5S 2S1, Canada.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Cunningham', 'Affiliation': 'Institute of Mental Health and Policy Research, Centre for Addiction and Mental Health, 33 Russell St., Toronto, ON, M5S 2S1, Canada. john.cunningham@camh.ca.'}]",Journal of gambling studies,['10.1007/s10899-020-09970-1'] 461,32744369,Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study.,"BACKGROUND Vitiligo is a common acquired pigmentary disorder. Bimatoprost ophthalmic solution was indicated in the treatment of open-angle glaucoma and eyebrow hypotrichosis. However, lid hyperpigmentation was reported as a complication. OBJECTIVE To study the efficacy and safety of 0.01% bimatoprost solution compared with 0.1% tacrolimus ointment in patients with nonsegmental facial vitiligo. METHODS Patients with more than 2 vitiliginous patches on the face were enrolled. Vitiliginous patches were randomized to receive topical 0.1% tacrolimus ointment or 0.01% bimatoprost ophthalmic solution, applied twice daily for 12 weeks. The vitiligo surface area (VSA, cm 2 ) was calculated, and the percentage of repigmentation was assessed. RESULTS Ten patients completed the study. At the baseline, the mean VSA was comparable between the two groups. By week 12, the VSA decreased at a statistically significant level among both groups compared to the baseline (P < .05). However, there was not a statistically significant difference between both groups. In terms of repigmentation at week 12, 20% of the patients in the bimatoprost group and 10% in the tacrolimus group achieved >50% repigmentation; the overall grading score between two groups were not different at a statistically significant level. The side effects of bimatoprost were reported as itching and burning. There were no changes in intraocular pressure in 2 patients who had lid involvement. CONCLUSION Topical bimatoprost solutions were safe and effective for the treatment of nonsegmental facial vitiligo with comparable results to tacrolimus ointment. It can be considered as an alternative treatment for facial vitiligo.",2021,Topical bimatoprost solutions were safe and effective for the treatment of non-segmental facial vitiligo with comparable results to tacrolimus ointment.,"['Vitiliginous patches', 'Patients with more than 2 vitiliginous patches on the face were enrolled', 'non-segmental facial vitiligo', 'patients with non-segmental facial vitiligo']","['tacrolimus ointment', 'topical bimatoprost', 'Topical bimatoprost solutions', 'bimatoprost solution', 'topical 0.1% tacrolimus ointment or 0.01% bimatoprost ophthalmic solution', 'tacrolimus', 'Bimatoprost ophthalmic solution']","['safe and effective', 'lid hyperpigmentation', 'mean VSA', 'overall grading score', 'itching and burning', 'VSA', 'efficacy and safety', 'intraocular pressure']","[{'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0205122', 'cui_str': 'Segmental'}, {'cui': 'C0042900', 'cui_str': 'Vitiligo'}]","[{'cui': 'C1253468', 'cui_str': 'Tacrolimus Topical Ointment'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0937917', 'cui_str': 'bimatoprost'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C1237705', 'cui_str': 'bimatoprost Ophthalmic Solution [Lumigan]'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}]",,0.0483403,Topical bimatoprost solutions were safe and effective for the treatment of non-segmental facial vitiligo with comparable results to tacrolimus ointment.,"[{'ForeName': 'Silada', 'Initials': 'S', 'LastName': 'Kanokrungsee', 'Affiliation': 'Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Duangrat', 'Initials': 'D', 'LastName': 'Pruettivorawongse', 'Affiliation': 'Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Natta', 'Initials': 'N', 'LastName': 'Rajatanavin', 'Affiliation': 'Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13648'] 462,32748570,"Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers.","Two open-label, single-dose, randomized crossover studies were conducted in healthy Japanesemen to (1) assess dose proportionality of 5 doses (1.38, 2.75, 5.5, 8.25, and 11.0 mg) of Lafenta, a novel matrix-type transdermal fentanyl patch with a rate-controlling membrane; and (2) compare patch bioequivalence (11.0 mg) with a commercially available reference patch (Durotep MT Patch [16.8 mg]). Pharmacokinetics, adhesion performance, residual fentanyl, and safety parameters were assessed. Increases in mean AUC 0-t and C max after application of the test patch were dose proportional. The test patch (11.0 mg) was bioequivalent to the 16.8-mg reference patch in terms of mean AUC 0-inf , AUC 0-t , and C max . Residual fentanyl levels 72 hours postapplication were lower in the test than in the reference patch. Differences in adhesion performance between the test and the reference patch did not affect delivery efficacy and reliability of the novel matrix patch. Safety findings were in line with previous experiences with fentanyl. Both studies showed low variation in fentanyl exposure and delivery via the test patch. The test patch provided equivalent fentanyl exposure at a lower dose than the reference patch formulation with lower variability and the potential to lower medicinal waste.",2021,Differences in adhesion performance between the test and the reference patch did not affect delivery efficacy and reliability of the novel matrix patch.,['Healthy Japanese Volunteers'],"['Lafenta, a novel matrix-type transdermal fentanyl patch with a rate-controlling membrane; and (2) compare patch bioequivalence', 'Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch']","['mean AUC 0-t and C max', 'Pharmacokinetics, adhesion performance, residual fentanyl, and safety parameters', 'adhesion performance', 'Safety, Tolerability, and Dose Proportionality', 'Residual fentanyl levels 72\xa0hours postapplication']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0040652', 'cui_str': 'Transdermal route'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0039789', 'cui_str': 'Equivalencies, Therapeutic'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0524136', 'cui_str': 'Fentanyl measurement'}, {'cui': 'C1292423', 'cui_str': '72 hours'}]",,0.019171,Differences in adhesion performance between the test and the reference patch did not affect delivery efficacy and reliability of the novel matrix patch.,"[{'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Lorch', 'Affiliation': ""Richmond Pharmacology Ltd., St George's University London, London, UK.""}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Pierscionek', 'Affiliation': ""Richmond Pharmacology Ltd., St George's University London, London, UK.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Freier', 'Affiliation': 'Richmond Research Institute, London, UK.'}, {'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Spencer', 'Affiliation': 'Richmond Research Institute, London, UK.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Täubel', 'Affiliation': ""Richmond Pharmacology Ltd., St George's University London, London, UK.""}]",Clinical pharmacology in drug development,['10.1002/cpdd.846'] 463,32715401,Tranexamic acid is beneficial for blood management of high tibial osteotomy: a randomized controlled study.,"INTRODUCTION The purpose of this study was to investigate whether TXA can effectively reduce blood loss after HTO and related complications and to evaluate its safety. MATERIALS AND METHODS From March 2016 to March 2018, 100 patients who underwent medial opening wedge HTO in the Department of Orthopedics, the second affiliated hospital of xi'an jiaotong university, with an average age of 52.8 ± 3.2 years, were randomly divided into the TXA group (using intravenous TXA) and the control group (using the same amount of normal saline), with 50 patients in each group. The postoperative wound drainage volume, decrease in hemoglobin and hematocrit value, total blood loss, wound healing, blood transfusion, deep venous thrombosis (DVT) and pulmonary embolism (PE) were compared between the two groups. RESULTS The drainage volume on the first postoperative day and the total drainage volume of the TXA group were significantly lower compared with those of the control group (145.7 vs 264.5 ml, 282.3 vs 413.2 ml, P < 0.05). The decreases in the hemoglobin and hematocrit values on the postoperative first, second and fifth days were lower in the TXA group than those in the control group (1.4 VS 3.5, 2.6 vs 3.3, 1.9 vs 2.9 g, P < 0.05; 3.3 vs 5.5, 5.0 vs 9.1, 3.8 vs 7.2%, P < 0.05), and the mean total blood loss was also lower in the TXA group than that in the control group (477.9 vs 834.6 ml, P < 0.05). In the control group, 1 patient had wound hematoma requiring additional paracentesis and pressure dressing, 1 patient had superficial wound infection requiring additional debridement, and 1 patient had postoperative blood transfusion compared to none in the TXA group (P > 0.05). There was no symptomatic DVT or PE in either of the groups. CONCLUSION Intravenous TXA can effectively and safely reduce blood loss and bleeding-related complications after HTO and was beneficial for the blood management of HTO.",2021,"The decreases in the hemoglobin and hematocrit values on the postoperative first, second and fifth days were lower in the TXA group than those in the control group (1.4 VS 3.5, 2.6 vs 3.3, 1.9 vs 2.9 ","[""100 patients who underwent medial opening wedge HTO in the Department of Orthopedics, the second affiliated hospital of xi'an jiaotong university, with an average age of 52.8\u2009±\u20093.2\xa0years"", 'high tibial osteotomy']","['TXA group (using intravenous TXA', 'Intravenous TXA', 'TXA', 'Tranexamic acid']","['wound hematoma requiring additional paracentesis and pressure dressing', 'symptomatic DVT or PE', 'postoperative wound drainage volume, decrease in hemoglobin and hematocrit value, total blood loss, wound healing, blood transfusion, deep venous thrombosis (DVT) and pulmonary embolism (PE', 'postoperative blood transfusion', 'hemoglobin and hematocrit values', 'superficial wound infection requiring additional debridement', 'total drainage volume', 'mean total blood loss', 'blood loss']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0439639', 'cui_str': 'Wedge'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0187826', 'cui_str': 'Osteotomy of tibia'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0281860', 'cui_str': 'Wound hematoma'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C1289828', 'cui_str': 'Pressure dressing'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0406834', 'cui_str': 'Wound discharge finding'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0162119', 'cui_str': 'Hemoglobin low'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0232100', 'cui_str': 'Exsanguination'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0332804', 'cui_str': 'Superficial wound'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",,0.0336011,"The decreases in the hemoglobin and hematocrit values on the postoperative first, second and fifth days were lower in the TXA group than those in the control group (1.4 VS 3.5, 2.6 vs 3.3, 1.9 vs 2.9 ","[{'ForeName': 'Jianlong', 'Initials': 'J', 'LastName': 'Ni', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Xiaoqian', 'Initials': 'X', 'LastName': 'Dang', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Zhibin', 'Initials': 'Z', 'LastName': 'Shi', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China. shizb1001@163.com.""}]",Archives of orthopaedic and trauma surgery,['10.1007/s00402-020-03558-5'] 464,32713721,"Effects of time-restricted feeding on body weight, body composition and vital signs in low-income women with obesity: A 12-month randomized clinical trial.","BACKGROUND & AIMS Time-restricted feeding (TRF) studies usually are of short-term, involving heterogeneous populations, without a control group with similar energy restriction. Besides, it seldom assess vital signs such as body temperature and heart rate, which may be influenced by the fasting state. In this investigation, we assessed the long-term effects of TRF on body weight, body composition and vital signs of low-income women with obesity undergoing diets with the same energy deficit. METHODS Low-income women with obesity were randomly allocated to a group with a hypoenergetic diet and 12 h of TRF or to a group with only a hypoenergetic diet, for 12 months. Body fat and waist circumference were estimated using a tetrapolar electrical bioimpedance and an inelastic measuring tape, respectively, at baseline and after 4, 6 and 12 months of intervention. Systolic and diastolic blood pressure, heart rate, and axillary temperature were measured at baseline and 12 months of intervention. The energy content of the diets was determined based on the women's resting metabolic rate (by indirect calorimetry) and level of physical activity (by triaxial accelerometers). Effects were analyzed using an intention-to-treat approach. RESULTS Fifty-eight women were randomized and 31 (53.44%) were lost to follow-up at 12 months. Dropout rates were similar between groups. In the intention-to-treat analysis, there were no significant changes in the body weight after 12 months (Differences in changes from baseline between groups: -0.05 95%CI [-2.34; 2.24] Kg; p = 0.96). An increase in axillary temperature (0.40 °C, 95% CI [-0.14; 0.67]°C, p < 0.01), a reduction in the percentage of body fat (-1.64%, 95% CI [-3.08; -0.19]%, p = 0.02) and waist circumference (-2.57 cm, 95% CI [-5.73; 0.58] cm, p = 0.03 in the mixed model involving 4 measurements) were observed in the intervention group, when compared to the control group. CONCLUSIONS TRF showed no effects on weight loss. Nevertheless the findings on waist circumference and body fat, although not clinically meaningful, suggest that this strategy may help in the long-term management of obesity in this population, since it is an easy to apply intervention. Axillary temperature findings warrants further investigation. Registered under www.ensaiosclinicos.gov.br Identifier no. RBR-387v6v. TRIAL REGISTRATION http://www.ensaiosclinicos.gov.br/rg/RBR-387v6v/.",2021,"An increase in axillary temperature (0.40 °C, 95% CI","['low-income women with obesity', 'low-income women with obesity undergoing diets with the same energy deficit', 'Fifty-eight women', 'Low-income women with obesity']","['RBR-387v6v', 'TRF', 'time-restricted feeding', 'hypoenergetic diet and 12\xa0h of TRF or to a group with only a hypoenergetic diet']","['waist circumference', 'axillary temperature', 'body weight', 'Dropout rates', 'weight loss', 'body weight, body composition and vital signs', 'percentage of body fat', 'Body fat and waist circumference', 'Systolic and diastolic blood pressure, heart rate, and axillary temperature']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C4517817', 'cui_str': '58'}]","[{'cui': 'C4704883', 'cui_str': 'Time Restricted Feeding'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1531924', 'cui_str': 'Axillary temperature'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",58.0,0.141779,"An increase in axillary temperature (0.40 °C, 95% CI","[{'ForeName': 'Isabele Rejane', 'Initials': 'IR', 'LastName': 'de Oliveira Maranhão Pureza', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'André Eduardo', 'Initials': 'AE', 'LastName': 'da Silva Junior', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Dafiny Rodrigues', 'Initials': 'DR', 'LastName': 'Silva Praxedes', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Laís Gomes', 'Initials': 'LG', 'LastName': 'Lessa Vasconcelos', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Mateus', 'Initials': 'M', 'LastName': 'de Lima Macena', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Ingrid Sofia', 'Initials': 'IS', 'LastName': 'Vieira de Melo', 'Affiliation': 'Instituto Federal de Alagoas, Rua 17 de agosto, s/n, 57120-000, Satuba-AL, Brazil.'}, {'ForeName': 'Telma Maria', 'Initials': 'TM', 'LastName': 'de Menezes Toledo Florêncio', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Nassib Bezerra', 'Initials': 'NB', 'LastName': 'Bueno', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil. Electronic address: nassib.bueno@fanut.ufal.br.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.06.036'] 465,32735514,Treatment Outcomes of a Multi-Component Mobile Health Smoking Cessation Pilot Intervention for People with Schizophrenia.,"OBJECTIVE The objective of this study was to investigate the feasibility and acceptability of a multi-component mobile contingency management (CM) pilot intervention for smoking cessation for people with schizophrenia. Methods: This intervention included mobile CM (i.e., monetary compensation for bioverification of abstinence through using a phone app), cognitive behavioral therapy (CBT), and pharmacotherapy for smoking cessation. This intervention was compared to an intensive treatment comparison (ITC), which contained all components except the CM. Participants were bioverified with carbon monoxide and saliva cotinine at a 6-month follow-up session. Results: In this pilot, the treatment group did not differ from the ITC at any time point. However, measures of treatment feasibility and acceptability indicated that smokers with schizophrenia were able to navigate the CM phone application and adhere to the protocol, demonstrating the potential utility of mobile interventions in this population. Conclusions: Despite lack of long-term abstinence for participants, adherence to the mobile application intervention indicates the potential for future investigation of mobile smoking cessation treatments for people with schizophrenia.",2020,"However, measures of treatment feasibility and acceptability indicated that smokers with schizophrenia were able to navigate the CM phone application and adhere to the protocol, demonstrating the potential utility of mobile interventions in this population. ","['People with Schizophrenia', 'people with schizophrenia', 'smokers with schizophrenia']","['multi-component mobile contingency management (CM) pilot intervention', 'mobile CM (i.e., monetary compensation for bioverification of abstinence through using a phone app), cognitive behavioral therapy (CBT), and pharmacotherapy for smoking cessation', 'Multi-Component Mobile Health Smoking Cessation Pilot Intervention']","['feasibility and acceptability', 'bioverified with carbon monoxide and saliva cotinine']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0010194', 'cui_str': 'Cotinine'}]",,0.0259744,"However, measures of treatment feasibility and acceptability indicated that smokers with schizophrenia were able to navigate the CM phone application and adhere to the protocol, demonstrating the potential utility of mobile interventions in this population. ","[{'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Medenblik', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Mann', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Tiffany A', 'Initials': 'TA', 'LastName': 'Beaver', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Dedert', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Wilson', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Patrick S', 'Initials': 'PS', 'LastName': 'Calhoun', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'Beckham', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}]",Journal of dual diagnosis,['10.1080/15504263.2020.1797259'] 466,32742642,A period of 10 weeks of increased protein consumption does not alter faecal microbiota or volatile metabolites in healthy older men: a randomised controlled trial.,"Diet has a major influence on the composition and metabolic output of the gut microbiome. Higher-protein diets are often recommended for older consumers; however, the effect of high-protein diets on the gut microbiota and faecal volatile organic compounds (VOC) of elderly participants is unknown. The purpose of the study was to establish if the faecal microbiota composition and VOC in older men are different after a diet containing the recommended dietary intake (RDA) of protein compared with a diet containing twice the RDA (2RDA). Healthy males (74⋅2 (sd 3⋅6) years; n 28) were randomised to consume the RDA of protein (0⋅8 g protein/kg body weight per d) or 2RDA, for 10 weeks. Dietary protein was provided via whole foods rather than supplementation or fortification. The diets were matched for dietary fibre from fruit and vegetables. Faecal samples were collected pre- and post-intervention for microbiota profiling by 16S ribosomal RNA amplicon sequencing and VOC analysis by head space/solid-phase microextraction/GC-MS. After correcting for multiple comparisons, no significant differences in the abundance of faecal microbiota or VOC associated with protein fermentation were evident between the RDA and 2RDA diets. Therefore, in the present study, a twofold difference in dietary protein intake did not alter gut microbiota or VOC indicative of altered protein fermentation.",2020,"After correcting for multiple comparisons, no significant differences in the abundance of faecal microbiota or VOC associated with protein fermentation were evident between the RDA and 2RDA diets.","['Healthy males (74⋅2 (sd 3⋅6) years; n 28', 'older men', 'healthy older men']",[],"['faecal microbiota composition and VOC', 'faecal microbiota or volatile metabolites', 'gut microbiota or VOC indicative of altered protein fermentation', 'abundance of faecal microbiota or VOC associated with protein fermentation']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}]",[],"[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C2350439', 'cui_str': 'Volatile Organic Compounds'}, {'cui': 'C0443769', 'cui_str': 'Volatile agent'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015852', 'cui_str': 'Fermentation'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]",28.0,0.0232378,"After correcting for multiple comparisons, no significant differences in the abundance of faecal microbiota or VOC associated with protein fermentation were evident between the RDA and 2RDA diets.","[{'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Mitchell', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'E J', 'Initials': 'EJ', 'LastName': 'McKenzie', 'Affiliation': 'Department of Physiology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'Mitchell', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Milan', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Zeng', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'R F', 'Initials': 'RF', 'LastName': ""D'Souza"", 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Ramzan', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Sharma', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Rettedal', 'Affiliation': 'Food Nutrition & Health Team, AgResearch, Palmerston North, New Zealand.'}, {'ForeName': 'S O', 'Initials': 'SO', 'LastName': 'Knowles', 'Affiliation': 'Food Nutrition & Health Team, AgResearch, Palmerston North, New Zealand.'}, {'ForeName': 'N C', 'Initials': 'NC', 'LastName': 'Roy', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sjödin', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Copenhagen University, Copenhagen, Denmark.'}, {'ForeName': 'K-H', 'Initials': 'KH', 'LastName': 'Wagner', 'Affiliation': 'Department of Nutritional Sciences and Research Platform Active Ageing, University of Vienna, Vienna, Austria.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': ""O'Sullivan"", 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cameron-Smith', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}]",Journal of nutritional science,['10.1017/jns.2020.15'] 467,32742646,Attenuation of glycaemic and insulin responses following tapioca resistant maltodextrin consumption in healthy subjects: a randomised cross-over controlled trial.,"Resistant maltodextrin (RMD) from various sources of starch has been extensively studied. However, studies which reported the effects of tapioca RMD (TRM) on glucose and insulin response are lacking. This study investigated the effect of TRM on postprandial plasma glucose and serum insulin in healthy subjects. Additionally, satiety and gastrointestinal tolerability were also evaluated. Sixteen healthy participants received five different treatments on five separate days. Participants received 50 g of either: glucose (GL), tapioca maltodextrin (TM), TRM, MIX15% (7⋅5 g TRM + 42⋅5 g TM) or MIX50% (25 g TRM + 25 g TM). Plasma glucose, serum insulin and subjective appetite responses were measured postprandially over 180 min. Gastrointestinal symptoms were evaluated by questionnaire before and after each test day. Results showed that at 30 min after treatment drinks, plasma glucose after TRM was significantly lowest (104⋅60 (sem 2⋅63 mg/dl) than after GL (135⋅87 (sem 4⋅88) mg/dl; P <0⋅001), TM (127⋅93 (sem 4⋅05) mg/dl; P = 0⋅001), MIX15% (124⋅67 (sem 5⋅73) mg/dl; P = 0⋅039) and MIX50% (129⋅33 (sem 5⋅23) mg/dl; P = 0⋅003) (1 mg/dl = 0⋅0555 mmol/l). In addition, TRM also significantly reduced serum insulin (13⋅01 (sem 2⋅12) μIU/ml) compared with GL (47⋅90 (sem 11⋅93) μIU/ml; P = 0⋅013), TM (52⋅96 (sem 17⋅68) μIU/ml; P = 0⋅002) and MIX50% (33⋅16 (sem 4⋅99) μIU/ml; P = 0⋅008). However, there were no significant differences in subjective appetite between treatments ( P > 0⋅05). A single high dose of TRM (50 g) caused flatulence ( P < 0⋅05). Tapioca resistant maltodextrin has low digestibility in the small intestine and, therefore, reduced incremental plasma glucose and serum insulin, without affecting satiety in healthy subjects over 180 min. Gastrointestinal tolerability of TRM should be considered when consumed in high doses.",2020,A single high dose of TRM (50 g) caused flatulence ( P < 0⋅05).,"['healthy subjects over 180 min', 'Sixteen healthy participants', 'healthy subjects']","['μIU', 'Tapioca resistant maltodextrin', 'tapioca RMD (TRM', 'tapioca resistant maltodextrin consumption', 'TRM', 'glucose (GL), tapioca maltodextrin (TM), TRM, MIX15% (7⋅5 g TRM + 42⋅5 g TM) or MIX50', 'Resistant maltodextrin (RMD']","['Plasma glucose, serum insulin and subjective appetite responses', 'serum insulin', 'postprandial plasma glucose and serum insulin', 'satiety and gastrointestinal tolerability', 'plasma glucose after TRM', 'Gastrointestinal tolerability', 'subjective appetite', 'flatulence', 'Gastrointestinal symptoms']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C3715157', 'cui_str': '16'}]","[{'cui': 'C0007335', 'cui_str': 'Manihot esculenta'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C1853698', 'cui_str': 'Rippling muscle disease'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}]","[{'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}]",16.0,0.0769949,A single high dose of TRM (50 g) caused flatulence ( P < 0⋅05).,"[{'ForeName': 'Junaida', 'Initials': 'J', 'LastName': 'Astina', 'Affiliation': 'Food and Nutrition Program, Department of Nutrition and Dietetics, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Suwimol', 'Initials': 'S', 'LastName': 'Sapwarobol', 'Affiliation': 'Department of Nutrition and Dietetics, Chulalongkorn University, Bangkok, Thailand.'}]",Journal of nutritional science,['10.1017/jns.2020.22'] 468,32745493,Optimal timing of postoperative patient telephone calls after Mohs micrographic surgery: A randomized controlled trial.,,2021,,['postoperative patient telephone calls after Mohs micrographic surgery'],[],[],"[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0079850', 'cui_str': 'Mohs surgery'}]",[],[],,0.218998,,"[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Bednarek', 'Affiliation': 'Department of Dermatology, University of Missouri, Columbia, Missouri. Electronic address: rbednare11@gmail.com.'}, {'ForeName': 'Cory', 'Initials': 'C', 'LastName': 'Jonak', 'Affiliation': 'University of Missouri School of Medicine, Columbia, Missouri.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Golda', 'Affiliation': 'Department of Dermatology, University of Missouri, Columbia, Missouri.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.07.106'] 469,32761620,Diagnostic workup including CD203c-based basophil activation test in immediate hypersensitivity due to metronidazole and ornidazole and evaluation of cross-reactivity in between.,"BACKGROUND Little is known about the diagnostic approaches for immediate hypersensitivity reactions (IHRs) due to 5-nitroimidazole antibiotics. The aim was to evaluate the usefulness of in vivo tests and basophil activation test (BAT) for the diagnosis of IHRs due to metronidazole and ornidazole and to determine possible cross-reactivity in between. METHODS Forty-nine patients with a clear history of IHRs due to these drugs and 20 healthy subjects who were known to tolerate these drugs were included. Skin tests (STs) and single-blind placebo-controlled drug provocation tests (SBPCDPTs) were performed with both drugs whereas BAT was applied only with the culprit drug. RESULTS The most and least common reaction types were urticaria/angioedema (34.7%) and anaphylaxis (14.3%), respectively. SBPCDPTs were positive in 15 out of 47 patients, and only 7 had positive STs. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of STs for metronidazole/ornidazole were 33.3%/16.6%, 94.2%/97.3%, 60%/50%, and 84.6%/88.1%, respectively. BAT was positive in 12 out of 15 patients and negative in 10 control subjects, giving a sensitivity rate of 71.4% (CI, 29.0%-96.3%) for metronidazole and 83.3% (CI, 35.8%-99.5%) for ornidazole. The optimal concentration of both drugs for BAT was determined as 5 mg/mL. No cross-reactivity among two drugs was observed according to in vivo tests. CONCLUSIONS Our study showed that SBPCDPT and BAT are both useful diagnostic tools for IHRs due to 5-nitroimidazole antibiotics and can be used as supplementary to each other. No cross-reactivity between metronidazole and ornidazole in IHRs exists.",2021,"The most and least common reaction types were urticaria/angioedema (34.7%) and anaphylaxis (14.3%), respectively.",['Forty-nine patients with a clear history of IHRs due to these drugs and 20 healthy subjects who were known to tolerate these drugs were included'],"['metronidazole', 'SBPCDPT and BAT', 'basophil activation test (BAT', 'Skin tests (STs), and single-blind placebo-controlled drug provocation tests (SBPCDPTs']","['sensitivity rate', 'urticaria/angioedema', 'Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of STs for metronidazole/ornidazole', 'BAT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0020523', 'cui_str': 'IgE-mediated allergic disorder'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0004827', 'cui_str': 'Basophils'}, {'cui': 'C0201781', 'cui_str': 'Activation test'}, {'cui': 'C0037296', 'cui_str': 'Hypersensitivity skin testing'}, {'cui': 'C0242570', 'cui_str': 'Single-Masked Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013168', 'cui_str': 'Drug Control'}, {'cui': 'C0449428', 'cui_str': 'Provocation'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0042109', 'cui_str': 'Urticaria'}, {'cui': 'C0002994', 'cui_str': 'Angioedema'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0037296', 'cui_str': 'Hypersensitivity skin testing'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0029274', 'cui_str': 'Ornidazole'}, {'cui': 'C0004827', 'cui_str': 'Basophils'}, {'cui': 'C0201781', 'cui_str': 'Activation test'}]",49.0,0.0301092,"The most and least common reaction types were urticaria/angioedema (34.7%) and anaphylaxis (14.3%), respectively.","[{'ForeName': 'Şengül', 'Initials': 'Ş', 'LastName': 'Beyaz', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Nilgün', 'Initials': 'N', 'LastName': 'Akdeniz', 'Affiliation': 'Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Abdullah', 'Initials': 'A', 'LastName': 'Yılmaz', 'Affiliation': 'Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Semra', 'Initials': 'S', 'LastName': 'Demir', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Nida', 'Initials': 'N', 'LastName': 'Öztop', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Bahauddin', 'Initials': 'B', 'LastName': 'Çolakoğlu', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Suna', 'Initials': 'S', 'LastName': 'Büyüköztürk', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Günnur', 'Initials': 'G', 'LastName': 'Deniz', 'Affiliation': 'Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Aslı', 'Initials': 'A', 'LastName': 'Gelincik', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}]",Allergy,['10.1111/all.14542'] 470,32766852,"In childhood mature B-NHL with CNS disease, patients with blasts in cerebrospinal fluid are at higher risk of failure.","To identify the factors influencing outcome in childhood mature B-cell non-Hodgkin lymphoma and acute leukemia (B-NHL/AL) with central nervous system (CNS) disease (CNS+), we analyzed patients <18 years with newly diagnosed B-NHL/AL registered in 3 Lymphomes Malins B studies in France between 1989 to 2011. CNS+ was diagnosed on fulfillment of ≥1 of the following criteria: any L3 cerebrospinal fluid (CSF) blasts (CSF+), cranial nerve palsy, isolated intracerebral mass but also clinical spinal cord compression, and cranial or spinal parameningeal extension. Two hundred seventeen out of 1690 patients (12.8%) were CNS+. CNS+ was significantly associated with male gender, head/neck locations, Burkitt histology, high initial lactate dehydrogenase (LDH) level, and bone marrow involvement. CSF+ was the most frequent pattern of CNS+ (45%). For the 217 CNS+ patients, the 5-year event-free survival (EFS) and overall survival rates (95% confidence interval) were 81.5% (75.8% to 86.1%) and 83.9% (78.4% to 88.2%), respectively. In multivariate analysis, among CNS+ patients, low EFS was associated with CSF+, high initial LDH level, and poor response to cyclophosphamide, oncovin (vincristine), prednisone prephase. These findings have been considered for patient's stratification in the international randomized phase 3 trial Inter-B-NHL-ritux 2010 for children and adolescents with high-risk B-NHL/AL with CNS+ CSF+ patients only receiving intensified chemotherapy.",2020,"For the 217 CNS+ patients, the 5-year event-free survival (EFS) and overall survival rates (95% confidence interval) were 81.5% (75.8% to 86.1%) and 83.9% (78.4% to 88.2%), respectively.","['Two hundred seventeen out of 1690 patients (12.8%) were CNS', 'childhood mature B-cell non-Hodgkin lymphoma and acute leukemia (B-NHL/AL) with central nervous system (CNS) disease (CNS+), we analyzed patients <18 years with newly diagnosed B-NHL/AL registered in 3 Lymphomes Malins B studies in France between 1989 to 2011', 'children and adolescents with high-risk B-NHL/AL with CNS+ CSF+ patients only receiving intensified chemotherapy']","['CSF', 'CNS', 'cyclophosphamide, oncovin (vincristine), prednisone']","['male gender, head/neck locations, Burkitt histology, high initial lactate dehydrogenase (LDH) level, and bone marrow involvement', '5-year event-free survival (EFS) and overall survival rates']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517547', 'cui_str': '12.8'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0205286', 'cui_str': 'Mature'}, {'cui': 'C0079731', 'cui_str': 'B-cell lymphoma (clinical)'}, {'cui': 'C0085669', 'cui_str': 'Acute leukemia'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0027769', 'cui_str': 'Nervousness'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0591904', 'cui_str': 'Oncovine'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",1690.0,0.0824711,"For the 217 CNS+ patients, the 5-year event-free survival (EFS) and overall survival rates (95% confidence interval) were 81.5% (75.8% to 86.1%) and 83.9% (78.4% to 88.2%), respectively.","[{'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Simonin', 'Affiliation': 'Department of Pediatric Oncology and Hematology, Armand Trousseau Hospital, Assistance Publique-Hôpitaux de Paris and Sorbonne University, Paris, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Auperin', 'Affiliation': 'Unit of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, INSERM 1018, Villejuif, France.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Bertrand', 'Affiliation': 'Department of Pediatric Hematology, Institute of Pediatric Hematology and Oncology, Claude Bernard University Lyon, Paris, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Aladjidi', 'Affiliation': 'Department of Pediatric Oncology and Haematology, University Hospital of Bordeaux, Bordeaux, France.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Baruchel', 'Affiliation': 'Department of Pediatric Hematology and Immunology, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris and University Paris Diderot, Paris, France.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Contet', 'Affiliation': 'Department of Pediatric Onco-Hematology, University Hospital of Nancy, Nancy, France.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Coze', 'Affiliation': 'Department of Pediatric Hematology and Oncology, Timone Enfants Hospital, Assistance Publique-Hôpitaux de Marseille and Aix-Marseille University, Marseille, France.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Gandemer', 'Affiliation': 'Department of Pediatric Onco-Hematology, University Hospital of Rennes, University of Rennes 1, Rennes, France.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Haouy', 'Affiliation': 'Department of Pediatric Onco-Hematology, University Hospital of Montpellier, Montpellier, France.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Leblanc', 'Affiliation': 'Department of Pediatric Hematology and Immunology, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris and University Paris Diderot, Paris, France.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Leverger', 'Affiliation': 'Department of Pediatric Oncology and Hematology, Armand Trousseau Hospital, Assistance Publique-Hôpitaux de Paris and Sorbonne University, Paris, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Michon', 'Affiliation': 'Pediatric Oncology Unit, SIREDO, Institut Curie, Paris, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Patte', 'Affiliation': 'Department of Pediatric and Adolescent Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; and.'}, {'ForeName': 'Veronique', 'Initials': 'V', 'LastName': 'Minard-Colin', 'Affiliation': 'Department of Pediatric and Adolescent Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; and.'}]",Blood advances,['10.1182/bloodadvances.2019001398'] 471,32770831,"Cannabidivarin for HIV-Associated Neuropathic Pain: A Randomized, Blinded, Controlled Clinical Trial.","HIV remains a major burden to the health care system and neuropathic pain is the most common neurological complication of HIV infection. Because current treatment strategies often lack satisfying pain relief, cannabinoids (CBs) are discussed as a new option. We investigated cannabidivarin (CBDV) as treatment for HIV-associated neuropathic pain. We conducted a randomized, double-blind, placebo-controlled crossover study. Patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV (400 mg/day) or placebo in a randomized order. A 3-week washout phase was designed to eliminate potential carry-over effects. Patients were followed up for 3 weeks after the end of the second treatment phase. The primary end point was pain intensity on an 11-point numeric rating scale, recorded in a diary. Secondary end points were additional pain medication, pain characteristics, and quality of life. We included 32 patients. The mean pain intensity under CBDV was 0.62 points higher compared with placebo (P = 0.16, 95% confidence interval -0.27 to 1.51). CBDV did not influence the amount of additional pain medication, pain characteristics, or quality of life. The incidence of adverse events was similar during both treatments. No suspected unexpected adverse reactions occurred during either treatment. CBDV was safe but failed to reduce neuropathic pain in patients with HIV. This may be explained by a lack of CB receptor activation, as indicated by preclinical experiments. Although a larger patient number might be desirable, we would not expect a change in the conclusions because the present differences are far from statistical significance. Therefore, we would currently not consider CBDV as a clinically meaningful treatment option for neuropathic pain.",2021,The mean pain intensity under cannabidivarin was 0.62 points higher compared to placebo (p=0.16; 95% CI -0.27 to 1.51).,"['HIV-associated neuropathic pain', '32 patients']","['cannabidivarin (400mg/d) or placebo', 'Cannabidivarin', 'placebo']","['mean pain intensity under cannabidivarin', 'pain intensity on an 11-point numeric rating scale', 'adverse events', 'adverse reactions', 'additional pain medication, pain characteristics or quality of life', 'neuropathic pain', 'additional pain medication, pain characteristics and quality of life']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C3657549', 'cui_str': 'cannabidivarin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C3657549', 'cui_str': 'cannabidivarin'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1286315', 'cui_str': 'Characteristic of pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}]",32.0,0.414352,The mean pain intensity under cannabidivarin was 0.62 points higher compared to placebo (p=0.16; 95% CI -0.27 to 1.51).,"[{'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Eibach', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Scheffel', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Cardebring', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Lettau', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Özgür Celik', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Morguet', 'Affiliation': 'Department of Cardiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Roehle', 'Affiliation': 'Institute of Biometry and Clinical Epidemiology, Coordinating Center for Clinical Studies, Berlin Institute of Health, Charité Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Stein', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.2016'] 472,32779375,"A randomized, split-face, double-blind, comparative study of the safety and efficacy of small- and large-particle hyaluronic acid fillers for the treatment of nasolabial folds.","BACKGROUND Injections of hyaluronic acid (HA) for tissue augmentation are one of the most common aesthetic treatments performed worldwide. However, few studies have compared the safety and efficacy of small- and large-particle HA (SP-HA; LP-HA). AIM To assess and compare the safety and efficacy of SP-HA and LP-HA for the correction of nasolabial folds (NLFs). METHODS A prospective, split-face, triple-blind study design was used. Ten female subjects were recruited. Patients underwent treatment at baseline, an optional touch up at Week 2, and a follow-up visit at Week 4. At weeks 2 and 4, a blinded reviewer assessed the patients using the Global Aesthetic Improvement Scale (GAIS) and Wrinkle Severity Rating Scale (WSRS); and subjects completed the Patient Satisfaction Questionnaire (PSQ). At all visits, 3-dimensional imagery and ultrasonography of patients' NLFs were captured. Adverse events (AEs) were evaluated by the Investigator and recorded by subjects in diaries. RESULTS The GAIS response rate, defined as ≥ ""improved"" from baseline, was between 90 (2 weeks) and 100% (1 month) for SP-HA and was 100% for LP-HA, at both visits. Paired-samples t tests revealed significant differences in the change in WSRS scores between groups, at both visits (P < .01). Differences in the clinical effect and lifting capacity of both products were observed in 3-dimensional imagery and ultrasonography. Treatment volumes varied, with 61.32% more SP-HA being required than LP-HA for achieving a ≥ one-grade WSRS improvement. There were no severe AEs throughout the trial, nor AEs related to the investigational device. CONCLUSIONS LP-HA demonstrates better efficacy for correcting bony resorption in the nasal pyriform region.",2021,"Paired-samples t-tests revealed significant differences in the change in WSRS scores between groups, at both visits (p <0.01).","['Ten female subjects were recruited', 'nasolabial folds']","['hyaluronic acid (HA', 'small- and large-particle hyaluronic acid fillers', 'SP-HA and LP-HA']","['3-dimensional imagery and ultrasonography', 'GAIS response rate, defined as ≥ ""improved', 'Global Aesthetic Improvement Scale (GAIS) and Wrinkle Severity Rating Scale (WSRS); and subjects completed the Patient Satisfaction Questionnaire (PSQ', 'Adverse events (AEs', 'WSRS scores']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0221328', 'cui_str': 'Nasolabial sulcus structure'}]","[{'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0729441', 'cui_str': 'Filler'}]","[{'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0037301', 'cui_str': 'Wrinkled skin'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",10.0,0.0475735,"Paired-samples t-tests revealed significant differences in the change in WSRS scores between groups, at both visits (p <0.01).","[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Nikolis', 'Affiliation': 'Erevna Innovations Clinical Research Unit, Westmount, QC, Canada.'}, {'ForeName': 'Kaitlyn M', 'Initials': 'KM', 'LastName': 'Enright', 'Affiliation': 'Erevna Innovations Clinical Research Unit, Westmount, QC, Canada.'}, {'ForeName': 'Åke', 'Initials': 'Å', 'LastName': 'Öhrlund', 'Affiliation': 'Galderma Aesthetics, Uppsala, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Winlöf', 'Affiliation': 'Galderma Aesthetics, Uppsala, Sweden.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Cotofana', 'Affiliation': 'Department of Clinical Anatomy, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13668'] 473,32777055,"Cyclic alternating pattern in children with obstructive sleep apnea and its relationship with adenotonsillectomy, behavior, cognition, and quality of life.","STUDY OBJECTIVES To determine in children with obstructive sleep apnea (OSA) the effect of adenotonsillectomy (AT) on the cyclic alternating pattern (CAP) and the relationship between CAP and behavioral, cognitive, and quality-of-life measures. METHODS CAP parameters were analyzed in 365 overnight polysomnographic recordings of children with mild-to-moderate OSA enrolled in the Childhood Adenotonsillectomy Trial (CHAT), randomized to either early AT (eAT) or watchful waiting with supportive care (WWSC). We also analyzed CAP in a subgroup of 72 children with moderate OSA (apnea-hypopnea index > 10) that were part of the CHAT sample. Causal mediation analysis was performed to determine the independent effect of changes in CAP on selected outcome measures. RESULTS At baseline, a higher number of A1 phases per hour of sleep was significantly associated with worse behavioral functioning (caregiver Behavior Rating Inventory of Executive Function (BRIEF) Global Executive Composite (GEC): ρ = 0.24, p = 0.042; caregiver Conners' Rating Scale Global Index: ρ = 0.25, p = 0.036) and lower quality of life (OSA-18: ρ = 0.27, p = 0.022; PedsQL: ρ = -0.29, p = 0.015) in the subgroup of children with moderate OSA, but not across the entire sample. At 7-months follow-up, changes in CAP parameters were comparable between the eAT and WWSC arms. CAP changes did not account for significant proportions of variations in behavioral, cognitive, and quality-of-life performance measures at follow-up. CONCLUSIONS We show a significant association between the frequency of slow, high-amplitude waves with behavioral functioning, as well as the quality of life in children with moderate OSA. Early AT in children with mild-to-moderate OSA does not alter the microstructure of nonrapid eye movement sleep compared with watchful waiting after an approximately 7-month period of follow-up. CLINICAL TRIAL The study ""A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome"" was registered at Clinicaltrials.gov (#NCT00560859).",2021,"CAP changes did not account for significant proportions of variations in behavioral, cognitive and quality-of-life performance measures at follow-up. ","['children with mild-to-moderate OSA', '72 children with moderate OSA (apnea-hypopnea index>10) that were part of the CHAT sample', '365 overnight polysomnographic recordings of children with mild-to-moderate OSA enrolled in the Childhood Adenotonsillectomy Trial (CHAT', 'children with obstructive sleep apnea', 'Children', 'children with moderate OSA', 'children with obstructive sleep apnea (OSA']","['Adenotonsillectomy', 'early adenotonsillectomy (eAT) or watchful waiting with supportive care (WWSC', 'adenotonsillectomy', 'Cyclic alternating pattern (CAP']","['CAP parameters', 'lower quality of life', 'quality-of-life', 'behavioral, cognitive and quality-of-life performance measures', 'CAP and behavioral, cognitive, and quality-of-life measures', 'higher number of A1-phases per hour of sleep', ""caregiver Conners' Rating Scale Global Index""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0235546', 'cui_str': 'Slow shallow breathing'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0680063', 'cui_str': 'Child of'}]","[{'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0344211', 'cui_str': 'Support'}, {'cui': 'C0439596', 'cui_str': 'Cyclic'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]","[{'cui': 'C0439596', 'cui_str': 'Cyclic'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0564385', 'cui_str': '/hour'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",72.0,0.0678171,"CAP changes did not account for significant proportions of variations in behavioral, cognitive and quality-of-life performance measures at follow-up. ","[{'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Hartmann', 'Affiliation': 'School of Electrical and Electronic Engineering, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Oliviero', 'Initials': 'O', 'LastName': 'Bruni', 'Affiliation': 'Department of Social and Developmental Psychology, Sapienza University, Rome, Italy.'}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'Ferri', 'Affiliation': 'Sleep Research Center; Department of Neurology IC, Oasi Research Institute-IRCCS, Troina, Italy.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Redline', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital and Beth Israel Deaconess Medical School, Harvard Medical School, Boston, MA.""}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Baumert', 'Affiliation': 'School of Electrical and Electronic Engineering, University of Adelaide, Adelaide, Australia.'}]",Sleep,['10.1093/sleep/zsaa145'] 474,32720384,Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?,"BACKGROUND The reduction of cardiovascular events with icosapent ethyl-intervention trial (REDUCE-IT) trial revealed robust atherosclerotic cardiovascular risk reduction with a strategy comprising high-dose omega-3 icosapent ethyl vs placebo in statin-treated patients with elevated triglycerides and controlled low-density lipoprotein cholesterol (LDL-C). HYPOTHESIS Are the results of the REDUCE-IT trial applicable to the French registry on acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) population? METHODS Data were extracted from the FAST-MI 2010 and 2015 registries. We applied the REDUCE-IT enrolment criteria (triglycerides 150-500 mg/dL and LDL-C 40-100 mg/dL on statins) to the FAST-MI population in patients aged ≥45 years who had detailed lipid values postacute hospitalization, focusing on their clinical profile and cardiovascular prognosis. RESULTS Of the 3789 FAST-MI patients with a full lipid profile (median 11.1 [IQR 7.6-17.4] months after hospitalization for myocardial infarction), 472 (12.5%; 95% CI 11.4-13.5) met the eligibility criteria for REDUCE-IT (REDUCE-IT-like group). The cardiovascular event rate (all-cause death, nonfatal myocardial infarction, nonfatal stroke) was 36.7 (95% CI 27.8-48.6) per 1000 person-years for the REDUCE-IT-like group, which compares with the 36.9 (95% CI 26.1-51.5) per 1000 person-years (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) reported in the REDUCE-IT trial. The residual cardiovascular risk related to elevated triglycerides in the REDUCE-IT-like group was similar to the risk in the REDUCE-IT trial. CONCLUSIONS If the results of REDUCE-IT are applied to patients hospitalized for a myocardial infarction in France, 12.5% of these patients could benefit from a strategy of high-dose omega-3 icosapent ethyl on top of contemporary therapy including statins to improve their clinical outcomes.",2020,"The cardiovascular event rate (all-cause death, nonfatal myocardial infarction, nonfatal stroke) was 36.7 (95% CI 27.8-48.6) per 1000 person-years for the REDUCE-IT-like group, which compares with the 36.9 (95% CI 26.1-51.5) per 1000 person-years (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) reported in the REDUCE-IT trial.","['patients aged ≥45\u2009years who had detailed lipid values postacute hospitalization, focusing on their clinical profile and cardiovascular prognosis', 'Of the 3789 FAST-MI patients with a', 'statin-treated patients with elevated triglycerides and controlled low-density lipoprotein cholesterol (LDL-C', 'Data were extracted from the FAST-MI 2010 and 2015 registries']","['LDL-C 40-100\u2009mg/dL on statins', 'omega-3 icosapent ethyl vs placebo']","['full lipid profile', 'cardiovascular event rate (all-cause death, nonfatal myocardial infarction, nonfatal stroke', '1000 person-years (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation'}, {'cui': 'C1276061', 'cui_str': 'Acute non-ST segment elevation myocardial infarction'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0020557', 'cui_str': 'Hypertriglyceridemia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}]","[{'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0058978', 'cui_str': 'icosapent ethyl'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",3789.0,0.0901599,"The cardiovascular event rate (all-cause death, nonfatal myocardial infarction, nonfatal stroke) was 36.7 (95% CI 27.8-48.6) per 1000 person-years for the REDUCE-IT-like group, which compares with the 36.9 (95% CI 26.1-51.5) per 1000 person-years (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) reported in the REDUCE-IT trial.","[{'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Ferrières', 'Affiliation': 'Department of Cardiology, Toulouse Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Bataille', 'Affiliation': 'Department of Cardiology, Toulouse Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Puymirat', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Cardiology, Hôpital Européen Georges Pompidou, Paris, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Schiele', 'Affiliation': 'Department of Cardiology, Regional University Hospital Jean Minjoz, Besançon, France.'}, {'ForeName': 'Tabassome', 'Initials': 'T', 'LastName': 'Simon', 'Affiliation': 'Department of Clinical Pharmacology and Unité de Recherche Clinique (URCEST), AP-HP, Hôpital Saint Antoine, Paris, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Danchin', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Cardiology, Hôpital Européen Georges Pompidou, Paris, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical cardiology,['10.1002/clc.23437'] 475,32749459,"Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial.","AIMS Cardiosphere-derived cells (CDCs) are cardiac progenitor cells that exhibit disease-modifying bioactivity in various models of cardiomyopathy and in previous clinical studies of acute myocardial infarction (MI), dilated cardiomyopathy, and Duchenne muscular dystrophy. The aim of the study was to assess the safety and efficacy of intracoronary administration of allogeneic CDCs in the multicentre, randomized, double-blinded, placebo-controlled, intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR) trial. METHODS AND RESULTS We enrolled patients 4 weeks to 12 months after MI, with left ventricular ejection fraction (LVEF) ≤45% and LV scar size ≥15% of LV mass by magnetic resonance imaging (MRI). A pre-specified interim analysis was performed when 6-month MRI data were available. The trial was subsequently stopped due to the low probability of detecting a significant treatment effect of CDCs based on the primary endpoint. Patients were randomly allocated in a 2:1 ratio to receive CDCs or placebo in the infarct-related artery by stop-flow technique. The primary safety endpoint was the occurrence, during 1-month post-intracoronary infusion, of acute myocarditis attributable to allogeneic CDCs, ventricular tachycardia- or ventricular fibrillation-related death, sudden unexpected death, or a major adverse cardiac event (death or hospitalization for heart failure or non-fatal MI or need for left ventricular assist device or heart transplant). The primary efficacy endpoint was the relative percentage change in infarct size at 12 months post-infusion as assessed by contrast-enhanced cardiac MRI. We randomly allocated 142 eligible patients of whom 134 were treated (90 to the CDC group and 44 to the placebo group). The mean baseline LVEF was 40% and the mean scar size was 22% of LV mass. No primary safety endpoint events occurred. There was no difference in the percentage change from baseline in scar size (P = 0.51) between CDCs and placebo groups at 6 months. Compared with placebo, there were significant reductions in LV end-diastolic volume (P = 0.02), LV end-systolic volume (P = 0.02), and N-terminal pro b-type natriuretic peptide (NT-proBNP) (P = 0.02) at 6 months in CDC-treated patients. CONCLUSION Intracoronary infusion of allogeneic CDCs in patients with post-MI LV dysfunction was safe but did not reduce scar size relative to placebo at 6 months. Nevertheless, the reductions in LV volumes and NT-proBNP reveal disease-modifying bioactivity of CDCs. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT01458405.",2020,There was no difference in the percentage change from baseline in scar size (P = 0.51) between CDCs and placebo groups at 6 months.,"['142 eligible patients of whom 134 were treated (90 to the CDC group and 44 to the placebo group', 'enrolled patients 4\u2009weeks to 12\u2009months after MI, with left ventricular ejection fraction (LVEF) ≤45% and LV scar size ≥15% of LV mass by magnetic resonance imaging (MRI', 'patients with post-MI LV dysfunction']","['Cardiosphere-derived cells (CDCs', 'placebo', 'CDCs or placebo', 'placebo-controlled, intracoronary ALLogeneic heart STem cells', 'Intracoronary ALLogeneic heart STem cells', 'allogeneic CDCs']","['relative percentage change in infarct size', 'mean baseline LVEF', 'scar size', 'LV volumes and NT-proBNP reveal disease-modifying bioactivity of CDCs', 'scar size relative', 'safety and efficacy', 'mean scar size', 'LV end-systolic volume', 'LV end-diastolic volume', 'occurrence, during 1-month post-intracoronary infusion, of acute myocarditis attributable to allogeneic CDCs, ventricular tachycardia- or ventricular fibrillation-related death, sudden unexpected death, or a major adverse cardiac event (death or hospitalization for heart failure or non-fatal MI or need for left ventricular assist device or heart transplant']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0007670', 'cui_str': 'Centers for Disease Control and Prevention (U.S.)'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0455825', 'cui_str': 'Left ventricular mass'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}]","[{'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0595454', 'cui_str': 'Intracoronary route'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0443289', 'cui_str': 'Revealed'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0595454', 'cui_str': 'Intracoronary route'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0155686', 'cui_str': 'Acute myocarditis'}, {'cui': 'C0042514', 'cui_str': 'Ventricular tachycardia'}, {'cui': 'C0042510', 'cui_str': 'Ventricular fibrillation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1276802', 'cui_str': 'Sudden'}, {'cui': 'C0277591', 'cui_str': 'Unexpected death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0085842', 'cui_str': 'Ventricular assist device'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}]",142.0,0.688567,There was no difference in the percentage change from baseline in scar size (P = 0.51) between CDCs and placebo groups at 6 months.,"[{'ForeName': 'Raj R', 'Initials': 'RR', 'LastName': 'Makkar', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.'}, {'ForeName': 'Dean J', 'Initials': 'DJ', 'LastName': 'Kereiakes', 'Affiliation': 'The Christ Hospital, Cincinnati, 2139 Auburn Ave, Cincinnati, OH 45219, USA.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Aguirre', 'Affiliation': 'Prairie/St. Johns Hospital, Springfield, 800 E Carpenter St, Springfield, IL 62769, USA.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Kowalchuk', 'Affiliation': 'Sanger Heart & Vascular, Charlotte, 1001 Blythe Blvd Ste 300, Charlotte, NC 28203, USA.'}, {'ForeName': 'Tarun', 'Initials': 'T', 'LastName': 'Chakravarty', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Malliaras', 'Affiliation': 'University of Athens, 17 Agiou Thoma street, 11527, Athens, Greece.'}, {'ForeName': 'Gary S', 'Initials': 'GS', 'LastName': 'Francis', 'Affiliation': 'University of Minnesota Heart Care, Minneapolis, 6405 France Ave S, Edina, MN 55435, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Povsic', 'Affiliation': 'Duke University Hospital, Durham, 2301 Erwin Rd, Durham, NC 27710, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Schatz', 'Affiliation': 'Scripps Green Hospital, 10666 N Torrey Pines Rd, La Jolla, CA 92037, USA.'}, {'ForeName': 'Jay H', 'Initials': 'JH', 'LastName': 'Traverse', 'Affiliation': 'Minneapolis Heart Institute Foundation, 920 E 28th St Ste 100, Minneapolis, MN 55407, USA.'}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Pogoda', 'Affiliation': '10Capricor Therapeutics, Los Angeles, 8840 Wilshire Blvd Ste 2, Beverly Hills, CA 90211, USA.'}, {'ForeName': 'Rachel R', 'Initials': 'RR', 'LastName': 'Smith', 'Affiliation': '10Capricor Therapeutics, Los Angeles, 8840 Wilshire Blvd Ste 2, Beverly Hills, CA 90211, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Marbán', 'Affiliation': '10Capricor Therapeutics, Los Angeles, 8840 Wilshire Blvd Ste 2, Beverly Hills, CA 90211, USA.'}, {'ForeName': 'Deborah D', 'Initials': 'DD', 'LastName': 'Ascheim', 'Affiliation': '10Capricor Therapeutics, Los Angeles, 8840 Wilshire Blvd Ste 2, Beverly Hills, CA 90211, USA.'}, {'ForeName': 'Mohammad R', 'Initials': 'MR', 'LastName': 'Ostovaneh', 'Affiliation': 'J ohns Hopkins University, 3400 N Charles St, Baltimore, MD 21218, USA.'}, {'ForeName': 'João A C', 'Initials': 'JAC', 'LastName': 'Lima', 'Affiliation': 'J ohns Hopkins University, 3400 N Charles St, Baltimore, MD 21218, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'DeMaria', 'Affiliation': 'University of California San Diego Medical Center, 200 W. Arbor Drive, San Diego, CA 92103, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Marbán', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Henry', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.'}]",European heart journal,['10.1093/eurheartj/ehaa541'] 476,32779711,The Impact of Moderate or High-Intensity Combined Exercise on Systemic Inflammation Among Older Persons With and Without HIV.,"BACKGROUND We investigated whether higher-intensity exercise provided greater decrease in markers of inflammation, and whether responses differed by HIV serostatus. METHODS People with HIV (PWH; n = 32) and controls (n = 37) aged 50-75 years completed 12 weeks moderate-intensity exercise, then were randomized to moderate- or high-intensity exercise for 12 additional weeks (n = 27 and 29, respectively). Inflammation biomarkers were measured at 0, 12, 24 weeks. Mixed and multiple regression models were adjusted for baseline inflammation, age, and body mass index. RESULTS Baseline tumor necrosis factor-α (TNF-α), soluble TNF receptor 2 (sTNFR2), and soluble CD14 (sCD14) were significantly higher among PWH than controls (P < .04). From week 0-12, changes in interleukin-6 (IL-6), TNF-α, and sTNFR1 were not significantly different by HIV serostatus. We found no significant interaction between HIV serostatus/exercise intensity on week 12-24 changes in IL-6, TNF-α, and sTNFR1. Among high-intensity exercisers, PWH and controls had significant increases in sCD14 (P ≤ .003), controls significant increases in IL-10 (P = .01), and PWH nonsignificant decrease in highly sensitive C-reactive protein (P = .07). Other markers were not significantly different by serostatus or intensity. CONCLUSIONS Moderate and high-intensity exercise elicited similar effects on inflammation among PWH and controls, with additional beneficial effects seen among high-intensity exercisers. Increase in sCD14 and attenuated IL-10 increase (PWH only) merit further study. CLINICAL TRIALS REGISTRATION NCT02404792.",2021,"We found no significant interaction between HIV serostatus/exercise intensity on week 12-24 changes in IL-6, TNF-α, sTNFR1.","['People with HIV (PWH; n=32) and controls (n=37) aged 50-75 completed 12 weeks of', 'Older Persons with and without HIV']","['moderate- or high-intensity exercise', 'Moderate or High-Intensity Combined Exercise', 'moderate-intensity combined exercise']","['hsCRP', 'Inflammation biomarkers', 'sCD14', 'Baseline TNF-α, sTNFR2, and sCD14', 'Systemic Inflammation', 'IL-6, TNF-α, sTNFR1', 'IL-10']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}]","[{'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}]",,0.129495,"We found no significant interaction between HIV serostatus/exercise intensity on week 12-24 changes in IL-6, TNF-α, sTNFR1.","[{'ForeName': 'Kristine M', 'Initials': 'KM', 'LastName': 'Erlandson', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Melissa P', 'Initials': 'MP', 'LastName': 'Wilson', 'Affiliation': 'School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'MaWhinney', 'Affiliation': 'School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Rapaport', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Cara C', 'Initials': 'CC', 'LastName': 'Wilson', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Jeremy T', 'Initials': 'JT', 'LastName': 'Rahkola', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Edward N', 'Initials': 'EN', 'LastName': 'Janoff', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Todd T', 'Initials': 'TT', 'LastName': 'Brown', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, Baltimore, Maryland, USA.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Campbell', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Jankowski', 'Affiliation': 'College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}]",The Journal of infectious diseases,['10.1093/infdis/jiaa494'] 477,32778721,Acute increases in brain-derived neurotrophic factor following high or moderate-intensity exercise is accompanied with better cognition performance in obese adults.,"The purpose of this study was to test if different intensities of aerobic exercise could influence abdominal fat, isoforms of BDNF and executive function. Twenty obese men (30.0 ± 5.4 years old; 34.4 ± 3.5 kg/m 2 ) were randomized to moderate-intensity continuous training (MICT, n = 10) and high-intensity intermittent training (HIIT, n = 10) three times a week for 6 weeks, with isoenergetic energetic expenditure for each exercise session (~ 300 kcal) between conditions. Abdominal fat was assessed pre- and post-intervention; executive function (Coding subtest from BETA-III non-verbal intelligence test and Stroop Color and Word Test), concentrations of mBDNF and proBDNF were assessed in response to acute exercise pre- and post-intervention. Abdominal fat did not change in either group. There was a significant increase in mBDNF immediately after acute exercise in both groups before and after intervention. proBDNF did not present changes acutely nor after 6 weeks. Executive function presented a main effect of time at pre- and post-intervention time-points Stroop Word and Stroop Color and Coding subtest presented improved performance from pre- to post-acute exercise session, in both groups. In conclusion, executive function improvements and acute exercise session-induced increases in mBDNF concentration were found from pre- to post-exercise intervention similarly between MICT and HIIT in obese men.",2020,"Executive function presented a main effect of time at pre- and post-intervention time-points Stroop Word and Stroop Color and Coding subtest presented improved performance from pre- to post-acute exercise session, in both groups.","['obese men', 'Twenty obese men (30.0\u2009±\u20095.4\xa0years old; 34.4\u2009±\u20093.5\xa0kg/m 2 ', 'obese adults']","['pre- and post-intervention time-points Stroop Word and Stroop Color and Coding subtest presented improved performance from pre- to post-acute exercise session', 'moderate-intensity continuous training (MICT, n\u2009=\u200910) and high-intensity intermittent training (HIIT, n\u2009=\u200910) three times a week for 6\xa0weeks, with isoenergetic energetic expenditure for each exercise session', 'proBDNF', 'aerobic exercise']","['mBDNF concentration', 'abdominal fat, isoforms of BDNF and executive function', 'Abdominal fat was assessed pre- and post-intervention; executive function (Coding subtest from BETA-III non-verbal intelligence test and Stroop Color and Word Test), concentrations of mBDNF and proBDNF', 'mBDNF', 'Abdominal fat', 'cognition performance']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4517792', 'cui_str': '5.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0007465', 'cui_str': 'Cause of death'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0556987', 'cui_str': 'Three times weekly'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0015316', 'cui_str': 'Expenditures'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1563742', 'cui_str': 'Fat, Abdominal'}, {'cui': 'C0597298', 'cui_str': 'Isoforms'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0007465', 'cui_str': 'Cause of death'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0021705', 'cui_str': 'Intelligence test'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",20.0,0.0297667,"Executive function presented a main effect of time at pre- and post-intervention time-points Stroop Word and Stroop Color and Coding subtest presented improved performance from pre- to post-acute exercise session, in both groups.","[{'ForeName': 'Daniela Sayuri', 'Initials': 'DS', 'LastName': 'Inoue', 'Affiliation': 'Exercise and Immunometabolism Research Group, Post-Graduation Program in Movement Sciences, Department of Physical Education, School of Technology and Sciences, State University (UNESP), Presidente Prudente, São Paulo, Brazil. dsinoue@gmail.com.'}, {'ForeName': 'Paula Alves', 'Initials': 'PA', 'LastName': 'Monteiro', 'Affiliation': 'Exercise and Immunometabolism Research Group, Post-Graduation Program in Movement Sciences, Department of Physical Education, School of Technology and Sciences, State University (UNESP), Presidente Prudente, São Paulo, Brazil.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Gerosa-Neto', 'Affiliation': 'Exercise and Immunometabolism Research Group, Post-Graduation Program in Movement Sciences, Department of Physical Education, School of Technology and Sciences, State University (UNESP), Presidente Prudente, São Paulo, Brazil.'}, {'ForeName': 'Priscilla Rodrigues', 'Initials': 'PR', 'LastName': 'Santana', 'Affiliation': 'Psychology Department, Universidade São Judas Tadeu and Fundação Santo André, São Paulo, Brazil.'}, {'ForeName': 'Fernando Pierin', 'Initials': 'FP', 'LastName': 'Peres', 'Affiliation': 'Medicine Department, Universidade Do Oeste Paulista, São Paulo, Brazil.'}, {'ForeName': 'Kate M', 'Initials': 'KM', 'LastName': 'Edwards', 'Affiliation': 'Charles Perkins Centre, Faculty of Health Sciences, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Fabio Santos', 'Initials': 'FS', 'LastName': 'Lira', 'Affiliation': 'Exercise and Immunometabolism Research Group, Post-Graduation Program in Movement Sciences, Department of Physical Education, School of Technology and Sciences, State University (UNESP), Presidente Prudente, São Paulo, Brazil. fabio.lira@unesp.br.'}]",Scientific reports,['10.1038/s41598-020-70326-1'] 478,32720717,Sample size calculation in three-level cluster randomized trials using generalized estimating equation models.,"Three-level cluster randomized trials (CRTs) are increasingly used in implementation science, where 2fold-nested-correlated data arise. For example, interventions are randomly assigned to practices, and providers within the same practice who provide care to participants are trained with the assigned intervention. Teerenstra et al proposed a nested exchangeable correlation structure that accounts for two levels of clustering within the generalized estimating equations (GEE) approach. In this article, we utilize GEE models to test the treatment effect in a two-group comparison for continuous, binary, or count data in three-level CRTs. Given the nested exchangeable correlation structure, we derive the asymptotic variances of the estimator of the treatment effect for different types of outcomes. When the number of clusters is small, researchers have proposed bias-corrected sandwich estimators to improve performance in two-level CRTs. We extend the variances of two bias-corrected sandwich estimators to three-level CRTs. The equal provider and practice sizes were assumed to calculate number of practices for simplicity. However, they are not guaranteed in practice. Relative efficiency (RE) is defined as the ratio of variance of the estimator of the treatment effect for equal to unequal provider and practice sizes. The expressions of REs are obtained from both asymptotic variance estimation and bias-corrected sandwich estimators. Their performances are evaluated for different scenarios of provider and practice size distributions through simulation studies. Finally, a percentage increase in the number of practices is proposed due to efficiency loss from unequal provider and/or practice sizes.",2020,Relative efficiency (RE) is defined as the ratio of variance of the estimator of the treatment effect for equal to unequal provider and practice sizes.,[],[],['Relative efficiency (RE'],[],[],"[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}]",,0.0599549,Relative efficiency (RE) is defined as the ratio of variance of the estimator of the treatment effect for equal to unequal provider and practice sizes.,"[{'ForeName': 'Jingxia', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine (WUSM), St. Louis, Missouri, USA.'}, {'ForeName': 'Graham A', 'Initials': 'GA', 'LastName': 'Colditz', 'Affiliation': 'Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine (WUSM), St. Louis, Missouri, USA.'}]",Statistics in medicine,['10.1002/sim.8670'] 479,32739974,"New evidence on prognostic features, prevention and treatment of congenital Cytomegalovirus infection.","PURPOSE OF REVIEW Congenital Cytomegalovirus (CMV) infection remains a major cause of lifelong disability, with no systematic screening implemented in pregnancy or the postnatal period. In this review article, we outline the preventive strategies, antenatal prognostic features and experimental therapies as well as evidence of efficacy from recent trials. RECENT FINDINGS A recent randomized, double blinded, placebo-controlled study investigated the efficacy of Valaciclovir in women contracting primary CMV in the periconception period or first trimester. They concluded that Valaciclovir at a dose of 8 g/day is effective in reducing the rate of foetal CMV infection following early maternal primary infection. Administration of CMV hyperimmune globulin (HIG) was investigated in a recent randomized double-masked controlled trial. This study concluded that CMV HIG was ineffective at reducing the risk of congenital CMV among women with primary CMV in early pregnancy. SUMMARY Congenital CMV infection remains a significant cause of disability. There is currently no vaccine available, with the best preventive strategy being patient education on transmission as well as hygiene measures to reduce risk of exposure. Experimental therapies have been investigated in recent years and there is evidence supporting the use of Valaciclovir. Data for the efficacy of CMV HIG remains inconsistent and administration is currently limited to clinical trial settings.",2020,"This study concluded that CMV HIG was ineffective at reducing the risk of congenital CMV among women with primary CMV in early pregnancy. ","['women with primary CMV in early pregnancy', 'women contracting primary CMV in the periconception period or first trimester']","['Valaciclovir', 'CMV hyperimmune globulin (HIG', 'CMV HIG', 'placebo']","['risk of congenital CMV', 'rate of foetal CMV infection']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0332522', 'cui_str': 'Contracts'}, {'cui': 'C0032979', 'cui_str': 'First trimester pregnancy'}]","[{'cui': 'C0249458', 'cui_str': 'valacyclovir'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C0017649', 'cui_str': 'Globulin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009678', 'cui_str': 'congenital'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}]",,0.471966,"This study concluded that CMV HIG was ineffective at reducing the risk of congenital CMV among women with primary CMV in early pregnancy. ","[{'ForeName': 'Mercede', 'Initials': 'M', 'LastName': 'Sebghati', 'Affiliation': ""Fetal Medicine Unit, St George's University Hospitals.""}, {'ForeName': 'Asma', 'Initials': 'A', 'LastName': 'Khalil', 'Affiliation': ""Fetal Medicine Unit, St George's University Hospitals.""}]",Current opinion in obstetrics & gynecology,['10.1097/GCO.0000000000000651'] 480,32739240,Attitudes Toward Computers Moderate the Effect of Computerized Cognitive Trainings in Oldest-Old Senior Living Center Residents.,"BACKGROUND AND OBJECTIVES Computerized cognitive interventions (CCIs) have been increasingly implemented among older adults with mild cognitive impairment (MCI). However, older individuals' attitudes toward technology may limit CCI engagement. This exploratory-developmental study examined whether a ""multi-functional interactive computer system"" (MICS), which provides pleasurable activities via computer, would improve attitudes toward computers and in turn increase the efficacy of a subsequent CCI. RESEARCH DESIGN AND METHODS A phase one double-blind trial randomized 49 seniors with MCI to a MICS + CCI condition or a CCI-only condition. Attitudes toward technology use was assessed using The Attitudes Toward Computers Questionnaire (ATCQ), and cognition was assessed using episodic memory and executive function composite scores at baseline, the ends of MICS and CCI phases, and 3-month follow-up. RESULTS The MICS + CCI group did not show significantly greater improvement in cognition than the CCI only group. Secondary analyses indicated that improvement in executive function from baseline occurred in both groups. Participants who did show improved attitudes toward computers, whether through MICS or simply computer exposure itself, showed improvement in executive function. DISCUSSION AND IMPLICATION Participants in the MICS + CCI group used MICS less than expected. A more structured and supervised approach may be needed to facilitate MICS exposure. Improved attitudes toward computers regardless of MICS exposure may benefit candidates for CCI.",2021,"Participants who did show improved attitudes toward computers, whether through MICS or simply computer exposure itself, showed improvement in executive function. ","['Oldest-Old Senior Living Center Residents', 'older adults with mild cognitive impairment (MCI', '49 seniors with MCI to a MICS\u202f+\u202fCCI condition or a CCI-only condition']","['multi-functional interactive computer system"" (MICS', 'Computerized cognitive interventions (CCIs', 'Computerized Cognitive Trainings']","['executive function', 'cognition', 'Attitudes Toward Computers Questionnaire (ATCQ), and cognition was assessed using episodic memory and executive function composite scores']","[{'cui': 'C0001795', 'cui_str': 'Oldest Old'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0009612', 'cui_str': 'Computer Systems'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0009612', 'cui_str': 'Computer Systems'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",49.0,0.016054,"Participants who did show improved attitudes toward computers, whether through MICS or simply computer exposure itself, showed improvement in executive function. ","[{'ForeName': 'Feng Vankee', 'Initials': 'FV', 'LastName': 'Lin', 'Affiliation': 'Elaine C. Hubbard Center for Nursing Research on Aging, School of Nursing (FVL, KC, KM, AJ), University of Rochester Medical Center, Rochester, NY; Department of Psychiatry, School of Medicine and Dentistry (FVL, AP, BPC), University of Rochester Medical Center, Rochester, NY; Department of Brain and Cognitive Sciences (FVL), University of Rochester; Department of Neuroscience, School of Medicine and Dentistry (FVL), University of Rochester Medical Center, Rochester, NY; Department of Neurology, School of Medicine and Dentistry (FVL, AP), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Kaylin', 'Initials': 'K', 'LastName': 'Cottone', 'Affiliation': 'Elaine C. Hubbard Center for Nursing Research on Aging, School of Nursing (FVL, KC, KM, AJ), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Mcdermott', 'Affiliation': 'Elaine C. Hubbard Center for Nursing Research on Aging, School of Nursing (FVL, KC, KM, AJ), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Alanna', 'Initials': 'A', 'LastName': 'Jacobs', 'Affiliation': 'Elaine C. Hubbard Center for Nursing Research on Aging, School of Nursing (FVL, KC, KM, AJ), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Dallas', 'Initials': 'D', 'LastName': 'Nelson', 'Affiliation': 'Division of Geriatrics & Aging, Department of Medicine, School of Medicine and Dentistry (DN), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Porsteinsson', 'Affiliation': 'Department of Psychiatry, School of Medicine and Dentistry (FVL, AP, BPC), University of Rochester Medical Center, Rochester, NY; Department of Neurology, School of Medicine and Dentistry (FVL, AP), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Benjamin P', 'Initials': 'BP', 'LastName': 'Chapman', 'Affiliation': 'Department of Psychiatry, School of Medicine and Dentistry (FVL, AP, BPC), University of Rochester Medical Center, Rochester, NY; Department of Public Health, School of Medicine and Dentistry (BPC), University of Rochester Medical Center, Rochester, NY. Electronic address: ben_chapman@urmc.rochester.edu.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2020.07.001'] 481,32755104,Effects of oral alcohol administration on heat pain threshold and ratings of supra-threshold stimuli.,"Background and aims Evidence for analgesic effects of oral alcohol consumption on heat pain has recently been documented in a placebo-controlled, randomized and double-blind design. We aimed at further investigating these effects and now set the focus on pain threshold and the ratings of supra-threshold pain to cover most of the pain range. Moreover, we now firstly evaluated sex differences in these effects. Methods We investigated 41 healthy participants (22 females) in a randomized, double-blind and placebo-controlled design and targeted two different moderate breath-alcohol levels of 0.06% and 0.08%. Before and after an alcoholic or placebo drink, contact heat was applied at the forearm. Subjects evaluated pain threshold (method of adjustment) and rated pain intensity and pain unpleasantness of supra-threshold stimuli (intensity: threshold +3 °C; duration: 5 s). Results Analgesic effects taking the form of increased pain thresholds were found after both alcohol doses, surprisingly with more pronounced effects for the lower dose. While the high alcohol dose exerted small analgesic effects on pain intensity ratings (i.e. decrease), slightly increased ratings of pain intensity and pain unpleasantness after the low alcohol dose rather suggest pain enhancement. Alcohol did not affect intensity vs. unpleasantness ratings differentially. We found no evidence for sex differences in any of these effects. Conclusions Overall, acute alcohol effects on pain were subtle. Our findings suggest that while low alcohol doses already exert analgesic effects on pain threshold, stronger doses are required for pain reduction on supra-threshold pain levels. Furthermore, sex differences could not be detected within our experimental paradigm but should be further explored in future research. Implications Analgesic effects of sub-toxic alcohol doses - as normally occurring during social drinking - might be weak; however, susceptibility to pain relieving effects of alcohol might be a risk factor for the use of alcohol as self-medication in acute pain states.",2020,"While the high alcohol dose exerted small analgesic effects on pain intensity ratings (i.e. decrease), slightly increased ratings of pain intensity and pain unpleasantness after the low alcohol dose rather suggest pain enhancement.",['41 healthy participants (22 females'],"['oral alcohol', 'oral alcohol consumption', 'placebo']","['pain thresholds', 'heat pain threshold and ratings of supra-threshold stimuli', 'pain threshold (method of adjustment) and rated pain intensity and pain unpleasantness of supra-threshold stimuli', 'pain intensity ratings', 'ratings of pain intensity and pain unpleasantness']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0449310', 'cui_str': 'Method of adjustment'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",41.0,0.229809,"While the high alcohol dose exerted small analgesic effects on pain intensity ratings (i.e. decrease), slightly increased ratings of pain intensity and pain unpleasantness after the low alcohol dose rather suggest pain enhancement.","[{'ForeName': 'Eva Susanne', 'Initials': 'ES', 'LastName': 'Capito', 'Affiliation': 'Physiological Psychology, University of Bamberg, Markusplatz 3, 96045 Bamberg, Germany, Phone: +49 951 863-1847.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Lautenbacher', 'Affiliation': 'Physiological Psychology, University of Bamberg, Bamberg, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Wolstein', 'Affiliation': 'Pathopsychology, University of Bamberg, Bamberg, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Horn-Hofmann', 'Affiliation': 'Physiological Psychology, University of Bamberg, Bamberg, Germany.'}]",Scandinavian journal of pain,['10.1515/sjpain-2019-0144'] 482,32753339,Less Is More: The Impact of Deprescribing Psychotropic Drugs on Behavioral and Psychological Symptoms and Daily Functioning in Nursing Home Patients. Results From the Cluster-Randomized Controlled COSMOS Trial.,"OBJECTIVE To investigate the impact of medication reviews using collegial mentoring and systematic clinical evaluation on psychotropic prescriptions, behavioral and psychological symptoms of dementia (BPSD), and activities of daily living (ADL). DESIGN Four-month multicenter, multicomponent, cluster-randomized, single-blinded controlled trial. SETTING Thirty-three Norwegian nursing homes including 67 nursing home wards (clusters). PARTICIPANTS A total of 723 enrolled patients, of which 428 participated in the study; 217 were randomized to the intervention and 211 to care as usual (control). INTERVENTION The COSMOS intervention consisted of Communication, Systematic pain management, Medication reviews, Organization of activities, and Safety. During medication review, the nursing home physician evaluated treatment with colleagues systematically using the results from validated clinical assessments. MEASUREMENTS Mean changes from baseline to month 4 in the number of prescribed psychotropic drugs (antipsychotics, anxiolytics, hypnotics or sedatives, antidepressants, and antidementia drugs); Neuropsychiatric Inventory Nursing Home Version (NPI-NH) and Cornell Scale of Depression in Dementia (CSDD); Lawton and Brody's Physical Self Maintenance Scale (PSMS). RESULTS Compared to control, the mean change in prescribed psychotropic drugs was reduced both in total and regular number, while mean changes in NPI-NH and CSDD scores did not differ between the groups. Mean change in PSMS showed improvement in the intervention group, and deterioration in the control group. CONCLUSION Medication reviews using collegial mentoring and systematic clinical evaluation led to safe deprescribing, as the reductions in psychotropic drug use did not negatively affect BPSD, while ADL improved.",2021,"Mean change in PSMS showed improvement in the intervention group, and deterioration in the control group. ","['A total of 723 enrolled patients, of which 428 participated in the study; 217 were randomized to the intervention and 211 to care as usual (control', 'Nursing Home Patients', 'Thirty-three Norwegian nursing homes including 67 nursing home wards (clusters']",[],"['Mean change in PSMS', ""number of prescribed psychotropic drugs (antipsychotics, anxiolytics, hypnotics or sedatives, antidepressants, and antidementia drugs); Neuropsychiatric Inventory Nursing Home Version (NPI-NH) and Cornell Scale of Depression in Dementia (CSDD); Lawton and Brody's Physical Self Maintenance Scale (PSMS"", 'psychotropic prescriptions, behavioral and psychological symptoms of dementia (BPSD), and activities of daily living (ADL', 'NPI-NH and CSDD scores', 'Behavioral and Psychological Symptoms and Daily Functioning']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517866', 'cui_str': '723'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517775', 'cui_str': '428'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517646', 'cui_str': '217'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1275588', 'cui_str': 'Physical self maintenance scale'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0033978', 'cui_str': 'Psychotherapeutic agent'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}, {'cui': 'C0040616', 'cui_str': 'Anxiolytic agent'}, {'cui': 'C0020591', 'cui_str': 'Hypnotic agent'}, {'cui': 'C0020592', 'cui_str': 'HYPNOTICS AND SEDATIVES'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",723.0,0.0755198,"Mean change in PSMS showed improvement in the intervention group, and deterioration in the control group. ","[{'ForeName': 'Marie H', 'Initials': 'MH', 'LastName': 'Gedde', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway; Haraldsplass Deaconess Hospital, Bergen, Norway. Electronic address: marie.gedde@uib.no.'}, {'ForeName': 'Bettina S', 'Initials': 'BS', 'LastName': 'Husebo', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway; Municipality of Bergen, Bergen, Norway.'}, {'ForeName': 'Janne', 'Initials': 'J', 'LastName': 'Mannseth', 'Affiliation': 'Section for Epidemiology and Medical Statistic, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Reidun L S', 'Initials': 'RLS', 'LastName': 'Kjome', 'Affiliation': 'Centre for Pharmacy/Department for Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Mala', 'Initials': 'M', 'LastName': 'Naik', 'Affiliation': 'Haraldsplass Deaconess Hospital, Bergen, Norway; Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Line I', 'Initials': 'LI', 'LastName': 'Berge', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway; NKS Olaviken Gerontopsychiatric Hospital, Bergen, Norway.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2020.07.004'] 483,32761844,Effects of resistance exercise on treatment outcome and laboratory parameters of Takayasu arteritis with magnetic resonance imaging diagnosis: A randomized parallel controlled clinical trial.,"BACKGROUND Elevated tumor necrosis factor-α (TNF-α) is correlated with refractory Takayasu arteritis (TA), and resistance exercise have been shown to inhibit TNF-α. HYPOTHESIS We aimed to explore the effect of resistance exercise in the clinical management of TA. METHODS This clinical trial enrolled a total of 342 acute TA patients, who were subsequently randomized to undergo either resistance exercise or relaxation control twice per week for 12 weeks. The disease activity was defined using the primary outcome of Birmingham Vascular Activity Score (BVAS). Secondary outcomes included levels of plasma TNF-α and C-reactive protein (CRP), and the erythrocyte sedimentation rate (ESR). RESULTS BVAS scores along with other laboratory parameters obtained from the patients in the resistance exercise group showed a gradual decline throughout the course of the trial. By contrast, outcomes appeared largely unaltered in the relaxation control group patients. Analyses also revealed that plasma TNF-α displayed strong linear correlations with ESR, BVAS scores, and plasma CRP levels. CONCLUSION Resistance exercise could substantially improve treatment outcomes as well as laboratory parameters in patients with acute TA, probably through decreasing TNF-α.",2020,"Secondary outcomes included levels of plasma TNF-α and C-reactive protein (CRP), and the erythrocyte sedimentation rate (ESR). ","['patients with acute TA, probably through decreasing TNF-α', '342 acute TA patients']","['resistance exercise or relaxation control', 'magnetic resonance imaging diagnosis', 'Resistance exercise', 'resistance exercise']","['ESR, BVAS scores, and plasma CRP levels', 'disease activity', 'levels of plasma TNF-α and C-reactive protein (CRP), and the erythrocyte sedimentation rate (ESR', 'Birmingham Vascular Activity Score (BVAS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0039263', 'cui_str': ""Takayasu's disease""}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C5191280', 'cui_str': '342'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0428493', 'cui_str': 'Plasma C-reactive protein measurement'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",342.0,0.160481,"Secondary outcomes included levels of plasma TNF-α and C-reactive protein (CRP), and the erythrocyte sedimentation rate (ESR). ","[{'ForeName': 'Guoce', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Fenghai', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Yancheng', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}]",Clinical cardiology,['10.1002/clc.23439'] 484,32764089,Study protocol for a cluster randomised controlled trial testing the effectiveness of the 'High schools High on life' intervention on reducing excessive drinking in Danish high schools.,"INTRODUCTION This paper describes the evaluation design of the 'High schools High on life' intervention; a school-based intervention to reduce excessive drinking among high school students in Denmark. The intervention includes a school environmental component to limit access to alcohol at school, a school-educational component to change social norms around alcohol among first year students and a parental component addressing parents' knowledge and attitudes towards alcohol. METHODS AND DESIGN The study will employ a cluster randomised controlled study design and will include a random sample of 16 high schools randomly allocated 1:1 to either intervention or control group. Target group: first year high school students. Timeline: baseline survey: January to March 2019, collected as part of the Danish National Youth Study 2019. Delivery of intervention: April 2019 to March 2020. Follow-up survey: April to May 2020. PRIMARY OUTCOME MEASURE 30% reduction in mean number of binge-drinking episodes (five or more alcoholic drinks on one occasion) within the last 30 days. SECONDARY OUTCOME MEASURES proportion of students who drink alcohol, mean weekly alcohol consumption, alcohol intake at last school party, alcohol intake at the school during last school party, proportion of students who agree to be able to have fun at a party without drinking and the proportion of students who think alcohol plays a too dominant part at the school. Implementation will be monitored through process evaluation. ETHICS AND DISSEMINATION The Scientific Ethics Committees for the Capital Region of Denmark has declared that the trial is not subject to notification (jnr. 19021957). The study is registered at the Research an Innovation Office at University of Southern Denmark (ref: 10.314) allowing collection of personal data. Results will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT03906500.",2020,The Scientific Ethics Committees for the Capital Region of Denmark has declared that the trial is not subject to notification (jnr.,"['Danish high schools', 'Target group: first year high school students', 'Timeline: baseline survey: January to March 2019, collected as part of the Danish National Youth Study 2019', 'random sample of 16 high schools', 'high school students in Denmark']","[""school environmental component to limit access to alcohol at school, a school-educational component to change social norms around alcohol among first year students and a parental component addressing parents' knowledge and attitudes towards alcohol"", ""High schools High on life' intervention"", 'school-based intervention']","['proportion of students who drink alcohol, mean weekly alcohol consumption, alcohol intake at last school party, alcohol intake', 'mean number of binge-drinking episodes ']","[{'cui': 'C0010969', 'cui_str': 'Danish language'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0145943', 'cui_str': 'TimeLine'}, {'cui': 'C0282121', 'cui_str': 'Baseline Survey'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0556346', 'cui_str': 'Drinking binge'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}]",16.0,0.0307791,The Scientific Ethics Committees for the Capital Region of Denmark has declared that the trial is not subject to notification (jnr.,"[{'ForeName': 'Veronica Sofie Clara', 'Initials': 'VSC', 'LastName': 'Pisinger', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark vepi@sdu.dk.'}, {'ForeName': 'Sofie', 'Initials': 'S', 'LastName': 'Hoffmann', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Johanne Aviaja', 'Initials': 'JA', 'LastName': 'Rosing', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Grønbæk', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Janne Schurmann', 'Initials': 'JS', 'LastName': 'Tolstrup', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Lau', 'Initials': 'L', 'LastName': 'Thygesen', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Rikke', 'Initials': 'R', 'LastName': 'Krølner', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}]",BMJ open,['10.1136/bmjopen-2020-038857'] 485,32768588,Evaluation of combined efficacy of photodynamic therapy using indocyanine green photosensitizer and non-surgical periodontal therapy on clinical and microbial parameters in the management of chronic periodontitis subjects: A randomized split-mouth design.,"BACKGROUND The clinical efficacy of multiple applications of Photodynamic therapy (PDT) needs to be better investigated for the management of chronic periodontitis subjects. AIM The aim of this study was to evaluate the clinical and antimicrobial efficacy of multiple application of PDT as an adjunct to scaling and root planning in management of moderate periodontal pockets. MATERIALS AND METHODS 33 patients with bilateral periodontal destruction in mandibular posterior sextants were randomly treated with either test (SRP + multiplePDT) or control (SRP) intervention. PDT was employed with diode laser(810 nm) and Indocyanine green(ICG) dye at baseline, 1 st, 2nd and 4th week post SRP. Probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), gingival bleeding index (GBI) were recorded at baseline, 3 and 6 months. Subgingival plaque samples were analysed for Porphyromonas gingivalis (P.g), Aggregatibacter actinomycetemcomitans (A.a), Tannerella forsythia (T.f), Fusobacterium nucleatum (F.n), Treponema denticola (T.d). RESULTS Statistically significant improvement was noted in all clinical parameters in both the groups from baseline to 3 and 6 months. The mean PPD and CAL decreased in control sites from 5.83 ± 0.64 and 5.60 ± 0.72 at baseline to 3.80 ± 0.40 and 3.70 ± 0.91 at 6 months and in test sites from 5.93 ± 0.82 and 5.73 ± 0.69 to 3.40 ± 0.56 and 3.00 ± 0.91 at 6 months (P ≤ 0.05). Test sites showed significantly greater reduction in P.g, A.a, T.f, F.n and T.d compared to control sites at 3 and 6 months (P ≤ 0.05). CONCLUSION The outcomes suggested that adjunctive multiple applications of PDT to SRP shows significant reduction in periodontal pathogens over SRP alone.",2020,"Probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), gingival bleeding index (GBI) were recorded at baseline, 3 and 6 months.","['chronic periodontitis subjects', '33 patients with bilateral periodontal destruction in mandibular posterior sextants']","['Photodynamic therapy (PDT', 'photodynamic therapy', 'PDT', 'Diode laser', 'test (SRP\u2009+\u2009multiplePDT) or control (SRP) intervention', 'indocyanine green photosensitizer and non-surgical periodontal therapy']","['mean PPD and CAL', 'Probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), gingival bleeding index (GBI', 'Porphyromonas gingivalis (P.g), Aggregatibacter actinomycetemcomitans (A.a), Tannerella forsythia (T.f), Fusobacterium nucleatum (F.n), Treponema denticola (T.d', 'periodontal pathogens']","[{'cui': 'C0266929', 'cui_str': 'Chronic periodontitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0236023', 'cui_str': 'Periodontal destruction'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}]","[{'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0074512', 'cui_str': 'SRP (Signal Recognition Particle)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0021234', 'cui_str': 'Indocyanine Green'}, {'cui': 'C0162713', 'cui_str': 'Photosensitizing agent'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0580084', 'cui_str': 'Gingival bleeding index'}, {'cui': 'C0085478', 'cui_str': 'Porphyromonas gingivalis'}, {'cui': 'C0085488', 'cui_str': 'Aggregatibacter actinomycetemcomitans'}, {'cui': 'C0314961', 'cui_str': 'Tannerella forsythia'}, {'cui': 'C0085479', 'cui_str': 'Fusobacterium nucleatum'}, {'cui': 'C0318222', 'cui_str': 'Treponema denticola'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0450254', 'cui_str': 'Pathogenic organism'}]",33.0,0.0339033,"Probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), gingival bleeding index (GBI) were recorded at baseline, 3 and 6 months.","[{'ForeName': 'Kanchana', 'Initials': 'K', 'LastName': 'Sukumar', 'Affiliation': 'Department of Periodontics SRM Dental College, Ramapuram, Chennai, 600089, Tamilnadu, India. Electronic address: kancha1308@gmail.com.'}, {'ForeName': 'Anupama', 'Initials': 'A', 'LastName': 'Tadepalli', 'Affiliation': 'Department of Periodontics SRM Dental College, Ramapuram, Chennai, 600089, Tamilnadu, India. Electronic address: anupamamds@gmail.com.'}, {'ForeName': 'Harinath', 'Initials': 'H', 'LastName': 'Parthasarathy', 'Affiliation': 'Department of Periodontics SRM Dental College, Ramapuram, Chennai, 600089, Tamilnadu, India. Electronic address: hari_feb14@hotmail.com.'}, {'ForeName': 'Deepa', 'Initials': 'D', 'LastName': 'Ponnaiyan', 'Affiliation': 'Department of Periodontics SRM Dental College, Ramapuram, Chennai, 600089, Tamilnadu, India. Electronic address: deepa_ponnaiyan@yahoo.co.in.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2020.101949'] 486,32770186,"How to Teach Medical Students About Pain and Dementia: E-Learning, Experiential Learning, or Both?","OBJECTIVE Pain management in persons with mild to moderate dementia poses unique challenges because of altered pain modulation and the tendency of some individuals to perseverate. We aimed to test the impact of an e-learning module about pain in communicative people with dementia on third-year medical students who had or had not completed an experiential geriatrics course. DESIGN Analysis of pre- to postlearning changes and comparison of the same across the student group. SETTING University of Pittsburgh School of Medicine and Saint Louis University School of Medicine. SUBJECTS One hundred four University of Pittsburgh and 57 Saint Louis University medical students. METHODS University of Pittsburgh students were randomized to view either the pain and dementia module or a control module on pain during a five-day geriatrics course. Saint Louis University students were asked to complete either of the two modules without the context of a geriatrics course. A 10-item multiple choice knowledge test and three-item attitudes and confidence questionnaires were administered before viewing the module and up to seven days later. RESULTS Knowledge increase was significantly greater among students who viewed the dementia module while participating in the geriatrics course than among students who viewed the module without engaging in the course (P < 0.001). The modules did not improve attitudes in any group, while student confidence improved in all groups. CONCLUSIONS Medical students exposed to e-learning or experiential learning demonstrated improved confidence in evaluating and managing pain in patients with dementia. Those exposed to both educational methods also significantly improved their knowledge.",2020,"The modules did not improve attitudes in any group, while student confidence improved in all groups. ","['University of Pittsburgh students', 'Saint Louis University students', 'patients with dementia', 'communicative people with dementia on third-year medical students who had or had not completed an experiential geriatrics course', 'One hundred four University of Pittsburgh and 57 Saint Louis University medical students', 'Teach Medical Students About Pain and Dementia', 'University of Pittsburgh School of Medicine and Saint Louis University School of Medicine', 'persons with mild to moderate dementia']","['e-learning module about pain', 'pain and dementia module or a control module']","['student confidence', 'confidence in evaluating and managing pain']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0014048', 'cui_str': 'St. Louis encephalitis virus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C1444661', 'cui_str': 'Stopped before completion'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]",,0.0317668,"The modules did not improve attitudes in any group, while student confidence improved in all groups. ","[{'ForeName': 'Keelin', 'Initials': 'K', 'LastName': 'Moehl', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Rollin M', 'Initials': 'RM', 'LastName': 'Wright', 'Affiliation': 'Department of Medicine (Geriatric Medicine), University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Shega', 'Affiliation': 'VITAS Healthcare and University of Central Florida, Orlando, Florida.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Malec', 'Affiliation': 'Department of Medicine (Geriatric and Palliative Medicine), University of Chicago, Chicago, Illinois.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Kelley Fitzgerald', 'Affiliation': 'Department of Physical Therapy, University of Pittsburgh School of Health and Rehabilitation Science, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Gregg', 'Initials': 'G', 'LastName': 'Robbins-Welty', 'Affiliation': 'Duke University Hospital, Durham, North Carolina.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Zoberi', 'Affiliation': 'Saint Louis University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Tait', 'Affiliation': 'Saint Louis University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Subashan', 'Initials': 'S', 'LastName': 'Perera', 'Affiliation': 'VITAS Healthcare and University of Central Florida, Orlando, Florida.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Deverts', 'Affiliation': 'Office of Research, University of Pittsburgh School of Dental Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Zsuzsa', 'Initials': 'Z', 'LastName': 'Horvath', 'Affiliation': 'Department of Dental Public Health, University of Pittsburgh School of Dental Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Debra K', 'Initials': 'DK', 'LastName': 'Weiner', 'Affiliation': 'Department of Medicine (Geriatric Medicine), University of Pittsburgh, Pittsburgh, Pennsylvania.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnaa187'] 487,32778150,Postprandial effects of a meal low in sulfur amino acids and high in polyunsaturated fatty acids compared to a meal high in sulfur amino acids and saturated fatty acids on stearoyl CoA-desaturase indices and plasma sulfur amino acids: a pilot study.,"OBJECTIVE The sulfur amino acid (SAA) cysteine is positively related, whereas polyunsaturated fatty acids (PUFAs) are inversely related to activity of the lipogenic enzyme stearoyl-CoA desaturase (SCD). High SCD activity promotes obesity in animals, and plasma activity indices positively associates with fat mass in humans. SCD may thus be a target for dietary intervention with SAA restriction and PUFA enrichment with unknown potential benefits for body composition. We randomized ten healthy individuals to a meal restricted in SAAs and enriched with PUFAs (Cys/Met low  + PUFA) (n = 5) or a meal enriched in SAA and saturated fatty acids (Cys/Met high  + SFA) (n = 5). We measured plasma SCD activity indices (SCD16 and SCD18) and SAAs response hourly from baseline and up to 4 h postprandial. RESULTS SCD16 was unchanged whereas SCD18 tended to increase in the Cys/Met low  + PUFA compared to the Cys/Met high  + SFA group (p time*group interaction  = 0.08). Plasma concentrations of total cysteine fractions including free and reduced cysteine decreased in the Cys/Met low  + PUFA compared to the Cys/Met high  + SFA group (both p time*group interaction  < 0.001). In conclusion, a meal low in SAA but high in PUFAs reduced plasma cysteine fractions but not SCD activity indices. This pilot study can be useful for the design and diet composition of future dietary interventions that targets SCD and SAA. Trial registration ClinicalTrials.gov: NCT02647970, registration date: 6 January 2016.",2020,Plasma concentrations of total cysteine fractions including free and reduced cysteine decreased in the Cys/Met low  + PUFA compared to the Cys/Met high  + SFA group (both p time*group interaction  < 0.001).,['healthy individuals to a meal restricted in SAAs and enriched with PUFAs (Cys/Met low \u2009+\u2009PUFA) (n\u2009=\u20095) or a'],"['SCD', 'sulfur amino acid (SAA) cysteine', 'meal enriched in SAA and saturated fatty acids (Cys/Met high \u2009+\u2009SFA']","['Postprandial effects', 'Plasma concentrations of total cysteine fractions including free and reduced cysteine', 'SCD18', 'plasma SCD activity indices (SCD16 and SCD18) and SAAs response hourly']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0002723', 'cui_str': 'Serum amyloid A protein'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated fatty acid'}]","[{'cui': 'C0038233', 'cui_str': 'Acyl-CoA desaturase'}, {'cui': 'C0002527', 'cui_str': 'Sulfur-bearing amino acid'}, {'cui': 'C0010654', 'cui_str': 'Cysteine'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0597423', 'cui_str': 'Saturated fat'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010654', 'cui_str': 'Cysteine'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0038233', 'cui_str': 'Acyl-CoA desaturase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0002723', 'cui_str': 'Serum amyloid A protein'}, {'cui': 'C0558292', 'cui_str': 'Hourly'}]",10.0,0.0315221,Plasma concentrations of total cysteine fractions including free and reduced cysteine decreased in the Cys/Met low  + PUFA compared to the Cys/Met high  + SFA group (both p time*group interaction  < 0.001).,"[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Olsen', 'Affiliation': 'Department of Nutrition, Institute of Medical Biosciences, University of Oslo, 0372, Oslo, Norway. thomas.olsen@medisin.uio.no.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Turner', 'Affiliation': 'Department of Pharmacology, University of Oxford, Oxford, OX1 3QT, UK.'}, {'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Øvrebø', 'Affiliation': 'Department of Nutrition, Institute of Medical Biosciences, University of Oslo, 0372, Oslo, Norway.'}, {'ForeName': 'Nasser E', 'Initials': 'NE', 'LastName': 'Bastani', 'Affiliation': 'Department of Nutrition, Institute of Medical Biosciences, University of Oslo, 0372, Oslo, Norway.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Refsum', 'Affiliation': 'Department of Nutrition, Institute of Medical Biosciences, University of Oslo, 0372, Oslo, Norway.'}, {'ForeName': 'Kathrine J', 'Initials': 'KJ', 'LastName': 'Vinknes', 'Affiliation': 'Department of Nutrition, Institute of Medical Biosciences, University of Oslo, 0372, Oslo, Norway.'}]",BMC research notes,['10.1186/s13104-020-05222-y'] 488,32780794,A randomized crossover trial on the effect of plant-based compared with animal-based meat on trimethylamine-N-oxide and cardiovascular disease risk factors in generally healthy adults: Study With Appetizing Plantfood-Meat Eating Alternative Trial (SWAP-MEAT).,"BACKGROUND Despite the rising popularity of plant-based alternative meats, there is limited evidence of the health effects of these products. OBJECTIVES We aimed to compare the effect of consuming plant-based alternative meat (Plant) as opposed to animal meat (Animal) on health factors. The primary outcome was fasting serum trimethylamine-N-oxide (TMAO). Secondary outcomes included fasting insulin-like growth factor 1, lipids, glucose, insulin, blood pressure, and weight. METHODS SWAP-MEAT (The Study With Appetizing Plantfood-Meat Eating Alternatives Trial) was a single-site, randomized crossover trial with no washout period. Participants received Plant and Animal products, dietary counseling, lab assessments, microbiome assessments (16S), and anthropometric measurements. Participants were instructed to consume ≥2 servings/d of Plant compared with Animal for 8 wk each, while keeping all other foods and beverages as similar as possible between the 2 phases. RESULTS The 36 participants who provided complete data for both crossover phases included 67% women, were 69% Caucasian, had a mean ± SD age 50 ± 14 y, and BMI 28 ± 5 kg/m2. Mean ± SD servings per day were not different by intervention sequence: 2.5 ± 0.6 compared with 2.6 ± 0.7 for Plant and Animal, respectively (P = 0.76). Mean ± SEM TMAO concentrations were significantly lower overall for Plant (2.7 ± 0.3) than for Animal (4.7 ± 0.9) (P = 0.012), but a significant order effect was observed (P = 0.023). TMAO concentrations were significantly lower for Plant among the n = 18 who received Plant second (2.9 ± 0.4 compared with 6.4 ± 1.5, Plant compared with Animal, P = 0.007), but not for the n = 18 who received Plant first (2.5 ± 0.4 compared with 3.0 ± 0.6, Plant compared with Animal, P = 0.23). Exploratory analyses of the microbiome failed to reveal possible responder compared with nonresponder factors. Mean ± SEM LDL-cholesterol concentrations (109.9 ± 4.5 compared with 120.7 ± 4.5 mg/dL, P = 0.002) and weight (78.7 ± 3.0 compared with 79.6 ± 3.0 kg, P < 0.001) were lower during the Plant phase. CONCLUSIONS Among generally healthy adults, contrasting Plant with Animal intake, while keeping all other dietary components similar, the Plant products improved several cardiovascular disease risk factors, including TMAO; there were no adverse effects on risk factors from the Plant products.This trial was registered at clinicaltrials.gov as NCT03718988.",2020,"Mean ± SEM TMAO concentrations were significantly lower overall for Plant (2.7 ± 0.3) than for Animal (4.7 ± 0.9) (P = 0.012), but a significant order effect was observed (P = 0.023).","['36 participants who provided complete data for both crossover phases included 67% women, were 69% Caucasian, had a mean\xa0±\xa0SD age 50\xa0±', 'generally healthy adults']","['consuming plant-based alternative meat (Plant', 'Plant and Animal products, dietary counseling, lab assessments, microbiome assessments (16S), and anthropometric measurements', 'SWAP-MEAT ', 'plant-based compared with animal-based meat on trimethylamine-N-oxide']","['fasting insulin-like growth factor 1, lipids, glucose, insulin, blood pressure, and weight', 'Mean\xa0±', 'weight', 'Mean\xa0±\xa0SEM LDL-cholesterol concentrations', 'TMAO concentrations', 'fasting serum trimethylamine-N-oxide (TMAO', 'Mean\xa0±\xa0SEM TMAO concentrations']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0003062', 'cui_str': 'Kingdom Animalia'}, {'cui': 'C0025018', 'cui_str': 'Meat products'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0077194', 'cui_str': 'trimethyloxamine'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0077194', 'cui_str': 'trimethyloxamine'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.0987864,"Mean ± SEM TMAO concentrations were significantly lower overall for Plant (2.7 ± 0.3) than for Animal (4.7 ± 0.9) (P = 0.012), but a significant order effect was observed (P = 0.023).","[{'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Crimarco', 'Affiliation': 'Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Sparkle', 'Initials': 'S', 'LastName': 'Springfield', 'Affiliation': 'Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Petlura', 'Affiliation': 'Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Streaty', 'Affiliation': 'Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Cunanan', 'Affiliation': 'Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Priya', 'Initials': 'P', 'LastName': 'Fielding-Singh', 'Affiliation': 'Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Matthew M', 'Initials': 'MM', 'LastName': 'Carter', 'Affiliation': 'Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Madeline A', 'Initials': 'MA', 'LastName': 'Topf', 'Affiliation': 'Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Hannah C', 'Initials': 'HC', 'LastName': 'Wastyk', 'Affiliation': 'Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Erica D', 'Initials': 'ED', 'LastName': 'Sonnenburg', 'Affiliation': 'Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Justin L', 'Initials': 'JL', 'LastName': 'Sonnenburg', 'Affiliation': 'Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Gardner', 'Affiliation': 'Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa203'] 489,32788743,Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus.,"Few studies were conducted to assess safety and efficacy of continuous antiviral therapy administrated from preconception. In the present study, 136 eligible women with chronic HBV infection were recruited, and assigned to active chronic hepatitis B (CHB) (Group A, B or C) or chronic HBV carrier (Group D). Antiviral therapy was administrated in preconception (Group A), in early (Group B) or late pregnancy (Group C and Group D). Immunoprophylaxis was administrated to all infants. Mothers' HBV status and ALT were assessed at delivery and 7 months postpartum. Offspring's HBV status was examined at 7 months old. Group A women showed low HBV DNA level and normal ALT throughout pregnancy. All women at delivery had an HBV DNA level of less than 10 6  IU/ml, but the proportion of patients with lower HBV DNA level in Group A was higher than any of other three groups (P < 0.05). No differences in obstetrical complications were found among the four groups. None of infants who completed follow-up showed positive HBsAg at age of 7 months. Congenital malformation and infant growth indicators were similar among study cohorts. Continuous antiviral therapy from preconception to entire pregnancy is effective and safe for active CHB mothers and their infants.",2020,Continuous antiviral therapy from preconception to entire pregnancy is effective and safe for active CHB mothers and their infants.,"['136 eligible women with chronic HBV infection were recruited, and assigned to active chronic hepatitis B (CHB', 'active CHB mothers and their infants']","['Antiviral therapy', 'Immunoprophylaxis', 'continuous antiviral therapy']","['low HBV DNA level and normal ALT', 'positive HBsAg', 'Congenital malformation and infant growth indicators', 'HBV DNA level', 'Efficacy and safety', 'obstetrical complications', 'safety and efficacy', ""Mothers' HBV status and ALT""]","[{'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0019163', 'cui_str': 'Type B viral hepatitis'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0520463', 'cui_str': 'Chronic active hepatitis'}, {'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0280274', 'cui_str': 'Antiviral therapy'}, {'cui': 'C0020971', 'cui_str': 'Immunization'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0019163', 'cui_str': 'Type B viral hepatitis'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0019168', 'cui_str': 'Hepatitis B surface antigen'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0178292', 'cui_str': 'Complication of pregnancy, childbirth and/or the puerperium'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",136.0,0.0306027,Continuous antiviral therapy from preconception to entire pregnancy is effective and safe for active CHB mothers and their infants.,"[{'ForeName': 'Xingfei', 'Initials': 'X', 'LastName': 'Pan', 'Affiliation': 'Department of Infectious Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Jingsi', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Fetal Medicine and Prenatal Diagnosis, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Liyang', 'Initials': 'L', 'LastName': 'Zhou', 'Affiliation': 'Department of Infectious Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Xueting', 'Initials': 'X', 'LastName': 'Ou', 'Affiliation': 'Department of Infectious Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'He', 'Affiliation': 'The Medical Centre for Critical Pregnant Women in Guangzhou, Guangzhou, China.'}, {'ForeName': 'Yifen', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'The Medical Centre for Critical Pregnant Women in Guangzhou, Guangzhou, China.'}, {'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Zheng', 'Affiliation': 'Department of Infectious Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Haibin', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Fujian Provincial Laboratory for Reproductive Health Research, School of Medicine, Xiamen University, Xiamen, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Cao', 'Affiliation': 'Fujian Provincial Laboratory for Reproductive Health Research, School of Medicine, Xiamen University, Xiamen, China.'}, {'ForeName': 'Zhijian', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Huishu', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ""Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou, China.""}, {'ForeName': 'Guocheng', 'Initials': 'G', 'LastName': 'Liu', 'Affiliation': ""Department of Obstetrics and Gynecology, Guangdong Provincial Maternal and Children's Hospital, Guangzhou, China.""}, {'ForeName': 'Zhenyu', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': 'Department of Obstetrics and Gynecology, Beijing TsingHua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.'}, {'ForeName': 'Guanxin', 'Initials': 'G', 'LastName': 'Shen', 'Affiliation': 'Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Shiliang', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'Dunjin', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou, China. gzdrchen@gzhmu.edu.cn.'}]",Scientific reports,['10.1038/s41598-020-70644-4'] 490,32783769,"Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial.","Aim : The aims of the study were to evaluate the non-inferiority of the safety and immunogenicity of a new trial purified vero cell-cultured rabies vaccine (trial vaccine) in healthy subjects comparing with the control purified vero cell-cultured rabies vaccine (control vaccine) following Essen regimen and to evaluate the non-inferiority of the safety and immunogenicity of the trial vaccine following two intramuscular regimens, between Zagreb and Essen regimen. Methods : Serum samples were collected before vaccination and on d 7, 14, 35/42 post vaccination. Adverse events (AEs) were recorded for 30 d following each vaccination. This study was registered in the Chinese Clinical Trial Registry (ChiCTR-PPR-15007057). Results : There was no significant difference in the incidence of AEs, local and systemic reactions, among Zagreb group, Essen group, and control group. But the incidence of solicited AEs was a significant difference among the three groups ( p = 0.0498). The incidence of solicited AEs was higher in Essen group than that in control group and Zagreb group ( p = 0.0278, p = 0.0248). In the subjects whose antibodies were seronegative before vaccination, the seroconversion rates of antibodies among three groups were all 100.0% on d 14 and d 35/42. The Essen group was not inferior to the control group, and the Zagreb group was not inferior to the Essen group on d 14. On d 14 and d 35/42, the geometric mean concentration of the three groups was much higher than the immune protection level of 0.5 IU/ml. Conclusions : The trial vaccine had good safety and immunogenicity, and the trial vaccine is not inferior to the control vaccine. Abbreviations: PVRV: purified vero cell-cultured rabies vaccine; AE: adverse event; CI: confidence interval; GMC: geometric mean concentration; IM: intramuscular; NIFDC: National Institutes for Food and Drug Control; PPS: per-protocol set; SS: safety set; REFIT: Rapid Fluorescent Focus Inhibition Test; RVNA: rabies virus neutralizing antibody; WHO: World Health Organization.",2021,"There was no significant difference in the incidence of AEs, local and systemic reactions, among Zagreb group, Essen group, and control group.","['healthy Chinese subjects', 'healthy subjects']","['new trial purified vero cell-cultured rabies vaccine (trial vaccine', 'control purified vero cell-cultured rabies vaccine (control vaccine', 'purified vero cell-cultured rabies vaccine', 'REFIT']","['geometric mean concentration', 'Adverse events (AEs', 'incidence of AEs, local and systemic reactions', 'good safety and immunogenicity', 'Immunogenicity and safety', 'incidence of solicited AEs', 'seroconversion rates of antibodies']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0042542', 'cui_str': 'Vero Cells'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}]",,0.170782,"There was no significant difference in the incidence of AEs, local and systemic reactions, among Zagreb group, Essen group, and control group.","[{'ForeName': 'Heng', 'Initials': 'H', 'LastName': 'Shen', 'Affiliation': 'Hubei Center for Disease Prevention and Control , Wuhan, China.'}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Hubei Center for Disease Prevention and Control , Wuhan, China.'}, {'ForeName': 'Beifang', 'Initials': 'B', 'LastName': 'Yang', 'Affiliation': 'Hubei Center for Disease Prevention and Control , Wuhan, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Cai', 'Affiliation': 'Hubei Center for Disease Prevention and Control , Wuhan, China.'}, {'ForeName': 'Changjun', 'Initials': 'C', 'LastName': 'Jiang', 'Affiliation': 'Dangyang Center for Disease Prevention and Control , Dangyang, China.'}, {'ForeName': 'Ronghua', 'Initials': 'R', 'LastName': 'Xie', 'Affiliation': 'Tuanfeng Center for Disease Prevention and Control , Huanggang, China.'}, {'ForeName': 'Haitao', 'Initials': 'H', 'LastName': 'Xiao', 'Affiliation': 'Dangyang Center for Disease Prevention and Control , Dangyang, China.'}, {'ForeName': 'Qunhui', 'Initials': 'Q', 'LastName': 'Ren', 'Affiliation': 'Dangyang Center for Disease Prevention and Control , Dangyang, China.'}, {'ForeName': 'Zhengxu', 'Initials': 'Z', 'LastName': 'Qi', 'Affiliation': 'Tuanfeng Center for Disease Prevention and Control , Huanggang, China.'}, {'ForeName': 'Jinghui', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Xianshengweike Biopharmaceutical Co., Ltd , Jiangsu, China.'}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Hubei Center for Disease Prevention and Control , Wuhan, China.'}, {'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Ye', 'Affiliation': 'Hubei Center for Disease Prevention and Control , Wuhan, China.'}, {'ForeName': 'Faxian', 'Initials': 'F', 'LastName': 'Zhan', 'Affiliation': 'Hubei Center for Disease Prevention and Control , Wuhan, China.'}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2020.1778408'] 491,32790575,Effects of Static and Dynamic Stretching With Strengthening Exercises in Patients With Patellofemoral Pain Who Have Inflexible Hamstrings: A Randomized Controlled Trial.,"BACKGROUND Patellofemoral pain (PFP) syndrome is closely associated with muscle tightness. However, studies regarding the effects of stretching exercises on PFP patients with inflexible hamstrings are scarce. The aim of the study was to compare the effects between static and dynamic hamstring stretching in patients with PFP who have inflexible hamstrings. HYPOTHESIS Compared with static hamstring stretching, dynamic hamstring stretching will improve the parameters of hamstring flexibility, knee muscle strength, muscle activation time, and clinical outcomes in this patient population. STUDY DESIGN Prospective randomized controlled trial. LEVEL OF EVIDENCE Level 2. METHODS A total of 46 patients (25, static stretching; 21, dynamic stretching) participated. Hamstring flexibility was assessed according to the popliteal angle during active knee extension. Muscle strength and muscle activation time were measured using an isokinetic device. Clinical outcomes were evaluated using the visual analog scale (VAS) for pain and the anterior knee pain scale (AKPS). RESULTS There were no differences in hamstring flexibility and knee muscle strength of the affected knees between the groups ( P > 0.05). Significantly improved muscle activation time and clinical outcomes of the affected knees were observed in the dynamic stretching group compared with the static stretching group (all Ps < 0.01 for hamstring, quadriceps, VAS, and AKPS). CONCLUSION In patients with PFP who have inflexible hamstrings, dynamic hamstring stretching with strengthening exercises was superior for improving muscle activation time and clinical outcomes compared with static hamstring stretching with strengthening exercises. CLINICAL RELEVANCE Clinicians and therapists could implement dynamic hamstring stretching to improve function and reduce pain in patients with PFP who have inflexible hamstrings.",2021,There were no differences in hamstring flexibility and knee muscle strength of the affected knees between the groups ( P > 0.05).,"['46 patients (25, static stretching; 21, dynamic stretching) participated', 'patients with PFP who have inflexible hamstrings', 'Patients With Patellofemoral Pain', 'Who Have Inflexible Hamstrings', 'PFP patients with inflexible hamstrings']","['static stretching', 'stretching exercises', 'static hamstring stretching with strengthening exercises', 'static hamstring stretching, dynamic hamstring stretching', 'static and dynamic hamstring stretching', 'Static and Dynamic Stretching With Strengthening Exercises']","['Muscle strength and muscle activation time', 'hamstring flexibility, knee muscle strength, muscle activation time, and clinical outcomes', 'hamstring flexibility and knee muscle strength', 'Hamstring flexibility', 'muscle activation time and clinical outcomes', 'visual analog scale (VAS) for pain and the anterior knee pain scale (AKPS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1720875', 'cui_str': 'Static Stretching'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0584895', 'cui_str': 'Posterior muscle of thigh structure'}]","[{'cui': 'C1720875', 'cui_str': 'Static Stretching'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0556829', 'cui_str': 'Hamstring stretching'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C1720869', 'cui_str': 'Dynamic Stretching'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0409326', 'cui_str': 'Anterior knee pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",46.0,0.0662771,There were no differences in hamstring flexibility and knee muscle strength of the affected knees between the groups ( P > 0.05).,"[{'ForeName': 'Jin Hyuck', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy and School of Health and Environmental Science, College of Health Science, Korea University, Seoul, Korea.'}, {'ForeName': 'Ki-Mo', 'Initials': 'KM', 'LastName': 'Jang', 'Affiliation': 'Department of Sports Medical Center, Korea University College of Medicine, Anam Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Eunseon', 'Initials': 'E', 'LastName': 'Kim', 'Affiliation': 'Department of Sports Medical Center, Korea University College of Medicine, Anam Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Hye Chang', 'Initials': 'HC', 'LastName': 'Rhim', 'Affiliation': 'Department of Orthopaedic Surgery, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hyeong-Dong', 'Initials': 'HD', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy and School of Health and Environmental Science, College of Health Science, Korea University, Seoul, Korea.'}]",Sports health,['10.1177/1941738120932911'] 492,32796442,MICROSTRUCTURAL CHANGES IN CYSTOID MACULAR EDEMA IN RETINITIS PIGMENTOSA AFTER INTRAVITREAL DEXAMETHASONE IMPLANT INJECTION.,"PURPOSE To evaluate microstructural changes in cystoid macular edema in retinitis pigmentosa after intravitreal dexamethasone implant injection. METHODS In an extended cohort of a randomized trial of intravitreal dexamethasone implant for the management of retinitis pigmentosa-associated cystoid macular edema, microstructural changes during six months after the treatment were evaluated using spectral-domain optical coherence tomography. RESULTS Forty-two eyes were included, and all had cystoid space in the inner nuclear layer (INL) at baseline. No eyes showed subretinal fluid, and 28.6% showed hyperreflective foci. Among 38 eyes with cystoid space both in the INL and outer nuclear layer/Henle's layer, 13 (34.2%) showed complete resolution and 12 (31.6%) showed cystoid space only in the INL at 2 months after injection, whereas others showed persistent cystoid space in both layers. After complete resolution, cystoid space recurrence was earlier in the INL than in the outer nuclear layer/Henle's layer. Multivariable analysis showed that greater cystoid space area in the INL and outer nuclear layer/Henle's layer, presence of macular leakage, and longer intact external limiting membrane at baseline were associated with greater cystoid space area decrease after the treatment. CONCLUSION Resolution and recurrence pattern of retinitis pigmentosa-associated cystoid macular edema after dexamethasone treatment showed that the INL is the primary layer of cystic change, and this suggests its pathogenesis is most likely caused by Müller cell dysfunction.",2021,"After complete resolution, cystoid space recurrence was earlier in the INL than in the ONL/HL.","['cystoid macular edema (CME) in retinitis pigmentosa (RP', 'Forty-two eyes were included, and all had cystoid space in the inner nuclear layer (INL) at baseline', 'Cystoid Macular Edema in Retinitis Pigmentosa after Intravitreal Dexamethasone Implant Injection']","['dexamethasone', 'intravitreal dexamethasone']","['hyperreflective foci', 'subretinal fluid', 'cystoid space recurrence', 'complete resolution', 'cystoid space']","[{'cui': 'C0024440', 'cui_str': 'Cystoid macular edema'}, {'cui': 'C0035334', 'cui_str': 'Retinitis pigmentosa'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}]","[{'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",42.0,0.0344495,"After complete resolution, cystoid space recurrence was earlier in the INL than in the ONL/HL.","[{'ForeName': 'Un Chul', 'Initials': 'UC', 'LastName': 'Park', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}, {'ForeName': 'Jung Hyun', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}, {'ForeName': 'Chang Ki', 'Initials': 'CK', 'LastName': 'Yoon', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}, {'ForeName': 'Hyeong Gon', 'Initials': 'HG', 'LastName': 'Yu', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002944'] 493,32796329,Modified Buried Vertical Mattress Suture Versus Buried Intradermal Suture: A Prospective Split-Scar Study.,"BACKGROUND The modified buried vertical mattress suture (MBVMS) is believed to provide excellent outcomes by relieving the tension on wound edges. However, clinical data on the topic remain sparse and inadequate. OBJECTIVE To compare the cosmetic results of the MBVMS and the buried intradermal suture (BIS) in chest wounds using a split-scar model. MATERIALS AND METHODS Twenty patients participated in the study. One randomly selected half of each chest wound was closed with the MBVMS; the other half was closed with the BIS. Immediately, postoperatively, the maximum degree of wound eversion was obtained. After 3 months, the wound complication rates were recorded, and the aesthetic appearance of each scar was evaluated by the Patient and Observer Scar Assessment Scale (POSAS), the Vancouver Scar Scale (VSS), the visual analog scale (VAS), and scar width. RESULTS The MBVMS yielded a greater mean postoperative eversion height and width (p < .05); lower POSAS, VSS, and VAS scores (p < .05); and a narrower scar width (p < .05) than did the BIS. CONCLUSION Compared with the BIS, the MBVMS provided significantly increased wound eversion immediately, postoperatively, and improved aesthetic outcomes at the end of the 3-month follow-up period.",2021,"Compared with the BIS, the MBVMS provided significantly increased wound eversion immediately, postoperatively, and improved aesthetic outcomes at the end of the 3-month follow-up period.",['Twenty patients participated in the study'],"['modified buried vertical mattress suture (MBVMS', 'Modified Buried Vertical Mattress Suture Versus Buried Intradermal Suture', 'MBVMS and the buried intradermal suture (BIS']","['POSAS, VSS, and VAS scores', 'aesthetic appearance of each scar', 'wound complication rates', 'wound eversion', 'Patient and Observer Scar Assessment Scale (POSAS), the Vancouver Scar Scale (VSS), the visual analog scale (VAS), and scar width', 'aesthetic outcomes', 'narrower scar width', 'mean postoperative eversion height and width', 'maximum degree of wound eversion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0263398', 'cui_str': 'Erythema elevatum diutinum'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0024940', 'cui_str': 'Mattress'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C1522475', 'cui_str': 'Intradermal route'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0015211', 'cui_str': 'Eversion'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",1.0,0.0127069,"Compared with the BIS, the MBVMS provided significantly increased wound eversion immediately, postoperatively, and improved aesthetic outcomes at the end of the 3-month follow-up period.","[{'ForeName': 'Zonghui', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Zhishui', 'Initials': 'Z', 'LastName': 'Tang', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Hao', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Xiangyu', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'He', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Xueyuan', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Youcheng', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Maoguo', 'Initials': 'M', 'LastName': 'Shu', 'Affiliation': ""Department of Aesthetic, Plastic and Maxillofacial Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002642'] 494,32799753,The immediate effect of the abdominal drawing-in maneuver technique on stature change in seated sedentary workers with chronic low back pain.,"Many studies have measured stature change arising from loads imposed on the spine during sitting. To improve stature recovery, it is important to stabilise the lumbar spine and compensate forces from the upper body. The abdominal drawing-in maneuver (ADIM) technique has been found to mainly activate deep trunk muscles. The purpose of this study was to determine whether activation of deep trunk muscles by the ADIM technique could immediately improve stature recovery during prolonged sitting. Twenty-four patients with chronic low back pain (CLBP) were randomly allocated into different orders of experimental conditions: control (sitting without ADIM technique) and intervention conditions (sitting with ADIM technique). The latter condition required participants to complete ADIM technique for 1 min and repeat it three times throughout 41 min prolonged sitting time. Stature recovery was improved by 3.292 mm in the intervention condition compared with control condition ( p -value = 0.001). Our finding demonstrated that ADIM technique improved stature recovery. Practitioner Summary: Prolonged sitting seemingly harms sedentary workers' health, particularly affecting the lower back. Activation of deep trunk muscles using abdominal drawing-in maneuver technique can promote spinal recovery. Clinicians can teach abdominal drawing-in maneuver technique to activate deep trunk muscles in chronic low back pain, thereby promoting self-management of seated stature recovery. Abbrevations: ADIM: abdominal drawing-in maneuver; RA: rectus abdominis; ICLT: iliocostalis lumborum pars thoracis; LM: lumbar multifidus; TrA: transversus abdominis; IO: internal oblique; CLBP: chronic low back pain; LBP: low back pain; RMDQ: Roland Morris disability questionnaire; NRS: numerical rating scale.",2021,Stature recovery was improved by 3.292 mm in the intervention condition compared with control condition (p-value =0.001).,"['Twenty-four patients with chronic low back pain (CLBP', 'seated sedentary workers with chronic low back pain']","['abdominal drawing-in maneuver technique', 'experimental conditions: control (sitting without ADIM technique) and intervention conditions (sitting with ADIM technique']","['stature recovery', 'Stature recovery']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C1306056', 'cui_str': 'Worker'}]","[{'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0005890', 'cui_str': 'Body height measure'}]",24.0,0.0123001,Stature recovery was improved by 3.292 mm in the intervention condition compared with control condition (p-value =0.001).,"[{'ForeName': 'Pongsatorn', 'Initials': 'P', 'LastName': 'Saiklang', 'Affiliation': 'School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Rungthip', 'Initials': 'R', 'LastName': 'Puntumetakul', 'Affiliation': 'School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Manida', 'Initials': 'M', 'LastName': 'Swangnetr Neubert', 'Affiliation': 'Research Center in Back, Neck, Other Joint Pain and Human Performance (BNOJPH), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Boucaut', 'Affiliation': 'International Centre for Allied Health Evidence, University of South Australia, Adelaide, Australia.'}]",Ergonomics,['10.1080/00140139.2020.1810326'] 495,32730170,Comparison of Graphic Organizers Versus Online Flash Cards as Study Aids in an Elective Veterinary Cardiology Course.,"The ideal study aid format for veterinary students remains unknown. Both graphic organizers (GOs) and flash cards (FCs) have shown utility for enhancing learning in specific contexts. A mixed-methods prospective randomized crossover trial was undertaken with veterinary students ( n  = 59) in an elective cardiology course. All students received identical content presented via weekly in-class lectures and were given study aids in either GO or FC format. One week later, students completed quizzes of content knowledge for each lesson and indicated amount of time spent studying. Crossover occurred such that groups of students alternated between receiving GOs and FCs. Quantitative and qualitative data were collected in the form of in-depth pre- and post-course surveys. Overall, there was no significant difference in quiz scores ( p  = .26) or time spent studying ( p  = .33) based on study aid type. Time spent studying for each quiz, as well as other measures of study habits, decreased significantly throughout the semester. Post-course survey responses showed overall higher student satisfaction for GOs compared to FCs ( p  = .022), as well as a shift in preference away from FCs throughout the semester ( p  = .03). Free-text survey responses revealed that individual students had strong preferences either for or against FCs in the context of their particular study habits. In an elective veterinary cardiology course, use of GO format compared to FC format study aids resulted in equivalent short-term learning outcomes and time spent studying, with each study aid format appealing to specific learning preferences of individual students.",2021,"Post-survey responses showed overall higher student satisfaction for GOs compared to FCs ( p = .022), as well as a shift in preference away from FCs throughout the semester ( p = .03).",['veterinary students ( n = 59) in an elective cardiology course'],"['graphic organizers (GOs) and flash cards (FCs', 'Graphic Organizers']","['quiz scores', 'student satisfaction']","[{'cui': 'C0042614', 'cui_str': 'veterinary'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0085635', 'cui_str': 'Photopsia'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0147144,"Post-survey responses showed overall higher student satisfaction for GOs compared to FCs ( p = .022), as well as a shift in preference away from FCs throughout the semester ( p = .03).","[{'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Ward', 'Affiliation': ''}, {'ForeName': 'Courtney A', 'Initials': 'CA', 'LastName': 'Vengrin', 'Affiliation': ''}]",Journal of veterinary medical education,['10.3138/jvme.2019-0136'] 496,32737585,Effects of state anxiety on gait: a 7.5% carbon dioxide challenge study.,"We used the 7.5% carbon dioxide (CO 2 ) model of anxiety induction to investigate the effects of state anxiety on normal gait and gait when navigating an obstacle. Healthy volunteers (n = 22) completed a walking task during inhalations of 7.5% CO 2 and medical air (placebo) in a within-subjects design. The order of inhalation was counterbalanced across participants and the gas was administered double-blind. Over a series of trials, participants walked the length of the laboratory, with each trial requiring participants to navigate through an aperture (width adjusted to participant size), with gait parameters measured via a motion capture system. The main findings were that walking speed was slower, but the adjustment in body orientation was greater, during 7.5% CO 2 inhalation compared to air. These findings indicate changes in locomotor behaviour during heightened state anxiety that may reflect greater caution when moving in an agitated state. Advances in sensing technology offer the opportunity to monitor locomotor behaviour, and these findings suggest that in doing so, we may be able to infer emotional states from movement in naturalistic settings.",2021,"The main findings were that walking speed was slower, but the adjustment in body orientation was greater, during 7.5% CO 2 inhalation compared to air.",['Healthy volunteers (n\u2009=\u200922'],"['carbon dioxide', 'walking task during inhalations of 7.5% CO 2 and medical air (placebo']","['gait', 'walking speed', 'body orientation']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C3536832', 'cui_str': 'Air'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}]",,0.0840547,"The main findings were that walking speed was slower, but the adjustment in body orientation was greater, during 7.5% CO 2 inhalation compared to air.","[{'ForeName': 'Angela S', 'Initials': 'AS', 'LastName': 'Attwood', 'Affiliation': 'MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. angela.attwood@bristol.ac.uk.'}, {'ForeName': 'Casimir J H', 'Initials': 'CJH', 'LastName': 'Ludwig', 'Affiliation': 'School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol, BS8 1TU, UK.'}, {'ForeName': 'Ian S', 'Initials': 'IS', 'LastName': 'Penton-Voak', 'Affiliation': 'School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol, BS8 1TU, UK.'}, {'ForeName': 'Jade', 'Initials': 'J', 'LastName': 'Poh', 'Affiliation': 'School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol, BS8 1TU, UK.'}, {'ForeName': 'Alex S F', 'Initials': 'ASF', 'LastName': 'Kwong', 'Affiliation': 'MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.'}, {'ForeName': 'Marcus R', 'Initials': 'MR', 'LastName': 'Munafò', 'Affiliation': 'MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.'}]",Psychological research,['10.1007/s00426-020-01393-2'] 497,32749491,Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.,"Importance Low levels of 25-hydroxyvitamin D have been associated with higher risk for depression later in life, but there have been few long-term, high-dose large-scale trials. Objective To test the effects of vitamin D3 supplementation on late-life depression risk and mood scores. Design, Setting, and Participants There were 18 353 men and women aged 50 years or older in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized clinical trial of cardiovascular disease and cancer prevention among 25 871 adults in the US. There were 16 657 at risk for incident depression (ie, no depression history) and 1696 at risk for recurrent depression (ie, depression history but no treatment for depression within the past 2 years). Randomization occurred from November 2011 through March 2014; randomized treatment ended on December 31, 2017, and this was the final date of follow-up. Intervention Randomized assignment in a 2 × 2 factorial design to vitamin D3 (2000 IU/d of cholecalciferol) and fish oil or placebo; 9181 were randomized to vitamin D3 and 9172 were randomized to matching placebo. Main Outcomes and Measures The primary outcomes were the risk of depression or clinically relevant depressive symptoms (total of incident and recurrent cases) and the mean difference in mood scores (8-item Patient Health Questionnaire depression scale [PHQ-8]; score range, 0 points [least symptoms] to 24 points [most symptoms]; the minimal clinically important difference for change in scores was 0.5 points). Results Among the 18 353 randomized participants (mean age, 67.5 [SD, 7.1] years; 49.2% women), the median treatment duration was 5.3 years and 90.5% completed the trial (93.5% among those alive at the end of the trial). Risk of depression or clinically relevant depressive symptoms was not significantly different between the vitamin D3 group (609 depression or clinically relevant depressive symptom events; 12.9/1000 person-years) and the placebo group (625 depression or clinically relevant depressive symptom events; 13.3/1000 person-years) (hazard ratio, 0.97 [95% CI, 0.87 to 1.09]; P = .62); there were no significant differences between groups in depression incidence or recurrence. No significant differences were observed between treatment groups for change in mood scores over time; mean change in PHQ-8 score was not significantly different from zero (mean difference for change in mood scores, 0.01 points [95% CI, -0.04 to 0.05 points]). Conclusions and Relevance Among adults aged 50 years or older without clinically relevant depressive symptoms at baseline, treatment with vitamin D3 compared with placebo did not result in a statistically significant difference in the incidence and recurrence of depression or clinically relevant depressive symptoms or for change in mood scores over a median follow-up of 5.3 years. These findings do not support the use of vitamin D3 in adults to prevent depression. Trial Registration ClinicalTrials.gov Identifiers: NCT01169259 and NCT01696435.",2020,"No significant differences were observed between treatment groups for change in mood scores over time; mean change in PHQ-8 score was not significantly different from zero (mean difference for change in mood scores, 0.01 points [95% CI, -0.04 to 0.05 points]). ","['Among the 18\u202f353 randomized participants (mean age, 67.5 [SD, 7.1] years; 49.2% women', 'Participants\n\n\nThere were 18\u202f353 men and women aged 50 years or older in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized clinical trial of cardiovascular disease and cancer prevention among 25\u202f871 adults in the US', 'adults aged 50 years or older without clinically', 'There were 16\u202f657 at risk for incident depression (ie, no depression history) and 1696 at risk for recurrent depression (ie, depression history but no treatment for depression within the past 2 years']","['Long-term Vitamin D3 Supplementation vs Placebo', '25-hydroxyvitamin D', 'vitamin D3 supplementation', 'vitamin D3 (2000 IU/d of cholecalciferol) and fish oil or placebo', 'vitamin D3', 'placebo']","['relevant depressive symptoms', 'late-life depression risk and mood scores', 'Risk of depression or clinically relevant depressive symptoms', 'depression incidence or recurrence', 'Risk of Depression or Clinically Relevant Depressive Symptoms', 'mood scores', 'risk of depression or clinically relevant depressive symptoms (total of incident and recurrent cases) and the mean difference in mood scores (8-item Patient Health Questionnaire depression scale [PHQ-8]; score range, 0 points [least symptoms', 'median treatment duration', 'Mood Scores', 'incidence and recurrence of depression or clinically relevant depressive symptoms', 'PHQ-8 score']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0057472', 'cui_str': '1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0206034', 'cui_str': 'Trials, Randomized Clinical'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0221480', 'cui_str': 'Recurrent depression'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444637', 'cui_str': 'Past'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}]",25871.0,0.741621,"No significant differences were observed between treatment groups for change in mood scores over time; mean change in PHQ-8 score was not significantly different from zero (mean difference for change in mood scores, 0.01 points [95% CI, -0.04 to 0.05 points]). ","[{'ForeName': 'Olivia I', 'Initials': 'OI', 'LastName': 'Okereke', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston.'}, {'ForeName': 'Charles F', 'Initials': 'CF', 'LastName': 'Reynolds', 'Affiliation': 'Department of Psychiatry, UPMC and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mischoulon', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Chang', 'Affiliation': 'Department of Psychiatry, VA Boston Healthcare System, Brockton, Massachusetts.'}, {'ForeName': 'Chirag M', 'Initials': 'CM', 'LastName': 'Vyas', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston.'}, {'ForeName': 'Nancy R', 'Initials': 'NR', 'LastName': 'Cook', 'Affiliation': 'Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Weinberg', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Vadim', 'Initials': 'V', 'LastName': 'Bubes', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Trisha', 'Initials': 'T', 'LastName': 'Copeland', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Friedenberg', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'I-Min', 'Initials': 'IM', 'LastName': 'Lee', 'Affiliation': 'Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Buring', 'Affiliation': 'Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}]",JAMA,['10.1001/jama.2020.10224'] 498,32758033,Secondhand Smoke Risk Communication: Effects on Parent Smokers' Perceptions and Intentions.,"This study examined effective strategies to communicate with parent smokers about the risks of secondhand smoke (SHS) exposure to children. An online, between-subjects experimental survey was administered via TurkPrime Panels to recruit participants ( N =  623) comprising adult smokers living with children (aged 0-15). Participants were assigned to messages conditions that differed by message recommendation (cessation; cessation+exposure reduction) and format (video; text-only) or to a no-message control. Participants in a message condition viewed a message, and all participants responded to questions about their perceptions and intentions. Parent smokers who viewed either message recommendation reported greater harm perceptions ( p <.001), self-efficacy ( p <.001), and help-seeking intentions ( p <.05) than the no-message control group. Cessation+exposure reduction recommendations elicited greater quit intentions than the no-message control ( p <.05). Compared to text-only, videos elicited greater reduce-exposure intentions ( p <.05) and interpersonal communication intentions ( p <.05). Only videos elicited greater quit intentions ( p <.01) and help-seeking intentions ( p <.01) than the no-message control. Communication about this topic can be optimized by recommending both cessation and exposure-reduction behaviors (versus cessation only), and by using videos (versus traditional print/text-based materials).",2020,Only videos elicited greater quit intentions ( p <.01) and help-seeking intentions ( p <.01) than the no-message control.,"['parent smokers about the risks of secondhand smoke (SHS) exposure to children', ""Parent Smokers' Perceptions and Intentions"", 'adult smokers living with children (aged 0-15']","['messages conditions that differed by message recommendation (cessation; cessation+exposure reduction) and format (video; text-only) or to a no-message control', 'Cessation+exposure']","['reduce-exposure intentions', 'harm perceptions', 'help-seeking intentions', 'quit intentions', 'interpersonal communication intentions', 'self-efficacy']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0037370', 'cui_str': 'Passive smoking'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0553288', 'cui_str': 'Lives with children'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1301627', 'cui_str': 'Format'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0086792', 'cui_str': 'Personal Communication'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",623.0,0.0101532,Only videos elicited greater quit intentions ( p <.01) and help-seeking intentions ( p <.01) than the no-message control.,"[{'ForeName': 'Jennah M', 'Initials': 'JM', 'LastName': 'Sontag', 'Affiliation': 'Center for Tobacco Studies, Rutgers University , New Brunswick, New Jersey, USA.'}, {'ForeName': 'Cristine D', 'Initials': 'CD', 'LastName': 'Delnevo', 'Affiliation': 'Center for Tobacco Studies, Rutgers University , New Brunswick, New Jersey, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hegyi', 'Affiliation': 'The SIDS Center of New Jersey, Department of Pediatrics, Robert Wood Johnson Medical School, Rutgers University , New Brunswick, New Jersey, USA.'}, {'ForeName': 'Barbara M', 'Initials': 'BM', 'LastName': 'Ostfeld', 'Affiliation': 'The SIDS Center of New Jersey, Department of Pediatrics, Robert Wood Johnson Medical School, Rutgers University , New Brunswick, New Jersey, USA.'}, {'ForeName': 'Olivia A', 'Initials': 'OA', 'LastName': 'Wackowski', 'Affiliation': 'Center for Tobacco Studies, Rutgers University , New Brunswick, New Jersey, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1797947'] 499,32769833,Concussion Symptom Treatment and Education Program: A Feasibility Study.,"OBJECTIVE To evaluate the feasibility and potential benefits of a manualized, brief cognitive-behavioral therapy-based intervention program for children and adolescents with persistent postconcussive symptoms. SETTING Two outpatient pediatric concussion programs in the United States. PARTICIPANTS Patients aged 8 to 17 years who sustained concussions between 2 and 12 months prior to enrollment. DESIGN Pre-/postretrospective study. MAIN MEASURES SCAT-3; HBI; PedsQL 4.0 Generic Core Scales; and RCADS. RESULTS Thirty children and adolescents completed the treatment program. Self- and parent-reported postconcussive symptoms, quality of life, and internalizing symptoms significantly improved with treatment. Mixed-effects models revealed a significant decline in self-reported postconcussive symptoms across treatment sessions, a = -2.07, SE = 0.25, P < .001. The largest change occurred between sessions 2 and 3, following the session focusing on concussion psychoeducation and sleep hygiene (estimated mean change between sessions 2 and 3 = -4.72, P < .0001). CONCLUSIONS Our findings indicate that a 6-session manualized cognitive behavioral intervention is feasible to initiate in an outpatient clinic 1 to 12 months following a pediatric mild traumatic brain injury. With a manualized format, clinicians at most levels of training should be able to implement this treatment manual and flexibly adapt as needed when working with children and adolescents who are experiencing delayed symptom recovery following concussion.",2021,"Self- and parent-reported postconcussive symptoms, quality of life, and internalizing symptoms significantly improved with treatment.","['Two outpatient pediatric concussion programs in the United States', 'children and adolescents with persistent postconcussive symptoms', 'Thirty children and adolescents completed the treatment program', 'Patients aged 8 to 17 years who sustained concussions between 2 and 12 months prior to enrollment']","['Concussion Symptom Treatment and Education Program', '6-session manualized cognitive behavioral intervention', 'manualized, brief cognitive-behavioral therapy-based intervention program']","['concussion psychoeducation and sleep hygiene', 'Self- and parent-reported postconcussive symptoms, quality of life, and internalizing symptoms']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}]","[{'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C4277672', 'cui_str': 'Good Sleep Habits'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",30.0,0.0277906,"Self- and parent-reported postconcussive symptoms, quality of life, and internalizing symptoms significantly improved with treatment.","[{'ForeName': 'Tess S', 'Initials': 'TS', 'LastName': 'Simpson', 'Affiliation': ""Department of Physical Medicine & Rehabilitation, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora (Drs Simpson, Peterson, and Forster); Department of Neurology, University of Washington School of Medicine and Seattle Children's Hospital, Seattle (Dr Patrick); Rocky Mountain Mental Illness Research, Education, and Clinical Center for Veteran Suicide Prevention, Rocky Mountain Regional Veterans Affairs (VA) Medical Facility, Aurora, Colorado (Dr Forster); and Department of Pediatrics, The Ohio State University and Nationwide Children's Hospital, Columbus (Dr McNally).""}, {'ForeName': 'Robin L', 'Initials': 'RL', 'LastName': 'Peterson', 'Affiliation': ''}, {'ForeName': 'Kristina E', 'Initials': 'KE', 'LastName': 'Patrick', 'Affiliation': ''}, {'ForeName': 'Jeri E', 'Initials': 'JE', 'LastName': 'Forster', 'Affiliation': ''}, {'ForeName': 'Kelly A', 'Initials': 'KA', 'LastName': 'McNally', 'Affiliation': ''}]",The Journal of head trauma rehabilitation,['10.1097/HTR.0000000000000592'] 500,32770667,Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended-Release Tablets.,"Alfuzosin is a medication approved by the US Food and Drug Administration to treat benign prostatic hyperplasia symptoms. Bioequivalence studies are demanded by regulatory authorities to evaluate the expected in vivo biological similarity of 2 formulations of a medication. The aim of this study is to assess the bioavailability of the generic (test) and branded (reference) formulations of 10-mg alfuzosin extended-release tablets after oral administration to healthy adults under fed conditions. The study used a comparative randomized, single-dose, 2-way crossover open-label study design. Thirty-three participants were recruited and completed the clinical assessment. The pharmacokinetic parameters maximum plasma concentration (C max ), area under the plasma concentration-time curve (AUC 0-t ), AUC extrapolated to infinity (AUC 0-∞ ), time to maximum concentration, and elimination half-life were estimated to prove bioequivalence. The confidence intervals for the log-transformed test/reference ratios for alfuzosin 110.7% (98.0-124.9) and 112.0% (101.9-123.1) for C max and AUC 0-t respectively, which are within the allowed limits specified by the regulatory authorities (80-125% for C max and AUC 0-t ). The test formulation can therefore be prescribed as an alternative to the reference for symptomatic treatment of benign prostatic hyperplasia.",2020,Bioequivalence studies are demanded by regulatory authorities to evaluate the expected in vivo biological similarity of 2 formulations of a medication.,"['Thirty-three participants were recruited and completed the clinical assessment', 'healthy adults under fed conditions']","['Alfuzosin Extended-Release Tablets', '10-mg alfuzosin', 'Alfuzosin', 'alfuzosin']","['pharmacokinetic parameters maximum plasma concentration (C max ), area under the plasma concentration-time curve (AUC 0-t ), AUC extrapolated to infinity (AUC 0-∞ ), time to maximum concentration, and elimination half-life']","[{'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0051150', 'cui_str': 'alfuzosin'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}]",33.0,0.0447721,Bioequivalence studies are demanded by regulatory authorities to evaluate the expected in vivo biological similarity of 2 formulations of a medication.,"[{'ForeName': 'Abdel Qader', 'Initials': 'AQ', 'LastName': 'Al Bawab', 'Affiliation': 'Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.'}, {'ForeName': 'Bashar A', 'Initials': 'BA', 'LastName': 'Alkhalidi', 'Affiliation': 'School of Pharmacy, The University of Jordan, Amman, Jordan.'}, {'ForeName': ""Esra'a"", 'Initials': 'E', 'LastName': 'Albarahmieh', 'Affiliation': 'School of Applied Medical Sciences, German Jordanian University, Amman, Jordan.'}, {'ForeName': 'Sami M A', 'Initials': 'SMA', 'LastName': 'Qassim', 'Affiliation': 'Tabuk Pharmaceuticals, Tabuk, Kingdom of Saudi Arabia.'}, {'ForeName': 'Mohammad A D', 'Initials': 'MAD', 'LastName': 'Al-Saifi', 'Affiliation': 'Tabuk Pharmaceuticals, Tabuk, Kingdom of Saudi Arabia.'}, {'ForeName': 'Bashar', 'Initials': 'B', 'LastName': 'Al-Saifi', 'Affiliation': 'Tabuk Pharmaceuticals, Tabuk, Kingdom of Saudi Arabia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Ling', 'Affiliation': 'University of Sunderland, Sunderland, UK.'}, {'ForeName': 'Walid', 'Initials': 'W', 'LastName': 'Al-Qerem', 'Affiliation': 'Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.860'] 501,32770686,A Randomized Controlled Trial of Novel Loop Drainage Technique Versus Standard Incision and Drainage in the Treatment of Skin Abscesses.,"OBJECTIVES The objective was to compare the failure rate of incision and drainage (I&D) with LOOP technique versus I&D with standard packing technique in adults and children presenting to the emergency department (ED) with subcutaneous abscess. METHODS This prospective, randomized controlled trial (NCT03398746) enrolled a convenience sample of patients presenting to two Level 1 trauma centers over 12 months with skin abscesses. Of 256 patients screened, 217 patients were enrolled, 109 randomized to I&D with packing (50%) and 108 (50%) to I&D with LOOP. The primary outcome was treatment failure defined by admission, IV antibiotics, or repeat drainage within 10-day follow-up. The secondary outcomes included ease of procedure, ease of care, pain, and satisfaction using a 10-point numeric rating scale. RESULTS There were no differences in patient characteristics between groups. Follow-up data were available in 196 (90%). Treatment failure occurred in 20% (range = 12%-28%) of packing patients and 13% (range = 6%-20%) of LOOP patients (p = 0.25). There were no significant differences in failure rates in adults (p = 0.82), but there was a significant difference in children (age ≤ 18 years) at 21% (range = 8%-34%) in the packing group and 0 (0%) in the LOOP group (p = 0.002). Operators reported no significant differences in ease of procedure between techniques (p = 0.221). There was significantly less pain at follow-up in the LOOP group versus packing (p = 0.004). The wound was much easier to care for over the first 36 hours in the LOOP group (p = 0.002). Patient satisfaction at 10 days postprocedure was significantly higher in the LOOP group (p = 0.005). CONCLUSIONS The LOOP and packing techniques had similar failure rates for treatment of subcutaneous abscesses in adults, but the LOOP technique had significantly fewer failures in children. Overall, pain and patient satisfaction were significantly better in patients treated using the LOOP technique.",2020,There was significantly less pain at follow-up in the LOOP group versus packing (p=0.004).,"['adults and children presenting to the ED with subcutaneous abscess', 'Skin Abscesses', '256 patients screened, 217 patients were enrolled, 109 randomized to I&D with packing (50%) and 108 (50%) to I&D with', 'patients presenting to two Level 1 trauma centers over 12-months with skin abscesses']","['LOOP', 'Novel Loop Drainage Technique versus Standard Incision and Drainage', 'incision and drainage (I&D) with LOOP technique versus I&D with standard packing technique']","['Patient satisfaction', 'Overall, pain and patient satisfaction', 'Treatment failure', 'treatment failure defined by admission, IV antibiotics, or repeat drainage within 10-day follow-up', 'ease of procedure, ease of care, pain and satisfaction using a 10-point numeric rating scale', 'pain', 'failure rates']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0149777', 'cui_str': 'Abscess of skin and/or subcutaneous tissue'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517646', 'cui_str': '217'}, {'cui': 'C0152277', 'cui_str': 'Incision AND drainage'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0456947', 'cui_str': 'Level 1'}, {'cui': 'C0040786', 'cui_str': 'Trauma center'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0152277', 'cui_str': 'Incision AND drainage'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]",217.0,0.152555,There was significantly less pain at follow-up in the LOOP group versus packing (p=0.004).,"[{'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Ladde', 'Affiliation': 'From the, Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, FL, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Baker', 'Affiliation': 'From the, Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, FL, USA.'}, {'ForeName': 'Natali', 'Initials': 'N', 'LastName': 'Lilburn', 'Affiliation': 'the, Pasco County Emergency Physicians, Morton Plant North Bay Hospital, New Port Richey, FL, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Wan', 'Affiliation': 'and the, Department of Emergency Medicine, Dekalb Medical Center, Atlanta, GA, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Papa', 'Affiliation': 'From the, Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, FL, USA.'}]",Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,['10.1111/acem.14106'] 502,32777710,Community-level interventions for pre-eclampsia (CLIP) in Pakistan: A cluster randomised controlled trial.,"OBJECTIVES To reduce all-cause maternal and perinatal mortality and major morbidity through Lady Health Worker (LHW)-facilitated community engagement and early diagnosis, stabilization and referral of women with preeclampsia, an important contributor to adverse maternal and perinatal outcomes given delays in early detection and initial management. STUDY DESIGN In the Pakistan Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomized controlled trial (NCT01911494), LHWs engaged the community, recruited pregnant women from 20 union councils (clusters), undertook mobile health-guided clinical assessment for preeclampsia, and referral to facilities after stabilization. MAIN OUTCOME MEASURES The primary outcome was a composite of maternal, fetal and newborn mortality and major morbidity. FINDINGS We recruited 39,446 women in intervention (N = 20,264) and control clusters (N = 19,182) with minimal loss to follow-up (3∙7% vs. 4∙5%, respectively). The primary outcome did not differ between intervention (26·6%) and control (21·9%) clusters (adjusted odds ratio, aOR, 1∙20 [95% confidence interval 0∙84-1∙72]; p = 0∙31). There was reduction in stillbirths (0·89 [0·81-0·99]; p = 0·03), but no impact on maternal death (1·08 [0·69, 1·71]; p = 0·74) or morbidity (1·12 [0·57, 2·16]; p = 0·77); early (0·95 [0·82-1·09]; p = 0·46) or late neonatal deaths (1·23 [0·97-1·55]; p = 0·09); or neonatal morbidity (1·22 [0·77, 1·96]; p = 0·40). Improvements in outcome rates were observed with 4-7 (p = 0·015) and ≥8 (p < 0·001) (vs. 0) CLIP contacts. INTERPRETATION The CLIP intervention was well accepted by the community and implemented by LHWs. Lack of effects on adverse outcomes could relate to quality care for mothers with pre-eclampsia in health facilities. Future strategies for community outreach must also be accompanied by health facility strengthening. FUNDING The University of British Columbia (PRE-EMPT), a grantee of the Bill & Melinda Gates Foundation (OPP1017337).",2020,"There was reduction in stillbirths (0·89 [0·81-0·99]; p = 0·03), but no impact on maternal death (1·08 [0·69, 1·71]; p = 0·74) or morbidity (1·12 [0·57, 2·16]; p = 0·77);","['39,446 women in intervention (N\xa0=\xa020,264) and control clusters (N\xa0=\xa019,182) with minimal loss to follow-up (3∙7% vs. 4∙5%, respectively', 'mothers with pre-eclampsia in health facilities', 'recruited pregnant women from 20 union councils (clusters), undertook mobile health-guided clinical assessment for preeclampsia, and referral to facilities after stabilization', 'pre-eclampsia (CLIP) in Pakistan', 'women with preeclampsia']","['Community-level interventions', 'CLIP intervention']","['late neonatal deaths', 'neonatal morbidity', 'outcome rates', 'maternal death', 'reduction in stillbirths', 'composite of maternal, fetal and newborn mortality and major morbidity']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}]","[{'cui': 'C0455987', 'cui_str': 'Late neonatal death'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0024923', 'cui_str': 'Maternal death'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",39446.0,0.261501,"There was reduction in stillbirths (0·89 [0·81-0·99]; p = 0·03), but no impact on maternal death (1·08 [0·69, 1·71]; p = 0·74) or morbidity (1·12 [0·57, 2·16]; p = 0·77);","[{'ForeName': 'Rahat N', 'Initials': 'RN', 'LastName': 'Qureshi', 'Affiliation': 'Centre of Excellence, Division of Woman and Child Health, Aga Khan University, Stadium Road, P. O. Box 3500, Karachi 74800, Pakistan.'}, {'ForeName': 'Sana', 'Initials': 'S', 'LastName': 'Sheikh', 'Affiliation': 'Centre of Excellence, Division of Woman and Child Health, Aga Khan University, Stadium Road, P. O. Box 3500, Karachi 74800, Pakistan.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Hoodbhoy', 'Affiliation': 'Centre of Excellence, Division of Woman and Child Health, Aga Khan University, Stadium Road, P. O. Box 3500, Karachi 74800, Pakistan.'}, {'ForeName': 'Sumedha', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Vidler', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada; Centre for International Child Health, University of British Columbia, 305-4088 Cambie Street, Vancouver, BC V5Z 2X8, Canada.'}, {'ForeName': 'Beth A', 'Initials': 'BA', 'LastName': 'Payne', 'Affiliation': 'Centre for International Child Health, University of British Columbia, 305-4088 Cambie Street, Vancouver, BC V5Z 2X8, Canada.'}, {'ForeName': 'Imran', 'Initials': 'I', 'LastName': 'Ahmed', 'Affiliation': 'Centre of Excellence, Division of Woman and Child Health, Aga Khan University, Stadium Road, P. O. Box 3500, Karachi 74800, Pakistan.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mark Ansermino', 'Affiliation': 'Centre for International Child Health, University of British Columbia, 305-4088 Cambie Street, Vancouver, BC V5Z 2X8, Canada.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Bone', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Dustin T', 'Initials': 'DT', 'LastName': 'Dunsmuir', 'Affiliation': 'Centre for International Child Health, University of British Columbia, 305-4088 Cambie Street, Vancouver, BC V5Z 2X8, Canada.'}, {'ForeName': 'Tang', 'Initials': 'T', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Hannah L', 'Initials': 'HL', 'LastName': 'Nathan', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King's College London, 1 Lambeth Palace Road, London SE1 7EH, UK.""}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Shennan', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King's College London, 1 Lambeth Palace Road, London SE1 7EH, UK.""}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Singer', 'Affiliation': ""Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, University of British Columbia, 588 - 1081 Burrard Street, St. Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.""}, {'ForeName': 'Domena K', 'Initials': 'DK', 'LastName': 'Tu', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Wong', 'Affiliation': ""Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, University of British Columbia, 588 - 1081 Burrard Street, St. Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.""}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Magee', 'Affiliation': ""Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada; Department of Women and Children's Health, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King's College London, 1 Lambeth Palace Road, London SE1 7EH, UK.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'von Dadelszen', 'Affiliation': ""Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada; Department of Women and Children's Health, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King's College London, 1 Lambeth Palace Road, London SE1 7EH, UK.""}, {'ForeName': 'Zulfiqar A', 'Initials': 'ZA', 'LastName': 'Bhutta', 'Affiliation': 'Centre of Excellence, Division of Woman and Child Health, Aga Khan University, Stadium Road, P. O. Box 3500, Karachi 74800, Pakistan; Centre for Global Child Health, Hospital for Sick Children, 525 University Avenue, Suite 702, Toronto, ON M5G 2L3, Canada. Electronic address: zulfiqar.bhutta@aku.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'the CLIP Pakistan Trial Working Group (Table S1).'}]",Pregnancy hypertension,['10.1016/j.preghy.2020.07.011'] 503,32781178,"A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis.",,2021,,[],['placebo'],[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.553573,,"[{'ForeName': 'Yoo Jung', 'Initials': 'YJ', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Redwood City, California.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Schiopu', 'Affiliation': 'Department of Rheumatology, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Katalin', 'Initials': 'K', 'LastName': 'Dankó', 'Affiliation': 'Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary.'}, {'ForeName': 'Tahseen', 'Initials': 'T', 'LastName': 'Mozaffar', 'Affiliation': 'Department of Neurology, University of California Irvine, Irvine, California.'}, {'ForeName': 'Srinivas', 'Initials': 'S', 'LastName': 'Chunduru', 'Affiliation': 'Idera Pharmaceuticals, Inc, Exton, Pennsylvania.'}, {'ForeName': 'Kirstin', 'Initials': 'K', 'LastName': 'Lees', 'Affiliation': 'Idera Pharmaceuticals, Inc, Exton, Pennsylvania.'}, {'ForeName': 'Namita A', 'Initials': 'NA', 'LastName': 'Goyal', 'Affiliation': 'Department of Neurology, University of California Irvine, Irvine, California.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Sarazin', 'Affiliation': 'Department of Rheumatology, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'David F', 'Initials': 'DF', 'LastName': 'Fiorentino', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: fiorentino@stanford.edu.'}, {'ForeName': 'Kavita Y', 'Initials': 'KY', 'LastName': 'Sarin', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: ksarin@stanford.edu.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.07.122'] 504,32789503,Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.,"BACKGROUND Hippocampal avoidance whole-brain radiotherapy (HA-WBRT) shows potential for neurocognitive preservation. This study aimed to evaluate whether HA-WBRT or conformal WBRT (C-WBRT) is better for preserving neurocognitive function. METHODS This single-blinded randomized phase II trial enrolled patients with brain metastases and randomly assigned them to receive HA-WBRT or C-WBRT. Primary endpoint is decline of the Hopkins Verbal Learning Test-Revised (HVLT-R) delayed recall at 4 months after treatment. Neurocognitive function tests were analyzed with a mixed effect model. Brain progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. RESULTS From March 2015 to December 2018, seventy patients were randomized to yield a total cohort of 65 evaluable patients (33 in the HA-WBRT arm and 32 in the C-WBRT arm) with a median follow-up of 12.4 months. No differences in baseline neurocognitive function existed between the 2 arms. The mean change of HVLT-R delayed recall at 4 months was -8.8% in the HA-WBRT arm and +3.8% in the C-WBRT arm (P = 0.31). At 6 months, patients receiving HA-WBRT showed favorable perpetuation of HVLT-R total recall (mean difference = 2.60, P = 0.079) and significantly better preservation of the HVLT-R recognition-discrimination index (mean difference = 1.78, P = 0.019) and memory score (mean difference = 4.38, P = 0.020) compared with patients undergoing C-WBRT. There were no differences in Trail Making Test Part A or Part B or the Controlled Oral Word Association test between the 2 arms at any time point. There were no differences in brain PFS or OS between arms as well. CONCLUSION Patients receiving HA-WBRT without memantine showed better preservation in memory at 6-month follow-up, but not in verbal fluency or executive function.",2021,"There were no differences in TMT part A, part B, or the COWA test between the two arms at any time point.","['enrolled patients with brain metastases', 'From March 2015 to December 2018, seventy patients were randomized to yield a total cohort of 65 evaluable patients (33 in the HA-WBRT arm and 32 in the C-WBRT arm) with a median follow-up of 12.4 months', 'Brain Metastases']","['HA-WBRT or C-WBRT', 'Hippocampal avoidance whole-brain radiotherapy (HA-WBRT', 'memantine', 'Hippocampal Avoidance Whole-brain Radiotherapy without Memantine', 'HA-WBRT or conformal WBRT (C-WBRT']","['Brain progression free survival (BPFS) and overall survival (OS', 'Neurocognitive function tests', 'memory score', 'HVLT-R recognition-discrimination index', 'verbal fluency or executive function', 'decline of Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall', 'favorable perpetuation of HVLT-R total recall', 'TMT part A, part B, or the COWA test', 'BPFS or OS', 'baseline neurocognitive function', 'mean change of HVLT-R delayed recall']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C1520143', 'cui_str': 'Whole brain radiation therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0026377', 'cui_str': 'Molecular conformation'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4517543', 'cui_str': '12.4'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C1520143', 'cui_str': 'Whole brain radiation therapy'}, {'cui': 'C0026377', 'cui_str': 'Molecular conformation'}, {'cui': 'C0025242', 'cui_str': 'Memantine'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042531', 'cui_str': 'Verbal learning'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040604', 'cui_str': 'Trail making test'}, {'cui': 'C3827022', 'cui_str': 'Controlled Oral Word Association Test'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",70.0,0.171341,"There were no differences in TMT part A, part B, or the COWA test between the two arms at any time point.","[{'ForeName': 'Wen-Chi', 'Initials': 'WC', 'LastName': 'Yang', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Ya-Fang', 'Initials': 'YF', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Chi-Cheng', 'Initials': 'CC', 'LastName': 'Yang', 'Affiliation': 'Department of Psychology, National Chengchi University, Taipei, Taiwan.'}, {'ForeName': 'Pei-Fang', 'Initials': 'PF', 'LastName': 'Wu', 'Affiliation': 'Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Hsing-Min', 'Initials': 'HM', 'LastName': 'Chan', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Jenny Ling-Yu', 'Initials': 'JL', 'LastName': 'Chen', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Guann-Yiing', 'Initials': 'GY', 'LastName': 'Chen', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Jason Chia-Hsien', 'Initials': 'JC', 'LastName': 'Cheng', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Sung-Hsin', 'Initials': 'SH', 'LastName': 'Kuo', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Feng-Ming', 'Initials': 'FM', 'LastName': 'Hsu', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}]",Neuro-oncology,['10.1093/neuonc/noaa193'] 505,32805013,Efficacy of Yoga vs Cognitive Behavioral Therapy vs Stress Education for the Treatment of Generalized Anxiety Disorder: A Randomized Clinical Trial.,"Importance Generalized anxiety disorder (GAD) is common, impairing, and undertreated. Although many patients with GAD seek complementary and alternative interventions, including yoga, data supporting yoga's efficacy or how it compares to first-line treatments are lacking. Objectives To assess whether yoga (Kundalini yoga) and cognitive behavioral therapy (CBT) for GAD are each more effective than a control condition (stress education) and whether yoga is noninferior to CBT for the treatment of GAD. Design, Setting, and Participants For this randomized, 3-arm, controlled, single-blind (masked independent raters) clinical trial, participants were recruited from 2 specialty academic centers starting December 1, 2013, with assessment ending October 25, 2019. Primary analyses, completed by February 12, 2020, included superiority testing of Kundalini yoga and CBT vs stress education and noninferiority testing of Kundalini yoga vs CBT. Interventions Participants were randomized to Kundalini yoga (n = 93), CBT for GAD (n = 90), or stress education (n = 43), which were each delivered to groups of 4 to 6 participants by 2 instructors during twelve 120-minute sessions with 20 minutes of daily homework. Main Outcomes and Measures The primary intention-to-treat outcome was acute GAD response (Clinical Global Impression-Improvement Scale score of much or very much improved) after 12 weeks as assessed by trained independent raters. Results Of 538 participants who provided consent and were evaluated, 226 (mean [SD] age, 33.4 [13.5] years; 158 [69.9%] female) with a primary diagnosis of GAD were included in the trial. A total of 155 participants (68.6%) completed the posttreatment assessment. Completion rates did not differ (Kundalini yoga, 60 [64.5%]; CBT, 67 [74.4%]; and stress education, 28 [65.1%]: χ2 = 2.39, df = 2, P = .30). Response rates were higher in the Kundalini yoga group (54.2%) than in the stress education group (33.%) (odds ratio [OR], 2.46 [95% CI, 1.12-5.42]; P = .03; number needed to treat, 4.59 [95% CI, 2.52-46.19]) and in the CBT group (70.8%) compared with the stress education group (33.0%) (OR, 5.00 [95% CI, 2.12-11.82]; P < .001; number needed to treat, 2.62 [95% CI, 1.91-5.68]). However, the noninferiority test did not find Kundalini yoga to be as effective as CBT (difference, 16.6%; P = .42 for noninferiority). Conclusions and Relevance In this trial, Kundalini yoga was efficacious for GAD, but the results support CBT remaining first-line treatment. Trial Registration ClinicalTrials.gov Identifier: NCT01912287.",2021,"Response rates were higher in the Kundalini yoga group (54.2%) than in the stress education group (33.%) (odds ratio [OR], 2.46 [95% CI, 1.12-5.42]; P = .03; number needed to treat, 4.59 [95% CI, 2.52-46.19]) and in the CBT group (70.8%) compared with the stress education group (33.0%) (","['participants were recruited from 2 specialty academic centers starting December 1, 2013, with assessment ending October 25, 2019', '538 participants who provided consent and were evaluated, 226 (mean [SD] age, 33.4 [13.5] years; 158 [69.9%] female) with a primary diagnosis of GAD were included in the trial', 'A total of 155 participants (68.6%) completed the posttreatment assessment', 'Generalized Anxiety Disorder']","['Kundalini yoga and CBT', 'Yoga vs Cognitive Behavioral Therapy vs Stress Education', 'CBT for GAD (n\u2009=\u200990), or stress education', 'Kundalini yoga', 'yoga (Kundalini yoga) and cognitive behavioral therapy (CBT']","['acute GAD response (Clinical Global Impression-Improvement Scale score of much or very much improved', 'Response rates', 'Completion rates']","[{'cui': 'C0037778', 'cui_str': 'Medical specialty'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517559', 'cui_str': '13.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332137', 'cui_str': 'Principal diagnosis'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517855', 'cui_str': '68.6'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0442824', 'cui_str': 'Very'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",155.0,0.0966532,"Response rates were higher in the Kundalini yoga group (54.2%) than in the stress education group (33.%) (odds ratio [OR], 2.46 [95% CI, 1.12-5.42]; P = .03; number needed to treat, 4.59 [95% CI, 2.52-46.19]) and in the CBT group (70.8%) compared with the stress education group (33.0%) (","[{'ForeName': 'Naomi M', 'Initials': 'NM', 'LastName': 'Simon', 'Affiliation': 'Department of Psychiatry, New York University Grossman School of Medicine, New York, New York.'}, {'ForeName': 'Stefan G', 'Initials': 'SG', 'LastName': 'Hofmann', 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rosenfield', 'Affiliation': 'Department of Psychology, Southern Methodist University, Dallas, Texas.'}, {'ForeName': 'Susanne S', 'Initials': 'SS', 'LastName': 'Hoeppner', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Hoge', 'Affiliation': 'Department of Psychiatry, Georgetown University Medical Center, Washington, DC.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Bui', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.'}, {'ForeName': 'Sat Bir S', 'Initials': 'SBS', 'LastName': 'Khalsa', 'Affiliation': ""Departments of Medicine and Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}]",JAMA psychiatry,['10.1001/jamapsychiatry.2020.2496'] 506,32820647,"Recruitment, retention, and adherence in a clinical trial: The Pediatric Heart Network's Marfan Trial experience.","BACKGROUND/AIMS The Pediatric Heart Network Marfan Trial was a randomized trial comparing atenolol versus losartan on aortic root dilation in 608 children and young adults with Marfan syndrome. Barriers to enrollment included a limited pool of eligible participants, restrictive entry criteria, and a diverse age range that required pediatric and adult expertise. Retention was complicated by a 3-year commitment to a complex study and medication regimen. The Network partnered with the Marfan Foundation, bridging the community with the research. The aims of this study are to report protocol and medication adherence and associated predictive factors, and to describe recruitment and retention strategies. METHODS Recruitment, retention, and adherence to protocol activities related to the primary outcome were measured. Retention was measured by percentage of enrolled participants with 3-year outcome data. Protocol adherence was calculated by completion rates of study visits, ambulatory electrocardiography (Holter monitoring), and quarterly calls. Medication adherence was assessed by the number of tablets or the amount of liquid in bottles returned. Centers were ranked according to adherence (high, medium, and low tertiles). Recruitment, retention, and adherence questionnaires were completed by sites. Descriptive statistics summarized recruitment, retention, and adherence, as well as questionnaire results. Regression modeling assessed predictors of adherence. RESULTS Completion rates for visits, Holter monitors, and quarterly calls were 99%, 94%, and 96%, respectively. Primary outcome data at 3 years were obtained for 88% of participants. The mean percentage of medication taken was estimated at 89%. Site and age were associated with all measures of adherence. Young adult and African American participants had lower levels of adherence. Higher adherence sites employed more strategies; had more staffing resources, less key staff turnover, and more collaboration with referring providers; utilized the Foundation's resources; and used a greater number of strategies to recruit, retain, and promote protocol and medication adherence. CONCLUSION Overall adherence was excellent for this trial conducted within a National Institutes of Health-funded clinical trial network. Strategies specifically targeted to young adults and African Americans may have been beneficial. Many strategies employed by higher adherence sites are ones that any site could easily use, such as greeting families at non-study hospital visits, asking for family feedback, providing calendars for tracking schedules, and recommending apps for medication reminders. Additional key learnings include adherence differences by age, race, and site, the value of collaborative learning, and the importance of partnerships with patient advocacy groups. These lessons could shape recruitment, retention, and adherence to improve the quality of future complex trials involving rare conditions.",2020,"Higher adherence sites employed more strategies; had more staffing resources, less key staff turnover, and more collaboration with referring providers; utilized the Foundation's resources; and used a greater number of strategies to recruit, retain, and promote protocol and medication adherence. ","['young adults and African Americans', 'Young adult and African American participants', 'eligible participants, restrictive entry criteria, and a diverse age range that required pediatric and adult expertise', '608 children and young adults with Marfan syndrome']","['losartan', 'atenolol']","['Medication adherence', 'Recruitment, retention, and adherence questionnaires', 'Retention', 'mean percentage of medication taken', 'Completion rates for visits, Holter monitors, and quarterly calls', 'completion rates of study visits, ambulatory electrocardiography (Holter monitoring), and quarterly calls', 'Recruitment, retention, and adherence', 'Protocol adherence', 'Overall adherence', 'lower levels of adherence']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0024796', 'cui_str': ""Marfan's syndrome""}]","[{'cui': 'C0126174', 'cui_str': 'Losartan'}, {'cui': 'C0004147', 'cui_str': 'Atenolol'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1290952', 'cui_str': 'Taking medication'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0013801', 'cui_str': 'Electrocardiography, Holter'}, {'cui': 'C0332179', 'cui_str': 'Trimonthly'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013799', 'cui_str': 'Ambulatory ECG'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",608.0,0.169075,"Higher adherence sites employed more strategies; had more staffing resources, less key staff turnover, and more collaboration with referring providers; utilized the Foundation's resources; and used a greater number of strategies to recruit, retain, and promote protocol and medication adherence. ","[{'ForeName': 'Michelle S', 'Initials': 'MS', 'LastName': 'Hamstra', 'Affiliation': ""Heart Institute Administration, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Victoria L', 'Initials': 'VL', 'LastName': 'Pemberton', 'Affiliation': 'National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Dagincourt', 'Affiliation': 'New England Research Institutes, Inc., Watertown, MA, USA.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Hollenbeck-Pringle', 'Affiliation': 'New England Research Institutes, Inc., Watertown, MA, USA.'}, {'ForeName': 'Felicia L', 'Initials': 'FL', 'LastName': 'Trachtenberg', 'Affiliation': 'New England Research Institutes, Inc., Watertown, MA, USA.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Cnota', 'Affiliation': ""Heart Institute Administration, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Atz', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Cappella', 'Affiliation': ""Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA.""}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'De Nobele', 'Affiliation': 'Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Grima', 'Affiliation': 'The Marfan Foundation, Port Washington, NY, USA.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'King', 'Affiliation': ""Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': 'Rosalind', 'Initials': 'R', 'LastName': 'Korsin', 'Affiliation': ""Children's Hospital of New York, New York, NY, USA.""}, {'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Lambert', 'Affiliation': ""Primary Children's Hospital, University of Utah, Salt Lake City, UT, USA.""}, {'ForeName': 'Meghan K', 'Initials': 'MK', 'LastName': 'MacNeal', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Larry W', 'Initials': 'LW', 'LastName': 'Markham', 'Affiliation': ""The Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA.""}, {'ForeName': 'Gretchen', 'Initials': 'G', 'LastName': 'MacCarrick', 'Affiliation': 'Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Donna M', 'Initials': 'DM', 'LastName': 'Sylvester', 'Affiliation': ""Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Walter', 'Affiliation': 'Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Mingfen', 'Initials': 'M', 'LastName': 'Xu', 'Affiliation': 'Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Ronald V', 'Initials': 'RV', 'LastName': 'Lacro', 'Affiliation': ""Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Clinical trials (London, England)",['10.1177/1740774520945988'] 507,32823324,[Abdominoplasty without closed-suction drains: a randomised controlled trial].,"INTRODUCTION There is insufficient scientific evidence from randomised controlled trials to support the routine use of closed-suction drains in body contouring procedures. The aim of this study was to evaluate cumulative seroma volume, length of hospital stay and complication rates in abdominoplasty patients without drains in direct comparison with a cohort receiving drains. MATERIAL AND METHODS Abdominoplasty patients were prospectively randomised in two study groups with (MD) and without (OD) placement of closed-suction drains. Patients with a BMI ≤ 30 kg/m 2 undergoing horizontal or combined horizontal/vertical incision abdominoplasty were included. Scarpa's fascia was preserved during dissection. Exclusion criteria comprised simultaneous liposuction, coagulation disorders and ASA score ≥ 3. Cumulative seroma volume over a four-week follow-up period was assessed as the primary outcome measure. Secondary outcome measures were complications requiring surgical revision and length of hospital stay. RESULTS This trial did not identify a statistically significant difference in cumulative seroma volume between the MD (30/53) and OD (23/53) cohorts in 53 patients (M MD 493 ± SD 407 ml; M OD 459 ± SD 624 ml; p = 0.812). However, a significantly shorter average length of hospital stay was observed in the OD population (M MD 5.1 ± SD 1.4 d; M OD 4.2 ± SD 1.5 d; p = 0.023). Complication rates were equal in both study groups (n MD  = 1; n OD  = 1). CONCLUSION The results of this trial do not justify routine placement of closed-suction drains in abdominoplasty procedures (horizontal or combined horizontal/vertical incision) in the pre-obese patient cohort (BMI ≤ 30 kg/m 2 ). Drain placement should be evaluated on an individual patient-specific basis.",2021,This trial did not identify a statistically significant difference in cumulative seroma volume between the MD (30/53) and OD (23/53) cohorts in 53 patients (M MD 493 ± SD 407 ml; M OD 459 ± SD 624 ml; p = 0.812).,"['Abdominoplasty patients', 'abdominoplasty patients without drains in direct comparison with a cohort receiving drains', 'Patients with a BMI\u2009≤\u200930\u2009kg']","['MD) and without (OD) placement of closed-suction drains', 'Drain placement', 'm 2 undergoing horizontal or combined horizontal/vertical incision abdominoplasty', 'Abdominoplasty without closed-suction drains', 'abdominoplasty procedures (horizontal or combined horizontal/vertical incision', 'closed-suction drains']","['complications requiring surgical revision and length of hospital stay', 'cumulative seroma volume', 'Cumulative seroma volume', 'cumulative seroma volume, length of hospital stay and complication rates', 'Complication rates', 'average length of hospital stay']","[{'cui': 'C0198542', 'cui_str': 'Repair of abdominal wall'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0441139', 'cui_str': 'Suction drain'}, {'cui': 'C3495845', 'cui_str': 'Drain placement'}, {'cui': 'C0205126', 'cui_str': 'Horizontal'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0198542', 'cui_str': 'Repair of abdominal wall'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",,0.216615,This trial did not identify a statistically significant difference in cumulative seroma volume between the MD (30/53) and OD (23/53) cohorts in 53 patients (M MD 493 ± SD 407 ml; M OD 459 ± SD 624 ml; p = 0.812).,"[{'ForeName': 'Alexandra M', 'Initials': 'AM', 'LastName': 'Anker', 'Affiliation': 'Universitätsklinikum Regensburg Zentrum für Plastische, Hand- und Wiederherstellungschirurgie.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Prantl', 'Affiliation': 'Universitätsklinikum Regensburg Zentrum für Plastische, Hand- und Wiederherstellungschirurgie.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Baringer', 'Affiliation': 'Universitätsklinikum Regensburg Zentrum für Plastische, Hand- und Wiederherstellungschirurgie.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ruewe', 'Affiliation': 'Universitätsklinikum Regensburg Zentrum für Plastische, Hand- und Wiederherstellungschirurgie.'}, {'ForeName': 'Silvan M', 'Initials': 'SM', 'LastName': 'Klein', 'Affiliation': 'Universitätsklinikum Regensburg Zentrum für Plastische, Hand- und Wiederherstellungschirurgie.'}]","Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V...",['10.1055/a-1170-5345'] 508,32757824,Preventing Type 2 Diabetes Among Midlife Women: A Feasibility Study Comparing a Combined Sleep and Lifestyle Intervention With a Standard Lifestyle Intervention.,"PURPOSE The purpose of this pilot study was to evaluate the feasibility, acceptability, and initial efficacy of adding a sleep extension intervention to a well-established diabetes prevention intervention among midlife women with short sleep duration at risk for type 2 diabetes. METHODS For this 2-group comparative design, 26 women with prediabetes or metabolic syndrome and sleep duration <7 hours were recruited from the community to participate in an 8-session diet and physical activity lifestyle intervention alone (L-alone) or L-alone plus a behavioral sleep intervention (L+Sleep). Body mass index (BMI), waist circumference, and other outcomes were compared at baseline and 3 and 6 months using analysis of covariance. RESULTS Incorporating a sleep intervention into lifestyle changes proved feasible and acceptable to midlife women at risk for type 2 diabetes. Significant decreases in BMI and waist circumference over time were observed in both groups, but comparative efficacy of L+Sleep versus L-alone yielded few group differences. Exploratory analysis indicated that women who increased their sleep to ≥7 h/night, regardless of group assignment, lost more weight than women who continued to report sleeping <7 h/night. CONCLUSION Adding sleep extension to a lifestyle change intervention proved feasible and satisfactory to participants, but initial efficacy did not differentiate the 2 intervention groups.",2020,"Adding sleep extension to a lifestyle change intervention proved feasible and satisfactory to participants, but initial efficacy did not differentiate the 2 intervention groups.","['midlife women at risk for type 2 diabetes', 'midlife women with short sleep duration at risk for type 2 diabetes', 'Midlife Women', '26 women with prediabetes or metabolic syndrome and sleep duration <7 hours were recruited from the community to participate in an']","['8-session diet and physical activity lifestyle intervention alone (L-alone) or L-alone plus a behavioral sleep intervention (L+Sleep', 'lifestyle change intervention', 'sleep intervention', 'Combined Sleep and Lifestyle Intervention', 'sleep extension intervention to a well-established diabetes prevention intervention', 'L+Sleep']","['feasibility, acceptability, and initial efficacy', 'BMI and waist circumference', 'Body mass index (BMI), waist circumference, and other outcomes']","[{'cui': 'C0026062', 'cui_str': 'Middle-age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",26.0,0.0198206,"Adding sleep extension to a lifestyle change intervention proved feasible and satisfactory to participants, but initial efficacy did not differentiate the 2 intervention groups.","[{'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Chesla', 'Affiliation': 'Department of Family Health Care Nursing, University of California, San Francisco, California.'}, {'ForeName': 'Caryl', 'Initials': 'C', 'LastName': 'Gay', 'Affiliation': 'Department of Family Health Care Nursing, University of California, San Francisco, California.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Bauer', 'Affiliation': 'Department of Social and Behavioral Sciences, University of California, San Francisco, California.'}, {'ForeName': 'Melinda Sarmiento', 'Initials': 'MS', 'LastName': 'Bender', 'Affiliation': 'Department of Family Health Care Nursing, University of California, San Francisco, California.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Department of Family Health Care Nursing, University of California, San Francisco, California.'}]",The Diabetes educator,['10.1177/0145721720943128'] 509,32791499,Use of a Supportive Kidney Care Video Decision Aid in Older Patients: A Randomized Controlled Trial.,"BACKGROUND There are few studies of patient-facing decision aids that include supportive kidney care as an option. We tested the efficacy of a video decision aid on knowledge of supportive kidney care among older patients with advanced CKD. METHODS Participants (age ≥ 65 years with advanced CKD) were randomized to receive verbal or video education. Primary outcome was knowledge of supportive kidney care (score range 0-3). Secondary outcomes included preference for supportive kidney care, and satisfaction and acceptability of the video. RESULTS Among all participants (n = 100), knowledge of supportive kidney care increased significantly after receiving education (p < 0.01); however, there was no difference between study arms (p = 0.68). There was no difference in preference for supportive kidney care between study arms (p = 0.49). In adjusted analyses, total health literacy score (aOR 1.08 [95% CI: 1.003-1.165]) and nephrologists' answer of ""No"" to the Surprise Question (aOR 4.87 [95% CI: 1.22-19.43]) were associated with preference for supportive kidney care. Most felt comfortable watching the video (96%), felt the content was helpful (96%), and would recommend the video to others (96%). CONCLUSIONS Among older patients with advanced CKD, we did not detect a significant difference between an educational verbal script and a video decision aid in improving knowledge of supportive kidney care or preferences. However, patients who received video education reported high satisfaction and acceptability ratings. Future research will determine the effectiveness of a supportive kidney care video decision aid on real-world patient outcomes. TRIAL REGISTRATION NCT02698722 (ClinicalTrials.gov).",2020,"In adjusted analyses, total health literacy score (aOR 1.08 [95% CI: 1.003-1.165]) and nephrologists' answer of ""No"" to the Surprise Question (aOR 4.87 [95% CI: 1.22-19.43]) were associated with preference for supportive kidney care.","['Participants (age ≥ 65 years with advanced CKD', 'Older Patients', 'older patients with advanced CKD']","['verbal or video education', 'video decision aid', 'Supportive Kidney Care Video Decision Aid']","['knowledge of supportive kidney care', 'satisfaction and acceptability ratings', 'total health literacy score', 'preference for supportive kidney care', 'educational verbal script', 'knowledge of supportive kidney care (score range 0-3', 'preference for supportive kidney care, and satisfaction and acceptability of the video']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0042655', 'cui_str': 'Video'}]",100.0,0.12439,"In adjusted analyses, total health literacy score (aOR 1.08 [95% CI: 1.003-1.165]) and nephrologists' answer of ""No"" to the Surprise Question (aOR 4.87 [95% CI: 1.22-19.43]) were associated with preference for supportive kidney care.","[{'ForeName': 'Nwamaka D', 'Initials': 'ND', 'LastName': 'Eneanya', 'Affiliation': 'Renal-Electrolyte Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA, nwamaka.eneanya@pennmedicine.upenn.edu.'}, {'ForeName': 'Shananssa G', 'Initials': 'SG', 'LastName': 'Percy', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Taylor L', 'Initials': 'TL', 'LastName': 'Stallings', 'Affiliation': 'Palliative and Advanced Illness Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Palliative and Advanced Illness Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'David J R', 'Initials': 'DJR', 'LastName': 'Steele', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Germain', 'Affiliation': 'Division of Nephrology, Baystate Medical Center, University of Massachusetts Medical School - Baystate, Springfield, Massachusetts, USA.'}, {'ForeName': 'Jane O', 'Initials': 'JO', 'LastName': 'Schell', 'Affiliation': 'Division of Renal-Electrolyte, Department of General Medicine, Section of Palliative Care and Medical Ethics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Paasche-Orlow', 'Affiliation': 'Section of General Internal Medicine, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.'}, {'ForeName': 'Angelo E', 'Initials': 'AE', 'LastName': 'Volandes', 'Affiliation': 'Division of General Medicine, Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.'}]",American journal of nephrology,['10.1159/000509711'] 510,32800385,High protein versus medium protein delivery under equal total energy delivery in critical care: A randomized controlled trial.,"BACKGROUND Appropriate protein delivery amounts during the acute phase of critical care are unknown. Along with nutrition, early mobilization and the combination are important. We conducted a randomized controlled trial during critical care to assess high-protein and medium-protein delivery under equal total energy delivery with and without active early rehabilitation. METHODS ICU patients of August 2018-September 2019 were allocated to a high-protein group (target energy 20 kcal/kg/day, protein 1.8 g/kg/day) or a medium-protein group (target energy 20 kcal/kg/day, protein 0.9 g/kg/day) with the same nutrition protocol by day 10. By dividing the study period, standard rehabilitation was administered during the initial period. Rehabilitation with belt-type electrical muscle stimulation was given from day 2 in the latter as a historical comparison. Femoral muscle volume was evaluated on day 1 and day 10 using computed tomography. RESULTS This study analyzed 117 eligible patients with similar characteristics assigned to a high-protein or medium-protein group. Total energy delivery was around 20 kcal/kg/day in both groups, but protein delivery was 1.5 g/kg/day and 0.8 g/kg/day. As a primary outcome, femoral muscle volume loss was 12.9 ± 8.5% in the high-protein group and 16.9 ± 7.0% in the medium-protein group, with significant difference (p = 0.0059). Persistent inflammation, immunosuppression, and catabolism syndrome were significantly less frequent in the high-protein group. Muscle volume loss was significantly less in the high-protein group only during the electrical muscle stimulation period. CONCLUSIONS For critical care, high protein delivery provided better muscle volume maintenance, but only with active early rehabilitation. REGISTRATION University Hospital Medical Information Network, UMIN000033783 Registered on 16 Aug 2018. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038538.",2021,"Persistent inflammation, immunosuppression, and catabolism syndrome were significantly less frequent in the high-protein group.","['critical care', 'ICU patients of August 2018-September 2019', '117 eligible patients with similar characteristics assigned to a high-protein or medium-protein group']","['High protein versus medium protein delivery', 'Rehabilitation with belt-type electrical muscle stimulation', 'high-protein and medium-protein delivery under equal total energy delivery with and without active early rehabilitation', 'high-protein group (target energy 20\xa0kcal/kg/day, protein 1.8\xa0g/kg/day) or a medium-protein']","['Persistent inflammation, immunosuppression, and catabolism syndrome', 'Muscle volume loss', 'femoral muscle volume loss', 'Femoral muscle volume', 'Total energy delivery']","[{'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0452227', 'cui_str': 'Belt'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1690969', 'cui_str': 'Kcal/kg/day'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C1532536', 'cui_str': 'g/kg/day'}]","[{'cui': 'C1265824', 'cui_str': 'Persistent inflammation'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}, {'cui': 'C0543484', 'cui_str': 'catabolism'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]",117.0,0.0284124,"Persistent inflammation, immunosuppression, and catabolism syndrome were significantly less frequent in the high-protein group.","[{'ForeName': 'Kensuke', 'Initials': 'K', 'LastName': 'Nakamura', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1, Jonan-cho, Hitachi, Ibaraki, 317-0077, Japan. Electronic address: knakamura-tky@umin.ac.jp.'}, {'ForeName': 'Hidehiko', 'Initials': 'H', 'LastName': 'Nakano', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1, Jonan-cho, Hitachi, Ibaraki, 317-0077, Japan. Electronic address: be.rann1988jp@gmail.com.'}, {'ForeName': 'Hiromu', 'Initials': 'H', 'LastName': 'Naraba', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1, Jonan-cho, Hitachi, Ibaraki, 317-0077, Japan; TXP Medical Co. Ltd., 3-13 Nihonbashiyokoyamacho, Chuo-ku, Tokyo, 103-0003, Japan. Electronic address: nrbhrm@gmail.com.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Mochizuki', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1, Jonan-cho, Hitachi, Ibaraki, 317-0077, Japan. Electronic address: kurakan72@gmail.com.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Takahashi', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1, Jonan-cho, Hitachi, Ibaraki, 317-0077, Japan. Electronic address: yuji.mail@icloud.com.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Sonoo', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1, Jonan-cho, Hitachi, Ibaraki, 317-0077, Japan; TXP Medical Co. Ltd., 3-13 Nihonbashiyokoyamacho, Chuo-ku, Tokyo, 103-0003, Japan. Electronic address: sonopy77@gmail.com.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Hashimoto', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1, Jonan-cho, Hitachi, Ibaraki, 317-0077, Japan. Electronic address: hidehashimoto-tky@umin.ac.jp.'}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Morimura', 'Affiliation': 'Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo, Tokyo, 113-8655, Japan. Electronic address: molimula@r6.dion.ne.jp.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.07.036'] 511,32807403,Effect of crystalline phase assemblage on reliability of 3Y-TZP.,"STATEMENT OF PROBLEM Strengthening mechanisms of zirconia ceramics stabilized with 3 mol% yttria (3Y-TZP) are complex and dictated by the crystalline phase assemblage. Although their clinical performance for dental restorations has been excellent, there is evidence that framework fractures do occur and have been underreported. Meanwhile, the relationship between phase assemblage and reliability of 3Y-TZP is not properly understood. PURPOSE The purpose of this in vitro study was to elucidate the relationship between crystalline phase assemblage and the reliability of 3Y-TZP and to calculate the associated probabilities of survival. MATERIAL AND METHODS Disks of 3Y-TZP were prepared from cylindrical blanks and randomly assigned to 12 experimental groups (n=20 per group). Different crystalline phase assemblages were produced by either varying the sintering temperature from 1350 °C to 1600 °C and/or treating the surface by airborne-particle abrasion with 50-mm alumina particles at a pressure of 0.2 MPa for 1 minute with or without subsequent heat treatment. Crystalline phases were analyzed by standard and grazing incidence X-ray diffraction (GIXRD). The relationship between phase assemblage and reliability was determined by measuring the biaxial flexural strength (BFS) according to ISO standard 6872 and by using Weibull statistics to calculate the Weibull modulus (m), probability of survival, and maximum allowable stresses. XRD results were analyzed by ANOVA to detect statistically significant differences between groups. Adjustment for all pairwise group comparisons was made using the Tukey method (α=.05). RESULTS Standard incidence XRD confirmed the presence of a small amount of cubic phase after sintering at 1350 °C. A cubic-derived nontransformable tetragonal t'-phase was observed at sintering temperatures of 1450 °C and above, the amount of which increased linearly. GIXRD revealed that airborne-particle abraded groups sintered at 1350 °C and 1600 °C had the highest variability in monoclinic phase fraction as a function of depth. These groups were also associated with the lowest reliability. Groups as-sintered at 1350 °C and 1600 °C had the lowest modulus (m=8.1 [0.5] and 7.0 [0.8], respectively) and probability of survival (Ps) for a maximum allowable stress of 700 MPa, while treated groups sintered at 1450 °C and 1550 °C were associated with the highest modulus (from 15.0 [1.4] to 20.9 [1.4]) and Ps (≥0.9999). The lower strength and reliability of groups sintered at 1600 °C was consistent with the presence of a significant amount of nontransformable t'-phase. The pattern of BFS results indicated that ferro-elastic domain switching was a dominant strengthening mechanism in 3Y-TZP. CONCLUSIONS The present study first reported on the detrimental effect of the cubic-derived nontransformable t'-phase on the mechanical properties of 3Y-TZP. It was demonstrated that phase assemblage determined reliability and was directly linked to the probability of survival.",2021,"Groups as-sintered at 1350 °C and 1600 °C had the lowest modulus (m=8.1 [0.5] and 7.0 [0.8], respectively) and probability of survival (Ps) for a maximum allowable stress of 700 MPa, while treated groups sintered at 1450 °C and 1550",['Disks of 3Y-TZP were prepared from cylindrical blanks and randomly assigned to 12 experimental groups (n=20 per group'],[],"['probability of survival', 'probability of survival (Ps', 'biaxial flexural strength (BFS', 'GIXRD', 'lower strength and reliability']","[{'cui': 'C1705370', 'cui_str': 'Disc - unit of product usage'}, {'cui': 'C0205114', 'cui_str': 'Cylindrical'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],"[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C4704755', 'cui_str': 'Fracture Strength'}, {'cui': 'C1302752', 'cui_str': 'Abrasion'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0043301', 'cui_str': 'Xray Diffraction'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}]",,0.0269623,"Groups as-sintered at 1350 °C and 1600 °C had the lowest modulus (m=8.1 [0.5] and 7.0 [0.8], respectively) and probability of survival (Ps) for a maximum allowable stress of 700 MPa, while treated groups sintered at 1450 °C and 1550","[{'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Denry', 'Affiliation': 'Professor, Iowa Institute for Oral Health Research, University of Iowa College of Dentistry and Department of Prosthodontics, Iowa City, Iowa. Electronic address: Isabelle-Denry@uiowa.edu.'}, {'ForeName': 'Maged', 'Initials': 'M', 'LastName': 'Abdelaal', 'Affiliation': 'Clinical Assistant Professor, Division of Prosthodontics, Department of General Dentistry, East Carolina University School of Dental Medicine, Greenville, NC.'}, {'ForeName': 'Deborah V', 'Initials': 'DV', 'LastName': 'Dawson', 'Affiliation': 'Professor, Department of Biostatistics, University of Iowa College of Public Health, Iowa City, Iowa.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Holloway', 'Affiliation': 'Professor and Head, Department of Prosthodontics, University of Iowa College of Dentistry, Iowa City, Iowa.'}, {'ForeName': 'John Robert', 'Initials': 'JR', 'LastName': 'Kelly', 'Affiliation': 'Professor, Department of Reconstructive Sciences, University of Connecticut Health Center, Farmington, Conn.'}]",The Journal of prosthetic dentistry,['10.1016/j.prosdent.2020.05.023'] 512,32819209,Designing creative spaces: an experimental examination of the effect of a nature poster on divergent thinking.,"This paper reports the results of an independent samples experiment designed to examine the effects of the presence of a large poster depicting a natural woodland scene on individual performance on two Divergent Thinking tasks. In comparison to the no-poster control condition, the presentation of a large poster depicting a nature scene was found to lead to greater levels of creativity as rated by judges who were blind to the experimental design. The effects of the large poster on Divergent Thinking were found to hold when controlling for Openness-to-Experience and Mood. Exploratory analyses of participant ratings of room characteristics indicated that the mechanism underlying the posters' effect related to elevated stimulation. Practitioner summary: This study compared the effects of presenting a large poster depicting a natural woodland scene (experimental condition) versus no poster (control condition) on individual creative thinking. Three judges, who were unaware of the design of the study, did not know the participant responses were from two different conditions and who did not facilitate the experiment rated the responses of the participants who were exposed to the large poster as significantly more creative.",2021,The effects of the large poster on Divergent Thinking were found to hold when controlling for Openness-to-Experience and Mood.,[],['large poster depicting a natural woodland scene (experimental condition) versus no poster (control condition'],[],[],"[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0376675', 'cui_str': 'Posters'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0086312', 'cui_str': 'Forest'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],2.0,0.0183787,The effects of the large poster on Divergent Thinking were found to hold when controlling for Openness-to-Experience and Mood.,"[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Batey', 'Affiliation': 'People and Performance, Manchester Metropolitan University, Manchester,\xa0UK.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Hughes', 'Affiliation': 'Organisational Psychology, University of Manchester Alliance Manchester Business School, Manchester, UK.'}, {'ForeName': 'Lana', 'Initials': 'L', 'LastName': 'Crick', 'Affiliation': 'PricewaterhouseCoopers International Ltd, London, UK.'}, {'ForeName': 'Andra', 'Initials': 'A', 'LastName': 'Toader', 'Affiliation': 'Organisational Psychology, University of Manchester Alliance Manchester Business School, Manchester, UK.'}]",Ergonomics,['10.1080/00140139.2020.1811398'] 513,32830127,12-month randomised trial of 360° and 180° Schlemm's canal incisions in suture trabeculotomy ab interno for open-angle glaucoma.,"BACKGROUND/AIMS To perform a 12-month comparison between the different extents and locations of Schlemm's canal incisions during suture trabeculotomy ab interno for open-angle glaucoma (OAG). METHODS This is a prospective, single-centre, three-arm randomised trial. A total of 99 eyes of 99 patients were randomly assigned to one of three groups: the 360° incision group (n=34), the upper-180° incision group (n=34) and the lower-180° incision group (n=31). Intraocular pressure (IOP), number of medications and complications were evaluated until 12 months after surgery. Surgical success (with or without medication) was defined as IOP ≤21 mmHg and ≥20% IOP reduction (criterion A) or IOP ≤15 mmHg and ≥20% IOP reduction (criterion B). RESULTS The mean IOP (±SD) in all eyes was reduced from 18.6 (5.9) mmHg with 3.1 (1.1) medications to 13.7 (3.4) mmHg (20.8% reduction; p <0.001) with 1.4 (1.3) medications (p<0.001) at postoperative 12-month. Each group produced comparable mean reductions in both IOP and the number of medications throughout 12 months of follow-up. Kaplan-Meier cumulative survival analyses showed no significance among these three groups for criterion A and criterion B. Postoperative hyphema with niveau formation occurred significantly more in the 360° group than in the lower-180° group (p=0.031). CONCLUSIONS The different extents and locations of Schlemm's canal incisions during suture trabeculotomy ab interno for OAG, including the 360° incision, the upper-180° incision and the lower-180° incision, do not affect both the IOP reduction and the medications throughout 12 months of follow-up. TRIAL REGISTRATION NUMBER UMIN000021169.",2021,"Kaplan-Meier cumulative survival analyses showed no significance among these three groups for criterion A and criterion B. Postoperative hyphema with niveau formation occurred significantly more in the 360° group than in the lower-180° group (p=0.031). ","['A total of 99 eyes of 99 patients', '360° and']","['suture trabeculotomy ab interno for OAG, including the 360° incision', 'upper-180° incision group', 'suture trabeculotomy ab interno', 'lower-180° incision group']","['Intraocular pressure (IOP), number of medications and complications', 'criterion B. Postoperative hyphema with niveau formation', 'mean IOP (±SD', 'Surgical success', 'IOP reduction']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319607', 'cui_str': '360'}]","[{'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0040576', 'cui_str': 'Trabeculotomy'}, {'cui': 'C0017612', 'cui_str': 'Open-angle glaucoma'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205251', 'cui_str': 'Low'}]","[{'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0020581', 'cui_str': 'Hyphema'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",99.0,0.148632,"Kaplan-Meier cumulative survival analyses showed no significance among these three groups for criterion A and criterion B. Postoperative hyphema with niveau formation occurred significantly more in the 360° group than in the lower-180° group (p=0.031). ","[{'ForeName': 'Tomoki', 'Initials': 'T', 'LastName': 'Sato', 'Affiliation': 'Sato Eye and Internal Medicine Clinic, Arao, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Kawaji', 'Affiliation': 'Sato Eye and Internal Medicine Clinic, Arao, Japan kawag@white.plala.or.jp.'}]",The British journal of ophthalmology,['10.1136/bjophthalmol-2020-316624'] 514,32768315,"Effects of high versus standard essential amino acid intakes on whole-body protein turnover and mixed muscle protein synthesis during energy deficit: A randomized, crossover study.","BACKGROUND & AIMS Consuming 0.10-0.14 g essential amino acids (EAA)/kg/dose (0.25-0.30 g protein/kg/dose) maximally stimulates muscle protein synthesis (MPS) during energy balance. Whether consuming EAA beyond that amount enhances MPS and whole-body anabolism following energy deficit is unknown. The aims of this study were to determine the effects of standard and high EAA ingestion on mixed MPS and whole-body protein turnover following energy deficit. DESIGN Nineteen males (mean ± SD; 23 ± 5 y; 25.4 ± 2.7 kg/m 2 ) completed a randomized, double-blind crossover study consisting of two, 5-d energy deficits (-30 ± 4% of total energy requirements), separated by 14-d. Following each energy deficit, mixed MPS and whole-body protein synthesis (PS), breakdown (PB), and net balance (NET) were determined at rest and post-resistance exercise (RE) using primed, constant L-[ 2 H 5 ]-phenylalanine and L-[ 2 H 2 ]-tyrosine infusions. Beverages providing standard (0.1 g/kg, 7.87 ± 0.87 g) or high (0.3 g/kg, 23.5 ± 2.54 g) EAA were consumed post-RE. Circulating EAA were measured. RESULTS Postabsorptive mixed MPS (%/h) at rest was not different (P = 0.67) between treatments. Independent of EAA, postprandial mixed MPS at rest (standard EAA, 0.055 ± 0.01; high EAA, 0.061 ± 0.02) and post-RE (standard EAA, 0.055 ± 0.01; high EAA, 0.065 ± 0.02) were greater than postabsorptive mixed MPS at rest (P = 0.02 and P = 0.01, respectively). Change in (Δ postabsorptive) whole-body (g/180 min) PS and PB was greater for high than standard EAA [mean treatment difference (95% CI), 3.4 (2.3, 4.4); P = 0.001 and -15.6 (-17.8, -13.5); P = 0.001, respectively]. NET was more positive for high than standard EAA [19.0 (17.3, 20.7); P = 0.001]. EAA concentrations were greater in high than standard EAA (P = 0.001). CONCLUSIONS These data demonstrate that high compared to standard EAA ingestion enhances whole-body protein status during underfeeding. However, the effects of consuming high and standard EAA on mixed MPS are the same during energy deficit. CLINICAL TRIAL REGISTRY NCT03372928, https://clinicaltrials.gov.",2021,"RESULTS Postabsorptive mixed MPS (%/h) at rest was not different (P = 0.67) between treatments.","['Nineteen males (mean\xa0±\xa0SD; 23\xa0±', 'energy deficit', 'y; 25.4\xa0±\xa02.7\xa0kg/m 2 ']","['high versus standard essential amino acid intakes', 'resistance exercise (RE) using primed, constant L-[ 2 H 5 ]-phenylalanine and L', 'standard and high EAA ingestion']","['Circulating EAA', 'EAA concentrations', 'PS and PB', 'mixed MPS and whole-body protein synthesis (PS), breakdown (PB), and net balance (NET']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517635', 'cui_str': '2.7'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0556115', 'cui_str': 'Essential amino acid intake'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0331021', 'cui_str': 'Ligustrum vulgare'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0031453', 'cui_str': 'Phenylalanine'}, {'cui': 'C0002525', 'cui_str': 'Essential amino acid'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0002525', 'cui_str': 'Essential amino acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0597295', 'cui_str': 'Genetic translation'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0026832', 'cui_str': 'Muscle Protein'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0699900', 'cui_str': 'Catabolism'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",,0.113231,"RESULTS Postabsorptive mixed MPS (%/h) at rest was not different (P = 0.67) between treatments.","[{'ForeName': 'Jess A', 'Initials': 'JA', 'LastName': 'Gwin', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA; Oak Ridge Institute for Science and Education, Belcamp, MD, USA.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Church', 'Affiliation': 'Department of Geriatrics, Donald W. Reynolds Institute on Aging, Center for Translational Research in Aging & Longevity, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Hatch-McChesney', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Emily E', 'Initials': 'EE', 'LastName': 'Howard', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA; Oak Ridge Institute for Science and Education, Belcamp, MD, USA.'}, {'ForeName': 'Christopher T', 'Initials': 'CT', 'LastName': 'Carrigan', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Murphy', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Marques A', 'Initials': 'MA', 'LastName': 'Wilson', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Lee M', 'Initials': 'LM', 'LastName': 'Margolis', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Carbone', 'Affiliation': 'School of Health Sciences, Eastern Michigan University, Ypsilanti, MI, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'Wolfe', 'Affiliation': 'Department of Geriatrics, Donald W. Reynolds Institute on Aging, Center for Translational Research in Aging & Longevity, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Arny A', 'Initials': 'AA', 'LastName': 'Ferrando', 'Affiliation': 'Department of Geriatrics, Donald W. Reynolds Institute on Aging, Center for Translational Research in Aging & Longevity, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Stefan M', 'Initials': 'SM', 'LastName': 'Pasiakos', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA. Electronic address: stefan.m.pasiakos.civ@mail.mil.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.07.019'] 515,32770222,Should Graphic Warning Labels Proposed for Cigarette Packages Sold in the United States Mention the Food and Drug Administration?,"INTRODUCTION Under the US Family Smoking Prevention and Tobacco Control Act, the US Food and Drug Administration (FDA) has the authority to implement graphic warning labels (GWLs) on cigarette packages. Neither the original labels proposed by the FDA nor the revised labels include a source to indicate sponsorship of the warnings. This study tests the potential impact of adding a sponsor to the content of GWLs. METHODS We recruited adult smokers (N = 245) and middle-school youth (N = 242) from low-income areas in the Northeastern US. We randomly assigned participants to view one of three versions of the original FDA-proposed warning labels in a between-subjects experiment: no sponsor, ""US Food and Drug Administration,"" or ""American Cancer Society"" sponsor. We tested the effect of varying sponsorship on source attribution and source credibility. RESULTS Compared to unsponsored labels, FDA sponsorship increased source attributions that the FDA sponsored the labels among both middle-school, largely nonsmoking youth and adult smokers. However, sponsorship had no effect on source credibility among either population. CONCLUSIONS We found no evidence that adding FDA as the source is likely to boost source credibility judgments, at least in the short term; though doing so would not appear to have adverse effects on credibility judgments. As such, our data are largely consistent with the Tobacco Control Act's provisions that allow, but do not require, FDA sponsorship on the labels. IMPLICATIONS This study addresses the FDA's regulatory efforts by informing the possible design and content of future cigarette warning labels. Our results do not offer compelling evidence that adding the FDA name on GWLs will directly increase source credibility. Future work may test more explicit FDA source labeling and continue to examine the credibility of tobacco message content among high-priority populations.",2021,"Compared to unsponsored labels, FDA sponsorship increased source attributions that the FDA sponsored the labels among both middle-school, largely non-smoking youth and adult smokers.",['adult smokers (N=245) and middle-school youth (N=242) from low-income areas in the Northeastern US'],"['original FDA-proposed warning labels in a between-subjects experiment: no sponsor, ""US Food and Drug Administration,"" or ""American Cancer Society"" sponsor']",['source credibility'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0557797', 'cui_str': 'Middle school'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0041714', 'cui_str': 'United States Food, Drug Administration'}, {'cui': 'C0002455', 'cui_str': 'American Cancer Society'}]","[{'cui': 'C0449416', 'cui_str': 'Source'}]",,0.0210051,"Compared to unsponsored labels, FDA sponsorship increased source attributions that the FDA sponsored the labels among both middle-school, largely non-smoking youth and adult smokers.","[{'ForeName': 'Mia', 'Initials': 'M', 'LastName': 'Jovanova', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Skurka', 'Affiliation': 'Department of Film/Video and Media Studies, Donald P. Bellisario College of Communications, Penn State University, University Park, PA.'}, {'ForeName': 'Sahara', 'Initials': 'S', 'LastName': 'Byrne', 'Affiliation': 'Department of Communication, Cornell University, Ithaca, NY.'}, {'ForeName': 'Motasem', 'Initials': 'M', 'LastName': 'Kalaji', 'Affiliation': 'Department of Communication, Cornell University, Ithaca, NY.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Greiner Safi', 'Affiliation': 'Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Porticella', 'Affiliation': 'Department of Communication, Cornell University, Ithaca, NY.'}, {'ForeName': 'Alan D', 'Initials': 'AD', 'LastName': 'Mathios', 'Affiliation': 'Department of Policy Analysis and Management, Cornell University, Ithaca, NY.'}, {'ForeName': 'Rosemary J', 'Initials': 'RJ', 'LastName': 'Avery', 'Affiliation': 'Department of Policy Analysis and Management, Cornell University, Ithaca, NY.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Dorf', 'Affiliation': 'Cornell Law School, Ithaca, NY.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Niederdeppe', 'Affiliation': 'Department of Communication, Cornell University, Ithaca, NY.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa142'] 516,32777606,Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.,"BACKGROUND Opioid use disorder (OUD) is associated with cognitive dysfunction. Understanding how pharmacotherapy may affect cognition is an important treatment consideration. METHODS This was a hybrid residential-outpatient, randomized trial assessing transition regimens (naltrexone/buprenorphine [NTX/BUP] vs placebo-NTX/buprenorphine [PBO-N]/BUP) to extended-release naltrexone (XR-NTX) in patients with OUD seeking BUP discontinuation. Cognition was assessed at baseline, Day 22 (XR-NTX Day 14), and Day 36 (XR-NTX Day 28) using a range of measures (Brief Assessment of Cognition Symbol Coding test, Controlled Oral Word Association Task, Wechsler Memory Scale-III Spatial Span test, Continuous Performance Test, and Test of Attentional Performance). Pre-specified exploratory analyses compared treatment groups. Post hoc analyses were treatment-arm-independent analyses overall and by baseline BUP dose (<8 mg/day [low-dose] or 8 mg/day [higher-dose]). RESULTS Baseline cognitive measures were similar between NTX/BUP and PBO-N/BUP groups and between BUP low-dose and higher-dose groups. There were improvements in several cognitive outcomes at Day 22 and Day 36 relative to baseline for the overall population, but no differences between NTX/BUP and PBO-N/BUP treatment groups were observed. Participants entering the study on low-dose BUP showed improvements at Day 36 relative to baseline in 5 of 7 cognitive outcomes; participants entering the study on higher-dose BUP generally did not show improvements in cognitive outcomes. CONCLUSIONS Improvements in most cognitive domains were associated with the transition from BUP to XR-NTX, particularly in participants entering the study on low-dose (<8 mg/day) BUP. These improvements may be due to the discontinuation of BUP, the treatment with XR-NTX, or both.",2020,"There were improvements in several cognitive outcomes at Day 22 and Day 36 relative to baseline for the overall population, but no differences between NTX/BUP and PBO-N/BUP treatment groups were observed.","['patients with OUD seeking BUP discontinuation', 'patients with opioid use disorder transitioned to extended-release injectable']","['naltrexone (XR-NTX', 'naltrexone', 'naltrexone/buprenorphine [NTX/BUP', 'buprenorphine', 'placebo-NTX/buprenorphine [PBO-N]/BUP']","['cognitive outcomes', 'range of measures (Brief Assessment of Cognition Symbol Coding test, Controlled Oral Word Association Task, Wechsler Memory Scale-III Spatial Span test, Continuous Performance Test, and Test of Attentional Performance', 'Cognition', 'several cognitive outcomes', 'Cognitive performance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0031962', 'cui_str': 'Piperonyl Butoxide'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C3827022', 'cui_str': 'Controlled Oral Word Association Test'}, {'cui': 'C0451575', 'cui_str': 'Wechsler memory scale'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]",,0.0245195,"There were improvements in several cognitive outcomes at Day 22 and Day 36 relative to baseline for the overall population, but no differences between NTX/BUP and PBO-N/BUP treatment groups were observed.","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kosten', 'Affiliation': 'Baylor College of Medicine and MEDVAMC, Houston, TX, United States. Electronic address: kosten@bcm.edu.'}, {'ForeName': 'Efrat', 'Initials': 'E', 'LastName': 'Aharonovich', 'Affiliation': 'Department of Psychiatry, Columbia University Medical Center, and The New York State Psychiatric Institute, New York, NY, United States.'}, {'ForeName': 'Narinder', 'Initials': 'N', 'LastName': 'Nangia', 'Affiliation': 'Alkermes, Inc., Waltham, MA, United States.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Zavod', 'Affiliation': 'Alkermes, Inc., Waltham, MA, United States.'}, {'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Akerman', 'Affiliation': 'Alkermes, Inc., Waltham, MA, United States.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lopez-Bresnahan', 'Affiliation': 'Alkermes, Inc., Waltham, MA, United States.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Sullivan', 'Affiliation': 'Department of Psychiatry, Columbia University Medical Center, and The New York State Psychiatric Institute, New York, NY, United States; Alkermes, Inc., Waltham, MA, United States.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106538'] 517,32785689,Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men with Unexplained or Iron-Deficiency Anemia.,"CONTEXT Testosterone treatment of hypogonadal men improves their hemoglobin, but the mechanism is not understood. OBJECTIVE To investigate possible mechanisms by which testosterone stimulates erythropoiesis in hypogonadal older men with unexplained or iron-deficiency anemia. DESIGN The Anemia Trial of The Testosterone Trials, a placebo-controlled study in older, hypogonadal men. SETTING Twelve academic medical centers. PARTICIPANTS A total of 95 hypogonadal men (testosterone < 275 ng/mL) ≥65 years with anemia (hemoglobin < 12.7 g/dL). They were classified as having unexplained (n = 58) or iron deficiency anemia (n = 37). INTERVENTION Testosterone or placebo gel for 1 year. MAIN OUTCOME MEASURES Markers of iron metabolism during the first 3 months of treatment. RESULTS Testosterone replacement significantly (P < 0.001) increased hemoglobin in the 58 men who had unexplained anemia (adjusted mean difference 0.58 g/dL; 95% confidence interval, 0.31-0.85). Testosterone replacement tended to increase hemoglobin in the 37 men who had iron deficiency (0.38 g/dL; -0.19, 0.95), but the response was more variable and not statistically significant (P = 0.19). In men with unexplained anemia, testosterone replacement suppressed hepcidin (-8.2 ng/mL; -13.7, -2.7; P = 0.004) and ferritin (-19.6 µg/L; -32.8, -6.3; P = 0.004), but in men with iron deficiency, testosterone replacement did not. The decrease in hepcidin was moderately correlated with the increase in hemoglobin in the men with unexplained anemia (correlation coefficient -0.35, P = 0.01) but not in those with iron deficiency anemia (correlation coefficient -0.07, P = 0.73). CONCLUSIONS Testosterone replacement of older hypogonadal men with unexplained anemia stimulates erythropoiesis associated with increased iron mobilization. This effect appears to be attenuated by iron deficiency.",2020,"RESULTS Testosterone replacement significantly (p<0.001) increased hemoglobin in the 58 men who had unexplained anemia (adjusted mean difference 0.58 g/dL; 95% CI 0.31-0.85).","['older, hypogonadal men', 'older hypogonadal men with unexplained anemia stimulates erythropoiesis', 'They were classified as having unexplained (58) or iron deficiency anemia (37', 'hypogonadal older men with unexplained or iron-deficiency anemia', 'Older Men with Unexplained or Iron-Deficiency Anemia', 'hypogonadal men', 'Twelve academic medical centers', '95 hypogonadal men (testosterone <275 ng/mL) ≥65 years with anemia (hemoglobin <12.7 g/dL']","['Testosterone-Mediated Erythropoiesis', 'testosterone', 'Testosterone replacement', 'Testosterone or placebo gel', 'placebo']","['hemoglobin', 'Markers of iron metabolism', 'unexplained anemia', 'hepcidin']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C4517676', 'cui_str': '275'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4517546', 'cui_str': '12.7'}, {'cui': 'C0439267', 'cui_str': 'g/dL'}]","[{'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0017243', 'cui_str': 'Gel'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}]",95.0,0.520846,"RESULTS Testosterone replacement significantly (p<0.001) increased hemoglobin in the 58 men who had unexplained anemia (adjusted mean difference 0.58 g/dL; 95% CI 0.31-0.85).","[{'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'Artz', 'Affiliation': 'City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, Duarte, California.'}, {'ForeName': 'Alisa J', 'Initials': 'AJ', 'LastName': 'Stephens-Shields', 'Affiliation': 'Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Shalender', 'Initials': 'S', 'LastName': 'Bhasin', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Susan S', 'Initials': 'SS', 'LastName': 'Ellenberg', 'Affiliation': 'Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Harvey J', 'Initials': 'HJ', 'LastName': 'Cohen', 'Affiliation': 'Duke University Medical Center, Center for the Study of Aging, Durham, North Carolina.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Snyder', 'Affiliation': 'Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa521'] 518,32800386,Long-term effects of folic acid and vitamin-B12 supplementation on fracture risk and cardiovascular disease: Extended follow-up of the B-PROOF trial.,"BACKGROUND & AIMS In the initial B-proof, we found inconsistent results of B vitamin supplementation. However, the debate regarding the effects of B vitamins on age-related diseases continues. Therefore, our aim was to investigate the long-term effects (5-7 years follow-up) of an intervention with folic acid and vitamin-B12 supplementation on fracture and cardiovascular disease risk. METHODS Extended follow-up of the B-PROOF trial, a multi-center, double-blind randomized placebo-controlled trial designed to assess the effect of 2-3 years daily supplementation with folic acid (400 μg) and vitamin-B12 (500 μg) versus placebo (n = 2,919). Primary outcome was verified self-reported fracture incidence and secondary outcomes were self-reported cardiovascular endpoints, which were collected through a follow-up questionnaires Proportional hazard analyses was used for the effect of the intervention on risk of fracture(s) and logistic regression for the effect of the intervention on risk of cardiovascular disease. RESULTS A total of 1,298 individuals (44.5%) participated in the second follow-up round with median of 54 months [51-58], (n = 662 and n = 636, treatment versus placebo group). Median age at baseline was 71.0 years [68.0-76.0] for both groups. No effect was observed of the intervention on osteoporotic fracture or any fracture risk after a follow-up (HR: 0.99, 95% CI: 0.62-1.59 and HR: 0.77; 95% CI: 0.50-1.19, respectively), nor on cardiovascular or cerebrovascular disease risk (OR: 1.05; 95%CI: 0.80-1.44 and OR: 0.85; 95%CI: 0.50-1.45, respectively). Potential interaction by baseline homocysteine concentration was observed for osteoporotic- and any fracture (p = 0.10 and 0.06 respectively), which indicated a significantly lower risk of any fracture in the treatment group with higher total homocysteine concentrations (>15.1 μmol/l). No age-dependent effects were present. CONCLUSIONS This study supports and extends previous null-findings of the B-PROOF trial and shows that supplementation of folic acid and vitamin-B12 has no effect on fracture risk, nor on cardiovascular disease in older individuals over a longer follow-up period. However, B-vitamin supplementation may be beneficial in reducing fractures in individuals with high total homocysteine concentrations, a finding which needs to be replicated.",2021,"No effect was observed of the intervention on osteoporotic fracture or any fracture risk after a follow-up (HR: 0.99, 95% CI: 0.62-1.59 and HR: 0.77; 95% CI: 0.50-1.19, respectively), nor on cardiovascular or cerebrovascular disease risk (OR: 1.05; 95%CI: 0.80-1.44 and OR: 0.85; 95%CI: 0.50-1.45, respectively).","['1,298 individuals (44.5%) participated in the second follow-up round with median of 54 months [51-58], (n\xa0=\xa0662 and n\xa0=\xa0636, treatment versus placebo group']","['folic acid (400\xa0μg) and vitamin-B12 (500\xa0μg) versus placebo', 'folic acid and vitamin-B12', 'B vitamins', 'vitamin supplementation', 'folic acid and vitamin-B12 supplementation', 'placebo']","['osteoporotic fracture or any fracture risk', 'baseline homocysteine concentration', 'total homocysteine concentrations', 'fracture risk and cardiovascular disease', 'cardiovascular or cerebrovascular disease risk', 'verified self-reported fracture incidence and secondary outcomes were self-reported cardiovascular endpoints', 'risk of cardiovascular disease']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332490', 'cui_str': 'Round shape'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042849', 'cui_str': 'Vitamin B Complex'}, {'cui': 'C0302837', 'cui_str': 'Vitamin supplement agent'}, {'cui': 'C4524262', 'cui_str': 'Vitamin B12 supplementation'}]","[{'cui': 'C0521170', 'cui_str': 'Osteoporotic fracture'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0019878', 'cui_str': 'Homocysteine'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0007820', 'cui_str': 'Cerebrovascular disease'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.549828,"No effect was observed of the intervention on osteoporotic fracture or any fracture risk after a follow-up (HR: 0.99, 95% CI: 0.62-1.59 and HR: 0.77; 95% CI: 0.50-1.19, respectively), nor on cardiovascular or cerebrovascular disease risk (OR: 1.05; 95%CI: 0.80-1.44 and OR: 0.85; 95%CI: 0.50-1.45, respectively).","[{'ForeName': 'Sadaf', 'Initials': 'S', 'LastName': 'Oliai Araghi', 'Affiliation': 'Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: s.oliaiaraghi@erasmusmc.nl.'}, {'ForeName': 'Jessica C', 'Initials': 'JC', 'LastName': 'Kiefte-de Jong', 'Affiliation': 'Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Public Health and Primary Care, Leiden University Medical Center/LUMC Campus, The Hague, the Netherlands.'}, {'ForeName': 'Suzanne C', 'Initials': 'SC', 'LastName': 'van Dijk', 'Affiliation': 'Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Geriatric Medicine, Franciscus Gasthuis & Vlietland, Schiedam, the Netherlands.'}, {'ForeName': 'Karin M A', 'Initials': 'KMA', 'LastName': 'Swart', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Kim J', 'Initials': 'KJ', 'LastName': 'Ploegmakers', 'Affiliation': 'Amsterdam UMC, (University) of Amsterdam, Section of Geriatric Medicine, Department of Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'M Carola', 'Initials': 'MC', 'LastName': 'Zillikens', 'Affiliation': 'Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Natasja M', 'Initials': 'NM', 'LastName': 'van Schoor', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Lisette C P G M', 'Initials': 'LCPGM', 'LastName': 'de Groot', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University, Wageningen, the Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Lips', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine, Endocrine Section, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Bruno H', 'Initials': 'BH', 'LastName': 'Stricker', 'Affiliation': 'Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'André G', 'Initials': 'AG', 'LastName': 'Uitterlinden', 'Affiliation': 'Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'van der Velde', 'Affiliation': 'Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands; Amsterdam UMC, (University) of Amsterdam, Section of Geriatric Medicine, Department of Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.07.033'] 519,32804876,Comparing the Analgesic Effects of 4 Nonpharmacologic Interventions on Term Newborns Undergoing Heel Lance: A Randomized Controlled Trial.,"This randomized trial compared the analgesic effect of 4 nonpharmacologic interventions (breastfeeding, oral sucrose, nonnutritive sucking, and skin-to-skin contact) on term newborns between 24 and 48 hours of age who underwent a heel lance. The Neonatal Pain, Agitation, and Sedation Scale was used to evaluate pain. The newborns (N = 226) were assigned to one of 4 intervention groups (n = 176) or a control group without pain intervention (n = 50). The results indicate that all intervention groups showed decreased pain levels when compared with the control group (P < .01). The oral sucrose group experienced a superior analgesic effect when compared with the skin-to-skin contact group (P < .01), but no difference was observed when compared with the breastfeeding group (P > .05) or the nonnutritive sucking group (P > .05). All intervention groups showed a shortened crying time (P < .01) and reduced procedural duration (P < .01) compared with the control group. All of these interventions are clinically applicable and acceptable when caring for a newborn during a minor painful procedure.",2020,The results indicate that all intervention groups showed decreased pain levels when compared with the control group (P < .01).,"['Term Newborns Undergoing Heel Lance', 'newborns (N = 226', 'term newborns between 24 and 48 hours of age who underwent a heel lance']","['Nonpharmacologic Interventions', '4 nonpharmacologic interventions (breastfeeding, oral sucrose, nonnutritive sucking, and skin-to-skin contact', 'control group without pain intervention']","['Neonatal Pain, Agitation, and Sedation Scale', 'procedural duration', 'superior analgesic effect', 'shortened crying time', 'pain levels']","[{'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0018870', 'cui_str': 'Heel structure'}, {'cui': 'C0522666', 'cui_str': 'Lance'}, {'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C1271035', 'cui_str': 'Provision of non-nutritive sucking'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}]",226.0,0.0326912,The results indicate that all intervention groups showed decreased pain levels when compared with the control group (P < .01).,"[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Chang', 'Affiliation': ""Maternity Department (Mss Chang and Filoteo) and Nursing Research and Evidence-Based Practice (Dr Nasr), Stanford Children's Health, Palo Alto, California; and Department of Pediatrics, Stanford School of Medicine, Stanford, California (Dr Nasr).""}, {'ForeName': 'Lourdes', 'Initials': 'L', 'LastName': 'Filoteo', 'Affiliation': ''}, {'ForeName': 'Annette S', 'Initials': 'AS', 'LastName': 'Nasr', 'Affiliation': ''}]",The Journal of perinatal & neonatal nursing,['10.1097/JPN.0000000000000495'] 520,32804892,"A Prospective, Split-Face, Comparative Study of Combined Treatment With Fractional Microneedle Radiofrequency and Nonablative 1927-nm Fractional Thulium Fiber Laser for Wrinkle Treatment.","BACKGROUND Fractional microneedle radiofrequency (FMR) and nonablative 1927-nm fractional thulium fiber laser (TFL) are widely used for skin rejuvenation treatment. OBJECTIVES To investigate the efficacy and safety of combined treatment with both devices for wrinkles. PATIENTS AND METHODS Twenty-five patients with wrinkles were enrolled. One side of the face was treated with FMR alone, while the other side was treated with a combination of FMR and TFL. Each treatment consisted of 3 sessions at four-week intervals and patients were followed up 12 weeks after the last treatment. Overall improvement was assessed by patient global assessment (PGA) and investigator global assessment (IGA). Depression scores for the evaluation of wrinkles were objectively assessed by Antera 3D system. RESULTS Both sides of the face led to clinical improvement in both mean PGA and IGA. Combination treatment demonstrated a greater improvement in both mean PGA and IGA compared with FMR alone. In addition, wrinkle grading scales and depression scores showed greater improvement in the combination group than in FMR alone. CONCLUSION This study demonstrated that FMR and TFL comprise a good combination treatment for the treatment of wrinkles because both treatments have a synergistic effect on wrinkle improvement.",2021,"In addition, wrinkle grading scales and depression scores showed greater improvement in the combination group than in FMR alone. ",['Twenty-five patients with wrinkles were enrolled'],"['FMR and TFL', 'Fractional microneedle radiofrequency (FMR) and nonablative 1927-nm fractional thulium fiber laser (TFL', 'FMR', 'Fractional Microneedle Radiofrequency and Nonablative 1927-nm Fractional Thulium Fiber Laser']","['Depression scores', 'mean PGA and IGA', 'efficacy and safety', 'wrinkle grading scales and depression scores', 'patient global assessment (PGA) and investigator global assessment (IGA']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037301', 'cui_str': 'Wrinkled skin'}]","[{'cui': 'C0040066', 'cui_str': 'Thulium'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0037301', 'cui_str': 'Wrinkled skin'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",25.0,0.0231949,"In addition, wrinkle grading scales and depression scores showed greater improvement in the combination group than in FMR alone. ","[{'ForeName': 'Min-Young', 'Initials': 'MY', 'LastName': 'Park', 'Affiliation': 'Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Shinwon', 'Initials': 'S', 'LastName': 'Hwang', 'Affiliation': 'Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Soo Il', 'Initials': 'SI', 'LastName': 'Chun', 'Affiliation': 'Chunsooil Skin Clinic, Seoul, Korea.'}, {'ForeName': 'Su Min', 'Initials': 'SM', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Abdurrahman', 'Initials': 'A', 'LastName': 'Almurayshid', 'Affiliation': 'Department of Dermatology, College of Medicine, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.'}, {'ForeName': 'Sang Ho', 'Initials': 'SH', 'LastName': 'Oh', 'Affiliation': 'Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002672'] 521,32811186,Comparison of electroacupuncture and manual acupuncture for patients with plantar heel pain syndrome: a randomized controlled trial.,"BACKGROUND Plantar heel pain syndrome (PHPS), also known as plantar fasciitis, affects millions of people worldwide. Electroacupuncture (EA) and manual acupuncture (MA) are the two acupuncture modalities frequently used for PHPS in the clinical setting. However, which modality is more effective has yet to be determined. OBJECTIVE To examine whether EA is more effective than MA with regards to pain relief for patients with PHPS. METHODS Participants were randomly assigned (1:1) to receive 12 treatment sessions of EA or MA over 4 weeks with 24 weeks of follow-up. The primary outcome was the proportion of treatment responders, defined as patients with at least a 50% reduction from baseline in the worst pain intensity experienced during the first steps in the morning after a 4-week treatment, measured using a visual analogue scale (VAS, 0-100; higher scores signify worse pain). Analysis was by intention-to-treat. RESULTS Ninety-two patients with a clinical diagnosis of PHPS were enrolled from 29 July 2018 through 28 June 2019. Of the patients, 78 (85%) completed the treatment and follow-up. The primary outcome occurred in 54.8% (23/42) of the EA group compared to 50.0% (21/42) of the MA group after the 4-week treatment (difference -4.76, 95% confidence interval, -26.10 to 16.57, P  = 0.662). There were no significant between-group differences for any secondary outcomes after 4 weeks of treatment and at 16 weeks and 28 weeks of follow-up. There were no serious treatment-related adverse events in either group. CONCLUSION Among patients with PHPS, EA did not have a better effect with respect to relieving pain intensity than MA at week 4, although both EA and MA appeared to have positive temporal effects, with decreased heel pain and improved plantar function. TRIAL REGISTRATION NUMBER ChiCTR1800016531 (Chinese Clinical Trial Registry).",2021,There were no significant between-group differences for any secondary outcomes after 4 weeks of treatment and at 16 weeks and 28 weeks of follow-up.,"['patients with plantar heel pain syndrome', 'patients with PHPS', 'Ninety-two patients with a clinical diagnosis of PHPS were enrolled from 29 July 2018 through 28 June 2019', 'Participants', 'Plantar heel pain syndrome (PHPS']","['EA', 'Electroacupuncture (EA) and manual acupuncture (MA', 'electroacupuncture and manual acupuncture', 'EA or MA']","['proportion of treatment responders', 'pain relief', 'serious treatment-related adverse events', 'visual analogue scale', 'worst pain intensity', 'heel pain and improved plantar function', 'relieving pain intensity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231786', 'cui_str': 'Plantar heel pain'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0231780', 'cui_str': 'Heel pain'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",92.0,0.247168,There were no significant between-group differences for any secondary outcomes after 4 weeks of treatment and at 16 weeks and 28 weeks of follow-up.,"[{'ForeName': 'Weiming', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Ruimin', 'Initials': 'R', 'LastName': 'Jiao', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Sixing', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Guizhou University of Traditional Chinese Medicine, Guiyang, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Zhishun', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}]",Acupuncture in medicine : journal of the British Medical Acupuncture Society,['10.1177/0964528420947739'] 522,32815384,"Effectiveness of dry needling for upper extremity spasticity, quality of life and function in subacute phase stroke patients.","BACKGROUND Stroke is the fourth leading cause of death in Europe, represents one of the most common causes of disability in adult patients, and involves considerable short- and long-term social and healthcare costs. The effectiveness of deep dry needling (DDN) on affected arm functionality was assessed throughout 8 weeks of treatment in patients with stroke in the subacute phase. METHODS Eighty patients were included in this two-group non-randomised study after a propensity score analysis was carried out. Both groups received standard physiotherapy treatment on the affected arm. The needling group also received six sessions of DDN during the 8-week period. Patients were evaluated before and after each session using the Fugl-Meyer upper extremity (FM UE) scale, the modified modified Ashworth scale (MMAS), the resistance to passive movement scale (REPAS) and a 10-point numeric pain rating scale (NPRS 10). The Brunnstrom recovery stage was recorded at the beginning and at the end of the study, and the EuroQoL quality of life survey was completed at the beginning of the study, after the first month of treatment and at the end of the study. RESULTS Patients treated with DDN showed a reduction in spasticity measured using the REPAS (p < 0.001) and the MMAS (p < 0.05). There was also an improvement in the Brunnstrom recovery stages (p < 0.05). CONCLUSION The addition of a specific DDN treatment to a standard physiotherapy treatment appeared to lead to a higher reduction in spasticity in the affected arm; however, it did not provide additional changes in functionality, pain and quality of life. Further studies with a randomised controlled trial design are required to confirm our findings.",2021,"RESULTS Patients treated with DDN showed a reduction in spasticity measured using the REPAS (p < 0.001) and the MMAS (p < 0.05).","['patients with stroke in the subacute phase', 'Eighty patients were included in this two-group non-randomised study after a propensity score analysis was carried out', 'subacute phase stroke patients']","['dry needling', 'deep dry needling (DDN', 'standard physiotherapy treatment']","['Fugl-Meyer upper extremity (FM UE) scale, the modified modified Ashworth scale (MMAS), the resistance to passive movement scale (REPAS) and a 10-point numeric pain rating scale (NPRS 10', 'functionality, pain and quality of life', 'Brunnstrom recovery stages', 'upper extremity spasticity, quality of life and function', 'reduction in spasticity', 'EuroQoL quality of life survey']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205365', 'cui_str': 'Subacute'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C2718044', 'cui_str': 'Propensity Score'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}]","[{'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0079991', 'cui_str': 'Passive movement'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]",80.0,0.0621348,"RESULTS Patients treated with DDN showed a reduction in spasticity measured using the REPAS (p < 0.001) and the MMAS (p < 0.05).","[{'ForeName': 'Juan Nicolás', 'Initials': 'JN', 'LastName': 'Cuenca Zaldívar', 'Affiliation': 'Rehabilitation Service, Guadarrama Hospital, Guadarrama, Spain.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Calvo', 'Affiliation': 'School of Health Sciences, San Jorge University, Zaragoza, Spain.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Bravo-Esteban', 'Affiliation': 'School of Health Sciences, San Jorge University, Zaragoza, Spain.'}, {'ForeName': 'Petronila', 'Initials': 'P', 'LastName': 'Oliva Ruiz', 'Affiliation': 'School of Health Sciences, Institute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA), University of Cádiz, Cádiz, Spain.'}, {'ForeName': 'Maria José', 'Initials': 'MJ', 'LastName': 'Santi-Cano', 'Affiliation': 'School of Health Sciences, Institute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA), University of Cádiz, Cádiz, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Herrero', 'Affiliation': 'School of Health Sciences, San Jorge University, Zaragoza, Spain.'}]",Acupuncture in medicine : journal of the British Medical Acupuncture Society,['10.1177/0964528420947426'] 523,32817407,"Bilateral ultrasound-guided thoracic erector spinae plane blocks using a programmed intermittent bolus improve opioid-sparing postoperative analgesia in pediatric patients after open cardiac surgery: a randomized, double-blind, placebo-controlled trial.","BACKGROUND Postoperative pain after pediatric cardiac surgery is usually treated with intravenous opioids. Recently, the focus has been on postoperative regional analgesia with the introduction of ultrasound-guided erector spinae plane blocks (ESPBs). We hypothesized that bilateral ESPB with a programmed intermittent bolus (PIB) regimen decreases postoperative morphine consumption at 48 hours and improves analgesia in children who undergo cardiac surgery. METHODS This randomized, double-blind, placebo-controlled study comprised 50 children who underwent cardiac surgery through midline sternotomy. The patients were allocated randomly into two groups: ultrasound-guided bilateral ESPB at the level of T3-T4 transverse process then PIB with saline infusion (group 1, n=23) or PIB with 0.2% ropivacaine (group 2, n=27). Intravenous morphine at 30 µg/kg/hour was used as rescue analgesia. Postoperative pain was assessed using the COMFORT-B score for extubation, drain removal, and mobilization, and the FLACC (Face, Legs, Activity, Cry, Consolability) scale at 0, 2, 4, 6, 8, 12, 16, 20, 24, 36, and 48 hours after surgery. Adverse events were noted. RESULTS The total dose of morphine in 48 hours was significantly decreased in patients receiving a bilateral ESPB with ropivacaine (120±320 µg/kg) compared with patients with saline infusion (512±560 µg/kg; p=0.03). Fourteen per cent of patients required rescue analgesia with morphine in group 2 compared with 41% in group 1 (p=0.05). The patients in group 2 demonstrated significantly reduced COMFORT-B scores at extubation, drain removal, and mobilization compared with those in group 1 and had reduced FLACC scale levels at 20 and 24 hours postoperatively (p=0.05 and p=0.001, respectively). No differences were reported for extubation and drain removal times or for length of hospital stay. In addition, vomiting episodes were decreased in group 2 (p=0.01). CONCLUSIONS In pediatric cardiac surgery, the results of this study confirm our hypothesis that bilateral ESPB analgesia with ropivacaine decreases the postoperative morphine consumption at 48 hours and demonstrates better postoperative analgesia compared with a control group. Trial registration number NCT03593642.",2020,The total dose of morphine in 48 hours was significantly decreased in patients receiving a bilateral ESPB with ropivacaine (120±320 µg/kg) compared with patients with saline infusion (512±560 µg/kg; p=0.03).,"['pediatric patients after open cardiac surgery', '50 children who underwent cardiac surgery through midline sternotomy', 'children who undergo cardiac surgery']","['opioid-sparing postoperative analgesia', 'Intravenous morphine', 'morphine', 'ropivacaine', 'PIB with 0.2% ropivacaine', 'ultrasound-guided bilateral ESPB at the level of T3-T4 transverse process then PIB with saline infusion', 'intravenous opioids', 'Bilateral ultrasound-guided thoracic erector spinae plane blocks', 'placebo']","['vomiting episodes', 'extubation and drain removal times or for length of hospital stay', 'Adverse events', 'rescue analgesia', 'reduced COMFORT-B scores at extubation, drain removal, and mobilization', 'COMFORT-B score for extubation, drain removal, and mobilization, and the FLACC (Face, Legs, Activity, Cry, Consolability) scale', 'postoperative morphine consumption', 'FLACC scale levels', 'postoperative analgesia', 'Postoperative pain']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0185792', 'cui_str': 'Sternotomy'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C1843661', 'cui_str': 'Spastic Paraplegia, Ataxia, And Mental Retardation'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1301695', 'cui_str': 'Intermittent bolus'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205106', 'cui_str': 'Transverse plane'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0411815', 'cui_str': 'Removal of drain'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]",50.0,0.598763,The total dose of morphine in 48 hours was significantly decreased in patients receiving a bilateral ESPB with ropivacaine (120±320 µg/kg) compared with patients with saline infusion (512±560 µg/kg; p=0.03).,"[{'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Macaire', 'Affiliation': 'Anesthesia and Pain Department, Vinmec International Hospital, Hanoi, Viet Nam.'}, {'ForeName': 'Nga', 'Initials': 'N', 'LastName': 'Ho', 'Affiliation': 'Department of Cardiac Surgery, Vinmec Central Park International Hospital, Ho Chi Minh City, Viet Nam.'}, {'ForeName': 'Vien', 'Initials': 'V', 'LastName': 'Nguyen', 'Affiliation': 'Department of Cardiac Surgery, Vinmec Central Park International Hospital, Ho Chi Minh City, Viet Nam.'}, {'ForeName': 'Hieu', 'Initials': 'H', 'LastName': 'Phan Van', 'Affiliation': 'Department of Pharmacology, Forensic Medicine Center, Ho Chi Minh City, Viet Nam.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Dinh Nguyen Thien', 'Affiliation': 'Department of Pharmacology, Forensic Medicine Center, Ho Chi Minh City, Viet Nam.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Bringuier', 'Affiliation': 'Department of Biostatistics, Hopital Lapeyronie, Montpellier, France.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Capdevila', 'Affiliation': 'Anesthesiology and Critical Care Department and Neurosciences Institute, Inserm U1051, Hopital Lapeyronie, Montpellier, France x-capdevila@chu-montpellier.fr.'}]",Regional anesthesia and pain medicine,['10.1136/rapm-2020-101496'] 524,32790066,Clinical and Model-Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study.,"Glasdegib is a potent, selective oral inhibitor of the Hedgehog signaling pathway. This phase 1 double-blind thorough QT study (NCT03162900) evaluated the effects of glasdegib on QTc interval. The study enrolled 36 healthy volunteers to receive a single dose of 150 mg glasdegib (representing a therapeutic dose), 300 mg glasdegib (representing a supratherapeutic dose), 400 mg moxifloxacin (positive control), or placebo under fasted conditions. The study demonstrated that therapeutic and supratherapeutic doses of glasdegib had no significant effect on QTc interval; the upper bound of the 2-sided 90% confidence intervals (CIs) for all time-matched least-squares mean differences in QT interval corrected using Fridericia's formula (QTcF) between glasdegib and placebo was below the prespecified criterion of 20 milliseconds (Food and Drug Administration correspondence reviewed and accepted). Based on an exposure-response analysis, glasdegib was determined not to have a meaningful effect on heart rate (change in RR interval). The mean (90%CI) model-derived baseline and placebo-adjusted QTcF at the average maximum observed concentration values corresponding to therapeutic and supratherapeutic glasdegib doses was 7.3 milliseconds (6.5-8.2 milliseconds) and 13.7 milliseconds (12.0-15.5 milliseconds), respectively. Together these results demonstrated that following therapeutic and supratherapeutic glasdegib dosing, the change in QTc from baseline was well below the 20-millisecond threshold of clinical concern in oncology.",2021,"Based on an exposure-response analysis, glasdegib was determined not to have a meaningful effect on heart rate (change in RR interval).",['36 healthy volunteers'],"['Glasdegib', 'moxifloxacin (positive control), or placebo', 'placebo']","['QTc interval', 'heart rate']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4519273', 'cui_str': 'glasdegib'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",36.0,0.114569,"Based on an exposure-response analysis, glasdegib was determined not to have a meaningful effect on heart rate (change in RR interval).","[{'ForeName': 'Joanna C', 'Initials': 'JC', 'LastName': 'Masters', 'Affiliation': 'Pfizer Inc., San Diego, California, USA.'}, {'ForeName': 'Naveed', 'Initials': 'N', 'LastName': 'Shaik', 'Affiliation': 'Pfizer Inc., San Diego, California, USA.'}, {'ForeName': 'Laure', 'Initials': 'L', 'LastName': 'Mendes da Costa', 'Affiliation': 'Pfizer Inc., Brussels, Belgium.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Hee', 'Affiliation': 'Pfizer Inc., Groton, Connecticut, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'LaBadie', 'Affiliation': 'Pfizer Inc., Groton, Connecticut, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.862'] 525,32792614,Alterations in acid-base balance and high-intensity exercise performance after short-term and long-term exposure to acute normobaric hypoxic conditions.,"This investigation assessed the course of renal compensation of hypoxia-induced respiratory alkalosis by elimination of bicarbonate ions and impairments in anaerobic exercise after different durations of hypoxic exposure. Study A: 16 participants underwent a resting 12-h exposure to normobaric hypoxia (3,000 m). Blood gas analysis was assessed hourly. While blood pH was significantly increased, PO 2 , PCO 2 , and SaO 2 were decreased within the first hour of hypoxia, and changes remained consistent. A substantial reduction in [HCO 3 - ] levels was observed after 12 h of hypoxic exposure (- 1.35 ± 0.29 mmol/L, p ≤ 0.05). Study B: 24 participants performed in a randomized, cross-over trial portable tethered sprint running (PTSR) tests under normoxia and after either 1 h (n = 12) or 12 h (n = 12) of normobaric hypoxia (3,000 m). No differences occurred for PTSR-related performance parameters, but the reduction in blood lactate levels was greater after 12 h compared with 1 h (- 1.9 ± 2.2 vs 0.0 ± 2.3 mmol/L, p ≤ 0.05). These results indicate uncompensated respiratory alkalosis after 12 h of hypoxia and similar impairment of high-intensity exercise after 1 and 12 h of hypoxic exposure, despite a greater reduction in blood lactate responses after 12 h compared with 1 h of hypoxic exposure.",2020,"No differences occurred for PTSR-related performance parameters, but the reduction in blood lactate levels was greater after 12 h compared with 1 h (- 1.9 ± 2.2 vs 0.0 ± 2.3 mmol/L, p ≤ 0.05).",[' 16 participants underwent a'],"['resting 12-h exposure to normobaric hypoxia', 'portable tethered sprint running (PTSR) tests under normoxia and after either 1\xa0h (n\u2009=\u200912) or 12\xa0h (n\u2009=\u200912) of normobaric hypoxia']","['PTSR-related performance parameters', 'blood pH', 'PO 2 , PCO 2 , and SaO 2', 'blood lactate levels', 'Blood gas analysis', 'blood lactate responses', 'respiratory alkalosis']",[],"[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0577538', 'cui_str': 'Tethered'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0700308', 'cui_str': 'Protium'}]","[{'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0853363', 'cui_str': 'Blood pH'}, {'cui': 'C0297199', 'cui_str': 'PO-2'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C1862322', 'cui_str': 'Southeast Asian ovalocytosis'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0428445', 'cui_str': 'D-lactate measurement'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0002064', 'cui_str': 'Respiratory alkalosis'}]",,0.0252108,"No differences occurred for PTSR-related performance parameters, but the reduction in blood lactate levels was greater after 12 h compared with 1 h (- 1.9 ± 2.2 vs 0.0 ± 2.3 mmol/L, p ≤ 0.05).","[{'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Limmer', 'Affiliation': 'Institute of Sports Medicine and Sports Nutrition, Ruhr-University Bochum, Bochum, Germany. mirjam.limmer@rub.de.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'de Marées', 'Affiliation': 'Institute of Sports Medicine and Sports Nutrition, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Platen', 'Affiliation': 'Institute of Sports Medicine and Sports Nutrition, Ruhr-University Bochum, Bochum, Germany.'}]",Scientific reports,['10.1038/s41598-020-70762-z'] 526,32815386,Efficacy of electroacupuncture plus warm needling therapy for plantar heel pain: a randomised waitlist-controlled trial.,"OBJECTIVE To investigate the therapeutic effects of electroacupuncture plus warm needling (EAWN) therapy on pain and foot function in adults with plantar heel pain (PHP). METHODS This prospective, randomised, parallel-group, waitlist-controlled trial was conducted at a Chinese medicine centre in Hong Kong between May 2018 and February 2019. Eighty eligible community-dwelling subjects with PHP (mean age 59.7 years; 85% female) were equally randomised to receive EAWN therapy or remain on a waitlist. The treatment group received six 30-min sessions of standardised EAWN therapy over 4 weeks; the control group received no treatment. The outcome measures were the visual analogue scale (VAS) score for first-step pain, foot function index (FFI) scores and global rating of change (GRC) scale scores. Assessments were made at baseline, week 2 and week 4 (primary endpoint). The treatment group underwent additional assessments at week 8. Outcomes were evaluated by intention-to-treat analysis. RESULTS Patients who received EAWN therapy exhibited greater improvements in the mean first-step pain VAS and all FFI scores than did those in the control group at weeks 2 and 4, with significant between-group differences (all P  < 0.001). Compared with baseline, there were significant decreases in mean first-step pain VAS scores at weeks 2 and 4, and FFI scores at week 4, in the treatment group but not in the control group. The improvements in the treatment group continued until week 8. GRC scores at week 4 indicated improvement in all treated patients and only 22.5% of the control group patients ( P  < 0.001). There were no study-related adverse events. CONCLUSION EAWN therapy could be an effective treatment for PHP in middle-aged and older adults. TRIAL REGISTRATION NUMBER ChiCTR1800014906 (Chinese Clinical Trials Registry).",2021,"RESULTS Patients who received EAWN therapy exhibited greater improvements in the mean first-step pain VAS and all FFI scores than did those in the control group at weeks 2 and 4, with significant between-group differences (all P  < 0.001).","['Eighty eligible community-dwelling subjects with PHP (mean age 59.7\u2009years; 85% female', 'middle-aged and older adults', 'Chinese medicine centre in Hong Kong between May 2018 and February 2019', 'plantar heel pain', 'adults with plantar heel pain (PHP']","['electroacupuncture plus warm needling therapy', 'electroacupuncture plus warm needling (EAWN) therapy']","['FFI scores', 'mean first-step pain VAS and all FFI scores', 'pain and foot function', 'visual analogue scale (VAS) score for first-step pain, foot function index (FFI) scores and global rating of change (GRC) scale scores', 'mean first-step pain VAS scores', 'GRC scores']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0231786', 'cui_str': 'Plantar heel pain'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C4706287', 'cui_str': 'Foot Function Index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",80.0,0.0808319,"RESULTS Patients who received EAWN therapy exhibited greater improvements in the mean first-step pain VAS and all FFI scores than did those in the control group at weeks 2 and 4, with significant between-group differences (all P  < 0.001).","[{'ForeName': 'Lai Fun', 'Initials': 'LF', 'LastName': 'Ho', 'Affiliation': 'Chinese Medicine Services, Pok Oi Hospital, Hong Kong, China.'}, {'ForeName': 'Yuanqi', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Chinese Medicine Services, Pok Oi Hospital, Hong Kong, China.'}, {'ForeName': 'Jessica Yuet-Ling', 'Initials': 'JY', 'LastName': 'Ching', 'Affiliation': 'School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Kam Leung', 'Initials': 'KL', 'LastName': 'Chan', 'Affiliation': 'School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Ping Him', 'Initials': 'PH', 'LastName': 'Tsang', 'Affiliation': 'Chinese Medicine Services, Pok Oi Hospital, Hong Kong, China.'}, {'ForeName': 'Man Hin', 'Initials': 'MH', 'LastName': 'Wong', 'Affiliation': 'Chinese Medicine Services, Pok Oi Hospital, Hong Kong, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'Chinese Medicine Services, Pok Oi Hospital, Hong Kong, China.'}, {'ForeName': 'Liyi', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Chinese Medicine Services, Pok Oi Hospital, Hong Kong, China.'}, {'ForeName': 'Bacon Fung-Leung', 'Initials': 'BF', 'LastName': 'Ng', 'Affiliation': 'Chinese Medicine Department, Hospital Authority, Hong Kong, China.'}, {'ForeName': 'Zhi Xiu', 'Initials': 'ZX', 'LastName': 'Lin', 'Affiliation': 'School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.'}]",Acupuncture in medicine : journal of the British Medical Acupuncture Society,['10.1177/0964528420946048'] 527,32815418,Exploring mechanisms of action in clinical trials of complex surgical interventions using mediation analysis.,"BACKGROUND Surgical interventions allow for tailoring of treatment to individual patients and implementation may vary with surgeon and healthcare provider. In addition, in clinical trials assessing two competing surgical interventions, the treatments may be accompanied by co-interventions. AIMS This study explores the use of causal mediation analysis to (1) delineate the treatment effect that results directly from the surgical intervention under study and the indirect effect acting through a co-intervention and (2) to evaluate the benefit of the surgical intervention if either everybody in the trial population received the co-intervention or nobody received it. METHODS Within a counterfactual framework, relevant direct and indirect effects of a surgical intervention are estimated and adjusted for confounding via parametric regression models, for the situation where both mediator and outcome are binary, with baseline stratification factors included as fixed effects and surgeons as random intercepts. The causal difference in probability of a successful outcome (estimand of interest) is calculated using Monte Carlo simulation with bootstrapping for confidence intervals. Packages for estimation within standard statistical software are reviewed briefly. A step by step application of methods is illustrated using the Amaze randomised trial of ablation as an adjunct to cardiac surgery in patients with irregular heart rhythm, with a co-intervention (removal of the left atrial appendage) administered to a subset of participants at the surgeon's discretion. The primary outcome was return to normal heart rhythm at one year post surgery. RESULTS In Amaze, 17% (95% confidence interval: 6%, 28%) more patients in the active arm had a successful outcome, but there was a large difference between active and control arms in the proportion of patients who received the co-intervention (55% and 30%, respectively). Causal mediation analysis suggested that around 1% of the treatment effect was attributable to the co-intervention (16% natural direct effect). The controlled direct effect ranged from 18% (6%, 30%) if the co-intervention were mandated, to 14% (2%, 25%) if it were prohibited. Including age as a moderator of the mediation effects showed that the natural direct effect of ablation appeared to decrease with age. CONCLUSIONS Causal mediation analysis is a useful quantitative tool to explore mediating effects of co-interventions in surgical trials. In Amaze, investigators could be reassured that the effect of the active treatment, not explainable by differential use of the co-intervention, was significant across analyses.",2020,"In Amaze, 17% (95% confidence interval: 6%, 28%) more patients in the active arm had a successful outcome, but there was a large difference between active and control arms in the proportion of patients who received the co-intervention (55% and 30%, respectively).","[""patients with irregular heart rhythm, with a co-intervention (removal of the left atrial appendage) administered to a subset of participants at the surgeon's discretion""]",['co-intervention or nobody received it'],['return to normal heart rhythm at one year post surgery'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205271', 'cui_str': 'Irregular'}, {'cui': 'C0232187', 'cui_str': 'Cardiac rhythm type'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0225832', 'cui_str': 'Structure of auricular appendage'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0232187', 'cui_str': 'Cardiac rhythm type'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",,0.133141,"In Amaze, 17% (95% confidence interval: 6%, 28%) more patients in the active arm had a successful outcome, but there was a large difference between active and control arms in the proportion of patients who received the co-intervention (55% and 30%, respectively).","[{'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Sharples', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Olympia', 'Initials': 'O', 'LastName': 'Papachristofi', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Saleema', 'Initials': 'S', 'LastName': 'Rex', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Landau', 'Affiliation': ""King's College London, London, UK.""}]","Clinical trials (London, England)",['10.1177/1740774520947644'] 528,32844550,Postprandial Triglyceride-Rich Lipoproteins from Type 2 Diabetic Women Stimulate Platelet Activation Regardless of the Fat Source in the Meal.,"SCOPE The aim of this study is to examine whether postprandial (PP) triglyceride-rich lipoproteins (TGRL) secreted after a moderate fat intake would activate platelets differently according to their fatty acid (FA) composition. METHODS AND RESULTS In a parallel single-blind randomized trial, 30 women with type 2 diabetes are assigned a breakfast containing 20 g lipids from butter versus hazelnut-cocoa spread (HCS) rich in palm oil. Blood samples are collected at fasting and 4 h PP. FA composition of fasting and PP TGRL and their effects on the activation of platelets from healthy blood donors are assessed. Both breakfasts similarly increase plasma ApoB-48, plasma, and TGRL triglycerides (p < 0.05). TGRL mean diameter increases after both breakfasts and is greater after the butter breakfast. Both breakfasts are rich in palmitic acid, and the HCS breakfast contains 45% oleic acid. TGRL FA composition reflects the dietary FA composition. Pre-incubation of platelets with fasting and PP TGRL increases collagen-stimulated aggregation (p < 0.01 vs control). Fasting and PP TGRL similarly increase agonist-induced thromboxane B 2 concentrations, and this effect is concentration-dependent for PP TGRL. CONCLUSION PP TGRL from type 2 diabetic women after a palm-oil spread versus butter-based mixed meal induce similar acute in vitro platelet activation.",2020,"Both breakfasts similarly increased plasma ApoB-48, plasma and TGRL triglycerides (p<0.05).",['30 women with type 2 diabetes'],"['breakfast containing 20 g lipids from butter vs hazelnut cocoa spread rich in palm oil', 'PP TGRL']","['Postprandial Triglyceride-Rich Lipoproteins', 'incubation of platelets with fasting and PP TGRL increased collagen-stimulated aggregation', 'Blood samples', 'plasma ApoB-48, plasma and TGRL triglycerides', 'FA composition of fasting and PP TGRL', 'Platelet Activation', 'postprandial (PP) triglyceride-rich lipoproteins (TGRL', 'TGRL mean diameter']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0450403', 'cui_str': '20G'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0006494', 'cui_str': 'Butter'}, {'cui': 'C0440288', 'cui_str': 'Hazelnut'}, {'cui': 'C0006622', 'cui_str': 'Theobroma cacao'}, {'cui': 'C0332261', 'cui_str': 'Spreading'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0069962', 'cui_str': 'Palm Oil'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C1096194', 'cui_str': 'Lipoprotein (a) increased'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0332621', 'cui_str': 'Aggregation'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0103839', 'cui_str': 'Apolipoprotein B-48'}, {'cui': 'C0065060', 'cui_str': 'lipoprotein triglyceride'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0032173', 'cui_str': 'Platelet activation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}]",30.0,0.059224,"Both breakfasts similarly increased plasma ApoB-48, plasma and TGRL triglycerides (p<0.05).","[{'ForeName': 'Marie Michèle', 'Initials': 'MM', 'LastName': 'Boulet', 'Affiliation': 'Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRAE UMR 1397, INSA Lyon, CENS-ELI Building 165 chemin du Grand Revoyet, Pierre-Bénite, 69310, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cheillan', 'Affiliation': 'Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRAE UMR 1397, INSA Lyon, CENS-ELI Building 165 chemin du Grand Revoyet, Pierre-Bénite, 69310, France.'}, {'ForeName': 'Mathilde', 'Initials': 'M', 'LastName': 'Di Filippo', 'Affiliation': 'Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRAE UMR 1397, INSA Lyon, CENS-ELI Building 165 chemin du Grand Revoyet, Pierre-Bénite, 69310, France.'}, {'ForeName': 'Taïssia', 'Initials': 'T', 'LastName': 'Lelekov-Boissard', 'Affiliation': ""Fédération d'endocrinologie, Maladies Métaboliques, Diabète et Nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, 69500, France.""}, {'ForeName': 'Charline', 'Initials': 'C', 'LastName': 'Buisson', 'Affiliation': 'Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRAE UMR 1397, INSA Lyon, CENS-ELI Building 165 chemin du Grand Revoyet, Pierre-Bénite, 69310, France.'}, {'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Lambert-Porcheron', 'Affiliation': 'Centre de Recherche en Nutrition Humaine Rhône-Alpes, Univ-Lyon, CarMeN Laboratory, Université Claude Bernard Lyon1, Hospices Civils de Lyon, CENS, FCRIN/FORCE Network, Pierre Bénite, 69310, France.'}, {'ForeName': 'Julie-Anne', 'Initials': 'JA', 'LastName': 'Nazare', 'Affiliation': 'Centre de Recherche en Nutrition Humaine Rhône-Alpes, Univ-Lyon, CarMeN Laboratory, Université Claude Bernard Lyon1, Hospices Civils de Lyon, CENS, FCRIN/FORCE Network, Pierre Bénite, 69310, France.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Tressou', 'Affiliation': 'UMR MIA-Paris, AgroParisTech, INRAE, Paris-Saclay University, Paris, 75005, France.'}, {'ForeName': 'Marie-Caroline', 'Initials': 'MC', 'LastName': 'Michalski', 'Affiliation': 'Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRAE UMR 1397, INSA Lyon, CENS-ELI Building 165 chemin du Grand Revoyet, Pierre-Bénite, 69310, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Calzada', 'Affiliation': 'Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRAE UMR 1397, INSA Lyon, CENS-ELI Building 165 chemin du Grand Revoyet, Pierre-Bénite, 69310, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Moulin', 'Affiliation': 'Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRAE UMR 1397, INSA Lyon, CENS-ELI Building 165 chemin du Grand Revoyet, Pierre-Bénite, 69310, France.'}]",Molecular nutrition & food research,['10.1002/mnfr.202000694'] 529,32784117,Idebenone does not inhibit disability progression in primary progressive MS.,"BACKGROUND Multiple sclerosis (MS) is a chronic, immune-mediated neurodegenerative disorder of the central nervous system (CNS). While current MS therapies target the inflammatory processes, no treatment explicitly targets mitochondrial dysfunction and resulting axonal loss. Therefore, the aim of this study was to determine whether idebenone inhibits mitochondrial dysfunction and accumulation of disability in primary progressive MS (PPMS) and to enhance understanding of pathogenic mechanisms of PPMS progression using cerebrospinal fluid (CSF) biomarkers. METHODS The double-blind, placebo-controlled Phase I/II clinical trial of Idebenone in patients with Primary Progressive MS (IPPoMS; NCT00950248) was an adaptively designed, baseline-versus-treatment, placebo-controlled, CSF-biomarker-supported trial. Based on interim analysis of the 1-year pre-treatment data, change in the area under the curve of Combinatorial Weight-Adjusted Disability Score (CombiWISE) became the primary outcome, with >80% power to detect ≥40% efficacy with 28 patients/arm treated for 2 years in baseline versus treatment paradigm. Changes in traditional disability scales and in brain ventricular volume were secondary outcomes. Exploratory outcomes included CSF biomarkers of mitochondrial dysfunction (Growth/differentiation factor 15 [GDF15] and lactate), axonal damage (neurofilament light chain [NFL]), innate immunity (sCD14), blood brain barrier leakage (albumin quotient) and retinal nerve fiber layer thinning. RESULTS Idebenone was well tolerated but did not inhibit disability progression or CNS tissue destruction. Concentrations of GDF15, secreted predominantly by astrocytes and choroid plexus epithelium in vitro, increased after exposure to mitochondrial toxin rotenone, validating the ability of this biomarker to measure intrathecal mitochondrial damage. CSF GDF15 levels correlated strongly with age and MS patients had CSF levels of GDF15 significantly above age-adjusted healthy volunteers, with highest levels measured in PPMS. Idebenone did not change CSF GDF15 levels. CONCLUSION Mitochondrial dysfunction exceeding normal aging reflected by age-adjusted CSF GDF15 is present in the majority of PPMS patients, but it is not inhibited by idebenone.",2020,"CSF GDF15 levels correlated strongly with age and MS patients had CSF levels of GDF15 significantly above age-adjusted healthy volunteers, with highest levels measured in PPMS.","['patients with Primary Progressive MS (IPPoMS', 'primary progressive MS (PPMS']","['Idebenone', 'idebenone', 'placebo']","['Mitochondrial dysfunction', 'traditional disability scales', 'CSF levels of GDF15', 'CSF biomarkers of mitochondrial dysfunction (Growth/differentiation factor 15 [GDF15] and lactate), axonal damage (neurofilament light chain [NFL]), innate immunity (sCD14), blood brain barrier leakage (albumin quotient) and retinal nerve fiber layer thinning', 'CSF GDF15 levels', 'Combinatorial Weight-Adjusted Disability Score (CombiWISE', 'disability progression or CNS tissue destruction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751964', 'cui_str': 'Primary progressive multiple sclerosis'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}]","[{'cui': 'C0123163', 'cui_str': 'idebenone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1431343', 'cui_str': 'GDF15 protein, human'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0020969', 'cui_str': 'Innate Immunity'}, {'cui': 'C0005854', 'cui_str': 'Brain-Blood Barrier'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C1720466', 'cui_str': 'Nerve fiber layer'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C1261381', 'cui_str': 'Destructive procedure'}]",,0.0721347,"CSF GDF15 levels correlated strongly with age and MS patients had CSF levels of GDF15 significantly above age-adjusted healthy volunteers, with highest levels measured in PPMS.","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kosa', 'Affiliation': 'Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Tianxia', 'Initials': 'T', 'LastName': 'Wu', 'Affiliation': 'Clinical trials Unit, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Phillips', 'Affiliation': 'Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Leinonen', 'Affiliation': 'Santhera Pharmaceuticals (Switzerland) AG, Pratteln Switzerland.'}, {'ForeName': 'Ruturaj', 'Initials': 'R', 'LastName': 'Masvekar', 'Affiliation': 'Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Komori', 'Affiliation': 'Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Wichman', 'Affiliation': 'Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Sandford', 'Affiliation': 'Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Bibiana', 'Initials': 'B', 'LastName': 'Bielekova', 'Affiliation': 'Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: Bibi.Bielekova@nih.gov.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102434'] 530,32787506,A Pilot Study of An Intervention to Increase Family Member Involvement in Nursing Home Care Plan Meetings.,"BACKGROUND AND OBJECTIVES Many family members struggle to negotiate their aging relative's care with nursing home staff, potentially leading to depression and other negative outcomes for residents' families. This pilot study tested an intervention designed to empower residents' family members to attend and participate in nursing home care plan meetings. RESEARCH DESIGN AND METHODS We conducted a small, randomized, controlled trial of the Families Involved in Nursing home Decision-making (FIND) intervention, which used web conferencing to facilitate family participation in care plan meetings. RESULTS Overall, FIND was feasible and acceptable. Family members who received the FIND intervention were more likely to experience decreased depressive symptoms than those who did not. DISCUSSION AND IMPLICATIONS FIND is a promising approach to reduce depression among family members of nursing home residents. Findings support the need for a follow-up clinical trial.",2021,"Family members who received the FIND intervention were more likely to experience decreased depressive symptoms than those who did not. ","['family members of nursing home residents', ""empower residents' family members to attend and participate in nursing home care plan meetings""]",[],['depressive symptoms'],"[{'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0178916', 'cui_str': 'Care plan'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}]",[],"[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",,0.0402854,"Family members who received the FIND intervention were more likely to experience decreased depressive symptoms than those who did not. ","[{'ForeName': 'Debra Parker', 'Initials': 'DP', 'LastName': 'Oliver', 'Affiliation': 'University of Missouri, Columbia, USA.'}, {'ForeName': 'Abigail J', 'Initials': 'AJ', 'LastName': 'Rolbiecki', 'Affiliation': 'University of Missouri, Columbia, USA.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Washington', 'Affiliation': 'University of Missouri, Columbia, USA.'}, {'ForeName': 'Robin L', 'Initials': 'RL', 'LastName': 'Kruse', 'Affiliation': 'University of Missouri, Columbia, USA.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Popejoy', 'Affiliation': 'University of Missouri, Columbia, USA.'}, {'ForeName': 'Jamie B', 'Initials': 'JB', 'LastName': 'Smith', 'Affiliation': 'University of Missouri, Columbia, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Demiris', 'Affiliation': 'The University of Pennsylvania School of Nursing, Philadelphia, USA.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464820946927'] 531,32795144,Content Analysis: First-Time Patient User Challenges with Top-Rated Commercial Diabetes Apps.,"Background/Introduction: Using a mobile application (app) may improve diabetes self-management. However, the use of diabetes apps is low, possibly due to design and usability issues. The purpose of this study was to identify barriers to app use among adult patients with diabetes who were testing diabetes apps for the first time. Materials and Methods: We conducted a content analysis of observation notes and patient comments collected during the testing of two top commercially available diabetes apps as part of a crossover randomized trial. Participants were adult patients with type 1 or type 2 diabetes on insulin therapy. We analyzed field notes and transcriptions of audio recordings. Open coding derived categories of usability issues, which then were grouped into themes and subthemes on usability problem types. Results: A total of 92 adult Android smartphone users were recruited online (e.g., Facebook) and in-person postings. Three major themes described problems with data input, app report display and presentation, and self-learning options. Data entry modes were problematic because of overcrowded app screens, complicated ""save data"" steps, and a lack of data entry confirmation. The app icons, wording, entry headings, and analysis reports were not intuitive to understand. Participants wanted self-learning options (e.g., pop-up messages) during app use. Conclusions: Patient testing of top commercially available diabetes apps revealed key usability design issues in data entry, app report, and self-help learning options. Good app training for patients is necessary for both initial use and long-term use of diabetes apps to support self-management.",2021,Good app training for patients is necessary for both initial use and long-term use of diabetes apps to support self-management.,"['92 adult Android smartphone users were recruited online (e.g., Facebook) and in-person postings', 'adult patients with diabetes who were testing diabetes apps for the first time', 'Participants were adult patients with type 1 or type 2 diabetes on insulin therapy']",[],[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0336541', 'cui_str': 'Android'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],[],92.0,0.036659,Good app training for patients is necessary for both initial use and long-term use of diabetes apps to support self-management.,"[{'ForeName': 'Helen N C', 'Initials': 'HNC', 'LastName': 'Fu', 'Affiliation': 'Center for Aging Science and Care Innovation, School of Nursing, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Jin', 'Affiliation': 'Institute for Health Informatics, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Terrence J', 'Initials': 'TJ', 'LastName': 'Adam', 'Affiliation': 'Institute for Health Informatics, University of Minnesota, Minneapolis, Minnesota, USA.'}]",Telemedicine journal and e-health : the official journal of the American Telemedicine Association,['10.1089/tmj.2020.0128'] 532,32809075,Safety and efficacy of brilliant blue g250 (BBG) for lens capsular staining: a phase III physician-initiated multicenter clinical trial.,"PURPOSE To evaluate the safety and efficacy of BBG (Brilliant Blue G250) for lens capsular staining during cataract surgery with continuous curvilinear capsulorhexis. STUDY DESIGN Prospective clinical study. METHODS This clinical trial enrolled 30 eyes of 30 patients who underwent cataract surgery with BBG (0.25 mg/mL Brilliant Blue G250) for capsular staining. Visualization of the lens capsule and the ease of capsulorhexis with BBG staining were evaluated in five grades (grade 0 to 4) by the Independent Data Monitoring Committee and the surgeons. The safety of BBG was also evaluated in terms of ocular and systemic tolerance for 7 days after surgery. RESULTS The use of BBG improved visualization of the lens capsule and complete capsulorhexis was performed in all patients. The major endpoint (Independent Data Monitoring Committee evaluation) showed that use of BBG improved visualization of the lens capsule and the ease of capsulorhexis (grades 2 to 4); the committee's grading results were similar to those of the surgeons. Frequent complications observed in more than two eyes were conjunctival injection, corneal edema and intraocular pressure elevation. No severe complications were observed in ocular and systemic evaluations. CONCLUSION BBG staining contributed to improved visualization of the lens capsule and aided in the completion of capsulorhexis during cataract surgery. The use of BBG for capsular staining also exhibited favorable safety results.",2020,The use of BBG improved visualization of the lens capsule and complete capsulorhexis was performed in all patients.,"['cataract surgery with continuous curvilinear capsulorhexis', '30 eyes of 30 patients who underwent cataract surgery with BBG (0.25\xa0mg/mL Brilliant Blue G250) for capsular staining']","['BBG (Brilliant Blue G250', 'brilliant blue g250 (BBG']","['BBG improved visualization of the lens capsule and complete capsulorhexis', 'BBG improved visualization of the lens capsule and the ease of capsulorhexis', 'Safety and efficacy', 'severe complications', 'ocular and systemic tolerance', 'safety of BBG', 'conjunctival injection, corneal edema and intraocular pressure elevation']","[{'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0525027', 'cui_str': 'Anterior capsulorrhexis'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0772270', 'cui_str': 'Brilliant blue FCF'}, {'cui': 'C0205151', 'cui_str': 'Capsular'}, {'cui': 'C0038128', 'cui_str': 'Stain'}]","[{'cui': 'C0772270', 'cui_str': 'Brilliant blue FCF'}]","[{'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0229232', 'cui_str': 'Structure of lens capsule'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0525027', 'cui_str': 'Anterior capsulorrhexis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C1761613', 'cui_str': 'Conjunctival hyperemia'}, {'cui': 'C0010037', 'cui_str': 'Corneal edema'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}]",30.0,0.0471436,The use of BBG improved visualization of the lens capsule and complete capsulorhexis was performed in all patients.,"[{'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Hisatomi', 'Affiliation': 'Department of Ophthalmology, Chikushi Hospital, Fukuoka University, Chikushino, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Enaida', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Saga University, Saga, Japan.'}, {'ForeName': 'Shigeo', 'Initials': 'S', 'LastName': 'Yoshida', 'Affiliation': 'Department of Ophthalmology, School of Medicine, Kurume University, Kurume, Japan.'}, {'ForeName': 'Akito', 'Initials': 'A', 'LastName': 'Hirakata', 'Affiliation': 'Kyorin Eye Center, School of Medicine, Kyorin University, Mitaka, Japan.'}, {'ForeName': 'Masahito', 'Initials': 'M', 'LastName': 'Ohji', 'Affiliation': 'Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan.'}, {'ForeName': 'Kohji', 'Initials': 'K', 'LastName': 'Nishida', 'Affiliation': 'Department of Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Kubota', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Oita University, Yufu , Japan.'}, {'ForeName': 'Nahoko', 'Initials': 'N', 'LastName': 'Ogata', 'Affiliation': 'Department of Ophthalmology, Nara Medical University, Kashihara, Japan.'}, {'ForeName': 'Takaaki', 'Initials': 'T', 'LastName': 'Matsui', 'Affiliation': 'Ohshima Eye Hospital, Fukuoka, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Kimura', 'Affiliation': 'Department of Ophthalmology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.'}, {'ForeName': 'Koh-Hei', 'Initials': 'KH', 'LastName': 'Sonoda', 'Affiliation': 'Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Makiko', 'Initials': 'M', 'LastName': 'Uchiyama', 'Affiliation': 'Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Junji', 'Initials': 'J', 'LastName': 'Kishimoto', 'Affiliation': 'Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Todaka', 'Affiliation': 'Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Nakanishi', 'Affiliation': 'Kitakyushu City Hospital Organization, Kitakyushu, Japan.'}, {'ForeName': 'Tatsuro', 'Initials': 'T', 'LastName': 'Ishibashi', 'Affiliation': 'Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan. ishi@med.kyushu-u.ac.jp.'}]",Japanese journal of ophthalmology,['10.1007/s10384-020-00763-y'] 533,32826167,Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: Phase I/2 safety study.,"BACKGROUND Impaired wound healing is a major cause of morbidity in diabetic patients by causing chronic ulcers. This study aimed to investigate the safety and outcomes after intralesional allogeneic adipose-derived mesenchymal stem cells injection in chronic diabetic foot ulcers. METHODS Twenty patients (12 male and eight female) were involved in the study. We randomized the patients into two groups of 10 patients each. The study group was treated with allogeneic adipose-derived mesenchymal stem cells injection with standard diabetic wound care. The control group received only standard diabetic wound care. Patient demographics, wound characteristics, wound closure time, amputation rates and clinical scores were evaluated. RESULTS The mean age was 57.3 ± 6.6 years. The mean follow-up duration was 48.0 (range, 26-50) months. Wound closure was achieved in 17 of 20 lesions (study group, 9 lesions; control group, 8 lesions; respectively). The mean time to wound closure was 31.0 ± 10.7 (range, 22-55) days in the study group, 54.8 + 15.0 (range, 30-78) days in the control group (p = 0.002). In three patients, minor amputations were performed (one patient in study group; two patients in the control group, p = 0.531). There was a significant difference between groups in terms of postoperative Short Form 36- physical functioning (p = 0.017) and Short Form 36-general health (p = 0.010). CONCLUSION Allogeneic adipose-derived mesenchymal stem cells injection was found to be a safe and effective method with a positive contribution to wound-healing time in the treatment of chronic diabetic foot ulcers.",2021,"There was a significant difference between groups in terms of postoperative Short Form 36- physical functioning (p = 0.017) and Short Form 36-general health (p = 0.010). ","['Twenty patients (12 male and eight female', 'chronic diabetic foot ulcer', 'chronic diabetic foot ulcers', 'patients into two groups of 10 patients each', 'diabetic patients by causing chronic ulcers', 'The mean age was 57.3\u2009±\u20096.6 years']","['intralesional allogeneic adipose-derived mesenchymal stem cells injection', 'Intralesional allogeneic adipose-derived stem cells application', 'standard diabetic wound care', 'allogeneic adipose-derived mesenchymal stem cells injection with standard diabetic wound care', 'Allogeneic adipose-derived mesenchymal stem cells injection']","['Wound closure', 'Patient demographics, wound characteristics, wound closure time, amputation rates and clinical scores', 'postoperative Short Form 36- physical functioning', 'mean time to wound closure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0333297', 'cui_str': 'Chronic ulcer'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517823', 'cui_str': '6.6'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1512955', 'cui_str': 'Intralesional route'}, {'cui': 'C4704950', 'cui_str': 'Mesenchymal Stem Cells, Adipose-Derived'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4728046', 'cui_str': 'Diabetic wound'}]","[{'cui': 'C0450015', 'cui_str': 'Method of wound closure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0305358,"There was a significant difference between groups in terms of postoperative Short Form 36- physical functioning (p = 0.017) and Short Form 36-general health (p = 0.010). ","[{'ForeName': 'Erdal', 'Initials': 'E', 'LastName': 'Uzun', 'Affiliation': 'Department of Orthopedics and Traumatology, Faculty of Medicine, Erciyes University, Kayseri, Turkey. Electronic address: erdaluzun@erciyes.edu.tr.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Güney', 'Affiliation': 'Department of Orthopedics and Traumatology, Faculty of Medicine, Erciyes University, Kayseri, Turkey. Electronic address: aguney@erciyes.edu.tr.'}, {'ForeName': 'Zeynep Burçin', 'Initials': 'ZB', 'LastName': 'Gönen', 'Affiliation': 'Oral and Maxillofacial Surgery, Genome and Stem Cell Center, Erciyes University, Kayseri, Turkey. Electronic address: zburcin@gmail.com.'}, {'ForeName': 'Yusuf', 'Initials': 'Y', 'LastName': 'Özkul', 'Affiliation': 'Department of Medical Genetics, Faculty of Medicine, Erciyes University, Kayseri, Turkey. Electronic address: ozkul@erciyes.edu.t.'}, {'ForeName': 'İbrahim Halil', 'Initials': 'İH', 'LastName': 'Kafadar', 'Affiliation': 'Department of Orthopedics and Traumatology, Faculty of Medicine, Erciyes University, Kayseri, Turkey. Electronic address: ihkafadar@gmail.com.'}, {'ForeName': 'Mahmut', 'Initials': 'M', 'LastName': 'Günay', 'Affiliation': 'Department of Orthopedics and Traumatology, Kanuni Training and Research Hospital, Trabzon, Turkey. Electronic address: drmahmut106@gmail.com.'}, {'ForeName': 'Mahmut', 'Initials': 'M', 'LastName': 'Mutlu', 'Affiliation': 'Department of Orthopedics and Traumatology, Faculty of Medicine, Erciyes University, Kayseri, Turkey. Electronic address: profmahmutmutlu@gmail.com.'}]",Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons,['10.1016/j.fas.2020.08.002'] 534,32831969,Conversational Therapy through Semi-Immersive Virtual Reality Environments for Language Recovery and Psychological Well-Being in Post Stroke Aphasia.,"Aphasia is a highly disabling acquired language disorder generally caused by a left-lateralized brain damage. Even if traditional therapies have been shown to induce an adequate clinical improvement, a large percentage of patients are left with some degree of language impairments. Therefore, new approaches to common speech therapies are urgently needed in order to maximize the recovery from aphasia. The recent application of virtual reality (VR) to aphasia rehabilitation has already evidenced its usefulness in promoting a more pragmatically oriented treatment than conventional therapies (CT). In the present study, thirty-six chronic persons with aphasia (PWA) were randomly assigned to two groups. The VR group underwent conversational therapy during VR everyday life setting observation, while the control group was trained in a conventional setting without VR support. All patients were extensively tested through a neuropsychological battery which included not only measures for language skills and communication efficacy but also self-esteem and quality of life questionnairies. All patients were trained through a conversational approach by a speech therapist twice a week for six months (total 48 sessions). After the treatment, no significant differences among groups were found in the different measures. However, the amount of improvement in the different areas was distributed over far more cognitive and psychological aspects in the VR group than in the control group. Indeed, the within-group comparisons showed a significant enhancement in different language tasks (i.e., oral comprehension, repetition, and written language) only in the VR group. Significant gains, after the treatment, were also found, in the VR group, in different psychological dimensions (i.e., self-esteem and emotional and mood state). Given the importance of these aspects for aphasia recovery, we believe that our results add to previous evidence which points to the ecological validity and feasibility of VR treatment for language recovery and psychosocial well-being.",2020,"However, the amount of improvement in the different areas was distributed over far more cognitive and psychological aspects in the VR group than in the control group.",['thirty-six chronic persons with aphasia (PWA'],"['conversational therapy', 'virtual reality (VR) to aphasia rehabilitation']","['cognitive and psychological aspects', 'language skills and communication efficacy but also self-esteem and quality of life questionnairies', 'language tasks (i.e., oral comprehension, repetition, and written language', 'psychological dimensions (i.e., self-esteem and emotional and mood state']","[{'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0003537', 'cui_str': 'Aphasia'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0003537', 'cui_str': 'Aphasia'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}]",36.0,0.0168358,"However, the amount of improvement in the different areas was distributed over far more cognitive and psychological aspects in the VR group than in the control group.","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Giachero', 'Affiliation': 'Aphasia Experimental Laboratory-Fondazione Carlo Molo Onlus, Turin, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Calati', 'Affiliation': 'Aphasia Experimental Laboratory-Fondazione Carlo Molo Onlus, Turin, Italy.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Pia', 'Affiliation': 'Dipartimento di Psicologia, University of Turin, Italy.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'La Vista', 'Affiliation': 'Aphasia Experimental Laboratory-Fondazione Carlo Molo Onlus, Turin, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Molo', 'Affiliation': 'Aphasia Experimental Laboratory-Fondazione Carlo Molo Onlus, Turin, Italy.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Rugiero', 'Affiliation': 'Aphasia Experimental Laboratory-Fondazione Carlo Molo Onlus, Turin, Italy.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Fornaro', 'Affiliation': 'Aphasia Experimental Laboratory-Fondazione Carlo Molo Onlus, Turin, Italy.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Marangolo', 'Affiliation': 'Aphasia Experimental Laboratory-Fondazione Carlo Molo Onlus, Turin, Italy.'}]",Behavioural neurology,['10.1155/2020/2846046'] 535,32839253,Analgesic efficacy of infiltration between the popliteal artery and capsule of the knee (iPACK) block added to local infiltration analgesia and continuous adductor canal block after total knee arthroplasty: a randomized clinical trial.,"BACKGROUND A combination of motor-sparing analgesia with local infiltration analgesia (LIA) and continuous adductor canal block (CACB) may improve postoperative pain and functional recovery for total knee arthroplasty (TKA). We hypothesized that the addition of a novel technique for posterior knee block, known as the infiltration between the popliteal artery and capsule of the knee (iPACK) block, to LIA with CACB would reduce opioid requirements. METHODS In this double-blinded randomized controlled trial, 72 patients were assigned to receive either LIA with CACB (LIA+CACB group) or iPACK block with LIA and CACB (iPACK+LIA+CACB group). The primary outcome was cumulative postoperative intravenous morphine consumption within 24 hours. The secondary outcomes included numerical rating scale pain scores, incidence of posterior knee pain, performance test results, patient satisfaction, length of stay, and adverse events. RESULTS Morphine consumption within 24 hours postoperatively showed no significant intergroup difference (LIA+CACB; 1.31±1.85 mg vs iPACK+LIA+CACB; 0.61±1.25 mg, p=0.08). There were no clinically significant differences in the overall pain scores between the groups. The lower Timed Up and Go test scores on postoperative days 1 and 2, along with a shorter duration of hospitalization, were found in the iPACK+LIA+CACB group (p<0.05). CONCLUSION The addition of an iPACK block to the LIA and CACB does not reduce the postoperative opioid consumption nor improve analgesia. However, it may improve immediate functional performance and reduce the length of hospitalization after TKA. TRIAL REGISTRATION NUMBER TCTR20180702001.",2020,The addition of an iPACK block to the LIA and CACB does not reduce the postoperative opioid consumption nor improve analgesia.,"['total knee arthroplasty (TKA', '72 patients', 'total knee arthroplasty']","['motor-sparing analgesia with local infiltration analgesia (LIA) and continuous adductor canal block (CACB', 'local infiltration analgesia and continuous adductor canal block', 'iPACK+LIA+CACB', 'LIA with CACB (LIA+CACB group) or iPACK block with LIA and CACB (iPACK+LIA+CACB group']","['cumulative postoperative intravenous morphine consumption', 'immediate functional performance', 'postoperative opioid consumption nor improve analgesia', 'numerical rating scale pain scores, incidence of posterior knee pain, performance test results, patient satisfaction, length of stay, and adverse events', 'overall pain scores', 'Analgesic efficacy']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1843661', 'cui_str': 'Spastic Paraplegia, Ataxia, And Mental Retardation'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0225273', 'cui_str': 'Structure of adductor canal'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0032649', 'cui_str': 'Structure of popliteal artery'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",72.0,0.504575,The addition of an iPACK block to the LIA and CACB does not reduce the postoperative opioid consumption nor improve analgesia.,"[{'ForeName': 'Chutikant', 'Initials': 'C', 'LastName': 'Vichainarong', 'Affiliation': 'Anesthesiology, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Wirinaree', 'Initials': 'W', 'LastName': 'Kampitak', 'Affiliation': 'Anesthesiology, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand nutong127@yahoo.com.'}, {'ForeName': 'Aree', 'Initials': 'A', 'LastName': 'Tanavalee', 'Affiliation': 'Orthopedics, King Chulalongkorn Memorial Hospital and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Srihatach', 'Initials': 'S', 'LastName': 'Ngarmukos', 'Affiliation': 'Orthopedics, King Chulalongkorn Memorial Hospital and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Nattaporn', 'Initials': 'N', 'LastName': 'Songborassamee', 'Affiliation': 'Anesthesiology, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}]",Regional anesthesia and pain medicine,['10.1136/rapm-2020-101396'] 536,32833539,Autologous Concentrated Growth Factors Combined with Topical Minoxidil for the Treatment of Male Androgenetic Alopecia: A Randomized Controlled Clinical Trial.,"Background: Minoxidil (MXD) is an U.S. Food and Drug Administration-approved drug for the topical treatment of androgenetic alopecia (AGA) with minor side effects, but its hair growth (HG) effect is unsatisfactory. Methods: A double-blinded within-subjects randomized clinical trial was conducted on 16 male AGA patients who showed limited improvement after MXD treatment. Eligible participants received three concentrated growth factor (CGF) injections on half of the scalp and the placebo on the other side at 4-week intervals, and MXD was applied twice daily on both sides throughout the follow-up period. The primary endpoint was the HG ratio at V4. The secondary endpoints included the HG ratios at V2, V3, and V5; hair density and T/V ratio at V2, V3, V4, and V5; Global Aesthetic Improvement Scale (GAIS) scores at V4 and V5; and participant satisfaction at V4. Results: Each group included 16 subjects; each half of the scalp was randomly assigned to the MXD+CGF or MXD group. The HG ratio at V4 was higher in the MXD+CGF group than in the MXD group. The MXD+CGF group had significant improvements in hair density, HG ratio, and T/V ratio compared with the MXD group over the follow-up period. The GAIS scores and participant satisfaction were higher in the MXD+CGF group than in the MXD group. Unexpectedly, the MXD+CGF treatment hastened HG, which was sustained for 3 months after discontinuation. No severe adverse events occurred. Conclusions: The combined treatment of MXD and CGF is safe and more efficient for AGA patients. Combining CGF can expedite the potency of MXD and provide patients with fast and lasting HG.",2021,The GAIS scores and participant satisfaction were higher in the MXD+CGF group than in the MXD group.,"['Male Androgenetic Alopecia', '16 male AGA patients who showed limited improvement after MXD treatment', 'Each group included 16 subjects; each half of the scalp']","['MXD', 'MXD+CGF or MXD', 'Autologous Concentrated Growth Factors Combined with Topical Minoxidil', 'MXD+CGF', 'Minoxidil (MXD', 'concentrated growth factor (CGF) injections on half of the scalp and the placebo', 'MXD and CGF']","['HG ratio at V4', 'HG ratio', 'HG ratios at V2, V3, and V5; hair density and T/V ratio at V2, V3, V4, and V5; Global Aesthetic Improvement Scale (GAIS) scores at V4 and V5; and participant satisfaction at V4', 'GAIS scores and participant satisfaction', 'severe adverse events', 'hair density, HG ratio, and T/V ratio']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0071561', 'cui_str': 'polyethylene glycol-glutaminase-asparaginase'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0036270', 'cui_str': 'Scalp structure'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0018284', 'cui_str': 'Growth factor'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0730881', 'cui_str': 'Regaine'}, {'cui': 'C0026196', 'cui_str': 'Minoxidil'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0036270', 'cui_str': 'Scalp structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0432284', 'cui_str': 'Infantile myofibromatosis'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0674679', 'cui_str': 'NBS1 protein, human'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}]",16.0,0.0695297,The GAIS scores and participant satisfaction were higher in the MXD+CGF group than in the MXD group.,"[{'ForeName': 'Poh-Ching', 'Initials': 'PC', 'LastName': 'Tan', 'Affiliation': ""Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.""}, {'ForeName': 'Pei-Qi', 'Initials': 'PQ', 'LastName': 'Zhang', 'Affiliation': ""Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.""}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Xie', 'Affiliation': ""Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.""}, {'ForeName': 'Yi-Ming', 'Initials': 'YM', 'LastName': 'Gao', 'Affiliation': ""Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.""}, {'ForeName': 'Qing-Feng', 'Initials': 'QF', 'LastName': 'Li', 'Affiliation': ""Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.""}, {'ForeName': 'Shuang-Bai', 'Initials': 'SB', 'LastName': 'Zhou', 'Affiliation': ""Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.""}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': ""Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.""}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Liu', 'Affiliation': ""Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.""}]",Facial plastic surgery & aesthetic medicine,['10.1089/fpsam.2020.0288'] 537,32860034,Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).,"AIMS The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine. METHODS AND RESULTS In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-treatment initiation was defined as the length of time between the index MI and the initiation of study medication. The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The relationship between endpoints and various TTI (<3, 4-7 and >8 days) was examined using multivariable Cox regression models. Amongst the 4661 patients included in this analysis, there were 1193, 720, and 2748 patients, respectively, in the three TTI strata. After a median follow-up of 22.7 months, there was a significant reduction in the incidence of the primary endpoint for patients in whom colchicine was initiated < Day 3 compared with placebo [hazard ratios (HR) = 0.52, 95% confidence intervals (CI) 0.32-0.84], in contrast to patients in whom colchicine was initiated between Days 4 and 7 (HR = 0.96, 95% CI 0.53-1.75) or > Day 8 (HR = 0.82, 95% CI 0.61-1.11). The beneficial effects of early initiation of colchicine were also demonstrated for urgent hospitalization for angina requiring revascularization (HR = 0.35), all coronary revascularization (HR = 0.63), and the composite of cardiovascular death, resuscitated cardiac arrest, MI, or stroke (HR = 0.55, all P < 0.05). CONCLUSION Patients benefit from early, in-hospital initiation of colchicine after MI. TRIAL REGISTRATION COLCOT ClinicalTrials.gov number, NCT02551094.",2020,"The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization.","['4661 patients included in this analysis, there were 1193, 720, and 2748 patients, respectively, in the three TTI strata']","['colchicine or placebo', 'colchicine', 'placebo']","['composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization', 'urgent hospitalization for angina requiring revascularization', 'composite of cardiovascular death, resuscitated cardiac arrest, MI, or stroke']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517865', 'cui_str': '720'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}]","[{'cui': 'C0009262', 'cui_str': 'Colchicine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C2587207', 'cui_str': 'For resuscitation'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]",4661.0,0.451585,"The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization.","[{'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Bouabdallaoui', 'Affiliation': 'Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada and Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Jean-Claude', 'Initials': 'JC', 'LastName': 'Tardif', 'Affiliation': 'Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada and Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Waters', 'Affiliation': 'San Francisco General Hospital, California.'}, {'ForeName': 'Fausto J', 'Initials': 'FJ', 'LastName': 'Pinto', 'Affiliation': 'Santa Maria University Hospital (CHULN), CAML, CCUL, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Aldo P', 'Initials': 'AP', 'LastName': 'Maggioni', 'Affiliation': 'ANMCO Research Center, Firenze, Italy.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Diaz', 'Affiliation': 'Estudios Clinicos Latinoamerica, Rosario, Argentina.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Berry', 'Affiliation': 'University of Glasgow and NHS Glasgow Clinical Research Facility, Glasgow, UK.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Koenig', 'Affiliation': 'Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lopez-Sendon', 'Affiliation': 'H La Paz, IdiPaz, UAM, Ciber-CV Madrid, Spain.'}, {'ForeName': 'Habib', 'Initials': 'H', 'LastName': 'Gamra', 'Affiliation': 'Fattouma Bourguiba University Hospital, Monastir, Tunisia.'}, {'ForeName': 'Ghassan S', 'Initials': 'GS', 'LastName': 'Kiwan', 'Affiliation': 'Bellevue Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Blondeau', 'Affiliation': 'The Montreal Health Innovations Coordinating Center (MHICC), Montreal, Canada.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Orfanos', 'Affiliation': 'The Montreal Health Innovations Coordinating Center (MHICC), Montreal, Canada.'}, {'ForeName': 'Reda', 'Initials': 'R', 'LastName': 'Ibrahim', 'Affiliation': 'Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada and Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'Grégoire', 'Affiliation': 'Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada and Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Marie-Pierre', 'Initials': 'MP', 'LastName': 'Dubé', 'Affiliation': 'Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada and Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Samuel', 'Affiliation': 'Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada and Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Morel', 'Affiliation': 'Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Lim', 'Affiliation': 'Department of Cardiology, AP-HP, Hôpital Universitaire Henri-Mondor and INSERM U955, Université Paris-Est Créteil, Créteil, France.'}, {'ForeName': 'Olivier F', 'Initials': 'OF', 'LastName': 'Bertrand', 'Affiliation': 'Institut de Cardiologie et Pneumologie de Québec, Quebec City, Canada.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Kouz', 'Affiliation': 'Centre Hospitalier Régional de Lanaudière, Joliette, Canada.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Guertin', 'Affiliation': 'The Montreal Health Innovations Coordinating Center (MHICC), Montreal, Canada.'}, {'ForeName': 'Philippe L', 'Initials': 'PL', 'LastName': ""L'Allier"", 'Affiliation': 'Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada and Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Roubille', 'Affiliation': 'Université de Montpellier, INSERM, CNRS, CHU de Montpellier, France.'}]",European heart journal,['10.1093/eurheartj/ehaa659'] 538,32811272,No panacea? Tai Chi enhances motoric but not executive functioning in a normal aging population.,"Tai Chi Chuan (TCC) is a promising intervention against age-related decline. Though previous studies have shown benefits in motoric and cognitive domains, it is unclear how these effects are functionally related. Therefore, a randomized controlled trial was conducted in an aging population (53-85). Two measures of motor functioning - motor speed and functional balance - and three cognitive control measures - shifting, updating and inhibition - were included. The TCC condition consisted of an online 10 week 20 lessons video program of increasing level and control condition of educational videos of similar length and frequency. All analyses were done with Bayesian statistics. Counter to expectation no differences were found in cognition between TCC and control pre-to-posttest. However, there was extreme evidence for TCC benefits on functional balance and moderate evidence for increased motoric speed. After weighing the evidence and limitations of the intervention we conclude that TCC does not enhance cognitive control.",2021,Counter to expectation no differences were found in cognition between TCC and control pre-to-posttest.,['aging population (53-85'],"['Tai Chi enhances motoric', 'TCC', 'Tai Chi Chuan (TCC']","['motor functioning\xa0- motor speed and functional balance\xa0- and three cognitive control measures\xa0- shifting, updating and inhibition ']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0376403', 'cui_str': 'Tai-chi'}]","[{'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]",,0.0943107,Counter to expectation no differences were found in cognition between TCC and control pre-to-posttest.,"[{'ForeName': 'Roderik J S', 'Initials': 'RJS', 'LastName': 'Gerritsen', 'Affiliation': 'Cognitive Psychology, Institute of Psychology, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Joëlle', 'Initials': 'J', 'LastName': 'Lafeber', 'Affiliation': 'Cognitive Psychology, Institute of Psychology, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'van den Beukel', 'Affiliation': 'Cognitive Psychology, Institute of Psychology, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Guido P H', 'Initials': 'GPH', 'LastName': 'Band', 'Affiliation': 'Cognitive Psychology, Institute of Psychology, Leiden University, Leiden, The Netherlands.'}]","Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition",['10.1080/13825585.2020.1809629'] 539,33234419,The Effects of Inhalation Aromatherapy on Postoperative Abdominal Pain: A Three-Arm Randomized Controlled Clinical Trial.,"PURPOSE This study compares the effects of inhalation aromatherapy using essential oils of sweet orange and damask rose on postoperative abdominal pain. DESIGN A randomized three-arm controlled trial. METHODS In this randomized double-blinded, and parallel-group controlled trial, a total of 120 patients who underwent open abdominal surgeries were enrolled using a sequential sampling method. Participants were then randomly assigned to three groups of sweet orange, damask rose, and placebo (distilled water) using the permuted block randomization. When the patients regained full consciousness, a clean gauze impregnated with four drops of either distilled water or essential oils of sweet orange or damask rose were attached to the collar of the patients, and they were asked to inhale the aroma through normal breathing for 30 minutes. Abdominal pain severity was recorded using the visual analog scale at four time points including before the intervention (baseline) and 4, 8, and 12 hours after the intervention. FINDINGS Pain reduction after sweet orange inhalation was significantly greater than placebo (at 8 and 12 hours after the intervention) and damask rose (at 12 hours after the intervention). The differences in the mean score of pain severity between all before-and-after observations were statistically significant in the three groups, except in the placebo group between the baseline score of pain severity and the pain severity score at 4 hours after the intervention. CONCLUSIONS Inhalation aromatherapy using sweet orange seems to be more effective than the damask rose in reducing pain severity after open abdominal surgeries.",2021,Inhalation aromatherapy using sweet orange seems to be more effective than the damask rose in reducing pain severity after open abdominal surgeries.,['120 patients who underwent open abdominal surgeries'],"['inhalation aromatherapy', 'sweet orange, damask rose, and placebo', 'placebo', 'Inhalation Aromatherapy']","['Postoperative Abdominal Pain', 'pain severity', 'Pain reduction', 'visual analog scale', 'mean score of pain severity', 'pain severity and the pain severity score', 'Abdominal pain severity']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0522462', 'cui_str': 'Citrus sinensis'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C4047372', 'cui_str': 'Postoperative abdominal pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}]",120.0,0.164872,Inhalation aromatherapy using sweet orange seems to be more effective than the damask rose in reducing pain severity after open abdominal surgeries.,"[{'ForeName': 'Masoomeh', 'Initials': 'M', 'LastName': 'Noruzi Zamenjani', 'Affiliation': 'Department of Nursing, School of Nursing, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Moloud', 'Initials': 'M', 'LastName': 'Farmahini Farahani', 'Affiliation': 'Department of Nursing, School of Nursing, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Amirmohseni', 'Affiliation': 'Department of Operating Room Nursing, Behbahan Faculty of Medical Sciences, Behbahan, Iran.'}, {'ForeName': 'Yasaman', 'Initials': 'Y', 'LastName': 'Pourandish', 'Affiliation': 'Student Research Committee, Department of Nursing, School of Nursing, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Soheila', 'Initials': 'S', 'LastName': 'Shamsikhani', 'Affiliation': 'Department of Nursing, School of Nursing, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Heydari', 'Affiliation': 'Student Research Committee, Department of Pharmacy, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Harorani', 'Affiliation': 'Department of Nursing, School of Nursing, Arak University of Medical Sciences, Arak, Iran. Electronic address: m.harorani@yahoo.com.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.07.001'] 540,32843108,FAST Performance in a Stationary versus In-Motion Military Ambulance Utilizing Handheld Ultrasound: A Randomized Controlled Study.,"OBJECTIVE On-scene prehospital conditions and patient instability may warrant a during-transport ultrasound (US) exam. The objective of this study was to assess the effect of ambulance turbulence on the performance of the Focused Assessment with Sonography in Trauma (FAST) with a handheld US device. METHODS This was a randomized controlled trial in which participants were randomized to perform a FAST in either a stationary or an in-motion military ambulance. Participants were physicians and physician assistants (PAs) with previous FAST training. All exams were performed on an US phantom model. The primary outcome was FAST completion time, reported as a mean, in seconds. Secondary outcomes included image acquisition score (range of 0-24, reported as a mean), diagnostic accuracy (reported as sensitivity and specificity), and a post-participation survey with five-item Likert-type scales. RESULTS Twenty-seven participants performed 27 FASTs, 14 in the stationary ambulance and 13 in the in-motion ambulance. All participants obtained the four requisite views of the FAST. A significant difference was detected in image acquisition scores in favor of the stationary ambulance group (19.4 versus 16.7 [95% CI for difference, 0.9-4.4]; P <.01). Significant differences in survey items between groups were related to obtaining and maintaining US images and the exam conditions. There was not a difference in FAST completion time between groups (98.5 seconds versus 78.7 seconds [95% CI for difference, -13.5 seconds to 53.1 seconds]; P = .23). Sensitivity and specificity of FAST in the stationary ambulance was 85.7% (95% CI, 67.3%-96.0%) and 96.4% (95% CI, 81.7%-99.9%) versus 96.2% (95% CI, 80.4%-99.9%) and 100.0% (95% CI, 86.8%-100.0%) in the in-motion ambulance group (P = .21). CONCLUSION Vehicular motion did not affect FAST completion time and diagnostic accuracy; however, it did reduce FAST image acquisition scores. The results suggest timely and diagnostically accurate FASTs may be completed by experienced sonographers during moderate levels of ambulance turbulence. Further investigation assessing the utility and limitations of newer handheld US devices in various prehospital conditions is warranted.",2020,"There was not a difference in FAST completion time between groups (98.5 seconds versus 78.7 seconds [95% CI for difference, -13.5 seconds to 53.1 seconds]; P = .23).","['Twenty-seven participants performed 27 FASTs, 14 in the stationary ambulance and 13 in the in-motion ambulance', 'Participants were physicians and physician assistants (PAs) with previous FAST training']","['Handheld Ultrasound', 'FAST']","['FAST completion time and diagnostic accuracy', 'FAST Performance', 'image acquisition scores', 'FAST image acquisition scores', 'image acquisition score (range of 0-24, reported as a mean), diagnostic accuracy (reported as sensitivity and specificity), and a post-participation survey with five-item Likert-type scales', 'FAST completion time', 'Sensitivity and specificity of FAST']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0439835', 'cui_str': 'Stationary'}, {'cui': 'C0002422', 'cui_str': 'Ambulance'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0031833', 'cui_str': 'Physician assistant'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0036668', 'cui_str': 'Sensitivity and Specificity'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",27.0,0.167557,"There was not a difference in FAST completion time between groups (98.5 seconds versus 78.7 seconds [95% CI for difference, -13.5 seconds to 53.1 seconds]; P = .23).","[{'ForeName': 'Cecil J', 'Initials': 'CJ', 'LastName': 'Simmons', 'Affiliation': 'Department of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, WashingtonUSA.'}, {'ForeName': 'Lisa D', 'Initials': 'LD', 'LastName': 'Mack', 'Affiliation': 'Department of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, WashingtonUSA.'}, {'ForeName': 'Aaron J', 'Initials': 'AJ', 'LastName': 'Cronin', 'Affiliation': 'Department of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, WashingtonUSA.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Monti', 'Affiliation': 'Department of Clinical Investigation, Madigan Army Medical Center, Joint Base Lewis-McChord, WashingtonUSA.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Perreault', 'Affiliation': 'Department of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, WashingtonUSA.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Ahern', 'Affiliation': 'Department of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, WashingtonUSA.'}]",Prehospital and disaster medicine,['10.1017/S1049023X20001028'] 541,32851435,Introducing free response short answer questions in anatomy spot tests: experiment study.,"PURPOSE A spot test is commonly used to assess practical knowledge through a series of specific questions related to the marked anatomical structures on cadavers. However, the continuous reviewing and developing of the medical curricula demands the need to improve the assessment method of the practical examination of anatomical knowledge. Therefore, the aim of the study was to examine the effectiveness of a free response short-answer questions (FRSAQs) test and traditional questions on medical students' performance. METHODS This is an experimental study using a Randomized Posttest-Only Control Group Design to compare the mean of students' performance in addition to their perceptions about the two versions of the spot tests. Two hundred and ninety preclinical-year medical students were invited to participate in this study. RESULTS Only 109 (38%) students participated in this study. The data analysis showed a significant improvement in students' performance in the FRSAQs test (5.3 ± 2.7) than the traditional spot test (4.7 ± 2.6), (P = 0.04). The majority of the students (70%) preferred the FRSAQs spot test, citing that it is good test to assess practical knowledge. The psychometric analysis revealed that the FRSAQs produced more ideal stations (60%) when compared to the traditional spot test (10%). CONCLUSION The current study found that the FRSAQs spot test had a significant impact on students' performance, and it was considered an ideal, flexible, and stress-free assessment method when compared to the traditional spot test. Implementation of the strategy in teaching and in assessment is recommended.",2021,"The psychometric analysis revealed that the FRSAQs produced more ideal stations (60%) when compared to the traditional spot test (10%). ","[""medical students' performance"", 'Only 109 (38%) students participated in this study', 'Two hundred and ninety preclinical-year medical students']",['free response short-answer questions (FRSAQs) test and traditional questions'],[],"[{'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C5191218', 'cui_str': '290'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]",[],290.0,0.0170839,"The psychometric analysis revealed that the FRSAQs produced more ideal stations (60%) when compared to the traditional spot test (10%). ","[{'ForeName': 'Abdulrahman', 'Initials': 'A', 'LastName': 'Alraddadi', 'Affiliation': 'Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), P.O.Box.3660, Riyadh, 11481, Saudi Arabia. aalraddadi.2012@gmail.com.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Hoja', 'Affiliation': 'Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), P.O.Box.3660, Riyadh, 11481, Saudi Arabia.'}, {'ForeName': 'Haifa', 'Initials': 'H', 'LastName': 'Alhawas', 'Affiliation': 'Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), P.O.Box.3660, Riyadh, 11481, Saudi Arabia.'}, {'ForeName': 'Bader', 'Initials': 'B', 'LastName': 'Khawaji', 'Affiliation': 'King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia.'}, {'ForeName': 'Yasser', 'Initials': 'Y', 'LastName': 'Alharbi', 'Affiliation': 'King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia.'}, {'ForeName': 'Sajida', 'Initials': 'S', 'LastName': 'Agha', 'Affiliation': 'King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia.'}, {'ForeName': 'Emad', 'Initials': 'E', 'LastName': 'Masuadi', 'Affiliation': 'King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia.'}, {'ForeName': 'Mohi Eldin', 'Initials': 'ME', 'LastName': 'Magzoub', 'Affiliation': 'Department of Medical Education, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.'}]",Surgical and radiologic anatomy : SRA,['10.1007/s00276-020-02550-3'] 542,32838555,Intent-to-treat analysis of cluster randomized trials when clusters report unidentifiable outcome proportions.,"BACKGROUND Cluster randomized trials are designed to evaluate interventions at the cluster or group level. When clusters are randomized but some clusters report no or non-analyzable data, intent-to-treat analysis, the gold standard for the analysis of randomized controlled trials, can be compromised. This article presents a very flexible statistical methodology for cluster randomized trials whose outcome is a cluster-level proportion (e.g. proportion from a cluster reporting an event) in the setting where clusters report non-analyzable data (which in general could be due to nonadherence, dropout, missingness, etc.). The approach is motivated by a previously published stratified randomized controlled trial called, ""The Randomized Recruitment Intervention Trial (RECRUIT),"" designed to examine the effectiveness of a trust-based continuous quality improvement intervention on increasing minority recruitment into clinical trials (ClinicalTrials.gov Identifier: NCT01911208). METHODS The novel approach exploits the use of generalized estimating equations for cluster-level reports, such that all clusters randomized at baseline are able to be analyzed, and intervention effects are presented as risk ratios. Simulation studies under different outcome missingness scenarios and a variety of intra-cluster correlations are conducted. A comparative analysis of the method with imputation and per protocol approaches for RECRUIT is presented. RESULTS Simulation results show the novel approach produces unbiased and efficient estimates of the intervention effect that maintain the nominal type I error rate. Application to RECRUIT shows similar effect sizes when compared to the imputation and per protocol approach. CONCLUSION The article demonstrates that an innovative bivariate generalized estimating equations framework allows one to implement an intent-to-treat analysis to obtain risk ratios or odds ratios, for a variety of cluster randomized designs.",2020,"RESULTS Simulation results show the novel approach produces unbiased and efficient estimates of the intervention effect that maintain the nominal type I error rate.",[],['trust-based continuous quality improvement intervention'],[],[],"[{'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C2936612', 'cui_str': 'Quality Improvement'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.232914,"RESULTS Simulation results show the novel approach produces unbiased and efficient estimates of the intervention effect that maintain the nominal type I error rate.","[{'ForeName': 'Stacia M', 'Initials': 'SM', 'LastName': 'DeSantis', 'Affiliation': 'Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Ruosha', 'Initials': 'R', 'LastName': 'Li', 'Affiliation': 'Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Yefei', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Xueying', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Sally W', 'Initials': 'SW', 'LastName': 'Vernon', 'Affiliation': 'Department of Health Promotions and Behavioral Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Barbara C', 'Initials': 'BC', 'LastName': 'Tilley', 'Affiliation': 'Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Koch', 'Affiliation': 'Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}]","Clinical trials (London, England)",['10.1177/1740774520936668'] 543,32833482,Behavioral strategies to reduce stress reactivity in opioid use disorder: Study design.,"OBJECTIVES More than 2 million people in the United States had an opioid use disorder in 2017. Treatment for opioid use disorder-particularly medication combined with psychosocial support-is effective for reducing opioid use and decreasing overdose risk. However, approximately 50% of people who receive treatment will relapse or drop out. Stress reactivity, defined as the subjective and physiological response to stress, is heightened in people with opioid use disorder and higher stress reactivity is associated with poorer outcomes. Preliminary studies suggest that stress reactivity may be a key mechanistic target for improving outcomes. This article describes the design of an ongoing study examining behavioral strategies for reducing stress reactivity in adults with opioid use disorder. Our objective is to test the efficacy of two behavioral strategies for reducing stress reactivity and enhancing behavioral persistence in the context of stress (distress tolerance). METHOD We will recruit 120 adults with opioid use disorder and randomly assign them to brief training in (a) cognitive reappraisal, (b) affect labeling, or (c) a psychoeducational control. Participants will receive the training intervention followed by a laboratory stressor during which they will be instructed to apply the trained skill. RESULTS Subjective and physiological responses to stress will be measured as indices of stress reactivity and the stressor task will include a behavioral persistence component as a measure of distress tolerance. CONCLUSIONS The ultimate goal of this study is to inform the development of behavioral interventions that can be used as an adjunct to medication-based treatment for opioid use disorder. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Treatment for opioid use disorder-particularly medication combined with psychosocial support-is effective for reducing opioid use and decreasing overdose risk.,"['120 adults with opioid use disorder and randomly assign them to', 'adults with opioid use disorder', 'More than 2 million people in the United States had an opioid use disorder in 2017']","['training intervention followed by a laboratory stressor', 'brief training in (a) cognitive reappraisal, (b) affect labeling, or (c) a psychoeducational control']",['stress reactivity'],"[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C1881839', 'cui_str': '1000000'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]",120.0,0.0281808,Treatment for opioid use disorder-particularly medication combined with psychosocial support-is effective for reducing opioid use and decreasing overdose risk.,"[{'ForeName': 'R Kathryn', 'Initials': 'RK', 'LastName': 'McHugh', 'Affiliation': 'Division of Alcohol and Drug Abuse, McLean Hospital.'}, {'ForeName': 'Minh D', 'Initials': 'MD', 'LastName': 'Nguyen', 'Affiliation': 'Division of Alcohol and Drug Abuse, McLean Hospital.'}, {'ForeName': 'Garrett M', 'Initials': 'GM', 'LastName': 'Fitzmaurice', 'Affiliation': 'Psychiatric Biostatistics Laboratory, McLean Hospital.'}, {'ForeName': 'Daniel G', 'Initials': 'DG', 'LastName': 'Dillon', 'Affiliation': 'Center for Depression Anxiety and Stress Research, McLean Hospital.'}]","Health psychology : official journal of the Division of Health Psychology, American Psychological Association",['10.1037/hea0000862'] 544,32847980,Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).,"To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1 and 36 days post-cycle 1 from patients enrolled on Gynecologic Oncology Group 0240, the phase III randomized trial that led directly to regulatory approval of the antiangiogenesis drug, bevacizumab, in women with recurrent/metastatic cervical cancer. CTCs (defined as anti-cytokeratin + /anti-CD45 - cells) were isolated from the buffy coat layer using an anti-EpCAM antibody-conjugated ferrofluid and rare earth magnet, and counted using a semiautomated fluorescence microscope. The median pre-cycle 1 CTC count was 7 CTCs/7.5 mL whole blood (range, 0-18) and, at 36 days posttreatment, was 4 (range, 0-17). The greater the declination in CTCs between time points studied, the lower the risk of death [HR, 0.87; 95% confidence interval (CI), 0.79-0.95)]. Among patients with high (≥ median) pretreatment CTCs, bevacizumab treatment was associated with a reduction in the hazard of death (HR, 0.57; 95% CI, 0.32-1.03) and PFS (HR, 0.59; 95% CI, 0.36-0.96). This effect was not observed with low (< median) CTCs. CTCs can be isolated from women with advanced cervical cancer and may have prognostic significance. A survival benefit conferred by bevacizumab among patients with high pretreatment CTCs may reflect increased tumor neovascularization and concomitant vulnerability to VEGF inhibition. These data support studying CTC capture as a potential predictive biomarker.",2020,"The greater the declination in CTCs between time points studied, the lower the risk of death (HR 0.87; 95% CI, 0.79-0.95).","['Advanced Cervical Cancer', 'women with advanced cervical cancer', 'women with recurrent/metastatic cervical cancer']","['regulatory approval of the anti-angiogenesis drug, bevacizumab', 'bevacizumab']","['median pre-cycle 1 CTC count', 'overall survival (OS) and progression-free survival (PFS', 'risk of death', 'declination in CTCs', 'hazard of death']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0278584', 'cui_str': 'Cervix cancer metastatic'}]","[{'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0027625', 'cui_str': 'Circulating Neoplastic Cells'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.128951,"The greater the declination in CTCs between time points studied, the lower the risk of death (HR 0.87; 95% CI, 0.79-0.95).","[{'ForeName': 'Krishnansu S', 'Initials': 'KS', 'LastName': 'Tewari', 'Affiliation': 'UC Irvine Medical Center, Orange, California. ktewari@uci.edu.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Sill', 'Affiliation': 'NRG Oncology/Gynecologic Oncology Group, SUNY at Buffalo, Buffalo, New York.'}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Monk', 'Affiliation': ""University of Arizona Cancer Center and Creighton University at St. Joseph's Hospital and Medical Center, Phoenix, Arizona.""}, {'ForeName': 'Richard T', 'Initials': 'RT', 'LastName': 'Penson', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Moore', 'Affiliation': 'Franciscan St. Francis Health-Indianapolis, Indianapolis, Indiana.'}, {'ForeName': 'Heather A', 'Initials': 'HA', 'LastName': 'Lankes', 'Affiliation': 'NRG Oncology/Gynecologic Oncology Group, SUNY at Buffalo, Buffalo, New York.'}, {'ForeName': 'Lois M', 'Initials': 'LM', 'LastName': 'Ramondetta', 'Affiliation': 'MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Landrum', 'Affiliation': 'Oklahoma University Health Science Center, Oklahoma City, Oklahoma.'}, {'ForeName': 'Leslie M', 'Initials': 'LM', 'LastName': 'Randall', 'Affiliation': 'UC Irvine Medical Center, Orange, California.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Oaknin', 'Affiliation': 'Grupo Espanol de Investigacion en Cancer de Ovario (GEICO), Barcelona, Spain.'}, {'ForeName': 'Mario M', 'Initials': 'MM', 'LastName': 'Leitao', 'Affiliation': 'Memorial Sloan-Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Eric L', 'Initials': 'EL', 'LastName': 'Eisenhauer', 'Affiliation': 'University of Cincinnati, Cincinnati, Ohio.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'DiSilvestro', 'Affiliation': 'Women & Infants Hospital, Providence, Rhode Island.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Van Le', 'Affiliation': 'University of North Carolina, Chapel Hill, North Carolina.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Pearl', 'Affiliation': 'Stony Brook University Medical Center, Stony Brook, New York.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Burke', 'Affiliation': 'Southeast Cancer Control Consortium CCOP, Winston-Salem, North Carolina.'}, {'ForeName': 'Ritu', 'Initials': 'R', 'LastName': 'Salani', 'Affiliation': 'The Ohio State University Medical Center, Columbus, Ohio.'}, {'ForeName': 'Debra L', 'Initials': 'DL', 'LastName': 'Richardson', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Helen E', 'Initials': 'HE', 'LastName': 'Michael', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, Indiana.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Kindelberger', 'Affiliation': 'Boston Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Birrer', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}]",Molecular cancer therapeutics,['10.1158/1535-7163.MCT-20-0276'] 545,32865102,Preventing Functional Urinary Incontinence in Hip-Fractured Older Adults Through Patient Education: A Randomized Controlled Trial.,"The purpose of this study was to evaluate whether an educational intervention would reduce the incidence of functional urinary incontinence (UI) in older adults with a fall-related hip fracture. The project was conducted as a multicenter randomized controlled trial (RCT). A total of 109 patients that had been admitted to six hospitals in Castilla-La Mancha (Spain) for acute treatment of hip fracture, previously continent and without cognitive impairment, were enrolled and randomly assigned to the experimental group (EG) or the control group (CG). Intervention (on EG): urinary habit training (Nursing Interventions Classifications taxonomy) was performed during hospital stay (second to fourth postoperative day), with a telephonic reinforcement 10 days after discharge. The CG received routine care. Primary outcome measure: incidence of UI. Follow-up: telephone assessment 3 and 6 months after discharge (blinded evaluation). The incidence of UI at 6 months was 49% (CG) versus 25.5% (EG) (relative risk = 0.52, 95% confidence interval [0.3, 0.9]; number necessary to treat = 4). The mean of UI episodes was 0.54 (EG) versus 1.8 (CG), p = .007. The educational intervention prevents the development of UI and decreases the number of episodes in case of appearance, in a statistically significant way.",2021,"The incidence of UI at 6 months was 49% (CG) versus 25.5% (EG) (relative risk = 0.52, 95% confidence interval [0.3, 0.9]; number necessary to treat = 4).","['Hip-Fractured Older Adults Through Patient Education', 'older adults with a fall-related hip fracture', '109 patients that had been admitted to six hospitals in Castilla-La Mancha (Spain) for acute treatment of hip fracture, previously continent and without cognitive impairment']","['Intervention (on EG): urinary habit training (Nursing Interventions Classifications taxonomy', 'educational intervention', 'control group (CG']","['incidence of UI', 'Functional Urinary Incontinence', 'functional urinary incontinence (UI', ' incidence of UI', 'mean of UI episodes']","[{'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030688', 'cui_str': 'Patient education'}, {'cui': 'C1561668', 'cui_str': 'History of fall'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0429956', 'cui_str': 'Bowels: fully continent'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0262739', 'cui_str': 'Urinary habit training'}, {'cui': 'C1140130', 'cui_str': 'NIC Terminology'}, {'cui': 'C0008903', 'cui_str': 'classification'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0150042', 'cui_str': 'Functional urinary incontinence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}]",109.0,0.149612,"The incidence of UI at 6 months was 49% (CG) versus 25.5% (EG) (relative risk = 0.52, 95% confidence interval [0.3, 0.9]; number necessary to treat = 4).","[{'ForeName': 'María-Pilar', 'Initials': 'MP', 'LastName': 'Córcoles-Jiménez', 'Affiliation': 'Gerencia de Atención Integrada de Albacete, Hospital General de Albacete, Albacete, Spain.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Candel-Parra', 'Affiliation': 'Facultad de Enfermería de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.'}, {'ForeName': 'Maria-Ángeles', 'Initials': 'MÁ', 'LastName': 'Del Egido-Fernández', 'Affiliation': 'Gerencia de Atención Integrada de Albacete, Hospital General de Albacete, Albacete, Spain.'}, {'ForeName': 'Ascensión', 'Initials': 'A', 'LastName': 'Villada-Munera', 'Affiliation': 'Gerencia de Atención Integrada de Albacete, Hospital General de Albacete, Albacete, Spain.'}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'Moreno-Moreno', 'Affiliation': 'Gerencia de Atención Integrada de Albacete, Hospital General de Albacete, Albacete, Spain.'}, {'ForeName': 'Antonio-Javier', 'Initials': 'AJ', 'LastName': 'Piña-Martínez', 'Affiliation': 'Gerencia de Atención Integrada de Albacete, Hospital General de Albacete, Albacete, Spain.'}, {'ForeName': 'María-Delirio', 'Initials': 'MD', 'LastName': 'Jiménez-Sánchez', 'Affiliation': 'Gerencia de Atención Integrada de Albacete, Hospital General de Albacete, Albacete, Spain.'}, {'ForeName': 'Ramón-Jesús', 'Initials': 'RJ', 'LastName': 'Azor-García', 'Affiliation': 'Hospital General de Hellín, Albacete, Spain.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464820952608'] 546,32861484,Derivation and validation of a simple anthropometric equation to predict fat-free mass in patients with chronic hepatitis C.,"BACKGROUND Loss of skeletal muscle mass is very common in chronic liver diseases and affects 30.0-70.0% of the patients with cirrhosis. Given the relevance of muscle wasting in hepatic diseases, a practical screening tool for earlier detection of skeletal muscle mass loss is of utmost significance. AIMS To develop and validate a simple anthropometric prediction equation for fat-free mass estimation by using Bioelectrical Impedance Analysis (BIA) as a reference method in patients with chronic hepatitis C (CHC). METHODS We prospectively, included 209 CHC patients, randomly allocated into two groups, 158 patients in a development model (derivation sample) and 51 patients in a validation group (validation sample). Predictive equations were developed using backward stepwise multiple regression and the most adequate and simplest derived predictive equation was further explored for agreement and bias in the validation sample. The accuracy of the predictive equation was evaluated using the coefficient of determination (R 2 ). RESULTS The predictive equation with an optimal R 2 was Fat-Free Mass (Kg) = Sex × 0.17 + Height (m) × 16.83 + Weight (Kg) × 0.62 + Waist Circumference (cm) × (-0.15) + Weight (Kg) × Sex × (-0.30) + Sex × Waist Circumference (cm) × 0.14-6.23; where sex = 1 for female and 0 for male. R 2  = 0.93, standard error of the estimate = 2.6 Kg and coefficient of variation = 20.0%, p < 0.001. CONCLUSIONS Our developed and cross-validated anthropometric prediction equation for fat-free mass estimation by using BIA attained a high coefficient of determination, a low standard error of the estimate, and lowermost coefficient of variation. This study indicates that predictive equations may be reliable and useful alternative methods for clinical evaluation of fat-free mass in patients with CHC.",2021,This study indicates that predictive equations may be reliable and useful alternative methods for clinical evaluation of fat-free mass in patients with CHC.,"['patients with CHC', '209 CHC patients, randomly allocated into two groups, 158 patients in a development model (derivation sample) and 51 patients in a validation group (validation sample', 'patients with chronic hepatitis C (CHC', 'patients with chronic hepatitis C']",['\xa0Weight (Kg'],"['Sex', 'Waist Circumference (cm']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524910', 'cui_str': 'Chronic hepatitis C'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}]",209.0,0.0854474,This study indicates that predictive equations may be reliable and useful alternative methods for clinical evaluation of fat-free mass in patients with CHC.,"[{'ForeName': 'Kiara Gonçalves Dias', 'Initials': 'KGD', 'LastName': 'Diniz', 'Affiliation': 'Sciences Applied to Adult Health Care Post-Graduate Programme, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil; Outpatient Clinic of Viral Hepatitis, Instituto Alfa de Gastroenterologia, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.'}, {'ForeName': 'Diego Alves', 'Initials': 'DA', 'LastName': 'Vieira', 'Affiliation': 'Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.'}, {'ForeName': 'Enrico Antonio', 'Initials': 'EA', 'LastName': 'Colosimo', 'Affiliation': 'Department of Statistics, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.'}, {'ForeName': 'Marta Paula Pereira', 'Initials': 'MPP', 'LastName': 'Coelho', 'Affiliation': 'Sciences Applied to Adult Health Care Post-Graduate Programme, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil; Outpatient Clinic of Viral Hepatitis, Instituto Alfa de Gastroenterologia, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.'}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Bering', 'Affiliation': 'Outpatient Clinic of Viral Hepatitis, Instituto Alfa de Gastroenterologia, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil; Department of Food and Nutrition, Universidade Federal de Mato Grosso (UFMT), Cuiabá, Mato Grosso, Brazil.'}, {'ForeName': 'Rosangela', 'Initials': 'R', 'LastName': 'Teixeira', 'Affiliation': 'Sciences Applied to Adult Health Care Post-Graduate Programme, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil; Outpatient Clinic of Viral Hepatitis, Instituto Alfa de Gastroenterologia, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil; Department of Internal Medicine, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.'}, {'ForeName': 'Maria Isabel Toulson Davidson', 'Initials': 'MITD', 'LastName': 'Correia', 'Affiliation': 'Department of Surgery, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.'}, {'ForeName': 'Gifone Aguiar', 'Initials': 'GA', 'LastName': 'Rocha', 'Affiliation': 'Laboratory of Research in Bacteriology, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.'}, {'ForeName': 'Luciana Diniz', 'Initials': 'LD', 'LastName': 'Silva', 'Affiliation': 'Sciences Applied to Adult Health Care Post-Graduate Programme, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil; Outpatient Clinic of Viral Hepatitis, Instituto Alfa de Gastroenterologia, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil; Department of Internal Medicine, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil. Electronic address: lucianadiniz@medicina.ufmg.br.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.011'] 547,32876714,Pre-emptive digitally guided pudendal block after posterior vaginal repair.,"INTRODUCTION AND HYPOTHESIS The aim of this study was to establish if digitally guided pre-emptive pudendal block (PDB) reduces postoperative pain and facilitates recovery after posterior vaginal repair under local anesthesia and sedation. METHODS We carried out a prospective, randomized, double-blind trial in an outpatient surgery facility. Forty-one women between 18 and 70 years of age, scheduled for primary posterior vaginal reconstructive outpatient surgery, completed the study. The surgery was performed using sedation and local anesthesia with bupivacaine/adrenaline. At the end of surgery, 20 ml of either ropivacaine 7.5 mg/ml or sodium chloride (placebo) was administered as a digitally guided PDB. The primary aim was to establish if PDB with ropivacaine compared with placebo reduced the maximal pain as reported by visual analog scale (VAS) during the first 24 h after surgery. Secondary aims were to compare the duration and experience of the hospital stay, nausea, need for additional opioids, and adverse events. RESULTS PDB with ropivacaine after local infiltration with bupivacaine/adrenaline after outpatient posterior repair did not significantly reduce maximal postoperative pain, need for hospital admittance, nausea, or opioid use. Mild transient sensory loss occurred after ropivacaine in two women. Two women the placebo group were unable to void owing to severe postoperative pain, which was resolved by a rescue PDB. CONCLUSIONS When bupivacaine/adrenaline is used for anesthesia in posterior vaginal repair, PDB with ropivacaine gives no benefit regarding postoperative pain, recovery or length of hospital stay. Rescue PDB can be useful for postoperative pain relief.",2021,Mild transient sensory loss occurred after ropivacaine in two women.,"['Forty-one women between 18 and 70\xa0years of age, scheduled for primary posterior vaginal reconstructive outpatient surgery, completed the study']","['digitally guided pre-emptive pudendal block (PDB', 'bupivacaine/adrenaline', 'ropivacaine', 'Pre-emptive digitally guided pudendal block after posterior vaginal repair', 'placebo', 'ropivacaine 7.5\xa0mg/ml or sodium chloride (placebo']","['postoperative pain relief', 'severe postoperative pain', 'visual analog scale (VAS', 'maximal postoperative pain, need for hospital admittance, nausea, or opioid use', 'maximal pain', 'Mild transient sensory loss', 'duration and experience of the hospital stay, nausea, need for additional opioids, and adverse events', 'postoperative pain, recovery or length of hospital stay']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0002428', 'cui_str': 'Ambulatory surgery'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0948498', 'cui_str': 'Pudendal block'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C1288276', 'cui_str': 'Vaginoplasty'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}]","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0278134', 'cui_str': 'Absence of sensation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",41.0,0.554543,Mild transient sensory loss occurred after ropivacaine in two women.,"[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Uustal', 'Affiliation': 'Department of Obstetrics and Gynecology, and Department of Clinical and Experimental Medicine, Linköping University, 581 85, Linköping, Sweden. Eva.uustal@gmail.com.'}]",International urogynecology journal,['10.1007/s00192-020-04488-x'] 548,32876858,"Preventive Effects of Qingfei Yihuo Capsules () on Air Pollution Associated Exacerbation of Chronic Obstructive Pulmonary Disease: A Single-blind, Randomized, Controlled Trial.","OBJECTIVE To investigate the efficacy of Qingfei Yihuo Capsules (, QYCs) in preventing the air pollution associated exacerbation of chronic obstructive pulmonary disease (COPD). METHODS This was a prospective, parallel, single-blind, randomized, placebo-controlled trial. Sixty patients with stable Group D COPD were randomly allocated to receive either oral QYCs (intervention group) or placebos (control group, 30 cases per group) for 15 days in the presumed high-incidence air pollution season and followed-up for 1 year. Both groups were given individualized Western medicine therapy according to the Global Initiative for Chronic Obstructive Lung Disease criteria as usual. Total and separate numbers of acute exacerbation (AE) associated with striking air pollution was the primary outcomes. Secondary outcomes included total numbers of deteriorating respiratory symptoms and separate numbers associated with striking air pollution, as well as scores of COPD Assessment Test (CAT) and modified Medical Research Council Scale (mMRC). RESULTS All the 60 patients completed the study. There was no statistical significance in total numbers of AE between the two groups (P>0.05). Compared with the control group, a significant reduction in air-pollution associated numbers of deteriorated respiratory symptoms was observed in the intervention group (1.9-1.2 vs. 3.6-2.4, P<0.01). At the end of follow-up, there was no significant difference in CAT and mMRC scores between the two groups (P>0.05). Only 2 patients in the intervention group reported diarrhea and recovered after drug discontinuance. CONCLUSION For patients with Group D COPD, oral QYCs in high-incidence season of air pollution can effectively mitigate respiratory symptoms associated with air pollution, although there was no evidence that it had a significant reductive effect on AEs. (Registered at Chinese Clinical Trial Registry, registration No. ChiCTR-IOR-17013827).",2020,"At the end of follow-up, there was no significant difference in CAT and mMRC scores between the two groups (P>0.05).","['chronic obstructive pulmonary disease (COPD', 'Chronic Obstructive Pulmonary Disease', 'Sixty patients with stable Group D COPD', '60 patients completed the study']","['Qingfei Yihuo Capsules (, QYCs', 'oral QYCs (intervention group) or placebos (control group, 30 cases per group) for 15 days in the presumed high-incidence air pollution season and followed-up for 1 year', 'Qingfei Yihuo Capsules ', 'individualized Western medicine therapy', 'placebo']","['diarrhea', 'total numbers of deteriorating respiratory symptoms and separate numbers associated with striking air pollution, as well as scores of COPD Assessment Test (CAT) and modified Medical Research Council Scale (mMRC', 'air-pollution associated numbers of deteriorated respiratory symptoms', 'total numbers of AE', 'CAT and mMRC scores']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0441838', 'cui_str': 'Group D'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0001873', 'cui_str': 'Air pollution'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0038452', 'cui_str': 'Employee Strikes'}, {'cui': 'C0001873', 'cui_str': 'Air pollution'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4284282', 'cui_str': 'COPD assessment test'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]",60.0,0.21995,"At the end of follow-up, there was no significant difference in CAT and mMRC scores between the two groups (P>0.05).","[{'ForeName': 'Wei-Ping', 'Initials': 'WP', 'LastName': 'Hu', 'Affiliation': 'Department of Pulmonary Medicine, Zhongshan Hospital of Fudan University, Shanghai, 200032, China.'}, {'ForeName': 'Xiao-Dan', 'Initials': 'XD', 'LastName': 'Wu', 'Affiliation': 'Department of Pulmonary Medicine, Zhongshan Hospital of Fudan University, Shanghai, 200032, China.'}, {'ForeName': 'Zhuo-Zhe', 'Initials': 'ZZ', 'LastName': 'Li', 'Affiliation': 'Department of Pulmonary Medicine, Zhongshan Hospital of Fudan University, Shanghai, 200032, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Pulmonary Medicine, Zhongshan Hospital of Fudan University, Shanghai, 200032, China. huxizhangjing@foxmail.com.'}]",Chinese journal of integrative medicine,['10.1007/s11655-020-3321-2'] 549,32870478,Efficacy of Chinese Medicine Acupoint Application Combined with Montelukast on Children with Perennial Allergic Rhinitis: A Randomized Controlled Trial.,"OBJECTIVE To evaluate the efficacy of Chinese medicine acupoint application (CMAA) combined with Western medicine for perennial allergic rhinitis (PAR) in children. METHODS In this prospective, parallel, randomized, placebo-controlled and single-blind trial from August to September, 2017, 180 children with PAR were randomly assigned to an integrative group (CMAA and Montelukast), CMAA group (CMAA and placebo tablet), or Montelukast group (placebo CMAA and Montelukast). Participants were applied with CMAA for 6 sessions over 2 weeks, and/or Montelukast Chewable Tablet orally once daily for 12 weeks. The changes in severity of symptoms were measured by Visual Analog Scale (VAS) and rhinitis control assessment test (RCAT) at 0, 2, 4 and 12 weeks of treatment. Blood samples were collected for serum interleukin-4, interferon gamma γ and T helper type 1 (Th1)/Th2 flow cytometric analysis at the time points of 0, 4 and 12 weeks. RESULTS Eight cases dropped out from the trial, 3 in the integrative group, 2 in the CMAA group and 3 in the Montelukast group. The VAS scores decreased significantly while the RCAT scores increased significantly in all three groups at 4 and 12 weeks compared with baseline (P<0.01 or P<0.05). The VAS scores were significantly lower while the RCAT scores were significantly higher in the integrative and CMAA groups than the Montelukast group at 2 and 4 weeks (P<0.01 or P<0.05). At 2, 4 and 12 weeks, the scores of nasal congestion, sneezing, sleep problem, and rhinitis symptom control in the integrative and CMAA groups increased significantly compared with baseline (P<0.01 or P<0.05). The least percentages of Th2 and the most alleviated Th2 shift (highest Th1/Th2) were observed in the integrative group at 12 weeks compared with the other two groups (P<0.05). CONCLUSION The combination of CMAA with Montelukast might be more effective and appropriate than either option alone for children with PAR. (Registered at Chinese Clinical Trial Register, registration No. ChiCTR-IOR-17012434).",2020,The VAS scores decreased significantly while the RCAT scores increased significantly in all three groups at 4 and 12 weeks compared with baseline (P<0.01 or P<0.05).,"['perennial allergic rhinitis (PAR) in children', 'August to September, 2017, 180 children with PAR', 'Children with Perennial Allergic Rhinitis', 'children with PAR']","['integrative group (CMAA and Montelukast), CMAA group (CMAA and placebo tablet), or Montelukast group (placebo CMAA and Montelukast', 'Montelukast', 'CMAA with Montelukast', 'Chinese medicine acupoint application (CMAA) combined with Western medicine', 'CMAA', 'placebo', 'Chinese Medicine Acupoint Application Combined with Montelukast']","['VAS scores', 'RCAT scores', 'serum interleukin-4, interferon gamma γ and T helper type 1 (Th1)/Th2 flow cytometric analysis', 'Visual Analog Scale (VAS) and rhinitis control assessment test (RCAT', 'scores of nasal congestion, sneezing, sleep problem, and rhinitis symptom control']","[{'cui': 'C0035457', 'cui_str': 'Perennial allergic rhinitis'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4319557', 'cui_str': '180'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0298130', 'cui_str': 'montelukast'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0021745', 'cui_str': 'Interferon Type II'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0027424', 'cui_str': 'Nasal congestion'}, {'cui': 'C0037383', 'cui_str': 'Sneezing'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}, {'cui': 'C1274136', 'cui_str': 'Symptom control'}]",180.0,0.0700816,The VAS scores decreased significantly while the RCAT scores increased significantly in all three groups at 4 and 12 weeks compared with baseline (P<0.01 or P<0.05).,"[{'ForeName': 'You-Jin', 'Initials': 'YJ', 'LastName': 'Li', 'Affiliation': ""Department of Otorhinolaryngology-Head and Neck Surgery, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Zong', 'Affiliation': 'Department of Clinical Laboratory, Shanghai East Hospital, School of Medicine, Tong Ji University, Shanghai, 200120, China.'}, {'ForeName': 'Li-Feng', 'Initials': 'LF', 'LastName': 'Ding', 'Affiliation': ""Department of Chinese Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Xiao-Qing', 'Initials': 'XQ', 'LastName': 'Rui', 'Affiliation': ""Department of Otorhinolaryngology-Head and Neck Surgery, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Bei-Yin', 'Initials': 'BY', 'LastName': 'Ma', 'Affiliation': ""Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Li-Ping', 'Initials': 'LP', 'LastName': 'Qin', 'Affiliation': 'Department of Chinese Medicine, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200090, China. bbb___123@126.com.'}]",Chinese journal of integrative medicine,['10.1007/s11655-020-3099-2'] 550,32876962,Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy.,"BACKGROUND AND PURPOSE High peak serum immunoglobulin G (IgG) levels may not be needed for maintenance intravenous immunoglobulin (IVIg) treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and such high levels may cause side effects. More frequent lower dosing may lead to more stable IgG levels and higher trough levels, which might improve efficacy. The aim of this trial is to investigate whether high frequent low dosage IVIg treatment is more effective than low frequent high dosage IVIg treatment. METHODS In this randomized placebo-controlled crossover trial, we included patients with CIDP proven to be IVIg-dependent and receiving an individually established stable dose and interval of IVIg maintenance treatment. In the control arm, patients received their individual IVIg dose and interval followed by a placebo infusion at half the interval. In the intervention arm, patients received half their individual dose at half the interval. After a wash-out phase patients crossed over. The primary outcome measure was handgrip strength (assessed using a Martin Vigorimeter). Secondary outcome indicators were health-related quality of life (36-item Short-Form Health Survey), disability (Inflammatory Rasch-built Overall Disability Scale), fatigue (Rasch-built Fatigue Severity Scale) and side effects. RESULTS Twenty-five patients were included and were treated at baseline with individually adjusted dosages of IVIg ranging from 20 to 80 g and intervals ranging from 14 to 35 days. Three participants did not complete the trial; the main analysis was therefore based on the 22 patients completing both treatment periods. There was no significant difference in handgrip strength change from baseline between the two treatment regimens (coefficient -2.71, 95% CI -5.4, 0.01). Furthermore, there were no significant differences in any of the secondary outcomes or side effects. CONCLUSIONS More frequent lower dosing does not further improve the efficacy of IVIg in stable IVIg-dependent CIDP and does not result in fewer side effects.",2021,"There was no significant difference in Vigorimeter change from baseline between the two treatment regimens (coefficient -2.71, 95% CI -5.4, 0.01).","['Twenty-five patients were included and were treated at baseline with individual adjusted dosages of IVIg ranging from 20-80 grams and intervals ranging from 14-35 days', 'CIDP patients proven to be IVIg dependent and receiving an individually established stable dose and interval of IVIg maintenance treatment', 'chronic inflammatory demyelinating polradiculoneuropathy']","['intravenous immunoglobulin maintenance', 'placebo']","['hand grip strength (Vigorimeter', 'side effects', 'Vigorimeter change', 'health related quality of life (SF-36), disability (I-RODS), fatigue (R-FSS) and side-effects']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0032587', 'cui_str': 'Polyradiculoneuropathy'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0265224', 'cui_str': 'Freeman-Sheldon syndrome'}]",25.0,0.427833,"There was no significant difference in Vigorimeter change from baseline between the two treatment regimens (coefficient -2.71, 95% CI -5.4, 0.01).","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kuitwaard', 'Affiliation': 'Department of Neurology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Brusse', 'Affiliation': 'Department of Neurology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'B C', 'Initials': 'BC', 'LastName': 'Jacobs', 'Affiliation': 'Department of Neurology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'A F J E', 'Initials': 'AFJE', 'LastName': 'Vrancken', 'Affiliation': 'Department of Neurology, Brain Centre Rudolf Magnus University Medical Centre Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Eftimov', 'Affiliation': 'Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'N C', 'Initials': 'NC', 'LastName': 'Notermans', 'Affiliation': 'Department of Neurology, Brain Centre Rudolf Magnus University Medical Centre Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'van der Kooi', 'Affiliation': 'Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'W-J R', 'Initials': 'WR', 'LastName': 'Fokkink', 'Affiliation': 'Department of Neurology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Nieboer', 'Affiliation': 'Department of Public Health, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'H F', 'Initials': 'HF', 'LastName': 'Lingsma', 'Affiliation': 'Department of Public Health, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'I S J', 'Initials': 'ISJ', 'LastName': 'Merkies', 'Affiliation': 'Department of Neurology, Curaçao Medical Centre Willemstad, Willemstad, Curaçao.'}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'van Doorn', 'Affiliation': 'Department of Neurology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.'}]",European journal of neurology,['10.1111/ene.14501'] 551,32873572,Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.,"PURPOSE Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc analysis of the phase III CheckMate 214 trial analyzed the efficacy of nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib in patients with sRCC. PATIENTS AND METHODS Patients with sRCC were identified via independent central pathology review of archival tumor tissue or histologic classification per local pathology report. Patients were randomized 1:1 to receive nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks (four doses) then nivolumab 3 mg/kg every 2 weeks, or sunitinib 50 mg orally every day (4 weeks; 6-week cycles). Outcomes in patients with sRCC were not prespecified. Endpoints in patients with sRCC and International Metastatic Renal Cell Carcinoma Database Consortium intermediate/poor-risk disease included overall survival (OS), progression-free survival (PFS) per independent radiology review, and objective response rate (ORR) per RECIST v1.1. Safety outcomes used descriptive statistics. RESULTS Of 1,096 randomized patients in CheckMate 214, 139 patients with sRCC and intermediate/poor-risk disease and six with favorable-risk disease were identified. With 42 months' minimum follow-up in patients with sRCC and intermediate/poor-risk disease, median OS [95% confidence interval (CI)] favored NIVO+IPI [not reached (NR) (25.2-not estimable [NE]); n = 74] versus sunitinib [14.2 months (9.3-22.9); n = 65; HR, 0.45 (95% CI, 0.3-0.7; P = 0.0004)]; PFS benefits with NIVO+IPI were similarly observed [median 26.5 vs. 5.1 months; HR, 0.54 (95% CI, 0.33-0.86; P = 0.0093)]. Confirmed ORR was 60.8% with NIVO+IPI versus 23.1% with sunitinib, with complete response rates of 18.9% versus 3.1%, respectively. No new safety signals emerged. CONCLUSIONS NIVO+IPI showed unprecedented long-term survival, response, and complete response benefits versus sunitinib in previously untreated patients with sRCC and intermediate/poor-risk disease, supporting the use of first-line NIVO+IPI for this population. See related commentary by Hwang et al., p. 5 .",2021,"CONCLUSIONS NIVO+IPI showed unprecedented long-term survival, response and complete response benefits versus SUN in previously untreated patients with sRCC and intermediate/poor-risk disease, supporting the use of first-line NIVO+IPI for this population.","['patients with sRCC', 'Patients with Advanced Sarcomatoid Renal Cell Carcinoma', 'patients with sRCC and IMDC intermediate/poor-risk disease included', '139 patients with sRCC and intermediate/poor-risk disease and six with favorable-risk disease', 'Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC', '1096 randomized patients in CheckMate 214', 'Patients with sRCC were identified via independent central pathology review of archival tumor tissue or histological classification per local pathology report']","['Nivolumab Plus Ipilimumab', 'NIVO 3 mg/kg Q2W, or SUN 50 mg orally QD', 'nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN', 'NIVO (3 mg/kg) plus IPI']","['overall survival (OS), progression-free survival (PFS) per independent radiology review, and objective response rate (ORR', 'complete response rates', 'ORR', 'intermediate/poor-risk disease, median OS', 'Efficacy and Safety', 'long-term survival, response and complete response benefits versus SUN', 'PFS benefits with NIVO+IPI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1266043', 'cui_str': 'Renal cell carcinoma, sarcomatoid'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0699752', 'cui_str': 'Review of'}, {'cui': 'C0475358', 'cui_str': 'Tumor tissue sample'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0807321', 'cui_str': 'Pathology report'}]","[{'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C1696717', 'cui_str': 'sunitinib 50 MG [Sutent]'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}, {'cui': 'C0668760', 'cui_str': 'diinosine pentaphosphate'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0034599', 'cui_str': 'Radiology - specialty'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}]",1096.0,0.0627441,"CONCLUSIONS NIVO+IPI showed unprecedented long-term survival, response and complete response benefits versus SUN in previously untreated patients with sRCC and intermediate/poor-risk disease, supporting the use of first-line NIVO+IPI for this population.","[{'ForeName': 'Nizar M', 'Initials': 'NM', 'LastName': 'Tannir', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. ntannir@mdanderson.org.'}, {'ForeName': 'Sabina', 'Initials': 'S', 'LastName': 'Signoretti', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Toni K', 'Initials': 'TK', 'LastName': 'Choueiri', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'David F', 'Initials': 'DF', 'LastName': 'McDermott', 'Affiliation': 'Division of Medical Oncology, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Motzer', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Abdallah', 'Initials': 'A', 'LastName': 'Flaifel', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Jean-Christophe', 'Initials': 'JC', 'LastName': 'Pignon', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Ficial', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Osvaldo Arén', 'Initials': 'OA', 'LastName': 'Frontera', 'Affiliation': 'Centro de Investigación Clínica Bradford Hill, Recoleta, Chile.'}, {'ForeName': 'Saby', 'Initials': 'S', 'LastName': 'George', 'Affiliation': 'Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Powles', 'Affiliation': 'Department of Urology, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom.'}, {'ForeName': 'Frede', 'Initials': 'F', 'LastName': 'Donskov', 'Affiliation': 'Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Harrison', 'Affiliation': 'Department of Medicine, Duke Cancer Institute, Durham, North Carolina.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Barthélémy', 'Affiliation': 'Medical Oncology Unit, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.'}, {'ForeName': 'Scott S', 'Initials': 'SS', 'LastName': 'Tykodi', 'Affiliation': 'Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Kocsis', 'Affiliation': 'Oncology Department, Debrecen University Clinical Center, Debrecen, Hungary.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Ravaud', 'Affiliation': 'Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.'}, {'ForeName': 'Jeronimo R', 'Initials': 'JR', 'LastName': 'Rodriguez-Cid', 'Affiliation': 'Centro Oncológico, Hospital Médica Sur, Mexico City, Mexico.'}, {'ForeName': 'Sumanta K', 'Initials': 'SK', 'LastName': 'Pal', 'Affiliation': 'Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California.'}, {'ForeName': 'Andre M', 'Initials': 'AM', 'LastName': 'Murad', 'Affiliation': 'CENANTRON-PERSONAL-Precision Oncology, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Ishii', 'Affiliation': 'Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey.'}, {'ForeName': 'Shruti Shally', 'Initials': 'SS', 'LastName': 'Saggi', 'Affiliation': 'Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey.'}, {'ForeName': 'M Brent', 'Initials': 'MB', 'LastName': 'McHenry', 'Affiliation': 'Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey.'}, {'ForeName': 'Brian I', 'Initials': 'BI', 'LastName': 'Rini', 'Affiliation': 'Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-2063'] 552,32718997,A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.,"PURPOSE This study reports the MTD, recommended phase 2 dose (RP2D), and preliminary efficacy of alpelisib or buparlisib used in combination with tamoxifen plus goserelin in premenopausal patients with hormone receptor-positive (HR + ), HER2-negative (HER2 - ) advanced breast cancer (ABC). PATIENTS AND METHODS This study enrolled premenopausal women with HR + , HER2 - ABC. Patients received tamoxifen (20 mg once daily) and goserelin acetate (3.6 mg every 28 days) with either alpelisib (350 mg once daily; n = 16) or buparlisib (100 mg once daily; n = 13) in 28-day cycles until MTD was observed. RESULTS The criteria for MTD were not met for both alpelisib and buparlisib. The RP2D of alpelisib and buparlisib in combination with tamoxifen and goserelin were 350 mg and 100 mg, respectively. Both combinations met protocol-specified criteria for tolerability. The most common grade 3/4 treatment-emergent adverse events (TEAE) were hypokalemia (12.5%), hyperglycemia (6.3%), and rash (6.3%) for alpelisib and alanine aminotransferase increase (30.8%), aspartate aminotransferase increase (23.1%), and anxiety (15.4%) for buparlisib. TEAEs led to treatment discontinuation in 18.8% and 53.8% of alpelisib- and buparlisib-treated patients, respectively. Progression-free survival was 25.2 months in the alpelisib group and 20.6 months in the buparlisib group. CONCLUSIONS The RP2Ds of alpelisib and buparlisib were 350 mg and 100 mg, respectively. No unexpected safety findings were reported. Although an early-phase study, data suggest that alpelisib plus endocrine therapy may be a potentially efficacious treatment that warrants further evaluation for premenopausal patients with HR + , HER2 - ABC. See related commentary by Clark et al., p. 371 .",2021,"Progression-free survival was 25.2 months in the alpelisib group and 20.6 months in the buparlisib group. ","['premenopausal patients with HR + , HER2 - ABC', 'premenopausal patients with hormone receptor-positive (HR + ), HER2-negative (HER2 - ) advanced breast cancer (ABC', 'Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer', 'enrolled premenopausal women with HR + , HER2 - ABC']","['alpelisib plus endocrine therapy', 'goserelin acetate', 'tamoxifen and goserelin', 'tamoxifen', 'buparlisib', 'tamoxifen plus goserelin', 'alpelisib', 'Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin']","['aspartate aminotransferase increase', 'Progression-free survival', 'rash', 'hyperglycemia', 'hypokalemia', 'alpelisib and alanine aminotransferase increase', 'anxiety']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0152244', 'cui_str': 'Aneurysmal bone cyst'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C4055478', 'cui_str': 'alpelisib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0700476', 'cui_str': 'Goserelin acetate'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}, {'cui': 'C0120107', 'cui_str': 'Goserelin'}]","[{'cui': 'C0151904', 'cui_str': 'Aspartate aminotransferase increased'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0020621', 'cui_str': 'Hypokalemia'}, {'cui': 'C4055478', 'cui_str': 'alpelisib'}, {'cui': 'C0151905', 'cui_str': 'Alanine aminotransferase increased'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.0460708,"Progression-free survival was 25.2 months in the alpelisib group and 20.6 months in the buparlisib group. ","[{'ForeName': 'Yen-Shen', 'Initials': 'YS', 'LastName': 'Lu', 'Affiliation': 'Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Keun Seok', 'Initials': 'KS', 'LastName': 'Lee', 'Affiliation': 'Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea.'}, {'ForeName': 'Tsu-Yi', 'Initials': 'TY', 'LastName': 'Chao', 'Affiliation': 'Division of Hematology/Oncology, Shuang Ho Hospital and Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan.'}, {'ForeName': 'Ling-Ming', 'Initials': 'LM', 'LastName': 'Tseng', 'Affiliation': 'Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Imjai', 'Initials': 'I', 'LastName': 'Chitapanarux', 'Affiliation': 'Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Shin-Cheh', 'Initials': 'SC', 'LastName': 'Chen', 'Affiliation': 'Breast Surgery Division, Chang Gung Memorial Hospital, Linkou, Taoyouan City, Taiwan.'}, {'ForeName': 'Chien-Ting', 'Initials': 'CT', 'LastName': 'Liu', 'Affiliation': 'Division of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan.'}, {'ForeName': 'Joohyuk', 'Initials': 'J', 'LastName': 'Sohn', 'Affiliation': 'Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea.'}, {'ForeName': 'Jee Hyun', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.'}, {'ForeName': 'Yuan-Ching', 'Initials': 'YC', 'LastName': 'Chang', 'Affiliation': 'Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan.'}, {'ForeName': 'Youngsen', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Taichung Veterans General Hospital, Taichung, Taiwan.'}, {'ForeName': 'Kanjana', 'Initials': 'K', 'LastName': 'Shotelersuk', 'Affiliation': 'Division of Therapeutic Radiology and Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Kyung Hae', 'Initials': 'KH', 'LastName': 'Jung', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Valenti', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'Slader', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Gao', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Yeon Hee', 'Initials': 'YH', 'LastName': 'Park', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea. yhparkhmo@skku.edu.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-1008'] 553,32891506,"[Single, immediate postoperative intra-vesical instillation (SI) compared to a single preoperative intra-vesical instillation of mitomycin C in non-muscle invasive bladder cancer (NMIBC). Phase II randomized trial].","OBJECTIVE A single immediate instillation of mitomycin C is recommended after a complete transurethral resection of the bladder (TURB) in low- and intermediate-risk patients with NMIBC. Actually, post-TURB instillation is seldom used due to logistical difficulties and surgical contraindications. Our aim was to compare patients with single pre-TURB intra-vesical instillation and patients with a single, immediate post-TURB intra-vesical instillation of mitomycin C. METHODS We performed a multicenter randomized trial between February 17, 2014 and November 24, 2016 (registration number 2012-004341-32). Sixty patients with two or less, primary or recurrent papillary bladder tumors and a negative urinary cytology were planned. Cystoscopy was performed at 3, 6 and 12 months after TURB. Our primary endpoint was disease-free interval. Secondary endpoints were recurrence rate at 3 and 12 months, rate of patients in whom instillation could not be performed and tolerance 1 month after TURB using BCI-Fr score. RESULTS Among 35 eligible participants, 20 were randomly assigned in the pre-TURB instillation group and 15 in the post-TURB instillation group. Follow-up was comparable: 12,3±1,6 months in the SI group and 10,2±4,5 months in the pre-TURB instillation group. In the post-TURB instillation group, 2 patients didn't have any instillation. We did not identify significant differences in disease-free interval. Tolerance at 1 month after TURB was similar in both groups. CONCLUSION Tolerance and efficacy were not significantly different. As expected, logisitics were easier for the health providers in the pre-TURB group where all patients had their instillation conversely to the post-TURB group. These results suggest that the advantages of a single immediate pre-TURB instillation warrant further evaluation of this strategy in a phase III randomized trial.",2021,"Secondary endpoints were recurrence rate at 3 and 12 months, rate of patients in whom instillation could not be performed and tolerance 1 month after TURB using BCI-Fr score. ","['February 17, 2014 and November 24, 2016 (registration number 2012-004341-32', 'Sixty patients with two or less, primary or recurrent papillary bladder tumors and a negative urinary cytology were planned', 'patients with single pre-TURB intra-vesical instillation and patients with a single, immediate post-TURB intra-vesical instillation of', 'low- and intermediate-risk patients with NMIBC', 'non-muscle invasive bladder cancer (NMIBC', '35 eligible participants']","['immediate postoperative intra-vesical instillation (SI', 'TURB instillation group and 15 in the post-TURB instillation', 'mitomycin C']","['recurrence rate', 'disease-free interval', 'Tolerance']","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0205312', 'cui_str': 'Papillary'}, {'cui': 'C0005695', 'cui_str': 'Neoplasm of bladder'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0010818', 'cui_str': 'Cytology'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0184959', 'cui_str': 'Instillation'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0184959', 'cui_str': 'Instillation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}]",60.0,0.0804939,"Secondary endpoints were recurrence rate at 3 and 12 months, rate of patients in whom instillation could not be performed and tolerance 1 month after TURB using BCI-Fr score. ","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Breton', 'Affiliation': ""Service d'urologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France. Electronic address: jbreto200e@gmail.com.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bernardeau', 'Affiliation': ""Service d'urologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Vallée', 'Affiliation': ""Service d'urologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Pillot', 'Affiliation': ""Service d'urologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lebacle', 'Affiliation': ""Service d'urologie, hôpital Bicêtre AP-HP, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France.""}, {'ForeName': 'P-O', 'Initials': 'PO', 'LastName': 'Delpech', 'Affiliation': ""Service d'urologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France.""}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Charles', 'Affiliation': ""Service d'urologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Biscans', 'Affiliation': ""Service d'urologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Vallat', 'Affiliation': ""Service d'urologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Pfister', 'Affiliation': ""Service d'urologie, CHU de Rouen, 37, boulevard Gambetta, 76000 Rouen, France.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Irani', 'Affiliation': ""Service d'urologie, hôpital Bicêtre AP-HP, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France.""}]",Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,['10.1016/j.purol.2020.07.245'] 554,32894227,Culprit lesion location and outcomes in patients with multivessel disease and infarct-related cardiogenic shock: a core laboratory analysis of the CULPRIT-SHOCK trial.,"BACKGROUND Critical culprit lesion locations (CCLL) such as left main (LM) and proximal left anterior descending (LAD) are associated with worse clinical outcome in myocardial infarction without cardiogenic shock (CS). AIMS We aimed to assess whether CCLL identify a subgroup of patients with poorer prognosis when presenting with CS. METHODS In the CULPRIT-SHOCK trial, a core laboratory reviewed all coronary angiograms to identify CCLL. A CCLL was defined as a culprit lesion with a >70% diameter stenosis of the LM, LM equivalent (>70% diameter stenosis of both proximal LAD and proximal circumflex), proximal LAD or last remaining vessel. We evaluated the primary study endpoint of the CULPRIT-SHOCK trial according to CCLL. RESULTS A total of 269 (43%) out of 626 patients eligible for this analysis had a CCLL. Death or renal replacement therapy within 30 days, death within 30 days and death within one year were significantly higher in the CCLL than in the non-CCLL group (58.4% vs 43.4%, p<0.001, 55.8% vs 39.5%, p<0.001, 61.0% vs 44.5%, p<0.001, respectively). This was consistent after adjustment for baseline and angiographic characteristics. No interaction with the randomisation group (culprit lesion-only or immediate multivessel PCI) was found. CONCLUSIONS CCLL is frequent in CS and independently associated with worse clinical outcomes irrespective of the revascularisation strategy. TRIAL REGISTRATION www.clinicaltrials.gov NCT01927549.",2021,"Death or renal replacement therapy within 30 days, death within 30 days and within 1 year were significantly higher in CCLL than in non-CCLL group (58.4% vs. 43.4%, p<0.001, 55.8% vs .","['A total of 269 (43%) out of 626 patients eligible for this analysis had a CCLL', 'myocardial infarction without cardiogenic shock (CS', 'patients with multi-vessel disease and infarct-related cardiogenic shock']",['CCLL'],"['CCLL', 'Death or renal replacement therapy']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0036980', 'cui_str': 'Cardiogenic shock'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}]","[{'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0450429', 'cui_str': 'Location'}]","[{'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}]",626.0,0.212562,"Death or renal replacement therapy within 30 days, death within 30 days and within 1 year were significantly higher in CCLL than in non-CCLL group (58.4% vs. 43.4%, p<0.001, 55.8% vs .","[{'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Hauguel-Moreau', 'Affiliation': 'Sorbonne Université, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie (AP-HP), Paris, France.'}, {'ForeName': 'Olvier', 'Initials': 'O', 'LastName': 'Barthélémy', 'Affiliation': ''}, {'ForeName': 'Serdar', 'Initials': 'S', 'LastName': 'Farhan', 'Affiliation': ''}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Huber', 'Affiliation': ''}, {'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Rouanet', 'Affiliation': ''}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Zeitouni', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Guedeney', 'Affiliation': ''}, {'ForeName': 'Georges', 'Initials': 'G', 'LastName': 'Hage', 'Affiliation': ''}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vicaut', 'Affiliation': ''}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Zeymer', 'Affiliation': ''}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Desch', 'Affiliation': ''}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Thiele', 'Affiliation': ''}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Montalescot', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-20-00561'] 555,32892305,Investigation on chronic tinnitus efficacy of combination of non-repetitive preferred music and educational counseling: a preliminary study.,"PURPOSE To improve the efficacy of music therapy on tinnitus relief, specific music that was not repetitively played and satisfies individualized preference was developed. The aim of this study was to investigate effects of combination of the specific music and educational counseling on tinnitus relief in short term. METHODS Sixty patients suffering from chronic tinnitus were included. The non-randomized controlled study was designed with two intervention groups: educational counseling (EC, which included a 1-h individualized instruction) and preferred music therapy [PMT, which included EC plus 15, 30-min preferred music sessions (PMS)]. Three assessments-the Chinese-Mandarin version of Tinnitus Handicap Inventory (THI-CM), Tinnitus Evaluation Questionnaire (TEQ), and Visual Analogue Scale (VAS) were administered before and 1, 2, 3 weeks after initiation of treatment to evaluate the efficacy. RESULTS Twenty-six patients in PMT group attained a clinically meaningful improvement in THI compared to 15 in the EC group, though both groups achieved a statistically relevant reduction in the 3 assessments. CONCLUSION The PMT had a positive impact on chronic tinnitus and related distress in a short term. It outperformed the separate EC, which is an appropriate treatment option in clinic. Therefore, it presents a possible complement to the therapeutic spectrum in chronic tinnitus. TRIAL REGISTRATION Chinese Clinical Trial Registry, ChiCTR1900022624. Registered on 19 April 2019.",2021,"RESULTS Twenty-six patients in PMT group attained a clinically meaningful improvement in THI compared to 15 in the EC group, though both groups achieved a statistically relevant reduction in the 3 assessments. ",['Sixty patients suffering from chronic tinnitus were included'],"['music therapy', 'specific music and educational counseling', 'educational counseling (EC, which included a 1-h individualized instruction) and preferred music therapy [PMT, which included EC plus 15, 30-min preferred music sessions (PMS', 'combination of non-repetitive preferred music and educational counseling', 'PMT']","['tinnitus relief', 'chronic tinnitus and related distress', 'THI', 'Chinese-Mandarin version of Tinnitus Handicap Inventory (THI-CM), Tinnitus Evaluation Questionnaire (TEQ), and Visual Analogue Scale (VAS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0026868', 'cui_str': 'Music therapy'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0376356', 'cui_str': 'Premenstrual tension syndrome'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}]","[{'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0272238', 'cui_str': 'Transient hypogammaglobulinemia of infancy'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",60.0,0.193372,"RESULTS Twenty-six patients in PMT group attained a clinically meaningful improvement in THI compared to 15 in the EC group, though both groups achieved a statistically relevant reduction in the 3 assessments. ","[{'ForeName': 'Jiemei', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'College of Electronics and Information Engineering, Sichuan University, Chengdu, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhong', 'Affiliation': 'Hearing Center/Hearing and Speech Science Laboratory, Department of Otolaryngology/Head and Neck Surgery, West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Zhaoli', 'Initials': 'Z', 'LastName': 'Meng', 'Affiliation': 'Hearing Center/Hearing and Speech Science Laboratory, Department of Otolaryngology/Head and Neck Surgery, West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Pan', 'Affiliation': 'College of Electronics and Information Engineering, Sichuan University, Chengdu, China.'}, {'ForeName': 'Leiyu', 'Initials': 'L', 'LastName': 'Qi', 'Affiliation': 'College of Electronics and Information Engineering, Sichuan University, Chengdu, China.'}, {'ForeName': 'Tiantian', 'Initials': 'T', 'LastName': 'He', 'Affiliation': 'College of Electronics and Information Engineering, Sichuan University, Chengdu, China.'}, {'ForeName': 'Jingzhe', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Hearing Center/Hearing and Speech Science Laboratory, Department of Otolaryngology/Head and Neck Surgery, West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Peiyu', 'Initials': 'P', 'LastName': 'He', 'Affiliation': 'College of Electronics and Information Engineering, Sichuan University, Chengdu, China. hpysbsy@163.com.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': 'Hearing Center/Hearing and Speech Science Laboratory, Department of Otolaryngology/Head and Neck Surgery, West China Hospital of Sichuan University, Chengdu, China. 1141679315@qq.com.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-020-06340-w'] 556,32886746,Effects of a Modified Mindfulness-Based Cognitive Therapy for Family Caregivers of People With Dementia: A Randomized Clinical Trial.,"BACKGROUND AND OBJECTIVES Family caregivers of people with dementia (PWD) experience high levels of stress resulting from caregiving. This study aimed to investigate the effects of a modified of Mindfulness-Based Cognitive Therapy (MBCT) for dementia caregiving. RESEARCH DESIGN AND METHODS 113 family caregivers of PWD were randomized to either the intervention group, receiving the 7-session modified MBCT for a period of 10 weeks with telephone follow-up or the control group, receiving the brief education on dementia care and usual care. The caregiving stress (primary outcome) and various psychological outcomes of caregivers and the behavioral and psychological symptoms of dementia (BPSD) in the care recipients were assessed and compared at baseline (T0), postintervention (T1), and at the 6-month follow-up (T2). RESULTS At both T1 and T2, the intervention group had a statistically greater improvement in stress (p = .02 and .03), depression (p = .001 and .04), anxiety (p = .007 and .03), and BPSD-related caregivers' distress (p = .003 and p = .04). A significant greater improvement was also demonstrated in mental health-related quality of life at T2 (p = .001) and BPSD of the care recipients at T1 (p = .04). The increased caregivers' level of mindfulness was significantly correlated with the improvement of various psychological outcomes at T1 and T2 with a correlation coefficient -0.64 to 0.43. DISCUSSION AND IMPLICATIONS The modified MBCT enhanced the level of mindfulness in the caregivers and was effective to reduce the caregivers' stress and promote their psychological well-being during a 6-month follow-up. Future research is recommended to further examine its effects on the varieties of psychological and behavioral outcomes of both caregivers and care recipients and their dyadic relationships, as well as explore its mechanism of action in facilitating dementia caregiving. CLINICAL TRIALS REGISTRATION NUMBER NCT03354819.",2021,The modified MBCT enhanced the level of mindfulness in the caregivers and was effective to reduce the caregivers' stress and promote their psychological well-being over 6-month follow-up.,"['Family caregivers of people with dementia (PWD', 'dementia caregiving', '113 family caregivers of PWD', 'family caregivers of people with dementia']","['telephone follow-up; or the control group, receiving the brief education on dementia care and usual care', '7-session modified MBCT', 'modified of Mindfulness-Based Cognitive Therapy (MBCT', 'modified mindfulness-based cognitive therapy']","['various psychological outcomes', 'mental health-related QoL at T2(p=0.001) and BPSD', 'various psychological outcomes of caregivers and the behavioral and psychological symptoms of dementia(BPSD']","[{'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]","[{'cui': 'C0178941', 'cui_str': 'Telephone follow-up'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]",113.0,0.0463095,The modified MBCT enhanced the level of mindfulness in the caregivers and was effective to reduce the caregivers' stress and promote their psychological well-being over 6-month follow-up.,"[{'ForeName': 'Patrick Pui Kin', 'Initials': 'PPK', 'LastName': 'Kor', 'Affiliation': 'The Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong.'}, {'ForeName': 'Justina Y W', 'Initials': 'JYW', 'LastName': 'Liu', 'Affiliation': 'The Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong.'}, {'ForeName': 'Wai Tong', 'Initials': 'WT', 'LastName': 'Chien', 'Affiliation': 'The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong.'}]",The Gerontologist,['10.1093/geront/gnaa125'] 557,32886189,Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients.,"A 12-month exercise program reversibly prevented hip bone loss in premenopausal women with early breast cancer. The bone-protective effect was maintained for 2 years after the end of the program but was lost thereafter. PURPOSE Breast cancer survivors are at an increased risk for osteoporosis and fracture. This 5-year follow-up of a randomized impact exercise intervention trial evaluated the maintenance of training effects on bone among breast cancer patients. METHODS Five hundred seventy-three early breast cancer patients aged 35-68 years and treated with adjuvant therapy were allocated into a 12-month exercise program or a control group. Four hundred forty-four patients (77%) were included in the 5-year analysis. The exercise intervention comprised weekly supervised step aerobics, circuit exercises, and home training. Areal bone mineral density (aBMD) was measured by dual-energy X-ray absorptiometry. Physical activity was estimated in metabolic equivalent (MET) hours per week and physical performance assessed by 2-km walking and figure-8 running tests. RESULTS In premenopausal patients, the 12-month exercise program maintained femoral neck (FN) and total hip (TH) aBMD for 3 years, but the protective effect was lost thereafter. The mean FN aBMD change in the exercise and control groups was - 0.2% and - 1.5% 1 year, - 1.1% and - 2.1% 3 years and - 3.3% versus - 2.4% 5 years after the beginning of the intervention, respectively. Lumbar spine (LS) bone loss was not prevented in premenopausal women and no training effects on aBMD were seen in postmenopausal women. The main confounding element of the study was the unexpected rise in physical activity among patients in the control group. The physical performance improved among premenopausal women in the exercise group compared with the controls. CONCLUSION The 12-month exercise program prevented FN and TH bone loss in premenopausal breast cancer patients for 3 years. The bone-protective effect was reversible and lost thereafter.",2021,Lumbar spine (LS) bone loss was not prevented in premenopausal women and no training effects on aBMD were seen in postmenopausal women.,"['premenopausal women with early breast cancer', 'early breast cancer patients', 'Five hundred seventy-three early breast cancer patients aged 35-68\xa0years and treated with adjuvant therapy', 'postmenopausal women', 'Breast cancer survivors', 'premenopausal women', 'premenopausal breast cancer patients for 3\xa0years', 'Four hundred forty-four patients (77%) were included in the 5-year analysis', 'breast cancer patients']","['aerobic and impact training', 'exercise program or a control group', 'exercise program', 'exercise intervention comprised weekly supervised step aerobics, circuit exercises, and home training']","['Lumbar spine (LS) bone loss', 'bone mineral density', 'mean FN aBMD change', 'Areal bone mineral density (aBMD', 'aBMD', 'bone-protective effect', '12-month exercise program maintained femoral neck (FN) and total hip (TH) aBMD', 'physical activity', 'Physical activity', 'FN and TH bone loss', 'physical performance', 'hip bone loss']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0741682', 'cui_str': 'Premenopausal breast cancer'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0030786', 'cui_str': 'Hip Bone'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",573.0,0.0181952,Lumbar spine (LS) bone loss was not prevented in premenopausal women and no training effects on aBMD were seen in postmenopausal women.,"[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Vehmanen', 'Affiliation': 'Department of Oncology, Helsinki University Central Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland. leena.vehmanen@hus.fi.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Sievänen', 'Affiliation': 'The UKK Institute for Health Promotion Research, Tampere, Finland.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Kellokumpu-Lehtinen', 'Affiliation': 'Department of Oncology, Faculty of Medicine, Tampere University Central Hospital, University of Tampere, Tampere, Finland.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Nikander', 'Affiliation': 'Department of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Huovinen', 'Affiliation': 'Department of Oncology, Turku University Central Hospital, Turku, Finland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ruohola', 'Affiliation': 'Department of Oncology, Turku University Central Hospital, Turku, Finland.'}, {'ForeName': 'H M', 'Initials': 'HM', 'LastName': 'Penttinen', 'Affiliation': 'Cancer Society of Pirkanmaa, Tampere, Finland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Utriainen', 'Affiliation': 'Department of Oncology, Helsinki University Central Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Tokola', 'Affiliation': 'The UKK Institute for Health Promotion Research, Tampere, Finland.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Blomqvist', 'Affiliation': 'Department of Oncology, Helsinki University Central Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Saarto', 'Affiliation': 'Department of Oncology, Helsinki University Central Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.'}]",Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,['10.1007/s00198-020-05611-w'] 558,32893049,Fermented infant formula (with Bifidobacterium breve C50 and Streptococcus thermophilus O65) with prebiotic oligosaccharides is safe and modulates the gut microbiota towards a microbiota closer to that of breastfed infants.,"BACKGROUND & AIMS Microbiome-modulators can help positively steer early-life microbiota development but their effects on microbiome functionality and associated safety and tolerance need to be demonstrated. We investigated the microbiome impact of a new combination of bioactive compounds, produced by the food-grade microorganisms Bifidobacterium breve C50 and Streptococcus thermophilus ST065 during a fermentation process, and prebiotics in an infant formula. Tolerance and safety were also assessed. METHODS An exploratory prospective, randomized, double-blind, controlled, multi-centre study was designed to investigate the effect of bioactive compounds and prebiotics (short-chain galacto-oligosaccharides (scGOS)/long-chain fructo-oligosaccharides (lcFOS) 9:1). Experimental formulas containing these bioactive compounds and prebiotics (FERM/scGOS/lcFOS), prebiotics (scGOS/lcFOS), or bioactive compounds (FERM), were compared to a standard cow's milk-based control formula (Control). Exclusively breastfed infants were included as a reference arm since exclusive breastfeeding is considered as the optimal feeding for infants. The study lasted six months and included visits to health care professionals at baseline, two, four and six months of age. Stool SIgA concentration was the primary study outcome parameter. RESULTS There were 280 infants randomized over the experimental arms and 70 infants entered the breastfed-reference arm. Demographics were balanced, growth and tolerance parameters were according to expectation and adverse events were limited. At four months of age the median SIgA concentration in the FERM/scGOS/lcFOS group was significantly higher compared to the Control group (p = 0.03) and was more similar to the concentrations found in the breastfed-reference group. Bifidobacterium increased over time in all groups. The FERM/scGOS/lcFOS combination resulted in a microbiota composition and metabolic activity closer to the breastfed infants' microbiome. CONCLUSION The FERM/scGOS/lcFOS combination showed a significant positive effect on SIgA levels. All formulas tested were associated with normal growth and were well-tolerated. Additionally, at four months of age the FERM/scGOS/lcFOS formula brought the microbiome composition and metabolic activity closer towards that of breastfed infants. CLINICAL TRIAL REGISTRY Registration number NTR2726 (Netherlands Trial Register; www.trialregister.nl/).",2021,Bifidobacterium increased over time in all groups.,['280 infants randomized over the experimental arms and 70 infants entered the breastfed-reference arm'],"['prebiotic oligosaccharides', 'bioactive compounds and prebiotics (short-chain galacto-oligosaccharides (scGOS)/long-chain fructo-oligosaccharides (lcFOS']","['Tolerance and safety', 'bioactive compounds and prebiotics (FERM/scGOS/lcFOS), prebiotics (scGOS/lcFOS), or bioactive compounds (FERM', 'median SIgA concentration', 'SIgA levels', 'microbiota composition and metabolic activity', 'Bifidobacterium', 'tolerated', 'Stool SIgA concentration']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}]","[{'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0028959', 'cui_str': 'Oligosaccharide'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0873033', 'cui_str': 'fructooligosaccharide'}]","[{'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0238394', 'cui_str': 'Female pseudohermaphroditism'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0020838', 'cui_str': 'Immunoglobulin A secretory'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0015733', 'cui_str': 'Feces'}]",280.0,0.0672141,Bifidobacterium increased over time in all groups.,"[{'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Béghin', 'Affiliation': 'Univ. Lille, CHU Lille, Clinical Investigation Center, CIC-1403-Inserm-CHU and U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Tims', 'Affiliation': 'Danone Nutricia Research, Utrecht, the Netherlands. Electronic address: sebastian.tims@danone.com.'}, {'ForeName': 'Mieke', 'Initials': 'M', 'LastName': 'Roelofs', 'Affiliation': 'Danone Nutricia Research, Utrecht, the Netherlands.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Rougé', 'Affiliation': 'Laboratoire Gallia, Limonest, France.'}, {'ForeName': 'Raish', 'Initials': 'R', 'LastName': 'Oozeer', 'Affiliation': 'Danone Nutricia Research, Utrecht, the Netherlands.'}, {'ForeName': 'Thameur', 'Initials': 'T', 'LastName': 'Rakza', 'Affiliation': ""Department of Neonatology, Lille University Jeanne de Flandre Children's Hospital and Faculty of Medicine, University of Lille, F-59000, Lille, France.""}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Chirico', 'Affiliation': 'Department of Neonatology, Spedali Civili, Brescia, Italy.'}, {'ForeName': 'Guus', 'Initials': 'G', 'LastName': 'Roeselers', 'Affiliation': 'Danone Nutricia Research, Utrecht, the Netherlands.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Knol', 'Affiliation': 'Danone Nutricia Research, Utrecht, the Netherlands; Laboratory of Microbiology, Wageningen University, the Netherlands.'}, {'ForeName': 'Jean Christophe', 'Initials': 'JC', 'LastName': 'Rozé', 'Affiliation': 'Department of Neonatal Medicine, Nantes University Hospital, Nantes, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Turck', 'Affiliation': ""Univ. Lille, CHU Lille, Clinical Investigation Center, CIC-1403-Inserm-CHU and U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France; Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lille University Jeanne de Flandre Children's Hospital and Faculty of Medicine, University of Lille, F-59000, Lille, France.""}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.07.024'] 559,32897605,"Transesophageal Echocardiography - Dysphagia Risk in Acute Stroke (TEDRAS): a prospective, blind, randomized and controlled clinical trial.","BACKGROUND AND PURPOSE Dysphagia is common in acute stroke and leads to worse overall outcome. Transesophageal echocardiography (TEE) is used in the diagnostic evaluation of stroke with regard to its etiology and is a known cause of postoperative dysphagia in cardiac surgery. The prevalence of dysphagia in acute stroke patients undergoing TEE remains unknown. The aim of the Transesophageal Echocardiography - Dysphagia Risk in Acute Stroke (TEDRAS) study was to assess the influence of TEE on swallowing among patients who have experienced acute stroke. METHODS The TEDRAS study was a prospective, blind, randomized, controlled trial that included two groups of patients with acute stroke. Simple unrestricted randomization was performed, and examiners were blinded to each other's results. Swallowing was tested using flexible endoscopic evaluation of swallowing (FEES) at three different time points in the intervention group (24 h before, immediately after and 24 h after TEE) and in the control group (FEES on three consecutive days and TEE earliest after the third FEES). Validated scales were used to assess dysphagia severity for all time points as primary outcome measures. RESULTS A total of 34 patients were randomized: 19 to the intervention group and 15 to the control group. The key findings of the repeated-measures between-group comparisons were significant increases in the intervention group for the following dysphagia measures: (1) secretion severity score (immediately after TEE: P < 0.001; 24 h after TEE: P < 0.001) and (2) Penetration-Aspiration Scale score for saliva (immediately after TEE: P < 0.001; 24 h after TEE: P = 0.007), for small (immediately after TEE: P = 0.009) and large liquid boli (immediately after TEE: P = 0.009; 24 h after TEE: P = 0.025). CONCLUSION The results indicate a negative influence of TEE on swallowing in acute stroke patients for at least 24 hours.",2021,"Swallowing was tested using Flexible Endoscopic Evaluation of Swallowing (FEES) at three different intervals in the intervention group (IG) (24 hours before, immediately after and 24 hours after TEE) and within the control group (CG)","['34 patients', 'acute stroke patients', 'Acute Stroke', 'acute stroke patients undergoing TEE remains unknown', 'patients with acute stroke in two groups']","['CG', 'TEE', 'Transesophageal echocardiography (TEE', 'Transesophageal Echocardiography - Dysphagia Risk', 'control group (CG']","['dysphagia severity', 'Flexible Endoscopic Evaluation of Swallowing (FEES', 'Penetration-aspiration-scale for saliva', 'prevalence of dysphagia', 'Secretion severity score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0206054', 'cui_str': 'Transesophageal echocardiography'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0206054', 'cui_str': 'Transesophageal echocardiography'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0443220', 'cui_str': 'Flexible'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}]",34.0,0.0945988,"Swallowing was tested using Flexible Endoscopic Evaluation of Swallowing (FEES) at three different intervals in the intervention group (IG) (24 hours before, immediately after and 24 hours after TEE) and within the control group (CG)","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Hamzic', 'Affiliation': 'Department of Neurology, University Hospital Giessen and Marburg GmbH, Justus-Liebig-University, Giessen, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Braun', 'Affiliation': 'Department of Neurology, University Hospital Giessen and Marburg GmbH, Justus-Liebig-University, Giessen, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Butz', 'Affiliation': 'Department of Neurology, University Hospital Giessen and Marburg GmbH, Justus-Liebig-University, Giessen, Germany.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Khilan', 'Affiliation': 'Department of Neurology, University Hospital Giessen and Marburg GmbH, Justus-Liebig-University, Giessen, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Weber', 'Affiliation': 'Department of Neurology/Stroke Unit, Gesundheitszentrum Wetterau, Friedberg, Hesse, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Yeniguen', 'Affiliation': 'Department of Neurology, University Hospital Giessen and Marburg GmbH, Justus-Liebig-University, Giessen, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Gerriets', 'Affiliation': 'Department of Neurology, University Hospital Giessen and Marburg GmbH, Justus-Liebig-University, Giessen, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Schramm', 'Affiliation': 'Heart and Brain Research Group, Heart-, Lung-, Vascular- and Rheumatic Centre Bad Nauheim, Kerckhoff Clinic GmbH, Bad Nauheim, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Juenemann', 'Affiliation': 'Department of Neurology, University Hospital Giessen and Marburg GmbH, Justus-Liebig-University, Giessen, Germany.'}]",European journal of neurology,['10.1111/ene.14516'] 560,32901255,"Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial.","BACKGROUND Loop diuretics are used to manage fluid retention in patients with end-stage kidney disease undergoing hemodialysis (HD). This randomized, double-blind, placebo-controlled, Phase 2 trial evaluated the efficacy and safety of tolvaptan, a vasopressin V2 receptor antagonist, in Japanese HD patients. METHODS A total of 124 patients (24-h urine volume ≥500 mL) on thrice-weekly HD were randomized to receive oral tolvaptan 15 mg/day (n = 40), tolvaptan 30 mg/day (n = 40) or placebo (n = 44) for 24 weeks. Efficacy endpoints were change from baseline in 24-h urine volume, total fluid removal by HD per week and interdialytic weight gain (IDWG). Safety was assessed via the incidence of treatment-emergent adverse events (TEAEs). RESULTS At treatment end, the difference (95% confidence interval) from the placebo group in the mean change from baseline in 24-h urine volume was significant in the tolvaptan 15 mg {429.1 mL [95% confidence interval (CI) 231.0, 627.2]; P < 0.0001} and 30 mg [371.6 mL (95% CI 144.1, 599.2); P = 0.0017] groups. The mean changes from baseline in total fluid removal by HD and IDWG were not significantly different in the tolvaptan groups versus the placebo group. Although the proportion of patients with TEAEs was lower in the placebo group (77.3%) than in the tolvaptan groups (92.3%), tolvaptan was safe and well-tolerated during the study period. CONCLUSIONS Tolvaptan significantly sustained diuretic action for 24 weeks in HD patients but did not reduce total fluid removal by HD per week and IDWG to the same extent.",2021,The mean changes from baseline in total fluid removal by HD and IDWG were not significantly different in the tolvaptan groups versus the placebo group.,"['patients with end-stage kidney disease undergoing hemodialysis (HD', 'patients undergoing hemodialysis', '124 patients (24-h urine volume ≥500\u2009mL) on thrice-weekly HD', 'Japanese HD patients']","['oral tolvaptan', 'tolvaptan, a vasopressin V2 receptor antagonist', 'tolvaptan 30\u2009mg/day (n\u2009=\u200940) or placebo', 'mL', 'placebo']","['24-h urine volume', 'sustained diuretic action', 'Efficacy and safety', 'total fluid removal by HD and IDWG', 'total fluid removal', '24-h urine volume, total fluid removal by HD per week and interdialytic weight gain (IDWG', 'tolvaptan was safe and well-tolerated']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0556987', 'cui_str': 'Three times weekly'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C0162829', 'cui_str': 'V2 Receptors'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C2684746', 'cui_str': 'tolvaptan 30 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0012798', 'cui_str': 'Diuretic'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C1176308', 'cui_str': 'tolvaptan'}]",124.0,0.488207,The mean changes from baseline in total fluid removal by HD and IDWG were not significantly different in the tolvaptan groups versus the placebo group.,"[{'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Ogata', 'Affiliation': 'Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan.'}, {'ForeName': 'Naoko', 'Initials': 'N', 'LastName': 'Shimofurutani', 'Affiliation': 'Headquarters of Clinical Development, Otsuka Pharmaceutical Co. Ltd, Osaka, Japan.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Okada', 'Affiliation': 'Headquarters of Clinical Development, Otsuka Pharmaceutical Co. Ltd, Osaka, Japan.'}, {'ForeName': 'Hisashi', 'Initials': 'H', 'LastName': 'Nagamoto', 'Affiliation': 'Medical Affairs, Otsuka Pharmaceutical Co. Ltd, Tokushima, Japan.'}, {'ForeName': 'Tadao', 'Initials': 'T', 'LastName': 'Akizawa', 'Affiliation': 'Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}]","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association",['10.1093/ndt/gfaa148'] 561,32900519,"Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study.","Ageing and menopause contribute to endothelial dysfunction, causing impaired cerebral perfusion, which is in turn associated with accelerated cognitive decline. In a 14-week pilot study, we showed that supplementation with low-dose resveratrol, a phytoestrogen that can enhance endothelial function, improved cerebrovascular and cognitive functions in postmenopausal women. We sought to confirm these benefits in a larger, longer-term trial. A 24-month randomized, placebo-controlled crossover trial was undertaken in 125 postmenopausal women, aged 45-85 years, who took 75 mg trans-resveratrol or placebo twice-daily for 12 months and then crossover to the alternative treatment for another 12 months. We evaluated within individual differences between each treatment period in measures of cognition (primary outcome), cerebrovascular function in the middle cerebral artery (cerebral blood flow velocity: CBFV, cerebrovascular responsiveness: CVR) and cardio-metabolic markers as secondary outcomes. Subgroup analyses examined effects of resveratrol by life stages. Compared to placebo, resveratrol supplementation resulted a significant 33% improvement in overall cognitive performance (Cohen's d = 0.170, P = 0.005). Women ≥65 years of age showed a relative improvement in verbal memory with resveratrol compared to those younger than 65 years. Furthermore, resveratrol improved secondary outcomes including resting mean CBFV (d = 0.275, P = 0.001), CVR to hypercapnia (d = 0.307, P = 0.027), CVR to cognitive stimuli (d = 0.259, P = 0.032), fasting insulin (d = 0.174, P = 0.025) and insulin resistance index (d = 0.102, P = 0.034). Regular supplementation with low-dose resveratrol can enhance cognition, cerebrovascular function and insulin sensitivity in postmenopausal women. This may translate into a slowing of the accelerated cognitive decline due to ageing and menopause, especially in late-life women. Further studies are warranted to observe whether these cognitive benefits of resveratrol can reduce the risk of dementia.",2021,"Compared to placebo, resveratrol supplementation resulted a significant 33% improvement in overall cognitive performance (Cohen's d = 0.170, P = 0.005).","['125 postmenopausal women, aged 45-85 years, who took 75\xa0mg trans-resveratrol or placebo twice-daily for 12 months and then crossover to the alternative treatment for another 12 months', 'Women ≥65 years of age', 'postmenopausal women']","['placebo, resveratrol supplementation', 'Regular supplementation with low-dose resveratrol', 'placebo']","['CVR to cognitive stimuli ', 'cognition, cerebrovascular function and cardio-metabolic markers', 'cognition, cerebrovascular function and insulin sensitivity', 'overall cognitive performance', 'CVR to hypercapnia', 'cerebrovascular and cognitive functions', 'resting mean CBFV', 'verbal memory', 'insulin resistance index ', 'cognition (primary outcome), cerebrovascular function in the middle cerebral artery (cerebral blood flow velocity: CBFV, cerebrovascular responsiveness: CVR) and cardio-metabolic markers', 'fasting insulin']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0073096', 'cui_str': 'resveratrol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0073096', 'cui_str': 'resveratrol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}]","[{'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1513159', 'cui_str': 'Metabolic marker'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0020440', 'cui_str': 'Hypercapnia'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0149566', 'cui_str': 'Structure of middle cerebral artery'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}]",125.0,0.295164,"Compared to placebo, resveratrol supplementation resulted a significant 33% improvement in overall cognitive performance (Cohen's d = 0.170, P = 0.005).","[{'ForeName': 'Jay Jay', 'Initials': 'JJ', 'LastName': 'Thaung Zaw', 'Affiliation': 'University of Newcastle, School of Biomedical Sciences and Pharmacy, Callaghan, NSW, 2308, Australia.'}, {'ForeName': 'Peter Rc', 'Initials': 'PR', 'LastName': 'Howe', 'Affiliation': 'University of Newcastle, School of Biomedical Sciences and Pharmacy, Callaghan, NSW, 2308, Australia; University of Southern Queensland, Institute for Resilient Regions, Springfield Central, QLD, 4300, Australia; University of South Australia, School of Health Sciences, Adelaide, SA, 5000, Australia.'}, {'ForeName': 'Rachel Hx', 'Initials': 'RH', 'LastName': 'Wong', 'Affiliation': 'University of Newcastle, School of Biomedical Sciences and Pharmacy, Callaghan, NSW, 2308, Australia; University of Southern Queensland, Institute for Resilient Regions, Springfield Central, QLD, 4300, Australia. Electronic address: Rachel.wong@newcastle.edu.au.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.025'] 562,32900520,Dietary stearic acid and palmitic acid do not differently affect ABCA1-mediated cholesterol efflux capacity in healthy men and postmenopausal women: A randomized controlled trial.,"BACKGROUND The saturated fatty acid stearic acid (C18:0) lowers HDL cholesterol compared with palmitic acid (C16:0). However, the ability of HDL particles to promote cholesterol efflux from macrophages (cholesterol efflux capacity; CEC) may better predict coronary heart disease (CHD) risk than HDL cholesterol concentrations. OBJECTIVE We examined effects of exchanging dietary palmitic acid for stearic acid on ATP-binding cassette transporter A1 (ABCA1)-mediated CEC, and other conventional and emerging cardiometabolic risk makers. DESIGN In a double-blind, randomized, crossover study with two 4-week isocaloric intervention periods, 34 healthy men and postmenopausal women (61.5 ± 5.7 years, BMI: 25.4 ± 2.5 kg/m 2 ) followed diets rich in palmitic acids or stearic acids. Difference in intakes was 6% of daily energy. ABCA1-mediated CEC was measured from J774 macrophages to apolipoprotein (apo)B-depleted serum. RESULTS Compared with the palmitic-acid diet, the stearic-acid diet lowered serum LDL cholesterol (-0.14 mmol/L; p = 0.010), HDL cholesterol (-0.09 mmol/L; p=<0.001), and apoA1 (-0.05 g/L; p < 0.001). ABCA1-mediated CEC did not differ between diets (p = 0.280). Cholesteryl ester transfer protein (CETP) mass was higher on stearic acid (0.11 mg/L; p = 0.003), but CETP activity was comparable. ApoB100 did not differ, but triacylglycerol concentrations tended to be higher on stearic acid (p = 0.100). Glucose concentrations were comparable. Effects on insulin and C-peptide were sex-dependent. In women, the stearic-acid diet increased insulin concentrations (1.57 μU/mL; p = 0.002), while in men, C-peptide concentrations were lower (-0.15 ng/mL; p = 0.037). Interleukin 6 (0.15 pg/mL; p = 0.039) and tumor necrosis factor alpha (0.18 pg/mL; p = 0.005), but not high-sensitivity C-reactive protein, were higher on stearic acid. Soluble intracellular adhesion molecule (9 ng/mL; p = 0.033), but not soluble vascular cell adhesion molecule and endothelial-selectin concentrations decreased after stearic-acid consumption. CONCLUSIONS As expected, stearic-acid intake lowered LDL cholesterol, HDL cholesterol, and apoA1. Insulin sensitivity in women and low-grade inflammation might be unfavorably affected by stearic-acid intake. However, palmitic-acid and stearic-acid intakes did not differently affect ABCA1-mediated CEC. CLINICAL TRIAL REGISTRY This trial was registered at clinicaltrials.gov as NCT02835651.",2021,"Soluble intracellular adhesion molecule (9 ng/mL; p = 0.033), but not soluble vascular cell adhesion molecule and endothelial-selectin concentrations decreased after stearic-acid consumption. ","['34 healthy men and postmenopausal women (61.5\xa0±\xa05.7 years, BMI: 25.4\xa0±\xa02.5\xa0kg/m 2 ) followed', 'healthy men and postmenopausal women']","['palmitic-acid diet, the stearic-acid diet', 'Dietary stearic acid and palmitic acid', 'saturated fatty acid stearic acid (C18:0', 'diets rich in palmitic acids or stearic acids', 'exchanging dietary palmitic acid', 'palmitic acid (C16:0']","['ABCA1-mediated cholesterol efflux capacity', 'tumor necrosis factor alpha', 'soluble vascular cell adhesion molecule and endothelial-selectin concentrations', 'Cholesteryl ester transfer protein (CETP) mass', 'CETP activity', 'triacylglycerol concentrations', 'HDL cholesterol', 'Soluble intracellular adhesion molecule', 'palmitic-acid and stearic-acid intakes', 'insulin concentrations', 'Insulin sensitivity', 'serum LDL cholesterol', 'LDL cholesterol, HDL cholesterol, and apoA1', 'Glucose concentrations', 'ABCA1-mediated CEC']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517795', 'cui_str': '5.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0030234', 'cui_str': 'Palmitic acid'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0038229', 'cui_str': 'Octadecanoic acid'}, {'cui': 'C0597423', 'cui_str': 'Saturated fat'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}]","[{'cui': 'C3711161', 'cui_str': 'ABCA1 protein, human'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0078056', 'cui_str': 'Lymphocyte antigen CD106'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0282651', 'cui_str': 'Selectins'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0055538', 'cui_str': 'Cholesterol ester transfer protein'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0175996', 'cui_str': 'Protoplasm'}, {'cui': 'C0007578', 'cui_str': 'Cell Adhesion Molecules'}, {'cui': 'C0030234', 'cui_str': 'Palmitic acid'}, {'cui': 'C0038229', 'cui_str': 'Octadecanoic acid'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0428474', 'cui_str': 'Serum LDL cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C1677784', 'cui_str': 'APOA1 protein, human'}, {'cui': 'C0427743', 'cui_str': 'Glucose concentration, test strip measurement'}, {'cui': 'C0318601', 'cui_str': 'Canine enteric calicivirus'}]",34.0,0.26991,"Soluble intracellular adhesion molecule (9 ng/mL; p = 0.033), but not soluble vascular cell adhesion molecule and endothelial-selectin concentrations decreased after stearic-acid consumption. ","[{'ForeName': 'Merel A', 'Initials': 'MA', 'LastName': 'van Rooijen', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM (School of Nutrition and Translational Research in Metabolism), Maastricht University Medical Center, Maastricht, the Netherlands.'}, {'ForeName': 'Jogchum', 'Initials': 'J', 'LastName': 'Plat', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM (School of Nutrition and Translational Research in Metabolism), Maastricht University Medical Center, Maastricht, the Netherlands.'}, {'ForeName': 'Wendy A M', 'Initials': 'WAM', 'LastName': 'Blom', 'Affiliation': 'Unilever Research and Development, Vlaardingen, the Netherlands.'}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Zock', 'Affiliation': 'Unilever Research and Development, Vlaardingen, the Netherlands.'}, {'ForeName': 'Ronald P', 'Initials': 'RP', 'LastName': 'Mensink', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM (School of Nutrition and Translational Research in Metabolism), Maastricht University Medical Center, Maastricht, the Netherlands. Electronic address: r.mensink@maastrichtuniversity.nl.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.016'] 563,32898029,De-implementing Prolonged Rest Advice for Concussion in Primary Care Settings: A Pilot Stepped Wedge Cluster Randomized Trial.,"OBJECTIVE To evaluate the feasibility and preliminary efficacy of a de-implementation intervention to support return-to-activity guideline use after concussion. SETTING Community. PARTICIPANTS Family physicians in community practice (n = 21 at 5 clinics). DESIGN Pilot stepped wedge cluster randomized trial with qualitative interviews. Training on new guidelines for return to activity after concussion was provided in education outreach visits. MAIN MEASURES The primary feasibility outcomes were recruitment, retention, and postencounter form completion (physicians prospectively recorded what they did for each new patient with concussion). Efficacy indicators included a knowledge test and guideline compliance based on postencounter form data. Qualitative interviews covered Theoretical Domains Framework elements. RESULTS Recruitment, retention, and postencounter form completion rates all fell below feasibility benchmarks. Family physicians demonstrated increased knowledge about the return-to-activity guideline (M = 8.8 true-false items correct out of 10 after vs 6.3 before) and improved guideline adherence (86% after vs 25% before) after the training. Qualitative interviews revealed important barriers (eg, beliefs about contraindications) and facilitators (eg, patient handouts) to behavior change. CONCLUSIONS Education outreach visits might facilitate de-implementation of prolonged rest advice after concussion, but methodological changes will be necessary to improve the feasibility of a larger trial. The qualitative findings highlight opportunities for refining the intervention.",2021,Family physicians demonstrated increased knowledge about the return-to-activity guideline (M = 8.8 true-false items correct out of 10 after vs 6.3 before) and improved guideline adherence (86% after vs 25% before) after the training.,"['Family physicians in community practice (n = 21 at 5 clinics', 'Community']","['De-implementing Prolonged Rest Advice for Concussion', 'de-implementation intervention']","['important barriers (eg, beliefs about contraindications) and facilitators (eg, patient handouts) to behavior change', 'knowledge about the return-to-activity guideline', 'recruitment, retention, and postencounter form completion (physicians', 'guideline adherence', 'Recruitment, retention, and postencounter form completion rates']","[{'cui': 'C1704221', 'cui_str': 'Family medicine specialist'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0525059', 'cui_str': 'Guideline Adherence'}]",,0.0427984,Family physicians demonstrated increased knowledge about the return-to-activity guideline (M = 8.8 true-false items correct out of 10 after vs 6.3 before) and improved guideline adherence (86% after vs 25% before) after the training.,"[{'ForeName': 'Noah D', 'Initials': 'ND', 'LastName': 'Silverberg', 'Affiliation': ""Division of Physical Medicine & Rehabilitation (Dr Silverberg), Rehabilitation Sciences (Ms Otamendi), and Departments of Psychiatry (Dr Panenka), Pediatrics (Dr Babul), and Physical Therapy (Dr Li), The University of British Columbia, Vancouver, Canada; Rehabilitation Research Program, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada (Dr Silverberg and Ms MacLellan); BC Mental Health & Substance Use Services Research Institute, Vancouver, British Columbia, Canada (Dr Panenka); British Columbia Provincial Neuropsychiatry Program, Vancouver, British Columbia, Canada (Dr Panenka); Department of Family Medicine and Emergency Medicine, Université Laval, Québec City, Quebec, Canada (Dr Archambault); Centre intégré de santé et de services sociaux de Chaudière-Appalaches, Ste-Marie, Ontario, Canada (Dr Archambault); Centre de recherche intégrée pour un système apprenant en santé et services sociaux, Lévis, Quebec, Canada (Dr Archambault); Centre de recherche sur les soins et les services de première ligne de l'Université Laval, Québec City, Quebec, Canada (Dr Archambault); Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval, Québec City, Quebec, Canada (Dr Archambault); BC Injury Research and Prevention Unit, BC Children's Hospital, Vancouver, British Columbia, Canada (Dr Babul); and Arthritis Research Canada, Richmond, British Columbia, Canada (Dr Li); on behalf of the Canadian TBI Research Consortium.""}, {'ForeName': 'Thalia', 'Initials': 'T', 'LastName': 'Otamendi', 'Affiliation': ''}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Panenka', 'Affiliation': ''}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Archambault', 'Affiliation': ''}, {'ForeName': 'Shelina', 'Initials': 'S', 'LastName': 'Babul', 'Affiliation': ''}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'MacLellan', 'Affiliation': ''}, {'ForeName': 'Linda C', 'Initials': 'LC', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of head trauma rehabilitation,['10.1097/HTR.0000000000000609'] 564,32897809,Maternal Support Is Protective Against Suicidal Ideation Among a Diverse Cohort of Young Transgender Women.,"Purpose: We assessed if young transgender women (YTW) with parents who are supportive of their transgender identity had lower odds of having suicidal ideation compared with YTW with unsupportive parents. Methods: This study analyzed baseline findings from a diverse sample of 297 sexually active, YTW 16-29 years of age who were enrolled in Project LifeSkills, a randomized controlled HIV prevention intervention efficacy trial in Chicago and Boston, between 2012 and 2015. Bivariate and multivariable logistic regression were used to assess if parental support was associated with a decreased odds of suicidal ideation. Results: Nearly one-fifth (18.9%) of YTW reported suicidal ideation at baseline. In our adjusted multivariable model, YTW with supportive mothers had 0.37 (95% confidence interval = 0.15-0.90) times the odds of having suicidal ideation compared with YTW with unsupportive mothers. Conclusion: This study found that the odds of suicidal ideation were lower among YTW who had mothers who were supportive of their transgender identity. Our results suggest that parent-focused interventions to improve the relationships between YTW and their parents may lower the odds of YTW having suicidal ideation. Clinical Trial Registration Identifier: NCT01575938.",2020,This study found that the odds of suicidal ideation were lower among YTW who had mothers who were supportive of their transgender identity.,"['diverse sample of 297 sexually active, YTW 16-29 years of age who were enrolled in Project LifeSkills, a randomized controlled HIV prevention intervention efficacy trial in Chicago and Boston, between 2012 and 2015', 'young transgender women (YTW) with parents who are supportive of their transgender identity had lower odds of having suicidal ideation compared with YTW with unsupportive parents']",[],['suicidal ideation'],"[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0241028', 'cui_str': 'Sexually active'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008044', 'cui_str': 'Chicago'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C1319927', 'cui_str': 'Male-to-female transsexual'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0558141', 'cui_str': 'Transsexual'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0332287', 'cui_str': 'With'}]",[],"[{'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}]",297.0,0.104996,This study found that the odds of suicidal ideation were lower among YTW who had mothers who were supportive of their transgender identity.,"[{'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Jin', 'Affiliation': 'Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.'}, {'ForeName': 'Arjee', 'Initials': 'A', 'LastName': 'Restar', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Goedel', 'Affiliation': 'Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.'}, {'ForeName': 'Adedotun', 'Initials': 'A', 'LastName': 'Ogunbajo', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island, USA.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Biello', 'Affiliation': 'Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.'}, {'ForeName': 'Don', 'Initials': 'D', 'LastName': 'Operario', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Kuhns', 'Affiliation': 'Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.'}, {'ForeName': 'Sari L', 'Initials': 'SL', 'LastName': 'Reisner', 'Affiliation': ""Division of General Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Garofalo', 'Affiliation': ""Division of Adolescent and Young Adult Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.""}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Mimiaga', 'Affiliation': 'Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.'}]",LGBT health,['10.1089/lgbt.2020.0219'] 565,32940793,Two-dimensional (2-D) vs. three-dimensional (3-D) laparoscopic right hemicolectomy with intracorporeal anastomosis for colon cancer: comparison of short-term results.,"BACKGROUND There are few reports comparing safety and efficacy of 2-D and 3-D video technology in laparoscopic right hemicolectomy. The aim of the study was to assess the short-term results of laparoscopic right hemicolectomy (LHR) with intracorporeal anastomosis with 2-D/3-D video in patients with right colon cancer. METHODS Data from 239 patients undergoing LRH for cancer in a 14-year period (June 2005-January 2020) were prospectively collected. Surgical procedures were performed by two expert laparoscopic surgeons. RESULTS One hundred and fourteen patients were included in the study: 55 (48.2%) operated with 2-D and 59 (51.8%) with 3-D video. Tumor site and postoperative stage distribution were similar. Mean operative time was comparable in the two groups (159.0 ± 48.8 min vs. 17.06 ± 36.0 min, p = ns, group 2-D and 3-D, respectively). Group 3-D patients had a similar percentage of associated procedures (44.1% vs. 29.1%, p = ns). Intraoperative complications were nil in both groups, while postoperative complications were similar (30.9% 2-D vs 25.4% 3-D, p = ns). The mean number of lymph nodes retrieved was similar in group 3-D (26.0 ± 14.6 vs. 22.9 ± 9.3, p = ns) and the length of stay was comparable in 3-D and 2-D patients (8.4 ± 2.6 vs. 9.1 ± 3.3 days, respectively, p = ns). CONCLUSIONS Laparoscopic 3-D vision is as equally effective as 2-D vision in LRH with intracorporeal anastomosis, with a similar proportion of associated procedures and number of lymph nodes retrieved in the same operative time. Further prospective larger randomized studies are necessary to verify if LRH with 3-D video can reduce postoperative complications, compared to 2-D video.",2021,"Mean operative time was comparable in the two groups (159.0 ± 48.8 min vs. 17.06 ± 36.0 min, p = ns, group 2-D and 3-D, respectively).","['239 patients undergoing LRH for cancer in a 14-year period (June 2005-January 2020', 'One hundred and fourteen patients were included in the study: 55 (48.2%) operated with 2-D and 59 (51.8%) with 3-D video', 'patients with right colon cancer']","['laparoscopic right hemicolectomy (LHR', 'intracorporeal anastomosis with 2-D/3-D video', 'Two-dimensional (2-D) vs. three-dimensional (3-D) laparoscopic right hemicolectomy with intracorporeal anastomosis']","['mean number of lymph nodes', 'Intraoperative complications', 'postoperative complications', 'Tumor site and postoperative stage distribution', 'length of stay', 'Mean operative time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C5191314', 'cui_str': '48.2'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C1305188', 'cui_str': 'Right colon structure'}]","[{'cui': 'C0585464', 'cui_str': 'Laparoscopic-assisted right colectomy'}, {'cui': 'C0201504', 'cui_str': 'Histamine release from leukocytes measurement'}, {'cui': 'C0332853', 'cui_str': 'Anastomosis'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0021890', 'cui_str': 'Intraoperative complication'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0475445', 'cui_str': 'Tumor site'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}]",239.0,0.152974,"Mean operative time was comparable in the two groups (159.0 ± 48.8 min vs. 17.06 ± 36.0 min, p = ns, group 2-D and 3-D, respectively).","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Portale', 'Affiliation': 'Department of General Surgery, Azienda Euganea ULSS 6, Via Casa di Ricovero, 40, 35013, Cittadella, Italy. portale@surgery.usc.edu.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Pedon', 'Affiliation': 'Department of General Surgery, Azienda Euganea ULSS 6, Via Casa di Ricovero, 40, 35013, Cittadella, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Benacchio', 'Affiliation': 'Department of Epidemiology, Azienda Euganea ULSS 6, Padua, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cipollari', 'Affiliation': 'Department of General Surgery, Azienda Euganea ULSS 6, Via Casa di Ricovero, 40, 35013, Cittadella, Italy.'}, {'ForeName': 'Valentino', 'Initials': 'V', 'LastName': 'Fiscon', 'Affiliation': 'Department of General Surgery, Azienda Euganea ULSS 6, Via Casa di Ricovero, 40, 35013, Cittadella, Italy.'}]",Surgical endoscopy,['10.1007/s00464-020-07977-8'] 566,32903953,The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial.,"Purpose To evaluate the efficacy and safety of low dose versus usual dose of Hyoscine during endoscopic retrograde cholangiopancreatography (ERCP). Patients and Methods This randomized, open-label clinical trial included 282 patients undergoing ERCP who had duodenal peristalsis interfering with cannulation. Patients were randomly divided into two groups: Group one and two received low (5 mg) and usual (10 mg) dose of Hyoscine, respectively. Cardiovascular service consultation was performed for all patients before entering the study and performing ERCP. Hyoscine was injected intravenously, and the spasmolytic effect of the drug was assessed while the papilla was in a completely enface view. The time interval between cessation of peristalsis and its further onset was recorded by the chronometer. Also, patient's heart rate and blood pressure were monitored during ERCP by digital monitoring. Results The results showed no statistically significant differences in the mean duration of peristalsis, the duration of the antispasmodic activity and the time required to increase the heart rate between two groups (P=0.38, P=0.48, P=0.32, respectively). No significant differences were observed regarding the average of heart rate and mean arterial blood pressure (MAP) before drug administration between the two groups (P=0.182 and P=0.29, respectively), but after the drug administration, tachycardia and hypotension were significantly higher in the second group (P=0.007 and P=0.001, respectively). There was no statistically significant difference in the frequency of arrhythmia between two groups (P=0.08). The results also showed that tachycardia and hypotension occurred more frequently in men and elderly patients (P <0.05). Conclusion A low dose of Hyoscine is as effective as the usual dose and its side effects such as alteration in blood pressure and heart rate are much fewer, especially in men and elderly patients.",2020,"The results also showed that tachycardia and hypotension occurred more frequently in men and elderly patients (P <0.05). ","['282 patients undergoing ERCP who had duodenal peristalsis interfering with cannulation', 'men and elderly patients']","['endoscopic retrograde cholangiopancreatography (ERCP', 'Hyoscine', 'Endoscopic Retrograde Cholangiopancreatography']","['heart rate and blood pressure', 'blood pressure and heart rate', 'tachycardia and hypotension', 'efficacy and safety', 'Cardiovascular service consultation', 'time interval between cessation of peristalsis and its further onset', 'mean duration of peristalsis, the duration of the antispasmodic activity', 'heart rate', 'frequency of arrhythmia', 'average of heart rate and mean arterial blood pressure (MAP']","[{'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0013303', 'cui_str': 'Duodenal'}, {'cui': 'C0031133', 'cui_str': 'Peristalsis'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0036442', 'cui_str': 'Scopolamine'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0031133', 'cui_str': 'Peristalsis'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0037766', 'cui_str': 'Antispasmodic'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}]",282.0,0.0284825,"The results also showed that tachycardia and hypotension occurred more frequently in men and elderly patients (P <0.05). ","[{'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Salmanroghani', 'Affiliation': 'Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Massoud', 'Initials': 'M', 'LastName': 'Mirvakili', 'Affiliation': 'Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Mahtabalsadat', 'Initials': 'M', 'LastName': 'Mirjalili', 'Affiliation': 'Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mahmud', 'Initials': 'M', 'LastName': 'Baghbanian', 'Affiliation': 'Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Roham', 'Initials': 'R', 'LastName': 'Salmanroghani', 'Affiliation': 'Medical Student Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}]",Clinical pharmacology : advances and applications,['10.2147/CPAA.S263531'] 567,32919897,"Dextrose prolotherapy versus radial extracorporeal shock wave therapy in the treatment of chronic plantar fasciitis: A randomized, controlled clinical trial.","In the recent years, prolotherapy is increasingly being used in the field of musculoskeletal medicine. However, few studies have investigated its effectiveness in plantar fasciitis (PF). The purpose of this study was to compare the effectiveness of ultrasound-guided dextrose prolotherapy with radial extracorporeal shock wave therapy (ESWT) in the treatment of chronic PF. This randomized controlled trial was conducted on 59 patients with chronic PF. Patients were randomly assigned into two groups receiving three sessions of radial ESWT (29 patients) vs. two sessions of ultrasound-guided intrafascial 2 cc dextrose 20% injection (30 patients). The following outcome measures were assessed before and then six weeks and 12 weeks after the treatments: pain intensity by visual analog scale (VAS), daily life and exercise activities by Foot and Ankle Ability Measure (FAAM), and the plantar fascia thickness by ultrasonographic imaging. The VAS and FAAM scales showed significant improvements of pain and function in both study groups 6 weeks and 12 weeks after the treatments. A significant reduction was noted for plantar fascia thickness at these intervals (all p < .05). The inter-group comparison revealed that except for the FAAM-sport subscale which favored ESWT, the interaction effects of group and time were not significant for other outcome measures. Dextrose prolotherapy has comparable efficacy to radial ESWT in reducing pain, daily-life functional limitation, and plantar fascia thickness in patients with PF. No serious adverse effects were observed in either group. LEVEL OF EVIDENCE: Level I, randomized controlled trial.",2021,The VAS and FAAM scales showed significant improvements of pain and function in both study groups 6 weeks and 12 weeks after the treatments.,"['patients with PF', 'chronic PF', '59 patients with chronic PF', 'chronic plantar fasciitis']","['Dextrose prolotherapy', 'radial ESWT', 'radial extracorporeal shock wave therapy', 'ultrasound-guided dextrose prolotherapy with radial extracorporeal shock wave therapy (ESWT', 'ultrasound-guided intrafascial 2 cc dextrose 20% injection']","['plantar fascia thickness', 'serious adverse effects', 'pain and function', 'pain intensity by visual analog scale (VAS), daily life and exercise activities by Foot and Ankle Ability Measure (FAAM), and the plantar fascia thickness by ultrasonographic imaging', 'pain, daily-life functional limitation, and plantar fascia thickness', 'FAAM-sport subscale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0149756', 'cui_str': 'Plantar fasciitis'}, {'cui': 'C1136148', 'cui_str': 'Fasciitis, Plantar, Chronic'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0500223', 'cui_str': 'Prolotherapy'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C1737238', 'cui_str': 'Extracorporeal shock wave therapy'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0549109', 'cui_str': 'Plantar fascia structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0038039', 'cui_str': 'Sport'}]",59.0,0.103734,The VAS and FAAM scales showed significant improvements of pain and function in both study groups 6 weeks and 12 weeks after the treatments.,"[{'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Asheghan', 'Affiliation': 'Exercise Physiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: m_asheghan@bmsu.ac.ir.'}, {'ForeName': 'Seyed Ebrahim', 'Initials': 'SE', 'LastName': 'Hashemi', 'Affiliation': 'Exercise Physiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Taghi', 'Initials': 'MT', 'LastName': 'Hollisaz', 'Affiliation': 'Exercise Physiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Peiman', 'Initials': 'P', 'LastName': 'Roumizade', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seyed Morteza', 'Initials': 'SM', 'LastName': 'Hosseini', 'Affiliation': 'Medicine, Quran and Hadith Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ghanjal', 'Affiliation': 'Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}]",Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons,['10.1016/j.fas.2020.08.008'] 568,32910084,INTERNAL LIMITING MEMBRANE PEELING DURING VITRECTOMY FOR DIABETIC VITREOUS HEMORRHAGE: A Randomized Clinical Trial.,"PURPOSE To evaluate the benefits of internal limiting membrane peeling in proliferative diabetic retinopathy subjects undergoing pars plana vitrectomy for the treatment of vitreous hemorrhage. METHODS Two hundred and fifty-eight proliferative diabetic retinopathy subjects undergoing pars plana vitrectomy for vitreous hemorrhage were enrolled into the trial. Patients were randomized into one of two cohorts: Group A patients underwent internal limiting membrane peeling, whereas Group B patients did not undergo internal limiting membrane peeling. The main outcome was best-corrected visual acuity at 6 months. Secondary outcomes were optical coherence tomography central macular thickness at 6 months, incidence of diabetic macular edema treatment during the postoperative trial period, and incidence of epiretinal membrane at 6 months. RESULTS Two hundred and seven patients were randomized and completed 6 months follow-up. Group A had better best-corrected visual acuity at 6 months than Group B (P < 0.01). Group A had a lower incidence of diabetic macular edema treatment during the postoperative trial period and a lower incidence of epiretinal membrane at 6 months than Group B (P = 0.02 and P < 0.001, respectively). There was a trend toward lower central macular thickness on optical coherence tomography in Group A than Group B (P = 0.09). There were no significant differences in baseline details or complications intraoperatively or postoperatively between cohorts. CONCLUSION This trial demonstrated better vision, fewer postoperative diabetic macular edema treatments, and a lower incidence of epiretinal membrane at 6 months when internal limiting membrane peeling was performed. Internal limiting membrane peeling may be considered a vital maneuver to perform in proliferative diabetic retinopathy subjects undergoing pars plana vitrectomy for vitreous hemorrhage.",2021,There was a trend towards lower CMT on OCT in Group A compared to Group B (p=0.09).,"['vitreous hemorrhage (VH', 'proliferative diabetic retinopathy (PDR) subjects undergoing', 'Two hundred and seven patients', 'Diabetic Vitreous Hemorrhage', 'Two hundred and fifty-eight PDR subjects undergoing PPV for VH were enrolled into the trial', 'PDR subjects undergoing PPV for VH']","['internal limiting membrane (ILM) peeling', 'Internal Limiting Membrane Peeling during Vitrectomy', 'pars plana vitrectomy (PPV', 'ILM peeling']","['ERM', 'optical coherence tomography (OCT) central macular thickness (CMT) at 6 months, incidence of diabetic macular edema (DME) treatment during the postoperative trial period, and incidence of epiretinal membrane (ERM', 'BCVA', 'corrected visual acuity (BCVA', 'incidence of DME treatment']","[{'cui': 'C0042909', 'cui_str': 'Vitreous hemorrhage'}, {'cui': 'C0154830', 'cui_str': 'Proliferative retinopathy with diabetes mellitus'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0730283', 'cui_str': 'Vitreous hemorrhage due to diabetes mellitus'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0042903', 'cui_str': 'Vitrectomy'}, {'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}]","[{'cui': 'C0339543', 'cui_str': 'Epiretinal membrane'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}]",258.0,0.164952,There was a trend towards lower CMT on OCT in Group A compared to Group B (p=0.09).,"[{'ForeName': 'Ryan B', 'Initials': 'RB', 'LastName': 'Rush', 'Affiliation': 'Instituto de la Visión- Hospital La Carlota, Zambrano, Montemorelos, Nuevo León, México.'}, {'ForeName': 'Agustin', 'Initials': 'A', 'LastName': 'Del Valle Penella', 'Affiliation': 'Instituto de la Visión- Hospital La Carlota, Zambrano, Montemorelos, Nuevo León, México.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Reinauer', 'Affiliation': 'Instituto de la Visión- Hospital La Carlota, Zambrano, Montemorelos, Nuevo León, México.'}, {'ForeName': 'Sloan W', 'Initials': 'SW', 'LastName': 'Rush', 'Affiliation': 'Panhandle Eye Group, Amarillo, Texas.'}, {'ForeName': 'Pedro Gomez', 'Initials': 'PG', 'LastName': 'Bastar', 'Affiliation': 'Instituto de la Visión- Hospital La Carlota, Zambrano, Montemorelos, Nuevo León, México.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002976'] 569,32917417,"Effects of brown seaweeds on postprandial glucose, insulin and appetite in humans - A randomized, 3-way, blinded, cross-over meal study.","BACKGROUND & AIMS Seaweed including brown seaweeds with rich bioactive components may be efficacious for a glycaemic management strategy and appetite control. We investigated the effects of two brown edible seaweeds, Laminaria digitata (LD) and Undaria pinnatifida (UP), on postprandial glucose metabolism and appetite following a starch load in a human meal study. METHODS Twenty healthy subjects were enrolled in a randomized, 3-way, blinded cross-over trial. The study was registered under ClinicalTrials.gov Identifier no. NCT00123456. At each test day, the subjects received one of three meals comprising 30 g of starch with 5 g of LD or UP or an energy-adjusted control meal containing pea protein. Fasting and postprandial blood glucose, insulin, C-peptide and glucagon-like peptide-1 (GLP-1) concentrations were measured. Subjective appetite sensations were scored using visual analogue scales (VAS). RESULTS Linear mixed model (LMM) analysis showed a lower blood glucose, insulin and C-peptide response following the intake of LD and UP, after correction for body weight. Participants weighing ≤ 63 kg had a reduced glucose response compared to control meal between 40 and 90 min both following LD and UP meals. Furthermore, LMM analysis for C-peptide showed a significantly lower response after intake of LD. Compared to the control meal, GLP-1 response was higher after the LD meal, both before and after the body weight adjustment. The VAS scores showed a decreased appetite sensation after intake of the seaweeds. Ad-libitum food intake was not different three hours after the seaweed meals compared to control. CONCLUSIONS Concomitant ingestion of brown seaweeds may help improving postprandial glycaemic and appetite control in healthy and normal weight adults, depending on the dose per body weight. CLINICAL TRIAL REGISTRY NUMBER Clinicaltrials.gov (ID# NCT02608372).",2021,"Fasting and postprandial blood glucose, insulin, C-peptide and glucagon-like peptide-1","['healthy and normal weight adults', 'Twenty healthy subjects']",['starch with 5\xa0g of LD or UP or an energy-adjusted control meal containing pea protein'],"['Laminaria digitata (LD) and Undaria pinnatifida (UP), on postprandial glucose metabolism and appetite', 'VAS scores', 'glucose response', 'appetite sensation', 'visual analogue scales (VAS', 'postprandial glycaemic and appetite control', 'GLP-1) concentrations', 'Subjective appetite sensations', 'GLP-1 response', 'postprandial glucose, insulin and appetite', 'Fasting and postprandial blood glucose, insulin, C-peptide and glucagon-like peptide-1', 'blood glucose, insulin and C-peptide response']","[{'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0751493', 'cui_str': 'Kelp'}, {'cui': 'C1030485', 'cui_str': 'Undaria pinnatifida'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C3535674', 'cui_str': 'Pea Proteins'}]","[{'cui': 'C0751493', 'cui_str': 'Kelp'}, {'cui': 'C1030485', 'cui_str': 'Undaria pinnatifida'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0003622', 'cui_str': 'Appetite control'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}]",20.0,0.129334,"Fasting and postprandial blood glucose, insulin, C-peptide and glucagon-like peptide-1","[{'ForeName': 'Nazikussabah', 'Initials': 'N', 'LastName': 'Zaharudin', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark; Faculty of Industrial Sciences and Technology, Universiti Malaysia Pahang, Gambang, Pahang, Malaysia.'}, {'ForeName': 'Mikkel', 'Initials': 'M', 'LastName': 'Tullin', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Ceyda Tugba', 'Initials': 'CT', 'LastName': 'Pekmez', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. Electronic address: ctp@nexs.ku.dk.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Sloth', 'Affiliation': 'Research Group for NanoBio Science, National Food Institute, Technical University of Denmark, Kgs Lyngby, Denmark.'}, {'ForeName': 'Rie R', 'Initials': 'RR', 'LastName': 'Rasmussen', 'Affiliation': 'Research Group for NanoBio Science, National Food Institute, Technical University of Denmark, Kgs Lyngby, Denmark.'}, {'ForeName': 'Lars O', 'Initials': 'LO', 'LastName': 'Dragsted', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.027'] 570,32919816,Effect of monthly vitamin D on diverticular disease hospitalization: Post-hoc analysis of a randomized controlled trial.,"BACKGROUND & AIMS Some studies have linked low vitamin D status and high risk of diverticular disease, but the causal relationship between vitamin D and diverticular disease remains unclear; clinical trial data are warranted. The objective was to assess the efficacy of vitamin D 3 supplementation on diverticular disease hospitalization. METHODS Post-hoc analysis of a community-based randomized double-blind placebo-controlled trial (RCT) with 5108 participants randomized to receive monthly 100,000 IU vitamin D (n = 2558) or identical placebo (n = 2550). The outcome was time to first diverticular disease hospitalization from randomization to the end of intervention (July 2015), including a prespecified subgroup analysis in participants with baseline deseasonalized 25-hydroxyvitamin D (25(OH)D) levels < 50 nmol/L. RESULTS Over a median of 3.3 years follow-up, 74 participants had diverticular disease hospitalization. There was no difference in the risk of diverticular disease hospitalization between vitamin D supplementation (35/2558 = 1.4%) and placebo (39/2550 = 1.5%) groups (adjusted hazard ratio (HR) = 0.90; p = 0.65), although in participants with deseasonalized 25(OH)D < 50 nmol/L (n = 1272), the risk was significantly lower in the vitamin D group than placebo (HR = 0.08, p = 0.02). DISCUSSION Monthly 100,000 IU vitamin D 3 does not reduce the risk of diverticular disease hospitalization in the general population. Further RCTs are required to investigate the effect of vitamin D supplementation on the diverticular disease in participants with low 25(OH)D levels.",2021,"There was no difference in the risk of diverticular disease hospitalization between vitamin D supplementation (35/2558 = 1.4%) and placebo (39/2550 = 1.5%) groups (adjusted hazard ratio (HR) = 0.90; p = 0.65), although in participants with deseasonalized 25(OH)D ","['participants with low 25(OH)D levels', '5108 participants randomized to receive monthly 100,000']","['vitamin D supplementation', 'vitamin D 3 supplementation', 'placebo', 'IU vitamin D (n\xa0=\xa02558) or identical placebo', 'monthly vitamin D']","['diverticular disease hospitalization', 'time to first diverticular disease hospitalization', 'risk of diverticular disease hospitalization', 'baseline deseasonalized 25-hydroxyvitamin D (25(OH)D) levels']","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C1510475', 'cui_str': 'Diverticula of intestine'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",5108.0,0.680732,"There was no difference in the risk of diverticular disease hospitalization between vitamin D supplementation (35/2558 = 1.4%) and placebo (39/2550 = 1.5%) groups (adjusted hazard ratio (HR) = 0.90; p = 0.65), although in participants with deseasonalized 25(OH)D ","[{'ForeName': 'Zhenqiang', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'School of Population Health, University of Auckland, Auckland, New Zealand; Department of Geriatric Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Broad', 'Affiliation': 'Department of Geriatric Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Sluyter', 'Affiliation': 'School of Population Health, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Waayer', 'Affiliation': 'School of Population Health, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Camargo', 'Affiliation': 'Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Scragg', 'Affiliation': 'School of Population Health, University of Auckland, Auckland, New Zealand. Electronic address: r.scragg@auckland.ac.nz.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.030'] 571,32919819,Six-month outcomes after individualized nutritional support during the hospital stay in medical patients at nutritional risk: Secondary analysis of a prospective randomized trial.,"BACKGROUND Among medical inpatients at risk of malnutrition, the use of individualized nutritional support during the hospital stay was found to reduce complications and improve mortality at short-term. We evaluated clinical outcomes at 6-months follow-up. METHODS We randomly assigned 2028 patients to receive protocol-guided individualized nutritional support to reach protein and energy goals (intervention group) or hospital food as usual (control group) during the hospital stay. The intervention was discontinued at hospital discharge and further nutritional support was based on the discretion of the treating team. We had complete follow-up information of 1995 patients (98%), which were included in the final analysis. The primary endpoint was all-cause mortality at 6-months. Prespecified secondary end points included non-elective hospital readmissions, functional outcome and quality of life. RESULTS At 6-month, 231 of 994 (23.2%) intervention group patients had died compared to 246 of 999 (24.6%) control group patients, resulting in a hazard ratio for death of 0.90 (95%CI 0.76 to 1.08, p = 0.277). Compared to control patients, intervention group patients had similar rates of hospital readmission (27.3% vs. 27.6%, HR 1.00 (95%CI 0.84 to 1.18), p = 0.974), falls (11.2% vs. 10.9%, HR 0.96 (95%CI 0.72 to 1.27), p = 0.773) and similar quality of life and activities of daily living scores. INTERPRETATION While individualized nutritional support during the hospital stay significantly reduced short-term mortality, there was no legacy effect on longer term outcomes. Future trials should investigate whether continuation of nutritional support after hospital discharge reduces the high malnutrition-associated mortality rates in this vulnerable patient population. TRIAL REGISTRATION ClinicalTrials.gov number, NCT02517476.",2021,"Compared to control patients, intervention group patients had similar rates of hospital readmission (27.3% vs. 27.6%, HR 1.00 (95%CI 0.84 to 1.18), p = 0.974), falls (11.2% vs. 10.9%, HR 0.96 (95%CI 0.72 to 1.27), p = 0.773) and similar quality of life and activities of daily living scores. ","['2028 patients to receive', 'medical patients at nutritional risk', 'medical inpatients at risk of malnutrition']","['individualized nutritional support', 'protocol-guided individualized nutritional support to reach protein and energy goals (intervention group) or hospital food as usual (control group']","['hazard ratio for death', 'cause mortality', 'non-elective hospital readmissions, functional outcome and quality of life', 'quality of life and activities of daily living scores', 'died', 'rates of hospital readmission']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}]","[{'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",2028.0,0.136654,"Compared to control patients, intervention group patients had similar rates of hospital readmission (27.3% vs. 27.6%, HR 1.00 (95%CI 0.84 to 1.18), p = 0.974), falls (11.2% vs. 10.9%, HR 0.96 (95%CI 0.72 to 1.27), p = 0.773) and similar quality of life and activities of daily living scores. ","[{'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Kaegi-Braun', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Tribolet', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland.'}, {'ForeName': 'Filomena', 'Initials': 'F', 'LastName': 'Gomes', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; The New York Academy of Sciences, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Fehr', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Baechli', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Geiser', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Deiss', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Kutz', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bregenzer', 'Affiliation': 'Internal Medicine, Spital Lachen, Switzerland.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Hoess', 'Affiliation': 'Internal Medicine, Kantonsspital Münsterlingen, Switzerland.'}, {'ForeName': 'Vojtech', 'Initials': 'V', 'LastName': 'Pavlicek', 'Affiliation': 'Internal Medicine, Kantonsspital Münsterlingen, Switzerland.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Schmid', 'Affiliation': 'Internal Medicine, Kantonsspital Münsterlingen, Switzerland.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Bilz', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Sigrist', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Brändle', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Benz', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Henzen', 'Affiliation': 'Internal Medicine, Kantonsspital Luzern, Switzerland.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Mattmann', 'Affiliation': 'Internal Medicine, Kantonsspital Luzern, Switzerland.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Thomann', 'Affiliation': 'Internal Medicine, Bürgerspital Solothurn, Switzerland.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Rutishauser', 'Affiliation': 'Internal Medicine, Kantonsspital Baselland, Switzerland.'}, {'ForeName': 'Drahomir', 'Initials': 'D', 'LastName': 'Aujesky', 'Affiliation': 'Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Rodondi', 'Affiliation': 'Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Switzerland.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Donzé', 'Affiliation': ""Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Zeno', 'Initials': 'Z', 'LastName': 'Stanga', 'Affiliation': 'Division of Diabetology, Endocrinology, Nutritional Medicine & Metabolism, Inselspital, Bern University Hospital, University of Bern, Switzerland.'}, {'ForeName': 'Beat', 'Initials': 'B', 'LastName': 'Mueller', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Schuetz', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland. Electronic address: schuetzph@gmail.com.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.019'] 572,32943241,"Specialized oral nutritional supplement (ONS) improves handgrip strength in hospitalized, malnourished older patients with cardiovascular and pulmonary disease: A randomized clinical trial.","BACKGROUND & AIMS Oral Nutritional Supplements (ONS) are used to treat malnutrition and improve clinical outcomes in malnourished patients. Poor handgrip strength (HGS) is associated with an increased risk of mortality, disability and other adverse health consequences. This analysis examined the effect of a specialized ONS on HGS and its relationship to nutritional status in hospitalized, older adults with malnutrition who were participants in the NOURISH trial. METHODS We enrolled older (≥65years), malnourished (Subjective Global Assessment [SGA] class B/C) adults hospitalized for cardiovascular and pulmonary events: congestive heart failure, acute myocardial infarction, pneumonia and/or chronic obstructive pulmonary disease exacerbation in a double-blind, randomized, placebo-controlled trial (NOURISH study). During hospitalization and until 90 days after discharge, participants received standard-of-care plus a high protein and beta-hydroxy-beta-methylbutyrate containing ONS (S-ONS; n = 328) or a placebo supplement (n = 324), aimed at 2 servings/day. HGS was evaluated by dynamometer at baseline, hospital discharge, day (d) 30, d60, and d90 post-discharge. RESULTS Post hoc, repeated measures analysis of data at discharge, d30, d60, and d90 showed significantly higher HGS in the S-ONS vs. the placebo group in the evaluable group (Least Squares Means ± Standard Error: (23.25 ± 0.25 vs. 22.63 ± 0.25, p = 0.043). At d90, there was a significant positive association between HGS and nutritional status (SGA) improvements in the entire cohort: 49% of participants with increased HGS from discharge had improved nutritional status versus 31% with unchanged or decreased HGS (p = 0.003). HGS and the scores on the Katz index of independence in activities of daily living (ADL) were positively associated at all visits including all ITT subjects (Pearson's r range: 0.24 to 0.34, all p < 0.0001). CONCLUSIONS S-ONS provided during hospitalization and up to 90 days post-discharge improves HGS in malnourished older adults following cardiovascular and pulmonary events and may contribute to improvement in patients' overall recovery. CLINICAL TRIAL REGISTRATION www.ClinicalTrials.gov NCT01626742.",2021,"HGS and the scores on the Katz index of independence in activities of daily living (ADL) were positively associated at all visits including all ITT subjects (Pearson's r range: 0.24 to 0.34, all p < 0.0001). ","['malnourished older adults', 'hospitalized, malnourished older patients with cardiovascular and pulmonary disease', 'enrolled older (≥65years), malnourished (Subjective Global Assessment [SGA] class B/C) adults hospitalized for cardiovascular and pulmonary events: congestive heart failure, acute myocardial infarction, pneumonia and/or chronic obstructive pulmonary disease exacerbation', 'hospitalized, older adults with malnutrition who were participants in the NOURISH trial', 'malnourished patients']","['specialized ONS', 'Specialized oral nutritional supplement (ONS', 'standard-of-care plus a high protein and beta-hydroxy-beta-methylbutyrate containing ONS (S-ONS; n\xa0=\xa0328) or a placebo supplement', 'placebo', 'Oral Nutritional Supplements (ONS']","['Katz index of independence in activities of daily living (ADL', 'HGS', 'handgrip strength', 'HGS and nutritional status (SGA) improvements', 'nutritional status', 'Poor handgrip strength (HGS']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0024115', 'cui_str': 'Disorder of lung'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0451514', 'cui_str': 'Subjective global assessment'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C3508933', 'cui_str': 'Chronic obstructive pulmonary disease exacerbation'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0053454', 'cui_str': '3-hydroxyisovaleric acid'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0451239', 'cui_str': 'Katz activities of daily living'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}]",,0.541382,"HGS and the scores on the Katz index of independence in activities of daily living (ADL) were positively associated at all visits including all ITT subjects (Pearson's r range: 0.24 to 0.34, all p < 0.0001). ","[{'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Matheson', 'Affiliation': 'Department of Family Medicine, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Nelson', 'Affiliation': 'Abbott Nutrition, Research and Development, Columbus, OH, USA. Electronic address: jeffrey.l.nelson@abbott.com.'}, {'ForeName': 'Geraldine E', 'Initials': 'GE', 'LastName': 'Baggs', 'Affiliation': 'Abbott Nutrition, Research and Development, Columbus, OH, USA.'}, {'ForeName': 'Menghua', 'Initials': 'M', 'LastName': 'Luo', 'Affiliation': 'Abbott Nutrition, Research and Development, Columbus, OH, USA.'}, {'ForeName': 'Nicolaas E', 'Initials': 'NE', 'LastName': 'Deutz', 'Affiliation': 'Center for Translational Research in Aging & Longevity, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.035'] 573,32913130,Effectiveness of providing university students with a mindfulness-based intervention to increase resilience to stress: 1-year follow-up of a pragmatic randomised controlled trial.,"BACKGROUND There is concern that increasing demand for student mental health services reflects deteriorating student well-being. We designed a pragmatic, parallel, single-blinded randomised controlled trial hypothesising that providing mindfulness courses to university students would promote their resilience to stress up to a year later. Here we present 1-year follow-up outcomes. METHODS University of Cambridge students without severe mental illness or crisis were randomised (1:1, remote software-generated random numbers), to join an 8-week mindfulness course adapted for university students (Mindfulness Skills for Students (MSS)), or to mental health support as usual (SAU). RESULTS We randomised 616 students; 53% completed the 1-year follow-up questionnaire. Self-reported psychological distress and mental well-being improved in the MSS arm for up to 1 year compared to SAU (p<0.001). Effects were smaller than during the examination period. No significant differences between arms were detected in the use of University Counselling Service and other support resources, but there was a trend for MSS participants having milder needs. There were no differences in students' workload management; MSS participants made more donations. Home practice had positive dose-response effects; few participants meditated. No adverse effects related to self-harm, suicidality or harm to others were detected. CONCLUSION Loss to follow-up is a limitation, but evidence suggests beneficial effects on students' average psychological distress that last for at least a year. Effects are on average larger at stressful times, consistent with the hypothesis that this type of mindfulness training increases resilience to stress. TRIAL REGISTRATION NUMBER ACTRN12615001160527.",2021,Self-reported psychological distress and mental well-being improved in the MSS arm for up to 1 year compared to SAU (p<0.001).,"['University of Cambridge students without severe mental illness or crisis', '616 students; 53% completed the 1-year follow-up questionnaire', 'university students with a', 'university students']","['mindfulness-based intervention', 'remote software-generated random numbers), to join an 8-week mindfulness course adapted for university students (Mindfulness Skills for Students (MSS)), or to mental health support as usual (SAU']",['University Counselling Service'],"[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0231224', 'cui_str': 'Crisis'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0037585', 'cui_str': 'Software'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]",616.0,0.239011,Self-reported psychological distress and mental well-being improved in the MSS arm for up to 1 year compared to SAU (p<0.001).,"[{'ForeName': 'Julieta', 'Initials': 'J', 'LastName': 'Galante', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK mjg231@cam.ac.uk.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Stochl', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Géraldine', 'Initials': 'G', 'LastName': 'Dufour', 'Affiliation': 'University Counselling Service, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Maris', 'Initials': 'M', 'LastName': 'Vainre', 'Affiliation': 'MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Adam Peter', 'Initials': 'AP', 'LastName': 'Wagner', 'Affiliation': 'National Institute for Health Research Applied Research Collaboration East of England, Cambridge, UK.'}, {'ForeName': 'Peter Brian', 'Initials': 'PB', 'LastName': 'Jones', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}]",Journal of epidemiology and community health,['10.1136/jech-2020-214390'] 574,32928579,"Effects of adequate dietary protein with whey protein, leucine, and vitamin D supplementation on sarcopenia in older adults: An open-label, parallel-group study.","BACKGROUND & AIMS Sarcopenia is defined as a syndrome characterized by declines in skeletal muscle mass and strength or an alteration in physical function. Although some studies showed nutritional supplementation alone might have health benefits for older sarcopenic patients, their results were inconsistent and remain controversial. The objective of this study was to evaluate if a diet with high protein supplementation (Supp) can lead to better improvement than additional protein intake via dietary counseling (Diet) in maintaining the muscle mass and strength among sarcopenic elders. METHODS This was an open-label, parallel-group (Supp vs. Diet) trial. In total, 56 sarcopenic elders completed this study. All subjects were advised to achieve adequate protein intake (1.2-1.5 g/kg body weight/day). This amount of protein is recommended for the elderly and is thought to prevent or retard muscle loss due to aging. The diet group (n = 28) was recommended to consume an ordinary protein-rich diet via counselling whereas the Supp group (n = 28) received a vitamin D- and leucine-enriched whey protein supplement for 12 weeks. The appendicular muscle mass index (AMMI), handgrip strength, gait speed, and calorie and macronutrients intake were evaluated after 4 and 12 weeks of the diet intervention. RESULTS Total energy and protein intake increased in both groups. The Supp group had higher intake than the Diet group. The AMMI increased in both groups, and handgrip strength improved in the Diet group. However, no significant differences in AMMI or handgrip strength were found between the two groups. Compared to the Diet group, the Supp group had better improvement in gait speed after 12 weeks of the supplement intervention especially in subjects younger than 75 years. CONCLUSIONS The AMMI can be improved as long as sufficient protein is consumed (1.2-1.5 g/kg body weight/day) in sarcopenic elders. Nutritional supplement allows the sarcopenic elderly to more conveniently meet their protein requirements. Supplementation with whey protein and vitamin D can further improve gait speed in elderly sarcopenic subjects, especially in the ""younger"" age group. TRIAL REGISTRATION ClinicalTrials.gov NCT03860194.",2021,"The appendicular muscle mass index (AMMI), handgrip strength, gait speed, and calorie and macronutrients intake were evaluated after 4 and 12 weeks of the diet intervention. ","['older adults', 'sarcopenic elders', 'older sarcopenic patients', 'elderly sarcopenic subjects', '56 sarcopenic elders']","['additional protein intake via dietary counseling (Diet', 'vitamin D- and leucine-enriched whey protein supplement', 'Nutritional supplement', 'diet with high protein supplementation (Supp', 'adequate dietary protein with whey protein, leucine, and\xa0vitamin D supplementation', 'ordinary protein-rich diet via counselling whereas the Supp group', 'Supplementation with whey protein and vitamin D']","['appendicular muscle mass index (AMMI), handgrip strength, gait speed, and calorie and macronutrients intake', 'adequate protein intake', 'handgrip strength', 'Total energy and protein intake', 'AMMI', 'gait speed', 'AMMI or handgrip strength']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0331055', 'cui_str': 'Genus Sambucus'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0770246', 'cui_str': 'Protein supplementation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0012177', 'cui_str': 'Proteins, Dietary'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0331049', 'cui_str': 'Ammi'}]",56.0,0.0148331,"The appendicular muscle mass index (AMMI), handgrip strength, gait speed, and calorie and macronutrients intake were evaluated after 4 and 12 weeks of the diet intervention. ","[{'ForeName': 'Chih-Chien', 'Initials': 'CC', 'LastName': 'Lin', 'Affiliation': 'School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan; Department of Family Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.'}, {'ForeName': 'Ming-Hsiung', 'Initials': 'MH', 'LastName': 'Shih', 'Affiliation': 'Department of Family Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; Department of Communications Engineering, Yuan Ze University, Taoyuan City, Taiwan.'}, {'ForeName': 'Chih-Dao', 'Initials': 'CD', 'LastName': 'Chen', 'Affiliation': 'Department of Family Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.'}, {'ForeName': 'Sung-Ling', 'Initials': 'SL', 'LastName': 'Yeh', 'Affiliation': 'School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan. Electronic address: sangling@tmu.edu.tw.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.017'] 575,32928580,"The effectiveness of a weight-loss Mediterranean diet/lifestyle intervention in the management of obstructive sleep apnea: Results of the ""MIMOSA"" randomized clinical trial.","BACKGROUND & AIMS Although continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnea (OSA), lifestyle interventions have also emerged as complementary therapeutic choices. We aimed to explore whether the addition of a weight-loss Mediterranean diet/lifestyle intervention to OSA standard care, i.e. CPAP prescription and brief written healthy lifestyle advice, has an incremental effect on improving OSA severity, over the effect of standard care alone. METHODS We designed a parallel, randomized, controlled, superiority clinical trial. Eligible participants were adult, overweight men and women, diagnosed with moderate-to-severe OSA [apnea-hypopnea index (AHI)≥ 15 events/h] through an attended overnight polysomnography. Participants were blindly randomized to a standard care group (SCG, n = 65), a Mediterranean diet group (MDG, n = 62) or a Mediterranean lifestyle group (MLG, n = 60). All three study groups were prescribed with CPAP. The SCG additionally received written healthy lifestyle advice, while intervention arms were subjected to a 6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet. The MLG also received counselling on physical activity and sleep habits. Polysomnographic data and OSA symptoms were evaluated pre- and post-intervention. RESULTS A total of 187 OSA patients were recruited. Seven patients were excluded post-randomization and 53/180 (29%) were lost to follow-up. No harms from the interventions applied were reported. According to intention-to-treat analysis (n = 180), mean (95% confidence interval) AHI change was -4.2 (-7.4, -1.0) for the SCG, -24.7 (-30.4, -19.1) for the MDG and -27.3 (-33.9, -20.6) for the MLG. Post-intervention age-, sex-, baseline- and CPAP use-adjusted AHI was significantly lower in the MDG and the MLG compared to the SCG (mean difference: -18.0, and -21.2, respectively, both P < 0.001), and the differences remained significant after further adjustment for body-weight change (P = 0.004 and 0.008, respectively). Other respiratory event indices, daytime sleepiness and insomnia were also significantly lower in both intervention arms compared to the SCG (all P < 0.05). The MLG only presented higher percent rapid-eye-movement sleep and lower daytime sleepiness compared to the MDG (both P < 0.05). Results were similar in the per-protocol analysis (n = 127). CONCLUSIONS A dietary/lifestyle intervention on top of standard care leads to greater improvements in OSA severity and symptomatology compared to standard care alone. Benefits are evident regardless of CPAP use and weight loss. TRIAL REGISTRATION Clinicaltrials.gov NCT02515357, https://clinicaltrials.gov/ct2/show/NCT02515357.",2021,"Other respiratory event indices, daytime sleepiness and insomnia were also significantly lower in both intervention arms compared to the SCG (all P < 0.05).","['187 OSA patients were recruited', 'Eligible participants were adult, overweight men and women, diagnosed with moderate-to-severe OSA [apnea-hypopnea index (AHI)≥ 15 events/h] through an attended overnight polysomnography', 'obstructive sleep apnea']","['standard care group (SCG, n\xa0=\xa065), a Mediterranean diet group (MDG, n\xa0=\xa062) or a Mediterranean lifestyle group (MLG, n\xa0=\xa060', 'weight-loss Mediterranean diet/lifestyle intervention', 'continuous positive airway pressure (CPAP', 'baseline- and CPAP', 'CPAP']","['Polysomnographic data and OSA symptoms', 'OSA severity', 'OSA severity and symptomatology', 'AHI change', 'daytime sleepiness and insomnia', 'rapid-eye-movement sleep and lower daytime sleepiness', 'body-weight change', 'physical activity and sleep habits']","[{'cui': 'C4517618', 'cui_str': '187'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0235546', 'cui_str': 'Slow shallow breathing'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0012694', 'cui_str': 'Cromolyn sodium'}, {'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C0024443', 'cui_str': 'Madagascar'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0574375', 'cui_str': 'Malagasy language'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0037322', 'cui_str': 'Rapid eye movement sleep'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2133558', 'cui_str': 'Sleep Habits'}]",187.0,0.0758424,"Other respiratory event indices, daytime sleepiness and insomnia were also significantly lower in both intervention arms compared to the SCG (all P < 0.05).","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Georgoulis', 'Affiliation': 'Department of Nutrition & Dietetics, School of Health Science & Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Nikos', 'Initials': 'N', 'LastName': 'Yiannakouris', 'Affiliation': 'Department of Nutrition & Dietetics, School of Health Science & Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Ioanna', 'Initials': 'I', 'LastName': 'Kechribari', 'Affiliation': 'Department of Nutrition & Dietetics, School of Health Science & Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Kallirroi', 'Initials': 'K', 'LastName': 'Lamprou', 'Affiliation': 'Center of Sleep Disorders, 1st Department of Critical Care and Pulmonary Services, Medical School of Athens University, Evangelismos Hospital, Athens, Greece.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Perraki', 'Affiliation': 'Center of Sleep Disorders, 1st Department of Critical Care and Pulmonary Services, Medical School of Athens University, Evangelismos Hospital, Athens, Greece.'}, {'ForeName': 'Emmanouil', 'Initials': 'E', 'LastName': 'Vagiakis', 'Affiliation': 'Center of Sleep Disorders, 1st Department of Critical Care and Pulmonary Services, Medical School of Athens University, Evangelismos Hospital, Athens, Greece.'}, {'ForeName': 'Meropi D', 'Initials': 'MD', 'LastName': 'Kontogianni', 'Affiliation': 'Department of Nutrition & Dietetics, School of Health Science & Education, Harokopio University, Athens, Greece. Electronic address: mkont@hua.gr.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.037'] 576,32926247,The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.,"INTRODUCTION/OBJECTIVES The effect of intravenous (IV) golimumab on health-related quality of life (HRQoL) and productivity in patients with ankylosing spondylitis (AS) was evaluated. METHOD Patients were randomized to IV golimumab 2 mg/kg (n = 105) at weeks 0, 4, then every 8 weeks (q8w) through week 52 or placebo (n = 103) at weeks 0, 4, 12, with crossover to golimumab 2 mg/kg at weeks 16, 20, then q8w through week 52. Changes from baseline in EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily productivity VAS, Work Limitations Questionnaire (WLQ), and Ankylosing Spondylitis Quality of Life (ASQoL) were assessed. Correlations between these outcomes and disease activity and patient functioning outcomes were evaluated post hoc. RESULTS At week 16, changes from baseline (mean ± standard deviation) in EQ-5D-5L index (0.17 ± 0.16 vs 0.05 ± 0.14), EQ-VAS (20.3 ± 24.6 vs 4.8 ± 23.5), daily productivity VAS (- 2.9 ± - 2.9 vs - 1.1 ± - 2.5), WLQ productivity loss score (- 3.5 ± - 5.3 vs - 1.9 ± - 4.0), and ASQoL (- 5.4 ± - 5.0 vs - 1.8 ± - 4.5) were greater in the IV golimumab versus placebo group, respectively. At week 28, changes from baseline were similar between the IV golimumab and placebo-crossover groups (EQ-5D-5L index: 0.18 ± 0.17 and 0.16 ± 0.16, EQ-VAS: 20.5 ± 27.9 and 22.5 ± 23.1, daily productivity VAS: - 3.1 ± - 3.0 and - 3.1 ± - 2.8, WLQ productivity loss: - 3.9 ± - 5.5 and - 4.5 ± - 4.5, and ASQoL: - 5.3 ± - 5.2 and - 5.3 ± - 4.8, respectively); improvements were maintained through week 52. HRQoL and productivity outcomes were generally moderately correlated with disease activity and functioning outcomes. CONCLUSIONS In patients with AS, IV golimumab produced sustained improvements in HRQoL and productivity through 1 year, which correlated with improvements in disease activity and functioning. ClinicalTrials.gov registry number is NCT02186873. Key Points • Intravenous (IV) golimumab resulted in clinically important improvement in general and ankylosing spondylitis-specific health-related quality of life (HRQoL) and productivity outcomes in patients with ankylosing spondylitis (AS) as early as week 8 and maintained improvement through 1 year • Improvements in HRQoL and productivity outcomes in these patients with AS were correlated with improvements in measures of disease activity and patient functional capability • IV golimumab is an effective treatment option for AS that can help mitigate the negative effects of the disease on HRQoL and productivity.",2021,Intravenous (IV) golimumab resulted in clinically important improvement in general and ankylosing spondylitis-specific health-related quality of life (HRQoL) and productivity outcomes in patients with ankylosing spondylitis (AS) as early as week 8 and maintained improvement through 1 year • Improvements in HRQoL and productivity outcomes in these patients with AS were correlated with improvements in measures of disease activity and patient functional capability • IV golimumab is an effective treatment option for AS that can help mitigate the negative effects of the disease on HRQoL and productivity.,"['adult patients with active ankylosing spondylitis', 'patients with ankylosing spondylitis (AS', 'Patients']","['intravenous golimumab', 'placebo', 'Intravenous (IV) golimumab', 'intravenous (IV) golimumab']","['HRQoL and productivity', 'health-related quality of life (HRQoL) and productivity', 'disease activity and functioning', 'disease activity and patient functioning outcomes', 'disease activity and functioning outcomes', 'EQ-5D-5L index', 'daily productivity VAS', 'WLQ productivity loss score', 'EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily productivity VAS, Work Limitations Questionnaire (WLQ), and Ankylosing Spondylitis Quality of Life (ASQoL', 'health-related quality of life and work productivity', 'HRQoL and productivity outcomes', 'general and ankylosing spondylitis-specific health-related quality of life (HRQoL) and productivity outcomes']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0038013', 'cui_str': 'Ankylosing spondylitis'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C2353893', 'cui_str': 'golimumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038013', 'cui_str': 'Ankylosing spondylitis'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",,0.223187,Intravenous (IV) golimumab resulted in clinically important improvement in general and ankylosing spondylitis-specific health-related quality of life (HRQoL) and productivity outcomes in patients with ankylosing spondylitis (AS) as early as week 8 and maintained improvement through 1 year • Improvements in HRQoL and productivity outcomes in these patients with AS were correlated with improvements in measures of disease activity and patient functional capability • IV golimumab is an effective treatment option for AS that can help mitigate the negative effects of the disease on HRQoL and productivity.,"[{'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Reveille', 'Affiliation': 'Department of Internal Medicine, Division of Rheumatology, The University of Texas McGovern Medical School, 6431 Fannin, MSB 5.270, Houston, TX, USA. Reveille@uth.tmc.edu.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Hwang', 'Affiliation': 'Department of Internal Medicine, Division of Rheumatology, The University of Texas McGovern Medical School, 6431 Fannin, MSB 5.270, Houston, TX, USA.'}, {'ForeName': 'Abhijeet', 'Initials': 'A', 'LastName': 'Danve', 'Affiliation': 'Section of Rheumatology, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Shelly', 'Initials': 'S', 'LastName': 'Kafka', 'Affiliation': 'Janssen Scientific Affairs, LLC, Horsham, PA, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Peterson', 'Affiliation': 'Janssen Global Services, LLC, Horsham, PA, USA.'}, {'ForeName': 'Kim Hung', 'Initials': 'KH', 'LastName': 'Lo', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Lilianne', 'Initials': 'L', 'LastName': 'Kim', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Hsia', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Eric K H', 'Initials': 'EKH', 'LastName': 'Chan', 'Affiliation': 'Patient Reported Outcomes, Janssen Global Services, LLC, Raritan, NJ, USA.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Deodhar', 'Affiliation': 'Oregon Health & Science University, Portland, OR, USA.'}]",Clinical rheumatology,['10.1007/s10067-020-05342-7'] 577,32947028,"Efficacy of aminolevulinic acid 20 % solution photodynamic therapy in the treatment of actinic keratoses on the upper extremities: A post hoc analysis of a phase 3, randomized, vehicle-controlled trial.","BACKGROUND Photodynamic therapy with 5-aminolevulinic acid is indicated for targeted treatment of actinic keratoses on the face, scalp, and upper extremities. This was a post hoc analysis of a phase 3 randomized trial assessing the efficacy of aminolevulinic acid/photodynamic therapy for treatment of actinic keratoses on the upper extremities. METHODS Adults with 4-15 grade 1-2 actinic keratosis lesions on ≥1 upper extremity were randomized (1:1) to receive aminolevulinic acid/photodynamic therapy or vehicle/photodynamic therapy applied to individual lesions followed by occlusion and blue light treatment. Assessments included the clearance rate of treated lesions vs baseline, cumulative disease area clearance, and complete clearance by lesion size. RESULTS There were 135 and 134 patients randomized to aminolevulinic acid/photodynamic therapy and vehicle/photodynamic therapy groups, respectively. At 12 weeks, clearance of treated lesions (80.6 % vs 45.5 %; P <0.0001) and the mean decrease in cumulative disease area (82.4 % vs 42.6 %; P <0.0001) was significantly higher for aminolevulinic acid/photodynamic therapy vs vehicle/photodynamic therapy, respectively. Rates of complete clearance and clearance by cutpoint (≥90 %, ≥85 %, ≥80 %, or ≥75 % clearance) were numerically higher for aminolevulinic acid/photodynamic therapy. Clearance of lesions was higher for aminolevulinic acid/photodynamic therapy vs vehicle/photodynamic therapy regardless of baseline lesion size. Aminolevulinic acid/photodynamic therapy was well tolerated with adverse events consistent with those expected with photodynamic therapy. CONCLUSIONS Aminolevulinic acid photodynamic therapy is effective and well tolerated for the treatment of actinic keratosis lesions of the extremities.",2020,Clearance of lesions was higher for aminolevulinic acid/photodynamic therapy vs vehicle/photodynamic therapy regardless of baseline lesion size.,"['Adults with 4-15 grade 1-2 actinic keratosis lesions on ≥1 upper extremity', 'actinic keratoses on the upper extremities']","['aminolevulinic acid/photodynamic therapy and vehicle/photodynamic therapy', '5-aminolevulinic acid', 'aminolevulinic acid/photodynamic therapy or vehicle/photodynamic therapy applied to individual lesions followed by occlusion and blue light treatment', 'Aminolevulinic acid/photodynamic therapy', 'aminolevulinic acid/photodynamic therapy vs vehicle/photodynamic therapy', 'aminolevulinic acid/photodynamic therapy', 'aminolevulinic acid 20% solution combined with photodynamic therapy']","['clearance rate of treated lesions vs baseline, cumulative disease area clearance, and complete clearance by lesion size', 'Rates of complete clearance and clearance', 'cumulative disease area', 'clearance of treated lesions', 'Clearance of lesions']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0022602', 'cui_str': 'Actinic keratosis'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0439681', 'cui_str': 'Actinic'}]","[{'cui': 'C0002563', 'cui_str': 'Aminolevulinic Acid'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0303896', 'cui_str': 'Blue light'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0025515', 'cui_str': 'Metabolic clearance rate'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0449453', 'cui_str': 'Lesion size'}]",,0.0843171,Clearance of lesions was higher for aminolevulinic acid/photodynamic therapy vs vehicle/photodynamic therapy regardless of baseline lesion size.,"[{'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Berman', 'Affiliation': 'Center for Clinical and Cosmetic Research, 2925 Aventura Blvd, Suite 205, Aventura, FL, 33180, USA; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1295 N.W. 14th St., Suite K-M, Miami, FL, 33136, USA. Electronic address: bbmdphd@gmail.com.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Bhatia', 'Affiliation': 'Therapeutics Clinical Research, 9025 Balboa Avenue, Suite 105, San Diego, CA, 92123, USA. Electronic address: nbhatia@therapeuticsresearch.com.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Piacquadio', 'Affiliation': 'Therapeutics, Inc., 9025 Balboa Ave, Suite 100, San Diego, CA, 92123, USA. Electronic address: Danp@therapeuticsinc.com.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Houlihan', 'Affiliation': 'DUSA Pharmaceuticals, Inc., 25 Upton Drive, Wilmington, MA, 01887, USA. Electronic address: houlihana@optonline.net.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Davidson', 'Affiliation': 'Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ, 08540, USA. Electronic address: David.Davidson@sunpharma.com.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Siegel', 'Affiliation': 'Department of Dermatology, The State University of New York Downstate Health Sciences University, 450 Clarkson Avenue, Brooklyn, NY, 11203, USA; Dermatology Service, Veterans Affairs New York Harbor Healthcare System, 800 Poly Place, Brooklyn, NY, 11209, USA. Electronic address: cyberderm@dermsurg.org.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2020.102013'] 578,32959182,"Comparison of two-dimensional high-definition, ultra high-definition and three-dimensional endovision systems: an ex-vivo randomised study.","BACKGROUND Two-dimensional high-definition (2D HD) endovision system is preferred for laparoscopic surgery. Recently, new generation three-dimensional (3D) HD and ultra-HD (4K) endovision systems are introduced to improve the safety and efficacy of laparoscopic surgery. There is limited evidence on superiority of one technology over the others. This experimental trial was designed to evaluate 2D HD, 3D HD and 4K HD endovision systems in performance of standardized tasks. METHODS This was a randomized, cross-over experimental study. Twenty-one surgical residents who were exposed to laparoscopic surgery were enrolled. Participants were randomly assigned into three groups. Each group performed standardised tasks i.e. peg transfer, precision cutting, navigating in space and intra-corporeal suturing using 2D HD, 4K HD and 3D HD endovision systems on a box trainer. Procedures were recorded as 2D HD videos and analysed later. Participant's perceived workload was assessed using Surg-TLX questionnaire. Primary endpoints were execution time in seconds and error score. Secondary endpoint was workload assessment. RESULTS The 3D HD had shorter execution time compared to 2D HD and 4K HD in all tasks except precision cutting (p = 0.004, 0.03, 0.001, 0.001 and p = 0.002, 0.191, 0.006, 0.005 in peg transfer, precision cutting, navigating in space and intra-corporeal suturing respectively). The 4K HD was significantly faster than 2D HD only in navigating in space task (p = 0.002). The error score between 3D HD and 4K HD were comparable in all tasks. The 2D HD had significantly more error scores compared to 4K HD, 3D HD in peg transfer task (p = 0.005, 0.014, respectively). 3D HD had significantly less workload than 2D HD and 4K HD in most of the dimensions of Surg-TLX CONCLUSIONS: 3D HD endovision system in comparison to 2D HD and 4K HD, may lead to faster execution without compromising safety of a task and is associated with less workload.",2021,Each group performed standardised tasks,['Twenty-one surgical residents who were exposed to laparoscopic surgery were enrolled'],['standardised tasks'],"['execution time in seconds and error score', 'shorter execution time', 'error score between 3D HD and 4K HD', 'workload assessment', 'error scores']","[{'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}]",[],"[{'cui': 'C1278561', 'cui_str': 'Judicial execution'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",21.0,0.0370364,Each group performed standardised tasks,"[{'ForeName': 'Hemanga K', 'Initials': 'HK', 'LastName': 'Bhattacharjee', 'Affiliation': 'Department of Surgical Disciplines, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India. dr_hkb75@yahoo.com.'}, {'ForeName': 'Shafneed', 'Initials': 'S', 'LastName': 'Chaliyadan', 'Affiliation': 'Department of Surgical Disciplines, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Ashwani K', 'Initials': 'AK', 'LastName': 'Mishra', 'Affiliation': 'National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Harshit', 'Initials': 'H', 'LastName': 'Agarwal', 'Affiliation': 'Department of Surgical Disciplines, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Suhani', 'Initials': 'S', 'LastName': 'Suhani', 'Affiliation': 'Department of Surgical Disciplines, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Mohit', 'Initials': 'M', 'LastName': 'Joshi', 'Affiliation': 'Department of Surgical Disciplines, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Rajinder', 'Initials': 'R', 'LastName': 'Parshad', 'Affiliation': 'Department of Surgical Disciplines, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}]",Surgical endoscopy,['10.1007/s00464-020-07980-z'] 579,32921503,Reduced mortality risk in malnourished hospitalized older adult patients with COPD treated with a specialized oral nutritional supplement: Sub-group analysis of the NOURISH study.,"BACKGROUND Hospitalized, malnourished older adults with chronic obstructive pulmonary disease (COPD) have an elevated risk of readmission and mortality. OBJECTIVE Post-hoc, sub-group analysis from the NOURISH study cohort examined the effect of a high-protein oral nutritional supplement (ONS) containing HMB (HP-HMB) in malnourished, hospitalized older adults with COPD and to identify predictors of outcomes. METHODS The NOURISH study (n = 652) was a multicenter, randomized, placebo-controlled, double-blind trial. The COPD subgroup (n = 214) included hospitalized, malnourished (based on Subjective Global Assessment), older adults (≥65 y), with admission diagnosis of COPD who received either standard-of-care plus HP-HMB (n = 109) or standard-of-care and a placebo supplement (n = 105) prescribed 2 servings/day from within 3 days of hospital admission (baseline) and up to 90 days after discharge. The primary study outcome was a composite endpoint of incidence of death or non-elective readmission up to 90-day post-discharge, while secondary endpoints included changes in hand-grip strength, body weight, and nutritional biomarkers over time. Categorical outcomes were analyzed using Cochran-Mantel-Haenszel tests, longitudinal data by repeated measures analysis of covariance; and changes from baseline by analysis of covariance. p-values ≤ 0.05 were considered statistically significant. Multivariate logistic regression was used to model predictors of the primary outcome and components. RESULTS In patients with COPD, 30, 60, and 90-day hospital readmission rate did not differ, but in contrast, 30, 60, and 90-day mortality risk was approximately 71% lower with HP-HMB supplementation relative to placebo (1.83%, 2.75%, 2.75% vs. 6.67%, 9.52% and 10.48%, p = 0.0395, 0.0193, 0.0113, resp.). In patients with COPD, compared to placebo, intake of HP-HMB resulted in a significant increase in handgrip strength (+1.56 kg vs. -0.34 kg, p = 0.0413) from discharge to day 30; increased body weight from baseline to hospital discharge (0.66 kg vs. -0.01 kg, p < 0.05) and, improvements in blood nutritional biomarker concentrations. The multivariate logistic regression predictors of the death, readmission or composite endpoints in these COPD patients showed that participants who were severely malnourished (p = 0.0191) and had a Glasgow prognostic score (GPS) Score of 1 or 2 had statistically significant odds of readmission or death (p = 0.0227). CONCLUSIONS Among malnourished, hospitalized patients with COPD, supplementation with HP-HMB was associated with a markedly decreased mortality risk, and improved handgrip strength, body weight, and nutritional biomarkers within a 90-day period after hospital discharge. This post-hoc, subgroup analysis highlights the importance of early identification of nutritional risk and administration of high-protein ONS in older, malnourished patients with COPD after hospital admission and continuing after hospital discharge.",2021,"In patients with COPD, compared to placebo, intake of HP-HMB resulted in a significant increase in handgrip strength (+1.56 kg vs. -0.34 kg, p = 0.0413) from discharge to day 30; increased body weight from baseline to hospital discharge (0.66 kg vs. ","['COPD subgroup (n\xa0=\xa0214) included hospitalized, malnourished (based on Subjective Global Assessment), older adults (≥65\xa0y), with admission diagnosis of COPD who received either', 'malnourished, hospitalized older adults with COPD', 'older, malnourished patients with COPD after hospital admission and continuing after hospital discharge', 'malnourished hospitalized older adult patients with COPD', 'malnourished, hospitalized patients with COPD, supplementation with HP-HMB', 'Hospitalized, malnourished older adults with chronic obstructive pulmonary disease (COPD']","['high-protein oral nutritional supplement (ONS) containing HMB (HP-HMB', 'placebo', 'standard-of-care plus HP-HMB (n\xa0=\xa0109) or standard-of-care and a placebo supplement']","['mortality risk', 'composite endpoint of incidence of death or non-elective readmission up to 90-day post-discharge, while secondary endpoints included changes in hand-grip strength, body weight, and nutritional biomarkers over time', 'hospital discharge', '90-day hospital readmission rate', 'GPS Score', 'handgrip strength', 'readmission or death', '90-day mortality risk', 'body weight', 'death, readmission or composite endpoints', 'mortality risk, and improved handgrip strength, body weight, and nutritional biomarkers', 'blood nutritional biomarker concentrations']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0451514', 'cui_str': 'Subjective global assessment'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0587438', 'cui_str': 'Day hospital'}, {'cui': 'C0272302', 'cui_str': 'Gray platelet syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.272438,"In patients with COPD, compared to placebo, intake of HP-HMB resulted in a significant increase in handgrip strength (+1.56 kg vs. -0.34 kg, p = 0.0413) from discharge to day 30; increased body weight from baseline to hospital discharge (0.66 kg vs. ","[{'ForeName': 'Nicolaas E', 'Initials': 'NE', 'LastName': 'Deutz', 'Affiliation': 'Texas A&M University, College Station, TX, USA. Electronic address: nep.deutz@ctral.org.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Ziegler', 'Affiliation': 'Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Matheson', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Matarese', 'Affiliation': 'Brody School of Medicine at East Carolina University, Greenville, NC, USA.'}, {'ForeName': 'Kelly A', 'Initials': 'KA', 'LastName': 'Tappenden', 'Affiliation': 'University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Geraldine E', 'Initials': 'GE', 'LastName': 'Baggs', 'Affiliation': 'Abbott Nutrition, Columbus, OH, USA.'}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Nelson', 'Affiliation': 'Abbott Nutrition, Columbus, OH, USA.'}, {'ForeName': 'Menghua', 'Initials': 'M', 'LastName': 'Luo', 'Affiliation': 'Abbott Nutrition, Columbus, OH, USA.'}, {'ForeName': 'Refaat', 'Initials': 'R', 'LastName': 'Hegazi', 'Affiliation': 'Abbott Nutrition, Columbus, OH, USA; Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}, {'ForeName': 'Satya S', 'Initials': 'SS', 'LastName': 'Jonnalagadda', 'Affiliation': 'Abbott Nutrition, Columbus, OH, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.031'] 580,32928796,"Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.","PURPOSE Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib. We evaluated the efficacy and safety of flumatinib versus imatinib, for first-line treatment of chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CML-CP). PATIENTS AND METHODS In this study, 394 patients were randomized 1:1 to flumatinib 600 mg once daily ( n = 196) or imatinib 400 mg once daily ( n = 198) groups. RESULTS The rate of major molecular response (MMR) at 6 months (primary endpoint) was significantly higher with flumatinib than with imatinib (33.7% vs. 18.3%; P = 0.0006), as was the rate of MMR at 12 months (52.6% vs. 39.6%; P = 0.0102). At 3 months, the rate of early molecular response (EMR) was significantly higher in patients receiving flumatinib than in those receiving imatinib (82.1% vs. 53.3%; P < 0.0001). Compared with patients receiving imatinib, more patients receiving flumatinib achieved molecular remission 4 (MR4) at 6, 9, and 12 months (8.7% vs. 3.6%, P = 0.0358; 16.8% vs. 5.1%, P = 0.0002; and 23.0% vs. 11.7%, P = 0.0034, respectively). No patients had progression to accelerated phase or blast crisis in the flumatinib arm versus 4 patients in the imatinib arm by 12 months. Adverse events of edema, pain in extremities, rash, neutropenia, anemia, and hypophosphatemia were more frequent in imatinib arm, whereas diarrhea and alanine transaminase elevation were more frequent in flumatinib arm. CONCLUSIONS Patients receiving flumatinib achieved significantly higher rates of responses, and faster and deeper responses compared with those receiving imatinib, indicating that flumatinib can be an effective first-line treatment for CML-CP. This trial was registered at www.clinicaltrials.gov as NCT02204644. See related commentary by Müller, p. 3 .",2021,"At 3 months, the rate of early molecular response (EMR) was significantly higher in patients receiving flumatinib than in those receiving imatinib (82.1% vs 53.3%, P<0.0001).","['Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia', 'chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CML-CP', '394 patients']","['flumatinib versus imatinib', 'Flumatinib versus Imatinib', 'flumatinib 600 mg once daily (n=196) or imatinib 400 mg once daily (n=198']","['MR4', 'efficacy and safety', 'rates of responses, faster and deeper responses', 'ABL1 tyrosine kinase', 'rate of major molecular response (MMR', 'Adverse events of edema, pain in extremities, rash, neutropenia, anemia, and hypophosphatemia', 'progression to accelerated phase or blast crisis', 'diarrhea and alanine transaminase elevation', 'rate of early molecular response (EMR', 'rate of MMR']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0023474', 'cui_str': 'Chronic phase chronic myeloid leukemia'}, {'cui': 'C0457343', 'cui_str': 'Chronic phase'}, {'cui': 'C0279543', 'cui_str': 'Philadelphia chromosome positive chronic myelogenous leukemia'}, {'cui': 'C0023473', 'cui_str': 'Chronic myeloid leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0935989', 'cui_str': 'imatinib'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C1331284', 'cui_str': 'imatinib 400 MG'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0033681', 'cui_str': 'Protein-tyrosine kinase'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0030196', 'cui_str': 'Pain in limb'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0085682', 'cui_str': 'Hypophosphatemia'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0457345', 'cui_str': 'Accelerated phase'}, {'cui': 'C0005699', 'cui_str': 'Blast crisis'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C1279919', 'cui_str': 'Early'}]",394.0,0.0563832,"At 3 months, the rate of early molecular response (EMR) was significantly higher in patients receiving flumatinib than in those receiving imatinib (82.1% vs 53.3%, P<0.0001).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, P.R. China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Meng', 'Affiliation': 'Tongji Hospital Tongji Medical College of Huazhong University of Science &Technology, Wuhan, Hubei, P.R. China.'}, {'ForeName': 'Bingcheng', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, P.R. China.'}, {'ForeName': 'Yanli', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Henan Cancer Hospital, Zhengzhou, Henan, P.R. China.'}, {'ForeName': 'Huanling', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'The West China College of Medicine, Sichuan University, Chengdu, Sichuan, P.R. China.'}, {'ForeName': 'Jiuwei', 'Initials': 'J', 'LastName': 'Cui', 'Affiliation': 'The First Hospital of Jilin University, Changchun, Jilin, P.R. China.'}, {'ForeName': 'Aining', 'Initials': 'A', 'LastName': 'Sun', 'Affiliation': 'The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, P.R. China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Jin', 'Affiliation': 'The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, P.R. China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': ""Peking University People's Hospital, Peking University Institute of Hematology, Beijing, P.R. China.""}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'The Second Affiliated Hospital of Army Medical University, Chongqing, P.R. China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'The First Hospital of China Medical University, Shenyang, P.R. China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': ""Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China.""}, {'ForeName': 'Wanggang', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': ""The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.""}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Gu', 'Affiliation': 'Clinical Medical College of Yangzhou University/Yangzhou Institute of Hematology, Yangzhou, Jiangsu, P.R. China.'}, {'ForeName': 'Jianhui', 'Initials': 'J', 'LastName': 'Qiao', 'Affiliation': ""The 307 Hospital of Military Chinese People's Liberation Army, Beijing, P.R. China.""}, {'ForeName': 'Guifang', 'Initials': 'G', 'LastName': 'Ouyang', 'Affiliation': 'Ningbo First Hospital, Ningbo, Zhejiang, P.R. China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'AnHui Provincial Hospital, Hefei, Anhui, P.R. China.'}, {'ForeName': 'Jianmin', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': 'Hebei Medical University Second Hospital, Shijiazhuang, Hebei, P.R. China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Jiang', 'Affiliation': 'The First Affiliated Hospital of Xinjiang Medical University, Urumqi, P.R. China.'}, {'ForeName': 'Xiaobao', 'Initials': 'X', 'LastName': 'Xie', 'Affiliation': ""The First People's Hospital of Changzhou, Changzhou, Jiangsu, P.R. China.""}, {'ForeName': 'Jianyong', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P.R. China.'}, {'ForeName': 'Chunting', 'Initials': 'C', 'LastName': 'Zhao', 'Affiliation': 'The Affiliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': ""The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.""}, {'ForeName': 'Tonghua', 'Initials': 'T', 'LastName': 'Yang', 'Affiliation': ""The First People's Hospital of Yunnan Province, Kunming, Yunnan, P.R. China.""}, {'ForeName': 'Jianxiang', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, P.R. China. wangjx@ihcams.ac.cn.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-1600'] 581,32925287,"Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.","BACKGROUND Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis (AS) through 5 years in pivotal Phase III studies. Here, we present efficacy and safety results (52-week) of secukinumab in patients with AS from the MEASURE 5 study. METHODS MEASURE 5 was a 52-week, Phase III, China-centric study. Eligible patients were randomly assigned (2:1) to receive subcutaneous secukinumab 150 mg or placebo weekly for the first five doses and then once every 4 weeks (q4w). All placebo patients switched to secukinumab 150 mg q4w starting at Week 16. Primary endpoint was Assessments of SpondyloArthritis international Society (ASAS) 20 at Week 16. Randomization was stratified by region (China vs. non-China). RESULTS Of 458 patients (secukinumab 150 mg, N = 305; placebo, N = 153) randomized, 327 (71.4%) were from China and 131 (28.6%) were not from China. Of these, 97.7% and 97.4% patients completed Week 16 and 91.1% and 95.3% (placebo-secukinumab) patients completed Week 52 of treatment. The primary endpoint was met; secukinumab significantly improved ASAS20 response at Week 16 vs. placebo (58.4% vs. 36.6%; P < 0.0001); corresponding rate in the Chinese population was 56.0% vs. 38.5% (P < 0.01). All secondary efficacy endpoints significantly improved with secukinumab 150 mg in the overall population at Week 16; responses were maintained with a trend toward increased efficacy from Week 16 to 52. No new or unexpected safety signals were reported up to Week 52. CONCLUSIONS Secukinumab 150 mg demonstrated rapid and significant improvement in signs and symptoms of AS. Secukinumab was well tolerated and the safety profile was consistent with previous reports. Efficacy and safety results were comparable between the overall and Chinese populations. TRIAL REGISTRATION ClinicalTrials.gov, NCT02896127; https://clinicaltrials.gov/ct2/show/NCT02896127?term=NCT02896127&draw=2&rank=1.",2020,All secondary efficacy endpoints significantly improved with secukinumab 150 mg in the overall population at Week 16; responses were maintained with a trend toward increased efficacy from Week 16 to 52.,"['Eligible patients', '458 patients (secukinumab 150 mg', 'patients with ankylosing spondylitis (AS', 'patients with AS from the MEASURE 5 study', '305; placebo, N\u200a=\u200a153) randomized, 327 (71.4%) were from China and 131 (28.6%) were not from China']","['Secukinumab', 'placebo', 'secukinumab', 'subcutaneous secukinumab 150 mg or placebo']","['signs and symptoms of ankylosing spondylitis', 'SpondyloArthritis international Society (ASAS', 'ASAS20 response', 'Efficacy and safety', 'tolerated and the safety profile', 'signs and symptoms of AS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C5191377', 'cui_str': '458'}, {'cui': 'C3179547', 'cui_str': 'secukinumab'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0038013', 'cui_str': 'Ankylosing spondylitis'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517703', 'cui_str': '305'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C4517679', 'cui_str': '28.6'}]","[{'cui': 'C3179547', 'cui_str': 'secukinumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C4321486', 'cui_str': '150'}]","[{'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0038013', 'cui_str': 'Ankylosing spondylitis'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0949690', 'cui_str': 'Arthritis of spine'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",458.0,0.232244,All secondary efficacy endpoints significantly improved with secukinumab 150 mg in the overall population at Week 16; responses were maintained with a trend toward increased efficacy from Week 16 to 52.,"[{'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Huang', 'Affiliation': ""Department of Rheumatology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.""}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Sun', 'Affiliation': ""Department of Rheumatology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.""}, {'ForeName': 'Wei-Guo', 'Initials': 'WG', 'LastName': 'Wan', 'Affiliation': 'Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China.'}, {'ForeName': 'Li-Jun', 'Initials': 'LJ', 'LastName': 'Wu', 'Affiliation': ""Department of Rheumatology & Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang 830001, China.""}, {'ForeName': 'Ling-Li', 'Initials': 'LL', 'LastName': 'Dong', 'Affiliation': 'Department of Rheumatology & Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei 430030, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Rheumatology & Immunology, Guangdong General Hospital, Guangzhou, Guangdong 510000, China.'}, {'ForeName': 'Tae-Hwan', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': 'Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.'}, {'ForeName': 'Raj', 'Initials': 'R', 'LastName': 'Sengupta', 'Affiliation': 'Royal National Hospital for Rheumatic Disease, Upper Borough Walls, Bath BA1 1RL, UK.'}, {'ForeName': 'Ladislav', 'Initials': 'L', 'LastName': 'Šenolt', 'Affiliation': 'Institute of Rheumatology, Prague, Czech Republic.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Hao-Min', 'Initials': 'HM', 'LastName': 'Qiu', 'Affiliation': 'China Novartis Institutes for Biomedical Research, Shanghai 201203, China.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Porter', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Sibylle', 'Initials': 'S', 'LastName': 'Haemmerle', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}]",Chinese medical journal,['10.1097/CM9.0000000000001099'] 582,32940718,The additional role of virtual to traditional dissection in teaching anatomy: a randomised controlled trial.,"INTRODUCTION Anatomy has traditionally been taught via dissection and didactic lectures. The rising prevalence of informatics plays an increasingly important role in medical education. It is hypothesized that virtual dissection can express added value to the traditional one. METHODS Second-year medical students were randomised to study anatomical structures by virtual dissection (intervention) or textbooks (controls), according to the CONSORT guidelines. Subsequently, they applied to the corresponding gross dissection, with a final test on their anatomical knowledge. Univariate analysis and multivariable binary logistic regression were performed. RESULTS The rate of completed tests was 76.7%. Better overall test performance was detected for the group that applied to the virtual dissection (OR 3.75 with 95% CI 0.91-15.49; p = 0.06). A comparable performance between groups in basic anatomical knowledge (p 0.45 to 0.92) but not muscles and 2D-3D reporting of anatomical structures was found, for which the virtual dissection was of tendential benefit (p 0.08 to 0.13). Medical students who applied to the virtual dissection were over three times more likely to report a positive outcome at the post-dissection test than those who applied to textbooks of topographical anatomy. This would be of benefit with particular reference to the understanding of 2D-3D spatial relationships between anatomical structures. CONCLUSION The combination of virtual to traditional gross dissection resulted in a significant improvement of second-year medical students' learning outcomes. It could be of help in maximizing the impact of practical dissection, overcoming the contraction of economic resources, and the shortage of available bodies.",2021,"A comparable performance between groups in basic anatomical knowledge (p 0.45 to 0.92) but not muscles and 2D-3D reporting of anatomical structures was found, for which the virtual dissection was of tendential benefit (p 0.08 to 0.13).",['Second-year medical students'],"['virtual dissection (intervention) or textbooks (controls), according to the CONSORT guidelines']",['Better overall test performance'],"[{'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}]","[{'cui': 'C0012737', 'cui_str': 'Dissection - action'}, {'cui': 'C0039712', 'cui_str': 'Textbooks'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",,0.0266685,"A comparable performance between groups in basic anatomical knowledge (p 0.45 to 0.92) but not muscles and 2D-3D reporting of anatomical structures was found, for which the virtual dissection was of tendential benefit (p 0.08 to 0.13).","[{'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Boscolo-Berto', 'Affiliation': 'Department of Neurosciences, Institute of Human Anatomy, University of Padova, Via Gabelli 65, Padova, Italy.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Tortorella', 'Affiliation': 'Department of Neurosciences, Institute of Human Anatomy, University of Padova, Via Gabelli 65, Padova, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Porzionato', 'Affiliation': 'Department of Neurosciences, Institute of Human Anatomy, University of Padova, Via Gabelli 65, Padova, Italy.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Stecco', 'Affiliation': 'Department of Neurosciences, Institute of Human Anatomy, University of Padova, Via Gabelli 65, Padova, Italy.'}, {'ForeName': 'Edgardo Enrico Edoardo', 'Initials': 'EEE', 'LastName': 'Picardi', 'Affiliation': 'Digestive System Surgery Division, European Institute of Oncology (IRCSS), Via Ripamonti 435, Milano, Italy.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Macchi', 'Affiliation': 'Department of Neurosciences, Institute of Human Anatomy, University of Padova, Via Gabelli 65, Padova, Italy. veronica.macchi@unipd.it.'}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'De Caro', 'Affiliation': 'Department of Neurosciences, Institute of Human Anatomy, University of Padova, Via Gabelli 65, Padova, Italy.'}]",Surgical and radiologic anatomy : SRA,['10.1007/s00276-020-02551-2'] 583,32943047,Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.,"BACKGROUND Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation and chronic inflammation. Predicting exacerbations of COPD, which contribute to disease progression, is important to guide preventative treatment and improve outcomes. Blood eosinophils are a biomarker for patient responsiveness to inhaled corticosteroids (ICS); however, their effectiveness as a predictive biomarker for COPD exacerbations is unclear. METHODS This post hoc analysis pooled data from 11 Boehringer Ingelheim-sponsored Phase III and IV randomised COPD studies with similar methodologies. Exacerbation data were collected from these studies, excluding patients from the ICS withdrawal arm of the WISDOM® study. Patients were grouped according to their baseline blood eosinophil count, baseline ICS use and number of exacerbations in the year prior to each study. RESULTS Exacerbation rate data and baseline eosinophil count were available for 22,125 patients; 45.6% presented with a baseline blood eosinophil count of ≤ 150 cells/μL, 34.3% with 150-300 cells/μL and 20.1% with > 300 cells/μL. The lowest exacerbation rates were observed in patients with ≤ 150 cells/μL, with small increases in exacerbation rate observed with increasing eosinophil count. When stratified by exacerbation history, the annual rate of exacerbations for patients with 0 exacerbations in the previous year increased in line with increasing eosinophil counts (0.38 for ≤ 150 cells/μL, 0.39 for 150-300 cells/μL and 0.44 for > 300 cells/μL respectively). A similar trend was identified for patients with one exacerbation in the previous year, 0.62, 0.66 and 0.67 respectively. For patients with ≥ 2 exacerbations, exacerbation rates fluctuated between 1.02 (≤ 150 cells/μL) to 1.10 (150-300 cells/μL) and 1.07 (> 300 cells/μL). Higher exacerbation rates were noted in patients treated with ICS at baseline (range 0.75 to 0.82 with increasing eosinophil count) compared with patients not on ICS (range 0.45 to 0.49). CONCLUSION We found no clinically important relationship between baseline blood eosinophil count and exacerbation rate. Hence, the current analysis does not support the use of blood eosinophils to predict exacerbation risk; however, previous exacerbation history was found to be a more reliable predictor of future exacerbations. TRIAL REGISTRATION ClinicalTrials.gov Identifiers: NCT00168844 , NCT00168831 , NCT00387088 , NCT00782210 , NCT00782509 , NCT00793624 , NCT00796653 , NCT01431274 , NCT01431287 , NCT02296138 and NCT00975195 .",2020,"Higher exacerbation rates were noted in patients treated with ICS at baseline (range 0.75 to 0.82 with increasing eosinophil count) compared with patients not on ICS (range 0.45 to 0.49). ","['300 cells/μL', 'Chronic obstructive pulmonary disease (COPD']",[],"['baseline blood eosinophil count and exacerbation rate', 'baseline blood eosinophil count, baseline ICS use and number of exacerbations', 'eosinophil counts', 'lowest exacerbation rates', 'exacerbation rate', 'Exacerbation rate data and baseline eosinophil count', 'baseline blood eosinophil count', 'Higher exacerbation rates']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]",[],"[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}]",,0.345667,"Higher exacerbation rates were noted in patients treated with ICS at baseline (range 0.75 to 0.82 with increasing eosinophil count) compared with patients not on ICS (range 0.45 to 0.49). ","[{'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Singh', 'Affiliation': 'Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK. DSingh@meu.org.uk.'}, {'ForeName': 'Jadwiga A', 'Initials': 'JA', 'LastName': 'Wedzicha', 'Affiliation': 'Respiratory Division, National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Salman', 'Initials': 'S', 'LastName': 'Siddiqui', 'Affiliation': 'NIHR Leicester Biomedical Research Centre: Respiratory Theme, and Department of Respiratory Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'de la Hoz', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Wenqiong', 'Initials': 'W', 'LastName': 'Xue', 'Affiliation': 'Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.'}, {'ForeName': 'Helgo', 'Initials': 'H', 'LastName': 'Magnussen', 'Affiliation': 'Pulmonary Research Institute at Lung Clinic Grosshansdorf, Grosshansdorf, Germany.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Miravitlles', 'Affiliation': ""Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.""}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Chalmers', 'Affiliation': 'Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.'}, {'ForeName': 'Peter M A', 'Initials': 'PMA', 'LastName': 'Calverley', 'Affiliation': 'Clinical Science Centre, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.'}]",Respiratory research,['10.1186/s12931-020-01482-1'] 584,32965471,Mindfulness Improves Brain-Computer Interface Performance by Increasing Control Over Neural Activity in the Alpha Band.,"Brain-computer interfaces (BCIs) are promising tools for assisting patients with paralysis, but suffer from long training times and variable user proficiency. Mind-body awareness training (MBAT) can improve BCI learning, but how it does so remains unknown. Here, we show that MBAT allows participants to learn to volitionally increase alpha band neural activity during BCI tasks that incorporate intentional rest. We trained individuals in mindfulness-based stress reduction (MBSR; a standardized MBAT intervention) and compared performance and brain activity before and after training between randomly assigned trained and untrained control groups. The MBAT group showed reliably faster learning of BCI than the control group throughout training. Alpha-band activity in electroencephalogram signals, recorded in the volitional resting state during task performance, showed a parallel increase over sessions, and predicted final BCI performance. The level of alpha-band activity during the intentional resting state correlated reliably with individuals' mindfulness practice as well as performance on a breath counting task. Collectively, these results show that MBAT modifies a specific neural signal used by BCI. MBAT, by increasing patients' control over their brain activity during rest, may increase the effectiveness of BCI in the large population who could benefit from alternatives to direct motor control.",2021,"Here, we show that MBAT allows participants to learn to volitionally increase alpha band neural activity during BCI tasks that incorporate intentional rest.",[],"['Mind-body awareness training (MBAT', 'mindfulness-based stress reduction (MBSR; a standardized MBAT intervention', 'Brain-computer interfaces (BCIs', 'MBAT']","['final BCI performance', 'level of alpha-band activity', 'learning of BCI', 'Mindfulness Improves Brain-Computer Interface Performance']",[],"[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3494288', 'cui_str': 'Brain-Computer Interface'}]","[{'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C2742590', 'cui_str': '2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C3494288', 'cui_str': 'Brain-Computer Interface'}]",,0.0128676,"Here, we show that MBAT allows participants to learn to volitionally increase alpha band neural activity during BCI tasks that incorporate intentional rest.","[{'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Stieger', 'Affiliation': 'Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Engel', 'Affiliation': 'Department of Psychology, University of Minnesota, Minneapolis, MN 55414, USA.'}, {'ForeName': 'Haiteng', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Cline', 'Affiliation': 'Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55414, USA.'}, {'ForeName': 'Mary Jo', 'Initials': 'MJ', 'LastName': 'Kreitzer', 'Affiliation': 'Earl E. Bakken Center for Spirituality & Healing, University of Minnesota, Minneapolis, MN 55414, USA.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'He', 'Affiliation': 'Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA.'}]","Cerebral cortex (New York, N.Y. : 1991)",['10.1093/cercor/bhaa234'] 585,32928328,Safety and Efficacy of CarbonCool Half-Body Vest for HAZMAT Decontamination Crews Wearing Personal Protective Equipment: A Pilot Study.,"BACKGROUND Personal protective equipment (PPE) are essential for medical personnel responding to hazardous materials (HAZMAT) incidents. However, their impermeable design causes increased physiological strain and reduced thermoregulation, limiting work times and causing heat-related illnesses (HRI). Use of wearable cooling devices slow heat accumulation and have been shown to reduce thermal and cardiovascular strain in such situations. METHODS This was a prospective clinical evaluation to determine the tolerability and effectiveness of the CarbonCool cooling system - a half-body cooling vest - in participants undergoing a HAZMAT decontamination recertification. Physiological measurements (heart rate [HR], weight, temperature, and blood pressure) and participant feedback were obtained. The main outcome of interest was participants' tolerability of the cooling vest. RESULTS A total of 23 healthy participants were recruited, with 10 randomized to the intervention group and 13 in the control group. Mean age in the control and intervention group was 35.5 years old (SD = 7.8) and 30.0 years old (SD = 6.2), respectively. Qualitative feedback obtained from participants regarding safety, mobility, and cooling efficacy was largely positive. Difference of before-after temperature and HR was 0.3°C (SD = 0.8) and 11.5bpm (SD = 13.6) in the control group compared to 0.0°C (SD = 0.5) and 0.0bpm (SD = 6.4) for the intervention group. CONCLUSION This clinical evaluation showed that the CarbonCool cooling vest is safe and tolerable in participants wearing PPE. Further trials with sample size powered to detect physiological outcomes are needed to assess the effect of the cooling vest on a subject's endurance to heat stress.",2020,"Qualitative feedback obtained from participants regarding safety, mobility, and cooling efficacy was largely positive.","['23 healthy participants', 'Mean age in the control and intervention group was 35.5 years old (SD = 7.8) and 30.0 years old (SD = 6.2), respectively', 'participants wearing PPE', 'participants undergoing a HAZMAT decontamination recertification']","['cooling vest', 'CarbonCool cooling system - a half-body cooling vest ', 'CarbonCool cooling vest', 'CarbonCool', 'Half-Body Vest for HAZMAT Decontamination Crews', 'Personal protective equipment (PPE']","['Physiological measurements (heart rate [HR], weight, temperature, and blood pressure) and participant feedback', 'Safety and Efficacy', 'physiological strain and reduced thermoregulation, limiting work times and causing heat-related illnesses (HRI', 'tolerability of the cooling vest', 'tolerability and effectiveness', 'safety, mobility, and cooling efficacy']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0018626', 'cui_str': 'Hazardous Materials'}, {'cui': 'C0011121', 'cui_str': 'Decontamination'}]","[{'cui': 'C0453884', 'cui_str': 'Vest'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0412808', 'cui_str': 'Active cooling of patient'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0018626', 'cui_str': 'Hazardous Materials'}, {'cui': 'C0011121', 'cui_str': 'Decontamination'}, {'cui': 'C1443871', 'cui_str': 'Personal protective equipment'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}]","[{'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0005905', 'cui_str': 'Thermoregulation, function'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0453884', 'cui_str': 'Vest'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}]",23.0,0.0636664,"Qualitative feedback obtained from participants regarding safety, mobility, and cooling efficacy was largely positive.","[{'ForeName': 'Pamela Jia Min', 'Initials': 'PJM', 'LastName': 'Tay', 'Affiliation': 'Duke-NUS Medical School, Singapore.'}, {'ForeName': 'Zhi Xiong', 'Initials': 'ZX', 'LastName': 'Koh', 'Affiliation': 'Department of Emergency Medicine, Singapore General Hospital, Singapore.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Hao', 'Affiliation': 'Health Services Research Centre, Singapore Health Services, Singapore.'}, {'ForeName': 'Mark Kwok Fai', 'Initials': 'MKF', 'LastName': 'Leong', 'Affiliation': 'Department of Emergency Medicine, Singapore General Hospital, Singapore.'}]",Prehospital and disaster medicine,['10.1017/S1049023X20001144'] 586,32941345,Effects on Firefighters' Nocturnal Cardiac Autonomic Activity and Sleep Quality of On-Call Nights With and Without Simulated Firefighting Interventions.,"OBJECTIVE To examine the effects on firefighters' nocturnal cardiac autonomic activity and sleep quality of one on-call night without intervention and one on-call night with intervention. METHODS Thirteen firefighters completed three experimental nights: a control night (CON), an on-call night without intervention (0-INTER), an on-call night with one simulated intervention (1-INTER). Sleep parameters were determined from nocturnal heart rate variability (HRV), objective and subjective sleep quality. RESULTS Derived parasympathetic HRV indices were higher in CON compared with 0-INTER and 1-INTER (P < 0.05). Subjective sleep quality and total sleep time were decreased in 1-INTER compared with CON and 0-INTER (P < 0.01). DISCUSSION These results revealed that for firefighters, being on-call during the night with and without interventions disturbs cardiac autonomic activity. Objective and subjective sleep quality were disrupted when on-call nights were interrupted by simulated firefighting interventions.",2020,"Subjective sleep quality and total sleep time were decreased in 1-INTER compared to CON and 0-INTER (p < 0.01). ",['Thirteen firefighters completed three experimental nights: a'],"['control night (CON), an on-call night without intervention (0-INTER), an on-call night with one simulated intervention (1-INTER', 'CON']","['parasympathetic HRV indices', ""Firefighters' Nocturnal Cardiac Autonomic Activity and Sleep Quality"", 'nocturnal heart rate variability (HRV), objective and subjective sleep quality', 'Subjective sleep quality and total sleep time', 'Objective and subjective sleep quality']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0221459', 'cui_str': 'Fire fighter'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0240526', 'cui_str': 'Night time'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0221459', 'cui_str': 'Fire fighter'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",13.0,0.0137091,"Subjective sleep quality and total sleep time were decreased in 1-INTER compared to CON and 0-INTER (p < 0.01). ","[{'ForeName': 'Philémon', 'Initials': 'P', 'LastName': 'Marcel-Millet', 'Affiliation': 'Laboratory C3S (EA 4660), Department of Sport and Performance, University of Bourgogne-Franche-Comte, Besançon, France.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Groslambert', 'Affiliation': ''}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Ravier', 'Affiliation': ''}]",Journal of occupational and environmental medicine,['10.1097/JOM.0000000000002025'] 587,32947474,A Randomized Controlled Trial of Antithrombin Supplementation During Extracorporeal Membrane Oxygenation.,"OBJECTIVES Supplementation of antithrombin might decrease the amount of heparin needed to achieve a given anticoagulation target during extracorporeal membrane oxygenation. However, exogenous antithrombin itself may increase the risk of bleeding. We conceived a study to evaluate the effect of antithrombin supplementation in adult patients requiring venovenous extracorporeal membrane oxygenation for respiratory failure on heparin dose, adequacy of anticoagulation, and safety. DESIGN Prospective randomized controlled trial. SETTING ICUs of two Italian referral extracorporeal membrane oxygenation centers. PATIENTS Adult patients requiring venovenous extracorporeal membrane oxygenation for severe respiratory failure and unfractionated heparin for systemic anticoagulation. INTERVENTIONS Before extracorporeal membrane oxygenation start, patients were randomized to either receive antithrombin concentrate to maintain a plasmatic level 80-120% (treatment) or not (control) during the extracorporeal membrane oxygenation course. MEASUREMENTS AND MAIN RESULTS The primary outcome was the total amount of heparin required to maintain activated partial thromboplastin time ratio 1.5-2. Secondary outcomes were anti-factor Xa, the incidence of hemorrhagic and thrombotic events, and the amount of blood products transfused. Twenty-four patients in the treatment group and 24 in the control group were included in the intention-to-treat analysis. Antithrombin was 109.5% (93.0-123.0%) in the treatment group and 84.0% (68.5-98.0%) in the control group (p = 0.001). Supplementation of antithrombin did not decrease heparin dose (13.5 international units/kg/hr [9.6-17.9 international units/kg/hr] vs 15.1 international units/kg/hr [10.7-18.3 international units/kg/hr] in the treatment and control group, respectively; p = 0.33) and anti-Factor Xa levels (0.4 international units/mL [0.3-0.5 international units/mL] vs 0.3 international units/mL [0.2-0.5 international units/mL] in the treatment group and control group respectively; p = 0.65). Bleeding, blood product transfusions, and thrombosis were not different in the two groups. CONCLUSIONS Antithrombin supplementation may not decrease heparin requirement nor diminish the incidence of bleeding and/or thrombosis in adult patients on venovenous extracorporeal membrane oxygenation.",2020,Antithrombin was 109.5% (93.0-123.0%) in the treatment group and 84.0% (68.5-98.0%) in the control group (p = 0.001).,"['adult patients on venovenous extracorporeal membrane oxygenation', 'adult patients requiring venovenous extracorporeal membrane oxygenation for respiratory failure', 'ICUs of two Italian referral extracorporeal membrane oxygenation centers', 'Twenty-four patients in the treatment group and 24 in the control group were included in the intention-to-treat analysis', 'Adult patients requiring', 'for severe respiratory failure and unfractionated heparin for systemic anticoagulation']","['venovenous extracorporeal membrane oxygenation', 'Antithrombin supplementation', 'antithrombin concentrate to maintain a plasmatic level 80-120% (treatment) or not (control) during the extracorporeal membrane oxygenation course', 'Antithrombin Supplementation', 'antithrombin supplementation', 'antithrombin']","['Antithrombin', 'anti-Factor Xa levels', 'risk of bleeding', 'bleeding and/or thrombosis', 'heparin dose, adequacy of anticoagulation, and safety', 'total amount of heparin required to maintain activated partial thromboplastin time ratio 1.5-2', 'anti-factor Xa, the incidence of hemorrhagic and thrombotic events, and the amount of blood products transfused', 'Bleeding, blood product transfusions, and thrombosis']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C5192099', 'cui_str': 'Venovenous extracorporeal membrane oxygenation'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0015357', 'cui_str': 'Extracorporeal membrane oxygenation'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}]","[{'cui': 'C5192099', 'cui_str': 'Venovenous extracorporeal membrane oxygenation'}, {'cui': 'C0003438', 'cui_str': 'Antithrombin III'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0015357', 'cui_str': 'Extracorporeal membrane oxygenation'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0003438', 'cui_str': 'Antithrombin III'}, {'cui': 'C0427612', 'cui_str': 'Anti factor Xa measurement'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C1272061', 'cui_str': 'Activated partial thromboplastin time ratio'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0443793', 'cui_str': 'Anti factor Xa'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0333275', 'cui_str': 'Hemorrhagic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0456388', 'cui_str': 'Blood product'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}]",,0.267968,Antithrombin was 109.5% (93.0-123.0%) in the treatment group and 84.0% (68.5-98.0%) in the control group (p = 0.001).,"[{'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Panigada', 'Affiliation': 'Department of Anaesthesia and Critical Care, ""Fondazione IRCCS Ca\' Granda, Ospedale Maggiore Policlinico,"" Milan, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Cucino', 'Affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Spinelli', 'Affiliation': 'Department of Anaesthesia and Critical Care, ""Fondazione IRCCS Ca\' Granda, Ospedale Maggiore Policlinico,"" Milan, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Occhipinti', 'Affiliation': 'Department of Anesthesiology and Intensive Care, ISMETT IRCCS (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), UPMC, Palermo, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Panarello', 'Affiliation': 'Department of Anesthesiology and Intensive Care, ISMETT IRCCS (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), UPMC, Palermo, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Novembrino', 'Affiliation': ""Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Consonni', 'Affiliation': ""Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Protti', 'Affiliation': 'Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Lissoni', 'Affiliation': 'Department of Anaesthesia and Critical Care, ""Fondazione IRCCS Ca\' Granda, Ospedale Maggiore Policlinico,"" Milan, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Arcadipane', 'Affiliation': 'Department of Anesthesiology and Intensive Care, ISMETT IRCCS (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), UPMC, Palermo, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Pesenti', 'Affiliation': 'Department of Anaesthesia and Critical Care, ""Fondazione IRCCS Ca\' Granda, Ospedale Maggiore Policlinico,"" Milan, Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Grasselli', 'Affiliation': 'Department of Anaesthesia and Critical Care, ""Fondazione IRCCS Ca\' Granda, Ospedale Maggiore Policlinico,"" Milan, Italy.'}]",Critical care medicine,['10.1097/CCM.0000000000004590'] 588,32913645,The impact of intuitive eating v . pinned eating on behavioural markers: a preliminary investigation.,"Two promising strategies to manage eating behaviour are intuitive eating (IE; following hunger) and pinned eating (PE; ignoring hunger/eating at specific times of the day). This study compared IE and PE on behavioural markers. Participants ( n 56) were randomly assigned to IE ( n 28) or PE ( n 28) and given instructions to follow for 1 week. Drive to eat, behaviour, behavioural intentions and self-efficacy were measured at baseline and follow-up. Participants also evaluated their specific intervention. Comparable changes over time were found for both conditions for many measures. Significant conditions by time interactions were found for healthy snacking, total self-efficacy and self-efficacy for weight loss: those following IE showed an increase in each of these outcomes compared to those following PE who showed no change. The IE group found their intervention more useful than those following PE. Further research is needed to build on these preliminary findings.",2020,"Significant conditions by time interactions were found for healthy snacking, total self-efficacy and self-efficacy for weight loss:",['Participants ( n 56'],"['PE', 'intuitive eating v . pinned eating']","['behavioural markers', 'healthy snacking, total self-efficacy and self-efficacy for weight loss', 'Drive to eat, behaviour, behavioural intentions and self-efficacy']",[],"[{'cui': 'C0021885', 'cui_str': 'Bone nailing'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",56.0,0.0331015,"Significant conditions by time interactions were found for healthy snacking, total self-efficacy and self-efficacy for weight loss:","[{'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Ogden', 'Affiliation': 'School of Psychology, University of Surrey, Guildford GU2 7XH, UK.'}, {'ForeName': 'Elina', 'Initials': 'E', 'LastName': 'Pavlova', 'Affiliation': 'School of Nutrition, University of Surrey, Guildford GU2 7XH, UK.'}, {'ForeName': 'Hollie', 'Initials': 'H', 'LastName': 'Fouracre', 'Affiliation': 'School of Psychology, University of Surrey, Guildford GU2 7XH, UK.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Lammyman', 'Affiliation': 'School of Psychology, University of Surrey, Guildford GU2 7XH, UK.'}]",Journal of nutritional science,['10.1017/jns.2020.25'] 589,32928582,Blunted nutrient-response pathways in adipose tissue following high fat meals in men with metabolic syndrome: A randomized postprandial transcriptomic study.,"BACKGROUND Excessive adipose tissue is central to disease burden posed by the Metabolic Syndrome (MetS). Whilst much is known of the altered transcriptomic regulation of adipose tissue under fasting conditions, little is known of the responses to high-fat meals. METHODS Nineteen middle-aged males (mean ± SD 52.0 ± 4.6 years), consumed two isocaloric high-fat, predominately dairy-based or soy-based, breakfast meals. Abdominal subcutaneous adipose biopsies were collected after overnight fast (0 h) and 4 h following each meal. Global gene expression profiling was performed by microarray (Illumina Human WG-6 v3). RESULTS In the fasted state, 13 genes were differently expressed between control and MetS adipose tissue (≥1.2 fold-difference, p < 0.05). In response to the meals, the control participants had widespread increases in genes related to cellular nutrient responses (≥1.2 fold-change, p < 0.05; 2444 & 2367 genes; dairy & soy, respectively). There was blunted response in the MetS group (≥1.2 fold-change, p < 0.05; 332 & 336 genes; dairy & soy, respectively). CONCLUSIONS In middle-aged males with MetS, a widespread suppression of the subcutaneous adipose tissue nutrient responsive gene expression suggests an inflexibility in the transcriptomic responsiveness to both high-fat meals.",2021,"There was blunted response in the MetS group (≥1.2 fold-change, p < 0.05; 332 & 336 genes; dairy & soy, respectively). ","['men with metabolic syndrome', 'Nineteen middle-aged males (mean\xa0±', 'middle-aged males with MetS']",[],"['Abdominal subcutaneous adipose biopsies', 'blunted response', 'cellular nutrient responses']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",[],"[{'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}]",13.0,0.03354,"There was blunted response in the MetS group (≥1.2 fold-change, p < 0.05; 332 & 336 genes; dairy & soy, respectively). ","[{'ForeName': 'Aimee L', 'Initials': 'AL', 'LastName': 'Dordevic', 'Affiliation': 'Department of Nutrition, Dietetics & Food, Monash University, Melbourne, Australia. Electronic address: aimee.dordevic@monash.edu.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Coort', 'Affiliation': 'Department of Bioinformatics - BiGCaT, NUTRIM School of Nutrition and Metabolism in Translational Research, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Chris T', 'Initials': 'CT', 'LastName': 'Evelo', 'Affiliation': 'Department of Bioinformatics - BiGCaT, NUTRIM School of Nutrition and Metabolism in Translational Research, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Murgia', 'Affiliation': 'School of Agriculture and Food, University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Sinclair', 'Affiliation': 'Department of Nutrition, Dietetics & Food, Monash University, Melbourne, Australia; Faculty of Health, Deakin University, Melbourne, Australia.'}, {'ForeName': 'Maxine P', 'Initials': 'MP', 'LastName': 'Bonham', 'Affiliation': 'Department of Nutrition, Dietetics & Food, Monash University, Melbourne, Australia.'}, {'ForeName': 'Amy E', 'Initials': 'AE', 'LastName': 'Larsen', 'Affiliation': 'Department of Physiology, Anatomy, and Microbiology, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Gran', 'Affiliation': 'Faculty of Health, Deakin University, Melbourne, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cameron-Smith', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand; The Riddet Institute, Massey University, Palmerston North, New Zealand; Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.024'] 590,32930336,Aging Modulates Prefrontal Plasticity Induced by Executive Control Training.,"While declines in inhibitory control, the capacity to suppress unwanted neurocognitive processes, represent a hallmark of healthy aging, whether this function is susceptible to training-induced plasticity in older populations remains largely unresolved. We addressed this question with a randomized controlled trial investigating the changes in behavior and electrical neuroimaging activity induced by a 3-week adaptive gamified Go/NoGo inhibitory control training (ICT). Performance improvements were accompanied by the development of more impulsive response strategies, but did not generalize to impulsivity traits nor quality of life. As compared with a 2-back working-memory training, the ICT in the older adults resulted in a purely quantitative reduction in the strength of the activity in a medial and ventrolateral prefrontal network over the 400 ms P3 inhibition-related event-related potentials component. However, as compared with young adults, the ICT induced distinct configurational modifications in older adults' 200 ms N2 conflict monitoring medial-frontal functional network. Hence, while older populations show preserved capacities for training-induced plasticity in executive control, aging interacts with the underlying plastic brain mechanisms. Training improves the efficiency of the inhibition process in older adults, but its effects differ from those in young adults at the level of the coping with inhibition demands.",2021,"Performance improvements were accompanied by the development of more impulsive response strategies, but did not generalize to impulsivity traits nor quality of life.",['older adults'],"['2-back working-memory training', 'ICT', 'NoGo inhibitory control training (ICT', 'Executive Control Training']","['impulsivity traits nor quality of life', 'efficiency of the inhibition process']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]","[{'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C1522240', 'cui_str': 'Process'}]",,0.027188,"Performance improvements were accompanied by the development of more impulsive response strategies, but did not generalize to impulsivity traits nor quality of life.","[{'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Najberg', 'Affiliation': 'Neurology Unit, Medicine Section, Faculty of Science and Medicine, University of Fribourg, 1700, Fribourg, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Wachtl', 'Affiliation': 'Neurology Unit, Medicine Section, Faculty of Science and Medicine, University of Fribourg, 1700, Fribourg, Switzerland.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Anziano', 'Affiliation': 'Neurology Unit, Medicine Section, Faculty of Science and Medicine, University of Fribourg, 1700, Fribourg, Switzerland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Mouthon', 'Affiliation': 'Neurology Unit, Medicine Section, Faculty of Science and Medicine, University of Fribourg, 1700, Fribourg, Switzerland.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Spierer', 'Affiliation': 'Neurology Unit, Medicine Section, Faculty of Science and Medicine, University of Fribourg, 1700, Fribourg, Switzerland.'}]","Cerebral cortex (New York, N.Y. : 1991)",['10.1093/cercor/bhaa259'] 591,32928161,"Effect of football activity and physical fitness on information processing, inhibitory control and working memory in adolescents.","BACKGROUND Whilst an acute bout of exercise has been shown to enhance subsequent cognition, including in adolescents, the effects of team games (of which Football is the most popular) has received little attention. Therefore, this study examined: the effect of an acute bout of outdoor Football activity on information processing, inhibitory control, working memory and circulating brain-derived neurotrophic factor (BDNF) in adolescents; the effect of physical fitness on cognition and; the moderating effect of physical fitness on the acute exercise responses. METHODS Following familiarisation, 36 adolescents (16 girls) took part in two trials (60-min Football and 60-min seated rest) separated by 7-d in a counterbalanced, crossover design. Information processing and inhibitory control (Stroop Test), and working memory (Sternberg Paradigm) were assessed 30-min before exercise/rest and immediately, 45- and 90-min post-exercise/rest. Capillary blood samples were obtained before exercise/rest and up to 120-min post-exercise/rest. The median split of distance covered on the MSFT was used to divide the group into high- and low-fit groups. RESULTS Performance on the cognitive function tasks was similar between Football and seated rest (trial*time interactions; all p > .05). However, the high-fit group had overall quicker response times on both levels of the Stroop Task and all three levels of the Sternberg Paradigm (main effect of fitness; all p < .001). Furthermore, the exercise-cognition relationship was moderated by physical fitness, with improvements in working memory response times seen post-exercise, only in the high-fit group (trial*time*fitness interaction, p < .05). Circulating BDNF was unaffected by the Football activity and physical fitness (p > .05). CONCLUSION The present study shows that higher levels of physical fitness are beneficial for cognitive function and provides novel evidence that an ecologically valid, and popular, form of exercise is beneficial for working memory following exercise, in high-fit participants only.",2020,"RESULTS Performance on the cognitive function tasks was similar between Football and seated rest (trial*time interactions; all p > .05).","['Following familiarisation, 36 adolescents (16 girls) took part in two trials (60-min Football and 60-min seated rest', 'adolescents']","['MSFT', '45- and 90-min post-exercise/rest', 'football activity and physical fitness']","['Circulating BDNF', 'cognitive function tasks', 'median split of distance', 'Football activity and physical fitness', 'Information processing and inhibitory control (Stroop Test), and working memory (Sternberg Paradigm', 'Capillary blood samples']","[{'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0016517', 'cui_str': 'American or Canadian football - sport'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0035253', 'cui_str': 'Rest'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0016517', 'cui_str': 'American or Canadian football - sport'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0016517', 'cui_str': 'American or Canadian football - sport'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0419342', 'cui_str': 'Capillary specimen collection'}]",36.0,0.0335067,"RESULTS Performance on the cognitive function tasks was similar between Football and seated rest (trial*time interactions; all p > .05).","[{'ForeName': 'Ryan A', 'Initials': 'RA', 'LastName': 'Williams', 'Affiliation': 'Department of Sport Science; Exercise and Health Research Group; Sport, Health and Performance Enhancement (SHAPE) Research Centre, Nottingham Trent University, Nottingham, UK.'}, {'ForeName': 'Simon B', 'Initials': 'SB', 'LastName': 'Cooper', 'Affiliation': 'Department of Sport Science; Exercise and Health Research Group; Sport, Health and Performance Enhancement (SHAPE) Research Centre, Nottingham Trent University, Nottingham, UK. simon.cooper@ntu.ac.uk.'}, {'ForeName': 'Karah J', 'Initials': 'KJ', 'LastName': 'Dring', 'Affiliation': 'Department of Sport Science; Exercise and Health Research Group; Sport, Health and Performance Enhancement (SHAPE) Research Centre, Nottingham Trent University, Nottingham, UK.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Hatch', 'Affiliation': 'Department of Sport Science; Exercise and Health Research Group; Sport, Health and Performance Enhancement (SHAPE) Research Centre, Nottingham Trent University, Nottingham, UK.'}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Morris', 'Affiliation': 'Department of Sport Science; Exercise and Health Research Group; Sport, Health and Performance Enhancement (SHAPE) Research Centre, Nottingham Trent University, Nottingham, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Sunderland', 'Affiliation': 'Department of Sport Science; Exercise and Health Research Group; Sport, Health and Performance Enhancement (SHAPE) Research Centre, Nottingham Trent University, Nottingham, UK.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Nevill', 'Affiliation': 'Department of Sport Science; Exercise and Health Research Group; Sport, Health and Performance Enhancement (SHAPE) Research Centre, Nottingham Trent University, Nottingham, UK.'}]",BMC public health,['10.1186/s12889-020-09484-w'] 592,32926507,First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.,"This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE-024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a programmed death ligand 1 (PD-L1) tumor proportion score of 50% or higher evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy (four to six cycles). The primary end-point was progression-free survival; secondary end-points included overall survival and safety. Of 305 patients randomized in KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). Median progression-free survival was 41.4 (95% confidence interval [CI], 4.2-42.5) months with pembrolizumab and 4.1 (95% CI, 2.8-8.3) months with chemotherapy (hazard ratio [HR], 0.27 [95% CI, 0.11-0.65]; one-sided, nominal P = .001). Median overall survival was not reached (NR) (95% CI, 22.9-NR) and 21.5 (95% CI, 5.2-35.0) months, respectively (HR, 0.39 [95% CI, 0.17-0.91]; one-sided, nominal P = .012). Treatment-related adverse events occurred in 21/21 (100%) pembrolizumab-treated and 18/19 (95%) chemotherapy-treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 3-5 events. Immune-mediated adverse events and infusion reactions occurred in 11 pembrolizumab-treated patients (52%) and four chemotherapy-treated patients (21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 3-5 events. Consistent with results from KEYNOTE-024 overall, first-line pembrolizumab improved progression-free survival and overall survival vs chemotherapy with manageable safety among Japanese patients with metastatic non-small-cell lung cancer without EGFR/ALK alterations and a PD-L1 tumor proportion score of 50% or higher. The trial is registered with Clinicaltrials.gov: NCT02142738.",2020,"Immune-mediated adverse events and infusion reactions occurred in 11 patients (52%) and 4 patients (21%), respectively; 4 patients (19%) and 1 patient (5%), respectively, had grade 3-5 events.","['305 patients randomized in KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19', 'Metastatic Non-Small-Cell Lung Cancer', 'Japanese patients with metastatic non-small-cell lung cancer', 'previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a PD-L1 tumor proportion score ≥50% evaluated clinical outcomes among patients enrolled in Japan']","['pembrolizumab versus chemotherapy', 'pembrolizumab', 'First-Line Pembrolizumab Versus Chemotherapy', 'platinum-based chemotherapy']","['overall survival and safety', 'adverse events', 'Median overall survival', 'progression-free survival', 'progression-free survival and overall survival', 'Immune-mediated adverse events and infusion reactions', 'Median progression-free survival']","[{'cui': 'C4517703', 'cui_str': '305'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0278987', 'cui_str': 'Metastatic non-small cell lung cancer'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C1663627', 'cui_str': 'ALK protein, human'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C4087225', 'cui_str': 'Immune-mediated adverse reaction'}, {'cui': 'C2368034', 'cui_str': 'Adverse reaction to drug or medicament administered by infusion'}]",305.0,0.576266,"Immune-mediated adverse events and infusion reactions occurred in 11 patients (52%) and 4 patients (21%), respectively; 4 patients (19%) and 1 patient (5%), respectively, had grade 3-5 events.","[{'ForeName': 'Miyako', 'Initials': 'M', 'LastName': 'Satouchi', 'Affiliation': 'Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan.'}, {'ForeName': 'Kaname', 'Initials': 'K', 'LastName': 'Nosaki', 'Affiliation': 'Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Takahashi', 'Affiliation': 'Division of Thoracic Oncology, Shizuoka Cancer Center, Shuntougun, Japan.'}, {'ForeName': 'Kazuhiko', 'Initials': 'K', 'LastName': 'Nakagawa', 'Affiliation': 'Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.'}, {'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Aoe', 'Affiliation': 'Department of Medical Oncology, National Hospital Organization Yamaguchi Ube Medical Center, Ube, Japan.'}, {'ForeName': 'Takayasu', 'Initials': 'T', 'LastName': 'Kurata', 'Affiliation': 'Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan.'}, {'ForeName': 'Akimasa', 'Initials': 'A', 'LastName': 'Sekine', 'Affiliation': 'Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Horiike', 'Affiliation': 'Department of Thoracic Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.'}, {'ForeName': 'Tatsuro', 'Initials': 'T', 'LastName': 'Fukuhara', 'Affiliation': 'Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan.'}, {'ForeName': 'Shunichi', 'Initials': 'S', 'LastName': 'Sugawara', 'Affiliation': 'Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan.'}, {'ForeName': 'Shigeki', 'Initials': 'S', 'LastName': 'Umemura', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Saka', 'Affiliation': 'Department of Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.'}, {'ForeName': 'Isamu', 'Initials': 'I', 'LastName': 'Okamoto', 'Affiliation': 'Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Yamamoto', 'Affiliation': 'Internal Medicine III, Wakayama Medical University, Wakayama, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Sakai', 'Affiliation': 'Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.'}, {'ForeName': 'Kazuma', 'Initials': 'K', 'LastName': 'Kishi', 'Affiliation': 'Department of Respiratory Medicine, Respiratory Center, Totanomon Hospital, Tokyo, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Katakami', 'Affiliation': 'Division of Integrated Oncology, Institute of Biomedical Research and Innovation Hospital, Kobe, Japan.'}, {'ForeName': 'Hidehito', 'Initials': 'H', 'LastName': 'Horinouchi', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Toyoaki', 'Initials': 'T', 'LastName': 'Hida', 'Affiliation': 'Department of Thoracic Oncology, Aichi Cancer Center, Aichi, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Okamoto', 'Affiliation': ""Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.""}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Atagi', 'Affiliation': 'Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.'}, {'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Ohira', 'Affiliation': 'Department of Surgery, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Shi Rong', 'Initials': 'SR', 'LastName': 'Han', 'Affiliation': 'MSD K.K., Tokyo, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Noguchi', 'Affiliation': 'MSD K.K., Tokyo, Japan.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Ebiana', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Katsuyuki', 'Initials': 'K', 'LastName': 'Hotta', 'Affiliation': 'Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.'}]",Cancer science,['10.1111/cas.14647'] 593,32942920,Ultrasound biomicroscopic features of the normal lower eyelid.,"PURPOSE To report the ultrasound biomicroscopic features of normal lower eyelid structures. METHODS Thirty lower eyelids of fifteen healthy adults were randomized and prospectively subjected to Ultrasound Biomicroscopy (Quantel Aviso with 50 MHz transducer) by two independent observers (an ophthalmologist and an optometrist). The measurements were performed in upgaze, with the probe perpendicular to the lower eyelid margin in the mid-pupillary line, two limbal lines, and two canthal lines. The tarsus, orbicularis, capsulopalpebral fascia, and retractor-conjunctiva complex were assessed for two parameters: echogenicity (hyper/hypoechoic) and measurement in millimeters. RESULTS Mean age was 25 years (range 20-39 years), 15 (50%) were right lower eyelids and 8 were males. The first layer, skin-orbicularis complex appeared hyperechoic. The second layer was hypoechoic band which represents the tarsal plate superiorly and capsulopalpebral fascia inferiorly. This was noted to be continuous and of almost uniform thickness in the normal eyelids. The glandular structure of meibomian glands was identified in 100% cases. The hyperechoic layer below the capsulopalpebral fascia is the retractor-conjunctiva complex. The mean thickness of pretarsal and pre-septal orbicularis was 0.68 ± 0.18 mm and 0.89 ± 0.16 mm, respectively. The tarsal plate measured 0.57 ± 0.12 mm, capsulopalpebral fascia 0.42 ± 0.13 mm and the retractor-conjunctiva complex 0.79 ± 0.18 mm. On Bland-Altman analysis, the majority of the measurements had mean agreements between -0.14 mm and +0.12 mm. Anatomical differentiation was not useful in the canthal region. CONCLUSION Echogenicity and thickness of normal lower eyelid structures as measured by UBM are reported. The test is non-invasive, with a good inter-observer agreement.",2021,"The mean thickness of pretarsal and pre-septal orbicularis was 0.68 ± 0.18 mm and 0.89 ± 0.16 mm, respectively.","['Mean age was 25\xa0years (range 20-39\xa0years), 15 (50%) were right lower eyelids and 8 were males', 'Thirty lower eyelids of fifteen healthy adults']",['Ultrasound Biomicroscopy (Quantel Aviso with 50\xa0MHz transducer) by two independent observers (an ophthalmologist and an optometrist'],"['glandular structure of meibomian glands', 'Ultrasound biomicroscopic features', 'mean thickness of pretarsal and pre-septal orbicularis']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0229258', 'cui_str': 'Lower eyelid structure'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C1301497', 'cui_str': 'Ultrasound biomicroscopy'}, {'cui': 'C0556962', 'cui_str': 'MHz'}, {'cui': 'C0040661', 'cui_str': 'Transducer'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C1704292', 'cui_str': 'Ophthalmologist'}, {'cui': 'C0029146', 'cui_str': 'Optometrist'}]","[{'cui': 'C0225353', 'cui_str': 'Glandular'}, {'cui': 'C0025181', 'cui_str': 'Structure of meibomian gland'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0442004', 'cui_str': 'Septal'}]",15.0,0.0316123,"The mean thickness of pretarsal and pre-septal orbicularis was 0.68 ± 0.18 mm and 0.89 ± 0.16 mm, respectively.","[{'ForeName': 'Varshitha Hemanth', 'Initials': 'VH', 'LastName': 'Vasanthapuram', 'Affiliation': 'Ophthalmic Plastic Surgery Service, L V Prasad Eye Institute, Hyderabad, India.'}, {'ForeName': 'Purabita', 'Initials': 'P', 'LastName': 'Saha', 'Affiliation': 'Ophthalmic Plastic Surgery Service, L V Prasad Eye Institute, Hyderabad, India.'}, {'ForeName': 'Ashik', 'Initials': 'A', 'LastName': 'Mohamed', 'Affiliation': 'Ophthalmic Biophysics, L V Prasad Eye Institute, Hyderabad, India.'}, {'ForeName': 'Milind N', 'Initials': 'MN', 'LastName': 'Naik', 'Affiliation': 'Ophthalmic Plastic Surgery Service, L V Prasad Eye Institute, Hyderabad, India.'}]","Orbit (Amsterdam, Netherlands)",['10.1080/01676830.2020.1812094'] 594,32950546,Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).,"BACKGROUND Topical psoriasis treatment relies on a reactive rather than a long-term proactive approach to disease relapse. OBJECTIVE Assess long-term efficacy and safety of proactive psoriasis management with twice-weekly calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam. METHODS Phase III trial (NCT02899962) included a 4-week open-label lead-in phase (Cal/BD foam once daily) and a 52-week, randomized, double-blind, maintenance phase. A total of 545 patients achieved treatment success (physician's global assessment ""clear""/""almost clear,"" ≥2-grade improvement from baseline) and were randomized to proactive management (Cal/BD foam; n = 272) or reactive management (vehicle foam; n = 273) twice-weekly, with rescue treatment of Cal/BD foam once daily for 4 weeks upon relapse. Primary endpoint was time to first relapse (physician's global assessment ""mild"" or higher). RESULTS A total of 251 randomized patients (46.1%) completed the trial. Median time to first relapse was 56 days (proactive) and 30 days (reactive). Patients in the proactive group had an additional 41 days in remission compared with the reactive group over 1 year (P < .001). Number of relapses per year of exposure was 3.1 (proactive) and 4.8 (reactive). Cal/BD foam was well tolerated. LIMITATIONS Maintenance phase dropout rate (53.9%) was within the expected range but provides challenges in statistical analysis. CONCLUSION Long-term proactive management with Cal/BD foam demonstrated superior efficacy vs reactive management.",2021,Patients in the proactive group had an additional 41 days in remission compared with the reactive group over 1 year (P < 0.001).,['545 patients'],"['calcipotriene / betamethasone dipropionate', 'proactive psoriasis management with twice-weekly calcipotriene', '0.005%/betamethasone dipropionate', '4-week open-label lead-in phase (Cal/BD foam once-daily']","[""time to first relapse (PGA ≥'mild"", 'tolerated', 'Median time']","[{'cui': 'C4517809', 'cui_str': '545'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0065767', 'cui_str': 'calcipotriene'}, {'cui': 'C0053523', 'cui_str': 'Betamethasone dipropionate'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C4517414', 'cui_str': '0.064'}, {'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.227363,Patients in the proactive group had an additional 41 days in remission compared with the reactive group over 1 year (P < 0.001).,"[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Lebwohl', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: lebwohl@aol.com.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Kircik', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Lacour', 'Affiliation': 'Department of Dermatology, University Hospital of Nice, Nice, France.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Liljedahl', 'Affiliation': 'LEO Pharma Ballerup, Ballerup, Denmark.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Lynde', 'Affiliation': 'Lynde Dermatology, Probity Medical Research, Markham, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Marie Holst', 'Initials': 'MH', 'LastName': 'Mørch', 'Affiliation': 'LEO Pharma Ballerup, Ballerup, Denmark.'}, {'ForeName': 'Kim A', 'Initials': 'KA', 'LastName': 'Papp', 'Affiliation': 'K. Papp Clinical Research, Waterloo, Ontario, Canada.'}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Perrot', 'Affiliation': 'Department of Dermatology, University Hospital of St-Etienne, St-Etienne, France.'}, {'ForeName': 'Linda Stein', 'Initials': 'LS', 'LastName': 'Gold', 'Affiliation': 'Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.'}, {'ForeName': 'Amrit', 'Initials': 'A', 'LastName': 'Takhar', 'Affiliation': 'Wansford and Kings Cliffe Practice, Wansford, Cambridgeshire, United Kingdom.'}, {'ForeName': 'Diamant', 'Initials': 'D', 'LastName': 'Thaçi', 'Affiliation': 'Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Warren', 'Affiliation': 'Dermatology Centre, Salford Royal National Health Service Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Wollenberg', 'Affiliation': 'Department of Dermatology and Allergology, Ludwig Maximilian University Munich, Munich, Germany.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.09.037'] 595,32965691,"Effects of different mean arterial pressure targets on plasma volume, ANP and glycocalyx-A randomized trial.","BACKGROUND Arterial haematocrit (Hct) has been shown to decrease after anaesthesia induction, most probably because of an increased plasma volume (PV). The primary objective was to quantify change in PV if mean arterial pressure (MAP) was kept at baseline level or allowed to decrease to 60 mm Hg. Our secondary objective was to evaluate underlying mechanisms of this response. METHODS Twenty-four coronary artery bypass patients were randomized to a higher (90 mm Hg, intervention group) or lower (60 mm Hg, control group) MAP by titration of norepinephrine. During the experimental procedure, no fluids were administered. Baseline PV was measured by 125 I-albumin and the change in PV was calculated from the change in Hct. Changes in MAP, plasma 125 I-albumin, colloid osmotic pressure, albumin, Mid Regional-pro Atrial Natriuretic Peptide (MR-proANP) and endothelial glycocalyx components were measured from baseline to 50 minutes after anaesthesia induction. RESULTS The MAP during the trial was 93 ± 9 mm Hg in the intervention group and 62 ± 5 mm Hg in the control group. PV increased with up to 420 ± 180 mL in the control group and 45 ± 130 mL in the intervention group (P < .001). Albumin and colloid osmotic pressure decreased significantly more in the control group. MR-proANP increased in the control group but no shedding of the glycocalyx layer was detected in either of the groups. CONCLUSION Allowing mean arterial pressure to fall to 60 mm Hg during anaesthesia induction, increases the plasma volume due to reabsorption of interstitial water, with no ANP-induced degradation of the endothelial glycocalyx.",2021,The MAP during the trial was 93 ± 9 mmHg in the intervention group and 62 ± 5 mmHg in the control group.,['Twenty-four coronary artery bypass patients'],['norepinephrine'],"['Albumin and colloid osmotic pressure', 'Baseline PV', 'glycocalyx layer', 'PV', 'plasma volume (PV', 'PV if mean arterial pressure (MAP', 'MR-proANP', 'Changes in MAP, plasma 125 I-albumin, colloid osmotic pressure, albumin, Mid Regional-pro Atrial Natriuretic Peptide (MR-proANP) and endothelial glycocalyx components']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0028351', 'cui_str': 'Norepinephrine'}]","[{'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0009361', 'cui_str': 'Colloids'}, {'cui': 'C0029393', 'cui_str': 'Osmotic pressure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032127', 'cui_str': 'Blood plasma volume'}, {'cui': 'C0061622', 'cui_str': 'Glycocalyx'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0796396', 'cui_str': 'Iodine-125'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0027481', 'cui_str': 'A-type natriuretic peptide'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",24.0,0.08616,The MAP during the trial was 93 ± 9 mmHg in the intervention group and 62 ± 5 mmHg in the control group.,"[{'ForeName': 'Tor', 'Initials': 'T', 'LastName': 'Damén', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Saadati', 'Affiliation': 'Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Forssell-Aronsson', 'Affiliation': 'Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Hesse', 'Affiliation': 'Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bentzer', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Helsingborg Hospital, Helsingborg and Lund University, Helsingborg, Sweden.'}, {'ForeName': 'Sven-Erik', 'Initials': 'SE', 'LastName': 'Ricksten', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Nygren', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13710'] 596,32962749,A tai chi/qigong intervention for older adults living with HIV: a study protocol of an exploratory clinical trial.,"BACKGROUND Almost half of people living with HIV (PLWH) in the USA are over 50 years of age; this is expected to increase to 70% by 2020. Yet, few interventions exist for older PLWH that address psychological and physical symptoms combined, both prevalent in this population. There is a need to find innovative and accessible interventions that can help older PLWH to manage their symptoms. Mind-body interventions, like tai chi/qigong (TCQ), improve both physical and psychological health. TCQ is a series of slow, low-impact meditative movements that integrates breathwork, meditation, and stances. METHODS The present study is an exploratory clinical trial that will evaluate the acceptability and feasibility of a 12-week, small group TCQ intervention (n = 24), a sham qigong control condition (n = 24), and a standard of care control condition (n = 24) for older people living with HIV/AIDS. It will also explore any preliminary associations between the TCQ intervention and symptom alleviation. Participants will be recruited from community-based health and social services organizations in Miami, FL, and randomized to one of the 3 conditions. DISCUSSION We will assess feasibility and acceptability through questionnaires and adherence to TCQ. We will assess preliminary associations with symptoms such as depression, anxiety, social support, chronic HIV-related fatigue, and clinical outcomes. These will be described through proportions, means, and changes over time through graphing techniques. Outcomes will be assessed at baseline, at post-intervention, and at 3 months follow-up. These preliminary analyses also will provide information necessary to estimate effect size and power needed for a larger clinical trial. TRIAL REGISTRATION ClinicalTrials.gov NCT03840525 . Registered on 16 July 2018.",2020,"Mind-body interventions, like tai chi/qigong (TCQ), improve both physical and psychological health.","['people living with HIV (PLWH', 'older adults living with HIV', 'older people living with HIV/AIDS', 'Participants will be recruited from community-based health and social services organizations in Miami, FL, and randomized to one of the 3 conditions']","['TCQ', 'tai chi/qigong intervention', 'Mind-body interventions, like tai chi/qigong (TCQ', 'sham qigong control condition (n\u2009=\u200924), and a standard of care control condition', 'small group TCQ intervention']",[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0037441', 'cui_str': 'Social Service'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0376403', 'cui_str': 'Tai-chi'}, {'cui': 'C0282077', 'cui_str': 'Qigong'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1513305', 'cui_str': 'Mind-Body Medicine'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],,0.134083,"Mind-body interventions, like tai chi/qigong (TCQ), improve both physical and psychological health.","[{'ForeName': 'Gladys E', 'Initials': 'GE', 'LastName': 'Ibañez', 'Affiliation': 'Department of Epidemiology, Florida International University, 11200 SW 8th St AHC5, Miami, FL, 33199, USA. gibanez@fiu.edu.'}, {'ForeName': 'Kristopher', 'Initials': 'K', 'LastName': 'Fennie', 'Affiliation': 'Division of Natural Sciences, New College of Florida, 5800 Bay Shore Road, Sarasota, FL, 34243, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Larkey', 'Affiliation': 'College of Nursing and Health Innovation, Arizona State University, 550 N 3rd St, Phoenix, AZ, 85004, USA.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Hu', 'Affiliation': 'Department of Biostatistics, Florida International University, 11200 SW 8th St AHC5, Miami, FL, 33199, USA.'}, {'ForeName': 'Angel B', 'Initials': 'AB', 'LastName': 'Algarin', 'Affiliation': 'Department of Epidemiology, Florida International University, 11200 SW 8th St AHC5, Miami, FL, 33199, USA.'}, {'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Valdivia', 'Affiliation': 'Department of Biostatistics, Florida International University, 11200 SW 8th St AHC5, Miami, FL, 33199, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Lavretsky', 'Affiliation': 'Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, The University of California, Los Angeles (UCLA), 760 Westwood Plaza, Los Angeles, CA, 90095, USA.'}]",Trials,['10.1186/s13063-020-04728-x'] 597,32968914,Randomized clinical trial on the use of a colon-occlusion device to assist rectal washout.,"BACKGROUND Transrectal Natural Orifice Transluminal Endoscopic Surgery is currently limited by the inherent risk of surgical site infection due to peritoneal contamination after rectotomy. Coloshield has been developed as a temporary colon occlusion device to facilitate rectal washout. However, effectiveness and safety has not been evaluated in humans. METHODS Twenty-two patients have been randomly assigned to undergo proctological intervention with a rectal washout with and without the use of Coloshield. Patients and assessors were blinded. Boston Bowel Preparation Scale (BBPS) has been determined 30 min as well as immediately after rectal washout. Feasibility, pain, intra- and postoperative morbidity as well as bowel function and continence 6 weeks after surgery were assessed. RESULTS BBPS 30 min after rectal washout with and without Coloshield was in mean 2.42 ± 1.02 and 2.12 ± 0.89 (p = 0.042). Mean BBPS immediately after rectal washout was 2.39 ± 1.02 and 2.24 ± 0.66 (p = 0.269). Mean BBPS immediately after rectal washout and 30 min thereafter did not differ (p = 0.711). Coloshield application was feasible without any complications. The median (interquartile range) numeric rating scale for pain 4 h after surgery was 1 (0-1) and 3 (0-4) (p = 0.212). Six weeks after surgery 0/11 and 1/11 patients suffered from evacuation difficulties (p = 1.0) and the median Vaizey-Wexner score was 1 (0-3) and 1 (0-2) (p = 0.360). CONCLUSIONS Coloshield application in humans is feasible and safe. Slight benefits in rectal preparation by washout are found when Coloshield is used. Colon occlusion by Coloshield for transrectal NOTES should be evaluated within clinical studies. TRIAL REGISTRATION Clinicaltrials.gov NCT02579330.",2021,Mean BBPS immediately after rectal washout and 30 min thereafter did not differ (p = 0.711).,['Twenty-two patients have been randomly assigned to undergo'],"['proctological intervention with a rectal washout with and without the use of Coloshield', 'colon-occlusion device']","['median (interquartile range) numeric rating scale for pain', 'median Vaizey-Wexner score', 'effectiveness and safety', 'Feasibility, pain, intra- and postoperative morbidity', 'Boston Bowel Preparation Scale (BBPS', 'Mean BBPS']","[{'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0193144', 'cui_str': 'Rectal irrigation'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0235328', 'cui_str': 'Obstruction of colon'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C4302285', 'cui_str': 'BBPS - Boston bowel preparation scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.257171,Mean BBPS immediately after rectal washout and 30 min thereafter did not differ (p = 0.711).,"[{'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Cordewener', 'Affiliation': 'Pelvic Floor Unit, Clarunis, University Center for Gastrointestinal and Liver Diseases, 4002, Basel, Switzerland.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Zürcher', 'Affiliation': 'Department of Surgery, Spital Thun STS AG, Krankenhausstrasse 12, 3600, Thun, Switzerland.'}, {'ForeName': 'Philip C', 'Initials': 'PC', 'LastName': 'Müller', 'Affiliation': 'Department of Visceral and Transplantation Surgery, University Hospital Zürich, Rämistrasse 100, 8032, Zurich, Switzerland.'}, {'ForeName': 'Beat P', 'Initials': 'BP', 'LastName': 'Müller-Stich', 'Affiliation': 'Department of Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Zerz', 'Affiliation': 'eSwiss Medical and Surgical Center, Klinik Stephanshorn, Brauerstrasse 97, 9016, St. Gallen, Switzerland.'}, {'ForeName': 'Georg R', 'Initials': 'GR', 'LastName': 'Linke', 'Affiliation': 'Department of Surgery, Spital Thun STS AG, Krankenhausstrasse 12, 3600, Thun, Switzerland.'}, {'ForeName': 'Daniel C', 'Initials': 'DC', 'LastName': 'Steinemann', 'Affiliation': 'Pelvic Floor Unit, Clarunis, University Center for Gastrointestinal and Liver Diseases, 4002, Basel, Switzerland. Daniel.steinemann@unibas.ch.'}]",Surgical endoscopy,['10.1007/s00464-020-07992-9'] 598,32968915,A comparative prospective study of short-term outcomes of extended view totally extraperitoneal (e-TEP) repair versus laparoscopic intraperitoneal on lay mesh (IPOM) plus repair for ventral hernia.,"BACKGROUND Currently, minimally invasive approach is preferred for the treatment of ventral hernias. After the introduction of extended view totally extraperitoneal (e-TEP) technique, there has been a constant debate over the choice of better approach. In this study, we compare the short-term outcomes of e-TEP and laparoscopic IPOM Plus repair for ventral hernias. METHODS This is a comparative, prospective single-center study done at GEM Hospital and research center Coimbatore, India from July 2018 to July 2019. All patients who underwent elective ventral hernia surgery with defect size of 2 to 6 cm were included. Patient demographics, hernia characteristics, operative and perioperative findings, and postoperative complications were systematically recorded and analyzed. RESULTS We evaluated 92 cases (n = 92), 46 in each group. Mean age, sex, BMI, location of hernia, primary and incisional hernia, and comorbidity were comparable in both the groups. Mean defect size for IPOM Plus and e-TEP was 4 cm and 3.89 cm, respectively. Operative time was significantly higher for e-TEP, while postoperative pain (VAS), analgesic requirement, and postoperative hospital stay were significantly less as compared to IPOM Plus. However, 2 cases (4.35%) of e-TEP had recurrence but none in IPOM Plus group. CONCLUSION e-TEP is an evolving procedure and comparable to IPOM Plus in terms of postoperative pain, analgesic requirement, cost of mesh, and length of hospital stay. More randomized controlled and multicentric studies are required with longer follow-up to validate our findings.",2021,"Operative time was significantly higher for e-TEP, while postoperative pain (VAS), analgesic requirement, and postoperative hospital stay were significantly less as compared to IPOM","['92 cases (n\u2009=\u200992), 46 in each group', 'ventral hernia', 'All patients who underwent elective ventral hernia surgery with defect size of 2 to 6\xa0cm were included']","['e-TEP and laparoscopic IPOM Plus repair', 'extended view totally extraperitoneal ', 'IPOM', 'e-TEP) repair versus laparoscopic intraperitoneal on lay mesh (IPOM) plus repair']","['Mean age, sex, BMI, location of hernia, primary and incisional hernia, and comorbidity', 'Operative time', 'postoperative pain, analgesic requirement, cost of mesh, and length of hospital stay', 'postoperative pain (VAS), analgesic requirement, and postoperative hospital stay', 'Patient demographics, hernia characteristics, operative and perioperative findings, and postoperative complications', 'Mean defect size for IPOM']","[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0019326', 'cui_str': 'Hernia of anterior abdominal wall'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0442090', 'cui_str': 'Extraperitoneal'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0442120', 'cui_str': 'Intraperitoneal'}, {'cui': 'C0023668', 'cui_str': 'Liechtenstein'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0267716', 'cui_str': 'Incisional hernia'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",,0.0852648,"Operative time was significantly higher for e-TEP, while postoperative pain (VAS), analgesic requirement, and postoperative hospital stay were significantly less as compared to IPOM","[{'ForeName': 'Neeraj', 'Initials': 'N', 'LastName': 'Kumar', 'Affiliation': 'GEM Hospital and Research Centre, Coimbatore, India. neeraj891677@yahoo.com.'}, {'ForeName': 'Nalankilli V', 'Initials': 'NV', 'LastName': 'Palanisamy', 'Affiliation': 'GEM Hospital and Research Centre, Coimbatore, India.'}, {'ForeName': 'Ramakrishnan', 'Initials': 'R', 'LastName': 'Parthasarathi', 'Affiliation': 'GEM Hospital and Research Centre, Coimbatore, India.'}, {'ForeName': 'Sandeep C', 'Initials': 'SC', 'LastName': 'Sabnis', 'Affiliation': 'GEM Hospital and Research Centre, Coimbatore, India.'}, {'ForeName': 'Sunil Kumar', 'Initials': 'SK', 'LastName': 'Nayak', 'Affiliation': 'GEM Hospital and Research Centre, Coimbatore, India.'}, {'ForeName': 'Chinnusamy', 'Initials': 'C', 'LastName': 'Palanivelu', 'Affiliation': 'GEM Hospital and Research Centre, Coimbatore, India.'}]",Surgical endoscopy,['10.1007/s00464-020-07990-x'] 599,32978675,The use of retinoic acid in association with microneedling in the treatment of epidermal melasma: efficacy and oxidative stress parameters.,"This study aimed to evaluate the effectiveness of isolated treatment with retinoic acid and its combination with the microneedling technique in facial melasma, seeking to associate these results with possible oxidative damage. This is a blinded randomized clinical trial with 42 women with facial melasma (skin phototype I-IV), randomized into Group A (microneedling and 5% retinoic acid) or Group B (5% retinoic acid alone). Four procedures were applied with 15 days intervals (4 blood collections). Clinical improvement was assessed using the Melasma Area Severity Index (MASI). Serum oxidative stress levels were evaluated by protein oxidation (carbonyl), lipid peroxidation (TBARS) and sulfhydryl groups, as well as enzyme activities of superoxide dismutase (SOD) and catalase (CAT). The statistical analyzes were performed by generalized estimation equation (GEE). There was a reduction in MASI scale and TBARS levels in both groups over time (p < 0.05), with no difference between groups (p = 0.416). There was also a substantial increase in the carbonyl levels at 30 days (p = 0.002). The SOD activity decreased after 30 days, regardless of group (p < 0.001), which was maintained after 60 days. In Group A, there was a reduction in sulfhydryl levels at 60 days (p < 0.001). It is important to highlight that both groups demonstrated efficacy in the clinical improvement of melasma within at least 60 days, reducing the MASI score by almost 50%. However, microneedling with retinoic acid seems to be the worst treatment because there is a reduction in the non-enzymatic antioxidant defense, which is important to protect against oxidative stress.",2021,"There was a reduction in MASI scale and TBARS levels in both groups over time (p < 0.05), with no difference between groups (p = 0.416).","['epidermal melasma', '42 women with facial melasma (skin phototype I-IV']","['Group A (microneedling and 5% retinoic acid) or Group B (5% retinoic acid alone', 'retinoic acid', 'retinoic acid and its combination with the microneedling technique']","['carbonyl levels', 'MASI scale and TBARS levels', 'protein oxidation (carbonyl), lipid peroxidation (TBARS) and sulfhydryl groups, as well as enzyme activities of superoxide dismutase (SOD) and catalase (CAT', 'Melasma Area Severity Index (MASI', 'SOD activity', 'Serum oxidative stress levels', 'sulfhydryl levels', 'MASI score']","[{'cui': 'C0014520', 'cui_str': 'Epidermis structure'}, {'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]","[{'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0040845', 'cui_str': 'Tretinoin'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0162781', 'cui_str': 'TBARs'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0023775', 'cui_str': 'Lipid peroxidation'}, {'cui': 'C0038734', 'cui_str': 'Sulfhydryls'}, {'cui': 'C0243102', 'cui_str': 'enzyme activity'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0007367', 'cui_str': 'CATALASE'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",42.0,0.0439211,"There was a reduction in MASI scale and TBARS levels in both groups over time (p < 0.05), with no difference between groups (p = 0.416).","[{'ForeName': 'Clarissa L M da Silva', 'Initials': 'CLMDS', 'LastName': 'Bergmann', 'Affiliation': 'Programa de Pós-Graduação em Biociências e Reabilitação, Centro Universitário Metodista - IPA, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Pochmann', 'Affiliation': 'Programa de Pós-Graduação em Biociências e Reabilitação, Centro Universitário Metodista - IPA, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Bergmann', 'Affiliation': 'Médico Cirurgião Geral Pela Universidade Federal do Rio Grande do Sul-Porto Alegre, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Fernanda Brasil', 'Initials': 'FB', 'LastName': 'Bocca', 'Affiliation': 'Programa de Pós-Graduação em Biociências e Reabilitação, Centro Universitário Metodista - IPA, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Proença', 'Affiliation': 'Programa de Pós-Graduação em Biociências e Reabilitação, Centro Universitário Metodista - IPA, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Marinho', 'Affiliation': 'Programa de Pós-Graduação em Biociências e Reabilitação, Centro Universitário Metodista - IPA, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Mello', 'Affiliation': 'Programa de Pós-Graduação em Biociências e Reabilitação, Centro Universitário Metodista - IPA, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Dani', 'Affiliation': 'Programa de Pós-Graduação em Biociências e Reabilitação, Centro Universitário Metodista - IPA, Porto Alegre, RS, Brazil. carolinedani@yahoo.com.br.'}]",Archives of dermatological research,['10.1007/s00403-020-02140-8'] 600,32979577,"Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis.","OBJECTIVES The aim was to investigate the correlation between biomarkers of brain injury and long-term neurocognitive outcome, and the interplay with intrathecal inflammation and neuronal autoimmunity, in patients with herpes simplex encephalitis (HSE). METHODS A total of 53 adult/adolescent HSE patients were included from a prospective cohort in a randomized placebo-controlled trial investigating the effect of a 3-month follow-up treatment with valaciclovir. Study subjects underwent repeated serum/cerebrospinal fluid (CSF) sampling and brain magnetic resonance imaging in the first 3 months along with cognitive assessment using the Mattis Dementia Rating Scale (MDRS) at 24 months. CSF samples were analysed for biomarkers of brain injury, inflammation and synaptic autoimmunity. The predefined primary analysis was the correlation between peak CSF neurofilament protein (NFL), a biomarker of neuronal damage, and MDRS at 24 months. RESULTS Impaired cognitive performance significantly correlated with NFL levels (rho = -0.36, p = 0.020). Development of IgG anti-N-methyl-D-aspartate receptor (NDMAR) antibodies was associated with a broad and prolonged proinflammatory CSF response. In a linear regression model, lower MDRS at 24 months was associated with previous development of IgG anti-N-methyl-D-aspartate receptor (NMDAR) (beta = -0.6249, p = 0.024) and age (z-score beta = -0.2784, p = 0.024), but not CSF NFL, which however significantly correlated with subsequent NMDAR autoimmunization (p = 0.006). DISCUSSION Our findings show that NFL levels are predictive of long-term neurocognitive outcome in HSE, and suggest a causative chain of events where brain tissue damage increases the risk of NMDAR autoimmunisation and subsequent prolongation of CSF inflammation. The data provides guidance for a future intervention study of immunosuppressive therapy administered in the recovery phase of HSE.",2021,"RESULTS Impaired cognitive performance significantly correlated with NFL levels (rho = -0.36, p = 0.020).","['patients with herpes simplex encephalitis (HSE', 'herpes simplex encephalitis', 'A total of 53 adult/adolescent HSE patients']","['placebo', 'immunosuppressive therapy', 'IgG anti-N-methyl-D-aspartate receptor (NDMAR) antibodies', 'valaciclovir']","['NFL levels', 'peak CSF neurofilament protein (NFL), a biomarker of neuronal damage, and MDRS', 'subsequent NMDAR autoimmunization', 'Mattis Dementia Rating Scale (MDRS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0228492', 'cui_str': 'Structure of posterior semilunar lobule'}, {'cui': 'C0014038', 'cui_str': 'Encephalitis'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}, {'cui': 'C0051979', 'cui_str': 'Anti-Immunoglobulin G antibody'}, {'cui': 'C2919931', 'cui_str': 'N-methyl-D-aspartate receptor antibody'}, {'cui': 'C0249458', 'cui_str': 'valacyclovir'}]","[{'cui': 'C0085418', 'cui_str': 'Neurofilament protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0907533', 'cui_str': 'NOS1 protein, human'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0451074', 'cui_str': 'Clinical dementia rating scale'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0080093', 'cui_str': 'N-Methyl-D-Aspartate Receptors'}]",53.0,0.106535,"RESULTS Impaired cognitive performance significantly correlated with NFL levels (rho = -0.36, p = 0.020).","[{'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Westman', 'Affiliation': 'Department of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden. Electronic address: gabriel.westman@medsci.uu.se.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Aurelius', 'Affiliation': 'Unit of Infectious Diseases, Department of Medicine, Karolinska Institutet, Department of Infectious Diseases, Karolinska University Hospital, Solna, Sweden.'}, {'ForeName': 'Clas', 'Initials': 'C', 'LastName': 'Ahlm', 'Affiliation': 'Department of Clinical Microbiology, Infection and Immunology, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Kaj', 'Initials': 'K', 'LastName': 'Blennow', 'Affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Eriksson', 'Affiliation': 'Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Liza', 'Initials': 'L', 'LastName': 'Lind', 'Affiliation': 'Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Schliamser', 'Affiliation': 'Department of Clinical Sciences, Division of Infection Medicine, Lund University, Lund, Sweden.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Sund', 'Affiliation': 'Department of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Zetterberg', 'Affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom; UK Dementia Research Institute at UCL, London, United Kingdom.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Studahl', 'Affiliation': 'Institute of Biomedicine, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.'}]",Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,['10.1016/j.cmi.2020.09.031'] 601,32958699,Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).,"PURPOSE Irinotecan/5-fluorouracil (5-FU; FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab, are approved, first-line treatments for metastatic colorectal cancer (mCRC). We aimed at identifying germline variants associated with survival in patients with mCRC treated with these regimens in Cancer and Leukemia Group B/SWOG 80405. EXPERIMENTAL DESIGN Patients with mCRC receiving either FOLFOX or FOLFIRI were randomized to either cetuximab or bevacizumab. DNA from peripheral blood was genotyped for approximately 700,000 SNPs. The association between SNPs and overall survival (OS) was tested in 613 patients of genetically estimated European ancestry using Cox proportional hazards models. RESULTS The four most significant SNPs associated with OS were three haplotypic SNPs between microsomal glutathione S-transferase 1 ( MGST1 ) and LIM domain only 3 ( LMO3 , representative HR, 1.56; P = 1.30 × 10 -6 ), and rs11644916 in AXIN1 (HR, 1.39, P = 4.26 × 10 -6 ). AXIN1 is a well-established tumor suppressor gene in colorectal cancer, and rs11644916 (G>A) conferred shorter OS. Median OS for patients with the AA, AG, or GG genotypes was 18.4, 25.6, or 36.4 months, respectively. In 90 patients with stage IV colorectal cancer from The Cancer Genome Atlas (TCGA), rs11649255 in AXIN1 [in almost complete linkage disequilibrium (LD) with rs11644916], was associated with shorter OS (HR, 2.24, P = 0.0096). Using rs11648673 in AXIN1 (in very high LD with rs11644916 and with functional evidence), luciferase activity in three colorectal cancer cell lines was reduced. CONCLUSIONS This is the first large genome-wide association study ever conducted in patients with mCRC treated with first-line standard treatment in a randomized phase III trial. A common SNP in AXIN1 conferred worse OS and the effect was replicated in TCGA. Further studies in colorectal cancer experimental models are required.",2021,"Median OS for patients with the AA, AG or GG genotypes was 18.4, 25.6, or 36.4 months, respectively.","['colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405', 'metastatic colorectal cancer (mCRC', 'Patients with mCRC receiving either FOLFOX or FOLFIRI', '613 patients of genetically-estimated European ancestry using Cox proportional hazards models']","['Irinotecan/5-FU (FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab', 'cetuximab or bevacizumab']","['shorter OS', 'SNPs and overall survival (OS', 'haplotypic SNPs between MGST1 and LMO3 (representative hazard ratios (HR', 'Median OS']","[{'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0010235', 'cui_str': 'Cox Proportional Hazards Models'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0752046', 'cui_str': 'Single Nucleotide Polymorphism'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.0360402,"Median OS for patients with the AA, AG or GG genotypes was 18.4, 25.6, or 36.4 months, respectively.","[{'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Innocenti', 'Affiliation': 'Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. innocent@unc.edu.'}, {'ForeName': 'Alexander B', 'Initials': 'AB', 'LastName': 'Sibley', 'Affiliation': 'Duke Cancer Institute, Duke University, Durham, North Carolina.'}, {'ForeName': 'Sushant A', 'Initials': 'SA', 'LastName': 'Patil', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Etheridge', 'Affiliation': 'Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Jiang', 'Affiliation': 'Duke Cancer Institute, Duke University, Durham, North Carolina.'}, {'ForeName': 'Fang-Shu', 'Initials': 'FS', 'LastName': 'Ou', 'Affiliation': 'Alliance Statistics and Data Management Center, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Stefanie D', 'Initials': 'SD', 'LastName': 'Howell', 'Affiliation': 'Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Sarah J', 'Initials': 'SJ', 'LastName': 'Plummer', 'Affiliation': 'Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Casey', 'Affiliation': 'Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Monica M', 'Initials': 'MM', 'LastName': 'Bertagnolli', 'Affiliation': ""Division of Surgical Oncology, Department of Surgery, Brigham & Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Howard L', 'Initials': 'HL', 'LastName': 'McLeod', 'Affiliation': 'Taneja College of Pharmacy, University of South Florida, Tampa, Florida.'}, {'ForeName': 'James T', 'Initials': 'JT', 'LastName': 'Auman', 'Affiliation': 'UNC Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Charles D', 'Initials': 'CD', 'LastName': 'Blanke', 'Affiliation': 'Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Furukawa', 'Affiliation': 'Division of Clinical Genome Research, Institute of Medical Science, the University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Alan P', 'Initials': 'AP', 'LastName': 'Venook', 'Affiliation': 'Department of Medicine, University of California at San Francisco, San Francisco, California.'}, {'ForeName': 'Michiaki', 'Initials': 'M', 'LastName': 'Kubo', 'Affiliation': 'Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Tokyo, Japan.'}, {'ForeName': 'Heinz-Josef', 'Initials': 'HJ', 'LastName': 'Lenz', 'Affiliation': 'Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.'}, {'ForeName': 'Joel S', 'Initials': 'JS', 'LastName': 'Parker', 'Affiliation': 'UNC Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Ratain', 'Affiliation': 'Department of Medicine, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Kouros', 'Initials': 'K', 'LastName': 'Owzar', 'Affiliation': 'Duke Cancer Institute, Duke University, Durham, North Carolina.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-2021'] 602,33236202,"Fractional CO2 laser, platelet rich plasma and narrow band ultraviolet B in the treatment of Vitiligo (A randomized clinical trial).","Vitiligo is a chronic acquired disease. Various therapeutic strategies are available but with variable degrees of success. Fractional CO2 laser is claimed to be effective in the treatment of refractory non-segmental vitiligo. Platelet-rich plasma may help in stimulation of the proliferation of melanocytes and repigmentation within vitiliginous patches.Our aim was to evaluate and compare the efficacy and safety of fractional CO2 laser, PRP, and NB-UVB either alone or in combination in the treatment of vitiligo. This self-controlled randomized clinical trial included 20 patients with at least 6 patches of vitiligo (VIDA score 1 and 0). Each patch was randomly assigned to receive either, fractional CO2 laser, PRP, combined fractional CO2 with PRP, combined fractional CO2 with NB-UVB, combined fractional CO2 with PRP and NB-UVB or left as a control. There was a statistically significant improvement in all treatment groups on comparing the surface area of vitiligo patches before and after treatment. However on comparing the percentage of reduction in surface area in different treatment groups, there was no statistically significant difference (P = 0.122). Fr: CO2 laser and PRP may be adjuvant therapeutic options to NB-UVB especially in the treatment of refractory cases of non-segmental vitiligo.",2021,There was a statistically significant improvement in all treatment groups on comparing the surface area of vitiligo patches before and after treatment.,"['vitiligo', '20 patients with at least 6 patches of vitiligo (VIDA score 1 and 0']","['fractional CO2 laser, PRP, and NB-UVB either alone or in combination', 'fractional CO2 laser, PRP, combined fractional CO2 with PRP, combined fractional CO2 with NB-UVB, combined fractional CO2 with PRP and NB-UVB or left as a control', 'Fractional CO2 laser', 'Fr: CO2 laser and PRP']","['Fractional CO2 laser, platelet rich plasma and narrow band ultraviolet B', 'surface area of vitiligo patches']","[{'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0032027', 'cui_str': 'Pityriasis rubra pilaris'}, {'cui': 'C0454530', 'cui_str': 'Ultraviolet B therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C1532472', 'cui_str': 'Ultra-violet'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}]",20.0,0.0360095,There was a statistically significant improvement in all treatment groups on comparing the surface area of vitiligo patches before and after treatment.,"[{'ForeName': 'Ahmed Abdelfattah', 'Initials': 'AA', 'LastName': 'Afify', 'Affiliation': 'Dermatology, Venereology and Andrology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. dr.ahmed_abdelfattah1982@yahoo.com.'}, {'ForeName': 'Nehal Mohamed', 'Initials': 'NM', 'LastName': 'Zuelfakkar', 'Affiliation': 'Dermatology, Venereology and Andrology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Mohamed Abdullah', 'Initials': 'MA', 'LastName': 'Eshafi', 'Affiliation': 'Tripoli University-Libya, Tripoli, Libya.'}]",Lasers in medical science,['10.1007/s10103-020-03195-9'] 603,32967939,MRI and 18 FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial.,"PURPOSE To explore a prognostic or predictive role of MRI and O-(2- 18 F-fluoroethyl)-L-tyrosine ( 18 FET) PET parameters for outcome in the randomized multicenter trial ARTE that compared bevacizumab plus radiotherapy with radiotherpay alone in elderly patients with glioblastoma. PATIENTS AND METHODS Patients with isocitrate dehydrogenase wild-type glioblastoma ages 65 years or older were included in this post hoc analysis. Tumor volumetric and apparent diffusion coefficient (ADC) analyses of serial MRI scans from 67 patients and serial 18 FET-PET tumor-to-brain intensity ratios (TBRs) from 31 patients were analyzed blinded for treatment arm and outcome. Multivariate Cox regression analysis was done to account for established prognostic factors and treatment arm. RESULTS Overall survival benefit from bevacizumab plus radiotherapy compared with radiotherapy alone was observed for larger pretreatment MRI contrast-enhancing tumor [HR per cm 3 0.94; 95% confidence interval (CI), 0.89-0.99] and for higher ADC (HR 0.18; CI, 0.05-0.66). Higher 18 FET-TBR on pretreatment PET scans was associated with inferior overall survival in both arms. Response assessed by standard MRI-based Response Assessment in Neuro-Oncology criteria was associated with overall survival in the bevacizumab plus radiotherapy arm by trend only ( P = 0.09). High 18 FET-TBR of noncontrast-enhancing tumor portions during bevacizumab therapy was associated with inferior overall survival on multivariate analysis (HR 5.97; CI, 1.16-30.8). CONCLUSIONS Large pretreatment contrast-enhancing tumor mass and higher ADCs identify patients who may experience a survival benefit from bevacizumab plus radiotherapy. Persistent 18 FET-PET signal of no longer contrast-enhancing tumor after concomitant bevacizumab plus radiotherapy suggests pseudoresponse and predicts poor outcome.",2021,"High 18 FET-TBR of non-contrast-enhancing tumor portions during bevacizumab therapy was associated with inferior overall survival on multivariate analysis (HR 5.97, CI 1.16-30.8). ","['67 patients and serial 18 FET-PET tumor-to-brain intensity ratios (TBR) from 31 patients', 'patients with IDH wild-type glioblastoma', 'Patients with isocitrate dehydrogenase wild-type glioblastoma aged 65 years or older', 'elderly patients with glioblastoma']","['magnetic resonance imaging (MRI) and O-(2- 18 F-fluoroethyl)-L-tyrosine ( 18 FET) positron emission tomography (PET', 'bevacizumab plus radiotherapy with radiotherpay alone', 'bevacizumab', 'bevacizumab plus radiotherapy', 'radiotherapy']","['inferior overall survival', 'Overall survival benefit', 'Tumor volumetric and apparent diffusion coefficient (ADC) analyses of serial MRI scans', 'overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0643582', 'cui_str': '11-(2-fluoroethyl)estradiol'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0017636', 'cui_str': 'Glioblastoma'}, {'cui': 'C0022157', 'cui_str': 'Isocitrate dehydrogenase'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0302995', 'cui_str': 'Fluorine-18'}, {'cui': 'C0041485', 'cui_str': 'Tyrosine'}, {'cui': 'C0643582', 'cui_str': '11-(2-fluoroethyl)estradiol'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0445383', 'cui_str': 'Volumetric'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]",31.0,0.381841,"High 18 FET-TBR of non-contrast-enhancing tumor portions during bevacizumab therapy was associated with inferior overall survival on multivariate analysis (HR 5.97, CI 1.16-30.8). ","[{'ForeName': 'Hans-Georg', 'Initials': 'HG', 'LastName': 'Wirsching', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland. hans-georg.wirsching@usz.ch.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Roelcke', 'Affiliation': 'Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Weller', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hundsberger', 'Affiliation': 'Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Andreas F', 'Initials': 'AF', 'LastName': 'Hottinger', 'Affiliation': 'Departments of Clinical Neurosciences and Medical Oncology, University Hospital Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'von Moos', 'Affiliation': 'Department of Medical Oncology, Cantonal Hospital Graubuenden, Chur, Switzerland.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Caparrotti', 'Affiliation': 'Department of Radiation Oncology, University Hospital Geneva, Geneva, Switzerland.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Conen', 'Affiliation': 'Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Remonda', 'Affiliation': 'Department of Neuroradiology, Cantonal Hospital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Roth', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Ochsenbein', 'Affiliation': 'Department of Medical Oncology, Inselspital, Berne University Hospital, University of Berne, Berne, Switzerland.'}, {'ForeName': 'Ghazaleh', 'Initials': 'G', 'LastName': 'Tabatabai', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Weller', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-2096'] 604,32979235,Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.,"BACKGROUND As treatment interruptions occur during psoriasis management in clinical practice, it is important to know the duration of clinical response after treatment withdrawal. OBJECTIVES To report time to and predictors of relapse in patients who were tildrakizumab 100 and 200 mg responders (≥75% improvement in Psoriasis Area and Severity Index, PASI 75) at week 28 re-randomized to placebo from reSURFACE 1 trial. METHODS Post hoc analysis of adult patients with moderate-to-severe plaque psoriasis from a 64-week phase 3 trial. Relapse was primarily defined as loss of PASI 75 response. Both relapses defined as loss of PASI 90 and loss of absolute PASI < 2 response were included as sensitivity analyses. PASI 75, PASI 90 and PASI < 2 responders re-randomized to placebo at week 28 and followed up until week 64 were included. The Kaplan-Meier (KM) estimates of the 64-week relapse rate were calculated. The log-rank test to compare KM curves from responders to tildrakizumab 100 and 200 mg was used. Independent predictors of relapse were explored. RESULTS Median time to loss of PASI 75/PASI 90/PASI < 2 response from week 28 was 142/111/112 days with tildrakizumab 100 mg and 172/140/113 days with tildrakizumab 200 mg, respectively (all not significant). Around 20% of patients did not relapse (either maintained a PASI 75 response or were lost to follow-up) during the 36-week period. Increase in body mass index (BMI) (hazard ratio, HR [95% confidence interval, CI] for loss of PASI 75 response: 1.0345 [1.0112-1.0582]) and increase in disease duration (HR [95% CI]: 1.0151 [1.0028-1.0275] for loss of PASI 75 response) were associated with an increased risk of relapse, regardless of the relapse definition. CONCLUSIONS When treatment is interrupted, tildrakizumab provides durable maintenance of efficacy with a median time to loss of PASI 75 response of 5-6 months, irrespective of the dose. Interventions on modifiable risk factors for relapse, such as BMI, may improve personalized long-term psoriasis management.",2021,Around 20% of patients did not relapse (either maintained a PASI 75 response or were lost to follow-up) during the 36-week period.,"['adult patients with moderate-to-severe plaque psoriasis from a 64-week phase 3 trial', 'patients who were tildrakizumab 100 and 200 mg responders (≥75% improvement in Psoriasis Area and Severity Index; PASI 75) at week 28 re-randomized to', 'patients with moderate-to-severe psoriasis']","['placebo', 'tildrakizumab']","['disease duration', 'Kaplan-Meier (KM) estimates of the 64-week relapse rate', 'body mass index (BMI) (hazard ratio, HR', 'risk of relapse, regardless of the relapse definition', 'Relapse', 'Median time to loss of PASI 75/PASI 90/PASI']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4043954', 'cui_str': 'tildrakizumab'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4043954', 'cui_str': 'tildrakizumab'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.124221,Around 20% of patients did not relapse (either maintained a PASI 75 response or were lost to follow-up) during the 36-week period.,"[{'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Warren', 'Affiliation': 'Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Carrascosa', 'Affiliation': 'Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Fumero', 'Affiliation': 'Almirall R&D, Barcelona, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Schoenenberger', 'Affiliation': 'Almirall R&D, Barcelona, Spain.'}, {'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Lebwohl', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Szepietowski', 'Affiliation': 'Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reich', 'Affiliation': 'Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, Skinflammation® Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}]",Journal of the European Academy of Dermatology and Venereology : JEADV,['10.1111/jdv.16964'] 605,32964565,Chronic immunoglobulin maintenance therapy in myasthenia gravis.,"BACKGROUND AND PURPOSE Long-term treatment of myasthenia gravis (MG) includes symptomatic and course-modifying therapies that target the immune system. Recently, both intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) have emerged as viable options for chronic therapy, considering the favourable safety-efficacy profile and possible immunosuppressant sparing properties. The aim was to investigate the outcomes of the long-term care of generalized MG with immunoglobulin (Ig). METHODS This is a retrospective, repeated-measures design study. Charts of generalized MG patients, treated with IVIG/SCIG for at least 6 months, from January 2015 to January 2020, were analysed. The primary outcome was the mean change in Myasthenia Gravis Impairment Index (MGII) after treatment with Ig, comparing baseline to IVIG and SCIG treatment periods. Secondary outcomes included the changes in pyridostigmine, immunosuppressive medications and patient-reported outcome 'percentage of normal' (0%-100%). RESULTS Thirty-four patients were treated with chronic Ig therapy (30 IVIG/SCIG, three SCIG, one IVIG). The mean durations of IVIG and SCIG periods were 21.8 ± 19.4 (range 3-64) months and 19.5 ± 11.3 (range 5-45) months respectively. There was a significant reduction in MGII scores (27.7 ± 15.7 baseline; 22.0 ± 17.4 IVIG period; 19.5 ± 18.1 SCIG period; F = 17.9; d.f. = 1.7; P < 0.01), pyridostigmine and immunosuppressant use (P = 0.00). The outcome 'percentage of normal' had a significant positive association with both treatments (P = 0.00). CONCLUSION Our study results suggest that patients can be successfully transitioned to IVIG and from IVIG to SCIG in the chronic treatment of generalized MG with reductions in impairments and use of other medications and improvement in overall status with Ig therapy. Prospective, randomized studies are needed to clarify costs and comparative effectiveness.",2021,"There was a significant reduction in MGII scores (27.7±15.7 baseline; 22.0±17.4 IVIG period;19.5±18.1 SCIG period;F=17.9; df =1.7;p<0.01), pyridostigmine and immunosuppressant use (p=0.00).","['Thirty-four patients were treated with chronic Ig therapy (30 IVIG/SCIG, 3 SCIG, 1 IVIG', 'for at least 6 months, from January 2015 to January 2020', 'myasthenia gravis']","['Chronic immunoglobulin maintenance therapy', 'generalized MG with immunoglobulins (Ig', 'pyridostigmine', 'IVIG and subcutaneous immunoglobulin (SCIG', 'IVIG/SCIG']","['changes in pyridostigmine, immunosuppressive medications and patient-reported outcome ""percentage of normal', 'Mean duration of IVIG and SCIG periods', 'MGII scores', 'mean change in Myasthenia Gravis Impairment Index (MGII']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0021022', 'cui_str': 'Immunoglobulin therapy'}, {'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0021027', 'cui_str': 'Immunoglobulin'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0026896', 'cui_str': 'Myasthenia gravis'}]","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0021027', 'cui_str': 'Immunoglobulin'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0472367', 'cui_str': 'Generalized myasthenia'}, {'cui': 'C0034261', 'cui_str': 'Pyridostigmine'}, {'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0034261', 'cui_str': 'Pyridostigmine'}, {'cui': 'C0021081', 'cui_str': 'Immunosuppressant agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0021027', 'cui_str': 'Immunoglobulin'}, {'cui': 'C0026896', 'cui_str': 'Myasthenia gravis'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",34.0,0.0723462,"There was a significant reduction in MGII scores (27.7±15.7 baseline; 22.0±17.4 IVIG period;19.5±18.1 SCIG period;F=17.9; df =1.7;p<0.01), pyridostigmine and immunosuppressant use (p=0.00).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Alcantara', 'Affiliation': 'Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Sarpong', 'Affiliation': 'Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Barnett', 'Affiliation': 'Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Katzberg', 'Affiliation': 'Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Bril', 'Affiliation': 'Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.'}]",European journal of neurology,['10.1111/ene.14547'] 606,32975829,Portable gluten sensors: qualitative assessments by adults and adolescents with coeliac disease.,"BACKGROUND Portable gluten sensors are now commercially available to the public, although there is genuine uncertainty within the medical community over whether they should be used for coeliac disease management. The present study described qualitatively the experience of using a portable gluten sensor for 15 adults and 15 adolescents with coeliac disease participating in a 3-month pilot clinical trial. METHODS Participants were 30 individuals, aged 13-70 years, with biopsy-confirmed coeliac disease on a gluten-free diet. All received a portable gluten sensor and were randomised to low, medium, and high numbers of single-use capsules. Open-ended questions addressed likes and dislikes using the portable gluten sensor after 3 months. Major themes were identified and described. RESULTS Participants liked that the portable gluten sensor provided extra assurance to check foods presented as gluten-free, the convenient size and portability, the added sense of control, and overall peace-of-mind. Participants disliked having attention drawn to them when using the sensor and feeling as if they were deterring others from eating. Participants also disliked the physical difficulty associated with using the capsules, questionable accuracy and the inability to test fermented foods. Adults were more enthusiastic about the sensor than adolescents. CONCLUSIONS Positive and negative experiences may be expected when using commercially available portable gluten sensors to help manage coeliac disease. As future versions of this and other gluten sensors become available, it will be important to investigate the relationship between users' experience with the sensors and long-term outcomes such as mucosal healing and quality of life.",2020,"RESULTS Participants liked that the portable gluten sensor provided extra assurance to check foods presented as gluten-free, the convenient size and portability, the added sense of control, and overall peace-of-mind.","['15 adults and 15 adolescents with coeliac disease participating in a 3-month pilot clinical trial', 'adults and adolescents with coeliac disease', 'Participants were 30 individuals, aged 13-70\xa0years, with biopsy-confirmed coeliac disease on a gluten-free diet']",['portable gluten sensor'],['mucosal healing and quality of life'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0007570', 'cui_str': 'Celiac disease'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0344351', 'cui_str': 'Gluten free diet'}]","[{'cui': 'C2362561', 'cui_str': 'Gluten'}, {'cui': 'C0183210', 'cui_str': 'Sensor device'}]","[{'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",15.0,0.0266346,"RESULTS Participants liked that the portable gluten sensor provided extra assurance to check foods presented as gluten-free, the convenient size and portability, the added sense of control, and overall peace-of-mind.","[{'ForeName': 'R L', 'Initials': 'RL', 'LastName': 'Wolf', 'Affiliation': 'Department of Health & Behavior Studies, Program in Nutrition, Teachers College, Columbia University, New York, NY, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Vipperman-Cohen', 'Affiliation': 'Department of Health & Behavior Studies, Program in Nutrition, Teachers College, Columbia University, New York, NY, USA.'}, {'ForeName': 'P H R', 'Initials': 'PHR', 'LastName': 'Green', 'Affiliation': 'Department of Medicine, Celiac Disease Center, Columbia University Irving Medical Center, Harkness Pavilion, New York, NY, USA.'}, {'ForeName': 'A R', 'Initials': 'AR', 'LastName': 'Lee', 'Affiliation': 'Department of Medicine, Celiac Disease Center, Columbia University Irving Medical Center, Harkness Pavilion, New York, NY, USA.'}, {'ForeName': 'N R', 'Initials': 'NR', 'LastName': 'Reilly', 'Affiliation': 'Department of Medicine, Celiac Disease Center, Columbia University Irving Medical Center, Harkness Pavilion, New York, NY, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Zybert', 'Affiliation': 'Department of Health & Behavior Studies, Program in Nutrition, Teachers College, Columbia University, New York, NY, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Lebwohl', 'Affiliation': 'Department of Medicine, Celiac Disease Center, Columbia University Irving Medical Center, Harkness Pavilion, New York, NY, USA.'}]",Journal of human nutrition and dietetics : the official journal of the British Dietetic Association,['10.1111/jhn.12810'] 607,32985064,Sex differences in the acute effects of oral and vaporized cannabis among healthy adults.,"Policy changes have increased access to cannabis for individuals with little or no prior exposure. Few studies have examined sex differences in cannabis effects among individuals with sporadic cannabis use or for nonsmoked routes of cannabis administration. Data from four double-blind, placebo-controlled studies were pooled to compare the acute pharmacodynamic effects of vaporized and oral cannabis in male (n = 27) and female (n = 23) participants who used cannabis infrequently (no use ≥30 days prior to randomization). Analyses compared peak change-from-baseline scores between male and female participants for subjective drug effects, cognitive/psychomotor performance, cardiovascular effects, and blood concentrations of Δ9-tetrahydrocannabinol (THC) and its primary metabolites (11-OH-THC, THC-COOH) after exposure to placebo cannabis or cannabis containing low-dose (5 or 10 mg) or high-dose THC (20 or 25 mg). Overall, cannabis elicited dose-orderly increases in subjective effects, impairment of cognitive/psychomotor performance, heart rate, and blood cannabinoid concentrations. Females exhibited greater peak blood 11-OH-THC concentrations and reported greater peak subjective ratings of ""drug effect"" that remained when controlling for body weight. When controlling for both body weight and peak blood cannabinoid concentrations, ratings of ""anxious/nervous,"" ""heart racing,"" and ""restless"" were significantly higher for females than males. Although additional research is needed to elucidate sex differences in responses to cannabis at a wider range of THC doses, other routes of administration, and products with diverse chemical composition, the current data indicate that public health messaging and clinical decision making around the use of cannabinoids should recommend lower starting doses for females and warnings about acute anxiogenic reactions.",2021,"Overall, cannabis elicited dose-orderly increases in subjective effects, impairment of cognitive/psychomotor performance, heart rate, and blood cannabinoid concentrations.","['male (n = 27) and female (n = 23) participants who used cannabis infrequently (no use ≥30 days prior to randomization', 'healthy adults']","['THC', 'placebo']","['peak blood 11-OH-THC concentrations', 'acute pharmacodynamic effects of vaporized and oral cannabis', 'subjective drug effects, cognitive/psychomotor performance, cardiovascular effects, and blood concentrations of Δ9-tetrahydrocannabinol (THC) and its primary metabolites (11-OH-THC, THC-COOH', 'subjective effects, impairment of cognitive/psychomotor performance, heart rate, and blood cannabinoid concentrations', 'body weight and peak blood cannabinoid concentrations, ratings of ""anxious/nervous,"" ""heart racing,"" and ""restless', 'peak subjective ratings']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0521114', 'cui_str': 'Infrequent'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0728866', 'cui_str': 'drug effects'}, {'cui': 'C0033923', 'cui_str': 'Psychomotor Performance'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0427728', 'cui_str': 'Blood concentration, dipstick - finding'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0948690', 'cui_str': 'Blood cannabinoids'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0027769', 'cui_str': 'Nervousness'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}]",23.0,0.370197,"Overall, cannabis elicited dose-orderly increases in subjective effects, impairment of cognitive/psychomotor performance, heart rate, and blood cannabinoid concentrations.","[{'ForeName': 'Dennis J', 'Initials': 'DJ', 'LastName': 'Sholler', 'Affiliation': 'Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Justin C', 'Initials': 'JC', 'LastName': 'Strickland', 'Affiliation': 'Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Tory R', 'Initials': 'TR', 'LastName': 'Spindle', 'Affiliation': 'Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Elise M', 'Initials': 'EM', 'LastName': 'Weerts', 'Affiliation': 'Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Vandrey', 'Affiliation': 'Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}]",Addiction biology,['10.1111/adb.12968'] 608,32981268,"Urtica Dioica Root Extract on Clinical and Biochemical Parameters in Patients with Benign Prostatic Hyperplasia, Randomized Controlled Trial.","BACKGROUND AND OBJECTIVES Benign Prostatic Hyperplasia (BPH) is a common urological disorder as men get older. BPH can cause uncomfortable urinary tract symptoms. Given the high incidence of the disease, further research is an undeniable necessity for its better management. In this research, the efficacy of Urtica Dioica root extract (UDE) on clinical and biochemical parameters were evaluated in this type of patients. MATERIALS AND METHODS Participants were 60 men with BPH that randomly allocated to two equal groups (Intervention = 30 and Comparison = 30). Block balanced Randomization method was performed using a computer by a trained nurse. Intervention and comparison groups received 450 mg day-1 UDE and placebo as tablets for 12 weeks, respectively. The main outcome was changes in International Prostate Symptoms Score (IPSS) from baseline to end of treatment. Data were collected by completing a standard questionnaire and performing relevant tests based on common laboratory methods. RESULTS UDE had an intermediate effect on IPSS, a small effect on serum high-sensitivity C-reactive protein (hs-CRP), intermediate to large effect on malondialdehyde (MDA) levels and intermediate effect on superoxide dismutase (SOD) activity. The magnitude of the effects of UDE on other parameters was overall negligible compared to the comparison and not significant. No side effects were seen in these patients following tablet usage. CONCLUSION UDE consumption for 12 weeks among BPH patients had clinically significant effects on IPSS, serum hs-CRP, MDA and SOD activity.",2020,"No side effects were seen in these patients following tablet usage. ","['Patients with Benign Prostatic Hyperplasia', 'Benign Prostatic Hyperplasia (BPH', 'Participants were 60 men with BPH that randomly allocated to two equal groups (Intervention = 30 and Comparison = 30']","['Urtica Dioica root extract (UDE', 'Urtica Dioica Root Extract', 'BPH', '450 mg day-1 UDE and placebo']","['International Prostate Symptoms Score (IPSS', 'side effects', 'IPSS, serum hs-CRP, MDA and SOD activity', 'malondialdehyde (MDA) levels', 'superoxide dismutase (SOD) activity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005001', 'cui_str': 'Hypertrophy, Benign Prostatic'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C3256737', 'cui_str': 'Urtica dioica root extract'}, {'cui': 'C0005001', 'cui_str': 'Hypertrophy, Benign Prostatic'}, {'cui': 'C3844104', 'cui_str': '450'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1998280', 'cui_str': 'International prostate symptom score'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",60.0,0.110757,"No side effects were seen in these patients following tablet usage. ","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Akbar Karami', 'Affiliation': ''}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Sheikhsoleimani', 'Affiliation': ''}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Reza Memarzadeh', 'Affiliation': ''}, {'ForeName': 'Elnaz', 'Initials': 'E', 'LastName': 'Haddadi', 'Affiliation': ''}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Bakhshpour', 'Affiliation': ''}, {'ForeName': 'Navid', 'Initials': 'N', 'LastName': 'Mohammadi', 'Affiliation': ''}, {'ForeName': 'Seyyed', 'Initials': 'S', 'LastName': 'Mehdi Mirhashemi', 'Affiliation': ''}]",Pakistan journal of biological sciences : PJBS,['10.3923/pjbs.2020.1338.1344'] 609,32987199,Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia.,"BACKGROUND Hypophosphatasia (HPP) is the rare, inherited, metabolic bone disease characterized by low activity of the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP) leading to excess extracellular inorganic pyrophosphate (PPi) and pyridoxal 5'-phosphate (PLP). Asfotase alfa is the human recombinant enzyme-replacement therapy that replaces deficient TNSALP. However, there is limited information concerning the appropriate dose of asfotase alfa for adult patients with pediatric-onset HPP. Thus, we evaluated the pharmacodynamics and safety/tolerability of different doses of asfotase alfa in such patients. METHODS This 13-week, Phase 2a, open-label study enrolled adults (aged ≥18 years) with pediatric-onset HPP. They were randomized 1:1:1 to receive a single subcutaneous dose of asfotase alfa (0.5, 2.0, or 3.0 mg/kg) at Week 1, then 3 times per week (ie, 1.5, 6.0, or 9.0 mg/kg/wk) starting at Week 3 for 7 weeks. Key outcome measures included change from Baseline to before the third dose during Week 9 (trough) in plasma PPi (primary outcome measure) and PLP (secondary outcome measure). RESULTS Twenty-seven adults received asfotase alfa 0.5 (n = 8), 2.0 (n = 10), and 3.0 (n = 9) mg/kg; all completed the study. Median (range) age was 45 (18-77) years; most patients were white (96%) and female (59%). Median plasma PPi and PLP concentrations decreased from Baseline to Week 9 in all 3 cohorts. Differences in least squares mean (LSM) changes in PPi were significant with 2.0 mg/kg (p = 0.0008) and 3.0 mg/kg (p < 0.0001) vs. 0.5 mg/kg. Differences in LSM changes in PLP were also significant for 2.0 mg/kg (p = 0.0239) and 3.0 mg/kg (p = 0.0128) vs. 0.5 mg/kg. Injection site reactions were the most frequent treatment-emergent adverse event (78%), showing increasing frequency with increasing dose. CONCLUSIONS Adults with pediatric-onset HPP receiving asfotase alfa at 6.0 mg/kg/wk (the recommended dose) or 9.0 mg/kg/wk had greater reductions in circulating PPi and PLP concentrations compared with a lower dose of 1.5 mg/kg/wk. TRIAL REGISTRATION Clinicaltrials.gov identifier NCT02797821.",2021,"Injection site reactions were the most frequent treatment-emergent adverse event (78%), showing increasing frequency with increasing dose. ","['Adults with pediatric-onset HPP receiving', 'Twenty-seven adults received asfotase alfa 0.5 (n=8), 2.0 (n=10), and 3.0 (n=9) mg/kg; all completed the study', 'adult patients with pediatric-onset HPP', 'Adults With Pediatric-Onset Hypophosphatasia', 'Median (range) age was 45 (18-77) years; most patients were white (96%) and female (59', '13-week, Phase 2a, open-label study enrolled adults (aged ≥18 years) with pediatric-onset HPP']","['single subcutaneous dose of asfotase alfa', 'asfotase alfa', 'Asfotase Alfa']","['Least squares mean (LSM) changes in PPi', 'LSM differences in PLP changes', 'change from Baseline to before the third dose during Week 9 (trough) in plasma PPi (primary outcome measure) and PLP (secondary outcome measure', 'circulating PPi and PLP concentrations', 'Median plasma PPi and PLP concentrations', 'pharmacodynamics and safety/tolerability']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0020630', 'cui_str': 'Hypophosphatasia'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C3490795', 'cui_str': 'asfotase alfa'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C3490795', 'cui_str': 'asfotase alfa'}]","[{'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0358591', 'cui_str': 'H+/K+-exchanging ATPase inhibitor'}, {'cui': 'C0034266', 'cui_str': 'pyridoxal phosphate'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.169277,"Injection site reactions were the most frequent treatment-emergent adverse event (78%), showing increasing frequency with increasing dose. ","[{'ForeName': 'Lothar', 'Initials': 'L', 'LastName': 'Seefried', 'Affiliation': 'Orthopedic Department, University of Würzburg, Würzburg, Bavaria, Germany. Electronic address: l-seefried.klh@uni-wuerzburg.de.'}, {'ForeName': 'Priya S', 'Initials': 'PS', 'LastName': 'Kishnani', 'Affiliation': 'Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Moseley', 'Affiliation': 'Alexion Pharmaceuticals, Inc., Boston, MA, USA.'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Denker', 'Affiliation': 'Alexion Pharmaceuticals, Inc., Boston, MA, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Watsky', 'Affiliation': 'Alexion Pharmaceuticals, Inc., Boston, MA, USA.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Whyte', 'Affiliation': 'Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children-St. Louis, St. Louis, MO, USA; Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St Louis, MO, USA.'}, {'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Dahir', 'Affiliation': 'Program for Metabolic Bone Disorders at Vanderbilt, Division of Diabetes and Endocrinology, Vanderbilt University Medical Center, Nashville, TN, USA.'}]",Bone,['10.1016/j.bone.2020.115664'] 610,33236949,Effect of acute psychosocial stress on the brain-derived neurotrophic factor in humans - a randomized cross within trial.,"The brain-derived neurotrophic factor (BDNF) is involved in the plasticity and development of the central nervous system. Thereby the protein synthesis is highly related to neuronal activity, and its signaling pathways are associated with several substances like, e.g. glucocorticoids, which seem to be able to activate BDNF-Tropomyosin receptor kinase B (TrkB). While there is evidence that acute physical stress can result in advantageous physiological outcomes like an enhanced BDNF level, outcome parameters in response to psychosocial stress are primarily focused on psychological parameters. The existing literature pointing on the impact of acute psychosocial stress on physiological parameters is controversial and differs depending on the species, the stressor used, and the study methodology. It was hypothesized that an acute standardized psychosocial stressor would increase the BDNF level and therefore show beneficial physiological outcome parameters through psychosocial stress. The serum BDNF levels of 32 healthy young males ( M  = 24.31 years of age, SD  = 3.35), who performed the Trier Social Stress Test (TSST), were assessed and compared to a control condition. To prove the stress-generating effect of the TSST, additional cortisol levels were measured. Acute psychosocial stress significantly increased the serum BDNF- and the cortisol-level, whereby no alteration was found during the control. This study expands the rare literature focusing on the effect of an acute standardized psychosocial stressor on the BDNF level in healthy humans, including a control condition. Implications for future studies are being discussed.",2021,"Acute psychosocial stress significantly increased the serum BDNF- and the cortisol-level, whereby no alteration was found during the control.","['32 healthy young males ( M \u2009=\u200924.31 years of age, SD \u2009=\u20093.35', 'healthy humans']","['acute psychosocial stress', 'acute standardized psychosocial stressor']","['Trier Social Stress Test (TSST', 'serum BDNF- and the cortisol-level', 'BDNF level', 'serum BDNF levels', 'TSST, additional cortisol levels', 'Acute psychosocial stress']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517691', 'cui_str': '3.35'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]","[{'cui': 'C0065404', 'cui_str': 'lysyl-5-fluorotryptophyl-lysine'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",32.0,0.0182691,"Acute psychosocial stress significantly increased the serum BDNF- and the cortisol-level, whereby no alteration was found during the control.","[{'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Hermann', 'Affiliation': 'Working group physical activity-related preventive research, Institute of Movement Therapy and Movement-oriented Prevention and Rehabilitation, German Sport University Cologne, Koln, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Schaller', 'Affiliation': 'Working group physical activity-related preventive research, Institute of Movement Therapy and Movement-oriented Prevention and Rehabilitation, German Sport University Cologne, Koln, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lay', 'Affiliation': 'Department Preventative and Rehabilitative Sports and Performance Medicine, German Sport University Cologne, Institute of Cardiology and Sports Medicine, Cologne, Germany.'}, {'ForeName': 'Wilhelm', 'Initials': 'W', 'LastName': 'Bloch', 'Affiliation': 'Department Molecular and Cellular Sports Medicine, German Sport University Cologne, Institute of Cardiology and Sports Medicine, Cologne, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Albus', 'Affiliation': 'Clinic and Policlinic for Psychosomatic and Psychotherapy, University Hospital Cologne, Cologne, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Petrowski', 'Affiliation': 'Medical Psychology and Medical Sociology, University Medicine Mainz, Mainz, Germany.'}]","Stress (Amsterdam, Netherlands)",['10.1080/10253890.2020.1854218'] 611,32985403,Audiovisual Consults by Paramedics to Reduce Hospital Transport After Low-Urgency Calls: Randomized Controlled Trial.,"INTRODUCTION The effect and subjective perception of audiovisual consults (AVCs) by paramedics with a distant physician in prehospital emergency care (PHEC) remain unexplained, especially in low-urgency calls. OBJECTIVES The primary objective of the study was to evaluate the effect of AVCs by paramedics with a base physician on the rate of patients treated on site without the need of hospital transfer. The co-primary safety outcome was the frequency of repeated ambulance trips within 48 hours to the same patient. Secondary objective was the qualitative analysis of perception of the AVCs. METHODS During a six-week period, the dispatching center of Karlovy Vary Emergency Medical Service (EMS) randomized low-urgency events from a rural area (n = 791) to receive either a mandatory phone-call consult (PHONE), AVC (VIDEO), or performed by the paramedic crew in a routine manner, when phone-call consultation is for paramedic crew optional (CONTROL). Secondarily, the qualitative analysis of subjective perception of AVCs compared to consultation over the phone by the paramedic and consulting physician was performed. RESULTS Per-protocol analysis (PPA) was performed (CONTROL, n = 258; PHONE, n = 193; and VIDEO, n = 192) in addition to the intention-to-treat (ITT) analysis. Patients (PPA) in both mandatory consulted groups were twice as likely to be treated and left on site compared to the CONTROL (PHONE: OR = 2.07; 95% CI, 1.19 to 3.58; P = 0.01 or VIDEO: OR = 2.01; 95% CI, 1.15 to 3.49; P = .01). Repeated trips to patients treated and left on site in 48 hours occurred in three (8.6%) of 35 cases in the PHONE group and in eight (23.5%) of 34 cases in the VIDEO group. CONCLUSIONS The AVCs of the emergency physician by paramedics was not superior to the mandatory conventional phone call in increasing the proportion of patients treated and left at home after a low-urgency call. The AVC improved the subjective feelings of safety by physicians, but not the satisfaction of patients or paramedics, and may lead to an increased need of repeated trips.",2020,The AVCs of the emergency physician by paramedics was not superior to the mandatory conventional phone call in increasing the proportion of patients treated and left at home after a low-urgency call.,"['patients treated on site without the need of hospital transfer', 'paramedics with a distant physician in prehospital emergency care (PHEC']","['mandatory phone-call consult (PHONE), AVC (VIDEO), or performed by the paramedic crew in a routine manner, when phone-call consultation is for paramedic crew optional (CONTROL']","['frequency of repeated ambulance trips', 'qualitative analysis of perception of the AVCs', 'Hospital Transport', 'subjective feelings of safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0013963', 'cui_str': 'Paramedic'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0033021', 'cui_str': 'Emergency Care, Prehospital'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0718184', 'cui_str': 'AVC brand of sulfanilamide'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0013963', 'cui_str': 'Paramedic'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0002422', 'cui_str': 'Ambulance'}, {'cui': 'C0077275', 'cui_str': 'Triptorelin'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0005528', 'cui_str': 'Biological transport'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0290467,The AVCs of the emergency physician by paramedics was not superior to the mandatory conventional phone call in increasing the proportion of patients treated and left at home after a low-urgency call.,"[{'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Sykora', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Third Faculty of Medicine, Charles University and FNKV University Hospital, Prague, Czech Republic.'}, {'ForeName': 'Metodej', 'Initials': 'M', 'LastName': 'Renza', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Third Faculty of Medicine, Charles University and FNKV University Hospital, Prague, Czech Republic.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Ruzicka', 'Affiliation': 'Emergency Medical Service of Karlovy Vary Region, Karlovy Vary, Czech Republic.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Bakurova', 'Affiliation': 'Emergency Medical Service of Karlovy Vary Region, Karlovy Vary, Czech Republic.'}, {'ForeName': 'Milos', 'Initials': 'M', 'LastName': 'Kukacka', 'Affiliation': 'Emergency Medical Service of Karlovy Vary Region, Karlovy Vary, Czech Republic.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Smetana', 'Affiliation': 'Emergency Medical Service of Karlovy Vary Region, Karlovy Vary, Czech Republic.'}, {'ForeName': 'Frantisek', 'Initials': 'F', 'LastName': 'Duska', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Third Faculty of Medicine, Charles University and FNKV University Hospital, Prague, Czech Republic.'}]",Prehospital and disaster medicine,['10.1017/S1049023X2000117X'] 612,32980623,Successful implementation of text-based blood pressure monitoring for postpartum hypertension.,"OBJECTIVES A clinical trial showed postpartum text-based blood pressure (BP) monitoring is effective in meeting clinical guidelines and reduces racial disparities in postpartum hypertension care. Our objective was to compare clinical outcomes to those from a clinical trial after implementation of the program in a second hospital within our hospital system. STUDY DESIGN Comparison of women randomized to text-based BP monitoring in a clinical trial compared to an implementation cohort clinically enrolled in text-based BP monitoring. BP outcomes and postpartum visit were compared in bivariate and multivariable analyses. MAIN OUTCOME MEASURES BP ascertainment was defined as at least 1 BP texted during the 10 days of monitoring. American College of Obstetricians and Gynecologists (ACOG) recommendation was defined as BP sent on postpartum day 3-4 and again day 7-10. RESULTS The implementation cohort had 333 women compared to 103 in the trial cohort. The implementation cohort was older (p < 0.001), and more likely to be non-Black race (p < 0.001), married (<0.001), and have commercial insurance (<0.001). BP ascertainment (95.5% vs. 92.2%, adjusted OR 1.41, [95% CI 0.55, 3.58]) and proportion meeting ACOG recommendations (84.7% vs. 81.6%, adjusted OR 0.89 [95% CI 0.48, 1.64]) were similar between groups. There were no differences in BP ascertainment among Black and non-Black women in the trial or implementation cohort. CONCLUSIONS Text-based BP monitoring performed similarly in an implementation cohort compared to the trial participants. This program is scalable to manage postpartum hypertension and reduce racial disparities in postpartum care in women with hypertensive disorders of pregnancy.",2020,"The implementation cohort was older (p < 0.001), and more likely to be non-Black race (p < 0.001), married (<0.001), and have commercial insurance (<0.001).","['postpartum hypertension', 'women with hypertensive disorders of pregnancy', '333 women compared to 103 in the trial cohort', 'American College of Obstetricians and Gynecologists (ACOG']","['text-based BP monitoring', 'text-based blood pressure monitoring', 'postpartum text-based blood pressure (BP) monitoring']","['BP ascertainment', 'proportion meeting ACOG recommendations', 'BP outcomes and postpartum visit']","[{'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0852260', 'cui_str': 'Hypertension associated disorders of pregnancy'}, {'cui': 'C4517724', 'cui_str': '333'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0586884', 'cui_str': 'Obstetrician and gynecologist'}, {'cui': 'C0237419', 'cui_str': 'Gynecologist'}]","[{'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026426', 'cui_str': 'Blood pressure monitoring'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0237419', 'cui_str': 'Gynecologist'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}]",,0.173943,"The implementation cohort was older (p < 0.001), and more likely to be non-Black race (p < 0.001), married (<0.001), and have commercial insurance (<0.001).","[{'ForeName': 'Jourdan E', 'Initials': 'JE', 'LastName': 'Triebwasser', 'Affiliation': 'Department of Obstetrics and Gynecology, Maternal and Child Health Research Center University of Pennsylvania Perelman School of Medicine, 421 Curie Boulevard, 1353 Biomedical Research Bldg. II/III, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, Pennsylvania Hospital University of Pennsylvania Perelman School of Medicine, 800 Spruce St. 2 Pine East, Philadelphia, PA 19107, USA. Electronic address: jourdan.triebwasser@pennmedicine.upenn.edu.'}, {'ForeName': 'Matthew K', 'Initials': 'MK', 'LastName': 'Janssen', 'Affiliation': 'Department of Obstetrics and Gynecology, Pennsylvania Hospital University of Pennsylvania Perelman School of Medicine, 800 Spruce St. 2 Pine East, Philadelphia, PA 19107, USA. Electronic address: matthew.janssen@pennmedicine.upenn.edu.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Hirshberg', 'Affiliation': 'Department of Obstetrics and Gynecology, Maternal and Child Health Research Center University of Pennsylvania Perelman School of Medicine, 421 Curie Boulevard, 1353 Biomedical Research Bldg. II/III, Philadelphia, PA 19104, USA. Electronic address: adi.hirshberg@pennmedicine.upenn.edu.'}, {'ForeName': 'Sindhu K', 'Initials': 'SK', 'LastName': 'Srinivas', 'Affiliation': 'Department of Obstetrics and Gynecology, Maternal and Child Health Research Center University of Pennsylvania Perelman School of Medicine, 421 Curie Boulevard, 1353 Biomedical Research Bldg. II/III, Philadelphia, PA 19104, USA. Electronic address: ssrinivas@pennmedicine.upenn.edu.'}]",Pregnancy hypertension,['10.1016/j.preghy.2020.09.001'] 613,32990529,Rate and maintenance of improvement of myofascial pain with dry needling alone vs. dry needling with intramuscular electrical stimulation: a randomized controlled trial.,"STUDY DESIGN Prospective, randomized. OBJECTIVES To determine the difference in rate and maintenance of improvement of pain and disability for Dry Needling (DN) compared to Dry Needling with Intramuscular Electrical Stimulation (DN/IMES), in Myofascial Pain Syndrome (MPS). BACKGROUND DN and neuromuscular electrical stimulation (NMES) have been shown to be efficacious in treating MPS. DN/IMES for MPS treatment has not been studied extensively, but initial results are promising. METHODS Forty-five subjects were randomly assigned to the DN (n = 25) or DN/IMES (n = 20) group. Both groups received six consecutive weekly treatments and completed NDI and NPRS questionnaires (week 0, 3, 6, and 12). RESULTS Both DN and DN/IMES groups showed significant improvement between weeks 0-6 on NDI (p = 0.008 and 0.00002, respectively) and NPRS scores (0 = 0.017 and p = 0.018, respectively). DN/IMES group showed significant within group changes on the NPRS between weeks 0-3 (p = 0.029). No changes were noted in the DN or DN/IMES groups between week 6-12 on NDI (p = 0.497 and p = 0.714, respectively) or NPRS (p = 0.801 and p = 0.164, respectively). CONCLUSION DN and DN/IMES demonstrated improvement and maintenance in disability and pain for 6 weeks. No differences in improvement of disability or pain existed between the groups at week 6 or 12.",2021,"No changes were noted in the DN or DN/IMES groups between week 6-12 on NDI (p = 0.497 and p = 0.714, respectively) or NPRS (p = 0.801 and p = 0.164, respectively). ","['Myofascial Pain Syndrome (MPS', 'Forty-five subjects']","['Dry Needling with Intramuscular Electrical Stimulation (DN/IMES', 'dry needling alone vs. dry needling with intramuscular electrical stimulation', 'neuromuscular electrical stimulation (NMES', 'DN and DN/IMES', 'DN/IMES']","['NPRS scores', 'rate and maintenance of improvement of pain and disability for Dry Needling (DN', 'NPRS', 'Rate and maintenance of improvement of myofascial pain', 'disability and pain', 'disability or pain']","[{'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C4319567', 'cui_str': '45'}]","[{'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0553642', 'cui_str': 'Myofascial pain'}]",45.0,0.0718534,"No changes were noted in the DN or DN/IMES groups between week 6-12 on NDI (p = 0.497 and p = 0.714, respectively) or NPRS (p = 0.801 and p = 0.164, respectively). ","[{'ForeName': 'Kindyle', 'Initials': 'K', 'LastName': 'Brennan', 'Affiliation': 'Doctor of Physical Therapy Program, University of Mary Hardin-Baylor, Belton, TX, USA.'}, {'ForeName': 'Katherine M', 'Initials': 'KM', 'LastName': 'Elifritz', 'Affiliation': 'Department of Physical Therapy, Virginia Sportsmedicine Institute, Arlington, VA, USA.'}, {'ForeName': 'Megan M', 'Initials': 'MM', 'LastName': 'Comire', 'Affiliation': 'Department of Physical Therapy, Inspire Physical Therapy, College Station, TX, USA.'}, {'ForeName': 'Daniel C', 'Initials': 'DC', 'LastName': 'Jupiter', 'Affiliation': 'Department of Preventive Medicine and Population Health, University of Texas Medical Branch, Galveston, TX, USA.'}]",The Journal of manual & manipulative therapy,['10.1080/10669817.2020.1824469'] 614,32988670,"Contrast-Enhanced Ultrasound Guided Transoral Core Needle Biopsy: A Novel, Safe and Well-Tolerated Procedure for Obtaining High-Quality Tissue in Patients with Oral Cancer.","The aim of the prospective study described here was to compare the tolerability, safety and diagnostic value of contrast-enhanced ultrasound-guided transoral core needle biopsy (CEUS-CNB) with that of conventional US-guided transoral CNB (US-CNB) and standard incisional biopsy in patients with oral masses. Between June 2017 and November 2019, consecutive patients with oral masses referred for biopsy were randomly assigned to undergo incisional biopsy, US-CNB or CEUS-CNB. Procedure time, intra‑operative blood loss volume, diagnostic performance and pain level before and after the procedure assessed by visual analogue score (VAS) were recorded and compared among the three procedures. Finally, 238 patients with pathology confirmation were analyzed: 80 patients underwent incisional biopsy, 78 patients US-CNB and 80 patients CEUS-CNB. In this study, no significant difference was found in biopsy time between CEUS-CNB, US-CNB and incisional biopsy (75 ± 11 s vs. 73.6 ± 12 s vs. 77 ± 13 s, p = 0.24). CEUS-CNB achieved the highest sensitivity (CEUS-CNB: 100%, US-CNB: 88.5%, incisional biopsy: 84.3%), negative predictive value (CEUS-CNB: 100%, US-CNB: 81.3%, incisional biopsy: 78.4%) and accuracy (CEUS-CNB: 100%, US-CNB: 92.3%, incisional biopsy: 90%). The VAS score for incision biopsy was higher (p = 0.01) and the amount of bleeding was larger (p < 0.001), yet there was no significant difference between CEUS-CNB and US-CNB. Our results indicate CEUS-guided transoral CNB is an efficient, safe and well-tolerated procedure, with biopsy time comparable to and diagnostic performance better than those of conventional US-guided transoral CNB and incisional biopsy.",2020,"The VAS score for incision biopsy was higher (p = 0.01) and the amount of bleeding was larger (p < 0.001), yet there was no significant difference between CEUS-CNB and US-CNB.","['Patients with Oral Cancer', '238 patients with pathology confirmation were analyzed: 80 patients underwent', 'patients with oral masses', 'Between June 2017 and November 2019, consecutive patients with oral masses referred for biopsy']","['incisional biopsy', 'contrast-enhanced ultrasound-guided transoral core needle biopsy (CEUS-CNB', 'standard incisional biopsy', 'incisional biopsy, US-CNB or CEUS-CNB', 'CEUS-guided transoral CNB', 'Contrast-Enhanced Ultrasound Guided Transoral Core Needle Biopsy', 'conventional US-guided transoral CNB (US-CNB']","['negative predictive value', 'biopsy time between CEUS-CNB, US-CNB and incisional biopsy', 'Procedure time, intra‑operative blood loss volume, diagnostic performance and pain level', 'VAS score for incision biopsy', 'amount of bleeding', 'visual analogue score (VAS', 'tolerability, safety and diagnostic value']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0153381', 'cui_str': 'Malignant tumor of oral cavity'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of'}, {'cui': 'C0577565', 'cui_str': 'Mass of oral cavity'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]","[{'cui': 'C0184922', 'cui_str': 'Incisional biopsy - action'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C1318309', 'cui_str': 'Core needle biopsy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C1318309', 'cui_str': 'Core needle biopsy'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0184922', 'cui_str': 'Incisional biopsy - action'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",238.0,0.0140257,"The VAS score for incision biopsy was higher (p = 0.01) and the amount of bleeding was larger (p < 0.001), yet there was no significant difference between CEUS-CNB and US-CNB.","[{'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Wei', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Man', 'Initials': 'M', 'LastName': 'Lu', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Electronic address: graceof@163.com.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Zirui', 'Initials': 'Z', 'LastName': 'Jiang', 'Affiliation': 'Electrical and Computer Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.'}, {'ForeName': 'Minggang', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Ziyue', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Xueqing', 'Initials': 'X', 'LastName': 'Cheng', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Zhenqi', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Xiaobo', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Tan', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Jifen', 'Initials': 'J', 'LastName': 'Liao', 'Affiliation': 'Department of Ultrasound Medical Center, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; North Sichuan Medical College, Nanchong, China.'}]",Ultrasound in medicine & biology,['10.1016/j.ultrasmedbio.2020.09.001'] 615,32979907,Beneficial Effects of Adding Topical Atorvastatin 5% Cream to Topical Betamethasone 1% Ointment on Chronic Hand Eczema.,"BACKGROUND Hand eczema (HE) refers to a common inflammatory dermatological condition. Several studies have shown that statins may have anti-inflammatory effects. This study aimed at investigating the efficacy of adding topical atorvastatin to topical betamethasone in the treatment of chronic HE. METHODS This randomized, double-blind, placebo-controlled research was done between October 2017 and August 2018 in Hamadan, Iran. Of 130 cases treated for HE, 88 were randomly assigned to groups receiving either betamethasone 1% ointment plus atorvastatin 5% cream (n = 44) or betamethasone 1% ointment plus vehicle cream (n=44). Both groups applied their medications twice a day for 10 days. The primary outcome was changes in the severity of HE, assessed by hand eczema severity index (HECSI). The secondary outcomes were changes in itching evaluated via visual analogue scale (VAS) and quality of life examined through dermatology life quality index (DLQI). RESULTS Seventy-two out of 88 eligible cases completed the study. The mean HECSI scores decreased in both groups after the intervention, although the change in HECSI was greater in the atorvastatin group (adjusted mean difference [AMD]: 5.756; 95% CI: 5.168 to 6.344, P <0.001). The mean VAS scores decreased in both groups after the intervention, although the change in VAS was greater in the atorvastatin group (AMD: 10.535; 95% CI: 7.005 to 14.064, P <0.001). Treatment with topical atorvastatin was more effective in improving DLQI (AMD: 1.990; 95% CI: 1.821 to 2.158, P <0.001). CONCLUSION Addition of topical atorvastatin to topical betamethasone is beneficial in treatment of chronic HE. TRIAL REGISTERATION Identifier: IRCT2017070922965N10; https://www.irct.ir/.",2020,"The mean VAS scores decreased in both groups after the intervention, although the change in VAS was greater in the atorvastatin group (AMD: 10.535; 95% CI: 7.005 to 14.064, P <0.001).","['October 2017 and August 2018 in Hamadan, Iran', 'Seventy-two out of 88 eligible cases completed the study', '130 cases treated for HE, 88']","['Topical Atorvastatin', 'betamethasone 1% ointment plus vehicle cream', 'betamethasone 1% ointment plus atorvastatin 5% cream', 'betamethasone', 'placebo', 'Topical Betamethasone', 'atorvastatin', 'topical atorvastatin']","['mean VAS scores', 'Chronic Hand Eczema', 'severity of HE, assessed by hand eczema severity index (HECSI', 'change in VAS', 'change in HECSI', 'changes in itching evaluated via visual analogue scale (VAS) and quality of life examined through dermatology life quality index (DLQI', 'DLQI', 'mean HECSI scores']","[{'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0239816', 'cui_str': 'Hand eczema'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C0028912', 'cui_str': 'Ointment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1276092', 'cui_str': 'Chronic hand eczema'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0239816', 'cui_str': 'Hand eczema'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",88.0,0.0957481,"The mean VAS scores decreased in both groups after the intervention, although the change in VAS was greater in the atorvastatin group (AMD: 10.535; 95% CI: 7.005 to 14.064, P <0.001).","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Mehrpooya', 'Affiliation': 'Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Ghaed-Amini', 'Affiliation': 'Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Farzin', 'Initials': 'F', 'LastName': 'Firozian', 'Affiliation': 'Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Younes', 'Initials': 'Y', 'LastName': 'Mohammadi', 'Affiliation': 'Modeling of Non-communicable Diseases Research Center, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Pedram', 'Initials': 'P', 'LastName': 'Alirezaei', 'Affiliation': 'Psoriasis Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.'}]",Archives of Iranian medicine,['10.34172/aim.2020.71'] 616,32990630,"Promoting Safe Injection Practices, Substance Use Reduction, Hepatitis C Testing, and Overdose Prevention Among Syringe Service Program Clients Using a Computer-Tailored Intervention: Pilot Randomized Controlled Trial.","BACKGROUND Syringe service programs (SSPs) are safe, highly effective programs for promoting health among people who inject drugs. However, resource limitations prevent the delivery of a full package of prevention services to many clients in need. Computer-tailored interventions may represent a promising approach for providing prevention information to people who inject drugs in resource-constrained settings. OBJECTIVE The aim of this paper is to assess the effect of a computer-tailored behavioral intervention, called Hep-Net, on safe injection practices, substance use reduction, overdose prevention, and hepatitis C virus (HCV) testing among SSP clients. METHODS Using a social network-based recruitment strategy, we recruited clients of an established SSP in Wisconsin and peers from their social networks. Participants completed a computerized baseline survey and were then randomly assigned to receive the Hep-Net intervention. Components of the intervention included an overall risk synthesis, participants' selection of a behavioral goal, and an individualized risk reduction exercise. Individuals were followed up 3 months later to assess their behavior change. The effect of Hep-Net on receiving an HCV screening test, undergoing Narcan training, reducing the frequency of drug use, and sharing drug equipment was assessed. The individual's readiness to change each behavior was also examined. RESULTS From 2014 to 2015, a total of 235 people who injected drugs enrolled into the Hep-Net study. Of these, 64.3% (151/235) completed the follow-up survey 3-6 months postenrollment. Compared with the control group, individuals who received the Hep-Net intervention were more likely to undergo HCV testing (odds ratio [OR] 2.23, 95% CI 1.05-4.74; P=.04) and receive Narcan training (OR 2.25, 95% CI 0.83-6.06; P=.11), and they shared drug equipment less frequently (OR 0.06, 95% CI 0.55-0.65; P<.001). Similarly, individuals who received the intervention were more likely to advance in their stage of readiness to change these 3 behaviors. However, intervention participants did not appear to reduce the frequency of drug use or increase their readiness to reduce drug use more than control participants, despite the fact that the majority of the intervention participants selected this as the primary goal to focus on after participation in the baseline survey. CONCLUSIONS Implementing computer-based risk reduction interventions in SSPs may reduce harms associated with the sharing of injection equipment and prevent overdose deaths; however, brief computerized interventions may not be robust enough to overcome the challenges associated with reducing and ceasing drug use when implemented in settings centered on the delivery of prevention services. TRIAL REGISTRATION ClinicalTrials.gov NCT02474043; https://clinicaltrials.gov/ct2/show/NCT02474043. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR1-10.2196/resprot.4830.",2020,"Computer-tailored interventions may represent a promising approach for providing prevention information to people who inject drugs in resource-constrained settings. ","['people who inject drugs', 'recruited clients of an established SSP in Wisconsin and peers from their social networks', 'SSP clients', 'From 2014 to 2015, a total of 235 people who injected drugs enrolled into the Hep-Net study']","['Hep-Net intervention', 'computer-tailored behavioral intervention', 'Hep-Net']","['overdose deaths', 'frequency of drug use, and sharing drug equipment', ""overall risk synthesis, participants' selection of a behavioral goal, and an individualized risk reduction exercise""]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1720154', 'cui_str': 'Inject'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C1857069', 'cui_str': 'Schöpf-Schulz-Passarge syndrome'}, {'cui': 'C0043193', 'cui_str': 'Wisconsin'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0162569', 'cui_str': 'Homozygous porphyria cutanea tarda'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0162569', 'cui_str': 'Homozygous porphyria cutanea tarda'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0029944', 'cui_str': 'Drug overdose'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0031222', 'cui_str': 'Personnel Selection'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",235.0,0.0773248,"Computer-tailored interventions may represent a promising approach for providing prevention information to people who inject drugs in resource-constrained settings. ","[{'ForeName': 'Karli R', 'Initials': 'KR', 'LastName': 'Hochstatter', 'Affiliation': 'Columbia University School of Social Work, New York, NY, United States.'}, {'ForeName': 'Shawnika J', 'Initials': 'SJ', 'LastName': 'Hull', 'Affiliation': 'Department of Prevention and Community Health, Milken Institute School of Public Health, The George Washington University, Washington DC, DC, United States.'}, {'ForeName': 'Ajay K', 'Initials': 'AK', 'LastName': 'Sethi', 'Affiliation': 'Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.'}, {'ForeName': 'Marguerite E', 'Initials': 'ME', 'LastName': 'Burns', 'Affiliation': 'Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.'}, {'ForeName': 'Marlon P', 'Initials': 'MP', 'LastName': 'Mundt', 'Affiliation': 'Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.'}, {'ForeName': 'Ryan P', 'Initials': 'RP', 'LastName': 'Westergaard', 'Affiliation': 'Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.'}]",Journal of medical Internet research,['10.2196/19703'] 617,32989542,Usefulness of narrow-band imaging for the detection of remnant sessile-serrated adenoma (SSA) tissue after endoscopic resection: the KASID multicenter study.,"BACKGROUND A sessile-serrated adenoma (SSA) has a high risk for incomplete resection. Little is known regarding how to immediately detect remnant SSA tissue after endoscopic resection. We investigated the usefulness of narrow-band imaging (NBI) to detect remnant SSA tissue after endoscopic mucosal resection (EMR). METHODS We performed a prospective randomized study on 138 patients who had suspicious SSA on colonoscopy at five centers. After EMR on the suspected SSA determined on the endoscopic morphology, all lesions were randomized into two inspection methods, NBI and white light endoscopy (WLE), to detect remnant tissue on the resected margin. If remnant tissue was detected, an additional resection was performed. Finally, we obtained quadrant biopsies on the resection margin to evaluate the incomplete resection. The proportion of incomplete resection was calculated by combining the detection of remnant tissue and the positivity of SSA cells on the final quadrant biopsies. The primary outcome was the proportion of remnant tissue detection, and the secondary outcome was the proportion of incomplete resection of SSA. RESULTS In all, 145 lesions from 138 patients were removed. The diagnostic rate of SSA was 87.6% (127/145). After randomization, NBI inspection was performed on 69 lesions, and WLE inspection was performed on 76 lesions. The histologic diagnostic rate of SSA was 89.9% (62/69) in the NBI group and 85.5% (65/76) in the WLE group (p > 0.05). There were no significant differences in the detection of remnant tissue (12.9% (8/62) vs. 15.4% (10/65), p > 0.05), the proportion of SSA in remnant tissue (11.3% (7/62) vs. 12.3% (8/65), p > 0.05), or the proportion of incomplete resection (6.5 (4/62) vs. 10.8 (7/65), p > 0.05) between the NBI and WLE inspection groups, respectively. CONCLUSION NBI was not superior to WLE for detecting remnant SSA tissue after EMR and could not decrease the proportion of incomplete resection of SSA.",2021,NBI was not superior to WLE for detecting remnant SSA tissue after EMR and could not decrease the proportion of incomplete resection of SSA.,"['145 lesions from 138 patients were removed', 'remnant sessile-serrated adenoma (SSA) tissue after endoscopic resection', '138 patients who had suspicious SSA on colonoscopy at five centers']","['narrow-band imaging', 'endoscopic mucosal resection (EMR', 'narrow-band imaging (NBI', 'WLE']","['proportion of incomplete resection of SSA', 'detection of remnant tissue', 'proportion of SSA in remnant tissue', 'histologic diagnostic rate of SSA', 'proportion of remnant tissue detection', 'diagnostic rate of SSA', 'proportion of incomplete resection']","[{'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C2732618', 'cui_str': 'Sessile serrated adenoma'}, {'cui': 'C0205348', 'cui_str': 'Sessile'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C3494253', 'cui_str': 'Narrowband Imaging'}, {'cui': 'C1700928', 'cui_str': 'Strip Biopsy'}, {'cui': 'C0563228', 'cui_str': 'White light'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}]","[{'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C2732618', 'cui_str': 'Sessile serrated adenoma'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0205348', 'cui_str': 'Sessile'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]",138.0,0.0250509,NBI was not superior to WLE for detecting remnant SSA tissue after EMR and could not decrease the proportion of incomplete resection of SSA.,"[{'ForeName': 'Yunho', 'Initials': 'Y', 'LastName': 'Jung', 'Affiliation': 'Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.'}, {'ForeName': 'Jung Rock', 'Initials': 'JR', 'LastName': 'Moon', 'Affiliation': 'Department of Internal Medicine, Soonchunhyang University College of Medicine, 59 Daesagwan ro, Yongsan gu, Seoul, 04401, Korea.'}, {'ForeName': 'Seong Ran', 'Initials': 'SR', 'LastName': 'Jeon', 'Affiliation': 'Department of Internal Medicine, Soonchunhyang University College of Medicine, 59 Daesagwan ro, Yongsan gu, Seoul, 04401, Korea.'}, {'ForeName': 'Jae Myung', 'Initials': 'JM', 'LastName': 'Cha', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Hyo-Joon', 'Initials': 'HJ', 'LastName': 'Yang', 'Affiliation': 'Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Suyeon', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'Biostatistical Consulting Unit, Soonchunhyang University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Yumi', 'Initials': 'Y', 'LastName': 'Ahn', 'Affiliation': 'Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea.'}, {'ForeName': 'Jeong-Sik', 'Initials': 'JS', 'LastName': 'Byeon', 'Affiliation': 'Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jsbyeon@amc.seoul.kr.'}, {'ForeName': 'Hyun Gun', 'Initials': 'HG', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Soonchunhyang University College of Medicine, 59 Daesagwan ro, Yongsan gu, Seoul, 04401, Korea. medgun@schmc.ac.kr.'}]",Surgical endoscopy,['10.1007/s00464-020-08016-2'] 618,32989543,The efficacy of the submucosal injection of lidocaine during endoscopic submucosal dissection for colorectal neoplasms: a multicenter randomized controlled study.,"BACKGROUND Endoscopic submucosal dissection (ESD) is currently a common procedure although it requires a long procedural time. We conducted a prospective study to determine the efficacy and safety of lidocaine injection for shortening the procedural time and relieving bowel peristalsis during ESD. METHODS A multicenter randomized controlled study was conducted in three hospitals. Ninety-one patients who underwent colorectal ESD were enrolled. Patients were randomly divided into two groups using the envelope method: the lidocaine group and saline group. The primary endpoint was the procedural time, and the secondary endpoints were the procedural time in each part of the colon and the grade of bowel peristalsis and the incidence and amounts of antispasmodic drugs use and adverse events. RESULTS The patients' demographics were not markedly different between the two groups. The mean procedural time in the lidocaine group was not markedly different from that in the saline group. In contrast, at the proximal site, the procedural time in the lidocaine group (57 min) was significantly shorter in the saline group (80 min). The grade of bowel peristalsis in the lidocaine group (0.67) was significantly lower than in the saline group (1.17). Antispasmodic drug use was significantly rarer in the lidocaine group than in the saline group. The incidence of adverse events was not markedly different between the two groups. CONCLUSIONS Local lidocaine injection is a feasible option for preventing bowel peristalsis, particularly in the proximal colon, leading to a reduced procedural time for ESD and decreased antispasmodic drug use. University Hospital Medical Information Network Center (UMIN number: 000022843).",2021,The grade of bowel peristalsis in the lidocaine group (0.67) was significantly lower than in the saline group (1.17).,"['Ninety-one patients who underwent colorectal ESD were enrolled', 'colorectal neoplasms', 'University Hospital Medical Information Network Center']","['lidocaine group and saline', 'endoscopic submucosal dissection', 'Endoscopic submucosal dissection (ESD', 'lidocaine injection', 'lidocaine']","['procedural time', 'grade of bowel peristalsis', 'procedural time in each part of the colon and the grade of bowel peristalsis and the incidence and amounts of antispasmodic drugs use and adverse events', 'efficacy and safety', 'incidence of adverse events', 'mean procedural time']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C1700929', 'cui_str': 'Endoscopic Submucosal Dissection'}, {'cui': 'C0009404', 'cui_str': 'Neoplasm of large intestine'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0021419', 'cui_str': 'Information Networks'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C1700929', 'cui_str': 'Endoscopic Submucosal Dissection'}, {'cui': 'C4049857', 'cui_str': 'Lidocaine Injection'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0031133', 'cui_str': 'Peristalsis'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0037766', 'cui_str': 'Antispasmodic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0364906,The grade of bowel peristalsis in the lidocaine group (0.67) was significantly lower than in the saline group (1.17).,"[{'ForeName': 'Masami', 'Initials': 'M', 'LastName': 'Ijiri', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Sasaki', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Mikihiro', 'Initials': 'M', 'LastName': 'Fujiya', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan. fjym@asahikawa-med.ac.jp.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Iwama', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Murakami', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Keitaro', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Kazuyuki', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': 'Department of Gastroenterology, Asahikawa Kosei Hospital, Asahikawa, Hokkaido, Japan.'}, {'ForeName': 'Katsuyoshi', 'Initials': 'K', 'LastName': 'Ando', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Nobuhiro', 'Initials': 'N', 'LastName': 'Ueno', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Kashima', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Moriichi', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Tanabe', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Saito', 'Affiliation': 'Department of Gastroenterology, Asahikawa City Hospital, Asahikawa, Hokkaido, Japan.'}, {'ForeName': 'Toshikatsu', 'Initials': 'T', 'LastName': 'Okumura', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.'}]",Surgical endoscopy,['10.1007/s00464-020-08017-1'] 619,33237330,The impact of different (rheumatoid) arthritis phenotypes on patients' lives.,"OBJECTIVES To compare patient-reported outcome (PRO) domains between three arthritis phenotypes [undifferentiated arthritis (UA), autoantibody-negative RA (RA-) and autoantibody-positive RA (RA+)] at diagnosis, after 2 years and over time. METHODS All UA (n = 130), RA- (n = 176) and RA+ (n = 331) patients from the tREACH trial, a stratified single-blinded trial with a treat-to-target approach, were used. PRO comparisons between phenotypes at baseline and after 2 years were performed with analysis of variance, while a linear mixed model compared them over time. Effect sizes were weighted against the minimal clinically important differences (MCIDs) for each PRO. RESULTS RA- patients had a higher disease burden compared with RA+ and UA. At baseline and after 2 years, RA- patients had more functional impairment and a poorer Physical Component Summary (PCS) compared with the other phenotypes, while they only scored worse for general health and morning stiffness duration at baseline. The MCIDs were exceeded at baseline, except for functional ability between RA+ and UA, while after 2 years only the MCID of the PCS was exceeded by RA- compared with UA and RA. After 2 years the PROs of all phenotypes improved, but PROs measuring functioning were still worse compared with the general population, even when patients had low disease activity. CONCLUSION RA- patients had the highest disease burden of all phenotypes. Although most patients have low disease activity after treatment, all clinical phenotypes still have a similar significant impact on patients' lives, which is mainly physical. Therefore it is important to assess and address PROs in daily practice because of persistent disease burden despite low disease activity. TRIAL REGISTRATION ISRCTN26791028.",2021,"The MCIDs were exceeded at baseline, except for functional ability between RA+ and UA, while after 2 years only the MCID of PCS was exceeded between RA- compared to UA and RA.","['All UA(n\u2009=\u2009130), RA-(n\u2009=\u2009176) and RA\u2009+\u2009(n=331) patients from the tREACH trial']",[],"['functional impairment and a poorer Physical Component Score (PCS', 'MCID of PCS', 'MCIDs']","[{'cui': 'C0205618', 'cui_str': 'Undifferentiated'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1882368', 'cui_str': 'Dynamic Light Scattering'}]",331.0,0.100302,"The MCIDs were exceeded at baseline, except for functional ability between RA+ and UA, while after 2 years only the MCID of PCS was exceeded between RA- compared to UA and RA.","[{'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Luurssen-Masurel', 'Affiliation': 'Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Angelique Elisabeth Adriana Maria', 'Initials': 'AEAM', 'LastName': 'Weel', 'Affiliation': 'Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Johanna Maria Wilhelmina', 'Initials': 'JMW', 'LastName': 'Hazes', 'Affiliation': 'Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Pascal Hendrik Pieter', 'Initials': 'PHP', 'LastName': 'de Jong', 'Affiliation': 'Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa845'] 620,32996592,"Local Transdermal Delivery of Telapristone Acetate Through Breast Skin, Compared With Oral Treatment: A Randomized Double-Blind, Placebo-Controlled Phase II Trial.","Oral breast cancer prevention medications entail systemic exposure, limiting acceptance by high-risk women. Delivery through the breast skin, although an attractive alternative, requires demonstration of drug distribution throughout the breast. We conducted a randomized double-blind, placebo-controlled phase II clinical trial comparing telapristone acetate, a progesterone receptor antagonist, administered orally (12 mg/day) or transdermally (12 mg/breast) for 4 ± 1 weeks to women planning mastectomy. Plasma and tissue concentrations, measured at five locations in the mastectomy specimen using liquid chromatography tandem mass spectrometry were compared. In 60 evaluable subjects, median drug concentration (ng/g tissue) was 103 (interquartile range (IQR): 46.3-336) in the oral vs. 2.82 (IQR: 1.4-5.5) in the transdermal group. Despite poor dermal permeation, within-breast drug distribution pattern was identical in both groups (R 2  = 0.88, P = 0.006), demonstrating that transdermally and orally delivered drug is distributed similarly through the breast, and is strongly influenced by tissue adiposity (P < 0.0001). Other skin-penetrant drugs should be tested for breast cancer prevention.",2021,"Despite poor dermal permeation, within-breast drug distribution pattern was identical in both groups (R 2 =0.88, p=0.006), demonstrating that transdermally and orally delivered drug is distributed similarly through the breast, and is strongly influenced by tissue adiposity (p<0.0001).","['60 evaluable subjects, median drug concentration (ng/g tissue) was 103 (IQR: 46.3-336) in the oral vs 2.82 (IQR: 1.4-5.5) in the transdermal group', 'high risk women']","['placebo', 'telapristone acetate', 'telapristone acetate (TPA), a progesterone receptor (PR) antagonist']",['Plasma and tissue concentrations'],"[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1627892', 'cui_str': 'ug/kg'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C2745478', 'cui_str': 'AM103'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4517503', 'cui_str': '1.4'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C0040652', 'cui_str': 'Transdermal route'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3501648', 'cui_str': 'telapristone acetate'}, {'cui': 'C0034833', 'cui_str': 'Progesterone receptor'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.134135,"Despite poor dermal permeation, within-breast drug distribution pattern was identical in both groups (R 2 =0.88, p=0.006), demonstrating that transdermally and orally delivered drug is distributed similarly through the breast, and is strongly influenced by tissue adiposity (p<0.0001).","[{'ForeName': 'Oukseub', 'Initials': 'O', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Pilewskie', 'Affiliation': 'Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Karlan', 'Affiliation': 'Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.'}, {'ForeName': 'Mary B', 'Initials': 'MB', 'LastName': 'Tull', 'Affiliation': 'Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Benante', 'Affiliation': 'Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Yanfei', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Blanco', 'Affiliation': 'Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Helenowski', 'Affiliation': 'Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Masha', 'Initials': 'M', 'LastName': 'Kocherginsky', 'Affiliation': 'Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Shivangi', 'Initials': 'S', 'LastName': 'Yadav', 'Affiliation': 'Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Hosseini', 'Affiliation': 'Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Hansen', 'Affiliation': 'Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Bethke', 'Affiliation': 'Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Muzzio', 'Affiliation': 'Analytical Chemistry Division, Illinois Institute of Technology Research Institute, Chicago, Illinois, USA.'}, {'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Troester', 'Affiliation': 'Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Dimond', 'Affiliation': 'National Cancer Institute Division of Cancer Prevention, Bethesda, Maryland, USA.'}, {'ForeName': 'Marjorie', 'Initials': 'M', 'LastName': 'Perloff', 'Affiliation': 'National Cancer Institute Division of Cancer Prevention, Bethesda, Maryland, USA.'}, {'ForeName': 'Brandy', 'Initials': 'B', 'LastName': 'Heckman-Stoddard', 'Affiliation': 'National Cancer Institute Division of Cancer Prevention, Bethesda, Maryland, USA.'}, {'ForeName': 'Seema A', 'Initials': 'SA', 'LastName': 'Khan', 'Affiliation': 'Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.2041'] 621,32989532,Hot snare polypectomy versus endoscopic mucosal resection for small colorectal polyps: a randomized controlled trial.,"BACKGROUND AND AIMS This study was performed to compare endoscopic mucosal resection (EMR) with hot snare polypectomy (HSP) in terms of the complete resection rate and the incidence of adverse events for resecting small (5-10 mm) colorectal polyps. METHODS Small colorectal polyps (5-10 mm) with neoplastic features were randomly allocated to either the HSP or EMR group. A submucosal injection was performed prior to hot snaring in the EMR group only. Complete resection was defined as the absence of neoplastic tissue from two additional biopsies of the polypectomy site. R0 resection was defined as the absence of neoplastic tissue at the margin of the resected specimen. RESULTS A total of 362 colon polyps from 272 patients were included, and 167 polyps in the HSP group and 155 polyps in the EMR group were analyzed. Between the polypectomy techniques, there was no significant difference in the complete resection rates, which were 96.4% (161/167) in the HSP group and 95.5% (148/155) in the EMR group (P = 0.67). The R0 resection rate in the HSP and EMR groups was significantly different, with 49.7% (83/167) and 74.8% (116/155), respectively (P < 0.001). There was no significant difference in the incidence of adverse events between the two groups. CONCLUSIONS The complete resection rates for small (5-10 mm) polyps were not different between HSP and EMR. TRIAL REGISTRY ClincialTrials.gov number NCT02239536.",2021,"Between the polypectomy techniques, there was no significant difference in the complete resection rates, which were 96.4% (161/167) in the HSP group and 95.5% (148/155) in the EMR group (P = 0.67).","['A total of 362 colon polyps from 272 patients were included, and 167 polyps in the HSP group and 155 polyps in the EMR group were analyzed', 'Small colorectal polyps (5-10\xa0mm) with neoplastic features', 'small colorectal polyps']","['endoscopic mucosal resection', 'HSP', 'Hot snare polypectomy', 'endoscopic mucosal resection (EMR) with hot snare polypectomy (HSP', 'HSP or EMR']","['R0 resection rate', 'incidence of adverse events', 'complete resection rates']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009376', 'cui_str': 'Polyp of colon'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0183362', 'cui_str': 'Snare'}, {'cui': 'C0521210', 'cui_str': 'Resection of polyp'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1700928', 'cui_str': 'Strip Biopsy'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0949059', 'cui_str': 'Polyp of large intestine'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]","[{'cui': 'C1700928', 'cui_str': 'Strip Biopsy'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0183362', 'cui_str': 'Snare'}, {'cui': 'C0521210', 'cui_str': 'Resection of polyp'}]","[{'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015250', 'cui_str': 'Complete excision'}]",362.0,0.0889935,"Between the polypectomy techniques, there was no significant difference in the complete resection rates, which were 96.4% (161/167) in the HSP group and 95.5% (148/155) in the EMR group (P = 0.67).","[{'ForeName': 'Seung-Jun', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Bo-In', 'Initials': 'BI', 'LastName': 'Lee', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea. gidoc4u@gmail.com.""}, {'ForeName': 'Eun Sun', 'Initials': 'ES', 'LastName': 'Jung', 'Affiliation': ""Department of Hospital Pathology, College of Medicine, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, 1021, Tongil-ro, Eunpyeong-gu, Seoul, 03312, Republic of Korea. esjung@catholic.ac.kr.""}, {'ForeName': 'Joon Sung', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Sun-Young', 'Initials': 'SY', 'LastName': 'Jun', 'Affiliation': ""Department of Hospital Pathology, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Woohyeon', 'Initials': 'W', 'LastName': 'Kim', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Hyoju', 'Initials': 'H', 'LastName': 'Ham', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Minah', 'Initials': 'M', 'LastName': 'Kim', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Sung Hak', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': ""Department of Hospital Pathology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Han Hee', 'Initials': 'HH', 'LastName': 'Lee', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Jae Myung', 'Initials': 'JM', 'LastName': 'Park', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Myung-Gyu', 'Initials': 'MG', 'LastName': 'Choi', 'Affiliation': ""Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}]",Surgical endoscopy,['10.1007/s00464-020-07994-7'] 622,32994235,Evaluating an implementation programme for medication review with follow-up in community pharmacy using a hybrid effectiveness study design: translating evidence into practice.,"OBJECTIVES To evaluate an implementation programme of a community pharmacy medication review with follow-up (MRF) service using a hybrid effectiveness-implementation study design, and to compare the clinical and humanistic outcomes with those in a previously conducted cluster randomised controlled trial (cRCT). SETTING Community pharmacies in Spain. PARTICIPANTS 135 community pharmacies and 222 pharmacists providing MRF to polymedicated patients aged 65 or over. INTERVENTION The intervention was an implementation programme for the MRF service. A national level group was established, mirrored with a provincial level group. A series of interventions were defined (1) to engage pharmacy owners with the implementation model and (2) to provide training to pharmacists consisting of clinical case studies, process of MRF, communication skills and data collection methods and (3) practice change facilitators. PRIMARY AND SECONDARY OUTCOME MEASURES The primary outcomes for the implementation programme were progress, reach, fidelity and integration. The secondary outcomes were number of medications, non-controlled health problems, emergency visits, hospitalisations and health-related quality of life, which were compared with a previous 6-month cluster RCT. RESULTS 55% of pharmacies reached the implementation phase and 35.6% remained in the testing phase at 12 months. A reach of 89.3% (n=844) was achieved. Fidelity average score was 8.45 (min: 6.2, max: 9.3) out of 10. The integration mean score was 3.39 (SD: 0.72) out of 5. MRF service outcomes were similar to the cluster RCT study; however, the magnitude of the outcomes was delayed. CONCLUSIONS The implementation of pharmacy services is a complex multifactorial process, conditioned by numerous implementation factors. In the absence of remuneration, the implementation of the MRF service is a slow process, taking at least 12 months to complete. TRIAL REGISTRATION NUMBER CGFTRA-2017-01.",2020,"Fidelity average score was 8.45 (min: 6.2, max: 9.3) out of 10.","['135 community pharmacies and 222 pharmacists providing MRF to polymedicated patients aged 65 or over', 'Community pharmacies in Spain']",[],"['number of medications, non-controlled health problems, emergency visits, hospitalisations and health-related quality of life', 'MRF service outcomes', 'progress, reach, fidelity and integration', 'integration mean score', 'Fidelity average score']","[{'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0009478', 'cui_str': 'Community Pharmacies'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0560023', 'cui_str': 'Review of medication'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0560023', 'cui_str': 'Review of medication'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0949128,"Fidelity average score was 8.45 (min: 6.2, max: 9.3) out of 10.","[{'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Varas-Doval', 'Affiliation': 'Department of Pharmaceutical Services, Spanish General Council of Official Colleges of Pharmacists, Madrid, Spain.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Gastelurrutia', 'Affiliation': 'Pharmaceutical Care Research Group, CTS-131, University of Granada Faculty of Pharmacy, Granada, Spain magastelu@farmanorte.org.'}, {'ForeName': 'Shalom I', 'Initials': 'SI', 'LastName': 'Benrimoj', 'Affiliation': 'Pharmaceutical Care Research Group, CTS-131, University of Granada Faculty of Pharmacy, Granada, Spain.'}, {'ForeName': 'Maria Jose', 'Initials': 'MJ', 'LastName': 'Zarzuelo', 'Affiliation': 'Pharmaceutical Care Research Group, CTS-131, University of Granada Faculty of Pharmacy, Granada, Spain.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Garcia-Cardenas', 'Affiliation': 'Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Perez-Escamilla', 'Affiliation': 'Pharmaceutical Care Research Group, CTS-131, University of Granada Faculty of Pharmacy, Granada, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Martínez-Martínez', 'Affiliation': 'Clinical Pharmacy Section, Pharmacy Department, Universidad de Granada, Granada, Spain.'}]",BMJ open,['10.1136/bmjopen-2019-036669'] 623,33232594,The Use of Endoscopic Clipping in Preventing Delayed Complications after Endoscopic Resection for Superficial Non-Ampullary Duodenal Tumors.,"BACKGROUND/AIMS Endoscopic resection (ER) has recently been accepted as the standard treatment modality for superficial nonampullary duodenal tumors (SNADTs). However, the procedure can cause adverse events such as perforation and bleeding. This study aimed to investigate the efficacy of prophylactic clipping in the prevention of delayed complications. METHODS A retrospective review of the medical records of patients who underwent ER for SNADT from 3 centers was performed. Patients were divided into 2 groups: the immediate clipping group (ICG) and the no clipping group (NCG). Various baseline characteristics and factors associated with the appearance of delayed complications, such as size of the lesion, tumor location, histologic type, and co-morbidities, were compared between the two groups. RESULTS A total of 99 lesions from 99 patients were included in this study. Fifty-two patients were allocated into ICG and 47 patients were allocated into NCG. Delayed bleeding occurred in 1 patient from ICG and in 8 patients from NCG. Delayed perforation occurred in 1 patient from ICG and in 3 patients from NCG. There were no procedure-related deaths in both groups. CONCLUSION Although the use of endoscopic clipping seemed to reduce the risk of developing delayed complications, further studies using a prospective design is required.",2021,"There were no procedure-related deaths in both groups. ","['Fifty-two patients were allocated into ICG and 47 patients', 'patients who underwent ER for SNADT from 3 centers was performed', 'Superficial NonAmpullary Duodenal Tumors', 'A total of 99 lesions from 99 patients were included in this study']","['Endoscopic resection (ER', 'prophylactic clipping', 'Endoscopic Clipping', 'immediate clipping group (ICG) and the no clipping group (NCG', 'NCG', 'endoscopic clipping']","['size of the lesion, tumor location, histologic type, and co-morbidities', 'Delayed bleeding', 'Delayed Complications', 'Delayed perforation', 'procedure-related deaths']","[{'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0013291', 'cui_str': 'Neoplasm of duodenum'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0449574', 'cui_str': 'Histologic type'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0549099', 'cui_str': 'Perforation'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",52.0,0.0196833,"There were no procedure-related deaths in both groups. ","[{'ForeName': 'Jee Young', 'Initials': 'JY', 'LastName': 'An', 'Affiliation': ""Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Korea.""}, {'ForeName': 'Byung-Wook', 'Initials': 'BW', 'LastName': 'Kim', 'Affiliation': ""Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Korea.""}, {'ForeName': 'Joon Sung', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': ""Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Korea.""}, {'ForeName': 'Jae-Myung', 'Initials': 'JM', 'LastName': 'Park', 'Affiliation': ""Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Tae Ho', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': ""Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea, Bucheon, Korea.""}, {'ForeName': 'Jaesin', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': ""Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Korea.""}]",Clinical endoscopy,['10.5946/ce.2020.109'] 624,33232628,"The Effect of Follow-Up Contact on Recovery After Benign Hysterectomy: A Randomized, Single-Blinded, Four-Arm, Controlled Multicenter Trial.","Background: The objective of this trial was to analyze the effect of follow-up programs using standard follow-up protocol and structured coaching on recovery after hysterectomy in an enhanced recovery after surgery setting. Materials and Methods: A randomized, four-armed, single-blinded, controlled multicenter trial comprising 487 women was conducted at five hospitals in the southeast region of Sweden. The women were allocated (1:1:1:1) to Group A: no planned follow-up contact; Group B: a single, planned, structured, broadly kept, follow-up telephone contact with the research nurse the day after discharge; Group C: planned, structured, broadly kept follow-up telephone contact with the research nurse the day after discharge and then once weekly for 6 weeks; and Group D: as Group C, but with planned, structured, coaching telephone contact. Recovery was assessed by the health-related quality of life (HRQoL) questionnaires EuroQoL-5 Dimension with three levels (EQ-5D-3L) and Short-Form-Health Survey with 36 items (SF-36) and duration of sick leave. Results: Neither the recovery of HRQoL as measured by the EQ-5D-3L and the SF-36 nor the duration of sick leave (mean 26.8-28.1 days) differed significantly between the four intervention groups. Irrespective of mode of follow-up contact used, the women had recovered to their baseline EQ-5D-3L health index 4 weeks after surgery. The occurrence of unplanned telephone contact was significantly lower (by nearly 30%) in the women who had structured coaching. Conclusion: Follow-up contact, including coaching, did not seem to expedite the postoperative recovery in HRQoL or reduce the sick leave after hysterectomy, but the coaching seemed to reduce unplanned telephone contact with the health care services. ClinicalTrial.gov (NCT01526668).",2021,The occurrence of unplanned telephone contact was significantly lower (by nearly 30%) in the women who had structured coaching. ,"['487 women was conducted at five hospitals in the southeast region of Sweden', 'After Benign Hysterectomy']",['standard follow-up protocol and structured coaching'],"['duration of sick leave', 'occurrence of unplanned telephone contact', 'health-related quality of life (HRQoL) questionnaires EuroQoL-5 Dimension with three levels (EQ-5D-3L) and Short-Form-Health Survey with 36 items (SF-36) and duration of sick leave', 'Recovery', 'recovery of HRQoL']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",487.0,0.109193,The occurrence of unplanned telephone contact was significantly lower (by nearly 30%) in the women who had structured coaching. ,"[{'ForeName': 'Gulnara', 'Initials': 'G', 'LastName': 'Kassymova', 'Affiliation': 'Department of Obstetrics and Gynecology, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Gunilla', 'Initials': 'G', 'LastName': 'Sydsjö', 'Affiliation': 'Department of Obstetrics and Gynecology, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Ninnie', 'Initials': 'N', 'LastName': 'Borendal Wodlin', 'Affiliation': 'Department of Obstetrics and Gynecology, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Nilsson', 'Affiliation': 'Department of Biomedical and Clinical Sciences, and Linköping University, Linköping, Sweden.'}, {'ForeName': 'Preben', 'Initials': 'P', 'LastName': 'Kjølhede', 'Affiliation': 'Department of Obstetrics and Gynecology, Linköping University, Linköping, Sweden.'}]",Journal of women's health (2002),['10.1089/jwh.2020.8752'] 625,32994091,Impact of Concomitant Medications on Biochemical Outcome in Localised Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy.,"AIMS Several classes of concomitant medications have been shown to affect oncological outcomes in patients with prostate cancer (PCa). We assessed the association between the use of commonly prescribed concomitant medications and biochemical relapse-free survival (bRFS) in patients with localised PCa treated with radiotherapy and androgen deprivation therapy (ADT). MATERIALS AND METHODS A secondary pooled analysis of two phase III randomised trials was carried out. In the first trial, patients with localised PCa with clinical stage T1b-T3, prostate-specific antigen <30 ng/ml and Gleason score ≤7 were treated with radical radiotherapy and 6 months of ADT starting 4 months before or concomitantly with radiotherapy. In the second trial, patients with high-risk PCa were treated with radical radiotherapy and 36 months of ADT with randomisation to three-dimensional conformal or intensity-modulated radiotherapy. Information on concomitant medications was collected from the medical record. Univariable and multivariable Cox regression was used to identify factors associated with bRFS. RESULTS Overall, 486 patients were evaluable. The median follow-up was 125 months; 10-year bRFS was 83.7%. On univariable analysis, receipt of metformin was significantly associated with worse bRFS. Ten-year bRFS was 73% and 85% for patients with and without concomitant metformin (adjusted hazard ratio 2.11, 95% confidence interval 1.03-4.33). Similar evidence of an association was observed with sulfonamide-based α1-receptor blockers (adjusted hazard ratio 2.72, 95% confidence interval 1.31-5.66). However, no such association was seen with receipt of quinazoline-based α1-receptor blockers (adjusted hazard ratio 1.09, 95% confidence interval 0.42-2.82). There was no significant association between bRFS and receipt of all other medication classes considered. CONCLUSIONS In this population of patients with localised PCa treated with radiotherapy and ADT, receipt of concomitant metformin and sulfonamide-based α1-receptor blockers was associated with inferior biochemical outcome. Randomised trials are required to assess the true effect of these medications on oncological outcomes in localised PCa.",2021,"Ten-year bRFS was 73% and 85% for patients with and without concomitant metformin (adjusted hazard ratio 2.11, 95% confidence interval 1.03-4.33).","['486 patients were evaluable', 'patients with localised PCa with clinical stage T1b-T3, prostate-specific antigen <30 ng/ml and Gleason score ≤7 were treated with', 'patients with prostate cancer (PCa', 'patients with high-risk PCa', 'patients with localised PCa treated with', 'Localised Prostate Cancer Treated with']","['metformin and sulfonamide-based α1-receptor blockers', 'Radiotherapy and Androgen Deprivation Therapy', 'radiotherapy and ADT', 'radiotherapy and androgen deprivation therapy (ADT', 'Concomitant Medications', 'radical radiotherapy', 'radiotherapy', 'dimensional conformal or intensity-modulated radiotherapy']","['10-year bRFS', 'biochemical relapse-free survival (bRFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392752', 'cui_str': 'Localized'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0205563', 'cui_str': 'Clinical stage finding'}, {'cui': 'C0475385', 'cui_str': 'Tumor stage T1b'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0332326', 'cui_str': 'Gleason grading system for prostatic cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0038760', 'cui_str': 'Sulfonamide'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0026377', 'cui_str': 'Molecular conformation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",486.0,0.146188,"Ten-year bRFS was 73% and 85% for patients with and without concomitant metformin (adjusted hazard ratio 2.11, 95% confidence interval 1.03-4.33).","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Roy', 'Affiliation': 'Radiation Medicine Program, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Malone', 'Affiliation': 'Radiation Medicine Program, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Division of Radiation Oncology, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Grimes', 'Affiliation': 'Radiation Medicine Program, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada.'}, {'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Morgan', 'Affiliation': 'Radiation Medicine Program, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Division of Radiation Oncology, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: smorgan@toh.ca.'}]",Clinical oncology (Royal College of Radiologists (Great Britain)),['10.1016/j.clon.2020.09.005'] 626,32997869,Acupuncture as a therapeutic resource for treatment of chronic pain in people with haemophilia.,"INTRODUCTION Chronic pain is common in individuals with severe and moderate haemophilia who did not receive prophylaxis during childhood. OBJECTIVE To verify the effectiveness of acupuncture in reducing intensity in chronic pain, changes in quality of life, joint function and impact on treatment satisfaction of haemophilia patients. METHODS Single-blinded randomized clinical trial with 28 participants divided into two groups: Acupuncture (G1) treated with traditional unilateral acupuncture (side of greatest referred pain) and Control (G2) treated with transcutaneous electrical nerve stimulation (TENS), with electrodes on the joint of most intense pain. Both groups had a 20-minute session per week, total of 05 consecutive sessions. Before starting treatment, participants underwent sociodemographic assessment, physical assessment (HJHS), quality of life questionnaire (Haem-a-Qol) and treatment expectation (Likert scale). After the end of the fifth session, Haem-a-Qol, HJHS and degree of satisfaction (Likert) were performed. The assessment of pain intensity using the visual analogue scale (VAS) was performed before the beginning and after the end of all sessions in both groups. Statistical analysis was performed using ANOVA, Bonferroni, t test and chi-square test (P < .05). RESULTS There was a statistical difference within and between groups G1 and G2 in reduction of VAS. In Haem-a-Qol, the groups showed similarity in quality of life. Both groups had high expectations for treatment. G1 presented a better degree of treatment satisfaction than G2. Total HJHS showed no difference within and between groups. CONCLUSION Acupuncture was effective in reducing pain intensity in haemophilia patients with chronic joint disease when compared to TENS.",2020,There was a statistical difference within and between groups G1 and G2 in reduction of VAS.,"['haemophilia patients', 'individuals with severe and moderate haemophilia who did not receive prophylaxis during childhood', 'haemophilia patients with chronic joint disease', 'people with haemophilia', '28 participants divided into two groups']","['Acupuncture', 'acupuncture', 'Acupuncture (G1) treated with traditional unilateral acupuncture (side of greatest referred pain) and Control (G2) treated with transcutaneous electrical nerve stimulation (TENS), with electrodes on the joint of most intense pain']","['pain intensity', 'reduction of VAS', 'pain intensity using the visual analogue scale (VAS', 'quality of life', 'quality of life, joint function', 'sociodemographic assessment, physical assessment (HJHS), quality of life questionnaire (Haem-a-Qol) and treatment expectation (Likert scale']","[{'cui': 'C0019069', 'cui_str': 'Hereditary factor VIII deficiency disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0022408', 'cui_str': 'Arthropathy'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0234250', 'cui_str': 'Referred pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040654', 'cui_str': 'Percutaneous electrical nerve stimulation'}, {'cui': 'C0013812', 'cui_str': 'Electrode'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0542330', 'cui_str': 'Joint mobilization'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0018966', 'cui_str': 'Heme'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}]",28.0,0.0616081,There was a statistical difference within and between groups G1 and G2 in reduction of VAS.,"[{'ForeName': 'Karen Cristina Pires', 'Initials': 'KCP', 'LastName': 'Oliveira', 'Affiliation': ""Department of Health Sciences and Children's Dentistry, School of Dentistry of Piracicaba, University of Campinas (FOP/Unicamp), Campinas, Brazil.""}, {'ForeName': 'Janaina Bosso da Silva', 'Initials': 'JBDS', 'LastName': 'Ricciardi', 'Affiliation': 'Department of Medical Clinic, School of Medical Sciences, University of Campinas (Unicamp), Campinas, Brazil.'}, {'ForeName': 'Cassia Maria', 'Initials': 'CM', 'LastName': 'Grillo', 'Affiliation': ""Department of Health Sciences and Children's Dentistry, School of Dentistry of Piracicaba, University of Campinas (FOP/Unicamp), Campinas, Brazil.""}, {'ForeName': 'Maria Imaculada de Lima', 'Initials': 'MIL', 'LastName': 'Montebello', 'Affiliation': 'Quantitative Methods Area Group, FGN Methodist University of Piracicaba - UNIMEP, Campinas, Brazil.'}, {'ForeName': 'Jorge Eji', 'Initials': 'JE', 'LastName': 'Sato', 'Affiliation': 'UNIFESP, Sao Paulo, Brazil.'}, {'ForeName': 'Maria da Luz Rosário', 'Initials': 'MDLR', 'LastName': 'de Sousa', 'Affiliation': ""Department of Health Sciences and Children's Dentistry, School of Dentistry of Piracicaba, University of Campinas (FOP/Unicamp), Campinas, Brazil.""}]",Haemophilia : the official journal of the World Federation of Hemophilia,['10.1111/hae.14151'] 627,32998649,Pilot Mobile Phone Intervention in Promoting Type 2 Diabetes Management in an Urban Area in Ghana: A Randomized Controlled Trial.,"PURPOSE The purpose of the study was to evaluate the feasibility and effectiveness of a nurse-led mobile phone call intervention on glycemic management and adherence to self-management practices among patients with type 2 diabetes mellitus (T2DM) in Ghana. METHODS This was a pilot randomized controlled trial to compare diabetes care as usual to a mobile phone call intervention delivered by nurses in addition to care as usual over a 12-week period in a tertiary referral hospital in Ghana. Sixty patients with T2DM were randomized to either the intervention or the control arm. The intervention group received up to 16 mobile phone calls (mean duration = 12 minutes) from a diabetes specialist nurse in addition to their care as usual. The control group received only care as usual. The primary outcome was the change in A1C over the 12-week period. The secondary outcomes were changes in self-reported adherence to medication and diabetes self-management measures over the 12-week period. RESULTS Mean baseline A1C was comparable between the intervention and control groups (9.54%, SD = 2.00% vs 9.07%, SD = 1.72%, P = .334). After 12 weeks, A1C was significantly lower in the intervention group compared to the control group. The difference in mean A1C in the control group rose by +0.26 ± 1.30% ( P = .282; 95% CI, -0.23 to 0.75), whereas that of the intervention group reduced by -1.51 ± 2.67% ( P = .004; 95% CI, -2.51 to -0.51). No improvements in self-management were recorded in the control group. In the intervention group, however, the only significant improvement was recorded in the area of foot care practices. Participant recruitment and retention were 100% without any attrition. About 87% (n = 26) of the intervention group completed at least 70% (≥11) of the calls. At the end of the trial, participants who received the intervention rated their satisfaction as 89.3% on average. CONCLUSION A mobile phone follow-up call by nurses emphasizing adherence to self-management practices is feasible and can improve short- to medium-term glycemic management among patients with T2DM.",2020,"After 12 weeks, A1C was significantly lower in the intervention group compared to the control group.","['in a tertiary referral hospital in Ghana', 'Type 2 Diabetes Management in an Urban Area in Ghana', 'Sixty patients with T2DM', 'patients with type 2 diabetes mellitus (T2DM) in Ghana', 'patients with T2DM']","['16 mobile phone calls (mean duration = 12\u2009minutes) from a diabetes specialist nurse in addition to their care as usual', 'Pilot Mobile Phone Intervention', 'nurse-led mobile phone call intervention', 'mobile phone call intervention delivered by nurses in addition to care as usual over a 12-week period']","['A1C', 'self-management', 'changes in self-reported adherence to medication and diabetes self-management measures', 'feasibility and effectiveness', 'Mean baseline A1C', 'glycemic management and adherence to self-management practices', 'area of foot care practices', 'mean A1C', 'change in A1C']","[{'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0017516', 'cui_str': 'Ghana'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1319140', 'cui_str': 'Diabetes self-management behavior'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0150240', 'cui_str': 'Foot care'}]",60.0,0.0605443,"After 12 weeks, A1C was significantly lower in the intervention group compared to the control group.","[{'ForeName': 'Ernest', 'Initials': 'E', 'LastName': 'Asante', 'Affiliation': 'Department of Nursing, Faculty of Allied Health Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Bam', 'Affiliation': 'Department of Nursing, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.'}, {'ForeName': 'Abigail Kusi-Amponsah', 'Initials': 'AK', 'LastName': 'Diji', 'Affiliation': 'Department of Nursing, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.'}, {'ForeName': 'Alberta Yemotsoo', 'Initials': 'AY', 'LastName': 'Lomotey', 'Affiliation': 'Department of Nursing, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.'}, {'ForeName': 'Agnes', 'Initials': 'A', 'LastName': 'Owusu Boateng', 'Affiliation': 'Directorate of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana.'}, {'ForeName': 'Osei', 'Initials': 'O', 'LastName': 'Sarfo-Kantanka', 'Affiliation': 'Directorate of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana.'}, {'ForeName': 'Eunice', 'Initials': 'E', 'LastName': 'Oparebea Ansah', 'Affiliation': 'Directorate of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Adjei', 'Affiliation': 'Department of Nursing, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.'}]",The Diabetes educator,['10.1177/0145721720954070'] 628,33006068,"Web-based and mixed-mode cognitive large-scale assessments in higher education: An evaluation of selection bias, measurement bias, and prediction bias.","Educational large-scale studies typically adopt highly standardized settings to collect cognitive data on large samples of respondents. Increasing costs alongside dwindling response rates in these studies necessitate exploring alternative assessment strategies such as unsupervised web-based testing. Before respective assessment modes can be implemented on a broad scale, their impact on cognitive measurements needs to be quantified. Therefore, an experimental study on N = 17,473 university students from the German National Educational Panel Study has been conducted. Respondents were randomly assigned to a supervised paper-based, a supervised computerized, and an unsupervised web-based mode to work on a test of scientific literacy. Mode-specific effects on selection bias, measurement bias, and predictive bias were examined. The results showed a higher response rate in web-based testing as compared to the supervised modes, without introducing a pronounced mode-specific selection bias. Analyses of differential test functioning showed systematically larger test scores in paper-based testing, particularly among low to medium ability respondents. Prediction bias for web-based testing was observed for one out of four criteria on study-related success factors. Overall, the results indicate that unsupervised web-based testing is not strictly equivalent to other assessment modes. However, the respective bias introduced by web-based testing was generally small. Thus, unsupervised web-based assessments seem to be a feasible option in cognitive large-scale studies in higher education.",2021,"Analyses of differential test functioning showed systematically larger test scores in paper-based testing, particularly among low to medium ability respondents.","['higher education', 'N = 17,473 university students from the German National Educational Panel Study']",[],['response rate'],"[{'cui': 'C0424933', 'cui_str': 'Higher education'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],[],,0.0242097,"Analyses of differential test functioning showed systematically larger test scores in paper-based testing, particularly among low to medium ability respondents.","[{'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Zinn', 'Affiliation': 'German Institute for Economic Research, Berlin, Germany.'}, {'ForeName': 'Uta', 'Initials': 'U', 'LastName': 'Landrock', 'Affiliation': 'Leibniz Institute for Educational Trajectories, Bamberg, Germany.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Gnambs', 'Affiliation': 'Leibniz Institute for Educational Trajectories, Bamberg, Germany. timo.gnambs@lifbi.de.'}]",Behavior research methods,['10.3758/s13428-020-01480-7'] 629,33004384,Developing a behavioural intervention package to identify and amend incorrect penicillin allergy records in UK general practice and subsequently change antibiotic use.,"OBJECTIVES To develop a behavioural intervention package to support clinicians and patients to amend incorrect penicillin allergy records in general practice. The intervention aimed to: (1) support clinicians to refer patients for penicillin allergy testing (PAT), (2) support patients to attend for PAT and (3) support clinicians and patients to prescribe or consume penicillin, when indicated, following a negative PAT result. METHODS Theory-based, evidence-based and person-based approaches were used in the intervention development. We used evidence from a rapid review, two qualitative studies, and expert consultations with the clinical research team to identify the intervention 'guiding principles' and develop an intervention plan. Barriers and facilitators to the target behaviours were mapped to behaviour change theory in order to describe the proposed mechanisms of change. In the final stage, think-aloud interviews were conducted to optimise intervention materials. RESULTS The collated evidence showed that the key barriers to referral of patients by clinicians were limited experience of referral and limited knowledge of referral criteria and PAT. Barriers for patients attending PAT were lack of knowledge of the benefits of testing and lack of motivation to get tested. The key barriers to the prescription and consumption of first-line penicillin following a negative test result were patient and clinician beliefs about the accuracy of PAT and whether taking penicillin was safe. Intervention materials were designed and developed to address these barriers. CONCLUSIONS We present a novel behavioural intervention package designed to address the multiple barriers to uptake of PAT in general practice by clinicians and patients. The intervention development details how behaviour change techniques have been incorporated to hypothesise how the intervention is likely to work to help amend incorrect penicillin allergy records. The intervention will go on to be tested in a feasibility trial and randomised controlled trial in England.",2020,Barriers and facilitators to the target behaviours were mapped to behaviour change theory in order to describe the proposed mechanisms of change.,"['patients attending PAT', 'support clinicians and patients to amend incorrect penicillin allergy records in general practice']","['penicillin allergy testing (PAT), (2) support patients to attend for PAT and (3) support clinicians and patients to prescribe or consume penicillin', 'behavioural intervention package']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0030824', 'cui_str': 'Allergy to penicillin'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}]","[{'cui': 'C0030824', 'cui_str': 'Allergy to penicillin'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0030842', 'cui_str': 'Penicillin'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}]",[],,0.0327525,Barriers and facilitators to the target behaviours were mapped to behaviour change theory in order to describe the proposed mechanisms of change.,"[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Santillo', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK marta.santillo@phc.ox.ac.uk.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Wanat', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Davoudianfar', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Bongard', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK.'}, {'ForeName': 'Sinisa', 'Initials': 'S', 'LastName': 'Savic', 'Affiliation': 'Faculty of Medicine and Health, University of Leeds, Leeds, Leeds, UK.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Savic', 'Affiliation': 'Faculty of Medicine and Health, University of Leeds, Leeds, Leeds, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Porter', 'Affiliation': 'Healthcare Associated Infection Group, University of Leeds, Leeds, West Yorkshire, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Fielding', 'Affiliation': 'Healthcare Associated Infection Group, University of Leeds, Leeds, West Yorkshire, UK.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Butler', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Pavitt', 'Affiliation': 'University of Leeds, Leeds, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Sandoe', 'Affiliation': 'Healthcare Associated Infection Group, University of Leeds, Leeds, West Yorkshire, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Tonkin-Crine', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-035793'] 630,33006057,Effects of N-Pep-12 dietary supplementation on neurorecovery after ischemic stroke.,"BACKGROUND The aim of the study was to evaluate the effects of N-Pep-12 dietary supplementation on neurorecovery of middle-aged and older adults with cognitive impairment after ischemic stroke, using neuropsychological outcome scales. METHODS This was a pilot randomized-controlled, phase IV, academic clinical trial that aimed to assess the effect and the safety of a single daily dose of oral 90 mg of N-Pep-12 for 90 days in supporting neurorecovery, as compared with a control group, performed on middle-aged and older adults after supratentorial ischemic stroke. RESULTS Study group differences in baseline changes at day 90 for Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS) - Anxiety subscale, Color Trails 1 and Symbol Search (number incorrect) were statistically significant (Mann-Whitney U test). For MoCA at day 90, a borderline 'intermediate effect' in favour of N-PEP-12 was observed (d Cohen = 0.491, η 2 = 0.057, OR = 2.436, p = 0.010). HADS Anxiety and Color Trails 1 at day 90 registered a 'small-to-intermediate' effect in favour of N-PEP-12 (d Cohen = 0.424, η 2 = 0.043, OR = 2.157, p = 0.026; d Cohen = 0.481, η 2 = 0.055, OR = 2.3927, p = 0.013, respectively). For symbol search errors, an 'intermediate' effect in favour of the control group was observed (d Cohen = 0.501, η 2 = 0.059, OR = 2.4811, p = 0.007). CONCLUSION This exploratory clinical trial indicates a signal for the benefit of dietary supplementation with N-Pep-12 for the enhancement of neurorecovery after supratentorial ischemic stroke.",2021,"Anxiety subscale, Color Trails 1 and Symbol Search (number incorrect) were statistically significant (Mann-Whitney U test).","['neurorecovery after ischemic stroke', 'neurorecovery of middle-aged and older adults with cognitive impairment after ischemic stroke', 'middle-aged and older adults after supratentorial ischemic stroke']","['oral 90 mg of N-Pep-12', 'dietary supplementation with N-Pep-12', 'N-Pep-12 dietary supplementation']","['HADS Anxiety and Color Trails', 'Anxiety subscale, Color Trails 1 and Symbol Search (number incorrect', 'Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS) ']","[{'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0441938', 'cui_str': 'Supratentorial'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1570845', 'cui_str': 'N-PEP-12'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}]",,0.0691924,"Anxiety subscale, Color Trails 1 and Symbol Search (number incorrect) were statistically significant (Mann-Whitney U test).","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Balea', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Codruta', 'Initials': 'C', 'LastName': 'Birle', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Cezara', 'Initials': 'C', 'LastName': 'Costin', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Marton', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Ioana Anamaria', 'Initials': 'IA', 'LastName': 'Muresanu', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Nicoleta', 'Initials': 'N', 'LastName': 'Jemna', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Livia Livint', 'Initials': 'LL', 'LastName': 'Popa', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Slavoaca', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Olivia Verisezan', 'Initials': 'OV', 'LastName': 'Rosu', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Adina', 'Initials': 'A', 'LastName': 'Stan', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Vitalie', 'Initials': 'V', 'LastName': 'Vacaras', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Strilciuc', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania.'}, {'ForeName': 'Dafin F', 'Initials': 'DF', 'LastName': 'Muresanu', 'Affiliation': 'RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 4004878, Cluj-Napoca, Romania. dafinm@ssnn.ro.'}]",Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,['10.1007/s10072-020-04707-9'] 631,33009489,Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.,"BACKGROUND Precision medicine approaches for managing patients with metastatic castrate-resistant prostate cancer (mCRPC) are lacking. Non-invasive approaches for molecular monitoring of disease are urgently needed, especially for patients suffering from bone metastases for whom tissue biopsy is challenging. Here we utilized baseline blood samples to identify mCRPC patients most likely to benefit from abiraterone plus prednisone (AAP) or enzalutamide. METHODS Baseline blood samples were collected for circulating tumor cell (CTC) enumeration and qPCR-based gene expression analysis from 51 men with mCRPC beginning treatment with abiraterone or enzalutamide. RESULTS Of 51 patients (median age 68 years [51-82]), 22 received AAP (abiraterone 1000 mg/day plus prednisone 10 mg/day) and 29 received enzalutamide (160 mg/day). The cohort was randomly divided into training (n = 37) and test (n = 14) sets. Baseline clinical variables (Gleason score, PSA, testosterone, and hemoglobin), CTC count, and qPCR-based gene expression data for 141 genes/isoforms in CTC-enriched blood were analyzed with respect to overall survival (OS). Genes with expression most associated with OS included MSLN, ARG2, FGF8, KLK3, ESRP2, NPR3, CCND1, and WNT5A. Using a Cox-elastic net model for our test set, the 8-gene expression signature had a c-index of 0.87 (95% CI [0.80, 0.94]) and was more strongly associated with OS than clinical variables or CTC count alone, or a combination of the three variables. For patients with a low-risk vs. high-risk gene expression signature, median OS was not reached vs. 18 months, respectively (HR 5.32 [1.91-14.80], p = 0.001). For the subset of 41 patients for whom progression-free survival (PFS) data was available, the median PFS for patients with a low-risk vs high-risk gene expression signature was 20 vs. 5 months, respectively (HR 2.95 [1.46-5.98], p = 0.003). CONCLUSIONS If validated in a larger prospective study, this test may predict patients most likely to benefit from second-generation antiandrogen therapy.",2021,"Genes with expression most associated with OS included MSLN, ARG2, FGF8, KLK3, ESRP2, NPR3, CCND1, and WNT5A. Using a Cox-elastic net model for our test set, the 8-gene expression signature had a c-index of 0.87 (95% CI [0.80, 0.94]) and was more strongly associated with OS than clinical variables or CTC count alone, or a combination of the three variables.","['51 patients (median age 68\u2009years [51-82', 'managing patients with metastatic castrate-resistant prostate cancer (mCRPC', '51 men with mCRPC beginning treatment with']","['abiraterone plus prednisone or enzalutamide', 'abiraterone plus prednisone (AAP) or enzalutamide', 'abiraterone or enzalutamide', 'AAP (abiraterone 1000\u2009mg/day plus prednisone', 'enzalutamide']","['MSLN, ARG2, FGF8, KLK3, ESRP2, NPR3, CCND1, and WNT5A. Using a Cox-elastic net model', 'overall survival (OS', 'progression-free survival (PFS) data', 'circulating tumor cell (CTC) enumeration and qPCR-based gene expression analysis', 'median OS', 'Baseline clinical variables (Gleason score, PSA, testosterone, and hemoglobin), CTC count, and qPCR-based gene expression data for 141 genes/isoforms in CTC-enriched blood']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C1328504', 'cui_str': 'Hormone refractory prostate cancer'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0754011', 'cui_str': 'abiraterone'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}]","[{'cui': 'C0380162', 'cui_str': 'mesothelin'}, {'cui': 'C1527809', 'cui_str': 'FGF8 protein, human'}, {'cui': 'C2934380', 'cui_str': 'kallikrein-related peptidase 3, human'}, {'cui': 'C1741716', 'cui_str': 'CCND1 protein, human'}, {'cui': 'C0250963', 'cui_str': 'WNT5A protein, human'}, {'cui': 'C0033551', 'cui_str': 'Prostaglandin synthase'}, {'cui': 'C0221839', 'cui_str': 'Orthodontic band, elastic'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027625', 'cui_str': 'Circulating Neoplastic Cells'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0332326', 'cui_str': 'Gleason grading system for prostatic cancer'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0597298', 'cui_str': 'Isoforms'}, {'cui': 'C0005767', 'cui_str': 'Blood'}]",51.0,0.0774655,"Genes with expression most associated with OS included MSLN, ARG2, FGF8, KLK3, ESRP2, NPR3, CCND1, and WNT5A. Using a Cox-elastic net model for our test set, the 8-gene expression signature had a c-index of 0.87 (95% CI [0.80, 0.94]) and was more strongly associated with OS than clinical variables or CTC count alone, or a combination of the three variables.","[{'ForeName': 'Naomi B', 'Initials': 'NB', 'LastName': 'Haas', 'Affiliation': 'Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'LaRiviere', 'Affiliation': 'Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Buckingham', 'Affiliation': 'Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Yauheniya', 'Initials': 'Y', 'LastName': 'Cherkas', 'Affiliation': 'Janssen, Pharmaceutical Companies of Johnson and Johnson, Spring House, PA, USA.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Calara-Nielsen', 'Affiliation': 'Janssen, Pharmaceutical Companies of Johnson and Johnson, Spring House, PA, USA.'}, {'ForeName': 'Brad', 'Initials': 'B', 'LastName': 'Foulk', 'Affiliation': 'Janssen, Pharmaceutical Companies of Johnson and Johnson, Spring House, PA, USA.'}, {'ForeName': 'Jaymala', 'Initials': 'J', 'LastName': 'Patel', 'Affiliation': 'Janssen, Pharmaceutical Companies of Johnson and Johnson, Spring House, PA, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Gross', 'Affiliation': 'Janssen, Pharmaceutical Companies of Johnson and Johnson, Spring House, PA, USA.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Smirnov', 'Affiliation': 'Janssen, Pharmaceutical Companies of Johnson and Johnson, Spring House, PA, USA.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Vaughn', 'Affiliation': 'Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Amaravadi', 'Affiliation': 'Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Kathryn E', 'Initials': 'KE', 'LastName': 'Wellen', 'Affiliation': 'Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Samantha L', 'Initials': 'SL', 'LastName': 'Savitch', 'Affiliation': 'Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Krishna J', 'Initials': 'KJ', 'LastName': 'Majmundar', 'Affiliation': 'Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Taylor A', 'Initials': 'TA', 'LastName': 'Black', 'Affiliation': 'Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': 'Yee', 'Affiliation': 'Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Miaoling', 'Initials': 'M', 'LastName': 'He', 'Affiliation': 'Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.'}, {'ForeName': 'Eun Jeong', 'Initials': 'EJ', 'LastName': 'Min', 'Affiliation': 'Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Long', 'Affiliation': 'Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Jeremy O', 'Initials': 'JO', 'LastName': 'Jones', 'Affiliation': 'Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.'}, {'ForeName': 'Sumanta K', 'Initials': 'SK', 'LastName': 'Pal', 'Affiliation': 'Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.'}, {'ForeName': 'Erica L', 'Initials': 'EL', 'LastName': 'Carpenter', 'Affiliation': 'Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. erical@upenn.edu.'}]",Prostate cancer and prostatic diseases,['10.1038/s41391-020-00295-z'] 632,33011805,"A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin.",,2021,,[],"['Against Human Rabies Immunoglobulin (HRIG', 'Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM']",[],[],"[{'cui': 'C1321098', 'cui_str': 'Human rabies'}, {'cui': 'C0021027', 'cui_str': 'Immunoglobulin'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}, {'cui': 'C0678420', 'cui_str': 'Cocktail'}]",[],,0.0405053,,"[{'ForeName': 'Anurag', 'Initials': 'A', 'LastName': 'Agarwal', 'Affiliation': 'Maulana Azad Medical College, New Delhi, India.'}, {'ForeName': 'Nandha', 'Initials': 'N', 'LastName': 'Kumar', 'Affiliation': 'Maulana Azad Medical College, New Delhi, India.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1506'] 633,33010323,"Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study.","BACKGROUND No long-term maintenance therapy has been tested in patients with seborrheic dermatitis (SD). OBJECTIVE We sought to compare the efficacy and tolerance of tacrolimus 0.1% ointment versus ciclopiroxolamine 1% cream as maintenance therapy for severe SD. METHODS This double-blind randomized controlled study was conducted from 2014 to 2017 in 5 Dermatology Departments and 15 dermatology practices in France. Consecutive patients with severe and chronic facial SD were included. Patients were initially treated with desonide 0.05% cream twice daily for 7 days. Patients cleared after this open phase were randomized to receive tacrolimus 0.1% or ciclopiroxolamine 1% cream 2 times a week 24 weeks. The primary endpoint was disease-free-duration, defined as the time from randomization to first relapse. RESULTS One hundred fourteen patients were randomized (tacrolimus, n = 57; ciclopiroxolamine, n = 57). Twelve patients relapsed in the tacrolimus group after a median delay of 91.5 days (range 15-195 days) versus 23 patients in the ciclopiroxolamine group (median delay, 27 days [range 13-201 days]). Comparison of disease-free duration curves showed that patients in the tacrolimus group had a longer duration of complete remission than those in the ciclopiroxolamine group (P = .018), corresponding to a hazard ratio of relapse of 0.44 (95% confidence interval 0.22-0.89; P = .022). LIMITATIONS The theoretical sample size was not reached. CONCLUSION Tacrolimus 0.1% is more effective than ciclopiroxolamine 1% as maintenance therapy for patients with facial SD.",2021,Tacrolimus 0.1% ointment applied twice a week after 7 days of topical corticosteroids is more effective than ciclopiroxolamine 1% as maintenance therapy in patients with severe facial seborrheic dermatitis.,['patients with severe facial seborrheic dermatitis'],"['Tacrolimus', 'ciclopiroxolamine']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1275433', 'cui_str': 'Facial seborrheic dermatitis'}]","[{'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0126169', 'cui_str': 'Ciclopirox olamine'}]",[],,0.214147,Tacrolimus 0.1% ointment applied twice a week after 7 days of topical corticosteroids is more effective than ciclopiroxolamine 1% as maintenance therapy in patients with severe facial seborrheic dermatitis.,"[{'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Joly', 'Affiliation': 'Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France. Electronic address: Pascal.Joly@chu-rouen.fr.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Tejedor', 'Affiliation': 'Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Tetart', 'Affiliation': 'Department of Allergology, Erik Satie Center, Rouen University Hospital, Rouen, France.'}, {'ForeName': 'Hélène Collas', 'Initials': 'HC', 'LastName': 'Cailleux', 'Affiliation': 'private practice in Le Mesnil-Esnard, France.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Barrel', 'Affiliation': 'private practice in the St-Antoine Private Clinic, Rouen, France.'}, {'ForeName': 'Paul Arnaud', 'Initials': 'PA', 'LastName': 'De Preville', 'Affiliation': 'private practice in Rouen, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Mion-Mouton', 'Affiliation': 'private practice in Mont-Saint-Aignan, France.'}, {'ForeName': 'Germaine', 'Initials': 'G', 'LastName': 'Gabison', 'Affiliation': 'private practice in Saint-Maurice, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Baricault', 'Affiliation': 'private practice in the St-Antoine Private Clinic, Rouen, France.'}, {'ForeName': 'Catherine Girardin', 'Initials': 'CG', 'LastName': 'Tordeur', 'Affiliation': 'private practice in Bois-Guillaume, France.'}, {'ForeName': 'Martin Xavier', 'Initials': 'MX', 'LastName': 'Dore', 'Affiliation': 'private practice in Le Havre, France.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Rossi', 'Affiliation': 'private practice in Rouen, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Bourseau-Quetier', 'Affiliation': 'private practice in Blanquefort, France.'}, {'ForeName': 'Mélanie', 'Initials': 'M', 'LastName': 'Chamaillard', 'Affiliation': 'private practice in Pessac, France.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Ly', 'Affiliation': 'private practice in Gradignan, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Chosidow', 'Affiliation': 'Department of Dermatology, Henri-Mondor University Hospital, Paris, France.'}, {'ForeName': 'Marie-Aleth', 'Initials': 'MA', 'LastName': 'Richard-Lallemand', 'Affiliation': 'CEReSS-EA 3279, Research Center in Health Services and Quality of Life Aix Marseille University, Dermatology Department, University Hospital Timone, Assistance Publique Hôpitaux de Marseille, Marseille, France.'}, {'ForeName': 'Jean-Claude', 'Initials': 'JC', 'LastName': 'Rzeznik', 'Affiliation': 'private practice in Fécamp, France.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Amici', 'Affiliation': 'private practice in Cenon, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Lair', 'Affiliation': 'private practice in Le Petit-Quevilly, France.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Bechu', 'Affiliation': 'private practice in the Mathilde Private Clinic, Rouen, France.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Benichou', 'Affiliation': 'Department of Biostatistics, Rouen University Hospital and INSERM U1219, Normandie University, Rouen, France.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Thill', 'Affiliation': 'Department of Biostatistics, Rouen University Hospital and INSERM U1219, Normandie University, Rouen, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Beylot-Barry', 'Affiliation': 'Department of Dermatology, INSERM U1053, Bordeaux University Hospital, Bordeaux, France.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.09.055'] 634,33015924,"Polypharmacy, functional outcome and treatment effect of intravenous alteplase for acute ischaemic stroke.","BACKGROUND AND PURPOSE Polypharmacy is an important challenge in clinical practice. Our aim was to determine the effect of polypharmacy on functional outcome and treatment effect of alteplase in acute ischaemic stroke. METHODS This was a post hoc analysis of the randomized, placebo-controlled WAKE-UP trial of magnetic resonance imaging guided intravenous alteplase in unknown onset stroke. Polypharmacy was defined as an intake of five or more medications at baseline. Comorbidities were assessed by the Charlson Comorbidity Index (CCI). The primary efficacy variable was favourable outcome defined by a score of 0-1 on the modified Rankin Scale at 90 days. Logistic regression analysis was used to test for an association of polypharmacy with functional outcome, and for interaction of polypharmacy and the effect of thrombolysis. RESULTS Polypharmacy was present in 133/503 (26%) patients. Patients with polypharmacy were older (mean age 70 vs. 64 years; p < 0.0001) and had a higher score on the National Institutes of Health Stroke Scale at baseline (median 7 vs. 5; p = 0.0007). A comorbidity load defined by a CCI score ≥ 2 was more frequent in patients with polypharmacy (48% vs. 8%; p < 0.001). Polypharmacy was associated with lower odds of favourable outcome (adjusted odds ratio 0.50, 95% confidence interval 0.30-0.85; p = 0.0099), whilst the CCI score was not. Treatment with alteplase was associated with higher odds of favourable outcome in both groups, with no heterogeneity of treatment effect (test for interaction of treatment and polypharmacy, p = 0.29). CONCLUSION In stroke patients, polypharmacy is associated with worse functional outcome after intravenous thrombolysis independent of comorbidities. However, polypharmacy does not interact with the beneficial effect of alteplase.",2021,"Treatment with alteplase was associated with higher odds of favorable outcome in both groups, with no heterogeneity of treatment effect (test for interaction of treatment and polypharmacy, P=0.29). ",['acute ischemic stroke'],"['polypharmacy', 'MRI-guided intravenous alteplase', 'placebo', 'alteplase', 'intravenous alteplase']","['CCI score', 'National Institutes of Health Stroke Scale', 'Charlson Comorbidity Index (CCI', 'score of 0-1 on the modified Rankin Scale']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}]","[{'cui': 'C2922974', 'cui_str': 'Polypharmacy'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C4546361', 'cui_str': 'Charlson Comorbidity Index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}]",,0.0952879,"Treatment with alteplase was associated with higher odds of favorable outcome in both groups, with no heterogeneity of treatment effect (test for interaction of treatment and polypharmacy, P=0.29). ","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Jensen', 'Affiliation': 'Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Boutitie', 'Affiliation': 'Service de Biostatistique, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Cheng', 'Affiliation': 'Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'T-H', 'Initials': 'TH', 'LastName': 'Cho', 'Affiliation': 'Department of Stroke Medicine, CREATIS CNRS UMR 5220-INSERM U1206, INSA-Lyon, Université Claude Bernard Lyon 1, Lyon, France.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ebinger', 'Affiliation': 'Centrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Endres', 'Affiliation': 'Centrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.'}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Fiebach', 'Affiliation': 'Centrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Fiehler', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Ford', 'Affiliation': 'Robertson Centre for Biostatistics, University of Glasgow, University Avenue, Glasgow, UK.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Galinovic', 'Affiliation': 'Centrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Königsberg', 'Affiliation': 'Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Puig', 'Affiliation': ""Department of Radiology, Institut de Diagnostic per la Image (IDI), Institut d'Investigació Biomèdica de Girona (IDIBGI), Hospital Dr Josep Trueta, Parc Hospitalari Martí i Julià de Salt - Edifici M2, Girona, Spain.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Roy', 'Affiliation': 'Service de Biostatistique, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Wouters', 'Affiliation': 'Department of Neurology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Thijs', 'Affiliation': 'Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Vic., Australia.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Lemmens', 'Affiliation': 'Department of Neurology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'K W', 'Initials': 'KW', 'LastName': 'Muir', 'Affiliation': 'Institute of Neuroscience and Psychology, University of Glasgow, University Avenue, Glasgow, UK.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Nighoghossian', 'Affiliation': 'Department of Stroke Medicine, CREATIS CNRS UMR 5220-INSERM U1206, INSA-Lyon, Université Claude Bernard Lyon 1, Lyon, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Pedraza', 'Affiliation': ""Department of Radiology, Institut de Diagnostic per la Image (IDI), Institut d'Investigació Biomèdica de Girona (IDIBGI), Hospital Dr Josep Trueta, Parc Hospitalari Martí i Julià de Salt - Edifici M2, Girona, Spain.""}, {'ForeName': 'C Z', 'Initials': 'CZ', 'LastName': 'Simonsen', 'Affiliation': 'Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Gerloff', 'Affiliation': 'Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Thomalla', 'Affiliation': 'Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}]",European journal of neurology,['10.1111/ene.14566'] 635,33028585,Infographic. Does foot mobility affect the outcome in the management of patellofemoral pain with foot orthoses versus hip exercises? A randomised clinical trial.,,2021,,[],[],[],[],[],[],,0.116639,,"[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Matthews', 'Affiliation': 'School of Sport, Ulster University, Belfast, UK.'}, {'ForeName': 'Michael Skovdal', 'Initials': 'MS', 'LastName': 'Rathleff', 'Affiliation': 'Department of Occupational Therapy and Physiotherapy, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Andrew Philip', 'Initials': 'AP', 'LastName': 'Claus', 'Affiliation': 'School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'McPoil', 'Affiliation': 'School of Physical Therapy, Regis University, Denver, Colorado, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Nee', 'Affiliation': 'School of Physical Therapy, Pacific University, Hillsboro, Oregon, USA.'}, {'ForeName': 'Kay M', 'Initials': 'KM', 'LastName': 'Crossley', 'Affiliation': 'La Trobe University-Bundoora Campus, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Kasza', 'Affiliation': 'Clinical Epidemiology at Cabrini, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Bill T', 'Initials': 'BT', 'LastName': 'Vicenzino', 'Affiliation': 'School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, Australia b.vicenzino@uq.edu.au.'}]",British journal of sports medicine,['10.1136/bjsports-2020-103081'] 636,33020088,AGT-Reha-WK study: protocol for a non-inferiority trial comparing the efficacy and costs of home-based telerehabilitation for shoulder diseases with medical exercise therapy.,"INTRODUCTION Shoulder lesions rank among the top 15 diagnoses accounting for days of incapacity to work. Inpatient or full-day outpatient rehabilitation are some of the standard therapies. For sustainable rehabilitation, continuation of rehabilitation after discharge from a rehabilitation centre is vital. Besides medical exercise therapy (MET), home-based physical exercise programmes are used. To monitor exercise quantity and quality, AGT-Reha, a health-enabling technology for home rehabilitation, has been developed and evaluated in a pilot study for technical feasibility and acceptance. To integrate the digital therapeutic AGT-Reha into regular healthcare processes, an efficacy evaluation is required. METHODS AND ANALYSIS AGT-Reha-WK is a prospective, monocentric, non-randomised, unblinded non-inferiority trial. Primary objective is to investigate whether AGT-Reha enhanced home-based exercise training is non-inferior to MET as standard aftercare. Secondary objective is to compare the costs of both therapies. Efficacy as medical success (primary outcome) is examined with regard to ability to work, return to work and sustainability of training (secondary outcomes). The outcome measure for non-inferiority is shoulder function (pain and disability) assessed by the standardised Shoulder Pain and Disability Index (SPADI). The non-inferiority margin is set to 10 points on SPADI score using a 95% CI. Subjects will be recruited at the Rehabilitation Center Bad Pyrmont, Germany. The total number of subjects should be 84 (42 per group). Treatment takes 6 months per patient. Subjects will be assessed at four time points: pre-baseline (admission to rehabilitation centre), baseline (discharge from rehabilitation centre), post-therapy and follow-up (3 months post-therapy). ETHICS AND DISSEMINATION Ethics approval was granted by the Ethics Committee of Hannover Medical School (ethics approval no: 7313). Results of the trial are planned to be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER German Clinical Trials Register DRKS00011596. Registered 2 June 2017. Recruitment started on 3 March 2017, and it is expected to continue until December 2020. PROTOCOL VERSION V2.0, 23 May 2018, Amendment 01: improved risk analysis, clarification of exclusion criteria to increase reproducibility, additional documentation with OpenClinica; these changes have no effect on structural equality.",2020,these changes have no effect on structural equality.,"['Subjects will be recruited at the Rehabilitation Center Bad Pyrmont, Germany', 'VERSION\n\n\nV2.0, 23 May 2018, Amendment 01']","['medical exercise therapy', 'AGT-Reha enhanced home-based exercise training', 'medical exercise therapy (MET), home-based physical exercise programmes', 'home-based telerehabilitation']","['ability to work, return to work and sustainability of training (secondary outcomes', 'standardised Shoulder Pain and Disability Index (SPADI', 'improved risk analysis, clarification of exclusion criteria to increase reproducibility, additional documentation with OpenClinica', 'non-inferiority is shoulder function (pain and disability']","[{'cui': 'C0034993', 'cui_str': 'Centers, Rehabilitation'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C2607870', 'cui_str': 'Version'}]","[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0002555', 'cui_str': 'Aminoglutethimide'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4042802', 'cui_str': 'Remote Rehabilitation'}]","[{'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0425105', 'cui_str': 'Returned to work'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0175636', 'cui_str': 'Documentation procedure'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.101456,these changes have no effect on structural equality.,"[{'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Steiner', 'Affiliation': 'Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Technische Universität Braunschweig, Braunschweig, Germany bianca.steiner@plri.de.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Elgert', 'Affiliation': 'Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Reinhold', 'Initials': 'R', 'LastName': 'Haux', 'Affiliation': 'Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Technische Universität Braunschweig, Braunschweig, Germany.'}, {'ForeName': 'Klaus-Hendrik', 'Initials': 'KH', 'LastName': 'Wolf', 'Affiliation': 'Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Hannover, Germany.'}]",BMJ open,['10.1136/bmjopen-2020-036881'] 637,33020099,Impact of COPD case finding on clinical care: a prospective analysis of the TargetCOPD trial.,"OBJECTIVES To investigate the impact of chronic obstructive pulmonary disease (COPD) case finding on clinical care. DESIGN We conducted a prospective observational analysis of data from a pragmatic cluster randomised controlled trial in primary care in the West Midlands, UK (TargetCOPD). This compared alternative methods of COPD case finding against usual care. Data were extracted from electronic healthcare records and self-reported questionnaires for a subset of patients with newly diagnosed COPD. SETTING 50 general practices that participated in the TargetCOPD trial. PARTICIPANTS Patients aged 40-79 years newly identified with COPD by targeted case finding or by usual care, from 10 August 2012 to 22 June 2014. PRIMARY AND SECONDARY OUTCOME MEASURES The primary outcome was addition to a COPD register by the end of the trial. The secondary outcome was a clinical care score, derived from the sum of clinical assessments and relevant interventions. Associations between participant characteristics and the primary and secondary outcomes were assessed using multilevel regression. RESULTS 857 patients identified with COPD by case finding and 764 by usual care were included. Only 21.2% of case-found patients had been added to a COPD register, compared with 92.7% of those diagnosed by usual care. The odds of being added were greater in smokers (adjusted OR 8.68, 95% CI 2.53 to 29.8), and in those with lower percentage of predicted forced expiratory volume in 1 s (adjusted OR 0.96 per percentage rise, 95% CI 0.95 to 0.98). Patients who had been added to a COPD register had a significantly higher clinical care score (mean difference 5.06, 95% CI 4.36 to 5.75). CONCLUSIONS Only one in five case-found patients had been registered with COPD. Patients added to a COPD register received significantly higher levels of appropriate clinical care. TRIAL REGISTRATION NUMBER ISRCTN14930255; Post-results.",2020,"The odds of being added were greater in smokers (adjusted OR 8.68, 95% CI 2.53 to 29.8), and in those with lower percentage of predicted forced expiratory volume in 1 s (adjusted OR 0.96 per percentage rise, 95% CI 0.95 to 0.98).","['Patients aged 40-79 years newly identified with COPD by targeted case finding or by usual care, from 10 August 2012 to 22 June 2014', 'primary care in the West Midlands, UK (TargetCOPD', '50 general practices that participated in the TargetCOPD trial', '857 patients identified with COPD by case finding and 764 by usual care were included']",[],"['levels of appropriate clinical care', 'forced expiratory volume', 'clinical care score, derived from the sum of clinical assessments and relevant interventions', 'clinical care score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0454882', 'cui_str': 'West Midlands'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",[],"[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",,0.303908,"The odds of being added were greater in smokers (adjusted OR 8.68, 95% CI 2.53 to 29.8), and in those with lower percentage of predicted forced expiratory volume in 1 s (adjusted OR 0.96 per percentage rise, 95% CI 0.95 to 0.98).","[{'ForeName': 'Shamil', 'Initials': 'S', 'LastName': 'Haroon', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK s.haroon@bham.ac.uk.'}, {'ForeName': 'Peymane', 'Initials': 'P', 'LastName': 'Adab', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Dickens', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Alice J', 'Initials': 'AJ', 'LastName': 'Sitch', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Kiran', 'Initials': 'K', 'LastName': 'Rai', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Enocson', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Fitzmaurice', 'Affiliation': 'Warwick Medical School - Health Sciences, University of Warwick, Coventry, UK.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Jordan', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}]",BMJ open,['10.1136/bmjopen-2020-038286'] 638,33025690,Does Intravenous Acetaminophen Reduce Opioid Requirement in Pediatric Emergency Department Patients With Acute Sickle Cell Crises?,"OBJECTIVE We evaluated the ability of intravenous (IV) acetaminophen to reduce the amount of opioid medication administered in pediatric patients with sickle cell disease (SCD) having vasoocclusive crisis (VOC) in an emergency department (ED) setting. METHODS This was a prospective, randomized, double-blind placebo-controlled trial at an academic urban pediatric ED. Participants included patients with SCD, aged 4 to 16 years, with VOC pain. All patients received a 0.1 mg/kg dose of IV morphine, 0.5 mg/kg ketorolac, or both. Patients were randomized to receive either 15 mg/kg IV acetaminophen or placebo. Patients were reassessed every 30 minutes to see whether additional opioid doses were indicated to a maximum of three doses. The total morphine given, pain scores, rates of admissions, 72-hour return visits, and adverse events were assessed for each group. RESULTS Of 71 subjects randomized, 35 patients in the acetaminophen group and 36 patients in the control group were analyzed. Baseline characteristics and initial pain scores were similar in both groups. The mean total amount of morphine given was 8.6 mg (95% confidence interval [CI] = 6.5 to 10.8) in the acetaminophen group and 8.0 mg (95% CI = 5.9 to 10.2) in the placebo group. The mean total cumulative morphine dosing was 0.2 mg/kg (95% CI = 0.1 to 0.2 mg/kg) in the acetaminophen group and 0.2 mg/kg (95% CI = 0.1 to 0.2 mg/kg) in the control group. The mean pain score at time of disposition was 5.5 (95% CI = 4.3 to 6.6) in the acetaminophen group and 5.2 (95% CI = 4.2 to 6.3) in the placebo group. There were no clinical or statistically significant differences between the rates of admission, 72-hour return visits, or adverse events. CONCLUSION In this study, patients who received IV acetaminophen did not receive less morphine than patients in the placebo group. Disposition pain scores for the two groups were also equivalent. We conclude that IV acetaminophen, when used in addition to morphine for pediatric sickle cell VOC pain, does not provide an opioid-sparing effect. Further searches for adjunctive nonaddictive pain medicines are indicated.",2021,"There were no clinical or statistically significant differences between the rates of admission, 72-hour return visits, or adverse events. ","['academic urban pediatric ED', 'pediatric patients with sickle cell disease (SCD) having vaso-occlusive crisis (VOC) in an emergency department (ED) setting', '71 subjects randomized, 35 patients in the', 'Pediatric Emergency Department Patients with Acute Sickle Cell Crises', 'pediatric sickle cell VOC pain', 'Participants included patients with SCD, aged 4-16 years, with VOC pain']","['acetaminophen', 'Acetaminophen', 'acetaminophen or placebo', 'placebo', 'intravenous (IV) acetaminophen', 'morphine', 'IV morphine, 0.5 mg/kg ketorolac']","['Baseline characteristics and initial pain scores', 'rates of admission, 72-hour return visits, or adverse events', 'mean total cumulative morphine', 'mean total amount morphine', 'total morphine given, pain scores, rates of admissions, 72-hour return visits, and adverse events', 'mean pain score at time of disposition', 'Disposition pain scores']","[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C1947917', 'cui_str': 'Occluded'}, {'cui': 'C0231224', 'cui_str': 'Crisis'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0238425', 'cui_str': 'Hemoglobin SS disease with crisis'}, {'cui': 'C0221283', 'cui_str': 'Drepanocyte'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0184758', 'cui_str': 'Patient disposition'}]",71.0,0.589693,"There were no clinical or statistically significant differences between the rates of admission, 72-hour return visits, or adverse events. ","[{'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Dhebaria', 'Affiliation': ""From the, Pediatric Emergency Department, Children's Hospital of New Jersey at Newark Beth Israel Medical Center, Newark, NJ, USA.""}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Sivitz', 'Affiliation': ""From the, Pediatric Emergency Department, Children's Hospital of New Jersey at Newark Beth Israel Medical Center, Newark, NJ, USA.""}, {'ForeName': 'Cena', 'Initials': 'C', 'LastName': 'Tejani', 'Affiliation': ""From the, Pediatric Emergency Department, Children's Hospital of New Jersey at Newark Beth Israel Medical Center, Newark, NJ, USA.""}]",Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,['10.1111/acem.14149'] 639,32951512,Acute psychosocial stress increases third-party helping but not punishing behavior.,"Despite extensive research on the effects of stress on the brain and behaviors, there is a debate whether stress promotes prosocial behaviors, especially acute stress due to intricate costly punishment in the ultimatum game. Therefore, the present study introduced an irrelevant third party to examine how acute stress and the triggered cortisol influence third parties' punishing and helping behaviors as more convincing altruistic behaviors. The 65 participants were exposed to a psychosocial stressor ( n  = 33) or a control condition ( n  = 32). Afterwards, two third-party intervention tasks (a token allocation task and criminal scenario judgment task) were completed, during which the participants, as an ""irrelevant"" third party, could choose whether to sacrifice their own interests to help the victim or punish the transgressor. Participants' affective states, heart rate, and salivary cortisol were repeatedly measured throughout the experiment. Results showed that acute stress can lead to more third-party helping behaviors but not more punishing behaviors. Specifically, participants under stress tended to transfer more monetary units to the victim in the token allocation task than the control-group participants, and they tended to help the victim in the scenario task. In contrast, there was no significant difference in punishing behavior between the stressed and control participants. These findings reveal that acute psychosocial stress triggers the ""tend and befriend"" response, which might reflect the prosocial intuition under acute stress.",2021,"In contrast, there was no significant difference in punishing behavior between the stressed and control participants.",['65 participants were exposed to a'],['psychosocial stressor ( n \u2009=\u200933) or a control condition'],"['punishing behavior', 'affective states, heart rate, and salivary cortisol']","[{'cui': 'C0332157', 'cui_str': 'Exposure to'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0458279', 'cui_str': 'Punishing'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}]",65.0,0.0217142,"In contrast, there was no significant difference in punishing behavior between the stressed and control participants.","[{'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Zhen', 'Affiliation': 'Psychological Health Education and Counseling Center, Ocean University of China, Qingdao, China.'}, {'ForeName': 'Huagen', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Ruida', 'Initials': 'R', 'LastName': 'Zhu', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Shen', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Jin', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Shaozheng', 'Initials': 'S', 'LastName': 'Qin', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}]","Stress (Amsterdam, Netherlands)",['10.1080/10253890.2020.1825672'] 640,33019950,"The efficacy of 'high in' warning labels, health star and traffic light front-of-package labelling: an online randomised control trial.","OBJECTIVE To examine the impact of front-of-package (FOP) labels on perceived healthfulness, purchasing intentions and understanding of common FOP systems. DESIGN A parallel, open-label design randomised participants to different FOP labelling conditions: 'high in' warning labels (WL), multiple traffic light labelling (TLL), health star ratings (HSR) (all displayed per serving) or control with no interpretive FOP labelling. Participants completed a brief educational session via a smartphone application and two experimental tasks. In Task 1, participants viewed healthy or unhealthy versions of four products and rated healthiness and purchasing intention on a seven-point Likert-type scale. In Task 2, participants ranked three sets of five products from healthiest to least healthy. SETTING Online commercial panel. PARTICIPANTS Canadian residents ≥ 18 years who were involved in household grocery shopping, owned a smartphone and met minimum screen requirements. RESULTS Data from 1997 participants (n 500/condition) were analysed. Task 1: across most product categories, the TLL and HSR increased perceived healthiness of healthier products. All FOP systems decreased perceived healthiness of less healthy products. Similar, albeit dampened, effects were seen regarding purchasing intentions. Task 2: participants performed best in the HSR, followed by the TLL, WL and control conditions. Lower health literacy was associated with higher perceived healthiness and purchasing intentions and poorer ranking task performance across all conditions. CONCLUSIONS All FOP labelling systems, after a brief educational session, improved task performance across a wide spectrum of foods. This effect differed depending on the nutritional quality of the products and the information communicated on labels.Trial Registration: NCT03290118.",2021,"Lower health literacy was associated with higher perceived healthiness and purchasing intentions and poorer ranking task performance across all conditions. ","['1997 participants (n 500/condition', 'Canadian residents ≥ 18 years who were involved in household grocery shopping, owned a smartphone and met minimum screen requirements']","['front-of-package (FOP) labels', 'brief educational session via a smartphone application and two experimental tasks', ""FOP labelling conditions: 'high in' warning labels (WL), multiple traffic light labelling (TLL), health star ratings (HSR) (all displayed per serving) or control with no interpretive FOP labelling""]","['Lower health literacy', 'healthiness and purchasing intentions and poorer ranking task performance', 'task performance']","[{'cui': 'C0730225', 'cui_str': '1997'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0150768', 'cui_str': 'Shopping'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0442664', 'cui_str': 'Traffic light'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0282064', 'cui_str': 'Stars, Celestial'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}]",,0.171194,"Lower health literacy was associated with higher perceived healthiness and purchasing intentions and poorer ranking task performance across all conditions. ","[{'ForeName': 'Lana', 'Initials': 'L', 'LastName': 'Vanderlee', 'Affiliation': ""Department of Nutritional Sciences and WHO Collaborating Centre on Nutrition Policy for Chronic Disease Prevention, Faculty of Medicine, University of Toronto, Medical Sciences Building, Room 5368m 1 King's College Circle, Toronto, ON, CanadaM5S 1A8.""}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Franco-Arellano', 'Affiliation': ""Department of Nutritional Sciences and WHO Collaborating Centre on Nutrition Policy for Chronic Disease Prevention, Faculty of Medicine, University of Toronto, Medical Sciences Building, Room 5368m 1 King's College Circle, Toronto, ON, CanadaM5S 1A8.""}, {'ForeName': 'Mavra', 'Initials': 'M', 'LastName': 'Ahmed', 'Affiliation': ""Department of Nutritional Sciences and WHO Collaborating Centre on Nutrition Policy for Chronic Disease Prevention, Faculty of Medicine, University of Toronto, Medical Sciences Building, Room 5368m 1 King's College Circle, Toronto, ON, CanadaM5S 1A8.""}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Oh', 'Affiliation': ""Department of Nutritional Sciences and WHO Collaborating Centre on Nutrition Policy for Chronic Disease Prevention, Faculty of Medicine, University of Toronto, Medical Sciences Building, Room 5368m 1 King's College Circle, Toronto, ON, CanadaM5S 1A8.""}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Lou', 'Affiliation': 'Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Mary R', 'Initials': 'MR', 'LastName': ""L'Abbé"", 'Affiliation': ""Department of Nutritional Sciences and WHO Collaborating Centre on Nutrition Policy for Chronic Disease Prevention, Faculty of Medicine, University of Toronto, Medical Sciences Building, Room 5368m 1 King's College Circle, Toronto, ON, CanadaM5S 1A8.""}]",Public health nutrition,['10.1017/S1368980020003213'] 641,33021466,Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial.,"BACKGROUND The RECOURSE trial (Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies) demonstrated an overall survival (OS) benefit of trifluridine/tipiracil (FTD/TPI) vs placebo in refractory metastatic colorectal cancer (mCRC). Given the limited benefit of later line treatments, we developed the Colon Life nomogram to assess the 12-week death probability in the refractory setting. METHODS This post hoc analysis of RECOURSE included patients with available data to calculate the nomogram score: Eastern Cooperative Oncology Group Performance Status, primary tumor resection, lactate dehydrogenase, and peritoneal metastases. The nomogram calibration was assessed by calibration plots and C-index. The nomogram prognostic and predictive ability was assessed by Cox model analyses and the nomogram score predictive value was explored according to the cutoff identified at maximum value of the Youden index in time-dependent receiver operating characteristic curve analysis. RESULTS Overall, 251 trial patients were evaluable: 90 in the placebo arm and 161 in the FTD/TPI arm. The calibration was optimal in the placebo arm (C-index 0.807) and suboptimal in the FTD/TPI arm (0.657). The cutoff of the nomogram score of 23 showed the best discriminative ability for 12-week OS (hazard ratio 3.46, 95% confidence interval 2.17-5.51 for scores 40 vs 15) and had maximum value of the Youden index (0.381). Median OS and 3-month PFS were 9.0 vs 7.5 months and 39.3% vs 5.2%, respectively, for FTD/TPI vs placebo in the low-risk group (score <23) and 4.8 vs 3.4 months and 22.3% vs 9.8% in the high-risk group (score ⩾23) (interaction NS). CONCLUSION The Colon Life nomogram is an accurate tool for estimating life expectancy in refractory mCRC. The benefit of FTD/TPI was independent of the predicted risk of early death.",2021,The calibration was optimal in the placebo arm (C-index 0.807) and suboptimal in the FTD/TPI arm (0.657).,"['refractory metastatic colorectal cancer (mCRC', 'patients with refractory metastatic colorectal cancer', '251 trial patients were evaluable: 90 in the placebo arm and 161 in the FTD/TPI arm', 'included patients with available data to calculate the nomogram score: Eastern Cooperative Oncology Group Performance Status, primary tumor resection, lactate dehydrogenase, and peritoneal metastases', 'Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies']","['trifluridine/tipiracil (FTD/TPI) vs placebo', 'TAS-102', 'placebo']",['Median OS and 3-month PFS'],"[{'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0338451', 'cui_str': 'Frontotemporal dementia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C1450294', 'cui_str': 'Nomogram chart'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C4761063', 'cui_str': 'Tumor resection'}, {'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement'}, {'cui': 'C0346989', 'cui_str': 'Secondary malignant neoplasm of peritoneum'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C4055631', 'cui_str': 'Tipiracil- and trifluridine-containing product'}, {'cui': 'C0338451', 'cui_str': 'Frontotemporal dementia'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1451803', 'cui_str': 'TAS-102'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.174029,The calibration was optimal in the placebo arm (C-index 0.807) and suboptimal in the FTD/TPI arm (0.657).,"[{'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Pietrantonio', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Fucà', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Manca', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Pagani', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Raimondi', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Prisciandaro', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Randon', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Corti', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'de Braud', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cremolini', 'Affiliation': 'Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Rosalba', 'Initials': 'R', 'LastName': 'Miceli', 'Affiliation': 'Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}]",Tumori,['10.1177/0300891620960808'] 642,33026515,The effect of preferred music on mental workload and laparoscopic surgical performance in a simulated setting (OPTIMISE): a randomized controlled crossover study.,"BACKGROUND Worldwide, music is commonly played in the operation room. The effect of music on surgical performance reportedly has varying results, while its effect on mental workload and key surgical stressor domains has only sparingly been investigated. Therefore, the aim is to assess the effect of recorded preferred music versus operating room noise on laparoscopic task performance and mental workload in a simulated setting. METHODS A four-sequence, four-period, two-treatment, randomized controlled crossover study design was used. Medical students, novices to laparoscopy, were eligible for inclusion. Participants were randomly allocated to one of four sequences, which decided the exposure order to music and operation room noise during the four periods. Laparoscopic task performance was assessed through motion analysis with a laparoscopic box simulator. Each period consisted of ten alternating peg transfer tasks. To account for the learning curve, a preparation phase was employed. Mental workload was assessed using the Surgery Task Load Index. This study was registered with the Netherlands Trial Register (NL7961). RESULTS From October 29, 2019 until March 12, 2020, 107 participants completed the study, with 97 included for analyzation. Laparoscopic task performance increased significantly during the preparation phase. No significant beneficial effect of music versus operating room noise was observed on time to task completion, path length, speed, or motion smoothness. Music significantly decreased mental workload, reflected by a lower score of the total weighted Surgery Task Load Index in all but one of the six workload dimensions. CONCLUSION Music significantly reduced mental workload overall and of several previously identified key surgical stressor domains, and its use in the operating room is reportedly viewed favorably. Music did not significantly improve laparoscopic task performance of novice laparoscopists in a simulated setting. Although varying results have been reported previously, it seems that surgical experience and task demand are more determinative.",2021,"No significant beneficial effect of music versus operating room noise was observed on time to task completion, path length, speed, or motion smoothness.","['107 participants completed the study, with 97 included for analyzation', 'From October 29, 2019 until March 12, 2020', 'Medical students, novices to laparoscopy, were eligible for inclusion', 'A four-sequence, four-period, two-treatment']","['Music', 'recorded preferred music versus operating room noise']","['laparoscopic task performance and mental workload', 'mental workload and laparoscopic surgical performance', 'total weighted Surgery Task Load Index', 'Laparoscopic task performance', 'mental workload', 'laparoscopic task performance', 'Mental workload', 'time to task completion, path length, speed, or motion smoothness']","[{'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0028263', 'cui_str': 'Noise'}]","[{'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0026597', 'cui_str': 'Motion'}]",,0.271679,"No significant beneficial effect of music versus operating room noise was observed on time to task completion, path length, speed, or motion smoothness.","[{'ForeName': 'Victor X', 'Initials': 'VX', 'LastName': 'Fu', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. v.fu@erasmusmc.nl.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Oomens', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.'}, {'ForeName': 'Vincent E E', 'Initials': 'VEE', 'LastName': 'Kleinrensink', 'Affiliation': 'Department of Neuroscience, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.'}, {'ForeName': 'Karel J', 'Initials': 'KJ', 'LastName': 'Sleurink', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.'}, {'ForeName': 'Willemijn M', 'Initials': 'WM', 'LastName': 'Borst', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.'}, {'ForeName': 'Pascale E', 'Initials': 'PE', 'LastName': 'Wessels', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.'}, {'ForeName': 'Johan F', 'Initials': 'JF', 'LastName': 'Lange', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.'}, {'ForeName': 'Gert-Jan', 'Initials': 'GJ', 'LastName': 'Kleinrensink', 'Affiliation': 'Department of Neuroscience, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Jeekel', 'Affiliation': 'Department of Neuroscience, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.'}]",Surgical endoscopy,['10.1007/s00464-020-07987-6'] 643,33030703,Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers.,"BACKGROUND Vericiguat, a direct stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for symptomatic chronic heart failure (HF) and ejection fraction < 45%. METHODS Safety, pharmacodynamic (PD), and pharmacokinetic (PK) interactions between vericiguat and drugs used in HF (sacubitril/valsartan [SV] and aspirin [acetylsalicylic acid]) or with a narrow therapeutic index (warfarin) were evaluated in three phase I studies. RESULTS Vericiguat 15 mg (single dose [SD]) had no effect on bleeding time or platelet aggregation when coadministered with aspirin 1000 mg versus aspirin alone: estimated differences in least squares means 2.7% (95% confidence interval [CI] - 90.4 to 95.8) and 2.4% (95% CI - 7.0 to 11.8) turbidimetry, respectively. Vericiguat 10 mg (once daily) had no effect on coagulation inhibition elicited by warfarin 25 mg (SD; mean ratios of area under the concentration-time curve from time zero to 96 h for clotting parameter treatment comparisons approximated 100.0%). There were no clinically relevant PD changes whether SV 97/103 mg was administered with single or multiple doses of vericiguat 2.5 mg or placebo (differences in systolic blood pressure [BP] - 1.66 mmHg [90% CI - 4.22 to 0.90]; diastolic BP - 1.80 mmHg [90% CI - 3.24 to - 0.36]; heart rate - 0.33 beats/min [90% CI - 2.25 to 1.60]). Vericiguat demonstrated no PK interactions when coadministered with aspirin, warfarin, or SV at steady state. Treatments were well tolerated. CONCLUSIONS Coadministration of vericiguat with SV, aspirin, or warfarin was well tolerated. No clinically relevant PD or PK interactions were observed, supporting concomitant use of these drugs, commonly used by patients with HF, with vericiguat and no dose adjustment. EUDRACT NUMBER 2014-000765-52; 2014-004880-19; 2015-004809-16.",2021,There were no clinically relevant PD changes whether SV 97/103 mg was administered with single or multiple doses of vericiguat 2.5 mg or placebo (differences in systolic blood pressure [BP] - 1.66 mmHg,"['Healthy Volunteers', 'Vericiguat 15', 'Vericiguat']","['HF (sacubitril/valsartan [SV] and aspirin [acetylsalicylic acid', 'SV, aspirin, or warfarin', 'vericiguat 2.5\xa0mg or placebo', 'warfarin', 'narrow therapeutic index (warfarin', 'aspirin', 'aspirin, warfarin']","['systolic blood pressure [BP', 'coagulation inhibition elicited', 'pharmacodynamic (PD), and pharmacokinetic (PK) interactions', 'tolerated', 'diastolic BP', 'bleeding time or platelet aggregation', 'relevant PD or PK interactions']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4078709', 'cui_str': 'vericiguat'}]","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C4033631', 'cui_str': 'valsartan and sacubitril'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C4078709', 'cui_str': 'vericiguat'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C0678793', 'cui_str': 'Therapeutic Index'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0449265', 'cui_str': 'Elicited by'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C1868980', 'cui_str': 'Pharmacokinetic interaction'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005729', 'cui_str': 'Bleeding time'}, {'cui': 'C0032176', 'cui_str': 'Platelet aggregation'}]",,0.125894,There were no clinically relevant PD changes whether SV 97/103 mg was administered with single or multiple doses of vericiguat 2.5 mg or placebo (differences in systolic blood pressure [BP] - 1.66 mmHg,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Boettcher', 'Affiliation': 'Clinical Pharmacology, Bayer AG, Research and Development, Pharmaceuticals, Aprather Weg 18a, 42113, Wuppertal, Germany.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Loewen', 'Affiliation': 'Chrestos Concept GmbH & Co. KG, Essen, Germany.'}, {'ForeName': 'Mireille', 'Initials': 'M', 'LastName': 'Gerrits', 'Affiliation': 'Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Corina', 'Initials': 'C', 'LastName': 'Becker', 'Affiliation': 'Clinical Pharmacology, Bayer AG, Research and Development, Pharmaceuticals, Aprather Weg 18a, 42113, Wuppertal, Germany. corina.becker@bayer.com.'}]",Clinical pharmacokinetics,['10.1007/s40262-020-00935-6'] 644,33032837,Randomized parallel-group pilot trial (Best foods for your heart) comparing the effects of a Mediterranean Portfolio diet with a low saturated fat diet on HIV dyslipidemia.,"BACKGROUND & AIMS Mediterranean diets reduce the risk of cardiovascular disease (CVD). However, the effect is unknown in people living with HIV, who have an increased risk potentially due to the additional burdens of infection, inflammation and antiretroviral treatment (ART). We examined the feasibility of a 6-month dietary intervention in adults with HIV dyslipidemia using a sample size adequate to detect differences in LDL-cholesterol. METHODS Sixty adults with stable HIV infection on ART and LDL-cholesterol >3 mmol/l were recruited. Participants were randomized (1:1) to receive dietary advice to reduce saturated fat intake to <10% of energy intake (Diet1), or supported to adopt the Mediterranean Portfolio Diet (Diet2) with additional cholesterol-lowering foods (nuts, stanols, soya, oats, beans) for 6 months. Recruitment, retention and intervention fidelity were monitored. Measurements were conducted at baseline, 6 and 12 months. A secondary analysis examined between group differences in CVD risk factors at month 6 adjusted for baseline values and potential confounders. RESULTS Rates of recruitment, participation and attrition were 35%, 91%, and 12% respectively. Reported dietary adherence was 68% to Mediterranean foods and 59% to Portfolio components. At 6 months Diet2 participants (n = 29) had a significantly lower LDL-cholesterol (mean difference adjusted for baseline -0.4 mmol/l, 95%CI -0.7 to -0.1, P = 0.01), and systolic blood pressure (-7 mmHg, 95%CI -2 to -12, P = 0.008) compared to those in Diet1 (n = 31). These effects were not sustained at 1 year (LDL-cholesterol -0.05 mmol/l, 95%CI -0.33 to 0.23, P = 0.7; systolic blood pressure -3.5 mmHg, 95%CI -9.4 to 2.5, P = 0.2). CONCLUSION We showed the feasibility of adopting a Mediterranean Portfolio diet in people living with HIV. Our findings suggest this intervention might equate to short term improvements in diet quality, blood pressure, and LDL-cholesterol. Further definitive evaluations are required to determine if this is a viable strategy to facilitate cardiovascular risk reduction. CLINICAL TRIAL REGISTRY ISRCTN32090191 Best Foods For your heart trial.",2021,"These effects were not sustained at 1 year (LDL-cholesterol -0.05 mmol/l, 95%CI -0.33 to 0.23, P = 0.7; systolic blood pressure -3.5 ","['adults with HIV dyslipidemia using a sample size adequate to detect differences in LDL-cholesterol', 'Sixty adults with stable HIV infection on ART and LDL-cholesterol', 'people living with HIV']","['Best Foods', 'Mediterranean Portfolio diet', 'dietary intervention', 'dietary advice to reduce saturated fat intake to <10% of energy intake (Diet1), or supported to adopt the Mediterranean Portfolio Diet (Diet2) with additional cholesterol-lowering foods (nuts, stanols, soya, oats, beans', 'Mediterranean Portfolio diet with a low saturated fat diet']","['dietary adherence', 'HIV dyslipidemia', 'systolic blood pressure ', 'LDL-cholesterol', 'CVD risk factors', 'systolic blood pressure', 'risk of cardiovascular disease (CVD', 'Rates of recruitment, participation and attrition', 'Recruitment, retention and intervention fidelity', 'diet quality, blood pressure, and LDL-cholesterol']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0599685', 'cui_str': 'Antiretroviral-containing product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0556120', 'cui_str': 'Saturated fat intake'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0425382', 'cui_str': 'Adopted'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0028723', 'cui_str': 'Nut'}, {'cui': 'C0037733', 'cui_str': 'Soya bean'}, {'cui': 'C0028753', 'cui_str': 'Oats'}, {'cui': 'C0004896', 'cui_str': 'Bean'}, {'cui': 'C0452298', 'cui_str': 'Low saturated fat diet'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",60.0,0.176734,"These effects were not sustained at 1 year (LDL-cholesterol -0.05 mmol/l, 95%CI -0.33 to 0.23, P = 0.7; systolic blood pressure -3.5 ","[{'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Stradling', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, UK; Birmingham Heartlands HIV Service, Department of Infection and Immunology, University Hospitals Birmingham NHS Foundation Trust, UK. Electronic address: clare.stradling@gmail.com.'}, {'ForeName': 'G Neil', 'Initials': 'GN', 'LastName': 'Thomas', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, UK.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Hemming', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Taylor', 'Affiliation': 'Birmingham Heartlands HIV Service, Department of Infection and Immunology, University Hospitals Birmingham NHS Foundation Trust, UK.'}, {'ForeName': 'Shahrad', 'Initials': 'S', 'LastName': 'Taheri', 'Affiliation': 'Clinical Research Core and Department of Medicine, Weill Cornell Medicine in Qatar and New York, Doha, Qatar.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.038'] 645,33021715,Effectiveness of Lifestyle and Drug Intervention on Hypertensive Patients: a Randomized Community Intervention Trial in Rural China.,"BACKGROUND Strict medication guidance and lifestyle interventions to manage blood pressure (BP) in hypertensive patients are typically difficult to follow. OBJECTIVE To evaluate the 1-year effectiveness of lifestyle and drug intervention in the management of rural hypertensive patients. DESIGN Randomized community intervention trial. PARTICIPANTS The control group comprised 967 patients who received standard antihypertensive drug intervention therapy from two communities, whereas the intervention group comprised 1945 patients who received antihypertensive drug and lifestyle intervention therapies from four communities in rural China. MAIN MEASURES Data on lifestyle behaviors and BP measurements at baseline and 1-year follow-up were collected. A difference-in-difference logistic regression model was used to assess the effect of the intervention. KEY RESULTS BP control after the 1-year intervention was better than that at baseline in both groups. The within-group change in BP control of 59.3% in the intervention group was much higher than the 25.2% change in the control group (P < 0.001). Along with the duration of the follow-up period, systolic and diastolic BP decreased rapidly in the early stages and then gradually after 6 months in the intervention group (P < 0.001). In the intervention group, drug therapy adherence was increased by 39.5% (from 48.1% at 1 month to 87.6% at 1 year) (P < 0.001), more in women (45.6%) than in men (31.2%; P < 0.001). The net effect of the lifestyle intervention improved the rate of BP control by 56.1% (70.8% for men and 44.7% for women). For all physiological and biochemical factors, such as body mass index, waist circumference, lipid metabolism, and glucose control, improvements were more significant in the behavioral intervention group than those in the control group (all P < 0.001). CONCLUSION The addition of lifestyle intervention by physicians or nurses helps control BP effectively and lowers BP better than usual care with antihypertensive drug therapy alone.",2020,"In the intervention group, drug therapy adherence was increased by 39.5% (from 48.1% at 1 month to 87.6% at 1 year)","['Rural China', 'Hypertensive Patients', 'rural hypertensive patients', '1945 patients who received', 'from four communities in rural China', '967 patients who received', 'hypertensive patients']","['Lifestyle and Drug Intervention', 'standard antihypertensive drug intervention therapy', 'lifestyle intervention', 'antihypertensive drug and lifestyle intervention therapies', 'lifestyle and drug intervention']","['systolic and diastolic BP', 'BP control', 'blood pressure (BP', 'drug therapy adherence', 'rate of BP control', 'lifestyle behaviors and BP measurements']","[{'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}]",,0.0558827,"In the intervention group, drug therapy adherence was increased by 39.5% (from 48.1% at 1 month to 87.6% at 1 year)","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Xiao', 'Affiliation': ""Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu, People's Republic of China.""}, {'ForeName': 'Wen-Long', 'Initials': 'WL', 'LastName': 'Ren', 'Affiliation': ""Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu, People's Republic of China.""}, {'ForeName': 'Yuan-Yuan', 'Initials': 'YY', 'LastName': 'Liang', 'Affiliation': ""Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu, People's Republic of China.""}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Shen', 'Affiliation': ""Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu, People's Republic of China.""}, {'ForeName': 'Yue-Xia', 'Initials': 'YX', 'LastName': 'Gao', 'Affiliation': ""Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu, People's Republic of China.""}, {'ForeName': 'Min-Jie', 'Initials': 'MJ', 'LastName': 'Chu', 'Affiliation': ""Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu, People's Republic of China.""}, {'ForeName': 'Zhou', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ""Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu, People's Republic of China.""}, {'ForeName': 'Xiao-Jian', 'Initials': 'XJ', 'LastName': 'Wang', 'Affiliation': ""Department of Chronic Disease and Prevention, Center for Disease Control and Prevention of Haian, Nantong, People's Republic of China.""}, {'ForeName': 'Zuo-Feng', 'Initials': 'ZF', 'LastName': 'Zhang', 'Affiliation': 'Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Xun', 'Initials': 'X', 'LastName': 'Zhuang', 'Affiliation': ""Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu, People's Republic of China. ntzhuang@163.com.""}, {'ForeName': 'Yong-Fu', 'Initials': 'YF', 'LastName': 'Yu', 'Affiliation': 'Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA.'}]",Journal of general internal medicine,['10.1007/s11606-019-05601-7'] 646,33022048,Brief behavioral treatment for insomnia improves psychosocial functioning in veterans: results from a randomized controlled trial.,"STUDY OBJECTIVES Our goal was to compare brief behavioral treatment for insomnia (BBTI) to a progressive muscle relaxation training (PMRT) control condition among veterans with insomnia, examining psychosocial functioning as a primary outcome and sleep-related outcomes, mood, cognition, and pain as secondary outcomes. METHODS Veterans were randomly assigned to either BBTI or PMRT (N = 91; 24-74 years; M = 49 years). BBTI consisted of two in-person (60-min and 30-min sessions) and two telephone sessions (20-min each), and the PMRT control condition was matched to BBTI for session duration and type. Veterans were assessed through clinical interview at baseline and self-report measures at pre-, mid-, and posttreatment, as well as 6-month follow-up for the BBTI condition to assess sustained response. Measures also included continuous sleep monitoring with sleep diary. RESULTS Intent-to-treat analyses demonstrated that individuals who completed BBTI versus PMRT reported greater improvements in work, home, social and cognitive functioning, insomnia symptom severity, mood, and energy. Improvements in psychosocial functioning, insomnia symptoms, and mood were maintained 6-months following BBTI treatment completion. CONCLUSIONS Veterans who received BBTI improved and maintained gains in psychosocial functioning, insomnia, and mood. BBTI is a treatment that can be implemented in primary care, mental health, or integrated care settings and provide symptom relief and improved functioning among those with insomnia, one of the most commonly reported mental health problems among veterans. CLINICAL TRIAL REGISTRATION NCT02571452.",2021,"RESULTS Intent-to-treat analyses demonstrated that individuals who completed BBTI vs. PMRT reported greater improvements in work, home, social and cognitive functioning, insomnia symptom severity, mood, and energy.","['Insomnia Improves Psychosocial Functioning in Veterans', 'Veterans', 'veterans with insomnia']","['BBTI or PMRT', 'Progressive Muscle Relaxation Training (PMRT) control condition', 'Brief Behavioral Treatment']","['work, home, social and cognitive functioning, insomnia symptom severity, mood, and energy', 'psychosocial functioning, insomnia and mood', 'continuous sleep monitoring with sleep diary', 'psychosocial functioning, insomnia symptoms and mood']","[{'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0454043', 'cui_str': 'Jacobson technique'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0416638,"RESULTS Intent-to-treat analyses demonstrated that individuals who completed BBTI vs. PMRT reported greater improvements in work, home, social and cognitive functioning, insomnia symptom severity, mood, and energy.","[{'ForeName': 'Shira', 'Initials': 'S', 'LastName': 'Maguen', 'Affiliation': 'San Francisco Veterans Affairs Health Care System, San Francisco, CA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Gloria', 'Affiliation': 'San Francisco Veterans Affairs Health Care System, San Francisco, CA.'}, {'ForeName': 'Joy', 'Initials': 'J', 'LastName': 'Huggins', 'Affiliation': 'San Francisco Veterans Affairs Health Care System, San Francisco, CA.'}, {'ForeName': 'Lizabeth A', 'Initials': 'LA', 'LastName': 'Goldstein', 'Affiliation': 'San Francisco Veterans Affairs Health Care System, San Francisco, CA.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Kanady', 'Affiliation': 'San Francisco Veterans Affairs Health Care System, San Francisco, CA.'}, {'ForeName': 'Laura D', 'Initials': 'LD', 'LastName': 'Straus', 'Affiliation': 'San Francisco Veterans Affairs Health Care System, San Francisco, CA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Metzler', 'Affiliation': 'San Francisco Veterans Affairs Health Care System, San Francisco, CA.'}, {'ForeName': 'Callan', 'Initials': 'C', 'LastName': 'Lujan', 'Affiliation': 'San Francisco Veterans Affairs Health Care System, San Francisco, CA.'}, {'ForeName': 'Thomas C', 'Initials': 'TC', 'LastName': 'Neylan', 'Affiliation': 'San Francisco Veterans Affairs Health Care System, San Francisco, CA.'}]",Sleep,['10.1093/sleep/zsaa205'] 647,33029861,Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.,"This phase 3, multicenter, open-label single-arm study evaluated adalimumab (ADA) in Japanese patients with moderate to severe hidradenitis suppurativa (HS). Fifteen patients received ADA 160 mg s.c. at week 0, 80 mg at week 2 and 40 mg at week 4 and every week thereafter. At any time after week 52, patients were given the option to receive 80 mg ADA every other week or remain on 40 mg every week. The primary end-point (achievement of HS Clinical Response [HiSCR] at week 24) and results up to week 24 were published previously. Secondary end-points included total abscess and inflammatory nodule (AN) count, 30% or more and 1 unit or more reduction in Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS30), modified Sartorius score and quality of life (QoL). After 12 weeks of ADA treatment, the achievement rate in HiSCR was 86.7%; HiSCR achievement rate was sustained through week 52 at 66.7%. Improvements at week 12 were also seen in the proportion of patients achieving an AN count of 0-2; NRS30 response rate among the nine patients with a baseline NRS of 3 or more; mean decrease in modified Sartorius score (61.4); and QoL as assessed by Dermatology Life Quality Index and Treatment Satisfaction Questionnaire; these improvements were maintained through 52 weeks. Similar efficacy was observed when patients switched dosing from ADA 40 mg every week to ADA 80 mg every other week. There were no new safety findings with ADA 40 mg weekly dosing during the study, and no differences in safety were found between patients who switched to 80 mg ADA every other week and patients who remained on 40 mg every week. The results of this study indicate that long-term ADA treatment is effective and well tolerated in Japanese patients with moderate to severe HS.",2021,"There were no new safety findings with ADA 40 mg weekly dosing during the study, and no differences in safety were found between patients who switched to 80 mg ADA every other week and patients who remained on 40 mg every week.","['Japanese patients with moderate to severe hidradenitis suppurativa', 'Japanese patients with moderate to severe hidradenitis suppurativa (HS', 'Japanese patients with moderate to severe HS']","['adalimumab', 'adalimumab (ADA', 'ADA']","['NRS30 response rate', 'effective and well tolerated', 'modified Sartorius score', 'Dermatology Life Quality Index and Treatment Satisfaction Questionnaire', 'HS Clinical Response [HiSCR', 'achievement rate in HiSCR', 'HiSCR achievement rate', ""total abscess and inflammatory nodule (AN) count, 30% or more and 1\xa0unit or more reduction in Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS30), modified Sartorius score and quality of life (QoL""]","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0162836', 'cui_str': 'Hidradenitis suppurativa'}]","[{'cui': 'C1122087', 'cui_str': 'adalimumab'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0224434', 'cui_str': 'Structure of sartorius muscle'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0162836', 'cui_str': 'Hidradenitis suppurativa'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0000833', 'cui_str': 'Abscess'}, {'cui': 'C0028259', 'cui_str': 'Nodule'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0241136', 'cui_str': 'Pain of skin'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",9.0,0.0145339,"There were no new safety findings with ADA 40 mg weekly dosing during the study, and no differences in safety were found between patients who switched to 80 mg ADA every other week and patients who remained on 40 mg every week.","[{'ForeName': 'Akimichi', 'Initials': 'A', 'LastName': 'Morita', 'Affiliation': 'Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.'}, {'ForeName': 'Hidetoshi', 'Initials': 'H', 'LastName': 'Takahashi', 'Affiliation': 'Takagi Dermatological Clinic, Hokkaido, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Ozawa', 'Affiliation': 'National Hospital Organization Osaka National Hospital, Osaka, Japan.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Imafuku', 'Affiliation': 'Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'Nakama', 'Initials': 'N', 'LastName': 'Takekuni', 'Affiliation': 'Kurume University School of Medicine, Fukuoka, Japan.'}, {'ForeName': 'Kenzo', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'University of Ryukyus, Okinawa, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Matsuyama', 'Affiliation': 'Tokai University, Tokyo, Japan.'}, {'ForeName': 'Yukari', 'Initials': 'Y', 'LastName': 'Okubo', 'Affiliation': 'Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Yiwei', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'AbbVie GK, Tokyo, Japan.'}, {'ForeName': 'Susumu', 'Initials': 'S', 'LastName': 'Kitamura', 'Affiliation': 'AbbVie GK, Tokyo, Japan.'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Takei', 'Affiliation': 'AbbVie GK, Tokyo, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Yokoyama', 'Affiliation': 'AbbVie GK, Tokyo, Japan.'}, {'ForeName': 'Nobukazu', 'Initials': 'N', 'LastName': 'Hayashi', 'Affiliation': 'Toranomon Hospital, Tokyo, Japan.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Terui', 'Affiliation': 'Nihon University School of Medicine, Tokyo, Japan.'}]",The Journal of dermatology,['10.1111/1346-8138.15605'] 648,33017854,Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study.,"INTRODUCTION The Comparison of Methylphenidate and Psychotherapy in adult ADHD Study (COMPAS) was a prospective, randomized multicenter clinical trial, comparing methylphenidate (MPH) with placebo (PLAC) in combination with cognitive behavioral group psychotherapy (GPT) or individual clinical management (CM) over the period of 1 year. Here, we report results on treatment safety. METHODS MPH and PLAC were flexibly dosed. Among 433 randomized patients, adverse events (AEs) were documented and analyzed on an ""as received"" basis during week 0-52. Electrocardiogram data were recorded at baseline and week 24. RESULTS Comparing 205 patients who received ≥1 dose of MPH with 209 patients who received PLAC, AEs occurring significantly more frequently in the MPH group were decreased appetite (22 vs. 3.8%), dry mouth (15 vs. 4.8%), palpitations (13 vs. 3.3%), gastrointestinal infection (11 vs. 4.8%), agitation (11 vs. 3.3%), restlessness (10 vs. 2.9%), hyperhidrosis, tachycardia, weight decrease (all 6.3 vs. 1.9%), depressive symptom, influenza (both 4.9 vs. 1.0%), and acute tonsillitis (4.4 vs. 0.5%). Syncope occurred significantly more often in the PLAC group (2.4 vs. 0%). Clinically relevant ECG changes occurred very rarely in both groups. Serious AEs were rare and without a significant group difference. The comparison of 206 patients treated with GPT versus 209 patients who received CM revealed no major differences. Serious AE classified as psychiatric occurred in 5 cases in the CM group and in 1 case in the GPT group. CONCLUSION In this so far longest-running clinical trial, methylphenidate treatment was safe and well-tolerated.",2020,Syncope occurred significantly more often in the PLAC group (2.4 vs. 0%).,"['206 patients treated with GPT versus 209 patients who received', 'Adult ADHD Patients - Results of the COMPAS Study']","['cognitive behavioral group psychotherapy (GPT) or individual clinical management (CM', 'Methylphenidate and Psychotherapy', 'PLAC', 'CM', 'Methylphenidate', 'methylphenidate (MPH) with placebo (PLAC', 'methylphenidate']","['dry mouth', 'gastrointestinal infection', 'acute tonsillitis', 'hyperhidrosis, tachycardia, weight decrease', 'palpitations', 'depressive symptom, influenza', 'Syncope', 'safe and well-tolerated', 'agitation', 'decreased appetite', 'ECG changes', 'adverse events (AEs', 'Electrocardiogram data', 'restlessness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0033971', 'cui_str': 'Group psychotherapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0033971', 'cui_str': 'Group psychotherapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0043352', 'cui_str': 'Xerostomia'}, {'cui': 'C0729555', 'cui_str': 'Infection of digestive system'}, {'cui': 'C0001361', 'cui_str': 'Acute tonsillitis'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0030252', 'cui_str': 'Palpitations'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0039070', 'cui_str': 'Syncope'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C0855329', 'cui_str': 'Electrocardiogram change'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}]",433.0,0.144004,Syncope occurred significantly more often in the PLAC group (2.4 vs. 0%).,"[{'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Kis', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, St. Elisabeth Hospital Niederwenigern, Contilia Group, Hattingen, Germany.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Lücke', 'Affiliation': 'Department of Psychiatry and Psychotherapy - University of Bonn, Bonn, Germany.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Abdel-Hamid', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center, Göttingen, Germany.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Heßmann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center, Göttingen, Germany.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Graf', 'Affiliation': 'Institute of Medical Biometry and Statistics, Clinical Trials Unit and Medical Faculty, University Medical Center - University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Berger', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Faculty, University Medical Center - University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Swantje', 'Initials': 'S', 'LastName': 'Matthies', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Faculty, University Medical Center - University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Borel', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Faculty, University Medical Center - University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Sobanski', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Alm', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Rösler', 'Affiliation': 'Institute for Forensic Psychology and Psychiatry, Saarland University Faculty of Medicine, Homburg/Saar, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Retz', 'Affiliation': 'Institute for Forensic Psychology and Psychiatry, Saarland University Faculty of Medicine, Homburg/Saar, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Jacob', 'Affiliation': 'Clinic for Psychiatry and Psychotherapy, Medius Clinic, Kirchheim, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Colla', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Huss', 'Affiliation': 'Department of Child and Adolescent Psychiatry and Psychotherapy, University Medicine Mainz, Mainz, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Jans', 'Affiliation': 'University Hospital of Würzburg, Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Würzburg, Germany.'}, {'ForeName': 'Ludger Tebartz', 'Initials': 'LT', 'LastName': 'van Elst', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Faculty, University Medical Center - University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Helge H O', 'Initials': 'HHO', 'LastName': 'Müller', 'Affiliation': 'Witten/Herdecke University, Faculty of Health/School of Medicine, Integrative Psychiatry and Psychotherapy, Witten, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Philipsen', 'Affiliation': 'Department of Psychiatry and Psychotherapy - University of Bonn, Bonn, Germany.'}]",Pharmacopsychiatry,['10.1055/a-1207-9851'] 649,33030349,Comparison of the Effect of Kinesio Taping and Manual Lymphatic Drainage on Breast Engorgement in Postpartum Women: A Randomized-Controlled Trial.,"Objectives: To investigate the effect of kinesio taping (KT) and manual lymphatic drainage (MLD) on pain severity, breast engorgement, and milk volume in postpartum women. Materials and Methods: In this prospective randomized-controlled trial, we recruited 67 postpartum women who had breast engorgement and randomly assigned them to the KT, MLD, and control group. In the KT group, taping plus breast care was performed, MLD plus breast care was performed in the MLD group, and in the control group, only routine breast care was given for 10 days. Pain, breast engorgement, body temperature, and milk volume were measured. Examinations were repeated on days 1, 4, and 10. Results: The MLD group had significant reductions in pain and breast engorgement at all postintervention days compared with the control and KT group ( p  < 0.05). Milk volume increased among three groups, but the change in the MLD group was higher than in the KT and control groups ( p  < 0.05). There was no significant difference in the milk volume among the KT and control groups at all postintervention days ( p  > 0.05). Conclusions: MLD relieved breast pain and firmness more and increased milk volume in postpartum women compared with the KT and control groups. MLD can be recommended to postnatal mothers to better manage breast engorgement.",2021,The MLD group had significant reductions in pain and breast engorgement at all postintervention days compared with the control and KT group ( p  < 0.05).,"['Postpartum Women', '67 postpartum women who had breast engorgement and randomly assigned them to the KT, MLD, and control group', 'postpartum women']","['kinesio taping (KT) and manual lymphatic drainage (MLD', 'MLD', 'Kinesio Taping and Manual Lymphatic Drainage']","['milk volume', 'pain and breast engorgement', 'pain severity, breast engorgement, and milk volume', 'Pain, breast engorgement, body temperature, and milk volume', 'Milk volume']","[{'cui': 'C0032804', 'cui_str': 'Postpartum Women'}, {'cui': 'C0085688', 'cui_str': 'Engorgement of breasts'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0023522', 'cui_str': 'Metachromatic leukodystrophy'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0556834', 'cui_str': 'Manual lymphatic drainage'}, {'cui': 'C0023522', 'cui_str': 'Metachromatic leukodystrophy'}]","[{'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0085688', 'cui_str': 'Engorgement of breasts'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}]",67.0,0.0503833,The MLD group had significant reductions in pain and breast engorgement at all postintervention days compared with the control and KT group ( p  < 0.05).,"[{'ForeName': 'Hanife', 'Initials': 'H', 'LastName': 'Doğan', 'Affiliation': 'Sarıkaya School of Physiotherapy and Rehabilitation, Yozgat Bozok University, Yozgat, Turkey.'}, {'ForeName': 'Semra', 'Initials': 'S', 'LastName': 'Eroğlu', 'Affiliation': 'Department of Gynecology and Obstetrics, Educational and Research Hospital, Başkent University, Konya, Turkey.'}, {'ForeName': 'Türkan', 'Initials': 'T', 'LastName': 'Akbayrak', 'Affiliation': 'Faculty of Physical Therapy and Rehabilitation, Hacettepe University, Ankara, Turkey.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0115'] 650,33032686,Postinflammatory Hyperpigmentation following Electrodesiccation with a Eutectic Mixture of Local Anesthetics.,"We assessed the effects of prior application of a eutectic mixture of local anesthetics (EMLA) on the appearance of dyschromia at the site of superficial electrodesiccation in an observer-blind, case-control study in 60 patients. Thirty subjects each were assigned to Groups A and B; both groups underwent radiofrequency (RFC) ablation for facial dermatosis papulosa nigrans (DPN). Group A received RFC ablation with prior application of EMLA, whereas Group B did not. No significant difference was observed in the dyschromia between both groups. EMLA cream was well tolerated by the study participants. ( SKINmed . 2020;18:222-225).",2020,No significant difference was observed in the dyschromia between both groups.,"['60 patients', 'Thirty subjects']","['radiofrequency (RFC) ablation for facial dermatosis papulosa nigrans (DPN', 'Electrodesiccation with a Eutectic Mixture of Local Anesthetics', 'EMLA cream', 'RFC ablation with prior application of EMLA', 'eutectic mixture of local anesthetics (EMLA']",['dyschromia'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0015456', 'cui_str': 'Facial Dermatosis'}, {'cui': 'C0037274', 'cui_str': 'Disorder of skin'}, {'cui': 'C0185056', 'cui_str': 'Electrodesiccation'}, {'cui': 'C0059079', 'cui_str': 'Eutectic Mixture of Local Anesthetics'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0151907', 'cui_str': 'Discoloration of skin'}]",60.0,0.0144264,No significant difference was observed in the dyschromia between both groups.,"[{'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Nagar', 'Affiliation': 'Department of Dermatology, Mahatma Gandhi Medical College & Maharaja Yashwantrao Hospital, Indore, Madhya Pradesh, India.'}, {'ForeName': 'Saurabh', 'Initials': 'S', 'LastName': 'Dubey', 'Affiliation': 'Department of Dermatology, Mahatma Gandhi Medical College & Maharaja Yashwantrao Hospital, Indore, Madhya Pradesh, India; sdubey17@gmail.com.'}, {'ForeName': 'Danish', 'Initials': 'D', 'LastName': 'Anwar', 'Affiliation': 'Department of Dermatology, Mahatma Gandhi Medical College & Maharaja Yashwantrao Hospital, Indore, Madhya Pradesh, India.'}, {'ForeName': 'Sushil', 'Initials': 'S', 'LastName': 'Yadav', 'Affiliation': 'Department of Dermatology, Mahatma Gandhi Medical College & Maharaja Yashwantrao Hospital, Indore, Madhya Pradesh, India.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Khare', 'Affiliation': 'Department of Dermatology, Mahatma Gandhi Medical College & Maharaja Yashwantrao Hospital, Indore, Madhya Pradesh, India.'}]",Skinmed,[] 651,33031130,The Impact of Nurse-Led Cardiac Rehabilitation on Quality of Life and Biophysiological Parameters in Patients With Heart Failure: A Randomized Clinical Trial.,"BACKGROUND Cardiovascular diseases are the leading cause of mortality in the Indian subcontinent, accounting for 38% of deaths annually. One cardiovascular disease in particular, heart failure, is a growing public health problem both in India and worldwide. PURPOSE Heart failure is a chronic, progressive disease with increasing rates of incidence and prevalence. This study was conducted to determine the influence of a nurse-led cardiac rehabilitation program on quality of life and biophysiological parameters in patients with chronic heart failure. In this study, it was hypothesized that participants in the cardiac rehabilitation program would report significantly more-positive changes in quality of life and biophysiological parameters than their peers who did not participate in this program. METHODS In this randomized controlled trial, the participants were patients with chronic heart failure who had been admitted to a tertiary care hospital in India. The participants assigned to the intervention group received both nurse-led cardiac rehabilitation and routine care. In addition, intervention group participants received a booklet on cardiac rehabilitation, Healthy Way to Healthy Heart, at discharge and fortnightly telephone reminders about good cardiac rehabilitation practices. A standard questionnaire was used to collect targeted information on participants' general and disease-specific quality of life at 1 and 3 months postintervention. Biophysiological parameters such as body mass index, blood pressure, and serum cholesterol values were also measured. RESULTS Two thirds of the participants in each group (65% in the intervention group and 66% in the control group) were between 51 and 70 years old. The mean score for the mental component summary of generic quality of life steadily decreased in the control group and steadily increased in the intervention group at the first and second posttests. CONCLUSIONS/IMPLICATIONS FOR PRACTICE Nurses working in cardiology units play a pivotal role in educating and managing the health status of patients with heart failure. Providing cardiac rehabilitation to patients with heart failure benefits the quality of life of these patients. Nurses working in cardiology units should encourage patients with heart failure to practice cardiac rehabilitation for a longer period to further improve their quality of life.",2020,"The mean score for the mental component summary of generic quality of life steadily decreased in the control group and steadily increased in the intervention group at the first and second posttests. ","['Patients With Heart Failure', 'patients with heart failure', 'patients with chronic heart failure', 'participants were patients with chronic heart failure who had been admitted to a tertiary care hospital in India']","['booklet on cardiac rehabilitation, Healthy Way to Healthy Heart, at discharge and fortnightly telephone reminders about good cardiac rehabilitation practices', 'nurse-led cardiac rehabilitation and routine care', 'Nurse-Led Cardiac Rehabilitation', 'nurse-led cardiac rehabilitation program']","['body mass index, blood pressure, and serum cholesterol values', 'Quality of Life and Biophysiological Parameters', 'quality of life and biophysiological parameters', 'mean score for the mental component summary of generic quality of life steadily', 'quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital'}, {'cui': 'C0021201', 'cui_str': 'India'}]","[{'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0585332', 'cui_str': 'Biweekly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0587184', 'cui_str': 'Serum cholesterol measurement'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}]",,0.0405611,"The mean score for the mental component summary of generic quality of life steadily decreased in the control group and steadily increased in the intervention group at the first and second posttests. ","[{'ForeName': 'Porkodi', 'Initials': 'P', 'LastName': 'Arjunan', 'Affiliation': 'PhD, RN, Reader, Faculty of Nursing, Sri Ramachandra Institute of Higher Education & Research (DU), Chennai, India.'}, {'ForeName': 'Ramakrishnan Venkatakrishnan', 'Initials': 'RV', 'LastName': 'Trichur', 'Affiliation': 'MD, Professor, Department of Emergency Medicine, Sri Ramachandra Institute of Higher Education & Research (DU), Chennai, India.'}]",The journal of nursing research : JNR,['10.1097/JNR.0000000000000407'] 652,33238991,"A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit.","BACKGROUND Community-acquired bacterial pneumonia (CABP) can lead to sepsis and is associated with high mortality rates in patients presenting with shock and/or respiratory failure and who require mechanical ventilation and admission to intensive care units, thus reflecting the limited effectiveness of current therapy. Preclinical studies support the efficacy of expanded allogeneic adipose-derived mesenchymal stem cells (eASCs) in the treatment of sepsis. In this study, we aim to test the safety, tolerability and efficacy of eASCs as adjunctive therapy in patients with severe CABP (sCABP). METHODS In addition to standard of care according to local guidelines, we will administer eASCs (Cx611) or placebo intravenously as adjunctive therapy to patients with sCABP. Enrolment is planned for approximately 180 patients who will be randomised to treatment groups in a 1:1 ratio according to a pre-defined randomization list. An equal number of patients is planned for allocation to each group. Cx611 will be administered on Day 1 and on Day 3 at a dose of 160 million cells (2 million cells / mL, total volume 80 mL) through a 20-30 min (240 mL/hr) intravenous (IV) central line infusion after dilution with Ringer Lactate solution. Placebo (Ringer Lactate) will also be administered through a 20-30 min (240 mL/hr) IV central line infusion at the same quantity (total volume of 80 mL) and following the same schedule as the active treatment. The study was initiated in January 2017 and approved by competent authorities and ethics committees in Belgium, Spain, Lithuania, Italy, Norway and France; monitoring will be performed at regular intervals. Funding is from the European Union's Horizon 2020 Research and Innovation Program. DISCUSSION SEPCELL is the first trial to assess the effects of eASCs in sCABP. The data generated will advance understanding of the mode of action of Cx611 and will provide evidence on the safety, tolerability and efficacy of Cx611 in patients with sCABP. These data will be critical for the design of future confirmatory clinical investigations and will assist in defining endpoints, key biomarkers of interest and sample size determination. TRIAL REGISTRATION NCT03158727 , retrospectively registered on 9 May 2017.",2020,Preclinical studies support the efficacy of expanded allogeneic adipose-derived mesenchymal stem cells (eASCs) in the treatment of sepsis.,"['patients with severe CABP (sCABP', '180 patients', 'patients with sCABP', 'patients presenting with shock and/or respiratory failure and who require mechanical ventilation and admission to intensive care units', 'patients with community-acquired bacterial pneumonia admitted to the intensive care unit']","['Placebo (Ringer Lactate', 'placebo', 'eASCs', 'expanded allogeneic adipose-derived mesenchymal stem cells (eASCs', 'expanded Cx611 allogeneic adipose-derived stem cells (eASCs']","['safety, tolerability and efficacy', 'safety and efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0456394', 'cui_str': 'Community acquired'}, {'cui': 'C0004626', 'cui_str': 'Bacterial pneumonia'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0583239', 'cui_str': 'Admission to intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0073385', 'cui_str': ""Lactated Ringer's Solution""}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C4704950', 'cui_str': 'Mesenchymal Stem Cells, Adipose-Derived'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.294273,Preclinical studies support the efficacy of expanded allogeneic adipose-derived mesenchymal stem cells (eASCs) in the treatment of sepsis.,"[{'ForeName': 'Pierre-François', 'Initials': 'PF', 'LastName': 'Laterre', 'Affiliation': 'Intensive Care Unit, St Luc University Hospital, Université Catholique de Louvain, 10 avenue, 1200, Brussels, Belgium. pierre-francois.laterre@uclouvain.be.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Sánchez-García', 'Affiliation': 'Intensive Care Department, Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'van der Poll', 'Affiliation': 'The Center of Experimental and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'de la Rosa', 'Affiliation': 'Takeda Madrid, Cell Therapy Technology Center, Tres Cantos, Spain.'}, {'ForeName': 'Kathy-Ann', 'Initials': 'KA', 'LastName': 'Cadogan', 'Affiliation': 'Takeda Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Eleuterio', 'Initials': 'E', 'LastName': 'Lombardo', 'Affiliation': 'Takeda Madrid, Cell Therapy Technology Center, Tres Cantos, Spain.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'François', 'Affiliation': 'Intensive Care Unit, and Inserm CIC1435 & UMR1092, Dupuytren University Hospital, Limoges, France.'}]",BMC pulmonary medicine,['10.1186/s12890-020-01324-2'] 653,33043552,The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial.,"BACKGROUND AND OBJECTIVE Non-selective beta-blockers impair the bronchodilator response to beta 2 -agonists. Cardio-selective beta 1 -blockers are less likely to cause this effect, yet they remain relatively contraindicated in asthma. We investigated whether the response to salbutamol is impaired during cardio-selective beta 1 -blocker treatment in people with asthma. METHODS A random-order, double-blind, placebo-controlled, non-inferiority, crossover study was conducted comparing up to 5 mg bisoprolol daily for 2 weeks with matching placebo, with an open-label extension of up to 10 mg bisoprolol daily. After each treatment period, mannitol was inhaled to induce bronchoconstriction with a 15% fall in forced expiratory volume in 1 s (FEV 1 ). Immediately after mannitol challenge, salbutamol (100, 100 and 200 μg) was administered via spacer at 5-min intervals with repeated FEV 1 measures. The FEV 1 recovery with salbutamol was measured as an area under recovery curve (AUC). Based on earlier research, a clinically relevant non-inferiority limit of a 30% reduction in the AUC was set. RESULTS A total of 19 adults with mild asthma and positive inhaled mannitol challenge completed the study. Adjusting for the FEV 1 fall induced by mannitol and treatment sequence, the mean AUC response to salbutamol after bisoprolol was 5% lower than after placebo, with a one-sided 95% confidence interval (CI) of 26% lower. Thirteen participants completed the open-label extension up to 10 mg bisoprolol daily with mean AUC 11% higher after bisoprolol with a 95% CI of 5% lower. CONCLUSION The bronchodilator response to rescue salbutamol after mannitol-induced bronchoconstriction is non-inferior during regular treatment with the cardio-selective beta 1 -blocker, bisoprolol, compared to placebo. CLINICAL TRIAL REGISTRATION ACTRN12618000306213 at https://www.anzctr.org.au.",2021,"The bronchodilator response to rescue salbutamol after mannitol-induced bronchoconstriction is non-inferior during regular treatment with the cardio-selective beta 1 -blocker, bisoprolol, compared to placebo. ","['asthma', 'people with asthma', '19 adults with mild asthma and positive inhaled mannitol challenge completed the study']","['mannitol', 'placebo', 'salbutamol', 'regular bisoprolol']",['mean AUC response'],"[{'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0581124', 'cui_str': 'Mild asthma'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0024730', 'cui_str': 'Mannitol'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0024730', 'cui_str': 'Mannitol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0053799', 'cui_str': 'Bisoprolol'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",19.0,0.588273,"The bronchodilator response to rescue salbutamol after mannitol-induced bronchoconstriction is non-inferior during regular treatment with the cardio-selective beta 1 -blocker, bisoprolol, compared to placebo. ","[{'ForeName': 'Miriam R', 'Initials': 'MR', 'LastName': 'Bennett', 'Affiliation': 'Respiratory Research Unit, Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand.'}, {'ForeName': 'Catherina L', 'Initials': 'CL', 'LastName': 'Chang', 'Affiliation': 'Respiratory Research Unit, Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Tuffery', 'Affiliation': 'Respiratory Research Unit, Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Hopping', 'Affiliation': 'Respiratory Research Unit, Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Hancox', 'Affiliation': 'Respiratory Research Unit, Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand.'}]","Respirology (Carlton, Vic.)",['10.1111/resp.13955'] 654,33045769,Effects of Intraoperative Ventilation Strategy on Perioperative Atelectasis Assessed by Lung Ultrasonography in Patients Undergoing Open Abdominal Surgery: a Prospective Randomized Controlled Study.,"BACKGROUND Protective mechanical ventilation using low tidal volume has been introduced to surgical patients to reduce the incidence of postoperative pulmonary complications. We investigated the effects of protective ventilation (PV) techniques on anesthesia-induced atelectasis identified via lung ultrasonography in patients undergoing abdominal surgery. METHODS A total of 42 adult patients who were scheduled for open abdominal surgery with an expected duration > 2 hours were included in the study. Patients were randomized to receive either conventional ventilation (CV; tidal volume of 9-10 mL/kg predicted body weight [PBW] with no positive end-expiratory pressure [PEEP]) or PV (tidal volume of 6-8 mL/kg PBW and 5 cmH₂O PEEP) via pressure-controlled ventilation with volume guaranteed. Lung ultrasonography was performed at four predefined time points to assess perioperative atelectasis by dividing each hemithorax into six quadrants based on a modified lung ultrasound (LUS) scoring system. RESULTS The tidal volume delivered to patients was 9.65 ± 1.65 mL/kg PBW in the CV group and 6.31 ± 0.62 mL/kg PBW in the PV group. Ventilation using low tidal volume led to similar LUS scores in all lung areas and at all time points compared to ventilation using high tidal volume. There was no significant difference between the groups in the number of patients requiring recruitment maneuvers at the end of surgery. CONCLUSION Ventilation with low tidal volume combined with 5 cmH₂O PEEP did not cause further loss of aeration compared to ventilation with high tidal volume. Low tidal volume ventilation can be used in patients without lung injury based on lung assessment by bedside lung ultrasonography. TRIAL REGISTRATION Clinical Research Information Service Identifier: KCT0003746.",2020,Ventilation using low tidal volume led to similar LUS scores in all lung areas and at all time points compared to ventilation using high tidal volume.,"['Patients Undergoing Open Abdominal Surgery', '42 adult patients who were scheduled for open abdominal surgery with an expected duration > 2 hours were included in the study', 'patients undergoing abdominal surgery', 'patients without lung injury based on lung assessment by bedside lung ultrasonography']","['Ventilation with low tidal volume combined with 5 cmH₂O PEEP', 'protective ventilation (PV) techniques', 'Low tidal volume ventilation', 'conventional ventilation (CV; tidal volume of 9-10 mL/kg predicted body weight [PBW] with no positive end-expiratory pressure [PEEP]) or PV (tidal volume of 6-8 mL/kg PBW and 5 cmH₂O PEEP) via pressure-controlled ventilation with volume guaranteed', 'Lung Ultrasonography', 'Intraoperative Ventilation Strategy', 'Lung ultrasonography']","['number of patients requiring recruitment maneuvers', 'LUS scores', 'tidal volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0273115', 'cui_str': 'Injury of lung'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0203463', 'cui_str': 'Ultrasonography of lung'}]","[{'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C1300574', 'cui_str': 'mL/kg'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0564626', 'cui_str': 'Pressure controlled ventilation'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0203463', 'cui_str': 'Ultrasonography of lung'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}]",42.0,0.0805521,Ventilation using low tidal volume led to similar LUS scores in all lung areas and at all time points compared to ventilation using high tidal volume.,"[{'ForeName': 'Sooyoung', 'Initials': 'S', 'LastName': 'Cho', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ewha Womans University, School of Medicine, Seoul, Korea.'}, {'ForeName': 'Hye Won', 'Initials': 'HW', 'LastName': 'Oh', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ewha Womans University, School of Medicine, Seoul, Korea.'}, {'ForeName': 'Min Hee', 'Initials': 'MH', 'LastName': 'Choi', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea.'}, {'ForeName': 'Hyun Jung', 'Initials': 'HJ', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ewha Womans University, School of Medicine, Seoul, Korea.'}, {'ForeName': 'Jae Hee', 'Initials': 'JH', 'LastName': 'Woo', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ewha Womans University, School of Medicine, Seoul, Korea.'}]",Journal of Korean medical science,['10.3346/jkms.2020.35.e327'] 655,33051044,Taurine supplementation associated with exercise increases mitochondrial activity and fatty acid oxidation gene expression in the subcutaneous white adipose tissue of obese women.,"PURPOSE To evaluate the effects of taurine supplementation associated or not with chronic exercise on body composition, mitochondrial function, and expression of genes related to mitochondrial activity and lipid oxidation in the subcutaneous white adipose tissue (scWAT) of obese women. METHODS A randomized and double-blind trial was developed with 24 obese women (BMI 33.1 ± 2.9 kg/m 2 , 32.9 ± 6.3 y) randomized into three groups: Taurine supplementation group (Tau, n = 8); Exercise group (Ex, n = 8); Taurine supplementation + exercise group (TauEx, n = 8). The intervention was composed of 3 g of taurine or placebo supplementation and exercise training for eight weeks. Anthropometry, body fat composition, indirect calorimetry, scWAT biopsy for mitochondrial respiration, and gene expression related to mitochondrial activity and lipid oxidation were assessed before and after the intervention. RESULTS No changes were observed for the anthropometric characteristics. The Ex group presented an increased resting energy expenditure rate, and the TauEx and Ex groups presented increased lipid oxidation and a decreased respiratory quotient. Both trained groups (TauEx and Ex) demonstrated improved scWAT mitochondrial respiratory capacity. Regarding mitochondrial markers, no changes were observed for the Tau group. The TauEx group had higher expression of CIDEA, PGC1a, PRDM16, UCP1, and UCP2. The genes related to fat oxidation (ACO2 and ACOX1) were increased in the Tau and Ex groups, while only the TauEx group presented increased expression of CPT1, PPARa, PPARγ, LPL, ACO1, ACO2, HSL, ACOX1, and CD36 genes. CONCLUSION Taurine supplementation associated with exercise improved lipid metabolism through the modulation of genes related to mitochondrial activity and fatty acid oxidation, suggesting a browning effect in the scWAT of obese women.",2021,"The genes related to fat oxidation (ACO2 and ACOX1) were increased in the Tau and Ex groups, while only the TauEx group presented increased expression of CPT1, PPARa, PPARγ, LPL, ACO1, ACO2, HSL, ACOX1, and CD36 genes. ","['obese women', '24 obese women (BMI 33.1\xa0±\xa02.9\xa0kg/m 2 , 32.9\xa0±\xa06.3']","['taurine or placebo supplementation and exercise training', 'Taurine supplementation group (Tau, n\xa0=\xa08); Exercise group (Ex, n\xa0=\xa08); Taurine supplementation\xa0+\xa0exercise group (TauEx, n\xa0=\xa08', 'Taurine supplementation', 'taurine supplementation']","['fat oxidation (ACO2 and ACOX1', 'resting energy expenditure rate', 'higher expression of CIDEA, PGC1a, PRDM16, UCP1, and UCP2', 'expression of CPT1, PPARa, PPARγ, LPL, ACO1, ACO2, HSL, ACOX1, and CD36 genes', 'lipid metabolism', 'mitochondrial activity and fatty acid oxidation gene expression', 'lipid oxidation and a decreased respiratory quotient', 'Anthropometry, body fat composition, indirect calorimetry, scWAT biopsy for mitochondrial respiration, and gene expression related to mitochondrial activity and lipid oxidation', 'body composition, mitochondrial function, and expression of genes related to mitochondrial activity and lipid oxidation', 'scWAT mitochondrial respiratory capacity']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517641', 'cui_str': '2.9'}, {'cui': 'C4319697', 'cui_str': '6.3'}]","[{'cui': 'C0039350', 'cui_str': 'Taurine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}]","[{'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0023816', 'cui_str': 'Lipoprotein lipase'}, {'cui': 'C0054954', 'cui_str': 'Lymphocyte antigen CD36'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0006781', 'cui_str': 'Indirect calorimetry'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C1704223', 'cui_str': 'White Adipose Tissue'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",24.0,0.0708696,"The genes related to fat oxidation (ACO2 and ACOX1) were increased in the Tau and Ex groups, while only the TauEx group presented increased expression of CPT1, PPARa, PPARγ, LPL, ACO1, ACO2, HSL, ACOX1, and CD36 genes. ","[{'ForeName': 'Flavia Giolo', 'Initials': 'FG', 'LastName': 'De Carvalho', 'Affiliation': 'School of Physical Education and Sport of Ribeirao Preto, University of Sao Paulo -EEFERP USP, Ribeirao Preto, Sao Paulo, Brazil.'}, {'ForeName': 'Camila Fernanda Cunha', 'Initials': 'CFC', 'LastName': 'Brandao', 'Affiliation': 'Internal Medicine Department, Ribeirao Preto Medical School, University of Sao Paulo - FMRP USP, Ribeirao Preto, Sao Paulo, Brazil; State University of Minas Gerais - UEMG, Divinopolis, Minas Gerais, Brazil.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Batitucci', 'Affiliation': 'Department of Food and Nutrition, School of Pharmaceutical Sciences of Araraquara, State University of Sao Paulo - FCF UNESP, Araraquara, Sao Paulo, Brazil.'}, {'ForeName': 'Anderson de Oliveira', 'Initials': 'AO', 'LastName': 'Souza', 'Affiliation': 'Department of BioMolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo - FCFRP USP, Ribeirao Preto, Sao Paulo, Brazil.'}, {'ForeName': 'Gustavo Duarte', 'Initials': 'GD', 'LastName': 'Ferrari', 'Affiliation': 'Department of BioMolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo - FCFRP USP, Ribeirao Preto, Sao Paulo, Brazil.'}, {'ForeName': 'Luciane Carla', 'Initials': 'LC', 'LastName': 'Alberici', 'Affiliation': 'Department of BioMolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo - FCFRP USP, Ribeirao Preto, Sao Paulo, Brazil.'}, {'ForeName': 'Vitor Rosetto', 'Initials': 'VR', 'LastName': 'Muñoz', 'Affiliation': 'Laboratory of Molecular Biology of Exercise, University of Campinas - FCA UNICAMP, Limeira, Sao Paulo, Brazil.'}, {'ForeName': 'José Rodrigo', 'Initials': 'JR', 'LastName': 'Pauli', 'Affiliation': 'Laboratory of Molecular Biology of Exercise, University of Campinas - FCA UNICAMP, Limeira, Sao Paulo, Brazil.'}, {'ForeName': 'Leandro Pereira', 'Initials': 'LP', 'LastName': 'De Moura', 'Affiliation': 'Laboratory of Molecular Biology of Exercise, University of Campinas - FCA UNICAMP, Limeira, Sao Paulo, Brazil.'}, {'ForeName': 'Eduardo Rochete', 'Initials': 'ER', 'LastName': 'Ropelle', 'Affiliation': 'Laboratory of Molecular Biology of Exercise, University of Campinas - FCA UNICAMP, Limeira, Sao Paulo, Brazil.'}, {'ForeName': 'Adelino Sanchez Ramos', 'Initials': 'ASR', 'LastName': 'da Silva', 'Affiliation': 'School of Physical Education and Sport of Ribeirao Preto, University of Sao Paulo -EEFERP USP, Ribeirao Preto, Sao Paulo, Brazil.'}, {'ForeName': 'Marcia Varella Morandi', 'Initials': 'MVM', 'LastName': 'Junqueira-Franco', 'Affiliation': 'Internal Medicine Department, Ribeirao Preto Medical School, University of Sao Paulo - FMRP USP, Ribeirao Preto, Sao Paulo, Brazil.'}, {'ForeName': 'Julio Sergio', 'Initials': 'JS', 'LastName': 'Marchini', 'Affiliation': 'Internal Medicine Department, Ribeirao Preto Medical School, University of Sao Paulo - FMRP USP, Ribeirao Preto, Sao Paulo, Brazil.'}, {'ForeName': 'Ellen Cristini', 'Initials': 'EC', 'LastName': 'de Freitas', 'Affiliation': 'School of Physical Education and Sport of Ribeirao Preto, University of Sao Paulo -EEFERP USP, Ribeirao Preto, Sao Paulo, Brazil; Department of Food and Nutrition, School of Pharmaceutical Sciences of Araraquara, State University of Sao Paulo - FCF UNESP, Araraquara, Sao Paulo, Brazil. Electronic address: ellenfreitas@usp.br.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.09.044'] 656,33047468,"Response to Eriksson et al A randomized, controlled trial comparing the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.",,2021,Optimizing protection from pneumococcal disease among high-risk patients is paramount and many countries have recommendations for solid organ transplant recipients to receive pneumococcal vaccines.,"['renal transplant patients', 'kidney transplant recipients']",['23-valent pneumococcal polysaccharide vaccination'],"['immunogenicity and safety', 'safety and immunogenicity']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0038410', 'cui_str': 'Streptococcus pneumoniae'}, {'cui': 'C0032594', 'cui_str': 'Polysaccharide'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}]",1.0,0.0733964,Optimizing protection from pneumococcal disease among high-risk patients is paramount and many countries have recommendations for solid organ transplant recipients to receive pneumococcal vaccines.,"[{'ForeName': 'Rachel Souza', 'Initials': 'RS', 'LastName': 'Dawson', 'Affiliation': 'Global Medical and Scientific Affairs (Vaccines), Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Feemster', 'Affiliation': 'Global Medical and Scientific Affairs (Vaccines), Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'E David G', 'Initials': 'EDG', 'LastName': 'McIntosh', 'Affiliation': 'MSD, UK.'}, {'ForeName': 'Ulrike K', 'Initials': 'UK', 'LastName': 'Buchwald', 'Affiliation': 'Global Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA.'}]",Transplant infectious disease : an official journal of the Transplantation Society,['10.1111/tid.13493'] 657,33048635,Feasibility and Acceptability of an Interactive Cancer-Communication Video Program Using African American Breast Cancer Survivor Stories.,"To examine the feasibility and acceptability of an interactive video program of African American breast cancer survivor stories, we explored story reactions among African American women with newly diagnosed breast cancer and associations between patient factors and intervention use. During a randomized controlled trial, patients in the intervention arm completed a baseline/pre-intervention interview, received the video intervention, and completed a post-intervention 1-month follow-up interview. Additional video exposures and post-exposure interviews occurred at 6- and 12-month follow-ups. Multivariable linear mixed-effects models examined interview and clinical data in association with changes in minutes and actions using the program. After Exposure1, 104 of 108 patients allocated to the intervention reported moderate-to-high levels of positive emotional reactions to stories and identification with storytellers. Exposure1 mean usage was high (139 minutes) but declined over time ( p <.0001). Patients receiving surgery plus radiation logged about 50 more minutes and actions over 12-month follow-up than patients receiving surgery only ( p <.05); patients reporting greater trust in storytellers logged 18.6 fewer actions over time ( p =.04). Patients' topical interests evolved, with patients watching more follow-up care and survivorship videos at Exposure3. The intervention was feasible and evaluated favorably. New videos might satisfy patients' changing interests.",2020,"After Exposure1, 104 of 108 patients allocated to the intervention reported moderate-to-high levels of positive emotional reactions to stories and identification with storytellers.","['African American women with newly diagnosed breast cancer and associations between patient factors and intervention use', 'African American breast cancer survivor stories']","['Interactive Cancer-Communication Video Program', 'baseline/pre-intervention interview, received the video intervention, and completed a post-intervention 1-month follow-up interview', 'interactive video program']","['Feasibility and Acceptability', 'moderate-to-high levels of positive emotional reactions to stories and identification with storytellers', 'feasibility and acceptability']","[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0221736', 'cui_str': 'Reaction emotional'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}]",,0.0261986,"After Exposure1, 104 of 108 patients allocated to the intervention reported moderate-to-high levels of positive emotional reactions to stories and identification with storytellers.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pérez', 'Affiliation': 'School of Medicine, Department of Medicine, Washington University in St. Louis , Saint Louis, Missouri, USA.'}, {'ForeName': 'Matthew W', 'Initials': 'MW', 'LastName': 'Kreuter', 'Affiliation': 'The Brown School, Washington University in St. Louis , Saint Louis, Missouri, USA.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine , Saint Louis, Missouri, USA.'}, {'ForeName': 'Tess', 'Initials': 'T', 'LastName': 'Thompson', 'Affiliation': 'The Brown School, Washington University in St. Louis , Saint Louis, Missouri, USA.'}, {'ForeName': 'Julianne', 'Initials': 'J', 'LastName': 'Sefko', 'Affiliation': 'School of Medicine, Department of Surgery, Washington University in St. Louis , St. Louis, Missouri, USA.'}, {'ForeName': 'Balaji', 'Initials': 'B', 'LastName': 'Golla', 'Affiliation': 'The Brown School, Washington University in St. Louis , Saint Louis, Missouri, USA.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Margenthaler', 'Affiliation': 'Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine , Saint Louis, Missouri, USA.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Colditz', 'Affiliation': 'Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine , Saint Louis, Missouri, USA.'}, {'ForeName': 'Donna B', 'Initials': 'DB', 'LastName': 'Jeffe', 'Affiliation': 'School of Medicine, Department of Medicine, Washington University in St. Louis , Saint Louis, Missouri, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1821132'] 658,33047417,Exploring patient and pharmacist perspectives on complex interventions for cardiovascular prevention: A qualitative descriptive process evaluation.,"BACKGROUND The Assessing outcomes of enhanced Chronic disease Care through patient Education and a value-baSed formulary Study (ACCESS) is a randomized controlled trial evaluating two interventions targeting barriers to care among those at high risk of cardiovascular disease: copayment elimination for cardioprotective medications, and a tailored self-management support programme. We designed a process evaluation to better understand participant perspectives on the interventions. DESIGN We used a qualitative descriptive study design, collecting patient and pharmacist feedback via individual semi-structured telephone interviews and in-person focus groups. Data were analysed inductively using thematic analysis. RESULTS Fifty-three patients (39 interviews and 14 in two focus groups) and 20 pharmacists participated. Copayment elimination provided quality of life benefits: minimizing the need to 'cut-back', allowing 'peace of mind' and providing emotional support. Health-related benefits included: improving adherence to covered medications, and helping to afford non-covered goods. The only criticism was that not all medications and testing supplies were covered. Patients reported that the educational materials provided helpful information, acted as a reminder, improved confidence, improved adherence to medication, and helped initiate conversations with providers about indicated medication. Some participants felt that the educational materials were repetitive, overly medication-focused and not tailored enough. Pharmacists felt that their patients benefitted from both interventions, which improved patient adherence and communication with their patients. CONCLUSION The success of interventions intended to change behaviour is largely dependent upon participant's feelings that the intervention is helpful. This process evaluation provided insights into participants' perceptions on these interventions. Reception of both was largely positive with a few criticisms noted.",2020,"Patients reported that the educational materials provided helpful information, acted as a reminder, improved confidence, improved adherence to medication, and helped initiate conversations with providers about indicated medication.",['Fifty-three patients (39 interviews and 14 in two focus groups) and 20 pharmacists participated'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}]",[],[],53.0,0.0754554,"Patients reported that the educational materials provided helpful information, acted as a reminder, improved confidence, improved adherence to medication, and helped initiate conversations with providers about indicated medication.","[{'ForeName': 'David J T', 'Initials': 'DJT', 'LastName': 'Campbell', 'Affiliation': 'Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Saunders-Smith', 'Affiliation': 'Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Braden J', 'Initials': 'BJ', 'LastName': 'Manns', 'Affiliation': 'Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Tonelli', 'Affiliation': 'Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Noah', 'Initials': 'N', 'LastName': 'Ivers', 'Affiliation': 'Department of Family & Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Brenda R', 'Initials': 'BR', 'LastName': 'Hemmelgarn', 'Affiliation': 'Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Ross T', 'Initials': 'RT', 'LastName': 'Tsuyuki', 'Affiliation': 'Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Raj', 'Initials': 'R', 'LastName': 'Pannu', 'Affiliation': 'Emergence Creative, New York, NY, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'King-Shier', 'Affiliation': 'Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}]",Health expectations : an international journal of public participation in health care and health policy,['10.1111/hex.13133'] 659,33053561,Subthreshold Pan-Retinal Photocoagulation Using Endpoint Management Algorithm for Severe Nonproliferative Diabetic Retinopathy: A Paired Controlled Pilot Prospective Study.,"PURPOSE The aim of this study was to report the efficacy and safety profile of subthreshold pan-retinal photocoagulation (PRP) using endpoint management (EPM) algorithm compared with conventional threshold PASCAL PRP for the treatment of severe nonproliferative diabetic retinopathy (NPDR). METHODS This was a prospective, single-center, paired randomized controlled trial of 56 eyes of 28 participants with bilateral symmetric severe NPDR. One eye of the participant was randomly assigned to receive the subthreshold EPM PRP, while the other eye of the same participant received the threshold PASCAL PRP. The primary outcome measures included the difference in the 1-year risk of progression to PDR between 2 groups, and mean changes of the logarithm of the minimal angle of resolution (logMAR) visual acuity (VA). The second outcome measures included central foveal thickness (CFT), 1-year risk of progression to PDR, and visual field (VF) parameters. RESULTS The subthreshold EPM PRP group and the threshold PASCAL PRP group had similar 1-year risk of progression to PDR during the 12-month follow-up visits (17.86 vs. 14.29%, p > 0.05). Slightly decreased VA was found in both groups (0.08 vs. 0.09 logMAR VA); however, no statistical difference was found for neither group (p > 0.05). Similar results were found for thickened CFT for both groups (23.59 vs. 28.34 μm, p > 0.05). Specifically, although substantial loss of VF was found in the threshold PASCAL PRP group (p < 0.05), no obvious damage to VF was seen in the subthreshold EPM PRP group (p > 0.05). CONCLUSION The subthreshold EPM PRP is noninferior to the conventional threshold PASCAL PRP in the treatment of severe NPDR during 12-month follow-up and could be an alternative treatment option for patients with severe NPDR.",2021,"Specifically, although substantial loss of VF was found in the threshold PASCAL PRP group (P<0.05), no obvious damage to VF was seen in the subthreshold EPM PRP group (P>0.05). ","['patients with severe NPDR', 'severe non-proliferative diabetic retinopathy (NPDR', 'Severe Non-proliferative Diabetic Retinopathy', 'fifty-six eyes of twenty-eight participants with bilateral symmetric severe NPDR']","['subthreshold pan-retinal photocoagulation (PRP) using endpoint management (EPM) algorithm', 'Subthreshold Pan-retinal Photocoagulation Using Endpoint Management Algorithm', 'subthreshold EPM PRP', 'threshold PASCAL PRP', 'conventional threshold PASCAL PRP']","['one-year risk of progression to PDR', 'substantial loss of VF', 'mean changes of the logarithm of the minimal angle of resolution (logMAR) visual acuity (VA', 'central foveal thickness (CFT), one-year risk of progression to PDR, and visual field (VF) parameters', 'VA', 'thickened CFT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0004606', 'cui_str': 'Nonproliferative diabetic retinopathy'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}]","[{'cui': 'C0030266', 'cui_str': 'Panama'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C0023694', 'cui_str': 'Photocoagulation'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0439473', 'cui_str': 'Pa'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C1845050', 'cui_str': 'Pigmentary Disorder, Reticulate, with Systemic Manifestations'}, {'cui': 'C3887875', 'cui_str': 'Visual field defect'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205400', 'cui_str': 'Thickened'}]",56.0,0.0346083,"Specifically, although substantial loss of VF was found in the threshold PASCAL PRP group (P<0.05), no obvious damage to VF was seen in the subthreshold EPM PRP group (P>0.05). ","[{'ForeName': 'Kunbei', 'Initials': 'K', 'LastName': 'Lai', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Hongkun', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Lijun', 'Initials': 'L', 'LastName': 'Zhou', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Chuangxin', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Xiaojing', 'Initials': 'X', 'LastName': 'Zhong', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yajun', 'Initials': 'Y', 'LastName': 'Gong', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Longhui', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Fabao', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Cong', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Chenjin', 'Initials': 'C', 'LastName': 'Jin', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}]",Ophthalmic research,['10.1159/000512296'] 660,33047216,"Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.","BACKGROUND Cemdisiran, an N-acetylgalactosamine (GalNAc) conjugated RNA interference (RNAi) therapeutic, is currently under development for the treatment of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein. This study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cemdisiran in healthy subjects and in patients with paroxysmal nocturnal hemoglobinuria (PNH) in order to support dose selection for late-stage clinical trials. METHODS Healthy volunteers (HVs; n = 32, including 12 Japanese subjects) were randomized (3:1) to receive single doses of subcutaneous cemdisiran (50-900 mg) or placebo, or repeat doses of subcutaneous cemdisiran (100-600 mg) or placebo weekly, biweekly, weekly/biweekly, or weekly/monthly for 5, 8, or 13 weeks (n = 24). Cemdisiran 200 or 400 mg was administered weekly in an open-label manner, for varying durations, as monotherapy in three eculizumab-naïve PNH patients or in combination with eculizumab in three PNH patients who were receiving stable label doses of eculizumab (900 or 1200 mg biweekly) before the start of the study. After the last dose of cemdisiran, patients were followed for safety and ongoing pharmacologic effects with the eculizumab regimen (600 or 900 mg every month). RESULTS In HVs, cemdisiran was rapidly converted to a major active metabolite, AS(N-2)3'-cemdisiran, both declining below the lower limit of quantification (LLOQ) in plasma within 48 h, and showing minimal renal excretion. AS(N-2)3'-cemdisiran exhibited more than dose-proportional PK. The C5 protein reductions were dose-dependent, with > 90% reduction of C5 protein beginning on days 21-28 and maintained for 10-13 months following single and biweekly doses of 600 mg. The dose-response relationship, described by an inhibitory sigmoid maximum effect (E max ) model, estimated half-maximal effective dose (ED 50 ) of 14.0 mg and maximum C5 reduction of 99% at 600 mg. The PK and PD were similar between Japanese and non-Japanese subjects, and PNH patients and HVs. One of 48 subjects tested transiently positive for antidrug antibody with low titer, with no impact on PK or PD. In PNH patients, C5 suppression by cemdisiran enabled effective inhibition of residual C5 levels with lower dose and/or dosing frequency of eculizumab, which was maintained for 6-10 months after the last dose of cemdisiran. CONCLUSIONS Consistent with the PK/PD properties of liver targeting GalNac conjugates, cemdisiran and AS(N-2)3'-cemdisiran plasma concentrations declined rapidly while showing rapid and robust C5 suppression maintained up to 13 months following single and multiple doses, which indicates long residence times of cemdisiran within hepatocytes. The long PD duration of action in liver, low immunogenicity and acceptable safety profiles enables low, infrequent SC dosing and support further evaluation of cemdisiran in complement-mediated diseases as monotherapy or in combination with a C5 inhibitor antibody. CLINICAL TRIAL REGISTRATION NO NCT02352493.",2021,"The C5 protein reductions were dose-dependent, with > 90% reduction of C5 protein beginning on days 21-28 and maintained for 10-13 months following single and biweekly doses of 600 mg.","['healthy subjects and in patients with paroxysmal nocturnal hemoglobinuria (PNH', 'Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria', 'Healthy volunteers (HVs; n\u2009=\u200932, including 12 Japanese subjects']","['subcutaneous cemdisiran', 'eculizumab-naïve PNH patients or in combination with eculizumab in three PNH patients who were receiving stable label doses of eculizumab', 'placebo, or repeat doses of subcutaneous cemdisiran (100-600\xa0mg) or placebo', 'eculizumab regimen', 'acetylgalactosamine (GalNAc) conjugated RNA interference (RNAi) therapeutic']","['C5 protein reductions', 'safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cemdisiran', ""cemdisiran and AS(N-2)3'-cemdisiran plasma concentrations"", 'residual C5 levels']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024790', 'cui_str': 'Paroxysmal nocturnal hemoglobinuria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C1541483', 'cui_str': 'eculizumab'}, {'cui': 'C0024790', 'cui_str': 'Paroxysmal nocturnal hemoglobinuria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0001055', 'cui_str': '2-Acetamido-2-D-galactopyranose'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C1136031', 'cui_str': 'Post-Transcriptional Gene Silencing'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0009519', 'cui_str': 'Complement component C5'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",12.0,0.0423508,"The C5 protein reductions were dose-dependent, with > 90% reduction of C5 protein beginning on days 21-28 and maintained for 10-13 months following single and biweekly doses of 600 mg.","[{'ForeName': 'Prajakta', 'Initials': 'P', 'LastName': 'Badri', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Alnylam Pharmaceuticals, 101 Main Street, Cambridge, MA, 02142, USA. pbadri@alnylam.com.'}, {'ForeName': 'Xuemin', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'Agios Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Borodovsky', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Alnylam Pharmaceuticals, 101 Main Street, Cambridge, MA, 02142, USA.'}, {'ForeName': 'Nader', 'Initials': 'N', 'LastName': 'Najafian', 'Affiliation': 'Alexion Pharmaceuticals, Boston, MA, USA.'}, {'ForeName': 'Jae', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Alnylam Pharmaceuticals, 101 Main Street, Cambridge, MA, 02142, USA.'}, {'ForeName': 'Valerie A', 'Initials': 'VA', 'LastName': 'Clausen', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Alnylam Pharmaceuticals, 101 Main Street, Cambridge, MA, 02142, USA.'}, {'ForeName': 'Varun', 'Initials': 'V', 'LastName': 'Goel', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Alnylam Pharmaceuticals, 101 Main Street, Cambridge, MA, 02142, USA.'}, {'ForeName': 'Bahru', 'Initials': 'B', 'LastName': 'Habtemariam', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Alnylam Pharmaceuticals, 101 Main Street, Cambridge, MA, 02142, USA.'}, {'ForeName': 'Gabriel J', 'Initials': 'GJ', 'LastName': 'Robbie', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Alnylam Pharmaceuticals, 101 Main Street, Cambridge, MA, 02142, USA.'}]",Clinical pharmacokinetics,['10.1007/s40262-020-00940-9'] 661,33051045,Skin toxicity following radiotherapy in patients with breast carcinoma: is anthocyanin supplementation beneficial?,"BACKGROUND The EU-supported ATHENA project stems from a previous study suggesting that moderate wine consumption reduced the side-effects of radiotherapy (RT) in breast cancer patients, an effect possibly due to non-alcoholic anthocyanin fractions of wine. OBJECTIVE To evaluate the role of anthocyanins on RT skin side effects in breast cancer patients. METHODS Randomized, controlled, double-blind clinical trial. Patients were assigned to an intensity modulated radiation therapy (IMRT) either for three or five weeks, then randomized to receive three times a day a water-soluble anthocyanin (125 mg)-rich extract of corn cob or a placebo. Supplementation started one week before till the end of RT. Skin characteristics were detected by a standardized, non-invasive Cutometer® dual-MPA580, providing quantitative indices of skin maximal distensibility (R0), elasticity (R2, R5, R7) and viscoelasticity (R6); a Mexameter® MX18 probe evaluated the skin erythema (Er) and melanin (M). Measures were performed before (T0), at the end of RT and of supplementation (T1), and 1, 6 and 12 months after RT (T2-T4). Acute and late skin toxicity were scored according to the RTOG/EORTG scale. Selected biomarkers were measured at T0 and T1. RESULTS 193 patients previously assigned to 3- or 5-week RT schedules were randomized to either anthocyanin (97) or placebo (96) supplementation. RT induced changes in skin parameters: R0, R2, R5 and R7 decreased, while R6 increased; the changes in R0 and R6 continued in the same direction up to one year, while the others recovered towards basal values; Er and M peaked at T1 and T2, respectively, and returned to basal values at T4. Comparable skin changes were apparent in anthocyanin and placebo groups. A moderate RT-induced increase in total and HDL cholesterol and triglycerides was prevented by anthocyanins. CONCLUSIONS Anthocyanin supplementation did not prevent RT-induced local skin toxicity. The supplementation was well tolerated and safe.",2021,"RT induced changes in skin parameters: R0, R2, R5 and R7 decreased, while R6 increased; the changes in R0 and R6 continued in the same direction up to one year, while the others recovered towards basal values; Er and M peaked at T1 and T2, respectively, and returned to basal values at T4.","['patients with breast carcinoma', 'breast cancer patients', '193 patients previously assigned to 3- or 5-week RT schedules']","['anthocyanins', 'water-soluble anthocyanin ', 'radiotherapy (RT', 'anthocyanin', '125\xa0mg)-rich extract of corn cob or a placebo', 'placebo (96) supplementation', 'radiotherapy', 'intensity modulated radiation therapy (IMRT', 'Anthocyanin supplementation']","['skin maximal distensibility (R0), elasticity (R2, R5, R7) and viscoelasticity (R6); a Mexameter® MX18 probe evaluated the skin erythema (Er) and melanin (M', 'skin parameters: R0, R2, R5 and R7', 'Acute and late skin toxicity', 'Skin toxicity', 'RT-induced local skin toxicity', 'tolerated and safe', 'total and HDL cholesterol and triglycerides', 'Skin characteristics']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0678222', 'cui_str': 'Carcinoma of breast'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C3667867', 'cui_str': 'corn cob extract'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1512814', 'cui_str': 'Intensity modulated radiation therapy'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0025196', 'cui_str': 'Melanin'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",193.0,0.139495,"RT induced changes in skin parameters: R0, R2, R5 and R7 decreased, while R6 increased; the changes in R0 and R6 continued in the same direction up to one year, while the others recovered towards basal values; Er and M peaked at T1 and T2, respectively, and returned to basal values at T4.","[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Bracone', 'Affiliation': 'Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, IS, Italy.'}, {'ForeName': 'Amalia', 'Initials': 'A', 'LastName': 'De Curtis', 'Affiliation': 'Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, IS, Italy.'}, {'ForeName': 'Augusto', 'Initials': 'A', 'LastName': 'Di Castelnuovo', 'Affiliation': 'Mediterranea Cardiocentro, Napoli, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Pilu', 'Affiliation': 'Department of Agricultural and Environmental Sciences - Production, Landscape, Agroenergy, Università degli Studi di Milano, Milano, Italy.'}, {'ForeName': 'Mariangela', 'Initials': 'M', 'LastName': 'Boccardi', 'Affiliation': 'Radiotherapy Unit, Gemelli Molise Hospital Campobasso, Italy.'}, {'ForeName': 'Savino', 'Initials': 'S', 'LastName': 'Cilla', 'Affiliation': 'Medical Physics Unit, Gemelli Molise Hospital Campobasso, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Macchia', 'Affiliation': 'Radiotherapy Unit, Gemelli Molise Hospital Campobasso, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Deodato', 'Affiliation': 'Radiotherapy Unit, Gemelli Molise Hospital Campobasso, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Costanzo', 'Affiliation': 'Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, IS, Italy.'}, {'ForeName': 'Licia', 'Initials': 'L', 'LastName': 'Iacoviello', 'Affiliation': 'Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, IS, Italy; Department of Medicine and Surgery, Research Center in Epidemiology and Preventive Medicine (EPIMED), University of Insubria, Varese, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'de Gaetano', 'Affiliation': 'Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, IS, Italy.'}, {'ForeName': 'Alessio Giuseppe', 'Initials': 'AG', 'LastName': 'Morganti', 'Affiliation': 'Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.'}, {'ForeName': 'Katia', 'Initials': 'K', 'LastName': 'Petroni', 'Affiliation': 'Department of Bioscience, Università degli Studi di Milano, Milano, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Tonelli', 'Affiliation': 'Department of Bioscience, Università degli Studi di Milano, Milano, Italy.'}, {'ForeName': 'Maria Benedetta', 'Initials': 'MB', 'LastName': 'Donati', 'Affiliation': 'Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, IS, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cerletti', 'Affiliation': 'Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, IS, Italy. Electronic address: chiara.cerletti@neuromed.it.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.09.030'] 662,33063308,"[The ""UPGRADE"" Study Protocol: Creative Strengthening Groups as an Innovative Preventive Intervention for Healthcare Workers].","Health care workers are subjected to particular job strains. Besides workload, exposure to the risks of violence and traumatic experiences can result in negative health effects. To date, there are hardly any preventive interventions. Supported by the German Innovationsfonds, we want to evaluate the effectiveness of a more intensive intervention for health care workers, the Creative Strengthening Groups. In this randomised controlled trial, 366 participants will be assigned to the intervention or the control group. The intervention group will participate in the Creative Strengthening Groups. At baseline and follow-up, all participants will complete questionnaires. The primary outcome is the change in job satisfaction as measured with the validated Copenhagen Psychosocial Questionnaire (COPSOQ). Secondary outcomes will be obtained by questionnaires that include items on psychosocial working conditions and organisational changes. We hypothesise that participation in the UPGRADE intervention will improve job satisfaction and thus constitute a structural and behavioural prevention strategy for the promotion of psychological well-being of health care workers.",2020,We hypothesise that participation in the UPGRADE intervention will improve job satisfaction and thus constitute a structural and behavioural prevention strategy for the promotion of psychological well-being of health care workers.,"['Healthcare Workers', '366 participants']",[],"['psychosocial working conditions and organisational changes', 'change in job satisfaction as measured with the validated Copenhagen Psychosocial Questionnaire (COPSOQ']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]",[],"[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0022397', 'cui_str': 'Work Satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",366.0,0.0453915,We hypothesise that participation in the UPGRADE intervention will improve job satisfaction and thus constitute a structural and behavioural prevention strategy for the promotion of psychological well-being of health care workers.,"[{'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Pieper', 'Affiliation': 'Institut für Medizinische Informatik, Biometrie und Epidemiologie, Universitätsklinikum Essen.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Schröer', 'Affiliation': 'Institut für Medizinische Informatik, Biometrie und Epidemiologie, Universitätsklinikum Essen.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Spanier', 'Affiliation': 'Institut für Medizinische Informatik, Biometrie und Epidemiologie, Universitätsklinikum Essen.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Cohen', 'Affiliation': 'Psychotherapie und Neurologie, Klinik für Psychiatrie, Helios Marien Klinik Duisburg.'}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Russ', 'Affiliation': 'Prävention, Novitas BKK, Duisburg.'}, {'ForeName': 'Udo', 'Initials': 'U', 'LastName': 'Baer', 'Affiliation': 'ISI - Trauma, ISI - Institut für soziale Innovationen, Duisburg.'}]","Psychotherapie, Psychosomatik, medizinische Psychologie",['10.1055/a-1248-2412'] 663,33053258,Effect of Action-Based Cognitive Remediation on cognitive impairment in patients with remitted bipolar disorder: A randomized controlled trial.,"OBJECTIVES Cognitive impairment affects many patients with bipolar disorder (BD), and treatments with replicated pro-cognitive effects are lacking. This study aimed to assess the effect of Action-Based Cognitive Remediation (ABCR) vs control treatment on cognitive impairment in patients with BD. METHODS Patients with remitted BD with objective cognitive impairment were randomized to 10 weeks of ABCR vs control treatment, and assessed at baseline, after 2 weeks of treatment, at treatment completion and at 6 months follow-up. The primary outcome was a cognitive composite score. Secondary outcomes were executive function and observer-rated functional capacity. Tertiary measures included additional neuropsychological tests, performance-based functional capacity and quality of life. Data were analysed with linear mixed effects models. RESULTS In total, 64 participants were randomized; given three dropouts before the baseline assessments, data were analysed for 61 participants (ABCR: n = 32, control: n = 29). There was no effect on ABCR vs control on the primary cognitive composite score (P-values ≥.60). At treatment completion, there was a large effect of ABCR vs control on the secondary executive function measure (treatment effect= -0.16, 95% CI [-0.27, -0.05], P ≤ .01, d = 0.65), and on subjective cognitive functioning (treatment effect = -5.38, 95% CI [-8.13, -2.67], P ≤ .001, d = 0.80), which disappeared at follow-up. There was no treatment-effect on functioning, and no association between cognitive and functional change. CONCLUSIONS There was no effect of ABCR on the cognitive composite score. However, there was an effect on executive function and subjective cognitive functioning suggesting that ABCR may be relevant for patients with executive dysfunction. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT03295305.",2021,"At treatment completion, there was a large effect of ABCR vs. control on the secondary executive function measure (treatment effect= -0.16, 95% CI [-0.27, -0.05], p≤0.01, d=0.65), and on subjective cognitive functioning (treatment effect=","['patients with BD', 'patients with executive dysfunction', '64 participants were randomised; given three dropouts before the baseline assessments, data were analysed for 61 participants (ABCR: n=32, control: n=29', 'Patients with remitted BD with objective cognitive impairment', 'patients with bipolar disorder (BD', 'patients with remitted bipolar disorder']","['Action-Based Cognitive Remediation (ABCR) vs. control treatment', 'ABCR', 'Action-Based Cognitive Remediation', 'ABCR vs. control treatment']","['primary cognitive composite score', 'additional neuropsychological tests, performance-based functional capacity and quality of life', 'cognitive impairment', 'executive function and observer-rated functional capacity', 'cognitive composite score', 'secondary executive function measure', 'executive function and subjective cognitive functioning', 'cognitive and functional change', 'subjective cognitive functioning']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C2748208', 'cui_str': 'Executive dysfunction'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4277695', 'cui_str': 'Cognitive Remediation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439600', 'cui_str': 'Remitting'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}]","[{'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4277695', 'cui_str': 'Cognitive Remediation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",64.0,0.244971,"At treatment completion, there was a large effect of ABCR vs. control on the secondary executive function measure (treatment effect= -0.16, 95% CI [-0.27, -0.05], p≤0.01, d=0.65), and on subjective cognitive functioning (treatment effect=","[{'ForeName': 'Caroline V', 'Initials': 'CV', 'LastName': 'Ott', 'Affiliation': 'Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Maj', 'Initials': 'M', 'LastName': 'Vinberg', 'Affiliation': 'Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Lars V', 'Initials': 'LV', 'LastName': 'Kessing', 'Affiliation': 'Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Bowie', 'Affiliation': ""Department of Psychology, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Forman', 'Affiliation': 'Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Kamilla W', 'Initials': 'KW', 'LastName': 'Miskowiak', 'Affiliation': 'Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}]",Bipolar disorders,['10.1111/bdi.13021'] 664,33063921,"""It felt very special, it felt customised to me""-A qualitative investigation of the experiences of participating in a clinical trial of CBT for young people at risk of bipolar disorder.","OBJECTIVES The Bipolar at Risk Trial (BART) was a feasibility randomized controlled trial investigating cognitive behavioral therapy (CBT) compared with treatment as usual (TAU) in young people at high risk of developing bipolar disorder (BD). This qualitative study aimed to investigate participants' experiences of trial involvement, and the acceptability of CBT for this population. DESIGN Participants were those identified as being at risk of bipolar disorder, determined by current symptoms or family history. A purposive sample of twenty-one participants from both the intervention and TAU arms of the trial was recruited. METHODS Twenty-one semi-structured interviews were conducted by service user researchers (13 participants had received therapy and 8 TAU). Interviews were audio recorded with consent from participants and transcribed verbatim. NVivo 11 Pro software was used to conduct an inductive thematic analysis. RESULTS Super-ordinate themes were ""adaptability and flexibility,"" ""feeling understood and valued,"" and ""relevance of study and intervention"" which had two sub-themes-""value of the trial therapy"" and ""acceptability of trial processes."" Participating in the trial and having therapy enabled participants to feel understood and valued by research assistants (RAs) and therapists. Participants viewed therapy as relevant to their current concerns and valued adaptability and flexibility of RAs and therapists. CONCLUSIONS Findings highlight the importance and value of flexibility, adaptability, and understanding in relationships between participants and trial staff. Findings also indicate that the trial processes and CBT focusing on mood swings are acceptable and relevant to participants from this at risk population. PRACTITIONER POINTS Young people at risk of bipolar disorder value a flexible approach to assessments and therapy, developing a rapport with research assistants and therapists and opening up to them when they feel comfortable to do so. CBT focusing on coping with mood swings was acceptable to the majority of participants who received it and it was perceived as helpful in ways that were personal to each participant.",2021,CBT focusing on coping with mood swings was acceptable to the majority of participants who received it and it was perceived as helpful in ways that were personal to each participant.,"['Participants were those identified as being at risk of bipolar disorder, determined by current symptoms or family history', 'young people at high risk of developing bipolar disorder (BD', 'young people at risk of bipolar disorder', 'Twenty-one semi-structured interviews were conducted by service user researchers (13 participants had received therapy and 8 TAU', 'A purposive sample of twenty-one participants from both the intervention and TAU arms of the trial was recruited']","['CBT', 'cognitive behavioral therapy (CBT', 'usual (TAU']","['adaptability and flexibility,"" ""feeling understood and valued,"" and ""relevance']","[{'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0241889', 'cui_str': 'Family history of clinical finding'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",21.0,0.0860395,CBT focusing on coping with mood swings was acceptable to the majority of participants who received it and it was perceived as helpful in ways that were personal to each participant.,"[{'ForeName': 'Wendy Theresa', 'Initials': 'WT', 'LastName': 'Jones', 'Affiliation': 'The Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Peters', 'Affiliation': 'Division of Psychology and Mental Health, University of Manchester, UK.'}, {'ForeName': 'Rory Edward', 'Initials': 'RE', 'LastName': 'Byrne', 'Affiliation': 'The Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Shiers', 'Affiliation': 'The Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Law', 'Affiliation': 'The Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Parker', 'Affiliation': 'The Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}]",Psychology and psychotherapy,['10.1111/papt.12313'] 665,33060126,Effect of BATHE interview technique on patient satisfaction in an ambulatory family medicine centre in South India.,"OBJECTIVE The objective of the study is to determine the effect of background, affect, trouble, handling and empathy (BATHE) versus usual interview technique on patient satisfaction during regular consultation with family physicians in ambulatory care. DESIGN The research design was a prospective, randomised control trial. SETTING The trial took place in a family practice unit in South India, which was one of the clinical service units of the academic Department of Family Medicine of a tertiary hospital. PARTICIPANT The eligible participants were adults above the age of 18 years, who did not have any acute presenting illness. The participants should have given consent and also not have any cognitive disability. A total of 138 participants took part in the trial, 70 in BATHE group and 68 in the non-BATHE group. All participants entering the trial completed the questionnaire. RESULT The BATHE group had a significantly higher mean score for questions grouped under professional satisfaction. This included questions on whether the patient felt that the physician treated them as a person and also whether they felt the appropriate clinical examination was communicated to them. The questionnaire used for scoring satisfaction had 18 questions with a maximum possible score of 90. When taking a cut-off of 75% (68) from the total possible score of 90, 72.9% (51) of the participants for whom the BATHE consultation technique was used were satisfied as compared with only 55.9% (30) for whom the routine consultation was carried out. This was statistically significant (χ 2 =11.15, p value=0.0006) CONCLUSION: The study suggests that using BATHE in this family practice centre is beneficial in improving the perception of person centeredness in the consultation. However, further studies ruling out all possible bias are needed in our setting before the range of probable benefits of the BATHE technique can be fully gauged.",2020,The BATHE group had a significantly higher mean score for questions grouped under professional satisfaction.,"['The trial took place in a family practice unit in South India, which was one of the clinical service units of the academic Department of Family Medicine of a tertiary hospital', 'patient satisfaction in an ambulatory family medicine centre in South India', 'eligible participants were adults above the age of 18 years, who did not have any acute presenting illness', 'patient satisfaction during regular consultation with family physicians in ambulatory care', '138 participants took part in the trial, 70 in BATHE group and 68 in the non-BATHE group']",['usual interview technique'],[],"[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C1704221', 'cui_str': 'Family medicine specialist'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",[],138.0,0.0481547,The BATHE group had a significantly higher mean score for questions grouped under professional satisfaction.,"[{'ForeName': 'Navnee', 'Initials': 'N', 'LastName': 'Chengappa', 'Affiliation': 'Department of Family Medicine, Christian Medical College, Vellore, Tamil Nadu, India.'}, {'ForeName': 'Prince Christopher', 'Initials': 'PC', 'LastName': 'Rajkumar Honest', 'Affiliation': 'Department of Family Medicine, Christian Medical College, Vellore, Tamil Nadu, India prince.christopher@gmail.com.'}, {'ForeName': 'Kirubah', 'Initials': 'K', 'LastName': 'David', 'Affiliation': 'Department of Family Medicine, Christian Medical College, Vellore, Tamil Nadu, India.'}, {'ForeName': 'Ruby Angeline', 'Initials': 'RA', 'LastName': 'Pricilla', 'Affiliation': 'Department of Community Medicine, Christian Medical College, Vellore, Tamil Nadu, India.'}, {'ForeName': 'Sajitha Mf', 'Initials': 'SM', 'LastName': 'Rahman', 'Affiliation': 'Department of Family Medicine, Christian Medical College, Vellore, Tamil Nadu, India.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Rebecca', 'Affiliation': 'Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.'}]",Family medicine and community health,['10.1136/fmch-2020-000327'] 666,33055462,Safety and Efficacy of Simultaneous Inoculations of Pneumococcal and Influenza Vaccines in Patients with Coronary Artery Disease.,"AIM Pneumococcal and influenza infections can cause serious morbidity and mortality in patients with cardiovascular diseases. The purpose of this study was to investigate the safety and efficacy of simultaneous inoculations of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and trivalent influenza vaccine (TIV) in patients with coronary artery disease (CAD). METHODS This was a prospective, randomized, single-blind, placebo-controlled study. A total of 40 patients with CAD were randomly assigned to the TIV＋PPSV23 (simultaneous inoculations of TIV and PPSV23) and TIV＋Placebo (inoculations of TIV and placebo) groups. Primary outcomes were the safety of simultaneous vaccinations and the changing of circulating cardiovascular biomarkers before, at 4-, and at 12-weeks after vaccinations. RESULTS The baseline characteristics between the two groups were identical. The prevalence of injection-site pain, swelling, and reddening were 47%, 37%, and 37% in the TIV＋PPSV23 group, and 10%, 5%, and 0% in the TIV＋Placebo group, respectively. All reactions were self-limited. Body temperature ＞37.0℃ or serious injection-related reaction was not observed. The levels of white blood cells, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, pentraxin-3, and malondialdehide-modified low-density lipoprotein (LDL), were not significantly different between the two groups before and after vaccinations. The levels of anti-oxidized LDL were significantly and step-wisely decreased from baseline, to 4-, and 12-weeks vaccinations in the both groups. No significant changes of other markers were observed in both groups at each time point. CONCLUSION Simultaneous inoculations of TIV and PPSV23 were safety in patients with CAD, suggesting that dual vaccinations can be considered even in patients with CAD.",2021,"The levels of anti-oxidized LDL were significantly and step-wisely decreased from baseline, to 4-, and 12-weeks vaccinations in the both groups.","['patients with coronary artery disease (CAD', '40 patients with CAD', 'patients with cardiovascular diseases', 'patients with CAD', 'Patients with Coronary Artery Disease']","['23-valent pneumococcal polysaccharide vaccine (PPSV23) and trivalent influenza vaccine (TIV', 'placebo', 'Simultaneous Inoculations of Pneumococcal and Influenza Vaccines', 'TIV＋Placebo', 'TIV＋PPSV23 (simultaneous inoculations of TIV and PPSV23) and TIV＋Placebo (inoculations of TIV and placebo', 'TIV＋PPSV23']","['Body temperature', 'safety of simultaneous vaccinations and the changing of circulating cardiovascular biomarkers', 'levels of white blood cells, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, pentraxin-3, and malondialdehide-modified low-density lipoprotein (LDL', 'Safety and Efficacy', 'levels of anti-oxidized LDL', 'safety and efficacy', 'prevalence of injection-site pain, swelling, and reddening']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'C0961101', 'cui_str': '23-valent pneumococcal capsular polysaccharide vaccine'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0038410', 'cui_str': 'Streptococcus pneumoniae'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0947642', 'cui_str': 'Pneumovax 23'}]","[{'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0174234', 'cui_str': 'PTX3 protein'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0348035', 'cui_str': 'Oxidized low density lipoprotein'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0151828', 'cui_str': 'Injection site pain'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}]",40.0,0.123126,"The levels of anti-oxidized LDL were significantly and step-wisely decreased from baseline, to 4-, and 12-weeks vaccinations in the both groups.","[{'ForeName': 'Kazunori', 'Initials': 'K', 'LastName': 'Shimada', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Morinaga', 'Affiliation': 'Division of Cardiovascular Medicine, Tokyo Metropolitan Tama Medical Center.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kiyanagi', 'Affiliation': 'Division of General Medicine, Obihiro Daiichi Hospital.'}, {'ForeName': 'Tetsuro', 'Initials': 'T', 'LastName': 'Miyazaki', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.'}, {'ForeName': 'Miho', 'Initials': 'M', 'LastName': 'Nishitani-Yokoyama', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.'}, {'ForeName': 'Iwao', 'Initials': 'I', 'LastName': 'Okai', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Tamura', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.'}, {'ForeName': 'Hakuoh', 'Initials': 'H', 'LastName': 'Konishi', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kurata', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.'}, {'ForeName': 'Katsumi', 'Initials': 'K', 'LastName': 'Miyauchi', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Daida', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.'}]",Journal of atherosclerosis and thrombosis,['10.5551/jat.58297'] 667,33059084,Computed Tomography Image Analysis of Neuromuscular Electrical Stimulation in the Treatment of Knee Osteoarthritis with Different Radiologic Characteristics Based on Iterative Reconstruction Algorithm.,"OBJECTIVE To use computed tomography image analysis of iterative reconstruction algorithm to understand effect of neuromuscular electrical stimulation of quadriceps on motor function rehabilitation after total knee arthroplasty. METHODS After total knee arthroplasty, 104 patients were randomly divided into 2 groups. The treatment group comprised 52 patients. The quadriceps femoris was stimulated by neuromuscular electrical stimulation, and patients were required to actively extend the knee along with the current stimulation. In the second group, which received cutaneous nerve electrical stimulation, 2 sets of electrodes were placed on knee pain points. All patients participated in conventional rehabilitation and were discharged from the hospital a mean 14.89 ± 3.65 days after treatment. Visual analog scale, range of motion of knee joint, and Knee Injury and Osteoarthritis Score were evaluated before discharge. The mean interval between follow-up evaluations after discharge was 9.5 months. Knee Society Score and Knee Injury and Osteoarthritis Score were assessed during follow-up. RESULTS Visual analog scale scores of treatment and control groups at discharge were 18.11 ± 9.66 and 16.13 ± 4.25, and active range of motion of the knee joint was 103.21° ± 15.44° and (99.21° ± 15.19°, respectively. Limitation of active knee extension in the treatment group was 1.93° ± 3.47°, which was significantly smaller than in the control group (6.26° ± 4.28°). CONCLUSIONS Neuromuscular electrical stimulation of the quadriceps muscle early after total knee arthroplasty helps to improve the function of the knee extension device and accelerate functional rehabilitation. Computed tomography has found that changes in tibial subchondral bone plate and subchondral cancellous bone in patients with knee osteoarthritis are mainly due to destruction of ultrastructural homeostasis. This change may be the cause of knee osteoarthritis.",2021,"The VAS scores of the treatment group and control group at discharge were (18.11±9.66) and (16.13±4.25), and the active range of motion (AROM) of the knee joint was (103.21°±15.44°) and (99.21°±15.19°), respectively The limitation of active knee extension in the treatment group was (1.93°±3.47°), which was significantly smaller than that of the control group (6.26°±4.28°).","['patients with knee osteoarthritis', 'total knee arthroplasty (TKR', '104 patients after TKR', 'Knee Osteoarthritis with Different Radiological Characteristics']","['conventional rehabilitation treatment', 'TKR surgery with neuromuscular electrical stimulation of the quadriceps muscle rehabilitation therapy', 'Neuromuscular Electrical Stimulation']","['active range of motion (AROM) of the knee joint', 'VAS scores', 'visual analogy scale (VAS), the range of motion of the knee joint, and the knee joint injury and osteoarthritis score scale (KOOS', 'limitation of active knee extension', 'American Knee Society Score (KSS) and KOOS scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C4517527', 'cui_str': '104'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0037455', 'cui_str': 'Societies'}]",104.0,0.0239004,"The VAS scores of the treatment group and control group at discharge were (18.11±9.66) and (16.13±4.25), and the active range of motion (AROM) of the knee joint was (103.21°±15.44°) and (99.21°±15.19°), respectively The limitation of active knee extension in the treatment group was (1.93°±3.47°), which was significantly smaller than that of the control group (6.26°±4.28°).","[{'ForeName': 'Weijin', 'Initials': 'W', 'LastName': 'Xing', 'Affiliation': 'Department of Radiology, Second Affiliated Hospital of Hainan Medical University, Haikou, China.'}, {'ForeName': 'Mubin', 'Initials': 'M', 'LastName': 'Cai', 'Affiliation': 'Department of Radiology, Second Affiliated Hospital of Hainan Medical University, Haikou, China.'}, {'ForeName': 'Chuanzi', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Radiology, Second Affiliated Hospital of Hainan Medical University, Haikou, China.'}, {'ForeName': 'Zhongshi', 'Initials': 'Z', 'LastName': 'Nie', 'Affiliation': 'Department of Radiology, Second Affiliated Hospital of Hainan Medical University, Haikou, China.'}, {'ForeName': 'Wencai', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Department of Radiology, Second Affiliated Hospital of Hainan Medical University, Haikou, China. Electronic address: tangwencai_hkhmu@126.com.'}]",World neurosurgery,['10.1016/j.wneu.2020.10.032'] 668,33259790,"Prolonged, Controlled Daytime versus Delayed Eating Impacts Weight and Metabolism.","A delayed eating schedule is associated with increased risk of obesity and metabolic dysfunction in humans. 1-9 However, there are no prolonged, highly controlled experimental studies testing the effects of meal timing on weight and metabolism in adults with a body mass index (BMI) of 19-27 kg/m 2 . 10-18 Twelve healthy adults (age: 26.3 ± 3.4 years; BMI: 21.9 ± 1.7 kg/m 2 ; 5 females) participated in a randomized crossover study in free-living conditions. Three meals and two snacks with comparable energy and macronutrient contents were provided during two, 8-week, counterbalanced conditions separated by a 2-week washout period: (1) daytime (intake limited to 0800 h-1900 h) and (2) delayed (intake limited to 1200 h-2300 h). Sleep-wake cycles and exercise levels were held constant. Weight, adiposity, energy expenditure, and circadian profiles of hormones and metabolites were assessed during four inpatient visits occurring before and after each condition. Body weight, insulin resistance (homeostatic model assessment of insulin resistance [HOMA-IR]), trunk-to-leg fat ratio, resting energy expenditure, respiratory quotient, and fasting glucose, insulin, total and high-density lipoprotein (dHDL) cholesterol, and adiponectin decreased on the daytime compared to the delayed schedule. These measures, as well as triglycerides, increased on the delayed compared to the daytime schedule (effect size range: d = 0.397-1.019). Circadian phase and amplitude of melatonin, cortisol, ghrelin, leptin, and glucose were not differentially altered by the eating schedules. Overall, an 8-week daytime eating schedule, compared to a delayed eating schedule, promotes weight loss and improvements in energy metabolism and insulin in adults with BMI 19-27 kg/m 2 , underscoring the efficacy and feasibility of daytime eating as a behavioral modification for real-world conditions.",2021,"Circadian phase and amplitude of melatonin, cortisol, ghrelin, leptin, and glucose were not differentially altered by the eating schedules.","['adults with a body mass index (BMI) of 19-27\xa0kg', '10-18 Twelve healthy adults (age: 26.3\xa0± 3.4 years; BMI: 21.9\xa0± 1.7\xa0kg/m 2 ; 5 females', 'humans']",[],"['Circadian phase and amplitude of melatonin, cortisol, ghrelin, leptin, and glucose', 'weight loss and improvements in energy metabolism and insulin', 'risk of obesity and metabolic dysfunction', 'Sleep-wake cycles and exercise levels', 'Weight, adiposity, energy expenditure, and circadian profiles of hormones and metabolites', 'weight and metabolism', 'Body weight, insulin resistance (homeostatic model assessment of insulin resistance [HOMA-IR]), trunk-to-leg fat ratio, resting energy expenditure, respiratory quotient, and fasting glucose, insulin, total and high-density lipoprotein (dHDL) cholesterol, and adiponectin']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517668', 'cui_str': '26.3'}, {'cui': 'C4517692', 'cui_str': '3.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]",[],"[{'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}]",12.0,0.0167302,"Circadian phase and amplitude of melatonin, cortisol, ghrelin, leptin, and glucose were not differentially altered by the eating schedules.","[{'ForeName': 'Kelly C', 'Initials': 'KC', 'LastName': 'Allison', 'Affiliation': 'Center for Weight and Eating Disorders, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: kca@pennmedicine.upenn.edu.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Hopkins', 'Affiliation': 'Center for Weight and Eating Disorders, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.'}, {'ForeName': 'Madelyn', 'Initials': 'M', 'LastName': 'Ruggieri', 'Affiliation': 'Center for Weight and Eating Disorders, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.'}, {'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Spaeth', 'Affiliation': 'Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ 08901, USA.'}, {'ForeName': 'Rexford S', 'Initials': 'RS', 'LastName': 'Ahima', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, MD 21287, USA.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': ""Department of Biomedical Informatics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.""}, {'ForeName': 'Deanne M', 'Initials': 'DM', 'LastName': 'Taylor', 'Affiliation': ""Department of Biomedical Informatics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.""}, {'ForeName': 'Namni', 'Initials': 'N', 'LastName': 'Goel', 'Affiliation': 'Division of Sleep and Chronobiology, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA; Biological Rhythms Research Laboratory, Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL 60612, USA.'}]",Current biology : CB,['10.1016/j.cub.2020.10.092'] 669,33063619,Impact of Graphic Warning Messages on Intentions to Use Alternate Tobacco Products.,"Graphic cigarette warnings increase quit attempts. Perceived message effectiveness and message avoidance are predictive of later quit attempts. We sought to examine whether randomized exposure to warning messages would inadvertently increase intentions to use alternate tobacco products while enhancing attempts to quit cigarettes. An online survey of 1392 adult smokers in the US asked participants to rate six randomly selected tobacco warnings (from a set of 319) on perceived effectiveness and avoidance intentions. These two indicators of message effectiveness were calculated at the message-level and then at the individual campaign-level to facilitate causal inference. After viewing a message campaign of six warning messages, participants indicated their intentions to use alternate tobacco products. Sixty-eight percent of participants reported some intention to use e-cigarettes and intentions to use other alternate tobacco products ranged from 31% to 40%. Campaigns of messages eliciting higher avoidance increased the odds of intending to use hookah (aOR: 4.32), smokeless tobacco (aOR: 4.88), and snus (aOR: 8.06), but not the intention to use electronic cigarettes. These relationships are mediated by intentions to quit smoking (all p <.05). Viewing campaigns with higher campaign-level perceived effectiveness increased the intentions to quit, which in turn increased intentions to try alternate tobacco products. Our findings increase the tobacco control community's understanding of unintended consequences of graphic tobacco warnings.",2020,"Campaigns of messages eliciting higher avoidance increased the odds of intending to use hookah (aOR: 4.32), smokeless tobacco (aOR: 4.88), and snus (aOR: 8.06), but not the intention to use electronic cigarettes.",['1392 adult smokers in the US asked participants to rate six randomly selected tobacco warnings (from a set of 319) on perceived'],['Graphic Warning Messages'],"['some intention to use e-cigarettes and intentions to use other alternate tobacco products', 'effectiveness and avoidance intentions']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0205452', 'cui_str': '6'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",[],"[{'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C3849993', 'cui_str': 'Electronic cigarette'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",1392.0,0.0296029,"Campaigns of messages eliciting higher avoidance increased the odds of intending to use hookah (aOR: 4.32), smokeless tobacco (aOR: 4.88), and snus (aOR: 8.06), but not the intention to use electronic cigarettes.","[{'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Morgan', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania , Philadelphia, USA.'}, {'ForeName': 'Jazmyne A', 'Initials': 'JA', 'LastName': 'Sutton', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania , Philadelphia, USA.'}, {'ForeName': 'Sijia', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania , Philadelphia, USA.'}, {'ForeName': 'Joseph N', 'Initials': 'JN', 'LastName': 'Cappella', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania , Philadelphia, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1827097'] 670,33060555,"Comparison of Regularly Scheduled Ibuprofen Versus ""Pro Re Nata"" for Ankle Sprains in Children Treated in the Emergency Department: A Randomized Controlled Trial.","OBJECTIVE We compared pain and degree of disability in patients with acute ankle sprains receiving regular scheduled ibuprofen versus pro re nata (PRN). METHODS This study is a randomized single-blinded controlled trial of children aged 7 to 17 years presenting with acute ankle sprain to an emergency department. Patients were randomized to receive 10 mg/kg of ibuprofen per dose (maximum 600 mg) every 6 hours regular scheduled versus PRN. Outcome measures included a 100-mm visual analog scale pain and degree of disability at day 4. A sample size of 72 children had a power of 80% to detect a clinically meaningful difference of 20 mm between the regular and PRN group. RESULTS We randomly assigned 99 patients to receive regular scheduled (n = 50) or PRN (n = 49) ibuprofen. Pain scores and degree of disability at day 4 showed no significant differences between groups. The rate of reported adverse effects was higher in the regular scheduled group (11.4% vs 9.5%) versus the PRN group. CONCLUSIONS Our study suggests that there is little benefit from routinely using a regular scheduled ibuprofen regimen for acute pediatric ankle sprains.",2020,Pain scores and degree of disability at day 4 showed no significant differences between groups.,"['children aged 7 to 17 years presenting with acute ankle sprain to an emergency department', 'Ankle Sprains in Children Treated in the Emergency Department', 'patients with acute ankle sprains receiving regular scheduled', 'acute pediatric ankle sprains', '99 patients to receive regular scheduled (n = 50) or']","['ibuprofen per dose (maximum 600 mg) every 6 hours regular scheduled versus PRN', 'ibuprofen versus pro re nata (PRN', 'Ibuprofen Versus ""Pro Re Nata', 'ibuprofen', 'PRN']","['100-mm visual analog scale pain and degree of disability at day 4', 'rate of reported adverse effects', 'pain and degree of disability', 'Pain scores and degree of disability']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0160087', 'cui_str': 'Sprain of ankle'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}]","[{'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0585325', 'cui_str': 'Every six hours'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0067792', 'cui_str': 'N-acetyltryptophanamide'}]","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",99.0,0.259092,Pain scores and degree of disability at day 4 showed no significant differences between groups.,"[{'ForeName': 'Rodrick', 'Initials': 'R', 'LastName': 'Lim', 'Affiliation': ''}, {'ForeName': 'Gurinder', 'Initials': 'G', 'LastName': 'Sangha', 'Affiliation': 'From the Department of Paediatrics, Western University.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Lepore', 'Affiliation': 'From the Department of Paediatrics, Western University.'}, {'ForeName': 'Katelyn M', 'Initials': 'KM', 'LastName': 'Bartlett', 'Affiliation': 'From the Department of Paediatrics, Western University.'}, {'ForeName': 'Jamie A', 'Initials': 'JA', 'LastName': 'Seabrook', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Rieder', 'Affiliation': ''}]",Pediatric emergency care,['10.1097/PEC.0000000000002282'] 671,33058438,Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis.,"BACKGROUND A randomized trial of phenytoin in acute optic neuritis (ON) demonstrated a 30% reduction in retinal nerve fiber layer (RNFL) loss with phenytoin versus placebo. Here we present the corresponding serum neurofilament analyses. METHODS Eighty-six acute ON cases were randomized to receive phenytoin (4-6 mg/kg/day) or placebo for 3 months, and followed up for 6 months. Serum was collected at baseline, 3 and 6 months for analysis of neurofilament heavy chain (NfH) and neurofilament light chain (NfL). RESULTS Sixty-four patients had blood sampling. Of these, 58 and 56 were available at 3 months, and 55 and 54 were available at 6 months for NfH and NfL, respectively. There was no significant correlation between serum NfH and NfL at the time points tested. For NfH, the difference in mean placebo - phenytoin was -44 pg/ml at 3 months (P = 0.019) and -27 pg/ml at 6 months (P = 0.234). For NfL, the difference was 1.4 pg/ml at 3 months (P = 0.726) and -1.6 pg/ml at 6 months (P = 0.766). CONCLUSIONS At 3 months, there was a reduction in NfH, but not NFL, in the phenytoin versus placebo group, while differences at 6 months were not statistically significant. This suggests a potential neuroprotective role for phenytoin in acute ON, with the lower NfH at 3 months, when levels secondary to degeneration of the anterior visual pathway are still elevated, but not at 6 months, when levels have normalized.",2021,"At 3 months, there was a reduction in NfH, but not NFL in the phenytoin versus placebo group, while differences at 6 months were not statistically significant.","['Sixty-four had blood sampling', 'Optic Neuritis', 'Eighty-six']","['placebo - phenytoin', 'placebo', 'Phenytoin', 'phenytoin versus placebo', 'phenytoin']","['acute', 'serum NfH and NfL']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0029134', 'cui_str': 'Optic neuritis'}, {'cui': 'C3816958', 'cui_str': '80'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0031507', 'cui_str': 'Phenytoin'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0337112', 'cui_str': 'Chain'}]",,0.258728,"At 3 months, there was a reduction in NfH, but not NFL in the phenytoin versus placebo group, while differences at 6 months were not statistically significant.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Raftopoulos', 'Affiliation': 'University College London Institute of Neurology, London, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Kuhle', 'Affiliation': 'Department of Neurology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Grant', 'Affiliation': 'University College London Institute of Neurology, London, UK.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Hickman', 'Affiliation': 'Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK.'}, {'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Altmann', 'Affiliation': 'Medical Statistics Department, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Leppert', 'Affiliation': 'Department of Neurology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Blennow', 'Affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Zetterberg', 'Affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Kapoor', 'Affiliation': 'University College London Institute of Neurology, London, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Giovannoni', 'Affiliation': 'Department of Neuroscience & Trauma, QMUL, London, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Gnanapavan', 'Affiliation': 'Department of Neuroscience & Trauma, QMUL, London, UK.'}]",European journal of neurology,['10.1111/ene.14591'] 672,33263170,Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study.,"Iron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient's perceived quality of life. A new oral iron formulation, Sucrosomial iron, bypassing the normal way of absorption, seems to be cost-effective in correcting iron deficiency anemia at doses higher than those usually effective with other oral iron formulations. In this multicentric randomized study, we analyze the cost-effectiveness of intravenous sodium ferrigluconate vs oral Sucrosomial iron in patients with iron deficiency anemia refractory/intolerant to oral iron sulfate without other interfering factors on iron absorption.",2021,"A new oral iron formulation, Sucrosomial iron, bypassing the normal way of absorption, seems to be cost-effective in correcting iron deficiency anemia at doses higher than those usually effective with other oral iron formulations.","['patients with iron deficiency anemia refractory/intolerant to oral iron sulfate without other interfering factors on iron absorption', 'sideropenic anemia patients intolerant/refractory to iron sulfate', 'patients who are refractory/intolerant to oral iron sulfate']","['Oral high-dose sucrosomial iron vs intravenous iron', 'intravenous sodium ferrigluconate vs oral Sucrosomial iron']",['cost-effectiveness'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0142871', 'cui_str': 'sodium iron(III)gluconate'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0652317,"A new oral iron formulation, Sucrosomial iron, bypassing the normal way of absorption, seems to be cost-effective in correcting iron deficiency anemia at doses higher than those usually effective with other oral iron formulations.","[{'ForeName': 'Giulio', 'Initials': 'G', 'LastName': 'Giordano', 'Affiliation': 'Division of Internal Medicine, Hematology Service, Regional Hospital ""A. Cardarelli"", Campobasso, Italy.'}, {'ForeName': 'Mariasanta', 'Initials': 'M', 'LastName': 'Napolitano', 'Affiliation': 'Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Haematology Unit, University Hospital ""P. Giaccone"", University of Palermo, Via del Vespro 127, 90127, Palermo, Italy. mariasanta.napolitano@unipa.it.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Di Battista', 'Affiliation': 'Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Lucchesi', 'Affiliation': 'Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}]",Annals of hematology,['10.1007/s00277-020-04361-3'] 673,33262012,"Preoperative Intravenous Versus Oral Acetaminophen in Outpatient Surgery: A Double-Blinded, Randomized Control Trial.","PURPOSE Preoperative acetaminophen is recognized as an effective part of the multimodal approach to perioperative pain management. The present study, conducted between April 12, 2018 and February 14, 2019, examined whether there are differences in patient-reported pain, postoperative opioid consumption, negative opioid effects, length of postanesthesia care unit stay, and patient satisfaction with pain control between patients who receive intravenous (IV) acetaminophen and patients who receive oral acetaminophen. DESIGN This double-blinded, randomized controlled trial was conducted among 120 patients undergoing outpatient surgery. METHODS Patients were randomized to receive preoperatively either intravenous (IV) acetaminophen (and oral placebo) or oral acetaminophen (and IV placebo). Results were analyzed using SPSS statistical software; statistical analyses consisted of Mann-Whitney U test, independent samples t test, and χ 2 test. In all analyses, a P value less than .05 was considered significant. FINDINGS There were no significant differences in any outcome measures based on the route of acetaminophen administration. CONCLUSIONS The findings of the present study support the practice of administering oral acetaminophen, as opposed to IV acetaminophen, preoperatively as part of the multimodal approach to manage postoperative pain in patients able to tolerate preoperative oral medications.",2021,"There were no significant differences in any outcome measures based on the route of acetaminophen administration. ","['patients able to tolerate preoperative oral medications', 'Patients', '120 patients undergoing outpatient surgery', 'Outpatient Surgery']","['acetaminophen', 'intravenous (IV) acetaminophen and patients who receive oral acetaminophen', 'intravenous (IV) acetaminophen (and oral placebo) or oral acetaminophen (and IV placebo', 'Preoperative Intravenous Versus Oral Acetaminophen']","['pain, postoperative opioid consumption, negative opioid effects, length of postanesthesia care unit stay, and patient satisfaction with pain control']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0002428', 'cui_str': 'Ambulatory surgery'}]","[{'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0262723', 'cui_str': 'Postanesthesia care'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]",120.0,0.313437,"There were no significant differences in any outcome measures based on the route of acetaminophen administration. ","[{'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Pelzer', 'Affiliation': 'TriHealth Bethesda Butler Hospital, Hamilton, OH. Electronic address: diana_pelzer@trihealth.com.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Burgess', 'Affiliation': 'Seven Hills Anesthesia, Cincinnati, OH.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Cox', 'Affiliation': 'TriHealth Bethesda Butler Hospital, Hamilton, OH.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Baker', 'Affiliation': 'TriHealth Corporate Nursing, Cincinnati, OH.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.07.010'] 674,33262006,Assessing measures of aspirin adherence in pregnancy: Secondary analysis of the TEST randomized controlled trial.,,2021,,['pregnancy'],[],['aspirin adherence'],"[{'cui': 'C0032961', 'cui_str': 'Pregnancy'}]",[],"[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",,0.180766,,"[{'ForeName': 'Fionnuala', 'Initials': 'F', 'LastName': 'Mone', 'Affiliation': 'Institute of Metabolism and Systems Research, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK; UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Mulcahy', 'Affiliation': 'UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Navaratnam', 'Affiliation': ""Centre for Women's Health Research, Institute of Translational Medicine, University of Liverpool, UK.""}, {'ForeName': 'Marie M', 'Initials': 'MM', 'LastName': 'Phelan', 'Affiliation': 'Institute of Integrative Biology & Technology Directorate. NMR Centre for Structural Biology. University of Liverpool, UK.'}, {'ForeName': 'Fionnuala', 'Initials': 'F', 'LastName': 'Breathnach', 'Affiliation': 'Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, Rotunda Hospital, Parnell Square, Dublin 1, Ireland.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Alfirevic', 'Affiliation': 'The Wolfson Centre for Personalised Medicine. Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, UK.'}, {'ForeName': 'Fionnuala M', 'Initials': 'FM', 'LastName': 'McAuliffe Frcog', 'Affiliation': 'UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland. Electronic address: Fionnuala.mcauliffe@ucd.ie.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.11.058'] 675,33259771,Synthetic versus Biologic Mesh for Complex Open Ventral Hernia Repair: A Pilot Randomized Controlled Trial.,"Background: Many surgeons utilize biologic mesh for elective complex ventral hernia repair (VHR; large hernias, contaminated fields, or patients with comorbid conditions). However, no randomized controlled trials (RCTs) have compared biologic and synthetic mesh. We hypothesize biologic mesh would result in fewer major complications at one-year post-operative compared with synthetic mesh. Patients and Methods: We performed a single-center, pilot RCT. All eligible patients undergoing complex, open VHR were randomly assigned to receive biologic or synthetic mesh placed in the retromuscular position. Primary outcome was major complications, namely, a composite of mesh infection, recurrence, or re-operation at one-year post-operative. Secondary outcomes included surgical site infections (SSI), seromas, hematomas, wound dehiscence, re-admissions, and Clavien-Dindo complication grade. Outcomes were assessed using Fisher exact test and Bayesian generalized linear models. Results: Of 87 patients, 44 were randomly assigned to biologic mesh and 43 to synthetic mesh. Most cases were wound class 2-4 (68%) and 75% had a hernia width >4 cm. Most patients were obese (70%) and had an American Society of Anesthesiogists (ASA) score of 3-4 (53%). Compared with patients in the synthetic mesh group, patients in the biologic mesh group had a higher percentage of: major complications at one-year post-operative (42.4% vs. 21.6%; relative risk [RR] = 1.96 [95% confidence interval {CI} = 0.94-4.08]; number needed to harm = 4.8; p = 0.071); SSI (15.9% vs. 9.3%; RR = 1.71 [95% CI = 0.54-5.42]; p = 0.362); wound dehiscence (25.0% vs. 14.0%; RR = 1.79 [95% CI = 0.73-4.41]; p = 0.205); and re-admissions (22.7% vs 9.3%; RR = 2.44 [95% CI = 0.83-7.20]; p = 0.105). Bayesian analysis demonstrated that compared with synthetic mesh, biologic mesh had a 95% probability of increased risk of major complications at one-year post-operative. No clear evidence of a difference was found on seromas, hematomas, or Clavien-Dindo complication grade. Conclusions: In elective complex open VHR, biologic mesh demonstrated no benefit compared with synthetic mesh in one-year outcomes. Moreover, Bayesian analysis suggests that biologic mesh may have an increased probability of major complications.",2021,"No clear evidence of a difference was found on seromas, hematomas, or Clavien-Dindo complication grade. ","['87 patients, 44 were randomly assigned to', 'Most patients were obese (70%) and had an American Society of Anesthesiogists (ASA) score of 3-4 (53', 'All eligible patients undergoing complex, open VHR', 'Complex Open Ventral Hernia Repair', 'patients with comorbid conditions']","['biologic mesh and 43 to synthetic mesh', 'biologic or synthetic mesh placed in the retromuscular position', 'Synthetic Versus Biologic Mesh']","['risk of major complications', 'percentage of: major complications', 'wound dehiscence', 'probability of major complications', 'major complications, namely, a composite of mesh infection, recurrence, or re-operation at one-year post-operative', 'surgical site infections (SSI), seromas, hematomas, wound dehiscence, re-admissions, and Clavien-Dindo complication grade', 'seromas, hematomas, or Clavien-Dindo complication grade']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1869199', 'cui_str': 'DUSP3 protein, human'}, {'cui': 'C0019334', 'cui_str': 'Repair of ventral hernia'}, {'cui': 'C1275743', 'cui_str': 'Co-morbid conditions'}]","[{'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0733755', 'cui_str': 'Position'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0259768', 'cui_str': 'Wound dehiscence'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0441800', 'cui_str': 'Grade'}]",,0.357939,"No clear evidence of a difference was found on seromas, hematomas, or Clavien-Dindo complication grade. ","[{'ForeName': 'Oscar A', 'Initials': 'OA', 'LastName': 'Olavarria', 'Affiliation': 'Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Bernardi', 'Affiliation': 'Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.'}, {'ForeName': 'Naila H', 'Initials': 'NH', 'LastName': 'Dhanani', 'Affiliation': 'Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.'}, {'ForeName': 'Nicole B', 'Initials': 'NB', 'LastName': 'Lyons', 'Affiliation': 'Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Harvin', 'Affiliation': 'Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.'}, {'ForeName': 'Stefanos G', 'Initials': 'SG', 'LastName': 'Millas', 'Affiliation': 'Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.'}, {'ForeName': 'Tien C', 'Initials': 'TC', 'LastName': 'Ko', 'Affiliation': 'Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.'}, {'ForeName': 'Lillian S', 'Initials': 'LS', 'LastName': 'Kao', 'Affiliation': 'Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.'}, {'ForeName': 'Mike K', 'Initials': 'MK', 'LastName': 'Liang', 'Affiliation': 'Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.'}]",Surgical infections,['10.1089/sur.2020.166'] 676,33267837,Oral clonazepam versus lorazepam in the treatment of methamphetamine-poisoned children: a pilot clinical trial.,"OBJECTIVES To evaluate the efficacy of oral clonazepam versus oral lorazepam following initial parenteral benzodiazepine administration to control methamphetamine-induced agitation in children. METHODS In a single-center clinical trial, intravenous diazepam (0.2 mg/Kg) was initially administered to all methamphetamine-poisoned pediatric patients to control their agitation, followed by a single dose of oral clonazepam (0.05 mg/Kg; n = 15) or oral lorazepam (0.05 mg/Kg; n = 15) to prevent relapse of toxicity. RESULTS The median age [IQR] (range) was 15 [10, 36] (6-144) months. The source of poisoning was methamphetamine exposure from oral ingestion in 23 (76.7%) and passive inhalation in 7 (23.3%) patients. The most common symptoms/signs were agitation (29; 96.7%), mydriatic pupils (26; 86.7%), and tachycardia (20; 66.6%). Two in each group (13.3%) needed re-administration of intravenous diazepam due to persistent agitation. There was no report of benzodiazepine complications in either group. CONCLUSIONS Clonazepam and lorazepam treatment was equally effective at similar doses. However, considering the higher potency of clonazepam, it seems that lorazepam is the safer benzodiazepine for oral maintenance treatment of methamphetamine-induced agitation in children and can be used with minimal complications. TRIAL REGISTRATION IRCT20180610040036N2, April 18th, 2020. Retrospectively registered.",2020,Two in each group (13.3%) needed re-administration of intravenous diazepam due to persistent agitation.,"['children', 'methamphetamine-poisoned children']","['methamphetamine-poisoned pediatric patients to control their agitation, followed by a single dose of oral clonazepam', 'Oral clonazepam versus lorazepam', 'Clonazepam and lorazepam', 'diazepam', 'benzodiazepine', 'lorazepam', 'clonazepam', 'oral lorazepam']","['median age [IQR', 'relapse of toxicity', 'benzodiazepine complications']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}]","[{'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0032346', 'cui_str': 'Toxic substance'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0009011', 'cui_str': 'Clonazepam'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0024002', 'cui_str': 'Lorazepam'}, {'cui': 'C0012010', 'cui_str': 'Diazepam'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.113702,Two in each group (13.3%) needed re-administration of intravenous diazepam due to persistent agitation.,"[{'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Farnaghi', 'Affiliation': 'Department of Pediatrics, Loghman-Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Razieh', 'Initials': 'R', 'LastName': 'Rahmani', 'Affiliation': 'Department of Pediatrics, Loghman-Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Hassanian-Moghaddam', 'Affiliation': 'Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. hassanian@sbmu.ac.ir.'}, {'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Zamani', 'Affiliation': 'Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'McDonald', 'Affiliation': ""National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Narges', 'Initials': 'N', 'LastName': 'Gholami', 'Affiliation': 'Department of Pediatrics, Loghman-Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Latif', 'Initials': 'L', 'LastName': 'Gachkar', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",BMC pediatrics,['10.1186/s12887-020-02441-x'] 677,33264161,"Cool Crosslinking: Riboflavin at 4°C for Pain Management After Crosslinking for Keratoconus Patients, A Randomized Clinical Trial.","PURPOSE To explore corneal cooling as a method of pain management in corneal-accelerated collagen cross-linking. METHODS This was a prospective and interventional randomized clinical trial registered in the National Institutes of Health Clinical Trials through the identifier NCT030760770. The research was conducted at the Institute of Ophthalmology ""Conde de Valenciana."" A total of 98 patients were randomly assigned to one of the following 2 groups: cold riboflavin (4°C) group or control group (riboflavin at room temperature). The inclusion criteria were patients of any sex, older than 18 years of age with keratoconus diagnosis who needed management with cross-linking in both eyes because of the evidence of progression. The exclusion criteria were patients who had cross-linking without epithelial debridement, unilateral cross-linking, or any other ocular pathologies besides keratoconus and any cognitive incapacity that would make the understanding of the pain test difficult. The main outcome measures were pain, tearing, photophobia, foreign body sensation, and irritation. RESULTS At 2 hours post-op, pain in the case and control groups was 3.80 ± 3.00 and 8.08 ± 2.21 (P < 0.05), tearing was 1.56 ± 1.96 and 8.29 ± 2.42 (P < 0.05), photophobia was 5.44 ± 3.57 and 7.83 ± 2.64 (P < 0.05), foreign body sensation was 2.20 ± 2.78 and 6.54 ± 2.73 (P < 0.05), and irritation was 3.48 ± 2.98 and 6.79 ± 3.00 (P < 0.05), respectively. A statistical significant difference was maintained in pain values on day 1 (2.79 ± 3.09 and 4.91 ± 3.27 [P < 0.05]), 2 (2.54 ± 2.41 and 4.00 ± 2.43 [P < 0.05]), and 4 (0.45 ± 0.76 and 1.22 ± 1.67 [P < 0.05]). CONCLUSIONS This study demonstrated that pain and associated symptoms decreased significantly in the riboflavin 4°C group.",2021,"A statistical significant difference was maintained in pain values on day 1 (2.79 ± 3.09 and 4.91 ± 3.27 [P < 0.05]), 2 (2.54 ± 2.41 and 4.00 ± 2.43 [P < 0.05]), and 4 (0.45 ± 0.76 and 1.22 ± 1.67 [P < 0.05]). ","['98 patients', 'patients who had cross-linking without epithelial debridement, unilateral cross-linking, or any other ocular pathologies besides keratoconus and any cognitive incapacity', 'The inclusion criteria were patients of any sex, older than 18 years of age with keratoconus diagnosis who needed management with cross-linking in both eyes because of the evidence of progression']","['Cool Crosslinking: Riboflavin', 'riboflavin', 'cold riboflavin (4°C) group or control group (riboflavin at room temperature']","['pain and associated symptoms', 'photophobia', 'pain, tearing, photophobia, foreign body sensation, and irritation', 'pain values', 'Pain Management', 'pain', 'foreign body sensation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332220', 'cui_str': 'Cross-linking'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0022578', 'cui_str': 'Keratoconus'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0229118', 'cui_str': 'Structure of both eyes'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]","[{'cui': 'C0035527', 'cui_str': 'Riboflavin'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521989', 'cui_str': 'Associated symptom'}, {'cui': 'C0085636', 'cui_str': 'Photophobia'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0423602', 'cui_str': 'Foreign body sensation'}, {'cui': 'C0441723', 'cui_str': 'Irritation'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]",98.0,0.0770776,"A statistical significant difference was maintained in pain values on day 1 (2.79 ± 3.09 and 4.91 ± 3.27 [P < 0.05]), 2 (2.54 ± 2.41 and 4.00 ± 2.43 [P < 0.05]), and 4 (0.45 ± 0.76 and 1.22 ± 1.67 [P < 0.05]). ","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Toro-Giraldo', 'Affiliation': 'Department of Cornea, External Disease and Refractive Surgery, Institute of Ophthalmology ""Conde de Valenciana,"" Mexico City, Mexico.'}, {'ForeName': 'Norma', 'Initials': 'N', 'LastName': 'Morales Flores', 'Affiliation': 'Department of Cornea, External Disease and Refractive Surgery, Institute of Ophthalmology ""Conde de Valenciana,"" Mexico City, Mexico.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Santana-Cruz', 'Affiliation': 'Department of Optometry, Institute of Ophthalmology ""Conde de Valenciana,"" Mexico City, Mexico; and.'}, {'ForeName': 'Arturo', 'Initials': 'A', 'LastName': 'Ramirez-Miranda', 'Affiliation': 'Department of Cornea, External Disease and Refractive Surgery, Institute of Ophthalmology ""Conde de Valenciana,"" Mexico City, Mexico.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Navas', 'Affiliation': 'Department of Cornea, External Disease and Refractive Surgery, Institute of Ophthalmology ""Conde de Valenciana,"" Mexico City, Mexico.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Olivo-Payne', 'Affiliation': 'Department of Cornea, External Disease and Refractive Surgery, Institute of Ophthalmology ""Conde de Valenciana,"" Mexico City, Mexico.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Lichtinger', 'Affiliation': 'Department of Cornea, External Disease and Refractive Surgery, Institute of Ophthalmology ""Conde de Valenciana,"" Mexico City, Mexico.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Jimenez-Corona', 'Affiliation': 'Department of Ocular Epidemiology and Public Health, Institute of Ophthalmology ""Conde de Valenciana,"" Mexico City, Mexico.'}, {'ForeName': 'Enrique O', 'Initials': 'EO', 'LastName': 'Graue-Hernández', 'Affiliation': 'Department of Cornea, External Disease and Refractive Surgery, Institute of Ophthalmology ""Conde de Valenciana,"" Mexico City, Mexico.'}]",Cornea,['10.1097/ICO.0000000000002484'] 678,33270316,What do these sounds tell us about the therapeutic alliance: Acoustic markers as predictors of alliance.,"Predicting the trajectories of alliance formation that the patient is likely to establish with the therapist during treatment, even before their first meeting, can help prevent the potentially harmful consequences of deterioration in alliance, such as poor outcome and premature dropout. The present study aimed to examine the ability of four pretreatment acoustic markers to predict the alliance that is likely to be formed in the course of treatment: F0 span, speech rate, pause proportion and jitter. Data from 560 observations of 38 patients were collected as part of an ongoing randomized clinical trial of short-term psychotherapy for major depressive disorder. The acoustic markers were measured using high-quality recordings at baseline, before the patient and therapist ever met or had any type of communication. A multilevel model was used to examine the ability of the four acoustic markers to predict the slopes of alliance formation in the course of treatment, all markers being introduced in the same model. The clinical utility of the acoustic markers was explored in two case studies. The model explained 22% of the variance in alliance formation. Higher levels of both jitter and pause proportion at baseline predicted less strengthening of the alliance in the course of treatment. The findings, which should be replicated in larger samples, suggest that much of the therapeutic alliance can be predicted based on the acoustic characteristics of the patient's voice in the first 3 min of their intake, before they even meet their therapist.",2021,Higher levels of both jitter and pause proportion at baseline predicted less strengthening of the alliance in the course of treatment.,"['Data from 560 observations of 38 patients', 'for major depressive disorder']",['short-term psychotherapy'],[],"[{'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]","[{'cui': 'C0033970', 'cui_str': 'Brief Psychotherapy'}]",[],38.0,0.0312188,Higher levels of both jitter and pause proportion at baseline predicted less strengthening of the alliance in the course of treatment.,"[{'ForeName': 'Aviv', 'Initials': 'A', 'LastName': 'Nof', 'Affiliation': 'Department of Psychology, University of Haifa, Haifa, Israel.'}, {'ForeName': 'Ofer', 'Initials': 'O', 'LastName': 'Amir', 'Affiliation': 'Department of Communication Disorders, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Goldstein', 'Affiliation': 'School of Public Health, University of Haifa, Haifa, Israel.'}, {'ForeName': 'Sigal', 'Initials': 'S', 'LastName': 'Zilcha-Mano', 'Affiliation': 'Department of Psychology, University of Haifa, Haifa, Israel.'}]",Clinical psychology & psychotherapy,['10.1002/cpp.2534'] 679,33274389,"Residual, differential neurobehavioral deficits linger after multiple recovery nights following chronic sleep restriction or acute total sleep deprivation.","STUDY OBJECTIVES The amount of recovery sleep needed to fully restore well-established neurobehavioral deficits from sleep loss remains unknown, as does whether the recovery pattern differs across measures after total sleep deprivation (TSD) and chronic sleep restriction (SR). METHODS In total, 83 adults received two baseline nights (10-12-hour time in bed [TIB]) followed by five 4-hour TIB SR nights or 36-hour TSD and four recovery nights (R1-R4; 12-hour TIB). Neurobehavioral tests were completed every 2 hours during wakefulness and a Maintenance of Wakefulness Test measured physiological sleepiness. Polysomnography was collected on B2, R1, and R4 nights. RESULTS TSD and SR produced significant deficits in cognitive performance, increases in self-reported sleepiness and fatigue, decreases in vigor, and increases in physiological sleepiness. Neurobehavioral recovery from SR occurred after R1 and was maintained for all measures except Psychomotor Vigilance Test (PVT) lapses and response speed, which failed to completely recover. Neurobehavioral recovery from TSD occurred after R1 and was maintained for all cognitive and self-reported measures, except for vigor. After TSD and SR, R1 recovery sleep was longer and of higher efficiency and better quality than R4 recovery sleep. CONCLUSIONS PVT impairments from SR failed to reverse completely; by contrast, vigor did not recover after TSD; all other deficits were reversed after sleep loss. These results suggest that TSD and SR induce sustained, differential biological, physiological, and/or neural changes, which remarkably are not reversed with chronic, long-duration recovery sleep. Our findings have critical implications for the population at large and for military and health professionals.",2021,"Neurobehavioral recovery from TSD occurred after R1 and was maintained for all cognitive and self-reported measures, except for vigor.",['chronic sleep restriction or acute total sleep deprivation'],[],"['self-reported sleepiness and fatigue', 'Psychomotor Vigilance Test (PVT) lapses and response speed', 'Neurobehavioral recovery from TSD', 'Neurobehavioral tests', 'cognitive performance', 'Neurobehavioral recovery from SR', 'physiological sleepiness', 'total sleep deprivation (TSD) and chronic sleep restriction (SR', 'SR, R1 recovery sleep']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}]",[],"[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0043012', 'cui_str': 'Wakefulness'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}]",83.0,0.0223471,"Neurobehavioral recovery from TSD occurred after R1 and was maintained for all cognitive and self-reported measures, except for vigor.","[{'ForeName': 'Erika M', 'Initials': 'EM', 'LastName': 'Yamazaki', 'Affiliation': 'Biological Rhythms Research Laboratory, Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Caroline A', 'Initials': 'CA', 'LastName': 'Antler', 'Affiliation': 'Biological Rhythms Research Laboratory, Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Charlotte R', 'Initials': 'CR', 'LastName': 'Lasek', 'Affiliation': 'Biological Rhythms Research Laboratory, Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Namni', 'Initials': 'N', 'LastName': 'Goel', 'Affiliation': 'Biological Rhythms Research Laboratory, Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL.'}]",Sleep,['10.1093/sleep/zsaa224'] 680,33276768,A randomized controlled TRIal of cognitive BEhavioral therapy for high Catastrophizing in patients undergoing lumbar fusion surgery: the TRIBECA study.,"BACKGROUND Around 20% of patients undergoing spinal fusion surgery have persistent back or leg pain despite surgery. Pain catastrophizing is the strongest psychological predictor for chronic postsurgical pain. Psychological variables are modifiable and could be target for intervention. However, randomized controlled trials evaluating the effectiveness of psychological interventions to reduce chronic pain and disability after spinal fusion in a population of patients with high preoperative pain catastrophizing scores are missing. The aim of our study is to examine whether an intervention targeting pain catastrophizing mitigates the risk of chronic postsurgical pain and disability. Our primary hypothesis is that targeted perioperative cognitive behavioral therapy decreases the risk of chronic postsurgical pain and disability after spinal fusion surgery in high catastrophizing patients. METHODS We will perform a two-center prospective, single-blind, randomized, controlled study comparing lumbar spinal fusion surgery outcome between 2 cohorts. Adult patients selected for lumbar spinal fusion with decompression surgery and a minimum score of 24 on the pain catastrophizing scale will be randomized with 1:1 allocation for either perioperative cognitive behavioral therapy (intervention group) or a perioperative education plus progressive exercise program (control group). Patients randomized to the intervention group will receive six individual sessions of cognitive behavioral therapy, two sessions before the operation and four after. Primary outcome is the Core Outcome Measures Index at 12 months. Secondary outcomes include pain, disability, depression and quality of life. DISCUSSION This is the first trial that evaluates the effectiveness of cognitive behavioral therapy as a perioperative tool to improve pain and disability after spinal fusion surgery in comparison with an educational/exercise control intervention, in patients with high levels of pain catastrophizing. If perioperative cognitive behavioral therapy proves to be effective, this might have important clinical implications, reducing the incidence of chronic postsurgical pain and improving outcome after spinal fusion surgery. TRIAL REGISTRATION Clinicaltrials ( NCT03969602 ). Registered 31 May 2019.",2020,Adult patients selected for lumbar spinal fusion with decompression surgery and a minimum score of 24 on the pain catastrophizing scale will be randomized with 1:1 allocation for either perioperative cognitive behavioral therapy (intervention group) or a perioperative education plus progressive exercise program (control group).,"['patients undergoing lumbar fusion surgery', 'patients undergoing spinal fusion surgery have persistent back or leg pain despite surgery', 'Adult patients selected for lumbar spinal fusion with decompression surgery and a minimum score of 24 on the pain catastrophizing scale', 'patients with high levels of pain catastrophizing']","['educational/exercise control intervention', 'cognitive behavioral therapy', 'intervention group will receive six individual sessions of cognitive behavioral therapy', 'perioperative cognitive behavioral therapy (intervention group) or a perioperative education plus progressive exercise program (control group', 'psychological interventions', 'perioperative cognitive behavioral therapy', 'cognitive BEhavioral therapy']","['pain and disability', 'chronic pain and disability', 'pain, disability, depression and quality of life', 'chronic postsurgical pain and disability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0919636', 'cui_str': 'Spinal fusion surgery'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0023222', 'cui_str': 'Pain in lower limb'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0186045', 'cui_str': 'Lumbar spinal fusion'}, {'cui': 'C0022983', 'cui_str': 'Laminectomy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}]",,0.121895,Adult patients selected for lumbar spinal fusion with decompression surgery and a minimum score of 24 on the pain catastrophizing scale will be randomized with 1:1 allocation for either perioperative cognitive behavioral therapy (intervention group) or a perioperative education plus progressive exercise program (control group).,"[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Scarone', 'Affiliation': 'Neurosurgical Service, Neurocenter of Southern Switzerland, Lugano, Switzerland. Pietro.scarone@eoc.ch.'}, {'ForeName': 'A Y J M', 'Initials': 'AYJM', 'LastName': 'Smeets', 'Affiliation': 'Department of Neurosurgery, Zuyderland Medical Center, Heerlen/Sittard-Geleen, The Netherlands.'}, {'ForeName': 'S M J', 'Initials': 'SMJ', 'LastName': 'van Kuijk', 'Affiliation': 'Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'van Santbrink', 'Affiliation': 'Department of Neurosurgery, Zuyderland Medical Center, Heerlen/Sittard-Geleen, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Peters', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Koetsier', 'Affiliation': 'Pain Management Center, Neurocenter of Southern Switzerland, Lugano, Switzerland.'}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03826-w'] 681,33275819,Rapid eye movement sleep behavior disorder: A proof-of-concept neuroprotection study for prodromal synucleinopathies.,"BACKGROUND AND PURPOSE To explore the feasibility of a neuroprotection trial in prodromal synucleinopathy, using idiopathic rapid eye movement sleep behavior disorder (iRBD) as the target population and 123 I-FP-CIT-SPECT as a biomarker of disease progression. METHODS Consecutive iRBD patients were randomly assigned to a treatment arm receiving selegiline and symptomatic rapid eye movement sleep behavior disorder treatment, or to a control arm receiving symptomatic treatment only. Selegiline was chosen because of a demonstrated neuroprotection effect in animal models. Patients underwent 123 I-FP-CIT-SPECT at baseline and after 30 months on average. The clinical outcome was the emergence of parkinsonism and/or dementia. A repeated-measures general linear model (GLM) was applied using group (control and treatment) as ""between"" factor, and both time (baseline and follow-up) and regions ( 123 I-FP-CIT-SPECT putamen and caudate uptake) as the ""within"" factors, adjusting for age. RESULTS Thirty iRBD patients completed the study (68.2 ± 6.9 years; 29 males; 21% dropout rate), 13 in the treatment arm, and 17 in the control arm. At follow-up (29.8 ± 9.0 months), three patients in the control arm developed dementia and one parkinsonism, whereas two patients in the treatment arm developed parkinsonism. Both putamen and caudate uptake decreased over time in the control arm. In the treatment arm, only the putamen uptake decreased over time, whereas caudate uptake remained stable. GLM analysis demonstrated an effect of treatment on the 123 I-FP-CIT-SPECT uptake change, with a significant interaction between the effect of group, time, and regions (p = 0.004). CONCLUSIONS A 30-months neuroprotection study for prodromal synucleinopathy is feasible, using iRBD as the target population and 123 I-FP-CIT-SPECT as a biomarker of disease progression.",2021,Both putamen and caudate uptake decreased over time in the control arm.,"['Consecutive iRBD patients', 'Thirty iRBD patients completed the study (68.2±6.9 years; 29 males; 21% drop-out rate), 13 in the treatment arm and 17 in the control arm']","['REMeDio', 'selegiline and symptomatic RBD treatment, or to a control arm, receiving symptomatic treatment only']","['dementia and one parkinsonism', 'emergence of parkinsonism and/or dementia']","[{'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0751772', 'cui_str': 'REM sleep behavior disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0036579', 'cui_str': 'Selegiline'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C1522002', 'cui_str': 'RRM Motif'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0242422', 'cui_str': 'Parkinsonism'}]",123.0,0.025836,Both putamen and caudate uptake decreased over time in the control arm.,"[{'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Arnaldi', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Famà', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Girtler', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Brugnolo', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Pardini', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Mattioli', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Meli', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Massa', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Orso', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Maria Pia', 'Initials': 'MP', 'LastName': 'Sormani', 'Affiliation': 'Department of Health Sciences, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Maria Isabella', 'Initials': 'MI', 'LastName': 'Donegani', 'Affiliation': 'IRCCS Ospedale Policlinico San Martino, Genoa, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Bauckneht', 'Affiliation': 'IRCCS Ospedale Policlinico San Martino, Genoa, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Morbelli', 'Affiliation': 'IRCCS Ospedale Policlinico San Martino, Genoa, Italy.'}, {'ForeName': 'Flavio', 'Initials': 'F', 'LastName': 'Nobili', 'Affiliation': 'Clinical Neurology, Department of Neuroscience (DINOGMI, University of Genoa, Genoa, Italy.'}]",European journal of neurology,['10.1111/ene.14664'] 682,33059997,Long-term outcomes of a prospective randomized trial of 131 Cs/ 125 I permanent prostate brachytherapy.,"PURPOSE Iodine-125 ( 125 I) is the most commonly used isotope for prostate brachytherapy (BT). Cesium-131 ( 131 Cs) has a higher dose rate and shorter dose delivery time resulting in decreased duration of acute urinary morbidity. Long-term data suggest excellent oncologic outcomes; it is not known how outcomes compare. A prospective randomized trial comparing the two isotopes was initiated. MATERIALS AND METHODS Patients with low- or intermediate-risk disease were treated with a BT in a single outpatient facility. Prescription dose was 144 Gy for 125 I and 115 Gy for 131 Cs. Androgen deprivation or supplemental EBRT was not allowed. The primary study objective was comparison of the mean EPIC Urinary Domain Score. Secondary objective was biochemical relapse-free survival (BRFS) comparison. Time-to-event for all outcomes of interest was measured from implant date. RESULTS One hundred forty men were enrolled; 81.4% were low-risk and 18.6% were intermediate-risk. The median followup was 97 months. Urinary and sexual health-related quality of life did not differ between isotopes at any recorded time point. At 2 months after implantation, bowel health-related quality of life was worse with 125 I; however, this difference was lost at subsequent time points. The 9-year BRFS was 87.2% and 84.0% for the 125 I and 131 Cs group, respectively (p = 0.897). There was no statistically significant difference in BRFS based on initial T stage, PSA, or Gleason score. CONCLUSIONS Short- and long-term urinary, sexual, and bowel quality of life, as well as long-term biochemical control were comparable between 125 I and 131 Cs. This report therefore supports the continued use of 131 Cs as an effective and comparable alternative isotope.",2021,"At 2 months after implantation, bowel health-related quality of life was worse with ","['One hundred forty men were enrolled; 81.4% were low-risk and 18.6% were intermediate-risk', 'Patients with low- or intermediate-risk disease were treated with a BT in a single outpatient facility', '125']","['131 Cs/ 125 I permanent prostate brachytherapy', 'Androgen deprivation or supplemental EBRT']","['BRFS based on initial T stage, PSA, or Gleason score', 'Urinary and sexual health-related quality of life', 'mean EPIC Urinary Domain Score', 'bowel health-related quality of life', '9-year BRFS', 'biochemical relapse-free survival (BRFS) comparison']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0006098', 'cui_str': 'Brachytherapy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C4319551', 'cui_str': '125'}]","[{'cui': 'C0796396', 'cui_str': 'Iodine-125'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0854662', 'cui_str': 'Brachytherapy to prostate'}, {'cui': 'C0002844', 'cui_str': 'Androgen'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0475455', 'cui_str': 'T - Tumor stage'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0332326', 'cui_str': 'Gleason grading system for prostatic cancer'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273342', 'cui_str': 'Epithelial cell count'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",140.0,0.0642372,"At 2 months after implantation, bowel health-related quality of life was worse with ","[{'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Moran', 'Affiliation': 'Prostate Cancer Foundation of Chicago, Westmont, IL.'}, {'ForeName': 'Antony', 'Initials': 'A', 'LastName': 'Koroulakis', 'Affiliation': 'Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Decesaris', 'Affiliation': 'Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD.'}, {'ForeName': 'Michelle H', 'Initials': 'MH', 'LastName': 'Braccioforte', 'Affiliation': 'Prostate Cancer Foundation of Chicago, Westmont, IL; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.'}, {'ForeName': 'Neha', 'Initials': 'N', 'LastName': 'Amin', 'Affiliation': 'Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.'}, {'ForeName': 'Manuj', 'Initials': 'M', 'LastName': 'Agarwal', 'Affiliation': 'Department of Radiation Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania Philadelphia, PA. Electronic address: magarwalmd@gmail.com.'}]",Brachytherapy,['10.1016/j.brachy.2020.07.005'] 683,33054533,"Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.","BACKGROUND The SPRINT-MS trial demonstrated benefit of ibudilast on brain atrophy over 96 weeks in progressive multiple sclerosis (MS). Optical coherence tomography (OCT) was performed in all trial participants. OBJECTIVE Report the OCT results of the SPRINT-MS trial. METHODS OCT was obtained at baseline and every 6 months using spectral domain OCT and analyzed by an OCT reading center. Change in each OCT outcome measure by treatment group was estimated using linear mixed models. RESULTS Change in pRNFL thickness was +0.0424 uM/year (95% confidence interval (CI): -0.3091 to 0.3939) for ibudilast versus -0.2630 uM (95% CI: -0.5973 to 0.0714) for placebo ( n  = 244, p  = 0.22). Macular volume change was -0.00503 mm 3 /year (-0.02693 to 0.01688) with ibudilast versus -0.03659 mm 3 /year (-0.05824 to -0.01494) for placebo in the Spectralis cohort ( n  = 61, p  = 0.044). For the Cirrus cohort, macular volume change was -0.00040 mm 3 /year (-0.02167, 0.020866) with ibudilast compared to -0.02083 mm 3 /year (-0.04134 to -0.00033) for placebo ( n  = 183, p  = 0.1734). Ganglion cell-inner plexiform layer thickness change, available from Cirrus, was -0.4893 uM/year (-0.9132, -0.0654) with ibudilast versus -0.9587 uM/year (-1.3677, -0.5498) with placebo ( n  = 183, p  = 0.12). CONCLUSION Retinal thinning in MS may be attenuated by ibudilast. Sample size estimates suggest OCT can be a viable outcome measure in progressive MS trials if a therapy has a large treatment effect. TRIAL REGISTRATION NN102/SPRINT-MS ClinicalTrials.gov number, NCT01982942.",2021,Macular volume change was -0.00503 mm 3 /year,['progressive multiple sclerosis'],"['Optical coherence tomography (OCT', 'placebo']","['Macular volume change', 'pRNFL thickness', 'Ganglion cell-inner plexiform layer thickness change']","[{'cui': 'C1095979', 'cui_str': 'Progressive multiple sclerosis'}]","[{'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0035316', 'cui_str': 'Retinal Ganglion Cells'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0450207', 'cui_str': 'Plexiform'}]",,0.511881,Macular volume change was -0.00503 mm 3 /year,"[{'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Bermel', 'Affiliation': 'Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Janel K', 'Initials': 'JK', 'LastName': 'Fedler', 'Affiliation': 'Data Coordinating Center, Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kaiser', 'Affiliation': 'Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Novalis', 'Affiliation': 'Digital Angiography Reading Center, Great Neck, NY, USA.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Schneebaum', 'Affiliation': 'Digital Angiography Reading Center, Great Neck, NY, USA.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Klingner', 'Affiliation': 'Data Coordinating Center, Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Williams', 'Affiliation': 'Digital Angiography Reading Center, Great Neck, NY, USA.'}, {'ForeName': 'Jon W', 'Initials': 'JW', 'LastName': 'Yankey', 'Affiliation': 'Data Coordinating Center, Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Dixie J', 'Initials': 'DJ', 'LastName': 'Ecklund', 'Affiliation': 'Data Coordinating Center, Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Chase', 'Affiliation': 'Clinical Coordinating Center, Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Naismith', 'Affiliation': 'Department of Neurology, Washington University, St. Louis, MI, USA.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'Klawiter', 'Affiliation': 'Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Goodman', 'Affiliation': 'Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Coffey', 'Affiliation': 'Data Coordinating Center, Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Fox', 'Affiliation': 'Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.'}]","Multiple sclerosis (Houndmills, Basingstoke, England)",['10.1177/1352458520964409'] 684,33054556,Augmenting Frontal Dopamine Tone Enhances Maintenance over Gating Processes in Working Memory.,"The contents of working memory must be maintained in the face of distraction, but updated when appropriate. To manage these competing demands of stability and flexibility, maintained representations in working memory are complemented by distinct gating mechanisms that selectively transmit information into and out of memory stores. The operations of such dopamine-dependent gating systems in the midbrain and striatum and their complementary dopamine-dependent memory maintenance operations in the cortex may therefore be dissociable. If true, selective increases in cortical dopamine tone should preferentially enhance maintenance over gating mechanisms. To test this hypothesis, tolcapone, a catechol-O-methyltransferase inhibitor that preferentially increases cortical dopamine tone, was administered in a randomized, double-blind, placebo-controlled, within-subject fashion to 49 participants who completed a hierarchical working memory task that varied maintenance and gating demands. Tolcapone improved performance in a condition with higher maintenance requirements and reduced gating demands, reflected in a reduction in the slope of RTs across the distribution. Resting-state fMRI data demonstrated that the degree to which tolcapone improved performance in individual participants correlated with increased connectivity between a region important for stimulus response mappings (left dorsal premotor cortex) and cortical areas implicated in visual working memory, including the intraparietal sulcus and fusiform gyrus. Together, these results provide evidence that augmenting cortical dopamine tone preferentially improves working memory maintenance.",2021,"Tolcapone improved performance in a condition with higher maintenance requirements and reduced gating demands, reflected in a reduction in the slope of RTs across the distribution.",['49 participants who completed a hierarchical working memory task that varied maintenance and gating demands'],"['placebo', 'Tolcapone']",['working memory maintenance'],"[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0246330', 'cui_str': 'tolcapone'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]",49.0,0.073384,"Tolcapone improved performance in a condition with higher maintenance requirements and reduced gating demands, reflected in a reduction in the slope of RTs across the distribution.","[{'ForeName': 'Daniella J', 'Initials': 'DJ', 'LastName': 'Furman', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Zhihao', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'University of California, Berkeley.'}, {'ForeName': 'Christopher H', 'Initials': 'CH', 'LastName': 'Chatham', 'Affiliation': 'F. Hoffman-La Roche AG, Basel Switzerland.'}, {'ForeName': 'Maxwell', 'Initials': 'M', 'LastName': 'Good', 'Affiliation': 'University of California, Berkeley.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Badre', 'Affiliation': 'Brown University.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Hsu', 'Affiliation': 'University of California, Berkeley.'}, {'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'Kayser', 'Affiliation': 'University of California, San Francisco.'}]",Journal of cognitive neuroscience,['10.1162/jocn_a_01641'] 685,33268424,"Simplifying and optimising management of acute malnutrition in children aged 6 to 59 months: study protocol for a community-based individually randomised controlled trial in Kasaï, Democratic Republic of Congo.","INTRODUCTION Acute malnutrition (AM) is a continuum condition, arbitrarily divided into moderate and severe AM (SAM) categories, funded and managed in separate programmes under different protocols. Optimising acute MAlnutrition (OptiMA) treatment aims to simplify and optimise AM management by treating children with mid-upper arm circumference (MUAC) <125 mm or oedema with one product-ready-to-use therapeutic food-at a gradually tapered dose. Our main objective was to compare the OptiMA strategy with the standard nutritional protocol in children 6-59 months presenting with MUAC <125 mm or oedema without additional complications, as well as in children classified as uncomplicated SAM (ie, MUAC <115 mm or weight-for-height Z-score (WHZ) <-3 or with oedema). METHODS AND ANALYSIS This study was a non-inferiority, individually randomised controlled clinical trial conducted at community level in the Democratic Republic of Congo. Children 6-59 months presenting with MUAC <125 mm or WHZ <-3 or with bipedal oedema and without medical complication were included after signed informed consent in outpatient health facilities. All participants were followed for 6 months. Success in both arms was defined at 6 months post inclusion as being alive, not acutely malnourished per the definition applied at inclusion and without an additional episode of AM throughout the 6-month observation period. Recovery among children with uncomplicated SAM was the main secondary outcome. For the primary objective, 890 participants were needed, and 480 children with SAM were needed for the main secondary objective. We will perform non-inferiority analyses in per-protocol and intention-to-treat basis for both outcomes. ETHICS AND DISSEMINATION Ethics approvals were obtained from the National Health Ethics Committee of the Democratic Republic of Congo and from the Ethics Evaluation Committee of Inserm, the French National Institute for Health and Medical Research (Paris, France). We will submit results for publication to a peer-reviewed journal and disseminate findings in international and national conferences and meetings. TRIAL REGISTRATION NUMBER NCT03751475. Registered 19 September 2018, https://clinicaltrials.gov/ct2/show/NCT03751475.",2020,"Success in both arms was defined at 6 months post inclusion as being alive, not acutely malnourished per the definition applied at inclusion and without an additional episode of AM throughout the 6-month observation period.","['children with uncomplicated SAM', 'children 6-59 months presenting with MUAC <125\u2009mm or oedema without additional complications, as well as in children classified as uncomplicated SAM (ie, MUAC <115\u2009mm or weight-for-height Z-score (WHZ) <-3 or with oedema', 'children aged 6 to 59 months: study protocol for a community-based individually randomised controlled trial in Kasaï, Democratic Republic of Congo', 'children with mid-upper arm circumference (MUAC) <125\u2009mm or oedema with one product-ready-to-use therapeutic food-at a gradually tapered dose', 'Children 6-59 months presenting with MUAC <125\u2009mm or WHZ <-3 or with bipedal oedema and without medical complication were included after signed informed consent in outpatient health facilities', 'community level in the Democratic Republic of Congo', '890 participants were needed, and 480 children with SAM']",[],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0424670', 'cui_str': 'Weight for height'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C2599718', 'cui_str': 'Clinical Trial Protocols'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009738', 'cui_str': 'Congo'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0441640', 'cui_str': 'Tapering - action'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0043444', 'cui_str': 'Zaire'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C4319609', 'cui_str': '480'}]",[],[],890.0,0.236807,"Success in both arms was defined at 6 months post inclusion as being alive, not acutely malnourished per the definition applied at inclusion and without an additional episode of AM throughout the 6-month observation period.","[{'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Cazes', 'Affiliation': 'University of Bordeaux, Inserm, French National Research Institute for Sustainable Development (IRD), Bordeaux Population Health Research Center, Team IDLIC, UMR 1219, Bordeaux, France cecile.cazes@u-bordeaux.fr.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Phelan', 'Affiliation': 'The Alliance for International Medical Action (ALIMA), Paris, France.'}, {'ForeName': 'Victoire', 'Initials': 'V', 'LastName': 'Hubert', 'Affiliation': 'The Alliance for International Medical Action (ALIMA), Kamuesha, Democratic Republic of Congo.'}, {'ForeName': 'Rodrigue', 'Initials': 'R', 'LastName': 'Alitanou', 'Affiliation': 'The Alliance for International Medical Action (ALIMA), Kamuesha, Democratic Republic of Congo.'}, {'ForeName': 'Harouna', 'Initials': 'H', 'LastName': 'Boubacar', 'Affiliation': 'The Alliance for International Medical Action (ALIMA), Kamuesha, Democratic Republic of Congo.'}, {'ForeName': 'Liévin', 'Initials': 'L', 'LastName': 'Izie Bozama', 'Affiliation': 'National Nutrition Programme (PRONANUT), Ministry of Health, Kinshasa, Democratic Republic of Congo.'}, {'ForeName': 'Gilbert', 'Initials': 'G', 'LastName': 'Tshibangu Sakubu', 'Affiliation': 'Kamuesha Health Zone in the Kasaï Province, Ministry of Health, Kamuesha, Democratic Republic of Congo.'}, {'ForeName': 'Aurélie', 'Initials': 'A', 'LastName': 'Beuscart', 'Affiliation': 'University of Bordeaux, Inserm, French National Research Institute for Sustainable Development (IRD), Bordeaux Population Health Research Center, Team IDLIC, UMR 1219, Bordeaux, France.'}, {'ForeName': 'Cyrille', 'Initials': 'C', 'LastName': 'Yao', 'Affiliation': ""PACCI Research Programme, University Hospital of Treichville, Abidjan, Côte d'Ivoire.""}, {'ForeName': 'Delphine', 'Initials': 'D', 'LastName': 'Gabillard', 'Affiliation': 'University of Bordeaux, Inserm, French National Research Institute for Sustainable Development (IRD), Bordeaux Population Health Research Center, Team IDLIC, UMR 1219, Bordeaux, France.'}, {'ForeName': 'Moumouni', 'Initials': 'M', 'LastName': 'Kinda', 'Affiliation': 'The Alliance for International Medical Action (ALIMA), Dakar, Senegal.'}, {'ForeName': 'Augustin', 'Initials': 'A', 'LastName': 'Augier', 'Affiliation': 'The Alliance for International Medical Action (ALIMA), Paris, France.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Anglaret', 'Affiliation': 'University of Bordeaux, Inserm, French National Research Institute for Sustainable Development (IRD), Bordeaux Population Health Research Center, Team IDLIC, UMR 1219, Bordeaux, France.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Shepherd', 'Affiliation': 'The Alliance for International Medical Action (ALIMA), Dakar, Senegal.'}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Becquet', 'Affiliation': 'University of Bordeaux, Inserm, French National Research Institute for Sustainable Development (IRD), Bordeaux Population Health Research Center, Team IDLIC, UMR 1219, Bordeaux, France.'}]",BMJ open,['10.1136/bmjopen-2020-041213'] 686,33270306,"Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the Mid-Bore Venous Vascular Closure System (VASCADE® MVP) following multi-access cardiac ablation procedures.","INTRODUCTION Manual compression (MC), historically the most common method to achieve hemostasis after percutaneous vascular procedures, is time consuming, requires prolonged bedrest, and is uncomfortable for patients and clinicians. Recent studies demonstrate the efficacy and safety of vascular closure devices and suggest shorter times to hemostasis and patient ambulation compared with MC. The current study evaluated the feasibility of the VASCADE® venous vascular closure system (VVCS) while allowing for urinary catheter (UC) elimination, and elimination of protamine and/or same calendar day discharge (SCDD). METHODS AND RESULTS In this prospective, multicenter trial, patients were enrolled and assigned to the following groups: no UC, no protamine, and/or SCDD (no co-enrollment in no protamine and SCDD). After completing the catheter-based cardiac procedure, access sites were closed using the VVCS. Outcomes included final hemostasis (all sites) without major access site-related complications at 30 days, rates of access site closure-related complications, device success, and study group success. All 168 patients had hemostasis without major access site-related complications through 30 days. In the no UC group, 160 out of 164 (97.6%) patients did not receive a UC. Additionally, 39 out of 41 (95.1%) patients received heparin without protamine reversal and no access site bleeding-related ambulation delays, and 18 out of 18 (100%) patients were discharged on the same day. There were no major access site closure-related complications, few minor complications, and adverse events were generally mild and well managed. CONCLUSION The VVCS was effective for achieving hemostasis following catheter-based procedures; access site closure-related complications and adverse events were well managed.",2021,The VVCS was effective for achieving hemostasis following catheter-based procedures; access site closure-related complications and adverse events were well managed.,['168 patients had hemostasis without major access site-related complications through 30 days'],"['no UC, no protamine, and/or SCDD (no co-enrollment in no protamine and SCDD', 'VASCADE® venous vascular closure system (VVCS', 'VVCS', 'Urinary Catheters and Protamine with Hemostasis via the Mid-Bore Venous Vascular Closure System (Vascade MVP', 'heparin', 'Manual compression (MC']","['final hemostasis (all sites) without major access site-related complications at 30 days, rates of access site closure-related complications, device success', 'no major access site closure-related complications, few minor complications, and adverse events', 'urinary catheter (UC) elimination, and elimination of protamine and/or same calendar day discharge (SCDD', 'access site bleeding-related ambulation delays']","[{'cui': 'C4319556', 'cui_str': '168'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0589360', 'cui_str': 'Site of access'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0179802', 'cui_str': 'Urinary catheter'}, {'cui': 'C0033603', 'cui_str': 'Protamines'}, {'cui': 'C1516147', 'cui_str': 'Calendars'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C2945608', 'cui_str': 'Bore'}, {'cui': 'C0026267', 'cui_str': 'Mitral valve prolapse syndrome'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0332459', 'cui_str': 'Compression'}]","[{'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0589360', 'cui_str': 'Site of access'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0179802', 'cui_str': 'Urinary catheter'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0033603', 'cui_str': 'Protamines'}, {'cui': 'C1516147', 'cui_str': 'Calendars'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]",168.0,0.181182,The VVCS was effective for achieving hemostasis following catheter-based procedures; access site closure-related complications and adverse events were well managed.,"[{'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Al-Ahmad', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Suneet', 'Initials': 'S', 'LastName': 'Mittal', 'Affiliation': 'The Valley Health System, Ridgewood, New Jersey, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'DeLurgio', 'Affiliation': ""Emory Heart and Vascular Center, Emory Saint Joseph's Hospital, Atlanta, Georgia, USA.""}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Joseph Gallinghouse', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Rodney P', 'Initials': 'RP', 'LastName': 'Horton', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Preminger', 'Affiliation': 'The Valley Health System, Ridgewood, New Jersey, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'David Burkhardt', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Natale', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}]",Journal of cardiovascular electrophysiology,['10.1111/jce.14828'] 687,33284503,A mortality risk score for heart transplants after contemporary ventricular assist device bridging.,"BACKGROUND We sought to derive a risk score for 1-year mortality following orthotopic heart transplantation (OHT) in patients bridged with a contemporary centrifugal left ventricular assist device (LVAD). METHODS Adult patients (≥18 years) in the United Network for Organ Sharing database undergoing OHT between 2010 and 2019 who were bridged with a HeartWare or HeartMate III device were included. Derivation and validation cohorts were randomly assigned with a 2:1 ratio. Threshold analysis and multivariable logistic regression were utilized to obtain adjusted odds ratios for 1-year post-OHT mortality. A risk score was generated using these adjusted odds ratios in the derivation cohort and the predictive performance of the composite index was evaluated in the validation set. RESULTS A total of 3434 patients were identified. In the derivation cohort, the mean age was 53.5 ± 12.1 years and 1758 (76.8%) were male; 1789 (78.1%) were bridged with a HeartWare device. Multivariable logistic regression revealed that recipient age ≥50 years, bilirubin level ≥2.4 mg/dl, ischemic time ≥4 h, and preoperative hemodialysis predicted 1-year post-transplant mortality. Stratification into risk groups in the validation cohort revealed significant differences in postoperative renal failure, stroke, and short-term mortality. One-year post-transplant mortality was 5%, 6.7%, and 14.8% in the low-, moderate-, and high-risk categories, respectively (p < .001). CONCLUSIONS Among patients bridged to OHT with newer generation centrifugal LVADs, older age, increasing bilirubin, longer ischemic time, and pre-OHT dialysis independently predicted post-transplant mortality. The composite risk score based on these factors may assist in patient selection and prognostication in those supported with contemporary LVADs.",2021,"Stratification into risk groups in the validation cohort revealed significant differences in postoperative renal failure, stroke, and short-term mortality.","['3434 patients were identified', 'patients bridged with a contemporary centrifugal left ventricular assist device (LVAD', 'Adult patients (≥18 years) in the United Network for Organ Sharing database undergoing OHT between 2010 and 2019 who were bridged with a HeartWare or HeartMate III device were included', 'In the derivation cohort, the mean age was 53.5\u2009±\u200912.1 years and 1758 (76.8%) were male; 1789 (78.1%) were bridged with a HeartWare device']",['orthotopic heart transplantation (OHT'],"['transplant mortality', 'postoperative renal failure, stroke, and short-term mortality', 'mortality risk score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0221821', 'cui_str': 'Dental bridge'}, {'cui': 'C1301962', 'cui_str': 'Centrifugal'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0574893', 'cui_str': 'Orthotopic'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0574893', 'cui_str': 'Orthotopic'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}]","[{'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0542211', 'cui_str': 'Postoperative renal failure'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",3434.0,0.0903304,"Stratification into risk groups in the validation cohort revealed significant differences in postoperative renal failure, stroke, and short-term mortality.","[{'ForeName': 'Lauren V', 'Initials': 'LV', 'LastName': 'Huckaby', 'Affiliation': 'Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Laura M', 'Initials': 'LM', 'LastName': 'Seese', 'Affiliation': 'Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Hickey', 'Affiliation': 'Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Sultan', 'Affiliation': 'Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Kilic', 'Affiliation': 'Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.'}]",Journal of cardiac surgery,['10.1111/jocs.15188'] 688,33261915,Support for a nicotine reduction policy among participants enrolled in a 20-week trial of very low nicotine content cigarettes.,"INTRODUCTION The Food and Drug Administration is considering a policy to drastically reduce the allowable nicotine content of cigarettes. The current study examined whether the policy implementation approach, i.e., either immediately reducing nicotine content to very low levels or gradually reducing nicotine content over an extended period, influences policy support among people who smoke cigarettes. METHODS Adults who smoked daily were randomly assigned (double-blind) to an immediate nicotine reduction condition (0.4 mg/g nicotine cigarettes), a gradual nicotine reduction condition (15.5 to 0.4 mg/g), or a control condition (15.5 mg/g) for 20 weeks. Participants were asked if they would ""support or oppose a law that reduced the amount of nicotine in cigarettes, to make cigarettes less addictive."" Logistic regression analyses assessed if policy support was affected by treatment condition, demographic covariates, interest in quitting, and subjective cigarette effects. RESULTS At Week 20 (N = 957 completers), 60.4% of participants supported the policy, 17.4% opposed, and 22.2% responded ""Don't know."" Policy support did not differ by treatment condition. Support was greater among those interested in quitting (OR = 3.37, 95% CI = 2.49, 4.55). Support was lower among males (OR = 0.49, 95% CI = 0.37, 0.67), those with greater dependence scores (OR = 0.92, 95% CI = 0.86, 0.99) and participants aged 18-24 (OR = 0.53, 95% CI = 0.28, 0.99). No other covariates were associated with policy support. CONCLUSIONS The majority of participants supported a nicotine reduction policy. The implementation approach, immediate or gradual reduction, did not affect policy support. Participants interested in quitting smoking were more likely to support a nicotine reduction policy.",2021,"Support was lower among males (OR = 0.49, 95% CI = 0.37, 0.67), those with greater dependence scores (OR = 0.92, 95% CI = 0.86, 0.99) and participants aged 18-24 (OR = 0.53, 95% CI = 0.28, 0.99).","['participants enrolled in a 20-week trial of very low nicotine content cigarettes', 'people who smoke cigarettes', 'Adults who smoked daily']","['gradual nicotine reduction condition', 'immediate nicotine reduction condition (0.4\xa0mg/g nicotine cigarettes']","['demographic covariates, interest in quitting, and subjective cigarette effects', 'quitting smoking']","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0442811', 'cui_str': 'Very low'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0439833', 'cui_str': 'Gradual'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C1300563', 'cui_str': 'g/kg'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}]",,0.0512707,"Support was lower among males (OR = 0.49, 95% CI = 0.37, 0.67), those with greater dependence scores (OR = 0.92, 95% CI = 0.86, 0.99) and participants aged 18-24 (OR = 0.53, 95% CI = 0.28, 0.99).","[{'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Denlinger-Apte', 'Affiliation': 'Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: rdenling@wakehealth.edu.'}, {'ForeName': 'Joseph S', 'Initials': 'JS', 'LastName': 'Koopmeiners', 'Affiliation': 'Division of Biostatistics, School of Public Health and Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: koopm007@umn.edu.'}, {'ForeName': 'Jennifer W', 'Initials': 'JW', 'LastName': 'Tidey', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI 02912, USA. Electronic address: jennifer_tidey@brown.edu.'}, {'ForeName': 'Xianghua', 'Initials': 'X', 'LastName': 'Luo', 'Affiliation': 'Division of Biostatistics, School of Public Health and Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: luox0054@umn.edu.'}, {'ForeName': 'Tracy T', 'Initials': 'TT', 'LastName': 'Smith', 'Affiliation': 'Hollings Cancer Center and Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29425, USA. Electronic address: smithtra@musc.edu.'}, {'ForeName': 'Lauren R', 'Initials': 'LR', 'LastName': 'Pacek', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27705, USA. Electronic address: lauren.pacek@duke.edu.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Joseph McClernon', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27705, USA.'}, {'ForeName': 'Joni A', 'Initials': 'JA', 'LastName': 'Jensen', 'Affiliation': 'Masonic Cancer Center and Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: jense010@umn.edu.'}, {'ForeName': 'Suzanne M', 'Initials': 'SM', 'LastName': 'Colby', 'Affiliation': 'Department Psychiatry and Human Behavior, Brown University, Providence, RI 02912, USA. Electronic address: suzanne_colby@brown.edu.'}, {'ForeName': 'Herbert H', 'Initials': 'HH', 'LastName': 'Severson', 'Affiliation': 'Oregon Research Institute, Eugene, OR 97403, USA. Electronic address: herb@ori.org.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'Donny', 'Affiliation': 'Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: edonny@wakehealth.edu.'}, {'ForeName': 'Dorothy K', 'Initials': 'DK', 'LastName': 'Hatsukami', 'Affiliation': 'Masonic Cancer Center and Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: hatsu001@umn.edu.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106727'] 689,33267922,The utility of household Grocery Purchase Quality Index scores as an individual diet quality metric.,"The Grocery Purchase Quality Index (GPQI) reflects concordance between household grocery purchases and US dietary recommendations. However, it is unclear whether GPQI scores calculated from partial purchasing records reflect individual-level diet quality. This secondary analysis of a 9-month randomised controlled trial examined concordance between the GPQI (range 0-75, scaled to 100) calculated from 3 months of loyalty-card linked partial (≥50 %) household grocery purchasing data and individual-level Healthy Eating Index (HEI) scores at baseline and 3 months calculated from FFQ (n 209). Concordance was assessed with overall and demographic-stratified partially adjusted correlations; covariate-adjusted percentage score differences, cross-classification and weighted κ coefficients assessed concordance across GPQI tertiles (T). Participants were middle aged (55·4 (13·9) years), female (90·3 %), from non-smoking households (96·4 %) and without children (70·7 %). Mean GPQI (54·8 (9·1) %) scores were lower than HEI scores (baseline: 73·2 (9·1) %, 3 months: 72·4 (9·4) %) and moderately correlated (baseline r 0·41 v. 3 months r 0·31, P < 0·001). Correlations were stronger among participants with ≤ bachelor's degree, obesity and children. Scores showed moderate agreement (κ = 0·25); concordance was highest in T3. Participants with high (T3) v. low (T1) GPQI scores had 7·3-10·6 higher odds of having HEI scores >80 % at both time points. Household-level GPQI was moderately correlated with self-reported intake, indicating their promise for evaluating diet quality. Partial purchasing data appear to moderately reflect individual diet quality and may be useful in interventions monitoring changes in diet quality.",2021,"Mean GPQI (54.8(9.1)%) scores were lower than HEI scores (baseline: 73.2(9.1)%, 3-months: 72.4(9.4)%), and moderately correlated (baseline r=0.41 vs. 3-month r=0.31, p<0.001).","['Participants were mostly middle-aged (55.4(13.9) years), female (90.3%), from non-smoking households (96.4%), without children (70.7']",[],"['grocery purchasing data and individual-level Healthy Eating Index', 'grocery purchase quality', 'Mean GPQI (54.8(9.1)%) scores', 'HEI) scores', 'HEI and GPQI concordance']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4280021', 'cui_str': 'Healthy Eating Index'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0390455,"Mean GPQI (54.8(9.1)%) scores were lower than HEI scores (baseline: 73.2(9.1)%, 3-months: 72.4(9.4)%), and moderately correlated (baseline r=0.41 vs. 3-month r=0.31, p<0.001).","[{'ForeName': 'Haley Wynne', 'Initials': 'HW', 'LastName': 'Parker', 'Affiliation': 'Department of Nutrition and Food Sciences, University of Rhode Island, Kingston, RI02881, USA.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'de Araujo', 'Affiliation': 'Department of Nutrition and Food Sciences, University of Rhode Island, Kingston, RI02881, USA.'}, {'ForeName': 'Anne N', 'Initials': 'AN', 'LastName': 'Thorndike', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA02114, USA.'}, {'ForeName': 'Maya K', 'Initials': 'MK', 'LastName': 'Vadiveloo', 'Affiliation': 'Department of Nutrition and Food Sciences, University of Rhode Island, Kingston, RI02881, USA.'}]",The British journal of nutrition,['10.1017/S0007114520004833'] 690,33283424,The effect of empathy training given to midwives on the empathic communication skills of midwives and the birth satisfaction of mothers giving birth with the help of these midwives: A quasi-experimental study.,"RATIONALE, AIMS, AND OBJECTIVES Empathic attitudes and behaviours of midwives directly affect obstetric outcomes. The study aims to examine the effect of empathy training on the empathic communication skills of midwives and the childbirth satisfaction of primiparous mothers. METHODS This quasi-experimental study has two sample groups including midwives working in the delivery unit (n = 15) and mothers giving birth with the help of these midwives (n = 134). Empathy training was given to the midwives through a 32-hour program involving didactic narrative, creative drama, and psychodrama techniques. A ""Descriptive Information Form,"" and the ""Empathic Communication Skills"" and ""Empathic Tendencies"" scales were used to collect data from the midwives, and another ""Descriptive Information Form"" and the ""Scale for Measuring Maternal Satisfaction in Normal Birth"" were used for the maternal data. RESULTS Empathic communication skills and empathic tendencies of the midwives were found to be higher right after and 8 weeks after the training than before the training (P = .001, P = .040, respectively). The total score and sub-dimensions of the maternal satisfaction scale (ie, midwifery care, respect for privacy, meeting expectations, postpartum care) were found to be higher in mothers giving birth after the midwives' empathy training than those giving birth before (P < .001). A higher level of maternal birth satisfaction was seen in mothers giving birth right after the training (94%) than those giving birth before training (3%). CONCLUSION The empathy training improved both the empathy skills of midwives, and translated to improved maternal satisfaction with birth among their mothers. It is recommended to increase the number of follow-ups to evaluate the long-term effect of empathy training.",2021,"The empathy training improved both the empathy skills of midwives, and translated to improved maternal satisfaction with birth among their mothers.","['two sample groups including midwives working in the delivery unit (n = 15) and mothers giving birth with the help of these midwives (n = 134', 'midwives and the childbirth satisfaction of primiparous mothers', 'midwives on the empathic communication skills of midwives and the birth satisfaction of mothers giving birth with the help of these midwives']","['Empathy training', 'empathy training']","['maternal birth satisfaction', 'total score and sub-dimensions of the maternal satisfaction scale (ie, midwifery care, respect for privacy, meeting expectations, postpartum care', 'Empathic communication skills and empathic tendencies', 'maternal satisfaction']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0026083', 'cui_str': 'Professional midwife'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0033150', 'cui_str': 'Para 1'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}]","[{'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0026082', 'cui_str': 'Midwifery'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C0080048', 'cui_str': 'Privacy'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0032782', 'cui_str': 'Postpartum care'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}]",134.0,0.0243447,"The empathy training improved both the empathy skills of midwives, and translated to improved maternal satisfaction with birth among their mothers.","[{'ForeName': 'Songul', 'Initials': 'S', 'LastName': 'Aktas', 'Affiliation': 'Department of Obstetrics and Gynecology Nursing, Faculty of Health Science, Karadeniz Technical University, Trabzon, Turkey.'}, {'ForeName': 'Türkan', 'Initials': 'T', 'LastName': 'Pasinlioğlu', 'Affiliation': 'Department of Obstetrics and Gynecology Nursing, Faculty of Health Science, Sanko University, Gaziantep, Turkey.'}]",Journal of evaluation in clinical practice,['10.1111/jep.13523'] 691,33260212,Impact of digitally acquired peer diagnostic input on diagnostic confidence in outpatient cases: A pragmatic randomized trial.,"OBJECTIVE The study sought to evaluate if peer input on outpatient cases impacted diagnostic confidence. MATERIALS AND METHODS This randomized trial of a peer input intervention occurred among 28 clinicians with case-level randomization. Encounters with diagnostic uncertainty were entered onto a digital platform to collect input from ≥5 clinicians. The primary outcome was diagnostic confidence. We used mixed-effects logistic regression analyses to assess for intervention impact on diagnostic confidence. RESULTS Among the 509 cases (255 control; 254 intervention), the intervention did not impact confidence (odds ratio [OR], 1.46; 95% confidence interval [CI], 0.999-2.12), but after adjusting for clinician and case traits, the intervention was associated with higher confidence (OR, 1.53; 95% CI, 1.01-2.32). The intervention impact was greater in cases with high uncertainty (OR, 3.23; 95% CI, 1.09- 9.52). CONCLUSIONS Peer input increased diagnostic confidence primarily in high-uncertainty cases, consistent with findings that clinicians desire input primarily in cases with continued uncertainty.",2021,"The intervention impact was greater in cases with high uncertainty (OR, 3.23; 95% CI, 1.09- 9.52). ","['Encounters with diagnostic uncertainty', '28 clinicians with case-level randomization', 'outpatient cases']","['digitally acquired peer diagnostic input', 'peer input intervention']",['diagnostic confidence'],"[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0087130', 'cui_str': 'Uncertain'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}]","[{'cui': 'C0439661', 'cui_str': 'Acquired'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}]",,0.13942,"The intervention impact was greater in cases with high uncertainty (OR, 3.23; 95% CI, 1.09- 9.52). ","[{'ForeName': 'Elaine C', 'Initials': 'EC', 'LastName': 'Khoong', 'Affiliation': 'Division of General Internal Medicine, Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Valy', 'Initials': 'V', 'LastName': 'Fontil', 'Affiliation': 'Division of General Internal Medicine, Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Natalie A', 'Initials': 'NA', 'LastName': 'Rivadeneira', 'Affiliation': 'Division of General Internal Medicine, Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Mekhala', 'Initials': 'M', 'LastName': 'Hoskote', 'Affiliation': 'Berkeley School of Public Health and UCSF School of Medicine, University of California, Berkeley-University of California, San Francisco Joint Medical Program, Berkeley, California, USA.'}, {'ForeName': 'Shantanu', 'Initials': 'S', 'LastName': 'Nundy', 'Affiliation': 'Milken Institute School of Public Health, Department of Health Policy and Management, George Washington University, Washington, DC, USA.'}, {'ForeName': 'Courtney R', 'Initials': 'CR', 'LastName': 'Lyles', 'Affiliation': 'Division of General Internal Medicine, Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Urmimala', 'Initials': 'U', 'LastName': 'Sarkar', 'Affiliation': 'Division of General Internal Medicine, Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.'}]",Journal of the American Medical Informatics Association : JAMIA,['10.1093/jamia/ocaa278'] 692,33268417,Adolescent transition to adult care for HIV-infected adolescents in Kenya (ATTACH): study protocol for a hybrid effectiveness-implementation cluster randomised trial.,"INTRODUCTION Successfully transitioning adolescents to adult HIV care is critical for optimising outcomes. Disclosure of HIV status, a prerequisite to transition, remains suboptimal in sub-Saharan Africa. Few interventions have addressed both disclosure and transition. An adolescent transition package (ATP) that combines disclosure and transition tools could support transition and improve outcomes. METHODS AND ANALYSIS In this hybrid type 1 effectiveness-implementation cluster randomised controlled trial, 10 HIV clinics with an estimated ≥100 adolescents and young adults age 10-24 living with HIV (ALWHIV) in Kenya will be randomised to implement the ATP and compared with 10 clinics receiving standard of care. The ATP includes provider tools to assist disclosure and transition. Healthcare providers at intervention clinics will receive training on ATP use and support to adapt it through continuous quality improvement cycles over the initial 6 months of the study, with continued implementation for 1 year. The primary outcome is transition readiness among ALWHIV ages 15-24 years, assessed 6 monthly using a 22-item readiness score. Secondary outcomes including retention and viral suppression among ALWHIV at the end of the intervention period (month 18), implementation outcomes (acceptability, feasibility, fidelity, coverage and penetration) and programme costs complement effectiveness outcomes. The primary analysis will be intent to treat, using mixed-effects linear regression models to compare transition readiness scores (overall and by domain (HIV literacy, self-management, communication, support)) over time in control and intervention sites with adjustment for multiple testing, accounting for clustering by clinic and repeated assessments. We will estimate the coefficients and 95% CIs with a two- sided α=0.05. ETHICS AND DISSEMINATION The study was approved by the University of Washington Institutional Review Board and the Kenyatta National Hospital Ethics and Research Committee. Study results will be shared with participating facilities, county and national policy-makers. TRIALS REGISTRATION NUMBER NCT03574129; Pre-results.",2020,"Secondary outcomes including retention and viral suppression among ALWHIV at the end of the intervention period (month 18), implementation outcomes (acceptability, feasibility, fidelity, coverage and penetration) and programme costs complement effectiveness outcomes.","['10 HIV clinics with an estimated ≥100 adolescents and young adults age 10-24 living with HIV (ALWHIV) in Kenya', 'Adolescent transition to adult care for HIV-infected adolescents in Kenya (ATTACH']",['10 clinics receiving standard of care'],"['transition readiness among ALWHIV ages 15-24 years, assessed 6 monthly using a 22-item readiness score', 'transition readiness scores (overall and by domain (HIV literacy, self-management, communication, support)) over time in control and intervention sites with adjustment for multiple testing, accounting for clustering by clinic and repeated assessments', 'retention and viral suppression among ALWHIV at the end of the intervention period (month 18), implementation outcomes (acceptability, feasibility, fidelity, coverage and penetration) and programme costs complement effectiveness outcomes']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C3178922', 'cui_str': 'Pediatric Transition To Adult Care'}]","[{'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0009498', 'cui_str': 'Complement'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",10.0,0.179408,"Secondary outcomes including retention and viral suppression among ALWHIV at the end of the intervention period (month 18), implementation outcomes (acceptability, feasibility, fidelity, coverage and penetration) and programme costs complement effectiveness outcomes.","[{'ForeName': 'Irene N', 'Initials': 'IN', 'LastName': 'Njuguna', 'Affiliation': 'Research and Programs, Kenyatta National Hospital, Nairobi, Kenya njugunairene06@yahoo.com.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Beima-Sofie', 'Affiliation': 'Global Health, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Caren W', 'Initials': 'CW', 'LastName': 'Mburu', 'Affiliation': 'Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Cyrus', 'Initials': 'C', 'LastName': 'Mugo', 'Affiliation': 'Research and Programs, Kenyatta National Hospital, Nairobi, Kenya.'}, {'ForeName': 'Jillian', 'Initials': 'J', 'LastName': 'Neary', 'Affiliation': 'Global Health, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Itindi', 'Affiliation': 'Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Alvin', 'Initials': 'A', 'LastName': 'Onyango', 'Affiliation': 'University of Nairobi, Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Barbra A', 'Initials': 'BA', 'LastName': 'Richardson', 'Affiliation': 'Global Health, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Arianna', 'Initials': 'A', 'LastName': 'Rubin Means', 'Affiliation': 'Global Health, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Monisha', 'Initials': 'M', 'LastName': 'Sharma', 'Affiliation': 'Global Health, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Bryan J', 'Initials': 'BJ', 'LastName': 'Weiner', 'Affiliation': 'Global Health, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Anjuli D', 'Initials': 'AD', 'LastName': 'Wagner', 'Affiliation': 'Global Health, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Oyiengo', 'Affiliation': 'Neonatal and Child Health Services, Ministry of Health, Nairobi, Kenya.'}, {'ForeName': 'Dalton', 'Initials': 'D', 'LastName': 'Wamalwa', 'Affiliation': 'Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'John-Stewart', 'Affiliation': 'Global Health, University of Washington, Seattle, Washington, USA.'}]",BMJ open,['10.1136/bmjopen-2020-039972'] 693,33269486,Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.,"AIMS Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE-TIMI 58. We hypothesized that baseline N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT) levels would help identify patients who are at higher baseline risk and we describe the treatment effects of dapagliflozin in patients according to their baseline NT-proBNP and hsTnT levels. METHODS AND RESULTS This was a pre-specified biomarker study from DECLARE-TIMI 58, a randomized, double-blind, placebo-controlled CV outcomes trial of dapagliflozin. Baseline NT-proBNP and hsTnT levels were measured in the TIMI Clinical Trials Laboratory in 14 565 patients. Among the included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of heart failure and the mean age was 63.9 years. The median baseline NT-proBNP and hsTnT levels were 75 pg/mL [interquartile range (IQR) 35-165] and 10.2 pg/mL (IQR 6.9-15.5), respectively. Patients with higher NT-proBNP and hsTnT quartiles had higher rates of CV death/HHF (Q4 vs. Q1: NT-proBNP: 4-year Kaplan-Meier event rates 13.7% vs. 1.0%; hsTnT: 11.8% vs. 1.4%; P-trend <0.001). Dapagliflozin consistently reduced the relative risk of CV death/HHF regardless of baseline NT-proBNP (P-interaction 0.72) or hsTnT quartiles (P-interaction 0.93). Given their higher baseline risk, patients with NT-proBNP and/or hsTnT levels above the median derived larger absolute risk reductions with dapagliflozin (NT-proBNP 1.9% vs. 0%, P-interaction 0.010; hsTnT 1.8% vs. 0.1%, P-interaction 0.026). CONCLUSION Patients with type 2 diabetes mellitus and higher NT-proBNP or hsTnT levels are at increased risk of CV death and HHF. Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT-proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels.",2021,"Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT-proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels.","['included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of HF and the mean age was 63.9', 'patients with type 2 diabetes (T2DM) in DECLARE-TIMI 58']","['Dapagliflozin', 'dapagliflozin', 'placebo', 'SGLT2 inhibitor therapy', 'NT-proBNP']","['risk of CV death and HHF', 'risk of the composite of cardiovascular death or hospitalization for heart failure (CV death/HHF', 'median baseline NT-proBNP and hsTnT levels', 'rates of CV death/HHF', 'Baseline NT-proBNP and hsTnT levels', 'relative risk of CV death/HHF irrespective of NT-proBNP and hsTnT levels', 'relative risk of CV death/HHF regardless of baseline NT-proBNP']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3273807', 'cui_str': 'SGLT2 Inhibitors'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}]",14565.0,0.393841,"Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT-proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels.","[{'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Zelniker', 'Affiliation': 'Division of Cardiology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Morrow', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Ofri', 'Initials': 'O', 'LastName': 'Mosenzon', 'Affiliation': 'Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.'}, {'ForeName': 'Erica L', 'Initials': 'EL', 'LastName': 'Goodrich', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Jarolim', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Sabina A', 'Initials': 'SA', 'LastName': 'Murphy', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Lawrence A', 'Initials': 'LA', 'LastName': 'Leiter', 'Affiliation': ""Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada.""}, {'ForeName': 'Darren K', 'Initials': 'DK', 'LastName': 'McGuire', 'Affiliation': 'Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Wilding', 'Affiliation': 'Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Bode', 'Affiliation': 'Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Basil S', 'Initials': 'BS', 'LastName': 'Lewis', 'Affiliation': 'Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Gause-Nilsson', 'Affiliation': 'BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Anna Maria', 'Initials': 'AM', 'LastName': 'Langkilde', 'Affiliation': 'BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Fredriksson', 'Affiliation': 'BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Itamar', 'Initials': 'I', 'LastName': 'Raz', 'Affiliation': 'Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.'}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Sabatine', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Wiviott', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}]",European journal of heart failure,['10.1002/ejhf.2073'] 694,33284201,Early or delayed parenteral nutrition for infants: what evidence is available?,"PURPOSE OF REVIEW To review the current evidence evaluating early versus delayed commencement of parenteral nutrition in infants. RECENT FINDINGS Recent studies in very premature infants (<32 weeks gestation) have shown that early commencement of parenteral nutrition immediately after birth improves physical growth. However, there are concerns that early use of very high dose of amino-acids (>3.5 g/kg/day immediately after birth) may cause metabolic acidosis, elevated blood urea, slower head growth and refeeding-hypophosphatemia syndrome. A recent multicentre randomized controlled trial found that commencement of parenteral nutrition within 24-h of admission increases the risk of infections and prolongs the duration of ventilation and ICU stay in full-term neonates, older infants and children. The study also found that delaying to day 8 of admission increased the risk of hypoglycaemia. SUMMARY Benefits of commencing parenteral nutrition on the first day of life appear to outweigh risks in very premature infants; however, it is prudent to avoid early very high doses of amino acids (>3.5 g/kg/day) in the first few days of life. In moderate to late preterm infants, if enteral feeds are not tolerated by 72 h, it is reasonable to commence parenteral nutrition. In full-term and older infants, it is preferable to avoid parenteral nutrition within 24 h of admission and consider delaying by further few days. Diligent monitoring of blood glucose, serum phosphate and other parameters is essential while on parenteral nutrition.",2021,Recent studies in very premature infants (<32 weeks gestation) have shown that early commencement of parenteral nutrition immediately after birth improves physical growth.,"['very premature infants', 'full-term neonates, older infants and children', 'very premature infants (<32 weeks gestation', 'infants']","['parenteral nutrition', 'amino-acids']","['risk of infections and prolongs the duration of ventilation and ICU stay', 'risk of hypoglycaemia']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C4551581', 'cui_str': 'Term baby'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}]",,0.0305143,Recent studies in very premature infants (<32 weeks gestation) have shown that early commencement of parenteral nutrition immediately after birth improves physical growth.,"[{'ForeName': 'Kwi', 'Initials': 'K', 'LastName': 'Moon', 'Affiliation': ""Pharmacy Department, Perth Children's Hospital, Nedlands.""}, {'ForeName': 'Shripada C', 'Initials': 'SC', 'LastName': 'Rao', 'Affiliation': 'Medical School, The University of Western Australia, Perth.'}]",Current opinion in clinical nutrition and metabolic care,['10.1097/MCO.0000000000000720'] 695,33789444,Diagnostic Labels for Rotator Cuff Disease Can Increase People's Perceived Need for Shoulder Surgery: An Online Randomized Controlled Trial.,"OBJECTIVE To investigate whether different labels for rotator cuff disease influence people's perceived need for surgery. DESIGN Randomized controlled experiment. METHODS Participants with and without shoulder pain read a vignette describing a patient with rotator cuff disease and were randomized to 1 of 6 terms describing rotator cuff disease: subacromial impingement syndrome , rotator cuff tear , bursitis , rotator cuff-related shoulder pain , shoulder sprain , and episode of shoulder pain . Perceived need for shoulder surgery was the primary outcome. Secondary outcomes included perceived need for imaging, an injection, a second opinion, and to see a specialist; perceived seriousness of the condition; recovery expectations; and perceived impact on work attendance. Using a Bonferroni correction (significance, P <.003), adjusted between-group mean differences and 99.67% confidence intervals (CIs) were obtained using a 1-way analysis of covariance. RESULTS One thousand three hundred eight (80% of 1626) responses were analyzed. Participants' mean ± SD age was 40.3 ± 16.0 years, and 59% were women. Mean perceived need for surgery (0-10 scale) was low and slightly higher among those assigned to the rotator cuff tear label compared to the bursitis label (2.6 versus 2.1; adjusted mean difference, 0.7; 99.67% CI: 0.0, 1.4). Mean perceived need for imaging (0-10) was moderate and slightly higher among those assigned to the rotator cuff tear (4.7 versus 3.7; adjusted mean difference, 1.0; 99.67% CI: 0.2, 1.9) and subacromial impingement syndrome labels (4.7 versus 3.7; adjusted mean difference, 1.0; 99.7% CI: 0.1, 1.9) compared to the bursitis label. CONCLUSION There were small differences in the perceived need for surgery and imaging between some labels, which could be important at the population level. J Orthop Sports Phys Ther 2021;51(8):401-411. Epub 31 Mar 2021. doi:10.2519/jospt.2021.10375 .",2021,"Mean perceived need for surgery (0-10 scale) was low and slightly higher among those assigned to the rotator cuff tear label compared to the bursitis label (2.6 vs. 2.1, MD 0.7, 99.67% CI: 0.0-1.4).","['Mean age (standard deviation) was 40.3 years (16.0), 59% were women', 'Shoulder Surgery', 'Participants with and without shoulder pain read a vignette describing a patient with rotator cuff disease']","['six labels: subacromial impingement syndrome, rotator cuff tear, bursitis, rotator-cuff-related shoulder pain, shoulder sprain and episode of shoulder pain ']","['subacromial impingement syndrome label', 'Mean perceived need for surgery', 'Mean perceived need for imaging', 'perceived need for imaging, an injection, a second opinion and to see a specialist, perceived seriousness of the condition, recovery expectations, and perceived impact on work attendance']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0186321', 'cui_str': 'Operative procedure on shoulder'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085515', 'cui_str': 'Structure of rotator cuff including muscles and tendons'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0376685', 'cui_str': 'Impingement syndrome of shoulder region'}, {'cui': 'C0263912', 'cui_str': 'Rotator cuff syndrome'}, {'cui': 'C0006444', 'cui_str': 'Bursitis'}, {'cui': 'C0085515', 'cui_str': 'Structure of rotator cuff including muscles and tendons'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0272869', 'cui_str': 'Sprain of shoulder'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}]","[{'cui': 'C0376685', 'cui_str': 'Impingement syndrome of shoulder region'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0036524', 'cui_str': 'Second Opinion'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0205404', 'cui_str': 'Serious'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}]",,0.33873,"Mean perceived need for surgery (0-10 scale) was low and slightly higher among those assigned to the rotator cuff tear label compared to the bursitis label (2.6 vs. 2.1, MD 0.7, 99.67% CI: 0.0-1.4).","[{'ForeName': 'Joshua R', 'Initials': 'JR', 'LastName': 'Zadro', 'Affiliation': ''}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': ""O'Keeffe"", 'Affiliation': ''}, {'ForeName': 'Giovanni E', 'Initials': 'GE', 'LastName': 'Ferreira', 'Affiliation': ''}, {'ForeName': 'Romi', 'Initials': 'R', 'LastName': 'Haas', 'Affiliation': ''}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Harris', 'Affiliation': ''}, {'ForeName': 'Rachelle', 'Initials': 'R', 'LastName': 'Buchbinder', 'Affiliation': ''}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Maher', 'Affiliation': ''}]",The Journal of orthopaedic and sports physical therapy,['10.2519/jospt.2021.10375'] 696,33292887,"Effect of a moderate dose of fructose in solid foods on TAG, glucose and uric acid before and after a 1-month moderate sugar-feeding period.","There are few data on the effects on TAG, glucose and uric acid of chronic consumption of a moderate dose of fructose in solid foods. Twenty-eight participants with prediabetes and/or obesity and overweight commenced the study (BMI 32·3 kg/m2, age 44·7 years, fasting glucose 5·3 (sd 0·89) mmol/l and 2-h glucose 6·6 (sd 1·8) mmol/l). Twenty-four men and women who completed the study consumed, in random order, two acute test meals of muffins sweetened with either fructose or sucrose. This was followed by 4-week chronic consumption of 42 g/d of either fructose or sucrose in low-fat muffins after which the two meal tests were repeated. The sugar type in the chronic feeding period was also randomised. Fasting TAG increased after chronic consumption of fructose by 0·31 (sd 0·37) mmol/l compared with sucrose in those participants with impaired fasting glucose (IFG)/impaired glucose tolerance (IGT) (P = 0·004). Total cholesterol (0·33 mmol/l), LDL-cholesterol (0·24 mmol/l) and HDL-cholesterol (0·08 mmol/l) increased significantly over the 1- month feeding period with no differences between muffin types. Fasting glucose was not different after 1 month of muffin consumption. Uric acid response was not different between the two sugar types either baseline or 1 month, and there were no differences between baseline and 1 month. The increase in fasting TAG in participants with IFG/IGT suggests the need for caution in people at increased risk of type 2 diabetes.",2021,Uric acid response was not different between the two sugar types either baseline or 1 month and there were no differences between baseline and 1 month.,"['and/or obesity and overweight commenced the study (BMI 32.3 kg/m2, age 44.7 years, fasting glucose 5.3', 'Twenty-eight participants with prediabetes', 'Twenty-four men and women who completed the study consumed, in random order, two acute test meals of muffins sweetened with either']","['fructose or sucrose', 'fructose']","['Fasting glucose', 'Total cholesterol (0.33 mmol/L), LDL cholesterol', 'triglyceride, glucose and uric acid', 'fasting triglyceride', 'Fasting triglyceride', 'HDL cholesterol', 'triglyceride, glucose and uric acid of chronic consumption', 'Uric acid response']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0452660', 'cui_str': 'Muffin'}]","[{'cui': 'C0016745', 'cui_str': 'Fructose'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C4517449', 'cui_str': '0.33'}, {'cui': 'C1532563', 'cui_str': 'mmol/L'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]",28.0,0.0240448,Uric acid response was not different between the two sugar types either baseline or 1 month and there were no differences between baseline and 1 month.,"[{'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Clifton', 'Affiliation': 'UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA5000, Australia.'}, {'ForeName': 'Jennifer B', 'Initials': 'JB', 'LastName': 'Keogh', 'Affiliation': 'UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA5000, Australia.'}]",The British journal of nutrition,['10.1017/S0007114520004845'] 697,33259999,Efficacy and safety of transvaginal high-intensity focused ultrasound therapy in women with symptomatic uterine leiomyomas: A clinical trial.,"OBJECTIVE To evaluate the efficacy and safety of transvaginal high-intensity focused ultrasound (vHIFU) therapy in women with symptomatic uterine leiomyomas. METHODS This first-in-human, two-center, prospective, unblinded, single-arm trial was performed in the Republic of Korea from December 2017 to February 2019. Premenopausal women with symptomatic, contrast-enhanced uterine leiomyomas with a diameter ≤5 cm were eligible. Under sedation or monitored anesthesia, leiomyomas were ablated with vHIFU under ultrasound guidance. The primary endpoint was the non-perfused volume (NPV) ratio measured immediately after therapy. Secondary endpoints were changes in Uterine Fibroid Symptom-Quality of Life (UFS-QOL) scores, dysmenorrhea visual analog scale (VAS), uterine leiomyoma volume, rate of subsequent therapy, and treatment-emergent adverse events (TEAE). RESULTS Thirty-five women were screened; 13 women were enrolled and underwent vHIFU therapy for 33 uterine leiomyomas. NPV ratios were 0.76 ± 0.27 (mean ± SD); the lower limit of a one-sided 97.5 % confidence interval was 0.67, surpassing the non-inferiority cut-off of 0.50. UFS-QOL scores (symptom severity score, median, baseline: 66.60, 3-month follow-up: 32.85; p = 0.0010; health related quality of life score, median, baseline: 41.40, 3-month follow-up: 73.30; p = 0.0010) and dysmenorrhea VAS (mean, baseline: 50.92, 3-month follow-up: 20.67; p = 0.0019) improved significantly. Volume of uterine leiomyoma was reduced (median, baseline: 8.10 cm 3 , 3-month follow=-up: 5.30 cm 3 ; p < 0.0001), and none received subsequent therapy. Twenty-six TEAEs from 8 participants were observed, and all TEAEs were resolved without sequelae. CONCLUSION vHIFU therapy exhibited promising efficacy and safety and might be considered as a treatment option for women with symptomatic uterine leiomyomas. Registration: This trial was registered at: www.clinicaltrial.gov (NCT03328260).",2021,"Volume of uterine leiomyoma was reduced (median, baseline: 8.10 cm 3 , 3-month follow=-up:","['Registration', 'Premenopausal women with symptomatic, contrast-enhanced uterine leiomyomas with a diameter ≤5 cm were eligible', 'Republic of Korea from December 2017 to February 2019', 'women with symptomatic uterine leiomyomas', 'Thirty-five women were screened; 13 women were enrolled and underwent']","['vHIFU therapy', 'transvaginal high-intensity focused ultrasound (vHIFU) therapy', 'transvaginal high-intensity focused ultrasound therapy']","['changes in Uterine Fibroid Symptom-Quality of Life (UFS-QOL) scores, dysmenorrhea visual analog scale (VAS), uterine leiomyoma volume, rate of subsequent therapy, and treatment-emergent adverse events (TEAE', 'Volume of uterine leiomyoma', 'non-perfused volume (NPV) ratio', 'Efficacy and safety', 'UFS-QOL scores (symptom severity score', 'health related quality of life score', 'NPV ratios', 'efficacy and safety', 'dysmenorrhea VAS']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0175672', 'cui_str': 'Vaginal approach'}, {'cui': 'C2348970', 'cui_str': 'High intensity focused ultrasound ablation'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013390', 'cui_str': 'Dysmenorrhea'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",13.0,0.27368,"Volume of uterine leiomyoma was reduced (median, baseline: 8.10 cm 3 , 3-month follow=-up:","[{'ForeName': 'Jae Young', 'Initials': 'JY', 'LastName': 'Lee', 'Affiliation': 'Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Kidong', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Electronic address: kidong.kim.md@gmail.com.'}, {'ForeName': 'Sung Il', 'Initials': 'SI', 'LastName': 'Hwang', 'Affiliation': 'Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Keonho', 'Initials': 'K', 'LastName': 'Son', 'Affiliation': 'Therapeutic Ultrasound Division, ALPINION Medical Systems, Seoul, Republic of Korea.'}, {'ForeName': 'Daeseung', 'Initials': 'D', 'LastName': 'Kim', 'Affiliation': 'Therapeutic Ultrasound Division, ALPINION Medical Systems, Seoul, Republic of Korea.'}, {'ForeName': 'Sun', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Therapeutic Ultrasound Division, ALPINION Medical Systems, Seoul, Republic of Korea.'}, {'ForeName': 'Yong Beom', 'Initials': 'YB', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.11.049'] 698,33268143,"Impact of specialized oral nutritional supplement on clinical, nutritional, and functional outcomes: A randomized, placebo-controlled trial in community-dwelling older adults at risk of malnutrition.","BACKGROUND & AIMS The world's over-65 population is expanding rapidly, and the risk of malnutrition is prevalent in this population. Meeting nutritional needs is a recognized strategy to reduce and address multiple debilitating adverse health outcomes associated with malnutrition. The objective of this randomized, controlled trial was to determine the effects of oral nutritional supplement (ONS) containing beta-hydroxy-beta-methylbutyrate (HMB), along with dietary counseling, on health outcomes in community-dwelling older adults at risk of malnutrition. METHODS Strengthening Health In ELDerly through nutrition (SHIELD) studied adults aged ≥ 65 years in Singapore who were recruited between August 2017 and March 2019. Participants were community ambulant and classified as medium or high risk for malnutrition using Malnutrition Universal Screening Tool (MUST). Participants (n = 811) were randomly assigned to one of two study treatments for 180 days: (i) two servings/day of ONS containing HMB with dietary counseling (n = 405) or (ii) two servings/day of placebo supplement with dietary counseling (n = 406). The primary composite outcome was 'survival without hospital (re)admission and with at least 5% weight gain to day 180'. Dietary intakes, nutritional and functional outcomes were measured at baseline, 30, 90, and 180 days. RESULTS A higher proportion in intervention group met the 180-day primary composite outcome compared to placebo (33.4% vs. 8.7%, P < 0.001), largely driven by body weight component (36.2% vs. 9.4%, P < 0.001). Survival and hospital (re)admission rate were not significantly different between the groups. Weight, BMI, and mid upper arm circumference were significantly greater in the intervention group compared to placebo during the study (all P < 0.001), and at days 30, 90, and 180 (all P < 0.05). The odds of having better nutritional status during the study were also significantly higher in the intervention group compared to placebo, as measured using MUST risk (OR = 2.68, P < 0.001) and vitamin D status (OR = 4.23, P < 0.001). Intervention group had significantly higher energy, protein, fat, and carbohydrate intakes than the placebo group (all P ≤ 0.017). Leg strength at day 90 was significantly greater for the intervention group than for the placebo group (LSM ± SE: 12.85 ± 0.22 vs. 12.17 ± 0.22; P = 0.030). Handgrip strength for females was significantly higher at day 180 for the intervention group compared to placebo (LSM ± SE: 14.18 ± 0.17 vs. 13.70 ± 0.17; P = 0.048). Within the low appendicular skeletal muscle mass index (ASMI) subgroup, the intervention group had significantly greater calf circumference at days 90 and 180 compared to placebo (both P ≤ 0.0289). CONCLUSIONS For community-dwelling older adults at risk of malnutrition, daily consumption of specialized ONS containing HMB and vitamin D for six months, along with dietary counseling, significantly improved nutritional and functional outcomes compared to placebo supplement with dietary counseling. CLINICAL TRIAL REGISTRATION www.ClinicalTrials.govNCT03245047.",2021,Handgrip strength for females was significantly higher at day 180 for the intervention group compared to placebo (LSM ± SE: 14.18 ± ,"['Participants (n\xa0', 'In ELDerly through nutrition (SHIELD) studied adults aged\xa0≥\xa065 years in Singapore who were recruited between August 2017 and March 2019', 'Strengthening Health', '811', 'community-dwelling older adults at risk of malnutrition', 'Participants were community ambulant and classified as medium or high risk for malnutrition using Malnutrition Universal Screening Tool (MUST']","['oral nutritional supplement (ONS) containing beta-hydroxy-beta-methylbutyrate (HMB', 'placebo', 'ONS containing HMB with dietary counseling', 'specialized oral nutritional supplement', 'dietary counseling', 'placebo supplement with dietary counseling']","['Handgrip strength for females', 'Weight, BMI, and mid upper arm circumference', 'nutritional and functional outcomes', 'survival without hospital (re)admission and with at least 5% weight gain to day 180', 'body weight component', 'vitamin D status ', 'calf circumference', 'higher energy, protein, fat, and carbohydrate intakes', 'Leg strength', 'Survival and hospital (re)admission rate', 'clinical, nutritional, and functional outcomes', 'Dietary intakes, nutritional and functional outcomes']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C1532006', 'cui_str': 'Malnutrition universal screening tool'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0053454', 'cui_str': '3-hydroxyisovaleric acid'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0205555', 'cui_str': 'Special'}]","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0230445', 'cui_str': 'Structure of calf of leg'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}]",811.0,0.338833,Handgrip strength for females was significantly higher at day 180 for the intervention group compared to placebo (LSM ± SE: 14.18 ± ,"[{'ForeName': 'Samuel Teong Huang', 'Initials': 'STH', 'LastName': 'Chew', 'Affiliation': 'Department of Geriatric Medicine, Changi General Hospital, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: samuel.chew.t.h@singhealth.com.sg.'}, {'ForeName': 'Ngiap Chuan', 'Initials': 'NC', 'LastName': 'Tan', 'Affiliation': 'SingHealth Polyclinics, Singapore; SingHealth-Duke NUS Family Medicine Academic Clinical Program, Singapore.'}, {'ForeName': 'Magdalin', 'Initials': 'M', 'LastName': 'Cheong', 'Affiliation': 'Department of Dietetic & Food Services, Changi General Hospital, Singapore.'}, {'ForeName': 'Jeffery', 'Initials': 'J', 'LastName': 'Oliver', 'Affiliation': 'Abbott Nutrition Research and Development, Columbus, OH, USA.'}, {'ForeName': 'Geraldine', 'Initials': 'G', 'LastName': 'Baggs', 'Affiliation': 'Abbott Nutrition Research and Development, Columbus, OH, USA.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Choe', 'Affiliation': 'Abbott Nutrition Research and Development, Columbus, OH, USA.'}, {'ForeName': 'Choon How', 'Initials': 'CH', 'LastName': 'How', 'Affiliation': 'SingHealth-Duke NUS Family Medicine Academic Clinical Program, Singapore; Care and Health Integration, Changi General Hospital, Singapore.'}, {'ForeName': 'Wai Leng', 'Initials': 'WL', 'LastName': 'Chow', 'Affiliation': 'Health Services Research, Changi General Hospital, Singapore.'}, {'ForeName': 'Cynthia Yan Ling', 'Initials': 'CYL', 'LastName': 'Tan', 'Affiliation': 'SingHealth Polyclinics, Singapore.'}, {'ForeName': 'Shuyi Charmaine', 'Initials': 'SC', 'LastName': 'Kwan', 'Affiliation': 'SingHealth Polyclinics, Singapore.'}, {'ForeName': 'Farah Safdar', 'Initials': 'FS', 'LastName': 'Husain', 'Affiliation': 'SingHealth Polyclinics, Singapore.'}, {'ForeName': 'Yen Ling', 'Initials': 'YL', 'LastName': 'Low', 'Affiliation': 'Abbott Nutrition Research and Development, Asia-Pacific Center, Singapore.'}, {'ForeName': 'Dieu Thi Thu', 'Initials': 'DTT', 'LastName': 'Huynh', 'Affiliation': 'Abbott Nutrition Research and Development, Asia-Pacific Center, Singapore.'}, {'ForeName': 'Siew Ling', 'Initials': 'SL', 'LastName': 'Tey', 'Affiliation': 'Abbott Nutrition Research and Development, Asia-Pacific Center, Singapore.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.015'] 699,33288629,A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD.,"BACKGROUND Exposure to high doses or a high cumulative dose of erythropoiesis-stimulating agents (ESAs) may contribute to cardiovascular events in patients with CKD and anemia. Whether using a low fixed ESA dose versus dosing based on a hemoglobin-based, titration-dose algorithm in such patients might reduce risks associated with high ESA doses and decrease the cumulative exposure-while reducing the need for red blood cell transfusions-is unknown. METHODS In this phase-3, randomized trial involving 756 adults with stage-3 to -5 CKD and anemia, we evaluated incidence of red blood cell transfusions for participants randomized to receive darbepoetin given as a fixed dose (0.45 µ g/kg every 4 weeks) versus administered according to a hemoglobin-based, titration-dose algorithm, for up to 2 years. Participants received transfusions as deemed necessary by the treating physician. RESULTS There were 379 patients randomized to the fixed-dose group, and 377 to the titration-dose group. The percentage of participants transfused did not differ (24.1% and 24.4% for the fixed-dose and titration-dose group, respectively), with similar time to first transfusion. The titration-dose group achieved significantly higher median hemoglobin (9.9 g/dl) compared with the fixed-dose group (9.4 g/dl). The fixed-dose group had a significantly lower median cumulative dose of darbepoetin (median monthly dose of 30.9 µ g) compared with the titration-dose group (53. 6 µg median monthly dose). The FD and TD group received a median (Q1, Q3) cumulative dose per 4 weeks of darbepoetin of 30.9 (21.8, 40.0) µ g and 53.6 (31.1, 89.9) µ g, respectively; the median of the difference between treatment groups was -22.1 (95% CI, -26.1 to -18.1) µ g. CONCLUSIONS These findings indicate no evidence of difference in incidence of red blood cell transfusion for a titration-dose strategy versus a fixed-dose strategy for darbepoetin. This suggests that a low fixed dose of darbepoetin may be used as an alternative to a dose-titration approach to minimize transfusions, with less cumulative dosing.",2021,The titration-dose group achieved significantly higher median hemoglobin (9.9 g/dl) compared with the fixed-dose group (9.4 g/dl).,"['756 adults with stage-3 to -5', '379 patients randomized to the fixed-dose group, and 377 to the titration-dose group', 'patients with CKD and anemia']","['erythropoiesis-stimulating agents (ESAs', 'Darbepoetin Alfa', 'darbepoetin']","['CKD and anemia', 'median cumulative dose of darbepoetin', 'median hemoglobin']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]","[{'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0937950', 'cui_str': 'darbepoetin alfa'}]","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0937950', 'cui_str': 'darbepoetin alfa'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",756.0,0.0743208,The titration-dose group achieved significantly higher median hemoglobin (9.9 g/dl) compared with the fixed-dose group (9.4 g/dl).,"[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Toto', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, Texas Robert.toto@utsouthwestern.edu.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Petersen', 'Affiliation': 'Amgen Inc., Thousand Oaks, California.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Berns', 'Affiliation': 'Perelman School of Medicine at the University of Pennsylvania and Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Eldrin Foster', 'Initials': 'EF', 'LastName': 'Lewis', 'Affiliation': 'Stanford University Medical School, Stanford, California.'}, {'ForeName': 'Qui', 'Initials': 'Q', 'LastName': 'Tran', 'Affiliation': 'Amgen Inc., Thousand Oaks, California.'}, {'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Weir', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2020050556'] 700,33292916,Comparing Performance Across In-person and Videoconference-Based Administrations of Common Neuropsychological Measures in Community-Based Survivors of Stroke.,"OBJECTIVE Neuropsychological assessment via videoconference could assist in bridging service access gaps due to geographical, mobility, or infection control barriers. We aimed to compare performances on neuropsychological measures across in-person and videoconference-based administrations in community-based survivors of stroke. METHOD Participants were recruited through a stroke-specific database and community advertising. Stroke survivors were eligible if they had no upcoming neuropsychological assessment, concurrent neurological and/or major psychiatric diagnoses, and/or sensory, motor, or language impairment that would preclude standardised assessment. Thirteen neuropsychological measures were administered in-person and via videoconference in a randomised crossover design (2-week interval). Videoconference calls were established between two laptop computers, facilitated by Zoom. Repeated-measures t tests, intraclass correlation coefficients (ICCs), and Bland-Altman plots were used to compare performance across conditions. RESULTS Forty-eight participants (26 men; Mage = 64.6, SD = 10.1; Mtime since stroke = 5.2 years, SD = 4.0) completed both sessions on average 15.8 (SD = 9.7) days apart. For most measures, the participants did not perform systematically better in a particular condition, indicating agreement between administration methods. However, on the Hopkins Verbal Learning Test - Revised, participants performed poorer in the videoconference condition (Total Recall Mdifference = -2.11). ICC estimates ranged from .40 to .96 across measures. CONCLUSIONS This study provides preliminary evidence that in-person and videoconference assessment result in comparable scores for most neuropsychological tests evaluated in mildly impaired community-based survivors of stroke. This preliminary evidence supports teleneuropsychological assessment to address service gaps in stroke rehabilitation; however, further research is needed in more diverse stroke samples.",2021,"For most measures, the participants did not perform systematically better in a particular condition, indicating agreement between administration methods.","['Stroke survivors were eligible if they had no upcoming neuropsychological assessment, concurrent neurological and/or major psychiatric diagnoses, and/or sensory, motor, or language impairment that would preclude standardised assessment', 'mildly impaired community-based survivors of stroke', 'person and videoconference-based administrations in community-based survivors of stroke', 'Community-Based Survivors of Stroke', 'Forty-eight participants (26 men; Mage = 64.6, SD = 10.1; Mtime since stroke = 5.2 years, SD = 4.0) completed both sessions on average 15.8 (SD = 9.7) days apart', 'Participants were recruited through a stroke-specific database and community advertising']",[],[],"[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0376338', 'cui_str': 'Psychiatric Diagnosis'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0023015', 'cui_str': 'Disorder of language'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C2945599', 'cui_str': 'Mild'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1450049', 'cui_str': 'Videoconference'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4517790', 'cui_str': '5.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C5191316', 'cui_str': '15.8'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0001690', 'cui_str': 'Advertising as Topic'}]",[],[],48.0,0.196022,"For most measures, the participants did not perform systematically better in a particular condition, indicating agreement between administration methods.","[{'ForeName': 'Jodie E', 'Initials': 'JE', 'LastName': 'Chapman', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Betina', 'Initials': 'B', 'LastName': 'Gardner', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'Ponsford', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Dominique A', 'Initials': 'DA', 'LastName': 'Cadilhac', 'Affiliation': 'Stroke & Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Renerus J', 'Initials': 'RJ', 'LastName': 'Stolwyk', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.'}]",Journal of the International Neuropsychological Society : JINS,['10.1017/S1355617720001174'] 701,33290939,Reducing negative symptoms in schizophrenia: Feasibility and acceptability of a combined cognitive-behavioral social skills training and compensatory cognitive training intervention.,"The current study examined the feasibility and acceptability of an integrated Cognitive-Behavioral Social Skills Training and Compensatory Cognitive Training (CBSST-CCT) intervention compared with Goal-Focused Supportive Contact (SC) in a pilot randomized controlled trial for people with schizophrenia with high negative symptom severity. The sample included 55 participants from five community settings; masters-level study clinicians delivered interventions on-site. Participants completed assessments of cognitive, functional, and psychiatric symptoms at baseline, mid-treatment, post-treatment (12.5 weeks), and 6-month follow-up. Enrollment goals were not initially met, necessitating the addition of a fifth site; however, all groups and assessments were completed on-site. Study procedures were acceptable, as evidenced by 100% enrollment and completion of baseline assessments following informed consent; however, over 1/3rd of participants dropped out. No modifications were necessary to the intervention procedures and CBSST-CCT fidelity ratings were acceptable. The intervention was deemed acceptable among participants who attended ≥1 session, as evidenced by similar attendance rates in CBSST-CCT compared to SC. Among CBSST-CCT participants, lower positive symptoms were significantly associated with better attendance. Overall, we found mixed evidence for the feasibility and acceptability of the CBSST-CCT protocol in people with schizophrenia with high negative symptoms. Challenges are highlighted and recommendations for future investigations are provided.",2021,No modifications were necessary to the intervention procedures and CBSST-CCT fidelity ratings were acceptable.,"['people with schizophrenia with high negative symptom severity', '55 participants from five community settings; masters-level study clinicians delivered interventions on-site', 'people with schizophrenia with high negative symptoms']","['Goal-Focused Supportive Contact (SC', 'CBSST-CCT', 'combined cognitive-behavioral social skills training and compensatory cognitive training intervention', 'integrated Cognitive-Behavioral Social Skills Training and Compensatory Cognitive Training (CBSST-CCT) intervention', 'CBSST-CCT protocol']","['feasibility and acceptability', 'positive symptoms', 'cognitive, functional, and psychiatric symptoms', 'CBSST-CCT fidelity ratings']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0444649', 'cui_str': 'Master'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0150777', 'cui_str': 'Social skills training'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0150777', 'cui_str': 'Social skills training'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]",55.0,0.0584527,No modifications were necessary to the intervention procedures and CBSST-CCT fidelity ratings were acceptable.,"[{'ForeName': 'Zanjbeel', 'Initials': 'Z', 'LastName': 'Mahmood', 'Affiliation': 'SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, 6363 Alvarado Court, Suite 103, San Diego, CA 92120, USA; Research Service, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116A), San Diego, CA 92120, USA. Electronic address: zmahmood@health.ucsd.edu.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Van Patten', 'Affiliation': 'Research Service, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116A), San Diego, CA 92120, USA; Department of Psychiatry, University of California San Diego, 9500 Gilman Drive (0603), La Jolla, CA 92093, USA. Electronic address: rvanpatten@health.ucsd.edu.'}, {'ForeName': 'Amber V', 'Initials': 'AV', 'LastName': 'Keller', 'Affiliation': 'SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, 6363 Alvarado Court, Suite 103, San Diego, CA 92120, USA; Research Service, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116A), San Diego, CA 92120, USA. Electronic address: avkeller@health.ucsd.edu.'}, {'ForeName': 'Hannah C', 'Initials': 'HC', 'LastName': 'Lykins', 'Affiliation': 'Research Service, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116A), San Diego, CA 92120, USA. Electronic address: Hannah.Lykins@va.gov.'}, {'ForeName': 'Dimitri', 'Initials': 'D', 'LastName': 'Perivoliotis', 'Affiliation': 'Department of Psychiatry, University of California San Diego, 9500 Gilman Drive (0603), La Jolla, CA 92093, USA; Psychology Service, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116B), San Diego, CA 92161, USA. Electronic address: dperivol@health.ucsd.edu.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Granholm', 'Affiliation': 'Department of Psychiatry, University of California San Diego, 9500 Gilman Drive (0603), La Jolla, CA 92093, USA; Psychology Service, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116B), San Diego, CA 92161, USA. Electronic address: egranholm@health.ucsd.edu.'}, {'ForeName': 'Elizabeth W', 'Initials': 'EW', 'LastName': 'Twamley', 'Affiliation': 'Research Service, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116A), San Diego, CA 92120, USA; Department of Psychiatry, University of California San Diego, 9500 Gilman Drive (0603), La Jolla, CA 92093, USA; Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116A), San Diego, CA 92161, USA. Electronic address: etwamley@health.ucsd.edu.'}]",Psychiatry research,['10.1016/j.psychres.2020.113620'] 702,33303119,Impact of COPD on Outcomes After MitraClip for Secondary Mitral Regurgitation: The COAPT Trial.,"OBJECTIVES The aim of this study was to examine the relationship between chronic obstructive pulmonary disease (COPD) and outcomes after transcatheter mitral valve repair (TMVr) for severe secondary mitral regurgitation. BACKGROUND TMVr with the MitraClip improves clinical and health-status outcomes in patients with heart failure and severe (3+ to 4+) secondary mitral regurgitation. Whether these benefits are modified by COPD is unknown. METHODS COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) was an open-label, multicenter, randomized trial of TMVr plus guideline-directed medical therapy (GDMT) versus GDMT alone. Patients on corticosteroids or continuous oxygen were excluded. Multivariable models were used to examine the associations of COPD with mortality, heart failure hospitalization (HFH), and health status and to test whether COPD modified the benefit of TMVr compared with GDMT. RESULTS Among 614 patients, 143 (23.2%) had COPD. Among patients treated with TMVr, unadjusted analyses demonstrated increased 2-year mortality in those with COPD (hazard ratio [HR]: 2.08; 95% confidence interval [CI]: 1.33 to 3.26), but this association was attenuated after risk adjustment (adjusted HR: 1.48; 95% CI: 0.87 to 2.52). Although TMVr led to reduced 2-year mortality among patients without COPD (adjusted HR: 0.47; 95% CI: 0.33 to 0.67), for patients with COPD, 2-year all-cause mortality was similar after TMVr versus GDMT alone (adjusted HR: 0.94; 95% CI: 0.54 to 1.65; p int  = 0.04), findings that reflect offsetting effects on cardiovascular and noncardiovascular mortality. In contrast, TMVr reduced HFH (adjusted HR: 0.48 [95% CI: 0.28 to 0.83] vs. 0.46 [95% CI: 0.34 to 0.63]; p int  = 0.89) and improved both generic and disease-specific health status to a similar extent compared with GDMT alone in patients with and without COPD (p int >0.30 for all scales). CONCLUSIONS In the COAPT trial, COPD was associated with attenuation of the survival benefit of TMVr versus GDMT compared with patients without COPD. However, the benefits of TMVr on both HFH and health status were similar regardless of COPD. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).",2020,"Although TMVr led to reduced 2-year mortality among patients without COPD (adjusted HR: 0.47; 95% CI: 0.33 to 0.67), for patients with COPD, 2-year all-cause mortality was similar after TMVr versus GDMT alone (adjusted HR: 0.94; 95% CI: 0.54 to 1.65; p int  = 0.04), findings that reflect offsetting effects on cardiovascular and noncardiovascular mortality.","['Failure Patients With Functional Mitral Regurgitation', 'Patients on corticosteroids or continuous oxygen were excluded', 'patients with heart failure and severe (3+ to 4+) secondary mitral regurgitation', '614 patients, 143 (23.2%) had COPD', 'Heart', 'Secondary Mitral Regurgitation']","['TMVr plus guideline-directed medical therapy (GDMT) versus GDMT alone', 'COPD', 'transcatheter mitral valve repair (TMVr', 'MitraClip', 'GDMT', 'MitraClip Percutaneous Therapy', 'TMVr']","['generic and disease-specific health status', 'COPD with mortality, heart failure hospitalization (HFH), and health status', 'survival benefit of TMVr', '2-year mortality', 'TMVr reduced HFH', 'chronic obstructive pulmonary disease (COPD', 'cardiovascular and noncardiovascular mortality']","[{'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0340369', 'cui_str': 'Functional mitral regurgitation'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C3179739', 'cui_str': 'lanthanum citrate'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0026266', 'cui_str': 'Mitral valve regurgitation'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}]","[{'cui': 'C2921039', 'cui_str': 'Transcatheter mitral valve repair'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C2921039', 'cui_str': 'Transcatheter mitral valve repair'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",614.0,0.191418,"Although TMVr led to reduced 2-year mortality among patients without COPD (adjusted HR: 0.47; 95% CI: 0.33 to 0.67), for patients with COPD, 2-year all-cause mortality was similar after TMVr versus GDMT alone (adjusted HR: 0.94; 95% CI: 0.54 to 1.65; p int  = 0.04), findings that reflect offsetting effects on cardiovascular and noncardiovascular mortality.","[{'ForeName': 'John T', 'Initials': 'JT', 'LastName': 'Saxon', 'Affiliation': ""Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USA.""}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Cohen', 'Affiliation': 'University of Missouri-Kansas City, Kansas City, Missouri, USA.'}, {'ForeName': 'Adnan K', 'Initials': 'AK', 'LastName': 'Chhatriwalla', 'Affiliation': ""Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USA.""}, {'ForeName': 'Lak N', 'Initials': 'LN', 'LastName': 'Kotinkaduwa', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.'}, {'ForeName': 'Saibal', 'Initials': 'S', 'LastName': 'Kar', 'Affiliation': 'Los Robles Regional Medical Center, Thousand Oaks, California, USA; Bakersfield Heart Hospital, Bakersfield, California, USA.'}, {'ForeName': 'D Scott', 'Initials': 'DS', 'LastName': 'Lim', 'Affiliation': 'Division of Cardiology, University of Virginia, Charlottesville, Virginia, USA.'}, {'ForeName': 'William T', 'Initials': 'WT', 'LastName': 'Abraham', 'Affiliation': 'Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'JoAnn', 'Initials': 'J', 'LastName': 'Lindenfeld', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplantation Section, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Mack', 'Affiliation': 'Baylor Scott & White Health, Plano, Texas, USA.'}, {'ForeName': 'Suzanne V', 'Initials': 'SV', 'LastName': 'Arnold', 'Affiliation': ""Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USA.""}, {'ForeName': 'Gregg W', 'Initials': 'GW', 'LastName': 'Stone', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: greggstone@mountsinai.org.'}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2020.09.023'] 703,33269975,Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.,"BACKGROUND Sex steroids could explain the course of multiple sclerosis (MS) in pregnancy. OBJECTIVE To compare the annualized relapse rate (ARR) 12 weeks post-partum in women treated with nomegestrol acetate (NOMAc) and 17-beta-estradiol (E2) versus placebo. METHODS POPARTMUS is a randomized, proof-of-concept trial in women with MS, receiving oral NOMAc 10 mg/day and transdermal estradiol 75 µg/week, or placebo. RESULTS Recruitment was stopped prematurely due to slow inclusions ( n  = 202). No treatment effect was observed on ARR after 12 weeks (sex steroids = 0.90 (0.58-1.39), placebo = 0.97 (0.63-1.50) ( p  = 0.79)). CONCLUSION POPARTMUS failed showing efficacy of a NOMAc-E2 combination in preventing post-partum relapses.",2021,"No treatment effect was observed on ARR after 12 weeks (sex steroids = 0.90 (0.58-1.39), placebo = 0.97 (0.63-1.50) ( p  = 0.79)). ","['women with MS, receiving', 'multiple sclerosis']","['Oral nomegestrol acetate and transdermal 17-beta-estradiol', 'nomegestrol acetate (NOMAc) and 17-beta-estradiol (E2) versus placebo', 'oral NOMAc 10\u2009mg/day and transdermal estradiol 75\u2009µg/week, or placebo', 'placebo']","['ARR', 'annualized relapse rate (ARR']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0132749', 'cui_str': 'Nomegestrol acetate'}, {'cui': 'C0040652', 'cui_str': 'Transdermal route'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}]",,0.0802177,"No treatment effect was observed on ARR after 12 weeks (sex steroids = 0.90 (0.58-1.39), placebo = 0.97 (0.63-1.50) ( p  = 0.79)). ","[{'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Vukusic', 'Affiliation': 'Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France/Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Observatoire Français de la Sclérose en Plaques, Lyon, France/Université Claude Bernard Lyon 1, Villeurbanne, France.'}, {'ForeName': 'Iuliana', 'Initials': 'I', 'LastName': 'Ionescu', 'Affiliation': 'Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Cornu', 'Affiliation': ""Centre d'Investigation Clinique INSERM1407, Hospices Civils de Lyon, Lyon, France/Service de Pharmaco-toxicologie, Lyon, France/UMR5558, Claude Bernard University, Lyon, France.""}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Bossard', 'Affiliation': 'Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique-Bioinformatique, Lyon, France/Université de Lyon, Université Lyon 1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France.'}, {'ForeName': 'Françoise', 'Initials': 'F', 'LastName': 'Durand-Dubief', 'Affiliation': 'Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France/CREATIS, UMR 5220 CNRS & U1044 Inserm, Université Claude Bernard Lyon1, Université de Lyon, Villeurbanne, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Cotton', 'Affiliation': 'CREATIS, UMR 5220 CNRS & U1044 Inserm, Université Claude Bernard Lyon1, Université de Lyon, Villeurbanne, France/Service de Radiologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Durelli', 'Affiliation': 'Clinical and Biological Sciences Department, University of Torino, Turin, Italy.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Marignier', 'Affiliation': 'Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France/Université Claude Bernard Lyon 1, Villeurbanne, France/Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Fluid team, Lyon, France.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Gignoux', 'Affiliation': 'Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France.'}, {'ForeName': 'David-Axel', 'Initials': 'DA', 'LastName': 'Laplaud', 'Affiliation': 'CHU de Nantes, Service de Neurologie & CIC015 INSERM, Nantes, France, INSERM CR1064, Nantes, France.'}, {'ForeName': 'Thibault', 'Initials': 'T', 'LastName': 'Moreau', 'Affiliation': 'Department of Neurology, EA4184, University Hospital of Dijon, Dijon, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Clavelou', 'Affiliation': ""Service de Neurologie, CHU Clermont-Ferrand, Clermont-Ferrand, France/Inserm U1107, Clermont Université, Université d'Auvergne, Neuro-Dol, Clermont-Ferrand, France.""}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'De Seze', 'Affiliation': 'Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, INSERM, Strasbourg, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Debouverie', 'Affiliation': 'EA 4360 Apemac, Lorraine University, Nancy, France/Department of Neurology, Nancy University Hospital, Nancy, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Brassat', 'Affiliation': 'Pôle Neurosciences, CHU Toulouse Purpan, Toulouse, France/INSERM U1043-CNRS UMR 5282, Université Toulouse III, Toulouse, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Pelletier', 'Affiliation': 'Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, Marseille, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Lebrun-Frenay', 'Affiliation': 'CRCSEP Department of Neurology, UR2CA URRIS, Nice, France.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Le Page', 'Affiliation': 'Clinical Neuroscience Centre, CIC-P 1414 INSERM, Rennes University Hospital, Rennes, France.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Castelnovo', 'Affiliation': 'Department of Neurology, CHU Nîmes, Hôpital Caremeau, Nîmes Cedex, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Berger', 'Affiliation': 'Department of Neurology, CHU Besançon, Besançon, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Hautecoeur', 'Affiliation': ""Service de Neurologie, Groupe Hospitalier de l'Institut Catholique de Lille, Lille Cedex, France.""}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Heinzlef', 'Affiliation': 'Neurology Department, Hospital of Poissy-St-Germain en Laye, Paris, France.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Trojano', 'Affiliation': 'Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Patti', 'Affiliation': 'Department of Medical and Surgical Sciences, and Advanced Technologies, GF Ingrassia, Multiple Sclerosis Center, University of Catania, Catania, Italy.'}, {'ForeName': 'Etienne-Emile', 'Initials': 'EE', 'LastName': 'Baulieu', 'Affiliation': 'INSERM U 1195, Le Kremlin-Bicêtre, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Remontet', 'Affiliation': 'Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique-Bioinformatique, Lyon, France/Université de Lyon, Université Lyon 1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'El-Etr', 'Affiliation': 'INSERM U 1195, Le Kremlin-Bicêtre, France.'}]","Multiple sclerosis (Houndmills, Basingstoke, England)",['10.1177/1352458520978218'] 704,33284944,Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.,"Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the MYD88 gene (MYD88WT) have demonstrated relatively poor outcomes to ibrutinib monotherapy, with no major responses reported in a phase 2 pivotal study. Zanubrutinib is a novel, selective Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target activity. The ASPEN study consisted of a randomized comparison of zanubrutinib and ibrutinib efficacy and safety in patients with WM who have the MYD88 mutation, as well as a separate cohort of patients without MYD88 mutation (MYD88WT) or with unknown mutational status who received zanubrutinib. Results from the latter single-arm cohort are reported herein. Efficacy endpoints included overall, major and complete (CR) or very good partial response (VGPR) rates, progression-free survival (PFS), duration of response (DOR), and overall survival (OS). Twenty-eight patients (23 relapsed/refractory; 5 treatment-naïve) were enrolled, including 26 with centrally confirmed MYD88WT disease and 2 with unknown MYD88 mutational status. At a median follow-up of 17.9 months, 7 of 26 MYD88WT patients (27%) had achieved a VGPR and 50% a major response (partial response or better); there were no CRs. At 18 months, the estimated PFS and OS rates were 68% and 88%, respectively, while the median DOR had not been reached. Two patients discontinued zanubrutinib due to adverse events. Treatment-emergent hypertension, atrial fibrillation, and major hemorrhages were reported in 3, 1 and 2 patients (including 1 concurrent with enoxaparin therapy), respectively. Results of this substudy demonstrate that zanubrutinib monotherapy can induce high quality responses in patients with MYD88WT WM. This trial is registered on www.clinicaltrials.gov as NCT #03053440.",2020,"At 18 months, the estimated PFS and OS rates were 68% and 88%, respectively, while the median DOR had not been reached.","['Twenty-eight patients (23 relapsed/refractory; 5 treatment-naïve) were enrolled, including 26 with centrally confirmed MYD88WT disease and 2 with unknown MYD88 mutational status', 'MYD88 wild-type Waldenström macroglobulinemia', 'patients with WM who have the MYD88 mutation, as well as a separate cohort of patients without MYD88 mutation (MYD88WT) or with unknown mutational status who received zanubrutinib', 'Patients with Waldenström macroglobulinemia (WM) lacking activating mutations']",[],"['quality responses', 'overall, major and complete (CR) or very good partial response (VGPR) rates, progression-free survival (PFS), duration of response (DOR), and overall survival (OS', 'Treatment-emergent hypertension, atrial fibrillation, and major hemorrhages', 'estimated PFS and OS rates', 'adverse events', 'median DOR']","[{'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0024419', 'cui_str': ""Waldenstrom's macroglobulinemia""}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C4683810', 'cui_str': 'zanubrutinib'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}]",[],"[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C3641222', 'cui_str': 'Very good'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.0473596,"At 18 months, the estimated PFS and OS rates were 68% and 88%, respectively, while the median DOR had not been reached.","[{'ForeName': 'Meletios', 'Initials': 'M', 'LastName': 'Dimopoulos', 'Affiliation': 'Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Ramon Garcia', 'Initials': 'RG', 'LastName': 'Sanz', 'Affiliation': 'Hospital Universitario de Salamanca, Salamanca, Spain.'}, {'ForeName': 'Hui-Peng', 'Initials': 'HP', 'LastName': 'Lee', 'Affiliation': 'Department of Haematology, Flinders Medical Centre, Adelaide, SA, Australia.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Trneny', 'Affiliation': '1st Department of Medicine, Faculty of Medicine 1, Charles University, General Hospital, Prague, Czech Republic.'}, {'ForeName': 'Marzia', 'Initials': 'M', 'LastName': 'Varettoni', 'Affiliation': 'Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico, San Matteo, Pavia, Italy.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Opat', 'Affiliation': 'Monash Health and.'}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': ""D'Sa"", 'Affiliation': 'University College London Hospital Foundation Trust, London, United Kingdom.'}, {'ForeName': 'Roger G', 'Initials': 'RG', 'LastName': 'Owen', 'Affiliation': 'St James University Hospital, Leeds, United Kingdom.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Cull', 'Affiliation': 'Sir Charles Gairdner Hospital, Perth, WA, Australia.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Mulligan', 'Affiliation': 'Royal North Shore Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Jaroslaw', 'Initials': 'J', 'LastName': 'Czyz', 'Affiliation': 'Szpital Uniwersytecki nr 2, Dr Jana Biziela, Kujawsko-pomorskie, Bydgoszcz, Poland.'}, {'ForeName': 'Jorge J', 'Initials': 'JJ', 'LastName': 'Castillo', 'Affiliation': 'Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Motta', 'Affiliation': 'AO Spedali Civili di Brescia, Lombardia, Italy.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Siddiqi', 'Affiliation': 'City of Hope National Medical Center, Duarte, CA.'}, {'ForeName': 'Mercedes', 'Initials': 'M', 'LastName': 'Gironella Mesa', 'Affiliation': ""Hospital Universitario Vall d'Hebrón, Barcelona, Spain.""}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Granell Gorrochategui', 'Affiliation': 'Hospital de La Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Dipti', 'Initials': 'D', 'LastName': 'Talaulikar', 'Affiliation': 'The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.'}, {'ForeName': 'Pier Luigi', 'Initials': 'PL', 'LastName': 'Zinzani', 'Affiliation': 'Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Askari', 'Affiliation': 'Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Grosicki', 'Affiliation': 'Department of Hematology and Cancer Prevention, Health Sciences Faculty, Medical University of Silesia, Katowice, Poland.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Oriol', 'Affiliation': ""Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.""}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Rule', 'Affiliation': 'Plymouth Hospitals National Health Service (NHS) Trust, Derriford Hospital, Devon, United Kingdom.'}, {'ForeName': 'Janusz', 'Initials': 'J', 'LastName': 'Kloczko', 'Affiliation': 'Uniwersytecki Szpital Kliniczny w Bialymstoku, Podlaskie, Poland.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Tedeschi', 'Affiliation': 'ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Buske', 'Affiliation': 'Comprehensive Cancer Center (CCC) Ulm, Universitätsklinikum Ulm, Baden-Württemberg, Germany.'}, {'ForeName': 'Veronique', 'Initials': 'V', 'LastName': 'Leblond', 'Affiliation': 'Clinical Hematology Department, Sorbonne University, Pitié Salpêtrière Hospital, Paris, France.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Trotman', 'Affiliation': 'Concord Repatriation General Hospital, Sydney, Concord, NSW, Australia.'}, {'ForeName': 'Wai Y', 'Initials': 'WY', 'LastName': 'Chan', 'Affiliation': 'BeiGene USA, Inc., San Mateo, CA.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Michel', 'Affiliation': 'BeiGene Switzerland GmbH, Basel, Switzerland.'}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Schneider', 'Affiliation': 'BeiGene USA, Inc., San Mateo, CA.'}, {'ForeName': 'Ziwen', 'Initials': 'Z', 'LastName': 'Tan', 'Affiliation': 'BeiGene (Beijing) Co., Ltd, Beijing, China.'}, {'ForeName': 'Aileen', 'Initials': 'A', 'LastName': 'Cohen', 'Affiliation': 'BeiGene USA, Inc., San Mateo, CA.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'BeiGene USA, Inc., San Mateo, CA.'}, {'ForeName': 'Constantine S', 'Initials': 'CS', 'LastName': 'Tam', 'Affiliation': 'Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}]",Blood advances,['10.1182/bloodadvances.2020003010'] 705,33287617,Menstrual variation in the acute testosterone and cortisol response to laboratory stressors correlate with baseline testosterone fluctuations at a within- and between-person level.,"Studies have compared HPA and HPG stress reactivity across the follicular and luteal phases to assess the menstrual impact of estradiol and progesterone fluctuations. Ovulatory shifts in baseline and stressor-induced testosterone among athletic women offer a new framework to explore these responses. Here we investigated menstrual variation in baseline testosterone as a predictor of the acute testosterone and cortisol response to laboratory stressors in female athletes. Using a semi-randomized crossover design, thirty athletic women completed a physical (4 × 6-s bike sprints) and psychological (5 × 2-min cognitive tests with social evaluation) stressor on day seven (D7), 14 (D14), and 21 (D21) of a menstrual cycle. Baseline fluctuations and acute changes in salivary testosterone and cortisol were measured. The D14 testosterone response to both stressors (13.7%) exceeded D7 (7.3%) and D21 (7.0%), whereas cortisol was less responsive on D14 (9.8%) than D7 (13.0%) and D21 (12.0%); all moderate to large effect size differences ( p  < 0.01). Baseline testosterone, which presented large individual and menstrual variation with a D14 peak, was significantly related (moderate correlations) to testosterone and cortisol stress reactivity on a between-person level. Both outcomes were related (weak correlations) to within-person fluctuations in baseline testosterone, but these effects were mediated by testing day. In conclusion, menstrual variation in baseline testosterone concentration correlated with testosterone and cortisol reactivity to a physical and psychological stressor. Thus, gradients of stressor-induced hormonal change showed some dependency to endogenous testosterone, both individual differences and fluctuations over time, among naturally cycling athletic women.Lay summaryThe female menstrual cycle is accompanied by dramatic shifts in estradiol and progesterone concentration, but less is known about testosterone variability and its role in stress regulation. In this study, menstrual fluctuations in baseline testosterone concentration correlated with acute testosterone and cortisol reactivity to laboratory stressors.",2021,"The D14 testosterone response to both stressors (13.7%) exceeded D7 (7.3%) and D21 (7.0%), whereas cortisol was less responsive on D14 (9.8%) than D7 (13.0%) and D21 (12.0%); all moderate to large effect size differences ( p  < 0.01).","['female athletes', 'thirty athletic women completed a', 'athletic women']",['physical (4\u2009×\u20096-second bike sprints) and psychological (5\u2009×\u20092-min cognitive tests with social evaluation) stressor'],"['salivary testosterone and cortisol', 'D14 testosterone response', 'HPA and HPG stress reactivity', 'Ovulatory shifts']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C1510656', 'cui_str': 'Athletics'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0005375', 'cui_str': 'Bicycle'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0085355', 'cui_str': 'Platelet-specific antigen'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0429470', 'cui_str': 'Ovulatory'}, {'cui': 'C0333051', 'cui_str': 'Shift'}]",30.0,0.103373,"The D14 testosterone response to both stressors (13.7%) exceeded D7 (7.3%) and D21 (7.0%), whereas cortisol was less responsive on D14 (9.8%) than D7 (13.0%) and D21 (12.0%); all moderate to large effect size differences ( p  < 0.01).","[{'ForeName': 'Christian J', 'Initials': 'CJ', 'LastName': 'Cook', 'Affiliation': 'Biomedical Discipline School of Science and Technology, University of New England, Armidale, Australia.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Fourie', 'Affiliation': 'Biomedical Discipline School of Science and Technology, University of New England, Armidale, Australia.'}, {'ForeName': 'Blair T', 'Initials': 'BT', 'LastName': 'Crewther', 'Affiliation': 'Hamlyn Centre, Imperial College, London, UK.'}]","Stress (Amsterdam, Netherlands)",['10.1080/10253890.2020.1860937'] 706,33289280,High-Flow Nasal Cannula Therapy for Exertional Dyspnea in Patients with Cancer: A Pilot Randomized Clinical Trial.,"BACKGROUND Exertional dyspnea is common in patients with cancer and limits their function. The impact of high-flow nasal cannula on exertional dyspnea in nonhypoxemic patients is unclear. In this double-blind, parallel-group, randomized trial, we assessed the effect of flow rate (high vs. low) and gas (oxygen vs. air) on exertional dyspnea in nonhypoxemic patients with cancer. PATIENTS AND METHODS Patients with cancer with oxygen saturation >90% at rest and exertion completed incremental and constant work (80% maximal) cycle ergometry while breathing low-flow air at 2 L/minute. They were then randomized to receive high-flow oxygen, high-flow air, low-flow oxygen, or low-flow air while performing symptom-limited endurance cycle ergometry at 80% maximal. The primary outcome was modified 0-10 Borg dyspnea intensity scale at isotime. Secondary outcomes included dyspnea unpleasantness, exercise time, and adverse events. RESULTS Seventy-four patients were enrolled, and 44 completed the study (mean age 63; 41% female). Compared with low-flow air at baseline, dyspnea intensity was significantly lower at isotime with high-flow oxygen (mean change, -1.1; 95% confidence interval [CI], -2.1, -0.12) and low-flow oxygen (-1.83; 95% CI, -2.7, -0.9), but not high-flow air (-0.2; 95% CI, -0.97, 0.6) or low-flow air (-0.5; 95% CI, -1.3, 0.4). Compared with low-flow air, high-flow oxygen also resulted in significantly longer exercise time (difference + 2.5 minutes, p = .009), but not low-flow oxygen (+0.39 minutes, p = .65) or high-flow air (+0.63 minutes, p = .48). The interventions were well tolerated without significant adverse effects. CONCLUSION Our preliminary findings support that high-flow oxygen improved both exertional dyspnea and exercise duration in nonhypoxemic patients with cancer. (ClinicalTrials.gov ID: NCT02357134). IMPLICATIONS FOR PRACTICE In this four-arm, double-blind, randomized clinical trial examining the role of high-flow nasal cannula on exertional dyspnea in patients with cancer without hypoxemia, high-flow oxygen, but not high-flow air, resulted in significantly lower dyspnea scores and longer exercise time. High-flow oxygen delivered by high-flow nasal cannula devices may improve clinically relevant outcomes even in patients without hypoxemia.",2021,"Compared to low-flow air, high-flow oxygen also resulted in significantly longer exercise time (difference +2.5 min, P=0.009), but not low-flow oxygen (+0.39 min, P=0.65) nor high-flow air (+0.63 min, P=0.48).","['non-hypoxemic cancer patients', 'Cancer patients with oxygen saturation >90% at rest and exertion completed incremental and constant work (80% maximal) cycle ergometry while breathing low-flow air at 2 L/min', 'patients without hypoxemia', '74 patients were enrolled and 44 completed the study (mean age 63; 41% female', 'non-hypoxemic patients', 'cancer patients without hypoxemia', 'Cancer Patients']","['high-flow oxygen, high-flow air, low-flow oxygen or low-flow air while performing symptom-limited endurance cycle ergometry', 'High Flow Nasal Cannula Therapy', 'High-flow oxygen delivered by high-flow nasal cannula devices', 'high-flow nasal cannula', 'high-flow nasal cannula (HFNC', 'flow rate (high vs. low) and gas (oxygen vs. air']","['dyspnea scores and longer exercise time', 'dyspnea unpleasantness, exercise time and adverse events', 'longer exercise time', 'exertional dyspnea and exercise duration', 'dyspnea intensity', 'low-flow air', 'exertional dyspnea', 'modified 0-10 Borg scale dyspnea intensity at isotime', 'tolerated without significant adverse effects', 'low-flow oxygen']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0439083', 'cui_str': '>90'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0085143', 'cui_str': 'Ergometry'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0439393', 'cui_str': 'L/min'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0085143', 'cui_str': 'Ergometry'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0017110', 'cui_str': 'Gas'}]","[{'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0439587', 'cui_str': 'Exercise time'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0231807', 'cui_str': 'Dyspnea on exertion'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449399', 'cui_str': 'Borg scale'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}]",74.0,0.408973,"Compared to low-flow air, high-flow oxygen also resulted in significantly longer exercise time (difference +2.5 min, P=0.009), but not low-flow oxygen (+0.39 min, P=0.65) nor high-flow air (+0.63 min, P=0.48).","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Hui', 'Affiliation': 'Department of Palliative Care, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Mahler', 'Affiliation': 'Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.'}, {'ForeName': 'Liliana', 'Initials': 'L', 'LastName': 'Larsson', 'Affiliation': 'Department of Palliative Care, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Jimin', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Saji', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': 'Department of Respiratory Care, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Harrison', 'Affiliation': 'Department of Behavioral Science, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Hess', 'Affiliation': 'Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Lopez-Mattei', 'Affiliation': 'Department of Cardiology, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Kara', 'Initials': 'K', 'LastName': 'Thompson', 'Affiliation': 'Department of Cardiology, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Gomez', 'Affiliation': 'Department of Thoracic Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Melenda', 'Initials': 'M', 'LastName': 'Jeter', 'Affiliation': 'Department of Thoracic Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Lin', 'Affiliation': 'Department of Thoracic Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Basen-Engquist', 'Affiliation': 'Department of Behavioral Science, MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Bruera', 'Affiliation': 'Department of Palliative Care, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas, USA.'}]",The oncologist,['10.1002/onco.13624'] 707,33295063,The Effect of an Exercise Intervention Program on Bone Health After Bariatric Surgery: A Randomized Controlled Trial.,"Exercise has been suggested as a therapeutic approach to attenuate bone loss induced by bariatric surgery (BS), but its effectiveness remains unclear. Our aim was to determine if an exercise-training program could induce benefits on bone mass after BS. Eighty-four patients, submitted to gastric bypass or sleeve gastrectomy, were randomized to either exercise (EG) or control group (CG). One month post-BS, EG underwent a 11-month supervised multicomponent exercise program, while CG received only standard medical care. Patients were assessed before BS and at 1, 6, and 12 months post-BS for body composition, areal bone mineral density (BMD), bone turnover markers, calciotropic hormones, sclerostin, bone material strength index, muscle strength, and daily physical activity. A primary analysis was conducted according to intention-to-treat principles and the primary outcome was the between-group difference on lumbar spine BMD at 12 months post-BS. A secondary analysis was also performed to analyze if the exercise effect depended on training attendance. Twelve months post-BS, primary analysis results revealed that EG had a higher BMD at lumbar spine (+0.024 g∙cm -2 [95% confidence interval (CI) 0.004, 0.044]; p = .015) compared with CG. Among total hip, femoral neck, and 1/3 radius secondary outcomes, only 1/3 radius BMD improved in EG compared with CG (+0.013 g∙cm -2 [95% CI 0.003, 0.023]; p = .020). No significant exercise effects were observed on bone biochemical markers or bone material strength index. EG also had a higher lean mass (+1.5 kg [95% CI 0.1, 2.9]; p = .037) and higher number of high impacts (+51.4 [95% CI 6.6, 96.1]; p = .026) compared with CG. In addition, secondary analysis results suggest that exercise-induced benefits may be obtained on femoral neck BMD but only on those participants with ≥50% exercise attendance compared with CG (+5.3% [95% CI 2.0, 8.6]; p = .006). Our findings suggest that an exercise program is an effective strategy to ameliorate bone health in post-BS patients. © 2020 American Society for Bone and Mineral Research (ASBMR).",2021,No significant exercise effects were observed on bone biochemical markers or bone material strength index.,['© 2020 American Society for Bone and Mineral Research (ASBMR'],"['exercise program', 'gastric bypass or sleeve gastrectomy', 'exercise-training program', 'supervised multicomponent exercise program, while CG received only standard medical care', 'exercise (EG) or control group (CG', 'Exercise Intervention Program']","['femoral neck BMD', 'bone health', 'radius BMD improved in EG', 'lumbar spine BMD', 'Bone Health', 'bone biochemical markers or bone material strength index', 'BMD at lumbar spine', 'body composition, areal bone mineral density (BMD), bone turnover markers, calciotropic hormones, sclerostin, bone material strength index, muscle strength, and daily physical activity']","[{'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0017125', 'cui_str': 'Bypass of stomach'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0496675', 'cui_str': 'Medical care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0034627', 'cui_str': 'Bone structure of radius'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1305784', 'cui_str': 'Calciotropic hormone'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.154129,No significant exercise effects were observed on bone biochemical markers or bone material strength index.,"[{'ForeName': 'Florêncio', 'Initials': 'F', 'LastName': 'Diniz-Sousa', 'Affiliation': 'Research Centre in Physical Activity, Health, and Leisure (CIAFEL), Faculty of Sport, University of Porto, Porto, Portugal.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Veras', 'Affiliation': 'Research Centre in Physical Activity, Health, and Leisure (CIAFEL), Faculty of Sport, University of Porto, Porto, Portugal.'}, {'ForeName': 'Giorjines', 'Initials': 'G', 'LastName': 'Boppre', 'Affiliation': 'Research Centre in Physical Activity, Health, and Leisure (CIAFEL), Faculty of Sport, University of Porto, Porto, Portugal.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Sa-Couto', 'Affiliation': 'Center for Research and Development in Mathematics and Applications (CIDMA), Department of Mathematics, Aveiro University, Aveiro, Portugal.'}, {'ForeName': 'Vítor', 'Initials': 'V', 'LastName': 'Devezas', 'Affiliation': 'General Surgery Department, São João Medical Center, Porto, Portugal.'}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Santos-Sousa', 'Affiliation': 'General Surgery Department, São João Medical Center, Porto, Portugal.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Preto', 'Affiliation': 'General Surgery Department, São João Medical Center, Porto, Portugal.'}, {'ForeName': 'João Paulo', 'Initials': 'JP', 'LastName': 'Vilas-Boas', 'Affiliation': 'Center of Research, Education, Innovation, and Intervention in Sport (CIFI2D), Faculty of Sport, University of Porto, Porto, Portugal.'}, {'ForeName': 'Leandro', 'Initials': 'L', 'LastName': 'Machado', 'Affiliation': 'Center of Research, Education, Innovation, and Intervention in Sport (CIFI2D), Faculty of Sport, University of Porto, Porto, Portugal.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Oliveira', 'Affiliation': 'Research Centre in Physical Activity, Health, and Leisure (CIAFEL), Faculty of Sport, University of Porto, Porto, Portugal.'}, {'ForeName': 'Hélder', 'Initials': 'H', 'LastName': 'Fonseca', 'Affiliation': 'Research Centre in Physical Activity, Health, and Leisure (CIAFEL), Faculty of Sport, University of Porto, Porto, Portugal.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.4213'] 708,33306562,A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago.,"OBJECTIVES We tested preliminary efficacy of a peer change agent type I network intervention to increase pre-exposure prophylaxis (PrEP) linkage to care among network members connected to young Black men who have sex with men. DESIGN Parent study is a pragmatic randomized controlled trial with 110 weeks of total follow-up. Interim midpoint analyses are performed here using participant data before crossover assignment at 55 weeks. METHODS We randomly assigned 423 participants in Chicago to receive the network intervention, an opinion leader workshop with telephonic booster sessions, versus a time-matched control from 2016 to 2018. The consolidated surrogate outcome was PrEP referral and linkage to clinical care among network members connected to study participants and was collected from independent administrative data. RESULTS Each study participant in the trial (n = 423) had on average 1822 network contacts who could be eligible for PrEP referral and linkage. During the 55-week observation period, PrEP referral was most likely to occur within 3 days of an intervention session compared to control [odds ratio (OR) 0.07 (0.02-0.013); P = 0.007] resulting in 1-2 referrals of network members per session. Network members with referral or linkage were more likely to be connected to study participants in the intervention arm than the control condition [aOR 1.50 (1.09-2.06); P = 0.012]. CONCLUSIONS A peer change agent type I network intervention is preliminarily effective at diffusing PrEP through a network of individuals highly susceptible to HIV over 55 weeks. This low-intensity intervention demonstrated network-level impact among populations that have experienced limited PrEP care engagement in the United States.",2021,"Network members with referral or linkage were more likely to be connected to study participants in the intervention arm than the control condition [aOR 1.50 (1.09-2.06); P = 0.012]. ","['Each study participant in the trial (n = 423) had on average 1822 network contacts who could be eligible for PrEP referral and linkage', '423 participants in Chicago to receive the', 'young Black men who have sex with men', 'HIV Prevention']","['peer change agent type I network intervention to increase pre-exposure prophylaxis (PrEP) linkage to care', 'network intervention, an opinion leader workshop with telephonic booster sessions']",[],"[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0008044', 'cui_str': 'Chicago'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C0034030', 'cui_str': 'Public Opinion'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0020975', 'cui_str': 'Booster vaccination'}]",[],423.0,0.147413,"Network members with referral or linkage were more likely to be connected to study participants in the intervention arm than the control condition [aOR 1.50 (1.09-2.06); P = 0.012]. ","[{'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Schneider', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Young', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Arthi', 'Initials': 'A', 'LastName': 'Ramachandran', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Michaels', 'Affiliation': 'NORC at the University of Chicago, Chicago, IL; and.'}, {'ForeName': 'Hildie', 'Initials': 'H', 'LastName': 'Cohen', 'Affiliation': 'NORC at the University of Chicago, Chicago, IL; and.'}, {'ForeName': 'Ishida', 'Initials': 'I', 'LastName': 'Robinson', 'Affiliation': 'NORC at the University of Chicago, Chicago, IL; and.'}, {'ForeName': 'Leigh', 'Initials': 'L', 'LastName': 'Alon', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Hill', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Nakasone', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Balenciaga', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Darnell', 'Initials': 'D', 'LastName': 'Motley', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Alida', 'Initials': 'A', 'LastName': 'Bouris', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Khanna', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Ferreira', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Valente', 'Affiliation': 'University of Southern California, Los Angeles, CA.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Schumm', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002518'] 709,33314799,Greater Somatosensory Afference With Acupuncture Increases Primary Somatosensory Connectivity and Alleviates Fibromyalgia Pain via Insular γ-Aminobutyric Acid: A Randomized Neuroimaging Trial.,"OBJECTIVE Acupuncture is a complex multicomponent treatment that has shown promise in the treatment of fibromyalgia (FM). However, clinical trials have shown mixed results, possibly due to heterogeneous methodology and lack of understanding of the underlying mechanism of action. The present study was undertaken to understand the specific contribution of somatosensory afference to improvements in clinical pain, and the specific brain circuits involved. METHODS Seventy-six patients with FM were randomized to receive either electroacupuncture (EA), with somatosensory afference, or mock laser acupuncture (ML), with no somatosensory afference, twice a week over 8 treatments. Patients with FM in each treatment group were assessed for pain severity levels, measured using Brief Pain Inventory (BPI) scores, and for levels of functional brain network connectivity, assessed using resting state functional magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy in the right anterior insula, before and after treatment. RESULTS Fibromyalgia patients who received EA therapy experienced a greater reduction in pain severity, as measured by the BPI, compared to patients who received ML therapy (mean difference in BPI from pre- to posttreatment was -1.14 in the EA group versus -0.46 in the ML group; P for group × time interaction = 0.036). Participants receiving EA treatment, as compared to ML treatment, also exhibited resting functional connectivity between the primary somatosensory cortical representation of the leg (S1 leg ; i.e. primary somatosensory subregion activated by EA) and the anterior insula. Increased S1 leg -anterior insula connectivity was associated with both reduced levels of pain severity as measured by the BPI (r = -0.44, P = 0.01) and increased levels of γ-aminobutyric acid (GABA+) in the anterior insula (r = 0.48, P = 0.046) following EA therapy. Moreover, increased levels of GABA+ in the anterior insula were associated with reduced levels of pain severity as measured by the BPI (r = -0.59, P = 0.01). Finally, post-EA treatment changes in levels of GABA+ in the anterior insula mediated the relationship between changes in S1 leg -anterior insula connectivity and pain severity on the BPI (bootstrap confidence interval -0.533, -0.037). CONCLUSION The somatosensory component of acupuncture modulates primary somatosensory functional connectivity associated with insular neurochemistry to reduce pain severity in FM.",2021,"RESULTS FM patients receiving EA experienced a greater reduction in pain severity compared to ML (mean difference, EA=-1.14, ML=-0.46, Group x Time interaction, p=0.036).","['76', 'FM patients']","['Acupuncture', 'electroacupuncture (EA, with somatosensory afference) or mock laser acupuncture (ML, with no somatosensory afference', 'acupuncture']","['pain severity', 'Brief Pain Inventory (BPI) Severity, resting state functional MRI (rs-fMRI), and proton magnetic resonance spectroscopy ( 1 H-MRS', 'Fibromyalgia Pain via Insular GABA', 'aINS gamma-aminobutyric acid (GABA', 'aINS GABA', 'resting functional connectivity', 'BPI severity']","[{'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0562577', 'cui_str': 'Mocking'}, {'cui': 'C0394654', 'cui_str': 'Laser acupuncture'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C3850002', 'cui_str': '1H-MRS'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0016904', 'cui_str': 'Gamma-aminobutyric acid'}, {'cui': 'C0347129', 'cui_str': 'Dysplasia of anus'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",76.0,0.197107,"RESULTS FM patients receiving EA experienced a greater reduction in pain severity compared to ML (mean difference, EA=-1.14, ML=-0.46, Group x Time interaction, p=0.036).","[{'ForeName': 'Ishtiaq', 'Initials': 'I', 'LastName': 'Mawla', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Ichesco', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Helge J', 'Initials': 'HJ', 'LastName': 'Zöllner', 'Affiliation': 'Johns Hopkins University School of Medicine and Kennedy Krieger Institute, Baltimore, Maryland.'}, {'ForeName': 'Richard A E', 'Initials': 'RAE', 'LastName': 'Edden', 'Affiliation': 'Johns Hopkins University School of Medicine and Kennedy Krieger Institute, Baltimore, Maryland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Chenevert', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Buchtel', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Meagan D', 'Initials': 'MD', 'LastName': 'Bretz', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Sloan', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Chelsea M', 'Initials': 'CM', 'LastName': 'Kaplan', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Harte', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Mashour', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Clauw', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Vitaly', 'Initials': 'V', 'LastName': 'Napadow', 'Affiliation': ""Massachusetts General Hospital, Harvard Medical School, and Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Harris', 'Affiliation': 'University of Michigan, Ann Arbor.'}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41620'] 710,33295809,A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome.,"BACKGROUND Toxicity from antimuscarinic agents precipitates a constellation of signs and symptoms; two of the most significant are agitation and delirium. Benzodiazepines are commonly used for treatment; physostigmine is also effective but is underutilized due to concerns for safety and short duration of action. The objective of this study was to compare lorazepam to physostigmine for the treatment of antimuscarinic delirium and agitation. METHODS This was a blinded, randomized clinical trial in patients presenting for antimuscarinic toxidrome. Inclusion criteria were: ≥10-<18 years old, at least one central and two peripheral antimuscarinic symptoms, delirium and moderate agitation. Subjects were randomized to either (1) lorazepam bolus (0.05 mg/kg) followed by a 4-h normal saline infusion, or (2) physostigmine 0.02 mg/kg bolus followed by a 4-h physostigmine infusion (0.02 mg/kg/h). Primary outcomes were the control of delirium and agitation after bolus and during the infusion. RESULTS Ten (53%) subjects were enrolled in the lorazepam arm, 9 (47%) in the physostigmine arm. Diphenhydramine was the most common agent ingested (16, 84%). Fewer patients receiving physostigmine had delirium after the initial bolus (44% vs 100%, p  = 0.01) and at the 4th hour of infusion (22% vs 100%, p  < 0.001) compared to patients who received lorazepam. There was a significant decrease in agitation scores in the physostigmine arm compared to the lorazepam arm after the initial bolus (89% vs 30%, p  = 0.02), but no difference at the 4th hour of infusion ( p  > 0.99). There were no seizures, bradycardia, bronchorrhea, bronchospasm, intubation, or cardiac dysrhythmias. CONCLUSION Physostigmine was superior to lorazepam in controlling antimuscarinic delirium and agitation after bolus dosing, and control of delirium after a 4-h infusion. There were no serious adverse events in either treatment arm. Physostigmine bolus and infusion should be considered in adolescent patients with significant delirium and agitation from antimuscarinic agents.",2021,"There were no seizures, bradycardia, bronchorrhea, bronchospasm, intubation, or cardiac dysrhythmias. ","['patients presenting for antimuscarinic toxidrome', 'Inclusion criteria were: ≥10-<18\u2009years old, at least one central and two peripheral antimuscarinic symptoms, delirium and moderate agitation', 'Ten (53%) subjects were enrolled in the', 'adolescent patients with significant delirium and agitation from antimuscarinic agents']","['Diphenhydramine', 'Benzodiazepines', 'Physostigmine', 'physostigmine', 'lorazepam', 'lorazepam bolus (0.05\u2009mg/kg) followed by a 4-h normal saline infusion, or (2) physostigmine 0.02\u2009mg/kg bolus followed by a 4-h physostigmine infusion', 'physostigmine vs lorazepam']","['seizures, bradycardia, bronchorrhea, bronchospasm, intubation, or cardiac dysrhythmias', 'serious adverse events', 'delirium', 'agitation scores', 'control of delirium and agitation after bolus and during the infusion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0003385', 'cui_str': 'Muscarinic receptor antagonist'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0750502', 'cui_str': 'Significant'}]","[{'cui': 'C0012522', 'cui_str': 'Diphenhydramine'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0031849', 'cui_str': 'Physostigmine'}, {'cui': 'C0024002', 'cui_str': 'Lorazepam'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C4517398', 'cui_str': '0.02'}]","[{'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0235568', 'cui_str': 'Bronchorrhea'}, {'cui': 'C0006266', 'cui_str': 'Bronchospasm'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]",,0.25198,"There were no seizures, bradycardia, bronchorrhea, bronchospasm, intubation, or cardiac dysrhythmias. ","[{'ForeName': 'George Sam', 'Initials': 'GS', 'LastName': 'Wang', 'Affiliation': ""Section of Emergency Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, CO, USA.""}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Baker', 'Affiliation': ""Departments of Emergency Medicine and Medical Toxicology, St. Luke's University Health Network, Bethlehem, PA, USA.""}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Ng', 'Affiliation': 'En route Care Research Center, Lackland AFB, San Antonio, TX, USA.'}, {'ForeName': 'Gregory C', 'Initials': 'GC', 'LastName': 'Janis', 'Affiliation': 'MedTox Laboratories, Laboratory Corporation of America Holdings, Saint Paul, MN, USA.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Leonard', 'Affiliation': ""Section of Emergency Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, CO, USA.""}, {'ForeName': 'Rakesh D', 'Initials': 'RD', 'LastName': 'Mistry', 'Affiliation': ""Section of Emergency Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, CO, USA.""}, {'ForeName': 'Kennon', 'Initials': 'K', 'LastName': 'Heard', 'Affiliation': 'Department of Emergency Medicine, University of Colorado Anschutz Medical Campus, University of Colorado Hospital, Aurora, CO, USA.'}]","Clinical toxicology (Philadelphia, Pa.)",['10.1080/15563650.2020.1854281'] 711,33307555,High-intensity Interval Training Shock Microcycle Improves Running Performance but not Economy in Female Soccer Players.,"This study aimed to evaluate the effect of high-intensity interval training shock microcycles (HIIT SM ) on endurance, running economy and change of direction economy in female soccer players. Nineteen sub-elite female soccer players were randomised to two groups: HIIT SM (10 HIIT sessions over 13 days) or HIIT TRAD (4 HIIT sessions over 13 days) interventions. Endurance performance was evaluated through the 30-15 intermittent fitness test (30-15 IFT ); running economy over a 5-min treadmill run; and change of direction economy over two conditions: (1) 5-min 20m shuttle run, and (2) 5-min 10m shuttle run. HIIT SM significantly improved 30-15 IFT scores compared to baseline (+4.4%, p=0.009; d =0.96) and 30-15 IFT scores relative to HIIT TRAD (p=0.002; d =2.01). There was no significant interaction (group×time) for running economy and change of direction economy. Pre- to post- intervention there was a significant main time effect for blood lactate over 20m and 10m shuttle runs (p<0.001 and p=0.037, respectively), with large ( d =0.93) an d moderate ( d =0.53) changes observed for the HIIT SM over the two distances, respectively. HIIT SM may be more effective than HIIT TRAD to improve 30-15 IFT over shorter training periods but may not affect running economy and change of direction economy.",2021,"there was a significant main time effect for blood lactate over 20m and 10m shuttle runs (p<0.001 and p=0.037, respectively), with large ( d =0.93) an d moderate ( d =0.53) changes observed for the HIIT SM over the two distances, respectively.","['Nineteen sub-elite female soccer players', 'Female Soccer Players', 'female soccer players']","['Pre- to post- intervention', 'HIIT SM (10 HIIT sessions over 13 days) or HIIT TRAD', 'high-intensity interval training shock microcycles (HIIT SM ', 'HIIT TRAD']","['blood lactate', 'endurance, running economy and change of direction economy', 'Endurance performance']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439755', 'cui_str': 'Directions'}]",,0.0315167,"there was a significant main time effect for blood lactate over 20m and 10m shuttle runs (p<0.001 and p=0.037, respectively), with large ( d =0.93) an d moderate ( d =0.53) changes observed for the HIIT SM over the two distances, respectively.","[{'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Dolci', 'Affiliation': 'School of Health Sciences, The University of Notre Dame Australia, Fremantle, Australia.'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Kilding', 'Affiliation': 'Division of Sport and Recreation, Auckland University of Technology, Auckland, Newzealand.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Spiteri', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Chivers', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Perth, Australia.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Piggott', 'Affiliation': 'School of Health Sciences, The University of Notre Dame Australia, Fremantle, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Maiorana', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Hart', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Perth, Australia.'}]",International journal of sports medicine,['10.1055/a-1302-8002'] 712,33314605,Prevention of pressure injury in the operating room: Heels operating room pressure injury trial.,"The objective was to evaluate the efficacy of multi-layered silicone foam (intervention) compared with transparent polyurethane film (control) in preventing heel pressure injuries caused by surgical positioning of individuals undergoing elective surgery. It was designed an intra-patient, open, parallel, randomised controlled trial was conducted in a university hospital in southern Brazil, from March 2019 to February 2020, with patients undergoing elective surgeries of cardiac and gastrointestinal specialties. The patients who met the selection criteria constituted, simultaneously, a single group receiving the intervention and active control, through paired analysis of the cutaneous sites (right heel and left heel). The outcome was the occurrence of PI, within the follow-up period was 72 hours. Brazilian Registry of Clinical Trials: RBR-5GKNG5. There was analysis of 135 patients/270 heels, with an overall incidence of 36.7%. The pressure injury incidence was significantly lower in the intervention group (26.7%), compared with the control group (P = .001); relative risk of 0.57. In the intervention group, the estimated pressure injury-free time (survival) was 57.5 hours and in the control group, 43.9 hours. It was concluded that Multi-layered silicone foam (intervention) is more efficacious than transparent polyurethane film (control) in the prevention of pressure injuries caused by surgical positioning of individuals undergoing elective surgery.",2021,"The pressure injury incidence was significantly lower in the intervention group (26.7%), compared with the control group (P = .001); relative risk of 0.57.","['university hospital in southern Brazil, from March 2019 to February 2020, with patients undergoing elective surgeries of cardiac and gastrointestinal specialties', 'patients who met the selection criteria constituted, simultaneously, a single group receiving the intervention and active control, through paired analysis of the cutaneous sites (right heel and left heel', 'individuals undergoing elective surgery']","['multi-layered silicone foam (intervention', 'transparent polyurethane film (control', 'Multi-layered silicone foam (intervention']","['estimated pressure injury-free time (survival', 'pressure injury incidence', 'occurrence of PI', 'heel pressure injuries']","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0037778', 'cui_str': 'Medical specialty'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0242801', 'cui_str': 'Selection Criteria'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0018870', 'cui_str': 'Heel structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0037114', 'cui_str': 'Silicones'}, {'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0522503', 'cui_str': 'Translucent'}, {'cui': 'C0032616', 'cui_str': 'Polyisocyanate'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0332679', 'cui_str': 'Crushing injury'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0018870', 'cui_str': 'Heel structure'}]",,0.0685419,"The pressure injury incidence was significantly lower in the intervention group (26.7%), compared with the control group (P = .001); relative risk of 0.57.","[{'ForeName': 'Thaís Dresch', 'Initials': 'TD', 'LastName': 'Eberhardt', 'Affiliation': 'Departamento de Enfermagem, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Suzinara Beatriz Soares', 'Initials': 'SBS', 'LastName': 'de Lima', 'Affiliation': 'Departamento de Enfermagem, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Rhea Silvia', 'Initials': 'RS', 'LastName': 'de Avila Soares', 'Affiliation': 'Colégio Politécnico, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Lidiana Batista Teixeira Dutra', 'Initials': 'LBTD', 'LastName': 'Silveira', 'Affiliation': 'Departamento de Enfermagem, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Bruna', 'Initials': 'B', 'LastName': 'Rossarola Pozzebon', 'Affiliation': 'Departamento de Enfermagem, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Cassia Ribeiro', 'Initials': 'CR', 'LastName': 'Reis', 'Affiliation': 'Departamento de Enfermagem, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Karla Priscilla Paulino', 'Initials': 'KPP', 'LastName': 'Dos Santos', 'Affiliation': 'Departamento de Enfermagem, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Paulo Jorge Pereira', 'Initials': 'PJP', 'LastName': 'Alves', 'Affiliation': 'Instituto de Ciências da Saúde, Universidade Católica Portuguesa, Porto, Portugal.'}]",International wound journal,['10.1111/iwj.13538'] 713,33319490,Assessing the use of a smartphone app to teach eye screening to opticians.,"INTRODUCTION Torch-light Eye Screening Test (TEST) is a simple eye screening technique designed for use by opticians to look for common anterior segment eye conditions. The TEACHES-Learning Electronic Module (TEACHES-LEM) is an e-learning platform that was developed to teach opticians to perform TEST. The objective of this study was to compare the effectiveness of TEACHES-LEM with face-to-face training (F2FT) in the training and assessment of knowledge among opticians. METHODS Participants were randomly assigned in this experimental study to receive either the intervention group ((TEACHES-LEM, n = 60) or the control group (F2FT, n = 57). The conceptual knowledge of TEST was assessed with a 20-item clinical scenario-based multiple choice question (MCQ) test before and after teaching (immediately post-teaching and 1-month post-teaching). The MCQ test was developed by three ophthalmologists to give face validity. RESULTS The pre-teaching test scores (TS), indicating prior knowledge, were comparable in both groups (10.02 ± 2.79 versus 10.40 ± 4.17, p = 0.563, independent t test). The mean immediate post teaching score for TEACHES-LEM was 13.3 ± 4.01 versus 12.3 ± 3.29 in the F2FT group (p = 0.170, independent t test). The mean post 1-month teaching score for TEACHES-LEM and F2FT groups were also comparable, 14.5 ± 4.19 versus 13.4 ± 3.90 respectively (p = 0.295, independent t test), indicating non-inferiority of TEACHES to F2FT. CONCLUSION The TEACHES-LEM e-learning tool is as effective as F2FT in teaching opticians to perform TEST. It is an alternative to face-to-face teaching in delivering knowledge and assessment. The obviation for physical contact will make it a useful teaching tool during the COVID-19 pandemic period.",2021,The TEACHES-LEM e-learning tool is as effective as F2FT in teaching opticians to perform TEST.,['Participants'],"['intervention group ((TEACHES-LEM, n\xa0=\xa060) or the control group (F2FT', 'TEACHES-LEM with face-to-face training (F2FT', 'Torch-light Eye Screening Test (TEST']","['pre-teaching test scores (TS', 'mean immediate post teaching score', 'mean post 1-month teaching score']",[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0115922', 'cui_str': 'endogenous pyrogen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0270173', 'cui_str': 'TORCH syndrome'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",,0.0233993,The TEACHES-LEM e-learning tool is as effective as F2FT in teaching opticians to perform TEST.,"[{'ForeName': 'W K', 'Initials': 'WK', 'LastName': 'Chee', 'Affiliation': 'Department of Ophthalmology, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'C C', 'Initials': 'CC', 'LastName': 'Yip', 'Affiliation': 'Department of Ophthalmology & Visual Sciences, Khoo Teck Puat Hospital, Singapore.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Department of Ophthalmology & Visual Sciences, Khoo Teck Puat Hospital, Singapore.'}, {'ForeName': 'Y K', 'Initials': 'YK', 'LastName': 'Soo', 'Affiliation': 'Human Resource Department, Khoo Teck Puat Hospital, Singapore.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Clinical Research Unit, Khoo Teck Puat Hospital, Singapore.'}, {'ForeName': 'Bcm', 'Initials': 'B', 'LastName': 'Chang', 'Affiliation': 'Department of Ophthalmology & Visual Sciences, Khoo Teck Puat Hospital, Singapore.'}]",The clinical teacher,['10.1111/tct.13310'] 714,33305973,Impact of Nipple Shield Use on Milk Transfer and Maternal Nipple Pain.,"Background: Nipple pain is a common cause of early cessation of breastfeeding. A nipple shield (shield) is often used to improve breastfeeding comfort. There are concerns that shield use may limit milk transfer. The aims of this study were to determine whether shield use reduces milk transfer and maternal nipple pain. Methods: A within-subject study of two groups of breastfeeding dyads (infants <6 months) was conducted; Control Group (CG): no breastfeeding difficulties; Pain Group (PG) shield used for nipple pain. There were two monitored sessions where shield use was randomized. Test weights and pain questionnaires were completed, and percentage of available milk removed (PAMR) was calculated. Results: Twenty-five PG (6 ± 4 postnatal weeks) and 34 CG (9 ± 6 postnatal weeks) had similar 24-hour milk production (PG: 676 ± 239 mL, CG: 775 ± 162 mL, p  = 0.083). PG mean milk transfer volume and PAMR did not differ with shield use (no shield: 46 mL, 59%; shield: 40 mL, 53%, volume p  = 0.38, PAMR p  = 0.64). CG mean volume and PAMR were reduced with shield use (no shield: 65 mL, 64%; shield: 31 mL, 33%, volume p  < 0.001, PAMR p  < 0.001). PG pain scores were similar with and without shield use (Visual Analog Scale p  = 0.44, McGill p  = 0.97). Conclusions: Shield use did not impact either milk production or milk transfer in breastfeeding women experiencing nipple pain.",2021,"PG pain scores were similar with and without shield use (Visual Analog Scale p  = 0.44, McGill p  = 0.97). ",['breastfeeding women experiencing nipple pain'],['Control Group (CG): no breastfeeding difficulties; Pain Group (PG) shield used for nipple pain'],"['Milk Transfer and Maternal Nipple Pain', 'milk transfer and maternal nipple pain', 'PG pain scores', 'percentage of available milk removed (PAMR', 'Test weights and pain questionnaires', '24-hour milk production', 'PG mean milk transfer volume and PAMR', 'milk production or milk transfer', 'CG mean volume and PAMR']","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0240515', 'cui_str': 'Nipple pain'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1998999', 'cui_str': 'Difficulty performing breast-feeding'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0183251', 'cui_str': 'Shield'}, {'cui': 'C0240515', 'cui_str': 'Nipple pain'}]","[{'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0240515', 'cui_str': 'Nipple pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0558187', 'cui_str': 'Lactation established'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",,0.0750484,"PG pain scores were similar with and without shield use (Visual Analog Scale p  = 0.44, McGill p  = 0.97). ","[{'ForeName': 'Viviane S', 'Initials': 'VS', 'LastName': 'Coentro', 'Affiliation': 'Faculty of Science, School of Molecular Sciences, The University of Western Australia, Crawley, Australia.'}, {'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Perrella', 'Affiliation': 'Faculty of Science, School of Molecular Sciences, The University of Western Australia, Crawley, Australia.'}, {'ForeName': 'Ching Tat', 'Initials': 'CT', 'LastName': 'Lai', 'Affiliation': 'Faculty of Science, School of Molecular Sciences, The University of Western Australia, Crawley, Australia.'}, {'ForeName': 'Alethea', 'Initials': 'A', 'LastName': 'Rea', 'Affiliation': 'Mathematics and Statistics, Murdoch University, Murdoch, Australia.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Murray', 'Affiliation': 'Faculty of Health and Medical Sciences, Population and Global Health, School of Population and Global Health, The University of Western Australia, Crawley, Australia.'}, {'ForeName': 'Donna T', 'Initials': 'DT', 'LastName': 'Geddes', 'Affiliation': 'Faculty of Science, School of Molecular Sciences, The University of Western Australia, Crawley, Australia.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0110'] 715,33315813,Blood Glucose Responses during Cardiopulmonary Incremental Exercise Testing in Type 1 Diabetes: A Pooled Analysis.,"PURPOSE This study aimed to determine the glycemic responses to cardiopulmonary exercise testing (CPET) in individuals with type 1 diabetes (T1D) and to explore the influence of starting blood glucose (BG) concentrations on subsequent CPET outcomes. METHODS This study was a retrospective, secondary analysis of pooled data from three randomized crossover trials using identical CPET protocols. During cycling, cardiopulmonary variables were measured continuously, with BG and lactate values obtained minutely via capillary earlobe sampling. Anaerobic threshold was determined using ventilatory parameters. Participants were split into (i) euglycemic ([Eu] >3.9 to ≤10.0 mmol·L-1, n = 26) and (ii) hyperglycemic ([Hyper] >10.0 mmol·L-1, n = 10) groups based on preexercise BG concentrations. Data were assessed via general linear modeling techniques and regression analyses. P values of ≤0.05 were accepted as significant. RESULTS Data from 36 individuals with T1D (HbA1c, 7.3% ± 1.1% [56.0 ± 11.5 mmol·mol-1]) were included. BG remained equivalent to preexercise concentrations throughout CPET, with an overall change in BG of -0.32 ± 1.43 mmol·L-1. Hyper had higher HR at peak (+10 ± 2 bpm, P = 0.04) and during recovery (+9 ± 2 bpm, P = 0.038) as well as lower O2 pulse during the cool down period (-1.6 ± 0.04 mL per beat, P = 0.021). BG responses were comparable between glycemic groups. Higher preexercise BG led to greater lactate formation during exercise. HbA1c was inversely related to time to exhaustion (r = -0.388, P = 0.04) as well as peak power output (r = -0.355, P = 0.006) and O2 pulse (r = -0.308, P = 0.015). CONCLUSIONS This study demonstrated 1) stable BG responses to CPET in patients with T1D; 2) although preexercise hyperglycemia did not influence subsequent glycemic dynamics, it did potentiate alterations in various cardiac and metabolic responses to CPET; and 3) HbA1c was a significant factor in the determination of peak performance outcomes during CPET.",2021,"L. Hyper had higher HR at peak (+10±2 bpm, p=0.04) and during recovery (+9±2 bpm, p=0.038) as well as lower O2 pulse during the cool down period (-1.6±0.04 mL.beat, p=0.021).","['patients with T1D 2', 'Type 1 Diabetes', 'individuals with type 1 diabetes (T1D', 'Data from thirty-six individuals with T1D (HbA1c; 7.3±1.1% [56.0±11.5 mmol.mol]) were included']",['cardiopulmonary exercise testing (CPET'],"['peak power output', 'lower O2 pulse', 'lactate formation', 'BG responses', 'Blood Glucose Responses', 'Anaerobic threshold (AT', 'starting blood glucose (BG) concentrations', 'time to exhaustion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0002749', 'cui_str': 'Anaerobic Threshold'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}]",36.0,0.0647826,"L. Hyper had higher HR at peak (+10±2 bpm, p=0.04) and during recovery (+9±2 bpm, p=0.038) as well as lower O2 pulse during the cool down period (-1.6±0.04 mL.beat, p=0.021).","[{'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'McCarthy', 'Affiliation': 'Applied Sport, Technology, Exercise and Medicine Research Centre (A-STEM), College of Engineering, Swansea University, Swansea, UNITED KINGDOM.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Pitt', 'Affiliation': 'Applied Sport, Technology, Exercise and Medicine Research Centre (A-STEM), College of Engineering, Swansea University, Swansea, UNITED KINGDOM.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Wellman', 'Affiliation': 'Applied Sport, Technology, Exercise and Medicine Research Centre (A-STEM), College of Engineering, Swansea University, Swansea, UNITED KINGDOM.'}, {'ForeName': 'Max L', 'Initials': 'ML', 'LastName': 'Eckstein', 'Affiliation': ''}, {'ForeName': 'Othmar', 'Initials': 'O', 'LastName': 'Moser', 'Affiliation': ''}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Bain', 'Affiliation': 'Diabetes Research Group, Medical School, Swansea University, Swansea, UNITED KINGDOM.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Bracken', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002584'] 716,33296943,Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.,"BAY 94-9027 (damoctocog alfa pegol, Jivi) is an extended-half-life recombinant factor VIII (rFVIII) shown to be well-tolerated and efficacious in bleeding prevention in previously treated patients with severe hemophilia A. During the PROTECT VIII study, prophylaxis patients received BAY 94-9027 at intervals determined based on their bleeding phenotype, observed during a 10-week run-in treatment period with twice-weekly dosing. Those with ≤ 1 spontaneous joint or muscle bleed were randomized to either 45 to 60 IU/kg every 5 days or 60 IU/kg every 7 days; patients could increase dosing frequency to every 5 days or twice weekly in the case of bleeds. Those enrolled after the randomization arms were full, and those with ≥ 2 bleeds in the run-in period, received 30 to 40 IU/kg twice weekly. Patients completing the main study could receive open-label BAY 94-9027 in the extension phase. Dosing regimen, total, and joint annualized bleeding rates were analyzed over three periods: prestudy, main study, and extension. A total of 80 patients who were on prophylaxis treatment prior to and during the study and had prior bleed data available were evaluated in this post hoc analysis of PROTECT VIII. Most patients (> 80%) required fewer infusions with BAY 94-9027 prophylaxis versus their previous standard-half-life (SHL) rFVIII product. Lower bleeding and joint bleeding rates were observed over time from the prestudy to the extension study period in all treatment regimens. Compared with SHL FVIII, BAY 94-9027 prophylaxis allows patients to reduce infusion frequency with maintained or improved protection from bleeds.",2021,Lower bleeding and joint bleeding rates were observed over time from the pre-study to the extension study period in all treatment regimens.,"['previously treated patients with severe hemophilia A', '80 patients who were on prophylaxis treatment prior to and during the study and had prior bleed data available', 'Those with ≤1 spontaneous joint or muscle bleed']",[],"['Bleeding Rates', 'total and joint annualized bleeding rates', 'Lower bleeding and joint bleeding rates']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0272322', 'cui_str': 'Severe hereditary factor VIII deficiency disease'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}]",[],"[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0018924', 'cui_str': 'Hemarthrosis'}]",80.0,0.0276824,Lower bleeding and joint bleeding rates were observed over time from the pre-study to the extension study period in all treatment regimens.,"[{'ForeName': 'Maria Elisa', 'Initials': 'ME', 'LastName': 'Mancuso', 'Affiliation': 'Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy.'}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Reding', 'Affiliation': 'University of Minnesota Medical Center, Minneapolis, Minnesota, United States.'}, {'ForeName': 'Claude', 'Initials': 'C', 'LastName': 'Negrier', 'Affiliation': 'Louis Pradel University Hospital, University Claude Bernard Lyon 1, Lyon, France.'}, {'ForeName': 'Bryce A', 'Initials': 'BA', 'LastName': 'Kerlin', 'Affiliation': ""Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio, United States.""}, {'ForeName': 'Savita', 'Initials': 'S', 'LastName': 'Rangarajan', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.'}, {'ForeName': 'Mindy L', 'Initials': 'ML', 'LastName': 'Simpson', 'Affiliation': 'Rush University Medical Center, Chicago, Illinois, United States.'}]",Thrombosis and haemostasis,['10.1055/a-1333-5536'] 717,33301386,Investigating the Feasibility of Exergame on Sleep and Emotion Among University Students.,"Sleep deprivation and emotional problems such as stress, anxiety, and depression commonly occur in university students. Exercise is beneficial to ameliorate those problems; however, university students are not serious to take up physical activity. Commercially available exergame such as Xbox ® 360 Kinect is one of the alternatives. This study aims at investigating the feasibility and the potential efficacy of using Xbox 360 Kinect game among health care undergraduate students. A pilot two-armed parallel randomized controlled trial was implemented. A total of 36 undergraduate students was recruited and randomly allocated into the intervention group (playing Xbox 360 Kinect) or the control group (continue with normal daily routine). The intervention group received 30 minutes of Xbox Kinect activity, three times per week for 6 weeks. Information on psychology (Depression, Anxiety, and Stress Scale-21) and sleep (Functional Outcome Sleep Questionnaire-30) status was collected at pre- and post-experiment. The researcher-developed feasibility questionnaire was given to the participants in the intervention group at post-experiment. Repeated-measures analysis of variance was used to investigate within-between group comparison, and significance value was set at p  ≤ 0.05. The analysis found potential improvement on sleep ( p  = 0.039) and psychological health ( p  = 0.002-0.067). The intervention protocol is feasible and highly accepted by the participants. The required optimum amount of dosage, sample size, and the use of outcome measures are suggested from the findings. This pilot and feasibility study supports the use of Xbox 360 Kinect games in practice and to be implemented for future research.",2020,The analysis found potential improvement on sleep ( p  = 0.039) and psychological health ( p  = 0.002-0.067).,"['36 undergraduate students', 'health care undergraduate students', 'university students', 'University Students']","['30 minutes of Xbox Kinect activity', 'Xbox 360 Kinect game', 'Xbox 360 Kinect games', 'intervention group (playing Xbox 360 Kinect) or the control group (continue with normal daily routine']","['psychological health', 'sleep', 'psychology (Depression, Anxiety, and Stress Scale-21) and sleep (Functional Outcome Sleep Questionnaire-30) status']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0033909', 'cui_str': 'Psychology'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",36.0,0.0378055,The analysis found potential improvement on sleep ( p  = 0.039) and psychological health ( p  = 0.002-0.067).,"[{'ForeName': 'Farahiyah', 'Initials': 'F', 'LastName': 'Wan Yunus', 'Affiliation': 'Centre for Rehabilitation and Special Needs Studies, Occupational Therapy Programme. Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Xiu Zhen', 'Initials': 'XZ', 'LastName': 'Tan', 'Affiliation': 'Centre for Rehabilitation and Special Needs Studies, Occupational Therapy Programme. Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Muhammad Hibatullah', 'Initials': 'MH', 'LastName': 'Romli', 'Affiliation': 'Department of Nursing and Rehabilitation, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.'}]",Games for health journal,['10.1089/g4h.2019.0077'] 718,33314313,"Effect of Low-Intensity Vibration on Bone Strength, Microstructure, and Adiposity in Pre-Osteoporotic Postmenopausal Women: A Randomized Placebo-Controlled Trial.","There has been evidence that cyclical mechanical stimulation may be osteogenic, thus providing opportunities for nonpharmacological treatment of degenerative bone disease. Here, we applied this technology to a cohort of postmenopausal women with varying bone mineral density (BMD) T-scores at the total hip (-0.524 ± 0.843) and spine (-0.795 ± 1.03) to examine the response to intervention after 1 year of daily treatment with 10 minutes of vibration therapy in a randomized double-blinded trial. The device operates either in an active mode (30 Hz and 0.3 g) or placebo. Primary endpoints were changes in bone stiffness at the distal tibia and marrow adiposity of the vertebrae, based on 3 Tesla high-resolution MRI and spectroscopic imaging, respectively. Secondary outcome variables included distal tibial trabecular microstructural parameters and vertebral deformity determined by MRI, volumetric and areal bone densities derived using peripheral quantitative computed tomography (pQCT) of the tibia, and dual-energy X-ray absorptiometry (DXA)-based BMD of the hip and spine. Device adherence was 83% in the active group (n = 42) and 86% in the placebo group (n = 38) and did not differ between groups (p = .7). The mean 12-month changes in tibial stiffness in the treatment group and placebo group were +1.31 ± 6.05% and -2.55 ± 3.90%, respectively (group difference 3.86%, p = .0096). In the active group, marrow fat fraction significantly decreased after 12 months of intervention (p = .0003), whereas no significant change was observed in the placebo group (p = .7; group difference -1.59%, p = .029). Mean differences of the changes in trabecular bone volume fraction (p = .048) and erosion index (p = .044) were also significant, as was pQCT-derived trabecular volumetric BMD (vBMD; p = .016) at the tibia. The data are commensurate with the hypothesis that vibration therapy is protective against loss in mechanical strength and, further, that the intervention minimizes the shift from the osteoblastic to the adipocytic lineage of mesenchymal stem cells. © 2020 American Society for Bone and Mineral Research (ASBMR).",2021,"In the active group, marrow fat fraction significantly decreased after 12 months of intervention (p = 0.0003), while no significant change was observed in the placebo group (p = 0.7; group difference - 1.59%, p = 0.029).","['postmenopausal women with varying bone mineral density (BMD) T-scores at the total hip (-0.524\u2009±\u20090.843) and spine (-0.795\u2009±\u20091.03', 'Pre-Osteoporotic Postmenopausal', 'Women']","['Placebo', 'Low Intensity Vibration', 'placebo', 'vibration therapy']","['trabecular bone volume fraction', 'erosion index', 'Bone Strength, Microstructure, and Adiposity', 'Device adherence', 'distal tibial trabecular microstructural parameters and vertebral deformity determined by MRI, volumetric and areal bone densities derived using peripheral quantitative computed tomography (pQCT) of the tibia, and dual-energy X-ray absorptiometry (DXA)-based BMD of the hip and spine', 'mean 12-month changes in tibial stiffness', 'marrow fat fraction', 'changes in bone stiffness at the distal tibia and marrow adiposity of the vertebrae, based on 3 Tesla high-resolution MRI and spectroscopic imaging, respectively']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0222660', 'cui_str': 'Trabecular substance of bone'}, {'cui': 'C0560268', 'cui_str': 'Volume fraction'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4708472', 'cui_str': 'Device adherence'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0445383', 'cui_str': 'Volumetric'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0412669', 'cui_str': 'Computerized tomography, bone density study'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0229602', 'cui_str': 'Structure of bone marrow fatty tissue'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0588200', 'cui_str': 'Bone structure of distal tibia'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}]",,0.372592,"In the active group, marrow fat fraction significantly decreased after 12 months of intervention (p = 0.0003), while no significant change was observed in the placebo group (p = 0.7; group difference - 1.59%, p = 0.029).","[{'ForeName': 'Chamith S', 'Initials': 'CS', 'LastName': 'Rajapakse', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Alyssa J', 'Initials': 'AJ', 'LastName': 'Johncola', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Alexandra S', 'Initials': 'AS', 'LastName': 'Batzdorf', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Brandon C', 'Initials': 'BC', 'LastName': 'Jones', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Al Mukaddam', 'Affiliation': 'Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Sexton', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Shults', 'Affiliation': 'Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Mary B', 'Initials': 'MB', 'LastName': 'Leonard', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.""}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Snyder', 'Affiliation': 'Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Felix W', 'Initials': 'FW', 'LastName': 'Wehrli', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.4229'] 719,32792555,Land vs. water HIIE effects on muscle oxygenation and physiological parameter responses in postmenopausal women.,"Muscle oxygenation (MO) status is the dynamic balance between O 2 utilization and O 2 delivery. Low-impact high-intensity interval exercise MO responses in the exercise and recovery stage are still unclear. We compared the differences in MO and physiological parameters between high-intensity interval water-based exercise (WHIIE) and high-intensity interval land bike ergonomic exercise (LBEHIIE) in postmenopausal women. Eleven postmenopausal women completed WHIIE or LBEHIIE in counter-balanced order. Eight sets were performed and each exercise set included high intensity with 80% heart rate reserve (HRR) in 30 s and dynamic recovery with 50% HRR in 90 s. Muscle tissue oxygen saturation index (TSI), total hemoglobin (tHb), oxy-hemoglobin (O 2 Hb), and deoxy-hemoglobin (HHb) were recorded. Blood lactate, heart rate and rating of perceived exertion (RPE) were measured at pre and post-exercise. Under similar exercise intensity, RPE in WHIIE was lower than that in LBEHIIE. The heart rate in WHIIE was lower than that in LBEHIIE at 1 and 2 min post-exercise. During the dynamic recovery, TSI, tHb, and O2Hb in water were higher than on land. A negative correlation was found between the change in TSI and lactate concentration (r = - 0.664). WHIIE produced greater muscle oxygenation during dynamic recovery. Muscle TSI% was inversely related to blood lactate concentration during exercise in water.",2020,The heart rate in WHIIE was lower than that in LBEHIIE at 1 and 2 min post-exercise.,"['postmenopausal women', 'Eleven postmenopausal women completed WHIIE or LBEHIIE in counter-balanced order']",['high-intensity interval water-based exercise (WHIIE) and high-intensity interval land bike ergonomic exercise (LBEHIIE'],"['blood lactate concentration', 'Muscle oxygenation (MO) status', 'muscle oxygenation and physiological parameter responses', 's. Muscle tissue oxygen saturation index (TSI), total hemoglobin (tHb), oxy-hemoglobin (O 2 Hb), and deoxy-hemoglobin (HHb', 'dynamic recovery, TSI, tHb, and O2Hb in water', 'TSI and lactate concentration', 'Blood lactate, heart rate and rating of perceived exertion (RPE', 'muscle oxygenation', 'heart rate in WHIIE']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0677601', 'cui_str': 'Counter'}, {'cui': 'C0205415', 'cui_str': 'Balanced'}, {'cui': 'C4284072', 'cui_str': 'Order document'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0005375', 'cui_str': 'Bicycle'}, {'cui': 'C0086246', 'cui_str': 'Human Engineering'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0475206', 'cui_str': '% total hemoglobin'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0057437', 'cui_str': 'Deoxyhemoglobin'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0040139', 'cui_str': 'Thyroid stimulating immunoglobulins'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}]",8.0,0.0227781,The heart rate in WHIIE was lower than that in LBEHIIE at 1 and 2 min post-exercise.,"[{'ForeName': 'Kuei-Yu', 'Initials': 'KY', 'LastName': 'Chien', 'Affiliation': 'Graduate Institute of Sports Science, National Taiwan Sport University, 250, Wenhua 1st Rd., Guishan District, Taoyuan City, 333325, Taiwan. chienkueiyu@gmail.com.'}, {'ForeName': 'Nai-Wen', 'Initials': 'NW', 'LastName': 'Kan', 'Affiliation': 'Center for General Education, Taipei Medical University, Taipei, Taiwan.'}, {'ForeName': 'Yi-Hung', 'Initials': 'YH', 'LastName': 'Liao', 'Affiliation': 'Department of Exercise and Health Science, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.'}, {'ForeName': 'Wen-Ting', 'Initials': 'WT', 'LastName': 'Yang', 'Affiliation': 'Graduate Institute of Sports Science, National Taiwan Sport University, 250, Wenhua 1st Rd., Guishan District, Taoyuan City, 333325, Taiwan.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Graduate Institute of Athletics and Coaching Science, National Taiwan Sport University, Taoyuan, Taiwan.'}]",Scientific reports,['10.1038/s41598-020-70599-6'] 720,33319386,An interactive technology enhanced coaching intervention for Black women with hypertension: Randomized controlled trial study protocol.,"In the United States, hypertension (HTN) is the leading risk factor for cardiovascular disease, and a more significant health problem for Blacks compared with other racial/ethnic groups. The prevalence of HTN in Black women is among the highest in the world, underscoring the need for effective prevention and management approaches for blood pressure (BP) control. We developed a two-arm randomized controlled trial repeated measures design study for improving HTN self-management among Black women. The study tests whether the Chronic Disease Self-Management Program (CDSMP) combined with interactive technology-enhanced coaching, can improve BP control and adherence to treatment (e.g., medication-taking, physical activity, calorie intake, and weight management) compared with the CDSMP alone. Repeated measurements were conducted at 3, 6, and 9 months. A sample of 90 community-dwelling Black women with uncontrolled Stage 1 HTN (BP ≥ 130/80) were enrolled, completed CDSMP training, and randomized. This study will contribute to our understanding of novel methods to empower Black women to increase their active involvement in self-care management of HTN.",2021,This study will contribute to our understanding of novel methods to empower Black women to increase their active involvement in self-care management of HTN.,"['Black women with hypertension', 'empower Black women', '90 community-dwelling Black women with uncontrolled Stage 1 HTN (BP\u2009≥\u2009130/80', 'Black women']","['interactive technology enhanced coaching intervention', 'CDSMP alone', 'Chronic Disease Self-Management Program (CDSMP) combined with interactive technology-enhanced coaching', 'CDSMP training']","['BP control and adherence to treatment (e.g., medication-taking, physical activity, calorie intake, and weight management', 'blood pressure (BP) control']","[{'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1290952', 'cui_str': 'Taking medication'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}]",90.0,0.0603735,This study will contribute to our understanding of novel methods to empower Black women to increase their active involvement in self-care management of HTN.,"[{'ForeName': 'Willie M', 'Initials': 'WM', 'LastName': 'Abel', 'Affiliation': 'School of Nursing, College of Health and Human Services, The University of North Carolina at Charlotte, Charlotte, North Carolina, USA.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'DeHaven', 'Affiliation': 'Department of Public Health Sciences, College of Health and Human Services, The University of North Carolina at Charlotte, Charlotte, North Carolina, USA.'}]",Research in nursing & health,['10.1002/nur.22090'] 721,33323430,Efficacy of low-magnitude high-frequency vibration (LMHFV) on musculoskeletal health of participants on wheelchair: a study protocol for a single-blinded randomised controlled study.,"BACKGROUND Osteoporosis is an age-related disease with progressive loss of bone, leading to fragile bone. It is one of the major health issues in older adults and causes medical, social and economic impacts globally. Patients with osteoporosis have high risk of osteoporotic fractures. Low-magnitude high-frequency vibration (LMHFV) is a non-invasive biophysical intervention providing whole-body mechanical stimulation. Previous studies showed that LMHFV is beneficial to muscle strength, postural control, balancing ability, new bone formation, spinal bone mineral density (BMD) and blood circulation. During the LMHFV treatment, older adults need to stand upright on the platform for 20 min/day. However, some physically weak elderlies with poor musculoskeletal ability cannot stand for a long period. Therefore, the design of vibration platform is modified for the disabled patients to treat at sitting position and the efficacy of LMHFV on this group of elderlies will be verified. It is hypothesised that new design of LMHFV is beneficial to wheelchair users in terms of vertebral BMD, muscle health and musculoskeletal functions. METHODS This study is a single-blinded randomised controlled trial to investigate the effect of LMHFV on vertebral BMD, muscle health, balancing ability and functional ability in wheelchair users (mainly on wheelchair for outdoor activities). Healthy elderlies aged 65 years or above with walking difficulties and using wheelchair are eligible. Exclusion criteria are those: (1) who cannot stand and walk independently, (2) who have vibration treatment before, (3) with malignancy, (4) with acute fractures or severe osteoarthritis, (5) with cardiovascular concern such as with pacemaker in situ, (6) with chronic inflammatory conditions known to affect muscle metabolism such as rheumatoid arthritis and (7) with high frequency of physical activities, such as participants who participated in regular exercise five times a week or more. Recruited participants will be randomised to either LMHFV or control group. Participant assigned to LMHFV group will receive LMHFV (35 Hz, 0.3g (g=gravitational acceleration), 20 min/day, at least three times/week) for 6 months. The primary outcome is BMD at the lumbar spine to be assessed by dual-energy X-ray absorptiometry that is clinically recommended for the diagnosis of osteoporosis. All primary and secondary outcome assessments for all groups will be performed in the investigators' institute at baseline and 6 months post treatment. DISCUSSION This study aims to investigate the effects of LMHFV on wheelchair users. The findings of this study will help to confirm the efficacy of LMHFV on vertebral BMD, muscle health, balancing ability and functional outcomes in wheelchair using elderlies. LMHFV therapy is an intervention strategy that is easy to implement at the community healthcare level or individually at home that has previously been proven to reduce fall risk and muscle strength at the lower limb. The ultimate goal is to improve their bone and muscle quality of wheelchair users, as well as enhancing their quality of life. TRIAL REGISTRATION NUMBER ClinicalTrials.gov (NCT04180267).",2020,"It is hypothesised that new design of LMHFV is beneficial to wheelchair users in terms of vertebral BMD, muscle health and musculoskeletal functions. ","['wheelchair users', 'musculoskeletal health of participants on wheelchair', 'older adults', 'Patients with osteoporosis have high risk of osteoporotic fractures', 'Exclusion criteria are those: (1) who cannot stand and walk independently, (2) who have vibration treatment before, (3) with malignancy, (4) with acute fractures or severe osteoarthritis, (5) with cardiovascular concern such as with pacemaker in situ, (6) with chronic inflammatory conditions known to affect muscle metabolism such as rheumatoid arthritis and (7) with high frequency of physical activities, such as participants who participated in regular exercise five times a week or more', 'Healthy elderlies aged 65 years or above with walking difficulties and using wheelchair are eligible', 'wheelchair users (mainly on wheelchair for outdoor activities']","['low-magnitude high-frequency vibration (LMHFV', 'LMHFV', 'Low-magnitude high-frequency vibration (LMHFV', 'LMHFV therapy']","['vertebral BMD, muscle health, balancing ability and functional ability', 'BMD at the lumbar spine', 'muscle strength, postural control, balancing ability, new bone formation, spinal bone mineral density (BMD) and blood circulation']","[{'cui': 'C0853966', 'cui_str': 'Wheelchair user'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0043143', 'cui_str': 'Wheelchair'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0521170', 'cui_str': 'Osteoporotic fracture'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0030163', 'cui_str': 'Cardiac pacemaker'}, {'cui': 'C0444498', 'cui_str': 'In situ'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0582191', 'cui_str': 'Regular exercise'}, {'cui': 'C0585298', 'cui_str': 'Five times weekly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0311394', 'cui_str': 'Difficulty walking'}, {'cui': 'C1290943', 'cui_str': 'Using wheelchair'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0449286', 'cui_str': 'Degree'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0560184', 'cui_str': 'Ability to balance'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0334168', 'cui_str': 'New bone formation'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}]",,0.0606987,"It is hypothesised that new design of LMHFV is beneficial to wheelchair users in terms of vertebral BMD, muscle health and musculoskeletal functions. ","[{'ForeName': 'Simon Kwoon Ho', 'Initials': 'SKH', 'LastName': 'Chow', 'Affiliation': 'Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, New Territories, Hong Kong.'}, {'ForeName': 'Chung Yan', 'Initials': 'CY', 'LastName': 'Ho', 'Affiliation': 'Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, New Territories, Hong Kong.'}, {'ForeName': 'Hiu Wun', 'Initials': 'HW', 'LastName': 'Wong', 'Affiliation': 'Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, New Territories, Hong Kong.'}, {'ForeName': 'Yu Ning', 'Initials': 'YN', 'LastName': 'Chim', 'Affiliation': 'Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, New Territories, Hong Kong.'}, {'ForeName': 'Ronald Man Yeung', 'Initials': 'RMY', 'LastName': 'Wong', 'Affiliation': 'Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, New Territories, Hong Kong.'}, {'ForeName': 'Wing Hoi', 'Initials': 'WH', 'LastName': 'Cheung', 'Affiliation': 'Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, New Territories, Hong Kong louischeung@cuhk.edu.hk.'}]",BMJ open,['10.1136/bmjopen-2020-038578'] 722,33326254,Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.,"PURPOSE Anti-GD2 monoclonal antibody (mAb) has proven efficacy in high-risk neuroblastoma (HR-NB). A small phase I GD2/GD3 vaccine trial (n = 15) described long-term survival and a favorable safety profile among patients with a history of disease progression (PD). The kinetics of mounting antibody response to vaccine and its prognostic impact on survival are now investigated in a phase II study (ClinicalTrials.gov identifier: NCT00911560). PATIENTS AND METHODS One hundred two patients with HR-NB who achieved remission after salvage therapies were enrolled in this trial. They received seven subcutaneous injections of GD2/GD3 vaccine spanning 1 year plus oral β-glucan starting at week 6 after the third dose of vaccine. Serum anti-vaccine antibody titers were quantified by enzyme-linked immunosorbent assay. Single nucleotide polymorphisms (SNPs) were determined by quantitative polymerase chain reaction. Kaplan-Meier and landmark Cox Regression models were used for survival estimates. RESULTS Patients had a history of one (63%), two (21%), or three to six (16%) episodes of PD. 82% of them progressed following anti-GD2 mAb (m3F8/dinutuximab/naxitamab) therapy. Vaccine-related toxicities were self-limited injection-associated local reactions and fever without any > grade 3 toxicities. The progression-free survival (PFS) was 32% ± 6%, and the overall survival (OS) was 71% ± 7% at 5 years. Serum anti-GD2 (immunoglobulin G1 [IgG1] and IgM) and anti-GD3 (IgG1) titers showed notable increases following the initiation of β-glucan at week 6. There was an association between IgG1 titer and SNP rs3901533 of dectin-1, the β-glucan receptor. Multivariable analyses showed that anti-GD2-IgG1 titer ≥ 150 ng/mL by week 8 was associated with favorable PFS and OS, while having prior episodes of PD and the time from last PD to vaccine were associated with PFS. CONCLUSION GD2/GD3 vaccine plus β-glucan elicited robust antibody responses in patients with HR-NB with prior PD. Higher anti-GD2-IgG1 titer was associated with improved survival.",2021,"There was an association between IgG1 titer and SNP rs3901533 of dectin-1, the β-glucan receptor.","['Patients With High-Risk Neuroblastoma with Prior Disease Progression', 'patients with HR-NB with prior PD', 'One hundred two patients with HR-NB who achieved remission after salvage therapies were enrolled in this trial', 'patients with a history of disease progression (PD']","['GD2/GD3 vaccine plus β-glucan', 'GD2/GD3 vaccine spanning 1 year plus oral β-glucan']","['Serum anti-vaccine antibody titers', 'antibody responses', 'survival', 'progression-free survival (PFS', 'overall survival (OS', 'Serum anti-GD2 (immunoglobulin G1 [IgG1] and IgM) and anti-GD3 (IgG1) titers', 'episodes of PD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0027819', 'cui_str': 'Neuroblastoma'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0085405', 'cui_str': 'Salvage therapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0262926', 'cui_str': 'History of'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0017692', 'cui_str': 'Glucan (BO)'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0474643', 'cui_str': 'Antibody titer measurement'}, {'cui': 'C0003261', 'cui_str': 'Antibody Production'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3489470', 'cui_str': 'Gd(BOPTA)2'}, {'cui': 'C0020855', 'cui_str': 'Immunoglobulin IgG1'}, {'cui': 'C0020861', 'cui_str': 'Immunoglobulin M'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}]",102.0,0.0553912,"There was an association between IgG1 titer and SNP rs3901533 of dectin-1, the β-glucan receptor.","[{'ForeName': 'Irene Y', 'Initials': 'IY', 'LastName': 'Cheung', 'Affiliation': 'Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Nai-Kong V', 'Initials': 'NV', 'LastName': 'Cheung', 'Affiliation': 'Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Shakeel', 'Initials': 'S', 'LastName': 'Modak', 'Affiliation': 'Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Mauguen', 'Affiliation': 'Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Feng', 'Affiliation': 'Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Basu', 'Affiliation': 'Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Stephen S', 'Initials': 'SS', 'LastName': 'Roberts', 'Affiliation': 'Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Govind', 'Initials': 'G', 'LastName': 'Ragupathi', 'Affiliation': 'Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Brian H', 'Initials': 'BH', 'LastName': 'Kushner', 'Affiliation': 'Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.01892'] 723,33330909,Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST).,"AIMS Delay of progression from paroxysmal to persistent atrial fibrillation (AF) is an important measure of long-term success of AF treatment. However, published data on the impact of catheter ablation on AF progression are limited. This study evaluates whether radiofrequency (RF) catheter ablation delays the progression of AF compared with antiarrhythmic drug (AAD) treatment using current AF management guidelines. METHODS This prospective, randomized, controlled, two-arm, open-label trial was conducted at 29 hospitals and medical centres across 13 countries. Patients were randomized 1 : 1 to RF ablation or AAD treatment. The primary endpoint was the rate of persistent AF/atrial tachycardia (AT) at 3 years. RESULTS After early study termination following slow enrolment, 255 (79%) of the planned 322 patients were enrolled (RF ablation, n = 128, AAD, n = 127); 36% of patients in the RF ablation group and 41% in the AAD group completed 3 years of follow-up. For the primary endpoint, the Kaplan-Meier estimate of the rate of persistent AF/AT at 3 years was significantly lower with RF ablation [2.4% (95% confidence interval (CI), 0.6-9.4%)] than with AAD therapy [17.5% (95% CI, 10.7-27.9%); one-sided P = 0.0009]. Patients ≥65 years were ∼4 times more likely to progress to persistent AF/AT than patients <65 years, suggesting RF ablation can delay disease progression [hazard ratio: 3.87 (95% CI, 0.88-17.00); P = 0.0727]. Primary adverse events were reported for eight patients in the RF ablation group. CONCLUSIONS Radiofrequency ablation is superior to guideline-directed AAD therapy in delaying the progression from paroxysmal to persistent AF.",2021,"Patients ≥65 years were ∼4 times more likely to progress to persistent AF/AT than patients <65 years, suggesting RF ablation can delay disease progression [hazard ratio: 3.87 (95% CI, 0.88-17.00); P = 0.0727].","['atrial fibrillation', '322 patients were enrolled (RF ablation, n\u2009=\u2009128, AAD, n\u2009=\u2009127); 36% of patients in the', '29 hospitals and medical centres across 13 countries']","['RF ablation or AAD treatment', 'Radiofrequency ablation', 'radiofrequency (RF) catheter ablation', 'RF ablation', 'catheter ablation', 'Catheter ablation or medical therapy', 'antiarrhythmic drug (AAD']","['rate of persistent AF/atrial tachycardia (AT', 'Kaplan-Meier estimate of the rate of persistent AF/AT']","[{'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C4517712', 'cui_str': '322'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0003195', 'cui_str': 'Antiarrhythmic agent'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0454664', 'cui_str': 'Country'}]","[{'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0003195', 'cui_str': 'Antiarrhythmic agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0162561', 'cui_str': 'Radiofrequency Catheter Ablation'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}]","[{'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}]",322.0,0.0783075,"Patients ≥65 years were ∼4 times more likely to progress to persistent AF/AT than patients <65 years, suggesting RF ablation can delay disease progression [hazard ratio: 3.87 (95% CI, 0.88-17.00); P = 0.0727].","[{'ForeName': 'Karl-Heinz', 'Initials': 'KH', 'LastName': 'Kuck', 'Affiliation': 'Department of Cardiology, Asklepios Klinik St. Georg, LANS Cardio, Stephansplatz 5, 20354 Hamburg, Germany.'}, {'ForeName': 'Dmitry S', 'Initials': 'DS', 'LastName': 'Lebedev', 'Affiliation': 'Almazov National Medical Research Centre, St. Petersburg, Russia.'}, {'ForeName': 'Evgeny N', 'Initials': 'EN', 'LastName': 'Mikhaylov', 'Affiliation': 'Almazov National Medical Research Centre, St. Petersburg, Russia.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Romanov', 'Affiliation': 'E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Novosibirsk, Russia.'}, {'ForeName': 'László', 'Initials': 'L', 'LastName': 'Gellér', 'Affiliation': 'Semmelweis University, Heart and Vascular Center, Budapest, Hungary.'}, {'ForeName': 'Oskars', 'Initials': 'O', 'LastName': 'Kalējs', 'Affiliation': 'P. Stradins Clinical University Hospital, Riga, Latvia.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Neumann', 'Affiliation': 'Kerckhoff Klinik, Bad Nauheim, Germany.'}, {'ForeName': 'Karapet', 'Initials': 'K', 'LastName': 'Davtyan', 'Affiliation': 'National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia.'}, {'ForeName': 'Young Keun', 'Initials': 'YK', 'LastName': 'On', 'Affiliation': 'Arrhythmia Center, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Popov', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Bongiorni', 'Affiliation': 'Second Division of Cardiology, University Hospital, Pisa, Italy.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schlüter', 'Affiliation': 'Asklepios Proresearch, Hamburg, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Willems', 'Affiliation': 'Department of Cardiology, Asklepios Klinik St. Georg, LANS Cardio, Stephansplatz 5, 20354 Hamburg, Germany.'}, {'ForeName': 'Feifan', 'Initials': 'F', 'LastName': 'Ouyang', 'Affiliation': 'Department of Cardiology, Asklepios Klinik St. Georg, LANS Cardio, Stephansplatz 5, 20354 Hamburg, Germany.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa298'] 724,33328932,Individualized Responses to Ipsilesional High-Frequency and Contralesional Low-Frequency rTMS in Chronic Stroke: A Pilot Study to Support the Individualization of Neuromodulation for Rehabilitation.,"Background : In this pilot study, we examined the effects of ipsilesional high-frequency rTMS (iHF-rTMS) and contralesional low-frequency rTMS (cLF-rTMS) applied via a double-cone coil on neurophysiological and gait variables in patients with chronic stroke. Objective/Hypothesis : To determine the group and individual level effects of two types of stimulation to better individualize neuromodulation for rehabilitation. Methods : Using a randomized, within-subject, double-blind, sham-controlled trial with 14 chronic stroke participants iHF-rTMS and cLF-rTMS were applied via a double-cone coil to the tibialis anterior cortical representation. Neurophysiological and gait variables were compared pre-post rTMS. Results : A small effect of cLF-rTMS indicated increased MEP amplitudes (Cohen's D; cLF-rTMS, d = -0.30). Group-level analysis via RMANOVA showed no significant group effects of stimulation ( P > 0.099). However, secondary analyses of individual data showed a high degree of response variability to rTMS. Individual percent changes in resting motor threshold and normalized MEP latency correlated with changes in gait propulsive forces and walking speed (iHF-rTMS, nLAT:Pp, R = 0.632 P = 0.015; cLF-rTMS, rMT:SSWS, R = -0.557, P = 0.039; rMT:Pp, R = 0.718, P = 0.004). Conclusions : Changes in propulsive forces and walking speed were seen in some individuals that showed neurophysiological changes in response to rTMS. The neurological consequences of stroke are heterogeneous making a ""one type fits all"" approach to neuromodulation for rehabilitation unlikely. This pilot study suggests that an individual's unique response to rTMS should be considered before the application/selection of neuromodulatory therapies. Before neuromodulatory therapies can be incorporated into standard clinical practice, additional work is needed to identify biomarkers of response and how best to prescribe neuromodulation for rehabilitation for post-stroke gait.",2020,Conclusions : Changes in propulsive forces and walking speed were seen in some individuals that showed neurophysiological changes in response to rTMS.,"['patients with chronic stroke', '14 chronic stroke participants iHF-rTMS and cLF-rTMS', 'Chronic Stroke']","['cLF-rTMS', 'Ipsilesional High-Frequency and Contralesional Low-Frequency rTMS', 'ipsilesional high-frequency rTMS (iHF-rTMS) and contralesional low-frequency rTMS (cLF-rTMS', ' ']","['Neurophysiological and gait variables', 'resting motor threshold and normalized MEP latency', 'gait propulsive forces and walking speed', 'MEP amplitudes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}]","[{'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0054871', 'cui_str': 'Cathepsin L'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C3653283', 'cui_str': 'PROPULSIVES'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}]",14.0,0.029802,Conclusions : Changes in propulsive forces and walking speed were seen in some individuals that showed neurophysiological changes in response to rTMS.,"[{'ForeName': 'John Harvey', 'Initials': 'JH', 'LastName': 'Kindred', 'Affiliation': 'Department of Research and Development, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, United States.'}, {'ForeName': 'Elizabeth Carr', 'Initials': 'EC', 'LastName': 'Wonsetler', 'Affiliation': 'Department of Public Health and Community Medicine, School of Medicine, Tufts University, Boston, MA, United States.'}, {'ForeName': 'Charalambos Costas', 'Initials': 'CC', 'LastName': 'Charalambous', 'Affiliation': 'Department of Basic and Clinical Sciences, Medical School, University of Nicosia, Nicosia, Cyprus.'}, {'ForeName': 'Shraddha', 'Initials': 'S', 'LastName': 'Srivastava', 'Affiliation': 'Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Barbara Khalibinzwa', 'Initials': 'BK', 'LastName': 'Marebwa', 'Affiliation': 'Department of Neurology, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Bonilha', 'Affiliation': 'Department of Neurology, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Kautz', 'Affiliation': 'Department of Research and Development, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, United States.'}, {'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Bowden', 'Affiliation': 'Department of Research and Development, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, United States.'}]",Frontiers in human neuroscience,['10.3389/fnhum.2020.578127'] 725,33334875,"SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial.","Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces cardiovascular morbidity and mortality in individuals with type 2 diabetes. Beneficial effects have been attributed to increased ketogenesis, reduced cardiac fatty acid oxidation, and diminished cardiac oxygen consumption. We therefore studied whether SGLT2 inhibition altered cardiac oxidative substrate consumption, efficiency, and perfusion. Thirteen individuals with type 2 diabetes were studied after 4 weeks' treatment with empagliflozin and placebo in a randomized, double-blind, placebo-controlled crossover study. Myocardial palmitate and glucose uptake were measured with 11 C-palmitate and 18 F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT). Oxygen consumption and myocardial external efficiency (MEE) were measured with 11 C-acetate PET/CT. Resting and adenosine stress myocardial blood flow (MBF) and myocardial flow reserve (MFR) were measured using 15 O-H 2 O PET/CT. Empagliflozin did not affect myocardial free fatty acids (FFAs) uptake but reduced myocardial glucose uptake by 57% ( P < 0.001). Empagliflozin did not change myocardial oxygen consumption or MEE. Empagliflozin reduced resting MBF by 13% ( P < 0.01), but did not significantly affect stress MBF or MFR. In conclusion, SGLT2 inhibition did not affect myocardial FFA uptake, but channeled myocardial substrate utilization from glucose toward other sources and reduced resting MBF. However, the observed metabolic and hemodynamic changes were modest and most likely contribute only partially to the cardioprotective effect of SGLT2 inhibition.",2021,"Empagliflozin reduced resting MBF by 13% (p<0.01), but did not significantly affect stress MBF or MFR.In conclusion, SGLT2 inhibition did not affect myocardial FFA uptake, but channeled myocardial substrate utilization from glucose towards other sources and reduced resting MBF.","['individuals with type 2 diabetes', 'Individuals', 'perfusion.13 individuals with type 2 diabetes']","['placebo', 'Sodium-glucose cotransporter 2', 'SGLT2) inhibition', 'Empagliflozin', 'Placebo', 'empagliflozin and placebo']","['myocardial FFA uptake', 'myocardial glucose uptake', 'Oxygen consumption and myocardial external efficiency (MEE', 'Myocardial Fatty Acid Oxidation or Uptake', 'myocardial oxygen consumption or MEE', 'cardiovascular morbidity and mortality', 'resting MBF', 'Myocardial Glucose Uptake and Blood Flow', 'Myocardial palmitate and glucose uptake', 'Resting and adenosine stress myocardial blood flow (MBF) and myocardial flow reserve (MFR']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}]","[{'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0428863', 'cui_str': 'Myocardial oxygen consumption'}, {'cui': 'C1301700', 'cui_str': 'Cardiovascular morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0030233', 'cui_str': 'Hexadecanoates'}, {'cui': 'C0001443', 'cui_str': 'Adenosine'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0671702', 'cui_str': 'PTPNS1 protein, human'}]",,0.320065,"Empagliflozin reduced resting MBF by 13% (p<0.01), but did not significantly affect stress MBF or MFR.In conclusion, SGLT2 inhibition did not affect myocardial FFA uptake, but channeled myocardial substrate utilization from glucose towards other sources and reduced resting MBF.","[{'ForeName': 'Katrine M', 'Initials': 'KM', 'LastName': 'Lauritsen', 'Affiliation': 'Steno Diabetes Center, Aarhus, Denmark.'}, {'ForeName': 'Bent R R', 'Initials': 'BRR', 'LastName': 'Nielsen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Lars P', 'Initials': 'LP', 'LastName': 'Tolbod', 'Affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus Denmark.'}, {'ForeName': 'Mogens', 'Initials': 'M', 'LastName': 'Johannsen', 'Affiliation': 'Department of Forensic Medicine, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Hansen', 'Affiliation': 'Department of Forensic Medicine, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Troels K', 'Initials': 'TK', 'LastName': 'Hansen', 'Affiliation': 'Steno Diabetes Center, Aarhus, Denmark.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Wiggers', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Møller', 'Affiliation': 'Steno Diabetes Center, Aarhus, Denmark.'}, {'ForeName': 'Lars C', 'Initials': 'LC', 'LastName': 'Gormsen', 'Affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus Denmark.'}, {'ForeName': 'Esben', 'Initials': 'E', 'LastName': 'Søndergaard', 'Affiliation': 'Steno Diabetes Center, Aarhus, Denmark esben.sondergaard@clin.au.dk.'}]",Diabetes,['10.2337/db20-0921'] 726,33307633,"Preemptive analgesic efficacy of ultrasound-guided transversalis fascia plane block in children undergoing inguinal herniorrhaphy: a randomized, double-blind, controlled study.","BACKGROUND Surgical repair of congenital inguinal hernia results in significant postoperative discomfort and pain. The aim of the current study was to evaluate the pre-emptive analgesic efficacy of a transversalis fascia plane (TFP) block after pediatric inguinal herniorrhaphy. METHODS Forty-four patients aged 12 to 60 months who underwent unilateral inguinal herniorrhaphy were enrolled. Four patients were excluded, and the remaining were allocated to the control group and the TFP block group. In the TFP block group, 0.4 mL/kg bupivacaine 0.25% was instilled in the plane between the transversus abdominis and transversalis fascia, while in the control group 0.9% saline was used instead of bupivacaine. The collected data were the total dose of paracetamol consumed during the first 12 h postoperatively, the postoperative Face, Leg, Activity, Cry, Consolability (FLACC) pain score, time to first use of rescue analgesia, number of patients required additional postoperative analgesics, and parents' satisfaction. RESULTS The median paracetamol consumption was significantly lower in the TFP block group than in the control group, and FLACC pain scores were significantly lower for all study times in the TFP block group with higher parental satisfaction scores than those for the control group. The number of patients who required additional analgesics was significantly lower in the TFP block group than in the control group. CONCLUSIONS The use of a TFP block decreases postoperative analgesic consumption and postoperative pain intensity after pediatric inguinal herniorrhaphy. Future studies with larger sample size are required to evaluate the actual complications rate of TFP block.",2021,"The time to first rescue analgesia was significantly longer and the number of patients who required additional analgesics were significantly lower in TFP block group than the control group. ","['44 patients aged 12 to 60 months, undergoing unilateral inguinal herniorrhaphy were enrolled', 'after pediatric inguinal herniorrhaphy', 'children undergoing inguinal herniorrhaphy']","['TFP block', 'ultrasound-guided transversalis fascia plane block', 'transversalis fascia plane (TFP) block', 'bupivacaine', 'TFP', 'TFP block group']","['postoperative discomfort and pain', 'postoperative analgesic consumption and postoperative pain intensity', 'median paracetamol consumption', 'number of patients who required additional analgesics', ""postoperative Face, Leg, Activity, Cry, Consolability (FLACC) pain score, time to first rescue analgesia, number of children required additional postoperative analgesics and parents' satisfaction Likert scale"", 'total dose of paracetamol consumed during the first postoperative 12 hours (h', 'time to first rescue analgesia', 'FLACC pain scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0021446', 'cui_str': 'Repair of inguinal hernia'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0015641', 'cui_str': 'Fascial'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0225232', 'cui_str': 'Transversalis fascia structure'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1292430', 'cui_str': '12 hours'}]",44.0,0.355963,"The time to first rescue analgesia was significantly longer and the number of patients who required additional analgesics were significantly lower in TFP block group than the control group. ","[{'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Abdelbaser', 'Affiliation': 'Department of Anesthesia and Surgical Intensive Care, Mansoura University Faculty of Medicine, Mansoura, Egypt.'}, {'ForeName': 'Nabil A', 'Initials': 'NA', 'LastName': 'Mageed', 'Affiliation': 'Department of Anesthesia and Surgical Intensive Care, Mansoura University Faculty of Medicine, Mansoura, Egypt.'}, {'ForeName': 'El-Sayed M', 'Initials': 'EM', 'LastName': 'El-Emam', 'Affiliation': 'Department of Anesthesia and Surgical Intensive Care, Mansoura University Faculty of Medicine, Mansoura, Egypt.'}, {'ForeName': 'Mahmoud M', 'Initials': 'MM', 'LastName': 'ALseoudy', 'Affiliation': 'Department of Anesthesia and Surgical Intensive Care, Mansoura University Faculty of Medicine, Mansoura, Egypt.'}, {'ForeName': 'Mohamed M', 'Initials': 'MM', 'LastName': 'Elmorsy', 'Affiliation': 'Department of Anesthesia and Surgical Intensive Care, Mansoura University Faculty of Medicine, Mansoura, Egypt.'}]",Korean journal of anesthesiology,['10.4097/kja.20601'] 727,33331082,Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial.,"Interleukin-6 (IL-6) is a proinflammatory cytokine and key regulator of Treg: T effector cell (Teff) balance. We hypothesized that IL-6 blockade with tocilizumab, a monoclonal antibody to IL-6R, would increase Tregs, dampen Teff function, and control graft inflammation. We conducted a randomized controlled clinical trial (2014-2018) of clinically stable kidney transplant recipients on calcineurin inhibitor, mycophenolate mofetil, and prednisone, with subclinical graft inflammation noted on surveillance biopsies during the first year posttransplant. Subjects received tocilizumab (8 mg/kg IV every 4 weeks; 6 doses; n = 16) or no treatment (controls; n = 14) on top of usual maintenance immunosuppression. Kidney biopsies pre- and post-treatment were analyzed using Banff criteria. Blood was analyzed for serum cytokines, Treg frequencies, and T cell effector molecule expression (IFN-γ, IL-17, granzyme B) post-stimulation ex vivo. Tocilizumab-treated subjects were more likely to show improved Banff ti-score (62.5% vs. 21.4%, p = .03), increased Treg frequency (7.1% ± 5.55% vs. 3.6% ± 1.7%, p = .0168), and a blunted Teff cytokine response compared to controls. Changes in Banff i- and t-scores were not significantly different. The treatment was relatively well tolerated with no patient deaths or graft loss. Blockade of IL-6 is a novel and promising treatment option to regulate the T cell alloimmune response in kidney transplant recipients. NCT02108600.",2021,"Blood was analyzed for serum cytokines, Treg frequencies, and T cell effector molecule expression (IFN-γ, IL-17, granzyme B) post-stimulation ex vivo.","['kidney transplant recipients', 'Renal Graft Inflammation', '2014-2018) of clinically stable kidney transplant recipients on', ' with subclinical graft inflammation noted on surveillance biopsies during the first year post-transplant']","['calcineurin inhibitor, mycophenolate mofetil and prednisone', 'no treatment (controls; n=14) on top of usual maintenance immunosuppression', 'Tocilizumab', 'tocilizumab', 'IL-6']","['tolerated with no patient deaths or graft loss', 'Interleukin-6 (IL-6', 'serum cytokines, Treg frequencies, and T cell effector molecule expression (IFN-γ, IL-17, granzyme B) post-stimulation ex vivo', 'Banff ti-score', 'blunted Teff cytokine response', 'Treg frequency']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}]","[{'cui': 'C1453118', 'cui_str': 'CABIN1 protein, human'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}, {'cui': 'C1609165', 'cui_str': 'tocilizumab'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877042', 'cui_str': 'Graft loss'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C4543203', 'cui_str': 'Effector'}, {'cui': 'C0567416', 'cui_str': 'Molecule'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0061878', 'cui_str': 'Granzyme B'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C0312740', 'cui_str': 'Immune effector cell'}]",,0.0829845,"Blood was analyzed for serum cytokines, Treg frequencies, and T cell effector molecule expression (IFN-γ, IL-17, granzyme B) post-stimulation ex vivo.","[{'ForeName': 'Sindhu', 'Initials': 'S', 'LastName': 'Chandran', 'Affiliation': 'Department of Medicine, University of California, San Francisco, California, USA.'}, {'ForeName': 'Joey', 'Initials': 'J', 'LastName': 'Leung', 'Affiliation': 'Department of Surgery, University of California, San Francisco, California, USA.'}, {'ForeName': 'Crystal', 'Initials': 'C', 'LastName': 'Hu', 'Affiliation': 'Department of Surgery, University of California, San Francisco, California, USA.'}, {'ForeName': 'Zoltan G', 'Initials': 'ZG', 'LastName': 'Laszik', 'Affiliation': 'Department of Pathology, University of California, San Francisco, California, USA.'}, {'ForeName': 'Qizhi', 'Initials': 'Q', 'LastName': 'Tang', 'Affiliation': 'Department of Surgery, University of California, San Francisco, California, USA.'}, {'ForeName': 'Flavio G', 'Initials': 'FG', 'LastName': 'Vincenti', 'Affiliation': 'Department of Medicine, University of California, San Francisco, California, USA.'}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.16459'] 728,33332819,Inspiratory Muscle Training With an Electronic Resistive Loading Device Improves Prolonged Weaning Outcomes in a Randomized Controlled Trial.,"OBJECTIVES To test if the use of an inspiratory muscle training program with an electronic resistive loading device is associated with benefits as to muscle strength, weaning, and survival in the ICU. DESIGN Prospective randomized controlled trial. SETTINGS Study conducted at the ICU of a Navy's hospital, Rio de Janeiro, Brazil, from January 2016 to September 2018. PATIENTS Tracheostomized patients (18-86 yr) on prolonged weaning. INTERVENTIONS Participants were assigned to inspiratory muscle training (intervention group) or a traditional T-piece protocol (control group). In the inspiratory muscle training group, participants underwent training with an electronic inspiratory training device (POWERbreathe K-5; Technologies Ltd, Birmingham, United Kingdom). MEASUREMENTS AND MAIN RESULTS Changes in respiratory muscle strength and rates of ICU survival and weaning success were compared between groups. Forty-eight participants in the inspiratory muscle training group and 53 ones in the control group were included in the final analysis. The inspiratory muscle training was associated with a substantially higher gain on muscle strength as assessed by the maximal inspiratory pressure (70.5 [51.0-82.5] vs -48.0 cm H2O [36.0-72.0 cm H2O]; p = 0.003) and the timed inspiratory effort index (1.56 [1.25-2.08] vs 0.99 cm H2O/s [0.65-1.71 cm H2O/s]; p = 0.001). Outcomes at the 60th day of ICU were significantly better in the intervention group regarding both survival (71.1% vs 48.9%; p = 0.030) and weaning success (74.8% vs 44.5%; p = 0.001). CONCLUSIONS The use of an inspiratory muscle training program with an electronic resistive loading device was associated with substantial muscle strength gain and positive impacts in two very relevant clinical outcomes: the rates of ICU survival and successful weaning.",2021,The inspiratory muscle training was associated with a substantially higher gain on muscle strength as assessed by the maximal inspiratory pressure (70.5 [51.0-82.5] vs -48.0 cm H2O [36.0-72.0 cm H2O]; p = 0.003) and the timed inspiratory effort index (1.56 [1.25-2.08] vs 0.99 cm H2O/s [0.65-1.71 cm H2O/s]; p = 0.001).,"['Tracheostomized patients (18-86 yr) on prolonged weaning', ""Study conducted at the ICU of a Navy's hospital, Rio de Janeiro, Brazil, from January 2016 to September 2018""]","['Inspiratory Muscle Training With an Electronic Resistive Loading Device', 'inspiratory muscle training program with an electronic resistive loading device', 'training with an electronic inspiratory training device (POWERbreathe K-5; Technologies Ltd, Birmingham, United Kingdom', 'inspiratory muscle training (intervention group) or a traditional T-piece protocol (control group', 'inspiratory muscle training']","['muscle strength', 'survival', 'weaning success', 'timed inspiratory effort index', 'maximal inspiratory pressure', 'rates of ICU survival and successful weaning', 'respiratory muscle strength and rates of ICU survival and weaning success']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043084', 'cui_str': 'Weaning'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0020014', 'cui_str': 'Hospitals, Navy'}, {'cui': 'C0445581', 'cui_str': 'Rio'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0108311', 'cui_str': 'capsular polysaccharide K5'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C1136140', 'cui_str': 'Long-Term Depression, Neurophysiologic'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0043084', 'cui_str': 'Weaning'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C4083126', 'cui_str': 'Maximum Inspiratory Pressure'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}]",2.0,0.0960346,The inspiratory muscle training was associated with a substantially higher gain on muscle strength as assessed by the maximal inspiratory pressure (70.5 [51.0-82.5] vs -48.0 cm H2O [36.0-72.0 cm H2O]; p = 0.003) and the timed inspiratory effort index (1.56 [1.25-2.08] vs 0.99 cm H2O/s [0.65-1.71 cm H2O/s]; p = 0.001).,"[{'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'da Silva Guimarães', 'Affiliation': 'Medical Science Post-graduation Program, Universidade Federal Fluminense, Rio de Janiero, Brazil.'}, {'ForeName': 'Leonardo Cordeiro', 'Initials': 'LC', 'LastName': 'de Souza', 'Affiliation': 'Physical Therapy School, Universidade Estácio de Sá, Rio de Janiero, Brazil.'}, {'ForeName': 'Hebe Faria', 'Initials': 'HF', 'LastName': 'Cordeiro', 'Affiliation': ""Physical Therapy Hospital Naval Marcilio Dias, Rio de Janiero, Brazil (Brazil's Navy).""}, {'ForeName': 'Thiago Loureiro', 'Initials': 'TL', 'LastName': 'Regis', 'Affiliation': ""Physical Therapy Hospital Naval Marcilio Dias, Rio de Janiero, Brazil (Brazil's Navy).""}, {'ForeName': 'Cristiane Almeida', 'Initials': 'CA', 'LastName': 'Leite', 'Affiliation': ""Physical Therapy Hospital Naval Marcilio Dias, Rio de Janiero, Brazil (Brazil's Navy).""}, {'ForeName': 'Fernanda Patricio', 'Initials': 'FP', 'LastName': 'Puga', 'Affiliation': ""Physical Therapy Hospital Naval Marcilio Dias, Rio de Janiero, Brazil (Brazil's Navy).""}, {'ForeName': 'Sergio Hernando', 'Initials': 'SH', 'LastName': 'Alvim', 'Affiliation': ""Intensive Care Unit Hospital Naval Marcilio Dias, Rio de Janiero, Brazil (Brazil's Navy).""}, {'ForeName': 'Jocemir Ronaldo', 'Initials': 'JR', 'LastName': 'Lugon', 'Affiliation': 'Division of Nephrology, Department of Medicine, Medical School, Universidade Federal Fluminense, Rio de Janiero, Brazil.'}]",Critical care medicine,['10.1097/CCM.0000000000004787'] 729,33332813,SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.,"PURPOSE To determine associations of systemic medications with the incidence and growth of geographic atrophy (GA) in participants of the comparison of age-related macular degeneration treatments trials. METHODS Participants of comparison of age-related macular degeneration treatments trials with new untreated choroidal neovascularization in the study eye (one study eye per participant) were randomized to receive treatment with bevacizumab or ranibizumab. Participants were released from clinical trial treatment at 2 years and examined at approximately 5 years. Color fundus photographs and fluorescein angiograms taken at baseline, Years 1, 2, and 5 were assessed for the presence and size of GA by two masked graders. Participants were interviewed about systemic medication use at baseline. Systemic medications previously reported to be associated with age-related macular degeneration were evaluated for associations with GA incidence in study eye using univariable and multivariable Cox models and for association with the GA growth using linear mixed effects models. RESULTS In multivariable analysis of 1,011 study eyes without baseline GA, systemic medications, including cholinesterase inhibitors, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, diuretics, aspirin, steroids, statins, hormone replacement therapy, antacids, and drugs targeting G protein-coupled receptors, were not associated with GA incidence in the study eye (all adjusted hazard ratios ≤1.86, P ≥ 0.18). In multivariable analysis of 214 study eyes with longitudinal GA size measurements, calcium channel blockers were associated with a higher GA growth rate (0.40 vs. 0.30 mm/year, P = 0.02). CONCLUSION None of the systemic medications analyzed were associated with GA incidence. However, calcium channel blockers were associated with a higher growth rate of GA in the study eye.",2021,"In multivariable analysis of 214 study eyes with longitudinal GA size measurements, calcium channel blockers were associated with higher GA growth rate (0.40 vs 0.30 mm/year, p=0.02). ","['participants of the Comparison of Age-related Macular Degeneration (AMD) Treatments Trials (CATT', 'Participants of CATT with new untreated choroidal neovascularization in the study eye (one study eye per participant']","['calcium channel blockers', 'cholinesterase inhibitor, ACE inhibitors, calcium channel blockers, beta-blockers, diuretics, aspirin, steroids, statins, hormone replacement therapy, antacids', 'bevacizumab or ranibizumab']","['growth rate of GA', 'higher GA growth rate']","[{'cui': 'C0242383', 'cui_str': 'Age related macular degeneration'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0600518', 'cui_str': 'Choroidal neovascularisation'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}]","[{'cui': 'C0006684', 'cui_str': 'Calcium channel blocker'}, {'cui': 'C0008425', 'cui_str': 'Cholinesterase inhibitor'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0001645', 'cui_str': 'Beta adrenergic receptor antagonist'}, {'cui': 'C0012798', 'cui_str': 'Diuretic'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy'}, {'cui': 'C0003138', 'cui_str': 'Antacid'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}]","[{'cui': 'C0449249', 'cui_str': 'Growth rate'}, {'cui': 'C1536085', 'cui_str': 'Dry Macular Degeneration'}, {'cui': 'C0205250', 'cui_str': 'High'}]",1011.0,0.181743,"In multivariable analysis of 214 study eyes with longitudinal GA size measurements, calcium channel blockers were associated with higher GA growth rate (0.40 vs 0.30 mm/year, p=0.02). ","[{'ForeName': 'Delu', 'Initials': 'D', 'LastName': 'Song', 'Affiliation': 'Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and.'}, {'ForeName': 'Peiying', 'Initials': 'P', 'LastName': 'Hua', 'Affiliation': 'Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'VanderBeek', 'Affiliation': 'Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and.'}, {'ForeName': 'Joshua L', 'Initials': 'JL', 'LastName': 'Dunaief', 'Affiliation': 'Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and.'}, {'ForeName': 'Juan E', 'Initials': 'JE', 'LastName': 'Grunwald', 'Affiliation': 'Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and.'}, {'ForeName': 'Ebenezer', 'Initials': 'E', 'LastName': 'Daniel', 'Affiliation': 'Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and.'}, {'ForeName': 'Maureen G', 'Initials': 'MG', 'LastName': 'Maguire', 'Affiliation': 'Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'Martin', 'Affiliation': 'Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Gui-Shuang', 'Initials': 'GS', 'LastName': 'Ying', 'Affiliation': 'Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000003075'] 730,33340400,A Preoperative Contingency Management Intervention for Smoking Abstinence in Cancer Patients: A Preliminary Randomized Controlled Trial.,"INTRODUCTION The purpose of this study was to evaluate a pilot preoperative contingency management (CM) intervention for smoking abstinence. AIMS AND METHODS This multisite pilot study was conducted at two cancer center-based tobacco treatment programs. Participants who were smoking, diagnosed with or suspected to have any type of operable cancer, and had a surgical procedure scheduled in the next 10 days to 5 weeks (N = 40) were randomized to receive standard care plus monitoring only (MO) or CM prior to surgery. All patients received breath carbon monoxide (CO) tests 3 times per week, nicotine patches, and counseling. The CM group also earned payments for self-reported smoking abstinence confirmed by CO breath test ≤6 ppm on an escalating schedule of reinforcement (with a reset if they smoked). Seven-day point prevalence abstinence rates on the day of surgery and at 3-month follow-up were compared between groups using repeated measures log-linear regression models utilizing generalized estimating equations. Participants lost to follow-up are assumed to have returned to smoking. RESULTS The sample was 50% female and 75% White. In covariate adjusted models, patients in the CM group had a greater probability of reported abstinence. On the day of surgery (end of treatment), 52% of CM patients were abstinent compared with 16% of patients in MO (risk ratio = 3.2 [1.1-9.3]; p = .03). At the 3-month follow-up, 43% of CM patients were abstinent compared with 5% in MO (risk ratio = 8.4 [1.5-48.3]; p = .02). CONCLUSIONS Providing monetary incentives contingent on abstinence prior to cancer surgery may produce significant improvements in smoking abstinence rates relative to breath CO MO. IMPLICATIONS In this pilot preoperative CM intervention for smoking abstinence, patients receiving a CM intervention prior to cancer surgery had a greater probability of smoking abstinence at the end of treatment compared with a breath MO group (52% vs. 16%, respectively). Thus, providing monetary incentives contingent on abstinence may produce significant improvements in smoking abstinence rates prior to cancer surgery relative to breath CO monitoring.",2021,Seven-day point prevalence abstinence rates on the day of surgery and at 3-month follow up were compared between groups using repeated measures log-linear regression models utilizing generalized estimating equations.,"['Participants who were smoking, diagnosed with or suspected to have any type of operable cancer, and had a surgical procedure scheduled in the next 10 days to 5 weeks (N=40', 'Cancer Patients', '2 cancer center-based tobacco treatment programs']","['standard care plus Monitoring Only (MO) or Contingency Management (CM) prior to surgery', 'Preoperative Contingency Management Intervention', 'pilot preoperative contingency management intervention', 'breath carbon monoxide (CO']","['smoking abstinence rates', 'probability of reported abstinence', 'prevalence abstinence rates']","[{'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205188', 'cui_str': 'Operable'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}]","[{'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}]",,0.0486328,Seven-day point prevalence abstinence rates on the day of surgery and at 3-month follow up were compared between groups using repeated measures log-linear regression models utilizing generalized estimating equations.,"[{'ForeName': 'Alana M', 'Initials': 'AM', 'LastName': 'Rojewski', 'Affiliation': 'Department of Public Health Sciences and Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Fucito', 'Affiliation': 'Department of Psychiatry and Emergency Medicine, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Nathaniel L', 'Initials': 'NL', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health Sciences and Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Suchitra', 'Initials': 'S', 'LastName': 'Krishnan-Sarin', 'Affiliation': 'Department of Psychiatry and Emergency Medicine, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Carpenter', 'Affiliation': 'Department of Public Health Sciences and Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Steven L', 'Initials': 'SL', 'LastName': 'Bernstein', 'Affiliation': 'Department of Psychiatry and Emergency Medicine, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Benjamin A', 'Initials': 'BA', 'LastName': 'Toll', 'Affiliation': 'Department of Public Health Sciences and Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa266'] 731,33315247,Mental contrasting with implementation intentions increases study time for university students.,"BACKGROUND Goal setting is a core aspect of human behaviour that drives action. The intention to achieve one's goals, however, does not necessarily translate into desired outcomes. Although the mental contrasting with implementation intentions (MCII) strategy has demonstrated strong efficacy, limited investigations have been conducted in a university academic goal-setting context. AIMS The current study sought to investigate the efficacy of MCII in facilitating academic goal attainment in university students. METHOD Fifty-eight students from Macquarie University, Australia, were randomly allocated to either MCII or stress management training, and were assessed on their progress towards the target goal of increased hours of study four weeks later. Goal attainment scaling (GAS) facilitated the generation of tailored specific goals and was the primary outcome measure. RESULTS An analysis of covariance indicated that students trained in MCII achieved significantly better goal outcomes than those trained in stress management for both broad (p = .038) and course- or unit-specific (p = .005) study goals. CONCLUSIONS Results highlight the efficacy of using MCII and GAS in combination to promote increased study time for university students.",2021,"An analysis of covariance indicated that students trained in MCII achieved significantly better goal outcomes than those trained in stress management for both broad (p = .038) and course- or unit-specific (p = .005) study goals. ","['Fifty-eight students from Macquarie University, Australia', 'university students']","['MCII and GAS', 'MCII', 'MCII or stress management training']",['goal outcomes'],"[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",58.0,0.033496,"An analysis of covariance indicated that students trained in MCII achieved significantly better goal outcomes than those trained in stress management for both broad (p = .038) and course- or unit-specific (p = .005) study goals. ","[{'ForeName': 'Melinda', 'Initials': 'M', 'LastName': 'Clark', 'Affiliation': 'Department of Psychology, Macquarie University, Sydney, New South Wales, Australia.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Miller', 'Affiliation': 'Department of Psychology, Macquarie University, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Berry', 'Affiliation': 'Department of Psychology, Macquarie University, Sydney, New South Wales, Australia.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Cheng', 'Affiliation': 'Department of Biological Sciences, Macquarie University, Sydney, New South Wales, Australia.'}]",The British journal of educational psychology,['10.1111/bjep.12396'] 732,33317342,Needle-free jet injection of insulin glargine improves glycemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system.,"Background : To investigate the effects of insulin glargine injection given with a QS-P jet injector on the glucose profile using a professional mode flash glucose monitoring (FGM) system in patients with type 2 diabetes mellitus (T2DM). Research design and methods : In this randomized, controlled, cross-sectional study, 66 patients with T2DM who received insulin glargine (12-18 IU/day) injection were enrolled. The patients were randomly divided into group A (jet injector before insulin pen) and group B (insulin pen before jet injector). Each subject injected insulin daily before breakfast. We analyzed the changes in the glucose profile using a professional mode FGM system. Results : Treatment with a jet injector led to significantly lower 24-h mean glucose, maximum blood glucose, area under the curve (AUC) > 10.0 mmol/L, time above range and increased AUC < 3.9 mmol/L and time below range than those when using an insulin pen. There was no difference in glycemic variability between the two groups. We observed that patients using a jet injector had significantly lower mean glucose between 12:00 to 22:00. Conclusions : Needle-free jet injection of insulin glargine was more effective than use of an insulin pen for good glycemic control in patients with T2DM. Clinical trial registration : www.clinicaltrials.gov identifier is NCT04093284.",2021,"RESULTS Treatment with a jet injector led to significantly lower 24-h mean glucose, maximum blood glucose, area under the curve (AUC) >10.0 mmol/L, time above range and increased AUC < 3.9 mmol/L and time below range than those when using an insulin pen.","['12-18 IU/day) injection were enrolled', 'patients with T2DM', '66 patients with T2DM who received', 'patients with type 2 diabetes mellitus', 'patients with type 2 diabetes mellitus (T2DM']","['professional mode flash glucose monitoring (FGM) system', 'QS-P jet injector', 'insulin glargine injection', 'Needle-free jet injection of insulin glargine', 'insulin glargine']","['glycemic variability', '24-h mean glucose, maximum blood glucose, area under the curve (AUC) >10.0 mmol/L, time above range and increased AUC', 'mean glucose', 'glycaemic control']","[{'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C0085635', 'cui_str': 'Photopsia'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C3888433', 'cui_str': 'Jet Injector'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0021496', 'cui_str': 'Jet Injections'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C1532563', 'cui_str': 'mmol/L'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",66.0,0.0140472,"RESULTS Treatment with a jet injector led to significantly lower 24-h mean glucose, maximum blood glucose, area under the curve (AUC) >10.0 mmol/L, time above range and increased AUC < 3.9 mmol/L and time below range than those when using an insulin pen.","[{'ForeName': 'Xiaocen', 'Initials': 'X', 'LastName': 'Kong', 'Affiliation': 'Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China.'}, {'ForeName': 'Menghui', 'Initials': 'M', 'LastName': 'Luo', 'Affiliation': 'Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Cai', 'Affiliation': 'Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China.'}, {'ForeName': 'Rengna', 'Initials': 'R', 'LastName': 'Yan', 'Affiliation': 'Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China.'}, {'ForeName': 'Huiqin', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China.'}]",Expert opinion on drug delivery,['10.1080/17425247.2021.1863945'] 733,33325645,Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.,"AIMS/INTRODUCTION To identify the effect of combination therapy with a dipeptidyl peptidase-4 inhibitor and a sodium-glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase-4 inhibitor to a sodium-glucose cotransporter 2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. MATERIALS AND METHODS A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was carried out in a multicenter, prospective, randomized, parallel-group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C-peptide (CPR) divided at baseline by the median. RESULTS ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (-29.2 ± 28.3 vs -20.0 ± 24.6, respectively; P = 0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group (P < 0.01). CONCLUSIONS COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion.",2021,"RESULTS ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (-29.2±28.3 vs. -20.0±24.6, respectively; P=0.60).","['patients with impaired endogenous insulin secretion', 'Japanese patients type 2 diabetes treated with', 'enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by', 'patients with or without impaired endogenous insulin secretion']","['switching to canagliflozin (SWITCH) or adding canagliflozin (COMB', 'dipeptidyl peptidase-4 (DPP-4) inhibitor and a sodium-glucose co-transporter-2 (SGLT2) inhibitor', 'canagliflozin plus teneligliptin', 'high CPR COMB', 'endogenous insulin secretion']","['mean amplitude of glycemic excursions (ΔMAGE', 'ΔMAGE', 'daily glucose variability', 'glucose variability', 'high or low CPR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C2974540', 'cui_str': 'canagliflozin'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0376161', 'cui_str': 'Comb'}, {'cui': 'C0081937', 'cui_str': 'Dipeptidyl peptidase IV'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598849', 'cui_str': 'Co-Transporters'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}]",,0.0294471,"RESULTS ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (-29.2±28.3 vs. -20.0±24.6, respectively; P=0.60).","[{'ForeName': 'Aika', 'Initials': 'A', 'LastName': 'Miya', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Akinobu', 'Initials': 'A', 'LastName': 'Nakamura', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Kyu Yong', 'Initials': 'KY', 'LastName': 'Cho', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Kawata', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nomoto', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'So', 'Initials': 'S', 'LastName': 'Nagai', 'Affiliation': 'Division of Diabetes and Endocrinology, Department of Medicine, NTT Sapporo Medical Center, Sapporo, Japan.'}, {'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Sugawara', 'Affiliation': 'Third Department of Internal Medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Taneda', 'Affiliation': 'Department of Diabetes Centre, Manda Memorial Hospital, Sapporo, Japan.'}, {'ForeName': 'Kazuhisa', 'Initials': 'K', 'LastName': 'Tsuchida', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Kazuno', 'Initials': 'K', 'LastName': 'Omori', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Yokoyama', 'Affiliation': 'Department of Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Takeuchi', 'Affiliation': 'Sapporo Diabetes and Thyroid Clinic, Sapporo, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Aoki', 'Affiliation': 'Aoki Clinic, Sapporo, Japan.'}, {'ForeName': 'Yoshio', 'Initials': 'Y', 'LastName': 'Kurihara', 'Affiliation': 'Kurihara Clinic, Sapporo, Japan.'}, {'ForeName': 'Tatsuya', 'Initials': 'T', 'LastName': 'Atsumi', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Miyoshi', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}]",Journal of diabetes investigation,['10.1111/jdi.13479'] 734,33338216,Oesophageal Probe Evaluation in Radiofrequency Ablation of Atrial Fibrillation (OPERA): results from a prospective randomized trial-Authors' reply.,,2021,,[],['Radiofrequency Ablation of Atrial Fibrillation (OPERA'],[],[],"[{'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]",[],,0.0196614,,"[{'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Schoene', 'Affiliation': 'Department of Electrophysiology, Heart Center, University of Leipzig, Struempellstrasse 39, 04289 Leipzig, Germany.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Sommer', 'Affiliation': 'Department of Electrophysiology, Herz- und Diabetes Zentrum NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa353'] 735,33315809,Endurance and Sprint Training Improve Glycemia and V˙O2peak but only Frequent Endurance Benefits Blood Pressure and Lipidemia.,"PURPOSE Sprint interval training (SIT) has gained popularity as a time-effective alternative to moderate-intensity endurance training (END). However, whether SIT is equally effective for decreasing cardiometabolic risk factors remains debatable, as many beneficial effects of exercise are thought to be transient, and unlike END, SIT is not recommended daily. Therefore, in line with current exercise recommendations, we examined the ability of SIT and END to improve cardiometabolic health in overweight/obese males. METHODS Twenty-three participants were randomized to perform 6 wk of constant workload SIT (3 d·wk-1, 4-6 × 30 s ~170% Wpeak, 2 min recovery, n = 12) or END (5 d·wk-1, 30-40 min, ~60% Wpeak, n = 11) on cycle ergometers. Aerobic capacity (V˙O2peak), body composition, blood pressure (BP), arterial stiffness, endothelial function, glucose and lipid tolerance, and free-living glycemic regulation were assessed pre- and posttraining. RESULTS Both END and SIT increased V˙O2peak (END ~15%, SIT ~5%) and glucose tolerance (~20%). However, only END decreased diastolic BP, abdominal fat, and improved postprandial lipid tolerance, representing improvements in cardiovascular risk factors that did not occur after SIT. Although SIT, but not END, increased endothelial function, arterial stiffness was not altered in either group. Indices of free-living glycemic regulation were improved after END and trended toward an improvement after SIT (P = 0.06-0.09). However, glycemic control was better on exercise compared with rest days, highlighting the importance of exercise frequency. Furthermore, in an exploratory nature, favorable individual responses (V˙O2peak, BP, glucose tolerance, lipidemia, and body fat) were more prevalent after END than low-frequency SIT. CONCLUSION As only high-frequency END improved BP and lipid tolerance, free-living glycemic regulation was better on days that participants exercised, and favorable individual responses were consistent after END, high-frequency END may favorably improve cardiometabolic health.",2021,Indices of free-living glycemic regulation were improved following END and trended towards an improvement following SIT (p=0.06-0.09).,"['overweight/obese males', 'Twenty-three participants']","['constant workload SIT (3d·wk, 4-6x30 s ~170%Wpeak', 'Endurance and Sprint Training', 'Sprint interval training (SIT', 'SIT']","['individual responses (VO2peak, BP, glucose tolerance, lipidemia, body fat', 'Indices of free-living glycemic regulation', 'cardiometabolic health', 'diastolic BP, abdominal fat, and improved post-prandial lipid tolerance', 'BP and lipid tolerance, free-living glycemic regulation', 'cardiovascular risk factors', 'glucose tolerance', 'endothelial function, arterial stiffness', 'Aerobic capacity (VO2peak), body composition, blood pressure (BP), arterial stiffness, endothelial function, glucose and lipid tolerance, and free-living glycemic regulation']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0450348', 'cui_str': '23'}]","[{'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C4279979', 'cui_str': 'Sprint Interval Training'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0454374', 'cui_str': 'Sprint training'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0020473', 'cui_str': 'Hyperlipidemia'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C1563742', 'cui_str': 'Fat, Abdominal'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}]",23.0,0.0270383,Indices of free-living glycemic regulation were improved following END and trended towards an improvement following SIT (p=0.06-0.09).,"[{'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Petrick', 'Affiliation': ''}, {'ForeName': 'Trevor J', 'Initials': 'TJ', 'LastName': 'King', 'Affiliation': 'Human Performance and Health Research Laboratory, Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, CANADA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Pignanelli', 'Affiliation': 'Human Performance and Health Research Laboratory, Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, CANADA.'}, {'ForeName': 'Tara E', 'Initials': 'TE', 'LastName': 'Vanderlinde', 'Affiliation': 'Human Performance and Health Research Laboratory, Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, CANADA.'}, {'ForeName': 'Jeremy N', 'Initials': 'JN', 'LastName': 'Cohen', 'Affiliation': 'Human Performance and Health Research Laboratory, Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, CANADA.'}, {'ForeName': 'Graham P', 'Initials': 'GP', 'LastName': 'Holloway', 'Affiliation': 'Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, CANADA.'}, {'ForeName': 'Jamie F', 'Initials': 'JF', 'LastName': 'Burr', 'Affiliation': 'Human Performance and Health Research Laboratory, Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, CANADA.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002582'] 736,33315812,Prenatal Exercise and Cardiovascular Health (PEACH) Study: Impact on Muscle Sympathetic Nerve (Re)Activity.,"PURPOSE Women who develop gestational hypertension have evidence of elevated muscle sympathetic nerve activity (MSNA) in early pregnancy, which continues to rise after diagnosis. Exercise has been shown to play a preventative role in the development of gestational hypertension and has been shown to reduce resting and reflex MSNA in nonpregnant populations. We sought to investigate whether aerobic exercise affected the sympathetic regulation of blood pressure between the second and third trimesters of pregnancy. METHODS We conducted a randomized controlled trial of structured aerobic exercise (n = 31) compared with no intervention (control, n = 28) beginning at 16-20 wk and continuing until 34-36 wk of gestation (NCT02948439). Women in the exercise group were prescribed aerobic activity at 50%-70% of their heart rate reserve, on 3-4 d·wk-1 for 25-40 min with a 5-min warm-up and 5-min cool-down (i.e., up to 160 min total activity per week). At preintervention and postintervention assessments, data from ~10 min of quiet rest and a 3-min cold pressor test were analyzed to determine sympathetic nervous system activity and reactivity. RESULTS MSNA was obtained in 51% of assessments. Resting MSNA burst frequency and burst incidence increased across gestation (main effect of gestational age, P = 0.002). Neurovascular transduction was blunted in the control group (P = 0.024) but not in exercisers (P = 0.873) at the postintervention time point. Lastly, MSNA reactivity during the cold pressor test was not affected by gestational age or exercise (P = 0.790, interaction). CONCLUSIONS These data show that exercise attenuates both the rise in MSNA and the blunting of neurovascular transduction. This may partially explain the lower risk of developing gestational hypertension in women who are active during their pregnancies.",2021,"Resting MSNA BF and BI increased across gestation (main effect of gestational age, p=0.002).","['Women who develop gestational hypertension', 'women who are active during their pregnancies']","['aerobic exercise', 'structured aerobic exercise', '3-minute cold pressor test (CPT']","['Muscle Sympathetic Nerve (Re)activity', 'Lastly, MSNA reactivity', 'aerobic activity', 'Prenatal Exercise and Cardiovascular Health', 'Neurovascular transduction (NVT', 'blood pressure', 'Resting MSNA BF and BI increased across gestation', 'gestational hypertension']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0341934', 'cui_str': 'Transient hypertension of pregnancy'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}, {'cui': 'C0006938', 'cui_str': 'Captopril'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0459521', 'cui_str': 'Sympathetic nerve structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0341934', 'cui_str': 'Transient hypertension of pregnancy'}]",,0.117672,"Resting MSNA BF and BI increased across gestation (main effect of gestational age, p=0.002).","[{'ForeName': 'Rachel J', 'Initials': 'RJ', 'LastName': 'Skow', 'Affiliation': ""Program for Pregnancy and Postpartum Health, Neurovascular Health Lab, Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Alberta, CANADA.""}, {'ForeName': 'Graham M', 'Initials': 'GM', 'LastName': 'Fraser', 'Affiliation': ""Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CANADA.""}, {'ForeName': 'Craig D', 'Initials': 'CD', 'LastName': 'Steinback', 'Affiliation': ""Program for Pregnancy and Postpartum Health, Neurovascular Health Lab, Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Alberta, CANADA.""}, {'ForeName': 'Margie H', 'Initials': 'MH', 'LastName': 'Davenport', 'Affiliation': ""Program for Pregnancy and Postpartum Health, Neurovascular Health Lab, Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Alberta, CANADA.""}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002583'] 737,33315660,Three-dimensional Video Assistance Improves Early Results in Minimally Invasive Mitral Valve Surgery.,"Compared with the mid-sternotomy approach, minimally invasive mitral valve surgery is usually associated with longer surgical times. The increasing use of new technology has facilitated this procedure and shortened its duration, which may further improve surgical results. Since 2004, 152 patients have undergone minimally invasive mitral valve repair. Video-assisted 2D technology was used for the first 112 patients, while video-assisted 3D technology was used for the remaining 40 patients. All patients were divided into three groups: group 1 - the first 50 patients (learning curve using 2D technology); group 2 - 62 patients (past the learning curve using 2D technology); and group 3 - 40 patients (3D technology). Mean patient age was 50 ± 12 years. There was no in-hospital mortality and no conversions to mid-sternotomy. Cardiopulmonary bypass and cross-clamp times were significantly shorter in group 3 compared with groups 2 and 1, respectively (108 ± 19 vs. 124 ± 22 vs. 139 ± 27, p < 0.001; and 76 ± 14 vs. 86 ± 18 vs. 97 ± 18, p < 0.001). Intraoperative echocardiography revealed higher freedom from more than mild residual mitral regurgitation after the first pump-run in group 3 compared to group 2 (97.5% vs. 90.3%, p = 0.04). Patients in the 3D group had less postoperative bleeding (p = 0.026) and a higher glomerular filtration rate before discharge (p < 0.001) compared with the 2D groups. No significant differences were observed in ventilation time (p = 0.066) and intensive care unit duration (p = 0.071). We concluded that in minimally invasive mitral valve repair, 3D video-assisted technology may provide shorter surgical times compared to 2D video-assisted technology.",2021,Patients in the 3D group had less postoperative bleeding (p = 0.026) and a higher glomerular filtration rate before discharge (p < 0.001) compared with the 2D groups.,"['Minimally Invasive Mitral Valve Surgery', '152 patients have undergone minimally invasive mitral valve repair', 'Mean patient age was 50 ± 12 years']","['Video-assisted 2D technology', '50 patients (learning curve using 2D technology); group 2 - 62 patients (past the learning curve using 2D technology); and group 3 - 40 patients (3D technology']","['hospital mortality', 'ventilation time', 'intensive care unit duration', 'Cardiopulmonary bypass and cross-clamp times', 'glomerular filtration rate before discharge', 'postoperative bleeding', 'mild residual mitral regurgitation']","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0026264', 'cui_str': 'Mitral valve structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0396849', 'cui_str': 'Mitral valvuloplasty'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2936637', 'cui_str': 'Learning Curve'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}]","[{'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0032788', 'cui_str': 'Postoperative hemorrhage'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0026266', 'cui_str': 'Mitral valve regurgitation'}]",152.0,0.0275298,Patients in the 3D group had less postoperative bleeding (p = 0.026) and a higher glomerular filtration rate before discharge (p < 0.001) compared with the 2D groups.,"[{'ForeName': 'Eilon', 'Initials': 'E', 'LastName': 'Ram', 'Affiliation': 'From the Department of Cardiac Surgery, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Yaron', 'Initials': 'Y', 'LastName': 'Moshkovitz', 'Affiliation': 'Department of Cardiothoracic Surgery, Assuta Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Ami', 'Initials': 'A', 'LastName': 'Shinfeld', 'Affiliation': 'From the Department of Cardiac Surgery, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Kogan', 'Affiliation': 'From the Department of Cardiac Surgery, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Yael', 'Initials': 'Y', 'LastName': 'Peled', 'Affiliation': 'Department of Cardiology, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Sternik', 'Affiliation': 'From the Department of Cardiac Surgery, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Ehud', 'Initials': 'E', 'LastName': 'Raanani', 'Affiliation': 'From the Department of Cardiac Surgery, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}]",ASAIO journal (American Society for Artificial Internal Organs : 1992),['10.1097/MAT.0000000000001326'] 738,33336359,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.","Fosphenytoin (FOS) and its active form, phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA) are commonly used second-line treatments of status epilepticus. However, limited information is available regarding LEV and VPA concentrations following high intravenous doses, particularly in young children. The Established Status Epilepticus Treatment Trial, a blinded, comparative effectiveness study of FOS, LEV, and VPA for benzodiazepine-refractory status epilepticus provided an opportunity to investigate early drug concentrations. Patients aged ≥2 years who continued to seizure despite receiving adequate doses of benzodiazepines were randomly assigned to FOS, LEV, or VPA infused over 10 minutes. A sparse blood-sampling approach was used, with up to 2 samples collected per patient within 2 hours following drug administration. The objective of this work was to report early drug exposure of PHT, LEV, and VPA and plasma protein binding of PHT and VPA. Twenty-seven children with median (interquartile range) age of 4 (2.5-6.5) years were enrolled. The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA. Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA. This is the first report in young children of LEV concentrations with convulsive status epilepticus as well as VPA concentrations after a 40 mg/kg dose. Several challenges limited patient enrollment and blood sampling. Additional studies with a larger sample size are required to evaluate the exposure-response relationships in this emergent condition.",2021,"The total plasma concentrations ranged from 69-151.3 μg/mL for LEV, 11.3-26.7 μg/mL for PHT and 126-223 μg/mL for VPA.","['Twenty-seven children with median (interquartile range) age of 4 (2.5, 6.5) years were enrolled', 'Patients ≥ 2 years who continued to seizure despite receiving adequate doses of', 'young children', 'Young Children with Benzodiazepine-refractory Status Epilepticus', 'young children of LEV concentrations with convulsive status epilepticus']","['benzodiazepines', 'Fosphenytoin (FOS) and its active form, phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA', 'FOS, LEV, and VPA for benzodiazepine-refractory status epilepticus', 'FOS, LEV or VPA', 'Fosphenytoin, Levetiracetam and Valproic acid']",['total plasma concentrations'],"[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0038220', 'cui_str': 'Status epilepticus'}, {'cui': 'C0377265', 'cui_str': 'Levetiracetam'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0311335', 'cui_str': 'Grand mal status'}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0244656', 'cui_str': 'fosphenytoin'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0031507', 'cui_str': 'Phenytoin'}, {'cui': 'C0377265', 'cui_str': 'Levetiracetam'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0042291', 'cui_str': 'valproic acid'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0038220', 'cui_str': 'Status epilepticus'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",27.0,0.042089,"The total plasma concentrations ranged from 69-151.3 μg/mL for LEV, 11.3-26.7 μg/mL for PHT and 126-223 μg/mL for VPA.","[{'ForeName': 'Abhishek G', 'Initials': 'AG', 'LastName': 'Sathe', 'Affiliation': 'Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Usha', 'Initials': 'U', 'LastName': 'Mishra', 'Affiliation': 'Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Ivaturi', 'Affiliation': 'Center for Translational Medicine, University of Maryland, Baltimore, Maryland, USA.'}, {'ForeName': 'Richard C', 'Initials': 'RC', 'LastName': 'Brundage', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Cloyd', 'Affiliation': 'Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Jordan J', 'Initials': 'JJ', 'LastName': 'Elm', 'Affiliation': 'Department of Public Health Science, Medical University of South Carolina, Charleston, South Carolina, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Chamberlain', 'Affiliation': ""Division of Emergency Medicine, Children's National Hospital and the Department of Pediatrics and Emergency Medicine, School of Medicine and Health Sciences, George Washington University, Washington, District of Columbia, USA.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Silbergleit', 'Affiliation': 'Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Jaideep', 'Initials': 'J', 'LastName': 'Kapur', 'Affiliation': 'Department of Neurology and Department of Neuroscience, Brain Institute, University of Virginia, Charlottesville, Virginia, USA.'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Lowenstein', 'Affiliation': 'Department of Neurology, University of California, San Francisco, California, USA.'}, {'ForeName': 'Shlomo', 'Initials': 'S', 'LastName': 'Shinnar', 'Affiliation': 'Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.'}, {'ForeName': 'Hannah R', 'Initials': 'HR', 'LastName': 'Cock', 'Affiliation': ""Clinical Neurosciences Academic Group, Institute of Molecular and Clinical Sciences, St George's University of London, London, UK.""}, {'ForeName': 'Nathan B', 'Initials': 'NB', 'LastName': 'Fountain', 'Affiliation': 'Department of Neurology, Comprehensive Epilepsy Program, Charlottesville, Virginia, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Babcock', 'Affiliation': 'Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.'}, {'ForeName': 'Lisa D', 'Initials': 'LD', 'LastName': 'Coles', 'Affiliation': 'Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1801'] 739,33340181,Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.,"BACKGROUND AND AIMS A recent study found that homeless individuals with opioid use disorder (OUD) had a lower risk of relapse on extended-release naltrexone (XR-NTX) versus buprenorphine-naloxone (BUP-NX), whereas non-homeless individuals had a lower risk of relapse on BUP-NX. This secondary study examined differences in mediation pathways to medication effect between homeless and non-homeless participants. DESIGN Secondary analysis of an open-label randomized controlled, 24-week comparative effectiveness trial, 2014-17. SETTING Eight community addiction treatment programs in the United States. PARTICIPANTS English-speaking adults with DSM-5 OUD, recruited during inpatient admission (n = 570). INTERVENTION(S) Randomization to monthly injection of XR-NTX or daily sublingual BUP-NX. MEASUREMENTS(S) Mediation analysis estimated the direct effect of XR-NTX versus BUP-NX on relapse and indirect effect through mediators of medication adherence, use of illicit opioids, depressive symptoms and pain, separately by homeless status. FINDINGS For the homeless subgroup, the protective indirect path contributed a 3.4 percentage point reduced risk of relapse [95% confidence interval (CI) = -12.0, 5.3] comparing XR-NTX to BUP-NX (explaining 21% of the total effect). For the non-homeless subgroup, the indirect path contributed a 9.4 percentage point increased risk of relapse (95% CI = 3.1, 15.7) comparing XR-NTX to BUP-NX (explaining 57% of the total effect). CONCLUSIONS A novel approach to mediation analysis shows that much of the difference in medication effectiveness (extended-release naltrexone versus buprenorphine-naloxone) on opioid relapse among non-homeless adults with opioid use disorder appears to be explained by mediators of adherence, illicit opioid use, depressive symptoms and pain.",2021,"For the non-homeless subgroup, the indirect path contributed a 9.4 percentage point increased risk of relapse (95% CI: 3.1, 15.7) comparing XR-NTX to BUP-NX (explaining 57% of the total effect). ","['Eight community addiction treatment programs in the United States', 'homeless and non-homeless participants', 'homeless subgroup', 'English-speaking adults with DSM-5 OUD, recruited during inpatient admission (N=570', 'non-homeless adults with opioid use disorder', 'homeless individuals with opioid use disorder (OUD']","['XR-NTX versus BUP-NX', 'buprenorphine-naloxone', 'buprenorphine-naloxone (BUP-NX', 'naltrexone', 'XR-NTX or daily sublingual BUPNX']","['medication effectiveness', 'risk of relapse', 'opioid relapse']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0237154', 'cui_str': 'Homeless'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0425242', 'cui_str': 'Homeless single person'}]","[{'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C1169989', 'cui_str': 'Buprenorphine- and naloxone-containing product'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}]",8.0,0.0394046,"For the non-homeless subgroup, the indirect path contributed a 9.4 percentage point increased risk of relapse (95% CI: 3.1, 15.7) comparing XR-NTX to BUP-NX (explaining 57% of the total effect). ","[{'ForeName': 'Kara E', 'Initials': 'KE', 'LastName': 'Rudolph', 'Affiliation': 'Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.'}, {'ForeName': 'Iván', 'Initials': 'I', 'LastName': 'Díaz', 'Affiliation': 'Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Nima S', 'Initials': 'NS', 'LastName': 'Hejazi', 'Affiliation': 'Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'van der Laan', 'Affiliation': 'Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Sean X', 'Initials': 'SX', 'LastName': 'Luo', 'Affiliation': 'Department of Psychiatry, School of Medicine, Columbia University and New York State Psychiatric Institute, New York, NY, USA.'}, {'ForeName': 'Matisyahu', 'Initials': 'M', 'LastName': 'Shulman', 'Affiliation': 'Department of Psychiatry, School of Medicine, Columbia University and New York State Psychiatric Institute, New York, NY, USA.'}, {'ForeName': 'Aimee', 'Initials': 'A', 'LastName': 'Campbell', 'Affiliation': 'Department of Psychiatry, School of Medicine, Columbia University and New York State Psychiatric Institute, New York, NY, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rotrosen', 'Affiliation': 'Department of Psychiatry, School of Medicine, New York University, New York, NY, USA.'}, {'ForeName': 'Edward V', 'Initials': 'EV', 'LastName': 'Nunes', 'Affiliation': 'Department of Psychiatry, School of Medicine, Columbia University and New York State Psychiatric Institute, New York, NY, USA.'}]","Addiction (Abingdon, England)",['10.1111/add.15377'] 740,33341955,Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects.,"This clinical trial was conducted to evaluate the pharmacokinetics and pharmacodynamics of tegoprazan when coadministered with amoxicillin/clarithromycin in healthy subjects. Cohort 1 was an open-label, randomized multiple-dose study to evaluate the mutual interaction of tegoprazan and amoxicillin/clarithromycin on the disposition of 3 tested drugs including tegoprazan M1 metabolite and 14-hydroxyclarithromycin (14-OH-clarithromycin). Cohort 2 was an open-label, randomized, active-controlled, parallel multiple-dose study to compare the intragastric pH profile after multiple oral doses of 50 or 100 mg tegoprazan coadministered with amoxicillin/clarithromycin 1000/500 mg for 7 days and pantoprazole-based triple therapy as the comparator arm. The coadministration of tegoprazan with amoxicillin/clarithromycin increased C ss,max (2.2-fold) and AUC τ (2.7-fold) of tegoprazan and M1 (2.1- and 2.2-fold for C ss,max and AUC τ , respectively) compared with administration of tegoprazan alone. The C ss,max and AUC τ of 14-OH-clarithromycin increased by 1.7- and 1.8-fold, respectively; the disposition of amoxicillin and clarithromycin were not significantly changed. On days 1 and 7 of treatment, tegoprazan-based therapies (both 50- and 100-mg therapies) maintained pH above 6 for more than 88% of the 24-hour period, which was significantly longer compared with pantoprazole-based therapy. Tegoprazan either alone or in combination with amoxicillin/clarithromycin was well tolerated in healthy subjects. In conclusion, the exposure of tegoprazan was increased after coadministration of amoxicillin/clarithromycin, which led to increase pharmacodynamic response measured by intragastric pH compared with tegoprazan alone. Therefore, tegoprazan-based triple therapy would be effective therapeutic regimen to manage intragastric pH in terms of gastric or duodenal ulcers healing, treatment of gastroesophageal reflux disease, and Helicobacter pylori eradication.",2021,Tegoprazan either alone or in combination with amoxicillin/clarithromycin was well tolerated in healthy subjects.,['healthy subjects'],"['tegoprazan-based triple therapy', 'tegoprazan with amoxicillin/clarithromycin', 'tegoprazan', 'tegoprazan and amoxicillin/clarithromycin', 'pantoprazole-based triple therapy', 'pantoprazole-based therapy', 'amoxicillin and clarithromycin', '14-hydroxyclarithromycin (14-OH-clarithromycin', 'Tegoprazan either alone or in combination with amoxicillin/clarithromycin', 'tegoprazan co-administered with amoxicillin/clarithromycin', 'tegoprazan co-administered with amoxicillin and clarithromycin', 'amoxicillin/clarithromycin']","['C ss,max and AUC τ of 14-OH-clarithromycin', 'exposure of tegoprazan', 'pharmacodynamic response', 'C ss,max (2.2-fold) and AUC τ (2.7-fold) of tegoprazan and M1']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4726822', 'cui_str': 'tegoprazan'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0081876', 'cui_str': 'pantoprazole'}, {'cui': 'C0090409', 'cui_str': '14-hydroxyclarithromycin'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0090409', 'cui_str': '14-hydroxyclarithromycin'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C4726822', 'cui_str': 'tegoprazan'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0185026', 'cui_str': 'Plication'}, {'cui': 'C4517635', 'cui_str': '2.7'}]",,0.018183,Tegoprazan either alone or in combination with amoxicillin/clarithromycin was well tolerated in healthy subjects.,"[{'ForeName': 'Jong-Lyul', 'Initials': 'JL', 'LastName': 'Ghim', 'Affiliation': 'Department of Pharmacology and Clinical Pharmacology, Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'May Chien', 'Initials': 'MC', 'LastName': 'Chin', 'Affiliation': 'Department of Pharmacology and Clinical Pharmacology, Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Jinah', 'Initials': 'J', 'LastName': 'Jung', 'Affiliation': 'Department of Pharmacology and Clinical Pharmacology, Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Jiwon', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Division of Clinical Development, HK inno.N Corp, Seoul, Korea.'}, {'ForeName': 'Seokuee', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Division of Clinical Development, HK inno.N Corp, Seoul, Korea.'}, {'ForeName': 'Bongtae', 'Initials': 'B', 'LastName': 'Kim', 'Affiliation': 'Division of Clinical Development, HK inno.N Corp, Seoul, Korea.'}, {'ForeName': 'Geun Seog', 'Initials': 'GS', 'LastName': 'Song', 'Affiliation': 'Division of Clinical Development, HK inno.N Corp, Seoul, Korea.'}, {'ForeName': 'Young-Kyung', 'Initials': 'YK', 'LastName': 'Choi', 'Affiliation': 'Department of Pharmacology and Clinical Pharmacology, Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Jae-Gook', 'Initials': 'JG', 'LastName': 'Shin', 'Affiliation': 'Department of Pharmacology and Clinical Pharmacology, Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea.'}]",Journal of clinical pharmacology,['10.1002/jcph.1805'] 741,33332191,Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.,"PURPOSE High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease. Treatments include intravesical maintenance Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC). We wanted to understand whether a randomized trial comparing these options was possible. MATERIALS AND METHODS We conducted a two-arm, prospective multicenter randomized study to determine the feasibility in Bacillus Calmette-Guerin -naive patients. Participants had new high-risk HRNMIBC suitable for both treatments. Random assignment was stratified by age, sex, center, stage, presence of carcinoma in situ, and prior low-risk bladder cancer. Qualitative work investigated how to maintain equipoise. The primary outcome was the number of patients screened, eligible, recruited, and randomly assigned. RESULTS We screened 407 patients, approached 185, and obtained consent from 51 (27.6%) patients. Of these, one did not proceed and therefore 50 were randomly assigned (1:1). In the mBCG arm, 23/25 (92.0%) patients received mBCG, four had nonmuscle invasive bladder cancer (NMIBC) after induction, three had NMIBC at 4 months, and four received RC. At closure, two patients had metastatic BC. In the RC arm, 20 (80.0%) participants received cystectomy, including five (25.0%) with no tumor, 13 (65.0%) with HRNMIBC, and two (10.0%) with muscle invasion in their specimen. At follow-up, all patients in the RC arm were free of disease. Adverse events were mostly mild and equally distributed (15/23 [65.2%] patients with mBCG and 13/20 [65.0%] patients with RC). The quality of life (QOL) of both arms was broadly similar at 12 months. CONCLUSION A randomized controlled trial comparing mBCG and RC will be challenging to recruit into. Around 10% of patients with high-risk HRNMIBC have a lethal disease and may be better treated by primary radical treatment. Conversely, many are suitable for bladder preservation and may maintain their prediagnosis QOL.",2021,Adverse events were mostly mild and equally distributed (15/23 [65.2%] patients with mBCG and 13/20 [65.0%] patients with RC).,"['Bacillus Calmette-Guerin -naive patients', 'High-Risk High-Grade Nonmuscle Invasive Bladder Cancer', '407 patients, approached 185, and obtained consent from 51 (27.6%) patients']","['Radical Cystectomy Against Intravesical BCG', 'intravesical maintenance Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC', 'mBCG']","['metastatic BC', 'Adverse events', 'quality of life (QOL', 'nonmuscle invasive bladder cancer (NMIBC']","[{'cui': 'C0004886', 'cui_str': 'BCG vaccine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C4517617', 'cui_str': '185'}, {'cui': 'C1532670', 'cui_str': 'Obtaining consent'}]","[{'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}, {'cui': 'C1289970', 'cui_str': 'Intravesical BCG'}, {'cui': 'C0442124', 'cui_str': 'Intravesical approach'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0004886', 'cui_str': 'BCG vaccine'}]","[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}]",407.0,0.200624,Adverse events were mostly mild and equally distributed (15/23 [65.2%] patients with mBCG and 13/20 [65.0%] patients with RC).,"[{'ForeName': 'James W F', 'Initials': 'JWF', 'LastName': 'Catto', 'Affiliation': 'Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Gordon', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Collinson', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Poad', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Twiddy', 'Affiliation': 'Institute of Clinical and Applied Health Research, University of Hull, Hull, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Johnson', 'Affiliation': 'Freeman Hospital, Newcastle, United Kingdom.'}, {'ForeName': 'Sunjay', 'Initials': 'S', 'LastName': 'Jain', 'Affiliation': ""St James's University Hospital, Leeds, United Kingdom.""}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Chahal', 'Affiliation': 'Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Simms', 'Affiliation': 'Hull and East Yorkshire NHS Trust, Hull, United Kingdom.'}, {'ForeName': 'Mohantha', 'Initials': 'M', 'LastName': 'Dooldeniya', 'Affiliation': 'Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Bell', 'Affiliation': 'Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Koenig', 'Affiliation': 'Airedale NHS Foundation Trust, Keighley, United Kingdom.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Conroy', 'Affiliation': 'Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Goodwin', 'Affiliation': 'Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom.'}, {'ForeName': 'Aidan P', 'Initials': 'AP', 'LastName': 'Noon', 'Affiliation': 'Department of Urology, Royal Hallamshire Hospital, Sheffield, United Kingdom.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Croft', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.'}, {'ForeName': 'Julia M', 'Initials': 'JM', 'LastName': 'Brown', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.01665'] 742,33338315,Change in personality traits and facets (Revised NEO Personality Inventory) following metacognitive therapy or cognitive behaviour therapy for generalized anxiety disorder: Results from a randomized controlled trial.,"OBJECTIVE We aimed to discover whether psychological treatment for generalized anxiety disorder (GAD) was associated with changes in the big five personality traits and their facets. METHOD Patients with GAD were randomized either to receive cognitive behaviour therapy (CBT, n = 28) or metacognitive therapy (MCT, n = 32). Before and after 12 sessions of treatment, 55 of the patients completed the full Revised NEO Personality Inventory (NEO-PI-R) (240 items). RESULTS Patients with GAD showed a personality profile with high Neuroticism and lower Extraversion and Openness. Treatment across conditions was associated with significant reduction in Neuroticism and increased Extraversion and Openness. There were no significant changes in Agreeableness and Conscientiousness. However, their facets of Actions and Trust increased. Post-treatment levels of neuroticism were associated with symptoms of worry before and after therapy, whereas post-treatment extraversion was related to depressive symptoms after treatment. MCT was associated with greater reduction of Neuroticism than CBT. CONCLUSIONS This is the first study to show that efficient treatment for a specific disorder resulted in changes across NEO-PI-R factors and facets and that more efficient treatment results in greater change. If this reflects a reduced trait vulnerability for mental disorder, this might provide evidence of relapse prevention.",2021,There were no significant changes in Agreeableness and Conscientiousness.,"['generalized anxiety disorder', 'Generalized Anxiety Disorder (GAD', 'Patients with GAD']","['metacognitive therapy or cognitive behavior therapy', 'cognitive behaviour therapy (CBT, n = 28) or metacognitive therapy (MCT', 'MCT']","['depressive symptoms', 'Neuroticism, and increased Extraversion and Openness', 'personality traits and facets (NEO-PI-R', 'Agreeableness and Conscientiousness']","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0026687', 'cui_str': 'Mucociliary clearance'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C1842981', 'cui_str': 'Neuroticism Traits'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0015382', 'cui_str': 'Extroversion, Psychological'}, {'cui': 'C0547049', 'cui_str': 'Openness'}, {'cui': 'C0233849', 'cui_str': 'Character trait finding'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}]",,0.0291294,There were no significant changes in Agreeableness and Conscientiousness.,"[{'ForeName': 'Leif Edward Ottesen', 'Initials': 'LEO', 'LastName': 'Kennair', 'Affiliation': 'Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Stian', 'Initials': 'S', 'LastName': 'Solem', 'Affiliation': 'Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Hagen', 'Affiliation': 'Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Audun', 'Initials': 'A', 'LastName': 'Havnen', 'Affiliation': 'Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Tor Erik', 'Initials': 'TE', 'LastName': 'Nysaeter', 'Affiliation': 'Department of Psychiatry, Sørlandet Hospital, Arendal, Norway.'}, {'ForeName': 'Odin', 'Initials': 'O', 'LastName': 'Hjemdal', 'Affiliation': 'Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.'}]",Clinical psychology & psychotherapy,['10.1002/cpp.2541'] 743,33339480,A target-oriented algorithm for maintaining serum calcium stability automatically in regional citrate anticoagulation.,"BACKGROUND Regional citrate anticoagulation (RCA) for renal replacement therapy is widely practiced in critically ill patients. However, concern exists regarding its labor-intensiveness for monitoring and the associated hypocalcemia. In this study, we provided an algorithm for prescribing RCA and evaluated its safety in patients. METHODS During 18 hemofiltration treatments with calcium-free replacement solution, participants were randomized to receive algorithm-based or trial-and-error RCA protocol. The effluent volume, post-filter and in vivo ionized calcium (iCa), and calcium in the sera and effluents were periodically measured at an interval of 1 to 2 h. RESULTS For patients received algorithm-based RCA protocol, no one had a serum iCa less than 0.9 mmol/L, and none needed calcium supplement adjustment to maintain serum calcium stability. For patients accepted trial-and-error protocol, all patients had a serum iCa below 0.9 mmol/L, their serum iCa and calcium levels fluctuated dramatically, and all patients need additional calcium supplement adjustment during RCA. None of the participants showed a post-filter iCa > 0.4 mmol/L. CONCLUSION We provided a safe algorithm for calculating calcium supplementation doses that could maintain serum calcium stability without additional adjustment during RCA.",2021,"None of the participants showed a post-filter iCa > 0.4 mmol/L. CONCLUSION We provided a safe algorithm for calculating calcium supplementation doses that could maintain serum calcium stability without additional adjustment during RCA.","['critically ill patients', 'patients']","['algorithm-based or trial-and-error RCA protocol', 'calcium-free replacement solution', 'Regional citrate anticoagulation (RCA']","['effluent volume, post-filter and in vivo ionized calcium (iCa), and calcium in the sera and effluents']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0008857', 'cui_str': 'Citrates'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0180860', 'cui_str': 'Filter'}, {'cui': 'C0373561', 'cui_str': 'Calcium electrolyte'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.051093,"None of the participants showed a post-filter iCa > 0.4 mmol/L. CONCLUSION We provided a safe algorithm for calculating calcium supplementation doses that could maintain serum calcium stability without additional adjustment during RCA.","[{'ForeName': 'Ruan-Mei', 'Initials': 'RM', 'LastName': 'Sheng', 'Affiliation': 'Department of Emergency Medicine and Intensive Care, Shanghai Songjiang Clinical Medical College of Nanjing Medical University, Shanghai, China.'}, {'ForeName': 'Wen-Biao', 'Initials': 'WB', 'LastName': 'Zhao', 'Affiliation': 'Department of Emergency Medicine and Intensive Care, Shanghai Songjiang Clinical Medical College of Nanjing Medical University, Shanghai, China.'}, {'ForeName': 'Li-Hong', 'Initials': 'LH', 'LastName': 'Huang', 'Affiliation': 'Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jian-Qin', 'Initials': 'JQ', 'LastName': 'Chen', 'Affiliation': 'Department of Emergency Medicine and Intensive Care, Shanghai Songjiang Clinical Medical College of Nanjing Medical University, Shanghai, China.'}, {'ForeName': 'Zhen-Juan', 'Initials': 'ZJ', 'LastName': 'Dai', 'Affiliation': 'Department of Emergency Medicine and Intensive Care, Shanghai Songjiang Clinical Medical College of Nanjing Medical University, Shanghai, China.'}, {'ForeName': 'Xue-Min', 'Initials': 'XM', 'LastName': 'Wang', 'Affiliation': 'Department of Emergency Medicine and Intensive Care, Shanghai Songjiang Clinical Medical College of Nanjing Medical University, Shanghai, China.'}]",The International journal of artificial organs,['10.1177/0391398820982620'] 744,33326634,Comparison of Fractional Micro-Plasma Radiofrequency and Fractional Microneedle Radiofrequency for the Treatment of Atrophic Acne Scars: A Pilot Randomized Split-Face Clinical Study in China.,"BACKGROUND AND OBJECTIVE Both fractional micro-plasma radiofrequency (RF) and fractional microneedle RF are novel devices that can be applied for the treatment of atrophic acne scars, and they have both been proved to be effective. To compare the clinical effectiveness and adverse reactions of fractional micro-plasma RF and fractional microneedle RF for the therapy of facial atrophic acne scars in a randomized split-face study. STUDY DESIGN/MATERIALS AND METHODS Sixty patients with facial atrophic acne scars received three applications at 2-month intervals in a randomized split-face study using fractional micro-plasma RF and fractional microneedle RF on different sides of the face. Three independent dermatologists evaluated the improvement in acne scars using the ECCA grading scale (Echelle d'Evaluation Clinique des Cicatrices d'Acné) by comparing the digital images and graded the improvement in the acne scars. Patients were asked to provide a self-evaluation of satisfaction for efficacy and safety. Adverse effects were also recorded after each treatment. RESULTS In total sixty patients completed the entire study. A significant improvement was observed in the appearance of acne scars, and the mean ECCA scores improved significantly after both modalities. The mean decrease in ECCA scores from the baseline was significantly more pronounced in fractional micro-plasma RF as compared with fractional microneedle RF (41.33 ± 20.19 vs 32.17 ± 17.35; P < 0.05). The degree of clinical improvement was also significantly better for fractional micro-plasma RF. Pain, erythema, and swelling were observed in all patients after both treatments. The pain was more intense during micro-plasma RF treatment (P = 0.000), and the duration of pain and erythema were longer than with fractional microneedle RF (P = 0.000). Postinflammatory hyperpigmentation (PIH) was observed in one patient on the fractional micro-plasma RF side while no PIH was observed on the fractional microneedle RF side. No infections or worsening of scarring was observed with either treatment. No subject was dissatisfied with the efficacy of either device. Rolling scars tended to respond better to fractional micro-plasma RF treatment compared with fractional microneedle RF (P = 0.000). CONCLUSIONS Both fractional micro-plasma RF and fractional microneedle RF are effective and safe methods for improving atrophic acne scars. Fractional micro-plasma RF is significantly more effective for atrophic acne scars, especially for rolling scars. However, fractional microneedle RF has fewer side effects plus shorter downtime, and patients are more comfortable after the treatment. Lasers Surg. Med. © 2020 Wiley Periodicals LLC.",2021,"Fractional micro-plasma RF is significantly more effective for atrophic acne scars, especially for rolling scars.","['facial atrophic acne scars', 'Sixty patients with facial atrophic acne scars', 'total sixty patients completed the entire study', 'Atrophic Acne Scars', 'China']","['Fractional Micro-Plasma Radiofrequency and Fractional Microneedle Radiofrequency', 'fractional micro-plasma RF and fractional microneedle RF', 'fractional micro-plasma radiofrequency (RF) and fractional microneedle']","['ECCA scores', 'Pain, erythema, and swelling', 'Adverse effects', 'mean ECCA scores', 'acne scars', 'fractional micro-plasma RF', 'No infections or worsening of scarring', 'appearance of acne scars', 'Postinflammatory hyperpigmentation (PIH', 'pain', 'duration of pain and erythema']","[{'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C1274728', 'cui_str': 'Atrophic acne scar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0423783', 'cui_str': 'Acne scar'}, {'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C2712105', 'cui_str': 'Absence of signs and symptoms of infection'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0333616', 'cui_str': 'Postinflammatory hyperpigmentation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",60.0,0.017341,"Fractional micro-plasma RF is significantly more effective for atrophic acne scars, especially for rolling scars.","[{'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Lan', 'Affiliation': 'Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, 400038, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Tang', 'Affiliation': 'Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, 400038, China.'}, {'ForeName': 'Aiai', 'Initials': 'A', 'LastName': 'Xia', 'Affiliation': 'Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, 400038, China.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Hamblin', 'Affiliation': 'Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Jian', 'Affiliation': 'Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Yin', 'Affiliation': 'Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, 400038, China.'}]",Lasers in surgery and medicine,['10.1002/lsm.23369'] 745,33340767,"Transcranial direct current stimulation for fatigue in patients with Sjogren's syndrome: A randomized, double-blind pilot study.","BACKGROUND Transcranial direct-current stimulation (tDCS) has shown promise to decrease fatigue. However, it has never been examined in primary Sjogren Syndrome (pSS). OBJECTIVE To assess the effect of a tDCS protocol on fatigue in patients with pSS. METHODS This is a parallel, double-blind pilot study (NCT04119128). Women aged 18-65 years, with pSS, on stable pharmacological therapy, with complaints of fatigue for at least three months, and with scores >5 on Fatigue Severity Scale (FSS) were included. We randomized 36 participants to receive five consecutive or sham tDCS sessions, with an intensity of 2 mA, for 20 min/day. RESULTS After five tDCS sessions, fatigue severity assessed by the FSS (primary outcome) demonstrated a mean group difference of -0.85 [95% confidence interval (CI) -1.57, -0.13; effect size 0.80] favouring the active group. The active group presented significantly greater reductions in fatigue as measured by the EULAR Sjögren's Syndrome Patient Reported Index after five tDCS sessions [mean group difference: 1.40; 95%CI -2.33, -0.48; effect size 1.04]. Although there were no between-group differences in the secondary outcomes of sleep, mood and anxiety, within-group comparisons evidenced a small but significant difference in the active group for pain and sleep. There were no significant cortisol changes. All reported adverse events were mild and transitory. CONCLUSION tDCS seems to be safe and reduce fatigue in pSS. A differential effect on pain and sleep may underlie its effects. Further studies are needed to optimise tDCS treatment strategies in pSS.",2021,"The active group presented significantly greater reductions in fatigue as measured by the EULAR Sjögren's Syndrome Patient Reported Index after five tDCS sessions [mean group difference: 1.40; 95%CI -2.33, -0.48; effect size 1.04].","['36 participants to receive five consecutive or', 'patients with pSS', 'Women aged 18-65 years, with pSS, on stable pharmacological therapy, with complaints of fatigue for at least three months, and with scores > 5 on Fatigue Severity Scale (FSS) were included', ""Patients with Sjogren's Syndrome""]","['Transcranial direct-current stimulation (tDCS', 'tDCS protocol', 'Transcranial Direct Current Stimulation', 'sham tDCS sessions']","['pain and sleep', 'fatigue', 'depression and sleep', 'sleep, mood and anxiety', 'adverse events', 'cortisol changes', 'fatigue severity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0151449', 'cui_str': ""Primary Sjögren's syndrome""}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C4082119', 'cui_str': 'Three months'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439084', 'cui_str': '>5'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1527336', 'cui_str': ""Sjögren's syndrome""}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",36.0,0.535796,"The active group presented significantly greater reductions in fatigue as measured by the EULAR Sjögren's Syndrome Patient Reported Index after five tDCS sessions [mean group difference: 1.40; 95%CI -2.33, -0.48; effect size 1.04].","[{'ForeName': 'Ana Carolina Pereira Nunes', 'Initials': 'ACPN', 'LastName': 'Pinto', 'Affiliation': 'Evidence-Based Health Program, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil; Fulbright Scholar at University of Pittsburgh, PA, USA; Biological and Health Sciences Department, Universidade Federal Do Amapa (UNIFAP), AP, Brazil.'}, {'ForeName': 'Sara Regina', 'Initials': 'SR', 'LastName': 'Piva', 'Affiliation': 'Department of Physical Therapy, School of Health and Rehabilitation Science, University of Pittsburgh. Pittsburgh, PA, USA. Electronic address: spiva@pitt.edu.'}, {'ForeName': 'Aléxia Gabriela da Silva', 'Initials': 'AGDS', 'LastName': 'Vieira', 'Affiliation': 'Evidence-Based Health Program, EPM, UNIFESP, São Paulo, SP, Brazil.'}, {'ForeName': 'Samantha Guerra Cabó Nunes', 'Initials': 'SGCN', 'LastName': 'Gomes', 'Affiliation': 'Evidence-Based Health Program, EPM, UNIFESP, São Paulo, SP, Brazil.'}, {'ForeName': 'Aline Pereira', 'Initials': 'AP', 'LastName': 'Rocha', 'Affiliation': 'Evidence-Based Health Program, EPM, UNIFESP, São Paulo, SP, Brazil.'}, {'ForeName': 'Daniela Regina Brandão', 'Initials': 'DRB', 'LastName': 'Tavares', 'Affiliation': 'Evidence-Based Health Program, EPM, UNIFESP, São Paulo, SP, Brazil.'}, {'ForeName': 'Márcia Valéria de Andrade', 'Initials': 'MVA', 'LastName': 'Santana', 'Affiliation': 'Evidence-Based Health Program, EPM, UNIFESP, São Paulo, SP, Brazil.'}, {'ForeName': 'Cristiane', 'Initials': 'C', 'LastName': 'Carlesso', 'Affiliation': 'Department of Physical Therapy, School of Health and Rehabilitation Science, University of Pittsburgh. Pittsburgh, PA, USA.'}, {'ForeName': 'Adagmar', 'Initials': 'A', 'LastName': 'Andriolo', 'Affiliation': 'Department of Medicine, EPM - UNIFESP, São Paulo, SP, Brazil.'}, {'ForeName': 'Fania Cristina', 'Initials': 'FC', 'LastName': 'Santos', 'Affiliation': 'Department of Geriatrics and Gerontology, EPM - UNIFESP, Brazil.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Fregni', 'Affiliation': 'Spaulding Neuromodulation Center, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Virgínia Fernandes Moça', 'Initials': 'VFM', 'LastName': 'Trevisani', 'Affiliation': 'Rheumatologist. Discipline of Emergency and Evidence-Based Medicine, EPM - UNIFESP, São Paulo, SP, Brazil.'}]",Brain stimulation,['10.1016/j.brs.2020.12.004'] 746,33350170,Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease.,"OBJECTIVE Response to immunosuppression is highly variable in systemic sclerosis (SSc)-related interstitial lung disease (ILD). This study was undertaken to determine whether a composite serum interferon (IFN)-inducible protein score exhibits predictive significance for the response to immunosuppression in SSc-ILD. METHODS Serum samples collected in the Scleroderma Lung Study II, a randomized controlled trial of mycophenolate mofetil (MMF) versus cyclophosphamide (CYC), were examined. Results were validated in an independent observational cohort receiving active treatment. A composite score of 6 IFN-inducible proteins IFNγ-inducible 10-kd protein, monokine induced by IFNγ, monocyte chemotactic protein 2, β 2 -microglobulin, tumor necrosis factor receptor type II, and macrophage inflammatory protein 3β) was calculated, and its predictive significance for longitudinal forced vital capacity percent predicted measurements was evaluated. RESULTS Higher baseline IFN-inducible protein score predicted better response over 3 to 12 months in the MMF arm (point estimate = 0.41, P = 0.001) and CYC arm (point estimate = 0.91, P = 0.009). In contrast, higher baseline C-reactive protein (CRP) levels were predictive of a worse ILD course in both treatment arms. The predictive significance of the IFN-inducible protein score and CRP levels remained after adjustment for baseline demographic and clinical predictors. During the second year of treatment, in which patients in the CYC arm were switched to placebo, a higher IFN-inducible protein score at 12 months showed a trend toward predicting a worse ILD course (point estimate = -0.61, P = 0.068), while it remained predictive of better response to active immunosuppression in the MMF arm (point estimate = 0.28, P = 0.029). The predictive significance of baseline IFN-inducible protein score was replicated in the independent cohort (r s = 0.43, P = 0.028). CONCLUSION A higher IFN-inducible protein score in SSc-ILD is predictive of better response to immunosuppression and could potentially be used to identify patients who may derive the most benefit from MMF or CYC.",2021,Higher Interferon Inducible Protein Score in SSc-ILD predicts better response to immunosuppression and could be potentially used for identifying patients who may derive the most benefit from these two treatments.,"['Serum samples collected in the Scleroderma Lung Study II', 'Systemic Sclerosis Related Interstitial Lung Disease']","['mycophenolate', 'mycophenolate versus cyclophosphamide', 'immunosuppression', 'cyclophosphamide', 'Serum Interferon Inducible Protein Score']","['higher baseline c-reactive protein (CRP) levels', 'higher Interferon Inducible Protein Score', 'composite score of 6 interferon inducible proteins (IP-10, MIG, MCP-2, B2M, TNFR2, and MIP-3 beta', 'Interferon Inducible Protein Score and CRP', 'baseline Interferon Inducible Protein Score']","[{'cui': 'C1550100', 'cui_str': 'Serum specimen'}, {'cui': 'C0011644', 'cui_str': 'Scleroderma'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0036421', 'cui_str': 'Systemic sclerosis'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}]","[{'cui': 'C0883242', 'cui_str': 'MYCOPHENOLATE'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C1533698', 'cui_str': 'Nitric Oxide Synthase, Type II'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C1533698', 'cui_str': 'Nitric Oxide Synthase, Type II'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1308752', 'cui_str': 'CXCL10 protein, human'}, {'cui': 'C0215469', 'cui_str': 'CXCL9 protein, human'}, {'cui': 'C0214737', 'cui_str': 'CCL8 protein, human'}, {'cui': 'C0005149', 'cui_str': 'Beta 2 microglobulin'}, {'cui': 'C0255813', 'cui_str': 'Lymphocyte antigen CD120B'}, {'cui': 'C1701118', 'cui_str': 'CCL19 protein, human'}]",,0.0811254,Higher Interferon Inducible Protein Score in SSc-ILD predicts better response to immunosuppression and could be potentially used for identifying patients who may derive the most benefit from these two treatments.,"[{'ForeName': 'Shervin', 'Initials': 'S', 'LastName': 'Assassi', 'Affiliation': 'University of Texas Health Science Center at Houston.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Volkmann', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Maureen D', 'Initials': 'MD', 'LastName': 'Mayes', 'Affiliation': 'University of Texas Health Science Center at Houston.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Rünger', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ying', 'Affiliation': 'University of Texas Health Science Center at Houston.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Roth', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Hinchcliff', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Khanna', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Frech', 'Affiliation': 'University of Utah, Salt Lake City.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Clements', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Furst', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Goldin', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Elana J', 'Initials': 'EJ', 'LastName': 'Bernstein', 'Affiliation': 'Columbia University, New York, New York.'}, {'ForeName': 'Flavia V', 'Initials': 'FV', 'LastName': 'Castelino', 'Affiliation': 'Massachusetts General Hospital and Harvard University, Boston, Massachusetts.'}, {'ForeName': 'Robyn T', 'Initials': 'RT', 'LastName': 'Domsic', 'Affiliation': 'University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Jessica K', 'Initials': 'JK', 'LastName': 'Gordon', 'Affiliation': 'Hospital for Special Surgery, New York, New York.'}, {'ForeName': 'Faye N', 'Initials': 'FN', 'LastName': 'Hant', 'Affiliation': 'Medical University of South Carolina, Charleston.'}, {'ForeName': 'Ami A', 'Initials': 'AA', 'LastName': 'Shah', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Victoria K', 'Initials': 'VK', 'LastName': 'Shanmugam', 'Affiliation': 'George Washington University, Washington, DC.'}, {'ForeName': 'Virginia D', 'Initials': 'VD', 'LastName': 'Steen', 'Affiliation': 'Georgetown University, Washington, DC.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Elashoff', 'Affiliation': ''}, {'ForeName': 'Donald P', 'Initials': 'DP', 'LastName': 'Tashkin', 'Affiliation': 'University of California, Los Angeles.'}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41627'] 747,33337731,Brief Educational Video Improves Patient Understanding of Mohs Surgery: A Randomized Controlled Trial.,"BACKGROUND Patient's retention and recall of material discussed in a medical consultation is often inadequate. OBJECTIVE To assess patient's knowledge, anxiety, and understanding of Mohs surgery after viewing a brief educational video. METHOD A prospective, investigator-blinded, randomized controlled trial of 120 consecutive patients before the first Mohs surgery procedure. Sixty subjects viewed an instructional video and 60 subjects did not. A survey was administered to both groups, measuring knowledge, anxiety, and understanding of Mohs surgery. RESULTS The video group scored higher than the control group on the knowledge portion of the survey (median score 78% vs 56%, p < .01), but there were no differences in anxiety or understanding scores between groups. The percentage of subjects who answered each knowledge question correctly was greater in the video group than in the control group. In the subgroup of patients who had not previously had a consultation with a Mohs surgeon, the video group had higher median knowledge scores (67% vs 44%, p < .01), higher median understanding scores (8 vs 6, p = .05), and lower median visual analogue anxiety scores (4 vs 6, p = .01) compared with the control group. CONCLUSION A brief educational video increases patient's knowledge of Mohs surgery. For patients who have not yet had a consultation with a Mohs surgeon, the video may also reduce anxiety.",2021,The percentage of subjects who answered each knowledge question correctly was greater in the video group than in the control group.,"['Sixty subjects viewed an instructional video and 60 subjects did not', '120 consecutive patients before the first Mohs surgery procedure', 'Mohs Surgery']","['Brief Educational Video', 'educational video']","['anxiety or understanding scores', 'median visual analogue anxiety scores', 'higher median understanding scores', 'median knowledge scores']","[{'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0079850', 'cui_str': 'Mohs surgery'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",120.0,0.0758213,The percentage of subjects who answered each knowledge question correctly was greater in the video group than in the control group.,"[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Lin', 'Affiliation': 'Division of Dermatologic Surgery, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Danielle P', 'Initials': 'DP', 'LastName': 'Dubin', 'Affiliation': 'Division of Dermatologic Surgery, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Younessi', 'Affiliation': 'Albany Medical College, Albany, New York.'}, {'ForeName': 'Hooman', 'Initials': 'H', 'LastName': 'Khorasani', 'Affiliation': 'Division of Dermatologic Surgery, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002843'] 748,33346587,Vaginal Bacteria and Risk of Incident and Persistent Infection With High-Risk Subtypes of Human Papillomavirus: A Cohort Study Among Kenyan Women.,"BACKGROUND Bacterial vaginosis (BV) is associated with an increased risk of high-risk human papillomavirus (hrHPV), whereas Lactobacillus-dominated vaginal microbiotas are associated with reduced burden of hrHPV. Few epidemiologic studies have prospectively investigated the relationships between vaginal bacteria and hrHPV, particularly among women from countries in Africa. METHODS We conducted a prospective cohort study nested within the Preventing Vaginal Infections trial to evaluate associations between vaginal bacteria and hrHPV incidence and persistence. Sexually active, HIV-seronegative women aged 18 to 45 years who had a vaginal infection at screening were eligible to enroll. Analyses were restricted to participants enrolled in Kenya and randomized to placebo. At enrollment and months 2, 4, 6, 8, 10, and 12, hrHPV testing, quantitative polymerase chain reaction (measuring taxon quantity per swab), and 16S rRNA gene amplicon sequencing of the vaginal microbiota were performed. Generalized estimating equations multinomial logistic regression models were fit to evaluate associations between vaginal bacteria and incident and persistent hrHPV. RESULTS Eighty-four participants were included in this analysis. Higher concentrations of Lactobacillus crispatus were inversely associated with persistent hrHPV detection. Specifically, 1 tertile higher L. crispatus concentration was associated with 50% reduced odds of persistent hrHPV detection (odds ratio, 0.50; 95% confidence interval, 0.29-0.85). CONCLUSIONS This study is consistent with reports that vaginal L. crispatus is associated with reduced susceptibility to hrHPV persistence. Evidence from in vitro studies provides insight into potential mechanisms by which L. crispatus may mediate hrHPV risk. Future studies should further explore in vivo mechanisms that may drive this relationship and opportunities for intervention.",2021,"Specifically, one tertile higher L. crispatus concentration was associated with 50% reduced odds of persistent hrHPV detection (OR = 0.50, 95% CI 0.29-0.85). ","['Kenyan women', 'women from countries in Africa', 'Sexually active, HIV-seronegative women age 18-45 who had a vaginal infection at screening were eligible to enroll', 'Eighty-four participants were included in this analysis']",['placebo'],"['vaginal bacteria and hrHPV incidence and persistence', 'persistent hrHPV detection', 'Vaginal bacteria and risk of incident and persistent infection', 'Higher concentrations of Lactobacillus crispatus', 'hrHPV testing, quantitative PCR (measuring taxon quantity per swab), and 16S rRNA gene amplicon sequencing of the vaginal microbiota']","[{'cui': 'C0337839', 'cui_str': 'Kenyans'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0001737', 'cui_str': 'Africa'}, {'cui': 'C0241028', 'cui_str': 'Sexually active'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0521144', 'cui_str': 'Seronegative'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0404521', 'cui_str': 'Infective vaginitis'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0546816', 'cui_str': 'Persistence'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1264606', 'cui_str': 'Persistent infection'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0317614', 'cui_str': 'Lactobacillus crispatus'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0183753', 'cui_str': 'Swab'}, {'cui': 'C0035899', 'cui_str': 'Ribosomal RNA Genes'}, {'cui': 'C0162801', 'cui_str': 'Analysis, Sequence'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}]",84.0,0.209436,"Specifically, one tertile higher L. crispatus concentration was associated with 50% reduced odds of persistent hrHPV detection (OR = 0.50, 95% CI 0.29-0.85). ","[{'ForeName': 'Kayla A', 'Initials': 'KA', 'LastName': 'Carter', 'Affiliation': 'From the Department of Epidemiology, University of Washington.'}, {'ForeName': 'Sujatha', 'Initials': 'S', 'LastName': 'Srinivasan', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Tina L', 'Initials': 'TL', 'LastName': 'Fiedler', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Omu', 'Initials': 'O', 'LastName': 'Anzala', 'Affiliation': 'Department of Medical Microbiology.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Kimani', 'Affiliation': 'University of Nairobi Institute for Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Vernon', 'Initials': 'V', 'LastName': 'Mochache', 'Affiliation': 'From the Department of Epidemiology, University of Washington.'}, {'ForeName': 'Jacqueline M', 'Initials': 'JM', 'LastName': 'Wallis', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'David N', 'Initials': 'DN', 'LastName': 'Fredricks', 'Affiliation': ''}, {'ForeName': 'R Scott', 'Initials': 'RS', 'LastName': 'McClelland', 'Affiliation': ''}, {'ForeName': 'Jennifer E', 'Initials': 'JE', 'LastName': 'Balkus', 'Affiliation': ''}]",Sexually transmitted diseases,['10.1097/OLQ.0000000000001343'] 749,32816351,Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial.,"Low-dose methotrexate (MTX) plus vinblastine (VBL) chemotherapy is an effective treatment for desmoid-type fibromatosis (DF). However, previous reports have described a weekly regimen, with no reports available on a biweekly one. The aim of this study was to determine the clinical outcomes of a biweekly regimen in a cohort prospectively treated in our single institution. Since 2010, we have prospectively treated refractory DF patients with biweekly MTX (30 mg/m 2 ) + VBL (6 mg/m 2 ). Efficacy, progression-free survival (PFS), and correlating factors were analyzed. Adverse events (AEs) were recorded. In total, 38 patients received low-dose MTX + VBL therapy, and its efficacy was assessed in 37 of them. Nineteen (51%) patients showed partial response (PR). Clinical benefit rate was 95%. PFS at 5 y was 80.8%. In PR cases, median time to response was 10 mo. Longer duration of therapy was significantly associated with the response of PR (P = .007) by univariate analysis. There was no clear association between various clinicopathological factors, including tumor size, location, catenin beta-1 (CTNNB1) mutation status with effect. Only 3 AEs of grade 3/4 were observed. Tumor regrowth after MTX + VBL discontinuation was observed in 5 (20%) of 25 patients. Biweekly administration of MTX + VBL chemotherapy was well tolerated compared with weekly administration, and its efficacy was anticipated in DF patents, although the time needed to achieve a response may be relatively long. The treatment interval should be determined taking into account both the condition of the tumor and the patient's preference.",2020,"Biweekly administration of MTX + VBL chemotherapy was well tolerated compared with weekly administration, and its efficacy was anticipated in DF patents, although the time needed to achieve a response may be relatively long.",[],"['MTX\xa0+\xa0VBL therapy', 'MTX\xa0+\xa0VBL chemotherapy', 'methotrexate (MTX) plus vinblastine (VBL) chemotherapy', 'methotrexate and vinblastine', 'MTX']","['partial response (PR', 'Clinical benefit rate', 'median time to response', 'Adverse events (AEs', 'Tumor regrowth', 'Efficacy, progression-free survival (PFS']",[],"[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0042670', 'cui_str': 'Vinblastine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.0396683,"Biweekly administration of MTX + VBL chemotherapy was well tolerated compared with weekly administration, and its efficacy was anticipated in DF patents, although the time needed to achieve a response may be relatively long.","[{'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Nishida', 'Affiliation': 'Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Shunsuke', 'Initials': 'S', 'LastName': 'Hamada', 'Affiliation': 'Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Urakawa', 'Affiliation': 'Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Kunihiro', 'Initials': 'K', 'LastName': 'Ikuta', 'Affiliation': 'Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Tomohisa', 'Initials': 'T', 'LastName': 'Sakai', 'Affiliation': 'Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Koike', 'Affiliation': 'Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Kan', 'Initials': 'K', 'LastName': 'Ito', 'Affiliation': 'Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Emoto', 'Affiliation': 'Department of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Ando', 'Affiliation': 'Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Shigeyuki', 'Initials': 'S', 'LastName': 'Matsui', 'Affiliation': 'Department of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}]",Cancer science,['10.1111/cas.14626'] 750,33347875,"Comment on ""How to improve the clinical experience for dermatology patients requiring a genital examination: A randomized trial of deodorizing wipes versus standard of care"".",,2021,,['dermatology patients requiring a genital examination'],['deodorizing wipes versus standard of care'],[],"[{'cui': 'C0011627', 'cui_str': 'Dermatology'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}]",[],,0.0256723,,"[{'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Felmingham', 'Affiliation': 'Alfred Hospital, Melbourne, Victoria, Australia. Electronic address: clairefelmingham@gmail.com.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Saunders', 'Affiliation': ""Dermatology Department, The Royal Women's Hospital, Melbourne, Victoria, Australia; Dermatology Department, St Vincent's Hospital, Melbourne, Victoria, Australia.""}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Veysey', 'Affiliation': ""Dermatology Department, The Royal Women's Hospital, Melbourne, Victoria, Australia; Dermatology Department, St Vincent's Hospital, Melbourne, Victoria, Australia.""}, {'ForeName': 'Rosemary L', 'Initials': 'RL', 'LastName': 'Nixon', 'Affiliation': 'Occupational Dermatology Research and Education Centre, Skin Health Institute, Melbourne, Victoria, Australia.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.11.069'] 751,33352601,Load-velocity Profiles Change after Training Programs with Different Set Configurations.,"This study explored the changes in load-velocity relationship of bench press and parallel squat exercises following two programs differing in the set configuration. A randomized controlled trial was carried out in a sample of 39 physically active individuals. Participants were assigned to rest redistribution set configuration, traditional set configuration, or control groups. Over 5 weeks, the experimental groups completed 10 sessions with the 10 repetitions maximum load of both exercises. Rest redistribution sets consisted in 16 sets of 2 repetitions with 60 s of rest between sets, and 5 min between exercises, whereas traditional sets entailed 4 sets of 8 repetitions with 5 min of rest between sets and exercises. The load-velocity relationships of both exercises were obtained before and after the training period. For bench press, an increase of the velocity axis intercept, and a decrease of the slope at post-test were observed in both rest redistribution (p<0.001, G=1.264; p<0.001; G=0.997) and traditional set (p=0.01, G=0.654; p=0.001; G=0.593) groups. For squat, the slope decreased (p<0.001; G=0.588) and the velocity axis intercept increased (p<0.001; G=0.727) only in the rest redistribution group. These results show that rest redistribution sets were particularly efficient for inducing changes in the load-velocity relationship.",2021,"For squat, the slope decreased (p<0.001; G=0.588) and the velocity axis intercept increased (p<0.001; G=0.727) only in the rest redistribution group.",['39 physically active individuals'],['parallel squat exercises'],['velocity axis intercept'],"[{'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}]",39.0,0.0336295,"For squat, the slope decreased (p<0.001; G=0.588) and the velocity axis intercept increased (p<0.001; G=0.727) only in the rest redistribution group.","[{'ForeName': 'Eliseo', 'Initials': 'E', 'LastName': 'Iglesias-Soler', 'Affiliation': 'Performance and Health Group, Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of A Coruna, A Coruña, Spain.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Rial-Vázquez', 'Affiliation': 'Performance and Health Group, Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of A Coruna, A Coruña, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Boullosa', 'Affiliation': 'INISA, Federal University of Mato Grosso do Sul, Campo Grande, Brazil.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Mayo', 'Affiliation': 'Observatory of Healthy and Active Living of Spain Active Foundation, Centre for Sport Studies, King Juan Carlos University, Madrid, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Fariñas', 'Affiliation': 'Performance and Health Group, Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of A Coruna, A Coruña, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Rúa-Alonso', 'Affiliation': 'Performance and Health Group, Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of A Coruna, A Coruña, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Santos', 'Affiliation': 'Department of Physical Education and Sport, University of León, León, Spain.'}]",International journal of sports medicine,['10.1055/a-1323-3456'] 752,33357531,12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation.,"OBJECTIVES This study reports the 12-month results of the RADIANCE-HTN (A Study of the ReCor Medical Paradise System in Clinical Hypertension) SOLO trial following unblinding of patients at 6 months. BACKGROUND The blood pressure (BP)-lowering efficacy and safety of endovascular ultrasound renal denervation (RDN) in the absence (2 months) and presence (6 months) of antihypertensive medications were previously reported. METHODS Patients with daytime ambulatory BP ≥135/85 mm Hg after 4 weeks off medication were randomized to RDN (n = 74) or sham (n = 72) and maintained off medication for 2 months. A standardized medication escalation protocol was instituted between 2 and 5 months (blinded phase). Between 6 and 12 months (unblinded phase), patients received antihypertensive medications at physicians' discretion. Outcomes at 12 months included medication burden, change in daytime ambulatory systolic BP (dASBP) and office or home systolic BP (SBP), visit-to-visit variability in SBP, and safety. RESULTS Sixty-five of 74 RDN patients and 67 of 72 sham patients had 12-month dASBP measurements. The proportion of patients on ≥2 medications (27.7% vs. 44.8%; p = 0.041), the number of medications (0 vs. 1.4; p = 0.015), and defined daily dose (1.4 vs. 2.2; p = 0.007) were less with RDN versus sham. The decrease in dASBP from baseline in the RDN group (-16.5 ± 12.9 mm Hg) remained stable at 12 months. The RDN versus sham adjusted difference at 12 months was -2.3 mm Hg (95% confidence interval [CI]: -5.9 to 1.3 mm Hg; p = 0.201) for dASBP, -6.3 mm Hg (95% CI: -11.1 to -1.5 mm Hg; p = 0.010) for office SBP, and -3.4 mm Hg (95% CI: -6.9 to 0.1 mm Hg; p = 0.062) for home SBP. Visit-to-visit variability in SBP was smaller in the RDN group. No renal artery injury was detected on computed tomographic or magnetic resonance angiography. CONCLUSIONS Despite unblinding, the BP-lowering effect of RDN was maintained at 12 months with fewer prescribed medications compared with sham.",2020,"The proportion of patients on ≥2 medications (27.7% vs. 44.8%; p = 0.041), the number of medications (0 vs. 1.4; p = 0.015), and defined daily dose (1.4 vs. 2.2; p = 0.007) were less with RDN versus sham.","['Sixty-five of 74 RDN patients and 67 of 72 sham patients had 12-month dASBP measurements', 'Patients with daytime ambulatory BP\xa0≥135/85\xa0mm', 'Hg', 'Clinical Hypertension']","['endovascular ultrasound renal denervation (RDN', 'HTN ', 'antihypertensive medications', 'RDN']","['BP-lowering effect of RDN', 'number of medications', 'Visit-to-visit variability in SBP', 'medication burden, change in daytime ambulatory systolic BP (dASBP) and office or home systolic BP (SBP), visit-to-visit variability in SBP, and safety', 'renal artery injury', 'dASBP']","[{'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0011307', 'cui_str': 'Denervation - action'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]","[{'cui': 'C0203408', 'cui_str': 'Echography of kidney'}, {'cui': 'C0011307', 'cui_str': 'Denervation - action'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0011307', 'cui_str': 'Denervation - action'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0160725', 'cui_str': 'Injury of renal artery'}]",,0.272457,"The proportion of patients on ≥2 medications (27.7% vs. 44.8%; p = 0.041), the number of medications (0 vs. 1.4; p = 0.015), and defined daily dose (1.4 vs. 2.2; p = 0.007) were less with RDN versus sham.","[{'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Azizi', 'Affiliation': 'Université de Paris, Paris, France; AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department and DMU CARTE, Paris, France; INSERM, CIC1418, Paris, France. Electronic address: michel.azizi@aphp.fr.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Daemen', 'Affiliation': 'Erasmus Medical Center, University Medical Center Rotterdam, Department of Cardiology, Rotterdam, the Netherlands.'}, {'ForeName': 'Melvin D', 'Initials': 'MD', 'LastName': 'Lobo', 'Affiliation': 'Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Mahfoud', 'Affiliation': 'Klinik für Innere Medizin III, Saarland University Hospital, Homburg/Saar, Germany; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Andrew S P', 'Initials': 'ASP', 'LastName': 'Sharp', 'Affiliation': 'University Hospital of Wales, Cardiff and University of Exeter, Exeter, United Kingdom.'}, {'ForeName': 'Roland E', 'Initials': 'RE', 'LastName': 'Schmieder', 'Affiliation': 'Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University, Erlangen, Germany.'}, {'ForeName': 'Yale', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Manish', 'Initials': 'M', 'LastName': 'Saxena', 'Affiliation': 'Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Lurz', 'Affiliation': 'Heart Center Leipzig, University of Leipzig, Leipzig, Germany.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Sayer', 'Affiliation': 'The Essex Cardiothoracic Centre, Essex, United Kingdom.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Bloch', 'Affiliation': 'Department of Medicine, University of Nevada School of Medicine, Vascular Care, Renown Institute of Heart and Vascular Health, Reno, Nevada, USA.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Basile', 'Affiliation': 'Seinsheimer Cardiovascular Health Program, Medical University of South Carolina, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Weber', 'Affiliation': 'Division of Cardiovascular Medicine, State University of New York, Downstate Medical Center, New York, New York, USA.'}, {'ForeName': 'Lars C', 'Initials': 'LC', 'LastName': 'Rump', 'Affiliation': 'University Clinic Dusseldorf, Dusseldorf, Germany.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Levy', 'Affiliation': 'Royal Bournemouth Hospital, Dorset, United Kingdom.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Sapoval', 'Affiliation': 'Université de Paris, Paris, France; AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department and DMU CARTE, Paris, France; INSERM, CIC1418, Paris, France.'}, {'ForeName': 'Kintur', 'Initials': 'K', 'LastName': 'Sanghvi', 'Affiliation': 'Deborah Heart & Lung Center, Brown Mills, New Jersey, USA.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Rader', 'Affiliation': 'Cedars-Sinai Heart Institute, Los Angeles, California, USA.'}, {'ForeName': 'Naomi D L', 'Initials': 'NDL', 'LastName': 'Fisher', 'Affiliation': ""Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Gosse', 'Affiliation': 'Hôpital Saint-André-CHU, Bordeaux, France.'}, {'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Abraham', 'Affiliation': 'University of Utah Medical Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Claude', 'Affiliation': 'ReCor Medical, Palo Alto, California, USA.'}, {'ForeName': 'Neil C', 'Initials': 'NC', 'LastName': 'Barman', 'Affiliation': 'ReCor Medical, Palo Alto, California, USA.'}, {'ForeName': 'Candace K', 'Initials': 'CK', 'LastName': 'McClure', 'Affiliation': 'NAMSA, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Yuyin', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'The Baim Institute for Clinical Research, Boston, Massachusetts, USA.'}, {'ForeName': 'Ajay J', 'Initials': 'AJ', 'LastName': 'Kirtane', 'Affiliation': 'Columbia University Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2020.09.054'] 753,33355924,Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis.,"The aim of this study was to assess the pharmacokinetics (PK) and safety of ELX-02 in a renally impaired population and apply these findings to the individualized dosing of patients with nephropathic cystinosis. This phase 1 renal impairment (RI; mild, moderate, or severe), single-dose, PK, and safety evaluation included 6 participants assigned to each RI group. Six healthy controls with normal renal function were matched to participants with renal impairment. All received a single subcutaneous dose of 1-mg/kg ELX-02 on day 1 and were monitored for 72 hours after dosing with serial blood and urine samples. An estimated glomerular filtration rate (eGFR)-PK model of ELX-02 was developed from the RI study data and used to implement individualized dosing in a phase 2a study in patients with nephropathic cystinosis to achieve a weekly targeted exposure (area under the plasma concentration-time curve [AUC]). In participants with RI, ELX-02 clearance decreased, and exposure increased with severity of RI. ELX-02 plasma exposure was similar to healthy controls in participants with mild RI, but increasing severity of RI resulted in significantly decreased clearance, increased maximum plasma concentration, AUC from time zero to infinity, and half-life compared to controls. ELX-02 urinary clearance showed a similar pattern. Relationships between eGFR and exposure were defined supporting individualized dose determination for prediction of dose and AUC in patients with nephropathic cystinosis, achieving overall mean 110.7% of AUC targets. ELX-02 was well tolerated by RI and nephropathic cystinosis populations. ELX-02 exhibits a consistent PK profile across increasing degrees of RI with reduced clearance, increased exposure, and prolonged renal elimination proportional to reductions in eGFR. The defined relationship between eGFR and plasma exposure enabled individualized dose adjustment in patients with nephropathic cystinosis.",2021,"plasma exposure was similar to HCs in mild RI participants, but increasing severity of RI resulted in significantly decreased clearance, increased C max , AUC inf and half-life compared to controls.","['mild RI participants', 'nephropathic cystinosis patients (NCPs', 'Six healthy controls (HC) with normal renal function were matched to participants with RI', 'Nephropathic Cystinosis Patients']",['ELX-02'],"['severity of RI', 'pharmacokinetics (PK) and safety of ELX-02', 'ELX-02 urinary clearance', 'plasma exposure', 'clearance, increased C max , AUC inf and half-life', 'ELX-02 clearance']","[{'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0015624', 'cui_str': 'Fanconi syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0232805', 'cui_str': 'Normal renal function'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]",[],"[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}]",6.0,0.046296,"plasma exposure was similar to HCs in mild RI participants, but increasing severity of RI resulted in significantly decreased clearance, increased C max , AUC inf and half-life compared to controls.","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Haverty', 'Affiliation': 'Eloxx Pharmaceuticals, Waltham, Massachusetts, USA.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Wyatt', 'Affiliation': 'Syneos Health, Miami, Florida, USA.'}, {'ForeName': 'Kaela M', 'Initials': 'KM', 'LastName': 'Porter', 'Affiliation': 'Pharmacokinetics Consultant, Eloxx Pharmaceuticals, Waltham, Massachusetts, USA.'}, {'ForeName': 'Andi', 'Initials': 'A', 'LastName': 'Leubitz', 'Affiliation': 'Eloxx Pharmaceuticals, Waltham, Massachusetts, USA.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Banks', 'Affiliation': 'Eloxx Pharmaceuticals, Waltham, Massachusetts, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Goodyer', 'Affiliation': 'McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Ming-Yi', 'Initials': 'MY', 'LastName': 'Hu', 'Affiliation': 'Eloxx Pharmaceuticals, Waltham, Massachusetts, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1807'] 754,33355918,Patient and Public Involvement Refines the Design of ProtOeus: A Proposed Phase II Trial of Proton Beam Therapy in Oesophageal Cancer.,"BACKGROUND Neoadjuvant chemoradiotherapy for oesophageal cancer significantly improves overall survival but is associated with severe post-operative complications. Proton beam therapy may reduce these toxicities by sparing normal tissues compared with standard radiotherapy. ProtOeus is a proposed randomised phase II study of neoadjuvant chemoradiotherapy in oesophageal cancer that compares proton beam therapy to standard radiotherapy techniques. As proton beam therapy services are often centralised in academic centres in major cities, proton beam therapy trials raise distinct challenges including patient acceptance of travelling for proton beam therapy, coordination of treatments with local centres and ensuring equity of access for patients. METHODS Focus groups were held early in the trial development process to establish patients' views on the trial proposal. Topics discussed include perception of proton beam therapy, patient acceptability of the trial pathway and design, patient-facing materials, and common clinical scenarios. Focus groups were led by the investigators and facilitated by patient involvement teams from the institutions who are involved in this research. Responses for each topic were analysed, and fed back to the trial's development group. RESULTS Three focus groups were held in separate locations in the UK (Manchester, Cardiff, Wigan). Proton beam therapy was perceived as superior to standard radiotherapy making the trial attractive. Patients felt strongly that travel costs should be reimbursed to ensure equity of access to proton beam therapy. They were very supportive of a shorter treatment schedule and felt that toxicity reduction was the most important endpoint. DISCUSSION AND CONCLUSIONS Incorporating patient views early in the trial development process resulted in significant trial design refinements including travel/accommodation provisions, choice of primary endpoint, randomisation ratio and fractionation schedule. Focus groups are a reproducible and efficient method of incorporating the patient and public voice into research.",2021,"BACKGROUND Neoadjuvant chemoradiotherapy for oesophageal cancer significantly improves overall survival but is associated with severe post-operative complications.","['Patient and Public Involvement Refines the Design of ProtOeus', 'Oesophageal Cancer']","['neoadjuvant chemoradiotherapy', 'Proton Beam Therapy', 'Proton beam therapy']","['toxicity reduction', 'toxicities', 'overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0546837', 'cui_str': 'Malignant tumor of esophagus'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0436226', 'cui_str': 'Proton therapy'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0498984,"BACKGROUND Neoadjuvant chemoradiotherapy for oesophageal cancer significantly improves overall survival but is associated with severe post-operative complications.","[{'ForeName': 'Owen J', 'Initials': 'OJ', 'LastName': 'Nicholas', 'Affiliation': 'South West Wales Cancer Centre, Singleton Hospital, Sketty Lane, Swansea, SA2 8QA, UK. owen.nicholas@wales.nhs.uk.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Joseph', 'Affiliation': 'Manchester University NHS Trust, Manchester, UK.'}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Keane', 'Affiliation': 'Manchester University NHS Trust, Manchester, UK.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Cleary', 'Affiliation': 'Public and Patient Involvement and Engagement, Wales Cancer Research Centre, Cardiff University, Wales, UK.'}, {'ForeName': 'Sue H', 'Initials': 'SH', 'LastName': 'Campbell', 'Affiliation': 'Patient Representative, Monmouth, UK.'}, {'ForeName': 'Sarah H', 'Initials': 'SH', 'LastName': 'Gwynne', 'Affiliation': 'South West Wales Cancer Centre, Singleton Hospital, Sketty Lane, Swansea, SA2 8QA, UK.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Crosby', 'Affiliation': 'Velindre University NHS Trust, Cardiff, UK.'}, {'ForeName': 'Ganesh', 'Initials': 'G', 'LastName': 'Radhakrishna', 'Affiliation': 'The Christie NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Hawkins', 'Affiliation': 'CRUK MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.'}]",The patient,['10.1007/s40271-020-00487-8'] 755,33351076,Focal Impulse and Rotor Modulation Ablation vs. Pulmonary Vein isolation for the treatment of paroxysmal Atrial Fibrillation: results from the FIRMAP AF study.,"AIMS Pulmonary vein isolation (PVI) is the gold standard for atrial fibrillation (AF) ablation. Recently, catheter ablation targeting rotors or focal sources has been developed for treatment of AF. This study sought to compare the safety and effectiveness of Focal Impulse and Rotor Modulation (FIRM)-guided ablation as the sole ablative strategy with PVI in patients with paroxysmal AF. METHODS AND RESULTS We conducted a multicentre, randomized trial to determine whether FIRM-guided radiofrequency ablation without PVI (FIRM group) was non-inferior to PVI (PVI group) for treatment of paroxysmal AF. The two primary efficacy end points were (i) acute success defined as elimination of AF rotors (FIRM group) or isolation of all pulmonary veins (PVI group) and (ii) long-term success defined as single-procedure freedom from AF/atrial tachycardia (AT) recurrence 12 months after ablation. The study was closed early by the sponsor. At the time of study closure, any pending follow-up visits were waived. A total of 51 patients (mean age 63 ± 10.6 years, 57% male) were enrolled. All PVs were successfully isolated in the PVI group and all rotors were successfully eliminated in the FIRM group. Single-procedure effectiveness was 31.3% (5/16) in the FIRM group and 80% (8/10) in the PVI group at 12 months. Three vascular access complications occurred in the FIRM group. CONCLUSION These partial study effectiveness results reinforce the importance of PVI in paroxysmal AF patients and indicate that FIRM-guided ablation alone (without PVI) is not an effective strategy for treatment of paroxysmal AF in most patients.",2021,Single-procedure effectiveness was 31.3% (5/16) in the FIRM group and 80% (8/10) in the PVI group at 12 months.,"['51 patients (mean age 63\u2009±\u200910.6\u2009years, 57% male) were enrolled', 'paroxysmal Atrial Fibrillation', 'paroxysmal AF patients', 'patients with paroxysmal AF']","['FIRM-guided ablation alone (without PVI', 'Pulmonary vein isolation (PVI', 'Focal Impulse and Rotor Modulation Ablation vs. Pulmonary Vein isolation', 'FIRM-guided radiofrequency ablation without PVI (FIRM group) was non-inferior to PVI (PVI group', 'Focal Impulse and Rotor Modulation (FIRM)-guided ablation']","['vascular access complications', 'acute success defined as elimination of AF rotors (FIRM group) or isolation of all pulmonary veins (PVI group) and (ii) long-term success defined as single-procedure freedom from AF/atrial tachycardia (AT) recurrence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation'}]","[{'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0443235', 'cui_str': 'Impulse'}, {'cui': 'C0220991', 'cui_str': 'Rotor syndrome'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}]","[{'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0220991', 'cui_str': 'Rotor syndrome'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0443235', 'cui_str': 'Impulse'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0034090', 'cui_str': 'Structure of vein of pulmonary circulation'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",51.0,0.0353055,Single-procedure effectiveness was 31.3% (5/16) in the FIRM group and 80% (8/10) in the PVI group at 12 months.,"[{'ForeName': 'Roland R', 'Initials': 'RR', 'LastName': 'Tilz', 'Affiliation': 'University Heart Center Lübeck, Medical Clinic II, Department of Electrophysiology, Lübeck, Germany.'}, {'ForeName': 'Corinna', 'Initials': 'C', 'LastName': 'Lenz', 'Affiliation': 'Unfallkrankenhaus Berlin, Klinik für Innere Medizin/Kardiologie, Berlin, Germany.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Sommer', 'Affiliation': 'Heart Center Leipzig, Department of Electrophysiology, Leipzig, Germany.'}, {'ForeName': 'Meyer-Saraei', 'Initials': 'MS', 'LastName': 'Roza', 'Affiliation': 'University Heart Center Lübeck, Medical Clinic II, Department of Electrophysiology, Lübeck, Germany.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Sarver', 'Affiliation': 'Abbott, Plymouth, MN, USA.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Williams', 'Affiliation': 'Abbott, Plymouth, MN, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Heeger', 'Affiliation': 'University Heart Center Lübeck, Medical Clinic II, Department of Electrophysiology, Lübeck, Germany.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Hindricks', 'Affiliation': 'Heart Center Leipzig, Department of Electrophysiology, Leipzig, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Vogler', 'Affiliation': 'University Heart Center Lübeck, Medical Clinic II, Department of Electrophysiology, Lübeck, Germany.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Eitel', 'Affiliation': 'University Heart Center Lübeck, Medical Clinic II, Department of Electrophysiology, Lübeck, Germany.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa378'] 756,33368190,"Piloting 'Clever Kids': A randomized-controlled trial assessing feasibility, efficacy, and acceptability of a socioemotional well-being programme for children with dyslexia.","Children with dyslexia are at elevated risk of internalizing (emotional) and externalizing (behavioural) problems. Clever Kids is a nine-week socioemotional well-being programme developed specifically for upper primary school children with dyslexia. In a small randomized-controlled trial, we tested the feasibility, efficacy, and acceptability of the Clever Kids programme. 'Forty children (M age  = 10.45 years, 65% male) with clinically diagnosed dyslexia too part in the study. Children were randomized to either attend Clever Kids (n = 20) or to a wait-list control condition (n = 20). Coping skills, self-esteem, resilience, emotion regulation, and internalizing and externalizing symptoms were measured at pre-programme, post-programme, and at three-month follow-up. Recruitment and retention rates indicate high feasibility for further evaluation of the programme. There was a significant interaction between intervention condition and time for non-productive coping [F(2, 76) = 4.29, p = 0.017, f 2  = 0.11]. Children who attended Clever Kids significantly reduced their use of non-productive coping strategies, and this was maintained at three-month follow-up assessment. For all other outcomes, the interactions between intervention condition and time were non-significant. The programme appears acceptable to children with dyslexia and their families, but may be improved by further reducing the number of activities involving reading and writing. Clever Kids improved the coping skills of children with dyslexia; however, a larger trial is needed to replicate this finding and investigate whether programme attendance is associated with additional improvements in children's socioemotional well-being.",2021,Clever Kids is a nine-week socioemotional well-being programme developed specifically for upper primary school children with dyslexia.,"['children with dyslexia', '10.45\xa0years, 65% male) with clinically diagnosed dyslexia too part in the study', 'Children with dyslexia are at elevated risk of internalizing (emotional) and externalizing (behavioural) problems', 'upper primary school children with dyslexia', 'Forty children (M age \xa0', 'children with dyslexia and their families', ""Piloting 'Clever Kids""]","['attend Clever Kids (n\xa0=\xa020) or to a wait-list control condition', 'socioemotional well-being programme']","['feasibility, efficacy, and acceptability', 'Coping skills, self-esteem, resilience, emotion regulation, and internalizing and externalizing symptoms']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0476254', 'cui_str': 'Dyslexia'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C1279682', 'cui_str': 'Clever'}, {'cui': 'C0680063', 'cui_str': 'Child of'}]","[{'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C1279682', 'cui_str': 'Clever'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0086059', 'cui_str': 'Coping Skills'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",40.0,0.0707472,Clever Kids is a nine-week socioemotional well-being programme developed specifically for upper primary school children with dyslexia.,"[{'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Boyes', 'Affiliation': 'School of Psychology, Curtin University, Perth, Western Australia, Australia.'}, {'ForeName': 'Suze', 'Initials': 'S', 'LastName': 'Leitão', 'Affiliation': 'School of Occupational Therapy, Social Work and Speech Pathology, Curtin University, Perth, Western Australia, Australia.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Claessen', 'Affiliation': 'School of Occupational Therapy, Social Work and Speech Pathology, Curtin University, Perth, Western Australia, Australia.'}, {'ForeName': 'Peta', 'Initials': 'P', 'LastName': 'Dzidic', 'Affiliation': 'School of Psychology, Curtin University, Perth, Western Australia, Australia.'}, {'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Badcock', 'Affiliation': 'School of Psychological Science, University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Mandy', 'Initials': 'M', 'LastName': 'Nayton', 'Affiliation': 'School of Occupational Therapy, Social Work and Speech Pathology, Curtin University, Perth, Western Australia, Australia.'}]",The British journal of educational psychology,['10.1111/bjep.12401'] 757,33368114,Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial.,"The role of rivaroxaban in the treatment of leg superficial venous thrombosis (SVT) is uncertain. This article aims to determine if rivaroxaban is an effective and safe treatment for leg SVT. Patients with symptomatic leg SVT of at least 5 cm length were randomized to 45 days of rivaroxaban 10 mg daily or to placebo, and followed for a total of 90 days. Treatment failure (required a nonstudy anticoagulant; had proximal deep vein thrombosis or pulmonary embolism; or had surgery for SVT) at 90 days was the primary efficacy outcome. Secondary efficacy outcomes included leg pain severity, and venous disease-specific and general health-related quality of life over 90 days. Major bleeding at 90 days was the primary safety outcome. Poor enrollment led to the trial being stopped after 85 of the planned 600 patients were randomized to rivaroxaban ( n  = 43) or placebo ( n  = 42). One rivaroxaban and five placebo patients had a treatment failure by 90 days (absolute risk reduction = 9.0%, 95% confidence interval: -22 to 5.9%). Leg pain improvement did not differ at 7 ( p  = 0.16) or 45 days ( p  = 0.89), but was greater with rivaroxaban at 90 days ( p  = 0.011). There was no difference in venous disease-specific ( p  = 0.99) or general health-related ( p  = 0.37) quality of life over 45 days. There were no major bleeds or deaths in either group. There were no identifiable differences in efficacy or safety between rivaroxaban and placebo in patients with symptomatic SVT but comparisons were undermined by a much smaller than planned sample size (NCT1499953).",2020,There were no identifiable differences in efficacy or safety between rivaroxaban and placebo in patients with symptomatic SVT but comparisons were undermined by a much smaller than planned sample size (NCT1499953).,"['Patients with symptomatic leg SVT of at least 5\u2009cm length', 'Leg Superficial Vein Thrombosis', 'leg superficial venous thrombosis (SVT']","['placebo', 'rivaroxaban', 'Rivaroxaban', 'Placebo', 'rivaroxaban 10\u2009mg daily or to placebo']","['efficacy or safety', 'Major bleeding', 'venous disease-specific', 'major bleeds or deaths', 'Leg pain improvement', 'leg pain severity, and venous disease-specific and general health-related quality of life over 90 days', 'quality of life', 'proximal deep vein thrombosis or pulmonary embolism']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0235511', 'cui_str': 'Superficial vein thrombosis'}, {'cui': 'C1444754', 'cui_str': 'Length'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C3162455', 'cui_str': 'rivaroxaban 10 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0235522', 'cui_str': 'Disorder of vein'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C3160769', 'cui_str': 'Major bleed'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0023222', 'cui_str': 'Pain in lower limb'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}]",600.0,0.448385,There were no identifiable differences in efficacy or safety between rivaroxaban and placebo in patients with symptomatic SVT but comparisons were undermined by a much smaller than planned sample size (NCT1499953).,"[{'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Kearon', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Carrier', 'Affiliation': 'Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Chu-Shu', 'Initials': 'CS', 'LastName': 'Gu', 'Affiliation': 'Department of Oncology, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Schulman', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Bates', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Kahn', 'Affiliation': 'Department of Medicine, McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Chagnon', 'Affiliation': 'Department of Medicine, University of Montreal, Montreal, Quebec, Canada.'}, {'ForeName': 'Doan Trang', 'Initials': 'DT', 'LastName': 'Nguyen', 'Affiliation': 'Department of Medicine, University of Montreal, Montreal, Quebec, Canada.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': 'Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Rudd-Scott', 'Affiliation': 'Department of Oncology, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Jim A', 'Initials': 'JA', 'LastName': 'Julian', 'Affiliation': 'Department of Oncology, McMaster University, Hamilton, Ontario, Canada.'}]",Seminars in thrombosis and hemostasis,['10.1055/s-0040-1718891'] 758,33358380,Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months.,,2021,,['histologic subtypes of advanced basal cell carcinoma'],['sonidegib'],[],"[{'cui': 'C1301142', 'cui_str': 'WHO tumor classification'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007117', 'cui_str': 'Basal cell carcinoma'}]","[{'cui': 'C3886731', 'cui_str': 'sonidegib'}]",[],,0.0399987,,"[{'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Dummer', 'Affiliation': 'Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch.'}, {'ForeName': 'John T', 'Initials': 'JT', 'LastName': 'Lear', 'Affiliation': 'Department of Dermatology, Salford Royal National Health Service Foundation Trust, Salford, United Kingdom.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Guminski', 'Affiliation': 'Department of Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.'}, {'ForeName': 'Liang Joo', 'Initials': 'LJ', 'LastName': 'Leow', 'Affiliation': ""Department of Dermatology, St. Vincent's Private Hospital, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia; St Vincent's & Mater Clinical School, University of Notre Dame Australia, Sydney, New South Wales, Australia.""}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Squittieri', 'Affiliation': 'Medical Affairs Oncology, Sun Pharmaceutical Industries, Inc, Princeton, New Jersey, United States.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Migden', 'Affiliation': 'Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.08.042'] 759,33356403,Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study.,"Renal denervation (RDN) is effective in lowering blood pressure (BP) in patients with hypertension. The issue remains how to best identify potential responders. Ambulatory BP monitoring may be useful. Baseline nighttime systolic BP (SBP) ≥136 mm Hg and its variability (SD) ≥12 mm Hg in DENER-HTN trial or 24-hour heart rate ≥73.5 bpm in SPYRAL HTN-OFF MED Trial were shown to predict the BP response to RDN. We applied these criteria to the patients with hypertension in the sham-controlled RADIANCE-HTN SOLO trial to predict the BP response to ultrasound RDN at 2 months while patients were maintained off medications. BP responders were defined as: clinical with 24-hour SBP <130 mm Hg (RDN: 22/64 versus sham: 7/58); meaningful with 24-hour SBP reduction ≥10 mm Hg (RDN: 24/64, sham: 7/58); and extreme with 24-hour SBP reduction above mean+2 SD of the SBP decrease in the sham group, that is, ≥16.5 mm Hg (RDN: 10/64 versus sham: 2/58). The predictive criteria reported above were tested for sensitivity, specificity, and positive and negative predictive values. The predictive value varied according to the definition of response, with the clinical definition being strongly influenced by regression to the mean. Baseline nighttime SBP and its variability, especially when combined, offered good specificity (>90% irrespective of definition) but low sensitivity (from 9.1% to 30% depending on the definition) to predict responders; the heart rate criterion had insufficient predictive value. This analysis suggests the potential role of nighttime SBP and its variability to predict BP response to RDN in patients with hypertension. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02649426.",2021,"Baseline nighttime SBP and its variability, especially when combined, offered good specificity (>90% irrespective of definition) but low sensitivity (from 9.1% to 30% depending on the definition) to predict responders; the heart rate criterion had insufficient predictive value.","['patients with hypertension', 'Renal Denervation']","['Ambulatory Blood Pressure Monitoring', 'Renal denervation (RDN']","['24-hour SBP reduction above mean+2', 'Baseline nighttime SBP', 'BP response to ultrasound RDN', 'blood pressure (BP', 'Baseline nighttime systolic BP (SBP) ≥136 mm Hg and its variability', 'low sensitivity', 'BP response to RDN', 'BP responders']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0011307', 'cui_str': 'Denervation - action'}]","[{'cui': 'C0242876', 'cui_str': 'Ambulatory Blood Pressure Monitoring'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0011307', 'cui_str': 'Denervation - action'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]","[{'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1997183', 'cui_str': 'Speed of blood pressure response'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",,0.0402917,"Baseline nighttime SBP and its variability, especially when combined, offered good specificity (>90% irrespective of definition) but low sensitivity (from 9.1% to 30% depending on the definition) to predict responders; the heart rate criterion had insufficient predictive value.","[{'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Gosse', 'Affiliation': 'From the Hôpital Saint-André-CHU, Bordeaux, France (P.G., A.C.).'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Cremer', 'Affiliation': 'From the Hôpital Saint-André-CHU, Bordeaux, France (P.G., A.C.).'}, {'ForeName': 'Ajay J', 'Initials': 'AJ', 'LastName': 'Kirtane', 'Affiliation': 'Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation (A.J.K.).'}, {'ForeName': 'Melvin D', 'Initials': 'MD', 'LastName': 'Lobo', 'Affiliation': 'Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.D.L., M.S.).'}, {'ForeName': 'Manish', 'Initials': 'M', 'LastName': 'Saxena', 'Affiliation': 'Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.D.L., M.S.).'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Daemen', 'Affiliation': 'Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, NL, the Netherlands (J.D.).'}, {'ForeName': 'Yale', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Minneapolis Heart Institute, Abbott Northwestern Hospital, MN (Y.W.).'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Stegbauer', 'Affiliation': 'Department of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany (J.S.).'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Weber', 'Affiliation': 'Division of Cardiovascular Medicine, State University of New York, Downstate Medical Center (M.A.W.).'}, {'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Abraham', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah, Salt lake city (J.A.).'}, {'ForeName': 'Kazuomi', 'Initials': 'K', 'LastName': 'Kario', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan (K.K.).'}, {'ForeName': 'Sripal', 'Initials': 'S', 'LastName': 'Bangalore', 'Affiliation': 'NYU School of Medicine, New York (S.B.).'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Claude', 'Affiliation': 'ReCor Medical, Inc, Palo Alto, CA (L.C.).'}, {'ForeName': 'Yuyin', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Baim Institute for Clinical Research, Boston, MA (Y.L.).'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Azizi', 'Affiliation': 'Université de Paris, F-75006 Paris, France (M.A.).'}]","Hypertension (Dallas, Tex. : 1979)",['10.1161/HYPERTENSIONAHA.120.16292'] 760,33356401,"Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.","Arterial stiffness is increased with increasing age, and pulse pressure (PP), a marker of arterial stiffness, is a predictor of incident cardiovascular disease and mortality. However, the prognostic relevance of PP in heart failure (HF) with preserved ejection fraction has not been fully understood. We studied 4796 patients with HF with preserved ejection fraction from the PARAGON-HF trial. All patients underwent sequential run-in phases of valsartan and sacubitril/valsartan before randomization. We categorized patients by PP quartile and evaluated the influence of baseline PP on the PARAGON-HF primary end point (total HF hospitalizations and cardiovascular death). At screening, the median PP was 58 mm Hg (interquartile range, 50-69 mm Hg). There was a nonlinear, J-shaped association between PP and outcomes. Multivariable Cox proportional hazards models showed that patients in the highest PP quartile had a higher risk of the primary end point (adjusted hazard ratio, 1.39 [95% CI, 1.14-1.69]; P =0.001), total HF hospitalizations (adjusted hazard ratio, 1.43 [95% CI, 1.15-1.79]; P =0.001), and myocardial infarction (adjusted hazard ratio, 1.54 [95% CI, 1.06-2.23]; P =0.022) compared with those in the second (lowest risk) PP quartile. Reductions in PP during sacubitril/valsartan run-in were associated with a decreased risk of the primary end point and total HF hospitalizations. One year after randomization, PP was significantly lower in the sacubitril/valsartan group compared with the valsartan group (3.0 mm Hg decrease [95% CI, 2.4-3.5]; P <0.001). In conclusion, PP was an independent predictor of cardiovascular events in patients with HF with preserved ejection fraction enrolled in PARAGON-HF. Sacubitril/valsartan lowered PP compared with valsartan.",2021,"One year after randomization, PP was significantly lower in the sacubitril/valsartan group compared with the valsartan group (3.0 mm Hg decrease [95% CI, 2.4-3.5]; P <0.001).","['4796 patients with HF with preserved ejection fraction from the PARAGON-HF trial', 'Heart Failure With Preserved Ejection Fraction', 'patients with HF with preserved ejection fraction enrolled in PARAGON-HF']","['Sacubitril/valsartan', 'valsartan and sacubitril/valsartan', 'valsartan', 'Sacubitril/Valsartan']","['median PP', 'pulse pressure (PP', 'total HF hospitalizations', 'myocardial infarction', 'Arterial stiffness', 'cardiovascular events', 'PP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2960127', 'cui_str': 'Heart failure with normal ejection fraction'}, {'cui': 'C0616412', 'cui_str': 'paragon'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C4033631', 'cui_str': 'valsartan and sacubitril'}, {'cui': 'C0216784', 'cui_str': 'valsartan'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0949236', 'cui_str': 'Pulse Pressure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",4796.0,0.130656,"One year after randomization, PP was significantly lower in the sacubitril/valsartan group compared with the valsartan group (3.0 mm Hg decrease [95% CI, 2.4-3.5]; P <0.001).","[{'ForeName': 'Kota', 'Initials': 'K', 'LastName': 'Suzuki', 'Affiliation': ""Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (K.S., B.C., M.M., M.A.P., S.D.S.).""}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Claggett', 'Affiliation': ""Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (K.S., B.C., M.M., M.A.P., S.D.S.).""}, {'ForeName': 'Masatoshi', 'Initials': 'M', 'LastName': 'Minamisawa', 'Affiliation': ""Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (K.S., B.C., M.M., M.A.P., S.D.S.).""}, {'ForeName': 'Kotaro', 'Initials': 'K', 'LastName': 'Nochioka', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Miyagi, Japan (K.N.).'}, {'ForeName': 'Gary F', 'Initials': 'GF', 'LastName': 'Mitchell', 'Affiliation': 'Cardiovascular Engineering, Inc., Norwood, MA (G.F.M.).'}, {'ForeName': 'Inder S', 'Initials': 'IS', 'LastName': 'Anand', 'Affiliation': 'Department of Cardiovascular Medicine, University of Minnesota, Minneapolis, MN (I.S.A.).'}, {'ForeName': 'Faiez', 'Initials': 'F', 'LastName': 'Zannad', 'Affiliation': ""INSERM Centre d'Investigation Clinic 1433 and Universite de Lorraine, Centre Hospitalier Regional et Universitaire, Nancy, France (F.Z.).""}, {'ForeName': 'Sanjiv J', 'Initials': 'SJ', 'LastName': 'Shah', 'Affiliation': 'Northwestern University, Chicago, IL (S.J.S.).'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Lefkowitz', 'Affiliation': 'Novartis, East Hanover, NJ (M.L., V.S.).'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Shi', 'Affiliation': 'Novartis, East Hanover, NJ (M.L., V.S.).'}, {'ForeName': 'Marc A', 'Initials': 'MA', 'LastName': 'Pfeffer', 'Affiliation': ""Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (K.S., B.C., M.M., M.A.P., S.D.S.).""}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'University of Glasgow, United Kingdom (J.J.V.M.).'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Solomon', 'Affiliation': ""Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (K.S., B.C., M.M., M.A.P., S.D.S.).""}]","Hypertension (Dallas, Tex. : 1979)",['10.1161/HYPERTENSIONAHA.120.16277'] 761,33353864,"Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial.","INTRODUCTION Men diagnosed with localized prostate cancer must navigate a highly preference-sensitive decision between treatment options with varying adverse outcome profiles. We evaluated whether use of a decision support tool previously shown to decrease decisional conflict also impacted the secondary outcome of post-treatment decision regret. METHODS Participants were randomized to receive personalized decision support via the Personal Patient Profile-Prostate or usual care prior to a final treatment decision. Symptoms were measured just before randomization and 6 months later; decision regret was measured at 6 months along with records review to ascertain treatment choices. Regression modeling explored associations between baseline variables including race and D`Amico risk, study group, and 6-month variables regret, choice, and symptoms. RESULTS At 6 months, 287 of 392 (73%) men returned questionnaires of which 257 (89%) had made a treatment choice. Of that group, 201 of 257 (78%) completely answered the regret scale. Regret was not significantly different between participants randomized to the P3P intervention compared to the control group (P = 0.360). In univariate analyses, we found that Black men, men with hormonal symptoms, and men with bowel symptoms reported significantly higher decision regret (all P < 0.01). Significant interactions were detected between race and study group (intervention vs. usual care) in the multivariable model; use of the Personal Patient Profile-Prostate was associated with significantly decreased decisional regret among Black men (P = 0.037). Interactions between regret, symptoms and treatment revealed that (1) men choosing definitive treatment and reporting no hormonal symptoms reported lower regret compared to all others; and (2) men choosing active surveillance and reporting bowel symptoms had higher regret compared to all others. CONCLUSION The Personal Patient Profile-Prostate decision support tool may be most beneficial in minimizing decisional regret for Black men considering treatment options for newly-diagnosed prostate cancer. TRIAL REGISTRATION NCT01844999.",2021,Regret was not significantly different between participants randomized to the P3P intervention compared to the control group (P = 0.360).,"['men with localized prostate cancer', 'Men diagnosed with localized prostate cancer', 'Participants']","['P3P intervention', 'personalized decision support via the Personal Patient Profile-Prostate or usual care prior to a final treatment decision']","['regret scale', 'Regret', 'decision regret', 'decisional regret', 'decisional conflict']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0080101', 'cui_str': 'Regret'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict'}]",,0.060924,Regret was not significantly different between participants randomized to the P3P intervention compared to the control group (P = 0.360).,"[{'ForeName': 'Donna L', 'Initials': 'DL', 'LastName': 'Berry', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA; University of Washington School of Nursing, Seattle, WA. Electronic address: donnalb@uw.edu.'}, {'ForeName': 'Fangxin', 'Initials': 'F', 'LastName': 'Hong', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Traci M', 'Initials': 'TM', 'LastName': 'Blonquist', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Halpenny', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Niya', 'Initials': 'N', 'LastName': 'Xiong', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Filson', 'Affiliation': 'Department of Urology, Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute, Emory Healthcare, Atlanta, GA; Atlanta VA Medical Center, Decatur, GA.'}, {'ForeName': 'Viraj A', 'Initials': 'VA', 'LastName': 'Master', 'Affiliation': 'Department of Urology, Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute, Emory Healthcare, Atlanta, GA.'}, {'ForeName': 'Martin G', 'Initials': 'MG', 'LastName': 'Sanda', 'Affiliation': 'Department of Urology, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Chang', 'Affiliation': 'Beth Israel Deaconess Medical Center, Boston, MA.'}, {'ForeName': 'Gary W', 'Initials': 'GW', 'LastName': 'Chien', 'Affiliation': 'Department of Urology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA.'}, {'ForeName': 'Randy A', 'Initials': 'RA', 'LastName': 'Jones', 'Affiliation': 'University of Virginia School of Nursing, Charlottesville, VA.'}, {'ForeName': 'Tracey L', 'Initials': 'TL', 'LastName': 'Krupski', 'Affiliation': 'University of Virginia School of Medicine, Charlottesville, VA.'}, {'ForeName': 'Seth', 'Initials': 'S', 'LastName': 'Wolpin', 'Affiliation': 'University of Washington School of Nursing, Seattle, WA.'}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Wilson', 'Affiliation': 'Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Julia H', 'Initials': 'JH', 'LastName': 'Hayes', 'Affiliation': ""Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Boston, MA.""}, {'ForeName': 'Quoc-Dien', 'Initials': 'QD', 'LastName': 'Trinh', 'Affiliation': ""Department of Urology, Brigham and Women's Hospital, Boston, MA.""}, {'ForeName': 'Mitchell', 'Initials': 'M', 'LastName': 'Sokoloff', 'Affiliation': 'Department of Urology, University of Massachusetts Medical Center, Worchester, MA.'}]",Urologic oncology,['10.1016/j.urolonc.2020.11.038'] 762,33358891,Improving the Stratification of Patients With Intermediate-risk Prostate Cancer.,"BACKGROUND Intermediate-risk prostate cancer (IR PCa) phenotypes may vary from favorable to unfavorable. National Comprehensive Cancer Network (NCCN) criteria help distinguish between those groups. We studied and attempted to improve this stratification. PATIENTS AND METHODS A total of 4048 (NCCN favorable: 2015 [49.8%] vs. unfavorable 2033 [50.2%]) patients with IR PCa treated with radical prostatectomy were abstracted from an institutional database (2000-2018). Multivariable logistic regression models predicting upstaging and/or upgrading (Gleason Grade Group [GGG] IV-V and/or ≥ pT3 or pN1) in IR PCa were developed, validated, and directly compared with the NCCN IR PCa stratification. RESULTS All 4048 patients were randomly divided between development (n = 2024; 50.0%) and validation cohorts (n = 2024; 50.0%). The development cohort was used to fit basic (age, prostate-specific antigen, clinical T stage, biopsy GGG, and percentage of positive cores [all P < .001]) and extended models (age, prostate-specific antigen, clinical T stage, biopsy GGG, prostate volume, and percentage of tumor within all biopsy cores [all P < .001]). In the validation cohort, the basic and the extended models were, respectively, 71.4% and 74.7% accurate in predicting upstaging and/or upgrading versus 66.8% for the NCCN IR PCa stratification. Both models outperformed NCCN IR PCa stratification in calibration and decision curve analyses (DCA). Use of NCCN IR PCa stratification would have misclassified 20.1% of patients with ≥ pT3 or pN1 and/or GGG IV to V versus 18.3% and 16.4% who were misclassified using the basic or the extended model, respectively. CONCLUSION Both newly developed and validated models better discriminate upstaging and/or upgrading risk than the NCCN IR PCa stratification.",2021,Both newly developed and validated models better discriminate upstaging and/or upgrading risk than the NCCN IR PCa stratification.,"['Intermediate-risk prostate cancer ', 'Patients With Intermediate-risk Prostate Cancer', 'A total of 4048 (NCCN favorable: 2015 [49.8%] vs. unfavorable 2033 [50.2%]) patients with IR PCa treated with radical prostatectomy were abstracted from an institutional database (2000-2018', 'All 4048 patients']",['NCCN IR PCa'],[],"[{'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0000857', 'cui_str': 'Abstracting as Topic'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0470277', 'cui_str': '2000'}]","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]",[],4048.0,0.019689,Both newly developed and validated models better discriminate upstaging and/or upgrading risk than the NCCN IR PCa stratification.,"[{'ForeName': 'Lara Franziska', 'Initials': 'LF', 'LastName': 'Stolzenbach', 'Affiliation': 'Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. Electronic address: fstolzenbach@icloud.com.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Nocera', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Collà-Ruvolo', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, Federico II University of Naples, Naples, Italy.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Tian', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Knipper', 'Affiliation': 'Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Maurer', 'Affiliation': 'Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Derya', 'Initials': 'D', 'LastName': 'Tilki', 'Affiliation': 'Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Graefen', 'Affiliation': 'Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Pierre I', 'Initials': 'PI', 'LastName': 'Karakiewicz', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.'}]",Clinical genitourinary cancer,['10.1016/j.clgc.2020.11.003'] 763,33367791,Daily Social Interactions and HPA Axis Activity Among Midlife and Older Adults.,"BACKGROUND AND OBJECTIVES Older people experience fewer negative interactions and report less stress in response to interpersonal tensions. Less is known, however, about the implications of daily social interactions for biological stress responses. We evaluated links between daily positive and negative interactions and two key biomeasures of the Hypothalamic Pituitary Adrenal (HPA) axis: salivary cortisol and dehydroepiandrosterone sulfate (DHEA-S). We also considered the moderating effects of age. RESEARCH DESIGN AND METHODS Participants included a random sample of 93 individuals aged 40-95 who completed 14 days of daily diary interviews and provided saliva samples during four of those days. RESULTS Three-level piecewise models showed that individuals had higher sustained DHEA-S levels on days after reporting more positive interactions. Young-old adults (60-79) had lower overall DHEA-S on days when they had more negative interactions than oldest-old adults (80 and older). Oldest-old adults showed a flatter decline in DHEA-S on days after they reported more negative interactions compared to midlife adults (40-59). Daily social interactions were not significantly associated with cortisol. DISCUSSION AND IMPLICATIONS Strategies to increase positive interactions may help to build physiological resilience to stress, particularly among midlife and young-old adults.",2020,Oldest-old adults showed a flatter decline in DHEA-S on days after they reported more negative interactions compared to midlife adults (40-59).,"['Participants included a random sample of 93 individuals aged 40-95 who completed 14 days of daily diary interviews and provided saliva samples during four of those days', 'midlife and young-old adults', 'Oldest-old adults', 'Midlife and Older Adults', 'Young-old adults (60-79) had lower overall DHEA-S on days when they had more negative interactions than oldest-old adults (80 and older']",['dehydroepiandrosterone sulfate (DHEA-S'],"['Daily Social Interactions and HPA Axis Activity', 'Daily social interactions', 'sustained DHEA-S levels']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0026062', 'cui_str': 'Middle-age'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001795', 'cui_str': 'Oldest Old'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0057277', 'cui_str': 'Dehydroepiandrosterone sulfate'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0057277', 'cui_str': 'Dehydroepiandrosterone sulfate'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0037420', 'cui_str': 'Interaction with others'}, {'cui': 'C0020663', 'cui_str': 'Hypothalamic structure'}, {'cui': 'C0032022', 'cui_str': 'Pituitary-Adrenal System'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0201983', 'cui_str': 'Dehydroepiandrosterone sulfate level'}]",93.0,0.0477411,Oldest-old adults showed a flatter decline in DHEA-S on days after they reported more negative interactions compared to midlife adults (40-59).,"[{'ForeName': 'Courtney A', 'Initials': 'CA', 'LastName': 'Polenick', 'Affiliation': 'Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Kira S', 'Initials': 'KS', 'LastName': 'Birditt', 'Affiliation': 'Aging and Biopsychosocial Innovations Program, Institute for Social Research, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Turkelson', 'Affiliation': 'Aging and Biopsychosocial Innovations Program, Institute for Social Research, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Emily A', 'Initials': 'EA', 'LastName': 'Perbix', 'Affiliation': 'Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Shreya M', 'Initials': 'SM', 'LastName': 'Salwi', 'Affiliation': 'Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Steven H', 'Initials': 'SH', 'LastName': 'Zarit', 'Affiliation': 'Department of Human Development and Family Studies, Pennsylvania State University, University Park, Pennsylvania, USA.'}]",The Gerontologist,['10.1093/geront/gnaa215'] 764,33372072,Protocol to assess the efficacy of carnosine supplementation in mitigating the adverse cardiovascular responses to particulate matter (PM) exposure: the Nucleophilic Defense Against PM Toxicity (NEAT) trial.,"INTRODUCTION Exposure to airborne particulate matter (PM) is associated with cardiovascular disease. These outcomes are believed to originate from pulmonary oxidative stress and the systemic delivery of oxidised biomolecules (eg, aldehydes) generated in the lungs. Carnosine is an endogenous di-peptide (β-alanine-L-histidine) which promotes physiological homeostasis in part by conjugating to and neutralising toxic aldehydes. We hypothesise that an increase of endogenous carnosine by dietary supplementation would mitigate the adverse cardiovascular outcomes associated with PM exposure in humans. METHODS AND ANALYSIS To test this, we designed the Nucleophilic Defense Against PM Toxicity trial. This trial will enroll 240 participants over 2 years and determine if carnosine supplementation mitigates the adverse effects of PM inhalation. The participants will have low levels of endogenous carnosine to facilitate identification of supplementation-specific outcomes. At enrollment, we will measure several indices of inflammation, preclinical cardiovascular disease and physical function. Participants will be randomly allocated to carnosine or placebo groups and instructed to take their oral supplement for 12 weeks with two return clinical visits and repeated assessments during times of peak PM exposure (June-September) in Louisville, Kentucky, USA. Statistical modelling approaches will be used to assess the efficacy of carnosine supplementation in mitigating adverse outcomes. ETHICS AND DISSEMINATION This study protocol has been approved by the Institutional Review Board at the University of Louisville. Results from this study will be disseminated at scientific conferences and in peer-reviewed publications. Trial registration: NCT03314987; Pre-results.",2020,Carnosine is an endogenous di-peptide (β-alanine-L-histidine) which promotes physiological homeostasis in part by conjugating to and neutralising toxic aldehydes.,['240 participants over 2\u2009years and determine if carnosine supplementation mitigates the adverse effects of PM inhalation'],"['carnosine supplementation', 'carnosine or placebo']",[],"[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0007267', 'cui_str': 'Carnosine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1720884', 'cui_str': 'Particulate Matter'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}]","[{'cui': 'C0007267', 'cui_str': 'Carnosine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],240.0,0.218833,Carnosine is an endogenous di-peptide (β-alanine-L-histidine) which promotes physiological homeostasis in part by conjugating to and neutralising toxic aldehydes.,"[{'ForeName': 'Timothy E', 'Initials': 'TE', 'LastName': ""O'Toole"", 'Affiliation': 'Division of Environmental Medicine, Christina Lee Brown Envirome Institute, University of Louisville, Louisville, Kentucky, USA teotoo01@louisville.edu.'}, {'ForeName': 'Alok A', 'Initials': 'AA', 'LastName': 'Amraotkar', 'Affiliation': 'Division of Environmental Medicine, Christina Lee Brown Envirome Institute, University of Louisville, Louisville, Kentucky, USA.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'DeFilippis', 'Affiliation': 'Department of Medicine, Vanderbilt University, Nashville, TN, USA.'}, {'ForeName': 'Shesh N', 'Initials': 'SN', 'LastName': 'Rai', 'Affiliation': 'Department of Biostatistics and Bioinfomatics, University of Louisville, Louisville, Kentucky, USA.'}, {'ForeName': 'Rachel J', 'Initials': 'RJ', 'LastName': 'Keith', 'Affiliation': 'Division of Environmental Medicine, Christina Lee Brown Envirome Institute, University of Louisville, Louisville, Kentucky, USA.'}, {'ForeName': 'Shahid P', 'Initials': 'SP', 'LastName': 'Baba', 'Affiliation': 'Division of Environmental Medicine, Christina Lee Brown Envirome Institute, University of Louisville, Louisville, Kentucky, USA.'}, {'ForeName': 'Pawel', 'Initials': 'P', 'LastName': 'Lorkiewicz', 'Affiliation': 'Division of Environmental Medicine, Christina Lee Brown Envirome Institute, University of Louisville, Louisville, Kentucky, USA.'}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Crandell', 'Affiliation': 'Department of Physical Therapy, Bellarmine University, Louisville, Kentucky, USA.'}, {'ForeName': 'Gina L', 'Initials': 'GL', 'LastName': 'Pariser', 'Affiliation': 'Department of Physical Therapy, Bellarmine University, Louisville, Kentucky, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Wingard', 'Affiliation': 'Department of Physical Therapy, Bellarmine University, Louisville, Kentucky, USA.'}, {'ForeName': 'C Arden', 'Initials': 'CA', 'LastName': 'Pope Iii', 'Affiliation': 'Department of Economics, Brigham Young University, Provo, Utah, USA.'}, {'ForeName': 'Aruni', 'Initials': 'A', 'LastName': 'Bhatnagar', 'Affiliation': 'Division of Environmental Medicine, Christina Lee Brown Envirome Institute, University of Louisville, Louisville, Kentucky, USA.'}]",BMJ open,['10.1136/bmjopen-2020-039118'] 765,33373538,Effect of Advance Care Planning on Surrogate Decision Makers' Preparedness for Decision Making: Results of a Mixed-Methods Randomized Controlled Trial.,"Background: Advance care planning (ACP) is intended to help patients and their spokespersons prepare for end-of-life decision making, yet little is known about what factors influence the extent to which spokespersons feel prepared for that role. Objective: To examine spokespersons' perceived preparedness for surrogate decision making after engaging in ACP. Design: Mixed methods experimental design with qualitative thematic analysis and data transformation (creating categorical data from rich qualitative data) of interviews collected during a randomized controlled trial (2012-2017). Setting/Participants: Two tertiary care medical centers (Hershey, PA and Boston, MA). Of 285 dyads (patients with advanced illness and their spokespersons) enrolled in the trial, 200 spokesperson interviews were purposively sampled and 198 included in the analyses. Main Outcomes and Measures: Interviews with spokespersons (four weeks post-intervention) explored spokespersons' perceived preparedness for surrogate decision making, occurrence of ACP conversations, and spokespersons' intentions regarding future surrogate decisions. Data transformation was used to categorize participants' responses into three categories: Very Prepared , Very Unprepared , or In Between Prepared and Unprepared . Themes and categories were compared across arms. Results: About 72.72% of spokespersons (144/198) reported being Very Prepared and 27.28% (54/198) reported being Very Unprepared or In Between with no differences in preparedness across study arms. Occurrence of post-intervention ACP conversations did not influence perceived preparedness; however, spokespersons who used an ACP decision aid reported more conversations. Four themes emerged to explain spokespersons' perceived preparedness: (1) perceptions about ACP; (2) level of comfort with uncertainty; (3) relational issues; and (4) personal characteristics. Regarding future intentions, it emerged that spokespersons believed their knowledge of patient wishes, as well as other personal, relational, situational, and emotional factors would influence their surrogate decisions. Conclusions: Factors extrinsic to specific ACP interventions influence how prepared spokespersons feel to act as spokespersons. Understanding these factors is important for understanding how to improve concordance between patients' stated end-of-life wishes and surrogate decisions. Trial Registration: NCT02429479.",2021,"Interviews with spokespersons (four weeks post-intervention) explored spokespersons' perceived preparedness for surrogate decision making, occurrence of ACP conversations, and spokespersons' intentions regarding future surrogate decisions.","['Setting/Participants', 'Two tertiary care medical centers (Hershey, PA and Boston, MA', '285 dyads (patients with advanced illness and their spokespersons) enrolled in the trial, 200 spokesperson interviews were purposively sampled and 198 included in the analyses']","[': Advance care planning (ACP', 'Advance Care Planning']",['preparedness: (1) perceptions about ACP; (2) level of comfort with uncertainty; (3) relational issues; and (4) personal characteristics'],"[{'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0001369', 'cui_str': 'Acyl Carrier Protein'}]","[{'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0001369', 'cui_str': 'Acyl Carrier Protein'}, {'cui': 'C0517225', 'cui_str': 'Comfort level'}, {'cui': 'C0087130', 'cui_str': 'Uncertain'}, {'cui': 'C0033213', 'cui_str': 'Problem'}]",,0.135092,"Interviews with spokespersons (four weeks post-intervention) explored spokespersons' perceived preparedness for surrogate decision making, occurrence of ACP conversations, and spokespersons' intentions regarding future surrogate decisions.","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Thiede', 'Affiliation': 'College of Nursing, Penn State University, University Park, Pennsylvania, USA.'}, {'ForeName': 'Benjamin H', 'Initials': 'BH', 'LastName': 'Levi', 'Affiliation': 'College of Medicine, Penn State University, Hershey, Pennsylvania, USA.'}, {'ForeName': 'Daniella', 'Initials': 'D', 'LastName': 'Lipnick', 'Affiliation': 'College of Medicine, Penn State University, Hershey, Pennsylvania, USA.'}, {'ForeName': 'Rhonda', 'Initials': 'R', 'LastName': 'Johnson', 'Affiliation': 'College of Medicine, Penn State University, Hershey, Pennsylvania, USA.'}, {'ForeName': 'In', 'Initials': 'I', 'LastName': 'Seo La', 'Affiliation': 'School of Nursing, University of Maryland, Baltimore, Maryland, USA.'}, {'ForeName': 'Erik B', 'Initials': 'EB', 'LastName': 'Lehman', 'Affiliation': 'College of Medicine, Penn State University, Hershey, Pennsylvania, USA.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Smith', 'Affiliation': 'College of Medicine, Penn State University, Hershey, Pennsylvania, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Wiegand', 'Affiliation': 'School of Nursing, University of Maryland, Baltimore, Maryland, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Green', 'Affiliation': 'College of Medicine, Penn State University, Hershey, Pennsylvania, USA.'}, {'ForeName': 'Lauren Jodi', 'Initials': 'LJ', 'LastName': 'Van Scoy', 'Affiliation': 'College of Medicine, Penn State University, Hershey, Pennsylvania, USA.'}]",Journal of palliative medicine,['10.1089/jpm.2020.0238'] 766,33352008,"Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.","This double-blind, randomized, placebo-controlled, dose-ascending, first-in-human study (NCT02766621) assessed the safety, tolerability, and pharmacokinetics (PK) of PF-06823859, an anti-interferon β monoclonal antibody. Healthy subjects were randomized to single ascending doses (SADs) of intravenous PF-06823859 30, 100, 300, 900, or 2000 mg or placebo; to multiple ascending doses (MADs) of subcutaneous PF-06823859 100 or 300 mg or placebo (once every 2 weeks for a total of 3 doses); or to MAD of intravenous PF-06823859 600 mg or placebo (once every 3 weeks or once every 4 weeks for a total of 2 doses). The incidence, severity, and causal relationship of adverse events (AEs) were assessed, along with immunogenicity and PK. In total, 62 subjects were randomized to treatment (SAD, n = 35; MAD, n = 27). There were 76 treatment-emergent all-causality AEs in the SAD (PF-06823859: n = 25; placebo: n = 4) and MAD (PF-06823859: n = 40; placebo: n = 7) cohorts. In the SAD cohorts, all treatment-emergent all-causality AEs were mild in severity; 4 AEs of moderate severity were identified in the MAD cohorts. No dose-limiting AEs, serious AEs, treatment-related discontinuations, dose reductions, or deaths occurred. PF-06823859 exposure increased dose-proportionally, with half-life values ranging between 23 and 35 days. The estimated subcutaneous bioavailability was 43% to 44%. Immunogenicity incidence rates were low (antidrug antibodies, 12.5%; neutralizing antibodies, 2.1%). No immunogenically related clinical responses of concern were observed. In conclusion, PF-06823859 demonstrated an acceptable safety, tolerability, and PK profile that supports clinical development for treating disorders associated with increased interferon β levels, such as dermatomyositis or systemic lupus erythematosus.",2021,"Immunogenicity incidence rates were low (antidrug antibodies, 12.5%; neutralizing antibodies, 2.1%).","['62 subjects', 'Healthy subjects']","['MAD of intravenous PF-06823859 600 mg or placebo', 'MAD (PF-06823859: n\xa0=\xa040; placebo', 'subcutaneous PF-06823859 100 or 300 mg or placebo', 'placebo']","['incidence, severity, and causal relationship of adverse events (AEs', 'Immunogenicity incidence rates', 'estimated subcutaneous bioavailability', 'Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody', 'safety, tolerability, and pharmacokinetics (PK', 'acceptable safety, tolerability, and PK profile']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}]",62.0,0.483026,"Immunogenicity incidence rates were low (antidrug antibodies, 12.5%; neutralizing antibodies, 2.1%).","[{'ForeName': 'Srividya', 'Initials': 'S', 'LastName': 'Neelakantan', 'Affiliation': 'Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Oemar', 'Affiliation': 'Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Johnson', 'Affiliation': 'Center for Therapeutic Innovation, Pfizer Inc, New York, New York, USA.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Rath', 'Affiliation': 'Pfizer Inc, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Mikhail', 'Initials': 'M', 'LastName': 'Salganik', 'Affiliation': 'Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Gabe', 'Initials': 'G', 'LastName': 'Berman', 'Affiliation': 'Pfizer Inc, San Diego, California, USA.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Pelletier', 'Affiliation': 'Pfizer Inc, Groton, Connecticut, USA.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Cox', 'Affiliation': 'Pfizer Inc, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Page', 'Affiliation': 'Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Messing', 'Affiliation': 'Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Sanela', 'Initials': 'S', 'LastName': 'Tarabar', 'Affiliation': 'Pfizer Clinical Research Unit, New Haven, Connecticut, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.887'] 767,33359595,"Evaluation of platelet-rich plasma on hair regrowth and lesional T-cell cytokine expression in alopecia areata: A randomized observer-blinded, placebo-controlled, split-head pilot study.","BACKGROUND Platelet-rich plasma has shown some promise in the treatment of alopecia areata. OBJECTIVE To evaluate the effect of platelet-rich plasma on hair regrowth and lesional T-cell cytokine expression in alopecia areata. METHODS This was a randomized, placebo-controlled, split-head study involving 27 patients with alopecia areata (Severity of Alopecia Tool score ≥25%). Alopecia patches on either side of the scalp were randomized to receive 3 intradermal injections of platelet-rich plasma or normal saline at monthly intervals and evaluated 3 months after the last session. Lesional T-cell cytokine messenger RNA expression was compared pre- and posttreatment in the platelet-rich plasma-treated sites. RESULTS The mean Severity of Alopecia Tool score did not change significantly compared with baseline with either platelet-rich plasma or placebo injections at any visit; however, the mean percentage reduction in the score in the platelet-rich plasma arm was more than in the placebo arm (9.05% ± 36.48% vs 4.99% ± 33.88%; P = .049) at final assessment. The mean interferon gamma (P = .001) and interleukin 17 cytokine (P = .009) messenger RNA expression decreased, whereas the mean interleukin 10 (P = .049) and FOXP3 (P = .011) messenger RNA expression increased significantly after platelet-rich plasma treatment. LIMITATIONS Small sample size and a relatively short follow-up. CONCLUSION Platelet-rich plasma was found to have limited efficacy in alopecia areata. However, it may play a role in restoring immune balance in the alopecic patches.",2021,"The mean IFN-gamma (p=0.001) and IL-17 cytokine (p=0.009) mRNA expression decreased, while the mean IL-10 (p=0.049) and FoxP3 (p=0.011) mRNA expression increased significantly after PRP treatment. ","['27 patients with alopecia areata (SALT>25', 'alopecia areata']","['Platelet-rich plasma (PRP', 'PRP', 'placebo', 'platelet-rich plasma', 'PRP or normal saline']","['mean SALT score', 'IL-17 cytokine (p=0.009) mRNA expression', 'Alopecia patches', 'SALT score', 'mean IFN-gamma', 'FoxP3', 'mean IL-10', 'Lesional T-cell cytokine mRNA expression', 'hair regrowth and lesional T-cell cytokine expression', 'mRNA expression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002170', 'cui_str': 'Alopecia'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0002170', 'cui_str': 'Alopecia'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0017011', 'cui_str': 'Gamma radiation'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}]",27.0,0.124138,"The mean IFN-gamma (p=0.001) and IL-17 cytokine (p=0.009) mRNA expression decreased, while the mean IL-10 (p=0.049) and FoxP3 (p=0.011) mRNA expression increased significantly after PRP treatment. ","[{'ForeName': 'Vishal', 'Initials': 'V', 'LastName': 'Gupta', 'Affiliation': 'Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: doctor.vishalgupta@gmail.com.'}, {'ForeName': 'Anita Singh', 'Initials': 'AS', 'LastName': 'Parihar', 'Affiliation': 'Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Vinod Kumar', 'Initials': 'VK', 'LastName': 'Sharma', 'Affiliation': 'Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Suman', 'Initials': 'S', 'LastName': 'Jain', 'Affiliation': 'Department of Physiology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Vishwajeet', 'Initials': 'V', 'LastName': 'Singh', 'Affiliation': 'Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Neena', 'Initials': 'N', 'LastName': 'Khanna', 'Affiliation': 'Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.12.039'] 768,33372439,Clinical evaluation of the effectiveness of interferential current therapy in the treatment of children with pelvic floor dyssynergia-type constipation: a randomized controlled study.,"BACKGROUND Despite several treatment modalities being described for pelvic floor dyssynergia-type constipation, the clinical evaluation of interferential current therapy (IFC) has not been examined. We aimed to examine the clinical effects of IFC therapy in the treatment of children with pelvic floor dyssynergia-type constipation. METHODS Between May 2018 and July 2019, this randomized controlled study included sixty-two children (46 boys and 16 girls) with pelvic floor dyssynergia-type constipation; their ages ranged between 7 and 15 years. The children were randomly divided into either the IFC group (n = 31) who received an active IFC therapy to stimulate the pelvic floor and external anal sphincter muscles, three times per week for four successive weeks, or the control group (n = 31) who received sham IFC stimulation. Stool-incontinence frequency per week, stool type, pelvic floor excursion, and myogenic activity of external anal sphincter were evaluated at the baseline, post-treatment, and three months after treatment termination. RESULTS The baseline evaluation showed non-significant differences between the IFC and control groups (p > 0.05). The post-treatment results showed a statistically significant difference between both groups regarding all variables, favoring the IFC group (p < 0.05). Further, the favorable effect of IFC on all variables continued at the follow-up, three months later. CONCLUSIONS IFC therapy appears to improve stool-incontinence frequency, stool type, pelvic floor excursion, and myogenic activities of the external anal sphincter in children with pelvic floor dyssynergia-type constipation. These results suggest that adding IFC therapy to the medical treatment could improve the main features of pelvic floor dyssynergia-type constipation.",2020,The baseline evaluation showed non-significant differences between the IFC and control groups (p > 0.05).,"['children with pelvic floor dyssynergia-type constipation', 'sixty-two children (46 boys and 16 girls) with pelvic floor dyssynergia-type constipation; their ages ranged between 7 and 15 years', 'Between May 2018 and July 2019']","['active IFC therapy', 'interferential current therapy (IFC', 'IFC therapy', 'sham IFC stimulation', 'interferential current therapy', 'IFC']","['stool-incontinence frequency, stool type, pelvic floor excursion, and myogenic activities of the external anal sphincter', 'pelvic floor dyssynergia-type constipation', 'Stool-incontinence frequency per week, stool type, pelvic floor excursion, and myogenic activity of external anal sphincter']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1535943', 'cui_str': 'Pelvic floor dyssynergia'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0224395', 'cui_str': 'External anal sphincter structure'}, {'cui': 'C1535943', 'cui_str': 'Pelvic floor dyssynergia'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0585296', 'cui_str': 'Frequency per week'}]",62.0,0.0185878,The baseline evaluation showed non-significant differences between the IFC and control groups (p > 0.05).,"[{'ForeName': 'Ahmed Fathy', 'Initials': 'AF', 'LastName': 'Samhan', 'Affiliation': ''}, {'ForeName': 'Walid Kamal', 'Initials': 'WK', 'LastName': 'Abdelbasset', 'Affiliation': ''}, {'ForeName': 'Ragab Kamal', 'Initials': 'RK', 'LastName': 'Elnaggar', 'Affiliation': ''}]",The Turkish journal of pediatrics,['10.24953/turkjped.2020.06.012'] 769,33373666,Dose-response relationship between serum fibroblast growth factor 21 and liver fat content in non-alcoholic fatty liver disease.,"BACKGROUND & AIM Although serum fibroblast growth factor 21 (FGF21) levels are associated with liver fat content in non-alcoholic liver fat disease (NAFLD), the precise nature of the association remains undetermined. Therefore, this study aimed to explore the potential dose-response relationship between FGF21 and liver fat content in NAFLD. METHODS For this exploratory study from a randomized trial, 220 NAFLD patients with central obesity were recruited via community-based screening and randomly assigned to either control, moderate or vigorous-moderate exercise groups for 12 months. After this exercise intervention, patients were followed-up for a further 12 months. Serum FGF21 levels were measured by ELISA. Intrahepatic triglyceride (IHTG) content was determined by proton magnetic resonance spectroscopy. RESULTS Of the 220 patients, 149 (67.7%) were female; mean age was 53.9 ± 7.1 years and mean BMI was 28.0 ± 2.9 kg/m 2 for all patients. Baseline IHGT increased gradually (P = 0.029 for trend) according to baseline serum FGF21 quartiles 1, 2, 3 and 4 (212.3, 358.9, 538.7 and 793.5 pg/mL, respectively). On grouping the distribution of serum FGF21 level changes into quartiles at month 12, the relative IHTG loss increased as serum FGF21 levels were reduced (P = 0.004 for trend). A similar trend was observed at month 24 (P = 0.006 for trend). Multivariate linear regression analysis revealed that changes in serum FGF21 levels were independently associated with changes in IHTG at both month 12 [β (SE), 0.136 (0.118); P = 0.048] and month 24 [β (SE), 0.152 (0.139); P = 0.041]. Using restricted cubic spline regression, changes in serum FGF21 were strongly and positively associated with their corresponding relative IHTG loss at both month 12 and follow-up (P overall  = 0.017, P non-linear  = 0.044 and P overall  = 0.020, P non-linear  = 0.361, respectively, for dose-response). CONCLUSION Serum FGF21 is strongly associated with liver fat content in a dose-response manner in centrally obese NAFLD patients. These findings support the use of serum FGF21 as a biomarker of liver fat content in NAFLD.",2020,"FGF21 quartiles 1, 2, 3 and 4 (212.3, 358.9, 538.7 and 793.5 pg/mL, respectively).","['non-alcoholic fatty liver disease', '220 NAFLD patients with central obesity were recruited via community-based screening and randomly assigned to either', 'Of the 220 patients, 149 (67.7%) were female; mean age was 53.9 ± 7.1 years and mean BMI was 28.0 ± 2.9 kg/m2 for all patients']","['control, moderate or vigorous-moderate exercise']","['Baseline IHGT', 'relative IHTG loss', 'FGF21 levels', 'Intrahepatic triglyceride (IHTG) content', 'serum FGF21', 'Serum FGF21 levels']","[{'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0311277', 'cui_str': 'Abdominal Obesity'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517641', 'cui_str': '2.9'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0972232', 'cui_str': 'fibroblast growth factor 21'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",220.0,0.0202485,"FGF21 quartiles 1, 2, 3 and 4 (212.3, 358.9, 538.7 and 793.5 pg/mL, respectively).","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Xiao', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Shi', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Huang', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': 'Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; Xiamen Diabetes Institute, Xiamen, China.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Zeng', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Yan', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Xiamen Diabetes Institute, Xiamen, China.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Song', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'School of Clinical Medicine, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Han', 'Affiliation': 'School of Clinical Medicine, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'School of Medicine, Xiamen University, Xiamen, China.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; Xiamen Diabetes Institute, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China. Electronic address: linmz65@126.com.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; Xiamen Diabetes Institute, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China. Electronic address: lixuejun@xmu.edu.cn.'}]",Diabetes & metabolism,['10.1016/j.diabet.2020.101221'] 770,33306873,Performance of different criteria for refractory myasthenia gravis.,"BACKGROUND AND PURPOSE Defining refractory myasthenia gravis is important, as this can drive clinical decision making, for example, by escalating treatments in refractory individuals. There are several definitions of refractory myasthenia, and their performances have not been compared. Having valid and reliable criteria can help select patients in whom more aggressive treatments may be needed. METHODS We applied five different refractory myasthenia criteria (Drachman, Mantegazza, Suh, the International Consensus Guideline (ICG), and the randomised controlled trial of eculizumab in refractory, anti-acetylcholine receptor positive, generalised myasthenia gravis (REGAIN), to a cohort of 237 patients. We compared the proportion of refractory patients among different criteria and their scores on disease severity, fatigue, and quality-of-life (QoL) scales. We also assessed the agreement for each criterion between two trained assessors. RESULTS The Drachman, Mantegazza, and Suh criteria resulted in high proportions of refractory individuals (40.1%, 39.2%, and 38.8%, respectively), compared with the ICG and REGAIN criteria (9.7% and 3.0%, respectively). Refractory patients by the ICG and REGAIN criteria had worse disease severity, QoL, and fatigue scores, compared with patients classified as refractory by other criteria. All criteria had high agreement between raters (between 70% and 100%). CONCLUSIONS There is high variability in the proportion of refractory myasthenia gravis patients depending on the criteria used, with ICG and REGAIN criteria capturing patients with worse disease severity. This reflects conceptual differences as to what refractory means. Further multicenter studies are needed to determine appropriate criteria for refractory myasthenia gravis.",2021,"Refractory patients by the ICG and REGAIN criteria had worse disease severity, QoL, and fatigue scores, compared with patients classified as refractory by other criteria.",['237 patients'],['eculizumab'],"['disease severity, fatigue, and quality-of-life (QoL) scales', 'disease severity, QoL, and fatigue scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1541483', 'cui_str': 'eculizumab'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",237.0,0.129347,"Refractory patients by the ICG and REGAIN criteria had worse disease severity, QoL, and fatigue scores, compared with patients classified as refractory by other criteria.","[{'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Tran', 'Affiliation': 'Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Aishani', 'Initials': 'A', 'LastName': 'Biswas', 'Affiliation': 'Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Meg', 'Initials': 'M', 'LastName': 'Mendoza', 'Affiliation': 'Division of Neurology, Department of Medicine, The Ellen and Prosserman Centre for Neuromuscular Diseases, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Katzberg', 'Affiliation': 'Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Bril', 'Affiliation': 'Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Barnett', 'Affiliation': 'Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}]",European journal of neurology,['10.1111/ene.14675'] 771,33369937,"A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease.","PURPOSE NOV03 has a unique dual mode of action to address dry eye disease (DED) associated with meibomian gland dysfunction. SEECASE evaluated the efficacy, safety, and tolerability of NOV03 at 2 dosing regimens compared with a saline comparator in patients with DED. METHODS SEECASE was a prospective, multicenter, randomized, double-masked, saline-controlled clinical study. A total of 336 DED patients [tear film breakup time ≤5 seconds, abnormal meibum secretion, total corneal fluorescein staining (tCFS) score of 4 ≤ X ≤ 11 (National Eye Institute scale), Schirmer of ≥5 mm] were randomized in a 2:2:1:1 manner to NOV03 4 times daily (QID), NOV03 twice daily (BID), saline BID, and saline QID, respectively. The primary efficacy endpoint was tCFS staining at 8 weeks for both regimens. Secondary endpoints included visual analog scales and the Ocular Surface Disease Index questionnaire for symptom assessment. RESULTS The study met its primary endpoint, change from baseline of tCFS over control, for both dosing regimens QID and BID (P < 0.001 and P = 0.009, respectively). NOV03 also showed pronounced improvement in various symptoms. For the Eye Dryness Score, changes from baseline were statistically significant compared with those of the control at week 8 [P < 0.001 (QID) and P = 0.002 (BID)]. Benefits on tCFS and symptoms started at 2 weeks after start of treatment and were maintained over the study duration. The effects were dosing schedule dependent. NOV03 was well tolerated with instillation site reactions below 3% in both treatment regimes. CONCLUSIONS The SEECASE study demonstrated that NOV03 improves signs and symptoms in patients with highly symptomatic evaporative dry eye disease.",2021,"For the Eye Dryness Score, changes from baseline were statistically significant compared with those of the control at week 8 [P < 0.001 (QID) and P = 0.002","['336 DED patients [tear film breakup time ≤5 seconds, abnormal meibum secretion, total corneal fluorescein staining (tCFS) score of 4 ≤ X ≤ 11 (National Eye Institute scale), Schirmer of ≥5 mm', 'patients with highly symptomatic evaporative dry eye disease', 'patients with DED']","['NOV03 4 times daily (QID), NOV03 twice daily (BID), saline BID, and saline QID', 'NOV03']","['efficacy, safety, and tolerability of NOV03', 'Efficacy, Safety, and Tolerability', 'visual analog scales and the Ocular Surface Disease Index questionnaire for symptom assessment', 'tCFS staining']","[{'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C5197842', 'cui_str': 'Meibomian Lipids'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1955969', 'cui_str': 'National Eye Institute'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C5197850', 'cui_str': 'Evaporative Dry Eye Syndrome'}]","[{'cui': 'C0585291', 'cui_str': 'Four times daily'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0038128', 'cui_str': 'Stain'}]",336.0,0.111619,"For the Eye Dryness Score, changes from baseline were statistically significant compared with those of the control at week 8 [P < 0.001 (QID) and P = 0.002","[{'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Tauber', 'Affiliation': 'Tauber Eye Center, Kansas City, MO.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Wirta', 'Affiliation': 'Eye Research Foundation, Newport Beach, CA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Sall', 'Affiliation': 'Sall Research Medical Center, Artesia, CA.'}, {'ForeName': 'Parag A', 'Initials': 'PA', 'LastName': 'Majmudar', 'Affiliation': 'Chicago Cornea Consultants, Chicago, IL; and.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Willen', 'Affiliation': 'Novaliq GmbH, Heidelberg, Germany.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Krösser', 'Affiliation': 'Novaliq GmbH, Heidelberg, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Cornea,['10.1097/ICO.0000000000002622'] 772,33361495,The Efficacy of a Multicomponent Functional Fitness Program Based on Exergaming on Cognitive Functioning of Healthy Older Adults: A Randomized Controlled Trial.,"BACKGROUND AND OBJECTIVES Regular physical exercise can attenuate age-related cognitive decline. This study aimed to investigate the effect of a physical exercise multicomponent training based on exergames on cognitive functioning (CF) in older adults. RESEARCH DESIGN AND METHODS This randomized controlled trial included older adults aged 61-78. Participants were randomly allocated to an intervention group (IG; n = 15) or active control group (CG; n = 16). The IG was exposed to a combined training with traditional exercise and exergaming, twice a week over a period of 12 weeks. The CG performed only traditional sessions. CF was assessed by the Cognitive Telephone Screening Instrument. The time points for assessment were at zero (pretest), 12 (posttest), and 17 weeks (follow-up). RESULTS Active CG and IG increased from pretest to posttest in short-term memory (STM), long-term memory (LTM), and Cognitive Telephone Screening Instrument total score 1.98 > Z < 3.00, ps < .005, with moderately large positive effects (.36 > r < .54). A significant increase was seen from posttest to follow-up in STM, Z = 2.74, p = .006, and LTM, Z = 2.31, p < .021, only in IG. Across the two time periods posttest to follow-up, there were significant interaction effects between program type and time for STM (p = .022, ηp2=.17) and LTM (p = .004, ηp2=.25), demonstrating a more beneficial effect of the exergames intervention compared to the CG. Discussion and Implications: The integration of exergaming in a multicomponent functional fitness exercise might have the potential to maintain and improve CF (in particular, STM and LTM) in older adults.",2020,"Active CG and IG increased from pretest to posttest in short-term memory (STM), long-term memory (LTM), and Cognitive Telephone Screening Instrument total score 1.98 > Z < 3.00, ps < .005, with moderately large positive effects (.36 >","['Healthy Older Adults', 'older adults', 'older adults aged 61-78']","['Multicomponent Functional Fitness Program', 'physical exercise multicomponent training', 'intervention group (IG; n = 15) or active control']","['short-term memory (STM), long-term memory (LTM), and Cognitive Telephone Screening Instrument total score', 'cognitive functioning (CF', 'Active CG and IG']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0423909', 'cui_str': 'Long-term memory performance'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",78.0,0.0500503,"Active CG and IG increased from pretest to posttest in short-term memory (STM), long-term memory (LTM), and Cognitive Telephone Screening Instrument total score 1.98 > Z < 3.00, ps < .005, with moderately large positive effects (.36 >","[{'ForeName': 'Élvio R', 'Initials': 'ÉR', 'LastName': 'Gouveia', 'Affiliation': ''}, {'ForeName': 'Asim', 'Initials': 'A', 'LastName': 'Smailagic', 'Affiliation': ''}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Ihle', 'Affiliation': ''}, {'ForeName': 'Adilson', 'Initials': 'A', 'LastName': 'Marques', 'Affiliation': ''}, {'ForeName': 'Bruna R', 'Initials': 'BR', 'LastName': 'Gouveia', 'Affiliation': ''}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'Cameirão', 'Affiliation': ''}, {'ForeName': 'Honorato', 'Initials': 'H', 'LastName': 'Sousa', 'Affiliation': ''}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Kliegel', 'Affiliation': ''}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Siewiorek', 'Affiliation': ''}]",Journal of aging and physical activity,['10.1123/japa.2020-0083'] 773,33361494,High-Speed Bodyweight Resistance Training Improves Functional Performance Through Maximal Velocity in Older Females.,"The authors compared the effects of bodyweight resistance training at moderate- or high-speed conditions on muscle power, velocity of movement, and functional performance in older females. In a randomized, single-blinded noncontrolled trial, participants completed 12 weeks (three sessions/week) of bodyweight resistance training at high (n = 14; age = 70.6 ± 4.3 years) or moderate (n = 12; age = 72.8 ± 4.2 years) speeds. Data were analyzed with an analysis of variance (Group × Time) with α level set at <.05. After the intervention, timed up and go test performance (p < .05) and the rising from a chair test mean (22.4%) and maximal velocity (28.5%), mean (24.4%) and maximal power (27.7%), normalized mean (25.1%), and normalized maximal power (28.5%) increased in the high-speed group (p < .05). However, the moderate-speed group achieved no improvements (Δ6.7-14.4%; p > .2). The authors conclude that high-speed bodyweight resistance training is an effective and economically practical strategy to improve the functional capacity of older women relevant to daily life activities.",2020,"After the intervention, timed up and go test performance (p < .05) and the rising from a chair test mean (22.4%) and maximal velocity (28.5%), mean (24.4%) and maximal power (27.7%), normalized mean (25.1%), and normalized maximal power (28.5%) increased in the high-speed group (p < .05).","['Older Females', 'at high (n = 14; age = 70.6 ± 4.3 years) or moderate (n = 12; age = 72.8 ± 4.2 years) speeds', 'older females']","['bodyweight resistance training', 'High-Speed Bodyweight Resistance Training', 'bodyweight resistance training at moderate- or high-speed conditions']","['muscle power, velocity of movement, and functional performance', 'normalized maximal power', 'maximal power', 'maximal velocity']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517759', 'cui_str': '4.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}]",14.0,0.0448935,"After the intervention, timed up and go test performance (p < .05) and the rising from a chair test mean (22.4%) and maximal velocity (28.5%), mean (24.4%) and maximal power (27.7%), normalized mean (25.1%), and normalized maximal power (28.5%) increased in the high-speed group (p < .05).","[{'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Jaque', 'Affiliation': ''}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Véliz', 'Affiliation': ''}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Ramirez-Campillo', 'Affiliation': ''}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Moran', 'Affiliation': ''}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Gentil', 'Affiliation': ''}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Cancino', 'Affiliation': ''}]",Journal of aging and physical activity,['10.1123/japa.2020-0129'] 774,33367669,Long-term observation of catheter ablation vs. pharmacotherapy in the management of persistent and long-standing persistent atrial fibrillation (CAPA study).,"AIMS The roles of radiofrequency catheter ablation (RFCA) and pharmacotherapy in treating persistent and long-standing persistent atrial fibrillation (AF) have not been sufficiently investigated. We conducted a multicentre, randomized, controlled trial to compare the effects of RFCA and pharmacotherapy on the prognosis of these patients. METHODS AND RESULTS A total of 648 patients with persistent and long-standing persistent AF were enrolled from 30 centres and randomized to either the ablation group (n = 327) or the pharmacotherapy group (n = 321). After 54.2 ± 10.6 months of follow-up, the primary endpoints occurred significantly more rarely in the ablation group than in the pharmacotherapy group (10.4% vs. 17.4%; hazard ratio 0.59, 95% confidence interval 0.48-0.75; P < 0.001). The incidence of stroke/transient ischaemic attack (TIA) was significantly lower in the ablation group (4.2% vs. 7.2%, P < 0.001). Likewise, the incidence of new-onset congestive heart failure (CHF) was lower in the ablation group (2.8% vs. 7.2%, P < 0.001). More patients had sinus rhythm in the ablation group than in the pharmacotherapy group (60.6% vs. 20.9%, P < 0.001), but fewer patients were on antiarrhythmic drugs (24.4% vs. 41.6%, P < 0.001) and warfarin (60.8% vs. 83.9%, P = 0.001). Both the 6-min walk distance and the quality of life (QoL) were improved in the ablation group at the end of follow-up. CONCLUSION In patients with persistent and long-standing persistent AF, RFCA-based treatment was superior to pharmacotherapy in decreasing stroke/TIA and new-onset CHF and improving QoL.",2021,"Both the 6-min walk distance and the quality of life (QoL) were improved in the ablation group at the end of follow-up. ",['648 patients with persistent and long-standing persistent AF'],"['warfarin', 'radiofrequency catheter ablation (RFCA) and pharmacotherapy', 'catheter ablation vs. pharmacotherapy', 'pharmacotherapy', 'RFCA and pharmacotherapy']","['incidence of new-onset congestive heart failure (CHF', '6-min walk distance and the quality of life (QoL', 'incidence of stroke/transient ischaemic attack (TIA', 'sinus rhythm', 'stroke/TIA and new-onset CHF and improving QoL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}]","[{'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0162561', 'cui_str': 'Radiofrequency Catheter Ablation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0232201', 'cui_str': 'Sinus rhythm'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",648.0,0.108956,"Both the 6-min walk distance and the quality of life (QoL) were improved in the ablation group at the end of follow-up. ","[{'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Wu', 'Affiliation': 'Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan university, Hubei Key Laboratory of Cardiology, Wuhan, Hubei 430060, China.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': 'Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan university, Hubei Key Laboratory of Cardiology, Wuhan, Hubei 430060, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Cai', 'Affiliation': ""Department of Cardiology, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.""}, {'ForeName': 'Yanzong', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Yu', 'Affiliation': 'Department of Cardiology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Yanhong', 'Initials': 'Y', 'LastName': 'Tang', 'Affiliation': 'Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan university, Hubei Key Laboratory of Cardiology, Wuhan, Hubei 430060, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan university, Hubei Key Laboratory of Cardiology, Wuhan, Hubei 430060, China.'}, {'ForeName': 'Congxin', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': 'Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan university, Hubei Key Laboratory of Cardiology, Wuhan, Hubei 430060, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa356'] 775,33370510,Comparison of intravenous ketorolac at three doses for treating renal colic in the emergency department: A noninferiority randomized controlled trial.,"BACKGROUND Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that is extensively used for the management of renal colic in the emergency department (ED). It has been proposed that ketorolac is used at doses above its analgesic ceiling with no more advantages and increased risk of adverse effects. In this study, we compared the analgesic effects of three doses of intravenous ketorolac in patients with renal colic. METHODS This noninferiority, randomized, double-blind clinical trial evaluated the analgesic efficacy of three doses of intravenous ketorolac (10, 20, and 30 mg) in adult patients presenting to the ED with renal colic. Exclusion criteria consisted of age > 65 years, active peptic ulcer disease, acute gastrointestinal hemorrhage, renal or hepatic insufficiency, NSAID hypersensitivity, pregnancy or breastfeeding, unstable vital signs, and patients who had received analgesics in the past 24 hours. Pain was recorded every 15 minutes from baseline up to 60 minutes, and the primary outcome was pain reduction at 30 minutes. If patients still required additional pain medications at 30 minutes, they would receive 0.1 mg/kg intravenous morphine sulfate as a rescue analgesic. RESULTS A total of 165 subjects enrolled in this study, 55 in each group. The median visual analog scale score in 30 minutes was improved from 90 at baseline to 40 among subjects who were randomized to 30-mg group. This improvement was 40 and 50 mm in 20- and 10-mg ketorolac treatment arms, respectively, with no significant difference between the three doses (p < 0.05). Secondary outcomes showed similar rescue analgesic administration and adverse effects. There was no serious adverse event. CONCLUSION Ketorolac at 10-, 20-, and 30-mg doses can produce similar analgesic efficacy in renal colic.",2021,"There was no serious adverse event. ","['One hundred and sixty five subjects enrolled in this study, 55 in each group', 'adult patients presenting to the ED with renal colic', '65, active peptic ulcer disease, acute gastrointestinal hemorrhage, renal or hepatic insufficiency, NSAID hypersensitivity, pregnancy or breastfeeding, unstable vital signs, and patients who had received analgesics in the past 24 hours', 'patients with renal colic']","['Intravenous Ketorolac', 'intravenous ketorolac', 'Ketorolac tromethamine', 'ketorolac', 'morphine sulfate', 'Ketorolac']","['analgesic efficacy', 'rescue analgesic administration and adverse effects', 'pain reduction', 'Pain', 'median VAS score', 'analgesic effects']","[{'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0152169', 'cui_str': 'Renal colic'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0030920', 'cui_str': 'Peptic ulcer'}, {'cui': 'C0266807', 'cui_str': 'Acute gastrointestinal hemorrhage'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C1306571', 'cui_str': 'Liver Insufficiency'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0443343', 'cui_str': 'Unstable status'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439584', 'cui_str': '24 hours'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}, {'cui': 'C0064326', 'cui_str': 'Ketorolac tromethamine'}, {'cui': 'C0066814', 'cui_str': 'Morphine sulfate'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0262176', 'cui_str': 'Administration of analgesic'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}]",165.0,0.526672,"There was no serious adverse event. ","[{'ForeName': 'Lily', 'Initials': 'L', 'LastName': 'Eidinejad', 'Affiliation': 'Emergency Medicine Department, Tehran University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Bahreini', 'Affiliation': 'Emergency Medicine Department, Tehran University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Ayat', 'Initials': 'A', 'LastName': 'Ahmadi', 'Affiliation': 'Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahtab', 'Initials': 'M', 'LastName': 'Yazdchi', 'Affiliation': 'Emergency Medicine Department, Tehran University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Venkatesh', 'Initials': 'V', 'LastName': 'Thiruganasambandamoorthy', 'Affiliation': 'Department of Emergency Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Mirfazaelian', 'Affiliation': 'Emergency Medicine Department, Tehran University of Medical Science, Tehran, Iran.'}]",Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,['10.1111/acem.14202'] 776,33370477,Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial.,"Mesenchymal stromal cells (MSC) have emerged as a promising therapy to minimize the immunosuppressive regimen or induce tolerance in solid organ transplantation. In this randomized open-label phase Ib/IIa clinical trial, 20 liver transplant patients were randomly allocated (1:1) to receive a single pretransplant intravenous infusion of third-party bone marrow-derived MSC or standard of care alone. The primary endpoint was the safety profile of MSC administration during the 1-year follow-up. In all, 19 patients completed the study, and none of those who received MSC experienced infusion-related complications. The incidence of serious and non-serious adverse events was similar in the two groups. Circulating Treg/memory Treg and tolerant NK subset of CD56 bright NK cells increased slightly over baseline, albeit not to a statistically significant extent, in MSC-treated patients but not in the control group. Graft function and survival, as well as histologic parameters and intragraft expression of tolerance-associated transcripts in 1-year protocol biopsies were similar in the two groups. In conclusion, pretransplant MSC infusion in liver transplant recipients was safe and induced mild positive changes in immunoregulatory T and NK cells in the peripheral blood. This study opens the way for a trial on possible tolerogenic efficacy of MSC in liver transplantation. ClinicalTrials.gov identifier: NCT02260375.",2021,"Circulating Treg/memory Treg and tolerant NK subset of CD56 bright NK cells increased slightly over baseline, albeit not to a statistically significant extent, in MSC-treated patients but not in the control group.","['liver transplant recipients', 'liver transplantation', '20 liver transplant patients']","['MSC', 'Mesenchymal stromal cells (MSC', 'party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation', 'single pre-transplant intravenous infusion of third-party bone marrow-derived MSC or standard of care alone']","['Circulating Treg/memory Treg and tolerant NK subset of CD56 bright NK cells', 'immunoregulatory T and NK cells', 'Graft function and survival', 'incidence of serious and non-serious adverse events', 'safety profile of MSC administration']","[{'cui': 'C0455647', 'cui_str': 'H/O: liver recipient'}, {'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C3178844', 'cui_str': 'Mesenchymal Stromal Cells'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0021440', 'cui_str': 'Intravenous infusion'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0108754', 'cui_str': 'Lymphocyte antigen CD56'}, {'cui': 'C0423899', 'cui_str': 'Above average intellect'}, {'cui': 'C0022688', 'cui_str': 'NK-cell'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3178844', 'cui_str': 'Mesenchymal Stromal Cells'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]",20.0,0.143704,"Circulating Treg/memory Treg and tolerant NK subset of CD56 bright NK cells increased slightly over baseline, albeit not to a statistically significant extent, in MSC-treated patients but not in the control group.","[{'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Casiraghi', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': 'Norberto', 'Initials': 'N', 'LastName': 'Perico', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': 'Manuel A', 'Initials': 'MA', 'LastName': 'Podestà', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Todeschini', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Zambelli', 'Affiliation': 'Department of Organ Failure and Transplantation, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Colledan', 'Affiliation': 'Department of Organ Failure and Transplantation, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Camagni', 'Affiliation': 'Department of Organ Failure and Transplantation, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Fagiuoli', 'Affiliation': 'Gastroenterology, Hepatology and Transplantation, Department of Medicine, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Antonio D', 'Initials': 'AD', 'LastName': 'Pinna', 'Affiliation': 'General Surgery and Transplant Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria-Policlinico S.Orsola-Malpighi, Bologna, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Cescon', 'Affiliation': 'General Surgery and Transplant Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria-Policlinico S.Orsola-Malpighi, Bologna, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Bertuzzo', 'Affiliation': 'General Surgery and Transplant Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria-Policlinico S.Orsola-Malpighi, Bologna, Italy.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Maroni', 'Affiliation': 'General Surgery and Transplant Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria-Policlinico S.Orsola-Malpighi, Bologna, Italy.'}, {'ForeName': 'Martino', 'Initials': 'M', 'LastName': 'Introna', 'Affiliation': 'G. Lanzani Laboratory of Cell Therapy, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Capelli', 'Affiliation': 'G. Lanzani Laboratory of Cell Therapy, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Josee T', 'Initials': 'JT', 'LastName': 'Golay', 'Affiliation': 'G. Lanzani Laboratory of Cell Therapy, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Buzzi', 'Affiliation': 'Emilia Romagna Cord Blood Bank, Immunohematology and Transfusion Medicine, Azienda Ospedaliero-Universitaria-Policlinico S. Orsola-Malpighi, Bologna, Italy.'}, {'ForeName': 'Marilena', 'Initials': 'M', 'LastName': 'Mister', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': 'Pamela Y R', 'Initials': 'PYR', 'LastName': 'Ordonez', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Breno', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Mele', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Villa', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Remuzzi', 'Affiliation': 'Aldo & Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.16468'] 777,33377146,Tobacco Advertising Features That May Contribute to Product Appeal Among US Adolescents and Young Adults.,"INTRODUCTION Cigarette advertising is a causal agent of smoking uptake among young people. Although prior research links ad receptivity to tobacco product interest and use, little is known regarding the specific advertising tactics associated with increased product appeal among young people. METHODS A national sample of 13-20 year-olds (N = 3688, youth) and 21-24 year-olds (N = 1556, young adults) in the US participated in an online survey in 2017 (mean age 18.1 years). The majority (72.0%) of youth and nearly half (44.8%) of young adults were never smokers. Participants were shown a cigarette ad, randomly assigned from a pool of 50 advertisements, and reported how much they liked the ad, and were curious about and interested in using the advertised product. All 50 advertisements were content analyzed for a variety of features. Data from the survey and content analysis were merged and mixed effects analyses used to identify the features associated with increased liking, curiosity, and interest in using, referred to collectively as product appeal. RESULTS Presence of a sweepstakes offer was associated with increased liking, curiosity and interest among youth and curiosity and interest among young adults. Outdoors settings, flora imagery, natural descriptors, and environmental themes were associated with increased appeal. Price reductions (eg, coupons) were associated with decreased appeal among youth. CONCLUSIONS This study identified several advertising tactics associated with increased appeal among youth and young adults. If additional research confirms these findings, the U.S. Food and Drug Association should consider restricting use of these tactics in tobacco advertising. IMPLICATIONS This study's findings provide insight into features of cigarette ads that appeal to youth and young adults. Overall, the presence of sweepstakes appealed to youth and young adults and outdoors and environmental themes were particularly appealing to young adults. Such tactics could serve to further brand engagement, improve brand image and lead to initiation or escalation of use. If confirmatory studies further demonstrate the effects of the tactics identified in this study on youth product appeal, U.S. Food and Drug Administration should consider using its authority to restrict the use of youth-appealing tactics.",2021,"RESULTS Presence of a sweepstakes offer was associated with increased liking, curiosity and interest among youth and curiosity and interest among young adults.","['A national sample of 13-20 year-olds (N=3,688, youth) and 21-24 year-olds (N=1,556, young adults) in the United States participated in an online survey in 2017 (mean age 18.1 years', 'young people', 'youth and young adults']",[],"['Outdoors settings, flora imagery, natural descriptors, and environmental themes', 'Price reductions', 'liking, curiosity and interest among youth and curiosity and interest']","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",[],"[{'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0282354', 'cui_str': 'Descriptor'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0080045', 'cui_str': 'Prices'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0010472', 'cui_str': 'Curiosity'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]",,0.0278902,"RESULTS Presence of a sweepstakes offer was associated with increased liking, curiosity and interest among youth and curiosity and interest among young adults.","[{'ForeName': 'Meghan Bridgid', 'Initials': 'MB', 'LastName': 'Moran', 'Affiliation': 'Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Heley', 'Affiliation': 'Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Czaplicki', 'Affiliation': 'Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'Weiger', 'Affiliation': 'Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Strong', 'Affiliation': 'Department of Family Medicine and Public Health, University of California San Diego School of Medicine, La Jolla, CA, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Pierce', 'Affiliation': 'Department of Family Medicine and Public Health, University of California San Diego School of Medicine, La Jolla, CA, USA.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa275'] 778,33357217,Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.,"BACKGROUND Atrial fibrillation (AF) is common in older people with frailty and is associated with an increased risk of stroke and systemic embolism. Whilst oral anticoagulation is associated with a reduction in this risk, there is a lack of data on the safety and efficacy of direct oral anticoagulants (DOACs) in people with frailty. This study aims to report clinical outcomes of patients with AF in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial by frailty status. METHODS Post hoc analysis of 20,867 participants in the ENGAGE AF-TIMI 48 trial, representing 98.8% of those randomised. This double-blinded double-dummy trial compared two once-daily regimens of edoxaban (a DOAC) with warfarin. Participants were categorised as fit, living with pre-frailty, mild-moderate, or severe frailty according to a standardised index, based upon the cumulative deficit model. The primary efficacy endpoint was stroke or systemic embolism and the safety endpoint was major bleeding. RESULTS A fifth (19.6%) of the study population had frailty (fit: n = 4459, pre-frailty: n = 12,326, mild-moderate frailty: n = 3722, severe frailty: n = 360). On average over the follow-up period, the risk of stroke or systemic embolism increased by 37% (adjusted HR 1.37, 95% CI 1.19-1.58) and major bleeding by 42% (adjusted HR 1.42, 1.27-1.59) for each 0.1 increase in the frailty index (four additional health deficits). Edoxaban was associated with similar efficacy to warfarin in every frailty category, and a lower risk of bleeding than warfarin in all but those living with severe frailty. CONCLUSIONS Edoxaban was similarly efficacious to warfarin across the frailty spectrum and was associated with lower rates of bleeding except in those with severe frailty. Overall, with increasing frailty, there was an increase in stroke and bleeding risk. There is a need for high-quality, frailty-specific population randomised control trials to guide therapy in this vulnerable population. TRIAL REGISTRATION ClinicalTrials.gov NCT00781391 . First registered on 28 October 2008.",2020,"Edoxaban was associated with similar efficacy to warfarin in every frailty category, and a lower risk of bleeding than warfarin in all but those living with severe frailty. ","['older people with frailty', 'people with frailty', 'had frailty (fit: n\u2009=\u20094459, pre-frailty: n\u2009=\u200912,326, mild-moderate frailty: n\u2009=\u20093722, severe frailty: n\u2009=\u2009360', '20,867 participants in the ENGAGE AF-TIMI 48 trial, representing 98.8% of those randomised', 'patients with AF in the Effective Anticoagulation with', 'patients with atrial fibrillation and frailty', 'Participants were categorised as fit, living with pre-frailty, mild-moderate, or severe frailty according to a standardised index, based upon the cumulative deficit model']","['edoxaban (a DOAC) with warfarin', 'Edoxaban', 'Factor Xa Next Generation', 'warfarin']","['stroke and bleeding risk', 'risk of stroke or systemic embolism', 'major bleeding', 'frailty index', 'stroke or systemic embolism and the safety endpoint was major bleeding', 'risk of bleeding']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C2975435', 'cui_str': 'edoxaban'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0015520', 'cui_str': 'Coagulation factor Xa'}, {'cui': 'C0079411', 'cui_str': 'Generations'}]","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013922', 'cui_str': 'Embolism'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C4075886', 'cui_str': 'Frailty Index'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",20867.0,0.579414,"Edoxaban was associated with similar efficacy to warfarin in every frailty category, and a lower risk of bleeding than warfarin in all but those living with severe frailty. ","[{'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Wilkinson', 'Affiliation': 'Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. Chris.Wilkinson@newcastle.ac.uk.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.'}, {'ForeName': 'Samuel D', 'Initials': 'SD', 'LastName': 'Searle', 'Affiliation': 'MRC Unit for Lifelong Health and Ageing, University College London, London, UK.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Todd', 'Affiliation': 'Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.'}, {'ForeName': 'Marlous', 'Initials': 'M', 'LastName': 'Hall', 'Affiliation': 'Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Kunadian', 'Affiliation': 'Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Clegg', 'Affiliation': 'Academic Unit for Ageing and Stroke Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Rockwood', 'Affiliation': 'MRC Unit for Lifelong Health and Ageing, University College London, London, UK.'}, {'ForeName': 'Chris P', 'Initials': 'CP', 'LastName': 'Gale', 'Affiliation': 'Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.'}]",BMC medicine,['10.1186/s12916-020-01870-w'] 779,33387056,"Multicentre, clinical trial of burst spinal cord stimulation for neck and upper limb pain NU-BURST: a trial protocol.","BACKGROUND Spinal cord stimulation (SCS) is an established therapy for chronic neuropathic pain and most frequently utilised for Failed Back Surgery Syndrome (FBSS). BurstDR™ also known as DeRidder Burst-SCS, a novel waveform, has demonstrated superiority to conventional tonic stimulation of the thoracic spine in FBSS. There are case reports of an improvement in multidimensional pain outcomes using DeRidder Burst-SCS in the cervical spine for chronic neck and cervical radicular pain. The safety and efficacy of cervical DeRidder Burst-SCS stimulation still however remain undetermined. METHODS/DESIGN This is a prospective, multicentre feasibility trial evaluating the safety and therapeutic efficacy of DeRidder Burst-SCS stimulation for the treatment of chronic intractable neck pain with or without radiation to the arm, shoulder, and upper back. After baseline evaluation, subjects will undergo an SCS trial using the Abbott Invisible Trial system according to standard clinical procedures. During the trial phase, SCS leads will be implanted in the cervical epidural space. At the end of the SCS trial, subjects experiencing at least 50% pain relief will be considered for permanent implant. Pain intensity, medication usage, and other multidimensional pain outcomes will be collected. The timing of these will be at baseline, end of the SCS trial and at 3-, 6-, and 12-month visits. Incidence of adverse events will be collected throughout the study duration. DISCUSSION The results of this feasibility study will validate the efficacy and safety of DeRidder Burst-SCS stimulation in the cervical spine. The results obtained in this study will potentially be used to generate a level 1 evidence-based study with formal statistical hypotheses testing. TRIAL REGISTRATION www.clinicaltrials.gov Identifier: NCT03159169.",2021,There are case reports of an improvement in multidimensional pain outcomes using DeRidder Burst-SCS in the cervical spine for chronic neck and cervical radicular pain.,"['chronic intractable neck pain with or without radiation to the arm, shoulder, and upper back', 'chronic neck and cervical radicular pain']","['DeRidder Burst-SCS', 'cervical DeRidder Burst-SCS stimulation', 'burst spinal cord stimulation', 'Spinal cord stimulation (SCS', 'DeRidder Burst-SCS stimulation']","['pain relief', 'Pain intensity, medication usage, and other multidimensional pain outcomes', 'Incidence of adverse events']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0230101', 'cui_str': 'Upper back structure'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C4552559', 'cui_str': 'Cervical radicular pain'}]","[{'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0394477', 'cui_str': 'Neurostimulation of spinal cord tissue'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.097443,There are case reports of an improvement in multidimensional pain outcomes using DeRidder Burst-SCS in the cervical spine for chronic neck and cervical radicular pain.,"[{'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Al-Kaisy', 'Affiliation': 'Guys & St. Thomas NHS Foundation Trust, London, UK. alkaisy@aol.com.'}, {'ForeName': 'Girish', 'Initials': 'G', 'LastName': 'Vajramani', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Love-Jones', 'Affiliation': 'Southmead Hospital NHS Foundation Trust, Bristol, UK.'}, {'ForeName': 'Nikunj K', 'Initials': 'NK', 'LastName': 'Patel', 'Affiliation': 'Southmead Hospital NHS Foundation Trust, Bristol, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Royds', 'Affiliation': 'Guys & St. Thomas NHS Foundation Trust, London, UK.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Palmisani', 'Affiliation': 'Guys & St. Thomas NHS Foundation Trust, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Pang', 'Affiliation': 'Guys & St. Thomas NHS Foundation Trust, London, UK.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Wesley', 'Affiliation': 'Guys & St. Thomas NHS Foundation Trust, London, UK.'}, {'ForeName': 'Hyun-Joo', 'Initials': 'HJ', 'LastName': 'Park', 'Affiliation': 'Abbott, Plano, TX, USA.'}, {'ForeName': 'Adil', 'Initials': 'A', 'LastName': 'Raza', 'Affiliation': 'Abbott, Plano, TX, USA.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Agnesi', 'Affiliation': 'Abbott, Plano, TX, USA.'}]",Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,['10.1007/s10072-020-04907-3'] 780,33387398,A comparison of the efficacy of silicone gel containing onion extract and aloe vera to silicone gel sheets to prevent postoperative hypertrophic scars and keloids.,"BACKGROUND Hypertrophic scars and keloids are postsurgery problems. Some studies showed that onion extract and aloe vera might be beneficial for postoperative scars. However, few of the randomized clinical trials were investigated. AIMS To compare the efficacy of silicone gel containing onion extract and aloe vera (SGOA) to silicone gel sheets (SGS) to prevent postoperative hypertrophic scars and keloids. METHODS The prospective randomized assessor-blind controlled trial was conducted with 40 patients who had undergone surgery. The patients were divided into two groups: one treated with SGOA, the other with SGS. The patients were evaluated after 1, 2, and 3 months. The objective assessment was to determine the incidences of scarring, erythema, and melanin values using Mexameter, and pliability through Cutometer. The subjective assessment consisted of the patient and observer scar assessment scale (POSAS) and patient satisfaction. RESULTS After the 12-week follow-up, there was no statistically significant difference in the scarring incidence rate of both groups. There were no statistical differences in the POSAS score, erythema, and melanin value between both groups. Using objective assessment, pliability in the SGOA group was statistically significantly higher compared to the SGS group. Pain and itchiness significantly decreased in both groups. No adverse effects were reported in either group. CONCLUSION Silicone gel containing onion extract and aloe vera is effective as SGS for postoperative scar prevention.",2021,"After the twelve-week follow up, there was no statistically significant difference in the scarring incidence rate of both groups.",['forty patients who had undergone surgery'],"['silicone gel containing onion extract and aloe vera to silicone gel sheets', 'SGOA', 'SGOA, the other with SGS', 'silicone gel containing onion extract and aloe vera (SGOA) to silicone gel sheets (SGS', 'onion extract and aloe vera']","['incidences of scarring, erythema, and melanin values using Mexameter, and pliability through Cutometer', 'Pain and itchiness', 'postoperative hypertrophic scars and keloids', 'observer scar assessment scale (POSAS) and patient satisfaction', 'POSAS score, erythema, and melanin value', 'scarring incidence rate', 'adverse effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0599034', 'cui_str': 'Silicone Gels'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0949117', 'cui_str': 'Onion extract'}, {'cui': 'C0718405', 'cui_str': 'Aloe vera'}, {'cui': 'C0439643', 'cui_str': 'Sheets'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0025196', 'cui_str': 'Melanin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0162810', 'cui_str': 'Hypertrophic scar'}, {'cui': 'C0022548', 'cui_str': 'Keloid'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",40.0,0.0349412,"After the twelve-week follow up, there was no statistically significant difference in the scarring incidence rate of both groups.","[{'ForeName': 'Watsachon', 'Initials': 'W', 'LastName': 'Pangkanon', 'Affiliation': 'Skin Center, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.'}, {'ForeName': 'Putthiporn', 'Initials': 'P', 'LastName': 'Yenbutra', 'Affiliation': 'Surgery Department, Faculty of Medicine, Rajavithi Hospital, Bangkok, Thailand.'}, {'ForeName': 'Nanticha', 'Initials': 'N', 'LastName': 'Kamanamool', 'Affiliation': 'Skin Center, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.'}, {'ForeName': 'Apichaya', 'Initials': 'A', 'LastName': 'Tannirandorn', 'Affiliation': 'Relief and Community Health Bureau, The Thai Red Cross Society, Bangkok, Thailand.'}, {'ForeName': 'Montree', 'Initials': 'M', 'LastName': 'Udompataikul', 'Affiliation': 'Skin Center, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13933'] 781,33393175,"Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial.","BACKGROUND AND PURPOSE Botulinum toxin (BT) injection into the laryngeal muscles has been a standard treatment for spasmodic dysphonia (SD). However, few high-quality clinical studies have appeared, and BT is used off-label in most countries. METHODS We performed a multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial to obtain approval for BT (Botox) therapy in Japan. Twenty-four patients (22 with adductor SD and two with abductor SD) were enrolled. The primary end point was the change in the number of aberrant morae (phonemes) at 4 weeks after drug injection. The secondary end points included the change in the number of aberrant morae, GRBAS scale, Voice Handicap Index (VHI), and visual analog scale (VAS) over the entire study period. RESULTS In the adductor SD group, the number of aberrant morae at 4 weeks after injection was reduced by 7.0 ± 2.30 (mean ± SE) in the BT group and 0.2 ± 0.46 in the placebo group (p = 0.0148). The improvement persisted for 12 weeks following BT injections. The strain element in GRBAS scale significantly reduced at 2 weeks after BT treatment. The VHI and VAS scores as subjective parameters also improved. In the abductor SD group, one patient responded to treatment. Adverse events included breathy hoarseness (77.3%) and aspiration when drinking (40.9%) but were mild and resolved in 4 weeks. CONCLUSIONS Botulinum toxin injection was safe and efficacious for the treatment of SD. Based on these results, BT injection therapy was approved as an SD treatment in Japan.",2021,"Adverse events included breathy hoarseness (77.3%) and aspiration when drinking (40.9%) but were mild and resolved in 4 weeks. ","['Twenty-four patients (22 with adductor SD and 2 with abductor SD', 'intrinsic laryngeal muscles to treat spasmodic dysphonia', 'Japan']","['BT (Botox ® ) therapy', 'placebo', 'Botulinum toxin injection', 'Botulinum toxin (BT) injection', 'BT injection', 'BT injection therapy']","['VHI and VAS scores', 'breathy hoarseness', 'change in the number of aberrant morae (phonemes', 'number of aberrant morae', 'change in the number of aberrant morae, GRBAS scale, Voice Handicap Index (VHI) and visual analogue scale (VAS', 'GRBAS scale']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0264589', 'cui_str': 'Adductor spastic dysphonia'}, {'cui': 'C0264597', 'cui_str': 'Abductor spastic dysphonia'}, {'cui': 'C0225580', 'cui_str': 'Structure of intrinsic laryngeal muscle'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0264588', 'cui_str': 'Spastic dysphonia'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0700702', 'cui_str': 'Botox'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1321035', 'cui_str': 'Injection of botulinum toxin'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C2985106', 'cui_str': 'Voice handicap index'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0443127', 'cui_str': 'Aberrant'}, {'cui': 'C0451192', 'cui_str': 'GRBAS scale'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",24.0,0.471636,"Adverse events included breathy hoarseness (77.3%) and aspiration when drinking (40.9%) but were mild and resolved in 4 weeks. ","[{'ForeName': 'Masamitsu', 'Initials': 'M', 'LastName': 'Hyodo', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Kochi University, Nankoku, Japan.'}, {'ForeName': 'Asuka', 'Initials': 'A', 'LastName': 'Nagao', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Kochi University, Nankoku, Japan.'}, {'ForeName': 'Kento', 'Initials': 'K', 'LastName': 'Asano', 'Affiliation': 'Department of Medical Innovation, Osaka University Hospital, Suita, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Sakaguchi', 'Affiliation': 'Department of Engineering Informatics, Osaka Electro Communication University, Neyagawa, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Mizoguchi', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Omori', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Tada', 'Affiliation': 'Department of Otolaryngology, Fukushima Medical University, Fukushima, Japan.'}, {'ForeName': 'Hiromitsu', 'Initials': 'H', 'LastName': 'Hatakeyama', 'Affiliation': 'Department of Otolaryngology, Yokohama City University, Yokohama, Japan.'}, {'ForeName': 'Nobuhiko', 'Initials': 'N', 'LastName': 'Oridate', 'Affiliation': 'Department of Otolaryngology, Yokohama City University, Yokohama, Japan.'}, {'ForeName': 'Kensei', 'Initials': 'K', 'LastName': 'Naito', 'Affiliation': 'Academy of Nursing, Fujita Health University, Toyoake, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Iwata', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Fujita Health University, Toyoake, Japan.'}, {'ForeName': 'Hirotaka', 'Initials': 'H', 'LastName': 'Shinomiya', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Kobe University, Kobe.'}, {'ForeName': 'Hirotaka', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Department of Otolaryngology, Kawasaki Medical School, Kurashiki, Japan.'}, {'ForeName': 'Tetsuji', 'Initials': 'T', 'LastName': 'Sanuki', 'Affiliation': 'Department of Otolaryngology, Nagoya City University, Nagoya, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Yumoto', 'Affiliation': 'Department of Otolaryngology, Kumamoto University, Kumamoto, Japan.'}]",European journal of neurology,['10.1111/ene.14714'] 782,33384892,Gradient Boosting Decision Tree Algorithm for the Prediction of Postoperative Intraocular Lens Position in Cataract Surgery.,"Purpose To develop a method for predicting postoperative anterior chamber depth (ACD) in cataract surgery patients based on preoperative biometry, demographics, and intraocular lens (IOL) power. Methods Patients who underwent cataract surgery and had both preoperative and postoperative biometry measurements were included. Patient demographics and IOL power were collected from the Sight Outcomes Research Collaborative (SOURCE) database. A gradient-boosting decision tree model was developed to predict the postoperative ACD. The mean absolute error (MAE) and median absolute error (MedAE) were used as evaluation metrics. The performance of the proposed method was compared with five existing formulas. Results In total, 847 patients were assigned randomly in a 4:1 ratio to a training/validation set (678 patients) and a testing set (169 patients). Using preoperative biometry and patient sex as predictors, the presented method achieved an MAE of 0.106 ± 0.098 (SD) on the testing set, and a MedAE of 0.082. MAE was significantly lower than that of the five existing methods ( P < 0.01). When keratometry was excluded, our method attained an MAE of 0.123 ± 0.109, and a MedAE of 0.093. When IOL power was used as an additional predictor, our method achieved an MAE of 0.105 ± 0.091 and a MedAE of 0.080. Conclusions The presented machine learning method achieved greater accuracy than previously reported methods for the prediction of postoperative ACD. Translational Relevance Increasing accuracy of postoperative ACD prediction with the presented algorithm has the potential to improve refractive outcomes in cataract surgery.",2020,MAE was significantly lower than that of the five existing methods ( P < 0.01).,"['Methods\n\n\nPatients who underwent cataract surgery and had both preoperative and postoperative biometry measurements were included', 'cataract surgery patients', 'Cataract Surgery', 'cataract surgery', '847 patients']",[],"['MAE', 'Patient demographics and IOL power', 'postoperative anterior chamber depth (ACD', 'mean absolute error (MAE) and median absolute error (MedAE', 'preoperative biometry, demographics, and intraocular lens (IOL) power']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0005544', 'cui_str': 'Biometry'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0429521', 'cui_str': 'Intraocular lens power'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0429492', 'cui_str': 'Depth of anterior chamber'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0005544', 'cui_str': 'Biometry'}, {'cui': 'C0023311', 'cui_str': 'Insertion of intraocular lens'}]",847.0,0.0356503,MAE was significantly lower than that of the five existing methods ( P < 0.01).,"[{'ForeName': 'Tingyang', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Yang', 'Affiliation': 'Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Stein', 'Affiliation': 'Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Nambi', 'Initials': 'N', 'LastName': 'Nallasamy', 'Affiliation': 'Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.'}]",Translational vision science & technology,['10.1167/tvst.9.13.38'] 783,33386619,A randomized controlled trial of a forgiveness intervention program with female acid attack survivors in Pakistan.,"Despite the traumatic effects of acid violence on its victims, treatment options are very limited. The present study was aimed at examining the efficacy of a forgiveness intervention with female survivors of acid attack violence in Pakistan. Female acid attack victims in Pakistan were randomized to either a forgiveness group (n = 8) or a treatment-as-usual (TAU; n = 8) control group. The forgiveness group received twice-a-week forgiveness sessions for 4 months, whereas the TAU group either received typical psychological treatment sessions for acid attack victims or no treatment. All participants were assessed on their levels of forgiveness, anger, anxiety, depression, and hope four times prior to the 4-month intervention period, twice after the intervention period, and once at the 1-year follow-up. Posttreatment, the forgiveness intervention group showed greater improvement in hope, anger, anxiety, and depression when compared with the TAU group. Upon further examinations, both groups improved on forgiveness from pretreatment to posttreatment, but the forgiveness group had a higher baseline. From pretreatment to the 12-month follow-up, the forgiveness group, when compared with the TAU group, showed greater improvement in all areas except for depression. This is the first study that examined the effects of a forgiveness intervention for acid attack victims in Pakistan. Results showing the improvement posttreatment as well as over a 1-year period posttreatment are encouraging.",2021,"Post treatment, the forgiveness intervention group showed greater improvement in hope, anger, anxiety, and depression when compared with the TAU group.","['Female acid attack victims in Pakistan', 'Female Acid Attack Survivors in Pakistan', 'female survivors of acid attack violence in Pakistan', 'acid attack victims in Pakistan']","['forgiveness intervention', 'forgiveness group (n = 8) or a treatment-as-usual (TAU; n = 8) control group', 'Forgiveness Intervention Program', 'typical psychological treatment sessions for acid attack victims or no treatment']","['depression', 'levels of forgiveness, anger, anxiety, depression', 'hope, anger, anxiety, and depression']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0042693', 'cui_str': 'Violence'}]","[{'cui': 'C0871753', 'cui_str': 'Forgiveness'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0004063', 'cui_str': 'Assault'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0871753', 'cui_str': 'Forgiveness'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0392347', 'cui_str': 'Hope'}]",,0.0187046,"Post treatment, the forgiveness intervention group showed greater improvement in hope, anger, anxiety, and depression when compared with the TAU group.","[{'ForeName': 'Zaineb', 'Initials': 'Z', 'LastName': 'Haroon', 'Affiliation': 'Department of Psychology, Government College University, Lahore, Lahore, Pakistan.'}, {'ForeName': 'Rabia', 'Initials': 'R', 'LastName': 'Iftikhar', 'Affiliation': 'Department of Psychology, Government College University, Lahore, Lahore, Pakistan.'}, {'ForeName': 'Jichan J', 'Initials': 'JJ', 'LastName': 'Kim', 'Affiliation': 'Department of Psychology, Liberty University, Lynchburg, Virginia, USA.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Volk', 'Affiliation': 'Department of Counselor Education and Family Studies, Liberty University, Virginia, USA.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Enright', 'Affiliation': 'Educational Psychology, University of Wisconsin-Madison, Madison, Wisconsin, USA.'}]",Clinical psychology & psychotherapy,['10.1002/cpp.2545'] 784,33389797,5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.,"There are no FDA-approved treatments for cannabis use disorder (CUD). Preclinical research has shown that the 5HT-2C agonist lorcaserin attenuates cue-induced reinstatement of THC seeking and self-administration. The goal of this placebo-controlled, counterbalanced, within-subject human laboratory study was to examine lorcaserin's effects on cannabis intoxication and self-administration. Lorcaserin (10 mg BID) was administered during one of two 13-day inpatient phases and placebo during the other; each phase was separated by ≥7 days of washout. Inpatient phases comprised (1) standardized cannabis administration (7.0% THC) at no financial cost (intoxication), counterbalanced with (2) the option to self-administer cannabis following either 0 or 3 days of abstinence. Cognitive task performance, food intake, subjective ratings of drug effects, objective/subjective sleep measures, and tobacco cigarette use were also assessed. Fifteen normal-weight, daily cannabis users (4F, 11M) not seeking treatment for CUD completed the study. Lorcaserin significantly reduced cannabis self-administration following 0 and 3 days of cannabis abstinence and also reduced craving for cannabis during abstinence. Lorcaserin produced small but significant increases in positive cannabis ratings and body weight relative to placebo. Lorcaserin also reduced tobacco cigarette smoking on days of cannabis administration relative to placebo. During abstinence, subjective but not objective measures of sleep quality worsened during lorcaserin maintenance. Overall, lorcaserin's ability to decrease drug taking and cannabis craving in nontreatment-seeking cannabis users supports further investigation of 5HT-2C agonists as potential pharmacotherapies for CUD.",2021,"Overall, lorcaserin's ability to decrease drug taking and cannabis craving in nontreatment-seeking cannabis users supports further investigation of 5HT-2C agonists as potential pharmacotherapies for CUD.","['daily cannabis smokers', 'Fifteen normal-weight, daily cannabis users (4F, 11M) not seeking treatment for CUD completed the study']","['5HT-2C agonist lorcaserin', 'Lorcaserin', 'placebo', 'standardized cannabis administration (7.0% THC) at no financial cost (intoxication), counterbalanced with (2) the option to self-administer cannabis']","['sleep quality', 'Cognitive task performance, food intake, subjective ratings of drug effects, objective/subjective sleep measures, and tobacco cigarette use', 'tobacco cigarette smoking', 'positive cannabis ratings and body weight relative']","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C2350948', 'cui_str': 'lorcaserin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0728866', 'cui_str': 'drug effects'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0080103', 'cui_str': 'Relative'}]",15.0,0.104401,"Overall, lorcaserin's ability to decrease drug taking and cannabis craving in nontreatment-seeking cannabis users supports further investigation of 5HT-2C agonists as potential pharmacotherapies for CUD.","[{'ForeName': 'Caroline A', 'Initials': 'CA', 'LastName': 'Arout', 'Affiliation': 'Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.'}, {'ForeName': 'Ziva D', 'Initials': 'ZD', 'LastName': 'Cooper', 'Affiliation': 'UCLA Cannabis Research Initiative, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Stephanie Collins', 'Initials': 'SC', 'LastName': 'Reed', 'Affiliation': 'Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Foltin', 'Affiliation': 'Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.'}, {'ForeName': 'Sandra D', 'Initials': 'SD', 'LastName': 'Comer', 'Affiliation': 'Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.'}, {'ForeName': 'Frances R', 'Initials': 'FR', 'LastName': 'Levin', 'Affiliation': 'Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Haney', 'Affiliation': 'Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.'}]",Addiction biology,['10.1111/adb.12993'] 785,33369354,Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson's Disease.,"BACKGROUND The subthalamic nucleus is the preferred neurosurgical target for deep-brain stimulation to treat cardinal motor features of Parkinson's disease. Focused ultrasound is an imaging-guided method for creating therapeutic lesions in deep-brain structures, including the subthalamic nucleus. METHODS We randomly assigned, in a 2:1 ratio, patients with markedly asymmetric Parkinson's disease who had motor signs not fully controlled by medication or who were ineligible for deep-brain stimulation surgery to undergo focused ultrasound subthalamotomy on the side opposite their main motor signs or a sham procedure. The primary efficacy outcome was the between-group difference in the change from baseline to 4 months in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score (i.e., part III) for the more affected body side (range, 0 to 44, with higher scores indicating worse parkinsonism) in the off-medication state. The primary safety outcome (procedure-related complications) was assessed at 4 months. RESULTS Among 40 enrolled patients, 27 were assigned to focused ultrasound subthalamotomy (active treatment) and 13 to the sham procedure (control). The mean MDS-UPDRS III score for the more affected side decreased from 19.9 at baseline to 9.9 at 4 months in the active-treatment group (least-squares mean difference, 9.8 points; 95% confidence interval [CI], 8.6 to 11.1) and from 18.7 to 17.1 in the control group (least-squares mean difference, 1.7 points; 95% CI, 0.0 to 3.5); the between-group difference was 8.1 points (95% CI, 6.0 to 10.3; P<0.001). Adverse events in the active-treatment group were dyskinesia in the off-medication state in 6 patients and in the on-medication state in 6, which persisted in 3 and 1, respectively, at 4 months; weakness on the treated side in 5 patients, which persisted in 2 at 4 months; speech disturbance in 15 patients, which persisted in 3 at 4 months; facial weakness in 3 patients, which persisted in 1 at 4 months; and gait disturbance in 13 patients, which persisted in 2 at 4 months. In 6 patients in the active-treatment group, some of these deficits were present at 12 months. CONCLUSIONS Focused ultrasound subthalamotomy in one hemisphere improved motor features of Parkinson's disease in selected patients with asymmetric signs. Adverse events included speech and gait disturbances, weakness on the treated side, and dyskinesia. (Funded by Insightec and others; ClinicalTrials.gov number, NCT03454425.).",2020,"Focused ultrasound is an imaging-guided method for creating therapeutic lesions in deep-brain structures, including the subthalamic nucleus. ","['40 enrolled patients, 27 were assigned to focused', ""patients with markedly asymmetric Parkinson's disease who had motor signs not fully controlled by medication or who were ineligible for deep-brain stimulation surgery to undergo focused ultrasound subthalamotomy on the side opposite their main motor signs or a sham procedure"", ""Parkinson's Disease"", 'selected patients with asymmetric signs']","['Ultrasound Subthalamotomy', 'ultrasound subthalamotomy', 'ultrasound subthalamotomy (active treatment) and 13 to the sham procedure (control']","['speech disturbance', 'primary safety outcome (procedure-related complications', ""Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score (i.e., part III) for the more affected body side"", 'gait disturbance', 'Adverse events', 'dyskinesia', 'facial weakness', 'mean MDS-UPDRS III score', 'speech and gait disturbances, weakness on the treated side, and dyskinesia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0522501', 'cui_str': 'Massive'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0332298', 'cui_str': 'Controlled by'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0233715', 'cui_str': 'Disturbance in speech'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0575081', 'cui_str': 'Abnormal gait'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013384', 'cui_str': 'Dyskinesia'}, {'cui': 'C0427055', 'cui_str': 'Weakness of face muscles'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C3714552', 'cui_str': 'Debility'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]",40.0,0.0888395,"Focused ultrasound is an imaging-guided method for creating therapeutic lesions in deep-brain structures, including the subthalamic nucleus. ","[{'ForeName': 'Raúl', 'Initials': 'R', 'LastName': 'Martínez-Fernández', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Jorge U', 'Initials': 'JU', 'LastName': 'Máñez-Miró', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Rodríguez-Rojas', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Del Álamo', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Binit B', 'Initials': 'BB', 'LastName': 'Shah', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Frida', 'Initials': 'F', 'LastName': 'Hernández-Fernández', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'Pineda-Pardo', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Mariana H G', 'Initials': 'MHG', 'LastName': 'Monje', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Fernández-Rodríguez', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Sperling', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mata-Marín', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Pasqualina', 'Initials': 'P', 'LastName': 'Guida', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Alonso-Frech', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Obeso', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Gasca-Salas', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Vela-Desojo', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'W Jeffrey', 'Initials': 'WJ', 'LastName': 'Elias', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}, {'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'Obeso', 'Affiliation': 'From HM Centro Integral en Neurociencias AC (CINAC), University Hospital HM Puerta del Sur, CEU San Pablo University, Mostoles (R.M.-F., J.U.M.-M., R.R.-R., M.A., F.H.-F., J.A.P.-P., M.H.G.M., B.F.-R., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.), and the Network Center for Biomedical Research on Neurodegenerative Diseases, Carlos III Institute, Madrid (R.M.-F., R.R.-R., M.A., F.H.-F., J.A.P.-P., D.M.-M., P.G., F.A.-F., I.O., C.G.-S., L.V.-D., J.A.O.) - both in Spain; and the University of Virginia Health Sciences Center, Charlottesville (B.B.S., S.A.S., W.J.E.).'}]",The New England journal of medicine,['10.1056/NEJMoa2016311'] 786,33385191,The immediate effect of two lumbar stabilization methods on postural control parameters and their reliability during two balance tasks.,"Background : Lumbosacral orthosis (LSO) and/or the isolated contraction of the transversus abdominis muscle by the abdominal drawing-in maneuver (ADIM) can increase lumbar stiffness, consequently influencing postural control. The purpose of this study was to compare the effects of LSO and ADIM on postural control during two balance tasks and determine their reliability. Methods : Twenty participants (50% men) randomly performed three experimental conditions: 1) without lumbar stabilization, 2) with LSO), and 3) with ADIM. Each experimental condition was tested in two postural tasks: semi-tandem and one-legged stance on a force platform for 30 seconds, while the Center of pressure postural (COP) parameters were computed. Results : The two methods of lumbar stabilization were comparable and did not significantly reduce the COP values across time, even though a few individuals presented a change in their COP data above the levels of measurement errors. The reliability of these measurements was generally acceptable and sometimes excellent ( ≥ 0.90 and ≤10% error measurement). Conclusions : Both LSO and isolated contraction of the transversus abdominis muscle by ADIM do not change postural control in one-legged stance and in semi-tandem tasks. These results have implications for use or not these methods for postural control on a rehabilitation perspective.",2021,The reliability of these measurements was generally acceptable and sometimes excellent ( ≥ 0.90 and ≤10% error measurement). ,['Twenty participants (50% men'],"['lumbar stabilization methods', 'LSO and ADIM', 'randomly performed three experimental conditions: 1) without lumbar stabilization, 2) with LSO), and 3) with ADIM', ' : Lumbosacral orthosis (LSO']","['lumbar stiffness', 'postural control parameters', 'COP values']","[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0023376', 'cui_str': 'Lesotho'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0450206', 'cui_str': 'Lumbosacral'}, {'cui': 'C0006086', 'cui_str': 'Brace'}]","[{'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0056471', 'cui_str': 'creatinolfosfate'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",50.0,0.0227922,The reliability of these measurements was generally acceptable and sometimes excellent ( ≥ 0.90 and ≤10% error measurement). ,"[{'ForeName': 'Mohamed Abdelhafid', 'Initials': 'MA', 'LastName': 'Kadri', 'Affiliation': 'Département des Sciences de la Santé, Centre intersectoriel en santé durable, Laboratoire de recherche BioNR - Université du Québec à santé (UQAC), Saguenay, Québec, Canada.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Violette', 'Affiliation': ""Programme de physiothérapie de l'Université McGill offert en extension à l'Université du Québec à Chicoutimi (UQAC), Saguenay, Québec, Canada.""}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Dallaire', 'Affiliation': ""Programme de physiothérapie de l'Université McGill offert en extension à l'Université du Québec à Chicoutimi (UQAC), Saguenay, Québec, Canada.""}, {'ForeName': 'Fábio Carlos Lucas', 'Initials': 'FCL', 'LastName': 'de Oliveira', 'Affiliation': 'Département des Sciences de la Santé, Centre intersectoriel en santé durable, Laboratoire de recherche BioNR - Université du Québec à santé (UQAC), Saguenay, Québec, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Lavallière', 'Affiliation': 'Département des Sciences de la Santé, Centre intersectoriel en santé durable, Laboratoire de recherche BioNR - Université du Québec à santé (UQAC), Saguenay, Québec, Canada.'}, {'ForeName': 'Suzy', 'Initials': 'S', 'LastName': 'Ngomo', 'Affiliation': 'Département des Sciences de la Santé, Centre intersectoriel en santé durable, Laboratoire de recherche BioNR - Université du Québec à santé (UQAC), Saguenay, Québec, Canada.'}, {'ForeName': 'Louis-David', 'Initials': 'LD', 'LastName': 'Beaulieu', 'Affiliation': 'Département des Sciences de la Santé, Centre intersectoriel en santé durable, Laboratoire de recherche BioNR - Université du Québec à santé (UQAC), Saguenay, Québec, Canada.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Larivière', 'Affiliation': 'Occupational Health and Safety Research Institute Robert-Sauvé, 505 boul. De Maisonneuve Ouest, Montreal, Quebec, Canada.'}, {'ForeName': 'Rubens A', 'Initials': 'RA', 'LastName': 'da Silva', 'Affiliation': 'Département des Sciences de la Santé, Centre intersectoriel en santé durable, Laboratoire de recherche BioNR - Université du Québec à santé (UQAC), Saguenay, Québec, Canada.'}]",The Journal of manual & manipulative therapy,['10.1080/10669817.2020.1864961'] 787,33387179,Examining Organizational Factors Supporting the Adoption and Use of Evidence-Based Interventions.,"The purpose of this study was to develop a greater understanding of the factors influencing the adoption of evidence-based interventions in outpatient mental health clinics serving youth. An improved understanding of these factors can potentially improve efforts to ensure effective adoption, implementation, and sustainment of evidence-based interventions, and thus improve treatment for youth in mental health settings. This explanatory cross-sectional study involves secondary data analysis of a longitudinal randomized control intervention trial. The SEM- based model that was tested supported the primary hypothesis that a more supportive organizational climate with greater readiness for change is more likely to improve the chances for the adoption of evidence-based interventions in outpatient mental health clinics serving youths.",2021,The SEM- based model that was tested supported the primary hypothesis that a more supportive organizational climate with greater readiness for change is more likely to improve the chances for the adoption of evidence-based interventions in outpatient mental health clinics serving youths.,"['outpatient mental health clinics serving youths', 'outpatient mental health clinics serving youth']",[],[],"[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C3839912', 'cui_str': 'Mental health clinic'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]",[],[],,0.0618809,The SEM- based model that was tested supported the primary hypothesis that a more supportive organizational climate with greater readiness for change is more likely to improve the chances for the adoption of evidence-based interventions in outpatient mental health clinics serving youths.,"[{'ForeName': 'Hanni B', 'Initials': 'HB', 'LastName': 'Flaherty', 'Affiliation': 'Wurzweiler School of Social Work, Yeshiva University, 2495 Amsterdam Avenue, New York, NY, 10033, USA. HanniFlaherty@gmail.com.'}, {'ForeName': 'Lindsay A', 'Initials': 'LA', 'LastName': 'Bornheimer', 'Affiliation': 'University of Michigan School of Social Work, 180 South University Avenue, Ann Arbor, MI, 48109, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Hamovitch', 'Affiliation': 'McSilver Institute for Poverty Policy & Research, Silver School of Social Work, New York University, 41 East 11th Street, New York, NY, 10003, USA.'}, {'ForeName': 'Elene', 'Initials': 'E', 'LastName': 'Garay', 'Affiliation': 'McSilver Institute for Poverty Policy & Research, Silver School of Social Work, New York University, 41 East 11th Street, New York, NY, 10003, USA.'}, {'ForeName': 'Maria L', 'Initials': 'ML', 'LastName': 'Mini de Zitella', 'Affiliation': 'McSilver Institute for Poverty Policy & Research, Silver School of Social Work, New York University, 41 East 11th Street, New York, NY, 10003, USA.'}, {'ForeName': 'Mary C', 'Initials': 'MC', 'LastName': 'Acri', 'Affiliation': 'McSilver Institute for Poverty Policy & Research, New York University Medical Center, 41 East 11th Street, New York, NY, 10003, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Mckay', 'Affiliation': 'Brown School, Washington University in St. Louis, One Brookings Drive, St. Louis, MO, 63130, USA.'}]",Community mental health journal,['10.1007/s10597-020-00751-z'] 788,33392930,Feasibility of Conducting a Trial Assessing Benefits and Risks of Planned Caesarean Section Versus Planned Vaginal Birth: A Cross-Sectional Study.,"INTRODUCTION Though interest is growing for trials comparing planned delivery mode (vaginal delivery [VD]; cesarean section [CS]) in low-risk nulliparous women, appropriate study design is unclear. Our objective was to assess feasibility of three designs (preference trial [PCT], randomized controlled trial [RCT], partially randomized patient preference trial [PRPPT]) for a trial comparing planned delivery mode in low-risk women. METHODS A cross-sectional survey of low-risk, nulliparous pregnant women (N = 416) and healthcare providers (N = 168) providing prenatal care and/or labor/delivery services was conducted in Argentina (2 public, 2 private hospitals). Proportion of pregnant women and providers willing to participate in each design and reasons for not participating were determined. RESULTS Few women (< 15%) or professionals (33.3%) would participate in an RCT, though more would participate in PCTs (88% women; 65.9% professionals) or PRPPTs (44.4% public, 63.4% private sector women; 44.0% professionals). However, most women would choose vaginal delivery in the PCT and PRPPT (> 85%). Believing randomization unacceptable (RCT, PRPPT) and desiring choice of delivery mode (RCT) were women's reasons for not participating. For providers, commonly cited reasons for not participating included unacceptability of performing CS without medical indication, difficulty obtaining informed consent, discomfort enrolling patients (all designs), and violating women's right to choose (RCT). CONCLUSIONS FOR PRACTICE Important limitations were found for each trial design evaluated. The necessity of stronger evidence regarding delivery mode in low-risk women suggests consideration of additional designs, such as a rigorously designed cohort study or an RCT within an obstetric population with equivocal CS indications.",2021,"Few women (< 15%) or professionals (33.3%) would participate in an RCT, though more would participate in PCTs (88% women; 65.9% professionals) or PRPPTs (44.4% public, 63.4% private sector women; 44.0% professionals).","['low-risk women', 'low-risk nulliparous women', 'A cross-sectional survey of low-risk, nulliparous pregnant women (N\u2009=\u2009416) and healthcare providers (N\u2009=\u2009168) providing prenatal care and/or labor/delivery services was conducted in Argentina (2 public, 2 private hospitals']","['Planned Caesarean Section Versus Planned Vaginal Birth', 'planned delivery mode (vaginal delivery [VD]; cesarean section [CS', 'PRPPT']",[],"[{'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C4319556', 'cui_str': '168'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0003761', 'cui_str': 'Argentina'}, {'cui': 'C0033173', 'cui_str': 'Private hospital'}]","[{'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}]",[],,0.170553,"Few women (< 15%) or professionals (33.3%) would participate in an RCT, though more would participate in PCTs (88% women; 65.9% professionals) or PRPPTs (44.4% public, 63.4% private sector women; 44.0% professionals).","[{'ForeName': 'Melissa M', 'Initials': 'MM', 'LastName': 'Amyx', 'Affiliation': 'School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St., #2400, New Orleans, LA, 70112, USA. mamyx@tulane.edu.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Althabe', 'Affiliation': ""Mother and Child's Health Research Department, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Dr. Emilio Ravignani 2024 (C1414CPV), Buenos Aires, Argentina.""}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Rivo', 'Affiliation': 'Duke University School of Medicine, Duke University, 8 Duke University Medical Center Greenspace, Durham, NC, 27703, USA.'}, {'ForeName': 'Verónica', 'Initials': 'V', 'LastName': 'Pingray', 'Affiliation': ""Mother and Child's Health Research Department, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Dr. Emilio Ravignani 2024 (C1414CPV), Buenos Aires, Argentina.""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Minckas', 'Affiliation': ""Mother and Child's Health Research Department, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Dr. Emilio Ravignani 2024 (C1414CPV), Buenos Aires, Argentina.""}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Belizán', 'Affiliation': ""Mother and Child's Health Research Department, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Dr. Emilio Ravignani 2024 (C1414CPV), Buenos Aires, Argentina.""}, {'ForeName': 'Luz', 'Initials': 'L', 'LastName': 'Gibbons', 'Affiliation': ""Mother and Child's Health Research Department, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Dr. Emilio Ravignani 2024 (C1414CPV), Buenos Aires, Argentina.""}, {'ForeName': 'Gerardo T', 'Initials': 'GT', 'LastName': 'Murga', 'Affiliation': 'Instituto de Maternidad Y Ginecología Nuestra Señora de Las Mercedes, Av. Mate de Luna 1535, 4000, San Miguel de Tucumán, Tucumán Province, Argentina.'}, {'ForeName': 'Ángel E', 'Initials': 'ÁE', 'LastName': 'Fiorillo', 'Affiliation': 'Centro de Educación Médica E Investigaciones Clínicas ""Norberto Quirno"" (CEMIC), Av. E. Galván 4102, C1431FWO, Buenos Aires, Argentina.'}, {'ForeName': 'Julio D', 'Initials': 'JD', 'LastName': 'Malamud', 'Affiliation': 'Sanatorio de La Mujer, San Luis 2493, S2002, Rosario, Santa Fe, Argentina.'}, {'ForeName': 'Roberto A', 'Initials': 'RA', 'LastName': 'Casale', 'Affiliation': 'Hospital Nacional A. Posadas, El Palomar, Buenos Aires, Argentina.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Cormick', 'Affiliation': ""Mother and Child's Health Research Department, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Dr. Emilio Ravignani 2024 (C1414CPV), Buenos Aires, Argentina.""}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'Belizán', 'Affiliation': ""Mother and Child's Health Research Department, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Dr. Emilio Ravignani 2024 (C1414CPV), Buenos Aires, Argentina.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Maternal and child health journal,['10.1007/s10995-020-03073-4'] 789,33389233,Does spaced education improve clinical knowledge among Family Medicine residents? A cluster randomized controlled trial.,"Spaced education is a learning strategy to improve knowledge acquisition and retention. To date, no robust evidence exists to support the utility of spaced education in the Family Medicine residency. We aimed to test whether alerts to encourage spaced education can improve clinical knowledge as measured by scores on the Canadian Family Medicine certification examination. METHOD We conducted a cluster randomized controlled trial to empirically and pragmatically test spaced education using two versions of the Family Medicine Study Guide mobile app. 12 residency training programs in Canada agreed to participate. At six intervention sites, we consented 335 of the 654 (51%) eligible residents. Residents in the intervention group were sent alerts through the app to encourage the answering of questions linked to clinical cases. At six control sites, 299 of 586 (51%) residents consented. Residents in the control group received the same app but with no alerts. Incidence rates of case completion between trial arms were compared using repeated measures analysis. We linked residents in both trial arms to their knowledge scores on the certification examination of the College of Family Physicians of Canada. RESULTS Over 67 weeks, there was no statistically significant difference in the completion of clinical cases by participants. The difference in mean exam scores and the associated confidence interval did not exceed the pre-defined limit of 4 percentage points. CONCLUSION Further research is recommended before deploying spaced educational interventions in the Family Medicine residency to improve knowledge.",2021,"The difference in mean exam scores and the associated confidence interval did not exceed the pre-defined limit of 4 percentage points. ","['Family Medicine residents', '12 residency training programs in Canada agreed to participate', 'College of Family Physicians of Canada', 'At six intervention sites, we consented 335 of the 654 (51%) eligible residents']",[],['mean exam scores and the associated confidence interval'],"[{'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0035182', 'cui_str': 'Residency'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C1704221', 'cui_str': 'Family medicine specialist'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C4709307', 'cui_str': '335'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}]",,0.0755889,"The difference in mean exam scores and the associated confidence interval did not exceed the pre-defined limit of 4 percentage points. ","[{'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Grad', 'Affiliation': 'Herzl Family Practice Centre, McGill University, 3755 Cote Ste Catherine Road, Montreal, H3T 1E2, Canada. Roland.grad@mcgill.ca.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Leger', 'Affiliation': 'Western University, London, Canada.'}, {'ForeName': 'Janusz', 'Initials': 'J', 'LastName': 'Kaczorowski', 'Affiliation': 'Université de Montréal, Montreal, Canada.'}, {'ForeName': 'Tibor', 'Initials': 'T', 'LastName': 'Schuster', 'Affiliation': 'Family Medicine, McGill University, Montreal, Canada.'}, {'ForeName': 'Samara', 'Initials': 'S', 'LastName': 'Adler', 'Affiliation': 'Université de Montréal, Montreal, Canada.'}, {'ForeName': 'Marya', 'Initials': 'M', 'LastName': 'Aman', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Archibald', 'Affiliation': 'University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Beaulieu', 'Affiliation': 'Université de Sherbrooke, Sherbrooke, Canada.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Chmelicek', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Evelyn', 'Initials': 'E', 'LastName': 'Cornelissen', 'Affiliation': 'University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Delleman', 'Affiliation': 'McMaster University, Hamilton, Canada.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Hadj-Mimoune', 'Affiliation': 'Université de Montréal, Montreal, Canada.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Horvey', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Macaluso', 'Affiliation': 'Western University, London, Canada.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Mintsioulis', 'Affiliation': 'University of Calgary, Calgary, Canada.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Murdoch', 'Affiliation': 'University of Toronto, Toronto, Canada.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Ng', 'Affiliation': 'University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Papineau', 'Affiliation': 'Université de Montréal, Montreal, Canada.'}, {'ForeName': 'Sohil', 'Initials': 'S', 'LastName': 'Rangwala', 'Affiliation': 'University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Rousseau', 'Affiliation': 'University of Toronto, Toronto, Canada.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Rudkin', 'Affiliation': 'Family Medicine, McGill University, Montreal, Canada.'}, {'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'Schabort', 'Affiliation': 'McMaster University, Hamilton, Canada.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Schultz', 'Affiliation': ""Queen's University, Kingston, Canada.""}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Snow', 'Affiliation': ""Memorial University of Newfoundland, St. John's, Canada.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Wong', 'Affiliation': 'Western University, London, Canada.'}, {'ForeName': 'Pearson', 'Initials': 'P', 'LastName': 'Wu', 'Affiliation': 'Herzl Family Practice Centre, McGill University, 3755 Cote Ste Catherine Road, Montreal, H3T 1E2, Canada.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Brailovsky', 'Affiliation': 'Université Laval, Quebec City, Canada.'}]",Advances in health sciences education : theory and practice,['10.1007/s10459-020-10020-z'] 790,33359603,tDCS-induced modulation of GABA concentration and dopamine release in the human brain: A combination study of magnetic resonance spectroscopy and positron emission tomography.,"BACKGROUND Transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) hypothetically modulates cognitive functions by facilitating or inhibiting neuronal activities chiefly in the cerebral cortex. The effect of tDCS in the deeper brain region, the basal ganglia-cortical circuit, remains unknown. OBJECTIVE To investigate the interaction between γ-aminobutyric acid (GABA) concentrations and dopamine release following tDCS. METHOD This study used a randomized, placebo-controlled, double-blind, crossover design. Seventeen healthy male subjects underwent active and sham tDCS (13 min twice at an interval of 20 min) with the anode placed at the left DLPFC and the cathode at the right DLPFC, followed by examinations with [ 11 C]-raclopride positron emission topography (PET) and GABA-magnetic resonance spectroscopy (MRS). MRS voxels were set in the left DLPFC and bilateral striata. Paired t-tests and regression analyses were performed for PET and MRS parameters. RESULTS MRS data analyses showed elevations in GABA in the left striatum along with moderate reductions in the right striatum and the left DLPFC after active tDCS. PET data analyses showed that reductions in [ 11 C]-raclopride binding potentials (increase in dopamine release) in the right striatum were inversely correlated with those in the left striatum after active tDCS. GABA reductions in the left DLPFC positively correlated with elevations in GABA in the left striatum and with increases in right striatal dopamine release and negatively correlated with increases in left striatal dopamine release. CONCLUSION The present results suggest that tDCS to the DLPFC modulates dopamine-GABA functions in the basal ganglia-cortical circuit.",2021,PET data analyses showed that reductions in [ 11 C]-raclopride binding potentials (increase in dopamine release) in the right striatum were inversely correlated with those in the left striatum after active tDCS.,"['human brain', 'Seventeen healthy male subjects underwent']","['placebo', 'magnetic resonance spectroscopy and positron emission tomography', 'tDCS', 'Transcranial direct current stimulation (tDCS', 'active and sham tDCS (13\xa0min twice at an interval of 20\xa0min) with the anode placed at the left DLPFC and the cathode at the right DLPFC, followed by examinations with [ 11 C]-raclopride positron emission topography (PET) and GABA-magnetic resonance spectroscopy (MRS']","['GABA reductions', 'right striatal dopamine release', 'left striatal dopamine release', 'MRS voxels']","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0003103', 'cui_str': 'Anode'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0007441', 'cui_str': 'Cathode'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0302944', 'cui_str': 'Carbon-11'}, {'cui': 'C0072953', 'cui_str': 'Raclopride'}, {'cui': 'C0032744', 'cui_str': 'Positive beta particle'}, {'cui': 'C0233929', 'cui_str': 'Emission'}, {'cui': 'C0016904', 'cui_str': 'Gamma-aminobutyric acid'}]","[{'cui': 'C0016904', 'cui_str': 'Gamma-aminobutyric acid'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}]",17.0,0.0419809,PET data analyses showed that reductions in [ 11 C]-raclopride binding potentials (increase in dopamine release) in the right striatum were inversely correlated with those in the left striatum after active tDCS.,"[{'ForeName': 'Tomoyasu', 'Initials': 'T', 'LastName': 'Bunai', 'Affiliation': 'Department of Biofunctional Imaging, Preeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Tetsu', 'Initials': 'T', 'LastName': 'Hirosawa', 'Affiliation': 'Department of Psychiatry and Neurobiology, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Mitsuru', 'Initials': 'M', 'LastName': 'Kikuchi', 'Affiliation': 'Department of Psychiatry and Neurobiology, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Fukai', 'Affiliation': 'Department of Psychiatry and Neurobiology, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Masamichi', 'Initials': 'M', 'LastName': 'Yokokura', 'Affiliation': 'Department of Psychiatry, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Shigeru', 'Initials': 'S', 'LastName': 'Ito', 'Affiliation': 'Hamamatsu Medical Imaging Center, Hamamatsu Medical Photonics Foundation, Hamamatsu, Japan; Global Strategic Challenge Center, Hamamatsu Photonics KK, Hamamatsu, Japan.'}, {'ForeName': 'Yohei', 'Initials': 'Y', 'LastName': 'Takata', 'Affiliation': 'Global Strategic Challenge Center, Hamamatsu Photonics KK, Hamamatsu, Japan.'}, {'ForeName': 'Tatsuhiro', 'Initials': 'T', 'LastName': 'Terada', 'Affiliation': 'Department of Biofunctional Imaging, Preeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Yasuomi', 'Initials': 'Y', 'LastName': 'Ouchi', 'Affiliation': 'Department of Biofunctional Imaging, Preeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan; Hamamatsu Medical Imaging Center, Hamamatsu Medical Photonics Foundation, Hamamatsu, Japan. Electronic address: ouchi@hama-med.ac.jp.'}]",Brain stimulation,['10.1016/j.brs.2020.12.010'] 791,33400330,"Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial.","BACKGROUND AND PURPOSE Although erenumab has demonstrated significant reduction in migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is known about long-term therapy. METHODS This study was an open-label, 5-year treatment phase following a 12-week, double-blind, placebo-controlled trial in adults with episodic migraine. Patients initially received open-label erenumab 70 mg, which increased to 140 mg following a protocol amendment. Efficacy analyses included change from baseline in monthly migraine days (MMDs), monthly acute migraine-specific medication (AMSM) days, and health-related quality of life. RESULTS Of 383 patients enrolled, 250 switched to 140 mg; 215 (56.1%) completed open-label treatment. Mean (standard error) change in MMDs from baseline of 8.7 (0.2) days was -5.3 (0.3) days; an average reduction of 62.3% at year 5. Among patients using AMSM at baseline (6.3 [2.8] treatment days), mean change in monthly AMSM days was -4.4 (0.3) days at the end of 5 years. Patient-reported outcomes indicated stable improvements in disability, headache impact, and migraine-specific quality of life. Exposure-adjusted patient incidence rates of adverse events (AEs) were 123.0/100 patient-years; AEs were most frequently nasopharyngitis, upper respiratory tract infection, and influenza. Serious AEs (SAEs) reported by 49 patients (3.8/100 patient-years) were mostly single occurrence. Two fatal adverse events were reported. There were no increases in incidence of AEs, SAEs, or AEs leading to treatment discontinuation over 5 years of exposure. CONCLUSIONS Treatment with erenumab was associated with reductions in migraine frequency and improvements in health-related quality of life that were maintained for at least 5 years. No new safety signals were observed.",2021,"There were no increases in incidence of AEs, SAEs, or AEs leading to treatment discontinuation over 5 years of exposure. ","['383 patients enrolled, 250 switched to 140 mg; 215 (56.1%) completed open-label treatment', 'adults with episodic migraine']","['erenumab', 'placebo']","['monthly migraine days (MMD), monthly acute migraine-specific medication (AMSM) days, and health-related quality of life', 'incidence of AEs, SAEs, or AEs leading to treatment discontinuation', 'migraine frequency and improvements in health-related quality of life', 'migraine frequency and improved quality of life', 'Mean (SE) change in MMD', 'disability, headache impact, and migraine-specific quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C4709308', 'cui_str': '215'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}]","[{'cui': 'C4542165', 'cui_str': 'erenumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1740836', 'cui_str': 'Acute migraine'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]",383.0,0.0697799,"There were no increases in incidence of AEs, SAEs, or AEs leading to treatment discontinuation over 5 years of exposure. ","[{'ForeName': 'Messoud', 'Initials': 'M', 'LastName': 'Ashina', 'Affiliation': 'Department of Neurology, Danish Headache Center, Faculty of Health and Medical Sciences, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Goadsby', 'Affiliation': ""NIHR/Wellcome Trust King's Clinical Research Facility, King's College London, London, UK.""}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Reuter', 'Affiliation': 'Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Silberstein', 'Affiliation': 'Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Dodick', 'Affiliation': 'Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Xue', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Paiva da Silva Lima', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Sunfa', 'Initials': 'S', 'LastName': 'Cheng', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Mikol', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}]",European journal of neurology,['10.1111/ene.14715'] 792,33402409,Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement.,"INTRODUCTION Optimal antithrombotic strategy following transcatheter aortic valve replacement (TAVR) is still unknown. We hypothesised that the direct factor Xa inhibitor edoxaban can potentially prevent subclinical leaflet thrombosis and cerebral embolisation compared with conventional dual antiplatelet therapy (DAPT) in patients undergoing TAVR. METHODS AND ANALYSIS The ADAPT-TAVR trial is an international, multicentre, randomised, open-label, superiority trial comparing edoxaban-based strategy and DAPT strategy in patients without an indication for oral anticoagulation who underwent successful TAVR. A total of 220 patients are randomised (1:1 ratio), 1-7 days after successful TAVR, to receive either edoxaban (60 mg daily or 30 mg daily if patients had dose-reduction criteria) or DAPT using aspirin (100 mg daily) plus clopidogrel (75 mg daily) for 6 months. The primary endpoint was an incidence of leaflet thrombosis on four-dimensional, volume-rendered cardiac CT imaging at 6 months post-TAVR. The key secondary endpoints were the number of new lesions and new lesion volume on brain diffusion-weighted MRI and the changes in neurological and neurocognitive function assessment between immediate post-TAVR and 6 months of study drug administration. Detailed clinical information on thromboembolic and bleeding events were also assessed. ETHICS AND DISSEMINATION Ethic approval has been obtained from the Ethics Committee/Institutional Review Board of Asan Medical Center (approval number: 2017-1317) and this trial is also approved by National Institute of Food and Drug Safety Evaluation of Republic of Korea (approval number: 31511). Results of this study will be disseminated in scientific publication in reputed journals. TRIAL REGISTRATION NUMBER NCT03284827.",2021,"We hypothesised that the direct factor Xa inhibitor edoxaban can potentially prevent subclinical leaflet thrombosis and cerebral embolisation compared with conventional dual antiplatelet therapy (DAPT) in patients undergoing TAVR. ","['leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement', 'patients without an indication for oral anticoagulation who underwent successful TAVR', 'patients undergoing TAVR', '220 patients']","['conventional dual antiplatelet therapy (DAPT', 'clopidogrel', 'direct factor Xa inhibitor edoxaban', 'edoxaban', 'transcatheter aortic valve replacement (TAVR', 'edoxaban and dual antiplatelet therapy', 'DAPT using aspirin']","['thromboembolic and bleeding events', 'incidence of leaflet thrombosis on four-dimensional, volume-rendered cardiac CT imaging', 'subclinical leaflet thrombosis and cerebral embolisation', 'number of new lesions and new lesion volume on brain diffusion-weighted MRI and the changes in neurological and neurocognitive function assessment']","[{'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0013931', 'cui_str': 'Embolization - action'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C4517650', 'cui_str': '220'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C3653500', 'cui_str': 'Direct factor Xa inhibitors'}, {'cui': 'C2975435', 'cui_str': 'edoxaban'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0412618', 'cui_str': 'Cardiac CT'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C4552573', 'cui_str': 'Subclinical leaflet thrombosis'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0013931', 'cui_str': 'Embolization - action'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0598801', 'cui_str': 'Diffusion weighted magnetic resonance imaging'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",,0.359201,"We hypothesised that the direct factor Xa inhibitor edoxaban can potentially prevent subclinical leaflet thrombosis and cerebral embolisation compared with conventional dual antiplatelet therapy (DAPT) in patients undergoing TAVR. ","[{'ForeName': 'Hanbit', 'Initials': 'H', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Do-Yoon', 'Initials': 'DY', 'LastName': 'Kang', 'Affiliation': 'Division of Cardiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Jung-Min', 'Initials': 'JM', 'LastName': 'Ahn', 'Affiliation': 'Division of Cardiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Kyung Won', 'Initials': 'KW', 'LastName': 'Kim', 'Affiliation': 'Asan Image Metrics, Clinical Trial Center, Asan Institute for Life Sciences, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Anthony Y T', 'Initials': 'AYT', 'LastName': 'Wong', 'Affiliation': 'Division of Cardiology, Department of Medicine, Queen Mary Hospital, Pok Fu Lam, Hong Kong.'}, {'ForeName': 'Simon C C', 'Initials': 'SCC', 'LastName': 'Lam', 'Affiliation': 'Division of Cardiology, Department of Medicine, Queen Mary Hospital, Pok Fu Lam, Hong Kong.'}, {'ForeName': 'Wei-Hsian', 'Initials': 'WH', 'LastName': 'Yin', 'Affiliation': 'Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Jeng', 'Initials': 'J', 'LastName': 'Wei', 'Affiliation': 'Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Yung-Tsai', 'Initials': 'YT', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Hsien-Li', 'Initials': 'HL', 'LastName': 'Kao', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Mao-Shin', 'Initials': 'MS', 'LastName': 'Lin', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Tsung-Yu', 'Initials': 'TY', 'LastName': 'Ko', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Hsin-Chu Branch, National Taiwan University Hospital, Hsin-Chu, Taiwan.'}, {'ForeName': 'Won-Jang', 'Initials': 'WJ', 'LastName': 'Kim', 'Affiliation': 'Department of Cardiology, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, The Republic of Korea.'}, {'ForeName': 'Se Hun', 'Initials': 'SH', 'LastName': 'Kang', 'Affiliation': 'Department of Cardiology, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, The Republic of Korea.'}, {'ForeName': 'Euihong', 'Initials': 'E', 'LastName': 'Ko', 'Affiliation': 'Division of Cardiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Dae-Hee', 'Initials': 'DH', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Hyun Jung', 'Initials': 'HJ', 'LastName': 'Koo', 'Affiliation': 'Department of Radiology and Research Institute of Radiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Dong Hyun', 'Initials': 'DH', 'LastName': 'Yang', 'Affiliation': 'Department of Radiology and Research Institute of Radiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Joon-Won', 'Initials': 'JW', 'LastName': 'Kang', 'Affiliation': 'Department of Radiology and Research Institute of Radiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Seung Chai', 'Initials': 'SC', 'LastName': 'Jung', 'Affiliation': 'Department of Radiology and Research Institute of Radiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Jae-Hong', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Sung-Cheol', 'Initials': 'SC', 'LastName': 'Yun', 'Affiliation': 'Department of Biostatistics, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Seung-Jung', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea.'}, {'ForeName': 'Duk-Woo', 'Initials': 'DW', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Asan Medical Center, Songpa-gu, Seoul, The Republic of Korea dwpark@amc.seoul.kr.'}]",BMJ open,['10.1136/bmjopen-2020-042587'] 793,33404150,"Behavioral counseling and abstinence-contingent take-home buprenorphine in general practitioners' offices in Malaysia: a randomized, open-label clinical trial.","BACKGROUND AND AIM To address the widespread severe problems with opioid use disorder, buprenorphine-naloxone treatment provided by primary care physicians has greatly expanded treatment access; however, treatment is often provided with minimal or no behavioral interventions. Whether or which behavioral interventions are feasible to implement in various settings and improve treatment outcomes has not been established. This study aimed to evaluate two behavioral interventions to improve buprenorphine-naloxone treatment. DESIGN A 2 × 2 factorial, repeated-measures, open-label, randomized clinical trial. SETTINGS General medical practice offices in Muar, Malaysia. PARTICIPANTS Opioid-dependent individuals (n = 234). INTERVENTIONS Participants were randomly assigned to one of four treatment conditions and received study interventions for 24 weeks: (1) physician management with or without behavioral counseling and (2) physician management with or without abstinence-contingent buprenorphine-naloxone (ACB) take-home doses. MEASUREMENTS The primary outcomes were proportions of opioid-negative urine tests and HIV risk behaviors [assessed by audio computer-assisted AIDS risk inventory (ACASI-ARI)]. FINDINGS The rates of opioid-negative urine tests over 24 weeks of treatment were significantly higher with [68.2%, 95% confidence interval (CI) = 65-71] than without behavioral counseling (59.2%, 95% CI = 56-62, P < 0.001) and with (71.0%, 95% CI = 68-74) than without ACB (56.4%, 95% CI = 53-59, P < 0.001); interaction effects between and among behavioral interventions and time were not statistically significant. Scores on ACASI-ARI decreased significantly from baseline across all treatment groups (P < 0.001) and did not differ significantly with or without behavioral counseling (P = 0.099) or with or without ACB (P = 0.339). CONCLUSIONS Providing opioid-dependent patients in Muar, Malaysia with buprenorphine-naloxone and physician management plus behavioral counseling or abstinence-contingent buprenorphine-naloxone (ACB) resulted in greater reductions of opioid use compared with providing buprenorphine-naloxone and physician management without behavioral counseling or ACB.",2021,"Scores on ACASI-ARI decreased significantly from baseline across all treatment groups (p <0.001) and did not differ significantly with or without Behavioral Counseling (p=.099) or with or without ACB (p=.339). ","['Opioid-dependent individuals (N=234', 'General medical practice offices in Muar, Malaysia', ""General Practitioners' Offices in Malaysia""]","['buprenorphine-naloxone', 'Behavioral Counseling and Abstinence-Contingent Take-home Buprenorphine', 'buprenorphine-naloxone (ACB', 'Physician Management with or without Behavioral Counseling, and 2) Physician Management with or without Abstinence-Contingent Buprenorphine-naloxone (ACB) take-home doses']","['ACASI-ARI', 'rates of opioid negative urine tests', 'proportions of opioid-negative urine tests and HIV risk behaviors (assessed by Audio Computer Assisted AIDS Risk Inventory']","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1319402', 'cui_str': 'General medical practice'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}, {'cui': 'C0017319', 'cui_str': 'General physician'}]","[{'cui': 'C1169989', 'cui_str': 'Buprenorphine- and naloxone-containing product'}, {'cui': 'C4546207', 'cui_str': 'Behavioral counseling'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0042014', 'cui_str': 'Urinalysis'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",,0.0472011,"Scores on ACASI-ARI decreased significantly from baseline across all treatment groups (p <0.001) and did not differ significantly with or without Behavioral Counseling (p=.099) or with or without ACB (p=.339). ","[{'ForeName': 'Richard S', 'Initials': 'RS', 'LastName': 'Schottenfeld', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Howard University College of Medicine, Washington, DC, USA.'}, {'ForeName': 'Marek C', 'Initials': 'MC', 'LastName': 'Chawarski', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Mahmud', 'Initials': 'M', 'LastName': 'Mazlan', 'Affiliation': 'Kuala Lumpur, Malaysia.'}]","Addiction (Abingdon, England)",['10.1111/add.15399'] 794,33384215,What's in a Name? Enhancing Communication in the Operating Room with the Use of Names and Roles on Surgical Caps.,"OBJECTIVE A pilot study was conducted in a tertiary referral center to assess whether wearing caps labeled with providers' names and roles has an impact on communication in the operating room (OR). METHODS Two obstetricians observed surgeries for name uses and missed communications. Following each case, all providers were given a short survey that queried their attitude about the use of labeled surgical caps, their ability to know the names and roles of other providers during a case, and the impact of scrub attire on identifying others. They were also asked to rate the ease of communication and their ability to recall name and roles of the personnel specific to the case. Patients were asked how they perceived the use of labeled caps by providers. RESULTS Twenty scheduled cesarean deliveries were randomized to either labeled (10) or nonlabeled (10) surgical caps. A total of 129 providers participated in the study, with 117 providing responses to the survey. Providers reported knowing the names and roles of colleagues more often with labeled caps vs. nonlabeled caps (names: 77.8% vs. 55.0%, 95% confidence interval [CI] = 64.4%-88.0% vs. 41.6%-67.9%, p = 0.011; roles: 92.5% vs. 78.3%, 95% CI = 81.8%-98.0% vs. 65.8%-88.0%, p = 0.036). Name uses increased (43 vs. 34, p = 0.208), and missed communications decreased (16 vs. 20, p = 0.614) when labeled caps were worn. Providers and patients had an overwhelmingly positive response to labeled caps. CONCLUSION This pilot study demonstrated that wearing labeled caps in the OR led to more frequent name uses and less frequent missed communications. Providers and patients embraced the concept of labeled caps and perceived wearing labeled caps as improving communication in the OR.",2021,"Name uses increased (43 vs. 34, p = 0.208), and missed communications decreased (16 vs. 20, p = 0.614) when labeled caps were worn.","['129 providers participated in the study, with 117 providing responses to the survey', 'Twenty scheduled cesarean deliveries']",['labeled (10) or nonlabeled (10) surgical caps'],['missed communications'],"[{'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}]","[{'cui': 'C0183707', 'cui_str': 'Surgical hood'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}]",129.0,0.0533102,"Name uses increased (43 vs. 34, p = 0.208), and missed communications decreased (16 vs. 20, p = 0.614) when labeled caps were worn.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Brodzinsky', 'Affiliation': ''}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Crowe', 'Affiliation': ''}, {'ForeName': 'Henry Chong', 'Initials': 'HC', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Sara N', 'Initials': 'SN', 'LastName': 'Goldhaber-Fiebert', 'Affiliation': ''}, {'ForeName': 'Lillian', 'Initials': 'L', 'LastName': 'Sie', 'Affiliation': ''}, {'ForeName': 'Kimber Lee', 'Initials': 'KL', 'LastName': 'Padua', 'Affiliation': ''}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Daniels', 'Affiliation': ''}]",Joint Commission journal on quality and patient safety,['10.1016/j.jcjq.2020.11.012'] 795,33372745,Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial.,"OBJECTIVES We obtained preliminary evidence on the efficacy of early prophylaxis on the risk of central venous catheter-associated deep venous thrombosis and its effect on thrombin generation in critically ill children. DESIGN Bayesian phase 2b randomized clinical trial. SETTING Seven PICUs. PATIENTS Children less than 18 years old with a newly inserted central venous catheter and at low risk of bleeding. INTERVENTION Enoxaparin adjusted to anti-Xa level of 0.2-0.5 international units/mL started at less than 24 hours after insertion of central venous catheter (enoxaparin arm) versus usual care without placebo (usual care arm). MEASUREMENTS AND MAIN RESULTS At the interim analysis, the proportion of central venous catheter-associated deep venous thrombosis on ultrasonography in the usual care arm, which was 54.2% of 24 children, was significantly higher than that previously reported. This resulted in misspecification of the preapproved Bayesian analysis, reversal of direction of treatment effect, and early termination of the randomized clinical trial. Nevertheless, with 30.4% of 23 children with central venous catheter-associated deep venous thrombosis on ultrasonography in the enoxaparin arm, risk ratio of central venous catheter-associated deep venous thrombosis was 0.55 (95% credible interval, 0.24-1.11). Including children without ultrasonography, clinically relevant central venous catheter-associated deep venous thrombosis developed in one of 27 children (3.7%) in the enoxaparin arm and seven of 24 (29.2%) in the usual care arm (p = 0.02). Clinically relevant bleeding developed in one child randomized to the enoxaparin arm. Response profile of endogenous thrombin potential, a measure of thrombin generation, was not statistically different between trial arms. CONCLUSIONS These findings suggest the efficacy and safety of early prophylaxis that should be validated in a pivotal randomized clinical trial.",2021,"Response profile of endogenous thrombin potential, a measure of thrombin generation, was not statistically different between trial arms. ","['Seven PICUs', 'Children less than 18 years old with a newly inserted central venous catheter and at low risk of bleeding', 'critically ill children', 'Critically Ill Children']","['Enoxaparin', 'central venous catheter (enoxaparin arm) versus usual care without placebo', 'Early Prophylaxis Against Catheter-Associated Thrombosis', 'enoxaparin']","['relevant central venous catheter-associated deep venous thrombosis', 'deep venous thrombosis', 'proportion of central venous catheter-associated deep venous thrombosis', 'efficacy and safety', 'risk ratio of central venous catheter-associated deep venous thrombosis']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C1046445', 'cui_str': 'Picus'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C1145640', 'cui_str': 'Central venous catheter'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}]","[{'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C1145640', 'cui_str': 'Central venous catheter'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}]","[{'cui': 'C1145640', 'cui_str': 'Central venous catheter'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",23.0,0.143175,"Response profile of endogenous thrombin potential, a measure of thrombin generation, was not statistically different between trial arms. ","[{'ForeName': 'E Vincent S', 'Initials': 'EVS', 'LastName': 'Faustino', 'Affiliation': 'Department of Pediatrics, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Shabanova', 'Affiliation': 'Department of Pediatrics, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Leslie J', 'Initials': 'LJ', 'LastName': 'Raffini', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA.""}, {'ForeName': 'Sarah B', 'Initials': 'SB', 'LastName': 'Kandil', 'Affiliation': 'Department of Pediatrics, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': ""Department of Pediatrics, New York Medical College, Maria Fareri Children's Hospital, Valhalla, NY.""}, {'ForeName': 'Matthew G', 'Initials': 'MG', 'LastName': 'Pinto', 'Affiliation': ""Department of Pediatrics, New York Medical College, Maria Fareri Children's Hospital, Valhalla, NY.""}, {'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Cholette', 'Affiliation': ""Department of Pediatrics, University of Rochester Golisano Children's Hospital, Rochester, NY.""}, {'ForeName': 'Sheila J', 'Initials': 'SJ', 'LastName': 'Hanson', 'Affiliation': 'Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Marianne E', 'Initials': 'ME', 'LastName': 'Nellis', 'Affiliation': 'Department of Pediatrics, NY Presbyterian Hospital - Weill Cornell Medicine, New York, NY.'}, {'ForeName': 'Cicero T', 'Initials': 'CT', 'LastName': 'Silva', 'Affiliation': 'Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Ranjit', 'Initials': 'R', 'LastName': 'Chima', 'Affiliation': ""Division of Critical Care Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH.""}, {'ForeName': 'Anjali', 'Initials': 'A', 'LastName': 'Sharathkumar', 'Affiliation': 'Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Thomas', 'Affiliation': 'Department of Pediatrics, Washington University in St. Louis, St. Louis, MO.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'McPartland', 'Affiliation': 'Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Joana A', 'Initials': 'JA', 'LastName': 'Tala', 'Affiliation': ""Pediatric Intensive Care Unit, Yale-New Haven Children's Hospital, New Haven, CT.""}, {'ForeName': 'Philip C', 'Initials': 'PC', 'LastName': 'Spinella', 'Affiliation': 'Department of Pediatrics, Washington University in St. Louis, St. Louis, MO.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004784'] 796,33394523,"Association between age at first reported e-cigarette use and subsequent regular e-cigarette, ever cigarette and regular cigarette use.","BACKGROUND AND AIMS Association of electronic cigarette use and subsequent smoking has received considerable attention, although age of first use has not. This study tested differences in regular (e-cigarettes, cigarettes) and ever (cigarettes) use between e-cigarette user groups: early versus never users, late versus never users, early versus late users and effects of controlling for covariates. DESIGN Prospective study with 12- and 24-month follow-up of e-cigarette/cigarette ever/regular use with data from an intervention. SETTING Forty-five schools in England (Staffordshire and Yorkshire). PARTICIPANTS Never smokers (3289 13-14-year-olds) who were part of a cluster randomized controlled trial. MEASUREMENTS The sample was divided into groups of e-cigarette users: early users (at 13-14 years), late users (at 14-15 years) and never users (at 13-14 and 14-15 years). Dependent variables were self-reported regular e-cigarette and cigarette use and ever cigarette use at 15-16 years. Covariates were assessed. FINDINGS Early and late users compared with never users were significantly more likely to be regular e-cigarette users [early: odds ratio (OR) = 9.42, 95% confidence interval (CI) = 5.38, 16.49, P < 0.001; late: OR = 6.89, 95% CI = 4.11, 11.54, P < 0.001], ever cigarette users (early: OR = 7.96, 95% CI = 6.02, 10.53, P < 0.001; late: OR = 5.13, 95% CI = 3.85, 6.84, P < 0.001) and regular cigarette users (early: OR = 7.80, 95% CI = 3.99, 15.27, P < 0.001; late: OR = 4.34, 95% CI = 1.93, 9.77, P < 0.001) at age 15-16 years. Late users compared with early users had significantly lower rates of ever use of cigarettes at 15-16 years (OR = 0.48, 95% CI = 0.35, 0.66, P < 0.001), although this difference was non-significant at 12 months after first use of e-cigarettes (OR = 0.89, 95% CI = 0.64, 1.25, P = 0.498). Controlling for covariates did not change the findings. CONCLUSIONS Adolescents in England who report using e-cigarettes at age 13-14 years have higher rates of subsequently initiating cigarette use than adolescents who report using e-cigarettes at age 14-15 years, a difference that may be attributable to a longer period of time to initiate cigarette use in former group.",2021,"This study tested differences in regular (e-cigarettes, cigarettes) and ever (cigarettes) use between e-cigarette user groups: early versus never users, late versus never users, early versus late users and effects of controlling for covariates. ","['Sample divided into groups of e-cigarette users: early users (at 13-14 years), late users (at 14-15 years), never users (at 13-14 and 14-15 years', 'Forty-five schools in England (Staffordshire and Yorkshire', 'Never smokers (3289 13-14 year olds) who were part of a cluster randomised controlled trial']",[],['rates of ever use of cigarettes'],"[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4505216', 'cui_str': 'Electronic cigarette user'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0454875', 'cui_str': 'Staffordshire'}, {'cui': 'C0425293', 'cui_str': 'Never smoked tobacco'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}]",,0.0598807,"This study tested differences in regular (e-cigarettes, cigarettes) and ever (cigarettes) use between e-cigarette user groups: early versus never users, late versus never users, early versus late users and effects of controlling for covariates. ","[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Conner', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Grogan', 'Affiliation': 'Department of Psychology, Manchester Metropolitan University, Manchester, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Simms-Ellis', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Cowap', 'Affiliation': 'Centre for Psychological Research, Science Centre, Staffordshire University, Stoke-on-Trent, UK.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Armitage', 'Affiliation': 'Manchester Centre for Health Psychology, Division of Psychology and Mental Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'West', 'Affiliation': 'Institute of Health Sciences, University of Leeds, Leeds, UK.'}, {'ForeName': 'Anna-Marie', 'Initials': 'AM', 'LastName': 'Marshall', 'Affiliation': 'Department of Health Sciences, University of York, York, UK.'}, {'ForeName': 'Kamran', 'Initials': 'K', 'LastName': 'Siddiqi', 'Affiliation': 'Department of Health Sciences, University of York, York, UK.'}]","Addiction (Abingdon, England)",['10.1111/add.15386'] 797,33394901,Both Traditional and Stair Climbing-based HIIT Cardiac Rehabilitation Induce Beneficial Muscle Adaptations.,"PURPOSE There is a lack of knowledge as to how different exercise-based cardiac rehabilitation programming affects skeletal muscle adaptations in coronary artery disease (CAD) patients. We first characterized the skeletal muscle from adults with CAD compared with a group of age- and sex-matched healthy adults. We then determined the effects of a traditional moderate-intensity continuous exercise program (TRAD) or a stair climbing-based high-intensity interval training program (STAIR) on skeletal muscle metabolism in CAD. METHODS Sixteen adults (n = 16, 61 ± 7 yr), who had undergone recent treatment for CAD, were randomized to perform (3 d·wk-1) either TRAD (n = 7, 30 min at 60%-80% of peak heart rate) or STAIR (n = 9, 3 × 6 flights) for 12 wk. Muscle biopsies were collected at baseline in both CAD and healthy controls (n = 9), and at 4 and 12 wk after exercise training in CAD patients undertaking TRAD or STAIR. RESULTS We found that CAD had a lower capillary-to-fiber ratio (C/Fi, 35% ± 25%, P = 0.06) and capillary-to-fiber perimeter exchange (CFPE) index (23% ± 29%, P = 0.034) in Type II fibers compared with healthy controls. However, 12 wk of cardiac rehabilitation with either TRAD or STAIR increased C/Fi (Type II, 23% ± 14%, P < 0.001) and CFPE (Type I, 10% ± 23%, P < 0.01; Type II, 18% ± 22%, P = 0.002). CONCLUSION Cardiac rehabilitation via TRAD or STAIR exercise training improved the compromised skeletal muscle microvascular phenotype observed in CAD patients.",2021,"We found that CAD had a lower capillary-to-fiber ratio (C/Fi, 35±25%, p=0.06), and capillary-to-fiber perimeter exchange (CFPE) index (23±29%, p=0.034) in type II fibers compared to healthy controls.","['adults with CAD compared to a group of age- and sex-matched healthy adults', 'coronary artery disease (CAD) patients', 'Sixteen adults (n=16, 61±7 yrs), who had undergone recent treatment for CAD', 'CAD patients']","['CAD', 'Traditional and Stair Climbing-based HIIT Cardiac Rehabilitation', 'TRAD ', 'traditional moderate-intensity continuous exercise program (TRAD) or a high-intensity interval training program via stair climbing (STAIR', 'Cardiac rehabilitation via TRAD or STAIR exercise training']","['lower capillary-to-fiber ratio', 'skeletal muscle microvascular phenotype', 'capillary-to-fiber perimeter exchange (CFPE) index', 'TRAD or STAIR increased C/Fi']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C1290942', 'cui_str': 'Climbing stairs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C0182215', 'cui_str': 'Perimeter'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",16.0,0.0275583,"We found that CAD had a lower capillary-to-fiber ratio (C/Fi, 35±25%, p=0.06), and capillary-to-fiber perimeter exchange (CFPE) index (23±29%, p=0.034) in type II fibers compared to healthy controls.","[{'ForeName': 'Changhyun', 'Initials': 'C', 'LastName': 'Lim', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, CANADA.'}, {'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Dunford', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, CANADA.'}, {'ForeName': 'Sydney E', 'Initials': 'SE', 'LastName': 'Valentino', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, CANADA.'}, {'ForeName': 'Sara Y', 'Initials': 'SY', 'LastName': 'Oikawa', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, CANADA.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'McGlory', 'Affiliation': 'School of Kinesiology and Health Studies, Queens University, Kingston, ON, CANADA.'}, {'ForeName': 'Steve K', 'Initials': 'SK', 'LastName': 'Baker', 'Affiliation': 'Department of Neurology, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, CANADA.'}, {'ForeName': 'Maureen J', 'Initials': 'MJ', 'LastName': 'Macdonald', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, CANADA.'}, {'ForeName': 'Stuart M', 'Initials': 'SM', 'LastName': 'Phillips', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, CANADA.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002573'] 798,33393636,Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study.,"OBJECTIVE Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints. TNF inhibitor (TNFi) drugs are recommended for patients not responding to NSAIDs; however, there is a significant need for biomarkers of response. IFN-regulated genes (IRGs) and other cytokines/chemokines are linked to autoimmune diseases and have been associated with treatment response. Our objective was to explore whether IRGs and cytokines/chemokines can be associated with response to TNFiagents in AS. METHODS Peripheral blood mononuclear cells were obtained from 26 AS patients who were to receive a TNFi (I, n = 15) or placebo (P, n = 11) at week 0 and week 22. Response (R)/non-response (NR) was defined as reduction in ASDAS ≥ 1.2 points or reduction in sacroiliac/vertebral MRI lesions. The expression of 96 genes was quantified using TaqMan assays. Finally, ELISA was used to measure IL-6 in serum samples from another 38 AS patients. RESULTS Analysis of gene expression in 26 baseline samples segregated patients into four groups defined by a signature of 15 genes (mainly IRGs). ASDAS response was associated with one group independently of treatment received. We then analysed response to the TNFi (n = 15) and identified a 12-gene signature associated with MRI response. A third IRG signature was also associated with a reduction in IRGs expression post-TNFi samples (n = 10 pairs). Finally, decreased circulating IL-6 was associated with BASDAI-R. CONCLUSION This pilot study suggests an association between IRG expression and response to TNFi in AS. These findings require validation in a larger cohort in order to construct predictive algorithms for patient stratification.",2021,We then analysed response to the TNFi (n = 15) and identified a 12-gene signature associated with MRI response.,"['ankylosing spondylitis patients', 'Peripheral blood mononuclear cells were obtained from 26 AS patients who were to receive a TNFi (I, n\u2009=\u200915) or']","['placebo', 'TNFi', 'Interferon', 'TNF inhibitor treatment', 'TNF inhibitor (TNFi']","['ASDAS response', 'circulating IL-6', 'Response (R)/non-response (NR']","[{'cui': 'C0038013', 'cui_str': 'Ankylosing spondylitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C3537192', 'cui_str': 'TNF Antagonists'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3537192', 'cui_str': 'TNF Antagonists'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}]",,0.0367219,We then analysed response to the TNFi (n = 15) and identified a 12-gene signature associated with MRI response.,"[{'ForeName': 'Stephanie R', 'Initials': 'SR', 'LastName': 'Harrison', 'Affiliation': 'University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.'}, {'ForeName': 'Agata N', 'Initials': 'AN', 'LastName': 'Burska', 'Affiliation': 'University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Emery', 'Affiliation': 'University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Marzo-Ortega', 'Affiliation': 'University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.'}, {'ForeName': 'Frederique', 'Initials': 'F', 'LastName': 'Ponchel', 'Affiliation': 'University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa817'] 799,33395734,Care partner-assisted intervention to improve oral health for older adults with cognitive impairment: A feasibility study.,"BACKGROUND AND OBJECTIVES Older adults with cognitive impairment often experience poor oral health outcomes due to inadequate oral hygiene practices. This pilot study aimed to evaluate the feasibility of a care partner-assisted intervention to improve the oral hygiene of community-dwelling older adults with cognitive impairment. MATERIAL AND METHODS The 6-month intervention included 25 older adults with mild dementia or mild cognitive impairment, who were randomly assigned to Treatment Group 1 or Treatment Group 2. Treatment Group 1 (n = 7) received an educational booklet. Treatment Group 2 (n = 18) received a booklet, a tailored care plan for the participants with cognitive impairment and the care partner received four coaching sessions to learn to facilitate good oral hygiene. Both groups received electric toothbrushes. The study consisted of a 3-month active intervention and 3-month maintenance phase. The outcomes of gingival index, plaque index and overall oral health status based on the Oral Health Assessment Tool were measured at baseline, 3 months (end of active intervention) and 6 months of the study. RESULTS This study had very low dropout rate. Participants' oral hygiene improved in this study. In comparison to Treatment Group 1, participants in Treatment Group 2 had a greater reduction in plaque level and gingival inflammation, and greater improvement in overall oral health status. CONCLUSION This study demonstrates the feasibility of this intervention designed to improve the oral health of persons with cognitive impairment and it lays the foundation for using this protocol in a future large randomised clinical trial.",2021,"In comparison to Treatment Group 1, participants in Treatment Group 2 had a greater reduction in plaque level and gingival inflammation, and greater improvement in overall oral health status. ","['community-dwelling older adults with cognitive impairment', 'older adults with cognitive impairment', 'Older adults with cognitive impairment often experience poor oral health outcomes due to inadequate oral hygiene practices', '25 older adults with mild dementia or mild cognitive impairment', 'persons with cognitive impairment']","['Care partner-assisted intervention', 'booklet, a tailored care plan for the participants with cognitive impairment and the care partner received four coaching sessions to learn to facilitate good oral hygiene', 'care partner-assisted intervention', 'educational booklet', 'electric toothbrushes']","['plaque level and gingival inflammation', 'overall oral health status', 'gingival index, plaque index and overall oral health status based on the Oral Health Assessment Tool']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C3494623', 'cui_str': 'Mild dementia'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0178916', 'cui_str': 'Care plan'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0457639', 'cui_str': 'Good oral hygiene'}, {'cui': 'C1740271', 'cui_str': 'Electric toothbrush'}]","[{'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017574', 'cui_str': 'Gingivitis'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0175637', 'cui_str': 'Health assessment'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]",25.0,0.049932,"In comparison to Treatment Group 1, participants in Treatment Group 2 had a greater reduction in plaque level and gingival inflammation, and greater improvement in overall oral health status. ","[{'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Wu', 'Affiliation': 'Hartford Institute for Geriatric Nursing, Rory Meyers College of Nursing, New York University, New York, NY, USA.'}, {'ForeName': 'Ruth A', 'Initials': 'RA', 'LastName': 'Anderson', 'Affiliation': 'School of Nursing, University of North Carolina Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Yaolin', 'Initials': 'Y', 'LastName': 'Pei', 'Affiliation': 'Rory Meyers College of Nursing, New York University, New York, NY, USA.'}, {'ForeName': 'Hanzhang', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'School of Nursing, Duke University, Durham, NC, USA.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Nye', 'Affiliation': 'School of Medicine, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Poole', 'Affiliation': 'Adams School of Dentistry, University of North Carolina Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Bunn', 'Affiliation': 'School of Nursing, Duke University, Durham, NC, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Lynn Downey', 'Affiliation': 'Adams School of Dentistry, University of North Carolina Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Brenda L', 'Initials': 'BL', 'LastName': 'Plassman', 'Affiliation': 'School of Medicine, Duke University, Durham, NC, USA.'}]",Gerodontology,['10.1111/ger.12528'] 800,33401676,The Combined Effects of Sports Smart Bracelet and Multi-Component Exercise Program on Exercise Motivation among the Elderly in Macau.,"Background and objectives: Faced with the serious problem of an aging population, exercise is one of the most effective ways to maintain the health of the elderly. In recent years, with the popularization of smartphones, the elderly have increasingly accepted technological products that incorporate artificial intelligence (AI). However, there is not much research on using artificial intelligence bracelets to enhance elders' motivation and participation in exercise. Therefore, the purpose of this study is to evaluate the effectiveness of the combination of sports smart bracelets and multi-sport training programs on the motivation of the elderly in Macau. Materials and Methods: The study was conducted with a randomized trial design in a 12 week multi-sport exercise training intervention. According to the evaluation, a total of sixty elders' pre- and post-test data were included in this study. Results: After 12 weeks of multi-sport exercise training, the evaluation scores on the exercise motivation scale (EMS) increased significantly in the group wearing exercise bracelets and those taking part in the multi-component exercise program, and the degree of progress reached a statistically significant level, but the control group did not show any statistically significant difference. The influence of the combination of sports smart bracelets and multi-sport training programs on elders' motivation is clearer. Conclusions: The use of sports smart bracelets by elderly people in conjunction with diverse exercise training can effectively enhance elders' motivation and increase their participation in regular exercise. The combination of sports smart bracelets and multi-sport training programs is worth promoting in the elderly population.",2021,"After 12 weeks of multi-sport exercise training, the evaluation scores on the exercise motivation scale (EMS) increased significantly in the group wearing exercise bracelets and those taking part in the multi-component exercise program, and the degree of progress reached a statistically significant level, but the control group did not show any statistically significant difference.","['elderly people in conjunction with', 'Elderly in Macau', 'elderly in Macau', ""sixty elders' pre- and post-test data were included in this study""]","['multi-sport exercise training', 'sport exercise training intervention', 'sports smart bracelets and multi-sport training programs', 'Sports Smart Bracelet and Multi-Component Exercise Program', 'diverse exercise training']","['Exercise Motivation', 'exercise motivation scale (EMS']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0024403', 'cui_str': 'Macao'}, {'cui': 'C0331055', 'cui_str': 'Genus Sambucus'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",60.0,0.0198155,"After 12 weeks of multi-sport exercise training, the evaluation scores on the exercise motivation scale (EMS) increased significantly in the group wearing exercise bracelets and those taking part in the multi-component exercise program, and the degree of progress reached a statistically significant level, but the control group did not show any statistically significant difference.","[{'ForeName': 'CheukKei', 'Initials': 'C', 'LastName': 'Lao', 'Affiliation': 'Doctorate Degree of Public Health, Faculty of Medicine, Macau University of Science Technology, Macau 999078, China.'}, {'ForeName': 'BingLong', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'School of Public Health, Peking Union Medical College, Beijing 100730, China.'}, {'ForeName': 'Richard S', 'Initials': 'RS', 'LastName': 'Wang', 'Affiliation': 'Affiliation Program of Data Analytics and Business Computing, Stern School of Business, New York University, New York 10012, NY, USA.'}, {'ForeName': 'HsiaoYun', 'Initials': 'H', 'LastName': 'Chang', 'Affiliation': 'Department of Athletic Training and Healthy, National Taiwan Sport University, Taoyuan 333019, Taiwan.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina57010034'] 801,33411195,Energy cost and psychological impact of robotic-assisted gait training in people with spinal cord injury: effect of two different types of devices.,"BACKGROUND In the last years, there has been an intense technological development of robotic devices for gait rehabilitation in spinal cord injury (SCI) patients. The aim of the present study was to evaluate energy cost and psychological impact during a rehabilitation program with two different types of robotic rehabilitation systems (stationary system on a treadmill, Lokomat, and overground walking system, Ekso GT). METHODS Fifteen SCI patients with different injury levels underwent robot-assisted gait training sessions, divided into 2 phases: in the first phase, all subjects completed 3 sessions both Lokomat and Ekso GT. Afterwards, participants were randomly assigned to Lokomat or the Ekso for 17 sessions. A questionnaire, investigating the subjective psychological impact (SPI) during gait training, was administered. The functional outcome measures were oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), metabolic equivalent of task (MET), walking economy, and heart rate (HR). RESULTS The metabolic responses (7.73 ± 1.02 mL/kg/min) and MET values (3.20 ± 1.01) during robotic overground walking resulted to be higher than those during robotic treadmill walking (3.91 ± 0.93 mL/kg/min and 1.58 ± 0.44; p < 0.01). Both devices showed high scores in emotion and satisfaction. Overground walking resulted in higher scores of fatigue, mental effort, and discomfort while walking with Lokomat showed a higher score in muscle relaxation. All patients showed improvements in walking economy due to a decrease in energy cost with increased speed and workload. CONCLUSIONS Overground robotic-assisted gait training in rehabilitation program needs higher cognitive and cardiovascular efforts than robot-assisted gait training on a treadmill.",2021,"Overground walking resulted in higher scores of fatigue, mental effort, and discomfort while walking with Lokomat showed a higher score in muscle relaxation.","['people with spinal cord injury', 'spinal cord injury (SCI) patients', 'Fifteen SCI patients with different injury levels underwent']","['robotic-assisted gait training', 'robotic rehabilitation systems (stationary system on a treadmill, Lokomat, and overground walking system, Ekso GT', 'Overground robotic-assisted gait training', 'robot-assisted gait training sessions']","['metabolic responses', 'oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), metabolic equivalent of task (MET), walking economy, and heart rate (HR', 'higher scores of fatigue, mental effort, and discomfort', 'energy cost and psychological impact', 'subjective psychological impact (SPI', 'energy cost with increased speed and workload', 'emotion and satisfaction']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439835', 'cui_str': 'Stationary'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C2983100', 'cui_str': 'Metabolic equivalent of task'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",15.0,0.0649239,"Overground walking resulted in higher scores of fatigue, mental effort, and discomfort while walking with Lokomat showed a higher score in muscle relaxation.","[{'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Corbianco', 'Affiliation': 'Interdepartmental Research Centre on Biology and Pathology of Aging, University of Pisa, via Roma 55, I-56126, Pisa, Italy. s.corbianco@ao-pisa.toscana.it.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Cavallini', 'Affiliation': 'Interdepartmental Research Centre on Biology and Pathology of Aging, University of Pisa, via Roma 55, I-56126, Pisa, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Dini', 'Affiliation': 'Interdepartmental Research Centre on Biology and Pathology of Aging, University of Pisa, via Roma 55, I-56126, Pisa, Italy.'}, {'ForeName': 'Ferdinando', 'Initials': 'F', 'LastName': 'Franzoni', 'Affiliation': 'Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': ""D'Avino"", 'Affiliation': 'Spinal Cord Unit, Pisa University Hospital, Pisa, Italy.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Gerini', 'Affiliation': 'Spinal Cord Unit, Pisa University Hospital, Pisa, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Stampacchia', 'Affiliation': 'Spinal Cord Unit, Pisa University Hospital, Pisa, Italy.'}]",Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,['10.1007/s10072-020-04954-w'] 802,33412932,Taxing working memory to modulate mental imagery of the 9/11 terrorist attacks following media exposure during childhood: a pilot study in young adult UK residents.,"BACKGROUND AND OBJECTIVES Media trauma in civilians is linked to intrusive imagery-based memory symptoms. We investigated whether mental imagery of the 9/11 terrorist attacks following media exposure is dampened by taxing working memory (WM). METHODS Forty-five young adult UK residents, who were exposed to the 9/11 terrorist attacks as children via the media, identified a personally-relevant mental image of the attacks. They were then randomly allocated to: (1) recall + Tetris, (2) recall + eye movements (EMs), or (3) recall-only. Ratings on imagery vividness and emotionality were provided at three time points: pre-, post-manipulations, and at 24-hr follow-up. RESULTS Repeated measures ANOVAs revealed that recall + Tetris and recall + EMs (relative to recall-only) significantly reduced imagery vividness and emotionality from pre- to post-manipulations, but not to follow-up. LIMITATIONS A passive control group is needed to fully rule out the role of natural memory decay; the follow-up was exploratory and took place outside the laboratory with reduced experimental control. CONCLUSIONS Aversive memory imagery from media trauma in civilians can be dampened by taxing WM, at least temporarily, which could be therapeutically useful. The use of such cognitive techniques may also hold relevance for public health approaches to address the impact of collective trauma.",2021,"Tetris and recall + EMs (relative to recall-only) significantly reduced imagery vividness and emotionality from pre- to post-manipulations, but not to follow-up. ","['young adult UK residents', 'Forty-five young adult UK residents, who were exposed to the 9/11 terrorist attacks as children via the media, identified a personally-relevant mental image of the attacks']",['recall\u2009'],"['recall\u2009', 'Tetris, (2) recall\u2009+\u2009eye movements (EMs), or (3) recall-only']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}]","[{'cui': 'C0034770', 'cui_str': 'Mental Recall'}]","[{'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0015413', 'cui_str': 'Eye Movements'}]",45.0,0.0315682,"Tetris and recall + EMs (relative to recall-only) significantly reduced imagery vividness and emotionality from pre- to post-manipulations, but not to follow-up. ","[{'ForeName': 'Libby A', 'Initials': 'LA', 'LastName': 'Rackham', 'Affiliation': 'School of Psychology, Cognitive Institute, Plymouth University, Plymouth, UK.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Lau-Zhu', 'Affiliation': 'Oxford Institute of Clinical Psychology Training and Research, Medical Sciences Division, University of Oxford, Oxford, UK.'}]","Anxiety, stress, and coping",['10.1080/10615806.2020.1870107'] 803,33413519,Effectiveness of chiropractic manipulation versus sham manipulation for recurrent headaches in children aged 7-14 years - a randomised clinical trial.,"BACKGROUND To investigate the effectiveness of chiropractic spinal manipulation versus sham manipulation in children aged 7-14 with recurrent headaches. METHODS Design: A two-arm, single-blind, superiority randomised controlled trial. SETTING One chiropractic clinic and one paediatric specialty practice in Denmark, November 2015 to August 2020. PARTICIPANTS 199 children aged 7 to 14 years, with at least one episode of headache per week for the previous 6 months and at least one musculoskeletal dysfunction identified. INTERVENTIONS All participants received standard oral and written advice to reduce headaches. In addition, children in the active treatment group received chiropractic spinal manipulation and children in the control group received sham manipulation for a period of 4 months. Number and frequency of treatments were based on the chiropractor's individual evaluation in the active treatment group; the children in the control group received approximately eight visits during the treatment period. PRIMARY OUTCOME MEASURES 'Number of days with headache', 'pain intensity' and 'medication' were reported weekly by text messages, and global perceived effect by text message after 4 months. A planned fixed sequence strategy based on an initial outcome data analysis was used to prioritize outcomes. 'Number of days with headache' and 'pain intensity' were chosen as equally important outcomes of highest priority, followed by global perceived effect and medication. The significance level for the first two outcomes was fixed to 0.025 to take multiplicity into account. RESULTS Chiropractic spinal manipulation resulted in significantly fewer days with headaches (reduction of 0.81 vs. 0.41, p = 0.019, NNT = 7 for 20% improvement) and better global perceived effect (dichotomized into improved/not improved, OR = 2.8 (95% CI: 1.5-5.3), NNT = 5) compared with a sham manipulation procedure. There was no difference between groups for pain intensity during headache episodes. Due to methodological shortcomings, no conclusions could be drawn about medication use. CONCLUSIONS Chiropractic spinal manipulation resulted in fewer headaches and higher global perceived effect, with only minor side effects. It did not lower the intensity of the headaches. Since the treatment is easily applicable, of low cost and minor side effects, chiropractic spinal manipulation might be considered as a valuable treatment option for children with recurrent headaches. TRIAL REGISTRATION ClinicalTrials.gov, identifier NCT02684916 , registered 02/18/2016 - retrospectively registered.",2021,"RESULTS Chiropractic spinal manipulation resulted in significantly fewer days with headaches (reduction of 0.81 vs. 0.41, p = 0.019, NNT = 7 for 20% improvement) and better global perceived effect (dichotomized into improved/not improved, OR = 2.8 (95% CI: 1.5-5.3), NNT = 5) compared with a sham manipulation procedure.","['One chiropractic clinic and one paediatric specialty practice in Denmark, November 2015 to August 2020', '199 children aged 7 to 14\u2009years, with at least one episode of headache per week for the previous 6\u2009months and at least one musculoskeletal dysfunction identified', 'children with recurrent headaches', 'Design', 'children aged 7-14 with recurrent headaches', 'recurrent headaches in children aged 7-14 years ']","['chiropractic manipulation versus sham manipulation', 'chiropractic spinal manipulation versus sham manipulation', 'standard oral and written advice', 'chiropractic spinal manipulation']","[""Number of days with headache' and 'pain intensity"", 'pain intensity', 'headaches', 'intensity of the headaches', 'text messages, and global perceived effect by text message', ""Number of days with headache', 'pain intensity' and 'medication""]","[{'cui': 'C0008138', 'cui_str': 'Chiropractic'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0037778', 'cui_str': 'Medical specialty'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0239888', 'cui_str': 'Headache recurrent'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0600577', 'cui_str': 'Chiropractic manipulation'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0008138', 'cui_str': 'Chiropractic'}, {'cui': 'C0086586', 'cui_str': 'Manipulation of spine'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",199.0,0.207033,"RESULTS Chiropractic spinal manipulation resulted in significantly fewer days with headaches (reduction of 0.81 vs. 0.41, p = 0.019, NNT = 7 for 20% improvement) and better global perceived effect (dichotomized into improved/not improved, OR = 2.8 (95% CI: 1.5-5.3), NNT = 5) compared with a sham manipulation procedure.","[{'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Lynge', 'Affiliation': 'Private Chiropractic Practice, Vivaldisvej 6, 9700, Broenderslev, Denmark.'}, {'ForeName': 'Kristina Boe', 'Initials': 'KB', 'LastName': 'Dissing', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Vach', 'Affiliation': 'Nordic Institute for Chiropractic and Clinical Biomechanics, Campusvej 55, 5230, Odense M, Denmark.'}, {'ForeName': 'Henrik Wulff', 'Initials': 'HW', 'LastName': 'Christensen', 'Affiliation': 'Nordic Institute for Chiropractic and Clinical Biomechanics, Campusvej 55, 5230, Odense M, Denmark.'}, {'ForeName': 'Lise', 'Initials': 'L', 'LastName': 'Hestbaek', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark. l.hestbaek@nikkb.dk.'}]",Chiropractic & manual therapies,['10.1186/s12998-020-00360-3'] 804,33411915,Parent Traumatic Events and Adolescent Internalizing Symptoms: The Mediating Role of Parental Depression Among Youth with Persistent Postconcussive Symptoms.,"OBJECTIVE Research has demonstrated associations between parental depression (PD) and negative psychological outcomes among their children. However, little is known about the pathways through which lifetime parent traumatic events (PTEs) influence their adolescents' internalizing symptoms. Our study examined whether PD mediates the association between PTE and adolescent depressive and anxious symptoms among youth with persistent postconcussive symptoms (PPCS). METHODS We used baseline data from a randomized effectiveness trial of collaborative care for treatment of persistent postconcussive symptoms among sports-injured adolescents aged 11-18 years. Parent-adolescent dyads were recruited from pediatric clinics throughout western Washington. Eligible adolescents had three or more PPCS that lasted for at least 1 month but <9 months and spoke English. Of 1,870 potentially eligible adolescents, 1,480 (79%) were excluded for not meeting the inclusion criteria. Of the eligible 390 adolescents, 189 (49%) declined to participate/consent. Participants included 200 parent-adolescent dyads (adolescent Mage = 14.7 years, SD = 1.7). Parent respondents were mostly female (83%) and mothers (81%). Adolescents reported on their depressive (Patient Health Questionnaire-9; PHQ-9) and anxious symptoms (Revised Child Anxiety and Depression Scale-Short Version [anxiety subscale]) and parents reported on their depressive symptoms (M = 3.7, SD = 3.7; PHQ-9). RESULTS Mediation analyses revealed two (out of four) significant indirect effects of PTE on both adolescent and parent report of depressive symptoms, but not anxiety. CONCLUSIONS This study elucidates one pathway (PD) through which PTE history influences adolescent depressive symptoms, supporting a two-generation approach to pediatric patient care for youth experiencing PPCS.",2021,"RESULTS Mediation analyses revealed two (out of four) significant indirect effects of PTE on both adolescent and parent report of depressive symptoms, but not anxiety. ","['Parent-adolescent dyads were recruited from pediatric clinics throughout western Washington', 'youth experiencing PPCS', 'Eligible adolescents', 'Youth with Persistent Postconcussive Symptoms', 'Of 1,870 potentially eligible adolescents, 1,480 (79%) were excluded for not meeting the inclusion criteria', 'Participants included 200 parent-adolescent dyads (adolescent Mage = 14.7\u2009years, SD = 1.7', 'youth with persistent postconcussive symptoms (PPCS', 'Of the eligible 390 adolescents, 189 (49%) declined to participate/consent', 'sports-injured adolescents aged 11-18\u2009years']","['PTE', 'collaborative care']","['depressive symptoms', 'depressive (Patient Health Questionnaire-9; PHQ-9) and anxious symptoms (Revised Child Anxiety and Depression Scale-Short Version [anxiety subscale']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C3839701', 'cui_str': 'Pediatric clinic'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C1136454', 'cui_str': 'Refusal to Participate'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0001779', 'cui_str': 'Age'}]",[],"[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4305166', 'cui_str': ""RCADS - Revised Children's Anxiety and Depression Scale""}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C2607870', 'cui_str': 'Version'}]",1870.0,0.0700922,"RESULTS Mediation analyses revealed two (out of four) significant indirect effects of PTE on both adolescent and parent report of depressive symptoms, but not anxiety. ","[{'ForeName': 'Lyscha A', 'Initials': 'LA', 'LastName': 'Marcynyszyn', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute.""}, {'ForeName': 'Carolyn A', 'Initials': 'CA', 'LastName': 'McCarty', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute.""}, {'ForeName': 'Frederick P', 'Initials': 'FP', 'LastName': 'Rivara', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute.""}, {'ForeName': 'Ashleigh M', 'Initials': 'AM', 'LastName': 'Johnson', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute.""}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Pediatrics, University of Washington.'}, {'ForeName': 'Douglas F', 'Initials': 'DF', 'LastName': 'Zatzick', 'Affiliation': 'Harborview Injury Prevention and Research Center, University of Washington.'}]",Journal of pediatric psychology,['10.1093/jpepsy/jsaa128'] 805,33413129,Methodology in core outcome set (COS) development: the impact of patient interviews and using a 5-point versus a 9-point Delphi rating scale on core outcome selection in a COS development study.,"BACKGROUND As the development of core outcome sets (COS) increases, guidance for developing and reporting high-quality COS continues to evolve; however, a number of methodological uncertainties still remain. The objectives of this study were: (1) to explore the impact of including patient interviews in developing a COS, (2) to examine the impact of using a 5-point versus a 9-point rating scale during Delphi consensus methods on outcome selection and (3) to inform and contribute to COS development methodology by advancing the evidence base on COS development techniques. METHODS Semi-structured patient interviews and a nested randomised controlled parallel group trial as part of the Pelvic Girdle Pain Core Outcome Set project (PGP-COS). Patient interviews, as an adjunct to a systematic review of outcomes reported in previous studies, were undertaken to identify preliminary outcomes for including in a Delphi consensus survey. In the Delphi survey, participants were randomised (1:1) to a 5-point or 9-point rating scale for rating the importance of the list of preliminary outcomes. RESULTS Four of the eight patient interview derived outcomes were included in the preliminary COS, however, none of these outcomes were included in the final PGP-COS. The 5-point rating scale resulted in twice as many outcomes reaching consensus after the 3-round Delphi survey compared to the 9-point scale. Consensus on all five outcomes included in the final PGP-COS was achieved by participants allocated the 5-point rating scale, whereas consensus on four of these was achieved by those using the 9-point scale. CONCLUSIONS Using patient interviews to identify preliminary outcomes as an adjunct to conducting a systematic review of outcomes measured in the literature did not appear to influence outcome selection in developing the COS in this study. The use of different rating scales in a Delphi survey, however, did appear to impact on outcome selection. The 5-point scale demonstrated greater congruency than the 9-point scale with the outcomes included in the final PGP-COS. Future research to substantiate our findings and to explore the impact of other rating scales on outcome selection during COS development, however, is warranted.",2021,The 5-point rating scale resulted in twice as many outcomes reaching consensus after the 3-round Delphi survey compared to the 9-point scale.,['Semi-structured patient interviews'],['Pelvic Girdle Pain Core Outcome Set project (PGP-COS'],"['5-point rating scale', 'final PGP-COS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]","[{'cui': 'C0240682', 'cui_str': 'Pelvic girdle pain'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]",,0.0454614,The 5-point rating scale resulted in twice as many outcomes reaching consensus after the 3-round Delphi survey compared to the 9-point scale.,"[{'ForeName': 'Alexandria', 'Initials': 'A', 'LastName': 'Remus', 'Affiliation': 'School of Nursing and Midwifery, Trinity College Dublin, Dublin, Ireland. alexandria.remus@ucdconnect.ie.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Smith', 'Affiliation': 'School of Nursing and Midwifery, Trinity College Dublin, Dublin, Ireland.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Wuytack', 'Affiliation': 'School of Nursing and Midwifery, Trinity College Dublin, Dublin, Ireland.'}]",BMC medical research methodology,['10.1186/s12874-020-01197-3'] 806,33416294,"Maternal and Perinatal Outcomes of Expectant Management of Full-Term, Low-Risk, Nulliparous Patients.","OBJECTIVE To compare risks of maternal and perinatal outcomes by completed week of gestation from 39 weeks in low-risk nulliparous patients undergoing expectant management. METHODS We conducted a secondary analysis of a multicenter randomized trial of elective induction of labor at 39 weeks of gestation compared with expectant management in low-risk nulliparous patients. Participants with nonanomalous neonates, who were randomized to and underwent expectant management and attained 39 0/7 weeks of gestation, were included. Delivery gestation was categorized by completed week: 39 0/7-39 6/7 (39 weeks), 40 0/7-40 6/7 (40 weeks), and 41 0/7-42 2/7 (41-42 weeks) (none delivered after 42 2/7). The coprimary outcomes were cesarean delivery and a perinatal composite (death, respiratory support, 5-minute Apgar score 3 or less, hypoxic ischemic encephalopathy, seizure, sepsis, meconium aspiration syndrome, birth trauma, intracranial or subgaleal hemorrhage, or hypotension requiring vasopressor support). Other outcomes included a maternal composite (blood transfusion, surgical intervention for postpartum hemorrhage, or intensive care unit admission), hypertensive disorders of pregnancy, peripartum infection, and neonatal intermediate or intensive care unit admission. For multivariable analysis, P<.0125 was considered to indicate statistical significance for the coprimary outcomes. RESULTS Of 2,502 participants who underwent expectant management, 964 (38.5%) delivered at 39 weeks of gestation, 1,111 (44.4%) at 40 weeks, and 427 (17.1%) at 41-42 weeks. The prevalence of medically indicated delivery was 37.9% overall and increased from 23.8% at 39 weeks of gestation to 80.3% at 41-42 weeks. The frequency of cesarean delivery (17.3%, 22.0%, 37.5%; P<.001) and the perinatal composite (5.1%, 5.9%, 8.2%; P=.03) increased with 39, 40, and 41-42 weeks of gestation, respectively, and hypertensive disorders of pregnancy decreased (16.4%, 12.1%, 10.8%, P=.001). The adjusted relative risk, 95% CI (39 weeks as referent) was significant for cesarean delivery at 41-42 weeks of gestation (1.93, 1.61-2.32) and for hypertensive disorders of pregnancy at 40 weeks (0.71, 0.58-0.88) and 41-42 weeks (0.61, 0.45-0.82). None of the other outcomes were significant. CONCLUSION In expectantly managed low-risk nulliparous participants, the frequency of medically indicated induction of labor, and the risks of cesarean delivery but not the perinatal composite outcome, increased significantly from 39 to 42 weeks of gestation.",2021,"The frequency of cesarean delivery (17.3%, 22.0%, 37.5%; P<.001) and the perinatal composite (5.1%, 5.9%, 8.2%; P=.03) increased with 39, 40, and 41-42 weeks of gestation, respectively, and hypertensive disorders of pregnancy decreased (16.4%, 12.1%, 10.8%, P=.001).","['low-risk nulliparous patients undergoing expectant management', 'Nulliparous Patients', 'low-risk nulliparous patients', 'Participants with nonanomalous neonates']","['elective induction of labor', 'expectant management']","['maternal composite (blood transfusion, surgical intervention for postpartum hemorrhage, or intensive care unit admission), hypertensive disorders of pregnancy, peripartum infection, and neonatal intermediate or intensive care unit admission', 'frequency of cesarean delivery', 'cesarean delivery and a perinatal composite (death, respiratory support, 5-minute Apgar score 3 or less, hypoxic ischemic encephalopathy, seizure, sepsis, meconium aspiration syndrome, birth trauma, intracranial or subgaleal hemorrhage, or hypotension requiring vasopressor support', 'hypertensive disorders of pregnancy', 'cesarean delivery', 'Delivery gestation', 'frequency of medically indicated induction of labor, and the risks of cesarean delivery', 'perinatal composite']","[{'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0700325', 'cui_str': 'Patient status observation'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}]","[{'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C0700325', 'cui_str': 'Patient status observation'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0852260', 'cui_str': 'Hypertension associated disorders of pregnancy'}, {'cui': 'C2936491', 'cui_str': 'Peripartum period'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0233245', 'cui_str': 'Apgar score 3'}, {'cui': 'C0752304', 'cui_str': 'Hypoxic ischemic encephalopathy'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0025048', 'cui_str': 'Meconium aspiration syndrome'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0475728', 'cui_str': 'Subgaleal hemorrhage'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",2502.0,0.22139,"The frequency of cesarean delivery (17.3%, 22.0%, 37.5%; P<.001) and the perinatal composite (5.1%, 5.9%, 8.2%; P=.03) increased with 39, 40, and 41-42 weeks of gestation, respectively, and hypertensive disorders of pregnancy decreased (16.4%, 12.1%, 10.8%, P=.001).","[{'ForeName': 'Alan T N', 'Initials': 'ATN', 'LastName': 'Tita', 'Affiliation': ""Departments of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama, Northwestern University, Chicago, Illinois, University of Utah Health Sciences Center, Salt Lake City, Utah, Stanford University, Stanford, California, Columbia University, New York, New York, Brown University, Providence, Rhode Island, University of Texas Medical Branch, Galveston, Texas, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston, Texas, The Ohio State University, Columbus, Ohio, Metro Health Medical Center-Case Western Reserve University, Cleveland, Ohio, University of Texas Southwestern Medical Center, Dallas, Texas; University of Pennsylvania, Philadelphia, Pennsylvania, Duke University, Durham, North Carolina, University of Pittsburgh, Pittsburgh, Pennsylvania, Washington University in St. Louis, St. Louis, Missouri; the George Washington University Biostatistics Center, Washington, DC; and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.""}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Doherty', 'Affiliation': ''}, {'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Grobman', 'Affiliation': ''}, {'ForeName': 'Uma M', 'Initials': 'UM', 'LastName': 'Reddy', 'Affiliation': ''}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Silver', 'Affiliation': ''}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Mallett', 'Affiliation': ''}, {'ForeName': 'Madeline Murguia', 'Initials': 'MM', 'LastName': 'Rice', 'Affiliation': ''}, {'ForeName': 'Yasser Y', 'Initials': 'YY', 'LastName': 'El-Sayed', 'Affiliation': ''}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Wapner', 'Affiliation': ''}, {'ForeName': 'Dwight J', 'Initials': 'DJ', 'LastName': 'Rouse', 'Affiliation': ''}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Saade', 'Affiliation': ''}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Thorp', 'Affiliation': ''}, {'ForeName': 'Suneet P', 'Initials': 'SP', 'LastName': 'Chauhan', 'Affiliation': ''}, {'ForeName': 'Maged M', 'Initials': 'MM', 'LastName': 'Costantine', 'Affiliation': ''}, {'ForeName': 'Edward K', 'Initials': 'EK', 'LastName': 'Chien', 'Affiliation': ''}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Casey', 'Affiliation': ''}, {'ForeName': 'Sindhu K', 'Initials': 'SK', 'LastName': 'Srinivas', 'Affiliation': ''}, {'ForeName': 'Geeta K', 'Initials': 'GK', 'LastName': 'Swamy', 'Affiliation': ''}, {'ForeName': 'Hyagriv N', 'Initials': 'HN', 'LastName': 'Simhan', 'Affiliation': ''}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Macones', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000004230'] 807,33420472,Effect of a nut-enriched low-calorie diet on body weight and selected markers of inflammation in overweight and obese stable coronary artery disease patients: a randomized controlled study.,"BACKGROUND/OBJECTIVES Weight loss through a low-calorie diet (LCD) could improve low-grade inflammation evident in the obese state. Few studies have evaluated the effect of the mixed nuts consumption in the context of a LCD on inflammatory biomarkers. This study compared the effects of a nut-enriched LCD (NELCD) with a nut-free LCD (NFLCD) on body weight and inflammatory markers in overweight or obese coronary artery disease (CAD) patients. SUBJECTS/METHOD In this randomized controlled parallel trial, patients with stable CAD of both genders were randomly allocated to 8-week NELCD or NFLCD. Body weight, plasma C-reactive protein (CRP), interleukin-6 (IL-6), interleukin 10 (IL-10), intercellular adhesion molecule-1 (ICAM-1), and monocyte chemoattractant protein (MCP-1) were assessed at baseline and 8 weeks. RESULTS Overall, 67 patients (aged 58.8 ± 7.4 years; BMI 30.9 ± 3.9 kg/m 2 ) completed the study. Participants in both groups lost weight to a comparable extent. Patients in the NELCD group showed a decrease in ICAM-1 (p = 0.04) and IL-6 (p = 0.02) concentrations compared to NFLCD group. No significant difference in concentrations of MCP-1, IL-10, or CRP was observed between diet groups. CONCLUSIONS Nuts are healthy energy-dense foods that if included in controlled amounts in a weight management program can still result in weight reduction and may improve some plasma concentration of inflammatory factors, such as ICAM-1 and IL-6.",2021,"Body weight, plasma C-reactive protein (CRP), interleukin-6 (IL-6), interleukin 10 (IL-10), intercellular adhesion molecule-1 (ICAM-1), and monocyte chemoattractant protein (MCP-1) were assessed at baseline and 8 weeks. ","['patients with stable CAD of both genders', '67 patients (aged 58.8\u2009±\u20097.4 years; BMI 30.9\u2009±\u20093.9\u2009kg/m 2 ) completed the study', 'overweight and obese stable coronary artery disease patients', 'overweight or obese coronary artery disease (CAD) patients']","['nut-enriched low-calorie diet', 'NELCD or NFLCD', 'nut-enriched LCD (NELCD) with a nut-free LCD (NFLCD', 'NELCD', 'low-calorie diet (LCD']","['body weight and selected markers of inflammation', 'ICAM-1', 'IL-6', 'body weight and inflammatory markers', 'Body weight, plasma C-reactive protein (CRP), interleukin-6 (IL-6), interleukin 10 (IL-10), intercellular adhesion molecule-1 (ICAM-1), and monocyte chemoattractant protein (MCP-1', 'concentrations of MCP-1, IL-10, or CRP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517858', 'cui_str': '7.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517698', 'cui_str': '3.9'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0028723', 'cui_str': 'Nut'}, {'cui': 'C2930544', 'cui_str': 'Calorie restricted diet'}, {'cui': 'C1690006', 'cui_str': 'Lattice corneal dystrophy Type I'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0063695', 'cui_str': 'Lymphocyte antigen CD54'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0282566', 'cui_str': 'Monocyte Chemotactic Proteins'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",67.0,0.0776425,"Body weight, plasma C-reactive protein (CRP), interleukin-6 (IL-6), interleukin 10 (IL-10), intercellular adhesion molecule-1 (ICAM-1), and monocyte chemoattractant protein (MCP-1) were assessed at baseline and 8 weeks. ","[{'ForeName': 'Matin', 'Initials': 'M', 'LastName': 'Ghanavati', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Susan Mohammadi', 'Initials': 'SM', 'LastName': 'Hosseinabadi', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeed Alipour', 'Initials': 'SA', 'LastName': 'Parsa', 'Affiliation': 'Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Morteza', 'Initials': 'M', 'LastName': 'Safi', 'Affiliation': 'Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Emamat', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Nasrollahzadeh', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. jnasrollahzadeh@gmail.com.'}]",European journal of clinical nutrition,['10.1038/s41430-020-00819-9'] 808,33407782,An exercise trial for adults undergoing neoadjuvant chemoradiotherapy for rectal cancer proves not feasible: recommendations for future trials.,"BACKGROUND The aim of this paper is to share the methodological problems of an unsuccessful prospective single-arm feasibility trial conducted to evaluate the safety and feasibility of a 12-week progressive exercise intervention for adults undergoing neoadjuvant chemoradiotherapy for rectal cancer, as well as offer recommendations for future trials. METHODS The initial plan was to recruit adults diagnosed with rectal cancer and scheduled for neoadjuvant chemoradiotherapy over a 12-month period. The exercise intervention was to consist of supervised exercise sessions delivered three times per week by a trained exercise specialist. Feasibility (i.e., recruitment, adherence, and compliance rates) and safety (i.e., adverse events) were to be assessed throughout the trial, and patient-reported and physical health outcomes were to be assessed pre- and post-intervention. After 8 months of open recruitment, we had been unable to successfully enroll patients into our trial. We therefore modified our eligibility criteria to increase the number of patients that could be recruited into our trial, and in turn increase our recruitment rate. We also amended our recruitment procedures to ensure we could reach patients who were either awaiting treatment, receiving treatment, or had completed treatments in the past 5 years. In doing so, we added a research objective, namely to determine the optimal timing of conducting an exercise intervention with adults diagnosed with rectal cancer (i.e., during neoadjuvant treatment, after surgery, during adjuvant treatment, or post-treatment). RESULTS Many problems continued to hinder the progress of our trial, particularly the low recruitment rate and the failure to enroll the required sample size that would make our results reliable. CONCLUSION This led us to conclude that our trial was not feasible and that it is advisable to consider some elements carefully (e.g., recruitment strategies, communication, and trial location) before designing and conducting future trials. If one or more of these elements still proves to be problematic, trial results risk being compromised and alternative approaches should be considered. TRIAL REGISTRATION ClinicalTrials.gov NCT03049124 . Registered on 02 September 2017.",2021,"Feasibility (i.e., recruitment, adherence, and compliance rates) and safety (i.e., adverse events) were to be assessed throughout the trial, and patient-reported and physical health outcomes were to be assessed pre- and post-intervention.","['adults undergoing neoadjuvant chemoradiotherapy for rectal cancer', 'adults diagnosed with rectal cancer (i.e., during neoadjuvant treatment, after surgery, during adjuvant treatment, or post-treatment', 'patients who were either awaiting treatment, receiving treatment, or had completed treatments in the past 5\u2009years', 'adults undergoing', 'adults diagnosed with rectal cancer and scheduled for']","['exercise intervention', 'neoadjuvant chemoradiotherapy', 'progressive exercise intervention']","['Feasibility (i.e., recruitment, adherence, and compliance rates) and safety (i.e., adverse events']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}]","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.162894,"Feasibility (i.e., recruitment, adherence, and compliance rates) and safety (i.e., adverse events) were to be assessed throughout the trial, and patient-reported and physical health outcomes were to be assessed pre- and post-intervention.","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Brunet', 'Affiliation': 'School of Human Kinetics, University of Ottawa, 125 University Private, Montpetit Hall, Room 339, Ottawa, Ontario, K1N 6N5, Canada. jennifer.brunet@uottawa.ca.'}, {'ForeName': 'Jenson', 'Initials': 'J', 'LastName': 'Price', 'Affiliation': 'School of Human Kinetics, University of Ottawa, 125 University Private, Montpetit Hall, Room 339, Ottawa, Ontario, K1N 6N5, Canada.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Delluc', 'Affiliation': 'Institut du savoir Montfort, Hôpital Montfort, Ottawa, Ontario, Canada.'}]",Trials,['10.1186/s13063-020-04958-z'] 809,33410265,"A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.","A phase 3 study was conducted to verify the efficacy and safety of 5% sofpironium bromide (BBI-4000) gel (hereinafter referred to as sofpironium) administrated for 6 weeks in Japanese patients with primary axillary hyperhidrosis. The primary efficacy end-point was the proportion of patients who satisfied both criteria of a Hyperhidrosis Disease Severity Score (HDSS) of 1 or 2 at the end of 6-week treatment and a 50% or more reduction in total gravimetric weight of sweat at the end of treatment relative to baseline. A total of 281 patients were randomized to receive 5% sofpironium (141 patients) or vehicle (140 patients), and all patients were included in the full analysis set (FAS). In the FAS, 70.1% of patients were female, and the median age was 35.0 years. The proportion of patients who achieved the primary efficacy end-point was 53.9% in the sofpironium group and 36.4% in the vehicle group, with a statistically significant difference of 17.5% (95% confidence interval, 6.02-28.93) between these two groups (P = 0.003). The incidence of adverse events was 44.0% in the sofpironium group and 30.7% in the vehicle group, and the incidence of adverse drug reactions was 16.3% in the sofpironium group and 5.0% in the vehicle group. Reported adverse events were generally mild or moderate in severity. In the sofpironium group, common events (incidence, ≥5%) were nasopharyngitis (14.2%) and dermatitis/erythema at the application site (8.5%/5.7%), with no serious adverse events reported. This study demonstrated the efficacy and safety of 5% sofpironium.",2021,"The incidence of adverse events was 44.0% in the sofpironium group and 30.7% in the vehicle group, and the incidence of adverse drug reactions was 16.3% in the sofpironium group and 5.0% in the vehicle group.","['Japanese patients with primary axillary hyperhidrosis', 'A total of 281 patients']","['5% sofpironium bromide (BBI-4000) gel', 'sofpironium bromide (BBI-4000) gel', '5% sofpironium']","['incidence of adverse drug reactions', 'proportion of patients who satisfied both criteria of a Hyperhidrosis Disease Severity Score (HDSS', 'nasopharyngitis', 'dermatitis/erythema', 'efficacy and safety', 'total gravimetric weight of sweat', 'adverse events', 'incidence of adverse events']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0004454', 'cui_str': 'Axillary'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0006222', 'cui_str': 'bromides'}, {'cui': 'C3842327', 'cui_str': '4000'}, {'cui': 'C0017243', 'cui_str': 'Gel'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0011603', 'cui_str': 'Dermatitis'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1278297', 'cui_str': 'Sweat weight measurement'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",281.0,0.098606,"The incidence of adverse events was 44.0% in the sofpironium group and 30.7% in the vehicle group, and the incidence of adverse drug reactions was 16.3% in the sofpironium group and 5.0% in the vehicle group.","[{'ForeName': 'Hiroo', 'Initials': 'H', 'LastName': 'Yokozeki', 'Affiliation': 'Department of Dermatology, Tokyo Medical and Dental University, Tokyo, Japan.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Fujimoto', 'Affiliation': 'Ikebukuro Nishiguchi Fukurou Dermatology Clinic, Tokyo, Japan.'}, {'ForeName': 'Yoichiro', 'Initials': 'Y', 'LastName': 'Abe', 'Affiliation': 'Department of Pain Clinic, NTT Medical Center Tokyo, Tokyo, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Igarashi', 'Affiliation': 'Igarashi Dermatology Clinic, Tokyo, Japan.'}, {'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Ishikoh', 'Affiliation': 'Kaminoge Hifuka Clinic, Tokyo, Japan.'}, {'ForeName': 'Tokuya', 'Initials': 'T', 'LastName': 'Omi', 'Affiliation': ""Department of Dermatology, Queen's Square Medical Center, Kanagawa, Japan.""}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Kanda', 'Affiliation': 'Mita Dermatology Clinic, Tokyo, Japan.'}, {'ForeName': 'Hiroto', 'Initials': 'H', 'LastName': 'Kitahara', 'Affiliation': 'Kitahara Dermatology Clinic, Tokyo, Japan.'}, {'ForeName': 'Miwako', 'Initials': 'M', 'LastName': 'Kinoshita', 'Affiliation': 'Kinoshita Dermatology Clinic, Tokyo, Japan.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Nakasu', 'Affiliation': 'Nemunoki Dermatology Clinic, Kanagawa, Japan.'}, {'ForeName': 'Naoko', 'Initials': 'N', 'LastName': 'Hattori', 'Affiliation': 'Naoko Dermatology Clinic, Tokyo, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Horiuchi', 'Affiliation': 'Akihabara Skin Clinic, Tokyo, Japan.'}, {'ForeName': 'Ryuji', 'Initials': 'R', 'LastName': 'Maruyama', 'Affiliation': 'Maruyama Dermatology Clinic, Tokyo, Japan.'}, {'ForeName': 'Haruko', 'Initials': 'H', 'LastName': 'Mizutani', 'Affiliation': 'Mizutani Dermatology Clinic, Tokyo, Japan.'}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Murakami', 'Affiliation': 'Mildix Skin Clinic, Tokyo, Japan.'}, {'ForeName': 'Chiharu', 'Initials': 'C', 'LastName': 'Watanabe', 'Affiliation': 'Chiharu Dermatology Clinic, Saitama, Japan.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Kume', 'Affiliation': 'Dermatology and Ophthalmology Kume Clinic, Osaka, Japan.'}, {'ForeName': 'Takaaki', 'Initials': 'T', 'LastName': 'Hanafusa', 'Affiliation': 'Senri-Chuo Hanafusa Dermatology Clinic, Osaka, Japan.'}, {'ForeName': 'Masamitsu', 'Initials': 'M', 'LastName': 'Hamaguchi', 'Affiliation': 'Hamaguchi Clinic, Osaka, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Yoshioka', 'Affiliation': 'Yoshioka Dermatology Clinic, Osaka, Japan.'}, {'ForeName': 'Yuriko', 'Initials': 'Y', 'LastName': 'Egami', 'Affiliation': 'Ekihigashi Dermatology and Allergology Clinic, Fukuoka, Japan.'}, {'ForeName': 'Keizo', 'Initials': 'K', 'LastName': 'Matsuo', 'Affiliation': 'Matsuo Clinic, Fukuoka, Japan.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Matsuda', 'Affiliation': 'Tomoko Matsuda Dermatological Clinic, Fukuoka, Japan.'}, {'ForeName': 'Motoki', 'Initials': 'M', 'LastName': 'Akamatsu', 'Affiliation': 'Kaken Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Toshiyuki', 'Initials': 'T', 'LastName': 'Yorozuya', 'Affiliation': 'Kaken Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Takayama', 'Affiliation': 'Kaken Pharmaceutical Co., Ltd., Tokyo, Japan.'}]",The Journal of dermatology,['10.1111/1346-8138.15668'] 810,33411362,Intraoperative dexmedetomidine for prevention of postoperative delirium in elderly patients with mild cognitive impairment.,"OBJECTIVES Delirium is the most common postoperative neurological complication and some evidence suggests that dexmedetomidine is associated with a decreased incidence of delirium. This study is designed to assess the effect of dexmedetomidine on postoperative delirium (POD) in elderly patients with mild cognitive impairment (MCI). METHODS Sixty geriatric patients with MCI were enrolled and ramdomly divided into two groups by a computer-generated randomisation sequence: dexmedetomidine group (D group) and normal saline group (C group). Patients in D group received a loading dose of 0.5 μg/kg dexmedetomidine over 10 minutes before anesthesia induction, followed by a continuous infusion of 0.4 μg·kg -1 ·h -1 until 30 minutes before the end of surgery; equal volume of normal saline was given in C group. Blood samples were extracted to detect the concentration of cytokines, including tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), heme oxygenase-1 (HO-1), matrix metalloproteinase-9 (MMP-9), and glial fibrillary acidic protein (GFAP) before anesthesia induction (T 1 ), before suture (T 2 ), and 30 minutes after surgery (T 3 ). Postoperative recovery times were recorded. Delirium was assessed with the 3-Minute Diagnostic Interview for confusion assessment method during the first 7 days postoperatively. RESULTS POD occurred in 10 (33.3%) of 30 patients in C group, and in 3 (10%) of 30 patients given dexmedetomidine (odds ratio [OR] 0.222, 95% CI 0.054-0.914; P = 0.028). The serum concentrations of TNF-α, MMP-9, and GFAP were significantly increased and IL-10 was decreased in the C group than in the D group at T 2 and T 3 . No differences were observed between groups in the level of HO-1. Analysis using random-effect multivariable logistic regression indicated that POD was associated with GFAP (odds ratio [OR] 16.691, 95% CI 2.288-121.746; P = 0.005). The positive predictive ability of the multivariate logistic regression model tested by ROC analysis showed an area under the curve of 0.713 (95% CI, 0.584-0.842). CONCLUSIONS Dexmedetomidine can alleviate POD in elderly patients with MCI and may be related to reduce the neuroinflammation by lowering the permeability of blood-brain barrier.",2021,"The serum concentrations of TNF-α, MMP-9, and GFAP were significantly increased and IL-10 was decreased in the C group than in the D group at T 2 and T 3 .","['Sixty geriatric patients with MCI', 'elderly patients with mild cognitive impairment', 'elderly patients with MCI', 'elderly patients with mild cognitive impairment (MCI']","['loading dose of 0.5 μg/kg dexmedetomidine', 'dexmedetomidine', 'Dexmedetomidine', 'Intraoperative dexmedetomidine', 'normal saline']","['level of HO-1', 'IL-10', 'Delirium', 'concentration of cytokines, including tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), heme oxygenase-1 (HO-1), matrix metalloproteinase-9 (MMP-9), and glial fibrillary acidic protein (GFAP', 'serum concentrations of TNF-α, MMP-9, and GFAP', 'POD', 'postoperative delirium (POD', 'Postoperative recovery times']","[{'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C3714444', 'cui_str': 'Loading dose'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0538674', 'cui_str': 'Hemeoxygenase 1'}, {'cui': 'C0165519', 'cui_str': 'Gelatinase B'}, {'cui': 'C0017626', 'cui_str': 'Glial fibrillary acidic protein'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C4721772', 'cui_str': 'Postoperative delirium'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",60.0,0.26275,"The serum concentrations of TNF-α, MMP-9, and GFAP were significantly increased and IL-10 was decreased in the C group than in the D group at T 2 and T 3 .","[{'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Xin', 'Affiliation': 'Department of Anesthesiology, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hua', 'Affiliation': 'Department of Anesthesiology, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China.'}, {'ForeName': 'Haiyun', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China.'}]",International journal of geriatric psychiatry,['10.1002/gps.5406'] 811,33419890,Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial.,"BACKGROUND Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF). METHODS Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label nintedanib for 40 weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients. RESULTS In total, 346 subjects were treated. Mean adherence to weekly home spirometry decreased over time but remained above 75% in every 4-week period. Over 52 weeks, mean adherence was 86%. Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry. Strong correlations were observed between home- and clinic-measured FVC at all time-points (r=0.72-0.84), but correlations between home- and clinic-measured rates of change in FVC were weak (r=0.26 for rate of decline in FVC over 52 weeks). CONCLUSION Home spirometry was a feasible and valid measure of lung function in patients with IPF and preserved FVC, but estimates of the rate of FVC decline obtained using home spirometry were poorly correlated with those based on clinic spirometry.",2021,Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry.,"['patients with idiopathic pulmonary fibrosis', '346 subjects were treated', 'patients with idiopathic pulmonary fibrosis (IPF).Subjects with IPF and preserved forced vital capacity (FVC']",['nintedanib or placebo'],"['mean adherence', 'Mean adherence to weekly home spirometry']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}]","[{'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}]",346.0,0.037761,Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry.,"[{'ForeName': 'Imre', 'Initials': 'I', 'LastName': 'Noth', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Cottin', 'Affiliation': 'National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France.'}, {'ForeName': 'Nazia', 'Initials': 'N', 'LastName': 'Chaudhuri', 'Affiliation': 'North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Tamera J', 'Initials': 'TJ', 'LastName': 'Corte', 'Affiliation': 'Royal Prince Alfred Hospital, Camperdown, Australia.'}, {'ForeName': 'Kerri A', 'Initials': 'KA', 'LastName': 'Johannson', 'Affiliation': 'Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Marlies', 'Initials': 'M', 'LastName': 'Wijsenbeek', 'Affiliation': 'Dept of Respiratory Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Stephane', 'Initials': 'S', 'LastName': 'Jouneau', 'Affiliation': 'Hôpital Pontchaillou - CHU de Rennes, IRSET UMR 1085, Université de Rennes 1, Rennes, France.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Michael', 'Affiliation': 'Syneos Health, Farnborough, UK.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Quaresma', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Klaus B', 'Initials': 'KB', 'LastName': 'Rohr', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Anne-Marie', 'Initials': 'AM', 'LastName': 'Russell', 'Affiliation': 'College of Medicine and Health, University of Exeter, Exeter, UK.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Stowasser', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Toby M', 'Initials': 'TM', 'LastName': 'Maher', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The European respiratory journal,['10.1183/13993003.01518-2020'] 812,33421265,Targeting the ectopy-triggering ganglionated plexuses without pulmonary vein isolation prevents atrial fibrillation.,"BACKGROUND Ganglionated plexuses (GPs) are implicated in atrial fibrillation (AF). Endocardial high-frequency stimulation (HFS) delivered within the local atrial refractory period can trigger ectopy and AF from specific GP sites (ET-GP). The aim of this study was to understand the role of ET-GP ablation in the treatment of AF. METHODS Patients with paroxysmal AF indicated for ablation were recruited. HFS mapping was performed globally around the left atrium to identify ET-GP. ET-GP was defined as atrial ectopy or atrial arrhythmia triggered by HFS. All ET-GP were ablated, and PVs were left electrically connected. Outcomes were compared with a control group receiving pulmonary vein isolation (PVI). Patients were followed-up for 12 months with multiple 48-h Holter ECGs. Primary endpoint was ≥30 s AF/atrial tachycardia in ECGs. RESULTS In total, 67 patients were recruited and randomized to ET-GP ablation (n = 39) or PVI (n = 28). In the ET-GP ablation group, 103 ± 28 HFS sites were tested per patient, identifying 21 ± 10 (20%) GPs. ET-GP ablation used 23.3 ± 4.1 kWs total radiofrequency (RF) energy per patient, compared with 55.7 ± 22.7 kWs in PVI (p = <.0001). Duration of procedure was 3.7 ± 1.0 and 3.3 ± 0.7 h in ET-GP ablation group and PVI, respectively (p = .07). Follow-up at 12 months showed that 61% and 49% were free from ≥30 s of AF/AT with PVI and ET-GP ablation respectively (log-rank p = .27). CONCLUSIONS It is feasible to perform detailed global functional mapping with HFS and ablate ET-GP to prevent AF. This provides direct evidence that ET-GPs are part of the AF mechanism. The lower RF requirement implies that ET-GP targets the AF pathway more specifically.",2021,Primary endpoint was ≥30s,"['Patients with paroxysmal AF indicated for ablation were recruited', '67 patients', 'n=39) or PVI (n=28']","['ET-GP ablation', 'Endocardial high frequency stimulation (HFS', 'Ganglionated plexuses (GP', 'ET-GP ablation used 23.3kWs±4.1 total radiofrequency (RF) energy', 'ectopy-triggering ganglionated plexuses without pulmonary vein isolation']",['Duration of procedure'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}]","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0014124', 'cui_str': 'Endocardial'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",67.0,0.0191164,Primary endpoint was ≥30s,"[{'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Sandler', 'Affiliation': 'Myocardial Function Section, National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Min-Young', 'Initials': 'MY', 'LastName': 'Kim', 'Affiliation': 'Myocardial Function Section, National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Markus B', 'Initials': 'MB', 'LastName': 'Sikkel', 'Affiliation': 'Myocardial Function Section, National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Louisa', 'Initials': 'L', 'LastName': 'Malcolme-Lawes', 'Affiliation': 'Imperial Centre for Cardiac Engineering, Imperial College London, London, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Koa-Wing', 'Affiliation': 'Imperial Centre for Cardiac Engineering, Imperial College London, London, UK.'}, {'ForeName': 'Zachary I', 'Initials': 'ZI', 'LastName': 'Whinnett', 'Affiliation': 'Imperial Centre for Cardiac Engineering, Imperial College London, London, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Coyle', 'Affiliation': 'Myocardial Function Section, National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Nick W F', 'Initials': 'NWF', 'LastName': 'Linton', 'Affiliation': 'Myocardial Function Section, National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Phang B', 'Initials': 'PB', 'LastName': 'Lim', 'Affiliation': 'Myocardial Function Section, National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Prapa', 'Initials': 'P', 'LastName': 'Kanagaratnam', 'Affiliation': 'Myocardial Function Section, National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of cardiovascular electrophysiology,['10.1111/jce.14870'] 813,33415555,Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of Newborn: A Pilot Randomized Controlled Trial.,"OBJECTIVES To investigate the effectiveness of nebulized magnesium sulfate in treating persistent pulmonary hypertension of newborn (PPHN). METHODS Twenty-eight mechanically ventilated term neonates with severe PPHN were randomized into two groups: NebMag group (n = 14), who receiving nebulized isotonic magnesium (1024 mg/h), and IVMag group (n = 14), who received intravenous magnesium (200 mg/kg over 30 min, followed by 50 mg/kg/h). The study time frame was 24 h. Outcome measures were the changes in oxygenation index (OI), mean arterial blood pressure (MABP), vasoactive inotropic score (VIS), and serum magnesium level. RESULTS Baseline demographic, ventilatory, and hemodynamic characteristics were comparable between the two groups. At the end of the study, the OI decreased by 44.3% in the NebMag group compared with 35.3% in the IVMag group (mean difference -3.14; 95%CI -5.08, -1.19; p 0.003). The NebMag group had a higher MABP (mean difference 2.29 mmHg; 95% CI 1.80, 2.77; p 0.000) and lower VIS (mean difference -14.64; 95% CI -16.52, -12.77; p 0.000) at the 24-h study time point. The increase in serum magnesium level, measured at 12-h study time point, was lower in the NebMag group (mean difference -2.26 mmol/L; 95% CI -2.58, -1.96; p 0.000). CONCLUSION Nebulized magnesium sulfate may be an effective therapeutic modality for neonates with severe PPHN on mechanical ventilation, but this should be confirmed by larger studies. Retrospectively registered at www.clinicaltrials.gov (identifier: NCT04328636).",2021,"The increase in serum magnesium level, measured at 12-h study time point, was lower in the NebMag group (mean difference -2.26 mmol/L; 95% CI -2.58, -1.96; p 0.000). ","['treating persistent pulmonary hypertension of newborn (PPHN', 'Persistent Pulmonary Hypertension of Newborn', 'Twenty-eight mechanically ventilated term neonates with severe PPHN', 'neonates with severe PPHN on mechanical ventilation']","['intravenous magnesium', 'nebulized magnesium sulfate', 'Nebulized Magnesium Sulfate', 'nebulized isotonic magnesium', 'Nebulized magnesium sulfate', 'IVMag']","['lower VIS', 'changes in oxygenation index (OI), mean arterial blood pressure (MABP), vasoactive inotropic score (VIS), and serum magnesium level', 'serum magnesium level', 'MABP', 'Baseline demographic, ventilatory, and hemodynamic characteristics']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0031190', 'cui_str': 'Persistent pulmonary hypertension of the newborn'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C4551581', 'cui_str': 'Term baby'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0024480', 'cui_str': 'Magnesium Sulfate'}, {'cui': 'C0454287', 'cui_str': 'Isotonic exercise'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index measurement'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0202125', 'cui_str': 'Magnesium measurement, serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}]",28.0,0.356573,"The increase in serum magnesium level, measured at 12-h study time point, was lower in the NebMag group (mean difference -2.26 mmol/L; 95% CI -2.58, -1.96; p 0.000). ","[{'ForeName': 'Elsayed', 'Initials': 'E', 'LastName': 'Abdelkreem', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt. d.elsayedmohammed@med.sohag.edu.eg.'}, {'ForeName': 'Shaimaa M', 'Initials': 'SM', 'LastName': 'Mahmoud', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt.'}, {'ForeName': 'Moustafa O', 'Initials': 'MO', 'LastName': 'Aboelez', 'Affiliation': 'Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Sohag University, Sohag, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Abd El Aal', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt.'}]",Indian journal of pediatrics,['10.1007/s12098-020-03643-y'] 814,33420257,Impact of improved small-scale livestock farming on human nutrition.,"Micronutrient deficiencies and stunting rates are high in many low-income countries. Increasing and diversifying food intake are often challenging for small-scale farmers in lowland areas as flooding often results in crop losses and drowning of livestock. A cluster-randomised controlled trial was conducted over 12-months in Bangladesh, involving 150 small-scale duck rearing households, including 50 control, and 50 households each in two intervention arms. Interventions focussing on improving duck health and duck nutrition were applied on a village level. Data analysis focussed on assessing the impact of interventions on duck mortality, sales and consumption, and on dietary diversity of household members. Improved duck rearing increased the consumption and the sales of ducks. Household selling more ducks were more likely to purchase and consume milk products, contributing to an improved households' dietary diversity. Our results suggest that improving duck rearing can provide a suitable and sustainable alternative to maintain and improve dietary diversity of households in flood-prone areas.",2021,Our results suggest that improving duck rearing can provide a suitable and sustainable alternative to maintain and improve dietary diversity of households in flood-prone areas.,"['12-months in Bangladesh, involving 150 small-scale duck rearing households, including 50 control, and 50 households each in two intervention arms', 'small-scale livestock farming on human nutrition']",[],"['duck mortality, sales and consumption, and on dietary diversity of household members']","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0013268', 'cui_str': 'Genus Anas'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C2936506', 'cui_str': 'Livestock'}, {'cui': 'C0001829', 'cui_str': 'Farming'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}]",[],"[{'cui': 'C0013268', 'cui_str': 'Genus Anas'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0036070', 'cui_str': 'Sales'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0680022', 'cui_str': 'Member of'}]",150.0,0.0349396,Our results suggest that improving duck rearing can provide a suitable and sustainable alternative to maintain and improve dietary diversity of households in flood-prone areas.,"[{'ForeName': 'Md Emran', 'Initials': 'ME', 'LastName': 'Hossain', 'Affiliation': 'Chattogram Veterinary and Animal Sciences University (CVASU), Chattogram, Bangladesh.'}, {'ForeName': 'Md Ahasanul', 'Initials': 'MA', 'LastName': 'Hoque', 'Affiliation': 'Chattogram Veterinary and Animal Sciences University (CVASU), Chattogram, Bangladesh.'}, {'ForeName': 'Emanuele', 'Initials': 'E', 'LastName': 'Giorgi', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Fournié', 'Affiliation': 'Department of Pathobiology and Population Sciences, Royal Veterinary College, London, UK.'}, {'ForeName': 'Goutam Buddha', 'Initials': 'GB', 'LastName': 'Das', 'Affiliation': 'Chattogram Veterinary and Animal Sciences University (CVASU), Chattogram, Bangladesh.'}, {'ForeName': 'Joerg', 'Initials': 'J', 'LastName': 'Henning', 'Affiliation': 'School of Veterinary Science, University of Queensland, Gatton, QLD, 4343, Australia. j.henning@uq.edu.au.'}]",Scientific reports,['10.1038/s41598-020-80387-x'] 815,33420241,Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin.,"The present study aimed to investigate the efficacy and toxicity of pegylated liposomal doxorubicin (PLD) in preoperative neoadjuvant chemotherapy for patients with breast cancer by comparing with conventional anthracycline. This study is a non-randomized controlled trial. Prospective analysis was conducted after matching as required. A total of 146 patients with confirmed diagnosis of breast cancer by histopathological examinations were enrolled into the observation group and control group in 1:1 ratio. Each of the cases in the observation group was required to correspond to another in the control group according to the requirements including age, molecular subtype, axillary node status, and regimen of the preoperative neoadjuvant chemotherapy. The chemotherapy was based on regimens consisting of anthracyclines, paclitaxel or docetaxel, and/or platinum. PLD was used at least twice in the observation group, with traditional anthracycline as a contrast in the control group. Clinical responses as well as cardiac side effects and other adverse reactions were evaluated by clinical and imaging examinations such as electrocardiogram (ECG) and color Doppler ultrasound during the chemotherapy. Pathologic examinations were performed following the surgeries after preoperative neoadjuvant chemotherapy. All the patients in both groups completed the preoperative neoadjuvant chemotherapy according to their original regimens. The postoperative pathological evaluation revealed a higher pathologic complete response (PCR) rate and significantly more patients of grade V of the Miller-Payne grading system in the observation group as compared to the control group (p = 0.047). In addition, the observation group recorded an evidently lower occurrence of the adverse cardiac events (p = 0.014), ECG changes (p = 0.048), and the relatively severe adverse reactions such as myelosuppression. Compared with conventional anthracycline drugs, PLD has a better pathologic response and safety performance, as well as a similar clinical effectiveness in preoperative neoadjuvant chemotherapy for breast cancer.",2021,"In addition, the observation group recorded an evidently lower occurrence of the adverse cardiac events (p = 0.014), ECG changes (p = 0.048), and the relatively severe adverse reactions such as myelosuppression.","['patients with breast cancer by comparing with', '146 patients with confirmed diagnosis of breast cancer by histopathological examinations']","['anthracyclines, paclitaxel or docetaxel, and/or platinum', 'pegylated liposomal doxorubicin (PLD', 'pegylated liposomal doxorubicin', 'conventional anthracycline drugs, PLD', 'conventional anthracycline', 'neoadjuvant chemotherapy', 'traditional anthracycline', 'preoperative neoadjuvant\xa0chemotherapy', 'pirarubicin']","['adverse cardiac events', 'pathologic response and safety performance', 'efficacy and toxicity', 'adverse reactions', 'ECG changes', 'pathologic complete response (PCR) rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0717726', 'cui_str': 'doxorubicin liposome'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0071126', 'cui_str': 'Pirarubicin'}]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0855329', 'cui_str': 'Electrocardiogram change'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}]",146.0,0.0194702,"In addition, the observation group recorded an evidently lower occurrence of the adverse cardiac events (p = 0.014), ECG changes (p = 0.048), and the relatively severe adverse reactions such as myelosuppression.","[{'ForeName': 'Weifang', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Department of Breast Surgery, Song Yuan Central Hospital, Changchun, China.'}, {'ForeName': 'Xiuxiang', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhao', 'Affiliation': 'Department of Thyroid and Breast Surgery, Affiliated Hospital of Jining Medical University, Shandong, China.'}, {'ForeName': 'Zhimin', 'Initials': 'Z', 'LastName': 'Fan', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Lirong', 'Initials': 'L', 'LastName': 'Bi', 'Affiliation': 'Department of Pathology, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Sijie', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Fu', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Song', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Zhao', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Du', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Aiping', 'Initials': 'A', 'LastName': 'Shi', 'Affiliation': 'Department of Breast Surgery, First Hospital of Jilin University, Changchun, China. liuwf18@mails.jlu.edu.cn.'}]",Scientific reports,['10.1038/s41598-020-80415-w'] 816,33418095,Cognitive effects of theta frequency bilateral subthalamic nucleus stimulation in Parkinson's disease: A pilot study.,"BACKGROUND There is significant evidence for cognitive decline following deep brain stimulation (DBS). Current stimulation paradigms utilize gamma frequency stimulation for optimal motor benefits; however, little has been done to optimize stimulation parameters for cognition. Recent evidence implicates subthalamic nucleus (STN) theta oscillations in executive function, and theta oscillations are well-known to relate to episodic memory, suggesting that theta frequency stimulation could potentially improve cognition in Parkinson's disease (PD). OBJECTIVE To evaluate the acute effects of theta frequency bilateral STN stimulation on executive function in PD versus gamma frequency and off, as well as investigate the differential effects on episodic versus nonepisodic verbal fluency. METHODS Twelve patients (all males, mean age 60.8) with bilateral STN DBS for PD underwent a double-blinded, randomized cognitive testing during stimulation at (1) 130-135 Hz (gamma), (2) 10 Hz (theta) and (3) off. Executive functions and processing speed were evaluated using verbal fluency tasks (letter, episodic category, nonepisodic category, and category switching), color-word interference task, and random number generation task. Performance at each stimulation frequency was compared within subjects. RESULTS Theta frequency significantly improved episodic category fluency compared to gamma, but not compared to off. There were no significant differences between stimulation frequencies in other tests. CONCLUSION In this pilot trial, our results corroborate the role of theta oscillations in episodic retrieval, although it is unclear whether this reflects direct modulation of the medial temporal lobe and whether similar effects can be found with more canonical memory paradigms. Further work is necessary to corroborate our findings and investigate the possibility of interleaving theta and gamma frequency stimulation for concomitant motor and cognitive effects.",2021,"RESULTS Theta frequency significantly improved episodic category fluency compared to gamma, but not compared to off.","[""Parkinson's Disease"", 'Twelve patients (all males, mean age 60.8) with bilateral STN DBS for PD underwent a double-blinded, randomized cognitive testing during stimulation at (1) 130-135Hz (gamma), (2) 10Hz (theta) and (3) off']","['theta frequency bilateral STN stimulation', 'Theta Frequency Bilateral Subthalamic Nucleus Stimulation']","['Executive functions and processing speed', 'stimulation frequencies', 'episodic category fluency', 'executive function', 'verbal fluency tasks (letter, episodic category, nonepisodic category, and category switching), color-word interference task, and random number generation task']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0152355', 'cui_str': 'Nucleus of Luys'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C1174074', 'cui_str': 'AT 130'}]","[{'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0152355', 'cui_str': 'Nucleus of Luys'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0079411', 'cui_str': 'Generations'}]",,0.173535,"RESULTS Theta frequency significantly improved episodic category fluency compared to gamma, but not compared to off.","[{'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Lam', 'Affiliation': 'Department of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, United States; USC Neurorestoration Center, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, United States; USC Neurorestoration Center, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Williams', 'Affiliation': ""King's College London Medical School, London, United Kingdom.""}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Cohn', 'Affiliation': 'Department of Psychology, University of Toronto, Toronto, Canada; Krembil Brain Institute, University Health Network, Toronto, Canada.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Wilson', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Mark', 'Affiliation': 'Department of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, United States; USC Neurorestoration Center, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Esnaashari', 'Affiliation': 'Department of Neurology, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Petkus', 'Affiliation': 'Department of Neurology, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hui', 'Affiliation': 'Department of Neurology, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Feigenbaum', 'Affiliation': 'Department of Neurology, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Liker', 'Affiliation': 'Department of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Charles Y', 'Initials': 'CY', 'LastName': 'Liu', 'Affiliation': 'Department of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, United States; USC Neurorestoration Center, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Lee', 'Affiliation': 'Department of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, United States; USC Neurorestoration Center, Keck School of Medicine of USC, Los Angeles, United States.'}, {'ForeName': 'Darrin J', 'Initials': 'DJ', 'LastName': 'Lee', 'Affiliation': 'Department of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, United States; USC Neurorestoration Center, Keck School of Medicine of USC, Los Angeles, United States. Electronic address: Darrin.lee@med.usc.edu.'}]",Brain stimulation,['10.1016/j.brs.2020.12.014'] 817,33421309,Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.,"AIMS/INTRODUCTION We recently reported the beneficial effect of the combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus. Additional favorable effects of combination therapy were explored in this secondary analysis. MATERIALS AND METHODS The CALMER study was a multicenter, open-label, prospective, randomized, parallel-group comparison trial for type 2 diabetes mellitus involving continuous glucose monitoring under meal tolerance tests. Patients were randomly assigned to switch from teneligliptin to canagliflozin (SWITCH group) or to add canagliflozin to teneligliptin (COMB group). The continuous glucose monitoring metrics, including time in target range, were investigated. RESULTS All 99 participants (mean age 62.3 years; mean glycated hemoglobin 7.4%) completed the trial. The time in target range was increased in the COMB group (71.2-82.7%, P < 0.001). The extent of the reduction in time above target range was significantly larger in the COMB group compared with the SWITCH group (-14.8% vs -7.5%, P < 0.01). Area under the curve values for glucose at 120 min after all meal tolerance tests were significantly decreased in the COMB group compared with the SWITCH group (P < 0.05). CONCLUSIONS Sodium-glucose cotransporter 2 inhibitor combined with dipeptidyl peptidase-4 inhibitor improved the quality of glycemic variability and reduced postprandial hyperglycemia compared with each monotherapy.",2021,"TIR was increased in the COMB group (71.2% to 82.7%, p<0.001).","['patients with type 2 diabetes mellitus (T2DM', 'All 99 participants (mean age: 62.3 years; mean HbA1c: 7.4%) completed the trial']","['T2DM involving continuous glucose monitoring (CGM) under meal tolerance tests (MTTs', 'teneligliptin to canagliflozin (SWITCH group) or to add canagliflozin to teneligliptin (COMB group', 'Teneligliptin', 'SGLT2 inhibitor combined with DPP-4 inhibitor', 'SGLT2 inhibitor and DPP-4 inhibitor']","['TIR', 'Improved Time in Range and Postprandial Hyperglycemia', 'quality of glycemic variability and reduced postprandial hyperglycemia', 'time above target range (TAR', 'daily glycemic variability', 'Area under the curve values for glucose', 'time in target range (TIR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C4517858', 'cui_str': '7.4'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0201777', 'cui_str': 'Tolerance test'}, {'cui': 'C2974540', 'cui_str': 'canagliflozin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0376161', 'cui_str': 'Comb'}, {'cui': 'C3273807', 'cui_str': 'SGLT2 Inhibitors'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0574173', 'cui_str': 'Tigrinya language'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0460094', 'cui_str': 'Within reference range'}, {'cui': 'C1855520', 'cui_str': 'Postprandial Hyperglycemia'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}]",,0.0344786,"TIR was increased in the COMB group (71.2% to 82.7%, p<0.001).","[{'ForeName': 'Kyu Yong', 'Initials': 'KY', 'LastName': 'Cho', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nomoto', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Akinobu', 'Initials': 'A', 'LastName': 'Nakamura', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Kawata', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Sugawara', 'Affiliation': 'Third Department of Internal Medicine, Hokkaido PWFAC Obihiro-Kosei General Hospital, Obihiro, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Takeuchi', 'Affiliation': 'Sapporo Diabetes and Thyroid Clinic, Sapporo, Japan.'}, {'ForeName': 'So', 'Initials': 'S', 'LastName': 'Nagai', 'Affiliation': 'Division of Diabetes and Endocrinology, Department of Medicine, Sapporo Medical Center, NTT East Corporation, Sapporo, Japan.'}, {'ForeName': 'Kazuno', 'Initials': 'K', 'LastName': 'Omori', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Kazuhisa', 'Initials': 'K', 'LastName': 'Tsuchida', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Aika', 'Initials': 'A', 'LastName': 'Miya', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Ikumi', 'Initials': 'I', 'LastName': 'Shigesawa', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Tsuchida', 'Affiliation': 'Diabetes Center, Manda Memorial Hospital, Sapporo, Japan.'}, {'ForeName': 'Shingo', 'Initials': 'S', 'LastName': 'Yanagiya', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hiraku', 'Initials': 'H', 'LastName': 'Kameda', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Yokoyama', 'Affiliation': 'Department of Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Taneda', 'Affiliation': 'Diabetes Center, Manda Memorial Hospital, Sapporo, Japan.'}, {'ForeName': 'Yoshio', 'Initials': 'Y', 'LastName': 'Kurihara', 'Affiliation': 'Kurihara Clinic, Sapporo, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Aoki', 'Affiliation': 'Aoki Clinic, Sapporo, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Nishimoto', 'Affiliation': 'Biostatistics Section, Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan.'}, {'ForeName': 'Tatsuya', 'Initials': 'T', 'LastName': 'Atsumi', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Miyoshi', 'Affiliation': 'Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}]",Journal of diabetes investigation,['10.1111/jdi.13498'] 818,33483869,Premixed bioceramics versus mineral trioxide aggregate in furcal perforation repair of primary molars: in vitro and in vivo study.,"OBJECTIVES The current study was carried out to (1) evaluate premixed bioceramic (BC) and mineral trioxide aggregate (MTA) sealing properties in a laboratory and (2) compare the performance of these two materials in repairing an immediate iatrogenic furcal perforation of primary molars both clinically and radiographically. MATERIALS AND METHODS In vitro sections including eighty mandibular second primary molars were sorted into 4 equal groups: (1) an intact furcation area group, (2) an artificial perforation group (unrepaired), (3) an artificial perforation group repaired with MTA, and (4) an artificial perforation group repaired with premixed BC. The dye extraction method was used to assess the sealing ability of the material. Clinically, the study was designed as an equivalent parallel randomized controlled trial. Seventy-six mandibular second primary molars with immediate furcal perforation were sealed with MTA and premixed BC. Teeth were evaluated clinically and radiographically at 3, 6, and 12 months. RESULTS Although the difference was statistically insignificant (p = 0.058), the premixed BC group had better sealing ability than the MTA group [mean difference = 0.020; 95% CI (-0.001, 0.040)]. Clinically and radiographically, the two materials had an equivalent success rate in the first 3 months [ARR = 0.05; 95% CI (-0.07, 0.17)] but inequivalent success rates at 6 and 12 months with premixed BC performing better than MTA. CONCLUSIONS The present findings confirm that premixed BC is a promising material that can be used to repair a furcal perforation of primary molars. Premixed BC has better sealing properties and better performance at the clinical and radiographic levels than MTA. CLINICAL RELEVANCE (1) Accidental furcal perforation in primary molars is one of the worst problems that results in diminishing the lifetime expectancy of primary teeth if not properly treated. Though new BC repair materials have been introduced to enhance healing and tissue inductive properties, there is an obvious shortage in clinical trials covering this area. The present study is a premier study that assesses a recently introduced premixed BC material in the furcal perforation of primary teeth and compares its outcomes with those of the widely used MTA. TRIAL REGISTRATION ClinicalTrials.gov PRS reference #NCT04137861.",2021,"Although the difference was statistically insignificant (p = 0.058), the premixed BC group had better sealing ability than the MTA group [mean difference = 0.020; 95% CI (-0.001, 0.040)].","['furcal perforation repair of primary molars', 'Seventy-six mandibular second primary molars with immediate furcal perforation']","['intact furcation area group, (2) an artificial perforation group (unrepaired), (3) an artificial perforation group repaired with MTA, and (4) an artificial perforation group repaired with premixed BC', 'Premixed bioceramics versus mineral trioxide aggregate', 'Premixed BC', 'premixed BC', 'premixed bioceramic (BC) and mineral trioxide aggregate (MTA) sealing properties', 'MTA and premixed BC', 'MTA']","['equivalent success rate', 'sealing ability', 'inequivalent success rates']","[{'cui': 'C0549099', 'cui_str': 'Perforation'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}]","[{'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2004457', 'cui_str': 'Artificial'}, {'cui': 'C0549099', 'cui_str': 'Perforation'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0253527', 'cui_str': 'mineral trioxide aggregate'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0871161', 'cui_str': 'Property'}]","[{'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",,0.0762772,"Although the difference was statistically insignificant (p = 0.058), the premixed BC group had better sealing ability than the MTA group [mean difference = 0.020; 95% CI (-0.001, 0.040)].","[{'ForeName': 'Mahmoud Ahmed', 'Initials': 'MA', 'LastName': 'Abdelmotelb', 'Affiliation': 'Paediatric and Community Dentistry, Minia University, Minya, Egypt.'}, {'ForeName': 'Yasser Fathi', 'Initials': 'YF', 'LastName': 'Gomaa', 'Affiliation': 'Dental Biomaterials, Faculty of Dentistry, Minia University, Minya, Egypt.'}, {'ForeName': 'Nagwa Mohmmad Ali', 'Initials': 'NMA', 'LastName': 'Khattab', 'Affiliation': 'Paediatric and Community Dentistry, Faculty of Dentistry, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Ahmad Abdel Hamid', 'Initials': 'AAH', 'LastName': 'Elheeny', 'Affiliation': 'Paediatric and Community Dentistry, Faculty of Dentistry, Minia University, Ard Shalaby, El Minia, Minya, 61519, Egypt. ahmedelheeny@mu.edu.eg.'}]",Clinical oral investigations,['10.1007/s00784-021-03800-3'] 819,33483617,Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.,,2021,,[],['pevonedistat plus azacitidine versus azacitidine'],[],[],"[{'cui': 'C2703093', 'cui_str': 'pevonedistat'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004475', 'cui_str': 'Azacitidine'}]",[],,0.0476138,,"[{'ForeName': 'Mikkael A', 'Initials': 'MA', 'LastName': 'Sekeres', 'Affiliation': 'Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. msekeres@med.miami.edu.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Watts', 'Affiliation': 'Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.'}, {'ForeName': 'Atanas', 'Initials': 'A', 'LastName': 'Radinoff', 'Affiliation': 'University Hospital Sveti Ivan Rislki, Sofia, Bulgaria.'}, {'ForeName': 'Montserrat Arnan', 'Initials': 'MA', 'LastName': 'Sangerman', 'Affiliation': ""Institut Català d'Oncologia-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet, Barcelona, Spain.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Cerrano', 'Affiliation': 'Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Turin, Italy.'}, {'ForeName': 'Patricia Font', 'Initials': 'PF', 'LastName': 'Lopez', 'Affiliation': 'Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.'}, {'ForeName': 'Joshua F', 'Initials': 'JF', 'LastName': 'Zeidner', 'Affiliation': 'University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.'}, {'ForeName': 'Maria Diez', 'Initials': 'MD', 'LastName': 'Campelo', 'Affiliation': 'University Hospital of Salamanca, IBSAL Institute for Biomedical Research of Salamanca, Salamanca, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Graux', 'Affiliation': 'Department of Hematology, Université Catholique de Louvain, CHU UCL Namur (Godinne site), Yvoir, Belgium.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Liesveld', 'Affiliation': 'The James P Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Selleslag', 'Affiliation': 'AZ Sint Jan Brugge-Oostende, Brugge, Belgium.'}, {'ForeName': 'Nikolay', 'Initials': 'N', 'LastName': 'Tzvetkov', 'Affiliation': 'MHAT Dr. Georgi Stranski, Clinic of Haematology, Pleven, Bulgaria.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Fram', 'Affiliation': 'Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Zhao', 'Affiliation': 'Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Bell', 'Affiliation': 'Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Friedlander', 'Affiliation': 'Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Douglas V', 'Initials': 'DV', 'LastName': 'Faller', 'Affiliation': 'Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Lionel', 'Initials': 'L', 'LastName': 'Adès', 'Affiliation': 'AP-HP, Hôpital Saint Louis, Paris, France.'}]",Leukemia,['10.1038/s41375-021-01125-4'] 820,33483796,Efficiency of coordinator-based osteoporosis intervention in fragility fracture patients: a prospective randomized trial.,"We examined the effectiveness of coordinators' interventions to prevent secondary fractures in patients with fragility fractures. These coordinator-based interventions improved bone density assessment implementation and treatment rates, and enhanced treatment persistence rates in the early stages following fractures. INTRODUCTION This study aimed to determine the efficiency of coordinator-based osteoporosis intervention in fragility fracture patients during a 2-year period. METHODS A prospective intervention randomized control study was conducted at seven medical facilities from January 2015 to March 2017. Postmenopausal women and men over 50 years old with fragility fractures were randomly divided into the coordinator intervention (LI; 70 patients) and without intervention (non-LI; 71 patients) groups. The osteoporosis treatment rate, osteoporosis treatment persistence rate, fall rate, fracture incidence rate, and bone density measurement rate 3 months, 6 months, 1 year, and 2 years after registration were compared between the two groups. Non-parametric tests were used to analyze data at each inspection period. RESULTS The osteoporosis treatment initiation rate was significantly higher in the LI group than in the non-LI group (85.7% vs. 71.8%; p = 0.04). The LI group had significantly higher bone density assessment implementation rates than the non-LI group at the time of registration (90.0% vs. 69.0%; p = 0.00) and 6 months after registration (50.0% vs. 29.6%; p = 0.01), but not 1 or 2 years after registration. In addition, no significant differences in fall or fracture incidence rates were found between the two groups. CONCLUSION The coordinator-based interventions for fragility fractures improved bone density assessment implementation and treatment rates and enhanced treatment persistence rates in the early stages following bone fractures. The findings suggest that liaison intervention may help both fracture and osteoporosis physicians for the evaluation of osteoporosis and initiation and continuation of osteoporosis medication.",2021,"These coordinator-based interventions improved bone density assessment implementation and treatment rates, and enhanced treatment persistence rates in the early stages following fractures. ","['Postmenopausal women and men over 50 years old with fragility fractures', 'fragility fracture patients', 'patients with fragility fractures', 'seven medical facilities from January 2015 to March 2017', 'fragility fracture patients during a 2-year period']","[""coordinators' interventions"", 'coordinator intervention (LI; 70 patients) and without intervention', 'coordinator-based osteoporosis intervention', 'liaison intervention']","['fall or fracture incidence rates', 'bone density assessment implementation rates', 'osteoporosis treatment rate, osteoporosis treatment persistence rate, fall rate, fracture incidence rate, and bone density measurement rate', 'bone density assessment implementation and treatment rates', 'osteoporosis treatment initiation rate']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4760971', 'cui_str': 'Fragility fracture'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}]","[{'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4303745', 'cui_str': 'Treatment for osteoporosis'}, {'cui': 'C0546816', 'cui_str': 'Persistence'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}]",,0.0234526,"These coordinator-based interventions improved bone density assessment implementation and treatment rates, and enhanced treatment persistence rates in the early stages following fractures. ","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Osaki', 'Affiliation': 'Rehabilitation Division, Tottori University Hospital, Tottori, 683-8504, Japan. osakim@tottori-u.ac.jp.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Okuda', 'Affiliation': 'School of Health Science, Faculty of Medicine, Tottori University, Tottori, Japan.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Saeki', 'Affiliation': 'Orthopedic Surgery Hospital Ward, Tottori University Hospital, Tottori, Japan.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Okano', 'Affiliation': 'Department of Orthopedic Surgery, San-in Rosai Hospital, Tottori, Japan.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Tsuda', 'Affiliation': 'Department of Orthopedic Surgery, Saiseikai Sakaiminato General Hospital, Tottori, Japan.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Nakamura', 'Affiliation': 'Department of Orthopedic Surgery, Hakuai Hospital, Tottori, Japan.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Morio', 'Affiliation': 'Department of Orthopedic Surgery, Misasa Onsen Hospital, Tottori, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Nagashima', 'Affiliation': 'Department of Orthopedic Surgery, Tottori University, Tottori, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Hagino', 'Affiliation': 'Rehabilitation Division, Tottori University Hospital, Tottori, 683-8504, Japan.'}]",Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,['10.1007/s00198-021-05825-6'] 821,33450291,Sleep time differs among people who co-use cocaine and cannabis compared to people who only use cocaine.,"OBJECTIVE People who use cocaine experience numerous sleep problems and often use cannabis to mitigate these problems. However, co-using cocaine and cannabis may result in worse sleep outcomes when compared to using cocaine only. The current study examined group differences in subjective sleep outcomes among people who use cocaine and people who co-use cocaine and cannabis. METHODS Participants were 82 individuals with cocaine use disorder who were enrolled in a randomized clinical trial for cocaine treatment. Sleep outcomes, assessed at baseline prior to treatment, were measured with the Saint Mary's Hospital Sleep Questionnaire and included total sleep time, perceived sleep quality, difficulty falling asleep, and daytime alertness. Analysis of covariance and Kruskal-Wallis tests were used to compare sleep outcomes between participants with urine samples that tested positive for both cocaine and cannabis at baseline, those who tested positive for cocaine only, and those who tested negative for all drugs. RESULTS Total reported sleep time was highest among those with a drug negative urine, followed by those with a cocaine positive urine and those who tested positive for cocaine and cannabis. There were no differences in perceived sleep quality, difficulty falling asleep, or daytime alertness between groups. CONCLUSIONS People who co-use cocaine and cannabis may report reduced sleep time relative to those who only use cocaine. Co-use of cannabis may exacerbate sleep difficulties in people who use cocaine by decreasing total sleep time, although it is important to note that the groups each reported similar sleep quality. Implications for treatment and directions for future research are discussed.",2021,"There were no differences in perceived sleep quality, difficulty falling asleep, or daytime alertness between groups. ","['People who use cocaine experience numerous sleep problems', 'Participants were 82 individuals with cocaine use disorder who were enrolled in a randomized clinical trial for', 'participants with urine samples that tested positive for both cocaine and cannabis at baseline, those who tested positive for cocaine only, and those who tested negative for all drugs', 'people who use cocaine and people who co-use cocaine and cannabis']",['cocaine'],"[""Saint Mary's Hospital Sleep Questionnaire and included total sleep time, perceived sleep quality, difficulty falling asleep, and daytime alertness"", 'Sleep time', 'total sleep time', 'worse sleep outcomes', 'subjective sleep outcomes', 'perceived sleep quality, difficulty falling asleep, or daytime alertness', 'sleep outcomes', 'sleep time', 'Sleep outcomes']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0206034', 'cui_str': 'Trials, Randomized Clinical'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0009170', 'cui_str': 'Cocaine'}]","[{'cui': 'C0242823', 'cui_str': 'Saints'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0393760', 'cui_str': 'Initial insomnia'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}]",82.0,0.0305043,"There were no differences in perceived sleep quality, difficulty falling asleep, or daytime alertness between groups. ","[{'ForeName': 'Paris B', 'Initials': 'PB', 'LastName': 'Wheeler', 'Affiliation': 'University of Kentucky College of Education, Department of Educational, School, and Counseling Psychology, 251 Scott Street, Lexington, KY 40508, United States of America. Electronic address: Paris.wheeler@uky.edu.'}, {'ForeName': 'Jardin N', 'Initials': 'JN', 'LastName': 'Dogan', 'Affiliation': 'University of Kentucky College of Education, Department of Educational, School, and Counseling Psychology, 251 Scott Street, Lexington, KY 40508, United States of America. Electronic address: Jndo224@uky.edu.'}, {'ForeName': 'Danelle', 'Initials': 'D', 'LastName': 'Stevens-Watkins', 'Affiliation': 'University of Kentucky College of Education, Department of Educational, School, and Counseling Psychology, 251 Scott Street, Lexington, KY 40508, United States of America. Electronic address: d.stevenswatkins@uky.edu.'}, {'ForeName': 'William W', 'Initials': 'WW', 'LastName': 'Stoops', 'Affiliation': 'University of Kentucky College of Medicine, Department of Behavioral Science, 465 East High Street, Suite 204B, Lexington, KY 40507, United States of America. Electronic address: William.stoops@uky.edu.'}]","Pharmacology, biochemistry, and behavior",['10.1016/j.pbb.2021.173109'] 822,33487528,"Brief interventions to prevent excessive alcohol use in adolescents at low-risk presenting to Emergency Departments: Three-arm, randomised trial of effectiveness and cost-effectiveness.","BACKGROUND Alcohol consumption and related harm increase rapidly from the age of 12 years. We evaluated whether alcohol screening and brief intervention is effective and cost-effective in delaying hazardous or harmful drinking amongst low-risk or abstaining adolescents attending Emergency Departments (EDs). METHODS This ten-centre, three-arm, parallel-group, single-blind, pragmatic, individually randomised trial screened ED attenders aged between 14 and 17 years for alcohol consumption. We sampled at random one third of those scoring at most 2 on AUDIT-C who had access to the internet and, if aged under 16, were Gillick competent or had informed consent from parent or guardian. We randomised them between: screening only (control intervention); one session of face-to-face Personalised Feedback and Brief Advice (PFBA); and PFBA plus an electronic brief intervention (eBI) on smartphone or web. We conducted follow-up after six and 12 months. The principal outcomes were alcohol consumed over the 3 months before 12-month follow up, measured by AUDIT-C; and quality-adjusted life-years. FINDINGS Between October 2014 and May 2015, we approached 5,016 eligible patients of whom 3,326 consented to be screened and participate in the trial; 2,571 of these were low-risk drinkers or abstainers, consuming an average 0.14 units per week. We randomised: 304 to screening only; 285 to PFBA; and 294 to PFBA and eBI. We found no significant difference between groups, notably in weekly alcohol consumption: those receiving screening only drank 0.10 units (95% confidence interval 0.05 to 0.18); PFBA 0.12 (0.06 to 0.21); PFBA and eBI 0.10 (0.05 to 0.19). INTERPRETATION While drinking levels remained low in this population, this trial found no evidence that PFBA with or without eBI was more effective than screening alone in reducing or delaying alcohol consumption.",2021,"We found no significant difference between groups, notably in weekly alcohol consumption: those receiving screening only drank 0.10 units (95% confidence interval 0.05 to 0.18); PFBA 0.12 (0.06 to 0.21); PFBA and eBI 0.10 (0.05 to 0.19). ","['random one third of those scoring at most 2 on AUDIT-C who had access to the internet and, if aged under 16, were Gillick competent or had informed consent from parent or guardian', 'adolescents attending Emergency Departments (EDs', 'adolescents at low-risk presenting to Emergency Departments', 'ED attenders aged between 14 and 17 years for alcohol consumption', '5,016 eligible patients of whom 3,326 consented to be screened and participate in the trial; 2,571 of these were low-risk drinkers or abstainers, consuming an average 0.14 units per week']","['screening only (control intervention); one session of face-to-face Personalised Feedback and Brief Advice (PFBA); and PFBA plus an electronic brief intervention (eBI) on smartphone or web', 'alcohol screening and brief intervention']",['reducing or delaying alcohol consumption'],"[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0023226', 'cui_str': 'Legal guardian'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0457801', 'cui_str': 'Non - drinker'}, {'cui': 'C4517430', 'cui_str': '0.14'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}]","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}]",5016.0,0.0966228,"We found no significant difference between groups, notably in weekly alcohol consumption: those receiving screening only drank 0.10 units (95% confidence interval 0.05 to 0.18); PFBA 0.12 (0.06 to 0.21); PFBA and eBI 0.10 (0.05 to 0.19). ","[{'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Deluca', 'Affiliation': ""Institute of Psychiatry, Psychology & Neuroscience, King's College London, London UK. Electronic address: paolo.deluca@kcl.ac.uk.""}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Coulton', 'Affiliation': 'Centre for Health Services Studies, University of Kent, Canterbury, UK.'}, {'ForeName': 'Mohammed Fasihul', 'Initials': 'MF', 'LastName': 'Alam', 'Affiliation': 'College of Health Sciences, QU Health, Qatar University, Doha, Qatar.'}, {'ForeName': 'Sadie', 'Initials': 'S', 'LastName': 'Boniface', 'Affiliation': ""Institute of Psychiatry, Psychology & Neuroscience, King's College London, London UK.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cohen', 'Affiliation': 'Health Economics and Policy Research Unit, University of South Wales, Pontypridd, UK.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Donoghue', 'Affiliation': ""Institute of Psychiatry, Psychology & Neuroscience, King's College London, London UK.""}, {'ForeName': 'Eilish', 'Initials': 'E', 'LastName': 'Gilvarry', 'Affiliation': 'Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Kaner', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Maconochie', 'Affiliation': 'Paediatric Emergency Medicine, Imperial College, London, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'McArdle', 'Affiliation': 'Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'McGovern', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Newbury-Birch', 'Affiliation': 'School of Social Sciences, Humanities and Law, Teesside University, Middlesbrough, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Patton', 'Affiliation': 'School of Psychology, University of Surrey, Guildford, UK.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Pellatt-Higgins', 'Affiliation': 'Centre for Health Services Studies, University of Kent, Canterbury, UK.'}, {'ForeName': 'Ceri', 'Initials': 'C', 'LastName': 'Phillips', 'Affiliation': 'Swansea Centre for Health Economics, College of Human and Health Sciences, Swansea University, Swansea, Wales, UK.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Phillips', 'Affiliation': ""Institute of Psychiatry, Psychology & Neuroscience, King's College London, London UK; Institute for Clinical and Applied Health Research, University of Hull, Hull, UK.""}, {'ForeName': 'Rhys D', 'Initials': 'RD', 'LastName': 'Pockett', 'Affiliation': 'Swansea Centre for Health Economics, College of Human and Health Sciences, Swansea University, Swansea, Wales, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Russell', 'Affiliation': 'Medical School, Swansea University, Swansea, Wales, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Strang', 'Affiliation': ""Institute of Psychiatry, Psychology & Neuroscience, King's College London, London UK.""}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Drummond', 'Affiliation': ""Institute of Psychiatry, Psychology & Neuroscience, King's College London, London UK.""}]",The International journal on drug policy,['10.1016/j.drugpo.2021.103113'] 823,33485813,Identifying medication-related problems in pharmacist-run home visits.,"BACKGROUND Home visits (HVs) may be warranted for many reasons (e.g., uncontrolled disease states, suspected psychosocial issues, frequent hospitalizations, poor health literacy). Patients who frequently visit the emergency department (ED) are high-risk individuals, oftentimes exhibiting health-related barriers and medication-related problems (MRPs). OBJECTIVES This study seeks to answer whether HVs for frequent ED users conducted by a pharmacist with pharmacy students will detect more MRPs compared to office visits (OVs) and enhance patient perception of HV services. METHODS Patients who visited the ED at least twice over a 12-month period were included in a retrospective chart review. Eligible patients were randomized into an HV group or OV group. Patients in the HV group were visited by a pharmacist and pharmacy students to identify and resolve MRPs, whereas patients in the OV arm brought their medications into the office for review. Patients in the HV group completed a pre- and postvisit survey about their experiences. RESULTS Eighteen patients participated in the study: 10 patients were randomized to the OV arm and 8 patients were randomized to the HV arm. A total of 39 MRPs were identified in 8 HVs versus 33 MRPs in 10 OVs (mean 5 ± 0.926 vs. 3.3 ± 1.89, P = 0.034). Overall, nonadherence was the most common MRP and medication reconciliation was the most common intervention. All 8 HV patients completed the pre- and post-HV surveys. Post-HV survey results indicated that patients agreed that student pharmacists were professional team members and that their HV was needed. The patients agreed to recommend a pharmacist-run HV. CONCLUSION Patient homes serve as alternative and convenient spaces for pharmacists to help manage their medications, specifically to identify MRPs and provide meaningful recommendations.",2021,"Overall, nonadherence was the most common MRP and medication reconciliation was the most common intervention.","['Eligible patients', 'frequent ED users conducted by a pharmacist with pharmacy students', 'Patients who visited the ED at least twice over a 12-month period were included in a retrospective chart review', 'Eighteen patients participated in the study: 10 patients', 'Patients who frequently visit the emergency department (ED) are high-risk individuals, oftentimes exhibiting health-related barriers and medication-related problems (MRPs', 'Patients in the HV group were visited by a pharmacist and pharmacy students to identify and resolve MRPs, whereas patients in the OV arm brought their medications into the office for review']",['HV group or OV'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0038497', 'cui_str': 'Pharmacy Student'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0035363', 'cui_str': 'Retrospective Study'}, {'cui': 'C0541653', 'cui_str': 'Chart evaluation by healthcare professional'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C3714811', 'cui_str': 'Resolved'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332302', 'cui_str': 'Brought on by'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0282443', 'cui_str': 'Review'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],39.0,0.0315235,"Overall, nonadherence was the most common MRP and medication reconciliation was the most common intervention.","[{'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Chim', 'Affiliation': ''}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Joseph', 'Affiliation': ''}]",Journal of the American Pharmacists Association : JAPhA,['10.1016/j.japh.2020.12.017'] 824,33491116,Process- and Outcome-Based Financial Incentives to Improve Self-Management and Glycemic Control in People with Type 2 Diabetes in Singapore: A Randomized Controlled Trial.,"BACKGROUND Sub-optimally controlled diabetes increases risks for adverse and costly complications. Self-management including glucose monitoring, medication adherence, and exercise are key for optimal glycemic control, yet, poor self-management remains common. OBJECTIVE The main objective of the Trial to Incentivize Adherence for Diabetes (TRIAD) study was to determine the effectiveness of financial incentives in improving glycemic control among type 2 diabetes patients in Singapore, and to test whether process-based incentives tied to glucose monitoring, medication adherence, and physical activity are more effective than outcome-based incentives tied to achieving normal glucose readings. METHODS TRIAD is a randomized, controlled, multi-center superiority trial. A total of 240 participants who had at least one recent glycated hemoglobin (HbA1c) being 8.0% or more and on oral diabetes medication were recruited from two polyclinics. They were block-randomized (blocking factor: current vs. new glucometer users) into the usual care plus (UC +) arm, process-based incentive arm, and outcome-based incentive arm in a 2:3:3 ratio. The primary outcome was the mean change in HbA1c at month 6 and was linearly regressed on binary variables indicating the intervention arms, baseline HbA1c levels, a binary variable indicating titration change, and other baseline characteristics. RESULTS Our findings show that the combined incentive arms trended toward better HbA1c than UC + , but the difference is estimated with great uncertainty (difference - 0.31; 95% confidence interval [CI] - 0.67 to 0.06). Lending credibility to this result, the proportion of participants who reduced their HbA1c is higher in the combined incentive arms relative to UC + (0.18; 95% CI 0.04, 0.31). We found a small improvement in process- relative to outcome-based incentives, but this was again estimated with great uncertainty (difference - 0.05; 95% CI - 0.42 to 0.31). Consistent with this improvement, process-based incentives were more effective at improving weekly medication adherent days (0.64; 95% CI - 0.04 to 1.32), weekly physically active days (1.37; 95% CI 0.60-2.13), and quality of life (0.04; 95% CI 0.0-0.07) than outcome-based incentives. CONCLUSION This study suggests that both incentive types may be part of a successful self-management strategy. Process-based incentives can improve adherence to intermediary outcomes, while outcome-based incentives focus on glycemic control and are simpler to administer.",2021,"We found a small improvement in process- relative to outcome-based incentives, but this was again estimated with great uncertainty (difference - 0.05; 95% CI - 0.42 to 0.31).","['240 participants who had at least one recent glycated hemoglobin (HbA1c) being 8.0% or more and on oral diabetes medication were recruited from two polyclinics', 'Diabetes', 'type 2 diabetes patients in Singapore', 'People with Type 2 Diabetes in Singapore']",[],"['quality of life', 'Process- and Outcome-Based Financial Incentives', 'mean change in HbA1c']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]",[],"[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",240.0,0.192119,"We found a small improvement in process- relative to outcome-based incentives, but this was again estimated with great uncertainty (difference - 0.05; 95% CI - 0.42 to 0.31).","[{'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Bilger', 'Affiliation': 'Health Economics and Policy, Vienna University of Business and Economics, Vienna, Austria. marcel.bilger@wu.ac.at.'}, {'ForeName': 'Mitesh', 'Initials': 'M', 'LastName': 'Shah', 'Affiliation': 'SingHealth Polyclinics, Singapore, Singapore.'}, {'ForeName': 'Ngiap Chuan', 'Initials': 'NC', 'LastName': 'Tan', 'Affiliation': 'SingHealth Polyclinics, Singapore, Singapore.'}, {'ForeName': 'Cynthia Y L', 'Initials': 'CYL', 'LastName': 'Tan', 'Affiliation': 'SingHealth Polyclinics, Singapore, Singapore.'}, {'ForeName': 'Filipinas G', 'Initials': 'FG', 'LastName': 'Bundoc', 'Affiliation': 'Health Services and Systems Research Program, Duke-NUS Medical School, Singapore, Singapore.'}, {'ForeName': 'Joann', 'Initials': 'J', 'LastName': 'Bairavi', 'Affiliation': 'Health Services and Systems Research Program, Duke-NUS Medical School, Singapore, Singapore.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Finkelstein', 'Affiliation': 'Health Services and Systems Research Program, Duke-NUS Medical School, Singapore, Singapore.'}]",The patient,['10.1007/s40271-020-00491-y'] 825,33484515,Effects of core muscle stability on low back pain and quality of life in post- menopausal women: A comparative study.,"OBJECTIVE To determine the effects of core stability exercises on backache and quality of life of postmenopausal women. METHODS he comparative study was conducted at the Department of Physical Therapy, Margalla General Hospital, Rawalpindi, Pakistan, from February to June 2018, and comprised post-menopausal woman aged 40-60 years having backache who were randomly divided into experimental group A and control group B. Group A underwent core stability exercises along with traditional therapy, while group B had traditional low backache physical therapy. Each participant was treated three days a week for 12 weeks. The outcome was assessed using the manual muscle testing numerical pain rating scale, Oswestry disability index and Utian quality of life scale at baseline, week 6 and week 12. Data was analysed using SPSS 21. RESULTS Of the 35 subjects initially enrolled, 24(68.5%) completed the study. Of them, 14(58.3%) cases were in group A and 10(41.6%) controls in group B. The overall mean age was 54.54±5.13 years, mean menopause duration was 99.79±50.02 months, and mean duration of backache complaint was 23.95±14.85 months. Differences in outcome were significant between the groups for flexion and extension manual muscle testing and Utian quality of life scale (p<0.05) and non-significant for numerical pain rating scaleand Oswestry disability index (p>0.05). CONCLUSIONS Core stability exercises were found to have the ability to reduce pain, disability and to improve strength and quality of life.",2021,"Differences in outcome were significant between the groups for flexion and extension manual muscle testing and Utian quality of life scale (p<0.05) and non-significant for numerical pain rating scaleand Oswestry disability index (p>0.05). ","['postmenopausal women', 'post- menopausal women', '35 subjects initially enrolled, 24(68.5%) completed the study', 'he comparative study was conducted at the Department of Physical Therapy, Margalla General Hospital, Rawalpindi, Pakistan, from February to June 2018, and comprised post-menopausal woman aged 40-60 years having backache']","['core stability exercises', 'control group B. Group A underwent core stability exercises along with traditional therapy, while group B had traditional low backache physical therapy']","['mean menopause duration', 'low back pain and quality of life', 'mean duration of backache complaint', 'manual muscle testing numerical pain rating scale, Oswestry disability index and Utian quality of life scale', 'numerical pain rating scaleand Oswestry disability index (p>0.05', 'strength and quality of life', 'flexion and extension manual muscle testing and Utian quality of life scale', 'backache and quality of life']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009491', 'cui_str': 'Comparative Studies'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0004604', 'cui_str': 'Backache'}]","[{'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0451362', 'cui_str': 'Oxford grading scale for muscle strength'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]",,0.0237492,"Differences in outcome were significant between the groups for flexion and extension manual muscle testing and Utian quality of life scale (p<0.05) and non-significant for numerical pain rating scaleand Oswestry disability index (p>0.05). ","[{'ForeName': 'Sumaira', 'Initials': 'S', 'LastName': 'Kanwal', 'Affiliation': 'Margalla Institute of Health Sciences, Rawalpindi, Pakistan.'}, {'ForeName': 'Irum', 'Initials': 'I', 'LastName': 'Yaqoob', 'Affiliation': 'Riphah International University, Islamabad, Pakistan.'}, {'ForeName': 'Syed', 'Initials': 'S', 'LastName': 'Shakil-Ur-Rehman', 'Affiliation': 'Riphah International University, Islamabad, Pakistan.'}, {'ForeName': 'Misbah', 'Initials': 'M', 'LastName': 'Ghous', 'Affiliation': 'Riphah International University, Islamabad, Pakistan.'}, {'ForeName': 'Javeria', 'Initials': 'J', 'LastName': 'Ghazal', 'Affiliation': 'Margalla Institute of Health Sciences, Rawalpindi, Pakistan.'}, {'ForeName': 'Nazma', 'Initials': 'N', 'LastName': 'Namroz', 'Affiliation': 'Abasyn University Islamabad Campus, Islamabad, Pakistan.'}]",JPMA. The Journal of the Pakistan Medical Association,['10.47391/JPMA.151'] 826,33481449,Efficacy and Safety of a New Botulinum Toxin (HU-014) Versus Existing Onabotulinumtoxin A in Subjects With Moderate to Severe Glabellar Lines.,"BACKGROUND Recently, the safety of a new botulinum toxin (HU-014) was confirmed through animal experiments. The evaluation of the efficacy and safety of this newly introduced botulinum toxin is required considering the risk of adverse events (AEs) and need for standardization before its universal use. OBJECTIVE The aim of this multicenter, double-blind, randomized, parallel, active-controlled phase III clinical trial was to investigate the noninferiority of HU-014 versus existing onabotulinumtoxin A for the treatment of moderate to severe glabellar lines. METHODS In total, 267 subjects were randomized to either the test (HU-014) or control (onabotulinumtoxin A) group. At the baseline and at weeks 4, 8, 12, and 16, investigator's live assessment, independent photographic assessment, subjects' improvement assessment, subjects' satisfaction assessment, and safety assessment were performed. RESULTS At week 4, the response rate was 90.15% and 92.31% in the test and control groups, respectively, as per investigator's live assessment while frowning, without a significant difference. Both groups also showed no significant differences in response rates in the other assessments. In addition, no serious AEs were reported. CONCLUSION HU-014 was noninferior to existing onabotulinumtoxin A in the treatment of glabellar lines at a 1:1 dose ratio, and both products were well tolerated.",2021,"At week 4, the response rate was 90.15% and 92.31% in the test and control groups, respectively, as per investigator's live assessment while frowning, without a significant difference.","['Subjects With Moderate to Severe Glabellar Lines', '267 subjects', 'moderate to severe glabellar lines']","['botulinum toxin (HU-014', 'test (HU-014) or control (onabotulinumtoxin A) group', 'HU-014 versus existing onabotulinumtoxin', 'New Botulinum Toxin (HU-014']","[""photographic assessment, subjects' improvement assessment, subjects' satisfaction assessment, and safety assessment"", 'response rates', 'response rate', 'Efficacy and Safety']","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0442019', 'cui_str': 'Glabellar'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C4517672', 'cui_str': '267'}]","[{'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2719767', 'cui_str': 'OnabotulinumtoxinA'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",267.0,0.130043,"At week 4, the response rate was 90.15% and 92.31% in the test and control groups, respectively, as per investigator's live assessment while frowning, without a significant difference.","[{'ForeName': 'Kwang Ho', 'Initials': 'KH', 'LastName': 'Yoo', 'Affiliation': 'Department of Dermatology, College of Medicine, Chung-Ang University Hospital, Seoul, Korea.'}, {'ForeName': 'Yang Won', 'Initials': 'YW', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, College of Medicine, Konkuk University Hospital, Seoul, Korea.'}, {'ForeName': 'Ji Su', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, College of Medicine, Konkuk University Hospital, Seoul, Korea.'}, {'ForeName': 'Soon Hyo', 'Initials': 'SH', 'LastName': 'Kwon', 'Affiliation': 'Department of Dermatology, College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea.'}, {'ForeName': 'Chang Hun', 'Initials': 'CH', 'LastName': 'Huh', 'Affiliation': 'Department of Dermatology, College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Beom Joon', 'Initials': 'BJ', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, College of Medicine, Chung-Ang University Hospital, Seoul, Korea.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002789'] 827,33487050,Randomized controlled trial of an education-based intervention to improve medication adherence: Design considerations in the medication adherence in glaucoma to improve care study.,"BACKGROUND Glaucoma treatment requires patients to follow daily, often times complex, eye drop regimens, but adherence is poor for many patients, putting them at risk for irreversible vision loss. A comprehensive approach is needed to address the challenges in the self-management of glaucoma. The purpose of this study is to improve glaucoma medication adherence in Veterans with medically treated glaucoma using an education-based intervention. METHODS/DESIGN This study is a single-site randomized controlled trial enrolling 200 Veterans and their companions, if companions are involved in their care. It has two arms: an intervention group and a control group. Participants in the intervention group receive an educational session with a non-physician interventionist and are provided with an AdhereTech smart bottle with the reminder functions activated. The control group is designed as an attention control such that they have a session on general eye health and are provided with a smart bottle but without the reminder functions activated. The primary outcome is the proportion of prescribed doses taken on schedule over 6 months following randomization according to the smart bottle. Secondary outcomes include intensification of glaucoma treatment, cost of intervention delivery, and cost-effectiveness of the intervention over 12 months. DISCUSSION The education-based intervention that we are testing is comprehensive in scope, to encompass a variety of barriers to adherence that glaucoma patients encounter, but personalized to address issues facing individual patients. Particular attention was given to feasibility in the real-world setting, as the high throughput of patients and lack of reimbursement for educational encounters in ophthalmology would limit implementation of a resource-intensive intervention.",2021,"Secondary outcomes include intensification of glaucoma treatment, cost of intervention delivery, and cost-effectiveness of the intervention over 12 months. ","['Veterans with medically treated glaucoma using an education-based intervention', '200 Veterans and their companions, if companions are involved in their care']","['educational session with a non-physician interventionist and are provided with an AdhereTech smart bottle with the reminder functions activated', 'education-based intervention']","['proportion of prescribed doses taken on schedule over 6\u2009months following randomization according to the smart bottle', 'glaucoma medication adherence', 'intensification of glaucoma treatment, cost of intervention delivery, and cost-effectiveness of the intervention over 12\u2009months']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0580931', 'cui_str': 'In care'}]","[{'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0179376', 'cui_str': 'Bottle'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0179376', 'cui_str': 'Bottle'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C1515995', 'cui_str': 'Antiglaucoma agent'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",200.0,0.0456767,"Secondary outcomes include intensification of glaucoma treatment, cost of intervention delivery, and cost-effectiveness of the intervention over 12 months. ","[{'ForeName': 'Jullia A', 'Initials': 'JA', 'LastName': 'Rosdahl', 'Affiliation': 'Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Aaron M', 'Initials': 'AM', 'LastName': 'Hein', 'Affiliation': 'Department of Medicine, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Hayden B', 'Initials': 'HB', 'LastName': 'Bosworth', 'Affiliation': 'Department of Medicine, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Woolson', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA.'}, {'ForeName': 'Maren', 'Initials': 'M', 'LastName': 'Olsen', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Kirshner', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Hung', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA.'}, {'ForeName': 'Kelly W', 'Initials': 'KW', 'LastName': 'Muir', 'Affiliation': 'Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA.'}]","Clinical trials (London, England)",['10.1177/1740774520988291'] 828,33492879,The Effect of Acupressure on Blood Pressure Level and Pulse Rate in Individuals With Essential Hypertension: A Randomized Controlled Trial.,"A total of 91 people including 47 in the intervention group and 44 in the placebo group were included to a randomized controlled study. It can be asserted that acupressure, applied to the Neiguan (PC 6) acupuncture point in individuals with essential hypertension, provides blood pressure regulation and is effective for management of numerous hypertension-related symptoms.",2021,"It can be asserted that acupressure, applied to the Neiguan (PC 6) acupuncture point in individuals with essential hypertension, provides blood pressure regulation and is effective for management of numerous hypertension-related symptoms.","['individuals with essential hypertension', '91 people including 47 in the intervention group and 44 in the', 'Individuals With Essential Hypertension']","['Acupressure', 'placebo', 'Neiguan (PC 6) acupuncture']",['Blood Pressure Level and Pulse Rate'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0085580', 'cui_str': 'Essential hypertension'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0282614', 'cui_str': 'Acupressure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}]",91.0,0.0890145,"It can be asserted that acupressure, applied to the Neiguan (PC 6) acupuncture point in individuals with essential hypertension, provides blood pressure regulation and is effective for management of numerous hypertension-related symptoms.","[{'ForeName': 'Sevil', 'Initials': 'S', 'LastName': 'Biçer', 'Affiliation': 'Department of Nursing, Faculty of Health Sciences, Erciyes University, Kayseri, Turkey (Drs Biçer and Taşcı); and Department of Nursing, School of Health, Ahi Evran University, Kırşehir, Turkey (Drs Ünsal, Demir, and Ceyhan).'}, {'ForeName': 'Ayla', 'Initials': 'A', 'LastName': 'Ünsal', 'Affiliation': ''}, {'ForeName': 'Sultan', 'Initials': 'S', 'LastName': 'Taşcı', 'Affiliation': ''}, {'ForeName': 'Gökçe', 'Initials': 'G', 'LastName': 'Demir', 'Affiliation': ''}, {'ForeName': 'Yasemin Şadiye', 'Initials': 'YŞ', 'LastName': 'Ceyhan', 'Affiliation': ''}]",Holistic nursing practice,['10.1097/HNP.0000000000000384'] 829,33492878,The Effect of Aromatherapy on Elderly Persons With Dry Skin: A Randomized Controlled Trial.,"Dry skin, which is one of the most frequent dermatological problems seen in the elderly population, is an important problem that increases with aging. This study was conducted as a randomized controlled experimental trial to determine the effect of aromatherapy, applied to elderly persons residing in a nursing home in a city center, on dry skin. Elderly persons were grouped into a control group (20 elderly persons), an olive oil group (20 elderly persons), and an aromatherapy group (20 elderly persons). When examining between-measurements differences of the groups in the study, skin moisture levels of the elderly individuals in the aromatherapy group increased in all zones, arm, leg, back, and chest, at measurements of the second and fourth weeks compared with the first measurements. This improvement was determined to be higher after the second week. Skin moisture levels of elderly persons in the olive oil group were determined to significantly increase at the arm zone in the fourth week and at the back zone in the second and fourth weeks compared with the first measurements. Skin moisture levels of elderly persons in the control group, on the contrary, did not change in the second and fourth weeks compared with the first measurements and their dry skin continued at the same level. The intervention performed in this manner in the present study can be used in the clinical practice as an effective nursing intervention to reducing dry skin among elderly persons.",2021,Skin moisture levels of elderly persons in the olive oil group were determined to significantly increase at the arm zone in the fourth week and at the back zone in the second and fourth weeks compared with the first measurements.,"['elderly persons residing in a nursing home in a city center, on dry skin', 'Elderly persons', 'Elderly Persons With Dry Skin', 'elderly persons', 'group (20 elderly persons), and an aromatherapy group (20 elderly persons']","['Aromatherapy', 'olive oil', 'aromatherapy']","['skin moisture levels', 'Skin moisture levels']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0151908', 'cui_str': 'Dry skin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0376547', 'cui_str': 'Aromatherapy'}]","[{'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",20.0,0.0117828,Skin moisture levels of elderly persons in the olive oil group were determined to significantly increase at the arm zone in the fourth week and at the back zone in the second and fourth weeks compared with the first measurements.,"[{'ForeName': 'Songül', 'Initials': 'S', 'LastName': 'Karadağ', 'Affiliation': 'Department of Internal Diseases Nursing, Faculty of Health Sciences, Çukurova University, Adana, Turkey (Dr Karadağ); Department of Internal Diseases Nursing, Faculty of Health Sciences, İzmir Bakırçay University, İzmir, Turkey (Dr Akça); Department of Internal Diseases Nursing, Faculty of Health Sciences, İzmir University of Economics, İzmir, Turkey (Dr Çürük); and İncesu Vocational School, Kayseri University, Kayseri, Turkey (Mr Kaplan).'}, {'ForeName': 'Nazan Kılıç', 'Initials': 'NK', 'LastName': 'Akça', 'Affiliation': ''}, {'ForeName': 'Gülsüm Nihal', 'Initials': 'GN', 'LastName': 'Çürük', 'Affiliation': ''}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Kaplan', 'Affiliation': ''}]",Holistic nursing practice,['10.1097/HNP.0000000000000420'] 830,33491327,Impact of cold and flu medication on obstructive sleep apnoea and its underlying traits: A pilot randomized controlled trial.,"BACKGROUND AND OBJECTIVE Animal studies indicate that alpha-1 adrenergic receptor agonists and antimuscarinic agents improve genioglossus muscle activity during sleep and may be candidates for the pharmacological treatment of OSA. On the other hand, noradrenergic stimulants may be wake-promoting or cause insomnia symptoms if taken before bedtime, and the addition of a medication with sedative properties, such as an antihistaminic, may reduce these side effects. In this study, we aimed to determine the effects of the combination of an alpha-1 adrenergic agonist (pseudoephedrine) and an antihistaminic-antimuscarinic (diphenhydramine) on OSA severity (AHI), genioglossus responsiveness and other endotypic traits (V passive , muscle compensation, LG and arousal threshold). METHODS Ten OSA patients performed a randomized, placebo-controlled, double-blind, crossover trial comparing one night of pseudoephedrine 120 mg plus diphenhydramine 50 mg (DAW1033D) to placebo administered prior to sleep. The AHI, genioglossus muscle responsiveness to negative oesophageal pressure and the endotypic traits were measured via PSG. RESULTS The participants' median (interquartile range) age was 50 (46-53) years and body mass index (BMI) was 34.3 (30.6-39.2) kg/m 2 . The drug combination had no effect on AHI (21.6 (9.1-49.8) on placebo vs 37.9 (5.1-55.4) events/h on DAW1033D, P > 0.5) or genioglossus responsiveness (6.0 (2.6-9.2) on placebo vs 4.0 (3.5-7.3) %/cm H 2 O). Amongst the phenotypic traits, only V passive was improved by 29 (3-55) % eupnoea, P = 0.03 (mean (95% CI)). CONCLUSION The combination of pseudoephedrine and diphenhydramine did not improve OSA severity or genioglossus responsiveness but induced a small improvement in upper airway collapsibility, possibly due to the decongestant effect of the medications. The results of this study do not support the use of these medications for OSA treatment.",2021,"The combination of pseudoephedrine and diphenhydramine did not improve OSA severity or genioglossus responsiveness but induced a small improvement in upper airway collapsibility, possibly due to the decongestant effect of the medications.","[""participants' median (interquartile range) age was 50 (46-53) years and body mass index (BMI) was 34.3 (30.6-39.2) kg/m 2 "", 'Ten OSA patients']","['pseudoephedrine 120\u2009mg plus diphenhydramine 50\u2009mg (DAW1033D) to placebo', 'alpha-1 adrenergic agonist (pseudoephedrine', 'placebo', 'cold and flu medication', 'antihistaminic-antimuscarinic (diphenhydramine', 'pseudoephedrine and diphenhydramine']","['OSA severity (AHI), genioglossus responsiveness and other endotypic traits (V passive , muscle compensation, LG and arousal threshold', 'genioglossus responsiveness', 'AHI, genioglossus muscle responsiveness to negative oesophageal pressure and the endotypic traits', 'OSA severity or genioglossus responsiveness', 'obstructive sleep apnoea', 'V passive', 'AHI']","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0989415', 'cui_str': 'Pseudoephedrine 120 MG'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0012522', 'cui_str': 'Diphenhydramine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0001648', 'cui_str': 'Adrenergic receptor agonist'}, {'cui': 'C0033798', 'cui_str': 'Pseudoephedrine'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0019590', 'cui_str': 'Histamine receptor antagonist'}, {'cui': 'C0003385', 'cui_str': 'Muscarinic receptor antagonist'}]","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0003385', 'cui_str': 'Muscarinic receptor antagonist'}, {'cui': 'C0224194', 'cui_str': 'Structure of genioglossus muscle'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0232531', 'cui_str': 'Esophageal pressure'}]",10.0,0.334397,"The combination of pseudoephedrine and diphenhydramine did not improve OSA severity or genioglossus responsiveness but induced a small improvement in upper airway collapsibility, possibly due to the decongestant effect of the medications.","[{'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Taranto-Montemurro', 'Affiliation': ""Division of Sleep and Circadian Disorders, Department of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Sands', 'Affiliation': ""Division of Sleep and Circadian Disorders, Department of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Azarbarzin', 'Affiliation': ""Division of Sleep and Circadian Disorders, Department of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Calianese', 'Affiliation': ""Division of Sleep and Circadian Disorders, Department of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Vena', 'Affiliation': ""Division of Sleep and Circadian Disorders, Department of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Hess', 'Affiliation': ""Division of Sleep and Circadian Disorders, Department of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Sang-Wook', 'Initials': 'SW', 'LastName': 'Kim', 'Affiliation': ""Division of Sleep and Circadian Disorders, Department of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'White', 'Affiliation': ""Division of Sleep and Circadian Disorders, Department of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wellman', 'Affiliation': ""Division of Sleep and Circadian Disorders, Department of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}]","Respirology (Carlton, Vic.)",['10.1111/resp.14009'] 831,33368766,Ablation guided by STAR-mapping in addition to pulmonary vein isolation is superior to pulmonary vein isolation alone or in combination with CFAE/linear ablation for persistent AF.,"INTRODUCTION The optimal ablation approach for persistent atrial fibrillation (AF) remains unclear. METHODS AND RESULTS Objective was to compare the long-term rates of freedom from AF/AT in patients that underwent STAR mapping guided ablation against outcomes of patients undergoing conventional ablation procedures. Patients undergoing ablation for persistent AF as part of the Stochastic Trajectory Analysis of Ranked signals (STAR) mapping study were included. Outcomes following 'pulmonary vein isolation (PVI) plus STAR mapping guided ablation (STAR mapping cohort) were compared to patients undergoing PVI alone ablation during the same time period and also a propensity-matched cohort undergoing PVI plus the addition of complex fractionated electrogram (CFAE) and/or linear ablation (""conventional ablation""). Rates of procedural AF termination and freedom from AF/AT during follow-up were compared. Sixty-five patients were included in both the STAR cohort and propensity matched conventional ablation cohort. AF termination rates were significantly higher in the STAR cohort (51/65, 78.5%) than conventional ablation cohort (10/65, 15.4%) and PVI alone ablation cohort (13/50, 26.0%; STAR cohort vs. other 2 cohorts both p < .001). There was no significant difference in procedure time between the three cohorts. During ≥20 months follow-up a lower proportion of patients had AF/AT recurrence in the STAR cohort (20.0%) compared with the conventional ablation cohort (50.8%) or the PVI alone ablation cohort (50.0%; both p < .05 compared to STAR cohort). CONCLUSIONS Outcomes of PVI plus STAR mapping guided ablation was superior to PVI alone or in combination with linear/CFAE ablation. A multicenter randomized controlled trial is planned to confirm these findings.",2021,"AF termination rates were significantly higher in the STAR cohort (51/65, 78.5%) than conventional ablation cohort (10/65, 15.4%) and PVI alone ablation cohort (13/50, 26.0%; STAR cohort vs. other 2 cohorts both p < .001).","['Patients undergoing ablation for persistent AF as part of the Stochastic Trajectory Analysis of Ranked signals (STAR) mapping study were included', 'patients undergoing conventional ablation procedures', 'Sixty-five patients were included in both the STAR cohort and propensity matched conventional ablation cohort']","['STAR mapping guided ablation', 'complex fractionated electrogram (CFAE) and/or linear ablation (""conventional ablation', 'Ablation guided by STAR-mapping', 'PVI alone ablation', 'pulmonary vein isolation (PVI) plus STAR mapping guided ablation (STAR mapping cohort']","['AF termination rates', 'procedure time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C1283195', 'cui_str': 'Mapping - action'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0282064', 'cui_str': 'Stars, Celestial'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0282064', 'cui_str': 'Stars, Celestial'}, {'cui': 'C1283195', 'cui_str': 'Mapping - action'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",65.0,0.0646352,"AF termination rates were significantly higher in the STAR cohort (51/65, 78.5%) than conventional ablation cohort (10/65, 15.4%) and PVI alone ablation cohort (13/50, 26.0%; STAR cohort vs. other 2 cohorts both p < .001).","[{'ForeName': 'Shohreh', 'Initials': 'S', 'LastName': 'Honarbakhsh', 'Affiliation': 'Barts Heart Centre, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Schilling', 'Affiliation': 'Barts Heart Centre, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Providencia', 'Affiliation': 'Barts Heart Centre, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Gurpreet', 'Initials': 'G', 'LastName': 'Dhillon', 'Affiliation': 'Barts Heart Centre, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Omotomilola', 'Initials': 'O', 'LastName': 'Bajomo', 'Affiliation': 'Barts Heart Centre, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Keating', 'Affiliation': 'Barts Heart Centre, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Malcolm', 'Initials': 'M', 'LastName': 'Finlay', 'Affiliation': 'Barts Heart Centre, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Ross J', 'Initials': 'RJ', 'LastName': 'Hunter', 'Affiliation': 'Barts Heart Centre, Barts Health NHS Trust, London, UK.'}]",Journal of cardiovascular electrophysiology,['10.1111/jce.14856'] 832,33422499,Comparison of PEAK PlasmaBlade™ to conventional diathermy in abdominal-based free-flap breast reconstruction surgery-A single-centre double-blinded randomised controlled trial.,"BACKGROUND Electrosurgery makes dissection with simultaneous haemostasis possible. The produced heat can cause injury to the surrounding tissue. The PEAK PlasmaBlade™(PPB) is a new electrosurgery device which may overcome this by having the ability to operate on a lower temperature, therefore reducing collateral thermal damage. METHOD A single-centre, double-blinded, randomised controlled trial (RCT) was conducted which included 108 abdominal-based free-flap breast reconstruction patients who had their flap raise performed using either the PPB (n = 56) or the conventional diathermy (n = 52). Data were collected during their in-patient stay and out-patient appointments. The primary outcome value was the number of days the abdominal drains were required. RESULTS Baseline characteristics were similar between the groups, except a significantly lower flap weight in the PPB group. The median number of days the drains were required did not differ significantly (p = 0.48; 6.0 days for the diathermy and 5.0 days for the PPB). The total drain output (p = 0.68), the inflammatory cytokine in the drain fluid (p>0.054) and complications (p>0.24) did not differ significantly between the two groups. At the 2-week follow-up appointment, there was a trend towards less abdominal seromas on abdominal ultrasound (p = 0.09) in the PPB group which were significantly smaller (p = 0.04). CONCLUSION The use of the PPB did not result in a significant reduction of drain requirement, total drain output or inflammatory cytokines but did reduce the size of seroma collections at the 2-week follow-up appointment. Therefore, the use of the PPB device could reduce early seroma formation after drain removal.",2021,"The use of the PPB did not result in a significant reduction of drain requirement, total drain output or inflammatory cytokines but did reduce the size of seroma collections at the 2-week follow-up appointment.","['abdominal-based free-flap breast reconstruction surgery-A single-centre', '108 abdominal-based free-flap breast reconstruction patients who had their flap raise performed using either the PPB (n\u202f=\u202f56) or the']","['conventional diathermy', 'PEAK PlasmaBlade™ to conventional diathermy']","['size of seroma collections', 'inflammatory cytokine in the drain fluid (p>0.054) and complications', 'drain requirement, total drain output or inflammatory cytokines', 'early seroma formation', 'flap weight', 'median number of days the drains', 'abdominal seromas on abdominal ultrasound', 'total drain output', 'number of days the abdominal drains']","[{'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0441031', 'cui_str': 'Free flap'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442818', 'cui_str': 'Raised'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0012002', 'cui_str': 'Diathermy'}, {'cui': 'C0444505', 'cui_str': 'Peak'}]","[{'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1328531', 'cui_str': 'Abdominal seroma'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0441140', 'cui_str': 'Abdominal drain'}]",,0.287754,"The use of the PPB did not result in a significant reduction of drain requirement, total drain output or inflammatory cytokines but did reduce the size of seroma collections at the 2-week follow-up appointment.","[{'ForeName': 'T R', 'Initials': 'TR', 'LastName': 'Friebel', 'Affiliation': 'St. Andrews Centre for Plastics and Burns, Court Road, Broomfield, Chelmsford CM17ET, United-Kingdom; Anglia Ruskin University, Bishop Hall Ln, Chelmsford CM11SQ, United Kingdom. Electronic address: t.friebel@nhs.net.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Narayan', 'Affiliation': 'St. Andrews Centre for Plastics and Burns, Court Road, Broomfield, Chelmsford CM17ET, United-Kingdom.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Ramakrishnan', 'Affiliation': 'St. Andrews Centre for Plastics and Burns, Court Road, Broomfield, Chelmsford CM17ET, United-Kingdom.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Morgan', 'Affiliation': 'St. Andrews Centre for Plastics and Burns, Court Road, Broomfield, Chelmsford CM17ET, United-Kingdom.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Cellek', 'Affiliation': 'Anglia Ruskin University, Bishop Hall Ln, Chelmsford CM11SQ, United Kingdom.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Griffiths', 'Affiliation': 'St. Andrews Centre for Plastics and Burns, Court Road, Broomfield, Chelmsford CM17ET, United-Kingdom.'}]","Journal of plastic, reconstructive & aesthetic surgery : JPRAS",['10.1016/j.bjps.2020.12.007'] 833,33426920,Surgical management of consecutive exotropia: Long-term outcomes.,"PURPOSE To compare lateral rectus recession (LRc) and medial rectus advancement (MRadv) for correction of consecutive exotropia (CXT). METHODS Of the 43 exotropic patients 20 of them underwent LRc (group 1) and 23 of them underwent MRadv (group 2). Postoperative exodrift, strabismic angle, dose effect relationship were compared with minimum 2 years follow‑up. RESULTS An average dose-effect in group 2 is higher than group 1 in the early postoperative period, however there was no significant difference at the second year follow-up (p=0,109). An average exodrift after 2 year follow-up was 6,6±7,12 PD in group 1, and 8,13±7,45 PD in group 2. Postoperative overall success rate was 50% in group 1 and 65% in group 2 at the last follow-up. The success rates were not significantly different between the groups (chi-square, p =0.31). CONCLUSION Although there was no statistically significant difference at the last follow-up, better results were obtained with MRadv than LRc in the treatment of CXT.",2021,"Although there was no statistically significant difference at the last follow-up, better results were obtained with MRadv than LRc in the treatment of CXT.",['Of the 43 exotropic patients'],[],"['success rates', 'lateral rectus recession (LRc) and medial rectus advancement (MRadv', 'Postoperative overall success rate', 'Postoperative exodrift, strabismic angle, dose effect relationship']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0395310', 'cui_str': 'Lateral rectus recession'}, {'cui': 'C0395299', 'cui_str': 'Medial rectus advancement'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",,0.017553,"Although there was no statistically significant difference at the last follow-up, better results were obtained with MRadv than LRc in the treatment of CXT.","[{'ForeName': 'Osman Melih', 'Initials': 'OM', 'LastName': 'Ceylan', 'Affiliation': 'Department of Ophthalmology, University of Health Science, Gulhane Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Yeşim Gedik', 'Initials': 'YG', 'LastName': 'Oğuz', 'Affiliation': 'Department of Ophthalmology, Gulhane Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Önder', 'Initials': 'Ö', 'LastName': 'Ayyıldız', 'Affiliation': 'Department of Ophthalmology, Gulhane Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Serkan', 'Initials': 'S', 'LastName': 'Köksal', 'Affiliation': 'Department of Ophthalmology, Gulhane Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Erhan', 'Initials': 'E', 'LastName': 'Yumuşak', 'Affiliation': 'Department of Ophthalmology, University of Health Science, Gulhane Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Fatih Mehmet', 'Initials': 'FM', 'LastName': 'Mutlu', 'Affiliation': 'Department of Ophthalmology, University of Health Science, Gulhane School of Medicine, Ankara, Turkey.'}]",European journal of ophthalmology,['10.1177/1120672120983199'] 834,33448539,Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?,"BACKGROUND It is unclear which cognitive outcome measure is the most useful for clinical trials in multiple sclerosis. To investigate the usefulness of the Symbol Digit Modalities Test (SDMT) as a clinical outcome measure in secondary progressive multiple sclerosis (SPMS), we describe the frequency of worsening and improvement events in a large randomized controlled trial (RCT) dataset. METHODS Using original trial data from the ASCEND trial (n = 889), a recent large RCT in SPMS, we describe worsening and similarly defined improvement with and without 3-month confirmation on the SDMT in the whole trial cohort and unconfirmed worsening and improvement on the Paced Auditory Serial Addition Test (PASAT) in a smaller subset (n = 107). RESULTS Somewhat unexpectedly, SDMT scores steadily increased throughout the 2 years of follow-up in this trial. There were overall few SDMT worsening events throughout the trial (generally fewer than 10% of participants), but improvement events steadily increased from around 50% of participants with improvement at 12 weeks to more than 70% at 84 weeks and beyond. PASAT scores followed a similar pattern. CONCLUSIONS In this well-characterized clinical trial cohort, the SDMT does not reflect the steady cognitive decline that patients with SPMS experience. Both SDMT and PASAT scores improve throughout follow-up, possibly due to a practice effect. The SDMT may not be a useful outcome measure of disease progression in 2-year clinical trials in SPMS.",2021,"PASAT scores followed a similar pattern. ","['patients with SPMS experience', 'secondary progressive multiple sclerosis (SPMS']",['Symbol Digit Modalities Test (SDMT'],"['SDMT scores steadily', 'PASAT scores', 'Paced Auditory Serial Addition Test (PASAT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751965', 'cui_str': 'Secondary progressive multiple sclerosis'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0451522', 'cui_str': 'Symbol digit modalities test'}]","[{'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4751126', 'cui_str': 'Paced Auditory Serial Addition Test score'}, {'cui': 'C0589060', 'cui_str': 'Paced auditory serial addition test'}]",,0.132741,"PASAT scores followed a similar pattern. ","[{'ForeName': 'Marcus W', 'Initials': 'MW', 'LastName': 'Koch', 'Affiliation': 'Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Jop', 'Initials': 'J', 'LastName': 'Mostert', 'Affiliation': 'Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.'}, {'ForeName': 'Pavle', 'Initials': 'P', 'LastName': 'Repovic', 'Affiliation': 'Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Bowen', 'Affiliation': 'Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Uitdehaag', 'Affiliation': 'Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Cutter', 'Affiliation': 'Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.'}]",European journal of neurology,['10.1111/ene.14732'] 835,33487060,Plaster immobilization versus anterior plating for dorsally displaced distal radial fractures in elderly patients in Pakistan.,"This prospective, multi-centred, randomized trial examined outcomes of 3- and 12-month follow-ups of 159 elderly participants aged more than 75 years with isolated distal radial fractures, treated by anterior locking plate or closed reduction and cast immobilization. The primary outcome was the patient-rated wrist evaluation (PRWE) score. The PRWE score at 12 months was not significantly different between the two groups; however, the radiological outcomes and complications rates were worse in the casting group. Level of evidence: III.",2021,"The PRWE score at 12 months was not significantly different between the two groups; however, the radiological outcomes and complications rates were worse in the casting group.","['elderly patients in Pakistan', '159 elderly participants aged more than 75 years with isolated distal radial fractures, treated by']","['anterior locking plate or closed reduction and cast immobilization', 'Plaster immobilization versus anterior plating']","['PRWE score', 'patient-rated wrist evaluation (PRWE) score', 'radiological outcomes and complications rates']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0034628', 'cui_str': 'Fracture of radius'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0179686', 'cui_str': 'Cast'}, {'cui': 'C0020944', 'cui_str': 'Immobilization - action'}, {'cui': 'C0460977', 'cui_str': 'Plasters'}, {'cui': 'C0407295', 'cui_str': 'Fixation of fracture using plate'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",159.0,0.0748595,"The PRWE score at 12 months was not significantly different between the two groups; however, the radiological outcomes and complications rates were worse in the casting group.","[{'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Tahir', 'Affiliation': 'Department of Orthopaedics, Jinnah Postgraduate Medical Centre, Karachi, Pakistan.'}, {'ForeName': 'Faridullah', 'Initials': 'F', 'LastName': 'Khan Zimri', 'Affiliation': 'Department of Orthopaedics, National Institute of Rehabilitation Medicine, Islamabad, Pakistan.'}, {'ForeName': 'Nadeem', 'Initials': 'N', 'LastName': 'Ahmed', 'Affiliation': 'Department of Orthopaedics, Jinnah Postgraduate Medical Centre, Karachi, Pakistan.'}, {'ForeName': 'Allah', 'Initials': 'A', 'LastName': 'Rakhio Jamali', 'Affiliation': 'Department of Orthopaedics, Jinnah Postgraduate Medical Centre, Karachi, Pakistan.'}, {'ForeName': 'Ghulam', 'Initials': 'G', 'LastName': 'Mehboob', 'Affiliation': 'Department of Orthopaedics, Sir Syed Medical College for Girls and Trust Hospital, Karachi, Pakistan.'}, {'ForeName': 'Katherine R', 'Initials': 'KR', 'LastName': 'Watson', 'Affiliation': 'Department of Orthopaedics, Leeds Teaching Hospital Trust, Leeds, UK.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Faraz', 'Affiliation': 'Department of Orthopaedics, Leeds Teaching Hospital Trust, Leeds, UK.'}]","The Journal of hand surgery, European volume",['10.1177/1753193420977780'] 836,33486526,"An Open-Label, Randomized, Controlled, Crossover Study to Assess Nicotine Pharmacokinetics and Subjective Effects of the JUUL System with Three Nicotine Concentrations Relative to Combustible Cigarettes in Adult Smokers.","INTRODUCTION This randomized, open-label, crossover clinical study evaluated nicotine pharmacokinetics (PK) and subjective effects of the JUUL System (JS; Juul Labs, Inc.) with three nicotine concentrations compared to the usual brand (UB) cigarettes in 24 adult smokers. METHODS At five study visits, subjects used either the JS in 59 mg/mL, JS 18 mg/mL (two visits), and JS 9 mg/mL (all tobacco-flavored) or smoked their UB cigarette first during a controlled puffing sequence (CPS) and then ad libitum (5 min) use sessions. Blood samples were taken at specified timepoints for 60 min in each session. The modified Product Evaluation Scale assessed subjective effects 30-min post-use in the CPS session. RESULTS Maximum plasma nicotine concentration (Cmax-BL), total nicotine exposure (AUC0-60-BL), and rate of plasma nicotine rise were significantly lower for all JS products compared to subjects' UB cigarette in CPS and ad libitum use sessions. In both use sessions these PK parameters were significantly higher for JS 59 mg/mL compared to 18 and 9 mg/mL. Subjective measures of cigarette craving relief and ""Enough Nicotine"" for JS 59 mg/mL did not differ significantly from UB cigarettes, but JS 18 and 9 mg/mL were rated significantly lower than JS 59 mg/mL and UB cigarettes. CONCLUSIONS Nicotine exposure and subjective relief were directly related to JS nicotine concentration: higher nicotine concentrations gave rise to significantly greater plasma nicotine levels and relief from craving. Heavier and more dependent smokers may require the greater nicotine delivery of JS 59 mg/mL to successfully transition away from cigarettes. IMPLICATIONS It has been suggested that electronic nicotine delivery systems (ENDS) and other alternative nicotine delivery products that more closely mimic the nicotine pharmacokinetics (PK) of cigarettes may facilitate smokers transitioning away from cigarettes. We examined nicotine PK and subjective effects of JUUL System (JS) ENDS with three nicotine concentrations (59, 18 and 9 mg/mL) compared to combustible cigarettes. Nicotine delivery from JS ENDS was nicotine concentration dependent, with higher nicotine concentrations giving rise to higher nicotine exposure. These findings suggest that heavier and more dependent smokers may require ENDS with nicotine concentrations greater than 20 mg/mL to successfully transition away from cigarettes.",2021,"In both use sessions these PK parameters were significantly higher for JS 59 mg/mL compared to 18 mg/mL and 9 mg/mL. Subjective measures of cigarette craving relief and ""Enough Nicotine"" for JS 59 ","['Adult Smokers', '24 adult smokers']","['nicotine pharmacokinetics (PK', 'JUUL System (JS) ENDS', 'JS in 59\xa0mg/mL, JS 18\xa0mg/mL (two visits) and JS 9\xa0mg/mL (all tobacco-flavoured) or smoked their UB cigarette first during controlled puffing sequence (CPS', 'usual brand (UB) cigarettes', 'ENDS']","['Maximum plasma nicotine concentration (CmaxBL), total nicotine exposure (AUC060BL) and rate of plasma nicotine rise']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0651569', 'cui_str': ""9-(1'-hydroxy-2'-(hydroxymethyl)ethoxy)methylguanine""}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0682897', 'cui_str': 'Flavor Enhancers'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0205435', 'cui_str': 'First'}, {'cui': 'C1533107', 'cui_str': 'Puff - unit of product usage'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0035853', 'cui_str': 'Rose'}]",24.0,0.0154838,"In both use sessions these PK parameters were significantly higher for JS 59 mg/mL compared to 18 mg/mL and 9 mg/mL. Subjective measures of cigarette craving relief and ""Enough Nicotine"" for JS 59 ","[{'ForeName': 'Nicholas I', 'Initials': 'NI', 'LastName': 'Goldenson', 'Affiliation': 'Juul Labs, Inc., Washington, DC, USA.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Fearon', 'Affiliation': 'whatIF? Consulting Ltd., Harwell, U.K.'}, {'ForeName': 'August R', 'Initials': 'AR', 'LastName': 'Buchhalter', 'Affiliation': 'PinneyAssociates, Inc., Bethesda, MD, USA.'}, {'ForeName': 'Jack E', 'Initials': 'JE', 'LastName': 'Henningfield', 'Affiliation': 'PinneyAssociates, Inc., Bethesda, MD, USA.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntab001'] 837,33428282,Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.,"BACKGROUND The topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ) are effective in psoriasis treatment. To mitigate adverse cutaneous reactions observed with monotherapy, a fixed- combination HP 0.01%/TAZ 0.045% lotion has been developed for the treatment of plaque psoriasis in adults. OBJECTIVES To investigate the long-term safety, efficacy and maintenance of response with HP/TAZ lotion. METHODS This was a 1-year, multicentre, open-label study in 555 adults with psoriasis [Investigator's Global Assessment (IGA) score of 3 ('moderate') or 4 ('severe') and body surface area (BSA) of 3-12% at baseline]. HP/TAZ was administered once daily for 8 weeks and then intermittently as needed in 4-week intervals for up to 1 year based on achievement of treatment success [IGA score of 0 ('clear') or 1 ('almost clear')]. Maximum continuous exposure was 24 weeks. RESULTS Of 550 participants with postbaseline safety data, 318 (57.8%) achieved treatment success during the study. Of those, 54.4% achieved treatment success within the first 8 weeks; retreatment was not required for >4 weeks in over half (55.3%), and 6.6% did not require any retreatment. Among participants enrolled for the full 52 weeks, 77.5% maintained BSA ≤5% on treatment. There were marked improvements in severity of itching, dryness and burning/stinging over the study course. The most common treatment-related adverse events were application site reactions of dermatitis, pruritus, pain and irritation. CONCLUSIONS Fixed-combination HP/TAZ lotion provided maintained efficacy with a favourable tolerability and safety profile, supporting its use for the long-term treatment and management of moderate-to-severe plaque psoriasis.",2021,"There were marked improvements in severity of itching, dryness, and burning/stinging over the study course.","['Moderate-to-Severe Plaque Psoriasis', '555 adults with psoriasis (Investigator\'s Global Assessment [IGA] score of 3 [""moderate""] or 4 [""severe""] and body surface area [BSA] of 3-12% at baseline', 'plaque psoriasis in adults']","['topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ', 'Fixed-combination HP/TAZ lotion', 'HP/TAZ', 'HP/TAZ lotion', 'Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion']","['severity of itching, dryness, and burning/stinging', 'dermatitis, pruritus, pain, and irritation', 'treatment success', 'tolerability and safety profile']","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C4517810', 'cui_str': '555'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0098735', 'cui_str': 'Halobetasol propionate'}, {'cui': 'C0035339', 'cui_str': 'Retinoid'}, {'cui': 'C0288792', 'cui_str': 'tazarotene'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0544341', 'cui_str': 'Lotion'}, {'cui': 'C4517410', 'cui_str': '0.045'}]","[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0677500', 'cui_str': 'Stinging'}, {'cui': 'C0011603', 'cui_str': 'Dermatitis'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441723', 'cui_str': 'Irritation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",555.0,0.047418,"There were marked improvements in severity of itching, dryness, and burning/stinging over the study course.","[{'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Lebwohl', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Stein Gold', 'Affiliation': 'Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Papp', 'Affiliation': 'Probity Medical Research and K. Papp Clinical Research, Waterloo, ON, Canada.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Han', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'D M', 'Initials': 'DM', 'LastName': 'Pariser', 'Affiliation': 'Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Lin', 'Affiliation': 'Ortho Dermatologics†, Bridgewater, NJ, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Harris', 'Affiliation': 'Bausch Health US, LLC†, Bridgewater, NJ, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Jacobson', 'Affiliation': 'Ortho Dermatologics†, Bridgewater, NJ, USA.'}]",Journal of the European Academy of Dermatology and Venereology : JEADV,['10.1111/jdv.17113'] 838,33425825,"A Digital Tool to Build the Capacity of Leaders to Improve Working Conditions Related to Psychological Health and Well-Being in Teams: Intervention Approach, Prototype, and Evaluation Design of the Web-Application ""wecoach"".","The ""wecoach"" is a web-application that builds the capacities of team leaders to improve working conditions that are positively related to the psychological health and well-being of their team members. The web-application works through an automated, rule-based chat enhanced by machine learning. This so-called conversational agent guides the team leader through a systematic project cycle, providing a mind map of work and health, training materials, self-assessments, and online tools to conduct team surveys and workshops, as well as self-evaluation of progress and effectiveness. In this paper, we present the development process of this web-application, which resulted in (1) a comprehensive intervention approach, (2) the prototype, and (3) the implementation of an evaluation design for a multi-level, randomized controlled trial.",2020,"This so-called conversational agent guides the team leader through a systematic project cycle, providing a mind map of work and health, training materials, self-assessments, and online tools to conduct team surveys and workshops, as well as self-evaluation of progress and effectiveness.",['Teams'],[],['Psychological Health'],[],[],"[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",,0.0362537,"This so-called conversational agent guides the team leader through a systematic project cycle, providing a mind map of work and health, training materials, self-assessments, and online tools to conduct team surveys and workshops, as well as self-evaluation of progress and effectiveness.","[{'ForeName': 'Luisa A', 'Initials': 'LA', 'LastName': 'Grimm', 'Affiliation': 'Center of Salutogenesis, University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Zurich, Switzerland.'}, {'ForeName': 'Georg F', 'Initials': 'GF', 'LastName': 'Bauer', 'Affiliation': 'Center of Salutogenesis, University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Zurich, Switzerland.'}, {'ForeName': 'Gregor J', 'Initials': 'GJ', 'LastName': 'Jenny', 'Affiliation': 'Center of Salutogenesis, University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Zurich, Switzerland.'}]",Frontiers in public health,['10.3389/fpubh.2020.521355'] 839,33430928,"A comparison of different community models of antiretroviral therapy delivery with the standard of care among stable HIV+ patients: rationale and design of a non-inferiority cluster randomized trial, nested in the HPTN 071 (PopART) study.","BACKGROUND Following the World Health Organization's (WHO) 2015 guidelines recommending initiation of antiretroviral therapy (ART) irrespective of CD4 count for all people living with HIV (PLHIV), many countries in sub-Saharan Africa have adopted this strategy to reach epidemic control. As the number of PLHIV on ART rises, maintenance of viral suppression on ART for over 90% of PLHIV remains a challenge to government health systems in resource-limited high HIV burden settings. Non facility-based antiretroviral therapy (ART) delivery for stable HIV+ patients may increase sustainable ART coverage in resource-limited settings. Within the HPTN 071 (PopART) trial, two models, home-based delivery (HBD) or adherence clubs (AC), were offered to assess whether they achieved similar viral load suppression (VLS) to standard of care (SoC). In this paper, we describe the trial design and discuss the methodological issues and challenges. METHODS A three-arm cluster randomized non-inferiority trial, nested in two urban HPTN 071 trial communities in Zambia, randomly allocated 104 zones to SoC (35), HBD (35), or AC (34). ART and adherence support were delivered 3-monthly at home (HBD), adherence clubs (AC), or clinic (SoC). Adult HIV+ patients defined as ""stable"" on ART were eligible for inclusion. The primary endpoint was the proportion of PLHIV with virological suppression (≤ 1000 copies HIV RNA/ml) at 12 months (± 3months) after study entry across all three arms. Viral load measurement was done at the routine government laboratories in accordance with national guidelines, annually. The study was powered to determine if either of the community-based interventions would yield a viral suppression rate drop compared to SoC of no more than 5% in its absolute value. Both community-based interventions were delivered by community HIV providers (CHiPs). An additional qualitative study using observations, interviews with PLHIV, and FGDs with community HIV providers was nested in this study to complement the quantitative data. DISCUSSION This trial was designed to provide rigorous randomized evidence of safety and efficacy of non-facility-based delivery of ART for stable PLHIV in high-burden resource-limited settings. This trial will inform policy regarding best practices and what is needed to strengthen scale-up of differentiated models of ART delivery in resource-limited settings. TRIAL REGISTRATION ClinicalTrials.gov NCT03025165 . Registered on 19 January 2017.",2021,Non facility-based antiretroviral therapy (ART) delivery for stable HIV+ patients may increase sustainable ART coverage in resource-limited settings.,"['stable HIV+ patients', 'A three-arm cluster randomized non-inferiority trial, nested in two urban HPTN 071 trial communities in Zambia, randomly allocated 104 zones to SoC (35), HBD (35), or AC (34', 'Adult HIV+ patients defined as ""stable"" on ART were eligible for inclusion']",['facility-based antiretroviral therapy (ART'],"['proportion of PLHIV with virological suppression', 'viral suppression rate', 'viral load suppression (VLS) to standard of care (SoC']","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C4505128', 'cui_str': 'Noninferiority Trial'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0043445', 'cui_str': 'Zambia'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0149651', 'cui_str': 'Clubbing'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]",,0.43143,Non facility-based antiretroviral therapy (ART) delivery for stable HIV+ patients may increase sustainable ART coverage in resource-limited settings.,"[{'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Limbada', 'Affiliation': 'Zambart, University of Zambia, School of Medicine, Zambart House, Ridgeway Campus, Off Nationalist Road, P.O. Box 50697, Lusaka, Zambia. Mohammed@zambart.org.zm.'}, {'ForeName': 'Chiti', 'Initials': 'C', 'LastName': 'Bwalya', 'Affiliation': 'Zambart, University of Zambia, School of Medicine, Zambart House, Ridgeway Campus, Off Nationalist Road, P.O. Box 50697, Lusaka, Zambia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Macleod', 'Affiliation': 'Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Sian', 'Initials': 'S', 'LastName': 'Floyd', 'Affiliation': 'Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Ab', 'Initials': 'A', 'LastName': 'Schaap', 'Affiliation': 'Zambart, University of Zambia, School of Medicine, Zambart House, Ridgeway Campus, Off Nationalist Road, P.O. Box 50697, Lusaka, Zambia.'}, {'ForeName': 'Vasty', 'Initials': 'V', 'LastName': 'Situmbeko', 'Affiliation': 'Zambart, University of Zambia, School of Medicine, Zambart House, Ridgeway Campus, Off Nationalist Road, P.O. Box 50697, Lusaka, Zambia.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Hayes', 'Affiliation': 'Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Fidler', 'Affiliation': 'Imperial College and Imperial College NIHR BRC, London, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Ayles', 'Affiliation': 'Zambart, University of Zambia, School of Medicine, Zambart House, Ridgeway Campus, Off Nationalist Road, P.O. Box 50697, Lusaka, Zambia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Trials,['10.1186/s13063-020-05010-w'] 840,33439282,"In women with spontaneous vaginal delivery, repair of perineal tears might be easier compared to episiotomy.","INTRODUCTION AND HYPOTHESIS To examine a common assumption that suturing of episiotomy, a straight performer-controlled incision, might be easier compared to repair of unpredictable spontaneous perineal tears. METHODS Data for this study were collected prospectively, as part of a randomized controlled trial examining the outcomes of episiotomy avoidance. Suturing characteristics were compared between vaginal deliveries with episiotomy vs. spontaneous perineal tears. Primary outcomes included the duration of the repair, number of suture packs used for the repair, and subjective rating of suturing difficulty (rated from 1 to 5 by practitioner performing the suturing). RESULTS Of 525 vaginal deliveries, episiotomy was performed in 165 (31.4%) of the cases, 59 of which (35.8%) were accompanied by additional vaginal tears. Spontaneous vaginal tears without episiotomy were noted in 272 deliveries (51.8%). Compared to spontaneous perineal tears, episiotomy performance was associated with an adverse effect on all three suturing characteristics in the overall cohort and in subgroup of non-operative deliveries. When comparing episiotomy only to second-degree tear suturing, in the subgroup of non-operative vaginal deliveries a higher rate of suturing duration < 10 min was noted in favor of spontaneous tears. However, in sub-analysis of vacuum-assisted deliveries, a benefit was noted in favor of the episiotomy-only group in terms of fewer suture packs and lower subjective difficulty. CONCLUSIONS In women with non-operative vaginal delivery, suturing of spontaneous perineal tears was easier and shorter compared to episiotomy repair. This might be related to the unpredictable nature of perineal tears, which might be shorter and shallower compared to the standard episiotomy incision.",2021,"Compared to spontaneous perineal tears, episiotomy performance was associated with an adverse effect on all three suturing characteristics in the overall cohort and in subgroup of non-operative deliveries.",['525 vaginal deliveries'],[],"['Spontaneous vaginal tears without episiotomy', 'rate of suturing duration', 'duration of the repair, number of suture packs used for the repair, and subjective rating of suturing difficulty (rated from 1 to 5 by practitioner performing the suturing']","[{'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}]",[],"[{'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0405244', 'cui_str': 'Laceration of vagina'}, {'cui': 'C0014586', 'cui_str': 'Episiotomy'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0457280', 'cui_str': 'Number of sutures'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]",525.0,0.0595628,"Compared to spontaneous perineal tears, episiotomy performance was associated with an adverse effect on all three suturing characteristics in the overall cohort and in subgroup of non-operative deliveries.","[{'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Sagi-Dain', 'Affiliation': 'Department of Obstetrics and Gynecology, Carmel Medical Center, 7 Michal St., Haifa, Israel. lena2303@gmail.com.'}, {'ForeName': 'Inna', 'Initials': 'I', 'LastName': 'Kreinin-Bleicher', 'Affiliation': 'Department of Obstetrics and Gynecology, Bnai-Zion Medical Center, Haifa, Israel.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Shkolnik', 'Affiliation': 'Department of Obstetrics and Gynecology, Bnai-Zion Medical Center, Haifa, Israel.'}, {'ForeName': 'Rabia', 'Initials': 'R', 'LastName': 'Bahous', 'Affiliation': 'Department of Obstetrics and Gynecology, Bnai-Zion Medical Center, Haifa, Israel.'}, {'ForeName': 'Shlomi', 'Initials': 'S', 'LastName': 'Sagi', 'Affiliation': 'The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.'}]",International urogynecology journal,['10.1007/s00192-020-04642-5'] 841,33440446,Does Performing Different Resistance Exercises for the Same Muscle Group Induce Non-homogeneous Hypertrophy?,"The study aimed to compare the effect of performing the same or different exercises for a muscle group on resistance training (RT) sessions on muscle hypertrophy at different sites along muscle length. Twenty-two detrained men (23.3±4.1 years) were randomly allocated to the following groups: a group that performed the same exercises in all training sessions (N-VAR=11) or one that varied the exercises for the same muscle groups (VAR=11). All were submitted to 3 weekly sessions for nine weeks. Muscle thickness was assessed at the proximal, middle, and distal sites of the lateral and anterior thigh, elbow flexors, and extensors by B-mode ultrasound. The VAR group significantly increased all the sites analyzed ( P <0.05). Furthermore, the proximal site of the lateral thigh showed a larger relative increase when compared to the middle site ( P <0.05). In contrast, the N-VAR group were not revealed significant improvements only for the middle site of the lateral thigh and the proximal site of the elbow flexors ( P >0.05). Our results suggest that to perform different resistance exercises can induce hypertrophy of all sites assessed in detrained young men.",2021,The VAR group significantly increased all the sites analyzed ( P <0.05).,"['detrained young men', 'Twenty-two detrained men (23.3±4.1 years', 'muscle hypertrophy at different sites along muscle length']","['resistance training (RT) sessions', 'same exercises in all training sessions (N-VAR=11) or one that varied the exercises for the same muscle groups (VAR=11']","['Muscle thickness', 'middle site of the lateral thigh and the proximal site of the elbow flexors']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0236033', 'cui_str': 'Muscle hypertrophy'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1444754', 'cui_str': 'Length'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C2945843', 'cui_str': 'Site of'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0449638', 'cui_str': 'Proximal site'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}]",22.0,0.0124444,The VAR group significantly increased all the sites analyzed ( P <0.05).,"[{'ForeName': 'Bruna Daniella de Vasconcelos', 'Initials': 'BDV', 'LastName': 'Costa', 'Affiliation': 'Metabolism, Nutrition and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Witalo', 'Initials': 'W', 'LastName': 'Kassiano', 'Affiliation': 'Metabolism, Nutrition and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'João Pedro', 'Initials': 'JP', 'LastName': 'Nunes', 'Affiliation': 'Metabolism, Nutrition and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Kunevaliki', 'Affiliation': 'Metabolism, Nutrition and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Pâmela', 'Initials': 'P', 'LastName': 'Castro-E-Souza', 'Affiliation': 'Metabolism, Nutrition and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Rodacki', 'Affiliation': 'Department of Physical Education, Federal University of Paraná, Curitiba, Brazil.'}, {'ForeName': 'Letícia Trindade', 'Initials': 'LT', 'LastName': 'Cyrino', 'Affiliation': 'Metabolism, Nutrition and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Edilson S', 'Initials': 'ES', 'LastName': 'Cyrino', 'Affiliation': 'Metabolism, Nutrition and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Leonardo de Sousa', 'Initials': 'LS', 'LastName': 'Fortes', 'Affiliation': 'Department of Physical Education, Federal University of Paraíba, João Pessoa, Brazil.'}]",International journal of sports medicine,['10.1055/a-1308-3674'] 842,33442031,A randomized controlled trial on home blood pressure monitoring and quality of care in stage 2 and 3 hypertension.,"In a 12-week, randomized, controlled trial, we investigated whether home blood pressure monitoring (HBPM) would improve treatment adherence and blood pressure control in stage 2 and 3 hypertension. Eligible patients (18-75 years of age and 160-199/100-119 mmHg of clinic systolic/diastolic blood pressure after a 1-week wash-out) were randomized in a 1:4 ratio to an experimental group (with HBPM) and a control group (without HBPM). All patients started antihypertensive treatment with the irbesartan 150 mg/hydrochlorothiazide 12.5 mg/day combination, with the possible addition of irbesartan 150 mg/day and uptitration to irbesartan 300 mg/hydrochlorothiazide 25 mg/day at 4 and 8 weeks of follow-up, respectively. The primary endpoint was the clinic blood pressure control (systolic/diastolic, nondiabetes <140/90 mmHg and diabetes <130/80 mmHg) rate at 12 weeks of follow-up. The randomized patients in the HBPM (n = 96) and control groups (n = 405) had similar characteristics at baseline and similar use of higher dosages of irbesartan/hydrochlorothiazide (300 mg/12.5-25 mg) at 4 (9.4% vs. 12.2%, P = 0.45) and 8 weeks of follow-up (27.1% vs. 35.5%, P = 0.13). During follow-up, both the cumulative treatment discontinuation rate (1.0% vs. 12.6%, P = 0.0008) and the less optimal treatment adherence rate (<90% of prescribed medication, 1.0% vs. 9.9%, P = 0.005) were significantly lower in the HBPM group than in the control group. The proportion of patients who achieved the goal of clinic blood pressure control at 12 weeks of follow-up was significantly higher in the HBPM group than in the control group (66.7% vs. 55.1%, P = 0.04). In conclusion, HBPM improved treatment adherence and blood pressure control in patients with hypertension, despite similar antihypertensive treatment intensities.",2021,"The proportion of patients who achieved the goal of clinic blood pressure control at 12 weeks of follow-up was significantly higher in the HBPM group than in the control group (66.7% vs. 55.1%, P = 0.04).","['in stage 2 and 3 hypertension', 'patients with hypertension', 'Eligible patients (18-75 years of age and 160-199/100-119\u2009mmHg of clinic systolic/diastolic blood pressure after a 1-week wash-out', 'stage 2 and 3 hypertension']","['control group (without HBPM', 'home blood pressure monitoring (HBPM', 'home blood pressure monitoring and quality of care', 'irbesartan/hydrochlorothiazide', 'experimental group (with HBPM', 'irbesartan 150\u2009mg/day and uptitration to irbesartan 300\u2009mg/hydrochlorothiazide', 'HBPM', 'hydrochlorothiazide']","['optimal treatment adherence rate', 'cumulative treatment discontinuation rate', 'goal of clinic blood pressure control', 'treatment adherence and blood pressure control', 'clinic blood pressure control (systolic/diastolic, nondiabetes <140/90\u2009mmHg and diabetes <130/80\u2009mmHg) rate']","[{'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1449681', 'cui_str': 'Home Blood Pressure Monitoring'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0288171', 'cui_str': 'irbesartan'}, {'cui': 'C0020261', 'cui_str': 'Hydrochlorothiazide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0986849', 'cui_str': 'irbesartan 150 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0986850', 'cui_str': 'irbesartan 300 MG'}]","[{'cui': 'C4505265', 'cui_str': 'Therapeutic Adherence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}]",,0.0387878,"The proportion of patients who achieved the goal of clinic blood pressure control at 12 weeks of follow-up was significantly higher in the HBPM group than in the control group (66.7% vs. 55.1%, P = 0.04).","[{'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Qi-Fang', 'Initials': 'QF', 'LastName': 'Huang', 'Affiliation': 'Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Ji-Guang', 'Initials': 'JG', 'LastName': 'Wang', 'Affiliation': 'Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. jiguangwang@aim.com.'}]",Hypertension research : official journal of the Japanese Society of Hypertension,['10.1038/s41440-020-00602-0'] 843,33441686,A non-inferiority randomised controlled trial comparing self-instruction with instructor-led method in training of layperson cardiopulmonary resuscitation.,"Our study aimed to compare the effect of self-instruction with manikin feedback to that of instructor-led method on cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) skill performance. In our randomized non-inferiority trial, 64 non-healthcare providers were randomly allocated into self-instruction and instructor-led groups. Both groups watched a 27-min standardized teaching video. Participants in the self-instruction group then performed hands-on practice on the Resusci Anne QCPR with a device-driven feedback, while those in the instructor-led group practiced manikins; feedback was provided and student's questions were answered by instructors. Outcomes were measured by blinded evaluators and SkillReporter software. The primary outcome was the pass rate. Secondary outcomes were scores of the knowledge test and items of individual skill performance. The baseline characteristics of the two groups were similar. The pass rates were 93.8% in both group (absolute difference 0%, p = 0.049 for noninferiority). The knowledge test scores were not significantly different. However, the self-instruction group performed better in some chest compression and ventilation skills, but performed worse in confirming environmental safety and checking normal breathing. There was no difference in AED skills between the two groups. Our results showed the self-instruction method is not inferior to the instructor-led method.",2021,"The pass rates were 93.8% in both group (absolute difference 0%, p = 0.049 for noninferiority).",['64 non-healthcare providers'],"['self-instruction with instructor-led method in training of layperson cardiopulmonary resuscitation', 'instructor-led method on cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) skill performance', 'hands-on practice on the Resusci Anne QCPR with a device-driven feedback, while those in the instructor-led group practiced manikins; feedback']","['chest compression and ventilation skills', 'scores of the knowledge test and items of individual skill performance', 'knowledge test scores', 'pass rates', 'pass rate', 'AED skills']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0180309', 'cui_str': 'Automated External Defibrillators'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0018262', 'cui_str': 'Group Practice'}, {'cui': 'C0024722', 'cui_str': 'Mannequins'}]","[{'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0180309', 'cui_str': 'Automated External Defibrillators'}]",64.0,0.0782917,"The pass rates were 93.8% in both group (absolute difference 0%, p = 0.049 for noninferiority).","[{'ForeName': 'Ying-Chih', 'Initials': 'YC', 'LastName': 'Ko', 'Affiliation': 'Department of Emergency Medicine, National Taiwan University Hospital, No. 7 Chung Shan South Rd., Taipei, 100, Taiwan.'}, {'ForeName': 'Chih-Wei', 'Initials': 'CW', 'LastName': 'Yang', 'Affiliation': 'Department of Emergency Medicine, National Taiwan University Hospital, No. 7 Chung Shan South Rd., Taipei, 100, Taiwan.'}, {'ForeName': 'Hao-Yang', 'Initials': 'HY', 'LastName': 'Lin', 'Affiliation': 'Department of Emergency Medicine, National Taiwan University Hospital, No. 7 Chung Shan South Rd., Taipei, 100, Taiwan.'}, {'ForeName': 'Wen-Chu', 'Initials': 'WC', 'LastName': 'Chiang', 'Affiliation': 'Department of Emergency Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan.'}, {'ForeName': 'Ming-Ju', 'Initials': 'MJ', 'LastName': 'Hsieh', 'Affiliation': 'Department of Emergency Medicine, National Taiwan University Hospital, No. 7 Chung Shan South Rd., Taipei, 100, Taiwan. erdrmjhsieh@gmail.com.'}, {'ForeName': 'Matthew Huei-Ming', 'Initials': 'MH', 'LastName': 'Ma', 'Affiliation': 'Department of Emergency Medicine, National Taiwan University Hospital, No. 7 Chung Shan South Rd., Taipei, 100, Taiwan. matthew@ntu.edu.tw.'}]",Scientific reports,['10.1038/s41598-020-79626-y'] 844,33486572,"Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial.","PURPOSE Viscous dietary fiber, functional seeds and ginseng roots have individually been proposed for the management of diabetes. We explored whether their co-administration would improve glycemic control in type 2 diabetes beyond conventional therapy. METHODS In a randomized, double-blind, controlled trial conducted at two academic centers (Toronto, Canada and Zagreb, Croatia), individuals with type 2 diabetes were assigned to either an active intervention (10 g viscous fiber, 60 g white chia seeds, 1.5 g American and 0.75 g Korean red ginseng extracts), or energy and fiber-matched control (53 g oat bran, 25 g inulin, 25 g maltodextrose and 2.25 g wheat bran) intervention for 24 weeks, while on conventional standard of care. The prespecified primary endpoint was end difference at week 24 in HbA1c, following an intent-to-treat analysis adjusted for center and baseline. RESULTS Between January 2016 and April 2018, 104 participants (60M:44F; mean ± SEM age 59 ± 0.8 years; BMI 29.0 ± 0.4 kg/m 2 ; HbA1c 7.0 ± 0.6%) managed with antihyperglycemic agent(s) (n = 98) or lifestyle (n = 6), were randomized (n = 52 test; n = 52 control). At week 24, HbA1c levels were 0.27 ± 0.1% lower on test compared to control (p = 0.03). There was a tendency towards an interaction by baseline HbA1c (p = 0.07), in which a greater reduction was seen in participants with baseline HbA1c > 7% vs ≤ 7% (- 0.56 ± 0.2% vs 0.03 ± 0.2%). Diet and body weight remained unchanged. The interventions were well tolerated with no related adverse events and with high retention rate of 84%. CONCLUSIONS Co-administration of selected dietary and herbal therapies was well-tolerated and may provide greater glycemic control as add-on therapy in type 2 diabetes. Registration: Clinicaltrials.gov NCT02553382 (registered on September 17, 2015).",2021,"At week 24, HbA1c levels were 0.27 ± 0.1% lower on test compared to control (p = 0.03).","['type 2 diabetes', 'Registration', 'Between January 2016 and April 2018, 104 participants (60M:44F; mean\u2009±\u2009SEM age 59\u2009±\u20090.8 years; BMI 29.0\u2009±\u20090.4\xa0kg/m 2 ; HbA1c 7.0\u2009±\u20090.6%) managed with antihyperglycemic agent(s) (n\u2009=\u200998) or lifestyle (n\u2009=\u20096', 'two academic centers (Toronto, Canada and Zagreb, Croatia), individuals with type 2 diabetes']","['Co-administration of viscous fiber, Salba-chia and ginseng', 'active intervention (10\xa0g viscous fiber, 60\xa0g white chia seeds, 1.5\xa0g American and 0.75\xa0g Korean red ginseng extracts), or energy and fiber-matched control (53\xa0g oat bran, 25\xa0g inulin, 25\xa0g maltodextrose and 2.25\xa0g wheat bran) intervention']","['Diet and body weight', 'HbA1c levels', 'glycemic control']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0010343', 'cui_str': 'Croatia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C3256719', 'cui_str': 'Salvia hispanica seed extract'}, {'cui': 'C0086767', 'cui_str': 'Ginseng'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1318182', 'cui_str': '10G'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C4068882', 'cui_str': '0.75'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0873137', 'cui_str': 'Korean ginseng preparation'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0795649', 'cui_str': 'OAT BRAN'}, {'cui': 'C0456638', 'cui_str': '25G'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C4068875', 'cui_str': '2.25'}, {'cui': 'C0043138', 'cui_str': 'Wheat bran'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.430941,"At week 24, HbA1c levels were 0.27 ± 0.1% lower on test compared to control (p = 0.03).","[{'ForeName': 'Andreea', 'Initials': 'A', 'LastName': 'Zurbau', 'Affiliation': 'Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Lea', 'Initials': 'L', 'LastName': 'Smircic Duvnjak', 'Affiliation': 'Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, Zagreb, Croatia.'}, {'ForeName': 'Sasa', 'Initials': 'S', 'LastName': 'Magas', 'Affiliation': 'Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, Zagreb, Croatia.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Jovanovski', 'Affiliation': 'Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Miocic', 'Affiliation': 'Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, Zagreb, Croatia.'}, {'ForeName': 'Alexandra L', 'Initials': 'AL', 'LastName': 'Jenkins', 'Affiliation': ""Clinical Nutrition and Risk Factor Modification Center, St. Michael's Hospital, Toronto, ON, Canada.""}, {'ForeName': 'David J A', 'Initials': 'DJA', 'LastName': 'Jenkins', 'Affiliation': 'Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Josse', 'Affiliation': 'Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Lawrence A', 'Initials': 'LA', 'LastName': 'Leiter', 'Affiliation': 'Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'John L', 'Initials': 'JL', 'LastName': 'Sievenpiper', 'Affiliation': 'Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Vuksan', 'Affiliation': 'Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. v.vuksan@utoronto.ca.'}]",European journal of nutrition,['10.1007/s00394-020-02434-7'] 845,33491052,Comparison of Lateral Perturbation-Induced Step Training and Hip Muscle Strengthening Exercise on Balance and Falls in Community Dwelling Older Adults: A Blinded Randomized Controlled Trial.,"BACKGROUND This factorial, assessor-blinded, randomized, and controlled study compared the effects of perturbation-induced step training (lateral waist-pulls), hip muscle strengthening, and their combination, on balance performance, muscle strength, and prospective falls among older adults. METHODS community-dwelling older adults were randomized to four training groups. Induced-step training (IST, n=25) involved 43 progressive perturbations. Hip abduction strengthening (HST, n=25) utilized progressive resistance exercises. Combined training (CMB, n=25) included IST and HST, and the control performed seated flexibility/relaxation exercises (SFR, n=27). Training involved 36 sessions over 12-weeks. The primary outcomes were the number of recovery steps and first step length, and maximum hip abduction torque. Fall frequency during 12 months after training was determined. RESULTS Overall, the number of recovery steps was reduced by 31%, and depended upon the first step type. IST and CMB increased the rate of more stable single lateral steps pre-post training than HST and SFR who used more multiple crossover and sequential steps. The improved rate of lateral steps for CMB exceeded the control (CMB/SFR rate ratio 2.68). First step length was unchanged, and HST alone increased hip torque by 25%. Relative to SFR, the fall rate ratios (falls/person/year) [95% confidence interval] were: CMB 0.26 [0.07 to 0.90], IST 0.44 [0.18 to 1.08], HST 0.30 (0.10 to 0.91). CONCLUSIONS Balance performance through stepping was best improved by combining perturbation and strength training and not strengthening alone. The interventions reduced future falls by 56% -74% over the control. Lateral balance perturbation training may enhance traditional programs for fall prevention.",2021,IST and CMB increased the rate of more stable single lateral steps pre-post training than HST and SFR who used more multiple crossover and sequential steps.,"['older adults', 'Community Dwelling Older Adults', 'community-dwelling older adults']","['Hip abduction strengthening (HST, n=25) utilized progressive resistance exercises', 'perturbation-induced step training (lateral waist-pulls), hip muscle strengthening, and their combination', 'Lateral Perturbation-Induced Step Training and Hip Muscle Strengthening Exercise', 'HST', 'Lateral balance perturbation training', 'Combined training (CMB, n=25) included IST and HST, and the control performed seated flexibility/relaxation exercises']","['number of recovery steps and first step length, and maximum hip abduction torque', 'fall rate ratios (falls/person/year', 'IST and CMB', 'Balance and Falls', 'hip torque', 'Fall frequency', 'rate of lateral steps for CMB', 'number of recovery steps']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0086505', 'cui_str': 'Kidnapping'}, {'cui': 'C1451207', 'cui_str': 'FGF4 protein, human'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0230097', 'cui_str': 'Structure of waist (surface region)'}, {'cui': 'C0580846', 'cui_str': 'Does pull'}, {'cui': 'C0224415', 'cui_str': 'Skeletal muscle structure of hip'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0203993', 'cui_str': 'Relaxation exercise'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0427126', 'cui_str': 'Step length'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0086505', 'cui_str': 'Kidnapping'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}]",,0.0495698,IST and CMB increased the rate of more stable single lateral steps pre-post training than HST and SFR who used more multiple crossover and sequential steps.,"[{'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Rogers', 'Affiliation': 'Department of Physical Therapy and Rehabilitation Science, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Creath', 'Affiliation': 'Department of Physical Therapy and Rehabilitation Science, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Vicki', 'Initials': 'V', 'LastName': 'Gray', 'Affiliation': 'Department of Physical Therapy and Rehabilitation Science, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Abarro', 'Affiliation': 'Department of Physical Therapy and Rehabilitation Science, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'McCombe Waller', 'Affiliation': 'Department of Physical Therapy and Rehabilitation Science, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Brock A', 'Initials': 'BA', 'LastName': 'Beamer', 'Affiliation': 'Division of Gerontology and Geriatric Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Sorkin', 'Affiliation': 'Division of Gerontology and Geriatric Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.'}]","The journals of gerontology. Series A, Biological sciences and medical sciences",['10.1093/gerona/glab017'] 846,33422683,Neuro-cardiac coupling predicts transcutaneous auricular vagus nerve stimulation effects.,"BACKGROUND Transcutaneous auricular Vagus Nerve Stimulation (taVNS) is a non-invasive neuromodulation technique that may constitute an effective treatment for a wide range of neurological, psychiatric, and medical conditions. One key challenge in taVNS research is the high interindividual response variability. To gain an understanding of this variability, reliable biomarkers for taVNS responsiveness would be highly desirable. In this study, we investigated physiological candidate biomarkers while systematically varying stimulation conditions and observing physiological state characteristics. METHODS Forty-four healthy young adults received taVNS and sham-stimulation. Subjects were pseudo-randomly assigned to stimulation of the left or right ear. Each subject underwent six blocks of stimulation. Across blocks, respiration-locking (inhalation-locked taVNS vs. exhalation-locked taVNS vs. sham) and the electrode location (tragus vs. cymba conchae) were varied. We analyzed heart rate (HR), various heart rate variability (HRV) scores, and neuro-cardiac coupling (NCC), indexed by the relationship between electroencephalographic delta power and heartbeat length. RESULTS We observed an effect of taVNS on HR and HRV scores during, but not after stimulation. The direction of the effects was consistent with parasympathetic activation. We did not observe any systematic influence of the stimulation conditions that we varied. However, we found baseline NCC scores to be significant predictors for the individual effect of taVNS on HRV scores. CONCLUSION Cardiac effects of taVNS indicate parasympathetic activation. These effects were short lived, which might explain that some previous studies were unable to detect them. We propose NCC as a novel candidate biomarker for responsiveness to taVNS.",2021,We did not observe any systematic influence of the stimulation conditions that we varied.,['Forty-four healthy young adults'],"['respiration-locking (inhalation-locked taVNS vs. exhalation-locked taVNS vs. sham', 'Transcutaneous auricular Vagus Nerve Stimulation (taVNS', 'taVNS', 'NCC', 'taVNS and sham-stimulation']","['heart rate (HR), various heart rate variability (HRV) scores, and neuro-cardiac coupling (NCC), indexed by the relationship between electroencephalographic delta power and heartbeat length', 'HR and HRV scores', 'HRV scores']","[{'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C1522191', 'cui_str': 'Otic route'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0027855', 'cui_str': 'Neurology'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027855', 'cui_str': 'Neurology'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0425583', 'cui_str': 'Heart beat'}, {'cui': 'C1444754', 'cui_str': 'Length'}]",44.0,0.102139,We did not observe any systematic influence of the stimulation conditions that we varied.,"[{'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Keute', 'Affiliation': 'Institute for Neuromodulation and Neurotechnology, Department of Neurosurgery and Neurotechnology, And Tuebingen NeuroCampus, University of Tuebingen, Tuebingen, Germany. Electronic address: marius.keute@uni-tuebingen.de.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Machetanz', 'Affiliation': 'Institute for Neuromodulation and Neurotechnology, Department of Neurosurgery and Neurotechnology, And Tuebingen NeuroCampus, University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Levan', 'Initials': 'L', 'LastName': 'Berelidze', 'Affiliation': 'Institute for Neuromodulation and Neurotechnology, Department of Neurosurgery and Neurotechnology, And Tuebingen NeuroCampus, University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Guggenberger', 'Affiliation': 'Institute for Neuromodulation and Neurotechnology, Department of Neurosurgery and Neurotechnology, And Tuebingen NeuroCampus, University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Gharabaghi', 'Affiliation': 'Institute for Neuromodulation and Neurotechnology, Department of Neurosurgery and Neurotechnology, And Tuebingen NeuroCampus, University of Tuebingen, Tuebingen, Germany. Electronic address: alireza.gharabaghi@uni-tuebingen.de.'}]",Brain stimulation,['10.1016/j.brs.2021.01.001'] 847,33431374,"Lifestyle Intervention in Pregnant Women With Obesity Impacts Cord Blood DNA Methylation, Which Associates With Body Composition in the Offspring.","Maternal obesity may lead to epigenetic alterations in the offspring and might thereby contribute to disease later in life. We investigated whether a lifestyle intervention in pregnant women with obesity is associated with epigenetic variation in cord blood and body composition in the offspring. Genome-wide DNA methylation was analyzed in cord blood from 208 offspring from the Treatment of Obese Pregnant women (TOP)-study, which includes pregnant women with obesity randomized to lifestyle interventions comprised of physical activity with or without dietary advice versus control subjects (standard of care). DNA methylation was altered at 379 sites, annotated to 370 genes, in cord blood from offspring of mothers following a lifestyle intervention versus control subjects (false discovery rate [FDR] <5%) when using the Houseman reference-free method to correct for cell composition, and three of these sites were significant based on Bonferroni correction. These 370 genes are overrepresented in gene ontology terms, including response to fatty acids and adipose tissue development. Offspring of mothers included in a lifestyle intervention were born with more lean mass compared with control subjects. Methylation at 17 sites, annotated to, for example, DISC1 , GBX2 , HERC2 , and HUWE1 , partially mediates the effect of the lifestyle intervention on lean mass in the offspring (FDR <5%). Moreover, 22 methylation sites were associated with offspring BMI z scores during the first 3 years of life ( P < 0.05). Overall, lifestyle interventions in pregnant women with obesity are associated with epigenetic changes in offspring, potentially influencing the offspring's lean mass and early growth.",2021,"DNA methylation was altered at 379 sites, annotated to 370 genes, in cord blood from offspring of mothers following a lifestyle intervention versus controls ( FDR <5%) when using the Houseman reference-free method to correct for cell composition and three of these sites were significant based on Bonferroni correction.","['pregnant women with obesity randomized to', 'pregnant women with obesity', 'Pregnant Women With Obesity Impacts']","['lifestyle interventions', 'physical activity with or without dietary advice versus controls (standard of care', 'lifestyle intervention', 'Lifestyle Intervention']","['offspring BMI z-scores', 'response to fatty acids and adipose tissue development', 'DNA methylation', 'Cord Blood DNA Methylation', 'lean mass']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0596843', 'cui_str': 'Adipogenesis'}, {'cui': 'C0376452', 'cui_str': 'DNA Methylation'}, {'cui': 'C0162371', 'cui_str': 'Cord blood'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]",,0.0258068,"DNA methylation was altered at 379 sites, annotated to 370 genes, in cord blood from offspring of mothers following a lifestyle intervention versus controls ( FDR <5%) when using the Houseman reference-free method to correct for cell composition and three of these sites were significant based on Bonferroni correction.","[{'ForeName': 'Josefine', 'Initials': 'J', 'LastName': 'Jönsson', 'Affiliation': 'Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden josefin.jonsson@med.lu.se charlotte.ling@med.lu.se.'}, {'ForeName': 'Kristina M', 'Initials': 'KM', 'LastName': 'Renault', 'Affiliation': 'Department of Obstetrics and Gynecology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'García-Calzón', 'Affiliation': 'Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Perfilyev', 'Affiliation': 'Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden.'}, {'ForeName': 'Angela C', 'Initials': 'AC', 'LastName': 'Estampador', 'Affiliation': 'Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Malmö, Sweden.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Nørgaard', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Mads Vendelbo', 'Initials': 'MV', 'LastName': 'Lind', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Frederiksberg, Denmark.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Vaag', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Line', 'Initials': 'L', 'LastName': 'Hjort', 'Affiliation': 'Department of Obstetrics, Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Kim F', 'Initials': 'KF', 'LastName': 'Michaelsen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Frederiksberg, Denmark.'}, {'ForeName': 'Emma Malchau', 'Initials': 'EM', 'LastName': 'Carlsen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Frederiksberg, Denmark.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Franks', 'Affiliation': 'Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Malmö, Sweden.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Ling', 'Affiliation': 'Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden josefin.jonsson@med.lu.se charlotte.ling@med.lu.se.'}]",Diabetes,['10.2337/db20-0487'] 848,33428709,Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study.,"BACKGROUND Frailty is a geriatric syndrome of decreased physiologic reserve and resistance to stressors that results in increased vulnerability to adverse health outcomes with aging. Diabetes and hyperglycemia are established risk factors for frailty. We sought to examine whether the odds of frailty among individuals at high risk of diabetes randomized to treatment with intensive lifestyle (ILS), metformin, or placebo differed after long-term follow-up. METHOD The sample comprised participants in the Diabetes Prevention Program (DPP) clinical trial, who continued follow-up in the DPP Outcomes Study (DPPOS) and completed frailty assessments in DPPOS Years 8 (n = 2385) and 10 (n = 2289), approximately 12 and 14 years after DPP randomization. Frailty was classified using Fried Frailty Phenotype criteria. GEE models adjusting for visit year with repeated measures pooled for Years 8 and 10 were used to estimate pairwise odds ratios (ORs) between ILS, metformin, and placebo for the outcomes of frail and prefrail versus nonfrail. RESULTS Frailty prevalence by treatment group was ILS = 3.0%, metformin = 5.4%, placebo = 5.7% at Year 8, and ILS = 3.6%, metformin = 5.3%, placebo = 5.4% at Year 10. Odds ratios (95% CI) estimated with GEE models were ILS versus placebo, 0.62 (0.42-0.93), p = .022; metformin versus placebo, 0.99 (0.69-1.42), p = .976; and ILS versus metformin, 0.63 (0.42-0.94), p = .022. Odds of being frail versus nonfrail were 37% lower for ILS compared to metformin and placebo. CONCLUSIONS Early ILS intervention, at an average age of about 50 years, in persons at high risk of diabetes may reduce frailty prevalence in later life. Metformin may be ineffective in reducing frailty prevalence. CLINICAL TRIALS REGISTRATION NUMBERS NCT00004992 (DPP) and NCT00038727 (DPPOS).",2021,"RESULTS Frailty prevalence by treatment group was ILS = 3.0%, metformin = 5.4%, placebo = 5.7% at Year 8, and ILS = 3.6%, metformin = 5.3%, placebo = 5.4% at Year 10.","['sample comprised participants in the Diabetes Prevention Program (DPP) clinical trial, who continued follow-up in the DPP Outcomes Study (DPPOS) and completed frailty assessments in DPPOS Years 8 (n = 2385) and 10 (n = 2289), approximately 12 and 14 years after DPP randomization']","['placebo', 'Metformin', 'intensive lifestyle (ILS), metformin, or placebo', 'metformin', 'Intensive Lifestyle and Metformin Interventions', 'ILS, metformin, and placebo']",['Odds ratios'],"[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0543472', 'cui_str': 'Outcome Studies'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",2385.0,0.104391,"RESULTS Frailty prevalence by treatment group was ILS = 3.0%, metformin = 5.4%, placebo = 5.7% at Year 8, and ILS = 3.6%, metformin = 5.3%, placebo = 5.4% at Year 10.","[{'ForeName': 'Helen P', 'Initials': 'HP', 'LastName': 'Hazuda', 'Affiliation': 'University of Texas Health Science Center at San Antonio.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Pan', 'Affiliation': 'Biostatistics Center, The George Washington University.'}, {'ForeName': 'Hermes', 'Initials': 'H', 'LastName': 'Florez', 'Affiliation': 'University of Miami, Florida.'}, {'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'Luchsinger', 'Affiliation': 'Columbia University Irving Medical Center, New York, New York.'}, {'ForeName': 'Jill P', 'Initials': 'JP', 'LastName': 'Crandall', 'Affiliation': 'Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Venditti', 'Affiliation': 'University of Pittsburgh, Pennsylvania.'}, {'ForeName': 'Sherita H', 'Initials': 'SH', 'LastName': 'Golden', 'Affiliation': 'Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Kriska', 'Affiliation': 'University of Pittsburgh, Pennsylvania.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Bray', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, Louisiana.'}]","The journals of gerontology. Series A, Biological sciences and medical sciences",['10.1093/gerona/glaa295'] 849,33433149,Inertial Load Power Cycling Training Increases Muscle Mass and Aerobic Power in Older Adults.,"PURPOSE Reductions in skeletal muscle mass, beginning after the third decade of life, reduce maximal neuromuscular power (Pmax). Maximal aerobic power generation is also reduced. The primary purpose of this study was to investigate the effectiveness of maximal power cycling (PC) training using an inertial load ergometer on skeletal muscle mass and cardiovascular function in untrained 50- to 68-yr-old participants. METHODS The study used a pre- or postoutcome exercise intervention testing untrained 50- to 68-yr-old adults (n = 39, M = 15, mean ± SE = 58.5 ± 0.8, range = 50-68 yr). Over the course of 8 wk, participants performed 15 min of training 3 times per week. Each session involved repeated (15-30 times) 4-s sprints of PC. Measurements were thigh muscle volume, total body lean mass, Pmax, peak oxygen consumption, cardio-ankle vascular index, performance on functional tests of living (FTLChair and FTLRamp), and intermuscular fat volume. RESULTS Training for 8 wk increased thigh muscle volume (3.7% ± 0.9%, P < 0.001) and total body lean mass (1.5% ± 0.4%, P < 0.01) while increasing total body mass (TBM) (1.4% ± 0.3%, P < 0.01). Physical performance measures increased significantly (all P < 0.05) with improvements in Pmax (12.0% ± 1.5%); peak oxygen consumption (9.8% ± 1.8%), and FTL (8.5% ± 1.3% to 17.2% ± 2%). Cardio-ankle vascular index was significantly decreased -2.3% ± 1.1% (P < 0.05), indicating reduced arterial stiffness. CONCLUSIONS These results demonstrate that 8 wk of PC training at true maximal power was effective at increasing muscle mass and maximal power, as well as maximal cardiovascular capacity and functional tasks in untrained 50- to 68-yr-olds.",2021,"RESULTS Training for 8 weeks increased TMV 3.7 ± 0.9% (p<0.001) and TBLM 1.5 ± 0.4% (p<0.01) while increasing total body mass (TBM) 1.4 ± 0.3% (p<0.01).","['untrained 50-68-year-old participants', 'Older Adults', 'untrained 50-68 year old adults (n=39; M=15; mean±SE 58.5 ± 0.8; range 50-68 y']","['Inertial Load Power Cycling Training', 'exercise intervention testing', 'maximal power cycling (PC) training', 'inertial load ergometer']","['skeletal muscle mass and cardiovascular function', 'thigh muscle volume (TMV), total body lean mass (TBLM), maximal neuromuscular power (Pmax), peak oxygen consumption (VO2peak), cardio-ankle vascular index (CAVI), performance on functional tasks of living (FTLChair & FTLRamp) and inter-muscular fat volume (IMFV', 'Physical performance measures', 'maximal cardiovascular capacity and functional tasks', 'arterial stiffness', 'maximal neuromuscular power (Pmax', 'CAVI']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}]","[{'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0007227', 'cui_str': 'Cardiovascular function'}, {'cui': 'C0224416', 'cui_str': 'Skeletal muscle structure of thigh'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C4034558', 'cui_str': 'Cardio-ankle vascular index'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}]",,0.0288185,"RESULTS Training for 8 weeks increased TMV 3.7 ± 0.9% (p<0.001) and TBLM 1.5 ± 0.4% (p<0.01) while increasing total body mass (TBM) 1.4 ± 0.3% (p<0.01).","[{'ForeName': 'Jakob R', 'Initials': 'JR', 'LastName': 'Allen', 'Affiliation': 'Human Performance Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX.'}, {'ForeName': 'Remzi', 'Initials': 'R', 'LastName': 'Satiroglu', 'Affiliation': 'Human Performance Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX.'}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Fico', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Tanaka', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX.'}, {'ForeName': 'Emre', 'Initials': 'E', 'LastName': 'Vardarli', 'Affiliation': 'Human Performance Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Luci', 'Affiliation': 'Department of Neuroscience and Biomedical Engineering, and the Biomedical Imaging Center, The University of Texas at Austin, Austin, TX.'}, {'ForeName': 'Edward F', 'Initials': 'EF', 'LastName': 'Coyle', 'Affiliation': 'Human Performance Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002588'] 850,33434277,Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial.,"OBJECTIVES To quantify the prevalence of co-morbidities in patients with early RA and determine their prognostic value for effectiveness outcomes in a randomized trial. METHODS We included patients from the 2-year pragmatic randomized CareRA trial, who had early RA (diagnosis < 1 year), were DMARD naïve and then treated-to-target with different remission induction schemes. Prevalence of co-morbidities was registered at baseline and the Rheumatic Diseases Comorbidity Index (RDCI; range 0-9) was calculated. We tested the relation between baseline RDCI and outcomes including disease activity (DAS28-CRP), physical function (HAQ index), quality of life (SF-36 domains) and hospitalizations over 2 years, using linear mixed models or generalized estimating equations models. RESULTS Of 379 included patients, 167 (44%) had a RDCI of minimum 1. RDCI scores of 1, 2 or ≥3 were obtained in 65 (17%), 70 (19%), and 32 (8%) participants, respectively. The most frequent co-morbidity was hypertension (22%). Patients with co-morbidities had significantly higher HAQ (β = 0.215; 95% CI: 0.071, 0.358), DAS28-CRP (β = 0.225; 95% CI: 0.132, 0.319) and lower SF-36 physical component summary scores (β =-3.195; 95% CI: -4.844, -1.546) over 2 years than patients without co-morbidities, after adjusting for possible confounders including disease activity and randomized treatment. Patients with co-morbidities had over time lower chances of achieving remission (OR = 0.724; 95% CI: 0.604, 0.867) and a higher risk of hospitalization (OR = 3.725; 95% CI: 2.136, 6.494). CONCLUSION At disease onset, almost half of RA patients had at least one clinically important co-morbidity. Having co-morbidities was associated with worse functionality and disease activity outcomes over 2 years, despite intensive remission induction treatment. TRIAL REGISTRATION Clinical trials NCT01172639.",2021,"Having co-morbidities was associated with worse functionality and disease activity outcomes over 2 years, despite intensive remission induction treatment. ","['Of 379 included patients, 167 (44%) had a RDCI of minimum 1', 'patients from the 2-year pragmatic randomized CareRA trial, who had early RA (diagnosis\u2009<\u20091\u2009year), were DMARD naïve and then treated-to-target with different remission induction schemes', 'patients with early RA']",[],"['disease activity (DAS28-CRP), physical function (HAQ index), quality of life (SF-36 domains) and hospitalizations over 2\u2009years, using linear mixed models or generalized estimating equations models', 'RDCI scores', 'Rheumatic Diseases Comorbidity Index', 'Prevalence of co-morbidities', 'higher risk of hospitalization', 'worse functionality and disease activity outcomes', 'lower SF-36 physical component summary scores', 'time lower chances of achieving remission', 'HAQ']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0009326', 'cui_str': 'Collagen disease'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0242708', 'cui_str': 'Disease-Modifying Antirheumatic Drugs'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0035052', 'cui_str': 'Induction of Remission'}]",[],"[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0102923', 'cui_str': 'ametantrone'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0009326', 'cui_str': 'Collagen disease'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}]",379.0,0.383344,"Having co-morbidities was associated with worse functionality and disease activity outcomes over 2 years, despite intensive remission induction treatment. ","[{'ForeName': 'Veerle', 'Initials': 'V', 'LastName': 'Stouten', 'Affiliation': 'KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, Leuven, Belgium.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Westhovens', 'Affiliation': 'KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, Leuven, Belgium.'}, {'ForeName': 'Diederik', 'Initials': 'D', 'LastName': 'De Cock', 'Affiliation': 'KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, Leuven, Belgium.'}, {'ForeName': 'Kristien', 'Initials': 'K', 'LastName': 'Van der Elst', 'Affiliation': 'KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, Leuven, Belgium.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Pazmino', 'Affiliation': 'KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, Leuven, Belgium.'}, {'ForeName': 'Delphine', 'Initials': 'D', 'LastName': 'Bertrand', 'Affiliation': 'KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, Leuven, Belgium.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Joly', 'Affiliation': 'Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Verschueren', 'Affiliation': 'KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, Leuven, Belgium.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa841'] 851,33434268,Randomized study defining the optimum target interlesion distance in ablation index-guided atrial fibrillation ablation: Authors' reply.,,2021,,[],['ablation index-guided atrial fibrillation ablation'],[],[],"[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]",[],,0.0258951,,"[{'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Hoffmann', 'Affiliation': 'Department of Cardiology and Angiology, Charité-University Medicine Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.'}, {'ForeName': 'Till F', 'Initials': 'TF', 'LastName': 'Althoff', 'Affiliation': 'Department of Cardiology and Angiology, Charité-University Medicine Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa354'] 852,33446036,The effects of a physical activity intervention based on a fatness and fitness smartphone app for University students.,"Since the 2012 Lancet Series on physical activity, progress regarding this topic has been negligible at global level. Thus, improving physical activity levels in specific populations through new methodologies is positioned as a priority. The aim of this study was to determine the effects of a physical activity intervention on body fatness composition, and measured and self-reported physical fitness components based on the use of a smartphone app. The investigation included 100 Spanish university students, cluster-randomized into the smartphone app intervention group or a control group ( n  = 35 and n  = 31 respectively, after applying exclusion criteria). The physical activity intervention comprised a 9-week programme designed to promote a healthy physical activity pattern using a smartphone app. Specifically, an mHealth approach was taken containing five BCTs. The results showed that the intervention group improved their physical fitness ( F  = 8.1, p  = .006) and reported better general scores in self-reported physical fitness ( F  = 7.4, p  = .008) over time, in comparison to the control group. However, the intervention group did not show any changes to their fatness. Further research is needed to disentangle which BCTs are more effective to achieve physical health improvements when using physical activity apps.",2021,"The results showed that the intervention group improved their physical fitness ( F  = 8.1, p  = .006) and reported better general scores in self-reported physical fitness ( F  = 7.4, p  = .008) over time, in comparison to the control group.","['100 Spanish university students, cluster-randomized into the', 'University students']","['smartphone app intervention group or a control group', 'physical activity intervention']","['physical fitness', 'body fatness composition', 'physical activity levels', 'general scores in self-reported physical fitness']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]",,0.0126901,"The results showed that the intervention group improved their physical fitness ( F  = 8.1, p  = .006) and reported better general scores in self-reported physical fitness ( F  = 7.4, p  = .008) over time, in comparison to the control group.","[{'ForeName': 'Adrià', 'Initials': 'A', 'LastName': 'Muntaner-Mas', 'Affiliation': 'Physical Activity and Sports Research Group (GICAFE), Faculty of Education, University of Balearic Islands, Balearic Islands, Spain.'}, {'ForeName': 'Victor A', 'Initials': 'VA', 'LastName': 'Sanchez-Azanza', 'Affiliation': 'Department of Applied Pedagogy and Educational Psychology, Faculty of Education, University of Balearic Islands, Balearic Islands, Spain.'}, {'ForeName': 'Francisco B', 'Initials': 'FB', 'LastName': 'Ortega', 'Affiliation': 'PROmoting FITness and Health through physical activity Research Group (PROFITH), Department of Physical Education and Sports, Faculty of Sports Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Vidal-Conti', 'Affiliation': ''}, {'ForeName': 'Pere Antoni', 'Initials': 'PA', 'LastName': 'Borràs', 'Affiliation': ''}, {'ForeName': 'Jaume', 'Initials': 'J', 'LastName': 'Cantallops', 'Affiliation': ''}, {'ForeName': 'Pere', 'Initials': 'P', 'LastName': 'Palou', 'Affiliation': 'Physical Activity and Sports Research Group (GICAFE), Faculty of Education, University of Balearic Islands, Balearic Islands, Spain.'}]",Health informatics journal,['10.1177/1460458220987275'] 853,33446035,Web-based education of the elderly improves drug utilization literacy: A randomized controlled trial.,"The aim of this study was to explore the effects of web-based education in the field of drug utilization on elderly individuals' knowledge of, concerns about and self-assessed understanding of drug utilization. The 260 included participants were randomized to a control group or an intervention group. To assess drug utilization literacy, we used a questionnaire containing 20 multiple-choice questions on drug utilization and ten statements about drug utilization (to which participants graded their response using a Likert scale: two about common concerns and eight about their self-assessed understanding of drug utilization). The Beliefs about Medicines Questionnaire-General was also used. The intervention group scored higher on the knowledge questions ( p  < 0.001) and on six of the eight statements about self-assessed understanding of drug utilization at the first check after 2 weeks ( p  < 0.05). At a second check 6 months later, the difference remained for the knowledge questions, but there was no difference in self-assessed understanding of drug utilization between the groups. There were no differences in the concerns about drug utilization or beliefs about medication at any time. We conclude that a web-based education can improve drug utilization literacy in elderly individuals and might contribute to the safer use of medications.",2021,The intervention group scored higher on the knowledge questions ( p  < 0.001) and on six of the eight statements about self-assessed understanding of drug utilization at the first check after 2 weeks ( p  < 0.05).,['elderly individuals'],[],"['knowledge questions', 'drug utilization literacy', 'self-assessed understanding of drug utilization']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",[],"[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0013223', 'cui_str': 'Utilization, Drug'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}]",260.0,0.0225976,The intervention group scored higher on the knowledge questions ( p  < 0.001) and on six of the eight statements about self-assessed understanding of drug utilization at the first check after 2 weeks ( p  < 0.05).,"[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Qvarfordt', 'Affiliation': ''}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Throfast', 'Affiliation': ''}, {'ForeName': 'Göran', 'Initials': 'G', 'LastName': 'Petersson', 'Affiliation': ''}, {'ForeName': 'Tora', 'Initials': 'T', 'LastName': 'Hammar', 'Affiliation': 'Linnaeus University, Sweden.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Hellström', 'Affiliation': 'Linnaeus University, Sweden.'}]",Health informatics journal,['10.1177/1460458220977585'] 854,33449418,Effects of a brief alcohol intervention addressing the full spectrum of drinking in an adult general population sample: a randomized controlled trial.,"BACKGROUND AND AIMS Evidence for efficacy of brief alcohol interventions (BAIs) is mainly limited to primary care and at-risk drinkers. The aim was to test the efficacy of a BAI addressing the full spectrum of alcohol use in a general population sample and across alcohol risk groups. DESIGN Two-parallel-group randomized controlled trial (allocation ratio 1:1) with post-baseline assessments at months 3, 6 and 12. SETTING One municipal registry office in Germany responsible for registration, passport and vehicle admission issues. PARTICIPANTS A total of 1646 proactively recruited 18-64-year-old adults with past year alcohol use (56% women, 66% low-risk drinkers) were randomized to intervention (n = 815) or control (n = 831). INTERVENTION AND COMPARATOR The intervention consisted of assessment plus computer-generated individualized feedback letters at baseline and months 3 and 6. Comparator was assessment only. MEASUREMENTS Primary outcome was change in the self-reported number of drinks/week from baseline to 12 months. Changes at 3 and 6 months were secondary outcomes. Moderator was alcohol risk group (low-risk versus at-risk drinking) according to the Alcohol Use Disorders Identification Test-Consumption, with scores from 1-3 (women) and from 1-4 (men) indicating low-risk drinking. FINDINGS For the whole sample, significant group differences were observed neither at 12-month follow-up [incidence rate ratio (IRR) = 1.01, 95% confidence interval (CI) = 0.87-1.17, Bayes factor (BE) = 0.52] nor at previous assessments (month 3: IRR = 1.01, 95% CI = 0.92-1.12, BE = 0.41; month 6: IRR = 0.93, 95% CI = 0.81-1.07, BE = 1.10). Moderator analyses revealed that low-risk drinkers were more likely to benefit from BAI only at month 6 than at-risk drinkers (IRR = 0.77, 95% CI = 0.70-0.86). CONCLUSIONS In a randomized controlled trial, there was no clear evidence for efficacy of a computer-based brief alcohol intervention in a general population sample, but there was some evidence of medium-term benefits in the large but understudied group of low-risk drinkers.",2021,"In a randomized controlled trial, there was no clear evidence for efficacy of a computer-based brief alcohol intervention in a general population sample, but there was some evidence of medium-term benefits in the large but understudied group of low-risk drinkers.","['general population sample and across alcohol risk groups', 'One municipal registry office in Germany responsible for registration, passport and vehicle admission issues', 'adult general population sample', '1,646 proactively recruited 18-to-64-year-old adults with past year alcohol use (56% women, 66% low-risk drinkers']","['computer-based brief alcohol intervention', 'alcohol interventions (BAIs', 'alcohol intervention']",['low-risk drinkers'],"[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C1273518', 'cui_str': 'Responsible to'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C3538919', 'cui_str': 'Low risk'}]",1646.0,0.149198,"In a randomized controlled trial, there was no clear evidence for efficacy of a computer-based brief alcohol intervention in a general population sample, but there was some evidence of medium-term benefits in the large but understudied group of low-risk drinkers.","[{'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Baumann', 'Affiliation': 'Faculty of Medicine, Institute and Policlinic of Occupational and Social Medicine, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Staudt', 'Affiliation': 'Faculty of Medicine, Institute and Policlinic of Occupational and Social Medicine, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Jennis', 'Initials': 'J', 'LastName': 'Freyer-Adam', 'Affiliation': 'Institute for Medical Psychology, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'Gallus', 'Initials': 'G', 'LastName': 'Bischof', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Meyer', 'Affiliation': 'Institute of Community Medicine, Department of Prevention Research and Social Medicine, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'John', 'Affiliation': 'Institute of Community Medicine, Department of Prevention Research and Social Medicine, University Medicine Greifswald, Greifswald, Germany.'}]","Addiction (Abingdon, England)",['10.1111/add.15412'] 855,33452051,Randomised controlled trial of naming outcomes in anterior temporal lobectomy versus selective amygdalohippocampectomy.,,2021,,[],['anterior temporal lobectomy versus selective amygdalohippocampectomy'],[],[],"[{'cui': 'C1136214', 'cui_str': 'Anterior Temporal Lobectomy'}, {'cui': 'C2921031', 'cui_str': 'Amygdalohippocampectomy'}]",[],,0.12479,,"[{'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Ives-Deliperi', 'Affiliation': 'Neuroscience Institute, University of Cape Town, Rondebosch, Western Cape, South Africa vickideliperi@icloud.com.'}, {'ForeName': 'James Thomas', 'Initials': 'JT', 'LastName': 'Butler', 'Affiliation': 'Neurology, University of Cape Town, Rondebosch, Western Cape, South Africa.'}]","Journal of neurology, neurosurgery, and psychiatry",['10.1136/jnnp-2020-324531'] 856,33449865,Effectiveness of Combined Complex Decongestive Therapy and Resistance Exercises in the Treatment of Lymphedema Associated with Breast Cancer and the Effect of Pain on Treatment Response.,"Background: The aim of this study was to compare the effects of complex decongestive therapy (CDT) accompanied by resistance exercises on extremity circumference, lymphedema volume, grip strength, functional status, and quality of life in the treatment of breast cancer-related lymphedema (BCRL) in patients with and without pain. Methods and Results: Fifty patients with unilateral BCRL were divided into groups: with pain (Group 1, n  = 25) and without pain (Group 2, n  = 25). Thirty minutes of manual lymphatic drainage and multilayered short-stretch bandaging were applied to all patients five times a week for 4 weeks. In addition, all patients were informed about skin care and given a supervised resistance exercise program throughout the treatment. During the 1-month follow-up period, patients were asked to use low-tension elastic garments and to continue their home exercise program. Differences in upper extremity circumference and volume; grip strength; Quick Disabilities of the Arm, Shoulder, and Hand; and Functional Assessment of Cancer Therapy-Breast scores were evaluated at baseline, after treatment (week 4), and at 1-month follow-up. Moreover, the pain intensity of patients in Group 1 was measured using the visual analog scale (VAS). Patients in both Group 1 and Group 2 showed a statistical improvement in all outcome measures after treatment and at follow-up ( p  < 0.05); however, no significant difference was observed between the groups ( p  > 0.05). In Group 1, a statistically significant decrease was observed in the VAS score both at the end of treatment (-1.7 ± 0.9) and at 1-month follow-up (-3.5 ± 1.2) ( p  < 0.05). Conclusion: Combined CDT and resistance exercises appear to be effective in BCRL patients both with and without pain.",2021,"Patients in both Group 1 and Group 2 showed a statistical improvement in all outcome measures after treatment and at follow-up ( p  < 0.05); however, no significant difference was observed between the groups ( p  > 0.05).","['Fifty patients with unilateral BCRL', 'breast cancer-related lymphedema (BCRL) in patients with and without pain', 'Lymphedema Associated with Breast Cancer']","['low-tension elastic garments and to continue their home exercise program', 'manual lymphatic drainage and multilayered short-stretch bandaging', 'complex decongestive therapy (CDT) accompanied by resistance exercises', 'Combined Complex Decongestive Therapy and Resistance Exercises', 'supervised resistance exercise program', 'Combined CDT and resistance exercises']","['upper extremity circumference and volume; grip strength; Quick Disabilities of the Arm, Shoulder, and Hand; and Functional Assessment of Cancer Therapy-Breast scores', 'pain intensity', 'extremity circumference, lymphedema volume, grip strength, functional status, and quality of life', 'visual analog scale (VAS', 'VAS score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C4277512', 'cui_str': 'Breast Cancer-Related Arm Lymphedema'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0221839', 'cui_str': 'Orthodontic band, elastic'}, {'cui': 'C0009072', 'cui_str': 'Garments'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program'}, {'cui': 'C0556834', 'cui_str': 'Manual lymphatic drainage'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0150468', 'cui_str': 'Application of bandage'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0054696', 'cui_str': 'Carbohydrate deficient transferrin'}]","[{'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",50.0,0.0184557,"Patients in both Group 1 and Group 2 showed a statistical improvement in all outcome measures after treatment and at follow-up ( p  < 0.05); however, no significant difference was observed between the groups ( p  > 0.05).","[{'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Corum', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Physical Medicine and Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ceyhun', 'Initials': 'C', 'LastName': 'Basoglu', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Istanbul Aydin University, Istanbul, Turkey.'}, {'ForeName': 'Merve Damla', 'Initials': 'MD', 'LastName': 'Korkmaz', 'Affiliation': 'Physical Medicine and Rehabilitation Clinic, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Mustafa Aziz', 'Initials': 'MA', 'LastName': 'Yildirim', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Physical Medicine and Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Kadriye', 'Initials': 'K', 'LastName': 'Ones', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Physical Medicine and Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}]",Lymphatic research and biology,['10.1089/lrb.2020.0099'] 857,33441917,A randomized clinical trial on the effect of a lidocaine patch on shoulder pain relief in laparoscopic cholecystectomy.,"The incidence of laparoscopy-related shoulder pain reaches 90% in women. We evaluated the effect of lidocaine patch 5% on the shoulder pain after laparoscopic cholecystectomy (LC) in female patients. Total 63 female patients were randomly allocated to patch group (n = 31) and control group (n = 32). Patch group received lidocaine patch 5% and dressing retention tape on both shoulder, and control group received only dressing retention tape. Abdominal and shoulder pains were evaluated with rating on numeric rating scale (0 = no pain and 10 = the worst pain) at baseline and at 30 min, 6 h, 24 h, and 48 h after surgery. There were no significant differences in patient characteristics and operation details. The overall incidence of shoulder pain was significantly lower in patch group than in control group (42% vs. 78%, P = 0.005). The severity of shoulder pain also was significantly reduced in patch group compared to control group at 24 h and 48 h after surgery (P = 0.01 and P = 0.015, respectively). Complications related to lidocaine patch were not found except nausea. Lidocaine patch 5% reduced the incidence and severity of postoperative shoulder pain in female patients undergoing LC without complications.",2021,"The severity of shoulder pain also was significantly reduced in patch group compared to control group at 24 h and 48 h after surgery (P = 0.01 and P = 0.015, respectively).","['Total 63 female patients', 'female patients', 'laparoscopic cholecystectomy', 'female patients undergoing LC without complications']","['lidocaine patch', 'lidocaine', 'lidocaine patch 5% and dressing retention tape on both shoulder, and control group received only dressing retention tape', 'Lidocaine', 'laparoscopic cholecystectomy (LC']","['incidence and severity of postoperative shoulder pain', 'shoulder pain', 'nausea', 'overall incidence of shoulder pain', 'severity of shoulder pain', 'shoulder pain relief', 'Abdominal and shoulder pains', 'numeric rating scale', 'incidence of laparoscopy-related shoulder pain']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0794811', 'cui_str': 'Lidocaine 50 microgram/mg cutaneous patch'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}]",63.0,0.0354889,"The severity of shoulder pain also was significantly reduced in patch group compared to control group at 24 h and 48 h after surgery (P = 0.01 and P = 0.015, respectively).","[{'ForeName': 'Ha Yeon', 'Initials': 'HY', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Republic of Korea.'}, {'ForeName': 'Jong Bum', 'Initials': 'JB', 'LastName': 'Choi', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Republic of Korea.'}, {'ForeName': 'Sang Kee', 'Initials': 'SK', 'LastName': 'Min', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Republic of Korea.'}, {'ForeName': 'Min Ying', 'Initials': 'MY', 'LastName': 'Chang', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Republic of Korea.'}, {'ForeName': 'Gang Mee', 'Initials': 'GM', 'LastName': 'Lim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Republic of Korea.'}, {'ForeName': 'Ji Eun', 'Initials': 'JE', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Republic of Korea. beye98@aumc.ac.kr.'}]",Scientific reports,['10.1038/s41598-020-80289-y'] 858,33427317,Effects of Implementing Multiple Components in a School-Wide Antibullying Program: A Randomized Controlled Trial in Elementary Schools.,"This study investigates the effectiveness of the PRIMA antibullying program for elementary education using a cluster-randomized trial with two experimental conditions (with and without student lessons) and a control group. Students of 31 schools participated in the study (N = 3,135; M age  = 10 years). Multilevel regression analyses demonstrated positive effects of the program on peer-reported victimization and reinforcing behavior. Implementing multiple program components was related to stronger program effects. The results provide partial experimental evidence for the beneficial effects of combining student lessons and teacher training in antibullying programs. Future experimental research is needed to investigate other approaches that reduce not only peer-reported victimization, but also self-perceived bullying and victimization.",2021,Multilevel regression analyses demonstrated positive effects of the program on peer-reported victimization and reinforcing behavior.,"['Students of 31 schools participated in the study (N\xa0=\xa03,135; M age \xa0=\xa010\xa0years', 'Elementary Schools', 'a School-Wide Antibullying Program']",['PRIMA antibullying program'],[],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}]",[],31.0,0.0319841,Multilevel regression analyses demonstrated positive effects of the program on peer-reported victimization and reinforcing behavior.,"[{'ForeName': 'Marloes D A', 'Initials': 'MDA', 'LastName': 'van Verseveld', 'Affiliation': 'Amsterdam University of Applied Sciences.'}, {'ForeName': 'Minne', 'Initials': 'M', 'LastName': 'Fekkes', 'Affiliation': 'TNO.'}, {'ForeName': 'Ruben G', 'Initials': 'RG', 'LastName': 'Fukkink', 'Affiliation': 'Amsterdam University of Applied Sciences.'}, {'ForeName': 'Ron J', 'Initials': 'RJ', 'LastName': 'Oostdam', 'Affiliation': 'Amsterdam University of Applied Sciences.'}]",Child development,['10.1111/cdev.13529'] 859,33438346,Evaluation of adding platelet-rich plasma to combined medical therapy in androgenetic alopecia.,"BACKGROUND Androgenetic alopecia (AGA) is a common hair loss disorder. OBJECTIVES To evaluate the therapeutic effects of platelet-rich plasma (PRP) in androgenetic alopecia. METHODS This study was done on 126 AGA patients, 42 patients survived as control group who received medical treatment, only other 84 patients were subdivided into two groups, and they received PRP sessions as co-adjuvant therapy using different methods administration. Patients were evaluated clinically, by dermoscopy and by digital dermoscopy to measure hair density and diameters before and after treatment. RESULTS PRP-treated patients showed statistically significant increase in hair density and diameter measurements than control group. These results increased by using microneedling as a method of PRP administration. CONCLUSION In AGA, the addition of ""PRP with microneedling"" to the combined medical treatment increases its efficacy and shortens the time needed for optimum improvement. STUDY DESIGN Single-blinded randomized controlled study.",2021,"RESULTS PRP-treated patients showed statistically significant increase in hair density and diameter measurements than control group.","['androgenetic alopecia', '126 AGA patients, 42 patients survived as control group who received medical treatment, only other 84 patients']","['platelet-rich plasma (PRP', 'platelet-rich plasma to combined medical therapy', 'PRP sessions as co-adjuvant therapy']",['hair density and diameter measurements'],"[{'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",126.0,0.0284204,"RESULTS PRP-treated patients showed statistically significant increase in hair density and diameter measurements than control group.","[{'ForeName': 'Wafaa Mohammad', 'Initials': 'WM', 'LastName': 'Ramadan', 'Affiliation': 'Department of Dermatology and Venereology, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Arwa Mohammad', 'Initials': 'AM', 'LastName': 'Hassan', 'Affiliation': 'Department of Dermatology and Venereology, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Mayada A', 'Initials': 'MA', 'LastName': 'Ismail', 'Affiliation': 'Department of Dermatology and Venereology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Yasmina Ahmed', 'Initials': 'YA', 'LastName': 'El Attar', 'Affiliation': 'Department of Dermatology and Venereology, Tanta University, Tanta, Egypt.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13935'] 860,33441315,CONservative TReatment of Appendicitis in Children: a randomised controlled feasibility Trial (CONTRACT).,"OBJECTIVE To establish the feasibility of a multicentre randomised controlled trial to assess the effectiveness and cost-effectiveness of a non-operative treatment pathway compared with appendicectomy in children with uncomplicated acute appendicitis. DESIGN Feasibility randomised controlled trial with embedded qualitative study to inform recruiter training to optimise recruitment and the design of a future definitive trial. SETTING Three specialist paediatric surgery centres in the UK. PATIENTS Children (aged 4-15 years) with a clinical diagnosis of uncomplicated acute appendicitis. INTERVENTIONS Appendicectomy or a non-operative treatment pathway (comprising broad-spectrum antibiotics and active observation). MAIN OUTCOME MEASURES Primary outcome measure was the proportion of eligible patients recruited. Secondary outcomes evaluated adherence to interventions, data collection during follow-up, safety of treatment pathways and clinical course. RESULTS Fifty per cent of eligible participants (95% CI 40 to 59) approached about the trial agreed to participate and were randomised. Repeated bespoke recruiter training was associated with an increase in recruitment rate over the course of the trial from 38% to 72%. There was high acceptance of randomisation, good patient and surgeon adherence to trial procedures and satisfactory completion of follow-up. Although more participants had perforated appendicitis than had been anticipated, treatment pathways were found to be safe and adverse event profiles acceptable. CONCLUSION Recruitment to a randomised controlled trial examining the effectiveness and cost-effectiveness of a non-operative treatment pathway compared with appendicectomy for the treatment of uncomplicated acute appendicitis in children is feasible. TRIAL REGISTRATION NUMBER ISRCTN15830435.",2021,"There was high acceptance of randomisation, good patient and surgeon adherence to trial procedures and satisfactory completion of follow-up.","['Three specialist paediatric surgery centres in the UK', 'children with uncomplicated acute appendicitis', 'uncomplicated acute appendicitis in children', 'Children (aged 4-15 years) with a clinical diagnosis of uncomplicated acute appendicitis', 'Appendicitis in Children']","['appendicectomy', 'CONservative TReatment', 'Appendicectomy or a non-operative treatment pathway (comprising broad-spectrum antibiotics and active observation']","['perforated appendicitis', 'effectiveness and cost-effectiveness', 'recruitment rate', 'adherence to interventions, data collection during follow-up, safety of treatment pathways and clinical course']","[{'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0279077', 'cui_str': 'Pediatric surgery'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0003615', 'cui_str': 'Appendicitis'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}]","[{'cui': 'C0003611', 'cui_str': 'Appendectomy'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]","[{'cui': 'C0549099', 'cui_str': 'Perforation'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0449259', 'cui_str': 'Clinical course'}]",,0.247977,"There was high acceptance of randomisation, good patient and surgeon adherence to trial procedures and satisfactory completion of follow-up.","[{'ForeName': 'Nigel J', 'Initials': 'NJ', 'LastName': 'Hall', 'Affiliation': 'University Surgery Unit, Faculty of Medicine, University of Southampton, Southampton, UK n.j.hall@soton.ac.uk.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Eaton', 'Affiliation': 'UCL Great Ormond Street Institute of Child Health, London, UK.'}, {'ForeName': 'Frances C', 'Initials': 'FC', 'LastName': 'Sherratt', 'Affiliation': 'Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Reading', 'Affiliation': 'Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Walker', 'Affiliation': 'Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Chorozoglou', 'Affiliation': 'Southampton Health Technology Assessment Centre, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Beasant', 'Affiliation': 'Centre for Academic Child Health, Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UK.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Wood', 'Affiliation': 'National Institute of Health Research (NIHR), Research Design Service South Central, University of Southampton, Southampton, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Stanton', 'Affiliation': ""Department of Paediatric Surgery and Urology, Southampton Children's Hospital, Southampton, UK.""}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Corbett', 'Affiliation': ""Department of Paediatric Surgery, Alder Hey Children's NHS foundation Trust, Liverpool, UK.""}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Rex', 'Affiliation': ""Department of Paediatric Surgery, St George's University Hospitals NHS Foundation Trust, London, UK.""}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Hutchings', 'Affiliation': 'Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Dixon', 'Affiliation': 'Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Grist', 'Affiliation': 'Patient and Public Involvement Representative, Southampton, UK.'}, {'ForeName': 'Esther M', 'Initials': 'EM', 'LastName': 'Crawley', 'Affiliation': 'Centre for Academic Child Health, Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UK.'}, {'ForeName': 'Bridget', 'Initials': 'B', 'LastName': 'Young', 'Affiliation': 'Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Jane M', 'Initials': 'JM', 'LastName': 'Blazeby', 'Affiliation': 'Centre for Surgical Research and NIHR Bristol Biomedical Research Centre, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}]",Archives of disease in childhood,['10.1136/archdischild-2020-320746'] 861,33432496,"A randomized-controlled trial comparing liposomal bupivacaine, plain bupivacaine, and the mixture of liposomal bupivacaine and plain bupivacaine in transversus abdominus plane block for postoperative analgesia for open abdominal hysterectomies.","PURPOSE Transversus abdominus plane (TAP) blocks are widely used for postoperative analgesia for abdominal surgical procedures. The purpose of this study was to compare the analgesic efficacy of plain bupivacaine, liposomal bupivacaine, and the mixture of plain bupivacaine with liposomal bupivacaine when used in a TAP block. METHODS This study was a single centre, prospective, patient-, observer-, and surgeon-blinded, randomized-controlled trial in which 90 patients undergoing an open abdominal hysterectomy with a midline incision were randomized to receive a TAP block with plain bupivacaine (group bupivacaine), liposomal bupivacaine (group liposomal), or a mixture of liposomal bupivacaine and plain bupivacaine (group mixture). Primary outcomes included time to the first rescue opioid analgesic and total opioid consumption during the first 72 postoperative hours. Secondary outcomes included pain scores, patient satisfaction, incidence of hemodynamic instability, presence of local anesthetic systemic toxicity, and length of hospital stay. RESULTS The median [interquartile range] time to first opioid was 51 [28-66] min in group bupivacaine, 63 [44-102] min in group liposomal, and 51 [24-84] min in group mixture (P = 0.20). The median [interquartile range] total opioid consumption in the first 72 postoperative hours was 208 [155-270] mg in group bupivacaine, 203 [153-283] mg in group liposomal, and 202 [116-325] mg in group mixture (P = 0.92). There were no significant differences in secondary outcomes between groups. CONCLUSIONS In this small study at risk of being under-powered, the mixture of liposomal bupivacaine with plain bupivacaine for TAP block did not improve analgesia compared with either liposomal bupivacaine or plain bupivacaine on their own. TRIAL REGISTRATION www.clinicaltrials.gov (NCT03250507); registered 5 April 2017.",2021,"There were no significant differences in secondary outcomes between groups. ","['90 patients undergoing an open abdominal hysterectomy with a midline incision', 'open abdominal hysterectomies']","['plain bupivacaine', 'liposomal bupivacaine', 'liposomal bupivacaine with plain bupivacaine', 'bupivacaine', 'TAP block with plain bupivacaine (group bupivacaine), liposomal bupivacaine (group liposomal), or a mixture of liposomal bupivacaine and plain bupivacaine', 'liposomal bupivacaine, plain bupivacaine, and the mixture of liposomal bupivacaine and plain bupivacaine', 'plain bupivacaine, liposomal bupivacaine, and the mixture of plain bupivacaine with liposomal bupivacaine']","['analgesic efficacy', 'median [interquartile range] total opioid consumption', 'time to the first rescue opioid analgesic and total opioid consumption during the first 72 postoperative hours', 'median [interquartile range] time to first opioid', 'pain scores, patient satisfaction, incidence of hemodynamic instability, presence of local anesthetic systemic toxicity, and length of hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0404077', 'cui_str': 'Abdominal hysterectomy'}, {'cui': 'C0456276', 'cui_str': 'Midline incision'}]","[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0948268', 'cui_str': 'Hemodynamic instability'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C4761262', 'cui_str': 'Local anaesthetic systemic toxicity'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",90.0,0.322563,"There were no significant differences in secondary outcomes between groups. ","[{'ForeName': 'Christina W', 'Initials': 'CW', 'LastName': 'Fidkowski', 'Affiliation': 'Department of Anesthesiology, Pain Management, and Perioperative Medicine, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI, 48202, USA. cfidkow1@hfhs.org.'}, {'ForeName': 'Nandak', 'Initials': 'N', 'LastName': 'Choksi', 'Affiliation': 'Department of Anesthesiology, Pain Management, and Perioperative Medicine, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI, 48202, USA.'}, {'ForeName': 'Mohamed-Rida', 'Initials': 'MR', 'LastName': 'Alsaden', 'Affiliation': 'Department of Anesthesiology, Pain Management, and Perioperative Medicine, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI, 48202, USA.'}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-020-01911-1'] 862,33433485,Bimanual motor skill learning and robotic assistance for chronic hemiparetic stroke: a randomized controlled trial.,"Using robotic devices might improve recovery post-stroke, but the optimal way to apply robotic assistance has yet to be determined. The current study aimed to investigate whether training under the robotic active-assisted mode improves bimanual motor skill learning (biMSkL) more than training under the active mode in stroke patients. Twenty-six healthy individuals (HI) and 23 chronic hemiparetic stroke patients with a detectable lesion on MRI or CT scan, who demonstrated motor deficits in the upper limb, were randomly allocated to two parallel groups. The protocol included a two-day training on a new bimanual cooperative task, LIFT-THE-TRAY, under either the active or active-assisted modes (where assistance decreased in a pre-determined stepwise fashion) with the bimanual version of the REAplan® robotic device. The hypothesis was that the active-assisted mode would result in greater biMSkL than the active mode. The biMSkL was quantified by a speed-accuracy trade-off (SAT) before (T1) and immediately after (T2) training on days 1 and 2 (T3 and T4). The change in SAT after 2 days of training (T4/T1) indicated that both HI and stroke patients learned and retained the bimanual cooperative task. After 2 days of training, the active-assisted mode did not improve biMSkL more than the active mode (T4/T1) in HI nor stroke patients. Whereas HI generalized the learned bimanual skill to different execution speeds in both the active and active-assisted subgroups, the stroke patients generalized the learned skill only in the active subgroup. Taken together, the active-assisted mode, applied in a pre-determined stepwise decreasing fashion, did not improve biMSkL more than the active mode in HI and stroke subjects. Stroke subjects might benefit more from robotic assistance when applied ""as-needed."" This study was approved by the local ethical committee (Comité d'éthique médicale, CHU UCL Namur, Mont-Godinne, Yvoir, Belgium; Internal number: 54/2010, EudraCT number: NUB B039201317382) on July 14, 2016 and was registered with ClinicalTrials.gov (Identifier: NCT03974750) on June 5, 2019.",2021,"After 2 days of training, the active-assisted mode did not improve biMSkL more than the active mode (T4/T1) in HI nor stroke patients.","['Twenty-six healthy individuals (HI) and 23 chronic hemiparetic stroke patients with a detectable lesion on MRI or CT scan, who demonstrated motor deficits in the upper limb', 'chronic hemiparetic stroke', 'stroke patients']","['new bimanual cooperative task, LIFT-THE-TRAY, under either the active or active-assisted modes (where assistance decreased in a pre-determined stepwise fashion) with the bimanual version of the REAplan® robotic device', 'Bimanual motor skill learning and robotic assistance']",['bimanual motor skill learning (biMSkL'],"[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0181620', 'cui_str': 'Hoist'}, {'cui': 'C0184054', 'cui_str': 'Tray'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]","[{'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]",26.0,0.110603,"After 2 days of training, the active-assisted mode did not improve biMSkL more than the active mode (T4/T1) in HI nor stroke patients.","[{'ForeName': 'Maral', 'Initials': 'M', 'LastName': 'Yeganeh Doost', 'Affiliation': 'UCLouvain, CHU UCL Namur - site Mont-Godinne, Department of Neurology, Stroke Unit, Yvoir; UCLouvain, Institute of NeuroScience (IoNS), Clinical neuroscience division (NEUR) division, Brussels; UCLouvain, Louvain Bionics, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Herman', 'Affiliation': 'UCLouvain, Louvain Bionics; UCLouvain, Institute of Mechanics, Materials and Civil Engineering (iMMC), Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Adrien', 'Initials': 'A', 'LastName': 'Denis', 'Affiliation': 'UCLouvain, Institute of Mechanics, Materials and Civil Engineering (iMMC), Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Sapin', 'Affiliation': 'AXINESIS SA, Wavre, Belgique.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Galinski', 'Affiliation': 'AXINESIS SA, Wavre, Belgique.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Riga', 'Affiliation': 'UCLouvain, CHU UCL Namur - site Mont-Godinne, Department of Neurology, Stroke Unit, Yvoir; UCLouvain, Institute of NeuroScience (IoNS), Clinical neuroscience division (NEUR) division, Brussels; UCLouvain, Louvain Bionics, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Laloux', 'Affiliation': 'UCLouvain, CHU UCL Namur - site Mont-Godinne, Department of Neurology, Stroke Unit, Yvoir; UCLouvain, Institute of NeuroScience (IoNS), Clinical neuroscience division (NEUR) division, Brussels, Belgium.'}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Bihin', 'Affiliation': 'Scientific Support Unit, CHU UCL Namur - site Mont-Godinne, Yvoir, Belgium.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Vandermeeren', 'Affiliation': 'UCLouvain, CHU UCL Namur - site Mont-Godinne, Department of Neurology, Stroke Unit, Yvoir; UCLouvain, Institute of NeuroScience (IoNS), Clinical neuroscience division (NEUR) division, Brussels; UCLouvain, Louvain Bionics, Louvain-la-Neuve, Belgium.'}]",Neural regeneration research,['10.4103/1673-5374.301030'] 863,33448617,Trajectories of change in the therapeutic alliance during Cognitive Analytic Therapy for depression.,"BACKGROUND Managing the alliance is considered to be a core competency and central therapeutic change process during cognitive analytic therapy (CAT). This study examined latent trajectories of change in the alliance and their relationship to depression treatment outcomes. DESIGN Secondary analysis of a randomized controlled trial. METHODS A sample of N = 79 depressed participants completed standardized alliance (WAI-SF) and depression symptom measures (PHQ-9) every session during an 8-session CAT intervention. Growth mixture modelling was applied to model alliance trajectories and to classify cases into different latent classes. Associations between alliance class and post-treatment PHQ-9 scores were examined using hierarchical linear regression, controlling for confounders. RESULTS There were two classes of alliance trajectories. The majority class (91%) displayed stable alliance trajectories, whilst a minority class (9%) had initially poor alliance ratings that significantly improved during treatment. Baseline severity and early change in depression symptoms significantly predicted treatment outcomes, but early alliance and longitudinal alliance change did not. CONCLUSIONS Alliance trajectories did not significantly predict depression treatment outcomes after controlling for initial symptom severity and early change. An important limitation concerns the small sample size, so future replication in larger samples is necessary.",2021,"The majority class (91%) displayed stable alliance trajectories, whilst a minority class (9%) had initially poor alliance ratings that significantly improved during treatment.",['A sample of N\xa0=\xa079 depressed participants completed'],['Cognitive Analytic Therapy'],"['Baseline severity and early change in depression symptoms', 'poor alliance ratings', 'stable alliance trajectories', 'standardized alliance (WAI-SF) and depression symptom measures (PHQ-9) every session']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C1272257', 'cui_str': 'Cognitive analytic therapy'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}]",79.0,0.038938,"The majority class (91%) displayed stable alliance trajectories, whilst a minority class (9%) had initially poor alliance ratings that significantly improved during treatment.","[{'ForeName': 'Mariia', 'Initials': 'M', 'LastName': 'Merzhvynska', 'Affiliation': 'Department of Psychology, University of Zurich, Switzerland.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Simmonds-Buckley', 'Affiliation': 'Clinical Psychology Unit, Department of Psychology, University of Sheffield, UK.'}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Delgadillo', 'Affiliation': 'Clinical Psychology Unit, Department of Psychology, University of Sheffield, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Kellett', 'Affiliation': 'Clinical Psychology Unit, Department of Psychology, University of Sheffield, UK.'}]",Psychology and psychotherapy,['10.1111/papt.12322'] 864,33454069,Instagram as a tool to enhance pharmacy student learning of ambulatory care pharmacy.,"INTRODUCTION This project utilized the social media platform Instagram, which focuses upon posting images with accompanied captions, as a supplemental learning tool. The objective was to assess the impact of using a clinical pharmacy-focused Instagram account on students' knowledge of ambulatory care pharmacy. METHODS A pre- and posttest quasi-experimental design was conducted in a third-year introductory pharmacy practice experience course during fall 2018. Pharmacy students were notified of the availability of an Instagram account managed by the principal investigator that posted ambulatory care clinical pearls as an optional supplemental educational tool. The primary outcome evaluated change in scores from pre- to posttest for the cohort of students in this course who followed the Instagram account (intervention group) compared to the cohort of students who did not follow the account (control group). RESULTS A total of 69 third-year pharmacy students completed the course, with 37 students choosing not to follow the Instagram account (control group) and 32 students opting to engage with the Instagram account (intervention group). Pretest mean scores were nonsignificant between groups. The intervention group resulted in a higher increase in mean scores from pre- to the posttest (15% vs. 3.1%). CONCLUSIONS Use of an educational Instagram account had a positive impact on students' knowledge relating to ambulatory care pharmacy as demonstrated by this comparison study.",2021,"The intervention group resulted in a higher increase in mean scores from pre- to the posttest (15% vs. 3.1%). ","['A pre- and posttest quasi-experimental design was conducted in a third-year introductory pharmacy practice experience course during fall 2018', ""students' knowledge of ambulatory care pharmacy"", 'Pharmacy students', 'A total of 69 third-year pharmacy students completed the course, with 37 students choosing not to follow the Instagram account (control group) and 32 students opting to engage with the Instagram account (intervention group']",['clinical pharmacy-focused Instagram account'],['mean scores'],"[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C0038497', 'cui_str': 'Pharmacy Student'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0286605,"The intervention group resulted in a higher increase in mean scores from pre- to the posttest (15% vs. 3.1%). ","[{'ForeName': 'Jarred', 'Initials': 'J', 'LastName': 'Prudencio', 'Affiliation': 'University of Hawaii at Hilo, the Daniel K. Inouye College of Pharmacy, 200 W, Kawili Street, Hilo, HI 96720, United States. Electronic address: jpjarred@gmail.com.'}, {'ForeName': 'Supakit', 'Initials': 'S', 'LastName': 'Wongwiwatthananukit', 'Affiliation': 'University of Hawaii at Hilo, the Daniel K. Inouye College of Pharmacy, 200 W, Kawili Street, Hilo, HI 96720, United States. Electronic address: supakit@hawaii.edu.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Lozano', 'Affiliation': 'Virginia Tech, One Riverside Circle, Suite 104, Roanoke, VA 24016, United States. Electronic address: alozano@vt.edu.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Drexel University, 3141 Chestnut St., Philadelphia, PA 19104, United States.'}]",Currents in pharmacy teaching & learning,['10.1016/j.cptl.2020.09.007'] 865,33454068,"Comparing perceptions of professionalism by pharmacy students, faculty, and staff during didactic education.","INTRODUCTION The objectives were to describe pharmacy students' perceptions of professionalism and to compare students and faculty/staff perceptions of professionalism during the didactic years at Touro University California College of Pharmacy in California (TUC COP). METHODS A two-part online survey was administered to the TUC COP faculty/staff and first-year (P1) and second-professional year (P2) students in May 2016. The first part of the survey collected demographic information, assessment of faculty/staff and students' overall opinions on behavior and conduct displayed by P1 and P2 students, students' responses about the average of missed lectures per month, and the average number of days of late arrival to lecture per week. The second part assessed professionalism perceptions responses to 20 scenarios using a 4-point Likert rating. RESULTS The study included 37 (88.4%) faculty/staff and 181 (96.4%) P1 and P2 students, for a 98% response rate. Of the faculty/staff, 59.5% perceived the students' overall behaviors and conduct as acceptable whereas 35.3% of students perceived the overall behavior of P1 and P2 students as acceptable, with the majority of students self-reporting missing on average fewer than five lectures per month (65.2%) and arriving late to lecture fewer than one day each week (71.8%). There were statistically significant differences between faculty/staff and students' responses in 9 of the 20 scenarios. CONCLUSIONS Differences in responses between faculty/staff and students regarding what is considered professional suggest that there is a gap in professionalism perceptions that should be addressed during didactic years.",2021,"There were statistically significant differences between faculty/staff and students' responses in 9 of the 20 scenarios. ","['37 (88.4%) faculty/staff and 181 (96.4', 'A two-part online survey was administered to the TUC COP faculty/staff and first-year (P1) and second-professional year (P2) students in May 2016', ""pharmacy students' perceptions of professionalism and to compare students and faculty/staff perceptions of professionalism during the didactic years at Touro University California College of Pharmacy in California (TUC COP""]",[],"[""faculty/staff and students' responses"", 'overall behavior of P1']","[{'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0038497', 'cui_str': 'Pharmacy Student'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0815219', 'cui_str': 'Professionalism'}]",[],"[{'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0277306,"There were statistically significant differences between faculty/staff and students' responses in 9 of the 20 scenarios. ","[{'ForeName': 'Fatima Ester', 'Initials': 'FE', 'LastName': 'Hernandez', 'Affiliation': 'Touro University California College of Pharmacy, Vallejo, CA, United States. Electronic address: fatima.hernandez@tu.edu.'}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Ouabo', 'Affiliation': 'Touro University California College of Pharmacy, Vallejo, CA, United States. Electronic address: tatiana.ouabo@tu.edu.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Long', 'Affiliation': 'Touro University California College of Pharmacy, Vallejo, CA, United States. Electronic address: Jacob.long@tu.edu.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Fox', 'Affiliation': 'Touro University California College of Pharmacy, Vallejo, CA, United States. Electronic address: danielle.fox@tu.edu.'}, {'ForeName': 'Tran Huynh', 'Initials': 'TH', 'LastName': 'Nguyen', 'Affiliation': 'Touro University California College of Pharmacy, Vallejo, CA, United States. Electronic address: tran.nguyen3@tu.edu.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Yee', 'Affiliation': 'Touro University California College of Pharmacy, Vallejo, CA, United States. Electronic address: christopher.yee@tu.edu.'}, {'ForeName': 'Vanishree', 'Initials': 'V', 'LastName': 'Rajagopalan', 'Affiliation': 'Touro University California College of Pharmacy, Vallejo, CA, United States. Electronic address: Vanishree.rajagopalan@tu.edu.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Schulte', 'Affiliation': 'Touro University California College of Pharmacy, Vallejo, CA, United States. Electronic address: Margaret.schulte@tu.edu.'}, {'ForeName': 'Shadi', 'Initials': 'S', 'LastName': 'Doroudgar', 'Affiliation': 'Touro University California College of Pharmacy, Vallejo, CA, United States; Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States. Electronic address: shadi.doroudgar@tu.edu.'}]",Currents in pharmacy teaching & learning,['10.1016/j.cptl.2020.09.003'] 866,33434087,A Randomized Controlled Trial of the Effect of Music During Cesarean Sections and the Early Postpartum Period on Breastfeeding Rates.,"Objective: The objective of this research was to study the role of music listening by mothers during a cesarean section and the postpartum period to achieve exclusive breastfeeding in the first 6 months. Methods and Study Design: This was a prospective, observational, randomized controlled trial study. A total of 185 singleton pregnant women, in at least 37 weeks of gestation, who were appointed for elective cesarean sections, were recruited. They were randomized into three groups, including pregnant women who did not listen to music (Group 1), listened to music during cesarean section (Group 2), and listened to music during cesarean section and the postpartum room for the first 2 days (Group 3). The breastfeeding results of all three groups were followed up at 7 days, 14 days, and then at months 1, 2, 3, and 6. Results: Success in exclusive breastfeeding among Groups 1, 2, and 3 and Groups 1 and 2 + 3 was not different in every lactating period (7 days-6 months). From subgroup analysis, mothers who listened to music in a private ward had more success in exclusive breastfeeding than those in a common ward. Mothers who listened to music and had an income of <20,000 baht, an educational level lower than university, planned the pregnancy, had their first pregnancy, and stayed in a private ward had more successful exclusive breastfeeding in a 6-month period than those mothers who did not listen to music, and the difference was statistically significant. Conclusions: Music listening by mothers during a cesarean section and in the postpartum ward did not enhance exclusive breastfeeding during the first 6 months of the postpartum period. However, from subgroup analysis, mothers who listened to music in a private ward had more success in exclusive breastfeeding than those in a common ward. Thai Clinical Trials Registry number was TCTR20180712001.",2021,"A total of 185 singleton pregnant women, in at least 37 weeks of gestation, who were appointed for elective cesarean sections, were recruited.","['185 singleton pregnant women, in at least 37 weeks of gestation, who were appointed for elective cesarean sections, were recruited', 'pregnant women who did not listen to music (Group 1']","['Music listening', 'listened to music during cesarean section (Group 2), and listened to music during cesarean section', 'music listening', 'Music During Cesarean Sections']","['Breastfeeding Rates', 'successful exclusive breastfeeding']","[{'cui': 'C4517617', 'cui_str': '185'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0242205', 'cui_str': 'Breastfeeding, Exclusive'}]",185.0,0.135994,"A total of 185 singleton pregnant women, in at least 37 weeks of gestation, who were appointed for elective cesarean sections, were recruited.","[{'ForeName': 'Saifon', 'Initials': 'S', 'LastName': 'Chawanpaiboon', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Vitaya', 'Initials': 'V', 'LastName': 'Titapant', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Julaporn', 'Initials': 'J', 'LastName': 'Pooliam', 'Affiliation': 'Clinical Epidemiological Unit, Office for Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0299'] 867,33433497,"Safety and efficacy of a nerve matrix membrane as a collagen nerve wrapping: a randomized, single-blind, multicenter clinical trial.","A new nerve matrix membrane derived from decellularized porcine nerves has been shown to retain the major extracellular matrix components, and to be effective in preventing adhesion between the nerve anastomosis sites and the surrounding tissues in a rat sciatic nerve transection model, thereby enhancing regeneration of the nerve. The effectiveness of the membrane may be attributed to its various bioactive components. In this prospective, randomized, single-blind, parallel-controlled multicenter clinical trial, we compared the safety and efficacy of the new nerve matrix membrane with a previously approved bovine tendon-derived type I collagen nerve wrapping. A total of 120 patients with peripheral nerve injury were recruited from Beijing Jishuitan Hospital, The First Bethune Hospital of Jilin University, and Yantai Yuhuangding Hospital, China. The patients were randomly assigned to undergo end-to-end and tension-free neurorrhaphy with nerve matrix membrane (n = 60, 52 male, 8 female, mean age 41.34 years, experimental group) or tendon-derived collagen nerve wrapping (n = 60, 42 male, 18 female, mean age 40.17 years, control group). Patients were followed-up at 14 ± 5, 30 ± 7, 90 ± 10 and 180 ± 20 days after the operation. Safety evaluation included analyses of local and systemic reactions, related laboratory tests, and adverse reactions. Efficacy evaluation included a static 2-point discrimination test, a moving 2-point discrimination test, and a Semmes-Weinstein monofilament examination. Sensory nerve function was evaluated with the British Medical Research Council Scale and Semmes-Weinstein monofilament examination. The ratio (percentage) of patients with excellent to good results in sensory nerve recovery 180 ± 20 days after the treatment was used as the primary effectiveness index. The percentages of patients with excellent to good results in the experimental and control groups were 98.00% and 94.44%, respectively, with no significant difference between the two groups. There were no significant differences in the results of routine blood tests, liver and renal function tests, coagulation function tests, or immunoglobulin tests at 14 and 180 days postoperatively between the two groups. These findings suggest that the novel nerve matrix membrane is similar in efficacy to the commercially-available bovine-derived collagen membrane in the repair of peripheral nerve injury, and it may therefore serve as an alternative in the clinical setting. The clinical trial was approved by the Institutional Ethics Committee of Beijing Jishuitan Hospital, China (approval No. 20160902) on October 8, 2016, the Institutional Ethics Committee of the First Bethune Hospital of Jilin University, China (approval No. 160518-088) on December 14, 2016, and the Institutional Ethics Committee of Yantai Yuhuangding Hospital, China (approval No. 2016-10-01) on December 9, 2016. The clinical trial was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR2000033324) on May 28, 2020.",2021,"There were no significant differences in the results of routine blood tests, liver and renal function tests, coagulation function tests, or immunoglobulin tests at 14 and 180 days postoperatively between the two groups.","['120 patients with peripheral nerve injury were recruited from Beijing Jishuitan Hospital, The First Bethune Hospital of Jilin University, and Yantai Yuhuangding Hospital, China', 'n = 60, 52 male, 8 female, mean age 41.34 years, experimental group) or', 'Beijing Jishuitan Hospital, China', '2016-10-01) on December 9, 2016', 'n = 60, 42 male, 18 female, mean age 40.17 years, control group']","['tendon-derived collagen nerve wrapping', 'undergo end-to-end and tension-free neurorrhaphy with nerve matrix membrane', 'bovine tendon-derived type I collagen nerve wrapping', 'nerve matrix membrane']","['Safety and efficacy', 'safety and efficacy', 'local and systemic reactions, related laboratory tests, and adverse reactions', 'routine blood tests, liver and renal function tests, coagulation function tests, or immunoglobulin tests']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0262593', 'cui_str': 'Injury of peripheral nerve'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0039508', 'cui_str': 'Tendon structure'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0445414', 'cui_str': 'Wrapping'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0027909', 'cui_str': 'Nerve sutured'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0850992', 'cui_str': 'Immunoglobulin analyses'}]",120.0,0.0592614,"There were no significant differences in the results of routine blood tests, liver and renal function tests, coagulation function tests, or immunoglobulin tests at 14 and 180 days postoperatively between the two groups.","[{'ForeName': 'Yong-Bin', 'Initials': 'YB', 'LastName': 'Gao', 'Affiliation': 'Department of Hand Surgery, Beijing Jishuitan Hospital, Beijing, China.'}, {'ForeName': 'Zhi-Gang', 'Initials': 'ZG', 'LastName': 'Liu', 'Affiliation': 'Department of Hand Surgery, The First Bethune Hospital of Jilin University, Changchun, Jilin Province, China.'}, {'ForeName': 'Guo-Dong', 'Initials': 'GD', 'LastName': 'Lin', 'Affiliation': 'Department of Hand and Foot Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong Province, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Department of Hand Surgery, Beijing Jishuitan Hospital, Beijing, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Hand Surgery, The First Bethune Hospital of Jilin University, Changchun, Jilin Province, China.'}, {'ForeName': 'Bo-Tao', 'Initials': 'BT', 'LastName': 'Huang', 'Affiliation': 'Department of Hand and Foot Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong Province, China.'}, {'ForeName': 'Yao-Bin', 'Initials': 'YB', 'LastName': 'Yin', 'Affiliation': 'Department of Hand Surgery, Beijing Jishuitan Hospital, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': 'Department of Hand Surgery, Beijing Jishuitan Hospital, Beijing, China.'}, {'ForeName': 'Li-Ying', 'Initials': 'LY', 'LastName': 'Sun', 'Affiliation': 'Department of Hand Surgery, Beijing Jishuitan Hospital, Beijing, China.'}, {'ForeName': 'Yan-Bo', 'Initials': 'YB', 'LastName': 'Rong', 'Affiliation': 'Department of Hand Surgery, Beijing Jishuitan Hospital, Beijing, China.'}, {'ForeName': 'Shanlin', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Department of Hand Surgery, Beijing Jishuitan Hospital, Beijing, China.'}]",Neural regeneration research,['10.4103/1673-5374.303040'] 868,33442937,Half-normal saline versus normal saline for irrigation of open-irrigated radiofrequency catheters in atrial fibrillation ablation.,"BACKGROUND The creation of effective and permanent lesions is a crucial factor in determining the success rate of atrial fibrillation (AF) ablation. By increasing the efficacy of radiofrequency (RF) energy-mediated lesion formation, half-normal saline (HNS) as an irrigant for open-irrigated ablation catheters has the potential to reduce procedural times and improve acute and long-term outcomes. METHODS This is a double-blind randomized clinical trial of 99 patients undergoing first-time RF catheter ablation for AF. Patients enrolled were randomly assigned in a 1:1 fashion to perform ablation using HNS or normal saline (NS) as an irrigant for the ablation catheter. RESULTS The use of HNS is associated with shorter RF times (26 vs. 33 min; p = .02) with comparable procedure times (104 vs. 104 min). The rate of acute pulmonary vein reconnections (16% vs. 18%) was comparable, with a median of 1 vein reconnection in the HNS arm versus 2 in the NS arm. There was no difference in procedure-related complications, including the incidence of postprocedural hyponatremia when using HNS. Over the 1-year follow-up, there is no significant difference between the HNS and NS with respect to the recurrence of any atrial arrhythmia (off antiarrhythmic drugs [AAD]: 47% vs. 52%; hazard ratio [HR]: 1.17, 95% confidence interval [CI]: 0.66-2.06; off/on AAD: 66% vs. 66%, HR: 1.06, 95% CI: 0.53-2.12), with a potential benefit of using HNS when considering the paroxysmal AF cohort (on/off AAD 73% vs. 62%, HR: 0.72, 95% CI: 0.19-2.70). CONCLUSIONS In a mixed cohort of patients undergoing first-time AF ablation, irrigation of open-irrigated RF ablation catheters with HNS is associated with shorter RF times, with a comparably low rate of procedure-related complications. In the long term, there is no significant difference with respect to the recurrence of any atrial arrhythmia. Larger studies with a more homogeneous population are necessary to determine whether HNS improves clinical outcomes.",2021,"Over 1-year follow-up, there is no significant difference between the HNS and NS with respect to recurrence of any atrial arrhythmia (off antiarrhythmic drugs - AAD: 47% vs 52%; HR 1.17, 95% CI 0.66 to 2.06; off/on AAD: 66% vs 66%, HR 1.06, 95% CI 0.53 to 2.12), with a potential benefit of using HNS when considering the paroxysmal AF cohort (on/off AAD 73% vs 62%, HR 0.72, 95% CI 0.19 to 2.70). ","['atrial fibrillation ablation', '99 patients undergoing first-time RF catheter ablation for AF']","['Half-normal saline vs normal saline for irrigation of open-irrigated radiofrequency catheters', 'HNS', 'ablation using HNS or normal saline (NS', 'radiofrequency (RF) energy-mediated lesion formation, half-normal saline (HNS']","['rate of acute pulmonary vein reconnections', 'recurrence of any atrial arrhythmia', 'procedure-related complications', 'shorter RF times', 'incidence of post-procedural hyponatremia']","[{'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0162561', 'cui_str': 'Radiofrequency Catheter Ablation'}]","[{'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0034090', 'cui_str': 'Structure of vein of pulmonary circulation'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0085611', 'cui_str': 'Atrial arrhythmia'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0020625', 'cui_str': 'Hyponatremia'}]",99.0,0.356243,"Over 1-year follow-up, there is no significant difference between the HNS and NS with respect to recurrence of any atrial arrhythmia (off antiarrhythmic drugs - AAD: 47% vs 52%; HR 1.17, 95% CI 0.66 to 2.06; off/on AAD: 66% vs 66%, HR 1.06, 95% CI 0.53 to 2.12), with a potential benefit of using HNS when considering the paroxysmal AF cohort (on/off AAD 73% vs 62%, HR 0.72, 95% CI 0.19 to 2.70). ","[{'ForeName': 'Carola', 'Initials': 'C', 'LastName': 'Gianni', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'G Joseph', 'Initials': 'GJ', 'LastName': 'Gallinghouse', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Al-Ahmad', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Rodney P', 'Initials': 'RP', 'LastName': 'Horton', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Shane M', 'Initials': 'SM', 'LastName': 'Bailey', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'J David', 'Initials': 'JD', 'LastName': 'Burkhardt', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Mohamed A', 'Initials': 'MA', 'LastName': 'Bassiouny', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Bryan C', 'Initials': 'BC', 'LastName': 'MacDonald', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Angel', 'Initials': 'A', 'LastName': 'Quintero Mayedo', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Domenico G', 'Initials': 'DG', 'LastName': 'Della Rocca', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Sanghamitra', 'Initials': 'S', 'LastName': 'Mohanty', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Chintan', 'Initials': 'C', 'LastName': 'Trivedi', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Di Biase', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Hranitzky', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Javier E', 'Initials': 'JE', 'LastName': 'Sanchez', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Natale', 'Affiliation': ""Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.""}]",Journal of cardiovascular electrophysiology,['10.1111/jce.14885'] 869,33451896,Using a Modified Surprise Question as a Tool to Improve Primary Palliative Care in a Neurocritical Care Unit.,"BACKGROUND Specialty palliative care is a limited resource. The surprise question (""Would you be surprised if this patient died within the next 12 months?"") is a screening tool for clinicians to identify people nearing the end of life. The researchers used a modified surprise question (MSQ) to improve primary palliative care in a neurocritical care unit. METHODS A palliative care physician attended interdisciplinary rounds up to three days a week and asked the primary neurocritical care team, for each patient admitted in the previous 24 hours, the MSQ: ""Would you be surprised if this patient died during this hospital stay?"" If the response was ""No,"" the unit social worker identified the patient's surrogate decision maker (SDM), and the primary team was encouraged to conduct a goals of care (GOC) conversation. The frequency of SDM documentation, occurrence and timing of GOC conversations, and palliative care and hospice consultations were measured for the baseline six months before the intervention, and six months after. RESULTS Among 350 patients admitted to the neurocritical care unit during the study, the age, gender, prehospitalization presence of advance directives, and mortality were comparable between the baseline (n = 173) and intervention (n = 177) periods. Compared to the baseline period, there was a higher frequency during the intervention period of documentation of SDM (31.8% vs. 54.2%, p = 0.00002), all GOC conversations (35.3% vs. 53.1%, p = 0.008), GOC conversations conducted by the primary team (27.2% vs. 47.5%, p = 0.00009), palliative care consultations (11.6% vs. 23.2%, p = 0.004), and hospice consultations (2.3% vs. 9.6%, p = 0.004). CONCLUSION The MSQ can be used as a tool to identify the risk of mortality, facilitate palliative care delivered by the primary team, and improve end-of-life care.",2021,"The MSQ can be used as a tool to identify the risk of mortality, facilitate palliative care delivered by the primary team, and improve end-of-life care.","['350 patients admitted to the neurocritical care unit during the study, the age, gender, prehospitalization presence of advance directives, and mortality were comparable between the baseline (n\u202f=\u202f173) and intervention (n\u202f=\u202f177) periods']",['modified surprise question (MSQ'],"['GOC conversations', 'hospice consultations', 'frequency of SDM documentation, occurrence and timing of GOC conversations, and palliative care and hospice consultations', 'palliative care consultations']","[{'cui': 'C4517735', 'cui_str': '350'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0001683', 'cui_str': 'Advance Directives'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}]","[{'cui': 'C2930505', 'cui_str': 'Goals of Care'}, {'cui': 'C0019947', 'cui_str': 'Hospice'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0554244', 'cui_str': 'Maker'}, {'cui': 'C0175636', 'cui_str': 'Documentation procedure'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0449243', 'cui_str': 'Timing'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}]",350.0,0.0372397,"The MSQ can be used as a tool to identify the risk of mortality, facilitate palliative care delivered by the primary team, and improve end-of-life care.","[{'ForeName': 'Shilpee', 'Initials': 'S', 'LastName': 'Sinha', 'Affiliation': ''}, {'ForeName': 'Kavitha', 'Initials': 'K', 'LastName': 'Subramoney', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Fraser', 'Affiliation': ''}, {'ForeName': 'Joycelyn', 'Initials': 'J', 'LastName': 'Howard', 'Affiliation': ''}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Sadowski', 'Affiliation': ''}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Azar', 'Affiliation': ''}, {'ForeName': 'Areeba', 'Initials': 'A', 'LastName': 'Kara', 'Affiliation': ''}]",Joint Commission journal on quality and patient safety,['10.1016/j.jcjq.2020.11.013'] 870,33454071,Student pharmacist opioid consultations with standardized limited English proficiency patients: A pre-post educational intervention study.,"BACKGROUND AND PURPOSE This study explored the effect of a structured educational intervention for student pharmacists to counsel limited English proficiency (LEP) patients on risks and safety of opioid medications for chronic pain. Specific aims were to compare 2018 pre-intervention versus 2019 post-intervention groups regarding: (1) dose and side effects discussed, (2) opioid risks and safety measures covered, and (3) LEP specific communication practices. EDUCATIONAL ACTIVITY AND SETTING Third-year student pharmacists (P3s) in a required communications course consulted LEP standardized patients (SPs) on opioid medications in 2018 and 2019. An educational intervention for the 2019 P3s consisted of a 50-min lecture, pre-lab instructions about techniques for communication about opioid risks and safety, and for LEP specific communication stressing teach-back. All consultations in the pre- and post-intervention phases were video recorded and quantitatively coded for verbal and non-verbal communication skills. Descriptive statistics and Fisher's exact tests were conducted on data. FINDINGS Twenty-three consultations were recorded in 2018 for the pre-intervention phase and 49 consultations were recorded in 2019 for the post-intervention phase. Only 17% of students in the pre- intervention phase called the medication an ""opioid"" or ""narcotic"" in the consultation as compared to 84% in the post-intervention phase. While 100% of students in the post-intervention phase used teach-back, only 61% did so in the pre-intervention group. Significant differences between the two groups were observed for minimizing dependency and overdose, offering naloxone, teach-back, integrating a patient handout into the consultation, and discussing use of alternate pain medications.",2021,"Significant differences between the two groups were observed for minimizing dependency and overdose, offering naloxone, teach-back, integrating a patient handout into the consultation, and discussing use of alternate pain medications.","['Twenty-three consultations were recorded in 2018 for the pre-intervention phase and 49 consultations were recorded in 2019 for the post-intervention phase', 'Student pharmacist opioid consultations with standardized limited English proficiency patients', 'Third-year student pharmacists', 'student pharmacists to counsel limited English proficiency (LEP) patients', 'chronic pain']","['structured educational intervention', 'opioid medications']","['minimizing dependency and overdose, offering naloxone, teach-back, integrating a patient handout into the consultation, and discussing use of alternate pain medications', 'opioid"" or ""narcotic']","[{'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0870816', 'cui_str': 'Limited English Proficient'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0341618', 'cui_str': 'Counsel'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0029944', 'cui_str': 'Drug overdose'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0027358', 'cui_str': 'Naloxone'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0027415', 'cui_str': 'Narcotic'}]",23.0,0.0329746,"Significant differences between the two groups were observed for minimizing dependency and overdose, offering naloxone, teach-back, integrating a patient handout into the consultation, and discussing use of alternate pain medications.","[{'ForeName': 'Tanvee', 'Initials': 'T', 'LastName': 'Thakur', 'Affiliation': 'Social and Administrative Sciences in Pharmacy Division, University of Wisconsin-Madison School of Pharmacy, United States. Electronic address: tmthakur@wisc.edu.'}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Frey', 'Affiliation': 'PGY2 Pharmacy Resident - Ambulatory Care Setting, University of Iowa Hospitals and Clinics, United States. Electronic address: meredith-frey@uiowa.edu.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Chewning', 'Affiliation': 'Social and Administrative Sciences in Pharmacy, University of Wisconsin-Madison School of Pharmacy, United States. Electronic address: betty.chewning@wisc.edu.'}]",Currents in pharmacy teaching & learning,['10.1016/j.cptl.2020.09.006'] 871,33475222,Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.,"AIMS/INTRODUCTION The prevalence and pathophysiological background of type 2 diabetes mellitus vary across ethnicities, and can affect treatment responses. Adding lixisenatide to basal insulin (BI) in type 2 diabetes mellitus patients has shown improvements in glycated hemoglobin (HbA1c) and postprandial glycemic (PPG) excursions, without increasing hypoglycemic events. We aim to compare the efficacy of lixisenatide in Asian and white patients inadequately controlled with basal insulin. MATERIALS AND METHODS An individual-level pooled analysis of two multi-national phase III studies, GetGoal-L and GetGoal-L-C, was carried out to assess the efficacy of lixisenatide versus placebo as an add-on treatment to BI ± metformin in Asian and white patients with type 2 diabetes mellitus. Change in HbA1c, 2-h PPG and PPG excursion were analyzed, along with possible predictors of glycemic control. RESULTS Pooled data showed that baseline characteristics were similar between Asian and white patients with the exception of bodyweight, body mass index and BI dose being higher in white patients. After 24 weeks, lixisenatide reduced HbA1c in both ethnic groups, with no statistically significant difference between the two groups (Asian patients least squares mean difference -0.49, 95% confidence interval -0.68 to - 0.30 and white patients least squares mean difference -0.45, 95% confidence interval -0.63 to - 0.26; P = 0.6287). Similarly, no significant difference was found in 2-h PPG reduction between both groups (least squares mean difference for Asian vs white patients: -3.37 vs -3.93; P = 0.3203). Treatment with lixisenatide contributed to HbA1c reduction of -0.56% after adjustment of baseline HbA1c level in Asian patients, and -0.41% in white patients. CONCLUSIONS Adding lixisenatide to BI significantly reduced HbA1c and 2-h PPG levels in both Asian and white participants with type 2 diabetes mellitus. No differences in treatment effect were observed between the two populations.",2021,"After 24-weeks, lixisenatide reduced HbA1c in both ethnic groups, with no statistically significant difference between the 2 groups [LS mean difference (LSMD) (95%CI): Asian [-0.49 (-0.68 to -0.30)] and Caucasian [-0.45 (-0.63 to -0.26)]; P=0.6287.","['Asians and Caucasians with T2DM', 'T2DM participants', 'Asian and Caucasian Adults with T2DM ', 'Asian and Caucasian participants with T2DM']","['lixisenatide', 'lixisenatide vs placebo', 'once-daily GLP-1RA Lixisenatide']","['Change in HbA1c, FPG, 2h-PPG and PPG excursion', 'HbA1c and 2-h PPG levels', 'body weight, BMI and BI', 'hypoglycemic events', 'PPG reduction', 'HbA1c and post prandial glycemic (PPG) excursions']","[{'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C2973895', 'cui_str': 'Lixisenatide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0018301', 'cui_str': 'Guadeloupe island'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.0757788,"After 24-weeks, lixisenatide reduced HbA1c in both ethnic groups, with no statistically significant difference between the 2 groups [LS mean difference (LSMD) (95%CI): Asian [-0.49 (-0.68 to -0.30)] and Caucasian [-0.45 (-0.63 to -0.26)]; P=0.6287.","[{'ForeName': 'Fuqiang', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Minzhi', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'BDM Consulting, Inc., Somerset, New Jersey, USA.'}, {'ForeName': 'Guangyu', 'Initials': 'G', 'LastName': 'Wu', 'Affiliation': 'Sanofi Investment Co., Ltd., Shanghai, China.'}, {'ForeName': 'Minlu', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Sanofi Investment Co., Ltd., Shanghai, China.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Sanofi Investment Co., Ltd., Shanghai, China.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Cui', 'Affiliation': 'Sanofi Investment Co., Ltd., Shanghai, China.'}, {'ForeName': 'Huiqiu', 'Initials': 'H', 'LastName': 'Yin', 'Affiliation': 'Sanofi Investment Co., Ltd., Shanghai, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China.'}]",Journal of diabetes investigation,['10.1111/jdi.13504'] 872,33480229,Clinical use of an analysis of oxidative stress and IL-6 as the promoters of diabetic polyneuropathy.,"Aim To investigate interleukin 6 (IL-6) values depending on duration of diabetes mellitus (DM) and evaluate possible correlation with diabetic polyneuropathy. Methods The research study included 90 patients with DM divided into three groups (30 patients each) according to the duration of DM: group A - patients who had DM for less than 10 years, group B - duration of DM was 10 to 20 years, and group C - patients with DM over 20 years. Control group (K) included 30 healthy participants. Results IL-6 was significantly higher in the healthy control group, 180.318 pg/mL±94.18, than in group A, 47.23pg/ml±34.8, group B, 43.31pg/ml±33.17, and group C, 70.39 pg/ml±59.26 (p=0.0001). All groups had significantly different values of IL-6 between each other (p=0.0001). Level of IL-6 was in correlation with diabetic polyneuropathy in the group A (the youngest participants) (p=0.0001). In other groups there was no significant correlation between IL-6 and diabetic polyneuropathy. Conclusion The level of IL-6 was in correlation with neuropathy among younger patients. A higher level of IL-6 in the control group than in diabetic groups is a sign of stronger inflammatory response among younger and healthy people than in patients with DM.",2021,"Results IL-6 was significantly higher in the healthy control group, 180.318 pg/mL±94.18, than in group A, 47.23pg/ml±34.8, group B, 43.31pg/ml±33.17, and group C, 70.39 pg/ml±59.26 (p=0.0001).","['30 healthy participants', '90 patients with DM divided into three groups (30 patients each) according to the duration of DM: group A - patients who had DM for less than 10 years, group B - duration of DM was 10 to 20 years, and group C - patients with DM over 20 years']",[],"['Level of IL-6', 'IL-6 and diabetic polyneuropathy', 'values of IL-6', 'Results IL-6', 'level of IL-6']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0441837', 'cui_str': 'Group C'}]",[],"[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0271680', 'cui_str': 'Diabetic polyneuropathy'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]",90.0,0.101529,"Results IL-6 was significantly higher in the healthy control group, 180.318 pg/mL±94.18, than in group A, 47.23pg/ml±34.8, group B, 43.31pg/ml±33.17, and group C, 70.39 pg/ml±59.26 (p=0.0001).","[{'ForeName': 'Emina', 'Initials': 'E', 'LastName': 'Karahmet', 'Affiliation': 'Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina.'}, {'ForeName': 'Besim', 'Initials': 'B', 'LastName': 'Prnjavorac', 'Affiliation': 'General Hospital, Tešanj, Bosnia and Herzegovina.'}, {'ForeName': 'Tamer', 'Initials': 'T', 'LastName': 'Bego', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Adaleta', 'Initials': 'A', 'LastName': 'Softić', 'Affiliation': 'Department of Biochemistry, University of Tuzla, Tuzla, Bosnia and Herzegovina.'}, {'ForeName': 'Lejla', 'Initials': 'L', 'LastName': 'Begić', 'Affiliation': 'Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina.'}, {'ForeName': 'Edin', 'Initials': 'E', 'LastName': 'Begić', 'Affiliation': 'Department of Cardiology, General Hospital ""Prim.dr. Abdulah Nakaš"", Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Esma', 'Initials': 'E', 'LastName': 'Karahmet', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Lejla', 'Initials': 'L', 'LastName': 'Prnjavorac', 'Affiliation': 'General Hospital, Tešanj, Bosnia and Herzegovina.'}, {'ForeName': 'Irfan', 'Initials': 'I', 'LastName': 'Prnjavorac', 'Affiliation': 'General Hospital, Tešanj, Bosnia and Herzegovina.'}]","Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina",['10.17392/1279-21'] 873,33451345,"A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.","BACKGROUND Xentuzumab-a humanised IgG1 monoclonal antibody-binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xentuzumab plus everolimus and exemestane in hormone receptor-positive, locally advanced and/or metastatic breast cancer (LA/MBC). METHODS Patients with hormone receptor-positive/HER2-negative LA/MBC resistant to non-steroidal aromatase inhibitors were enrolled. Maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of xentuzumab/everolimus/exemestane were determined in phase I (single-arm, dose-escalation). In phase II (open-label), patients were randomised 1:1 to the RP2D of xentuzumab/everolimus/exemestane or everolimus/exemestane alone. Randomisation was stratified by the presence of visceral metastases. Primary endpoint was progression-free survival (PFS). RESULTS MTD was determined as xentuzumab 1000 mg weekly plus everolimus 10 mg/day and exemestane 25 mg/day. A total of 140 patients were enrolled in phase II (70 to each arm). Further recruitment was stopped following an unfavourable benefit-risk assessment by the internal Data Monitoring Committee appointed by the sponsor. Xentuzumab was discontinued; patients could receive everolimus/exemestane if clinically indicated. Median PFS was 7.3 months (95% CI 3.3-not calculable) in the xentuzumab/everolimus/exemestane group and 5.6 months (3.7-9.1) in the everolimus/exemestane group (hazard ratio 0.97, 95% CI 0.57-1.65; P = 0.9057). In a pre-specified subgroup of patients without visceral metastases at screening, xentuzumab/everolimus/exemestane showed evidence of PFS benefit versus everolimus/exemestane (hazard ratio 0.21 [0.05-0.98]; P = 0.0293). Most common any-cause adverse events in phase II were diarrhoea (29 [41.4%] in the xentuzumab/everolimus/exemestane group versus 20 [29.0%] in the everolimus/exemestane group), mucosal inflammation (27 [38.6%] versus 21 [30.4%]), stomatitis (24 [34.3%] versus 24 [34.8%]), and asthenia (21 [30.0%] versus 24 [34.8%]). CONCLUSIONS Addition of xentuzumab to everolimus/exemestane did not improve PFS in the overall population, leading to early discontinuation of the trial. Evidence of PFS benefit was observed in patients without visceral metastases when treated with xentuzumab/everolimus/exemestane, leading to initiation of the phase II XENERA™-1 trial (NCT03659136). TRIAL REGISTRATION ClinicalTrials.gov, NCT02123823 . Prospectively registered, 8 March 2013.",2021,"Evidence of PFS benefit was observed in patients without visceral metastases when treated with xentuzumab/everolimus/exemestane, leading to initiation of the phase II XENERA™-1 trial (NCT03659136). ","['140 patients were enrolled in phase II (70 to each arm', 'hormone receptor-positive, locally advanced and/or metastatic breast cancer (LA/MBC', 'hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer', 'Patients with hormone receptor-positive/HER2-negative LA/MBC resistant to non-steroidal aromatase inhibitors were enrolled', 'patients without visceral metastases']","['xentuzumab/everolimus/exemestane', 'exemestane and everolimus', 'exemestane', 'everolimus/exemestane', 'Xentuzumab', 'xentuzumab plus everolimus and exemestane', 'xentuzumab to everolimus/exemestane', 'RP2D of xentuzumab/everolimus/exemestane or everolimus/exemestane alone']","['PFS', 'asthenia', 'PFS benefit', 'diarrhoea', 'stomatitis', 'Median PFS', 'progression-free survival (PFS', 'mucosal inflammation']","[{'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]","[{'cui': 'C4508939', 'cui_str': 'xentuzumab'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0851344', 'cui_str': 'exemestane'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0004093', 'cui_str': 'Asthenia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0038362', 'cui_str': 'Stomatitis'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}]",140.0,0.0530687,"Evidence of PFS benefit was observed in patients without visceral metastases when treated with xentuzumab/everolimus/exemestane, leading to initiation of the phase II XENERA™-1 trial (NCT03659136). ","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Schmid', 'Affiliation': 'Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. p.schmid@qmul.ac.uk.'}, {'ForeName': 'Marie-Paule', 'Initials': 'MP', 'LastName': 'Sablin', 'Affiliation': 'Department of Drug Development and Innovation, Institut Curie, Paris, France.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Bergh', 'Affiliation': 'Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Seock-Ah', 'Initials': 'SA', 'LastName': 'Im', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Yen-Shen', 'Initials': 'YS', 'LastName': 'Lu', 'Affiliation': 'Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Noelia', 'Initials': 'N', 'LastName': 'Martínez', 'Affiliation': 'Department of Oncology, Ramon y Cajal University Hospital, Madrid, Spain.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Neven', 'Affiliation': 'Department of Oncology, UZ Leuven, Campus Gasthuisberg, Leuven, Belgium.'}, {'ForeName': 'Keun Seok', 'Initials': 'KS', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Serafín', 'Initials': 'S', 'LastName': 'Morales', 'Affiliation': 'Department of Medical Oncology, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain.'}, {'ForeName': 'J Alejandro', 'Initials': 'JA', 'LastName': 'Pérez-Fidalgo', 'Affiliation': 'Medical Oncology Unit, Hospital Clinico Universitario Valencia, Biomedical Research Institute INCLIVA, CIBERONC, Valencia, Spain.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Adamson', 'Affiliation': 'Department of Medical Oncology, Ninewells Hospital, Tayside Cancer Centre, Dundee, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Gonçalves', 'Affiliation': 'Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille University, CRCM, CNRS, INSERM, Marseille, France.'}, {'ForeName': 'Aleix', 'Initials': 'A', 'LastName': 'Prat', 'Affiliation': 'Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Hospital Clínic of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Jerusalem', 'Affiliation': 'Department of Medical Oncology, Centre Hospitalier Universitaire de Liège, and Liège University, Liège, Belgium.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Schlieker', 'Affiliation': 'External statistician on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG., Staburo GmbH & Co. KG., Munich, Germany.'}, {'ForeName': 'Rosa-Maria', 'Initials': 'RM', 'LastName': 'Espadero', 'Affiliation': 'Medical Department (Clinical Operations), Boehringer Ingelheim España S.A, Barcelona, Spain.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bogenrieder', 'Affiliation': 'Medical Department, Boehringer Ingelheim, RCV, Vienna, Austria.'}, {'ForeName': 'Dennis Chin-Lun', 'Initials': 'DC', 'LastName': 'Huang', 'Affiliation': 'Medical Department, Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Crown', 'Affiliation': ""Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.""}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Cortés', 'Affiliation': ""Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}]",Breast cancer research : BCR,['10.1186/s13058-020-01382-8'] 874,33454291,Indigo Aspiration System for Treatment of Pulmonary Embolism: Results of the EXTRACT-PE Trial.,"OBJECTIVES This study sought to prospectively evaluate the safety and efficacy of the Indigo aspiration system in submassive acute pulmonary embolism (PE). BACKGROUND PE treatment with thrombolytics has bleeding risks. Aspiration thrombectomy can remove thrombus without thrombolytics, but data are lacking. METHODS This study was a prospective, single-arm, multicenter study that enrolled patients with symptomatic acute PE ≤14 days, systolic blood pressure ≥90 mm Hg, and right ventricular-to-left ventricular (RV/LV) ratio >0.9. The primary efficacy endpoint was change in RV/LV ratio from baseline to 48 h post-procedure on core lab-adjudicated computed tomography angiography. The primary safety endpoint was a composite of 48-h major adverse events: device-related death, major bleeding, and device-related serious adverse events (clinical deterioration, pulmonary vascular, or cardiac injury). All sites received Institutional Review Board approval. RESULTS A total of 119 patients (mean age 59.8 ± 15.0 years) were enrolled at 22 U.S. sites between November 2017 and March 2019. Median device insertion to removal time was 37.0 (interquartile range: 23.5 to 60.0) min. Two (1.7%) patients received intraprocedural thrombolytics. Mean RV/LV ratio reduction from baseline to 48 h post-procedure was 0.43 (95% confidence interval: 0.38 to 0.47; p < 0.0001). Two (1.7%) patients experienced 3 major adverse events. Rates of cardiac injury, pulmonary vascular injury, clinical deterioration, major bleeding, and device-related death at 48 h were 0%, 1.7%, 1.7%, 1.7%, and 0.8%, respectively. CONCLUSIONS In this prospective, multicenter study the Indigo aspiration system was associated with a significant reduction in the RV/LV ratio and a low major adverse event rate in submassive PE patients. Intraprocedural thrombolytic drugs were avoided in 98.3% of patients. (Evaluating the Safety and Efficacy of the Indigo aspiration system in Acute Pulmonary Embolism [EXTRACT-PE]; NCT03218566).",2021,In this multicenter prospective study the Indigo aspiration system was associated with a significant reduction in the RV/LV ratio and a low major adverse event rate in submassive PE patients.,"['119 patients (mean age 59.8 ± 15.0 years) were enrolled at 22 U.S. sites between November 2017 and March 2019', 'submassive acute pulmonary embolism (PE', 'Pulmonary Embolism', 'submassive PE patients', 'enrolled patients with symptomatic acute PE\xa0≤14\xa0days, systolic blood pressure\xa0≥90\xa0mm\xa0Hg, and right ventricular-to-left ventricular (RV/LV']","['Indigo Aspiration System', 'Indigo aspiration system']","['3 major adverse events', 'RV/LV ratio and a low major adverse event rate', 'safety and efficacy', 'Rates of cardiac injury, pulmonary vascular injury, clinical deterioration, major bleeding, and device-related death at 48\xa0h', 'composite of 48-h major adverse events: device-related death, major bleeding, and device-related serious adverse events (clinical deterioration, pulmonary vascular, or cardiac injury', 'Mean RV/LV ratio reduction', 'Median device insertion to removal time', 'change in RV/LV ratio']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C2882221', 'cui_str': 'Acute pulmonary embolism'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}]","[{'cui': 'C0021218', 'cui_str': 'Indigo'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0178324', 'cui_str': 'Injury of blood vessel'}, {'cui': 'C4505323', 'cui_str': 'Clinical Deterioration'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",119.0,0.161462,In this multicenter prospective study the Indigo aspiration system was associated with a significant reduction in the RV/LV ratio and a low major adverse event rate in submassive PE patients.,"[{'ForeName': 'Akhilesh K', 'Initials': 'AK', 'LastName': 'Sista', 'Affiliation': 'From the Department of Radiology, NYU Grossman School of Medicine, New York, New York, USA. Electronic address: akhilesh.sista@nyulangone.org.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Horowitz', 'Affiliation': 'From the Department of Radiology, NYU Grossman School of Medicine, New York, New York, USA.'}, {'ForeName': 'Victor F', 'Initials': 'VF', 'LastName': 'Tapson', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Rosenberg', 'Affiliation': 'Department of Radiology, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Mahir D', 'Initials': 'MD', 'LastName': 'Elder', 'Affiliation': 'Cardiovascular Institute, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA; School of Medicine, Michigan State University, East Lansing, Michigan, USA.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Schiro', 'Affiliation': 'Miami Cardiac and Vascular Institute, Baptist Hospital of Miami, Miami, Florida, USA.'}, {'ForeName': 'Suhail', 'Initials': 'S', 'LastName': 'Dohad', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.'}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Amoroso', 'Affiliation': 'From the Department of Radiology, NYU Grossman School of Medicine, New York, New York, USA.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Dexter', 'Affiliation': 'Department of Vascular Surgery, Sentara Norfolk General Hospital, Norfolk, Virginia, USA.'}, {'ForeName': 'Christopher T', 'Initials': 'CT', 'LastName': 'Loh', 'Affiliation': 'Department of Vascular and Interventional Radiology, St. Joseph Health, Orange, California, USA.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Leung', 'Affiliation': 'Department of Vascular Interventional Radiology, Christiana Care Health, Newark, Delaware, USA.'}, {'ForeName': 'Bruce Kirke', 'Initials': 'BK', 'LastName': 'Bieneman', 'Affiliation': 'Department of Radiology, Mercy Health System, St. Louis, Missouri, USA.'}, {'ForeName': 'Paul E', 'Initials': 'PE', 'LastName': 'Perkowski', 'Affiliation': 'Department of Vascular Surgery, Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, USA.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Chuang', 'Affiliation': 'Cardiovascular Imaging Core Laboratory, Beth Israel Deaconess Medical Center, Boston Massachusetts, USA.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Benenati', 'Affiliation': 'Miami Cardiac and Vascular Institute, Baptist Hospital of Miami, Miami, Florida, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2020.09.053'] 875,33462817,A New Randomized Binary Prior Model for Hydraulic Tomography in Fractured Aquifers.,"We present a novel pilot-point-based hydraulic tomography (HT) inversion procedure to delineate preferential flow paths and estimate hydraulic properties in a fractured aquifer. Our procedure considers a binary prior model developed using a randomized algorithm. The randomized algorithm involves discretizing the domain into grid cells, assigning a binary label to each cell, traversing the grid randomly, and choosing the optimal grid configuration cell-by-cell. This binary prior model is used to guide the placement of pilot points and to constrain aquifer parameters during pilot-point-based HT inversion. A two-dimensional fractured granite rock block was considered to test our methodology under controlled laboratory conditions. Multiple pumping tests were conducted at selected ports and the pressure responses were monitored. The pumping datasets thus obtained were preprocessed using median filters to remove random noise, and then analyzed using the proposed procedure. The proposed binary prior algorithm was implemented in C++ by supplying the forward groundwater model, HydroGeoSphere (HGS). Pilot-point-assisted HT inversion was performed using the parameter-estimation tool, coupled to HGS. The resulting parameter distributions were assessed by: (1) a visual comparison of the K- and S s -tomograms with the known topology of the fractures and (2) comparing model predictions with measurements made at two validation ports that were not used in calibration. The performance assessment revealed that HT with the proposed randomized binary prior could be used to recover fracture-connectivity and to predict drawdowns in fractured aquifers with reasonable accuracy, when compared to a conventional pilot-point inversion scheme.",2021,"The performance assessment revealed that HT with the proposed randomized binary prior could be used to recover fracture-connectivity and to predict drawdowns in fractured aquifers with reasonable accuracy, when compared to a conventional pilot-point inversion scheme.",[],"['hydraulic tomography (HT) inversion procedure', 'HydroGeoSphere ']",[],[],"[{'cui': 'C0040395', 'cui_str': 'Diagnostic tomography'}, {'cui': 'C0021943', 'cui_str': 'Chromosome inversion'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",[],,0.0143287,"The performance assessment revealed that HT with the proposed randomized binary prior could be used to recover fracture-connectivity and to predict drawdowns in fractured aquifers with reasonable accuracy, when compared to a conventional pilot-point inversion scheme.","[{'ForeName': 'Sarada', 'Initials': 'S', 'LastName': 'Poduri', 'Affiliation': 'Department of Civil Engineering, Indian Institute of Technology, Hyderabad, Telangana, India.'}, {'ForeName': 'Bvnp', 'Initials': 'B', 'LastName': 'Kambhammettu', 'Affiliation': 'Department of Civil Engineering, Indian Institute of Technology, Hyderabad, Telangana, India.'}, {'ForeName': 'Saisrinivas', 'Initials': 'S', 'LastName': 'Gorugantula', 'Affiliation': 'Department of Civil Engineering, Indian Institute of Technology, Hyderabad, Telangana, India.'}]",Ground water,['10.1111/gwat.13074'] 876,33468118,The impact of writing on academic performance for medical students.,"BACKGROUND Writing is a useful learning activity that promotes higher-order thinking, but there are limited studies that prove its effectiveness. In previous research, researchers tested the effect of summary writing on students' comprehension and found no significant difference from that of re-studying texts. The purpose of this study, therefore, is to expand previous findings and investigate the effect of two types of writing tasks on medical students' academic performance, specifically in the transfer of knowledge. METHODS An experiment was conducted with 139 medical students from Seoul National University College of Medicine. They were randomly assigned to three study conditions: self-study (SS), expository writing (EW), and argumentative writing (AW) group. Each group studied the given material by the method they were assigned, and they were tested on their comprehension and transfer of knowledge using rote-memory type items and transfer type items respectively. RESULTS The results showed that the two writing groups displayed better performance than the SS group in transfer type items, while there was no difference in scores between the EW and AW group. However, the three groups showed no significant difference in their scores for rote-memory type items. Also, there was a positive correlation between the writing scores and transfer type item scores in the AW group. CONCLUSIONS This study provides empirical evidence for writing to be adopted in medical education for greater educational benefits. Our findings indicate that writing can enhance learning and higher-order thinking, which are critical for medical students.",2021,"However, the three groups showed no significant difference in their scores for rote-memory type items.","['medical students', '139 medical students from Seoul National University College of Medicine']","['self-study (SS), expository writing (EW), and argumentative writing (AW) group', 'SS']",['writing scores and transfer type item scores'],"[{'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C3850150', 'cui_str': 'Seoul'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0018582', 'cui_str': 'Handwriting'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0559741', 'cui_str': 'Item score'}]",139.0,0.0333265,"However, the three groups showed no significant difference in their scores for rote-memory type items.","[{'ForeName': 'Songeui', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Psychology, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Ji Won', 'Initials': 'JW', 'LastName': 'Yang', 'Affiliation': 'Department of Psychology, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Jaeseo', 'Initials': 'J', 'LastName': 'Lim', 'Affiliation': 'Department of Psychology, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Seunghee', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Medical Education, College of Medicine, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Jungjoon', 'Initials': 'J', 'LastName': 'Ihm', 'Affiliation': 'Interdisciplinary Program in Cognitive Science, Seoul National University, Seoul, South Korea. ijj127@snu.ac.kr.'}, {'ForeName': 'Jooyong', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Department of Psychology, Seoul National University, Seoul, South Korea. jooypark@snu.ac.kr.'}]",BMC medical education,['10.1186/s12909-021-02485-2'] 877,33474962,A novel full endoscopic annular repair technique combined with autologous conditioned plasma intradiscal injection: a new safe serial therapeutic model for the treatment of lumbar disc herniation.,"BACKGROUND Recurrent intervertebral disc herniation and an exacerbated degenerative process have been identified as the most important factors contributing to persistent pain and disability after surgical discectomy. Defects in the annulus fibrosus remain a surgical challenge, as the preference for minimally invasive surgical approaches for lumbar microdiscectomy, surgical access, and the specifics of anatomy limit the types of devices that permit annulus fibrosus repair. Furthermore, the intervertebral disc is a relatively avascular structure, and surgical procedures can accelerate the degenerative disc process. This study aimed to evaluate the clinical safety and efficacy of a novel microdiscectomy annular repair technique combined with an autologous conditioned plasma (ACP) intradiscal injection for the treatment of lumbar disc herniation (LDH). METHODS From July 2017 to December 2018 this study recruited 75 patients with LDH (single segment) and randomly divided these patients into the following three groups: group A, full endoscopic discectomy; group B: full endoscopic discectomy and annular repair; group C, full endoscopic discectomy annular repair and ACP intradiscal injection. The pre- and postoperative neurological function and pain status were evaluated by the visual analog scale (VAS) score and the Oswestry disability index (ODI). Patients were followed up once preoperatively, and at 1, 3, and 6 months postoperatively. RESULTS The procedure was successfully performed in all cases. No cases required conversion to an open procedure. The preoperative symptoms were alleviated significantly after surgery. The VAS scores for lower back and lower limb pain and ODI score were significantly difference at 1 month, 3 months, 6 months post operation compared to pre-operation scores (P<0.05). For VAS scores of the lower back, the difference between group A and group C was statistically significant (A>C), as was the difference between group B and group C (B>C). CONCLUSIONS Early results showed that the use of the novel full endoscopic annular repair technique and ACP intradiscal injection serial therapeutic model are beneficial for short term outcomes and demonstrates a reduction in symptomatic disc reherniation with low postoperative complication rates. This new serial therapeutic model may significantly improve the symptoms of postoperative lower back pain.",2021,"The VAS scores for lower back and lower limb pain and ODI score were significantly difference at 1 month, 3 months, 6 months post operation compared to pre-operation scores (P<0.05).","['lumbar disc herniation', 'From July 2017 to December 2018 this study recruited 75 patients with LDH (single segment', 'lumbar disc herniation (LDH']","['full endoscopic discectomy; group B: full endoscopic discectomy and annular repair; group C, full endoscopic discectomy annular repair and ACP intradiscal injection', 'novel microdiscectomy annular repair technique combined with an autologous conditioned plasma (ACP) intradiscal injection', 'endoscopic annular repair technique combined with autologous conditioned plasma intradiscal injection']","['preoperative symptoms', 'pre- and postoperative neurological function and pain status', 'VAS scores for lower back and lower limb pain and ODI score', 'visual analog scale (VAS) score and the Oswestry disability index (ODI', 'clinical safety and efficacy']","[{'cui': 'C0281899', 'cui_str': 'Prolapsed lumbar intervertebral disc'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0441635', 'cui_str': 'Segment'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0206078', 'cui_str': 'Discectomy of spine'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C1512934', 'cui_str': 'Intradiscal route'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0457629', 'cui_str': 'Lumbar microdiscectomy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0023222', 'cui_str': 'Pain in lower limb'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",75.0,0.020896,"The VAS scores for lower back and lower limb pain and ODI score were significantly difference at 1 month, 3 months, 6 months post operation compared to pre-operation scores (P<0.05).","[{'ForeName': 'Jizheng', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics, First Clinical Medical College of Yunnan University of Traditional Chinese Medicine, Kunming, China.'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Yuan', 'Affiliation': ""Department of Orthopedics, the First People's Hospital of Kunming, Kunming, China.""}, {'ForeName': 'Fanbing', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics, First Clinical Medical College of Yunnan University of Traditional Chinese Medicine, Kunming, China.'}, {'ForeName': 'Fuke', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Department of Sports Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Yanlin', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Sports Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Enbin', 'Initials': 'E', 'LastName': 'Wang', 'Affiliation': 'Department of Orthopedics, Baoshan Hospital of Traditional Chinese Medicine, Baoshan, China.'}, {'ForeName': 'Xianguang', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Sports Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Yaoyu', 'Initials': 'Y', 'LastName': 'Xiang', 'Affiliation': 'Department of Sports Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'En', 'Initials': 'E', 'LastName': 'Song', 'Affiliation': 'Department of Sports Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming, China. Email: 641634233@qq.com.'}]",Annals of palliative medicine,['10.21037/apm-20-2257'] 878,33452350,Effect of volatile and total intravenous anesthesia on syndecan-1 shedding after minimally invasive gastrectomy: a randomized trial.,"This study aimed to compare the effects of volatile anesthesia and total intravenous anesthesia (TIVA) on syndecan-1 shedding in patients with gastric cancer undergoing minimally invasive gastrectomy. Patients were randomly assigned to either the Volatile (n = 68) or the TIVA (n = 68) group. Anesthesia was maintained with sevoflurane/remifentanil or propofol/remifentanil in the Volatile and TIVA groups, respectively. Serum syndecan-1 was evaluated at pre-operation, end of operation, and postoperative day (POD) 1. Inflammatory markers including white blood cell (WBC) count, neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP), were also measured at pre-operation, end of operation, and POD 1, 2, 3, and 5. The TIVA group showed significantly lower levels of syndecan-1 at the end of the operation compared to the Volatile group; however, no difference was seen between the groups at POD 1. The WBC count and NLR were significantly lower in the TIVA group at the end of the operation than the Volatile group, but there were no differences between the groups at POD 1, 2, 3, and 5. CRP levels were similar between the groups at all time points. In conclusion, despite TIVA being superior to volatile anesthesia in protecting endothelial glycocalyx during the operation, both did not prevent postoperative syndecan-1 shedding after gastrectomy.Clinical trial registration number: NCT04183296 (ClinicalTrial.gov, 03/12/2019).",2021,"The WBC count and NLR were significantly lower in the TIVA group at the end of the operation than the Volatile group, but there were no differences between the groups at POD 1, 2, 3, and 5.","['after minimally invasive gastrectomy', 'patients with gastric cancer undergoing minimally invasive gastrectomy']","['volatile anesthesia and total intravenous anesthesia (TIVA', 'volatile and total intravenous anesthesia', 'sevoflurane/remifentanil or propofol/remifentanil', 'TIVA']","['Serum syndecan-1', 'postoperative day (POD', 'CRP levels', 'WBC count and NLR', 'syndecan-1 shedding', 'Inflammatory markers including white blood cell (WBC) count, neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP', 'levels of syndecan-1']","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}]","[{'cui': 'C0443769', 'cui_str': 'Volatile agent'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0473965', 'cui_str': 'Total intravenous anesthesia'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0753253', 'cui_str': 'SDC1 protein, human'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0141593,"The WBC count and NLR were significantly lower in the TIVA group at the end of the operation than the Volatile group, but there were no differences between the groups at POD 1, 2, 3, and 5.","[{'ForeName': 'Na Young', 'Initials': 'NY', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.'}, {'ForeName': 'Ki Jun', 'Initials': 'KJ', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.'}, {'ForeName': 'Ki-Young', 'Initials': 'KY', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.'}, {'ForeName': 'Hye Jung', 'Initials': 'HJ', 'LastName': 'Shin', 'Affiliation': 'Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jaein', 'Initials': 'J', 'LastName': 'Cho', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.'}, {'ForeName': 'Da Jeong', 'Initials': 'DJ', 'LastName': 'Nam', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.'}, {'ForeName': 'So Yeon', 'Initials': 'SY', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. kimsy326@yuhs.ac.'}]",Scientific reports,['10.1038/s41598-021-81012-1'] 879,33478324,Single dose pharmacokinetics of topical iodiconazole creams in healthy Chinese volunteers.,"1.In this study, the pharmacokinetics of new triazole antifungal iodiconzole creams at target sites after single-dose topical application was investigated.2.30 healthy Chinese volunteers were randomly divided into three groups after being stratified by sex, each group was given a single topical dose of 1%, 2%, 4% iodiconazole cream (0.4 g). Stratum corneum (SC) samples of treated sites were collected by tape-stripping method after the chosen contact times, and were extracted and analysed by a validated LC-MS method.3.After single-dose topical application of 1%, 2%, 4% iodiconazole creams, the C max of iodiconazole in SC was 1.2 ± 0.7, 2.2 ± 1.0, 2.4 ± 1.0 mg/g; T max was 3.3 ± 1.1, 2.9 ± 1.1, 3.8 ± 0.4 h; t 1/2 was 6.6 ± 3.4 h, 7.2 ± 4.1 h, 5.9 ± 2.9 h; AUC 0-t was 10.9 ± 3.0, 20.8 ± 10.4, 20.9 ± 7.9 mg·h/g; AUC 0-∞ was 11.6 ± 2.9, 23.5 ± 14.4, 22.2 ± 8.9 mg·h/g, respectively. The results showed that C max , AUC 0-t and AUC 0-∞ did not increase proportionately with dose, which could also be due to the drug being saturated in the formulation at ∼2%.4.The results of this study could provide reference for the clinical medication and further study of the formulations.",2021,"The results showed that C max , AUC 0-t and AUC 0-∞ did not increase proportionately with dose, which could also be due to the drug being saturated in the formulation at 2%.","['healthy Chinese volunteers', '30 healthy Chinese volunteers']","['topical iodiconazole creams', 'iodiconazole cream']","['C max , AUC 0-t and AUC']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C2714899', 'cui_str': '1-(1H-1,2,4-triazole)-2-(2,4-difluorophenyl)-3-(N-methyl-N-(4-iodobenzyl)amino)-2-propanol'}, {'cui': 'C0700385', 'cui_str': 'Cream'}]","[{'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",30.0,0.0177558,"The results showed that C max , AUC 0-t and AUC 0-∞ did not increase proportionately with dose, which could also be due to the drug being saturated in the formulation at 2%.","[{'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Institute of Dermatology and Hospital for Skin Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Zhou', 'Affiliation': 'Department of dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.'}, {'ForeName': 'Wenkai', 'Initials': 'W', 'LastName': 'Zong', 'Affiliation': 'Institute of Dermatology and Hospital for Skin Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Institute of Dermatology and Hospital for Skin Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.'}, {'ForeName': 'Chunquan', 'Initials': 'C', 'LastName': 'Sheng', 'Affiliation': 'Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai, China.'}]",Xenobiotica; the fate of foreign compounds in biological systems,['10.1080/00498254.2021.1876962'] 880,33822209,Letter: A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.,,2021,,"['Letter', 'Patients']",[],[],"[{'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],[],,0.0433458,,"[{'ForeName': 'Abdur', 'Initials': 'A', 'LastName': 'Rahman', 'Affiliation': 'Dhaka Medical College and Hospital Dhaka, Bangladesh.'}, {'ForeName': 'Ivan D', 'Initials': 'ID', 'LastName': 'Lozada-Martinez', 'Affiliation': 'Medical and Surgical Research Center University of Cartagena Cartagena, Colombia.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Rahman', 'Affiliation': 'Department of Public Health Independent University-Bangladesh Dhaka, Bangladesh.'}, {'ForeName': 'A H M', 'Initials': 'AHM', 'LastName': 'Ataullah', 'Affiliation': 'Sher-e-Bangla Medical College Hospital Barishal, Bangladesh.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Muñoz-Baez', 'Affiliation': 'Colombian Clinical Research Group in Neurocritical Care University of Cartagena Cartagena, Colombia.'}, {'ForeName': 'Luis Rafael', 'Initials': 'LR', 'LastName': 'Moscote-Salazar', 'Affiliation': 'Colombian Clinical Research Group in Neurocritical Care Faculty of Medicine University of Cartagena Cartagena, Colombia.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Agrawal', 'Affiliation': 'Department of Neurosurgery All India Institute of Medical Sciences Bhopal, India.'}, {'ForeName': 'Md Moshiur', 'Initials': 'MM', 'LastName': 'Rahman', 'Affiliation': 'Neurosurgery Department Holy Family Red Crescent Medical College Dhaka, Bangladesh.'}]",Neurosurgery,['10.1093/neuros/nyab097'] 881,33493023,Acute effects of hemp protein consumption on glycemic and satiety control: results of 2 randomized crossover trials.,"Research investigating hemp protein consumption on glycemic response is limited. The effects of hemp protein consumption on blood glucose (BG), insulin, and satiety compared with soybean protein and a carbohydrate control were examined. Two acute randomized repeated-measures crossover experiments were conducted. In both, participants consumed the following isocaloric treatments: 40 g of hemp protein (hemp40), 20 g of hemp protein (hemp20), 40 g of soybean protein (soy40), 20 g of soybean protein (soy20), and a carbohydrate control. In experiments 1 ( n = 27) and 2 ( n = 16), appetite and BG were measured before (0-60 min, pre-pizza) and after a pizza meal (80-200 min, post-pizza). In experiment 1, food intake was measured at 60 min by ad libitum meal; in experiment 2 a fixed meal was provided (based on body weight) and insulin was measured pre-pizza and post-pizza. In both experiments, BG response was affected by treatment ( p < 0.01), time ( p < 0.001) and time-by-treatment ( p < 0.001) from 0-200 min. Protein treatments lowered 0-60-min BG overall mean and area under the curve compared with control ( p < 0.05) dose-dependently. In experiment 2, hemp40 and soy40 lowered ( p < 0.05) overall mean insulin concentrations compared with hemp20, soy20, and control pre-meal. Results suggest that hemp protein, like soybean, dose-dependently lowers postprandial BG and insulin concentrations compared with a carbohydrate control. Clinical trial registry: NCT02366598 (experiment 1) and NCT02458027 (experiment 2). Novelty: Hemp protein concentrate dose-dependently leads to lower postprandial BG response compared with a carbohydrate control. No differences were seen between hemp and soy protein.",2021,"In experiment 2, hemp40 and soy40 lowered (p<0.05) overall mean insulin concentrations compared to hemp20, soy20, and control pre-meal.",[],"['hemp protein consumption', 'isocaloric treatments 40g of hemp protein (hemp40), 20g of hemp protein (hemp20), 40g of soybean protein (soy40), 20g of soybean protein (soy20), and a carbohydrate control', 'pizza meal']","['appetite and BG', 'post-prandial BG and insulin concentrations', 'Protein treatments lowered 0-60 min BG overall mean, and area under the curve (AUC', 'Novelty bullets', 'glycemic and satiety control', 'blood glucose (BG), insulin, and satiety', 'hemp40 and soy40 lowered (p<0.05) overall mean insulin concentrations', 'BG response']",[],"[{'cui': 'C0162335', 'cui_str': 'HEMP'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0450403', 'cui_str': '20G'}, {'cui': 'C0950114', 'cui_str': 'Soy Bean Proteins'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0453577', 'cui_str': 'Pizza'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0336699', 'cui_str': 'Bullet'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}]",,0.0161929,"In experiment 2, hemp40 and soy40 lowered (p<0.05) overall mean insulin concentrations compared to hemp20, soy20, and control pre-meal.","[{'ForeName': 'Rebecca C', 'Initials': 'RC', 'LastName': 'Mollard', 'Affiliation': 'Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Alie', 'Initials': 'A', 'LastName': 'Johnston', 'Affiliation': 'Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'Serrano Leon', 'Affiliation': 'Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Haizhou', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Jones', 'Affiliation': 'Nutritional Fundamentals for Health, Vaudreuil-Dorion, Quebec, Canada.'}, {'ForeName': 'Dylan S', 'Initials': 'DS', 'LastName': 'MacKay', 'Affiliation': 'Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2020-0907'] 882,33454584,Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.,"BACKGROUND Cognitive dysfunction, including slowed cognitive processing speed (CPS), is one of the most disabling symptoms of multiple sclerosis (MS). The Symbol Digit Modalities Test (SDMT) is a preferred measure of CPS for MS trials and routine screening. Based on encouraging SDMT results in the phase 3 SUNBEAM trial, these post hoc, exploratory analyses were conducted to further compare effects of the sphingosine 1-phosphate receptor modulator ozanimod versus intramuscular interferon β-1a on CPS in participants with relapsing multiple sclerosis (RMS). METHODS In the phase 3, double-blind, double-dummy, SUNBEAM study, adults (aged 18‒55 years) with RMS (N=1,346) were randomized to once-daily oral ozanimod 0.92 or 0.46 mg, or weekly intramuscular interferon β-1a 30 µg. The study continued until the last participant was treated for 12 months. CPS was measured as part of a secondary endpoint using the SDMT. Exploratory, post hoc analyses evaluated SDMT change and percentages of participants with clinically meaningful (≥4-point) SDMT improvement or worsening at months 6 and 12, and relationship between SDMT and brain volume on magnetic resonance imaging. RESULTS Ozanimod improved SDMT scores compared with interferon β-1a at months 6 and 12. At month 12, least squares mean difference in SDMT z-scores for ozanimod 0.92 mg versus interferon β-1a was 0.102 (95% CI, 0.031‒0.174, nominal p = 0.0051; standardized mean difference = 0.1376). A greater percentage of ozanimod 0.92 mg‒treated participants had clinically meaningful improvements in SDMT scores versus interferon β-1a at month 6 (30.0% versus 22.2%) and month 12 (35.6% versus 27.9%). Of those with SDMT improvement at month 6, 66.4% of those treated with ozanimod 0.92 mg and 55.9% of those treated with interferon β-1a had sustained improvement at month 12. Brain volume loss was similar for those with SDMT improvement versus worsening at month 12. CONCLUSIONS In these exploratory analyses, ozanimod had modestly beneficial effects on CPS in RMS participants. The effects of ozanimod on SDMT are being further evaluated in an ongoing 3-year clinical trial. SUNBEAM is registered on clinicaltrials.gov (NCT02294058) and the European Clinical Trials Database (EudraCT 2014-002320-27).",2021,A greater percentage of ozanimod 0.92 mg‒treated participants had clinically meaningful improvements in SDMT scores versus interferon β-1a at month 6 (30.0% versus 22.2%) and month 12 (35.6% versus 27.9%).,"['adults (aged 18‒55 years) with RMS (N=1,346', 'Relapsing MS', 'participants with relapsing multiple sclerosis (RMS']","['sphingosine 1-phosphate receptor modulator ozanimod versus intramuscular interferon β-1a', 'daily oral ozanimod 0.92 or 0.46 mg, or weekly intramuscular interferon β-1a 30 µg', 'Ozanimod', 'ozanimod']","['CPS', 'SDMT change and percentages of participants with clinically meaningful (≥4-point) SDMT improvement or worsening', 'SDMT scores', 'Symbol Digit Modalities Test Performance', 'SDMT scores versus interferon β-1a', 'SDMT z-scores', 'Brain volume loss']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0856120', 'cui_str': 'Multiple sclerosis relapse'}]","[{'cui': 'C4760638', 'cui_str': 'Sphingosine Receptor Modulators'}, {'cui': 'C4278675', 'cui_str': 'ozanimod'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4517485', 'cui_str': '0.92'}, {'cui': 'C4517460', 'cui_str': '0.46'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}]","[{'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0451522', 'cui_str': 'Symbol digit modalities test'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",1346.0,0.0960854,A greater percentage of ozanimod 0.92 mg‒treated participants had clinically meaningful improvements in SDMT scores versus interferon β-1a at month 6 (30.0% versus 22.2%) and month 12 (35.6% versus 27.9%).,"[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'DeLuca', 'Affiliation': 'Kessler Foundation, 1199 Pleasant Valley Way, West Orange, NJ 07052 USA and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark 07103, NJ, USA. Electronic address: jdeluca@kesslerfoundation.org.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Schippling', 'Affiliation': 'Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Hospital and University of Zürich and Neuroscience Center Zürich, University of Zürich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland and Federal Institute of Technology (ETH) Zürich, Rämistrasse 101, 8092 Zürich, Switzerland. Electronic address: sven.schippling@usz.ch.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Montalban', 'Affiliation': ""Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Pg. Vall d'Hebron, 119-129, 08035 Barcelona, Spain. Electronic address: xavier.montalban@cem-cat.org.""}, {'ForeName': 'Ludwig', 'Initials': 'L', 'LastName': 'Kappos', 'Affiliation': 'Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland. Electronic address: ludwig.kappos@usb.ch.'}, {'ForeName': 'Bruce A C', 'Initials': 'BAC', 'LastName': 'Cree', 'Affiliation': 'Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, 675 Nelson Rising Lane, San Francisco, CA 94158 USA. Electronic address: bruce.cree@ucsf.edu.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Comi', 'Affiliation': 'Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, via Olgettina 48, 20132 Milan, Italy. Electronic address: comi.giancarlo@hsr.it.'}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Arnold', 'Affiliation': 'NeuroRx Research and Montréal Neurological Institute, McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada. Electronic address: douglas.arnold@mcgill.ca.'}, {'ForeName': 'Hans-Peter', 'Initials': 'HP', 'LastName': 'Hartung', 'Affiliation': 'Department of Neurology, Medical Faculty, Heinrich-Heine University, University Hospital Dusseldorf, Moorenstr. 5 40225 Dusseldorf, Germany. Electronic address: hans-peter.hartung@uni-duesseldorf.de.'}, {'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Sheffield', 'Affiliation': 'Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA. Electronic address: James.Sheffield@bms.com.'}, {'ForeName': 'Hongjuan', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA. Electronic address: Hongjuan.Liu@bms.com.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Silva', 'Affiliation': 'Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA. Electronic address: Diego.Silva@bms.com.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Cohen', 'Affiliation': 'Department of Neurology, Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 USA. Electronic address: COHENJ@ccf.org.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102673'] 883,33454398,Effect of exergaming versus combined exercise on cognitive function and brain activation in frail older adults: A randomised controlled trial.,"BACKGROUND Cognitive impairment is prevalent among frail older adults. Traditional exercise and exergaming positively affect cognition in healthy older people. However, few studies have investigated the effects of exergaming on cognition and brain activation in frail older adults. OBJECTIVE This study compared the effect of Kinect based exergaming (EXER) and combined physical exercise (CPE) training on cognitive function and brain activation in frail older adults in Taiwan. We hypothesised that EXER would be superior to CPE in this population. METHODS We randomised 46 community-dwelling frail older adults to the EXER or CPE group for 36 sessions (three 60-min training sessions per week) over 12 weeks. Outcome measures for cognitive function included global cognition measured by the Montreal Cognitive Assessment, executive function measured by the Executive Interview 25, verbal memory measured by the Chinese version of the California Verbal Learning Test, attention measured by the Stroop Colour and Word Test and Trail Making Test (part B), and working memory measured by spatial n-back tests. Prefrontal cortex activation during the global cognition test was documented with functional near-infrared spectroscopy (fNIRS). RESULTS Both groups improved significantly in global cognition (P<0.05), executive function (P<0.05), and attention (P<0.05) after the 12-week intervention. The group×time interaction indicated that EXER training significantly enhanced global cognition more than CPE training (F(1,44)=5.277, P=0.026). Moreover, only the EXER group showed significant improvements in verbal (P<0.05) and working (P<0.05) memory after the intervention. The fNIRS hemodynamics data revealed decreased activation in prefrontal cortices of both groups (P<0.05) during the post-training cognitive assessment, thereby suggesting greater neural efficiency; however, we found no significant group difference. CONCLUSION In frail older adults, exergaming and CPE could improve cognitive function, most likely by increasing neural efficiency. Moreover, exergaming may be superior to CPE, particularly in improving global cognition.",2021,"Both groups improved significantly in global cognition (p<0.05), executive function (p<0.05), and attention (p<0.05) after the 12-week intervention.","['healthy older people', 'frail older adults', 'frail older adults in Taiwan', '46 community-dwelling frail older adults']","['EXER', 'EXER training', 'Kinect based exergaming (EXER) and combined physical exercise (CPE) training', 'Traditional exercise', 'EXER or CPE', 'exergaming versus combined exercise']","['Prefrontal cortex activation', 'cognitive function and brain activation', 'global cognition (p<0.05), executive function (p<0.05), and attention (p<0.05', 'activation in prefrontal cortices', 'global cognition', 'verbal (p<0.05) and working (p<0.05) memory', 'cognitive function', 'cognitive function included global cognition measured by the Montreal Cognitive Assessment, executive function measured by the Executive Interview 25, verbal memory measured by the Chinese version of the California Verbal Learning Test, attention measured by the Stroop Color and Word Test and Trail Making Test (part B), and working memory measured by spatial n-back tests']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]","[{'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0589055', 'cui_str': 'California verbal learning test'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}]",46.0,0.0271811,"Both groups improved significantly in global cognition (p<0.05), executive function (p<0.05), and attention (p<0.05) after the 12-week intervention.","[{'ForeName': 'Ying-Yi', 'Initials': 'YY', 'LastName': 'Liao', 'Affiliation': 'Department of gerontological health care, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.'}, {'ForeName': 'I-Hsuan', 'Initials': 'IH', 'LastName': 'Chen', 'Affiliation': 'Department of physical therapy, Fooyin University, Kaohsiung, Taiwan.'}, {'ForeName': 'Wei-Chun', 'Initials': 'WC', 'LastName': 'Hsu', 'Affiliation': 'Graduate Institute of biomedical engineering, National Taiwan University of Science and Technology, Taipei, Taiwan.'}, {'ForeName': 'Han-Yun', 'Initials': 'HY', 'LastName': 'Tseng', 'Affiliation': 'Department of gerontological health care, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.'}, {'ForeName': 'Ray-Yau', 'Initials': 'RY', 'LastName': 'Wang', 'Affiliation': 'Department of physical therapy and assistive technology, National Yang-Ming University, Taipei, Taiwan. Electronic address: rywang@ym.edu.tw.'}]",Annals of physical and rehabilitation medicine,['10.1016/j.rehab.2021.101492'] 884,33479931,Hospital-Level Care at Home for Acutely Ill Adults: a Qualitative Evaluation of a Randomized Controlled Trial.,"BACKGROUND Substitutive hospital-level care in a patient's home (""home hospital"") has been shown to lower cost, utilization, and readmission compared to traditional hospital care. However, patients' perspectives to help explain how and why interventions like home hospital accomplish many of these results are lacking. OBJECTIVE Elucidate and explain patient perceptions of home hospital versus traditional hospital care to better describe the different perceptions of care in both settings. DESIGN Qualitative evaluation of a randomized controlled trial. PARTICIPANTS 36 hospitalized patients (19 home; 17 control). INTERVENTION Traditional hospital (""control"") versus home hospital (""home""), including nurse and physician home visits, intravenous medications, remote monitoring, video communication, and point-of-care testing. APPROACH We conducted a thematic content analysis of semi-structured interviews. Team members developed a coding structure through a multiphase approach, utilizing a constant comparative method. KEY RESULTS Themes clustered around 3 domains: clinician factors, factors promoting healing, and systems factors. Clinician factors were similar in both groups; both described beneficial interactions with clinical staff; however, home patients identified greater continuity of care. For factors promoting healing, home patients described a locus of control surrounding their sleep, activity, and environmental comfort that control patients lacked. For systems factors, home patients experienced more efficient processes and logistics, particularly around admission and technology use, while both noted difficulty with discharge planning. CONCLUSIONS Compared to control patients, home patients had better experiences with their care team, had more experiences promoting healing such as better sleep and physical activity, and had better experiences with systems factors such as the admission processes. Potential explanations include continuity of care, the power and familiarity of the home, and streamlined logistics. Future improvements include enhanced care transitions and ensuring digital interfaces are usable. TRIAL REGISTRATION NCT03203759.",2021,"Clinician factors were similar in both groups; both described beneficial interactions with clinical staff; however, home patients identified greater continuity of care.","['36 hospitalized patients (19 home; 17 control', 'Acutely Ill Adults']","['Traditional hospital (""control"") versus home hospital (""home', 'Hospital-Level Care at Home']",[],"[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",[],36.0,0.0420481,"Clinician factors were similar in both groups; both described beneficial interactions with clinical staff; however, home patients identified greater continuity of care.","[{'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Levine', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA. dmlevine@bwh.harvard.edu.""}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Pian', 'Affiliation': ""Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': 'Karthiyayini', 'Initials': 'K', 'LastName': 'Mahendrakumar', 'Affiliation': 'Lake Erie School of Osteopathic Medicine, Erie, PA, USA.'}, {'ForeName': 'Apexa', 'Initials': 'A', 'LastName': 'Patel', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Agustina', 'Initials': 'A', 'LastName': 'Saenz', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Schnipper', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.""}]",Journal of general internal medicine,['10.1007/s11606-020-06416-7'] 885,33493624,A direct comparison of neuronavigated and non-neuronavigated intermittent theta burst stimulation in the treatment of depression.,"OBJECTIVE To investigate whether a four-week course of neuronavigated intermittent theta burst stimulation (iTBS) of the left dorsolateral prefrontal cortex is superior to the non-neuronavigated F3-EEG method of positioning. METHODS We conducted a single-center, two-arm, randomized and double-blinded study (clinicaltrials.gov NCT03953521). 37 inpatients with an at least moderate depressive episode were randomized to receive either neuronavigated or 10-20-EEG-system based F3 guided iTBS. Both groups received twenty week daily sessions of iTBS while continuing to receive standard-of-care treatment by their ward physicians. For navigated iTBS, we used magnetic resonance imaging to target the border between the anterior and middle third of the middle frontal gyrus considered to represent the left dorsolateral prefrontal cortex (lDLPFC). Differences in the treatment arms were blinded by completely mimicking the procedures of the respective other treatment group. Rating physicians were not involved in the treatment procedure. Primary outcome was defined as the change of the 21-item version of the Hamilton Depression Score (HAMD) from baseline to end of treatment at week 4. Secondary outcomes included HAMD score during the treatment, Patient Health Questionnaire-9, WHO Quality of Life-BREF and Clinical Global Impression. For primary outcome, we used a planned group comparison for the absolute change in the HAMD. For secondary outcome measures we calculated analyses of variance (ANOVAs) with the within-subjects factor time (primary: baseline vs. week 4; secondary: all visits) and the between-subjects factor group (navigated vs. F3 guided group). We also did planned contrasts between both groups for all variables and all treatment and follow-up visits with the aim not to oversee any group differences. For group contrasts we used Student T-tests for metric and chi-square tests for categorial variables. Significance threshold was set to 5% uncorrected for multiple comparisons. RESULTS Enrolment of 80 patients with interim analysis was planned. Interim analysis was performed after 37 patients (intention to treat). 6 patients dropped out, leaving 31 for analysis. With respect to primary outcome criteria, absolute change in the HAMD did not differ significantly between groups. In accordance, relative change and number of responders and remitters were not significantly different. Overall number of responders was 53% and of remitters was 60%. On a descriptive level, the results favor the clinical effects of the F3 group for the absolute and relative change in the HAMD and the number of responders. Number of remitters were exactly the same for both groups. Therefore, we decided to stop the trial due to the added burden of magnetic resonance imaging and neuronavigated treatment in relation to the effect. Secondary outcomes did also not differ significantly between groups. Patients did not differ in their baseline characteristics nor with respect to intake of medication during the trial period and all had access to the same therapeutic interventions. CONCLUSION We noticed a high antidepressive effect of add-on iTBS treatment to standard inpatient treatment but failed to demonstrate a clinical superiority of neuronavigated localization. The non-navigated, F3 guided iTBS treatment used as a control group may be sophisticated enough to dilute potential added benefits, and the difference between the localization approaches is either negligible or too small to justify the additional efforts of navigation. The effects of concomitant treatment may mask effects, but our patient population reflects clinical reality in an inpatient setting. Further prospective studies are warranted to compare neuronavigated with surface-based approaches.",2021,"Patients did not differ in their baseline characteristics nor with respect to intake of medication during the trial period and all had access to the same therapeutic interventions. ","['80 patients with interim analysis was planned', '37 inpatients with an at least moderate depressive episode']","['neuronavigated or 10-20-EEG-system based F3 guided iTBS', 'neuronavigated intermittent theta burst stimulation', 'neuronavigated and non-neuronavigated intermittent theta burst stimulation', 'intermittent theta burst stimulation while continuing to receive standard-of-care treatment by their ward physicians']","['absolute change in the HAMD', 'Overall number of responders', 'HAMD score during the treatment, Patient Health Questionnaire-9, WHO Quality of Life-BREF and Clinical Global Impression', 'change of the 21-item version of the Hamilton Depression Score (HAMD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0494398', 'cui_str': 'Moderate depressive episode'}]","[{'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0031831', 'cui_str': 'Physician'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C2607870', 'cui_str': 'Version'}]",80.0,0.0960668,"Patients did not differ in their baseline characteristics nor with respect to intake of medication during the trial period and all had access to the same therapeutic interventions. ","[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Hebel', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Germany. Electronic address: tobias.hebel@medbo.de.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Göllnitz', 'Affiliation': 'Faculty of Medicine, University of Regensburg, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schoisswohl', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Germany.'}, {'ForeName': 'Franziska C', 'Initials': 'FC', 'LastName': 'Weber', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Germany.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Abdelnaim', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Germany.'}, {'ForeName': 'Thomas C', 'Initials': 'TC', 'LastName': 'Wetter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Rupprecht', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Germany.'}, {'ForeName': 'Berthold', 'Initials': 'B', 'LastName': 'Langguth', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schecklmann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Germany.'}]",Brain stimulation,['10.1016/j.brs.2021.01.013'] 886,33502815,Characterization of the Abuse Potential in Adult Smokers of a Novel Oral Tobacco Product Relative to Combustible Cigarettes and Nicotine Polacrilex Gum.,"Novel noncombustible tobacco products offer adult smokers (ASs) alternatives to combustible cigarettes lower on the continuum of risk; however, the abuse potential of such products has not been well studied. The objective of this study was to evaluate the abuse potential of 2 chewable tobacco-derived nicotine containing products, VERVE Chews Blue Mint (test 1) and Green Mint (test 2), in ASs compared with own-brand cigarettes (CIGS) and nicotine polacrilex gum (GUM) using subjective measures and nicotine pharmacokinetics. ASs used the test products during a 5-day at-home trial prior to completing an in-clinic 4-period randomized crossover study. During the study ASs used test products, CIGS, and GUM once on separate days. Responses to Tobacco/Nicotine Withdrawal and Direct Effects of Product questionnaires were documented, and blood samples were collected to assess nicotine pharmacokinetics during each product use. Nicotine pharmacokinetic parameters (C max and AUC) were statistically significantly lower with use of test products compared with CIGS and statistically significantly higher compared with GUM. No appreciable differences were noted between the 2 flavors for any of the end points measured. Reductions in maximum urge to smoke and maximum responses to the question ""Is the Product 'Pleasant' Right Now?"" for the test products were statistically significantly lower than CIGS but comparable to GUM. Similar results were observed for responses to other items in the 2 questionnaires. The test products, under the conditions of this study, carry lower abuse potential than own-brand cigarettes and similar to nicotine polacrilex gum.",2021,Nicotine pharmacokinetic parameters (C max and AUC) were statistically significantly lower with use of test products compared with CIGS and statistically significantly higher compared with GUM.,"['adult smokers (ASs', 'Adult Smokers of a Novel Oral Tobacco Product Relative to Combustible Cigarettes and Nicotine Polacrilex Gum']","['nicotine polacrilex gum', '2 chewable tobacco-derived nicotine containing products, VERVE Chews Blue Mint (test 1) and Green Mint (test 2), in ASs compared with own-brand cigarettes (CIGS) and nicotine polacrilex gum (GUM', 'Novel noncombustible tobacco products']",['Nicotine pharmacokinetic parameters (C max and AUC'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0008038', 'cui_str': 'Chewing tobacco'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0068722', 'cui_str': 'Nicotine polacrilex'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}]","[{'cui': 'C0068722', 'cui_str': 'Nicotine polacrilex'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0024888', 'cui_str': 'Mastication'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0452249', 'cui_str': 'Mint'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",,0.0198384,Nicotine pharmacokinetic parameters (C max and AUC) were statistically significantly lower with use of test products compared with CIGS and statistically significantly higher compared with GUM.,"[{'ForeName': 'Jianmin', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Altria Client Services LLC, Richmond, Virginia, USA.'}, {'ForeName': 'Jingzhu', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Altria Client Services LLC, Richmond, Virginia, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Vansickel', 'Affiliation': 'Altria Client Services LLC, Richmond, Virginia, USA.'}, {'ForeName': 'Jeffery', 'Initials': 'J', 'LastName': 'Edmiston', 'Affiliation': 'Altria Client Services LLC, Richmond, Virginia, USA.'}, {'ForeName': 'Donald', 'Initials': 'D', 'LastName': 'Graff', 'Affiliation': 'Celerion Inc., Lincoln, Nebraska, USA.'}, {'ForeName': 'Mohamadi', 'Initials': 'M', 'LastName': 'Sarkar', 'Affiliation': 'Altria Client Services LLC, Richmond, Virginia, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.909'] 887,33471169,"Intranasal sodium citrate in quantitative and qualitative olfactory dysfunction: results from a prospective, controlled trial of prolonged use in 60 patients.","OBJECTIVES We have previously shown that treatment with intranasal sodium citrate may be beneficial in post-infectious olfactory dysfunction. Sodium citrate reduces free intranasal calcium and is, therefore, thought to prevent calcium-mediated feedback inhibition at the level of the olfactory receptor. We aimed to determine whether treatment with a 2-week course of intranasal sodium citrate improves quantitative olfactory function in patients with post-infectious impairment. We also aimed to determine whether sodium citrate is beneficial in treating qualitative olfactory dysfunction. METHODS We performed a prospective, controlled study. Patients applied intranasal sodium citrate solution to the right nasal cavity for 2 weeks. The left nasal cavity was untreated and, therefore, acted as an internal control. Monorhinal olfactory function was assessed using the ""Sniffin' Sticks"" composite 'TDI' score, before and after treatment. The presence of parosmia and phantosmia was also assessed. RESULTS Overall, there was a significant increase in TDI after treatment (using the best of right and left sides). Treatment with sodium citrate did not significantly improve quantitative olfactory function, compared to control. The proportion of patients reporting parosmia did not change significantly after treatment. However, there was a significant reduction in the proportion of patients reporting phantosmia, at the end of the study period. CONCLUSIONS Treatment with intranasal sodium citrate for a period of 2 weeks does not appear to improve quantitative olfactory function in patients with post-infectious impairment, compared to control. It may, however, be beneficial in treating phantosmia, which should be further addressed in future work.",2021,"Treatment with sodium citrate did not significantly improve quantitative olfactory function, compared to control.","['60 patients', 'patients with post-infectious impairment']","['intranasal sodium citrate', 'intranasal sodium citrate solution', 'Sodium citrate', 'sodium citrate', 'Intranasal sodium citrate']","['Monorhinal olfactory function', 'quantitative and qualitative olfactory dysfunction', 'left nasal cavity', 'quantitative olfactory function', 'TDI', 'proportion of patients reporting parosmia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0142825', 'cui_str': 'sodium citrate'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0027423', 'cui_str': 'Nasal cavity structure'}, {'cui': 'C0205976', 'cui_str': 'Toluene di-isocyanate-containing product'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0235287', 'cui_str': 'Dysosmia'}]",,0.0202948,"Treatment with sodium citrate did not significantly improve quantitative olfactory function, compared to control.","[{'ForeName': 'K L', 'Initials': 'KL', 'LastName': 'Whitcroft', 'Affiliation': 'Interdisciplinary Center for Smell & Taste, Department of Otorhinolaryngology, TU Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Gunder', 'Affiliation': 'Interdisciplinary Center for Smell & Taste, Department of Otorhinolaryngology, TU Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Cuevas', 'Affiliation': 'Interdisciplinary Center for Smell & Taste, Department of Otorhinolaryngology, TU Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Andrews', 'Affiliation': 'Ear Institute, University College London, London, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Menzel', 'Affiliation': 'Interdisciplinary Center for Smell & Taste, Department of Otorhinolaryngology, TU Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Haehner', 'Affiliation': 'Interdisciplinary Center for Smell & Taste, Department of Otorhinolaryngology, TU Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Hummel', 'Affiliation': 'Interdisciplinary Center for Smell & Taste, Department of Otorhinolaryngology, TU Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. thummel@msx.tu-dresden.de.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-020-06567-7'] 888,33469717,"Do length and gauge of dental needle affect success in performing an inferior alveolar nerve block during extraction of adult mandibular molars? A prospective, randomized observer-blind, clinical trial.","OBJECTIVE Association between length and gauge of dental needle and success rate and pain perception during an inferior alveolar nerve block (IANB) has not been investigated using a randomized clinical trial (RCT). This RCT aimed to compare the success rate of IANB and perceived pain using 27- or 30-gauge needles for the extraction of adult mandibular molars. MATERIAL AND METHOD A prospective RCT was conducted on two hundred and twelve adult patients requiring extraction of mandibular molars using standard methods as described by Malamed with 1.8 ml of 2% lidocaine with 1:80,000 adrenaline. One hundred six patients received IANB using 27-gauge needles (32 mm × 0.2 mm) and one hundred six patients received IANB using 30-gauge needles (25 mm × 0.15 mm). Predictor variables were 27-gauge and short and 30-gauge. Outcome variables were the success rate of IANB and pain perception during injection using a visual analogue scale. RESULTS There was a highly significantly increase in the success of IANB using 27-gauge needle (95.28%) versus 30-gauge needle (41.51%) (P = 0.001). There was a significant increase in pain perception for patients who received IANB by shorter and thinner needle (30-gauge) when compared to the long and thicker needle (27-gauge). CONCLUSION This RCT demonstrated that 27-gauge needle seems to be associated with a higher success rate of IANB and lower pain perception during injection when compared to 30-gauge needle in the extraction of adult mandibular molars when compared to 30-gauge needles. CLINICAL RELEVANCE For adult patients, when thickness of soft tissue to be penetrated is essential to achieve bony contact, long or large gauge dental needle is preferred to get a higher success rate of IANB with less pain perception during injection.",2021,There was a highly significantly increase in the success of IANB using 27-gauge needle (95.28%) versus 30-gauge needle (41.51%) (P = 0.001).,"['For adult patients', 'One hundred six patients received', 'two hundred and twelve adult patients requiring extraction of mandibular molars using standard methods as described by Malamed with 1.8\xa0ml of 2', 'adult mandibular molars']","['lidocaine with 1:80,000 adrenaline', 'inferior alveolar nerve block (IANB', 'IANB using 30-gauge needles', 'IANB using 27-gauge needles']","['success rate of IANB and perceived pain', 'success rate of IANB and lower pain perception', 'pain perception', 'success of IANB', 'success rate of IANB and pain perception during injection using a visual analogue scale']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4068742', 'cui_str': '1.8'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0394801', 'cui_str': 'Local anesthetic inferior alveolar nerve block'}, {'cui': 'C0456564', 'cui_str': 'Gauges'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}]","[{'cui': 'C0394801', 'cui_str': 'Local anesthetic inferior alveolar nerve block'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",212.0,0.0911601,There was a highly significantly increase in the success of IANB using 27-gauge needle (95.28%) versus 30-gauge needle (41.51%) (P = 0.001).,"[{'ForeName': 'Essam Ahmed', 'Initials': 'EA', 'LastName': 'Al-Moraissi', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Thamar University, Thamar, Yemen. dressamalmoraissi@gmail.com.'}, {'ForeName': 'Abeer Mohammed', 'Initials': 'AM', 'LastName': 'Al-Selwi', 'Affiliation': 'Department of Oral Surgery and Dental Implantology, College of Dentistry, University of Science and Technology, Sanaa, Yemen.'}, {'ForeName': 'Elham Aziz', 'Initials': 'EA', 'LastName': 'Al-Zendani', 'Affiliation': 'Department of Oral Surgery and Dental Implantology, College of Dentistry, University of Science and Technology, Sanaa, Yemen.'}]",Clinical oral investigations,['10.1007/s00784-021-03796-w'] 889,33469657,Encephaloduroarteriosynangiosis Averts Stroke in Atherosclerotic Patients With Border-Zone Infarct: Post Hoc Analysis From a Performance Criterion Phase II Trial.,"BACKGROUND Intracranial atherosclerotic disease (ICAD) is one of the leading causes of stroke worldwide. Patients with ICAD who initially present with ischemia in border-zone areas and undergo intensive medical management (IMM) have the highest recurrence rates (37% at 1 yr) because of association with hemodynamic failure and poor collaterals. OBJECTIVE To evaluate the effect of encephaloduroarteriosynagiosis (EDAS) on stroke recurrence in patients with ICAD and border-zone stroke (BDZS) at presentation. METHODS A phase II clinical trial of EDAS revascularization for symptomatic ICAD failing medical management (EDAS Revascularization for Symptomatic Intracranial Atherosclerosis Steno-occlusive [ERSIAS]) was recently concluded. We analyze the outcomes of the subgroup of patients with BDZS at presentation treated with EDAS vs the previously reported Stenting versus Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) IMM subgroup with BDZS at presentation. RESULTS Of 52 patients included in the ERSIAS trial, 35 presented with strokes at baseline, and 28 had a BDZ pattern, including 15 (54%) with exclusive BDZS and 13 (46%) with mixed patterns (BDZ plus other distribution). Three of the 28 (10.7%) had recurrent strokes up to a median follow-up of 24 months. The rate of recurrent stroke in ICAD patients with BDZS at presentation after EDAS was significantly lower than the rate reported in the SAMMPRIS IMM subgroup with BDZS at presentation (10.7% vs 37% P = .004, 95% CI = 0.037-0.27). CONCLUSION ICAD patients with BDZS at presentation have lower rates of recurrent stroke after EDAS surgery than those reported with medical management in the SAMMPRIS trial. These results support further investigation of EDAS in a randomized clinical trial.",2021,Three of the 28 (10.7%) had recurrent strokes up to a median follow-up of 24 months.,"['Patients with ICAD who initially present with ischemia in border-zone areas and undergo intensive medical management (IMM', 'Of 52 patients included in the ERSIAS trial, 35 presented with strokes at baseline, and 28 had a BDZ pattern, including 15 (54%) with exclusive BDZS and 13 (46%) with mixed patterns (BDZ plus other distribution', 'Atherosclerotic Patients With Border-Zone Infarct', 'subgroup of patients with BDZS at presentation treated with EDAS vs the previously reported Stenting versus Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) IMM subgroup with BDZS at presentation', 'patients with ICAD and border-zone stroke (BDZS) at presentation', 'A phase II clinical trial of EDAS revascularization for symptomatic ICAD failing medical management (EDAS Revascularization for Symptomatic Intracranial Atherosclerosis Steno-occlusive [ERSIAS']","['encephaloduroarteriosynagiosis (EDAS', 'Encephaloduroarteriosynangiosis']","['rate of recurrent stroke', 'recurrent stroke', 'recurrent strokes', 'recurrence rates', 'stroke recurrence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0333557', 'cui_str': 'Watershed infarct'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C1836785', 'cui_str': 'Recurrent stroke'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0751007', 'cui_str': 'Intracranial Atherosclerosis'}, {'cui': 'C0524571', 'cui_str': 'Steno bredanensis'}, {'cui': 'C1947917', 'cui_str': 'Occluded'}]","[{'cui': 'C1504429', 'cui_str': 'Encephalo-duro-arterio-synangiosis'}]","[{'cui': 'C1836785', 'cui_str': 'Recurrent stroke'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",35.0,0.0533673,Three of the 28 (10.7%) had recurrent strokes up to a median follow-up of 24 months.,"[{'ForeName': 'Miguel D', 'Initials': 'MD', 'LastName': 'Quintero-Consuegra', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Toscano', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Babadjouni', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Peyton', 'Initials': 'P', 'LastName': 'Nisson', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Mohammad N', 'Initials': 'MN', 'LastName': 'Kayyali', 'Affiliation': 'Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Chang', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Eyad', 'Initials': 'E', 'LastName': 'Almallouhi', 'Affiliation': 'Department of Neurology, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Saver', 'Affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, California.'}, {'ForeName': 'Nestor R', 'Initials': 'NR', 'LastName': 'Gonzalez', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California.'}]",Neurosurgery,['10.1093/neuros/nyaa563'] 890,33446608,Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial.,"BACKGROUND Adjunctive intravenous corticosteroid treatment has been shown to reduce length of stay (LOS) in adults hospitalised with community-acquired pneumonia (CAP). We aimed to assess the effect of oral dexamethasone on LOS and whether this effect is disease severity dependent. METHODS In this multicentre, stratified randomised, double-blind, placebo-controlled trial, immunocompetent adults with CAP were randomly assigned (1:1 ratio) to receive oral dexamethasone (6 mg once daily) or placebo for 4 days in four teaching hospitals in the Netherlands. Randomisation (blocks of four) was stratified by CAP severity (pneumonia severity index class I-III and IV-V). The primary outcome was LOS. RESULTS Between December 2012 and November 2018, 401 patients were randomised to receive dexamethasone (n=203) or placebo (n=198). Median LOS was shorter in the dexamethasone group (4.5 days, 95% CI 4.0-5.0 days) than in the placebo group (5.0 days, 95% CI 4.6-5.4 days; p=0.033). Within both CAP severity subgroups, differences in LOS between treatment groups were not statistically significant. The secondary ICU admission rate was lower in the dexamethasone arm (5 (3%) versus 14 (7%); p=0.030); 30-day mortality did not differ between groups. In the dexamethasone group the rate of hospital readmission tended to be higher (20 (10%) versus 9 (5%); p=0.051) and hyperglycaemia (14 (7%) versus 1 (1%); p=0.001) was more prevalent. CONCLUSION Oral dexamethasone reduced LOS and ICU admission rate in adults hospitalised with CAP. It remains unclear for which patients the risk-benefit ratio is optimal.",2021,"Secondary ICU admission rate was lower in the dexamethasone arm (5 (3%) versus 14 (7%), p=0.030), 30-day mortality did not differ between groups.","['401 patients', 'Between December 2012 and November 2018', 'adults hospitalised with community-acquired pneumonia (CAP', 'immunocompetent adults with CAP', 'adults hospitalised with CAP', 'non-ICU patients hospitalised with community-acquired pneumonia']","['oral dexamethasone', 'placebo', 'dexamethasone']","['Median LOS', 'LOS and ICU admission rate', 'hyperglycaemia', '30-day mortality', 'LOS', 'rate of hospital readmission', 'length of stay (LOS', 'Secondary ICU admission rate', 'CAP severity (pneumonia severity index class']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]","[{'cui': 'C0360528', 'cui_str': 'Dexamethasone-containing product in oral dose form'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1321595', 'cui_str': 'Pneumonia severity index'}, {'cui': 'C0456387', 'cui_str': 'Class'}]",401.0,0.811254,"Secondary ICU admission rate was lower in the dexamethasone arm (5 (3%) versus 14 (7%), p=0.030), 30-day mortality did not differ between groups.","[{'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Wittermans', 'Affiliation': 'Dept of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands e.wittermans@antoniusziekenhuis.nl.'}, {'ForeName': 'Stefan M T', 'Initials': 'SMT', 'LastName': 'Vestjens', 'Affiliation': 'Dept of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands.'}, {'ForeName': 'Simone M C', 'Initials': 'SMC', 'LastName': 'Spoorenberg', 'Affiliation': 'Dept of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands.'}, {'ForeName': 'Willem L', 'Initials': 'WL', 'LastName': 'Blok', 'Affiliation': 'Dept of Internal Medicine, OLVG, Amsterdam, The Netherlands.'}, {'ForeName': 'Jan C', 'Initials': 'JC', 'LastName': 'Grutters', 'Affiliation': 'Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Janssen', 'Affiliation': 'Dept of Pulmonology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.'}, {'ForeName': 'Ger T', 'Initials': 'GT', 'LastName': 'Rijkers', 'Affiliation': 'Dept of Science, University College Roosevelt, Middelburg, The Netherlands.'}, {'ForeName': 'Frank W J M', 'Initials': 'FWJM', 'LastName': 'Smeenk', 'Affiliation': 'Dept of Pulmonology, Catharina Hospital, Eindhoven, The Netherlands.'}, {'ForeName': 'G Paul', 'Initials': 'GP', 'LastName': 'Voorn', 'Affiliation': 'Dept of Medical Microbiology and Immunology, St Antonius Hospital, Nieuwegein, The Netherlands.'}, {'ForeName': 'Ewoudt M W', 'Initials': 'EMW', 'LastName': 'van de Garde', 'Affiliation': 'Dept of Clinical Pharmacology, St Antonius Hospital, Nieuwegein, The Netherlands.'}, {'ForeName': 'Willem Jan W', 'Initials': 'WJW', 'LastName': 'Bos', 'Affiliation': 'Dept of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The European respiratory journal,['10.1183/13993003.02535-2020'] 891,33452288,Acquisition of concrete and abstract words is modulated by tDCS of Wernicke's area.,"Previous behavioural and neuroimaging research suggested distinct cortical systems involved in processing abstract and concrete semantics; however, there is a dearth of causal evidence to support this. To address this, we applied anodal, cathodal, or sham (placebo) tDCS over Wernicke's area before a session of contextual learning of novel concrete and abstract words (n = 10 each), presented five times in short stories. Learning effects were assessed at lexical and semantic levels immediately after the training and, to attest any consolidation effects of overnight sleep, on the next day. We observed successful learning of all items immediately after the session, with decreased performance in Day 2 assessment. Importantly, the results differed between stimulation conditions and tasks. Whereas the accuracy of semantic judgement for abstract words was significantly lower in the sham and anodal groups on Day 2 vs. Day 1, no significant performance drop was observed in the cathodal group. Similarly, the cathodal group showed no significant overnight performance reduction in the free recall task for either of the stimuli, unlike the other two groups. Furthermore, between-group analysis showed an overall better performance of both tDCS groups over the sham group, particularly expressed for abstract semantics and cathodal stimulation. In sum, the results suggest overlapping but diverging brain mechanisms for concrete and abstract semantics and indicate a larger degree of involvement of core language areas in storing abstract knowledge. Furthermore, they demonstrate a possiblity to improve learning outcomes using neuromodulatory techniques.",2021,"Whereas the accuracy of semantic judgement for abstract words was significantly lower in the sham and anodal groups on Day 2 vs. Day 1, no significant performance drop was observed in the cathodal group.",[],"['anodal, cathodal, or sham (placebo) tDCS']","['learning outcomes', 'accuracy of semantic judgement for abstract words', 'Learning effects']",[],"[{'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0036612', 'cui_str': 'Semantics'}, {'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0000857', 'cui_str': 'Abstracting as Topic'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.0289542,"Whereas the accuracy of semantic judgement for abstract words was significantly lower in the sham and anodal groups on Day 2 vs. Day 1, no significant performance drop was observed in the cathodal group.","[{'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Kurmakaeva', 'Affiliation': 'Laboratory of Behavioural Neurodynamics, Saint Petersburg University, Saint Petersburg, 199004, Russian Federation. diana.s-pb@mail.ru.'}, {'ForeName': 'Evgeny', 'Initials': 'E', 'LastName': 'Blagovechtchenski', 'Affiliation': 'Laboratory of Behavioural Neurodynamics, Saint Petersburg University, Saint Petersburg, 199004, Russian Federation.'}, {'ForeName': 'Daria', 'Initials': 'D', 'LastName': 'Gnedykh', 'Affiliation': 'Laboratory of Behavioural Neurodynamics, Saint Petersburg University, Saint Petersburg, 199004, Russian Federation.'}, {'ForeName': 'Nadezhda', 'Initials': 'N', 'LastName': 'Mkrtychian', 'Affiliation': 'Laboratory of Behavioural Neurodynamics, Saint Petersburg University, Saint Petersburg, 199004, Russian Federation.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Kostromina', 'Affiliation': 'Laboratory of Behavioural Neurodynamics, Saint Petersburg University, Saint Petersburg, 199004, Russian Federation.'}, {'ForeName': 'Yury', 'Initials': 'Y', 'LastName': 'Shtyrov', 'Affiliation': 'Laboratory of Behavioural Neurodynamics, Saint Petersburg University, Saint Petersburg, 199004, Russian Federation.'}]",Scientific reports,['10.1038/s41598-020-79967-8'] 892,33496536,The Efficacy of Intraoperative Freehand Erector Spinae Plane Block in Lumbar Spondylolisthesis: A Randomized Controlled Study.,"STUDY DESIGN Prospective randomized comparative (controlled) study. OBJECTIVE Management of the severe postoperative back pain followed the major spinal surgeries remains a challenge. The search is going on to find simple, efficient, and reliable perioperative analgesia with low side effects. We aimed to investigate the efficacy of intraoperative freehand erector spinae plane block (ESBP) after spinal surgeries. SUMMARY OF BACKGROUND DATA A few case reports and randomized controlled studies demonstrated the analgesic efficacy of ESPB in spinal surgeries. Up-to-date, no randomized controlled studies investigated the effectiveness of ESPB on spinal instrumentation surgeries. METHODS We randomly divided 56 consecutive adult patients who underwent posterior spinal instrumentation and fusion for spondylolisthesis into two groups. The study (ESPB) group (n = 28) received intraoperative freehand bilateral ESPB with a 20-mL mixture solution of 0.25% bupivacaine and 1.0% lidocaine equally divided into all operating levels. In the control group (n = 28), 20 mL physiological saline was injected. Postoperatively, we ordered 1 g paracetamol thrice/day, besides patient-controlled analgesia pumps with morphine. We performed a postoperative evaluation with a visual analog scale (VAS), morphine consumption, ESPB-related adverse effects, and postoperative length of hospital stay (PLOS). RESULTS Morphine consumption was significantly higher in the controls within the first postoperative 24-hour 44.75 ± 12.3 mg versus 33.75 ± 6.81 mg in the ESPB participants (P < 0.001). Except for postoperative 24th-hour VAS (P = 0.127), all postoperative VAS scores recorded at all time-points were significantly higher in the controls (P < 0.05). In control individuals, the first analgesic demand time was shorter, and PLOS was longer (P < 0.001). Patient satisfaction was significantly higher in the ESPB group. We observed no significant difference regarding postoperative complications. CONCLUSION Intraoperative ESPB as a part of multimodal analgesia was effective. For posterior instrumented patients with spondylolisthesis, it can relieve postoperative backache and reduce opioid consumption.Level of Evidence: 1.",2021,"In control individuals, the first analgesic demand time was shorter, and PLOS was longer (p < 0.001).","['Lumbar Spondylolisthesis', 'randomly divided fifty-six consecutive adult patients who underwent', 'For posterior instrumented patients with spondylolisthesis']","['Intraoperative Freehand Erector Spinae Plane Block', 'morphine', 'intraoperative freehand erector spinae plane block (ESBP', 'intraoperative freehand bilateral ESPB with a 20\u200aml mixture solution of 0.25% bupivacaine and 1.0% lidocaine', 'ESPB', 'posterior spinal instrumentation and fusion for spondylolisthesis']","['postoperative 24th-hour VAS', 'Morphine consumption', 'visual analog scale (VAS), morphine consumption, ESPB-related adverse effects, and postoperative length of hospital stay (PLOS', 'analgesic demand time', 'Patient satisfaction', 'Level of Evidence', 'postoperative backache and reduce opioid consumption', 'postoperative VAS scores']","[{'cui': 'C0746025', 'cui_str': 'Lumbar spondylolisthesis'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0038016', 'cui_str': 'Spondylolisthesis'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0589058', 'cui_str': 'Posterior spinal instrumentation'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0038016', 'cui_str': 'Spondylolisthesis'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",56.0,0.110671,"In control individuals, the first analgesic demand time was shorter, and PLOS was longer (p < 0.001).","[{'ForeName': 'Serdar', 'Initials': 'S', 'LastName': 'Yeşiltaş', 'Affiliation': 'Department of Anesthesiology and Reanimation, Bezmialem Vakif University, Istanbul, Turkey.'}, {'ForeName': 'Anas', 'Initials': 'A', 'LastName': 'Abdallah', 'Affiliation': 'Department of Neurosurgery, Private Aile Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ömer', 'Initials': 'Ö', 'LastName': 'Uysal', 'Affiliation': 'Department of Biostatistics, Bezmialem Vakif University, Istanbul, Turkey.'}, {'ForeName': 'Sinan', 'Initials': 'S', 'LastName': 'Yilmaz', 'Affiliation': 'Department of Anesthesiology and Reanimation, Bezmialem Vakif University, Istanbul, Turkey.'}, {'ForeName': 'İrfan', 'Initials': 'İ', 'LastName': 'Çinar', 'Affiliation': 'Department of Neurosurgery, Private Aile Hospital, Istanbul, Turkey.'}, {'ForeName': 'Kazim', 'Initials': 'K', 'LastName': 'Karaaslan', 'Affiliation': 'Department of Anesthesiology and Reanimation, Bezmialem Vakif University, Istanbul, Turkey.'}]",Spine,['10.1097/BRS.0000000000003966'] 893,33500169,Abdominal Surgical Patients Randomized to Aromatherapy for Pain Management.,"PURPOSE Evaluate aromatherapy for postoperative abdominal pain in hospitalized patients. DESIGN A randomized controlled trial design. METHODS Study participants (n = 172) were randomized to receive either standard care or standard care and aromatherapy (AT) for postsurgical pain up to 24 hours after admission to a nonintensive care surgical unit. A convenience sample was recruited before surgery and given instructions on self-rating pain intensity. The AT group was topically administered a drop of lavender essential oil after medication and at random for pain. Pain scores and medications data were collected. FINDINGS Of the evaluable patients (n = 147), demographic data were similar (standard care and AT groups). The use of aromatherapy showed no substantial benefit at improving pain scores or reducing medication use (the primary objectives of the study). A subgroup analysis of patients who received a regional nerve block for pain management, however, showed more than fivefold improvement in pain scores after the use of aromatherapy. The AT group used more medications at baseline (P = .032), whereas 70% less medications were used (P = .031) by 24 hours. CONCLUSIONS Aromatherapy aided in control of pain intensity for abdominal surgical patients. In patients who received a regional nerve block, significant improvement in pain level occurred as effects of the block diminished.",2021,"The AT group used more medications at baseline (P = .032), whereas 70% less medications were used (P = .031) by 24 hours. ","['abdominal surgical patients', 'hospitalized patients', 'Study participants (n\xa0= 172', 'evaluable patients (n\xa0= 147']","['Aromatherapy', 'lavender essential oil', 'aromatherapy', 'standard care or standard care and aromatherapy (AT']","['pain level', 'pain intensity', 'pain scores', 'Pain scores and medications data']","[{'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517601', 'cui_str': '172'}]","[{'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0524903', 'cui_str': 'Lavender'}, {'cui': 'C0028910', 'cui_str': 'Volatile oil'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",172.0,0.115016,"The AT group used more medications at baseline (P = .032), whereas 70% less medications were used (P = .031) by 24 hours. ","[{'ForeName': 'Lois M', 'Initials': 'LM', 'LastName': 'Stallings Welden', 'Affiliation': 'Deaconess Health System, Interprofessional Development and Nursing Quality, Evansville, IN. Electronic address: lois.welden@deaconess.com.'}, {'ForeName': 'Pam', 'Initials': 'P', 'LastName': 'Leatherland', 'Affiliation': 'Deaconess Health System, Surgical Medical Care Center, Evansville, IN.'}, {'ForeName': 'Mary B', 'Initials': 'MB', 'LastName': 'Schitter', 'Affiliation': 'Deaconess Health System, Surgical Medical Care Center, Evansville, IN.'}, {'ForeName': 'Andee', 'Initials': 'A', 'LastName': 'Givens', 'Affiliation': 'Deaconess Health System, Surgical Medical Care Center, Evansville, IN.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Stallings', 'Affiliation': 'Data InDeed, LLC, Frederick, MD.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.08.005'] 894,33507574,Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension.,"Combined teriparatide and denosumab rapidly and substantially increases bone mineral density (BMD) at all anatomic sites. Discontinuation of denosumab however, results in high-turnover bone loss and increased fracture risk. The optimal way to prevent this bone loss remains undefined. This study is a preplanned extension of the DATA-HD study, where postmenopausal women with osteoporosis were randomized to receive 9 months of either 20 μg or 40 μg of teriparatide daily overlapping with denosumab (60 mg administered at months 3 and 9). At the completion of this 15-month study, women were invited to enroll in the DATA-HD Extension where they received a single dose of zoledronic acid (5 mg) 24 to 35 weeks after the last denosumab dose. Areal BMD and bone turnover markers were measured at month 27 and 42 (12 and 27 months after zoledronic acid, respectively) and spine and hip volumetric bone density by quantitative CT was measured at month 42. Fifty-three women enrolled in the DATA-HD Extension. At the femoral neck and total hip, the mean 5.6% and 5.1% gains in BMD achieved from month 0 to 15 were maintained both 12 and 27 months after zoledronic acid administration. At the spine, the mean 13.6% gain in BMD achieved from month 0 to 15 was maintained for the first 12 months but modestly decreased thereafter, resulting in a 3.0% reduction (95% CI, -4.0% to -2.0%, p < .0001) 27 months after zoledronic acid. The pattern of BMD changes between months 15 and 42 were qualitatively similar in the 20-μg and 40-μg groups. A single dose of zoledronic acid effectively maintains the large and rapid total hip and femoral neck BMD increases achieved with combination teriparatide/denosumab therapy for at least 27 months following the transition. Spine BMD was also largely, though not fully, maintained during this period. These data suggest that the DATA-HD Extension regimen may be an effective strategy in the long-term management of patients at high risk of fragility fracture. © 2021 American Society for Bone and Mineral Research (ASBMR).",2021,Combined teriparatide and denosumab rapidly and substantially increases bone mineral density (BMD) at all anatomic sites.,"['Fifty-three women enrolled in the DATA-HD Extension', 'postmenopausal women with osteoporosis']","['20-μg or 40-μg of teriparatide daily overlapping with denosumab', 'Zoledronic Acid', 'Combined teriparatide and denosumab', 'denosumab', 'zoledronic acid']","['fracture risk', 'BMD', 'spine and hip volumetric bone density by quantitative CT', 'Areal BMD and bone turnover markers', 'large and rapid total hip and femoral neck BMD', 'Maintaining Areal and Volumetric Bone Density', 'BMD changes', 'Spine BMD', 'bone mineral density (BMD']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}]","[{'cui': 'C0070093', 'cui_str': 'Teriparatide'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0185027', 'cui_str': 'Imbrication'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0445383', 'cui_str': 'Volumetric'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",53.0,0.0662527,Combined teriparatide and denosumab rapidly and substantially increases bone mineral density (BMD) at all anatomic sites.,"[{'ForeName': 'Sabashini K', 'Initials': 'SK', 'LastName': 'Ramchand', 'Affiliation': 'Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.'}, {'ForeName': 'Natalie L', 'Initials': 'NL', 'LastName': 'David', 'Affiliation': 'Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Lee', 'Affiliation': 'Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Eastell', 'Affiliation': 'Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Joy N', 'Initials': 'JN', 'LastName': 'Tsai', 'Affiliation': 'Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.'}, {'ForeName': 'Benjamin Z', 'Initials': 'BZ', 'LastName': 'Leder', 'Affiliation': 'Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.4259'] 895,33465768,Treatment with Diazepam in Acute Stroke Prevents Poststroke Seizures: A Substudy of the EGASIS Trial.,"OBJECTIVE The frequency of seizures after stroke is high, with a severe impact on the quality of life. However, little is known about their prevention. Therefore, we investigated whether early administration of diazepam prevents the development of seizures in acute stroke patients. METHODS We performed a substudy of the EGASIS trial, a multicenter double-blind, randomized trial in which acute stroke patients were treated with diazepam or placebo for 3 days. Follow-up was after 2 weeks and 3 months. The occurrence of seizures was registered prospectively as one of the prespecified secondary outcomes. RESULTS 784 EGASIS patients were eligible for this substudy (389 treated with diazepam [49.6%] and 395 treated with placebo [50.4%]). Seizures were reported in 19 patients (2.4% of the total patient group). Seizures occurred less frequently in patients treated with diazepam (1.5 vs. 3.3% in the placebo group); however, this difference was only statistically significant in patients with a cortical anterior circulation infarction (0.9% in the diazepam group vs. 4.6% in the placebo group, incidence rate ratio 0.20, 95% CI: 0.05-0.78, p = 0.02, NNT = 27). CONCLUSION We found that a 3-day treatment with diazepam after acute cortical anterior circulation stroke prevents the occurrence of seizures in the first 3 months following stroke.",2021,"Seizures occurred less frequently in patients treated with diazepam (1.5 vs. 3.3% in the placebo group); however, this difference was only statistically significant in patients with a cortical anterior circulation infarction (0.9% in the diazepam group vs. 4.6% in the placebo group, incidence rate ratio 0.20, 95% CI: 0.05-0.78, p = 0.02, NNT = 27). ","['784 EGASIS patients were eligible for this substudy (389 treated with', 'acute stroke patients']","['diazepam or placebo', 'diazepam', 'placebo', 'Diazepam']","['Poststroke Seizures', 'Seizures', 'cortical anterior circulation infarction', 'occurrence of seizures']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517752', 'cui_str': '389'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}]","[{'cui': 'C0012010', 'cui_str': 'Diazepam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}]",784.0,0.633547,"Seizures occurred less frequently in patients treated with diazepam (1.5 vs. 3.3% in the placebo group); however, this difference was only statistically significant in patients with a cortical anterior circulation infarction (0.9% in the diazepam group vs. 4.6% in the placebo group, incidence rate ratio 0.20, 95% CI: 0.05-0.78, p = 0.02, NNT = 27). ","[{'ForeName': 'Julia H', 'Initials': 'JH', 'LastName': 'van Tuijl', 'Affiliation': 'Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Elisabeth P M', 'Initials': 'EPM', 'LastName': 'van Raak', 'Affiliation': 'Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'van Oostenbrugge', 'Affiliation': 'Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Albert P', 'Initials': 'AP', 'LastName': 'Aldenkamp', 'Affiliation': 'Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Rob P W', 'Initials': 'RPW', 'LastName': 'Rouhl', 'Affiliation': 'Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands, R.Rouhl@mumc.nl.'}]","Cerebrovascular diseases (Basel, Switzerland)",['10.1159/000512799'] 896,33475935,The Effect of Whole Body Vibration on Postural Control of Ataxic Patients: a Randomized Controlled Cross-Over Study.,"Whole body vibration (WBV) applications have been used in recent years to increase muscle strength, power, and postural control in healthy and various disease populations. This study aims to investigate the effects of WBV on postural control in patients with ataxia. Twenty-four patients were randomly allocated to two groups. In the first group, whole body vibration and exercise therapy (WBV + E) were applied together for the first 8 weeks; after 1 week washout, only exercise program (OE) was applied for the second 8 weeks. In the second group, the OE program was applied first followed by the WBV + E program. Outcome measures were Sensory Organization Test (SOT), Adaptation Test (ADT), Limits of Stability Test (LOS), International Classification Ataxia Ratio Scale (ICARS), Berg Balance Scale (BBS), and Timed Up and Go Test with cognitive task (TUG-C). Twenty patients (mean age ± SD, 34.00 ± 9.16 years) completed the study. The scores of SOT, ICARS, and BBS improved significantly after both OE and WBV + E program (p < 0.05). Improvements in the WBV + E program were higher (p < 0.05). The scores of ADT, TUG-C, and three parameters of LOS improved significantly after WBV + E (p < 0.05), while there was no significant change after OE (p > 0.05). This study demonstrated that exercise programs supported by WBV can play an important role in the improvement of all components of postural control in patients with ataxia. ClinicalTrial.gov Identifier: NCT02977377.",2021,"The scores of SOT, ICARS, and BBS improved significantly after both OE and WBV + E program (p < 0.05).","['patients with ataxia', 'healthy and various disease populations', 'Twenty-four patients', 'Twenty patients (mean age ± SD, 34.00\u2009±\u20099.16\xa0years) completed the study', 'Ataxic Patients']","['Whole Body Vibration', 'whole body vibration and exercise therapy (WBV + E', 'WBV']","['scores of ADT, TUG-C, and three parameters of LOS', 'scores of SOT, ICARS, and BBS', 'Sensory Organization Test (SOT), Adaptation Test (ADT), Limits of Stability Test (LOS), International Classification Ataxia Ratio Scale (ICARS), Berg Balance Scale (BBS), and Timed Up and Go Test with cognitive task (TUG-C']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004134', 'cui_str': 'Ataxia'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0234366', 'cui_str': 'Ataxic'}]","[{'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C4720873', 'cui_str': 'Sensory organization test'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0004134', 'cui_str': 'Ataxia'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}]",24.0,0.00828802,"The scores of SOT, ICARS, and BBS improved significantly after both OE and WBV + E program (p < 0.05).","[{'ForeName': 'Ender', 'Initials': 'E', 'LastName': 'Ayvat', 'Affiliation': 'Faculty of Physical Therapy and Rehabilitation, Hacettepe University, 06100, Ankara, Turkey.'}, {'ForeName': 'Muhammed', 'Initials': 'M', 'LastName': 'Kılınç', 'Affiliation': 'Faculty of Physical Therapy and Rehabilitation, Hacettepe University, 06100, Ankara, Turkey.'}, {'ForeName': 'Fatma', 'Initials': 'F', 'LastName': 'Ayvat', 'Affiliation': 'Faculty of Physical Therapy and Rehabilitation, Hacettepe University, 06100, Ankara, Turkey.'}, {'ForeName': 'Özge', 'Initials': 'Ö', 'LastName': 'Onursal Kılınç', 'Affiliation': 'Faculty of Physical Therapy and Rehabilitation, Hacettepe University, 06100, Ankara, Turkey. ozgeonursal@hotmail.com.'}, {'ForeName': 'Sibel', 'Initials': 'S', 'LastName': 'Aksu Yıldırım', 'Affiliation': 'Faculty of Physical Therapy and Rehabilitation, Hacettepe University, 06100, Ankara, Turkey.'}]","Cerebellum (London, England)",['10.1007/s12311-021-01233-y'] 897,33475577,Outcomes of extra oral versus intraoral approach for Mandibular angle fracture reduction.,"OBJECTIVE To compare the outcomes of intraoral versus extraoral approach in the treatment of mandibular angle fracture. Methods The randomised controlled trail was conducted at the Department of Maxillofacial Surgery, Mayo Hospital, Lahore Pakistan, from September 2016 to March 2017, and comprised patients of mandibular angle fracture who were divided into two equal extraoral group A and intraoral group B. . Baseline and post-operative data on 1st and 7th days as well as 3 months following the surgery was collected. Data was analysed using SPSS 20. RESULTS Of the 100 patients, there were 50(50%) in each of the two groups. Mean age of group A was 32.28±7.79 years compared to 33.72±8.13 years in group B. There were 39 (78%) males in group A and 36(72%) in group B. The mean pain score at baseline in the groups was not significantly different (p=0.795). On the 7th day and 3 months post-operation, mean pain score was significantly lower in group A (p=0.002). Nerve complication in group A was significantly high compared to group A (p=0.005). CONCLUSIONS Extra oral approach for the management of mandibular angle fracture is better with regards to pain while intra-oral approach is less associated with nerve complications.",2020,The mean pain score at baseline in the groups was not significantly different (p=0.795).,"['Department of Maxillofacial Surgery, Mayo Hospital, Lahore Pakistan, from September 2016 to March 2017, and comprised patients of mandibular angle fracture', 'Mandibular angle fracture reduction', '100 patients']","['extra oral versus intraoral approach', 'intraoral versus extraoral approach']","['mean pain score', 'Nerve complication']","[{'cui': 'C0038908', 'cui_str': 'Oral surgery'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0016641', 'cui_str': 'Fixation of fracture'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0442119', 'cui_str': 'Intraoral approach'}, {'cui': 'C0442089', 'cui_str': 'Extraoral approach'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.042317,The mean pain score at baseline in the groups was not significantly different (p=0.795).,"[{'ForeName': 'Yasir', 'Initials': 'Y', 'LastName': 'Bilal', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, King Edward Medical University, Mayo Hospital, Lahore, Pakistan.'}, {'ForeName': 'Ashfaq Ur', 'Initials': 'AU', 'LastName': 'Rahim', 'Affiliation': 'Department of Maxillofacial Surgery, The University of Lahore. Pakistan.'}, {'ForeName': 'Shazia Mahar', 'Initials': 'SM', 'LastName': 'Gul', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, King Edward Medical University, Mayo Hospital, Lahore, Pakistan.'}, {'ForeName': 'Riaz Ahmed', 'Initials': 'RA', 'LastName': 'Warraich', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Mayo Hospital, Lahore, Pakistan.'}]",JPMA. The Journal of the Pakistan Medical Association,['10.47391/JPMA.673'] 898,33509602,"Effect of Different Tourniquet Pressure on Postoperative Pain and Complications After Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial.","BACKGROUND Tourniquet pressure inflation is commonly selected between 100 and 150 mm Hg above the systolic blood pressure (SBP). Given the lack of evidence to support a given inflation pressure, our study aimed to ascertain the lowest tourniquet pressure that facilitated total knee arthroplasty (TKA) and resulted in the least postoperative pain and complications. METHODS In a double-blind, randomized controlled trial of patients scheduled for unilateral primary TKA, 150 were assigned to use tourniquet pressures of SBP + 75 mm Hg (group I), SBP + 100 mm Hg (group II), and SBP + 150 mm Hg (group III). The quality of the bloodless field, total blood loss, and limb swelling were determined perioperatively. Clinical outcomes were evaluated by visual analog scale for pain at thigh and surgical site, serum creatinine phosphokinase levels, wound complications, range of motion, and Knee Society Score. RESULTS Visual analog scale for pain at thigh and surgical site were lowest in group I (P < .01) and highest in group III (P < .01). However, the quality of bloodless field at the tibial cutting surface was significantly better in group III compared to group I/II but not at the femoral cutting surface. The total blood loss and limb swelling showed no difference among 3 groups. Postoperative serum creatinine phosphokinase levels at 24 and 48 hours and wound complications in group III were significantly higher than group I (P < .01) and group II (P < .01). Nevertheless, postoperative knee range of motion and Knee Society Score were not significantly different among 3 groups. CONCLUSION Post TKA, the lowest tourniquet pressure was associated with significantly less postoperative tourniquet and surgical site pain, muscle damage, and wound complications.",2021,Postoperative serum creatinine phosphokinase levels at 24 and 48 hours and wound complications in group III were significantly higher than group I (P < .01) and group II (P < .01).,"['After Total Knee Arthroplasty', 'patients scheduled for unilateral primary TKA, 150 were assigned to use']","['tourniquet pressures of SBP\xa0+ 75 mm Hg', 'SBP\xa0+ 100 mm Hg (group II), and SBP\xa0+ 150 mm Hg', 'Tourniquet Pressure']","['quality of bloodless field at the tibial cutting surface', 'postoperative knee range of motion and Knee Society Score', 'total blood loss and limb swelling', 'postoperative tourniquet and surgical site pain, muscle damage, and wound complications', 'Postoperative Pain and Complications', 'quality of the bloodless field, total blood loss, and limb swelling', 'systolic blood pressure (SBP', 'wound complications', 'lowest tourniquet pressure', 'Visual analog scale for pain at thigh and surgical site', 'Postoperative serum creatinine phosphokinase levels', 'visual analog scale for pain at thigh and surgical site, serum creatinine phosphokinase levels, wound complications, range of motion, and Knee Society Score']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4321486', 'cui_str': '150'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0576094', 'cui_str': 'Knee joint - range of movement'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0232100', 'cui_str': 'Exsanguination'}, {'cui': 'C0158369', 'cui_str': 'Swelling of limb'}, {'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0332850', 'cui_str': 'Operative site'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}]",150.0,0.085044,Postoperative serum creatinine phosphokinase levels at 24 and 48 hours and wound complications in group III were significantly higher than group I (P < .01) and group II (P < .01).,"[{'ForeName': 'Piya', 'Initials': 'P', 'LastName': 'Pinsornsak', 'Affiliation': 'Department of Orthopaedic Surgery, Thammasat University, Pathum Thani, Bangkok, Thailand.'}, {'ForeName': 'Punnawit', 'Initials': 'P', 'LastName': 'Pinitchanon', 'Affiliation': 'Department of Orthopaedic Surgery, Thammasat University, Pathum Thani, Bangkok, Thailand.'}, {'ForeName': 'Krit', 'Initials': 'K', 'LastName': 'Boontanapibul', 'Affiliation': 'Department of Orthopaedic Surgery, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Bangkok, Thailand.'}]",The Journal of arthroplasty,['10.1016/j.arth.2020.12.049'] 899,33514869,Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury.,"BACKGROUND The present study aims to investigate the effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury. METHODS In a double-blind randomized controlled trial, 158 recruited alcoholic liver injury patients were randomized to three treatments for 60 days: low-dose group (LP, n = 58, 100 ml of Lactobacillus casei strain Shirota (LcS)), high-dose group (HP, n = 54, 200 ml of LcS), and positive control group (PC, n = 46, 100 ml of special drinks without active Lactobacillus casei). Another group of 20 healthy people was served as normal control group (NC). RESULTS The serum levels of TG and LDLC in the HP group were significantly decreased by 26.56% and 23.83%, respectively than those in the PC group (P < 0.05). After supplementation of Lactobacillus casei, there was a significant increase in the amount of Lactobacillus and Bifidobacterium when compared with the PC group (P < 0.05). CONCLUSIONS Supplementation of Lactobacillus casei can improve lipid metabolism and regulate intestinal flora disorders in patients with alcoholic liver injury.",2021,"After supplementation of Lactobacillus casei, there was a significant increase in the amount of Lactobacillus and Bifidobacterium when compared with the PC group (P < 0.05). ","['20 healthy people', 'patients with alcoholic liver injury', '158 recruited alcoholic liver injury patients']","['Lactobacillus casei', 'low-dose group (LP, n\u2009=\u200958, 100\u2009ml of Lactobacillus casei strain Shirota (LcS)), high-dose group (HP, n\u2009=\u200954, 200\u2009ml of LcS), and positive control group (PC, n\u2009=\u200946, 100\u2009ml of special drinks without active Lactobacillus casei', 'normal control group (NC']","['serum levels of TG and LDLC', 'lipid metabolism', 'amount of Lactobacillus and Bifidobacterium', 'lipid metabolism and intestinal microflora']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687725', 'cui_str': 'Problem drinker'}, {'cui': 'C0160390', 'cui_str': 'Injury of liver'}]","[{'cui': 'C0022940', 'cui_str': 'Lactobacillus casei'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0268314', 'cui_str': 'Cholestasis-edema syndrome, Norwegian type'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205307', 'cui_str': 'Normal'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}]",158.0,0.0615718,"After supplementation of Lactobacillus casei, there was a significant increase in the amount of Lactobacillus and Bifidobacterium when compared with the PC group (P < 0.05). ","[{'ForeName': 'Xuelong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Human Nutrition, College of Public Health, Qingdao University, 38 Dengzhou Road, Qingdao, 266021, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Basic Medical College, Qingdao University of Medicine, 308 Ningxia Road, Qingdao, 266071, China.'}, {'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Department of Human Nutrition, College of Public Health, Qingdao University, 38 Dengzhou Road, Qingdao, 266021, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'Department of Human Nutrition, College of Public Health, Qingdao University, 38 Dengzhou Road, Qingdao, 266021, China.'}, {'ForeName': 'Huaqi', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Human Nutrition, College of Public Health, Qingdao University, 38 Dengzhou Road, Qingdao, 266021, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Liang', 'Affiliation': 'Department of Human Nutrition, College of Public Health, Qingdao University, 38 Dengzhou Road, Qingdao, 266021, China. qdlianghui@qdu.edu.cn.'}]",European journal of clinical nutrition,['10.1038/s41430-020-00852-8'] 900,33467421,Effects of 4-Week Inspiratory Muscle Training on Sport Performance in College 800-Meter Track Runners.,"Background and objectives: Respiratory muscle fatigue is one of the important factors limiting sports performance due to the metaboreflex. This reflex will cause a decrease in blood flow to the extremities and accelerate exercising limb fatigue. Previous studies found that inspiratory muscle training (IMT) can effectively enhance the respiratory muscle endurance and reduce fatigue during long-duration exercise or aerobic exercise, thereby enhancing athletic performance. However, the mechanism between inspiratory muscle strength, change of limb blood flow and sports performance still requires investigation, especially in short-duration exercise, anaerobic or both aerobic and anaerobic exercise. The purpose of this study was to investigate the effects of 4-week inspiratory muscle training on respiratory muscle strength, limb blood flow change rate and sports performance in recreational 800-m college runners. Materials and Methods: Twenty healthy 800-m college runners randomized into the IMT group (11 subjects) and control group (9 subjects). IMT consisted of 30 inspiratory efforts twice daily, 5 days a week, with intensity at 50%, 60%, 70% and 80% of maximum inspiratory pressure (MIP) for 4 weeks, while a control group kept 50% of MIP for 4 weeks. An 800-m trial test, limb blood flow change rate by using Impedance Plethysmography, and MIP were as the outcome measured variables and be evaluated. All measured variables were assessed before and after 4-week IMT training. Two-way ANOVA was conducted for statistical analysis. Results: The results showed significantly interaction between groups and pre-posttest. IMT group significantly decreased limb blood flow change rate from 19.91 ± 11.65% to 9.63 ± 7.62% after received the IMT training program ( p < 0.05). The MIP significantly improved from 112.95 ± 27.13 cmH 2 O to 131.09 ± 28.20 cm H 2 O in IMT group, and the 800-m trial test also shorted the running time from 162.97 ± 24.96 s to 156.75 ± 20.73 s. But the control group no significantly changed in MIP and 800-m trial test. Conclusions: Our results indicated that the 4-week IMT training (twice a day, 5 days a week) significantly improves participants' inspiratory muscle strength, 800-m running performance and decreases the limb blood flow change rate.",2021,IMT group significantly decreased limb blood flow change rate from 19.91 ± 11.65% to 9.63 ± 7.62% after received the IMT training program ( p < 0.05).,"['recreational 800-m college runners', 'College 800-Meter Track Runners', 'Twenty healthy 800-m college runners']","['4-Week Inspiratory Muscle Training', 'IMT', 'IMT training', 'inspiratory muscle training (IMT', '4-week inspiratory muscle training']","['Sport Performance', 'limb blood flow change rate by using Impedance Plethysmography, and MIP', 'respiratory muscle strength, limb blood flow change rate and sports performance', ""participants' inspiratory muscle strength, 800-m running performance"", 'blood flow', 'MIP', 'limb blood flow change rate']","[{'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C0040594', 'cui_str': 'Track'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C0334121', 'cui_str': 'Inflammatory myofibroblastic tumor'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0871966', 'cui_str': 'Sports Performance'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0032222', 'cui_str': 'Impedance plethysmography'}, {'cui': 'C0376579', 'cui_str': 'Macrophage Inflammatory Proteins'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",30.0,0.0277533,IMT group significantly decreased limb blood flow change rate from 19.91 ± 11.65% to 9.63 ± 7.62% after received the IMT training program ( p < 0.05).,"[{'ForeName': 'Yun-Chi', 'Initials': 'YC', 'LastName': 'Chang', 'Affiliation': 'Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei 112, Taiwan.'}, {'ForeName': 'Hsiao-Yun', 'Initials': 'HY', 'LastName': 'Chang', 'Affiliation': 'Department of Athletic Training and Health, National Taiwan Sport University, Taoyuan 333, Taiwan.'}, {'ForeName': 'Chien-Chang', 'Initials': 'CC', 'LastName': 'Ho', 'Affiliation': 'Department of Physical Education, Fu Jen Catholic University, New Taipei City 242, Taiwan.'}, {'ForeName': 'Po-Fu', 'Initials': 'PF', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Education, Fu Jen Catholic University, New Taipei City 242, Taiwan.'}, {'ForeName': 'Yi-Chen', 'Initials': 'YC', 'LastName': 'Chou', 'Affiliation': 'Physical Education Office, National Tsing Hua University, Hsinchu City 300, Taiwan.'}, {'ForeName': 'Mei-Wun', 'Initials': 'MW', 'LastName': 'Tsai', 'Affiliation': 'Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei 112, Taiwan.'}, {'ForeName': 'Li-Wei', 'Initials': 'LW', 'LastName': 'Chou', 'Affiliation': 'Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei 112, Taiwan.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina57010072'] 901,33474952,Application of a new drainage plug for large mandibular cysts after fenestration decompression.,"BACKGROUND In order to improve the postoperative decompression and drainage of large mandibular cysts after fenestration decompression, a new drainage plug was designed and its feasibility for clinical application was explored. METHODS A total of 74 patients with large mandibular cysts requiring fenestration decompression were included and randomly divided into the control group (n=34) and model group (n=40). Patients in the control group were given a conventional plug, while patients in the model group were given the new silicone drainage plug. The drainage plug mold was printed using 3D printing technology. Subsequently, the mold was filled with silicone material and the drainage tube was placed into the mold to make a drainage plug. The clinical effect of the new drainage plug was assessed, and the postoperative recovery time was compared between the 2 groups. RESULTS In the model group, the average wear time of the new drainage plug was approximately 13 months. Compared with the control group, the course of treatment in the model group was shortened by approximately 5 months, with a better fit, less food debris, and easier installation and removal. CONCLUSIONS The new drainage plug provides more convenience and better prognosis for patients after fenestration decompression, and holds great promise for clinical application.",2021,"Compared with the control group, the course of treatment in the model group was shortened by approximately 5 months, with a better fit, less food debris, and easier installation and removal. ","['74 patients with large mandibular cysts requiring fenestration decompression', 'large mandibular cysts after fenestration decompression']","['new silicone drainage plug', 'conventional plug']","['average wear time of the new drainage plug', 'postoperative recovery time', 'food debris, and easier installation and removal']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0010709', 'cui_str': 'Cyst'}, {'cui': 'C0015825', 'cui_str': 'Inner ear fenestration'}, {'cui': 'C0011117', 'cui_str': 'Decompression'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0037114', 'cui_str': 'Silicones'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0182324', 'cui_str': 'Plug'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0182324', 'cui_str': 'Plug'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0440266', 'cui_str': 'Debris'}, {'cui': 'C0332219', 'cui_str': 'Easy'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]",74.0,0.0240135,"Compared with the control group, the course of treatment in the model group was shortened by approximately 5 months, with a better fit, less food debris, and easier installation and removal. ","[{'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Prosthodontics, The Affiliated Stomatological Hospital of Nanchang University, Nanchang, China; The Key Laboratory of Oral Biomedicine, Nanchang, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Pei', 'Affiliation': 'The Key Laboratory of Oral Biomedicine, Nanchang, China; Department of Oral Pathology, The Affiliated Stomatological Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Huang', 'Affiliation': 'Department of Prosthodontics, The Affiliated Stomatological Hospital of Nanchang University, Nanchang, China; The Key Laboratory of Oral Biomedicine, Nanchang, China.'}, {'ForeName': 'Wenwei', 'Initials': 'W', 'LastName': 'Lian', 'Affiliation': 'Department of Prosthodontics, The Affiliated Stomatological Hospital of Nanchang University, Nanchang, China; The Key Laboratory of Oral Biomedicine, Nanchang, China. Email: Lianwenwei1967@126.com.'}]",Annals of palliative medicine,['10.21037/apm-20-2464'] 902,33464732,"A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease.","INTRODUCTION Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live biotherapeutic, under development for Crohn's disease, that antagonizes transcription factor nuclear factor kappa B, reducing proinflammatory cytokines, particularly tumor necrosis factor alpha. We aimed to assess safety and tolerability in adolescents with Crohn's disease in remission. METHODS Subjects who were 16-18 years with Crohn's in remission (weighted pediatric Crohn's disease activity index <12.5) were recruited. Each active dose comprised ∼108.2±1.4 colony forming units of B. thetaiotaomicron (randomized 4:1 active:placebo). Part A was single dose. Part B involved 7.5 days twice daily dosing. Serial stools were analyzed for calprotectin, 16S rRNA sequencing, and B. thetaiotaomicron real-time polymerase chain reaction. Bloods were taken serially. Subjects reported adverse events and recorded temperature twice daily. RESULTS Fifteen subjects were treated-8 in part A (75% men, median 17.1 years) and 10 in part B, including 3 from part A (80% men, median 17.1 years); all 18 completed. Seventy percent took concurrent immunosuppression. Reported compliance was >99% in part B. Two subjects reported adverse events deemed related-one in part A with eructation, flatulence, and reflux; one in part B with dizziness, abdominal pain, and headache. No serious adverse events were reported. There was no significant change in median calprotectin across part B (87.8 [4.4-447] to 50.5 [5.3-572], P = 0.44 by the Fisher exact test in the active group). No significant differences were found in microbiota profiles, but diversity seemed to increase in treated subjects. DISCUSSION Thetanix, after single and multiple doses, was well tolerated. Although the numbers in this study were small, the safety profile seems good. Future studies should explore efficacy.",2020,"There was no significant change in median calprotectin across part B (87.8 [4.4-447] to 50.5 [5.3-572], P = 0.44 by the Fisher exact test in the active group).","['Fifteen subjects were treated-8 in part A (75% men, median 17.1 years) and 10 in part B, including 3 from part A (80% men, median 17.1 years); all 18 completed', ""adolescents with Crohn's disease in remission"", ""Adolescent Crohn's Disease"", ""Subjects who were 16-18 years with Crohn's in remission (weighted pediatric Crohn's disease activity index <12.5) were recruited""]","['Thetanix) Bacteroides thetaiotaomicron', 'Placebo', 'Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron', 'placebo']","['median calprotectin', 'serious adverse events', 'safety and tolerability', 'microbiota profiles', 'dizziness, abdominal pain, and headache', 'adverse events and recorded temperature twice daily', 'tolerated', 'Safety and Tolerability']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1960764', 'cui_str': ""Crohn's disease in remission""}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C2931133', 'cui_str': ""Pediatric Crohn's disease""}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C4517544', 'cui_str': '12.5'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0950624', 'cui_str': 'Calprotectin'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]",15.0,0.125548,"There was no significant change in median calprotectin across part B (87.8 [4.4-447] to 50.5 [5.3-572], P = 0.44 by the Fisher exact test in the active group).","[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Hansen', 'Affiliation': 'Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.'}, {'ForeName': 'Ian R', 'Initials': 'IR', 'LastName': 'Sanderson', 'Affiliation': 'Blizard Institute, Queen Mary University of London, London, UK.'}, {'ForeName': 'Rafeeq', 'Initials': 'R', 'LastName': 'Muhammed', 'Affiliation': ""Paediatric Gastroenterology, Birmingham Children's Hospital, Birmingham, UK.""}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Allen', 'Affiliation': 'Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Tzivinikos', 'Affiliation': ""Paediatric Gastroenterology, Alder Hey Children's Hospital, Liverpool, UK.""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Henderson', 'Affiliation': 'Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Gervais', 'Affiliation': 'Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.'}, {'ForeName': 'Ian B', 'Initials': 'IB', 'LastName': 'Jeffery', 'Affiliation': '4D pharma Cork Limited, University College Cork, Cork, Ireland.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Mullins', 'Affiliation': '4D pharma Cork Limited, University College Cork, Cork, Ireland.'}, {'ForeName': 'Eileen A', 'Initials': 'EA', 'LastName': ""O'Herlihy"", 'Affiliation': '4D pharma Cork Limited, University College Cork, Cork, Ireland.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Weinberg', 'Affiliation': '4D pharma, Leeds, UK.'}, {'ForeName': 'Geoff', 'Initials': 'G', 'LastName': 'Kitson', 'Affiliation': 'ProPharma Partners Limited, Horsham, UK.'}, {'ForeName': 'Richard K', 'Initials': 'RK', 'LastName': 'Russell', 'Affiliation': 'Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, UK.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Wilson', 'Affiliation': 'Child Life and Health, University of Edinburgh, Edinburgh, UK.'}]",Clinical and translational gastroenterology,['10.14309/ctg.0000000000000287'] 903,33478652,Compression Garment Reduces Orthostatic Tachycardia and Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome.,"BACKGROUND Postural orthostatic tachycardia syndrome (POTS) is a chronic form of orthostatic intolerance associated with a significant symptom burden. Compression garments are a frequently prescribed treatment, but the effectiveness of waist-high compression has not been evaluated in adults with POTS. OBJECTIVES This study evaluated compression garments as a treatment for POTS using a head-up tilt test (HUT), and a noninflatable core and lower body compression garment. METHODS Thirty participants completed 10-min HUT with each of 4 compression conditions in a randomized crossover design. The conditions were no compression (NONE), lower leg compression (LEG), abdominal/thigh compression (ABDO), and full abdominal/leg compression (FULL). Heart rate, beat-to-beat blood pressure, and Vanderbilt Orthostatic Symptom Score ratings were measured during each HUT. RESULTS The compression garment reduced heart rate (NONE: 109 ± 19 beats/min; LEG: 103 ± 16 beats/min; ABDO: 97 ± 15 beats/min; FULL: 92 ± 14 beats/min; p < 0.001) and improved symptoms (p < 0.001) during HUT in a dose-dependent manner. During HUT, stroke volume and systolic blood pressure were better maintained with FULL and ABDO compression compared with LEG and NONE compression. CONCLUSIONS Abdominal and lower body compression reduced heart rate and improved symptoms during HUT in adult patients with POTS. These effects were driven by improved stroke volume with compression. Abdominal compression alone might also provide a clinical benefit if full lower body compression is not well tolerated. (Hemodynamic Effects of Compression in POTS; NCT03484273).",2021,"During HUT, stroke volume and systolic blood pressure were better maintained with FULL and ABDO compression compared with LEG and NONE compression. ","['adult patients with POTS', 'Thirty participants completed 10-min HUT with each of 4 compression conditions', 'adults with POTS', 'Patients With Postural Orthostatic Tachycardia Syndrome']",['Compression Garment'],"['heart rate', 'Orthostatic Tachycardia and Symptoms', 'During HUT, stroke volume and systolic blood pressure', 'improved symptoms', 'no compression (NONE), lower leg compression (LEG), abdominal/thigh compression (ABDO), and full abdominal/leg compression (FULL', 'Heart rate, beat-to-beat blood pressure, and Vanderbilt Orthostatic Symptom Score ratings']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299624', 'cui_str': 'Postural orthostatic tachycardia syndrome'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1293898', 'cui_str': 'Head up'}, {'cui': 'C0242880', 'cui_str': 'Tilt table test'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C2985539', 'cui_str': 'Compression garment'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1293898', 'cui_str': 'Head up'}, {'cui': 'C0242880', 'cui_str': 'Tilt table test'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0230446', 'cui_str': 'Both lower legs'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",30.0,0.0581545,"During HUT, stroke volume and systolic blood pressure were better maintained with FULL and ABDO compression compared with LEG and NONE compression. ","[{'ForeName': 'Kate M', 'Initials': 'KM', 'LastName': 'Bourne', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Sheldon', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Hall', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Lloyd', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Kogut', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Nasia', 'Initials': 'N', 'LastName': 'Sheikh', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Juliana', 'Initials': 'J', 'LastName': 'Jorge', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Ng', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Derek V', 'Initials': 'DV', 'LastName': 'Exner', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'John V', 'Initials': 'JV', 'LastName': 'Tyberg', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Satish R', 'Initials': 'SR', 'LastName': 'Raj', 'Affiliation': 'Department of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada. Electronic address: Satish.raj@ucalgary.ca.'}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2020.11.040'] 904,33501773,Parental decision making regarding consent to randomization on Children's Oncology Group AALL0932.,"BACKGROUND Within pediatric oncology, parental decision making regarding participation in clinical trials that aim to reduce therapy to mitigate side effects is not well studied. The recently completed Children's Oncology Group trial for standard-risk acute lymphoblastic leukemia (AALL0932) included a reduction in maintenance therapy, and required consent for randomization immediately prior to starting maintenance. At our institution, 40% of children enrolled on AALL0932 were withdrawn from protocol therapy prior to randomization due to parental choice. This study sought to identify factors that impacted parental decision making regarding randomization on AALL0932. PROCEDURE Parents of children enrolled on AALL0932 at our institution were eligible if their child met criteria for the average-risk randomization. Parents were invited to participate in a 30-50-minute phone interview. Questions focused on factors that shaped parental decision making about randomization, as well as their perspectives about the clinical trial experience more generally. RESULTS Fear of receiving less therapy and subsequent relapse was the predominant reason to decline randomization. Reasons given for consenting to randomization included trust in the physician, altruism, hope for less therapy, and potential for fewer side effects. Parents also reflected on ways to support future families making decisions about clinical trial participation. CONCLUSION While many parents recognize the importance of clinical trials aiming to mitigate side effects, the fear of their own child relapsing with less than standard therapy may dissuade them from study participation. Recognizing and addressing these concerns will be important for enrollment and retention in future clinical trials.",2021,"The recently completed Children's Oncology Group trial for standard-risk acute lymphoblastic leukemia (AALL0932) included a reduction in maintenance therapy, and required consent for randomization immediately prior to starting maintenance.",['Parents of children enrolled on AALL0932 at our institution were eligible if their child met criteria for the average-risk randomization'],['AALL0932'],[],"[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]",[],[],,0.0357326,"The recently completed Children's Oncology Group trial for standard-risk acute lymphoblastic leukemia (AALL0932) included a reduction in maintenance therapy, and required consent for randomization immediately prior to starting maintenance.","[{'ForeName': 'Kellee', 'Initials': 'K', 'LastName': 'Parker', 'Affiliation': 'Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Cottrell', 'Affiliation': 'Oregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, Oregon.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Stork', 'Affiliation': 'Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Lindemulder', 'Affiliation': 'Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.'}]",Pediatric blood & cancer,['10.1002/pbc.28907'] 905,33512412,Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group.,"Survivors of Hodgkin lymphoma (HL) have an increased risk of subsequent malignant neoplasms (SMNs). Response-adapted treatment may decrease this risk by reducing exposure to therapy associated with SMN risk. The Children's Oncology Group study AHOD0031 evaluated response-adapted therapy for children and adolescents with intermediate-risk HL. We report the SMNs among 1711 patients enrolled in AHOD0031. Patients were treated with 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide with or without involved-field radiation therapy (RT). Patients with a slow early response to initial chemotherapy were randomized to 2 additional cycles of dexamethasone, etoposide, cisplatin and cytarabine or no additional chemotherapy, and all received RT. At a median follow-up of 7.3 years, an analysis of SMNs was performed. The 10-year cumulative incidence of SMN was 1.3% (95% confidence interval [CI], 0.6-2.0). SMNs included 3 patients with acute myeloid leukemia (AML), 11 with solid tumors, and 3 with non-Hodgkin lymphoma. Sixteen of 17 patients with an SMN had received combined modality therapy. The standardized incidence ratio for SMN was 9.5 (95% CI, 4.5-15.2) with an excess absolute risk of 1.2 per 1000 person-years. The cumulative incidence of SMNs was higher among patients who received RT (P = .037). In multivariate analysis, RT, B symptoms, and race were associated with SMN risk. Given the latency from exposure, we have likely captured all cases of secondary leukemia and myelodysplastic syndrome (MDS). Longer follow-up is needed to determine the risk of solid tumors. Avoidance of RT without sacrificing disease control should remain a goal for future therapeutic approaches. This trial was registered at www.clinicaltrials.gov as #NCT00025259.",2021,"The standardized incidence ratio for SMN was 9.5 (95% CI 4.5-15.2) with an excess absolute risk of 1.2 per 1,000 person-years.","['children with Hodgkin lymphoma', 'Sixteen of 17 patients with an', 'Survivors of Hodgkin lymphoma (HL', '3 patients with AML, 11 with solid tumors, and 3 with non-Hodgkin lymphoma', '1,711 patients enrolled on AHOD0031', 'children and adolescents with intermediate-risk HL', 'Patients with a slow early response to initial chemotherapy']","['doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide with or without involved field radiation therapy (RT', 'dexamethasone, etoposide, cisplatin and cytarabine or no additional chemotherapy, and all received RT', 'combined modality therapy', 'SMN']","['standardized incidence ratio for SMN', 'cumulative incidence of SMNs', '10-year cumulative incidence of SMN']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0019829', 'cui_str': 'Hodgkin lymphoma'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0024305', 'cui_str': 'Malignant lymphoma, non-Hodgkin'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0005740', 'cui_str': 'Bleomycin'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0163617', 'cui_str': 'SNRPN'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0163617', 'cui_str': 'SNRPN'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0439234', 'cui_str': 'year'}]",3.0,0.0446326,"The standardized incidence ratio for SMN was 9.5 (95% CI 4.5-15.2) with an excess absolute risk of 1.2 per 1,000 person-years.","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Giulino-Roth', 'Affiliation': 'Department of Pediatrics, Weill Cornell Medical College, New York, NY.'}, {'ForeName': 'Qinglin', 'Initials': 'Q', 'LastName': 'Pei', 'Affiliation': 'Department of Biostatistics, University of Florida, Gainesville, FL.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Buxton', 'Affiliation': ""Children's Oncology Group Statistics and Data Center, Monrovia, CA.""}, {'ForeName': 'Rizvan', 'Initials': 'R', 'LastName': 'Bush', 'Affiliation': ""Children's Oncology Group Statistics and Data Center, Monrovia, CA.""}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Biostatistics, University of Florida, Gainesville, FL.'}, {'ForeName': 'Suzanne L', 'Initials': 'SL', 'LastName': 'Wolden', 'Affiliation': 'Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Louis S', 'Initials': 'LS', 'LastName': 'Constine', 'Affiliation': 'Department of Radiation Oncology and.'}, {'ForeName': 'Kara M', 'Initials': 'KM', 'LastName': 'Kelly', 'Affiliation': 'Department of Pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY.'}, {'ForeName': 'Cindy L', 'Initials': 'CL', 'LastName': 'Schwartz', 'Affiliation': 'Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Debra L', 'Initials': 'DL', 'LastName': 'Friedman', 'Affiliation': 'Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; and.'}]",Blood,['10.1182/blood.2020007225'] 906,33515093,Sleep and physical activity in healthy 8-9-year-old children are affected by oily fish consumption in the FiSK Junior randomized trial.,"PURPOSE Studies indicate that long-chain n-3 PUFA (n-3LCPUFA) affect sleep and physical activity (PA) in childhood. However, few studies used objective tools and none studies examined the effect of fish per se. We aimed to explore if fish consumption affected sleep and PA assessed by accelerometry in children, and if effects were modified by sex. METHODS In a randomized 12-week trial, 199 healthy 8-9-year-old children received ~ 300 g/week of oily fish or poultry. Sleep and PA were pre-specified explorative outcomes examined by accelerometers that the children wore on their hip for 7 days at baseline and endpoint, while parents registered sleep. Compliance was verified by erythrocyte n-3LCPUFA. RESULTS The children slept 9.4 ± 0.5 h/night but the sleep duration variability across the week was 6.0 (95%CI: 0.8, 11.1) min lower in the fish vs poultry group. Furthermore, children in the fish group exhibited increased spare time sedentary activity [9.4 (95%CI: 1.8, 16.9) min/day] at the expense of light PA [- 8.2 (95%CI: - 14.4, - 2.0) min/day]. These effects were supported by dose-dependency with n-3LCPUFA. Additionally, latency to sleep onset was reduced by 3.6 (95%CI: 1.0, 6.3) min on weekends and moderate-vigorous PA during school hours was 3.5 (95%CI: 0.1, 6.8) min longer in fish vs poultry. P values for sex interactions were all > 0.05 but the effects tended to be most pronounced on sleep in girls and PA in boys. CONCLUSION Oily fish intake altered sleep and PA patterns among healthy schoolchildren, with some slight indications of sex differences. These findings warrant further investigation. CLINICAL TRIAL REGISTRY At clinicaltrials.gov (NCT02809508) and a published protocol in Trials [Damsgaard et al. in Trials, 2016].",2021,"P values for sex interactions were all > 0.05 but the effects tended to be most pronounced on sleep in girls and PA in boys. ","['199 healthy 8-9-year-old children received', 'healthy schoolchildren', 'healthy 8-9-year-old children', 'childhood']","['long-chain n-3 PUFA (n-3LCPUFA', '\u2009300\xa0g/week of oily fish or poultry']","['sleep and PA patterns', 'sleep and physical activity (PA', 'Sleep and physical activity', 'spare time sedentary activity', 'latency to sleep onset', 'sleep duration variability']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0556978', 'cui_str': 'g/week'}, {'cui': 'C0453017', 'cui_str': 'Fatty fish'}, {'cui': 'C0032850', 'cui_str': 'Fowls, Domestic'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}]",199.0,0.11266,"P values for sex interactions were all > 0.05 but the effects tended to be most pronounced on sleep in girls and PA in boys. ","[{'ForeName': 'Stine', 'Initials': 'S', 'LastName': 'Vuholm', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Marie N', 'Initials': 'MN', 'LastName': 'Teisen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Mølgaard', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Lotte', 'Initials': 'L', 'LastName': 'Lauritzen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg C, Denmark. ll@nexs.ku.dk.'}, {'ForeName': 'Camilla T', 'Initials': 'CT', 'LastName': 'Damsgaard', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg C, Denmark.'}]",European journal of nutrition,['10.1007/s00394-021-02490-7'] 907,33515092,"Co-ingestion of NUTRALYS ® pea protein and a high-carbohydrate beverage influences the glycaemic, insulinaemic, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) responses: preliminary results of a randomised controlled trial.","PURPOSE Plant-based proteins may have the potential to improve glycaemic and gastrointestinal hormone responses to foods and beverages. The aim of this study was to investigate the effect of two doses of pea protein on postprandial glycaemic, insulinaemic, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) response following a high-carbohydrate beverage intake in healthy individuals. METHODS In a single-blind, randomised, controlled, repeat measure, crossover design trial, thirty-one participants were randomly assigned to ingest 50 g glucose (Control), 50 g glucose with 25 g pea protein (Test 1) and 50 g glucose with 50 g pea protein (Test 2) on three separate days. Capillary blood samples (blood glucose and plasma insulin measurements) and venous blood samples (GIP and GLP-1 concentrations) were taken before each test and at fixed intervals for 180 min. The data were compared using repeated-measures ANOVA or the Friedman test. RESULTS Glucose incremental Area under the Curve (iAUC180) was significantly lower (p < 0.001) after Test 2 compared with Control (- 53%), after Test 1 compared with Control (- 31%) and after Test 2 compared with Test 1 (-32%). Insulin iAUC 180 was significantly higher (p < 0.001) for Test 1 (+ 28%) and Test 2 (+ 40%) compared with Control and for Test 2 (+ 17%) compared with Test 1 (p = 0.003). GIP and GLP-1 release showed no clear difference between Control and Pea protein drinks. CONCLUSION The consumption of pea protein reduced postprandial glycaemia and stimulated insulin release in healthy adults with a dose-response effect, supporting its role in regulating glycaemic and insulinaemic responses.",2021,"The consumption of pea protein reduced postprandial glycaemia and stimulated insulin release in healthy adults with a dose-response effect, supporting its role in regulating glycaemic and insulinaemic responses.","['healthy individuals', 'healthy adults']","['ingest 50\xa0g glucose (Control), 50\xa0g glucose with 25\xa0g pea protein (Test 1) and 50\xa0g glucose with 50\xa0g pea protein', 'pea protein']","['Glucose incremental Area under the Curve (iAUC180', 'glycaemic, insulinaemic, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1', 'postprandial glycaemic, insulinaemic, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1', 'Capillary blood samples (blood glucose and plasma insulin measurements) and venous blood samples (GIP and GLP-1 concentrations']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0456638', 'cui_str': '25G'}, {'cui': 'C3535674', 'cui_str': 'Pea Proteins'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0419342', 'cui_str': 'Capillary specimen collection'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C1276042', 'cui_str': 'Plasma insulin measurement'}, {'cui': 'C0444255', 'cui_str': 'Venous blood specimen'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",31.0,0.0537322,"The consumption of pea protein reduced postprandial glycaemia and stimulated insulin release in healthy adults with a dose-response effect, supporting its role in regulating glycaemic and insulinaemic responses.","[{'ForeName': 'Pariyarath Sangeetha', 'Initials': 'PS', 'LastName': 'Thondre', 'Affiliation': 'Oxford Brookes Centre for Nutrition and Health, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK. pthondre@brookes.ac.uk.'}, {'ForeName': 'Ifunanya', 'Initials': 'I', 'LastName': 'Achebe', 'Affiliation': 'Oxford Brookes Centre for Nutrition and Health, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK.'}, {'ForeName': 'Alistair', 'Initials': 'A', 'LastName': 'Sampson', 'Affiliation': 'Oxford Brookes Centre for Nutrition and Health, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK.'}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Maher', 'Affiliation': 'Oxford Brookes Centre for Nutrition and Health, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK.'}, {'ForeName': 'Laetitia', 'Initials': 'L', 'LastName': 'Guérin-Deremaux', 'Affiliation': 'Nutrition and Health R&D, Roquette Frères, Rue de la Haute Loge, 62180, Lestrem, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Lefranc-Millot', 'Affiliation': 'Nutrition and Health R&D, Roquette Frères, Rue de la Haute Loge, 62180, Lestrem, France.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Ahlström', 'Affiliation': 'Oxford Brookes Centre for Nutrition and Health, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Lightowler', 'Affiliation': 'Oxford Brookes Centre for Nutrition and Health, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK.'}]",European journal of nutrition,['10.1007/s00394-021-02481-8'] 908,33496831,Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling.,"In postmenopausal osteoporotic women in ACTIVE, abaloparatide reduced fracture risk and increased areal bone mineral density (BMD) more than teriparatide at the hip and wrist. DXA-based 3D modeling showed significantly greater increases in hip cortical volumetric BMD with abaloparatide versus teriparatide. This may explain differences reported in aBMD by DXA. INTRODUCTION In ACTIVE, abaloparatide (ABL) increased bone mineral density (BMD) shown by dual-energy X-ray absorptiometry (DXA) while reducing fracture incidence in postmenopausal osteoporotic women. Changes in DXA BMD with ABL, 80 μg, were significantly greater than with open-label teriparatide (TPTD), 20 μg, at cortical sites including total hip, femoral neck, and 1/3 distal radius. The purpose of this study was to better understand the relative effects of ABL and TPTD on cortical and cancellous compartments in the proximal femur. METHODS Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18. RESULTS Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months. In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD. In the TPTD group, changes in cortical vBMD were inversely correlated with changes in serum CTX (carboxy-terminal telopeptide of type I collagen) and PINP (procollagen type I N-terminal propeptide), suggesting that higher bone turnover may have attenuated cortical gains. CONCLUSION These results suggest previously reported differences in areal BMD increases between ABL and TPTD may be due to differential effects on cortical vBMD. Further studies are warranted to investigate how these differences affect therapeutic impact on hip strength in postmenopausal women with osteoporosis.",2021,"In postmenopausal osteoporotic women in ACTIVE, abaloparatide reduced fracture risk and increased areal bone mineral density (BMD) more than teriparatide at the hip and wrist.","['postmenopausal osteoporotic women', 'postmenopausal women with osteoporosis', 'Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm']","['ABL and TPTD', 'teriparatide', 'abaloparatide and teriparatide', 'PINP (procollagen type', 'open-label teriparatide (TPTD', 'dual-energy X-ray absorptiometry (DXA']","['hip cortical volumetric BMD', 'areal BMD', 'trabecular volumetric BMD (vBMD, + 9%) and cortical thickness', 'areal bone mineral density (BMD', 'cortical vBMD and cortical surface BMD', 'bone mineral density (BMD', 'cortical vBMD', 'serum CTX (carboxy-terminal telopeptide of type']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C4042342', 'cui_str': 'abaloparatide'}, {'cui': 'C0070093', 'cui_str': 'Teriparatide'}, {'cui': 'C0072053', 'cui_str': 'Procollagen peptide, type 1 N-terminal'}, {'cui': 'C0033235', 'cui_str': 'Procollagen'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}]","[{'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0445383', 'cui_str': 'Volumetric'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]",,0.0389859,"In postmenopausal osteoporotic women in ACTIVE, abaloparatide reduced fracture risk and increased areal bone mineral density (BMD) more than teriparatide at the hip and wrist.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Winzenrieth', 'Affiliation': 'Galgo Medical, Carrer de París, 179 2°, Barcelona, 08036, Spain.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Ominsky', 'Affiliation': 'Radius Health, Inc., 950 Winter Street, Waltham, MA, 02451, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Radius Health, Inc., 950 Winter Street, Waltham, MA, 02451, USA.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Humbert', 'Affiliation': 'Galgo Medical, Carrer de París, 179 2°, Barcelona, 08036, Spain.'}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Weiss', 'Affiliation': 'Radius Health, Inc., 950 Winter Street, Waltham, MA, 02451, USA. rweiss@radiuspharm.com.'}]",Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,['10.1007/s00198-020-05806-1'] 909,33502511,The Association Between Smoking Abstinence and Pain Trajectory Among Veterans Engaged in U.S. Department of Veterans Affairs Mental Health Care.,"OBJECTIVE To prospectively examine associations between smoking and nicotine abstinence and pain trajectory over 12 months among smokers with low, moderate, and severe pain and to assess whether these associations differ over time. DESIGN A secondary analysis of the ""Proactive Outreach for Smokers in VA Mental Health"" study, a randomized controlled trial of proactive outreach for veteran smokers engaged in U.S. Department of Veterans Affairs (VA) mental health care. METHODS Participants were categorized into ""low"" (n = 616), ""moderate"" (n = 479), and ""severe"" pain (n = 656) groups according to baseline pain score. Associations between self-reported abstinence from smoking and nicotine at 6 and 12 months and pain trajectory, measured via the PEG scale (Pain intensity, Enjoyment of life, General activity) composite score, were assessed through the use of general linear mixed models. Interaction tests assessed whether these associations differed at 6 and 12 months. Analyses were conducted within the overall sample and within the separate pain groups. RESULTS There were significant interactions in the overall sample and the low and moderate pain groups, such that 7-day point prevalence smoking abstinence was associated with lower pain scores at 6 but not 12 months. In the severe pain group, 7-day abstinence from both smoking and nicotine was associated with lower pain scores across both time points. Six-month prolonged abstinence was not associated with pain scores. CONCLUSIONS In this prospective analysis conducted among veteran smokers engaged in mental health services, 7-day abstinence from smoking and nicotine was associated with significantly lower levels of pain. Education efforts could help better inform smokers on the relationship between smoking and pain.",2021,"Six-month prolonged abstinence was not associated with pain scores. ","['veteran smokers engaged in VA mental health care', 'Veterans Engaged in VA Mental Health Care', 'smokers with low, moderate, and severe pain', 'Participants were categorized into ""low"" (n\u2009=\u2009616), ""moderate"" (n\u2009=\u2009479), and ""severe"" pain (n\u2009=\u2009656) groups according to baseline pain score']","['Proactive Outreach', 'proactive outreach']","['7-day point prevalence smoking abstinence', 'PEG scale (Pain intensity, Enjoyment of life, General activity) composite score', 'Smoking Abstinence and Pain Trajectory', 'levels of pain', 'pain scores']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0184643', 'cui_str': 'Mental health care'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0278140', 'cui_str': 'Severe pain'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",[],"[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0424131', 'cui_str': 'Enjoyment of life'}, {'cui': 'C0441655', 'cui_str': 'Activity'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",,0.0512167,"Six-month prolonged abstinence was not associated with pain scores. ","[{'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Hammett', 'Affiliation': 'VA HSR&D Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Businelle', 'Affiliation': 'Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.'}, {'ForeName': 'Brent C', 'Initials': 'BC', 'LastName': 'Taylor', 'Affiliation': 'VA HSR&D Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Erbes', 'Affiliation': 'VA HSR&D Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Bastian', 'Affiliation': 'VA Connecticut Healthcare System, West Haven, Connecticut.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Doran', 'Affiliation': 'VA San Diego Healthcare System, San Diego, California.'}, {'ForeName': 'Scott E', 'Initials': 'SE', 'LastName': 'Sherman', 'Affiliation': 'VA New York Harbor Healthcare System, New York.'}, {'ForeName': 'Erin S', 'Initials': 'ES', 'LastName': 'Rogers', 'Affiliation': 'VA New York Harbor Healthcare System, New York.'}, {'ForeName': 'Diana J', 'Initials': 'DJ', 'LastName': 'Burgess', 'Affiliation': 'VA HSR&D Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota.'}, {'ForeName': 'Steven S', 'Initials': 'SS', 'LastName': 'Fu', 'Affiliation': 'VA HSR&D Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnab009'] 910,33506965,Fish Oil Supplementation in Pregnancy and Neurodevelopment in Childhood-A Randomized Clinical Trial.,"A double-blind randomized controlled trial of n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation or matching placebo during third trimester of pregnancy was conducted within the COPSAC 2010 mother-child cohort consisting of 736 women and their children. The objective was to determine if maternal n-3 LCPUFA pregnancy supplementation affects offspring neurodevelopment until 6 years. Neurodevelopment was evaluated in 654 children assessing age of motor milestone achievement, language development, cognitive development, general neurodevelopment, and emotional and behavioral problems. Maternal n-3 LCPUFA supplementation during pregnancy improved early language development and reduced the impact of emotional and behavioral problems. The n-3 LCPUFA supplementation was in boys associated with the earlier achievement of gross motor milestones, improved cognitive development, and a reduced impact of emotional and behavioral problems.",2021,Maternal n-3 LCPUFA supplementation during pregnancy improved early language development and reduced the impact of emotional and behavioral problems.,"['during third trimester of pregnancy was conducted within the COPSAC 2010 mother-child cohort consisting of 736 women and their children', '654 children assessing age of']","['n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation or matching placebo', 'n-3 LCPUFA supplementation', 'Fish Oil Supplementation', 'maternal n-3 LCPUFA pregnancy supplementation', 'Maternal n-3 LCPUFA supplementation']","['motor milestone achievement, language development, cognitive development, general neurodevelopment, and emotional and behavioral problems']","[{'cui': 'C0032981', 'cui_str': 'Third trimester pregnancy'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0023013', 'cui_str': 'Language Development'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}]",654.0,0.448034,Maternal n-3 LCPUFA supplementation during pregnancy improved early language development and reduced the impact of emotional and behavioral problems.,"[{'ForeName': 'Laerke', 'Initials': 'L', 'LastName': 'Sass', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Elín', 'Initials': 'E', 'LastName': 'Bjarnadóttir', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Stokholm', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Chawes', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Rebecca K', 'Initials': 'RK', 'LastName': 'Vinding', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Anna-Rosa C', 'Initials': 'AC', 'LastName': 'Mora-Jensen', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Thorsen', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Noergaard', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Bjørn H', 'Initials': 'BH', 'LastName': 'Ebdrup', 'Affiliation': 'Copenhagen University Hospital.'}, {'ForeName': 'Jens R M', 'Initials': 'JRM', 'LastName': 'Jepsen', 'Affiliation': 'Copenhagen University Hospital.'}, {'ForeName': 'Birgitte', 'Initials': 'B', 'LastName': 'Fagerlund', 'Affiliation': 'Copenhagen University Hospital.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Bønnelykke', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Lotte', 'Initials': 'L', 'LastName': 'Lauritzen', 'Affiliation': 'University of Copenhagen.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Bisgaard', 'Affiliation': 'University of Copenhagen.'}]",Child development,['10.1111/cdev.13541'] 911,33509035,Aerobic exercise improves hippocampal blood flow for hypertensive Apolipoprotein E4 carriers.,"Cerebrovascular dysfunction likely contributes causally to Alzheimer's disease (AD). The strongest genetic risk factor for late-onset AD, Apolipoprotein E4 ( APOE4 ), may act synergistically with vascular risk to cause dementia. Therefore, interventions that improve vascular health, such as exercise, may be particularly beneficial for APOE4 carriers. We assigned cognitively normal adults (65-87 years) to an aerobic exercise intervention or education only. Arterial spin labeling MRI measured hippocampal blood flow (HBF) before and after the 52-week intervention. We selected participants with hypertension at enrollment (n = 44). For APOE4 carriers, change in HBF (ΔHBF) was significantly ( p  = 0.006) higher for participants in the exercise intervention (4.09 mL/100g/min) than the control group (-2.08 mL/100g/min). There was no difference in ΔHBF between the control (-0.32 mL/100g/min) and exercise (-0.54 mL/100g/min) groups for non-carriers (p = 0.918). Additionally, a multiple regression showed an interaction between change in systolic blood pressure (ΔSBP) and APOE4 carrier status on ΔHBF ( p  = 0.035), with reductions in SBP increasing HBF for APOE4 carriers only. Aerobic exercise improved HBF for hypertensive APOE4 carriers only. Additionally, only APOE4 carriers exhibited an inverse relationship between ΔSBP and ΔHBF. This suggests exercise interventions, particularly those that lower SBP, may be beneficial for individuals at highest genetic risk of AD. ClinicalTrials.gov Identifier : NCT02000583 .",2021,"For APOE4 carriers, change in HBF (ΔHBF) was significantly ( p  = 0.006) higher for participants in the exercise intervention (4.09 mL/100g/min) than the control group (-2.08 mL/100g/min).","['cognitively normal adults (65-87\u2009years', 'hypertensive Apolipoprotein E4 carriers', 'participants with hypertension at enrollment (n\u2009=\u200944']","['Aerobic exercise', 'aerobic exercise intervention or education only']","['ΔHBF', 'hippocampal blood flow', 'systolic blood pressure (ΔSBP) and APOE4 carrier status on ΔHBF', 'HBF (ΔHBF', 'Arterial spin labeling MRI measured hippocampal blood flow (HBF']","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0052201', 'cui_str': 'Apolipoprotein E4'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0052201', 'cui_str': 'Apolipoprotein E4'}, {'cui': 'C0449439', 'cui_str': 'Carrier status'}, {'cui': 'C0015936', 'cui_str': 'Hemoglobin F'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0831955,"For APOE4 carriers, change in HBF (ΔHBF) was significantly ( p  = 0.006) higher for participants in the exercise intervention (4.09 mL/100g/min) than the control group (-2.08 mL/100g/min).","[{'ForeName': 'Carolyn S', 'Initials': 'CS', 'LastName': 'Kaufman', 'Affiliation': 'Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Robyn A', 'Initials': 'RA', 'LastName': 'Honea', 'Affiliation': ""University of Kansas Alzheimer's Disease Center, Fairway, KS, USA.""}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Pleen', 'Affiliation': ""University of Kansas Alzheimer's Disease Center, Fairway, KS, USA.""}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Lepping', 'Affiliation': 'Hoglund Biomedical Imaging Center, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Watts', 'Affiliation': 'Department of Psychology, University of Kansas, Lawrence, KS, USA.'}, {'ForeName': 'Jill K', 'Initials': 'JK', 'LastName': 'Morris', 'Affiliation': ""University of Kansas Alzheimer's Disease Center, Fairway, KS, USA.""}, {'ForeName': 'Sandra A', 'Initials': 'SA', 'LastName': 'Billinger', 'Affiliation': 'Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Burns', 'Affiliation': ""University of Kansas Alzheimer's Disease Center, Fairway, KS, USA.""}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Vidoni', 'Affiliation': ""University of Kansas Alzheimer's Disease Center, Fairway, KS, USA.""}]",Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,['10.1177/0271678X21990342'] 912,33512942,"A Multicenter, Open-Label, Randomized Controlled Trial of a Conservative Fluid Management Strategy Compared With Usual Care in Participants After Cardiac Surgery: The Fluids After Bypass Study.","OBJECTIVES There is little evidence to guide fluid administration to patients admitted to the ICU following cardiac surgery. This study aimed to determine if a protocolized strategy known to reduce fluid administration when compared with usual care reduced ICU length of stay following cardiac surgery. DESIGN Prospective, multicenter, parallel-group, randomized clinical trial. SETTING Five cardiac surgical centers in New Zealand conducted from November 2016 to December 2018 with final follow-up completed in July 2019. PATIENTS Seven-hundred fifteen patients undergoing cardiac surgery; 358 intervention and 357 usual care. INTERVENTIONS Randomization to protocol-guided strategy utilizing stroke volume variation to guide administration of bolus fluid or usual care fluid administration until desedation or up to 24 hours. Primary outcome was length of stay in ICU. Organ dysfunction, mortality, process of care measures, patient-reported quality of life, and disability-free survival were collected up to day 180. MEASUREMENTS AND MAIN RESULTS Overall 666 of 715 (93.1%) received at least one fluid bolus. Patients in the intervention group received less bolus fluid (median [interquartile range], 1,000 mL [250-2,000 mL] vs 1,500 mL [500-2,500 mL]; p < 0.0001) and had a lower overall fluid balance (median [interquartile range], 319 mL [-284 to 1,274 mL] vs 673 mL [38-1,641 mL]; p < 0.0001) in the intervention period. There was no difference in ICU length of stay between the two groups (27.9 hr [21.8-53.5 hr] vs 25.6 hr [21.9-64.6 hr]; p = 0.95). There were no differences seen in development of organ dysfunction, quality of life, or disability-free survival at any time points. Hospital mortality was higher in the intervention group (4% vs 1.4%; p = 0.04). CONCLUSIONS A protocol-guided strategy utilizing stroke volume variation to guide administration of bolus fluid when compared with usual care until desedation or up to 24 hours reduced the amount of fluid administered but did not reduce the length of stay in ICU.",2021,"There were no differences seen in development of organ dysfunction, quality of life, or disability-free survival at any time points.","['Seven-hundred fifteen patients undergoing cardiac surgery; 358 intervention and 357 usual care', 'Participants', 'Five cardiac surgical centers in New Zealand conducted from November 2016 to December 2018 with final follow-up completed in July 2019']",['Conservative Fluid Management Strategy Compared With Usual Care'],"['Organ dysfunction, mortality, process of care measures, patient-reported quality of life, and disability-free survival', 'ICU length of stay', 'overall fluid balance', 'Hospital mortality', 'development of organ dysfunction, quality of life, or disability-free survival', 'length of stay in ICU']","[{'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0553741', 'cui_str': 'Fluid balance regulation'}]","[{'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0016284', 'cui_str': 'Fluid balance'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}]",715.0,0.298907,"There were no differences seen in development of organ dysfunction, quality of life, or disability-free survival at any time points.","[{'ForeName': 'Rachael L', 'Initials': 'RL', 'LastName': 'Parke', 'Affiliation': 'Cardiothoracic and Vascular ICU, Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Gilder', 'Affiliation': 'Cardiothoracic and Vascular ICU, Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Gillham', 'Affiliation': 'Cardiothoracic and Vascular ICU, Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'Laurence J C', 'Initials': 'LJC', 'LastName': 'Walker', 'Affiliation': 'Cardiothoracic and Vascular ICU, Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Bailey', 'Affiliation': 'ANZIC-Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Shay P', 'Initials': 'SP', 'LastName': 'McGuinness', 'Affiliation': 'Cardiothoracic and Vascular ICU, Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004883'] 913,33821935,"Prospective, Randomized, Comparative Study of the Cutaneous Effects of a Topical Body Treatment Compared to a Bland Moisturizer.","BACKGROUND Over time human skin thins and loses elasticity, and topical treatments attempt to reverse this process. OBJECTIVES Assess the efficacy of TransFORM Body Treatment (TFB) in skin rejuvenation compared to a bland moisturizer on the extensor and volar forearms. METHODS Blinded participants were given two products to apply on the designated forearms with follow-up at 4, 8 and 12 weeks. Measurements included skin thickness, photography, dermatopathology, cutaneous elasticity by two separate devices, and patient reported outcomes. All were compared to baseline. RESULTS Change in roughness: extensor -0.09 mm for bland moisturizer and -0.26 mm for TFB (P = 0.174); volar 0.01mm for bland moisturizer and -0.23 mm for TFB (P = 0.004). Change in recoil velocity: volar -56 degree/s for bland moisturizer and -24 degree/s for TFB (p = 0.61); extensor -95 degree/s for bland moisturizer and -63 degree/s for TFB (p = 0.57). Change in retraction speed: volar -3.25 ms for bland moisturizer and -20.08 ms for TFB (p = 0.33); extensor -2.17 ms for bland moisturizer and -10.83 ms for TFB (p = 0.66). Histology: TFB showed an increase in mucopolysaccharide content, new collagen and increase in elastin fibers in the papillary dermis. Change in Rao-Goldman score: volar -0.17 for bland moisturizer and -0.33 for TFB (p = 0.25); extensor -0.08 for bland moisturizer and -0.17 for TFB (p = 0.36). CONCLUSIONS Histology showed production of new collagen and elastin. Quantification of changes using skin thickness, skin retraction speed and skin recoil velocity showed trends that agree with the visual data.",2021,"TFB showed an increase in mucopolysaccharide content, new collagen and increase in elastin fibers in the papillary dermis.",['Histology'],"['TransFORM Body Treatment (TFB', 'TFB', 'Topical Body Treatment']","['skin thickness, skin retraction speed and skin recoil velocity', 'skin thickness, photography, dermatopathology, cutaneous elasticity', 'degree/s for TFB', 'mucopolysaccharide content, new collagen and increase in elastin fibers']","[{'cui': 'C0019638', 'cui_str': 'Histology'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332237', 'cui_str': 'Topical'}]","[{'cui': 'C0423756', 'cui_str': 'Thickness of skin'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0332523', 'cui_str': 'Retraction'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0031749', 'cui_str': 'Photography'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017973', 'cui_str': 'Mucopolysaccharide'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0230899', 'cui_str': 'Elastic fiber'}]",,0.0813113,"TFB showed an increase in mucopolysaccharide content, new collagen and increase in elastin fibers in the papillary dermis.","[{'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Carruthers', 'Affiliation': 'Carruthers Instruments Inc., Vancouver, BC, Canada.'}, {'ForeName': 'Gyasi', 'Initials': 'G', 'LastName': 'Bourne', 'Affiliation': 'Carruthers Instruments Inc., Vancouver, BC, Canada.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Bell', 'Affiliation': 'Alastin Skin Care Inc., Vancouver, BC, Canada.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Widgerow', 'Affiliation': 'Alastin Skin Care Inc., Vancouver, BC, Canada.'}]",Aesthetic surgery journal,['10.1093/asj/sjab161'] 914,33522102,Adaptive functioning and academic achievement in survivors of childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group.,"PURPOSE To characterize academic and adaptive skill outcomes in survivors of high-risk B-lineage acute lymphoblastic leukemia (HR B-ALL). METHODS Participants were 178 patients enrolled on a nontherapeutic clinical trial that aimed to characterize neurocognitive and functional outcomes (ie, academic achievement and adaptive skills) following treatment for childhood HR B-ALL. Eligible patients were treated on Children's Oncology Group AALL0232 clinical trial that included two treatment randomizations: methotrexate delivery (high or escalating dose) and corticosteroid (dexamethasone or prednisone). Academic achievement and adaptive skills were evaluated at one time point, 8-24 months after completing treatment. RESULTS Multivariable logistic regression showed no significant association between treatment variables and outcomes after accounting for age at diagnosis, sex, and insurance status. In multivariable analyses accounting for sex and insurance status, survivors <10 years old at diagnosis had significantly lower scores in Math (P = .02). In multivariable analyses accounting for sex and age at diagnosis, scores for children with US public health insurance were significantly lower than those with US private or military insurance across all academic and adaptive skills (all P-values ≤.04). Results from univariate analyses showed that boys had significantly lower scores than girls across all adaptive skill domains (all P-values ≤.04). CONCLUSION Regardless of treatment randomization, survivors of HR B-ALL <10 years at diagnosis are at risk for deficits in Math and overall adaptive functioning; overall adaptive skills for boys were significantly poorer. Screening and early intervention for patients at highest risk, particularly young patients and lower resourced families, should be prioritized.",2021,"Results from univariate analyses showed that boys had significantly lower scores than girls across all adaptive skill domains (all P-values ≤.04). ","['Participants were 178 patients enrolled on a nontherapeutic clinical trial that aimed to characterize neurocognitive and functional outcomes (ie, academic achievement and adaptive skills) following treatment for childhood HR B-ALL', 'survivors of high-risk B-lineage acute lymphoblastic leukemia (HR B-ALL', ""Eligible patients were treated on Children's Oncology Group AALL0232 clinical trial that included two treatment randomizations"", 'survivors of childhood acute lymphoblastic leukemia']",['methotrexate delivery (high or escalating dose) and corticosteroid (dexamethasone or prednisone'],"['Academic achievement and adaptive skills', 'Adaptive functioning and academic achievement']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0013658', 'cui_str': 'Educational achievement'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0023452', 'cui_str': 'Lymphoblastic Leukemia, Acute, Childhood'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C0013658', 'cui_str': 'Educational achievement'}]",178.0,0.0386604,"Results from univariate analyses showed that boys had significantly lower scores than girls across all adaptive skill domains (all P-values ≤.04). ","[{'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Jacola', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Baran', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Robert B', 'Initials': 'RB', 'LastName': 'Noll', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Victoria W', 'Initials': 'VW', 'LastName': 'Willard', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Kristina K', 'Initials': 'KK', 'LastName': 'Hardy', 'Affiliation': ""Children's National Hospital and the George Washington University School of Medicine, Washington, District of Columbia.""}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Embry', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Stephanie E', 'Initials': 'SE', 'LastName': 'Hullmann', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, Indiana.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'Larsen', 'Affiliation': ""Maine Children's Cancer Program, Scarborough, Maine.""}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Winick', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Kairalla', 'Affiliation': 'University of Florida Colleges of Medicine, Public Health and Health Professions, Gainesville, Florida.'}]",Pediatric blood & cancer,['10.1002/pbc.28913'] 915,33526372,The Effect on Pain and Anxiety of Hot Pad Applied to Patients During Transrectal Prostate Biopsy.,"AIM The aim of the study was to evaluate the effect of the application of a heating pad on the sacral region on pain and anxiety during a transrectal prostate biopsy. DESIGN This was a quasi-experimental study. METHODS The quasi-experimental study was conducted in the Urology Outpatient Clinic of a Training and Research Hospital in Istanbul. A total of 40 males were nonrandomly divided into two groups: experimental group (n = 20) and control group (n = 20). A heating pad (40-45°C) was applied to the sacral region of the patients in the experimental group during transrectal prostate biopsy. Data were collected using the Beck Anxiety Inventory (BAI) and visual analogue scale (VAS). RESULTS It was detected that the mean scores of the BAI were significantly lower in the experimental group compared with the control group (p < .001). The scores of the VAS were significantly lower in the experimental group compared with the control (p = .016). CONCLUSION Applying a heating pad to the sacral region during a transrectal prostate biopsy is an effective non-pharmacologic method to increase patient comfort and reduce pain and anxiety.",2021,"The scores of the VAS were significantly lower in the experimental group compared with the control (p = .016). ","['A total of 40 males', 'Urology Outpatient Clinic of a Training and Research Hospital in Istanbul']","['transrectal prostate biopsy', 'heating pad']","['mean scores of the BAI', 'Beck Anxiety Inventory (BAI) and visual analogue scale (VAS', 'scores of the VAS', 'Pain and Anxiety', 'pain and anxiety']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0401641', 'cui_str': 'Transrectal biopsy of prostate'}, {'cui': 'C0018851', 'cui_str': 'Heating'}, {'cui': 'C0332568', 'cui_str': 'Pad'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",40.0,0.0298348,"The scores of the VAS were significantly lower in the experimental group compared with the control (p = .016). ","[{'ForeName': 'Ezgi', 'Initials': 'E', 'LastName': 'Seyhan Ak', 'Affiliation': 'Istanbul University-Cerrahpaşa, Florence Nightingale Nursing Faculty, Department of Surgical Nursing, Istanbul, Turkey.'}, {'ForeName': 'Yeliz', 'Initials': 'Y', 'LastName': 'Culha', 'Affiliation': 'Istanbul University-Cerrahpaşa, Florence Nightingale Nursing Faculty, Department of Nursing Fundamentals, Istanbu, Turkey. Electronic address: yeliz.culha@istanbul.edu.tr.'}, {'ForeName': 'Mehmet Gokhan', 'Initials': 'MG', 'LastName': 'Culha', 'Affiliation': 'University of Health Sciences, Okmeydani Training and Research Hospital, Urology Clinic, Istanbul, Turkey.'}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Ozer', 'Affiliation': 'University of Health Sciences, Okmeydani Training and Research Hospital, Urology Clinic, Istanbul, Turkey.'}, {'ForeName': 'Ayfer', 'Initials': 'A', 'LastName': 'Ozbas', 'Affiliation': 'Istanbul University-Cerrahpaşa, Florence Nightingale Nursing Faculty, Department of Surgical Nursing, Istanbul, Turkey.'}]",Pain management nursing : official journal of the American Society of Pain Management Nurses,['10.1016/j.pmn.2020.12.008'] 916,33821515,Cognitive Processing Therapy for Substance-Involved Sexual Assault: Does an Account Help or Hinder Recovery?,"Sexual assault (SA) often occurs in the context of substances, which can impair the trauma memory and contribute to negative cognitions like self-blame. Although these factors may affect posttraumatic stress disorder (PTSD) treatment, outcomes for substance-involved SA have not been evaluated or compared with other types of SA. As such, we conducted a secondary analysis of a dismantling trial for cognitive processing therapy (CPT), focusing on 58 women with an index trauma of SA that occurred since age 14. Women who experienced a substance-involved SA (n = 21) were compared with those who experienced a non-substance-involved SA (n = 37). Participants were randomized to CPT, CPT with written account (CPT+A), or written account only (WA). Regressions controlling for pretreatment symptom levels revealed no differences by SA type in PTSD severity at posttreatment. At 6-month follow-up, substance-involved SA was associated with more severe residual PTSD severity than non-substance-involved SA, with no significant differences by treatment condition. Among participants in the substance-involved SA group, the largest effect for reduced PTSD symptom severity from pretreatment to follow-up emerged in the CPT condition, d = -2.02, with reductions also observed in the CPT+A, d = -0.92, and WA groups, d = -1.23. Although more research in larger samples is needed, these preliminary findings suggest that following substance-involved SA, a cognitive treatment approach without a trauma account may facilitate lasting change in PTSD symptoms. We encourage replications to better understand the relative value of cognitive and exposure-based treatment for PTSD following substance-involved SAs.",2021,"At 6-month follow-up, substance-involved SA was associated with more severe residual PTSD severity than non-substance-involved SA, with no significant differences by treatment condition.","['58 women with an index trauma of SA that occurred since age 14', 'Women who experienced a substance-involved SA (n = 21) were compared with those who experienced a non-substance-involved SA (n = 37', 'Substance-Involved Sexual Assault']","['Cognitive Processing Therapy', 'cognitive processing therapy (CPT', 'CPT, CPT with written account (CPT+A), or written account only (WA']","['severe residual PTSD severity', 'reduced PTSD symptom severity']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0451546', 'cui_str': 'Trauma index'}, {'cui': 'C0237236', 'cui_str': 'Sexual assault'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}]","[{'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0043266', 'cui_str': 'Writing'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}]",58.0,0.0382512,"At 6-month follow-up, substance-involved SA was associated with more severe residual PTSD severity than non-substance-involved SA, with no significant differences by treatment condition.","[{'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Jaffe', 'Affiliation': 'Department of Psychology, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Kaysen', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.'}, {'ForeName': 'Brian N', 'Initials': 'BN', 'LastName': 'Smith', 'Affiliation': ""Women's Health Sciences Division, National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts, USA.""}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Galovski', 'Affiliation': ""Women's Health Sciences Division, National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts, USA.""}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Resick', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke Health, Durham, North Carolina, USA.'}]",Journal of traumatic stress,['10.1002/jts.22674'] 917,33530713,Patient accrual and understanding of informed consent in a two-stage consent design.,"BACKGROUND We previously introduced the concept of ""two-stage"" (or ""just-in-time"") informed consent for randomized trials with usual care control. We argued that conducting consent in two stages-splitting information about research procedures from information about the experimental intervention-would reduce the decisional anxiety, confusion, and information overload commonly associated with informed consent. We implemented two-stage consent in a low-stakes randomized trial of a mindfulness meditation intervention for procedural distress in patients undergoing prostate biopsy. Here, we report accrual rates and patient understanding of the consent process. METHODS Patients approached for consent for the biopsy trial were asked to complete the standard ""Quality of Informed Consent"" questionnaire to assess their knowledge and understanding of the trial. RESULTS Accrual was excellent with 108 of 110 (98%) patients approached for consent signing first-stage consent. All 51 patients randomized to the experimental arm and who later presented for biopsy signed second-stage consent and received the mindfulness intervention. Quality of Informed Consent data were available for 48 patients assigned to the mindfulness treatment arm and 44 controls. The mean Quality of Informed Consent score was similar in the meditation and control arms with and overall mean of 75 (95% confidence interval = 74-76) for the knowledge section and 86 (95% confidence interval = 81-90) for understanding, comparable to the normative scores of 80 and 88. On further analysis and patient interview, two of the Quality of Informed Consent questions were found to be misleading in the context of a two-stage consent study for a mindfulness intervention. Excluding these questions increased knowledge scores to 88 (95% confidence interval = 87-90). CONCLUSION We found promising data that two-stage consent facilitated accrual without compromising patient understanding of randomized trials or compliance with allocated treatment. Further research is needed incorporating randomized comparison of two-stage consent to standard consent approaches, measuring patient anxiety and distress as an outcome, using suitable modifications to the Quality of Informed Consent questionnaire and trials with higher stakes.",2021,"Excluding these questions increased knowledge scores to 88 (95% confidence interval = 87-90). ","['Patients approached for consent for the biopsy trial', '48 patients assigned to the mindfulness treatment arm and 44 controls', 'patients undergoing prostate biopsy']","['biopsy signed second-stage consent and received the mindfulness intervention', 'mindfulness meditation intervention']","['mean Quality of Informed Consent score', 'knowledge scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0194804', 'cui_str': 'Biopsy of prostate'}]","[{'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",51.0,0.0882619,"Excluding these questions increased knowledge scores to 88 (95% confidence interval = 87-90). ","[{'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Vickers', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Emily A', 'Initials': 'EA', 'LastName': 'Vertosick', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Sigrid V', 'Initials': 'SV', 'LastName': 'Carlsson', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Behfar', 'Initials': 'B', 'LastName': 'Ehdaie', 'Affiliation': 'Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Scott Y H', 'Initials': 'SYH', 'LastName': 'Kim', 'Affiliation': 'Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD, USA.'}]","Clinical trials (London, England)",['10.1177/1740774520988500'] 918,33538113,Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.,"OBJECTIVE To assess the long-term safety and 16-week efficacy of subcutaneous tanezumab in patients with hip or knee osteoarthritis (OA). METHODS This was a phase III randomized, double-blind, active treatment-controlled (using nonsteroidal antiinflammatory drugs [NSAIDs] as the active treatment control) safety trial of tanezumab (56-week treatment/24-week posttreatment follow-up) in adults who were receiving stable-dose NSAID therapy at the time of screening and who had Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function scores of ≥5; patient global assessment (PtGA) of OA of fair, poor, or very poor; history of inadequate pain relief with standard analgesics; and no history or radiographic evidence of prespecified bone/joint conditions beyond OA. Patients received oral naproxen, celecoxib, or diclofenac twice daily (NSAID group; n = 996) or tanezumab 2.5 mg (n = 1,002) or 5 mg (n = 998) subcutaneously every 8 weeks. Coprimary efficacy end points at week 16 were changes in WOMAC pain and physical function scores and changes in PtGA. The primary joint safety end point over 80 weeks comprised adjudicated rapidly progressive OA type 1 or 2, primary osteonecrosis, subchondral insufficiency fracture, or pathologic fracture. Mean values, least squares mean values, and least squares mean differences between groups (with 95% confidence intervals [95% CIs]) were calculated. RESULTS Of 3,021 randomized patients, 2,996 received ≥1 treatment dose. Adverse events (AEs) were similar between patients treated with tanezumab 2.5 mg and those treated with NSAIDs, and were more prevalent in those treated with tanezumab 5 mg. Composite joint safety events were significantly more prevalent with tanezumab 2.5 mg and tanezumab 5 mg than with NSAIDs (observation time-adjusted rate/1,000 patient-years 38.3 [95% CI 28.0, 52.5] and 71.5 [95% CI 56.7, 90.2], respectively, versus 14.8 [95% CI 8.9, 24.6]; P = 0.001 for tanezumab 2.5 mg versus NSAIDs; P < 0.001 for tanezumab 5 mg versus NSAIDs). Tanezumab 5 mg significantly improved pain and physical function but did not improve PtGA at week 16 when compared to NSAIDs; corresponding differences between the tanezumab 2.5 mg and NSAID groups were not statistically significant. CONCLUSION In patients previously receiving a stable dose of NSAIDs, tanezumab administered subcutaneously resulted in more joint safety events than continued NSAIDs, with differences being dose dependent. Pain and physical function improved with both doses of tanezumab compared to NSAIDs, reaching statistical significance with tanezumab 5 mg at 16 weeks.",2021,"Tanezumab 5mg significantly improved Pain and Physical Function but not PGA-OA at week 16 versus NSAID; corresponding differences for tanezumab 2.5mg were not statistically significant. ","['patients with hip or knee OA', 'adults receiving stable dose NSAID therapy at the time of screening and WOMAC 1 Pain and Physical Function scores ≥5; patient\'s global assessment of osteoarthritis (PGA-OA; ""fair,"" ""poor,"" or ""very poor""); history of inadequate pain relief with standard analgesics; without history or radiographic evidence of prespecified bone/joint conditions beyond OA', 'Hip or Knee Osteoarthritis', '3,021 randomized patients']","['Tanezumab', 'tanezumab', 'subcutaneous tanezumab', 'naproxen, celecoxib or diclofenac', 'Subcutaneous Tanezumab', 'NSAID, subcutaneous tanezumab']","['Composite joint safety events', 'progressive osteoarthritis type 1 or 2, primary osteonecrosis, subchondral insufficiency fracture, or pathologic fracture', 'Pain and physical function', 'WOMAC Pain and Physical Function and in PGA-OA scores', 'Pain and Physical Function', 'joint safety events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C2911689', 'cui_str': 'Fair'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C1708484', 'cui_str': 'Inadequate pain relief'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}]","[{'cui': 'C2346819', 'cui_str': 'tanezumab'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0027396', 'cui_str': 'Naproxen'}, {'cui': 'C0538927', 'cui_str': 'celecoxib'}, {'cui': 'C0012091', 'cui_str': 'Diclofenac'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}]","[{'cui': 'C0224502', 'cui_str': 'Compound joint structure'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0029445', 'cui_str': 'Bone necrosis'}, {'cui': 'C4523990', 'cui_str': 'Subchondral insufficiency fracture'}, {'cui': 'C0016663', 'cui_str': 'Pathological fracture'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}]",3021.0,0.082985,"Tanezumab 5mg significantly improved Pain and Physical Function but not PGA-OA at week 16 versus NSAID; corresponding differences for tanezumab 2.5mg were not statistically significant. ","[{'ForeName': 'Marc C', 'Initials': 'MC', 'LastName': 'Hochberg', 'Affiliation': 'University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Carrino', 'Affiliation': 'Hospital for Special Surgery, New York, New York.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Schnitzer', 'Affiliation': 'Northwestern University Feinberg School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Guermazi', 'Affiliation': 'Boston University School of Medicine, Boston, Massachusetts.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Walsh', 'Affiliation': 'Arthritis Research UK Pain Centre, NIHR Nottingham Biomedical Research Centre, and University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'White', 'Affiliation': 'Progressive Medical Research, Port Orange, Florida.'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Nakajo', 'Affiliation': 'Nakajo Orthopaedic Clinic, Miyagi, Japan.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Fountaine', 'Affiliation': 'Pfizer, Inc., Groton, Connecticut.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Hickman', 'Affiliation': 'Pfizer, Inc., Groton, Connecticut.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Pixton', 'Affiliation': 'Pfizer, Inc., Morrisville, North Carolina.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Viktrup', 'Affiliation': 'Eli Lilly, Indianapolis, Indiana.'}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Brown', 'Affiliation': 'Pfizer, Inc., Groton, Connecticut.'}, {'ForeName': 'Christine R', 'Initials': 'CR', 'LastName': 'West', 'Affiliation': 'Pfizer, Inc., Groton, Connecticut.'}, {'ForeName': 'Kenneth M', 'Initials': 'KM', 'LastName': 'Verburg', 'Affiliation': 'Pfizer, Inc., Groton, Connecticut.'}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41674'] 919,33538094,Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.,"OBJECTIVE Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in terms of radiographically evident quantitative lung involvement. We undertook this study to assess the impact of TCZ on lung function preservation in a post hoc analysis, stratifying treatment arms according to the degree of lung involvement. METHODS The focuSSced trial was a phase III randomized placebo-controlled trial of TCZ in patients with SSc and progressive skin disease. Participants underwent baseline and serial spirometry along with high-resolution chest computed tomography at baseline and at week 48. Quantitative interstitial lung disease (QILD) and fibrosis scores were assessed by computer software. We classified QILD into the following categories of lung involvement: mild (>5-10%), moderate (>10-20%), and severe (>20%). RESULTS Of 210 participants recruited for the trial, 136 patients (65%) had ILD. The majority of these patients (77%) had moderate-to-severe involvement (defined as >10% lung involvement). The TCZ arm demonstrated preservation of forced vital capacity percent predicted (FVC%) over 48 weeks (least squares mean change in FVC% = -0.1) compared to placebo (-6.3%). For mild, moderate, and severe QILD, the mean ± SD change in FVC% in the TCZ arm at 48 weeks were -4.1 ± 2.5% (n = 11), 0.7 ± 1.9% (n =19), and 2.1 ± 1.6% (n = 26), respectively, and in the placebo group were -10.0 ± 2.6% (n = 11), -5.7 ± 1.6% (n = 26), and -6.7 ± 2.0% (n = 16), respectively. Similar treatment-related preservation findings were seen independent of fibrosis severity. CONCLUSION TCZ in early SSc-associated ILD with progressive skin disease stabilized FVC% over 48 weeks, independent of the extent of radiographically evident QILD.",2021,"Tocilizumab in early SSc- associated interstitial lung disease with progressive skin disease stabilized forced vital capacity over 48 weeks, independent of the extent of quantitative radiographic interstitial lung disease or fibrosis.","['mild (5-10%), moderate (>10-20%), or severe (>20%) categories', 'early systemic sclerosis (SSc', 'early SSc- associated interstitial lung disease with progressive skin disease', '210 participants recruited in the trial, 136 [65%] had interstitial lung disease', 'Participants had baseline and serial spirometry along with high resolution chest CT at baseline and week 48', 'patients with SSc and progressive skin disease']","['Tocilizumab', 'tocilizumab', 'placebo']",['preservation of forced vital capacity'],"[{'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0036421', 'cui_str': 'Systemic sclerosis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0037274', 'cui_str': 'Disorder of skin'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0202823', 'cui_str': 'CT of chest'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1609165', 'cui_str': 'tocilizumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}]",210.0,0.159553,"Tocilizumab in early SSc- associated interstitial lung disease with progressive skin disease stabilized forced vital capacity over 48 weeks, independent of the extent of quantitative radiographic interstitial lung disease or fibrosis.","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Roofeh', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Celia J F', 'Initials': 'CJF', 'LastName': 'Lin', 'Affiliation': 'Genentech, South San Francisco, California.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Goldin', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Grace Hyun', 'Initials': 'GH', 'LastName': 'Kim', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Furst', 'Affiliation': 'University of California, Los Angeles, University of Washington, Seattle, and University of Florence, Florence, Italy.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Denton', 'Affiliation': 'University College London, London, UK.'}, {'ForeName': 'Suiyuan', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Khanna', 'Affiliation': 'University of Michigan, Ann Arbor.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41668'] 920,33543763,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults.","OBJECTIVE To evaluate the analgesic potential, safety, tolerability, and pharmacokinetics of VX-150, a pro-drug of a highly selective NaV1.8 inhibitor, in healthy subjects. DESIGN This was a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. SUBJECTS Twenty healthy male subjects with an age of 18-55 years, inclusive, were enrolled. Eligibility was based on general fitness, absence of current or previous medical conditions that could compromise subject safety, and a training assessment of pain tolerance across pain tests to exclude highly tolerant individuals whose tolerance could compromise the ability to detect analgesic responses. All dosed subjects completed the study. METHODS Subjects were randomized 1:1 to one of two sequences receiving a single VX-150 dose and subsequently placebo, or vice versa, with at least 7 days between dosing. A battery of pain tests (pressure, electrical stair, [capsaicin-induced] heat, and cold pressor) was administered before dosing and repetitively up to 10 h after dosing, with blood sampling up to 24 h after dosing. Safety was monitored throughout the study. Data were analyzed with a repeated-measures mixed-effects model. RESULTS VX-150 induced analgesia in a variety of evoked pain tests, without affecting subject safety. Significant effects were reported for the cold pressor and heat pain thresholds. Maximum median concentration for the active moiety was 4.30 µg/mL at 4 h after dosing. CONCLUSION Results of this proof-of-mechanism study are supportive of the potential of VX-150, a highly selective NaV1.8 channel inhibitor, to treat various pain indications.",2021,Significant effects were reported for cold pressor and heat pain thresholds.,"['Healthy Male Adults', 'healthy subjects', 'Subjects', 'Twenty healthy male subjects with an age of 18-55, inclusive, were enrolled']","['single VX-150 dose and subsequently placebo', 'placebo', 'VX-150', 'pain tests (pressure, electrical stair, (capsaicin-induced) heat and cold pressor', 'Placebo']","['evoked pain tests', 'analgesic potential, safety, tolerability and pharmacokinetics', 'Safety', 'Maximum median concentration', 'cold pressor and heat pain thresholds']","[{'cui': 'C0686751', 'cui_str': 'Well male adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0006931', 'cui_str': 'Capsaicin'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}]","[{'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}]",20.0,0.236883,Significant effects were reported for cold pressor and heat pain thresholds.,"[{'ForeName': 'Hemme J', 'Initials': 'HJ', 'LastName': 'Hijma', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Pieter S', 'Initials': 'PS', 'LastName': 'Siebenga', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Marieke L', 'Initials': 'ML', 'LastName': 'de Kam', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Geert Jan', 'Initials': 'GJ', 'LastName': 'Groeneveld', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnab032'] 921,33497715,Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users.,"BACKGROUND Smoking mixtures containing synthetic cannabinoids (SCs) have become very popular over the last years but pose a serious risk for public health. Limited knowledge is, however, available regarding the acute effects of SCs on cognition and psychomotor performance. Earlier we demonstrated signs of impairment in healthy volunteers after administering one of the first SCs, JWH-018, even though subjective intoxication was low. In the current study, we aimed to investigate the acute effects of JWH-018 on several cognitive and psychomotor tasks in participants who are demonstrating representative levels of acute intoxication. METHODS 24 healthy cannabis-experienced participants took part in this placebo-controlled, cross-over study. Participants inhaled the vapor of 75 μg JWH-018/kg body weight and were given a booster dose if needed to induce a minimum level of subjective high. They were subsequently monitored for 4 h, during which psychomotor and cognitive performance, vital signs, and subjective experience were measured, and serum concentrations were determined. RESULTS Maximum subjective high (average 64%) was reached 30 min after administration of JWH-018, while the maximum blood concentration was shown after 5 min (8 ng/mL). JWH-018 impaired motor coordination (CTT), attention (DAT and SST), memory (SMT), it lowered speed-accuracy efficiency (MFFT) and slowed down response speed (DAT). CONCLUSION In accordance with our previous studies, we demonstrated acute psychomotor and cognitive effects of a relatively low dose of JWH-018.",2021,"JWH-018 impaired motor coordination (CTT), attention (DAT and SST), memory (SMT), it lowered speed-accuracy efficiency (MFFT) and slowed down response speed (DAT). ","['recreational cannabis users', 'healthy volunteers', 'participants who are demonstrating representative levels of acute intoxication', '24 healthy cannabis-experienced participants took part in this placebo-controlled, cross-over study']","['Smoking mixtures containing synthetic cannabinoids (SCs', 'JWH-018', 'synthetic cannabinoid (JWH-018']","['JWH-018 impaired motor coordination (CTT), attention (DAT and SST), memory (SMT), it lowered speed-accuracy efficiency (MFFT) and slowed down response speed (DAT', 'Maximum subjective high', 'several cognitive and psychomotor tasks', 'maximum blood concentration']","[{'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0456824', 'cui_str': 'Acute drug intoxication'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}]","[{'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0006864', 'cui_str': 'cannabinoids'}, {'cui': 'C2974687', 'cui_str': 'JWH 018'}]","[{'cui': 'C2974687', 'cui_str': 'JWH 018'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0037659', 'cui_str': 'Somatostatin'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0013080', 'cui_str': 'Trisomy 21'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0427728', 'cui_str': 'Blood concentration, dipstick - finding'}]",24.0,0.0414869,"JWH-018 impaired motor coordination (CTT), attention (DAT and SST), memory (SMT), it lowered speed-accuracy efficiency (MFFT) and slowed down response speed (DAT). ","[{'ForeName': 'Eef L', 'Initials': 'EL', 'LastName': 'Theunissen', 'Affiliation': 'Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands. Electronic address: e.theunissen@maastrichtuniversity.nl.'}, {'ForeName': 'Johannes T', 'Initials': 'JT', 'LastName': 'Reckweg', 'Affiliation': 'Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Nadia R P W', 'Initials': 'NRPW', 'LastName': 'Hutten', 'Affiliation': 'Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Kim P C', 'Initials': 'KPC', 'LastName': 'Kuypers', 'Affiliation': 'Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Stefan W', 'Initials': 'SW', 'LastName': 'Toennes', 'Affiliation': 'Department of Forensic Toxicology, Institute of Legal Medicine, Goethe University of Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Merja A', 'Initials': 'MA', 'LastName': 'Neukamm', 'Affiliation': 'Institute of Forensic Medicine, Forensic Toxicology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Halter', 'Affiliation': 'Institute of Forensic Medicine, Forensic Toxicology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; Hermann Staudinger Graduate School, University of Freiburg, Hebelstr. 27, 79104 Freiburg, Germany.'}, {'ForeName': 'Johannes G', 'Initials': 'JG', 'LastName': 'Ramaekers', 'Affiliation': 'Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}]","Pharmacology, biochemistry, and behavior",['10.1016/j.pbb.2021.173118'] 922,33497643,Comparison of contrast-enhanced versus conventional EUS-guided FNA/fine-needle biopsy in diagnosis of solid pancreatic lesions: a randomized controlled trial.,"BACKGROUND AND AIMS Contrast-enhanced harmonic EUS (CEH-EUS) is useful in the differential diagnosis of solid pancreatic lesions (SPLs). However, there is lack of verification about the usefulness of CEH-EUS-guided FNA/fine-needle biopsy (FNB) sampling. This study aimed to investigate the usefulness of CEH-EUS-guided FNA/FNB sampling without on-site cytopathology. METHODS Patients with SPLs were prospectively enrolled and randomly assigned (1:1) to 2 parallel groups, the interventional group (CEH-EUS) or the control group (conventional EUS). The diagnostic sensitivity and optimal number of needle passes for pathologic diagnosis were investigated and compared between groups. RESULTS Two hundred forty patients were enrolled from March 2016 to September 2019, with 120 patients assigned to each group. Pancreatic malignancies and neuroendocrine tumors were found in 202 (90.83%) and 9 (3.75%) patients, respectively. There was no statistically significant difference between the groups in terms of age, sex, lesion size (30.96 ± 12.09 mm in the CEH-EUS group vs 33.09 ± 16.39 mm in the conventional EUS group; P = .252), lesion location, adverse event rate, and disease distribution. The diagnostic sensitivity values in the CEH-EUS and conventional EUS groups were 85.8% and 88.3%, respectively (P = .564). All patients in the conventional EUS group and most in the CEH-EUS group received a pathologic diagnosis within 3 needle passes. CONCLUSIONS Diagnostic sensitivity for SPLs was not different between the CEH-EUS and conventional EUS groups, and no independent factors were found that could improve diagnostic sensitivity. CEH-EUS-guided FNA/FNB sampling does not need to be used routinely and may be selectively considered for small, indeterminate lesions. (Clinical trial registration number: KCT 0001840.).",2021,"There was no statistically significant difference between the groups in terms of age, sex, lesion size (30.96±12.09 mm in the CEH-EUS group vs 33.09 ± 16.39 mm in the conventional EUS group; p=0.252), location, adverse event rate, and disease distribution.","['240 patients were enrolled from March 2016 to September 2019, with 120 patients assigned to each group', 'diagnosis of solid pancreatic lesions', 'Patients with SPLs']","['CEH-EUS-guided fine-needle aspiration/biopsy (FNA/B', 'interventional group (CEH-EUS) or control group (conventional EUS', 'CEH-EUS', 'contrast-enhanced versus conventional EUS-guided fine-needle aspiration/biopsy', 'harmonic endoscopic ultrasound (CEH-EUS', 'conventional EUS']","['diagnostic sensitivity', 'diagnostic sensitivity values', 'age, sex, lesion size', 'Pancreatic malignancies and neuroendocrine tumors', 'location, adverse event rate, and disease distribution']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0030274', 'cui_str': 'Pancreatic structure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C1880510', 'cui_str': 'EUS-FNA'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C1510483', 'cui_str': 'Fine needle aspiration biopsy - action'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0376443', 'cui_str': 'Endoscopic ultrasonography'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0449453', 'cui_str': 'Lesion size'}, {'cui': 'C0030274', 'cui_str': 'Pancreatic structure'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0206754', 'cui_str': 'Neuroendocrine tumor'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}]",240.0,0.0348527,"There was no statistically significant difference between the groups in terms of age, sex, lesion size (30.96±12.09 mm in the CEH-EUS group vs 33.09 ± 16.39 mm in the conventional EUS group; p=0.252), location, adverse event rate, and disease distribution.","[{'ForeName': 'In Rae', 'Initials': 'IR', 'LastName': 'Cho', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Seok-Hoo', 'Initials': 'SH', 'LastName': 'Jeong', 'Affiliation': ""Department of Internal Medicine, Catholic Kwandong University International Saint Mary's Hospital, Incheon, Korea.""}, {'ForeName': 'Huapyong', 'Initials': 'H', 'LastName': 'Kang', 'Affiliation': 'Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.'}, {'ForeName': 'Eui Joo', 'Initials': 'EJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.'}, {'ForeName': 'Yeon Suk', 'Initials': 'YS', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.'}, {'ForeName': 'Jae Hee', 'Initials': 'JH', 'LastName': 'Cho', 'Affiliation': 'Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.'}]",Gastrointestinal endoscopy,['10.1016/j.gie.2021.01.018'] 923,33507305,Effects of sleep restriction on the sleep electroencephalogram of adolescents.,"STUDY OBJECTIVES This report describes findings from an ongoing longitudinal study of the effects of varied sleep durations on wake and sleep electroencephalogram (EEG) and daytime function in adolescents. Here, we focus on the effects of age and time in bed (TIB) on total sleep time (TST) and nonrapid eye movement (NREM) and rapid eye movement (REM) EEG. METHODS We studied 77 participants (41 male) ranging in age from 9.9 to 16.2 years over the 3 years of this study. Each year, participants adhered to each of three different sleep schedules: four consecutive nights of 7, 8.5, or 10 h TIB. RESULTS Altering TIB successfully modified TST, which averaged 406, 472 and 530 min on the fourth night of 7, 8.5, and 10 h TIB, respectively. As predicted by homeostatic models, shorter sleep durations produced higher delta power in both NREM and REM although these effects were small. Restricted sleep more substantially reduced alpha power in both NREM and REM sleep. In NREM but not REM sleep, sleep restriction strongly reduced both the all-night accumulation of sigma EEG activity (11-15 Hz energy) and the rate of sigma production (11-15 Hz power). CONCLUSIONS The EEG changes in response to TIB reduction are evidence of insufficient sleep recovery. The decrease in sigma activity presumably reflects depressed sleep spindle activity and suggests a manner by which sleep restriction reduces waking cognitive function in adolescents. Our results thus far demonstrate that relatively modest TIB manipulations provide a useful tool for investigating adolescent sleep biology.",2021,"As predicted by homeostatic models, shorter sleep durations produced higher delta power in both NREM and REM although these effects were small.","['77 participants (41 male) ranging in age from 9.9 to 16.2 years over the 3 years of this study', 'adolescents']",['sleep restriction'],"['sigma activity', 'REM sleep, sleep restriction', 'sigma EEG activity', 'total sleep time (TST) and nonrapid eye movement (NREM) and rapid eye movement (REM) EEG', 'wake and sleep electroencephalogram (EEG) and daytime function', 'rate of sigma production']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319690', 'cui_str': '16.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}]","[{'cui': 'C1719918', 'cui_str': 'Sigma'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0037322', 'cui_str': 'Rapid eye movement sleep'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015413', 'cui_str': 'Eye Movements'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0200101', 'cui_str': 'Sleep electroencephalogram'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",77.0,0.0202721,"As predicted by homeostatic models, shorter sleep durations produced higher delta power in both NREM and REM although these effects were small.","[{'ForeName': 'Ian G', 'Initials': 'IG', 'LastName': 'Campbell', 'Affiliation': 'Department of Psychiatry, University of California Davis.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Cruz-Basilio', 'Affiliation': 'Department of Psychiatry, University of California Davis.'}, {'ForeName': 'Nato', 'Initials': 'N', 'LastName': 'Darchia', 'Affiliation': 'Ilia State University, Tbilisi.'}, {'ForeName': 'Zoey Y', 'Initials': 'ZY', 'LastName': 'Zhang', 'Affiliation': 'Department of Psychiatry, University of California Davis.'}, {'ForeName': 'Irwin', 'Initials': 'I', 'LastName': 'Feinberg', 'Affiliation': 'Department of Psychiatry, University of California Davis.'}]",Sleep,['10.1093/sleep/zsaa280'] 924,33514368,"Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether-lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso.","BACKGROUND The use of pyronaridine-artesunate (PA) has been associated with scarce transaminitis in patients. This analysis aimed to evaluate the hepatic safety profile of repeated treatment with PA versus artemether-lumefantrine (AL) in patients with consecutive uncomplicated malaria episodes in Bobo-Dioulasso, Burkina Faso. METHODS This study analysed data from a clinical trial conducted from 2012 to 2015, in which participants with uncomplicated malaria were assigned to either PA or AL arms and followed up to 42 days. Subsequent malaria episodes within a 2-years follow up period were also treated with the same ACT initially allocated. Transaminases (AST/ALT), alkaline phosphatase (ALP), total and direct bilirubin were measured at days 0 (baseline), 3, 7, 28 and on some unscheduled days if required. The proportions of non-clinical hepatic adverse events (AEs) following first and repeated treatments with PA and AL were compared within study arms. The association of these AEs with retreatment in each arm was also determined using a logistic regression model. RESULTS A total of 1379 malaria episodes were included in the intention to treat analysis with 60% of all cases occurring in the AL arm. Overall, 179 non-clinical hepatic AEs were recorded in the AL arm versus 145 in the PA arm. Elevated ALT was noted in 3.05% of treated malaria episodes, elevated AST 3.34%, elevated ALP 1.81%, and elevated total and direct bilirubin in 7.90% and 7.40% respectively. Retreated participants were less likely to experience elevated ALT and AST than first episode treated participants in both arms. One case of Hy's law condition was recorded in a first treated participant of the PA arm. Participants from the retreatment group were 76% and 84% less likely to have elevated ALT and AST, respectively, in the AL arm and 68% less likely to present elevated ALT in the PA arm. In contrast, they were almost 2 times more likely to experience elevated total bilirubin in both arms. CONCLUSIONS Pyronaridine-artesunate and artemether-lumefantrine showed similar hepatic safety when used repeatedly in participants with uncomplicated malaria. Pyronaridine-artesunate represents therefore a suitable alternative to the current first line anti-malarial drugs in use in endemic areas. Trial registration Pan African Clinical Trials Registry. PACTR201105000286876.",2021,"Elevated ALT was noted in 3.05% of treated malaria episodes, elevated AST 3.34%, elevated ALP 1.81%, and elevated total and direct bilirubin in 7.90% and 7.40% respectively.","['participants with uncomplicated malaria', 'patients with consecutive uncomplicated malaria episodes in Bobo-Dioulasso, Burkina Faso', '1379 malaria episodes', 'patients with uncomplicated malaria', '2012 to 2015, in which participants with uncomplicated malaria']","['PA versus artemether-lumefantrine (AL', 'Pyronaridine-artesunate and artemether-lumefantrine', 'pyronaridine-artesunate (PA', 'Pyronaridine-artesunate', 'PA or AL', 'pyronaridine-artesunate versus artemether-lumefantrine']","['Transaminases (AST/ALT), alkaline phosphatase (ALP), total and direct bilirubin', 'hepatic safety', 'total bilirubin', 'hepatic safety profile', 'Hepatic safety', 'proportions of non-clinical hepatic adverse events (AEs', 'Elevated ALT', 'elevated total and direct bilirubin']","[{'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0006409', 'cui_str': 'Burkina Faso'}]","[{'cui': 'C0072768', 'cui_str': 'pyronaridine'}, {'cui': 'C0052432', 'cui_str': 'artesunate'}, {'cui': 'C0936150', 'cui_str': 'artemether and lumefantrine'}]","[{'cui': 'C0002594', 'cui_str': 'Aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0201916', 'cui_str': 'Bilirubin, direct measurement'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0151905', 'cui_str': 'Alanine aminotransferase increased'}, {'cui': 'C0205250', 'cui_str': 'High'}]",,0.185503,"Elevated ALT was noted in 3.05% of treated malaria episodes, elevated AST 3.34%, elevated ALP 1.81%, and elevated total and direct bilirubin in 7.90% and 7.40% respectively.","[{'ForeName': 'Yves Daniel', 'Initials': 'YD', 'LastName': 'Compaoré', 'Affiliation': ""Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina Faso. yvesdaniel.co@gmail.com.""}, {'ForeName': 'Issaka', 'Initials': 'I', 'LastName': 'Zongo', 'Affiliation': ""Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina Faso.""}, {'ForeName': 'Anyirékun F', 'Initials': 'AF', 'LastName': 'Somé', 'Affiliation': ""Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina Faso.""}, {'ForeName': 'Nouhoun', 'Initials': 'N', 'LastName': 'Barry', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Nikiéma', 'Affiliation': ""Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina Faso.""}, {'ForeName': 'Talato N', 'Initials': 'TN', 'LastName': 'Kaboré', 'Affiliation': 'Ministry of Health, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Aminata', 'Initials': 'A', 'LastName': 'Ouattara', 'Affiliation': 'Ministry of Health, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Zachari', 'Initials': 'Z', 'LastName': 'Kabré', 'Affiliation': ""Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina Faso.""}, {'ForeName': 'Kadidiatou', 'Initials': 'K', 'LastName': 'Wermi', 'Affiliation': ""Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina Faso.""}, {'ForeName': 'Moussa', 'Initials': 'M', 'LastName': 'Zongo', 'Affiliation': ""Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina Faso.""}, {'ForeName': 'Rakiswende S', 'Initials': 'RS', 'LastName': 'Yerbanga', 'Affiliation': ""Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina Faso.""}, {'ForeName': 'Issaka', 'Initials': 'I', 'LastName': 'Sagara', 'Affiliation': 'Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Abdoulaye', 'Initials': 'A', 'LastName': 'Djimdé', 'Affiliation': 'Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Jean Bosco', 'Initials': 'JB', 'LastName': 'Ouédraogo', 'Affiliation': ""Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina Faso.""}]",Malaria journal,['10.1186/s12936-021-03593-6'] 925,33517746,Dementia stigma reduction (DESeRvE) through education and virtual contact in the general public: A multi-arm factorial randomised controlled trial.,"OBJECTIVE To examine the efficacy of the Dementia Stigma Reduction (DESeRvE) programme, aimed at reducing the general public dementia-related stigma utilising 'education' and 'contact' approaches. METHODS A total of 1024 Australians aged between 40 and 87 years (M = 60.8, SD = 10.1) participated in a factorial randomised controlled trial. This trial examined four conditions: online education programme (ED), contact through simulated contact with people with dementia and carers (CT), education and contact (ED+CT) and active control. Cognitive, emotional and behavioural aspects of dementia-related stigma were measured with a modified Attribution Questionnaire, and dementia knowledge was measured with the Dementia Knowledge Assessment Scale at the baseline, immediately and 12 weeks after the completion of the intervention. RESULTS All four groups improved (reduction in scores) significantly from baseline to week 12 in dementia-related stigma, and the effects were stronger for those with higher baseline stigma scores. Intervention groups also improved significantly from baseline in dementia knowledge. Especially, the ED (β = .85, SE = .07; p < .001) and ED+CT (β = .78, SE = .08; p < .001) groups at immediate follow-up and CT (β = .21, SE = .09; p < .05) and ED+CT (β = .32, SE = .09; p < .001) at 12-week follow-up showed significant effects. CONCLUSIONS Findings suggest that DESeRvE can be a valuable tool to enhance public's dementia knowledge and reduce dementia-related stigma, especially for those with higher levels of stigma. Reduction in stigma, however, may take a longer time to achieve, whereas improvement in dementia knowledge is instant.",2021,"All four groups improved (reduction in scores) significantly from baseline to week 12 in dementia-related stigma, and the effects were stronger for those with higher baseline stigma scores.","['A total of 1024 Australians aged between 40 and 87\xa0years (M = 60.8, SD = 10.1']","['online education programme (ED), contact through simulated contact with people with dementia and carers (CT), education and contact (ED+CT) and active control', 'Dementia Stigma Reduction (DESeRvE) programme']","['dementia knowledge', 'Dementia Knowledge Assessment Scale', 'modified Attribution Questionnaire, and dementia knowledge', 'Cognitive, emotional and behavioural aspects of dementia-related stigma']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C4505477', 'cui_str': 'Online Education'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]","[{'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}]",1024.0,0.0860172,"All four groups improved (reduction in scores) significantly from baseline to week 12 in dementia-related stigma, and the effects were stronger for those with higher baseline stigma scores.","[{'ForeName': 'Sarang', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Centre for Research on Ageing, Health & Wellbeing, Research School of Population Health, 2219Australian National University, Canberra, Australia; Wicking Dementia Research & Education Centre, 3925University of Tasmania, Hobart, Australia.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Richardson', 'Affiliation': 'Statistical Consulting Unit, 2219Australian National University, Canberra, Australia.'}, {'ForeName': 'Perla', 'Initials': 'P', 'LastName': 'Werner', 'Affiliation': 'Department of Community Mental Health, 26748University of Haifa, Israel.'}, {'ForeName': 'Kaarin J', 'Initials': 'KJ', 'LastName': 'Anstey', 'Affiliation': '6803Neuroscience Research Australia, Sydney, Australia; School of Psychology, 7800University of New South Wales, Sydney, Australia.'}]","Dementia (London, England)",['10.1177/1471301220987374'] 926,33532874,"The effects of Chlorella supplementation on glycemic control, lipid profile and anthropometric measures on patients with type 2 diabetes mellitus.","BACKGROUND Diabetes is a chronic disease and the prevalence of it is rapidly increasing. Recently, the use of natural products in chronic diseases such as diabetes has gained more attention. Chlorella, a single-celled green alga, is one of them. There have been some studies on the effects of chlorella supplementation in chronic diseases such as NAFLD, prediabetes, and diabetic mice, but none of them examined the effects of chlorella in patients with T2DM. The present study was designed to evaluate the effects of chlorella supplementation on glycemic control, lipid profile, and anthropometric indices in type 2 diabetic patients. METHODS This study is a double-blind, randomized controlled trial. 84 patients with T2DM assigned into two groups, receiving 1500 mg/day C. vulgaris or placebo for 8 weeks. Anthropometric information, blood pressure, 24-h food intake recall, and blood samples were collected at the beginning and end of the study to determine the changes of FBS, HbA1c, insulin concentration, insulin resistance, and lipid profile. RESULTS None of the variables investigated in this study showed a significant change after 8 weeks of intervention with C. vulgaris. CONCLUSION According to the findings of this study, supplementation with C. vulgaris with a dosage of 1500 mg/day for 8 weeks, does not improve the anthropometric measurements, glycemic status, and lipid profile as well. Thus, it cannot be considered as a complementary therapeutic approach to common medications at this dosage and duration. However, future studies with a higher dosage of C. vulgaris and more prolonged than 8 weeks are needed to be done.",2021,"None of the variables investigated in this study showed a significant change after 8 weeks of intervention with C. vulgaris. ","['patients with type 2 diabetes mellitus', '84 patients with T2DM assigned into two groups', 'patients with T2DM', 'type 2 diabetic patients']","['receiving 1500\xa0mg/day C. vulgaris or placebo', 'Chlorella supplementation', 'chlorella supplementation']","['glycemic control, lipid profile and anthropometric measures', 'changes of FBS, HbA1c, insulin concentration, insulin resistance, and lipid profile', 'Anthropometric information, blood pressure, 24-h food intake recall, and blood samples', 'anthropometric measurements, glycemic status, and lipid profile', 'glycemic control, lipid profile, and anthropometric indices']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}]","[{'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0008190', 'cui_str': 'Chlorella'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C3495427', 'cui_str': 'Fanconi-Bickel Syndrome'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",84.0,0.0511491,"None of the variables investigated in this study showed a significant change after 8 weeks of intervention with C. vulgaris. ","[{'ForeName': 'Amir Mehdi', 'Initials': 'AM', 'LastName': 'Hosseini', 'Affiliation': 'Faculty of Medical Sciences and Technologies, Science and Research Branch, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Seyed Ali', 'Initials': 'SA', 'LastName': 'Keshavarz', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. S_akeshavarz@yahoo.com.'}, {'ForeName': 'Ensieh', 'Initials': 'E', 'LastName': 'Nasli-Esfahani', 'Affiliation': 'Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran.'}, {'ForeName': 'Fatemehsadat', 'Initials': 'F', 'LastName': 'Amiri', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Janani', 'Affiliation': 'Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}]",European journal of nutrition,['10.1007/s00394-021-02492-5'] 927,33540038,Effect of Exercise Adjunct to Radiation and Androgen Deprivation Therapy on Patient-Reported Treatment Toxicity in Men With Prostate Cancer: A Secondary Analysis of 2 Randomized Controlled Trials.,"PURPOSE Physical inactivity, in addition to clinical factors, has been associated with higher levels of late pelvic symptoms in patients with prostate cancer (PCa) after radiation therapy. The aim of this study was to investigate the effect of a structured multicomponent exercise program comprised of aerobic and resistance training as well as impact loading on the prevalence and severity of symptoms commonly resulting from androgen deprivation therapy (ADT) and pelvic radiation therapy. METHODS AND MATERIALS We performed a secondary analysis of pooled data from 2 randomized controlled trials that investigated the role of exercise on treatment-related side effects in patients with PCa receiving ADT. Patients were included in the analysis if they had undergone radiation therapy during the intervention in addition to ADT. Patient-reported quality of life and functional and symptom scales were assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 and PR25 before and after 6 months of exercise or usual care (UC). RESULTS One-hundred and fifteen patients with PCa receiving ADT, aged 47 to 84 years, who also underwent radiation therapy were included in the analysis (exercise, n = 72; UC, n = 43). There was a significant reduction in physical functioning (P = .019) and increased fatigue (P = .007) in the control group, with no change observed in the exercise group. Similarly, there was a trend toward reduced sexual activity in the control group (P = .064), with a mean adjusted change of -7.1 points. Furthermore, the prevalence of clinically important pain at 6 months was lower in the exercise group compared with UC (18.1 vs 37.2%, P = .022). No between-group differences were found for urinary (P = .473) or hormonal treatment-related symptoms (P = .552). CONCLUSIONS Exercise during concomitant hormone and radiation treatment for men with PCa may mitigate some adverse changes in patient-reported fatigue, physical functioning, and possibly sexual activity. The promotion and provision of exercise to counter a range of treatment-related adverse effects in patients with PCa undergoing radiation therapy and ADT should be actively encouraged.",2021,"No between-group differences were found for urinary (p=0.473) or hormonal treatment-related symptoms (p=0.552). ","['PCa patients receiving ADT', 'PCa patients undergoing', 'men with prostate cancer', 'prostate cancer (PCa) patients after radiotherapy', 'Patients were included in the analysis if they had undergone radiotherapy during the intervention in addition to ADT', 'men with PCa', 'One-hundred and fifteen PCa patients receiving ADT, aged 47-84 years, who also underwent radiotherapy were included in the analysis (exercise, n=72; UC, n=43']","['androgen deprivation therapy (ADT) and pelvic radiotherapy', 'aerobic and resistance training', 'structured multicomponent exercise program', 'exercise adjunct to radiation and androgen deprivation therapy', 'radiotherapy and ADT']","['fatigue', 'physical functioning', 'sexual activity', 'quality of life, functional and symptom scales', 'prevalence of clinically important pain']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",115.0,0.13791,"No between-group differences were found for urinary (p=0.473) or hormonal treatment-related symptoms (p=0.552). ","[{'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Schumacher', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Galvão', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.'}, {'ForeName': 'Dennis R', 'Initials': 'DR', 'LastName': 'Taaffe', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Spry', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia; Faculty of Medicine, University of Western Australia, Nedlands, WA, Australia; GenesisCare, Joondalup, WA, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Joseph', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia; Faculty of Medicine, University of Western Australia, Nedlands, WA, Australia; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Tang', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Chee', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia; GenesisCare, Joondalup, WA, Australia.'}, {'ForeName': 'Robert U', 'Initials': 'RU', 'LastName': 'Newton', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia; School of Human Movement and Nutrition Sciences, University of Queensland, Brisbane, QLD, Australia. Electronic address: r.newton@ecu.edu.au.'}]",Practical radiation oncology,['10.1016/j.prro.2021.01.005'] 928,33544370,Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study Using Mobile Health Technology.,"There are no effective treatments in progressive supranuclear palsy (PSP). The aim of this study was to test the efficacy of theta burst repetitive transcranial magnetic stimulation (rTMS) on postural instability in PSP. Twenty PSP patients underwent a session of sham or real cerebellar rTMS in a crossover design. Before and after stimulation, static balance was evaluated with instrumented (lower back accelerometer, Rehagait®, Hasomed, Germany) 30-s trials in semitandem and tandem positions. In tandem and semitandem tasks, active stimulation was associated with increase in time without falls (both p=0.04). In the same tasks, device-extracted parameters revealed significant improvement in area (p=0.007), velocity (p=0.005), acceleration and jerkiness of sway (p=0.008) in real versus sham stimulation. Cerebellar rTMS showed a significant effect on stability in PSP patients, when assessed with mobile digital technology, in a double-blind design. These results should motivate larger and longer trials using non-invasive brain stimulation for PSP patients.",2021,"In tandem and semitandem tasks, active stimulation was associated with increase in time without falls (both p=0.04).",['Twenty PSP patients underwent a'],"['session of sham or real cerebellar rTMS', 'theta burst repetitive transcranial magnetic stimulation (rTMS', 'Cerebellar rTMS']","['time without falls', 'velocity (p=0.005), acceleration and jerkiness of sway', 'stability']","[{'cui': 'C0038868', 'cui_str': 'Progressive supranuclear palsy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0007765', 'cui_str': 'Cerebellar structure'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}, {'cui': 'C0858470', 'cui_str': 'Jerkiness'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",20.0,0.277387,"In tandem and semitandem tasks, active stimulation was associated with increase in time without falls (both p=0.04).","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Pilotto', 'Affiliation': 'Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, P.zale Spedali Civili, 1, 25123, Brescia, Italy. pilottoandreae@gmail.com.'}, {'ForeName': 'Maria Cristina', 'Initials': 'MC', 'LastName': 'Rizzetti', 'Affiliation': ""Parkinson's Disease Rehabilitation Unit, FERB Onlus Trescore Balneario, Bergamo, Italy.""}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Lombardi', 'Affiliation': 'Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, P.zale Spedali Civili, 1, 25123, Brescia, Italy.'}, {'ForeName': 'Clint', 'Initials': 'C', 'LastName': 'Hansen', 'Affiliation': 'Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Biggi', 'Affiliation': 'Physical Therapy Unit, Milano Bicocca University, Bergamo, Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Verzeroli', 'Affiliation': 'Physical Therapy Unit, Milano Bicocca University, Bergamo, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Martinelli', 'Affiliation': 'Physical Therapy Unit, Milano Bicocca University, Bergamo, Italy.'}, {'ForeName': 'Robbin', 'Initials': 'R', 'LastName': 'Romijnders', 'Affiliation': 'Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Borroni', 'Affiliation': 'Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, P.zale Spedali Civili, 1, 25123, Brescia, Italy.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Maetzler', 'Affiliation': 'Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Padovani', 'Affiliation': 'Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, P.zale Spedali Civili, 1, 25123, Brescia, Italy.'}]","Cerebellum (London, England)",['10.1007/s12311-021-01239-6'] 929,33550418,Impact of in-flight use of FFP2 masks on oxygen saturation: an experimental crossover study.,,2021,"This study was able to show in a crossover design that neither at resting conditions nor during a simulated 80 minutes flight wearing the examined FFP2 face mask leads to changes in the SpO2, the heart rate or the parameters of the capillary blood gas analysis.",[],['FFP2 masks'],['oxygen saturation'],[],"[{'cui': 'C0024861', 'cui_str': 'Mask'}]","[{'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}]",,0.0110445,"This study was able to show in a crossover design that neither at resting conditions nor during a simulated 80 minutes flight wearing the examined FFP2 face mask leads to changes in the SpO2, the heart rate or the parameters of the capillary blood gas analysis.","[{'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Sammito', 'Affiliation': 'German Air Force Centre of Aerospace Medicine, 51147 Cologne, Germany.'}, {'ForeName': 'Geraldine P J', 'Initials': 'GPJ', 'LastName': 'Müller', 'Affiliation': 'German Air Force Centre of Aerospace Medicine, 51147 Cologne, Germany.'}, {'ForeName': 'Oliver Maria', 'Initials': 'OM', 'LastName': 'Erley', 'Affiliation': 'German Air Force Centre of Aerospace Medicine, 51147 Cologne, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Werner', 'Affiliation': 'German Air Force Centre of Aerospace Medicine, 51147 Cologne, Germany.'}]",Journal of travel medicine,['10.1093/jtm/taab018'] 930,33549654,"Comment on ""The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial"": Phototrichogram analysis.",,2021,,['female androgenetic alopecia'],['platelet-rich plasma'],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}]",[],,0.11734,,"[{'ForeName': 'Sehwan', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Biomedical Engineering, College of Medicine, Dankook University, Cheonan, Republic of Korea.'}, {'ForeName': 'Jesse H', 'Initials': 'JH', 'LastName': 'Lam', 'Affiliation': 'Beckman Laser Institute, University of California, Irvine, Irvine, California.'}, {'ForeName': 'Kelsey J', 'Initials': 'KJ', 'LastName': 'Tu', 'Affiliation': 'Department of Biomedical Engineering, College of Medicine, Dankook University, Cheonan, Republic of Korea.'}, {'ForeName': 'Byung Cheol', 'Initials': 'BC', 'LastName': 'Park', 'Affiliation': 'Department of Dermatology, College of Medicine, Dankook University, Cheonan, Republic of Korea. Electronic address: 4exodus@daum.net.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.12.093'] 931,33507722,Efficacy of daily GnRH agonist for luteal phase support following GnRH agonist triggered ICSI cycles versus conventional strategy: A Randomized controlled trial.,"OBJECTIVE The use of gonadotropin-releasing hormone agonist (GnRHa) as an alternative for human chronic gonadotropin (hCG) trigger has potential benefits, but the optimal luteal phase support (LPS) following GnRHa trigger remains to be elucidated. We aimed to investigate a new strategy (daily GnRH agonist for LPS following GnRH agonist trigger) as an alternative for the conventional approach to the patients undergoing intracytoplasmic sperm injection (ICSI). METHODS In this randomized controlled trial study, 44 ICSI patients were randomly assigned into two groups: group 1, patients received standard strategy (hCG trigger [10000 IU] and progesterone bid [400 mg/BD] for LPS); group 2, patients received a dose of GnRHa (0.2 mg) for ovulation trigger and subcutaneous injection of GnRHa bid (0.2 mg) for LPS. RESULTS The pregnancy, miscarriage, and live birth rates for the patients undergoing LPS following the GnRHa trigger were similar to those of patients undergoing the standard strategy. CONCLUSIONS We showed that a daily subcutaneous injection of GnRHa for LPS following the GnRHa trigger can be successfully performed as an alternative to the standard strategy, with comparable pregnancy and live birth rates in ICSI patients.",2021,"The pregnancy, miscarriage, and live birth rates for the patients undergoing LPS following the GnRHa trigger were similar to those of patients undergoing the standard strategy. ","['patients undergoing intracytoplasmic sperm injection (ICSI', '44 ICSI patients', 'ICSI patients']","['gonadotropin-releasing hormone agonist (GnRHa', 'daily GnRH agonist', 'GnRHa (0.2 mg) for ovulation trigger and subcutaneous injection of GnRHa bid (0.2 mg) for LPS', 'standard strategy (hCG trigger [10000 IU] and progesterone bid [400 mg/BD] for LPS', 'conventional strategy']","['pregnancy, miscarriage, and live birth rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}]","[{'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0029965', 'cui_str': 'Ovulation'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous injection'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}, {'cui': 'C0024153', 'cui_str': 'Menstrual Cycle, Luteal Phase'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018061', 'cui_str': 'Gonadotropin'}, {'cui': 'C4319546', 'cui_str': '10000'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}]",44.0,0.221153,"The pregnancy, miscarriage, and live birth rates for the patients undergoing LPS following the GnRHa trigger were similar to those of patients undergoing the standard strategy. ","[{'ForeName': 'Saghar', 'Initials': 'S', 'LastName': 'Salehpour', 'Affiliation': 'Department of Obstetrics and Gynecology, Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Nazari', 'Affiliation': 'Department of Obstetrics and Gynecology, Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Sedighe', 'Initials': 'S', 'LastName': 'Hosseini', 'Affiliation': 'Department of Obstetrics and Gynecology, Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Azizi', 'Affiliation': 'Department of Biology and Anatomical Sciences, Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Borumandnia', 'Affiliation': 'Urology and Nephrology Research Center (UNRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Teibeh', 'Initials': 'T', 'LastName': 'Hashemi', 'Affiliation': 'Department of Obstetrics and Gynecology, Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",JBRA assisted reproduction,['10.5935/1518-0557.20200077'] 932,33508499,Clinical and Functional Connectivity Outcomes of 5-Hz Repetitive Transcranial Magnetic Stimulation as an Add-on Treatment in Cocaine Use Disorder: A Double-Blind Randomized Controlled Trial.,"BACKGROUND Cocaine use disorder (CUD) is a global condition lacking effective treatment. Repetitive transcranial magnetic stimulation (rTMS) may reduce craving and frequency of cocaine use, but little is known about its efficacy and neural effects. We sought to elucidate short- and long-term clinical benefits of 5-Hz rTMS as an add-on to standard treatment in patients with CUD and discern underlying functional connectivity effects using magnetic resonance imaging. METHODS A total of 44 patients with CUD were randomly assigned to complete the 2-week double-blind randomized controlled trial (acute phase) (sham [n = 20, 2 female] and active [n = 24, 4 female]), in which they received two daily sessions of rTMS on the left dorsolateral prefrontal cortex (PFC). Subsequently, 20 patients with CUD continued to an open-label maintenance phase for 6 months (two weekly sessions for up to 6 mo). RESULTS rTMS plus standard treatment for 2 weeks significantly reduced craving (baseline: 3.9 ± 3.6; 2 weeks: 1.5 ± 2.4, p = .013, d = 0.77) and impulsivity (baseline: 64.8 ± 16.8; 2 weeks: 53.1 ± 17.4, p = .011, d = 0.79) in the active group. We also found increased functional connectivity between the left dorsolateral PFC and ventromedial PFC and between the ventromedial PFC and right angular gyrus. Clinical and functional connectivity effects were maintained for 3 months, but they dissipated by 6 months. We did not observe reduction in positive results for cocaine in urine; however, self-reported frequency and grams consumed for 6 months were reduced. CONCLUSIONS With this randomized controlled trial, we show that 5-Hz rTMS has potential promise as an adjunctive treatment for CUD and merits further research.",2021,"We did not observe reduction of positive cocaine urine tests, however, self-reported frequency and grams consumed for 6 months were reduced. ","['Forty-four CUD patients', 'cocaine use disorder', 'CUD patients and discern underlying functional connectivity (FC', 'Sham (n=20, 2 female) and Active (n=24, 4 female']","['5-Hz rTMS', 'magnetic resonance imaging', 'rTMS', 'RCT', 'magnetic transcranial stimulation (rTMS', '5-Hz repeated transcranial magnetic stimulation']","['reduced craving', 'FC between lDLPFC-vmPFC and vmPFC-right angular gyrus Clinical and functional connectivity effects']","[{'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0152305', 'cui_str': 'Structure of angular gyrus'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",44.0,0.264267,"We did not observe reduction of positive cocaine urine tests, however, self-reported frequency and grams consumed for 6 months were reduced. ","[{'ForeName': 'Eduardo A', 'Initials': 'EA', 'LastName': 'Garza-Villarreal', 'Affiliation': 'Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM) campus Juriquilla, Queretaro, Mexico; Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría ""Ramón de la Fuente Muñiz,"" Mexico City, Mexico. Electronic address: egarza@comunidad.unam.mx.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Alcala-Lozano', 'Affiliation': 'Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría ""Ramón de la Fuente Muñiz,"" Mexico City, Mexico.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Fernandez-Lozano', 'Affiliation': 'Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría ""Ramón de la Fuente Muñiz,"" Mexico City, Mexico; Faculty of Psychology, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Morelos-Santana', 'Affiliation': 'Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría ""Ramón de la Fuente Muñiz,"" Mexico City, Mexico; Faculty of Psychology, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Dávalos', 'Affiliation': 'Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría ""Ramón de la Fuente Muñiz,"" Mexico City, Mexico; Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.'}, {'ForeName': 'Viviana', 'Initials': 'V', 'LastName': 'Villicaña', 'Affiliation': 'Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría ""Ramón de la Fuente Muñiz,"" Mexico City, Mexico; Faculty of Psychology, Universidad Anahuac Sur, Mexico City, Mexico.'}, {'ForeName': 'Sarael', 'Initials': 'S', 'LastName': 'Alcauter', 'Affiliation': 'Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM) campus Juriquilla, Queretaro, Mexico.'}, {'ForeName': 'F Xavier', 'Initials': 'FX', 'LastName': 'Castellanos', 'Affiliation': 'Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York; Nathan Kline Institute for Psychiatric Research, Orangeburg, New York.'}, {'ForeName': 'Jorge J', 'Initials': 'JJ', 'LastName': 'Gonzalez-Olvera', 'Affiliation': 'Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría ""Ramón de la Fuente Muñiz,"" Mexico City, Mexico.'}]",Biological psychiatry. Cognitive neuroscience and neuroimaging,['10.1016/j.bpsc.2021.01.003'] 933,33508448,"Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3).","BACKGROUND Selecting the most effective treatment represents a critical challenge with the potential of modifying the long-term prognosis of individuals suffering a first break of psychosis. Head-to-head clinical trials comparing effectiveness among antipsychotic drugs in individuals with a first-episode of non-affective psychosis (FEP) are scarce. METHODS The rationale and design of a 3 phases clinical trial (PAFIP-3, NCT02305823) comparing the effectiveness of aripiprazole and risperidone, and to additionally assess the benefits of an early use of clozapine in primary treatment-resistant patients is reported. The design encompasses of 5 work packages (medication algorithm, cognitive functioning, psychoeducation/vocational functioning, imaging and biological markers) addressing critical issues and needs of first episode psychosis individuals and their cares. The primary outcome measure was treatment effectiveness assessed by all-cause treatment discontinuation rate. RESULTS 266 individuals have been included in the randomization study phase I (risperidone vs. aripiprazole). At 3 months, the retention rate was of 94% (249/266), 48(19.3%) patients have gone through phase II (olanzapine treatment), and 7(2.8%) entered the clozapine phase (phase III). DISCUSSION The PAFIP 3 clinical trial may provide relevant information about clinical guidelines to optimally treat patients with a first episode of non-affective psychosis and the benefits and risks of an early use of clozapine in treatment resistant patients. Clinicaltrials.gov: NCT02305823.",2021,,['first episode non-affective psychosis'],"['aripiprazole', 'risperidone']",[],"[{'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0001723', 'cui_str': 'Affective psychosis'}]","[{'cui': 'C0299792', 'cui_str': 'aripiprazole'}, {'cui': 'C0073393', 'cui_str': 'Risperidone'}]",[],,0.0117071,,"[{'ForeName': 'Mayoral-van', 'Initials': 'MV', 'LastName': 'Son J', 'Affiliation': 'Hospital Universitario Virgen del Rocío, Departamento de Psiquiatría, Universidad de Sevilla, IBiS, CIBERSAM, Sevilla, Spain. Electronic address: jacquelinemvs@yahoo.es.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Gómez-Revuelta', 'Affiliation': 'Hospital Universitario Marques de Valdecilla, Departamento de Psiquiatría, Universidad de Cantabria, IDIVAL, CIBERSAM, Santander, Spain. Electronic address: marcos.gomezr@scsalud.es.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Ayesa-Arriola', 'Affiliation': 'Hospital Universitario Marques de Valdecilla, Departamento de Psiquiatría, Universidad de Cantabria, IDIVAL, CIBERSAM, Santander, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Vázquez-Bourgón', 'Affiliation': 'Hospital Universitario Marques de Valdecilla, Departamento de Psiquiatría, Universidad de Cantabria, IDIVAL, CIBERSAM, Santander, Spain.'}, {'ForeName': 'Víctor Ortiz-García de la', 'Initials': 'VO', 'LastName': 'Foz', 'Affiliation': 'Hospital Universitario Marques de Valdecilla, Departamento de Psiquiatría, Universidad de Cantabria, IDIVAL, CIBERSAM, Santander, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Ruiz-Veguilla', 'Affiliation': 'Hospital Universitario Virgen del Rocío, Departamento de Psiquiatría, Universidad de Sevilla, IBiS, CIBERSAM, Sevilla, Spain.'}, {'ForeName': 'Nathalia', 'Initials': 'N', 'LastName': 'Garrido', 'Affiliation': 'Hospital Universitario Virgen del Rocío, Departamento de Psiquiatría, Universidad de Sevilla, IBiS, CIBERSAM, Sevilla, Spain.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Tordesillas-Gutiérrez', 'Affiliation': 'Hospital Universitario Marques de Valdecilla, Departamento de Psiquiatría, Universidad de Cantabria, IDIVAL, CIBERSAM, Santander, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Setién-Suero', 'Affiliation': 'Hospital Universitario Marques de Valdecilla, Departamento de Psiquiatría, Universidad de Cantabria, IDIVAL, CIBERSAM, Santander, Spain.'}, {'ForeName': 'Benedicto', 'Initials': 'B', 'LastName': 'Crespo-Facorro', 'Affiliation': 'Hospital Universitario Virgen del Rocío, Departamento de Psiquiatría, Universidad de Sevilla, IBiS, CIBERSAM, Sevilla, Spain.'}]",Revista de psiquiatria y salud mental,['10.1016/j.rpsm.2021.01.004'] 934,33527192,RCT on the effectiveness of the intraligamentary anesthesia and inferior alveolar nerve block on pain during dental treatment.,"OBJECTIVE To compare the effectiveness and complications of intraligamentary anesthesia (ILA) with conventional inferior alveolar nerve block (IANB) during injection and dental treatment of mandibular posterior teeth. MATERIALS AND METHODS In this randomized, prospective clinical trial, 72 patients (39 males, 33 females), scheduled for dental treatment of mandibular posterior teeth, were randomly allocated to ILA group (n = 35) received ILA injection or IANB group (n = 37) received the conventional IANB. Our primary outcome was to assess pain and stress (discomfort) during the injection and dental treatment, using the numeric rating scale (NRS) from 0 to 10 (0 = no pain, 10= the worst pain imaginable), whereas recording 24-h postoperative complications was our secondary outcomes. RESULTS Patients in ILA group reported significantly less pain during injection when compared with IANB group (p = 0.03), while pain during dental treatment was similar in both groups (p = 0.2). Patients in both groups also reported similar law values of discomfort during treatment (p = 0.7). Although no signs of nerve contact or any other postoperative complications were observed, five patients in IANB group (none in ILA group) reported temporary irritations. CONCLUSION This study showed equivalent effectiveness of both intraligamentary anesthesia and conventional inferior alveolar nerve block, for pain control during routine dental treatment of mandibular posterior teeth. Nevertheless, ILA showed significantly less pain during injection. No major postoperative complications in both groups were observed. CLINICAL RELEVANCE ILA could be considered as an effective alternative for routine dental treatment. TRIAL REGISTRATION NCT04563351.",2021,"RESULTS Patients in ILA group reported significantly less pain during injection when compared with IANB group (p = 0.03), while pain during dental treatment was similar in both groups (p = 0.2).","['pain control during routine dental treatment of mandibular posterior teeth', 'mandibular posterior teeth', '72 patients (39 males, 33 females), scheduled for dental treatment of mandibular posterior teeth']","['IANB', 'ILA injection or IANB', 'intraligamentary anesthesia and conventional inferior alveolar nerve block', 'conventional IANB', 'ILA', 'RCT', 'intraligamentary anesthesia (ILA) with conventional inferior alveolar nerve block (IANB', 'intraligamentary anesthesia and inferior alveolar nerve block']","['major postoperative complications', 'numeric rating scale (NRS', 'postoperative complications', 'pain during injection', 'pain and stress (discomfort', 'recording 24-h postoperative complications', 'law values of discomfort', 'pain']","[{'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0011331', 'cui_str': 'Dental care'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0394801', 'cui_str': 'Local anesthetic inferior alveolar nerve block'}, {'cui': 'C4285981', 'cui_str': 'Intraligamentary anaesthesia'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1096717', 'cui_str': 'Pain during injection'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0023150', 'cui_str': 'Law'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",72.0,0.149021,"RESULTS Patients in ILA group reported significantly less pain during injection when compared with IANB group (p = 0.03), while pain during dental treatment was similar in both groups (p = 0.2).","[{'ForeName': 'Bahaa R', 'Initials': 'BR', 'LastName': 'Youssef', 'Affiliation': 'Departments of Preventive Dentistry and Pediatric Dentistry, University Medicine of Greifswald, Fleischmannstr. 42, 17487, Greifswald, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Söhnel', 'Affiliation': 'Department of Prosthetic Dentistry, Gerodontology and Biomaterials, University Medicine of Greifswald, Greifswald, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Welk', 'Affiliation': 'Department of Restorative Dentistry, Periodontology and Endodotontology, University Medicine of Greifswald, Greifswald, Germany.'}, {'ForeName': 'Mohamed H', 'Initials': 'MH', 'LastName': 'Abudrya', 'Affiliation': 'Departments of Preventive Dentistry and Pediatric Dentistry, University Medicine of Greifswald, Fleischmannstr. 42, 17487, Greifswald, Germany.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Baider', 'Affiliation': 'Departments of Preventive Dentistry and Pediatric Dentistry, University Medicine of Greifswald, Fleischmannstr. 42, 17487, Greifswald, Germany.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Alkilzy', 'Affiliation': 'Departments of Preventive Dentistry and Pediatric Dentistry, University Medicine of Greifswald, Fleischmannstr. 42, 17487, Greifswald, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Splieth', 'Affiliation': 'Departments of Preventive Dentistry and Pediatric Dentistry, University Medicine of Greifswald, Fleischmannstr. 42, 17487, Greifswald, Germany. splieth@uni-greifswald.de.'}]",Clinical oral investigations,['10.1007/s00784-021-03787-x'] 935,33533688,"Positive Effects of Kangaroo Mother Care on Long-Term Breastfeeding Rates, Growth, and Neurodevelopment in Preterm Infants.","Background and Objectives: Kangaroo mother care (KMC) benefits preterm infants' health through increasing breastfeeding, but the longitudinal effects of KMC remain unknown. This study investigates the impact of KMC on breastfeeding and health outcomes in Chinese preterm infants. Methods: A longitudinal randomized controlled study was conducted with 79 preterm infant-mother dyads. The KMC group ( n  = 36) was provided 2.5 hours/day KMC during the neonatal intensive care unit (NICU) hospitalization, while the control group ( n  = 43) received standard care. Infant's feeding regimens and physical growth were documented daily at NICU. Physical growth and Neonatal Behavioral Neurological Assessment were measured at 40 weeks, 3 months, and 6 months of corrected age (CA). Breastfeeding outcomes were documented at 6 months of CA. Results: Compared with the control group, KMC infants received higher mothers' milk proportion during hospitalization ( B  = 0.16, confidence interval [CI] = [0.11-0.21]) and less feeding intolerance at discharge (odds ratio [OR] = 0.11, CI = [0.02-0.43]); and higher exclusive breastfeeding proportion (OR = 14.6, CI = [3.5-60.9]) at 6 months CA. KMC infants also had significant increased body weight and body length at hospital discharge; and more increases of body weight, body length, and head circumference in follow-ups. The neurobehavioral score was also higher in the KMC group compared to the control group over time. Conclusions: Longitudinal KMC effects are significant in promoting preterm infants' breastfeeding outcomes, growth, and neurodevelopment. Early initiation of KMC practice is highly recommended to the parent-infant population in Chinese NICUs to promote breastfeeding and developmental outcomes.",2021,"Compared with the control group, KMC infants received higher mothers' milk proportion during hospitalization ( B  = 0.16, confidence interval [CI] = [0.11-0.21]) and less feeding intolerance at discharge (odds ratio [OR] = 0.11, CI = [0.02-0.43]); and higher exclusive breastfeeding proportion (OR = 14.6, CI = [3.5-60.9]) at 6 months CA.","['Preterm Infants', 'Chinese preterm infants', '79 preterm infant-mother dyads']","['Kangaroo mother care (KMC', 'standard care', 'Kangaroo Mother Care', 'KMC']","['Physical growth and Neonatal Behavioral Neurological Assessment', 'body weight, body length, and head circumference', 'neurobehavioral score', 'breastfeeding and health outcomes', ""preterm infants' breastfeeding outcomes, growth, and neurodevelopment"", 'feeding intolerance at discharge', 'body weight and body length at hospital discharge', 'Long-Term Breastfeeding Rates, Growth, and Neurodevelopment']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C1257803', 'cui_str': 'Kangaroo-Mother Care'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0027853', 'cui_str': 'Neurological examination'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0221097', 'cui_str': 'Length of body'}, {'cui': 'C0262499', 'cui_str': 'Head circumference'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C1820738', 'cui_str': 'Feeding intolerance'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]",79.0,0.0865375,"Compared with the control group, KMC infants received higher mothers' milk proportion during hospitalization ( B  = 0.16, confidence interval [CI] = [0.11-0.21]) and less feeding intolerance at discharge (odds ratio [OR] = 0.11, CI = [0.02-0.43]); and higher exclusive breastfeeding proportion (OR = 14.6, CI = [3.5-60.9]) at 6 months CA.","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Neonatal Intensive Care Unit, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Zhao', 'Affiliation': 'School of Nursing, University of Connecticut, Storrs, Connecticut, USA.'}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Statistics; University of Connecticut, Storrs, Connecticut, USA.'}, {'ForeName': 'Siying', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Neonatal Intensive Care Unit, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiaomei', 'Initials': 'X', 'LastName': 'Cong', 'Affiliation': 'School of Nursing, University of Connecticut, Storrs, Connecticut, USA.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0358'] 936,33541242,Effects of SNAG mobilization combined with a self-SNAG home-exercise for the treatment of cervicogenic headache: a pilot study.,"INTRODUCTION Cervicogenic headache (CGH) may originate from the C1-C2 zygapophyseal joints. CGH is often associated with loss of range of motion (ROM), specific to this segment, and measurable by the cervical flexion-rotation test (CFRT). The main purposes of the study were: 1) to investigate the immediate effect of C1-C2 rotation SNAG mobilizations plus C1-C2 self-SNAG rotation exercise for patients with CGH and 2) to explore the link between the CFRT results and treatment response. METHODS A prospective quasi-experimental single-arm design was used where patients with CGH received eight physical therapy treatments using a C1-C2 rotational SNAG technique combined with a C1-C2 self-SNAG rotation exercise over a four-week period. Outcome measures were pain intensity/frequency and duration, active cervical ROM, CFRT, neck-related and headache-related self-perceived physical function, fear-avoidance beliefs, pain catastrophizing and kinesiophobia. RESULTS The intervention produced strong effects on pain intensity, CFRT, physical function and pain catastrophizing. Moderate improvement was noted on active cervical ROM and on fear-avoidance beliefs and kinesiophobia. No link was found between pre-intervention CFRT ROM and treatment response. CONCLUSION SNAG mobilization combined with a self-SNAG exercise resulted in favorable outcomes for the treatment of CGH on patient-important and biomechanical outcomes, as well as pain-related cognitive-affective factors.",2021,"The intervention produced strong effects on pain intensity, CFRT, physical function and pain catastrophizing.","['cervicogenic headache', 'patients with CGH', 'patients with CGH and 2']","['SNAG mobilization combined with a self-SNAG exercise', 'C1-C2 rotation SNAG mobilizations plus C1-C2 self-SNAG rotation exercise', 'SNAG mobilization combined with a self-SNAG home-exercise', 'CGH', 'C1-C2 rotational SNAG technique combined with a C1-C2 self-SNAG rotation exercise']","['pain intensity, CFRT, physical function and pain catastrophizing', 'active cervical ROM and on fear-avoidance beliefs and kinesiophobia', 'pain intensity/frequency and duration, active cervical ROM, CFRT, neck-related and headache-related self-perceived physical function, fear-avoidance beliefs, pain catastrophizing and kinesiophobia']","[{'cui': 'C0458101', 'cui_str': 'Cervicogenic headache'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0796358', 'cui_str': 'Comparative Genome Hybridization'}]","[{'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0796358', 'cui_str': 'Comparative Genome Hybridization'}, {'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0948106', 'cui_str': 'Amniorrhexis'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",,0.0213356,"The intervention produced strong effects on pain intensity, CFRT, physical function and pain catastrophizing.","[{'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Paquin', 'Affiliation': 'Faculty of Medicine and Health Sciences, Université De Sherbrooke, Sherbrooke, QC, Canada.'}, {'ForeName': 'Yannick', 'Initials': 'Y', 'LastName': 'Tousignant-Laflamme', 'Affiliation': 'School of Rehabilitation, Faculty of Medicine and Health Sciences, Université De Sherbrooke, Sherbrooke, QC, Canada.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Dumas', 'Affiliation': 'School of Rehabilitation, Faculty of Medicine and Health Sciences, Université De Sherbrooke, Sherbrooke, QC, Canada.'}]",The Journal of manual & manipulative therapy,['10.1080/10669817.2020.1864960'] 937,33547927,App-based rehabilitation program after total knee arthroplasty: a randomized controlled trial.,"INTRODUCTION New app-based programs for postoperative rehabilitation have been developed, but no long-term study has been published to date. Thus, a prospective randomized control trial with 2-year follow-up was performed to evaluate the effectiveness of app-based rehabilitation (GenuSport) compared to a control group after total knee arthroplasty (TKA). METHODS Between April and October 2016, 60 patients were enrolled in the study. Twenty-five patients were lost to follow-up, leaving 35 patients undergoing TKA for inclusion. In this group, twenty patients received app-based exercise program and 15 were randomized to the control group. The mean age was 64.37 ± 9.32 years with a mean follow-up of 23.51 ± 1.63 months. Patients in the app group underwent an app-based knee training starting on the day of surgery; whereas, patients in the control group underwent regular physiotherapy. Functional outcome scores using the Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Society Score (KSS) and VAS of pain were analyzed. RESULTS In the short term, significant differences between the app group and control group in time of 10-m walk (19.66 ± 7.80 vs. 27.08 ± 15.46 s; p = 0.029), VAS pain at rest and activity (2.65 ± 0.82 vs. 3.57 ± 1.58, respectively 4.03 ± 1.26 vs. 5.05 ± 1.21; p < 0.05) were observed. In the long term, a variety of different tendencies was found, highest in KSS Function with 76.32 ± 16.49 (app group) vs. 67.67 ± 16.57 (control group) (p = 0.130). Additionally, patients in the app group required less painkillers (10.0% vs. 26.7%) and more likely to participate in sports (65.0% vs. 53.3%). CONCLUSIONS An app-based knee trainer is a promising tool in improving functional outcomes such as KSS function score and VAS after TKA. LEVEL OF EVIDENCE Level II, prospective randomized control trial.",2021,"CONCLUSIONS An app-based knee trainer is a promising tool in improving functional outcomes such as KSS function score and VAS after TKA. ","['Between April and October 2016', 'after total knee arthroplasty', '60 patients were enrolled in the study', 'The mean age was 64.37\u2009±\u20099.32\xa0years with a mean follow-up of 23.51\u2009±\u20091.63\xa0months']","['app-based rehabilitation (GenuSport', 'app-based exercise program', 'control group after total knee arthroplasty (TKA', 'app-based knee training starting', 'App-based rehabilitation program', 'control group underwent regular physiotherapy']","['time of 10-m walk', 'VAS pain at rest and activity', 'Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Society Score (KSS) and VAS of pain', 'less painkillers']","[{'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0234253', 'cui_str': 'Rest pain'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C3476088', 'cui_str': 'Knee Injury and Osteoarthritis Outcome Score'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}]",25.0,0.063105,"CONCLUSIONS An app-based knee trainer is a promising tool in improving functional outcomes such as KSS function score and VAS after TKA. ","[{'ForeName': 'Henrik C', 'Initials': 'HC', 'LastName': 'Bäcker', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Charité Berlin, University Hospital, Chariteplatz 1, 10117, Berlin, Germany. Henrik.baecker@sports-med.org.'}, {'ForeName': 'Chia H', 'Initials': 'CH', 'LastName': 'Wu', 'Affiliation': 'Department of Orthopedics and Sports Medicine, Baylor College of Medicine Medical Center, Houston, TX, USA.'}, {'ForeName': 'Matthias R G', 'Initials': 'MRG', 'LastName': 'Schulz', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Charité Berlin, University Hospital, Chariteplatz 1, 10117, Berlin, Germany.'}, {'ForeName': 'Thomas Sanjay', 'Initials': 'TS', 'LastName': 'Weber-Spickschen', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, Podbielskistrasse 380, 30659, Hannover, Germany.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Perka', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Charité Berlin, University Hospital, Chariteplatz 1, 10117, Berlin, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Hardt', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Charité Berlin, University Hospital, Chariteplatz 1, 10117, Berlin, Germany.'}]",Archives of orthopaedic and trauma surgery,['10.1007/s00402-021-03789-0'] 938,33547855,Effects of allogenic acellular dermal matrix combined with autologous razor-thin graft on hand appearance and function of patients with extensive burn combined with deep hand burn.,"The aim of the study was to observe the effect of allogeneic acellular dermal matrix (ADM) combined with autologous razor-thin graft on the appearance and function of hands in patients with extremely large area burns combined with deep hand burns. Sixty-four patients with severe burn combined with deep burn of the hand in our hospital from August 2015 to August 2019 were selected as the study subjects. All patients were randomly divided into the study group (32 cases, given allogeneic ADM combined with autologous razor-thin graft) and the control group (32 cases, given autologous scar tissue combined with autologous razor-thin graft). Hand appearance, wound healing, wound contraction, hand function, and quality of life were compared between the two groups at 3 and 6 months after treatment. The vascular distribution, skin thickness, and flexibility scores of the two groups 6 months post operation were lower than those of the 3 months post operation (P < .05). At 6 months after operation, there were significant differences in blood vessel distribution, skin thickness, flexibility, and colour between the two groups (P < .05). The wound healing rate and wound contraction rate of the two groups at 6 months after operation were higher than those at 3 months after operation (P < .05). The wound healing rate of the study group was higher than that of the control group (P < .05), but there was no significant difference in the wound contraction rate between the two groups. Hand function was better in both groups 6 months after operation than 3 months after operation (P < .05). The hand function of the experimental group was better than that of the control group at 3 and 6 months after operation (P < .05). The quality of life in the two groups at 6 months after operation was significantly higher than that at 3 months after operation, and the quality of life in the study group was consistently higher than that in the control group (P < .05). Allogeneic ADM combined with razor-thin graft in the treatment of patients with extensive burns and deep hand burns can effectively restore the shape and function of the hand, which is conducive to wound healing and improve the quality of life of patients, and it is worthy of wide clinical application.",2021,"The quality of life in the two groups at 6 months after operation was significantly higher than that at 3 months after operation, and the quality of life in the study group was consistently higher than that in the control group (P < .05).","['patients with extensive burns and deep hand burns', 'Sixty-four patients with severe burn combined with deep burn of the hand in our hospital from August 2015 to August 2019 were selected as the study subjects', 'patients with extensive burn combined with deep hand burn', 'patients with extremely large area burns combined with deep hand burns']","['allogeneic ADM combined with autologous razor-thin graft) and the control group (32 cases, given autologous scar tissue combined with autologous razor-thin graft', 'allogeneic acellular dermal matrix (ADM) combined with autologous razor-thin graft', 'Allogeneic ADM combined with razor-thin graft', 'allogenic acellular dermal matrix combined with autologous razor-thin graft']","['vascular distribution, skin thickness, and flexibility scores', 'wound contraction rate', 'wound healing rate', 'blood vessel distribution, skin thickness, flexibility, and colour', 'Hand function', 'Hand appearance, wound healing, wound contraction, hand function, and quality of life', 'quality of life', 'wound healing rate and wound contraction rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205231', 'cui_str': 'Extensive'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0274089', 'cui_str': 'Burn of hand'}, {'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205403', 'cui_str': 'Extreme'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C3494272', 'cui_str': 'Acellular Dermal Matrix'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0336670', 'cui_str': 'Razor'}, {'cui': 'C0205168', 'cui_str': 'Thin'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0241158', 'cui_str': 'Scar of skin'}]","[{'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0423756', 'cui_str': 'Thickness of skin'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0562230', 'cui_str': 'Hand functions'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",64.0,0.0137176,"The quality of life in the two groups at 6 months after operation was significantly higher than that at 3 months after operation, and the quality of life in the study group was consistently higher than that in the control group (P < .05).","[{'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Shang', 'Affiliation': ""Department of Burns, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China.""}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Hou', 'Affiliation': ""Department of Burns, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China.""}]",International wound journal,['10.1111/iwj.13532'] 939,33515757,The Effect of Prestudy Insulin Therapy on Safety and Efficacy of Human Regular U-500 Insulin by Pump or Injection: A Posthoc Analysis.,"OBJECTIVE We conducted a posthoc analysis of the VIVID study (Safety and Efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Parallel Clinical Trial), comparing 2 delivery methods of human regular U-500 insulin (U-500R), continuous subcutaneous insulin infusion (CSII) versus multiple daily injection (MDI), in type 2 diabetes requiring high insulin, to determine influence of prestudy insulin on glycemic outcomes. METHODS We compared A1C, total daily insulin dose (TDD), weight, and hypoglycemia by subgroups of prestudy insulin (prestudy U-500R vs non-U-500R) and treatment (CSII vs MDI). RESULTS At baseline, prestudy U-500R had higher TDD, higher body mass index, lower A1C and fasting plasma glucose, and higher rate of hypoglycemia compared to non-U-500R. Active titration of U-500R reduced A1C in both subgroups, with maximum benefit at 8 weeks. At 26 weeks, CSII provided the greatest reduction in A1C in both subgroups, with a greater reduction in non-U-500R. MDI provided an A1C reduction in both subgroups, with the greater reduction in non-U-500R. At 8 weeks, prestudy U-500R reached its lowest A1C; thereafter, A1C rebounded with MDI and remained stable with CSII. In non-U-500R, A1C continued to decrease to study end. In non-U-500R, hypoglycemia increased during active titration, but then decreased in the posttitration maintenance period. In both subgroups, TDD increased from baseline with MDI but not with CSII. Body weight increased in both subgroups but was greater in prestudy U-500R with CSII compared to MDI. CONCLUSION Regardless of previous insulin, people on high-dose insulin could lower A1C with U-500R, with additional benefit from CSII. These results may provide guidance for use of U-500R in clinical practice.",2021,"Body weight increased in both subgroups but was greater in Prestudy U-500R with CSII compared to MDI. ",['type 2 diabetes requiring high insulin'],"['Human Regular U-500 insulin (U-500R), continuous subcutaneous insulin infusion (CSII) vs multiple daily injection (MDI', 'Prestudy Insulin Therapy', 'Human Regular U-500 Insulin by Pump or Injection']","['TDD, higher BMI, lower A1C and fasting plasma glucose, and higher rate of hypoglycemia', 'TDD', 'A1C reduction', 'hypoglycemia', 'Safety and Efficacy', 'total daily insulin dose (TDD), weight, and hypoglycemia by subgroups of prestudy insulin (Prestudy U-500R vs Non-U-500R) and treatment (CSII vs MDI', 'Body weight']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0020459', 'cui_str': 'Hyperinsulinism'}]","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0199782', 'cui_str': 'Administration of insulin'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0182537', 'cui_str': 'Pump'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0199782', 'cui_str': 'Administration of insulin'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]",,0.0231699,"Body weight increased in both subgroups but was greater in Prestudy U-500R with CSII compared to MDI. ","[{'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Hood', 'Affiliation': 'Endocrine Clinic of Southeast Texas, Beaumont, Texas. Electronic address: setxendo@yahoo.com.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Techdata Service Company, LLC, King of Prussia, Pennsylvania.'}, {'ForeName': 'Dana K', 'Initials': 'DK', 'LastName': 'Sindelar', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.'}, {'ForeName': 'Trang', 'Initials': 'T', 'LastName': 'Ly', 'Affiliation': 'Insulet Corporation, Acton, Massachusetts.'}, {'ForeName': 'Rattan', 'Initials': 'R', 'LastName': 'Juneja', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.'}, {'ForeName': 'R Daniel', 'Initials': 'RD', 'LastName': 'Pollom', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.'}, {'ForeName': 'Liza', 'Initials': 'L', 'LastName': 'Ilag', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Wysham', 'Affiliation': 'Rockwood Clinic, Spokane, Washington.'}]",Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,['10.1016/j.eprac.2021.01.012'] 940,33516859,Pinging the brain with transcranial magnetic stimulation reveals cortical reactivity in time and space.,"BACKGROUND Single-pulse transcranial magnetic stimulation (TMS) elicits an evoked electroencephalography (EEG) potential (TMS-evoked potential, TEP), which is interpreted as direct evidence of cortical reactivity to TMS. Thus, combining TMS with EEG can be used to investigate the mechanism underlying brain network engagement in TMS treatment paradigms. However, controversy remains regarding whether TEP is a genuine marker of TMS-induced cortical reactivity or if it is confounded by responses to peripheral somatosensory and auditory inputs. Resolving this controversy is of great significance for the field and will validate TMS as a tool to probe networks of interest in cognitive and clinical neuroscience. OBJECTIVE Here, we delineated the cortical origin of TEP by spatially and temporally localizing successive TEP components, and modulating them with transcranial direct current stimulation (tDCS) to investigate cortical reactivity elicited by single-pulse TMS and its causal relationship with cortical excitability. METHODS We recruited 18 healthy participants in a double-blind, cross-over, sham-controlled design. We collected motor-evoked potentials (MEPs) and TEPs elicited by suprathreshold single-pulse TMS targeting the left primary motor cortex (M1). To causally test cortical and corticospinal excitability, we applied tDCS to the left M1. RESULTS We found that the earliest TEP component (P25) was localized to the left M1. The following TEP components (N45 and P60) were largely localized to the primary somatosensory cortex, which may reflect afferent input by hand-muscle twitches. The later TEP components (N100, P180, and N280) were largely localized to the auditory cortex. As hypothesized, tDCS selectively modulated cortical and corticospinal excitability by modulating the pre-stimulus mu-rhythm oscillatory power. CONCLUSION Together, our findings provide causal evidence that the early TEP components reflect cortical reactivity to TMS.",2021,"The later TEP components (N100, P180, and N280) were largely localized to the auditory cortex.","['18 healthy participants in a double-blind, cross-over, sham-controlled design']","['collected motor-evoked potentials (MEPs) and TEPs elicited by suprathreshold single-pulse TMS', 'Transcranial Magnetic Stimulation', 'TEP', 'transcranial direct current stimulation (tDCS', 'pulse transcranial magnetic stimulation (TMS']",['cortical and corticospinal excitability'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0282617', 'cui_str': 'Motor Evoked Potentials'}, {'cui': 'C0145334', 'cui_str': 'tetraethylpyrazine'}, {'cui': 'C0449265', 'cui_str': 'Elicited by'}, {'cui': 'C1564622', 'cui_str': 'Transcranial Magnetic Stimulation, Single Pulse'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}]","[{'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}]",18.0,0.0660331,"The later TEP components (N100, P180, and N280) were largely localized to the auditory cortex.","[{'ForeName': 'Sangtae', 'Initials': 'S', 'LastName': 'Ahn', 'Affiliation': 'School of Electronics Engineering, Kyungpook National University, Daegu, 41566, South Korea; School of Electronic and Electrical Engineering, Kyungpook National University, Daegu, 41566, South Korea; Carolina Center for Neurostimulation, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.'}, {'ForeName': 'Flavio', 'Initials': 'F', 'LastName': 'Fröhlich', 'Affiliation': 'Carolina Center for Neurostimulation, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. Electronic address: flavio_frohlich@med.unc.edu.'}]",Brain stimulation,['10.1016/j.brs.2021.01.018'] 941,33523004,Cognitive Effects of Aerobic Exercise in Alzheimer's Disease: A Pilot Randomized Controlled Trial.,"BACKGROUND Aerobic exercise has shown inconsistent cognitive effects in older adults with Alzheimer's disease (AD) dementia. OBJECTIVE To examine the immediate and longitudinal effects of 6-month cycling on cognition in older adults with AD dementia. METHODS This randomized controlled trial randomized 96 participants (64 to cycling and 32 to stretching for six months) and followed them for another six months. The intervention was supervised, moderate-intensity cycling for 20-50 minutes, 3 times a week for six months. The control was light-intensity stretching. Cognition was assessed at baseline, 3, 6, 9, and 12 months using the AD Assessment Scale-Cognition (ADAS-Cog). Discrete cognitive domains were measured using the AD Uniform Data Set battery. RESULTS The participants were 77.4±6.8 years old with 15.6±2.9 years of education, and 55% were male. The 6-month change in ADAS-Cog was 1.0±4.6 (cycling) and 0.1±4.1 (stretching), which were both significantly less than the natural 3.2±6.3-point increase observed naturally with disease progression. The 12-month change was 2.4±5.2 (cycling) and 2.2±5.7 (control). ADAS-Cog did not differ between groups at 6 (p = 0.386) and 12 months (p = 0.856). There were no differences in the 12-month rate of change in ADAS-Cog (0.192 versus 0.197, p = 0.967), memory (-0.012 versus -0.019, p = 0.373), executive function (-0.020 versus -0.012, p = 0.383), attention (-0.035 versus -0.033, p = 0.908), or language (-0.028 versus -0.026, p = 0.756). CONCLUSION Exercise may reduce decline in global cognition in older adults with mild-to-moderate AD dementia. Aerobic exercise did not show superior cognitive effects to stretching in our pilot trial, possibly due to the lack of power.",2021,ADAS-Cog did not differ between groups at 6 (p = 0.386) and 12 months (p = 0.856).,"['older adults with mild-to-moderate AD dementia', ""Alzheimer's Disease"", ""older adults with Alzheimer's disease (AD) dementia"", 'participants were 77.4±6.8 years old with 15.6±2.9 years of education, and 55%were male', 'older adults with AD dementia', '96 participants (64 to cycling and 32 to stretching for six months) and followed them for another six months']","['Aerobic exercise', 'Aerobic Exercise', 'Exercise']","['global cognition', '12-month rate of change in ADAS-Cog', 'Discrete cognitive domains', 'executive function', 'AD Assessment Scale-Cognition (ADAS-Cog', 'ADAS', 'ADAS-Cog']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0001457', 'cui_str': 'Adenosine deaminase'}]",96.0,0.236741,ADAS-Cog did not differ between groups at 6 (p = 0.386) and 12 months (p = 0.856).,"[{'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Yu', 'Affiliation': 'University of Minnesota Division of Biostatistics, Minneapolis, MN, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Vock', 'Affiliation': 'University of Minnesota Division of Biostatistics, Minneapolis, MN, USA.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'University of Minnesota Division of Biostatistics, Minneapolis, MN, USA.'}, {'ForeName': 'Dereck', 'Initials': 'D', 'LastName': 'Salisbury', 'Affiliation': 'University of Minnesota School of Nursing, Minneapolis, MN, USA.'}, {'ForeName': 'Nathaniel W', 'Initials': 'NW', 'LastName': 'Nelson', 'Affiliation': 'University of Saint Thomas, Saint Paul, MN, USA.'}, {'ForeName': 'Lisa S', 'Initials': 'LS', 'LastName': 'Chow', 'Affiliation': 'University of Minnesota School of Medicine, Minneapolis, MN, USA.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Smith', 'Affiliation': 'University of Florida Department of Clinical and Health Psychology, Gainesville, FL, USA.'}, {'ForeName': 'Terry R', 'Initials': 'TR', 'LastName': 'Barclay', 'Affiliation': 'HealthPartners Center for Memory and Aging, Saint Paul, MN, USA.'}, {'ForeName': 'Maurice', 'Initials': 'M', 'LastName': 'Dysken', 'Affiliation': 'University of Minnesota School of Medicine, Minneapolis, MN, USA.'}, {'ForeName': 'Jean F', 'Initials': 'JF', 'LastName': 'Wyman', 'Affiliation': 'University of Minnesota School of Nursing, Minneapolis, MN, USA.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201100'] 942,33534044,"The Impact of Thoracic Epidural Analgesia Versus Four Quadrant Transversus Abdominis Plane Block on Quality of Recovery After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Surgery: A Single-Center, Noninferiority, Randomized, Controlled Trial.","BACKGROUND Recovery after CRS-HIPEC influenced by several factors, including pain and opioid consumption. We hypothesized that 4Q-TAP blocks provide not inferior quality of recovery compared with TEA after CRS-HIPEC. We conducted a randomized, controlled trial to determine whether 4-quadrant transversus abdominis plane (4Q-TAP) block analgesia was noninferior to thoracic epidural (TEA) among patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS HIPEC). METHODS Patients 18 years or older who underwent a CRS-HIPEC surgery were randomly assigned to have either TEA or 4Q-TAP blocks. The primary outcome of this study was the change in quality of recovery 2 days after surgery. Secondary outcomes included quality of recovery on Days 1, 3, 5, 7, 10, and 30 postoperatively, opioid consumption, pain intensity, length of stay, and postoperative complications. Analyses were performed on a per-protocol basis. RESULTS Sixty-eight patients were included in the analysis. The difference between 4Q-TAP and TEA in the mean QoR-15 change from surgery at postoperative Days 1, 2, and 3 was 0.80 (P = 0.004), -4.5 (P = 0.134), and 3.4 (P = 0.003), respectively. All differences through postoperative day 30 were significantly within the noninferiority boundary of -10 except at postoperative Day 2 (P = 0.134). Length of stay, opioid-related adverse events, and frequency and grade of complications were not significantly different between TEA and 4Q-TAP patients. CONCLUSIONS Despite the significantly higher use of opioids after CRS-HIPEC in patients with 4Q-TAP blocks, their short-term quality of recovery was not inferior to those treated with TEA. Patients undergoing CRS-HIPEC can be effectively managed with 4Q-TAP blocks.",2021,"Length of stay, opioid-related adverse events, and frequency and grade of complications were not significantly different between TEA and 4Q-TAP patients. ","['patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS HIPEC', 'Patients 18 years or older who underwent a CRS-HIPEC surgery', 'Sixty-eight patients were included in the analysis']","['CRS-HIPEC', 'thoracic epidural (TEA', 'Thoracic Epidural Analgesia Versus Four Quadrant Transversus Abdominis Plane Block', '4-quadrant transversus abdominis plane (4Q-TAP) block analgesia', 'TEA', 'TEA or 4Q-TAP blocks', '4Q-TAP blocks', 'Hyperthermic Intraperitoneal Chemotherapy Surgery']","['Length of stay, opioid-related adverse events, and frequency and grade of complications', 'Quality of Recovery', 'quality of recovery on Days 1, 3, 5, 7, 10, and 30 postoperatively, opioid consumption, pain intensity, length of stay, and postoperative complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive surgery'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0010278', 'cui_str': 'Craniosynostosis syndrome'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0010278', 'cui_str': 'Craniosynostosis syndrome'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0439738', 'cui_str': 'Four quadrants'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}]",68.0,0.537122,"Length of stay, opioid-related adverse events, and frequency and grade of complications were not significantly different between TEA and 4Q-TAP patients. ","[{'ForeName': 'Juan P', 'Initials': 'JP', 'LastName': 'Cata', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX, 77005, USA. JCata@mdanderson.org.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Fournier', 'Affiliation': 'Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'German', 'Initials': 'G', 'LastName': 'Corrales', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX, 77005, USA.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Owusu-Agyemang', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX, 77005, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Soliz', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX, 77005, USA.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Bravo', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX, 77005, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Wilks', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX, 77005, USA.'}, {'ForeName': 'Antoinette', 'Initials': 'A', 'LastName': 'Van Meter', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX, 77005, USA.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Hernandez', 'Affiliation': 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Gottumukkala', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX, 77005, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of surgical oncology,['10.1245/s10434-021-09622-7'] 943,33544206,Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial.,"PURPOSE Inulin-type fructans (ITF) are prebiotic dietary fibre (DF) that may confer beneficial health effects, by interacting with the gut microbiota. We have tested the hypothesis that a dietary intervention promoting inulin intake versus placebo influences fecal microbial-derived metabolites and markers related to gut integrity and inflammation in obese patients. METHODS Microbiota (16S rRNA sequencing), long- and short-chain fatty acids (LCFA, SCFA), bile acids, zonulin, and calprotectin were analyzed in fecal samples obtained from obese patients included in a randomized, placebo-controlled trial. Participants received either 16 g/d native inulin (prebiotic n = 12) versus maltodextrin (placebo n = 12), coupled to dietary advice to consume inulin-rich versus inulin-poor vegetables for 3 months, in addition to dietary caloric restriction. RESULTS Both placebo and prebiotic interventions lowered energy and protein intake. A substantial increase in Bifidobacterium was detected after ITF treatment (q = 0.049) supporting our recent data obtained in a larger cohort. Interestingly, fecal calprotectin, a marker of gut inflammation, was reduced upon ITF treatment. Both prebiotic and placebo interventions increased the ratio of tauro-conjugated/free bile acids in feces. Prebiotic treatment did not significantly modify fecal SCFA content but it increased fecal rumenic acid, a conjugated linoleic acid (cis-9, trans-11 CLA) with immunomodulatory properties, that correlated notably to the expansion of Bifidobacterium (p = 0.031; r = 0.052). CONCLUSIONS Our study demonstrates that ITF-prebiotic intake during 3 months decreases a fecal marker of intestinal inflammation in obese patients. Our data point to a potential contribution of microbial lipid-derived metabolites in gastro-intestinal dysfunction related to obesity. CLINICALTRIALS. GOV IDENTIFIER NCT03852069 (February 22, 2019 retrospectively, registered).",2021,A substantial increase in Bifidobacterium was detected after ITF treatment (q = 0.049) supporting our recent data obtained in a larger cohort.,['obese patients'],"['placebo', 'dietary intervention promoting inulin intake versus placebo', 'Prebiotic dietary fibre intervention', 'prebiotic and placebo', 'placebo and prebiotic interventions', 'ITF-prebiotic intake', '16\xa0g/d native inulin (prebiotic n\u2009=\u200912) versus maltodextrin (placebo n\u2009=\u200912), coupled to dietary advice to consume inulin-rich versus inulin-poor vegetables for 3\xa0months, in addition to dietary caloric restriction', 'Inulin-type fructans (ITF) are prebiotic dietary fibre (DF']","['ratio of tauro-conjugated/free bile acids', 'Bifidobacterium', 'fecal marker of intestinal inflammation', 'fecal rumenic acid, a conjugated linoleic acid (cis-9, trans-11 CLA', 'long- and short-chain fatty acids (LCFA, SCFA), bile acids, zonulin, and calprotectin', 'fecal SCFA content', 'fecal markers', 'energy and protein intake', 'fecal calprotectin, a marker of gut inflammation']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0016743', 'cui_str': 'Levans'}, {'cui': 'C0456636', 'cui_str': '16G'}, {'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C1135809', 'cui_str': 'Decreased energy diet'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0005390', 'cui_str': 'Bile acid'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C3889047', 'cui_str': 'Intestinal inflammation'}, {'cui': 'C0956901', 'cui_str': '9,11-linoleic acid, (E,Z)-isomer'}, {'cui': 'C0050156', 'cui_str': '9,11-linoleic acid'}, {'cui': 'C0007099', 'cui_str': 'Carcinoma in situ'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0914216', 'cui_str': 'zonulin'}, {'cui': 'C0950624', 'cui_str': 'Calprotectin'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",,0.324266,A substantial increase in Bifidobacterium was detected after ITF treatment (q = 0.049) supporting our recent data obtained in a larger cohort.,"[{'ForeName': 'Audrey M', 'Initials': 'AM', 'LastName': 'Neyrinck', 'Affiliation': 'Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Rodriguez', 'Affiliation': 'Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.'}, {'ForeName': 'Zhengxiao', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Medicine, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Seethaler', 'Affiliation': 'Institute of Nutritional Medicine, University of Hohenheim, Hohenheim, Germany.'}, {'ForeName': 'Cándido Robles', 'Initials': 'CR', 'LastName': 'Sánchez', 'Affiliation': 'Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Roumain', 'Affiliation': 'Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Hiel', 'Affiliation': 'Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.'}, {'ForeName': 'Laure B', 'Initials': 'LB', 'LastName': 'Bindels', 'Affiliation': 'Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.'}, {'ForeName': 'Patrice D', 'Initials': 'PD', 'LastName': 'Cani', 'Affiliation': 'Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Paquot', 'Affiliation': 'Laboratory of Diabetology, Nutrition and Metabolic Disease, Université de Liège, Liège, Belgium.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Cnop', 'Affiliation': 'ULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium.'}, {'ForeName': 'Julie-Anne', 'Initials': 'JA', 'LastName': 'Nazare', 'Affiliation': 'Rhône-Alpes Research Center for Human Nutrition, Université-Lyon, CarMeN Laboratory, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Laville', 'Affiliation': 'Rhône-Alpes Research Center for Human Nutrition, Université-Lyon, CarMeN Laboratory, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'Giulio G', 'Initials': 'GG', 'LastName': 'Muccioli', 'Affiliation': 'Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Stephan C', 'Initials': 'SC', 'LastName': 'Bischoff', 'Affiliation': 'Institute of Nutritional Medicine, University of Hohenheim, Hohenheim, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Walter', 'Affiliation': 'Department of Medicine, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Jean-Paul', 'Initials': 'JP', 'LastName': 'Thissen', 'Affiliation': 'Pole of Endocrinology, Diabetes and Nutrition, Institut de Recherche Expérimentale et Clinique, UCLouvain, Université catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Nathalie M', 'Initials': 'NM', 'LastName': 'Delzenne', 'Affiliation': 'Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium. nathalie.delzenne@uclouvain.be.'}]",European journal of nutrition,['10.1007/s00394-021-02484-5'] 944,33549795,Effects of Exercise Mode on Arterial Stiffness in Symptomatic Peripheral Artery Disease Patients: A Randomized Crossover Clinical Trial.,"BACKGROUND Exercise program has been recommended for the treatment of symptomatic peripheral artery disease (PAD) patients. However, whether exercise promotes reduction in arterial stiffness in these patients, who exhibit high arterial stiffness, is poor known. AIM To analyze the effects of a single session of resistance, walking, and combined exercises on arterial stiffness in symptomatic PAD patients and to describe individual responses and identify clinical predictors of arterial stiffness responses after exercises. METHODS Twelve patients with symptomatic PAD underwent four experimental sessions in random order: walking exercise (W - 10 bouts of 2-min walking at the speed corresponding to the onset of claudication pain with 2-min interval among sets), resistance exercise (R - 2 sets of 10 reps in eight resistance exercises), combined exercise (CO - 1 set of 10 reps in eight resistance exercises + 5 bouts of 2-min walking with 2-min interval between) and control session (C - resting in exercise room). Ambulatory arterial stiffness index (AASI) was obtained during ambulatory period after each session. Body mass index, ankle brachial index, sex and age also were evaluated. RESULTS AASI was lower in R compared to other sessions (R - 0.52 ± 0.05; W - 0.59 ± 0.05; CO - 0.64 ± 0.05; C - 0.60 ± 0.05, P < 0.001), with 75% of patients presenting lower AASI after R session. No difference was found between W, CO and C sessions (P> 0.05). Ankle brachial index was negatively correlated with R and W sessions net effect (r = -0.618 and -0.750, respectively; P< 0.05 for both), no correlation was found with CO. CONCLUSION A single bout of resistance exercise acutely reduces arterial stiffness in symptomatic PAD, while walking and combined exercise did not alter this variable. This response is more likely to occur in individuals with less severe disease.",2021,"A single bout of resistance exercise acutely reduces arterial stiffness in symptomatic PAD, while walking, combined exercise did not alter this variable.","['symptomatic PAD patients', 'symptomatic peripheral artery disease (PAD) patients', 'symptomatic peripheral artery disease patients', 'individuals with less severe disease', 'Twelve patients with symptomatic PAD underwent four experimental sessions in random order']","['Exercise program', 'single session of resistance, walking and combined exercises', 'exercise mode', 'walking exercise (W - 10 bouts of 2-min walking at the speed corresponding to the onset of claudication pain with 2-min interval among sets), resistance exercise (R - 2 sets of 10 reps in eight resistance exercises), combined exercise (CO - 1 set of 10 reps in eight resistance exercises\u202f+\u202f5 bouts of 2-min walking with 2-min interval between) and control session (C - resting in exercise room']","['arterial stiffness', 'Ambulatory arterial stiffness index (AASI', 'Ankle brachial index']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4284072', 'cui_str': 'Order document'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0035253', 'cui_str': 'Rest'}]","[{'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1328319', 'cui_str': 'Ankle brachial pressure index'}]",12.0,0.0367087,"A single bout of resistance exercise acutely reduces arterial stiffness in symptomatic PAD, while walking, combined exercise did not alter this variable.","[{'ForeName': 'Evans Gleicivan', 'Initials': 'EG', 'LastName': 'Dias-Santos', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe, SE, Brazil.'}, {'ForeName': 'Breno Quintela', 'Initials': 'BQ', 'LastName': 'Farah', 'Affiliation': 'Department of Physical Education, Federal Rural University of Pernambuco, PE, Brazil.'}, {'ForeName': 'Antonio Henrique', 'Initials': 'AH', 'LastName': 'Germano-Soares', 'Affiliation': 'Associated Graduate Program in Physical Education UPE/UFPB, University of Pernambuco, PE, Brazil.'}, {'ForeName': 'Marilia de Almeida', 'Initials': 'MA', 'LastName': 'Correia', 'Affiliation': 'Graduate Program in Medicine, Universidade Nove de Julho, São Paulo, Brazil.'}, {'ForeName': 'Allana Andrade', 'Initials': 'AA', 'LastName': 'Souza', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe, SE, Brazil.'}, {'ForeName': 'Josefa Ediglezia Jesus', 'Initials': 'JEJ', 'LastName': 'Hora', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe, SE, Brazil.'}, {'ForeName': 'Raphael Mendes', 'Initials': 'RM', 'LastName': 'Ritti-Dias', 'Affiliation': 'Graduate Program in Sciences of Rehabilitation, Universidade Nove de Julho, São Paulo, Brazil.'}, {'ForeName': 'Aluísio', 'Initials': 'A', 'LastName': 'Andrade-Lima', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe, SE, Brazil. Electronic address: aluisiolima@live.com.'}]",Annals of vascular surgery,['10.1016/j.avsg.2020.12.049'] 945,33549776,Utility of the Pectoral Nerve Block (PECS II) for Analgesia Following Transaxillary First Rib Section.,"BACKGROUND The transaxillary approach to resection of the first rib is one of several operative techniques for treating thoracic outlet syndrome. Unfortunately, moderate to severe postoperative pain is anticipated for patients undergoing this particular operation. While opioids can be used for analgesia, they have well-described side effects that has led investigators to search for clinically relevant alternative analgesic modalities. We hypothesized that a regional analgesic procedure, commonly called a pectoral nerve (PECS II) block, which anesthetizes the second through sixth intercostal nerves as well as the long thoracic nerve and the medial and lateral pectoral nerves, would improve postoperative analgesia for patients undergoing a transaxillary first rib resection. METHODS We performed a retrospective study by reviewing the charts of all patients that had undergone a transaxillary first rib resection for thoracic outlet syndrome during the defined study period. Patients that received a PECS II block were compared to those that did not. The primary outcome was a comparison of numeric rating scale pain scores during the first 24 hours following the operation. Secondary outcomes included cumulative opioid consumption during the same time period. RESULTS Pain scores during the first 24 hours following the operation were not statistically different between groups (Block Group: 3.9 [2.1-5.3] [median (IQR 25-75%)] versus Non-block Group: 3.6 [2.4-4.1]; P = 0.40. In addition, opioid use through the first 24 hours after the operation was not significantly different (43.5 [22.0-81.0] [median morphine equivalents in mg's] versus 42.0 [12.5-75.0]; P = 0.53). CONCLUSIONS An ultrasound-guided PECS II nerve block did not reduce postoperative pain scores or opioid consumption for patients undergoing a transaxillary first rib resection. However, a prospective, randomized, study with improved power would be beneficial to further explore the potential utility of a PECS II block for patients presenting for this surgical procedure.",2021,An ultrasound-guided PECS II nerve block did not reduce postoperative pain scores or opioid consumption for patients undergoing a transaxillary first rib resection.,"['charts of all patients that had undergone a transaxillary first rib resection for thoracic outlet syndrome during the defined study period', 'patients undergoing a transaxillary first rib resection', 'patients presenting for this surgical procedure']","['PECS II block', 'ultrasound-guided PECS II nerve block', 'Pectoral Nerve Block (PECS II']","['cumulative opioid consumption during the same time period', 'comparison of numeric rating scale pain scores', 'postoperative pain scores', 'Pain scores']","[{'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442341', 'cui_str': 'Transaxillary approach'}, {'cui': 'C0222819', 'cui_str': 'Bone structure of first rib'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0039984', 'cui_str': 'Thoracic outlet syndrome'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C4273496', 'cui_str': 'PECS II block'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0055065', 'cui_str': 'CEP combination'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0205967', 'cui_str': 'Pectoral Nerves'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1948053', 'cui_str': 'Time periods'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0661085,An ultrasound-guided PECS II nerve block did not reduce postoperative pain scores or opioid consumption for patients undergoing a transaxillary first rib resection.,"[{'ForeName': 'Daryl S', 'Initials': 'DS', 'LastName': 'Henshaw', 'Affiliation': 'Department of Anesthesiology, Wake Forest School of Medicine, Winston Salem, NC. Electronic address: dhenshaw@wakehealth.edu.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': ""O'Rourke"", 'Affiliation': 'Department of Anesthesiology, Wake Forest School of Medicine, Winston Salem, NC.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Weller', 'Affiliation': 'Department of Anesthesiology, Wake Forest School of Medicine, Winston Salem, NC.'}, {'ForeName': 'Gregory B', 'Initials': 'GB', 'LastName': 'Russell', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Freischlag', 'Affiliation': 'Department of Vascular Surgery, Wake Forest School of Medicine, Winston-Salem, NC.'}]",Annals of vascular surgery,['10.1016/j.avsg.2020.12.038'] 946,33555720,The Effect of Acupressure on Daytime Sleepiness and Sleep Quality in Hemodialysis Patients.,"This study was carried out to evaluate the effect of acupressure applied to hemodialysis patients on the level of daytime sleepiness and sleep quality. The data were collected using the Descriptive Information Form, Pittsburgh Sleep Quality Index, and Epworth Sleepiness Scale. In the study, a total of 12 sessions of acupressure were applied to the Shenmen (HT7), Sanyingjao (Sp6), and Yungquan (KI1) points in the experimental group for 4 weeks. No intervention was applied to the control group. After the acupressure, it was determined that the sleep quality of the experimental group was better than that of the control group and that daytime sleepiness was less compared with the control group. After the acupressure, it was determined that the sleep latency of the experimental group was statistically significantly less and their total sleep duration was higher compared with the control group (P < .05). Although there was a decrease in the sleep quality of the experimental group 1 month after the cessation of the acupressure, it was determined that the sleep quality of the experimental group was better than that of the control group (P < .05). It was concluded that acupressure was an effective nursing intervention in increasing sleep quality and decreasing daytime sleepiness of hemodialysis patients.",2021,"Although there was a decrease in the sleep quality of the experimental group 1 month after the cessation of the acupressure, it was determined that the sleep quality of the experimental group was better than that of the control group (P < .05).","['hemodialysis patients', 'Hemodialysis Patients']","['Acupressure', 'acupressure']","['daytime sleepiness', 'Shenmen (HT7), Sanyingjao (Sp6), and Yungquan (KI1) points', 'sleep quality', 'Pittsburgh Sleep Quality Index, and Epworth Sleepiness Scale', 'sleep latency', 'total sleep duration', 'Daytime Sleepiness and Sleep Quality', 'daytime sleepiness and sleep quality']","[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0282614', 'cui_str': 'Acupressure'}]","[{'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C3541276', 'cui_str': 'Epworth Sleepiness Scale'}, {'cui': 'C4505222', 'cui_str': 'Sleep Onset Latency'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}]",,0.0111692,"Although there was a decrease in the sleep quality of the experimental group 1 month after the cessation of the acupressure, it was determined that the sleep quality of the experimental group was better than that of the control group (P < .05).","[{'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Derya Ister', 'Affiliation': 'Nursing Department, Faculty of Health Sciences, Kahramanmaras Sutcu Imam Universıty, Kahramanmaraş, Turkey (Dr Derya Ister); and Department of Internal Medicine Nursing, Nursing Faculty, Inonu University, Malatya, Turkey (Dr Citlik Saritas).'}, {'ForeName': 'Seyhan', 'Initials': 'S', 'LastName': 'Citlik Saritas', 'Affiliation': ''}]",Holistic nursing practice,['10.1097/HNP.0000000000000436'] 947,33559157,Early life stress sensitizes youth to the influence of stress-induced cortisol on memory for affective words.,"Early life stress (ELS) is a well-established risk factor for psychopathology across the lifespan. Cognitive vulnerability to stress-induced cortisol may explain risk and resilience. The current study aimed to elucidate a psychobiological pathway linking stress to altered memory for affective words among youth with and without exposure to ELS. One hundred and fifteen youth (ages 9-16, 47% female) were randomized either to a psychosocial stressor or a control condition. Immediately following the stress or control condition, participants completed a memory task for affective words. Change in salivary cortisol from immediately before to 25 min after stress onset were used to predict memory for affective words. Exposure to the acute laboratory stressor led to activation of the HPA axis. Greater cortisol reactivity was associated with less accurate recognition of negative valence words. Among youth exposed to ELS, greater cortisol reactivity to acute stress was associated with poorer recognition of dysphoric and neutral words. Acute increases in cortisol may interfere with negatively-valenced information processing that has implications for memory. Youth exposed to high ELS may be particularly vulnerable to the effects of cortisol, which may explain one pathway through which stress leads to psychopathology among at-risk youth.",2021,"Among youth exposed to ELS, greater cortisol reactivity to acute stress was associated with poorer recognition of dysphoric and neutral words.","['One hundred and fifteen youth (ages 9-16, 47% female', 'youth with and without exposure to ELS']",['psychosocial stressor or a control condition'],"['cortisol reactivity', 'Change in salivary cortisol', 'Greater cortisol reactivity']","[{'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0038443', 'cui_str': 'Psychological Stress'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0205393', 'cui_str': 'Most'}]",,0.0127031,"Among youth exposed to ELS, greater cortisol reactivity to acute stress was associated with poorer recognition of dysphoric and neutral words.","[{'ForeName': 'Kate R', 'Initials': 'KR', 'LastName': 'Kuhlman', 'Affiliation': 'Department of Psychological Science, School of Social Ecology, University of California Irvine, Irvine, CA, USA.'}, {'ForeName': 'Stefanie E', 'Initials': 'SE', 'LastName': 'Mayer', 'Affiliation': 'Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Vargas', 'Affiliation': 'Department of Psychological Science, University of Arkansas, Fayetteville, AR, USA.'}, {'ForeName': 'Nestor L', 'Initials': 'NL', 'LastName': 'Lopez-Duran', 'Affiliation': 'Department of Psychology, University of Michigan, Ann Arbor, MI, USA.'}]",Developmental psychobiology,['10.1002/dev.22105'] 948,33558417,Changing personality traits with the help of a digital personality change intervention.,"Personality traits predict important life outcomes, such as success in love and work life, well-being, health, and longevity. Given these positive relations to important outcomes, economists, policy makers, and scientists have proposed intervening to change personality traits to promote positive life outcomes. However, nonclinical interventions to change personality traits are lacking so far in large-scale naturalistic populations. This study ( n = 1,523) examined the effects of a 3-mo digital personality change intervention using a randomized controlled trial and the smartphone application PEACH (PErsonality coACH). Participants who received the intervention showed greater self-reported changes compared to participants in the waitlist control group who had to wait 1 mo before receiving the intervention. Self-reported changes aligned with intended goals for change and were significant for those desiring to increase on a trait ( d = 0.52) and for those desiring to decrease on a trait (d = -0.58). Observers such as friends, family members, or intimate partners also detected significant personality changes in the desired direction for those desiring to increase on a trait ( d = 0.35). Observer-reported changes for those desiring to decrease on a trait were not significant ( d = -0.22). Moreover, self- and observer-reported changes persisted until 3 mo after the end of the intervention. This work provides the strongest evidence to date that normal personality traits can be changed through intervention in nonclinical samples.",2021,Participants who received the intervention showed greater self-reported changes compared to participants in the waitlist control group who had to wait 1 mo before receiving the intervention.,[],"['smartphone application PEACH (PErsonality coACH', '3-mo digital personality change intervention']","['success in love and work life, well-being, health, and longevity']",[],"[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0330659', 'cui_str': 'Prunus persica'}, {'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0240735', 'cui_str': 'Personality change'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0024028', 'cui_str': 'Love'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0023980', 'cui_str': 'Longevity'}]",,0.0195446,Participants who received the intervention showed greater self-reported changes compared to participants in the waitlist control group who had to wait 1 mo before receiving the intervention.,"[{'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Stieger', 'Affiliation': 'Department of Psychology, Brandeis University, Waltham, MA 02453; stieger@brandeis.edu mathias.allemand@uzh.ch.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Flückiger', 'Affiliation': 'Department of Psychology, University of Zurich, 8050 Zürich, Switzerland.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Rüegger', 'Affiliation': 'Center for Digital Health Interventions, Chair of Information Management, ETH Zurich, 8092 Zurich, Switzerland.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Kowatsch', 'Affiliation': 'Center for Digital Health Interventions, Chair of Information Management, ETH Zurich, 8092 Zurich, Switzerland.'}, {'ForeName': 'Brent W', 'Initials': 'BW', 'LastName': 'Roberts', 'Affiliation': 'Department of Psychology, University of Illinois at Urbana-Champaign, Champaign, IL 61820.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Allemand', 'Affiliation': 'Department of Psychology, University of Zurich, 8050 Zürich, Switzerland; stieger@brandeis.edu mathias.allemand@uzh.ch.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.2017548118'] 949,33556601,Surgical or Endovascular Management of Middle Cerebral Artery Aneurysms: A Randomized Comparison.,"OBJECTIVE There are few randomized data comparing clipping and coiling for middle cerebral artery (MCA) aneurysms. We analyzed results from patients with MCA aneurysms enrolled in the CURES (Collaborative UnRuptured Endovascular vs. Surgery) and ISAT-2 (International Subarachnoid Aneurysm Trial II) randomized trials. METHODS Both trials are investigator-led parallel-group 1:1 randomized studies. CURES includes patients with 3-mm to 25-mm unruptured intracranial aneurysms (UIAs), and ISAT-2 includes patients with ruptured aneurysms (RA) for whom uncertainty remains after ISAT. The primary outcome measure of CURES is treatment failure: 1) failure to treat the aneurysm, 2) intracranial hemorrhage during follow-up, or 3) residual aneurysm at 1 year. The primary outcome of ISAT-2 is death or dependency (modified Rankin Scale score >2) at 1 year. One-year angiographic outcomes are systematically recorded. RESULTS There were 100 unruptured and 71 ruptured MCA aneurysms. In CURES, 90 patients with UIA have been treated and 10 await treatment. Surgical and endovascular management of unruptured MCA aneurysms led to treatment failure in 3/42 (7%; 95% confidence interval [CI], 0.02-0.19) for clipping and 13/48 (27%; 95% CI, 0.17-0.41) for coiling (P = 0.025). All 71 patients with RA have been treated. In ISAT-2, patients with ruptured MCA aneurysms managed surgically had died or were dependent (modified Rankin Scale score >2) in 7/38 (18%; 95% CI, 0.09-0.33) cases, and 8/33 (24%; 95% CI, 0.13-0.41) for endovascular. One-year imaging results were available in 80 patients with UIA and 62 with RA. Complete aneurysm occlusion was found in 30/40 (75%; 95% CI, 0.60-0.86) patients with UIA allocated clipping, and 14/40 (35%; 95% CI, 0.22-0.50) patients with UIA allocated coiling. Complete aneurysm occlusion was found in 24/34 (71%; 95% CI, 0.54-0.83) patients with RA allocated clipping, and 15/28 (54%; 95% CI, 0.36-0.70) patients with RA allocated coiling. CONCLUSIONS Randomized data from 2 trials show that better efficacy may be obtained with surgical management of patients with MCA aneurysms.",2021,"Complete aneurysm occlusion was found in 24/34 (71%;95%CI:0.54-0.83) RA patients allocated clipping, and 15/28 (54%;95%CI:0.36-0.70)","['middle cerebral artery aneurysms', 'MCA aneurysm patients enrolled in the CURES and ISAT-2 randomized trials', 'middle cerebral artery (MCA) aneurysms', 'UIA patients allocated clipping, and 14/40 (35%;95%CI:0.22-0.50']","['Surgical or endovascular management', 'clipping and coiling']","['CURES is Treatment Failure', 'ISAT-2 is death or dependency (mRS>2', 'Complete aneurysm occlusion']","[{'cui': 'C0740385', 'cui_str': 'Aneurysm of middle cerebral artery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0149566', 'cui_str': 'Structure of middle cerebral artery'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0175722', 'cui_str': 'Clip'}]","[{'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}]",,0.379636,"Complete aneurysm occlusion was found in 24/34 (71%;95%CI:0.54-0.83) RA patients allocated clipping, and 15/28 (54%;95%CI:0.36-0.70)","[{'ForeName': 'Tim E', 'Initials': 'TE', 'LastName': 'Darsaut', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, Mackenzie Health Sciences Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Keough', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, Mackenzie Health Sciences Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Abdelaziz', 'Initials': 'A', 'LastName': 'Sagga', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, Mackenzie Health Sciences Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Vivien K Y', 'Initials': 'VKY', 'LastName': 'Chan', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, Mackenzie Health Sciences Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Ange', 'Initials': 'A', 'LastName': 'Diouf', 'Affiliation': ""Service of Neuroradiology, Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Boisseau', 'Affiliation': ""Service of Neuroradiology, Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Elsa', 'Initials': 'E', 'LastName': 'Magro', 'Affiliation': 'Service of Neurosurgery, CHU Cavale Blanche, InsermUMR 1101 LaTIM, Brest, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Kotowski', 'Affiliation': ""Service of Neuroradiology, Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Roy', 'Affiliation': ""Service of Neuroradiology, Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Weill', 'Affiliation': ""Service of Neuroradiology, Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Iancu', 'Affiliation': ""Service of Neuroradiology, Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Michel W', 'Initials': 'MW', 'LastName': 'Bojanowski', 'Affiliation': ""Service of Neurosurgery, Department of Surgery, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Chiraz', 'Initials': 'C', 'LastName': 'Chaalala', 'Affiliation': ""Service of Neurosurgery, Department of Surgery, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Bilocq', 'Affiliation': 'Centre Hospitalier Régional de Trois-Rivières Service of Neurosurgery, Trois-Rivières, Quebec, Canada.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Estrade', 'Affiliation': 'Department of Interventional Neuroradiology, Centre Hospitalier Universitaire de Lille, Lille, France.'}, {'ForeName': 'Jean-Paul', 'Initials': 'JP', 'LastName': 'Lejeune', 'Affiliation': 'Department of Neurosurgery, Centre Hospitalier Universitaire de Lille, Lille, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Bricout', 'Affiliation': 'Department of Interventional Neuroradiology, Centre Hospitalier Universitaire de Lille, Lille, France.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Scholtes', 'Affiliation': 'Department of Neurosurgery, Centre Hospitalier Universitaire de Liège, Liège, Belgium.'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Martin', 'Affiliation': 'Department of Neurosurgery, Centre Hospitalier Universitaire de Liège, Liège, Belgium.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Otto', 'Affiliation': 'Division of Medical Imaging, Department of Medical Physics, Centre Hospitalier Universitaire de Liège, Liège, Belgium.'}, {'ForeName': 'J Max', 'Initials': 'JM', 'LastName': 'Findlay', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, Mackenzie Health Sciences Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Chow', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, Mackenzie Health Sciences Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Cian J', 'Initials': 'CJ', 'LastName': ""O'Kelly"", 'Affiliation': 'Division of Neurosurgery, Department of Surgery, Mackenzie Health Sciences Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Ashforth', 'Affiliation': 'Department of Radiology and Diagnostic Imaging, Mackenzie Health Sciences Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Jeremy L', 'Initials': 'JL', 'LastName': 'Rempel', 'Affiliation': 'Department of Radiology and Diagnostic Imaging, Mackenzie Health Sciences Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Lesiuk', 'Affiliation': 'Section of Neurosurgery, Department of Surgery, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Sinclair', 'Affiliation': 'Section of Neurosurgery, Department of Surgery, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Altschul', 'Affiliation': 'Department of Neurological Surgery and Radiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.'}, {'ForeName': 'Fuat', 'Initials': 'F', 'LastName': 'Arikan', 'Affiliation': ""Department of Neurosurgery and Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron University Hospital and Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Guilbert', 'Affiliation': ""Service of Neuroradiology, Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Chagnon', 'Affiliation': 'Department of Mathematics and Statistics, Université de Montréal, Montréal, Quebec, Canada.'}, {'ForeName': 'Behzad', 'Initials': 'B', 'LastName': 'Farzin', 'Affiliation': ""Interventional Neuroradiology Laboratory, Research Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Guylaine', 'Initials': 'G', 'LastName': 'Gevry', 'Affiliation': ""Interventional Neuroradiology Laboratory, Research Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.""}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Raymond', 'Affiliation': ""Service of Neuroradiology, Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada; Interventional Neuroradiology Laboratory, Research Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada. Electronic address: jean.raymond@umontreal.ca.""}]",World neurosurgery,['10.1016/j.wneu.2021.01.142'] 950,33565243,Clinical observation and dermoscopy evaluation of fractional CO 2 laser combined with topical tranexamic acid in melasma treatments.,"BACKGROUND Melasma is an acquired refractory pigmentary disorder, which is a skin disease that predominantly affects females. This investigation aims to assess the efficacy of a low-power fractional CO 2 laser combined with tranexamic acid (TXA) for melasma topical treatment with MASI and dermoscopy. MATERIALS AND METHODS A randomized comparative split-face study was performed. Each treatment interval was 3 weeks with four times in total. At the same time, we applied TXA solution twice a day. Assessments were made by the MASI score of the melasma area severity index, and the dermoscopy performance was collected and analyzed. RESULTS After treatments, the patient MASI score decreased significantly. Compared with the baseline, the MASI score was significantly lower than that of control group (P < .05), and the decrease ratio was higher than that of controls. Dermoscopy examination results verified that all lesions performed reticuloglobular pattern, granular, or punctate, with no structural pigmentation and obvious capillary dilation. After comprehensive treatments, the pigmentation area displayed lighter chroma, the follicle pore uniformity was completely improved, and the capillary dilation was significantly reduced. CONCLUSIONS Low-power fractional CO 2 laser combined with topical TXA solution is a comparatively effective and safe method for melasma treatment. TXA could reduce the dilation of blood vessels.",2021,"Compared with the baseline, the MASI score was significantly lower than that of control group (P < 0.05), and the decrease ratio was higher than that of controls.",['melasma treatments'],"['topical TXA solution', 'low-power fractional CO 2 laser combined with tranexamic acid (TXA', 'TXA', 'fractional CO 2 laser combined with topical tranexamic acid']","['MASI score of the melasma area severity index, and the dermoscopy performance', 'MASI score', 'dilation of blood vessels', 'capillary dilation', 'patient MASI score', 'pigmentation area displayed lighter chroma, the follicle pore uniformity', 'decrease ratio']","[{'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1449565', 'cui_str': 'Dermatoscopy'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031911', 'cui_str': 'Pigmentation'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0018120', 'cui_str': 'Ovarian follicle structure'}, {'cui': 'C0439827', 'cui_str': 'Uniformities'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0464321,"Compared with the baseline, the MASI score was significantly lower than that of control group (P < 0.05), and the decrease ratio was higher than that of controls.","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Qu', 'Affiliation': 'Department of Dermatology, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai, Shandong, China.'}, {'ForeName': 'Fengjuan', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': ""Dongying District People's Hospital of Dongying City, Dongying, China.""}, {'ForeName': 'Junru', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Yantai Yuhuangding Hospital Laishan Branch, Yantai, China.'}, {'ForeName': 'Xiujuan', 'Initials': 'X', 'LastName': 'Xia', 'Affiliation': 'Department of Dermatology, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai, Shandong, China.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13992'] 951,33563104,"Carbamazepine for Irritability and Aggression after Traumatic Brain Injury: A Randomized, Placebo-Controlled Study.","This study tested the hypothesis that carbamazepine (CBZ) reduces irritability/aggression among individuals >6 months post-traumatic brain injury (TBI). Seventy individuals were enrolled in a parallel-group, randomized, double-blind, placebo-controlled, forced-titration trial of CBZ ( n  = 35) versus placebo ( n  = 35). Participants were randomly assigned to receive CBZ or placebo 42 days with outcome assessed at baseline and Day 42. Dose was titrated up to 400 mg CBZ or placebo equivalent two times daily. Symptoms of irritability and aggression were measured using the Neuropsychiatric Inventory Irritability (NPI-I) and Aggression (NPI-A) domains as a composite measure (NPI-I/A). Global impression of change was recorded from participant, observer, and study clinician. The CBZ group did not differ significantly from the placebo group ( p  = 0.60 and 0.59 for NPI-I/A observer and participant ratings, respectively). High placebo effects were observed with minimal clinically important difference in observer NPI-I/A 57% in CBZ group and 77% in placebo group ( p  = 0.09). Findings were similar for participant ratings. Eighteen of 35 had therapeutic CBZ level ≥4. Therapeutic sample analysis revealed similar high placebo response and non-significant differences except clinician ratings favoring CBZ. Non-serious adverse events occurred more frequently in the CBZ group with greater nervous system effects. CBZ up to 400 mg two times daily was not superior to placebo at reducing irritability/aggression according observers and participants. Large placebo effects may have masked the detection of differences. Clinician rating metrics suggest benefit, and thus, CBZ should remain a treatment option for the experienced brain injury clinician. Data are provided that may aid treatment decisions.",2021,The CBZ group did not differ significantly from the placebo group (p=0.60 and 0.59 for NPI-I/A observer and participant ratings respectively).,"['70 individuals', 'after Traumatic Brain Injury', 'individuals > 6 months post-traumatic brain injury (TBI']","['Carbamazepine', 'CBZ', 'carbamazepine (CBZ', 'placebo', 'CBZ or placebo', 'Placebo']","['Irritability and Aggression', 'irritability/aggression', 'observer NPI', 'Neuropsychiatric Inventory Irritability (NPI-I) and Aggression ', 'Symptoms of irritability and aggression']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C0006949', 'cui_str': 'Carbamazepine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022107', 'cui_str': 'Feeling irritable'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",70.0,0.742074,The CBZ group did not differ significantly from the placebo group (p=0.60 and 0.59 for NPI-I/A observer and participant ratings respectively).,"[{'ForeName': 'Flora M', 'Initials': 'FM', 'LastName': 'Hammond', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}, {'ForeName': 'Ross D', 'Initials': 'RD', 'LastName': 'Zafonte', 'Affiliation': ""Spaulding Rehabilitation Hospital, Massachusetts General Hospital, Brigham and Women's Hospital, Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Tang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}, {'ForeName': 'Jeong Hoon', 'Initials': 'JH', 'LastName': 'Jang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}]",Journal of neurotrauma,['10.1089/neu.2020.7530'] 952,33561289,"Change in Brain Oscillations as a Mechanism of Mindfulness-Meditation, Cognitive Therapy, and Mindfulness-Based Cognitive Therapy for Chronic Low Back Pain.","OBJECTIVE Psychological treatments for chronic low back pain (CLBP) are effective. However, limited research has investigated their neurophysiological mechanisms. This study examined electroencephalography- (EEG-) assessed brain oscillation changes as potential mechanisms of cognitive therapy (CT), mindfulness-meditation (MM), and mindfulness-based cognitive therapy (MBCT) for CLBP. The a priori bandwidths of interest were changes in theta, alpha and beta power, measured at pre- and post-treatment. DESIGN A secondary analysis of a clinical trial. SETTING University of Queensland Psychology Clinic. SUBJECTS Adults (N = 57) with CLBP who completed pre- and post-treatment EEG and pain outcome assessments. METHODS EEG data were examined for five regions of interest (ROIs); the primary outcome was pain intensity. RESULTS A significant reduction in theta (P=.015) and alpha (P=.006) power in the left frontal ROI across all treatments was found, although change in theta and alpha power in this region was not differentially associated with outcome across treatments. There were significant reductions in beta power in all five ROIs across all treatments (P≤.013). Beta power reduction in the central ROI showed a significant association with reduced pain intensity in MBCT only (P=.028). Changes in other regions were not statistically significant. CONCLUSIONS These findings provide support for the capacity of psychological CLBP treatments to induce changes in brain activity. The reduced beta power in all five ROIs indicated that all three treatments engendered a state of lowered cortical arousal. The growing body of research in this area could potentially inform novel directions towards remedying central nervous system abnormalities associated with CLBP.",2021,"A significant reduction in theta (p=.015) and alpha (p=.006) power in the left frontal ROI across all treatments was found, although change in theta and alpha power in this region was not differentially associated with outcome across treatments.","['chronic low back pain (CLBP', 'Adults (N\u2009=\u200957) with CLBP who completed pre- and post-treatment EEG and pain outcome assessments', 'University of Queensland Psychology Clinic', 'chronic low back pain']","['electroencephalography- (EEG', 'cognitive therapy (CT), mindfulness-meditation (MM), and mindfulness-based cognitive therapy (MBCT', 'mindfulness-meditation, cognitive therapy, and mindfulness-based cognitive therapy']","['pain intensity', 'brain activity', 'beta power']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0085565', 'cui_str': 'Outcome Assessment (Health Care)'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C3811912', 'cui_str': 'Psychology clinic'}]","[{'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0330390', 'cui_str': 'Beta'}]",57.0,0.0276876,"A significant reduction in theta (p=.015) and alpha (p=.006) power in the left frontal ROI across all treatments was found, although change in theta and alpha power in this region was not differentially associated with outcome across treatments.","[{'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Day', 'Affiliation': 'School of Psychology, University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Matthews', 'Affiliation': 'School of Psychology, University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Jason B', 'Initials': 'JB', 'LastName': 'Mattingley', 'Affiliation': 'School of Psychology, University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Dawn M', 'Initials': 'DM', 'LastName': 'Ehde', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Aaron P', 'Initials': 'AP', 'LastName': 'Turner', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Rhonda M', 'Initials': 'RM', 'LastName': 'Williams', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Jensen', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, USA.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnab049'] 953,33567942,Using a Warm Hand-Off Approach to Enroll African American Caregivers in a Multi-Site Clinical Trial: The Handshake Protocol.,"""Testing Tele-Savvy"" was a three-arm randomized controlled trial that recruited participants from four National Institute on Aging (NIA)-funded Alzheimer's Disease Centers with Emory University serving as the coordinating center. The enrollment process involved each center providing a list of eligible caregivers to the coordinating center to consent. Initially, the site proposed to recruit primarily African American caregivers generated a significant amount of referrals to the coordinating center, but a gap occurred in translating them into enrolled participants. To increase the enrollment rate, a ""Handshake Protocol"" was established, which included a warm handoff approach. During preset phone calls each week, the research site coordinator introduced potential participants to a culturally congruent co-investigator from the coordinating center who then completed the consent process. Within the first month of implementation, the team was 97% effective in meeting its goals. This protocol is an example of a successful, innovative approach to enrolling minority participants in multi-site clinical trials.",2021,"Initially, the site proposed to recruit primarily African American caregivers generated a significant amount of referrals to the coordinating center, but a gap occurred in translating them into enrolled participants.","[""recruited participants from four National Institute on Aging (NIA)-funded Alzheimer's Disease Centers with Emory University serving as the coordinating center""]",['Testing Tele-Savvy'],[],"[{'cui': 'C1955974', 'cui_str': 'NIA (US)'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}]","[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1515258', 'cui_str': 'Telephone number (property)'}]",[],,0.0535454,"Initially, the site proposed to recruit primarily African American caregivers generated a significant amount of referrals to the coordinating center, but a gap occurred in translating them into enrolled participants.","[{'ForeName': 'Fayron', 'Initials': 'F', 'LastName': 'Epps', 'Affiliation': 'Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Glenna', 'Initials': 'G', 'LastName': 'Brewster', 'Affiliation': 'Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Judy S', 'Initials': 'JS', 'LastName': 'Phillips', 'Affiliation': ""Rush Alzheimer's Disease Center, Rush University University Medical Center, Chicago, IL, USA.""}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Nash', 'Affiliation': 'Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Raj C', 'Initials': 'RC', 'LastName': 'Shah', 'Affiliation': ""Rush Alzheimer's Disease Center, Rush University University Medical Center, Chicago, IL, USA.""}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Hepburn', 'Affiliation': 'Emory University, Atlanta, GA, USA.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464821992920'] 954,33569770,Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment.,"BACKGROUND The AMAZES randomized controlled trial demonstrated that long-term low-dose azithromycin treatment reduces exacerbations of poorly controlled asthma, but the therapeutic mechanisms remain unclear. Dysregulation of the inflammatory tumour necrosis factor (TNF) pathway is implicated in asthma and could be suppressed by azithromycin. We aimed to determine the inflammatory and clinical associations of soluble TNF signalling proteins (TNF receptors [TNFR] 1 and 2, TNF) in sputum and serum, and to test the effect of 48 weeks of azithromycin vs placebo on TNF markers. METHODS Sputum supernatant and serum TNFR1, TNFR2 (n = 142; 75 azithromycin-treated, 67 placebo-treated) and TNF (n = 48; 22 azithromycin-treated, 26 placebo-treated) were measured by ELISA in an AMAZES trial sub-population at baseline and end of treatment. Baseline levels were compared between sputum inflammatory phenotypes, severe/non-severe asthma and frequent/non-frequent exacerbators. Effect of azithromycin on markers was tested using linear mixed models. RESULTS Baseline sputum TNFR1 and TNFR2 were significantly increased in neutrophilic vs non-neutrophilic asthma phenotypes, while serum markers did not differ. Sputum TNFR1 and TNFR2 were increased in severe asthma and correlated with poorer lung function, worse asthma control and increasing age. Serum TNFR1 was also increased in severe asthma. Sputum and serum TNFR2 were increased in frequent exacerbators. Azithromycin treatment significantly reduced sputum TNFR2 and TNF relative to placebo, specifically in non-eosinophilic participants. CONCLUSIONS We demonstrate dysregulation of TNF markers, particularly in the airways, that relates to clinically important phenotypes of asthma including neutrophilic and severe asthma. Suppression of dysregulated TNF signalling by azithromycin could contribute to its therapeutic mechanism.",2021,"Sputum TNFR1 and TNFR2 were increased in severe asthma, and correlated with poorer lung function, worse asthma control and increasing age.",[],"['Azithromycin', 'placebo', 'azithromycin', 'Baselinesputum', 'soluble TNF signalling proteins (TNFreceptors [TNFR', 'azithromycin-treated, 67 placebo-treated) and TNF', 'azithromycin-treated, 26 placebo-treated) were measured by ELISA', 'azithromycin vs placebo']","['Sputum and serum TNFR2', 'poorer lung function', 'TNFR1 and TNFR2', 'Sputum TNFR1 and TNFR2', 'Serum TNFR1']",[],"[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1456820', 'cui_str': 'Tumor necrosis factor alpha'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0077503', 'cui_str': 'Tumor Necrosis Factor Receptor'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}]","[{'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0255813', 'cui_str': 'Lymphocyte antigen CD120B'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0255808', 'cui_str': 'Lymphocyte antigen CD120A'}]",,0.104325,"Sputum TNFR1 and TNFR2 were increased in severe asthma, and correlated with poorer lung function, worse asthma control and increasing age.","[{'ForeName': 'Natalie M', 'Initials': 'NM', 'LastName': 'Niessen', 'Affiliation': 'Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, Australia.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Gibson', 'Affiliation': 'Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, Australia.'}, {'ForeName': 'Katherine J', 'Initials': 'KJ', 'LastName': 'Baines', 'Affiliation': 'Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, Australia.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Barker', 'Affiliation': 'Hunter Medical Research Institute, Newcastle, NSW, Australia.'}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Yang', 'Affiliation': 'Faculty of Medicine, Department of Thoracic Medicine, The Prince Charles Hospital, The University of Queensland, Brisbane, Qld, Australia.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Upham', 'Affiliation': 'Diamantina Institute, The University of Queensland, Brisbane, Qld, Australia.'}, {'ForeName': 'Paul N', 'Initials': 'PN', 'LastName': 'Reynolds', 'Affiliation': 'Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Hodge', 'Affiliation': 'Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'James', 'Affiliation': 'Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Jenkins', 'Affiliation': 'Respiratory Trials, The George Institute for Global Health, Sydney, NSW, Australia.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Peters', 'Affiliation': 'Department of Thoracic Medicine, Concord General Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Guy B', 'Initials': 'GB', 'LastName': 'Marks', 'Affiliation': 'Woolcock Institute of Medical Research, Sydney, NSW, Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Baraket', 'Affiliation': 'Medicine Faculty, Respiratory Medicine Department and Ingham Institute Liverpool Hospital, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Jodie L', 'Initials': 'JL', 'LastName': 'Simpson', 'Affiliation': 'Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Fricker', 'Affiliation': 'Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, Australia.'}]",Allergy,['10.1111/all.14768'] 955,33571293,Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.,"BACKGROUND Cannabis is often used by patients with ulcerative colitis, but controlled studies are few. We aimed to assess the effect of cannabis in improving clinical and inflammatory outcomes in ulcerative colitis patients. METHODS In a double-blind, randomized, placebo-controlled trial, patients received either cigarettes containing 0.5 g of dried cannabis flowers with80mgTetrahydrocannabinol (THC)or placebo cigarettes for 8 weeks. Parameters of disease including Lichtiger disease activity index, C reactive protein (CRP), calprotectin, Mayo endoscopic score and quality of life (QOL) were assessed before, during and after treatment. RESULTS The study included 32 patients. Mean age was 30 years, 14 (43%) females. Lichtiger index improved in the cannabis group from 10.9 (IQR 9-14) to5 (IQR 1-7), (p<0.000), and in the placebo group from 11 (IQR 9-13) to 8 (IQR 7-10)(p = 0.15, p between groups 0.001). QOL improved in the cannabis group from 77±4 to 98±20 (p = 0.000) but not in the placebo group (78±3 at week 0 and 78±17 at week 8;p = 0.459; p between groups 0.007). Mayo endoscopic score changed in the cannabis group from 2.13±1 to 1.25±2 (p = 0.015) and in the placebo group from 2.15±1to 1.69±1 (p = 0.367, p between groups 0.17). CONCLUSION Short term treatment with THC rich cannabis induced clinical remission and improved quality of life in patients with mild to moderately active ulcerative colitis. However, these beneficial clinical effects were not associated with significant anti-inflammatory improvement in the Mayo endoscopic score or laboratory markers for inflammation.(clinicaltrials.gov NCT01040910).",2021,QOL improved in the cannabis group from 77±4 to 98±20 (p = 0.000) but not in the placebo group (78±3 at week 0 and 78±17 at week 8;p = 0.459; p between groups 0.007).,"['32 patients', 'ulcerative colitis', 'patients with ulcerative colitis', 'patients with mild to moderately active ulcerative colitis', 'Mean age was 30 years, 14 (43%) females', 'ulcerative colitis patients']","['cannabis', 'cigarettes containing 0.5 g of dried cannabis flowers with80mgTetrahydrocannabinol (THC)or placebo cigarettes', 'placebo', 'THC rich cannabis']","['Lichtiger index', 'QOL', 'clinical remission', 'quality of life', 'Mayo endoscopic score', 'Lichtiger disease activity index, C reactive protein (CRP), calprotectin, Mayo endoscopic score and quality of life (QOL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0330090', 'cui_str': 'Flowers'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}]","[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0950624', 'cui_str': 'Calprotectin'}]",32.0,0.711852,QOL improved in the cannabis group from 77±4 to 98±20 (p = 0.000) but not in the placebo group (78±3 at week 0 and 78±17 at week 8;p = 0.459; p between groups 0.007).,"[{'ForeName': 'Timna', 'Initials': 'T', 'LastName': 'Naftali', 'Affiliation': 'Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba, Israel.'}, {'ForeName': 'Lihi', 'Initials': 'L', 'LastName': 'Bar-Lev Schleider', 'Affiliation': 'Research Department, Tikun-Olam - Cannbit Pharmaceuticals, Tel-Aviv, Israel.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Scklerovsky Benjaminov', 'Affiliation': 'Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba, Israel.'}, {'ForeName': 'Fred Meir', 'Initials': 'FM', 'LastName': 'Konikoff', 'Affiliation': 'Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba, Israel.'}, {'ForeName': 'Shelly Tartakover', 'Initials': 'ST', 'LastName': 'Matalon', 'Affiliation': 'Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba, Israel.'}, {'ForeName': 'Yehuda', 'Initials': 'Y', 'LastName': 'Ringel', 'Affiliation': 'Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba, Israel.'}]",PloS one,['10.1371/journal.pone.0246871'] 956,33520825,Effectiveness of acceptance and commitment therapy (ACT) on depression and sleep quality in painful diabetic neuropathy: a randomized clinical trial.,"Background Neuropathic pain is a complicated phenomenon in patients with diabetes. These patients have many problems, especially depression and Sleep disturbance. This study aimed to assess the effectiveness of Acceptance and Commitment Therapy on depression and Sleep disturbance in patients with painful diabetic neuropathy. Methods The current paper was conducted according to the clinical trial method with 50 participants. Participants were separated into intervention and control groups randomly. Based on the diagnosis of neurologists, all participants received standard medications to regulate neuropathic pain. The intervention group received ACT for eight sessions. The results were evaluated in the pre-test, post-test, and follow-up. The tools used were the Pittsburgh sleep quality index (PSQI) and Beck's depression inventory. Statistical analysis includes descriptive statistics, and repeated-measures (ANOVA) conducted by SPSS (version 26) software. Results: Results showed that in the intervention group, the treatment led to improved depressive symptoms (F = 6.81, P  < 0.05). Besides, for sleep quality, treatment in all subscales, except for the Hypnotic medicine subscale, significantly improved the intervention group's situations. It was also observed that the overall quality of sleep in the ACT group showed a more significant improvement ( P  < 0.05). All the above results remained the same until the end of the follow-up period ( P  < 0.05). Conclusion ACT, as a complementary treatment, can improve the psychiatric symptoms and problems in people with neuropathic pain. Therefore, it is necessary to include psychotherapy services along with medical treatment in outpatient and hospitalization units. Trial registration number IRCT201802050388630N4. Registered in 02/05/2018.",2020,"Results showed that in the intervention group, the treatment led to improved depressive symptoms (F = 6.81, P  < 0.05).","['patients with diabetes', 'painful diabetic neuropathy', 'patients with painful diabetic neuropathy', '50 participants', 'people with neuropathic pain']","['ACT', 'standard medications', 'Acceptance and Commitment Therapy', 'acceptance and commitment therapy (ACT']","['depression and sleep quality', 'depression and Sleep disturbance', 'depressive symptoms', ""Pittsburgh sleep quality index (PSQI) and Beck's depression inventory"", 'overall quality of sleep', 'Hypnotic medicine subscale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751074', 'cui_str': 'Neuralgia, Diabetic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}]","[{'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0020591', 'cui_str': 'Hypnotic agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",50.0,0.0601307,"Results showed that in the intervention group, the treatment led to improved depressive symptoms (F = 6.81, P  < 0.05).","[{'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Davoudi', 'Affiliation': 'Department of clinical psychology, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'Amir Abbas', 'Initials': 'AA', 'LastName': 'Taheri', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Ali Akbar', 'Initials': 'AA', 'LastName': 'Foroughi', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Seyed Mojtaba', 'Initials': 'SM', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Khatereh', 'Initials': 'K', 'LastName': 'Heshmati', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]",Journal of diabetes and metabolic disorders,['10.1007/s40200-020-00609-x'] 957,33532878,"The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study.","BACKGROUND More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) in BC patients with de novo stage IV bone only metastasis (BOM). METHODS The prospective, multicenter registry study BOMET MF14-01 was initiated in May 2014. Patients with de novo stage IV BOM BC were divided into two groups: those receiving systemic treatment (ST group) and those receiving LRT (LRT group). Patients who received LRT were further divided into two groups: ST after LRT (LRT + ST group) and ST before LRT (ST + LRT group). RESULTS We included 505 patients in this study; 240 (47.5%) patients in the ST group and 265 (52.5%) in the LRT group. One hundred and thirteen patients (26.3%) died in the 34-month median follow-up, 85 (35.4%) in the ST group and 28 (10.5%) in LRT group. Local progression was observed in 39 (16.2%) of the patients in the ST group and 18 (6.7%) in the LRT group (p = 0.001). Hazard of death was 60% lower in the LRT group compared with the ST group (HR 0.40, 95% CI 0.30-0.54, p < 0.0001). CONCLUSION In this prospectively maintained registry study, we found that LRT prolonged survival and decreased locoregional recurrence in the median 3-year follow-up. Timing of primary breast surgery either at diagnosis or after ST provided a survival benefit similar to ST alone in de novo stage IV BOM BC patients.",2021,Timing of primary breast surgery either at diagnosis or after ST provided a survival benefit similar to ST alone in de novo stage IV BOM BC patients.,"['Patients with de novo stage IV BOM BC', 'BC patients with de novo stage IV bone only metastasis (BOM', 'Patients who received LRT', 'Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01', '505 patients in this study; 240 (47.5%) patients in the ST group and 265 (52.5%) in the LRT group']","['Primary Surgery', 'locoregional treatment (LRT', 'ST after LRT (LRT\xa0+\xa0ST group) and ST before LRT (ST\xa0+\xa0LRT group', 'systemic treatment (ST group) and those receiving LRT (LRT', 'LRT']","['Local progression', 'overall survival (OS', 'LRT prolonged survival and decreased locoregional recurrence', 'Hazard of death', 'survival benefit']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0346993', 'cui_str': 'Secondary malignant neoplasm of female breast'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0153690', 'cui_str': 'Secondary malignant neoplasm of bone'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517802', 'cui_str': '52.5'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",505.0,0.0336859,Timing of primary breast surgery either at diagnosis or after ST provided a survival benefit similar to ST alone in de novo stage IV BOM BC patients.,"[{'ForeName': 'Atilla', 'Initials': 'A', 'LastName': 'Soran', 'Affiliation': 'Division of Surgical Oncology, UPMC (University of Pittsburgh Medical Center) Magee-Womens Hospital, Pittsburgh, USA. asoran@upmc.edu.'}, {'ForeName': 'Lutfi', 'Initials': 'L', 'LastName': 'Dogan', 'Affiliation': 'Department of Surgical Oncology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.'}, {'ForeName': 'Arda', 'Initials': 'A', 'LastName': 'Isik', 'Affiliation': 'Department of Surgery, Erzincan Binali Yıldırım University, Erzincan, Turkey.'}, {'ForeName': 'Serdar', 'Initials': 'S', 'LastName': 'Ozbas', 'Affiliation': 'Private, Breast and Endocrine Surgeon, Ankara, Turkey.'}, {'ForeName': 'Didem Can', 'Initials': 'DC', 'LastName': 'Trabulus', 'Affiliation': 'Department of Surgery, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.'}, {'ForeName': 'Umut', 'Initials': 'U', 'LastName': 'Demirci', 'Affiliation': 'Department of Medical Oncology, Memorial Ankara Hospital, University of Uskudar School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Karanlik', 'Affiliation': 'Surgical Oncology Unit, Istanbul University Institute of Oncology, Istanbul, Turkey.'}, {'ForeName': 'Aykut', 'Initials': 'A', 'LastName': 'Soyder', 'Affiliation': 'Department of Surgery, School of Medicine, Adnan Menderes University, Aydın, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Dag', 'Affiliation': 'Department of Surgery, School of Medicine, Mersin University, Mersin, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Bilici', 'Affiliation': 'Department of Medical Oncology, School of Medicine, Medipol University, Istanbul, Turkey.'}, {'ForeName': 'Mutlu', 'Initials': 'M', 'LastName': 'Dogan', 'Affiliation': 'Department of Medical Oncology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.'}, {'ForeName': 'Hande', 'Initials': 'H', 'LastName': 'Koksal', 'Affiliation': 'Department of Surgery, Konya Training and Research Hospital, University of Health Sciences, Konya, Turkey.'}, {'ForeName': 'Mehmet Ali Nahit', 'Initials': 'MAN', 'LastName': 'Sendur', 'Affiliation': 'Department of Medical Oncology, School of Medicine, Yıldırım Beyazit University, Ankara, Turkey.'}, {'ForeName': 'Mehmet Ali', 'Initials': 'MA', 'LastName': 'Gulcelik', 'Affiliation': 'Department of Surgical Oncology, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.'}, {'ForeName': 'Gokturk', 'Initials': 'G', 'LastName': 'Maralcan', 'Affiliation': 'Department of Surgery, School of Medicine, Sanko University, Gaziantep, Turkey.'}, {'ForeName': 'Neslihan', 'Initials': 'N', 'LastName': 'Cabioglu', 'Affiliation': 'Department of Surgery, School of Medicine Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Levent', 'Initials': 'L', 'LastName': 'Yeniay', 'Affiliation': 'Department of Surgery, School of Medicine, Ege University, Izmir, Turkey.'}, {'ForeName': 'Zafer', 'Initials': 'Z', 'LastName': 'Utkan', 'Affiliation': 'Department of Surgery, School of Medicine, Kocaeli University, İzmit, Turkey.'}, {'ForeName': 'Turgay', 'Initials': 'T', 'LastName': 'Simsek', 'Affiliation': 'Department of Surgery, School of Medicine, Kocaeli University, İzmit, Turkey.'}, {'ForeName': 'Nuri', 'Initials': 'N', 'LastName': 'Karadurmus', 'Affiliation': 'Department of Medical Oncology, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.'}, {'ForeName': 'Gul', 'Initials': 'G', 'LastName': 'Daglar', 'Affiliation': 'Private, Breast and Endocrine Surgeon, Ankara, Turkey.'}, {'ForeName': 'Birol', 'Initials': 'B', 'LastName': 'Yildiz', 'Affiliation': 'Department of Medical Oncology, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.'}, {'ForeName': 'Cihan', 'Initials': 'C', 'LastName': 'Uras', 'Affiliation': 'Department of Surgery, Acibadem University School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Tukenmez', 'Affiliation': 'Department of Surgery, School of Medicine Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Yildirim', 'Affiliation': 'Department of Medical Oncology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.'}, {'ForeName': 'Suat', 'Initials': 'S', 'LastName': 'Kutun', 'Affiliation': 'Department of Surgical Oncology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.'}, {'ForeName': 'Cihangir', 'Initials': 'C', 'LastName': 'Ozaslan', 'Affiliation': 'Department of Surgical Oncology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.'}, {'ForeName': 'Niyazi', 'Initials': 'N', 'LastName': 'Karaman', 'Affiliation': 'Department of Surgery, Ankara Oncology Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Müfide Nuran', 'Initials': 'MN', 'LastName': 'Akcay', 'Affiliation': 'Department of Surgery, School of Medicine, Atatürk University, Erzurum, Turkey.'}, {'ForeName': 'Osman', 'Initials': 'O', 'LastName': 'Toktas', 'Affiliation': 'Department of Surgery, School of Medicine, Yuzuncuyıl University, Van, Turkey.'}, {'ForeName': 'Efe', 'Initials': 'E', 'LastName': 'Sezgin', 'Affiliation': 'Department of Food and Engineering, Faculty of Engineering, Izmir Institute of Technology, Izmir, Turkey.'}]",Annals of surgical oncology,['10.1245/s10434-021-09621-8'] 958,33547573,Comparison of Two Methods for Implementing Comfort Care Order Sets in the Inpatient Setting: a Cluster Randomized Trial.,"BACKGROUND There is an ongoing need for interventions to improve quality of end-of-life care for patients in inpatient settings. OBJECTIVE To compare two methods for implementing a Comfort Care Education Intervention for Palliative Care Consultation Teams (PCCT) in Veterans Affairs Medical Centers (VAMCs). DESIGN Cluster randomized implementation trial conducted March 2015-April 2019. PCCTs were assigned to a traditional implementation approach using a teleconference or to an in-person, train-the-champion workshop to prepare PCCTs to be clinical champions at their home sites. PARTICIPANTS One hundred thirty-two providers from PCCTs at 47 VAMCs. INTERVENTIONS Both training modalities involved review of educational materials, instruction on using an electronic Comfort Care Order Set, and coaching to deliver the intervention to other providers. MAIN MEASUREMENTS Several processes of care were identified a priori as quality endpoints for end-of-life care (last 7 days) and abstracted from medical records of veterans who died within 9 months before or after implementation (n = 6,491). The primary endpoint was the presence of an active order for opioid medication at time of death. Secondary endpoints were orders/administration of antipsychotics, benzodiazepines, and scopolamine, do-not-resuscitate orders, advance directives, locations of death, palliative care consultations, nasogastric tubes, intravenous lines, physical restraints, pastoral care visits, and family presence at/near time of death. Generalized estimating equations were conducted adjusting for potential covariates. KEY RESULTS Eighty-eight providers from 23 VAMCs received teleconference training; 44 providers from 23 VAMCs received in-person workshop training. Analyses found no significant differences between intervention groups in any process-of-care endpoints (primary endpoint AOR (CI) = 1.18 (0.74, 1.89). Furthermore, pre-post changes were not significant for any endpoints (primary endpoint AOR (CI) = 1.16 (0.92, 1.46). Analyses may have been limited by high baseline values on key endpoints with little room for improvement. CONCLUSION Findings suggest the clinical effectiveness of palliative care educational intervention was not dependent on which of the two implementation methods was used. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02383173.",2021,"Analyses found no significant differences between intervention groups in any process-of-care endpoints (primary endpoint AOR (CI) = 1.18 (0.74, 1.89).","['patients in inpatient settings', 'Eighty-eight providers from 23 VAMCs received teleconference training; 44 providers from 23', 'Veterans Affairs Medical Centers (VAMCs', 'One hundred thirty-two providers from PCCTs at 47 VAMCs']","['Comfort Care Education Intervention', 'palliative care educational intervention', 'VAMCs received in-person workshop training']","['quality endpoints for end-of-life care (last 7 days) and abstracted from medical records of veterans who died', 'presence of an active order for opioid medication at time of death', 'orders/administration of antipsychotics, benzodiazepines, and scopolamine, do-not-resuscitate orders, advance directives, locations of death, palliative care consultations, nasogastric tubes, intravenous lines, physical restraints, pastoral care visits, and family presence at/near time of death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0039450', 'cui_str': 'Teleconference'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450357', 'cui_str': '32'}]","[{'cui': 'C1161173', 'cui_str': 'Comfort care education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0039548', 'cui_str': 'Terminal care'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0000857', 'cui_str': 'Abstracting as Topic'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1301931', 'cui_str': 'Time of death'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0036442', 'cui_str': 'Scopolamine'}, {'cui': 'C0079252', 'cui_str': 'Do-Not-Resuscitate Orders'}, {'cui': 'C0001683', 'cui_str': 'Advance Directives'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0085678', 'cui_str': 'Nasogastric tube'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0035260', 'cui_str': 'Physical restraint'}, {'cui': 'C0030643', 'cui_str': 'Pastoral care'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}]",6491.0,0.14616,"Analyses found no significant differences between intervention groups in any process-of-care endpoints (primary endpoint AOR (CI) = 1.18 (0.74, 1.89).","[{'ForeName': 'F Amos', 'Initials': 'FA', 'LastName': 'Bailey', 'Affiliation': 'Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Birmingham VA Medical Center, Birmingham, AL, USA. Amos.bailey@cuanschutz.edu.'}, {'ForeName': 'Beverly R', 'Initials': 'BR', 'LastName': 'Williams', 'Affiliation': 'Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Birmingham VA Medical Center, Birmingham, AL, USA.'}, {'ForeName': 'Patricia S', 'Initials': 'PS', 'LastName': 'Goode', 'Affiliation': 'Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Birmingham VA Medical Center, Birmingham, AL, USA.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Kennedy', 'Affiliation': 'Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Birmingham VA Medical Center, Birmingham, AL, USA.'}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Redden', 'Affiliation': 'Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Birmingham VA Medical Center, Birmingham, AL, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Kvale', 'Affiliation': 'Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Birmingham VA Medical Center, Birmingham, AL, USA.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Bakitas', 'Affiliation': 'Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Birmingham VA Medical Center, Birmingham, AL, USA.'}, {'ForeName': 'J Nicholas', 'Initials': 'JN', 'LastName': 'Dionne-Odom', 'Affiliation': 'University of Alabama at Birmingham School of Nursing, Birmingham, AL, USA.'}, {'ForeName': 'Kathryn L', 'Initials': 'KL', 'LastName': 'Burgio', 'Affiliation': 'Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Birmingham VA Medical Center, Birmingham, AL, USA.'}]",Journal of general internal medicine,['10.1007/s11606-020-06482-x'] 959,33565017,Healing of intrabony defects following regenerative surgery by means of single-flap approach in conjunction with either hyaluronic acid or an enamel matrix derivative: a 24-month randomized controlled clinical trial.,"OBJECTIVES The aim of this randomized controlled clinical trial was to compare the clinical outcomes obtained in intrabony defects following regenerative periodontal surgery using the single-flap approach (SFA) in conjunction with either hyaluronic acid (HA) or enamel matrix derivative (EMD). MATERIALS AND METHODS Thirty-two intrabony defects in 32 healthy subjects were randomly assigned: HA (test group) or EMD (control group). Clinical attachment level (CAL), probing depth (PD), gingival recession (REC), and bleeding on probing (BOP) were recorded at baseline,12, 18, and 24 months after surgery. RESULTS At 24 months, both treatments resulted in statistically significant clinical improvements evidenced by PD-reduction and CAL-gain (p<0.001). The mean CAL-gain was 2.19±1.11 mm in the test and 2.94±1.12 mm in the control sites (p=0.067). PD-reduction was statistically significantly higher for the control group (4.5±0.97 mm) than the test group (3.31±0.70 mm), (p=0.001). CAL-gain ≤ 3 mm was observed in 87.5% and in 62.5% of the test and control sites, respectively. Test sites showed slightly lower REC values than the control sites. No statistically significant differences were found for BOP between treatments. CONCLUSIONS The present findings indicate that both treatments led to statistically significant clinical improvements compared to baseline, although the application of EMD resulted in statistically significantly higher PD-reduction compared to the use of HA. CLINICAL RELEVANCE The use of HA in conjunction with a SFA resulted in significant PD-reduction and CAL-gain, pointing to the potential clinical relevance of this material in regenerative periodontal surgery.",2021,"PD-reduction was statistically significantly higher for the control group (4.5±0.97 mm) than the test group (3.31±0.70 mm), (p=0.001).",['Thirty-two intrabony defects in 32 healthy subjects'],"['hyaluronic acid', 'EMD', 'hyaluronic acid (HA) or enamel matrix derivative (EMD', 'regenerative periodontal surgery using the single-flap approach (SFA']","['Clinical attachment level (CAL), probing depth (PD), gingival recession (REC), and bleeding on probing (BOP', 'PD-reduction and CAL-gain', 'mean CAL-gain', 'BOP', 'Healing of intrabony defects', 'REC values', 'CAL-gain ≤ 3 mm', 'PD-reduction']","[{'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0243072', 'cui_str': 'derivatives'}, {'cui': 'C0398950', 'cui_str': 'Periodontal operation'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0017572', 'cui_str': 'Gingival recession'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0333047', 'cui_str': 'Recession'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",32.0,0.116283,"PD-reduction was statistically significantly higher for the control group (4.5±0.97 mm) than the test group (3.31±0.70 mm), (p=0.001).","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Pilloni', 'Affiliation': 'Section of Periodontology, Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, 6 Caserta Street, 00161, Rome, Italy.'}, {'ForeName': 'Mariana A', 'Initials': 'MA', 'LastName': 'Rojas', 'Affiliation': 'Section of Periodontology, Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, 6 Caserta Street, 00161, Rome, Italy.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Marini', 'Affiliation': 'Section of Periodontology, Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, 6 Caserta Street, 00161, Rome, Italy. lorenzo.marini@uniroma1.it.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Russo', 'Affiliation': 'Section of Periodontology, Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, 6 Caserta Street, 00161, Rome, Italy.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Shirakata', 'Affiliation': 'Department of Periodontology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Sculean', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Iacono', 'Affiliation': 'Section of Periodontology, Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, 6 Caserta Street, 00161, Rome, Italy.'}]",Clinical oral investigations,['10.1007/s00784-021-03822-x'] 960,33566149,Risk factors for fellow eye treatment in protocol T.,"PURPOSE To identify risk factors for fellow eye treatment of diabetic retinopathy with Vascular Endothelial Growth Factor (VEGF) injections during the Diabetic Retinopathy Clinical Research Network (DRCR.Net) Protocol T trial METHODS: In this post-hoc analysis of randomized clinical trial data, Cox regression analysis was performed at 52 and 104 weeks to determine risk factors for treatment in 360 fellow eyes. Survival analysis was performed to determine mean time to treatment based upon medication used. RESULTS Of 360 fellow eyes, 142 (39.4%) required treatment between weeks 4 and 104. Risk factors predicting a lower likelihood of year 1 treatment included older subject age (Hazard Ratio [HR]=0.98, 95% CI 0.96-0.99; p = 0.02) and higher baseline study eye ETDRS score (HR=0.98, 95% CI 0.97-0.99, p = 0.04). Center-involving DME at baseline in the fellow eye was predictive of a higher treatment need at both 52 (HR=1.89, 95% CI 1.42-2.51, p < 0.0001) and 104 weeks (HR=2.68, 95% CI 1.75-4.11, p < 0.0001). Subjects treated in the study eye with aflibercept (HR=0.574, 95% CI 0.371-0.887, p = 0.013) and ranibizumab (HR=0.58, 95%CI 0.36-0.94, p = 0.03) were less likely to require first year fellow eye injection than subjects treated with bevacizumab although this difference was no longer significant at week 104 (aflibercept HR=0.77, 95% CI 0.52-1.16, p = 0.21; ranibizumab HR=0.66, 95% CI 0.43-1.00, p = 0.05). Mean time to treatment was significantly shorter in the bevacizumab group (bevacizumab 25.83 weeks, aflibercept 38.75 weeks, ranibizumab 34.70 weeks (p=0.012)). CONCLUSION Bilateral treatment with intravitreal anti-VEGF injections was common during the DRCR.net Protocol T. Medication choice may impact the risk of fellow eye treatment.",2021,"Mean time to treatment was significantly shorter in the bevacizumab group (bevacizumab 25.83 weeks, aflibercept 38.75 weeks, ranibizumab 34.70 weeks (p=0.012)). ","['360 fellow eyes', 'Of 360 fellow eyes, 142\xa0(39.4%) required treatment between weeks 4 and 104']","['bevacizumab group (bevacizumab', 'bevacizumab', 'intravitreal anti-VEGF injections', 'aflibercept', 'Vascular Endothelial Growth Factor (VEGF) injections', 'ranibizumab']","['Mean time to treatment', 'higher baseline study eye ETDRS score', 'likely to require first year fellow eye injection']","[{'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4517527', 'cui_str': '104'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3494202', 'cui_str': 'Time to Treatment'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0196998', 'cui_str': 'Injection of eye'}]",360.0,0.519659,"Mean time to treatment was significantly shorter in the bevacizumab group (bevacizumab 25.83 weeks, aflibercept 38.75 weeks, ranibizumab 34.70 weeks (p=0.012)). ","[{'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Ness', 'Affiliation': 'Department of Ophthalmology, Boston University School of Medicine, 85 East Concord Street, 8th floor, Boston, MA, 02118, USA. steven.ness@bmc.org.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Green', 'Affiliation': 'Department of Ophthalmology, Boston University School of Medicine, 85 East Concord Street, 8th floor, Boston, MA, 02118, USA.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Loporchio', 'Affiliation': 'Department of Ophthalmology, Boston University School of Medicine, 85 East Concord Street, 8th floor, Boston, MA, 02118, USA.'}, {'ForeName': 'Alexander D', 'Initials': 'AD', 'LastName': 'Port', 'Affiliation': 'Department of Ophthalmology, Boston University School of Medicine, 85 East Concord Street, 8th floor, Boston, MA, 02118, USA.'}, {'ForeName': 'Xuejing', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Ophthalmology, Boston University School of Medicine, 85 East Concord Street, 8th floor, Boston, MA, 02118, USA.'}, {'ForeName': 'Nicole H', 'Initials': 'NH', 'LastName': 'Siegel', 'Affiliation': 'Department of Ophthalmology, Boston University School of Medicine, 85 East Concord Street, 8th floor, Boston, MA, 02118, USA.'}, {'ForeName': 'Vasiliki', 'Initials': 'V', 'LastName': 'Poulaki', 'Affiliation': 'Veterans Affairs Boston Healthcare System, Jamaica Plain, Boston, MA, USA.'}, {'ForeName': 'Manju L', 'Initials': 'ML', 'LastName': 'Subramanian', 'Affiliation': 'Department of Ophthalmology, Boston University School of Medicine, 85 East Concord Street, 8th floor, Boston, MA, 02118, USA.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-021-05108-0'] 961,33567883,Virtual interview training for autistic transition age youth: A randomized controlled feasibility and effectiveness trial.,"LAY ABSTRACT Autistic transition age youth struggle with obtaining employment, and interviewing is a critical barrier to getting a job. We adapted an efficacious virtual reality job interview intervention to meet the needs of autistic transition age youth, called the Virtual Interview Training for Transition Age Youth. This study evaluated whether Virtual Interview Training for Transition Age Youth can be feasibly delivered in high school special education settings and whether Virtual Interview Training for Transition Age Youth improves job interview skills, job interview self-efficacy, job interview anxiety, and access to employment. Forty-eight autistic transition age youth received school-based pre-employment services as usual with Virtual Interview Training for Transition Age Youth, while 23 autistic transition age youth received services as usual only. Local teachers trained and supervised autistic transition age youth using Virtual Interview Training for Transition Age Youth. Participants reported Virtual Interview Training for Transition Age Youth was highly acceptable. Participants receiving services as usual and Virtual Interview Training for Transition Age Youth, compared to participants receiving services as usual only, had better job interview skills and lower job interview anxiety as well as greater access to jobs. Overall, Virtual Interview Training for Transition Age Youth appears to be effective at teaching job interview skills that are associated with accessing competitive jobs. Moreover, youth enjoyed Virtual Interview Training for Transition Age Youth and teachers feasibly implemented the tool within special education pre-employment transition services. Future research needs to better understand how autistic transition age youth from culturally diverse backgrounds and different social, behavioral, or mental health challenges may respond to Virtual Interview Training for Transition Age Youth.",2021,"We adapted an efficacious virtual reality job interview intervention to meet the needs of autistic transition age youth, called the Virtual Interview Training for Transition Age Youth.","['for Transition Age Youth, while 23 autistic transition age youth received services as usual only', 'Forty-eight autistic transition age youth received', 'autistic transition age youth', 'Participants receiving services as usual and Virtual Interview Training for Transition Age Youth, compared to participants receiving services as usual only, had better job interview skills and lower job interview anxiety as well as greater access to jobs', 'Local teachers trained and supervised autistic transition age youth using Virtual Interview Training for Transition Age Youth']","['Virtual interview training', 'school-based pre-employment services as usual with Virtual Interview Training', 'Virtual Interview Training']","['job interview skills, job interview self-efficacy, job interview anxiety, and access to employment']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0871930', 'cui_str': 'Teacher Education'}]","[{'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0014003', 'cui_str': 'Employment'}]",48.0,0.0224401,"We adapted an efficacious virtual reality job interview intervention to meet the needs of autistic transition age youth, called the Virtual Interview Training for Transition Age Youth.","[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Smith', 'Affiliation': 'University of Michigan, USA.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Sherwood', 'Affiliation': 'University of Michigan, USA.'}, {'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Ross', 'Affiliation': 'University of Michigan, USA.'}, {'ForeName': 'Justin D', 'Initials': 'JD', 'LastName': 'Smith', 'Affiliation': 'Northwestern University, USA.'}, {'ForeName': 'Leann', 'Initials': 'L', 'LastName': 'DaWalt', 'Affiliation': 'University of Wisconsin-Madison, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Bishop', 'Affiliation': 'University of Wisconsin-Madison, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Humm', 'Affiliation': 'SIMmersion LLC, USA.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Elkins', 'Affiliation': 'SIMmersion LLC, USA.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Steacy', 'Affiliation': 'SIMmersion LLC, USA.'}]",Autism : the international journal of research and practice,['10.1177/1362361321989928'] 962,33571035,Novel Clinician-Lead Intervention to Address Fear of Cancer Recurrence in Breast Cancer Survivors.,"PURPOSE Fear of cancer recurrence (FCR) affects 50%-70% of cancer survivors. This multicenter, single-arm study sought to determine the participant-rated usefulness of an oncologist-delivered FCR intervention. METHODS Women who completed treatment for early breast cancer (could be receiving endocrine therapy) with baseline FCR > 0 were invited to participate. FCR was measured using a validated 42-item FCR Inventory. The brief oncologist-delivered intervention entailed (1) FCR normalization; (2) provision of personalized prognostic information; (3) recurrence symptoms education, (4) advice on managing worry, and (5) referral to psycho-oncologist if FCR was high. FCR, depression, and anxiety were assessed preintervention (T0), at 1 week (T1), and 3 months (T2) postintervention. The primary outcome was participant-rated usefulness. Secondary outcomes included feasibility and efficacy. RESULTS Five oncologists delivered the intervention to 61/255 women invited. Mean age was 58 ± 12 years. Mean time since breast cancer diagnosis was 2.5 ± 1.3 years. Forty-three women (71%) were on adjuvant endocrine therapy. Of 58 women who completed T1 assessment, 56 (97%) found the intervention to be useful. FCR severity decreased significantly at T1 (F = 18.5, effect size = 0.39, P < .0001) and T2 (F = 24, effect size = 0.68, P < .0001) compared with baseline. There were no changes in unmet need or depression or anxiety. Mean consultation length was 22 minutes (range, 7-47 minutes), and mean intervention length was 8 minutes (range, 2-20 minutes). The intervention was perceived as useful and feasible by oncologists. CONCLUSION A brief oncologist-delivered intervention to address FCR is useful and feasible, and has preliminary efficacy in reducing FCR. Plans for a cluster randomized trial are underway.",2021,"FCR severity decreased significantly at T1 (F = 18.5, effect size = 0.39, P < .0001) and T2 (F = 24, effect size = 0.68, P < .0001) compared with baseline.","['Breast Cancer Survivors', 'Women who completed treatment for early breast cancer (could be receiving endocrine therapy) with baseline FCR > 0 were invited to participate', 'Mean age was 58 ± 12 years', '58 women who completed T1 assessment, 56 (97%) found the intervention to be useful', 'Forty-three women (71%) were on adjuvant endocrine therapy']","['brief oncologist-delivered intervention entailed (1) FCR normalization; (2) provision of personalized prognostic information; (3) recurrence symptoms education, (4) advice on managing worry, and (5) referral to psycho-oncologist if FCR', 'oncologist-delivered FCR intervention', 'Novel Clinician-Lead Intervention']","['FCR, depression, and anxiety', 'Mean time since breast cancer diagnosis', 'feasibility and efficacy', 'Mean consultation length', 'FCR severity', 'mean intervention length', 'unmet need or depression or anxiety', 'FCR']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0233705', 'cui_str': 'Fear of getting cancer'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0259990', 'cui_str': 'Oncologists'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0233705', 'cui_str': 'Fear of getting cancer'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]","[{'cui': 'C0233705', 'cui_str': 'Fear of getting cancer'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0678222', 'cui_str': 'Carcinoma of breast'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027552', 'cui_str': 'Needed'}]",,0.071032,"FCR severity decreased significantly at T1 (F = 18.5, effect size = 0.39, P < .0001) and T2 (F = 24, effect size = 0.68, P < .0001) compared with baseline.","[{'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Crown Princess Mary Cancer Centre, Westmead, Australia.'}, {'ForeName': 'Phyllis', 'Initials': 'P', 'LastName': 'Butow', 'Affiliation': 'Psycho-Oncology Co-operative Research Group, University of Sydney, Camperdown, Australia.'}, {'ForeName': 'Kim T', 'Initials': 'KT', 'LastName': 'Bui', 'Affiliation': 'Concord Cancer Centre, Concord Repatriation General Hospital, Concord, Australia.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Serafimovska', 'Affiliation': 'Psycho-Oncology Co-operative Research Group, University of Sydney, Camperdown, Australia.'}, {'ForeName': 'Daniel S J', 'Initials': 'DSJ', 'LastName': 'Costa', 'Affiliation': 'Pain Management Research Institute, St Leonards, Australia.'}, {'ForeName': 'Belinda E', 'Initials': 'BE', 'LastName': 'Kiely', 'Affiliation': 'Western Sydney University, Campbelltown, Australia.'}, {'ForeName': 'Mun N', 'Initials': 'MN', 'LastName': 'Hui', 'Affiliation': ""The Chris O'Brien Lifehouse, Camperdown, Australia.""}, {'ForeName': 'Annabel', 'Initials': 'A', 'LastName': 'Goodwin', 'Affiliation': 'Western Sydney University, Campbelltown, Australia.'}, {'ForeName': 'Catriona M', 'Initials': 'CM', 'LastName': 'McNeil', 'Affiliation': ""The Chris O'Brien Lifehouse, Camperdown, Australia.""}, {'ForeName': 'Jane M', 'Initials': 'JM', 'LastName': 'Beith', 'Affiliation': 'Psycho-Oncology Co-operative Research Group, University of Sydney, Camperdown, Australia.'}]",JCO oncology practice,['10.1200/OP.20.00799'] 963,33539971,Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.,"INTRODUCTION Smoking cessation has been reported to benefit patients even after a diagnosis of lung cancer. We studied the smoking behavior of patients who participated in a phase 3 trial of adjuvant therapy following resection of stages IB-IIIA NSCLC. METHODS The ECOG-ACRIN 1505 was conducted to determine whether the addition of bevacizumab to adjuvant chemotherapy would improve overall survival (OS) for patients with early-stage NSCLC. Studying the association between smoking status and OS was a secondary end point. Patients completed a questionnaire on their smoking habits at baseline, 3, 6, 9, and 12 months. RESULTS A total of 1501 patients were enrolled, and 99.8%, 95%, 94%, 93%, and 93% responded to the questionnaire at baseline, 3, 6, 9, and 12 months, respectively. A total of 90% reported a current or previous history of cigarette smoking. In addition, 60% of nonsmokers at enrollment reported smoking after diagnosis (before randomization); however, 1% of them reported smoking at 12 months. Furthermore, 94% of the respondents smoked none/fewer cigarettes daily at 12 months. The incidence of grades 3-5 toxicity on treatment was 68%, 76%, and 72% in never, former, and current smokers, respectively (p = 0.05). The disease-free survival for never-smokers relative to current and former smokers was (hazard ratio [HR] 0.93, p = 0.64 and HR 1.05, p = 0.72), and OS was (adjusted HR for death 0.54, p = 0.005 and adjusted HR for death 0.68, p = 0.03), respectively. CONCLUSIONS This is the first comprehensive, prospective report of smoking habits in patients with NSCLC patients from a phase III early-stage trial. There was a high rate of smoking reduction and cessation following study entry. The disease-free survival did not differ significantly between smokers and never smokers, though there were less grade 3-5 toxicities and more favorable OS in never-smokers.",2021,"DFS did not differ significantly between smokers and never smokers, though there were less grade 3-5 toxicities and more favorable OS in never-smokers.","['1501 patients', 'patients who participated in a phase 3 trial of adjuvant therapy following resection of stages IB-IIIA non-small cell lung cancer (NSCLC', 'Patients with Early Stage NSCLC', 'patients with early stage NSCLC']",['bevacizumab to adjuvant chemotherapy'],"['Smoking Behavior', 'overall survival (OS', 'DFS', 'incidence of grades 3-5 toxicity', 'grade 3-5 toxicities', 'disease-free survival (DFS', 'current or previous history of cigarette smoking']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0456597', 'cui_str': 'Stage 1B'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}]",1501.0,0.0482112,"DFS did not differ significantly between smokers and never smokers, though there were less grade 3-5 toxicities and more favorable OS in never-smokers.","[{'ForeName': 'Conor E', 'Initials': 'CE', 'LastName': 'Steuer', 'Affiliation': 'Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia. Electronic address: csteuer@emory.edu.'}, {'ForeName': 'Opeyemi A', 'Initials': 'OA', 'LastName': 'Jegede', 'Affiliation': 'Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Suzanne E', 'Initials': 'SE', 'LastName': 'Dahlberg', 'Affiliation': ""Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Heather A', 'Initials': 'HA', 'LastName': 'Wakelee', 'Affiliation': 'Stanford University School of Medicine and Stanford Cancer Institute, Stanford, California.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Keller', 'Affiliation': 'Merck, Kenilworth, New Jersey.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Tester', 'Affiliation': 'Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Gandara', 'Affiliation': 'University of California Davis Comprehensive Cancer Center, Sacramento, California.'}, {'ForeName': 'Stephen L', 'Initials': 'SL', 'LastName': 'Graziano', 'Affiliation': 'State University of New York Upstate Medical University, Syracuse, New York.'}, {'ForeName': 'Alex A', 'Initials': 'AA', 'LastName': 'Adjei', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Charles A', 'Initials': 'CA', 'LastName': 'Butts', 'Affiliation': 'Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'Suresh S', 'Initials': 'SS', 'LastName': 'Ramalingam', 'Affiliation': 'Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Joan H', 'Initials': 'JH', 'LastName': 'Schiller', 'Affiliation': 'Inova Schar Cancer Institute, Falls Church, Virginia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,['10.1016/j.jtho.2020.12.017'] 964,33541535,3-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation.,"OBJECTIVES The aim of this study was to explore the difference in target vessel failure (TVF) 3 years after intravascular ultrasound (IVUS) guidance versus angiographic guidance among all comers undergoing second-generation drug-eluting stent (DES) implantation. BACKGROUND The multicenter randomized ULTIMATE (Intravascular Ultrasound Guided Drug Eluting Stents Implantation in ""All-Comers"" Coronary Lesions) trial showed a lower incidence of 1-year TVF after IVUS-guided DES implantation among all comers compared with angiographic guidance. However, the 3-year clinical outcomes of the ULTIMATE trial remain unknown. METHODS A total of 1,448 all comers undergoing DES implantation who were randomly assigned to either IVUS guidance or angiographic guidance in the ULTIMATE trial were followed for 3 years. The primary endpoint was the risk for TVF at 3 years. The safety endpoint was definite or probable stent thrombosis (ST). RESULTS At 3 years, TVF occurred in 47 patients (6.6%) in the IVUS-guided group and in 76 patients (10.7%) in the angiography-guided group (p = 0.01), driven mainly by the decrease in clinically driven target vessel revascularization (4.5% vs. 6.9%; p = 0.05). The rate of definite or probable ST was 0.1% in the IVUS-guided group and 1.1% in the angiography-guided group (p = 0.02). Notably, the IVUS-defined optimal procedure was associated with a significant reduction in 3-year TVF relative to that with the suboptimal procedure. CONCLUSIONS IVUS-guided DES implantation was associated with significantly lower rates of TVF and ST during 3-year follow-up among all comers, particularly those who underwent the IVUS-defined optimal procedure compared with those with angiographic guidance. (Intravascular Ultrasound Guided Drug Eluting Stents Implantation in ""All-Comers"" Coronary Lesions; NCT02215915).",2021,"At 3 years, TVF occurred in 47 patients (6.6%) in the IVUS-guided group and in 76 patients (10.7%) in the angiography-guided group (p = 0.01), driven mainly by the decrease in clinically driven target vessel revascularization (4.5% vs. 6.9%; p = 0.05).","['all comers undergoing second-generation drug-eluting stent (DES) implantation', 'A total of 1,448 all comers undergoing DES implantation']","['IVUS guidance or angiographic guidance', 'IVUS-guided DES implantation', 'intravascular ultrasound (IVUS) guidance versus angiographic guidance', 'Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation']","['rate of definite or probable ST', 'clinically driven target vessel revascularization', 'probable stent thrombosis (ST', 'rates of TVF and ST', 'TVF', 'risk for TVF', '3-year TVF relative']","[{'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}]","[{'cui': 'C0439544', 'cui_str': 'Definite'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0449618', 'cui_str': 'Target vessel'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0080103', 'cui_str': 'Relative'}]",,0.0550515,"At 3 years, TVF occurred in 47 patients (6.6%) in the IVUS-guided group and in 76 patients (10.7%) in the angiography-guided group (p = 0.01), driven mainly by the decrease in clinically driven target vessel revascularization (4.5% vs. 6.9%; p = 0.05).","[{'ForeName': 'Xiao-Fei', 'Initials': 'XF', 'LastName': 'Gao', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Ge', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Xiang-Quan', 'Initials': 'XQ', 'LastName': 'Kong', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Kan', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Leng', 'Initials': 'L', 'LastName': 'Han', 'Affiliation': ""Department of Cardiology, Changshu No. 1 People's Hospital, Changshu, China.""}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Lu', 'Affiliation': ""Department of Cardiology, The First People's Hospital of Taicang, Taicang, China.""}, {'ForeName': 'Nai-Liang', 'Initials': 'NL', 'LastName': 'Tian', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Lin', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Qing-Hua', 'Initials': 'QH', 'LastName': 'Lu', 'Affiliation': 'Department of Cardiology, The Second Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Xiao-Yan', 'Initials': 'XY', 'LastName': 'Wang', 'Affiliation': ""Department of Cardiology, Wuxi Third People's Hospital, Wuxi, China.""}, {'ForeName': 'Qi-Hua', 'Initials': 'QH', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, Changzhou Traditional Chinese Medicine Hospital, Changzhou, China.'}, {'ForeName': 'Zhi-Zhong', 'Initials': 'ZZ', 'LastName': 'Liu', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China.'}, {'ForeName': 'Xue-Song', 'Initials': 'XS', 'LastName': 'Qian', 'Affiliation': ""Department of Cardiology, The First People's Hospital of Zhangjiagang, Zhangjiagang, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Cardiology, Changshu No. 1 People's Hospital, Changshu, China.""}, {'ForeName': 'Da-Yang', 'Initials': 'DY', 'LastName': 'Chai', 'Affiliation': ""Department of Cardiology, The First People's Hospital of Taicang, Taicang, China.""}, {'ForeName': 'Chong-Hao', 'Initials': 'CH', 'LastName': 'Chen', 'Affiliation': ""Department of Cardiology, Wuxi Third People's Hospital, Wuxi, China.""}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Pan', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Ye', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Jun-Jie', 'Initials': 'JJ', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Electronic address: jameszll@163.com.'}, {'ForeName': 'Shao-Liang', 'Initials': 'SL', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Electronic address: chmengx@126.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2020.10.001'] 965,33549019,"Comparison of PSORI-CM01 granules and Yinxieling tablets for patients with chronic plaque psoriasis: a pilot study for a randomized, double-blinded, double-dummy, multicentre trial.","BACKGROUND To compare the efficacy and safety of PSORI-CM01 granules with Yinxieling tablets in patients with chronic plaque psoriasis (CPP), we plan to conduct a multicentre, randomized, double-blinded, double-dummy, controlled trial. This pilot study was conducted to determine the feasibility and the potential of the protocol for the full-scale randomized controlled trial (RCT). METHODS This pilot study was conducted in three centers, and compared PSORI-CM01 granules with Yinxieling tablets in patients with CPP during a 12-week treatment and 3-month follow-up period. The primary efficacy endpoint was the decrease of the psoriasis area severity index (PASI) at week 12. The secondary outcome measures included reduction rates of PASI, pruritus scores on the Visual Analogue Scale (VAS), body surface area (BSA), and the Dermatology Life Quality Index (DLQI). Safety was assessed via the incidence of adverse events (AEs) in each treatment group. RESULTS A total of 211 patients were screened, and 63 subjects who met the inclusion criteria were randomised to PSORI-CM01 granule group (N=31) or Yinxieling tablets group (N=32) while 39 subjects finished the study. The primary outcome measure showed a mean decrease of PASI of 2.03 in the PSORICM01 group compared to 0.89 in the Yinxieling group at week 12. Except for the VAS score (t=-2.261, P=0.027), the secondary outcomes showed no significant improvement from baseline in both groups at week 12. No safety or tolerability concerns related to the drugs were observed in either group. CONCLUSIONS This pilot study showed that the RCT is feasible for randomization, patient recruitment, and assessment. Major strategies are necessary to reduce the patient dropout rate before conducting the full RCT. In this pilot study, the PSORI-CM01 granule exhibited greater potential for development compared to its original formula (Yinxieling tablets) for the treatment of CPP.",2021,"The secondary outcome measures included reduction rates of PASI, pruritus scores on the Visual Analogue Scale (VAS), body surface area (BSA), and the Dermatology Life Quality Index (DLQI).","['patients with chronic plaque psoriasis (CPP', 'group (N=32) while 39 subjects finished the study', '211 patients were screened, and 63 subjects who met the inclusion criteria', 'patients with CPP during a 12-week treatment and 3-month follow-up period', 'patients with chronic plaque psoriasis']","['RCT', 'PSORI-CM01 granules and Yinxieling tablets', 'PSORI-CM01 granule group (N=31) or Yinxieling tablets', 'PSORI-CM01 granules with Yinxieling tablets']","['mean decrease of PASI', 'psoriasis area severity index (PASI', 'reduction rates of PASI, pruritus scores on the Visual Analogue Scale (VAS), body surface area (BSA), and the Dermatology Life Quality Index (DLQI', 'safety or tolerability concerns', 'VAS score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1706059', 'cui_str': 'Finish'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4079304', 'cui_str': 'PSORI-CM01'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C4324362', 'cui_str': 'Psoriasis area severity index'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",211.0,0.440126,"The secondary outcome measures included reduction rates of PASI, pruritus scores on the Visual Analogue Scale (VAS), body surface area (BSA), and the Dermatology Life Quality Index (DLQI).","[{'ForeName': 'Dan-Ni', 'Initials': 'DN', 'LastName': 'Yao', 'Affiliation': 'Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China; Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.'}, {'ForeName': 'Chuan-Jian', 'Initials': 'CJ', 'LastName': 'Lu', 'Affiliation': 'Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China; Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine; Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research. lcj@gzucm.edu.cn.'}, {'ForeName': 'Ze-Huai', 'Initials': 'ZH', 'LastName': 'Wen', 'Affiliation': 'Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China; National Centre for Design Measurement and Evaluation of Clinical Research, Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Yu-Hong', 'Initials': 'YH', 'LastName': 'Yan', 'Affiliation': 'Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China; Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.'}, {'ForeName': 'Li-Ming', 'Initials': 'LM', 'LastName': 'Lu', 'Affiliation': 'Clinical Research and Data Center, South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Hui-Mei', 'Initials': 'HM', 'LastName': 'Wu', 'Affiliation': 'Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Zi-Yang', 'Initials': 'ZY', 'LastName': 'He', 'Affiliation': 'Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Deng', 'Affiliation': 'Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China; Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.'}, {'ForeName': 'Jing-Wen', 'Initials': 'JW', 'LastName': 'Deng', 'Affiliation': 'Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China; Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.'}]",Annals of palliative medicine,['10.21037/apm-20-2575'] 966,33541378,"Immediate impact of extremity manipulation on dual task performance: a randomized, crossover clinical trial.","BACKGROUND Previous research demonstrated that manipulation of the extremities was associated with changes in multisegmental postural sway as well as improvement in a lower extremity balancing task. We were interested if these effects would extend to an upper extremity task. Our aim in this study was to investigate whether extremity manipulation could influence dual task performance where the explicit suprapostural task was balancing a water filled tube in the frontal plane. METHODS Participants were healthy volunteers (aged 21-32 years). Upper- or lower-extremity manipulations were delivered in a participant and assessor blinded, randomized crossover, clinical trial. Postural (center of pressure) and suprapostural (tube motion) measurements in the frontal plane were made pre-post manipulation under eyes open and eyes closed conditions using a BTrackS™ force plate and a Shimmer inertial measurement unit, respectively. Pathlength, range, root mean square and sample entropy were calculated to describe each signal during the dual task performance. RESULTS There was no main effect of manipulation or vision for the suprapostural task (tube motion). However, follow-up to interaction effects indicates that roll pathlength, range and root means square of tube motion all decreased (improvement) following lower extremity manipulation with eyes open. Regarding the postural task, there was a main effect of manipulation on mediolateral center of pressure such that pathlength reduced with both upper and lower extremity manipulation with larger decreases in pathlength values following upper extremity manipulation. CONCLUSION Our findings show that manipulation of the extremities enhanced stability (e.g. tube stabilization and standing balance) on performance of a dual task. This furthers the argument that site-specific manipulations influence context specific motor behavior/coordination. However, as this study focused only on the immediate effects of extremity manipulation, caution is urged in generalizing these results to longer time frames until more work has been done examining the length of time these effects last. TRIAL REGISTRATION Clinicaltrials.gov , NCT03877367 , Registered 15 March 2019. Data collection took place July 2019.",2021,There was no main effect of manipulation or vision for the suprapostural task (tube motion).,['Participants were healthy volunteers (aged 21-32\u2009years'],"['Upper- or lower-extremity manipulations', 'extremity manipulation']","['manipulation or vision for the suprapostural task (tube motion', 'Postural (center of pressure) and suprapostural (tube motion) measurements', 'roll pathlength, range and root means square of tube motion', 'Pathlength, range, root mean square and sample entropy', 'dual task performance']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}]","[{'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0376522', 'cui_str': 'Entropy'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}]",,0.0528218,There was no main effect of manipulation or vision for the suprapostural task (tube motion).,"[{'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Malaya', 'Affiliation': 'Center for Neuromotor and Biomechanics Research, University of Houston, Houston, TX, USA. christopher.malaya@gmail.com.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Haworth', 'Affiliation': 'Department of Human Movement Science, Oakland University, Rochester, MI, USA.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Pohlman', 'Affiliation': 'Research Center, Parker University, Dallas, TX, USA.'}, {'ForeName': 'Dean L', 'Initials': 'DL', 'LastName': 'Smith', 'Affiliation': 'Department of Kinesiology and Health, Miami University, Oxford, Ohio, USA.'}]",Chiropractic & manual therapies,['10.1186/s12998-021-00366-5'] 967,33541330,Application and practice of a step-by-step method combined with case-based learning in Chinese otoendoscopy education.,"BACKGROUND Standardized training allows more physicians to master otoendoscopic surgery. However, the lecture-based learning (LBL) applied in otoendoscopy teaching may not be conducive to training students in clinical thinking and surgical ability. It is necessary to explore innovative methods for otoendoscopy teaching. This study aimed to determine the effect of a step-by-step (SBS) method combined with case-based learning (CBL) in otoendoscopy teaching. METHODS Fifty-nine physicians who participated in otoendoscopy training were selected as the study subjects and randomly divided into two groups (A and B). Group A underwent training with the SBS & CBL method, while Group B underwent training with the LBL & CBL method. The effects of these two methods for otoendoscopy training were compared by evaluation of professional skills and questionnaires before and after the training. RESULTS Proficiency in otoendoscopic anatomy and grades for both professional knowledge and otoendoscopic skills were significantly higher in Group A than in Group B(P < 0.05). In terms of learning interest, surgical ability, acting capacity during surgery, reducing surgical complications, and satisfaction with learning experience, all responses from Group A were better than those from Group B(P < 0.05). CONCLUSIONS The SBS & CBL method may help to improve ability in otoendoscopic surgery and clinical thinking and appears suitable for endoscopy teaching.",2021,"In terms of learning interest, surgical ability, acting capacity during surgery, reducing surgical complications, and satisfaction with learning experience, all responses from Group A were better than those from Group B(P < 0.05). ","['Fifty-nine physicians who participated in', 'Chinese otoendoscopy education']","['otoendoscopy training', 'step-by-step method combined with case-based learning', 'lecture-based learning (LBL', 'step-by-step (SBS) method combined with case-based learning (CBL']","['professional knowledge and otoendoscopic skills', 'surgical complications, and satisfaction with learning experience']","[{'cui': 'C3830128', 'cui_str': '59'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0376683', 'cui_str': 'Lectures'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",59.0,0.0140939,"In terms of learning interest, surgical ability, acting capacity during surgery, reducing surgical complications, and satisfaction with learning experience, all responses from Group A were better than those from Group B(P < 0.05). ","[{'ForeName': 'Fanqin', 'Initials': 'F', 'LastName': 'Wei', 'Affiliation': ""Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangdong, 510080, Guangzhou, People's Republic of China.""}, {'ForeName': 'Qiyang', 'Initials': 'Q', 'LastName': 'Sun', 'Affiliation': ""Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangdong, 510080, Guangzhou, People's Republic of China.""}, {'ForeName': 'Zili', 'Initials': 'Z', 'LastName': 'Qin', 'Affiliation': ""Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangdong, 510080, Guangzhou, People's Republic of China.""}, {'ForeName': 'Huiwen', 'Initials': 'H', 'LastName': 'Zhuang', 'Affiliation': ""Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangdong, 510080, Guangzhou, People's Republic of China.""}, {'ForeName': 'Guangli', 'Initials': 'G', 'LastName': 'Jiang', 'Affiliation': ""Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangdong, 510080, Guangzhou, People's Republic of China.""}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': ""Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangdong, 510080, Guangzhou, People's Republic of China. hyjiangwu@163.com.""}]",BMC medical education,['10.1186/s12909-021-02513-1'] 968,33560322,Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.,"Importance The optimal transfusion strategy in patients with acute myocardial infarction and anemia is unclear. Objective To determine whether a restrictive transfusion strategy would be clinically noninferior to a liberal strategy. Design, Setting, and Participants Open-label, noninferiority, randomized trial conducted in 35 hospitals in France and Spain including 668 patients with myocardial infarction and hemoglobin level between 7 and 10 g/dL. Enrollment could be considered at any time during the index admission for myocardial infarction. The first participant was enrolled in March 2016 and the last was enrolled in September 2019. The final 30-day follow-up was accrued in November 2019. Interventions Patients were randomly assigned to undergo a restrictive (transfusion triggered by hemoglobin ≤8; n = 342) or a liberal (transfusion triggered by hemoglobin ≤10 g/dL; n = 324) transfusion strategy. Main Outcomes and Measures The primary clinical outcome was major adverse cardiovascular events (MACE; composite of all-cause death, stroke, recurrent myocardial infarction, or emergency revascularization prompted by ischemia) at 30 days. Noninferiority required that the upper bound of the 1-sided 97.5% CI for the relative risk of the primary outcome be less than 1.25. The secondary outcomes included the individual components of the primary outcome. Results Among 668 patients who were randomized, 666 patients (median [interquartile range] age, 77 [69-84] years; 281 [42.2%] women) completed the 30-day follow-up, including 342 in the restrictive transfusion group (122 [35.7%] received transfusion; 342 total units of packed red blood cells transfused) and 324 in the liberal transfusion group (323 [99.7%] received transfusion; 758 total units transfused). At 30 days, MACE occurred in 36 patients (11.0% [95% CI, 7.5%-14.6%]) in the restrictive group and in 45 patients (14.0% [95% CI, 10.0%-17.9%]) in the liberal group (difference, -3.0% [95% CI, -8.4% to 2.4%]). The relative risk of the primary outcome was 0.79 (1-sided 97.5% CI, 0.00-1.19), meeting the prespecified noninferiority criterion. In the restrictive vs liberal group, all-cause death occurred in 5.6% vs 7.7% of patients, recurrent myocardial infarction occurred in 2.1% vs 3.1%, emergency revascularization prompted by ischemia occurred in 1.5% vs 1.9%, and nonfatal ischemic stroke occurred in 0.6% of patients in both groups. Conclusions and Relevance Among patients with acute myocardial infarction and anemia, a restrictive compared with a liberal transfusion strategy resulted in a noninferior rate of MACE after 30 days. However, the CI included what may be a clinically important harm. Trial Registration ClinicalTrials.gov Identifier: NCT02648113.",2021,"At 30 days, MACE occurred in 36 patients (11.0% [95% CI, 7.5%-14.6%]) in the restrictive group and in 45 patients (14.0% [95% CI, 10.0%-17.9%]) in the liberal group (difference, -3.0% [95% CI, -8.4% to 2.4%]).","['patients with acute myocardial infarction and anemia', 'The first participant was enrolled in March 2016 and the last was enrolled in September 2019', '668 patients who were randomized, 666 patients (median [interquartile range] age, 77 [69-84] years; 281 [42.2%] women) completed the 30-day follow-up, including 342 in the restrictive transfusion group (122 [35.7%] received transfusion; 342 total units of packed red blood cells transfused) and 324 in the liberal transfusion group ', '35 hospitals in France and Spain including 668 patients with myocardial infarction and hemoglobin level between 7 and 10 g/dL. Enrollment could be considered at any time during the index admission for myocardial infarction', 'Patients With Acute Myocardial Infarction and Anemia']","['MACE', 'Restrictive vs Liberal Blood Transfusion Strategy', 'restrictive (transfusion triggered by hemoglobin ≤8; n\u2009=\u2009342) or a liberal (transfusion triggered by hemoglobin ≤10 g/dL; n\u2009=\u2009324) transfusion strategy']","['cause death', 'major adverse cardiovascular events (MACE; composite of all-cause death, stroke, recurrent myocardial infarction, or emergency revascularization prompted by ischemia', 'nonfatal ischemic stroke', 'recurrent myocardial infarction', 'Major Cardiovascular Events', 'individual components of the primary outcome', 'ischemia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C5191280', 'cui_str': '342'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C4517713', 'cui_str': '324'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C1318182', 'cui_str': '10G'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C5191280', 'cui_str': '342'}, {'cui': 'C0439267', 'cui_str': 'g/dL'}, {'cui': 'C4517713', 'cui_str': '324'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",668.0,0.185332,"At 30 days, MACE occurred in 36 patients (11.0% [95% CI, 7.5%-14.6%]) in the restrictive group and in 45 patients (14.0% [95% CI, 10.0%-17.9%]) in the liberal group (difference, -3.0% [95% CI, -8.4% to 2.4%]).","[{'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Ducrocq', 'Affiliation': 'Université de Paris, AP-HP, French Alliance for Cardiovascular Trials (FACT), INSERM U1148, Paris, France.'}, {'ForeName': 'Jose R', 'Initials': 'JR', 'LastName': 'Gonzalez-Juanatey', 'Affiliation': 'Cardiology Department, University Hospital, IDIS, CIBERCV, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Puymirat', 'Affiliation': 'Université de Paris, AP-HP, Hôpital Européen Georges Pompidou, French Alliance for Cardiovascular Trials (FACT), Paris, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Lemesle', 'Affiliation': 'Institut Cœur Poumon, Centre Hospitalier Universitaire de Lille, Faculté de Médecine de Lille, Université de Lille, Institut Pasteur de Lille, Inserm U1011, Lille, France.'}, {'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Cachanado', 'Affiliation': 'Department of Clinical Pharmacology and Clinical Research Platform of the East of Paris (URC-CRC-CRB), AP-HP, Hôpital St Antoine, Paris, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Durand-Zaleski', 'Affiliation': 'AP-HP Health Economics Research Unit, Hotel Dieu Hospital, INSERM UMR 1153 CRESS, Paris, France.'}, {'ForeName': 'Joan Albert', 'Initials': 'JA', 'LastName': 'Arnaiz', 'Affiliation': 'Clinical Trials Unit, Clinical Pharmacology Department, Hospital Clinic, Barcelona, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Martínez-Sellés', 'Affiliation': 'Clinical Trials Unit, Clinical Pharmacology Department, Hospital Clinic, Barcelona, Spain.'}, {'ForeName': 'Johanne', 'Initials': 'J', 'LastName': 'Silvain', 'Affiliation': 'Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), INSERM UMRS 1166, Paris, France.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Ariza-Solé', 'Affiliation': 'University Hospital Bellvitge, Heart Disease Institute, Barcelona, Spain.'}, {'ForeName': 'Emile', 'Initials': 'E', 'LastName': 'Ferrari', 'Affiliation': ""Université Côte d'Azur, CHU de Nice, Hôpital Pasteur 1, Service de Cardiologie, Nice, France.""}, {'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Calvo', 'Affiliation': 'Àrea del Medicament, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Danchin', 'Affiliation': 'Université de Paris, AP-HP, Hôpital Européen Georges Pompidou, French Alliance for Cardiovascular Trials (FACT), Paris, France.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Avendaño-Solá', 'Affiliation': 'Clinical Pharmacology Service, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.'}, {'ForeName': 'Jerome', 'Initials': 'J', 'LastName': 'Frenkiel', 'Affiliation': 'AP-HP Health Economics Research Unit, Hotel Dieu Hospital, INSERM UMR 1153 CRESS, Paris, France.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Rousseau', 'Affiliation': 'Department of Clinical Pharmacology and Clinical Research Platform of the East of Paris (URC-CRC-CRB), AP-HP, Hôpital St Antoine, Paris, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vicaut', 'Affiliation': 'AP-HP, Department of Biostatistics, Université Paris-Diderot, Sorbonne-Paris Cité, Fernand Widal Hospital, France.'}, {'ForeName': 'Tabassome', 'Initials': 'T', 'LastName': 'Simon', 'Affiliation': 'Department of Clinical Pharmacology and Clinical Research Platform of the East of Paris (URC-CRC-CRB), AP-HP, Hôpital St Antoine, Paris, France.'}, {'ForeName': 'Philippe Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'Université de Paris, AP-HP, French Alliance for Cardiovascular Trials (FACT), INSERM U1148, Paris, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2021.0135'] 969,33560320,"Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.","Importance Endurance exercise is effective in improving peak oxygen consumption (peak V̇o2) in patients with heart failure with preserved ejection fraction (HFpEF). However, it remains unknown whether differing modes of exercise have different effects. Objective To determine whether high-intensity interval training, moderate continuous training, and guideline-based advice on physical activity have different effects on change in peak V̇o2 in patients with HFpEF. Design, Setting, and Participants Randomized clinical trial at 5 sites (Berlin, Leipzig, and Munich, Germany; Antwerp, Belgium; and Trondheim, Norway) from July 2014 to September 2018. From 532 screened patients, 180 sedentary patients with chronic, stable HFpEF were enrolled. Outcomes were analyzed by core laboratories blinded to treatment groups; however, the patients and staff conducting the evaluations were not blinded. Interventions Patients were randomly assigned (1:1:1; n = 60 per group) to high-intensity interval training (3 × 38 minutes/week), moderate continuous training (5 × 40 minutes/week), or guideline control (1-time advice on physical activity according to guidelines) for 12 months (3 months in clinic followed by 9 months telemedically supervised home-based exercise). Main Outcomes and Measures Primary end point was change in peak V̇o2 after 3 months, with the minimal clinically important difference set at 2.5 mL/kg/min. Secondary end points included changes in metrics of cardiorespiratory fitness, diastolic function, and natriuretic peptides after 3 and 12 months. Results Among 180 patients who were randomized (mean age, 70 years; 120 women [67%]), 166 (92%) and 154 (86%) completed evaluation at 3 and 12 months, respectively. Change in peak V̇o2 over 3 months for high-intensity interval training vs guideline control was 1.1 vs -0.6 mL/kg/min (difference, 1.5 [95% CI, 0.4 to 2.7]); for moderate continuous training vs guideline control, 1.6 vs -0.6 mL/kg/min (difference, 2.0 [95% CI, 0.9 to 3.1]); and for high-intensity interval training vs moderate continuous training, 1.1 vs 1.6 mL/kg/min (difference, -0.4 [95% CI, -1.4 to 0.6]). No comparisons were statistically significant after 12 months. There were no significant changes in diastolic function or natriuretic peptides. Acute coronary syndrome was recorded in 4 high-intensity interval training patients (7%), 3 moderate continuous training patients (5%), and 5 guideline control patients (8%). Conclusions and Relevance Among patients with HFpEF, there was no statistically significant difference in change in peak V̇o2 at 3 months between those assigned to high-intensity interval vs moderate continuous training, and neither group met the prespecified minimal clinically important difference compared with the guideline control. These findings do not support either high-intensity interval training or moderate continuous training compared with guideline-based physical activity for patients with HFpEF. Trial Registration ClinicalTrials.gov Identifier: NCT02078947.",2021,"Change in peak V̇o2 over 3 months for high-intensity interval training vs guideline control was 1.1 vs -0.6 mL/kg/min (difference, 1.5 [95% CI, 0.4 to 2.7]); for moderate continuous training vs guideline control, 1.6 vs -0.6 mL/kg/min (difference, 2.0 [95% CI, 0.9 to 3.1]); and for high-intensity interval training vs moderate continuous training, 1.1 vs 1.6 mL/kg/min (difference, -0.4 [95% CI, -1.4 to 0.6]).","['patients with heart failure with preserved ejection fraction (HFpEF', 'Patients With Heart Failure With Preserved Ejection Fraction', '180 patients who were randomized (mean age, 70 years; 120 women [67%]), 166 (92%) and 154 (86%) completed evaluation at 3 and 12 months, respectively', '532 screened patients, 180 sedentary patients with chronic, stable HFpEF were enrolled', 'patients with HFpEF']","['Endurance exercise', 'moderate continuous training (5\u2009×\u200940 minutes/week), or guideline control (1-time advice on physical activity according to guidelines) for 12 months (3 months in clinic followed by 9 months telemedically supervised home-based exercise', 'High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice', 'high-intensity interval training', 'high-intensity interval training, moderate continuous training, and guideline-based advice']","['Acute coronary syndrome', 'peak oxygen consumption', 'diastolic function or natriuretic peptides', 'changes in metrics of cardiorespiratory fitness, diastolic function, and natriuretic peptides after 3 and 12 months', 'Peak Oxygen Consumption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2960127', 'cui_str': 'Heart failure with normal ejection fraction'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C5191361', 'cui_str': '166'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]","[{'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0556975', 'cui_str': 'mins/week'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}]","[{'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1144709', 'cui_str': 'Natriuretic Peptide Hormones'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",180.0,0.110967,"Change in peak V̇o2 over 3 months for high-intensity interval training vs guideline control was 1.1 vs -0.6 mL/kg/min (difference, 1.5 [95% CI, 0.4 to 2.7]); for moderate continuous training vs guideline control, 1.6 vs -0.6 mL/kg/min (difference, 2.0 [95% CI, 0.9 to 3.1]); and for high-intensity interval training vs moderate continuous training, 1.1 vs 1.6 mL/kg/min (difference, -0.4 [95% CI, -1.4 to 0.6]).","[{'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Mueller', 'Affiliation': 'Department of Prevention and Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Ephraim B', 'Initials': 'EB', 'LastName': 'Winzer', 'Affiliation': 'Heart Center Dresden-University Hospital, Department of Internal Medicine and Cardiology, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Duvinage', 'Affiliation': 'Department of Prevention and Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Andreas B', 'Initials': 'AB', 'LastName': 'Gevaert', 'Affiliation': 'Research Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Edelmann', 'Affiliation': 'Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Haller', 'Affiliation': 'Institute of Medical Informatics, Statistics and Epidemiology, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Pieske-Kraigher', 'Affiliation': 'Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Beckers', 'Affiliation': 'Research Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Bobenko', 'Affiliation': 'Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hommel', 'Affiliation': 'Heart Center Dresden-University Hospital, Department of Internal Medicine and Cardiology, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Caroline M', 'Initials': 'CM', 'LastName': 'Van de Heyning', 'Affiliation': 'Research Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Esefeld', 'Affiliation': 'Department of Prevention and Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Pia', 'Initials': 'P', 'LastName': 'von Korn', 'Affiliation': 'Department of Prevention and Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Jeffrey W', 'Initials': 'JW', 'LastName': 'Christle', 'Affiliation': 'Department of Prevention and Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Haykowsky', 'Affiliation': 'Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Linke', 'Affiliation': 'Heart Center Dresden-University Hospital, Department of Internal Medicine and Cardiology, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Ulrik', 'Initials': 'U', 'LastName': 'Wisløff', 'Affiliation': 'The Cardiac Exercise Research Group at Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Adams', 'Affiliation': 'Heart Center Dresden-University Hospital, Department of Internal Medicine and Cardiology, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Burkert', 'Initials': 'B', 'LastName': 'Pieske', 'Affiliation': 'Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Emeline M', 'Initials': 'EM', 'LastName': 'van Craenenbroeck', 'Affiliation': 'Research Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Halle', 'Affiliation': 'Department of Prevention and Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2020.26812'] 970,33568137,Incremental impact on malaria incidence following indoor residual spraying in a highly endemic area with high standard ITN access in Mozambique: results from a cluster-randomized study.,"BACKGROUND Attaining the goal of reducing the global malaria burden is threatened by recent setbacks in maintaining the effectiveness of vector control interventions partly due to the emergence of pyrethroid resistant vectors. One potential strategy to address these setbacks could be combining indoor residual spraying (IRS) with non-pyrethroids and standard insecticide-treated nets (ITNs). This study aimed to provide evidence on the incremental epidemiological benefit of using third-generation IRS product in a highly endemic area with high ITN ownership. METHODS A cluster-randomized, open-label, parallel-arms, superiority trial was conducted in the Mopeia district in Zambezia, Mozambique from 2016 to 2018. The district had received mass distribution of alphacypermethrin ITNs two years before the trial and again mid-way. 86 clusters were defined, stratified and randomized to receive or not receive IRS with pirimiphos-methyl (Actellic®300 CS). Efficacy of adding IRS was assessed through malaria incidence in a cohort of children under five followed prospectively for two years, enhanced passive surveillance at health facilities and by community health workers, and yearly cross-sectional surveys at the peak of the transmission season. FINDINGS A total of 1536 children were enrolled in the cohort. Children in the IRS arm experienced 4,801 cases (incidence rate of 3,532 per 10,000 children-month at risk) versus 5,758 cases in the no-IRS arm (incidence rate of 4,297 per 10,000 children-month at risk), resulting in a crude risk reduction of 18% and an incidence risk ratio of 0.82 (95% CI 0.79-0.86, p-value < 0.001). Facility and community passive surveillance showed a malaria incidence of 278 per 10,000 person-month in the IRS group (43,974 cases over 22 months) versus 358 (95% CI 355-360) per 10,000 person-month at risk in the no-IRS group (58,030 cases over 22 months), resulting in an incidence rate ratio of 0.65 (95% CI 0.60-0.71, p < 0.001). In the 2018 survey, prevalence in children under five in the IRS arm was significantly lower than in the no-IRS arm (OR 0.54, 95% CI, 0.31-0.92, p = 0.0241). CONCLUSION In a highly endemic area with high ITN access and emerging pyrethroid resistance, adding IRS with pirimiphos-methyl resulted in significant additional protection for children under five years of age. TRIAL REGISTRATION ClinicalTrials.gov identifier NCT02910934, registered 22 September 2016, https://clinicaltrials.gov/ct2/show/NCT02910934?term=NCT02910934&draw=2&rank=1 .",2021,"In the 2018 survey, prevalence in children under five in the IRS arm was significantly lower than in the no-IRS arm (OR 0.54, 95% CI, 0.31-0.92, p = 0.0241). ","['cohort of children under five followed prospectively for two years, enhanced passive surveillance at health facilities and by community health workers, and yearly cross-sectional surveys at the peak of the transmission season', '1536 children were enrolled in the cohort', '86 clusters', 'registered 22 September 2016, https://clinicaltrials.gov/ct2/show/NCT02910934?term=NCT02910934&draw=2&rank=1 ', 'Mopeia district in Zambezia, Mozambique from 2016 to 2018', 'malaria incidence following indoor residual spraying in a highly endemic area with high standard ITN access in Mozambique']","['IRS with pirimiphos-methyl (Actellic®300 CS', 'IRS']","['malaria incidence', 'incidence risk ratio']","[{'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0026655', 'cui_str': 'Mozambique'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0243130', 'cui_str': 'endemics'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0071138', 'cui_str': 'Pirimiphos methyl'}, {'cui': 'C0101333', 'cui_str': 'Actellic'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",1536.0,0.14779,"In the 2018 survey, prevalence in children under five in the IRS arm was significantly lower than in the no-IRS arm (OR 0.54, 95% CI, 0.31-0.92, p = 0.0241). ","[{'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Chaccour', 'Affiliation': 'ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. carlos.chaccour@isglobal.org.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Zulliger', 'Affiliation': ""President's Malaria Initiative, US Centers for Disease Control and Prevention, Maputo, Mozambique.""}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Wagman', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'Aina', 'Initials': 'A', 'LastName': 'Casellas', 'Affiliation': 'ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Amilcar', 'Initials': 'A', 'LastName': 'Nacima', 'Affiliation': 'Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.'}, {'ForeName': 'Eldo', 'Initials': 'E', 'LastName': 'Elobolobo', 'Affiliation': 'Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.'}, {'ForeName': 'Binete', 'Initials': 'B', 'LastName': 'Savaio', 'Affiliation': 'PATH, Maputo, Mozambique.'}, {'ForeName': 'Abuchahama', 'Initials': 'A', 'LastName': 'Saifodine', 'Affiliation': ""President's Malaria Initiative, United States Agency for International Development, Maputo, Mozambique.""}, {'ForeName': 'Christen', 'Initials': 'C', 'LastName': 'Fornadel', 'Affiliation': 'Innovative Vector Control Consortium, Liverpool, UK.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Richardson', 'Affiliation': 'Innovative Vector Control Consortium, Liverpool, UK.'}, {'ForeName': 'Baltazar', 'Initials': 'B', 'LastName': 'Candrinho', 'Affiliation': 'ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Robertson', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Saute', 'Affiliation': 'Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.'}]",Malaria journal,['10.1186/s12936-021-03611-7'] 971,33591439,Influence of dynamic neck motion on the clinical usefulness of multi-positional MRI in cervical degenerative spondylosis.,"PURPOSE The purpose of this study was to find out additional indications for multi-positional MRI in cervical degenerative spondylosis (CDS) patients. MATERIAL AND METHODS A total of 63 patients with cervical spondylotic myelopathy that underwent multi-positional MRI and X-ray were included. Muhle's grade, C2-7 angle, and C7 slope were measured. Patients were assigned to the stenosis group (Group S) when Muhle's grades were increased by more than two or maximum grade was reached. Other patients were assigned to the maintenance group (Group M). Receiver operating characteristic (ROC) analysis was performed. Statistical significance was accepted for p values of < 0.05. RESULTS A total of 24 patients were assigned to the S group and 39 patients to the M group. Mean C2-7 angle difference in extension (eC27A) between S and M groups was 10.97° (p = 0.002). The mean inter-group difference between C2-7 angle in extension and neutral positions (e-nC27A) was 14.39° (p = 0.000). Mean C7 slope difference in neutral position was  - 6.53° (p = 0.002). Based on areas under ROC curves (AUCs), e-nC27A, eC27A, and negative C7 slope had AUCs of 0.934 (95% CI 0.876-0.992), 0.752 (95% CI 0.624-0.880), and 0.720 (95% CI 0.588-0.851), respectively. The optimal cutoff value of e-nC27A was 15.4 degrees, which had a diagnostic accuracy of 88.9%. CONCLUSION Multi-positional MRI helps to find dynamic cord compressive lesion in CDS patients. The higher eC27A, e-nC27A values and smaller C7 slope were found to increase the likelihood of cervical dynamic stenosis. Among other factors, we recommend multi-positional MRI before surgery especially when a patient's e-nC27A is > 15.4 degrees. LEVEL OF EVIDENCE I Diagnostic: individual cross-sectional studies with the consistently applied reference standard and blinding.",2021,Mean C2-7 angle difference in extension (eC27A) between S and M groups was 10.97° (p = 0.002).,"['CDS patients', 'cervical degenerative spondylosis (CDS) patients', '63 patients with cervical spondylotic myelopathy that underwent multi-positional\xa0MRI and X-ray\xa0were included', '24 patients were assigned to the S group and 39 patients to the M group', 'cervical degenerative spondylosis']","['dynamic neck motion', 'multi-positional MRI']","['likelihood of cervical dynamic stenosis', 'higher eC27A, e-nC27A values and smaller C7 slope', ""Muhle's grade, C2-7 angle, and C7 slope"", 'Mean\xa0C2-7 angle\xa0difference in extension (eC27A', 'Mean C7 slope\xa0difference in neutral position', 'areas under ROC curves (AUCs), e-nC27A, eC27A, and\xa0negative C7 slope']","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0011164', 'cui_str': 'Degeneration'}, {'cui': 'C0038019', 'cui_str': 'Spondylosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005956', 'cui_str': 'Bone marrow disorder'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0205160', 'cui_str': 'Negative'}]",63.0,0.0567535,Mean C2-7 angle difference in extension (eC27A) between S and M groups was 10.97° (p = 0.002).,"[{'ForeName': 'Jong Beom', 'Initials': 'JB', 'LastName': 'Lee', 'Affiliation': 'Department of Neurosurgery, Chungbuk National University of Korea, Cheongju, Korea.'}, {'ForeName': 'Jong- Hyeok', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': ""Department of Neurosurgery, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Korea.""}, {'ForeName': 'Jung Jae', 'Initials': 'JJ', 'LastName': 'Lee', 'Affiliation': 'Department of Neurosurgery, Gangneung Asan Hospital, The Ulsan University, Gangneung, Korea.'}, {'ForeName': 'Ho Jin', 'Initials': 'HJ', 'LastName': 'Lee', 'Affiliation': ""Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.""}, {'ForeName': 'Il Sup', 'Initials': 'IS', 'LastName': 'Kim', 'Affiliation': ""Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.""}, {'ForeName': 'Jung-Woo', 'Initials': 'JW', 'LastName': 'Hur', 'Affiliation': ""Department of Neurosurgery, Eunpyung St. Mary's Hospital, The Catholic University of Korea, Tongil-ro, Eunpyeng-Gu, Seoul, 102103312, Korea.""}, {'ForeName': 'Jae Taek', 'Initials': 'JT', 'LastName': 'Hong', 'Affiliation': ""Department of Neurosurgery, Eunpyung St. Mary's Hospital, The Catholic University of Korea, Tongil-ro, Eunpyeng-Gu, Seoul, 102103312, Korea. jatagi15@gmail.com.""}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-021-06760-0'] 972,33591390,Diet- and sex-related changes of gut microbiota composition and functional profiles after 4 months of weight loss intervention.,"PURPOSE Obesity has been related to intestinal dysbiosis and the modification of gut microbiota composition by dietary strategies becomes a promising strategy to help manage obesity. The aim of the current study was to evaluate the effect of two weight-loss diets on the composition and functional profile of gut microbiota. METHODS 55 men and 124 women with BMI > 25 kg/m 2 were randomly assigned to moderately high-protein (MHP) or low-fat (LF) diet. Differences in fecal bacteria abundance (based on 16 s rRNA sequencing) between before and after 4 months of calorie restriction was analyzed using EdgeR tool in MicrobiomeAnalyst platform. Bacterial functional profile was predicted using Tax4Fun and metagenomeSeq analysis. Significant KEGG Orthology (KO) terms were selected for the metabolomic study using chromatography. RESULTS After the intervention, MHP-men showed a significant decrease in Negativicutes, Selenomonadales, Dielma and Dielma fastidiosa. LF-men showed a significant increase in Bacilli, Lactobacillales, Christensenellaceae, Peptococcaceae, and Streptococcaceae, Peptococcus, Streptococcus and Christensenella, Duncaniella dubosii_CP039396_93.49%, Roseburia sp_AB744234_98.96% and Alistipes inops_KJ572413_99.57%. MHP-women increased Pasteurellales, Phascolarctobacterium succinatutens, Ruthenibacterium lactatiformans_LR215981_99.55% and decreased in Phascolarctobacterium succinatutens_NR112902_99.56%. Finally, LF-women presented a significant decrease in Bacteroides clarus and Erysipelothrix inopinata_CP060715_84.4%. Surprisingly, no matching bacterial changes were found between these four groups. A total of 42 KO, 10 metabolic pathways and 107 related metabolites related were found implicated in these bacterial changes. Seven metabolites were confirmed in plasma. CONCLUSION Weight-loss-related-changes in gut microbiome composition and the functional profile occur in a sex- and diet-related manner, showing that women and men could differentially benefit from the consumption of MHP and LF diets. TRIAL REGISTRATION NCT02737267, 10th March 2016 retrospectively registered.",2021,"Finally, LF-women presented a significant decrease in Bacteroides clarus and Erysipelothrix inopinata_CP060715_84.4%.",['55 men and 124 women with BMI\u2009>\u200925\xa0kg/m 2'],"['weight-loss diets', 'moderately high-protein (MHP) or low-fat (LF) diet']","['Bacterial functional profile', 'Bacilli, Lactobacillales, Christensenellaceae, Peptococcaceae, and Streptococcaceae, Peptococcus, Streptococcus and Christensenella', 'fecal bacteria abundance', 'Bacteroides clarus', 'Negativicutes, Selenomonadales, Dielma and Dielma fastidiosa', 'composition and functional profile of gut microbiota']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0012167', 'cui_str': 'Weight reduction diet'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0004587', 'cui_str': 'Bacillus'}, {'cui': 'C0030964', 'cui_str': 'Peptococcaceae'}, {'cui': 'C0038394', 'cui_str': 'Streptococcaceae'}, {'cui': 'C0030965', 'cui_str': 'Peptococcus'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C3131019', 'cui_str': 'Genus Christensenella'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C3473406', 'cui_str': 'Clarus'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}]",55.0,0.0408434,"Finally, LF-women presented a significant decrease in Bacteroides clarus and Erysipelothrix inopinata_CP060715_84.4%.","[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Cuevas-Sierra', 'Affiliation': 'Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008, Pamplona, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Romo-Hualde', 'Affiliation': 'Center for Nutrition Research, University of Navarra, 31008, Pamplona, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Aranaz', 'Affiliation': 'Center for Nutrition Research, University of Navarra, 31008, Pamplona, Spain.'}, {'ForeName': 'Leticia', 'Initials': 'L', 'LastName': 'Goni', 'Affiliation': 'Department of Preventive Medicine and Public Health, University of Navarra, 31008, Pamplona, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Cuervo', 'Affiliation': 'Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008, Pamplona, Spain.'}, {'ForeName': 'J Alfredo', 'Initials': 'JA', 'LastName': 'Martínez', 'Affiliation': 'Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008, Pamplona, Spain.'}, {'ForeName': 'Fermín I', 'Initials': 'FI', 'LastName': 'Milagro', 'Affiliation': 'Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008, Pamplona, Spain. fmilagro@unav.es.'}, {'ForeName': 'José I', 'Initials': 'JI', 'LastName': 'Riezu-Boj', 'Affiliation': 'Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008, Pamplona, Spain.'}]",European journal of nutrition,['10.1007/s00394-021-02508-0'] 973,33549194,"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.","BACKGROUND Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. We aimed to assess non-inferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis. METHODS We did a randomised, prospective, double-blind, double-dummy, controlled trial comparing posaconazole (intravenous or oral posaconazole 300 mg twice on day 1, followed by 300 mg once a day for days 2-84) with voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2-84) for 12 weeks or less in the primary treatment of invasive aspergillosis. Participants were from 91 study sites in 26 countries, were aged 13 years or older, weighed at least 40 kg, and met criteria for proven, probable, or possible fungal disease. Participants were randomly assigned (1:1) via a computer-generated randomisation schedule with stratification by risk status. The primary endpoint was cumulative all-cause mortality up until day 42 in the intention-to-treat (ITT) population (defined as randomly assigned participants who received ≥1 dose of study drug), with a 10% non-inferiority margin. The ITT population was also evaluated for safety. This study is registered with ClinicalTrials.gov, NCT01782131, and EudraCT, 2011-003938-14. FINDINGS Between Oct 25, 2013, and Sept 10, 2019, of 653 individuals assessed for eligibility, 575 ITT participants were randomly assigned and received one or more doses of study drug (n=288 [50%] posaconazole, n=287 [50%] voriconazole). Mortality up until day 42 was 15% (44 of 288) in the posaconazole group and 21% (59 of 287) in the voriconazole group (treatment difference -5·3% [95% CI -11·6 to 1·0]; p<0·0001). Mortality up until day 42 in the full-analysis-set subpopulation (ITT participants with proven or probable invasive aspergillosis) supported this conclusion: 31 (19%) of 163 participants in the posaconazole group and 32 (19%) of 171 participants in the voriconazole group (treatment difference 0·3% [95% CI -8·2 to 8·8]). The most frequently reported treatment-related adverse events (incidence >3%) were increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT), nausea, hypokalaemia, and vomiting in the posaconazole group and increased ALT, AST, or alkaline phosphatase, hallucination, increased γ-glutamyltransferase peptidase, nausea, and blurred vision in the voriconazole group. The overall incidence of treatment-related adverse event rates in the ITT population was 30% for posaconazole and 40% for voriconazole (treatment difference -10·2% [95% CI -17·9 to -2·4]). INTERPRETATION Posaconazole was non-inferior to voriconazole for all-cause mortality up until day 42 in participants with invasive aspergillosis. Posaconazole was well tolerated, and participants had fewer treatment-related adverse events than in the voriconazole group. This study supports the use of posaconazole as a first-line treatment for the condition. FUNDING Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc.",2021,"INTERPRETATION Posaconazole was non-inferior to voriconazole for all-cause mortality up until day 42 in participants with invasive aspergillosis.","['Participants were from 91 study sites in 26 countries, were aged 13 years or older, weighed at least 40 kg, and met criteria for proven, probable, or possible fungal disease', 'patients with invasive aspergillosis', 'Between Oct 25, 2013, and Sept 10, 2019, of 653 individuals assessed for eligibility, 575 ITT participants', 'primary treatment of invasive aspergillosis', 'participants with invasive aspergillosis', 'ITT participants with proven or probable invasive aspergillosis']","['posaconazole to voriconazole', 'Posaconazole', 'Posaconazole versus voriconazole', 'posaconazole', 'voriconazole', 'posaconazole, n=287 [50%] voriconazole', 'posaconazole (intravenous or oral posaconazole']","['aspartate aminotransferase (AST) or alanine aminotransferase (ALT), nausea, hypokalaemia, and vomiting', 'cumulative all-cause mortality', 'Mortality', 'ALT, AST, or alkaline phosphatase, hallucination, increased γ-glutamyltransferase peptidase, nausea, and blurred vision', 'adverse events', 'tolerated', 'overall incidence of treatment-related adverse event rates']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0332149', 'cui_str': 'Possible'}, {'cui': 'C0026946', 'cui_str': 'Mycosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238013', 'cui_str': 'Invasive aspergillosis'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C3844102', 'cui_str': '575'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}]","[{'cui': 'C0936148', 'cui_str': 'posaconazole'}, {'cui': 'C0393080', 'cui_str': 'voriconazole'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0020621', 'cui_str': 'Hypokalemia'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0018524', 'cui_str': 'Hallucinations'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0678107', 'cui_str': 'Glutamyl transferase'}, {'cui': 'C0030940', 'cui_str': 'Peptide Hydrolases'}, {'cui': 'C0344232', 'cui_str': 'Hazy vision'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",575.0,0.55414,"INTERPRETATION Posaconazole was non-inferior to voriconazole for all-cause mortality up until day 42 in participants with invasive aspergillosis.","[{'ForeName': 'Johan A', 'Initials': 'JA', 'LastName': 'Maertens', 'Affiliation': 'Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium; Department of Hematology, University Hospitals Leuven, Leuven, Belgium. Electronic address: johan.maertens@uzleuven.be.'}, {'ForeName': 'Galia', 'Initials': 'G', 'LastName': 'Rahav', 'Affiliation': 'Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel.'}, {'ForeName': 'Dong-Gun', 'Initials': 'DG', 'LastName': 'Lee', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, The Catholic University of Korea, Seoul, South Korea.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Ponce-de-León', 'Affiliation': 'Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México.'}, {'ForeName': 'Isabel Cristina', 'Initials': 'IC', 'LastName': 'Ramírez Sánchez', 'Affiliation': 'Hospital Pablo Tobón Uribe, Universidad de Antioquia, Medellín, Colombia.'}, {'ForeName': 'Nikolay', 'Initials': 'N', 'LastName': 'Klimko', 'Affiliation': 'Department of Clinical Mycology, Allergy and Immunology, North Western State Medical University, St Petersburg, Russia.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Sonet', 'Affiliation': 'CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium.'}, {'ForeName': 'Shariq', 'Initials': 'S', 'LastName': 'Haider', 'Affiliation': 'Juravinski Hospital and Cancer Center, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Diego Vélez', 'Affiliation': 'Fundación Valle del Lili, Cali, Colombia.'}, {'ForeName': 'Issam', 'Initials': 'I', 'LastName': 'Raad', 'Affiliation': 'The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Liang-Piu', 'Initials': 'LP', 'LastName': 'Koh', 'Affiliation': 'National University Cancer Institute, National University Health System, Singapore.'}, {'ForeName': 'Meinolf', 'Initials': 'M', 'LastName': 'Karthaus', 'Affiliation': 'Klinikum Neuperlach, Munich, Germany.'}, {'ForeName': 'Jianying', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Respiratory Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Ronen', 'Initials': 'R', 'LastName': 'Ben-Ami', 'Affiliation': 'Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Mary R', 'Initials': 'MR', 'LastName': 'Motyl', 'Affiliation': 'Department of Clinical Microbiology, Merck & Co, Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Seongah', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': 'Department of Diabetes/NASH, Merck & Co, Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Anjana', 'Initials': 'A', 'LastName': 'Grandhi', 'Affiliation': 'Department of Biostatistics, Merck & Co, Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Hetty', 'Initials': 'H', 'LastName': 'Waskin', 'Affiliation': 'Department of Infectious Disease, Merck & Co, Inc, Kenilworth, NJ, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(21)00219-1'] 974,33546681,Physicians' attitudes to disability pension - impact of diagnosis: an experimental study.,"BACKGROUND The purpose of this study is to increase understanding of physicians' attitudes towards disability pension applicants, and the impact of diagnosis. We hypothesize that physicians are more likely to think that patients with physical illnesses should get a disability pension than those with mental illness or alcohol dependence. Disability pension is an important source of income for those unable to work because of a disability and type of diagnosis should not impact accessing these benefits. METHODS We conducted an experiment with a 2 by 3 factorial structure in Sweden. Each physician was randomly assigned one of six patient vignettes, with the same background description but with a different diagnosis. Each vignette had a diagnosis of either depression, alcohol dependence or low back pain, and was about a man or a woman. Logistic regression was used to examine the odds of a physician reporting that a patient should get a disability pension. Effects are reported in terms of odds ratios (ORs). RESULTS 1414 Swedish registered physicians in psychiatry or general practice (24% response rate) completed the survey. Physicians assigned the alcohol dependent vignette had OR 0.45 (95% CI: 0.34 to 0.60) for perceiving that a patient should get a disability pension compared to physicians assigned the low back pain vignette. Physicians assigned the depression vignette had OR 1.89 (95% CI: 1.42 to 2.50) for perceiving that a patient should get a disability pension compared to physicians assigned the low back pain vignette. CONCLUSION The patient diagnosis was associated with the physicians' response regarding if the patient should get a disability pension. A physician's perception is likely to impact a patient's access to disability pension.",2021,Physicians assigned the alcohol dependent vignette had OR 0.45 (95% CI: 0.34 to 0.60) for perceiving that a patient should get a disability pension compared to physicians assigned the low back pain vignette.,"['1414', 'patients with physical illnesses', 'Swedish registered physicians in psychiatry or general practice (24% response rate)\xa0completed the survey']",[],['odds ratios (ORs'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0038996', 'cui_str': 'Swedish language'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]",[],"[{'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",1414.0,0.0769523,Physicians assigned the alcohol dependent vignette had OR 0.45 (95% CI: 0.34 to 0.60) for perceiving that a patient should get a disability pension compared to physicians assigned the low back pain vignette.,"[{'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'McAllister', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden. ashley.mcallister@unimelb.edu.au.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Milner', 'Affiliation': 'Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Engblom', 'Affiliation': 'Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Corrigan', 'Affiliation': 'Department of Psychology, Illinois Institute of Technology, Chicago, USA.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Burström', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}]",BMC health services research,['10.1186/s12913-020-06043-2'] 975,33554255,Extra-pulmonary vein driver mapping and ablation for persistent atrial fibrillation in obese patients.,"AIMS The aim of this study was to determine whether driver ablation effectively treats persistent atrial fibrillation (AF) in obese patients. METHODS AND RESULTS We randomly assigned 124 persistent AF obese patients to two groups, one undergoing conventional ablation (n = 62) and the other undergoing driver ablation (n = 62). Sixty-two non-obese patients with persistent AF undergoing driver ablation served as matched controls. Bipolar electrogram dispersion was analysed for driver mapping. Epicardial adipose tissue (EAT) volume was measured using cardiac computed tomography. Obese patients had a higher proportion of driver regions in the posterior wall (56.5% vs. 32.3%, P = 0.007). Driver complexity, measured as the average number and area of driver regions, was higher in the obese group than in the non-obese group (3.5 ± 1.0 vs. 2.9 ± 0.9, P < 0.001; 15.5% ± 4.2% vs. 9.8 ± 2.6%, P < 0.001, respectively). Left atrial EAT volume correlated better with the proportion of area of driver regions than did body mass index (BMI) and total EAT (BMI: r2 = 0.250, P < 0.001; total EAT: r2 = 0.379, P < 0.001; and left atrial EAT: r2 = 0.439, P < 0.001). The rate of AF termination was significantly higher in the driver ablation group than in the conventional ablation group (82.9% vs. 22.8%, P < 0.001). During the follow-up period of 16.9 ± 6.5 months, patients in the driver ablation group had significantly better AF-free survival (91.91% vs. 79.0%, log rank test, P = 0.026) and AF/atrial tachycardia-free survival (83.9% vs. 64.5%, log rank test, P = 0.011) than did patients in the conventional ablation group. CONCLUSION Obesity is associated with increased driver complexity. Driver ablation improves long-term outcomes in obese patients with persistent AF.",2021,"Obese patients had a higher proportion of driver regions in the posterior wall (56.5% vs. 32.3%, P = 0.007).","['Sixty-two non-obese patients with persistent AF undergoing driver ablation served as matched controls', 'obese patients with persistent AF', 'obese patients', '124 persistent AF obese patients to two groups, one undergoing']","['Driver ablation', 'conventional ablation (n\u2009=\u200962) and the other undergoing driver ablation', 'Extra-pulmonary vein driver mapping and ablation']","['Epicardial adipose tissue (EAT) volume', 'Driver complexity', 'average number and area of driver regions', 'rate of AF termination', 'AF/atrial tachycardia-free survival', 'atrial fibrillation (AF', 'AF-free survival']","[{'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0034090', 'cui_str': 'Structure of vein of pulmonary circulation'}, {'cui': 'C1283195', 'cui_str': 'Mapping - action'}]","[{'cui': 'C0442016', 'cui_str': 'Epicardial'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",124.0,0.059631,"Obese patients had a higher proportion of driver regions in the posterior wall (56.5% vs. 32.3%, P = 0.007).","[{'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Xuhui District, Shanghai 200030, China.'}, {'ForeName': 'Weifeng', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': 'Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Xuhui District, Shanghai 200030, China.'}, {'ForeName': 'Shaohui', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': 'Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Xuhui District, Shanghai 200030, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Xu', 'Affiliation': 'Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Xuhui District, Shanghai 200030, China.'}, {'ForeName': 'Daoliang', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Xuhui District, Shanghai 200030, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Xuhui District, Shanghai 200030, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Xuhui District, Shanghai 200030, China.'}, {'ForeName': 'Mu', 'Initials': 'M', 'LastName': 'Qin', 'Affiliation': 'Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Xuhui District, Shanghai 200030, China.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa314'] 976,33559538,Attachment and attitudes toward children: effects of security priming in parents and non-parents.,"The present two-study investigation is the first to examine whether experimentally boosting attachment security (security priming) affects attitudes in the parenting domain for both parents and non-parents. Mothers (n = 72) and childless undergraduates (n = 82) were randomly assigned to a neutral or a secure prime condition and then completed measures of implicit attitudes (a child-focused version of the Go/No-Go Association Task) and explicit attitudes (self-reported) toward children. Following the priming manipulation, mothers in the secure prime condition had more positive implicit attitudes toward their child compared to mothers in the neutral prime condition. Security priming also increased mothers' positive explicit attitudes toward their children, but only among mothers who scored high on self-reported attachment-related avoidance. No priming effects emerged among non-parents. These results provide the first evidence for a causal link between parental attachment security and parental attitudes toward children.",2021,No priming effects emerged among non-parents.,"['parents and non-parents', 'Mothers (n\xa0=\xa072) and childless undergraduates (n\xa0=\xa082']",['neutral or a secure prime condition and then completed measures of implicit attitudes (a child-focused version of the Go'],"[""mothers' positive explicit attitudes"", 'positive implicit attitudes']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C0071973', 'cui_str': 'PRIME protocol'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C2607870', 'cui_str': 'Version'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}]",82.0,0.0168331,No priming effects emerged among non-parents.,"[{'ForeName': 'Jason D', 'Initials': 'JD', 'LastName': 'Jones', 'Affiliation': ""Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Stern', 'Affiliation': 'Department of Psychology, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Megan H', 'Initials': 'MH', 'LastName': 'Fitter', 'Affiliation': 'Department of Psychology, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Mikulincer', 'Affiliation': 'School of Psychology, Interdisciplinary Center Herzlyia, Herzliya, Israel.'}, {'ForeName': 'Phillip R', 'Initials': 'PR', 'LastName': 'Shaver', 'Affiliation': 'Department of Psychology, University of California, Davis, CA, USA.'}, {'ForeName': 'Jude', 'Initials': 'J', 'LastName': 'Cassidy', 'Affiliation': 'Department of Psychology, University of Maryland, College Park, MD, USA.'}]",Attachment & human development,['10.1080/14616734.2021.1881983'] 977,33559524,A Randomized Controlled Trial of Local Delivery of a Rho Inhibitor (VX-210) in Patients with Acute Traumatic Cervical Spinal Cord Injury.,"Acute traumatic spinal cord injury (SCI) can result in severe, lifelong neurological deficits. After SCI, Rho activation contributes to collapse of axonal growth cones, failure of axonal regeneration, and neuronal loss. This randomized, double-blind, placebo-controlled phase 2b/3 study evaluated the efficacy and safety of Rho inhibitor VX-210 (9 mg) in patients after acute traumatic cervical SCI. The study enrolled patients 14-75 years of age with acute traumatic cervical SCIs, C4-C7 (motor level) on each side, and American Spinal Injury Association Impairment Scale (AIS) Grade A or B who had spinal decompression/stabilization surgery commencing within 72 h after injury. Patients were randomized 1:1 with stratification by age (<30 vs. ≥30 years) and AIS grade (A vs. B with sacral pinprick preservation vs. B without sacral pinprick preservation). A single dose of VX-210 or placebo in fibrin sealant was administered topically onto the dura over the site of injury during decompression/stabilization surgery. Patients were evaluated for medical, neurological, and functional changes, and serum was collected for pharmacokinetics and immunological analyses. Patients were followed up for up to 12 months after treatment. A planned interim efficacy-based futility analysis was conducted after ∼33% of patients were enrolled. The pre-defined futility stopping rule was met, and the study was therefore ended prematurely. In the final analysis, the primary efficacy end-point was not met, with no statistically significant difference in change from baseline in upper-extremity motor score at 6 months after treatment between the VX-210 (9-mg) and placebo groups. This work opens the door to further improvements in the design and conduct of clinical trials in acute SCI.",2021,"In the final analysis, the primary efficacy endpoint was not met, with no statistically significant difference in change from baseline in upper-extremity motor score at 6 months after treatment between the VX-210 9-mg and placebo groups.","['enrolled patients aged 14 to 75 years with acute traumatic cervical SCIs, C4 to C7 (motor level) on each side, and American Spinal Injury Association Impairment Scale (AIS', 'Acute traumatic spinal cord injury (SCI', 'Patients With Acute Traumatic Cervical Spinal Cord Injury', 'patients after acute traumatic cervical SCI']","['Rho-Inhibitor (VX-210', 'placebo', 'sacral pinprick preservation vs B without sacral pinprick preservation', 'VX-210 or placebo', 'Rho inhibitor VX-210']","['upper-extremity motor score', 'efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4720884', 'cui_str': 'American Spinal Injury Association impairment scale'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0840414', 'cui_str': 'Cervical spinal cord injury'}]","[{'cui': 'C1720675', 'cui_str': 'Rho'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036037', 'cui_str': 'Bone structure of sacrum'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}]","[{'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.534659,"In the final analysis, the primary efficacy endpoint was not met, with no statistically significant difference in change from baseline in upper-extremity motor score at 6 months after treatment between the VX-210 9-mg and placebo groups.","[{'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Fehlings', 'Affiliation': 'Division of Neurosurgery and Spine Program, University of Toronto and Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.'}, {'ForeName': 'Bizhan', 'Initials': 'B', 'LastName': 'Aarabi', 'Affiliation': 'University of Maryland, Baltimore, Maryland, USA.'}, {'ForeName': 'Faiz', 'Initials': 'F', 'LastName': 'Ahmad', 'Affiliation': 'Department of Neurosurgery, Emory University, Atlanta, Georgia, USA.'}, {'ForeName': 'Kim D', 'Initials': 'KD', 'LastName': 'Anderson', 'Affiliation': 'Case Western Reserve University, Cleveland, Ohio, USA.'}, {'ForeName': 'Travis', 'Initials': 'T', 'LastName': 'Dumont', 'Affiliation': 'Neurovascular Surgery Program, University of Arizona College of Medicine, Tucson, Arizona, USA.'}, {'ForeName': 'Daryl R', 'Initials': 'DR', 'LastName': 'Fourney', 'Affiliation': 'Neurosurgery, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Harrop', 'Affiliation': 'Division of Spine and Peripheral Nerve Surgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Kee D', 'Initials': 'KD', 'LastName': 'Kim', 'Affiliation': 'University of California Davis Health, Sacramento, California, USA.'}, {'ForeName': 'Brian K', 'Initials': 'BK', 'LastName': 'Kwon', 'Affiliation': 'University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Hari K', 'Initials': 'HK', 'LastName': 'Lingam', 'Affiliation': 'Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Rizzo', 'Affiliation': 'Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.'}, {'ForeName': 'Ludy C', 'Initials': 'LC', 'LastName': 'Shih', 'Affiliation': 'Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.'}, {'ForeName': 'Eve C', 'Initials': 'EC', 'LastName': 'Tsai', 'Affiliation': 'The Ottawa Hospital, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Vaccaro', 'Affiliation': 'Rothman Orthopaedics, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'McKerracher', 'Affiliation': 'BioAxone BioSciences, Inc, Boston, Massachusetts, USA.'}]",Journal of neurotrauma,['10.1089/neu.2020.7096'] 978,33564993,Postoperative hemodynamics after high spinal block with or without intrathecal morphine in cardiac surgical patients: a randomized-controlled trial.,"PURPOSE There is some evidence for the use of intrathecal morphine as a means to provide prolonged analgesia in selective cardiac surgical patients; however, the hemodynamic effects of intrathecal morphine are not well defined. This study was designed to study the effect of intrathecal morphine on hemodynamic parameters in cardiac surgery patients. METHODS In a prospective, double-blind study, 100 adult cardiac surgical patients were randomized to receive either intrathecal 40 mg of 0.5% hyperbaric bupivacaine alone (intrathecal bupivacaine [ITB] group, n = 50) or intrathecal 250 µg of morphine added to 40 mg of 0.5% bupivacaine (intrathecal bupivacaine and morphine [ITBM] group, n = 50). Hemodynamic data, pain scores, rescue analgesic use, spirometry, and vasopressor use were recorded every four hours after surgery for 48 hr. The primary outcome was the incidence of vasoplegia in each group, which was defined as a cardiac index > 2.2 L·min -1 ·m -2 with the requirement of vasopressors to maintain the mean arterial pressure > 60 mmHg with the hemodynamic episode lasting > four hours. RESULTS Eighty-seven patients were analyzed (ITB group, n = 42, and ITBM group, n =45). The incidence of vasoplegia was higher in the ITBM group than in the ITB group [14 (31%) vs 5 (12%), respectively; relative risk, 2.6; 95% confidence interval [CI], 1.0 to 6.6; P = 0.04]. The mean (standard deviation [SD]) duration of vasoplegia was significantly longer in the ITBM group than in the ITB group [8.9 (3.0) hr vs 4.3 (0.4) hr, respectively; difference in means, 4.6; 95% CI, 3.7 to 5.5; P < 0.001]. CONCLUSION Intrathecal morphine added to bupivacaine for high spinal anesthesia increases the incidence and duration of vasoplegia in cardiac surgery patients. TRIAL REGISTRATION www.clinicaltrials.gov (NCT02825056); registered 19 June 2016.",2021,"Hemodynamic data, pain scores, rescue analgesic use, spirometry, and vasopressor use were recorded every four hours after surgery for 48 hr.","['cardiac surgery patients', 'Eighty-seven patients were analyzed (ITB group, n = 42, and ITBM group, n =45', 'cardiac surgical patients', '100 adult cardiac surgical patients']","['morphine', 'intrathecal 250 µg of morphine added to 40 mg of 0.5% bupivacaine (intrathecal bupivacaine and morphine [ITBM', 'intrathecal 40 mg of 0.5% hyperbaric bupivacaine alone (intrathecal bupivacaine [ITB', 'ITBM', 'bupivacaine', 'intrathecal morphine']","['Postoperative hemodynamics', 'mean (standard deviation [SD]) duration of vasoplegia', 'Hemodynamic data, pain scores, rescue analgesic use, spirometry, and vasopressor use', 'incidence of vasoplegia', 'incidence and duration of vasoplegia', 'hemodynamic parameters']","[{'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517895', 'cui_str': '87'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C2717957', 'cui_str': 'Vasoplegia'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",100.0,0.4675,"Hemodynamic data, pain scores, rescue analgesic use, spirometry, and vasopressor use were recorded every four hours after surgery for 48 hr.","[{'ForeName': 'Imran', 'Initials': 'I', 'LastName': 'Bhat', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Virendra K', 'Initials': 'VK', 'LastName': 'Arya', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India. aryavk_99@yahoo.com.'}, {'ForeName': 'Banashree', 'Initials': 'B', 'LastName': 'Mandal', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Aveek', 'Initials': 'A', 'LastName': 'Jayant', 'Affiliation': 'Department of Anaesthesiology and Critical Care Medicine, Amrita Institute of Medical Sciences, Kochi, India.'}, {'ForeName': 'Vikas', 'Initials': 'V', 'LastName': 'Dutta', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Max Rady College of Medicine, University of Manitoba, St. Boniface Hosptial, Winnipeg, MB, Canada.'}, {'ForeName': 'Sandeep Singh', 'Initials': 'SS', 'LastName': 'Rana', 'Affiliation': 'Department of Cardiothoracic and Vascular Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-021-01937-z'] 979,33563035,Evidence of the Associations between Individual and Partner Autonomy Support and Physiological Stress in the Context of Conversations about Weight among Couples Who are Overweight or Obese during a 6-Month Intervention.,"The aim of the study was to examine the impact of supportive communication on acute physiological stress responses during weight-related conversations taking place throughout a couples' weight loss program. Participants were 47 married or cohabitating couples where each partner had a BMI of 25-40 kg/m 2 . Couples were randomized as a dyad into a traditional weight loss program or a program that also included training in providing support to one's partner throughout the weight loss process. Structured conversations between partners about weight management were videotaped at baseline and 6 months. Participants provided saliva samples before and after the conversations, which were assayed for cortisol and salivary alpha-amylase (sAA) to determine physiological stress and anxiety responses to conversations about weight. The results indicated that receiving support from one's partner when discussing weight-related issues was associated with greater physiological stress, as indicated by higher cortisol and sAA levels, whereas providing support to one's partner was associated with lower cortisol levels and higher sAA levels. The findings suggest that receiving support is not a universally positive experience, especially for populations facing health issues. The mixed findings for support provision align with previous studies identifying a negative association between affectionate communication and cortisol levels, as well as a positive association between sAA and anxiety and emotional arousal. The findings and their implications for understanding the physiological correlates of couples' conversations about weight are discussed.",2021,"The results indicated that receiving support from one's partner when discussing weight-related issues was associated with greater physiological stress, as indicated by higher cortisol and sAA levels, whereas providing support to one's partner was associated with lower cortisol levels and higher sAA levels.","['Participants were 47 married or cohabitating couples where each partner had a BMI of 25-40 kg/m 2 ', 'Couples', ""weight-related conversations taking place throughout a couples' weight loss program"", 'Who are Overweight or Obese during a 6-Month Intervention']","[""traditional weight loss program or a program that also included training in providing support to one's partner throughout the weight loss process"", 'supportive communication']","['cortisol levels and higher sAA levels', 'cortisol and sAA levels']","[{'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C3179079', 'cui_str': 'Weight Loss Programs'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C3179079', 'cui_str': 'Weight Loss Programs'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0009452', 'cui_str': 'Communication'}]","[{'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C2350322', 'cui_str': 'Salivary alpha-Amylases'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}]",47.0,0.0198954,"The results indicated that receiving support from one's partner when discussing weight-related issues was associated with greater physiological stress, as indicated by higher cortisol and sAA levels, whereas providing support to one's partner was associated with lower cortisol levels and higher sAA levels.","[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Denes', 'Affiliation': 'Department of Communication, University of Connecticut.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Crowley', 'Affiliation': 'Department of Communication, University of Delaware.'}, {'ForeName': 'Ambyre L P', 'Initials': 'ALP', 'LastName': 'Ponivas', 'Affiliation': 'Departments of Communication Studies and Psychology, Young Harris College.'}, {'ForeName': 'Talea', 'Initials': 'T', 'LastName': 'Cornelius', 'Affiliation': 'Center for Behavioral Cardiovascular Health, Columbia University Irving Medical Center.'}, {'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Allred', 'Affiliation': 'Department of Communication Studies, University of Wisconsin Oshkosh.'}, {'ForeName': 'Katelyn M', 'Initials': 'KM', 'LastName': 'Gettens', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital.'}, {'ForeName': 'Theodore A', 'Initials': 'TA', 'LastName': 'Powers', 'Affiliation': 'Psychology Department, University of Massachusetts Dartmouth.'}, {'ForeName': 'Amy A', 'Initials': 'AA', 'LastName': 'Gorin', 'Affiliation': 'Institute for Collaboration on Health, Intervention, and Policy (InCHIP) and Psychological Sciences, University of Connecticut.'}]",Health communication,['10.1080/10410236.2021.1880685'] 980,33561725,Scaffolding the attention-deficit/hyperactivity disorder brain using transcranial direct current and random noise stimulation: A randomized controlled trial.,"OBJECTIVE Improving symptomology and cognitive deficits in neurodevelopmental disorders is a crucial challenge. We examined whether neurostimulation protocols, which have been shown to yield long-term effects when combined with cognitive training, could benefit children with Attention-deficit/hyperactivity-disorder (ADHD), the most common neurodevelopmental disorder in childhood. METHODS We used a randomized double-blind active-controlled crossover study of 19 unmedicated children with ADHD, who received either anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex (dlPFC) or random noise stimulation (tRNS) over the bilateral dlPFC, while completing executive functions training. RESULTS For our primary outcome, tRNS yielded a clinical improvement as indicated by the reduced ADHD rating-scale score from baseline, and in comparison to the changes observed in tDCS. The effect of brain stimulation one week after completion of treatment yielded further improvement, suggesting a neuroplasticity-related effect. Finally, tRNS improved working memory compared to tDCS, and a larger tRNS effect on ADHD rating-scale was predicted for those who showed the greatest improvement in working memory. CONCLUSIONS We found that our intervention can have a lasting effect, rather than a merely immediate effect as was shown for in previous medical interventions in ADHD. SIGNIFICANCE Our results provide a promising direction toward a novel intervention in ADHD.",2021,"For our primary outcome, tRNS yielded a clinical improvement as indicated by the reduced ADHD rating-scale score from baseline, and in comparison to the changes observed in tDCS.","['19 unmedicated children with ADHD, who received either']","['transcranial direct current and random noise stimulation', 'cognitive training', 'anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex (dlPFC) or random noise stimulation (tRNS) over the bilateral dlPFC, while completing executive functions training']","['reduced ADHD rating-scale score', 'ADHD rating-scale']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}]","[{'cui': 'C0442348', 'cui_str': 'Transcranial approach'}, {'cui': 'C0442831', 'cui_str': 'Direct current'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589092', 'cui_str': 'Executive functions training'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",19.0,0.249495,"For our primary outcome, tRNS yielded a clinical improvement as indicated by the reduced ADHD rating-scale score from baseline, and in comparison to the changes observed in tDCS.","[{'ForeName': 'Itai', 'Initials': 'I', 'LastName': 'Berger', 'Affiliation': 'Pediatric Neurology Unit, Hadassah-Hebrew University Medical Center, Israel; School of Social Work and Social Welfare, Hebrew University of Jerusalem, Israel. Electronic address: itai.berger@mail.huji.ac.il.'}, {'ForeName': 'Ornella', 'Initials': 'O', 'LastName': 'Dakwar-Kawar', 'Affiliation': 'School of Occupational Therapy, Hebrew University of Jerusalem, Israel.'}, {'ForeName': 'Ephraim S', 'Initials': 'ES', 'LastName': 'Grossman', 'Affiliation': 'Pediatric Neurology Unit, Hadassah-Hebrew University Medical Center, Israel.'}, {'ForeName': 'Mor', 'Initials': 'M', 'LastName': 'Nahum', 'Affiliation': 'School of Occupational Therapy, Hebrew University of Jerusalem, Israel.'}, {'ForeName': 'Roi', 'Initials': 'R', 'LastName': 'Cohen Kadosh', 'Affiliation': 'Wellcome Centre for Integrative Neuroimaging, Department of Experimental Psychology, University of Oxford, UK. Electronic address: roi.cohenkadosh@psy.ox.ac.uk.'}]",Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology,['10.1016/j.clinph.2021.01.005'] 981,33567041,Comparison of the hypotensor effect between latanoprost versus selective laser trabeculoplasty obtained with the water drinking test.,"PURPOSE Glaucoma is the main cause of irreversible blindness worldwide. Peak intraocular pressure is one of the main risk factors for glaucoma progression, and intraocular pressure reduction remains the only therapeutic strategy for all types of glaucoma. The main purpose of our study was to compare the baseline and peak intraocular pressure reduction obtained with the water drinking test between the two eyes of the same patients using 0.005% latanoprost in one eye and selective laser trabeculoplasty application in the contralateral eye. METHODS This was a prospective, interventional, longitudinal, and randomized clinical trial, in which 30 consecutive glaucomatous patients, medically controlled using latanoprost monotherapy, were recruited from a single ophthalmological center. The patients' eyes were randomized, and one eye was selected for SLT treatment and topical 0.005% latanoprost was introduced in the contralateral eye. The baseline intraocular pressure and peak intraocular pressure were evaluated 1 month (water drinking test 2) and 6 months (water drinking test 3) after treatment. RESULTS There was no significant difference between the mean pre-washout intraocular pressure in the randomized eyes for selective laser trabeculoplasty and latanoprost (13.6 ± 2.1 and 13.3 ± 1.8 mmHg, respectively; p=0.182). Regarding baseline intraocular pressure, there was no significant difference in the water drinking test 2 (p=0.689) and water drinking test 3 (p=0.06) between the groups. There was no significant difference in the intraocular pressure peak between the SLT and latanoprost groups at water drinking test 2 (p=0.771) or water drinking test 3 (p=0.774). CONCLUSIONS The intraocular pressure reduction efficacy is similar between latanoprost and selective laser trabeculoplasty. Glaucomatous patients who are medically controlled with latanoprost and switch treatment to selective laser trabeculoplasty maintain control of intraocular pressure.",2021,"There was no significant difference in the intraocular pressure peak between the SLT and latanoprost groups at water drinking test 2 (p=0.771) or water drinking test 3 (p=0.774). ","['30 consecutive glaucomatous patients, medically controlled using latanoprost monotherapy, were recruited from a single ophthalmological center', 'Glaucomatous patients who are medically controlled with latanoprost and switch treatment to selective laser trabeculoplasty maintain control of intraocular pressure']","['SLT and latanoprost', 'selective laser trabeculoplasty application', 'selective laser trabeculoplasty and latanoprost', 'SLT treatment and topical 0.005% latanoprost', 'selective laser trabeculoplasty', 'latanoprost and selective laser trabeculoplasty', 'latanoprost']","['intraocular pressure peak', 'baseline and peak intraocular pressure reduction', 'Peak intraocular pressure', 'intraocular pressure reduction efficacy', 'baseline intraocular pressure and peak intraocular pressure', 'mean pre-washout intraocular pressure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0090306', 'cui_str': 'latanoprost'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C2013096', 'cui_str': 'OPHTHALMOLOGICALS'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1271447', 'cui_str': 'Selective laser trabeculoplasty'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}]","[{'cui': 'C0090306', 'cui_str': 'latanoprost'}, {'cui': 'C1271447', 'cui_str': 'Selective laser trabeculoplasty'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C4517389', 'cui_str': '0.005'}]","[{'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]",30.0,0.0319919,"There was no significant difference in the intraocular pressure peak between the SLT and latanoprost groups at water drinking test 2 (p=0.771) or water drinking test 3 (p=0.774). ","[{'ForeName': 'Renato Antunes Schiave', 'Initials': 'RAS', 'LastName': 'Germano', 'Affiliation': 'Ophthalmology Department, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Hatanaka', 'Affiliation': 'Ophthalmology Department, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Arthur Sônego', 'Initials': 'AS', 'LastName': 'Garcia', 'Affiliation': 'Centro de Excelência em Oftalmologia, Bauru, SP, Brazil.'}, {'ForeName': 'Flavio Augusto Schiave', 'Initials': 'FAS', 'LastName': 'Germano', 'Affiliation': 'Centro de Excelência em Oftalmologia, Bauru, SP, Brazil.'}, {'ForeName': 'Caroline Schiave', 'Initials': 'CS', 'LastName': 'Germano', 'Affiliation': 'Ophthalmology Department, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Felipe Biscegli', 'Initials': 'FB', 'LastName': 'Cid', 'Affiliation': 'Centro de Excelência em Oftalmologia, Bauru, SP, Brazil.'}, {'ForeName': 'Jorge Estéfano', 'Initials': 'JE', 'LastName': 'Germano', 'Affiliation': 'Centro de Excelência em Oftalmologia, Bauru, SP, Brazil.'}]",Arquivos brasileiros de oftalmologia,['10.5935/0004-2749.20210052'] 982,33570841,Embedding Learning in a Learning Health Care System to Improve Clinical Practice.,"PROBLEM In an ideal learning health care system (LHS), clinicians learn from what they do and do what they learn, closing the evidence-to-practice gap. In operationalizing an LHS, great strides have been made in knowledge generation. Yet, considerable challenges remain to the broad uptake of identified best practices. To bridge the gap from generating actionable knowledge to applying that knowledge in clinical practice, and ultimately to improving outcomes, new information must be disseminated to and implemented by frontline clinicians. To date, the dissemination of this knowledge through traditional avenues has not achieved meaningful practice change quickly. APPROACH Vanderbilt University Medical Center (VUMC) developed QuizTime, a smartphone application learning platform, to provide a mechanism for embedding workplace-based clinician learning in the LHS. QuizTime leverages spaced education and retrieval-based practice to facilitate practice change. Beginning in January 2020, clinician-researchers and educators at VUMC designed a randomized, controlled trial to test whether the QuizTime learning system influenced clinician behavior in the context of recent evidence supporting the use of balanced crystalloids rather than saline for intravenous fluid management and new regulations around opioid prescribing. OUTCOMES Whether spaced education and retrieval-based practice influence clinician behavior and patient outcomes at the VUMC system level will be tested using the data currently being collected. NEXT STEPS These findings will inform future directions for developing and deploying learning approaches at scale in an LHS, with the goal of closing the evidence-to-practice gap.",2021,"These findings will inform future directions for developing and deploying learning approaches at scale in an LHS, with the goal of closing the evidence-to-practice gap.",[],['QuizTime learning system'],[],[],"[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",[],,0.0320398,"These findings will inform future directions for developing and deploying learning approaches at scale in an LHS, with the goal of closing the evidence-to-practice gap.","[{'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'McEvoy', 'Affiliation': ""M.D. McEvoy is professor of anesthesiology and surgery, vice chair for educational affairs, program director of the perioperative medicine fellowship, and director of the Center for Innovation in Perioperative Health, Education, and Research, Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee. M.L. Dear is project manager, Learning Healthcare System Platform, Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee. R. Buie is health policy service analyst, Learning Healthcare System Platform, Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee. L.C. Fowler is director of the Educational Development and Research Office of Educational Affairs, Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee. B. Miller is professor of medical education and administration and vice president for educational affairs, Vanderbilt University Medical Center, Nashville, Tennessee. G.M. Fleming was professor of pediatrics and associate director of the pediatric critical care fellowship, Monroe Carell Jr. Children's Hospital, and vice president, Continuous Professional Development, Office of Health Sciences Education, Vanderbilt University Medical Center, Nashville, Tennessee. D. Moore is professor of medical education and administration and director of the Office for Continuing Professional Development, Vanderbilt University School of Medicine, Nashville, Tennessee. T.W. Rice is associate professor of medicine, Department of Allergy, Pulmonary and Critical Care Medicine, and medical director, Vanderbilt Human Research Protection Program, Vanderbilt University Medical Center, Nashville, Tennessee. G.R. Bernard is the Melinda Owen Bass Professor of Medicine, executive vice president for research, senior associate dean for clinical sciences, and director of the Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee. C.J. Lindsell is professor of biostatistics, associate director of the Center for Clinical Quality and Implementation Research, director of the Vanderbilt Institute for Clinical and Translational Research Methods Program, and director of the Center for Health Data Science, Vanderbilt University Medical Center, Nashville, Tennessee.""}, {'ForeName': 'Mary Lynn', 'Initials': 'ML', 'LastName': 'Dear', 'Affiliation': ''}, {'ForeName': 'Reagan', 'Initials': 'R', 'LastName': 'Buie', 'Affiliation': ''}, {'ForeName': 'Leslie C', 'Initials': 'LC', 'LastName': 'Fowler', 'Affiliation': ''}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'Geoffrey M', 'Initials': 'GM', 'LastName': 'Fleming', 'Affiliation': ''}, {'ForeName': 'Don', 'Initials': 'D', 'LastName': 'Moore', 'Affiliation': ''}, {'ForeName': 'Todd W', 'Initials': 'TW', 'LastName': 'Rice', 'Affiliation': ''}, {'ForeName': 'Gordon R', 'Initials': 'GR', 'LastName': 'Bernard', 'Affiliation': ''}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Lindsell', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Academic medicine : journal of the Association of American Medical Colleges,['10.1097/ACM.0000000000003969'] 983,33596356,Avacopan for the Treatment of ANCA-Associated Vasculitis.,"BACKGROUND The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. METHODS In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on a tapering schedule. All the patients received either cyclophosphamide (followed by azathioprine) or rituximab. The first primary end point was remission, defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 (on a scale from 0 to 63, with higher scores indicating greater disease activity) at week 26 and no glucocorticoid use in the previous 4 weeks. The second primary end point was sustained remission, defined as remission at both weeks 26 and 52. Both end points were tested for noninferiority (by a margin of 20 percentage points) and for superiority. RESULTS A total of 331 patients underwent randomization; 166 were assigned to receive avacopan, and 165 were assigned to receive prednisone. The mean BVAS at baseline was 16 in both groups. Remission at week 26 (the first primary end point) was observed in 120 of 166 patients (72.3%) receiving avacopan and in 115 of 164 patients (70.1%) receiving prednisone (estimated common difference, 3.4 percentage points; 95% confidence interval [CI], -6.0 to 12.8; P<0.001 for noninferiority; P = 0.24 for superiority). Sustained remission at week 52 (the second primary end point) was observed in 109 of 166 patients (65.7%) receiving avacopan and in 90 of 164 patients (54.9%) receiving prednisone (estimated common difference, 12.5 percentage points; 95% CI, 2.6 to 22.3; P<0.001 for noninferiority; P = 0.007 for superiority). Serious adverse events (excluding worsening vasculitis) occurred in 37.3% of the patients receiving avacopan and in 39.0% of those receiving prednisone. CONCLUSIONS In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone taper with respect to remission at week 26 and was superior to prednisone taper with respect to sustained remission at week 52. All the patients received cyclophosphamide or rituximab. The safety and clinical effects of avacopan beyond 52 weeks were not addressed in the trial. (Funded by ChemoCentryx; ADVOCATE ClinicalTrials.gov number, NCT02994927.).",2021,"Serious adverse events (excluding worsening vasculitis) occurred in 37.3% of the patients receiving avacopan and in 39.0% of those receiving prednisone. ","['331 patients underwent randomization; 166 were assigned to receive', 'patients with ANCA-associated vasculitis in a 1:1 ratio to receive']","['prednisone', 'cyclophosphamide (followed by azathioprine) or rituximab', 'oral avacopan at a dose of 30 mg twice daily or oral prednisone', 'cyclophosphamide or rituximab', 'avacopan', 'Avacopan']","['Sustained remission', 'mean BVAS', 'sustained remission', 'disease activity', 'remission, defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 (on a scale', 'Serious adverse events', 'Remission']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C5191361', 'cui_str': '166'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0103647', 'cui_str': 'Anti neutrophilic cytoplasm antibody'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0042384', 'cui_str': 'Vasculitis'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4507514', 'cui_str': 'avacopan'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042384', 'cui_str': 'Vasculitis'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",331.0,0.176126,"Serious adverse events (excluding worsening vasculitis) occurred in 37.3% of the patients receiving avacopan and in 39.0% of those receiving prednisone. ","[{'ForeName': 'David R W', 'Initials': 'DRW', 'LastName': 'Jayne', 'Affiliation': ""From Addenbrooke's Hospital, Cambridge, United Kingdom (D.R.W.J.); the University of Pennsylvania, Philadelphia (P.A.M.); and ChemoCentryx, Mountain View, CA (T.J.S., P.B.).""}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Merkel', 'Affiliation': ""From Addenbrooke's Hospital, Cambridge, United Kingdom (D.R.W.J.); the University of Pennsylvania, Philadelphia (P.A.M.); and ChemoCentryx, Mountain View, CA (T.J.S., P.B.).""}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Schall', 'Affiliation': ""From Addenbrooke's Hospital, Cambridge, United Kingdom (D.R.W.J.); the University of Pennsylvania, Philadelphia (P.A.M.); and ChemoCentryx, Mountain View, CA (T.J.S., P.B.).""}, {'ForeName': 'Pirow', 'Initials': 'P', 'LastName': 'Bekker', 'Affiliation': ""From Addenbrooke's Hospital, Cambridge, United Kingdom (D.R.W.J.); the University of Pennsylvania, Philadelphia (P.A.M.); and ChemoCentryx, Mountain View, CA (T.J.S., P.B.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2023386'] 984,33592077,Lack of association between heart period variability asymmetry and respiratory sinus arrhythmia in healthy and chronic heart failure individuals.,"Temporal asymmetry is a peculiar aspect of heart period (HP) variability (HPV). HPV asymmetry (HPVA) is reduced with aging and pathology, but its origin is not fully elucidated. Given the impact of respiration on HPV resulting in the respiratory sinus arrhythmia (RSA) and the asymmetric shape of the respiratory pattern, a possible link between HPVA and RSA might be expected. In this study we tested the hypothesis that HPVA is significantly associated with RSA and asymmetry of the respiratory rhythm. We studied 42 middle-aged healthy (H) subjects, and 56 chronic heart failure (CHF) patients of whom 26 assigned to the New York Heart Association (NYHA) class II (CHF-II) and 30 to NYHA class III (CHF-III). Electrocardiogram and lung volume were monitored for 8 minutes during spontaneous breathing (SB) and controlled breathing (CB) at 15 breaths/minute. The ratio of inspiratory (INSP) to expiratory (EXP) phases, namely the I/E ratio, and RSA were calculated. HPVA was estimated as the percentage of negative HP variations, traditionally measured via the Porta's index (PI). Departures of PI from 50% indicated HPVA and its significance was tested via surrogate data. We found that RSA increased during CB and I/E ratio was smaller than 1 in all groups and experimental conditions. In H subjects the PI was about 50% during SB and it increased significantly during CB. In both CHF-II and CHF-III groups the PI was about 50% during SB and remained unmodified during CB. The PI was uncorrelated with RSA and I/E ratio regardless of the experimental condition and group. Pooling together data of different experimental conditions did not affect conclusions. Therefore, we conclude that the HPVA cannot be explained by RSA and/or I/E ratio, thus representing a peculiar feature of the cardiac control that can be aroused in middle-aged H individuals via CB.",2021,In both CHF-II and CHF-III groups the PI was about 50% during SB and remained unmodified during CB.,"['42 middle-aged healthy (H) subjects, and 56 chronic heart failure (CHF) patients of whom 26 assigned to the New York Heart Association (NYHA) class II (CHF-II) and 30 to NYHA class III (CHF-III', 'healthy and chronic heart failure individuals']","['spontaneous breathing (SB) and controlled breathing (CB', 'HPV asymmetry (HPVA']","['ratio of inspiratory (INSP) to expiratory (EXP) phases, namely the I/E ratio, and RSA', 'Electrocardiogram and lung volume', 'HPVA', 'RSA increased during CB and I/E ratio']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441886', 'cui_str': 'Class 2'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0003813', 'cui_str': 'Sinus arrhythmia'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0231953', 'cui_str': 'Lung volume'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",42.0,0.0179518,In both CHF-II and CHF-III groups the PI was about 50% during SB and remained unmodified during CB.,"[{'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'De Maria', 'Affiliation': 'IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy.'}, {'ForeName': 'Laura Adelaide', 'Initials': 'LA', 'LastName': 'Dalla Vecchia', 'Affiliation': 'IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Maestri', 'Affiliation': 'IRCCS Istituti Clinici Scientifici Maugeri, Montescano, Pavia, Italy.'}, {'ForeName': 'Gian Domenico', 'Initials': 'GD', 'LastName': 'Pinna', 'Affiliation': 'IRCCS Istituti Clinici Scientifici Maugeri, Montescano, Pavia, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Parati', 'Affiliation': 'IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Perego', 'Affiliation': 'IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy.'}, {'ForeName': 'Vlasta', 'Initials': 'V', 'LastName': 'Bari', 'Affiliation': 'Department of Cardiothoracic, Vascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Cairo', 'Affiliation': 'Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Gelpi', 'Affiliation': 'Department of Cardiothoracic, Vascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.'}, {'ForeName': 'Maria Teresa', 'Initials': 'MT', 'LastName': 'La Rovere', 'Affiliation': 'IRCCS Istituti Clinici Scientifici Maugeri, Montescano, Pavia, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Porta', 'Affiliation': 'Department of Cardiothoracic, Vascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.'}]",PloS one,['10.1371/journal.pone.0247145'] 985,33555374,Metabolic and satiating effects and consumer acceptance of a fibre-enriched Leberkas meal: a randomized cross-over trial.,"PURPOSE The Western diet is poor in dietary fibre and previous efforts to increase fibre intake were not successful. The aim of this study was to develop sensorically appealing, fibre-enriched convenience foods. As a showcase, we prepared a fibre-enriched, fat-reduced Leberkas served in a roll and compared the reformulated product with the standard product. METHODS The design was a randomized, single-blinded cross-over study. A Leberkas meal enriched with 19.2 g of wheat fibre and resistant dextrin as well as fat- and energy-reduced (30% less calories) was served to 20 middle-aged healthy volunteers (10 male, 10 female) and compared to the standard product in a random order. Blood was repeatedly taken over a 4 h period to measure metabolic parameters as well as satiety hormones, such as glucagon-like-peptide 1, cholecystokinin, peptide YY. Satiety and consumer acceptance of the fibre-enriched meal were assessed by visual analogue scales and a questionnaire. RESULTS The fibre-enriched meal showed very small significant effects at only single time points in postprandial blood glucose (at 120 min, p = 0.050) and glucose AUC fibre 22,079 ± 2819, standard 22,912 ± 3583 (p = 0.030). The profiles of satiety hormones were comparable between both meals. No differences in subjective satiation, taste and consumer acceptance were observed between the two products, despite a marked reduction in fat and energy content of the reformulated product. CONCLUSION It is possible to enrich a popular convenience product with dietary fibre and to markedly reduce energy content without loss of sensory qualities or satiety suggesting that development and promotion of healthier convenience foods may be a useful strategy to tackle obesity and other diet-related diseases.",2021,"The fibre-enriched meal showed very small significant effects at only single time points in postprandial blood glucose (at 120 min, p = 0.050) and glucose AUC fibre 22,079 ± 2819, standard 22,912 ± 3583 (p = 0.030).","['20 middle-aged healthy volunteers (10 male, 10 female']",['fibre-enriched Leberkas meal'],"['postprandial blood glucose', 'subjective satiation, taste and consumer acceptance', 'satiety hormones', 'fat and energy content', 'Satiety and consumer acceptance']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0039336', 'cui_str': 'Finding of sense of taste'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}]",,0.0443376,"The fibre-enriched meal showed very small significant effects at only single time points in postprandial blood glucose (at 120 min, p = 0.050) and glucose AUC fibre 22,079 ± 2819, standard 22,912 ± 3583 (p = 0.030).","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Rennekamp', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Chair of Nutritional Medicine, School of Life Sciences, Technical University of Munich, Freising, Germany.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Brandl', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Chair of Nutritional Medicine, School of Life Sciences, Technical University of Munich, Freising, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Giesbertz', 'Affiliation': 'Department of Nutritional Physiology, Technical University of Munich, Freising, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Skurk', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Chair of Nutritional Medicine, School of Life Sciences, Technical University of Munich, Freising, Germany.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Hauner', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Chair of Nutritional Medicine, School of Life Sciences, Technical University of Munich, Freising, Germany. hans.hauner@tum.de.'}]",European journal of nutrition,['10.1007/s00394-020-02472-1'] 986,33559354,Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.,"INTRODUCTION Amyloid beta (Aβ) oligomers are one of the most toxic structural forms of the Aβ protein and are hypothesized to cause synaptotoxicity and memory failure as they build up in Alzheimer's disease (AD) patients' brain tissue. We previously demonstrated that antagonists of the sigma-2 receptor complex effectively block Aβ oligomer toxicity. CT1812 is an orally bioavailable, brain penetrant small molecule antagonist of the sigma-2 receptor complex that appears safe and well tolerated in healthy elderly volunteers. We tested CT1812's effect on Aβ oligomer pathobiology in preclinical AD models and evaluated CT1812's impact on cerebrospinal fluid (CSF) protein biomarkers in mild to moderate AD patients in a clinical trial (ClinicalTrials.gov NCT02907567). METHODS Experiments were performed to measure the impact of CT1812 versus vehicle on Aβ oligomer binding to synapses in vitro, to human AD patient post mortem brain tissue ex vivo, and in living APP Swe /PS1dE9 transgenic mice in vivo. Additional experiments were performed to measure the impact of CT1812 versus vehicle on Aβ oligomer-induced deficits in membrane trafficking rate, synapse number, and protein expression in mature hippocampal/cortical neurons in vitro. The impact of CT1812 on cognitive function was measured in transgenic Thy1 huAPP Swe/Lnd+ and wild-type littermates. A multicenter, double-blind, placebo-controlled parallel group trial was performed to evaluate the safety, tolerability, and impact on protein biomarker expression of CT1812 or placebo given once daily for 28 days to AD patients (Mini-Mental State Examination 18-26). CSF protein expression was measured by liquid chromatography with tandem mass spectrometry or enzyme-linked immunosorbent assay in samples drawn prior to dosing (Day 0) and at end of dosing (Day 28) and compared within each patient and between pooled treated versus placebo-treated dosing groups. RESULTS CT1812 significantly and dose-dependently displaced Aβ oligomers bound to synaptic receptors in three independent preclinical models of AD, facilitated oligomer clearance into the CSF, increased synaptic number and protein expression in neurons, and improved cognitive performance in transgenic mice. CT1812 significantly increased CSF concentrations of Aβ oligomers in AD patient CSF, reduced concentrations of synaptic proteins and phosphorylated tau fragments, and reversed expression of many AD-related proteins dysregulated in CSF. DISCUSSION These preclinical studies demonstrate the novel disease-modifying mechanism of action of CT1812 against AD and Aβ oligomers. The clinical results are consistent with preclinical data and provide evidence of target engagement and impact on fundamental disease-related signaling pathways in AD patients, supporting further development of CT1812.",2021,"CT1812 significantly increased CSF concentrations of Aβ oligomers in AD patient CSF, reduced concentrations of synaptic proteins and phosphorylated tau fragments, and reversed expression of many AD-related proteins dysregulated in CSF. ","['healthy elderly volunteers', 'mild to moderate AD patients', '28 days to AD patients (Mini-Mental State Examination 18-26']","['CT1812', 'CT1812 or placebo', 'placebo']","['CSF concentrations', 'CSF protein expression', 'cognitive performance', 'safety, tolerability', 'cognitive function', 'concentrations of synaptic proteins and phosphorylated tau fragments, and reversed expression of many AD-related proteins dysregulated in CSF']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0007810', 'cui_str': 'Proteins, Cerebrospinal Fluid'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0332255', 'cui_str': 'Fragment of'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",,0.0874143,"CT1812 significantly increased CSF concentrations of Aβ oligomers in AD patient CSF, reduced concentrations of synaptic proteins and phosphorylated tau fragments, and reversed expression of many AD-related proteins dysregulated in CSF. ","[{'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Izzo', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Carla M', 'Initials': 'CM', 'LastName': 'Yuede', 'Affiliation': 'Washington University, St. Louis, Missouri, USA.'}, {'ForeName': 'Kelsie M', 'Initials': 'KM', 'LastName': 'LaBarbera', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Colleen S', 'Initials': 'CS', 'LastName': 'Limegrover', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Rehak', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Yurko', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Lora', 'Initials': 'L', 'LastName': 'Waybright', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Look', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Gilbert', 'Initials': 'G', 'LastName': 'Rishton', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Hank', 'Initials': 'H', 'LastName': 'Safferstein', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Hamby', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Williams', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Sadlek', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Hannah M', 'Initials': 'HM', 'LastName': 'Edwards', 'Affiliation': 'Washington University, St. Louis, Missouri, USA.'}, {'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Davis', 'Affiliation': 'CSD Biostatistics Inc., Oro Valley, Arizona, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Grundman', 'Affiliation': 'Global R&D Partners, San Diego, California, USA.'}, {'ForeName': 'Lon S', 'Initials': 'LS', 'LastName': 'Schneider', 'Affiliation': 'Keck School of Medicine of USC, Los Angeles, California, USA.'}, {'ForeName': 'Steven T', 'Initials': 'ST', 'LastName': 'DeKosky', 'Affiliation': 'McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Chelsky', 'Affiliation': 'Caprion Biosciences, Montreal, Quebec, Canada.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Pike', 'Affiliation': 'Proteome Sciences, London, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Henstridge', 'Affiliation': 'University of Dundee School of Medicine, Dundee, UK.'}, {'ForeName': 'Kaj', 'Initials': 'K', 'LastName': 'Blennow', 'Affiliation': 'University of Gothenburg, Mölndal, Sweden.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Zetterberg', 'Affiliation': 'University of Gothenburg, Mölndal, Sweden.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'LeVine', 'Affiliation': 'Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.'}, {'ForeName': 'Tara L', 'Initials': 'TL', 'LastName': 'Spires-Jones', 'Affiliation': 'The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Cirrito', 'Affiliation': 'Washington University, St. Louis, Missouri, USA.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Catalano', 'Affiliation': 'Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, USA.'}]",Alzheimer's & dementia : the journal of the Alzheimer's Association,['10.1002/alz.12302'] 987,33556518,The Effect of Patient Oral Intake Status on Abdominal Aortic Ultrasound Visualization.,"BACKGROUND The standard abdominal aortic duplex ultrasound protocol requires fasting for 8-12 hours prior to examination in attempt to reduce bowel gas and improve visualization. Such practice results in frequent testing delays and patient non-compliance. The aim of this study was to determine whether fasting improves visualization of the abdominal aorta in patients undergoing duplex ultrasound or influences diagnostic properties. METHODS This was a prospective, randomized, double-blind imaging trail at a single institution. Ninety patients were randomized to one of three dietary groups, including NPO, clear liquids or control (regular diet). Diagnostic ultrasound examinations were performed by accredited Registered Vascular Technologists who remained blinded to the patients' diet. Sonographers commented on the presence of limited visualization in the study based on their ability to accurately measure aortic diameter. Examination results were randomly assigned to interpreting physicians who were also blinded to the patients' diet. Following interpretation, the reading physician was asked to comment whether they had sufficient information for a conclusive diagnostic interpretation. RESULTS All ultrasound studies were deemed diagnostic by the interpreting physician regardless of the patients' dietary status. Limited visualization was reported in 19 of the 90 study patients (21.1%) with no significant difference existing between the dietary groups (P = 0.344). The NPO group contained the most patients with studies deemed to have limited visualization. CONCLUSION Oral intake status did not affect visualization of the abdominal aorta or the rate of diagnostic studies in patients undergoing DUS at a single center. These results suggest that dietary restrictions prior to DUS evaluation of the abdominal aorta is unnecessary.",2021,"CONCLUSION Oral intake status did not affect visualization of the abdominal aorta or the rate of diagnostic studies in patients undergoing DUS at a single center.","['patients undergoing DUS at a single center', 'patients undergoing duplex ultrasound or influences diagnostic properties', 'Ninety patients']","['NPO, clear liquids or control (regular diet']",['Abdominal Aortic Ultrasound Visualization'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013261', 'cui_str': ""Duane's syndrome""}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0242845', 'cui_str': 'Duplex ultrasound'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C3816959', 'cui_str': '90'}]","[{'cui': 'C0029247', 'cui_str': 'Non-profit organization'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184625', 'cui_str': 'Normal diet'}]","[{'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]",90.0,0.0681346,"CONCLUSION Oral intake status did not affect visualization of the abdominal aorta or the rate of diagnostic studies in patients undergoing DUS at a single center.","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Goldschmidt', 'Affiliation': 'Univerity of Toledo, General Surgery Department, Toledo, OH; Promedica, Jobst Vascular Institute, Department of Vascular Surgery, Ann Arbor, MI.'}, {'ForeName': 'Somya', 'Initials': 'S', 'LastName': 'Al-Embideen', 'Affiliation': 'Univerity of Toledo, General Surgery Department, Toledo, OH.'}, {'ForeName': 'Jihad', 'Initials': 'J', 'LastName': 'Abbas', 'Affiliation': 'Promedica, Jobst Vascular Institute, Department of Vascular Surgery, Ann Arbor, MI.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Russell', 'Affiliation': 'Promedica, Jobst Vascular Institute, Department of Vascular Surgery, Ann Arbor, MI.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Paolini', 'Affiliation': 'Promedica, Jobst Vascular Institute, Department of Vascular Surgery, Ann Arbor, MI.'}, {'ForeName': 'Laith', 'Initials': 'L', 'LastName': 'Al-Balbissi', 'Affiliation': 'Promedica, Jobst Vascular Institute, Department of Vascular Surgery, Ann Arbor, MI.'}, {'ForeName': 'Fedor', 'Initials': 'F', 'LastName': 'Lurie', 'Affiliation': 'Promedica, Jobst Vascular Institute, Department of Vascular Surgery, Ann Arbor, MI; University of Michigan, Section of Vascular Surgery, Toledo, OH. Electronic address: Fedor.lurie@promedica.org.'}]",Annals of vascular surgery,['10.1016/j.avsg.2020.12.035'] 988,33567423,Calcium Carbonate Attenuates Withdrawal and Reduces Craving: A Randomized Controlled Trial in Alcohol-Dependent Patients.,"INTRODUCTION Preclinical studies have shown that calcium seems to be the active component of the anti-craving drug acamprosate (Ca2+ bis-acetyl-homotaurinate). Clinical effects in humans have also indicated an association between increased calcium plasma concentration due to acamprosate treatment and better outcome relating to time to relapse and cumulative abstinence. In contrast, low calcium concentration in alcohol-dependent patients was related with craving for alcohol. The main goal of the trial was to investigate whether an oral calcium administration is able to affect craving, withdrawal, and relapse risk in alcohol-dependent patients. METHODS We conducted a single-blind, randomized, monocentric, controlled clinical two-arm trial in alcohol-dependent patients (Clinical Trials Registration: DRKS00011293). A total of 55 alcohol-dependent subjects received calcium carbonate (800 mg + 5 μg vitamin D) versus sodium bicarbonate (1,000 mg) daily during the 14 days of inpatient alcohol-withdrawal treatment. RESULTS Based on an intention-to-treat protocol, withdrawal intensity (assessed with CIWA-Ar) in the calcium carbonate group attenuated faster than in the sodium bicarbonate subgroup. Alcohol craving (assessed with OCDS) in the calcium carbonate subgroup was also significantly reduced versus the sodium bicarbonate subgroup. CONCLUSION Our data support earlier findings and show that treatment with calcium carbonate during alcohol withdrawal reduces symptoms of alcohol withdrawal as well as alcohol craving in a controlled clinical pilot study. Mode of actions will need to be determined to allow the further development of pharmacological interventions beyond Ca2+ bis-acetyl-homotaurinate.",2021,"Alcohol craving (assessed with OCDS) in the calcium carbonate subgroup was also significantly reduced versus the sodium bicarbonate subgroup. ","['A total of 55 alcohol-dependent subjects received', 'Alcohol-Dependent Patients', 'alcohol-dependent patients']","['Calcium Carbonate', 'calcium carbonate (800 mg + 5 μg vitamin D) versus sodium bicarbonate', 'oral calcium', 'calcium carbonate']","['Craving', 'Alcohol craving', 'craving, withdrawal, and relapse risk']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0581116', 'cui_str': 'Dependent patient'}]","[{'cui': 'C0006681', 'cui_str': 'Calcium Carbonate'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0556385', 'cui_str': 'Craving for alcohol'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",55.0,0.0620374,"Alcohol craving (assessed with OCDS) in the calcium carbonate subgroup was also significantly reduced versus the sodium bicarbonate subgroup. ","[{'ForeName': 'Rilana', 'Initials': 'R', 'LastName': 'Schuster', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany, rilana.schuster@med.uni-heidelberg.de.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Winkler', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Koopmann', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Bach', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Hoffmann', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Reinhard', 'Affiliation': 'Biostatistik, Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim/Universität Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Spanagel', 'Affiliation': 'Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'J Malte', 'Initials': 'JM', 'LastName': 'Bumb', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Wolfgang H', 'Initials': 'WH', 'LastName': 'Sommer', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Falk', 'Initials': 'F', 'LastName': 'Kiefer', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}]",European addiction research,['10.1159/000512763'] 989,33570654,The use of luspatercept for thalassemia in adults.,"Luspatercept is an activin receptor ligand trap that has been shown to enhance late-stage erythropoiesis in animal models of β-thalassemia. A multicenter, international, phase 2 dose-finding study was initiated in adult patients with β-thalassemia, either non-transfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Positive results of the phase 2 study paved the way to a randomized phase 3 clinical trial (BELIEVE) to assess the efficacy and safety of luspatercept. The BELIEVE trial is a randomized, double-blind, placebo-controlled phase 3 trial. Three hundred thirty-six patients aged ≥18 years with TDT (regularly transfused, 6-20 red blood cell units within 24 weeks before randomization) were included in the trial. Patients received luspatercept or placebo subcutaneously every 21 days for ≥48 weeks and best supportive care. Forty-eight of 224 patients (21.4%) in the luspatercept group achieved the primary end points (≥33% reduction in transfusion burden) compared with those in the placebo group (4.5%; P < .001). Moreover, more patients had a ≥33% reduction in transfusion burden during any rolling 12-week interval (70.5% vs 29.5%) or any 24-week interval (41.1% vs 2.7%) with luspatercept than with the placebo. Transfusion independence was achieved by 11% of patients in the luspatercept group. Transient adverse events were more frequent with luspatercept than with placebo, but were manageable. Luspatercept was approved by the US Food and Drug Administration in 2019 and by the European Medicines Agency in 2020. The luspatercept trial is registered on www.clinicaltrials.gov at #NCT01749540 and the BELIEVE trial at #NCT02604433.",2021,Forty-eight of 224 patients (21.4%) in the luspatercept group achieved the primary end points (≥33% reduction in transfusion burden) compared with those in the placebo group (4.5%; P < .001).,"['adults', 'adult patients with β-thalassemia, either non-transfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT', 'Three hundred thirty-six patients aged ≥18 years with TDT (regularly transfused, 6-20 red blood cell units within 24 weeks before randomization) were included in the trial']","['luspatercept or placebo', 'placebo']","['Transfusion independence', 'efficacy and safety of luspatercept', 'transfusion burden', 'Transient adverse events']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039730', 'cui_str': 'Thalassemia'}, {'cui': 'C3805143', 'cui_str': 'Non-transfusion dependent thalassaemia'}, {'cui': 'C4760934', 'cui_str': 'Transfusion dependent thalassaemia'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C4086553', 'cui_str': 'luspatercept'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4086553', 'cui_str': 'luspatercept'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",336.0,0.549574,Forty-eight of 224 patients (21.4%) in the luspatercept group achieved the primary end points (≥33% reduction in transfusion burden) compared with those in the placebo group (4.5%; P < .001).,"[{'ForeName': 'Maria Domenica', 'Initials': 'MD', 'LastName': 'Cappellini', 'Affiliation': ""Department of Clinical Sciences and Community, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Policlinico Hospital, University of Milan, Milan, Italy; and.""}, {'ForeName': 'Ali T', 'Initials': 'AT', 'LastName': 'Taher', 'Affiliation': 'Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.'}]",Blood advances,['10.1182/bloodadvances.2020002725'] 990,33571302,The effect of a Housing First intervention on primary care retention among homeless individuals with mental illness.,"BACKGROUND Primary care retention, defined as ongoing periodic contact with a consistent primary care provider, is beneficial for people with serious chronic illnesses. This study examined the effect of a Housing First intervention on primary care retention among homeless individuals with mental illness. METHODS Two hundred individuals enrolled in the Toronto site of the At Home Project and randomized to Housing First or Treatment As Usual were studied. Medical records were reviewed to determine if participants were retained in primary care, defined as having at least one visit with the same primary care provider in each of two consecutive six-month periods during the 12 month period preceding and following randomization. RESULTS Medical records were obtained for 47 individuals randomized to Housing First and 40 individuals randomized to Treatment As Usual. During the one year period following randomization, the proportion of Housing First and Treatment As Usual participants retained in primary care was not significantly different (38.3% vs. 47.5%, p = 0.39). The change in primary care retention rates from the year preceding randomization to the year following randomization was +10.6% in the Housing First group and -5.0% in the Treatment As Usual group. CONCLUSION Among homeless individuals with mental illness, Housing First did not significantly affect primary care retention over the follow-up period. These findings suggest Housing First interventions may need to place greater emphasis on connecting clients with primary care providers.",2021,"As Usual participants retained in primary care was not significantly different (38.3% vs. 47.5%, p = 0.39).","['people with serious chronic illnesses', 'Two hundred individuals enrolled in the Toronto site of the At Home Project and randomized to Housing First or Treatment', 'Medical records were reviewed to determine if participants were retained in primary care, defined as having at least one visit with the same primary care provider in each of two consecutive six-month periods during the 12 month period preceding and following randomization', 'homeless individuals with mental illness']",['Housing First intervention'],"['proportion of Housing First and Treatment', 'primary care retention']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C2945843', 'cui_str': 'Site of'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0425242', 'cui_str': 'Homeless single person'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}]","[{'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}]",200.0,0.0484532,"As Usual participants retained in primary care was not significantly different (38.3% vs. 47.5%, p = 0.39).","[{'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Whisler', 'Affiliation': ""MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Naheed', 'Initials': 'N', 'LastName': 'Dosani', 'Affiliation': 'Inner City Health Associates, Toronto, Ontario, Canada.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'To', 'Affiliation': ""MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': ""O'Brien"", 'Affiliation': ""MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Young', 'Affiliation': ""MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Stephen W', 'Initials': 'SW', 'LastName': 'Hwang', 'Affiliation': ""MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}]",PloS one,['10.1371/journal.pone.0246859'] 991,33574076,Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study.,"BACKGROUND Several studies have shown that statins have beneficial effects in COPD regarding lung function decline, rates and severity of exacerbation, hospitalisation and need for mechanical ventilation. METHODS We performed a randomised double-blind placebo-controlled single-centre trial of simvastatin at a daily dose of 40 mg versus placebo in patients with Global Initiative for Chronic Obstructive Lung Disease criteria grades 2-4 at a tertiary care pulmonology department in Austria. Scheduled treatment duration was 12 months and the main outcome parameter was time to first exacerbation. RESULTS Overall, 209 patients were enrolled. In the 105 patients taking simvastatin, time to first exacerbation was significantly longer compared to the 104 patients taking placebo: median 341 versus 140 days (log-rank test p<0.001). Hazard ratio for risk of first exacerbation for the simvastatin group was 0.51 (95% CI 0.34-0.75; p=0.001). Rate of exacerbations was significantly lower with simvastatin: 103 (41%) versus 147 (59%) (p=0.003). The annualised exacerbation rate was 1.45 events per patient-year in the simvastatin group and 1.9 events per patient-year in the placebo group (incidence rate ratio 0.77, 95% CI 0.60-0.99). We found no effect on quality of life, lung function, 6-min walk test and high-sensitivity C-reactive protein. More patients dropped out in the simvastatin group compared to the placebo group (39 versus 29). CONCLUSION In our single-centre RCT, simvastatin at a dose of 40 mg daily significantly prolonged time to first COPD exacerbation and reduced exacerbation rate.",2021,Rate of exacerbations was significantly lower with simvastatin: 103 (41%) versus ,"['Overall 209 patients were enrolled', '105 patients taking', 'patients with Global Initiative for COPD criteria II-IV at a tertiary care pulmonology department in Austria']","['simvastatin', 'placebo', 'Simvastatin']","['annualised exacerbation rate', 'time to first exacerbation', 'prolonged time to first COPD exacerbation and reduced exacerbation rate', 'Hazard ratio for risk of first exacerbation', 'quality of life, lung function, 6-minute walk test and high-sensitivity C-reactive protein', 'Rate of exacerbations']","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0034060', 'cui_str': 'Pulmonary medicine'}, {'cui': 'C0004348', 'cui_str': 'Austria'}]","[{'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3508933', 'cui_str': 'Chronic obstructive pulmonary disease exacerbation'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",209.0,0.654114,Rate of exacerbations was significantly lower with simvastatin: 103 (41%) versus ,"[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Schenk', 'Affiliation': 'Landesklinikum Hochegg, Pulmologische Abteilung, Grimmenstein, Austria peter.schenk@hochegg.lknoe.at.'}, {'ForeName': 'Alexander O', 'Initials': 'AO', 'LastName': 'Spiel', 'Affiliation': 'Medical University Vienna, Dept of Emergency Medicine, Vienna, Austria.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Hüttinger', 'Affiliation': 'Landesklinikum Hochegg, Pulmologische Abteilung, Grimmenstein, Austria.'}, {'ForeName': 'Micheline', 'Initials': 'M', 'LastName': 'Gmeiner', 'Affiliation': 'Landesklinikum Hochegg, Pulmologische Abteilung, Grimmenstein, Austria.'}, {'ForeName': 'Josefine', 'Initials': 'J', 'LastName': 'Fugger', 'Affiliation': 'Landesklinikum Mödling, Pharmacy, Mödling, Austria.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Pichler', 'Affiliation': 'Landesklinikum Hochegg, Pulmologische Abteilung, Grimmenstein, Austria.'}, {'ForeName': 'Gernot', 'Initials': 'G', 'LastName': 'Pichler', 'Affiliation': 'Landesklinikum Hochegg, Pulmologische Abteilung, Grimmenstein, Austria.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Schmeikal', 'Affiliation': 'Baden, Austria.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Janistyn', 'Affiliation': 'Wr. Neustadt, Austria.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schügerl', 'Affiliation': 'Neunkirchen, Austria.'}, {'ForeName': 'Constantin', 'Initials': 'C', 'LastName': 'Sajdik', 'Affiliation': 'Landesklinikum Hochegg, Pulmologische Abteilung, Grimmenstein, Austria.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Herkner', 'Affiliation': 'Medical University Vienna, Dept of Emergency Medicine, Vienna, Austria.'}]",The European respiratory journal,['10.1183/13993003.01798-2020'] 992,33580297,Modulation of human intestinal microbiota in a clinical trial by consumption of a β-D-glucan-enriched extract obtained from Lentinula edodes.,"PURPOSE The aim of this study was to evaluate the hypocholesterolemic, immune- and microbiota-modulatory effect of a mushroom extract in hypercholesterolemic subjects. METHODS A randomized, controlled, double-blind, and parallel clinical trial was carried out with subjects from 18 to 65 years old (n = 52) with untreated mild hypercholesterolemia. Volunteers consumed a β-D-glucan-enriched (BGE) mixture (10.4 g/day) obtained from shiitake mushrooms (Lentinula edodes) ensuring a 3.5 g/day of fungal β-D-glucans or a placebo incorporated in three different commercial creams. RESULTS This mixture showed hypocholesterolemic activities in vitro and in animal studies. After eight weeks intervention, no significant differences in lipid- or cholesterol-related parameters were found compared to placebo subjects as well as before and after the BGE mixture administration. No inflammatory or immunomodulatory responses were noticed and no changes in IL-1β, IL-6, TNF-α or oxLDL were recorded. However, consumption of the BGE mixture was safe and managed to achieve the dietary fibre intake recommended as cardiovascular protective diet. Moreover, the BGE mixture modulated the colonic microbiota differently compared to placebo. Microbial community composition varied from before to after the intervention with several genera being positively or negatively correlated with some biomarkers related to cholesterol metabolism. CONCLUSION These results suggested a relation between cholesterol metabolism, microbiota and BGE administration. Nevertheless, the precise significance of this differential modulation was not fully elucidated and requires further studies.",2021,"No inflammatory or immunomodulatory responses were noticed and no changes in IL-1β, IL-6, TNF-α or oxLDL were recorded.","['hypercholesterolemic subjects', 'subjects from 18 to 65\xa0years old (n\u2009=\u200952) with untreated mild hypercholesterolemia']","['placebo', 'β-D-glucan-enriched (BGE) mixture', 'mushroom extract']","['inflammatory or immunomodulatory responses', 'hypocholesterolemic activities', 'colonic microbiota', 'IL-1β, IL-6, TNF-α or oxLDL', 'lipid- or cholesterol-related parameters']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0020443', 'cui_str': 'Hypercholesterolemia'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0219900', 'cui_str': 'polyglucosan'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0001774', 'cui_str': 'Order Agaricales'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0348035', 'cui_str': 'Oxidized low density lipoprotein'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",,0.129338,"No inflammatory or immunomodulatory responses were noticed and no changes in IL-1β, IL-6, TNF-α or oxLDL were recorded.","[{'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Morales', 'Affiliation': 'Department of Production and Characterization of Novel Foods, Institute of Food Science Research - CIAL (UAM+CSIC), Universidad Autónoma de Madrid, C/ Nicolas Cabrera 9, Campus de Cantoblanco, 28049, Madrid, Spain. diegomoraleshdz@gmail.com.'}, {'ForeName': 'Sudarshan A', 'Initials': 'SA', 'LastName': 'Shetty', 'Affiliation': 'Laboratory of Microbiology, Wageningen University and Research, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.'}, {'ForeName': 'Bricia', 'Initials': 'B', 'LastName': 'López-Plaza', 'Affiliation': 'Nutrition Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), 28046, Madrid, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Gómez-Candela', 'Affiliation': 'Nutrition Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), 28046, Madrid, Spain.'}, {'ForeName': 'Hauke', 'Initials': 'H', 'LastName': 'Smidt', 'Affiliation': 'Laboratory of Microbiology, Wageningen University and Research, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.'}, {'ForeName': 'Francisco Ramón', 'Initials': 'FR', 'LastName': 'Marín', 'Affiliation': 'Department of Production and Characterization of Novel Foods, Institute of Food Science Research - CIAL (UAM+CSIC), Universidad Autónoma de Madrid, C/ Nicolas Cabrera 9, Campus de Cantoblanco, 28049, Madrid, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Soler-Rivas', 'Affiliation': 'Department of Production and Characterization of Novel Foods, Institute of Food Science Research - CIAL (UAM+CSIC), Universidad Autónoma de Madrid, C/ Nicolas Cabrera 9, Campus de Cantoblanco, 28049, Madrid, Spain.'}]",European journal of nutrition,['10.1007/s00394-021-02504-4'] 993,33577401,Striking muscle adaptations induced by volume-dependent repeated bouts of low-intensity eccentric exercise of the elbow flexors.,"We investigated the effects of repeating 30 low-intensity eccentric contractions with a dumbbell corresponding to 10% maximal isometric strength (10%EC) on muscle strength and hypertrophy, and muscle damage after 30 maximal eccentric contractions (MaxEC) of the elbow flexors. Young men were placed into 1 of 3 experimental groups that performed 10%EC either once, twice a week for 4 (8 bouts) or 8 weeks (16 bouts) before MaxEC, or a control group that performed 2 bouts of MaxEC separated by 2 weeks ( n = 13/group). Repeating 16 bouts of 10%EC increased ( P < 0.05) maximal voluntary contraction strength (30 ± 21%) and muscle thickness (4.2 ± 2.3%) greater than 8 bouts (16 ± 4%, 1.9 ± 1.3%). Changes in the muscle damage markers after MaxEC were smaller ( P < 0.05) for the experimental groups than the control group, and the magnitude of muscle damage protection was greater ( P < 0.05) after 16 bouts (65 ± 30%) than 8 bouts (55 ± 33%), followed by 1 bout (34 ± 27%). The protection by 16 bouts was similar ( P = 0.81) to that shown by the second MaxEC of the control group. These results showed that 10%EC produced potent muscle adaptation effects accumulatively and conferred muscle damage protection, but 1 bout of 10%EC was still effective for conferring approximately 20% of the protection of that by 16 bouts. Novelty: Repeating low-intensity eccentric exercise induces large increases in muscle strength and hypertrophy. Low-intensity eccentric exercise protects muscle damage induced by maximal eccentric contractions, and the protection is reinforced by repeating it. These are especially beneficial for individuals who are frail and cannot tolerate high-intensity resistance training.",2021,"Changes in the muscle damage markers after MaxEC were smaller (P<0.05) for the experimental groups than the control group, and the magnitude of muscle damage protection was greater (P<0.05) after 16 (65±30%) than 8 bouts (55±33%), followed by one bout (34±27%).","['Young men', 'individuals who are frail and cannot tolerate high-intensity resistance training']","['low-intensity eccentric exercise', '●Low-intensity eccentric exercise', 'repeating 30 low-intensity eccentric contractions with a dumbbell corresponding to 10% maximal isometric strength (10%EC']","['muscle strength and hypertrophy, and muscle damage', 'muscle strength and hypertrophy', 'maximal voluntary contraction strength', 'magnitude of muscle damage protection', 'muscle thickness']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0020564', 'cui_str': 'Hypertrophy'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0449286', 'cui_str': 'Degree'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",30.0,0.0178045,"Changes in the muscle damage markers after MaxEC were smaller (P<0.05) for the experimental groups than the control group, and the magnitude of muscle damage protection was greater (P<0.05) after 16 (65±30%) than 8 bouts (55±33%), followed by one bout (34±27%).","[{'ForeName': 'Trevor C', 'Initials': 'TC', 'LastName': 'Chen', 'Affiliation': 'Department of Physical Education, National Taiwan Normal University, Taipei City, Taiwan.'}, {'ForeName': 'Wei-Chin', 'Initials': 'WC', 'LastName': 'Tseng', 'Affiliation': 'Department of Exercise and Health Sciences, University of Taipei, Taipei City, Taiwan.'}, {'ForeName': 'Hsin-Lian', 'Initials': 'HL', 'LastName': 'Chen', 'Affiliation': 'Department of Physical Education, Health and Recreation, National Chiayi University, Chaiyi County, Taiwan.'}, {'ForeName': 'Kuo-Wei', 'Initials': 'KW', 'LastName': 'Tseng', 'Affiliation': 'Department of Exercise and Health Sciences, University of Taipei, Taipei City, Taiwan.'}, {'ForeName': 'Tai-Ying', 'Initials': 'TY', 'LastName': 'Chou', 'Affiliation': 'Department of Athletic Performance, National Taiwan Normal University, Taipei City, Taiwan.'}, {'ForeName': 'Yuh-Chuan', 'Initials': 'YC', 'LastName': 'Huang', 'Affiliation': 'Physical Education Office, Ming Chuan University, Taipei City, Taiwan.'}, {'ForeName': 'Kazunori', 'Initials': 'K', 'LastName': 'Nosaka', 'Affiliation': 'Centre for Exercise and Sports Science Research, School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2020-1016'] 994,33581146,Take-home kits to detect respiratory viruses among healthcare personnel: Lessons learned from a cluster randomized clinical trial.,"BACKGROUND Health care personnel (HCP) working in outpatient settings routinely interact with patients with acute respiratory illnesses. Absenteeism following symptom development and lack of staff trained to obtain samples limit efforts to identify pathogens among infected HCP. METHODS The Respiratory Protection Effectiveness Clinical Trial assessed respiratory infection incidence among HCP between 2011 and 2015. Research assistants obtained anterior nasal and oropharyngeal swabs from HCP in the workplace following development of respiratory illness symptoms and randomly while asymptomatic. Participants received take-home kits to self-collect swabs when absent from work. Samples mailed to a central laboratory were tested for respiratory viruses by reverse transcription polymerase chain reaction. RESULTS Among 2,862 participants, 3,467 swabs were obtained from symptomatic participants. Among symptomatic HCP, respiratory virus was detected in 904 of 3,467 (26.1%) samples. Self-collected samples by symptomatic HCP at home had higher rates of viral detection (40.3%) compared to 24% obtained by trained research assistants in the workplace (P < .001). CONCLUSIONS In this randomized clinical trial, take-home kits were an easily implemented, effective method to self-collect samples by HCP. Other studies have previously shown relative equivalence of self-collected samples to those obtained by trained healthcare workers. Take-home kit self-collection could diminish workforce exposures and decrease the demand for personnel protective equipment worn to protect workers who collect respiratory samples.",2021,"Among symptomatic HCP, respiratory virus was detected in 904 of 3,467 (26.1%) samples.","['2,862 participants, 3,467 swabs were obtained from symptomatic participants', 'patients with acute respiratory illnesses', 'Healthcare Personnel']",[],['viral detection'],"[{'cui': 'C0183753', 'cui_str': 'Swab'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}]",[],"[{'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",3467.0,0.15521,"Among symptomatic HCP, respiratory virus was detected in 904 of 3,467 (26.1%) samples.","[{'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Los', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: jlos1@jhmi.edu.'}, {'ForeName': 'Charlotte A', 'Initials': 'CA', 'LastName': 'Gaydos', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Cynthia L', 'Initials': 'CL', 'LastName': 'Gibert', 'Affiliation': 'Washington DC Veterans Affairs Medical Center, Washington, DC.'}, {'ForeName': 'Geoffrey J', 'Initials': 'GJ', 'LastName': 'Gorse', 'Affiliation': 'VA St. Louis Health Care System and Saint Louis University School of Medicine St. Louis, MO.'}, {'ForeName': 'Jacquelyn', 'Initials': 'J', 'LastName': 'Lykken', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Ann-Christine', 'Initials': 'AC', 'LastName': 'Nyquist', 'Affiliation': ""Children's Hospital Colorado, Aurora, CO; University of Colorado School of Medicine, Aurora, CO.""}, {'ForeName': 'Connie S', 'Initials': 'CS', 'LastName': 'Price', 'Affiliation': 'University of Colorado School of Medicine, Aurora, CO; Denver Health and Hospital, Denver, CO.'}, {'ForeName': 'Lewis J', 'Initials': 'LJ', 'LastName': 'Radonovich', 'Affiliation': 'Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Atlanta, GA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Rattigan', 'Affiliation': 'University of Florida, Gainesville, FL.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Reich', 'Affiliation': 'University of Massachusetts, Amherst, MA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Rodriguez-Barradas', 'Affiliation': 'Michael E. DeBakey VA Medical Center, Houston, TX.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Simberkoff', 'Affiliation': 'New York Harbor Healthcare System, New York, NY.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Bessesen', 'Affiliation': 'University of Colorado School of Medicine, Aurora, CO; VA-Eastern Colorado Healthcare System, Denver, CO.'}, {'ForeName': 'Alexandria', 'Initials': 'A', 'LastName': 'Brown', 'Affiliation': 'University of Massachusetts, Amherst, MA.'}, {'ForeName': 'Derek A T', 'Initials': 'DAT', 'LastName': 'Cummings', 'Affiliation': 'University of Florida, Gainesville, FL.'}, {'ForeName': 'Trish M', 'Initials': 'TM', 'LastName': 'Perl', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD; University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of infection control,['10.1016/j.ajic.2021.02.001'] 995,33583120,"Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial.","Belatacept results in improved kidney transplant outcomes, but utilization has been limited by logistical barriers related to monthly (q1m) intravenous infusions. Every 2-month (q2m) belatacept has potential to increase utilization, therefore we conducted a randomized noninferiority trial in low immunologic risk renal transplant recipients greater than 1-year posttransplant. Patients on belatacept were randomly assigned to q1m or q2m therapy. The primary objective was a noninferiority comparison of renal function (eGFR) at 12 months with a noninferiority margin (NIM) of 6.0 ml/min/1.73 m 2 . One hundred and sixty-six participants were randomized to q1m (n = 82) or q2m (n = 84) belatacept, 163 patients received treatment, and 76 q1m and 77 q2m subjects completed the 12-month study period. Every 2-month belatacept was noninferior to q1m, as the difference in mean eGFR adjusted for baseline renal function did not exceed the NIM. Two-month dosing was safe and well tolerated, with no patient deaths or graft losses. Four rejection episodes and three cases of donor-specific antibodies (DSAs) occurred among q2m subjects; however, only one rejection and one instance of DSA were observed in subjects adherent to the study protocol. Every 2-month belatacept therapy may facilitate long-term utilization of costimulation blockade, but future multicenter studies with long-term follow-up will further elucidate immunologic risk. (ClinicalTrials.gov NCT02560558).",2021,"Every 2-month belatacept was non-inferior to q1m, as the difference in mean eGFR adjusted for baseline renal function did not exceed the NIM.","['kidney transplant recipients greater than one-year post-transplant', 'low immunologic risk renal transplant recipients greater than one-year post-transplant', '166 participants were randomized to q1m (n=82) or q2m (n=84) belatacept, 163 patients received treatment, and 76 q1m and 77 q2m subjects completed the 12-month study period']",[],"['renal function (eGFR', 'safe and well tolerated, with no patient deaths or graft losses', 'mean eGFR adjusted for baseline renal function', 'donor-specific antibodies (DSA']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C3887292', 'cui_str': 'Greater than one year'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0152036', 'cui_str': 'Immunology'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C5191361', 'cui_str': '166'}, {'cui': 'C1880609', 'cui_str': 'Every two months'}, {'cui': 'C1619962', 'cui_str': 'belatacept'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877042', 'cui_str': 'Graft loss'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0443640', 'cui_str': 'Specific antibody'}]",166.0,0.0239052,"Every 2-month belatacept was non-inferior to q1m, as the difference in mean eGFR adjusted for baseline renal function did not exceed the NIM.","[{'ForeName': 'Idelberto R', 'Initials': 'IR', 'LastName': 'Badell', 'Affiliation': 'Emory Transplant Center, Atlanta, Georgia, USA.'}, {'ForeName': 'Ronald F', 'Initials': 'RF', 'LastName': 'Parsons', 'Affiliation': 'Emory Transplant Center, Atlanta, Georgia, USA.'}, {'ForeName': 'Geeta', 'Initials': 'G', 'LastName': 'Karadkhele', 'Affiliation': 'Emory Transplant Center, Atlanta, Georgia, USA.'}, {'ForeName': 'Octav', 'Initials': 'O', 'LastName': 'Cristea', 'Affiliation': 'Emory Transplant Center, Atlanta, Georgia, USA.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Mead', 'Affiliation': 'Emory Transplant Center, Atlanta, Georgia, USA.'}, {'ForeName': 'Shine', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': 'Emory Transplant Center, Atlanta, Georgia, USA.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Robertson', 'Affiliation': 'Emory Transplant Center, Atlanta, Georgia, USA.'}, {'ForeName': 'Grace S', 'Initials': 'GS', 'LastName': 'Kim', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Hanfelt', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.'}, {'ForeName': 'Stephen O', 'Initials': 'SO', 'LastName': 'Pastan', 'Affiliation': 'Emory Transplant Center, Atlanta, Georgia, USA.'}, {'ForeName': 'Christian P', 'Initials': 'CP', 'LastName': 'Larsen', 'Affiliation': 'Emory Transplant Center, Atlanta, Georgia, USA.'}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.16538'] 996,33600025,Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design.,"INTRODUCTION Success rates of catheter ablation in persistent atrial fibrillation (AF) remain suboptimal. A better and more targeted ablation strategy is urgently needed to optimize outcomes of AF treatment. We sought to assess the safety and efficacy of targeting atrial fibrosis during ablation of persistent AF patients in improving procedural outcomes. METHODS The DECAAF II trial (ClinicalTrials. gov identifier number NCT02529319) is a prospective, randomized, multicenter trial of patients with persistent AF. Patients with persistent AF undergoing a first-time ablation procedure were randomized in a 1:1 fashion to receive conventional pulmonary vein isolation (PVI) ablation (Group 1) or PVI + fibrosis-guided ablation (Group 2). Left atrial fibrosis and ablation induced scarring were defined by late gadolinium enhancement magnetic resonance imaging at baseline and at 3-12 months postablation, respectively. The primary endpoint is the recurrence of atrial arrhythmia postablation, including atrial fibrillation, atrial flutter, or atrial tachycardia after the 90-day postablation blanking period. Patients were followed for a period of 12-18 months with a smartphone ECG Device (ECG Check Device, Cardiac Designs Inc.). With an anticipated enrollment of 900 patients, this study has an 80% power to detect a 26% reduction in the hazard ratio of the primary endpoint. RESULTS AND CONCLUSION The DECAAF II trial is the first prospective, randomized, multicenter trial of patients with persistent AF using imaging defined atrial fibrosis as a treatment target. The trial will help define an optimal approach to catheter ablation of persistent AF, further our understanding of influencers of ablation lesion formation, and refine selection criteria for ablation based on atrial myopathy burden.",2021,"The primary endpoint is the recurrence of atrial arrhythmia post-ablation, including atrial fibrillation, atrial flutter, or atrial tachycardia after the 90-day post-ablation blanking period.","['patients with persistent AF using imaging defined atrial fibrosis', 'Patients with persistent AF undergoing a first-time ablation procedure', '900 patients', 'Atrial Fibrillation', 'patients with persistent AF']","['conventional PVI ablation (Group 1) or PVI + fibrosis-guided ablation', 'catheter ablation', 'smartphone ECG Device (ECG Check Device', 'LGE-MRI-Guided Fibrosis Ablation vs. Conventional Catheter Ablation']","['recurrence of atrial arrhythmia post-ablation, including atrial fibrillation, atrial flutter, or atrial tachycardia after the 90-day post-ablation blanking period', 'safety and efficacy', 'Left atrial fibrosis and ablation induced scarring']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0085611', 'cui_str': 'Atrial arrhythmia'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0004239', 'cui_str': 'Atrial flutter'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]",,0.0664261,"The primary endpoint is the recurrence of atrial arrhythmia post-ablation, including atrial fibrillation, atrial flutter, or atrial tachycardia after the 90-day post-ablation blanking period.","[{'ForeName': 'Nassir F', 'Initials': 'NF', 'LastName': 'Marrouche', 'Affiliation': 'Department of Cardiology, Tulane University School of Medicine, New Orleans, Louisiana, USA.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Greene', 'Affiliation': 'University of Utah, Salt Lake City, Utah, USA.'}, {'ForeName': 'J Michael', 'Initials': 'JM', 'LastName': 'Dean', 'Affiliation': 'University of Utah, Salt Lake City, Utah, USA.'}, {'ForeName': 'Eugene G', 'Initials': 'EG', 'LastName': 'Kholmovski', 'Affiliation': 'University of Utah, Salt Lake City, Utah, USA.'}, {'ForeName': 'Leonie Morrison-de', 'Initials': 'LM', 'LastName': 'Boer', 'Affiliation': 'University of Utah, Salt Lake City, Utah, USA.'}, {'ForeName': 'Moussa', 'Initials': 'M', 'LastName': 'Mansour', 'Affiliation': 'Department of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Calkins', 'Affiliation': 'Department of Cardiology, Johns Hopkins Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Marchlinski', 'Affiliation': 'Department of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Wilber', 'Affiliation': 'Department of Cardiology, Loyola University Medical Center, Chicago, Illinois, USA.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Hindricks', 'Affiliation': 'Department of Cardiology, Leipzig University, Leipzig, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Mahnkopf', 'Affiliation': 'Department of Cardiology, Klinikum Coburg, Coburg, Germany.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Jais', 'Affiliation': 'Department of Cardiology, Segalen University, Bordeaux, France.'}, {'ForeName': 'Prashanthan', 'Initials': 'P', 'LastName': 'Sanders', 'Affiliation': 'Department of Cardiology, Centre for Heart Rhythm Disorders, Royal Adelaide Hospital, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Brachmann', 'Affiliation': 'Department of Cardiology, Klinikum Coburg, Coburg, Germany.'}, {'ForeName': 'Jereon', 'Initials': 'J', 'LastName': 'Bax', 'Affiliation': 'Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Lilas', 'Initials': 'L', 'LastName': 'Dagher', 'Affiliation': 'Department of Cardiology, Tulane University School of Medicine, New Orleans, Louisiana, USA.'}, {'ForeName': 'Oussama', 'Initials': 'O', 'LastName': 'Wazni', 'Affiliation': 'Department of Cardiology, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Nazem', 'Initials': 'N', 'LastName': 'Akoum', 'Affiliation': 'Department of Cardiology, University of Washington Medical Center, Seattle, Washington, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of cardiovascular electrophysiology,['10.1111/jce.14957'] 997,33600915,Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).,"BACKGROUND Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. OBJECTIVE To evaluate the efficacy and safety of baricitinib monotherapy in a North American phase 3 trial (BREEZE-AD5/NCT03435081) of adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. METHODS Patients (N = 440) were randomized 1:1:1 to once-daily placebo or baricitinib (1 mg or 2 mg). The primary endpoint was the proportion of patients achieving ≥75% reduction in the Eczema Area and Severity Index at week 16. A key secondary endpoint was the proportion of patients achieving a validated Investigator Global Assessment for AD score of 0 (clear)/1(almost clear) with ≥2-point improvement. RESULTS At week 16, the proportion of patients achieving Eczema Area and Severity Index was 8%, 13%, and 30% (P < .001, 2 mg vs placebo) and those with a validated Investigator Global Assessment for AD score of 0/1 were 5%, 13%, and 24% (P < .001, 2 mg vs placebo) for placebo, baricitinib 1 mg, and baricitinib 2 mg, respectively. Safety findings were similar to those of other baricitinib AD studies. LIMITATIONS Short-term clinical trial results may not be generalizable to real-world settings. CONCLUSION Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.",2021,Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.,"['patients with moderate-to-severe AD', 'adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy', 'patients with moderate-to-severe atopic dermatitis', 'Patients (N=440', 'moderate-to-severe atopic dermatitis (AD) in adults']","['baricitinib monotherapy', 'placebo or baricitinib', 'placebo']","['proportion of patients achieving ≥75% reduction in the Eczema Area and Severity Index (EASI75', 'proportion of patients achieving EASI75', 'efficacy and safety', 'proportion of patients achieving a validated Investigator Global Assessment for AD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C4044947', 'cui_str': 'baricitinib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}]",440.0,0.272111,Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.,"[{'ForeName': 'Eric L', 'Initials': 'EL', 'LastName': 'Simpson', 'Affiliation': 'Oregon Health and Science University, Portland, Oregon. Electronic address: simpsone@ohsu.edu.'}, {'ForeName': 'Seth', 'Initials': 'S', 'LastName': 'Forman', 'Affiliation': 'ForCare Clinical Research, Tampa, Florida.'}, {'ForeName': 'Jonathan I', 'Initials': 'JI', 'LastName': 'Silverberg', 'Affiliation': 'George Washington University, Washington, DC.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Zirwas', 'Affiliation': 'Bexley Dermatology Research Clinic, Bexley, Ohio.'}, {'ForeName': 'Emanual', 'Initials': 'E', 'LastName': 'Maverakis', 'Affiliation': 'University of California Davis, Sacramento, California.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Han', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Guttman-Yassky', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Marnell', 'Affiliation': 'Medical Center for Clinical Research-Wake Research, San Diego, California.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Bissonnette', 'Affiliation': 'Innovaderm Research, Montreal, Quebec, Canada.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Waibel', 'Affiliation': 'Miami Dermatology and Laser Institute, Miami, Florida.'}, {'ForeName': 'Fabio P', 'Initials': 'FP', 'LastName': 'Nunes', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Amy M', 'Initials': 'AM', 'LastName': 'DeLozier', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Robinette', 'Initials': 'R', 'LastName': 'Angle', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Gamalo', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Holzwarth', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Orin', 'Initials': 'O', 'LastName': 'Goldblum', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Jinglin', 'Initials': 'J', 'LastName': 'Zhong', 'Affiliation': 'IQVIA, Morrisville, North Carolina.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Janes', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Papp', 'Affiliation': 'K Papp Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2021.02.028'] 998,33560104,Trauma patients at risk for venous thromboembolism who undergo routine duplex ultrasound screening experience fewer pulmonary emboli: A prospective randomized trial.,"BACKGROUND Although guidelines are established for the prevention and management of venous thromboembolism (VTE) in trauma, no consensus exists regarding protocols for the diagnostic approach. We hypothesized that at-risk trauma patients who undergo duplex ultrasound (DUS) surveillance for lower extremity deep venous thrombosis (DVT) will have a lower rate of symptomatic or fatal pulmonary embolism (PE) than those who do not undergo routine surveillance. METHODS Prospective, randomized trial between March 2017 and September 2019 of trauma patients admitted to a single, level 1 trauma center, with a risk assessment profile score of ≥5. Patients were randomized to receive either bilateral lower extremity DUS surveillance on days 1, 3, and 7 and weekly during hospitalization ultrasound group (US) or no surveillance no ultrasound group (NoUS). Rates of in-hospital and 90-day DVT and PE were reported as was DVT propagation and all-cause mortality. Standard care for the prevention and management of VTE per established institutional protocols was provided to all patients. RESULTS A total of 3,236 trauma service admissions were screened, and 1,989 moderate- and high-risk patients were randomized (US, 995; NoUS, 994). The mean ± SD age was 62 ± 20.1 years, Injury Severity Score was 14 ± 9.7, risk assessment profile was 7.1 ± 2.4, and 97% suffered blunt trauma. There was no difference in demographics or VTE risk factors between the groups. There were significantly fewer in-hospital PE in the US group than the NoUS group (1 [0.1%] vs. 9 [0.9%], p = 0.01). The US group experienced more in-hospital below-knee DVTs (124 [12.5%] vs. 8 [0.8%], p < 0.001) and above-knee DVTs (19 [1.9%] vs. 8 [0.8%], p = 0.05). There was no difference in 90-day PE or DVT, or overall mortality. CONCLUSION The implementation of a selective routine DUS protocol was associated with significantly fewer in-hospital PE. More DVTs were identified with routine screening; however, surveillance bias appears to exist primarily with distal DVT. Larger trials are needed to further characterize the relationship between routine DUS screening and VTE outcomes in the high-risk trauma population. LEVEL OF EVIDENCE Therapeutic/care management, level II.",2021,"No difference in 90-day PE or DVT, or overall mortality. ","['March 2017 and September 2019 of trauma patients admitted to a single, Level 1 trauma center, with a risk assessment profile (RAP) score ≥5', '1,989 moderate and high-risk patients', '3,236 trauma service admissions', 'Trauma Patients at Risk for Venous Thromboembolism who Undergo Routine Duplex Ultrasound Screening Experience Fewer Pulmonary Emboli']","['bilateral lower extremity DUS surveillance', 'duplex ultrasound (DUS) surveillance']","['demographics or VTE risk factors', '90-day PE or DVT, or overall mortality', 'hospital PE', 'hospital below-knee DVTs', 'Rates of in-hospital and 90-day DVT and PE']","[{'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0456947', 'cui_str': 'Level 1'}, {'cui': 'C0040786', 'cui_str': 'Trauma center'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0242845', 'cui_str': 'Duplex ultrasound'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0242845', 'cui_str': 'Duplex ultrasound'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0151950', 'cui_str': 'Deep thrombophlebitis'}]",,0.048219,"No difference in 90-day PE or DVT, or overall mortality. ","[{'ForeName': 'Annika B', 'Initials': 'AB', 'LastName': 'Kay', 'Affiliation': 'From the Division of Trauma Services and Surgical Critical Care (A.B.K., D.S.M., S.M.), Department of Medicine (S.C.W., S.M.S.), Intermountain Medical Center, Murray; Department of Medicine (S.C.W., S.M.S.), University of Utah School of Medicine, Salt Lake City; Department of Emergency Medicine (J.R.B.), Intermountain Medical Center, Murray; Medical Informatics (J.F.L.), Intermountain Medical Center; and Office of Research (D.S.C.), Intermountain Medical Center, Murray, Utah.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Morris', 'Affiliation': ''}, {'ForeName': 'Scott C', 'Initials': 'SC', 'LastName': 'Woller', 'Affiliation': ''}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Stevens', 'Affiliation': ''}, {'ForeName': 'Joseph R', 'Initials': 'JR', 'LastName': 'Bledsoe', 'Affiliation': ''}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Lloyd', 'Affiliation': ''}, {'ForeName': 'Dave S', 'Initials': 'DS', 'LastName': 'Collingridge', 'Affiliation': ''}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Majercik', 'Affiliation': ''}]",The journal of trauma and acute care surgery,['10.1097/TA.0000000000003104'] 999,33558346,"COPAHS Study: protocol of a randomised experimental study comparing the effects of hypnosis, mindfulness meditation, and spiritual practices on experimental pain in healthy adults.","BACKGROUND There has been an increasing interest in studying the potential benefits of so-called complementary and alternative approaches for pain management, such as hypnosis and mindfulness-based interventions. More recently, researchers have been interested in studying the effects of spiritual practices on pain experience as well. These practices may increase pain tolerance, result in a positive re-appraisal of pain and influence other psychological variables that are known to be associated with pain experience. The purpose of this study is to evaluate and compare the immediate effects of self-hypnosis, mindfulness meditation, and a spiritual intervention relative to a control condition for increasing pain tolerance and reducing pain intensity and pain-related stress, in response to experimental painful stimulation. METHODS AND ANALYSIS Recruitment is anticipated to start in November 2020. This is a randomised quantitative experimental mixed-design repeated-measures study with three assessment points: baseline (T0), pre-test (T1) and post-test (T2). Eligible healthy adults will be randomised to one of the four study conditions. Interventions will be a 20-minute audio-guided practice of either self-hypnosis, mindfulness meditation, or Christian prayer. Participants in the control group will not be instructed to use any specific strategy during the painful stimulation. Participants will be submitted to a first cycle of Cold Pressor Arm Wrap. They will then listen to a 20-minute audio recording inducing one of the three interventions, or, in the case of the control group, to a 20-minute audio recording of text from a natural history textbook. Primary outcomes are pain intensity and pain tolerance. Pain-related stress as measured by salivary cortisol level and heart rate variability are secondary outcomes. ETHICS AND DISSEMINATION This study was approved by ISPA-University Institute's internal Ethics Committee for Research on 3rd December 2018 (reference I/010/12/2018). Findings will be published in peer-reviewed indexed journals and presented at conferences. TRIAL REGISTRATION NUMBER ClinicalTrials.gov registry (NCT04491630). Stage: pre-results.",2021,"Interventions will be a 20-minute audio-guided practice of either self-hypnosis, mindfulness meditation, or Christian prayer.","['Eligible healthy adults', 'healthy adults']","['self-hypnosis, mindfulness meditation, and a spiritual intervention relative to a control condition', 'hypnosis, mindfulness meditation, and spiritual practices', 'Cold Pressor Arm Wrap']","['salivary cortisol level and heart rate variability', 'pain intensity and pain tolerance', 'pain tolerance', 'pain intensity and pain-related stress']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",,0.135821,"Interventions will be a 20-minute audio-guided practice of either self-hypnosis, mindfulness meditation, or Christian prayer.","[{'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Ferreira-Valente', 'Affiliation': 'William James Center for Research, ISPA - University Institute, Lisbon, Portugal mafvalente@gmail.com.'}, {'ForeName': 'Filipa', 'Initials': 'F', 'LastName': 'Pimenta', 'Affiliation': 'William James Center for Research, ISPA - University Institute, Lisbon, Portugal.'}, {'ForeName': 'Rui M', 'Initials': 'RM', 'LastName': 'Costa', 'Affiliation': 'William James Center for Research, ISPA - University Institute, Lisbon, Portugal.'}, {'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Day', 'Affiliation': 'The University of Queensland, School of Psychology, Saint Lucia, Queensland, Australia.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Pais-Ribeiro', 'Affiliation': 'William James Center for Research, ISPA - University Institute, Lisbon, Portugal.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Jensen', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, USA.'}]",BMJ open,['10.1136/bmjopen-2020-040068'] 1000,33565286,"""Big girls don't cry"": the effect of the experimenter's sex and pain catastrophising on pain.","OBJECTIVES The expression of pain in males and females involves complex socio-psychological mechanisms. Males may report lower pain to a female experimenter to appear strong, whereas females may report higher pain to a male experimenter to appear weak and to seek protection. However, evidence to support these stereotypes is inconclusive. Individuals who catastrophise about pain rate higher pain than those who do not. How pain catastrophising interacts with the effect of the experimenter's sex on pain reports is yet to be explored. Thus, the aim of this study was to determine whether pain catastrophising moderated the effect of the experimenter's sex on pain reports in healthy males and females. METHODS Participants (n=60, 30 males) were assigned to one of four experimental conditions: males tested by male experimenters, males tested by female experimenters, females tested by male experimenters, and females tested by female experimenters. Participants completed the Pain Catastrophising Scale, and then sensitivity to heat and to blunt (pressure-pain threshold) and sharp stimuli was assessed on both forearms, and to high frequency electrical stimulation (HFS) administered to one forearm. RESULTS Females reported lower pressure-pain thresholds than males irrespective of the experimenters' sex. Females reported lower sharpness ratings to male than female experimenters only when the test stimuli were moderately or intensely sharp. Higher pain catastrophising scores were associated with higher sharpness ratings in females but not males. Additionally, higher pain catastrophising scores were associated with greater temporal summation of pain to HFS, and with lower pressure-pain thresholds in females who were tested by male experimenters. CONCLUSIONS These findings indicate that the experimenters' sex and the participant's pain catastrophising score influence pain reports, particularly in females. Awareness of these psychosocial factors is important in order to interpret pain responses in a meaningful way, especially when females are tested by male experimenters. A greater awareness of sex/gender role biases and their potential interaction with pain catastrophising may help researchers and clinicians to interpret pain reports in meaningful ways. In turn, this may help to improve delivery of treatments for patients with chronic pain.",2021,Females reported lower sharpness ratings to male than female experimenters only when the test stimuli were moderately or intensely sharp.,"['healthy males and females', 'Participants (n=60, 30 males) were assigned to one of four experimental conditions: males tested by male experimenters, males tested by female experimenters, females tested by male experimenters, and females tested by female experimenters', 'in females who were tested by male experimenters', 'patients with chronic pain']",[],"['higher pain catastrophising scores', 'sharpness ratings', 'pressure-pain thresholds', 'Higher pain catastrophising scores', 'Pain Catastrophising Scale, and then sensitivity to heat and to blunt (pressure-pain threshold) and sharp stimuli', 'expression of pain']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C1444775', 'cui_str': 'Sharp sensation quality'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",,0.0246425,Females reported lower sharpness ratings to male than female experimenters only when the test stimuli were moderately or intensely sharp.,"[{'ForeName': 'Lechi', 'Initials': 'L', 'LastName': 'Vo', 'Affiliation': 'College of Science, Health, Education and Engineering, Discipline of Psychology, Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Peter D', 'Initials': 'PD', 'LastName': 'Drummond', 'Affiliation': 'College of Science, Health, Education and Engineering, Discipline of Psychology, Murdoch University, Perth, Western Australia, Australia.'}]",Scandinavian journal of pain,['10.1515/sjpain-2020-0157'] 1001,33562452,Study on the Effects of Melatonin on Glycemic Control and Periodontal Parameters in Patients with Type II Diabetes Mellitus and Periodontal Disease.,"Background and Objectives : There is evidence that melatonin could improve the periodontal status and also glycemic control of patients with diabetes mellitus. Therefore, the aim of this study was to assess the effects of scaling and root planing plus adjunctive systemic treatment with melatonin on periodontal parameters and glycemic control in patients with type 2 diabetes and chronic periodontitis. Materials and Methods : The study was conducted on 54 subjects with periodontitis and diabetes mellitus randomly assigned to the study group ( n = 27, subjects with scaling and root planing + melatonin) or control group ( n = 27, subjects with scaling and root planing + placebo). Periodontal parameters (probing depth-PD; clinical attachment loss-CAL; bleeding on probing-BOP; and hygiene level) and glycated hemoglobin (HbA1c) were assessed at baseline and 8 weeks after. Results : At baseline, there were no significant differences between groups, but at the second evaluation 8 weeks later the association of melatonin with the non-surgical periodontal therapy exerted statistically significant improvements, both in periodontal parameters, with a significant decrease in periodontal disease severity, and glycated hemoglobin when compared to the control subjects. Conclusions : In our study, combined non-surgical periodontal treatment and systemic treatment with melatonin provided additional improvements to severe periodontal condition and the glycemic control of patients with diabetes type 2 when compared to non-surgical periodontal treatment alone.",2021,"At baseline, there were no significant differences between groups, but at the second evaluation 8 weeks later the association of melatonin with the non-surgical periodontal therapy exerted statistically significant improvements, both in periodontal parameters, with a significant decrease in periodontal disease severity, and glycated hemoglobin when compared to the control subjects. ","['54 subjects with periodontitis and diabetes mellitus randomly assigned to the study group ( n = 27, subjects with', 'patients with type 2 diabetes and chronic periodontitis', 'Patients with Type II Diabetes Mellitus and Periodontal Disease', 'patients with diabetes type 2', 'patients with diabetes mellitus']","['melatonin', 'scaling and root planing + melatonin) or control group ( n = 27, subjects with scaling and root planing + placebo', 'Melatonin', 'Materials and Methods ']","['Glycemic Control and Periodontal Parameters', 'periodontal parameters and glycemic control', 'periodontal parameters', 'severe periodontal condition', 'periodontal disease severity, and glycated hemoglobin', 'Periodontal parameters (probing depth-PD; clinical attachment loss-CAL; bleeding on probing-BOP; and hygiene level) and glycated hemoglobin (HbA1c']","[{'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0266929', 'cui_str': 'Chronic periodontitis'}, {'cui': 'C0031090', 'cui_str': 'Periodontal disease'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0085287', 'cui_str': 'Root planing of tooth'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0031090', 'cui_str': 'Periodontal disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0796232', 'cui_str': 'Bohring Opitz syndrome'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",54.0,0.0193139,"At baseline, there were no significant differences between groups, but at the second evaluation 8 weeks later the association of melatonin with the non-surgical periodontal therapy exerted statistically significant improvements, both in periodontal parameters, with a significant decrease in periodontal disease severity, and glycated hemoglobin when compared to the control subjects. ","[{'ForeName': 'Diana-Maria', 'Initials': 'DM', 'LastName': 'Anton', 'Affiliation': 'Faculty of Dentistry, ""Grigore T. Popa"" University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.'}, {'ForeName': 'Maria-Alexandra', 'Initials': 'MA', 'LastName': 'Martu', 'Affiliation': 'Faculty of Dentistry, ""Grigore T. Popa"" University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Maris', 'Affiliation': 'Faculty of Dental Medicine, ""Titu Maiorescu"" University, 67A Gheorghe Petrascu Str., 031593 Bucharest, Romania.'}, {'ForeName': 'George-Alexandru', 'Initials': 'GA', 'LastName': 'Maftei', 'Affiliation': 'Faculty of Dentistry, ""Grigore T. Popa"" University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.'}, {'ForeName': 'Irina-Georgeta', 'Initials': 'IG', 'LastName': 'Sufaru', 'Affiliation': 'Faculty of Dentistry, ""Grigore T. Popa"" University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Tatarciuc', 'Affiliation': 'Faculty of Medicine, ""Grigore T. Popa"" University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.'}, {'ForeName': 'Ionut', 'Initials': 'I', 'LastName': 'Luchian', 'Affiliation': 'Faculty of Dentistry, ""Grigore T. Popa"" University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.'}, {'ForeName': 'Nicoleta', 'Initials': 'N', 'LastName': 'Ioanid', 'Affiliation': 'Faculty of Dentistry, ""Grigore T. Popa"" University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Martu', 'Affiliation': 'Faculty of Dentistry, ""Grigore T. Popa"" University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina57020140'] 1002,33566466,A Post Hoc Analysis of Osmotherapy Use in the Erythropoietin in Traumatic Brain Injury Study-Associations With Acute Kidney Injury and Mortality.,"OBJECTIVES Mannitol and hypertonic saline are used to treat raised intracerebral pressure in patients with traumatic brain injury, but their possible effects on kidney function and mortality are unknown. DESIGN A post hoc analysis of the erythropoietin trial in traumatic brain injury (ClinicalTrials.gov NCT00987454) including daily data on mannitol and hypertonic saline use. SETTING Twenty-nine university-affiliated teaching hospitals in seven countries. PATIENTS A total of 568 patients treated in the ICU for 48 hours without acute kidney injury of whom 43 (7%) received mannitol and 170 (29%) hypertonic saline. INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS We categorized acute kidney injury stage according to the Kidney Disease Improving Global Outcome classification and defined acute kidney injury as any Kidney Disease Improving Global Outcome stage-based changes from the admission creatinine. We tested associations between early (first 2 d) mannitol and hypertonic saline and time to acute kidney injury up to ICU discharge and death up to 180 days with Cox regression analysis. Subsequently, acute kidney injury developed more often in patients receiving mannitol (35% vs 10%; p < 0.001) and hypertonic saline (23% vs 10%; p < 0.001). On competing risk analysis including factors associated with acute kidney injury, mannitol (hazard ratio, 2.3; 95% CI, 1.2-4.3; p = 0.01), but not hypertonic saline (hazard ratio, 1.6; 95% CI, 0.9-2.8; p = 0.08), was independently associated with time to acute kidney injury. In a Cox model for predicting time to death, both the use of mannitol (hazard ratio, 2.1; 95% CI, 1.1-4.1; p = 0.03) and hypertonic saline (hazard ratio, 1.8; 95% CI, 1.02-3.2; p = 0.04) were associated with time to death. CONCLUSIONS In this post hoc analysis of a randomized controlled trial, the early use of mannitol, but not hypertonic saline, was independently associated with an increase in acute kidney injury. Our findings suggest the need to further evaluate the use and choice of osmotherapy in traumatic brain injury.",2021,"Subsequently, acute kidney injury developed more often in patients receiving mannitol (35% vs 10%; p < 0.001) and hypertonic saline (23% vs 10%; p < 0.001).","['568 patients treated in the ICU for 48 hours without acute kidney injury of whom 43 (7%) received', 'Twenty-nine university-affiliated teaching hospitals in seven countries', 'patients with traumatic brain injury']","['Mannitol and hypertonic saline', 'mannitol and hypertonic saline', 'hypertonic saline', 'mannitol', 'mannitol and hypertonic saline use']","['time to death', 'acute kidney injury', 'categorized acute kidney injury stage according to the Kidney Disease Improving Global Outcome classification and defined acute kidney injury as any Kidney Disease Improving Global Outcome stage-based changes from the admission creatinine']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}]","[{'cui': 'C0024730', 'cui_str': 'Mannitol'}, {'cui': 'C0036085', 'cui_str': 'sodium chloride, hypertonic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}]",568.0,0.577368,"Subsequently, acute kidney injury developed more often in patients receiving mannitol (35% vs 10%; p < 0.001) and hypertonic saline (23% vs 10%; p < 0.001).","[{'ForeName': 'Markus B', 'Initials': 'MB', 'LastName': 'Skrifvars', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bailey', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Moore', 'Affiliation': 'Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Mårtensson', 'Affiliation': 'Department of Physiology and Pharmacology, Section of Anaesthesia and Intensive Care, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'French', 'Affiliation': 'Department of Intensive Care, Western Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Presneill', 'Affiliation': 'Department of Intensive Care, Royal Melbourne Hospital, Melbourne, VIC, Australia.'}, {'ForeName': 'Alistair', 'Initials': 'A', 'LastName': 'Nichol', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Little', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Duranteau', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Hôpitaux universitaires Paris Sud (HUPS), Université Paris Sud XI, Paris, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Huet', 'Affiliation': ""Departement d'anesthésie-réanimation, Hopital de la Cavale Blanche, Boulevard Tanguy Prigent, CHRU de Brest, Univeristé de Bretagne Occidental, Brest, France.""}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Haddad', 'Affiliation': 'King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.'}, {'ForeName': 'Yaseen M', 'Initials': 'YM', 'LastName': 'Arabi', 'Affiliation': 'King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'McArthur', 'Affiliation': 'Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'David James', 'Initials': 'DJ', 'LastName': 'Cooper', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Stepani', 'Initials': 'S', 'LastName': 'Bendel', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Kuopio University Hospital & University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004853'] 1003,33566465,Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.,"OBJECTIVES We explored the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin against central venous catheter-associated deep venous thrombosis in critically ill children. DESIGN Post hoc analysis of a Bayesian phase 2b randomized clinical trial. SETTING Seven PICUs. PATIENTS Children less than 18 years old with newly inserted central venous catheter. INTERVENTIONS Enoxaparin started less than 24 hours after insertion of central venous catheter and adjusted to anti-Xa level of 0.2-0.5 international units/mL versus usual care. MEASUREMENTS AND MAIN RESULTS Of 51 children randomized, 24 were infants less than 1 year old. Risk ratios of central venous catheter-associated deep venous thrombosis with prophylaxis with enoxaparin were 0.98 (95% credible interval, 0.37-2.44) in infants and 0.24 (95% credible interval, 0.04-0.82) in older children greater than or equal to 1 year old. Infants and older children achieved anti-Xa level greater than or equal to 0.2 international units/mL at comparable times. While central venous catheter was in situ, endogenous thrombin potential, a measure of thrombin generation, was 223.21 nM.min (95% CI, 8.78-437.64 nM.min) lower in infants. Factor VIII activity, a driver of thrombin generation, was also lower in infants by 45.1% (95% CI, 15.7-74.4%). Median minimum platelet count while central venous catheter was in situ was higher in infants by 39 × 103/mm3 (interquartile range, 17-61 × 103/mm3). Central venous catheter:vein ratio was not statistically different. Prophylaxis with enoxaparin was less efficacious against central venous catheter-associated deep venous thrombosis at lower factor VIII activity and at higher platelet count. CONCLUSIONS The relatively lesser contribution of thrombin generation on central venous catheter-associated thrombus formation in critically ill infants potentially explains the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin.",2021,"Prophylaxis with enoxaparin was less efficacious against central venous catheter-associated deep venous thrombosis at lower factor VIII activity and at higher platelet count. ","['critically ill children', 'Critically Ill Children', 'Infants and older children', 'Children less than 18 years old with newly inserted central venous catheter', '51 children randomized, 24 were infants less than 1 year old', 'Seven PICUs']","['Enoxaparin', 'thrombin generation', 'enoxaparin against central venous catheter', 'Central venous catheter', 'enoxaparin']","['Risk ratios of central venous catheter-associated deep venous thrombosis', 'Median minimum platelet count while central venous catheter', 'anti-Xa level', 'Factor VIII activity, a driver of thrombin generation', 'vein ratio']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C1145640', 'cui_str': 'Central venous catheter'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C1046445', 'cui_str': 'Picus'}]","[{'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0040018', 'cui_str': 'Thrombin'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C1145640', 'cui_str': 'Central venous catheter'}]","[{'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C1145640', 'cui_str': 'Central venous catheter'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0019139', 'cui_str': 'Low molecular weight heparin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015506', 'cui_str': 'Factor VIII'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0040018', 'cui_str': 'Thrombin'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",51.0,0.107856,"Prophylaxis with enoxaparin was less efficacious against central venous catheter-associated deep venous thrombosis at lower factor VIII activity and at higher platelet count. ","[{'ForeName': 'E Vincent S', 'Initials': 'EVS', 'LastName': 'Faustino', 'Affiliation': 'Department of Pediatrics, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Leslie J', 'Initials': 'LJ', 'LastName': 'Raffini', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA.""}, {'ForeName': 'Sheila J', 'Initials': 'SJ', 'LastName': 'Hanson', 'Affiliation': 'Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Cholette', 'Affiliation': ""Department of Pediatrics, University of Rochester Golisano Children's Hospital, Rochester, NY.""}, {'ForeName': 'Matthew G', 'Initials': 'MG', 'LastName': 'Pinto', 'Affiliation': ""Department of Pediatrics, New York Medical College, Maria Fareri Children's Hospital, Valhalla, NY.""}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': ""Department of Pediatrics, New York Medical College, Maria Fareri Children's Hospital, Valhalla, NY.""}, {'ForeName': 'Sarah B', 'Initials': 'SB', 'LastName': 'Kandil', 'Affiliation': 'Department of Pediatrics, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Marianne E', 'Initials': 'ME', 'LastName': 'Nellis', 'Affiliation': 'Department of Pediatrics, NY Presbyterian Hospital/Weill Cornell Medicine, New York, NY.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Shabanova', 'Affiliation': 'Department of Pediatrics, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Cicero T', 'Initials': 'CT', 'LastName': 'Silva', 'Affiliation': 'Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Joana A', 'Initials': 'JA', 'LastName': 'Tala', 'Affiliation': ""Pediatric Intensive Care Unit, Yale-New Haven Children's Hospital, New Haven, CT.""}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'McPartland', 'Affiliation': 'Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Philip C', 'Initials': 'PC', 'LastName': 'Spinella', 'Affiliation': 'Department of Pediatrics, Washington University in St. Louis, St. Louis, MO.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004848'] 1004,33576844,Effect of high intake of cod or salmon on serum total neopterin concentration: a randomised clinical trial.,"PURPOSE Primarily, to investigate the effect of high intake of cod (lean fish) or salmon (fatty fish) on serum concentration of total neopterin, a marker of cellular immune activation that is associated with cardiovascular disease. Second, to investigate effects of high cod/salmon intake on antioxidant vitamins and elements essential for activity of antioxidant enzymes. METHODS In this randomised clinical trial, 63 participants with overweight/obesity consumed 750 g/week of either Atlantic cod (N = 22) or Atlantic salmon (N = 22) or were instructed to continue their normal eating habits but avoid fish intake (Control group, N = 19) for 8 weeks. Food intake was recorded, and fasting serum were collected at baseline and endpoint. RESULTS Serum total neopterin concentration was reduced in the Cod group (median change - 2.65 (25th, 75th percentiles - 3.68, - 0.45) nmol/l, P = 0.018) but not in the Salmon group (median change 0.00 (25th, 75th percentiles - 4.15, 3.05) nmol/l, P = 0.59) when compared with the Control group after 8 weeks. The estimated daily intake of selenium, iron, magnesium and zinc were similar between all groups. Increased serum concentration of selenium was observed only after cod intake when compared to the Control group (P = 0.017). Changes in serum concentrations of copper, iron, magnesium, all-trans retinol, α-tocopherol and γ-tocopherol were similar between the groups. CONCLUSION A high intake of cod, but not of salmon, lowered serum total neopterin concentration when compared to the Control group. CLINICAL TRIAL REGISTRATION This trial was registered at clinicaltrials.gov as NCT02350595.",2021,Increased serum concentration of selenium was observed only after cod intake when compared to the Control group (P = 0.017).,['63 participants with overweight/obesity consumed 750\xa0g/week of either Atlantic cod (N\u2009=\u200922) or Atlantic salmon (N\u2009=\u200922) or were'],"['cod or salmon', 'cod (lean fish) or salmon (fatty fish', 'instructed to continue their normal eating habits but avoid fish intake (Control group, N\u2009=\u200919) for 8\xa0weeks']","['serum concentrations of copper, iron, magnesium, all-trans retinol, α-tocopherol and γ-tocopherol', 'Food intake', 'estimated daily intake of selenium, iron, magnesium and zinc', 'Serum total neopterin concentration', 'serum total neopterin concentration', 'serum concentration of selenium']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C0556978', 'cui_str': 'g/week'}, {'cui': 'C0328433', 'cui_str': 'Gadus morhua'}, {'cui': 'C0327949', 'cui_str': 'Salmo salar'}]","[{'cui': 'C0007465', 'cui_str': 'Cause of death'}, {'cui': 'C0036110', 'cui_str': 'Salmon'}, {'cui': 'C0016163', 'cui_str': 'Fish'}, {'cui': 'C0453017', 'cui_str': 'Fatty fish'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0566568', 'cui_str': 'Eating normal'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0233535', 'cui_str': 'Butting'}, {'cui': 'C0556216', 'cui_str': 'Fish intake'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009968', 'cui_str': 'Copper'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0068527', 'cui_str': 'Neopterin'}]",63.0,0.149291,Increased serum concentration of selenium was observed only after cod intake when compared to the Control group (P = 0.017).,"[{'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Helland', 'Affiliation': 'Department of Clinical Medicine, University of Bergen, Haukeland University Hospital, 5021, Bergen, Norway.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Bratlie', 'Affiliation': 'Department of Clinical Medicine, University of Bergen, Haukeland University Hospital, 5021, Bergen, Norway.'}, {'ForeName': 'Ingrid V', 'Initials': 'IV', 'LastName': 'Hagen', 'Affiliation': 'Department of Clinical Medicine, University of Bergen, Haukeland University Hospital, 5021, Bergen, Norway.'}, {'ForeName': 'Øivind', 'Initials': 'Ø', 'LastName': 'Midttun', 'Affiliation': 'Bevital AS, Jonas Lies veg 87, 5021, Bergen, Norway.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Sveier', 'Affiliation': 'Lerøy Seafood Group ASA, PO Box 7600, 5020, Bergen, Norway.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Mellgren', 'Affiliation': 'Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.'}, {'ForeName': 'Per Magne', 'Initials': 'PM', 'LastName': 'Ueland', 'Affiliation': 'Bevital AS, Jonas Lies veg 87, 5021, Bergen, Norway.'}, {'ForeName': 'Oddrun A', 'Initials': 'OA', 'LastName': 'Gudbrandsen', 'Affiliation': 'Department of Clinical Medicine, University of Bergen, Haukeland University Hospital, 5021, Bergen, Norway. oddrun.gudbrandsen@k1.uib.no.'}]",European journal of nutrition,['10.1007/s00394-021-02497-0'] 1005,33579857,One-Year Aerobic Exercise Reduced Carotid Arterial Stiffness and Increased Cerebral Blood Flow in Amnestic Mild Cognitive Impairment.,"BACKGROUND Central arterial stiffness and brain hypoperfusion are emerging risk factors of Alzheimer's disease (AD). Aerobic exercise training (AET) may improve central arterial stiffness and brain perfusion. OBJECTIVE To investigate the effects of AET on central arterial stiffness and cerebral blood flow (CBF) in patients with amnestic mild cognitive impairment (MCI), a prodromal stage of AD. METHODS This is a proof-of-concept, randomized controlled trial that assigned 70 amnestic MCI patients into a 12-month program of moderate-to-vigorous AET or stretching-and-toning (SAT) intervention. Carotid β-stiffness index and CBF were measured by color-coded duplex ultrasonography and applanation tonometry. Total CBF was measured as the sum of CBF from both the internal carotid and vertebral arteries, and divided by total brain tissue mass assessed with MRI to obtain normalized CBF (nCBF). Episodic memory and executive function were assessed using standard neuropsychological tests (CVLT-II and D-KEFS). Changes in cardiorespiratory fitness were measured by peak oxygen uptake (VO2peak). RESULTS Total 48 patients (29 in SAT and 19 in AET) were completed one-year training. AET improved VO2peak, decreased carotid β-stiffness index and CBF pulsatility, and increased nCBF. Changes in VO2peak were associated positively with changes in nCBF (r = 0.388, p = 0.034) and negatively with carotid β-stiffness index (r = -0.418, p = 0.007) and CBF pulsatility (r = -0.400, p = 0.014). Decreases in carotid β-stiffness were associated with increases in cerebral perfusion (r = -0.494, p = 0.003). AET effects on cognitive performance were minimal compared with SAT. CONCLUSION AET reduced central arterial stiffness and increased CBF which may precede its effects on neurocognitive function in patients with MCI.",2021,Episodic memory and executive function were assessed using standard neuropsychological tests (CVLT-II and D-KEFS).,"['patients with MCI', 'patients with amnestic mild cognitive impairment (MCI), a prodromal stage of AD', '70 amnestic MCI patients into a 12-month program of moderate-to', 'Amnestic Mild Cognitive Impairment', 'Total 48 patients (29 in SAT and 19 in AET']","['vigorous AET or stretching-and-toning (SAT) intervention', 'AET', 'Aerobic exercise training (AET']","['neurocognitive function', 'cognitive performance', 'central arterial stiffness', 'cardiorespiratory fitness', 'central arterial stiffness and cerebral blood flow (CBF', 'carotid β-stiffness index', 'cerebral perfusion', 'Total CBF', 'Carotid Arterial Stiffness and Increased Cerebral Blood Flow', 'Episodic memory and executive function', 'AET improved VO2peak, decreased carotid β-stiffness index and CBF pulsatility, and increased nCBF', 'nCBF', 'CBF pulsatility', 'peak oxygen uptake (VO2peak', 'Carotid β-stiffness index and CBF', 'carotid β-stiffness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C3494361', 'cui_str': 'Prodromal Stage'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0577317', 'cui_str': 'Pulsatility'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",70.0,0.0775787,Episodic memory and executive function were assessed using standard neuropsychological tests (CVLT-II and D-KEFS).,"[{'ForeName': 'Tsubasa', 'Initials': 'T', 'LastName': 'Tomoto', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Pharmacology, Physiology and Neuroscience, Rutgers University, Newark, NJ, USA.'}, {'ForeName': 'Benjamin Y', 'Initials': 'BY', 'LastName': 'Tseng', 'Affiliation': 'Department of Health and Kinesiology, The University of Texas at Tyler, Tyler, TX, USA.'}, {'ForeName': 'Evan P', 'Initials': 'EP', 'LastName': 'Pasha', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.'}, {'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'Cardim', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Tarumi', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.'}, {'ForeName': 'Linda S', 'Initials': 'LS', 'LastName': 'Hynan', 'Affiliation': 'Department of psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Munro Cullum', 'Affiliation': 'Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201456'] 1006,33579842,"Mixed-Methods Study on Caregiver Strain, Quality of Life, and Perceived Health.","BACKGROUND Caring for someone with dementia is associated with negative and positive experiences. There is little evidence based on large datasets. OBJECTIVE To present data around the experience of caring for someone with dementia, to identify support (emotional and practical) needs, and inform future service provision. METHODS A mixed-methods study embedded in the Promoting Activity, Independence and Stability in Early Dementia (PrAISED) Randomized Controlled Trial. We administered questionnaires on strain, quality of life (QoL), and perceived health to 301 caregivers and assessment of cognitive performance, depression, anxiety, and disability in activities of daily living to 301 participants with dementia. Data were analyzed through descriptive and modelling statistics. A subsample of 20 patient-caregiver dyads were qualitatively interviewed. Data around caregivers' experience of providing care were extrapolated and analyzed through inductive thematic analysis. RESULTS There were significant negative associations between caregiver strain and QoL (p < 0.01) and between caregiver age and QoL (p < 0.01), and significant positive associations between caregiver strain and disability (p < 0.01), cognitive impairment (p < 0.01), depression (p < 0.05), and anxiety of the person with dementia (p < 0.05). Older caregivers reported a lack of support, reinforced by their reluctance to seek help. All caregivers reported contradictory emotions associated with caring and accumulation of strain over time. CONCLUSION While there is recognition that it is essential to support caregivers, dedicated intervention programs, and support strategies to respond to the needs of older caregivers are still needed.",2021,"There were significant negative associations between caregiver strain and QoL (p <  0.01) and between caregiver age and QoL (p <  0.01), and significant positive associations between caregiver strain and disability (p <  0.01), cognitive impairment (p <  0.01), depression (p <  0.05), and anxiety of the person with dementia (p <  0.05).","['Older caregivers', '301 participants with dementia', 'A subsample of 20 patient-caregiver dyads']",[],"['caregiver strain and QoL', 'strain, quality of life (QoL), and perceived health to 301 caregivers and assessment of cognitive performance, depression, anxiety, and disability in activities of daily living', 'caregiver strain and disability', 'anxiety of the person with dementia', 'Caregiver Strain, Quality of Life, and Perceived Health', 'cognitive impairment', 'depression']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}]",301.0,0.155168,"There were significant negative associations between caregiver strain and QoL (p <  0.01) and between caregiver age and QoL (p <  0.01), and significant positive associations between caregiver strain and disability (p <  0.01), cognitive impairment (p <  0.01), depression (p <  0.05), and anxiety of the person with dementia (p <  0.05).","[{'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Di Lorito', 'Affiliation': 'Division of Rehabilitation, Ageing and Wellbeing, School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Bosco', 'Affiliation': 'Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Godfrey', 'Affiliation': 'Division of Rehabilitation, Ageing and Wellbeing, School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Dunlop', 'Affiliation': 'Division of Rehabilitation, Ageing and Wellbeing, School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Lock', 'Affiliation': 'Division of Rehabilitation, Ageing and Wellbeing, School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Pollock', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Rowan H', 'Initials': 'RH', 'LastName': 'Harwood', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'van der Wardt', 'Affiliation': 'Zentrum für Methodenwissenschaften und Gesundheitsforschung, Abteilung für Allgemeinmedizin, Präventive und Rehabilitative Medizin, Philipps-Universität Marburg, Marburg, Germany.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201257'] 1007,33598693,Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.,"In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid leukemia (AML). However, only 59% of patients in the midostaurin arm achieved protocol-specified complete remission (CR), and almost half of patients achieving CR relapsed. To explore underlying mechanisms of resistance, we studied patterns of clonal evolution in patients with FLT3-internal tandem duplications (ITD)-positive AML who were entered in the RATIFY or German-Austrian Acute Myeloid Leukemia Study Group 16-10 trial and received treatment with midostaurin. To this end, paired samples from 54 patients obtained at time of diagnosis and at time of either relapsed or refractory disease were analyzed using conventional Genescan-based testing for FLT3-ITD and whole exome sequencing. At the time of disease resistance or progression, almost half of the patients (46%) became FLT3-ITD negative but acquired mutations in signaling pathways (eg, MAPK), thereby providing a new proliferative advantage. In cases with FLT3-ITD persistence, the selection of resistant ITD clones was found in 11% as potential drivers of disease. In 32% of cases, no FLT3-ITD mutational change was observed, suggesting either resistance mechanisms bypassing FLT3 inhibition or loss of midostaurin inhibitory activity because of inadequate drug levels. In summary, our study provides novel insights into the clonal evolution and resistance mechanisms of FLT3-ITD-mutated AML under treatment with midostaurin in combination with intensive chemotherapy.",2021,"In 32% of cases, no FLT3-ITD mutational change was observed suggesting either resistance mechanisms bypassing FLT3-inhibition or loss of midostaurin inhibitory activity due to inadequate drug levels.","['patients with FLT3-internal tandem duplications (ITD) positive AML who were entered on the RATIFY or the AMLSG 16-10 trial and received treatment with', 'patients 18-59 years of age with FLT3-mutated acute myeloid leukemia (AML', '54 patients obtained at time of diagnosis and at time of either relapsed or refractory disease']",['midostaurin'],"['protocol-specified complete remission (CR', 'overall and event-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0251006', 'cui_str': 'FLT3 protein, human'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0075804', 'cui_str': 'TANDEM'}, {'cui': 'C0332597', 'cui_str': 'Duplication'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0526371', 'cui_str': 'midostaurin'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}]",,0.047767,"In 32% of cases, no FLT3-ITD mutational change was observed suggesting either resistance mechanisms bypassing FLT3-inhibition or loss of midostaurin inhibitory activity due to inadequate drug levels.","[{'ForeName': 'Laura K', 'Initials': 'LK', 'LastName': 'Schmalbrock', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Dolnik', 'Affiliation': 'Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Sibylle', 'Initials': 'S', 'LastName': 'Cocciardi', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Sträng', 'Affiliation': 'Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Frauke', 'Initials': 'F', 'LastName': 'Theis', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Jahn', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Ekaterina', 'Initials': 'E', 'LastName': 'Panina', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Tamara J', 'Initials': 'TJ', 'LastName': 'Blätte', 'Affiliation': 'Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Herzig', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Skambraks', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Frank G', 'Initials': 'FG', 'LastName': 'Rücker', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Verena I', 'Initials': 'VI', 'LastName': 'Gaidzik', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Paschka', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Fiedler', 'Affiliation': 'Section of Pneumology, Department of Oncology, Hematology and Bone Marrow Transplantation, Hubertus Wald University Cancer Center, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Helmut R', 'Initials': 'HR', 'LastName': 'Salih', 'Affiliation': 'Department of Hematology and Oncology, Eberhard Karls University Tübingen, Tübingen, Germany.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Wulf', 'Affiliation': 'Department of Hematology and Oncology, Georg-August-University Göttingen, Göttingen, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Schroeder', 'Affiliation': 'Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lübbert', 'Affiliation': 'Department of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Faculty of Medicine, Freiburg, Germany.'}, {'ForeName': 'Richard F', 'Initials': 'RF', 'LastName': 'Schlenk', 'Affiliation': 'National Center of Tumor Diseases, NCT-Trial Center, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'Felicitas', 'Initials': 'F', 'LastName': 'Thol', 'Affiliation': 'Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Heuser', 'Affiliation': 'Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Larson', 'Affiliation': 'Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.'}, {'ForeName': 'Arnold', 'Initials': 'A', 'LastName': 'Ganser', 'Affiliation': 'Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Hendrik G', 'Initials': 'HG', 'LastName': 'Stunnenberg', 'Affiliation': 'Department of Molecular Biology, Faculty of Science, Radboud University, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.'}, {'ForeName': 'Saverio', 'Initials': 'S', 'LastName': 'Minucci', 'Affiliation': 'Department of Experimental Oncology, European Institute of Oncology, Milan, Italy.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Stone', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and.'}, {'ForeName': 'Clara D', 'Initials': 'CD', 'LastName': 'Bloomfield', 'Affiliation': 'Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Döhner', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Konstanze', 'Initials': 'K', 'LastName': 'Döhner', 'Affiliation': 'Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Bullinger', 'Affiliation': 'Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Germany.'}]",Blood,['10.1182/blood.2020007626'] 1008,33594596,Double-lumen endotracheal tubes and bronchial blockers exhibit similar lung collapse physiology during lung isolation.,"PURPOSE Double-lumen endotracheal tubes (DL-ETT) and bronchial blockers (BB) are frequently used to allow one-lung ventilation (OLV) during video-assisted thoracic surgery (VATS). Recently, faster lung collapse has been documented with a BB than with a DL-ETT. The physiologic mechanisms behind this faster collapse remained unknown. We aimed to measure ambient air absorption (V resorb ) and intra-bronchial pressure (P airway ) into the non-ventilated lung during OLV using DL-ETT and BB. METHODS Patients undergoing VATS and OLV for lung resection were randomly assigned to have measurements made of V resorb or P airway within the non-ventilated lung using either a DL-ETT or BB. RESULTS Thirty-nine patients were included in the analyses. The mean (standard error of the mean [SEM]) V resorb was similar in the DL-ETT and BB groups [504 (85) vs 630 (86) mL, respectively; mean difference, 126; 95% confidence interval [CI], -128 to 380; P = 0.31]. The mean (SEM) P airway became progressively negative in the non-ventilated lung in both the DL-ETT and the BB groups reaching [-20 (5) and -31 (10) cmH 2 O, respectively; mean difference, -11; 95% CI, -34 to 12; P = 0.44] at the time of the pleural opening. CONCLUSIONS During OLV before pleural opening, entrainment of ambient air into the non-ventilated lung occurs when the lumen of the lung isolation device is kept open. This phenomenon is prevented by occluding the lumen of the isolation device before pleural opening, resulting in a progressive build-up of negative pressure in the non-ventilated lung. Future clinical studies are needed to confirm these physiologic results and their impact on lung collapse and operative outcomes. TRIAL REGISTRATION www.clinicaltrials.gov (NCT02919267); registered 28 September 2016.",2021,"2 O, respectively; mean difference, -11; 95% CI, -34 to 12; P = 0.44] at the time of the pleural opening. ","['Thirty-nine patients were included in the analyses', 'Patients undergoing VATS and OLV for lung resection']","['V resorb or P airway within the non-ventilated lung using either a DL-ETT or BB', 'Double-lumen endotracheal tubes (DL-ETT) and bronchial blockers (BB', 'Double-lumen endotracheal tubes and bronchial blockers']","['mean (standard error of the mean [SEM', 'ambient air absorption (V resorb ) and intra-bronchial pressure']","[{'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C0396565', 'cui_str': 'Lung excision'}]","[{'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C2584423', 'cui_str': 'Double lumen tracheobronchial tube'}, {'cui': 'C0205039', 'cui_str': 'Bronchial'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0205039', 'cui_str': 'Bronchial'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",39.0,0.0701886,"2 O, respectively; mean difference, -11; 95% CI, -34 to 12; P = 0.44] at the time of the pleural opening. ","[{'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Moreault', 'Affiliation': 'Department of Anesthesiology and Critical Care, Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'Etienne J', 'Initials': 'EJ', 'LastName': 'Couture', 'Affiliation': 'Department of Anesthesiology and Critical Care, Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'Steeve', 'Initials': 'S', 'LastName': 'Provencher', 'Affiliation': 'Department of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, QC, Canada.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Somma', 'Affiliation': 'Department of Anesthesiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, 2725, Chemin Sainte-Foy, Quebec City, QC, G1V 4G5, Canada.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Lohser', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Paula A', 'Initials': 'PA', 'LastName': 'Ugalde', 'Affiliation': 'Department of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, QC, Canada.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Lemieux', 'Affiliation': 'Department of Anesthesiology and Critical Care, Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Lellouche', 'Affiliation': 'Department of Anesthesiology and Critical Care, Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'Jean S', 'Initials': 'JS', 'LastName': 'Bussières', 'Affiliation': 'Department of Anesthesiology and Critical Care, Université Laval, Quebec City, QC, Canada. jbuss@criucpq.ulaval.ca.'}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-021-01938-y'] 1009,33615512,Intense Pulsed Light as a Treatment for Senile Purpura: A Pilot Study.,"BACKGROUND AND OBJECTIVES Senile purpura is a common condition characterized by recurrent ecchymoses in the elderly on the extensor surfaces of the forearms, hands, and legs. Our objective is to assess the efficacy and safety of a protocol using intense pulsed light (BBL; Sciton Inc., Palo Alto, CA) to improve the appearance of senile purpura on subjects' extensor forearms. STUDY DESIGN/MATERIALS AND METHODS Five subjects over 65 years of age, with ecchymotic lesions measuring over 1 cm on each forearm and five younger subjects under 35 years of age, without any ecchymotic lesions, were included in the study. The subjects were treated on one randomized forearm with a new intense pulsed light protocol for four weekly sessions. Photographs and subject questionnaires were taken weekly before each treatment as well as 1 month after all treatments. Skin biopsies were taken 1 day after the last of four weekly treatments. Histological analysis, including hematoxylin and eosin, elastic van Gieson, and Masson's Trichrome staining, were carried out to assess both the epidermal thickness and dermal connective tissue structure. The protocol consists of multiple passes using an intense pulsed light (BBL; Sciton Inc.) device in which the wavelength, filter, and fluence are adjusted for each step. Step 1 uses infrared light (800-1,400 nm), high intensity, a smooth adapter, and a constant motion technique. Step 2 employs a 590-nm filter with two different fluences and step 3 utilizes a 560-nm filter. The fluence of steps 2-3 is increased by 1 J each treatment if no side effects are noted. RESULTS Using a new intense pulsed light protocol in subjects with senile purpura, both the number and square area of ecchymoses on the treated arm were significantly reduced (P = 0.02 and P = 0.04, respectively, paired t test) as compared with the untreated arm at 1 month after four weekly treatments. Despite this pilot study including challenging cases of subjects on both inhaled and injected corticosteroids and blood thinners, all subjects with senile purpura had at least a 50% reduction in the total square area of their ecchymoses on their treated arm. There were no significant or long-lasting side effects, and all subjects reported satisfaction with the treatment with a desire to continue treatments on their control arm. Blinded evaluators were able to select 100% of the time in the subjects with senile purpura, which was the treated arm as compared with the control arm when reviewing photographs from 1 month after the last treatment. In addition, several subjects were noted to have a significant improvement in the appearance of hemosiderin deposition and photodamage. Histologically, intense pulsed light treatments significantly increased epidermal thickness in elderly subjects by 21.14% (P = 0.0153, two-tailed, paired t test), to levels comparable with young subjects. Such restoration is consistent with the other histological observations by blinded evaluators of more abundant and organized collagen fibers in the dermis and reduced aggregates of disorganized elastin fibers. CONCLUSION This new intense pulsed light protocol is safe and effective in improving the clinical appearance of senile purpura as well as preventing future lesions by improving the structure of the skin by increasing epidermal thickness and improving collagen and elastic fiber morphology. The treatment was well-tolerated, adverse effects were minimal, and there was high patient satisfaction. Lasers Surg. Med. 2020. © 2020 Wiley Periodicals LLC.",2021,This new intense pulsed light protocol is safe and effective in improving the clinical appearance of senile purpura as well as preventing future lesions by improving the structure of the skin by increasing epidermal thickness and improving collagen and elastic fiber morphology.,"['challenging cases of subjects on both inhaled and injected corticosteroids and blood thinners, all subjects with senile purpura had at least a 50% reduction in the total square area of their ecchymoses on their treated arm', ""subjects' extensor forearms"", 'Senile Purpura', 'subjects with senile purpura', 'Five subjects over 65 years of age, with ecchymotic lesions measuring over 1\u2009cm on each forearm and five younger subjects under 35 years of age, without any ecchymotic lesions, were included in the study']","['protocol using intense pulsed light (BBL; Sciton Inc., Palo Alto, CA', 'Intense Pulsed Light']","['appearance of hemosiderin deposition and photodamage', 'efficacy and safety', 'tolerated, adverse effects', 'epidermal thickness', 'Skin biopsies', 'long-lasting side effects']","[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C1720154', 'cui_str': 'Inject'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0149766', 'cui_str': 'Senile purpura'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0179336', 'cui_str': 'Blood bag'}]","[{'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0333629', 'cui_str': 'Hemosiderin pigmentation'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0014520', 'cui_str': 'Epidermis structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0150866', 'cui_str': 'Biopsy of skin'}, {'cui': 'C0205166', 'cui_str': 'Long'}]",5.0,0.0165073,This new intense pulsed light protocol is safe and effective in improving the clinical appearance of senile purpura as well as preventing future lesions by improving the structure of the skin by increasing epidermal thickness and improving collagen and elastic fiber morphology.,"[{'ForeName': 'Robyn', 'Initials': 'R', 'LastName': 'Siperstein', 'Affiliation': 'Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Siperstein Dermatology Group, 9897 Hagen Ranch Road, Boynton Beach, Florida, 33472.'}, {'ForeName': 'Tongyu C', 'Initials': 'TC', 'LastName': 'Wikramanayake', 'Affiliation': 'Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1600 NW 10th Avenue, RMSB 2023A, Miami, Florida, 33136.'}]",Lasers in surgery and medicine,['10.1002/lsm.23358'] 1010,33618060,Enhancing Reach Out and Read With a Video and Text Messages: A Randomized Trial in a Low-Income Predominantly Latino Sample.,"OBJECTIVE To determine the effect of adding a video and text messages to Reach Out and Read (ROR) on parent-reported literacy activities compared to the standard version. STUDY DESIGN We conducted a mixed methods hybrid type I effectiveness-implementation randomized trial in a community health center that serves low-income Latino families. We assessed shared reading frequency and the StimQ Reading subscale, at enrollment and 6-month follow-up and the StimQ Parent Verbal Responsivity subscale, Parent Reading Belief Inventory, and Survey of Wellbeing of Young Children-Milestones at follow-up. We randomized 160 parent-child dyads to ROR or ROR plus video and text messages (enhanced ROR). We collected process data on ROR and engagement with texts. We interviewed 15 enhanced ROR participants. We analyzed quantitative data using regression and qualitative data using immersion/crystallization. RESULTS One hundred thirty-seven parent-child dyads completed the study (87% Latino, mean child age 9 months). We found differences in the StimQ Reading subscale (B = 0.32; P = .034) and marginal differences in attitudes about reading favoring enhanced ROR. Between-group differences for shared reading frequency, verbal responsivity, and developmental delay were not significant. Qualitative themes provided insight into the enhanced ROR including how it encouraged parents, remaining barriers like competing priorities and lack of social support, and unanticipated benefits (ie, parent appreciation for attention on their families' wellbeing). CONCLUSIONS A video and text message enhancement to ROR resulted in modest improvements in the home literacy environment over ROR alone. Additional strategies are needed to overcome potent barriers faced by low-income families.",2021,We found differences in the StimQ Reading subscale (B=0.32; p=0.034) and marginal differences in attitudes about reading favoring enhanced ROR.,"['137 parent-child dyads completed the study (87% Latino', '15 enhanced ROR participants', 'community health center that serves low-income Latino families', 'Low-income Predominantly Latino Sample']","['Video and Text Messages', 'video and text messages to Reach Out and Read (ROR', 'ROR or ROR plus video and text messages (enhanced ROR']","['shared reading frequency, verbal responsivity, and developmental delay', 'StimQ Reading subscale', 'StimQ Parent Verbal Responsivity subscale']","[{'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0009469', 'cui_str': 'Satellite Centers'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0424605', 'cui_str': 'Developmental delay'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]",160.0,0.081781,We found differences in the StimQ Reading subscale (B=0.32; p=0.034) and marginal differences in attitudes about reading favoring enhanced ROR.,"[{'ForeName': 'Manuel E', 'Initials': 'ME', 'LastName': 'Jimenez', 'Affiliation': ""The Department of Pediatrics, Rutgers Robert Wood Johnson Medical School (ME Jimenez, D Lima, and PA Shelton), New Brunswick, NJ; Boggs Center on Developmental Disabilities, Rutgers Robert Wood Johnson Medical School (ME Jimenez), New Brunswick, NJ; Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School (ME Jimenez), New Brunswick, NJ; Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School (ME Jimenez, BF Crabtree, SV Hudson, and M Pellerano), New Brunswick, NJ; Children's Specialized Hospital (ME Jimenez), New Brunswick, NJ. Electronic address: jimenema@rwjms.rutgers.edu.""}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Crabtree', 'Affiliation': 'Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School (ME Jimenez, BF Crabtree, SV Hudson, and M Pellerano), New Brunswick, NJ.'}, {'ForeName': 'Shawna V', 'Initials': 'SV', 'LastName': 'Hudson', 'Affiliation': 'Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School (ME Jimenez, BF Crabtree, SV Hudson, and M Pellerano), New Brunswick, NJ.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Mendelsohn', 'Affiliation': 'NYU Grossman School of Medicine (AL Mendelsohn), New York, NY.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lima', 'Affiliation': 'The Department of Pediatrics, Rutgers Robert Wood Johnson Medical School (ME Jimenez, D Lima, and PA Shelton), New Brunswick, NJ.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Shelton', 'Affiliation': 'The Department of Pediatrics, Rutgers Robert Wood Johnson Medical School (ME Jimenez, D Lima, and PA Shelton), New Brunswick, NJ.'}, {'ForeName': 'Julissa', 'Initials': 'J', 'LastName': 'Veras', 'Affiliation': 'School of Medicine and Dentistry University of Rochester (J Veras), Rochester, NY.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': 'Rutgers School of Public Health (Y Lin), Piscataway, NJ.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pellerano', 'Affiliation': 'Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School (ME Jimenez, BF Crabtree, SV Hudson, and M Pellerano), New Brunswick, NJ.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Morrow', 'Affiliation': 'Rutgers Graduate School of Education (L Morrow), New Brunswick, NJ.'}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'Strom', 'Affiliation': 'Rutgers Biomedical Health Sciences (BL Strom), Newark, NJ.'}]",Academic pediatrics,['10.1016/j.acap.2021.02.011'] 1011,33625153,Effect of Tranexamic Acid Administration on Postoperative Ecchymosis and Edema in Excision of Lipomas.,"BACKGROUND Previous studies have shown that systemic tranexamic acid reduces bleeding during soft tissue surgeries and reduces postoperative ecchymosis and edema experienced by surgical patients. OBJECTIVE To evaluate the effect of postoperative tranexamic acid administration on the reduction of ecchymosis and edema after lipoma surgery. MATERIALS AND METHODS A total of 40 patients who underwent lipoma excision were included in the comparative analysis. In the tranexamic acid group (n = 20), 1 g of tranexamic acid was administered daily for 5 consecutive postoperative days. Tranexamic acid was not administered to the control group (n = 20). The severity of ecchymosis and edema at the first visit after surgery was rated on a 4-point scale by 2 blinded dermatologists. RESULTS The mean interval of the initial visit after surgery was 1.1 ± 0.5 (range: 1-4) days. Mean ecchymosis scores were significantly lower in the tranexamic acid group (0.5 ± 0.8) than in the control group (1.2 ± 1.0) (p < .05). No statistical difference was seen in mean edema scores between groups (0.5 ± 0.6 in tranexamic acid vs 0.7 ± 0.8 in control). CONCLUSION We observed that postoperative administration of tranexamic acid significantly decreased ecchymosis in lipoma excision.",2021,"No statistical difference was seen in mean edema scores between groups (0.5 ± 0.6 in tranexamic acid vs 0.7 ± 0.8 in control). ",['40 patients who underwent lipoma excision'],"['tranexamic acid', 'systemic tranexamic acid', 'postoperative tranexamic acid', 'Tranexamic acid', 'Tranexamic Acid Administration']","['Postoperative Ecchymosis and Edema in Excision of Lipomas', 'ecchymosis', 'mean interval of the initial visit', 'mean edema scores', 'severity of ecchymosis and edema', 'ecchymosis and edema', 'Mean ecchymosis scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0554640', 'cui_str': 'Excision of lipoma'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0013491', 'cui_str': 'Ecchymosis'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0554640', 'cui_str': 'Excision of lipoma'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",40.0,0.0657481,"No statistical difference was seen in mean edema scores between groups (0.5 ± 0.6 in tranexamic acid vs 0.7 ± 0.8 in control). ","[{'ForeName': 'Young-Jun', 'Initials': 'YJ', 'LastName': 'Choi', 'Affiliation': 'Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hyeon Jeong', 'Initials': 'HJ', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'Heun Joo', 'Initials': 'HJ', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Ga-Young', 'Initials': 'GY', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Won-Serk', 'Initials': 'WS', 'LastName': 'Kim', 'Affiliation': ''}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002680'] 1012,33575989,Intravenous Methylprednisolone Versus Oral Prednisolone for West Syndrome: A Randomized Open-Label Trial.,"OBJECTIVE To compare intravenous methylprednisolone (IVMP) with oral prednisolone (OP) for the treatment of West syndrome. METHODS In this randomized, open-label trial, children aged 2 to 30 mo presenting with epileptic spasms with hypsarrhythmia or its variants on EEG were randomized to receive either IVMP (30 mg/kg/d for 3 d followed by oral prednisolone taper) or OP (4 mg/kg/d for two weeks followed by taper). The primary outcome measure was spasms cessation on day 14. Secondary outcomes included time to response, electroclinical remission at 2 and 6 wk, and frequency of adverse effects. ( ClinicalTrials.gov Identifier: NCT03876444). RESULTS Sixty children were enrolled; 31 in the IVMP and 29 in the OP arm. Proportion of children achieving spasms cessation at day 14 was similar in both groups (54.8% versus 68.9%, p = 0.26). Time to achieve remission was lower in the IVMP group (mean 5.4 ± 0.9 versus 9.5 ± 2.6 d, p < 0.0001). Electroclinical remission at 2 wk was similar in both groups (51.6% versus 44.8%, p = 0.59) but lower at 6 wk in the IVMP group (45.2% versus 75.9%, p < 0.015). Adverse effects like sleep disturbance, irritability and hypertension were more common in IVMP group whereas weight gain was more common in the OP group. CONCLUSIONS There was no significant difference in spasms cessation between the groups on day 14 although remission was higher at 6 wk in OP group. Our study suggests that OP was better than IVMP in efficacy and sustained remission with fewer adverse effects.",2021,There was no significant difference in spasms cessation between the groups on day 14 although remission was higher at 6 wk in OP group.,"['West syndrome', 'children aged 2 to 30 mo presenting with epileptic spasms with hypsarrhythmia or its variants on EEG', 'West Syndrome', 'Sixty children were enrolled; 31 in the IVMP and 29 in the OP arm']","['IVMP', 'Prednisolone', 'methylprednisolone (IVMP) with oral prednisolone (OP', 'Intravenous Methylprednisolone', 'OP']","['Time to achieve remission', 'Proportion of children achieving spasms cessation', 'Adverse effects like sleep disturbance, irritability and hypertension', 'time to response, electroclinical remission at 2 and 6 wk, and frequency of adverse effects', 'Electroclinical remission', 'spasms cessation on day 14', 'weight gain', 'spasms cessation']","[{'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1527366', 'cui_str': 'Salaam Seizures'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0358513', 'cui_str': 'Prednisolone-containing product in oral dose form'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0358513', 'cui_str': 'Prednisolone-containing product in oral dose form'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0026821', 'cui_str': 'Cramp'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0022107', 'cui_str': 'Feeling irritable'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}]",60.0,0.164485,There was no significant difference in spasms cessation between the groups on day 14 although remission was higher at 6 wk in OP group.,"[{'ForeName': 'Dipti', 'Initials': 'D', 'LastName': 'Kapoor', 'Affiliation': ""Division of Neurology, Department of Pediatrics, Kalawati Saran Children's Hospital and Lady Hardinge Medical College, New Delhi, 110001, India.""}, {'ForeName': 'Suvasini', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': ""Division of Neurology, Department of Pediatrics, Kalawati Saran Children's Hospital and Lady Hardinge Medical College, New Delhi, 110001, India. sharma.suvasini@gmail.com.""}, {'ForeName': 'Divyani', 'Initials': 'D', 'LastName': 'Garg', 'Affiliation': 'Department of Neurology, Smt. Sucheta Kriplani Hospital and Lady Hardinge Medical College, New Delhi, India.'}, {'ForeName': 'Sukla', 'Initials': 'S', 'LastName': 'Samaddar', 'Affiliation': ""Division of Neurology, Department of Pediatrics, Kalawati Saran Children's Hospital and Lady Hardinge Medical College, New Delhi, 110001, India.""}, {'ForeName': 'Isha', 'Initials': 'I', 'LastName': 'Panda', 'Affiliation': ""Division of Neurology, Department of Pediatrics, Kalawati Saran Children's Hospital and Lady Hardinge Medical College, New Delhi, 110001, India.""}, {'ForeName': 'Bijoy', 'Initials': 'B', 'LastName': 'Patra', 'Affiliation': ""Division of Neurology, Department of Pediatrics, Kalawati Saran Children's Hospital and Lady Hardinge Medical College, New Delhi, 110001, India.""}, {'ForeName': 'Sharmila B', 'Initials': 'SB', 'LastName': 'Mukherjee', 'Affiliation': ""Division of Neurology, Department of Pediatrics, Kalawati Saran Children's Hospital and Lady Hardinge Medical College, New Delhi, 110001, India.""}, {'ForeName': 'Harish K', 'Initials': 'HK', 'LastName': 'Pemde', 'Affiliation': ""Division of Neurology, Department of Pediatrics, Kalawati Saran Children's Hospital and Lady Hardinge Medical College, New Delhi, 110001, India.""}]",Indian journal of pediatrics,['10.1007/s12098-020-03630-3'] 1013,33575971,Increase in Daily Steps During the Early Phase of a Physical Activity Intervention for Type 2 Diabetes as a Predictor of Intervention Outcome.,"BACKGROUND This pilot study aimed to test whether increase in daily steps and day-to-day consistency in daily steps during the first several weeks of a physical activity intervention predicted outcomes. METHODS This was a secondary analysis from two concurrent studies testing a positive psychology-motivational interviewing intervention to increase physical activity and positive affect in individuals with type 2 diabetes. Steps were measured with accelerometers at study assessments (baseline, end-of-treatment, and 8-week follow-up) and were measured daily throughout the intervention by participants using provided pedometers. We calculated change in steps from intervention week 1 to week 3, along with variability in daily steps over the first 3 weeks, using the best fitting regression line modeling their change. Multiple regression analyses tested whether these predictors were associated with change in physical activity at the end of treatment and at 8-week follow-up. Additionally, we explored the utility of specific cutoffs (e.g., 500 steps) for early step change using a minimum p-value approach. RESULTS In 52 participants, larger step increases by week 3 predicted activity increase at end-of-treatment and follow-up. Variability in early steps was not associated with outcomes. Early increase cutoffs of 500 and 2000 steps may have practical relevance. CONCLUSION Early response to a physical activity intervention appears to be a useful predictor of outcome and could be used to identify those unlikely to succeed in a given intervention early in treatment. TRIAL REGISTRATION ClinicalTrials.gov identifiers NCT03150199 and NCT03001999.",2021,"In 52 participants, larger step increases by week 3 predicted activity increase at end-of-treatment and follow-up.",['individuals with type 2 diabetes'],"['Physical Activity Intervention', 'positive psychology-motivational interviewing intervention', 'physical activity intervention']",['physical activity'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1510628', 'cui_str': 'Positive Psychology'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0427616,"In 52 participants, larger step increases by week 3 predicted activity increase at end-of-treatment and follow-up.","[{'ForeName': 'Emily H', 'Initials': 'EH', 'LastName': 'Feig', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA. efeig@mgh.harvard.edu.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Harnedy', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Celano', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.'}, {'ForeName': 'Jeff C', 'Initials': 'JC', 'LastName': 'Huffman', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.'}]",International journal of behavioral medicine,['10.1007/s12529-021-09966-0'] 1014,33580351,Maxillary dentoskeletal outcomes of the expander with differential opening and the fan-type expander: a randomized controlled trial.,"OBJECTIVES The aim of this study was to compare the maxillary dentoskeletal outcomes of the expander with differential opening (EDO) and the fan-type expander (FE). MATERIAL AND METHODS Forty-eight patients with maxillary arch constriction in the mixed dentition were randomly allocated into EDO and FE groups. Cone-beam computed tomography scans were acquired before and after expansion. Linear and angular three-dimensional changes were assessed after cranial base superimposition using the ITK-SNAP and the 3D Slicer software. T or Mann-Whitney U tests were used for intergroup comparisons (P<0.05). RESULTS The EDO group comprised 24 patients treated with the EDO (13 female, 11 male; 7.6 years). The FE group comprised 24 patients treated with the FE (14 female, 10 male; 7.8 years). Skeletal lateral displacements were greater in the EDO group with greater expansion in the orbital, nasal cavity, zygomatic bone, and palate regions (mean intergroup differences of 0.4, 0.8, 0.9, and 1.1 mm, respectively). Intercanine expansion and canine buccal inclination were greater in the FE group, while intermolar distance changes and molar buccal inclination were greater in the EDO group. Similar changes were observed for vertical and anteroposterior displacements and palatal plane rotation. CONCLUSIONS The EDO produced greater transverse skeletal expansion compared to the FE, with similar vertical and anteroposterior effects. Dental changes were greater in the molar region for patients treated with the EDO and in the canine region for patients treated with the FE. CLINICAL RELEVANCE The EDO and the FE are capable of producing skeletal changes in the mixed dentition. The decision between both expanders will depend on the amount of expansion required in the molar region and in the nasomaxillary complex. TRIAL REGISTRATION The trial was registered at ClinicalTrials.gov , under the identifier NCT03705871.",2021,"Skeletal lateral displacements were greater in the EDO group with greater expansion in the orbital, nasal cavity, zygomatic bone, and palate regions (mean intergroup differences of 0.4, 0.8, 0.9, and 1.1 mm, respectively).","['Forty-eight patients with maxillary arch constriction in the mixed dentition', '24 patients treated with the FE (14 female, 10 male; 7.8 years', '24 patients treated with the EDO (13 female, 11 male; 7.6 years']","['FE', 'EDO and FE', 'expander with differential opening (EDO) and the fan-type expander (FE', 'T or Mann-Whitney', 'Cone-beam computed tomography scans']","['transverse skeletal expansion', 'Intercanine expansion and canine buccal inclination', 'orbital, nasal cavity, zygomatic bone, and palate regions', 'intermolar distance changes and molar buccal inclination', 'Dental changes', 'Skeletal lateral displacements', 'vertical and anteroposterior displacements and palatal plane rotation']","[{'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0230467', 'cui_str': 'Structure of arch of foot'}, {'cui': 'C0009813', 'cui_str': 'Constriction'}, {'cui': 'C0011444', 'cui_str': 'Mixed dentition'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0441039', 'cui_str': 'Fan'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0443199', 'cui_str': 'Differential'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0441039', 'cui_str': 'Fan'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0443199', 'cui_str': 'Differential'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}]","[{'cui': 'C0205106', 'cui_str': 'Transverse plane'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0699036', 'cui_str': 'Orbital'}, {'cui': 'C0027423', 'cui_str': 'Nasal cavity structure'}, {'cui': 'C0043539', 'cui_str': 'Zygomatic bone structure'}, {'cui': 'C0700374', 'cui_str': 'Palatal'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0333046', 'cui_str': 'Lateral displacement'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}]",48.0,0.0697716,"Skeletal lateral displacements were greater in the EDO group with greater expansion in the orbital, nasal cavity, zygomatic bone, and palate regions (mean intergroup differences of 0.4, 0.8, 0.9, and 1.1 mm, respectively).","[{'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'Massaro', 'Affiliation': 'Department of Orthodontics, Bauru Dental School, University of São Paulo, Alameda Octávio Pinheiro Brisolla 9-75, Bauru, SP, 17012-901, Brazil. camilamassaro@usp.br.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Garib', 'Affiliation': 'Department of Orthodontics, Bauru Dental School and Hospital for Rehabilitation of Craniofacial Anomalies, University of São Paulo, Alameda Octávio Pinheiro Brisolla 9-75, Bauru, SP, 17012-901, Brazil.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Cevidanes', 'Affiliation': 'Department of Orthodontics and Pediatric Dentistry, School of Dentistry, University of Michigan, 1011 N University Avenue, Ann Arbor, MI, 48109, USA.'}, {'ForeName': 'Guilherme', 'Initials': 'G', 'LastName': 'Janson', 'Affiliation': 'Department of Orthodontics, Bauru Dental School, University of São Paulo, Alameda Octávio Pinheiro Brisolla 9-75, Bauru, SP, 17012-901, Brazil.'}, {'ForeName': 'Marilia', 'Initials': 'M', 'LastName': 'Yatabe', 'Affiliation': 'Department of Orthodontics and Pediatric Dentistry, School of Dentistry, University of Michigan, 1011 N University Avenue, Ann Arbor, MI, 48109, USA.'}, {'ForeName': 'José Roberto Pereira', 'Initials': 'JRP', 'LastName': 'Lauris', 'Affiliation': 'Department of Community Health, Bauru Dental School, University of São Paulo, Alameda Octávio Pinheiro Brisolla 9-75, Bauru, SP, 17012-901, Brazil.'}, {'ForeName': 'Antonio Carlos', 'Initials': 'AC', 'LastName': 'Ruellas', 'Affiliation': 'Department of Orthodontics and Pediatric Dentistry, School of Dentistry, University of Michigan, 1011 N University Avenue, Ann Arbor, MI, 48109, USA.'}]",Clinical oral investigations,['10.1007/s00784-021-03832-9'] 1015,33587381,Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program.,"BACKGROUND Pivotal studies of approved botulinum toxin type A (BoNTA) formulations for treatment of glabellar lines have mostly included treatment-naive participants, and the impact of prior BoNTA treatment on efficacy and safety is not well documented. OBJECTIVE To evaluate whether prior BoNTA treatment affects efficacy, duration of response, and tolerability for treatment of glabellar lines. METHODS Adults with moderate or severe glabellar lines treated with DaxibotulinumtoxinA for Injection (DAXI) or placebo from the randomized, double-blind SAKURA 1/2 trials and the open-label SAKURA 3 safety study were analyzed by prior BoNTA treatment status. Efficacy was evaluated using investigator and participant assessments. RESULTS In this analysis, 609 participants (52.2% BoNTA-experienced) from the SAKURA 1/2 trials and 2,380 (38.0% BoNTA-experienced) from the SAKURA 3 study were evaluated. Proportion of participants with none or mild glabellar lines and duration of response were similar between the BoNTA-naive and BoNTA-experienced cohorts in both the DAXI and placebo groups. The incidence of adverse events was also comparable regardless of prior BoNTA treatment status. CONCLUSION Efficacy and tolerability were similar with DAXI and placebo regardless of prior BoNTA treatment. Assuming an appropriate washout is observed, future BoNTA trials should enroll both treatment-experienced and treatment-naive participants to reflect clinical practice.",2021,Proportion of participants with none or mild glabellar lines and duration of response were similar between the BoNTA-naive and BoNTA-experienced cohorts in both the DAXI and placebo groups.,"['Adults with moderate or severe glabellar lines treated with', '609 participants (52.2% BoNTA-experienced) from the SAKURA 1/2 trials and 2,380 (38.0% BoNTA-experienced) from the SAKURA 3 study were evaluated']","['Botulinum Toxin Treatment', 'DaxibotulinumtoxinA for Injection (DAXI) or placebo', 'DAXI and placebo', 'botulinum toxin type A (BoNTA) formulations', 'DaxibotulinumtoxinA']","['Efficacy', 'Efficacy and tolerability', 'efficacy, duration of response, and tolerability', 'mild glabellar lines and duration of response', 'adverse events']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0442019', 'cui_str': 'Glabellar'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C4517801', 'cui_str': '52.2'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0580272', 'cui_str': '1/2'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0442019', 'cui_str': 'Glabellar'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",3.0,0.179842,Proportion of participants with none or mild glabellar lines and duration of response were similar between the BoNTA-naive and BoNTA-experienced cohorts in both the DAXI and placebo groups.,"[{'ForeName': 'Joel L', 'Initials': 'JL', 'LastName': 'Cohen', 'Affiliation': 'AboutSkin Dermatology and DermSurgery PC, Greenwood Village, Colorado.'}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Green', 'Affiliation': 'Department of Dermatology, George Washington University School of Medicine, Washington, District of Columbia.'}, {'ForeName': 'Kenneth R', 'Initials': 'KR', 'LastName': 'Beer', 'Affiliation': 'Beer Dermatology, West Palm Beach, Florida.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Revance Therapeutics, Inc., Newark, California.'}, {'ForeName': 'Conor J', 'Initials': 'CJ', 'LastName': 'Gallagher', 'Affiliation': 'Revance Therapeutics, Inc., Newark, California.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002877'] 1016,33587369,"A Randomized, Controlled, Evaluator-Blinded, Multi-Center Study of Hyaluronic Acid Filler Effectiveness and Safety in Lip Fullness Augmentation.","BACKGROUND HARK was recently approved in the US for lip augmentation and correction of upper perioral rhytids. OBJECTIVE To demonstrate noninferiority of HARK versus a control (HAJV) in lip fullness augmentation at Week 8 after last injection (blinded evaluation). Secondary objectives were to evaluate the effectiveness and safety of HARK in lip fullness augmentation and correction of upper perioral rhytids. METHODS AND MATERIALS Treatment with HARK or control (randomized 2:1) was administered on Day 1 in this 48-week, evaluator-blinded study with optional touch-up at Week 4. Primary endpoint was change from baseline to Week 8 in lip fullness. Secondary endpoints included lip fullness, wrinkle severity, aesthetic improvement, subject satisfaction, adverse events, and local tolerability (subject diary entries). RESULTS The primary objective was met; HARK was noninferior to control in lip fullness augmentation at Week 8. Lip fullness and wrinkle severity improvement persisted at Week 48, and was accompanied by high aesthetic improvement and subject satisfaction scores. The mean volume of HARK injected was approximately 20% lower than control. Treatment-related adverse events and local tolerability symptoms were predominantly mild and transient. CONCLUSION HARK was noninferior to control in lip fullness augmentation at Week 8, well-tolerated, and effective throughout this 48-week study.",2021,"Secondary endpoints included lip fullness, wrinkle severity, aesthetic improvement, subject satisfaction, adverse events, and local tolerability (subject diary entries). ",['Lip Fullness Augmentation'],"['Hyaluronic Acid', 'HARK', 'HARK versus a control (HAJV']","['lip fullness, wrinkle severity, aesthetic improvement, subject satisfaction, adverse events, and local tolerability (subject diary entries', 'aesthetic improvement and subject satisfaction scores', 'Lip fullness and wrinkle severity improvement', 'adverse events and local tolerability symptoms', 'change from baseline to Week 8 in lip fullness', 'mean volume of HARK', 'effectiveness and safety of HARK in lip fullness augmentation and correction of upper perioral rhytids']","[{'cui': 'C0023759', 'cui_str': 'Lip structure'}, {'cui': 'C0439650', 'cui_str': 'Fullness'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}]","[{'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0023759', 'cui_str': 'Lip structure'}, {'cui': 'C0439650', 'cui_str': 'Fullness'}, {'cui': 'C0037301', 'cui_str': 'Wrinkled skin'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0277938', 'cui_str': 'Circumoral rhytides'}]",,0.103697,"Secondary endpoints included lip fullness, wrinkle severity, aesthetic improvement, subject satisfaction, adverse events, and local tolerability (subject diary entries). ","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Weiss', 'Affiliation': 'Maryland Dermatology, Laser, Skin and Vein Institute, Hunt Valley, Maryland.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Beer', 'Affiliation': 'Research Institute of SouthEast, West Palm Beach, Florida.'}, {'ForeName': 'Sue E', 'Initials': 'SE', 'LastName': 'Cox', 'Affiliation': 'Aesthetic Solutions, Chapel Hill, North Carolina.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Palm', 'Affiliation': 'Art of Skin Maryland, Solana Beach, California.'}, {'ForeName': 'Joely', 'Initials': 'J', 'LastName': 'Kaufman-Janette', 'Affiliation': 'Skin Research Institute, LLC, Coral Gables, Florida.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Bassichis', 'Affiliation': 'Center for Advanced Clinical Research, Dallas, Texas.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Biesman', 'Affiliation': 'Brian S. Biesman, Nashville, Tennessee.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Joseph', 'Affiliation': 'Clinical Testing of Beverly Hills, Encino, California.'}, {'ForeName': 'Birgitta', 'Initials': 'B', 'LastName': 'Almegård', 'Affiliation': 'Galderma Aesthetics, Clinical Development, Uppsala, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Nilsson', 'Affiliation': 'Galderma Aesthetics, Clinical Development, Uppsala, Sweden.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Edwartz', 'Affiliation': 'Galderma Aesthetics, Global Medical Affairs, Uppsala, Sweden.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002856'] 1017,33587993,Understanding the Role of Knowledge in Advance Care Planning Engagement.,"CONTEXT Advance care planning remains underutilized. A better understanding of the role of education in promoting engagement is needed. OBJECTIVES To examine advance care planning knowledge and its relationship to engagement in middle-aged and older adults. METHODS This cross-sectional study utilized baseline data from 921 participants age ≥55 years enrolled in the STAMP randomized controlled trial, including a knowledge scale consisting of seven questions regarding the purpose and mechanisms of advance care planning and measures of participation. RESULTS Only 11.9% of participants answered all 7 questions correctly, and 25.6% of participants answered ≤3 correctly (defined as ""low knowledge""). Low knowledge was independently associated with male gender (odds ratio [OR] 2.1, 95% confidence interval [CI]: 1.5, 3.0), non-white race (OR 1.5, 95% CI: 1.1, 2.2), older age (OR 2.2, 95% CI: 1.4, 3.4), lower income (OR 1.5, 95% CI: 1.1, 2.1), and lower education level (OR 2.9, 95% CI: 2.0, 4.1). Higher knowledge was independently associated with communicating with a loved one about quality versus quantity of life (OR 1.7, 95% CI: 1.2, 2.4) and with living will completion (OR 1.6, 95% CI: 1.0, 2.5), but not with healthcare agent assignment. Factors including race and education remained associated with engagement after accounting for knowledge. CONCLUSION Knowledge deficits regarding advance care planning are common and associated with the same sociodemographic factors linked to other healthcare disparities. While improving knowledge is an important component of intervention, it is unlikely sufficient in and of itself to increase engagement.",2021,"Low knowledge was independently associated with male gender (OR 2.1, 95% CI: 1.5, 3.0), non-white race (OR 1.5, 95% CI: 1.1, 2.2), older age (OR 2.2, 95% CI: 1.4, 3.4), lower income (OR 1.5, 95% CI: 1.1, 2.1), and lower education level (OR 2.9, 95% CI: 2.0, 4.1).","['middle-aged and older adults', '921 participants age ≥55 years enrolled in the']",['STAMP'],"['lower education level', 'Low knowledge']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],"[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",921.0,0.0577878,"Low knowledge was independently associated with male gender (OR 2.1, 95% CI: 1.5, 3.0), non-white race (OR 1.5, 95% CI: 1.1, 2.2), older age (OR 2.2, 95% CI: 1.4, 3.4), lower income (OR 1.5, 95% CI: 1.1, 2.1), and lower education level (OR 2.9, 95% CI: 2.0, 4.1).","[{'ForeName': 'Laura I', 'Initials': 'LI', 'LastName': 'van Dyck', 'Affiliation': 'Department of Medicine, School of Medicine, Yale University (L.I.v.D., T.R.F.), New Haven, Connecticut, USA. Electronic address: laura.vandyck@yale.edu.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Paiva', 'Affiliation': 'Cancer Prevention Research Center, College of Health Sciences, University of Rhode Island (A.P., C.A.R.), Kingston, Rhode Island, USA; Psychology Department, College of Health Sciences, University of Rhode Island (A.P., C.A.R.), Kingston, Rhode Island, USA.'}, {'ForeName': 'Colleen A', 'Initials': 'CA', 'LastName': 'Redding', 'Affiliation': 'Cancer Prevention Research Center, College of Health Sciences, University of Rhode Island (A.P., C.A.R.), Kingston, Rhode Island, USA; Psychology Department, College of Health Sciences, University of Rhode Island (A.P., C.A.R.), Kingston, Rhode Island, USA.'}, {'ForeName': 'Terri R', 'Initials': 'TR', 'LastName': 'Fried', 'Affiliation': 'Department of Medicine, School of Medicine, Yale University (L.I.v.D., T.R.F.), New Haven, Connecticut, USA; Clinical Epidemiology Research Center, Veterans Affairs Connecticut Healthcare System (T.R.F.), West Haven, Connecticut, USA.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2021.02.011'] 1018,33601996,Predictive Capacity of Pulmonary Function Tests for Acute Mountain Sickness.,"Small, Elan, Nicholas Juul, David Pomeranz, Patrick Burns, Caleb Phillips, Mary Cheffers, and Grant S. Lipman. Predictive capacity of pulmonary function tests for acute mountain sickness. High Alt Med Biol . 22: 193-200, 2021. Background: Pulmonary function as measured by spirometry has been investigated at altitude with heterogenous results, though data focused on spirometry and acute mountain sickness (AMS) are limited. The objective of this study was to investigate the capacity of pulmonary function tests (PFTs) to predict the development of AMS. Materials and Methods: This study was a blinded prospective observational study run during a randomized controlled trial comparing acetazolamide, budesonide, and placebo for AMS prevention on White Mountain, CA. Spirometry measurements of forced expiratory volume in one second (FEV 1 ), forced vital capacity (FVC), and peak expiratory flow were taken at a baseline altitude of 1,250 m, and the evening of and morning after ascent to 3,810 m. Measurements were assessed for correlation with AMS. Results: One hundred three participants were analyzed with well-matched baseline demographics and AMS incidence of 75 (73%) and severe AMS of 48 (47%). There were no statistically significant associations between changes in mean spirometry values on ascent to high altitude with incidence of AMS or severe AMS. Lake Louise Questionnaire scores were negatively correlated with FVC ( r  = -0.31) and FEV 1 ( r  = -0.29) the night of ascent. Baseline PFT had a predictive accuracy of 65%-73% for AMS, with a receiver operating characteristic of 0.51-0.65. Conclusions: Spirometry did not demonstrate statistically significant changes on ascent to high altitude, nor were there significant associations with incidence of AMS or severe AMS. Low-altitude spirometry did not accurately predict development of AMS, and it should not be recommended for risk stratification.",2021,There were no statistically significant associations between changes in mean spirometry values on ascent to high altitude with incidence of AMS or severe AMS.,"['White Mountain, CA', 'One hundred three participants were analyzed with well-matched baseline demographics and AMS incidence of 75 (73%) and severe AMS of 48 (47', 'Acute Mountain Sickness', 'acute mountain sickness']","['acetazolamide, budesonide, and placebo']","['mean spirometry values', 'Lake Louise Questionnaire scores', 'Spirometry measurements of forced expiratory volume in one second (FEV 1 ), forced vital capacity (FVC), and peak expiratory flow']","[{'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0442533', 'cui_str': 'Mountain'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1860224', 'cui_str': 'Ablepharon macrostomia syndrome'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0238284', 'cui_str': 'Acute mountain sickness'}]","[{'cui': 'C0000981', 'cui_str': 'Acetazolamide'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0337049', 'cui_str': 'Lake'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}]",103.0,0.0267756,There were no statistically significant associations between changes in mean spirometry values on ascent to high altitude with incidence of AMS or severe AMS.,"[{'ForeName': 'Elan', 'Initials': 'E', 'LastName': 'Small', 'Affiliation': 'Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Juul', 'Affiliation': 'Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Pomeranz', 'Affiliation': 'Inyo Hospital, Bishop, California, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Burns', 'Affiliation': 'Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA.'}, {'ForeName': 'Caleb', 'Initials': 'C', 'LastName': 'Phillips', 'Affiliation': 'Department of Computational Science, University of Colorado, Boulder, Colorado, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Cheffers', 'Affiliation': 'Department of Emergency Medicine, Keck School of Medicine, Los Angeles, California, USA.'}, {'ForeName': 'Grant S', 'Initials': 'GS', 'LastName': 'Lipman', 'Affiliation': 'Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA.'}]",High altitude medicine & biology,['10.1089/ham.2020.0150'] 1019,33600441,The influence of negative mood on solitary drinking preference: An experiment with young adult solitary drinkers.,"Solitary drinking is a risk marker for alcohol use disorder; thus, it is important to identify why individuals drink alone and for whom this association is particularly relevant. Evidence suggests the desire to ameliorate negative affect (NA) motivates solitary drinking, with some individuals particularly likely to drink alone to cope, but all past studies are cross-sectional. The present study therefore aimed to determine whether 1) experimentally induced NA increased preferences to drink alcohol alone, and 2) whether the relationship between NA and choosing to drink alcohol alone was moderated by neuroticism, drinking to cope motives, and social anxiety. Current drinkers (ages 21-29) with a solitary drinking history (N=126) were randomly assigned to either NA, positive affect [PA], or no affect change (control) conditions via differing cognitive task feedback. After the mood manipulation, participants chose between drinking alcoholic or nonalcoholic beverages in one of two contexts: alone or socially. Evidence regarding effectiveness of the mood manipulation was mixed, and few chose non-alcoholic beverages in either context. Condition did not influence outcome choice. Across conditions, increases in NA and the importance placed on receiving one's context choice were associated with solitary (versus social) alcohol preference. Neuroticism and its interaction with NA change also influenced choice; individuals high in neuroticism chose more solitary (versus social) drinking contexts while the opposite was true for those low in neuroticism, and among the latter, the preference difference was more pronounced with relatively smaller NA increases. Findings are discussed based on the existing solitary drinking literature.",2021,Condition did not influence outcome choice.,"['Current drinkers (ages 21-29) with a solitary drinking history (N=126', 'young adult solitary drinkers']","['NA, positive affect [PA], or no affect change (control) conditions via differing cognitive task feedback']",[],"[{'cui': 'C0556297', 'cui_str': 'Current drinker'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205171', 'cui_str': 'Singular'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]",[],126.0,0.0149013,Condition did not influence outcome choice.,"[{'ForeName': 'Carillon J', 'Initials': 'CJ', 'LastName': 'Skrzynski', 'Affiliation': 'Department of Psychology, Carnegie Mellon University, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Kasey G', 'Initials': 'KG', 'LastName': 'Creswell', 'Affiliation': 'Department of Psychology, Carnegie Mellon University, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Verstynen', 'Affiliation': 'Department of Psychology, Carnegie Mellon University, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Bachrach', 'Affiliation': 'Center for Health Equity Research and Promotion, Mental Illness Research, Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Tammy', 'Initials': 'T', 'LastName': 'Chung', 'Affiliation': 'Department of Psychiatry, Institute for Health, Healthcare Policy and Aging Research, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States of America.'}]",PloS one,['10.1371/journal.pone.0247202'] 1020,33593789,Protocol for a cluster randomised trial evaluating a multifaceted intervention starting preconceptionally-Early Interventions to Support Trajectories for Healthy Life in India (EINSTEIN): a Healthy Life Trajectories Initiative (HeLTI) Study.,"INTRODUCTION The Healthy Life Trajectories Initiative is an international consortium comprising four harmonised but independently powered trials to evaluate whether an integrated intervention starting preconceptionally will reduce non-communicable disease risk in their children. This paper describes the protocol of the India study. METHODS AND ANALYSIS The study set in rural Mysore will recruit ~6000 married women over the age of 18 years. The village-based cluster randomised design has three arms (preconception, pregnancy and control; 35 villages per arm). The longitudinal multifaceted intervention package will be delivered by community health workers and comprise: (1) measures to optimise nutrition; (2) a group parenting programme integrated with cognitive-behavioral therapy; (3) a lifestyle behaviour change intervention to support women to achieve a diverse diet, exclusive breast feeding for the first 6 months, timely introduction of diverse and nutritious infant weaning foods, and adopt appropriate hygiene measures; and (4) the reduction of environmental pollution focusing on indoor air pollution and toxin avoidance.The primary outcome is adiposity in children at age 5 years, measured by fat mass index. We will report on a host of intermediate and process outcomes. We will collect a range of biospecimens including blood, urine, stool and saliva from the mothers, as well as umbilical cord blood, placenta and specimens from the offspring.An intention-to-treat analysis will be adopted to assess the effect of interventions on outcomes. We will also undertake process and economic evaluations to determine scalability and public health translation. ETHICS AND DISSEMINATION The study has been approved by the institutional ethics committee of the lead institute. Findings will be published in peer-reviewed journals. We will interact with policy makers at local, national and international agencies to enable translation. We will also share the findings with the participants and local community through community meetings, newsletters and local radio. TRIAL REGISTRATION NUMBER ISRCTN20161479, CTRI/2020/12/030134; Pre-results.",2021,The Healthy Life Trajectories Initiative is an international consortium comprising four harmonised but independently powered trials to evaluate whether an integrated intervention starting preconceptionally will reduce non-communicable disease risk in their children.,"['community health workers and comprise', 'for Healthy Life in India (EINSTEIN): a Healthy Life Trajectories Initiative (HeLTI) Study', '6000 married women over the age of 18 years']","['optimise nutrition; (2) a group parenting programme integrated with cognitive-behavioral therapy; (3) a lifestyle behaviour change intervention to support women to achieve a diverse diet, exclusive breast feeding for the first 6 months, timely introduction of diverse and nutritious infant weaning foods, and adopt appropriate hygiene measures; and (4) the reduction of environmental pollution focusing on indoor air pollution and toxin avoidance', 'multifaceted intervention starting preconceptionally-Early Interventions to Support Trajectories']","['adiposity in children at age 5 years, measured by fat mass index']","[{'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3842326', 'cui_str': '6000'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0242205', 'cui_str': 'Breastfeeding, Exclusive'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0043084', 'cui_str': 'Weaning'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0425382', 'cui_str': 'Adopted'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0014419', 'cui_str': 'Environmental pollution'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0085420', 'cui_str': 'Indoor Air Pollution'}, {'cui': 'C0040549', 'cui_str': 'Toxin'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0242687', 'cui_str': 'Provision of early intervention service for child'}]","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.109907,The Healthy Life Trajectories Initiative is an international consortium comprising four harmonised but independently powered trials to evaluate whether an integrated intervention starting preconceptionally will reduce non-communicable disease risk in their children.,"[{'ForeName': 'Kalyanaraman', 'Initials': 'K', 'LastName': 'Kumaran', 'Affiliation': 'Epidemiology Research Unit, CSI Holdsworth Memorial Hospital, Mysore, Karnataka, India kk@mrc.soton.ac.uk.'}, {'ForeName': 'Ghattu V', 'Initials': 'GV', 'LastName': 'Krishnaveni', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Kumar Gavali', 'Initials': 'KG', 'LastName': 'Suryanarayana', 'Affiliation': 'Department of Academics and Research, Vivekananda Memorial Hospital, Saragur, Karnataka, India.'}, {'ForeName': 'Manohar Prabhu', 'Initials': 'MP', 'LastName': 'Prasad', 'Affiliation': 'Department of Academics and Research, Vivekananda Memorial Hospital, Saragur, Karnataka, India.'}, {'ForeName': 'Antonisamy', 'Initials': 'A', 'LastName': 'Belavendra', 'Affiliation': 'Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Atkinson', 'Affiliation': 'Department of Paediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Ramaswamy', 'Initials': 'R', 'LastName': 'Balasubramaniam', 'Affiliation': 'Development Support, Swami Vivekananda Youth Movement, Mysore, India.'}, {'ForeName': 'Robert H J', 'Initials': 'RHJ', 'LastName': 'Bandsma', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Zulfiqar A', 'Initials': 'ZA', 'LastName': 'Bhutta', 'Affiliation': 'Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Giriraj Ratan', 'Initials': 'GR', 'LastName': 'Chandak', 'Affiliation': 'Genomic Research on Complex Diseases, CSIR - Centre for Cellular and Molecular Biology, Hyderabad, Telangana, India.'}, {'ForeName': 'Elena M', 'Initials': 'EM', 'LastName': 'Comelli', 'Affiliation': 'Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Sandra T', 'Initials': 'ST', 'LastName': 'Davidge', 'Affiliation': 'Department of Obstetrics & Gynecology, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Cindy-Lee', 'Initials': 'CL', 'LastName': 'Dennis', 'Affiliation': 'Lawrence S. Bloomberg Faculty of Nursing and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Geoffrey L', 'Initials': 'GL', 'LastName': 'Hammond', 'Affiliation': 'Department of Cellular & Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Prabhat', 'Initials': 'P', 'LastName': 'Jha', 'Affiliation': 'Epidemiology Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'K S', 'Initials': 'KS', 'LastName': 'Joseph', 'Affiliation': 'Department of Obstetrics & Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Sadhana R', 'Initials': 'SR', 'LastName': 'Joshi', 'Affiliation': 'Nutritional Medicine Division, Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune, India.'}, {'ForeName': 'Murali', 'Initials': 'M', 'LastName': 'Krishna', 'Affiliation': 'Foundation for Research and Advocacy in Mental Health (FRAMe), Mysore, India.'}, {'ForeName': 'Kang', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Department of Applied Psychology and Human Development, OISE/University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Lye', 'Affiliation': 'Alliance for Human Development, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'McGowan', 'Affiliation': 'Department of Biological Sciences, University of Toronto Scarborough, Toronto, Ontario, Canada.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Nepomnaschy', 'Affiliation': 'Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Padvetnaya', 'Affiliation': 'Jindal School of Government and Public Policy, O.P. Jindal Global University, Sonipat, Haryana, India.'}, {'ForeName': 'Saumyadipta', 'Initials': 'S', 'LastName': 'Pyne', 'Affiliation': 'Public Health Dynamics Lab and Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Harshpal Singh', 'Initials': 'HS', 'LastName': 'Sachdev', 'Affiliation': 'Department of Pediatrics and Clinical Epidemiology, Sitaram Bhartia Institute of Science and Research, New Delhi, India.'}, {'ForeName': 'Sirazul Ameen', 'Initials': 'SA', 'LastName': 'Sahariah', 'Affiliation': 'Reproductive Maternal Newborn Child and Adolescent Health and Nutrition, MAMTA Health Institute for Mother and Child, New Delhi, Delhi, India.'}, {'ForeName': 'Nalini', 'Initials': 'N', 'LastName': 'Singhal', 'Affiliation': 'Department of Paediatrics, University of Calgary, Calgary, Mull, Canada.'}, {'ForeName': 'Jacquetta', 'Initials': 'J', 'LastName': 'Trasler', 'Affiliation': 'Departments of Pediatrics, Human Genetics, and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Chittaranjan S', 'Initials': 'CS', 'LastName': 'Yajnik', 'Affiliation': 'Diabetes Unit, King Edward Memorial Hospital and Research Centre, Pune, India.'}, {'ForeName': 'Janis', 'Initials': 'J', 'LastName': 'Baird', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Barker', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Martin', 'Affiliation': 'Alliance for Human Development, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.'}, {'ForeName': 'Nusrat', 'Initials': 'N', 'LastName': 'Husain', 'Affiliation': 'Division of Psychology and Mental Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Sellen', 'Affiliation': 'Joannah and Brian Lawson Centre for Child Nutrition, Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Caroline H D', 'Initials': 'CHD', 'LastName': 'Fall', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Prakesh S', 'Initials': 'PS', 'LastName': 'Shah', 'Affiliation': 'Department of Paediatrics, Mount Sinai Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Stephen G', 'Initials': 'SG', 'LastName': 'Matthews', 'Affiliation': 'Alliance for Human Development, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.'}]",BMJ open,['10.1136/bmjopen-2020-045862'] 1021,33593788,Protocol for a randomised feasibility study of Point-Of-care HIV viral load testing to Enhance Re-suppression in South Africa: the POwER study.,"INTRODUCTION Access to HIV viral load testing remains difficult for many people on antiretroviral therapy (ART) in low-income and middle-income countries. Weak laboratory and clinic systems often delay the detection and management of viraemia, which can lead to morbidity, drug resistance and HIV transmission. Point-of-care testing could overcome these challenges. We aim to assess whether it is feasible to conduct a randomised trial of point-of-care viral load testing to manage viraemia. METHODS AND ANALYSIS We will conduct an open-label, single-site, individually randomised, feasibility study of Point-Of-care HIV viral load testing to Enhance Re-suppression, in Durban, South Africa. We will enrol approximately 100 people living with HIV who are aged ≥18 years, receiving first-line ART but with recent viraemia ≥1000 copies/mL, and randomise them 1:1 to receive point-of-care viral load or standard laboratory viral load monitoring, after 12 weeks. All participants will continue to receive care from public sector healthcare workers following South African HIV management guidelines. Participants with persistent viraemia ≥1000 copies/mL will be considered for switching to second-line ART. We will compare the proportion in each study arm who achieve the primary outcome of viral suppression <50 copies/mL at 24 weeks after enrolment. Additional outcomes include proportions retained in the study, proportions with HIV drug resistance, time to viral load results and time to switching to second-line ART. We will assess implementation of point-of-care viral load testing using process evaluation data, and through interviews and focus groups with healthcare workers. ETHICS AND DISSEMINATION University of Oxford Tropical Research Ethics Committee and the Biomedical Research Ethics Committee of the University of KwaZulu-Natal have approved the study. We will present results to stakeholders, and through conferences and open-access, peer-reviewed journals. TRIAL REGISTRATION NUMBER PACTR202001785886049.",2021,"Weak laboratory and clinic systems often delay the detection and management of viraemia, which can lead to morbidity, drug resistance and HIV transmission.","['South Africa', '100 people living with HIV who are aged ≥18 years, receiving first-line ART but with recent viraemia ≥1000 copies/mL, and randomise them 1:1 to receive point-of-care viral load or standard laboratory viral load monitoring, after 12 weeks', 'Durban, South Africa', 'All participants will continue to receive care from public sector healthcare workers following South African HIV management guidelines']",['Point-Of-care HIV viral load testing'],"['proportions with HIV drug resistance, time to viral load results and time to switching to second-line ART']","[{'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0042749', 'cui_str': 'Viremia'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0034035', 'cui_str': 'Public Sector'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}]","[{'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C1168369', 'cui_str': 'HIV viral load'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0013203', 'cui_str': 'Drug resistance'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]",,0.298025,"Weak laboratory and clinic systems often delay the detection and management of viraemia, which can lead to morbidity, drug resistance and HIV transmission.","[{'ForeName': 'Jienchi', 'Initials': 'J', 'LastName': 'Dorward', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK jienchi.dorward@phc.ox.ac.uk.'}, {'ForeName': 'Yukteshwar', 'Initials': 'Y', 'LastName': 'Sookrajh', 'Affiliation': 'eThekwini Municipality Health Unit, Durban, South Africa.'}, {'ForeName': 'Hope', 'Initials': 'H', 'LastName': 'Ngobese', 'Affiliation': 'eThekwini Municipality Health Unit, Durban, South Africa.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Lessells', 'Affiliation': 'Centre for the Aids Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Fathima', 'Initials': 'F', 'LastName': 'Sayed', 'Affiliation': 'Centre for the Aids Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Elliot', 'Initials': 'E', 'LastName': 'Bulo', 'Affiliation': 'eThekwini Municipality Health Unit, Durban, South Africa.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Moodley', 'Affiliation': 'Department of Virology, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Samsunder', 'Affiliation': 'Centre for the Aids Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Lewis', 'Affiliation': 'Centre for the Aids Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Tonkin-Crine', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Paul K', 'Initials': 'PK', 'LastName': 'Drain', 'Affiliation': 'Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Hayward', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Butler', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Garrett', 'Affiliation': 'Centre for the Aids Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}]",BMJ open,['10.1136/bmjopen-2020-045373'] 1022,33605656,Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial.,"ABSTRACT It is commonly believed that blinding to treatment assignment is necessary for placebos to have an effect. However, placebos administered without concealment (ie, open-label placebos [OLPs]) have recently been shown to be effective in some conditions. This study had 2 objectives: first, to determine whether OLP treatment is superior to no-pill control (NPC) in irritable bowel syndrome (IBS) and, second, to compare the efficacy of OLP against double-blind placebo (DBP). In a 6-week, 3-arm, randomized clinical trial, participants were randomized in equal proportions to 3 arms: OLP, DBP, or NPC. Two hundred sixty-two adults (72.9% women), with a mean age of 42.0 (SD = 18.1) years, participated in the primary study. The mean improvement on the IBS Severity Scoring System from baseline to the 6-week end point was significantly greater in OLP compared with that in NPC (90.6 vs 52.3, P = 0.038). Open-label placebo and DBP did not differ significantly on IBS Severity Scoring System improvement (100.3 vs 90.6, P = 0.485). Standardized effect sizes were moderate for OLP vs NPC (d = 0.43) and small for OLP vs DBP (d = 0.10). Participants treated with OLP reported clinically meaningful improvements in IBS symptoms that were significantly greater than those on NPC. Open-label placebo and DBP had similar effects that did not differ significantly, suggesting that blinding may not be necessary for placebos to be effective and that OLP could play a role in the management of patients with refractory IBS.",2021,"Standardized effect sizes were moderate for OLP vs. NPC (d=.43), and small for OLP vs DBP (d=.10).","['irritable bowel syndrome (IBS', 'irritable bowel syndrome', '262 adults (72.9% women), mean age 42.0 (SD=18.1) participated in the primary study']","['placebos', 'OLP', 'OLP against double-blind placebo (DBP', 'pill control (NPC', 'Open-label placebo vs double-blind placebo', 'OLP, DBP or NPC']","['IBS symptoms', 'OLP and DBP', 'IBS-SSS improvement', 'IBS Severity Scoring System (IBS-SSS']","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0037052', 'cui_str': 'Sick sinus syndrome'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",262.0,0.4842,"Standardized effect sizes were moderate for OLP vs. NPC (d=.43), and small for OLP vs DBP (d=.10).","[{'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Lembo', 'Affiliation': ""Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States Department of Psychology, Endicott College, Beverly, MA, United States Program in Placebo Studies, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.""}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Kelley', 'Affiliation': ''}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Nee', 'Affiliation': ''}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Ballou', 'Affiliation': ''}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Iturrino', 'Affiliation': ''}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Cheng', 'Affiliation': ''}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Rangan', 'Affiliation': ''}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Katon', 'Affiliation': ''}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Hirsch', 'Affiliation': ''}, {'ForeName': 'Irving', 'Initials': 'I', 'LastName': 'Kirsch', 'Affiliation': ''}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Hall', 'Affiliation': ''}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Davis', 'Affiliation': ''}, {'ForeName': 'Ted J', 'Initials': 'TJ', 'LastName': 'Kaptchuk', 'Affiliation': ''}]",Pain,['10.1097/j.pain.0000000000002234'] 1023,33609174,"Ready-to-eat cereal and milk for breakfast compared with no breakfast has a positive acute effect on cognitive function and subjective state in 11-13-year-olds: a school-based, randomised, controlled, parallel groups trial.","PURPOSE We tested the acute effect of breakfast (ready-to-eat-cereal [RTEC] and milk) versus (vs.) no breakfast on cognitive function and subjective state in adolescents. METHODS Healthy adolescents (n = 234) aged 11-13 years were recruited to take part in this school-based, acute, randomised, controlled, parallel groups trial with two interventions; Breakfast or No Breakfast. The breakfast intervention consisted of ad libitum intake of RTEC (up to 70 g) with milk (up to 300 ml) administered in a naturalistic school breakfast programme environment. Cognitive function was assessed at baseline and + 70 and + 215 min post-intervention in a group-testing situation, similar to a school classroom context. The CANTAB test battery included: Simple Reaction Time (SRT), 5-Choice Reaction Time (5-CRT), Rapid Visual Information Processing (RVIP), and Paired Associates Learning (PAL; primary outcome). Data collection commenced January 2011 and ended May 2011. This trial was retrospectively registered at www.clinicaltrials.gov as NCT03979027 on 07/06/2019. RESULTS A significant effect of the intervention (CMH[1] = 7.29, p < 0.01) was found for the number of levels achieved on the PAL task. A significant difference between interventions was found when baseline performance reached level 2 (JT, z = 2.58, p < 0.01), such that 100% of participants in the breakfast intervention reached the maximum level 4 but only 41.7% of those in the no breakfast intervention reached level 4. A significant baseline*intervention interaction (F[1,202] = 6.95, p < 0.01) was found for total errors made on the PAL task, indicating that participants who made above-average errors at baseline reduced the total number of errors made at subsequent test sessions following breakfast consumption whilst those in the no breakfast intervention did not. There was a positive effect of breakfast on reaction time and visual-sustained attention. The results also demonstrated interactions of intervention with baseline cognitive performance, such that breakfast conferred a greater advantage for performance when baseline performance was poorer. CONCLUSION Consuming breakfast has a positive acute effect on cognition in adolescents.",2021,"A significant effect of the intervention (CMH[1] = 7.29, p < 0.01) was found for the number of levels achieved on the PAL task.","['Healthy adolescents (n\u2009=\u2009234) aged 11-13\xa0years', 'adolescents']","['breakfast intervention consisted of ad libitum intake of RTEC', 'breakfast (ready-to-eat-cereal [RTEC', 'interventions; Breakfast or No Breakfast', 'Ready-to-eat cereal and milk for breakfast compared with no breakfast', 'naturalistic school breakfast programme environment']","['cognitive function and subjective state', 'Cognitive function', 'Simple Reaction Time (SRT), 5-Choice Reaction Time (5-CRT), Rapid Visual Information Processing (RVIP), and Paired Associates Learning (PAL; primary outcome', 'maximum level', 'reaction time and visual-sustained attention']","[{'cui': 'C0686747', 'cui_str': 'Well adolescent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0007757', 'cui_str': 'Cereal'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0589099', 'cui_str': 'Sustained attention'}]",,0.118135,"A significant effect of the intervention (CMH[1] = 7.29, p < 0.01) was found for the number of levels achieved on the PAL task.","[{'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Adolphus', 'Affiliation': 'Human Appetite Research Unit, School of Psychology, University of Leeds, Leeds, LS2 9JT, UK. k.adolphus@leeds.ac.uk.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'Hoyland', 'Affiliation': 'The Kellogg Company, Orange Tower Media City, Salford, Greater Manchester, UK.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Walton', 'Affiliation': 'HarvestPlus, International Food Policy Research Institute, 1201 Eye Street NW, Washington, DC, 20005, USA.'}, {'ForeName': 'Frits', 'Initials': 'F', 'LastName': 'Quadt', 'Affiliation': 'Quadt Consultancy BV, Oostvoorne, The Netherlands.'}, {'ForeName': 'Clare L', 'Initials': 'CL', 'LastName': 'Lawton', 'Affiliation': 'Human Appetite Research Unit, School of Psychology, University of Leeds, Leeds, LS2 9JT, UK.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Dye', 'Affiliation': 'Human Appetite Research Unit, School of Psychology, University of Leeds, Leeds, LS2 9JT, UK.'}]",European journal of nutrition,['10.1007/s00394-021-02506-2'] 1024,33606739,Effects of pneumoperitoneum on kidney injury biomarkers: A randomized clinical trial.,"BACKGROUND Increased intra-abdominal pressure causes hemodynamic changes that may affect renal biomarkers. METHODS This randomized, single-blind, single-center clinical trial recruited patients undergoing laparoscopic cholecystectomy at a tertiary care center in Brazil. They were randomly allocated to a standard intra-abdominal pressure group (P10-12, 10-12 mm Hg) and a low intra-abdominal pressure group (P6-8, 6-8 mm Hg). The primary outcome was the change in neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C levels measured at the beginning of the procedure (T0), at the end of the procedure (T1), and 24 hours after the procedure (T2). P-values < 0.05 were considered statistically significant. RESULTS In total, 64 patients completed the study-33 were given standard pressure and 31 were given low pressure. There was no significant difference in the biomarker between the groups (P = 0.580), but there was a significant difference between the time points with elevation at T1 (P < 0.001). Similar to NGAL, cystatin C had an elevation at T1 in both groups (P = 0.021), but no difference was found when comparing the groups. CONCLUSIONS In laparoscopic cholecystectomy, pneumoperitoneum increases NGAL and cystatin C levels intraoperatively, and the use of low-pressure pneumoperitoneum does not change the course of these biomarkers.",2021,"Similar to NGAL, cystatin C had an elevation at T1 in both groups (P = 0.021), but no difference was found when comparing the groups. ","['64 patients completed the study-33 were given standard pressure and 31 were given low pressure', 'patients undergoing laparoscopic cholecystectomy at a tertiary care center in Brazil']","['pneumoperitoneum', 'standard intra-abdominal pressure']","['change in neutrophil gelatinase-associated lipocalin (NGAL) and', 'cystatin C levels', 'kidney injury biomarkers']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0032320', 'cui_str': 'Pneumoperitoneum'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1512911', 'cui_str': 'Intraabdominal route'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0206528', 'cui_str': 'Gelatinase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}, {'cui': 'C0071744', 'cui_str': 'Cystatin C'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0160420', 'cui_str': 'Injury of kidney'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",64.0,0.357762,"Similar to NGAL, cystatin C had an elevation at T1 in both groups (P = 0.021), but no difference was found when comparing the groups. ","[{'ForeName': 'Marcos Antonio', 'Initials': 'MA', 'LastName': 'Marton Filho', 'Affiliation': 'Department of Surgical Specialties and Anesthesiology, Botucatu School of Medicine, Universidade Estadual Paulista (UNESP), Botucatu, São Paulo, Brazil.'}, {'ForeName': 'Rodrigo Leal', 'Initials': 'RL', 'LastName': 'Alves', 'Affiliation': 'Department of Anesthesiology, São Rafael Hospital and Federal University of Bahia, Salvador, Brazil.'}, {'ForeName': 'Paulo do', 'Initials': 'PD', 'LastName': 'Nascimento', 'Affiliation': 'Department of Surgical Specialties and Anesthesiology, Botucatu School of Medicine, Universidade Estadual Paulista (UNESP), Botucatu, São Paulo, Brazil.'}, {'ForeName': 'Gabriel Dos Santos', 'Initials': 'GDS', 'LastName': 'Tarquinio', 'Affiliation': 'Clínica de Anestesiologia de Ribeirão Preto (CARP), Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Paulo Ferreira', 'Initials': 'PF', 'LastName': 'Mega', 'Affiliation': 'School of Medicine, Pontifícia Universidade Católica de Campinas (PUC-CAMPINAS), Campinas, São Paulo, Brazil.'}, {'ForeName': 'Norma Sueli', 'Initials': 'NS', 'LastName': 'Pinheiro Módolo', 'Affiliation': 'Department of Surgical Specialties and Anesthesiology, Botucatu School of Medicine, Universidade Estadual Paulista (UNESP), Botucatu, São Paulo, Brazil.'}]",PloS one,['10.1371/journal.pone.0247088'] 1025,33630447,"Robotic Versus Laparoscopic Ventral Hernia Repair: One-year Results From a Prospective, Multicenter, Blinded Randomized Controlled Trial.","OBJECTIVE The aim of this study was to compare clinical and patient-reported outcomes of robotic versus laparoscopic ventral hernia repair (LVHR) at 1-year postoperative. SUMMARY OF BACKGROUND DATA Despite a relative lack of research at low risk for bias assessing robotic ventral hernia repair (RVHR), the growth of RVHR has been rapid. We previously reported short-term results of the first randomized control trial comparing RVHR versus LVHR; there was no clear difference in clinical outcomes but increased operative time and cost with robotic repair. METHODS Patients from a multicenter, blinded randomized control trial comparing RVHR versus LVHR were followed at 1 year. Outcomes included wound complication (surgical site infection, surgical site occurrence, wound dehiscence), hernia occurrence including recurrence and port site hernia, readmission, reoperation, and patient-reported outcomes (functional status, pain, and satisfaction with repair and cosmesis). RESULTS A total of 124 patients were randomized and 113 patients (91%; 60 robot, 53 laparoscopic) completed 1-year follow-up. Baseline demographics were similar in both groups. No differences were seen in wound complication (15% vs 15%; P = 0.899), hernia recurrence (7% vs 9%; P = 0.576), or readmission (2% vs 6%; P = 0.251). No patients underwent reoperation in the robotic arm, whereas 5 (9%) did in the laparoscopic arm (P = 0.020). No differences were seen in patient-reported outcomes. Both arms reported clinically significant improvements in functional status, low pain scores, and high satisfaction scores at 1-year post repair. CONCLUSION This study confirms that robotic ventral hernia repair is safe when compared to laparoscopy. Further studies are needed to confirm these findings.",2021,"Both arms reported clinically significant improvements in functional status, low pain scores and high satisfaction scores at one-year post repair. ","['124 patients were randomized and 113 patients (91%; 60 robot, 53 laparoscopic) completed one-year follow-up', 'Patients from a multicenter, blinded']","['Robotic versus Laparoscopic Ventral Hernia Repair', 'robotic versus laparoscopic ventral hernia repair (LVHR', 'RCT comparing RVHR versus LVHR', 'robotic ventral hernia repair']","['readmission', 'functional status, low pain scores and high satisfaction scores', 'wound complication', 'hernia recurrence', 'operative time and cost with robotic repair', 'wound complication (surgical site infection, surgical site occurrence, wound dehiscence), hernia occurrence including recurrence and port site hernia, readmission, reoperation, and patient-reported outcomes (functional status, pain, and satisfaction with repair and cosmesis']","[{'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0019334', 'cui_str': 'Repair of ventral hernia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0332850', 'cui_str': 'Operative site'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0259768', 'cui_str': 'Wound dehiscence'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0452253', 'cui_str': 'Port'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",124.0,0.369011,"Both arms reported clinically significant improvements in functional status, low pain scores and high satisfaction scores at one-year post repair. ","[{'ForeName': 'Naila H', 'Initials': 'NH', 'LastName': 'Dhanani', 'Affiliation': 'Department of Surgery, McGovern Medical School at UTHealth, Houston, Texas.'}, {'ForeName': 'Oscar A', 'Initials': 'OA', 'LastName': 'Olavarria', 'Affiliation': 'Department of Surgery, McGovern Medical School at UTHealth, Houston, Texas.'}, {'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Holihan', 'Affiliation': 'Department of Surgery, McGovern Medical School at UTHealth, Houston, Texas.'}, {'ForeName': 'Shinil K', 'Initials': 'SK', 'LastName': 'Shah', 'Affiliation': 'Department of Surgery, McGovern Medical School at UTHealth, Houston, Texas.'}, {'ForeName': 'Todd D', 'Initials': 'TD', 'LastName': 'Wilson', 'Affiliation': 'Department of Surgery, McGovern Medical School at UTHealth, Houston, Texas.'}, {'ForeName': 'Michele M', 'Initials': 'MM', 'LastName': 'Loor', 'Affiliation': 'Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Tien C', 'Initials': 'TC', 'LastName': 'Ko', 'Affiliation': 'Department of Surgery, McGovern Medical School at UTHealth, Houston, Texas.'}, {'ForeName': 'Lillian S', 'Initials': 'LS', 'LastName': 'Kao', 'Affiliation': 'Department of Surgery, McGovern Medical School at UTHealth, Houston, Texas.'}, {'ForeName': 'Mike K', 'Initials': 'MK', 'LastName': 'Liang', 'Affiliation': 'Department of Surgery, University of Houston, HCA Healthcare, Kingwood, Texas.'}]",Annals of surgery,['10.1097/SLA.0000000000004795'] 1026,33632904,The effect of low flow anesthesia on hemodynamic and peripheral oxygenation parameters in obesity surgery.,"OBJECTIVES To investigate the effects of low-flow anesthesia on hemodynamic parameters and recovery from anesthesia in obese individuals undergoing laparoscopic surgery. METHODS This randomized-controlled and prospective study included 44 obese patients who underwent laparoscopic sleeve gastrectomy operation. The patients were randomly allocated into 2 groups as low-flow and high-flow anesthesia. Further, the groups compared in terms of hemodynamic parameters, anesthesia recovery times, operation times, and arterial blood gas parameters. RESULTS The groups were similar with respect to demographic data. Heart rate, peripheral oxygen saturation, arterial blood pressure measurements, end-tidal, and CO 2 , lactate levels measurements were similar in both groups during the entire procedure. There was also no statistically significant difference in terms of arterial blood gas parameters or anesthesia recovery periods. CONCLUSION Low-flow anesthesia in laparoscopic obesity surgery seems to be safer compared to high-flow anesthesia in terms of the adequacy of tissue perfusion, depth of anesthesia, and postoperative recovery.",2021,"There was also no statistically significant difference in terms of arterial blood gas parameters or anesthesia recovery periods. ","['44 obese patients who underwent', 'obese individuals undergoing laparoscopic surgery', 'obesity surgery']","['laparoscopic sleeve gastrectomy operation', 'Low-flow anesthesia', 'low flow anesthesia', 'low-flow anesthesia', 'low-flow and high-flow anesthesia']","['arterial blood gas parameters or anesthesia recovery periods', 'hemodynamic and peripheral oxygenation parameters', 'Heart rate, peripheral oxygen saturation, arterial blood pressure measurements, end-tidal, and CO 2 , lactate levels measurements', 'hemodynamic parameters, anesthesia recovery times, operation times, and arterial blood gas parameters']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C1167841', 'cui_str': 'Obesity surgery'}]","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0002908', 'cui_str': 'Recovery Period, Anesthesia'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C1272641', 'cui_str': 'Systemic arterial pressure'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0428445', 'cui_str': 'D-lactate measurement'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",44.0,0.017898,"There was also no statistically significant difference in terms of arterial blood gas parameters or anesthesia recovery periods. ","[{'ForeName': 'Mesut', 'Initials': 'M', 'LastName': 'Öterkuş', 'Affiliation': 'From the Department of Anesthesiology and Reanimation (Öterkuş), Faculty of Medicine, Malatya Turgut Özal University, Malatya; from the Department of Anesthesiology and Reanimation (Dönmez), Beyoglu Eye Training and Research Hospital, İstanbul; from the Department of Anesthesiology and Reanimation (Nadir), Izmir Katip Celebi University Ataturk Training and Research Hospital, İzmir; and from the Department of Cardiology (Rencüzoğulları, Karabağ), Department of General Surgery (Binnetoğlu), Medical Faculty, Kafkas University, Kars, Turkey.'}, {'ForeName': 'İlksen', 'Initials': 'İ', 'LastName': 'Dönmez', 'Affiliation': 'From the Department of Anesthesiology and Reanimation (Öterkuş), Faculty of Medicine, Malatya Turgut Özal University, Malatya; from the Department of Anesthesiology and Reanimation (Dönmez), Beyoglu Eye Training and Research Hospital, İstanbul; from the Department of Anesthesiology and Reanimation (Nadir), Izmir Katip Celebi University Ataturk Training and Research Hospital, İzmir; and from the Department of Cardiology (Rencüzoğulları, Karabağ), Department of General Surgery (Binnetoğlu), Medical Faculty, Kafkas University, Kars, Turkey.'}, {'ForeName': 'Aysu H', 'Initials': 'AH', 'LastName': 'Nadir', 'Affiliation': 'From the Department of Anesthesiology and Reanimation (Öterkuş), Faculty of Medicine, Malatya Turgut Özal University, Malatya; from the Department of Anesthesiology and Reanimation (Dönmez), Beyoglu Eye Training and Research Hospital, İstanbul; from the Department of Anesthesiology and Reanimation (Nadir), Izmir Katip Celebi University Ataturk Training and Research Hospital, İzmir; and from the Department of Cardiology (Rencüzoğulları, Karabağ), Department of General Surgery (Binnetoğlu), Medical Faculty, Kafkas University, Kars, Turkey.'}, {'ForeName': 'İbrahim', 'Initials': 'İ', 'LastName': 'Rencüzoğulları', 'Affiliation': 'From the Department of Anesthesiology and Reanimation (Öterkuş), Faculty of Medicine, Malatya Turgut Özal University, Malatya; from the Department of Anesthesiology and Reanimation (Dönmez), Beyoglu Eye Training and Research Hospital, İstanbul; from the Department of Anesthesiology and Reanimation (Nadir), Izmir Katip Celebi University Ataturk Training and Research Hospital, İzmir; and from the Department of Cardiology (Rencüzoğulları, Karabağ), Department of General Surgery (Binnetoğlu), Medical Faculty, Kafkas University, Kars, Turkey.'}, {'ForeName': 'Yavuz', 'Initials': 'Y', 'LastName': 'Karabağ', 'Affiliation': 'From the Department of Anesthesiology and Reanimation (Öterkuş), Faculty of Medicine, Malatya Turgut Özal University, Malatya; from the Department of Anesthesiology and Reanimation (Dönmez), Beyoglu Eye Training and Research Hospital, İstanbul; from the Department of Anesthesiology and Reanimation (Nadir), Izmir Katip Celebi University Ataturk Training and Research Hospital, İzmir; and from the Department of Cardiology (Rencüzoğulları, Karabağ), Department of General Surgery (Binnetoğlu), Medical Faculty, Kafkas University, Kars, Turkey.'}, {'ForeName': 'Kenan', 'Initials': 'K', 'LastName': 'Binnetoğlu', 'Affiliation': 'From the Department of Anesthesiology and Reanimation (Öterkuş), Faculty of Medicine, Malatya Turgut Özal University, Malatya; from the Department of Anesthesiology and Reanimation (Dönmez), Beyoglu Eye Training and Research Hospital, İstanbul; from the Department of Anesthesiology and Reanimation (Nadir), Izmir Katip Celebi University Ataturk Training and Research Hospital, İzmir; and from the Department of Cardiology (Rencüzoğulları, Karabağ), Department of General Surgery (Binnetoğlu), Medical Faculty, Kafkas University, Kars, Turkey.'}]",Saudi medical journal,['10.15537/smj.2021.42.3.20200575'] 1027,33631359,"Incorporating Nutrition, Vests, Education, and Strength Training (INVEST) in Bone Health: Trial Design and Methods.","BACKGROUND Achievement of 5-10% weight loss (WL) among older adults living with obesity considerably improves prognosis of health-related outcomes; however, concomitant declines in bone mineral density (BMD) limit overall benefit by increasing fracture risk. Declines in mechanical loading contribute to WL-associated BMD loss, with pilot data signaling the addition of external weight replacement (via weighted vest use) during intentional WL mitigates bone loss at weight bearing sites to a similar degree as resistance exercise training (RT). Definitive data in support of weighted vest use as a potential strategy to mitigate WL-associated bone loss in this population are needed. METHODS In the Incorporating Nutrition, Vests, Education, and Strength Training (INVEST) in Bone Health trial (NCT04076618), 192 older adults (60-85 years) who are overweight (BMI ≥ 27 kg/m 2 ) with at least one obesity-related risk factor or obese (BMI = 30-40 kg/m 2 ) will be randomly assigned to participate in one of three 12-month intervention groups: WL alone, WL + weighted vest use (WL + VEST), or WL + RT. The primary aim is to determine the effects of WL + VEST compared to WL alone and WL + RT on indicators of bone health and subsequent fracture risk. DISCUSSION Determining effective, translatable strategies that minimize bone loss during intentional WL among older adults holds public health potential. The INVEST in Bone Health trial offers an innovative approach for increasing mechanical stress during intentional WL in the absence of RT. If successful, findings from this study will provide evidence in support of a scalable solution to minimize bone loss during intentional WL among older adults with obesity.",2021,"The primary aim is to determine the effects of WL + VEST compared to WL alone and WL + RT on indicators of bone health and subsequent fracture risk. ","['older adults living with obesity', 'older adults with obesity', '192 older adults (60-85\u202fyears) who are overweight (BMI\u202f≥\u202f27\u202fkg/m 2 ) with at least one obesity-related risk factor or obese (BMI\u202f=\u202f30-40\u202fkg/m 2 ']","['Incorporating nutrition, vests, education, and strength training (INVEST', 'WL\u202f+\u202fVEST', 'WL alone, WL\u202f+\u202fweighted vest use (WL\u202f+\u202fVEST), or WL\u202f+\u202fRT', 'WL alone and WL\u202f+\u202fRT']",[],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}]","[{'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0453884', 'cui_str': 'Vest'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]",[],192.0,0.0738632,"The primary aim is to determine the effects of WL + VEST compared to WL alone and WL + RT on indicators of bone health and subsequent fracture risk. ","[{'ForeName': 'Ryan M', 'Initials': 'RM', 'LastName': 'Miller', 'Affiliation': 'Department of Internal Medicine-Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': 'Beavers', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Peggy M', 'Initials': 'PM', 'LastName': 'Cawthon', 'Affiliation': 'Research Institute, California Pacific Medical Center, San Francisco, CA, United States of America; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States of America.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Crotts', 'Affiliation': 'Department of Internal Medicine-Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Fanning', 'Affiliation': 'Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, United States of America.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Gerosa', 'Affiliation': 'Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Greene', 'Affiliation': 'Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Hsieh', 'Affiliation': 'Department of Internal Medicine-Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Kiel', 'Affiliation': 'Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, MD, United States of America.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Lawrence', 'Affiliation': 'Department of Internal Medicine-Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Lenchik', 'Affiliation': 'Department of Diagnostic Radiology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'S Delanie', 'Initials': 'SD', 'LastName': 'Lynch', 'Affiliation': 'Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Beverly A', 'Initials': 'BA', 'LastName': 'Nesbit', 'Affiliation': 'Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Nicklas', 'Affiliation': 'Department of Internal Medicine-Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Ashley A', 'Initials': 'AA', 'LastName': 'Weaver', 'Affiliation': 'Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.'}, {'ForeName': 'Kristen M', 'Initials': 'KM', 'LastName': 'Beavers', 'Affiliation': 'Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, United States of America. Electronic address: beaverkm@wfu.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106326'] 1028,33637001,Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.,"BACKGROUND Differences in serotonergic neurotransmission could lead to sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitors (SSRIs). AIMS We investigated whether women have greater reductions in depressive symptoms than men after treatment with an SSRI (citalopram) compared with a noradrenaline reuptake inhibitor (reboxetine) control, and after antidepressant treatment irrespective of class. We also investigated tolerability and the influence of menopausal status. METHODS Secondary analyses of the GENPOD (GENetic and clinical Predictors Of treatment response in Depression) trial. Six hundred and one people with depression were recruited from UK primary care and randomized to citalopram or reboxetine. Beck Depression Inventory (BDI-II) score at 6 weeks was the primary outcome. Secondary outcomes included BDI-II score at 12 weeks, and physical symptoms and treatment discontinuation. We calculated main effects and interaction terms using linear and logistic regression models. RESULTS There was no evidence that women experienced greater reductions in depressive symptoms than men when treated with citalopram compared with reboxetine. We also found no evidence of sex differences at six or 12 weeks (irrespective of antidepressant class): men scored -0.31 (95% confidence interval (CI) -2.23 to 1.62) BDI-II points lower than women at six weeks and -0.44 (95% CI -2.62 to 1.74) points lower at 12 weeks. There was no evidence of sex differences in physical symptoms or treatment discontinuation and no evidence for an influence of menopausal status. CONCLUSION Citalopram was not more effective in women compared with men and there was no difference in tolerability. Women and men had similar prognosis after SSRI treatment and similar prognosis regardless of antidepressant class. Findings were unaltered by menopausal status.",2021,"There was no evidence of sex differences in physical symptoms or treatment discontinuation and no evidence for an influence of menopausal status. ",['Six hundred and one people with depression were recruited from UK primary care and randomized to'],"['citalopram', 'noradrenaline reuptake inhibitor (reboxetine', 'reboxetine', 'citalopram or reboxetine', 'SSRI (citalopram', 'Citalopram']","['depressive symptoms and tolerability', 'depressive symptoms', 'tolerability', 'Beck Depression Inventory (BDI-II) score', 'BDI-II points lower', 'BDI-II score at 12\u2009weeks, and physical symptoms and treatment discontinuation']","[{'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]","[{'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C1319313', 'cui_str': 'Norepinephrine reuptake inhibitor-containing product'}, {'cui': 'C0168388', 'cui_str': 'reboxetine'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0006448', 'cui_str': 'Burundi'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]",601.0,0.40205,"There was no evidence of sex differences in physical symptoms or treatment discontinuation and no evidence for an influence of menopausal status. ","[{'ForeName': 'Marilia', 'Initials': 'M', 'LastName': 'Gougoulaki', 'Affiliation': 'Barnet, Enfield and Haringey Mental Health NHS Trust, London, UK.'}, {'ForeName': 'Glyn', 'Initials': 'G', 'LastName': 'Lewis', 'Affiliation': 'Division of Psychiatry, Faculty of Brain Sciences, University College London, London, UK.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Nutt', 'Affiliation': 'Department of Psychiatry, Division of Brain Science, Imperial College, London, UK.'}, {'ForeName': 'Tim J', 'Initials': 'TJ', 'LastName': 'Peters', 'Affiliation': 'Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Nicola J', 'Initials': 'NJ', 'LastName': 'Wiles', 'Affiliation': 'Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Lewis', 'Affiliation': 'Division of Psychiatry, Faculty of Brain Sciences, University College London, London, UK.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120986417'] 1029,33653932,The Severe Respiratory Insufficiency Application (SRI App): a pilot randomised controlled trial.,"An application (app) for the Severe Respiratory Insufficiency Questionnaire (SRI) has been designed and developed for mobile devices. In a randomised controlled trial comprising 60 patients with chronic respiratory failure, the app was compared with the classic paper SRI. Thereby, it was shown that the SRI app is a practical tool that is well accepted. Missing values can be completely avoided by using the SRI app. Finally, reliability, convergent and discriminant validities were established. Accordingly, for the individual SRI subscales, Cronbach's alpha ranged between 0.56 and 0.81 (app) and between 0.54 and 0.83 (paper), respectively. The multilingual SRI app is accessible free of charge for non-profit research purposes.",2021,"Accordingly, for the individual SRI subscales, Cronbach's alpha ranged between 0.56 and 0.81 (app) and between 0.54 and 0.83 (paper), respectively.","['60 patients with chronic respiratory failure, the app was compared with the classic paper SRI']",[],['Severe Respiratory Insufficiency Application (SRI App'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0264492', 'cui_str': 'Chronic respiratory failure'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0439658', 'cui_str': 'Classic'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0034088', 'cui_str': 'Pulmonic valve regurgitation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",[],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0034088', 'cui_str': 'Pulmonic valve regurgitation'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]",60.0,0.0534687,"Accordingly, for the individual SRI subscales, Cronbach's alpha ranged between 0.56 and 0.81 (app) and between 0.54 and 0.83 (paper), respectively.","[{'ForeName': 'Daniel Sebastian', 'Initials': 'DS', 'LastName': 'Majorski', 'Affiliation': 'Lung Clinic, Kliniken der Stadt Köln gGmbH, Köln, Germany.'}, {'ForeName': 'Sarah Bettina', 'Initials': 'SB', 'LastName': 'Schwarz', 'Affiliation': 'Lung Clinic, Kliniken der Stadt Köln gGmbH, Köln, Germany.'}, {'ForeName': 'Friederike Sophie', 'Initials': 'FS', 'LastName': 'Magnet', 'Affiliation': 'Lung Clinic, Kliniken der Stadt Köln gGmbH, Köln, Germany.'}, {'ForeName': 'Rebar', 'Initials': 'R', 'LastName': 'Ahmad', 'Affiliation': 'Informatics, Hochschule Niederrhein, Krefeld, Germany.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Mathes', 'Affiliation': 'Institute for Research in Operative Medicine, University Witten/Herdecke, Köln, Germany.'}, {'ForeName': 'Wolfram', 'Initials': 'W', 'LastName': 'Windisch', 'Affiliation': 'Lung Clinic, Kliniken der Stadt Köln gGmbH, Köln, Germany windischw@kliniken-koeln.de.'}]",Thorax,['10.1136/thoraxjnl-2020-216319'] 1030,33586283,Introducing mindfulness and compassion-based interventions to improve verbal creativity in students of clinical and health psychology.,"OBJECTIVES In the field of psychotherapy, verbal creativity has been suggested as an important aspect in psychotherapists' training. In the present study, the effects of a mindfulness and compassion-based intervention (MCBI) on verbal creativity are analysed in students of clinical and health psychology (N = 90). DESIGN Students were randomly assigned to an experimental group (n = 37), in which an MCBI was applied, and a waiting list group (n = 26) with no intervention. We also assessed a non-randomized active control group (n = 27), in which students received training in basic psychotherapy skills. METHODS Verbal creativity (fluency, flexibility, and originality) was evaluated in a pre-, post-, and follow-up assessment. RESULTS Results indicated a significant increase in fluency (p = .001, d = .64), flexibility (p = .017, d = .67), and originality (p = .004, d = .72) in the experimental group, relative to the waiting list group, in the post-assessment. Fluency (p = .010, d = .64) and flexibility (p = .033, d = .62) were also found to be higher in the follow-up assessment. In addition, results indicated a significant increase in flexibility (p = .034, d = .74) in the experimental group, relative to the active control group, in the follow-up assessment. CONCLUSIONS Introducing MCBI in the university education of psychotherapists seems to be a useful strategy to improve their verbal creativity, which could positively influence their ability to explore and appropriately respond to their patients' needs. PRACTITIONER POINTS Mindfulness and compassion-based interventions (MCBIs) could be a useful strategy to improve verbal creativity in the university education of psychotherapists. After the MCBI, students of clinical and health psychology increased the number of ideas they produced when facing a specific situation, as well as their variety and originality.",2021,"RESULTS Results indicated a significant increase in fluency (p = .001, d = .64), flexibility (p = .017, d = .67), and originality (p = .004, d = .72) in the experimental group, relative to the waiting list group, in the post-assessment.","['Students', 'students of clinical and health psychology']","['training in basic psychotherapy skills', 'mindfulness and compassion-based intervention (MCBI', 'Mindfulness and compassion-based interventions (MCBIs']","['flexibility', 'Fluency', 'fluency', 'Verbal creativity (fluency, flexibility, and originality', 'verbal creativity']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0302827', 'cui_str': 'Psychology, Health'}]","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0010297', 'cui_str': 'Creative thought'}]",,0.0242308,"RESULTS Results indicated a significant increase in fluency (p = .001, d = .64), flexibility (p = .017, d = .67), and originality (p = .004, d = .72) in the experimental group, relative to the waiting list group, in the post-assessment.","[{'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Bellosta-Batalla', 'Affiliation': 'El Arte de Escuchar, Psychotherapy and Mindfulness, Valencia, Spain.'}, {'ForeName': 'Ausiàs', 'Initials': 'A', 'LastName': 'Cebolla', 'Affiliation': 'Department of Personality, Evaluation and Psychological Treatment, University of Valencia, Spain.'}, {'ForeName': 'Josefa', 'Initials': 'J', 'LastName': 'Pérez-Blasco', 'Affiliation': 'Department of Evolutionary and Educational Psychology, University of Valencia, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Moya-Albiol', 'Affiliation': 'Department of Psychobiology, University of Valencia, Spain.'}]",Psychology and psychotherapy,['10.1111/papt.12329'] 1031,33591012,Prior Exposure to Angiotensin II Receptor Blockers in Patients With Septic Shock to Individualize Mean Arterial Pressure Target? A Post Hoc Analysis of the Sepsis and Mean Arterial Pressure (SEPSISPAM) Trial.,"OBJECTIVES Individualizing a target mean arterial pressure is challenging during the initial resuscitation of patients with septic shock. The Sepsis and Mean Arterial Pressure (SEPSISPAM) trial suggested that targeting high mean arterial pressure might reduce the occurrence of acute kidney injury among those included patients with a past history of chronic hypertension. We investigated whether the class of antihypertensive medications used before the ICU stay in chronic hypertensive patients was associated with the severity of acute kidney injury occurring after inclusion, according to mean arterial pressure target. DESIGN Post hoc analysis of the SEPSISPAM trial. SETTING The primary outcome was the occurrence of severe acute kidney injury during the ICU stay defined as kidney disease improving global outcome stage 2 or higher. Secondary outcomes were mortality at day 28 and mortality at day 90. PATIENTS All patients with chronic hypertension included in SEPSISPAM with available antihypertensive medications data in the hospitalization report were included. MEASUREMENTS AND MAIN RESULTS We analyzed 297 patients. Severe acute kidney injury occurred in 184 patients, without difference according to pre-ICU exposure to antihypertensive medications. Patients with pre-ICU exposure to angiotensin II receptor blockers had significantly less severe acute kidney injury in the high mean arterial pressure target group (adjusted odd ratio 0.24 with 95% CI [0.09-0.66]; p = 0.006). No statistically significant association was found after adjustment for pre-ICU exposure to antihypertensive medications and survival. CONCLUSIONS Our results suggest that patients with septic shock and chronic hypertension treated with angiotensin II receptor blocker may benefit from a high mean arterial pressure target to reduce the risk of acute kidney injury occurrence.",2021,Patients with pre-ICU exposure to angiotensin II receptor blockers had significantly less severe acute kidney injury in the high mean arterial pressure target group (adjusted odd ratio 0.24 with 95% CI [0.09-0.66]; p = 0.006).,"['patients with septic shock and chronic hypertension', 'Patients With Septic Shock to Individualize Mean Arterial Pressure Target', 'chronic hypertensive patients', 'patients with septic shock', 'All patients with chronic hypertension included in SEPSISPAM with available antihypertensive medications data in the hospitalization report were included']","['Angiotensin II Receptor Blockers', 'angiotensin II receptor blockers', 'angiotensin II receptor blocker']","['mortality at day 28 and mortality', 'Severe acute kidney injury', 'severe acute kidney injury', 'occurrence of severe acute kidney injury during the ICU stay defined as kidney disease improving global outcome stage 2 or higher']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0205250', 'cui_str': 'High'}]",297.0,0.122298,Patients with pre-ICU exposure to angiotensin II receptor blockers had significantly less severe acute kidney injury in the high mean arterial pressure target group (adjusted odd ratio 0.24 with 95% CI [0.09-0.66]; p = 0.006).,"[{'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Demiselle', 'Affiliation': 'Department of Medical Intensive Care, University Hospital of Angers, Angers, France.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Seegers', 'Affiliation': ""Service de Biométrie, Institut de Cancérologie de l'Ouest, Centre Paul Papin, Angers, France.""}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Lemerle', 'Affiliation': 'Department of Medical Intensive Care, University Hospital of Angers, Angers, France.'}, {'ForeName': 'Ferhat', 'Initials': 'F', 'LastName': 'Meziani', 'Affiliation': 'Department of Medical Intensive Care, University Hospital of Strasbourg, Nouvel Hôpital Civil, Strasbourg, France.'}, {'ForeName': 'Fabien', 'Initials': 'F', 'LastName': 'Grelon', 'Affiliation': 'Medical and Surgical Intensive Care Unit, Le Mans Hospital, Le Mans, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Megarbane', 'Affiliation': 'Department of Medical and Toxicological Intensive Care, Lariboisière University Hospital, University of Paris, INSERM UMRS-1144, Paris, France.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Anguel', 'Affiliation': 'Department of Medical Intensive Care, Bicêtre University Hospital, AP-HP, Paris-Saclay University, Le Kremlin Bicêtre, France.'}, {'ForeName': 'Jean-Paul', 'Initials': 'JP', 'LastName': 'Mira', 'Affiliation': 'Department of Medical Intensive Care, Cochin University Hospital, Paris, France.'}, {'ForeName': 'Pierre-François', 'Initials': 'PF', 'LastName': 'Dequin', 'Affiliation': 'Department of Medical Intensive Care, Tours University Hospital, Tours, France.'}, {'ForeName': 'Soizic', 'Initials': 'S', 'LastName': 'Gergaud', 'Affiliation': 'Department of Surgical Intensive Care, University Hospital of Angers, Angers, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Weiss', 'Affiliation': 'Department of Medical Intensive Care, Georges Pompidou European Hospital, Paris, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Legay', 'Affiliation': 'Department of Medical Intensive Care, Saint Brieuc Hospital, Saint Brieuc, France.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Le Tulzo', 'Affiliation': 'Department of Infectious Diseases and Medical Intensive Care, Rennes University Hospital, Rennes, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Conrad', 'Affiliation': 'Department of Medical Intensive Care, Nancy University Hospital, Nancy, France.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Robert', 'Affiliation': 'Department of Medical Intensive Care, Université de Poitiers, CHU Poitiers, Poitiers, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Gonzalez', 'Affiliation': 'Department of Medical and Surgical Intensive Care, Avicenne Teaching Hospital, Bobigny, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Guitton', 'Affiliation': 'Department of Medical Intensive Care, Nantes University Hospital, Nantes, France.'}, {'ForeName': 'Fabienne', 'Initials': 'F', 'LastName': 'Tamion', 'Affiliation': 'Department of Medical Intensive Care, Rouen University Hospital, Rouen, France.'}, {'ForeName': 'Jean-Marie', 'Initials': 'JM', 'LastName': 'Tonnelier', 'Affiliation': 'Department of Medical Intensive Care, Brest University Hospital, Brest, France.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Bédos', 'Affiliation': 'Department of Medical and Surgical Intensive Care, Versailles Hospital, Versailles, France.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Van Der Linden', 'Affiliation': 'Department of Intensive Care, Saint Philibert hospital, Catholic university of Lille, Lille, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Vieillard-Baron', 'Affiliation': 'Department of Medical and Surgical Intensive Care, Boulogne Billancourt University Hospital, Boulogne Billancourt, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Mariotte', 'Affiliation': 'Department of Intensive Care, Saint Louis Hospital, Paris, France.'}, {'ForeName': 'Gaël', 'Initials': 'G', 'LastName': 'Pradel', 'Affiliation': 'Department of Intensive Care, Avignon Hospital, Avignon, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Lesieur', 'Affiliation': 'Department of Medical and Surgical Intensive Care, La Rochelle Saint Louis Hospital, La Rochelle, France.'}, {'ForeName': 'Jean-Damien', 'Initials': 'JD', 'LastName': 'Ricard', 'Affiliation': 'Department of Medico-Surgical Intensive Care, Université de Paris, Assistance Publique - Hôpitaux de Paris, Louis Mourier Hospital, Colombes, France.'}, {'ForeName': 'Fabien', 'Initials': 'F', 'LastName': 'Hervé', 'Affiliation': 'Department of Medical and Surgical Intensive Care, Quimper Hospital, Quimper, France.'}, {'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'du Cheyron', 'Affiliation': 'Department of Medical Intensive Care, Caen University Hospital, Caen, France.'}, {'ForeName': 'Claude', 'Initials': 'C', 'LastName': 'Guerin', 'Affiliation': 'Department of Medical Intensive Care, Edouard Herriot Hospital, Lyon, France.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Teboul', 'Affiliation': 'Department of Medical Intensive Care, Bicêtre University Hospital, AP-HP, Paris-Saclay University, Le Kremlin Bicêtre, France.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Helms', 'Affiliation': 'Department of Medical Intensive Care, University Hospital of Strasbourg, Nouvel Hôpital Civil, Strasbourg, France.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Radermacher', 'Affiliation': 'Institut für Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinikum, Helmholtzstrasse 8-1, Ulm, Germany.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Asfar', 'Affiliation': 'Department of Medical Intensive Care, University Hospital of Angers, Angers, France.'}]",Critical care medicine,['10.1097/CCM.0000000000004872'] 1032,33591858,Effects of whey protein on skeletal muscle microvascular and mitochondrial plasticity following 10 weeks of exercise training in men with type 2 diabetes.,"Skeletal muscle microvascular dysfunction and mitochondrial rarefaction feature in type 2 diabetes mellitus (T2DM) linked to low tissue glucose disposal rate (GDR). Exercise training and milk protein supplementation independently promote microvascular and metabolic plasticity in muscle associated with improved nutrient delivery, but combined effects are unknown. In a randomised-controlled trial, 24 men (55.6 y, SD 5.7) with T2DM ingested whey protein drinks (protein/carbohydrate/fat: 20/10/3 g; WHEY) or placebo (carbohydrate/fat: 30/3 g; CON) before/after 45 mixed-mode intense exercise sessions over 10 weeks, to study effects on insulin-stimulated (hyperinsulinemic clamp) skeletal-muscle microvascular blood flow (mBF) and perfusion (near-infrared spectroscopy), and histological, genetic, and biochemical markers (biopsy) of microvascular and mitochondrial plasticity. WHEY enhanced insulin-stimulated perfusion (WHEY-CON 5.6%; 90% CI -0.1, 11.3), while mBF was not altered (3.5%; -17.5, 24.5); perfusion, but not mBF, associated (regression) with increased GDR. Exercise training increased mitochondrial (range of means: 40%-90%) and lipid density (20%-30%), enzyme activity (20%-70%), capillary:fibre ratio (∼25%), and lowered systolic (∼4%) and diastolic (4%-5%) blood pressure, but without WHEY effects. WHEY dampened PGC1 α -2.9% (90% compatibility interval: -5.7, -0.2) and NOS3 -6.4% (-1.4, -0.2) expression, but other messenger RNA (mRNA) were unclear. Skeletal muscle microvascular and mitochondrial exercise adaptations were not accentuated by whey protein ingestion in men with T2DM. ANZCTR Registration Number: ACTRN12614001197628. Novelty: Chronic whey ingestion in T2DM with exercise altered expression of several mitochondrial and angiogenic mRNA. Whey added no additional benefit to muscle microvascular or mitochondrial adaptations to exercise. Insulin-stimulated perfusion increased with whey but was without impact on glucose disposal.",2021,"WHEY dampened PGC1α -2.9% (90%CI -5.7, -0.2) and NOS3 -6.4% (-1.4, -0.2) expression, but other mRNA were unclear.","['men with T2DM', '24 men (55.6 y, SD5.7) with T2DM ingested whey protein drinks (protein/carbohydrate/fat', 'type-2 diabetes mellitus (T2DM', 'Men with Type-2 Diabetes']","['Whey Protein', 'Exercise training and milk protein supplementation', 'Exercise Training', 'placebo (carbohydrate/fat', 'Exercise training']","['lipid density', 'Skeletal Muscle Microvascular and Mitochondrial Plasticity', 'mBF', 'enzyme activity', 'glucose disposal', 'insulin-stimulated (hyperinsulinemic clamp) skeletal-muscle microvascular blood flow (mBF) and perfusion (near-infrared spectroscopy), and histological, genetic, and biochemical markers (biopsy) of microvascular and mitochondrial plasticity']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0026138', 'cui_str': 'Milk protein'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]","[{'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0678558', 'cui_str': 'Plasticity'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0243102', 'cui_str': 'enzyme activity'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0376519', 'cui_str': 'Near-infrared spectroscopy'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}]",24.0,0.0631237,"WHEY dampened PGC1α -2.9% (90%CI -5.7, -0.2) and NOS3 -6.4% (-1.4, -0.2) expression, but other mRNA were unclear.","[{'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Gaffney', 'Affiliation': 'School of Sport, Exercise and Nutrition, Massey University, Wellington and Auckland, New Zealand.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Lucero', 'Affiliation': 'School of Sport, Exercise and Nutrition, Massey University, Wellington and Auckland, New Zealand.'}, {'ForeName': 'Donia', 'Initials': 'D', 'LastName': 'Macartney-Coxson', 'Affiliation': 'Human Genomics, Institute of Environmental and Scientific Research Ltd (ESR). Porirua, Wellington, New Zealand.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Clapham', 'Affiliation': 'Human Genomics, Institute of Environmental and Scientific Research Ltd (ESR). Porirua, Wellington, New Zealand.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Whitfield', 'Affiliation': 'Department of Medicine, University of Otago, Wellington, New Zealand.'}, {'ForeName': 'Barry R', 'Initials': 'BR', 'LastName': 'Palmer', 'Affiliation': 'School of Health Sciences, Massey University, Wellington, New Zealand.'}, {'ForeName': 'StJohn', 'Initials': 'S', 'LastName': 'Wakefield', 'Affiliation': 'Department of Medicine, University of Otago, Wellington, New Zealand.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Faulkner', 'Affiliation': 'School of Sport, Health and Community, University of Winchester, Winchester, England.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Stoner', 'Affiliation': 'Department of Exercise and Sport Science, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Rowlands', 'Affiliation': 'School of Sport, Exercise and Nutrition, Massey University, Wellington and Auckland, New Zealand.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2020-0943'] 1033,33604969,Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.,"BACKGROUND Hand-foot skin reaction (HFSR) is the most common regorafenib-induced adverse event and is in need of effective prevention and palliation. MATERIALS AND METHODS The Regorafenib Dose Optimization Study (ReDOS), a four-arm, previously published trial with a 1:1:1:1 randomization scheme, was analyzed in a manner in keeping with the original protocol to assess whether clobetasol 0.05% cream (a corticosteroid) applied to the palms and soles twice per day for 8 weeks was more effective when prescribed preemptively (before the development of HFSR) versus reactively (after the development of HFSR). Patients were assessed during the first two cycles of regorafenib. RESULTS Sixty-one patients received preemptive clobetasol, and 55 received reactive clobetasol. Groups were balanced on demographics. Over the first two cycles, no evidence of HFSR occurred in 30% with preemptive clobetasol versus 13% with reactive clobetasol (p = .03). During the first cycle, 54% and 45% of patients had no HFSR with preemptive and reactive clobetasol, respectively (p = .35). During the second cycle, 33% and 15% had no HFSR with preemptive and reactive clobetasol, respectively (p = .02). During the second cycle, rates of grade 1, 2, and 3 HFSR were 30%, 8%, and 3%, respectively, with preemptive clobetasol and 43%, 18%, and 7%, respectively, with reactive clobetasol (p = .12). Patient-reported outcomes showed HFSR compromised nearly all activities of daily living with worse quality of life in patients who received reactive versus preemptive clobetasol. No clobetasol-induced adverse events were reported. CONCLUSION Preemptive clobetasol might lessen regorafenib-induced hand-foot reactions compared with reactive therapy. Further confirmatory studies are needed in a larger patient cohort. IMPLICATIONS FOR PRACTICE Regorafenib causes hand-foot skin reactions. Preemptive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event. Although further study is needed, the favorable adverse event profile of this intervention might prompt clinicians to discuss this option with their patients.",2021,"emotive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event.",[],['Pre-Emptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions'],"['HFSR', 'rates of grade 1, 2, and 3 HFSR', 'adverse events', 'activities of daily living with worse quality of life']",[],"[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0008992', 'cui_str': 'Clobetasol'}, {'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]","[{'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0222289', 'cui_str': 'Skin structure of foot'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",61.0,0.0522288,"emotive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event.","[{'ForeName': 'Aminah', 'Initials': 'A', 'LastName': 'Jatoi', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Fang-Shu', 'Initials': 'FS', 'LastName': 'Ou', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Ahn', 'Affiliation': 'Mayo Clinic, Scottsdale, Arizona, USA.'}, {'ForeName': 'Tyler J', 'Initials': 'TJ', 'LastName': 'Zemla', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Jennifer G', 'Initials': 'JG', 'LastName': 'Le-Rademacher', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Boland', 'Affiliation': 'Roswell Park Cancer Institute, Buffalo, New York, USA.'}, {'ForeName': 'Kristen K', 'Initials': 'KK', 'LastName': 'Ciombor', 'Affiliation': 'Vanderbilt University, Nashville, Tennessee, USA.'}, {'ForeName': 'Nisha L', 'Initials': 'NL', 'LastName': 'Jacobs', 'Affiliation': 'Minnesota Hematology Oncology, Coon Rapids, Minnesota, USA.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Pasche', 'Affiliation': 'Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Cleary', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, Massachusetts, USA.'}, {'ForeName': 'Jeannine S', 'Initials': 'JS', 'LastName': 'McCune', 'Affiliation': 'City of Hope, Duarte, California, USA.'}, {'ForeName': 'Katrina S', 'Initials': 'KS', 'LastName': 'Pedersen', 'Affiliation': 'Washington University in St. Louis, St. Louis, Missouri, USA.'}, {'ForeName': 'Afsaneh', 'Initials': 'A', 'LastName': 'Barzi', 'Affiliation': 'City of Hope, Duarte, California, USA.'}, {'ForeName': 'E Gabriela', 'Initials': 'EG', 'LastName': 'Chiorean', 'Affiliation': 'University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Erica N', 'Initials': 'EN', 'LastName': 'Heying', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Heinz-Josef', 'Initials': 'HJ', 'LastName': 'Lenz', 'Affiliation': 'USC Norris Comprehensive Cancer Center, California, Los Angeles, USA.'}, {'ForeName': 'Jeff A', 'Initials': 'JA', 'LastName': 'Sloan', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Grothey', 'Affiliation': 'West Cancer Center, Germantown, Tennessee, USA.'}, {'ForeName': 'Mario E', 'Initials': 'ME', 'LastName': 'Lacouture', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Tanios', 'Initials': 'T', 'LastName': 'Bekaii-Saab', 'Affiliation': 'Mayo Clinic, Scottsdale, Arizona, USA.'}]",The oncologist,['10.1002/onco.13730'] 1034,33606764,Inhalational versus intravenous maintenance of anesthesia for quality of recovery in patients undergoing corrective lower limb osteotomy: A randomized controlled trial.,"BACKGROUND Inhalational anesthesia and propofol-based total intravenous anesthesia (TIVA) are the two most popular methods of general anesthesia with distinct characteristics that may affect quality of recovery (QOR) differently. This study compared QOR after corrective lower limb osteotomy between desflurane-based inhalational anesthesia and propofol-based TIVA. METHODS Sixty-eight patients, ASA class I or II who underwent corrective lower limb osteotomy were randomized to receive either desflurane anesthesia or propofol TIVA. The primary outcome was quality of recovery 40 (QoR-40) questionnaire scores on postoperative day (POD) 1 and 2. Postoperative nausea scores, antiemetic requirements, and amount of opioid consumption via intravenous patient-controlled analgesia (IV PCA) were assessed as secondary outcomes. RESULTS Global QoR-40 scores on POD 1 (153.5 (140.3, 171.3) vs. 140.0 (120.0, 173.0), P = 0.056, 95% CI; -22.5, 0.2) and POD 2 (155.5 (146.8, 175.5) vs. 152.0 (134.0, 179.0), P = 0.209, 95% CI; -17.5, 3.9) were comparable between the two groups. Among the five dimensions of QoR-40, physical independence scores were significantly higher in the TIVA group compared to the Desflurane group on POD both 1 and 2. Nausea scores (0.0 (0.0, 0.0) vs. 1.0 (0.0, 3.5), P < 0.001) and number of patients requiring rescue antiemetics (0% vs. 15.2%, P = 0.017) were significantly lower in the TIVA group at the post anesthesia care unit (PACU). Although the number of bolus attempts between 0-24 h and the morphine equivalent dose of analgesics administered via IV PCA between 12-24 h were significantly less in the TIVA group compared to the Desflurane group, there was no significant difference between groups for the overall 48 h postoperative period. CONCLUSIONS Propofol-based TIVA did not improve global QoR-40 scores compared with desflurane-based inhalational anesthesia. However, considering the better QoR-40 scores in the domain of physical independence and less nausea in the early postoperative period, propofol TIVA should be considered as a useful option in patients undergoing corrective lower limb osteotomy.",2021,"CONCLUSIONS Propofol-based TIVA did not improve global QoR-40 scores compared with desflurane-based inhalational anesthesia.","['I or II who underwent corrective lower limb osteotomy', 'Sixty-eight patients, ASA class', 'patients undergoing corrective lower limb osteotomy']","['Propofol-based TIVA', 'desflurane anesthesia or propofol TIVA', 'morphine', 'Desflurane', 'desflurane-based inhalational anesthesia', 'Inhalational versus intravenous maintenance of anesthesia', 'Inhalational anesthesia and propofol-based total intravenous anesthesia (TIVA', 'desflurane-based inhalational anesthesia and propofol-based TIVA']","['global QoR-40 scores', 'Postoperative nausea scores, antiemetic requirements, and amount of opioid consumption via intravenous patient-controlled analgesia (IV PCA', 'nausea', 'quality of recovery 40 (QoR-40) questionnaire scores on postoperative day (POD) 1 and 2', 'Nausea scores', 'QoR-40, physical independence scores', 'number of patients requiring rescue antiemetics']","[{'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0029468', 'cui_str': 'Osteotomy'}, {'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0473965', 'cui_str': 'Total intravenous anesthesia'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0853213', 'cui_str': 'Maintenance of anaesthesia'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0520904', 'cui_str': 'Postoperative nausea'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic agent'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",,0.0969969,"CONCLUSIONS Propofol-based TIVA did not improve global QoR-40 scores compared with desflurane-based inhalational anesthesia.","[{'ForeName': 'Seung Hyun', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Hyang Mi', 'Initials': 'HM', 'LastName': 'Ju', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Chong-Hyuck', 'Initials': 'CH', 'LastName': 'Choi', 'Affiliation': 'Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Hae Ri', 'Initials': 'HR', 'LastName': 'Park', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Seokyung', 'Initials': 'S', 'LastName': 'Shin', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.'}]",PloS one,['10.1371/journal.pone.0247089'] 1035,33615404,Anatomic single- and double-bundle ACL reconstruction both restore dynamic knee function: a randomized clinical trial-part II: knee kinematics.,"PURPOSE Compare side-to-side differences for knee kinematics between anatomic single-bundle (SB) and anatomic double-bundle (DB) ACLR during downhill running at 6 and 24 months post ACLR using high-accuracy dynamic stereo X-ray imaging. It was hypothesized that anatomic DB ACLR would better restore tibio-femoral kinematics compared to SB ACLR, based on comparison to the contralateral, uninjured knee. METHODS Active individuals between 14 and 50 years of age that presented within 12 months of injury were eligible to participate. Individuals with prior injury or surgery of either knee, greater than a grade 1 concomitant knee ligament injury, or ACL insertion sites less than 14 mm or greater than 18 mm were excluded. Subjects were randomized to undergo SB or DB ACLR with a 10 mm-wide quadriceps tendon autograft harvested with a patellar bone block and were followed for 24 months. Dynamic knee function was assessed during treadmill downhill running using a dynamic stereo X-ray tracking system at 6 and 24 months after surgery. Three-dimensional tibio-femoral kinematics were calculated and compared between limbs (ACLR and uninjured contralateral) at each time point. RESULTS Fifty-seven subjects were randomized (29 DB) and 2-year follow-up was attained from 51 (89.5%). No significant differences were found between SB and DB anatomic ACLR for any of the primary kinematic variables. CONCLUSIONS Contrary to the study hypothesis, double-bundle reconstruction did not show superior kinematic outcomes compared to the single-bundle ACLR. While neither procedure fully restored normal knee kinematics, both anatomic reconstructions were similarly effective for restoring near-normal dynamic knee function. The findings of this study indicate both SB and DB techniques can be used for patients with average size ACL insertion sites. LEVEL OF EVIDENCE Level I.",2021,"Contrary to the study hypothesis, double-bundle reconstruction did not show superior kinematic outcomes compared to the single-bundle ACLR.","['Individuals with prior injury or surgery of either knee, greater than a grade 1 concomitant knee ligament injury, or ACL insertion sites less than 14\xa0mm or greater than 18\xa0mm were excluded', 'Active individuals between 14 and 50\xa0years of age that presented within 12\xa0months of injury were eligible to participate', 'Fifty-seven subjects', 'patients with average size ACL insertion sites']","['Anatomic single- and double-bundle ACL reconstruction', 'anatomic single-bundle (SB) and anatomic double-bundle (DB) ACLR', 'SB or DB ACLR with a 10\xa0mm-wide quadriceps tendon autograft harvested with a patellar bone block']","['restore tibio-femoral kinematics', 'Dynamic knee function', 'normal knee kinematics', 'SB and DB anatomic ACLR']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0877583', 'cui_str': 'Injury of ligament of knee'}, {'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0449682', 'cui_str': 'Site of insertion'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456389', 'cui_str': 'Size'}]","[{'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0224941', 'cui_str': 'Structure of quadriceps tendon'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}, {'cui': 'C1293164', 'cui_str': 'Bone block procedure'}]","[{'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}]",57.0,0.0780364,"Contrary to the study hypothesis, double-bundle reconstruction did not show superior kinematic outcomes compared to the single-bundle ACLR.","[{'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Tashman', 'Affiliation': 'Steadman Philippon Research Institute, Vail, CO, USA.'}, {'ForeName': 'Payam', 'Initials': 'P', 'LastName': 'Zandiyeh', 'Affiliation': 'Steadman Philippon Research Institute, Vail, CO, USA.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Irrgang', 'Affiliation': 'Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, USA. jirrgang@pitt.edu.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Musahl', 'Affiliation': 'UPMC Center for Sports Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Robin Vereeke', 'Initials': 'RV', 'LastName': 'West', 'Affiliation': 'Inova Sports Medicine, Fairfax, VA, USA.'}, {'ForeName': 'Neha', 'Initials': 'N', 'LastName': 'Shah', 'Affiliation': 'Department of Orthopaedic Surgery, University of Pittsburgh, 3471 Fifth Avenue, Pittsburgh, PA, 15213, USA.'}, {'ForeName': 'Freddie H', 'Initials': 'FH', 'LastName': 'Fu', 'Affiliation': 'Department of Orthopaedic Surgery, University of Pittsburgh, 3471 Fifth Avenue, Pittsburgh, PA, 15213, USA.'}]","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA",['10.1007/s00167-021-06479-x'] 1036,33620551,"A randomized, double-blind study of iodine supplementation during pregnancy in Sweden: pilot evaluation of maternal iodine status and thyroid function.","PURPOSE Pregnant women in Sweden are mildly iodine deficient. We investigated the effect of daily iodine supplementation on the iodine and thyroid status of pregnant women. METHODS In this pilot, randomized, double-blind trial, 200 thyroid-healthy pregnant women were recruited at mean (standard deviation) pregnancy week 8.85 (1.62) and assigned (1:1) to daily intake of a multivitamin tablet with or without 150 μg of iodine. Urine and serum samples were collected at baseline and once during the second and third trimesters. Urinary iodine concentration (UIC), serum thyroglobulin (Tg), thyroid-stimulating hormone (TSH), free thyroxine (FT4), and thyroid peroxidase antibodies (TPOabs) were analyzed. Neonatal TSH data were collected. UIC and Tg were also analyzed in a group of 89 thyroid-healthy non-pregnant women of reproductive age (WRA). RESULTS At baseline, the intervention and the control groups had similar median UIC (interquartile range (IQR)): 110 μg/L (74-119) and 111 μg/L (66-168), respectively. The intervention group reached iodine sufficiency with median UIC (IQR) 139 μg/L (89-234) and 136 μg/L (91-211) in the second and third trimester, respectively, without significant difference from the lower limit of the recommended range, i.e. 150-250 μg/L (p = 0.42 and p = 0.87, respectively). The intervention group had higher median UIC and lower median Tg compared to the control group during the second (p < 0.001 and p = 0.019, respectively) and third trimester (p < 0.001 and p = 0.003, respectively), whereas thyroid hormones, serum TPOabs, and neonatal TSH were similar. The WRA group presented median UIC (IQR) 65 μg/L (30-98) and median Tg (IQR) 18 μg/L (13-27). CONCLUSION A daily supplement containing 150 μg of iodine to a group of pregnant women with mild iodine deficiency improved the iodine status from mild ID to iodine sufficiency. This improvement seems to have had a positive impact on maternal thyroglobulin. This study is now under extension to investigate the children's neuropsychological development. TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT02378246, May 3, 2015, retrospectively registered.",2021,A daily supplement containing 150 μg of iodine to a group of pregnant women with mild iodine deficiency improved the iodine status from mild ID to iodine sufficiency.,"[""children's neuropsychological development"", '200 thyroid-healthy pregnant women were recruited at mean (standard deviation) pregnancy week 8.85 (1.62) and assigned (1:1) to daily intake of a', '89 thyroid-healthy non-pregnant women of reproductive age (WRA', 'Pregnant women in Sweden are mildly iodine deficient', 'pregnant women with mild iodine deficiency improved the iodine status from mild ID to iodine sufficiency', 'pregnancy in Sweden', '65\xa0μg', 'pregnant women']","['multivitamin tablet with or without 150\xa0μg of iodine', 'daily iodine supplementation', 'iodine supplementation']","['Urine and serum samples', 'iodine sufficiency with median UIC', 'median UIC (IQR', 'higher median UIC and lower median Tg', 'thyroid hormones, serum TPOabs, and neonatal TSH', 'Urinary iodine concentration (UIC), serum thyroglobulin (Tg), thyroid-stimulating hormone (TSH), free thyroxine (FT4), and thyroid peroxidase antibodies (TPOabs', 'median UIC (interquartile range (IQR']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0040132', 'cui_str': 'Thyroid structure'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C2945599', 'cui_str': 'Mild'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C4759669', 'cui_str': 'Iodine deficiency'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0301532', 'cui_str': 'Multivitamin preparation'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C1550100', 'cui_str': 'Serum specimen'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0040123', 'cui_str': 'Thyroglobulin'}, {'cui': 'C0040135', 'cui_str': 'Thyroid hormone'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0076635', 'cui_str': 'Thyroid microsomal antibody'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0040160', 'cui_str': 'Thyrotropin'}, {'cui': 'C0202225', 'cui_str': 'T4 free measurement'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]",200.0,0.355709,A daily supplement containing 150 μg of iodine to a group of pregnant women with mild iodine deficiency improved the iodine status from mild ID to iodine sufficiency.,"[{'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Manousou', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. sofia.manousou@vgregion.se.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Eggertsen', 'Affiliation': 'School of Public Health and Community Medicine/General Medicine, R and D Centre Gothenburg and Södra Bohuslän, University of Gothenburg, Göteborg, Sweden.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Hulthén', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Filipsson Nyström', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.'}]",European journal of nutrition,['10.1007/s00394-021-02515-1'] 1037,33620550,"A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis.","PURPOSE Coenzyme Q10 (CoQ10), having potent antioxidant and anti-inflammatory pharmacological properties, has recently been shown to be a safe and promising agent in maintaining remission of ulcerative colitis (UC). This trial was, therefore, designed to determine CoQ10 efficacy on inflammation and antioxidant status, antimicrobial peptides, and microRNA-146a expression in UC patients. METHODS In this randomized double-blind controlled trial, 88 mild-to-moderate UC patients were randomly allocated to receive CoQ10 (200 mg/day) or placebo (rice flour) for 2 months. At the baseline and at an 8-week follow-up, serum levels of Nrf2, cathelicidin LL-37, β-defensin 2, IL-10, IL-17, NF-κB p65 activity in peripheral blood mononuclear cells (PBMCs), simple clinical colitis activity index questionnaire (SCCAIQ), and quality of life (IBDQ-32 score), as well as an expression rate of microRNA-146a were measured. RESULTS A significant reduction was detected in the serum IL-17 level, activity of NF-κB p65 in PBMCs, and also SCCAI score in the CoQ10 group compared to the placebo group, whereas IL-10 serum concentrations and IBDQ-32 score of the CoQ10 group considerably increased versus the control group; the changes of these variables were also significantly different within and between groups at the end of the study. Furthermore, CoQ10 remarkably increased serum levels of cathelicidin LL-37. A significant change in serum cathelicidin LL-37 levels was also observed between the two groups. No statistical difference, however, was seen between the two groups in terms of the serum levels of Nrf2 and β-defensin 2 and the relative expression of microRNA-146a. CONCLUSIONS Our results indicate that CoQ10 supplementation, along with drug therapy, appears to be an efficient reducer of inflammation in patients with mild-to-moderate UC at a remission phase. TRIAL REGISTRATION The research has also been registered at the Iranian Registry of Clinical Trials (IRCT): IRCT20090822002365N17.",2021,"A significant reduction was detected in the serum IL-17 level, activity of NF-κB p65 in PBMCs, and also SCCAI score in the CoQ10 group compared to the placebo group, whereas IL-10 serum concentrations and IBDQ-32 score of the CoQ10 group considerably increased versus the control group; the changes of these variables were also significantly different within and between groups at the end of the study.","['88 mild-to-moderate UC patients', 'UC patients', 'patients with mild-to-moderate ulcerative colitis']","['CoQ10 supplementation', 'coenzyme Q10', 'placebo', 'CoQ10', 'Coenzyme Q10 (CoQ10', 'placebo (rice flour']","['serum levels of Nrf2, cathelicidin LL-37, β-defensin 2, IL-10, IL-17, NF-κB p65 activity in peripheral blood mononuclear cells (PBMCs), simple clinical colitis activity index questionnaire (SCCAIQ), and quality of life (IBDQ-32 score), as well as an expression rate of microRNA-146a', 'CoQ10 efficacy on inflammation and antioxidant status, antimicrobial peptides, and microRNA-146a expression', 'IL-10 serum concentrations and IBDQ-32 score', 'serum levels of cathelicidin LL-37', 'serum levels of Nrf2 and β-defensin 2 and the relative expression of microRNA-146a', 'serum IL-17 level, activity of NF-κB p65 in PBMCs, and also SCCAI score', 'immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression', 'serum cathelicidin LL-37 levels']","[{'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0056077', 'cui_str': 'Ubiquinone'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C0016260', 'cui_str': 'Flour'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1565078', 'cui_str': 'NFE2L2 protein, human'}, {'cui': 'C0108282', 'cui_str': 'CAP18 lipopolysaccharide-binding protein'}, {'cui': 'C0057256', 'cui_str': 'Defensins'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0299809', 'cui_str': 'PAK2 Kinase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0009319', 'cui_str': 'Colitis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C1101610', 'cui_str': 'MicroRNA'}, {'cui': 'C0056077', 'cui_str': 'Ubiquinone'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}]",88.0,0.192894,"A significant reduction was detected in the serum IL-17 level, activity of NF-κB p65 in PBMCs, and also SCCAI score in the CoQ10 group compared to the placebo group, whereas IL-10 serum concentrations and IBDQ-32 score of the CoQ10 group considerably increased versus the control group; the changes of these variables were also significantly different within and between groups at the end of the study.","[{'ForeName': 'Farnaz', 'Initials': 'F', 'LastName': 'Farsi', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nasser', 'Initials': 'N', 'LastName': 'Ebrahimi-Daryani', 'Affiliation': 'Head of Gastroenterology Ward, School of Medicine, Imam Khomeini Hospital, Tehran, Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Golab', 'Affiliation': 'Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Abolfazl', 'Initials': 'A', 'LastName': 'Akbari', 'Affiliation': 'Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Janani', 'Affiliation': 'Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Yahya', 'Initials': 'MY', 'LastName': 'Karimi', 'Affiliation': 'Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Pardis', 'Initials': 'P', 'LastName': 'Irandoost', 'Affiliation': 'Student Research Committee, Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Naimeh Mesri', 'Initials': 'NM', 'LastName': 'Alamdari', 'Affiliation': 'Student Research Committee, Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shahram', 'Initials': 'S', 'LastName': 'Agah', 'Affiliation': 'Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Vafa', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. vafa.m@iums.ac.ir.'}]",European journal of nutrition,['10.1007/s00394-021-02514-2'] 1038,33627163,Spinal manipulation and modulation of pain sensitivity in persistent low back pain: a secondary cluster analysis of a randomized trial.,"BACKGROUND Pain hypersensitivity can be assessed using Quantitative Sensory Testing (QST) and is associated with persistent low back pain. Spinal manipulation appears to modify pain hypersensitivity, and this could function as one mechanism leading to clinical improvements. In the current study, we applied a comprehensive QST battery to assess pain sensitivity in a cohort of low back pain patients before and after spinal manipulation to improve our understanding of the association between QST and clinical improvements. This study addresses two questions: Are clinical improvements following spinal manipulation in low back pain patients contingent on pain hypersensitivity, and does pain sensitivity change following spinal manipulation? METHODS We performed a secondary analysis of data from a randomized clinical trial. One hundred and thirty-two participants with persistent LBP were treated with spinal manipulation four times over two weeks. Patient-reported outcomes and QST were assessed at baseline, after the fourth spinal manipulation session, and 14-days later. The clinical outcomes were changes in low back pain intensity and disability. Using latent profile analysis, we categorized the participants into clusters depending on their baseline QST scores. We used linear mixed models to examine the association between clusters and changes in patient-reported outcomes and QST. RESULTS Two clusters emerged: a Sensitized and a Not sensitized. The former had significantly lower regional pressure and thermal pain thresholds, remote pressure pain tolerance, and lower inhibitory conditioned pain modulation than the Not sensitized group. However, we only found between-cluster differences for regional pressure pain threshold following spinal manipulation. Thus, the clusters were not associated with patient-reported pain and disability changes or the remaining QST outcomes. CONCLUSIONS We report that the baseline QST profile was not associated with clinical improvements following spinal manipulation. We did observe a substantial change for regional pressure pain threshold, which suggests that any effect of spinal manipulation on pain sensitivity is most likely to be observed as changes in regional, mechanical pain threshold. However, the mechanism that invokes clinical improvement and pain sensitivity changes appear distinct. Due to methodological caveats, we advise caution when interpreting the results. TRIAL REGISTRATION Clinical.Trial.gov identifier: NCT04086667 , registered 11 September 2019 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04086667.",2021,"The former had significantly lower regional pressure and thermal pain thresholds, remote pressure pain tolerance, and lower inhibitory conditioned pain modulation than the Not sensitized group.","['registered 11 September 2019', 'persistent low back pain', 'One hundred and thirty-two participants with persistent LBP']",['comprehensive QST battery'],"['pain sensitivity', 'regional pressure pain', 'pain sensitivity change', 'pain and disability changes', 'low back pain intensity and disability', 'regional pressure and thermal pain thresholds, remote pressure pain tolerance, and lower inhibitory conditioned pain modulation']","[{'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}]","[{'cui': 'C0430838', 'cui_str': 'Quantitative sensory test'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}]",132.0,0.214763,"The former had significantly lower regional pressure and thermal pain thresholds, remote pressure pain tolerance, and lower inhibitory conditioned pain modulation than the Not sensitized group.","[{'ForeName': 'Casper Glissmann', 'Initials': 'CG', 'LastName': 'Nim', 'Affiliation': 'Medical Research Unit, Spine Center of Southern Denmark, University Hospital of Southern Denmark, Østrehougvej 55, 5500, Middelfart, Denmark. casper.nim@rsyd.dk.'}, {'ForeName': 'Kenneth Arnold', 'Initials': 'KA', 'LastName': 'Weber', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, USA.'}, {'ForeName': 'Gregory Neill', 'Initials': 'GN', 'LastName': 'Kawchuk', 'Affiliation': 'Department of Physical Therapy, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': ""O'Neill"", 'Affiliation': 'Medical Research Unit, Spine Center of Southern Denmark, University Hospital of Southern Denmark, Østrehougvej 55, 5500, Middelfart, Denmark.'}]",Chiropractic & manual therapies,['10.1186/s12998-021-00367-4'] 1039,33637882,Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.,"Relapse is the major cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Effective preventive intervention in high-risk AML may be crucial. In this study, we investigated the clinical efficacy and safety of low dose decitabine (DAC) as part of a modified Busulfan-Cyclophosphamide (Bu-Cy) regimen for high-risk AML patients undergoing allo-HSCT to reduce relapse rate. Fifty-nine patients received DAC (20 mg/m 2 /d, i.v.) for 5 days, followed by modified Bu-Cy (DAC group). A matched-pair control (CON) group of 177 patients (matched 1:3) received modified Bu-Cy only. The differences were more substantial among patients with active disease: 2-year OS, 80.7% (DAC) versus 43.5% (CON), P = 0.011 and 2-year LFS, 64.9% (DAC) versus 39.2% (CON), P = 0.024. Median time to relapse was 8 months (DAC) versus 5 months (CON) for the entire groups and 6.5 months (DAC) versus 3.5 months (CON) for patients with active disease. In summary, our data indicated that the conditioning regimen containing low dose DAC may confer a survival advantage in high-risk AML patients with active disease undergoing allo-HSCT, and a prospective randomized trial is warranted to confirm these observations.",2021,"The differences were more substantial among patients with active disease: 2-year OS, 80.7% (DAC) versus 43.5% (CON), P = 0.011 and 2-year LFS, 64.9% (DAC) versus 39.2% (CON), P = 0.024.","['high-risk AML patients with active disease undergoing allo-HSCT', 'AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation', 'patients with active disease', 'group of 177 patients (matched 1:3) received', 'patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT', 'high-risk AML patients undergoing allo-HSCT to reduce relapse rate']","['DAC', 'modified Busulfan-Cyclophosphamide (Bu-Cy', 'low dose decitabine (DAC', 'modified Bu-Cy only', 'pair control (CON']","['survival advantage', 'survival', 'Median time to relapse', 'clinical efficacy and safety']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]","[{'cui': 'C0049065', 'cui_str': 'decitabine'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0006463', 'cui_str': 'Busulfan'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",177.0,0.0263956,"The differences were more substantial among patients with active disease: 2-year OS, 80.7% (DAC) versus 43.5% (CON), P = 0.011 and 2-year LFS, 64.9% (DAC) versus 39.2% (CON), P = 0.024.","[{'ForeName': 'Xiaowen', 'Initials': 'X', 'LastName': 'Tang', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China. xwtang1020@163.com.'}, {'ForeName': 'Benigno C', 'Initials': 'BC', 'LastName': 'Valdez', 'Affiliation': 'Department of Stem Cell Transplantation & Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Yunju', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Qianqian', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Changju', 'Initials': 'C', 'LastName': 'Qu', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Haiping', 'Initials': 'H', 'LastName': 'Dai', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Yin', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Xu', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Xiaming', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Zixing', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.'}, {'ForeName': 'Depei', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China. drwudepei@163.com.'}, {'ForeName': 'Borje S', 'Initials': 'BS', 'LastName': 'Andersson', 'Affiliation': 'Department of Stem Cell Transplantation & Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA.'}]",Bone marrow transplantation,['10.1038/s41409-021-01238-5'] 1040,33641272,Effects of dynamic stabilization exercises and muscle energy technique on selected biopsychosocial outcomes for patients with chronic non-specific low back pain: a double-blind randomized controlled trial.,"OBJECTIVES Low back pain is the most prevalent musculoskeletal condition, and causes activity limitations which result in reduced work productivity and high medical expenditure. The management of this condition has been challenging to both clinicians and researchers. While the use of Muscle Energy Technique (MET) as a potentially effective treatment strategy seems promising, studies examining MET combined with exercise therapy are scarce and studies with strong methodology are lacking. Therefore, this study aims to determine the effects of a combination of Dynamic Stabilization Exercises (DSE) and MET on selected biopsychosocial outcomes compared to DSE alone or conventional physiotherapy in the management of chronic non-specific low back pain (NSLBP). METHODS A total of 125 (80 male and 45 female) patients with chronic NSLBP were involved in this study, they were recruited from Rasheed Shekoni Teaching hospital and Federal Medical centre Birnin-Kudu, Jigawa State, Nigeria. A random number generator method was used to allocate patients to either DSE + MET (n=41), DSE alone (n=39) or conventional physiotherapy (n=45). Interventions were administered twice a week over 12 weeks. Outcome measures included pain intensity, lumbar (flexion and extension) range of motion, functional-disability, self-perceived health status, limitations in activities and participation restrictions. These were assessed at baseline, mid-intervention at six weeks, post-intervention at 12 weeks and long term follow-up at 24 weeks. Data was analyzed using repeated-measures ANOVA to determine significance difference within groups and between groups. RESULTS All intervention groups showed within-groups changes of the study outcomes over time (p<0.001). However, between-group comparisons showed greater improvements in pain intensity (F=7.91, p<0.001), lumbar ROM (flexion F=1.51, p<0.001; extension F=3.25, p<0.001), activity limitations/participation restrictions (F=3.7, p<0.001) and health status (F=10.9, p<0.001) for the intervention in which MET and DSE were combined. The MET plus DSE interventions were superior to DSE and convention physiotherapy for all outcome measures, except for functional disability (F=0.53, p=0.590). CONCLUSIONS The data from this study showed MET combined with DSE had greater therapeutic benefits compared to DSE or conventional physiotherapy on selected biopsychosocial outcomes in patients with chronic NSLBP. The findings from the study show that the combination of MET with DSE is safe and has beneficial effects in the management of patients with chronic NSLBP. CLINICAL TRIAL REGISTRATION The study protocol has been registered with www.ClinicalTrial.gov with the registration number NCT3449810.",2021,"The MET plus DSE interventions were superior to DSE and convention physiotherapy for all outcome measures, except for functional disability (F=0.53, p=0.590). ","['patients with chronic non-specific low back pain', 'A total of 125 (80 male and 45 female) patients with chronic NSLBP were involved in this study, they were recruited from Rasheed Shekoni Teaching hospital and Federal Medical centre Birnin-Kudu, Jigawa State, Nigeria', 'chronic non-specific low back pain (NSLBP', 'patients with chronic NSLBP']","['DSE alone or conventional physiotherapy', 'dynamic stabilization exercises and muscle energy technique', 'DSE', 'DSE or conventional physiotherapy', 'DSE\xa0+\xa0MET', 'Dynamic Stabilization Exercises (DSE) and MET', 'DSE alone (n=39) or conventional physiotherapy', 'Muscle Energy Technique (MET']","['functional disability', 'activity limitations/participation restrictions', 'pain intensity', 'health status', 'lumbar ROM', 'pain intensity, lumbar (flexion and extension) range of motion, functional-disability, self-perceived health status, limitations in activities and participation restrictions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0028075', 'cui_str': 'Nigeria'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C1562466', 'cui_str': 'Muscle energy technique'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0948106', 'cui_str': 'Amniorrhexis'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",125.0,0.171088,"The MET plus DSE interventions were superior to DSE and convention physiotherapy for all outcome measures, except for functional disability (F=0.53, p=0.590). ","[{'ForeName': 'Usman Abba', 'Initials': 'UA', 'LastName': 'Ahmed', 'Affiliation': 'Department of Physiotherapy, Rasheed Shekoni Specialist Hospital, Dutse, Jigawa State, Nigeria.'}, {'ForeName': 'Sonill Sooknunan', 'Initials': 'SS', 'LastName': 'Maharaj', 'Affiliation': 'Division of Physiotherapy, School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Van Oosterwijck', 'Affiliation': 'Department of Rehabilitation Sciences, SPINE Research Unit Ghent, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.'}]",Scandinavian journal of pain,['10.1515/sjpain-2020-0133'] 1041,33642357,Comparative evaluation of efficacy and safety of drotaverine versus mebeverine in irritable bowel syndrome: A randomized double-blind controlled study.,"Background Drotaverine and Mebeverine are used for alleviating the pain of IBS, but the evidence for their efficacy is scarce. In this randomised control study, we evaluated and compared their efficacy in improving severity, frequency of pain and its associated symptoms. Methods Patients fulfilling the ROME III criteria of IBS were evaluated in this randomised control trial during 4 weeks of treatment. Group A (n = 100) received 80 mg Drotaverine and Group B (n = 100) received 135 mg Mebeverine three times a day, 1 hour before meals. Primary outcome measure was, the reduction in severity of pain (>30% reduction) assessed by VAS (0 to 10 scale) & PSS (patient symptoms scores). Results The pain severity score fell from 6.02 to 4.8 on day 3 in Group A as compared to decrease from 6.72 to 6.62 in Group B (p < 0.01). This significant reduction in pain severity was observed till the end of the study, reducing from 6.02 to 1.78 (74% reduction) in Group A compared to 6.72 to 3.62 (46.1% reduction) in Group B (p < 0.05). There was a significant reduction in pain frequency, straining on stool, a change in one score in Bristol stool chart (BSC), achievement of complete spontaneous smooth bowel movement in Group A, compared to Group B patients. A significant improvement in Patient's evaluation of Global Assessment of Symptoms (p < 0.05) and Patient Assessment of Constipation - Quality Of Life (PAC-QOL) (p < 0.01) was observed in Group A compared to Group B. Conclusion Drotaverine was significantly superior in efficacy as compared to Mebeverine in alleviating pain severity (starting from day 3), frequency and stools-elated symptoms of IBS.",2021,"A significant improvement in Patient's evaluation of Global Assessment of Symptoms (p < 0.05) and Patient Assessment of Constipation - Quality Of Life (PAC-QOL) (p < 0.01) was observed in Group A compared to Group B. Conclusion Drotaverine was significantly superior in efficacy as compared to Mebeverine in alleviating pain severity (starting from day 3), frequency and stools-elated symptoms of IBS.","['Methods\n\n\nPatients fulfilling the ROME III criteria of IBS', 'irritable bowel syndrome']","['80 mg Drotaverine', 'drotaverine versus mebeverine', 'Mebeverine']","['pain severity', 'alleviating pain severity', 'Patient Assessment of Constipation - Quality Of Life (PAC-QOL', 'pain severity score', ""Patient's evaluation of Global Assessment of Symptoms"", 'frequency and stools-elated symptoms of IBS', 'reduction in severity of pain', 'pain frequency, straining on stool, a change in one score in Bristol stool chart (BSC), achievement of complete spontaneous smooth bowel movement', 'VAS (0 to 10 scale) & PSS (patient symptoms scores']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}]","[{'cui': 'C0058762', 'cui_str': 'drotaverin'}, {'cui': 'C0065832', 'cui_str': 'mebeverine'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0033036', 'cui_str': 'Atrial premature complex'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0233492', 'cui_str': 'Elation'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0205357', 'cui_str': 'Smooth'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.116626,"A significant improvement in Patient's evaluation of Global Assessment of Symptoms (p < 0.05) and Patient Assessment of Constipation - Quality Of Life (PAC-QOL) (p < 0.01) was observed in Group A compared to Group B. Conclusion Drotaverine was significantly superior in efficacy as compared to Mebeverine in alleviating pain severity (starting from day 3), frequency and stools-elated symptoms of IBS.","[{'ForeName': 'Ramesh R', 'Initials': 'RR', 'LastName': 'Rai', 'Affiliation': 'Department of Gastroenterology, Indian Gastro-Hep Research Foundation, Sodala, Jaipur, Rajasthan, India.'}, {'ForeName': 'Sandeep', 'Initials': 'S', 'LastName': 'Nijhawan', 'Affiliation': 'Department of Gastroenterology, Clinical Research Foundation, Gokul Bhai Bhatt Marg, Durgapura, Jaipur, Rajasthan, India.'}]",Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association,['10.4103/sjg.SJG_266_20'] 1042,33646860,Increased cardiorespiratory stress during submaximal cycling after ketone monoester ingestion in endurance-trained adults.,"There is growing interest in the effect of exogenous ketone body supplementation on exercise responses and performance. The limited studies to date have yielded equivocal data, likely due in part to differences in dosing strategy, increase in blood ketones, and participant training status. Using a randomized, double-blind, counterbalanced design, we examined the effect of ingesting a ketone monoester (KE) supplement (600 mg/kg body mass) or flavour-matched placebo in endurance-trained adults ( n = 10 males, n = 9 females; V̇ O 2peak = 57 ± 8 mL/kg/min). Participants performed a 30-min cycling bout at ventilatory threshold intensity (71 ± 3% V̇ O 2peak ), followed 15 min later by a 3 kJ/kg body mass time-trial. KE versus placebo ingestion increased plasma β-hydroxybutyrate concentration before exercise (3.9 ± 1.0 vs 0.2 ± 0.3 mM, p < 0.0001, d z = 3.4), ventilation (77 ± 17 vs 71 ± 15 L/min, p < 0.0001, d z = 1.3) and heart rate (155 ± 11 vs 150 ± 11 beats/min, p < 0.001, d z = 1.2) during exercise, and rating of perceived exertion at the end of exercise (15.4 ± 1.6 vs 14.5 ± 1.2, p < 0.01, d z = 0.85). Plasma β-hydroxybutyrate concentration remained higher after KE vs placebo ingestion before the time-trial (3.5 ± 1.0 vs 0.3 ± 0.2 mM, p < 0.0001, d z = 3.1), but performance was not different (KE: 16:25 ± 2:50 vs placebo: 16:06 ± 2:40 min:s, p = 0.20; d z = 0.31). We conclude that acute ingestion of a relatively large KE bolus dose increased markers of cardiorespiratory stress during submaximal exercise in endurance-trained participants. Novelty: Limited studies have yielded equivocal data regarding exercise responses after acute ketone body supplementation. Using a randomized, double-blind, placebo-controlled, counterbalanced design, we found that ingestion of a large bolus dose of a commercial ketone monoester supplement increased markers of cardiorespiratory stress during cycling at ventilatory threshold intensity in endurance-trained adults.",2021,"KE versus placebo ingestion increased plasma [β-hydroxybutyrate] before exercise (3.9±1.0 vs 0.2±0.3 mM, p<0.0001, dz=3.4), ventilation (77±17 vs 71±15","['endurance-trained adults', 'endurance-trained adults (n=10 males, n=9 females; VO2peak=57±8 ml/kg/min', 'Endurance-Trained Adults', 'endurance-trained participants']","['commercial ketone monoester supplement', 'ingesting a ketone monoester (KE) supplement (600 mg/kg body mass) or flavour-matched placebo', 'placebo', 'KE versus placebo', 'exogenous ketone body supplementation', 'Ketone Monoester Ingestion', 'Submaximal Cycling', '30-min cycling bout at ventilatory threshold intensity (71±3% VO2peak']","['plasma [β-hydroxybutyrate', 'heart rate', 'Novelty bullets', 'cardiorespiratory stress', 'Plasma [β-hydroxybutyrate', 'Cardiorespiratory Stress']","[{'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439402', 'cui_str': 'mL/min/kg'}]","[{'cui': 'C0022634', 'cui_str': 'Ketone'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0682897', 'cui_str': 'Flavor Enhancers'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0022631', 'cui_str': 'Ketone body'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0020332', 'cui_str': 'Hydroxybutyrates'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0336699', 'cui_str': 'Bullet'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",,0.68456,"KE versus placebo ingestion increased plasma [β-hydroxybutyrate] before exercise (3.9±1.0 vs 0.2±0.3 mM, p<0.0001, dz=3.4), ventilation (77±17 vs 71±15","[{'ForeName': 'Devin G', 'Initials': 'DG', 'LastName': 'McCarthy', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Bostad', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Fiona J', 'Initials': 'FJ', 'LastName': 'Powley', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Jonathan P', 'Initials': 'JP', 'LastName': 'Little', 'Affiliation': 'School of Health and Exercise Sciences, The University of British Columbia Okanagan, Kelowna, BC, Canada.'}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Richards', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'Gibala', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2020-0999'] 1043,33648860,Comparison of Intracuff Pressure and Postoperative Sore Throat Following Use of Laryngeal Mask Airway Protector With or Without Nitrous Oxide Anesthesia.,"PURPOSE In general anesthesia, the laryngeal mask airway (LMA) is a frequently used effective option. The effect of nitrous oxide on intracuff pressure of the LMA and postoperative sore throat is well known; however, there are no studies related to the second-generation LMA Protector. The purpose of this study was to determine the differences in intracuff pressure and postoperative sore throat, depending on the use of nitrous oxide during general anesthesia using the LMA Protector. DESIGN This randomized double-blind prospective study was conducted among 88 patients aged 20 to 70 years. METHODS The cuff pressure started with a baseline of 40 cm H 2 O and was measured using a digital cuff pressure manometer for 30 minutes. Postoperative sore throat, dysphonia, dysphagia, and numeric rating scale scores were also recorded. FINDINGS Over time, the intracuff pressure of the nitrous oxide group increased significantly compared with that of the air group. Furthermore, postoperative sore throat and pharyngolaryngeal complications were not significantly different between the two groups. CONCLUSIONS Intracuff pressure of the LMA Protector increased during anesthesia using nitrous oxide. When the anesthesia time was less than 2 hours, however, there was no difference in postoperative sore throat.",2021,"Furthermore, postoperative sore throat and pharyngolaryngeal complications were not significantly different between the two groups. ",['88 patients aged 20 to 70\xa0years'],"['Nitrous Oxide Anesthesia', 'nitrous oxide', 'Laryngeal Mask Airway Protector', 'laryngeal mask airway (LMA']","['Intracuff Pressure and Postoperative Sore Throat', 'postoperative sore throat', 'intracuff pressure', 'Postoperative sore throat, dysphonia, dysphagia, and numeric rating scale scores', 'postoperative sore throat and pharyngolaryngeal complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0028215', 'cui_str': 'Nitrous Oxide'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}]","[{'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",88.0,0.131181,"Furthermore, postoperative sore throat and pharyngolaryngeal complications were not significantly different between the two groups. ","[{'ForeName': 'Young Uk', 'Initials': 'YU', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Catholic Kwandong University, College of Medicine, International ST. Mary`s Hospital, Incheon, Republic of Korea.'}, {'ForeName': 'Byong Hyon', 'Initials': 'BH', 'LastName': 'Cho', 'Affiliation': 'Department of Anesthesiology and Pain Medine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Republic of Korea.'}, {'ForeName': 'Hyung Rae', 'Initials': 'HR', 'LastName': 'Cho', 'Affiliation': 'Department of Anesthesiology and Pain Medine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Republic of Korea. Electronic address: callmex@hanmail.net.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.10.001'] 1044,33653620,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial.","PURPOSE To evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of single- and multiple-dose SPH3127 in healthy individuals. METHODS This was a randomized, double-blind, placebo-controlled, Phase I dose-escalation study. FINDINGS SPH3127 exposure, expressed as C max , AUC 0-t , and AUC 0-∞ , was proportionally increased with dose for a range of 25-800 mg (single ascending dose [SAD]) and 100-400 mg daily (multiple ascending doses [MADs]). In an SAD, the C max values with 25, 50, 100, 200, 400, and 800 mg of SPH3127 were 90.67, 344.50, 523.50, 1239.50, 2445.00, and 5753.33 ng/mL, respectively. The corresponding AUC 0-t values were 294.48, 843.62, 1109.33, 2858.56, 6697.50, and 13057.83 h × ng/mL. In MADs, after the first dose of SPH3127, the C max values with 100, 200, and 400 mg of SPH3127 were 421.50, 969.00, and 2468.33 ng/mL, respectively. The corresponding AUC 0-t values were 1279.28, 2275.77, and 5934.26 h × ng/mL. At steady state, the C max values with 100, 200, and 400 mg of SPH3127 were 514.67, 1419.17, and 2513.33 ng/mL, respectively. The corresponding AUC 0-24 values were 1638.14, 3096.20, and 7577.70 h × ng/mL. The median T max range from 0.33 to 1.0 h and the median t 1/2 from 3 to 4 h. In an SAD, when the dose was >100 mg, plasma renin activity inhibition of up to 90% lasted up to 24 h. In MADs, renin activity was continuously inhibited by up to 90% in each group for 24 h after the last administration. Treatment-emergent adverse events (AEs) were reported in 29.2% of individuals receiving the SAD and 33.3% of those receiving MADs. Only mild adverse events occurred. IMPLICATIONS SPH3127 was well tolerated and had robust and sustained suppression of plasma renin activity. CLINICALTRIALS. GOV IDENTIFIERS NCT03128138 (SAD study) and NCT03255993 (MAD study).",2021,"Only mild adverse events occurred. ",['healthy individuals'],"['single- and multiple-dose SPH3127', 'placebo', 'NCT03255993', 'SPH3127', 'Placebo']","['pharmacokinetics, pharmacodynamics, safety, and tolerability', 'renin activity', 'mild adverse events', 'median T max range', 'plasma renin activity inhibition', 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics']","[{'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]",,0.449326,"Only mild adverse events occurred. ","[{'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Jing', 'Affiliation': 'Clinical Pharmacology Centre, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Ranchi', 'Initials': 'R', 'LastName': 'Xu', 'Affiliation': 'Central Research Institute, Shanghai Pharmaceuticals Holding Co., Ltd, Shanghai, China.'}, {'ForeName': 'Kexu', 'Initials': 'K', 'LastName': 'Yang', 'Affiliation': 'Clinical Pharmacology Centre, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Wenfang', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Clinical Pharmacology Centre, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Leduo', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Central Research Institute, Shanghai Pharmaceuticals Holding Co., Ltd, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Ke', 'Affiliation': 'Central Research Institute, Shanghai Pharmaceuticals Holding Co., Ltd, Shanghai, China.'}, {'ForeName': 'Guangxin', 'Initials': 'G', 'LastName': 'Xia', 'Affiliation': 'Central Research Institute, Shanghai Pharmaceuticals Holding Co., Ltd, Shanghai, China. Electronic address: xiagx@sphchina.com.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': 'Clinical Pharmacology Centre, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Electronic address: icp@anzhengcp.com.'}]",Clinical therapeutics,['10.1016/j.clinthera.2021.01.025'] 1045,33653616,Impact of Music Therapy on Preoperative Anxiety and Degree of Cooperation With Anesthesia Induction in Children With Simple Congenital Heart Disease.,"PURPOSE To evaluate the impact of music therapy (MT) on preoperative anxiety and degree of cooperation with anesthesia induction in children with simple congenital heart disease (CHD). DESIGN A randomized controlled clinical study. METHODS Ninety children were randomly assigned to the MT and control groups. The MT groups underwent a preoperative 30-minute session of MT, whereas the control group did not listen to any music and had the same amount of quiet time. The modified Yale Preoperative Anxiety Scale-Short Form (mYPAS-SF) was used to evaluate the patients' preoperative anxiety on entering the anesthesia waiting area (T1), 10 minutes after entering the waiting area (T2), and during the initiation of anesthesia induction (T3); the degree of cooperation with anesthesia induction was assessed using the Induction Compliance Checklist. The mean arterial blood pressure (MAP) and heart rate (HR) at T1, T2, T3, and T4 (the time of successful anesthesia) were also recorded. FINDINGS One child was excluded from the MT group, and one was excluded from the control group. No difference was found in the mYPAS-SF score, MAP, or HR between the two groups at T1. The mYPAS-SF scores of the MT group were significantly lower than those of the control group at T2 and T3. At T2, T3, and T4, the MAP and HR of the MT group were lower than those of the control group. A statistically significant difference was found in the Induction Compliance Checklist score between the two groups. CONCLUSIONS MT can reduce preoperative anxiety and improve the degree of cooperation with anesthesia induction.",2021,"No difference was found in the mYPAS-SF score, MAP, or HR between the two groups at T1.","['Children With Simple Congenital Heart Disease', 'children with simple congenital heart disease (CHD', 'Ninety children']","['Music Therapy', 'music therapy (MT']","['mYPAS-SF scores', 'preoperative anxiety', 'mean arterial blood pressure (MAP) and heart rate (HR) at T1, T2, T3, and T4 (the time of successful anesthesia', 'Induction Compliance Checklist score', 'Preoperative Anxiety and Degree of Cooperation With Anesthesia Induction', 'mYPAS-SF score, MAP, or HR']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0152021', 'cui_str': 'Congenital heart disease'}, {'cui': 'C3816959', 'cui_str': '90'}]","[{'cui': 'C0026868', 'cui_str': 'Music therapy'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0473960', 'cui_str': 'Induction of general anesthesia'}]",90.0,0.0264484,"No difference was found in the mYPAS-SF score, MAP, or HR between the two groups at T1.","[{'ForeName': 'Ya-Li', 'Initials': 'YL', 'LastName': 'Huang', 'Affiliation': ""Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China; Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, Fuzhou, China.""}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Xu', 'Affiliation': ""Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China; Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, Fuzhou, China; Department of Cardiovascular Surgery, Union Hospital, Fujian Medical University, Fuzhou, China.""}, {'ForeName': 'Shu-Ting', 'Initials': 'ST', 'LastName': 'Huang', 'Affiliation': ""Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China; Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, Fuzhou, China; Department of Cardiovascular Surgery, Union Hospital, Fujian Medical University, Fuzhou, China.""}, {'ForeName': 'Zeng-Chun', 'Initials': 'ZC', 'LastName': 'Wang', 'Affiliation': ""Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China; Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, Fuzhou, China; Department of Cardiovascular Surgery, Union Hospital, Fujian Medical University, Fuzhou, China.""}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Cao', 'Affiliation': ""Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China; Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, Fuzhou, China.""}, {'ForeName': 'Xian-Rong', 'Initials': 'XR', 'LastName': 'Yu', 'Affiliation': ""Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China; Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, Fuzhou, China.""}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': ""Department of Cardiac Surgery, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China; Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, Fuzhou, China; Department of Cardiovascular Surgery, Union Hospital, Fujian Medical University, Fuzhou, China. Electronic address: chenqiang2228@163.com.""}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.08.004'] 1046,33652128,Exercise training and cognition in multiple sclerosis: The GET Smart trial protocol.,"BACKGROUND AND OBJECTIVES Multiple sclerosis (MS) causes cognitive impairment in approximately 50% of cases. Disease modifying medications and cognitive rehabilitation produce only small positive effects on cognition in MS. Converging animal and human research suggests that aerobic exercise may improve cognition in people with MS, but definitive trials are lacking. We describe the design of the GET Smart study, a randomized controlled trial comparing the effects of aerobic exercise versus stretching and toning on cognition in MS. METHODS The study is a single-blind, parallel group randomized (1:1) controlled trial that compares aerobic exercise training with an active control group consisting of stretching and toning exercises for improving cognition. Participants are nondepressed, ambulatory, non-exercising adults with MS aged 18-54 years who have below average cognitive processing speed. Both treatments were designed to generate equivalent outcome expectancies and entailed supervised, progressive exercise programs, 3 times per week for up to 40 min over a 6 month period. PROJECTED PATIENT OUTCOMES The primary hypothesis is that the aerobic training group will demonstrate significantly greater cognitive processing speed compared with the control group at the end of the treatment phase (6 months) as measured by a composite of the Paced Auditory Serial Additon Test and the oral Symbol-Digit Modalities Test using intent-to treat analyses. Secondary outcomes are neuropsychological functioning and cardiorespiratory fitness as well as participant reported outcomes such as depression, sleep, and fatigue. Study findings will inform future research, patient education, clinical care and policymaking. TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT02106052.",2021,"Both treatments were designed to generate equivalent outcome expectancies and entailed supervised, progressive exercise programs, 3 times per week for up to 40 min over a 6 month period. ","['Participants are nondepressed, ambulatory, non-exercising adults with MS aged 18-54\u202fyears who have below average cognitive processing speed', 'multiple sclerosis']","['aerobic exercise versus stretching and toning', 'stretching and toning exercises', 'aerobic exercise training', 'aerobic training', 'aerobic exercise', 'Exercise training and cognition']","['cognitive processing speed', 'neuropsychological functioning and cardiorespiratory fitness as well as participant reported outcomes such as depression, sleep, and fatigue']","[{'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]","[{'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",,0.0992249,"Both treatments were designed to generate equivalent outcome expectancies and entailed supervised, progressive exercise programs, 3 times per week for up to 40 min over a 6 month period. ","[{'ForeName': 'Charles H', 'Initials': 'CH', 'LastName': 'Bombardier', 'Affiliation': 'Department of Rehabilitation Medicine, School of Medicine, University of Washington, Box 359612, Harborview Medical Center, 325 9(th) Ave, Seattle, WA 98104, USA. Electronic address: chb@uw.edu.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Motl', 'Affiliation': 'Department of Physical Therapy, University of Alabama, SHPB 336, 1716 9th Avenue South, Birmingham, AL 35233, USA.'}, {'ForeName': 'Ralph H B', 'Initials': 'RHB', 'LastName': 'Benedict', 'Affiliation': 'Departments of Neurology and Psychiatry, University at Buffalo, UBMD Physicians Group, 1001 Main Street, 4th Floor, Buffalo, NY 14203, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Temkin', 'Affiliation': 'Departments of Neurological Surgery, School of Medicine and Biostatistics, School of Public Health, University of Washington, Box 359925, Harborview Medical Center, 325 9(th) Ave, Seattle, WA 98104, USA.'}, {'ForeName': 'Peiqing', 'Initials': 'P', 'LastName': 'Qian', 'Affiliation': 'Multiple Sclerosis Center, Swedish Neuroscience Institute, 1600 E Jefferson St, Seattle, WA 98122, USA.'}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'Alexander', 'Affiliation': 'Department of Rehabilitation Medicine, School of Medicine, University of Washington, Box 359612, Harborview Medical Center, 325 9(th) Ave, Seattle, WA 98104, USA.'}, {'ForeName': 'Annabeth', 'Initials': 'A', 'LastName': 'Evans', 'Affiliation': 'Department of Rehabilitation Medicine, School of Medicine, University of Washington, Box 359612, Harborview Medical Center, 325 9(th) Ave, Seattle, WA 98104, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Thomas', 'Affiliation': 'Department of Rehabilitation Medicine, School of Medicine, University of Washington, Box 359612, Harborview Medical Center, 325 9(th) Ave, Seattle, WA 98104, USA.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Toms', 'Affiliation': 'Department of Rehabilitation Medicine, School of Medicine, University of Washington, Box 359612, Harborview Medical Center, 325 9(th) Ave, Seattle, WA 98104, USA.'}, {'ForeName': 'Cathea M', 'Initials': 'CM', 'LastName': 'Carey', 'Affiliation': 'Department of Rehabilitation Medicine, School of Medicine, University of Washington, Box 359612, Harborview Medical Center, 325 9(th) Ave, Seattle, WA 98104, USA.'}, {'ForeName': 'George H', 'Initials': 'GH', 'LastName': 'Kraft', 'Affiliation': 'Department of Rehabilitation Medicine, School of Medicine, University of Washington, Box 359612, Harborview Medical Center, 325 9(th) Ave, Seattle, WA 98104, USA; Departments of Rehabilitation Medicine and Neurology, University of Washington, Box 356490, UW Medical Center-Montlake, 1959 NE Pacific St., Seattle, WA 98195, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106331'] 1047,33652127,Improving transition from inpatient rehabilitation following traumatic brain injury: Protocol for the BRITE pragmatic comparative effectiveness trial.,"Moderate to severe traumatic brain injury (TBI) is a common cause of long-term disability. Due to challenges that include inconsistent access to follow-up care, persons with TBI being discharged from inpatient rehabilitation facilities (IRFs) are at risk for rehospitalization, poor reintegration into the community, family stress, and other unfavorable outcomes resulting from unmet needs. In a six-center randomized pragmatic comparative effectiveness study, the BRITE trial (Brain Injury Rehabilitation: Improving the Transition Experience, ClinicalTrials.govNCT03422276), we compare the effectiveness of two existing methods for transition from IRF to community living or long-term nursing care. The Rehabilitation Discharge Plan (RDP) includes patient/family education and referrals for continued care. The Rehabilitation Transition Plan (RTP) provides RDP plus individualized, manualized care management via phone or videoconference, for 6 months. Nine hundred patients will be randomized (1:1) to RDP or RTP, with caregivers also invited to participate and contribute caregiver-reported outcomes. Extensive stakeholder input, including active participation of persons with TBI and their families, has informed all aspects of trial design and implementation planning. We hypothesize that RTP will result in better patient- and caregiver-reported outcomes (societal participation, quality of life, caregiver well-being) and more efficient use of healthcare resources at 6-months (primary outcome) and 12-months post-discharge, compared to RDP alone. Planned analyses will explore which participants benefit most from each transition model. With few exclusion criteria and other pragmatic features, the findings of this trial are expected to have a broad impact on improving transitions from inpatient TBI rehabilitation. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03422276.",2021,"We hypothesize that RTP will result in better patient- and caregiver-reported outcomes (societal participation, quality of life, caregiver well-being) and more efficient use of healthcare resources at 6-months (primary outcome) and 12-months post-discharge, compared to RDP alone.","['persons with TBI being discharged from inpatient rehabilitation facilities (IRFs', 'Nine hundred patients', 'persons with TBI and their families', 'Brain Injury Rehabilitation']","['RDP or RTP', 'RTP']",[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C4047961', 'cui_str': 'Discharge from inpatient rehabilitation facility'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C3845566', 'cui_str': 'Rehabilitation facility'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0012622', 'cui_str': 'Discharge planning'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]",[],900.0,0.108676,"We hypothesize that RTP will result in better patient- and caregiver-reported outcomes (societal participation, quality of life, caregiver well-being) and more efficient use of healthcare resources at 6-months (primary outcome) and 12-months post-discharge, compared to RDP alone.","[{'ForeName': 'Jesse R', 'Initials': 'JR', 'LastName': 'Fann', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356560, Seattle, WA 98195, United States of America. Electronic address: fann@uw.edu.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Hart', 'Affiliation': 'Moss Rehabilitation Research Institute, 50 Township Line Road, Elkins Park, PA 19027, United States of America. Electronic address: thart@einstein.edu.'}, {'ForeName': 'Marcia A', 'Initials': 'MA', 'LastName': 'Ciol', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356490, Seattle, WA 98195, United States of America. Electronic address: marciac@uw.edu.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Moore', 'Affiliation': 'School of Social Work and Harborview Injury Prevention and Research Center, University of Washington, 4101 15(th) Avenue NE, Seattle, WA 98105, United States of America. Electronic address: mm99@uw.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Bogner', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, The Ohio State University, 480 Medical Center Drive, Columbus, OH 43210, United States of America. Electronic address: Jennifer.Bogner@osumc.edu.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Corrigan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, The Ohio State University, 480 Medical Center Drive, Columbus, OH 43210, United States of America. Electronic address: John.Corrigan@osumc.edu.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': ""Dams-O'Connor"", 'Affiliation': ""Department of Rehabilitation Medicine, Department of Neurology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place Box 1163, New York, NY 10029, United States of America. Electronic address: Kristen.dams-o'connor@mountsinai.org.""}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Driver', 'Affiliation': 'Department of Sports Therapy and Research, Baylor Scott and White Research Institute, 3434 Live Oak, Dallas, TX 75204, United States of America. Electronic address: simon.driver@bswhealth.org.'}, {'ForeName': 'Rosemary', 'Initials': 'R', 'LastName': 'Dubiel', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Baylor Scott and White Institute for Rehabilitation, 909 N. Washington Avenue, Dallas, TX 75246, United States of America. Electronic address: rdubiel@bswrehab.com.'}, {'ForeName': 'Flora M', 'Initials': 'FM', 'LastName': 'Hammond', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Indian University School of Medicine, 4141 Shore Drive, Indianapolis, IN 46254, United States of America. Electronic address: Flora.hammond@rhin.com.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Kajankova', 'Affiliation': 'Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place Box 1163, New York, NY 10029, United States of America. Electronic address: Maria.kajankova@mountsinai.org.'}, {'ForeName': 'Thomas K', 'Initials': 'TK', 'LastName': 'Watanabe', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, MossRehab at Elkins Park/Einstein Healthcare Network, 60 Township Line Road, Elkins Park, PA 19027, United States of America. Electronic address: watanabt@einstein.edu.'}, {'ForeName': 'Jeanne M', 'Initials': 'JM', 'LastName': 'Hoffman', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356490, Seattle, WA 98195, United States of America. Electronic address: jeanneh@uw.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106332'] 1048,33657870,Effectiveness of Lifestyle Interventions in an Active Duty Air Force Population.,"PURPOSE To examine the effectiveness of 3 lifestyle intervention programs in an active duty military population. DESIGN Experimental design with stratified random assignment to 1 of 3 intervention groups. Measures were taken at baseline, 3 months and 6 months. SETTING A Military Treatment Facility in the western U.S. SUBJECTS/INTERVENTION 122 active duty service members were enrolled and randomly assigned to 1 of 3 lifestyle intervention programs: the Diabetes Prevention Program-Group Lifestyle Balance (DPP-GLB), the Better Body Better Life (BBBL) program or the Fitness Improvement Program (FIP). MEASURES weight, abdominal circumference, lipid and HbA1c levels, physical activity, and well-being as measured by the RAND SF-36 questionnaire. ANALYSIS Statistical analyses were performed to assess changes over time. RESULTS 83 participants completed the study (BBBL N = 23, FIP N = 30, DPP-GLB N = 30). The DPP-GLB participants had statistically significant decreases in weight (-3.1 pounds, p = .01) and abdominal circumference (-0.9 inches; p = .01) over time. HbA1c was also significantly lower in this group at 6 months compared to baseline ( p = .036). There were no statistically significant changes in weight, abdominal circumference, or HbA1c in the FIP or BBBL groups. No significant changes were observed in lipids in any of the groups. CONCLUSION Results from this study indicate that the DPP-GLB program may be effective in reducing weight, abdominal circumference, and HbA1c in an active duty U.S. military population.",2021,"There were no statistically significant changes in weight, abdominal circumference, or HbA1c in the FIP or BBBL groups.","['Active Duty Air Force Population', 'A Military Treatment Facility in the western U.S.\nSUBJECTS/INTERVENTION', 'active duty military population', '122 active duty service members', '83 participants completed the study (BBBL N = 23, FIP N = 30, DPP-GLB N = 30']","['lifestyle intervention programs: the Diabetes Prevention Program-Group Lifestyle Balance (DPP-GLB), the Better Body Better Life (BBBL) program or the Fitness Improvement Program (FIP', '3 lifestyle intervention programs', 'Lifestyle Interventions']","['lipids', 'weight', 'weight, abdominal circumference, lipid and HbA1c levels, physical activity, and well-being as measured by the RAND SF-36 questionnaire', 'weight, abdominal circumference, or HbA1c', 'weight, abdominal circumference, and HbA1c', 'abdominal circumference']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3831794', 'cui_str': 'Active duty military'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0376558', 'cui_str': 'Life'}]","[{'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1300813', 'cui_str': 'Abdominal circumference'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",122.0,0.0169396,"There were no statistically significant changes in weight, abdominal circumference, or HbA1c in the FIP or BBBL groups.","[{'ForeName': 'Nicole H', 'Initials': 'NH', 'LastName': 'Armitage', 'Affiliation': '273806Dayton VA Medical Center, Dayton, OH, USA.'}, {'ForeName': 'M Kaye', 'Initials': 'MK', 'LastName': 'Kramer', 'Affiliation': '6614University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Mary S', 'Initials': 'MS', 'LastName': 'Nelson', 'Affiliation': 'U.S. Air Force, Washington, DC, USA.'}, {'ForeName': 'DawnKimberly', 'Initials': 'D', 'LastName': 'Hopkins', 'Affiliation': 'David Grant Medical Center, Travis AFB, OH, USA.'}, {'ForeName': 'Ruby', 'Initials': 'R', 'LastName': 'Langeslay', 'Affiliation': '22494Virginia Commonwealth University Richmond School of Medicine, VA, USA.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Thornton', 'Affiliation': 'David Grant Medical Center, Travis AFB, CA, USA.'}]",American journal of health promotion : AJHP,['10.1177/0890117121997308'] 1049,33594278,Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of αβ T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia.,"Depletion of αβ T cells from the graft prevents graft-vs.-host disease (GVHD) and improves outcome of HSCT from haploidentical donors. In a randomized trial, we aimed to evaluate the safety and efficacy of low-dose memory (CD45RA-depleted) donor lymphocytes (mDLI) after HSCT with αβ T-cell depletion. A cohort of 149 children was enrolled, 76 were randomized to receive scheduled mDLI and 73 received standard care. Conditioning was based on either 12 Gy total body irradiation or treosulfan. Rabbit antithymocyte globulin was replaced by tocilizumab and abatacept. Primary end points were the incidence of acute GVHD grades II-IV and the incidence of cytomegalovirus (CMV) viremia. The incidence of grades II-IV aGVHD was 14% in the experimental arm and 12% in the control arm, p-0.8. The incidence of CMV viremia was 45% in the experimental arm and 55% in the control arm, p-0.4. Overall, in the total cohort 2-year NRM was 2%, cumulative incidence of relapse was 25%, event-free survival 71%, and overall survival 80%, without difference between the study arms. Memory DLI was associated with improved recovery of CMV-specific T-cell responses in a subcohort of CMV IgG seropositive recipients.",2021,"The incidence of grades II-IV aGVHD was 14% in the experimental arm and 12% in the control arm, p-0.8.","['149 children', 'recipients of αβ T cell-depleted haploidentical grafts']","['Rabbit antithymocyte globulin', 'low-dose memory (CD45RA-depleted) donor lymphocytes (mDLI', 'scheduled mDLI and 73 received standard care', 'low-dose memory (CD45RA-depleted) donor lymphocyte infusion']","['incidence of acute GVHD grades II-IV and the incidence of cytomegalovirus (CMV) viremia', 'CMV viremia', 'Depletion of αβ T cells', 'safety and efficacy', 'incidence of grades II-IV aGVHD', 'recovery of CMV-specific T-cell responses', 'Safety and efficacy', 'cumulative incidence of relapse', 'overall survival']","[{'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}]","[{'cui': 'C0359156', 'cui_str': 'Rabbit anti-human T-lymphocyte globulin'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0108789', 'cui_str': 'Lymphocyte antigen CD45RA'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4521533', 'cui_str': 'Donor lymphocyte infusion'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0018133', 'cui_str': 'Graft versus host disease'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0877635', 'cui_str': 'Cytomegalovirus viremia'}, {'cui': 'C0333668', 'cui_str': 'Depletion'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0856825', 'cui_str': 'Acute graft-versus-host disease'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",149.0,0.120178,"The incidence of grades II-IV aGVHD was 14% in the experimental arm and 12% in the control arm, p-0.8.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Dunaikina', 'Affiliation': 'Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Zhanna', 'Initials': 'Z', 'LastName': 'Zhekhovtsova', 'Affiliation': 'Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Larisa', 'Initials': 'L', 'LastName': 'Shelikhova', 'Affiliation': 'Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Glushkova', 'Affiliation': 'Transplantation Immunology and Immunotherapy Laboratory, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Ruslan', 'Initials': 'R', 'LastName': 'Nikolaev', 'Affiliation': 'Stem Cell Physiology Laboratory, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Blagov', 'Affiliation': 'Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Rimma', 'Initials': 'R', 'LastName': 'Khismatullina', 'Affiliation': 'Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Dmitriy', 'Initials': 'D', 'LastName': 'Balashov', 'Affiliation': 'Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Kurnikova', 'Affiliation': 'Transfusion Medicine Service, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Dmitriy', 'Initials': 'D', 'LastName': 'Pershin', 'Affiliation': 'Transplantation Immunology and Immunotherapy Laboratory, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Yakov', 'Initials': 'Y', 'LastName': 'Muzalevskii', 'Affiliation': 'Transfusion Medicine Service, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Kazachenok', 'Affiliation': 'Transfusion Medicine Service, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Osipova', 'Affiliation': 'Stem Cell Physiology Laboratory, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Miakova', 'Affiliation': 'Clinical Center, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Dmitriy', 'Initials': 'D', 'LastName': 'Litvinov', 'Affiliation': 'Clinical Center, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Galina', 'Initials': 'G', 'LastName': 'Novichkova', 'Affiliation': 'Clinical Center, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Maschan', 'Affiliation': 'Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Maschan', 'Affiliation': 'Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. mmaschan@yandex.ru.'}]",Bone marrow transplantation,['10.1038/s41409-021-01232-x'] 1050,33593938,Lawmakers' use of scientific evidence can be improved.,"Core to the goal of scientific exploration is the opportunity to guide future decision-making. Yet, elected officials often miss opportunities to use science in their policymaking. This work reports on an experiment with the US Congress-evaluating the effects of a randomized, dual-population (i.e., researchers and congressional offices) outreach model for supporting legislative use of research evidence regarding child and family policy issues. In this experiment, we found that congressional offices randomized to the intervention reported greater value of research for understanding issues than the control group following implementation. More research use was also observed in legislation introduced by the intervention group. Further, we found that researchers randomized to the intervention advanced their own policy knowledge and engagement as well as reported benefits for their research following implementation.",2021,"In this experiment, we found that congressional offices randomized to the intervention reported greater value of research for understanding issues than the control group following implementation.",[],[],[],[],[],[],,0.0238978,"In this experiment, we found that congressional offices randomized to the intervention reported greater value of research for understanding issues than the control group following implementation.","[{'ForeName': 'D Max', 'Initials': 'DM', 'LastName': 'Crowley', 'Affiliation': 'Evidence-to-Impact Collaborative, Pennsylvania State University, University Park, PA 16802; dmc397@psu.edu.'}, {'ForeName': 'J Taylor', 'Initials': 'JT', 'LastName': 'Scott', 'Affiliation': 'Evidence-to-Impact Collaborative, Pennsylvania State University, University Park, PA 16802.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Long', 'Affiliation': 'Evidence-to-Impact Collaborative, Pennsylvania State University, University Park, PA 16802.'}, {'ForeName': 'Lawrie', 'Initials': 'L', 'LastName': 'Green', 'Affiliation': 'Evidence-to-Impact Collaborative, Pennsylvania State University, University Park, PA 16802.'}, {'ForeName': 'Azaliah', 'Initials': 'A', 'LastName': 'Israel', 'Affiliation': 'Evidence-to-Impact Collaborative, Pennsylvania State University, University Park, PA 16802.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Supplee', 'Affiliation': 'Child Trends, Bethesda, MD 20814.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Jordan', 'Affiliation': 'Child Trends, Bethesda, MD 20814.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Oliver', 'Affiliation': 'Transforming Evidence, London School of Hygiene & Tropical Medicine, London, WC1H 9SR, United Kingdom.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Guillot-Wright', 'Affiliation': 'Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, TX 77550.'}, {'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Gay', 'Affiliation': 'Department of Psychology, University of Maryland, Baltimore County, Baltimore, MD21250.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Storace', 'Affiliation': 'Evidence-to-Impact Collaborative, Pennsylvania State University, University Park, PA 16802.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Torres-Mackie', 'Affiliation': 'Teachers College, Columbia University, New York, NY 10027.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Murphy', 'Affiliation': 'Evidence-to-Impact Collaborative, Pennsylvania State University, University Park, PA 16802.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Donnay', 'Affiliation': 'The Racial Equity Initiative, Skillman, NJ 08558.'}, {'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Reardanz', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, AL 35487-0348.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Smith', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA 23238.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'McGuire', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA 23238.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Baker', 'Affiliation': 'Department of Psychology, University of Calgary, Calgary, Alberta, Canada T2N 1N4.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Antonopoulos', 'Affiliation': 'Georgetown University Medical School, Washington, DC20007.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'McCauley', 'Affiliation': 'Evidence-to-Impact Collaborative, Pennsylvania State University, University Park, PA 16802.'}, {'ForeName': 'Cagla', 'Initials': 'C', 'LastName': 'Giray', 'Affiliation': 'Evidence-to-Impact Collaborative, Pennsylvania State University, University Park, PA 16802.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.2012955118'] 1051,33607327,Single-Dose Effects of Citalopram on Neural Responses to Affective Stimuli in Borderline Personality Disorder: A Randomized Clinical Trial.,"BACKGROUND Psychiatric medication that has a soothing effect on limbic responses to affective stimuli could improve affective instability symptoms as observed in borderline personality disorder (BPD). The objective of this study was to investigate whether citalopram versus placebo reduces the response of the affective neural circuitry during an emotional challenge. METHODS A total of 30 female individuals with a BPD diagnosis participated in a placebo-controlled, double-blind crossover trial design. Three hours after oral drug intake, individuals with BPD viewed affective pictures while undergoing functional magnetic resonance imaging. Blood oxygen level-dependent responses to images of negative affective scenes and faces showing negative emotional expressions were assessed in regions of interest (amygdala, anterior cingulate cortex, anterior insula, dorsolateral prefrontal cortex). Blood perfusion at rest was assessed with arterial spin labeling. RESULTS The neural response to pictures showing negative affective scenes was not significantly affected by citalopram (n = 23). Citalopram significantly reduced the amygdala response to pictures of faces with negative affective expressions (n = 25, treatment difference left hemisphere: -0.06 ± 0.16, p < .05; right hemisphere: -0.06 ± 0.17, p < .05). We observed no significant effects of citalopram on the other regions. The drug did not significantly alter blood perfusion at rest. CONCLUSIONS Citalopram can alter the amygdala response to affective stimuli in BPD, which is characterized by overly responsive affective neural circuitry.",2021,The neural response to pictures showing negative affective scenes was not significantly affected by Citalopram (N=23).,"['femaie individuals with BPD diagnosis participated in a', 'borderline personality disorder', 'N=30']","['Citalopram', 'Citalopram vs. Placebo', 'Placebo']","['neural response to pictures showing negative affective scenes', 'blood perfusion', 'amygdala response to pictures of faces with negative affective expressions', 'Blood perfusion']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0006012', 'cui_str': 'Borderline personality disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",30.0,0.265569,The neural response to pictures showing negative affective scenes was not significantly affected by Citalopram (N=23).,"[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Paret', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany; Sagol Brain Institute, Wohl Institute for Advanced Imaging, Tel-Aviv Sourasky Medical Center and School of Psychological Sciences, Tel-Aviv University, Israel. Electronic address: christian.paret@zi-mannheim.de.'}, {'ForeName': 'Inga', 'Initials': 'I', 'LastName': 'Niedtfeld', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Lotter', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Wunder', 'Affiliation': 'Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Grimm', 'Affiliation': 'MSB Medical School Berlin, Hochschule für Gesundheit und Medizin, Berlin, Germany.'}, {'ForeName': 'Maarten', 'Initials': 'M', 'LastName': 'Mennes', 'Affiliation': 'SBGneuro Ltd., Oxford, United Kingdom.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Okell', 'Affiliation': 'SBGneuro Ltd., Oxford, United Kingdom; Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Beckmann', 'Affiliation': 'SBGneuro Ltd., Oxford, United Kingdom.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schmahl', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany. Electronic address: christian.schmahl@zi-mannheim.de.'}]",Biological psychiatry. Cognitive neuroscience and neuroimaging,['10.1016/j.bpsc.2021.02.002'] 1052,33616224,Cryosurgical Ablation for Treatment of Rhinitis: Two-Year Results of a Prospective Multicenter Study.,"OBJECTIVES/HYPOTHESIS To assess the long-term (12-24 months) safety and effectiveness of cryoablation of the posterior nasal nerve as treatment for chronic rhinitis. STUDY DESIGN A multicenter, prospective, single-arm clinical study. METHODS The study was conducted from February 2017 to April 2020. Study endpoints included change from baseline in the reflective Total Nasal Symptom Score (rTNSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), physician assessment of improvement using the Clinical Global Impression-Improvement (CGI-I), and the incidence of treatment-related adverse events. RESULTS Ninety-one participants completed the study through the initial 12-month study period. Sixty-two participants consented to the long-term follow-up with 57 completing the 24-month follow-up. Significant improvements in the total rTNSS were reflected in a median change from baseline of -3.0 or -4.0 at all timepoints (P < .001). Greater than 80.0% of participants achieved the minimum clinically important difference (MCID) of improvement by ≥1 point on the rTNSS at all follow-ups. Total RQLQ scores indicated significant improvement (P < .0001) in quality of life. Over 77% of participants achieved the MCID (≥0.5 points) for the total RQLQ score. According to the CGI-I, ≥83.0% experienced improvement at all but the 12-month visit (61.9%). One participant experienced two treatment-related serious adverse events (epistaxis and retained pledget). A total of 29 nonserious treatment-related AEs were reported in 23 participants; most events were transient and resolved with little to no intervention. CONCLUSIONS Cryotherapy significantly and clinically improves rhinitis symptoms and quality of life with outcomes that are durable through 24 months after treatment. LEVEL OF EVIDENCE 4 Laryngoscope, 131:1952-1957, 2021.",2021,"CONCLUSIONS Cryotherapy significantly and clinically improves rhinitis symptoms and quality of life with outcomes that are durable through 24 months after treatment. ","['chronic rhinitis', 'Rhinitis', 'Ninety-one participants completed the study through the initial 12-month study period', 'Sixty-two participants consented to the long-term follow-up with 57 completing the 24-month follow-up', 'February 2017 to April 2020']",['Cryosurgical Ablation'],"['rhinitis symptoms and quality of life', 'total RQLQ score', 'serious adverse events (epistaxis and retained pledget', 'total rTNSS', 'reflective Total Nasal Symptom Score (rTNSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), physician assessment of improvement using the Clinical Global Impression-Improvement (CGI-I), and the incidence of treatment-related adverse events', 'quality of life', 'Total RQLQ scores']","[{'cui': 'C0008711', 'cui_str': 'Chronic rhinitis'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0010408', 'cui_str': 'Cryosurgery'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0861155', 'cui_str': 'Rhinoconjunctivitis'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C4521311', 'cui_str': 'Pledget'}, {'cui': 'C0231918', 'cui_str': 'Nose symptoms'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",62.0,0.0431302,"CONCLUSIONS Cryotherapy significantly and clinically improves rhinitis symptoms and quality of life with outcomes that are durable through 24 months after treatment. ","[{'ForeName': 'Randall A', 'Initials': 'RA', 'LastName': 'Ow', 'Affiliation': 'Sacramento Ear, Nose, and Throat, Roseville, CA, U.S.A.'}, {'ForeName': 'Ellen M', 'Initials': 'EM', 'LastName': ""O'Malley"", 'Affiliation': 'Clinical Affairs, Stryker ENT, Plymouth, MN, U.S.A.'}, {'ForeName': 'Joseph K', 'Initials': 'JK', 'LastName': 'Han', 'Affiliation': 'Otolaryngology, Eastern Virginia Medical School, Norfolk, VA, U.S.A.'}, {'ForeName': 'Kent K', 'Initials': 'KK', 'LastName': 'Lam', 'Affiliation': 'Otolaryngology, Eastern Virginia Medical School, Norfolk, VA, U.S.A.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Yen', 'Affiliation': 'Specialty Physician Associates, Bethlehem, PA, U.S.A.'}]",The Laryngoscope,['10.1002/lary.29453'] 1053,33611431,Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.,"BACKGROUND The combination of conventional transarterial chemoembolization (cTACE) and systemic therapy has the potential to treat chemotherapy-refractory unresectable colorectal liver metastases (CRLMs). This study aimed to compare survival after this combined treatment versus systemic chemotherapy alone. METHODS This single-centre RCT included patients with unresectable CRLMs that progressed after first-line treatment. Patients were randomized on a 1 : 1 basis to either systemic chemotherapy with or without cTACE, without further stratification. The primary outcome was progression-free survival (PFS). Secondary outcomes were overall response rate, disease control rate, conversion rate to liver resection, overall survival, and adverse events. RESULTS Of 180 patients recruited, 168 were randomized. Eighty-five patients in arm A received systemic chemotherapy plus cTACE and 83 in arm B received systemic chemotherapy alone. Median PFS was longer in arm A than B (6.7 versus 3.8 months; hazard ratio (HR) 0.67, 95 per cent c.i. 0.49 to 0.91; P = 0.009), but did not translate into prolonged median overall survival (18.4 versus 14.8 months; HR = 0.92, 0.62 to 1.36; P = 0.669). Overall response rates (20 versus 22 per cent; P = 0.788) and conversion rate to liver resection (18 versus 16 per cent; P = 0.730) were no different between arms A and B. The disease control rate was higher in arm A than arm B (67 versus 51 per cent; P = 0.030). No adverse event higher than grade 3 according to the Common Terminology Criteria for Adverse Events was observed during treatment. CONCLUSION Systemic chemotherapy plus cTACE is a safe option as second-line treatment for unresectable colorectal liver metastases, with a modest effect on PFS. Registration number: NCT03783559 (http://www.clinicaltrials.gov).",2021,Overall response rates (20 versus 22 per cent; P = 0.788) and conversion rate to liver resection (18 versus 16 per cent; P = 0.730) were no different between arms A and B.,"['unresectable colorectal liver metastases', '180 patients recruited, 168 were randomized']","['Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone', 'systemic chemotherapy with or without cTACE', 'conventional transarterial chemoembolization (cTACE) and systemic therapy', 'Systemic chemotherapy plus cTACE', 'systemic chemotherapy alone', 'systemic chemotherapy plus cTACE']","['conversion rate to liver resection', 'survival', 'Overall response rates', 'overall response rate, disease control rate, conversion rate to liver resection, overall survival, and adverse events', 'disease control rate', 'median overall survival', 'Median PFS', 'progression-free survival (PFS']","[{'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0494165', 'cui_str': 'Secondary malignant neoplasm of liver'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319556', 'cui_str': '168'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0522522', 'cui_str': 'Transarterial approach'}, {'cui': 'C0796679', 'cui_str': 'Chemoembolization'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0019144', 'cui_str': 'Liver excision'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",180.0,0.352083,Overall response rates (20 versus 22 per cent; P = 0.788) and conversion rate to liver resection (18 versus 16 per cent; P = 0.730) were no different between arms A and B.,"[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Colorectal Cancer Centre, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Chang', 'Affiliation': 'Colorectal Cancer Centre, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Zhou', 'Affiliation': 'Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': 'Colorectal Cancer Centre, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Colorectal Cancer Centre, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Liang', 'Affiliation': 'Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Colorectal Cancer Centre, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Yan', 'Affiliation': 'Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lv', 'Affiliation': 'Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Ren', 'Affiliation': 'Colorectal Cancer Centre, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Colorectal Cancer Centre, Zhongshan Hospital, Fudan University, Shanghai, China.'}]",The British journal of surgery,['10.1093/bjs/znaa155'] 1054,33620131,Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial.,"AIMS Nitroxyl provokes vasodilatation and inotropic and lusitropic effects in animals via post-translational modification of thiols. We aimed to compare effects of the nitroxyl donor cimlanod (BMS-986231) with those of nitroglycerin (NTG) or placebo on cardiac function in patients with chronic heart failure with reduced ejection fraction (HFrEF). METHODS AND RESULTS In a randomized, multicentre, double-blind, crossover trial, 45 patients with stable HFrEF were given a 5 h intravenous infusion of cimlanod, NTG, or placebo on separate days. Echocardiograms were done at the start and end of each infusion period and read in a core laboratory. The primary endpoint was stroke volume index derived from the left ventricular outflow tract at the end of each infusion period. Stroke volume index with placebo was 30 ± 7 mL/m 2 and was lower with cimlanod (29 ± 9 mL/m 2 ; P = 0.03) and NTG (28 ± 8 mL/m 2 ; P = 0.02). Transmitral E-wave Doppler velocity on cimlanod or NTG was lower than on placebo and, consequently, E/e' (P = 0.006) and E/A ratio (P = 0.003) were also lower. NTG had similar effects to cimlanod on these measurements. Blood pressure reduction was similar with cimlanod and NTG and greater than with placebo. CONCLUSION In patients with chronic HFrEF, the haemodynamic effects of cimlanod and NTG are similar. The effects of cimlanod may be explained by venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing trials of cimlanod will further define its potential role in the treatment of heart failure.",2021,"Transmitral E-wave Doppler velocity on cimlanod or NTG was lower than on placebo and, consequently, E/e' (p = 0.006) and E/A ratio (p = 0.003) were also lower.","['45 patients with stable HFrEF', 'Chronic Heart Failure', 'patients with chronic heart failure with reduced ejection fraction (HFrEF']","['cimlanod, NTG, or placebo', 'NTG', 'placebo', 'nitroglycerin (NTG) or placebo', 'Nitroxyl Donor Cimlanod (BMS-986231', 'HNO donor cimlanod (BMS-986231']","['cardiac function', 'Blood pressure reduction', 'stroke volume index (SVI) derived from the left ventricular outflow tract', 'Transmitral E-wave Doppler velocity on cimlanod or NTG']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C4280934', 'cui_str': 'Reduced ejection fraction co-occurrent and due to chronic heart failure'}]","[{'cui': 'C0017887', 'cui_str': 'Nitroglycerin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0068882', 'cui_str': 'nitroxyl'}, {'cui': 'C0013018', 'cui_str': 'Donors'}]","[{'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0554756', 'cui_str': 'Doppler studies'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0017887', 'cui_str': 'Nitroglycerin'}]",45.0,0.366756,"Transmitral E-wave Doppler velocity on cimlanod or NTG was lower than on placebo and, consequently, E/e' (p = 0.006) and E/A ratio (p = 0.003) were also lower.","[{'ForeName': 'Ninian N', 'Initials': 'NN', 'LastName': 'Lang', 'Affiliation': 'BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Faheem A', 'Initials': 'FA', 'LastName': 'Ahmad', 'Affiliation': 'BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Cleland', 'Affiliation': 'Robertson Centre for Biostatistics & Clinical Trials, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': ""O'Connor"", 'Affiliation': 'Inova Heart & Vascular Institute, Falls Church, VA, USA.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Teerlink', 'Affiliation': 'Department of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Adriaan A', 'Initials': 'AA', 'LastName': 'Voors', 'Affiliation': 'Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Jorg', 'Initials': 'J', 'LastName': 'Taubel', 'Affiliation': 'Richmond Pharmacology Limited, London, UK.'}, {'ForeName': 'Anke R', 'Initials': 'AR', 'LastName': 'Hodes', 'Affiliation': 'Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Anwar', 'Affiliation': 'Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Karra', 'Affiliation': 'Department of Medicine, Duke Advanced Heart and Lung Failure Clinic, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Sakata', 'Affiliation': 'Department of Cardiovascular Medicine, Osaka University Hospital, Suita, Osaka, Japan.'}, {'ForeName': 'Shiro', 'Initials': 'S', 'LastName': 'Ishihara', 'Affiliation': 'Department of Cardiology, Nippon Medical School, Kawasaki-shi, Japan.'}, {'ForeName': 'Roxy', 'Initials': 'R', 'LastName': 'Senior', 'Affiliation': 'Department of Cardiovascular Research, Northwick Park Hospital & Department of Cardiology, Royal Brompton Hospital, London, UK.'}, {'ForeName': 'Abhishek', 'Initials': 'A', 'LastName': 'Khemka', 'Affiliation': 'Department of Cardiology, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'Narayana G', 'Initials': 'NG', 'LastName': 'Prasad', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Mary M', 'Initials': 'MM', 'LastName': 'DeSouza', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Seiffert', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'June Y', 'Initials': 'JY', 'LastName': 'Ye', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Kessler', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Borentain', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Solomon', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'G Michael', 'Initials': 'GM', 'LastName': 'Felker', 'Affiliation': 'Division of Cardiology, Duke Clinical Research Institute (DCRI), Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.'}]",European journal of heart failure,['10.1002/ejhf.2138'] 1055,33819769,"Bactericidal effect of Er,Cr:YSGG laser irradiation on endodontic biofilm: An ex vivo study.","AIM This ex vivo study aimed to evaluate the of Er,Cr:YSGG laser effectiveness in the decontamination of an endodontic biofilm. MATERIALS AND METHODS Seventy-three single rooted human teeth, freshly were chosen. Each tooth was exposed to four associated species in an endodontic biofilm (Enterococcus faecalis, Streptococcus salivarius, Porphyromonas gingivalis, and Prevotella intermedia) and randomly allocated to one of the seven experimental groups. The group 1 (7 teeth) was used to finalize the reliable biofilm-forming technique. The groups 2 and 3 (15 teeth each group) were irradiated with two different Er;Cr:YSGG laser settings (0,75 W - 40 Hz and 4 W - 40 Hz, respectively). The groups 4 and 5 (15 teeth each group) were irrigated with two different solutions and laser irradiated with the same settings (1,5 W - 15 Hz). The group 6 (6 teeth) was the control group treated only with 4 ml 2,5% NaOCl irrigation during 60 s. RESULTS The observations of group 2 and 3 specimens showed the ripeness of the biofilm with the presence of Enterococcus faecalis and Streptococcus salivarius in chains but in group 3 thermal edge effects produced by the optic fiber in the canal walls were present. The group 4 specimens observation showed an average cleaning of the root canal walls while on the canal walls of group 5 samples the apical third presented several debris and smear layer and in the centre cracks and melting dentin of the radicular wall were observed. CONCLUSION In those experimental conditions, this study, demonstrated that Er,Cr:YSGG laser has a canals decontamination ability when associated to NaOCl irrigation.",2021,"The group 4 specimens observation showed an average cleaning of the root canal walls while on the canal walls of group 5 samples the apical third presented several debris and smear layer and in the centre cracks and melting dentin of the radicular wall were observed. ","['Seventy-three single rooted human teeth, freshly were chosen']","['irradiated with two different Er;Cr:YSGG laser settings (0,75', 'Er,Cr:YSGG laser', 'Er,Cr:YSGG laser irradiation', 'control group treated only with 4\xa0ml 2,5% NaOCl irrigation']","['endodontic biofilm', 'average cleaning of the root canal walls']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}]","[{'cui': 'C1277077', 'cui_str': 'Irradiated blood product'}, {'cui': 'C0879167', 'cui_str': 'Yttrium-Scandium-Gallium Garnet Lasers'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}]","[{'cui': 'C0332274', 'cui_str': 'Endodontic'}, {'cui': 'C0081786', 'cui_str': 'Biofilm'}, {'cui': 'C0542277', 'cui_str': 'Cleans drug injection equipment'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0205380', 'cui_str': 'Walled'}]",73.0,0.017378,"The group 4 specimens observation showed an average cleaning of the root canal walls while on the canal walls of group 5 samples the apical third presented several debris and smear layer and in the centre cracks and melting dentin of the radicular wall were observed. ","[{'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Merigo', 'Affiliation': ""University Côte d'Azur, Micoralis Research Laboratory UPR7354, 24 Avenue des Diables bleus, 06357 Nice Cedex 4, France. Electronic address: elisabetta.merigo@univ-cotedazur.fr.""}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Bufflier', 'Affiliation': 'Diplôme Universitaire Oral laser Applications (DUOLA), Université de Nice ""Sophia Antipolis"", 24 Avenue des Diables bleus, 06357 Nice Cedex 4, France. Electronic address: dr-bufflier@espace-dentaire-leman.fr.'}, {'ForeName': 'Jean-Paul', 'Initials': 'JP', 'LastName': 'Rocca', 'Affiliation': ""University Côte d'Azur, Micoralis Research Laboratory UPR7354, 24 Avenue des Diables bleus, 06357 Nice Cedex 4, France; 2(nd) Hospital, International Department of Stomatology, Shijiazhuang, Hebei Province, China. Electronic address: jean-paul.rocca@univ-cotedazur.fr.""}, {'ForeName': 'Marlène', 'Initials': 'M', 'LastName': 'Chevalier', 'Affiliation': ""University Côte d'Azur, Micoralis Research Laboratory UPR7354, 24 Avenue des Diables bleus, 06357 Nice Cedex 4, France. Electronic address: marlene.chevalier@univ-cotedazur.fr.""}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Medioni', 'Affiliation': ""University Côte d'Azur, Micoralis Research Laboratory UPR7354, 24 Avenue des Diables bleus, 06357 Nice Cedex 4, France. Electronic address: etienne.medioni@univ-cotedazur.fr.""}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Meng', 'Affiliation': '2(nd) Hospital, International Department of Stomatology, Shijiazhuang, Hebei Province, China. Electronic address: zhaomeng3718@163.com.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Fornaini', 'Affiliation': ""University Côte d'Azur, Micoralis Research Laboratory UPR7354, 24 Avenue des Diables bleus, 06357 Nice Cedex 4, France; 2(nd) Hospital, International Department of Stomatology, Shijiazhuang, Hebei Province, China. Electronic address: carlo@fornainident.it.""}]","Journal of photochemistry and photobiology. B, Biology",['10.1016/j.jphotobiol.2021.112185'] 1056,33632742,Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.,"Previously, we demonstrated low-dose antithymocyte globulin (ATG) and granulocyte colony-stimulating factor (GCSF) immunotherapy preserved C-peptide for 2 years in a pilot study of patients with established type 1 diabetes ( n = 25). Here, we evaluated the long-term outcomes of ATG/GCSF in study participants with 5 years of available follow-up data ( n = 15). The primary end point was area under the curve (AUC) C-peptide during a 2-h mixed-meal tolerance test. After 5 years, there were no statistically significant differences in AUC C-peptide when comparing those who received ATG/GCSF versus placebo ( P = 0.41). A modeling framework based on mean trajectories in C-peptide AUC over 5 years, accounting for differing trends between groups, was applied to recategorize responders ( n = 9) and nonresponders ( n = 7). ATG/GCSF reponders demonstrated nearly unchanged HbA 1c over 5 years (mean [95% CI] adjusted change 0.29% [-0.69%, 1.27%]), but the study was not powered for comparisons against nonresponders 1.75% (-0.57%, 4.06%) or placebo recipients 1.44% (0.21%, 2.66%). These data underscore the importance of long-term follow-up in previous and ongoing phase 2 trials of low-dose ATG in recent-onset type 1 diabetes.",2021,"After five years, there were no statistically significant differences in AUC C-peptide when comparing subjects who received ATG/GCSF versus placebo (p = 0.41).","['Established Type 1 Diabetes', 'study participants with five years of available follow-up data (n=15', 'subjects with established type 1 diabetes (n=25']","['Low-dose ATG/GCSF', 'low-dose anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) immunotherapy preserved C-peptide', 'placebo', 'ATG/GCSF']","['AUC C-peptide', 'area under the curve (AUC) C-peptide during a two-hour mixed-meal tolerance test (MMTT']","[{'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0003442', 'cui_str': 'Lymphocyte Immune Globulin, Anti-Thymocyte Globulin'}, {'cui': 'C0079459', 'cui_str': 'Colony-stimulating factor, granulocytic'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0201777', 'cui_str': 'Tolerance test'}]",,0.0804782,"After five years, there were no statistically significant differences in AUC C-peptide when comparing subjects who received ATG/GCSF versus placebo (p = 0.41).","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Lin', 'Affiliation': 'Department of Pathology, Immunology, and Laboratory Medicine, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Jasmine A', 'Initials': 'JA', 'LastName': 'Mack', 'Affiliation': 'Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, FL.'}, {'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Bruggeman', 'Affiliation': 'Department of Pediatrics, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Laura M', 'Initials': 'LM', 'LastName': 'Jacobsen', 'Affiliation': 'Department of Pediatrics, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Posgai', 'Affiliation': 'Department of Pathology, Immunology, and Laboratory Medicine, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Clive H', 'Initials': 'CH', 'LastName': 'Wasserfall', 'Affiliation': 'Department of Pathology, Immunology, and Laboratory Medicine, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Todd M', 'Initials': 'TM', 'LastName': 'Brusko', 'Affiliation': 'Department of Pathology, Immunology, and Laboratory Medicine, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Atkinson', 'Affiliation': 'Department of Pathology, Immunology, and Laboratory Medicine, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Gitelman', 'Affiliation': 'Division of Endocrinology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Gottlieb', 'Affiliation': 'Division of Endocrinology, Department of Pediatrics and Medicine, University of Colorado, Denver, CO.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Gurka', 'Affiliation': 'Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, FL.'}, {'ForeName': 'Clayton E', 'Initials': 'CE', 'LastName': 'Mathews', 'Affiliation': 'Department of Pathology, Immunology, and Laboratory Medicine, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Desmond A', 'Initials': 'DA', 'LastName': 'Schatz', 'Affiliation': 'Department of Pediatrics, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Haller', 'Affiliation': 'Department of Pediatrics, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL hallemj@peds.ufl.edu.'}]",Diabetes,['10.2337/db20-1103'] 1057,33630712,"Aerobic training, resistance training, or their combination as a means to fight against excess weight and metabolic syndrome in obese students - which is the most effective modality? A randomized controlled trial.","This study aimed to determine the effects of either aerobic training (AT) or resistance training (RT) or both (A+RT) on obesity and its comorbidities in young adults. A total of 61 participants, aged 21.74 ± 1.42 years and with a body mass (BM) index (BMI) of 36.21 ± 2.43 kg/m 2 , were randomized for 12 weeks into control (CONT, n = 15), AT ( n = 15), RT ( n = 16), and A+RT ( n = 15) groups. BM, body composition, and cardiovascular disease risk factors were assessed before and after intervention. BM did not change in the CONT and RT groups but decreased significantly by 7.5 kg in the AT ( p ≤ 0.05) and 8.82 kg in the A+RT ( p ≤ 0.05) groups, respectively. Significant reductions were also noted in waist circumference, BMI, and body fat percentage in the exercising groups. The most significant variations were in the A+RT group. High-density lipoprotein cholesterol (HDL-C) concentrations were increased after A+RT by 2.39 mg/dL. Significant reductions were also noted in very-low-density lipoprotein cholesterol (VLDL-C) concentrations (-2.84 mg/dL) in the A+RT group. AT alone is effective in improving BM and body composition, while RT alone improves the body composition and A+RT ensures better outcomes concerning BM, body composition, HDL-C, and VLDL-C. Novelty: Aerobic training alone is effective in improving BM and body composition. Resistance training alone improves the body composition. The combination of aerobic and resistance exercises ensures better outcomes for BM, body composition, HDL-C, and VLDL-C.",2021,HDL-C concentrations were increased after A+RT by 2.39 mg/dL. Significant reductions were also noted in VLDL-C concentrations (-2.84 mg/dL) in the A+RT group.,"['A total of 61 participants, aged 21.74 ± 1.42 years and with a body mass', 'young adults', 'Obese Students']","['Aerobic Training, Resistance Training, or Their Combination as a Means to Fight against Excess Weight', 'aerobic and resistance exercises', 'aerobic training (AT) or resistance training (RT) or both (A+RT']","['waist circumference, BMI, and body fat percentage', 'body composition', 'BM, body composition, and cardiovascular disease risk (CVR) factors', 'VLDL-C concentrations', 'HDL-C concentrations', 'BM', 'body mass, body composition, HDL-C, and VLD-C']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0521124', 'cui_str': 'Against'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0023825', 'cui_str': 'Very low density lipoprotein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}]",61.0,0.0178309,HDL-C concentrations were increased after A+RT by 2.39 mg/dL. Significant reductions were also noted in VLDL-C concentrations (-2.84 mg/dL) in the A+RT group.,"[{'ForeName': 'Mohamed Ahmed', 'Initials': 'MA', 'LastName': 'Said', 'Affiliation': 'Physical Education Department, College of Education, King Faisal University, Saudi Arabia.'}, {'ForeName': 'Mohamed Abdelrahman', 'Initials': 'MA', 'LastName': 'Abdelmoneim', 'Affiliation': 'Physical Education Department, College of Education, King Faisal University, Saudi Arabia.'}, {'ForeName': 'Mohamed Shaab', 'Initials': 'MS', 'LastName': 'Alibrahim', 'Affiliation': 'Physical Education Department, College of Education, King Faisal University, Saudi Arabia.'}, {'ForeName': 'Ahmed Abdel Hamed', 'Initials': 'AAH', 'LastName': 'Kotb', 'Affiliation': 'Physical Education Department, College of Education, King Faisal University, Saudi Arabia.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2020-0972'] 1058,33637429,Improving Handoff by Deliberate Cognitive Processing: Results from a Randomized Controlled Experimental Study.,"BACKGROUND Although a number of successful handoff interventions have been reported, the handoff process remains vulnerable because it relies on memory. The aim of this study was to investigate the effect of deliberate cognitive processing (i.e., analytical, conscious, and effortful thinking) on recall of information from a simulated handoff. METHODS This two-phased experiment was executed in the Netherlands in 2015. A total of 78 pediatric residents were randomly divided into an intervention group (n = 37) and a control group (n = 41). In phase 1, participants received written handoffs from 8 patients. The intervention group was asked to develop a contingency plan for each patient, deliberately processing the information. The control group received no specific instructions. In phase 2, all participants were asked to write down as much as they recalled from the handoffs. The outcome was the amount and accuracy of recalled information, calculated by scoring for idea units (single information elements) and inferences (conclusions computed by participants based on two or more idea units). RESULTS Participants in the intervention group recalled significantly more inferences (7.24 vs. 3.22) but fewer correct idea units (21.1% vs. 25.3%) than those in the control group. There was no difference with regard to incorrectly recalled information. CONCLUSION Our study revealed that deliberate cognitive processing leads to creation of more correct inferences, but fewer idea units. This suggests that deliberate cognitive processing results in interpretation of the information into higher level concepts, rather than remembering specific pieces of information separately. This implies better understanding of patients' problems.",2021,"RESULTS Participants in the intervention group recalled significantly more inferences (7.24 vs. 3.22) but fewer correct idea units (21.1% vs. 25.3%) than those in the control group.",['78 pediatric residents'],"['no specific instructions', 'deliberate cognitive processing (i.e., analytical, conscious, and effortful thinking', 'Deliberate Cognitive Processing']",['correct idea units'],"[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}]","[{'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0459920', 'cui_str': 'Ability to think abstractly'}, {'cui': 'C0439148', 'cui_str': 'Unit'}]",78.0,0.0520658,"RESULTS Participants in the intervention group recalled significantly more inferences (7.24 vs. 3.22) but fewer correct idea units (21.1% vs. 25.3%) than those in the control group.","[{'ForeName': 'Gwen', 'Initials': 'G', 'LastName': 'van Heesch', 'Affiliation': ''}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Frenkel', 'Affiliation': ''}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Kollen', 'Affiliation': ''}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Zwaan', 'Affiliation': ''}, {'ForeName': 'Sílvia', 'Initials': 'S', 'LastName': 'Mamede', 'Affiliation': ''}, {'ForeName': 'Henk', 'Initials': 'H', 'LastName': 'Schmidt', 'Affiliation': ''}, {'ForeName': 'Matthijs', 'Initials': 'M', 'LastName': 'de Hoog', 'Affiliation': ''}]",Joint Commission journal on quality and patient safety,['10.1016/j.jcjq.2020.11.008'] 1059,33637409,The Use of Tablet Computers to Reduce Preoperative Anxiety in Children Before Anesthesia: A Randomized Controlled Study.,"PURPOSE Children undergoing surgery and general anesthesia often experience preoperative anxiety (POA) with related negative short-, medium- and long-term consequences. Anxiolytic premedication has negative side effects, and nonpharmacologic interventions are often resource demanding and not always readily available in a busy clinical setting. The use of an age-appropriate game on a tablet computer may reduce POA, postoperative pain, and occurrence of emergence delirium (ED). DESIGN Children aged 3 to 6 years scheduled to undergo elective minor surgery were randomly assigned to play a game on a tablet computer while in the holding area before anesthesia (n = 30) or prepared as per departmental standard only (n = 30). METHODS POA, ED, and levels of pain were assessed by the modified Yale Preoperative Anxiety Scale, Pediatric Anesthesia Emergence Delirium, and Face, Legs, Activity, Cry, Consolability scale, respectively. FINDINGS A total of 60 children were randomized to either the intervention group or the control group. Gender, bodyweight, duration of anesthesia and surgery, and fentanyl dosages were comparable between the two groups. Tablet-gaming children tended to be less anxious than control subjects at the time of anesthesia induction (modified Yale Preoperative Anxiety Scale, 55.7 vs 65.8; 95% confidence interval, -0.63 to 20.8; P = .066). There was no difference in occurrence of ED or pain 20 minutes after arrival in the postanesthesia care unit. CONCLUSIONS Although not statistically significant, the use of an age-appropriate tablet computer game may reduce the level of anxiety at the anesthetic induction in 3 to 6 years old children undergoing elective day-case surgery. However, the occurrence of ED and levels of pain appeared unaffected. Standardization of nonpharmacologic interventions to reduce perioperative anxiety and pain is required.",2021,"Tablet-gaming children tended to be less anxious than control subjects at the time of anesthesia induction (modified Yale Preoperative Anxiety Scale, 55.7 vs 65.8; 95% confidence interval, -0.63 to 20.8; P = .066).","['Children aged 3 to 6\xa0years scheduled to undergo elective minor surgery', '60 children', '6 years old children undergoing elective day-case surgery', 'Children undergoing surgery and general anesthesia often experience preoperative anxiety (POA) with related negative short-, medium- and long-term consequences', 'Children Before Anesthesia']","['Anxiolytic premedication', 'nonpharmacologic interventions', 'play a game on a tablet computer while in the holding area before anesthesia (n\xa0=\xa030) or prepared as per departmental standard only (n\xa0=\xa030']","['Gender, bodyweight, duration of anesthesia and surgery, and fentanyl dosages', 'occurrence of ED or pain', 'level of anxiety', 'POA, postoperative pain, and occurrence of emergence delirium (ED', 'perioperative anxiety and pain', 'Preoperative Anxiety', 'modified Yale Preoperative Anxiety Scale, Pediatric Anesthesia Emergence Delirium, and Face, Legs, Activity, Cry, Consolability scale, respectively', 'occurrence of ED and levels of pain']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0038904', 'cui_str': 'Minor Surgical Procedure'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}]","[{'cui': 'C0040616', 'cui_str': 'Anxiolytic agent'}, {'cui': 'C0033045', 'cui_str': 'Premedication'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C4045980', 'cui_str': 'Tablet Computers'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0920253', 'cui_str': 'Agitated Emergence'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",60.0,0.0402828,"Tablet-gaming children tended to be less anxious than control subjects at the time of anesthesia induction (modified Yale Preoperative Anxiety Scale, 55.7 vs 65.8; 95% confidence interval, -0.63 to 20.8; P = .066).","[{'ForeName': 'Nicola G', 'Initials': 'NG', 'LastName': 'Clausen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, University Hospital Odense, Odense, Denmark; Department of Clinical Research - Anaesthesiology, University of Southern Denmark, Odense, Denmark. Electronic address: Nicola.Groes.Clausen2@rsyd.dk.'}, {'ForeName': 'Dorthe', 'Initials': 'D', 'LastName': 'Madsen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, University Hospital Odense, Odense, Denmark; Department of Clinical Research - Anaesthesiology, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Rosenkilde', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, University Hospital Odense, Odense, Denmark; Department of Clinical Research - Anaesthesiology, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Dorthe', 'Initials': 'D', 'LastName': 'Hasfeldt-Hansen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, University Hospital Odense, Odense, Denmark; Department of Clinical Research - Anaesthesiology, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Line G', 'Initials': 'LG', 'LastName': 'Larsen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, University Hospital Odense, Odense, Denmark.'}, {'ForeName': 'Tom G', 'Initials': 'TG', 'LastName': 'Hansen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, University Hospital Odense, Odense, Denmark; Department of Clinical Research - Anaesthesiology, University of Southern Denmark, Odense, Denmark.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.09.012'] 1060,33641346,Prior exercise impairs subsequent performance in an intensity- and duration-dependent manner.,"Prior constant-load exercise performed for 30-min at or above maximal lactate steady state (MLSS p ) significantly impairs subsequent time-to-task failure (TTF) compared with TTF performed without prior exercise. We tested the hypothesis that TTF would decrease in relation to the intensity and the duration of prior exercise compared with a baseline TTF trial. Eleven individuals (6 males, 5 females, aged 28 ± 8 yrs) completed the following tests on a cycle ergometer (randomly assigned after MLSS p was determined): ( i ) a ramp-incremental test; ( ii ) a baseline TTF trial performed at 80% of peak power (TTF b ); ( iii ) five 30-min constant-PO rides at 5% below lactate threshold (LT -5% ), halfway between LT and MLSS p (Delta 50 ), 5% below MLSS p (MLSS -5% ), MLSS p , and 5% above MLSS p (MLSS +5% ); and ( iv ) 15- and 45-min rides at MLSS p (MLSS 15 and MLSS 45 , respectively). Each condition was immediately followed by a TTF trial at 80% of peak power. Compared with TTF b (330 ± 52 s), there was 8.0 ± 24.1, 23.6 ± 20.2, 41.0 ± 14.8, 52.2 ± 18.9, and 75.4 ± 7.4% reduction in TTF following LT -5% , Delta 50 , MLSS -5% , MLSS p , and MLSS +5% , respectively. Following MLSS 15 and MLSS 45 there were 29.0 ± 20.1 and 69.4 ± 19.6% reductions in TTF, respectively ( P < 0.05). It is concluded that TTF is reduced following prior exercise of varying duration at MLSS p and at submaximal intensities below MLSS. Novelty: Prior constant-PO exercise, performed at intensities below MLSS p , reduces subsequent TTF performance. Subsequent TTF performance is reduced in a linear fashion following an increase in the duration of constant-PO exercise at MLSS p.",2021,•Subsequent TTF performance is reduced in a linear fashion following an increase in the duration of constant-PO exercise at MLSSp.,"['Eleven individuals (6 men, 5 women, 28 ± 8 yrs) completed the following tests on a cycle ergometer (randomly assigned after MLSSp was determined']","['halfway between LT and MLSSp (Delta50), 5% below MLSSp (MLSS-5%), MLSSp, and 5% above MLSSp (MLSS+5%), and iv', 'Prior constant-load exercise performed for 30-min at or above maximal lactate steady state (MLSSp', 'Prior exercise', 'TTF']","['•Subsequent TTF performance', 'subsequent time-to-task failure (TTF', 'reduces subsequent TTF performance']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}]","[{'cui': 'C0796070', 'cui_str': 'Microphthalmia with linear skin defect syndrome'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C4087167', 'cui_str': 'Tumour treating fields therapy'}]","[{'cui': 'C4087167', 'cui_str': 'Tumour treating fields therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",11.0,0.0433458,•Subsequent TTF performance is reduced in a linear fashion following an increase in the duration of constant-PO exercise at MLSSp.,"[{'ForeName': 'Madison M', 'Initials': 'MM', 'LastName': 'Fullerton', 'Affiliation': 'Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Passfield', 'Affiliation': 'Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'MacInnis', 'Affiliation': 'Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'Iannetta', 'Affiliation': 'Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Juan M', 'Initials': 'JM', 'LastName': 'Murias', 'Affiliation': 'Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2020-0689'] 1061,33642166,Caffeine slows heart rate autonomic recovery following strength exercise in healthy subjects.,"INTRODUCTION AND OBJECTIVES Studies assessing the effects of caffeine (CAF) on the cardiovascular system have demonstrated that CAF can delay cardiac recovery following exercise. This study intended to assess the impact of CAF intake before physical exercise on heart rate variability (HRV) and cardiovascular parameters. METHODS This is a prospective, crossover, controlled clinical trial conducted at the University of Pernambuco, Petrolina, PE, Brazil. The experimental protocol was split into three stages with a minimum of 48 hours between them. Exercises intensity was standardized based on the one repetition maximum test (1RM), obtaining the load of each volunteer for the intensity of 75% of 1RM. In the second and third phases, the control protocols were applied and 300 mg caffeine was given 45 minutes before training. HRV indices were determined at the subsequent times: 0 to 5 minutes of rest (before) and during 30 minutes of recovery (Rec) (after exercise), divided into six intervals, each of 5 minutes. RESULTS The final sample involved 30 volunteers. CAF delayed HRV recovery after resistance exercise. In general, CAF impaired recovery of HRV after resistance exercise. Significant changes were observed in the RMSSD, SDNN, TINN, SD1, low frequency and high frequency indices between the control and CAF group. CONCLUSION CAF protocol delayed parasympathetic regulation of heart rhythm following exercise, slowing recovery of HR, blood pressure and HRV indices after exercise.",2021,"Significant changes were observed in the RMSSD, SDNN, TINN, SD1, low frequency and high frequency indices between the control and CAF group. ","['30 volunteers', 'healthy subjects']","['caffeine (CAF', 'caffeine', 'CAF intake before physical exercise', 'strength exercise', 'Caffeine', 'CAF']","['parasympathetic regulation of heart rhythm following exercise, slowing recovery of HR, blood pressure and HRV indices', 'CAF delayed HRV recovery', 'HRV indices', 'RMSSD, SDNN, TINN, SD1, low frequency and high frequency indices', 'heart rate variability (HRV) and cardiovascular parameters']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C1160592', 'cui_str': 'Cardiac Chronotropy'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C1861380', 'cui_str': 'Syndactyly, Type I'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",30.0,0.0322193,"Significant changes were observed in the RMSSD, SDNN, TINN, SD1, low frequency and high frequency indices between the control and CAF group. ","[{'ForeName': 'Cicero Jonas R', 'Initials': 'CJR', 'LastName': 'Benjamim', 'Affiliation': 'Development, Nutrition, Phytotherapy and Hygiene Research Group, University of Pernambuco, Petrolina, PE, Brazil.'}, {'ForeName': 'Larissa Raylane L', 'Initials': 'LRL', 'LastName': 'Monteiro', 'Affiliation': 'Nucleus of Studies in Physiological and Collective Sciences, School of Juazeiro do Norte, Juazeiro do Norte, CE, Brazil.'}, {'ForeName': 'Yasmim M de Moraes', 'Initials': 'YMM', 'LastName': 'Pontes', 'Affiliation': 'Nucleus of Studies in Physiological and Collective Sciences, School of Juazeiro do Norte, Juazeiro do Norte, CE, Brazil.'}, {'ForeName': 'Amanda A Marcelino da', 'Initials': 'AAMD', 'LastName': 'Silva', 'Affiliation': 'Development, Nutrition, Phytotherapy and Hygiene Research Group, University of Pernambuco, Petrolina, PE, Brazil.'}, {'ForeName': 'Thays K Marinho de', 'Initials': 'TKM', 'LastName': 'Souza', 'Affiliation': 'Development, Nutrition, Phytotherapy and Hygiene Research Group, University of Pernambuco, Petrolina, PE, Brazil.'}, {'ForeName': 'Vitor E', 'Initials': 'VE', 'LastName': 'Valenti', 'Affiliation': 'Center for the Study of the Autonomic Nervous System (CESNA), UNESP, Marilia, SP, Brazil.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Garner', 'Affiliation': 'Center for the Study of the Autonomic Nervous System (CESNA), UNESP, Marilia, SP, Brazil; Cardiorespiratory Research Group, Department of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, United Kingdom.'}, {'ForeName': 'Taisy C Ferro', 'Initials': 'TCF', 'LastName': 'Cavalcante', 'Affiliation': 'Development, Nutrition, Phytotherapy and Hygiene Research Group, University of Pernambuco, Petrolina, PE, Brazil. Electronic address: taisy.cavalcante@upe.br.'}]",Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology,['10.1016/j.repc.2020.07.015'] 1062,33608727,Applying an intraoperative predictive indicator for postoperative pancreatic fistula: randomized preclinical trial.,,2021,"In this preclinical efficacy assessment study, SmartPAN was capable of detecting sites associated with biochemical leak and POPF-related symptoms, thereby guiding effective closure.",['postoperative pancreatic fistula'],[],[],"[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030290', 'cui_str': 'Pancreatic fistula'}]",[],[],,0.0392831,"In this preclinical efficacy assessment study, SmartPAN was capable of detecting sites associated with biochemical leak and POPF-related symptoms, thereby guiding effective closure.","[{'ForeName': 'T M', 'Initials': 'TM', 'LastName': 'Pausch', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Mitzscherling', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Aubert', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Gesslein', 'Affiliation': 'Magle Chemoswed, Malmö, Sweden.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Bruckner', 'Affiliation': 'Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'F K F', 'Initials': 'FKF', 'LastName': 'Kommoss', 'Affiliation': 'Institute of Pathology, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Golriz', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Mehrabi', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Hackert', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.'}]",The British journal of surgery,['10.1093/bjs/znaa115'] 1063,33608712,PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.,"BACKGROUND The aim of this study was to investigate whether the PAM-50-based 46-gene assay carries prognostic value for risk of local recurrence of breast cancer. METHODS The Austrian Breast and Colorectal Cancer Study Group (ABCSG) 8 RCT compared 5 years of tamoxifen with tamoxifen for 2 years followed by anastrozole for 3 years in postmenopausal women with endocrine receptor-positive breast cancer. This study included patients from the trial who had breast-conserving surgery for whom tumour blocks were available for PAM-50 analysis. RESULTS Tumour blocks from 1204 patients who had breast-conserving surgery were available for the PAM-50 analysis, and 1034 of these received radiotherapy. After a median follow-up of 10.8 years, 23 local events had been observed, corresponding to an overall local recurrence risk of 2.2 per cent. Univariable competing-risk analysis demonstrated that patients at low risk according to PAM-50 analysis (risk-of-recurrence (ROR) score less than 57) had a significantly lower incidence of local recurrence than those in the high-risk group at 5 years (0.1 (95 per cent c.i. 0 to 0.7) versus 2.2 (0.9 to 4.6) per cent respectively; subhazard ratio (SHR) 17.18, 95 per cent c.i. 2.06 to 142.88; P = 0.009) and 10 years (0.9 (0.4 to 2.0) versus 3.8 (1.9 to 6.6) per cent; SHR 4.76, 1.72 to 13.17; P = 0.003). Multivariable analyses that included ROR score, age, tumour size, nodal status, type of surgery, tumor grade, and trial-specific endocrine therapy confirmed that ROR score was an independent prognostic factor for risk of local recurrence. Analysis of the women randomized to radiotherapy or control after breast conservation showed that PAM-50 was not predictive of radiotherapy effect. CONCLUSION PAM-50 can be used as a prognostic tool for local recurrence risk in postmenopausal women with hormone receptor-positive breast cancer treated with endocrine therapy. The test was not predictive for the benefit of radiotherapy.",2021,"Analysis of the women randomized to radiotherapy or control after breast conservation showed that PAM-50 was not predictive of radiotherapy effect. ","['postmenopausal women with endocrine receptor-positive breast cancer', 'postmenopausal patients with ER+/HER2- disease', 'patients from the trial who had breast-conserving surgery for whom tumour blocks were available for PAM-50 analysis', 'postmenopausal women with hormone receptor-positive breast cancer treated with', '1204 patients who had breast-conserving surgery', '1204 patients in the randomized ABCSG-8 trial']","['PAM-50', 'radiotherapy', 'tamoxifen with tamoxifen', 'anastrozole', 'PAM-50-based 46-gene assay', 'endocrine therapy']","['ROR score', 'local recurrence', 'overall local recurrence risk']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C2931826', 'cui_str': 'Potassium aggravated myotonia'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C2931826', 'cui_str': 'Potassium aggravated myotonia'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}, {'cui': 'C0290883', 'cui_str': 'anastrozole'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.231096,"Analysis of the women randomized to radiotherapy or control after breast conservation showed that PAM-50 was not predictive of radiotherapy effect. ","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Fitzal', 'Affiliation': 'Department of Surgery, Medical University Vienna, Vienna, Austria.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Filipits', 'Affiliation': 'Institute of Cancer Research, Department of Medicine I, Medical University Vienna, Vienna, Austria.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Fesl', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rudas', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Greil', 'Affiliation': 'Third Medical Department with Haematology and Oncology, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Balic', 'Affiliation': 'Division of Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Moinfar', 'Affiliation': 'Department of Pathology, Ordensklinikum Linz/Hospital of the Sisters of Charity, Linz, Austria.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Herz', 'Affiliation': 'Department of Surgery, Landeskrankenhaus Hochsteiermark/Leoben, Leoben, Austria.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Dubsky', 'Affiliation': 'Department of Surgery, Medical University Vienna, Vienna, Austria.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Bartsch', 'Affiliation': 'Department of Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ferree', 'Affiliation': 'Nanostring Technologies, Seattle, Washington, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Schaper', 'Affiliation': 'Nanostring Technologies, Seattle, Washington, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gnant', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The British journal of surgery,['10.1093/bjs/znaa089'] 1064,33610215,"Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.","BACKGROUND Patients with advanced oesophageal cancer have a median survival of 3-6 months, and most require intervention for dysphagia. Self-expanding metal stent (SEMS) insertion is the most typical form of palliation in these patients, but dysphagia deterioration and re-intervention are common. This study examined the efficacy of adjuvant external beam radiotherapy (EBRT) compared with usual care alone in preventing dysphagia deterioration and reducing service use after SEMS insertion. METHODS This was a multicentre, open-label, phase 3 randomised controlled trial based at cancer centres and acute care hospitals in England, Scotland, and Wales. Patients (aged ≥16 years) with incurable oesophageal carcinoma receiving stent insertion for primary management of dysphagia were randomly assigned (1:1) to receive usual care alone or EBRT (20 Gy in five fractions or 30 Gy in ten fractions) plus usual care after stent insertion. Usual care was implemented according to need as identified by the local multidisciplinary team (MDT). Randomisation was via the method of minimisation stratified by treating centre, stage at diagnosis (I-III vs IV), histology (squamous or non-squamous), and MDT intent to give chemotherapy (yes vs no). The primary outcome was difference in proportions of participants with dysphagia deterioration (>11 point decrease on patient-reported European Organisation for Research and Treatment of Cancer quality of life questionnaire-oesophagogastric module [QLQ-OG25], or a dysphagia-related event consistent with such a deterioration) or death by 12 weeks in a modified intention-to-treat (ITT) population, which excluded patients who did not have a stent inserted and those without a baseline QLQ-OG25 assessment. Secondary outcomes included survival, quality of life (QoL), morbidities (including time to first bleeding event or hospital admission for bleeding event and first dysphagia-related stent complications or re-intervention), and cost-effectiveness. Safety analysis was undertaken in the modified ITT population. The study is registered with the International Standard Randomised Controlled Trial registry, ISRCTN12376468, and ClinicalTrials.gov, NCT01915693, and is completed. FINDINGS 220 patients were randomly assigned between Dec 16, 2013, and Aug 24, 2018, from 23 UK centres. The modified ITT population (n=199) comprised 102 patients in the usual care group and 97 patients in the EBRT group. Radiotherapy did not reduce dysphagia deterioration, which was reported in 36 (49%) of 74 patients receiving usual care versus 34 (45%) of 75 receiving EBRT (adjusted odds ratio 0·82 [95% CI 0·40-1·68], p=0·59) in those with complete data for the primary endpoint. No significant difference was observed in overall survival: median overall survival was 19·7 weeks (95% CI 14·4-27·7) with usual care and 18·9 weeks (14·7-25·6) with EBRT (adjusted hazard ratio 1·06 [95% CI 0·78-1·45], p=0·70; n=199). Median time to first bleeding event or hospital admission for a bleeding event was 49·0 weeks (95% CI 33·3-not reached) with usual care versus 65·9 weeks (52·7-not reached) with EBRT (adjusted subhazard ratio 0·52 [95% CI 0·28-0·97], p=0·038; n=199). No time versus treatment interaction was observed for prespecified QoL outcomes. We found no evidence of differences between trial group in time to first stent complication or re-intervention event. The most common (grade 3-4) adverse event was fatigue, reported in 19 (19%) of 102 patients receiving usual care alone and 22 (23%) of 97 receiving EBRT. On cost-utility analysis, EBRT was more expensive and less efficacious than usual care. INTERPRETATION Patients with advanced oesophageal cancer having SEMS insertion for the primary management of their dysphagia did not gain additional benefit from concurrent palliative radiotherapy and it should not be routinely offered. For a minority of patients clinically considered to be at high risk of tumour bleeding, concurrent palliative radiotherapy might reduce bleeding risk and the need for associated interventions. FUNDING National Institute for Health Research Health Technology Assessment Programme.",2021,"No significant difference was observed in overall survival: median overall survival was 19·7 weeks (95% CI 14·4-27·7) with usual care and 18·9 weeks (14·7-25·6) with EBRT (adjusted hazard ratio 1·06 [95% CI 0·78-1·45], p=0·70; n=199).","['cancer centres and acute care hospitals in England, Scotland, and Wales', 'Patients with advanced oesophageal cancer', 'Patients (aged ≥16 years) with incurable oesophageal carcinoma receiving stent insertion for primary management of dysphagia', 'Patients with advanced oesophageal cancer having SEMS insertion for the primary management of their dysphagia did not gain additional benefit from concurrent', 'after oesophageal cancer stenting (ROCS', '102 patients in the usual care group and 97 patients in the EBRT group', '220 patients were randomly assigned between Dec 16, 2013, and Aug 24, 2018, from 23 UK centres']","['palliative radiotherapy', 'usual care alone', 'Radiotherapy', 'Self-expanding metal stent (SEMS) insertion', 'adjuvant external beam radiotherapy (EBRT', 'usual care alone or EBRT (20 Gy in five fractions or 30 Gy in ten fractions) plus usual care after stent insertion', 'Palliative radiotherapy']","['Median time to first bleeding event or hospital admission for a bleeding event', 'survival, quality of life (QoL), morbidities (including time to first bleeding event or hospital admission for bleeding event and first dysphagia-related stent complications or re-intervention), and cost-effectiveness', 'bleeding risk', 'proportions of participants with dysphagia deterioration', 'overall survival: median overall survival', 'patient-reported European Organisation for Research and Treatment of Cancer quality of life questionnaire-oesophagogastric module [QLQ-OG25], or a dysphagia-related event consistent with such a deterioration) or death', 'dysphagia deterioration']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C3661916', 'cui_str': 'Acute care hospital'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0546837', 'cui_str': 'Malignant tumor of esophagus'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0152018', 'cui_str': 'Carcinoma of esophagus'}, {'cui': 'C0522776', 'cui_str': 'Placement of stent'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C0441290', 'cui_str': 'Metal stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0419095', 'cui_str': 'Teleradiotherapy procedure'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0587605', 'cui_str': 'Palliative care service'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C0441290', 'cui_str': 'Metal stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0419095', 'cui_str': 'Teleradiotherapy procedure'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0522776', 'cui_str': 'Placement of stent'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C4087536', 'cui_str': 'Stent complication'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0451149', 'cui_str': 'EORTC - Quality of life questionnaire'}, {'cui': 'C0475468', 'cui_str': 'Esophagogastric'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",220.0,0.246033,"No significant difference was observed in overall survival: median overall survival was 19·7 weeks (95% CI 14·4-27·7) with usual care and 18·9 weeks (14·7-25·6) with EBRT (adjusted hazard ratio 1·06 [95% CI 0·78-1·45], p=0·70; n=199).","[{'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Adamson', 'Affiliation': 'Tayside Cancer Centre, Ninewells Hospital, Dundee, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Byrne', 'Affiliation': 'Division of Population Medicine, Cardiff University, Cardiff, UK; Marie Curie Palliative Care Research Centre, Cardiff University, Cardiff, UK; Velindre University NHS Trust, Cardiff, UK. Electronic address: anthony.byrne2@wales.nhs.uk.'}, {'ForeName': 'Catharine', 'Initials': 'C', 'LastName': 'Porter', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Blazeby', 'Affiliation': 'Bristol Centre for Surgical Research, National Institute for Health Research Bristol and Weston Biomedical Research Centre, Bristol University, Bristol, UK.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Griffiths', 'Affiliation': 'University of Southampton, Southampton, UK.'}, {'ForeName': 'Annmarie', 'Initials': 'A', 'LastName': 'Nelson', 'Affiliation': 'Marie Curie Palliative Care Research Centre, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Sewell', 'Affiliation': 'Swansea Centre for Health Economics, Swansea University, Swansea, UK.'}, {'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Jones', 'Affiliation': 'Swansea Centre for Health Economics, Swansea University, Swansea, UK.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Svobodova', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Fitzsimmons', 'Affiliation': 'Swansea Centre for Health Economics, Swansea University, Swansea, UK.'}, {'ForeName': 'Lisette', 'Initials': 'L', 'LastName': 'Nixon', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Fitzgibbon', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Millin', 'Affiliation': 'Radiotherapy Trials Quality Assurance Group, Velindre Cancer Centre, Cardiff, UK.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Crosby', 'Affiliation': 'Velindre University NHS Trust, Cardiff, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Staffurth', 'Affiliation': 'Radiotherapy Trials Quality Assurance Group, Velindre Cancer Centre, Cardiff, UK; Velindre University NHS Trust, Cardiff, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Hurt', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(21)00004-2'] 1065,33612282,The Use of Tranexamic Acid to Reduce the Need for Nasal Packing in Epistaxis (NoPAC): Randomized Controlled Trial.,"STUDY OBJECTIVE Epistaxis is a common emergency department (ED) presentation and, if simple first aid measures fail, can lead to a need for anterior nasal packing. Tranexamic acid is an agent that contributes to blood clot stability. The aim of this study is to investigate the effectiveness of topical intranasal tranexamic acid in adult patients presenting to the ED with persistent epistaxis, and whether it reduces the need for anterior nasal packing. METHODS From May 5, 2017, to March 31, 2019, a double-blind, placebo-controlled, multicenter, 1:1, randomized controlled trial was conducted across 26 EDs in the United Kingdom. Participants with spontaneous epistaxis, persisting after simple first aid and the application of a topical vasoconstrictor, were randomly allocated to receive topical tranexamic acid or placebo. The primary outcome was the need for anterior nasal packing of any kind during the index ED attendance. Secondary outcome measures included hospital admission, need for blood transfusion, recurrent epistaxis, and any thrombotic events requiring any hospital reattendance within 1 week. RESULTS The study sample consisted of 496 participants with spontaneous epistaxis, persisting after simple first aid and application of a topical vasoconstrictor. In total, 211 participants (42.5%) received anterior nasal packing during the index ED attendance, including 111 of 254 (43.7%) in the tranexamic acid group versus 100 of 242 (41.3%) in the placebo group. The difference was not statistically significant (odds ratio 1.107; 95% confidence interval 0.769 to 1.594; P=.59). Furthermore, there were no statistically significant differences between tranexamic acid and placebo for any of the secondary outcome measures. CONCLUSION In patients presenting to an ED with atraumatic epistaxis that is uncontrolled with simple first aid measures, topical tranexamic acid applied in the bleeding nostril on a cotton wool dental roll is no more effective than placebo at controlling bleeding and reducing the need for anterior nasal packing.",2021,The difference was not statistically significant (odds ratio 1.107; 95% confidence interval 0.769 to 1.594; P=.59).,"['496 participants with spontaneous epistaxis, persisting after simple first aid and application of a topical vasoconstrictor', 'adult patients presenting to the ED with persistent epistaxis', 'Nasal Packing in Epistaxis (NoPAC', 'Participants with spontaneous epistaxis, persisting after simple first aid and the application of a topical vasoconstrictor', 'patients presenting to an ED with atraumatic epistaxis']","['topical intranasal tranexamic acid', 'anterior nasal packing', 'topical tranexamic acid or placebo', 'placebo', 'tranexamic acid and placebo', 'topical tranexamic acid', 'tranexamic acid', 'Tranexamic Acid', 'Tranexamic acid']","['need for anterior nasal packing of any kind during the index ED attendance', 'hospital admission, need for blood transfusion, recurrent epistaxis, and any thrombotic events requiring any hospital reattendance within 1 week']","[{'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0016143', 'cui_str': 'First aid'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1442452', 'cui_str': 'One week'}]",496.0,0.460367,The difference was not statistically significant (odds ratio 1.107; 95% confidence interval 0.769 to 1.594; P=.59).,"[{'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Reuben', 'Affiliation': 'Royal Devon and Exeter NHS Foundation Trust, Exeter, England. Electronic address: adam.reuben@nhs.net.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Appelboam', 'Affiliation': 'Royal Devon and Exeter NHS Foundation Trust, Exeter, England.'}, {'ForeName': 'Kara N', 'Initials': 'KN', 'LastName': 'Stevens', 'Affiliation': 'Medical Statistics Group, Faculty of Health, Medicine, Dentistry and Human Sciences, University of Plymouth University, Plymouth, England.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Vickery', 'Affiliation': 'Peninsula Clinical Trials Unit, Faculty of Health, Medicine, Dentistry and Human Sciences, University of Plymouth University, Plymouth, England.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Ewings', 'Affiliation': 'National Institute of Health Research (NIHR) Research Design Service South West, United Kingdom; Taunton and Somerset NHS Foundation Trust, Taunton, Somerset, England.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Ingram', 'Affiliation': 'Peninsula Clinical Trials Unit, Faculty of Health, Medicine, Dentistry and Human Sciences, University of Plymouth University, Plymouth, England.'}, {'ForeName': 'Alison N', 'Initials': 'AN', 'LastName': 'Jeffery', 'Affiliation': 'Peninsula Clinical Trials Unit, Faculty of Health, Medicine, Dentistry and Human Sciences, University of Plymouth University, Plymouth, England.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Body', 'Affiliation': 'Division of Cardiovascular Science, The University of Manchester, Emergency Department, Manchester University NHS Foundation Trust, Manchester, England.'}, {'ForeName': 'Malcolm', 'Initials': 'M', 'LastName': 'Hilton', 'Affiliation': 'Royal Devon and Exeter NHS Foundation Trust, Exeter, England.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Coppell', 'Affiliation': 'Royal Devon and Exeter NHS Foundation Trust, Exeter, England.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Wainman', 'Affiliation': 'Peninsula Clinical Trials Unit, Faculty of Health, Medicine, Dentistry and Human Sciences, University of Plymouth University, Plymouth, England.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Barton', 'Affiliation': 'National Institute of Health Research (NIHR) Research Design Service South West, United Kingdom.'}]",Annals of emergency medicine,['10.1016/j.annemergmed.2020.12.013'] 1066,33621675,Dissociating the causal role of left and right dorsal premotor cortices in planning and executing bimanual movements - A neuro-navigated rTMS study.,"BACKGROUND The dorsal premotor cortex (PMd) is a key region in bimanual coordination. However, causal evidence linking PMd functionality during motor planning and execution to movement quality is lacking. OBJECTIVE We investigated how left (PMd L ) and right PMd (PMd R ) are causally involved in planning and executing bimanual movements, using short-train repetitive transcranial magnetic stimulation (rTMS). Additionally, we explored to what extent the observed rTMS-induced modulation of performance could be explained by rTMS-induced modulation of PMd-M1 interhemispheric interactions (IHI). METHODS Twenty healthy adults (mean age ± SD = 22.85 ± 3.73 years) participated in two sessions, in which either PMd L or PMd R was targeted with rTMS (10 Hz) in a pseudo-randomized design. PMd functionality was transiently modulated during the planning or execution of a complex bimanual task, whereby the participant was asked to track a moving dot by controlling two dials. The effect of rTMS on several performance measures was investigated. Concurrently, rTMS-induced modulation of PMd-M1 IHI was measured using a dual-coil paradigm, and associated with the rTMS-induced performance modulation. RESULTS rTMS over PMd L during planning increased bilateral hand movement speed (p = 0.03), thereby improving movement accuracy (p = 0.02). In contrast, rTMS over PMd R during both planning and execution induced deterioration of movement stability (p = 0.04). rTMS-induced modulation of PMd-M1 IHI during planning did not predict rTMS-induced performance modulation. CONCLUSION The current findings support the growing evidence on PMd L dominance during motor planning, as PMd L was crucially involved in planning the speed of each hand, subserving bimanual coordination accuracy. Moreover, the current results suggest that PMd R fulfills a role in continuous adjustment processes of movement.",2021,"rTMS-induced modulation of PMd-M1 IHI during planning did not predict rTMS-induced performance modulation. ",['Twenty healthy adults (mean age ± SD = 22.85±3.73 years'],"['rTMS', 'PMd L or PMd R was targeted with rTMS (10Hz', 'left (PMd L ) and right PMd (PMd R ']","['movement accuracy', 'PMd-M1 IHI', 'PMd functionality', 'bilateral hand movement speed', 'deterioration of movement stability']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205711', 'cui_str': 'Pelizaeus-Merzbacher disease'}, {'cui': 'C0205090', 'cui_str': 'Right'}]","[{'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0205711', 'cui_str': 'Pelizaeus-Merzbacher disease'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",20.0,0.032337,"rTMS-induced modulation of PMd-M1 IHI during planning did not predict rTMS-induced performance modulation. ","[{'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Verstraelen', 'Affiliation': 'Neuroplasticity and Movement Control Research Group, Rehabilitation Research Institute (REVAL), Hasselt University, Diepenbeek, Belgium. Electronic address: stefanie.verstraelen@uhasselt.be.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'van Dun', 'Affiliation': 'Neuroplasticity and Movement Control Research Group, Rehabilitation Research Institute (REVAL), Hasselt University, Diepenbeek, Belgium.'}, {'ForeName': 'Siel', 'Initials': 'S', 'LastName': 'Depestele', 'Affiliation': 'Neuroplasticity and Movement Control Research Group, Rehabilitation Research Institute (REVAL), Hasselt University, Diepenbeek, Belgium.'}, {'ForeName': 'Sybren', 'Initials': 'S', 'LastName': 'Van Hoornweder', 'Affiliation': 'Neuroplasticity and Movement Control Research Group, Rehabilitation Research Institute (REVAL), Hasselt University, Diepenbeek, Belgium.'}, {'ForeName': 'Asif', 'Initials': 'A', 'LastName': 'Jamil', 'Affiliation': 'Neuroplasticity and Movement Control Research Group, Rehabilitation Research Institute (REVAL), Hasselt University, Diepenbeek, Belgium; Department of Psychology and Neurosciences, Leibniz Research Center for Working Environment and Human Factors, Dortmund, Germany.'}, {'ForeName': 'Ensiyeh', 'Initials': 'E', 'LastName': 'Ghasemian-Shirvan', 'Affiliation': 'Department of Psychology and Neurosciences, Leibniz Research Center for Working Environment and Human Factors, Dortmund, Germany; International Graduate School of Neuroscience, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Nitsche', 'Affiliation': 'Department of Psychology and Neurosciences, Leibniz Research Center for Working Environment and Human Factors, Dortmund, Germany; Department of Neurology, University Medical Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Shanti', 'Initials': 'S', 'LastName': 'Van Malderen', 'Affiliation': 'Movement Control and Neuroplasticity Research Group, Department of Movement Sciences, Group Biomedical Sciences, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Stephan P', 'Initials': 'SP', 'LastName': 'Swinnen', 'Affiliation': 'Movement Control and Neuroplasticity Research Group, Department of Movement Sciences, Group Biomedical Sciences, KU Leuven, Leuven, Belgium; Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Cuypers', 'Affiliation': 'Neuroplasticity and Movement Control Research Group, Rehabilitation Research Institute (REVAL), Hasselt University, Diepenbeek, Belgium; Movement Control and Neuroplasticity Research Group, Department of Movement Sciences, Group Biomedical Sciences, KU Leuven, Leuven, Belgium; Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Raf L J', 'Initials': 'RLJ', 'LastName': 'Meesen', 'Affiliation': 'Neuroplasticity and Movement Control Research Group, Rehabilitation Research Institute (REVAL), Hasselt University, Diepenbeek, Belgium; Movement Control and Neuroplasticity Research Group, Department of Movement Sciences, Group Biomedical Sciences, KU Leuven, Leuven, Belgium.'}]",Brain stimulation,['10.1016/j.brs.2021.02.006'] 1067,33620880,Negative-Pressure Isolation Mask for Endoscopic Examination During the Coronavirus Disease 2019 Pandemic: A Randomized Controlled Trial.,"INTRODUCTION During the coronavirus disease 2019 (COVID-19) pandemic, endoscopists have high risks of exposure to exhaled air from patients during gastroscopy. To minimize this risk, we transformed the oxygen mask into a fully closed negative-pressure gastroscope isolation mask. This study aimed to evaluate the effectiveness, safety, and feasibility of use of this mask during gastroscopy. METHODS From February 28, 2020, to March 10, 2020, 320 patients undergoing gastroscopy were randomly assigned into the mask group (n = 160) or conventional group (n = 160). Patients in the mask group wore the isolation mask during gastroscopy, whereas patients in the conventional group did not wear the mask. The adenosine triphosphate fluorescence and carbon dioxide (CO2) concentration in patients' exhaled air were measured to reflect the degree of environmental pollution by exhaled air. Patients' vital signs, operation time, and adverse events during endoscopy were also evaluated. RESULTS Four patients were excluded because of noncooperation or incomplete data. A total of 316 patients were included in the final analysis. The difference between the highest CO2 concentration around patients' mouth and CO2 concentration in the environment was significantly decreased in the mask group compared with the conventional group. There was no significant difference in the adenosine triphosphate fluorescence, vital signs, and operation time between the 2 groups. No severe adverse events related to the isolation mask, endoscopy failure, or new coronavirus infection during follow-up were recorded. DISCUSSION This new isolation mask showed excellent feasibility of use and safety compared with routine gastroscopy during the COVID-19 pandemic.",2021,"No severe adverse events related to the isolation mask, endoscopy failure, or new coronavirus infection during follow-up were recorded. ","['Four patients were excluded because of noncooperation or incomplete data', '2019 Pandemic', 'A total of 316 patients were included in the final analysis', 'From February 28, 2020, to March 10, 2020, 320 patients undergoing gastroscopy were randomly assigned into the mask group (n = 160) or conventional group (n = 160']","['oxygen mask into a fully closed negative-pressure gastroscope isolation mask', 'routine gastroscopy', 'Negative-Pressure Isolation Mask']","['CO2 concentration', 'severe adverse events', 'isolation mask, endoscopy failure, or new coronavirus infection', 'adenosine triphosphate fluorescence, vital signs, and operation time', 'highest CO2 concentration', ""Patients' vital signs, operation time, and adverse events"", 'isolation mask', 'adenosine triphosphate fluorescence and carbon dioxide (CO2) concentration']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0450356', 'cui_str': '316'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C0017195', 'cui_str': 'Endoscopy of stomach'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0181744', 'cui_str': 'Oxygen mask'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0181020', 'cui_str': 'Gastroscope'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0017195', 'cui_str': 'Endoscopy of stomach'}]","[{'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206750', 'cui_str': 'Coronavirus infection'}, {'cui': 'C0001480', 'cui_str': 'Adenosine Triphosphate'}, {'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0428653', 'cui_str': 'Carbon dioxide concentration'}]",320.0,0.026443,"No severe adverse events related to the isolation mask, endoscopy failure, or new coronavirus infection during follow-up were recorded. ","[{'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Xie', 'Affiliation': 'Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Lian-Song', 'Initials': 'LS', 'LastName': 'Ye', 'Affiliation': 'Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': 'Department of Endoscopy Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Qiong-Ying', 'Initials': 'QY', 'LastName': 'Zhang', 'Affiliation': 'Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Hu', 'Affiliation': 'Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}]",Clinical and translational gastroenterology,['10.14309/ctg.0000000000000314'] 1068,33630448,Long-term Outcomes of a Randomized Controlled Trial of Single-incision Versus Multi-port Laparoscopic Colectomy for Colon Cancer.,"OBJECTIVE The aim of this study was to evaluate the long-term outcomes that were the secondary endpoints of a RCT of multi-port laparoscopic colectomy (MPC) versus SILC in colon cancer surgery. SUMMARY OF BACKGROUND DATA The actual long-term outcomes, such as the 5-year RFS, OS, and recurrence patterns after surgery, have not been evaluated by a RCT. METHODS Patients with histologically proven colon carcinoma located in the cecum, ascending, sigmoid or rectosigmoid colon clinically diagnosed as stage 0-III were eligible for this study. Patients were preoperatively randomized and underwent complete mesocolic excision. The 5-year RFS, OS, and recurrence patterns were analyzed (UMIN-CTR 000007220). RESULTS Between March 1, 2012, and March 31, 2015, a total of 200 patients were randomly assigned to either the MPC arm (n = 100) or SILC arm (n = 100). The median follow-up for all patients was 61.0 months. An intention-to-treat analysis showed that the 5-year RFS was 91.0% [95% confidence interval (CI) 85.1%-96.9%] in the MPC arm and 88.0% (95% CI 82.1%-93.9%) in the SILC arm (hazard ratio: 1.37; 95% CI 0.58-3.24; P = 0.479). The 5-year OS was 95.0% (95% CI 91.1%-98.9%) in the MPC arm and 93.0% (87.1%-98.9%) in the SILC arm (hazard ratio: 1.39; 95% CI 0.44-4.39; P = 0.568). There were no significant differences in the recurrence patterns between the 2 arms. CONCLUSIONS Even though the results of the 5-year OS and RFS in this trial were exploratory and underpowered, there were no statistically significant differences between the SILC and MPC arms. SILC may be an acceptable treatment option for select patients with colon cancer.",2021,The 5-year OS was 95.0% (95% CI 91.1%-98.9%) in the MPC arm and 93.0% (87.1%-98.9%) in the SILC arm (hazard ratio: 1.39; 95% CI 0.44-4.39; P = 0.568).,"['Colon Cancer', 'colon cancer surgery', 'Patients with histologically proven colon carcinoma located in the cecum, ascending, sigmoid or rectosigmoid colon clinically diagnosed as stage 0-III were eligible for this study', 'a total of 200 patients', 'patients with colon cancer']","['RCT of multi-port laparoscopic colectomy (MPC) versus SILC', 'Single-incision Versus Multi-port Laparoscopic Colectomy', 'complete mesocolic excision', 'SILC', 'MPC']","['5-year OS and RFS', '5-year RFS, OS, and recurrence patterns', 'recurrence patterns', '5-year RFS', '5-year OS']","[{'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0699790', 'cui_str': 'Carcinoma of colon'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0007531', 'cui_str': 'Cecum structure'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0227391', 'cui_str': 'Sigmoid colon structure'}, {'cui': 'C0521377', 'cui_str': 'Rectosigmoid structure'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441763', 'cui_str': 'Stage 0'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0452253', 'cui_str': 'Port'}, {'cui': 'C1517722', 'cui_str': 'Laparoscopic colectomy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0341703', 'cui_str': 'Adult Fanconi syndrome'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]",200.0,0.437843,The 5-year OS was 95.0% (95% CI 91.1%-98.9%) in the MPC arm and 93.0% (87.1%-98.9%) in the SILC arm (hazard ratio: 1.39; 95% CI 0.44-4.39; P = 0.568).,"[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Watanabe', 'Affiliation': 'Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Ishibe', 'Affiliation': 'Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Suwa', 'Affiliation': 'Department of Surgery, Yokosuka Kyosai Hosiptal, Yokosuka, Japan.'}, {'ForeName': 'Mitsuyoshi', 'Initials': 'M', 'LastName': 'Ota', 'Affiliation': 'Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Shoichi', 'Initials': 'S', 'LastName': 'Fujii', 'Affiliation': 'Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Kazumi', 'Initials': 'K', 'LastName': 'Kubota', 'Affiliation': 'Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Chikara', 'Initials': 'C', 'LastName': 'Kunisaki', 'Affiliation': 'Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Itaru', 'Initials': 'I', 'LastName': 'Endo', 'Affiliation': 'Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.'}]",Annals of surgery,['10.1097/SLA.0000000000004252'] 1069,33634319,Effect of low-iron micronutrient powder (MNP) on the composition of gut microbiota of Bangladeshi children in a high-iron groundwater setting: a randomized controlled trial.,"PURPOSE Adverse effects of iron fortification/supplements such as Micronutrient Powder (MNP) on gut microbiota have previously been found in infection-prone African settings. This study examined the adversaries of a low-iron MNP compared with the standard MNP on the composition of gut microbiota in Bangladeshi children exposed to a high concentration of iron from potable groundwater. METHODS A randomized controlled trial was conducted in 2- to 5-year-old children, drinking groundwater with a high concentration of iron (≥ 2 mg/L). Children were randomized to receive one sachet per day of either standard MNP (12.5 mg iron) or low-iron MNP (5 mg iron), for 2 months. A sub-sample of 53 children was considered for paired assessment of the gut microbiome by 16S rRNA amplicon sequencing. RESULTS At baseline, the gut microbiota consisted of Bifidobacteriaceae (15.6%), Prevotellaceae (12.2%), Lactobacillaceae (3.6%), Clostridiaceae (4.1%) and Enterobacteriaceae (2.8%). Overall, there was no significant treatment effect of the low-iron MNP compared to the standard MNP. However, an apparent treatment effect was observed in children with a relative adult-like microbiota, with a higher relative abundance of potentially pathogenic Enterobacteriaceae after receiving the standard MNP compared to the low-iron MNP. This effect, however, was statistically non-significant (p = 0.07). CONCLUSION In Bangladeshi children drinking iron-rich groundwater, a low-iron MNP supplementation did not have a significant impact on their gut microbiota profile/composition compared to the standard MNP. The trial registration number is ISRCTN60058115; Date of registration 03/07/2019; retrospectively registered.",2021,"In Bangladeshi children drinking iron-rich groundwater, a low-iron MNP supplementation did not have a significant impact on their gut microbiota profile/composition compared to the standard MNP.","['Bangladeshi children in a high-iron groundwater setting', 'Bangladeshi children exposed to a high concentration of iron from potable groundwater', '2- to 5-year-old children, drinking groundwater with a high concentration of iron (≥\u20092\xa0mg/L', '53 children was considered for paired assessment of the gut microbiome by 16S rRNA amplicon sequencing']","['standard MNP (12.5\xa0mg iron) or low-iron MNP', 'low-iron micronutrient powder (MNP', 'iron fortification/supplements such as Micronutrient Powder (MNP', 'standard MNP']","['Prevotellaceae', 'Lactobacillaceae', 'gut microbiota consisted of Bifidobacteriaceae']","[{'cui': 'C0422784', 'cui_str': 'Bangladeshi'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0860976', 'cui_str': 'Iron increased'}, {'cui': 'C0596631', 'cui_str': 'Underground Water'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0035701', 'cui_str': 'Ribosomal RNA'}, {'cui': 'C0162801', 'cui_str': 'Analysis, Sequence'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0860975', 'cui_str': 'Iron low'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C1080666', 'cui_str': 'Family Prevotellaceae'}, {'cui': 'C0022937', 'cui_str': 'Lactobacillaceae'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C1003847', 'cui_str': 'Bifidobacteriaceae'}]",53.0,0.174854,"In Bangladeshi children drinking iron-rich groundwater, a low-iron MNP supplementation did not have a significant impact on their gut microbiota profile/composition compared to the standard MNP.","[{'ForeName': 'Sabuktagin', 'Initials': 'S', 'LastName': 'Rahman', 'Affiliation': 'Public Health, School of Medicine, Griffith University, Gold Coast Campus, Parklands Dr., Gold Coast, QLD, 4222, Australia.'}, {'ForeName': 'Guus A M', 'Initials': 'GAM', 'LastName': 'Kortman', 'Affiliation': 'NIZO Food Research B.V., Ede, The Netherlands.'}, {'ForeName': 'Jos', 'Initials': 'J', 'LastName': 'Boekhorst', 'Affiliation': 'NIZO Food Research B.V., Ede, The Netherlands.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Lee', 'Affiliation': 'Public Health, School of Medicine, Griffith University, Gold Coast Campus, Parklands Dr., Gold Coast, QLD, 4222, Australia.'}, {'ForeName': 'Moududur R', 'Initials': 'MR', 'LastName': 'Khan', 'Affiliation': 'Institute of Nutrition and Food Science, University of Dhaka, Dhaka, 1000, Bangladesh.'}, {'ForeName': 'Faruk', 'Initials': 'F', 'LastName': 'Ahmed', 'Affiliation': 'Public Health, School of Medicine, Griffith University, Gold Coast Campus, Parklands Dr., Gold Coast, QLD, 4222, Australia. f.ahmed@griffith.edu.au.'}]",European journal of nutrition,['10.1007/s00394-021-02523-1'] 1070,33632533,"Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults.","PURPOSE FT218 is an investigational, once-nightly, modified-release formulation of sodium oxybate (SO). SO effectively treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. Current approved SO formulations, at effective doses of 6, 7.5, and 9 g, require twice-nightly divided dosing, with the first dose taken at bedtime and the second 2.5-4 h later. The purpose of the following studies was to evaluate the pharmacokinetic properties, safety profile, and tolerability of FT218 in healthy adults. METHODS Four crossover, single-dose studies were conducted. The first was a pilot study (n = 16) that compared 3 prototype formulations of FT218 4.5 g to twice-nightly SO 4.5 g (2 divided doses of 2.25 g); the second, a dose-proportionality study (n = 20) that evaluated FT218 4.5, 7.5, and 9 g; the third, a relative bioavailability study (n = 28) that compared FT218 6 g with twice-nightly SO 6 g (2 divided doses of 3 g); and the fourth, a food-effect study (n = 16) of FT218 6 g. RESULTS In the pilot study, FT218 prototype 2 had a lower C max , lower plasma concentration 8 h after dosing (C 8h ), similar exposure (AUC), and comparable interperson variability to twice-nightly SO 4.5 g. Exploratory pharmacodynamic data indicated similar sleep quality and morning alertness between FT218 and twice-nightly SO. Prototype 2 was selected for further development. In the dose-proportionality study, FT218 had dose proportionality for C max and slightly more than dose proportionality for AUC. The relative bioavailability study confirmed that FT218 6 g had lower C max and C 8h than twice-nightly SO 6 g but equivalent AUC and comparable variability. In the food-effect study, FT218 6 g had longer t max (1 h later), lower C max (67%), and decreased AUC (86%) in fed versus fasted states. For all studies, adverse events with FT218 were mostly mild or moderate in severity, nonserious, and known to be associated with SO. Most common adverse events included somnolence, dizziness, and nausea. Safety profiles of FT218 and twice-nightly SO at 4.5 and 6 g were similar. IMPLICATIONS Once-nightly FT218 at 4.5 and 6 g had lower overall C max and C 8h and similar exposure and variability compared with twice-nightly SO. FT218 was generally well tolerated and comparable to twice-nightly SO.",2021,"In the pilot study, FT218 prototype 2 had a lower C max , lower plasma concentration 8 h after dosing (C 8h ), similar exposure (AUC), and comparable interperson variability","['patients with narcolepsy', 'Healthy Adults', 'healthy adults']","['sodium oxybate (SO', 'FT218, a Once-Nightly Sodium Oxybate Formulation', 'FT218 6\xa0g with twice-nightly', 'FT218 6', 'FT218 4.5\xa0g to twice-nightly SO 4.5\xa0g']","['sleep quality and morning alertness', 'tolerated', 'pharmacokinetic properties, safety profile, and tolerability', 'AUC', 'lower C max , lower plasma concentration', 'somnolence, dizziness, and nausea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027404', 'cui_str': 'Narcolepsy'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0037537', 'cui_str': 'Sodium Oxybate'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C1722869', 'cui_str': '(glycyl-prolyl-glycyl-glycyl-alanyl)6-glycine'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C3844009', 'cui_str': '4.5'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",,0.0398122,"In the pilot study, FT218 prototype 2 had a lower C max , lower plasma concentration 8 h after dosing (C 8h ), similar exposure (AUC), and comparable interperson variability","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Seiden', 'Affiliation': 'Avadel Pharmaceuticals, Chesterfield, MO, USA. Electronic address: dseiden@avadel.com.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Tyler', 'Affiliation': 'Avadel Pharmaceuticals, Chesterfield, MO, USA.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Dubow', 'Affiliation': 'Avadel Pharmaceuticals, Chesterfield, MO, USA.'}]",Clinical therapeutics,['10.1016/j.clinthera.2021.01.017'] 1071,33631943,Intermittent theta burst stimulation over the posterior superior temporal sulcus for children with autism spectrum disorder: A 4-week randomized blinded controlled trial followed by another 4-week open-label intervention.,"LAY ABSTRACT Intermittent theta burst stimulation is a varied form of repetitive transcranial magnetic non-invasive brain stimulation technique used to treat several neurological and psychiatric disorders. Its feasibility and therapeutic effects on the bilateral posterior superior temporal sulcus in children with autism are unknown. We conducted a single-blind, sham-controlled parallel randomized clinical trial in a hitherto largest sample of intellectually able children with autism ( N  = 78). Participants randomized to the active group received two-session/week intermittent theta burst stimulation for continuous 8 weeks. Those in the sham group received two-session/week sham stimulations in the first 4 weeks and then active intervention for the following 4 weeks after unblinding. First, we found that continuous 8-week intermittent theta burst stimulation on the bilateral posterior superior temporal sulcus in children with autism is safe and tolerable. Second, we found that 8-week intermittent theta burst stimulation produced greater therapeutic efficacy, although we did not find any significant effects of 4-week intermittent theta burst stimulation on core symptoms and social cognitive performances in autism. Further analysis revealed that participants with higher intelligence and better social cognitive performance, alongside less attention-deficit hyperactivity disorder severity at baseline, were more likely to be responders. This study identified that the factors contribute to responders and the results suggest that longer courses of non-invasive brain stimulation may be needed to produce therapeutic benefits in autism, with consideration of heterogeneous responses.",2021,"Further analysis revealed that participants with higher intelligence and better social cognitive performance, alongside less attention-deficit hyperactivity disorder severity at baseline, were more likely to be responders.","['intellectually able children with autism ( N \u2009=\u200978', 'children with autism', 'children with autism spectrum disorder', 'autism']","['Intermittent theta burst stimulation over the posterior superior temporal sulcus', '4-week intermittent theta burst stimulation', 'continuous 8-week intermittent theta burst stimulation']","['therapeutic efficacy', 'core symptoms and social cognitive performances', 'social cognitive performance']","[{'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0228237', 'cui_str': 'Structure of superior temporal sulcus'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.078359,"Further analysis revealed that participants with higher intelligence and better social cognitive performance, alongside less attention-deficit hyperactivity disorder severity at baseline, were more likely to be responders.","[{'ForeName': 'Hsing-Chang', 'Initials': 'HC', 'LastName': 'Ni', 'Affiliation': 'Chang Gung Memorial Hospital at Linkou, Taiwan.'}, {'ForeName': 'Yi-Lung', 'Initials': 'YL', 'LastName': 'Chen', 'Affiliation': 'Asia University, Taiwan.'}, {'ForeName': 'Yi-Ping', 'Initials': 'YP', 'LastName': 'Chao', 'Affiliation': 'Chang Gung Memorial Hospital at Linkou, Taiwan.'}, {'ForeName': 'Chen-Te', 'Initials': 'CT', 'LastName': 'Wu', 'Affiliation': 'Chang Gung Memorial Hospital at Linkou, Taiwan.'}, {'ForeName': 'Yu-Yu', 'Initials': 'YY', 'LastName': 'Wu', 'Affiliation': 'Chang Gung Memorial Hospital at Linkou, Taiwan.'}, {'ForeName': 'Sophie Hsin-Yi', 'Initials': 'SH', 'LastName': 'Liang', 'Affiliation': 'Chang Gung Memorial Hospital at Linkou, Taiwan.'}, {'ForeName': 'Wei-Chih', 'Initials': 'WC', 'LastName': 'Chin', 'Affiliation': 'Chang Gung Memorial Hospital at Linkou, Taiwan.'}, {'ForeName': 'Tai-Li', 'Initials': 'TL', 'LastName': 'Chou', 'Affiliation': 'National Taiwan University, Taiwan.'}, {'ForeName': 'Susan Shur-Fen', 'Initials': 'SS', 'LastName': 'Gau', 'Affiliation': 'National Taiwan University, Taiwan.'}, {'ForeName': 'Ying-Zu', 'Initials': 'YZ', 'LastName': 'Huang', 'Affiliation': 'Chang Gung Memorial Hospital at Linkou, Taiwan.'}, {'ForeName': 'Hsiang-Yuan', 'Initials': 'HY', 'LastName': 'Lin', 'Affiliation': 'Centre for Addiction and Mental Health, Canada.'}]",Autism : the international journal of research and practice,['10.1177/1362361321990534'] 1072,33637625,Pericapsular nerve group (PENG) block provides improved short-term analgesia compared with the femoral nerve block in hip fracture surgery: a single-center double-blinded randomized comparative trial.,"BACKGROUND The femoral nerve block (FNB) may be used for analgesia in hip fracture surgery. The pericapsular nerve group (PENG) block is a novel regional technique and may provide better pain reduction while preserving motor function, but these blocks have not been directly compared. METHODS In a single-center double-blinded randomized comparative trial, patients presenting for hip fracture surgery received analgesia with either FNB or PENG block. The primary outcome measure was pain scores (Numeric Rating Scale (NRS) 0 to 10). Secondary outcomes were postoperative quadriceps strength, opiate use, complications, length of hospital stay, and patient-reported outcomes. RESULTS Sixty patients were randomized and equally allocated between groups. Baseline demographics were similar. Postoperatively in recovery (day 0), the PENG group experienced less pain compared with the FNB group. (In the PENG group, 63% experienced no pain, 27% mild pain, and 10% moderate to severe pain. In comparison, 30% of the FNB group reported no pain, 27% mild pain, and 36% moderate to severe pain; p=0.04). This was assessed using an 11-point Likert NRS. Quadriceps strength was better preserved in the PENG group in the recovery unit (assessed using Oxford muscle strength grading, 60% intact in the PENG group vs none intact in the FNB group; p<0.001) and on day 1 (90% intact vs 50%, respectively; p=0.004). There was no difference in other outcomes. CONCLUSIONS Patients receiving a PENG block for intraoperative and postoperative analgesia during hip fracture surgery experience less postoperative pain in the recovery room with no difference detected by postoperative day 1. Quadriceps strength was better preserved with the PENG block. Despite the short-term analgesic benefit and improved quadriceps strength, there were no differences detected in the quality of recovery.",2021,"Despite the short-term analgesic benefit and improved quadriceps strength, there were no differences detected in the quality of recovery.","['Sixty patients', 'patients presenting for hip fracture surgery received', 'hip fracture surgery']","['pericapsular nerve group (PENG) block', 'femoral nerve block', 'analgesia with either FNB or PENG block', 'FNB', 'PENG', 'Pericapsular nerve group (PENG) block', 'femoral nerve block (FNB']","['mild pain', 'pain scores (Numeric Rating Scale (NRS', 'postoperative pain', 'quality of recovery', 'quadriceps strength', 'severe pain', 'Quadriceps strength', 'postoperative quadriceps strength, opiate use, complications, length of hospital stay, and patient-reported outcomes', 'pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0394739', 'cui_str': 'Local anesthetic femoral nerve block'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0278138', 'cui_str': 'Mild pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0278140', 'cui_str': 'Severe pain'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0242401', 'cui_str': 'Opiates'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",60.0,0.44597,"Despite the short-term analgesic benefit and improved quadriceps strength, there were no differences detected in the quality of recovery.","[{'ForeName': 'D-Yin', 'Initials': 'DY', 'LastName': 'Lin', 'Affiliation': 'Anesthesiology, Flinders Medical Centre, Bedford Park, South Australia, Australia d-yin.lin@sa.gov.au.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Morrison', 'Affiliation': 'Anesthesiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Brigid', 'Initials': 'B', 'LastName': 'Brown', 'Affiliation': 'Anesthesiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Alexander Andrew', 'Initials': 'AA', 'LastName': 'Saies', 'Affiliation': 'Orthopaedics, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Reshma', 'Initials': 'R', 'LastName': 'Pawar', 'Affiliation': 'Anesthesiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Marthinus', 'Initials': 'M', 'LastName': 'Vermeulen', 'Affiliation': 'Anesthesiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Stewart Robert', 'Initials': 'SR', 'LastName': 'Anderson', 'Affiliation': 'Anesthesiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Tsai Sheng', 'Initials': 'TS', 'LastName': 'Lee', 'Affiliation': 'Anesthesiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Job', 'Initials': 'J', 'LastName': 'Doornberg', 'Affiliation': 'Orthopaedics, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Hidde Maarten', 'Initials': 'HM', 'LastName': 'Kroon', 'Affiliation': 'Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Ruurd Lukas', 'Initials': 'RL', 'LastName': 'Jaarsma', 'Affiliation': 'Orthopaedics and Trauma Surgery, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}]",Regional anesthesia and pain medicine,['10.1136/rapm-2020-102315'] 1073,33638931,Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the prevention of COPD exacerbations) trial.,"BACKGROUND Statins are widely used to lower lipids and reduce cardiovascular events. In vitro studies and small studies in patients with hyperlipidemias show statins inhibit tissue factor (TF) and blood coagulation mechanisms. We assessed the effects of simvastatin on TF and coagulation biomarkers in patients entered in STATCOPE, a multicenter, randomized, placebo-controlled trial of simvastatin (40 mg daily) versus placebo on exacerbation rates in patients with chronic obstructive pulmonary disease (COPD). METHODS In 227 patients (114 simvastatin, 113 placebo; mean [± standard error of the mean] age 62 ± 0.53 years, 44.5% women) we measured (baseline, and 6 and 12 months): whole blood membrane TF-procoagulant activity (TF-PCA) and plasma factors VIIa, VII, VIII, fibrinogen, TF antigen, tissue factor pathway inhibitor (TFPI), thrombin-antithrombin complexes (TAT), and D-dimer. We excluded patients with diabetes, cardiovascular disease, and those taking or requiring a statin. RESULTS In the statin group, there was a small increase in TF-PCA (from 25.18 ± 1.08 to 30.36 ± 1.10 U/ml; p = .03) over 12 months; factors VIIa and VIII, fibrinogen, TAT, and D-dimer did not change. Plasma TFPI (from 52.4 ± 1.75 to 44.7 ± 1.78 ng/ml; p < .0001) and FVIIC (1.23 ± 0.04 to 1.15 ± 0.03 U/ml; p = .03) decreased and correlated with total cholesterol levels. No changes in biomarkers were observed with placebo. CONCLUSIONS In contrast to previous studies on statins, in COPD patients without diabetes, cardiovascular disease, or requiring a statin treatment, simvastatin (40 mg per day) did not decrease TF or factors VIIa and VIII, fibrinogen, TAT, or D-dimer. The decreases in TFPI and factor VII reflect the decrease in serum lipids.",2021,Plasma TFPI (from 52.4±1.75 to 44.7±1.78 ng/mL; p< 0.0001) and FVIIC (1.23±0.04 to 1.15±0.03 U/mL; p=0.03) decreased and correlated with total cholesterol levels.,"['COPD Exacerbations', 'COPD patients without diabetes, cardiovascular disease or requiring a statin treatment', 'patients with hyperlipidemias', 'patients with chronic obstructive pulmonary disease (COPD', '227 patients (114 simvastatin; 113 placebo; mean (±SEM) age 62 ± 0.53 years, 44.5 % women', 'patients with diabetes, cardiovascular disease and those taking or requiring a statin']","['simvastatin', 'placebo', 'Simvastatin']","['blood membrane TF-procoagulant activity (TF-PCA) and plasma factors VIIa, VII, VIII, fibrinogen, TF antigen, tissue factor pathway inhibitor (TFPI), thrombin-antithrombin complexes (TAT) and D-dimer', 'TF-PCA', 'FVIIC', 'Plasma TFPI', 'TF and coagulation biomarkers', 'total cholesterol levels', 'TFPI and factor VII', 'exacerbation rates', 'TF or factors VIIa and VIII, fibrinogen, TAT or D-dimer', 'Tissue Factor Pathway of Blood Coagulation', 'factors VIIa and VIII, fibrinogen, TAT and D-dimer', 'serum lipids']","[{'cui': 'C3508933', 'cui_str': 'Chronic obstructive pulmonary disease exacerbation'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0020473', 'cui_str': 'Hyperlipidemia'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0040048', 'cui_str': 'Thromboplastin'}, {'cui': 'C0030131', 'cui_str': 'p-Chloramphetamine'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0015505', 'cui_str': 'Factor VIIa'}, {'cui': 'C0445385', 'cui_str': 'VII'}, {'cui': 'C0445599', 'cui_str': 'VIII'}, {'cui': 'C0016006', 'cui_str': 'Fibrinogen'}, {'cui': 'C0003320', 'cui_str': 'Antigen'}, {'cui': 'C0164707', 'cui_str': 'Tissue factor pathway inhibitor'}, {'cui': 'C0052128', 'cui_str': 'Thrombin-antithrombin complex'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015502', 'cui_str': 'factor VII'}, {'cui': 'C0428462', 'cui_str': 'Measurement of serum lipid level'}]",227.0,0.25184,Plasma TFPI (from 52.4±1.75 to 44.7±1.78 ng/mL; p< 0.0001) and FVIIC (1.23±0.04 to 1.15±0.03 U/mL; p=0.03) decreased and correlated with total cholesterol levels.,"[{'ForeName': 'A Koneti', 'Initials': 'AK', 'LastName': 'Rao', 'Affiliation': 'Sol Sherry Thrombosis Research Center, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Fabiola', 'Initials': 'F', 'LastName': 'Del Carpio-Cano', 'Affiliation': 'Sol Sherry Thrombosis Research Center, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Sumalaxmi', 'Initials': 'S', 'LastName': 'Janapati', 'Affiliation': 'Sol Sherry Thrombosis Research Center, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Huaqing', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Voelker', 'Affiliation': 'Department of Biostatistics, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Xiaoning', 'Initials': 'X', 'LastName': 'Lu', 'Affiliation': 'Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Criner', 'Affiliation': 'Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.15282'] 1074,33640829,The effect of delayed photobiomodulation on neurosensory disturbance recovery after zygomatic trauma: A parallel controlled clinical trial.,"INTRODUCTION Zygomatic fractures are usually accompanied with neural complications, which are routinely treated by surgery or medication. However, photobiomodulation has been proven as a non-invasive method with better results in nerve's regeneration and repair. Therefore, in this study, we aimed to investigate the healing effect of photobiomodulation on neurosensory defect after facial trauma. PATIENTS AND METHODS In this parallel controlled clinical trial, 35 control cases and 36 patients with zygomaticomaxillary complex (ZMC) fractures as well as the sustained infraorbital nerve paresthesia were included. Afterward, Laser irradiation was applied using a GaAlAs diode laser (810 nm, 27 J/cm 2 , 200 mW) on 12 points on malar area of paresthesia during 12 sessions within six weeks. Neurosensory evaluations were performed in four sessions as follows: at baseline, the end of treatment, one month, and three months after the last session of irradiation, which were achieved through three tests including visual analogue scales (VAS) for general sensitivity, two-point discrimination, and pain discrimination. Repeated measure ANOVA, independent t-test, and Chi-square test were used for comparing time trends, each time point, and gender, respectively. P-values less than 0.05 were considered to be statistically significant. RESULTS The patients and controls were matched in both terms of age and gender. Baseline results showed non-significant differences between the two groups based on the VAS, pain, and two-point discrimination. Moreover, for VAS scale, some significant differences were observed between the groups by passing ""one month and three months from therapy"". Pain and two-point discriminations showed a significant difference between the intervention and control groups in ""one month after therapy"" and ""at the end of the therapy, one month after therapy, and three months after therapy"", respectively. CONCLUSION Photobiomodulation could be considered as an effective treatment option for post-traumatic neurosensory disturbance of facial area in terms of VAS, pain and two-point discrimination, even if not performed early after trauma.",2021,"Pain and two-point discriminations showed a significant difference between the intervention and control groups in ""one month after therapy"" and ""at the end of the therapy, one month after therapy, and three months after therapy"", respectively. ","['after zygomatic trauma', '35 control cases and 36 patients with zygomaticomaxillary complex (ZMC) fractures as well as the sustained infraorbital nerve paresthesia were included']","['Laser irradiation was applied using a GaAlAs diode laser', 'delayed photobiomodulation', 'photobiomodulation']","['neurosensory disturbance recovery', 'VAS, pain', 'Pain', 'visual analogue scales (VAS) for general sensitivity, two-point discrimination, and pain discrimination', 'VAS scale']","[{'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0228731', 'cui_str': 'Structure of infraorbital nerve'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",35.0,0.0294301,"Pain and two-point discriminations showed a significant difference between the intervention and control groups in ""one month after therapy"" and ""at the end of the therapy, one month after therapy, and three months after therapy"", respectively. ","[{'ForeName': 'Shahryar', 'Initials': 'S', 'LastName': 'Bashiri', 'Affiliation': 'Department of Oral and Maxillofacial surgery, Faculty of Dentistry, AJA University of Medical Sciences, Tehran, Iran. Electronic address: dr.s.bashiri@gmail.com.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Malekzadeh', 'Affiliation': 'Department of Oral and Maxillofacial surgery, Faculty of Dentistry, AJA University of Medical Sciences, Tehran, Iran. Electronic address: hamid_malekzadeh_28@yahoo.com.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Fekrazad', 'Affiliation': 'Radiation Sciences Research Center, Laser Research Center in Medical Sciences, AJA University of Medical Sciences, Tehran, Iran; International Network for Photo Medicine and Photo Dynamic Therapy (INPMPDT), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: rezafekrazad@gmail.com.'}]","Journal of photochemistry and photobiology. B, Biology",['10.1016/j.jphotobiol.2021.112153'] 1075,33640257,Effect of Lavender Aromatherapy On Arteriovenous Fistula Puncture Pain and the Level of State and Trait Anxiety in Hemodialysis Patients: A Randomized Controlled Trial.,"BACKGROUND Patients undergoing haemodialysis suffer from anxiety and pain due to the insertion of haemodialysis needles, estimated totally 320 times per year. AIMS This randomized controlled trial was conducted in order to determine the effect of lavender aromatherapy, performed through inhalation for five minutes three times a week, on pain and anxiety experienced by patients undergoing haemodialysis after needle insertion into a fistula. DESIGN Patient information form, Numeric Rating Scale (NRS) and State-Trait Anxiety Inventory (STAI) were applied to patients in the intervention group at the first follow up (the first interview before aromatherapy administration). SETTINGS The researcher completed the data collection forms by conducting face-to-face interview with the patients and applied lavender oil to all the patients in the intervention group at the last hour of every dialysis session. PARTICIPANTS/SUBJECTS Totally three sessions were carried out as three times for one week in accordance with protocol of aromatherapy inhalation. METHODS It took 5 minutes to complete each session. Olive oil was applied to the placebo group since it has no therapeutic value. At the end of the application, NRS and STAI were applied to the patients again. RESULTS The use of lavander aromatherapy significantly reduced the scores of arteriovenous fistula (AVF) puncture-related pain, which was 6.24±1.24 in the first session, to 3.56±1.28 in the second session (p=0.002). It was found that scores of STAI obtained at the first follow-up) were higher in the intervention group than the placebo group but the difference between them was not statistically significant (p>0.05). The STAI mean scores of the patients in the intervention group after aromatherapy were 39.12±6.71 in the state anxiety subscale and30.04±1.39 in the trait anxiety subscale. All subscale scores of STAI decreased significantly in the intervention group in the second follow-up compared to the first follow-up (p<0.05). CONCLUSIONS Lavender inhalation could be used as a safe, simple, and low-cost method in nursing care if it is proved to be effective in reducing anxiety and relieving pain after needle insertion into a fistula in patients undergoing haemodialysis.",2021,"All subscale scores of STAI decreased significantly in the intervention group in the second follow-up compared to the first follow-up (p<0.05). ","['patients undergoing haemodialysis', 'Patients undergoing haemodialysis suffer from anxiety and pain due to the insertion of haemodialysis needles, estimated totally 320 times per year', 'patients undergoing haemodialysis after needle insertion into a fistula', 'Hemodialysis Patients']","['placebo', 'lavander aromatherapy', 'lavender aromatherapy', 'Olive oil', 'Lavender Aromatherapy']","['anxiety and relieving pain', 'STAI mean scores', 'Numeric Rating Scale (NRS) and State-Trait Anxiety Inventory (STAI', 'Arteriovenous Fistula Puncture Pain and the Level of State and Trait Anxiety', 'All subscale scores of STAI', 'pain and anxiety', 'scores of arteriovenous fistula (AVF) puncture-related pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C1139760', 'cui_str': 'Hemodialysis needle'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439508', 'cui_str': '/year'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0524903', 'cui_str': 'Lavender'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0459443', 'cui_str': 'Subscale score'}]",3.0,0.0169308,"All subscale scores of STAI decreased significantly in the intervention group in the second follow-up compared to the first follow-up (p<0.05). ","[{'ForeName': 'Sevil', 'Initials': 'S', 'LastName': 'Şahin', 'Affiliation': 'Erciyes University, Faculty of Health Sciences, Kayseri, Turkey.. Electronic address: sevilbicer@erciyes.edu.tr.'}, {'ForeName': 'Bülent', 'Initials': 'B', 'LastName': 'Tokgöz', 'Affiliation': 'Erciyes University, Faculty of Medicine Sciences, Department of Nephrology, Kayseri, Turkey.'}, {'ForeName': 'Gökçe', 'Initials': 'G', 'LastName': 'Demir', 'Affiliation': 'Ahi Evran University, School of Health, Department of Nursing, Kırşehir, Turkey.'}]",Pain management nursing : official journal of the American Society of Pain Management Nurses,['10.1016/j.pmn.2021.01.009'] 1076,33675398,Paraffin bath therapy in De Quervain's tenosynovitis: a single-blind randomized controlled trial.,"Data on the efficacy of treatment modalities in De Quervain's tenosynovitis (DQT) is limited. Paraffin therapy is routinely used in treating hand osteoarthritis and neuropathies. However, there are not enough studies investigating paraffin effectiveness. This study evaluates the effectiveness of paraffin bath therapy on pain, functional status, muscle strength, and quality of life in patients with DQT. This prospective, single-blind, randomized, controlled study enrolled 51 DQT patients. Group 1 (n = 26) received paraffin bath + splint + exercise; Group 2 (n = 25) received splint + exercise therapy. Pain, handgrip strength, thumb palmar pinch strength, functional status, and quality of life were evaluated. Both treatment combinations improved pain, grip strength, palmar pinch strength of the thumb, functional status, and quality of life. The paraffin group provided more effective pain control than the paraffin-free group and was more effective in improving functional status, handgrip strength, and quality of life (p < 0.05). Apparently, adding paraffin therapy to the combination of the splint and therapeutic exercise positively affects the patient's treatment outcomes. For this reason, paraffin therapy should be included in the conservative treatment combinations in DQT.",2021,"The paraffin group provided more effective pain control than the paraffin-free group and was more effective in improving functional status, handgrip strength, and quality of life (p < 0.05).","[""De Quervain's tenosynovitis"", ""De Quervain's tenosynovitis (DQT"", 'patients with DQT', 'enrolled 51 DQT patients']","['paraffin bath + splint + exercise', 'splint + exercise therapy', 'paraffin bath therapy', 'Paraffin bath therapy', 'Paraffin therapy']","['Pain, handgrip strength, thumb palmar pinch strength, functional status, and quality of life', 'pain, functional status, muscle strength, and quality of life', 'effective pain control', 'pain, grip strength, palmar pinch strength of the thumb, functional status, and quality of life', 'functional status, handgrip strength, and quality of life']","[{'cui': 'C0149870', 'cui_str': 'Radial styloid tenosynovitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0030415', 'cui_str': 'Paraffin'}, {'cui': 'C0038009', 'cui_str': 'Splint'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C1504484', 'cui_str': 'Bath therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0040067', 'cui_str': 'Thumb structure'}, {'cui': 'C1184147', 'cui_str': 'Palmar'}, {'cui': 'C1720876', 'cui_str': 'Pinch Strength'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}]",51.0,0.040675,"The paraffin group provided more effective pain control than the paraffin-free group and was more effective in improving functional status, handgrip strength, and quality of life (p < 0.05).","[{'ForeName': 'İlknur Aykurt', 'Initials': 'İA', 'LastName': 'Karlıbel', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Health Sciences Bursa Yuksek İhtisas Training and Research Hospital, 16800 Yildirim, Bursa, Turkey. karlibeli@hotmail.com.'}, {'ForeName': 'Meliha Kasapoğlu', 'Initials': 'MK', 'LastName': 'Aksoy', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Health Sciences Bursa Yuksek İhtisas Training and Research Hospital, 16800 Yildirim, Bursa, Turkey.'}, {'ForeName': 'Ayşe', 'Initials': 'A', 'LastName': 'Alkan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Health Sciences Bursa Yuksek İhtisas Training and Research Hospital, 16800 Yildirim, Bursa, Turkey.'}]",International journal of biometeorology,['10.1007/s00484-021-02111-2'] 1077,33677449,Neurofeedback Training versus Treatment-as-Usual for Alcohol Dependence: Results of an Early-Phase Randomized Controlled Trial and Neuroimaging Correlates.,"INTRODUCTION Alcohol dependence is one of the most common substance use disorders, and novel treatment options are urgently needed. Neurofeedback training (NFT) based on real-time functional magnetic resonance imaging (rtf-MRI) has emerged as an attractive candidate for add-on treatments in psychiatry, but its use in alcohol dependence has not been formally investigated in a clinical trial. We investigated the use of rtfMRI-based NFT to prevent relapse in alcohol dependence. METHODS Fifty-two alcohol-dependent patients from the UK who had completed a detoxification program were randomly assigned to a treatment group (receiving rtfMRI NFT in addition to standard care) or the control group (receiving standard care only). At baseline, alcohol consumption was assessed as the primary outcome measure and a variety of psychological, behavioral, and neural parameters as secondary outcome measures to determine feasibility and secondary training effects. Participants in the treatment group underwent 6 NFT sessions over 4 months and were trained to downregulate their brain activation in the salience network in the presence of alcohol stimuli and to upregulate frontal activation in response to pictures related to positive goals. Four, 8, and 12 months after baseline assessment, both groups were followed up with a battery of clinical and psychometric tests. RESULTS Primary outcome measures showed very low relapse rates for both groups. Analysis of neural secondary outcome measures indicated that the majority of patients modulated the salience system in the desired directions, by decreasing activity in response to alcohol stimuli and increasing activation in response to positive goals. The intervention had a good safety and acceptability profile. CONCLUSION We demonstrated that rtfMRI-neurofeedback targeting hyperactivity of the salience network in response to alcohol cues is feasible in currently abstinent patients with alcohol dependence.",2021,"RESULTS Primary outcome measures showed very low relapse rates for both groups.","['abstinent patients with alcohol dependence', 'Fifty-two alcohol-dependent patients from the UK who had completed a detoxification program']","['rtfMRI-based NFT', 'NFT sessions', 'Neurofeedback Training versus Treatment-as-Usual for Alcohol Dependence', 'Neurofeedback training (NFT) based on real-time functional magnetic resonance imaging (rtf-MRI', 'rtfMRI NFT in addition to standard care) or the control group (receiving standard care only']","['low relapse rates', 'good safety and acceptability profile', 'alcohol consumption', 'variety of psychological, behavioral, and neural parameters']","[{'cui': 'C0457801', 'cui_str': 'Non - drinker'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0581116', 'cui_str': 'Dependent patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0025516', 'cui_str': 'Detoxication, Drug, Metabolic'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",52.0,0.0520849,"RESULTS Primary outcome measures showed very low relapse rates for both groups.","[{'ForeName': 'Leena', 'Initials': 'L', 'LastName': 'Subramanian', 'Affiliation': 'MRC Centre for Neuropsychiatric Genetics and Genomics and Cardiff University Brain Research Imaging Centre, Schools of Medicine and Psychology, Cardiff University, Cardiff, United Kingdom.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Skottnik', 'Affiliation': 'School for Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands, l.skottnik@maastrichtuniversity.nl.'}, {'ForeName': 'W Miles', 'Initials': 'WM', 'LastName': 'Cox', 'Affiliation': 'School of Psychology, Bangor University, Bangor, United Kingdom.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lührs', 'Affiliation': 'Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'McNamara', 'Affiliation': 'Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, United Kingdom.'}, {'ForeName': 'Kerry', 'Initials': 'K', 'LastName': 'Hood', 'Affiliation': 'Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, United Kingdom.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Watson', 'Affiliation': 'Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, United Kingdom.'}, {'ForeName': 'Joseph R', 'Initials': 'JR', 'LastName': 'Whittaker', 'Affiliation': 'School of Physics and Astronomy, Cardiff University, Cardiff, United Kingdom.'}, {'ForeName': 'Angharad N', 'Initials': 'AN', 'LastName': 'Williams', 'Affiliation': 'Adaptive Memory Research Group, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.'}, {'ForeName': 'Raman', 'Initials': 'R', 'LastName': 'Sakhuja', 'Affiliation': 'Addiction Services, Cwm Taf Morgannwg University Health Board, Mountain Ash, United Kingdom.'}, {'ForeName': 'Niklas', 'Initials': 'N', 'LastName': 'Ihssen', 'Affiliation': 'Department of Psychology, Durham University, Durham, United Kingdom.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Goebel', 'Affiliation': 'Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Playle', 'Affiliation': 'Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, United Kingdom.'}, {'ForeName': 'David E J', 'Initials': 'DEJ', 'LastName': 'Linden', 'Affiliation': 'MRC Centre for Neuropsychiatric Genetics and Genomics and Cardiff University Brain Research Imaging Centre, Schools of Medicine and Psychology, Cardiff University, Cardiff, United Kingdom.'}]",European addiction research,['10.1159/000513448'] 1078,33676866,Good health-related quality-of-life and high patient-reported satisfaction after delayed breast reconstruction with pedicled flaps from the back.,"BACKGROUND This paper presents the results of a randomized controlled trial (RCT) that focus on health-related quality-of-life (QoL) and patient-reported satisfaction following breast reconstruction with pedicled flaps from the back. MATERIALS & METHODS We included women for unilateral delayed breast reconstruction. Patients were randomized to reconstruction by either a latissimus dorsi (LD) flap or a thoracodorsal artery perforator (TAP) flap. Assessment of QoL and patient satisfaction was made using two different patient-reported outcome measures (PROMs): The EORTC QLQ-30 and the Breast-Q questionnaire for post-mastectomy breast reconstruction. RESULTS A total of 50 women were enrolled over a two-year period and allocated to reconstruction. Forty patients completed both surgery and follow-up and were included in the analysis - 18 in the LD group and 22 in the TAP group. The EORTC QLQ-30 was administered at the baseline and at one-year follow-up. There was no significant effect of introducing the TAP flap on either the summary score, the global QoL-score or the financial impact-score when compared to the LD flap. The Breast-Q questionnaire was administered only at one-year follow-up. There was no significant difference between the two groups for the scores for satisfaction with the reconstructed breast, the overall outcome and QoL related to psycho-social, sexual and physical well-being. CONCLUSION Women from both groups report high satisfaction and QoL following the reconstruction. The quality of the dataset and the study design are, however, insufficient to rule out any existing difference. A larger cohort, longer follow-up and different design are warranted to assess the true clinical significance these reconstructions might have on satisfaction and QoL.",2021,"There was no significant difference between the two groups for the scores for satisfaction with the reconstructed breast, the overall outcome and QoL related to psycho-social, sexual and physical well-being. ","['Forty patients completed both surgery and follow-up and were included in the analysis - 18 in the LD group and 22 in the TAP group', 'We included women for unilateral delayed breast reconstruction', 'A total of 50 women were enrolled over a two-year period and allocated to reconstruction']",['latissimus dorsi (LD) flap or a thoracodorsal artery perforator (TAP) flap'],"['Assessment of QoL and patient satisfaction', 'global QoL-score or the financial impact-score', 'Good health-related quality-of-life', 'scores for satisfaction with the reconstructed breast, the overall outcome and QoL related to psycho-social, sexual and physical well-being']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0224362', 'cui_str': 'Structure of latissimus dorsi muscle'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0182209', 'cui_str': 'Perforator'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}]","[{'cui': 'C0224362', 'cui_str': 'Structure of latissimus dorsi muscle'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0182209', 'cui_str': 'Perforator'}]","[{'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",50.0,0.0444776,"There was no significant difference between the two groups for the scores for satisfaction with the reconstructed breast, the overall outcome and QoL related to psycho-social, sexual and physical well-being. ","[{'ForeName': 'Mikkel Børsen', 'Initials': 'MB', 'LastName': 'Rindom', 'Affiliation': 'Department of Plastic Surgery, Lillebaelt Hospital, Vejle, Denmark; OPEN, Open Patient data Explorative Network, Odense University Hospital, Odense, Denmark. Electronic address: mikkoc@rm.dk.'}, {'ForeName': 'Gudjon L', 'Initials': 'GL', 'LastName': 'Gunnarsson', 'Affiliation': 'Department of Plastic Surgery, Telemark Hospital, Skien, Norway.'}, {'ForeName': 'Marianne D', 'Initials': 'MD', 'LastName': 'Lautrup', 'Affiliation': 'Department of Breast Surgery, Lillebaelt Hospital, Vejle, Denmark.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Tos', 'Affiliation': 'Department of Plastic Surgery, Herlev & Gentofte Hospital, Herlev, Denmark.'}, {'ForeName': 'Professor Lisbet R', 'Initials': 'PLR', 'LastName': 'Hölmich', 'Affiliation': 'Department of Plastic Surgery, Herlev & Gentofte Hospital, Herlev, Denmark.'}, {'ForeName': 'Professor Jens A', 'Initials': 'PJA', 'LastName': 'Sørensen', 'Affiliation': 'Department of Plastic Surgery, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Jørn B', 'Initials': 'JB', 'LastName': 'Thomsen', 'Affiliation': 'Department of Plastic Surgery, Lillebaelt Hospital, Vejle, Denmark; Department of Plastic Surgery, Odense University Hospital, Odense, Denmark.'}]","Journal of plastic, reconstructive & aesthetic surgery : JPRAS",['10.1016/j.bjps.2020.12.019'] 1079,33683710,Midazolam versus dexamethasone-ondansetron in preventing post-operative nausea-vomiting in patients undergoing laparoscopic surgeries.,"BACKGROUND Midazolam reduces post-operative nausea and vomiting (PONV) when compared to a placebo or when used as an adjuvant to other antiemetics. The present study was designed to compare midazolam with a combination of dexamethasone-ondansetron in preventing PONV. METHODS One hundred and twenty patients undergoing laparoscopic surgeries having 2 or more risk factors for PONV (simplified Apfel score) were randomised into 2 groups of 60 each. Patients in group D received 8-mg dexamethasone and 4-mg ondansetron for PONV prophylaxis while those in group M received 2-mg midazolam towards the end of surgery. The proportion of patients (frequency) who had PONV, post-operative nausea (PON) and post-operative vomiting (POV) was noted over 24 hours over the following intervals: 0-2 hours, 2-24 hours and 0-24 hours. RESULTS The frequency of PONV at 24 hours in group D and group M was 30% and 33.3% respectively and was not significantly different (P = .70). There was no difference in the time to achieve post-anaesthesia discharge score of ≥9 between the two groups {5 minutes (5, 5) in group D; 5 minutes (1.25, 5) in group M, P = .48}. Ten patients in group D and 11 in group M required a rescue antiemetic over 24 hours (P = .81). The frequency of PON, POV and PONV as well as the median PONV score was similar at all time periods. CONCLUSION Midazolam does not result in significantly different frequency of PONV than a combination of dexamethasone-ondansetron.",2021,Midazolam does not result in significantly different frequency of PONV than a combination of dexamethasone-ondansetron.,"['patients undergoing laparoscopic surgeries', 'One hundred and twenty patients undergoing laparoscopic surgeries having 2 or more risk factors for PONV (simplified Apfel score']","['dexamethasone-ondansetron', 'placebo', 'midazolam', 'ondansetron', 'Midazolam', 'dexamethasone']","['time to achieve post anaesthesia discharge score', 'frequency of PON, POV and PONV', 'proportion of patients (frequency) who had PONV, postoperative nausea (PON), postoperative vomiting (POV', 'frequency of PONV', 'median PONV score', 'postoperative nausea-vomiting', 'postoperative nausea and vomiting (PONV']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0520904', 'cui_str': 'Postoperative nausea'}, {'cui': 'C0520905', 'cui_str': 'Postoperative vomiting'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}]",120.0,0.191362,Midazolam does not result in significantly different frequency of PONV than a combination of dexamethasone-ondansetron.,"[{'ForeName': 'Kelika', 'Initials': 'K', 'LastName': 'Prakash', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Institute of Liver and Biliary Sciences, New Delhi, India.'}, {'ForeName': 'Tanvi', 'Initials': 'T', 'LastName': 'Meshram', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Institute of Liver and Biliary Sciences, New Delhi, India.'}, {'ForeName': 'Priyanka', 'Initials': 'P', 'LastName': 'Jain', 'Affiliation': 'Department of Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13813'] 1080,33616185,Psychosocial Moderators and Outcomes of a Randomized Effectiveness Trial for Child Asthma.,"OBJECTIVE Psychosocial factors play a role in child asthma morbidity and disparities, but their impact on asthma intervention effectiveness is less understood. This study examined how child, parent, and family psychosocial factors moderated asthma response to, and changed in response to, 2 community asthma interventions among urban minority youth. METHODS Asthma Action at Erie was a randomized comparative effectiveness trial examining a community health worker (CHW) home intervention versus certified asthma educator (AE-C) services for children aged 5-16 with uncontrolled asthma (N = 223; mean age = 9.37, SD = 3.02; 85.2% Hispanic). Asthma control was assessed via the Asthma Control Test (ACT)/childhood ACT and activity limitation. Baseline child/parent depression and posttraumatic stress disorder (PTSD) symptoms, family chaos, and social support were examined as treatment moderators. We also tested intervention effects on psychosocial outcomes. RESULTS For parents with higher baseline depression symptoms, youth in the CHW group had greater ACT improvement by 24 months (7.49 points) versus AE-C (4.76 points) and 51% reduction in days of limitation by 6 months versus AE-C (ß = -0.118; p = .0145). For higher parent PTSD symptoms, youth in CHW had 68% fewer days of limitation at 24 months versus AE-C (ß = -0.091; p = .0102). Psychosocial outcomes did not vary by group, but parent depression, parent and child PTSD symptoms, and social support improved for all. CONCLUSIONS CHW intervention was associated with improved asthma control among families with higher parent strain. Findings have implications for utilizing tailored CHW home interventions to optimize asthma outcomes in at-risk families.",2021,"Psychosocial outcomes did not vary by group, but parent depression, parent and child PTSD symptoms, and social support improved for all. ","['Child Asthma', 'Asthma Action at Erie', 'children aged 5-16 with uncontrolled asthma (N\u2009=\u2009223; mean age\u2009=\u20099.37, SD\u2009=\u20093.02; 85.2% Hispanic', 'urban minority youth']","['community health worker (CHW) home intervention versus certified asthma educator (AE-C) services', 'CHW intervention']","['Psychosocial outcomes', 'ACT improvement', 'parent depression, parent and child PTSD symptoms, and social support', 'Baseline child/parent depression and posttraumatic stress disorder (PTSD) symptoms, family chaos, and social support']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]","[{'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0007836', 'cui_str': 'Certification'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C4048375', 'cui_str': 'Asthma control test'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1194380', 'cui_str': 'Chaos'}]",,0.0217911,"Psychosocial outcomes did not vary by group, but parent depression, parent and child PTSD symptoms, and social support improved for all. ","[{'ForeName': 'Sally M', 'Initials': 'SM', 'LastName': 'Weinstein', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago.'}, {'ForeName': 'Oksana', 'Initials': 'O', 'LastName': 'Pugach', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago.'}, {'ForeName': 'Genesis', 'Initials': 'G', 'LastName': 'Rosales', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago.'}, {'ForeName': 'Giselle S', 'Initials': 'GS', 'LastName': 'Mosnaim', 'Affiliation': 'Department of Allergy, Immunology & Asthma, NorthShore University Health System.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Orozco', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago.'}, {'ForeName': 'Andrea A', 'Initials': 'AA', 'LastName': 'Pappalardo', 'Affiliation': 'Department of Pediatrics, University of Illinois at Chicago.'}, {'ForeName': 'Molly A', 'Initials': 'MA', 'LastName': 'Martin', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago.'}]",Journal of pediatric psychology,['10.1093/jpepsy/jsab011'] 1081,33615722,Effects of Dietary Patterns on Serum Urate: Results From a Randomized Trial of the Effects of Diet on Hypertension.,"OBJECTIVE To determine whether the Dietary Approaches to Stop Hypertension (DASH) diet or an alternative, simplified diet, emphasizing high-fiber fruits and vegetables (the FV diet), lowers serum urate levels. METHODS We conducted a secondary study of the DASH feeding study, a 3-arm, parallel-design, randomized trial of 459 adults with systolic blood pressure (BP) of <160 mm Hg and diastolic BP of 80-95 mm Hg, who were not receiving BP medications. Participants were randomized to receive 8 weeks of monitored feeding and ate 1 of 3 diets: 1) a typical American diet (control), 2) the FV diet, a diet rich in fruits and vegetables but otherwise similar to the control diet, or 3) the DASH diet, which was rich in fruits, vegetables, and low-fat dairy products, and reduced in fat, saturated fat, and cholesterol. Body weight was kept constant throughout the study. Serum urate levels were measured at baseline and after 8 weeks of feeding. RESULTS For the 327 participants with available specimens (mean ± SD age 45.4 ± 11.0 years, 47% women, 50% African American), the mean ± SD baseline serum urate level was 5.7 ± 1.5 mg/dl. Compared to the control diet, the FV diet reduced the mean serum urate level by 0.17 mg/dl (95% confidence interval [95% CI] -0.34, 0.00; P = 0.051) and the DASH diet reduced the mean serum urate level by 0.25 mg/dl (95% CI -0.43, -0.08; P = 0.004). These effects increased with increasing baseline serum urate levels (<5, 5-5.9, 6-6.9, 7-7.9, and ≥8 mg/dl) for those receiving the DASH diet (a reduction of 0.08, 0.12, 0.42, 0.44, and 0.73 mg/dl, respectively; P for trend = 0.04), but not for those receiving the FV diet. CONCLUSION Our findings indicate that the DASH diet reduces serum urate levels, particularly among those with hyperuricemia. These findings support the growing need for a dedicated trial to test the DASH diet among patients with hyperuricemia and gout.",2021,"mean baseline SU was 5.7±1.5 mg/dL. Compared to the control diet, the FV diet reduced SU by 0.17 mg/dL","['patients with hyperuricemia and gout', '327 participants with available specimens', '459 adults with systolic blood pressure (SBP) <160 mmHg and diastolic blood pressure (DBP) of 80-95 mmHg, not on BP medications']","['typical American diet (control), 2) a fruit and vegetable (FV)-rich diet but otherwise similar to control, or 3) the DASH diet which was rich in fruit, vegetables, and low-fat dairy products, and reduced in fat, saturated fat and cholesterol', 'Dietary Patterns', '95%CI', 'Dietary Approaches to Stop Hypertension (DASH) diet or an alternative, simplified diet, emphasizing high fiber fruit and vegetables']","['Serum Urate', 'SU', 'baseline SU levels', 'DASH reduced SU', 'mean baseline SU', 'Body weight']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0740394', 'cui_str': 'Hyperuricemia'}, {'cui': 'C0018099', 'cui_str': 'Gout'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0010947', 'cui_str': 'Dairy foods'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0202239', 'cui_str': 'Uric acid measurement'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0455272', 'cui_str': 'Serum urate measurement'}, {'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]",459.0,0.0312125,"mean baseline SU was 5.7±1.5 mg/dL. Compared to the control diet, the FV diet reduced SU by 0.17 mg/dL","[{'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Juraschek', 'Affiliation': 'Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Chio', 'Initials': 'C', 'LastName': 'Yokose', 'Affiliation': 'Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'McCormick', 'Affiliation': 'Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Edgar R', 'Initials': 'ER', 'LastName': 'Miller', 'Affiliation': 'Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Appel', 'Affiliation': 'Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Hyon K', 'Initials': 'HK', 'LastName': 'Choi', 'Affiliation': 'Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41614'] 1082,33611615,The effect of vitamin D supplementation and nutritional intake on skeletal maturity and bone health in socio-economically deprived children.,"PURPOSE 1. To determine the effect of vitamin D supplementation on bone age (BA), a marker of skeletal maturity, and Bone Health Index (BHI), a surrogate marker of bone density. 2. To characterise the differences in nutritional intake and anthropometry between children with advanced vs. delayed BA. METHODS The current study is a post hoc analysis of radiographs obtained as part of a randomised controlled trial. In this double-blind, placebo-controlled trial, deprived Afghan children (n = 3046) aged 1-11 months were randomised to receive six doses of oral placebo or vitamin D3 (100,000 IU) every 3 months for 18 months. Dietary intake was assessed through semi-quantitative food frequency questionnaires at two time points. Anthropometric measurements were undertaken at baseline and 18 months. Serum 25OHD was measured at five time points on a random subset of 632 children. Knee and wrist radiographs were obtained from a random subset (n = 641), of which 565 wrist radiographs were digitised for post-hoc analysis of BA and BHI using BoneXpert version 3.1. RESULTS Nearly 93% (522, male = 291) of the images were analysable. The placebo (n = 258) and vitamin D (n = 264) groups were comparable at baseline. The mean (± SD) age of the cohort was 2 (± 0.3) years. At study completion, there was no difference in mean 25-hydroxy vitamin D concentrations [47 (95% CI 41, 56) vs. 55 (95% CI 45, 57) nmol/L, p = 0.2], mean (± SD) BA SDS [- 1.04 (1.36) vs. - 1.14 (1.26) years, p = 0.3] or mean (± SD) BHI SDS [- 0.30 (0.86) vs. - 0.31 (0.80), p = 0.8] between the placebo and vitamin D groups, respectively. Children with advanced skeletal maturity (BA SDS ≥ 0) when compared to children with delayed skeletal maturity (BA SDS < 0), had consumed more calories [mean (± SD) calories 805 (± 346) vs 723 (± 327) kcal/day, respectively, p < 0.05], were significantly less stunted (height SDS - 1.43 vs. - 2.32, p < 0.001) and underweight (weight SDS - 0.82 vs. - 1.45, p < 0.001), with greater growth velocity (11.57 vs 10.47 cm/ year, p < 0.05). CONCLUSION Deprived children have significant delay in skeletal maturation but no substantial impairment in bone health as assessed by BHI. BA delay was influenced by total calorie intake, but not bolus vitamin D supplementation.",2021,"At study completion, there was no difference in mean 25-hydroxy vitamin D concentrations [47 (95% CI 41, 56) vs. 55 (95% CI 45, 57) nmol/L, p = 0.2],","['Afghan children (n\u2009=\u20093046) aged 1-11\xa0months', 'Children with advanced skeletal maturity (BA SDS\u2009≥\u20090', 'children with advanced vs. delayed BA', 'socio-economically deprived children']","['placebo', 'vitamin D supplementation and nutritional intake', 'vitamin D (n\u2009', 'vitamin D supplementation', 'oral placebo or vitamin D3']","['skeletal maturity and bone health', 'mean (±\u2009SD) BA SDS', 'growth velocity', 'Knee and wrist radiographs', 'mean 25-hydroxy vitamin D concentrations', 'bone age (BA), a marker of skeletal maturity, and Bone Health Index (BHI', 'BA delay', 'skeletal maturation', 'Serum 25OHD']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0429620', 'cui_str': 'Bone age'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0541764', 'cui_str': 'Delayed bone age'}, {'cui': 'C0013556', 'cui_str': 'Economics'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0429620', 'cui_str': 'Bone age'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C1306645', 'cui_str': 'Plain radiography'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0541764', 'cui_str': 'Delayed bone age'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.68623,"At study completion, there was no difference in mean 25-hydroxy vitamin D concentrations [47 (95% CI 41, 56) vs. 55 (95% CI 45, 57) nmol/L, p = 0.2],","[{'ForeName': 'Suma', 'Initials': 'S', 'LastName': 'Uday', 'Affiliation': ""Department of Endocrinology and Diabetes, Birmingham Women's and Children's Hospital, Steelhouse lane, Birmingham, UK.""}, {'ForeName': 'Semira', 'Initials': 'S', 'LastName': 'Manaseki-Holland', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK. s.manasekiholland@bham.ac.uk.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Bowie', 'Affiliation': 'College of Medical and Dental Sciences, University of Birmingham, Rm G31, Public Health Building, Edgbaston, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Mohamed Zulf', 'Initials': 'MZ', 'LastName': 'Mughal', 'Affiliation': ""Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK.""}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Crowe', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Högler', 'Affiliation': 'Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham, UK.'}]",European journal of nutrition,['10.1007/s00394-021-02511-5'] 1083,33618592,Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial.,"Treatment-specific responses and comprehensive disease characteristics are limited in black patients with cutaneous T-cell lymphoma (CTCL). These shortcomings prompted us to perform a subgroup analysis of black patients enrolled in the MAVORIC trial - an international, randomized, phase 3 trial comparing mogamulizumab vs. vorinostat in relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). Ten percent ( N  = 37) of the entire MAVORIC population ( N  = 372) identified as black. Significant clinical differences in black patients when compared to non-black patients included a younger median age at enrollment (53 vs. 66 years; p  < 0.001), an increased frequency of MF as opposed to SS (73% vs. 52.8%; p  < 0.001), and higher rates of earlier-stage disease (IB-IIA) at enrollment (37.8% vs. 21.2%; p  = 0.022). Mogamulizumab offered similar response rates and progression-free survival in black patients (7.57 months) compared to the entire MAVORIC population (7.7 months) and was associated with a similar safety profile.",2021,Mogamulizumab offered similar response rates and progression-free survival in black patients (7.57 months) compared to the entire MAVORIC population (7.7 months) and was associated with a similar safety profile.,"['in relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS', 'black patients with mycosis fungoides and Sézary syndrome', 'black patients with cutaneous T-cell lymphoma (CTCL']","['Mogamulizumab', 'mogamulizumab vs. vorinostat']","['frequency of MF', 'response rates and progression-free survival', 'rates of earlier-stage disease']","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0854850', 'cui_str': 'Mycosis fungoides refractory'}, {'cui': 'C0036920', 'cui_str': 'Sezary syndrome'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0862196', 'cui_str': 'Mycosis fungoides/Sezary syndrome NOS'}, {'cui': 'C0079773', 'cui_str': 'Cutaneous T-cell lymphoma'}]","[{'cui': 'C2987603', 'cui_str': 'mogamulizumab'}, {'cui': 'C0672708', 'cui_str': 'Vorinostat'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",,0.111933,Mogamulizumab offered similar response rates and progression-free survival in black patients (7.57 months) compared to the entire MAVORIC population (7.7 months) and was associated with a similar safety profile.,"[{'ForeName': 'William T', 'Initials': 'WT', 'LastName': 'Johnson', 'Affiliation': 'Department of Medicine, Lymphoma Division; Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Saritha', 'Initials': 'S', 'LastName': 'Kartan', 'Affiliation': 'Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Sokol', 'Affiliation': 'Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Neda', 'Initials': 'N', 'LastName': 'Nikbakht', 'Affiliation': 'Department of Dermatology, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Pierluigi', 'Initials': 'P', 'LastName': 'Porcu', 'Affiliation': 'Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.'}]",Leukemia & lymphoma,['10.1080/10428194.2021.1888376'] 1084,33621601,"Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial.","BACKGROUND Severity of illness in COVID-19 is consistently lower in women. A focus on sex as a biological factor may suggest a potential therapeutic intervention for this disease. We assessed whether adding progesterone to standard of care (SOC) would improve clinical outcomes of hospitalized men with moderate to severe COVID-19. RESEARCH QUESTION Does short-term subcutaneous administration of progesterone safely improve clinical outcome in hypoxemic men hospitalized with COVID-19? STUDY DESIGN AND METHODS We conducted a pilot, randomized, open-label, controlled trial of subcutaneous progesterone in men hospitalized with confirmed moderate to severe COVID-19. Patients were randomly assigned to receive SOC plus progesterone (100 mg subcutaneously twice daily for up to 5 days) or SOC alone. In addition to assessment of safety, the primary outcome was change in clinical status on day 7. Length of hospital stay and number of days on supplemental oxygen were key secondary outcomes. RESULTS Forty-two patients were enrolled from April 2020 to August 2020; 22 were randomized to the control group and 20 to the progesterone group. Two patients from the progesterone group withdrew from the study before receiving progesterone. There was a 1.5-point overall improvement in median clinical status score on a seven-point ordinal scale from baseline to day 7 in patients in the progesterone group as compared with control subjects (95% CI, 0.0-2.0; P = .024). There were no serious adverse events attributable to progesterone. Patients treated with progesterone required three fewer days of supplemental oxygen (median, 4.5 vs 7.5 days) and were hospitalized for 2.5 fewer days (median, 7.0 vs 9.5 days) as compared with control subjects. INTERPRETATION Progesterone at a dose of 100 mg, twice daily by subcutaneous injection in addition to SOC, may represent a safe and effective approach for treatment in hypoxemic men with moderate to severe COVID-19. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT04365127; URL: www.clinicaltrials.gov.",2021,"Patients treated with progesterone required 3 fewer days of supplemental oxygen (median of 4.5 vs 7.5 days) and were hospitalized for 2.5 fewer days (median of 7.0 vs 9.5 days) as compared to controls. ","['Men Hospitalized with Moderate to Severe COVID-19', 'hypoxemic men with moderate to severe COVID-19', 'Forty-two patients were enrolled from April - August 2020; 22', 'men hospitalized with confirmed moderate to severe COVID-19', 'hypoxemic men hospitalized with COVID-19', 'hospitalized men with moderate to severe COVID-19']","['subcutaneous progesterone', 'standard of care (SOC) plus progesterone', 'progesterone', 'Progesterone', 'SOC alone', 'Care Versus Standard of Care Alone']","['median clinical status score', 'supplemental oxygen', 'Length of hospital stay and number of days on supplemental oxygen']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449440', 'cui_str': 'Clinical status'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",42.0,0.133826,"Patients treated with progesterone required 3 fewer days of supplemental oxygen (median of 4.5 vs 7.5 days) and were hospitalized for 2.5 fewer days (median of 7.0 vs 9.5 days) as compared to controls. ","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Ghandehari', 'Affiliation': 'Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA. Electronic address: sara.ghandehari@cshs.org.'}, {'ForeName': 'Yuri', 'Initials': 'Y', 'LastName': 'Matusov', 'Affiliation': 'Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Pepkowitz', 'Affiliation': 'Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Donald', 'Initials': 'D', 'LastName': 'Stein', 'Affiliation': 'Department of Emergency Medicine, Emory University, Atlanta, GA.'}, {'ForeName': 'Tamana', 'Initials': 'T', 'LastName': 'Kaderi', 'Affiliation': 'Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Narayanan', 'Affiliation': 'Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Hwang', 'Affiliation': 'Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Chang', 'Affiliation': 'Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Goodman', 'Affiliation': 'Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Heli', 'Initials': 'H', 'LastName': 'Ghandehari', 'Affiliation': 'independent biostatistical consultant, San Diego, CA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Mirocha', 'Affiliation': 'Biostatistics Core, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Bresee', 'Affiliation': 'Biostatistics Core, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Tapson', 'Affiliation': 'Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lewis', 'Affiliation': 'Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.'}]",Chest,['10.1016/j.chest.2021.02.024'] 1085,33622047,Negative Correlation Between Health Care Coverage and Postpartum Depression Among Hispanic Women.,"Postpartum depression (PPD) affects women across all races with serious health consequences for mothers and infants. Maternal factors may increase PPD risk, but research in exclusive Hispanic populations is limited. This secondary analysis evaluated the associations between maternal sociodemographic characteristics and reliable decrease in depressive symptoms in Hispanic women between prenatal study enrollment and 2 months postpartum. Data from all women ( n = 178) who completed a randomized control trial assessing the efficacy of a home-visitation program were included. Most women were from Mexico (66.9%), had incomes <$10,000/year (68.5%), had health insurance (58.4%), and intended to breastfeed (84.2%). Few women had high school education/graduate equivalency degree (19.3%) or a health care provider (2.3%). Using multivariate logistic regression and controlling for baseline Edinburgh Postnatal Depression Score, gestational age at enrollment, and group assignment, health care coverage ( OR = 4.04, 95% CI 1.27, 12.76, p = 0.017) increased the likelihood of a decrease in level of depressive symptoms at 2 months postpartum. Acculturation, breastfeeding behaviors, and age were not associated with change in depressive symptoms. Results increase our understanding of variability of depressive symptoms in Hispanic women. Having access to health care coverage is critical. Findings provide guidance for culturally competent interventions and policies.",2021,"Acculturation, breastfeeding behaviors, and age were not associated with change in depressive symptoms.","['mothers and infants', 'Hispanic Women', 'Hispanic women between prenatal study enrollment and 2 months postpartum', 'Data from all women ( n = 178', 'Most women were from Mexico (66.9%), had incomes <$10,000/year (68.5%), had health insurance (58.4%), and intended to breastfeed (84.2', 'Hispanic women', 'Few women had high school education/graduate equivalency degree (19.3%) or a health care provider (2.3']",['home-visitation program'],"['variability of depressive symptoms', 'depressive symptoms', 'level of depressive symptoms', 'Postpartum depression\xa0(PPD', 'PPD risk']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0455002', 'cui_str': 'Education and schooling detail'}, {'cui': 'C0588053', 'cui_str': 'Graduate'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0034131', 'cui_str': 'Purified Protein Derivative of Tuberculin'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.148107,"Acculturation, breastfeeding behaviors, and age were not associated with change in depressive symptoms.","[{'ForeName': 'Sneha', 'Initials': 'S', 'LastName': 'Rajendran', 'Affiliation': 'Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Lutenbacher', 'Affiliation': 'Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Mary S', 'Initials': 'MS', 'LastName': 'Dietrich', 'Affiliation': 'Vanderbilt University School of Medicine, Nashville, TN, USA.'}]",Hispanic health care international : the official journal of the National Association of Hispanic Nurses,['10.1177/1540415321993428'] 1086,33626500,Effect of an Exercise Program That Includes Deadlifts on Low Back Pain.,"Clinical Scenario: Low back pain is a common condition for the general population with 29% of adults having low back pain within the last 3 months. A deadlift is described as a free weight exercise in which a barbell is lifted from the floor in a continuous motion by extending the knees and hips. For those without low back pain, the deadlift was found to have the highest muscle activation of paraspinal musculature compared with other exercises. There are a limited number of studies that investigate the usefulness of incorporating deadlifts as part of a rehabilitation program for low back pain. Clinical Question: For those who live with low back pain, is an exercise routine that includes a deadlift a viable treatment option to improve pain and/or function? Summary of Key Findings: The literature search yielded 3 total studies meeting the inclusion and exclusion criteria: 1 randomized control trial, 1 secondary analysis of a randomized control trial, and 1 cohort study. Exercise programs that include deadlifts can yield improvements in both pain and function for those living with low back pain but were not found to be more beneficial than low load motor control exercises. Those with lower pain levels and higher baseline lumbar extension strength may be most appropriate to participate in an exercise program that includes deadlifts. Further research is needed to compare exercise programs that include deadlifts to other interventions for those living with low back pain. Clinical Bottom Line: There is minimal evidence that exercise programs that included deadlifts are a clinically effective option for the treatment of low back pain for both pain scores and functional outcome measures. Strength of Recommendation: Level B evidence exists that exercise programs that include deadlifts are a clinically effective option for the treatment of low back pain for both pain scores and functional outcome measures.",2021,"For those without low back pain, the deadlift was found to have the highest muscle activation of paraspinal musculature compared with other exercises.",['general population with 29% of adults having low back pain within the last 3 months'],['Exercise Program'],"['Low Back Pain', 'Strength of Recommendation']","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0024031', 'cui_str': 'Low back pain'}]",1.0,0.0634834,"For those without low back pain, the deadlift was found to have the highest muscle activation of paraspinal musculature compared with other exercises.","[{'ForeName': 'Samuel C', 'Initials': 'SC', 'LastName': 'Fischer', 'Affiliation': ''}, {'ForeName': 'Darren Q', 'Initials': 'DQ', 'LastName': 'Calley', 'Affiliation': ''}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Hollman', 'Affiliation': ''}]",Journal of sport rehabilitation,['10.1123/jsr.2020-0324'] 1087,33629816,A treatment protocol to guide the delivery of dialogical engagement with auditory hallucinations: Experience from the Talking With Voices pilot trial.,"PURPOSE To present a treatment protocol for delivering Talking With Voices, a novel intervention for people with psychosis that involves dialogical engagement with auditory hallucinations. METHOD This paper presents a manualized approach to therapy employed in the Talking With Voices trial, a feasibility and acceptability randomized control trial of 50 adult participants. A rationale for following a treatment manual is provided, followed by the theoretical underpinnings of the intervention and its principles and values, including the main tenet that voices can often be understood as dissociated parts of the self which serve a protective function by indicating social-emotional vulnerabilities. The four therapy phases for improving the relationship between the voice-hearer and their voices are outlined: (1) engagement and psychoeducation, (2) creating a formulation, (3) dialoguing with voices, and (4) consolidating outcomes, including key milestones at each phase. Implementation issues are discussed, as well as recommendations for best practice and future research. RESULTS The Talking With Voices treatment protocol indicates that it is feasible to manualize a dissociation-based approach to support service users who are distressed by hearing voices. CONCLUSION For some individuals, it is possible to engage in productive dialogue with even extremely hostile or distressing voices. Developing coping strategies, creating a formulation, and ultimately establishing a dialogue with voices has the potential to improve the relationship between voice(s) and voice-hearer. Further research is now required to evaluate feasibility, acceptability, and efficacy. PRACTITIONER POINTS It is feasible to integrate a dissociation model of voice-hearing within a psychological intervention for people with psychosis. Combining psychosocial education, formulation and direct dialogue can be used to facilitate a more peaceful relationship between clients and their voices. Practitioners trained in other therapeutic modalities can draw on existing transferrable skills to dialogue with their clients' voices. The input of those with lived experience of mental health difficulties has an important role in guiding treatment design and delivery.",2021,"Combining psychosocial education, formulation and direct dialogue can be used to facilitate a more peaceful relationship between clients and their voices.","['50 adult participants', 'people with psychosis', 'people with psychosis that involves dialogical engagement with auditory hallucinations']",[],[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0233762', 'cui_str': 'Auditory hallucinations'}]",[],[],50.0,0.0205871,"Combining psychosocial education, formulation and direct dialogue can be used to facilitate a more peaceful relationship between clients and their voices.","[{'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Longden', 'Affiliation': 'Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Corstens', 'Affiliation': 'GGZ Noord-Holland Noord, Texel/den Helder, The Netherlands.'}, {'ForeName': 'Anthony P', 'Initials': 'AP', 'LastName': 'Morrison', 'Affiliation': 'Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Larkin', 'Affiliation': 'Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Murphy', 'Affiliation': 'Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Holden', 'Affiliation': 'Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Steele', 'Affiliation': 'Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Branitsky', 'Affiliation': 'Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Bowe', 'Affiliation': 'Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, UK.'}]",Psychology and psychotherapy,['10.1111/papt.12331'] 1088,33634740,Targeting Physical Inactivity - Effects of Three Different Consequence Frames on Population Subgroups' Health-Related Perceptions and Behavioral Intentions.,"Physical inactivity constitutes a major health problem in many Western societies affecting a variety of social groups. As these groups often differ in responsivity to physical inactivity messages, the strategy of message targeting, i.e. the customization of messages toward shared characteristics of a social group provides a useful framework for designing effective communication. Whereas focusing on health consequences of physical inactivity might prove useful for some social groups, it might be more effective to emphasize its social or financial consequences for others. The current examination compares the effects of three types of consequence framing (health consequences vs. social consequences vs. financial consequences of physical inactivity) on health-related perceptions and intentions for different population subgroups. An experiment with a one-factorial between subjects design based on a quota sample was conducted. 348 respondents differing in terms of age, sex, and formal education were randomly assigned to one of the three experimental conditions and read an accordingly manipulated newspaper article. Findings show that financial and social consequence frames were more effective than health consequence frames. Both frames positively influenced behavioral intentions through perceptions of susceptibility. These effects were largely independent of sociodemographic variables, although sex and education emerged as moderators in some cases.",2021,"348 respondents differing in terms of age, sex, and formal education were randomly assigned to one of the three experimental conditions and read an accordingly manipulated newspaper article.","['348 respondents differing in terms of age, sex, and formal education']",['physical inactivity'],['behavioral intentions'],"[{'cui': 'C4517733', 'cui_str': '348'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C3890554', 'cui_str': 'Physical Inactivity'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",348.0,0.0168247,"348 respondents differing in terms of age, sex, and formal education were randomly assigned to one of the three experimental conditions and read an accordingly manipulated newspaper article.","[{'ForeName': 'Anna J M', 'Initials': 'AJM', 'LastName': 'Wagner', 'Affiliation': 'University of Augsburg, Augsburg, Germany.'}, {'ForeName': 'Freya', 'Initials': 'F', 'LastName': 'Sukalla', 'Affiliation': 'Leipzig University, Leipzig, Germany.'}]",Journal of health communication,['10.1080/10810730.2020.1868025'] 1089,33633081,Impact of Metronidazole Treatment and Dientamoeba Fragilis Colonization on Gut Microbiota Diversity.,"OBJECTIVES The intestinal parasite Dientamoeba fragilis is a common colonizer of children in Denmark. Metronidazole has been used to reduce gastrointestinal symptoms in children colonized with D fragilis. We aimed to identify gut microbiota changes associated with D fragilis carrier status and metronidazole treatment of D fragilis-positive children. METHODS The fecal microbiota of 275 fecal samples from children treated with metronidazole (n = 48) or placebo (n = 48) were characterized by ribosomal DNA sequencing. Samples collected before (T1), 2 weeks after (T2), and 8 weeks (T5) after treatment were included. Seventy fecal samples from 70 age-matched parasite-negative children served as controls. RESULTS The abundance of 24 bacterial genera differed significantly according to D fragilis carrier status, with Flavonifractor being remarkably more abundant in children testing negative for D fragilis. Eight bacterial genera changed significantly in abundance in children losing versus keeping D fragilis after metronidazole treatment. Of these, 7 returned to pretreatment (T1) levels at T5. Meanwhile, the abundance of Flavonifractor continued to differ at T5, whereas for Ruminococcus the abundance only remained high in children who were D fragilis-negative at T2 and T5. Increases in Hungatella, Sutterella, and Streptococcus abundances observed at T2 were specific to metronidazole exposure and hence independent of D fragilis colonization. CONCLUSIONS This study revealed that specific bacterial genera were associated with D fragilis colonization. Metronidazole treatment had a short-term impact on the abundance of some bacterial genera, with most of these reverting to pretreatment levels 8 weeks after completed treatment.",2021,Metronidazole has been used to reduce gastrointestinal symptoms in children colonized with D. fragilis.,"['children in Denmark', 'Seventy fecal samples from 70 age-matched parasite-negative children served as controls', 'D. fragilis-positive children', 'children colonized with D. fragilis']","['metronidazole', 'Metronidazole', 'placebo']","['abundance of Flavonifractor', 'gut Microbiota Diversity', 'abundance of some bacterial genera', 'fecal microbiota', 'gastrointestinal symptoms', 'abundance of 24 bacterial genera', 'Hungatella, Sutterella, and Streptococcus abundances']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0030498', 'cui_str': 'Parasite'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2959924', 'cui_str': 'Flavonifractor'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C1008916', 'cui_str': 'Sutterella'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}]",,0.0259253,Metronidazole has been used to reduce gastrointestinal symptoms in children colonized with D. fragilis.,"[{'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Gotfred-Rasmussen', 'Affiliation': 'Laboratory of Parasitology.'}, {'ForeName': 'Christen Rune', 'Initials': 'CR', 'LastName': 'Stensvold', 'Affiliation': 'Laboratory of Parasitology.'}, {'ForeName': 'Anna Cäcilia', 'Initials': 'AC', 'LastName': 'Ingham', 'Affiliation': 'Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Artillerivej 5, Copenhagen S.'}, {'ForeName': 'Thor Bech', 'Initials': 'TB', 'LastName': 'Johannesen', 'Affiliation': 'Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Artillerivej 5, Copenhagen S.'}, {'ForeName': ""Lee O'Brien"", 'Initials': 'LO', 'LastName': 'Andersen', 'Affiliation': 'Laboratory of Parasitology.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Röser', 'Affiliation': 'Department of Paediatrics, Copenhagen University Hospital Hvidovre, Kettegård Alle 30, Hvidovre, Denmark.'}, {'ForeName': 'Henrik Vedel', 'Initials': 'HV', 'LastName': 'Nielsen', 'Affiliation': 'Laboratory of Parasitology.'}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000003096'] 1090,33637332,Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects.,"PURPOSE Tegoprazan is a potassium-competitive acid blocker used for gastric acid suppression, which may be used with Helicobacter pylori eradication therapies. The goal of this study was to evaluate the pharmacokinetic interaction between tegoprazan and triple-antibiotic therapy containing metronidazole, tetracycline, and bismuth. METHODS An open-label, 2-cohort, randomized, multiple-dose, crossover study was conducted in healthy subjects. In cohort 1, tegoprazan (100 mg/d) was administered orally with or without triple-antibiotic therapy (1500 mg/d metronidazole, 2000 mg/d tetracycline, and 1200 mg/d bismuth) for 7 days in each period. In cohort 2, triple-antibiotic therapy was administered orally with or without tegoprazan for 7 days in each period. Pharmacokinetic blood samples were collected within 24 h after the last dose. Safety assessments were performed. FINDINGS Eleven cohort 1 subjects and ten cohort 2 subjects were included in the pharmacokinetic analysis. The AUC τ and C max at steady state geometric mean ratios (90% CIs) were 0.78 (0.73-0.83) and 0.75 (0.68-0.82) for tegoprazan; 0.77 (0.68-0.88) and 0.84 (0.72-0.98) for tegoprazan metabolite M1; 1.03 (0.98-1.08) and 1.08 (0.99-1.18) for metronidazole; 0.63 (0.56-0.70) and 0.64 (0.56-0.74) for tetracycline; and 1.55 (0.99-2.44) and 1.38 (0.72-2.66) for bismuth, respectively. All reported adverse events were mild. IMPLICATIONS Changes in the tegoprazan, tetracycline, and bismuth pharmacokinetic parameters were detected after concurrent administration. These changes were considered mainly due to the pharmacodynamic effect of tegoprazan. The adverse events were predictable and reported as frequent adverse events during triple-antibiotic therapy. There were no significant differences in safety or tolerability between quadruple therapy, including tegoprazan and triple-antibiotic therapy. ClinicalTrials.gov identifier: NCT04066257.",2021,"There were no significant differences in safety or tolerability between quadruple therapy, including tegoprazan and triple-antibiotic therapy.","['Eleven cohort 1 subjects and ten cohort 2 subjects', 'Healthy Korean Male Subjects', 'healthy subjects']","['metronidazole', 'metronidazole, 2000\xa0mg/d tetracycline, and 1200\xa0mg/d bismuth', 'tegoprazan', 'Tegoprazan and Metronidazole/Tetracycline/Bismuth', 'tetracycline', 'Tegoprazan', 'tegoprazan and triple-antibiotic therapy containing metronidazole, tetracycline, and bismuth']","['safety or tolerability', 'Pharmacokinetic Interactions', 'Pharmacokinetic blood samples', 'adverse events', 'AUC τ and C max at steady state geometric mean ratios', 'pharmacokinetic interaction']","[{'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0039644', 'cui_str': 'Tetracycline'}, {'cui': 'C4517548', 'cui_str': '1200'}, {'cui': 'C0005642', 'cui_str': 'Bismuth'}, {'cui': 'C4726822', 'cui_str': 'tegoprazan'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1868980', 'cui_str': 'Pharmacokinetic interaction'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",2.0,0.0742988,"There were no significant differences in safety or tolerability between quadruple therapy, including tegoprazan and triple-antibiotic therapy.","[{'ForeName': 'Ji-Young', 'Initials': 'JY', 'LastName': 'Jeon', 'Affiliation': 'Center for Clinical Pharmacology and Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju, Republic of Korea.'}, {'ForeName': 'Sun-Young', 'Initials': 'SY', 'LastName': 'Kim', 'Affiliation': 'Center for Clinical Pharmacology and Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju, Republic of Korea.'}, {'ForeName': 'Seol Ju', 'Initials': 'SJ', 'LastName': 'Moon', 'Affiliation': 'Center for Clinical Pharmacology and Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju, Republic of Korea.'}, {'ForeName': 'Kyeongmin', 'Initials': 'K', 'LastName': 'Oh', 'Affiliation': 'Division of Clinical Development, HK Inno.N Corp., Seoul, Republic of Korea.'}, {'ForeName': 'Jiwon', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Division of Clinical Development, HK Inno.N Corp., Seoul, Republic of Korea.'}, {'ForeName': 'Bongtae', 'Initials': 'B', 'LastName': 'Kim', 'Affiliation': 'Division of Clinical Development, HK Inno.N Corp., Seoul, Republic of Korea.'}, {'ForeName': 'Geun Seog', 'Initials': 'GS', 'LastName': 'Song', 'Affiliation': 'Division of Clinical Development, HK Inno.N Corp., Seoul, Republic of Korea.'}, {'ForeName': 'Min-Gul', 'Initials': 'MG', 'LastName': 'Kim', 'Affiliation': 'Center for Clinical Pharmacology and Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju, Republic of Korea; Research Institute of Clinical Medicine of Jeonbuk National University, Jeonju, Republic of Korea; Department of Pharmacology, School of Medicine, Jeonbuk National University, Jeonju, Republic of Korea. Electronic address: mgkim@jbnu.ac.kr.'}]",Clinical therapeutics,['10.1016/j.clinthera.2021.01.026'] 1091,33637020,Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.,"Background: Radioiodine-refractory differentiated thyroid cancer (RR-DTC) has a low 10-year patient-survival rate and is challenging to treat. Lenvatinib is a multikinase inhibitor approved for the treatment of RR-DTC. This study aims to assess Eastern Cooperative Oncology Group performance status (ECOG PS) and neutrophil-to-lymphocyte ratio (NLR) as prognostic markers for patients with RR-DTC treated with lenvatinib. Methods: In this retrospective analysis of the S tudy of ( E 7080) LE nvatinib in Differentiated C ancer of the T hyroid (SELECT), patients randomly assigned to receive lenvatinib were classified according to baseline ECOG PS (0 or 1) or baseline NLR (≤3 or >3). The effects of baseline ECOG PS and NLR on progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were evaluated. In addition, the effects of baseline ECOG PS on the change in diameter of target lesions and correlations between baseline NLR and the sums of the diameters of target lesions were calculated. Results: Among patients who received lenvatinib, patients with a baseline ECOG PS of 0 had statistically improved PFS (hazard ratio [HR] 0.52; 95% confidence interval [CI 0.35-0.77]; p  = 0.001), OS (HR 0.42 [CI 0.26-0.69]; p  = 0.0004), and ORR (odds ratio [OR] 3.51 [CI 2.02-6.10]; p  < 0.0001) compared with patients with a baseline ECOG PS of 1. Patients who received lenvatinib with a baseline NLR ≤3 also had improved PFS (HR 0.43 [CI 0.29-0.65]; p  < 0.0001) and OS (HR 0.48 [CI 0.29-0.78]; p  = 0.0029) versus patients with a baseline NLR >3. Moreover, patients with a baseline NLR ≤3 had a trend toward increased ORR (OR 1.57 [CI 0.94-2.64]; p  = 0.08) compared with patients with a baseline NLR >3. Treatment-emergent adverse events were generally similar among patients who received lenvatinib, irrespective of patients' ECOG PS at baseline. Conclusion: Lower ECOG PS and NLR may provide prognostic value for improved efficacy in patients with RR-DTC. ClinicalTrials.gov no. NCT01321554.",2021,"Treatment-emergent adverse events were generally similar among patients who received lenvatinib, irrespective of patients' ECOG PS at baseline. ",['patients with RR-DTC treated with lenvatinib'],"['Lenvatinib', 'baseline ECOG PS and NLR', 'Radioiodine-Refractory Differentiated Thyroid Cancer', 'Radioiodine-refractory differentiated thyroid cancer (RR-DTC']","['progression-free survival (PFS), overall survival (OS), and objective response rate (ORR', 'PFS', 'ORR', 'performance status (ECOG PS) and neutrophil-to-lymphocyte ratio (NLR', 'Performance Status and Neutrophil-Lymphocyte Ratio With Efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C4722172', 'cui_str': 'Primary differentiated carcinoma of thyroid gland'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C2986924', 'cui_str': 'lenvatinib'}]","[{'cui': 'C2986924', 'cui_str': 'lenvatinib'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C2828294', 'cui_str': 'iodide ion I-131'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C4722172', 'cui_str': 'Primary differentiated carcinoma of thyroid gland'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.391544,"Treatment-emergent adverse events were generally similar among patients who received lenvatinib, irrespective of patients' ECOG PS at baseline. ","[{'ForeName': 'Matthew H', 'Initials': 'MH', 'LastName': 'Taylor', 'Affiliation': 'Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA.'}, {'ForeName': 'Shunji', 'Initials': 'S', 'LastName': 'Takahashi', 'Affiliation': 'Department of Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan.'}, {'ForeName': 'Jaume', 'Initials': 'J', 'LastName': 'Capdevila', 'Affiliation': ""Medical Oncology Department, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Tahara', 'Affiliation': 'Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Leboulleux', 'Affiliation': 'Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Kiyota', 'Affiliation': 'Department of Medical Oncology and Hematology and Cancer Center, Kobe University Hospital, Kusunoki Cho, Chuo-ku, Japan.'}, {'ForeName': 'Corina E', 'Initials': 'CE', 'LastName': 'Dutcus', 'Affiliation': 'Eisai Inc., Woodcliff Lake, New Jersey, USA.'}, {'ForeName': 'Ran', 'Initials': 'R', 'LastName': 'Xie', 'Affiliation': 'Department of Biostatistics, Eisai Inc., Woodcliff Lake, New Jersey, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Robinson', 'Affiliation': 'Royal North Shore Hospital, University of Sydney, Australia.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Sherman', 'Affiliation': 'Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Mouhammed Amir', 'Initials': 'MA', 'LastName': 'Habra', 'Affiliation': 'Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Rossella', 'Initials': 'R', 'LastName': 'Elisei', 'Affiliation': 'Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Lori J', 'Initials': 'LJ', 'LastName': 'Wirth', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}]",Thyroid : official journal of the American Thyroid Association,['10.1089/thy.2020.0779'] 1092,33640289,Use of Mentholated Popsicle in the Management of the Elderly Patient's Thirst in the Immediate Postoperative Period: A Randomized Controlled Trial.,"PURPOSE This study aimed to compare a mentholated popsicle with usual care (absolute fasting) in the change in thirst intensity and discomfort in elderly patients in the immediate postoperative period (IPP). DESIGN A randomized controlled trial. METHODS The sample consisted of 50 elderly patients (60 years or older) in the IPP who were randomly assigned to two groups: experimental group (20 mL mentholated popsicle) and control group (usual care). The outcomes, thirst intensity and discomfort, were assessed at baseline and 20 minutes after the intervention. FINDINGS The mentholated popsicle presented a statistically significant (P < .001) decrease in thirst intensity and discomfort by 5.0 in the median and a Cohen's r large effect size for both outcomes. There were no adverse events or side effects. CONCLUSIONS The use of a mentholated popsicle decreased the intensity and discomfort of the elderly patient's thirst in the IPP.",2021,The mentholated popsicle presented a statistically significant (P < .001) decrease in thirst intensity and discomfort by 5.0 in the median and a Cohen's r large effect size for both outcomes.,"['elderly patients in the immediate postoperative period (IPP', '50 elderly patients (60\xa0years or older) in the IPP']","['Mentholated Popsicle', 'mentholated popsicle with usual care (absolute fasting', 'experimental group (20\xa0mL mentholated popsicle) and control group (usual care']","['intensity and discomfort', 'thirst intensity and discomfort', 'adverse events or side effects']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C3853215', 'cui_str': 'Popsicle'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0039971', 'cui_str': 'Thirst'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",50.0,0.126958,The mentholated popsicle presented a statistically significant (P < .001) decrease in thirst intensity and discomfort by 5.0 in the median and a Cohen's r large effect size for both outcomes.,"[{'ForeName': 'Marilia F', 'Initials': 'MF', 'LastName': 'Conchon', 'Affiliation': 'State University of Londrina, Londrina, Paraná, Brazil. Electronic address: lili_conchon@hotmail.com.'}, {'ForeName': 'Ligia F', 'Initials': 'LF', 'LastName': 'Fonseca', 'Affiliation': 'State University of Londrina, Londrina, Paraná, Brazil.'}, {'ForeName': 'Cristina M', 'Initials': 'CM', 'LastName': 'Galvão', 'Affiliation': 'Ribeirão Preto College of Nursing, University of São Paulo, São Paulo, Brazil.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.09.013'] 1093,33641220,Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic low-dose loop diuretic therapy.,"AIMS To study loop diuretic response and effect of loop diuretic omission in ambulatory heart failure (HF) patients on chronic low-dose loop diuretics. METHODS AND RESULTS Urine collections were performed on two consecutive days in 40 ambulatory HF patients with 40-80 mg furosemide (day 1 with loop diuretic; day 2 without loop diuretic). Three phases were collected each day: (i) first 6 h; (ii) rest of the day; and (iii) night. On the day of loop diuretic intake, the total natriuresis was 125.9 (86.9-155.0) mmol/24 h and urine output was 1650 (1380-2025) mL/24 h. There was a clear loop diuretic response with a natriuresis of 9.4 (6.7-15.9) mmol/h and a urine output of 117 (83-167) mL/h during the first 6 h, followed by a significant drop in natriuresis and urine output during the rest of the day [2.6 (1.8-4.8) mmol/h and 55 (33-71) mL/h] and night [2.2 (1.6-3.5) mmol/h and 44 (34-73) mL/h]. On day 2, after loop diuretic omission, the natriuresis and urine output remained similarly low the entire day, resulting in a 50% reduction in natriuresis [55.1 (33.5-77.7) mmol/24 h; P < 0.001] and a 31% reduction in urine output [1035 (875-1425) mL/24 h; P < 0.001] compared with the day of loop diuretic intake. CONCLUSION Patients with HF on chronic loop diuretic treatment still have a clear diuretic response phase, while loop diuretic omission leads to a significant drop in natriuresis and urine output, arguing against routine cessation of low-dose loop diuretics.",2021,"On day 2, after LD omission, the natriuresis and urine output remained similarly low the entire day, resulting in a 50% reduction in natriuresis (55.1 [33.5-77.7] mmol/24h; p<0.001) and a 31% reduction in urine output (1035 [875-1425] mL/24h; p<0.001) compared with the day of LD intake. ","['Urine collections were performed on 2 consecutive days in 40 ambulatory HF patients with 40-80 mg furosemide (day 1 with LD; day 2 without LD', 'ambulatory heart failure (HF) patients on chronic low dose LD', 'Ambulatory Heart Failure Patients on Chronic Low Dose Loop Diuretic Therapy']","['LD omission', 'Diuretic Omission']","['natriuresis and urine output', 'natriuresis', 'total natriuresis', 'urine output', 'clear LD response']","[{'cui': 'C0200354', 'cui_str': 'Urine specimen collection'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0016860', 'cui_str': 'Furosemide'}, {'cui': 'C0354100', 'cui_str': 'Loop diuretic'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0354100', 'cui_str': 'Loop diuretic'}, {'cui': 'C0012798', 'cui_str': 'Diuretic'}]","[{'cui': 'C0027477', 'cui_str': 'Natriuresis'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0354100', 'cui_str': 'Loop diuretic'}]",40.0,0.0694963,"On day 2, after LD omission, the natriuresis and urine output remained similarly low the entire day, resulting in a 50% reduction in natriuresis (55.1 [33.5-77.7] mmol/24h; p<0.001) and a 31% reduction in urine output (1035 [875-1425] mL/24h; p<0.001) compared with the day of LD intake. ","[{'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Dauw', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Martens', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}, {'ForeName': 'Gregorio', 'Initials': 'G', 'LastName': 'Tersalvi', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}, {'ForeName': 'Joren', 'Initials': 'J', 'LastName': 'Schouteden', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Deferm', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}, {'ForeName': 'Henri', 'Initials': 'H', 'LastName': 'Gruwez', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'De Moor', 'Affiliation': 'Department of Nephrology, Jessa Ziekenhuis, Hasselt, Belgium.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Nijst', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Dupont', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}, {'ForeName': 'Wilfried', 'Initials': 'W', 'LastName': 'Mullens', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}]",European journal of heart failure,['10.1002/ejhf.2145'] 1094,33641208,"Association among periodontitis severity, anti-agalactosyl immunoglobulin G titer, and the disease activity of rheumatoid arthritis.","OBJECTIVE The aim of the present study was to evaluate the association between the periodontal and serological parameters and the disease activity of rheumatoid arthritis (RA) and between the anti-agalactosyl immunoglobulin G (IgG) titer and periodontitis severity. The objective was also to assess the effect of supragingival scaling on the serological parameters in patients with RA. BACKGROUND The periodontal and serological parameters in relation to the autoimmune inflammatory response have been linked to RA disease activity. However, the association of the anti-agalactosyl IgG titer with RA disease activity and periodontitis severity has not been elucidated. METHODS The periodontal, rheumatologic, and serological data were collected from 127 patients with RA in a retrospective cohort study. Of the 127 patients, 21 had been randomly assigned to receive oral hygiene instruction and supragingival scaling. The anti-agalactosyl IgG titer was determined by an electrochemiluminescence immunoassay. RESULTS The patients with a moderate to high RA disease activity showed significantly higher levels of probing depth (PD), clinical attachment level, anti-cyclic citrullinated peptide IgG, and anti-agalactosyl IgG titer and greater mean percentages of severe periodontitis than those with a low RA disease activity (p < .05 for all). Both univariate and multivariate analyses revealed a significantly positive correlation between the PD and RA disease activity (p = .009 and p = .001), between the anti-agalactosyl IgG titer and RA disease activity (p = .002 and p < .001), and between the anti-agalactosyl IgG titer and PD (p < .001 for both). Supragingival scaling significantly decreased the anti-agalactosyl IgG titer (p = 0.03). CONCLUSION The PD and anti-agalactosyl IgG titer are positively interrelated, both of which are correlated positively with RA disease activity and influenced by supragingival scaling in patients with RA.",2021,"The patients with a moderate to high RA disease activity showed significantly higher levels of probing depth (PD), clinical attachment level, anti-cyclic citrullinated peptide IgG, and anti-agalactosyl IgG titer and greater mean percentages of severe periodontitis than those with a low RA disease activity (p < .05 for all).","['patients with RA', '127 patients, 21 had been randomly assigned to receive', '127 patients with RA in a retrospective cohort study']","['oral hygiene instruction and supragingival scaling', 'supragingival scaling']","['levels of probing depth (PD), clinical attachment level, anti-cyclic citrullinated peptide IgG, and anti-agalactosyl IgG titer', 'anti-agalactosyl IgG titer and RA disease activity', 'PD and RA disease activity', 'anti-agalactosyl IgG titer', 'anti-agalactosyl IgG titer and PD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0035363', 'cui_str': 'Retrospective Study'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0204131', 'cui_str': 'Oral hygiene education'}, {'cui': 'C0086959', 'cui_str': 'Supragingival scaling'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0439596', 'cui_str': 'Cyclic'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",127.0,0.0370998,"The patients with a moderate to high RA disease activity showed significantly higher levels of probing depth (PD), clinical attachment level, anti-cyclic citrullinated peptide IgG, and anti-agalactosyl IgG titer and greater mean percentages of severe periodontitis than those with a low RA disease activity (p < .05 for all).","[{'ForeName': 'Chihiro', 'Initials': 'C', 'LastName': 'Kaneko', 'Affiliation': 'Division of Periodontology, Department of Oral Biological Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.'}, {'ForeName': 'Tetsuo', 'Initials': 'T', 'LastName': 'Kobayashi', 'Affiliation': 'Division of Periodontology, Department of Oral Biological Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Ito', 'Affiliation': 'Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Sugita', 'Affiliation': 'Division of Periodontology, Department of Oral Biological Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Murasawa', 'Affiliation': 'Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan.'}, {'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Ishikawa', 'Affiliation': 'Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Tabeta', 'Affiliation': 'Division of Periodontology, Department of Oral Biological Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.'}]",Journal of periodontal research,['10.1111/jre.12867'] 1095,33685850,"Does glucosamine, chondroitin sulfate, and methylsulfonylmethane supplementation improve the outcome of temporomandibular joint osteoarthritis management with arthrocentesis plus intraarticular hyaluronic acid injection. A randomized clinical trial.","The purpose of this study was to compare clinical outcomes obtained with the use of glucosamine, chondroitin sulfate, and methylsulfonylmethane (GCM) supplementation after arthrocentesis plus intraarticular hyaluronic acid (HA) injection. A randomized clinical trial was implemented with adult participants with TMJ-OA who were referred to the author's clinic between February 2014 and May 2015. The sample was entirely composed of patients with TMJ-OA who were treated randomly with a one-session arthrocentesis plus intraarticular HA injection only (control group), or an initial one-session arthrocentesis plus intraarticular HA injection followed by 3 months of GCM supplementation (study group). The predictor variable was management (treatment) technique. The outcome variables were visual analog scale evaluations (masticatory efficiency, pain complaint, joint sound) and mandibular mobility (maximal interincisal opening [MIO], and lateral and protrusive motions of the mandible). The outcome variables were recorded preoperatively and 12 months postoperatively. Thirty-one participants were enrolled in the study. Five were lost during follow-up. The final study sample consisted of 26 participants (age 28.35 ± 10.85 y): 14 in the control group (age 28.71 ± 10.94 y); and 12 in the study group (age 27.92 ± 11.20 y). Pain complaints (p < 0.001) and joint sounds (p = 0.030 for the control group; p = 0.023 for the study group) showed statistically significant decreases. Masticatory efficiency (p < 0.001 for the control group; p = 0.040 for the study group) and lateral mandibular motion (p = 0.040 for the control group; p = 0.004 for study group) showed statistically significant increases in both groups, whereas MIO and protrusive mandibular motion showed no significant changes in either group (p > 0.05). After estimating the differences between the follow-up and baseline outcomes, the mean changes in the primary outcome variables (VAS scores, MIO, and mandibular motion) showed no statistically significant differences between the two groups (p > 0.05). Progressions (reparative remodeling) of hard-tissue TMJ structures were observed on CBCT scans of some participants in both groups. These findings suggested that the use of GCM supplementation after arthrocentesis plus intraarticular HA injection produced no additional clinical benefits or improvements for patients with TMJ-OA compared with arthrocentesis plus intraarticular HA injection alone.",2021,Pain complaints (p < 0.001) and joint sounds (p = 0.030 for the control group; p = ,"[""adult participants with TMJ-OA who were referred to the author's clinic between February 2014 and May 2015"", '10.94\xa0y); and 12 in the study group (age 27.92\xa0±\xa011.20\xa0y', '26 participants (age 28.35\xa0±\xa010.85\xa0y): 14 in the control group (age 28.71\xa0±', 'Thirty-one participants were enrolled in the study', 'patients with TMJ-OA']","['one-session arthrocentesis plus intraarticular HA injection only (control group), or an initial one-session arthrocentesis plus intraarticular HA injection followed by 3 months of GCM supplementation', 'glucosamine, chondroitin sulfate, and methylsulfonylmethane supplementation', 'glucosamine, chondroitin sulfate, and methylsulfonylmethane (GCM) supplementation after arthrocentesis plus intraarticular hyaluronic acid (HA) injection', 'arthrocentesis plus intraarticular hyaluronic acid injection']","['MIO and protrusive mandibular motion', 'Masticatory efficiency', 'VAS scores, MIO, and mandibular motion', 'lateral mandibular motion', 'joint sounds', 'Pain complaints', 'visual analog scale evaluations (masticatory efficiency, pain complaint, joint sound) and mandibular mobility (maximal interincisal opening [MIO], and lateral and protrusive motions of the mandible']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039493', 'cui_str': 'Temporomandibular joint structure'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C3812881', 'cui_str': 'Author'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0204854', 'cui_str': 'Arthrocentesis'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0442108', 'cui_str': 'Intra-articular'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0017718', 'cui_str': 'Glucosamine'}, {'cui': 'C0008466', 'cui_str': 'Chondroitin Sulfates'}, {'cui': 'C0058231', 'cui_str': 'methylsulfonylmethane'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0175566', 'cui_str': 'Open'}]",31.0,0.0540017,Pain complaints (p < 0.001) and joint sounds (p = 0.030 for the control group; p = ,"[{'ForeName': 'Songül', 'Initials': 'S', 'LastName': 'Cömert Kılıç', 'Affiliation': 'Department of Oral and Maxillofacial Surgery,Faculty of Dentistry, Atatürk University, Erzurum, 25240, Turkey. Electronic address: drsckilic@yahoo.com.tr.'}]",Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,['10.1016/j.jcms.2021.02.012'] 1096,33684963,Improv to improve medical student communication.,"BACKGROUND Effective patient provider communication skills can be difficult and time-consuming to teach. Deliberate practice of communication skills through improvisational theatre exercises, with structured debriefing, can provide a solution for teaching patient-centred communication skills in time-limited settings. The objective of this study was to determine if improvisational theatre exercises improved the ratings of patient satisfaction and empathetic communication by standardised patients. METHODS This was a randomised controlled trial looking at the effect of improvisational theatre exercises on ratings of patient satisfaction and empathetic communication. Third-year medical students (n = 188) participated in a formative team-based standardised patient (SP) experience. Prior to the SP experience, teams of students were randomly assigned to receive a 45-minute communication-focused improvisation intervention (immediately before the SP experience) or to a control arm without intervention. All teams then participated in the SP experience; the SPs (blinded to team randomisation assignment) then assessed each team's empathetic communication and completed patient satisfaction questions focused on physician behaviours derived from Press Ganey TM and the Hospital Consumer Assessment of Healthcare Providers and System Surveys TM . Fifty teams of three or four students participated; 20 teams in the intervention arm and 30 teams in the control arm. RESULTS Student teams in the improvisation intervention group had increased measures of empathetic communication (p = 0.04) compared to the control group. The intervention group had increased patient satisfaction survey ratings of 'ability to listen carefully' (p = 0.001) and of 'physician skills' compared to control groups (p = 0.03). DISCUSSION Improv exercises with students increased students' empathetic communication and patient satisfaction as assessed by standardised patients.",2021,"RESULTS Student teams in the improvisation intervention group had increased measures of empathetic communication (p = 0.04) compared to the control group.","['Fifty teams of three or four students participated; 20 teams in the intervention arm and 30 teams in the control arm', 'Third-year medical students (n\xa0=\xa0188) participated in a formative team-based standardised patient (SP) experience']","['45-minute communication-focused improvisation intervention (immediately before the SP experience) or to a control arm without intervention', 'improvisational theatre exercises']","['empathetic communication', 'physician skills', 'ratings of patient satisfaction and empathetic communication', ""students' empathetic communication and patient satisfaction"", ""patient satisfaction survey ratings of 'ability to listen carefully""]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C1442463', 'cui_str': 'Forty-five minutes'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0475307', 'cui_str': 'Theatre'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}]",188.0,0.0639559,"RESULTS Student teams in the improvisation intervention group had increased measures of empathetic communication (p = 0.04) compared to the control group.","[{'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Grossman', 'Affiliation': 'Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Lemay', 'Affiliation': 'Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.'}, {'ForeName': 'Le', 'Initials': 'L', 'LastName': 'Kang', 'Affiliation': 'Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Byland', 'Affiliation': 'School of the Arts, Department of Theatre, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'Aaron D', 'Initials': 'AD', 'LastName': 'Anderson', 'Affiliation': 'School of the Arts, Department of Theatre, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Nestler', 'Affiliation': 'Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.'}, {'ForeName': 'Sally A', 'Initials': 'SA', 'LastName': 'Santen', 'Affiliation': 'Department of Emergency Medicine, Virginia Commonwealth University School of Medicine, Virginia, USA.'}]",The clinical teacher,['10.1111/tct.13336'] 1097,33691517,"Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania.","BACKGROUND Brexpiprazole is a dopamine/serotonin receptor partial agonist (D 2 , 5-HT 1A ) and antagonist (5-HT 2A ) approved for treatment of schizophrenia and major depressive disorder (adjunct to antidepressants). AIMS This study aimed to investigate brexpiprazole as monotherapy in acute mania (bipolar I disorder) in two short-term (ST) studies (study 080 and study 081) and one open-label (OL) extension (study 083). METHODS ST studies were three-week randomized, double-blind, flexible dose (2-4 mg/day), placebo-controlled studies. The primary endpoint was mean change in Young Mania Rating Scale (YMRS) total score from baseline to day 21. The OL study was a 26-week flexible dose (2-4 mg/day) study for patients completing the ST studies. RESULTS A total of 164 and 158 (study 080) and 170 and 162 (study 081) inpatients with DSM-5 mania with/without mixed features were randomized to placebo or brexpiprazole, respectively. The primary analyses did not show a statistically significant difference between brexpiprazole and placebo: study 080: least squares mean difference (95% confidence limits): 0.14 (-1.74, 2.03), p  = 0.8797; study 081: -1.62 (-3.56, 0.32), p  = 0.1011. OL study patients ( n  = 381) demonstrated a gradual improvement in YMRS total score. Akathisia was the only adverse event, with an incidence of ⩾5% with brexpiprazole and more than placebo in the ST studies, or ⩾5% in the OL study. Brexpiprazole was more efficacious in patients with impaired or no insight (predominantly EU patients) than in patients with excellent insight (predominantly US patients). CONCLUSIONS Further studies are necessary to address the potential efficacy of brexpiprazole in acute mania, which should ensure that the study sample is severe enough (especially with regard to insight), and that the dose/titration schedule is not too modest.",2021,"Akathisia was the only adverse event, with an incidence of ⩾5% with brexpiprazole and more than placebo in the ST studies, or ⩾5% in the OL study.","['bipolar mania', 'A total of 164 and 158 (study 080) and 170 and 162 (study 081) inpatients with DSM-5 mania with/without mixed features', 'acute mania (bipolar I disorder) in two short-term (ST) studies (study 080 and study 081) and one open-label (OL) extension (study 083']","['Brexpiprazole', 'antagonist (5-HT 2A ', 'brexpiprazole as monotherapy', 'placebo', 'brexpiprazole', 'placebo or brexpiprazole']","['mean change in Young Mania Rating Scale (YMRS) total score', 'Akathisia', 'YMRS total score']","[{'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0338831', 'cui_str': 'Mania'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C5191360', 'cui_str': '162'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0235165', 'cui_str': 'Mania acute'}, {'cui': 'C0853193', 'cui_str': 'Bipolar I disorder'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C3885614', 'cui_str': 'brexpiprazole'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4087288', 'cui_str': 'Young mania rating scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392156', 'cui_str': 'Akathisia'}]",,0.454056,"Akathisia was the only adverse event, with an incidence of ⩾5% with brexpiprazole and more than placebo in the ST studies, or ⩾5% in the OL study.","[{'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Vieta', 'Affiliation': 'Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Sachs', 'Affiliation': 'Massachusetts General Hospital, Boston, USA.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Chang', 'Affiliation': 'Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, USA.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Hellsten', 'Affiliation': 'H. Lundbeck A/S, Valby, Denmark.'}, {'ForeName': 'Claudette', 'Initials': 'C', 'LastName': 'Brewer', 'Affiliation': 'Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, USA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Peters-Strickland', 'Affiliation': 'Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, USA.'}, {'ForeName': 'Nanco', 'Initials': 'N', 'LastName': 'Hefting', 'Affiliation': 'H. Lundbeck A/S, Valby, Denmark.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120985102'] 1098,33819571,Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study.,"OBJECTIVE To assess the effectiveness of corticosteroids among older adults with coronavirus disease 2019 (COVID-19) pneumonia requiring oxygen. METHODS We used routine care data from 36 hospitals in France and Luxembourg to assess the effectiveness of corticosteroids with at least 0.4 mg/kg/day equivalent prednisone (treatment group) versus standard of care (control group). Participants were adults aged 80 years or older with PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or CT scan images typical of COVID-19 pneumonia, requiring oxygen ≥3 L/min, and with an inflammatory syndrome (C-reactive protein ≥40 mg/L). The primary outcome was overall survival at day 14. In our main analysis, characteristics of patients at baseline (i.e. time when patients met all inclusion criteria) were balanced by using propensity-score inverse probability of treatment weighting. RESULTS Among the 267 patients included in the analysis, 98 were assigned to the treatment group. Their median age was 86 years (interquartile range 83-90 years) and 95% had a SARS-CoV-2 PCR-confirmed diagnosis. In total, 43/98 (43.9%) patients in the treatment group and 84/166 (50.6%) in the control group died before day 14 (weighted hazard ratio 0.67, 95% CI 0.46-0.99). The treatment and control groups did not differ significantly for the proportion of patients discharged to home/rehabilitation at day 14 (weighted relative risk 1.12, 95% CI 0.68-1.82). Twenty-two (16.7%) patients receiving corticosteroids developed adverse events, but only 11 (6.4%) from the control group. CONCLUSIONS Corticosteroids were associated with a significant increase in the overall survival at day 14 of patients aged 80 years and older hospitalized for severe COVID-19.",2021,"The treatment and control groups did not differ significantly for the proportion of patients discharged to home/rehabilitation at day 14 (wRR 1.12, 95% CI 0.68 to 1.82).","['older adults with COVID-19 pneumonia requiring oxygen', '267 patients included in the analysis, 98 were assigned to the treatment group', 'older adults with severe SARS-Cov2 infection treated with', '≥ 80\xa0years old with PCR-confirmed SARS-CoV-2 infection or CT-scan images typical of COVID-19 pneumonia, requiring oxygen ≥ 3 L/min, and with an inflammatory syndrome (C-reactive protein ≥ 40 mg/L', 'Their median age was 86\xa0years (interquartile range 83 to 90), and 95% had a SARS-CoV-2 PCR-confirmed diagnosis', '36 hospitals in France and Luxembourg']","['prednisone', 'standard of care (control group', 'corticosteroid', 'corticosteroids']","['overall survival', 'adverse events', 'proportion of patients discharged to home/rehabilitation', '14-Day survival']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C4517672', 'cui_str': '267'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0439393', 'cui_str': 'L/min'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0024176', 'cui_str': 'Luxembourg'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",267.0,0.264782,"The treatment and control groups did not differ significantly for the proportion of patients discharged to home/rehabilitation at day 14 (wRR 1.12, 95% CI 0.68 to 1.82).","[{'ForeName': 'Laure', 'Initials': 'L', 'LastName': 'Gallay', 'Affiliation': 'Département de Médecine Interne et Immunologie Clinique, Centre Hospitalo-Universitaire Edouard Herriot, Hospices Civils de Lyon, Université Claude Bernard Lyon, Lyon, France.'}, {'ForeName': 'Viet-Thi', 'Initials': 'VT', 'LastName': 'Tran', 'Affiliation': ""Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris / Université de Paris, Centre de Recherche Epidémiologie et Statistiques (CRESS UMR 1153), Paris, France.""}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Perrodeau', 'Affiliation': ""Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris / Université de Paris, Centre de Recherche Epidémiologie et Statistiques (CRESS UMR 1153), Paris, France.""}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Vignier', 'Affiliation': 'Groupe Hospitalier Sud Ile-de-France, Inserm CIC 1424 & Sorbonne Université, IPLESP, Inserm UMR 1136, Paris, France.'}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Mahevas', 'Affiliation': 'Service de Médecine Interne, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Bisio', 'Affiliation': 'Département de Médecine, Centre Hospitalier de Vierzon, Vierzon, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Forestier', 'Affiliation': 'Service de Maladies Infectieuses, Centre Hospitalier Métropole Savoie, Chambéry, France.'}, {'ForeName': 'Francois-Xavier', 'Initials': 'FX', 'LastName': 'Lescure', 'Affiliation': 'Service de Maladies Infectieuses et Tropicales, Hôpital Bichat, Assistance Publique Hôpitaux de Paris / Université de Paris, IAME, Inserm UMR 1137, 75018, Paris, France. Electronic address: xavier.lescure@aphp.fr.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,['10.1016/j.cmi.2021.03.021'] 1099,33629804,An evaluation of compassion-focused therapy within adult mental health inpatient settings.,"OBJECTIVES This study aimed to examine the effectiveness of a compassion-focused therapy (CFT) group in improving patient outcomes compared to those receiving treatment as usual (TAU) with a trans-diagnostic population who are inpatients within an acute psychiatric ward. DESIGN Quantitative data were gathered as part of routine clinical practice within three adult psychiatric wards using the Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM) at admission and discharge and non-standardized Likert scales pre- and post-group sessions. METHOD Between April and August 2017, the Acute Psychology Service (APS) gathered CORE-OM admission and discharge data from inpatients across three acute wards (n = 32) whilst 249 pre/post-group data sets were gathered from CFT group work undertaken on the inpatient wards. Current inpatients self-allocated to receive either CFT or TAU based on their desire for psychological involvement. Those self-allocating to receive psychological involvement (n = 19) were compared to those who did not (n = 13) across the four subdomains of the CORE-OM: Wellbeing, Functioning, Problem/Symptoms, and Risk. The Likert scales included subdomains to evaluate changes in self-compassion, compassion to others, and threat. Those receiving CFT group work also received TAU. RESULTS Significant improvements to all CORE-OM subdomains were observed for those receiving CFT group input, in particular the Wellbeing and Functioning subdomains. Those receiving TAU only noted a significant improvement in the area of Risk whilst levels of Wellbeing were identical at admission and discharge with no improvements noted. Pre/post-group results indicated significant results for areas of self-compassion and compassion to others, whilst results by session for the threat subdomain are mixed dependant on session. Overall, all areas noted significant improvements. Session content was observed to be most effective for breathing and Mindfulness-based sessions and those utilizing imagery techniques. CONCLUSION Compassion-Focused Therapy appears to be an effective group intervention for a trans-diagnostic population within adult inpatient settings. Patient outcomes are positively improved across a range of areas whilst undertaking psychological input in the form of CFT group work whilst also receiving TAU during an inpatient admission. The use of the CFT model to address trans-diagnostic difficulties supports targeting underlying psychological constructs in comparison to symptom treatment alone. PRACTITIONER POINTS Compassion-focused therapy is a multi-model approach designed to target high levels of self-criticism. Previous research has demonstrated its effectiveness for a range of specific diagnosis; however, there is a limited research base with open groups and a trans-diagnostic population. Groups can be structured with standalone sessions to accommodate the unpredictable admissions and discharge patterns of acute psychiatric wards. Group sessions focused around Mindfulness and Imagery yielded the greatest significant improvements to pre-sessions scores. The provision of compassion-focused therapy groups within trans-diagnostic inpatient settings is feasible and has shown to significantly improve overall levels of distress and risk compared to those receiving treatment as usual. The lack of standardized Likert group measures limits the power of the study. Whilst a RCT would provide more reliable data, this was not possible as part of routine clinical practice for ethical reasons.",2021,Those receiving TAU only noted a significant improvement in the area of Risk whilst levels of Wellbeing were identical at admission and discharge with no improvements noted.,"['inpatients across three acute wards (n\xa0=\xa032) whilst 249 pre/post-group data sets were gathered from CFT group work undertaken on the inpatient wards', 'adult mental health inpatient settings', 'Between April and August 2017', 'usual (TAU) with a trans-diagnostic population who are inpatients within an acute psychiatric ward']","['CFT or TAU', 'compassion-focused therapy (CFT', 'RCT', 'CFT']","['self-compassion, compassion to others, and threat', 'areas of self-compassion and compassion', 'area of Risk whilst levels of Wellbeing', 'CORE-OM subdomains']","[{'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}]","[{'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}]",19.0,0.0348381,Those receiving TAU only noted a significant improvement in the area of Risk whilst levels of Wellbeing were identical at admission and discharge with no improvements noted.,"[{'ForeName': 'James', 'Initials': 'J', 'LastName': 'Stroud', 'Affiliation': '1st affiliation Hywel Dda Health Board, NHS Wales, UK.'}, {'ForeName': 'Carys', 'Initials': 'C', 'LastName': 'Griffiths', 'Affiliation': '1st affiliation Hywel Dda Health Board, NHS Wales, UK.'}]",Psychology and psychotherapy,['10.1111/papt.12334'] 1100,33632072,"Oxytocin, cortisol, and cognitive control during acute and naturalistic stress.","Although stress is a strong risk factor for poor health, especially for women, it remains unclear how stress affects the key neurohormones cortisol and oxytocin, which influence stress-related risk and resilience. Whereas cortisol mediates energy mobilization during stress, oxytocin has anti-inflammatory, anxiolytic, and analgesic effects that support social connection and survival across the lifespan. However, how these neurohormones interrelate and are associated with cognitive control of emotional information during stress remains unclear. To address these issues, we recruited 37 college-aged women ( M age = 19.19, SD  = 1.58) and randomly assigned each to a one-hour experimental session consisting of either an acute stress (emotionally stressful video) or control (non-stressful video) condition in a cross-sectional manner across the semester. Salivary cortisol and oxytocin samples were collected at baseline and after the video, at which point participants also completed measures assessing affect and an emotional Stroop task. As hypothesized, the emotional stressor induced negative emotions that were associated with significant elevations in cortisol and faster Stroop reaction times. Moreover, higher baseline oxytocin predicted greater positive affect after the stressor and also better cognitive accuracy on the Stroop. Analyses examining the naturalistic stress effects revealed that basal oxytocin levels rose steeply three weeks before the semester's end, followed by rising cortisol levels one week later, with both neurohormones remaining elevated through the very stressful final exam period. Considered together, these data suggest that women's collective experiences of stress may be potentially buffered by a synchronous oxytocin surge that enhances cognitive accuracy and reduces stress ""when the going gets tough"".",2021,"As hypothesized, the emotional stressor induced negative emotions that were associated with significant elevations in cortisol and faster Stroop reaction times.","['37 college-aged women ( M age = 19.19, SD \u2009=\u20091.58']",['acute stress (emotionally stressful video) or control (non-stressful video) condition in a cross-sectional manner across the semester'],"['cognitive accuracy', 'basal oxytocin levels', 'Salivary cortisol and oxytocin samples', 'Oxytocin, cortisol, and cognitive control', 'emotional Stroop task']","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}]","[{'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}]",,0.0417613,"As hypothesized, the emotional stressor induced negative emotions that were associated with significant elevations in cortisol and faster Stroop reaction times.","[{'ForeName': 'Shari', 'Initials': 'S', 'LastName': 'Young Kuchenbecker', 'Affiliation': 'Department of Psychology, Chapman University, Orange, CA, USA.'}, {'ForeName': 'Sarah D', 'Initials': 'SD', 'LastName': 'Pressman', 'Affiliation': 'Department of Psychological Science, University of California, Irvine, CA, USA.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Celniker', 'Affiliation': 'Department of Psychology, Chapman University, Orange, CA, USA.'}, {'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Grewen', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Kenneth D', 'Initials': 'KD', 'LastName': 'Sumida', 'Affiliation': 'Department of Health Sciences, Chapman University, Orange, CA, USA.'}, {'ForeName': 'Naveen', 'Initials': 'N', 'LastName': 'Jonathan', 'Affiliation': 'Department of Marriage and Family Therapy, Chapman University, Orange, CA, USA.'}, {'ForeName': 'Brendan', 'Initials': 'B', 'LastName': 'Everett', 'Affiliation': 'Department of Psychology, Chapman University, Orange, CA, USA.'}, {'ForeName': 'George M', 'Initials': 'GM', 'LastName': 'Slavich', 'Affiliation': 'Cousins Center for Psychoneuroimmunology and Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.'}]","Stress (Amsterdam, Netherlands)",['10.1080/10253890.2021.1876658'] 1101,33635408,Effects of exercise before and/or after a mixed lunch on postprandial metabolic responses in healthy male individuals.,"PURPOSE Exercise plays an important role in preventing and treating postprandial dysmetabolism. We investigated the postprandial metabolic responses to a standard lunch when a session of aerobic exercise is performed in the early postprandial phase or divided between the pre- and postprandial period. METHODS Nine healthy volunteers consumed a standardised mixed lunch and rested for the following 3 h (Con) or performed 40 min of cycling at 65% V̇O 2 max after lunch (CPPEx), or two 20-min sessions, one before (SplitEx1) and the other after lunch (SplitEx2), at the same intensity. RESULTS At 1-h post-lunch, a significant reduction (P < 0.001) in glycaemia was observed for CPPEx (- 25 ± 10%) and SplitEx (- 34 ± 7%) compared to Con. Yet, a post-exercise rebound lessened the exercise effect on the glycaemic area under the curve (AUC) at 2 and 3 h. At 1 h, a significant reduction (P < 0.009) in plasma insulin (SplitEx - 53 ± 31%; CCPEx - 48 ± 20%) and C-peptide (SplitEx - 57 ± 20%; CCPEx - 47 ± 24%) was observed compared to Con. Glucose-dependent insulinotropic polypeptide (GIP) increased after the meal, without differences between conditions. Compared with SplitEx1, cortisol response was attenuated during SplitEx2 and CPPEx. At 3 hours, triglyceride AUC was significantly higher (P = 0.039) in SplitEx compared to Con (+ 19 ± 8%). CONCLUSION Forty minutes of postprandial exercise or 20 min of pre- and postprandial exercise are both effective at attenuating the glycaemic and insulinaemic response to a mixed lunch, while a higher lipaemia was found in the pre- and postprandrial exercise condition.",2021,"At 1 h, a significant reduction (P < 0.009) in plasma insulin (SplitEx - 53 ± 31%; CCPEx - 48 ± 20%) and C-peptide (SplitEx - 57 ± 20%; CCPEx - 47 ± 24%) was observed compared to Con.","['healthy male individuals', 'Nine healthy volunteers']","['standardised mixed lunch and rested for the following 3\xa0h (Con) or performed 40\xa0min of cycling at 65% V̇O 2 max after lunch (CPPEx', 'triglyceride', 'SplitEx', 'exercise before and/or after a mixed lunch', 'postprandial exercise or 20\xa0min of pre- and postprandial exercise']","['glycaemia', 'postprandial metabolic responses', 'Glucose-dependent insulinotropic polypeptide (GIP', 'AUC', 'plasma insulin', 'cortisol response']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C2697949', 'cui_str': 'Lunch'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0041119', 'cui_str': 'Tritium'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C1879668', 'cui_str': 'After lunch'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}]",9.0,0.0413184,"At 1 h, a significant reduction (P < 0.009) in plasma insulin (SplitEx - 53 ± 31%; CCPEx - 48 ± 20%) and C-peptide (SplitEx - 57 ± 20%; CCPEx - 47 ± 24%) was observed compared to Con.","[{'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Sacchetti', 'Affiliation': 'Unit of Exercise Physiology, Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Piazza Lauro de Bosis 6, 00135, Rome, Italy. massimo.sacchetti@uniroma4.it.'}, {'ForeName': 'Jonida', 'Initials': 'J', 'LastName': 'Haxhi', 'Affiliation': 'Unit of Exercise Physiology, Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Piazza Lauro de Bosis 6, 00135, Rome, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Sgrò', 'Affiliation': 'Unit of Endocrinology, Department of Movement, University of Rome ""Foro Italico"", Piazza Lauro de Bosis 6, 00135, Rome, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Scotto di Palumbo', 'Affiliation': 'Unit of Exercise Physiology, Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Piazza Lauro de Bosis 6, 00135, Rome, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Nicolò', 'Affiliation': 'Unit of Exercise Physiology, Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Piazza Lauro de Bosis 6, 00135, Rome, Italy.'}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Bellini', 'Affiliation': 'Unit of Exercise Physiology, Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Piazza Lauro de Bosis 6, 00135, Rome, Italy.'}, {'ForeName': 'Ilenia', 'Initials': 'I', 'LastName': 'Bazzucchi', 'Affiliation': 'Unit of Exercise Physiology, Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Piazza Lauro de Bosis 6, 00135, Rome, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'di Luigi', 'Affiliation': 'Unit of Endocrinology, Department of Movement, University of Rome ""Foro Italico"", Piazza Lauro de Bosis 6, 00135, Rome, Italy.'}]",European journal of nutrition,['10.1007/s00394-021-02512-4'] 1102,33636401,Transcranial laser stimulation: Mitochondrial and cerebrovascular effects in younger and older healthy adults.,"BACKGROUND Transcranial laser stimulation is a novel method of noninvasive brain stimulation found safe and effective for improving prefrontal cortex neurocognitive functions in healthy young adults. This method is different from electric and magnetic stimulation because it causes the photonic oxidation of cytochrome-c-oxidase, the rate-limiting enzyme for oxygen consumption and the major intracellular acceptor of photons from near-infrared light. This photobiomodulation effect promotes mitochondrial respiration, cerebrovascular oxygenation and neurocognitive function. Pilot studies suggest that transcranial photobiomodulation may also induce beneficial effects in aging individuals. OBJECTIVES Randomized, sham-controlled study to test photobiomodulation effects caused by laser stimulation on cytochrome-c-oxidase oxidation and hemoglobin oxygenation in the prefrontal cortex of 68 healthy younger and older adults, ages 18-85. METHODS Broadband near-infrared spectroscopy was used for the noninvasive quantification of bilateral cortical changes in oxidized cytochrome-c-oxidase and hemoglobin oxygenation before, during and after 1064-nm wavelength laser (IR-A laser, area: 13.6 cm 2 , power density: 250 mW/cm 2 ) or sham stimulation of the right anterior prefrontal cortex (Brodmann Area 10). RESULTS As compared to sham control, there was a significant laser-induced increase in oxidized cytochrome-c-oxidase during laser stimulation, followed by a significant post-stimulation increase in oxygenated hemoglobin and a decrease in deoxygenated hemoglobin. Furthermore, there was a greater laser-induced effect on cytochrome-c-oxidase with increasing age, while laser-induced effects on cerebral hemodynamics decreased with increasing age. No adverse laser effects were found. CONCLUSION The findings support the use of transcranial photobiomodulation for cerebral oxygenation and alleviation of age-related decline in mitochondrial respiration. They justify further research on its therapeutic potential in neurologic and psychiatric diseases.",2021,"As compared to sham control, there was a significant laser-induced increase in oxidized cytochrome-c-oxidase during laser stimulation, followed by a significant post-stimulation increase in oxygenated hemoglobin and a decrease in deoxygenated hemoglobin.","['younger and older healthy adults', 'healthy young adults', '68 healthy younger and older adults, ages 18-85']","['transcranial photobiomodulation', 'Transcranial laser stimulation', 'laser stimulation on cytochrome-c-oxidase oxidation and hemoglobin oxygenation', '1064-nm wavelength laser (IR-A laser, area: 13.6 cm 2 , power density: 250 mW/cm 2 ) or sham stimulation of the right anterior prefrontal cortex (Brodmann Area 10']","['mitochondrial respiration, cerebrovascular oxygenation and neurocognitive function', 'cerebral hemodynamics', 'adverse laser effects', 'oxygenated hemoglobin', 'deoxygenated hemoglobin', 'oxidized cytochrome-c-oxidase']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0442348', 'cui_str': 'Transcranial approach'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0010760', 'cui_str': 'Cytochrome c oxidase'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0449819', 'cui_str': 'Wavelength'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C4517560', 'cui_str': '13.6'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0441997', 'cui_str': 'Right anterior'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0599720', 'cui_str': 'Brodmann area'}]","[{'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0010760', 'cui_str': 'Cytochrome c oxidase'}]",,0.0291808,"As compared to sham control, there was a significant laser-induced increase in oxidized cytochrome-c-oxidase during laser stimulation, followed by a significant post-stimulation increase in oxygenated hemoglobin and a decrease in deoxygenated hemoglobin.","[{'ForeName': 'Celeste L', 'Initials': 'CL', 'LastName': 'Saucedo', 'Affiliation': 'Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Courtois', 'Affiliation': 'Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Zachary S', 'Initials': 'ZS', 'LastName': 'Wade', 'Affiliation': 'Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Meghan N', 'Initials': 'MN', 'LastName': 'Kelley', 'Affiliation': 'Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Nusha', 'Initials': 'N', 'LastName': 'Kheradbin', 'Affiliation': 'Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Douglas W', 'Initials': 'DW', 'LastName': 'Barrett', 'Affiliation': 'Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Gonzalez-Lima', 'Affiliation': 'Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Austin, TX, USA. Electronic address: gonzalezlima@utexas.edu.'}]",Brain stimulation,['10.1016/j.brs.2021.02.011'] 1103,33647946,"The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction.","BACKGROUND Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) still reaches excessively high mortality rates. This analysis is aimed to develop a new easily applicable biomarker-based risk score. METHODS AND RESULTS A biomarker-based risk score for 30-day mortality was developed from 458 patients with CS complicating AMI included in the randomized CULPRIT-SHOCK trial. The selection of relevant predictors and the coefficient estimation for the prognostic model were performed by a penalized multivariate logistic regression analysis. Validation was performed internally, internally externally as well as externally in 163 patients with CS included in the randomized IABP-SHOCK II trial. Blood samples were obtained at randomization. The two trials are registered with ClinicalTrials.gov (NCT01927549 and NCT00491036), are closed to new participants, and follow-up is completed. Out of 58 candidate variables, the four strongest predictors for 30-day mortality were included in the CLIP score (cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide). The score was well calibrated and yielded high c-statistics of 0.82 [95% confidence interval (CI) 0.78-0.86] in internal validation, 0.82 (95% CI 0.75-0.89) in internal-external (temporal) validation, and 0.73 (95% CI 0.65-0.81) in external validation. Notably, it outperformed the Simplified Acute Physiology Score II and IABP-SHOCK II risk score in prognostication (0.83 vs 0.62; P < 0.001 and 0.83 vs. 0.76; P = 0.03, respectively). CONCLUSIONS A biomarker-only score for 30-day mortality risk stratification in infarct-related CS was developed, extensively validated and calibrated in a prospective cohort of contemporary patients with CS after AMI. The CLIP score outperformed other clinical scores and may be useful as an early decision tool in CS.",2021,"The score was well calibrated and yielded high c-statistics of 0.82 [95% confidence interval (CI) 0.78-0.86] in internal validation, 0.82 (95% CI 0.75-0.89) in internal-external (temporal) validation, and 0.73 (95% CI 0.65-0.81) in external validation.","['163 patients with CS included in the randomized IABP-SHOCK II trial', 'cardiogenic shock after acute myocardial infarction', '458 patients with CS complicating AMI']",[],"['novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score', 'CLIP score (cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide', 'Simplified Acute Physiology Score II and IABP-SHOCK II risk score', '30-day mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036980', 'cui_str': 'Cardiogenic shock'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0702122', 'cui_str': 'Intra-aortic balloon pump'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C5191377', 'cui_str': '458'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}]",[],"[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0071744', 'cui_str': 'Cystatin C'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175722', 'cui_str': 'Clip'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0031842', 'cui_str': 'Physiology'}, {'cui': 'C0702122', 'cui_str': 'Intra-aortic balloon pump'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",163.0,0.299852,"The score was well calibrated and yielded high c-statistics of 0.82 [95% confidence interval (CI) 0.78-0.86] in internal validation, 0.82 (95% CI 0.75-0.89) in internal-external (temporal) validation, and 0.73 (95% CI 0.65-0.81) in external validation.","[{'ForeName': 'Uta', 'Initials': 'U', 'LastName': 'Ceglarek', 'Affiliation': 'Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, P.-List-Str. 13, 04103 Leipzig, Germany.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Schellong', 'Affiliation': 'Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, P.-List-Str. 13, 04103 Leipzig, Germany.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Rosolowski', 'Affiliation': 'Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, P.-List-Str. 13, 04103 Leipzig, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Scholz', 'Affiliation': 'Institute of Medical Informatics, Statistics and Epidemiology, University Leipzig, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Willenberg', 'Affiliation': 'Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, P.-List-Str. 13, 04103 Leipzig, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Kratzsch', 'Affiliation': 'Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, P.-List-Str. 13, 04103 Leipzig, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Zeymer', 'Affiliation': 'Klinikum Ludwigshafen und Institut für Herzinfarktforschung, Ludwigshafen, Germany.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Fuernau', 'Affiliation': 'University Heart Center Lübeck, Lübeck, Germany.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'de Waha-Thiele', 'Affiliation': 'University Heart Center Lübeck, Lübeck, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Büttner', 'Affiliation': 'Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology, Strümpellstr.. 39, 04289 Leipzig, and Leipzig Heart Institute, Leipzig, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Jobs', 'Affiliation': 'German Center for Cardiovascular Research (DZHK), Lübeck, Germany.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Freund', 'Affiliation': 'Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology, Strümpellstr.. 39, 04289 Leipzig, and Leipzig Heart Institute, Leipzig, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Desch', 'Affiliation': 'German Center for Cardiovascular Research (DZHK), Lübeck, Germany.'}, {'ForeName': 'Hans-Josef', 'Initials': 'HJ', 'LastName': 'Feistritzer', 'Affiliation': 'Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology, Strümpellstr.. 39, 04289 Leipzig, and Leipzig Heart Institute, Leipzig, Germany.'}, {'ForeName': 'Berend', 'Initials': 'B', 'LastName': 'Isermann', 'Affiliation': 'Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, P.-List-Str. 13, 04103 Leipzig, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Thiery', 'Affiliation': 'Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, P.-List-Str. 13, 04103 Leipzig, Germany.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Pöss', 'Affiliation': 'Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology, Strümpellstr.. 39, 04289 Leipzig, and Leipzig Heart Institute, Leipzig, Germany.'}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Thiele', 'Affiliation': 'Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology, Strümpellstr.. 39, 04289 Leipzig, and Leipzig Heart Institute, Leipzig, Germany.'}]",European heart journal,['10.1093/eurheartj/ehab110'] 1104,33650444,Null effects of therapy dog interaction on adolescent anxiety during a laboratory-based social evaluative stressor.,"BACKGROUND AND OBJECTIVES Animal-assisted interventions (AAIs) are increasingly popular as treatments to reduce anxiety. However, there is little empirical evidence testing the mechanisms of action in AAIs, especially among adolescents. We examined whether two possible mechanisms, social interaction and/or physical contact with a therapy dog, might reduce anxiety during a social stressor. DESIGN AND METHODS To test these mechanisms, we randomly assigned 75 adolescents with low, middle, and high levels of social anxiety to complete a laboratory-based social evaluative stressor in one of three conditions: social interaction with a therapy dog (no physical interaction), social plus physical interaction with a therapy dog, or no interaction with a therapy dog. We measured self-reported anxiety and autonomic reactivity during the social stressor to assess the effects of contact with a therapy dog. RESULTS AND CONCLUSIONS We found no evidence that the presence of a real dog, with or without the opportunity to touch it, reduced anxiety or autonomic reactivity or improved cognitive performance relative to the presence of a stuffed dog in the control condition, regardless of levels of preexisting social anxiety. Trial registration: ClinicalTrials.gov identifier: NCT03249116.",2021,"We found no evidence that the presence of a real dog, with or without the opportunity to touch it, reduced anxiety or autonomic reactivity or improved cognitive performance relative to the presence of a stuffed dog in the control condition, regardless of levels of preexisting social anxiety.","['adolescent anxiety during a laboratory-based social evaluative stressor', '75 adolescents with low, middle, and high levels of social anxiety to complete a laboratory-based social evaluative stressor in one of three conditions']","['social interaction with a therapy dog (no physical interaction), social plus physical interaction with a therapy dog, or no interaction with a therapy dog']",['anxiety and autonomic reactivity'],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0037420', 'cui_str': 'Interaction with others'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0012984', 'cui_str': 'Canis lupus familiaris'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]",75.0,0.0251336,"We found no evidence that the presence of a real dog, with or without the opportunity to touch it, reduced anxiety or autonomic reactivity or improved cognitive performance relative to the presence of a stuffed dog in the control condition, regardless of levels of preexisting social anxiety.","[{'ForeName': 'Megan K', 'Initials': 'MK', 'LastName': 'Mueller', 'Affiliation': 'Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, USA.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'Anderson', 'Affiliation': 'Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Scarborough, ME, USA.'}, {'ForeName': 'Erin K', 'Initials': 'EK', 'LastName': 'King', 'Affiliation': 'Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, USA.'}, {'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Urry', 'Affiliation': 'Department of Psychology, Tufts University, Medford, MA, USA.'}]","Anxiety, stress, and coping",['10.1080/10615806.2021.1892084'] 1105,33657443,"The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.","BACKGROUND Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD); no approved therapies for NASH currently exist. Pegbelfermin (PGBF), a human fibroblast growth factor 21 analog, has metabolic effects that may provide benefit for patients with NASH. DESIGN The FALCON 1 and 2 studies are phase 2b, multicenter, double-blind, placebo-controlled, randomized trials to assess safety and efficacy of PGBF treatment in patients who have histologically-confirmed NASH with stage 3 liver fibrosis (FALCON 1; NCT03486899) or compensated cirrhosis (FALCON 2; NCT03486912). In both studies, randomized patients receive once weekly subcutaneous injections of PGBF (10, 20, or 40 mg) or placebo during a 48-week treatment period and are then followed for an additional 4 weeks. ENDPOINTS The primary efficacy endpoint for FALCON 1 is the proportion of patients who achieve ≥1 stage improvement in fibrosis (by NASH CRN fibrosis score) without NASH worsening or NASH improvement (≥2 point decrease in NAFLD Activity Score) without fibrosis worsening at Week 24. For FALCON 2, the primary efficacy endpoint is ≥1 stage improvement in fibrosis without NASH worsening at Week 48. Key safety endpoints for both studies include incidence and frequency of adverse events, bone mineral density and immunogenicity. SUMMARY Previous clinical trial data show that PGBF can reduce hepatic fat and improve metabolic factors and biomarkers of hepatic injury and fibrosis. The FALCON studies aim to evaluate PGBF treatment specifically in patients with NASH and advanced fibrosis, who are at greatest risk of poor clinical outcomes over time.",2021,The primary efficacy endpoint for FALCON 1 is the proportion of patients who achieve ≥1 stage improvement in fibrosis (by NASH CRN fibrosis score) without NASH worsening or NASH improvement (≥2 point decrease in NAFLD Activity Score) without fibrosis worsening at Week 24.,"['patients who have histologically-confirmed NASH with stage 3 liver fibrosis (FALCON 1; NCT03486899) or compensated cirrhosis ', 'patients with NASH', 'patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis', 'patients with NASH and advanced fibrosis']","['Nonalcoholic steatohepatitis (NASH', 'Pegbelfermin (PGBF', 'placebo', 'PGBF', 'pegbelfermin']","['incidence and frequency of adverse events, bone mineral density and immunogenicity', 'safety and efficacy', 'NAFLD Activity Score) without fibrosis worsening', 'efficacy and safety', 'proportion of patients who achieve ≥1 stage improvement in fibrosis (by NASH CRN fibrosis score) without NASH worsening or NASH improvement', 'hepatic fat and improve metabolic factors and biomarkers of hepatic injury and fibrosis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0239946', 'cui_str': 'Hepatic fibrosis'}, {'cui': 'C0999244', 'cui_str': 'Falco'}, {'cui': 'C0205432', 'cui_str': 'Compensated'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C0334160', 'cui_str': 'Bridging fibrosis'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}]","[{'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}, {'cui': 'C5139693', 'cui_str': 'Pegbelfermin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}, {'cui': 'C0010031', 'cui_str': 'Corneal structure'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0160390', 'cui_str': 'Injury of liver'}]",,0.507137,The primary efficacy endpoint for FALCON 1 is the proportion of patients who achieve ≥1 stage improvement in fibrosis (by NASH CRN fibrosis score) without NASH worsening or NASH improvement (≥2 point decrease in NAFLD Activity Score) without fibrosis worsening at Week 24.,"[{'ForeName': 'Manal F', 'Initials': 'MF', 'LastName': 'Abdelmalek', 'Affiliation': 'Duke University School of Medicine, Durham, NC, United States of America.'}, {'ForeName': 'Edgar D', 'Initials': 'ED', 'LastName': 'Charles', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, United States of America. Electronic address: edgar.charles@bms.com.'}, {'ForeName': 'Arun J', 'Initials': 'AJ', 'LastName': 'Sanyal', 'Affiliation': 'Virginia Commonwealth University, Richmond, VA, United States of America.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Harrison', 'Affiliation': 'Pinnacle Clinical Research, San Antonio, TX, United States of America.'}, {'ForeName': 'Brent A', 'Initials': 'BA', 'LastName': 'Neuschwander-Tetri', 'Affiliation': 'Saint Louis University, St. Louis, MO, United States of America.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Goodman', 'Affiliation': 'Inova Fairfax Hospital, Falls Church, VA, United States of America.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Ehman', 'Affiliation': 'Mayo Clinic College of Medicine, Rochester, MN, United States of America.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Karsdal', 'Affiliation': 'Nordic Bioscience, Herlev, Denmark.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Nakajima', 'Affiliation': 'Yokohama City University, Yokohama, Japan.'}, {'ForeName': 'Shuyan', 'Initials': 'S', 'LastName': 'Du', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, United States of America.'}, {'ForeName': 'Giridhar S', 'Initials': 'GS', 'LastName': 'Tirucherai', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, United States of America.'}, {'ForeName': 'George H', 'Initials': 'GH', 'LastName': 'Klinger', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, United States of America.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Mora', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, United States of America.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Yamaguchi', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, United States of America.'}, {'ForeName': 'Diane E', 'Initials': 'DE', 'LastName': 'Shevell', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, United States of America.'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Loomba', 'Affiliation': 'University of California at San Diego, San Diego, CA, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106335'] 1106,33655650,Randomized trial comparing radial hemostasis techniques; catechol conjugated chitosan pad (InnoSEAL) versus pneumatic compression band.,"OBJECTIVES Primary objectives: to compare radial artery occlusion rate (RAO) after cardiac catheterization between catecholamine-chitosan pad (InnoSEAL) and pneumatic compression device (PCD) and to compare difference in hemostasis time and radial monitoring termination time between two arms. Secondary objectives: to compare radial site bleeding and ease of use of two methods by cath-lab technicians. BACKGROUND Hemostatic pads may be an effective alternative to PCD with lesser chance of access site complications with advantage of shortened compression time. METHODS Patients (N = 606) undergoing trans-radial, diagnostic or interventional procedures were randomized to either InnoSEAL arm or PCD. RAO was assessed using US Duplex; performed 6-24 hr posthemostatic device removal. Time to hemostasis was recorded as per defined protocols. Ease of use among cath-lab technicians was assessed through 5 point Likert scale. RESULTS Data of 597 patients was analyzed (299 InnoSEAL, 298 PCD). RAO rate was 8.5% in InnoSEAL and 9.4% in PCD arm (p value >.05). The pooled median hemostasis time and time to termination of radial monitoring was 42 versus 225 min and 50 versus 240 min in InnoSEAL and PCD arms, respectively (p value: <.01). There was no difference in Grade I/II hematoma (InnoSEAL: 1.3% vs. PCD: 3.4%). InnoSEAL was marginally acceptable compared to PCD by technicians. CONCLUSION Hemostasis time is significantly shorter in InnoSEAL arm with reasonable acceptability to its usage among cath lab staff. RAO and bleeding complications are comparable between the arms. Based on our findings, it seems feasible to include Chitosan based hemostasis pad routinely in cath lab.",2021,RAO rate was 8.5% in InnoSEAL and 9.4% in PCD arm (p value >.05).,"['Patients (N = 606) undergoing trans-radial, diagnostic or interventional procedures', '597 patients was analyzed (299 InnoSEAL, 298 PCD']","['InnoSEAL arm or PCD', 'radial hemostasis techniques; catechol conjugated chitosan pad (InnoSEAL) versus pneumatic compression band', 'catecholamine-chitosan pad (InnoSEAL) and pneumatic compression device (PCD']","['radial site bleeding and ease of use of two methods by cath-lab technicians', 'Time to hemostasis', 'RAO and bleeding complications', 'RAO rate', 'Grade I/II hematoma', 'pooled median hemostasis time and time to termination of radial monitoring', 'radial artery occlusion rate (RAO', 'RAO', 'hemostasis time and radial monitoring termination time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0007413', 'cui_str': 'ortho-Dihydroxybenzenes'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0162969', 'cui_str': 'Chitosan'}, {'cui': 'C0332568', 'cui_str': 'Pad'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0007412', 'cui_str': 'Catecholamine'}]","[{'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0162857', 'cui_str': 'Structure of radial artery'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}]",606.0,0.141549,RAO rate was 8.5% in InnoSEAL and 9.4% in PCD arm (p value >.05).,"[{'ForeName': 'Asad Z', 'Initials': 'AZ', 'LastName': 'Pathan', 'Affiliation': 'Department of cardiology, Tabba Heart Institute Karachi, Karachi, Pakistan.'}, {'ForeName': 'Saba', 'Initials': 'S', 'LastName': 'Aijaz', 'Affiliation': 'Department of cardiology, Tabba Heart Institute Karachi, Karachi, Pakistan.'}, {'ForeName': 'Sana', 'Initials': 'S', 'LastName': 'Sheikh', 'Affiliation': 'Department of cardiology, Tabba Heart Institute Karachi, Karachi, Pakistan.'}, {'ForeName': 'Saadia', 'Initials': 'S', 'LastName': 'Sattar', 'Affiliation': 'Department of cardiology, Tabba Heart Institute Karachi, Karachi, Pakistan.'}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.29578'] 1107,33675192,Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer.,"BACKGROUND Ovarian cancer is the seventh most common cancer in women worldwide and the eighth most common cause of cancer death. Due to the lack of effective early detection strategies and the unspecific onset of symptoms, it is diagnosed at an advanced stage in 75% of cases. The cancer antigen (CA) 125 is used as a prognostic marker and its level is elevated in more than 85% of women with advanced stages of epithelial ovarian cancer (EOC). The standard treatment is primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT), but the later approach is neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). Several studies have been conducted to find out whether preoperative CA-125 serum levels influence treatment choice, surgical resection and survival outcome. The aim of our study was to analyse experience of single institution as Cancer comprehensive center with preoperative usefulness of CA-125. PATIENTS AND METHODS At the Institute of Oncology Ljubljana a retrospective analysis of 253 women with stage FIGO IIIC and IV ovarian cancer was conducted. Women were divided into two groups based on their primary treatment. The first group was the NACT group (215 women) and the second the PDS group (38 women). The differences in patient characteristics were compared using the Chi-square test and ANOVA and the Kaplan-Meier method was used for calculating progression-free survival (PFS) and overall survival (OS). RESULTS The median serum CA-125 level was higher in the NACT group than in the PDS group, 972 IU/ml and 499 IU/ ml, respectively. The PFS in the NACT group was 8 months (95% CI 6.4-9.5) and 18 months (95% CI 12.5-23.4) in the PDS group. The median OS was lower in the NACT group than in the PDS group, 25 months (95% CI 20.6-29.5) and 46 months (95% CI 32.9-62.1), respectively. CONCLUSIONS Preoperative CA-125 cut off value of 500 IU/ml is a promising threshold to predict a successful PDS.",2021,"The median serum CA-125 level was higher in the NACT group than in the PDS group, 972 IU/ml and 499 IU/ ml, respectively.","['patients with advanced stage epithelial ovarian cancer', 'women with advanced stages of epithelial ovarian cancer (EOC', '253 women with stage FIGO IIIC and IV ovarian cancer']","['primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT), but the later approach is neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS', 'NACT']","['cancer antigen (CA', 'median serum CA-125 level', 'progression-free survival (PFS) and overall survival (OS', 'median OS', 'Preoperative serum CA-125 level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C4721610', 'cui_str': 'Epithelial Ovarian Carcinoma'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0003320', 'cui_str': 'Antigen'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006610', 'cui_str': 'Cancer antigen 125'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]",253.0,0.0944176,"The median serum CA-125 level was higher in the NACT group than in the PDS group, 972 IU/ml and 499 IU/ ml, respectively.","[{'ForeName': 'Sebastjan', 'Initials': 'S', 'LastName': 'Merlo', 'Affiliation': 'Department of Gynaecological Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Nikola', 'Initials': 'N', 'LastName': 'Besic', 'Affiliation': 'Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Drmota', 'Affiliation': 'Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Kovacevic', 'Affiliation': 'Department of Gynaecological Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.'}]",Radiology and oncology,['10.2478/raon-2021-0013'] 1108,33677724,Patient-controlled outpatient follow-up on demand for patients with rheumatoid arthritis: a 2-year randomized controlled trial.,"INTRODUCTION Scheduled routine visits in patients with rheumatoid arthritis (RA) may be in a stable period without active disease. Consequently, there is a demand for developing outpatient control procedures which cater to the needs of the individual patient. OBJECTIVE This study aims to compare a patient-controlled outpatient follow-up system, Open Outpatient Clinic Programme (OOCP), with traditional scheduled routine follow-up (TSRF) regarding patient satisfaction and disease activity markers in RA patients. METHOD In a 2-year randomized controlled trial, RA patients were allocated to OOCP or TSRF. OOCP patients had no scheduled appointments but were allowed acute appointments with their rheumatologist and had access to nurse-led consultations and a telephone helpline. Appointments for the TSRF group were scheduled according to routine procedures (clinical parameters: DAS-28, C-reactive protein, VAS pain, tender and swollen joint count, HAQ-DI and radiographs; psychological parameters: VAS patient satisfaction and EQ-5D). RESULTS Of 282 patients, 239 completed the study (OOCP/TSRF characteristics: age 61.4 ± 10.5/60.9 ± 12.2 years, females 77/74%, ACPA positive 66/65%). At years 1 and 2, OCCP had fewer visits (year 2: 2.6 ± 1.6 vs. 3.5 ± 2; p < 0.0005) but more phone calls (year 2: 0.7 ± 1.4 vs. 0.1 ± 0.3; p < 0.0005) compared to TSRF. OOCP was comparable to TSRF regarding clinical and psychological outcome measures, and no radiographic progression was observed. CONCLUSIONS OOCP was associated with significantly fewer visits but with more phone calls to the nurse and was comparable with TSGentofte University HospitalRF regarding clinical, psychological and radiographic outcomes. Thus, the organization of outpatient care according to OOCP may be applied to strengthen patient-centred care in patients with RA. ClinicalTrials.gov Identifier (July 20, 2020): NCT04476875 Key points • In a patient-controlled outpatient follow-up system, RA patients had significantly fewer visits compared to traditional follow-up. • The patient-controlled follow-up system was comparable with traditional follow-up regarding clinical, psychological and radiographic outcomes. • Organization of outpatient care according to a patient-controlled follow-up system may be applied to strengthen patient-centred care in patients with RA.",2021,"In a patient-controlled outpatient follow-up system, RA patients had significantly fewer visits compared to traditional follow-up.","['patients with rheumatoid arthritis', 'RA patients', 'patients with RA', 'Of 282 patients, 239 completed the study (OOCP/TSRF characteristics: age 61.4 ± 10.5/60.9 ± 12.2 years, females 77/74%, ACPA positive 66/65', 'patients with rheumatoid arthritis (RA']","['patient-controlled outpatient follow-up system, Open Outpatient Clinic Programme (OOCP), with traditional scheduled routine follow-up (TSRF', 'OOCP', 'OOCP or TSRF']","['OOCP', 'radiographic progression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",,0.047552,"In a patient-controlled outpatient follow-up system, RA patients had significantly fewer visits compared to traditional follow-up.","[{'ForeName': 'René Panduro', 'Initials': 'RP', 'LastName': 'Poggenborg', 'Affiliation': 'Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Copenhagen, Denmark. poggenborg@dadlnet.dk.'}, {'ForeName': 'Ole Rintek', 'Initials': 'OR', 'LastName': 'Madsen', 'Affiliation': 'Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Copenhagen, Denmark.'}, {'ForeName': 'Lene', 'Initials': 'L', 'LastName': 'Dreyer', 'Affiliation': 'Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Copenhagen, Denmark.'}, {'ForeName': 'Gunhild', 'Initials': 'G', 'LastName': 'Bukh', 'Affiliation': 'Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Copenhagen, Denmark.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Hansen', 'Affiliation': 'Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Copenhagen, Denmark.'}]",Clinical rheumatology,['10.1007/s10067-021-05674-y'] 1109,33682146,Efficacy of a multimodal nursing intervention strategy in the process of becoming a mother: A randomized controlled trial.,"The lack of knowledge and skills for transitioning to motherhood places first-time mothers at greater risk of depression and stress, may lower their perceived self-efficacy and satisfaction with the maternal role, and potentially affects the mother-infant bond. The purpose of this study was to test the efficacy of a multimodal nursing intervention (AMACOMPRI), based on Mercer's Becoming a Mother Theory, in supporting the process of becoming a mother in first-time mothers of term infants. This study was a parallel-group, double-blind, randomized, controlled trial with a 4-month postpartum follow-up. The outcome measures were the process of becoming a mother, functional social support, mother-infant bond, and perceived maternal self-efficacy. Sixty-six first-time mothers completed the study: 33 in the intervention group and 33 in the control group. The intervention was effective in supporting the process of becoming a mother, with a large effect size (Cohen's d = 1.50) and higher scores on the Becoming-a-Mother Scale in the intervention group compared with the control group (intergroup difference 13.04 points; 95% confidence interval: 8.72-17.34). Participants in the intervention group demonstrated higher scores in functional social support, perceived maternal self-efficacy, and mother-infant bond. This study provides evidence for the efficacy of an innovative nursing intervention that supports the process of becoming a mother. Further testing of the intervention is required in different settings and first-time mothers of low and high risk newborns.",2021,"The intervention was effective in supporting the process of becoming a mother, with a large effect size (Cohen's d = 1.50) and higher scores on the Becoming-a-Mother Scale in the intervention group compared with the control group (intergroup difference 13.04 points; 95% confidence interval: 8.72-17.34).",['Sixty-six first-time mothers completed the study: 33 in the intervention group and 33 in the control group'],"['innovative nursing intervention', 'multimodal nursing intervention strategy', 'multimodal nursing intervention (AMACOMPRI']","['process of becoming a mother, functional social support, mother-infant bond, and perceived maternal self-efficacy', 'higher scores in functional social support, perceived maternal self-efficacy, and mother-infant bond']","[{'cui': 'C4517841', 'cui_str': '66'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0532653,"The intervention was effective in supporting the process of becoming a mother, with a large effect size (Cohen's d = 1.50) and higher scores on the Becoming-a-Mother Scale in the intervention group compared with the control group (intergroup difference 13.04 points; 95% confidence interval: 8.72-17.34).","[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Vargas-Porras', 'Affiliation': 'Department of Nursing, Advanced Nursing Research Group, Universitat Rovira i Virgili, Tarragona, Catalunya, Spain.'}, {'ForeName': 'Zayne M', 'Initials': 'ZM', 'LastName': 'Roa-Díaz', 'Affiliation': 'Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Hernán G', 'Initials': 'HG', 'LastName': 'Hernández-Hincapié', 'Affiliation': 'Division of Health Sciences, Universidad Santo Tomás, Bucaramanga, Santander, Colombia.'}, {'ForeName': 'Carme', 'Initials': 'C', 'LastName': 'Ferré-Grau', 'Affiliation': 'Department of Nursing, Advanced Nursing Research Group, Universitat Rovira i Virgili, Tarragona, Catalunya, Spain.'}, {'ForeName': 'María I', 'Initials': 'MI', 'LastName': 'de Molina-Fernández', 'Affiliation': 'Department of Nursing, Advanced Nursing Research Group, Universitat Rovira i Virgili, Tarragona, Catalunya, Spain.'}]",Research in nursing & health,['10.1002/nur.22123'] 1110,33693863,Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.,"BACKGROUND We examined the efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP-targeted mAbs) as add-on therapy for patients with chronic migraine (CM) undergoing treatment with onabotulinumtoxinA (onabot) who require additional preventive therapy. METHODS We reviewed medical records of patients with CM receiving treatment with onabot who were subsequently prescribed a CGRP-targeted mAb medication. The primary outcome was the change in number of monthly headache days (MHDs) reported. Secondary outcomes were change in headache pain severity, discontinuation due to lack of tolerability, and severe adverse events. RESULTS Of 153 patients, 111 (72.5%) reported a decrease in either MHDs or headache pain severity, with documentation of MHDs in 66 patients. Among these 66 patients, the average number of MHDs before initiation of onabot treatment was 25.7. After onabot treatment, an average decrease of 10.9 MHDs was reported (P < 0.001). After the addition of a CGRP-targeted mAb medication, patients experienced a further decrease of 5.7 MHDs (P < 0.001). With combined therapy, patients reported a total decrease of 16.6 MHDs (P < 0.001). Adverse effects occurred in 13 patients (8.5%) after addition of the CGRP-targeted mAb and included constipation, injection site reaction, and fatigue. No serious adverse events were reported. CONCLUSION Adding a CGRP-targeted mAb to onabot in patients with CM was associated with further reductions in MHDs without major tolerability issues across a range of mAbs. This retrospective review supports the conduct of a well-designed double-blind study adding a CGRP-targeted mAb or placebo to onabot.",2021,"With combined therapy, patients reported a total decrease of 16.6 MHDs (p < 0.001).","['patients with chronic migraine (CM) undergoing treatment with onabotulinumtoxinA(onabot) who require additional preventive therapy', 'Patients with Chronic Migraine', 'patients with CM receiving treatment with onabot who were subsequently prescribed a CGRP-targeted mAb medication']","['Calcitonin Gene-Related Peptide Targeted Monoclonal Antibody Medications', 'calcitonin gene-related peptide targeted monoclonal antibodies (CGRP-targeted mAbs', 'CGRP-targeted mAb or placebo']","['Adverse effects', 'Efficacy and Tolerability', 'constipation, injection site reaction, and/or fatigue', 'serious adverse events', 'headache pain severity, discontinuation due to lack of tolerability, and severe adverse events', 'MHDs or headache pain severity', 'change in number of monthly headache days (MHDs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1960870', 'cui_str': 'Transformed migraine'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C2719767', 'cui_str': 'OnabotulinumtoxinA'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0006669', 'cui_str': 'Calcitonin gene-related peptide'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0006669', 'cui_str': 'Calcitonin gene-related peptide'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",153.0,0.362231,"With combined therapy, patients reported a total decrease of 16.6 MHDs (p < 0.001).","[{'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Cohen', 'Affiliation': 'Department of Medicine, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Armand', 'Affiliation': 'Department of Neurology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'Department of Neurology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Vollbracht', 'Affiliation': 'Department of Neurology, Columbia University Medical Center, New York, New York, USA.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnab093'] 1111,33716036,A Randomized Controlled Trial of a Modified Cystoscopy Technique using the Peak-End Rule in order to Improve Pain and Anxiety.,"OBJECTIVE To determine if a modified cystoscopy technique utilizing the peak-end rule cognitive bias decreases pain and anxiety during flexible cystoscopy in patients who undergo cystoscopy. METHODS A total of 85 participants undergoing their first diagnostic cystoscopy were enrolled in a blinded single-center, prospective, randomized controlled trial. Patients with lower urinary tract abnormalities, prior radiation and chronic pelvic pain were excluded. Participants were randomized to a standard cystoscopy (arm A) or a modified cystoscopy (arm B) where a two-minute period at the end of the procedure was completed during which the cystoscope was left in the bladder without being manipulated. Following the cystoscopy, participants completed a standard pain and anxiety questionnaire. Differences in mean pain and anxiety score between arms were evaluated using a Mann-Whitney test with a two-sided alpha of 0.05. RESULTS Eighty-five patients were randomized and underwent flexible cystoscopy. Three participants were ineligible, one required secondary procedures, and two did not complete the questionnaires. Among the 82 eligible patients, 45 were randomized to standard cystoscopy (arm A) and 37 to the modified cystoscopy (arm B) with mean pain scores of 23.20 and 11.97, respectively (P = .039). Mean anxiety scores were 2.09 and 0.88 for arm A and B, respectively (P = .013). CONCLUSION This study demonstrated a clinically meaningful decrease in pain and anxiety for patients undergoing flexible cystoscopy when employing the modified cystoscopy technique versus the standard practice. This free and straightforward method to improve patient comfort and decrease stress during first time flexible cystoscopy should be considered by clinicians.",2021,This study demonstrated a clinically meaningful decrease in pain and anxiety for patients undergoing flexible cystoscopy when employing the modified cystoscopy technique versus the standard practice.,"['82 eligible patients, 45 were randomized to', 'Eighty-five patients', '85 participants undergoing their first diagnostic cystoscopy', 'patients who undergo cystoscopy', 'Patients with lower urinary tract abnormalities, prior radiation and chronic pelvic pain were excluded', 'patients undergoing']","['Modified Cystoscopy Technique', 'modified cystoscopy technique utilizing the peak-end rule cognitive bias', 'standard cystoscopy (arm A) or a modified cystoscopy', 'standard cystoscopy', 'flexible cystoscopy']","['pain and anxiety', 'mean pain and anxiety score', 'Mean anxiety scores', 'standard pain and anxiety questionnaire', 'Pain and Anxiety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0401483', 'cui_str': 'Diagnostic cystoscopy'}, {'cui': 'C0010702', 'cui_str': 'Cystoscopy'}, {'cui': 'C0729866', 'cui_str': 'Lower urinary tract structure'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0404484', 'cui_str': 'Chronic pelvic pain of female'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0010702', 'cui_str': 'Cystoscopy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0522637', 'cui_str': 'Measuring ruler'}, {'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0577992', 'cui_str': 'Flexible cystoscopy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",85.0,0.0827035,This study demonstrated a clinically meaningful decrease in pain and anxiety for patients undergoing flexible cystoscopy when employing the modified cystoscopy technique versus the standard practice.,"[{'ForeName': 'Khalil', 'Initials': 'K', 'LastName': 'Hetou', 'Affiliation': 'Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Halstuch', 'Affiliation': 'Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.'}, {'ForeName': 'Arnon', 'Initials': 'A', 'LastName': 'Lavi', 'Affiliation': 'Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.'}, {'ForeName': 'Shiva M', 'Initials': 'SM', 'LastName': 'Nair', 'Affiliation': 'Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.'}, {'ForeName': 'Ailsa May Li', 'Initials': 'AML', 'LastName': 'Gan', 'Affiliation': 'Division of Urology, Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Huynh', 'Affiliation': 'Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Izawa', 'Affiliation': 'Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.'}, {'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Chin', 'Affiliation': 'Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.'}, {'ForeName': 'Nicholas E', 'Initials': 'NE', 'LastName': 'Power', 'Affiliation': 'Division of Urology, Department of Surgery, Western University, London, Ontario, Canada. Electronic address: Nicholas.power@lhsc.on.ca.'}]",Urology,['10.1016/j.urology.2021.02.033'] 1112,33714677,Two decades of research towards a potential first anti-epileptic drug.,"The basic mechanisms by which brain insults, such as trauma, stroke or status epilepticus produce epilepsy are not completely understood, and effective preventive measures and treatment are still not available in the clinical setting. Over the last 2 decades we have conducted several studies with animal models of epilepsy (rodents and non-human primates) and demonstrated that drugs that modify neuronal plastic processes, such as anticholinergic agents (e.g., antimuscarinic compounds), if administered soon after brain injury and over a period of 10-20 days, have the potential to modify the natural course of post-traumatic epilepsy. To that end treatment with scopolamine showed promising results as a candidate agent in both the pilocarpine and kainate models. We then showed that biperiden, yet another cholinergic antagonist acting in the muscarinic receptor, that is widely used to treat Parkinson's disease, also decreased the incidence and intensity of spontaneous epileptic seizures, delaying their appearance in the pilocarpine model of epilepsy. In other words, biperiden showed to be a potential candidate to be further investigated as an antiepileptogenic agent. Accordingly, we tested the safety of biperiden in a small group of patients (as a small phase II safety assessment) and confirmed its safety in the context of traumatic brain injury (TBI). Now, we provide information on our ongoing project to evaluate the efficacy of biperiden in preventing the development of epilepsy in patients that suffered TBI, in a double blind, randomized, placebo-controlled trial.",2021,To that end treatment with scopolamine showed promising results as a candidate agent in both the pilocarpine and kainate models.,['patients that suffered TBI'],"['placebo', 'scopolamine']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036442', 'cui_str': 'Scopolamine'}]",[],,0.187968,To that end treatment with scopolamine showed promising results as a candidate agent in both the pilocarpine and kainate models.,"[{'ForeName': 'Simone Kastropil', 'Initials': 'SK', 'LastName': 'Benassi', 'Affiliation': 'Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Julieta Goncalves Silva Macedo', 'Initials': 'JGSM', 'LastName': 'Alves', 'Affiliation': 'Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Cristiane Gorgatti', 'Initials': 'CG', 'LastName': 'Guidoreni', 'Affiliation': 'Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Cristina Gonçalves', 'Initials': 'CG', 'LastName': 'Massant', 'Affiliation': 'Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Claudio M', 'Initials': 'CM', 'LastName': 'Queiroz', 'Affiliation': 'Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Garrido-Sanabria', 'Affiliation': 'Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Rafael Duarte de Souza', 'Initials': 'RDS', 'LastName': 'Loduca', 'Affiliation': 'Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Maria Alice', 'Initials': 'MA', 'LastName': 'Susemihl', 'Affiliation': 'Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Wellingson Silva', 'Initials': 'WS', 'LastName': 'Paiva', 'Affiliation': 'Department of Neurology, Division of Neurosurgery, Hospital das Clínicas, University of São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Almir Ferreira', 'Initials': 'AF', 'LastName': 'de Andrade', 'Affiliation': 'Department of Neurology, Division of Neurosurgery, Hospital das Clínicas, University of São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Manoel Jacobsen', 'Initials': 'MJ', 'LastName': 'Teixeira', 'Affiliation': 'Department of Neurology, Division of Neurosurgery, Hospital das Clínicas, University of São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Joaquina Queiroz', 'Initials': 'JQ', 'LastName': 'Andrade', 'Affiliation': 'Department of Neurology, Division of Neurologic Clinic, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP Brazil.'}, {'ForeName': 'Eliana', 'Initials': 'E', 'LastName': 'Garzon', 'Affiliation': 'Department of Neurology, Division of Neurologic Clinic, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP Brazil.'}, {'ForeName': 'Maira Licia', 'Initials': 'ML', 'LastName': 'Foresti', 'Affiliation': ""Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil; Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil.""}, {'ForeName': 'Luiz E', 'Initials': 'LE', 'LastName': 'Mello', 'Affiliation': ""Physiology Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil; Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil. Electronic address: lemello@unifesp.br.""}]",Seizure,['10.1016/j.seizure.2021.02.031'] 1113,33719833,Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.,"Among acute myeloid leukemia (AML) patients treated with 7 + 3 induction, we evaluate the association between complete morphologic remission (CR) and long-term overall survival (OS) over four decades. We analyzed 1247 patients age ≤ 65 randomized to 7 + 3 arms from five SWOG studies. OS has improved over the four decades. Hazards for death in the two most recent studies fell after year 2. In multivariable models, decade of therapy was the most important variable with respect to long-term survival and CR by day 100 the second most important variable. Protocol/decade, which captures many factors not included in our multivariable model, was the most important predictor of being alive at year 2 or 3. The next most important factor was achievement of first CR by day 100.",2021,"In multivariable models, decade of therapy was the most important variable with respect to long-term survival and CR by day 100 the second most important variable.","['acute myeloid leukemia (AML) patients', '1247 patients age ≤ 65 randomized to 7\u2009+\u20093 arms from five SWOG studies']",[],"['complete morphologic remission (CR) and long-term overall survival (OS', '3-year survival']","[{'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439234', 'cui_str': 'year'}]",1247.0,0.0406057,"In multivariable models, decade of therapy was the most important variable with respect to long-term survival and CR by day 100 the second most important variable.","[{'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Othus', 'Affiliation': 'SWOG Statistical Center, Seattle, WA, USA.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Garcia-Manero', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Godwin', 'Affiliation': 'Providence Onc/Hem Care Clinic, Portland, OR, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Weick', 'Affiliation': 'VA Medical Center, North Palm Beach, FL, USA.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Stirewalt', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Appelbaum', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Erba', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Elihu', 'Initials': 'E', 'LastName': 'Estey', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}]",Leukemia & lymphoma,['10.1080/10428194.2021.1885663'] 1114,33706345,Association of Breastfeeding and Child IQ Score at Age 5 Years.,"OBJECTIVE To evaluate whether breastfeeding and its duration are associated with a reduced risk of low IQ scores or other neurodevelopmental problems. METHODS We conducted a secondary analysis of two parallel multicenter, double-blinded randomized controlled trials in which participants with a singleton pregnancy and either subclinical hypothyroidism or hypothyroxinemia were treated with thyroxine or placebo. Our primary outcome was a low IQ score (less than 85 on the WPPSI-III [Wechsler Preschool and Primary Scale of Intelligence III] at age 5 years). Secondary outcomes included performance measures on other validated neurodevelopmental tests. Univariable and multivariable analyses were performed to evaluate the association between breastfeeding and neurodevelopmental outcomes. Stepwise backward proceeding linear and logistic regression models were used to develop the final adjusted models. RESULTS Of the 772 participants studied, 614 (80%) reported breastfeeding. Of these, 31% reported breastfeeding for less than 4 months, 19% for 4-6 months, 11% for 7-9 months, 15% for 10-12 months and 23% for more than 12 months. IQ scores were available for 756 children; mean age-5 scores were higher with any breastfeeding (96.7±15.1) than without (91.2±15.0, mean difference 5.5, 95% CI 2.8-8.2), and low IQ scores were less frequent with any breastfeeding (21.5%) than with no breastfeeding (36.2%, odds ratio 0.48, 95% CI 0.33-0.71). In adjusted analyses, breastfeeding remained associated with reduced odds of low IQ score (adjusted odds ratio [aOR] 0.62, 95% CI 0.41-0.93), and each additional month of breastfeeding was associated with lower odds of a low IQ scores (aOR 0.97, 95% CI 0.939-0.996). No significant associations between breastfeeding and other neurodevelopmental outcomes were identified in adjusted analyses. CONCLUSION Breastfeeding and its duration are associated with lower odds of low IQ score at age 5 years.",2021,"IQ scores were available for 756 children; mean age-5 scores were higher with any breastfeeding (96.7±15.1) than without (91.2±15.0, mean difference 5.5, 95% CI 2.8-8.2), and low IQ scores were less frequent with any breastfeeding (21.5%) than with no breastfeeding (36.2%, odds ratio 0.48, 95% CI 0.33-0.71).","['participants with a singleton pregnancy and either subclinical hypothyroidism or hypothyroxinemia were treated with', '772 participants studied, 614 (80%) reported breastfeeding']",['thyroxine or placebo'],"['WPPSI-III [Wechsler Preschool and Primary Scale of Intelligence III', 'low IQ score', 'breastfeeding and other neurodevelopmental outcomes', 'performance measures on other validated neurodevelopmental tests', 'IQ scores', 'low IQ scores', 'Association of Breastfeeding and Child IQ Score']","[{'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0271790', 'cui_str': 'Subclinical hypothyroidism'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]","[{'cui': 'C0040165', 'cui_str': 'levothyroxine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2828074', 'cui_str': 'WPPSI'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",772.0,0.403636,"IQ scores were available for 756 children; mean age-5 scores were higher with any breastfeeding (96.7±15.1) than without (91.2±15.0, mean difference 5.5, 95% CI 2.8-8.2), and low IQ scores were less frequent with any breastfeeding (21.5%) than with no breastfeeding (36.2%, odds ratio 0.48, 95% CI 0.33-0.71).","[{'ForeName': 'Beth A', 'Initials': 'BA', 'LastName': 'Plunkett', 'Affiliation': 'Departments of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois, University of Texas, Southwestern, Dallas, Texas, University of Utah Health Sciences Center, Salt Lake City, Utah, Wayne State University, Detroit, Michigan, Columbia University, New York, New York, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, University of Texas Medical Branch at Galveston, Galveston, Texas, University of Alabama at Birmingham, Birmingham, Alabama, Brown University, Providence, Rhode Island, University of Texas, Houston, Houston, Texas, Case Western Reserve University, Cleveland, Ohio, Oregon Health & Science University, Portland, OR, and University of Pittsburgh, Pittsburgh, Pennsylvania; and the George Washington University Biostatistics Center, Washington, DC; and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Mele', 'Affiliation': ''}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Casey', 'Affiliation': ''}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Varner', 'Affiliation': ''}, {'ForeName': 'Yoram', 'Initials': 'Y', 'LastName': 'Sorokin', 'Affiliation': ''}, {'ForeName': 'Uma M', 'Initials': 'UM', 'LastName': 'Reddy', 'Affiliation': ''}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Wapner', 'Affiliation': ''}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Thorp', 'Affiliation': ''}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Saade', 'Affiliation': ''}, {'ForeName': 'Alan T N', 'Initials': 'ATN', 'LastName': 'Tita', 'Affiliation': ''}, {'ForeName': 'Dwight J', 'Initials': 'DJ', 'LastName': 'Rouse', 'Affiliation': ''}, {'ForeName': 'Baha', 'Initials': 'B', 'LastName': 'Sibai', 'Affiliation': ''}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Mercer', 'Affiliation': ''}, {'ForeName': 'Jorge E', 'Initials': 'JE', 'LastName': 'Tolosa', 'Affiliation': ''}, {'ForeName': 'Steve N', 'Initials': 'SN', 'LastName': 'Caritis', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000004314'] 1115,33646146,Low Doses of Ionizing Radiation as a Treatment for Alzheimer's Disease: A Pilot Study.,"BACKGROUND In 2015, a patient in hospice with Alzheimer's disease (AD) was treated with ionizing radiation to her brain using repeated CT scans. Improvement in cognition, speech, movement, and appetite was observed. These improvements were so momentous that she was discharged from the hospice to a long-term care home. Based on this case, we conducted a pilot clinical trial to examine the effect of low-dose ionizing radiation (LDIR) in severe AD. OBJECTIVE To determine whether the previously reported benefits of LDIR in a single case with AD could be observed again in other cases with AD when the same treatments are given. METHODS In this single-arm study, four patients were treated with three consecutive treatments of LDIR, each spaced two weeks apart. Qualitative changes in communication and behavior with close relatives were observed and recorded. Quantitative measures of cognition and behavior were administered pre and post LDIR treatments. RESULTS Minor improvements on quantitative measures were noted in three of the four patients following treatment. However, the qualitative observations of cognition and behavior suggested remarkable improvements within days post-treatment, including greater overall alertness. One patient showed no change. CONCLUSION LDIR may be a promising, albeit controversial therapy for AD. Trials of patients with less severe AD, double-blind and placebo-controlled, should be carried out to determine the benefits of LDIR. Quantitative measures are needed that are sensitive to the remarkable changes induced by LDIR, such as biological markers of oxidative stress that are associated with AD.",2021,"However, the qualitative observations of cognition and behavior suggested remarkable improvements within days post-treatment, including greater overall alertness.","['patients with less severe AD', ""Alzheimer's Disease"", ""In 2015, a patient in hospice with Alzheimer's disease (AD"", 'severe AD']","['placebo', 'Ionizing Radiation', 'low-dose ionizing radiation (LDIR', 'ionizing radiation to her brain using repeated CT scans']","['cognition, speech, movement, and appetite', 'overall alertness', 'quantitative measures']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0019947', 'cui_str': 'Hospice'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0034538', 'cui_str': 'Ionizing radiation'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",4.0,0.161687,"However, the qualitative observations of cognition and behavior suggested remarkable improvements within days post-treatment, including greater overall alertness.","[{'ForeName': 'Jerry M', 'Initials': 'JM', 'LastName': 'Cuttler', 'Affiliation': 'Cuttler & Associates, Vaughan, ON, Canada.'}, {'ForeName': 'Eslam', 'Initials': 'E', 'LastName': 'Abdellah', 'Affiliation': 'Baycrest Health Sciences, Toronto, ON, Canada.'}, {'ForeName': 'Yael', 'Initials': 'Y', 'LastName': 'Goldberg', 'Affiliation': 'Baycrest Health Sciences, Toronto, ON, Canada.'}, {'ForeName': 'Sarmad', 'Initials': 'S', 'LastName': 'Al-Shamaa', 'Affiliation': 'Baycrest Health Sciences, Toronto, ON, Canada.'}, {'ForeName': 'Sean P', 'Initials': 'SP', 'LastName': 'Symons', 'Affiliation': 'Departments of Medical Imaging and Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Sandra E', 'Initials': 'SE', 'LastName': 'Black', 'Affiliation': 'Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON, Canada.'}, {'ForeName': 'Morris', 'Initials': 'M', 'LastName': 'Freedman', 'Affiliation': 'Baycrest Health Sciences, Toronto, ON, Canada.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-200620'] 1116,33650766,Validation of hair ethyl glucuronide using transdermal monitoring and self-reported alcohol use in women of childbearing potential.,"AIM The present study aimed to evaluate the validity of hair ethyl glucuronide concentrations compared with transdermal alcohol concentration and self-reported alcohol use. METHODS This trial included 25 adolescent and young adult females, aged 16-24, who reported at least one heavy drinking episode (≥4 drinks) in the two weeks prior to baseline. All participants were asked to wear an alcohol biosensor over a one-month prospective study. Detailed self-report of drinking behaviors was assessed weekly. Estimates of blood alcohol concentration were computed from self-report data using the National Highway and Transportation Safety Administration equation. Transdermal alcohol concentration and estimated blood alcohol concentration data were categorized into at-risk (>0.05 g/dL alcohol) and high-risk (>0.08 g/dL alcohol) drinking events. Hair ethyl glucuronide concentration, total number of drinking events, moderate (>0.05 g/dL) and high level (>0.08 g/dL) of transdermal alcohol concentration, and estimated blood alcohol concentration drinking events were analyzed with Spearman's rank correlation test for validity comparisons. RESULTS No significant correlations were found between hair ethyl glucuronide values and total number, and moderate or high levels of detected drinking events by estimated blood alcohol concentration or transdermal alcohol concentration. Total number of drinking events detected and number of drinking events >0.08 g/dL using estimated blood alcohol concentration and transdermal alcohol concentration methods were significantly correlated with each other (respectively, R = .33, P < .05; R = .42, P < .05). CONCLUSION Our findings indicate that, due to the number of false negatives, hair ethyl glucuronide concentrations should be used with caution for monitoring abstinence from alcohol use.",2021,"No significant correlations were found between hair ethyl glucuronide values and total number, and moderate or high levels of detected drinking events by estimated blood alcohol concentration or transdermal alcohol concentration.","['25 adolescent and young adult females, aged 16-24, who reported at least one heavy drinking episode (≥4 drinks) in the two weeks prior to baseline', 'women of childbearing potential']","['hair ethyl glucuronide', 'hair ethyl glucuronide concentrations']","['blood alcohol concentration and transdermal alcohol concentration methods', 'Transdermal alcohol concentration and estimated blood alcohol concentration data', 'blood alcohol concentration', 'blood alcohol concentration drinking events', 'Detailed self-report of drinking behaviors', 'hair ethyl glucuronide values and total number, and moderate or high levels of detected drinking events', 'blood alcohol concentration or transdermal alcohol concentration', 'Total number of drinking events detected and number of drinking events', 'Hair ethyl glucuronide concentration, total number of drinking events, moderate']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0556342', 'cui_str': 'Drinking episode'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C4082118', 'cui_str': 'Two weeks'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0298229', 'cui_str': 'Ethyl glucuronide'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]","[{'cui': 'C0684262', 'cui_str': 'Blood Alcohol Concentration'}, {'cui': 'C0040652', 'cui_str': 'Transdermal route'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0013124', 'cui_str': 'Drinking Behavior'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0298229', 'cui_str': 'Ethyl glucuronide'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0452428', 'cui_str': 'Drink'}]",25.0,0.01251,"No significant correlations were found between hair ethyl glucuronide values and total number, and moderate or high levels of detected drinking events by estimated blood alcohol concentration or transdermal alcohol concentration.","[{'ForeName': 'Andrea L', 'Initials': 'AL', 'LastName': 'Blair', 'Affiliation': 'Oklahoma State University Center for Health Sciences, National Center for Wellness & Recovery, Tulsa, OK, USA.'}, {'ForeName': 'Ashleigh L', 'Initials': 'AL', 'LastName': 'Chiaf', 'Affiliation': 'Oklahoma State University Center for Health Sciences, National Center for Wellness & Recovery, Tulsa, OK, USA.'}, {'ForeName': 'Erica K', 'Initials': 'EK', 'LastName': 'Crockett', 'Affiliation': 'Oklahoma State University Center for Health Sciences, National Center for Wellness & Recovery, Tulsa, OK, USA.'}, {'ForeName': 'Tracy Kent', 'Initials': 'TK', 'LastName': 'Teague', 'Affiliation': 'Integrative Immunology Lab, Department of Surgery, University of Oklahoma-Tulsa, Tulsa, OK, USA.'}, {'ForeName': 'Julie M', 'Initials': 'JM', 'LastName': 'Croff', 'Affiliation': 'Oklahoma State University Center for Health Sciences, National Center for Wellness & Recovery, Tulsa, OK, USA.'}]",Neuropsychopharmacology reports,['10.1002/npr2.12151'] 1117,33648834,A randomized trial to examine the impact of food on pharmacokinetics of 4-phenylbutyrate and change in amino acid availability after a single oral administration of sodium 4-phenylbutyrarte in healthy volunteers.,"Urea cycle disorders (UCDs), inborn errors of hepatocyte metabolism, result in the systemic accumulation of ammonia to toxic levels. Sodium 4-phenylbutyrate (NaPB), a standard therapy for UCDs for over 20 years, generates an alternative pathway of nitrogen deposition through glutamine consumption. Administration during or immediately after a meal is the accepted use of NaPB. However, this regimen is not based on clinical evidence. Here, an open-label, single-dose, five-period crossover study was conducted in healthy adults to investigate the effect of food on the pharmacokinetics of NaPB and determine any subsequent change in amino acid availability. Twenty subjects were randomized to one of four treatment groups. Following an overnight fast, NaPB was administered orally at 4.3 g/m 2 (high dose, HD) or 1.4 g/m 2 (low dose, LD) either 30 min before or just after breakfast. At both doses, compared with post-breakfast administration, pre-breakfast administration significantly increased systemic exposure of PB and decreased plasma glutamine availability. Pre-breakfast LD administration attenuated plasma glutamine availability to the same extent as post-breakfast HD administration. Regardless of the regimen, plasma levels of branched-chain amino acids (BCAA) were decreased below baseline in a dose-dependent manner. In conclusion, preprandial oral administration of NaPB maximized systemic exposure of the drug and thereby its potency to consume plasma glutamine. This finding may improve poor medication compliance because of the issues with odor, taste, and pill burden of NaPB and reduce the risk of BCAA deficiency in NaPB therapy.",2021,"Regardless of the regimen, plasma levels of branched-chain amino acids (BCAA) were decreased below baseline in a dose-dependent manner.","['healthy volunteers', 'Twenty subjects', 'healthy adults']","['Sodium 4-phenylbutyrate (NaPB', 'sodium 4-phenylbutyrarte']","['Urea cycle disorders (UCDs), inborn errors of hepatocyte metabolism, result in the systemic accumulation of ammonia to toxic levels', 'systemic exposure of PB and decreased plasma glutamine availability', 'plasma glutamine availability', 'plasma levels of branched-chain amino acids (BCAA']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0718066', 'cui_str': 'sodium phenylbutyrate'}, {'cui': 'C1834304', 'cui_str': 'Hereditary Neuralgic Amyotrophy'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}]","[{'cui': 'C0154246', 'cui_str': 'Disorder of the urea cycle metabolism'}, {'cui': 'C0227525', 'cui_str': 'Hepatic parenchymal cell'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0002607', 'cui_str': 'Ammonia'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0002521', 'cui_str': 'Branched-chain amino acid'}]",20.0,0.0594796,"Regardless of the regimen, plasma levels of branched-chain amino acids (BCAA) were decreased below baseline in a dose-dependent manner.","[{'ForeName': 'Shuhei', 'Initials': 'S', 'LastName': 'Osaka', 'Affiliation': 'Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Science, The University of Tokyo, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Nakano', 'Affiliation': 'Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Science, The University of Tokyo, Japan; Department of Pediatrics, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Tadahaya', 'Initials': 'T', 'LastName': 'Mizuno', 'Affiliation': 'Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Science, The University of Tokyo, Japan.'}, {'ForeName': 'Yuka', 'Initials': 'Y', 'LastName': 'Hiraoka', 'Affiliation': 'Laboratory of Proteomics and Biomolecular Science, Research Support Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Minowa', 'Affiliation': 'Department of Pediatrics, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Saeko', 'Initials': 'S', 'LastName': 'Hirai', 'Affiliation': 'Department of Pediatrics, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Ayumu', 'Initials': 'A', 'LastName': 'Mizutani', 'Affiliation': 'Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Science, The University of Tokyo, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Sabu', 'Affiliation': 'Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Science, The University of Tokyo, Japan.'}, {'ForeName': 'Yoshiki', 'Initials': 'Y', 'LastName': 'Miura', 'Affiliation': 'Laboratory of Proteomics and Biomolecular Science, Research Support Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Shimizu', 'Affiliation': 'Department of Pediatrics, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Kusuhara', 'Affiliation': 'Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Science, The University of Tokyo, Japan.'}, {'ForeName': 'Mitsuyoshi', 'Initials': 'M', 'LastName': 'Suzuki', 'Affiliation': 'Department of Pediatrics, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hisamitsu', 'Initials': 'H', 'LastName': 'Hayashi', 'Affiliation': 'Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Science, The University of Tokyo, Japan. Electronic address: hayapi@mol.f.u-tokyo.ac.jp.'}]",Molecular genetics and metabolism,['10.1016/j.ymgme.2021.02.002'] 1118,33647246,"Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.","BACKGROUND High systolic blood pressure after successful endovascular therapy for acute ischaemic stroke is associated with increased risk of intraparenchymal haemorrhage. However, no randomised controlled trials are available to guide optimal management. We therefore aimed to assess whether an intensive systolic blood pressure target resulted in reduced rates of intraparenchymal haemorrhage compared with a standard systolic blood pressure target. METHODS We did a multicentre, open-label, randomised controlled trial at four academic hospital centres in France. Eligible individuals were adults (aged ≥18 years) with an acute ischaemic stroke due to a large-vessel occlusion that was successfully treated with endovascular therapy. Patients were randomly assigned (1:1) to either an intensive systolic blood pressure target group (100-129 mm Hg) or a standard care systolic blood pressure target group (130-185 mm Hg), by means of a central web-based procedure, stratified by centre and intravenous thrombolysis use before endovascular therapy. In both groups, the target systolic blood pressure had to be achieved within 1 h after randomisation and maintained for 24 h with intravenous blood pressure lowering treatments. The primary outcome was the rate of radiographic intraparenchymal haemorrhage at 24-36 h and the primary safety outcome was the occurrence of hypotension. Analyses were done on an intention-to-treat basis. BP-TARGET is registered with ClinicalTrials.gov, number NCT03160677, and the trial is closed at all participating sites. FINDINGS Between June 21, 2017, and Sept 27, 2019, 324 patients were enrolled in the four participating stroke centres: 162 patients were randomly assigned to the intensive target group and 162 to the standard target group. Four (2%) of 162 patients were excluded from the intensive target group and two (1%) of 162 from the standard target group for withdrawal of consent or legal reasons. The mean systolic blood pressure during the first 24 h after reperfusion was 128 mm Hg (SD 11) in the intensive target group and 138 mm Hg (17) in the standard target group. The primary outcome was observed in 65 (42%) of 154 patients in the intensive target group and 68 (43%) of 157 in the standard target group on brain CT within 24-36 h after reperfusion] (adjusted odds ratio 0·96, 95% CI 0·60-1·51; p=0·84). Hypotensive events were not significantly different between both groups and occurred in 12 (8%) of 158 patients in the intensive target and five (3%) of 160 in the standard target group. Mortality within the first week after randomisation occurred in 11 (7%) of 158 patients in the intensive target group and in seven (4%) of 160 in the standard target group. INTERPRETATION An intensive systolic blood pressure target of 100-129 mm Hg after successful endovascular therapy did not reduce radiographic intraparenchymal haemorrhage rates at 24-36 h as compared with a standard care systolic blood pressure target of 130-185 mm Hg. Notably, these results are applicable to patients with successful reperfusion and systolic blood pressures of more than 130 mm Hg at the end of procedure. Further studies are needed to understand the association between blood pressure and outcomes after reperfusion. FUNDING French Health Ministry.",2021,"Mortality within the first week after randomisation occurred in 11 (7%) of 158 patients in the intensive target group and in seven (4%) of 160 in the standard target group. ","['acute ischaemic stroke (BP-TARGET', '324 patients were enrolled in the four participating stroke centres: 162 patients', 'four academic hospital centres in France', 'acute ischaemic stroke', 'Eligible individuals were adults (aged ≥18 years) with an acute ischaemic stroke due to a large-vessel occlusion that was successfully treated with', '162 patients were excluded from the intensive target group and two (1%) of 162 from the standard target group for withdrawal of consent or legal reasons', 'Between June 21, 2017, and Sept 27, 2019']","['endovascular therapy', 'intensive blood pressure lowering after successful endovascular therapy', 'intensive systolic blood pressure target group (100-129 mm Hg) or a standard care systolic blood pressure target group']","['mean systolic blood pressure', 'Mortality', 'Hypotensive events', 'target systolic blood pressure', 'radiographic intraparenchymal haemorrhage rates', 'rate of radiographic intraparenchymal haemorrhage', 'rates of intraparenchymal haemorrhage', 'occurrence of hypotension', 'systolic blood pressures', 'brain CT']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C4517713', 'cui_str': '324'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C5191360', 'cui_str': '162'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0225990', 'cui_str': 'Large blood vessel structure'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C1301860', 'cui_str': 'Legal'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1277632', 'cui_str': 'Target systolic blood pressure'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0412585', 'cui_str': 'Computerized axial tomography of brain'}]",324.0,0.308852,"Mortality within the first week after randomisation occurred in 11 (7%) of 158 patients in the intensive target group and in seven (4%) of 160 in the standard target group. ","[{'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Mazighi', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; Université de Paris, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: mmazighi@for.paris.'}, {'ForeName': 'Sebastien', 'Initials': 'S', 'LastName': 'Richard', 'Affiliation': 'Department of Neurology, Stroke Unit, University Hospital of Nancy, Nancy, France; Université de Lorraine, INSERM, Nancy, France.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Lapergue', 'Affiliation': 'Department of Neurology, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Sibon', 'Affiliation': 'Stroke Unit, CHU Bordeaux, Université de Bordeaux, Bordeaux, France.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Gory', 'Affiliation': 'Department of Diagnostic and Therapeutic Neuroradiology, CHRU-Nancy, Université de Lorraine, Nancy, France; Université de Lorraine, IADI, INSERM U1254, Nancy, France.'}, {'ForeName': 'Jerome', 'Initials': 'J', 'LastName': 'Berge', 'Affiliation': 'Interventional and Diagnostic Neuroradiology Department, Bordeaux University Hospital, Bordeaux, France.'}, {'ForeName': 'Arturo', 'Initials': 'A', 'LastName': 'Consoli', 'Affiliation': 'Department of Neuroradiology, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Labreuche', 'Affiliation': 'Department of Biostatistics, University Lille, CHU de Lille, Lille, France.'}, {'ForeName': 'Jean-Marc', 'Initials': 'JM', 'LastName': 'Olivot', 'Affiliation': 'Stroke Unit, Toulouse University Hospital, Toulouse, France.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Broderick', 'Affiliation': 'Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Duhamel', 'Affiliation': 'Department of Biostatistics, University Lille, CHU de Lille, Lille, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Touze', 'Affiliation': 'Department of Neurology, Université Caen Normandie, INSERM U1237, CHU Caen Normandie, Caen, France.'}, {'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': ""Department of Neurology, University of Missouri, Women's and Children's Hospital, Columbia, MO, USA.""}, {'ForeName': 'Amélie', 'Initials': 'A', 'LastName': 'Yavchitz', 'Affiliation': 'Department of Clinical Research, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Escalard', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Desilles', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; Université de Paris, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Hocine', 'Initials': 'H', 'LastName': 'Redjem', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Stanislas', 'Initials': 'S', 'LastName': 'Smajda', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Fahed', 'Affiliation': 'Division of Neurology and Department of Medical Imaging, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Solène', 'Initials': 'S', 'LastName': 'Hébert', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Maïer', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; Université de Paris, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Delvoye', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Perrine', 'Initials': 'P', 'LastName': 'Boursin', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Malek Ben', 'Initials': 'MB', 'LastName': 'Maacha', 'Affiliation': 'Department of Clinical Research, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Obadia', 'Affiliation': 'Stroke Unit, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Candice', 'Initials': 'C', 'LastName': 'Sabben', 'Affiliation': 'Stroke Unit, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Blanc', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Savatovsky', 'Affiliation': 'Diagnostic Imaging and Radiology Department, Rothschild Foundation Hospital, Paris, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Piotin', 'Affiliation': 'Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Neurology,['10.1016/S1474-4422(20)30483-X'] 1119,33651438,MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.,"AIM To evaluate whether neuroimaging-delineated regions of hypothalamic injury are associated with a differential treatment response to a glucagon-like peptide-1 receptor agonist (GLP-1RA) in patients with hypothalamic obesity (HO). MATERIALS AND METHODS We performed a prespecified secondary analysis of a randomized, multicentre, double-blind, placebo-controlled trial of people aged 10-25 years with hypothalamic injury and HO randomized to the GLP-1RA exenatide once-weekly (ExQW) or placebo for 36 weeks. Subjects underwent MRI prior to enrolment and the degree of hypothalamic damage was assessed using an integrative hypothalamic lesion score (HLS). Mammillary body (MB) damage was specifically determined. The main clinical endpoints were % change in body mass index (BMI) and change in % body fat. Nested ANCOVA models including a treatment × imaging measure interaction were compared using partial F-tests to assess whether the effect of ExQW treatment differed by severity of hypothalamic damage. RESULTS Complete data were available in 35/42 randomized participants (placebo, n = 15; ExQW, n = 20). ExQW-treated patients with worse HLS or bilateral MB damage had greater reductions in % body fat at 36 weeks (interaction coefficient estimates for HLS: -0.9%, 95% CI -1.6% to -0.2%, p = .02; for MB damage: -7.4%, 95% CI -10.1% to -4.7%, p < .001, respectively) but not for BMI % change. Similarly, patients with more damaged and smaller MB cross-sectional areas had greater reductions in % body fat following ExQW (interaction coefficient estimate 0.3%, 95% CI 0.2%-0.4%, p < .001). CONCLUSIONS In people with HO, greater hypothalamic damage as determined by MRI, in particular MB injury, is associated with greater reductions in adiposity following GLP-1RA treatment.",2021,"ExQW-treated patients with worse HLS or bilateral MB damage had greater reductions in % body fat at 36-weeks (interaction coefficient estimates for HLS: -0.9%, 95% CI -1.6% to 0.2%, P=0.02; for MB damage: -7.4%, 95% CI -10.1% to -4.7%, P<0.001, respectively) but not for BMI % change.","['10-25-year-old people with hypothalamic injury and HO randomized to', 'people with hypothalamic obesity', 'patients with hypothalamic obesity (HO']","['GLP-1RA exenatide (ExQW) or placebo', 'placebo', 'glucagon-like peptide receptor agonist (GLP-1RA']","['hypothalamic damage', 'BMI and change in % body fat', 'adiposity', 'integrative hypothalamic lesion score (HLS', 'Mammillary body (MB) damage']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0442857', 'cui_str': 'Hypothalamic injury'}, {'cui': 'C0271885', 'cui_str': 'Hypothalamic obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0018301', 'cui_str': 'Guadeloupe island'}, {'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4042844', 'cui_str': 'GLPR Proteins'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0020663', 'cui_str': 'Hypothalamic structure'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0024670', 'cui_str': 'Mammillary body structure'}]",,0.639815,"ExQW-treated patients with worse HLS or bilateral MB damage had greater reductions in % body fat at 36-weeks (interaction coefficient estimates for HLS: -0.9%, 95% CI -1.6% to 0.2%, P=0.02; for MB damage: -7.4%, 95% CI -10.1% to -4.7%, P<0.001, respectively) but not for BMI % change.","[{'ForeName': 'Francisco A', 'Initials': 'FA', 'LastName': 'Perez', 'Affiliation': ""Department of Radiology, Seattle Children's and University of Washington, Seattle, Washington, USA.""}, {'ForeName': 'Clinton', 'Initials': 'C', 'LastName': 'Elfers', 'Affiliation': ""Seattle Children's Research Institute, Seattle, Washington, USA.""}, {'ForeName': 'Jack A', 'Initials': 'JA', 'LastName': 'Yanovski', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Ashley H', 'Initials': 'AH', 'LastName': 'Shoemaker', 'Affiliation': 'Division of Pediatric Endocrinology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'M Jennifer', 'Initials': 'MJ', 'LastName': 'Abuzzahab', 'Affiliation': ""McNeely Pediatric Diabetes Center and Endocrinology Clinic, Children's Minnesota, St. Paul, Minnesota, USA.""}, {'ForeName': 'Christian L', 'Initials': 'CL', 'LastName': 'Roth', 'Affiliation': ""Seattle Children's Research Institute, Seattle, Washington, USA.""}]","Diabetes, obesity & metabolism",['10.1111/dom.14366'] 1120,33652129,Adherence rates during a randomized controlled trial evaluating the use of blinded acetaminophen and ibuprofen in children with asthma.,"BACKGROUND/AIMS When conducting clinical trials comparing over-the-counter (OTC) medications, the wide availability of these treatments are a potential challenge to maintaining study integrity. We seek to describe adherence to a study protocol involving widely available OTC medications. METHODS To prospectively evaluate associations between acetaminophen use and asthma in 300 children aged 1-5 years, we conducted a double blind, randomized, controlled trial where parents administered blinded forms of either acetaminophen or ibuprofen as needed to their children over a 48 week period. Written and verbal instructions encouraged the exclusive use of the blinded study medication and discouraged OTC use. Adherence was determined by evaluating the frequency of use of per-protocol blinded study medication compared to off-protocol use of OTC medications. RESULTS 4195 doses of acetaminophen or ibuprofen were received by children during the study which included 3664 doses (87.3%) of blinded study medication adhering to the protocol and 531 doses (12.7%) of OTC products deviating from the protocol with better adherence among those randomized to ibuprofen as compared to acetaminophen (89.5% vs. 85.5% of doses, p < 0.01). Individually, 227 participants (75.7%) remained fully adherent by not receiving any OTC medications. Pre-study preference for either acetaminophen or ibuprofen by the participants' families was not associated with differential rates of adherence to the blinded medication. CONCLUSION This parallel study demonstrated greater than 85% of acetaminophen or ibuprofen doses were blinded study medications adhering to the protocol while less than 15% were OTC deviations from the protocol. This successfully implemented study design provides a template to comparatively evaluate these and other OTC medications.",2021,"Pre-study preference for either acetaminophen or ibuprofen by the participants' families was not associated with differential rates of adherence to the blinded medication. ","['227 participants (75.7%) remained fully adherent by not receiving any OTC medications', '300 children aged 1-5\u202fyears', 'children with asthma']","['acetaminophen', 'acetaminophen or ibuprofen', 'ibuprofen', 'acetaminophen and ibuprofen']","['OTC deviations', 'Adherence', 'Adherence rates']","[{'cui': 'C0013231', 'cui_str': 'Drugs, Non-Prescription'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}]","[{'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}]","[{'cui': 'C0013231', 'cui_str': 'Drugs, Non-Prescription'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",300.0,0.306415,"Pre-study preference for either acetaminophen or ibuprofen by the participants' families was not associated with differential rates of adherence to the blinded medication. ","[{'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Sheehan', 'Affiliation': ""Boston Children's Hospital, Division of Allergy and Immunology, Harvard Medical School, Boston, MA, United States of America; Children's National Hospital, Division of Allergy and Immunology, George Washington University School of Medicine and Health Sciences, Washington DC, United States of America.""}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Paul', 'Affiliation': 'Penn State College of Medicine, Department of Pediatrics, Hershey, PA, United States of America.'}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Mauger', 'Affiliation': 'Penn State College of Medicine, Department of Public Health Sciences, Hershey, PA, United States of America.'}, {'ForeName': 'James N', 'Initials': 'JN', 'LastName': 'Moy', 'Affiliation': 'Stroger Hospital of Cook County, Department of Pediatrics, Rush University Medical Center, Chicago, IL, United States of America.'}, {'ForeName': 'Stanley J', 'Initials': 'SJ', 'LastName': 'Szefler', 'Affiliation': ""Children's Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, United States of America.""}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Jackson', 'Affiliation': 'University of Wisconsin School of Medicine and Public Health, Section of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Madison, WI, United States of America.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Fitzpatrick', 'Affiliation': 'Emory University, Department of Pediatrics, Atlanta, GA, United States of America.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Cabana', 'Affiliation': 'University of California, San Francisco, Department of Pediatrics, San Francisco, CA, United States of America.'}, {'ForeName': 'Ronina', 'Initials': 'R', 'LastName': 'Covar', 'Affiliation': 'National Jewish Health, Department of Pediatrics, Denver, CO, United States of America.'}, {'ForeName': 'Rachel G', 'Initials': 'RG', 'LastName': 'Robison', 'Affiliation': ""Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Allergy and Immunology, Chicago, IL, United States of America.""}, {'ForeName': 'Wanda', 'Initials': 'W', 'LastName': 'Phipatanakul', 'Affiliation': ""Boston Children's Hospital, Division of Allergy and Immunology, Harvard Medical School, Boston, MA, United States of America. Electronic address: wanda.phipatanakul@childrens.harvard.edu.""}]",Contemporary clinical trials,['10.1016/j.cct.2021.106334'] 1121,33657912,Effect of physician prescribed information on hospital readmission and death after discharge among patients with health failure: A randomized controlled trial.,"In order to understand if a physician prescribed medical information changes, the number of hospital readmission, and death among the heart failure patients. A 12-month randomized controlled trial was conducted (December 2013-2014). Totally, 120 patients were randomly allocated into two groups of intervention ( n  = 60) and control ( n  = 60). Accordingly, the control group was given the routine oral information by the nurse or physician, and the intervention group received the Information Prescription (IP) prescribed by the physician as well as the routine oral information. The data was collected via telephone interviews with the follow-up intervals of 6 and 12 months, and also for 1 year after the discharge. The patients with the median age of (IQR) 69.5 years old (19.8) death upon adjusting a Cox survival model, [RR = 0.67, 95%CI: 0.46-0.97]. Few patients died during 1 year in the intervention group compared to the controls (7 vs 15) [RR = 0.47, 95%CI: 0.20-1.06]. During a period of 6-month follow-up there was not statistically significant on death and readmission between two groups. Physician prescribed information was clinically and statistically effective on the reduction of death and hospital readmission rates among the HF patients in long term follow-up.",2021,Physician prescribed information was clinically and statistically effective on the reduction of death and hospital readmission rates among the HF patients in long term follow-up.,"['patients with the median age of (IQR) 69.5\u2009years old (19.8) death upon adjusting a Cox survival model, [RR\u2009=\u20090.67, 95%CI: 0.46-0.97', 'heart failure patients', '120 patients', 'patients with health failure']",['physician prescribed information'],"['death and readmission', 'death and hospital readmission rates', 'hospital readmission and death', 'number of hospital readmission, and death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0033551', 'cui_str': 'Prostaglandin synthase'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C4517472', 'cui_str': '0.67'}, {'cui': 'C4517460', 'cui_str': '0.46'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]","[{'cui': 'C0031831', 'cui_str': 'Physician'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",120.0,0.0284513,Physician prescribed information was clinically and statistically effective on the reduction of death and hospital readmission rates among the HF patients in long term follow-up.,"[{'ForeName': 'Faranak', 'Initials': 'F', 'LastName': 'Kazemi Majd', 'Affiliation': 'Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Vahideh Zarea', 'Initials': 'VZ', 'LastName': 'Gavgani', 'Affiliation': 'Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Golmohammadi', 'Affiliation': 'Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Jafari-Khounigh', 'Affiliation': 'Tabriz University of Medical Sciences, Tabriz, Iran.'}]",Health informatics journal,['10.1177/1460458221996409'] 1122,33657675,Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial.,"BACKGROUND AND PURPOSE The aim was to study the effect of intravenous alteplase on the development of post-stroke depression (PSD) in acute stroke patients, and to identify predictors of PSD. METHODS This post hoc analysis included patients with unknown onset stroke randomized to treatment with alteplase or placebo in the WAKE-UP trial (ClinicalTrials.gov number, NCT01525290), in whom a composite end-point of PSD was defined as a Beck Depression Inventory ≥10, medication with an antidepressant, or depression recorded as an adverse event. Multiple logistic regression was used to identify predictors of PSD at 90 days. Structural equation modelling was applied to assess the indirect effect of thrombolysis on PSD mediated by the modified Rankin Scale. RESULTS Information on the composite end-point was available for 438 of 503 randomized patients. PSD was present in 96 of 224 (42.9%) patients in the alteplase group and 115 of 214 (53.7%) in the placebo group (odds ratio 0.63; 95% confidence interval 0.43-0.94; p = 0.022; adjusted for age and National Institutes of Health Stroke Scale at baseline). Prognostic factors associated with PSD included baseline medication with antidepressants, higher lesion volume, history of depression and assignment to placebo. While 65% of the effect of thrombolysis on PSD were caused directly, 35% were mediated by an improvement of the mRS. CONCLUSIONS Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which were only partially explained by reduced functional disability. Predictors of PSD including history and clinical characteristics may help in identifying patients at risk of PSD.",2021,"CONCLUSIONS Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which was only partially explained by reduced functional disability.","['patients with acute stroke', 'acute stroke patients', 'patients with unknown onset stroke']","['alteplase or placebo', 'intravenous alteplase', 'placebo']","['functional disability', 'rates of depression', 'Beck Depression Inventory BDI ≥10, medication with an antidepressant, or depression recorded as an adverse event', 'post-stroke depression', 'PSD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0006448', 'cui_str': 'Burundi'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2938940', 'cui_str': 'Post stroke depression'}]",503.0,0.373695,"CONCLUSIONS Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which was only partially explained by reduced functional disability.","[{'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Königsberg', 'Affiliation': 'Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Sehner', 'Affiliation': 'Institut für Medizinische Biometrie und Epidemiologie, Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Sönke', 'Initials': 'S', 'LastName': 'Arlt', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Evangelical Hospital Alsterdorf, Hamburg, Germany.'}, {'ForeName': 'Bastian', 'Initials': 'B', 'LastName': 'Cheng', 'Affiliation': 'Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Claus Z', 'Initials': 'CZ', 'LastName': 'Simonsen', 'Affiliation': 'Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Florent', 'Initials': 'F', 'LastName': 'Boutitie', 'Affiliation': ""Service de Biostatistique, Centre d'Investigation Clinique, Hospices Civils de Lyon, Lyon, France.""}, {'ForeName': 'Joaquin', 'Initials': 'J', 'LastName': 'Serena', 'Affiliation': ""Department of Neurology, Hospital Universitario Dr Josep Trueta, Institut d'Investigació Biomèdica de Girona, Girona, Spain.""}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Thijs', 'Affiliation': 'Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Ebinger', 'Affiliation': 'Centrum für Schlaganfallforschung Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Endres', 'Affiliation': 'Centrum für Schlaganfallforschung Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Jochen B', 'Initials': 'JB', 'LastName': 'Fiebach', 'Affiliation': 'Centrum für Schlaganfallforschung Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Lemmens', 'Affiliation': 'Department of Neurology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Keith W', 'Initials': 'KW', 'LastName': 'Muir', 'Affiliation': 'Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Nighoghossian', 'Affiliation': 'Department of Neurology, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'Salvador', 'Initials': 'S', 'LastName': 'Pedraza', 'Affiliation': ""Department of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut d'Investgació Biomèdica de Girona (IDIBGI), Girona, Spain.""}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Gerloff', 'Affiliation': 'Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Götz', 'Initials': 'G', 'LastName': 'Thomalla', 'Affiliation': 'Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of neurology,['10.1111/ene.14797'] 1123,33657674,Sociability-based fitness approach in Parkinson's disease: Comparison with conventional rehabilitation.,"BACKGROUND AND PURPOSE The effect of a sociability-based fitness approach on parkinsonian disability in patients with Parkinson's disease (PD) was assessed. METHODS Eighty patients diagnosed with PD were randomly assigned to either the group-based rehabilitation (GBR) group (n = 40) or the individual-based rehabilitation (IBR) group (n = 40). The primary outcome was the difference between the two groups in the mean change from baseline to post-training in the total score on the Unified Parkinson's Disease Rating Scale (UPDRS). The secondary outcomes included the change in mental status and the difference in the mean change from baseline to month 3 and month 6 in the total score on the UPDRS. RESULTS The mean (±SD) UPDRS scores were 72.0 ± 21.0 in the GBR group and 72.1 ± 18.6 in the IBR group. The UPDRS scores from baseline to post-training were 22.8 ± 13.5 in the GBR group and 10.9 ± 8.8 in the IBR group (difference 11.8 points; 95% confidence interval [CI] 5.0-18.6; p = 0.001). The difference between the groups from baseline to month 3 (difference 10.06 points; 95% CI 3.3-16.8) and the difference between the groups from baseline to month 6 (difference 11.7 points; 95% CI 4.9-18.5) were also significant (p = 0.004 and p = 0.001, respectively). The scores of cognitive function and depression had not changed significantly. CONCLUSIONS Patients receiving GBR demonstrated significant improvements in parkinsonian symptoms, suggesting that the sociability-based fitness can be applied to clinical treatment by sustaining the motivation in PD.",2021,"The UPDRS scores from baseline to post-training were 22.8±13.5 in the GBR group and 10.9±8.8 in the IBR group (difference, 11.8 points; 95% confidence interval [CI], 5.0 to 18.6; P=0.001).","[""Parkinson's disease"", ""patients with Parkinson's disease (PD"", 'Eighty patients diagnosed with PD']","['Sociability-based fitness approach', 'group-based rehabilitation (GBR) group (n=40) or the individual-based rehabilitation (IBR', 'conventional rehabilitation', 'sociability-based fitness approach']","['total score on the UPDRS', 'UPDRS scores', 'mean (±Standard Deviation', 'parkinsonian symptoms', 'scores of cognitive function and depression', 'parkinsonian disability', ""mean change from baseline to post-training in the total score on the Unified Parkinson's Disease Rating Scale (UPDRS""]","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0558182', 'cui_str': 'Ability to interact with others'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0242422', 'cui_str': 'Parkinsonism'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",80.0,0.0784878,"The UPDRS scores from baseline to post-training were 22.8±13.5 in the GBR group and 10.9±8.8 in the IBR group (difference, 11.8 points; 95% confidence interval [CI], 5.0 to 18.6; P=0.001).","[{'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Mitsui', 'Affiliation': 'Department of Neurology, Tokushima National Hospital National Hospital Organization, Tokushima, Japan.'}, {'ForeName': 'Yoshiharu', 'Initials': 'Y', 'LastName': 'Arii', 'Affiliation': 'Department of Neurology, Tokushima National Hospital National Hospital Organization, Tokushima, Japan.'}, {'ForeName': 'Ai', 'Initials': 'A', 'LastName': 'Tsukamoto', 'Affiliation': 'Department of Neurology, Tokushima National Hospital National Hospital Organization, Tokushima, Japan.'}, {'ForeName': 'Koichiro', 'Initials': 'K', 'LastName': 'Taniguchi', 'Affiliation': 'Department of Neurology, Tokushima National Hospital National Hospital Organization, Tokushima, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Mabuchi', 'Affiliation': 'Department of Rehabilitation, Tokushima National Hospital, National Hospital Organization, Tokushima, Japan.'}, {'ForeName': 'Arisa', 'Initials': 'A', 'LastName': 'Shimizu', 'Affiliation': 'Department of Clinical Research, Tokushima National Hospital National Hospital Organization, Tokushima, Japan.'}, {'ForeName': 'Nichika', 'Initials': 'N', 'LastName': 'Sumitomo', 'Affiliation': 'Department of Clinical Research, Tokushima National Hospital National Hospital Organization, Tokushima, Japan.'}, {'ForeName': 'Yukiko Kuroda', 'Initials': 'YK', 'LastName': 'Maki', 'Affiliation': 'Department of Clinical Research, Tokushima National Hospital National Hospital Organization, Tokushima, Japan.'}]",European journal of neurology,['10.1111/ene.14798'] 1124,33656380,Training executive functions using an adaptive procedure over 21 days (10 training sessions) and an active control group.,"The degree to which executive function (EF) abilities (including working memory [WM], inhibitory control [IC], and cognitive flexibility [CF]) can be enhanced through training is an important question; however, research in this area is inconsistent. Previous cognitive training studies largely agree that training leads to improvements in the trained task, but the generalisability of this improvement to other related tasks remains controversial. In this article, we present a pre-registered experiment that used an adaptive training procedure to examine whether EFs can be enhanced through cognitive training, and directly compared the efficacy and generalisability across sub-components of EF using training programmes that target WM, IC, or CF versus an active control group. Participants ( n  = 160) first completed a battery of tasks that assessed EFs, then were randomly assigned to one of the four training groups, and completed an adaptive procedure over 21 days (10 training sessions) that targeted a specific sub-component of EF (or was comparatively engaging and challenging, but did not train a specific EF). At post-test, participants returned to the lab to repeat the battery of EF tasks. Results revealed robust direct training effects (i.e., on trained task), but limited evidence to support near (i.e., same EF, different task) and far (i.e., different EF and task) transfer effects. Where indirect training benefits emerged, the effects were more readily attributable to the overlapping training/assessment task routines, rather than more general enhancements to the underlying cognitive processes or neural circuits.",2021,"Results revealed robust direct training effects (i.e. on trained task), but limited evidence to support near (i.e. same EF, different task) and far (i.e. different EF and task) transfer effects.",['Participants (n=160) first completed a battery of tasks that assessed EFs'],"['specific sub-component of EF (or was comparatively engaging and challenging, but did not train a specific EF']","['degree to which executive function (EF) abilities (including working memory (WM), inhibitory control (IC), and cognitive flexibility (CF']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}]",,0.01874,"Results revealed robust direct training effects (i.e. on trained task), but limited evidence to support near (i.e. same EF, different task) and far (i.e. different EF and task) transfer effects.","[{'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'De Lillo', 'Affiliation': 'School of Psychology, Keynes College, University of Kent, Kent, UK.'}, {'ForeName': 'Victoria Ea', 'Initials': 'VE', 'LastName': 'Brunsdon', 'Affiliation': 'School of Psychology, Keynes College, University of Kent, Kent, UK.'}, {'ForeName': 'Elisabeth Ef', 'Initials': 'EE', 'LastName': 'Bradford', 'Affiliation': 'School of Psychology, Keynes College, University of Kent, Kent, UK.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Gasking', 'Affiliation': 'School of Psychology, Keynes College, University of Kent, Kent, UK.'}, {'ForeName': 'Heather J', 'Initials': 'HJ', 'LastName': 'Ferguson', 'Affiliation': 'School of Psychology, Keynes College, University of Kent, Kent, UK.'}]",Quarterly journal of experimental psychology (2006),['10.1177/17470218211002509'] 1125,33825030,Intraocular pressure responses to walking with surgical and FFP2/N95 face masks in primary open-angle glaucoma patients.,"PURPOSE The use of face mask is globally recommended as a preventive measure against COVID-19. However, the intraocular pressure (IOP) changes caused by face masks remain unknown. The objective of this study was to assess the impact of wearing surgical and FFP2/N95 face masks during a 400-m walking protocol on IOP in primary open-angle glaucoma (POAG) patients. METHODS Thirteen subjects diagnosed of POAG (21 eyes) were enrolled in this study. IOP was measured at baseline, during the 400-m walking protocol and after 5 min of passive recovery while POAG patients wore a surgical mask, FFP2/N95 mask and no mask in randomized order. From the 21 POAG eyes, we analyzed the IOP changes caused by physical exercise with two face masks and without wearing any face mask. RESULTS At rest (baseline and recovery measurements), the use of the different face masks did not affect IOP levels (mean differences ranging from 0.1 to 0.6 mmHg). During physical activity, wearing an FFP2/N95 mask caused a small (mean differences ranging from 1 to 2 mmHg), but statistically significant, IOP rise in comparison to both the surgical mask and control conditions (Cohen's d = 0.63 and 0.83, respectively). CONCLUSION Face masks must be used to minimize the risk of SARS-CoV-2 transmission, and POAG patients can safely use FFP2/N95 and surgical masks at rest. However, due to the IOP rise observed while walking with the FFP2/N95 mask, when possible, POAG patients should prioritized the use of surgical masks during physical activity.",2021,"At rest (baseline and recovery measurements), the use of the different face masks did not affect IOP levels (mean differences ranging from 0.1 to 0.6 mmHg).","['Thirteen subjects diagnosed of POAG (21 eyes', 'primary open-angle glaucoma (POAG) patients', 'primary open-angle glaucoma patients']","['wearing surgical and FFP2/N95 face masks', 'walking with surgical and FFP2/N95 face masks', 'surgical mask, FFP2/N95 mask and no mask']","['Intraocular pressure responses', 'intraocular pressure (IOP) changes', 'IOP changes', 'IOP levels', 'IOP rise', 'IOP']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0339573', 'cui_str': 'Primary open angle glaucoma'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0181758', 'cui_str': 'Surgical face mask'}]","[{'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035853', 'cui_str': 'Rose'}]",13.0,0.0310017,"At rest (baseline and recovery measurements), the use of the different face masks did not affect IOP levels (mean differences ranging from 0.1 to 0.6 mmHg).","[{'ForeName': 'Danica', 'Initials': 'D', 'LastName': 'Janicijevic', 'Affiliation': 'Research Academy of Human Biomechanics, The Affiliated Hospital of Medical School of Ningbo University, Ningbo University, Ningbo, China.'}, {'ForeName': 'Beatríz', 'Initials': 'B', 'LastName': 'Redondo', 'Affiliation': 'CLARO (Clinical and Laboratory Applications of Research in Optometry) Research Group, Department of Optics, Faculty of Sciences, University of Granada, Campus de la Fuentenueva 2, 18001, Granada, Spain. beatrizrc@ugr.es.'}, {'ForeName': 'Raimundo', 'Initials': 'R', 'LastName': 'Jiménez', 'Affiliation': 'CLARO (Clinical and Laboratory Applications of Research in Optometry) Research Group, Department of Optics, Faculty of Sciences, University of Granada, Campus de la Fuentenueva 2, 18001, Granada, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Lacorzana', 'Affiliation': 'Department of Ophthalmology, Virgen de las Nieves University Hospital, Granada, Spain.'}, {'ForeName': 'Amador', 'Initials': 'A', 'LastName': 'García-Ramos', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Vera', 'Affiliation': 'CLARO (Clinical and Laboratory Applications of Research in Optometry) Research Group, Department of Optics, Faculty of Sciences, University of Granada, Campus de la Fuentenueva 2, 18001, Granada, Spain.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-021-05159-3'] 1126,33667495,"Effect of One Night of Nocturnal Oxygen Supplementation on Highland Patients With OSA: A Randomized, Crossover Trial.","BACKGROUND The treatment of OSA in highland residents is not established. RESEARCH QUESTIONS Does nocturnal oxygen supplementation (NOS) improve sleep-related breathing disturbances, nocturnal oxygenation, and cognitive performance in patients with OSA living at 3,200 m? STUDY DESIGN AND METHODS Forty patients with OSA permanently living in Shangri-La, China at 3,200 m (median age [interquartile range], 47.0 [44.0-53.0] years; oxygen desaturation index, 38.4/h [34.2/h-52.3/h]), were randomly assigned to receive nasal NOS and sham oxygen (ambient air), for one night each, at 2 L/min, in a crossover design, separated by a washout period of 2 weeks. During treatment nights polysomnography was performed, and further outcomes were evaluated the next morning. The primary outcome was the difference in apnea-hypopnea index (AHI) between nights with NOS and nights with sham oxygen. RESULTS During nights with sham oxygen, the median (interquartile range) total AHI was 43.4/h (31.1/h-67.5/h), the obstructive AHI was 41.9/h (28.5/h-66.8/h), and the central AHI was 0.6/h (0.1/h-1.3/h); blood oxygenation as determined by pulse oximetry (Spo 2 ) was 87.0% (84.5%-89.0%). In intention-to-treat analysis, NOS decreased the total AHI by a median of 17.9/h (95% CI, 8.0/h-27.1/h; P < .001), through a reduction in obstructive AHI by 16.0/h (95% CI, 6.8/h-26.0/h; P < .001) and central AHI by 0.4/h (95% CI, 0.1/h-0.9/h; P < .001). NOS also increased Spo 2 by 7.0% (95% CI, 6.0%-8.0%; P < .001). Heart rate during sleep and pulse rate in the morning after NOS were significantly reduced, but subjective sleep quality and cognitive performance showed no changes. INTERPRETATION In highland residents with OSA, NOS significantly improved sleep-related breathing disturbances and nocturnal oxygenation. NOS also reduced heart rate during sleep and morning pulse rate. If these beneficial effects are confirmed in longer term studies, NOS may be a treatment option for highland patients with OSA who cannot be treated by CPAP. TRIAL REGISTRY Chinese Clinical Trial Registry; No.: ChiCTR1800017715; URL: http://www.chictr.org.cn/showproj.aspx?proj=29768.",2021,"Heart rate during sleep and pulse rate in the morning after NOS were significantly reduced, but subjective sleep quality and cognitive performance showed no changes. ","['patients with OSA living at 3200 m', 'and Methods', 'highland OSA patients', '40 OSA patients permanently living in Shangri-La, China, at 3200m, median (quartiles) age 47.0 (44.0;53.0) years, oxygen desaturation index 38.4 (34.2;52.3)/h', 'obstructive sleep apnea (OSA) in highland residents', 'highland OSA patients who cannot use CPAP']","['nasal NOS and sham oxygen (ambient air', 'nocturnal oxygen supplementation', 'nocturnal oxygen supplementation (NOS']","['subjective sleep quality and cognitive performance', 'median (quartiles) total AHI', 'total AHI', 'obstructive AHI', 'Heart rate during sleep and pulse rate', 'apnea-hypopnea index (AHI', 'heart rate during sleep and morning pulse rate', 'sleep-related breathing disturbances and nocturnal oxygenation', 'central AHI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0454911', 'cui_str': 'Highland'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0445107', 'cui_str': 'Not used'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}]","[{'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0919655', 'cui_str': 'Oxygen supplementation'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0001861', 'cui_str': 'Air'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0235546', 'cui_str': 'Slow shallow breathing'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0587116', 'cui_str': 'During sleep'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0520680', 'cui_str': 'Apnea, Central Sleep'}]",40.0,0.178134,"Heart rate during sleep and pulse rate in the morning after NOS were significantly reduced, but subjective sleep quality and cognitive performance showed no changes. ","[{'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Tan', 'Affiliation': 'Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Taomei', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Deping', 'Initials': 'D', 'LastName': 'He', 'Affiliation': ""Department of Neurology, Diqing Tibetan Autonomous Prefectural People's Hospital, Shangri-La, China.""}, {'ForeName': 'Lian', 'Initials': 'L', 'LastName': 'Luo', 'Affiliation': 'Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Lei', 'Affiliation': 'Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Ren', 'Affiliation': 'Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Jiaming', 'Initials': 'J', 'LastName': 'He', 'Affiliation': ""Department of Neurology, Diqing Tibetan Autonomous Prefectural People's Hospital, Shangri-La, China.""}, {'ForeName': 'Konrad E', 'Initials': 'KE', 'LastName': 'Bloch', 'Affiliation': 'Department of Respiratory Medicine, Sleep Disorders Center, University Hospital of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Xiangdong', 'Initials': 'X', 'LastName': 'Tang', 'Affiliation': 'Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. Electronic address: 2372564613@qq.com.'}]",Chest,['10.1016/j.chest.2021.02.046'] 1127,33674988,"Effects of melatonin supplementation on disease activity, oxidative stress, inflammatory, and metabolic parameters in patients with rheumatoid arthritis: a randomized double-blind placebo-controlled trial.","OBJECTIVE Considering the pathologic significance of inflammation and oxidative stress in rheumatoid arthritis (RA) as well as the antioxidant, anti-inflammatory and hypolipidemic effects of melatonin, the current research is designed to investigate the effect of melatonin supplementation on disease activity, oxidative stress, inflammatory, and metabolic parameters in RA patients. METHODS In this randomized double-blind, placebo-controlled trial, 64 RA cases were selected and randomly assigned into 2 groups to take 6 mg/day melatonin or placebo for 12 weeks. Before and after trial, serum malondialdehyde (MDA), total antioxidant capacity (TAC), erythrocyte sedimentation rate (ESR), lipid profile, fasting blood sugar (FBS), and insulin levels were measured and disease activity was determined by disease activity score-28 (DAS-28). RESULTS Compared to the baseline, melatonin significantly decreased DAS-28, ESR, MDA, and LDL-C by 50.5%, 59%, 97%, and 13%, respectively (P<0.001) and significantly increased TAC by 89% (P=0.013) and HDL-C by 22% (P<0.001). After treatment, considerable differences were only seen between the two groups in serum MDA (P<0.001) and LDL-C (P=0.007) concentrations, adjusted for baseline measures. Moreover, there were no significant changes in DAS-28, ESR, TAC, triglyceride, total cholesterol, HDL-C, FBS, and insulin levels compared to placebo group (P>0.05). CONCLUSIONS Although melatonin supplementation had no beneficial effects on DAS-28, it could lower serum MDA and LDL-C levels. It seems that melatonin supplementation should not be used as a replace for routine drugs prescribed in RA treatment. Further investigations should be conducted to fully understand the effects of melatonin in RA. Key Points • Compared to baseline, melatonin significantly decreased DAS-28, ESR, MDA, and LDL-C and significantly increased TAC and HDL-C. • After treatment, considerable differences were only seen between melatonin and placebo groups in serum MDA and LDL-C concentrations. • After treatment, there were no significant changes in DAS-28, ESR, TAC, triglyceride, total cholesterol, HDL-C, FBS, and insulin levels compared to the placebo group.",2021,"Compared to baseline, melatonin significantly decreased DAS-28, ESR, MDA, and LDL-C and significantly increased TAC and HDL-C. •","['patients with rheumatoid arthritis', 'rheumatoid arthritis (RA', '64 RA cases', 'RA patients']","['placebo', 'melatonin', 'melatonin and placebo', 'melatonin supplementation', 'melatonin or placebo']","['serum MDA (P<0.001) and LDL-C', 'serum MDA and LDL-C levels', 'disease activity score-28 (DAS-28', 'disease activity, oxidative stress, inflammatory, and metabolic parameters', 'DAS-28, ESR, MDA, and LDL-C and significantly increased TAC and HDL-C. •', 'serum malondialdehyde (MDA), total antioxidant capacity (TAC), erythrocyte sedimentation rate (ESR), lipid profile, fasting blood sugar (FBS), and insulin levels', 'DAS-28, ESR, TAC, triglyceride, total cholesterol, HDL-C, FBS, and insulin levels', 'serum MDA and LDL-C concentrations', 'DAS-28, ESR, MDA, and LDL-C', 'TAC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0868928', 'cui_str': 'Case'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",64.0,0.327987,"Compared to baseline, melatonin significantly decreased DAS-28, ESR, MDA, and LDL-C and significantly increased TAC and HDL-C. •","[{'ForeName': 'Kamal', 'Initials': 'K', 'LastName': 'Esalatmanesh', 'Affiliation': 'Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Amirhossein', 'Initials': 'A', 'LastName': 'Loghman', 'Affiliation': 'Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Roozbeh', 'Initials': 'R', 'LastName': 'Esalatmanesh', 'Affiliation': 'Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Soleimani', 'Affiliation': 'Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Khabbazi', 'Affiliation': 'Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St, P.O Box 5166614756, Tabriz, Iran. dr_khabbazi@yahoo.com.'}, {'ForeName': 'Aida Malek', 'Initials': 'AM', 'LastName': 'Mahdavi', 'Affiliation': 'Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St, P.O Box 5166614756, Tabriz, Iran. aidamalek@gmail.com.'}, {'ForeName': 'Seyed Gholam Abbas', 'Initials': 'SGA', 'LastName': 'Mousavi', 'Affiliation': 'Department of Statistics and Public Health, Faculty of Health, Kashan University of Medical Sciences, Kashan, Iran.'}]",Clinical rheumatology,['10.1007/s10067-021-05670-2'] 1128,33725800,Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration.,"BACKGROUND Atopic dermatitis (AD) is one of the most common inflammatory skin diseases and has aesthetic, physical, and emotional-social sequelae when left untreated. OBJECTIVE To classify the most common adverse reactions associated with dupilumab treatment in patients with AD. METHODS The United States Food and Drug Administration Adverse Event Reporting (FAERS) database was analyzed for common adverse reactions associated with dupilumab, topical pimecrolimus, and topical tacrolimus. Phase III clinical trial data were used to compare the rate of herpes infections between the treatment group and placebo group. RESULTS The most common adverse reaction associated with dupilumab was ocular complications. Herpes infections were extremely rare in the patients with AD being treated with dupilumab. LIMITATIONS Prescribing information for dupilumab, topical pimecrolimus, and topical tacrolimus is not available. Adverse effects are reported by patients, health care providers, and pharmaceutical companies, they have not been corroborated. CONCLUSIONS Ocular complications are the most common complication associated with dupilumab. The rate of herpes infection is low in patients being treated with dupilumab, topical pimecrolimus, and topical tacrolimus. There is no significant difference for the rate of herpes infection between, placebo, dupilumab, topical pimecrolimus, and the topical tacrolimus treatment group, suggesting that dupilumab does not affect herpes infection rates.",2021,"There is no significant difference for the rate of herpes infection between, placebo, dupilumab, topical pimecrolimus, and the topical tacrolimus treatment group, suggesting that dupilumab does not affect herpes infection rates.","['patients being treated with', 'Atopic dermatitis (AD', 'patients with AD being treated with dupilumab', 'patients with AD']","['placebo', 'dupilumab, topical pimecrolimus, and topical tacrolimus', 'pimecrolimus, and topical tacrolimus']","['Adverse effects', 'Herpes infections', 'rate of herpes infection', 'herpes infection rates', 'rate of herpes infections']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C1099414', 'cui_str': 'Pimecrolimus'}, {'cui': 'C0939241', 'cui_str': 'Tacrolimus-containing product in cutaneous dose form'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",,0.415316,"There is no significant difference for the rate of herpes infection between, placebo, dupilumab, topical pimecrolimus, and the topical tacrolimus treatment group, suggesting that dupilumab does not affect herpes infection rates.","[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Renaissance School of Medicne at Stony Brook University, Stony Brook, New York.'}, {'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Jorizzo', 'Affiliation': 'Department of Dermatology, Wake Forest University, Winston-Salem, North Carolina; Department of Dermatology, Weill Cornell Medicine, New York, New York. Electronic address: jjorizzo@wakehealth.edu.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.11.042'] 1129,33727034,Continuous Pneumatic Regulation of Tracheal Cuff Pressure to Decrease Ventilator-associated Pneumonia in Trauma Patients Who Were Mechanically Ventilated: The AGATE Multicenter Randomized Controlled Study.,"BACKGROUND Ventilator-associated pneumonia (VAP) is the most frequent health care-associated infection in severely ill patients, and aspiration of contaminated oropharyngeal content around the cuff of the tracheal tube is the main route of contamination. RESEARCH QUESTION Is continuous regulation of tracheal cuff pressure using a pneumatic device superior to manual assessment three times daily using a portable manometer (routine care) in preventing VAP in patients with severe trauma? STUDY DESIGN AND METHODS In this open-label, randomized controlled superiority trial conducted in 13 French ICUs, adults (age ≥ 18 years) with severe trauma (Injury Severity Score > 15) and requiring invasive mechanical ventilation for ≥ 48 h were enrolled. Patients were randomly assigned (1:1) via a secure Web-based random number generator in permuted blocks of variable sizes to one of two groups according to the method of tracheal cuff pressure control. The primary outcome was the proportion of patients developing VAP within 28 days following the tracheal intubation, as determined by two assessors masked to group assignment, in the modified intention-to-treat population. This study is closed to new participants. RESULTS A total of 434 patients were recruited between July 31, 2015, and February 15, 2018, of whom 216 were assigned to the intervention group and 218 to the control group. Seventy-three patients (33.8%) developed at least one episode of VAP within 28 days following the tracheal intubation in the intervention group compared with 64 patients (29.4%) in the control group (adjusted subdistribution hazard ratio, 0.96; 95% CI, 0.76-1.20; P = .71). No serious adverse events related to the use of the pneumatic device were noted. INTERPRETATION Continuous regulation of cuff pressure of the tracheal tube using a pneumatic device was not superior to routine care in preventing VAP in patients with severe trauma. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov; No.: NCT02534974; URL: www.clinicaltrials.gov.",2021,73 patients (33·8%) developed at least one episode of VAP within 28 days following the tracheal intubation in the intervention group compared with 64 patients (29·4%) in the control group (adjusted sub-distribution HR 0·96,"['severe trauma patients', '434 patients were recruited between 31/07/2015 and 15/02/2018, of which 216 were assigned to the intervention group and 218 to the control group', '13 French intensive care units, we enrolled adults (age ≥18 years) suffering from severe trauma (Injury severity score >15) and requiring invasive mechanical ventilation for 48 hours or longer', 'mechanically ventilated trauma patients']","['Continuous pneumatic regulation of tracheal cuff pressure', 'pneumatic device superior to manual assessment three times daily using a portable manometer (routine care']",['proportion of patients developing VAP'],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4708905', 'cui_str': '216'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517647', 'cui_str': '218'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021504', 'cui_str': 'Injury severity score'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C2945595', 'cui_str': 'Tracheal'}, {'cui': 'C0441107', 'cui_str': 'Device cuff'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0556984', 'cui_str': 'Three times daily'}, {'cui': 'C2720530', 'cui_str': 'Manometer'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}]",434.0,0.0638993,73 patients (33·8%) developed at least one episode of VAP within 28 days following the tracheal intubation in the intervention group compared with 64 patients (29·4%) in the control group (adjusted sub-distribution HR 0·96,"[{'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Marjanovic', 'Affiliation': 'Service des Urgences et SAMU 86 Centre 15, CHU de Poitiers, France; Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM CIC1402 Team 5 Acute Lung Injury and Ventilatory Support, Pharmacologie des Agents anti-infectieux, France.'}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Boisson', 'Affiliation': ""Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France; Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France.""}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Asehnoune', 'Affiliation': ""Service d'Anesthésie-Réanimation chirurgicale, CHU de Nantes, France.""}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Foucrier', 'Affiliation': 'Anesthésie-Réanimation, AP-HP Nord Hôpital Beaujon, France.'}, {'ForeName': 'Sigismond', 'Initials': 'S', 'LastName': 'Lasocki', 'Affiliation': ""Département d'Anesthésie-Réanimation, CHU d'Angers, France.""}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Ichai', 'Affiliation': 'Service de Réanimation Polyvalente, CHU de Nice, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Leone', 'Affiliation': ""Aix Marseille Université, Service d'Anesthésie et de Réanimation, Assistance Publique Hôpitaux Universitaires de Marseille, Hôpital Nord, France.""}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Pottecher', 'Affiliation': ""Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Service d'Anesthésie-Réanimation & Médecine Péri-Opératoire, Strasbourg, France; Université de Strasbourg, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France.""}, {'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Lefrant', 'Affiliation': 'EA 2992 IMAGINE, Université de Montpellier, Montpellier, France; Pôle Anesthésie Réanimation Douleur Urgences, CHU Nîmes, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Falcon', 'Affiliation': 'Pole Anesthésie Réanimation, CHU de Grenoble, France.'}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Veber', 'Affiliation': 'Surgical Intensive Care Unit, Rouen University Hospital, France.'}, {'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Chabanne', 'Affiliation': 'Department of Perioperative Medicine, Neurocritical Care Unit, Neuro-Anesthesiology Clinic, CHU de Clermont-Ferrand, France.'}, {'ForeName': 'Claire-Marie', 'Initials': 'CM', 'LastName': 'Drevet', 'Affiliation': 'Department of Anesthesiology and Intensive Care, CHU Dijon, France.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Pili-Floury', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, CHU de Besancon, Besançon, France; EA3920 and SFR-FED 4234 INSERM, Université de Franche-Comté, Besançon, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Dahyot-Fizelier', 'Affiliation': ""Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France; Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France.""}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kerforne', 'Affiliation': ""Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France; Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France.""}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Seguin', 'Affiliation': ""Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France.""}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'de Keizer', 'Affiliation': 'Plateforme Méthodologie-Biostatistique-Data-Management, CHU de Poitiers, France.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Frasca', 'Affiliation': ""Université de Poitiers, Faculté de Médecine, Poitiers, France; Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France; INSERM U1246, Methods in Patients-centered outcomes and Health Research-SPHERE, Nantes, France.""}, {'ForeName': 'Jérémy', 'Initials': 'J', 'LastName': 'Guenezan', 'Affiliation': 'Service des Urgences et SAMU 86 Centre 15, CHU de Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Mimoz', 'Affiliation': 'Service des Urgences et SAMU 86 Centre 15, CHU de Poitiers, France; Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France. Electronic address: Olivier.mimoz@chu-poitiers.fr.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Chest,['10.1016/j.chest.2021.03.007'] 1130,33655429,Comparing the effectiveness of home visiting paraprofessionals and mental health professionals delivering a postpartum depression preventive intervention: a cluster-randomized non-inferiority clinical trial.,"To determine whether pregnant women receiving the Mothers and Babies group-based intervention exhibited greater depressive symptom reductions and fewer new cases of major depression than women receiving usual community-based services, and to examine whether groups run by paraprofessional home visitors and mental health professionals yielded similar depressive symptom reductions and prevention of major depression. Using a cluster-randomized design, 37 home visiting programs were randomized to usual home visiting, Mothers and Babies delivered via home visiting paraprofessionals, or Mothers and Babies delivered via mental health professionals. Baseline assessments were conducted prenatally with follow-up extending to 24 weeks postpartum. Eligibility criteria were ≥ 16 years old, ≤ 33 gestation upon referral, and Spanish/English speaking. Depressive symptoms at 24 weeks postpartum was the primary outcome. Eight hundred seventy-four women were enrolled. Neither intervention arm was superior to usual care in decreasing depressive symptoms across the sample (p = 0.401 home visiting paraprofessional vs. control; p = 0.430 mental health professional vs. control). Post hoc analyses suggest a positive intervention effect for women exhibiting mild depressive symptoms at baseline. We have evidence of non-inferiority, as the model-estimated mean difference in depressive symptoms between intervention arms (0.01 points, 95% CI: -0.79, 0.78) did not surpass our pre-specified margin of non-inferiority of two points. Although we did not find statistically significant differences between intervention and control arms, non-inferiority analyses found paraprofessional home visitors generated similar reductions in depressive symptoms as mental health professionals. Additionally, Mothers and Babies appears to reduce depressive symptoms among women with mild depressive symptoms when delivered by mental health professionals. This trial is registered on ClinicalTrials.gov (initial post: December 1, 2016; identifier: NCT02979444).",2021,Neither intervention arm was superior to usual care in decreasing depressive symptoms across the sample (p = 0.401 home visiting paraprofessional vs. control; p = 0.430 mental health professional vs. control).,"['16\xa0years old, ≤ 33 gestation upon referral, and Spanish/English speaking', 'Eight hundred seventy-four women were enrolled', 'pregnant women receiving the Mothers and Babies group', '37 home visiting programs']","['home visiting paraprofessionals and mental health professionals delivering a postpartum depression preventive intervention', 'based intervention', 'usual home visiting, Mothers and Babies delivered via home visiting paraprofessionals, or Mothers and Babies delivered via mental health professionals']","['depressive symptom reductions', 'Depressive symptoms', 'depressive symptoms', 'mild depressive symptoms', 'depressive symptom reductions and prevention of major depression']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]",874.0,0.38567,Neither intervention arm was superior to usual care in decreasing depressive symptoms across the sample (p = 0.401 home visiting paraprofessional vs. control; p = 0.430 mental health professional vs. control).,"[{'ForeName': 'S Darius', 'Initials': 'SD', 'LastName': 'Tandon', 'Affiliation': 'Institute for Public Health and Medicine, Center for Community Health, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA. dtandon@northwestern.edu.'}, {'ForeName': 'Jessica K', 'Initials': 'JK', 'LastName': 'Johnson', 'Affiliation': 'Institute for Public Health and Medicine, Center for Community Health, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Diebold', 'Affiliation': 'Institute for Public Health and Medicine, Center for Community Health, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Segovia', 'Affiliation': 'Institute for Public Health and Medicine, Center for Community Health, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.'}, {'ForeName': 'Jackie K', 'Initials': 'JK', 'LastName': 'Gollan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.'}, {'ForeName': 'Aria', 'Initials': 'A', 'LastName': 'Degillio', 'Affiliation': 'Institute for Public Health and Medicine, Center for Community Health, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Zakieh', 'Affiliation': 'Institute for Public Health and Medicine, Center for Community Health, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yeh', 'Affiliation': 'Department of Preventive Medicine, Division of Biostatistics, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.'}, {'ForeName': 'Jesus', 'Initials': 'J', 'LastName': 'Solano-Martinez', 'Affiliation': 'Institute for Public Health and Medicine, Center for Community Health, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.'}, {'ForeName': 'Jody D', 'Initials': 'JD', 'LastName': 'Ciolino', 'Affiliation': 'Department of Preventive Medicine, Division of Biostatistics, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.'}]",Archives of women's mental health,['10.1007/s00737-021-01112-9'] 1131,33655380,The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.,"INTRODUCTION/OBJECTIVES To evaluate changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA). METHODS Patients were randomized to IV golimumab 2 mg/kg (n=241) at Weeks 0, 4, then every 8 weeks (q8w) through Week 52 or placebo (n=239) at Weeks 0, 4, then q8w, with crossover to IV golimumab 2 mg/kg at Weeks 24, 28, then q8w through Week 52. Change from baseline in EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily productivity VAS, and the Work Limitations Questionnaire (WLQ) was assessed. Relationships between these outcomes and disease activity and patient functional capability were evaluated post hoc. RESULTS At Week 8, change from baseline in EQ-5D-5L index (0.14 vs 0.04), EQ-VAS (17.16 vs 3.69), daily productivity VAS (-2.91 vs -0.71), and WLQ productivity loss score (-2.92 vs -0.78) was greater in the golimumab group versus the placebo group, respectively. At Week 52, change from baseline was similar in the golimumab and placebo-crossover groups (EQ-5D-5L index: 0.17 and 0.15; EQ-VAS: 21.61 and 20.84; daily productivity VAS: -2.89 and -3.31; WLQ productivity loss: -4.49 and -3.28, respectively). HRQoL and productivity were generally associated with disease activity and functional capability, with continued association from Week 8 through Week 52. CONCLUSION IV golimumab resulted in early and sustained improvements in HRQoL and productivity from Week 8 through 1 year in patients with PsA. HRQoL and productivity improvements were associated with improvements in disease activity and patient functional capability. Key Points • In patients with active psoriatic arthritis (PsA), intravenous (IV) golimumab improved health-related quality of life (HRQoL) and productivity as early as 8 weeks and maintained improvement through 1 year • Improvements in HRQoL and productivity outcomes in patients with PsA treated with IV golimumab were associated with improvements in disease activity and patient functional capability outcomes • IV golimumab is an effective treatment option for PsA that can mitigate the negative effects of the disease on HRQoL and productivity.",2021,"CONCLUSION IV golimumab resulted in early and sustained improvements in HRQoL and productivity from Week 8 through 1 year in patients with PsA. HRQoL and productivity improvements were associated with improvements in disease activity and patient functional capability.","['patients with psoriatic arthritis (PsA', 'patients with active psoriatic arthritis', 'Patients', 'patients with active psoriatic arthritis (PsA']","['intravenous golimumab', 'IV golimumab', 'placebo', 'intravenous (IV) golimumab']","['daily productivity VAS ', 'HRQoL and productivity', 'EQ-5D-5L index', 'health-related quality of life (HRQoL) and productivity', 'disease activity and patient functional capability', 'EQ-VAS', 'disease activity and functional capability', 'health-related quality of life and work productivity', 'WLQ productivity loss score', 'HRQoL and productivity outcomes', 'disease activity and patient functional capability outcomes', 'EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily productivity VAS, and the Work Limitations Questionnaire (WLQ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003872', 'cui_str': 'Psoriatic arthritis'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C2353893', 'cui_str': 'golimumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.212572,"CONCLUSION IV golimumab resulted in early and sustained improvements in HRQoL and productivity from Week 8 through 1 year in patients with PsA. HRQoL and productivity improvements were associated with improvements in disease activity and patient functional capability.","[{'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Ogdie', 'Affiliation': 'University of Pennsylvania, 3400 Spruce St, White Building, Room 5023, Philadelphia, PA, 19104, USA. alexis.ogdie@uphs.upenn.edu.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Walsh', 'Affiliation': 'University of Utah, George E. Wahlen Veterans Affairs, Salt Lake City, UT, USA.'}, {'ForeName': 'Soumya D', 'Initials': 'SD', 'LastName': 'Chakravarty', 'Affiliation': 'Janssen Scientific Affairs, LLC, Horsham, PA, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Peterson', 'Affiliation': 'Janssen Global Services, LLC, Horsham, PA, USA.'}, {'ForeName': 'Kim Hung', 'Initials': 'KH', 'LastName': 'Lo', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Lilianne', 'Initials': 'L', 'LastName': 'Kim', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Janssen Global Services, LLC, Raritan, NJ, USA.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Hsia', 'Affiliation': 'University of Pennsylvania, 3400 Spruce St, White Building, Room 5023, Philadelphia, PA, 19104, USA.'}, {'ForeName': 'Eric K H', 'Initials': 'EKH', 'LastName': 'Chan', 'Affiliation': 'Janssen Global Services, LLC, Raritan, NJ, USA.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Kavanaugh', 'Affiliation': 'University of California-San Diego, San Diego, CA, USA.'}, {'ForeName': 'M Elaine', 'Initials': 'ME', 'LastName': 'Husni', 'Affiliation': 'Cleveland Clinic, Cleveland, OH, USA.'}]",Clinical rheumatology,['10.1007/s10067-021-05639-1'] 1132,33655299,Transforming clinical research by involving and empowering patients- the RATE-AF randomized trial.,,2021,,[],[],[],[],[],[],,0.0434221,,"[{'ForeName': 'Karina V', 'Initials': 'KV', 'LastName': 'Bunting', 'Affiliation': 'Cardiac Physiologist & Postdoctoral Fellow, University of Birmingham & University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Stanbury', 'Affiliation': 'Lead for the Patient & Public Involvement Team, RATE-AF trial.'}, {'ForeName': 'Otilia', 'Initials': 'O', 'LastName': 'Tica', 'Affiliation': 'Cardiologist & Postdoctoral Fellow, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Dipak', 'Initials': 'D', 'LastName': 'Kotecha', 'Affiliation': 'Professor of Cardiology, Institute of Cardiovascular Sciences, University of Birmingham & University Hospitals Birmingham NHS Foundation Trust, Vincent Drive, Birmingham B15 2TT, UK.'}]",European heart journal,['10.1093/eurheartj/ehab098'] 1133,33677004,"Response to ""Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months"".",,2021,,['histologic subtypes of advanced basal cell carcinoma'],['sonidegib'],[],"[{'cui': 'C1301142', 'cui_str': 'WHO tumor classification'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007117', 'cui_str': 'Basal cell carcinoma'}]","[{'cui': 'C3886731', 'cui_str': 'sonidegib'}]",[],,0.0397414,,"[{'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Villani', 'Affiliation': 'Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Electronic address: ali.vil@hotmail.it.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Fabbrocini', 'Affiliation': 'Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Costa', 'Affiliation': 'Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Massimiliano', 'Initials': 'M', 'LastName': 'Scalvenzi', 'Affiliation': 'Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2021.02.074'] 1134,33711209,Feasibility randomized-controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN study.,"BACKGROUND Neuropathic pain negatively affects quality of life among people living with HIV (PLWH). This study examined the feasibility of conducting a full-scale randomized-controlled trial of online acceptance and commitment therapy (""ACT OPEN"") for neuropathic pain in PLWH. METHODS Using a parallel-groups design, thirty-eight participants were randomized to ACT OPEN or a waitlist control (2:1). Participants completed standard self-report outcome measures at baseline, and two- and five-months post-randomization. Participants were aware of their allocation, but assessment was blinded. RESULTS Twenty-five participants were randomized to ACT OPEN and 13 to the control (of 133 referrals). ACT OPEN completion was 69% and two-month trial retention was 82%. Treatment credibility and satisfaction scores for ACT OPEN were comparable to scores reported in previous trials of cognitive-behavioural treatments for pain. Four adverse events were reported during the study, including one serious adverse event; all of these were unrelated to the research procedures. Small to moderate effects and 95% confidence intervals suggest that the true effect may favour ACT OPEN for improvements in pain intensity/interference and depression. CONCLUSIONS A full-scale RCT of online ACT for pain management in PLWH may be feasible with refinements to trial design to facilitate recruitment. SIGNIFICANCE Research on pain management in people living with HIV has primarily focused on pharmacological treatments with limited success. This is the first study to show the potential feasibility of a psychological treatment based on acceptance and commitment therapy delivered online and tailored for pain management in people with HIV (""ACT OPEN""). ACT OPEN may be a promising treatment in this population and further evaluation in a full-scale randomized-controlled trial appears warranted. TRIAL REGISTRATION The trial was registered (clinicaltrials.gov; NCT03584412).",2021,Treatment credibility and satisfaction scores for ACT OPEN were comparable to scores reported in previous trials of cognitive-behavioural treatments for pain.,"['people living with HIV (PLWH', 'Twenty-five participants', 'People Living with HIV']","['ACT OPEN', 'online acceptance and commitment therapy (""ACT OPEN', 'Online Acceptance and Commitment Therapy']","['Treatment credibility and satisfaction scores', 'pain intensity/interference and depression']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C3715062', 'cui_str': '25'}]","[{'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",38.0,0.15956,Treatment credibility and satisfaction scores for ACT OPEN were comparable to scores reported in previous trials of cognitive-behavioural treatments for pain.,"[{'ForeName': 'Whitney', 'Initials': 'W', 'LastName': 'Scott', 'Affiliation': ""Health Psychology Section, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Beth J', 'Initials': 'BJ', 'LastName': 'Guildford', 'Affiliation': ""Dental Psychology Service, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Badenoch', 'Affiliation': ""Health Psychology Section, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Driscoll', 'Affiliation': ""INPUT Pain Management Unit, Guy's & St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Chilcot', 'Affiliation': ""Health Psychology Section, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Norton', 'Affiliation': ""Health Psychology Section, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Harriet I', 'Initials': 'HI', 'LastName': 'Kemp', 'Affiliation': 'Pain Research Group, Faculty of Medicine, Department of Surgery & Cancer, Imperial College London, London, UK.'}, {'ForeName': 'Ming J', 'Initials': 'MJ', 'LastName': 'Lee', 'Affiliation': ""Harrison Wing, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Julianne', 'Initials': 'J', 'LastName': 'Lwanga', 'Affiliation': ""Harrison Wing, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Boffito', 'Affiliation': 'Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Moyle', 'Affiliation': 'Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Frank A', 'Initials': 'FA', 'LastName': 'Post', 'Affiliation': ""Caldecot Centre, King's College Hospital NHS Foundation Trust, London, UK.""}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Campbell', 'Affiliation': ""Caldecot Centre, King's College Hospital NHS Foundation Trust, London, UK.""}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Josh', 'Affiliation': 'UK Community Advisory Board, London, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Clift', 'Affiliation': 'UK Community Advisory Board, London, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'C de C Williams', 'Affiliation': 'Research Department of Clinical, Educational, and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Andrew Sc', 'Initials': 'AS', 'LastName': 'Rice', 'Affiliation': 'Pain Research Group, Faculty of Medicine, Department of Surgery & Cancer, Imperial College London, London, UK.'}, {'ForeName': 'Lance M', 'Initials': 'LM', 'LastName': 'McCracken', 'Affiliation': 'Department of Psychology, Uppsala University, Uppsala, Sweden.'}]","European journal of pain (London, England)",['10.1002/ejp.1762'] 1135,33712249,Clinical utility of epidural volume extension following reduced intrathecal doses: a randomized controlled trial.,"BACKGROUND AND OBJECTIVES Epidural Volume Extension (EVE) involves instillation of normal saline into the epidural space soon after an intrathecal injection, with the aim to augment the sensory block height. Its clinical relevance lies in the possibility of using reduced intrathecal dose and yet achieving the desired sensory block level. Intrathecal dose is a known determinant of the level of sensory block. Whether EVE is dependent on intrathecal dose is not known. METHODS We conducted a randomized, controlled, double-blind study to compare the maximum sensory level (S max ) achieved with or without application of EVE to two different reduced intrathecal doses. Eighty four adult male patients of ASA status I or II with body weight between 50-70kg and height in the range of 150-180cm, scheduled for orthopedic lower limb surgery using combined spinal epidural anesthesia were randomized to receive, either intrathecal dose (5 or 8mg) with or without EVE, in accordance to group allocation. RESULTS S max was lowered by application of EVE to 5mg intrathecal bupivacaine (T 8.9 ±4.3 vs. T 6.4 ±1.9 with and without EVE respectively; p = 0.030). S max was similar when EVE was applied to 8mg intrathecal bupivacaine than without it (T 5.8 ±1.8 vs. T 6.4 ±2.2 respectively; p= 0.324). CONCLUSION EVE should not be applied to 5mg plain bupivacaine during a combined spinal epidural block in patients undergoing lower limb orthopedic surgery as it may result in a decrease in the maximum sensory level.",2021,"S max was similar when EVE was applied to 8mg intrathecal bupivacaine than without it (T 5.8 ±1.8 vs. T 6.4 ±2.2 respectively; p= 0.324). ","['patients undergoing lower limb orthopedic surgery', 'Eighty four adult male patients of ASA status I or II with body weight between 50-70kg and height in the range of 150-180cm, scheduled for orthopedic lower limb surgery using combined spinal epidural anesthesia']","['intrathecal dose (5 or 8mg) with or without EVE, in accordance to group allocation', 'epidural volume extension', 'intrathecal bupivacaine', 'plain bupivacaine']","['maximum sensory level (S max ', 'S max']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}]","[{'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1262068', 'cui_str': 'Sensory level'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",84.0,0.257151,"S max was similar when EVE was applied to 8mg intrathecal bupivacaine than without it (T 5.8 ±1.8 vs. T 6.4 ±2.2 respectively; p= 0.324). ","[{'ForeName': 'Asha', 'Initials': 'A', 'LastName': 'Tyagi', 'Affiliation': 'University College of Medical Sciences and GTB Hospital, Department of Anaesthesiology and Critical Care, Delhi, India.'}, {'ForeName': 'Mukundan', 'Initials': 'M', 'LastName': 'Ramanujam', 'Affiliation': 'Dr. Ram Manohar Lohia Hospital, Department of Anaesthesiology, Delhi, India. Electronic address: iammukundan@gmail.com.'}, {'ForeName': 'Ashok Kumar', 'Initials': 'AK', 'LastName': 'Sethi', 'Affiliation': 'University College of Medical Sciences and GTB Hospital, Department of Anaesthesiology and Critical Care, Delhi, India.'}, {'ForeName': 'Medha', 'Initials': 'M', 'LastName': 'Mohta', 'Affiliation': 'University College of Medical Sciences and GTB Hospital, Department of Anaesthesiology and Critical Care, Delhi, India.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2020.12.005'] 1136,33712246,"Airway patency in children undergoing magnetic resonance imaging using neck collars: a single center, randomized, double-blind, prospective study.","BACKGROUND AND OBJECTIVES Maneuvers precluding the downward shift of the mandibula and providing slight extension of the head have been shown to increase upper airway dimensions. This study aimed to investigate the role of Neck Collars (NC) in maintaining airway patency during Magnetic Resonance Imaging (MRI) examination in a pediatric population aged between 0 and 16 years. METHODS One hundred twenty-five children were recruited in this prospective study. Subjects were randomly assigned to NC group (NC+) or standard imaging group (NC-). Measurements of anteroposterior and transverse dimensions and cross-sectional area were performed to determine the upper airway size at three distinct levels: soft palate, base of the tongue, and tip of the epiglottis. RESULTS The anteroposterior diameter and cross-sectional area at the levels of base of the tongue and soft palate were significantly higher in NC+ patients compared to NC- patients. However, anteroposterior dimensions and cross-sectional areas at the epiglottis level were similar in the two groups. When patients were analyzed according to age groups of 0-2, 2-8, and 8-16 years, the anteroposterior diameter and cross-sectional area at the levels of base of the tongue and soft palate were significantly higher in NC+ patients compared to NC- patients in all age groups. CONCLUSIONS This study clearly demonstrates that the application of a NC may improve retropalatal end and retroglossal airway dimensions in a pediatric population undergoing MRI examination and receiving sedation in supine position.",2021,The anteroposterior diameter and cross-sectional area at the levels of base of the tongue and soft palate were significantly higher in NC+ patients compared to NC- patients.,"['pediatric population aged between 0 and 16 years', 'pediatric population undergoing MRI examination and receiving sedation in supine position', 'One hundred twenty-five children', 'children undergoing magnetic resonance imaging using neck collars']","['NC group (NC+) or standard imaging group (NC', 'Neck Collars (NC', 'NC', 'Magnetic Resonance Imaging (MRI) examination']",['anteroposterior diameter and cross-sectional area at the levels of base of the tongue and soft palate'],"[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0175751', 'cui_str': 'Cervical collar'}]","[{'cui': 'C0175751', 'cui_str': 'Cervical collar'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0226958', 'cui_str': 'Structure of root of tongue'}, {'cui': 'C0030219', 'cui_str': 'Soft palate structure'}]",125.0,0.0364009,The anteroposterior diameter and cross-sectional area at the levels of base of the tongue and soft palate were significantly higher in NC+ patients compared to NC- patients.,"[{'ForeName': 'Gulseren', 'Initials': 'G', 'LastName': 'Yilmaz', 'Affiliation': 'University of Health Sciences, Faculty of Medicine, Kanuni Sultan Suleyman Hospital, Department of Anesthesiology & Reanimation, Istanbul, Turkey. Electronic address: drgulseren83@gmail.com.'}, {'ForeName': 'Kenan', 'Initials': 'K', 'LastName': 'Varol', 'Affiliation': 'University of Health Sciences, Faculty of Medicine, Kanuni Sultan Suleyman Hospital, Department of Radiology, Istanbul, Turkey.'}, {'ForeName': 'Osman', 'Initials': 'O', 'LastName': 'Esen', 'Affiliation': 'University of Health Sciences, Faculty of Medicine, Mehmet Akif Ersoy Hospital, Department of Anesthesiology & Reanimation, Istanbul, Turkey.'}, {'ForeName': 'Arda', 'Initials': 'A', 'LastName': 'Kayhan', 'Affiliation': 'University of Health Sciences, Faculty of Medicine, Kanuni Sultan Suleyman Hospital, Department of Radiology, Istanbul, Turkey.'}, {'ForeName': 'Ziya', 'Initials': 'Z', 'LastName': 'Salihoglu', 'Affiliation': 'University of Health Sciences, Faculty of Medicine, Kanuni Sultan Suleyman Hospital, Department of Anesthesiology & Reanimation, Istanbul, Turkey.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2020.12.002'] 1137,33710427,"Association of Pelvic Organ Prolapse Quantification examination D point with uterosacral ligament suspension outcomes: the ""OPTIMAL"" D point.","INTRODUCTION AND HYPOTHESIS The objective was to determine the relationship between the preoperative D-point and apical outcomes at 24 months, using the Operations and Pelvic Muscle Training in the Management of Apical Support Loss (OPTIMAL) dataset. METHODS This was a secondary analysis of the OPTIMAL trial, a randomized multi-centered study comparing outcomes of sacrospinous ligament fixation and transvaginal uterosacral ligament suspension (USLS). The 2-year dataset utilized included women undergoing USLS with concomitant hysterectomy. The primary outcome was the relationship between preoperative D-point and apical outcomes at 24 months. Secondary objectives were to determine the relationship between preoperative D-point and anatomical, composite and subjective outcomes, and to determine a D-point cut-off that could be used to predict success in each of these categories. RESULTS Of the 186 women in the USLS arm, 120 were available for analysis of anatomical failure at 24 months. A higher preoperative D-point correlated with improved apical outcome (C-point) at 24 months (r = 0.34; p value = 0.0002). Using ROC curves, a moderate association was found between the preoperative D-point and apical and anatomical success, (AUC 0.689 and 0.662). There was no relationship between preoperative D-point and composite or subjective success (AUC 0.577 and 0.458). Based on the ROC curves, a ""cut-off"" D-point value of -4.25 cm (sensitivity = 0.58, specificity = 0.67) was determined to be a predictor of postoperative anatomical success at 2 years. CONCLUSIONS Preoperative D-point correlates with postoperative anatomical and apical support, but is less successful at predicting subjective outcomes. The strongest predictive D-point cut-off for anatomical and apical success at 24 months was -4.25 cm.",2021,A higher preoperative D-point correlated with improved apical outcome (C-point) at 24 months (r = 0.34; p value = 0.0002).,"['women undergoing USLS with concomitant hysterectomy', '186 women in the USLS arm']","['Operations and Pelvic Muscle Training', 'uterosacral ligament suspension', 'sacrospinous ligament fixation and transvaginal uterosacral ligament suspension (USLS']","['preoperative D-point and composite or subjective success', 'relationship between preoperative D-point and apical outcomes', 'preoperative D-point and anatomical, composite and subjective outcomes']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0230306', 'cui_str': 'Structure of uterosacral ligament'}, {'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0448421', 'cui_str': 'Skeletal muscle structure of pelvis'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0230306', 'cui_str': 'Structure of uterosacral ligament'}, {'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0225049', 'cui_str': 'Structure of sacrospinous ligament'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0175672', 'cui_str': 'Vaginal approach'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0205111', 'cui_str': 'Apical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}]",186.0,0.138307,A higher preoperative D-point correlated with improved apical outcome (C-point) at 24 months (r = 0.34; p value = 0.0002).,"[{'ForeName': 'Lee A', 'Initials': 'LA', 'LastName': 'Richter', 'Affiliation': 'MedStar National Center for Advanced Pelvic Surgery, Georgetown University School of Medicine, Washington, DC, USA. Lee.Ann.Richter@medstar.net.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Bradley', 'Affiliation': 'Department of Obstetrics and Gynecology, Mission Hospital, Asheville, NC, USA.'}, {'ForeName': 'Sameer', 'Initials': 'S', 'LastName': 'Desale', 'Affiliation': 'Department of Biostatistics and Epidemiology, MedStar Health Research Institute, Washington, DC, USA.'}, {'ForeName': 'Holly E', 'Initials': 'HE', 'LastName': 'Richter', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Park', 'Affiliation': ""OB/GYN & Women's Health Institute, Cleveland Clinic, Cleveland, OH, USA.""}, {'ForeName': 'Cheryl B', 'Initials': 'CB', 'LastName': 'Iglesia', 'Affiliation': 'MedStar National Center for Advanced Pelvic Surgery, Georgetown University School of Medicine, Washington, DC, USA.'}]",International urogynecology journal,['10.1007/s00192-021-04687-0'] 1138,33709262,"A randomized controlled trial comparing nociception level (NOL) index, blood pressure, and heart rate responses to direct laryngoscopy versus videolaryngoscopy for intubation: the NOLint project.","PURPOSE The effect of direct laryngoscopy using a Macintosh blade (MAC) vs GlideScope™ videolaryngoscopy using a Spectrum LoPro blade (GVL) on nociceptive stimulation has not been quantitatively studied. This study used the new nociception level (NOL) index to compare the nociceptive response induced by GVL or MAC during laryngoscopy with or without intubation. METHODS Patients underwent two laryngoscopies at four-minute intervals (L1, L2), one with GVL and the other with MAC (first randomization). A third laryngoscopy (L3) followed by tracheal intubation was performed four minutes after L2 (GVL or MAC, second randomization). Nociception was quantitatively assessed by NOL and standard hemodynamic parameters (heart rate [HR] and mean arterial pressure). For the crossover design, blade comparisons accounted for sequence and blade type. A possible carryover effect between laryngoscopies was assessed. RESULTS In the 50 patients randomized, there was no carryover effect from one laryngoscopy to the next for all analyzed parameters. Nociception level index peak values were higher with MAC than GVL. Analysis of ΔNOL showed a lower nociceptive response with GVL for L1+L2 combined. Mean peak NOL values were significantly higher after L3+intubation than after L1+L2, for both GVL and MAC groups. Analysis of ΔHR values did not show a significant difference between GVL and MAC for any laryngoscopy. CONCLUSION Laryngoscopy alone with GVL induces less nociception than with MAC. The NOL was more sensitive than HR at detecting nociceptive responses to MAC vs GVL. Additionally, and irrespective of which technique/blade was used, the combination of laryngoscopy + tracheal intubation produced a much greater nociceptive response than the laryngoscopy alone. TRIAL REGISTRATION www.clinicaltrials.gov (NCT03277872); registered 29 August 2017.",2021,"In the 50 patients randomized, there was no carryover effect from one laryngoscopy to the next for all analyzed parameters.","['Patients underwent two laryngoscopies at four-minute intervals (L1, L2), one with GVL and the other with MAC (first randomization']","['direct laryngoscopy using a Macintosh blade (MAC) vs GlideScope™ videolaryngoscopy using a Spectrum LoPro blade (GVL', 'laryngoscopy + tracheal intubation', 'GVL', 'direct laryngoscopy versus videolaryngoscopy', 'GVL or MAC']","['Nociception level index peak values', 'Nociception', 'Mean peak', 'nociception level (NOL) index, blood pressure, and heart rate responses', 'NOL values', 'NOL and standard hemodynamic parameters (heart rate [HR] and mean arterial pressure', 'nociceptive response', 'new nociception level (NOL) index']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023072', 'cui_str': 'Laryngoscopy'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0600554', 'cui_str': 'Graft-vs-Leukemia Effect'}, {'cui': 'C2948008', 'cui_str': 'Blade'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C0392823', 'cui_str': 'Direct laryngoscopy'}, {'cui': 'C2948008', 'cui_str': 'Blade'}, {'cui': 'C0600554', 'cui_str': 'Graft-vs-Leukemia Effect'}, {'cui': 'C0023072', 'cui_str': 'Laryngoscopy'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C0234194', 'cui_str': 'Nociperception'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1997754', 'cui_str': 'Heart rate response'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0205314', 'cui_str': 'New'}]",50.0,0.0270636,"In the 50 patients randomized, there was no carryover effect from one laryngoscopy to the next for all analyzed parameters.","[{'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Sbeghen', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Verdonck', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'McDevitt', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Zaphiratos', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Brulotte', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Loubert', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Issam', 'Initials': 'I', 'LastName': 'Tanoubi', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Drolet', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Marie-Eve', 'Initials': 'ME', 'LastName': 'Belanger', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Louis-Philippe', 'Initials': 'LP', 'LastName': 'Fortier', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Godin', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada.""}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Guertin', 'Affiliation': 'Department of Statistics, Montreal Health Innovations Coordinating Center (MHICC), Montréal, QC, Canada.'}, {'ForeName': 'Annik', 'Initials': 'A', 'LastName': 'Fortier', 'Affiliation': 'Department of Statistics, Montreal Health Innovations Coordinating Center (MHICC), Montréal, QC, Canada.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Richebé', 'Affiliation': ""Department of Anesthesiology and Pain Medicine of University of Montreal, and the Department of Anesthesiology and Pain Medicine of Maisonneuve Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montréal, University of Montreal, 5415, Boulevard de l'Assomption, Montréal, QC, H1T 2M4, Canada. philippe.richebe@umontreal.ca.""}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-021-01936-0'] 1139,33721359,Does muscular or mental fatigue have an influence on the nociceptive flexion reflex? A randomized cross-over study in healthy people.,"BACKGROUND The nociceptive flexion reflex (NFR) is a spinally-mediated withdrawal reflex occurring in response to noxious stimuli and is used as an electrophysiological marker of spinal nociception. Although it is well-documented that the NFR is subject to powerful modulation of several personal factors, the effects of experimentally induced fatigue on the NFR have not yet been examined. Hence, this study aimed to characterize if and how fatigue affects spinal nociception in healthy adults. METHODS The NFR of 58 healthy people was measured prior to and following rest and two fatiguing tasks performed in randomized order. The NFR was elicited by transcutaneous electrical stimulation of the sural nerve and objectified by electromyographic recordings from the biceps femoris muscle. An isokinetic fatiguing protocol was used to induce localized muscle fatigue of the hamstrings. The modified incongruent Stroop-word task was used to provoke mental fatigue. A linear mixed model analysis was performed to assess the influence of fatigue on the NFR. RESULTS Low-to-moderate levels experimentally induced localized muscle and mental fatigue did not affect the NFR in healthy adults. These results suggest that descending pain inhibitory processes to dampen spinal nociception are resistant to the effects of localized muscle and mental fatigue. CONCLUSIONS The relative robustness of the NFR to fatigue may be beneficial in both clinical and research settings where the influence of confounders complicates interpretation. Furthermore, the findings possibly help enhance our understanding on why even demanding cognitive/physical exercise-based treatment programs form effective treatment strategies for patients with chronic pain. SIGNIFICANCE The present study unraveled that low-to-moderate levels experimentally induced localized muscle and mental fatigue did not affect the NFR. These results suggest that descending pain inhibitory processes to dampen spinal nociception are resistant to the effects of localized muscle and mental fatigue. This relative robustness of the NFR may be beneficial in a clinical setting in which the evaluation of spinal nociception that is unaffected by clinical symptoms of fatigue may be useful (e.g. chronic fatigue syndrome, cancer-related fatigue, etc.).",2021,"Fatigue is a widespread complaint in both healthy and diseased individuals (Engberg et al., 2017; Finsterer et al., 2014) that is often described as an overwhelming sense of tiredness, lack of energy, and feeling of exhaustion (Gruet et al., 2013).",['healthy people'],[],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}]",[],[],,0.0569837,"Fatigue is a widespread complaint in both healthy and diseased individuals (Engberg et al., 2017; Finsterer et al., 2014) that is often described as an overwhelming sense of tiredness, lack of energy, and feeling of exhaustion (Gruet et al., 2013).","[{'ForeName': 'Evy', 'Initials': 'E', 'LastName': 'Dhondt', 'Affiliation': 'SPINE Research Unit Ghent, Department of Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Lieven', 'Initials': 'L', 'LastName': 'Danneels', 'Affiliation': 'SPINE Research Unit Ghent, Department of Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Rijckaert', 'Affiliation': 'SPINE Research Unit Ghent, Department of Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Tanneke', 'Initials': 'T', 'LastName': 'Palmans', 'Affiliation': 'SPINE Research Unit Ghent, Department of Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Van Oosterwijck', 'Affiliation': 'SPINE Research Unit Ghent, Department of Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Van Oosterwijck', 'Affiliation': 'SPINE Research Unit Ghent, Department of Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.'}]","European journal of pain (London, England)",['10.1002/ejp.1763'] 1140,33694206,Wall thickness-based adjustment of ablation index improves efficacy of pulmonary vein isolation in atrial fibrillation: Real-time assessment by intracardiac echocardiography.,"BACKGROUND Ablation index (AI) linearly correlates with lesion depth and may yield better therapeutic performance in pulmonary vein isolation (PVI) when tailored to a patient's wall thickness (WT) in the left atrium (LA). METHODS AND RESULTS First study: In paroxysmal atrial fibrillation patients (PAF; n = 20), the average LA WT (mm) in each anatomical segment for PVI was measured by intracardiac echocardiography (ICE) placed in the LA; the optimal AI for creating 1-mm transmural lesion (AI/mm) was calculated. Second study: PAF (n = 80) patients were randomly assigned either to a force-time integral protocol (FTI; 400 g·s, n = 40) or a tailored-AI protocol (TAI; n = 40). In TAI, the LA WT in each segment was individually measured by ICE before starting ablation; a target AI was adjusted according to the individual WT in each segment (AI/mm × WT). The acute procedure outcomes and the 1-year AF-recurrence rate were compared between FTI and TAI. TAI had higher success rate of first-pass isolation (88% vs. 65%) and had lower incidence of residual PV-potentials/conduction-gaps after a circular ablation than FTI (15% vs. 45%). The procedure time to complete PVI decreased in TAI compared to FTI (52 vs. 83 min), being attributed to the increased radiofrequency power and the decreased radiofrequency application time in each point in TAI. TAI had a lower 1-year AF-recurrence rate than FTI. CONCLUSION TAI increased acute procedure success, decreased time for PVI, and reduced the 1-year AF-recurrence rate, compared to FTI. Understanding the precise ablation target and tailoring AI would improve the efficacy of PVI.",2021,"The procedure time to complete PVI decreased in TAI compared to FTI (52 vs. 83 min), being attributed to the increased radiofrequency power and the decreased radiofrequency application time in each point in TAI.","['atrial fibrillation', 'paroxysmal atrial fibrillation patients (PAF; n\u2009=\u200920), the average LA WT (mm) in each anatomical segment for PVI was measured by', 'n\u2009=\u200980) patients']","['TAI', 'force-time integral protocol (FTI; 400\u2009g·s, n\u2009=\u200940) or a tailored-AI protocol', 'PAF', 'intracardiac echocardiography (ICE) placed in the LA']","['1-year AF-recurrence rate', 'acute procedure success', 'radiofrequency application time', 'procedure time to complete PVI', 'time for PVI', 'success rate of first-pass isolation']","[{'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032172', 'cui_str': 'Platelet activating factor'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443238', 'cui_str': 'Integral'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0032172', 'cui_str': 'Platelet activating factor'}, {'cui': 'C0729936', 'cui_str': 'Cardiac chamber structure'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0225860', 'cui_str': 'Left atrial structure'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0444693', 'cui_str': 'First pass'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}]",,0.0316345,"The procedure time to complete PVI decreased in TAI compared to FTI (52 vs. 83 min), being attributed to the increased radiofrequency power and the decreased radiofrequency application time in each point in TAI.","[{'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Motoike', 'Affiliation': 'Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan.'}, {'ForeName': 'Masahide', 'Initials': 'M', 'LastName': 'Harada', 'Affiliation': 'Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan.'}, {'ForeName': 'Takehiro', 'Initials': 'T', 'LastName': 'Ito', 'Affiliation': 'Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Nomura', 'Affiliation': 'Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan.'}, {'ForeName': 'Asuka', 'Initials': 'A', 'LastName': 'Nishimura', 'Affiliation': 'Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Koshikawa', 'Affiliation': 'Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan.'}, {'ForeName': 'Eiichi', 'Initials': 'E', 'LastName': 'Watanabe', 'Affiliation': 'Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan.'}, {'ForeName': 'Yukio', 'Initials': 'Y', 'LastName': 'Ozaki', 'Affiliation': 'Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Izawa', 'Affiliation': 'Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan.'}]",Journal of cardiovascular electrophysiology,['10.1111/jce.15000'] 1141,33737199,The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation.,"ED-INNOVATION (Emergency Department-INitiated bupreNOrphine VAlidaTION) is a Hybrid Type-1 Implementation-Effectiveness multisite emergency department (ED) study funded through The Helping to End Addiction Long-term SM Initiative, or NIH HEAL Initiative SM efforts to increase access to medications for opioid use disorder (OUD). We use components of Implementation Facilitation to enhance adoption of ED-initiated buprenorphine (BUP) at approximately 30 sites. Subsequently we compare the effectiveness of two BUP formulations, sublingual (SL-BUP) and 7-day extended-release injectable (CAM2038, XR-BUP) in a randomized clinical trial (RCT) of approximately 2000 patients with OUD on the primary outcome of engagement in formal addiction treatment at 7 days. Secondary outcomes assessed at 7 and 30 days include self-reported opioid use, craving and satisfaction, health service utilization, overdose events, and engagement in formal addiction treatment (30 days) and receipt of medications for OUD (at 7 and 30 days). A sample size of 1000 per group provides 90% power at the 2-sided significance level to detect a difference in the primary outcome of 8% and accommodates a 15% dropout rate. We will compare the cost effectiveness of the two treatments on the primary outcome using the incremental cost-effectiveness ratio. We will also conduct an ancillary study in approximately 75 patients experiencing minimal to no opioid withdrawal who will undergo XR-BUP initiation. If the ancillary study demonstrates safety, we will expand the eligibility criteria for the RCT to include individuals with minimal to no opioid withdrawal. The results of these studies will inform implementation of ED-initiated BUP in diverse EDs which has the potential to improve treatment access.",2021,A sample size of 1000 per group provides 90% power at the 2-sided significance level to detect a difference in the primary outcome of 8% and accommodates a 15% dropout rate.,"['individuals with minimal to no opioid withdrawal', '2000 patients with OUD on the primary outcome of engagement in formal addiction treatment at 7\u202fdays', 'approximately 75 patients experiencing minimal to no opioid withdrawal who will undergo XR-BUP initiation']","['bupreNOrphine VAlidaTION', 'NIH HEAL', 'BUP formulations, sublingual (SL-BUP) and 7-day extended-release injectable (CAM2038, XR-BUP', 'buprenorphine (BUP', 'buprenorphine']","['incremental cost-effectiveness ratio', 'self-reported opioid use, craving and satisfaction, health service utilization, overdose events, and engagement in formal addiction treatment (30\u202fdays) and receipt of medications for OUD']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0029104', 'cui_str': 'Opioid withdrawal'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}]","[{'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0027468', 'cui_str': 'United States National Institutes of Health'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030672', 'cui_str': 'Health Care Utilization'}, {'cui': 'C0029944', 'cui_str': 'Drug overdose'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",,0.123448,A sample size of 1000 per group provides 90% power at the 2-sided significance level to detect a difference in the primary outcome of 8% and accommodates a 15% dropout rate.,"[{'ForeName': 'Gail', 'Initials': 'G', 'LastName': ""D'Onofrio"", 'Affiliation': 'Emergency Medicine, Yale School of Medicine, New Haven, CT, United States; Yale School of Public Health, New Haven, CT, United States. Electronic address: gail.donofrio@yale.edu.'}, {'ForeName': 'Kathryn F', 'Initials': 'KF', 'LastName': 'Hawk', 'Affiliation': 'Emergency Medicine, Yale School of Medicine, New Haven, CT, United States.'}, {'ForeName': 'Andrew A', 'Initials': 'AA', 'LastName': 'Herring', 'Affiliation': 'Department of Emergency Medicine, Highland Hospital, Oakland, CA, United States.'}, {'ForeName': 'Jeanmarie', 'Initials': 'J', 'LastName': 'Perrone', 'Affiliation': 'Department of Emergency Medicine Perelman, School of Medicine at the University of Pennsylvania, PA, United States.'}, {'ForeName': 'Ethan', 'Initials': 'E', 'LastName': 'Cowan', 'Affiliation': 'Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Ryan P', 'Initials': 'RP', 'LastName': 'McCormack', 'Affiliation': 'Department of Emergency Medicine, NYU Langone Medical Center, New York, NY, United States.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Dziura', 'Affiliation': 'Emergency Medicine, Yale School of Medicine, New Haven, CT, United States.'}, {'ForeName': 'R Andrew', 'Initials': 'RA', 'LastName': 'Taylor', 'Affiliation': 'Emergency Medicine, Yale School of Medicine, New Haven, CT, United States.'}, {'ForeName': 'Edouard', 'Initials': 'E', 'LastName': 'Coupet', 'Affiliation': 'Emergency Medicine, Yale School of Medicine, New Haven, CT, United States.'}, {'ForeName': 'E Jennifer', 'Initials': 'EJ', 'LastName': 'Edelman', 'Affiliation': 'Yale School of Public Health, New Haven, CT, United States; Internal Medicine Yale School of Medicine, New Haven, CT, United States.'}, {'ForeName': 'Michael V', 'Initials': 'MV', 'LastName': 'Pantalon', 'Affiliation': 'Emergency Medicine, Yale School of Medicine, New Haven, CT, United States.'}, {'ForeName': 'Patricia H', 'Initials': 'PH', 'LastName': 'Owens', 'Affiliation': 'Emergency Medicine, Yale School of Medicine, New Haven, CT, United States.'}, {'ForeName': 'Shara H', 'Initials': 'SH', 'LastName': 'Martel', 'Affiliation': 'Emergency Medicine, Yale School of Medicine, New Haven, CT, United States.'}, {'ForeName': 'Patrick G', 'Initials': 'PG', 'LastName': ""O'Connor"", 'Affiliation': 'Yale School of Public Health, New Haven, CT, United States; Internal Medicine Yale School of Medicine, New Haven, CT, United States.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Van Veldhuisen', 'Affiliation': 'The Emmes Corporation, Rockville, MD, United States.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'DeVogel', 'Affiliation': 'The Emmes Corporation, Rockville, MD, United States.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Huntley', 'Affiliation': 'The National Institute on Drug Abuse, Rockville, MD, United States.'}, {'ForeName': 'Sean M', 'Initials': 'SM', 'LastName': 'Murphy', 'Affiliation': 'Weill Cornell Medical College, NY, New York, United States.'}, {'ForeName': 'Michelle R', 'Initials': 'MR', 'LastName': 'Lofwall', 'Affiliation': 'University of Kentucky, College of Medicine Center on Drug and Alcohol Research, Lexington, KY, United States.'}, {'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Walsh', 'Affiliation': 'University of Kentucky, College of Medicine Center on Drug and Alcohol Research, Lexington, KY, United States.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Fiellin', 'Affiliation': 'Emergency Medicine, Yale School of Medicine, New Haven, CT, United States; Yale School of Public Health, New Haven, CT, United States; Internal Medicine Yale School of Medicine, New Haven, CT, United States.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106359'] 1142,33737196,Protocol for a randomized controlled trial of low-intensity physical activity for frail older adults: Promoting seniors' health with home care aides (Pro-Home).,"Regular participation in physical activity benefits older adults physically and mentally. However, the availability and assessment of physical activity programs that are safe and appropriate for homebound older adults at risk for nursing home admission are limited. Here we describe the protocol for a randomized controlled trial that examines the effectiveness of a gentle physical activity program. Delivered by home care aides who regularly help hard-to-reach older home care clients with housekeeping and routine personal care services in the home, this program is implemented in a real-world context of caregiver-client dyads in a Medicaid-funded home care program. The trial uses a two-group repeated measures design (baseline, Month 4, and Month 8) with 300 pairs of eligible home care clients and their home care aides. The results from this trial could provide evidence and guidelines for a new model of home care, which would facilitate the working together of older home care clients and their home care aides to maintain or improve the functional status of nursing home-eligible older adults.",2021,"Delivered by home care aides who regularly help hard-to-reach older home care clients with housekeeping and routine personal care services in the home, this program is implemented in a real-world context of caregiver-client dyads in a Medicaid-funded home care program.","['300 pairs of eligible home care clients and their home care aides', 'nursing home-eligible older adults', ""frail older adults: Promoting Seniors' health with home care aides (Pro-Home"", 'older adults physically and mentally']","['home care aides who regularly help hard-to-reach older home care clients with housekeeping and routine personal care services in the home, this program is implemented in a real-world context of caregiver-client dyads in a Medicaid-funded home care program', 'low-intensity physical activity', 'gentle physical activity program']",['physical activity benefits'],"[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0204977', 'cui_str': 'Home care of patient'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0242797', 'cui_str': 'Home health aide'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033382', 'cui_str': 'Proline'}]","[{'cui': 'C0242797', 'cui_str': 'Home health aide'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0204977', 'cui_str': 'Home care of patient'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0020053', 'cui_str': 'Housework'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0449255', 'cui_str': 'Context'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0025071', 'cui_str': 'Medicaid coverage'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0393265,"Delivered by home care aides who regularly help hard-to-reach older home care clients with housekeeping and routine personal care services in the home, this program is implemented in a real-world context of caregiver-client dyads in a Medicaid-funded home care program.","[{'ForeName': 'Naoko', 'Initials': 'N', 'LastName': 'Muramatsu', 'Affiliation': 'Division of Community Health Sciences, School of Public Health, University of Illinois Chicago, USA; Institute for Health Research and Policy, University of Illinois Chicago, USA. Electronic address: naoko@uic.edu.'}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Yin', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois Chicago, USA.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Berbaum', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois Chicago, USA.'}, {'ForeName': 'David X', 'Initials': 'DX', 'LastName': 'Marquez', 'Affiliation': 'Department of Kinesiology and Nutrition, University of Illinois Chicago, USA.'}, {'ForeName': 'Surrey M', 'Initials': 'SM', 'LastName': 'Walton', 'Affiliation': 'Department of Pharmacy Systems Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Caceres', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois Chicago, USA.'}, {'ForeName': 'Katya Y', 'Initials': 'KY', 'LastName': 'Cruz Madrid', 'Affiliation': 'Division of Academic Internal Medicine and Geriatrics, University of Illinois Chicago, USA; Jesse Brown VA Medical Center, Chicago, Illinois, USA.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Zanoni', 'Affiliation': 'Division of Environmental and Occupational Health Sciences, School of Public Health, University of Illinois Chicago, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106362'] 1143,33676009,Medial Prefrontal High-Definition Transcranial Direct Current Stimulation to Improve Pain Modulation in Chronic Low Back Pain: A Pilot Randomized Double-blinded Placebo-Controlled Crossover Trial.,"Chronic low back pain (CLBP) is highly disabling, but often without identifiable source. Focus has been on impaired anti-nociceptive mechanisms contributing to pain maintenance, though methods of targeting this impairment remain limited. This randomised-controlled cross-over pilot trial used active versus sham medial prefrontal cortex (mPFC) high-definition transcranial direct current stimulation (HD-tDCS) for 3-consecutive days to improve descending pain inhibitory function. Twelve CLBP patients were included with an average visual analogue scale (VAS) pain intensity of 3.0 ± 1.5 and pain duration of 5.3 ± 2.6 years. Pressure pain thresholds (PPTs), conditioned pain modulation (CPM), and temporal summation of pain (TSP) assessed by cuff algometry, as well as pain symptomatology (intensity, unpleasantness, quality, disability) and related psychological features (pain catastrophizing, anxiety, affect), were assessed on Day1 before 3 consecutive days of HD-tDCS sessions (each 20 minutes), at 24-hours (Day 4) and 2-weeks (Day 21) following final HD-tDCS. Blinding was successful. No significant differences in psychophysical (PPT, CPM, TSP), symptomatology or psychological outcomes were observed between active and sham HD-tDCS on Day4 and Day21. CPM-effects at Day 1 negatively correlated with change in CPM-effect at Day4 following active HD-tDCS (P = .002). Lack of efficacy was attributed to several factors, not least that patients did not display impaired CPM at baseline. TRIAL REGISTRATION: : ClinicalTrials.gov (NCT03864822). PERSPECTIVE: Medial prefrontal HD-tDCS did not alter pain, psychological nor psychophysical outcomes, though correlational analysis suggested response may depend on baseline pain inhibitory efficacy, with best potential effects in patients with severe impairments in descending pain inhibitory mechanisms. Future work should focus on appropriate patient selection and optimising stimulation targeting.",2021,"No significant differences in psychophysical (PPT, CPM, TSP), symptomatology or psychological outcomes were observed between active and sham HD-tDCS on Day4 and Day21.","['Chronic Low Back Pain', 'Twelve CLBP patients', 'Chronic low back pain (CLBP', 'patients with severe impairments in descending pain inhibitory mechanisms']","['Placebo', 'Medial Prefrontal High-Definition Transcranial Direct Current Stimulation', 'active versus sham medial prefrontal cortex (mPFC) high-definition transcranial direct current stimulation (HD-tDCS']","['Pressure pain thresholds (PPTs), conditioned pain modulation (CPM), and temporal summation of pain (TSP) assessed by cuff algometry, as well as pain symptomatology (intensity, unpleasantness, quality, disability) and related psychological features (pain catastrophizing, anxiety, affect', 'psychophysical (PPT, CPM, TSP), symptomatology or psychological outcomes', 'CPM-effects', 'average visual analogue scale (VAS) pain intensity']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0205386', 'cui_str': 'Descending'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}]","[{'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0234110', 'cui_str': 'Temporal summation'}, {'cui': 'C0441107', 'cui_str': 'Device cuff'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0032334', 'cui_str': 'podofilox'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",12.0,0.469232,"No significant differences in psychophysical (PPT, CPM, TSP), symptomatology or psychological outcomes were observed between active and sham HD-tDCS on Day4 and Day21.","[{'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'McPhee', 'Affiliation': 'Center for Neuroplasticity and Pain (CNAP), Aalborg University, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Graven-Nielsen', 'Affiliation': 'Center for Neuroplasticity and Pain (CNAP), Aalborg University, Denmark. Electronic address: tgn@hst.aau.dk.'}]",The journal of pain,['10.1016/j.jpain.2021.02.012'] 1144,33677113,"Spa Therapy for the Treatment of Fibromyalgia: An Open, Randomized Multicenter Trial.","Fibromyalgia is a common chronic pain pathology with an incidence of 4.3 per 1,000 person-years. An open, randomized clinical trial of patients with fibromyalgia comparing an immediate vs. delayed 18-day spa therapy in five spa therapy care facilities in France enrolled 220 patients. Randomization was in blocks of four, stratified by center, severity of fibromyalgia and previous spa therapy. Patients continued usual treatment. The main endpoint was the number of patients achieving minimal clinically important difference at 6 months, defined as 14% change in their baseline fibromyalgia impact questionnaire score. The intention-to-treat analysis included 100 and 106 patients in the intervention and control groups, respectively. At 6 months, 45/100 (45.0%) and 30/106 (28.3%) patients in the intervention and control groups, respectively, achieved a minimal clinically important difference (P= .013). There was also a significant improvement in pain, fatigue, and symptom severity (secondary outcomes) in the intervention group but not for generic quality of life (QOL), sleep or physical activity. None of the 33 serious adverse events reported by 25 patients were related to the spa therapy. Our results demonstrate the benefit of spa treatment in patients with fibromyalgia. PERSPECTIVE: A 12-month, open, randomized clinical trial of 220 patients with fibromyalgia compared an immediate versus delayed (ie, after 6 months) 18-day spa therapy. The results showed a clinically significant improvement at 6 months for those who received immediate therapy which was maintained up to 12 months. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT02265029.",2021,The results showed a clinically significant improvement at 6 months for those who received immediate therapy which was maintained up to 12 months.,"['220 patients with fibromyalgia compared an immediate vs. delayed (i.e. after 6 months) 18-day spa therapy', 'patients with fibromyalgia', 'patients with fibromyalgia comparing an', 'fibromyalgia', 'five spa therapy care facilities in France enrolled 220 patients']","['immediate vs. delayed 18-day spa therapy', 'Spa therapy']","['number of patients achieving minimal clinically important difference (MCID', 'generic quality of life (QOL), sleep or physical activity', 'baseline fibromyalgia impact questionnaire (FIQ) score', 'pain, fatigue, and symptom severity']","[{'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0016674', 'cui_str': 'France'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4277733', 'cui_str': 'Minimal Clinically Important Difference'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}]",220.0,0.159302,The results showed a clinically significant improvement at 6 months for those who received immediate therapy which was maintained up to 12 months.,"[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Maindet', 'Affiliation': 'Pain Medicine Department, CHU Grenoble Alpes, Grenoble, France; University of Grenoble Alpes, CNRS, TIMC-IMAG (UMR 5525), Grenoble, France.'}, {'ForeName': 'Aurore', 'Initials': 'A', 'LastName': 'Maire', 'Affiliation': 'Centre for the Study and Treatment of Pain, Hôpital Lariboisière, AP-HP, Paris, France.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Vermorel', 'Affiliation': 'University of Grenoble Alpes, CNRS, TIMC-IMAG (UMR 5525), Grenoble, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Cracowski', 'Affiliation': 'Pharmacology Department, INSERM CIC 1406, Grenoble, France.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Rolland', 'Affiliation': 'University of Grenoble Alpes, CNRS, TIMC-IMAG (UMR 5525), Grenoble, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Forestier', 'Affiliation': 'Centre for Rheumatology and Balneotherapy Research, Aix Les Bains, France.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'Comte', 'Affiliation': 'University of Grenoble Alpes, CNRS, TIMC-IMAG (UMR 5525), Grenoble, France.'}, {'ForeName': 'Christian-François', 'Initials': 'CF', 'LastName': 'Roques', 'Affiliation': 'University of Toulouse, Toulouse, France (President of AFRETH Scientific Committee).'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Serra', 'Affiliation': 'CHU Amiens, Laboratoire PSITEC EA/ULR 4072, Lille, France.'}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Bosson', 'Affiliation': 'University of Grenoble Alpes, CNRS, TIMC-IMAG (UMR 5525), Grenoble, France; Public Health Department, CHU Grenoble Alpes, Grenoble, France. Electronic address: jean-luc.bosson@univ-grenoble-alpes.fr.'}]",The journal of pain,['10.1016/j.jpain.2021.02.010'] 1145,33706569,Effects of inspiratory muscle training on walking capacity of individuals after stroke: A double-blind randomized trial.,"OBJECTIVES Identify the effects of inspiratory muscle training (IMT) on walking capacity, strength and inspiratory muscle endurance, activities of daily living, and quality of life poststroke. DESIGN Double-blind randomized trial. SETTING The Sarah Network of Rehabilitation Hospitals. SUBJECTS Adult poststroke inpatients with inspiratory muscle weakness. INTERVENTIONS The Experimental Group (EG) ( n  = 23) underwent IMT for 30 minutes/day, five times/week over six weeks. The Control Group (CG) ( n  = 27) performed sham IMT. Both groups underwent standard rehabilitation. MAIN MEASURES Primary outcome was post-intervention six-minute walking test (6MWT) distance. We also measured maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), inspiratory muscle endurance, activities of daily living (functional independence measure - FIM), and quality of life at baseline and post-intervention. Three months after intervention, we measured MIP, walking capacity and quality of life. RESULTS Baseline characteristics were similar, with mean age 53 ± 11 years and FIM 74 ± 10p. Both groups similarly increased the walking capacity at six weeks (63 vs 67 m, P  = 0.803). Compared to the CG, the EG increased the inspiratory endurance (22 vs 7 cmH 2 O, P  = 0.034) but there was no variation in MEP (14 vs 5 cmH 2 O, P  = 0.102), MIP (27 vs 19 cmH 2 O, P  = 0.164), FIM (6 vs 6, P  = 0.966) or quality of life (0 vs 0.19, P  = 0.493). Gains in both groups were sustained at three months. CONCLUSION Adding IMT to a rehabilitation program improves inspiratory muscle endurance, but does not further improve MIP, 6-MWT distance, activities of daily living or quality of life of individuals after stroke beyond rehabilitation alone.Registered in Clinical Trials, NCT03171272.",2021,"Both groups similarly increased the walking capacity at six weeks (63 vs 67 m, P  = 0.803).","['Adult poststroke inpatients with inspiratory muscle weakness', 'individuals after stroke']","['inspiratory muscle training (IMT', 'sham IMT', 'standard rehabilitation', 'IMT', 'inspiratory muscle training']","['walking capacity, strength and inspiratory muscle endurance, activities of daily living, and quality of life poststroke', 'MIP, walking capacity and quality of life', 'quality of life', 'inspiratory endurance', 'MEP', 'maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), inspiratory muscle endurance, activities of daily living (functional independence measure - FIM), and quality of life', 'post-intervention six-minute walking test (6MWT) distance', 'FIM', 'inspiratory muscle endurance', 'MIP, 6-MWT distance, activities of daily living or quality of life', 'walking capacity', 'MIP']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0030552', 'cui_str': 'Paresis'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C4083126', 'cui_str': 'Maximum Inspiratory Pressure'}, {'cui': 'C4082175', 'cui_str': 'Maximum Expiratory Pressure'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429925', 'cui_str': 'Test distance'}, {'cui': 'C0012751', 'cui_str': 'Distance'}]",,0.246808,"Both groups similarly increased the walking capacity at six weeks (63 vs 67 m, P  = 0.803).","[{'ForeName': 'Lorena de Oliveira', 'Initials': 'LO', 'LastName': 'Vaz', 'Affiliation': 'The SARAH Network of Rehabilitation Hospitals, Salvador, Bahia, Brazil.'}, {'ForeName': 'Juliana de Carvalho', 'Initials': 'JC', 'LastName': 'Almeida', 'Affiliation': 'The SARAH Network of Rehabilitation Hospitals, Salvador, Bahia, Brazil.'}, {'ForeName': 'Karla Simone Dos Santos Oliveira', 'Initials': 'KSDSO', 'LastName': 'Froes', 'Affiliation': 'The SARAH Network of Rehabilitation Hospitals, Salvador, Bahia, Brazil.'}, {'ForeName': 'Cristiane', 'Initials': 'C', 'LastName': 'Dias', 'Affiliation': 'Motor Behavior and Neurorehabilitation Research Group, Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil.'}, {'ForeName': 'Elen Beatriz', 'Initials': 'EB', 'LastName': 'Pinto', 'Affiliation': 'Motor Behavior and Neurorehabilitation Research Group, Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil.'}, {'ForeName': 'Jamary', 'Initials': 'J', 'LastName': 'Oliveira-Filho', 'Affiliation': 'Postgraduate Program in Health Sciences, Federal University of Bahia School of Medicine, Salvador, Bahia, Brazil.'}]",Clinical rehabilitation,['10.1177/0269215521999591'] 1146,33705169,"A randomized trial of an online, coach-assisted self-management PTSD intervention tailored for women veterans.","OBJECTIVE Scalable, efficiently delivered treatments are needed to address the needs of women Veterans with PTSD. This randomized clinical trial compared an online, coach-assisted cognitive behavioral intervention tailored for women Veterans with PTSD to phone monitoring only. METHOD Women Veterans who met diagnostic criteria for PTSD were randomized to an 8-week web-based intervention, called DElivery of Self TRaining and Education for Stressful Situations (DESTRESS)-Women Veterans version (WV), or to phone monitoring only (N = 102). DESTRESS-WV consisted of online sessions and 15-min weekly phone calls from a study coach. Phone monitoring included 15-min weekly phone calls from a study coach to offer general support. PTSD symptom severity (PTSD Symptom-Checklist-Version 5 [PCL-5]) was evaluated pre and posttreatment, and at 3 and 6 months posttreatment. RESULTS More participants completed phone monitoring than DESTRESS-WV (96% vs. 76%, p = 0.01), although treatment satisfaction was significantly greater in the DESTRESS-WV condition. We failed to confirm the superiority of DESTRESS-WV in intent-to-treat slope changes in PTSD symptom severity. Both treatments were associated with significant reductions in PTSD symptom severity over time. However, post hoc analyses of treatment completers and of those with baseline PCL ≥ 33 revealed that the DESTRESS-WV group had greater improvement in PTSD symptom severity relative to phone monitoring with significant differences at the 3-month follow-up assessment. CONCLUSIONS Both DESTRESS-WV and phone monitoring resulted in significant improvements in women Veterans' PTSD symptoms. DESTRESS-WV may be an appropriate care model for women Veterans who can engage in the demands of the treatment and have higher baseline symptoms. Future research should explore characteristics of and the methods of reliably identifying women Veterans who are most likely to benefit. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"RESULTS More participants completed phone monitoring than DESTRESS-WV (96% vs. 76%, p = 0.01), although treatment satisfaction was significantly greater in the DESTRESS-WV condition.","[""women Veterans' PTSD symptoms"", 'women veterans', 'women Veterans who can engage in the demands of the treatment and have higher baseline symptoms', 'women Veterans with PTSD', 'women Veterans with PTSD to phone monitoring only', 'Women Veterans who met diagnostic criteria for PTSD']","['online, coach-assisted cognitive behavioral intervention', 'online, coach-assisted self-management PTSD intervention', '8-week web-based intervention, called DElivery of Self TRaining and Education for Stressful Situations (DESTRESS)-Women Veterans version (WV), or to phone monitoring only']","['PTSD symptom severity (PTSD Symptom-Checklist-Version 5 [PCL-5', 'PTSD symptom severity', 'treatment satisfaction']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C3898714', 'cui_str': 'Internet Intervention'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0451524', 'cui_str': 'Symptom checklist'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C1704423', 'cui_str': 'Hereditary lymphedema'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0248316,"RESULTS More participants completed phone monitoring than DESTRESS-WV (96% vs. 76%, p = 0.01), although treatment satisfaction was significantly greater in the DESTRESS-WV condition.","[{'ForeName': 'Keren', 'Initials': 'K', 'LastName': 'Lehavot', 'Affiliation': 'Health Services Research & Development Center of Innovation.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Millard', 'Affiliation': 'Geriatric Research Education and Clinical Center.'}, {'ForeName': 'Rachel M', 'Initials': 'RM', 'LastName': 'Thomas', 'Affiliation': 'Health Services Research & Development Center of Innovation.'}, {'ForeName': 'Konstantina', 'Initials': 'K', 'LastName': 'Yantsides', 'Affiliation': 'Health Services Research & Development Center of Innovation.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Upham', 'Affiliation': 'Health Services Research & Development Center of Innovation.'}, {'ForeName': 'Kerry', 'Initials': 'K', 'LastName': 'Beckman', 'Affiliation': 'Health Services Research & Development Center of Innovation.'}, {'ForeName': 'Alison B', 'Initials': 'AB', 'LastName': 'Hamilton', 'Affiliation': 'VA HSR&D Center for the Study of Healthcare Innovation, Implementation, & Policy.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Sadler', 'Affiliation': 'The Center for Comprehensive Access & Delivery Research and Evaluation.'}, {'ForeName': 'Brett', 'Initials': 'B', 'LastName': 'Litz', 'Affiliation': 'Massachusetts Veterans Epidemiological Research and Information Center.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Simpson', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000556'] 1147,33710344,Reducing NF-κB Signaling Nutritionally is Associated with Expedited Recovery of Skeletal Muscle Function After Damage.,"CONTEXT The early events regulating the remodeling program following skeletal muscle damage are poorly understood. OBJECTIVE The objective of this study was to determine the association between myofibrillar protein synthesis (myoPS) and nuclear factor-kappa B (NF-κB) signaling by nutritionally accelerating the recovery of muscle function following damage. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTIONS Healthy males and females consumed daily postexercise and prebed protein-polyphenol (PP; n = 9; 4 females) or isocaloric maltodextrin placebo (PLA; n = 9; 3 females) drinks (parallel design) 6 days before and 3 days after 300 unilateral eccentric contractions of the quadriceps during complete dietary control. MAIN OUTCOME MEASURES Muscle function was assessed daily, and skeletal muscle biopsies were taken after 24, 27, and 36 hours for measurements of myoPS rates using deuterated water, and gene ontology and NF-κB signaling analysis using a quantitative reverse transcription PCR (RT-qPCR) gene array. RESULTS Eccentric contractions impaired muscle function for 48 hours in PLA intervention, but just for 24 hours in PP intervention (P = 0.047). Eccentric quadricep contractions increased myoPS compared with the control leg during postexercise (24-27 hours; 0.14 ± 0.01 vs 0.11 ± 0.01%·h-1, respectively; P = 0.075) and overnight periods (27-36 hours; 0.10 ± 0.01 vs 0.07 ± 0.01%·h-1, respectively; P = 0.020), but was not further increased by PP drinks (P > 0.05). Protein-polyphenol drinks decreased postexercise and overnight muscle IL1R1 (PLA = 2.8 ± 0.4, PP = 1.1 ± 0.4 and PLA = 1.9 ± 0.4, PP = 0.3 ± 0.4 log2 fold-change, respectively) and IL1RL1 (PLA = 4.9 ± 0.7, PP = 1.6 ± 0.8 and PLA = 3.7 ± 0.6, PP = 0.7 ± 0.7 log2 fold-change, respectively) messenger RNA expression (P < 0.05) and downstream NF-κB signaling compared with PLA. CONCLUSION Protein-polyphenol drink ingestion likely accelerates recovery of muscle function by attenuating inflammatory NF-κB transcriptional signaling, possibly to reduce aberrant tissue degradation rather than increase myoPS rates.",2021,PP decreased post-exercise and overnight muscle IL1R1,['Healthy males and females'],"['PP ingestion', 'myofibrillar protein synthesis (myoPS) and nuclear factor-kappa B (NF-κB', 'consumed daily post-exercise and pre-bed protein-polyphenol', 'isocaloric maltodextrin placebo (PLA; n=9; 3 females) drinks (parallel design']","['Muscle function was assessed daily, and skeletal muscle biopsies', 'muscle function', 'PP decreased post-exercise and overnight muscle IL1R1', 'EC increased myoPS', 'IL1RL1']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0597295', 'cui_str': 'Genetic translation'}, {'cui': 'C0079904', 'cui_str': 'Immunoglobulin Enhancer-Binding Protein'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2315740', 'cui_str': 'Biopsy of skeletal muscle'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0597295', 'cui_str': 'Genetic translation'}, {'cui': 'C0212532', 'cui_str': 'IL1RL1 protein, human'}]",,0.0637587,PP decreased post-exercise and overnight muscle IL1R1,"[{'ForeName': 'Tom S O', 'Initials': 'TSO', 'LastName': 'Jameson', 'Affiliation': 'Nutritional Physiology Group, Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, Exeter, Devon EX1 2LU, UK.'}, {'ForeName': 'George F', 'Initials': 'GF', 'LastName': 'Pavis', 'Affiliation': 'Nutritional Physiology Group, Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, Exeter, Devon EX1 2LU, UK.'}, {'ForeName': 'Marlou L', 'Initials': 'ML', 'LastName': 'Dirks', 'Affiliation': 'Nutritional Physiology Group, Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, Exeter, Devon EX1 2LU, UK.'}, {'ForeName': 'Benjamin P', 'Initials': 'BP', 'LastName': 'Lee', 'Affiliation': 'Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, University of Exeter, Exeter, Devon EX1 2LU, UK.'}, {'ForeName': 'Doaa R', 'Initials': 'DR', 'LastName': 'Abdelrahman', 'Affiliation': 'Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Murton', 'Affiliation': 'Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555, USA.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Porter', 'Affiliation': 'Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555, USA.'}, {'ForeName': 'Nima', 'Initials': 'N', 'LastName': 'Alamdari', 'Affiliation': 'Beachbody LLC, Santa Monica, CA 90404, USA.'}, {'ForeName': 'Catherine R', 'Initials': 'CR', 'LastName': 'Mikus', 'Affiliation': 'Beachbody LLC, Santa Monica, CA 90404, USA.'}, {'ForeName': 'Benjamin T', 'Initials': 'BT', 'LastName': 'Wall', 'Affiliation': 'Nutritional Physiology Group, Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, Exeter, Devon EX1 2LU, UK.'}, {'ForeName': 'Francis B', 'Initials': 'FB', 'LastName': 'Stephens', 'Affiliation': 'Nutritional Physiology Group, Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, Exeter, Devon EX1 2LU, UK.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgab106'] 1148,33724542,Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.,"We prospectively assessed, with predefined criteria, the location and rates of all femur fractures (hip, subtrochanteric/femoral shaft [ST/FS], including atypical [AFF] and distal fractures) in women at increased fracture risk during treatment with the cathepsin K inhibitor, odanacatib (ODN), or placebo over 5 years in the Long-Term ODN Fracture Trial (LOFT and LOFT Extension [NCT00529373, EudraCT 2007-002693-66]). ODN was an investigational antiresorptive agent previously in development as an osteoporosis treatment that, unlike bisphosphonates, reduces bone formation only transiently. Women aged ≥65 years with a bone mineral density (BMD) T-score ≤-2.5 at the total hip (TH) or femoral neck (FN) or with a radiographic vertebral fracture and T-scores ≤-1.5 at the TH or FN were randomized (1:1) to receive ODN 50 mg/week or placebo. All patients received vitamin D 3 (5600 IU/week) and calcium (total 1200 mg/d); the analysis included 16,071 women. Rates of all adjudicated low-energy femoral fractures were 0.38 versus 0.58/100 patient-years for ODN and placebo, respectively (hazard ratio [HR] = 0.65; 95% confidence interval [CI] 0.51-0.82; nominal p < .001), and for low-energy hip fractures were 0.29 versus 0.56/100 patient-years, respectively (HR = 0.52; 95% CI 0.40-0.67; p < .001). The cumulative incidence of combined hip and ST/FS or hip fractures alone in the ODN group was consistently lower than in the placebo group (1.93% versus 3.11% for combined fractures and 1.53% versus 3.03% for hip fractures at 5 years, respectively). However, low-energy ST/FS fractures were more frequent in ODN-treated women than in placebo-treated women (24 versus 6, respectively). Among these, 12 fractures were adjudicated as AFF in 10 patients treated with ODN (0.03/100 patient-years) compared with none in the 6 placebo-treated women (estimated difference 0.03; 95% CI 0.02-0.06). These results provide insight into possible pathogeneses of AFF, suggesting that the current criteria for diagnosing these fractures may need to be reconsidered. © 2021 American Society for Bone and Mineral Research (ASBMR)..",2021,"However, low-energy ST/FS fractures were more frequent in ODN-treated women than placebo-treated women (24 versus 6, respectively).","['Postmenopausal Women with Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial', 'Women aged ≥65\u2009years with a BMD T-score\u2009≤\u2009-2.5 at the TH or FN, or with a radiographic vertebral fracture and T-scores ≤\u2009-\u20091.5 at the TH or FN', 'over 5\u2009years in the Long-Term ODN Fracture Trial (LOFT and LOFT Extension [NCT00529373, EudraCT 2007-002693-66']","['calcium', 'vitamin D', 'placebo', 'cathepsin K inhibitor, odanacatib (ODN), or placebo', 'Hip and Subtrochanteric/Femoral Shaft Fractures', 'ODN 50\u2009mg/week or placebo']","['low-energy hip fractures', 'low-energy ST/FS fractures', 'cumulative incidence of combined hip and ST/FS or hip fractures alone', 'location and rates of all femur fractures (hip, subtrochanteric/femoral shaft [ST/FS], including atypical [AFF], and distal fractures']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C2351970', 'cui_str': 'odanacatib'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0080179', 'cui_str': 'Fracture of vertebral column'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0563050', 'cui_str': 'Attic'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0284930', 'cui_str': 'Cathepsin K'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C2351970', 'cui_str': 'odanacatib'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0272753', 'cui_str': 'Fracture of shaft of femur'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0015802', 'cui_str': 'Fracture of femur'}, {'cui': 'C0588193', 'cui_str': 'Bone structure of shaft of femur'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205182', 'cui_str': 'Atypical'}, {'cui': 'C0205108', 'cui_str': 'Distal'}]",16071.0,0.234306,"However, low-energy ST/FS fractures were more frequent in ODN-treated women than placebo-treated women (24 versus 6, respectively).","[{'ForeName': 'Socrates', 'Initials': 'S', 'LastName': 'Papapoulos', 'Affiliation': 'Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Bone', 'Affiliation': 'Michigan Bone & Mineral Clinic, Detroit, MI, USA.'}, {'ForeName': 'Felicia', 'Initials': 'F', 'LastName': 'Cosman', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Dempster', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'McClung', 'Affiliation': 'Oregon Osteoporosis Center, Portland, OR, USA.'}, {'ForeName': 'Toshitaka', 'Initials': 'T', 'LastName': 'Nakamura', 'Affiliation': 'University of Occupational and Environmental Health, Fukuoka, Japan.'}, {'ForeName': 'José Fernando Molina', 'Initials': 'JFM', 'LastName': 'Restrepo', 'Affiliation': 'Reumalab, Medellín, Colombia.'}, {'ForeName': 'Mary L', 'Initials': 'ML', 'LastName': 'Bouxsein', 'Affiliation': 'Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, and Department of Orthopedic Surgery, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Dosinda', 'Initials': 'D', 'LastName': 'Cohn', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'de Papp', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Rachid', 'Initials': 'R', 'LastName': 'Massaad', 'Affiliation': 'MSD Europe Inc., Brussels, Belgium.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Santora', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.4284'] 1149,33723507,Use of ivermectin in the treatment of Covid-19: A pilot trial.,"Objectives In this randomized open-label trial pilot study we assessed the antiviral effects and safety of various doses of ivermectin in patients with mild clinical symptoms of COVID-19. Methods Patients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS-CoV-2 RT PCR tests within 7 days of the start of the dosing period. This study was registered at ClinicalTrials.gov (NCT04431466). Results A total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious adverse events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for obtaining two consecutive negative SARS-CoV-2 RT PCR tests. Conclusions Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load. This antiviral effect appears to depend on the dose used, and if confirmed in future studies, it suggests that ivermectin may be a useful adjuvant to the SOC treatment in patients with mild COVID-19 symptoms.",2021,"Conclusions Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load.","['patients with mild COVID-19 symptoms', 'Covid-19', 'patients with mild clinical symptoms of COVID-19', '32 patients']","['standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin', 'Ivermectin', 'ivermectin']","['serious adverse events', 'antiviral effects and safety', 'SARS-CoV-2 viral load', 'consecutive negative SARS-CoV-2 RT PCR tests']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0022322', 'cui_str': 'Ivermectin'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1627892', 'cui_str': 'ug/kg'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0003451', 'cui_str': 'Antiviral'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",32.0,0.130416,"Conclusions Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load.","[{'ForeName': 'Henrique', 'Initials': 'H', 'LastName': 'Pott-Junior', 'Affiliation': 'Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.'}, {'ForeName': 'Mônica Maria', 'Initials': 'MM', 'LastName': 'Bastos Paoliello', 'Affiliation': 'Department of Molecular Pharmacology, Albert Einstein College of Medicine, 10461, Bronx, New York, United States.'}, {'ForeName': 'Alice de Queiroz Constantino', 'Initials': 'AQC', 'LastName': 'Miguel', 'Affiliation': 'University Hospital of the Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.'}, {'ForeName': 'Anderson Ferreira', 'Initials': 'AF', 'LastName': 'da Cunha', 'Affiliation': 'Department of Genetics and Evolution, Federal University of São Carlos (UFSCar); 13565-905, São Carlos, São Paulo, Brazil.'}, {'ForeName': 'Caio Cesar', 'Initials': 'CC', 'LastName': 'de Melo Freire', 'Affiliation': 'Department of Genetics and Evolution, Federal University of São Carlos (UFSCar); 13565-905, São Carlos, São Paulo, Brazil.'}, {'ForeName': 'Fábio Fernandes', 'Initials': 'FF', 'LastName': 'Neves', 'Affiliation': 'Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.'}, {'ForeName': 'Lucimar Retto', 'Initials': 'LR', 'LastName': 'da Silva de Avó', 'Affiliation': 'Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.'}, {'ForeName': 'Meliza Goi', 'Initials': 'MG', 'LastName': 'Roscani', 'Affiliation': 'Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.'}, {'ForeName': 'Sigrid De Sousa', 'Initials': 'SS', 'LastName': 'Dos Santos', 'Affiliation': 'Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.'}, {'ForeName': 'Silvana Gama Florêncio', 'Initials': 'SGF', 'LastName': 'Chachá', 'Affiliation': 'Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.'}]",Toxicology reports,['10.1016/j.toxrep.2021.03.003'] 1150,33728429,Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation.,"AIMS Treatment guidelines for patients with atrial fibrillation (AF) suggest that patients should be managed with an antiarrhythmic drug (AAD) before undergoing catheter ablation (CA). This study evaluated whether pulmonary vein isolation employing cryoballoon CA is superior to AAD therapy for the prevention of atrial arrhythmia (AA) recurrence in rhythm control naive patients with paroxysmal AF (PAF). METHODS AND RESULTS A total of 218 treatment naive patients with symptomatic PAF were randomized (1 : 1) to cryoballoon CA (Arctic Front Advance, Medtronic) or AAD (Class I or III) and followed for 12 months. The primary endpoint was ≥1 episode of recurrent AA (AF, atrial flutter, or atrial tachycardia) >30 s after a prespecified 90-day blanking period. Secondary endpoints included the rate of serious adverse events (SAEs) and recurrence of symptomatic palpitations (evaluated via patient diaries). Freedom from AA was achieved in 82.2% of subjects in the cryoballoon arm and 67.6% of subjects in the AAD arm (HR = 0.48, P = 0.01). There were no group differences in the time-to-first (HR = 0.76, P = 0.28) or overall incidence [incidence rate ratio (IRR)=0.79, P = 0.28] of SAEs. The incidence rate of symptomatic palpitations was lower in the cryoballoon (7.61 days/year) compared with the AAD arm (18.96 days/year; IRR = 0.40, P < 0.001). CONCLUSIONS Cryoballoon CA was superior to AAD therapy, significantly reducing AA recurrence in treatment naive patients with PAF. Additionally, cryoballoon CA was associated with lower symptom recurrence and a similar rate of SAEs compared with AAD therapy.",2021,"Additionally, cryoballoon CA was associated with lower symptom recurrence and a similar rate of SAEs compared with AAD therapy.","['218 treatment naive patients with symptomatic PAF', 'patients with atrial fibrillation (AF) suggest that patients should be managed with an antiarrhythmic drug (AAD) before undergoing catheter ablation (CA', 'patients with paroxysmal atrial fibrillation', 'rhythm control naive patients with paroxysmal AF (PAF']","['Cryoballoon ablation vs. antiarrhythmic drugs', 'pulmonary vein isolation employing cryoballoon CA', 'cryoballoon CA (Arctic Front Advance, Medtronic) or AAD (Class I or III) and followed for 12\u2009months']","['≥1 episode of recurrent AA (AF, atrial flutter, or atrial tachycardia', 'overall incidence [incidence rate ratio', 'AA recurrence', 'symptom recurrence', 'time-to-first', 'atrial arrhythmia (AA) recurrence', 'incidence rate of symptomatic palpitations', 'rate of serious adverse events (SAEs) and recurrence of symptomatic palpitations (evaluated via patient diaries']","[{'cui': 'C4517647', 'cui_str': '218'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0003195', 'cui_str': 'Antiarrhythmic agent'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0003195', 'cui_str': 'Antiarrhythmic agent'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0003740', 'cui_str': 'Arctic Regions'}, {'cui': 'C0441885', 'cui_str': 'Class 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0004239', 'cui_str': 'Atrial flutter'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C4524105', 'cui_str': 'Symptom recurrence'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0085611', 'cui_str': 'Atrial arrhythmia'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0030252', 'cui_str': 'Palpitations'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}]",218.0,0.0760093,"Additionally, cryoballoon CA was associated with lower symptom recurrence and a similar rate of SAEs compared with AAD therapy.","[{'ForeName': 'Malte', 'Initials': 'M', 'LastName': 'Kuniss', 'Affiliation': 'Kerckhoff Heart Center, Benekestrasse 2-8, 61231 Bad Nauheim, Germany.'}, {'ForeName': 'Nikola', 'Initials': 'N', 'LastName': 'Pavlovic', 'Affiliation': 'Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia.'}, {'ForeName': 'Vedran', 'Initials': 'V', 'LastName': 'Velagic', 'Affiliation': 'University Hospital Centre Zagreb, Zagreb, Croatia.'}, {'ForeName': 'Jean Sylvain', 'Initials': 'JS', 'LastName': 'Hermida', 'Affiliation': ""Centre Hospitalier Universitaire d'Amiens-Picardie, Amiens, France.""}, {'ForeName': 'Stewart', 'Initials': 'S', 'LastName': 'Healey', 'Affiliation': 'Monash Health, Clayton, Australia.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Arena', 'Affiliation': 'Ospedale Apuane, Massa Carrara, Italy.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Badenco', 'Affiliation': 'AP-HP Sorbonne Université, ICAN Institute, Hopital Pitié-Salpétrière, Paris, France.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Meyer', 'Affiliation': 'University Heart Center, Hamburg, Cardiac Neuro- and Electrophysiology Research Consortium, EVK Düsseldorf, Düsseldorf, Germany.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Haukeland University Hospital, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Saverio', 'Initials': 'S', 'LastName': 'Iacopino', 'Affiliation': 'Maria Cecilia Hospital, GVM Care&Research, Cotignola, Italy.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Anselme', 'Affiliation': 'CHU de Rouen, Rouen, France.'}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Packer', 'Affiliation': ""Mayo Clinic Hospital-St. Mary's Campus, Rochester, MN, USA.""}, {'ForeName': 'Heinz-Friedrich', 'Initials': 'HF', 'LastName': 'Pitschner', 'Affiliation': 'Kerckhoff Heart Center, Benekestrasse 2-8, 61231 Bad Nauheim, Germany.'}, {'ForeName': 'Carlo de', 'Initials': 'C', 'LastName': 'Asmundis', 'Affiliation': 'Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel, Postgraduate program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Willems', 'Affiliation': 'University Heart Center, Hamburg, Asklepios Klinik St. Georg, Hamburg, Germany.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Di Piazza', 'Affiliation': 'Medtronic, Core Clinical Solutions, Study and Scientific Solutions, Rome, Italy.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Becker', 'Affiliation': 'Medtronic, Meerbusch, Germany.'}, {'ForeName': 'Gian-Battista', 'Initials': 'GB', 'LastName': 'Chierchia', 'Affiliation': 'Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel, Postgraduate program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euab029'] 1151,33734369,Transfer of fresh or frozen embryos: a randomised controlled trial.,"STUDY QUESTION Is IVF with frozen-thawed blastocyst transfer (freeze-all strategy) more effective than IVF with fresh and frozen-thawed blastocyst transfer (conventional strategy)? SUMMARY ANSWER The freeze-all strategy was inferior to the conventional strategy in terms of cumulative ongoing pregnancy rate per woman. WHAT IS KNOWN ALREADY IVF without transfer of fresh embryos, thus with frozen-thawed embryo transfer only (freeze-all strategy), is increasingly being used in clinical practice because of a presumed benefit. It is still unknown whether this new IVF strategy increases IVF efficacy. STUDY DESIGN, SIZE, DURATION A single-centre, open label, two arm, parallel group, randomised controlled superiority trial was conducted. The trial was conducted between January 2013 and July 2015 in the Netherlands. The intervention was one IVF cycle with frozen-thawed blastocyst transfer(s) versus one IVF cycle with fresh and frozen-thawed blastocyst transfer(s). The primary outcome was cumulative ongoing pregnancy resulting from one IVF cycle within 12 months after randomisation. Couples were allocated in a 1:1 ratio to the freeze-all strategy or the conventional strategy with an online randomisation programme just before the start of down-regulation. PARTICIPANTS/MATERIALS, SETTING, METHODS Participants were subfertile couples with any indication for IVF undergoing their first IVF cycle, with a female age between 18 and 43 years. Differences in cumulative ongoing pregnancy rates were expressed as relative risks (RR) with 95% CI. All outcomes were analysed following the intention-to-treat principle. MAIN RESULTS AND THE ROLE OF CHANCE Two-hundred-and-five couples were randomly assigned to the freeze-all strategy (n = 102) or to the conventional strategy (n = 102). The cumulative ongoing pregnancy rate per woman was significantly lower in women allocated to the freeze-all strategy (19/102 (19%)) compared to women allocated to the conventional strategy (32/102 (31%); RR 0.59; 95% CI 0.36-0.98). LIMITATIONS, REASONS FOR CAUTION As this was a single-centre study, we were unable to study differences in study protocols and clinic performance. This, and the limited sample size, should make one cautious in using the results as the basis for definitive policy. All patients undergoing IVF, including those with a poor prognosis, were included; therefore, the outcome could differ in women with a good prognosis of IVF treatment success. WIDER IMPLICATIONS OF THE FINDINGS Our results indicate that there might be no benefit of a freeze-all strategy in terms of cumulative ongoing pregnancy rates. The efficacy of the freeze-all strategy in subgroups of patients, different stages of embryo development, and different freezing protocols needs to be further established and balanced against potential benefits and harms for mothers and children. STUDY FUNDING/COMPETING INTEREST(S) The Netherlands Organisation for Health Research and Development (ZonMW grant 171101007). S.M., F.M. and M.v.W. stated they are authors of the Cochrane review 'Fresh versus frozen embryo transfers in assisted reproduction'. TRIAL REGISTRATION NUMBER Dutch Trial Register, NTR3187. TRIAL REGISTRATION DATE 9 December 2011. DATE OF FIRST PATIENT’S ENROLMENT 8 January 2013.",2021,The cumulative ongoing pregnancy rate per woman was significantly lower in women allocated to the freeze-all strategy (19/102 (19%)) compared to women allocated to the conventional strategy (32/102 (31%);,"['Participants were subfertile couples with any indication for IVF undergoing their first IVF cycle, with a female age between 18 and 43\u2009years', 'Two-hundred-and-five couples', 'January 2013 and July 2015 in the Netherlands']","['freeze-all strategy or the conventional strategy with an online randomisation programme', 'Transfer of fresh or frozen embryos', 'IVF with fresh and frozen-thawed blastocyst transfer (conventional strategy']","['cumulative ongoing pregnancy rates', 'IVF efficacy', 'cumulative ongoing pregnancy resulting from one IVF cycle', 'cumulative ongoing pregnancy rate per woman']","[{'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]","[{'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0440733', 'cui_str': 'Frozen embryo'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0936221', 'cui_str': 'Blastocyst Transfer'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",205.0,0.229585,The cumulative ongoing pregnancy rate per woman was significantly lower in women allocated to the freeze-all strategy (19/102 (19%)) compared to women allocated to the conventional strategy (32/102 (31%);,"[{'ForeName': 'K M', 'Initials': 'KM', 'LastName': 'Wong', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Centre for Reproductive Medicine, Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'van Wely', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Centre for Reproductive Medicine, Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Verhoeve', 'Affiliation': 'Department of Obstetrics and Gynaecology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Kaaijk', 'Affiliation': 'Department of Obstetrics and Gynaecology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Mol', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Centre for Reproductive Medicine, Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'van der Veen', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Centre for Reproductive Medicine, Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Repping', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Mastenbroek', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Centre for Reproductive Medicine, Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/deaa305'] 1152,33740465,"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.","BACKGROUND Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, improve long-term survival, and shorten treatment duration; however, few have been tested clinically. Therefore, we aimed to assess the safety and preliminary efficacy of four host-directed therapies for tuberculosis. METHODS In this prospective, open-label, phase 2, randomised controlled trial, patients with pulmonary tuberculosis were recruited at three clinical sites in South Africa. Eligible patients were aged 18-65 years, HIV-1-negative, and had rifampicin-susceptible Mycobacterium tuberculosis, a sputum Xpert cycle threshold of less than 20, and moderately advanced or far advanced disease on chest radiography. By use of numbers generated in blocks of ten and stratification by site, eligible patients were randomly assigned (1:1:1:1:1) to receive one of the four oral host-directed treatments plus standard tuberculosis treatment or standard treatment alone (the control group). Host-directed treatments were: CC-11050 (200 mg twice daily, taken with food; day 1-112); everolimus (0·5 mg/day; day 1-112); auranofin (3 mg/day for seven doses, then 6 mg/day; day 1-112); and ergocalciferol (5 mg on day 1, then 2·5 mg on day 28 and day 56). All study participants received oral rifabutin-substituted standard tuberculosis treatment for 180 days. Patients and clinicians were not masked to treatment assignment. Spirometry and sputum culture with solid and liquid media were done at baseline and up to 180 days at specified intervals throughout treatment. The primary endpoint was safety and tolerability up to day 210. Secondary preliminary efficacy endpoints were treatment effects on sputum microbiology (culture status at day 56 and the hazard ratio for stable culture conversion up to day 180) and lung function (FEV 1 and forced vital capacity [FVC]) measured by spirometry at day 56, day 180, and day 540. Safety was analysed in the intention-to-treat population and preliminary efficacy primarily in the per-protocol population. The trial is registered at ClinicalTrials.gov, NCT02968927. Post-treatment follow-up was completed in 2020. FINDINGS Between Nov 18, 2016, and Sept 27, 2018, 200 patients were screened and randomly assigned to different treatment groups (n=40 per group, apart from n=39 in the everolimus group after one patient withdrew consent). 11 treatment-emergent serious adverse events occurred either during treatment or within 30 days after treatment discontinuation, of which three were attributable to a host-directed treatment. Life-threatening thrombocytopenia occurred in an auranofin recipient; apparent intra-abdominal sepsis leading to death occurred in another auranofin recipient and was classified as a suspected unexpected serious adverse reaction. Tuberculous spondylitis occurred as an apparent paradoxical reaction in a patient receiving ergocalciferol. Two patients in the control group had life-threatening, treatment-attributable liver injury. No treatment-emergent, treatment-attributable serious adverse events occurred in patients receiving CC-11050 or everolimus. Mean FEV 1 in the control group was 61·7% of predicted (95% CI 56·3-67·1) at baseline and 69·1% (62·3-75·8) at day 180. Patients treated with CC-11050 and everolimus had increased recovery of FEV 1 at day 180 relative to the control group (mean difference from control group 6·30%, 95% CI 0·06-12·54; p=0·048; and 6·56%, 0·18-12·95; p=0·044, respectively), whereas auranofin and ergocalciferol recipients did not. None of the treatments had an effect on FVC during 180 days of follow-up or on measures of sputum culture status over the course of the study. INTERPRETATION CC-11050 and everolimus were safe and reasonably well tolerated as adjunctive therapies for tuberculosis, and analysis of preliminary efficacy suggests they might also enhance the recovery of FEV 1 , a key measure of lung function and predictor of all-cause mortality. Further studies of these candidates are warranted. FUNDING The Bill & Melinda Gates Foundation and the South African Medical Research Council.",2021,"None of the treatments had an effect on FVC during 180 days of follow-up or on measures of sputum culture status over the course of the study. ","['pulmonary tuberculosis', 'Eligible patients were aged 18-65 years, HIV-1-negative, and had rifampicin-susceptible Mycobacterium tuberculosis, a sputum Xpert cycle threshold of less than 20, and moderately advanced or far advanced disease on chest radiography', 'patients with pulmonary tuberculosis were recruited at three clinical sites in South Africa', 'Between Nov 18, 2016, and Sept 27, 2018, 200 patients']","['ergocalciferol', 'CC-11050 or everolimus', 'everolimus', 'oral rifabutin-substituted standard tuberculosis treatment', 'CC-11050', 'auranofin', 'CC-11050 and everolimus', 'oral host-directed treatments plus standard tuberculosis treatment or standard treatment alone', 'Adjunctive host-directed therapies']","['sputum microbiology (culture status at day 56 and the hazard ratio for stable culture conversion up to day 180) and lung function (FEV 1 and forced vital capacity [FVC', 'Tuberculous spondylitis', 'life-threatening, treatment-attributable liver injury', 'Mean FEV', 'safety and tolerability', 'Life-threatening thrombocytopenia', 'recovery of FEV 1', 'Safety', 'serious adverse events', 'FVC']","[{'cui': 'C0041327', 'cui_str': 'Pulmonary tuberculosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0035608', 'cui_str': 'Rifampin'}, {'cui': 'C0231204', 'cui_str': 'Susceptible'}, {'cui': 'C0026926', 'cui_str': 'Mycobacterium tuberculosis'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0014695', 'cui_str': 'Ergocalciferol'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0140575', 'cui_str': 'Rifabutin'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0004320', 'cui_str': 'Auranofin'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0025952', 'cui_str': 'Microbiology'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0041330', 'cui_str': 'Tuberculosis of vertebral column'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0160390', 'cui_str': 'Injury of liver'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",200.0,0.478519,"None of the treatments had an effect on FVC during 180 days of follow-up or on measures of sputum culture status over the course of the study. ","[{'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Wallis', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa; Department of Medicine, Vanderbilt University, Nashville, TN, USA; Department of Medicine, Case Western Reserve University, Cleveland, OH, USA. Electronic address: rwallis@auruminstitute.org.'}, {'ForeName': 'Sibuse', 'Initials': 'S', 'LastName': 'Ginindza', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa.'}, {'ForeName': 'Trevor', 'Initials': 'T', 'LastName': 'Beattie', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa.'}, {'ForeName': 'Nishanee', 'Initials': 'N', 'LastName': 'Arjun', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa.'}, {'ForeName': 'Morongwe', 'Initials': 'M', 'LastName': 'Likoti', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa.'}, {'ForeName': 'Vinodh A', 'Initials': 'VA', 'LastName': 'Edward', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa; Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA; School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Rassool', 'Affiliation': 'Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa; Clinical HIV Research Unit, Johannesburg, South Africa.'}, {'ForeName': 'Khatija', 'Initials': 'K', 'LastName': 'Ahmed', 'Affiliation': 'Setshaba Research Centre, Soshanguve, South Africa; Department of Medical Microbiology, Faculty of Health Science, University of Pretoria, Pretoria, South Africa.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Fielding', 'Affiliation': 'School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Bintou A', 'Initials': 'BA', 'LastName': 'Ahidjo', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa.'}, {'ForeName': 'Mboyo D T', 'Initials': 'MDT', 'LastName': 'Vangu', 'Affiliation': 'Nuclear Medicine and Molecular Imaging, CM Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Churchyard', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(20)30448-3'] 1153,33743292,Medical high-protein nutrition therapy and loss of muscle mass in adult ICU patients: A randomized controlled trial.,"BACKGROUND & AIMS The degradation of muscle mass and loss of functional proteins due to catabolism are associated with adverse outcomes in critically ill patients. While an adequate supply of protein within a medical nutrition concept is suggested to minimize proteolysis, the specificities on appropriate dosage and timing are still under debate. The current study aimed to evaluate the effect of two different quantities of protein as part of a standardized energetically controlled nutrition therapy for the preservation of muscle mass in the later phase of critical illness. METHODS A randomized controlled trial was conducted in 42 critically ill patients (age 65 ± 15; 12 females; SAPS 45 ± 11; TISS 20 ± 7; SOFA-score 7 ± 3). The subjects were randomly assigned to either the intervention (1.8 g protein/kg body weight [BW]/d) or standard (1.2 g protein/kg BW/d) group. Nutrient supply via enteral and/or parenteral nutrition was calculated based on the individual energy expenditure measured by indirect calorimetry and target protein content. Quadriceps muscle layer thickness (QMLT) was observed through sonography at inclusion, and during the follow-up period, two and four weeks after inclusion. The measurement points were fixed on two sides at the midpoint and two-thirds between the anterior superior iliac spine and top of the patella. The data were analyzed descriptively wherein chi-squared tests or unpaired two-samle t-tests checked group differences. Daily changes in muscle mass were estimated using a linear mixed model. All data are shown as the mean ± standard deviation (SD). RESULTS Actual protein intake reached 1.5 ± 0.5 g and 1.0 ± 0.5 g/kg BW/d in the intervention and standard group, respectively. Mean values of all measurements of QMLT at inclusion (day 13 ± 2 after ICU admission) were 13.5 ± 7.4 mm and 13.4 ± 7.1 mm in the intervention and standard group, respectively (P = 0.967). In both the groups, QMLT decreased over time (P < 0.001), while the estimated mean values of daily QMLT changes were -0.15 ± 0.08 mm (intervention) and -0.28 ± 0.08 mm (standard) without significant between-group differences (intervention effect, P = 0.368; time x intervention effect, P = 0.242). Illness scores and clinical outcomes showed no group differences. CONCLUSION In this single-center trial the increased amounts of protein (1.5 g vs. 1.0 g/kg BW/d) provided through medical nutrition therapy in the late phase of critical illness did not achieve a statistically significant impact on the loss of muscle mass in long-term immobilized ICU patients. Larger multi-center trials are needed to evaluate whether observed numerical differences in muscle mass could be a true finding, and will translate into improved clinical outcomes. TRIAL REGISTRATION German Clinical Trials Register (http://www.drks.de/), DRKS-ID: DRKS00013594.",2021,"In both the groups, QMLT decreased over time (P < 0.001), while the estimated mean values of daily QMLT changes were -0.15 ","['adult ICU patients', '42 critically ill patients (age 65\xa0±\xa015; 12 females; SAPS 45\xa0±\xa011; TISS 20\xa0±\xa07; SOFA-score 7\xa0±\xa03', 'critically ill patients']","['QMLT', 'medical nutrition therapy', 'Medical high-protein nutrition therapy']","['mean values of daily QMLT changes', 'loss of muscle mass', 'Illness scores and clinical outcomes', 'Quadriceps muscle layer thickness (QMLT']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1740186', 'cui_str': 'SKAP2 protein, human'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0225358', 'cui_str': 'Muscularis propria'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1257928', 'cui_str': 'Medical Nutrition Therapy'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0242739', 'cui_str': 'Nutritional support'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0225358', 'cui_str': 'Muscularis propria'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",42.0,0.0942149,"In both the groups, QMLT decreased over time (P < 0.001), while the estimated mean values of daily QMLT changes were -0.15 ","[{'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Dresen', 'Affiliation': 'Department of Nutrition and Food Sciences, Nutritional Physiology, University of Bonn, Nußallee 9, 53115, Bonn, Germany. Electronic address: e.dresen@uni-bonn.de.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Weißbrich', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, University Hospital of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. Electronic address: carsten.weissbrich@ukbonn.de.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Fimmers', 'Affiliation': 'Institute of Medical Biometry, Information Technology and Epidemiology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. Electronic address: fimmers@imbie.meb.uni-bonn.de.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Putensen', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, University Hospital of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. Electronic address: christian.putensen@ukbonn.de.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Stehle', 'Affiliation': 'Department of Nutrition and Food Sciences, Nutritional Physiology, University of Bonn, Nußallee 9, 53115, Bonn, Germany. Electronic address: pstehle@uni-bonn.de.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2021.02.021'] 1154,33706002,Supporting families of children with overweight and obesity to live healthy lifestyles: Design and rationale for the Fitline cluster randomized controlled pediatric practice-based trial.,"BACKGROUND Over a third of preadolescent children with overweight or obesity. The American Academy of Pediatrics (AAP) recommends pediatric providers help families make changes in eating and activity to improve body mass index (BMI). However, implementation is challenging given limited time and referral sources, and family burden to access in-person weight management programs. PURPOSE To describe the design of a National Heart Blood and Lung Institute sponsored cluster randomized controlled pediatric-based trial evaluating the effectiveness of the Fitline pediatric practice-based referral program to reduce BMI and improve diet and physical activity in children with overweight or obesity. Comparison will be made between brief provider intervention plus referral to (1) eight weekly nutritionist-delivered coaching calls with workbook to help families make AAP-recommended lifestyle changes (Fitline-Coaching), vs. (2) the same workbook in eight mailings without coaching (Fitline-Workbook). METHODS Twenty practices are pair-matched and randomized to one of the two conditions; 494 parents and their children ages 8-12 with a BMI of ≥85th percentile are being recruited. The primary outcome is child BMI; secondary outcomes are child's diet and physical activity at baseline and 6- and 12-months post-baseline. Cost-effectiveness of the two interventions also will be examined. CONCLUSION This is the first randomized controlled trial to examine use of a centrally located telephonic coaching service to support families of children with overweight and obesity in making AAP-recommended lifestyle changes. If effective, the Fitline program will provide an innovative model for widespread dissemination, setting new standards for weight management care in pediatric practice. TRIAL REGISTRATION The ClinicalTrials.gov registration number is NCT03143660.",2021,This is the first randomized controlled trial to examine use of a centrally located telephonic coaching service to support families of children with overweight and obesity in making AAP-recommended lifestyle changes.,"['preadolescent children with overweight or obesity', 'children with overweight and obesity to live healthy lifestyles', 'children with overweight and obesity in making AAP-recommended lifestyle changes', 'Twenty practices are pair-matched and randomized to one of the two conditions; 494 parents and their children ages 8-12 with a BMI of ≥85th percentile are being recruited', 'children with overweight or obesity']","['Fitline pediatric practice-based referral program', 'centrally located telephonic coaching service']","[""child BMI; secondary outcomes are child's diet and physical activity"", 'Cost-effectiveness']","[{'cui': 'C1444711', 'cui_str': 'Pre-teen'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C0000876', 'cui_str': 'Academies'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",494.0,0.0822427,This is the first randomized controlled trial to examine use of a centrally located telephonic coaching service to support families of children with overweight and obesity in making AAP-recommended lifestyle changes.,"[{'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Pbert', 'Affiliation': 'Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States. Electronic address: lori.pbert@umassmed.edu.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Trivedi', 'Affiliation': 'Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, United States.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Druker', 'Affiliation': 'Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Bram', 'Affiliation': 'Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, United States.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Olendzki', 'Affiliation': 'Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.'}, {'ForeName': 'Sybil', 'Initials': 'S', 'LastName': 'Crawford', 'Affiliation': 'Graduate School of Nursing, University of Massachusetts Medical School, Worcester, MA, United States.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Frisard', 'Affiliation': 'Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Andersen', 'Affiliation': 'Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.'}, {'ForeName': 'Molly E', 'Initials': 'ME', 'LastName': 'Waring', 'Affiliation': 'Department of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Clements', 'Affiliation': 'Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Schneider', 'Affiliation': 'Department of Psychology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States.'}, {'ForeName': 'Alan C', 'Initials': 'AC', 'LastName': 'Geller', 'Affiliation': 'Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA, United States.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106348'] 1155,33746024,Efficacy and safety of rivaroxaban and ticagrelor in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention.,"AIMS To compare the efficacy and safety of a dual therapy (rivaroxaban and ticagrelor) with a triple therapy (aspirin, clopidogrel and warfarin) in Chinese elderly patients with nonvalvular atrial fibrillation (NVAF) undergoing percutaneous coronary intervention (PCI). METHODS A total of 106 elderly Chinese patients with NAVF after PCI were randomly divided into a dual therapy group treated with ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily after PCI, and a triple therapy group treated with aspirin 100 mg and clopidogrel 75 mg once daily combined with the dose-adjusted vitamin K antagonist warfarin once daily. The mean follow-up time was 1 year. The primary endpoint was the composite death rate from cardiovascular causes, myocardial infarction, stroke or stent thrombosis. The safety endpoint was clinically significant bleeding (a composite value of major, minor and minimal bleeding). RESULTS There were no significant differences between the 2 groups regarding the basic characteristics of the patients. The primary composite endpoint of the dual therapy group after 1 year was not significantly different from the triple therapy group (16.7% vs 15.2%, P = 0.86; HR 1.02; 95% CI: 0.82-1.24), but there was a significant difference in the incidence of hemorrhage (7.4% vs 26.9% P = 0.01; HR 0.71; 95% CI: 0.62-0.83) between the 2 groups. CONCLUSIONS In elderly Chinese patients with NVAF undergoing PCI, the efficacy of dual (ticagrelor plus rivaroxaban) treatments was comparable to the triple antithrombotic regime (warfarin plus dual antiplatelet therapy). The overall incidence of bleeding was significantly reduced with dual treatment compared to the triple treatment regime.",2021,"The primary composite endpoint of the dual therapy group after 1 year was not significantly different from the triple therapy group (16.7% vs 15.2%, P = 0.86; HR 1.02; 95% CI: 0.82-1.24), but there was a significant difference in the incidence of hemorrhage (7.4% vs 26.9% P = 0.01; HR 0.71; 95% CI: 0.62-0.83) between the 2 groups. ","['Chinese elderly patients with nonvalvular atrial fibrillation (NVAF) undergoing percutaneous coronary intervention (PCI', '106 elderly Chinese patients with NAVF after PCI', 'elderly patients with atrial fibrillation undergoing percutaneous coronary intervention', 'elderly Chinese patients with NVAF undergoing PCI']","['rivaroxaban and ticagrelor', 'triple therapy (aspirin, clopidogrel and warfarin', 'dual therapy (rivaroxaban and ticagrelor', 'ticagrelor 90\u202fmg twice daily and rivaroxaban', 'aspirin 100\u202fmg and clopidogrel 75\u202fmg once daily combined with the dose-adjusted vitamin K antagonist warfarin', 'dual (ticagrelor plus rivaroxaban']","['composite death rate from cardiovascular causes, myocardial infarction, stroke or stent thrombosis', 'overall incidence of bleeding', 'bleeding (a composite value of major, minor and minimal bleeding', 'efficacy and safety', 'incidence of hemorrhage', 'Efficacy and safety']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C3163568', 'cui_str': 'Ticagrelor 90 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C1124475', 'cui_str': 'Aspirin 100 MG'}, {'cui': 'C1124675', 'cui_str': 'clopidogrel 75 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",106.0,0.0479896,"The primary composite endpoint of the dual therapy group after 1 year was not significantly different from the triple therapy group (16.7% vs 15.2%, P = 0.86; HR 1.02; 95% CI: 0.82-1.24), but there was a significant difference in the incidence of hemorrhage (7.4% vs 26.9% P = 0.01; HR 0.71; 95% CI: 0.62-0.83) between the 2 groups. ","[{'ForeName': 'Xinbing', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Cardiology, Shanghai Shi Dong Hospital, Shanghai 200438, China.'}, {'ForeName': 'Linlin', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Critical Care Medicine, Shanghai Shi Dong Hospital, Shanghai 200438, China. Electronic address: wanglinlin163163@163.com.'}, {'ForeName': 'Mingcheng', 'Initials': 'M', 'LastName': 'Zhou', 'Affiliation': 'Department of Cardiology, The First Rehabilitation Hospital of Shanghai, Shanghai 200090, China.'}, {'ForeName': 'Liuliu', 'Initials': 'L', 'LastName': 'Feng', 'Affiliation': 'Department of Cardiology, Shanghai Shi Dong Hospital, Shanghai 200438, China.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106365'] 1156,33744193,The Effects of Spironolactone and Eplerenone on Left Ventricular Function Using Echocardiography in Symptomatic Patients With New-Onset Systolic Heart Failure: A Comparative Randomised Controlled Trial.,"BACKGROUND Heart failure (HF), as a serious health condition, is characterised by the decreasing ability of the heart to pump enough blood around the body. This study compared the effects of spironolactone and eplerenone on the echocardiographic variables of the left ventricular (LV) function in symptomatic patients diagnosed with new-onset systolic HF. METHOD This study was a randomised controlled trial, including 85 symptomatic patients with new-onset systolic HF (namely, dilated cardiomyopathy). The patients were then randomly assigned to two groups in a 1:1 ratio and received either spironolactone or eplerenone in addition to optimal HF therapy for 6 months. Echocardiography was performed to visualise alterations in two-dimensional, pulse Doppler, tissue Doppler, and deformation indices of LV function. RESULTS The results revealed that the group receiving eplerenone had a significantly greater increase in LV ejection fraction (LVEF) and a decrease in end-systolic LV internal diameter compared with the group receiving spironolactone (intergroup p=0.002 and p=0.006, respectively). There was a significant reduction in the end-diastolic LV internal diameter and the left atrial diameter, and a significant rise in tissue Doppler peak systolic mitral annular velocity in the group taking eplerenone; there were no significant changes in these variables in the group receiving spironolactone (intergroup p=0.006 and p=0.049, respectively). Accordingly, eplerenone had greater favourable effects on LVEF and the global longitudinal strain than spironolactone (B=5.207 [p<0.001] and B= -2.072 [p=0.044]), respectively. CONCLUSIONS This study established that adding eplerenone to optimal HF therapy might be associated with more improvements in echocardiographic variables of LV function than spironolactone in symptomatic patients with new-onset systolic HF.",2021,"Accordingly, eplerenone had greater favourable effects on LVEF and the global longitudinal strain than spironolactone (B=5.207 [p<0.001] and B= -2.072 [p=0.044]), respectively. ","['85 symptomatic patients with new-onset systolic HF (namely, dilated cardiomyopathy', 'symptomatic patients with new-onset systolic HF', 'Symptomatic Patients With New-Onset Systolic Heart Failure', 'symptomatic patients diagnosed with new-onset systolic HF']","['spironolactone', 'spironolactone and eplerenone', 'eplerenone', 'spironolactone or eplerenone in addition to optimal HF therapy', 'Spironolactone and Eplerenone']","['echocardiographic variables of the left ventricular (LV) function', 'end-systolic LV internal diameter', 'LVEF and the global longitudinal strain', 'end-diastolic LV internal diameter and the left atrial diameter', 'LV ejection fraction (LVEF', 'Left Ventricular Function', 'tissue Doppler peak systolic mitral annular velocity', 'echocardiographic variables of LV function']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C1135191', 'cui_str': 'Systolic heart failure'}, {'cui': 'C0007193', 'cui_str': 'Dilated cardiomyopathy'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0037982', 'cui_str': 'Spironolactone'}, {'cui': 'C0961485', 'cui_str': 'eplerenone'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C1142544', 'cui_str': 'Systolic left ventricular internal diameter'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0919652', 'cui_str': 'Diastolic left ventricular internal diameter'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0080310', 'cui_str': 'Left ventricular function'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0554756', 'cui_str': 'Doppler studies'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}]",85.0,0.0541943,"Accordingly, eplerenone had greater favourable effects on LVEF and the global longitudinal strain than spironolactone (B=5.207 [p<0.001] and B= -2.072 [p=0.044]), respectively. ","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Nabati', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: dr.mr.nabati@gmail.com.'}, {'ForeName': 'Sasan', 'Initials': 'S', 'LastName': 'Tabiban', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Afshin', 'Initials': 'A', 'LastName': 'Khani', 'Affiliation': 'Student Research Committee, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Jamshid', 'Initials': 'J', 'LastName': 'Yazdani', 'Affiliation': 'Department of Biostatics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Hamideh', 'Initials': 'H', 'LastName': 'Vafainezhad', 'Affiliation': 'Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}]","Heart, lung & circulation",['10.1016/j.hlc.2021.02.005'] 1157,33749643,"Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial.","BACKGROUND The neuroprotective benefits of combined folic acid and docosahexaenoic acid (DHA) on cognitive function in mild cognitive impairment (MCI) patients are suggested but unconfirmed. OBJECTIVE To explore the effects of 6-month folic acid + DHA on cognitive function in patients with MCI. METHODS Our randomized controlled trial (trial number ChiCTR-IOR-16008351) was conducted in Tianjin, China. We divided 160 MCI patients aged > 60 years into four regimen groups randomly: folic acid (0.8 mg/day) + DHA (800 mg/day), folic acid (0.8 mg/day), DHA (800 mg/day), and placebo, for 6 months. Cognitive function and blood amyloid-β peptide (Aβ) biomarker levels were measured at baseline and 6 months. Cognitive function was also measured at 12 months. RESULTS A total of 138 patients completed this trial. Folic acid improved the full-scale intelligence quotient (FSIQ), arithmetic, and picture complement scores; DHA improved the FSIQ, information, arithmetic, and digit span scores; folic acid + DHA improved the arithmetic (difference 1.67, 95% CI 1.02 to 2.31) and digital span (1.33, 0.24 to 2.43) scores compared to placebo. At 12 months, all scores declined in the intervention groups. Folic acid and folic acid + DHA increased blood folate (folic acid + DHA: 7.70, 3.81 to 11.59) and S-adenosylmethionine (23.93, 1.86 to 46.00) levels and reduced homocysteine levels (-6.51, -10.57 to -2.45) compared to placebo. DHA lower the Aβ40 levels (-40.57, -79.79 to -1.35) compared to placebo (p < 0.05), and folic acid + DHA reduced the Aβ42 (-95.59, -150.76 to -40.43) and Aβ40 levels (-45.75, -84.67 to -6.84) more than DHA (p < 0.05). CONCLUSION Folic acid and DHA improve cognitive function and reduce blood Aβ production in MCI patients. Combination therapy may be more beneficial in reducing blood Aβ-related biomarkers.",2021,"DHA lower the Aβ40 levels (-40.57, -79.79 to -1.35) compared to placebo (p <  0.05), and folic acid + DHA reduced the Aβ42 (-95.59, -150.76 to -40.43) and Aβ40 levels (-45.75, -84.67 to -6.84) more than DHA (p <  0.05). ","['Older Adults with Mild Cognitive Impairment', '138 patients completed this trial', '160 MCI patients aged\u200a> \u200a60 years into four regimen groups randomly', 'MCI patients', 'mild cognitive impairment (MCI) patients', 'patients with MCI']","['folic acid', 'DHA', 'Folic acid and folic acid\u200a+\u200aDHA', 'Folic acid', 'placebo', 'Folic acid and DHA', 'Folic Acid Combined with DHA Supplementation', 'folic acid\u200a+\u200aDHA', 'Placebo', 'combined folic acid and docosahexaenoic acid (DHA', 'folic acid (0.8\u200amg/day)\u200a+\u200aDHA']","['digital span', 'Aβ) biomarker levels', 'Cognitive function', 'blood folate', 'Cognitive Function and Amyloid-β-Related Biomarkers', 'homocysteine levels', 'full-scale intelligence quotient (FSIQ), arithmetic, and picture complement scores; DHA improved the FSIQ, information, arithmetic, and digit span scores; folic acid\u200a+\u200aDHA improved the arithmetic', 'Cognitive function and blood amyloid-β peptide', 'cognitive function']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0556102', 'cui_str': 'Docosahexaenoic acid supplementation'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0427417', 'cui_str': 'Blood folate'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C2242817', 'cui_str': 'Homocysteine measurement'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0456149', 'cui_str': 'Intelligence quotient'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0009498', 'cui_str': 'Complement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}]",138.0,0.363042,"DHA lower the Aβ40 levels (-40.57, -79.79 to -1.35) compared to placebo (p <  0.05), and folic acid + DHA reduced the Aβ42 (-95.59, -150.76 to -40.43) and Aβ40 levels (-45.75, -84.67 to -6.84) more than DHA (p <  0.05). ","[{'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Bai', 'Affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Junting', 'Initials': 'J', 'LastName': 'Fan', 'Affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Mengyue', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Cuixia', 'Initials': 'C', 'LastName': 'Dong', 'Affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Fu', 'Affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Guowei', 'Initials': 'G', 'LastName': 'Huang', 'Affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-200997'] 1158,33684595,Continuous infusion versus intermittent administration of meropenem in critically ill patients (MERCY): A multicenter randomized double-blind trial. Rationale and design.,"OBJECTIVE Meropenem is a β-lactam, carbapenem antibacterial agent with antimicrobial activity against gram-negative, gram-positive and anaerobic micro-organisms and is important in the empirical treatment of serious infections in Intensive Care Unit (ICU) patients. Multi-drug resistant gram-negative organisms, coupled with scarcity of new antibiotic classes, forced healthcare community to optimize the therapeutic potential of available antibiotics. Our aim is to investigate the effect of continuous infusion of meropenem against bolus administration, as indicated by a composite outcome of reducing death and emergence of extensive or pan drug-resistant pathogens in a population of ICU patients. DESIGN Double blind, double dummy, multicenter randomized controlled trial (1:1 allocation ratio). SETTING Tertiary and University hospitals. INTERVENTIONS 600 ICU patients with sepsis or septic shock, needing by clinical judgment antibiotic therapy with meropenem, will be randomized to receive a continuous infusion of meropenem 3 g/24 h or an equal dose divided into three daily boluses (i.e. 1g q8h). MEASUREMENTS The primary endpoint will be a composite outcome of reducing death and emergence of extensive or pan drug-resistant pathogens. Secondary endpoints will be death from any cause at day 90, antibiotic-free days at day 28, ICU-free days at day 28, cumulative SOFA-free (Sequential Organ Failure Assessment) score from randomization to day 28 and the two, separate, components of the primary endpoint. We expect a primary outcome reduction from 52 to 40% in the continuous infusion group. CONCLUSIONS The trial will provide evidence for choosing intermittent or continuous infusion of meropenem for critically ill patients with multi-drug resistant gram-negative infections.",2021,"Secondary endpoints will be death from any cause at day 90, antibiotic-free days at day 28, ICU-free days at day 28, cumulative SOFA-free (Sequential Organ Failure Assessment) score from randomization to day 28 and the two, separate, components of the primary endpoint.","['critically ill patients with multi-drug resistant gram-negative infections', 'a population of ICU patients', 'Intensive Care Unit (ICU) patients', 'critically ill patients (MERCY', '600 ICU patients with sepsis or septic shock, needing by clinical judgment antibiotic therapy with', 'Tertiary and University hospitals']","['meropenem', 'Meropenem']","['composite outcome of reducing death and emergence of extensive or pan drug-resistant pathogens', 'death and emergence of extensive or pan drug-resistant pathogens', 'death from any cause at day 90, antibiotic-free days at day 28, ICU-free days at day 28, cumulative SOFA-free (Sequential Organ Failure Assessment) score']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0066005', 'cui_str': 'meropenem'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205231', 'cui_str': 'Extensive'}, {'cui': 'C0030266', 'cui_str': 'Panama'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0450254', 'cui_str': 'Pathogenic organism'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",600.0,0.746191,"Secondary endpoints will be death from any cause at day 90, antibiotic-free days at day 28, ICU-free days at day 28, cumulative SOFA-free (Sequential Organ Failure Assessment) score from randomization to day 28 and the two, separate, components of the primary endpoint.","[{'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Monti', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: landoni.giovanni@hsr.it.'}, {'ForeName': 'Carola', 'Initials': 'C', 'LastName': 'Galbiati', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Toffoletto', 'Affiliation': 'Azienda ULSS 4 Veneto Orientale, San Donà di Piave (VE), Italy.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Calabrò', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Colombo', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Ferrara', 'Affiliation': 'Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Giardina', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Rosalba', 'Initials': 'R', 'LastName': 'Lembo', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Marzaroli', 'Affiliation': 'Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Moizo', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Milena', 'Initials': 'M', 'LastName': 'Mucci', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Pasculli', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Valentina Paola', 'Initials': 'VP', 'LastName': 'Plumari', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Anna Mara', 'Initials': 'AM', 'LastName': 'Scandroglio', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Margherita', 'Initials': 'M', 'LastName': 'Tozzi', 'Affiliation': 'Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Momesso', 'Affiliation': 'Azienda ULSS 4 Veneto Orientale, San Donà di Piave (VE), Italy.'}, {'ForeName': 'Nicoletta', 'Initials': 'N', 'LastName': 'Boffa', 'Affiliation': 'Azienda ULSS 4 Veneto Orientale, San Donà di Piave (VE), Italy.'}, {'ForeName': 'Rosetta', 'Initials': 'R', 'LastName': 'Lobreglio', 'Affiliation': ""'Città della Salute e della Scienza' Hospital - Turin - Italy.""}, {'ForeName': 'Giorgia', 'Initials': 'G', 'LastName': 'Montrucchio', 'Affiliation': ""'Città della Salute e della Scienza' Hospital - Turin - Italy.""}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Guarracino', 'Affiliation': 'Azienda Ospedaliero - Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Umberto', 'Initials': 'U', 'LastName': 'Benedetto', 'Affiliation': 'University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Biondi-Zoccai', 'Affiliation': 'Sapienza University of Rome, Latina, Italy; Mediterranea Cardiocentro, Napoli, Italy.'}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': ""D'Ascenzo"", 'Affiliation': ""'Città della Salute e della Scienza' Hospital - Turin - Italy.""}, {'ForeName': 'Natascia', 'Initials': 'N', 'LastName': ""D'Andrea"", 'Affiliation': 'Università degli Studi di Udine, Udine, Italy.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Paternoster', 'Affiliation': 'Azienda Ospedaliera Regionale ""San Carlo"", Potenza, Italy.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Ananiadou', 'Affiliation': 'ASST Cremona - Presidio Ospedaliero di Cremona, Cremona, Italy.'}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Ballestra', 'Affiliation': 'Ente Ospedaliero Ospedali Galliera, Genova, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'De Sio', 'Affiliation': 'Pineta Grande Hospital, Castel Volturno (CE), Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Pota', 'Affiliation': 'Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Cotoia', 'Affiliation': 'University Hospital O.O.R.R. Foggia, Foggia, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Della Selva', 'Affiliation': 'Azienda Sanitaria Locale CN2 Alba - Bra, Alba (CN), Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Bruni', 'Affiliation': 'Magna Graecia University, Catanzaro, Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Iapichino', 'Affiliation': 'IRCCS Humanitas Clinical and Research Center, Rozzano (MI), Italy.'}, {'ForeName': 'Nikola', 'Initials': 'N', 'LastName': 'Bradić', 'Affiliation': 'University Hospital Dubrava, Zagreb, Croatia.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Corradi', 'Affiliation': 'Azienda Ospedaliero - Universitaria Pisana, Pisa, Italy; Ente Ospedaliero Ospedali Galliera, Genova, Italy; Università di Pisa, Pisa, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Gemma', 'Affiliation': 'ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico, Milan, Italy.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Nogtev', 'Affiliation': 'I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Petrova', 'Affiliation': 'Federal Research and Clinical Center of Resuscitation and Rehabilitation, Moscow, Russia.'}, {'ForeName': 'Felice Eugenio', 'Initials': 'FE', 'LastName': 'Agrò', 'Affiliation': 'Campus Bio Medico University and Teaching Hospital, Rome, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Cabrini', 'Affiliation': ""ASST dei Sette Laghi - Ospedale di Circolo e Fondazione Macchi di Varese, Varese, Italy; Università degli Studi dell'Insubria, Varese, Italy.""}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Forfori', 'Affiliation': 'Azienda Ospedaliero - Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy.'}, {'ForeName': 'Valery', 'Initials': 'V', 'LastName': 'Likhvantsev', 'Affiliation': 'I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; Federal Research and Clinical Center of Resuscitation and Rehabilitation, Moscow, Russia.'}, {'ForeName': 'Tiziana', 'Initials': 'T', 'LastName': 'Bove', 'Affiliation': 'Università degli Studi di Udine, Udine, Italy; Azienda Sanitaria Universitaria Friuli Centrale - Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Italy.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Finco', 'Affiliation': 'Università degli Studi di Cagliari, Cagliari, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Landoni', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Zangrillo', 'Affiliation': 'IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2021.106346'] 1159,33684596,Predicting deseasonalised serum 25 hydroxy vitamin D concentrations in the D-Health Trial: An analysis using boosted regression trees.,"BACKGROUND The D-Health Trial aims to determine whether monthly high-dose vitamin D supplementation can reduce the mortality rate and prevent cancer. We did not have adequate statistical power for subgroup analyses, so could not justify the high cost of collecting blood samples at baseline. To enable future exploratory analyses stratified by baseline vitamin D status, we developed models to predict baseline serum 25 hydroxy vitamin D [25(OH)D] concentration. METHODS We used data and serum 25(OH)D concentrations from participants who gave a blood sample during the trial for compliance monitoring and were randomised to placebo. Data were partitioned into training (80%) and validation (20%) datasets. Deseasonalised serum 25(OH)D concentrations were dichotomised using cut-points of 50, 60 and 75 nmol/L. We fitted boosted regression tree models, based on 13 predictors, and evaluated model performance using the validation data. RESULTS The training and validation datasets had 1788 (10.5% <50 nmol/L, 23.1% <60 nmol, 48.8 <75 nmol/L) and 447 (11.9% <50 nmol/L, 25.7% <60 nmol/L, and 49.2% <75 nmol/L) samples, respectively. Ambient UV radiation and total intake of vitamin D were the strongest predictors of 'low' serum 25(OH)D concentration. The area under the receiver operating characteristic curves were 0.71, 0.70, and 0.66 for cut-points of <50, <60 and <75 nmol/L respectively. CONCLUSIONS We exploited compliance monitoring data to develop models to predict serum 25(OH)D concentration for D-Health participants at baseline. This approach may prove useful in other trial settings where there is an obstacle to exhaustive data collection.",2021,Ambient UV radiation and total intake of vitamin D were the strongest predictors of 'low' serum 25(OH)D concentration.,['participants who gave a blood sample during the trial for compliance monitoring'],"['vitamin D supplementation', 'placebo']","['mortality rate and prevent cancer', 'Deseasonalised serum 25(OH)D concentrations', 'Ambient UV radiation and total intake of vitamin D']","[{'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0041625', 'cui_str': 'Ultraviolet radiation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}]",,0.180473,Ambient UV radiation and total intake of vitamin D were the strongest predictors of 'low' serum 25(OH)D concentration.,"[{'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Waterhouse', 'Affiliation': 'Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Electronic address: mary.waterhouse@qimrberghofer.edu.au.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Baxter', 'Affiliation': 'Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Electronic address: Catherine.Baxter@qimrberghofer.edu.au.'}, {'ForeName': 'Briony', 'Initials': 'B', 'LastName': 'Duarte Romero', 'Affiliation': 'Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Electronic address: Briony.DuarteRomero@qimrberghofer.edu.au.'}, {'ForeName': 'Donald S A', 'Initials': 'DSA', 'LastName': 'McLeod', 'Affiliation': ""Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia; Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Brisbane, Australia. Electronic address: Donald.McLeod@qimrberghofer.edu.au.""}, {'ForeName': 'Dallas R', 'Initials': 'DR', 'LastName': 'English', 'Affiliation': 'Melbourne School of Population Health, University of Melbourne, Melbourne, Australia; Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Australia. Electronic address: d.english@unimelb.edu.au.'}, {'ForeName': 'Bruce K', 'Initials': 'BK', 'LastName': 'Armstrong', 'Affiliation': 'School of Public Health, University of Sydney, Sydney, Australia. Electronic address: bruce@brucekarmstrong.org.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Clarke', 'Affiliation': 'Metabolomics Australia, Centre for Microscopy, Characterisation and Analysis, The University of Western Australia, Perth, Australia. Electronic address: michael.clarke@uwa.edu.au.'}, {'ForeName': 'Peter R', 'Initials': 'PR', 'LastName': 'Ebeling', 'Affiliation': 'Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia. Electronic address: peter.ebeling@monash.edu.'}, {'ForeName': 'Gunter', 'Initials': 'G', 'LastName': 'Hartel', 'Affiliation': 'Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Electronic address: Gunter.Hartel@qimrberghofer.edu.au.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Kimlin', 'Affiliation': 'Queensland University of Technology (QUT), School of Biomedical Sciences, Faculty of Health, Brisbane, Australia. Electronic address: m.kimlin@qut.edu.au.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': ""O'Connell"", 'Affiliation': 'NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. Electronic address: rachel.oconnell@ctc.usyd.edu.au.'}, {'ForeName': 'Hai', 'Initials': 'H', 'LastName': 'Pham', 'Affiliation': 'Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia; School of Public Health, The University of Queensland, Brisbane, Australia. Electronic address: Hai.Pham@qimrberghofer.edu.au.'}, {'ForeName': 'Rachael M', 'Initials': 'RM', 'LastName': 'Rodney Harris', 'Affiliation': 'National Centre for Epidemiology and Population Health, College of Health & Medicine, The Australian National University, Canberra, Australia. Electronic address: Rachael.Rodney@anu.edu.au.'}, {'ForeName': 'Jolieke C', 'Initials': 'JC', 'LastName': 'van der Pols', 'Affiliation': 'Queensland University of Technology (QUT), School of Exercise and Nutrition Sciences, Faculty of Health, Brisbane, Australia. Electronic address: j.vanderpols@qut.edu.au.'}, {'ForeName': 'Alison J', 'Initials': 'AJ', 'LastName': 'Venn', 'Affiliation': 'Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia. Electronic address: alison.venn@utas.edu.au.'}, {'ForeName': 'Penelope M', 'Initials': 'PM', 'LastName': 'Webb', 'Affiliation': 'Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Electronic address: Penny.Webb@qimrberghofer.edu.au.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Whiteman', 'Affiliation': 'Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Electronic address: David.Whiteman@qimrberghofer.edu.au.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Neale', 'Affiliation': 'Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia; School of Public Health, The University of Queensland, Brisbane, Australia. Electronic address: Rachel.Neale@qimrberghofer.edu.au.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106347'] 1160,33689238,"Developing and validating the Caesarean risk assessment nomogram and comparing the effect of cervical ripening balloon, evening primrose oil and misoprostol on childbirth outcomes in term pregnancies: A study protocol.","AIM To develop and validate the nomogram for risk estimation of Caesarean delivery and to compare the effect of cervical ripening balloon, evening primrose oil (EPO) and misoprostol on Bishop Score and duration of the first stage of labour. DESIGN The first phase is a prospective study, and the second phase is a randomized controlled trial. METHODS In the first phase, the nomogram will be developed and validated over 300 participants, and in the second phase, the 90 participants will be allocated to three groups: vaginal 25mcg misoprostol, vaginal 4000mg EPO and double-balloon catheter, through block randomization method. The Bishop score will be evaluated every 4 hr, and if required the same dose will be repeated. Maximum waiting time for balloon is 12 hr if not effective, the catheter will be removed, and other interventions will be done according to guidelines. DISCUSSION The nomogram will help informed decision-making for women undergoing an induction with an unfavourable cervix and introducing effective low-complication methods of labour induction can improve the pregnancy outcomes.",2021,The nomogram will help informed decision-making for women undergoing an induction with an unfavourable cervix and introducing effective low-complication methods of labour induction can improve the pregnancy outcomes.,"['300 participants, and in the second phase, the 90 participants', 'term pregnancies', 'women undergoing an induction with an unfavourable cervix']","['cervical ripening balloon, evening primrose oil (EPO) and misoprostol', 'cervical ripening balloon, evening primrose oil and misoprostol', 'vaginal 25mcg misoprostol, vaginal 4000mg EPO and double-balloon catheter']","['Maximum waiting time', 'Bishop Score and duration of the first stage of labour', 'childbirth outcomes']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0232991', 'cui_str': 'Term pregnancy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0007874', 'cui_str': 'Cervix uteri structure'}]","[{'cui': 'C1960759', 'cui_str': 'Cervical ripening with balloon'}, {'cui': 'C0700602', 'cui_str': 'Evening primrose oil'}, {'cui': 'C0085174', 'cui_str': 'Misoprostol'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C3842327', 'cui_str': '4000'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0441127', 'cui_str': 'Balloon dilatation catheter'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2225498', 'cui_str': 'Bishop score'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0022871', 'cui_str': 'First stage of labor'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",90.0,0.0706461,The nomogram will help informed decision-making for women undergoing an induction with an unfavourable cervix and introducing effective low-complication methods of labour induction can improve the pregnancy outcomes.,"[{'ForeName': 'Shahla', 'Initials': 'S', 'LastName': 'Hemmatzadeh', 'Affiliation': ""Students' Research Committee, Midwifery Department, Tabriz University of Medical sciences, Tabriz, Iran.""}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Abbasalizadeh', 'Affiliation': 'Department of Gynecology, Faculty of medicine, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Sakineh', 'Initials': 'S', 'LastName': 'Mohammad-Alizadeh-Charandabi', 'Affiliation': 'Department of Midwifery, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Asghari Jafarabady', 'Affiliation': 'Mohammad Asghari, Faculty of health, Department of Epidemiology, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Mirghafourvand', 'Affiliation': 'Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}]",Nursing open,['10.1002/nop2.846'] 1161,33694294,Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial.,"OBJECTIVES To compare 2-year outcome following treatment with drug-eluting stents (DES) for acute myocardial infarction (MI) versus non-MI clinical syndromes. In acute MI patients, a stent-level comparison was performed, comparing Resolute Onyx versus Orsiro stents. BACKGROUND In patients presenting with acute MI, higher adverse event rates have been reported. So far, no clinical results >1 year have been published of acute MI patients treated with Resolute Onyx. METHODS This post-hoc analysis of the randomized BIONYX trial(NCT02508714) assessed the main outcome target vessel failure (TVF: cardiac death, target vessel MI, or target vessel revascularization) with Kaplan-Meier methods. RESULTS Of all 2,488 trial participants, acute MI patients (n = 1,275[51.2%]) were significantly younger and had less comorbidities than non-MI patients (n = 1,213[48.8%]). TVF rates were lower in acute MI patients (77/1,275[6.1%] vs. 103/1,213[8.6%], HR:0.70, 95%-CI 0.52-0.94; p log-rank  = 0.02), mainly driven by target vessel revascularization (4.1 vs. 6.1%, p log-rank  = 0.03). Multivariate analysis showed no independent association of clinical syndrome with TVF (adjusted-HR: 0.81, 95%-CI 0.60-1.10; p = .17). In MI patients treated with Resolute Onyx (n = 626) versus Orsiro (n = 649), there was no difference in TVF (6.2 vs. 6.1%; p log-rank  = 0.97) and its components. There was only 1(0.2%) definite-or-probable stent thrombosis in RO-ZES and 8(1.2%) in O-SES (p = .053). CONCLUSIONS Two years after treatment with thin-strut DES in this randomized trial, patients treated for acute MI had lower adverse event rates than non-MI patients. Yet, these findings were mainly attributable to between-group differences in patient and lesion characteristics. In patients who underwent PCI for acute MI, both Resolute Onyx and Orsiro showed favorable and similar 2-year outcomes.",2021,"TVF rates were lower in acute MI patients (77/1,275[6.1%] vs. 103/1,213[8.6%], HR:0.70, 95%-CI 0.52-0.94; p log-rank = 0.02), mainly driven by target vessel revascularization (4.1 vs. 6.1%, p log-rank = 0.03).",['acute myocardial infarction (MI) versus non-MI clinical syndromes'],"['drug-eluting stents (DES', 'novel Resolute Onyx and Orsiro stents']","['TVF rates', 'definite-or-probable stent thrombosis', 'TVF', 'adverse event rates', 'vessel failure (TVF: cardiac death, target vessel MI, or target vessel revascularization) with Kaplan-Meier methods', 'mainly driven by target vessel revascularization']","[{'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}]","[{'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0038257', 'cui_str': 'Stent'}]","[{'cui': 'C0449618', 'cui_str': 'Target vessel'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0439544', 'cui_str': 'Definite'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0004379', 'cui_str': 'Driving'}]",,0.163056,"TVF rates were lower in acute MI patients (77/1,275[6.1%] vs. 103/1,213[8.6%], HR:0.70, 95%-CI 0.52-0.94; p log-rank = 0.02), mainly driven by target vessel revascularization (4.1 vs. 6.1%, p log-rank = 0.03).","[{'ForeName': 'Eline H', 'Initials': 'EH', 'LastName': 'Ploumen', 'Affiliation': 'Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands.'}, {'ForeName': 'Rosaly A', 'Initials': 'RA', 'LastName': 'Buiten', 'Affiliation': 'Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Zocca', 'Affiliation': 'Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands.'}, {'ForeName': 'Carine J M', 'Initials': 'CJM', 'LastName': 'Doggen', 'Affiliation': 'Department of Health Technology and Services Research, Faculty BMS, Technical Medical Center, University of Twente, Enschede, The Netherlands.'}, {'ForeName': 'Gillian A J', 'Initials': 'GAJ', 'LastName': 'Jessurun', 'Affiliation': 'Department of Cardiology, Treant Zorggroep, Scheper Hospital, Emmen, The Netherlands.'}, {'ForeName': 'Carl E', 'Initials': 'CE', 'LastName': 'Schotborgh', 'Affiliation': 'Department of Cardiology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Roguin', 'Affiliation': 'Department of Cardiology, Hillel Yaffe Medical Center, Hadera and B. Rappaport-Faculty of Medicine, Israel, Institute of Technology, Haifa, Israel.'}, {'ForeName': 'Peter W', 'Initials': 'PW', 'LastName': 'Danse', 'Affiliation': 'Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands.'}, {'ForeName': 'Edouard', 'Initials': 'E', 'LastName': 'Benit', 'Affiliation': 'Department of Cardiology, Jessa Hospital, Hasselt, Belgium.'}, {'ForeName': 'Adel', 'Initials': 'A', 'LastName': 'Aminian', 'Affiliation': 'Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium.'}, {'ForeName': 'Rutger L', 'Initials': 'RL', 'LastName': 'Anthonio', 'Affiliation': 'Department of Cardiology, Treant Zorggroep, Scheper Hospital, Emmen, The Netherlands.'}, {'ForeName': 'Samer', 'Initials': 'S', 'LastName': 'Somi', 'Affiliation': 'Department of Cardiology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Gerard C M', 'Initials': 'GCM', 'LastName': 'Linssen', 'Affiliation': 'Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, Almelo, The Netherlands.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Hartmann', 'Affiliation': 'Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands.'}, {'ForeName': 'Marlies M', 'Initials': 'MM', 'LastName': 'Kok', 'Affiliation': 'Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'von Birgelen', 'Affiliation': 'Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands.'}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.29594'] 1162,33690909,No increased suggestibility to placebo in functional neurological disorder.,"BACKGROUND AND PURPOSE On the basis of occasional strong placebo responses, increased susceptibility to placebo has been proposed as a characteristic of functional neurological disorder (FND). The aim of this study was to clarify whether people with FND have a stronger placebo analgesic response than healthy controls. METHODS A study using a classic placebo paradigm, with additional conditioning and open-label components, was performed in 30 patients with FND, and in 30 healthy controls. Ratings of mildly to moderately painful electrotactile stimuli were compared before and after the application of a placebo ""anaesthetic"" cream versus a control cream, after an additional conditioning exposure, and after full disclosure (open-label component). RESULTS Pain intensity ratings at the placebo compared to the control site were similarly reduced in both groups. The conditioning exposure had no additional effect. After placebo disclosure a residual analgesic effect remained. CONCLUSION Patients with FND did not have stronger placebo responses than healthy controls. The notion of generally increased suggestibility or increased suggestibility to placebo in FND seems mistaken. Instead, occasional dramatic placebo responses may occur because functional symptoms are inherently more changeable than those due to organic disease.",2021,"RESULTS Pain intensity ratings at the placebo compared to the control site were similarly reduced in both groups.","['Functional neurological disorder patients', '30 patients with a functional neurological disorder, and in 30 healthy controls', 'people with functional neurological disorder']","['Placebo', 'placebo', 'placebo ""anaesthetic"" cream', 'additional conditioning and open-label components']",['Pain intensity ratings'],"[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0027765', 'cui_str': 'Disorder of nervous system'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0449432', 'cui_str': 'Component'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",30.0,0.109623,"RESULTS Pain intensity ratings at the placebo compared to the control site were similarly reduced in both groups.","[{'ForeName': 'Anne-Catherine M L', 'Initials': 'AML', 'LastName': 'Huys', 'Affiliation': 'Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, UK.'}, {'ForeName': 'Brianna', 'Initials': 'B', 'LastName': 'Beck', 'Affiliation': 'School of Psychology, University of Kent, UK.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Haggard', 'Affiliation': 'Institute of Cognitive Neuroscience, University College London, London, UK.'}, {'ForeName': 'Kailash P', 'Initials': 'KP', 'LastName': 'Bhatia', 'Affiliation': 'Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, UK.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Edwards', 'Affiliation': ""Neuroscience Research Centre, Institute of Molecular and Cell Sciences, St George's University of London, London, UK.""}]",European journal of neurology,['10.1111/ene.14816'] 1163,33704352,Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.,"Importance Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses. Design, Setting, and Participants Twenty-five participants were enrolled from July 29, 2020, to August 7, 2020, and the follow-up for this day 71 interim analysis was completed on October 3, 2020; follow-up to assess durability will continue for 2 years. This study was conducted at a single clinical site in Boston, Massachusetts, as part of a randomized, double-blind, placebo-controlled phase 1 clinical trial of Ad26.COV2.S. Interventions Participants were randomized to receive 1 or 2 intramuscular injections with 5 × 1010 viral particles or 1 × 1011 viral particles of Ad26.COV2.S vaccine or placebo administered on day 1 and day 57 (5 participants in each group). Main Outcomes and Measures Humoral immune responses included binding and neutralizing antibody responses at multiple time points following immunization. Cellular immune responses included immunospot-based and intracellular cytokine staining assays to measure T-cell responses. Results Twenty-five participants were randomized (median age, 42; age range, 22-52; 52% women, 44% male, 4% undifferentiated), and all completed the trial through the day 71 interim end point. Binding and neutralizing antibodies emerged rapidly by day 8 after initial immunization in 90% and 25% of vaccine recipients, respectively. By day 57, binding and neutralizing antibodies were detected in 100% of vaccine recipients after a single immunization. On day 71, the geometric mean titers of spike-specific binding antibodies were 2432 to 5729 and the geometric mean titers of neutralizing antibodies were 242 to 449 in the vaccinated groups. A variety of antibody subclasses, Fc receptor binding properties, and antiviral functions were induced. CD4+ and CD8+ T-cell responses were induced. Conclusion and Relevance In this phase 1 study, a single immunization with Ad26.COV2.S induced rapid binding and neutralization antibody responses as well as cellular immune responses. Two phase 3 clinical trials are currently underway to determine the efficacy of the Ad26.COV2.S vaccine. Trial Registration ClinicalTrials.gov Identifier: NCT04436276.",2021,"Binding and neutralizing antibodies emerged rapidly by day 8 after initial immunization in 90% and 25% of vaccine recipients, respectively.","['Participants\n\n\nTwenty-five participants were enrolled from July 29, 2020, to August 7, 2020, and the follow-up for this day 71 interim analysis was completed on October 3, 2020; follow-up', 'Twenty-five participants were randomized (median age, 42; age range, 22-52; 52% women, 44% male, 4% undifferentiated), and all completed the trial through the day 71 interim end point', 'controlled phase 1 clinical trial of Ad26.COV2.S.\nInterventions\n\n\nParticipants']","['placebo', 'intramuscular injections with 5\u2009×\u20091010 viral particles or 1\u2009×\u20091011 viral particles of Ad26.COV2.S vaccine or placebo', 'Ad26.COV2.S vaccine (Janssen/Johnson & Johnson']","['Immunogenicity', 'binding and neutralizing antibodies', 'CD4+ and CD8+ T-cell responses', 'geometric mean titers of spike-specific binding antibodies', 'geometric mean titers of neutralizing antibodies', 'Measures\n\n\nHumoral immune responses included binding and neutralizing antibody responses']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205618', 'cui_str': 'Undifferentiated'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0282459', 'cui_str': 'Clinical Trial, Phase 1'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0021492', 'cui_str': 'Intramuscular injection'}, {'cui': 'C0042760', 'cui_str': 'Virion'}, {'cui': 'C0450317', 'cui_str': '1011'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0282682', 'cui_str': 'Blocking antibody'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0020967', 'cui_str': 'Humoral Immunity'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",25.0,0.500399,"Binding and neutralizing antibodies emerged rapidly by day 8 after initial immunization in 90% and 25% of vaccine recipients, respectively.","[{'ForeName': 'Kathryn E', 'Initials': 'KE', 'LastName': 'Stephenson', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Le Gars', 'Affiliation': 'Janssen Vaccines & Prevention, Leiden, the Netherlands.'}, {'ForeName': 'Jerald', 'Initials': 'J', 'LastName': 'Sadoff', 'Affiliation': 'Janssen Vaccines & Prevention, Leiden, the Netherlands.'}, {'ForeName': 'Anne Marit', 'Initials': 'AM', 'LastName': 'de Groot', 'Affiliation': 'Janssen Vaccines & Prevention, Leiden, the Netherlands.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Heerwegh', 'Affiliation': 'Janssen Research & Development, Beerse, Belgium.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Truyers', 'Affiliation': 'Janssen Research & Development, Beerse, Belgium.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Atyeo', 'Affiliation': 'Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts.'}, {'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Loos', 'Affiliation': 'Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts.'}, {'ForeName': 'Abishek', 'Initials': 'A', 'LastName': 'Chandrashekar', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'McMahan', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Lisa H', 'Initials': 'LH', 'LastName': 'Tostanoski', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Jingyou', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Makda S', 'Initials': 'MS', 'LastName': 'Gebre', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Jacob-Dolan', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Zhenfeng', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Shivani', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Peter', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Jinyan', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Erica N', 'Initials': 'EN', 'LastName': 'Borducchi', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Nkolola', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Morgana', 'Initials': 'M', 'LastName': 'Souza', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Chen Sabrina', 'Initials': 'CS', 'LastName': 'Tan', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Zash', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Julg', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Ruvandhi R', 'Initials': 'RR', 'LastName': 'Nathavitharana', 'Affiliation': 'Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Roger L', 'Initials': 'RL', 'LastName': 'Shapiro', 'Affiliation': 'Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Ahmed Abdul', 'Initials': 'AA', 'LastName': 'Azim', 'Affiliation': 'Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Carolyn D', 'Initials': 'CD', 'LastName': 'Alonso', 'Affiliation': 'Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Jaegle', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Ansel', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Diane G', 'Initials': 'DG', 'LastName': 'Kanjilal', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Caitlin J', 'Initials': 'CJ', 'LastName': 'Guiney', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Connor', 'Initials': 'C', 'LastName': 'Bradshaw', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Tyler', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Tatenda', 'Initials': 'T', 'LastName': 'Makoni', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Katherine E', 'Initials': 'KE', 'LastName': 'Yanosick', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Seaman', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Douglas A', 'Initials': 'DA', 'LastName': 'Lauffenburger', 'Affiliation': 'Massachusetts Institute of Technology, Cambridge.'}, {'ForeName': 'Galit', 'Initials': 'G', 'LastName': 'Alter', 'Affiliation': 'Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Struyf', 'Affiliation': 'Janssen Research & Development, Beerse, Belgium.'}, {'ForeName': 'Macaya', 'Initials': 'M', 'LastName': 'Douoguih', 'Affiliation': 'Janssen Vaccines & Prevention, Leiden, the Netherlands.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Van Hoof', 'Affiliation': 'Janssen Vaccines & Prevention, Leiden, the Netherlands.'}, {'ForeName': 'Hanneke', 'Initials': 'H', 'LastName': 'Schuitemaker', 'Affiliation': 'Janssen Vaccines & Prevention, Leiden, the Netherlands.'}, {'ForeName': 'Dan H', 'Initials': 'DH', 'LastName': 'Barouch', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}]",JAMA,['10.1001/jama.2021.3645'] 1164,33712909,Effects of balneological outpatient treatment on clinical parameters and serum cytokine levels in patients with chronic low back pain: a single-blind randomized controlled trial.,"This study aimed to investigate the effects of balneological outpatient treatment (hydrotherapy and peloidotherapy) on clinical status and serum cytokine levels in patients with chronic low back pain (CLBP). Seventy-four patients with CLBP who accepted to participate to the study were randomly divided into two groups. The study group was given ten sessions (in 2 weeks) of hydrotherapy, peloidotherapy, and home exercise, while the control group was given only home exercise. All patients were assessed before and at the end of therapy, at the 1st and 3rd months. The primary outcomes were pain intensity on the visual analog scale (VAS) (VAS-pain, VAS-rest, VAS-exercise) and Oswestry Disability Index (ODI). The secondary outcome measures included patient's and physician's global assessment (VAS-PGA), (VAS-DGA), finger-to-floor distance (FFD), modified Schober test, Short Form-36 (SF-36), and the use of analgesic drug. Venous blood samples were drawn from all patients before/1st day and after therapy/12th day to measure serum interleukin (IL)-6 and IL-10 levels. Significant improvement was observed in the study group in VAS-pain, VAS-rest, VAS-exercise, VAS-PGA, VAS-DGA, ODI, and SF-36 parameters after treatment and improvement maintained for 3 months. In the control group, significant improvement was observed in VAS-pain, VAS-exercise, VAS-PGA, VAS-DGA, and ODI scores on the 12th day and continued for 3 months. Decrease in pain, pain during rest and exercise, modified Schober test, VAS-PGA, VAS-DGA, ODI scores, and the increase in SF-36 pain and general health scores showed superiority in favor of the study group in all evaluations. There was a significant increase in IL-10 values from baseline at the end of treatment in the study group. The use of non-steroidal anti-inflammatory drug (NSAID) was significantly lower in the study group compared with the use of NSAID in the control group in the 3rd month. Balneological outpatient treatment improved clinical status in CLBP patients. Although no significant correlation was clearly determined between IL-10 levels and pain score, this effect might be related to the observed increase in the anti-inflammatory cytokine IL-10 levels that was observed only in the study group.",2021,"In the control group, significant improvement was observed in VAS-pain, VAS-exercise, VAS-PGA, VAS-DGA, and ODI scores on the 12th day and continued for 3 months.","['Seventy-four patients with CLBP who accepted to participate to the study', 'patients with chronic low back pain (CLBP', 'CLBP patients', 'patients with chronic low back pain']","['balneological outpatient treatment', 'hydrotherapy, peloidotherapy, and home exercise, while the control group was given only home exercise', 'balneological outpatient treatment (hydrotherapy and peloidotherapy']","[""patient's and physician's global assessment (VAS-PGA), (VAS-DGA), finger-to-floor distance (FFD), modified Schober test, Short Form-36 (SF-36), and the use of analgesic drug"", 'VAS-pain, VAS-exercise, VAS-PGA, VAS-DGA, and ODI scores', 'clinical status', 'pain, pain during rest and exercise, modified Schober test, VAS-PGA, VAS-DGA, ODI scores', 'IL-10 levels and pain score', 'anti-inflammatory cytokine IL-10 levels', 'VAS-pain, VAS-rest, VAS-exercise, VAS-PGA, VAS-DGA, ODI, and SF-36 parameters', 'pain intensity on the visual analog scale (VAS) (VAS-pain, VAS-rest, VAS-exercise) and Oswestry Disability Index (ODI', 'Venous blood samples', 'clinical status and serum cytokine levels', 'serum interleukin (IL)-6 and IL-10 levels', 'IL-10 values', 'clinical parameters and serum cytokine levels', 'SF-36 pain and general health scores']","[{'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1947971', 'cui_str': 'Give'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0231626', 'cui_str': 'Finger to floor distance'}, {'cui': 'C0430750', 'cui_str': 'Modified Schober test'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2960603', 'cui_str': 'Oswestry disability index score'}, {'cui': 'C0449440', 'cui_str': 'Clinical status'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0444255', 'cui_str': 'Venous blood specimen'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",74.0,0.0156384,"In the control group, significant improvement was observed in VAS-pain, VAS-exercise, VAS-PGA, VAS-DGA, and ODI scores on the 12th day and continued for 3 months.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Yücesoy', 'Affiliation': 'Department of Medical Ecology and Hydroclimatology, Antalya Education and Research Hospital, University of Health Sciences, Varlık Mh. Kazım Karabekir Cd., 07100 Muratpaşa, Antalya, Turkey. hidayetyucesoy@gmail.com.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Dönmez', 'Affiliation': 'Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Çapa, Istanbul, Turkey.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Atmaca-Aydın', 'Affiliation': 'Department of Medical Ecology and Hydroclimatology, Antalya Education and Research Hospital, University of Health Sciences, Varlık Mh. Kazım Karabekir Cd., 07100 Muratpaşa, Antalya, Turkey.'}, {'ForeName': 'S P', 'Initials': 'SP', 'LastName': 'Yentür', 'Affiliation': 'Department of Physiology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Çapa, 34093, Istanbul, Turkey.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Saruhan-Direskeneli', 'Affiliation': 'Department of Physiology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Çapa, 34093, Istanbul, Turkey.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Ankaralı', 'Affiliation': 'Department of Biostatistics and Medical Informatics, Istanbul Medeniyet University Medical Faculty, 34093, Kadıköy, Turkey.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Erdoğan', 'Affiliation': 'Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Çapa, Istanbul, Turkey.'}, {'ForeName': 'M Z', 'Initials': 'MZ', 'LastName': 'Karagülle', 'Affiliation': 'Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Çapa, Istanbul, Turkey.'}]",International journal of biometeorology,['10.1007/s00484-021-02109-w'] 1165,33710976,Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age.,"BACKGROUND Infections with Gram-positive bacteria, including acute bacterial skin and skin structure infections (ABSSSIs), are common in children. We describe a single-dose pharmacokinetics and safety study of tedizolid phosphate, a new oxazolidinone under investigation for the treatment of ABSSSIs in children, in hospitalized participants 2 to <12 years of age. METHODS This open-label, multicenter, phase 1 trial (NCT02750761) enrolled hospitalized children 2 to <12 years of age receiving treatment for a confirmed/suspected Gram-positive bacterial infection. Participants were stratified by age (2 to <6 years and 6 to <12 years) to receive a single oral or intravenous dose of tedizolid phosphate. Evaluations included safety and pharmacokinetics of tedizolid phosphate and its active metabolite, tedizolid. Palatability of the oral suspension was also evaluated. RESULTS Thirty-two participants were enrolled and received 3-6 mg/kg of study medication. For both routes of administration, tedizolid phosphate was rapidly converted to tedizolid; median time to maximum tedizolid plasma concentration was 1-2 hours after initiation of the 1-hour intravenous infusion and 2-3 hours after oral dosing. The tedizolid mean terminal half-life was 5-6 hours and 6-7 hours for the intravenous and oral administration groups, respectively. The oral tedizolid phosphate suspension demonstrated high bioavailability comparable to that of the parenteral administration. A single dose of intravenous or oral tedizolid phosphate was well tolerated; no unexpected safety findings were observed. CONCLUSIONS Pharmacokinetic and safety observations provide the information necessary for the continued development of tedizolid phosphate for the treatment of Gram-positive infections in children, particularly ABSSSIs.",2021,"A single dose of intravenous or oral tedizolid phosphate was well tolerated; no unexpected safety findings were observed. ","['ABSSSIs in children, in hospitalized participants 2 to <12 years of age', 'Participants were stratified by age (2 to <6 years and 6 to <12 years', 'Children 2 to <12 Years of Age', 'Thirty-two participants', 'enrolled hospitalized children 2 to <12 years of age receiving treatment for a confirmed/suspected Gram-positive bacterial infection']","['single oral or intravenous dose of tedizolid phosphate', 'intravenous or oral tedizolid phosphate', 'tedizolid phosphate', 'Single-dose Tedizolid Phosphate']","['tedizolid plasma concentration', 'Pharmacokinetics and Safety', 'safety and pharmacokinetics of tedizolid phosphate and its active metabolite, tedizolid', 'tedizolid mean terminal half-life']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0008098', 'cui_str': 'Children, Hospitalized'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0085426', 'cui_str': 'Bacterial Infections, Gram-Positive'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C2930762', 'cui_str': 'Tedizolid phosphate'}]","[{'cui': 'C2744850', 'cui_str': 'tedizolid'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2930762', 'cui_str': 'Tedizolid phosphate'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}]",32.0,0.11161,"A single dose of intravenous or oral tedizolid phosphate was well tolerated; no unexpected safety findings were observed. ","[{'ForeName': 'Antonio C', 'Initials': 'AC', 'LastName': 'Arrieta', 'Affiliation': ""From the Children's Hospital of Orange County, Orange, California.""}, {'ForeName': 'Jocelyn Y', 'Initials': 'JY', 'LastName': 'Ang', 'Affiliation': ""Children's Hospital of Michigan, Detroit, Michigan.""}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Espinosa', 'Affiliation': 'University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Oleksandr', 'Initials': 'O', 'LastName': 'Fofanov', 'Affiliation': 'Ivano-Frankivsk Regional Children Clinical Hospital, Ivano-Frankivsk, Ukraine.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Tøndel', 'Affiliation': 'Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Margaret Z', 'Initials': 'MZ', 'LastName': 'Chou', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Carisa S', 'Initials': 'CS', 'LastName': 'De Anda', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Jason Y', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Sabato', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Sears', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Bradley', 'Affiliation': 'University of California, San Diego, California.'}]",The Pediatric infectious disease journal,['10.1097/INF.0000000000003030'] 1166,33715300,A comparison between the effects of school-based education programs provided by peer group versus health practitioners on premenstrual syndrome in adolescents: A protocol for a non-masked clinical trial.,"AIM To compare the effect of school-based education programs, by peer group versus health practitioner on Premenstrual Syndrome (PMS) in adolescent girls. DESIGN Non-masked three-armed clinical trial. METHODS Ninety 11th-grade students with moderate to severe PMS will be allocated to Intervention Group 1 (IG1), Intervention Group 2 (IG2) and Comparison Group (CG). Three weeks (six online sessions) of parallel education will be implemented in IG1 by trained peer educators and in IG2 by a health practitioner. The primary outcome will be changes in PMS severity score between three groups over time (measured by Daily Record of Severity of Problems). Secondary outcomes include changes in Premenstrual Dysphoric Disorder and General Health. Data collection will be conducted in two-time points, at baseline, and at the end of the intervention. RESULTS Our study will explore the effect of school-based education programs, by peer group versus health practitioner on PMS. This will add to the evidence-based interventions to PMS management and the effectiveness of peer education in health promotion of adolescents girls.",2021,This will add to the evidence-based interventions to PMS management and the effectiveness of peer education in health promotion of adolescents girls.,"['Non-masked three-armed clinical trial', 'premenstrual syndrome in adolescents', 'adolescents girls', 'adolescent girls', 'Ninety 11th-grade students with moderate to severe PMS']","['school-based education programs provided by peer group versus health practitioners', 'Intervention Group 1 (IG1), Intervention Group 2 (IG2) and Comparison Group (CG', 'school-based education programs, by peer group versus health practitioner']","['Premenstrual Dysphoric Disorder and General Health', 'Premenstrual Syndrome (PMS', 'changes in PMS severity score']","[{'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0033046', 'cui_str': 'Premenstrual syndrome'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0030767', 'cui_str': 'Peer Group'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0520676', 'cui_str': 'Premenstrual dysphoric disorder'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0033046', 'cui_str': 'Premenstrual syndrome'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}]",90.0,0.081953,This will add to the evidence-based interventions to PMS management and the effectiveness of peer education in health promotion of adolescents girls.,"[{'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Babapour', 'Affiliation': 'Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Forouzan', 'Initials': 'F', 'LastName': 'Elyasi', 'Affiliation': 'Sexual and Reproductive Health Research Center, Psychiatry and Behavioral Sciences Research Center, School of Medicine, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Jamshid', 'Initials': 'J', 'LastName': 'Yazdani-Charati', 'Affiliation': 'Health Sciences Research Center, School of Health, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Shahhosseini', 'Affiliation': 'Sexual and Reproductive Health Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}]",Nursing open,['10.1002/nop2.858'] 1167,33712253,Intraoperative clonidine to prevent postoperative emergence delirium following sevoflurane anesthesia in pediatric patients: a randomized clinical trial.,"INTRODUCTION AND OBJECTIVE Emergence Delirium (ED), particularly in children, is characterized by mental confusion, irritability, disorientation, and inconsolable crying. ED prolongs the time required in the Post-Anesthesia Care Unit (PACU) and increases concern and anxiety in parents. The present study aimed to determine the effectiveness and safety of low-dose clonidine in preventing ED in children receiving sevoflurane anesthesia for tonsillectomy/adenotonsillectomy. METHODS A randomized, double-blind clinical trial was conducted between November 2013 and January 2014. Sixty-two children aged 2-12 years, scheduled to undergo tonsillectomy/adenotonsillectomy, and classified as American Society of Anesthesiologists (ASA) physical status I/II were included, with 29 being randomized to receive 1 μg.kg -1 clonidine intravenously, and 33 allocated to a control group that received no clonidine. Anesthesia was induced and maintained with sevoflurane. Children with altered state of consciousness, neurological deficit, history of allergy to dipyrone, or receiving other drugs such as preanesthetic agents were excluded from the study. The primary outcome was the presence of ED in the initial 20 minutes in the PACU according to the Pediatric Anesthesia Emergence Delirium (PAED) scale. The Chi-Square test and Fisher's two-tailed exact test were used for statistical analysis, as applicable. Significance level was set at 5%, and Risk Ratios (RR) and their 95% Confidence Intervals (95% CI) were calculated. RESULTS The frequency of ED was significantly decreased in the group of children who received clonidine (17.2% vs. 57.6%; RR = 0.30; 95% CI 0.13-0.70; p =  0.001). There was no difference between groups with respect to the frequency of postoperative self-harm (falls and bruises), dislodged catheters, and for most of the other adverse events evaluated. CONCLUSIONS The use of 1 μg.kg -1 intravenous clonidine during anesthesia induction can effectively reduce the incidence of ED in children undergoing elective tonsillectomy/adenotonsillectomy under general inhalation anesthesia with sevoflurane. CLINICALTRIALS. GOV IDENTIFIER NCT02181543.",2021,"There was no difference between groups with respect to the frequency of postoperative self-harm (falls and bruises), dislodged catheters, and for most of the other adverse events evaluated. ","['children receiving sevoflurane anesthesia for tonsillectomy/adenotonsillectomy', 'Sixty-two children aged 2-12 years, scheduled to undergo tonsillectomy/adenotonsillectomy, and classified as American Society of Anesthesiologists (ASA) physical status I/II were included, with 29 being randomized to', 'Children with altered state of consciousness, neurological deficit, history of allergy to dipyrone, or receiving other drugs such as preanesthetic agents were excluded from the study', 'pediatric patients', 'children undergoing elective tonsillectomy/adenotonsillectomy under general inhalation anesthesia with', 'parents', 'November 2013 and January 2014']","['sevoflurane', 'control group that received no clonidine', 'Intraoperative clonidine', 'receive 1\xa0μg.kg -1 clonidine', 'sevoflurane anesthesia', 'clonidine']","['incidence of ED', 'presence of ED in the initial 20\xa0minutes in the PACU according to the Pediatric Anesthesia Emergence Delirium (PAED) scale', 'frequency of ED', 'frequency of postoperative self-harm (falls and bruises), dislodged catheters', 'postoperative emergence delirium', 'effectiveness and safety', 'Risk Ratios (RR']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0150450', 'cui_str': 'Altered state of consciousness'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C3840229', 'cui_str': 'Allergy to dipyrone'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0002917', 'cui_str': 'Anesthesia, Inhalation'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009014', 'cui_str': 'Clonidine'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0920253', 'cui_str': 'Agitated Emergence'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0034871', 'cui_str': 'Postoperative anesthesia care unit'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0085271', 'cui_str': 'Self-injurious behavior'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0009938', 'cui_str': 'Contusion'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",62.0,0.365196,"There was no difference between groups with respect to the frequency of postoperative self-harm (falls and bruises), dislodged catheters, and for most of the other adverse events evaluated. ","[{'ForeName': 'Fernando A', 'Initials': 'FA', 'LastName': 'Sousa-Júnior', 'Affiliation': 'Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Departamento de Anestesiologia, Recife, PE, Brazil.'}, {'ForeName': 'Alex S R', 'Initials': 'ASR', 'LastName': 'Souza', 'Affiliation': 'Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, PE, Brazil; Universidade Federal de Pernambuco (UFPE), Departamento de Saúde da Mulher e da Criança, Recife, PE, Brazil; Universidade Católica de Pernambuco (Unicap), Recife, PE, Brazil.'}, {'ForeName': 'Luciana C', 'Initials': 'LC', 'LastName': 'Lima', 'Affiliation': 'Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Departamento de Anestesiologia, Recife, PE, Brazil.'}, {'ForeName': 'Ítalo G M', 'Initials': 'ÍGM', 'LastName': 'Santos', 'Affiliation': 'Faculdade Pernambucana de Saúde (FPS), Recife, PE, Brazil.'}, {'ForeName': 'Leonardo A P', 'Initials': 'LAP', 'LastName': 'Menezes', 'Affiliation': 'Faculdade Pernambucana de Saúde (FPS), Recife, PE, Brazil.'}, {'ForeName': 'Pedro A P L', 'Initials': 'PAPL', 'LastName': 'Ratis', 'Affiliation': 'Faculdade Pernambucana de Saúde (FPS), Recife, PE, Brazil.'}, {'ForeName': 'Tania C M', 'Initials': 'TCM', 'LastName': 'Couceiro', 'Affiliation': 'Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Departamento de Anestesiologia, Recife, PE, Brazil. Electronic address: taniacouceiro@yahoo.com.br.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2020.12.003'] 1168,33712252,Ultrasound-guided pectoral nerve block for pain control after breast augmentation: a randomized clinical study.,"BACKGROUND AND OBJECTIVE Pectoral nNerve (PECS) block type-1 is an Ultrasound (US)-guided interfacial block that can be performed for postoperative analgesia management after breast surgery. In the procedure, a local anesthetic solution is injected into the interfacial area between the Pectoralis Major muscles (PMm) and Pectoralis minor muscles (Pmm). The present study compared PECS block type-1 administered preoperatively or postoperatively for postoperative analgesia after breast augmentation surgery. METHODS The patients were randomly divided into three groups (n = 30 in each): a preoperative PECS block group (Pregroup), postoperative PECS block group (Postgroup), and control group (Group C). Opioid consumption and Visual Analogue Scale (VAS) scores were evaluated at postoperative period. RESULTS The pains scores in the Pregroup were significantly lower than those in the control group. Although there was no significantly difference in the VAS scores of the Postgroup and control group at postoperative 1 hour, the scores in the Postgroup were significantly lower than those in the control group at all the other evaluated times (p < 0.05). The VAS scores in the Pregroup were significantly lower than those in the Postgroup 8 hours after the surgery. Opioid consumption was significantly lower in the Pregroup as compared with that in the other two groups (p < 0.05). The use of rescue analgesia in the Pregroup was significantly lower than that in the other groups (p < 0.05). CONCLUSION Performing PECS block type-1 preoperatively reduced VAS scores and opioid consumption after breast augmentation.",2021,"The use of rescue analgesia in the Pregroup was significantly lower than that in the other groups (p < 0.05). ",[],"['preoperative PECS block group (Pregroup), postoperative PECS block group (Postgroup), and control group', 'Ultrasound-guided pectoral nerve block for pain control after breast augmentation']","['VAS scores', 'Opioid consumption and Visual Analogue Scale (VAS) scores', 'VAS scores and opioid consumption', 'Opioid consumption', 'pains scores']",[],"[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205967', 'cui_str': 'Pectoral Nerves'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0191925', 'cui_str': 'Augmentation mammoplasty'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",,0.0223405,"The use of rescue analgesia in the Pregroup was significantly lower than that in the other groups (p < 0.05). ","[{'ForeName': 'Bahadır', 'Initials': 'B', 'LastName': 'Ciftci', 'Affiliation': 'Istanbul Medipol University, Department of Anesthesiology and Reanimation, Istanbul, Turkey. Electronic address: bciftci@medipol.edu.tr.'}, {'ForeName': 'Mursel', 'Initials': 'M', 'LastName': 'Ekinci', 'Affiliation': 'Istanbul Medipol University, Department of Anesthesiology and Reanimation, Istanbul, Turkey.'}, {'ForeName': 'Erkan Cem', 'Initials': 'EC', 'LastName': 'Celik', 'Affiliation': 'Erzurum Regional Training and Research Hospital, Department of Anesthesiology and Reanimation, Erzurum, Turkey.'}, {'ForeName': 'Pelin', 'Initials': 'P', 'LastName': 'Karaaslan', 'Affiliation': 'Istanbul Medipol University, Department of Anesthesiology and Reanimation, Istanbul, Turkey.'}, {'ForeName': 'İsmail Cem', 'Initials': 'İC', 'LastName': 'Tukac', 'Affiliation': 'Istanbul Medipol University, Department of Anesthesiology and Reanimation, Istanbul, Turkey.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2020.12.004'] 1169,33712250,Residual neuromuscular blockade and late neuromuscular blockade at the post-anesthetic recovery unit: prospective cohort study.,"INTRODUCTION AND OBJECTIVES The use of neuromuscular blockers during surgery represented a landmark for anesthesiology. However, their use can prompt residual Neuromuscular Blockade ( R NMB) and objective monitoring of neuromuscular function is crucial to warrant the recovery of muscle strength. The present study aimed to estimate the incidence of R NMB and late Neuromuscular Blockade ( L NMB) at the Post-Anesthetic Recovery Unit (PACU). METHOD The study included 85 patients, 43 of which received cisatracurium and 42 of which, rocuronium. The depth of the Neuromuscular Blockade (NMB) was assessed by Train Of Four (TOF). NMB reversal was performed with the administration of neostigmine and atropine. R NMB was defined when a patient presented TOF below 90% at the PACU. RESULTS R NMB at the PACU was diagnosed in 39.5% and 40.5% of the patients receiving cisatracurium and rocuronium, respectively (p = 1.0). L NMB at the PACU was found in 32.6% and 16.7% of the patients receiving cisatracurium and rocuronium, respectively (p = 0.131). CONCLUSIONS The incidence of R NMB remains significant despite the use of intermediate-acting neuromuscular blockers and reversal agents. There was no statistically significant difference in the incidence of R NMB or L NMB in patients receiving cisatracurium or rocuronium. The use of objective NMB monitoring is effective for the diagnosis of R NMB, as well as for treatment management.",2021,There was no statistically significant difference in the incidence of R NMB or L NMB in patients receiving cisatracurium or rocuronium.,"['85 patients, 43 of which received cisatracurium and 42 of which']","['neostigmine and atropine', 'rocuronium', 'neuromuscular blockers']","['incidence of R NMB and late Neuromuscular Blockade ( L NMB', 'R NMB', 'incidence of R NMB or L NMB', 'depth of the Neuromuscular Blockade (NMB']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1096766', 'cui_str': 'Cisatracurium'}]","[{'cui': 'C0027679', 'cui_str': 'Neostigmine'}, {'cui': 'C0004259', 'cui_str': 'Atropine'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0027866', 'cui_str': 'Neuromuscular blocking agent'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0234119', 'cui_str': 'Neuromuscular blockade'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0205125', 'cui_str': 'Deep'}]",85.0,0.043571,There was no statistically significant difference in the incidence of R NMB or L NMB in patients receiving cisatracurium or rocuronium.,"[{'ForeName': 'Pedro Marcos Silva E', 'Initials': 'PMSE', 'LastName': 'Gonçalves', 'Affiliation': 'Universidade Federal de Minas Gerais (UFMG), Faculdade de Medicina, Programa de Pós-Graduação em Ciências Aplicadas à Cirurgia e à Oftalmologia, Belo Horizonte, MG, Brasil. Electronic address: pedro.marcoss@yahoo.com.br.'}, {'ForeName': 'Alexandra de Vasconcelos', 'Initials': 'AV', 'LastName': 'Vieira', 'Affiliation': 'Hospital Unimed BH - Unidade Contorno, Serviço de Anestesiologia, Belo Horizonte, MG, Brasil.'}, {'ForeName': 'Claudia Helena Ribeiro da', 'Initials': 'CHRD', 'LastName': 'Silva', 'Affiliation': 'Hospital Unimed BH - Unidade Contorno, Serviço de Anestesiologia, Belo Horizonte, MG, Brasil.'}, {'ForeName': 'Renato Santiago', 'Initials': 'RS', 'LastName': 'Gomez', 'Affiliation': 'Universidade Federal de Minas Gerais (UFMG), Faculdade de Medicina, Programa de Pós-Graduação em Ciências Aplicadas à Cirurgia e à Oftalmologia, Belo Horizonte, MG, Brasil.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2020.12.009'] 1170,33758387,Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial.,"OBJECTIVE This study evaluates the 24-month follow-up for the NICHD Neonatal Research Network (NRN) Inositol for Retinopathy Trial. STUDY DESIGN Bayley Scales of Infants Development-III and a standardized neurosensory examination were performed in infants enrolled in the main trial. Moderate/severe NDI was defined as BSID-III Cognitive or Motor composite score <85, moderate or severe cerebral palsy, blindness, or hearing loss that prevents communication despite amplification were assessed. RESULTS Primary outcome was determined for 605/638 (95%). The mean gestational age was 25.8 ± 1.3 weeks and mean birthweight was 805 ± 192 g. Treatment group did not affect the risk for the composite outcome of death or survival with moderate/severe NDI (60% vs 56%, p = 0.40). CONCLUSIONS Treatment group did not affect the risk of death or survival with moderate/severe NDI. Despite early termination, this study represents the largest RCT of extremely preterm infants treated with myo-inositol with neurodevelopmental outcome data.",2021,"The mean gestational age was 25.8 ± 1.3 weeks and mean birthweight was 805 ± 192 g. Treatment group did not affect the risk for the composite outcome of death or survival with moderate/severe NDI (60% vs 56%, p = 0.40). ","['Bayley Scales of Infants Development-III and a standardized neurosensory examination were performed in infants enrolled in the main trial', 'preterm infants enrolled in myo-inositol randomized controlled trial']",[],"['mean gestational age', 'BSID-III Cognitive or Motor composite score <85, moderate or severe cerebral palsy, blindness, or hearing loss', 'Moderate/severe NDI', 'risk of death or survival', 'death or survival with moderate/severe NDI']","[{'cui': 'C0451021', 'cui_str': 'Bayley scale of infant development'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0021547', 'cui_str': 'Inositol'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C1563705', 'cui_str': 'Diabetes Insipidus, Nephrogenic, Type I'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.283315,"The mean gestational age was 25.8 ± 1.3 weeks and mean birthweight was 805 ± 192 g. Treatment group did not affect the risk for the composite outcome of death or survival with moderate/severe NDI (60% vs 56%, p = 0.40). ","[{'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Adams-Chapman', 'Affiliation': ""Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.""}, {'ForeName': 'Kristi L', 'Initials': 'KL', 'LastName': 'Watterberg', 'Affiliation': 'University of New Mexico Health Sciences Center, Albuquerque, NM, USA.'}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'Nolen', 'Affiliation': 'Social, Statistical and Environmental Sciences Unit, RTI International, Research Triangle Park, North Carolina, NC, USA.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Hirsch', 'Affiliation': 'Social, Statistical and Environmental Sciences Unit, RTI International, Research Triangle Park, North Carolina, NC, USA.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Cole', 'Affiliation': 'University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.'}, {'ForeName': 'C Michael', 'Initials': 'CM', 'LastName': 'Cotten', 'Affiliation': 'Department of Pediatrics, Duke University, Durham, NC, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Oh', 'Affiliation': ""Department of Pediatrics, Women & Infants' Hospital, Brown University, Providence, RI, USA.""}, {'ForeName': 'Brenda B', 'Initials': 'BB', 'LastName': 'Poindexter', 'Affiliation': ""Department of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, USA.""}, {'ForeName': 'Kristin M', 'Initials': 'KM', 'LastName': 'Zaterka-Baxter', 'Affiliation': 'Social, Statistical and Environmental Sciences Unit, RTI International, Research Triangle Park, North Carolina, NC, USA.'}, {'ForeName': 'Abhik', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'Social, Statistical and Environmental Sciences Unit, RTI International, Rockville, MD, USA.'}, {'ForeName': 'Conra Backstrom', 'Initials': 'CB', 'LastName': 'Lacy', 'Affiliation': 'University of New Mexico Health Sciences Center, Albuquerque, NM, USA.'}, {'ForeName': 'Ann Marie', 'Initials': 'AM', 'LastName': 'Scorsone', 'Affiliation': 'University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.'}, {'ForeName': 'Andrea F', 'Initials': 'AF', 'LastName': 'Duncan', 'Affiliation': 'Department of Pediatrics, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Sara B', 'Initials': 'SB', 'LastName': 'DeMauro', 'Affiliation': ""Department of Pediatrics, The Children's Hospital of Philadelphia and The University of Pennsylvania, Philadelphia, PA, USA.""}, {'ForeName': 'Ricki F', 'Initials': 'RF', 'LastName': 'Goldstein', 'Affiliation': 'Department of Pediatrics, Duke University, Durham, NC, USA.'}, {'ForeName': 'Tarah T', 'Initials': 'TT', 'LastName': 'Colaizy', 'Affiliation': 'Department of Pediatrics, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Deanne E', 'Initials': 'DE', 'LastName': 'Wilson-Costello', 'Affiliation': ""Department of Pediatrics, Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, OH, USA.""}, {'ForeName': 'Isabell B', 'Initials': 'IB', 'LastName': 'Purdy', 'Affiliation': 'Department of Pediatrics, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Hintz', 'Affiliation': ""Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'Roy J', 'Initials': 'RJ', 'LastName': 'Heyne', 'Affiliation': 'Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Gary J', 'Initials': 'GJ', 'LastName': 'Myers', 'Affiliation': 'University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.'}, {'ForeName': 'Janell', 'Initials': 'J', 'LastName': 'Fuller', 'Affiliation': 'University of New Mexico Health Sciences Center, Albuquerque, NM, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Merhar', 'Affiliation': ""Department of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, USA.""}, {'ForeName': 'Heidi M', 'Initials': 'HM', 'LastName': 'Harmon', 'Affiliation': 'Department of Pediatrics, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Peralta-Carcelen', 'Affiliation': 'Division of Neonatology, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Howard W', 'Initials': 'HW', 'LastName': 'Kilbride', 'Affiliation': ""Department of Pediatrics, Children's Mercy Hospital and University of Missouri Kansas City School of Medicine, Kansas City, MO, USA.""}, {'ForeName': 'Nathalie L', 'Initials': 'NL', 'LastName': 'Maitre', 'Affiliation': ""Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, USA.""}, {'ForeName': 'Betty R', 'Initials': 'BR', 'LastName': 'Vohr', 'Affiliation': ""Department of Pediatrics, Women & Infants' Hospital, Brown University, Providence, RI, USA.""}, {'ForeName': 'Girija', 'Initials': 'G', 'LastName': 'Natarajan', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Mintz-Hittner', 'Affiliation': 'Department of Ophthalmology and Visual Science, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Graham E', 'Initials': 'GE', 'LastName': 'Quinn', 'Affiliation': ""Department of Ophthalmology, The Children's Hospital of Philadelphia and The University of Pennsylvania, Philadelphia, PA, USA.""}, {'ForeName': 'David K', 'Initials': 'DK', 'LastName': 'Wallace', 'Affiliation': 'Department of Ophthalmology, Duke University, Durham, NC, USA.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Olson', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Faruk H', 'Initials': 'FH', 'LastName': 'Orge', 'Affiliation': ""Department of Ophthalmology, Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, OH, USA.""}, {'ForeName': 'Irena', 'Initials': 'I', 'LastName': 'Tsui', 'Affiliation': 'Department of Ophthalmology, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gaynon', 'Affiliation': ""Department of Ophthalmology, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'Amy K', 'Initials': 'AK', 'LastName': 'Hutchinson', 'Affiliation': ""Department of Ophthalmology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.""}, {'ForeName': 'Yu-Guang', 'Initials': 'YG', 'LastName': 'He', 'Affiliation': 'Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Timothy W', 'Initials': 'TW', 'LastName': 'Winter', 'Affiliation': 'Division of Ophthalmology/Department of Surgery, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Yang', 'Affiliation': ""Department of Ophthalmology, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, USA.""}, {'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Haider', 'Affiliation': 'Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Cogen', 'Affiliation': 'Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Hug', 'Affiliation': ""Department of Ophthalmology, Children's Mercy Hospital and University of Missouri Kansas City School of Medicine, Kansas City, MO, USA.""}, {'ForeName': 'Don L', 'Initials': 'DL', 'LastName': 'Bremer', 'Affiliation': ""Department of Ophthalmology, Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Donahue', 'Affiliation': 'Alpert Medical School of Brown University and Consulting Staff, Women & Infants Hospital of Rhode Island, Providence, RI, USA.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Lucas', 'Affiliation': 'Department of Ophthalmology, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'Dale L', 'Initials': 'DL', 'LastName': 'Phelps', 'Affiliation': 'University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.'}, {'ForeName': 'Rosemary D', 'Initials': 'RD', 'LastName': 'Higgins', 'Affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. rhiggin@gmu.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-021-01018-5'] 1171,33764531,Incorporating Virtual Reality to Improve Otolaryngology Resident Wellness: One Institution's Experience.,"OBJECTIVE Burnout is defined as work-related emotional exhaustion, depersonalization, and decreased sense of accomplishment. Virtual reality (VR) has emerged as an effective treatment modality for various conditions related to anxiety, however, few studies have assessed its role for stress management in residents. We hypothesize that VR-based mindfulness meditation can reduce resident burnout in real-world settings. STUDY DESIGN Prospective randomized crossover trial. METHODS Resident participants completed the validated Maslach Burnout Inventory (MBI). One group used a VR-based meditation app; the second group received no intervention. After a 2-month rotation, all subjects completed an MBI and crossed over to the other arm. Wilcoxon rank-sum tests were used to compare MBI scores before and after intervention, and to compare results by gender and postgraduate year. Mann-Whitney U tests were used to assess qualitative differences between participants. RESULTS Eighteen residents completed the study. Five participants were female and 13 were male. Weekly use of VR-guided meditation and paced breathing was associated with a significant decrease in emotional exhaustion (P = .009), and on subgroup analysis, male gender specifically was associated with a decrease in emotional exhaustion (P = .027). In the post-intervention survey, 42.9% subjects reported that VR encouraged them to employ paced breathing techniques, 71.4% reported that they would use the technology if regularly available, and 21.4% reported they would use paced breathing in the future. CONCLUSION VR-based therapy may serve as a successful tool in stress management and reduce the rate of burnout among otolaryngology residents. LEVEL OF EVIDENCE NA Laryngoscope, 131:1972-1976, 2021.",2021,"Weekly use of VR-guided meditation and paced breathing was associated with a significant decrease in emotional exhaustion (P = .009), and on subgroup analysis, male gender specifically was associated with a decrease in emotional exhaustion (P = .027).","['Eighteen residents completed the study', 'Resident participants completed the validated Maslach Burnout Inventory (MBI', 'Five participants were female and 13 were male']","['VR-guided meditation and paced breathing', 'VR-based therapy', 'VR-based meditation app; the second group received no intervention', 'VR-based mindfulness meditation', 'Virtual reality (VR']","['MBI scores', 'emotional exhaustion']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]","[{'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}]",5.0,0.00638287,"Weekly use of VR-guided meditation and paced breathing was associated with a significant decrease in emotional exhaustion (P = .009), and on subgroup analysis, male gender specifically was associated with a decrease in emotional exhaustion (P = .027).","[{'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Weitzman', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Wong', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A.'}, {'ForeName': 'Douglas M', 'Initials': 'DM', 'LastName': 'Worrall', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Park', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'McKee', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A.'}, {'ForeName': 'Ryan E', 'Initials': 'RE', 'LastName': 'Tufts', 'Affiliation': 'Department of Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A.'}, {'ForeName': 'Marita S', 'Initials': 'MS', 'LastName': 'Teng', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A.'}, {'ForeName': 'Alfred M', 'Initials': 'AM', 'LastName': 'Iloreta', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A.'}]",The Laryngoscope,['10.1002/lary.29529'] 1172,33764445,Randomized trial of granulocyte colony-stimulating factor for spinal cord injury.,"Attenuation of the secondary injury of spinal cord injury (SCI) can suppress the spread of spinal cord tissue damage, possibly resulting in spinal cord sparing that can improve functional prognoses. Granulocyte colony-stimulating factor (G-CSF) is a haematological cytokine commonly used to treat neutropenia. Previous reports have shown that G-CSF promotes functional recovery in rodent models of SCI. Based on preclinical results, we conducted early phase clinical trials, showing safety/feasibility and suggestive efficacy. These lines of evidence demonstrate that G-CSF might have therapeutic benefits for acute SCI in humans. To confirm this efficacy and to obtain strong evidence for pharmaceutical approval of G-CSF therapy for SCI, we conducted a phase 3 clinical trial designed as a prospective, randomized, double-blinded and placebo-controlled comparative trial. The current trial included cervical SCI [severity of American Spinal Injury Association (ASIA) Impairment Scale (AIS) B or C] within 48 h after injury. Patients are randomly assigned to G-CSF and placebo groups. The G-CSF group was administered 400 μg/m2/day × 5 days of G-CSF in normal saline via intravenous infusion for five consecutive days. The placebo group was similarly administered a placebo. Allocation was concealed between blinded evaluators of efficacy/safety and those for laboratory data, as G-CSF markedly increases white blood cell counts that can reveal patient treatment. Efficacy and safety were evaluated by blinded observer. Our primary end point was changes in ASIA motor scores from baseline to 3 months after drug administration. Each group includes 44 patients (88 total patients). Our protocol was approved by the Pharmaceuticals and Medical Device Agency in Japan and this trial is funded by the Center for Clinical Trials, Japan Medical Association. There was no significant difference in the primary end point between the G-CSF and the placebo control groups. In contrast, one of the secondary end points showed that the ASIA motor score 6 months (P = 0.062) and 1 year (P = 0.073) after drug administration tend to be higher in the G-CSF group compared with the placebo control group. Moreover, in patients aged over 65 years old, motor recovery 6 months after drug administration showed a strong trend towards a better recovery in the G-CSF treated group (P = 0.056) compared with the control group. The present trial failed to show a significant effect of G-CSF in primary end point although the subanalyses of the present trial suggested potential G-CSF benefits for specific population.",2021,There was no significant difference in the primary end point between the G-CSF and the placebo control groups.,"['spinal cord injury', '44 patients (88 total patients']","['granulocyte colony-stimulating factor', 'G-CSF and placebo', 'placebo', 'Granulocyte colony-stimulating factor (G-CSF', 'G-CSF']","['cervical SCI [severity of American Spinal Injury Association (ASIA', 'Impairment Scale (AIS) B or C', 'ASIA motor scores', 'efficacy/safety', 'Efficacy and safety', 'ASIA motor score']","[{'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0079459', 'cui_str': 'Colony-stimulating factor, granulocytic'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0840414', 'cui_str': 'Cervical spinal cord injury'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0037937', 'cui_str': 'Spinal injury'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.462054,There was no significant difference in the primary end point between the G-CSF and the placebo control groups.,"[{'ForeName': 'Masao', 'Initials': 'M', 'LastName': 'Koda', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Hanaoka', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yasuhisa', 'Initials': 'Y', 'LastName': 'Fujii', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Michiko', 'Initials': 'M', 'LastName': 'Hanawa', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yohei', 'Initials': 'Y', 'LastName': 'Kawasaki', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yoshihito', 'Initials': 'Y', 'LastName': 'Ozawa', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Tadami', 'Initials': 'T', 'LastName': 'Fujiwara', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Takeo', 'Initials': 'T', 'LastName': 'Furuya', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Ijima', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Junya', 'Initials': 'J', 'LastName': 'Saito', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Mitsuhiro', 'Initials': 'M', 'LastName': 'Kitamura', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Miyamoto', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Seiji', 'Initials': 'S', 'LastName': 'Ohtori', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yukei', 'Initials': 'Y', 'LastName': 'Matsumoto', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Abe', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Takahashi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Hirano', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Ohashi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Shoji', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Tatsuki', 'Initials': 'T', 'LastName': 'Mizouchi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Norio', 'Initials': 'N', 'LastName': 'Kawahara', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Masahito', 'Initials': 'M', 'LastName': 'Kawaguchi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yugo', 'Initials': 'Y', 'LastName': 'Orita', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Sasamoto', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Masahito', 'Initials': 'M', 'LastName': 'Yoshioka', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Fujii', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Katsutaka', 'Initials': 'K', 'LastName': 'Yonezawa', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Soma', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Taneichi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Daisaku', 'Initials': 'D', 'LastName': 'Takeuchi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Inami', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Moridaira', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Haruki', 'Initials': 'H', 'LastName': 'Ueda', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Futoshi', 'Initials': 'F', 'LastName': 'Asano', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Shibao', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Ikuo', 'Initials': 'I', 'LastName': 'Aita', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Takeuchi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Mimura', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Shimbo', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yukio', 'Initials': 'Y', 'LastName': 'Someya', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Sumio', 'Initials': 'S', 'LastName': 'Ikenoue', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Sameda', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Kan', 'Initials': 'K', 'LastName': 'Takase', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Ikeda', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Fumitake', 'Initials': 'F', 'LastName': 'Nakajima', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Mitsuhiro', 'Initials': 'M', 'LastName': 'Hashimoto', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Fumio', 'Initials': 'F', 'LastName': 'Hasue', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Fujiyoshi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Koshiro', 'Initials': 'K', 'LastName': 'Kamiya', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Watanabe', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Katoh', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yukihiro', 'Initials': 'Y', 'LastName': 'Matsuyama', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Tomohiko', 'Initials': 'T', 'LastName': 'Hasegawa', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Go', 'Initials': 'G', 'LastName': 'Yoshida', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Arima', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Yamato', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Oe', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Togawa', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Sho', 'Initials': 'S', 'LastName': 'Kobayashi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Akeda', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Kawamoto', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Imai', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Toshihiko', 'Initials': 'T', 'LastName': 'Sakakibara', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Sudo', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Ito', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kikuchi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Tomoyuki', 'Initials': 'T', 'LastName': 'Takigawa', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Morita', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Nobuhiro', 'Initials': 'N', 'LastName': 'Tanaka', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Kazuyoshi', 'Initials': 'K', 'LastName': 'Nakanishi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Naosuke', 'Initials': 'N', 'LastName': 'Kamei', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Kotaka', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Baba', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Tsuyoshi', 'Initials': 'T', 'LastName': 'Okudaira', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Konishi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yamaguchi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Keigo', 'Initials': 'K', 'LastName': 'Ito', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Katayama', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Taro', 'Initials': 'T', 'LastName': 'Matsumoto', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Matsumoto', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Haruo', 'Initials': 'H', 'LastName': 'Kanno', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Toshimi', 'Initials': 'T', 'LastName': 'Aizawa', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Ko', 'Initials': 'K', 'LastName': 'Hashimoto', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Toshimitsu', 'Initials': 'T', 'LastName': 'Eto', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Takehiro', 'Initials': 'T', 'LastName': 'Sugaya', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Michiharu', 'Initials': 'M', 'LastName': 'Matsuda', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Kazunari', 'Initials': 'K', 'LastName': 'Fushimi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Nozawa', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Chizuo', 'Initials': 'C', 'LastName': 'Iwai', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Toshihiko', 'Initials': 'T', 'LastName': 'Taguchi', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Tsukasa', 'Initials': 'T', 'LastName': 'Kanchiku', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Hidenori', 'Initials': 'H', 'LastName': 'Suzuki', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Norihiro', 'Initials': 'N', 'LastName': 'Nishida', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Funaba', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Sakai', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Yasuaki', 'Initials': 'Y', 'LastName': 'Imajo', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Yamazaki', 'Affiliation': 'G-SPIRIT Study Group, Chiba, Japan.'}]",Brain : a journal of neurology,['10.1093/brain/awaa466'] 1173,33715477,Effects of tailored lateral wedge insoles on medial knee osteoarthritis based on biomechanical analysis: 12-week randomized controlled trial.,"BACKGROUND Lateral wedge insoles adjusted by biomechanical analysis may improve the condition of patients with medial knee osteoarthritis. DESIGN This is a prospective, randomized, controlled, single-blind clinical trial. SETTING The study was conducted in a biomechanics laboratory. SUBJECTS A total of 38 patients with medial knee osteoarthritis were allocated to either an experimental group (lateral wedge insoles) or a control group (neutral insoles). INTERVENTIONS Experimental group ( n  = 20) received an adjusted lateral wedge insole of 2, 4, 6, 8, or 10 degrees, after previous biomechanical analysis. Control group ( n  = 18) received a neutral insole (0 degrees). All patients used the insoles for 12 weeks. MAIN MEASURES Visual analogue scale, Knee Injury and Osteoarthritis Outcome Score questionnaire, biomechanical parameters: first and second peak of the external knee adduction moment and knee adduction angular impulse, and physical performance tests: 30-second sit-to-stand test, the 40-m fast-paced walk test, and the 12-step stair-climb test. RESULTS After 12 weeks, between-group differences did not differ significantly for pain intensity (-12.5 mm, (95% CI -29.4-4.4)), biomechanical parameters ( p  = 0.05), Knee Injury and Osteoarthritis Outcome Score, and physical performance tests, except on the Knee Injury and Osteoarthritis Outcome Score subscale other symptoms ( p  = 0.002; 13.8 points, (95% CI 5.6-22.0)). CONCLUSION Tailored wedge insoles were no more effective at improving biomechanical or clinically meaningful outcomes than neutral insoles, except on symptoms. More participants from the experimental group reported they felt some improvement. However, these effects were minimal and without clinical significance.",2021,"After 12 weeks, between-group differences did not differ significantly for pain intensity (-12.5 mm, (95% CI -29.4-4.4)), biomechanical parameters ( p  = 0.05), Knee Injury and Osteoarthritis Outcome Score, and physical performance tests, except on the Knee Injury and Osteoarthritis Outcome Score subscale other symptoms ( p  = 0.002; 13.8 points, (95% CI 5.6-22.0)). ","['patients with medial knee osteoarthritis', '38 patients with medial knee osteoarthritis']","['tailored lateral wedge insoles', 'experimental group (lateral wedge insoles) or a control group (neutral insoles']","['biomechanical parameters', 'Knee Injury and Osteoarthritis Outcome Score subscale other symptoms', 'medial knee osteoarthritis', 'Visual analogue scale, Knee Injury and Osteoarthritis Outcome Score questionnaire, biomechanical parameters: first and second peak of the external knee adduction moment and knee adduction angular impulse, and physical performance tests: 30-second sit-to-stand test, the 40-m fast-paced walk test, and the 12-step stair-climb test', 'pain intensity', 'Knee Injury and Osteoarthritis Outcome Score, and physical performance tests']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}]","[{'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0439639', 'cui_str': 'Wedge'}, {'cui': 'C3873740', 'cui_str': 'Insole'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C3476088', 'cui_str': 'Knee Injury and Osteoarthritis Outcome Score'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231457', 'cui_str': 'Adduction'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0443235', 'cui_str': 'Impulse'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0560801', 'cui_str': 'Does stand from sitting'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0432601', 'cui_str': 'Stairs climbed'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",38.0,0.122643,"After 12 weeks, between-group differences did not differ significantly for pain intensity (-12.5 mm, (95% CI -29.4-4.4)), biomechanical parameters ( p  = 0.05), Knee Injury and Osteoarthritis Outcome Score, and physical performance tests, except on the Knee Injury and Osteoarthritis Outcome Score subscale other symptoms ( p  = 0.002; 13.8 points, (95% CI 5.6-22.0)). ","[{'ForeName': 'Vitor', 'Initials': 'V', 'LastName': 'Ferreira', 'Affiliation': 'School of Health Sciences, University of Aveiro (ESSUA), Aveiro, Portugal.'}, {'ForeName': 'Leandro', 'Initials': 'L', 'LastName': 'Machado', 'Affiliation': 'CIF2D, LABIOMEP, Faculdade de Desporto da Universidade do Porto, Porto, Portugal.'}, {'ForeName': 'Adélio', 'Initials': 'A', 'LastName': 'Vilaça', 'Affiliation': 'Department of Orthopaedics, Centro Hospitalar Universitário do Porto, Porto, Portugal.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Xará-Leite', 'Affiliation': 'Department of Orthopaedics, Centro Hospitalar Universitário do Porto, Porto, Portugal.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Roriz', 'Affiliation': 'Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, LABIOMEP (Porto Biomechanics Laboratory), 4475-690 Maia, Portugal.'}]",Clinical rehabilitation,['10.1177/0269215521997988'] 1174,33720637,Donanemab in Early Alzheimer's Disease.,"BACKGROUND A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS We conducted a phase 2 trial of donanemab in patients with early symptomatic Alzheimer's disease who had tau and amyloid deposition on positron-emission tomography (PET). Patients were randomly assigned in a 1:1 ratio to receive donanemab (700 mg for the first three doses and 1400 mg thereafter) or placebo intravenously every 4 weeks for up to 72 weeks. The primary outcome was the change from baseline in the score on the Integrated Alzheimer's Disease Rating Scale (iADRS; range, 0 to 144, with lower scores indicating greater cognitive and functional impairment) at 76 weeks. Secondary outcomes included the change in scores on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), the 13-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog 13 ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).",2021,"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.","[""patients with early Alzheimer's disease"", ""Early Alzheimer's Disease"", 'A total of 257 patients were enrolled; 131 were assigned to receive', ""patients with early symptomatic Alzheimer's disease who had tau and amyloid deposition on positron-emission tomography (PET""]","['donanemab', 'placebo']","[""change in scores on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), the 13-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog 13 ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET"", 'baseline iADRS score', 'amyloid plaque level and the global tau load', 'iADRS score', ""Integrated Alzheimer's Disease Rating Scale (iADRS; range, 0 to 144, with lower scores indicating greater cognitive and functional impairment""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0011560', 'cui_str': 'Amyloid deposition'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451074', 'cui_str': 'Clinical dementia rating scale'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0001457', 'cui_str': 'Adenosine deaminase'}, {'cui': 'C0009738', 'cui_str': 'Congo'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0333463', 'cui_str': 'Senile plaque'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]",257.0,0.892077,"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.","[{'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Mintun', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Albert C', 'Initials': 'AC', 'LastName': 'Lo', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Duggan Evans', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Alette M', 'Initials': 'AM', 'LastName': 'Wessels', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Ardayfio', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Scott W', 'Initials': 'SW', 'LastName': 'Andersen', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Shcherbinin', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'JonDavid', 'Initials': 'J', 'LastName': 'Sparks', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Sims', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Miroslaw', 'Initials': 'M', 'LastName': 'Brys', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Liana G', 'Initials': 'LG', 'LastName': 'Apostolova', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Salloway', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Skovronsky', 'Affiliation': 'From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).'}]",The New England journal of medicine,['10.1056/NEJMoa2100708'] 1175,33720388,Comparison of Sugammadex Dose for Intraoperative Neuromonitoring in Thyroid Surgery: A Randomized Controlled Trial.,"OBJECTIVES/HYPOTHESIS To compare effect of 1 and 2 mg/kg of sugammadex on the incidence of intraoperative bucking and intraoperative neuromonitoring (IONM) quality in thyroid surgery. STUDY DESIGN Randomized controlled trial. METHODS Patients qualified for thyroid surgery with IONM were eligible for this double-blind, randomized, controlled trial. After tracheal intubation with 0.6 mg/kg rocuronium, 1 or 2 mg/kg of sugammadex was administered to patients in group I or II, respectively. The quality of the IONM for the external branch of the superior laryngeal nerve (EBSLN) was evaluated (strong/intermediate/weak). The initial amplitude of electromyography for the vagus nerve (V1) and the recurrent laryngeal nerve (R1) were recorded. Intraoperative bucking movements was recorded. RESULTS A total of 102 patients (51 in each group) completed the study. Time from sugammadex administration to initial checking for the EBSLN was not different between group I and II (25.0 ± 7.9 vs. 25.5 ± 9.0 minutes, P = .788). There was no difference in the neuromonitoring quality for the EBSLN between group I and II (strong/intermediate/weak: 46/5/0 vs. 50/1/0, P = .205). The amplitudes of V1 (1,086.3 ± 673.3 μV vs. 1,161.8 ± 727.5 μV, P = .588) and R1 (1,328.2 ± 934.1 μV vs. 1,410.5 ± 919.6 μV, P = .655) were comparable between the groups. Patients who experienced bucking were significantly fewer in the group I than the group II (13.7% vs. 35.3%, P = .020). CONCLUSION A dose of 1 mg/kg sugammadex induced less bucking than 2 m/kg while providing comparable IONM quality during thyroid surgery. LEVEL OF EVIDENCE 2 Laryngoscope, 131:2154-2159, 2021.",2021,The initial amplitude of electromyography for the vagus nerve (V1) and the recurrent laryngeal nerve (R1) were recorded.,"['102 patients (51 in each group) completed the study', 'Patients qualified for thyroid surgery with IONM', 'Thyroid Surgery']","['Intraoperative Neuromonitoring', 'rocuronium, 1 or 2\u2009mg/kg of sugammadex', '1 and 2\u2009mg/kg of sugammadex', 'Sugammadex']","['initial amplitude of electromyography for the vagus nerve (V1) and the recurrent laryngeal nerve (R1', 'neuromonitoring quality', 'intraoperative bucking and intraoperative neuromonitoring (IONM) quality', 'IONM quality', 'quality of the IONM for the external branch of the superior laryngeal nerve (EBSLN']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0193769', 'cui_str': 'Operation on thyroid gland'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C1700695', 'cui_str': 'Sugammadex'}]","[{'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0042276', 'cui_str': 'Vagus nerve structure'}, {'cui': 'C0034898', 'cui_str': 'Structure of recurrent laryngeal nerve'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0852885', 'cui_str': 'Bucking'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C1253959', 'cui_str': 'Branch of'}, {'cui': 'C0205814', 'cui_str': 'Structure of superior laryngeal nerve'}]",102.0,0.281008,The initial amplitude of electromyography for the vagus nerve (V1) and the recurrent laryngeal nerve (R1) were recorded.,"[{'ForeName': 'Young Jun', 'Initials': 'YJ', 'LastName': 'Chai', 'Affiliation': 'Department of Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jung-Man', 'Initials': 'JM', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Dongwook', 'Initials': 'D', 'LastName': 'Won', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jiwon', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Jin-Young', 'Initials': 'JY', 'LastName': 'Hwang', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Tae Kyong', 'Initials': 'TK', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jee-Eun', 'Initials': 'JE', 'LastName': 'Chang', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hyerim', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hyo Jun', 'Initials': 'HJ', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Seong-Won', 'Initials': 'SW', 'LastName': 'Min', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.'}]",The Laryngoscope,['10.1002/lary.29515'] 1176,33705727,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.","BACKGROUND BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg) formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from a double-blind, multicentre, randomised, controlled phase 1 trial on the safety and immunogenicity of three different formulations of BBV152 (3 μg with Algel-IMDG, 6 μg with Algel-IMDG, or 6 μg with Algel) and one Algel-only control (no antigen), with the first dose administered on day 0 and the second dose on day 14. The 3 μg and 6 μg with Algel-IMDG formulations were selected for this phase 2 study. Herein, we report interim findings of the phase 2 trial on the immunogenicity and safety of BBV152, with the first dose administered on day 0 and the second dose on day 28. METHODS We did a double-blind, randomised, multicentre, phase 2 clinical trial to evaluate the immunogenicity and safety of BBV152 in healthy adults and adolescents (aged 12-65 years) at nine hospitals in India. Participants with positive SARS-CoV-2 nucleic acid and serology tests were excluded. Participants were randomly assigned (1:1) to receive either 3 μg with Algel-IMDG or 6 μg with Algel-IMDG. Block randomisation was done by use of an interactive web response system. Participants, investigators, study coordinators, study-related personnel, and the sponsor were masked to treatment group allocation. Two intramuscular doses of vaccine were administered on day 0 and day 28. The primary outcome was SARS-CoV-2 wild-type neutralising antibody titres and seroconversion rates (defined as a post-vaccination titre that was at least four-fold higher than the baseline titre) at 4 weeks after the second dose (day 56), measured by use of the plaque-reduction neutralisation test (PRNT 50 ) and the microneutralisation test (MNT 50 ). The primary outcome was assessed in all participants who had received both doses of the vaccine. Cell-mediated responses were a secondary outcome and were assessed by T-helper-1 (Th1)/Th2 profiling at 2 weeks after the second dose (day 42). Safety was assessed in all participants who received at least one dose of the vaccine. In addition, we report immunogenicity results from a follow-up blood draw collected from phase 1 trial participants at 3 months after they received the second dose (day 104). This trial is registered at ClinicalTrials.gov, NCT04471519. FINDINGS Between Sept 5 and 12, 2020, 921 participants were screened, of whom 380 were enrolled and randomly assigned to the 3 μg with Algel-IMDG group (n=190) or 6 μg with Algel-IMDG group (n=190). Geometric mean titres (GMTs; PRNT 50 ) at day 56 were significantly higher in the 6 μg with Algel-IMDG group (197·0 [95% CI 155·6-249·4]) than the 3 μg with Algel-IMDG group (100·9 [74·1-137·4]; p=0·0041). Seroconversion based on PRNT 50 at day 56 was reported in 171 (92·9% [95% CI 88·2-96·2] of 184 participants in the 3 μg with Algel-IMDG group and 174 (98·3% [95·1-99·6]) of 177 participants in the 6 μg with Algel-IMDG group. GMTs (MNT 50 ) at day 56 were 92·5 (95% CI 77·7-110·2) in the 3 μg with Algel-IMDG group and 160·1 (135·8-188·8) in the 6 μg with Algel-IMDG group. Seroconversion based on MNT 50 at day 56 was reported in 162 (88·0% [95% CI 82·4-92·3]) of 184 participants in the 3 μg with Algel-IMDG group and 171 (96·6% [92·8-98·8]) of 177 participants in the 6 μg with Algel-IMDG group. The 3 μg with Algel-IMDG and 6 μg with Algel-IMDG formulations elicited T-cell responses that were biased to a Th1 phenotype at day 42. No significant difference in the proportion of participants who had a solicited local or systemic adverse reaction in the 3 μg with Algel-IMDG group (38 [20·0%; 95% CI 14·7-26·5] of 190) and the 6 μg with Algel-IMDG group (40 [21·1%; 15·5-27·5] of 190) was observed on days 0-7 and days 28-35; no serious adverse events were reported in the study. From the phase 1 trial, 3-month post-second-dose GMTs (MNT 50 ) were 39·9 (95% CI 32·0-49·9) in the 3μg with Algel-IMDG group, 69·5 (53·7-89·9) in the 6 μg with Algel-IMDG group, 53·3 (40·1-71·0) in the 6 μg with Algel group, and 20·7 (14·5-29·5) in the Algel alone group. INTERPRETATION In the phase 1 trial, BBV152 induced high neutralising antibody responses that remained elevated in all participants at 3 months after the second vaccination. In the phase 2 trial, BBV152 showed better reactogenicity and safety outcomes, and enhanced humoral and cell-mediated immune responses compared with the phase 1 trial. The 6 μg with Algel-IMDG formulation has been selected for the phase 3 efficacy trial. FUNDING Bharat Biotech International. TRANSLATION For the Hindi translation of the abstract see Supplementary Materials section.",2021,Geometric mean titres (GMTs; PRNT 50 ) at day 56 were significantly higher in the 6 μg with Algel-IMDG group (197·0,"['184 participants in the 3 μg with Algel-IMDG group and 171 (96·6% [92·8-98·8]) of 177 participants in the 6 μg with Algel-IMDG group', 'Participants with positive SARS-CoV-2 nucleic acid and serology tests were excluded', '921 participants were screened, of whom 380 were enrolled and randomly assigned to the 3 μg with', 'Between Sept 5 and 12, 2020', 'healthy adults and adolescents (aged 12-65 years) at nine hospitals in India']","['BBV152', 'Algel-IMDG group (n=190) or 6 μg with Algel-IMDG', 'inactivated SARS-CoV-2 vaccine, BBV152', '3 μg with Algel-IMDG or 6 μg with Algel-IMDG', 'BBV152 (3 μg with Algel-IMDG, 6 μg with Algel-IMDG, or 6 μg with Algel) and one Algel-only control (no antigen', 'vaccine']","['SARS-CoV-2 wild-type neutralising antibody titres and seroconversion rates (defined as a post-vaccination titre', 'immunogenicity and safety', 'Geometric mean titres', 'Safety and immunogenicity', 'neutralising antibody responses', 'reactogenicity and safety outcomes, and enhanced humoral and cell-mediated immune responses', 'solicited local or systemic adverse reaction', 'Safety', 'serious adverse events', 'safety and immunogenicity', 'immunogenicity and safety of BBV152']","[{'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0028606', 'cui_str': 'Nucleic acid'}, {'cui': 'C0036743', 'cui_str': 'Serologic test'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4319693', 'cui_str': '380'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0021201', 'cui_str': 'India'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003320', 'cui_str': 'Antigen'}]","[{'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0475463', 'cui_str': 'Neutralizing antibody'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",921.0,0.523255,Geometric mean titres (GMTs; PRNT 50 ) at day 56 were significantly higher in the 6 μg with Algel-IMDG group (197·0,"[{'ForeName': 'Raches', 'Initials': 'R', 'LastName': 'Ella', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Siddharth', 'Initials': 'S', 'LastName': 'Reddy', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Harsh', 'Initials': 'H', 'LastName': 'Jogdand', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Vamshi', 'Initials': 'V', 'LastName': 'Sarangi', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Brunda', 'Initials': 'B', 'LastName': 'Ganneru', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Sai', 'Initials': 'S', 'LastName': 'Prasad', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Dipankar', 'Initials': 'D', 'LastName': 'Das', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Dugyala', 'Initials': 'D', 'LastName': 'Raju', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Usha', 'Initials': 'U', 'LastName': 'Praturi', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Gajanan', 'Initials': 'G', 'LastName': 'Sapkal', 'Affiliation': 'Indian Council of Medical Research-National Institute of Virology, Pune, India.'}, {'ForeName': 'Pragya', 'Initials': 'P', 'LastName': 'Yadav', 'Affiliation': 'Indian Council of Medical Research-National Institute of Virology, Pune, India.'}, {'ForeName': 'Prabhakar', 'Initials': 'P', 'LastName': 'Reddy', 'Affiliation': 'Nizams Institute of Medical Sciences, Hyderabad, India.'}, {'ForeName': 'Savita', 'Initials': 'S', 'LastName': 'Verma', 'Affiliation': 'Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India.'}, {'ForeName': 'Chandramani', 'Initials': 'C', 'LastName': 'Singh', 'Affiliation': 'All India Institute of Medical Sciences, Patna, India.'}, {'ForeName': 'Sagar Vivek', 'Initials': 'SV', 'LastName': 'Redkar', 'Affiliation': 'Redkar Hospital, Dargalim, India.'}, {'ForeName': 'Chandra Sekhar', 'Initials': 'CS', 'LastName': 'Gillurkar', 'Affiliation': 'Gillurkar Hospital, Nagpur, India.'}, {'ForeName': 'Jitendra Singh', 'Initials': 'JS', 'LastName': 'Kushwaha', 'Affiliation': 'Prakhar Hospital, Kanpur, India.'}, {'ForeName': 'Satyajit', 'Initials': 'S', 'LastName': 'Mohapatra', 'Affiliation': 'SRM Hospital and Research Centre, Kattankulathur, India.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Bhate', 'Affiliation': 'Jeevan Rekha Hospital, Belgaum, India.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Rai', 'Affiliation': 'All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Samiran', 'Initials': 'S', 'LastName': 'Panda', 'Affiliation': 'Indian Council of Medical Research, New Delhi, India.'}, {'ForeName': 'Priya', 'Initials': 'P', 'LastName': 'Abraham', 'Affiliation': 'Indian Council of Medical Research-National Institute of Virology, Pune, India.'}, {'ForeName': 'Nivedita', 'Initials': 'N', 'LastName': 'Gupta', 'Affiliation': 'Indian Council of Medical Research, New Delhi, India.'}, {'ForeName': 'Krishna', 'Initials': 'K', 'LastName': 'Ella', 'Affiliation': 'Bharat Biotech, Hyderabad, India.'}, {'ForeName': 'Balram', 'Initials': 'B', 'LastName': 'Bhargava', 'Affiliation': 'Indian Council of Medical Research, New Delhi, India.'}, {'ForeName': 'Krishna Mohan', 'Initials': 'KM', 'LastName': 'Vadrevu', 'Affiliation': 'Bharat Biotech, Hyderabad, India. Electronic address: kmohan@bharatbiotech.com.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(21)00070-0'] 1177,33710815,"Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial.","OBJECTIVE This phase 3 study aimed to test equivalence in efficacy and safety for QL1101, a bevacizumab analogue in Chinese patients with untreated locally advanced non-squamous non-small cell lung cancer (NSCLC). METHODS Eligible patients were randomly assigned 1:1 to receive carboplatin and paclitaxel in combination with either QL1101 or bevacizumab, 15 mg/kg every 3-week for 6 cycles. This was followed by maintenance treatment with single agent QL1101 every 3-week. The primary end-point was objective response rate (ORR), with secondary end-points being progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and adverse events (AEs). RESULTS Of 675 patients, 535 eligible patients were randomized to the QL1101 group ( n = 269) and bevacizumab group ( n = 266). ORRs were 52.8% and 56.8%, respectively, for the QL1101 and bevacizumab groups, with an ORR hazard ratio 0.93 (95% confidence interval: 0.8-0131.1). The PFS, OS, DCR, and AEs were comparable between the 2 groups, which remained the same after stratification according to epidermal growth factor receptor mutation or smoking history. CONCLUSIONS QL1101 showed similar efficacy and safety profiles as compared to bevacizumab among Chinese patients with untreated locally advanced non-squamous NSCLC.",2021,"The PFS, OS, DCR, and AEs were comparable between the 2 groups, which remained the same after stratification according to epidermal growth factor receptor mutation or smoking history. ","['Chinese patients with untreated locally advanced non-squamous non-small cell lung cancer (NSCLC', 'Eligible patients', '675 patients, 535 eligible patients', 'Chinese patients with untreated locally advanced non-squamous NSCLC', 'untreated advanced non-squamous non-small cell lung cancer patients']","['QL1101 and bevacizumab', 'carboplatin and paclitaxel in combination with either QL1101 or bevacizumab', 'QL1101', 'bevacizumab', 'bevacizumab analogue']","['efficacy and safety profiles', 'PFS, OS, DCR, and AEs', 'objective response rate (ORR), with secondary end-points being progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and adverse events (AEs', 'ORRs']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C4324656', 'cui_str': 'Non-squamous non-small cell lung cancer'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C4517854', 'cui_str': '675'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0444930', 'cui_str': 'End'}]",675.0,0.5909,"The PFS, OS, DCR, and AEs were comparable between the 2 groups, which remained the same after stratification according to epidermal growth factor receptor mutation or smoking history. ","[{'ForeName': 'Tianqing', 'Initials': 'T', 'LastName': 'Chu', 'Affiliation': 'Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.'}, {'ForeName': 'Minghong', 'Initials': 'M', 'LastName': 'Bi', 'Affiliation': 'Department of Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China.'}, {'ForeName': 'Helong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': ""Department of Oncology, Tangdu Hospital, Air Force Medical University of PLA, Xi'an 710038, China.""}, {'ForeName': 'Wu', 'Initials': 'W', 'LastName': 'Zhuang', 'Affiliation': 'Department of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Department of Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Department of Oncology, Linyi Cancer Hospital, Linyi 276000, China.'}, {'ForeName': 'Zhendong', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Oncology, The Second Hospital of Anhui Medical University, Hefei 230601, China.'}, {'ForeName': 'Xiaochun', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266071, China.'}, {'ForeName': 'Qisen', 'Initials': 'Q', 'LastName': 'Guo', 'Affiliation': 'Department of Internal Medicine, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, China.'}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': 'Department of Oncology, Affiliated Hospital of Jiang Nan University, Wuxi 214122, China.'}, {'ForeName': 'Huijuan', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Department of Internal Medicine, Henan Province Tumor Hospital, Zhengzhou University, Zhengzhou 450008, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Fang', 'Affiliation': 'Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing 100142, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Oncology, Chinese PLA General Hospital, Beijing 100039, China.'}, {'ForeName': 'Xiuwen', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Oncology, Qilu Hospital of Shandong University, Jinan 250012, China.'}, {'ForeName': 'Cuicui', 'Initials': 'C', 'LastName': 'Han', 'Affiliation': 'Department of Clinical Research Centre, Qilu Pharmaceutical Co., Ltd, Jinan 250101, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': ""Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Baohui', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.'}]",Cancer biology & medicine,['10.20892/j.issn.2095-3941.2020.0212'] 1178,33710814,Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies.,"OBJECTIVE Chemotherapy-induced nausea and vomiting (CINV) are common with doxorubicin-cyclophosphamide (AC) chemotherapy. Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine type-3 receptor antagonist (5HT3RA), corticosteroid, and dopamine antagonists. This post-hoc analysis compared results of 3 prospective antiemetic studies conducted among Chinese breast cancer patients who received (neo)adjuvant AC, in order to identify optimal antiemetic prophylaxis. METHODS A total of 304 patients were included: Group 1, ondansetron/dexamethasone (D1); Group 2, aprepitant/ondansetron/dexamethasone (D1); Group 3, aprepitant/ondansetron/dexamethasone (D1-3); Group 4, aprepitant/ondansetron/dexamethasone (D1-3)/olanzapine; and Group 5, netupitant/palonosetron/dexamethasone (D1-3). Antiemetic efficacies of Groups 3, 4, and 5 during cycle 1 of AC were individually compared with Group 1. In addition, emesis outcomes of patients in Groups 3 and 5, and those of Groups 2 and 3, were compared. RESULTS When comparing efficacies of a historical doublet (5HT3RA/dexamethasone) with triplet antiemetic regimens (NK1RA/5HT3RA/dexamethasone) with/without olanzapine, complete response (CR) percentages and quality of life (QOL) in overall phase of cycle 1 AC were compared between Group 1 and the other groups: Group 1 vs. 3, 41.9% vs. 38.3% ( P = 0.6849); Group 1 vs. 4, 41.9% vs. 65.0% ( P = 0.0107); and Group 1 vs. 5, 41.9% vs. 60.0% ( P = 0.0460). Groups 4 and 5 achieved a better QOL. When comparing netupitant-based (Group 3) with aprepitant-based (Group 5) triplet antiemetics, CR percentages were 38.3% vs. 60.0%, respectively ( P = 0.0176); Group 5 achieved a better QOL. When comparing 1 day (Group 2) vs. 3 day (Group 3) dexamethasone, CR percentages were 46.8% and 38.3%, respectively ( P = 0.3459); Group 3 had a worse QOL. CONCLUSIONS Aprepitant-containing triplets were non-superior to doublet antiemetics. Netupitant-containing triplets and adding olanzapine to aprepitant-containing triplets were superior to doublets. Netupitant/palonosetron/dexamethasone was superior to aprepitant/ondansetron/dexamethasone. Protracted administration of dexamethasone provided limited additional benefit.",2021,Netupitant/palonosetron/dexamethasone was superior to aprepitant/ondansetron/dexamethasone.,"['304 patients were included: Group 1', 'Chinese breast cancer patients', 'Chinese cancer patients']","['dexamethasone', 'Netupitant/palonosetron/dexamethasone', 'doxorubicin-cyclophosphamide chemotherapy', '5-hydroxytryptamine type-3 receptor antagonist (5HT3RA), corticosteroid, and dopamine antagonists', 'olanzapine', 'historical doublet (5HT3RA/dexamethasone) with triplet antiemetic regimens (NK1RA/5HT3RA/dexamethasone', 'ondansetron/dexamethasone', 'ondansetron/dexamethasone (D1); Group 2, aprepitant/ondansetron/dexamethasone (D1); Group 3, aprepitant/ondansetron/dexamethasone (D1-3); Group 4, aprepitant/ondansetron/dexamethasone (D1-3)/olanzapine; and Group 5, netupitant/palonosetron/dexamethasone (D1-3', 'doxorubicin-cyclophosphamide (AC) chemotherapy']","['Antiemetic efficacies', 'emesis outcomes', 'nausea and vomiting (CINV', 'complete response (CR) percentages and quality of life (QOL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C3858052', 'cui_str': 'Netupitant- and palonosetron-containing product'}, {'cui': 'C0050385', 'cui_str': 'AC protocol'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0441731', 'cui_str': 'Type 3'}, {'cui': 'C4543207', 'cui_str': 'Receptor antagonist'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0242702', 'cui_str': 'Dopamine receptor antagonist'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0041095', 'cui_str': 'Triplets'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic agent'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0164209', 'cui_str': 'Substance P Receptor'}, {'cui': 'C0162466', 'cui_str': 'Hydroxytryptamine'}, {'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C1176306', 'cui_str': 'aprepitant'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205214', 'cui_str': 'Common'}]","[{'cui': 'C0003297', 'cui_str': 'Antiemetic agent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0401160', 'cui_str': 'Chemotherapy-induced nausea and vomiting'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",304.0,0.0886739,Netupitant/palonosetron/dexamethasone was superior to aprepitant/ondansetron/dexamethasone.,"[{'ForeName': 'Winnie', 'Initials': 'W', 'LastName': 'Yeo', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Leung', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Thomas Kh', 'Initials': 'TK', 'LastName': 'Lau', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Kwai T', 'Initials': 'KT', 'LastName': 'Lai', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Vicky Tc', 'Initials': 'VT', 'LastName': 'Chan', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Kwan H', 'Initials': 'KH', 'LastName': 'Wong', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Christopher Ch', 'Initials': 'CC', 'LastName': 'Yip', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Pang', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Cheung', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Chan', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Carol Ch', 'Initials': 'CC', 'LastName': 'Kwok', 'Affiliation': 'Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong, China.'}, {'ForeName': 'Joyce Js', 'Initials': 'JJ', 'LastName': 'Suen', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}, {'ForeName': 'Frankie Kf', 'Initials': 'FK', 'LastName': 'Mo', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong, China.'}]",Cancer biology & medicine,['10.20892/j.issn.2095-3941.2020.0241'] 1179,33720895,The Cognition and Flow Study: A Feasibility Randomized Controlled Trial of the Effects of Cognitive Training on Cerebral Blood Flow.,"BACKGROUND Cognitive training (CT) has demonstrated benefits for healthy older adults (HG) and mild cognitive impairment (MCI), but the effects on vascular function are unknown. OBJECTIVE This is a feasibility trial investigating the effects of CT on cerebral blood flow velocity (CBFv). METHODS Twenty HG, 24 with Alzheimer's disease (AD), and 12 with MCI were randomized to 12 weeks of multi-domain CT or control. Outcomes included: cognition (Addenbrooke's Cognitive Examination III), mood, quality of life (QoL), physical, and neurovascular function (transcranial Doppler ultrasonography measured task activation of CBFv responses). Data are presented as mean difference (MD) and 95% confidence interval (CI). RESULTS 47 participants completed the trial. There were three dropouts from the training arm in the AD group, and one in the HG group. The intervention was acceptable and feasible to the majority of participants with a high completion rate (89%). The dropout rate was higher among participants with dementia. Few changes were identified on secondary analyses, but QoL was significantly improved in HG post-training (MD: 4.83 [95% CI: 1.13, 8.54]). CBFv response rate was not significantly different in HG (MD: 1.84 [95% CI: -4.81, 1.12]), but a significant increase was seen in the patient group (MD: 1.79 [95% CI: 0.005, 3.58]), requiring sample sizes of 56 and 84 participants respectively for a fully-powered trial. CONCLUSION A 12-week CT program was acceptable and feasible in HG, AD, and MCI. CT may be associated with alterations in vascular physiology which require further investigation in an appropriately powered randomized controlled trial.",2021,"CBFv response rate was not significantly different in HG (MD: 1.84 [95% CI: -4.81, 1.12]), but a significant increase was seen in the patient group (MD: 1.79 [95% CI: 0.005, 3.58]), requiring sample sizes of 56 and 84 participants respectively for a fully-powered trial. ","['healthy older adults (HG) and mild cognitive impairment (MCI', 'participants with dementia', ""Twenty HG, 24 with Alzheimer's disease (AD), and 12 with MCI"", '47 participants completed the trial']","['multi-domain CT or control', 'Cognitive training (CT', 'Cognitive Training', 'CT']","['cerebral blood flow velocity (CBFv', ""cognition (Addenbrooke's Cognitive Examination III), mood, quality of life (QoL), physical, and neurovascular function (transcranial Doppler ultrasonography measured task activation of CBFv responses"", 'Cerebral Blood Flow', 'CBFv response rate', 'dropout rate']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0206077', 'cui_str': 'Transcranial doppler ultrasonography'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",47.0,0.314675,"CBFv response rate was not significantly different in HG (MD: 1.84 [95% CI: -4.81, 1.12]), but a significant increase was seen in the patient group (MD: 1.79 [95% CI: 0.005, 3.58]), requiring sample sizes of 56 and 84 participants respectively for a fully-powered trial. ","[{'ForeName': 'Lucy C', 'Initials': 'LC', 'LastName': 'Beishon', 'Affiliation': 'University of Leicester, Department of Cardiovascular Sciences, Leicester, UK.'}, {'ForeName': 'Ronney B', 'Initials': 'RB', 'LastName': 'Panerai', 'Affiliation': 'University of Leicester, Department of Cardiovascular Sciences, Leicester, UK.'}, {'ForeName': 'Charley', 'Initials': 'C', 'LastName': 'Budgeon', 'Affiliation': 'University of Leicester, Department of Cardiovascular Sciences, Leicester, UK.'}, {'ForeName': 'Hari', 'Initials': 'H', 'LastName': 'Subramaniam', 'Affiliation': 'The Evington Centre, Leicestershire Partnership NHS Trust, Leicester, UK.'}, {'ForeName': 'Elizabeta', 'Initials': 'E', 'LastName': 'Mukaetova-Ladinska', 'Affiliation': 'The Evington Centre, Leicestershire Partnership NHS Trust, Leicester, UK.'}, {'ForeName': 'Thompson G', 'Initials': 'TG', 'LastName': 'Robinson', 'Affiliation': 'University of Leicester, Department of Cardiovascular Sciences, Leicester, UK.'}, {'ForeName': 'Victoria J', 'Initials': 'VJ', 'LastName': 'Haunton', 'Affiliation': 'University of Leicester, Department of Cardiovascular Sciences, Leicester, UK.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201444'] 1180,33720893,Neurocognitive Plasticity Is Associated with Cardiorespiratory Fitness Following Physical Exercise in Older Adults with Amnestic Mild Cognitive Impairment.,"BACKGROUND Aerobic training has been shown to promote structural and functional neurocognitive plasticity in cognitively intact older adults. However, little is known about the neuroplastic potential of aerobic exercise in individuals at risk of Alzheimer's disease (AD) and dementia. OBJECTIVE We aimed to explore the effect of aerobic exercise intervention and cardiorespiratory fitness improvement on brain and cognitive functions in older adults with amnestic mild cognitive impairment (aMCI). METHODS 27 participants with aMCI were randomized to either aerobic training (n = 13) or balance and toning (BAT) control group (n = 14) for a 16-week intervention. Pre- and post-assessments included functional MRI experiments of brain activation during associative memory encoding and neural synchronization during complex information processing, cognitive evaluation using neuropsychological tests, and cardiorespiratory fitness assessment. RESULTS The aerobic group demonstrated increased frontal activity during memory encoding and increased neural synchronization in higher-order cognitive regions such as the frontal cortex and temporo-parietal junction (TPJ) following the intervention. In contrast, the BAT control group demonstrated decreased brain activity during memory encoding, primarily in occipital, temporal, and parietal areas. Increases in cardiorespiratory fitness were associated with increases in brain activationin both the left inferior frontal and precentral gyri. Furthermore, changes in cardiorespiratory fitness were also correlated with changes in performance on several neuropsychological tests. CONCLUSION Aerobic exercise training may result in functional plasticity of high-order cognitive areas, especially, frontal regions, among older adults at risk of AD and dementia. Furthermore, cardiorespiratory fitness may be an important mediating factor of the observed changes in neurocognitive functions.",2021,Increases in cardiorespiratory fitness were associated with increases in brain activationin both the left inferior frontal and precentral gyri.,"['older adults with amnestic mild cognitive impairment (aMCI', 'cognitively intact older adults', '27 participants with aMCI', ""individuals at risk of Alzheimer's disease (AD) and dementia"", 'older adults at risk of AD and dementia', 'Older Adults with Amnestic Mild Cognitive Impairment']","['Aerobic training', 'aerobic exercise', 'Aerobic exercise training', 'aerobic exercise intervention', 'aerobic training (n\u200a=\u200a13) or balance and toning (BAT) control group', 'Physical Exercise']","['cardiorespiratory fitness', 'brain activationin', 'Cardiorespiratory Fitness', 'frontal cortex and temporo-parietal junction (TPJ', 'brain activity during memory encoding, primarily in occipital, temporal, and parietal areas', 'brain and cognitive functions', 'frontal activity during memory encoding and increased neural synchronization']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0016733', 'cui_str': 'Frontal lobe structure'}, {'cui': 'C0442030', 'cui_str': 'Parietal'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}]",27.0,0.0455546,Increases in cardiorespiratory fitness were associated with increases in brain activationin both the left inferior frontal and precentral gyri.,"[{'ForeName': 'Galit', 'Initials': 'G', 'LastName': 'Yogev-Seligmann', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Tamir', 'Initials': 'T', 'LastName': 'Eisenstein', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Elissa', 'Initials': 'E', 'LastName': 'Ash', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Nir', 'Initials': 'N', 'LastName': 'Giladi', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Haggai', 'Initials': 'H', 'LastName': 'Sharon', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Shikma', 'Initials': 'S', 'LastName': 'Nachman', 'Affiliation': 'Sagol Brain Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Noa', 'Initials': 'N', 'LastName': 'Bregman', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Einat', 'Initials': 'E', 'LastName': 'Kodesh', 'Affiliation': 'Department of Physical Therapy Faculty of Social Welfare & Health Sciences, University of Haifa, Haifa, Israel.'}, {'ForeName': 'Talma', 'Initials': 'T', 'LastName': 'Hendler', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Yulia', 'Initials': 'Y', 'LastName': 'Lerner', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201429'] 1181,33720882,Functional Connectivity and Response Inhibition: A Secondary Analysis of an 8-Week Randomized Controlled Trial of Computerized Cognitive Training.,"BACKGROUND Evidence suggests that computerized cognitive training (CCT) can improve cognitive function in older adults, particularly executive functions. However, the underlying mechanisms by which CCT may improve executive functions are not well established. OBJECTIVE To determine: 1) inter-network functional connectivity correlates of changes in executive functions; and 2) the effect of CCT on these functional connectivity correlates. METHODS This secondary analysis included a subset of 124 adults aged 65-85 years enrolled in an 8-week randomized controlled trial of CCT. Participants were randomized to either: 1) group-based CCT 3x/week for 1 hour plus 3x/week home-based training; 2) group-based CCT preceded by brisk walking (Ex+CCT) 3x/week for 1 hour plus 3x/week home-based training; or 3) group-based balanced and toned (BAT) classes 3x/week for 1 hour (control). At baseline and trial completion, 65 of the 124 participants completed resting-state functional magnetic resonance imaging and neuropsychological tests of executive functions, specifically the Stroop Colour-Word Test and Flanker Test. RESULTS Improved performance on the Stroop Colour-Word Test and Flanker Test were associated with decreased correlation between the default mode network (DMN) and the fronto-parietal network (FPN) (p < 0.05). Compared with BAT, CCT alone significantly decreased correlation between the left dorsolateral prefrontal cortex and both the left and right medial temporal gyrus (-0.143, 95%CI [-0.256,-0.030], p = 0.014, and -0.123, 95%CI [-0.242,-0.004], p = 0.043, respectively). CONCLUSION Decreased correlation between DMN and FPN, indicating less connection between these networks, may be an underlying mechanism by which CCT improves executive functions. Future studies are needed to replicate this finding.",2021,"RESULTS Improved performance on the Stroop Colour-Word Test and Flanker Test were associated with decreased correlation between the default mode network (DMN) and the fronto-parietal network (FPN) (p <  0.05).","['124 participants completed', 'older adults', '124 adults aged 65-85 years enrolled']","['BAT, CCT', 'CCT', 'computerized cognitive training (CCT', 'Computerized Cognitive Training', 'CCT 3x/week for 1 hour plus 3x/week home-based training; 2) group-based CCT preceded by brisk walking (Ex-CCT) 3x/week for 1 hour plus 3x/week home-based training (exercise+CCT); or 3) group-based balanced and toned (BAT) classes']","['executive functions', 'left dorsolateral prefrontal cortex and both the left and right medial temporal gyrus', 'Functional Connectivity and Response Inhibition', 'resting-state functional magnetic resonance imaging and neuropsychological tests of executive functions', 'Stroop Colour-Word Test and Flanker Test', 'default mode network (DMN) and the fronto-parietal network (FPN', 'cognitive function']","[{'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0006298', 'cui_str': 'Brown fat'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0205415', 'cui_str': 'Balanced'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0228234', 'cui_str': 'Structure of temporal lobe gyrus'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0582675', 'cui_str': 'Stroop neuropsychological screening test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0442030', 'cui_str': 'Parietal'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",124.0,0.103034,"RESULTS Improved performance on the Stroop Colour-Word Test and Flanker Test were associated with decreased correlation between the default mode network (DMN) and the fronto-parietal network (FPN) (p <  0.05).","[{'ForeName': 'Lisanne F', 'Initials': 'LF', 'LastName': 'Ten Brinke', 'Affiliation': 'Aging, Mobility, and Cognitive Neuroscience Laboratory, Department of Physical Therapy, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Chun Liang', 'Initials': 'CL', 'LastName': 'Hsu', 'Affiliation': 'Aging, Mobility, and Cognitive Neuroscience Laboratory, Department of Physical Therapy, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Kirk I', 'Initials': 'KI', 'LastName': 'Erickson', 'Affiliation': 'Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Handy', 'Affiliation': 'Department of Psychology, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Liu-Ambrose', 'Affiliation': 'Aging, Mobility, and Cognitive Neuroscience Laboratory, Department of Physical Therapy, University of British Columbia, Vancouver, British Columbia, Canada.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-200844'] 1182,33725408,Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial.,"Personalizing immunosuppression is a major objective in transplantation. Transplant recipients are heterogeneous regarding their immunological memory and primary alloimmune susceptibility. This biomarker-guided trial investigated whether in low immunological-risk kidney transplants without pretransplant DSA and donor-specific T cells assessed by a standardized IFN-γ ELISPOT, low immunosuppression (LI) with tacrolimus monotherapy would be non-inferior regarding 6-month BPAR than tacrolimus-based standard of care (SOC). Due to low recruitment rates, the trial was terminated when 167 patients were enrolled. ELISPOT negatives (E-) were randomized to LI (n = 48) or SOC (n = 53), E+ received the same SOC. Six- and 12-month BPAR rates were higher among LI than SOC/E- (4/35 [13%] vs. 1/43 [2%], p = .15 and 12/48 [25%] vs. 6/53 [11.3%], p = .073, respectively). E+ patients showed similarly high BPAR rates than LI at 6 and 12 months (12/55 [22%] and 13/66 [20%], respectively). These differences were stronger in per-protocol analyses. Post-hoc analysis revealed that poor class-II eplet matching, especially DQ, discriminated E- patients, notably E-/LI, developing BPAR (4/28 [14%] low risk vs. 8/20 [40%] high risk, p = .043). Eplet mismatch also predicted anti-class-I (p = .05) and anti-DQ (p < .001) de novo DSA. Adverse events were similar, but E-/LI developed fewer viral infections, particularly polyoma-virus-associated nephropathy (p = .021). Preformed T cell alloreactivity and HLA eplet mismatch assessment may refine current baseline immune-risk stratification and guide immunosuppression decision-making in kidney transplantation.",2021,Eplet mismatch also predicted anti-class-I (p=0.05) and anti-DQ (p=0.001) de novo DSA.,"['Transplant recipients', '167 patients were enrolled', 'Kidney Transplantation']","['Tacrolimus monotherapy', 'pretransplant DSA and donor-specific T cells assessed by a standardized IFN-γ ELISPOT, low immunosuppression (LI) with tacrolimus monotherapy']","['Six and 12-month BPAR', 'viral infections, particularly Polyoma-virus associated nephropathy', 'BPAR rates', 'Adverse events']","[{'cui': 'C0376387', 'cui_str': 'Recipient, Transplant'}, {'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}]","[{'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0920508', 'cui_str': 'Enzyme linked immunospot assay'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0032556', 'cui_str': 'Genus Polyomavirus'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",167.0,0.145921,Eplet mismatch also predicted anti-class-I (p=0.05) and anti-DQ (p=0.001) de novo DSA.,"[{'ForeName': 'Oriol', 'Initials': 'O', 'LastName': 'Bestard', 'Affiliation': 'Kidney Transplant Unit, Nephrology department, Bellvitge University Hospital, IDIBELL, Barcelona University, Barcelona, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Meneghini', 'Affiliation': 'Kidney Transplant Unit, Nephrology department, Bellvitge University Hospital, IDIBELL, Barcelona University, Barcelona, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Crespo', 'Affiliation': 'Nephrology and Transplantation Laboratory, IDIBELL, Barcelona University, Barcelona, Spain.'}, {'ForeName': 'Frederike', 'Initials': 'F', 'LastName': 'Bemelman', 'Affiliation': 'Renal Transplant Unit, Department of Internal Medicine, Amsterdam University Medical Centers, Academic Medical Center - University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Koch', 'Affiliation': 'Department of Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Hans D', 'Initials': 'HD', 'LastName': 'Volk', 'Affiliation': 'BeCAT, BCRT, and Department of Nephrology & Intensive Care, Charité Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Ondrej', 'Initials': 'O', 'LastName': 'Viklicky', 'Affiliation': 'Transplant Laboratory, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.'}, {'ForeName': 'Magali', 'Initials': 'M', 'LastName': 'Giral', 'Affiliation': 'Nantes Université, Inserm, CHU Nantes, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Banas', 'Affiliation': 'Department of Nephrology, University Medical Center Regensburg, Regensburg, Germany.'}, {'ForeName': 'Juan C', 'Initials': 'JC', 'LastName': 'Ruiz', 'Affiliation': 'Department of Nephrology, Hospital Universitario ""Marqués de Valdecilla"", Instituto de Investigación ""Marqués de Valdecilla"" (IDIVAL, Santander, Spain.'}, {'ForeName': 'Edoardo', 'Initials': 'E', 'LastName': 'Melilli', 'Affiliation': 'Kidney Transplant Unit, Nephrology department, Bellvitge University Hospital, IDIBELL, Barcelona University, Barcelona, Spain.'}, {'ForeName': 'Liu', 'Initials': 'L', 'LastName': 'Hu', 'Affiliation': 'Renal Transplant Unit, Department of Internal Medicine, Amsterdam University Medical Centers, Academic Medical Center - University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'van Duivenvoorden', 'Affiliation': 'Renal Transplant Unit, Department of Internal Medicine, Amsterdam University Medical Centers, Academic Medical Center - University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Nashan', 'Affiliation': 'Department of Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Friedrich', 'Initials': 'F', 'LastName': 'Thaiss', 'Affiliation': 'Department of Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Natalie M', 'Initials': 'NM', 'LastName': 'Otto', 'Affiliation': 'BeCAT, BCRT, and Department of Nephrology & Intensive Care, Charité Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Gantuja', 'Initials': 'G', 'LastName': 'Bold', 'Affiliation': 'BeCAT, BCRT, and Department of Nephrology & Intensive Care, Charité Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Maik', 'Initials': 'M', 'LastName': 'Stein', 'Affiliation': 'BeCAT, BCRT, and Department of Nephrology & Intensive Care, Charité Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Anett', 'Initials': 'A', 'LastName': 'Sefrin', 'Affiliation': 'BeCAT, BCRT, and Department of Nephrology & Intensive Care, Charité Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Lachmann', 'Affiliation': 'HLA-Laboratory, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Hruba', 'Affiliation': 'Transplant Laboratory, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Stranavova', 'Affiliation': 'Transplant Laboratory, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Brouard', 'Affiliation': 'Nantes Université, Inserm, CHU Nantes, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Braudeau', 'Affiliation': 'Nantes Université, Inserm, CHU Nantes, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Blancho', 'Affiliation': 'Nantes Université, Inserm, CHU Nantes, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Banas', 'Affiliation': 'Department of Nephrology, University Medical Center Regensburg, Regensburg, Germany.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Irure', 'Affiliation': 'Immunology Department, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Christakoudi', 'Affiliation': ""Institute of Liver Studies, MRC Centre for Transplantation, Department of Inflammation Biology, Faculty of Sciences & Medicine, King's College London, London, UK.""}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Sanchez-Fueyo', 'Affiliation': ""Institute of Liver Studies, MRC Centre for Transplantation, Department of Inflammation Biology, Faculty of Sciences & Medicine, King's College London, London, UK.""}, {'ForeName': 'Kathryn J', 'Initials': 'KJ', 'LastName': 'Wood', 'Affiliation': 'Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Reinke', 'Affiliation': 'BeCAT, BCRT, and Department of Nephrology & Intensive Care, Charité Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Josep M', 'Initials': 'JM', 'LastName': 'Grinyó', 'Affiliation': 'Kidney Transplant Unit, Nephrology department, Bellvitge University Hospital, IDIBELL, Barcelona University, Barcelona, Spain.'}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.16563'] 1183,33728717,Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?,"BACKGROUND To evaluate if early improvements in pain and function with subcutaneous tanezumab are meaningful and sustained over 24 weeks. METHODS Patients with moderate-to-severe osteoarthritis (hip or knee) in Europe and Japan were randomized to placebo, tanezumab 2.5 mg or tanezumab 5 mg (baseline, Week 8 and Week 16). Outcomes included: average daily index joint pain score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscales, rescue medication use, WOMAC responders (within-patient ≥30% reduction in WOMAC Pain or Physical Function), Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) responders (within-patient) and Patient-reported Treatment Impact Assessment-Modified questionnaire. RESULTS Patients received placebo (n = 282), tanezumab 2.5 mg (n = 283) or tanezumab 5 mg (n = 284). Changes from baseline in average daily index joint pain (within the first week) and WOMAC subscales (Week 2 through Week 24) were greater for each tanezumab group versus placebo (least squares [LS] mean, unadjusted p ≤ .05). Rescue medication use (days/week) was lower for each tanezumab group versus placebo from Week 2 through Week 12 (LS mean, unadjusted p ≤ .05) but not at Week 16 or 24. A higher proportion of each tanezumab group than placebo achieved ≥30% reduction from baseline in WOMAC Pain or Physical Function, or OMERACT-OARSI response (Week 2 through Week 24, unadjusted p ≤ .05), or were satisfied with treatment at Week 24 (unadjusted p ≤ .05). CONCLUSIONS Subcutaneous tanezumab, compared with placebo, reduced pain within the first week, and pain and function were improved throughout 24 weeks. The proportions of responders and patients satisfied were higher with tanezumab than placebo. ClinicalTrials.gov:NCT02709486. SIGNIFICANCE This exploratory analysis of data from a placebo-controlled, Phase 3 study of patients with moderate-to-severe osteoarthritis of the hip or knee for whom standard analgesics were not effective or could not be taken, found that onset of efficacy of subcutaneous tanezumab was within the first week, and efficacy was maintained through the 24-week treatment period. Tanezumab was effective in those patients with the most radiologically severe osteoarthritis.",2021,"Rescue medication use (days/week) was lower for each tanezumab group versus placebo from Week 2 through Week 12 (LS mean, unadjusted p≤0.05) but not at Week 16 or 24.","['Patients with moderate-to-severe osteoarthritis (hip or knee) in Europe and Japan', 'osteoarthritis']","['tanezumab', 'subcutaneous tanezumab', 'placebo', 'Subcutaneous tanezumab', 'placebo, tanezumab 2.5 mg, or tanezumab']","['pain and function', 'pain', 'average daily index joint pain score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscales, rescue medication use, WOMAC responders', 'WOMAC subscales', 'average daily index joint pain', 'WOMAC Pain or Physical Function, or OMERACT-OARSI response', 'WOMAC Pain or Physical Function), Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) responders (within-patient), and Patient-reported Treatment Impact Assessment-Modified questionnaire']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C2346819', 'cui_str': 'tanezumab'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3844011', 'cui_str': '2.5'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3472647', 'cui_str': 'Western Ontario and McMaster Universities osteoarthritis index'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.287465,"Rescue medication use (days/week) was lower for each tanezumab group versus placebo from Week 2 through Week 12 (LS mean, unadjusted p≤0.05) but not at Week 16 or 24.","[{'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Berenbaum', 'Affiliation': 'Department of Rheumatology, Sorbonne Université, INSERM CRSA, AP-HP Hopital Saint Antoine, Paris, France.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Langford', 'Affiliation': ""Pain and Anaesthesia Research Centre, St Bartholomew's Hospital, London, UK.""}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Perrot', 'Affiliation': 'Cochin Hospital, Paris University, INSERM U987, Paris, France.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Miki', 'Affiliation': 'Faculty of Health Science, Osaka Yukioka College of Health Science, Hayaishi Hospital, Osaka, Japan.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Blanco', 'Affiliation': 'Servicio de Reumatología, INIBC-Complejo Hospitalario Universitario A Coruña, Universidad de A Coruña, CICA-INIBIC, La Coruña, Spain.'}, {'ForeName': 'Takaharu', 'Initials': 'T', 'LastName': 'Yamabe', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Isogawa', 'Affiliation': 'Pfizer R&D Japan, Tokyo, Japan.'}, {'ForeName': 'Rod', 'Initials': 'R', 'LastName': 'Junor', 'Affiliation': 'Pfizer Ltd, Tadworth, UK.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Carey', 'Affiliation': 'Pfizer Ltd, Tadworth, UK.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Viktrup', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Christine R', 'Initials': 'CR', 'LastName': 'West', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Brown', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Kenneth M', 'Initials': 'KM', 'LastName': 'Verburg', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}]","European journal of pain (London, England)",['10.1002/ejp.1764'] 1184,33771685,SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation.,"BACKGROUND/AIMS The development of decompensation in cirrhosis demarcates a marked change in the natural history of chronic liver disease. HMG-CoA reductase inhibitors (statins) exert pleiotropic effects that reduce inflammation and fibrosis as well as improve vascular reactivity. Retrospective studies uniformly have associated statin utilization with improved outcomes for patients with cirrhosis. Prospective human studies have shown that statins reduce portal hypertension and reduce death in patients with decompensated cirrhosis after variceal hemorrhage when added to standard therapy with an acceptable safety profile. This proposal aims to extend these findings to demonstrate that simvastatin reduces incident hepatic decompensation events among cirrhotic patients at high risk for hepatic decompensation. METHODS We will perform the SACRED Trial (NCT03654053), a phase III, prospective, multi-center, double-blind, randomized clinical trial at 11 VA Medical Centers. Patients with compensated cirrhosis with clinically significant portal hypertension will be stratified based upon the concomitant use of nonselective beta-blockers and randomized to simvastatin 40 mg/day versus placebo for up to 24 months. Patients will be observed for the development of hepatic decompensation (variceal hemorrhage, ascites, encephalopathy), hepatocellular carcinoma, liver-related death, death from any cause, and/or complications of statin therapy. Ancillary studies will evaluate patient-reported outcomes and pharmacogenetic corollaries of safety and/or efficacy. CONCLUSION Statins have a long track-record of safety and tolerability. This class of medications is generic and inexpensive, and thus, if the hypothesis is proven, there will be few barriers to widespread acceptance of the role of statins to prevent decompensation in patients with compensated cirrhosis. ClinicalTrials.gov Identifier: NCT03654053.",2021,The development of decompensation in cirrhosis demarcates a marked change in the natural history of chronic liver disease.,"['subjects with high-risk compensated cirrhosis: Statins and cirrhosis', 'cirrhotic patients at high risk for hepatic decompensation', 'patients with compensated cirrhosis', 'Patients with compensated cirrhosis with clinically significant portal hypertension', 'patients with cirrhosis', 'patients with decompensated cirrhosis after variceal hemorrhage']","['HMG-CoA reductase inhibitors (statins', 'simvastatin 40\u202fmg/day versus placebo', 'simvastatin']","['safety and tolerability', 'hepatic decompensation and death']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0205432', 'cui_str': 'Compensated'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0439686', 'cui_str': 'Cirrhotic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1394798', 'cui_str': 'Hepatic decompensation'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0020541', 'cui_str': 'Portal hypertension'}, {'cui': 'C0333106', 'cui_str': 'Bleeding varices'}]","[{'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0989916', 'cui_str': 'Simvastatin 40 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0074554', 'cui_str': 'Simvastatin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1394798', 'cui_str': 'Hepatic decompensation'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.372598,The development of decompensation in cirrhosis demarcates a marked change in the natural history of chronic liver disease.,"[{'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Kaplan', 'Affiliation': 'Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States of America. Electronic address: dakaplan@pennmedicine.upenn.edu.'}, {'ForeName': 'Rajni', 'Initials': 'R', 'LastName': 'Mehta', 'Affiliation': 'VA Connecticut Healthcare System, West Haven, CT, United States of America.'}, {'ForeName': 'Guadalupe', 'Initials': 'G', 'LastName': 'Garcia-Tsao', 'Affiliation': 'VA Connecticut Healthcare System, West Haven, CT, United States of America.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Albrecht', 'Affiliation': 'Minneapolis VA Medical Center, Minneapolis, MN, United States of America.'}, {'ForeName': 'Ayse', 'Initials': 'A', 'LastName': 'Aytaman', 'Affiliation': 'VA New York Harbor Health Care System, Brooklyn, NY, United States of America.'}, {'ForeName': 'Gyorgy', 'Initials': 'G', 'LastName': 'Baffy', 'Affiliation': 'VA Boston Healthcare System, Boston, MA, United States of America.'}, {'ForeName': 'Jasmohan', 'Initials': 'J', 'LastName': 'Bajaj', 'Affiliation': 'Hunter Holmes McGuire VA Medical Center, Richmond, VA, United States of America.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Hernaez', 'Affiliation': 'Michael E. DeBakey VA Medical Center, Houston, TX, United States of America.'}, {'ForeName': 'Kristel', 'Initials': 'K', 'LastName': 'Hunt', 'Affiliation': 'James J. Peters VA Medical Center, Bronx, NY, United States of America.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Ioannou', 'Affiliation': 'VA Puget Sound Medical Center, Seattle, WA, United States of America.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Johnson', 'Affiliation': 'VA Puget Sound Medical Center, Seattle, WA, United States of America.'}, {'ForeName': 'Fasiha', 'Initials': 'F', 'LastName': 'Kanwal', 'Affiliation': 'Michael E. DeBakey VA Medical Center, Houston, TX, United States of America.'}, {'ForeName': 'Tae-Hoon', 'Initials': 'TH', 'LastName': 'Lee', 'Affiliation': 'James J. Peters VA Medical Center, Bronx, NY, United States of America.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Monto', 'Affiliation': 'San Francisco VA Medical Center, San Francisco, CA, United States of America.'}, {'ForeName': 'Prashant', 'Initials': 'P', 'LastName': 'Pandya', 'Affiliation': 'Kansas City VA Medical Center, Kansas City, MO, United States of America.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Schaubel', 'Affiliation': 'Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States of America.'}, {'ForeName': 'Tamar H', 'Initials': 'TH', 'LastName': 'Taddei', 'Affiliation': 'VA Connecticut Healthcare System, West Haven, CT, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106367'] 1185,33774921,Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.,"BACKGROUND Oral postmenopausal hormone therapy (HT) increases the risk of venous thrombosis (VT). We postulated that activated protein C (APC) resistance induced by HT is one of the mechanisms causing VT, and also assessed the role of one of the main determinants of APC resistance (i.e., tissue factor pathway inhibitor [TFPI]). METHODS We performed a nested case-control study embedded within two Women's Health Initiative hormone trials. Women were randomized to hormone therapy or placebo. Biomarkers were measured at baseline and after 1 year in 217 cases and 817 controls. RESULTS Increased APC resistance and decreased TFPI at baseline were associated with VT (odds ratio 1.20-2.06). However, women with such prothrombotic profile at baseline did not have further increased risk of VT when randomized to HT compared with placebo. Although there was no change in APC resistance or TFPI in placebo group after 1 year, HT group showed prothrombotic changes in the biomarkers (i.e., an increase in APC resistance) (mean [standard deviation] 0.39 [0.54]) and decrease in TFPI (-0.21 [0.50]: free TFPI, -0.24 [0.22]: TFPI activity -0.22 [0.20]: total TFPI). However, HT induced prothrombotic change in biomarkers did not increase risk of VT. CONCLUSION Women with prothrombotic levels of APC resistance and TFPI at baseline were not at increased risk of VT when randomized to HT compared with placebo. This suggests that testing for these biomarkers before starting HT is not required. HT led to prothrombotic change in these biomarkers after one year, but this did not relate to increased risk of VT.",2021,"HT led to prothrombotic change in these biomarkers after one year, but this did not relate to increased risk of VT.","[""nested case-control study embedded within two Women's Health Initiative (WHI) hormone trials""]","['hormone therapy or placebo', 'placebo', 'oral postmenopausal hormone therapy', 'HT', 'Oral postmenopausal hormone therapy (HT']","['risk of venous thrombosis (VT', 'APC resistance', 'APC resistance and decreased TFPI', 'risk of VT', 'TFPI (-0.21(0.50): free TFPI, -0.24(0.22): TFPI activity and -0.22(0.20): total TFPI', 'APC resistance and TFPI', 'APC resistance or TFPI']","[{'cui': 'C0007328', 'cui_str': 'Case Control Studies'}, {'cui': 'C0080339', 'cui_str': ""Woman's Health""}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}, {'cui': 'C0600433', 'cui_str': 'Resistance to activated protein C due to Factor V Leiden'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0164707', 'cui_str': 'Tissue factor pathway inhibitor'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.181739,"HT led to prothrombotic change in these biomarkers after one year, but this did not relate to increased risk of VT.","[{'ForeName': 'Deeksha', 'Initials': 'D', 'LastName': 'Khialani', 'Affiliation': 'Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Sowmya', 'Initials': 'S', 'LastName': 'Vasan', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Cushman', 'Affiliation': 'Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.'}, {'ForeName': 'Anders Erik Astrup', 'Initials': 'AEA', 'LastName': 'Dahm', 'Affiliation': 'Department of Haematology, Akershus University Hospital, Lørenskog, Norway.'}, {'ForeName': 'Per Morten', 'Initials': 'PM', 'LastName': 'Sandset', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Rossouw', 'Affiliation': 'National Heart, Lung, and Blood Institute, Bethesda, MD, USA.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'van Hylckama Vlieg', 'Affiliation': 'Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.15319'] 1186,33779943,Incident Gallstones During Somatostatin Analog Treatment are Associated with Acute Biliary Complications Especially After Discontinuation.,"INTRODUCTION Gallstones are a known adverse effect of somatostatin analogs, but the exact incidence and clinical implications are unknown. OBJECTIVES The aim of this study was to investigate the incidence of gallstones on imaging and related complications in unbiased trial data. METHODS Data from the DIPAK 1 trial, in which 305 polycystic kidney disease patients were randomized to standard of care (SoC) or lanreotide for 120 weeks, were used. Magnetic resonance imaging (MRI) was performed at baseline and end of treatment and was assessed for the presence, number, and size of gallstones. For all patients who had gallstones at the end of the trial, we obtained follow-up after the trial. RESULTS Of 249 patients with data available, 11 patients randomized to lanreotide and four randomized to SoC had gallstones at baseline. During the study, new gallstones were formed in 19/124 patients using lanreotide (15%) and 1/125 patients receiving SoC (1%). The odds ratio for gallstone formation with lanreotide use was 25.9 (95% confidence interval 3.37-198.8; p < 0.001). Gallstones during lanreotide treatment were multiple (> 20 stones in 69% of patients) and small (≤ 3 mm in 63% of patients). Of the 19 patients with incident gallstones during lanreotide treatment, 9 experienced gallstone-associated complications, 8 of whom experienced gallstone-associated complications after discontinuation of treatment (median time after discontinuation 2.5 years). In patients with gallstones at baseline and in patients receiving SoC, no complications occurred. CONCLUSIONS Treatment with a somatostatin analog leads to the formation of multiple, small gallstones that are associated with severe complications, especially after discontinuation of therapy. CLINICAL TRIAL REGISTRY WEBSITE AND TRIAL NUMBER ClinicalTrials.gov ( https://clinicaltrials.gov ); NCT01616927.",2021,"During the study, new gallstones were formed in 19/124 patients using lanreotide (15%) and 1/125 patients receiving SoC (1%).","['Incident Gallstones', '249 patients with data available', '305 polycystic kidney disease patients', '19 patients with incident gallstones during']","['lanreotide', 'Magnetic resonance imaging (MRI', 'standard of care (SoC) or lanreotide']","['gallstone-associated complications', 'Gallstones', 'odds ratio for gallstone formation']","[{'cui': 'C0008350', 'cui_str': 'Biliary calculus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C4517703', 'cui_str': '305'}, {'cui': 'C0022680', 'cui_str': 'Polycystic kidney, unspecified'}]","[{'cui': 'C0209211', 'cui_str': 'lanreotide'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0008350', 'cui_str': 'Biliary calculus'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}]",305.0,0.31095,"During the study, new gallstones were formed in 19/124 patients using lanreotide (15%) and 1/125 patients receiving SoC (1%).","[{'ForeName': 'Sophie E', 'Initials': 'SE', 'LastName': 'Aapkes', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.'}, {'ForeName': 'Robbert J', 'Initials': 'RJ', 'LastName': 'de Haas', 'Affiliation': 'Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Lucas H P', 'Initials': 'LHP', 'LastName': 'Bernts', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Charles J', 'Initials': 'CJ', 'LastName': 'Blijdorp', 'Affiliation': 'Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Sosha E I', 'Initials': 'SEI', 'LastName': 'Dekker', 'Affiliation': 'Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Maatje D A', 'Initials': 'MDA', 'LastName': 'van Gastel', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Meijer', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Veldman', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.'}, {'ForeName': 'Joost P H', 'Initials': 'JPH', 'LastName': 'Drenth', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Ron T', 'Initials': 'RT', 'LastName': 'Gansevoort', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. r.t.gansevoort@umcg.nl.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Drugs in R&D,['10.1007/s40268-021-00342-7'] 1187,33709920,Impact of lifestyle interventions on reducing dietary sodium intake and blood pressure in patients with hypertension: A randomized controlled trial.,"OBJECTIVE The objective of this study is to determine the impact of applying lifestyle intervention in the form of a continuous care model (CCM) on reducing dietary sodium intake and blood pressure (BP) in patients with hypertension. METHODS This randomized controlled trial was conducted in a 2-group design on a total of 50 patients who were hypertensive (experimental and control) as a pre‒post test study. A healthy lifestyle (emphasizing physical activity and heart-healthy diet) in the form of CCM, which considers the patient as an active agent in the health process, was conducted in the experimental group over a period of 4 months. The mean BP value and dietary sodium intake in both groups were measured at the beginning and the end of the study. RESULTS The mean sodium intake, the mean systolic BP, and the mean diastolic BP decreased to 2.42±0.73 mm Hg (from 3.12±0.79), 128.4±13.04 mm Hg (from 144.20±13.12), and 79.4±8.93 mm Hg (from 89±9.12), respectively, after the intervention in the experimental group (p=0.021, p<0.001, and p=0.011, respectively). CONCLUSION Applying lifestyle intervention in the form of CCM may be recommended to reduce dietary sodium intake and mean systolic and diastolic BP in patients who are hypertensive. Considering the fact that lifestyle modifications are quite important regardless of the use of antihypertensive drugs, lifestyle intervention in the form of CCM is recommended to improve patient's adherence to dietary restrictions and consequently, treatment outcomes in patients who are hypertensive.",2021,"The mean sodium intake, the mean systolic BP, and the mean diastolic BP decreased to 2.42±0.73 mm Hg (from 3.12±0.79),","['patients with hypertension', 'patients who are hypertensive', '50 patients who were hypertensive (experimental and control) as a pre‒post test study']","['lifestyle intervention', 'lifestyle interventions', 'continuous care model (CCM']","['mean sodium intake, the mean systolic BP, and the mean diastolic BP', 'dietary sodium intake and blood pressure', 'mean BP value and dietary sodium intake', 'dietary sodium intake and mean systolic and diastolic BP', 'dietary sodium intake and blood pressure (BP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0425433', 'cui_str': 'Dietary sodium intake'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}]",50.0,0.0336011,"The mean sodium intake, the mean systolic BP, and the mean diastolic BP decreased to 2.42±0.73 mm Hg (from 3.12±0.79),","[{'ForeName': 'Shams Aldin', 'Initials': 'SA', 'LastName': 'Shamsi', 'Affiliation': 'Department of Medical Surgical Nursing, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Salehzadeh', 'Affiliation': 'Department of Medical Surgical Nursing, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Haleh', 'Initials': 'H', 'LastName': 'Ghavami', 'Affiliation': 'Department of Medical Surgical Nursing, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Rasoul Ghare', 'Initials': 'RG', 'LastName': 'Aghaji Asl', 'Affiliation': 'Department of Medical Surgical Nursing, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Kamal Khadem', 'Initials': 'KK', 'LastName': 'Vatani', 'Affiliation': 'Department of Medical Surgical Nursing, Urmia University of Medical Sciences, Urmia, Iran.'}]",Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir,['10.5543/tkda.2021.81669'] 1188,33717869,Comparison of midterm results of Platelet Rich Plasma (PRP) versus Steroid for plantar fasciitis: A randomized control trial of 118 patients.,"Background Plantar fasciitis, which is a common cause of heel pain, often results in significant morbidity. In cases who are not responsive to initial conservative treatment, invasive procedures, often in the form of local infiltration of steroid are required. These procedures are associated with significant complications. Local Platelet Rich Plasma (PRP) infiltration is an emerging addition to these treatments. However, whether it is more effective in reducing pain and improving function than other treatments (such as steroid injections or whole blood) remains controversial. Methods Skeletally mature patients with plantar fasciitis who had failed conservative therapy were randomized using envelope method into 2 groups: PRP and Steroid group. The participants were assessed for pain using Visual Analog Scale on the day of presentation, and then after therapy at 2 weeks, 4 weeks, 3 months, and 6 months. They were additionally assessed on final follow-up using AOFAS hind-foot Score. Results 118 patients were randomized into 2 groups: 58 patients to the PRP group and 60 to the Steroid group. PRP was associated with greater improvement in VAS score and resulted in superior AOFAS score at 6 months as compared to steroid injection. The authors did not find any local or systemic complications in any of the groups. The result and difference were more pronounced as the time from injection increased and maximal benefit was observed at 6 months follow-up. None of the patients needed a repeat injection at 6 months. Conclusion Our study expands on the previous studies to provide a better evidence for superiority of PRP over local injection of steroid in plantar fasciitis, and the authors conclude that PRP provides better pain relief and function as compared to steroid injection. Level of evidence Level 1 Prospective Randomized Control Trial (RCT).",2021,PRP was associated with greater improvement in VAS score and resulted in superior AOFAS score at 6 months as compared to steroid injection.,"['Skeletally mature patients with plantar fasciitis who had failed conservative therapy', '118 patients', 'plantar fasciitis', '118 patients were randomized into 2 groups: 58 patients to the PRP group and 60 to the Steroid group']","['Platelet Rich Plasma (PRP) versus Steroid', 'PRP and Steroid', 'PRP']","['VAS score', 'pain and improving function', 'time from injection increased and maximal benefit', 'local or systemic complications', 'pain using Visual Analog Scale', 'superior AOFAS score']","[{'cui': 'C0205286', 'cui_str': 'Mature'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0149756', 'cui_str': 'Plantar fasciitis'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1282910', 'cui_str': 'Upper'}]",118.0,0.0159891,PRP was associated with greater improvement in VAS score and resulted in superior AOFAS score at 6 months as compared to steroid injection.,"[{'ForeName': 'Ankit', 'Initials': 'A', 'LastName': 'Khurana', 'Affiliation': 'Department of Orthopaedics, Dr BSA Medical College and Hospital, Delhi, India.'}, {'ForeName': 'Vaneet', 'Initials': 'V', 'LastName': 'Dhankhar', 'Affiliation': 'Department of Orthopaedics, Dr BSA Medical College and Hospital, Delhi, India.'}, {'ForeName': 'Navneet', 'Initials': 'N', 'LastName': 'Goel', 'Affiliation': 'Department of Orthopaedics, Dr BSA Medical College and Hospital, Delhi, India.'}, {'ForeName': 'Rishi', 'Initials': 'R', 'LastName': 'Gupta', 'Affiliation': 'Department of Biostatistics, Manokalp Clinic, Delhi, India.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Goyal', 'Affiliation': 'Department of Orthopaedics, Dr BSA Medical College and Hospital, Delhi, India.'}]",Journal of clinical orthopaedics and trauma,['10.1016/j.jcot.2020.09.002'] 1189,33722490,The Learning Curves for Transradial and Ultrasound-Guided Arterial Access: An Analysis of the SURF Trial.,"INTRODUCTION Historically, coronary angiography and percutaneous coronary intervention involved accessing the femoral artery via palpation. However, recently there has been a trend towards using a transradial approach and ultrasound guidance for arterial access. Studies have shown that these techniques respectively improve major bleeding rates and access outcomes. There have been no studies conducted that assess the time it takes to train operators to attain proficiency. This sub-analysis of the Standard versus Ultrasound-guided Radial and Femoral access in coronary angiography and intervention (SURF) trial aims to assess the number of procedures required to attain proficiency in ultrasound-guided transradial and transfemoral access. METHODS The SURF trial randomised 1,388 patients undergoing coronary angiography and/or percutaneous coronary intervention into standard or ultrasound-guidance and radial or femoral access in a 2×2 factorial design. Operators who participated in this trial were required to have performed at least 50 standard and 10 ultrasound-guided punctures for each of transradial and transfemoral access. Cases were then chronologically ordered and stratified into groups of five, from which the primary endpoint measured was a progression in mean access time and first-pass success rates. RESULTS Across all operators, there was a reduction in mean access time between procedures one to five and six to 10 with ultrasound-guided femoral punctures (60.5 secs-51.5 secs, p=0.029) and between procedures 11 to 15 and 16 to 20 ultrasound-guided radial punctures (74s to 62.5 secs, p=0.082). This trend was more obvious in trainees, with significant reductions in mean access time between procedures one to five and six to 10 from 73.5 to 53.5 seconds (p<0.001) for ultrasound-guided femoral access and from 99.5 seconds to 60 seconds (p=0.024) for ultrasound-guided radial access. There were no trends with standard transradial access. CONCLUSION The numbers required to attain competency in ultrasound-guided femoral and radial access are 15 and 25 punctures, respectively. Fifty (50) punctures appear adequate for proficiency in a standard transradial approach. These numbers are useful in incorporating into training program for advanced trainees and interventionalists.",2021,"Across all operators, there was a reduction in mean access time between procedures one to five and six to 10 with ultrasound-guided femoral punctures (60.5 secs-51.5 secs, p=0.029) and between procedures 11 to 15 and 16 to 20 ultrasound-guided radial punctures (74s to 62.5 secs, p=0.082).","['1,388 patients undergoing coronary angiography and/or percutaneous coronary intervention into standard or ultrasound-guidance and radial or femoral access in a 2×2 factorial design']","['coronary angiography and percutaneous coronary intervention', 'Ultrasound-guided Radial and Femoral access in coronary angiography and intervention (SURF']","['progression in mean access time and first-pass success rates', 'mean access time', 'major bleeding rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085532', 'cui_str': 'Coronary angiography'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0085532', 'cui_str': 'Coronary angiography'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0336932', 'cui_str': 'Surfing'}]","[{'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0444693', 'cui_str': 'First pass'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",1388.0,0.157927,"Across all operators, there was a reduction in mean access time between procedures one to five and six to 10 with ultrasound-guided femoral punctures (60.5 secs-51.5 secs, p=0.029) and between procedures 11 to 15 and 16 to 20 ultrasound-guided radial punctures (74s to 62.5 secs, p=0.082).","[{'ForeName': 'Sumedh', 'Initials': 'S', 'LastName': 'Jayanti', 'Affiliation': 'South-Western Sydney Clinical School, University of New South Wales, Liverpool Hospital, Sydney, NSW, Australia. Electronic address: sumedh.jayanti@health.nsw.gov.au.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Juergens', 'Affiliation': 'South-Western Sydney Clinical School, University of New South Wales, Liverpool Hospital, Sydney, NSW, Australia; Liverpool Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Makris', 'Affiliation': 'Liverpool Hospital, Sydney, NSW, Australia; Western Sydney University, Liverpool Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Annemarie', 'Initials': 'A', 'LastName': 'Hennessy', 'Affiliation': 'Liverpool Hospital, Sydney, NSW, Australia; Western Sydney University, Liverpool Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Phong', 'Initials': 'P', 'LastName': 'Nguyen', 'Affiliation': 'Liverpool Hospital, Sydney, NSW, Australia; Western Sydney University, Liverpool Hospital, Sydney, NSW, Australia.'}]","Heart, lung & circulation",['10.1016/j.hlc.2021.02.006'] 1190,33728988,Effects of Aerobic and Resistance Exercise Training on Carotid Intima-Media Thickness in Abdominal Obese Women.,"Aims: The purpose of this study was to investigate the effects of a 12-week aerobic and resistance training program on waist circumference (WC) and carotid intima-media thickness (CIMT) in abdominal obese middle-aged women. Methods: Subjects were 40 middle-aged women with abdominal obesity (WC >85 cm) but no specific diseases. Subjects were divided into a combined exercise group (aerobic and resistance exercise) and a control group that did not participate in any lifestyle modification. Carotid variables were measured using B-mode ultrasound. A treadmill exercise test was conducted to directly assess the peak oxygen uptake (VO 2 peak). Differences in the carotid variables and relative changes between baseline and after 12 weeks were evaluated. Results: After 12 weeks, body weight (70.6 ± 7.8 to 65.6 ± 6.3 kg, P  < 0.05), WC (88.8 ± 3.6 to 85.6 ± 3.1 cm, P  < 0.01), total cholesterol (215.5 ± 38.4 to 188.2 ± 25.8 mmHg, P  < 0.05), low-density lipoprotein cholesterol (150.5 ± 30.6 to 131.6 ± 22.3 mmHg, P  < 0.05), triglycerides (164.5 ± 82.3 to 119.9 ± 60.6 mmHg, P  < 0.01), VO 2 peak (24.2 ± 6.2 to 28.7 ± 4.4 mL/kg/min, P  < 0.01), and CIMT (0.61 ± 0.13 to 0.58 ± 0.12 mm, P  < 0.05) were significantly improved in the combined exercise group but not in the control group; changes in CIMT were associated with changes in WC decrease ( r  = 0.41, P  < 0.01) and VO 2 peak ( r  = -0.53, P  < 0.01). Conclusions: Combined exercise training in abdominal obese women decreased CIMT; these changes were also associated with reduced WC and improved VO 2 peak.",2021,Conclusions: Combined exercise training in abdominal obese women decreased CIMT; these changes were also associated with reduced WC and improved VO 2 peak.,"['Subjects were 40 middle-aged women with abdominal obesity (WC >85\u2009cm) but no specific diseases', 'Abdominal Obese Women', 'abdominal obese middle-aged women', 'abdominal obese women decreased CIMT']","['aerobic and resistance training program', 'Aerobic and Resistance Exercise Training', 'Combined exercise training', 'combined exercise group (aerobic and resistance exercise) and a control group that did not participate in any lifestyle modification']","['Carotid Intima-Media Thickness', 'low-density lipoprotein cholesterol (150.5\u2009±', 'waist circumference (WC) and carotid intima-media thickness (CIMT', 'total cholesterol', 'body weight', 'peak oxygen uptake (VO 2 peak', 'triglycerides']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0311277', 'cui_str': 'Abdominal Obesity'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]","[{'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",,0.0161676,Conclusions: Combined exercise training in abdominal obese women decreased CIMT; these changes were also associated with reduced WC and improved VO 2 peak.,"[{'ForeName': 'Do Kyung', 'Initials': 'DK', 'LastName': 'Kim', 'Affiliation': 'Department of Sports Medicine Center, and Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jae Hwan', 'Initials': 'JH', 'LastName': 'Jee', 'Affiliation': 'Department of Health Promotion Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Won Hah', 'Initials': 'WH', 'LastName': 'Park', 'Affiliation': 'Department of Sports Medicine Center, and Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}]",Metabolic syndrome and related disorders,['10.1089/met.2020.0118'] 1191,33727160,Pain Catastrophizing Mediates and Moderates the Link Between Acute Pain and Working Memory.,"The bidirectional relationship between pain and working memory (WM) deficits is well-documented but poorly understood. Pain catastrophizing-exaggerated, negative cognitive and emotional responses toward pain-may contribute to WM deficits by occupying finite, shared cognitive resources. The present study assessed the role of pain catastrophizing as both a state-level process and trait-level disposition in the link between acute pain and WM. Healthy, young adults were randomized to an experimentally-induced ischemic pain or control task, during which they completed verbal and non-verbal WM tests. Participants also completed measures of state- and trait-level pain catastrophizing. Simple mediation analyses indicated that participants in the pain group (vs. control) engaged in more state-level catastrophizing about pain, which led to worse verbal and non-verbal WM. Moderated mediation analyses indicated that the indirect (mediation) effect of state-level pain catastrophizing was moderated by trait-level pain catastrophizing for both verbal and non-verbal WM. Participants in the pain group who reported a greater trait-level tendency to catastrophize about pain experienced greater state-level catastrophizing about pain during the ischemic task, which led to worse verbal and non-verbal WM performance. These results provide evidence for pain catastrophizing as an important mechanism and moderating factor of WM deficits in acute pain. Future research should replicate these results in chronic pain samples, investigate other potential mechanisms (e.g., sleep disturbances), and determine if interventions that target pain catastrophizing directly can ameliorate cognitive deficits in people with pain. PERSPECTIVE: This article presents a laboratory study examining the relationships among pain, pain catastrophizing, and working memory in healthy participants. The results shed new light on these relationships and raise the possibility that interventions that reduce catastrophizing may lead to improved cognitive function among people with pain.",2021,"Simple mediation analyses indicated that participants in the pain group (vs. control) engaged in more state-level catastrophizing about pain, which led to worse verbal and non-verbal WM.","['people with pain', 'Healthy, young adults', 'healthy participants']","['experimentally-induced ischemic pain or control task, during which they completed verbal and non-verbal WM tests']","['state- and trait-level pain catastrophizing', 'worse verbal and non-verbal WM performance', 'pain and working memory (WM) deficits', 'indirect (mediation) effect of state-level pain catastrophizing', 'cognitive function']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.114278,"Simple mediation analyses indicated that participants in the pain group (vs. control) engaged in more state-level catastrophizing about pain, which led to worse verbal and non-verbal WM.","[{'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Procento', 'Affiliation': 'Department of Psychology, Indiana University-Purdue University, Indianapolis, Indiana.'}, {'ForeName': 'Kevin L', 'Initials': 'KL', 'LastName': 'Rand', 'Affiliation': 'Department of Psychology, Indiana University-Purdue University, Indianapolis, Indiana.'}, {'ForeName': 'Jesse C', 'Initials': 'JC', 'LastName': 'Stewart', 'Affiliation': 'Department of Psychology, Indiana University-Purdue University, Indianapolis, Indiana.'}, {'ForeName': 'Adam T', 'Initials': 'AT', 'LastName': 'Hirsh', 'Affiliation': 'Department of Psychology, Indiana University-Purdue University, Indianapolis, Indiana. Electronic address: athirsh@iupui.edu.'}]",The journal of pain,['10.1016/j.jpain.2021.03.138'] 1192,33735463,Does rocking motion calm delirious patients in ICU? A multicentre randomised clinical trial protocol (RockingICU).,"BACKGROUND Rocking chair therapy has been explored in patients with dementia to promote the feeling of relaxation, but not in Intensive Care Unit (ICU) patients with delirium. AIM The aim is to investigate the effect of a chair with or without rocking motion on the duration of delirium and intensity of agitation in critically ill patients admitted to the ICU. DESIGN This is an investigator-initiated pragmatic, multicentre, parallel-grouped, centrally randomised, stratified, data analyst-blinded trial. METHOD We will include patients for 1:1 web-based randomisation, stratified by site in patients 18 y or older with a positive delirium score identified by a validated tool. We will exclude patients mainly due to mobilisation restrictions, body weight exceeding 130 kg, inability to provide consent, and presence of multiresistant bacteria or viral droplet infections. The intervention group will receive a minimum of 20 min of rocking therapy daily. The control group will be transferred to the same type of chair but without rocking therapy daily. A power calculation with a risk reduction of 20%, a power of 80% with an alpha cut-off on 5% and further 20% inclusion gives 76 patients in intervention and control group reaching a total of n = 152 inclusion in the trial. CONCLUSION The RockingICU trial will provide important new knowledge and raise research questions regarding nonpharmacological interventions to alleviate delirium in ICU patients.",2021,"METHOD We will include patients for 1:1 web-based randomisation, stratified by site in patients 18 years or older with a positive delirium score identified by a validated tool.","['patients for 1:1 web-based randomisation, stratified by site in patients 18 years or older with a positive delirium score identified by a validated tool', 'patients with dementia to promote the feeling of relaxation, but not in Intensive Care Unit (ICU) patients with delirium', 'ICU patients', 'critically ill patients admitted to the ICU']","['Rocking chair therapy', 'chair with or without rocking motion']",['duration of delirium and intensity of agitation'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0522165', 'cui_str': 'Feeling calm'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0005899', 'cui_str': 'Repetitive rocking movements'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0026597', 'cui_str': 'Motion'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}]",152.0,0.0892483,"METHOD We will include patients for 1:1 web-based randomisation, stratified by site in patients 18 years or older with a positive delirium score identified by a validated tool.","[{'ForeName': 'Marie Oxenbøll', 'Initials': 'MO', 'LastName': 'Collet', 'Affiliation': 'Department of Intensive Care, Rigshospitalet University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Gitte Meldgaard', 'Initials': 'GM', 'LastName': 'Nielsen', 'Affiliation': 'Department of Intensive Care, Rigshospitalet University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Benita', 'Initials': 'B', 'LastName': 'Bang', 'Affiliation': 'Department of Neurointensive care, Rigshospitalet University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Laerkner', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Fischer', 'Affiliation': 'Department of Intensive care, Sydvestjysk Hospital, Esbjerg, Denmark.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Langvad', 'Affiliation': 'Department of CardioThoracic Anaesthesiology, Intensive Care, Rigshospitalet University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Linette', 'Initials': 'L', 'LastName': 'Thorn', 'Affiliation': 'Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Theis', 'Initials': 'T', 'LastName': 'Lange', 'Affiliation': 'Deparment of Public Health, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Egerod', 'Affiliation': 'Department of Intensive Care, Rigshospitalet University Hospital, Copenhagen, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13821'] 1193,33742169,Roles of cardiovascular autonomic regulation and sleep patterns in high blood pressure induced by mild cold exposure in rats.,"Increased blood pressure (BP) caused by exposure to cold temperatures can partially explain the increased incidence of cardiovascular events in winter. However, the physiological mechanisms involved in cold-induced high BP are not well established. Many studies have focused on physiological responses to severe cold exposure. In this study, we aimed to perform a comprehensive analysis of cardiovascular autonomic function and sleep patterns in rats during exposure to mild cold, a condition relevant to humans in subtropical areas, to clarify the physiological mechanisms underlying mild cold-induced hypertension. BP, electroencephalography, electromyography, electrocardiography, and core body temperature were continuously recorded in normotensive Wistar-Kyoto rats over 24 h. All rats were housed in thermoregulated chambers at ambient temperatures of 23, 18, and 15 °C in a randomized crossover design. These 24-h physiological recordings either with or without sleep scoring showed that compared with the control temperature of 23 °C, the lower ambient temperatures of 18 and 15 °C not only increased BP, vascular sympathetic activity, and heart rate but also decreased overall autonomic activity, parasympathetic activity, and baroreflex sensitivity in rats. In addition, cold exposure reduced the delta power percentage and increased the incidence of interruptions during sleep. Moreover, a correlation analysis revealed that all of these cold-induced autonomic dysregulation and sleep problems were associated with elevation of BP. In conclusion, mild cold exposure elicits autonomic dysregulation and poor sleep quality, causing BP elevation, which may have critical implications for cold-related cardiovascular events.",2021,Increased blood pressure (BP) caused by exposure to cold temperatures can partially explain the increased incidence of cardiovascular events in winter.,"['rats', 'normotensive Wistar-Kyoto rats over 24\u2009h']",[],"['Increased blood pressure (BP', 'cardiovascular events', 'delta power percentage', 'overall autonomic activity, parasympathetic activity, and baroreflex sensitivity', 'incidence of interruptions during sleep', 'elevation of BP', 'autonomic dysregulation and sleep problems', 'BP, vascular sympathetic activity, and heart rate', 'BP, electroencephalography, electromyography, electrocardiography, and core body temperature']","[{'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure'}, {'cui': 'C0034709', 'cui_str': 'Kyoto Wistar rat'}]",[],"[{'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0206162', 'cui_str': 'Baroreceptor reflex'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0587116', 'cui_str': 'During sleep'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0013363', 'cui_str': 'Dysautonomia'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0456240', 'cui_str': 'Core body temperature'}]",,0.031345,Increased blood pressure (BP) caused by exposure to cold temperatures can partially explain the increased incidence of cardiovascular events in winter.,"[{'ForeName': 'Chieh-Wen', 'Initials': 'CW', 'LastName': 'Chen', 'Affiliation': 'Sleep Research Center, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Cheng-Han', 'Initials': 'CH', 'LastName': 'Wu', 'Affiliation': 'Sleep Research Center, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Yu-Syuan', 'Initials': 'YS', 'LastName': 'Liou', 'Affiliation': 'Sleep Research Center, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Kuan-Liang', 'Initials': 'KL', 'LastName': 'Kuo', 'Affiliation': 'Institute of BioMedical Informatics, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Cheng-Hung', 'Initials': 'CH', 'LastName': 'Chung', 'Affiliation': 'Sleep Research Center, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Yu-Ting', 'Initials': 'YT', 'LastName': 'Lin', 'Affiliation': 'Sleep Research Center, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Terry B J', 'Initials': 'TBJ', 'LastName': 'Kuo', 'Affiliation': 'Sleep Research Center, National Yang-Ming University, Taipei, Taiwan. tbjkuo@ym.edu.tw.'}, {'ForeName': 'Cheryl C H', 'Initials': 'CCH', 'LastName': 'Yang', 'Affiliation': 'Sleep Research Center, National Yang-Ming University, Taipei, Taiwan. cchyang@ym.edu.tw.'}]",Hypertension research : official journal of the Japanese Society of Hypertension,['10.1038/s41440-021-00619-z'] 1194,33706001,"A culturally tailored intervention to reduce risk of alcohol-exposed pregnancies in American Indian communities: Rationale, design, and methods.","INTRODUCTION Prenatal exposure to alcohol can cause lifelong physical and cognitive challenges in the form of fetal alcohol syndrome and other fetal alcohol spectrum disorders (FASDs). The prevention of prenatal alcohol exposure is thus a public health priority - and one that should account for the particular needs of subpopulations, including in American Indian/Alaska Native (AI/AN) communities. Prior to conception, alcohol-exposed pregnancy prevention is accomplished by encouraging the reduction or elimination of risky alcohol use and/or promoting effective contraceptive use among risky drinkers who could become pregnant. The current study builds on promising findings about the impact of the Centers for Disease Control and Prevention CHOICES intervention with AI/AN communities by implementing a randomized control trial of Native CHOICES, a cultural adaptation of CHOICES, with AI/AN women in a rural reservation community. METHODS AI/AN women aged 18-44 who are at-risk for an alcohol-exposed pregnancy are being recruited. Participants are randomized in 1:1 proportion to the intervention and a services-as-usual, waitlist control condition. The Native CHOICES intervention consists of 2 motivational interviewing (MI) sessions, an elective contraception counseling session, and electronic messaging to boost the effects of MI. Data are collected at baseline and at 6 weeks, 3 months, and 6 months post-baseline. Those assigned to the control group are eligible to enroll in Native CHOICES following the completion of the 6 months post-baseline data collection. In addition to testing intervention effectiveness, the study is designed to yield a comprehensive economic evaluation, which will provide important information regarding the financial feasibility and sustainability of Native CHOICES for healthcare systems serving AI/ANs.",2021,Those assigned to the control group are eligible to enroll in Native CHOICES following the completion of the 6 months post-baseline data collection.,"['American Indian communities', 'risky drinkers who could become pregnant', 'AN women aged 18-44 who are at-risk for an alcohol-exposed pregnancy are being recruited']","['services-as-usual, waitlist control condition', 'motivational interviewing (MI) sessions, an elective contraception counseling session, and electronic messaging']",[],"[{'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1443484', 'cui_str': 'Contraception care education'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}]",[],,0.0257983,Those assigned to the control group are eligible to enroll in Native CHOICES following the completion of the 6 months post-baseline data collection.,"[{'ForeName': 'Jessica D', 'Initials': 'JD', 'LastName': 'Hanson', 'Affiliation': 'Department of Applied Human Sciences, University of Minnesota Duluth, Duluth, MN, USA. Electronic address: jdhanson@d.umn.edu.'}, {'ForeName': 'Kyra', 'Initials': 'K', 'LastName': 'Oziel', 'Affiliation': 'Initiative for Research and Education to Advance Community Health, Washington State University, Seattle, WA, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Sarche', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Colorado School of Public Health, Centers for American Indian and Alaska Native Health, Aurora, CO, USA.'}, {'ForeName': 'Richard F', 'Initials': 'RF', 'LastName': 'MacLehose', 'Affiliation': 'Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Rosenman', 'Affiliation': 'Initiative for Research and Education to Advance Community Health, Washington State University, Seattle, WA, USA; School of Economic Sciences, Washington State University, Pullman, WA, USA.'}, {'ForeName': 'Dedra', 'Initials': 'D', 'LastName': 'Buchwald', 'Affiliation': 'Initiative for Research and Education to Advance Community Health, Washington State University, Seattle, WA, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106351'] 1195,33743290,Nutritional risk is a predictor for long-term mortality: 5-Year follow-up of the EFFORT trial.,"BACKGROUND AND AIMS The nutritional risk screening (NRS 2002) is a validated screening tool for malnutrition. This study aims to investigate the prognostic value of the NRS 2002 and its individual components regarding long-term mortality and adverse outcomes in a well-characterized cohort of medical inpatients. METHODS We performed a 5-year follow-up investigation of patients included in the investigator-initiated, prospective, randomized controlled multicenter EFFORT trial that evaluated the effects of individualized nutritional intervention vs. standard hospital food. We used multivariable cox regression analyses adjusted for randomisation arm, study centre, comorbidities and main admission diagnosis to investigate associations between NRS 2002 total scores at time of hospital admission and several long-term outcomes. RESULTS We had confirmed mortality data over the mean follow-up time of 3.2 years in 1874 from the initial cohort of 2028 EFFORT patients. Mortality showed a step-wise increase in patients with NRS 3 (289/565 [51.2%]) and NRS 4 (355/717 [49.6%]) to 59.5% (353/593) in patient with NRS≥5 corresponding to an adjusted Hazard Ratio (HR) of 1.28 (95%CI 1.15 to 1.42, p ≤ 0.001) for mortality after one year and 1.13 (95%CI 1.05 to 1.23, p = 0.002) for the overall time period. All individual components of NRS including disease severity, food intake, weight loss and BMI provided prognostic information regarding long-term mortality risk. CONCLUSION Nutritional risk mirrored by a NRS 2002 total score is a strong and independent predictor of long-term mortality and morbidity in polymorbid medical inpatients particularly in patients with high nutritional risk with an NRS ≥5 points.",2021,"Mortality showed a step-wise increase in patients with NRS 3 (289/565 [51.2%]) and NRS 4 (355/717 [49.6%]) to 59.5% (353/593) in patient with NRS≥5 corresponding to an adjusted Hazard Ratio (HR) of 1.28 (95%CI 1.15 to 1.42, p ≤ 0.001) for mortality after one year and 1.13 (95%CI 1.05 to 1.23, p = 0.002) for the overall time period.","['a well-characterized cohort of medical inpatients', 'polymorbid medical inpatients particularly in patients with high nutritional risk with an NRS ≥5 points']",['individualized nutritional intervention vs. standard hospital food'],"['disease severity, food intake, weight loss and BMI provided prognostic information regarding long-term mortality risk', 'Nutritional risk', 'mortality', 'Mortality']","[{'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}]","[{'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016452', 'cui_str': 'Foods'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}]",2028.0,0.0632958,"Mortality showed a step-wise increase in patients with NRS 3 (289/565 [51.2%]) and NRS 4 (355/717 [49.6%]) to 59.5% (353/593) in patient with NRS≥5 corresponding to an adjusted Hazard Ratio (HR) of 1.28 (95%CI 1.15 to 1.42, p ≤ 0.001) for mortality after one year and 1.13 (95%CI 1.05 to 1.23, p = 0.002) for the overall time period.","[{'ForeName': 'Andriana', 'Initials': 'A', 'LastName': 'Efthymiou', 'Affiliation': 'Division of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Hersberger', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Reber', 'Affiliation': 'Division of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Katja A', 'Initials': 'KA', 'LastName': 'Schönenberger', 'Affiliation': 'Inselspital, Bern, Switzerland.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Kägi-Braun', 'Affiliation': 'Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Tribolet', 'Affiliation': 'Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Beat', 'Initials': 'B', 'LastName': 'Mueller', 'Affiliation': 'Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Schuetz', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland. Electronic address: schuetzph@gmail.com.'}, {'ForeName': 'Zeno', 'Initials': 'Z', 'LastName': 'Stanga', 'Affiliation': 'Division of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2021.02.032'] 1196,33748882,The catastrophization effects of an MRI report on the patient and surgeon and the benefits of 'clinical reporting': results from an RCT and blinded trials.,"PURPOSE Inappropriate use of MRI leads to increasing interventions and surgeries for low back pain (LBP). We probed the potential effects of a routine MRI report on the patient's perception of his spine and functional outcome of treatment. An alternate 'clinical reporting' was developed and tested for benefits on LBP perception. METHODS In Phase-I, 44 LBP patients were randomized to Group A who had a factual explanation of their MRI report or Group B, who were reassured that the MRI findings showed normal changes. The outcome was compared at 6 weeks by VAS, PSEQ-2, and SF-12. In Phase-II, clinical reporting was developed, avoiding potential catastrophizing terminologies. In Phase-III, 20 MRIs were reported by both routine and clinical methods. The effects of the two methods were tested on four categories of health care professionals (HCP) who read them blinded on their assessment of severity of disease, possible treatment required, and the probability of surgery. RESULTS Both groups were comparable initial by demographics and pain. After 6 weeks of treatment, Group A had a more negative perception of their spinal condition, increased catastrophization, decreased pain improvement, and poorer functional status(p = significant for all). The alternate method of clinical reporting had significant benefits in assessment of lesser severity of the disease, shift to lesser severity of intervention and surgery in three groups of HCPs. CONCLUSION Routine MRI reports produce a negative perception and poor functional outcomes in LBP. Focussed clinical reporting had significant benefits, which calls for the need for 'clinical reporting' rather than 'Image reporting'.",2021,"After 6 weeks of treatment, Group A had a more negative perception of their spinal condition, increased catastrophization, decreased pain improvement, and poorer functional status(p = significant for all).","['low back pain (LBP', '44 LBP patients']",['routine MRI'],"['negative perception of their spinal condition, increased catastrophization, decreased pain improvement']","[{'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0563150', 'cui_str': 'Catastrophization'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",44.0,0.138439,"After 6 weeks of treatment, Group A had a more negative perception of their spinal condition, increased catastrophization, decreased pain improvement, and poorer functional status(p = significant for all).","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Rajasekaran', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Hospital, 313, Mettupalayam Road, Coimbatore, India. rajasekaran.orth@gmail.com.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Dilip Chand Raja', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Hospital, 313, Mettupalayam Road, Coimbatore, India.'}, {'ForeName': 'Bhari Thippeswamy', 'Initials': 'BT', 'LastName': 'Pushpa', 'Affiliation': 'Department of Radiology, Ganga Hospital, 313, Mettupalayam Road, Coimbatore, India.'}, {'ForeName': 'Kumar Behera', 'Initials': 'KB', 'LastName': 'Ananda', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Hospital, 313, Mettupalayam Road, Coimbatore, India.'}, {'ForeName': 'Shetty', 'Initials': 'S', 'LastName': 'Ajoy Prasad', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Hospital, 313, Mettupalayam Road, Coimbatore, India.'}, {'ForeName': 'Mugesh Kanna', 'Initials': 'MK', 'LastName': 'Rishi', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Hospital, 313, Mettupalayam Road, Coimbatore, India.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-021-06809-0'] 1197,33754400,Adventure-based training to enhance resilience and reduce depressive symptoms among juveniles: A randomized controlled trial.,"There is growing concern about mental health problems among juveniles. Evidence shows that adventure-based training can reduce depressive symptoms in school children. However, a rigorous empirical investigation of the effectiveness of such training in enhancing resilience among juveniles has not yet been performed. In this study, a randomized controlled trial was conducted to examine the effectiveness of adventure-based training in enhancing resilience and self-esteem and reducing depressive symptoms among juveniles. Secondary school students from grades 7 to 9 (aged 12-16 years) who attended the Integrated Children and Youth Services Centre in a large public housing estate in Hong Kong from December 20, 2018 to November 25, 2019 were invited to participate in this study. We randomly assigned 228 eligible adolescents to an experimental group (n = 115) that received a 2-day/1-night adventure-based training or a placebo control group (n = 113) that received 2 days of leisure activities organized by the Integrated Children and Youth Services Centre. Data were collected at baseline and 3 and 6 months after the corresponding interventions. The primary outcome was resilience at 6 months. The secondary outcomes were depressive symptoms and self-esteem at 6 months. Compared with the placebo control group, the experimental group showed significantly higher resilience (p = 0.001) and fewer depressive symptoms (p = 0.02) at 6 months, and significantly higher self-esteem at 3 months (p = 0.04), but not at 6 months (p = 0.12). However, the generalizability of the findings is limited as we used a convenience sample.",2021,"Compared with the placebo control group, the experimental group showed significantly higher resilience (p = 0.001) and fewer depressive symptoms (p = 0.02) at 6 months, and significantly higher self-esteem at 3 months (p = 0.04), but not at 6 months (p = 0.12).","['228 eligible adolescents to an experimental group (n\u2009=\u2009115) that received a', 'juveniles', 'Secondary school students from grades 7 to 9 (aged 12-16\u2009years) who attended the Integrated Children and Youth Services Centre in a large public housing estate in Hong Kong from December 20, 2018 to November 25, 2019 were invited to participate in this study', 'school children']","['adventure-based training', '2-day/1-night adventure-based training or a placebo control group (n\u2009=\u2009113) that received 2\u2009days of leisure activities organized by the Integrated Children and Youth Services Centre', 'Adventure-based training']","['self-esteem', 'depressive symptoms', 'enhancing resilience and self-esteem', 'depressive symptoms and self-esteem', 'higher resilience']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C3146221', 'cui_str': 'Juvenile'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0034028', 'cui_str': 'Public Housing'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0260267', 'cui_str': 'School child'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0023292', 'cui_str': 'Leisure Activities'}, {'cui': 'C1300196', 'cui_str': 'Organized'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0205250', 'cui_str': 'High'}]",228.0,0.115694,"Compared with the placebo control group, the experimental group showed significantly higher resilience (p = 0.001) and fewer depressive symptoms (p = 0.02) at 6 months, and significantly higher self-esteem at 3 months (p = 0.04), but not at 6 months (p = 0.12).","[{'ForeName': 'Joyce O K', 'Initials': 'JOK', 'LastName': 'Chung', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic Universit, Hung Hom, Kowloon, Hong Kong, HKSAR.'}, {'ForeName': 'William H C', 'Initials': 'WHC', 'LastName': 'Li', 'Affiliation': 'School of Nursing, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong, HKSAR.'}, {'ForeName': 'K Y', 'Initials': 'KY', 'LastName': 'Ho', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic Universit, Hung Hom, Kowloon, Hong Kong, HKSAR.'}, {'ForeName': 'Katherine K W', 'Initials': 'KKW', 'LastName': 'Lam', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic Universit, Hung Hom, Kowloon, Hong Kong, HKSAR.'}, {'ForeName': 'Ankie T', 'Initials': 'AT', 'LastName': 'Cheung', 'Affiliation': 'School of Nursing, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong, HKSAR.'}, {'ForeName': 'Laurie L K', 'Initials': 'LLK', 'LastName': 'Ho', 'Affiliation': 'School of Nursing, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong, HKSAR.'}, {'ForeName': 'Jessie J', 'Initials': 'JJ', 'LastName': 'Lin', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic Universit, Hung Hom, Kowloon, Hong Kong, HKSAR.'}, {'ForeName': 'Violeta', 'Initials': 'V', 'LastName': 'Lopez', 'Affiliation': 'School of Nursing, Hubei University of Medicine, Shiyan, Hubei Province, China.'}]",Research in nursing & health,['10.1002/nur.22127'] 1198,33753456,FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.,"On December 20, 2019, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki [DS-8201a; T-DXd; tradename ENHERTU (Daiichi Sankyo)] for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. Approval was based on data from study DS8201-A-U201 (DESTINY-Breast01) with supportive safety data from study DS8201-A-J101. The primary efficacy endpoint in DESTINY-Breast01 was overall response rate (ORR) based on confirmed responses by blinded independent central review (ICR) using RECIST v1.1 in all participants who were assigned to receive the recommended dose of 5.4 mg/kg while secondary endpoints included duration of response (DoR). The confirmed ORR based on ICR in these 184 patients was 60.3% [95% confidence interval (CI): 52.9-67.4] and the median DoR was 14.8 months (95% CI: 13.8-16.9). Interstitial lung disease, including pneumonitis, was experienced in patients treated with T-DXd and can be severe, life threatening, or fatal. In addition, neutropenia and left ventricular dysfunction were included as Warnings and Precautions in labeling. Other important common adverse reactions were nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia, diarrhea, and thrombocytopenia. Overall, the totality of efficacy and safety data supported the accelerated approval of T-DXd for the intended indication.",2021,"Overall, the totality of efficacy and safety data supported the accelerated approval of T-DXd for the intended indication.","['adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting', 'unresectable or metastatic HER2-positive breast cancer']",[],"['overall response rate (ORR', 'Interstitial lung disease (ILD', 'nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia, diarrhea, and thrombocytopenia', 'median DoR', 'duration of response (DoR', 'neutropenia and left ventricular dysfunction']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C1960398', 'cui_str': 'HER2-positive carcinoma of breast'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0002170', 'cui_str': 'Alopecia'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0242698', 'cui_str': 'Impaired left ventricular function'}]",,0.280871,"Overall, the totality of efficacy and safety data supported the accelerated approval of T-DXd for the intended indication.","[{'ForeName': 'Preeti', 'Initials': 'P', 'LastName': 'Narayan', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. preeti.narayan@fda.hhs.gov.'}, {'ForeName': 'Christy L', 'Initials': 'CL', 'LastName': 'Osgood', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Harpreet', 'Initials': 'H', 'LastName': 'Singh', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Haw-Jyh', 'Initials': 'HJ', 'LastName': 'Chiu', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Tiffany K', 'Initials': 'TK', 'LastName': 'Ricks', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'Chiu Yuen Chow', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Junshan', 'Initials': 'J', 'LastName': 'Qiu', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Song', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Jingyu', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Namuswe', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Guiterrez-Lugo', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Sherry', 'Initials': 'S', 'LastName': 'Hou', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Pierce', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Kirsten B', 'Initials': 'KB', 'LastName': 'Goldberg', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Shenghui', 'Initials': 'S', 'LastName': 'Tang', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Laleh', 'Initials': 'L', 'LastName': 'Amiri-Kordestani', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Marc R', 'Initials': 'MR', 'LastName': 'Theoret', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pazdur', 'Affiliation': 'Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Julia A', 'Initials': 'JA', 'LastName': 'Beaver', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-4557'] 1199,33752148,Effects of preoperative oral single-dose and double-dose carbohydrates on insulin resistance in patients undergoing gastrectomy:a prospective randomized controlled trial.,"BACKGROUND & AIMS Preoperative oral carbohydrates are strongly recommended for routine use before various elective procedures. The regimen mainly includes preoperative oral single-dose carbohydrate (2-3 h before surgery) and preoperative oral double-dose carbohydrates (10 h before surgery and 2-3 h before surgery). The choice between the two options is still controversial. METHODS A total of 139 patients with gastric cancer who underwent radical gastrectomy were recruited from a hospital in Sichuan Province, China. The patients were randomly assigned to a single-dose group (n = 70) or a double-dose group (n = 69). Insulin resistance indicators, subjective comfort indicators, inflammatory mediators, immunological indicators, postoperative recovery indexes, and complications were compared between the two groups. RESULTS There were no differences in insulin resistance indicators (fasting plasma glucose, fasting insulin, and homeostasis model assessment indexes), inflammatory mediators (C-reactive protein, interleukin-6, and tumor necrosis factor-α), immunological indicators (CD3+, CD4+, CD8+, and CD4+/CD8+) between the single-dose group and double-dose group (all P > 0.05) at preoperative day 1, preoperative 3 h, and postoperative day 1. There were no differences in subjective comfort indicators (thirst, hunger, anxiety, nausea, fatigue, and weakness) between the two groups (all P > 0.05) at preoperative day 1, preoperative 3 h, preoperative 1 h, and postoperative day 1. The postoperative recovery indexes and complications (exhaust time, liquid intake time, postoperative hospital stay, complication incidence, unplanned readmission rate, and unplanned reoperation rate 30 days after operation) did not significantly differ between the two groups (all P > 0.05). The number of preoperative nighttime urinations in the double-dose group was higher than that in the single-dose group (88.3% VS 48.5%, P < 0.001), and the number of hours of preoperative sleep in the double-dose group was lower than that in the single-dose group (4.56 ± 0.68 VS 5.71 ± 0.57, P < 0.001). CONCLUSION Oral carbohydrates administered the night before surgery did not enhance the effects of oral carbohydrates administered 2-3 h before surgery on insulin resistance, subjective comfort, inflammation, and immunity and might affect the patients' night rest. In making a decision between oral carbohydrate regimes, evening carbohydrates could be omitted. TRIAL REGISTRATION ChiCTR, ChiCTR1900020608. Registered January 10, 2019, http://www.chictr.org.cn: ChiCTR1900020608.",2021,"There were no differences in subjective comfort indicators (thirst, hunger, anxiety, nausea, fatigue, and weakness) between the two groups (all P > 0.05) at preoperative day 1, preoperative 3 h, preoperative 1 h, and postoperative day 1.","['139 patients with gastric cancer who underwent radical gastrectomy were recruited from a hospital in Sichuan Province, China', 'Registered January 10, 2019, http://www.chictr.org.cn', 'patients undergoing gastrectomy']","['preoperative oral single-dose carbohydrate (2-3\xa0h before surgery) and preoperative oral double-dose carbohydrates', 'preoperative oral single-dose and double-dose carbohydrates']","['insulin resistance, subjective comfort, inflammation, and immunity', 'insulin resistance', 'number of preoperative nighttime urinations', 'Insulin resistance indicators, subjective comfort indicators, inflammatory mediators, immunological indicators, postoperative recovery indexes, and complications', 'postoperative recovery indexes and complications (exhaust time, liquid intake time, postoperative hospital stay, complication incidence, unplanned readmission rate, and unplanned reoperation rate 30 days after operation', 'insulin resistance indicators (fasting plasma glucose, fasting insulin, and homeostasis model assessment indexes), inflammatory mediators (C-reactive protein, interleukin-6, and tumor necrosis factor-α), immunological indicators (CD3+, CD4+, CD8+, and CD4+/CD8', 'subjective comfort indicators (thirst, hunger, anxiety, nausea, fatigue, and weakness', 'number of hours of preoperative sleep']","[{'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0565313', 'cui_str': 'Radical gastrectomy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0041119', 'cui_str': 'Tritium'}, {'cui': 'C0205173', 'cui_str': 'Double'}]","[{'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0020964', 'cui_str': 'Immune status'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0205470', 'cui_str': 'Immunologic'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0108779', 'cui_str': 'Lymphocyte antigen CD3'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0039971', 'cui_str': 'Thirst'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C3714552', 'cui_str': 'Debility'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",139.0,0.226818,"There were no differences in subjective comfort indicators (thirst, hunger, anxiety, nausea, fatigue, and weakness) between the two groups (all P > 0.05) at preoperative day 1, preoperative 3 h, preoperative 1 h, and postoperative day 1.","[{'ForeName': 'Xinrong', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'West China School of Nursing /West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.'}, {'ForeName': 'Ka', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': 'West China School of Nursing /West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China. Electronic address: lika127@126.com.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Yang', 'Affiliation': 'Department of Gastrointestinal Surgery, West China Hospital,Sichuan University, Chengdu, 610041, Sichuan Province, China.'}, {'ForeName': 'Jiankun', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Department of Gastrointestinal Surgery, West China Hospital,Sichuan University, Chengdu, 610041, Sichuan Province, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Gastrointestinal Surgery, West China Hospital,Sichuan University, Chengdu, 610041, Sichuan Province, China.'}, {'ForeName': 'Jinhua', 'Initials': 'J', 'LastName': 'Feng', 'Affiliation': 'West China School of Nursing /West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.'}, {'ForeName': 'Yanjie', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'West China School of Nursing /West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.'}, {'ForeName': 'Xingxia', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'West China School of Nursing /West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2021.03.002'] 1200,33771469,The Impact of Guided Imagery on Pain and Anxiety in Hospitalized Adults.,"BACKGROUND The use and impact of guided imagery in the acute care setting is limited. AIMS The purpose of this quality improvement project was to evaluate the feasibility of a guided imagery intervention to change pain scores, anxiety scores, and opioid analgesia usage among hospitalized adults in an acute care setting. DESIGN Quality improvement project using three measurements (baseline, 24 hours, and 48 hours). SETTINGS Acute care hospital. PARTICIPANTS/SUBJECTS Adult inpatients referred to an APRN-led pain management service. METHODS The intervention was the use of a 30-minute guided imagery recording delivered via MP3 player which patients used twice daily. RESULTS Limited changes were seen in pain scores, with no statistically significant results (p = .449). Statistically significant reductions were found in both anxiety scores (p < .001) and opioid analgesia usage (p = .043). CONCLUSIONS Findings from this quality improvement project support the impact of guided imagery on anxiety and opioid analgesia use. Changes in pain scores were not demonstrated in this project. Additional research with a rigorous design is needed to determine cause and effect conclusions. CLINICAL IMPLICATIONS The use of guided imagery as an adjunctive intervention for pain control may engage and empower the patient in self-care activities, which may have an impact on how care is perceived. Guided imagery is a low-cost, easily implemented approach that can be incorporated into patient care to reduce anxiety and, potentially, opioid analgesia use.",2021,"Statistically significant reductions were found in both anxiety scores (p < .001) and opioid analgesia usage (p = .043). ","['Acute care hospital', 'hospitalized adults in an acute care setting', 'Hospitalized Adults', 'Adult inpatients referred to an APRN-led pain management service']","['guided imagery intervention', '30-minute guided imagery recording delivered via MP3 player which patients used twice daily', 'guided imagery', 'Guided Imagery']","['pain scores', 'anxiety scores', 'opioid analgesia usage', 'pain scores, anxiety scores, and opioid analgesia usage', 'Pain and Anxiety']","[{'cui': 'C3661916', 'cui_str': 'Acute care hospital'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0587604', 'cui_str': 'Pain management service'}]","[{'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C2350433', 'cui_str': 'MP3-Player'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.058798,"Statistically significant reductions were found in both anxiety scores (p < .001) and opioid analgesia usage (p = .043). ","[{'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Cole', 'Affiliation': 'From the Cizik School of Nursing, University of Texas Health Science Center, Houston, TX. Electronic address: Linda.Cole@uth.tmc.edu.'}]",Pain management nursing : official journal of the American Society of Pain Management Nurses,['10.1016/j.pmn.2021.02.007'] 1201,33795567,Pulse-Dye Laser Followed by Betamethasone-Calcipotriol and Fractional Ablative CO2-Laser-Assisted Delivery for Nail Psoriasis.,"BACKGROUND Nail psoriasis is a common and potentially debilitating condition for which no effective and safe nonsystemic therapy is currently available. Recently, laser-assisted drug delivery (LADD) is being increasingly used to facilitate transcutaneous penetration of topical treatments. OBJECTIVES We set to assess the efficacy and safety of combined pulse-dye laser and fractional CO2 laser-assisted betamethasonecalcipotriol gel delivery for the treatment of nail psoriasis. MATERIAL AND METHODS We conducted a prospective, intrapatient comparative study in a series of 22 patients with bilateral fingernail psoriasis. Nails on the randomized hand were treated with 3 monthly sessions of pulse-dye laser to the proximal and lateral nail folds followed by fractional ablative CO2 laser to the nail plate. Between treatments and one month following the last treatment, the participants applied betamethasone propionate-calcipotriol gel once daily to the nail plate. Clinical outcome was ascertained using nails photography, the Nail Psoriasis Severity Index (NAPSI) and patient satisfaction. RESULTS Seventeen completed the study. Three participants withdrew from the study because of treatment-associated pain. Treatment was associated with a statistically significant improvement of the NAPSI scale (p < .002). Patient satisfaction was high. CONCLUSION Combined PDL and fractional ablative CO2-LADD of betamethasone-calcipotriol gel should be considered for the treatment of nail psoriasis.",2021,Treatment was associated with a statistically significant improvement of the NAPSI scale (p < .002).,"['22 patients with bilateral fingernail psoriasis', 'Seventeen completed the study', 'Nail Psoriasis']","['laser-assisted drug delivery (LADD', 'combined pulse-dye laser and fractional CO2 laser-assisted betamethasonecalcipotriol gel delivery', 'Pulse-Dye Laser Followed by Betamethasone-Calcipotriol and Fractional Ablative CO2-Laser-Assisted Delivery', 'pulse-dye laser to the proximal and lateral nail folds followed by fractional ablative CO2 laser to the nail plate', 'betamethasone propionate-calcipotriol gel once daily to the nail plate', 'betamethasone-calcipotriol gel']","['pain', 'nails photography, the Nail Psoriasis Severity Index (NAPSI) and patient satisfaction', 'efficacy and safety', 'NAPSI scale', 'Patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0222001', 'cui_str': 'Fingernails'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0406322', 'cui_str': 'Psoriasis of nail'}]","[{'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1289859', 'cui_str': 'Pulsed dye laser device'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C0065767', 'cui_str': 'calcipotriene'}, {'cui': 'C0877233', 'cui_str': 'Assisted delivery'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0222000', 'cui_str': 'Structure of lateral nail fold'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0106166', 'cui_str': 'betamethasone propionate'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0031749', 'cui_str': 'Photography'}, {'cui': 'C0406322', 'cui_str': 'Psoriasis of nail'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",22.0,0.0295758,Treatment was associated with a statistically significant improvement of the NAPSI scale (p < .002).,"[{'ForeName': 'Waseem', 'Initials': 'W', 'LastName': 'Shehadeh', 'Affiliation': 'Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Hagit', 'Initials': 'H', 'LastName': 'Matz', 'Affiliation': 'Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Eran', 'Initials': 'E', 'LastName': 'Ellenbogen', 'Affiliation': 'Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Eli', 'Initials': 'E', 'LastName': 'Sprecher', 'Affiliation': 'Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Ofir', 'Initials': 'O', 'LastName': 'Artzi', 'Affiliation': 'Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002835'] 1202,33728558,Making Implementation Last: The Impact of Training Design on the Sustainability of an Evidence-Based Treatment in a Randomized Controlled Trial.,"Although advances have been made in facilitating the implementation of evidence-based treatments, little is known about the most effective way to sustain their use over time. The current study examined the sustainability of one evidence-based treatment, Parent-Child Interaction Therapy (PCIT), following a statewide implementation trial testing three training methods: Cascading Model, Learning Collaborative, and Distance Education. Participants included 100 clinicians and 50 administrators from 50 organizations across Pennsylvania. Clinicians and administrators reported on sustainability at 24-months, as measured by the number of clients receiving PCIT and the continued use of the PCIT protocol. Multi-level path analysis was utilized to examine the role of training on sustainability. Clinicians and administrators reported high levels of sustainability at 24-months. Clinicians in the Cascading Model reported greater average PCIT caseloads at 24-months, whereas clinicians in the Learning Collaborative reported greater full use of the PCIT protocol at 24-months. Attending consultation calls was associated with delivering PCIT to fewer families. Implications for the sustainable delivery of PCIT beyond the training year as well as for the broader field of implementation science are discussed.",2021,Attending consultation calls was associated with delivering PCIT to fewer families.,['Participants included 100 clinicians and 50 administrators from 50 organizations across Pennsylvania'],['Parent-Child Interaction Therapy (PCIT'],[],"[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0085751', 'cui_str': 'Administrators'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}]","[{'cui': 'C0030542', 'cui_str': 'Parent-Child Relationship'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],100.0,0.070665,Attending consultation calls was associated with delivering PCIT to fewer families.,"[{'ForeName': 'Carrie B', 'Initials': 'CB', 'LastName': 'Jackson', 'Affiliation': 'Department of Psychology, West Virginia University, Morgantown, USA. carriebethjackson@gmail.com.'}, {'ForeName': 'Amy D', 'Initials': 'AD', 'LastName': 'Herschell', 'Affiliation': 'Insurance Services Division, Community Care Behavioral Health Organization of UPMC, 339 Sixth Avenue Suite 1300, Pittsburgh, PA, 15222, USA.'}, {'ForeName': 'Ashley T', 'Initials': 'AT', 'LastName': 'Scudder', 'Affiliation': 'Iowa State University, Ames, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Hart', 'Affiliation': 'UMPC Western Psychiatric Hospital, Pittsburgh, USA.'}, {'ForeName': 'Kristen F', 'Initials': 'KF', 'LastName': 'Schaffner', 'Affiliation': 'Psychology Department, California University of Pennsylvania, California, USA.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Kolko', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, USA.'}, {'ForeName': 'Stanley', 'Initials': 'S', 'LastName': 'Mrozowski', 'Affiliation': ""Children's Bureau, Harrisburg, USA.""}]",Administration and policy in mental health,['10.1007/s10488-021-01126-6'] 1203,33734433,Safety and efficacy of an oral misoprostol standard-dose regimen vs a low-dose regimen for induction of labour in Papua New Guinean women: An open-label randomised controlled trial.,"BACKGROUND Oral misoprostol is widely used for induction of labour (IOL) in developing countries because of its many advantages. However, limited data exist concerning its safety and efficacy when lower doses are used. AIM To determine the safety and efficacy of a low-dose oral misoprostol regimen (commencing at 12 μg) compared to a standard-dose regimen (commencing at 25 μg) in Papua New Guinea (PNG) women undergoing IOL. MATERIALS AND METHODS This was an open-label non-inferiority randomised controlled trial conducted at a provincial hospital in PNG. Women with singleton pregnancies ≥36 weeks with cephalic presentation and a Bishops score of <6, requiring IOL were enrolled. Both regimens were incremented second-hourly to a maximum required dose within 24 h or until commencement of labour. The primary outcome was the proportion of women who delivered within 24 h of drug administration without any severe adverse events. RESULTS Of the 262 women induced (130 standard-dose vs 132 low-dose), rates of successful induction were high for both regimens (120/130 (92%) vs 118/132 (89%); P = 0.52). Fourteen women (11%) in the standard-dose regimen and 20 (15%) in the low-dose regimen had severe adverse events. There was no significant difference in the safety profile of the two regimens (106/130 (82%) vs 98/132 (74%); P = 0.18). The induction-to-delivery time was significantly shorter in the standard-dose arm (15.2 ± 8.7 h vs 18.0 ± 9.1 h; P = 0.01). CONCLUSION The standard-dose regimen for IOL has greater efficacy in reducing induction-to-delivery time compared to the low-dose regimen. There was no significant difference in the number of adverse events between the two regimens.",2021,There was no significant difference in the number of adverse events between the two regimens.,"['262 women induced', 'Women with singleton pregnancies ≥36\xa0weeks with cephalic presentation and a Bishops score of <6, requiring IOL were enrolled', 'Papua New Guinea (PNG) women undergoing IOL', 'Papua New Guinean women']","['oral misoprostol', 'misoprostol', 'low-dose oral misoprostol']","['safety profile', 'safety and efficacy', 'Safety and efficacy', 'induction-to-delivery time', 'number of adverse events', 'rates of successful induction', 'proportion of women who delivered within 24\xa0h of drug administration without any severe adverse events', 'severe adverse events']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205096', 'cui_str': 'Cephalic'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C2225498', 'cui_str': 'Bishop score'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C0030375', 'cui_str': 'Papua New Guinea'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0085174', 'cui_str': 'Misoprostol'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C1301668', 'cui_str': 'Time of delivery'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0150270', 'cui_str': 'Management of drug regimen'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}]",262.0,0.108234,There was no significant difference in the number of adverse events between the two regimens.,"[{'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Bolnga', 'Affiliation': 'Department of Obstetrics and Gynaecology, Modilon Hospital, Madang, Papua New Guinea.'}, {'ForeName': 'Glen D L', 'Initials': 'GDL', 'LastName': 'Mola', 'Affiliation': 'Department of Obstetrics and Gynaecology, School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Totona', 'Affiliation': 'Department of Obstetrics and Gynaecology, Modilon Hospital, Madang, Papua New Guinea.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Ao', 'Affiliation': 'Department of Obstetrics and Gynaecology, Modilon Hospital, Madang, Papua New Guinea.'}, {'ForeName': 'Elvin', 'Initials': 'E', 'LastName': 'Lufele', 'Affiliation': 'Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}, {'ForeName': 'Moses', 'Initials': 'M', 'LastName': 'Laman', 'Affiliation': 'Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}]",The Australian & New Zealand journal of obstetrics & gynaecology,['10.1111/ajo.13331'] 1204,33733955,Child- compared with parent-report ratings on psychosocial measures following a mild traumatic brain injury among youth with persistent post-concussion symptoms.,"Primary Objective : To compare child- and parent-report ratings on the Health Behavior Inventory, Revised Child Anxiety and Depression Scale-Short Version (anxiety subscale), Patient Health Questionnaire-9, and Pediatric Quality of Life Inventory TM among children with persistent post-concussive symptoms following a sports- or recreation-related concussion, overall and by child age and gender. Research Design : Cross-sectional study examining baseline data from a randomized, comparative effectiveness trial. Methods and Procedures : Inter-rater reliability was assessed using two-way random effects model (absolute agreement) intraclass correlations, correlations were examined using Spearman's rho, mean differences were determined using paired t-tests, and agreement was examined using Bland-Altman plots. Main Outcomes and Results : The final analytic sample was 200 parent-child dyads [child M age  = 14.7 (95% CI: 14.5, 15.0)]. Reliability and correlations were modest overall. When considering child age and gender, reliability ranged from poor to excellent (-1.01-0.95) and correlations ranged from weak to strong (-0.64-0.94). Overall, children reported more symptoms but better functioning than parents, and mean differences in scores were greater among females (versus males) and ages 16-18 (versus younger groups). Conclusions : Findings should inform the use and interpretation of psychosocial measures when developing appropriate youth concussion treatment plans.",2021,"Overall, children reported more symptoms but better functioning than parents, and mean differences in scores were greater among females (versus males) and ages 16-18 (versus younger groups).","['children with persistent post-concussive symptoms following a sports- or recreation-related concussion, overall and by child age and gender', '200 parent-child dyads [child M age \xa0=\xa014.7', 'mild traumatic brain injury among youth with persistent post-concussion symptoms']",[],"['Health Behavior Inventory, Revised Child Anxiety and Depression Scale-Short Version (anxiety subscale), Patient Health Questionnaire-9, and Pediatric Quality of Life Inventory TM']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0546983', 'cui_str': 'Postconcussion syndrome'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0034872', 'cui_str': 'Recreation'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]",[],"[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C4305166', 'cui_str': ""RCADS - Revised Children's Anxiety and Depression Scale""}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0990962,"Overall, children reported more symptoms but better functioning than parents, and mean differences in scores were greater among females (versus males) and ages 16-18 (versus younger groups).","[{'ForeName': 'Ashleigh M', 'Initials': 'AM', 'LastName': 'Johnson', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, US.""}, {'ForeName': 'Carolyn A', 'Initials': 'CA', 'LastName': 'McCarty', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, US.""}, {'ForeName': 'Lyscha A', 'Initials': 'LA', 'LastName': 'Marcynyszyn', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, US.""}, {'ForeName': 'Douglas F', 'Initials': 'DF', 'LastName': 'Zatzick', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, US.'}, {'ForeName': 'Sara Pd', 'Initials': 'SP', 'LastName': 'Chrisman', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, US.""}, {'ForeName': 'Frederick P', 'Initials': 'FP', 'LastName': 'Rivara', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, US.""}]",Brain injury,['10.1080/02699052.2021.1889663'] 1205,33737200,Peer coach delivered storytelling program improved diabetes medication adherence: A cluster randomized trial.,"BACKGROUND Because medication adherence is linked to better diabetes outcomes, numerous interventions have aimed to improve adherence. However, suboptimal adherence persists and necessitate continued research into intervention strategies. This study evaluated the effectiveness of an intervention that combined storytelling and peer support to improve medication adherence and health outcomes in adults with diabetes. METHODS Living Well with Diabetes was a cluster randomized controlled trial. Intervention participants received a six-month, 11-session peer-delivered behavioral diabetes self-care program over the phone. Control participants received a self-paced general health program. Outcomes were changes in medication adherence and physiologic measures (hemoglobin A1c, systolic blood pressure, low-density lipoprotein cholesterol, body mass index). RESULTS Of the 403 participants with follow-up data, mean age was 57 (±SD 11), 78% were female, 91% were African American, 56.4% had high school education or less, and 70% had an annual income of < $20,000. At follow-up, compared to controls, intervention participants had greater improvement in medication adherence (β = -0.25 [95% CI -0.35, -0.15]). Physiologic measures did not change significantly in either group. Intervention participants had significant improvements in beliefs about the necessity of medications (β = 0.87 [95% CI 0.27, 1.47]) concerns about the negative effects of medication (β = -0.91 [95% CI -1.35, -0.47]), and beliefs that medications are harmful (β = -0.50 [95% CI -0.89, -0.10]). In addition, medication use self-efficacy significantly improved in intervention participants (β = 1.0 [95% CI 0.23, 1.76]). 473 individuals were enrolled in the study and randomized. DISCUSSION Living Well intervention resulted in improved medication adherence, medication beliefs, and medication use self-efficacy but not improved risk factor levels.",2021,"Well intervention resulted in improved medication adherence, medication beliefs, and medication use self-efficacy but not improved risk factor levels.","['Living', 'adults with diabetes', '403 participants with follow-up data, mean age was 57 (±SD 11), 78% were female, 91% were African American, 56.4% had high school education or less, and 70% had an annual income of < $20,000']","['six-month, 11-session peer-delivered behavioral diabetes self-care program over the phone', 'self-paced general health program', 'combined storytelling and peer support', 'Peer coach delivered storytelling program']","['risk factor levels', 'beliefs about the necessity of medications', 'medication adherence and health outcomes', 'medication adherence, medication beliefs, and medication use self-efficacy', 'medication adherence', 'medication use self-efficacy', 'diabetes medication adherence', 'medication adherence and physiologic measures (hemoglobin A1c, systolic blood pressure, low-density lipoprotein cholesterol, body mass index', 'Physiologic measures']","[{'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0455002', 'cui_str': 'Education and schooling detail'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0021162', 'cui_str': 'Income'}]","[{'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0557773', 'cui_str': 'Coach'}]","[{'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",403.0,0.0745538,"Well intervention resulted in improved medication adherence, medication beliefs, and medication use self-efficacy but not improved risk factor levels.","[{'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Andreae', 'Affiliation': 'Department of Kinesiology, University of Wisconsin-Madison, Madison, WI, United States of America. Electronic address: sandreae@wisc.edu.'}, {'ForeName': 'Lynn J', 'Initials': 'LJ', 'LastName': 'Andreae', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America. Electronic address: landreae@uabmc.edu.'}, {'ForeName': 'Andrea L', 'Initials': 'AL', 'LastName': 'Cherrington', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America. Electronic address: acherrington@uabmc.edu.'}, {'ForeName': 'Joshua S', 'Initials': 'JS', 'LastName': 'Richman', 'Affiliation': 'Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, United States of America. Electronic address: jrichman@uabmc.edu.'}, {'ForeName': 'Ethel', 'Initials': 'E', 'LastName': 'Johnson', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America. Electronic address: ethelj@uab.edu.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Clark', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America. Electronic address: debrasclark@uabmc.edu.'}, {'ForeName': 'Monika M', 'Initials': 'MM', 'LastName': 'Safford', 'Affiliation': 'Department of Medicine, Weill Medical College of Cornell University, New York, NY, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106358'] 1206,33736675,"Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.","BACKGROUND The recommended starting dose of eribulin in patients with hepatic impairment is based on the Child-Pugh score, largely informed by a pharmacokinetic study of 18 patients. In the pivotal studies of eribulin in metastatic breast cancer (Study 301 and Study 305 [EMBRACE]), entry criteria and dose modifications were based on liver-function test (LFT) results rather than Child-Pugh score. In populations such as patients with metastatic breast cancer, in which metastatic infiltration is the predominant cause of hepatic impairment, using Child-Pugh score may be problematic; in clinical practice, it has been more common for oncologists to make dosing decisions based on LFTs. To address this, the effects of abnormal baseline LFT results on eribulin efficacy and safety were investigated. METHODS In this pooled post hoc analysis, 1062 patients who were randomized to receive eribulin in Studies 301 and 305 were divided into 4 groups: (A) no elevated LFT results (no liver impairment); (B) increased levels of aspartate aminotransferase and/or alanine aminotransferase; (C) decreased albumin and/or increased levels of aspartate aminotransferase and/or alanine aminotransferase but not increased bilirubin; and (D) increased bilirubin. Patients were subcategorized by presence of liver metastasis. Drug exposure, dose intensity, and treatment-emergent adverse events (TEAEs) were analyzed. RESULTS Eribulin mesylate mean dosage was 0.82 (group A)-0.65 mg/m 2 /week (group D). Group D had shorter treatment, more dose reductions/delays, more TEAEs leading to dose modifications, and numerically lower objective response rates and clinical benefit rates versus groups A-C. TEAE rates leading to dose modification were similar between group D (45.5%) and groups A-C (range, 43.5-54.9%) in the absence of liver metastases, but higher in group D (91.3%) compared with groups A-C (range, 41.7-54.3%) if liver metastases were present. CONCLUSIONS Mild elevations in bilirubin levels were associated with increased toxicity and a greater requirement for dose modifications. Based both on these study data and existing recommendations, we propose a novel scheme to guide initial dose selection in patients with metastatic breast cancer and hepatic impairment that is based on LFTs rather than Child-Pugh score.",2021,"Group D had shorter treatment, more dose reductions/delays, more TEAEs leading to dose modifications, and numerically lower objective response rates and clinical benefit rates versus groups A-C. TEAE rates leading to dose modification were similar between group D (45.5%) and groups A-C (range, 43.5-54.9%) in the absence of liver metastases, but higher in group D (91.3%) compared with groups A-C (range, 41.7-54.3%) if liver metastases were present. ","['pivotal breast cancer studies 301 and 305', 'patients with metastatic breast cancer and hepatic impairment that is based on LFTs rather than Child', 'patients with metastatic breast cancer', 'patients with hepatic impairment', '1062 patients']",[],"['bilirubin levels', 'toxicity', 'eribulin efficacy and safety', 'objective response rates and clinical benefit rates', 'levels of aspartate aminotransferase and/or alanine aminotransferase; (C) decreased albumin and/or increased levels of aspartate aminotransferase and/or alanine aminotransferase but not increased bilirubin; and (D) increased bilirubin']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517703', 'cui_str': '305'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0948807', 'cui_str': 'Hepatic impairment'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0023901', 'cui_str': 'Hepatic function panel'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",[],"[{'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C2350866', 'cui_str': 'eribulin'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0860864', 'cui_str': 'Decreased albumin'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0311468', 'cui_str': 'Increased bilirubin level'}]",1062.0,0.148327,"Group D had shorter treatment, more dose reductions/delays, more TEAEs leading to dose modifications, and numerically lower objective response rates and clinical benefit rates versus groups A-C. TEAE rates leading to dose modification were similar between group D (45.5%) and groups A-C (range, 43.5-54.9%) in the absence of liver metastases, but higher in group D (91.3%) compared with groups A-C (range, 41.7-54.3%) if liver metastases were present. ","[{'ForeName': 'Iain R', 'Initials': 'IR', 'LastName': 'Macpherson', 'Affiliation': 'Institute of Cancer Sciences, CR-UK Beatson Institute, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Yaohua', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Formerly of Eisai Inc., Woodcliff Lake, NJ, USA.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Palmieri', 'Affiliation': 'Department of Molecular and Clinical Cancer Medicine, The Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Ashton Street, Liverpool, L69 3GE, UK. c.palmieri@liverpool.ac.uk.'}]",Breast cancer research : BCR,['10.1186/s13058-021-01407-w'] 1207,33740215,Assessing Potential Outcomes Mediation in HIV Interventions.,"Knowledge of causal processes through mediation analysis can help improve the effectiveness and reduce costs of public health programs, like HIV prevention and treatment interventions. Advancements in mediation using the potential outcomes framework provide a method for estimating the causal effect of interventions on outcomes via a mediating variable. The purpose of this paper is to provide practical information about mediation and the potential outcomes framework that can enhance data analysis and causal inference for intervention studies. Causal mediation effects are defined and then estimated using data from an HIV intervention randomized trial among people who inject drugs (PWID) in Ukraine. Results from a potential outcomes mediation analysis show that the intervention had a total causal effect on incident HIV infection such that participants in the experimental group were 36% less likely to become infected during the 12-month study than those in the control arm, but that neither self-efficacy nor network communication mediated this effect. Because neither putative mediator was significant, measurement and confounding issues should be investigated to rule out these mediators. Other putative mediators, such as injection frequency, route of administration, or HIV knowledge can be considered. Future research is underway to examine additional, multiple mediators explaining efficacy of the current intervention and sensitivity to confounding effects.",2021,"Knowledge of causal processes through mediation analysis can help improve the effectiveness and reduce costs of public health programs, like HIV prevention and treatment interventions.",['people who inject drugs (PWID) in Ukraine'],[],['total causal effect on incident HIV infection'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1720154', 'cui_str': 'Inject'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0041580', 'cui_str': 'Ukraine'}]",[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}]",,0.0771755,"Knowledge of causal processes through mediation analysis can help improve the effectiveness and reduce costs of public health programs, like HIV prevention and treatment interventions.","[{'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Smyth', 'Affiliation': 'Department of Psychology, Arizona State University, PO Box 871104, Tempe, AZ, 85287-1104, USA. Heather.Smyth@asu.edu.'}, {'ForeName': 'Eileen V', 'Initials': 'EV', 'LastName': 'Pitpitan', 'Affiliation': 'School of Social Work, San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'MacKinnon', 'Affiliation': 'Department of Psychology, Arizona State University, PO Box 871104, Tempe, AZ, 85287-1104, USA.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Booth', 'Affiliation': 'Department of Psychiatry, University of Colorado, Denver, CO, USA.'}]",AIDS and behavior,['10.1007/s10461-021-03207-x'] 1208,33743185,"""Walking in Their Shoes"": The effects of an immersive digital story intervention on empathy in nursing students.","AIM To evaluate the effects of a novel, immersive digital story intervention on empathy. DESIGN A randomized trial with three phases. RESULTS A total of 238 2nd year nursing students were recruited between May 2018 and December 2019. At baseline, no significant differences in empathy between the groups were found (p = .760). However, at post-test, empathy was significantly higher in the intervention group (M: 118.76, SD: 10.65) than it was in the control group (M: 114.60, SD: 15.40) (p = .012). At follow-up, there were no significant differences in empathy between the groups (p = .364). CONCLUSION The intervention resulted in an immediate increase in empathy in nursing students. However, further development of effective intervention delivery modes and fundamental redesign of the intervention itself would be needed to sustain this improvement over the long term.",2021,"At follow-up, there were no significant differences in empathy between the groups (p = .364). ","['nursing students', 'A total of 238 2nd year nursing students were recruited between May 2018 and December 2019']","['immersive digital story intervention', 'Walking', 'novel, immersive digital story intervention']",['empathy'],"[{'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0013989', 'cui_str': 'Empathy'}]",,0.0375406,"At follow-up, there were no significant differences in empathy between the groups (p = .364). ","[{'ForeName': 'Juping', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK.'}, {'ForeName': 'Gareth S', 'Initials': 'GS', 'LastName': 'Parsons', 'Affiliation': 'Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Lancastle', 'Affiliation': 'Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK.'}, {'ForeName': 'Emma T', 'Initials': 'ET', 'LastName': 'Tonkin', 'Affiliation': 'Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK.'}, {'ForeName': 'Siva', 'Initials': 'S', 'LastName': 'Ganesh', 'Affiliation': 'Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK.'}]",Nursing open,['10.1002/nop2.860'] 1209,33744356,"Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.","BACKGROUND Atopic dermatitis (AD) is a chronic inflammatory skin disease. Interleukin (IL) 13 is a type 2 cytokine that is key to the inflammation underlying AD. Tralokinumab is a first-in-class, fully human, monoclonal antibody that specifically binds with high affinity to IL-13, neutralizing it in AD. Immunomodulatory treatments may impair vaccine-induced immune responses. OBJECTIVE Assess the immune responses to standard vaccines in adults with moderate-to-severe AD who are undergoing treatment with tralokinumab. METHODS ECZema TRAlokinumab Trial No. 5 (ECZTRA 5; NCT03562377) was a phase 2, double-blind, randomized, placebo-controlled trial taking place over 30 weeks. Eligible adults were randomized 1:1, with 107 patients receiving tralokinumab 300 mg and 108 patients receiving a placebo every 2 weeks for 16 weeks. All patients received Tdap (tetanus/diphtheria/pertussis) and meningococcal vaccines at week 12. The primary end points were positive antitetanus and antimeningococcal responses between weeks 12 and 16 (noninferiority margin, -25%; responder, >3-fold increase in IgG). RESULTS The noninferiority of tralokinumab versus placebo for immune response to Tdap (91.9% vs 96.1%) and meningococcal (86.0% vs 84.2%) vaccines was demonstrated at week 16. During treatment, the rates of adverse events were lower for tralokinumab than for the placebo, with most events being mild or moderate. LIMITATIONS Responses to other vaccines (including influenza) were not examined. CONCLUSIONS Treatment with tralokinumab 300 mg every 2 weeks did not affect immune responses to Tdap and meningococcal vaccines. Treatment was well tolerated when administered concomitantly with the vaccines and demonstrated a safety profile comparable to phase 3 trials.",2021,"Tralokinumab 300 mg q2w treatment did not affect immune responses to Tdap and meningococcal vaccines, and was well tolerated when administered concomitantly, with safety profile comparable to phase 3 trials.","['Adults With Moderate-to-severe Atopic Dermatitis', 'Eligible adults', 'tralokinumab-treated adults with moderate-to-severe AD']","['Tdap (tetanus/diphtheria/pertussis) and meningococcal vaccines', 'tralokinumab versus placebo', 'tralokinumab 300 mg or placebo', 'placebo', 'Tralokinumab', 'Placebo']","['positive anti-tetanus and anti-meningococcal responses', 'adverse-event rates']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C3658667', 'cui_str': 'tralokinumab'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0039614', 'cui_str': 'Tetanus'}, {'cui': 'C0012546', 'cui_str': 'Diphtheria'}, {'cui': 'C0031237', 'cui_str': 'Pertussis Vaccine'}, {'cui': 'C0700144', 'cui_str': 'Meningococcus vaccine'}, {'cui': 'C3658667', 'cui_str': 'tralokinumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0039614', 'cui_str': 'Tetanus'}, {'cui': 'C0127526', 'cui_str': 'Meningococcal polysaccharide vaccine'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.631567,"Tralokinumab 300 mg q2w treatment did not affect immune responses to Tdap and meningococcal vaccines, and was well tolerated when administered concomitantly, with safety profile comparable to phase 3 trials.","[{'ForeName': 'Joseph F', 'Initials': 'JF', 'LastName': 'Merola', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: jfmerola@bwh.harvard.edu.""}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Bagel', 'Affiliation': 'Eczema Treatment Center of New Jersey, East Windsor, New Jersey.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Almgren', 'Affiliation': 'LEO Pharma A/S, Ballerup, Denmark.'}, {'ForeName': 'Mads A', 'Initials': 'MA', 'LastName': 'Røpke', 'Affiliation': 'LEO Pharma A/S, Ballerup, Denmark.'}, {'ForeName': 'Katja W', 'Initials': 'KW', 'LastName': 'Lophaven', 'Affiliation': 'LEO Pharma A/S, Ballerup, Denmark.'}, {'ForeName': 'Natacha Strange', 'Initials': 'NS', 'LastName': 'Vest', 'Affiliation': 'LEO Pharma A/S, Ballerup, Denmark.'}, {'ForeName': 'Parbeer', 'Initials': 'P', 'LastName': 'Grewal', 'Affiliation': 'Division of Dermatology, University of Alberta, Edmonton, Canada.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2021.03.032'] 1210,33743283,SLC6A4 polymorphisms modulate the efficacy of a tryptophan-enriched diet on age-related depression and social cognition.,"BACKGROUND & AIMS In a placebo controlled study we sought to determine if a four-weeks tryptophan-enriched diet is able to improve age-related depression or social cognitive impairment, depending on polymorphisms located in the promoter region of Solute Carrier Family 6 Member 4 (SLC6A4), also known as serotonin transporter (SERT1) gene. METHODS 91 young volunteers (age: 21 ± 2 yrs) and 127 above 50 years old (58 ± 6 yrs) healthy volunteers completed the study. Participants from the placebo and tryptophan group followed the same protocol. Before starting the study blood samples, to measure serotonin-transporter-linked polymorphic region (5-HTTLPR) and rs25531 polymorphisms, were collected. In addition, before and after completing the study urine samples (to measure 5-hydroxyindolacetic acid (5-HIAA) were taken, while psychological questionnaires (to assess depression and social cognition levels), and a one week dietary record (to calculate the tryptophan (TRP) intake) were assessed. RESULTS The triallelic approach of SLC6A4 showed that in S'S´ subjects there was a positive correlation between TRP intake and 5-HIAA levels. Age of participants, SLC6A4 genotype, and experimental condition were important factors contributing to the outcome of depression and social cognition. CONCLUSIONS 5-HTTLPR and rs25531 polymorphisms play a key role in the response to the TRP- based nutritional intervention, improving only age-related depressive symptoms and empathy in S'S´ subjects who have a higher risk to show signs of depression during their lifetime.",2021,"Age of participants, SLC6A4 genotype, and experimental condition were important factors contributing to the outcome of depression and social cognition. ","['healthy volunteers', '91 young volunteers (age: 21\xa0±\xa02\xa0yrs) and 127 above 50 years old (58\xa0±\xa06\xa0yrs']","['placebo', 'tryptophan-enriched diet', 'placebo and tryptophan']","['TRP intake and 5-HIAA levels', 'tryptophan (TRP) intake']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0020361', 'cui_str': '5-hydroxyindole acetic acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",91.0,0.0537935,"Age of participants, SLC6A4 genotype, and experimental condition were important factors contributing to the outcome of depression and social cognition. ","[{'ForeName': 'Lierni', 'Initials': 'L', 'LastName': 'Ugartemendia', 'Affiliation': 'Department of Physiology, Neuroimmunophysiology and Chrononutrition Research Group, Faculty of Science, University of Extremadura, Badajoz, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Bravo', 'Affiliation': 'Department of Physiology, Neuroimmunophysiology and Chrononutrition Research Group, Faculty of Science, University of Extremadura, Badajoz, Spain. Electronic address: rbravo@unex.es.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Reuter', 'Affiliation': 'Biological & Personality Psychology, Laboratory of Neurogenetics, Department of Psychology, University of Bonn, Bonn, Germany.'}, {'ForeName': 'M Yolanda', 'Initials': 'MY', 'LastName': 'Castaño', 'Affiliation': 'Department of Physiology, Neuroimmunophysiology and Chrononutrition Research Group, Faculty of Science, University of Extremadura, Badajoz, Spain.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Plieger', 'Affiliation': 'Biological & Personality Psychology, Laboratory of Neurogenetics, Department of Psychology, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Zamoscik', 'Affiliation': 'Department of Clinical Psychology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kirsch', 'Affiliation': 'Department of Clinical Psychology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.'}, {'ForeName': 'Ana B', 'Initials': 'AB', 'LastName': 'Rodríguez', 'Affiliation': 'Department of Physiology, Neuroimmunophysiology and Chrononutrition Research Group, Faculty of Science, University of Extremadura, Badajoz, Spain.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2021.02.023'] 1211,33749349,Effects of a home-based rehabilitation program in community-dwelling older people after discharge from hospital: A subgroup analysis of a randomized controlled trial.,"OBJECTIVE To examine whether pre-admission community mobility explains the effects of a rehabilitation program on physical performance and activity in older adults recently discharged from hospital. DESIGN A secondary analysis of a randomized controlled trial. SETTING Home and community. PARTICIPANTS Community-dwelling adults aged ⩾60 years recovering from a lower limb or back injury, surgery or other disorder who were randomized to a rehabilitation ( n  = 59) or standard care control ( n  = 58) group. They were further classified into subgroups that were not planned a priori: (1) mild, (2) moderate, or (3) severe pre-admission restrictions in community mobility. INTERVENTIONS The 6-month intervention consisted of a motivational interview, goal attainment process, guidance for safe walking, a progressive home exercise program, physical activity counselling, and standard care. MEASUREMENTS Physical performance was measured with the Short Physical Performance Battery and physical activity with accelerometers and self-reports. Data were analysed by generalized estimating equation models with the interactions of intervention, time, and subgroup. RESULTS Rehabilitation improved physical performance more in the intervention ( n  = 30) than in the control group ( n  = 28) among participants with moderate mobility restriction: score of the Short Physical Performance Battery was 4.4 ± 2.3 and 4.2 ± 2.2 at baseline, and 7.3 ± 2.6 and 5.8 ± 2.9 at 6 months in the intervention and control group, respectively (mean difference 1.6 points, 95% Confidence Interval 0.2 to 3.1). Rehabilitation did not increase accelerometer-based physical activity in the aforementioned subgroup and did not benefit those with either mild or severe mobility restrictions. CONCLUSIONS Pre-admission mobility may determine the response to the largely counselling-based rehabilitation program.",2021,"RESULTS Rehabilitation improved physical performance more in the intervention ( n  = 30) than in the control group ( n  = 28) among participants with moderate mobility restriction: score of the Short Physical Performance Battery was 4.4 ± 2.3 and 4.2 ± 2.2 at baseline, and 7.3 ± 2.6 and 5.8 ± 2.9 at 6 months in the intervention and control group, respectively (mean difference 1.6 points, 95% Confidence Interval 0.2 to 3.1).","['Home and community', 'older adults recently discharged from hospital', 'Community-dwelling adults aged ⩾60\u2009years recovering from a lower limb or back injury, surgery or other disorder who were randomized to a rehabilitation ( n \u2009=\u200959) or', 'They were further classified into subgroups that were not planned a priori: (1) mild, (2) moderate, or (3) severe pre-admission restrictions in community mobility', 'community-dwelling older people after discharge from hospital']","['standard care control', 'motivational interview, goal attainment process, guidance for safe walking, a progressive home exercise program, physical activity counselling, and standard care', 'home-based rehabilitation program', 'rehabilitation program']","['Short Physical Performance Battery and physical activity with accelerometers and self-reports', 'moderate mobility restriction: score of the Short Physical Performance Battery', 'physical performance and activity', 'Physical performance', 'accelerometer-based physical activity', 'physical performance']","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0438953', 'cui_str': 'Discharged from hospital'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0004601', 'cui_str': 'Traumatic and/or non-traumatic injury of back'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0559269', 'cui_str': 'Pre-admission'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}]","[{'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]",,0.0374468,"RESULTS Rehabilitation improved physical performance more in the intervention ( n  = 30) than in the control group ( n  = 28) among participants with moderate mobility restriction: score of the Short Physical Performance Battery was 4.4 ± 2.3 and 4.2 ± 2.2 at baseline, and 7.3 ± 2.6 and 5.8 ± 2.9 at 6 months in the intervention and control group, respectively (mean difference 1.6 points, 95% Confidence Interval 0.2 to 3.1).","[{'ForeName': 'Turunen', 'Initials': 'T', 'LastName': 'Katri Maria', 'Affiliation': 'Gerontology Research Center, and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Aaltonen-Määttä', 'Initials': 'AM', 'LastName': 'Laura', 'Affiliation': 'Gerontology Research Center, and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Portegijs', 'Initials': 'P', 'LastName': 'Erja', 'Affiliation': 'Gerontology Research Center, and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Rantalainen', 'Initials': 'R', 'LastName': 'Timo', 'Affiliation': 'Gerontology Research Center, and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Keikkala', 'Initials': 'K', 'LastName': 'Sirkka', 'Affiliation': 'Health Centre Hospital, Health Centre of Jyväskylä Cooperation Area, City of Jyväskylä, Finland.'}, {'ForeName': 'Kinnunen', 'Initials': 'K', 'LastName': 'Marja-Liisa', 'Affiliation': 'Health Centre Hospital, Health Centre of Jyväskylä Cooperation Area, City of Jyväskylä, Finland.'}, {'ForeName': 'Sipilä', 'Initials': 'S', 'LastName': 'Sarianna', 'Affiliation': 'Gerontology Research Center, and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Nikander', 'Initials': 'N', 'LastName': 'Riku', 'Affiliation': 'Gerontology Research Center, and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}]",Clinical rehabilitation,['10.1177/02692155211001672'] 1212,33754207,The influence of chest X-ray results on antibiotic prescription for childhood pneumonia in the emergency department.,"The aim of this study is to evaluate the influence of chest X-ray (CXR) results on antibiotic prescription in children suspected of lower respiratory tract infections (RTI) in the emergency department (ED). We performed a secondary analysis of a stepped-wedge, cluster randomized trial of children aged 1 month to 5 years with fever and cough/dyspnoea in 8 EDs in the Netherlands (2016-2018), including a 1-week follow-up. We analysed the observational data of the pre-intervention period, using multivariable logistic regression to evaluate the influence of CXR result on antibiotic prescription. We included 597 children (median age 17 months [IQR 9-30, 61% male). CXR was performed in 109/597 (18%) of children (range across hospitals 9 to 50%); 52/109 (48%) showed focal infiltrates. Children who underwent CXR were more likely to receive antibiotics, also when adjusted for clinical signs and symptoms, hospital and CXR result (OR 7.25 [95% CI 2.48-21.2]). Abnormalities on CXR were not significantly associated with antibiotic prescription.Conclusion: Performance of CXR was independently associated with more antibiotic prescription, regardless of its results. The limited influence of CXR results on antibiotic prescription highlights the inferior role of CXR on treatment decisions for suspected lower RTI in the ED. What is Known: • Chest X-ray (CXR) has a high inter-observer variability and cannot distinguish between bacterial or viral pneumonia. • Current guidelines recommend against routine use of CXR in children with uncomplicated respiratory tract infections (RTIs) in the outpatient setting. What is New: • CXR is still frequently performed in non-complex children suspected of lower RTIs in the emergency department • CXR performance was independently associated with more antibiotic prescriptions, regardless of its results, highlighting the inferior role of chest X-rays in treatment decisions.",2021,"CXR performance was independently associated with more antibiotic prescriptions, regardless of its results, highlighting the inferior role of chest X-rays in treatment decisions.","['children with uncomplicated respiratory tract infections (RTIs', 'children aged 1 month to 5 years with fever and cough/dyspnoea in 8 EDs in the Netherlands (2016-2018), including a 1-week follow-up', 'children suspected of lower respiratory tract infections (RTI) in the emergency department (ED', 'childhood pneumonia in the emergency department', '597 children (median age 17 months [IQR 9-30, 61% male']","['CXR', '• Chest X-ray (CXR', 'chest X-ray (CXR']","['CXR', 'CXR performance', 'Abnormalities on CXR', 'focal infiltrates']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0035243', 'cui_str': 'Respiratory tract infection'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0149725', 'cui_str': 'Lower respiratory tract infection'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}]","[{'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}]",597.0,0.0512636,"CXR performance was independently associated with more antibiotic prescriptions, regardless of its results, highlighting the inferior role of chest X-rays in treatment decisions.","[{'ForeName': 'Josephine S', 'Initials': 'JS', 'LastName': 'van de Maat', 'Affiliation': ""Department of General Paediatrics, Erasmus MC - Sophia Children's Hospital, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands.""}, {'ForeName': 'Daniella', 'Initials': 'D', 'LastName': 'Garcia Perez', 'Affiliation': ""Department of General Paediatrics, Erasmus MC - Sophia Children's Hospital, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands.""}, {'ForeName': 'Gertjan J A', 'Initials': 'GJA', 'LastName': 'Driessen', 'Affiliation': ""Department of Paediatrics, HAGA-Juliana Children's Hospital, Den Haag, The Netherlands.""}, {'ForeName': 'Anne-Marie', 'Initials': 'AM', 'LastName': 'van Wermeskerken', 'Affiliation': 'Department of Paediatrics, Flevoziekenhuis, Almere, The Netherlands.'}, {'ForeName': 'Frank J', 'Initials': 'FJ', 'LastName': 'Smit', 'Affiliation': 'Department of Paediatrics, Maasstad Ziekenhuis, Rotterdam, The Netherlands.'}, {'ForeName': 'Jeroen G', 'Initials': 'JG', 'LastName': 'Noordzij', 'Affiliation': 'Department of Paediatrics, Reinier de Graaf Gasthuis, Delft, The Netherlands.'}, {'ForeName': 'Gerdien', 'Initials': 'G', 'LastName': 'Tramper-Stranders', 'Affiliation': 'Department of Paediatrics, Franciscus Gasthuis &Vlietland, locatie Gasthuis, Rotterdam, The Netherlands.'}, {'ForeName': 'Charlie C', 'Initials': 'CC', 'LastName': 'Obihara', 'Affiliation': 'Department of Paediatrics, Elisabeth Tweestedenziekenhuis, Tilburg, The Netherlands.'}, {'ForeName': 'Jeanine', 'Initials': 'J', 'LastName': 'Punt', 'Affiliation': 'Department of Paediatrics, Langeland Ziekenhuis, Zoetermeer, The Netherlands.'}, {'ForeName': 'Henriette A', 'Initials': 'HA', 'LastName': 'Moll', 'Affiliation': ""Department of General Paediatrics, Erasmus MC - Sophia Children's Hospital, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands.""}, {'ForeName': 'Rianne', 'Initials': 'R', 'LastName': 'Oostenbrink', 'Affiliation': ""Department of General Paediatrics, Erasmus MC - Sophia Children's Hospital, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands. r.oostenbrink@erasmusmc.nl.""}]",European journal of pediatrics,['10.1007/s00431-021-03996-2'] 1213,33752452,Dog training intervention improves adaptive social communication skills in young children with autism spectrum disorder: A controlled crossover study.,"LAY ABSTRACT There is some evidence that using therapy dogs for children with autism spectrum disorder generally results in improved social communication skills and reduced behavioral problems. However, well-controlled studies that examine its effectiveness are scarce. This study examined the effectiveness of a ""Dog Training Intervention."" The study included 73 participants diagnosed with autism spectrum disorder (61 males, 12 females) with age range of 2:10-7:6 years ( M = 4:10 ± 1:0) who attend autism spectrum disorder-specific special education schools. The study population was divided into two groups. Each group received the dog training intervention during one part of the school year (first half or second half) in addition to the standard interventions provided by the special education school settings. The dog training intervention was given twice weekly for 4 months within the school setting. The group that received the dog training intervention first showed a significant increase in adaptive social and communication skills in comparison to the second group that did not receive the intervention in this period. This improvement was maintained after the dog training intervention. The second group, which received intervention at the second half of the year, showed improvement in communication and socialization adaptive skills only during the period in which they received the dog training intervention. The positive impact on social communication adaptive skills of the dog training intervention among young children with autism spectrum disorder suggests that dogs may serve as an effective model for establishing social interaction. Dog training intervention appears to be an effective adjunct treatment to the interventions provided in special education schools for young children with autism spectrum disorder.",2021,Dog training intervention appears to be an effective adjunct treatment to the interventions provided in special education schools for young children with autism spectrum disorder.,"['young children with autism spectrum disorder', 'children with autism spectrum disorder', '73 participants diagnosed with autism spectrum disorder (61 males, 12 females) with age range of 2:10-7:6\u2009years ( M = 4:10 ± 1:0) who attend autism spectrum disorder-specific special education schools']","['Dog training intervention', 'Dog Training Intervention', 'dog training intervention', 'dog training intervention during one part of the school year (first half or second half) in addition to the standard interventions provided by the special education school settings']","['social communication adaptive skills', 'communication and socialization adaptive skills', 'adaptive social communication skills', 'social communication skills and reduced behavioral problems', 'adaptive social and communication skills']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0013649', 'cui_str': 'Special Education'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C0012984', 'cui_str': 'Canis lupus familiaris'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013649', 'cui_str': 'Special Education'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0037447', 'cui_str': 'Socialization'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}]",73.0,0.00276994,Dog training intervention appears to be an effective adjunct treatment to the interventions provided in special education schools for young children with autism spectrum disorder.,"[{'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Ben-Itzchak', 'Affiliation': 'Bruckner Autism Research Center, Department of Communication Disorders, Ariel University, Israel.'}, {'ForeName': 'Ditza A', 'Initials': 'DA', 'LastName': 'Zachor', 'Affiliation': 'The Autism Center/ALUT, Department of Pediatrics, Shamir Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel.'}]",Autism : the international journal of research and practice,['10.1177/13623613211000501'] 1214,33751155,Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low.,"PURPOSE Sertraline, a selective serotonin reuptake inhibitor (SSRI), is one of the most commonly used antidepressant during pregnancy. Plasma sertraline concentrations vary markedly between individuals, partly explained by variability in hepatic drug metabolizing cytochrome P450-enzyme activity. Our purpose was to study the variability in the plasma concentrations in pregnant women and the passage to their infants. METHOD Pregnant women with moderate untreated depression were recruited in 2016-2019 in Stockholm Region and randomized to treatment with sertraline or placebo. All received Internet-based cognitive behavior therapy as non-medical treatment. Sertraline plasma concentrations were measured around pregnancy weeks 21 and 30, at delivery, 1-month postpartum, in cord blood and at 48 h of age in the infant. The clinical course of the infants was followed. RESULTS Nine mothers and 7 infants were included in the analysis. Median dose-adjusted sertraline concentration in second trimester was 0.15(ng/mL) /(mg/day), in third trimester and at delivery 0.19 and 1-month postpartum 0.25, with a 67% relative difference between second trimester and postpartum. The interindividual variation was 10-fold. Median concentrations in the infants were 33% and 25% of their mothers', measured in cord blood, and infant plasma, respectively. Only mild and transient adverse effects were seen on the infants. CONCLUSION Placental passage of sertraline to the infant is low. However, the interindividual variation in maternal concentrations during pregnancy is huge, why therapeutic drug monitoring might assist in finding the poor metabolizers at risk for adversity and increase the safety of the treatment. TRIAL REGISTRATION The trial was registered at clinicaltrials.gov July 9, 2014 with TRN: NCT02185547.",2021,"Only mild and transient adverse effects were seen on the infants. ","['pregnant women and the passage to their infants', 'Nine mothers and 7 infants', 'pregnant women', 'Pregnant women with moderate untreated depression were recruited in 2016-2019 in Stockholm Region and randomized to treatment with']","['Sertraline', 'sertraline or placebo', 'Internet-based cognitive behavior therapy', 'sertraline']","['Plasma sertraline concentrations', 'Sertraline plasma concentrations', 'Median concentrations']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0439799', 'cui_str': 'Channel'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.0877344,"Only mild and transient adverse effects were seen on the infants. ","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Heinonen', 'Affiliation': 'Division of Paediatrics at the Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden. essi.heinonen@ki.se.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Blennow', 'Affiliation': 'Division of Paediatrics at the Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Blomdahl-Wetterholm', 'Affiliation': 'Psychiatry South West, Stockholm Healthcare Region, Stockholm, Sweden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hovstadius', 'Affiliation': 'Division of Paediatrics at the Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Nasiell', 'Affiliation': 'Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pohanka', 'Affiliation': 'Division of Clinical Pharmacology at the Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'L L', 'Initials': 'LL', 'LastName': 'Gustafsson', 'Affiliation': 'Division of Clinical Pharmacology at the Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Wide', 'Affiliation': 'Division of Paediatrics at the Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden.'}]",European journal of clinical pharmacology,['10.1007/s00228-021-03122-z'] 1215,33761970,"Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.","BACKGROUND Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic role of CTC counts in patients enrolled in the cTREnd study, a pre-planned translational sub-study of TREnd (NCT02549430), that randomized patients with ABC to palbociclib alone or palbociclib plus the endocrine therapy received in the prior line of treatment. Moreover, we evaluated RB1 gene expression on CTCs and explored its prognostic role within the cTREnd subpopulation. METHODS Forty-six patients with ER-positive, HER2-negative ABC were analyzed. Blood samples were collected before starting palbociclib treatment (timepoint T0), after the first cycle of treatment (timepoint T1), and at disease progression (timepoint T2). CTCs were isolated and counted by CellSearch® System using the CellSearch™Epithelial Cell kit. Progression-free survival (PFS), clinical benefit (CB) during study treatment, and time to treatment failure (TTF) after study treatment were correlated with CTC counts. Samples with ≥ 5 CTCs were sorted by DEPArray system® (DA). RB1 and GAPDH gene expression levels were measured by ddPCR. RESULTS All 46 patients were suitable for CTCs analysis. CTC count at T0 did not show significant prognostic value in terms of PFS and CB. Patients with at least one detectable CTC at T1 (n = 26) had a worse PFS than those with 0 CTCs (n = 16) (p = 0.02). At T1, patients with an increase of at least three CTCs showed reduced PFS compared to those with no increase (mPFS = 3 versus 9 months, (p = 0.004). Finally, patients with ≥ 5 CTCs at T2 (n = 6/23) who received chemotherapy as post-study treatment had a shorter TTF (p = 0.02). Gene expression data for RB1 were obtained from 19 patients. CTCs showed heterogeneous RB1 expression. Patients with detectable expression of RB1 at any timepoint showed better, but not statistically significant, outcomes than those with undetectable levels. CONCLUSIONS CTC count seems to be a promising modality in monitoring palbociclib response. Moreover, CTC count at the time of progression could predict clinical outcome post-palbociclib. RB1 expression analysis on CTCs is feasible and may provide additional prognostic information. Results should be interpreted with caution given the small studied sample size.",2021,6/23) who received chemotherapy as post-study treatment had a shorter TTF (p = 0.02).,"['patients enrolled in the cTREnd study, a pre-planned translational sub-study of TREnd', 'patients with ≥\u20095 CTCs at T2 (n\xa0', 'All 46 patients were suitable for CTCs analysis', 'patients with ER-positive, HER2-negative advanced breast cancer', 'patients with advanced breast cancer (ABC', 'Forty-six patients with ER-positive, HER2-negative ABC were analyzed']","['palbociclib alone or palbociclib plus the endocrine therapy', 'chemotherapy']","['time to treatment failure (TTF', 'PFS', 'Progression-free survival (PFS), clinical benefit (CB', 'RB1 and GAPDH gene expression levels', 'Blood samples', 'CTC count', 'heterogeneous RB1 expression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0040833', 'cui_str': 'trends'}, {'cui': 'C0027625', 'cui_str': 'Circulating Neoplastic Cells'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0279754', 'cui_str': 'ESR1 positive'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}]","[{'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C3494202', 'cui_str': 'Time to Treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0035335', 'cui_str': 'Retinoblastoma'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0027625', 'cui_str': 'Circulating Neoplastic Cells'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0242960', 'cui_str': 'Heterogeneity, Genetic'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",46.0,0.0938207,6/23) who received chemotherapy as post-study treatment had a shorter TTF (p = 0.02).,"[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Galardi', 'Affiliation': '""Sandro Pitigliani"" Translational Research Unit, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'De Luca', 'Affiliation': '""Sandro Pitigliani"" Translational Research Unit, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Biagioni', 'Affiliation': 'Bioinformatics Unit, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Ilenia', 'Initials': 'I', 'LastName': 'Migliaccio', 'Affiliation': '""Sandro Pitigliani"" Translational Research Unit, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Curigliano', 'Affiliation': 'Division of Early Drug Development, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.'}, {'ForeName': 'Alessandro M', 'Initials': 'AM', 'LastName': 'Minisini', 'Affiliation': 'Department of Oncology, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Bonechi', 'Affiliation': '""Sandro Pitigliani"" Translational Research Unit, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Moretti', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Risi', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'McCartney', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Benelli', 'Affiliation': 'Bioinformatics Unit, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Romagnoli', 'Affiliation': 'Bioinformatics Unit, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Cappadona', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Gabellini', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Guarducci', 'Affiliation': '""Sandro Pitigliani"" Translational Research Unit, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Valerio', 'Initials': 'V', 'LastName': 'Conti', 'Affiliation': ""Pediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Children's Hospital A. Meyer-University of Florence, Florence, Italy.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Biganzoli', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Di Leo', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Malorni', 'Affiliation': '""Sandro Pitigliani"" Translational Research Unit, Hospital of Prato, Prato, Italy. luca.malorni@uslcentro.toscana.it.'}]",Breast cancer research : BCR,['10.1186/s13058-021-01415-w'] 1216,33764538,Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.,"OBJECTIVE To assess long-term (up to 2 years) efficacy, tolerability, and safety of erenumab for the prevention of episodic migraine (EM) in Japanese patients. BACKGROUND Previously published results from the double-blind treatment phase (DBTP) of a phase 2 clinical study have demonstrated the efficacy and safety of erenumab in Japanese patients with EM. METHODS Patients completing the 24-week placebo-controlled DBTP could continue into the 76-week open-label treatment phase (OLTP), receiving erenumab 70 mg or 140 mg subcutaneously once monthly. The initial dose in the OLTP was erenumab 70 mg monthly, which was later changed to 140 mg. After study completion, the following were assessed: change from baseline in monthly migraine days (MMD), change from baseline in monthly acute migraine-specific medication days (MSMD), percentage of patients achieving ≥50% and ≥75% reduction in MMD, change from baseline in the 6-item Headache Impact Test (HIT-6™) score, and safety (exposure-adjusted patient-incidence of adverse events [AEs], calculated as number of patients per 100 patient-years). RESULTS Of 475 patients enrolled in the DBTP, 459 (96.6%) continued in the OLTP. The mean (SD) MMD was 7.9 (2.3) at baseline with the overall change from baseline at week 100 of -2.9 (4.1) days. The monthly acute MSMD was 5.7 (2.8) at baseline with change from baseline at week 100 of -1.7 (3.7) days. The proportion of patients who achieved ≥50% and ≥75% reduction in MMD from baseline at week 100 was 177/398 (44.5%) and 94/398 (23.6%), respectively. The HIT-6™ score was 58.4 (5.4) at baseline with a change of -6.4 (8.2) at week 100. The exposure-adjusted patient-incidence of AEs during the OLTP was 207.1/100 patient-years for the combined erenumab group, similar to that observed for either erenumab (271.0/100 patient-years) or placebo (257.3/100 patient-years) during the DBTP, and no new safety signals were detected during the OLTP. CONCLUSION Long-term erenumab treatment in Japanese patients with EM demonstrated sustained efficacy for up to 2 years, with a safety profile similar to previous studies, supporting erenumab as a potential new therapy for EM prevention in Japan.",2021,"Long-term erenumab treatment in Japanese patients with EM demonstrated sustained efficacy for up to 2 years, with a safety profile similar to previous studies, supporting erenumab as a potential new therapy for EM prevention in Japan.","['Japanese patients with episodic migraine', 'Patients completing the 24-week', 'Japanese patients with EM', '475 patients enrolled in the DBTP, 459 (96.6%) continued in the OLTP', 'Japanese patients']","['placebo-controlled DBTP', '76-week open-label treatment phase (OLTP), receiving erenumab 70 mg or 140\xa0mg subcutaneously once monthly', 'placebo', 'open-label erenumab treatment']","['6-item Headache Impact Test (HIT-6™) score, and safety', 'mean (SD) MMD', 'sustained efficacy', 'MMD', 'monthly acute MSMD', 'HIT-6™ score', 'monthly migraine days (MMD), change from baseline in monthly acute migraine-specific medication days (MSMD']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4517786', 'cui_str': '475'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C4542165', 'cui_str': 'erenumab'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0585302', 'cui_str': 'Once monthly'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1740836', 'cui_str': 'Acute migraine'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",475.0,0.357158,"Long-term erenumab treatment in Japanese patients with EM demonstrated sustained efficacy for up to 2 years, with a safety profile similar to previous studies, supporting erenumab as a potential new therapy for EM prevention in Japan.","[{'ForeName': 'Fumihiko', 'Initials': 'F', 'LastName': 'Sakai', 'Affiliation': 'Neurology, Saitama International Headache Center, Saitama, Japan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Takeshima', 'Affiliation': 'Headache Center, Department of Neurology, Tominaga Hospital, Osaka, Japan.'}, {'ForeName': 'Yoshihisa', 'Initials': 'Y', 'LastName': 'Tatsuoka', 'Affiliation': 'Department of Neurology, Tatsuoka Neurology Clinic, Kyoto, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Hirata', 'Affiliation': 'Department of Neurology, Dokkyo Medical University, Tochigi, Japan.'}, {'ForeName': 'Sunfa', 'Initials': 'S', 'LastName': 'Cheng', 'Affiliation': 'Global Development, Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Yotaro', 'Initials': 'Y', 'LastName': 'Numachi', 'Affiliation': 'Research & Development, Amgen K.K., Tokyo, Japan.'}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Peng', 'Affiliation': 'Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Xue', 'Affiliation': 'Global Safety, Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Mikol', 'Affiliation': 'Global Development, Amgen Inc., Thousand Oaks, CA, USA.'}]",Headache,['10.1111/head.14096'] 1217,33725153,"Is fresh, leucodepleted, whole blood transfusion superior to blood component transfusion in pediatric patients undergoing spinal deformity surgeries? A prospective, randomized study analyzing postoperative serological parameters and clinical recovery.","PURPOSE To compare the effectiveness of fresh whole blood (FWB) and blood component transfusion in improving clinical outcome and serological parameters in the early postoperative period following spinal deformity surgery. METHODS Patients undergoing major spinal deformity surgeries involving ≥ 6 levels of fusion and expected blood loss ≥ 750 ml between September 2017 and August 2018 were included in the study. The patients were randomized into two groups: FWBG and CG, receiving fresh whole blood and component transfusions, respectively. RESULTS A total of 65 patients with spinal deformities of different etiologies were included. The mean age was 14.0 and 14.9 years in FWB and CG, respectively. All other preoperative parameters were comparable. The mean fusion levels and surgical time were 11.1 and 221.20 min in FWB, as compared with 10.70 and 208.74minutes in CG, respectively. Intraoperative blood losses were 929 ml (FWBG) and 847 ml(CG), and the mean volumes of transfusion were 1.90 (FWBG) and 1.65 units (CG). FWBG was significantly superior to CG in the following clinical and laboratory parameters: duration of oxygen dependence [36.43 (FWBG) vs. 43.45 h (CG); P = 0.0256], mean arterial pH [7.442 (FWBG) vs. 7.394 (CG); p < 0.001], interleukin-6 [30.04 (FWBG) vs. 35.10 (CG); p < 0.019], mean duration of HDU stay [40.6 hours (FWBG) vs 46.51 hours (CG); p = 0.0234] and postoperative facial puffiness [7/30 in FWBG vs. 18/35 (CG) (P < 0.02)]. CONCLUSION FWB transfusion can potentially improve the immediate postoperative outcome in patients undergoing major spinal deformity surgeries by reducing the duration of intensive care unit stay and oxygen dependence. The other potential benefits of this practice, based on our study, include a reduced inflammatory response (reduced lactate and IL-6) and postoperative facial puffiness. However, further large-scale validation studies in future are necessary to precisely determine the role of FWB in spine surgeries. LEVEL OF EVIDENCE II Diagnostic: individual cross-sectional studies with the consistently applied reference standard and blinding.",2021,"FWBG was significantly superior to CG in the following clinical and laboratory parameters: duration of oxygen dependence [36.43 (FWBG) vs. 43.45 h (CG); P = 0.0256], mean arterial pH [7.442 (FWBG) vs. 7.394 (CG); p < 0.001], interleukin-6 [30.04 (FWBG) vs. 35.10 (CG); p < 0.019], mean duration of HDU stay [40.6 hours (FWBG) vs 46.51 hours (CG); p = 0.0234] and postoperative facial puffiness [7/30 in FWBG vs. 18/35 (CG) (P < 0.02)]. ","['patients undergoing major spinal deformity surgeries', 'pediatric patients undergoing spinal deformity surgeries', '65 patients with spinal deformities of different etiologies were included', '750\xa0ml between September 2017 and August 2018 were included in the study', 'Patients undergoing major spinal deformity surgeries involving\u2009≥\u20096 levels of fusion and expected blood loss\u2009≥']","['FWB transfusion', 'fresh whole blood (FWB) and blood component transfusion', 'FWBG and CG, receiving fresh whole blood and component transfusions, respectively']","['Intraoperative blood losses', 'postoperative facial puffiness', 'mean volumes of transfusion', 'mean duration of HDU stay', 'FWBG', 'mean arterial pH', 'inflammatory response (reduced lactate and IL-6) and postoperative facial puffiness', 'mean fusion levels and surgical time', 'oxygen dependence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0575157', 'cui_str': 'Deformity of spine'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]","[{'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0199961', 'cui_str': 'Transfusion of whole blood'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0449432', 'cui_str': 'Component'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0151602', 'cui_str': 'Facial swelling'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0428199', 'cui_str': 'pH measurement, arterial'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}]",65.0,0.0492428,"FWBG was significantly superior to CG in the following clinical and laboratory parameters: duration of oxygen dependence [36.43 (FWBG) vs. 43.45 h (CG); P = 0.0256], mean arterial pH [7.442 (FWBG) vs. 7.394 (CG); p < 0.001], interleukin-6 [30.04 (FWBG) vs. 35.10 (CG); p < 0.019], mean duration of HDU stay [40.6 hours (FWBG) vs 46.51 hours (CG); p = 0.0234] and postoperative facial puffiness [7/30 in FWBG vs. 18/35 (CG) (P < 0.02)]. ","[{'ForeName': 'P Keerthi', 'Initials': 'PK', 'LastName': 'Vasan', 'Affiliation': 'Department of Spine Surgery, Ganga Medical Centre and Hospital, 313, Mettupalayam Road, Sai Baba Colony, Coimbatore, Tamil Nadu, 641001, India.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Rajasekaran', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Medical Centre and Hospital, 313, Mettupalayam Road, Sai Baba Colony, Coimbatore, Tamil Nadu, 641001, India. rajasekaran.orth@gmail.com.'}, {'ForeName': 'Vibhu Krishnan', 'Initials': 'VK', 'LastName': 'Viswanathan', 'Affiliation': 'Department of Spine Surgery, Ganga Medical Centre and Hospital, 313, Mettupalayam Road, Sai Baba Colony, Coimbatore, Tamil Nadu, 641001, India.'}, {'ForeName': 'Ajoy Prasad', 'Initials': 'AP', 'LastName': 'Shetty', 'Affiliation': 'Department of Spine Surgery, Ganga Medical Centre and Hospital, 313, Mettupalayam Road, Sai Baba Colony, Coimbatore, Tamil Nadu, 641001, India.'}, {'ForeName': 'Rishi Mugesh', 'Initials': 'RM', 'LastName': 'Kanna', 'Affiliation': 'Department of Spine Surgery, Ganga Medical Centre and Hospital, 313, Mettupalayam Road, Sai Baba Colony, Coimbatore, Tamil Nadu, 641001, India.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-021-06798-0'] 1218,33740610,Prospective evaluation of third-generation small bowel capsule endoscopy videos by independent readers demonstrates poor reproducibility of cleanliness classifications.,"OBJECTIVE The detection of lesions during small bowel (SB) capsule endoscopy (CE) depends on the cleanliness of the intestine. Quality reporting and comparison of different preparation methods require reliable scores. Three scores known as quantitative index (QI), qualitative evaluation (QE), and overall adequacy assessment (OAA), have been proposed to assess SB cleanliness, and are sometimes used in clinical practice and in clinical trials. However, none of these scores has received any external validation. The aim of our study was to re-assess the reproducibility of these three specific scores. METHODS One-hundred-and-fifty-five complete third-generation SB-CE video recordings were extracted from a multicenter randomized controlled trial (PREPINTEST) which evaluated three modalities of SB preparation for CE. Three experts independently read the 155 SB-CE video recordings twice, in a random order, over 48 -h periods at 6-week intervals, using the QI, QE and OAA scores. Cohen's linearly weighted kappa coefficients were calculated to assess intra-observer and inter-observer agreements. RESULTS Intra-observer reproducibility was fair to moderate, with kappa coefficients between 0.37 and 0.46 for QI, 0.41 and 0.51 for QE, 0.41 and 0.50 for OAA. Inter-observer reproducibility was fair to substantial according to kappa coefficients between experts varying from 0.40 to 0.64, 0.29 to 0.65, and 0.52 to 0.71, for QI, QE and OAA, respectively. CONCLUSIONS QI, QE and OAA scores, currently used for evaluation of the quality of the preparation of SB-CE, are not sufficiently reproducible. Other scores or methods are therefore needed for SB-CE cleanliness assessment.",2021,"Inter-observer reproducibility was fair to substantial according to kappa coefficients between experts varying from 0.40 to 0.64, 0.29 to 0.65, and 0.52 to 0.71, for QI, QE and OAA, respectively. ",['One-hundred-and-fifty-five complete third-generation SB-CE video recordings'],['third-generation small bowel capsule endoscopy videos'],"['QE and OAA scores', 'quantitative index (QI), qualitative evaluation (QE), and overall adequacy assessment (OAA']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C4285996', 'cui_str': 'Small bowel capsule endoscopy'}, {'cui': 'C0042650', 'cui_str': 'Audiovisual Recording'}]","[{'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C4285996', 'cui_str': 'Small bowel capsule endoscopy'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0034375', 'cui_str': 'Qualitative Evaluation'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",,0.0530148,"Inter-observer reproducibility was fair to substantial according to kappa coefficients between experts varying from 0.40 to 0.64, 0.29 to 0.65, and 0.52 to 0.71, for QI, QE and OAA, respectively. ","[{'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Dray', 'Affiliation': 'Sorbonne University, Center for Digestive Endoscopy, Hôpital Saint-Antoine, APHP, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France. Electronic address: xavier.dray@aphp.fr.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Houist', 'Affiliation': 'Department of Hepato-Gastroenterology, Centre Hospitalier du Sud Francilien, 40 Avenue Serge Dassault, 91100 Corbeil-Essonnes, France.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Le Mouel', 'Affiliation': 'Department of Hepato-Gastroenterology, Amiens University Hospital, Amiens, France.'}, {'ForeName': 'Jean-Christophe', 'Initials': 'JC', 'LastName': 'Saurin', 'Affiliation': 'Department of Hepato-gastroenterology, E. Herriot Hospital, Hospices Civils de Lyon, France.'}, {'ForeName': 'Geoffroy', 'Initials': 'G', 'LastName': 'Vanbiervliet', 'Affiliation': ""Department of Hepato-Gastroenterology, L'Archet 2 Hospital, Nice University Hospital, Nice, F-06202 Cedex 3, France.""}, {'ForeName': 'Chloé', 'Initials': 'C', 'LastName': 'Leandri', 'Affiliation': 'Department of Hepato-Gastroenterology, Cochin Hospital, AP-HP, 75014, Paris, France.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Rahmi', 'Affiliation': 'Department of Hepato-Gastroenterology, Georges Pompidou European Hospital, AP-HP, Paris Descartes University, France.'}, {'ForeName': 'Clotilde', 'Initials': 'C', 'LastName': 'Duburque', 'Affiliation': 'Delegations for Clinical Research and Innovation - Department of Gastroenterology Lille Catholic Hospitals - Lille Catholic University, Lille, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Kirchgesner', 'Affiliation': 'Sorbonne University and Department of Gastroenterology, Hôpital Saint-Antoine, Paris, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Leenhardt', 'Affiliation': 'Sorbonne University, Center for Digestive Endoscopy, Hôpital Saint-Antoine, APHP, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Cholet', 'Affiliation': 'Department of Hepato-Gastroenterology, Brest University Hospital, Bd Tanguy Prigent, 29200 BREST, France.'}]",Clinics and research in hepatology and gastroenterology,['10.1016/j.clinre.2020.101612'] 1219,33738521,Yoga-An Alternative Form of Therapy in Patients with Blunt Chest Trauma: A Randomized Controlled Trial.,"BACKGROUND Yoga as alternative form of therapy has shown positive impact on pulmonary functions, exercise capacity, behavioral changes, and inflammation in non-trauma patients. However, the efficacy of Yoga has not been studied in chest trauma patients. METHODS This randomized controlled trial was conducted at level-1 Trauma Centre. Isolated chest injury patients were randomized into either standard physiotherapy or Yogatherapy groups. Patients in physiotherapy group received conventional chest physiotherapy and Yogatherapy group received a set of Yogic exercises in addition to conventional chest physiotherapy. Primary outcome measure was changes in pulmonary function tests (PFT) at 4 weeks of discharge. Secondary outcomes were changes in quality of life (QoL), respiratory muscle strength and endurance, chest wall mobility, and levels of cytokines at 4 weeks. Data were analyzed using STATA v14.0. RESULTS A total of 89 eligible patients were randomized to physiotherapy (n = 46) and Yoga therapy (n = 43) groups. Demographic characteristics were comparable in both the groups. There were statistically significant improvements in PFT in the Yogatherapy group compared with physiotherapy with an increase in Forced vital capacity (p = 0.02) and Forced expiratory volume (p = 0.01) at 4 weeks. In addition, there were significant improvement in physical component of QoL, respiratory muscle endurance (p = 0.003) and axillary cirtometry (p = 0.009) in the Yogatherapy group. However, no statistically significant difference in the trends of cytokine markers seen between the groups. CONCLUSION Yoga was found to be effective in improving pulmonary functions and QoL in patients with chest trauma. (Trial registered at ctri.nic.in/clinicaltrials/login.php, numberREF/2016/05/011,287).",2021,There were statistically significant improvements in PFT in the Yogatherapy group compared with physiotherapy with an increase in Forced vital capacity (p = 0.02) and Forced expiratory volume (p = 0.01) at 4 weeks.,"['89 eligible patients', 'Isolated chest injury patients', 'chest trauma patients', 'patients with chest trauma', 'Patients with Blunt Chest Trauma', 'non-trauma patients']","['Yoga therapy', 'standard physiotherapy or Yogatherapy', 'physiotherapy', 'conventional chest physiotherapy and Yogatherapy group received a set of Yogic exercises in addition to conventional chest physiotherapy', 'Yoga-An Alternative Form of Therapy']","['changes in pulmonary function tests (PFT', 'cytokine markers', 'Forced expiratory volume', 'axillary cirtometry', 'Demographic characteristics', 'physical component of QoL, respiratory muscle endurance', 'pulmonary functions and QoL', 'Forced vital capacity', 'changes in quality of life (QoL), respiratory muscle strength and endurance, chest wall mobility, and levels of cytokines at 4\xa0weeks', 'PFT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0039980', 'cui_str': 'Chest injury'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0199467', 'cui_str': 'Physiotherapy of chest'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0004454', 'cui_str': 'Axillary'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0205076', 'cui_str': 'Chest wall structure'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439230', 'cui_str': 'week'}]",89.0,0.0569644,There were statistically significant improvements in PFT in the Yogatherapy group compared with physiotherapy with an increase in Forced vital capacity (p = 0.02) and Forced expiratory volume (p = 0.01) at 4 weeks.,"[{'ForeName': 'Mallikarjun', 'Initials': 'M', 'LastName': 'Gunjiganvi', 'Affiliation': 'Sanjay Gandhi Post Graduate Institute of Medical Sciences, Specialty of Trauma Surgery, Apex Trauma Center, Lucknow, India.'}, {'ForeName': 'Purva', 'Initials': 'P', 'LastName': 'Mathur', 'Affiliation': 'Department of Laboratory Medicine, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Minu', 'Initials': 'M', 'LastName': 'Kumari', 'Affiliation': 'Division of Trauma Surgery and Critical Care, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Karan', 'Initials': 'K', 'LastName': 'Madan', 'Affiliation': 'Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Atin', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': 'Department of Radiology, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Sagar', 'Affiliation': 'Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Sushma', 'Initials': 'S', 'LastName': 'Sagar', 'Affiliation': 'Division of Trauma Surgery and Critical Care, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Gupta', 'Affiliation': 'Division of Trauma Surgery and Critical Care, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Biplab', 'Initials': 'B', 'LastName': 'Mishra', 'Affiliation': 'Division of Trauma Surgery and Critical Care, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Altaf Hussain', 'Initials': 'AH', 'LastName': 'Mir', 'Affiliation': 'Department of Physiotherapy, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Mohini', 'Initials': 'M', 'LastName': 'Meti', 'Affiliation': 'Division of Trauma Surgery and Critical Care, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Subodh', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Division of Trauma Surgery and Critical Care, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India. subodh6@gmail.com.'}]",World journal of surgery,['10.1007/s00268-021-06057-9'] 1220,33713841,"Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis.","INTRODUCTION With the growing use of online study management systems and rapid availability of data, timely data review and quality assessments are necessary to ensure proper clinical trial implementation. In this report we describe central monitoring used to ensure protocol compliance and accurate data reporting, implemented during a large phase 3 clinical trial. MATERIAL AND METHODS The Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) study A5349 (S31) is an international, multi-site, randomized, open-label, controlled, non-inferiority phase 3 clinical trial comparing two 4-month regimens to a standard 6 month regimen for treatment of drug-susceptible tuberculosis (TB) among adolescents and adults with a sample size of 2500 participants. RESULTS Central monitoring utilized primary study data in a five-tiered approach, including (1) real-time data checks & topic-specific intervention reports, (2) missing forms reports, (3) quality assurance metrics, (4) critical data reports and (5) protocol deviation identification, aimed to detect and resolve quality challenges. Over the course of the study, 240 data checks and reports were programed across the five tiers used. DISCUSSION This use of primary study data to identify issues rapidly allowed the study sponsor to focus quality assurance and data cleaning activities on prioritized data, related to protocol compliance and accurate reporting of study results. Our approach enabled us to become more efficient and effective as we informed sites about deviations, resolved missing or inconsistent data, provided targeted guidance, and gained a deeper understanding of challenges experienced at clinical trial sites. TRIAL REGISTRATION This trial was registered with ClinicalTrials.gov (Identifier: NCT02410772) on April 8, 2015.",2021,"Our approach enabled us to become more efficient and effective as we informed sites about deviations, resolved missing or inconsistent data, provided targeted guidance, and gained a deeper understanding of challenges experienced at clinical trial sites. ","['pulmonary tuberculosis', 'adolescents and adults with a sample size of 2500 participants']",[],[],"[{'cui': 'C0041327', 'cui_str': 'Pulmonary tuberculosis'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C4319601', 'cui_str': '2500'}]",[],[],2500.0,0.338964,"Our approach enabled us to become more efficient and effective as we informed sites about deviations, resolved missing or inconsistent data, provided targeted guidance, and gained a deeper understanding of challenges experienced at clinical trial sites. ","[{'ForeName': 'Kia E', 'Initials': 'KE', 'LastName': 'Bryant', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America. Electronic address: kebryant@cdc.gov.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Engle', 'Affiliation': 'Audie L. Murphy Veterans Affairs Medical Center, University of Texas Health Science Center, San Antonio, TX, United States of America.'}, {'ForeName': 'Ekaterina V', 'Initials': 'EV', 'LastName': 'Kurbatova', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Allen-Blige', 'Affiliation': 'Peraton, Herndon, VA, United States of America.'}, {'ForeName': 'Kumar', 'Initials': 'K', 'LastName': 'Batra', 'Affiliation': 'Peraton, Herndon, VA, United States of America.'}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Brown', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Kuo Wei', 'Initials': 'KW', 'LastName': 'Chiu', 'Affiliation': 'Peraton, Herndon, VA, United States of America.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Davis', 'Affiliation': 'Peraton, Herndon, VA, United States of America.'}, {'ForeName': 'Mascha', 'Initials': 'M', 'LastName': 'Elskamp', 'Affiliation': 'Columbia University Irving Medical Center, New York, NY, United States of America.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Fagley', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Fedrick', 'Affiliation': 'Peraton, Herndon, VA, United States of America.'}, {'ForeName': 'Kimberley N C', 'Initials': 'KNC', 'LastName': 'Hedges', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America; Peraton, Herndon, VA, United States of America.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Narunsky', 'Affiliation': 'University of Cape Town Lung Institute, Cape Town, South Africa.'}, {'ForeName': 'Joanita', 'Initials': 'J', 'LastName': 'Nassali', 'Affiliation': 'Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Mimi', 'Initials': 'M', 'LastName': 'Phan', 'Affiliation': 'Northrop Grumman Corporation, San Diego, CA, United States of America.'}, {'ForeName': 'Ha', 'Initials': 'H', 'LastName': 'Phan', 'Affiliation': 'Vietnam National Tuberculosis Program, University of California San Francisco Research Collaboration, Hanoi, Viet Nam.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Purfield', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America; US Public Health Service Commissioned Corps, Rockville, MD, United States of America.'}, {'ForeName': 'Jessica N', 'Initials': 'JN', 'LastName': 'Ricaldi', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Robergeau-Hunt', 'Affiliation': 'Westat, Rockville, MD, United States of America.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Whitworth', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Sizemore', 'Affiliation': 'U.S. Centers for Disease Control & Prevention, Atlanta, GA, United States of America.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2021.106355'] 1221,33713840,Design of CLARO (Collaboration Leading to Addiction Treatment and Recovery from other Stresses): A randomized trial of collaborative care for opioid use disorder and co-occurring depression and/or posttraumatic stress disorder.,"INTRODUCTION Opioid use disorder (OUD) co-occurring with depression and/or posttraumatic stress disorder (PTSD) is common and, if untreated, may lead to devastating consequences. Despite the availability of evidence-based treatments for these disorders, receipt of treatment is low. Even when treatment is provided, quality is variable. Primary care is an important and underutilized setting for treating co-occurring disorders (COD) because OUD, depression and PTSD are frequently co-morbid with medical conditions and most people visit a primary care provider at least once a year. With rising rates of OUD and opioid-related fatalities, this is a critical treatment and quality gap in a vulnerable and stigmatized population. METHODS CLARO (Collaboration Leading to Addiction Treatment and Recovery from Other Stresses) is a multi-site, randomized pragmatic trial of collaborative care (CC) for co-occurring disorders in 13 rural and urban primary care clinics in New Mexico to improve care for patients with OUD and co-occurring depression and/or PTSD. CC, a service delivery approach that uses multi-faceted interventions, has not been tested with COD. We will enroll and randomize 900 patients to either CC adapted for COD (CC-COD) or enhanced usual care (EUC) and will collect patient data at baseline, 3-, and 6-month follow-up. Our primary outcomes are medications for OUD (MOUD) access, MOUD continuity of care, depression symptoms, and PTSD symptoms. DISCUSSION Although CC is effective for improving outcomes in primary care among patients with mental health conditions, it has not been tested for COD. This article describes the CLARO CC-COD intervention and clinical trial.",2021,"Although CC is effective for improving outcomes in primary care among patients with mental health conditions, it has not been tested for COD.","['13 rural and urban primary care clinics in New Mexico to improve care for patients with OUD and co-occurring depression and/or PTSD', 'patients with mental health conditions']","['collaborative care (CC', 'CLARO CC-COD intervention', 'CLARO', 'CC', 'CC adapted for COD (CC-COD) or enhanced usual care (EUC']","['medications for OUD (MOUD) access, MOUD continuity of care, depression symptoms, and PTSD symptoms']","[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0027972', 'cui_str': 'New Mexico'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0009853', 'cui_str': 'Continuity of Care'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.126415,"Although CC is effective for improving outcomes in primary care among patients with mental health conditions, it has not been tested for COD.","[{'ForeName': 'Lisa S', 'Initials': 'LS', 'LastName': 'Meredith', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90407-2138, USA; VA HSR&D Center for Healthcare Innovation, Implementation & Policy, Sepulveda, CA, USA. Electronic address: lisa_meredith@rand.org.'}, {'ForeName': 'Miriam S', 'Initials': 'MS', 'LastName': 'Komaromy', 'Affiliation': 'Grayken Center for Addiction, Boston Medical Center, Boston, MA 02118, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Cefalu', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90407-2138, USA.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Murray-Krezan', 'Affiliation': 'University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Page', 'Affiliation': 'University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.'}, {'ForeName': 'Karen Chan', 'Initials': 'KC', 'LastName': 'Osilla', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90407-2138, USA.'}, {'ForeName': 'Alex R', 'Initials': 'AR', 'LastName': 'Dopp', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90407-2138, USA.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Leamon', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90407-2138, USA.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Tarhuni', 'Affiliation': 'University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Hindmarch', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90407-2138, USA.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Jacobsohn', 'Affiliation': 'First Choice Community Healthcare, 2001 North Centro Familiar, Albuquerque, NM 87105, USA.'}, {'ForeName': 'Katherine E', 'Initials': 'KE', 'LastName': 'Watkins', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90407-2138, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2021.106354'] 1222,33750646,"Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.","PURPOSE SPN-812 (viloxazine extended-release) is under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. This Phase III study evaluated the efficacy and tolerability of SPN-812 200 and 400 mg once daily in children 6-11 years of age with ADHD. METHODS Patients were randomly assigned to receive SPN-812 200 mg, SPN-812 400 mg, or placebo, once daily for 8 weeks (including ≤3 weeks titration period). The primary efficacy endpoint was the change from baseline (CFB) in ADHD Rating Scale (RS)-5 Total score at end of study (EOS). Key secondary endpoints included Clinical Global Impression-Improvement (CGI-I) score at EOS, CFB in Conners 3-Parent Short Form (PS) composite T-score at EOS, and CFB in Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) Total average score at EOS. FINDINGS A total of 313 patients were enrolled, with 301 in the intent-to-treat population (194 boys, 107 girls; mean age [SD], 8.4 [1.7] years). At EOS, the CFBs in ADHD-RS-5 Total score and CGI-I score were significantly improved with both 200- and 400-mg/d SPN-812 versus placebo (ADHD-RS-5, P = 0.0038 and 0.0063, respectively; CGI-I, P = 0.0028 and 0.0099). At EOS, the CFB in Conners 3-PS composite T-score was significantly improved with 200- (P = 0.0064), but not 400-mg/d (P = 0.0917), SPN-812 compared to placebo. No significant difference between the groups was found in WFIRS-P Total average score. The rate of discontinuations due to adverse events in both SPN-812 treatment groups combined was <5%. IMPLICATIONS SPN-812 200 and 400 mg once daily was associated with improvements in ADHD symptoms in school-aged children and was generally well tolerated. ClinicalTrials.gov identifier: NCT03247543.",2021,SPN-812 200 and 400 mg once daily was associated with improvements in ADHD symptoms in school-aged children and was generally well tolerated.,"['children 6-11 years of age with ADHD', '313 patients were enrolled, with 301 in the intent-to-treat population (194 boys, 107 girls; mean age [SD], 8.4 [1.7] years', 'children and adolescents', 'Patients', 'School-aged Children']","['SPN-812 (viloxazine extended-release', 'SPN-812\xa0200\xa0mg, SPN-812\xa0400\xa0mg, or placebo', '43:XXX-XXX', 'placebo', 'SPN-812']","['tolerated', 'change from baseline (CFB) in ADHD Rating Scale (RS)-5 Total score at end of study (EOS', 'efficacy and tolerability', 'WFIRS-P Total average score', 'CFBs in ADHD-RS-5 Total score and CGI-I score', 'rate of discontinuations due to adverse events', 'Total average score at EOS', 'ADHD symptoms', 'CFB in Conners 3-PS composite T-score', 'Clinical Global Impression-Improvement (CGI-I) score at EOS, CFB in Conners 3-Parent Short Form (PS) composite T-score at EOS, and CFB in Weiss Functional Impairment Rating Scale-Parent (WFIRS-P']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C4517707', 'cui_str': '313'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C2350019', 'cui_str': 'Solitary nodule of lung'}, {'cui': 'C0042665', 'cui_str': 'Viloxazine'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C3854607', 'cui_str': 'T score'}]",313.0,0.203645,SPN-812 200 and 400 mg once daily was associated with improvements in ADHD symptoms in school-aged children and was generally well tolerated.,"[{'ForeName': 'Azmi', 'Initials': 'A', 'LastName': 'Nasser', 'Affiliation': 'Supernus Pharmaceuticals, Inc., Rockville, MD, USA. Electronic address: anasser@supernus.com.'}, {'ForeName': 'Tesfaye', 'Initials': 'T', 'LastName': 'Liranso', 'Affiliation': 'Supernus Pharmaceuticals, Inc., Rockville, MD, USA.'}, {'ForeName': 'Toyin', 'Initials': 'T', 'LastName': 'Adewole', 'Affiliation': 'Supernus Pharmaceuticals, Inc., Rockville, MD, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Fry', 'Affiliation': 'Supernus Pharmaceuticals, Inc., Rockville, MD, USA.'}, {'ForeName': 'Joseph T', 'Initials': 'JT', 'LastName': 'Hull', 'Affiliation': 'Supernus Pharmaceuticals, Inc., Rockville, MD, USA.'}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Chowdhry', 'Affiliation': 'Supernus Pharmaceuticals, Inc., Rockville, MD, USA.'}, {'ForeName': 'Gregory D', 'Initials': 'GD', 'LastName': 'Busse', 'Affiliation': 'Supernus Pharmaceuticals, Inc., Rockville, MD, USA.'}, {'ForeName': 'Zare', 'Initials': 'Z', 'LastName': 'Melyan', 'Affiliation': 'Supernus Pharmaceuticals, Inc., Rockville, MD, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Cutler', 'Affiliation': 'SUNY Upstate Medical University, and Neuroscience Education Institute, Lakewood Ranch, FL, USA.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Findling', 'Affiliation': 'School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schwabe', 'Affiliation': 'Supernus Pharmaceuticals, Inc., Rockville, MD, USA.'}]",Clinical therapeutics,['10.1016/j.clinthera.2021.01.027'] 1223,33759278,Visual illusions modulate body perception disturbance and pain in Complex Regional Pain Syndrome: A randomized trial.,"BACKGROUND Effective treatment of longstanding Complex Regional Pain Syndrome (CRPS) is a challenge, as causal mechanisms remain elusive. People with CRPS frequently report distorted subjective perceptions of their affected limb. Evidence of pain reduction when the affected limb is visually altered in size suggests that visual illusions used to target central processing could restore coherence of this disrupted limb representation. We hypothesized that using virtual reality that alters hand image to match the patient's desired hand appearance would improve body perception disturbance and pain. Also, repeated exposure would maintain any therapeutic effect. METHODS A blinded randomized controlled trial of 45 participants with refractory upper-limb CRPS and body perception disturbance (BPD) viewed a digital image of their affected hand for 1 min. The image was digitally altered according to the patient's description of how they desired their hand to look in the experimental group and unaltered in the control group. BPD and pain were measured pre- and post-intervention. A subgroup was followed up 2 weeks after a course of repeated interventions. RESULTS BPD (mean-6, ±SD 7.9, p = 0.036, effect size [ES] = 0.6) and pain intensity (mean-0.43, ±SD 1.3, p = 0.047, ES = 0.5) reduced in 23 participants after single exposure compared to controls (n = 22). At follow-up, the subgroup (experimental n = 21; control n = 18) showed sustained pain reduction only (p = 0.037, ±SD 1.9, ES = 0.7), with an overall 1.2 decrease on an 11-point scale. CONCLUSIONS Visually changing the CRPS hand to a desired appearance modulates BPD and pain suggesting therapeutic potential for those with refractory CRPS. Further research to optimize this therapeutic effect is required. SIGNIFICANCE Visual bodily illusions that change the shape and appearance of the painful CRPS hand to that desired by the patient result in a rapid amelioration of pain and body perception disturbance in people with longstanding CRPS. These findings highlight the future potential of this drug-free approach in the treatment of refractory CRPS.",2021,"At follow-up, the subgroup (experimental n=21; control n=18) showed sustained pain reduction only (p=0.037, ±SD 1.9, ES=0.7), with an overall 1.2 decrease on an 11-point scale. ","['45 participants with refractory upper-limb CRPS and body perception disturbance (BPD) viewed a digital image of their affected hand for one minute', 'longstanding Complex Regional Pain Syndrome (CRPS', 'Complex Regional Pain Syndrome', '23 participants after single exposure compared to controls (n=22']",['Visual illusions'],"['BPD and pain', 'body perception disturbance and pain', '11-point scale', 'sustained pain reduction', 'pain intensity', 'pain reduction']","[{'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0458219', 'cui_str': 'Complex regional pain syndrome'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0233746', 'cui_str': 'Disturbance of perception'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0751246', 'cui_str': 'Illusions, Visual'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0233746', 'cui_str': 'Disturbance of perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",45.0,0.0796438,"At follow-up, the subgroup (experimental n=21; control n=18) showed sustained pain reduction only (p=0.037, ±SD 1.9, ES=0.7), with an overall 1.2 decrease on an 11-point scale. ","[{'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Lewis', 'Affiliation': 'Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHS Trust, Bath, UK.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Newport', 'Affiliation': 'University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Taylor', 'Affiliation': 'University of Exeter, Exeter, UK.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Smith', 'Affiliation': 'Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHS Trust, Bath, UK.'}, {'ForeName': 'Candida S', 'Initials': 'CS', 'LastName': 'McCabe', 'Affiliation': 'University of the West of England, Bristol, UK.'}]","European journal of pain (London, England)",['10.1002/ejp.1766'] 1224,33761288,Two Weekly Sessions of High-Intensity Interval Training Improve Metabolic Syndrome and Hypertriglyceridemic Waist Phenotype in Older Adults: A Randomized Controlled Trial.,"Background: Exercise training provides physiological benefits for maintaining good health. A common exercise strategy is high-intensity interval training (HIIT). HIIT may alleviate metabolic syndrome (MetS) and hypertriglyceridemic waist (HTGW) phenotype, but remains largely unstudied in ageing participants. The aim of this research was to investigate the impact of 2 weekly HIIT sessions on MetS markers and HTGW-related factors in older adults. Methods: In this randomized controlled trial, 140 older men and women were randomized into two groups, the experimental group (EG), and the control group (CG). The EG performed 2 weekly sessions of HIIT during 12 weeks. HIIT sessions consisted of 40 min treadmill running/walking: a 10 min warm-up at 50%-60% of maximum heart rate (HR max ), followed by 10 sets of 1 min bouts at 85%-90% of HR max interspersed with 1 min walking at self-selected pace (totaling 20 min), and 10 min cool-down walking at self-selected pace. The CG did not perform any type of intense exercise during the intervention period. Results: Participants in the EG of both sexes decreased MetS, HTGW, blood pressure, cholesterol, and glycemia ( P  < 0.05). After training, the number of hypertensive men decreased by 100% and women by 70%. There was a 75% reduction in women with diabetes, a 100% reduction in MetS indicators and over 80% reduction in HTGW in participants of both sexes. Conclusion: Two weekly sessions of HIIT proved to be feasible and effective to induce clinically relevant improvements in MetS and HTGW indicators.",2021,Conclusion: Two weekly sessions of HIIT proved to be feasible and effective to induce clinically relevant improvements in MetS and HTGW indicators.,"['Older Adults', 'older adults', '140 older men and women']","['High-Intensity Interval Training', 'HIIT sessions consisted of 40\u2009min treadmill running/walking: a 10\u2009min warm-up at 50%-60% of maximum heart rate (HR max ), followed by 10 sets of 1\u2009min bouts at 85%-90% of HR max interspersed with 1\u2009min walking at self-selected pace (totaling 20\u2009min), and 10\u2009min cool-down walking at self-selected pace', 'Exercise training']","['number of hypertensive men', 'MetS indicators', 'MetS, HTGW, blood pressure, cholesterol, and glycemia', 'metabolic syndrome (MetS) and hypertriglyceridemic waist (HTGW) phenotype']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C2350169', 'cui_str': 'Warming-Up Exercise'}, {'cui': 'C0744679', 'cui_str': 'Maximum heart rate'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C3658248', 'cui_str': 'Enlarged Waist Elevated Triglycerides'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}]",140.0,0.0469125,Conclusion: Two weekly sessions of HIIT proved to be feasible and effective to induce clinically relevant improvements in MetS and HTGW indicators.,"[{'ForeName': 'Dihogo Gama', 'Initials': 'DG', 'LastName': 'de Matos', 'Affiliation': 'Group of Studies and Research of Performance, Sport, Health and Paralympic Sports-GEPEPS, Federal University of Sergipe, UFS, São Cristovão, Brazil.'}, {'ForeName': 'Paulo Francisco', 'Initials': 'PF', 'LastName': 'de Almeida-Neto', 'Affiliation': 'Department of Physical Education, Federal University of Rio Grande do Norte, Natal, Brazil.'}, {'ForeName': 'Osvaldo Costa', 'Initials': 'OC', 'LastName': 'Moreira', 'Affiliation': 'Institute of Biological Sciences and Health, Federal University of Viçosa, Campus Florestal, Minas Gerais, Brazil.'}, {'ForeName': 'Raphael Fabrício', 'Initials': 'RF', 'LastName': 'de Souza', 'Affiliation': 'Group of Studies and Research of Performance, Sport, Health and Paralympic Sports-GEPEPS, Federal University of Sergipe, UFS, São Cristovão, Brazil.'}, {'ForeName': 'Breno Guilherme de Araújo', 'Initials': 'BGA', 'LastName': 'Tinoco Cabral', 'Affiliation': 'Department of Physical Education, Federal University of Rio Grande do Norte, Natal, Brazil.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Chilibeck', 'Affiliation': 'College of Kinesiology, University of Saskatchewan, Saskatoon, Canada.'}, {'ForeName': 'Felipe J', 'Initials': 'FJ', 'LastName': 'Aidar', 'Affiliation': 'Group of Studies and Research of Performance, Sport, Health and Paralympic Sports-GEPEPS, Federal University of Sergipe, UFS, São Cristovão, Brazil.'}]",Metabolic syndrome and related disorders,['10.1089/met.2020.0136'] 1225,33773111,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.","BACKGROUND Although several COVID-19 vaccines have been developed so far, they will not be sufficient to meet the global demand. Development of a wider range of vaccines, with different mechanisms of action, could help control the spread of SARS-CoV-2 globally. We developed a protein subunit vaccine against COVID-19 using a dimeric form of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein as the antigen. We aimed to assess the safety and immunogenicity of this vaccine, ZF2001, and determine the appropriate dose and schedule for an efficacy study. METHODS We did two randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Phase 1 was done at two university hospitals in Chongqing and Beijing, China, and phase 2 was done at the Hunan Provincial Center for Disease Control and Prevention in Xiangtan, China. Healthy adults aged 18-59 years, without a history of SARS-CoV or SARS-CoV-2 infection, an RT-PCR-positive test result for SARS-CoV-2, a history of contact with confirmed or suspected COVID-19 cases, and severe allergies to any component of the vaccine were eligible for enrolment. In phase 1, participants were randomly assigned (2:2:1) to receive three doses of the vaccine (25 μg or 50 μg) or placebo intramuscularly, 30 days apart. In phase 2, participants were randomly assigned (1:1:1:1:1:1) to receive the vaccine (25 μg or 50 μg) or placebo intramuscularly, 30 days apart, in either a two-dose schedule or a three-dose schedule. Investigators, participants, and the laboratory team were masked to group allocation. For phase 1, the primary outcome was safety, measured by the occurrence of adverse events and serious adverse events. For phase 2, the primary outcome was safety and immunogenicity (the seroconversion rate and the magnitude, in geometric mean titres [GMTs], of SARS-CoV-2-neutralising antibodies). Analyses were done on an intention-to-treat and per-protocol basis. These trials are registered with ClinicalTrials.gov (NCT04445194 and NCT04466085) and participant follow-up is ongoing. FINDINGS Between June 22 and July 3, 2020, 50 participants were enrolled into the phase 1 trial and randomly assigned to receive three doses of placebo (n=10), the 25 μg vaccine (n=20), or the 50 μg vaccine (n=20). The mean age of participants was 32·6 (SD 9·4) years. Between July 12 and July 17, 2020, 900 participants were enrolled into the phase 2 trial and randomly assigned to receive two doses of placebo (n=150), 25 μg vaccine (n=150), or 50 μg vaccine (n=150), or three doses of placebo (n=150), 25 μg vaccine (n=150), or 50 μg vaccine (n=150). The mean age of participants was 43·5 (SD 9·2) years. In both phase 1 and phase 2, adverse events reported within 30 days after vaccination were mild or moderate (grade 1 or 2) in most cases (phase 1: six [60%] of ten participants in the placebo group, 14 [70%] of 20 in the 25 μg group, and 18 [90%] of 20 in the 50 μg group; phase 2: 37 [25%] of 150 in the two-dose placebo group, 43 [29%] of 150 in the two-dose 25 μg group, 50 [33%] of 150 in the two-dose 50 μg group, 47 [31%] of 150 in the three-dose placebo group, 72 [48%] of 150 in the three-dose 25 μg group, and 65 [43%] of 150 in the three-dose 50 μg group). In phase 1, two (10%) grade 3 or worse adverse events were reported in the 50 μg group. In phase 2, grade 3 or worse adverse events were reported by 18 participants (four [3%] in the two-dose 25 μg vaccine group, two [1%] in the two-dose 50 μg vaccine group, two [1%] in the three-dose placebo group, four [3%] in the three-dose 25 μg vaccine group, and six [4%] in the three-dose 50 μg vaccine group), and 11 were considered vaccine related (two [1%] in the two-dose 25 μg vaccine group, one [1%] in the two-dose 50 μg vaccine group, one [1%] in the three-dose placebo group, two [1%] in the three-dose 25 μg vaccine group, and five [3%] in the three-dose 50 μg vaccine group); seven participants reported serious adverse events (one [1%] in the two-dose 25 μg vaccine group, one [1%] in the two-dose 50 μg vaccine group, two [1%] in the three-dose placebo group, one [1%] in the three-dose 25 μg vaccine group, and two [1%] in the three-dose 50 μg vaccine group), but none was considered vaccine related. In phase 2, on the two-dose schedule, seroconversion rates of neutralising antibodies 14 days after the second dose were 76% (114 of 150 participants) in the 25 μg group and 72% (108 of 150) in the 50 μg group; on the three-dose schedule, seroconversion rates of neutralising antibodies 14 days after the third dose were 97% (143 of 148 participants) in the 25 μg group and 93% (138 of 148) in the 50 μg group. In the two-dose groups in phase 2, the SARS-CoV-2-neutralising GMTs 14 days after the second dose were 17·7 (95% CI 13·6-23·1) in the 25 μg group and 14·1 (10·8-18·3) in the 50 μg group. In the three-dose groups in phase 2, the SARS-CoV-2-neutralising GMTs 14 days after the third dose were 102·5 (95% CI 81·8-128·5) in the 25 μg group and 69·1 (53·0-90·0) in the 50 μg group. INTERPRETATION The protein subunit vaccine ZF2001 appears to be well tolerated and immunogenic. The safety and immunogenicity data from the phase 1 and 2 trials support the use of the 25 μg dose in a three-dose schedule in an ongoing phase 3 trial for large-scale evaluation of ZF2001's safety and efficacy. FUNDING National Program on Key Research Project of China, National Science and Technology Major Projects of Drug Discovery, Strategic Priority Research Program of the Chinese Academy of Sciences, and Anhui Zhifei Longcom Biopharmaceutical. TRANSLATION For the Chinese translation of the abstract see Supplementary Materials section.",2021,"In phase 1, two (10%) grade 3 or worse adverse events were reported in the 50 μg group.","['adults', 'mean age of participants was 43·5', 'Between June 22 and July 3, 2020', 'Healthy adults aged 18-59 years, without a history of SARS-CoV or SARS-CoV-2 infection, an RT-PCR-positive test result for SARS-CoV-2, a history of contact with confirmed or suspected COVID-19 cases, and severe allergies to any component of the vaccine were eligible for enrolment', 'Between July 12 and July 17, 2020, 900 participants were enrolled into the phase 2 trial', 'The mean age of participants was 32·6 (SD 9·4) years', '50 participants were enrolled into the phase 1 trial', 'Phase 1 was done at two university hospitals in Chongqing and Beijing, China, and phase 2 was done at the Hunan Provincial Center for Disease Control and Prevention in Xiangtan, China']","['recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001', 'placebo', '25 μg vaccine (n=150), or 50 μg vaccine (n=150), or three doses of placebo', 'vaccine']","['seroconversion rates of neutralising antibodies', 'safety and immunogenicity (the seroconversion rate and the magnitude, in geometric mean titres [GMTs], of SARS-CoV-2-neutralising antibodies', 'occurrence of adverse events and serious adverse events', 'adverse events', 'grade 3 or worse adverse events', 'serious adverse events', 'safety and immunogenicity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0002111', 'cui_str': 'Allergy - specialty'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439559', 'cui_str': 'Phase 1'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0007670', 'cui_str': 'Centers for Disease Control and Prevention (U.S.)'}]","[{'cui': 'C0039290', 'cui_str': 'Tandem Repeats'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0599220', 'cui_str': 'Protein Subunit'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0475463', 'cui_str': 'Neutralizing antibody'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449286', 'cui_str': 'Degree'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}]",50.0,0.434996,"In phase 1, two (10%) grade 3 or worse adverse events were reported in the 50 μg group.","[{'ForeName': 'Shilong', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Lianpan', 'Initials': 'L', 'LastName': 'Dai', 'Affiliation': 'CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Jianfeng', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'He', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Changgui', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Fang', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Chenfei', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Enqi', 'Initials': 'E', 'LastName': 'Huang', 'Affiliation': 'Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.'}, {'ForeName': 'Changwei', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': 'Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.'}, {'ForeName': 'Zaixin', 'Initials': 'Z', 'LastName': 'Zhong', 'Affiliation': 'Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.'}, {'ForeName': 'Fengze', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Xiaomin', 'Initials': 'X', 'LastName': 'Duan', 'Affiliation': 'CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Siyu', 'Initials': 'S', 'LastName': 'Tian', 'Affiliation': 'CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Chongqing Medleader Bio-Pharm, Chongqing, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': 'Beijing Keytech Statistical Technology, Beijing, China.'}, {'ForeName': 'Zhihai', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Fangjun', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Hunan Provincial Center for Disease Control and Prevention, Changsha, China.'}, {'ForeName': 'Junhua', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Hunan Provincial Center for Disease Control and Prevention, Changsha, China.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': 'The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Ren', 'Affiliation': 'The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Lihong', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Shufang', 'Initials': 'S', 'LastName': 'Meng', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Jinghua', 'Initials': 'J', 'LastName': 'Yan', 'Affiliation': 'CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Zhongyu', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Lidong', 'Initials': 'L', 'LastName': 'Gao', 'Affiliation': 'Hunan Provincial Center for Disease Control and Prevention, Changsha, China. Electronic address: gldlj@hotmail.com.'}, {'ForeName': 'George F', 'Initials': 'GF', 'LastName': 'Gao', 'Affiliation': 'CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. Electronic address: gaof@im.ac.cn.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(21)00127-4'] 1226,33790860,Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands.,"Medical treatment for acromegaly commonly involves receiving intramuscular or deep subcutaneous injections of somatostatin receptor ligands (SRLs) in most patients. In addition to side effects of treatment, acromegaly patients often still experience disease symptoms even when therapy is successful in controlling GH and IGF-1 levels. Symptoms and side effects can negatively impact patients' health-related quality of life. In this study, we examine the disease- and treatment-related burden associated with SRL injections as reported through the use of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ © ) and clinician-reported symptom severity through the Acromegaly Index of Severity (AIS). Patients included in this analysis were enrolled in a randomized phase 3 study, were biochemically-controlled (an IGF-1 < 1.3 × the upper limit of normal [ULN] and average GH < 2.5 ng/ml) and receiving SRL injections for ≥6 months with a stable dose of either long-acting octreotide or lanreotide monotherapy for ≥4 months. The sample (N = 91) was 65% female, 91% Caucasian, with a mean [standard deviation (SD)] age of 53 (1) years. Two-thirds of patients reported that they still experience acromegaly symptoms; 82% of these said they experience symptoms all of the time. Three-fourths experienced gastrointestinal (GI) side effects after injections, and 77% experienced treatment-related injection site reactions (ISRs). Patients commonly reported that these interfered with their daily life, leisure, and work activities. Those with higher symptom severity, as measured by the AIS, scored significantly worse on several Acro-TSQ domains: Symptom Interference, GI Interference, Treatment Satisfaction, and Emotional Reaction. Despite being biochemically controlled with injectable SRLs, most patients reported experiencing acromegaly symptoms that interfere with daily life, leisure, and work. GI side effects and ISRs were also common. This study highlights the significant disease burden that still persists for patients with acromegaly that have achieved biochemical control with the use of injectable SRLs.",2021,"Those with higher symptom severity, as measured by the AIS, scored significantly worse on several Acro-TSQ domains: Symptom Interference, GI Interference, Treatment Satisfaction, and Emotional Reaction.","['Patients included in this analysis were enrolled in a randomized phase 3 study, were biochemically-controlled (an IGF-1 < 1.3 × the upper limit of normal [ULN] and average GH < 2.5 ng/ml) and receiving', 'patients with acromegaly that have achieved biochemical control with the use of injectable SRLs', 'Patients With Acromegaly', 'age of 53 (1) years', 'The sample (N = 91) was 65% female, 91% Caucasian, with a mean [standard deviation (SD']","['SRL injections for ≥6 months with a stable dose of either long-acting octreotide or lanreotide monotherapy', 'somatostatin receptor ligands (SRLs']","['gastrointestinal (GI) side effects', 'several Acro-TSQ domains: Symptom Interference, GI Interference, Treatment Satisfaction, and Emotional Reaction', 'daily life, leisure, and work activities', 'GI side effects and ISRs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0001206', 'cui_str': 'Acromegaly'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0074830', 'cui_str': 'Somatostatin Receptor'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]","[{'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0028833', 'cui_str': 'Octreotide'}, {'cui': 'C0209211', 'cui_str': 'lanreotide'}, {'cui': 'C0074830', 'cui_str': 'Somatostatin Receptor'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0221736', 'cui_str': 'Reaction emotional'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0086542', 'cui_str': 'Leisure'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",91.0,0.0501567,"Those with higher symptom severity, as measured by the AIS, scored significantly worse on several Acro-TSQ domains: Symptom Interference, GI Interference, Treatment Satisfaction, and Emotional Reaction.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Fleseriu', 'Affiliation': 'Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health and Science University, Portland, OR, United States.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Molitch', 'Affiliation': 'Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Dreval', 'Affiliation': 'Department of Clinical Endocrinology, Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia.'}, {'ForeName': 'Nienke R', 'Initials': 'NR', 'LastName': 'Biermasz', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Murray B', 'Initials': 'MB', 'LastName': 'Gordon', 'Affiliation': 'Allegheny Neuroendocrinology Center, Allegheny General Hospital, Pittsburgh, PA, United States.'}, {'ForeName': 'Ross D', 'Initials': 'RD', 'LastName': 'Crosby', 'Affiliation': 'Outcomes Research, Health Outcomes Solutions, Winter Park, FL, United States.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Ludlam', 'Affiliation': 'Clinical Development, Chiasma, Inc., Needham, MA, United States.'}, {'ForeName': 'Asi', 'Initials': 'A', 'LastName': 'Haviv', 'Affiliation': 'Clinical Development, Chiasma, Inc., Needham, MA, United States.'}, {'ForeName': 'Yossi', 'Initials': 'Y', 'LastName': 'Gilgun-Sherki', 'Affiliation': 'Clinical Development, Chiasma, Inc., Needham, MA, United States.'}, {'ForeName': 'Susan D', 'Initials': 'SD', 'LastName': 'Mathias', 'Affiliation': 'Outcomes Research, Health Outcomes Solutions, Winter Park, FL, United States.'}]",Frontiers in endocrinology,['10.3389/fendo.2021.627711'] 1227,33797074,"A prospective, randomized, double-blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department.","OBJECTIVE To compare the efficacy of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department (ED). BACKGROUND Migraine is a common, incapacitating neurological condition. Although chlorpromazine and prochlorperazine are known to be safe, efficacious treatments for migraine, they have never been directly compared. DESIGN We performed a prospective, randomized, double-blind clinical trial at a tertiary hospital in Melbourne, Australia. Adults aged 18-65 years, who presented with migraine, were eligible for recruitment. Sixty-six patients were randomized to either chlorpromazine 12.5 mg or prochlorperazine 12.5 mg, both infused in 500 ml of sodium chloride 0.9% over 30 min. Headache severity score, nausea severity score, and the presence of photophobia and phonophobia were assessed at 0, 30, 60, and 120 min. Adverse effects and the need for rescue therapy were recorded. The primary outcome was a reduction in headache severity score from baseline at 60 min post-commencement of the study medicine infusion. RESULTS Sixty-five patients were included in the analysis. There was a median reduction in headache severity score at 60 min of 3.0 (interquartile range 1.0-4.0) in the chlorpromazine arm versus 2.0 (1.0-4.0) in the prochlorperazine arm (median difference -0.5 (95% confidence interval, -1.9 to 0.9)). We saw no evidence of a difference in secondary outcomes at 30, 60, or 120 min. Side effects were reported in 16/32 (50%) patients in the chlorpromazine group versus 7/33 (21%) in the prochlorperazine group (p = 0.020). Rescue therapy was required in 7/32 (22%) patients in the chlorpromazine group versus 12/33 (36%) in the prochlorperazine group (p = 0.277). CONCLUSIONS Both chlorpromazine and prochlorperazine are efficacious treatments for acute migraine in adult patients presenting to the ED. This trial found no evidence of superiority of either agent over the other. Caution should be used when prescribing these medicines in the borderline hypotensive patient; in that circumstance, prochlorperazine should be preferentially used.",2021,Side effects were reported in 16/32 (50%) patients in the chlorpromazine group versus 7/33 (21%) in the prochlorperazine group (p = 0.020).,"['Sixty-five patients were included in the analysis', 'tertiary hospital in Melbourne, Australia', 'Sixty-six patients', 'acute migraine in adults presenting to the emergency department', 'adult patients presenting to the ED', 'Adults aged 18-65\xa0years, who presented with migraine, were eligible for recruitment', 'acute migraine in adults presenting to the emergency department (ED']","['prochlorperazine', 'chlorpromazine', 'chlorpromazine 12.5\xa0mg or prochlorperazine 12.5\xa0mg, both infused in 500\xa0ml of sodium chloride 0.9% over 30\xa0min']","['headache severity score', 'Side effects', 'Adverse effects', 'Headache severity score, nausea severity score, and the presence of photophobia and phonophobia']","[{'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C4517841', 'cui_str': '66'}, {'cui': 'C1740836', 'cui_str': 'Acute migraine'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}]","[{'cui': 'C0033229', 'cui_str': 'Prochlorperazine'}, {'cui': 'C0008286', 'cui_str': 'Chlorpromazine'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C4707055', 'cui_str': 'Infuse'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0456693', 'cui_str': '/30 min'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0085636', 'cui_str': 'Photophobia'}, {'cui': 'C0751466', 'cui_str': 'Phonophobia'}]",66.0,0.529346,Side effects were reported in 16/32 (50%) patients in the chlorpromazine group versus 7/33 (21%) in the prochlorperazine group (p = 0.020).,"[{'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Hodgson', 'Affiliation': 'Emergency Department, Austin Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Harding', 'Affiliation': 'Emergency Department, Austin Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Elyssia M', 'Initials': 'EM', 'LastName': 'Bourke', 'Affiliation': 'Emergency Department, Austin Health, Melbourne, VIC, Australia.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Taylor', 'Affiliation': 'Emergency Department, Austin Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Shaun L', 'Initials': 'SL', 'LastName': 'Greene', 'Affiliation': 'Emergency Department, Austin Health, Melbourne, VIC, Australia.'}]",Headache,['10.1111/head.14091'] 1228,33797023,"Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.","BACKGROUND This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). METHODS Eligible women had progressed on (neo)adjuvant endocrine therapy (ET), ≤ 12 months from end of adjuvant ET, or on first-line ET for ABC, and had not received chemotherapy for ABC. Patients were randomized 2:1 to receive abemaciclib or placebo plus fulvestrant. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), pharmacokinetics (PK), health-related quality of life (HRQoL), and safety. RESULTS In Japan, 95 patients were randomized (abemaciclib, n = 64; placebo, n = 31). At final PFS analysis (February 14, 2017), median PFS was 21.2 and 14.3 months, respectively, in the abemaciclib and placebo groups (hazard ratio: 0.672; 95% confidence interval: 0.380-1.189). Abemaciclib had a higher objective response rate (37.5%) than placebo (12.9%). PK and safety profiles for Japanese patients were consistent with those of the overall population, without clinically meaningful differences across most HRQoL dimensions evaluated. The most frequent adverse events in the abemaciclib versus placebo groups were diarrhea (95.2 versus 25.8%), neutropenia (79.4 versus 0%), and leukopenia (66.7 versus 0%). At a second data cutoff (June 20, 2019), median OS was not reached with abemaciclib and 47.3 months with placebo (hazard ratio: 0.755; 95% confidence interval: 0.390-1.463). CONCLUSIONS Results of the Japanese subpopulation were consistent with the improved clinical outcomes and manageable safety profile observed in the overall population. CLINICAL TRIAL REGISTRATION NCT02107703; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02107703 .",2021,Abemaciclib had a higher objective response rate (37.5%) than placebo (12.9%).,"['Eligible women had progressed on (neo)adjuvant endocrine therapy (ET),\u2009≤\u200912\xa0months from end of adjuvant ET, or on first-line ET for ABC, and had not received chemotherapy for ABC', 'Japanese patients', 'Japanese subpopulation analysis of MONARCH 2', 'patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC']","['placebo', 'abemaciclib plus fulvestrant', 'abemaciclib or placebo plus fulvestrant']","['diarrhea', 'median PFS', 'PK and safety profiles', 'objective response rate', 'overall survival (OS), pharmacokinetics (PK), health-related quality of life (HRQoL), and safety', 'leukopenia', 'median OS', 'neutropenia', 'progression-free survival (PFS']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1257890', 'cui_str': 'Group'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3852841', 'cui_str': 'abemaciclib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}]",95.0,0.8151,Abemaciclib had a higher objective response rate (37.5%) than placebo (12.9%).,"[{'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Inoue', 'Affiliation': 'Saitama Cancer Center, Saitama, Japan.'}, {'ForeName': 'Norikazu', 'Initials': 'N', 'LastName': 'Masuda', 'Affiliation': 'National Hospital Organization, Osaka National Hospital, Osaka, Japan.'}, {'ForeName': 'Hiroji', 'Initials': 'H', 'LastName': 'Iwata', 'Affiliation': 'Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Takahashi', 'Affiliation': 'National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Ito', 'Affiliation': 'The Cancer Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Miyoshi', 'Affiliation': 'Hyogo College of Medicine, Hyogo, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Nakayama', 'Affiliation': 'Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Mukai', 'Affiliation': 'National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Jan-Stefan', 'Initials': 'JS', 'LastName': 'van der Walt', 'Affiliation': 'Eli Lilly and Company, Surrey, UK.'}, {'ForeName': 'Joji', 'Initials': 'J', 'LastName': 'Mori', 'Affiliation': 'Eli Lilly Japan K.K., Kobe, Japan.'}, {'ForeName': 'Sachi', 'Initials': 'S', 'LastName': 'Sakaguchi', 'Affiliation': 'Eli Lilly Japan K.K., Kobe, Japan.'}, {'ForeName': 'Tsutomu', 'Initials': 'T', 'LastName': 'Kawaguchi', 'Affiliation': 'Eli Lilly Japan K.K., Kobe, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Tanizawa', 'Affiliation': 'Eli Lilly Japan K.K., Kobe, Japan.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Llombart-Cussac', 'Affiliation': 'Hospital Arnau de Vilanova, Valencia, Spain.'}, {'ForeName': 'George W', 'Initials': 'GW', 'LastName': 'Sledge', 'Affiliation': 'Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Masakazu', 'Initials': 'M', 'LastName': 'Toi', 'Affiliation': 'Breast Cancer Unit, Breast Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507, Japan. toi@kuhp.kyoto-u.ac.jp.'}]","Breast cancer (Tokyo, Japan)",['10.1007/s12282-021-01239-8'] 1229,33797018,Non-ventilated lung deflation during one-lung ventilation with a double-lumen endotracheal tube: a randomized-controlled trial of occluding the non-ventilated endobronchial lumen before pleural opening.,"PURPOSE Lung deflation during one-lung ventilation (OLV) is thought to be faster using a double-lumen endotracheal tube (DL-ETT) than with a bronchial blocker, especially when the non-ventilated lumen is opened to allow egress of air from the operative lung. Nevertheless, ambient air can also be entrained into the non-ventilated lumen before pleural opening and subsequently delay deflation. We therefore hypothesized that occluding the non-ventilated DL-ETT lumen during OLV before pleural opening would prevent air entrainment and consequently enhance operative lung deflation during video-assisted thoracoscopic surgery (VATS). METHODS Thirty patients undergoing VATS using DL-ETT to allow OLV were randomized to having the lumen of the operative lung either open (control group) or occluded (intervention group) to ambient air. The primary outcome was the time to lung collapse evaluated intraoperatively by the surgeons. The T 50 , an index of rate of deflation, was also determined from a probabilistic model derived from intraoperative video clips presented in random order to three observers. RESULTS The median [interquartile range] time to lung deflation occurred faster in the intervention group than in the control group (24 [20-37] min vs 54 [48-68] min, respectively; median difference, 30 min; 95% confidence interval [CI], 14 to 46; P < 0.001). The estimated T 50 was 32.6 min in the intervention group compared with 62.3 min in the control group (difference, - 29.7 min; 95% CI, - 51.1 to - 8.4; P = 0.008). CONCLUSION Operative lung deflation during OLV with a DL-ETT is faster when the operative lumen remains closed before pleural opening thus preventing it from entraining ambient air during the closed chest phase of OLV. TRIAL REGISTRATION www.clinicaltrials.gov (NCT03508050); registered 27 September 2017.",2021,"The median [interquartile range] time to lung deflation occurred faster in the intervention group than in the control group (24 [20-37] min vs 54 [48-68] min, respectively; median difference, 30 min; 95% confidence interval [CI], 14 to 46; P < 0.001).",['Thirty patients undergoing VATS using DL-ETT to allow OLV'],"['ventilated lung deflation during one-lung ventilation with a double-lumen endotracheal tube', 'Lung deflation during one-lung ventilation (OLV', 'operative lung either open (control group) or occluded (intervention group) to ambient air']","['time to lung collapse evaluated intraoperatively by the surgeons', 'median [interquartile range] time to lung deflation']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}, {'cui': 'C2584423', 'cui_str': 'Double lumen tracheobronchial tube'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}]","[{'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C2584423', 'cui_str': 'Double lumen tracheobronchial tube'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001861', 'cui_str': 'Air'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0004144', 'cui_str': 'Atelectasis'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}]",30.0,0.108967,"The median [interquartile range] time to lung deflation occurred faster in the intervention group than in the control group (24 [20-37] min vs 54 [48-68] min, respectively; median difference, 30 min; 95% confidence interval [CI], 14 to 46; P < 0.001).","[{'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Somma', 'Affiliation': 'Department of Anesthesiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, 2725, Chemin Sainte-Foy, Quebec City, QC, G1V 4G5, Canada.'}, {'ForeName': 'Étienne J', 'Initials': 'ÉJ', 'LastName': 'Couture', 'Affiliation': 'Department of Anesthesiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, 2725, Chemin Sainte-Foy, Quebec City, QC, G1V 4G5, Canada.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Pelletier', 'Affiliation': 'Department of Anesthesiology and Critical Care, Laval University, Quebec City, QC, Canada.'}, {'ForeName': 'Steeve', 'Initials': 'S', 'LastName': 'Provencher', 'Affiliation': 'Department of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Moreault', 'Affiliation': 'Department of Anesthesiology and Critical Care, Laval University, Quebec City, QC, Canada.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Lohser', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada.'}, {'ForeName': 'Paula A', 'Initials': 'PA', 'LastName': 'Ugalde', 'Affiliation': 'Department of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Vigneault', 'Affiliation': 'Department of Anesthesiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, 2725, Chemin Sainte-Foy, Quebec City, QC, G1V 4G5, Canada.'}, {'ForeName': 'Jérome', 'Initials': 'J', 'LastName': 'Lemieux', 'Affiliation': 'Department of Anesthesiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, 2725, Chemin Sainte-Foy, Quebec City, QC, G1V 4G5, Canada.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Somma', 'Affiliation': ""Faculté des sciences et génie, Departement d'informatique et de génie logiciel, Laval University, Quebec City, QC, Canada.""}, {'ForeName': 'Sarah-Elizabeth', 'Initials': 'SE', 'LastName': 'Guay', 'Affiliation': 'Laval University, Quebec City, QC, Canada.'}, {'ForeName': 'Jean S', 'Initials': 'JS', 'LastName': 'Bussières', 'Affiliation': 'Department of Anesthesiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, 2725, Chemin Sainte-Foy, Quebec City, QC, G1V 4G5, Canada. jbuss@criucpq.ulaval.ca.'}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-021-01957-9'] 1230,33787415,"Long-Term Effect of Receiving a Family Strengths-Oriented Intervention on Family Cancer Caregiver Stress, Anxiety, and Depression Symptoms: A Longitudinal Quasi-Experimental Study.","The aim of this longitudinal study was to evaluate the long-term effects of providing a therapeutic conversation intervention, based on Family Systems Nursing, to family caregivers of a close relative with advanced cancer over the period before and during bereavement. To prevent adverse outcomes, caregivers need ongoing support that begins pre-loss and extends into the post-loss period. This study employed a one-group pre-test, post-test quasi-experimental design. Twenty-four caregivers participated in two intervention trials conducted over a 42-month period, receiving two intervention sessions pre-loss (Trial 1) and one intervention session post-loss (Trial 2). Significant decreases in anxiety and stress were noted over the three post-loss assessments. The final post-loss stress outcome was significantly lower than the first pre-loss score. For the depression score, there was not a significant change over time within the pre- or post-loss period. The findings provide evidence of decreasing anxiety and stress following the implementation of an extended family nursing intervention for bereaved family caregivers.",2021,The findings provide evidence of decreasing anxiety and stress following the implementation of an extended family nursing intervention for bereaved family caregivers.,[],"['Receiving a Family Strengths-Oriented Intervention', 'therapeutic conversation intervention']","['Family Cancer Caregiver Stress, Anxiety, and Depression Symptoms', 'anxiety and stress']",[],"[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1998980', 'cui_str': 'Caregiver role strain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",24.0,0.0254958,The findings provide evidence of decreasing anxiety and stress following the implementation of an extended family nursing intervention for bereaved family caregivers.,"[{'ForeName': 'Asta B', 'Initials': 'AB', 'LastName': 'Petursdottir', 'Affiliation': 'School of Health Sciences, Faculty of Nursing, University of Iceland, Reykjavík, Iceland.'}, {'ForeName': 'Mary Kay', 'Initials': 'MK', 'LastName': 'Rayens', 'Affiliation': 'University of Kentucky, Lexington, USA.'}, {'ForeName': 'Valgerdur', 'Initials': 'V', 'LastName': 'Sigurdardottir', 'Affiliation': 'Landspitali The National University Hospital, Reykjavík, Iceland.'}, {'ForeName': 'Erla Kolbrun', 'Initials': 'EK', 'LastName': 'Svavarsdottir', 'Affiliation': 'School of Health Sciences, Faculty of Nursing, University of Iceland, Reykjavík, Iceland.'}]",Journal of family nursing,['10.1177/1074840721994332'] 1231,33793018,Effect of surgical intervention for mild childhood obstructive sleep apnoea on attention and behavioural outcomes: A randomized controlled study.,"BACKGROUND AND OBJECTIVE We evaluated inattention and behavioural outcomes following surgery versus watchful waiting (WW) in school-aged children with mild obstructive sleep apnoea (OSA). METHODS A prospective randomized controlled study was performed in pre-pubertal children aged 6-11 years with polysomnography (PSG)-confirmed mild OSA. They were assigned randomly to early surgical intervention (ES) or WW. The surgical intervention consisting of tonsillectomy with or without adenoidectomy and turbinate reduction was carried out within 4-6 weeks after randomization. Both groups underwent PSG, attention and behavioural assessment and review by an otorhinolaryngologist at baseline and 9-month follow-up. The primary outcome was omission T score from Conners' continuous performance test (CPT). Secondary outcomes were parent-reported behaviours, quality of life, symptoms and PSG parameters. RESULTS A total of 114 participants were randomized. Data of 35 subjects from the ES and 36 from the WW group were available for final analysis. No significant treatment effect could be found in all CPT parameters and behavioural outcomes. Nevertheless, significantly greater reductions were seen in PSG parameters (obstructive apnoea-hypopnoea index [-1.4 ± 2.0 cf. +0.3 ± 4.1/h, p = 0.038] and arousal index [-1.3 ± 4.4 cf. +1.4 ± 4.5/h, p = 0.013]) and OSA-18 total symptom score (-17.3 ± 19.7 cf. -3.6 ± 14.1, p = 0.001) in the ES group. Subjects who underwent surgery also had significantly greater weight gain (+3.3 ± 2.1 cf. +2.2 ± 1.5 kg, p = 0.014) and increase in systolic blood pressure (+5.1 ± 12.4 cf. -1.2 ± 8.7 mm Hg, p = 0.016). CONCLUSION Despite improvements in PSG parameters and parent-reported symptoms, surgical treatment did not lead to parallel improvements in objective attention measures in school-aged children with mild OSA.",2021,"Subjects who underwent surgery also had significantly greater weight gain (+3.3 ± 2.1 cf. +2.2 ± 1.5 kg, p = 0.014) and increase in systolic blood pressure (+5.1 ± 12.4 cf.","['school-aged children with mild obstructive sleep apnoea (OSA', 'pre-pubertal children aged 6-11\u2009years with polysomnography (PSG)-confirmed mild OSA', 'mild childhood obstructive sleep apnoea on attention and behavioural outcomes', '114 participants were randomized', '35 subjects from the ES and 36 from the WW group were available for final analysis', 'school-aged children with mild OSA']","['surgery versus watchful waiting (WW', 'surgical intervention', 'tonsillectomy with or without adenoidectomy and turbinate reduction', 'early surgical intervention (ES) or WW']","['OSA-18 total symptom score', 'CPT parameters and behavioural outcomes', 'PSG parameters and parent-reported symptoms', 'objective attention measures', 'parent-reported behaviours, quality of life, symptoms and PSG parameters', 'systolic blood pressure', 'weight gain', 'PSG parameters (obstructive apnoea-hypopnoea index', ""omission T score from Conners' continuous performance test (CPT"", 'arousal index']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C1628325', 'cui_str': 'Pre-pubertal'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0700325', 'cui_str': 'Patient status observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0700325', 'cui_str': 'Patient status observation'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C0001425', 'cui_str': 'Adenoid excision'}, {'cui': 'C1266928', 'cui_str': 'Nasal turbinate bone structure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1279919', 'cui_str': 'Early'}]","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",114.0,0.0814203,"Subjects who underwent surgery also had significantly greater weight gain (+3.3 ± 2.1 cf. +2.2 ± 1.5 kg, p = 0.014) and increase in systolic blood pressure (+5.1 ± 12.4 cf.","[{'ForeName': 'Chun T', 'Initials': 'CT', 'LastName': 'Au', 'Affiliation': 'Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Kate C C', 'Initials': 'KCC', 'LastName': 'Chan', 'Affiliation': 'Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Dennis L Y', 'Initials': 'DLY', 'LastName': 'Lee', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Leung', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Samuel M W', 'Initials': 'SMW', 'LastName': 'Chow', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Judy S', 'Initials': 'JS', 'LastName': 'Chow', 'Affiliation': 'Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Yun K', 'Initials': 'YK', 'LastName': 'Wing', 'Affiliation': 'Sleep Assessment Unit, Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Albert M', 'Initials': 'AM', 'LastName': 'Li', 'Affiliation': 'Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}]","Respirology (Carlton, Vic.)",['10.1111/resp.14050'] 1232,33243172,Can an mhealth clinical decision-making support system improve adherence to neonatal healthcare protocols in a low-resource setting?,"BACKGROUND This study assessed health workers' adherence to neonatal health protocols before and during the implementation of a mobile health (mHealth) clinical decision-making support system (mCDMSS) that sought to bridge access to neonatal health protocol gap in a low-resource setting. METHODS We performed a cross-sectional document review within two purposively selected clusters (one poorly-resourced and one well-resourced), from each arm of a cluster-randomized trial at two different time points: before and during the trial. The total trial consisted of 16 clusters randomized into 8 intervention and 8 control clusters to assess the impact of an mCDMSS on neonatal mortality in Ghana. We evaluated health workers' adherence (expressed as percentages) to birth asphyxia, neonatal jaundice and cord sepsis protocols by reviewing medical records of neonatal in-patients using a checklist. Differences in adherence to neonatal health protocols within and between the study arms were assessed using Wilcoxon rank-sum and permutation tests for each morbidity type. In addition, we tracked concurrent neonatal health improvement activities in the clusters during the 18-month intervention period. RESULTS In the intervention arm, mean adherence was 35.2% (SD = 5.8%) and 43.6% (SD = 27.5%) for asphyxia; 25.0% (SD = 14.8%) and 39.3% (SD = 27.7%) for jaundice; 52.0% (SD = 11.0%) and 75.0% (SD = 21.2%) for cord sepsis protocols in the pre-intervention and intervention periods respectively. In the control arm, mean adherence was 52.9% (SD = 16.4%) and 74.5% (SD = 14.7%) for asphyxia; 45.1% (SD = 12.8%) and 64.6% (SD = 8.2%) for jaundice; 53.8% (SD = 16.0%) and 60.8% (SD = 11.7%) for cord sepsis protocols in the pre-intervention and intervention periods respectively. We observed nonsignificant improvement in protocol adherence in the intervention clusters but significant improvement in protocol adherence in the control clusters. There were 2 concurrent neonatal health improvement activities in the intervention clusters and over 12 in the control clusters during the intervention period. CONCLUSION Whether mHealth interventions can improve adherence to neonatal health protocols in low-resource settings cannot be ascertained by this study. Neonatal health improvement activities are however likely to improve protocol adherence. Future mHealth evaluations of protocol adherence must account for other concurrent interventions in study contexts.",2020,Differences in adherence to neonatal health protocols within and between the study arms were assessed using Wilcoxon rank-sum and permutation tests for each morbidity type.,[],[],"['mean adherence', ""health workers' adherence"", 'protocol adherence', 'neonatal health improvement activities']",[],[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C4042838', 'cui_str': 'Neonatal Health'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",16.0,0.0641559,Differences in adherence to neonatal health protocols within and between the study arms were assessed using Wilcoxon rank-sum and permutation tests for each morbidity type.,"[{'ForeName': 'Hannah Brown', 'Initials': 'HB', 'LastName': 'Amoakoh', 'Affiliation': 'Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Centre, Utrecht University, Utrecht, The Netherlands. ansomaame@hotmail.com.'}, {'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Klipstein-Grobusch', 'Affiliation': 'Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Centre, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Irene Akua', 'Initials': 'IA', 'LastName': 'Agyepong', 'Affiliation': 'Research and Development Division, Ghana Health Service, Dodowa, Accra, Ghana.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Amoakoh-Coleman', 'Affiliation': 'Noguchi Memorial Institute, University of Ghana, Legon, Accra, Ghana.'}, {'ForeName': 'Gbenga A', 'Initials': 'GA', 'LastName': 'Kayode', 'Affiliation': 'Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Centre, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Reitsma', 'Affiliation': 'Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Centre, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Diederick E', 'Initials': 'DE', 'LastName': 'Grobbee', 'Affiliation': 'Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Centre, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Evelyn K', 'Initials': 'EK', 'LastName': 'Ansah', 'Affiliation': 'University of Health and Allied Sciences, Ho, Ghana.'}]",BMC pediatrics,['10.1186/s12887-020-02378-1'] 1233,33247380,"Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial.","No specific treatment for COVID-19 infection is available up till now, and there is a great urge for effective treatment to reduce morbidity and mortality during this pandemic. We aimed to evaluate the effect of combining chloroquine/hydroxychloroquine (CQ/HCQ) and zinc in the treatment of COVID-19 patients. This was a randomized clinical trial conducted at three major University hospitals in Egypt. One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection were randomized into two groups: group I (96) patients received both HCQ and zinc, and group II (95) received HCQ only. The primary endpoints were the recovery within 28 days, the need for mechanical ventilation, and death. The two groups were matched for age and gender. They had no significant difference regarding any of the baseline laboratory parameters or clinical severity grading. Clinical recovery after 28 days was achieved by 79.2% in the zinc group and 77.9% in zinc-free treatment group, without any significant difference (p = 0.969). The need for mechanical ventilation and the overall mortality rates did not show any significant difference between the 2 groups either (p = 0.537 and 0.986, respectively). The age of the patient and the need for mechanical ventilation were the only risk factors associated with the patients' mortality by the univariate regression analysis (p = 0.001 and < 0.001, respectively). Zinc supplements did not enhance the clinical efficacy of HCQ. More randomized studies are needed to evaluate the value of adding zinc to other therapies for COVID 19. ClinicalTrials.gov Identifier: NCT04447534.",2021,"The need for mechanical ventilation and the overall mortality rates did not show any significant difference between the 2 groups either (p = 0.537 and 0.986, respectively).","['COVID-19 patients', 'One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection', 'three major University hospitals in Egypt']","['chloroquine/hydroxychloroquine (CQ/HCQ', 'Zinc supplements', 'HCQ only', 'Hydroxychloroquine', 'HCQ and zinc']","['recovery within 28\xa0days, the need for mechanical ventilation, and death', 'clinical efficacy of HCQ', 'overall mortality rates', 'Clinical recovery']","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0013715', 'cui_str': 'Egypt'}]","[{'cui': 'C0008269', 'cui_str': 'Chloroquine'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C3541396', 'cui_str': 'Zinc'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",191.0,0.227374,"The need for mechanical ventilation and the overall mortality rates did not show any significant difference between the 2 groups either (p = 0.537 and 0.986, respectively).","[{'ForeName': 'Sherief', 'Initials': 'S', 'LastName': 'Abd-Elsalam', 'Affiliation': 'Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, El-Giash Street, Tanta, 31527, Egypt. sherif.abdelbaky@med.tanta.edu.eg.'}, {'ForeName': 'Shaimaa', 'Initials': 'S', 'LastName': 'Soliman', 'Affiliation': 'Public health and Community Medicine, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Eslam Saber', 'Initials': 'ES', 'LastName': 'Esmail', 'Affiliation': 'Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, El-Giash Street, Tanta, 31527, Egypt.'}, {'ForeName': 'Mai', 'Initials': 'M', 'LastName': 'Khalaf', 'Affiliation': 'Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, El-Giash Street, Tanta, 31527, Egypt.'}, {'ForeName': 'Ehab F', 'Initials': 'EF', 'LastName': 'Mostafa', 'Affiliation': 'Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Mohammed A', 'Initials': 'MA', 'LastName': 'Medhat', 'Affiliation': 'Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Ossama Ashraf', 'Initials': 'OA', 'LastName': 'Ahmed', 'Affiliation': 'Internal Medicine Department, Ain-shams University, Cairo, Egypt.'}, {'ForeName': 'Mohamed Samir Abd', 'Initials': 'MSA', 'LastName': 'El Ghafar', 'Affiliation': 'Department of Anesthesia, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Alboraie', 'Affiliation': 'Department of Internal Medicine, Al-Azhar University, Cairo, Egypt.'}, {'ForeName': 'Sahar M', 'Initials': 'SM', 'LastName': 'Hassany', 'Affiliation': 'Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.'}]",Biological trace element research,['10.1007/s12011-020-02512-1'] 1234,33757688,Effect of botulinum toxin-A on pain and mouth opening following surgical intervention in oral submucous fibrosis - A controlled clinical trial.,"The purpose of this trial was to study the effect on pain and mouth opening of intramuscular injection of botulinum toxin-A into masticatory muscles following surgical intervention in oral submucous fibrosis (OSMF) cases. Injections of either botulinum toxin A (BTX-A) (study group) or normal saline (control group) were given 2 weeks prior to surgical intervention in OSMF patients, into the bilateral masseter and temporalis muscles. All patients were evaluated for pain and ease of active physiotherapy at 1 week and 1, 3, and 6 months after surgery using a numerical rating scale and appropriate questionnaires, with comparisons made between the study and control group patients. Electromyographic studies of the masticator muscles were also carried out in all patients before injection, and at 1 month and 6 months after injection. 20 OSMF patients were equally divided into study and control groups (n = 10 each). At 1, 3, and 6 months after surgery, the study group patients showed significantly greater decreases in pain (p-values of 0.007, 0.001, and 0.005, respectively) and greater ease in physiotherapy compared with the control group. EMG recordings of masticator muscles showed a transient drop in microvolt value in the study group 1 month after injection, unlike the control group recordings. It was concluded that preoperative BTX-A injection was a good addition to surgical therapy in the patient group.",2021,"EMG recordings of masticator muscles showed a transient drop in microvolt value in the study group 1 month after injection, unlike the control group recordings.","['20 OSMF patients', 'oral submucous fibrosis (OSMF) cases']","['botulinum toxin-A', 'botulinum toxin A (BTX-A) (study group) or normal saline (control group']","['pain and mouth opening', 'pain and ease of active physiotherapy', 'pain']","[{'cui': 'C0029172', 'cui_str': 'Oral submucosal fibrosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0868928', 'cui_str': 'Case'}]","[{'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}]",20.0,0.0354757,"EMG recordings of masticator muscles showed a transient drop in microvolt value in the study group 1 month after injection, unlike the control group recordings.","[{'ForeName': 'Saatvik', 'Initials': 'S', 'LastName': 'Shandilya', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, King George Medical University, Lucknow, Uttar Pradesh, 226003, India. Electronic address: saatvik_shand@rediffmail.com.'}, {'ForeName': 'Sujata', 'Initials': 'S', 'LastName': 'Mohanty', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Maulana Azad Institute of Dental Sciences, Bahadur Shah Zafar Marg, New Delhi, 110002, India. Electronic address: drsujatam@hotmail.com.'}, {'ForeName': 'Pankaj', 'Initials': 'P', 'LastName': 'Sharma', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Maulana Azad Institute of Dental Sciences, Bahadur Shah Zafar Marg, New Delhi, 110002, India. Electronic address: spankaj_in@yahoo.com.'}, {'ForeName': 'Zainab', 'Initials': 'Z', 'LastName': 'Chaudhary', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Maulana Azad Institute of Dental Sciences, Bahadur Shah Zafar Marg, New Delhi, 110002, India. Electronic address: zainabgauri@yahoo.co.in.'}, {'ForeName': 'Sanchaita', 'Initials': 'S', 'LastName': 'Kohli', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Maulana Azad Institute of Dental Sciences, Bahadur Shah Zafar Marg, New Delhi, 110002, India. Electronic address: sanchaita.kohli@gmail.com.'}, {'ForeName': 'Rudra Deo', 'Initials': 'RD', 'LastName': 'Kumar', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, All India Institute of Medical Sciences, New Delhi, 110023, India. Electronic address: Rudraadhir@gmail.com.'}]",Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,['10.1016/j.jcms.2021.01.019'] 1235,33760976,Lip morphology estimation models based on three-dimensional images in a modern adult population from China.,"Lips are the main part of the lower facial soft tissue and are vital to forensic facial approximation (FFA). Facial soft tissue thickness (FSTT) and linear measurements in three dimensions are used in the quantitative analysis of lip morphology. With most FSTT analysis methods, the surface of soft tissue is unexplicit. Our study aimed to determine FSTT and explore the relationship between the hard and soft tissues of lips in different skeletal occlusions based on cone-beam CT (CBCT) and 3dMD images in a Chinese population. The FSTT of 11 landmarks in CBCT and 29 lip measurements in CBCT and 3dMD of 180 healthy Chinese individuals (90 males, 90 females) between 18 and 30 years were analyzed. The subjects were randomly divided into two groups with different skeletal occlusions distributed equally: 156 subjects in the experimental group to establish the prediction regression formulae of lip morphology and 24 subjects in the test group to assess the accuracy of the formulae. The results indicated that FSTT in the lower lip region varied among different skeletal occlusions. Furthermore, sex discrepancy was noted in the FSTT in midline landmarks and linear measurements. Measurements showing the highest correlation between soft and hard tissues were between total upper lip height and Ns-Pr (0.563 in males, 0.651 in females). The stepwise multiple regression equations were verified to be reliable with an average error of 1.246 mm. The method of combining CBCT with 3dMD provides a new perspective in predicting lip morphology and expands the database for FFA.",2021,Facial soft tissue thickness (FSTT) and linear measurements in three dimensions are used in the quantitative analysis of lip morphology.,"['modern adult population from China', 'Chinese population', '180 healthy Chinese individuals (90 males, 90 females) between 18 and 30\xa0years were analyzed']",['FSTT'],['Facial soft tissue thickness (FSTT'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]","[{'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",180.0,0.025552,Facial soft tissue thickness (FSTT) and linear measurements in three dimensions are used in the quantitative analysis of lip morphology.,"[{'ForeName': 'Jia-Min', 'Initials': 'JM', 'LastName': 'Zhao', 'Affiliation': ""Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, 98 XiWu Road, Xi'an, 710004, Shaanxi, People's Republic of China.""}, {'ForeName': 'Ling-Ling', 'Initials': 'LL', 'LastName': 'Ji', 'Affiliation': ""Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, 98 XiWu Road, Xi'an, 710004, Shaanxi, People's Republic of China.""}, {'ForeName': 'Meng-Qi', 'Initials': 'MQ', 'LastName': 'Han', 'Affiliation': ""Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, 98 XiWu Road, Xi'an, 710004, Shaanxi, People's Republic of China.""}, {'ForeName': 'Qing-Nan', 'Initials': 'QN', 'LastName': 'Mou', 'Affiliation': ""Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, 98 XiWu Road, Xi'an, 710004, Shaanxi, People's Republic of China.""}, {'ForeName': 'Guang', 'Initials': 'G', 'LastName': 'Chu', 'Affiliation': ""Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, 98 XiWu Road, Xi'an, 710004, Shaanxi, People's Republic of China.""}, {'ForeName': 'Teng', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': ""College of Medicine and Forensics, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, Xi'an, 710004, Shaanxi, People's Republic of China.""}, {'ForeName': 'Shao-Yi', 'Initials': 'SY', 'LastName': 'Du', 'Affiliation': ""Institute of Artificial Intelligence and Robotics, Xi'an Jiaotong University, 28 Xianning West Road, Xi'an, 710049, Shaanxi, People's Republic of China.""}, {'ForeName': 'Yu-Xia', 'Initials': 'YX', 'LastName': 'Hou', 'Affiliation': ""Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, 98 XiWu Road, Xi'an, 710004, Shaanxi, People's Republic of China. 369hyx@163.com.""}, {'ForeName': 'Yu-Cheng', 'Initials': 'YC', 'LastName': 'Guo', 'Affiliation': ""Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, 98 XiWu Road, Xi'an, 710004, Shaanxi, People's Republic of China. xjtu-guoyucheng@163.com.""}]",International journal of legal medicine,['10.1007/s00414-021-02559-2'] 1236,33763879,Immediate and lasting effects of aerobic exercise on the actigraphic sleep parameters of female nurses: A randomized controlled trial.,"Sleep disturbance is highly prevalent among shift-working nurses. We aimed to evaluate whether aerobic exercise (i.e., walking combined with jogging) improves objective sleep parameters among female nurses who met eligibility criterion as poor sleepers at the end of an 8-week exercise program and 4 weeks after study completion. This single-blinded, parallel-design, randomized controlled trial was conducted in a classroom of a hospital in northern Taiwan. Sixty eligible female nurses were randomly assigned to either the aerobic exercise (n = 30) or usual activity status (n = 30) group. A moderate-intensity aerobic exercise program was administered over 5 days (60 min per day) a week for 8 weeks after the nurses' day shifts. Objective sleep outcomes including total sleep time (TST), sleep onset latency (SOL), wake after sleep onset (WASO), and sleep efficiency (SE) were retrieved using an actigraph device. A generalized estimating equation model was used for data analysis. The aerobic exercise group exhibited improvements in TST and SE at 4 and 8 weeks compared with the baseline evaluation (TST: B = 70.49 and 55.96; SE: B = 5.21 and 3.98). Between-group differences were observed in SOL and WASO at 4 weeks but not 8 weeks compared with the baseline evaluation (SOL: B = -7.18; WASO: B = -11.38). Positive lasting effects for TST were observed only until the 4-week follow-up. To improve sleep quality and quantity, we encourage female nurses who sleep poorly to regularly perform moderate-intensity aerobic exercise.",2021,Between-group differences were observed in SOL and WASO at 4 weeks but not 8 weeks compared with the baseline evaluation (SOL: B = -7.18; WASO: B = -11.38).,"['classroom of a hospital in northern Taiwan', 'female nurses who sleep poorly to regularly perform moderate-intensity aerobic exercise', 'female nurses who met eligibility criterion as poor sleepers at the end of an 8-week exercise program and 4 weeks after study completion', 'Sixty eligible female nurses', 'female nurses']","['aerobic exercise', 'aerobic exercise (n\u2009=\u200930) or usual activity status', 'intensity aerobic exercise program', 'aerobic exercise (i.e., walking combined with jogging']","['Sleep disturbance', 'total sleep time (TST), sleep onset latency (SOL), wake after sleep onset (WASO), and sleep efficiency (SE', 'SOL and WASO', 'objective sleep parameters', 'actigraphic sleep parameters', 'sleep quality and quantity', 'TST and SE']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0205169', 'cui_str': 'Bad'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0022400', 'cui_str': 'Jogging'}]","[{'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C4505222', 'cui_str': 'Sleep Onset Latency'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}]",60.0,0.0703031,Between-group differences were observed in SOL and WASO at 4 weeks but not 8 weeks compared with the baseline evaluation (SOL: B = -7.18; WASO: B = -11.38).,"[{'ForeName': 'Shu-Fen', 'Initials': 'SF', 'LastName': 'Niu', 'Affiliation': 'Department of Nursing, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.'}, {'ForeName': 'Chia-Jou', 'Initials': 'CJ', 'LastName': 'Lin', 'Affiliation': 'School of Nursing, Taipei Medical University, Taipei, Taiwan.'}, {'ForeName': 'Pin-Yuan', 'Initials': 'PY', 'LastName': 'Chen', 'Affiliation': 'School of Medicine, Chang Gung University, Taoyuan, Taiwan.'}, {'ForeName': 'Yen-Chun', 'Initials': 'YC', 'LastName': 'Fan', 'Affiliation': 'School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan.'}, {'ForeName': 'Hui-Chuan', 'Initials': 'HC', 'LastName': 'Huang', 'Affiliation': 'School of Nursing, Taipei Medical University, Taipei, Taiwan.'}, {'ForeName': 'Hsiao-Yean', 'Initials': 'HY', 'LastName': 'Chiu', 'Affiliation': 'School of Nursing, Taipei Medical University, Taipei, Taiwan.'}]",Research in nursing & health,['10.1002/nur.22126'] 1237,33768603,Efficacy of Triprolidine in the Treatment of Temporary Sleep Disturbance.,"Triprolidine, a first-generation antihistamine for allergic rhinitis, has a shorter half-life and fewer persistent effects relative to other antihistamines and may be useful in the treatment of temporary sleep disturbance. Patients aged ≥18 years old were randomized 1:1:1 to receive either triprolidine 2.5 mg (n = 65), triprolidine 5 mg (n = 66), or placebo (n = 67) on 3 consecutive nights. Sleep disturbance index was monitored via wrist actimeter. Subjective measures were assessed via diary card. Triprolidine 2.5 mg had a significantly lower sleep disturbance index versus placebo on night 1 (P = .02); however, when adjusted for outliers, sleep disturbance index did not significantly differ between either dose of triprolidine versus placebo on night 1. Adjusted sleep disturbance index was significantly lower with triprolidine 2.5 and 5 mg versus placebo on night 3 (P = .0017 and P = .011, respectively) and for the mean of all 3 nights (P = .01 and P = .015, respectively). Sleep latency was significantly improved for triprolidine 2.5 mg versus placebo on nights 2 and 3 and for the mean of all 3 nights and for triprolidine 5 mg versus placebo for the mean of all 3 nights. Subjective measures showed those on both doses of triprolidine felt more refreshed on awakening versus placebo for the mean of all 3 nights, with no increase in daytime sleepiness. The frequency of adverse events was similar across groups. The optimum dose of triprolidine for treatment of temporary sleep disturbance was 2.5 mg. There were improvements in both objective and subjective measures of sleep quality versus placebo, with no safety concerns raised.",2021,"Adjusted sleep disturbance index was significantly lower with triprolidine 2.5 mg and 5 mg versus placebo on Night 3 (p = 0.0017 and p = 0.011, respectively), and for mean of all 3 nights (p = 0.01 and p = 0.015, respectively).","['temporary sleep disturbance', 'Patients aged ≥18 years old']","['Triprolidine', 'triprolidine', 'placebo']","['sleep disturbance index', 'temporary sleep disturbance', 'Adjusted sleep disturbance index', 'daytime sleepiness', 'Sleep disturbance index', 'Sleep latency', 'objective and subjective measures of sleep quality', 'frequency of adverse events']","[{'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0041098', 'cui_str': 'Triprolidine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}, {'cui': 'C4505222', 'cui_str': 'Sleep Onset Latency'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.178671,"Adjusted sleep disturbance index was significantly lower with triprolidine 2.5 mg and 5 mg versus placebo on Night 3 (p = 0.0017 and p = 0.011, respectively), and for mean of all 3 nights (p = 0.01 and p = 0.015, respectively).","[{'ForeName': 'Ana Santos', 'Initials': 'AS', 'LastName': 'Cravo', 'Affiliation': 'Global Medical Affairs Senior Advisor (Respiratory), Reckitt Benckiser Healthcare Ltd, Slough, UK.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Shephard', 'Affiliation': 'Global Marketing Director, Reckitt Benckiser Healthcare Ltd, Slough, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Shea', 'Affiliation': 'Senior Medical Scientist (Respiratory), Reckitt Benckiser Inc., Parsippany, New Jersey, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1861'] 1238,33768599,Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study.,"AIMS Implementation of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) remains incomplete. Non-cardiovascular hospitalization may present opportunities for GDMT optimization. We assessed the efficacy and durability of a virtual, multidisciplinary 'GDMT Team' on medical therapy prescription for HFrEF. METHODS AND RESULTS Consecutive hospitalizations in patients with HFrEF (ejection fraction ≤40%) were prospectively identified from 3 February to 1 March 2020 (usual care group) and 2 March to 28 August 2020 (intervention group). Patients with critical illness, de novo heart failure, and systolic blood pressure <90 mmHg in the preceeding 24 hs prior to enrollment were excluded. In the intervention group, a pharmacist-physician GDMT Team provided optimization suggestions to treating teams based on an evidence-based algorithm. The primary outcome was a GDMT optimization score, the sum of positive (+1 for new initiations or up-titrations) and negative therapeutic changes (-1 for discontinuations or down-titrations) at hospital discharge. Serious in-hospital safety events were assessed. Among 278 consecutive encounters with HFrEF, 118 met eligibility criteria; 29 (25%) received usual care and 89 (75%) received the GDMT Team intervention. Among usual care encounters, there were no changes in GDMT prescription during hospitalization. In the intervention group, β-blocker (72% to 88%; P = 0.01), angiotensin receptor-neprilysin inhibitor (6% to 17%; P = 0.03), mineralocorticoid receptor antagonist (16% to 29%; P = 0.05), and triple therapy (9% to 26%; P < 0.01) prescriptions increased during hospitalization. After adjustment for clinically relevant covariates, the GDMT Team was associated with an increase in GDMT optimization score (+0.58; 95% confidence interval +0.09 to +1.07; P = 0.02). There were no serious in-hospital adverse events. CONCLUSIONS Non-cardiovascular hospitalizations are a potentially safe and effective setting for GDMT optimization. A virtual GDMT Team was associated with improved heart failure therapeutic optimization. This implementation strategy warrants testing in a prospective randomized controlled trial.",2021,"In the intervention group, β-blocker (72% to 88%; P=0.01), ARNI (6% to 17%; P=0.03), MRA (16% to 29%; P=0.05), and triple therapy (9% to 26%; P<0.01) prescriptions increased during hospitalization.","['Consecutive hospitalizations in patients with HFrEF≤40% were prospectively identified from February 3 to March 1, 2020 (usual care group) and March 2 to August 28, 2020 (intervention group', 'Hospitalized Patients with Heart Failure with Reduced Ejection Fraction', 'Patients with critical illness, de-novo HF, and SBP<90mmHg were excluded', '278 consecutive encounters with HFrEF, 118 met eligibility criteria; 29 (25%) received usual care and 89 (75%) received the']","['HFrEF', 'Virtual Optimization of Guideline-Directed Medical Therapy', 'GDMT Team intervention']","['GDMT optimization score, the net of positive (+1 for new initiations or up-titrations) & negative therapeutic changes (-1 for discontinuations or down-titrations) at hospital discharge', 'GDMT optimization score', 'hospital adverse events', 'ARNI', 'β-blocker', 'efficacy and durability', 'MRA']","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0243032', 'cui_str': 'Magnetic resonance imaging (MRI) of vessels'}]",,0.0314161,"In the intervention group, β-blocker (72% to 88%; P=0.01), ARNI (6% to 17%; P=0.03), MRA (16% to 29%; P=0.05), and triple therapy (9% to 26%; P<0.01) prescriptions increased during hospitalization.","[{'ForeName': 'Ankeet S', 'Initials': 'AS', 'LastName': 'Bhatt', 'Affiliation': ""Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Anubodh S', 'Initials': 'AS', 'LastName': 'Varshney', 'Affiliation': ""Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Mahan', 'Initials': 'M', 'LastName': 'Nekoui', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Alea', 'Initials': 'A', 'LastName': 'Moscone', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Jonathan W', 'Initials': 'JW', 'LastName': 'Cunningham', 'Affiliation': ""Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Karola S', 'Initials': 'KS', 'LastName': 'Jering', 'Affiliation': ""Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Parth N', 'Initials': 'PN', 'LastName': 'Patel', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Sinnenberg', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Thomas D', 'Initials': 'TD', 'LastName': 'Bernier', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Leo F', 'Initials': 'LF', 'LastName': 'Buckley', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Bryan M', 'Initials': 'BM', 'LastName': 'Cook', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Jillian', 'Initials': 'J', 'LastName': 'Dempsey', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Kelly', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Danielle M', 'Initials': 'DM', 'LastName': 'Knowles', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Lupi', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Rhynn', 'Initials': 'R', 'LastName': 'Malloy', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Lina S', 'Initials': 'LS', 'LastName': 'Matta', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Megan N', 'Initials': 'MN', 'LastName': 'Rhoten', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Krishan', 'Initials': 'K', 'LastName': 'Sharma', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Caroline A', 'Initials': 'CA', 'LastName': 'Snyder', 'Affiliation': 'Brown University, Providence, RI, USA.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Ting', 'Affiliation': ""Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'McElrath', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Mary G', 'Initials': 'MG', 'LastName': 'Amato', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Alobaidly', 'Affiliation': ""Department of Quality and Safety, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Ulbricht', 'Affiliation': 'Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.'}, {'ForeName': 'Niteesh K', 'Initials': 'NK', 'LastName': 'Choudhry', 'Affiliation': ""Center for Healthcare Delivery Sciences, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Dale S', 'Initials': 'DS', 'LastName': 'Adler', 'Affiliation': ""Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Muthiah', 'Initials': 'M', 'LastName': 'Vaduganathan', 'Affiliation': ""Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}]",European journal of heart failure,['10.1002/ejhf.2163'] 1239,33772892,The Effect of Therapeutic Alliance on Dropout in Cognitive Processing Therapy for Posttraumatic Stress Disorder.,"A substantial number of individuals who undergo cognitive processing therapy (CPT) for posttraumatic stress disorder (PTSD) drop out before receiving a full course of treatment. Therapeutic alliance, defined as the working relationship between the therapist and client, is a dynamic process within therapy that may change over time. Research suggests that therapeutic alliance is associated with dropout in various treatments. However, no studies have yet examined the association between therapeutic alliance and dropout in CPT, and few studies have examined therapeutic alliance longitudinally over the course of treatment. Examining alliance in CPT through different methods may increase clinicians' understanding of how to tailor interventions to prevent treatment dropout. The present study examined the association between therapeutic alliance and treatment dropout among 169 participants in a randomized implementation effectiveness trial. In total, 33.1% of clients dropped out over the course of CPT, and nearly half of these individuals dropped out during the first six sessions. Continuous-time survival analysis results indicated that mean ratings of alliance significantly predicted treatment dropout, Wald χ 2 (1, N = 167) = 4.08, Exp(β) = .64, p = .043, whereas initial alliance, late alliance, and change in alliance over treatment did not. These findings suggest that overall therapeutic alliance is an important predictor of dropout from CPT.",2021,"whereas initial alliance, late alliance, and change in alliance over treatment did not.","['169 participants', 'Posttraumatic Stress Disorder']",['cognitive processing therapy (CPT'],"['initial alliance, late alliance, and change in alliance']","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}]","[{'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",169.0,0.0259118,"whereas initial alliance, late alliance, and change in alliance over treatment did not.","[{'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Sijercic', 'Affiliation': 'Department of Psychology, Ryerson University, Toronto, Canada.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Liebman', 'Affiliation': 'Department of Psychology, Ryerson University, Toronto, Canada.'}, {'ForeName': 'Shannon Wiltsey', 'Initials': 'SW', 'LastName': 'Stirman', 'Affiliation': 'National Center for PTSD, Menlo Park, California, USA.'}, {'ForeName': 'Candice M', 'Initials': 'CM', 'LastName': 'Monson', 'Affiliation': 'Department of Psychology, Ryerson University, Toronto, Canada.'}]",Journal of traumatic stress,['10.1002/jts.22676'] 1240,33775203,The effects of 12-months supervised periodized training on health-related physical fitness in coronary artery disease: a randomized controlled trial.,"We compared the impact of a one-year periodized exercise training versus a non-periodized exercise training on health-related physical fitness (HRPF) including body composition, cardiorespiratory and muscular fitness in patients with coronary artery disease (CAD). Fifty CAD patients (60.4 ± 9.9 years) were randomized to either a periodized training group (PG) (n = 25) or a non-periodized training group (NPG) (n = 25). Both consisted of a combined training programme, performed 3 days/week for 12 months. Thirty-six CAD patients (PG: n = 18, NPG: n = 18) successfully completed the exercise regimes. In both groups, a favourable main effect for time was evident for peak VO 2 , peak workload, anaerobic threshold and respiratory compensation point workloads and VO 2 , whole body skeletal muscle mass and quality index at 12 months.In conclusion, a periodized model is as effective as a non-periodized model in promoting increases in HRPF outcomes following a one-year intervention. These findings indicate that health-professionals can add variation to cardiac rehabilitation workouts without compromising effectiveness.",2021,"In conclusion, a periodized model is as effective as a non-periodized model in promoting increases in HRPF outcomes following a one-year intervention.","['Fifty CAD patients (60.4\xa0±\xa09.9\xa0years', 'patients with coronary artery disease (CAD', 'Thirty-six CAD patients (PG: n =\xa018, NPG: n =\xa018) successfully completed the exercise regimes', 'coronary artery disease']","['12-months supervised periodized training', 'periodized exercise training versus a non-periodized exercise training', 'periodized training group (PG) (n\xa0=\xa025) or a non-periodized training group (NPG']","['HRPF outcomes', 'peak VO 2 , peak workload, anaerobic threshold and respiratory compensation point workloads and VO 2 , whole body skeletal muscle mass and quality index', 'health-related physical fitness', 'health-related physical fitness (HRPF) including body composition, cardiorespiratory and muscular fitness']","[{'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0454291', 'cui_str': 'Exercise regime'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0002749', 'cui_str': 'Anaerobic Threshold'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}]",50.0,0.0109503,"In conclusion, a periodized model is as effective as a non-periodized model in promoting increases in HRPF outcomes following a one-year intervention.","[{'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Pinto', 'Affiliation': 'Serviço de Cardiologia, Departamento Coração E Vasos, Centro Hospitalar Universitário Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Melo', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Cruz Quebrada, Portugal.'}, {'ForeName': 'Vitor', 'Initials': 'V', 'LastName': 'Angarten', 'Affiliation': 'Faculdade de Motricidade Humana, Universidade de Lisboa, Cruz Quebrada, Portugal.'}, {'ForeName': 'Madalena Lemos', 'Initials': 'ML', 'LastName': 'Pires', 'Affiliation': 'Serviço de Cardiologia, Departamento Coração E Vasos, Centro Hospitalar Universitário Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Borges', 'Affiliation': 'Serviço de Cardiologia, Departamento Coração E Vasos, Centro Hospitalar Universitário Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Santos', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Cruz Quebrada, Portugal.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Abreu', 'Affiliation': 'Serviço de Cardiologia, Departamento Coração E Vasos, Centro Hospitalar Universitário Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Santa-Clara', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Cruz Quebrada, Portugal.'}]",Journal of sports sciences,['10.1080/02640414.2021.1907062'] 1241,33793734,Cost-effectiveness of immediate total-body CT in patients with severe trauma (REACT-2 trial).,"BACKGROUND The effect of immediate total-body CT (iTBCT) on health economic aspects in patients with severe trauma is an underreported issue. This study determined the cost-effectiveness of iTBCT compared with conventional radiological imaging with selective CT (standard work-up (STWU)) during the initial trauma evaluation. METHODS In this multicentre RCT, adult patients with a high suspicion of severe injury were randomized in-hospital to iTBCT or STWU. Hospital healthcare costs were determined for the first 6 months after the injury. The probability of iTBCT being cost-effective was calculated for various levels of willingness-to-pay per extra patient alive. RESULTS A total of 928 Dutch patients with complete clinical follow-up were included. Mean costs of hospital care were €25 809 (95 per cent bias-corrected and accelerated (bca) c.i. €22 617 to €29 137) for the iTBCT group and €26 155 (€23 050 to €29 344) for the STWU group, a difference per patient in favour of iTBCT of €346 (€4987 to €4328) (P = 0.876). Proportions of patients alive at 6 months were not different. The proportion of patients alive without serious morbidity was 61.6 per cent in the iTBCT group versus 66.7 per cent in the STWU group (difference -5.1 per cent; P = 0.104). The probability of iTBCT being cost-effective in keeping patients alive remained below 0.56 for the whole group, but was higher in patients with multiple trauma (0.8-0.9) and in those with traumatic brain injury (more than 0.9). CONCLUSION Economically, from a hospital healthcare provider perspective, iTBCT should be the diagnostic strategy of first choice in patients with multiple trauma or traumatic brain injury.",2021,"The probability of iTBCT being cost-effective in keeping patients alive remained below 0.56 for the whole group, but was higher in patients with multiple trauma (0.8-0.9) and in those with traumatic brain injury (more than 0.9). ","['22', '928 Dutch patients with complete clinical follow-up were included', '617 to €29\xa0137) for the iTBCT group and €26', 'patients with multiple trauma or traumatic brain injury', 'adult patients with a high suspicion of severe injury', 'patients with severe trauma', 'patients with severe trauma (REACT-2 trial']","['immediate total-body CT', 'conventional radiological imaging with selective CT (standard work-up (STWU', 'iTBCT', 'immediate total-body CT (iTBCT']","['proportion of patients alive without serious morbidity', 'probability of iTBCT being cost-effective', 'Mean costs of hospital care', 'Hospital healthcare costs', 'Cost-effectiveness']","[{'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0026771', 'cui_str': 'Multiple injuries'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0242114', 'cui_str': 'Suspicion'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C4224854', 'cui_str': 'React'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0557391', 'cui_str': 'Quality of work'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0085552', 'cui_str': 'Health Costs'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",928.0,0.0617057,"The probability of iTBCT being cost-effective in keeping patients alive remained below 0.56 for the whole group, but was higher in patients with multiple trauma (0.8-0.9) and in those with traumatic brain injury (more than 0.9). ","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Treskes', 'Affiliation': 'Trauma Unit, Department of Surgery, Amsterdam University Medical Centre, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Sierink', 'Affiliation': 'Trauma Unit, Department of Surgery, Amsterdam University Medical Centre, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'M J R', 'Initials': 'MJR', 'LastName': 'Edwards', 'Affiliation': 'Trauma Unit, Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands.'}, {'ForeName': 'B J A', 'Initials': 'BJA', 'LastName': 'Beuker', 'Affiliation': 'Trauma Unit, Department of Surgery, University Medical Centre Groningen, Groningen, the Netherlands.'}, {'ForeName': 'E M M', 'Initials': 'EMM', 'LastName': 'Van Lieshout', 'Affiliation': 'Trauma Unit, Department of Surgery, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hohmann', 'Affiliation': 'Department of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'T P', 'Initials': 'TP', 'LastName': 'Saltzherr', 'Affiliation': 'Department of Surgery, Haaglanden Medical Centre, Den Haag, the Netherlands.'}, {'ForeName': 'M W', 'Initials': 'MW', 'LastName': 'Hollmann', 'Affiliation': 'Department of Anaesthesiology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Van Dieren', 'Affiliation': 'Department of Surgery, Amsterdam University Medical Centre, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Goslings', 'Affiliation': 'Trauma Unit, Department of Surgery, Amsterdam University Medical Centre, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'M G W', 'Initials': 'MGW', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Epidemiology and Data Science, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The British journal of surgery,['10.1093/bjs/znaa091'] 1242,33798731,The feasibility and acceptability of a web-based physical activity for the heart (PATH) intervention designed to reduce the risk of heart disease among inactive African Americans: Protocol for a pilot randomized controlled trial.,"BACKGROUND Many studies have used the internet to promote physical activity (PA) in several settings, including the home environment, but few have been tailored for African Americans (AAs). To address this research gap, we conducted focus groups with AAs to inform the development of a web-based intervention, Physical Activity for The Heart (PATH), that leverages openly accessible platforms, such as YouTube, to promote PA in any setting. PURPOSE To describe the rationale and design of a pilot randomized clinical trial (RCT), that examines the feasibility and acceptability of the PATH intervention among 30 AA adults aged 40--70 years without history of cardiovascular disease. METHODS A 12-week, single-site, wait-listed RCT with subjects randomized 1:1 to either: 1) treatment group - participants receive the PATH intervention, including the online portal and twice a month phone calls from a PA coach, or 2) attention control group - participants receive a self-help PA handout and twice a month general health newsletter. All participants self-monitor step count using actigraphy. The primary outcomes of this 12-week, pilot RCT are recruitment, retention, and adherence to self-monitoring (Actigraph wear time) and the intervention protocol (PATH utilization). The secondary outcomes include changes in PA (step count, moderate-to-vigorous PA, exercise self-efficacy), and cardiometabolic risk (HbA1C, HDL, LDL, total cholesterol, type 2 diabetes risk score, percent body fat, weight, and waist circumference) from baseline to 12 weeks. CONCLUSIONS This study will provide PATH intervention feasibility and acceptability data among inactive AA adults and will inform a future, full-scale RCT testing efficacy.",2021,"The secondary outcomes include changes in PA (step count, moderate-to-vigorous PA, exercise self-efficacy), and cardiometabolic risk (HbA1C, HDL, LDL, total cholesterol, type 2 diabetes risk score, percent body fat, weight, and waist circumference) from baseline to 12 weeks. ","['inactive African Americans', '30 AA adults aged 40-70\u202fyears without history of cardiovascular disease', 'African Americans (AAs', 'inactive AA adults']","[' 1) treatment group - participants receive the PATH intervention, including the online portal and twice a month phone calls from a PA coach, or 2) attention control group - participants receive a self-help PA handout and twice a month general health newsletter', 'web-based physical activity for the heart (PATH) intervention', 'PATH intervention']","['changes in PA (step count, moderate-to-vigorous PA, exercise self-efficacy), and cardiometabolic risk (HbA1C, HDL, LDL, total cholesterol, type 2 diabetes risk score, percent body fat, weight, and waist circumference', 'recruitment, retention, and adherence to self-monitoring (Actigraph wear time) and the intervention protocol (PATH utilization']","[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0455539', 'cui_str': 'H/O: cardiovascular disease'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0027988', 'cui_str': 'Newsletters'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0851408', 'cui_str': 'Changes in physical activity'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",,0.0893407,"The secondary outcomes include changes in PA (step count, moderate-to-vigorous PA, exercise self-efficacy), and cardiometabolic risk (HbA1C, HDL, LDL, total cholesterol, type 2 diabetes risk score, percent body fat, weight, and waist circumference) from baseline to 12 weeks. ","[{'ForeName': 'Jacob K', 'Initials': 'JK', 'LastName': 'Kariuki', 'Affiliation': 'University of Pittsburgh, PA, USA. Electronic address: kigok@pitt.edu.'}, {'ForeName': 'Bethany B', 'Initials': 'BB', 'LastName': 'Gibbs', 'Affiliation': 'University of Pittsburgh, PA, USA.'}, {'ForeName': 'Kirk I', 'Initials': 'KI', 'LastName': 'Erickson', 'Affiliation': 'University of Pittsburgh, PA, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Kriska', 'Affiliation': 'University of Pittsburgh, PA, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Sereika', 'Affiliation': 'University of Pittsburgh, PA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ogutu', 'Affiliation': 'Ritiko Cloud-based Home-care Software, MA, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Milton', 'Affiliation': 'New York University, NY, USA.'}, {'ForeName': ""La'Vette"", 'Initials': 'L', 'LastName': 'Wagner', 'Affiliation': 'University of Pittsburgh, PA, USA.'}, {'ForeName': 'Neel', 'Initials': 'N', 'LastName': 'Rao', 'Affiliation': 'University of Pittsburgh, PA, USA.'}, {'ForeName': 'Ray', 'Initials': 'R', 'LastName': 'Peralta', 'Affiliation': 'New York University, NY, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Bobb', 'Affiliation': 'Medtronic Medical Device Company, MN, USA.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Bermudez', 'Affiliation': 'University of Pittsburgh, PA, USA.'}, {'ForeName': 'Sabina', 'Initials': 'S', 'LastName': 'Hirshfield', 'Affiliation': 'SUNY Downstate Medical Center, NY, USA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Goetze', 'Affiliation': 'Primary Health Network, PA, USA.'}, {'ForeName': 'Lora E', 'Initials': 'LE', 'LastName': 'Burke', 'Affiliation': 'University of Pittsburgh, PA, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106380'] 1243,33811392,Development of an assessment measure for sexual disinhibition in dementia.,"OBJECTIVE Sexual disinhibition (SD), a neuropsychiatric symptom characterized by sexually inappropriate comments and/or behaviors, remains under identified in dementia, possibly due to a lack of standardized assessment methods. A recent systematic review of measures used to assess SD proposed four behavioral domains and identified the need for a population-specific measure. The present study addressed this by examining the underlying factor structure of SD to create a new caregiver-report measure. METHODS Dementia caregivers (n = 622) recruited online were randomly assigned to Initial Validation (n = 311) or Cross-Validation (n = 311) groups. RESULTS Initial Validation revealed five behavioral domains that served as provisional scales for cross-validation, leading to measure development. CONCLUSIONS The current study is the first to statistically evaluate the underlying factor structure of SD, resulting in a new measure that can help better characterize and identify SD.",2021,"The present study addressed this by examining the underlying factor structure of sexual disinhibition to create a new caregiver-report measure. ","['Sexual Disinhibition in Dementia', 'Dementia caregivers (n=622) recruited online were randomly assigned to Initial Validation (n=311) or Cross-Validation (n=311) groups']",[],[],"[{'cui': 'C0562557', 'cui_str': 'Sexually disinhibited behavior'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],[],622.0,0.0790599,"The present study addressed this by examining the underlying factor structure of sexual disinhibition to create a new caregiver-report measure. ","[{'ForeName': 'Kimberly R', 'Initials': 'KR', 'LastName': 'Chapman', 'Affiliation': 'Department of Psychological Sciences, Kent State University, Kent, Ohio, USA.'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Tremont', 'Affiliation': 'Department of Psychiatry, Rhode Island Hospital, Providence, Rhode Island, USA.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Spitznagel', 'Affiliation': 'Department of Psychological Sciences, Kent State University, Kent, Ohio, USA.'}]",International journal of geriatric psychiatry,['10.1002/gps.5552'] 1244,33813906,Improving efficiency in the stepped-wedge trial design via Bayesian modeling with an informative prior for the time effects.,"BACKGROUND In a cross-sectional stepped-wedge cluster randomized trial comparing usual care to a new intervention, treatment allocation and time are correlated by design because participants enrolled early in the trial predominantly receive usual care while those enrolled late in the trial predominantly receive the new intervention. Current guidelines recommend adjustment for time effects when analyzing stepped-wedge cluster randomized trials to remove the confounding bias induced by this correlation. However, adjustment for time effects impacts study power. Within the Frequentist framework, adopting a sample size calculation that includes time effects would ensure the trial having adequate power regardless of the magnitude of the effect of time on the outcome. But if in fact time effects were negligible, this would overestimate the required sample size and could lead to the trial being deemed infeasible due to cost or unavailability of the required numbers of clusters or participants. In this study, we explore the use of prior information on time effects to potentially reduce the required sample size of the trial. METHODS We applied a Bayesian approach to incorporate the prior information on the time effects into cluster-level statistical models (for continuous, binary, or count outcomes) for the stepped-wedge cluster randomized trial. We conducted simulations to illustrate how the bias in the intervention effect estimate and the trial power vary as a function of the prior precision and the mis-specification of the prior means of the time effects in an example scenario. RESULTS When a nearly flat prior for the time effects was used, the power or sample size calculated using the Bayesian approach matched the result obtained using the Frequentist approach with time effects included. When a highly precise prior for the time effects (with accurately specified prior means) was used, the Bayesian result matched the Frequentist result obtained with time effects excluded. When the prior means of the time effects were nearly correctly specified, including this information improved the efficiency of the trial with little bias introduced into the intervention effect estimate. When the prior means of the time effects were greatly mis-specified and a precise prior was used, this bias was substantial. CONCLUSION Including prior information on time effects using a Bayesian approach may substantially reduce the required sample size. When the prior can be justified, results from applying this approach could support the conduct of a trial, which would be deemed infeasible if based on the larger sample size obtained using a Frequentist calculation. Caution is warranted as biased intervention effect estimates may arise when the prior distribution for the time effects is concentrated far from their true values.",2021,"When a nearly flat prior for the time effects was used, the power or sample size calculated using the Bayesian approach matched the result obtained using the Frequentist approach with time effects included.",['participants enrolled early in the trial predominantly receive usual care while those enrolled late in the trial predominantly receive the new intervention'],[],[],"[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],[],,0.0273089,"When a nearly flat prior for the time effects was used, the power or sample size calculated using the Bayesian approach matched the result obtained using the Frequentist approach with time effects included.","[{'ForeName': 'Denghuang', 'Initials': 'D', 'LastName': 'Zhan', 'Affiliation': 'School of Population & Public Health, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Yongdong', 'Initials': 'Y', 'LastName': 'Ouyang', 'Affiliation': 'School of Population & Public Health, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'School of Population & Public Health, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Wong', 'Affiliation': 'School of Population & Public Health, University of British Columbia, Vancouver, BC, Canada.'}]","Clinical trials (London, England)",['10.1177/1740774520980052'] 1245,33781394,The effectiveness of illness management and recovery program in patients with schizophrenia.,"AIM This study was conducted to determine the effect of the illness management and recovery program in patients with schizophrenia. METHODS This study was conducted using a pretest, posttest and follow up experimental design with randomized controlled. The sample of this study consisted of patients with schizophrenia (n = 50). The patients were assigned to intervention (n = 25) and control (n = 25) groups using the randomisation method. The intervention group consisted of 10 modules and 20 sessions of Illness Management and Recovery Program, while in the control group, a face-to-face interview. Data were collected by the Illness Management and Recovery Scale-Patient Form (IMRS-P) and Social Functioning Scale-Patient Form (SFS-P). RESULTS There were significant differences in posttest and 1-month follow-up IMRS-P points between the intervention and control groups. There was no significant difference in post-test and 1-month follow-up SFS-P total points between the intervention and control groups. There were only significant differences for the pro-social activities' subscale of SFS-P. CONCLUSION The Illness Management and Recovery Program have a positive effect on illness management and social functionality in patients with schizophrenia. In the light of this study, it was suggested that this structured program should be used by mental health and psychiatric nurses.",2021,There were significant differences in posttest and 1-month follow-up IMRS-P points between the intervention and control groups.,"['patients with schizophrenia (n\xa0=\xa050', 'patients with schizophrenia']","['10 modules and 20 sessions of Illness Management and Recovery Program, while in the control group, a face-to-face interview']","['Illness Management and Recovery Scale-Patient Form (IMRS-P) and Social Functioning Scale-Patient Form (SFS-P', ""pro-social activities' subscale""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]","[{'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]","[{'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C2585826', 'cui_str': 'Social functioning scale'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",50.0,0.00603735,There were significant differences in posttest and 1-month follow-up IMRS-P points between the intervention and control groups.,"[{'ForeName': 'Selda', 'Initials': 'S', 'LastName': 'Polat', 'Affiliation': 'Bahcesehir University, Faculty of Health Sciences, Nursing Department, Istanbul, Turkey. Electronic address: selda.polat@hes.bau.edu.tr.'}, {'ForeName': 'Yasemin', 'Initials': 'Y', 'LastName': 'Kutlu', 'Affiliation': 'Istanbul University-Cerrahpasa, Florence Nightingale Faculty of Nursing, Mental Health and Psychiatric Nursing Department, Istanbul, Turkey. Electronic address: kutluy@istanbul.edu.tr.'}]",Archives of psychiatric nursing,['10.1016/j.apnu.2021.01.004'] 1246,33238805,Visual Attention to the Use of #ad versus #sponsored on e-Cigarette Influencer Posts on Social Media: A Randomized Experiment.,"Youth and young adults are the largest consumers of social media content. Individuals with large followers are paid to share social media content using specific products for compensation. This type of activity is considered commercial sponsorship and requires a disclosure in order to comply with Federal Trade Commission regulations. Between July and August 2019, youth and young adult (ages 16-24; n = 200) participants were recruited into an eye-tracking laboratory to view their native Instagram feed on a mobile device where a set of posts from e-cigarette influencers were inserted with one of the two potential labeling strategies: #ad and #sponsored. Participants spent an average of 6.6 seconds viewing e-cigarette influencer posts. Youth and young adults spent 3.1 seconds on the area labeled #ad, compared to 2.2 seconds on the area of interest labeled #sponsored ( p = .03). After accounting for age, current tobacco use, and dependence, #ad drew 0.93 seconds more than #sponsored on influencer posts ( p = .02). Both labeling strategies drew visual attention to Instagram e-cigarette influencer posts, with nearly 1 second more attention paid to the presence of #ad. Labeling commercially sponsored content on social media is a viable strategy to attract the attention of youth and young adults.",2020,"After accounting for age, current tobacco use, and dependence, #ad drew 0.93 seconds more than #sponsored on influencer posts ( p = .02).","['youth and young adults', 'Participants spent an average of 6.6\xa0seconds viewing e-cigarette influencer posts', 'Between July and August 2019, youth and young adult (ages 16-24; n =\xa0200) participants were recruited into an eye-tracking laboratory to view their native Instagram feed on a mobile device where a set of posts from e-cigarette influencers', 'Youth and young adults']",[],[],"[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C4517823', 'cui_str': '6.6'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C3849993', 'cui_str': 'Electronic cigarette'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]",[],[],200.0,0.0183349,"After accounting for age, current tobacco use, and dependence, #ad drew 0.93 seconds more than #sponsored on influencer posts ( p = .02).","[{'ForeName': 'Elizabeth G', 'Initials': 'EG', 'LastName': 'Klein', 'Affiliation': 'Division of Health Behavior & Health Promotion, Ohio State University College of Public Health, Columbus, Ohio, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Czaplicki', 'Affiliation': 'Truth Initiative, Washington, District of Columbia, USA.'}, {'ForeName': 'Micah', 'Initials': 'M', 'LastName': 'Berman', 'Affiliation': 'Division of Health Services, Management and Policy, Ohio State University College of Public Health, Columbus, Ohio, USA.'}, {'ForeName': 'Sherry', 'Initials': 'S', 'LastName': 'Emery', 'Affiliation': 'Social Data Collaboratory, NORC at the University of Chicago, Chicago, Illinois, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Schillo', 'Affiliation': 'Truth Initiative, Washington, District of Columbia, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1849464'] 1247,33242754,A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.,"PURPOSE Despite triple antiemetic therapy use for breast cancer patients receiving emetogenic chemotherapy, nausea remains a clinical challenge. We evaluated adding olanzapine (5 mg) to triple therapy on nausea control in patients at high personal risk of chemotherapy-induced nausea and vomiting (CINV). METHODS This multi-centre, placebo-controlled, double-blind trial randomized breast cancer patients scheduled to receive neo/adjuvant chemotherapy with anthracycline-cyclophosphamide or platinum-based chemotherapy to olanzapine (5 mg, days 1-4) or placebo. Primary endpoint was frequency of self-reported significant nausea, repeated for all cycles of chemotherapy. Secondary endpoints included: duration of nausea, overall total control of CINV, Health Related Quality of Life (HRQoL) using FLIE questionnaire, use of rescue mediation and treatment-related adverse events. RESULTS 218 eligible patients were randomised to placebo (105) or olanzapine (113). From days 0-5 following each cycle of chemotherapy, 41.3% (95%CI: 36.1-46.7%) of patients in the placebo group reported significant nausea compared to 27.7% (95%CI: 23.2-32.4%) in the olanzapine group (p = 0.001). Across all cycles of chemotherapy, patients receiving olanzapine experienced a statistically significant improvement in HRQoL (p < 0.001). Grade 1/2 sedation was the most commonly side effect reported at 40.8% in the placebo group vs. 54.1% with olanzapine (p < 0.001). CONCLUSION In patients at high personal risk of CINV, the addition of olanzapine 5 mg daily to standard antiemetic therapy significantly improves the control of nausea, HRQoL, with no unexpected toxicities.",2020,"Across all cycles of chemotherapy, patients receiving olanzapine experienced a statistically significant improvement in HRQoL (p < 0.001).","['breast cancer patients receiving', 'patients at high personal risk of chemotherapy-induced nausea and vomiting (CINV', '218 eligible patients', 'breast cancer patients scheduled to receive', 'breast cancer patients at high risk for chemotherapy-induced nausea and vomiting']","['placebo', 'individualized versus standard of care antiemetic therapy', 'emetogenic chemotherapy', 'neo/adjuvant chemotherapy with anthracycline-cyclophosphamide or platinum-based chemotherapy to olanzapine', 'olanzapine']","['duration of nausea, overall total control of CINV, Health Related Quality of Life (HRQoL) using FLIE questionnaire, use of rescue mediation and treatment-related adverse events', 'nausea', 'control of nausea, HRQoL, with no unexpected toxicities', 'frequency of self-reported significant nausea, repeated for all cycles of chemotherapy', 'HRQoL', 'Grade 1/2 sedation', 'nausea control']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0401160', 'cui_str': 'Chemotherapy-induced nausea and vomiting'}, {'cui': 'C4517647', 'cui_str': '218'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0013973', 'cui_str': 'Emetic'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0401160', 'cui_str': 'Chemotherapy-induced nausea and vomiting'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0680727', 'cui_str': 'Mediation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0580272', 'cui_str': '1/2'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}]",218.0,0.520525,"Across all cycles of chemotherapy, patients receiving olanzapine experienced a statistically significant improvement in HRQoL (p < 0.001).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Clemons', 'Affiliation': 'Department of Medicine and Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada; Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Clinical Epidemiology Program, The Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada. Electronic address: mclemons@toh.ca.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Dranitsaris', 'Affiliation': 'Consultant Biostatistician, 283 Danforth Ave, Toronto, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Sienkiewicz', 'Affiliation': 'Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sehdev', 'Affiliation': 'Department of Medicine and Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Ng', 'Affiliation': 'Department of Medicine and Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Robinson', 'Affiliation': 'Cancer Centre of Southeastern Ontario, Kingston General Hospital, Kingston, ON, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mates', 'Affiliation': 'Cancer Centre of Southeastern Ontario, Kingston General Hospital, Kingston, ON, Canada.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Hsu', 'Affiliation': 'Department of Medicine and Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'McGee', 'Affiliation': 'Department of Medicine and Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Freedman', 'Affiliation': 'Division of Medical Oncology, Durham Regional Cancer Centre, Oshawa, Ontario, Canada.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Kumar', 'Affiliation': 'Markham Stouffville Hospital, Shakir Rehmatullah Cancer Clinic, Markham, Ontario, Canada.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Fergusson', 'Affiliation': 'Clinical Epidemiology Program, The Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Hutton', 'Affiliation': 'Clinical Epidemiology Program, The Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Vandermeer', 'Affiliation': 'Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hilton', 'Affiliation': 'Department of Medicine and Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada; Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.11.002'] 1248,33246064,Transcranial Magnetic Stimulation and H 1 -Magnetic Resonance Spectroscopy Measures of Excitation and Inhibition Following Lorazepam Administration.,"This study aimed at better understanding the neurochemistry underlying transcranial magnetic stimulation (TMS) and magnetic resonance spectroscopy (MRS) measurements as it pertains to GABAergic activity following administration of allosteric GABA A receptor agonist lorazepam. Seventeen healthy adults (8 females, 26.0 ± 5.4 years old) participated in a double-blind, crossover, placebo-controlled study, where participants underwent TMS and MRS two hours after drug intake (placebo or lorazepam; 2.5 mg). Neuronavigated TMS measures reflecting cortical inhibition and excitation were obtained in the left primary motor cortex. Sensorimotor cortex and occipital cortex MRS data were acquired using a 3T scanner with a MEGA-PRESS sequence, allowing water-referenced [GABA] and [Glx] (glutamate + glutamine) quantification. Lorazepam administration decreased occipital [GABA], decreased motor cortex excitability and increased GABA A -receptor mediated motor cortex inhibition (short intracortical inhibition (SICI)). Lorazepam intake did not modulate sensorimotor [GABA] and TMS measures of intra-cortical facilitation, long-interval cortical inhibition, cortical silent period, and resting motor threshold. Furthermore, higher sensorimotor [GABA] was associated with higher cortical inhibition (SICI) following lorazepam administration, suggesting that baseline sensorimotor [GABA] may be valuable in predicting pharmacological or neuromodulatory treatment response. Finally, the differential effects of lorazepam on MRS and TMS measures, with respect to GABA, support the idea that TMS measures of cortical inhibition reflect synaptic GABAergic phasic inhibitory activity while MRS reflects extrasynaptic GABA.",2021,"Lorazepam administration decreased occipital [GABA], decreased motor cortex excitability and increased GABA A -receptor mediated motor cortex inhibition (SICI).","['Seventeen healthy adults (8 females, 26.0 ± 5.4 years old']","['Lorazepam', 'placebo', 'TMS', 'lorazepam', 'TMS and MRS two hours after drug intake (placebo or lorazepam', 'Neuronavigated TMS']","['occipital [GABA', 'sensorimotor [GABA] and TMS measures of intra-cortical facilitation, long-interval cortical inhibition, cortical silent period, and resting motor threshold', 'motor cortex excitability and increased GABA A -receptor mediated motor cortex inhibition (SICI']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517792', 'cui_str': '5.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0024002', 'cui_str': 'Lorazepam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}]","[{'cui': 'C0016904', 'cui_str': 'Gamma-aminobutyric acid'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0443304', 'cui_str': 'Silent'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0026607', 'cui_str': 'Motor cortex'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0034807', 'cui_str': 'GABA-benzodiazepine receptor'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}]",17.0,0.180561,"Lorazepam administration decreased occipital [GABA], decreased motor cortex excitability and increased GABA A -receptor mediated motor cortex inhibition (SICI).","[{'ForeName': 'Marie Chantal', 'Initials': 'MC', 'LastName': 'Ferland', 'Affiliation': 'Département de psychologie, Université de Montréal, Québec, Canada.'}, {'ForeName': 'Jean-Marc', 'Initials': 'JM', 'LastName': 'Therrien-Blanchet', 'Affiliation': 'Département de psychologie, Université de Montréal, Québec, Canada.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Proulx', 'Affiliation': 'Mcgill University, Montréal, Canada.'}, {'ForeName': 'Gabrielle', 'Initials': 'G', 'LastName': 'Klees-Themens', 'Affiliation': 'Département de psychologie, Université de Montréal, Québec, Canada.'}, {'ForeName': 'Benoit-Antoine', 'Initials': 'BA', 'LastName': 'Bacon', 'Affiliation': 'Department of Psychology, Carleton University, Ottawa, Canada.'}, {'ForeName': 'Thien Thanh', 'Initials': 'TT', 'LastName': 'Dang Vu', 'Affiliation': 'Center for Studies in Behavioral Neurobiology and Perform Center, Department of Health, Kinesiology and Applied Physiology, Concordia University, Montreal, QC, Canada; Research Center, Institut Universitaire de Gériatrie de Montréal, Montréal, Qc, Canada.'}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Théoret', 'Affiliation': ""Département de psychologie, Université de Montréal, Québec, Canada; Centre de recherche du Centre Hospitalier Universitaire de l'Hôpital Sainte-Justine, Montréal, Québec, Canada. Electronic address: hugo.theoret@umontreal.ca.""}]",Neuroscience,['10.1016/j.neuroscience.2020.11.011'] 1249,33791829,Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers.,"PURPOSE Comorbid conditions of heart and liver disorders added to HCV-induced hepatic steatosis make co-administration of statins, and direct-acting antivirals is common in clinical practice. This study aimed to evaluate the pharmacokinetic interaction of atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir ""FDCSL"" with rationalization to the underlying mechanism. METHODS A randomized, three-phase crossover study that involves 12 healthy volunteers was performed. Participants received a single-dose of atorvastatin 80 mg alone, atorvastatin 80-mg plus tablets containing 400/90 mg FDCSL, or tablets containing 400/90 mg FDCSL alone. Plasma samples were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for atorvastatin, sofosbuvir, ledipasvir, and sofosbuvir metabolite ""GS-331007,"" and their pharmacokinetics parameters were determined. RESULTS Compared to atorvastatin alone, the administration of FDCSL caused a significant increase in both areas under the concentration-time curve from time zero to infinity (AUC 0-∞ ) and maximum plasma concentration (C max ) of atorvastatin by 65.5% and 156.0%, respectively. Also, atorvastatin caused a significant increase in the AUC 0-∞ and C max of sofosbuvir by 32.0% and 11.0%, respectively. Similarly, AUC 0-∞ and C max of sofosbuvir metabolite significantly increased by 84.0% and 74.0%, respectively. However, ledipasvir AUC 0-∞ showed no significant change after atorvastatin intake. The elimination rate in all drugs revealed no significant changes. CONCLUSION After concurrent administration of FDCSL with atorvastatin, the AUC 0-∞ of both atorvastatin and sofosbuvir were increased. Caution should be taken with close monitoring for possible side effects after co-administration of atorvastatin and FDCSL in clinical practice.",2021,"Also, atorvastatin caused a significant increase in the AUC 0-∞ and C max of sofosbuvir by 32.0% and 11.0%, respectively.","['12 healthy volunteers', 'healthy male Egyptian volunteers']","['atorvastatin and FDCSL', 'FDCSL', 'FDCSL with atorvastatin', 'atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir', 'atorvastatin', 'atorvastatin 80 mg alone, atorvastatin 80-mg plus tablets containing 400/90 mg FDCSL, or tablets containing 400/90 mg FDCSL alone', 'atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir ""FDCSL"" with rationalization']","['concentration-time curve from time zero to infinity (AUC 0-∞ ) and maximum plasma concentration (C max ) of atorvastatin', 'Pharmacokinetic interaction', 'AUC 0-∞ and C max of sofosbuvir metabolite', 'AUC 0-∞ and C max of sofosbuvir', 'elimination rate']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0013717', 'cui_str': 'Egyptian language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C2976303', 'cui_str': 'sofosbuvir'}, {'cui': 'C3851350', 'cui_str': 'ledipasvir'}, {'cui': 'C1124482', 'cui_str': 'atorvastatin 80 MG'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0034692', 'cui_str': 'Rationalization - mental defense mechanism'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C1868980', 'cui_str': 'Pharmacokinetic interaction'}, {'cui': 'C2976303', 'cui_str': 'sofosbuvir'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}]",12.0,0.0307602,"Also, atorvastatin caused a significant increase in the AUC 0-∞ and C max of sofosbuvir by 32.0% and 11.0%, respectively.","[{'ForeName': 'H A', 'Initials': 'HA', 'LastName': 'Elmekawy', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Kafrelsheikh University, Kafr El-Sheikh, 33511, Egypt.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Belal', 'Affiliation': 'Department of Analytical Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, 35516, Egypt.'}, {'ForeName': 'A E', 'Initials': 'AE', 'LastName': 'Abdelaziz', 'Affiliation': 'Department of Pharmaceutical Technology, Faculty of Pharmacy, Kafrelsheikh University, Kafr El-Sheikh, Egypt.'}, {'ForeName': 'K S', 'Initials': 'KS', 'LastName': 'Abdelkawy', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Kafrelsheikh University, Kafr El-Sheikh, 33511, Egypt.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Ali', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Kafrelsheikh University, Kafr El-Sheikh, 33511, Egypt.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Elbarbry', 'Affiliation': 'Pacific University Oregon School of Pharmacy, Hillsboro, OR, 97123, USA. Fawzy.elbarbry@pacificu.edu.'}]",European journal of clinical pharmacology,['10.1007/s00228-021-03130-z'] 1250,33249593,The effects of recombinant human insulin-like growth factor-1/insulin-like growth factor binding protein-3 administration on lipid and carbohydrate metabolism in recreational athletes.,"OBJECTIVE Previous studies suggested that recombinant human IGF-1 (rhIGF-1) administration affects carbohydrate and lipid metabolism in healthy people and in people with diabetes. This study aimed to determine the effects of rhIGF-1/rhIGF binding protein-3 (rhIGFBP-3) administration on glucose homeostasis and lipid metabolism in healthy recreational athletes. DESIGN AND SETTING Randomized, double-blind, placebo-controlled rhIGF-1/rhIGFBP-3 administration study at Southampton General Hospital, UK. PARTICIPANTS 56 recreational athletes (30 men, 26 women). METHODS Participants were randomly assigned to receive placebo, low-dose rhIGF-1/rhIGFBP-3 (30 mg/day) or high-dose rhIGF-1/rhIGFBP-3 (60 mg/day) for 28 days. The following variables were measured before and immediately after the treatment period: fasting lipids, glucose, insulin, C-peptide and glycated haemoglobin. The homeostatic model assessment (HOMA-IR) was used to estimate insulin sensitivity and indirect calorimetry to assess substrate oxidation rates. The general linear model approach was used to compare treatment group changes with the placebo group. RESULTS Compared with the placebo group, there was a significant reduction in fasting triglycerides in participants treated with high-dose rhIGF-1/rhIGFBP-3 (p = .030), but not in the low-dose group (p = .390). In women, but not in men, there were significant increases in total cholesterol (p = .003), HDL cholesterol (p = .001) and LDL cholesterol (p = .008). These lipid changes were associated with reduced fasting insulin (p = .010), C-peptide (p = .001) and HOMA-IR (p = .018) in women and reduced C-peptide (p = .046) in men. CONCLUSIONS rhIGF-1/rhIGFBP-3 administration for 28 days reduced insulin concentration, improved insulin sensitivity and had significant effects on lipid profile including decreased fasting triglycerides.",2021,"These lipid changes were associated with reduced fasting insulin (p = .010), C-peptide (p = .001) and HOMA-IR (p = .018) in women and reduced C-peptide (p = .046) in men. ","['56 recreational athletes (30 men, 26 women', 'healthy people and in people with diabetes', 'Participants', 'healthy recreational athletes', 'recreational athletes', 'administration study at Southampton General Hospital, UK']","['rhIGF-1/rhIGF binding protein-3 (rhIGFBP-3', 'placebo', 'placebo, low-dose rhIGF-1/rhIGFBP-3 (30\xa0mg/day) or high-dose rhIGF-1/rhIGFBP-3', 'rhIGF-1/rhIGFBP-3', 'recombinant human IGF-1 (rhIGF-1', 'recombinant human insulin-like growth factor-1/insulin-like growth factor binding protein-3 administration', 'placebo-controlled rhIGF-1/rhIGFBP-3']","['fasting lipids, glucose, insulin, C-peptide and glycated haemoglobin', 'HOMA-IR', 'fasting triglycerides', 'reduced fasting insulin', 'lipid profile including decreased fasting triglycerides', 'glucose homeostasis and lipid metabolism', 'insulin concentration, improved insulin sensitivity', 'substrate oxidation rates', 'LDL cholesterol', 'HDL cholesterol', 'total cholesterol']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}]","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0037657', 'cui_str': 'Somatomedin'}, {'cui': 'C0443625', 'cui_str': 'Binding protein 3'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0795635', 'cui_str': 'Regular Insulin, Human'}, {'cui': 'C0018284', 'cui_str': 'Growth factor'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}]",56.0,0.398484,"These lipid changes were associated with reduced fasting insulin (p = .010), C-peptide (p = .001) and HOMA-IR (p = .018) in women and reduced C-peptide (p = .046) in men. ","[{'ForeName': 'Nishan', 'Initials': 'N', 'LastName': 'Guha', 'Affiliation': 'Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Simon P', 'Initials': 'SP', 'LastName': 'Nevitt', 'Affiliation': 'Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Francis', 'Affiliation': 'Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Walailuck', 'Initials': 'W', 'LastName': 'Böhning', 'Affiliation': 'Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Dankmar', 'Initials': 'D', 'LastName': 'Böhning', 'Affiliation': 'Southampton Statistical Sciences Research Institute, University of Southampton, Southampton, UK.'}, {'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': 'Sönksen', 'Affiliation': 'Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Richard I G', 'Initials': 'RIG', 'LastName': 'Holt', 'Affiliation': 'Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}]",Clinical endocrinology,['10.1111/cen.14370'] 1251,33249268,Analgesic Efficacy of Intrauterine Lidocaine Flushing in Hysterosalpingo-foam Sonography: A Double-blind Randomized Controlled Trial.,"STUDY OBJECTIVE To evaluate the efficacy of flushing the uterine cavity with lidocaine before hysterosalpingo-foam sonography (HyFoSy) to reduce procedure-related pain. DESIGN A double-blind randomized controlled trial was conducted at the Department of Obstetrics and Gynecology, Shamir Medical Center, Israel between June 2020 and September 2020 involving 80 women undergoing a HyFoSy procedure. SETTING University-affiliated medical center. PATIENTS A total of 40 women were assigned randomly to the lidocaine group and 40 to the saline (placebo) group using a predetermined randomization code. Intrauterine instillation before the procedure consisting of either lidocaine 2% or normal saline alone was conducted, respectively. INTERVENTIONS The primary outcome measure was the visual analog scale (VAS) pain score during the phase of intrauterine foam instillation reported by the women after the procedure. The VAS consisted of a 10-cm line ranging from 0 to 10 (anchored by 0 = no pain and 10 = very severe pain). On the basis of the VAS scores, the pain level ratings were classified as mild (rated 1-3), moderate (4-6), or severe (7-10). MEASUREMENTS AND MAIN RESULTS The patient characteristics and obstetric data were found to be similar in both groups. Comparison of the VAS pain scores experienced during the procedure showed that women in the lidocaine flushing group rated the procedure less painful than the women in the saline group (3.0 ± 1.3 vs 6.3 ± 1.5, respectively; p = .001). The incidence of severe pain was significantly lower in the lidocaine group than the saline group (2.5% and 45.0%, respectively, p = .001). CONCLUSION Lidocaine flushing of the uterine cavity before HyFoSy significantly decreased the pain known to be caused by this procedure and had the advantage of no side effects. It is easily applied, relatively inexpensive, and may affect compliance with this procedure.",2021,"The incidence of severe pain was significantly lower in the lidocaine group as compared to the saline group (2.5% and 45.0%, respectively, p=0.0001). ","['hysterosalpingo-foam sonography', 'Forty women', 'Department of Obstetrics & Gynecology, Shamir Medical Center, Israel between June 2020 and September 2020 involving 80 women undergoing HyFoSy procedure', 'University-affiliated medical center']","['intrauterine lidocaine flushing', 'lidocaine before Hysterosalpingo-Foam Sonography (HyFoSy', 'lidocaine', 'saline (placebo', 'Lidocaine']","['VAS scores, the pain level ratings', 'Analgesic efficacy', 'VAS pain scores', 'incidence of severe pain', 'visual analog scale (VAS) pain score', 'pain']","[{'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0022271', 'cui_str': 'Israel'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0694756', 'cui_str': 'Intrauterine'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0016382', 'cui_str': 'Flushing'}, {'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0278140', 'cui_str': 'Severe pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",80.0,0.439911,"The incidence of severe pain was significantly lower in the lidocaine group as compared to the saline group (2.5% and 45.0%, respectively, p=0.0001). ","[{'ForeName': 'Yaakov', 'Initials': 'Y', 'LastName': 'Melcer', 'Affiliation': 'From the Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (all authors).. Electronic address: ymeltcer@gmail.com.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Nimrodi', 'Affiliation': 'From the Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (all authors).'}, {'ForeName': 'Orna', 'Initials': 'O', 'LastName': 'Levinsohn-Tavor', 'Affiliation': 'From the Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (all authors).'}, {'ForeName': 'Maayan', 'Initials': 'M', 'LastName': 'Gal-Kochav', 'Affiliation': 'From the Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (all authors).'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Pekar-Zlotin', 'Affiliation': 'From the Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (all authors).'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Maymon', 'Affiliation': 'From the Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (all authors).'}]",Journal of minimally invasive gynecology,['10.1016/j.jmig.2020.11.019'] 1252,33252584,SILICONE OIL VERSUS PERFLUOROPROPANE GAS TAMPONADE DURING VITRECTOMY FOR TRACTIONAL RETINAL DETACHMENT OR FIBROUS PROLIFERATION: A Randomized Clinical Trial.,"PURPOSE To compare vitreous substitution with silicone oil to perfluoropropane gas in proliferative diabetic retinopathy subjects undergoing pars plana vitrectomy (PPV) for the treatment of tractional retinal detachment or extensive fibrous proliferation. DESIGN Randomized clinical trial. METHODS Three hundred and two proliferative diabetic retinopathy subjects with tractional retinal detachment or extensive fibrous proliferation requiring PPV were enrolled into the trial. Subjects were prospectively randomized into one of two vitreous substitution groups during PPV: Group A subjects underwent 1,000 centistoke silicone oil tamponade, whereas Group B subjects underwent 14% to 16% silicone oil to perfluoropropane gas tamponade. The principal outcome was the best-corrected visual acuity at 6-month follow-up. Secondary outcomes were postoperative complications and unplanned PPV during the 6-month trial interval. RESULTS Two hundred and fifty-eight subjects were randomized to receive a vitreous substitute and completed 6-month follow-up. Group B had better best-corrected visual acuity, more subjects ending up with 0.4 logarithm of the minimum angle of resolution (20/50) or better visual acuity, and more subjects ending up with 1 logarithm of the minimum angle of resolution (20/200) or better visual acuity at 6 months compared with Group A (P < 0.001, P = 0.02, P < 0.001, respectively). There were no significant differences in baseline characteristics, intraoperative or postoperative complications, or incidence of unplanned PPV between groups. CONCLUSION This trial demonstrated that vitreous substitution with silicone oil to perfluoropropane gas resulted in better visual acuity at 6 months compared with silicone oil tamponade in proliferative diabetic retinopathy patients undergoing PPV for tractional retinal detachment or extensive fibrous proliferation. Surgeons should consider silicone oil to perfluoropropane gas tamponade as the first-line vitreous substitute in this patient population.",2021,"There were no significant differences in baseline characteristics, intraoperative or postoperative complications, or incidence of unplanned PPV between groups. ","['Two hundred and fifty-eight subjects', 'proliferative diabetic retinopathy (PDR) subjects undergoing', 'Tractional Retinal Detachment or Fibrous Proliferation', 'Three hundred and two PDR subjects with TRD or extensive fibrous proliferation requiring PPV', 'PDR patients undergoing PPV for TRD or extensive fibrous proliferation']","['vitreous substitution groups during PPV: Group A subjects underwent 1,000 centistoke silicone oil tamponade', 'silicone oil tamponade', 'Silicone Oil versus Perfluoropropane Gas Tamponade during Vitrectomy', 'pars plana vitrectomy (PPV', 'silicone oil to perfluoropropane (C3F8) gas', 'vitreous substitute']","['corrected visual acuity (BCVA', 'visual acuity', 'postoperative complications and unplanned PPV during the 6-month trial interval', 'baseline characteristics, intraoperative or postoperative complications, or incidence of unplanned PPV']","[{'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0154830', 'cui_str': 'Proliferative retinopathy with diabetes mellitus'}, {'cui': 'C0154828', 'cui_str': 'Traction detachment of retina'}, {'cui': 'C0439709', 'cui_str': 'Fibrous'}, {'cui': 'C0334094', 'cui_str': 'Proliferation'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0205231', 'cui_str': 'Extensive'}, {'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0560172', 'cui_str': 'cSt'}, {'cui': 'C0037111', 'cui_str': 'Silicone oil'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0937858', 'cui_str': 'Perflutren'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0042903', 'cui_str': 'Vitrectomy'}]","[{'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",258.0,0.195912,"There were no significant differences in baseline characteristics, intraoperative or postoperative complications, or incidence of unplanned PPV between groups. ","[{'ForeName': 'Ryan B', 'Initials': 'RB', 'LastName': 'Rush', 'Affiliation': 'Instituto de la Visión-Hospital La Carlota, Nuevo León, México.'}, {'ForeName': 'Agustin', 'Initials': 'A', 'LastName': 'Del Valle Penella', 'Affiliation': 'Instituto de la Visión-Hospital La Carlota, Nuevo León, México.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Reinauer', 'Affiliation': 'Instituto de la Visión-Hospital La Carlota, Nuevo León, México.'}, {'ForeName': 'Sloan W', 'Initials': 'SW', 'LastName': 'Rush', 'Affiliation': 'Panhandle Eye Group, Amarillo, Texas.'}, {'ForeName': 'Pedro G', 'Initials': 'PG', 'LastName': 'Bastar', 'Affiliation': 'Instituto de la Visión-Hospital La Carlota, Nuevo León, México.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000003052'] 1253,33256869,Impact of the Dietary Approaches to Stop Hypertension (DASH) diet on glycaemic control and consumption of processed and ultraprocessed foods in pregnant women with pre-gestational diabetes mellitus: a randomised clinical trial.,"The aim of this study was to evaluate the impact of the Dietary Approaches to Stop Hypertension (DASH) diet on glycaemic control and consumption of processed (PF) and ultraprocessed (UPF) foods in pregnant women with pre-gestational diabetes mellitus (PGDM). This is a randomised, controlled, single-blind clinical trial with forty-nine adult women with PGDM, followed at a public maternity hospital in Rio de Janeiro, Brazil. The control group (CG) received a standard diet consisting of 45-55 % of the total energy intake of carbohydrates, 15-20 % of proteins and 25-30 % of lipids. The DASH group (DG) received an adapted DASH diet, which did not differ from the standard diet in the percentage of macronutrients, but had higher contents of fibre, unsaturated fats and minerals such as Ca, Mg and K; and lower contents of Na and saturated fats than the standard diet. In the analysis by protocol, the DG presented a higher incidence of glycaemic control after 12 weeks of intervention (57·1 v. 8·3 %, P = 0·01, moderate effect size) and a lower mean consumption of UPF (-9·9 %, P = 0·01) compared with the CG. There was no statistically significant difference in fasting and postprandial blood glucose concentrations, or in the consumption of PF between the groups (P > 0·05). The DASH diet may be a strategy for glycaemic control in pregnant women with PGDM, favouring the adoption of a nutritionally adequate diet with lower consumption of UPF. Further studies are needed to investigate the effect of the DASH diet on glycaemic profile, and maternal and perinatal outcomes in women with PGDM.",2021,,['pregnant women with pre-gestational diabetes mellitus'],['DASH diet'],['glycaemic control and consumption of processed and ultra-processed foods'],"[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}]","[{'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0344355', 'cui_str': 'Convenience food'}]",,0.110407,,"[{'ForeName': 'Sanmira', 'Initials': 'S', 'LastName': 'Fagherazzi', 'Affiliation': 'Maternity School, Federal University of Rio de Janeiro, Rio de Janeiro22240-000, Brazil.'}, {'ForeName': 'Dayana Rodrigues', 'Initials': 'DR', 'LastName': 'Farias', 'Affiliation': 'Social and Applied Nutrition Department, Josué de Castro Institute of Nutrition, Federal University of Rio de Janeiro, Rio de Janeiro21941-590, Brazil.'}, {'ForeName': 'Gabriella Pinto', 'Initials': 'GP', 'LastName': 'Belfort', 'Affiliation': 'Josué de Castro Institute of Nutrition, Federal University of Rio de Janeiro, Rio de Janeiro21941-590, Brazil.'}, {'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'Dos Santos', 'Affiliation': 'Josué de Castro Institute of Nutrition, Federal University of Rio de Janeiro, Rio de Janeiro21941-590, Brazil.'}, {'ForeName': 'Thaissa', 'Initials': 'T', 'LastName': 'Santana Vieira de Lima', 'Affiliation': 'Maternity School, Federal University of Rio de Janeiro, Rio de Janeiro22240-000, Brazil.'}, {'ForeName': 'Mayara', 'Initials': 'M', 'LastName': 'Silva Dos Santos', 'Affiliation': 'Maternity School, Federal University of Rio de Janeiro, Rio de Janeiro22240-000, Brazil.'}, {'ForeName': 'Cláudia', 'Initials': 'C', 'LastName': 'Saunders', 'Affiliation': 'Maternity School, Federal University of Rio de Janeiro, Rio de Janeiro22240-000, Brazil.'}]",The British journal of nutrition,['10.1017/S0007114520004791'] 1254,33766760,Translating evidence-based psychological interventions for older adults with depression and anxiety into public and private mental health settings using a stepped care framework: Study protocol.,"BACKGROUND With expected increases in the number of older adults worldwide, the delivery of stepped psychological care for depression and anxiety in older populations may improve both treatment and allocative efficiency for individual patients and the health system. DESIGN A multisite pragmatic randomised controlled trial evaluating the clinical and cost-effectiveness of a stepped care model of care for treating depression and anxiety among older adults compared to treatment as usual (TAU) will be conducted. Eligible participants (n = 666) with clinically interfering anxiety and/or depression symptoms will be recruited from and treated within six Australian mental health services. The intervention group will complete a low intensity cognitive behavioural therapy (CBT) program: Internet-delivered or using a work-at-home book with brief therapist calls (STEP 1). Following STEP 1 a higher intensity face-to-face CBT (STEP 2) will then be offered if needed. Intention-to-treat analyses will be used to examine changes in primary outcomes (e.g. clinician-rated symptom severity changes) and secondary outcomes (e.g. self-reported symptoms severity, health related quality of life and service utilisation costs). An economic evaluation will be conducted using a cost-utility analysis to derive the incremental cost-effectiveness ratio for the stepped care intervention. DISCUSSION This study will demonstrate the relative clinical and economic benefits of stepped care model of psychological care for older adults experiencing anxiety and/or depression compared to TAU. The evaluation of the intervention within existing mental health services means that results will have significant implications for the translation of evidence-based interventions in older adult services across urban and rural settings. TRAIL REGISTRATION Prospectively registered on anzctr.org.au (ACTRN12619000219189) and isrctn.com (ISRCTN37503850).",2021,"BACKGROUND With expected increases in the number of older adults worldwide, the delivery of stepped psychological care for depression and anxiety in older populations may improve both treatment and allocative efficiency for individual patients and the health system. ","['older adult services across urban and rural settings', 'Eligible participants (n\u202f=\u202f666) with clinically interfering anxiety and/or depression symptoms will be recruited from and treated within six Australian mental health services', 'older adults', 'older adults with depression and anxiety into public and private mental health settings', 'older adults experiencing anxiety and/or depression compared to TAU']","['stepped care model of care', 'usual (TAU', 'Translating evidence-based psychological interventions', 'low intensity cognitive behavioural therapy (CBT) program: Internet-delivered or using a work-at-home book with brief therapist calls (STEP 1']",[],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0025355', 'cui_str': 'Mental health service'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040710', 'cui_str': 'Translating'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0557392', 'cui_str': 'Works at home'}, {'cui': 'C0006002', 'cui_str': 'Book'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C1301776', 'cui_str': 'Step 1'}]",[],666.0,0.0390583,"BACKGROUND With expected increases in the number of older adults worldwide, the delivery of stepped psychological care for depression and anxiety in older populations may improve both treatment and allocative efficiency for individual patients and the health system. ","[{'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Meuldijk', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Faculty of Medicine and Health Sciences, Macquarie University, Sydney 2109, Australia; Centre for Ageing, Cognition and Wellbeing, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney 2109, Australia. Electronic address: denise.meuldijk@mq.edu.au.'}, {'ForeName': 'Viviana M', 'Initials': 'VM', 'LastName': 'Wuthrich', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Faculty of Medicine and Health Sciences, Macquarie University, Sydney 2109, Australia; Centre for Ageing, Cognition and Wellbeing, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney 2109, Australia.'}, {'ForeName': 'Ronald M', 'Initials': 'RM', 'LastName': 'Rapee', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Faculty of Medicine and Health Sciences, Macquarie University, Sydney 2109, Australia; Centre for Ageing, Cognition and Wellbeing, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney 2109, Australia.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Draper', 'Affiliation': ""Older Persons' Mental Health Services, Euroa Centre, Prince of Wales Hospital, Sydney 2031, Australia; Centre of Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney 2052, Australia.""}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Brodaty', 'Affiliation': ""Older Persons' Mental Health Services, Euroa Centre, Prince of Wales Hospital, Sydney 2031, Australia; Centre of Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney 2052, Australia.""}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Cuijpers', 'Affiliation': 'Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Cutler', 'Affiliation': 'Centre for the Health Economy, Macquarie University, Sydney 2109, Australia.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Hobbs', 'Affiliation': 'New England Institute of Healthcare Research, University of New England, Armidale 2351, Australia.'}, {'ForeName': 'Carly', 'Initials': 'C', 'LastName': 'Johnco', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Faculty of Medicine and Health Sciences, Macquarie University, Sydney 2109, Australia; Centre for Ageing, Cognition and Wellbeing, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney 2109, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jones', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Faculty of Medicine and Health Sciences, Macquarie University, Sydney 2109, Australia.'}, {'ForeName': 'Jessamine T H', 'Initials': 'JTH', 'LastName': 'Chen', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Faculty of Medicine and Health Sciences, Macquarie University, Sydney 2109, Australia; Centre for Ageing, Cognition and Wellbeing, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney 2109, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Partington', 'Affiliation': 'Centre for the Health Economy, Macquarie University, Sydney 2109, Australia; College of Medicine & Public Health, Flinders University, Adelaide 5042, Australia.'}, {'ForeName': 'Chanaka', 'Initials': 'C', 'LastName': 'Wijeratne', 'Affiliation': ""Older Persons' Mental Health Service, Aged Care - North Shore Ryde, Royal North Shore Hospital, Sydney 2065, Australia.""}]",Contemporary clinical trials,['10.1016/j.cct.2021.106360'] 1255,33772220,Discordant results between conventional newborn screening and genomic sequencing in the BabySeq Project.,"PURPOSE Newborn screening (NBS) is performed to identify neonates at risk for actionable, severe, early-onset disorders, many of which are genetic. The BabySeq Project randomized neonates to receive conventional NBS or NBS plus exome sequencing (ES) capable of detecting sequence variants that may also diagnose monogenic disease or indicate genetic disease risk. We therefore evaluated how ES and conventional NBS results differ in this population. METHODS We compared results of NBS (including hearing screens) and ES for 159 infants in the BabySeq Project. Infants were considered ""NBS positive"" if any abnormal result was found indicating disease risk and ""ES positive"" if ES identified a monogenic disease risk or a genetic diagnosis. RESULTS Most infants (132/159, 84%) were NBS and ES negative. Only one infant was positive for the same disorder by both modalities. Nine infants were NBS positive/ES negative, though seven of these were subsequently determined to be false positives. Fifteen infants were ES positive/NBS negative, all of which represented risk of genetic conditions that are not included in NBS programs. No genetic explanation was identified for eight infants referred on the hearing screen. CONCLUSION These differences highlight the complementarity of information that may be gleaned from NBS and ES in the newborn period.",2021,"No genetic explanation was identified for eight infants referred on the hearing screen. ","['159 infants in the BabySeq Project', 'eight infants referred on the hearing screen']","['Newborn screening (NBS', 'NBS', 'conventional NBS or NBS plus exome sequencing (ES']",['NBS and ES negative'],"[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0027617', 'cui_str': 'Neonatal screening'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3640077', 'cui_str': 'Complete Exome Sequencing'}]","[{'cui': 'C0027617', 'cui_str': 'Neonatal screening'}, {'cui': 'C3640077', 'cui_str': 'Complete Exome Sequencing'}, {'cui': 'C0205160', 'cui_str': 'Negative'}]",15.0,0.072564,"No genetic explanation was identified for eight infants referred on the hearing screen. ","[{'ForeName': 'Monica H', 'Initials': 'MH', 'LastName': 'Wojcik', 'Affiliation': ""Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA. monica.wojcik@childrens.harvard.edu.""}, {'ForeName': 'Tian', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': ""Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Ozge', 'Initials': 'O', 'LastName': 'Ceyhan-Birsoy', 'Affiliation': 'Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Casie A', 'Initials': 'CA', 'LastName': 'Genetti', 'Affiliation': ""Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Lebo', 'Affiliation': 'Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine, Cambridge, MA, USA.'}, {'ForeName': 'Timothy W', 'Initials': 'TW', 'LastName': 'Yu', 'Affiliation': ""Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Parad', 'Affiliation': ""Department of Pediatric Newborn Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Ingrid A', 'Initials': 'IA', 'LastName': 'Holm', 'Affiliation': ""Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Heidi L', 'Initials': 'HL', 'LastName': 'Rehm', 'Affiliation': 'Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.'}, {'ForeName': 'Alan H', 'Initials': 'AH', 'LastName': 'Beggs', 'Affiliation': ""Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Green', 'Affiliation': 'Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.'}, {'ForeName': 'Pankaj B', 'Initials': 'PB', 'LastName': 'Agrawal', 'Affiliation': ""Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA. pagrawal@enders.tch.harvard.edu.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Genetics in medicine : official journal of the American College of Medical Genetics,['10.1038/s41436-021-01146-5'] 1256,33776935,Motivational Interviewing and Glycemic Control in Adolescents With Poorly Controlled Type 1 Diabetes: A Randomized Controlled Pilot Trial.,"A multicenter randomized controlled pilot trial investigated whether motivational interviewing (MI) by diabetes physicians improves glycemic control and variability in the context of follow-up for adolescent patients with poorly controlled type 1 diabetes. Patients ( n = 47) aged 12 to 15.9 years who showed poor glycemic control (HbA1c >75 mmol/mol/9.0%) were randomized to standard education (SE) only or MI+SE, with study physicians randomized to employ MI+SE ( N = 24 patients) or SE only ( N = 23). For one year of follow-up, the main outcome measurements were obtained at three-month visits (HbA1c) or six-monthly: time in range (TIR) and glycemic variability (CV). Mean adjusted 12-month change in HbA1c was similar between the MI+SE and SE-only group (-3.6 vs. -1.0 mmol/mol), and no inter-group differences were visible in the mean adjusted 12-month change in TIR (-0.8 vs. 2.6%; P = 0.53) or CV (-0.5 vs. -6.2; P = 0.26). However, the order of entering the study correlated significantly with the 12-month change in HbA1c in the MI+SE group ( r  = -0.5; P = 0.006) and not in the SE-only group ( r = 0.2; P = 0.4). No link was evident between MI and changes in quality of life. The authors conclude that MI's short-term use by diabetes physicians managing adolescents with poorly controlled type 1 diabetes was not superior to SE alone; however, improved skills in applying the MI method at the outpatient clinic may produce greater benefits in glycemic control.",2021,"Mean adjusted 12-month change in HbA1c was similar between the MI+SE and SE-only group (-3.6 vs. -1.0 mmol/mol), and no inter-group differences were visible in the mean adjusted 12-month change in TIR (-0.8 vs. 2.6%; P = 0.53) or CV","['adolescent patients with poorly controlled type 1 diabetes', 'Patients ( n = 47) aged 12 to 15.9 years who showed poor glycemic control (HbA1c >75 mmol/mol/9.0', 'Adolescents With Poorly Controlled Type 1 Diabetes']","['MI+SE', 'CV', 'Motivational Interviewing and Glycemic Control', 'motivational interviewing (MI', 'standard education (SE) only or MI+SE']","['quality of life', 'time in range (TIR) and glycemic variability (CV', 'Mean adjusted 12-month change in HbA1c', 'glycemic control and variability']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0342299', 'cui_str': 'Poor glycemic control'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0439190', 'cui_str': 'mmol'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0460094', 'cui_str': 'Within reference range'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0160344,"Mean adjusted 12-month change in HbA1c was similar between the MI+SE and SE-only group (-3.6 vs. -1.0 mmol/mol), and no inter-group differences were visible in the mean adjusted 12-month change in TIR (-0.8 vs. 2.6%; P = 0.53) or CV","[{'ForeName': 'Anna-Kaisa', 'Initials': 'AK', 'LastName': 'Tuomaala', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Hero', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Martti T', 'Initials': 'MT', 'LastName': 'Tuomisto', 'Affiliation': 'Faculty of Social Sciences (Psychology), Tampere University, Tampere, Finland.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lähteenmäki', 'Affiliation': 'Faculty of Social Sciences (Psychology), Tampere University, Tampere, Finland.'}, {'ForeName': 'Päivi J', 'Initials': 'PJ', 'LastName': 'Miettinen', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Tiina', 'Initials': 'T', 'LastName': 'Laine', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Karoliina', 'Initials': 'K', 'LastName': 'Wehkalampi', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Sanne', 'Initials': 'S', 'LastName': 'Kiiveri', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Pekka', 'Initials': 'P', 'LastName': 'Ahonen', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Marja', 'Initials': 'M', 'LastName': 'Ojaniemi', 'Affiliation': 'Department of Pediatrics and Research Unit for Pediatrics, Pediatric Neurology, Pediatric Surgery, Child Psychiatry, Dermatology, Clinical Genetics, Obstetrics and Gynecology, Otorhinolaryngology and Ophthalmology, Oulu University Hospital and University of Oulu, Oulu, Finland.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Kaunisto', 'Affiliation': 'Department of Pediatrics and Research Unit for Pediatrics, Pediatric Neurology, Pediatric Surgery, Child Psychiatry, Dermatology, Clinical Genetics, Obstetrics and Gynecology, Otorhinolaryngology and Ophthalmology, Oulu University Hospital and University of Oulu, Oulu, Finland.'}, {'ForeName': 'Päivi', 'Initials': 'P', 'LastName': 'Tossavainen', 'Affiliation': 'Department of Pediatrics and Research Unit for Pediatrics, Pediatric Neurology, Pediatric Surgery, Child Psychiatry, Dermatology, Clinical Genetics, Obstetrics and Gynecology, Otorhinolaryngology and Ophthalmology, Oulu University Hospital and University of Oulu, Oulu, Finland.'}, {'ForeName': 'Risto', 'Initials': 'R', 'LastName': 'Lapatto', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Taisto', 'Initials': 'T', 'LastName': 'Sarkola', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Mari-Anne', 'Initials': 'MA', 'LastName': 'Pulkkinen', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}]",Frontiers in endocrinology,['10.3389/fendo.2021.639507'] 1257,33788987,"Light emitting diode-red light for reduction of post-surgical scarring: Results from a dose-ranging, split-face, randomized controlled trial.","Scarring has significant esthetic and functional consequences for patients. A need exists for anti-scarring therapeutics. Light emitting diode-red light (LED-RL) has been shown to modulate skin fibrosis. The aim of this study is to evaluate the safety and efficacy of LED-RL to reduce post-operative scarring. Cutaneous Understanding of Red-light Efficacy on Scarring was a randomized, mock-controlled, single-blind, dose-ranging, split-face phase II clinical trial. Starting 1 week post-surgery, patients received LED-RL irradiation and temperature-controlled mock therapy to incision sites at fluences of 160, 320 or 480 J/cm 2 , triweekly for 3 weeks. Efficacy was assessed at 1, 3 and 6-12 months. The primary endpoint was difference in scar pliability between LED-RL-treated and control sites. Secondary outcomes included Patient and Observer Scar Assessment Scale, collagen and water concentration, and adverse events. There were no significant differences in scar pliability between treated and control scars. At certain fluences, treated scars showed greater improvements in observer rating and scar pliability, reflected by greater reductions in induration, from baseline to 6 months compared to control scars. Treatment-site adverse events included blistering (n = 2) and swelling (n = 1), which were mild and resolved without sequelae. LED-RL phototherapy is safe in the early postoperative period and may reduce scarring.",2021,"At certain fluences, treated scars showed greater improvements in observer rating and scar pliability, reflected by greater reductions in induration, from baseline to 6 months compared to control scars.","['post-surgical scarring', 'patients']","['Light emitting diode-red light', 'LED-RL phototherapy', 'LED-RL', 'LED-RL irradiation and temperature-controlled mock therapy', 'Light emitting diode-red light (LED-RL']","['Patient and Observer Scar Assessment Scale, collagen and water concentration, and adverse events', 'observer rating and scar pliability', 'blistering (n=2) and swelling (n=1), which were mild and resolved without sequelae', 'Efficacy', 'scar pliability']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0162676', 'cui_str': 'Enzyme-multiplied immunoassay technique'}, {'cui': 'C0563227', 'cui_str': 'Red light'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0562577', 'cui_str': 'Mocking'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0005758', 'cui_str': 'Blister'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C3714811', 'cui_str': 'Resolved'}, {'cui': 'C0243088', 'cui_str': 'sequels'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.109828,"At certain fluences, treated scars showed greater improvements in observer rating and scar pliability, reflected by greater reductions in induration, from baseline to 6 months compared to control scars.","[{'ForeName': 'Alana', 'Initials': 'A', 'LastName': 'Kurtti', 'Affiliation': 'Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.'}, {'ForeName': 'Julie K', 'Initials': 'JK', 'LastName': 'Nguyen', 'Affiliation': 'Dermatology Service, VA New York Harbor Healthcare System, Brooklyn, New York, USA.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Weedon', 'Affiliation': 'Office of the SVP for Research, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Mamalis', 'Affiliation': 'Department of Dermatology, The Permanente Medical Group, Modesto, California, USA.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Lai', 'Affiliation': 'Dermatology Service, VA New York Harbor Healthcare System, Brooklyn, New York, USA.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Masub', 'Affiliation': 'Dermatology Service, VA New York Harbor Healthcare System, Brooklyn, New York, USA.'}, {'ForeName': 'Amaris', 'Initials': 'A', 'LastName': 'Geisler', 'Affiliation': 'Dermatology Service, VA New York Harbor Healthcare System, Brooklyn, New York, USA.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Siegel', 'Affiliation': 'Dermatology Service, VA New York Harbor Healthcare System, Brooklyn, New York, USA.'}, {'ForeName': 'Jared R', 'Initials': 'JR', 'LastName': 'Jagdeo', 'Affiliation': 'Dermatology Service, VA New York Harbor Healthcare System, Brooklyn, New York, USA.'}]",Journal of biophotonics,['10.1002/jbio.202100073'] 1258,33793754,Percutaneous tibial nerve stimulation in patients with severe low anterior resection syndrome: randomized clinical trial.,"BACKGROUND Treatment of low anterior resection syndrome (LARS) is challenging. Percutaneous tibial nerve stimulation (PTNS) can improve select bowel disorders. An RCT was conducted to assess the efficacy of PTNS compared with sham stimulation in patients with severe LARS. METHOD This was a multicentre, double-blind RCT. Patients with major LARS score were allocated to receive PTNS or sham therapy (needle placement simulation without nerve stimulation). The study included 16 sessions of 30 min once a week for 12 consecutive weeks, followed by four additional sessions once a fortnight for the following 4 weeks. The primary endpoint was efficacy of PTNS defined by the LARS score 12 months after treatment. Secondary endpoints included faecal incontinence, quality of life (QoL), and sexual function. RESULTS Between September 2016 and July 2018, 46 eligible patients were assigned randomly in a 1 : 1 ratio to PTNS or sham therapy. Baseline characteristics were similar. LARS scores were reduced in both groups, but only patients who received PTNS maintained the effect in the long term (mean(s.d.) score 36.4(3.9) at baseline versus 30.7(11.5) at 12 months; P = 0.018; effect size -5.4, 95 per cent c.i. -9.8 to -1.0), with a mean reduction of 15.7 per cent at 12-month follow-up. The faecal incontinence score was improved after 12 months in the PTNS group (mean(s.d.) score 15.4(5.2) at baseline versus 12.5(6.4) at 12 months; P = 0.018). No major changes in QoL and sexual function were observed in either group. There was no therapy-associated morbidity. Three patients discontinued the study, but none owing to study-related issues. CONCLUSION PTNS has positive effects in some patients with major LARS, especially in those with faecal incontinence. Registration number: NCT02517853 (http://www.clinicaltrials.gov).",2021,"LARS scores were reduced in both groups, but only patients who received PTNS maintained the effect in the long term (mean(s.d.)","['low anterior resection syndrome (LARS', 'Between September 2016 and July 2018', 'Patients with major LARS score', '46 eligible patients', 'patients with severe low anterior resection syndrome', 'patients with severe LARS']","['PTNS', 'Percutaneous tibial nerve stimulation (PTNS', 'PTNS or sham therapy (needle placement simulation without nerve stimulation', 'PTNS or sham therapy', 'Percutaneous tibial nerve stimulation']","['efficacy of PTNS defined by the LARS score', 'LARS scores', 'faecal incontinence, quality of life (QoL), and sexual function', 'QoL and sexual function', 'morbidity', 'faecal incontinence score']","[{'cui': 'C4524073', 'cui_str': 'Low anterior resection syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C3805249', 'cui_str': 'Percutaneous tibial nerve stimulation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3805249', 'cui_str': 'Percutaneous tibial nerve stimulation'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C4524073', 'cui_str': 'Low anterior resection syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",46.0,0.162787,"LARS scores were reduced in both groups, but only patients who received PTNS maintained the effect in the long term (mean(s.d.)","[{'ForeName': 'F G', 'Initials': 'FG', 'LastName': 'Marinello', 'Affiliation': ""Colorectal Surgery Unit, Vall d'Hebrón University Hospital, Barcelona, Spain.""}, {'ForeName': 'L M', 'Initials': 'LM', 'LastName': 'Jiménez', 'Affiliation': 'Colorectal Surgery Unit, Hospital Gregorio Marañón, Madrid, Spain.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Talavera', 'Affiliation': ""Colorectal Surgery Unit, Vall d'Hebrón University Hospital, Barcelona, Spain.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Fraccalvieri', 'Affiliation': 'Colorectal Surgery Unit, Hospital Universitari de Bellvitge, Barcelona, Spain.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Alberti', 'Affiliation': ""Colorectal Surgery Unit, Vall d'Hebrón University Hospital, Barcelona, Spain.""}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Ostiz', 'Affiliation': 'Rehabilitation Unit, CAP Sant Andreu, Barcelona, Spain.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Frago', 'Affiliation': 'Colorectal Surgery Unit, Hospital Universitari de Bellvitge, Barcelona, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Blanco', 'Affiliation': 'Colorectal Surgery Unit, Hospital Universitari de Bellvitge, Barcelona, Spain.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Pellino', 'Affiliation': ""Colorectal Surgery Unit, Vall d'Hebrón University Hospital, Barcelona, Spain.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Espín-Basany', 'Affiliation': ""Colorectal Surgery Unit, Vall d'Hebrón University Hospital, Barcelona, Spain.""}]",The British journal of surgery,['10.1093/bjs/znaa171'] 1259,33793753,Reinforced versus standard stapler transection on postoperative pancreatic fistula in distal pancreatectomy: multicentre randomized clinical trial.,"BACKGROUND Postoperative pancreatic fistula is the leading cause of morbidity after distal pancreatectomy. Strategies investigated to reduce the incidence have been disappointing. Recent data showed a reduction in postoperative pancreatic fistula with the use of synthetic mesh reinforcement of the staple line. METHODS An RCT was conducted between May 2014 and February 2016 at four tertiary referral centres in Sweden. Patients scheduled for distal pancreatectomy were eligible. Enrolled patients were randomized during surgery to stapler transection with biological reinforcement or standard stapler transection. Patients were blinded to the allocation. The primary endpoint was the development of any postoperative pancreatic fistula. Secondary endpoints included morbidity, mortality, and duration of hospital stay. RESULTS Some 107 patients were randomized and 106 included in an intention-to-treat analysis (56 in reinforced stapling group, 50 in standard stapling group). No difference was demonstrated in terms of clinically relevant fistulas (grade B and C): 6 of 56 (11 per cent) with reinforced stapling versus 8 of 50 (16 per cent) with standard stapling (P = 0.332). There was no difference between groups in overall postoperative complications: 45 (80 per cent) and 39 (78 per cent) in reinforced and standard stapling groups respectively (P = 0.765). Duration of hospital stay was comparable: median 8 (range 2-35) and 9 (2-114) days respectively (P = 0.541). CONCLUSION Biodegradable stapler reinforcement at the transection line of the pancreas did not reduce postoperative pancreatic fistula compared with regular stapler transection in distal pancreatectomy. Registration number: NCT02149446 (http://www.clinicaltrials.gov).",2021,There was no difference between groups in overall postoperative complications: 45 (80 per cent) and 39 (78 per cent) in reinforced and standard stapling groups respectively (P = 0.765).,"['May 2014 and February 2016 at four tertiary referral centres in Sweden', '107 patients were randomized and 106 included in an intention-to-treat analysis (56 in reinforced stapling group, 50 in standard stapling group', 'Patients scheduled for distal pancreatectomy were eligible']","['surgery to stapler transection with biological reinforcement or standard stapler transection', 'standard stapler transection', 'standard stapling', 'reinforced stapling']","['development of any postoperative pancreatic fistula', 'morbidity, mortality, and duration of hospital stay', 'overall postoperative complications', 'postoperative pancreatic fistula', 'Duration of hospital stay', 'clinically relevant fistulas (grade B and C']","[{'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0185012', 'cui_str': 'Closure by staple'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0176940', 'cui_str': 'Distal subtotal pancreatectomy'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0441062', 'cui_str': 'Stapler'}, {'cui': 'C0152060', 'cui_str': 'Transection'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0035007', 'cui_str': 'Psychological Reinforcement'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0185012', 'cui_str': 'Closure by staple'}]","[{'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030290', 'cui_str': 'Pancreatic fistula'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C0441806', 'cui_str': 'Grade B'}]",107.0,0.521662,There was no difference between groups in overall postoperative complications: 45 (80 per cent) and 39 (78 per cent) in reinforced and standard stapling groups respectively (P = 0.765).,"[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wennerblom', 'Affiliation': 'Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Ateeb', 'Affiliation': 'Division of Surgery, Department of Clinical Sciences, Intervention and Technology (CLINTECH), Karolinska Institutet at Centre for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Jönsson', 'Affiliation': 'Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Björnsson', 'Affiliation': 'Department of Surgery in Linköping, Linköping University, Linköping, Sweden.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Tingstedt', 'Affiliation': 'Department of Surgery, Clinical Sciences Lund, Skåne University Hospital at Lund and Lund University, Lund, Sweden.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Williamsson', 'Affiliation': 'Department of Surgery, Clinical Sciences Lund, Skåne University Hospital at Lund and Lund University, Lund, Sweden.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Sandström', 'Affiliation': 'Department of Surgery in Linköping, Linköping University, Linköping, Sweden.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Ansorge', 'Affiliation': 'Division of Surgery, Department of Clinical Sciences, Intervention and Technology (CLINTECH), Karolinska Institutet at Centre for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Blomberg', 'Affiliation': 'Division of Surgery, Department of Clinical Sciences, Intervention and Technology (CLINTECH), Karolinska Institutet at Centre for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Del Chiaro', 'Affiliation': 'Division of Surgery, Department of Clinical Sciences, Intervention and Technology (CLINTECH), Karolinska Institutet at Centre for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.'}]",The British journal of surgery,['10.1093/bjs/znaa113'] 1260,33793743,Systemic versus Oral and Systemic Antibiotic Prophylaxis (SOAP) study in colorectal surgery: prospective randomized multicentre trial.,"BACKGROUND There is no consensus regarding the role of mechanical bowel preparation (MBP) and oral antibiotic prophylaxis (OABP) in reducing postoperative complications in colorectal surgery. The aim of this study was to examine the effect of OABP given in addition to MBP in the setting of a prospective randomized trial. METHODS Patients awaiting elective colorectal surgery in four Hungarian colorectal centres were included in this multicentre, prospective, randomized, assessor-blinded study. Patients were randomized to receive MBP with or without OABP (OABP+ and OABP- groups respectively). The primary endpoints were surgical-site infection (SSI) and postoperative ileus. Secondary endpoints were anastomotic leak, mortality, and hospital readmission within 30 days. RESULTS Of 839 patients assessed for eligibility between November 2016 and June 2018, 600 were randomized and 529 were analysed. Trial participation was discontinued owing to adverse events in seven patients in the OABP+ group (2.3 per cent). SSI occurred in eight patients (3.2 per cent) in the OABP+ and 27 (9.8 per cent) in the OABP- group (P = 0.001). The incidence of postoperative ileus did not differ between groups. Anastomotic leakage occurred in four patients (1.6 per cent) in the OABP+ and 13 (4.7 per cent) in the OABP- (P = 0.02) group. There were no differences in hospital readmission (12 (4.7 per cent) versus 10 (3.6 per cent); P = 0.25) or mortality (3 (1.2 per cent) versus 4 (1.4 per cent); P = 0.39). CONCLUSION OABP given with MBP reduced the rate of SSI and AL after colorectal surgery with anastomosis, therefore routine use of OABP is recommended.",2021,Anastomotic leakage occurred in four patients (1.6 per cent) in the OABP+ and 13 (4.7 per cent) in the OABP- (P = 0.02) group.,"['Patients awaiting elective colorectal surgery in four Hungarian colorectal centres', 'colorectal surgery', '839 patients assessed for eligibility between November 2016 and June 2018, 600 were randomized and 529 were analysed']","['mechanical bowel preparation (MBP) and oral antibiotic prophylaxis (OABP', 'OABP', 'Systemic versus Oral and Systemic Antibiotic Prophylaxis (SOAP', 'MBP with or without OABP (OABP+ and OABP']","['anastomotic leak, mortality, and hospital readmission within 30 days', 'mortality', 'Anastomotic leakage', 'incidence of postoperative ileus', 'rate of SSI and AL', 'SSI', 'hospital readmission', 'surgical-site infection (SSI) and postoperative ileus']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}, {'cui': 'C0020173', 'cui_str': 'Hungarian language'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C4517806', 'cui_str': '529'}]","[{'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0282638', 'cui_str': 'Antibiotic prophylaxis'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}]","[{'cui': 'C0919691', 'cui_str': 'Anastomotic leak'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0400877', 'cui_str': 'Postoperative ileus'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}]",,0.110668,Anastomotic leakage occurred in four patients (1.6 per cent) in the OABP+ and 13 (4.7 per cent) in the OABP- (P = 0.02) group.,"[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Papp', 'Affiliation': 'Department of General Surgery and Surgical Oncology, Uzsoki Hospital, Budapest, Hungary.'}, {'ForeName': 'Gy', 'Initials': 'G', 'LastName': 'Saftics', 'Affiliation': 'Department of General Surgery and Surgical Oncology, Uzsoki Hospital, Budapest, Hungary.'}, {'ForeName': 'B E', 'Initials': 'BE', 'LastName': 'Szabó', 'Affiliation': 'Department of General Surgery and Surgical Oncology, Uzsoki Hospital, Budapest, Hungary.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Baracs', 'Affiliation': 'Department of Surgery, University of Pécs Clinical Centre, Pécs, Hungary.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Vereczkei', 'Affiliation': 'Department of Surgery, University of Pécs Clinical Centre, Pécs, Hungary.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Kollár', 'Affiliation': 'Department of General Surgery, Petz Aladár Teaching Hospital, Győr, Hungary.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Oláh', 'Affiliation': 'Department of General Surgery, Petz Aladár Teaching Hospital, Győr, Hungary.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Mészáros', 'Affiliation': 'Department of Visceral Surgery, National Institute of Oncology, Centre of Oncosurgery, Budapest, Hungary.'}, {'ForeName': 'Zs', 'Initials': 'Z', 'LastName': 'Dubóczki', 'Affiliation': 'Department of Visceral Surgery, National Institute of Oncology, Centre of Oncosurgery, Budapest, Hungary.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bursics', 'Affiliation': 'Department of General Surgery and Surgical Oncology, Uzsoki Hospital, Budapest, Hungary.'}]",The British journal of surgery,['10.1093/bjs/znaa131'] 1261,33798801,Young women's body image following upwards comparison to Instagram models: The role of physical appearance perfectionism and cognitive emotion regulation.,"The present study examined whether trait physical appearance perfectionism moderates young women's body image following upwards appearance comparison to idealized body images on social media, and whether cognitive coping mediates the relationship between physical appearance perfectionism and resulting body image from social comparison processes. Female undergraduate students (N = 142) were randomly assigned to either 1) compare the size of their body parts to the body parts of attractive Instagram models, or 2) an appearance-neutral control condition. All participants completed measures of trait physical appearance perfectionism, pre and post measures of state body image, and state cognitive coping processes. Appearance comparison to the models resulted in lowered confidence and increased appearance and weight dissatisfaction. High trait physical appearance perfectionism predicted lower confidence and higher weight dissatisfaction and appearance dissatisfaction, and these relationships were mediated by engagement in rumination and catastrophizing. Clinical implications of the findings are discussed.",2021,"High trait physical appearance perfectionism predicted lower confidence and higher weight dissatisfaction and appearance dissatisfaction, and these relationships were mediated by engagement in rumination and catastrophizing.",['Female undergraduate students (N = 142'],"['physical appearance perfectionism and cognitive emotion regulation', 'size of their body parts to the body parts of attractive Instagram models, or 2) an appearance-neutral control condition']","['appearance and weight dissatisfaction', 'trait physical appearance perfectionism, pre and post measures of state body image, and state cognitive coping processes']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0750731', 'cui_str': 'Body, Physical Appearance'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0229962', 'cui_str': 'Body part structure'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0750731', 'cui_str': 'Body, Physical Appearance'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C1522240', 'cui_str': 'Process'}]",142.0,0.00653255,"High trait physical appearance perfectionism predicted lower confidence and higher weight dissatisfaction and appearance dissatisfaction, and these relationships were mediated by engagement in rumination and catastrophizing.","[{'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'McComb', 'Affiliation': 'Department of Psychology, York University, 4700 Keele St, Toronto, ON, M3J 1P3, Canada. Electronic address: mccombs@yorku.ca.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Mills', 'Affiliation': 'Department of Psychology, York University, 4700 Keele St, Toronto, ON, M3J 1P3, Canada. Electronic address: jsmills@yorku.ca.'}]",Body image,['10.1016/j.bodyim.2021.03.012'] 1262,33798487,"Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial.","BACKGROUND Strongyloidiasis represents a major public health issue, particularly in resource-limited countries. Preliminary studies suggest that moxidectin might serve as an alternative to the only available treatment option, ivermectin. We aimed to evaluate the efficacy and safety of ascending doses of moxidectin in Strongyloides stercoralis-infected patients. METHODS We did a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial in four villages in northern Laos. Eligible adults (aged 18-65 years) with S stercoralis infection intensities of at least 0·4 larvae per g of stool in at least two stool samples were randomly assigned (1:1:1:1:1:1:1) by use of computerised, stratified, block randomisation into seven treatment groups: 2 mg of moxidectin, 4 mg of moxidectin, 6 mg of moxidectin, 8 mg of moxidectin, 10 mg of moxidectin, 12 mg of moxidectin, or placebo. Participants and primary outcome assessors were masked to treatment allocation, but study site investigators were not. Participants received a single oral dose of their allocated dose of moxidectin in 2 mg tablets, or four placebo tablets. Three stool samples were collected at baseline and two stool samples were collected 28 days after treatment from each participant. A Baermann assay was used to quantify S stercoralis infection and Kato-Katz thick smears were used to qualitatively identify coinfections with additional helminths species. The primary endpoint was cure rate against S stercoralis and was analysed in an available case analysis set, defined as all randomly assigned participants with primary endpoint data. Predicted cure rates and associated CIs were estimated with hyperbolic E max models. Safety was evaluated in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT04056325, and is complete. FINDINGS Between Nov 27, 2019, and March 15, 2020, 785 adults were screened for trial eligibility. Of these, 223 participants were randomly assigned to treatment groups and 209 completed the study and were analysed for the primary outcome. 2 mg of moxidectin had a predicted cure rate of 75% (95% CI 59-87; 22 [73%] of 30 cured) against S stercoralis compared with a predicted cure rate of 14% (5-31; four [14%] of 29 cured) for placebo. With escalating doses, the probability of cure increased from 83% (95% CI 76-88; 26 [90%] of 29 cured) at 4 mg to 86% (79-90; 27 [84%] of 32 cured) at 6 mg, and to 87% (80-92; 24 [83%] of 29 cured) at 8 mg, levelling off at 88% (80-93; 29 [97%] of 30 cured) at 10 mg and 88% (80-93; 26 [87%] of 30 cured) at 12 mg. Moxidectin was well tolerated across all treatment groups, with no serious adverse events being recorded and all reported symptoms being classified as mild. INTERPRETATION 4-12 mg of moxidectin showed promising tolerability and efficacy profiles in the treatment of S stercoralis infections in adults. Because 8 mg of moxidectin is used for the treatment of onchocerciasis and has been evaluated for other helminth infections, we recommend this dose for phase 2b and phase 3 trials of strongyloidiasis therapy. FUNDING Fondazione Adiuvare.",2021,2 mg of moxidectin had a predicted cure rate of 75% (95% CI 59-87; 22 [73%] of 30 cured) against S stercoralis compared with a predicted cure rate of 14% (5-31; four [14%] of 29 cured) for placebo.,"['223 participants', 'Eligible adults (aged 18-65 years) with S stercoralis infection intensities of at least 0·4 larvae per g of stool in at least two stool samples', 'four villages in northern Laos', 'adults', 'Strongyloides stercoralis-infected patients', 'Between Nov 27, 2019, and March 15, 2020, 785 adults were screened for trial eligibility']","['moxidectin in 2 mg tablets, or four placebo tablets', 'moxidectin', 'ivermectin', 'placebo', 'moxidectin, 4 mg of moxidectin, 6 mg of moxidectin, 8 mg of moxidectin, 10 mg of moxidectin, 12 mg of moxidectin, or placebo', 'Moxidectin']","['cure rates and associated CIs', 'tolerated', 'probability of cure', 'cure rate against S stercoralis', 'efficacy and safety', 'Safety', 'cure rate', 'tolerability and efficacy profiles', 'Efficacy and safety']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0023047', 'cui_str': 'Larvae'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1550661', 'cui_str': 'Stool specimen'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0023034', 'cui_str': 'Laos'}, {'cui': 'C0038462', 'cui_str': 'Strongyloides stercoralis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}]","[{'cui': 'C0163557', 'cui_str': 'Moxidectin'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0022322', 'cui_str': 'Ivermectin'}]","[{'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0007099', 'cui_str': 'Carcinoma in situ'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",785.0,0.470656,2 mg of moxidectin had a predicted cure rate of 75% (95% CI 59-87; 22 [73%] of 30 cured) against S stercoralis compared with a predicted cure rate of 14% (5-31; four [14%] of 29 cured) for placebo.,"[{'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Hofmann', 'Affiliation': 'Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.'}, {'ForeName': 'Somphou', 'Initials': 'S', 'LastName': 'Sayasone', 'Affiliation': 'Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland; Lao Tropical and Public Health Institute, Vientiane, Laos.'}, {'ForeName': 'Khanpaseuth', 'Initials': 'K', 'LastName': 'Sengngam', 'Affiliation': 'Lao Tropical and Public Health Institute, Vientiane, Laos.'}, {'ForeName': 'Bounthunh', 'Initials': 'B', 'LastName': 'Chongvilay', 'Affiliation': 'Lao Tropical and Public Health Institute, Vientiane, Laos.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Hattendorf', 'Affiliation': 'Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Keiser', 'Affiliation': 'Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland. Electronic address: jennifer.keiser@swisstph.ch.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30691-5'] 1263,33810776,Investigating feasibility and preliminary efficacy of a simulator-based driving intervention for people with acquired brain injury: A randomised controlled pilot study.,"OBJECTIVE To investigate the feasibility and preliminary efficacy of a driving simulator intervention on driving outcomes following acquired brain injury. DESIGN Pilot randomised controlled trial. SETTING Occupational therapy driver assessment and rehabilitation service. SUBJECTS Individuals post-acquired brain injury aiming to return to driving. INTERVENTION Eight sessions of simulated driver training over four weeks, in addition to usual care. Control: Usual care only. MAIN MEASURES Feasibility outcomes: Participant recruitment and retention; data completeness; therapy attendance and fidelity; adverse events. Performance outcomes: on-road driving performance; Simulator Sickness Questionnaire; Brain Injury Driving Self-Awareness Measure and Driving Comfort Scale - Daytime, assessed at baseline and five weeks post-randomisation. RESULTS Out of 523 individuals screened, 22 (4%) were recruited and randomised, with 20 completing their allocated group ( n  = 12 Simulator, n  = 8 Usual Care). For those who completed training, session attendance was 100% with simulator sickness rated, on average, as mild. Six individuals (50%) in the Simulator group failed the on-road assessment, versus two (25%) in the Usual Care group ( P  = 0.373). On average, the Simulator group reported a positive change in confidence ratings ( M  = 5.77, SD = 13.96) compared to the Usual Care group, who reported a negative change ( M  = -6.97, SD = 8.47), P  = 0.034. The Simulator group ( M  = 0.67, SD = 3.34) demonstrated no significant change in self-awareness relative to the Usual Care group ( M  = -0.83, SD = 1.83, P  = 0.325). CONCLUSIONS With adjustments to inclusion criteria and recruitment strategies, it may be feasible to deliver the intervention and conduct a larger trial. There is potential benefit of simulator training for improving driver confidence after acquired brain injury.",2021,"Performance outcomes: on-road driving performance; Simulator Sickness Questionnaire; Brain Injury Driving Self-Awareness Measure and Driving Comfort Scale - Daytime, assessed at baseline and five weeks post-randomisation. ","['Individuals post-acquired brain injury aiming to return to driving', 'people with acquired brain injury', 'Out of 523 individuals screened, 22 (4']","['simulated driver training', 'simulator-based driving intervention', 'driving simulator intervention', 'simulator training', 'Control']","['road driving performance; Simulator Sickness Questionnaire; Brain Injury Driving Self-Awareness Measure and Driving Comfort Scale - Daytime', 'self-awareness relative', 'Feasibility outcomes: Participant recruitment and retention; data completeness; therapy attendance and fidelity; adverse events', 'positive change in confidence ratings']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0336490', 'cui_str': 'Underground or elevated train driver'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0442650', 'cui_str': 'Road'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C3146223', 'cui_str': 'Awareness of self'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0439812', 'cui_str': 'Completeness'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}]",,0.0501647,"Performance outcomes: on-road driving performance; Simulator Sickness Questionnaire; Brain Injury Driving Self-Awareness Measure and Driving Comfort Scale - Daytime, assessed at baseline and five weeks post-randomisation. ","[{'ForeName': 'Bleydy', 'Initials': 'B', 'LastName': 'Dimech-Betancourt', 'Affiliation': 'School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Jennie L', 'Initials': 'JL', 'LastName': 'Ponsford', 'Affiliation': 'School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Judith L', 'Initials': 'JL', 'LastName': 'Charlton', 'Affiliation': 'Monash University Accident Research Centre, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Pamela E', 'Initials': 'PE', 'LastName': 'Ross', 'Affiliation': 'Monash-Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Gooden', 'Affiliation': 'School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Renerus J', 'Initials': 'RJ', 'LastName': 'Stolwyk', 'Affiliation': 'School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.'}]",Clinical rehabilitation,['10.1177/02692155211002455'] 1264,33817809,No benefit of an adjunctive phototherapy protocol in treatment of periodontitis: A split-mouth randomized controlled trial.,"AIM To assess the efficacy of a commercially available adjunctive phototherapy protocol (""Perio-1"") in treatment of periodontitis. MATERIALS AND METHODS In an examiner-blind, randomized, controlled, split-mouth, multicentre study, 60 periodontitis patients received root surface debridement (RSD) in sextants either alone (control sextants) or with the adjunctive phototherapy protocol (test sextants). Re-evaluation was performed at 6, 12 and 24 weeks. RESULTS No statistically significant differences in mean (± standard deviation) clinical attachment level (CAL) change from baseline to week 24 were observed between test (-1.00 ± 1.16 mm) and control sextants (-0.87 ± 0.79 mm) at sites with probing pocket depths (PPDs) ≥5 mm (""deep sites"") at baseline (p = .212). Comparisons between test and control sextants for all other parameters (CAL change at all sites, PPD change at deep sites/all sites, bleeding on probing, plaque scores), and for all change intervals, failed to identify any statistically significant differences. CONCLUSIONS The phototherapy protocol did not provide any additional clinical benefits over those achieved by RSD alone. (German Clinical Trials Register DRKS00011229).",2021,"No statistically significant differences in mean (± standard deviation) clinical attachment level (CAL) change from baseline to week 24 were observed between test (-1.00±1.16 mm) and control sextants (-0.87±0.79 mm) at sites with probing pocket depths (PPDs) ≥ 5 mm (""deep sites"") at baseline (p=0.212).",['60 periodontitis patients received'],"[""commercially-available adjunctive phototherapy protocol ('Perio-1"", 'root surface debridement (RSD) in sextants either alone (control sextants) or with the adjunctive phototherapy protocol (test sextants', 'Adjunctive Phototherapy Protocol']","['mean (± standard deviation) clinical attachment level (CAL) change', 'Periodontitis']","[{'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}]",60.0,0.328111,"No statistically significant differences in mean (± standard deviation) clinical attachment level (CAL) change from baseline to week 24 were observed between test (-1.00±1.16 mm) and control sextants (-0.87±0.79 mm) at sites with probing pocket depths (PPDs) ≥ 5 mm (""deep sites"") at baseline (p=0.212).","[{'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Preshaw', 'Affiliation': 'School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Ide', 'Affiliation': ""Faculty of Dentistry Oral and Craniofacial Sciences, King's College London, London, UK.""}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Bissett', 'Affiliation': 'School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Holliday', 'Affiliation': 'School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Nichola', 'Initials': 'N', 'LastName': 'Lansdowne', 'Affiliation': 'School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Pickering', 'Affiliation': 'School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Judy A', 'Initials': 'JA', 'LastName': 'Taylor', 'Affiliation': ""Faculty of Dentistry Oral and Craniofacial Sciences, King's College London, London, UK.""}, {'ForeName': 'Ana M', 'Initials': 'AM', 'LastName': 'Levonian', 'Affiliation': ""Faculty of Dentistry Oral and Craniofacial Sciences, King's College London, London, UK.""}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Pleasance', 'Affiliation': ""Faculty of Dentistry Oral and Craniofacial Sciences, King's College London, London, UK.""}, {'ForeName': 'Maria Elena', 'Initials': 'ME', 'LastName': 'Guarnelli', 'Affiliation': 'Research Centre for the Study of Periodontal and Peri-implant Diseases, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Simonelli', 'Affiliation': 'Research Centre for the Study of Periodontal and Peri-implant Diseases, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Fabbri', 'Affiliation': 'Research Centre for the Study of Periodontal and Peri-implant Diseases, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Farina', 'Affiliation': 'Research Centre for the Study of Periodontal and Peri-implant Diseases, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Fotinos S', 'Initials': 'FS', 'LastName': 'Panagakos', 'Affiliation': 'West Virginia University School of Dentistry, Morgantown, WV, USA.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Trombelli', 'Affiliation': 'Research Centre for the Study of Periodontal and Peri-implant Diseases, University of Ferrara, Ferrara, Italy.'}]",Journal of clinical periodontology,['10.1111/jcpe.13465'] 1265,33813753,Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.,"Increased bone turnover and rapid bone loss follow discontinuation of denosumab. We investigated the long-term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab. In this randomized, open-label, interventional study, we included 61 postmenopausal women and men older than 50 years discontinuing denosumab after 4.6 ± 1.6 years. We administered ZOL 6 months (6 M) or 9 months (9 M) after the last denosumab or when bone turnover had increased (observation group [OBS]). ZOL was readministrated if p-cross-linked C-terminal telopeptide (p-CTX) increased ≥1.26 μg/L or BMD decreased ≥5%. The results after 12 months have previously been published; here we report the outcome after 24 months (ClinicalTrials NCT03087851). Fifty-eight patients completed the study. From 12 to 24 months after the initial ZOL, lumbar spine (LS) BMD was maintained: 0.9 ± 0.9%, 0.4 ± 0.8%, and 0.3 ± 0.7% in the 6 M, 9 M, and OBS groups, respectively (p > .05, no between-group differences). Similarly, total hip (TH) and femoral neck (FN) BMD did not change in any group during year 2. From baseline to 24 months after ZOL, LS BMD decreased by 4.0 ± 0.8%, 4.1 ± 0.8%, and 4.3 ± 1.5% in the 6 M, 9 M, and OBS groups, respectively (p < .001, no between-group differences). Significant bone loss (LS, TH, or FN) was found in all groups 24 months after ZOL: 6 M group: n = 12 (60%), 9 M group: n = 7 (37%), and OBS group: n = 10 (53%). P-CTX did not change significantly during the second year (p > .05, no between-group differences). No patient fulfilled the CTX or fracture criteria for retreatment during year 2; however, 9 patients were retreated at M24 due to BMD loss ≥5%. Two patients sustained a non-vertebral fracture during year 2. Treatment with ZOL subsequent to long-term denosumab did not fully prevent increased bone turnover and bone loss during the first year; however, CTX remained with the reference range and BMD was maintained during the second year. © 2021 American Society for Bone and Mineral Research (ASBMR).",2021,"P-CTX did not change significantly during the second year (p>0.05, no between group differences).","['Fifty-eight patients completed the study', '61 postmenopausal women and men above 50\u2009years discontinuing denosumab after 4.6±1.6\u2009years', 'osteoporosis']","['ZOL', 'zoledronate (ZOL', 'denosumab', 'zoledronate subsequent to denosumab']","['lumbar spine (LS) BMD', 'FN) BMD', 'Significant bone loss (LS, TH or FN', 'bone turnover and bone loss', 'ZOL LS BMD', 'total hip (TH) and femoral neck ', 'BMD loss']","[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}]","[{'cui': 'C0392938', 'cui_str': 'Zoledronate'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0392938', 'cui_str': 'Zoledronate'}]",61.0,0.0285948,"P-CTX did not change significantly during the second year (p>0.05, no between group differences).","[{'ForeName': 'Anne Sophie', 'Initials': 'AS', 'LastName': 'Sølling', 'Affiliation': 'Department of Internal Medicine, Randers Regional Hospital, Randers, Denmark.'}, {'ForeName': 'Torben', 'Initials': 'T', 'LastName': 'Harsløf', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Langdahl', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.4305'] 1266,33781003,Effect of aromatherapy massage by orange essential oil on post-cesarean anxiety: a randomized clinical trial.,"OBJECTIVES Many women in recent years have been willing to undergo puncture surgery for childbirth, which, like other surgeries, has physical and psychological side effects such as incision, infertility, chronic pain, and anxiety. Therefore, it is important to reduce and improve these side effects. The aim of this study was to determine the effect of foot massage with orange essential oil on anxiety in women undergoing cesarean section. METHODS This randomized clinical trial study was conducted in 2019 on 80 women referred to Bahar Shahroud Hospital after cesarean section surgery. The samples were divided into two groups by intervention (foot massage with orange essential oil) and control (foot massage without orange essential oil). The Spielberger scale was used to determine anxiety scores after cesarean section. In the intervention group, the feet were massaged with orange essential oil, and in the control group, the orange essential oil massage was performed without oil. Anxiety before, immediately after, and 60 min after the intervention was measured and evaluated in both groups. Data analysis was performed using descriptive and inferential statistics. Significant levels were considered for all statistical tests (p<0.05). RESULTS The anxiety score before the intervention in the two groups of intervention and control was 57.12 ± 3.12 and 57.07 ± 3.54, respectively, which were not significantly different, but immediately after the intervention, the anxiety scores in both groups decreased significantly so that there was a further decrease in the intervention group (52.10 ± 4.75 and 56.02 ± 3.77), 1 h after the intervention, the anxiety score in the intervention group decreased compared to the previous stage and increased in the control group (50.40 ± 3.74 and 56.85 ± 4.27). CONCLUSIONS Foot massage with orange essential oil can probably be effective as a proper nursing intervention in reducing anxiety after cesarean section surgery.",2021,"The anxiety score before the intervention in the two groups of intervention and control was 57.12 ± 3.12 and 57.07 ± 3.54, respectively, which were not significantly different, but immediately after the intervention, the anxiety scores in both groups decreased significantly so that there was a further decrease in the intervention group (52.10 ± 4.75 and 56.02 ± 3.77), 1 h after the intervention, the anxiety score in the intervention group decreased compared to the previous stage and increased in the control group (50.40 ± 3.74 and 56.85 ± 4.27). ","['women undergoing cesarean section', '2019 on 80 women referred to Bahar Shahroud Hospital after cesarean section surgery', 'after cesarean section']","['orange essential oil massage was performed without oil', 'intervention (foot massage with orange essential oil) and control (foot massage without orange essential oil', 'foot massage with orange essential oil', 'aromatherapy massage with orange essential oil']","['anxiety scores', 'anxiety score', 'postoperative pain', 'pain and anxiety']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0440277', 'cui_str': 'Orange - fruit'}, {'cui': 'C0028910', 'cui_str': 'Volatile oil'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2585844', 'cui_str': 'Aromatherapy massage'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",80.0,0.00864906,"The anxiety score before the intervention in the two groups of intervention and control was 57.12 ± 3.12 and 57.07 ± 3.54, respectively, which were not significantly different, but immediately after the intervention, the anxiety scores in both groups decreased significantly so that there was a further decrease in the intervention group (52.10 ± 4.75 and 56.02 ± 3.77), 1 h after the intervention, the anxiety score in the intervention group decreased compared to the previous stage and increased in the control group (50.40 ± 3.74 and 56.85 ± 4.27). ","[{'ForeName': 'Seyedmohammad', 'Initials': 'S', 'LastName': 'Mirhosseini', 'Affiliation': 'Student Research Committee, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Abbasi', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Nastaran', 'Initials': 'N', 'LastName': 'Norouzi', 'Affiliation': 'Imam Hossein Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Mobaraki', 'Affiliation': 'Imam Hossein Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Mohammad Hasan', 'Initials': 'MH', 'LastName': 'Basirinezhad', 'Affiliation': 'Department of Epidemiology and Biostatistics,School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Mohammadpourhodki', 'Affiliation': 'Kashmar Center of Higher Health Education, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Journal of complementary & integrative medicine,['10.1515/jcim-2020-0138'] 1267,34391294,The effect of pilates on metabolic control and oxidative stress of diabetics type 2 - A randomized controlled clinical trial.,"INTRODUCTION The Pilates method is an approach to body and mind exercises that has as its foundation the gain of stability, strength and flexibility, and the work of muscular control, posture and breathing, which can generate repercussions on oxidative stress and ROS production, it is expected that Pilates can satisfactorily influence glycemic and oxidative stress reduction in elderly diabetes. AIM To analyze the effect of a Pilates protocol on variables indicative of metabolic control and oxidative stress in patients with Type 2 Diabetes Mellitus. METHOD Randomized clinical trial in type 2 diabetics enrolled in Hiperdia Parnaíba. A Pilates protocol was performed for 8 weeks, with 2 weekly consultations. The tested variables were: blood glucose, glycated hemoglobin, lipid profile, C-reactive protein and malondialdehyde. ANOVA tests, correlation of Wilcoxon, Friedman and Spearman, were used, with a significance level of 5%. RESULTS 44 diabetics participated in the study (intervention group: 22; control: 22), with a mean age of 61.23 ± 8.49years, the majority being female (77.3%), married (59.1%), literate (31.8%), with an average BMI of 26.96 ± 4.35 kg/m 2 . When analyzing the effects of the protocol, there was a significant reduction in glycated hemoglobin (p = 0.002) and oxidative stress (p = 0.004) in the intervention group, however, there were no differences in fasting glucose (p = 0.055) and in the profile lipid, expressed by the total cholesterol (p = 0.654), HDL (p = 0.591), LDL (p = 0.564) and triglycerides (0.192). There was a moderate positive correlation between oxidative stress and glycated hemoglobin (r = 0.44, p = 0.000). CONCLUSION The exercise protocol based on the Pilates method produced a reduction in glycated hemoglobin and oxidative stress.",2021,"When analyzing the effects of the protocol, there was a significant reduction in glycated hemoglobin (p = 0.002) and oxidative stress (p = 0.004) in the intervention group, however, there were no differences in fasting glucose (p = 0.055) and in the profile lipid, expressed by the total cholesterol (p = 0.654), HDL (p = 0.591), LDL (p = 0.564) and triglycerides (0.192).","['44 diabetics participated in the study (intervention group: 22; control: 22), with a mean age of 61.23\xa0±\xa08.49years, the majority being female (77.3%), married (59.1%), literate (31.8%), with an average BMI of 26.96\xa0±\xa04.35\xa0kg/m 2 ', 'diabetics type 2 ', 'type 2 diabetics enrolled in Hiperdia Parnaíba', 'patients with Type 2 Diabetes Mellitus']",['Pilates protocol'],"['glycated hemoglobin and oxidative stress', 'glycated hemoglobin', 'LDL', 'fasting glucose', 'oxidative stress', 'oxidative stress and glycated hemoglobin', 'total cholesterol', 'HDL', 'blood glucose, glycated hemoglobin, lipid profile, C-reactive protein and malondialdehyde', 'metabolic control and oxidative stress']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",44.0,0.0398265,"When analyzing the effects of the protocol, there was a significant reduction in glycated hemoglobin (p = 0.002) and oxidative stress (p = 0.004) in the intervention group, however, there were no differences in fasting glucose (p = 0.055) and in the profile lipid, expressed by the total cholesterol (p = 0.654), HDL (p = 0.591), LDL (p = 0.564) and triglycerides (0.192).","[{'ForeName': 'Samara Sousa', 'Initials': 'SS', 'LastName': 'Vasconcelos Gouveia', 'Affiliation': 'Federal University of Delta do Parnaíba, Parnaíba, Piauí, Brazil. Electronic address: samaragouveia@ufpi.edu.br.'}, {'ForeName': 'Guilherme', 'Initials': 'G', 'LastName': 'Pertinni de Morais Gouveia', 'Affiliation': 'Federal University of Delta do Parnaíba, Evaluative and Therapeutic Physiotherapy - GPFAT, Parnaíba, Piauí, Brazil. Electronic address: gpfatufpi@ufpi.edu.br.'}, {'ForeName': 'Leydnaya Maria', 'Initials': 'LM', 'LastName': 'Souza', 'Affiliation': 'Federal University of Piauí, Parnaíba, Piauí, Brazil. Electronic address: leydnayasouza@gmail.com.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Cunha da Costa', 'Affiliation': 'Federal University of Piauí, Parnaíba, Piauí, Brazil. Electronic address: brunuhcunha@gmail.com.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Iles', 'Affiliation': 'Federal University of Piauí, Parnaíba, Piauí, Brazil. Electronic address: iles630@gmail.com.'}, {'ForeName': 'Vanádia Almeida', 'Initials': 'VA', 'LastName': 'Pinho', 'Affiliation': 'Federal University of Piauí, Parnaíba, Piauí, Brazil. Electronic address: vanadia.pinho@hotmail.com.'}, {'ForeName': 'Samila Sousa', 'Initials': 'SS', 'LastName': 'Vasconcelos', 'Affiliation': 'UNINTA University Center, Sobral, Ceará, Brazil. Electronic address: samilasousa@hotmail.com.'}, {'ForeName': 'Jand Venes', 'Initials': 'JV', 'LastName': 'Rolim Medeiros', 'Affiliation': 'Federal University of Delta do Parnaíba, Parnaíba, Piauí, Brazil. Electronic address: jandvenes@ufpi.edu.br.'}, {'ForeName': 'Rosangela', 'Initials': 'R', 'LastName': 'Lago da Silva', 'Affiliation': 'Federal University of Delta do Parnaíba, Evaluative and Therapeutic Physiotherapy - GPFAT, Parnaíba, Piauí, Brazil. Electronic address: rohsangella@gmail.com.'}, {'ForeName': 'Luiz Gonzaga', 'Initials': 'LG', 'LastName': 'Porto Pinheiro', 'Affiliation': 'Federal University of Ceará, Fortaleza, Ceará, Brazil. Electronic address: luizgportop@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.01.004'] 1268,34391293,Dry needling trigger points around knee and hip joints improves function in patients with mild to moderate knee osteoarthritis.,"INTRODUCTION Dry needling may be an effective method to alleviate pain and improve range of motion. Controversial results have been found in previous studies using dry needling in knee problems. So, the aim of current study is to exert dry needling technique on unilateral muscles around the hip and knee joints and evaluate its effects on knee osteoarthritic patients. METHOD For this double-blind randomized clinical trial, 40 female patients with mild to moderate knee osteoarthritis (aged 45-70 years old) were recruited. They entered the study if they had any trigger points around the hip or knee joints of the examined side and randomized into two groups. Pain, sensitivity of trigger points, balance and function measured by visual analogue scale, algometer, Y-balance test, timed up and go, self-paced walk tests beside KOOS questionnaire respectively before and after intervention. The intervention group received 3 sessions of dry needling on marked trigger points while the sham group received sham treatment consisting of only the plastic cover of a needle. Both groups reexamined 2 weeks after primary evaluation. RESULTS Comparing results before and after implementing dry needling revealed significant improvements in all measured variables in treatment group whereas, pain and timed up and go increased and peak pain pressure decreased in sham group. Between group comparison revealed significant differences in all variables. CONCLUSION Using 3 sessions of dry needling can increase functional activity, sensitivity and balance and decrease pain in patients with knee osteoarthritis in short term.",2021,"Using 3 sessions of dry needling can increase functional activity, sensitivity and balance and decrease pain in patients with knee osteoarthritis in short term.","['patients with knee osteoarthritis in short term', '40 female patients with mild to moderate knee osteoarthritis (aged 45-70 years old', 'patients with mild to moderate knee osteoarthritis', 'knee osteoarthritic patients']","['3 sessions of dry needling on marked trigger points while the sham group received sham treatment consisting of only the plastic cover of a needle', 'Dry needling trigger points around knee and hip joints']","['Pain, sensitivity of trigger points, balance and function measured by visual analogue scale, algometer, Y-balance test, timed up and go, self-paced walk tests beside KOOS questionnaire', 'pain and timed up and go increased and peak pain pressure', 'functional activity, sensitivity and balance and decrease pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}]","[{'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0032167', 'cui_str': 'Plastic'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}]",40.0,0.0515614,"Using 3 sessions of dry needling can increase functional activity, sensitivity and balance and decrease pain in patients with knee osteoarthritis in short term.","[{'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Farazdaghi', 'Affiliation': 'Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Kordi Yoosefinejad', 'Affiliation': 'Department of Physical Therapy, School of Rehabilitation Sciences, University, Shiraz University of Medical Sciences, Shiraz, Iran; Rehabilitation Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Najmeh', 'Initials': 'N', 'LastName': 'Abdollahian', 'Affiliation': 'Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mahvash', 'Initials': 'M', 'LastName': 'Rahimi', 'Affiliation': 'Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Motealleh', 'Affiliation': 'Department of Physical Therapy, School of Rehabilitation Sciences, University, Shiraz University of Medical Sciences, Shiraz, Iran; Rehabilitation Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: motealleh@sums.ac.ir.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.011'] 1269,34122763,"Distal Chevron Osteotomy vs The Simple, Effective, Rapid, Inexpensive Technique (SERI) for Mild to Moderate Isolated Hallux Valgus: A Randomized Controlled Study.","Background Hallux valgus is a common foot deformity that leads to functional disability with serious sequelae. Minimally invasive surgery is often used to treat hallux valgus in order to reduce wound complications and improve recovery time. The objective of this study was to compare a Simple, Effective, Rapid, Inexpensive (SERI) technique with a simple Chevron technique in patients with minimum of 1-year follow-up. Methods and Materials Between the years 2014-2015, we performed a prospective study comparing the SERI minimally invasive technique to treat symptomatic hallux valgus with a standard chevron osteotomy technique. All procedures were performed by a single fellowship trained foot and ankle surgeon. Twenty-one patients were randomized to the SERI cohort and 15 to the standard Chevron technique. Results The mean preoperative intermetatarsal angle (IMA) of the SERI group was 14.8 ± 1.9 (11.9-22.9). The mean preoperative IMA of the Chevron control group was 13.3 ± 2.3 (10.4-18.2) ( p  = 0.038). The mean IMA two weeks after the surgery was 6.0 ± 2.3 (2.4-12) in the SERI group, and 6.1 ± 3 (2.6-13.1) in the control group. At the two-week and 1-year follow-up, there was no significant difference found in the IMA between the two groups ( p  = 0.871). The mean hallux valgus angle reduction was 11.85 ± 4.88 (3-20.8) and 11.09 ± 6.51 (- 1.1 to 22.5) in the SERI and Chevron groups, respectively ( p  = 0.69). Neither groups reported symptomatic transfer metatarsalgia throughout the follow-up period. The SERI group had increased metatarsophalangeal joint (MTPJ) motion ( p  < 0.001); however, all other parameters with similar. Conclusion The SERI technique provided comparable outcomes at up to 1-year follow-up when compared with a standard Chevron osteotomy for moderate hallux valgus. This study demonstrated good reproducible results using the SERI technique for moderate hallux valgus. Level of Evidence Level II Prospective Study. Trial Registration Approved by local IRB at MMC.",2021,"The SERI group had increased metatarsophalangeal joint (MTPJ) motion ( p  < 0.001); however, all other parameters with similar. ","['Between the years 2014-2015', 'patients with minimum of 1-year follow-up', 'Twenty-one patients were randomized to the SERI cohort and 15 to the standard Chevron technique', 'Mild to Moderate Isolated Hallux Valgus']","['Rapid, Inexpensive (SERI) technique with a simple Chevron technique', 'standard Chevron osteotomy', 'SERI minimally invasive technique to treat symptomatic hallux valgus with a standard chevron osteotomy technique', 'SERI technique']","['mean IMA', 'IMA', 'symptomatic transfer metatarsalgia', 'metatarsophalangeal joint (MTPJ) motion', 'mean preoperative intermetatarsal angle (IMA', 'mean preoperative IMA', 'mean hallux valgus angle reduction']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0443173', 'cui_str': 'Chevron'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0018536', 'cui_str': 'Hallux valgus'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0443173', 'cui_str': 'Chevron'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3163986', 'cui_str': 'Chevron osteotomy'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0018536', 'cui_str': 'Hallux valgus'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0025587', 'cui_str': 'Metatarsalgia'}, {'cui': 'C0025589', 'cui_str': 'Metatarsophalangeal joint structure'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0018536', 'cui_str': 'Hallux valgus'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",21.0,0.0201736,"The SERI group had increased metatarsophalangeal joint (MTPJ) motion ( p  < 0.001); however, all other parameters with similar. ","[{'ForeName': 'Ezequiel', 'Initials': 'E', 'LastName': 'Palmanovich', 'Affiliation': 'Department of Orthopaedic Surgery, Meir Medical Center, Affiliated with the Sackler Faculty of Medicine, Kfar Saba, Israel.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Ohana', 'Affiliation': 'Department of Orthopaedic Surgery, Meir Medical Center, Affiliated with the Sackler Faculty of Medicine, Kfar Saba, Israel.'}, {'ForeName': 'Segal', 'Initials': 'S', 'LastName': 'David', 'Affiliation': 'Department of Orthopaedic Surgery, Meir Medical Center, Affiliated with the Sackler Faculty of Medicine, Kfar Saba, Israel.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Small', 'Affiliation': 'Department of Orthopaedic Surgery, Tel Aviv Medical Center, Tel Aviv University, Affiliated with the Sackler Faculty of Medicine, Tel Aviv, Israel.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Hetsroni', 'Affiliation': 'Department of Orthopaedic Surgery, Meir Medical Center, Affiliated with the Sackler Faculty of Medicine, Kfar Saba, Israel.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Amar', 'Affiliation': 'Department of Orthopaedic Surgery, Tel Aviv Medical Center, Tel Aviv University, Affiliated with the Sackler Faculty of Medicine, Tel Aviv, Israel.'}, {'ForeName': 'Z T', 'Initials': 'ZT', 'LastName': 'Sharfman', 'Affiliation': 'Department of Orthopaedic Surgery Montefiore, Bronx, NY USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Segal', 'Affiliation': 'Department of Orthopaedic Surgery, Meir Medical Center, Affiliated with the Sackler Faculty of Medicine, Kfar Saba, Israel.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Atzmon', 'Affiliation': 'Department of Orthopaedic Surgery, Assuta Medical Center, Affiliated with the Faculty of Health and Science, Ben Gurion University, Ashdod, Israel.'}]",Indian journal of orthopaedics,['10.1007/s43465-020-00209-0'] 1270,33795571,Phase I/III Clinical Trial to Evaluate the Safety and Efficacy of a New Botulinum Toxin (HU-014) Versus OnabotulinumtoxinA in Subjects With Moderate-to-Severe Crow's Feet Lines.,"BACKGROUND HU-014, a newly introduced botulinum toxin type A, has not been investigated for its efficacy and safety in crow's feet line (CFL) treatment. OBJECTIVE Here, we compared the efficacy and safety of HU-014 and onabotulinumtoxinA in CFL treatment. METHODS This was a randomized, double-blind, active drug-controlled, multicenter, 16-week, Phase I/III study designed to determine the noninferiority of HU-014 compared with onabotulinumtoxinA in moderate-to-severe CFL treatment. In the Phase III study, 290 subjects were randomized at a 1:1 ratio to receive a single treatment of HU-014 or onabotulinumtoxinA. The primary endpoint was the proportion of subjects achieving Grade 0 or 1 in the facial wrinkle scale on maximum smile at Week 4. RESULTS The primary endpoint was achieved by 72% of the subjects with HU-014 and onabotulinumtoxinA treatments, supporting the noninferiority of HU-014 compared with onabotulinumtoxinA. All secondary efficacy outcomes were achieved by the subjects. The 2 groups showed no significant differences in the safety analysis. CONCLUSION HU-014 has noninferior efficacy and safety compared with onabotulinumtoxinA in the treatment of CFL.",2021,"The 2 groups showed no significant differences in the safety analysis. ","[""Subjects With Moderate-to-Severe Crow's Feet Lines"", '290 subjects', 'moderate-to-severe CFL treatment']","['onabotulinumtoxinA', 'OnabotulinumtoxinA', 'HU-014 and onabotulinumtoxinA', 'New Botulinum Toxin', 'HU-014 or onabotulinumtoxinA']","['noninferior efficacy and safety', 'efficacy and safety', 'safety analysis', 'Safety and Efficacy']","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0277939', 'cui_str': ""Crow's feet""}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C5191218', 'cui_str': '290'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C2719767', 'cui_str': 'OnabotulinumtoxinA'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0006055', 'cui_str': 'botulinum toxin'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",290.0,0.255431,"The 2 groups showed no significant differences in the safety analysis. ","[{'ForeName': 'Hye Sung', 'Initials': 'HS', 'LastName': 'Han', 'Affiliation': 'Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Kwang Ho', 'Initials': 'KH', 'LastName': 'Yoo', 'Affiliation': 'Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Ji Su', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Chang-Hun', 'Initials': 'CH', 'LastName': 'Huh', 'Affiliation': 'Department of Dermatology, Seoul National University Bundang Hospital, Seoul, Korea.'}, {'ForeName': 'Soon-Hyo', 'Initials': 'SH', 'LastName': 'Kwon', 'Affiliation': 'Department of Dermatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Yang Won', 'Initials': 'YW', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Beom Joon', 'Initials': 'BJ', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002807'] 1271,33795569,Does Double-Pass Pulsed-Dye Laser With Long and Short Pulse Duration Increase Treatment Efficacy of Port-Wine Stain? A Randomized Clinical Trial.,"BACKGROUND Although pulsed-dye laser (PDL) 595 nm is known as the gold standard for treatment of port-wine stains (PWS), complete clearance of lesions occurs in a minority of cases. OBJECTIVE To compare the efficacy and safety of double-pass pulsed-dye laser (DPL), long pulse duration (20 m/s) followed by short pulse duration (1.5 m/s) within 20 minutes interval, with single-pass pulsed-dye laser (SPL) for (1.5 m/s) in the treatment of PWS. METHODS Twenty-four patients with PWS underwent 3 sessions of PDL. Each lesion was randomly divided into 2 portions to receive DPL or SPL. Colorimetric and dermoscopic evaluations were used to determine the response objectively. In addition, improvement was scored subjectively using the visual analog scale (VAS). RESULTS According to colorimetric analysis, the mean blanching rates for DPL and SPL treated sites were 48% (SD = 0.215) and 37% (SD = 0.213), respectively (p = .001). With VAS, 3.79 (SD = 0.93) and 3.33 (SD = 0.91) improvement scores were reported in the DPL and SPL treated areas, respectively (p = .008). Dermoscopic images showed that larger deep vessels were the most common remnant vessels in both treatment areas. CONCLUSION Compared with SPL, DPL with 20 minutes interval seems to be a more effective and safe method for the treatment of PWS.",2021,"(SD = 0.91) improvement scores were reported in the DPL and SPL treated areas, respectively (p = .008).",['Twenty-four patients with PWS underwent 3 sessions of'],"['single-pass pulsed-dye laser (SPL', 'double-pass pulsed-dye laser (DPL', 'pulsed-dye laser (PDL', 'DPL or SPL', 'PDL']","['visual analog scale (VAS', 'efficacy and safety']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206733', 'cui_str': 'Strawberry nevus of skin'}]","[{'cui': 'C0445262', 'cui_str': 'Single pass'}, {'cui': 'C1289859', 'cui_str': 'Pulsed dye laser device'}, {'cui': 'C0205173', 'cui_str': 'Double'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",24.0,0.113385,"(SD = 0.91) improvement scores were reported in the DPL and SPL treated areas, respectively (p = .008).","[{'ForeName': 'Pedram', 'Initials': 'P', 'LastName': 'Noormohammadpour', 'Affiliation': 'All authors are affiliated with the Department of Dermatology, Razi Hospital, Tehran University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Amir H', 'Initials': 'AH', 'LastName': 'Ehsani', 'Affiliation': ''}, {'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Mahmoudi', 'Affiliation': ''}, {'ForeName': 'Kamran', 'Initials': 'K', 'LastName': 'Balighi', 'Affiliation': ''}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Razavi', 'Affiliation': ''}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002819'] 1272,33792730,Cost-effectiveness of a Smoking Cessation Intervention for Parents in Pediatric Primary Care.,"Importance Parental smoking adversely affects parents' and children's health. There are effective interventions delivered in pediatric settings to help parents quit smoking. The cost-effectiveness of this type of intervention is not known. Objective To evaluate the cost-effectiveness of a parental smoking cessation intervention, the Clinical Effort Against Secondhand Smoke Exposure (CEASE) program, delivered in pediatric primary care, compared with usual care from a health care organization's perspective. Design, Setting, and Participants This economic evaluation used data on intervention costs and parental smoking cessation collected prospectively as part of the CEASE randomized clinical trial. Data were collected at pediatric offices in 5 US states from April 2015 to October 2017. Participants included parents of children attending 10 pediatric primary care practices (5 control, 5 intervention). Data analysis was performed from October 2019 to August 2020. Exposures The trial compared CEASE (practice training and support to address family tobacco use) vs usual care. Main Outcomes and Measures The overall cost and incremental cost per quit of the CEASE intervention were calculated using microcosting methods. CEASE effectiveness was estimated using 2 trial outcomes measures assessed in repeated cross-sections: (1) change in smoking prevalence assessed by parental report for intervention vs usual care practices at 2 weeks after program initiation (baseline) and at 2-year follow-up and (2) changes in the proportion of smokers who achieved cotinine-confirmed smoking cessation in the previous 2 years at baseline vs follow-up. Monte Carlo analyses were used to provide 95% CIs. Results The study included a total of 3054 participants (1523 at baseline and 1531 at follow-up); 2163 (70.8%) were aged 25 to 44 years old, and 2481 (81.2%) were women. Over 2 years, the total cost of implementing and sustaining CEASE across 5 intervention practices was $115 778. The incremental cost per quit for CEASE compared with usual care was $1132 (95% CI, $653-$3603), according to the change in parent-reported smoking prevalence, and $762 (95% CI, $418-$2883), according to cotinine-confirmed cessation. CEASE was cost-effective at a willingness-to-pay threshold of $2000 per quit in 88.0% of simulations based on the parent-reported smoking prevalence and 94.6% of simulations based on cotinine-confirmed smoking cessation measures. Conclusions and Relevance These findings suggest that the CEASE intervention was associated with an incremental cost per quit that compared favorably with those of other clinical smoking cessation interventions. CEASE is inexpensive to initiate and maintain in the clinical pediatric setting, suggesting that it has the potential for a high impact on population health.",2021,"The incremental cost per quit for CEASE compared with usual care was $1132 (95% CI, $653-$3603), according to the change in parent-reported smoking prevalence, and $762 (95% CI, $418-$2883), according to cotinine-confirmed cessation.","['3054 participants (1523 at baseline and 1531 at follow-up); 2163 (70.8%) were aged 25 to 44 years old, and 2481 (81.2%) were women', 'Participants included parents of children attending 10 pediatric primary care practices (5 control, 5 intervention', 'Parents in Pediatric Primary Care']","['CEASE intervention', 'CEASE', 'Secondhand Smoke Exposure (CEASE) program', 'CEASE (practice training', 'parental smoking cessation intervention', 'Smoking Cessation Intervention']","['total cost of implementing and sustaining CEASE', 'incremental cost per quit', 'repeated cross-sections: (1) change in smoking prevalence', 'overall cost and incremental cost per quit of the CEASE intervention', 'cost-effectiveness', 'incremental cost per quit for CEASE', 'Cost-effectiveness', 'CEASE effectiveness']","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0037370', 'cui_str': 'Passive smoking'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C1692317', 'cui_str': 'Smoking cessation assistance'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0037370', 'cui_str': 'Passive smoking'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",3054.0,0.0239411,"The incremental cost per quit for CEASE compared with usual care was $1132 (95% CI, $653-$3603), according to the change in parent-reported smoking prevalence, and $762 (95% CI, $418-$2883), according to cotinine-confirmed cessation.","[{'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Drouin', 'Affiliation': 'Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine, Montréal, Quebec, Canada.'}, {'ForeName': 'Ryoko', 'Initials': 'R', 'LastName': 'Sato', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Jeremy E', 'Initials': 'JE', 'LastName': 'Drehmer', 'Affiliation': 'Division of General Academic Pediatrics, Massachusetts General Hospital for Children, Boston.'}, {'ForeName': 'Emara', 'Initials': 'E', 'LastName': 'Nabi-Burza', 'Affiliation': 'Division of General Academic Pediatrics, Massachusetts General Hospital for Children, Boston.'}, {'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Hipple Walters', 'Affiliation': 'Division of General Academic Pediatrics, Massachusetts General Hospital for Children, Boston.'}, {'ForeName': 'Jonathan P', 'Initials': 'JP', 'LastName': 'Winickoff', 'Affiliation': 'Division of General Academic Pediatrics, Massachusetts General Hospital for Children, Boston.'}, {'ForeName': 'Douglas E', 'Initials': 'DE', 'LastName': 'Levy', 'Affiliation': 'Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.3927'] 1273,33792729,Comparison of 4-Factor Prothrombin Complex Concentrate With Frozen Plasma for Management of Hemorrhage During and After Cardiac Surgery: A Randomized Pilot Trial.,"Importance Approximately 15% of patients undergoing cardiac surgery receive frozen plasma (FP) for bleeding. Four-factor prothrombin complex concentrates (PCCs) have logistical and safety advantages over FP and may be a suitable alternative. Objectives To determine the proportion of patients who received PCC and then required FP, explore hemostatic effects and safety, and assess the feasibility of study procedures. Design, Setting, and Participants Parallel-group randomized pilot study conducted at 2 Canadian hospitals. Adult patients requiring coagulation factor replacement for bleeding during cardiac surgery (from September 23, 2019, to June 19, 2020; final 28-day follow-up visit, July 17, 2020). Data analysis was initiated on September 15, 2020. Interventions Prothrombin complex concentrate (1500 IU for patients weighing ≤60 kg and 2000 IU for patients weighing >60 kg) or FP (3 U for patients weighing ≤60 kg and 4 U for patients weighing >60 kg), repeated once as needed within 24 hours (FP used for any subsequent doses in both groups). Patients and outcome assessors were blinded to treatment allocation. Main Outcomes and Measures Hemostatic effectiveness (whether patients received any hemostatic therapies from 60 minutes to 4 and 24 hours after initiation of the intervention, amount of allogeneic blood components administered within 24 hours after start of surgery, and avoidance of red cell transfusions within 24 hours after start of surgery), protocol adherence, and adverse events. The analysis set comprised all randomized patients who had undergone cardiac surgery, received at least 1 dose of either treatment, and provided informed consent after surgery. Results Of 169 screened patients, 131 were randomized, and 101 were treated (54 with PCC and 47 with FP), provided consent, and were included in the analysis (median age, 64 years; interquartile range [IQR], 54-73 years; 28 [28%] were female; 82 [81%] underwent complex operations). The PCC group received a median 24.9 IU/kg (IQR, 21.8-27.0 IU/kg) of PCC (2 patients [3.7%; 95% CI, 0.4%-12.7%] required FP). The FP group received a median 12.5 mL/kg (IQR, 10.0-15.0 mL/kg) of FP (4 patients [8.5%; 95% CI, 2.4%-20.4%] required >2 doses of FP). Hemostatic therapy was not required at the 4-hour time point for 43 patients (80%) in the PCC group and for 32 patients (68%) in the FP group (P = .25) nor at the 24-hour time point for 41 patients (76%) in the PCC group and for 31 patients (66%) patients in the FP group (P = .28). The median numbers of units for 24-hour cumulative allogeneic transfusions (red blood cells, platelets, and FP) were 6.0 U (IQR, 4.0-11.0 U) in the PCC group and 14.0 U (IQR, 8.0-20.0 U) in the FP group (ratio, 0.58; 95% CI, 0.45-0.77; P < .001). After exclusion of FP administered as part of the investigational medicinal product, the median numbers of units were 6.0 U (IQR, 4.0-11.0 U) in the PCC group and 10.0 U (IQR, 6.0-16.0 U) in the FP group (ratio, 0.80; 95% CI, 0.59-1.08; P = .15). For red blood cells alone, the median numbers were 1.5 U (IQR, 0.0-4.0 U) in the PCC group and 3.0 U (IQR, 1.0-5.0 U) in the FP group (ratio, 0.69; 95% CI, 0.47-0.99; P = .05). During the first 24 hours after start of surgery, 15 patients in the PCC group (28%) and 8 patients in the FP group (17%) received no red blood cells (P = .24). Adverse event profiles were similar. Conclusions and Relevance This randomized clinical trial found that the study protocols were feasible. Adequately powered randomized clinical trials are warranted to determine whether PCC is a suitable substitute for FP for mitigation of bleeding in cardiac surgery. Trial Registration ClinicalTrials.gov Identifier: NCT04114643.",2021,Hemostatic therapy was not required at the 4-hour time point for 43 patients (80%) in the PCC group and for 32 patients (68%) in the FP group (P = .25) nor at the 24-hour time point for 41 patients (76%) in the PCC group and for 31 patients (66%) patients in the FP group (P = .28).,"['2 Canadian hospitals', 'patients undergoing cardiac surgery receive', 'Adult patients requiring coagulation factor replacement for bleeding during cardiac surgery (from September 23, 2019, to June 19, 2020; final 28-day follow-up visit, July 17, 2020', '169 screened patients, 131 were randomized, and 101 were treated (54 with PCC and 47 with FP), provided consent, and were included in the analysis (median age, 64 years; interquartile range [IQR], 54-73 years; 28 [28%] were female; 82 [81%] underwent complex operations']","['frozen plasma (FP', '4-Factor Prothrombin Complex Concentrate With Frozen Plasma', 'Prothrombin complex concentrate', 'Four-factor prothrombin complex concentrates (PCCs', 'PCC', 'FP']","['Hemostatic effectiveness', 'Hemostatic therapy', 'median numbers of units for 24-hour cumulative allogeneic transfusions (red blood cells, platelets, and FP', 'median numbers', 'no red blood cells', 'Hemorrhage']","[{'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005789', 'cui_str': 'Blood clotting factor'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0589121', 'cui_str': 'Follow-up visit'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0044609', 'cui_str': '1-piperidinocyclohexanecarbonitrile'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C4048712', 'cui_str': 'factor IX complex'}, {'cui': 'C0044609', 'cui_str': '1-piperidinocyclohexanecarbonitrile'}]","[{'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449961', 'cui_str': 'Number of units'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",,0.316996,Hemostatic therapy was not required at the 4-hour time point for 43 patients (80%) in the PCC group and for 32 patients (68%) in the FP group (P = .25) nor at the 24-hour time point for 41 patients (76%) in the PCC group and for 31 patients (66%) patients in the FP group (P = .28).,"[{'ForeName': 'Keyvan', 'Initials': 'K', 'LastName': 'Karkouti', 'Affiliation': ""Department of Anesthesia and Pain Management; University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Justyna', 'Initials': 'J', 'LastName': 'Bartoszko', 'Affiliation': ""Department of Anesthesia and Pain Management; University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Deep', 'Initials': 'D', 'LastName': 'Grewal', 'Affiliation': ""Department of Anesthesia and Pain Management; University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Cielo', 'Initials': 'C', 'LastName': 'Bingley', 'Affiliation': ""Department of Anesthesia and Pain Management; University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Armali', 'Affiliation': 'Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Carroll', 'Affiliation': ""Department of Anesthesia and Pain Management; University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Hans-Peter', 'Initials': 'HP', 'LastName': 'Hucke', 'Affiliation': 'Department of Biostatistics, Ergomed CDS GmbH, Cologne, Germany.'}, {'ForeName': 'Amie', 'Initials': 'A', 'LastName': 'Kron', 'Affiliation': 'Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Stuart A', 'Initials': 'SA', 'LastName': 'McCluskey', 'Affiliation': ""Department of Anesthesia and Pain Management; University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Rao', 'Affiliation': 'Peter Munk Cardiac Centre and Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Jeannie', 'Initials': 'J', 'LastName': 'Callum', 'Affiliation': 'Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.3936'] 1274,33797501,Temporal profile of the pro- and anti-inflammatory responses to severe hemorrhage in patients with venous thromboembolism: Findings from the PROPPR trial.,"BACKGROUND The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial showed that 15% of patients developed venous thromboembolism (VTE) following hemorrhage, but the mechanisms are unknown. Since inflammation is associated with hypercoagulability and thrombosis, our goal was to compare the temporal inflammatory profile following hemorrhagic shock in patients with and without VTE. STUDY DESIGN Secondary analysis was performed on data collected from PROPPR. Blood samples collected at 0 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours following admission were assayed on a 27-target cytokine panel, and compared between VTE (n = 83) and non-VTE (n = 475) patients. p < 0.05 indicated significance. RESULTS Over time, both groups exhibited elevations in proinflammatory mediators interleukin (IL)-6, IL-8, IL-10, granulocyte colony-stimulating factor 57, monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β, and anti-inflammatory mediators IL-1ra and IL-10 (p < 0.05 vs. admission). Venous thromboembolism patients showed amplified responses for IL-6 (6-72 hours) and IL-8 (6-24 hours), which peaked at later time points, and granulocyte colony-stimulating factor 57 (12-24 hours), monocyte chemoattractant protein 1 (6-72 hours), and macrophage inflammatory protein-1 β (2-12 hours) (p < 0.05 vs. non-VTE per time point) that peaked at similar time points to non-VTE patients. The anti-inflammatory responses were similar between groups, but the interleukin-mediated proinflammatory responses continued to rise after the peak anti-inflammatory response in the VTE group. The occurrence rate of adverse events was higher in VTE (97%) versus non-VTE (87%, p = 0.009) and was associated with higher inflammation. CONCLUSION Patients with VTE following hemorrhagic shock exhibited a prolonged and amplified proinflammatory responses mediated by select interleukin, chemotactic, and glycoprotein cytokines that are not antagonized by anti-inflammatory mediators. This response is not related to randomization group, injury severity or degree of shock, but may be linked to adverse events. LEVEL OF EVIDENCE Prognostic, level III.",2021,VTE patients showed amplified responses for IL-6 (6-72 hours) and IL-8,"['patients with and without VTE', 'patients with venous thromboembolism']",['VTE'],"['venous thromboembolism (VTE', 'pro-inflammatory mediators interleukin (IL)-6, IL-8, IL-10, granulocyte colony-stimulating (G-CSF) 57, monocyte chemoattractant protein (MCP)-1 and macrophage inflammatory protein (MIP)-1β, and anti-inflammatory mediators IL-1ra and IL-10', 'occurrence rate of adverse events', 'IL-8', 'anti-inflammatory responses']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}]","[{'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}]","[{'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0018183', 'cui_str': 'Granulocyte'}, {'cui': 'C0439158', 'cui_str': 'colonies'}, {'cui': 'C0079459', 'cui_str': 'Colony-stimulating factor, granulocytic'}, {'cui': 'C0282566', 'cui_str': 'Monocyte Chemotactic Proteins'}, {'cui': 'C0376579', 'cui_str': 'Macrophage Inflammatory Proteins'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",475.0,0.21612,VTE patients showed amplified responses for IL-6 (6-72 hours) and IL-8,"[{'ForeName': 'Belinda H', 'Initials': 'BH', 'LastName': 'McCully', 'Affiliation': 'From the Division of Trauma, Critical Care & Acute Care Surgery, Department of Surgery (B.H.M., M.A.S.), Oregon Health & Science University, Portland, Oregon; Center for Translational Injury Research, Division of Acute Care Surgery, Department of Surgery (C.E.W., E.E.F.), University of Texas Health Science Center, Houston, Texas; Division of Acute Care Surgery, Department of Surgery (K.I.), University of Southern California, Los Angeles, California; Department of Surgery (M.J.C.), Denver Health Medical Center and the University of Colorado; Denver, Colorado; and Department of Surgery (J.B.H.), University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Charlie E', 'Initials': 'CE', 'LastName': 'Wade', 'Affiliation': ''}, {'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Fox', 'Affiliation': ''}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Inaba', 'Affiliation': ''}, {'ForeName': 'Mitchell J', 'Initials': 'MJ', 'LastName': 'Cohen', 'Affiliation': ''}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Holcomb', 'Affiliation': ''}, {'ForeName': 'Martin A', 'Initials': 'MA', 'LastName': 'Schreiber', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The journal of trauma and acute care surgery,['10.1097/TA.0000000000003088'] 1275,33811444,"A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.","AIMS CONCERT-HF is an NHLBI-sponsored, double-blind, placebo-controlled, Phase II trial designed to determine whether treatment with autologous bone marrow-derived mesenchymal stromal cells (MSCs) and c-kit positive cardiac cells (CPCs), given alone or in combination, is feasible, safe, and beneficial in patients with heart failure (HF) caused by ischaemic cardiomyopathy. METHODS AND RESULTS Patients were randomized (1:1:1:1) to transendocardial injection of MSCs combined with CPCs, MSCs alone, CPCs alone, or placebo, and followed for 12 months. Seven centres enrolled 125 participants with left ventricular ejection fraction of 28.6 ± 6.1% and scar size 19.4 ± 5.8%, in New York Heart Association class II or III. The proportion of major adverse cardiac events (MACE) was significantly decreased by CPCs alone (-22% vs. placebo, P = 0.043). Quality of life (Minnesota Living with Heart Failure Questionnaire score) was significantly improved by MSCs alone (P = 0.050) and MSCs + CPCs (P = 0.023) vs. placebo. Left ventricular ejection fraction, left ventricular volumes, scar size, 6-min walking distance, and peak oxygen consumption did not differ significantly among groups. CONCLUSIONS This is the first multicentre trial assessing CPCs and a combination of two cell types from different tissues in HF patients. The results show that treatment is safe and feasible. Even with maximal guideline-directed therapy, both CPCs and MSCs were associated with improved clinical outcomes (MACE and quality of life, respectively) in ischaemic HF without affecting left ventricular function or structure, suggesting possible systemic or paracrine cellular mechanisms. Combining MSCs with CPCs was associated with improvement in both these outcomes. These results suggest potential important beneficial effects of CPCs and MSCs and support further investigation in HF patients.",2021,Quality of life (MLHFQ score) was significantly improved by MSCs alone (P = 0.050) and MSCs+CPCs (P = 0.023) vs. placebo.,"['Patients', 'Patients with Ischemic Heart Failure', 'Seven centers enrolled 125 participants with left ventricular ejection fraction (LVEF) of 28.6\u2009±\u20096.1% and scar size 19.4\u2009±\u20095.8%, in NYHA class II or III', 'HF patients', 'patients with heart failure (HF) caused by ischemic cardiomyopathy']","['autologous bone marrow-derived mesenchymal stromal cells (MSCs) and c-kit positive cardiac cells (CPCs', 'placebo', 'transendocardial injection of MSCs combined with CPCs, MSCs alone, CPCs alone, or placebo', 'Autologous Mesenchymal Stromal Cells and c-kit Positive Cardiac Cells, Alone or in Combination']","['proportion of major adverse cardiac events (MACE', 'LVEF, LV volumes, scar size, 6-min walking distance, and peak VO 2', 'Quality of life (MLHFQ score', 'clinical outcomes (MACE and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C4517679', 'cui_str': '28.6'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C4709305', 'cui_str': '19.4'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C1275491', 'cui_str': 'New York Heart Association Classification'}, {'cui': 'C0441886', 'cui_str': 'Class 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0349782', 'cui_str': 'Generalized ischemic myocardial dysfunction'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C3178844', 'cui_str': 'Mesenchymal Stromal Cells'}, {'cui': 'C0072470', 'cui_str': 'Lymphocyte antigen CD117'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",125.0,0.185245,Quality of life (MLHFQ score) was significantly improved by MSCs alone (P = 0.050) and MSCs+CPCs (P = 0.023) vs. placebo.,"[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Bolli', 'Affiliation': 'University of Louisville, School of Medicine, Louisville, KY, USA.'}, {'ForeName': 'Raul D', 'Initials': 'RD', 'LastName': 'Mitrani', 'Affiliation': 'University of Miami, Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Hare', 'Affiliation': 'University of Miami, Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Carl J', 'Initials': 'CJ', 'LastName': 'Pepine', 'Affiliation': 'University of Florida College of Medicine, Gainesville, FL, USA.'}, {'ForeName': 'Emerson C', 'Initials': 'EC', 'LastName': 'Perin', 'Affiliation': ""Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, TX, USA.""}, {'ForeName': 'James T', 'Initials': 'JT', 'LastName': 'Willerson', 'Affiliation': ""Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, TX, USA.""}, {'ForeName': 'Jay H', 'Initials': 'JH', 'LastName': 'Traverse', 'Affiliation': 'Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, and University of Minnesota School of Medicine, Minneapolis, MN, USA.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Henry', 'Affiliation': 'The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, OH, USA.'}, {'ForeName': 'Phillip C', 'Initials': 'PC', 'LastName': 'Yang', 'Affiliation': 'Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Murphy', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, IN.'}, {'ForeName': 'Keith L', 'Initials': 'KL', 'LastName': 'March', 'Affiliation': 'University of Florida College of Medicine, Gainesville, FL, USA.'}, {'ForeName': 'Ivonne H', 'Initials': 'IH', 'LastName': 'Schulman', 'Affiliation': 'University of Miami, Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Sohail', 'Initials': 'S', 'LastName': 'Ikram', 'Affiliation': 'University of Louisville, School of Medicine, Louisville, KY, USA.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Lee', 'Affiliation': 'Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Connor', 'Initials': 'C', 'LastName': ""O'Brien"", 'Affiliation': 'Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Joao A', 'Initials': 'JA', 'LastName': 'Lima', 'Affiliation': 'Johns Hopkins University, Cardiovascular Imaging, Baltimore, MD, USA.'}, {'ForeName': 'Mohammad R', 'Initials': 'MR', 'LastName': 'Ostovaneh', 'Affiliation': 'Johns Hopkins University, Cardiovascular Imaging, Baltimore, MD, USA.'}, {'ForeName': 'Bharath', 'Initials': 'B', 'LastName': 'Ambale-Venkatesh', 'Affiliation': 'Johns Hopkins University, Cardiovascular Imaging, Baltimore, MD, USA.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Lewis', 'Affiliation': 'Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Aisha', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': 'University of Miami, Miller School of Medicine, Interdisciplinary Stem Cell Institute, Miami, FL, USA.'}, {'ForeName': 'Ketty', 'Initials': 'K', 'LastName': 'Bacallao', 'Affiliation': 'University of Miami, Miller School of Medicine, Interdisciplinary Stem Cell Institute, Miami, FL, USA.'}, {'ForeName': 'Krystalenia', 'Initials': 'K', 'LastName': 'Valasaki', 'Affiliation': 'University of Miami, Miller School of Medicine, Interdisciplinary Stem Cell Institute, Miami, FL, USA.'}, {'ForeName': 'Bangon', 'Initials': 'B', 'LastName': 'Longsomboon', 'Affiliation': 'University of Miami, Miller School of Medicine, Interdisciplinary Stem Cell Institute, Miami, FL, USA.'}, {'ForeName': 'Adrian P', 'Initials': 'AP', 'LastName': 'Gee', 'Affiliation': 'Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Richman', 'Affiliation': 'Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Doris A', 'Initials': 'DA', 'LastName': 'Taylor', 'Affiliation': ""Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, TX, USA.""}, {'ForeName': 'Dejian', 'Initials': 'D', 'LastName': 'Lai', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.'}, {'ForeName': 'Shelly L', 'Initials': 'SL', 'LastName': 'Sayre', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Bettencourt', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.'}, {'ForeName': 'Rachel W', 'Initials': 'RW', 'LastName': 'Vojvodic', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.'}, {'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': 'Cohen', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Simpson', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Aguilar', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.'}, {'ForeName': 'Catalin', 'Initials': 'C', 'LastName': 'Loghin', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA.'}, {'ForeName': 'Lem', 'Initials': 'L', 'LastName': 'Moyé', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.'}, {'ForeName': 'Ray F', 'Initials': 'RF', 'LastName': 'Ebert', 'Affiliation': 'NIH, National Heart, Lung and Blood Institute, Bethesda, MD, USA.'}, {'ForeName': 'Barry R', 'Initials': 'BR', 'LastName': 'Davis', 'Affiliation': 'UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Simari', 'Affiliation': 'University of Kansas, School of Medicine, Kansas City, KS, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of heart failure,['10.1002/ejhf.2178'] 1276,33812327,The effect of oral magnesium supplementation on acute non-specific low back pain: Prospective randomized clinical trial.,"OBJECTIVE We aimed to investigate the effect of oral magnesium supplementation for acute low back pain. METHODS This is a three-arm, prospective randomized open label clinical trial, which included two hundred and forty patients. We based our sample size calculation assumptions on a recently published clinical trial, thus we enrolled 80 patients for each group. NSAID alone group included (400 mg etodolac twice a day), NSAID + mg group included NSAID - magnesium combination treatment (400 mg etodolac twice a day with 365 mg oral magnesium supplementation) and NSAID + paracetamol group included NSAID - paracetamol combination treatment (400 mg etodolac twice a day with 500 mg paracetamol twice a day). Follow-up visits after initiation of relevant treatment were performed at 4th and 10th days and outcome measures included pain (Visual analogue scale - VAS), mobility of lumbar spine and functional outcome (RMDQ). RESULTS Thirty-one patients were considered lost to follow-up or excluded due to use of other medications and final analysis was performed with 209 participants in three groups (71 patients in NSAID alone group, 68 patients in NSAID + mg group and 70 patients in NSAID + paracetamol group). NSAID + mg showed a significantly higher improvement in RMDQ and VAS scores at acute stage (at 4th day visit) compared to two other study groups However, there was no significant difference between three groups in terms of mean improvement of RMDQ, VAS scores and lumbar mobility between initial visit and 10-day. CONCLUSION Results of this study suggest that addition of magnesium to acute low-back pain treatment does not significantly improve final clinical outcomes. LEVEL OF EVIDENCE Level I, prospective randomized controlled study.",2021,NSAID + mg showed a significantly higher improvement in RMDQ and VAS scores at acute stage (at 4th day visit) compared to two other study groups,"['enrolled 80 patients for each group', 'Thirty-one patients were considered lost to follow-up or excluded due to use of other medications and final analysis was performed with 209 participants in three groups (71 patients in NSAID alone group, 68 patients in', 'acute non-specific low back pain', 'two hundred and forty patients']","['oral magnesium supplementation', 'NSAID + mg group included NSAID - magnesium combination treatment', 'NSAID', 'NSAID + mg group and 70 patients in NSAID + paracetamol', 'magnesium', 'NSAID + paracetamol group included NSAID - paracetamol combination treatment']","['RMDQ and VAS scores', 'mean improvement of RMDQ, VAS scores and lumbar mobility', 'pain (Visual analogue scale - VAS), mobility of lumbar spine and functional outcome (RMDQ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C1302313', 'cui_str': 'Lost to follow-up'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C4319600', 'cui_str': '240'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1096534', 'cui_str': 'Magnesium supplement therapy'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",80.0,0.0747373,NSAID + mg showed a significantly higher improvement in RMDQ and VAS scores at acute stage (at 4th day visit) compared to two other study groups,"[{'ForeName': 'Serkan', 'Initials': 'S', 'LastName': 'Bayram', 'Affiliation': 'Department of Orthopedics and Traumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey. Electronic address: dr.serkanbayram89@gmail.com.'}, {'ForeName': 'Koray', 'Initials': 'K', 'LastName': 'Şahin', 'Affiliation': 'Department of Orthopedics and Traumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Fikret Berkan', 'Initials': 'FB', 'LastName': 'Anarat', 'Affiliation': 'Department of Orthopedics and Traumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Chasan Memet', 'Initials': 'CM', 'LastName': 'Chousein', 'Affiliation': 'Department of Orthopedics and Traumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Emre', 'Initials': 'E', 'LastName': 'Kocazeybek', 'Affiliation': 'Department of Orthopedics and Traumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Altan', 'Affiliation': 'Department of Orthopedics and Traumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Turgut', 'Initials': 'T', 'LastName': 'Akgül', 'Affiliation': 'Department of Orthopedics and Traumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2021.03.078'] 1277,33814441,Association of Plasma Hemoglobin A1c with Improvement of Cognitive Functions by Probiotic Bifidobacterium breve Supplementation in Healthy Adults with Mild Cognitive Impairment.,"We demonstrated the benefit of the probiotic strain, Bifidobacterium breve MCC1274 (synonym B. breve A1), at improving cognition in our previous double-blind, placebo-controlled clinical study. Analysis of the association of blood parameters changes with the improvement of cognitive function revealed an inverse correlation of HbA1c with total RBANS score amelioration after the study only in the probiotic group (ρ= -0.4218, p = 0.0067). A stratified analysis based on baseline HbA1c with a median value showed a more remarkable benefit by the probiotic supplementation in the higher median subgroup. These data support the mechanism of anti-inflammation in improving cognition by the probiotic strain.",2021,A stratified analysis based on baseline HbA1c with a median value showed a more remarkable benefit by the probiotic supplementation in the higher median subgroup.,['Healthy Adults with Mild Cognitive Impairment'],"['Probiotic Bifidobacterium breve Supplementation', 'placebo', 'probiotic strain, Bifidobacterium breve MCC1274 (synonym B. breve A1']",['HbA1c with total RBANS score amelioration'],"[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0314975', 'cui_str': 'Bifidobacterium breve'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C3541381', 'cui_str': 'Synonym'}]","[{'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.249559,A stratified analysis based on baseline HbA1c with a median value showed a more remarkable benefit by the probiotic supplementation in the higher median subgroup.,"[{'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Bernier', 'Affiliation': 'Morinaga Milk Industry Co., Ltd., Next Generation Science Institute, Kanagawa, Japan.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Ohno', 'Affiliation': 'Morinaga Milk Industry Co., Ltd., Next Generation Science Institute, Kanagawa, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Katsumata', 'Affiliation': 'Morinaga Milk Industry Co., Ltd., Next Generation Science Institute, Kanagawa, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Shimizu', 'Affiliation': 'Morinaga Milk Industry Co., Ltd., Next Generation Science Institute, Kanagawa, Japan.'}, {'ForeName': 'Jinzhong', 'Initials': 'J', 'LastName': 'Xiao', 'Affiliation': 'Morinaga Milk Industry Co., Ltd., Next Generation Science Institute, Kanagawa, Japan.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201488'] 1278,33814437,"β-Lactolin Enhances Neural Activity, Indicated by Event-Related P300 Amplitude, in Healthy Adults: A Randomized Controlled Trial.","BACKGROUND Epidemiological studies have shown that dairy product consumption is beneficial for cognitive function in elderly individuals. β-lactolin is a Gly-Thr-Trp-Tyr lacto-tetrapeptide rich in fermented dairy products that improves memory retrieval, attention, and executive function in older adults with subjective cognitive decline and prevents the pathology of Alzheimer's disease in rodents. There has been no study on the effects of β-lactolin on neural activity in humans. OBJECTIVE We investigated the effects of β-lactolin on neural activity and cognitive function in healthy adults. METHODS In this randomized, double-blind, placebo-controlled study, 30 participants (45-64 years old) consumed β-lactolin or placebo for 6 weeks. Neural activity during auditory and language tasks was measured through 64-channel electroencephalography. Moreover, verbal fluency tests were performed at baseline and after 6 weeks. RESULTS The β-lactolin group had a significantly higher P300 amplitude at the Cp2 site (a part of the parietal lobe near the center of brain, p = 0.011), and C4 site (the area between the frontal and parietal lobe, p = 0.02) during the auditory tasks after 6 weeks than the placebo group. Thus, β-lactolin supplementation promoted neural activity in the parietal area, which increases concentration and attention during auditory cognitive tasks. Compared with the placebo group, the β-lactolin group also showed significant changes in the scores of verbal fluency test after 6 weeks (p = 0.033). CONCLUSION Our findings provide insight into the mechanisms underlying the effects of β-lactolin on attention in healthy adults.",2021,"Compared with the placebo group, the β-lactolin group also showed significant changes in the scores of verbal fluency test after 6 weeks (p = 0.03). ","['Healthy Adults', ""older adults with subjective cognitive decline and prevents the pathology of Alzheimer's disease in rodents"", '30 participants (45-64 years old) consumed', 'elderly individuals', 'healthy adults']","['β-lactolin or placebo', 'placebo', 'β-lactolin', 'β-Lactolin', 'β-lactolin supplementation']","['neural activity and cognitive function', 'P300 amplitude', 'scores of verbal fluency test', 'Neural activity during auditory and language tasks', 'verbal fluency tests', 'memory retrieval, attention, and executive function', 'neural activity']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0234985', 'cui_str': 'Mental Deterioration'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0035804', 'cui_str': 'Order Rodentia'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0444781', 'cui_str': 'P300 (P3)'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",30.0,0.505265,"Compared with the placebo group, the β-lactolin group also showed significant changes in the scores of verbal fluency test after 6 weeks (p = 0.03). ","[{'ForeName': 'Ayana', 'Initials': 'A', 'LastName': 'Kanatome', 'Affiliation': 'Kirin Central Research Institute, Kirin Holdings Company, Ltd., Fujisawa, Kanagawa, Japan.'}, {'ForeName': 'Yasuhisa', 'Initials': 'Y', 'LastName': 'Ano', 'Affiliation': 'Kirin Central Research Institute, Kirin Holdings Company, Ltd., Fujisawa, Kanagawa, Japan.'}, {'ForeName': 'Kazushi', 'Initials': 'K', 'LastName': 'Shinagawa', 'Affiliation': 'Department of Psychology, Keio University, Mita, Minato-ku, Tokyo, Japan.'}, {'ForeName': 'Yumiko', 'Initials': 'Y', 'LastName': 'Ide', 'Affiliation': 'Tokyo Center Clinic, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Midori', 'Initials': 'M', 'LastName': 'Shibata', 'Affiliation': 'Department of Psychology, Keio University, Mita, Minato-ku, Tokyo, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Umeda', 'Affiliation': 'Department of Psychology, Keio University, Mita, Minato-ku, Tokyo, Japan.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201413'] 1279,33814432,Cognitive Domain Associations with Balance Performance in Community-Dwelling Older People with Cognitive Impairment.,"BACKGROUND In older people with cognitive impairment (CI), executive function (EF) has been associated with motor performance including balance and gait. The literature examining and supporting a relationship between balance performance and other cognitive domains is limited. OBJECTIVE To investigate the relationship between global cognition and cognitive domain function and balance performance in older people with CI. METHODS The iFOCIS randomized controlled trial recruited 309 community-dwelling older people with CI. Baseline assessments completed before randomization were used for analyses including the Addenbrooke's Cognitive Examination-III (ACE-III; global cognition) and its individual cognitive domains (attention; memory; verbal fluency; language; visuospatial ability) and the Frontal Assessment Battery (FAB), a measure of EF. A composite balance score was derived from postural sway and leaning balance tests. RESULTS In linear regression analyses adjusted for covariates, global cognition and each cognitive domain were significantly associated with balance performance. EF (verbal fluency; β= -0.254, p < 0.001, adjusted R2 = 0.387) and visuospatial ability (β= -0.258, p < 0.001, adjusted R2 = 0.391) had the strongest associations with balance performance. In a comprehensively adjusted multivariable model including all of the ACE-III cognitive domains, visuospatial ability and EF (verbal fluency) were independently and significantly associated with balance performance. CONCLUSION Poorer global cognition and cognitive domain function were associated with poorer balance performance in this sample of people with CI. Visuospatial ability and EF were independently associated with balance, highlighting potential shared neural networks and the role higher-level cognitive processes and spatial perception/processing play in postural control.",2021,Poorer global cognition and cognitive domain function were associated with poorer balance performance in this sample of people with CI.,"['older people with cognitive impairment (CI), executive function (EF', 'older people with CI', 'Community-Dwelling Older People with Cognitive Impairment', '309 community-dwelling older people with CI']",[],"['Poorer global cognition and cognitive domain function', ""Addenbrooke's Cognitive Examination-III (ACE-III; global cognition) and its individual cognitive domains (attention; memory; verbal fluency; language; visuospatial ability) and the Frontal Assessment Battery (FAB), a measure of EF"", 'balance performance', 'visuospatial ability', 'Visuospatial ability and EF', 'global cognition and cognitive domain function and balance performance', 'ACE-III cognitive domains, visuospatial ability and EF (verbal fluency', 'EF (verbal fluency']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0009462', 'cui_str': 'Community'}]",[],"[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C2732353', 'cui_str': 'Frontal assessment battery'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",309.0,0.134626,Poorer global cognition and cognitive domain function were associated with poorer balance performance in this sample of people with CI.,"[{'ForeName': 'Morag E', 'Initials': 'ME', 'LastName': 'Taylor', 'Affiliation': 'Neuroscience Research Australia, UNSW Sydney, Randwick, NSW, Australia.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Toots', 'Affiliation': 'Department of Community Medicine and Rehabilitation, Physiotherapy, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Stephen R', 'Initials': 'SR', 'LastName': 'Lord', 'Affiliation': 'Neuroscience Research Australia, UNSW Sydney, Randwick, NSW, Australia.'}, {'ForeName': 'Narelle', 'Initials': 'N', 'LastName': 'Payne', 'Affiliation': 'Neuroscience Research Australia, UNSW Sydney, Randwick, NSW, Australia.'}, {'ForeName': 'Jacqueline C T', 'Initials': 'JCT', 'LastName': 'Close', 'Affiliation': 'Neuroscience Research Australia, UNSW Sydney, Randwick, NSW, Australia.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201325'] 1280,33781107,A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties.,"BACKGROUND Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. AIM The aim of the current study was to explore the psychedelic experiences and sustained impact of ketamine in major depressive disorder. METHODS In the current study, ketamine (0.44 mg/kg) was administered to 32 volunteers with major depressive disorder in a crossover design with the active-placebo remifentanil, in a magnetic resonance imaging (MRI) environment. The 11-dimension altered states of consciousness questionnaire and individual qualitative interviews were used to capture the acute psychedelic experience. The Montgomery-Asberg Depression Rating Scale and further interviewing explored lasting effects. The second qualitative interview took place ⩾3 weeks post-ketamine. RESULTS Greater antidepressant response (reduction in Montgomery-Asberg Depression Rating Scale at 24 h) correlated with the 11-dimension altered states of consciousness dimensions: spirituality, experience of unity, and insight. The first qualitative interview revealed that all participants experienced perceptual changes. Additional themes emerged including loss of control and emotional and mood changes. The final interview showed evidence of a psychedelic afterglow, and changes to perspective on life, people, and problems, as well as changes to how participants felt about their depression and treatments. CONCLUSIONS The current study provides preliminary evidence for a role of the psychedelic experience and afterglow in ketamine's antidepressant properties. Reflexive thematic analysis provided a wealth of information on participants' experience of the study and demonstrated the psychedelic properties of ketamine are not fully captured by commonly used questionnaires.",2021,"RESULTS Greater antidepressant response (reduction in Montgomery-Asberg Depression Rating Scale at 24 h) correlated with the 11-dimension altered states of consciousness dimensions: spirituality, experience of unity, and insight.",['32 volunteers with major depressive disorder'],"['ketamine', 'Ketamine', 'active-placebo remifentanil', 'magnetic resonance imaging (MRI) environment']","['loss of control and emotional and mood changes', 'Montgomery-Asberg Depression Rating Scale']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",32.0,0.0752787,"RESULTS Greater antidepressant response (reduction in Montgomery-Asberg Depression Rating Scale at 24 h) correlated with the 11-dimension altered states of consciousness dimensions: spirituality, experience of unity, and insight.","[{'ForeName': 'Rachael L', 'Initials': 'RL', 'LastName': 'Sumner', 'Affiliation': 'School of Pharmacy, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Emme', 'Initials': 'E', 'LastName': 'Chacko', 'Affiliation': 'Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'McMillan', 'Affiliation': 'School of Pharmacy, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Meg J', 'Initials': 'MJ', 'LastName': 'Spriggs', 'Affiliation': 'Centre for Psychedelic Research, Imperial College London, London, UK.'}, {'ForeName': 'Christie', 'Initials': 'C', 'LastName': 'Anderson', 'Affiliation': 'School of Pharmacy, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'School of Pharmacy, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'French', 'Affiliation': 'School of Pharmacy, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'SungHun', 'Initials': 'S', 'LastName': 'Jung', 'Affiliation': 'School of Pharmacy, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Akshaya', 'Initials': 'A', 'LastName': 'Rajan', 'Affiliation': 'School of Pharmacy, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Malpas', 'Affiliation': 'Department of Anaesthesia and Perioperative Medicine, Auckland District Health Board, Auckland, New Zealand.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Hay', 'Affiliation': 'Department of Anaesthesia and Perioperative Medicine, Auckland District Health Board, Auckland, New Zealand.'}, {'ForeName': 'Rhys', 'Initials': 'R', 'LastName': 'Ponton', 'Affiliation': 'School of Pharmacy, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Suresh D', 'Initials': 'SD', 'LastName': 'Muthukumaraswamy', 'Affiliation': 'School of Pharmacy, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Sundram', 'Affiliation': 'Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881121998321'] 1281,33784020,Intra-cavernous injection of BOTOX ® (50 and 100 Units) for treatment of vasculogenic erectile dysfunction: Randomized controlled trial.,"BACKGROUND Erectile dysfunction (ED) is a socioeconomic problem.There are several options for its management including intra-cavernosal injection (ICI). OBJECTIVE To compare the safety, efficacy, and durability of ICI of onabotulinum toxin-A (BTX) in different doses (50 and 100 U) against placebo (saline) in the management of vasculogenic ED non-responding to pharmacological therapy (phosphodiesterase type 5 inhibitors or/and ICI of trimix). MATERIALS AND METHODS A prospective randomized double-blind placebo-controlled trial was conducted between July 2016 and February 2019. A total of 176 patients were randomly assigned (1:1:1) to one of the treatment sequences: Botox 100 U group (BTX-100; 62 patients), Botox 50 U group (BTX-50; 59 patients), or placebo group (55 patients). All patients were followed up for 6 months. RESULTS Significant improvement in all parameters, that is, SHIM score & Erection Hardness Score (EHS), Sexual Encounter Profile (SEP), Global Assessment Score (GAS), and Doppler parameters (p < 0.001) was observed in patients of BTX-100 and BTX-50 groups with maximum improvement at 3rd month of treatment. Around 40% of patients were responders and were able to engage in sexual intercourse. Patients in placebo group did not experience significant improvement (p = 0.264). It was noted that at the 2nd week and 3rd months after treatment, there was no statistically significant difference in the improvement of these parameters in BTX-100 and BTX-50 groups (p > 0.05). In the 6th month, there was a statistically significant difference between the aforementioned groups in favor of BTX-100 (p < 0.01). CONCLUSIONS Only one-time ICI of BTX (50 U and 100 U) is effective and safe for the treatment of refractory ED. This agent has a considerable long duration of action, particularly BTX-100U seems to be more durable.",2021,"In the 6 th month, there was a statistically significant difference between the aforementioned groups in favor of BTX-100 (P< 0.01). ","['July 2016 to February 2019', 'Vasculogenic ED non-responding to pharmacological therapy (phosphodiesterase type 5 inhibitors or/and ICI of trimix', 'A total of 176 patients', 'Vasculogenic Erectile Dysfunction']","['Botox 100', 'BTX', 'Onabotulinum toxin-A (BTX)in different doses (50 & 100 U) against placebo (saline', 'placebo', 'Placebo', 'Botox 50']","['safety, efficacy, and durability', 'EHS), Sexual Encounter Profile (SEP), Global Assessment Score (GAS) and Doppler parameters', 'SHIM score & Erection Hardness Score', 'BTX-100']","[{'cui': 'C0242350', 'cui_str': 'Impotence'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1318700', 'cui_str': 'Phosphodiesterase 5 inhibitor'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0077210', 'cui_str': 'trimix'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0700702', 'cui_str': 'Botox'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4743433', 'cui_str': 'onabotulinum toxin A'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C2960554', 'cui_str': 'Erection hardness score'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0554756', 'cui_str': 'Doppler studies'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0142223', 'cui_str': 'SHIMS'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0700702', 'cui_str': 'Botox'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",176.0,0.149959,"In the 6 th month, there was a statistically significant difference between the aforementioned groups in favor of BTX-100 (P< 0.01). ","[{'ForeName': 'Waleed', 'Initials': 'W', 'LastName': 'El-Shaer', 'Affiliation': 'Department of Urology, Banha University Hospital, Banha, Egypt.'}, {'ForeName': 'Hussein', 'Initials': 'H', 'LastName': 'Ghanem', 'Affiliation': 'Andrology Department, Cairo University Hospitals, Cairo, Egypt.'}, {'ForeName': 'Tamer', 'Initials': 'T', 'LastName': 'Diab', 'Affiliation': 'Department of Urology, Banha University Hospital, Banha, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Abo-Taleb', 'Affiliation': 'Department of Urology, Banha University Hospital, Banha, Egypt.'}, {'ForeName': 'Wael', 'Initials': 'W', 'LastName': 'Kandeel', 'Affiliation': 'Department of Urology, Banha University Hospital, Banha, Egypt.'}]",Andrology,['10.1111/andr.13010'] 1282,33783104,Health behaviour outcomes of a family based intervention for paediatric obesity in primary care: A randomized type II hybrid effectiveness-implementation trial.,"BACKGROUND Paediatric obesity is a multifaceted public health problem. Family based behavioural interventions are the recommended approach for the prevention of excess weight gain in children and adolescents, yet few have been tested under ""real-world"" conditions. OBJECTIVES To evaluate the effectiveness of a family based intervention, delivered in coordination with paediatric primary care, on child and family health outcomes. METHODS A sample of 240 families with racially and ethnically diverse (86% non-White) and predominantly low-income children (49% female) ages 6 to 12 years (M = 9.5 years) with body mass index (BMI) ≥85th percentile for age and gender were identified in paediatric primary care. Participants were randomized to either the Family Check-Up 4 Health (FCU4Health) program (N = 141) or usual care plus information (N = 99). FCU4Health, an assessment-driven individually tailored intervention designed to preempt excess weight gain by improving parenting skills was delivered for 6 months in clinic, at home and in the community. Child BMI and body fat were assessed using a bioelectrical impedance scale and caregiver-reported health behaviours (eg, diet, physical activity and family health routines) were obtained at baseline, 3, 6 and 12 months. RESULTS Change in child BMI and percent body fat did not differ by group assignment. Path analysis indicated significant group differences in child health behaviours at 12 months, mediated by improved family health routines at 6 months. CONCLUSION The FCU4Health, delivered in coordination with paediatric primary care, significantly impacted child and family health behaviours that are associated with the development and maintenance of paediatric obesity. BMI did not significantly differ.",2021,"Path analysis indicated significant group differences in child health behaviours at 12 months, mediated by improved family health routines at 6 months. ","['children and adolescents', '240 families with racially and ethnically diverse (86% non-White) and predominantly low-income children (49% female) ages 6 to 12\u2009years (M = 9.5\u2009years) with body mass index (BMI) ≥85th percentile for age and gender were identified in paediatric primary care', 'paediatric obesity in primary care']",['Family Check-Up 4 Health (FCU4Health) program (N = 141) or usual care plus information'],"['child BMI and percent body fat', 'family health routines', 'Child BMI and body fat', 'BMI', 'child health behaviours', 'bioelectrical impedance scale and caregiver-reported health behaviours (eg, diet, physical activity and family health routines']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0420160', 'cui_str': 'History and physical examination, school'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0600220', 'cui_str': 'Family health status'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0162536', 'cui_str': 'Biolectric Impedance'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",240.0,0.050455,"Path analysis indicated significant group differences in child health behaviours at 12 months, mediated by improved family health routines at 6 months. ","[{'ForeName': 'Justin D', 'Initials': 'JD', 'LastName': 'Smith', 'Affiliation': 'Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, Utah, USA.'}, {'ForeName': 'Cady', 'Initials': 'C', 'LastName': 'Berkel', 'Affiliation': 'Integrated Behavioral Health Program, College of Health Solutions, Arizona State University, Tempe, Arizona, USA.'}, {'ForeName': 'Allison J', 'Initials': 'AJ', 'LastName': 'Carroll', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Fu', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Grimm', 'Affiliation': 'Department of Psychology, Arizona State University, Tempe, Arizona, USA.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Mauricio', 'Affiliation': 'Prevention Science Institute, University of Oregon, Eugene, Oregon, USA.'}, {'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Rudo-Stern', 'Affiliation': ""Phoenix Children's Hospital, Phoenix, Arizona, USA.""}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Winslow', 'Affiliation': 'REACH Institute, Department of Psychology, Arizona State University, Tempe, Arizona, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Dishion', 'Affiliation': 'REACH Institute, Department of Psychology, Arizona State University, Tempe, Arizona, USA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Jordan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Atkins', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA.'}, {'ForeName': 'Shrikanth S', 'Initials': 'SS', 'LastName': 'Narayanan', 'Affiliation': 'Department of Electrical Engineering and Computer Science, University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Gallo', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Meg M', 'Initials': 'MM', 'LastName': 'Bruening', 'Affiliation': 'Department of Nutrition, College of Health Solutions, Arizona State University, Tempe, Arizona, USA.'}, {'ForeName': 'Charlton', 'Initials': 'C', 'LastName': 'Wilson', 'Affiliation': 'Mercy Care, Phoenix, Arizona, USA.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Lokey', 'Affiliation': ""Palo Verde Pediatrics, Phoenix Children's Hospital, Phoenix, Arizona, USA.""}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Samaddar', 'Affiliation': ""Phoenix Children's Hospital, Phoenix, Arizona, USA.""}]",Pediatric obesity,['10.1111/ijpo.12780'] 1283,33237990,Adding Mindfulness Practice to Exercise Therapy for Female Recreational Runners With Patellofemoral Pain: A Randomized Controlled Trial.,"CONTEXT Considering current models that highlight the role of psychological components in pain management, mindfulness practice may be an effective strategy in the management of pain. OBJECTIVE To examine the effects of adding an 8-week mindfulness program to exercise therapy on the perceptions of pain severity, knee function, fear of movement, and pain catastrophizing of female recreational runners with patellofemoral pain (PFP). DESIGN Randomized controlled clinical trial. SETTING University laboratory. PATIENTS OR OTHER PARTICIPANTS Thirty female runners (age = 28.3 ± 7.08 years) with PFP were randomly assigned to the exercise or mindfulness-exercise group. INTERVENTION(S) The exercise-only group followed a protocol (18 weeks, 3 sessions/wk) that featured training modifications to help control injury-related symptoms. The mindfulness-exercise group received an 8-week mindfulness intervention in addition to the exercise protocol. The mindfulness component started 4 weeks before the exercise component; therefore, the 2 components overlapped during the first 4 weeks of the intervention. MAIN OUTCOME MEASURE(S) Usual pain, pain during stepping, and pain during running were assessed using visual analog scales. Functional limitations of the knee were assessed using the Knee Outcome Survey. Fear of movement, pain catastrophizing, and coping strategies were measured via the Tampa Scale for Kinesiophobia, the Pain Catastrophizing Scale, and the Coping Strategies Questionnaire, respectively. These outcomes were assessed at baseline, at week 9, and after 18 weeks. RESULTS Pain during running, pain during stepping, and functional limitations of the knee were less for the mindfulness-exercise group than for the exercise-only group (P values < .05). The mindfulness-exercise group reported greater perceived treatment effects than the exercise-only group (P < .05). Pain catastrophizing was less and coping strategies were more favorable for mindfulness-exercise participants than for exercise-only participants (P values < .05). CONCLUSIONS Mindfulness practice can be an effective adjunct to exercise therapy in the rehabilitation of PFP in recreational female runners.",2021,Pain catastrophizing was lower and coping strategies were more favorable for mindfulness-exercise participants than for exercise participants (p<.05).,"['female recreational runners with patellofemoral pain (PFP', 'Intervention(s', 'female recreational runners with patellofemoral pain', 'Thirty female runners (age 28.3±7.08 years) with PFP', 'Patients or Other Participants', 'recreational female runners']","['8-week mindfulness intervention in addition to the exercise program', 'exercise group and mindfulness-exercise group', 'eight-week mindfulness program to exercise therapy', 'exercise program for symptoms control and training modifications', 'exercise therapy']","['pain severity, knee function, fear of movement, and pain catastrophizing', 'Pain catastrophizing', 'Usual pain, pain during stepping, and pain during running were assessed through visual analog scales (VAS', 'Fear of movement, pain catastrophizing, and coping strategies', 'Pain during running, pain during stepping, and functional limitations of the knee', 'Tampa Scale for Kinesiophobia, the Pain Catastrophizing Scale']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C1274136', 'cui_str': 'Symptom control'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}]",,0.0434255,Pain catastrophizing was lower and coping strategies were more favorable for mindfulness-exercise participants than for exercise participants (p<.05).,"[{'ForeName': 'Shahabeddin', 'Initials': 'S', 'LastName': 'Bagheri', 'Affiliation': 'School of Humanities, University of Nahavand, Hamedan, Iran.'}, {'ForeName': 'Aynollah', 'Initials': 'A', 'LastName': 'Naderi', 'Affiliation': 'School of Sport Sciences, Shahrood University of Technology, Iran.'}, {'ForeName': 'Samira', 'Initials': 'S', 'LastName': 'Mirali', 'Affiliation': 'Department of Sport Science, University College of Omran and Tosseeh, Hamedan, Iran.'}, {'ForeName': 'Luís', 'Initials': 'L', 'LastName': 'Calmeiro', 'Affiliation': 'School of Social and Health Sciences, Abertay University, Dundee, UK.'}, {'ForeName': 'Britton W', 'Initials': 'BW', 'LastName': 'Brewer', 'Affiliation': 'Department of Psychology, Springfield College, MA.'}]",Journal of athletic training,['10.4085/1062-6050-0214.20'] 1284,33237996,Efficacy of an Educational Intervention for Improving the Hydration Status of Female Collegiate Indoor-Sport Athletes.,"CONTEXT Research focusing on improving hydration status and knowledge in female indoor-sport athletes is limited. Investigators have demonstrated that hydration education is an optimal tool for improving the hydration status of athletes. OBJECTIVE To assess the hydration status and fluid intake of collegiate female indoor-sport athletes before and after a 1-time educational intervention. DESIGN Controlled laboratory study. SETTING Collegiate women's volleyball and basketball practices. PATIENTS OR OTHER PARTICIPANTS A total of 25 female collegiate volleyball and basketball athletes (age = 21 ± 1 years, height = 173.5 ± 8.7 cm, weight = 72.1 ± 10.0 kg) were assessed during 6 days of practices. INTERVENTION(S) Participants' hydration status and habits were monitored for 3 practice days before they underwent a hydration educational intervention. Postintervention, participants were observed for 3 more practice days. MAIN OUTCOME MEASURE(S) Change in body mass, fluid consumed, urine specific gravity (Usg), urine color (Ucol), and sweat rate were recorded for 6 practice days. Participants completed a hydration-knowledge questionnaire before and after the intervention. RESULTS Three-day mean Usg and Ucol were considered euhydrated prepractice (Usg = 1.015 ± 0.006, Ucol = 4 ± 1) and remained euhydrated postpractice (Usg = 1.019 ± 0.005, Ucol = 5 ± 2) during the preintervention period. Decreased prepractice Ucol (P < .01) and increased hydration knowledge (P < .01) were present postintervention. Basketball athletes had greater body mass losses from prepractice to postpractice than did volleyball athletes (P < .001). Overall increases were evident when we compared prepractice and postpractice measures of Usg and Ucol in the preintervention (P < .001 and P = .001, respectively) and postintervention (P = .001 and P < .001) period, respectively. No correlation was found between hydration knowledge and physiological indices of hydration and fluid intake. CONCLUSIONS Overall, female collegiate indoor-sport athletes were hydrated and knowledgeable on hydration. However, our variable findings indicated that further research on these athletes is needed; clinically, attention should be given to the individual needs of each athlete. More examination will demonstrate whether a 1-time educational intervention may be an effective tool for improving hydration status in this population.",2021,Decreases in pre-practice Ucol (p<.01) and increases (p<.01) in hydration knowledge were found post-intervention.,"['indoor female athletes', 'Basketball athletes', ""women's volleyball and basketball practices"", 'Participants: Twenty-five female collegiate volleyball and basketball athletes (21±1years; 173.5±8.7cm, 72.1±10.0kg) were assessed during six days of practices', 'collegiate female indoor athletes', 'Indoor College Athletes']","['Educational Intervention', 'hydration educational intervention']","['hydration knowledge', 'BM losses', 'hydration knowledge and physiological indices of hydration and fluid intake', 'hydration knowledge questionnaire (HAQ', 'Change in body mass (BM), fluid consumed, urine specific gravity (USG), urine color (Ucol), and sweat rate']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0004818', 'cui_str': 'Basketball'}, {'cui': 'C1956059', 'cui_str': 'Volleyball'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0557806', 'cui_str': 'College'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}]","[{'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0429791', 'cui_str': 'Fluid intake'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0202517', 'cui_str': 'Urinalysis, specific gravity measurement'}, {'cui': 'C0278030', 'cui_str': 'Color of urine'}, {'cui': 'C0038984', 'cui_str': 'Sweat'}]",,0.0369134,Decreases in pre-practice Ucol (p<.01) and increases (p<.01) in hydration knowledge were found post-intervention.,"[{'ForeName': 'Isabella S', 'Initials': 'IS', 'LastName': 'Abbasi', 'Affiliation': 'Department of Orthopaedics and Sports Medicine, School of Physical Therapy and Rehabilitation Sciences, University of South Florida, Tampa.'}, {'ForeName': 'Rebecca M', 'Initials': 'RM', 'LastName': 'Lopez', 'Affiliation': 'Department of Orthopaedics and Sports Medicine, School of Physical Therapy and Rehabilitation Sciences, University of South Florida, Tampa.'}, {'ForeName': 'Yi-Tzu', 'Initials': 'YT', 'LastName': 'Kuo', 'Affiliation': 'Barry University, Miami Shores, FL.'}, {'ForeName': 'B Sue', 'Initials': 'BS', 'LastName': 'Shapiro', 'Affiliation': 'Barry University, Miami Shores, FL.'}]",Journal of athletic training,['10.4085/1062-6050-0495.19'] 1285,34132071,"Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.","BACKGROUND The second-line chemotherapy using paclitaxel, carboplatin, and bevacizumab for treating platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer frequently cause chemotherapy-induced peripheral neuropathy (CIPN), which is significantly associated with deterioration of quality of life. Despite the potential of some agents to prevent and treat CIPN, and there is still a lack of evidence of the effect. Although selenium has been suggested as an antioxidant candidate to prevent CIPN, there are insufficient data regarding its effect due to its low dose by oral administration. Thus, we hypothesized intravenous administration of high-dose selenium (2,000 μg/day) at each cycle of the second-line chemotherapy would prevent and reduce CIPN in patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer. METHOD This trial is an investigator-initiated, phase III, double-blinded, randomized controlled trial to evaluate the efficacy and safety of intravenous administration of high-dose selenium (2,000 μg/day) for preventing CIPN in patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer who receive paclitaxel, carboplatin, and bevacizumab. A total of 68 patients will be randomly assigned to the experimental and control groups at a 1:1 ratio. As the primary endpoint, the incidence rate of CIPN three months after six cycles of chemotherapy will be compared between the two groups according to the combined criteria of neuropathy using the World Health Organization-CIPN criteria and Common Terminology Criteria for Adverse Events version 5.0. As secondary endpoints, we will compare adverse events, patient-reported quality of life, and requirement of concomitant drugs for reducing CIPN between the two groups. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04201561.",2021,"As the primary endpoint, the incidence rate of CIPN three months after six cycles of chemotherapy will be compared between the two groups according to the combined criteria of neuropathy using the World Health Organization-CIPN criteria and Common Terminology Criteria for Adverse Events version 5.0.","['68 patients', 'platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer', 'patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer who receive', 'patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer']","['intravenous administration of high-dose selenium', 'paclitaxel, carboplatin, and bevacizumab', 'high-dose selenium']","['incidence rate of CIPN', 'adverse events, patient-reported quality of life, and requirement of concomitant drugs for reducing CIPN', 'efficacy and safety', 'Efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0153467', 'cui_str': 'Malignant tumor of peritoneum'}]","[{'cui': 'C0021440', 'cui_str': 'Intravenous infusion'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C3873567', 'cui_str': 'Peripheral neuropathy due to and following chemotherapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",68.0,0.277624,"As the primary endpoint, the incidence rate of CIPN three months after six cycles of chemotherapy will be compared between the two groups according to the combined criteria of neuropathy using the World Health Organization-CIPN criteria and Common Terminology Criteria for Adverse Events version 5.0.","[{'ForeName': 'Soo Jin', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Ga Won', 'Initials': 'GW', 'LastName': 'Yim', 'Affiliation': 'Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea.'}, {'ForeName': 'Haerin', 'Initials': 'H', 'LastName': 'Paik', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Nara', 'Initials': 'N', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Seungmee', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Hee Seung', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. bboddi0311@gmail.com.'}]",Journal of gynecologic oncology,['10.3802/jgo.2021.32.e73'] 1286,34391281,The treatment effect of intramuscular stimulation on carpal tunnel syndrome: A blinded randomized trial on 75 patients.,"BACKGROUND Carpal tunnel syndrome (CTS) is a disorder with a prevalence of about 5.8% for females and 0.6% for males. This study aims to determine whether intramuscular stimulation (IMS) to the pronator teres muscle subsequently reduces the severity of clinical parameters and the diameter of the median nerve. METHODS Seventy-five individuals with a cross-sectional diameter of the median nerve of more than 2 mm were included in this randomized clinical trial. Thirty-seven individuals received IMS to the pronator teres muscle with a depth of up to 45-50 mm. The 38 individuals in the control group received an acupuncture needle at Li11 with a depth of 4-5 mm. Both groups had 7 treatments within 7 weeks. The primary outcome was the cross-section of the median nerve in the carpal tunnel. Additionally, Phalen's test, Tinel's sign, VAS for pain intensity, and pincer grip strength were measured. RESULTS Both IMS subjects and controls showed significant reductions in the cross-section of the median nerve from baseline to follow-up (p < 0.001 and p = 0.002 respectively). The IMS group had the largest change, but the difference in change between the groups was not significant (p = 0.39). On all clinical tests, IMS subjects showed significant improvement from baseline compared with the control group (largest p = 0.002). CONCLUSION In this study we found that IMS to the pronator teres muscle significantly improved all clinical variables measured, compared with the group receiving acupuncture. Furthermore, the cross-section of the median nerve reduced over time for both groups. IMS may be a low-risk alternative while patients are waiting for surgery. TRIAL REGISTRATION Clinicaltrials. gov Identifier: NCT01102868. Retrospectively registered: March 29th , 2010.",2021,Both IMS subjects and controls showed significant reductions in the cross-section of the median nerve from baseline to follow-up (p < 0.001 and p = 0.002 respectively).,"['carpal tunnel syndrome', 'Seventy-five individuals with a cross-sectional diameter of the median nerve of more than 2\xa0mm', '75 patients']","['intramuscular stimulation', 'acupuncture needle at Li11 with a depth of 4-5\xa0mm', 'intramuscular stimulation (IMS', 'IMS']","['cross-section of the median nerve', ""Tinel's sign, VAS for pain intensity, and pincer grip strength"", 'cross-section of the median nerve in the carpal tunnel']","[{'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0025058', 'cui_str': 'Structure of median nerve'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0181956', 'cui_str': 'Acupuncture needle'}, {'cui': 'C0450487', 'cui_str': 'LI11'}, {'cui': 'C0205125', 'cui_str': 'Deep'}]","[{'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0025058', 'cui_str': 'Structure of median nerve'}, {'cui': 'C0277843', 'cui_str': ""Tinel's sign""}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0429273', 'cui_str': 'Tip pinch'}, {'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}]",75.0,0.205206,Both IMS subjects and controls showed significant reductions in the cross-section of the median nerve from baseline to follow-up (p < 0.001 and p = 0.002 respectively).,"[{'ForeName': 'Knut Birger', 'Initials': 'KB', 'LastName': 'Kvist', 'Affiliation': 'IMS Pain Clinic, Hilland Physical Institute, Bergen, Norway.'}, {'ForeName': 'Ronnie', 'Initials': 'R', 'LastName': 'Hilland', 'Affiliation': 'IMS Pain Clinic, Hilland Physical Institute, Bergen, Norway.'}, {'ForeName': 'Rune', 'Initials': 'R', 'LastName': 'Enehaug', 'Affiliation': 'Stadium Physiotherapy, Brann Footballstadium, Bergen, Norway.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Schjelderup', 'Affiliation': 'Idrettsveien General Practice, Brann Footballstadium, Bergen, Norway.'}, {'ForeName': 'Stein Atle', 'Initials': 'SA', 'LastName': 'Lie', 'Affiliation': 'Department of Clinical Dentistry, University of Bergen, Norway. Electronic address: stein.lie@uib.no.'}, {'ForeName': 'Anne-Kristine', 'Initials': 'AK', 'LastName': 'Halse', 'Affiliation': 'Department of Clinical Science, University of Bergen, Norway; Department of Rheumatology, Haukeland University Hospital, Bergen, Norway.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.020'] 1287,33797949,Mapping the Synchronization Effect of Gamma-Aminobutyric Acid Inhibition on the Cerebral Cortex Using Magnetic Resonance Imaging.,"Background: Functional magnetic resonance imaging (fMRI) of spontaneous brain activity permits the identification of functional networks on the basis of region synchrony. The functional coupling between the elements of a neural system increases during brain activation. However, neural synchronization may also be the effect of inhibitory gamma-aminobutyric acid (GABA) neurons in states of brain inhibition such as sleep or pharmacological sedation. We investigated the effects of an oral dose of alprazolam, a classical benzodiazepine known to enhance inhibitory neurotransmission, using recently developed measures of local functional connectivity. Methods: In a randomized, double-blind, placebo-controlled, crossover design, 32 non-treatment-seeking individuals with social anxiety underwent two identical resting-state fMRI sessions on separate days after receiving 0.75 mg of alprazolam and placebo. Functional connectivity maps of the cerebral cortex were generated by using multidistance functional connectivity measures defined within iso-distant local areas. Results: Relative to placebo, increased intracortical functional connectivity was observed in the alprazolam condition in visual, auditory, and sensorimotor cortices, and in areas of sensory integration such as the posterior insula and orbitofrontal cortex (OFC). Alprazolam significantly reduced subjective arousal compared with placebo, and the change was associated with variations in multidistance functional connectivity measures in the OFC. Discussion: In conclusion, we report evidence that alprazolam significantly modifies neural activity coupling at rest in the form of functional connectivity enhancement within the cerebral cortex. The effect of alprazolam was particularly evident in the cortical sensory system, which would further suggest a differentiated effect of GABA inhibition on sensory processing.",2021,"Alprazolam significantly reduced subjective arousal compared with placebo, and the change was associated with variations in multidistance functional connectivity measures in the OFC. ",['32 non-treatment-seeking individuals with social anxiety underwent two'],"['Functional magnetic resonance imaging (fMRI', 'Alprazolam', 'placebo', 'identical resting-state fMRI sessions', 'alprazolam and placebo', 'Gamma-Aminobutyric Acid Inhibition', 'alprazolam']","['spontaneous brain activity', 'visual, auditory, and sensorimotor cortices, and in areas of sensory integration such as the posterior insula and orbitofrontal cortex (OFC', 'subjective arousal', 'multidistance functional connectivity measures', 'intracortical functional connectivity']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}]","[{'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0002333', 'cui_str': 'Alprazolam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0016904', 'cui_str': 'Gamma-aminobutyric acid'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]","[{'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C3499125', 'cui_str': 'Sensory Motor Cortex'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0228261', 'cui_str': 'Structure of long insular gyrus'}, {'cui': 'C0152301', 'cui_str': 'Structure of orbital gyrus'}, {'cui': 'C1861537', 'cui_str': 'Orofacial Cleft 1'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",32.0,0.134374,"Alprazolam significantly reduced subjective arousal compared with placebo, and the change was associated with variations in multidistance functional connectivity measures in the OFC. ","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Blanco-Hinojo', 'Affiliation': 'MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain.'}, {'ForeName': 'Jesus', 'Initials': 'J', 'LastName': 'Pujol', 'Affiliation': 'MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain.'}, {'ForeName': 'Dídac', 'Initials': 'D', 'LastName': 'Macià', 'Affiliation': 'MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Martínez-Vilavella', 'Affiliation': 'MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Martín-Santos', 'Affiliation': ""Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Pérez-Sola', 'Affiliation': 'Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM, Barcelona, Spain.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Deus', 'Affiliation': 'MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain.'}]",Brain connectivity,['10.1089/brain.2020.0844'] 1288,33813110,Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial.,"OBJECTIVES To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk of worsening. METHODS We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: need for supplemental oxygen, age ≥75 years, age between 60 and 74 years and presence of at least one co-morbidity. Severely ill patients requiring oxygen therapy >3 L/min or intensive care were excluded. Eligible patients were randomized in a 1:1 ratio to receive either 800 mg hydroxychloroquine on day 0 followed by 400 mg per day for 8 days or a placebo. The primary end point was a composite of death or start of invasive mechanical ventilation within 14 days following randomization. Secondary end points included mortality and clinical evolution at days 14 and 28, and viral shedding at days 5 and 10. RESULTS The trial was stopped after 250 patients were included because of a slowing down of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and hydroxychloroquine groups, respectively. The median age was 77 years (interquartile range 58-86 years) and 151/250 (60.4%) patients required oxygen therapy. The primary end point occurred in 9/124 (7.3%) patients in the hydroxychloroquine group and 8/123 (6.5%) patients in the placebo group (relative risk 1.12; 95% CI 0.45-2.80). The rates of positive SARS-CoV-2 RT-PCR tests at days 5 and 10 were 72.8% (75/103) and 57.1% (52/91) in the hydroxychloroquine group, versus 73.0% (73/100) and 56.6% (47/83) in the placebo group, respectively. No difference was observed between the two groups in any of the other secondary end points. CONCLUSION In this underpowered trial involving mainly older patients with mild to moderate COVID-19, patients treated with hydroxychloroquine did not experience better clinical or virological outcomes than those receiving the placebo. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04325893 (https://clinicaltrials.gov/ct2/show/NCT04325893).",2021,"The rate of positive SARS-CoV-2 RT-PCR at day 5 and 10 was 72.8% (75/103) and 57.1% (52/91) in the hydroxychloroquine group, versus 73.0% (73/100) and 56.6% (47/83) in the placebo group, respectively.","['mainly older patients with mild-to-moderate COVID-19, patients treated with', 'Eligible patients', 'patients with mild-to-moderate COVID-19 at high risk of worsening', 'COVID-19 patients with at least one of the following risk factors for worsening: need for supplemental oxygen, age ≥75\xa0years, age between 60 - 74\xa0years and presence of at least one comorbidity', 'mild-to-moderate COVID-19', 'The median age was 77 (interquartile range 58 - 86) years and 151/250 (60.4', '250 patients were included due to a slowdown of the pandemic in France', 'Severely ill patients requiring oxygen therapy > 3L/min or intensive care were excluded']","['oxygen therapy', 'placebo', 'placebo and hydroxychloroquine', 'Hydroxychloroquine', 'hydroxychloroquine']","['mortality and clinical evolution at Day 14 and 28, viral shedding at Day 5 and 10', 'composite of death or start of invasive mechanical ventilation', 'rate of positive SARS-CoV-2 RT-PCR', 'virological outcomes', 'risk of adverse outcome']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0015219', 'cui_str': 'Biological Evolution'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0162633', 'cui_str': 'Viral Shedding'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",250.0,0.824461,"The rate of positive SARS-CoV-2 RT-PCR at day 5 and 10 was 72.8% (75/103) and 57.1% (52/91) in the hydroxychloroquine group, versus 73.0% (73/100) and 56.6% (47/83) in the placebo group, respectively.","[{'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Dubée', 'Affiliation': ""Service des Maladies Infectieuses et Tropicales, CHU d'Angers, Angers, France; CRCINA, Inserm, Université de Nantes, Université d'Angers, Angers, France. Electronic address: vincent.dubee@chu-angers.fr.""}, {'ForeName': 'Pierre-Marie', 'Initials': 'PM', 'LastName': 'Roy', 'Affiliation': ""Emergency Department, CHU d'Angers, Angers, France; Institut MitoVasc, UMR CNRS 6215 INSERM 1083, Université d'Angers, Angers, France.""}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Vielle', 'Affiliation': ""Biostatistics and Methodology Department, Maison de La Recherche, CHU d'Angers, Angers, France.""}, {'ForeName': 'Elsa', 'Initials': 'E', 'LastName': 'Parot-Schinkel', 'Affiliation': ""Biostatistics and Methodology Department, Maison de La Recherche, CHU d'Angers, Angers, France.""}, {'ForeName': 'Odile', 'Initials': 'O', 'LastName': 'Blanchet', 'Affiliation': ""Centre de Ressources Biologiques, BB-0033-00038, CHU d'Angers, Angers, France.""}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Darsonval', 'Affiliation': ""Service Pharmacie, CHU d'Angers, Angers, France.""}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Lefeuvre', 'Affiliation': 'Département des Agents Infectieux, Laboratoire de Virologie, CHU Angers, Angers, France.'}, {'ForeName': 'Chadi', 'Initials': 'C', 'LastName': 'Abbara', 'Affiliation': ""Laboratoire de Pharmacologie-toxicologie, CHU d'Angers, Angers, France.""}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Boucher', 'Affiliation': ""Institut MitoVasc, UMR CNRS 6215 INSERM 1083, Université d'Angers, Angers, France; Service d'ORL et Chirurgie Cervico-faciale, CHU d'Angers, Angers, France.""}, {'ForeName': 'Edouard', 'Initials': 'E', 'LastName': 'Devaud', 'Affiliation': 'Service de Médecine Interne et Maladies Infectieuses, CH R. Dubos, Pontoise, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Robineau', 'Affiliation': 'Service Universitaire des Maladies Infectieuses et du Voyageur, CH de Tourcoing, Tourcoing, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Rispal', 'Affiliation': 'Service de Médecine Interne, CH Agen, Agen, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Guimard', 'Affiliation': 'Service de Médecine Post-urgence, CH Départemental de Vendée, La Roche sur Yon, France.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': ""d'Anglejean"", 'Affiliation': 'Service de Médecine Interne et Maladies Infectieuses, CH Versailles-Hôpital André Mignot, Le Chesnay, France.'}, {'ForeName': 'Sylvain', 'Initials': 'S', 'LastName': 'Diamantis', 'Affiliation': 'Service de Médecine Polyvalente et Maladies Infectieuses, Groupe Hospitalier Sud Ile de France, Melun, France.'}, {'ForeName': 'Marc-Antoine', 'Initials': 'MA', 'LastName': 'Custaud', 'Affiliation': ""Institut MitoVasc, UMR CNRS 6215 INSERM 1083, Université d'Angers, Angers, France; Centre de Recherche Clinique, CHU d'Angers, Angers, France.""}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Pellier', 'Affiliation': ""Unité d'hématologie et d'oncologie Pédiatrique, CHU d'Angers, Inserm U1232-CRCINA, Université d'Angers, Angers, France.""}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Mercat', 'Affiliation': ""Département de Médecine Intensive-Réanimation, CHU d'Angers, Université d'Angers, Angers, France.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,['10.1016/j.cmi.2021.03.005'] 1289,33818780,Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.,"OBJECTIVE To evaluate the impact of two calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (mAbs), erenumab and galcanezumab, on the pharmacokinetic (PK) profile, safety, and tolerability of ubrogepant. BACKGROUND People taking CGRP-targeted mAbs for migraine prevention sometimes take ubrogepant, an oral small-molecule CGRP receptor antagonist, for acute treatment of breakthrough migraine attacks. DESIGN In this two-arm, multicenter, open-label, phase 1b trial, adults with migraine were randomized to arm 1 (ubrogepant ± erenumab) or arm 2 (ubrogepant ± galcanezumab). The PK profile of ubrogepant was characterized for administration before and 4 days after CGRP-targeted mAb injection. Participants received single-dose ubrogepant 100 mg on day 1, subcutaneous erenumab 140 mg (arm 1) or galcanezumab 240 mg (arm 2) on day 8, and ubrogepant 100 mg once daily on days 12-15. In each study arm, serial blood samples were drawn on days 1 and 12 for measurement of plasma ubrogepant concentrations. The primary outcomes were area under the plasma ubrogepant concentration-time curve (AUC) from time 0 to t post-dose (AUC 0- t ) and from time 0 to infinity (AUC 0-inf ), and maximum plasma concentration (C max ) of ubrogepant when ubrogepant was administered before or after a single dose of erenumab or galcanezumab. Vital signs and laboratory parameters were monitored. RESULTS Forty participants enrolled (20 per arm; mean [standard deviation] ages, 32.2 [8.9] and 38.4 [8.8] years; 50% [10/20] and 60% [12/20] female in arms 1 and 2, respectively). There were no significant differences in ubrogepant C max after versus before erenumab administration (geometric least-squares mean [LSM] ratio, 1.04 [90% CI, 0.93-1.16]), and no significant differences in AUC 0- t (1.06 [0.96-1.16]) or AUC 0-inf (1.05 [0.96-1.15]). Similarly, ubrogepant C max (1.00 [90% CI, 0.82-1.20]), AUC 0- t (1.05 [0.90-1.23]), and AUC 0-inf (1.05 [0.90-1.22]) geometric LSM ratios were statistically equivalent after galcanezumab versus ubrogepant alone. Treatment-emergent adverse events (TEAEs) were similar to those reported with each treatment alone. No serious TEAEs, TEAEs leading to discontinuation, or clinically relevant changes in laboratory parameters or vital signs were reported. CONCLUSIONS The PK profile of ubrogepant was not significantly changed and no safety concerns were identified when ubrogepant was coadministered with erenumab or galcanezumab.",2021,"No serious TEAEs, TEAEs leading to discontinuation, or clinically relevant changes in laboratory parameters or vital signs were reported. ","['participants with migraine', 'adults with migraine', 'Forty participants enrolled (20 per arm; mean [standard deviation] ages, 32.2 [8.9] and 38.4 [8.8] years; 50% [10/20] and 60% [12/20] female in arms 1 and 2, respectively']","['arm 1 (ubrogepant\xa0±\xa0erenumab) or arm 2 (ubrogepant\xa0±\xa0galcanezumab', 'erenumab or galcanezumab', 'single-dose ubrogepant 100\xa0mg on day 1, subcutaneous erenumab 140\xa0mg (arm 1) or galcanezumab', 'galcanezumab', 'calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives', 'calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (mAbs), erenumab and galcanezumab']","['pharmacokinetic (PK) profile, safety, and tolerability', 'time 0 to infinity (AUC 0-inf ), and maximum plasma concentration (C max ', 'area under the plasma ubrogepant concentration-time curve (AUC) from time 0 to t\xa0post-dose ', 'AUC 0', 'geometric LSM ratios', 'ubrogepant C max']","[{'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517882', 'cui_str': '8.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C4505936', 'cui_str': 'ubrogepant'}, {'cui': 'C4542165', 'cui_str': 'erenumab'}, {'cui': 'C4694273', 'cui_str': 'galcanezumab'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0006669', 'cui_str': 'Calcitonin gene-related peptide'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C4505936', 'cui_str': 'ubrogepant'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0439568', 'cui_str': 'Post-dose'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",40.0,0.259096,"No serious TEAEs, TEAEs leading to discontinuation, or clinically relevant changes in laboratory parameters or vital signs were reported. ","[{'ForeName': 'Abhijeet', 'Initials': 'A', 'LastName': 'Jakate', 'Affiliation': 'Clinical Pharmacology, AbbVie, Madison, NJ, USA.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Blumenfeld', 'Affiliation': 'Headache Center of Southern California, Carlsbad, CA, USA.'}, {'ForeName': 'Ramesh', 'Initials': 'R', 'LastName': 'Boinpally', 'Affiliation': 'Clinical Pharmacology, AbbVie, Madison, NJ, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Butler', 'Affiliation': 'Clinical Pharmacology, AbbVie, Madison, NJ, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Borbridge', 'Affiliation': 'Bioanalysis, Non-clinical and Translational Sciences, AbbVie, Irvine, CA, USA.'}, {'ForeName': 'Janette', 'Initials': 'J', 'LastName': 'Contreras-De Lama', 'Affiliation': 'Clinical Pharmacology, AbbVie, Madison, NJ, USA.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'McGeeney', 'Affiliation': 'Clinical Pharmacology, AbbVie, Madison, NJ, USA.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Periclou', 'Affiliation': 'Clinical Pharmacology, AbbVie, Madison, NJ, USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'The Saul R. Korey Department of Neurology, Department of Psychiatry and Behaviorial Sciences, Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.'}]",Headache,['10.1111/head.14095'] 1290,33783868,"Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.","Antibody-mediated rejection (ABMR) at early or late post-transplantation remains challenging. We performed a single-center single-arm study where four cases of acute ABMR and nine cases of chronic active ABMR (defined by Banff classification) were treated with double-filtration plasmapheresis (two cycles of three consecutive daily sessions with a 4-day gap between). At the end of the third and sixth DFPP sessions, the patients received rituximab 375 mg/m 2 . After a median follow-up of 1078 (61-1676) days, kidney-allograft survival was 50%. Before DFPP/rituximab therapy, the median donor-specific alloantibody (DSA) mean fluorescence intensity (MFI) was 9160 (4000-15 400); 45 days (D45) later it had significantly decreased to 7375 (215-18 100) (P = .018). In addition, at one-year (Y1) post-therapy, MFI had decreased further, that is, 4060 (400-7850) (P = .001). In two patients, DSA MFIs decreased and remained below 2000. The slope of estimated glomerular-filtration rate within the 6 months preceding intervention was -1.18 mL/min/month and remained unchanged at -1.29 mL/min/month within the year after intervention. Proteinuria remained unchanged. Baseline Banff scores on repeat allograft biopsies (post-therapy D45, Y1) did not show any improvement. Side-effects were mild to moderate. We conclude that the combined DFPP/rituximab significantly decreased DSAs in ABMR kidney-transplant recipients but did not improve renal function or renal histology at 1-year follow-up.",2021,"Baseline Banff scores on repeat allograft biopsies (post-therapy D45, Y1) did not show any improvement.",['after kidney transplantation'],"['DFPP/rituximab', 'double-filtration plasmapheresis', 'rituximab', 'antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab']","['kidney-allograft survival', 'Antibody-mediated rejection (ABMR', 'median donor-specific alloantibody (DSA) mean fluorescence intensity (MFI', 'DSA MFIs', 'chronic active ABMR', 'Proteinuria', 'renal function or renal histology', 'DSAs', 'slope of estimated glomerular-filtration rate']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C5200809', 'cui_str': 'Double Filtration Plasmapheresis'}, {'cui': 'C1608421', 'cui_str': 'Antibody-mediated rejection'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1608421', 'cui_str': 'Antibody-mediated rejection'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0022144', 'cui_str': 'Isoantibody'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0332212', 'cui_str': 'Chronic active'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}]",,0.0187483,"Baseline Banff scores on repeat allograft biopsies (post-therapy D45, Y1) did not show any improvement.","[{'ForeName': 'Hamza', 'Initials': 'H', 'LastName': 'Naciri Bennani', 'Affiliation': 'Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Mélanie', 'Initials': 'M', 'LastName': 'Daligault', 'Affiliation': 'Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Noble', 'Affiliation': 'Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Béatrice', 'Initials': 'B', 'LastName': 'Bardy', 'Affiliation': 'HLA Laboratory, EFS, La Tronche, France.'}, {'ForeName': 'Lionel', 'Initials': 'L', 'LastName': 'Motte', 'Affiliation': 'Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Giovannini', 'Affiliation': 'Pathology Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Emprou', 'Affiliation': 'Pathology Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Gaëlle', 'Initials': 'G', 'LastName': 'Fiard', 'Affiliation': 'Department of Urology and Kidney Transplantation, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Farida', 'Initials': 'F', 'LastName': 'Imerzoukene', 'Affiliation': 'Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Bourdin', 'Affiliation': 'HLA Laboratory, EFS, La Tronche, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Masson', 'Affiliation': 'HLA Laboratory, EFS, La Tronche, France.'}, {'ForeName': 'Bénédicte', 'Initials': 'B', 'LastName': 'Janbon', 'Affiliation': 'Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Malvezzi', 'Affiliation': 'Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Lionel', 'Initials': 'L', 'LastName': 'Rostaing', 'Affiliation': 'Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Jouve', 'Affiliation': 'Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.'}]",Journal of clinical apheresis,['10.1002/jca.21897'] 1291,33782701,Smartphone electrocardiogram for detecting atrial fibrillation after a cerebral ischaemic event: a multicentre randomized controlled trial.,"AIMS Atrial fibrillation (AF) is a preventable cause of ischaemic stroke but it is often undiagnosed and undertreated. The utility of smartphone electrocardiogram (ECG) for the detection of AF after ischaemic stroke is unknown. The aim of this study is to determine the diagnostic yield of 30-day smartphone ECG recording compared with 24-h Holter monitoring for detecting AF ≥30 s. METHODS AND RESULTS In this multicentre, open-label study, we randomly assigned 203 participants to undergo one additional 24-h Holter monitoring (control group, n = 98) vs. 30-day smartphone ECG monitoring (intervention group, n = 105) using KardiaMobile (AliveCor®, Mountain View, CA, USA). Major inclusion criteria included age ≥55 years old, without known AF, and ischaemic stroke or transient ischaemic attack (TIA) within the preceding 12 months. Baseline characteristics were similar between the two groups. The index event was ischaemic stroke in 88.5% in the intervention group and 88.8% in the control group (P = 0.852). AF lasting ≥30 s was detected in 10 of 105 patients in the intervention group and 2 of 98 patients in the control group (9.5% vs. 2.0%; absolute difference 7.5%; P = 0.024). The number needed to screen to detect one AF was 13. After the 30-day smartphone monitoring, there was a significantly higher proportion of patients on oral anticoagulation therapy at 3 months compared with baseline in the intervention group (9.5% vs. 0%, P = 0.002). CONCLUSIONS Among patients ≥55 years of age with a recent cryptogenic stroke or TIA, 30-day smartphone ECG recording significantly improved the detection of AF when compared with the standard repeat 24-h Holter monitoring.",2021,The index event was ischaemic stroke in 88.5% in the intervention group and 88.8% in the control group (P = 0.852).,"['Major inclusion criteria included age ≥55\u2009years old, without known AF, and ischaemic stroke or transient ischaemic attack (TIA) within the preceding 12\u2009months', 'patients ≥55\u2009years of age with a recent cryptogenic stroke or TIA', '203 participants to undergo one additional 24-h Holter monitoring (control group, n\u2009=\u200998) vs']","['30-day smartphone ECG', 'Smartphone electrocardiogram', 'smartphone electrocardiogram (ECG', '30-day smartphone ECG monitoring (intervention group, n\u2009=\u2009105) using KardiaMobile (AliveCor®, Mountain View, CA, USA']","['detection of AF', 'index event was ischaemic stroke', 'AF lasting ≥30\u2009s']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0013801', 'cui_str': 'Electrocardiography, Holter'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0442533', 'cui_str': 'Mountain'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}]",203.0,0.0633902,The index event was ischaemic stroke in 88.5% in the intervention group and 88.8% in the control group (P = 0.852).,"[{'ForeName': 'Keng Tat', 'Initials': 'KT', 'LastName': 'Koh', 'Affiliation': 'Department of Cardiology, Sarawak Heart Centre, 3rd Roundabout, Samarahan Expressway, 94300 Kota Samarahan, Sarawak, Malaysia.'}, {'ForeName': 'Wan Chung', 'Initials': 'WC', 'LastName': 'Law', 'Affiliation': 'Department of Medicine, Neurology Unit, Sarawak General Hospital, Jalan Hospital, 93586 Kuching, Sarawak, Malaysia.'}, {'ForeName': 'Win Moe', 'Initials': 'WM', 'LastName': 'Zaw', 'Affiliation': 'Department of Medicine, Neurology Unit, Sarawak General Hospital, Jalan Hospital, 93586 Kuching, Sarawak, Malaysia.'}, {'ForeName': 'Diana Hui Ping', 'Initials': 'DHP', 'LastName': 'Foo', 'Affiliation': 'Clinical Research Centre, Institute for Clinical Research, Sarawak General Hospital, Jalan Hospital, 93586 Kuching, Sarawak, Malaysia.'}, {'ForeName': 'Chen Ting', 'Initials': 'CT', 'LastName': 'Tan', 'Affiliation': 'Department of Cardiology, Sarawak Heart Centre, 3rd Roundabout, Samarahan Expressway, 94300 Kota Samarahan, Sarawak, Malaysia.'}, {'ForeName': 'Anderson', 'Initials': 'A', 'LastName': 'Steven', 'Affiliation': 'Department of Medicine, Neurology Unit, Sarawak General Hospital, Jalan Hospital, 93586 Kuching, Sarawak, Malaysia.'}, {'ForeName': 'Desmond', 'Initials': 'D', 'LastName': 'Samuel', 'Affiliation': 'Department of Medicine, Miri Hospital, Jalan Cahaya, 98000 Miri, Sarawak, Malaysia.'}, {'ForeName': 'Tem Lom', 'Initials': 'TL', 'LastName': 'Fam', 'Affiliation': 'Department of Medicine, Miri Hospital, Jalan Cahaya, 98000 Miri, Sarawak, Malaysia.'}, {'ForeName': 'Ching Hua', 'Initials': 'CH', 'LastName': 'Chai', 'Affiliation': 'Department of Medicine, Miri Hospital, Jalan Cahaya, 98000 Miri, Sarawak, Malaysia.'}, {'ForeName': 'Zhai Sing', 'Initials': 'ZS', 'LastName': 'Wong', 'Affiliation': 'Department of Medicine, Miri Hospital, Jalan Cahaya, 98000 Miri, Sarawak, Malaysia.'}, {'ForeName': 'Sivaraj', 'Initials': 'S', 'LastName': 'Xaviar', 'Affiliation': 'Department of Cardiology, Sarawak Heart Centre, 3rd Roundabout, Samarahan Expressway, 94300 Kota Samarahan, Sarawak, Malaysia.'}, {'ForeName': 'Chandan Deepak', 'Initials': 'CD', 'LastName': 'Bhavnani', 'Affiliation': 'Department of Medicine, Bintulu Hospital, Jalan Bukit Nyabau, 97000 Bintulu, Sarawak, Malaysia.'}, {'ForeName': 'Jason Seng Hong', 'Initials': 'JSH', 'LastName': 'Tan', 'Affiliation': 'Department of Medicine, Bintulu Hospital, Jalan Bukit Nyabau, 97000 Bintulu, Sarawak, Malaysia.'}, {'ForeName': 'Yen Yee', 'Initials': 'YY', 'LastName': 'Oon', 'Affiliation': 'Department of Cardiology, Sarawak Heart Centre, 3rd Roundabout, Samarahan Expressway, 94300 Kota Samarahan, Sarawak, Malaysia.'}, {'ForeName': 'Asri', 'Initials': 'A', 'LastName': 'Said', 'Affiliation': 'Department of Cardiology, Sarawak Heart Centre, 3rd Roundabout, Samarahan Expressway, 94300 Kota Samarahan, Sarawak, Malaysia.'}, {'ForeName': 'Alan Yean Yip', 'Initials': 'AYY', 'LastName': 'Fong', 'Affiliation': 'Department of Cardiology, Sarawak Heart Centre, 3rd Roundabout, Samarahan Expressway, 94300 Kota Samarahan, Sarawak, Malaysia.'}, {'ForeName': 'Tiong Kiam', 'Initials': 'TK', 'LastName': 'Ong', 'Affiliation': 'Department of Cardiology, Sarawak Heart Centre, 3rd Roundabout, Samarahan Expressway, 94300 Kota Samarahan, Sarawak, Malaysia.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euab036'] 1292,33788249,Desflurane consumption with automated vapour control systems in two different anaesthesia machines. A randomized controlled study.,"BACKGROUND In general anaesthesia practice a fresh gas flow (FGF) of ≥0.5 L/min is usually applied. Automated gas delivery devices are developed to reduce volatile anaesthetic consumption by limiting gas flow. This study aimed to compare desflurane consumption between automated gas control devices compared to conventional low flow anaesthesia in the Flow-I and Aisys anaesthesia machines, and to compare desflurane consumption between the two automated gas delivery devices. We hypothesised that desflurane consumption would be lower with automated gas delivery compared to conventional low flow anaesthesia, and that desflurane consumption could differ between the different gas delivery devices. METHODS We allocated 160 patients undergoing robot-assisted laparoscopic surgery into four groups, Flow-I with automated gas control, Flow-i with conventional low-flow (1 L/min), Aisys with end tidal gas control and Aisys with conventional low flow. Patients were maintained at minimum alveolar concentration (MAC) 0.7-0.8. Desflurane consumption was recorded after 9, 30 and 60 minutes of anaesthesia. RESULTS After 60 minutes, compared to conventional low flow anaesthesia, automated gas delivery systems reduced desflurane consumption from 25.8 to 15.2 mL for the Aisys machine (P < .001) and from 22.1 to 16.8 mL for the Flow-I (P < .001). Time to MAC 0.7 and stable FGF was shorter with Aisys endtidal control compared to Flow-I automated gas control. CONCLUSION Under clinical conditions, we found a reduction in desflurane consumption when using automated gas delivery devices compared to conventional low flow anaesthesia. Both devices were reliable in use.",2021,"Time to MAC 0.7 and stable FGF was shorter with Aisys endtidal control compared to Flow-I automated gas control. ","['160 patients undergoing', 'two different anaesthesia machines']","['Desflurane consumption with automated vapor control systems', 'robot assisted laparoscopic surgery into four groups, Flow-I with automated gas control, Flow-I with conventional low flow (1 l/min), Aisys with end tidal gas control and Aisys with conventional low flow']","['Desflurane consumption', 'volatile anaesthetic consumption', 'desflurane consumption']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0179064', 'cui_str': 'Anesthesia machine'}]","[{'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0597635', 'cui_str': 'Vapor'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439393', 'cui_str': 'L/min'}, {'cui': 'C0444930', 'cui_str': 'End'}]","[{'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0443769', 'cui_str': 'Volatile agent'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}]",160.0,0.11179,"Time to MAC 0.7 and stable FGF was shorter with Aisys endtidal control compared to Flow-I automated gas control. ","[{'ForeName': 'Dagmar', 'Initials': 'D', 'LastName': 'Mostad', 'Affiliation': ""Clinic of Anaesthesia and Intensive Care, St. Olav's University Hospital, Trondheim, Norway.""}, {'ForeName': 'Pål', 'Initials': 'P', 'LastName': 'Klepstad', 'Affiliation': ""Clinic of Anaesthesia and Intensive Care, St. Olav's University Hospital, Trondheim, Norway.""}, {'ForeName': 'Turid', 'Initials': 'T', 'LastName': 'Follestad', 'Affiliation': 'Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.'}, {'ForeName': 'Hilde', 'Initials': 'H', 'LastName': 'Pleym', 'Affiliation': ""Clinic of Anaesthesia and Intensive Care, St. Olav's University Hospital, Trondheim, Norway.""}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13825'] 1293,33780888,Dissonance-based eating disorder prevention among Brazilian young women: A randomized efficacy trial of the Body Project.,"A randomized controlled trial was conducted to assess the efficacy of the Body Project eating disorder prevention program in reducing eating disorder risk factors and symptoms in young Brazilian women. A total of 141 female university students aged 18-30 years old were randomly assigned to one of two conditions: assessment-only condition (n = 78) and Body Project condition (n = 63). Participants completed scales assessing body dissatisfaction, sociocultural influence, disordered eating attitudes and behaviors, eating disorders symptoms, body appreciation, depressive mood and negative affect at baseline, posttest, and at 1- and 6-month follow-ups. Body Project participants showed significantly greater reductions in body dissatisfaction, sociocultural influence, disordered eating, eating disorder symptoms, depressive symptoms, and negative affect, and greater increases in body appreciation (d = .35-.48) compared to assessment-only participants. Most of the effects persisted through 6-month follow-up (d = .35-.74). Results provide evidence that the Body Project is an effective intervention to reduce eating disorder risk factors and eating disorder symptoms among Brazilian young women, and that this intervention is naturally culturally adaptive.",2021,"Results provide evidence that the Body Project is an effective intervention to reduce eating disorder risk factors and eating disorder symptoms among Brazilian young women, and that this intervention is naturally culturally adaptive.","['young Brazilian women', '141 female university students aged 18-30 years old', 'Brazilian young women']","['Body Project eating disorder prevention program', 'Dissonance-based eating disorder prevention']","['eating disorder risk factors and eating disorder symptoms', 'scales assessing body dissatisfaction, sociocultural influence, disordered eating attitudes and behaviors, eating disorders symptoms, body appreciation, depressive mood and negative affect', 'body appreciation', 'body dissatisfaction, sociocultural influence, disordered eating, eating disorder symptoms, depressive symptoms', 'eating disorder risk factors and symptoms']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009242', 'cui_str': 'Cognitive Dissonance'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0855228', 'cui_str': 'Eating disorder symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2732632', 'cui_str': 'Dissatisfaction with body image'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",141.0,0.010489,"Results provide evidence that the Body Project is an effective intervention to reduce eating disorder risk factors and eating disorder symptoms among Brazilian young women, and that this intervention is naturally culturally adaptive.","[{'ForeName': 'Tassiana Aparecida', 'Initials': 'TA', 'LastName': 'Hudson', 'Affiliation': 'Department of Physical Education, Federal University of Juiz de Fora, s/n José Lourenço Kelmer Street, University Campus, Juiz de Fora, 36036-900, Brazil. Electronic address: tassiana.hudson@estudante.ufjf.br.'}, {'ForeName': 'Ana Carolina Soares', 'Initials': 'ACS', 'LastName': 'Amaral', 'Affiliation': 'Federal Institute of Education, Science and Technology of Southeast of Minas Gerais, 204 Monsenhor José Augusto Street, Barbacena, Minas Gerais, 36205-018, Brazil. Electronic address: ana.amaral@ifsudestemg.edu.br.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Stice', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Road, Stanford, CA 94305, United States. Electronic address: estice@stanford.edu.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Gau', 'Affiliation': 'Oregon Research Institute, 1776 Millrace Dr, Eugene, OR 97403, United States. Electronic address: jeffg@ori.org.'}, {'ForeName': 'Maria Elisa Caputo', 'Initials': 'MEC', 'LastName': 'Ferreira', 'Affiliation': 'Department of Physical Education, Federal University of Juiz de Fora, s/n José Lourenço Kelmer Street, University Campus, Juiz de Fora, 36036-900, Brazil. Electronic address: maria.elisa@ufjf.edu.br.'}]",Body image,['10.1016/j.bodyim.2021.03.008'] 1294,33792355,A Comparison of Two Diabetes Self-Management Education Programs for the Reduction of Participant A1c Levels.,"PURPOSE Compare the effectiveness of two educational teaching methods for diabetic patients. DESIGN Quasi-experimental study comparing two interventions using a pretest/post-test design. SETTING Three clinics within a western U.S. regional health system. SUBJECTS 818 adult diabetic participants (60.5 mean age, 52% female) attended one to four sessions between 2013-2017, and had A1c tests within 180 days of first attended session and 30 to 365 days after last attended session. INTERVENTION A group-based, highly interactive learning experience (n = 561) and a traditional, lecture-style class (n = 257). MEASURES Pre and post measures of A1c. ANALYSIS Paired t-tests measured change within each group pre-post intervention. Two-sample t-tests measured mean change pre-post intervention between the two groups. Multivariable linear regression measured mean change in A1c between groups, adjusted for pre-test scores and controlling for demographic variables. RESULTS Both interactive and traditional teaching interventions were effective at significantly reducing patient A1c levels by 1.3 ( p < 0.001) and 1.0 ( p < 0.001) points respectively. The between groups difference in A1c was not significant, t(512) = 1.66, p = 0.0985, but when controlling for age, pre-A1c and days post-A1c, the interactive intervention was significantly ( p < 0.05) more effective reducing patient A1c levels by 0.19 points than the traditional intervention. CONCLUSION Group-based, interactive diabetes self-management education programs may be an effective model for reducing patient A1c levels.",2021,Both interactive and traditional teaching interventions were effective at significantly reducing patient A1c levels by 1.3 ( p < 0.001) and 1.0 ( p < 0.001) points respectively.,"['diabetic patients', '818 adult diabetic participants (60.5 mean age, 52% female) attended one to four sessions between 2013-2017, and had A1c tests within 180 days of first attended session and 30 to 365 days after last attended session', 'Three clinics within a western U.S. regional health system']","['highly interactive learning experience', 'educational teaching methods']","['patient A1c levels', 'effective reducing patient A1c levels']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0815244', 'cui_str': 'Interactive Learning'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0039403', 'cui_str': 'Teaching Methods'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",818.0,0.0110862,Both interactive and traditional teaching interventions were effective at significantly reducing patient A1c levels by 1.3 ( p < 0.001) and 1.0 ( p < 0.001) points respectively.,"[{'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Sharpless', 'Affiliation': 'Department of Health Services Administration, 48654School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Borkowski', 'Affiliation': 'Department of Health Services Administration, 48654School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Health Services Administration, 48654School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Larry', 'Initials': 'L', 'LastName': 'Hearld', 'Affiliation': 'Department of Health Services Administration, 48654School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Jeffery', 'Initials': 'J', 'LastName': 'Szychowski', 'Affiliation': 'Department of Biostatics, 48654School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.'}]",American journal of health promotion : AJHP,['10.1177/08901171211003829'] 1295,33243032,Reduced glutathione does not further reduce contrast-induced nephropathy in elderly patients with diabetes receiving percutaneous coronary intervention.,"OBJECTIVE To investigate the preventive effect of hydration combined with reduced glutathione on contrast-induced nephropathy (CIN) after coronary intervention therapy in elderly Chinese patients with diabetes. METHODS Patients with diabetes aged ≥65 years, who received percutaneous coronary intervention (PCI) between 1 August 2016 and 31 December 2018, were enrolled and randomized into two groups: patients treated with hydration combined with reduced glutathione (treatment group) and patients who received hydration alone (controls). Serum creatinine and creatinine clearance levels were measured in all patients before PCI and then daily for 3 days after PCI. Occurrence of CIN (the primary endpoint) was defined as serum creatinine value 25% or 44.2 mmol/l (0.5 mg/dl) above baseline at 72 h after an exposure to contrast medium. RESULTS A total of 396 patients were included (treatment group, n  = 204; and controls, n  = 192). The CIN occurrence rate in the treatment and control group was 5.88% and 6.77%, respectively, with no statistically significant between-group difference. CONCLUSION In elderly patients with diabetes receiving PCI, the risk of CIN was not effectively lowered by hydration combined with reduced glutathione.",2020,"The CIN occurrence rate in the treatment and control group was 5.88% and 6.77%, respectively, with no statistically significant between-group difference. ","['elderly patients with diabetes receiving percutaneous coronary intervention', '396 patients were included (treatment group, n \u2009=\u2009204; and controls, n \u2009=\u2009192', 'Patients with diabetes aged ≥65 years, who received', 'elderly patients with diabetes receiving PCI, the risk of CIN', 'elderly Chinese patients with diabetes', 'PCI) between 1 August 2016 and 31 December 2018']","['coronary intervention therapy', 'hydration combined with reduced glutathione', 'percutaneous coronary intervention', 'hydration combined with reduced glutathione (treatment group) and patients who received hydration alone (controls']","['Serum creatinine and creatinine clearance levels', 'serum creatinine value', 'Occurrence of CIN', 'CIN occurrence rate']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C5191354', 'cui_str': '396'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}]",396.0,0.0398822,"The CIN occurrence rate in the treatment and control group was 5.88% and 6.77%, respectively, with no statistically significant between-group difference. ","[{'ForeName': 'Lingqing', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Department of Cardiovascular Medicine, Taizhou First People's Hospital of Wenzhou Medical University, Taizhou, China.""}, {'ForeName': 'Enguo', 'Initials': 'E', 'LastName': 'Xu', 'Affiliation': ""Department of Cardiovascular Medicine, Taizhou First People's Hospital of Wenzhou Medical University, Taizhou, China.""}, {'ForeName': 'Shijia', 'Initials': 'S', 'LastName': 'Ren', 'Affiliation': ""Department of Cardiovascular Medicine, Taizhou First People's Hospital of Wenzhou Medical University, Taizhou, China.""}, {'ForeName': 'Xingjian', 'Initials': 'X', 'LastName': 'Gu', 'Affiliation': ""Department of Cardiovascular Medicine, Taizhou First People's Hospital of Wenzhou Medical University, Taizhou, China.""}, {'ForeName': 'Jiping', 'Initials': 'J', 'LastName': 'Zheng', 'Affiliation': ""Department of Cardiovascular Medicine, Taizhou First People's Hospital of Wenzhou Medical University, Taizhou, China.""}, {'ForeName': 'Jianguang', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': ""Department of Cardiovascular Medicine, Taizhou First People's Hospital of Wenzhou Medical University, Taizhou, China.""}]",The Journal of international medical research,['10.1177/0300060520964017'] 1296,33244404,"Social support, adherence to Mediterranean diet and physical activity in adults: results from a community-based cross-sectional study.","There is a growing recognition that social support can potentially exert consistent or opposing effects in influencing health behaviours. The present paper presents a cross-sectional study, including 2,064 adults from Italy, Spain and Greece, who were participants in a multi-centre randomised controlled trial (C4H study), aiming to examine whether social support is correlated with adherence to a healthy Mediterranean diet and physical activity. Social support data were available for 1,572 participants. The majority of the sample reported emotional support availability (84·5 %), financial support availability (72·6 %) and having one or more close friends (78·2 %). Mediterranean diet adherence was significantly associated with emotional support ( P = 0·009) and social network support ( P = 0·021). No statistically significant associations were found between participant physical activity and the social support aspects studied. In conclusion, emotional and social network support may be associated with increased adherence to the Mediterranean diet. However, further research is needed to evaluate the role of social support in adherence to healthy Mediterranean diet.",2020,Mediterranean diet adherence was significantly associated with emotional support ( P = 0·009) and social network support ( P = 0·021).,"['adults', '1,572 participants', '2,064 adults from Italy, Spain and Greece, who were participants in a multi-centre randomised controlled trial (C4H study']",[],['Mediterranean diet adherence'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0018226', 'cui_str': 'Greece'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",2064.0,0.0215859,Mediterranean diet adherence was significantly associated with emotional support ( P = 0·009) and social network support ( P = 0·021).,"[{'ForeName': 'Elpiniki', 'Initials': 'E', 'LastName': 'Laiou', 'Affiliation': 'Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.'}, {'ForeName': 'Iro', 'Initials': 'I', 'LastName': 'Rapti', 'Affiliation': 'Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Markozannes', 'Affiliation': 'Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.'}, {'ForeName': 'Luisella', 'Initials': 'L', 'LastName': 'Cianferotti', 'Affiliation': 'Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Fleig', 'Affiliation': 'Department of Health Psychology, Freie Universität Berlin, Berlin, Germany.'}, {'ForeName': 'Lisa Marie', 'Initials': 'LM', 'LastName': 'Warner', 'Affiliation': 'Department of Health Psychology, Freie Universität Berlin, Berlin, Germany.'}, {'ForeName': 'Lourdes', 'Initials': 'L', 'LastName': 'Ribas', 'Affiliation': 'Nutrition Research Foundation, Barcelona Science Park, Barcelona, Spain.'}, {'ForeName': 'Joy', 'Initials': 'J', 'LastName': 'Ngo', 'Affiliation': 'Nutrition Research Foundation, Barcelona Science Park, Barcelona, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Salvatore', 'Affiliation': 'ISBEM, University of Salento, Lecce, Italy.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Trichopoulou', 'Affiliation': 'Hellenic Health Foundation, Athens, Greece.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Vigilanza', 'Affiliation': 'ISBEM, University of Salento, Lecce, Italy.'}, {'ForeName': 'Stavroula', 'Initials': 'S', 'LastName': 'Tsiara', 'Affiliation': 'Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Martimianaki', 'Affiliation': 'Hellenic Health Foundation, Athens, Greece.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Pampaloni', 'Affiliation': 'Fondazione F.I.R.M.O., Florence, Italy.'}, {'ForeName': 'Luis Serra', 'Initials': 'LS', 'LastName': 'Majem', 'Affiliation': 'Nutrition Research Foundation, Barcelona Science Park, Barcelona, Spain.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Schwarzer', 'Affiliation': 'Department of Health Psychology, Freie Universität Berlin, Berlin, Germany.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Brandi', 'Affiliation': 'Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Evangelia E', 'Initials': 'EE', 'LastName': 'Ntzani', 'Affiliation': 'Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.'}]",Journal of nutritional science,['10.1017/jns.2020.46'] 1297,33244443,Novel Extranasal Tear Stimulation: Pivotal Study Results.,"Purpose To evaluate the efficacy and safety of iTEAR, a novel, portable, sonic external neuromodulation device, for the treatment of dry eye disease (DED). Methods This was a multicenter, open-label, single-arm clinical trial that included adult patients with DED with a Schirmer score of ≤10 mm in at least one eye. Enrolled subjects were instructed to apply the study device at least twice per day for 30 seconds bilaterally to the external nasal nerve. After the initial baseline visit, patients were followed up at days 3, 14, 30, 90, and 180. The primary efficacy endpoint was the Schirmer index (change from unstimulated to stimulated tear production as measured by the Schirmer test) at day 30. The major secondary endpoint was the change in symptoms of DED at day 30 evaluated using the Ocular Surface Disease Index (OSDI). Results A total of 101 subjects evaluated at day 30 had a mean Schirmer index of 9.4 mm (95% confidence interval [CI], 7.4-11.3), and the baseline OSDI improved by an average of 14.4 (95% CI, 11.1-17.7). Both endpoints were highly statistically and clinically significant at all time points. There were two mild unanticipated adverse events definitely related to the device. Conclusions The safety and efficacy of the iTEAR device observed in this study support its indication for treating DED. Translational Relevance Neurostimulation has the potential to improve signs and symptoms of DED.",2020,Both endpoints were highly statistically and clinically significant at all time points.,"['dry eye disease (DED', 'adult patients with DED with a Schirmer score of ≤10 mm in at least one eye']",['iTEAR'],"['mean Schirmer index', 'baseline OSDI', 'Schirmer index (change from unstimulated to stimulated tear production as measured by the Schirmer test', 'change in symptoms of DED at day 30 evaluated using the Ocular Surface Disease Index (OSDI']","[{'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439819', 'cui_str': 'Unstimulated'}, {'cui': 'C0423153', 'cui_str': 'Lacrimation'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0200152', 'cui_str': ""Schirmer's test""}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",,0.0732423,Both endpoints were highly statistically and clinically significant at all time points.,"[{'ForeName': 'Marco H', 'Initials': 'MH', 'LastName': 'Ji', 'Affiliation': 'Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Darius M', 'Initials': 'DM', 'LastName': 'Moshfeghi', 'Affiliation': 'Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Periman', 'Affiliation': 'Evergreen Eye Center, Seattle, WA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kading', 'Affiliation': 'Specialty Eyecare Group, Seattle, WA, USA.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Matossian', 'Affiliation': 'Matossian Eye Associates, Pennington, NJ, USA.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Walman', 'Affiliation': 'Arizona Eye Specialists, Phoenix, AZ, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Markham', 'Affiliation': 'M&M Eye Institute, Prescott, AZ, USA.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Mu', 'Affiliation': 'NV Eye Surgery, Las Vegas, NV, USA.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Jayaram', 'Affiliation': 'Mid-Peninsula Ophthalmology Medical Group, Menlo Park, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gertner', 'Affiliation': 'Olympic Ophthalmics, Inc., Issaquah, WA, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Karpecki', 'Affiliation': 'Kentucky Eye Institute, Lexington, KY, USA.'}, {'ForeName': 'Neil J', 'Initials': 'NJ', 'LastName': 'Friedman', 'Affiliation': 'Mid-Peninsula Ophthalmology Medical Group, Menlo Park, CA, USA.'}]",Translational vision science & technology,['10.1167/tvst.9.12.23'] 1298,33249458,A Pilot Randomized Clinical Trial of Remote Varenicline Sampling to Promote Treatment Engagement and Smoking Cessation.,"INTRODUCTION Medication sampling is a clinically useful tool to engage smokers in the quitting process. Whether varenicline is suitable for sampling purposes is unclear. The purpose of this study was to examine the feasibility, uptake, and preliminary outcomes of varenicline sampling. METHODS Smokers (N = 99), both motivated to quit and not, were recruited and randomized to varenicline sampling versus not, with 12 week follow-up. The intervention consisted of mailing one-time samples of varenicline (lasting 2-4 wks), with minimally suggestive guidance on use. RESULTS Uptake of varenicline was strong, at 2 weeks (54% any use, 66% daily use) and 4 weeks (38%, 46%), with 58% of medication users seeking additional medication. Most users followed conventional titration patterns, self-titrating from 0.5 mg to 2 mg. Relative to control, varenicline sampling increased motivation (p = 0.006) and confidence to quit (p = 0.02), and decreased cigarette smoking (p = 0.02). Smokers receiving varenicline samples were significantly more likely to achieve 50% reduction in cigarettes per day (CPD), both immediately following the sampling exercise (Adjusted Odds Ratio [AOR] = 4.12; 95% CI: 1.39 to 12.17) and at final follow-up (AOR = 4.50; 95% CI: 1.56 to 13.01). Though cessation outcomes were not statistically significant, there was a 1.5 to 3-fold increase in quit attempts and abstinence from varenicline sampling throughout follow-up. These outcomes were comparable among smokers motivated to quit and not. CONCLUSIONS Unguided, user-driven sampling of varenicline sampling is a concrete behavioral exercise that is feasible to do and seems to suggest clinical utility. Sampling is a pragmatic clinical approach to engage more smokers in quitting. IMPLICATIONS Use of evidence-based pharmacotherapies for smoking cessation is low. Medication sampling is a pragmatic behavioral exercise that allows smokers to experience the benefits of using them, while promoting positive downstream effects towards quitting. While previous studies have shown that nicotine replacement therapy (NRT) sampling is viable and effective, whether this extends to varenicline is unclear. Results from this trial demonstrate that varenicline sampling is feasible, safe, and suggestive of clinically important steps toward quitting, deserving of a larger trial. CLINICAL TRIAL REGISTRATION NCT #03742154.",2021,"Relative to control, varenicline sampling increased motivation (p=0.006) and confidence to quit (p=0.02), and decreased cigarette smoking (p=0.02).","['Smokers (N=99), both motivated to quit and not']","['varenicline sampling', 'Remote Varenicline', 'varenicline (lasting 2-4wks), with minimally suggestive guidance on use', 'varenicline']","['motivation', 'cigarette smoking', 'quit attempts and abstinence', 'CPD']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C1569608', 'cui_str': 'varenicline'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0055816', 'cui_str': 'citrate phosphate dextrose'}]",,0.0395438,"Relative to control, varenicline sampling increased motivation (p=0.006) and confidence to quit (p=0.02), and decreased cigarette smoking (p=0.02).","[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Carpenter', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina (MUSC), Charleston, SC.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Gray', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina (MUSC), Charleston, SC.'}, {'ForeName': 'Amy E', 'Initials': 'AE', 'LastName': 'Wahlquist', 'Affiliation': 'Department of Public Health Sciences, MUSC, Charleston, SC.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Cropsey', 'Affiliation': 'Department of Psychiatry, University of Alabama, Birmingham, UK.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Saladin', 'Affiliation': 'Department of Health Sciences and Research, MUSC, Charleston, SC.'}, {'ForeName': 'Brett', 'Initials': 'B', 'LastName': 'Froeliger', 'Affiliation': 'Department of Psychiatry, University of Missouri, Columbia, MI.'}, {'ForeName': 'Tracy T', 'Initials': 'TT', 'LastName': 'Smith', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina (MUSC), Charleston, SC.'}, {'ForeName': 'Benjamin A', 'Initials': 'BA', 'LastName': 'Toll', 'Affiliation': 'Department of Public Health Sciences, MUSC, Charleston, SC.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Dahne', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina (MUSC), Charleston, SC.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa241'] 1299,34060209,Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.,"Oral semaglutide is the first oral glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and showed significant benefits in glycaemic control and weight reduction versus active comparators in the PIONEER phase 3a randomized controlled trial programme. In this retrospective study, we present early data on the use of oral semaglutide in clinical practice, from the US IBM Explorys electronic health record database. In 782 patients prescribed oral semaglutide, 54.5% were women, and the mean age (SD) was 57.8 years (11.3); 66.0% of patients received their prescription from a primary care practitioner. Although prescribing information recommends increasing the dose to 7 mg after 30 days, 37.0% of patients received a prescription only for the initial 3 mg dose. Mean body mass index was 36.2 kg/m 2 (7.6); mean HbA1c was 8.4% (1.8%). Mean HbA1c change from baseline to approximately 6 months after oral semaglutide initiation was -0.9% (95% CI: -1.1%; -0.6%), with greater reductions in patients with higher baseline HbA1c. These data indicate prevalent early adoption of oral semaglutide in primary care, show real-world improvements in glycaemic control, and identify potential treatment gaps.",2021,"Mean HbA1c change from baseline to approximately 6 months after oral semaglutide initiation was -0.9% (95% CI: -1.1%; -0.6%), with greater reductions in patients with higher baseline HbA1c.","['782 patients prescribed oral semaglutide, 54.5% were women, and the mean age (SD) was 57.8\u2009years (11.3); 66.0% of patients received their prescription from a primary care practitioner']",[],"['Mean HbA1c change', 'Mean body mass index']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",,0.171426,"Mean HbA1c change from baseline to approximately 6 months after oral semaglutide initiation was -0.9% (95% CI: -1.1%; -0.6%), with greater reductions in patients with higher baseline HbA1c.","[{'ForeName': 'Vanita R', 'Initials': 'VR', 'LastName': 'Aroda', 'Affiliation': ""Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Mads', 'Initials': 'M', 'LastName': 'Faurby', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Lophaven', 'Affiliation': 'Omicron ApS, Roskilde, Denmark.'}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Noone', 'Affiliation': 'Novo Nordisk, Plainsboro Township, New Jersey, USA.'}, {'ForeName': 'Michael Lyng', 'Initials': 'ML', 'LastName': 'Wolden', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Ildiko', 'Initials': 'I', 'LastName': 'Lingvay', 'Affiliation': 'Department of Internal Medicine/Endocrinology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14453'] 1300,34133856,Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.,"BACKGROUND The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. METHODS We randomly assigned, in a 1:1 ratio, hospitalized adults with Covid-19 pneumonia to receive either tofacitinib at a dose of 10 mg or placebo twice daily for up to 14 days or until hospital discharge. The primary outcome was the occurrence of death or respiratory failure through day 28 as assessed with the use of an eight-level ordinal scale (with scores ranging from 1 to 8 and higher scores indicating a worse condition). All-cause mortality and safety were also assessed. RESULTS A total of 289 patients underwent randomization at 15 sites in Brazil. Overall, 89.3% of the patients received glucocorticoids during hospitalization. The cumulative incidence of death or respiratory failure through day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% confidence interval [CI], 0.41 to 0.97; P = 0.04). Death from any cause through day 28 occurred in 2.8% of the patients in the tofacitinib group and in 5.5% of those in the placebo group (hazard ratio, 0.49; 95% CI, 0.15 to 1.63). The proportional odds of having a worse score on the eight-level ordinal scale with tofacitinib, as compared with placebo, was 0.60 (95% CI, 0.36 to 1.00) at day 14 and 0.54 (95% CI, 0.27 to 1.06) at day 28. Serious adverse events occurred in 20 patients (14.1%) in the tofacitinib group and in 17 (12.0%) in the placebo group. CONCLUSIONS Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. (Funded by Pfizer; STOP-COVID ClinicalTrials.gov number, NCT04469114.).",2021,"The cumulative incidence of death or respiratory failure through day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% confidence interval [CI], 0.41 to 0.97; P = 0.04).","['patients hospitalized with Covid-19 pneumonia', 'patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia', 'hospitalized adults with Covid-19 pneumonia to receive either', 'Patients Hospitalized with Covid-19 Pneumonia', '289 patients underwent randomization at 15 sites in Brazil']","['glucocorticoids', 'tofacitinib', 'Tofacitinib', 'tofacitinib at a dose of 10 mg or placebo', 'placebo']","['cumulative incidence of death or respiratory failure', 'occurrence of death or respiratory failure through day 28 as assessed with the use of an eight-level ordinal scale', 'risk of death or respiratory failure', 'Serious adverse events', 'Death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C2930696', 'cui_str': 'tofacitinib'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",289.0,0.722453,"The cumulative incidence of death or respiratory failure through day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% confidence interval [CI], 0.41 to 0.97; P = 0.04).","[{'ForeName': 'Patrícia O', 'Initials': 'PO', 'LastName': 'Guimarães', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Quirk', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Remo H', 'Initials': 'RH', 'LastName': 'Furtado', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Lilia N', 'Initials': 'LN', 'LastName': 'Maia', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'José F', 'Initials': 'JF', 'LastName': 'Saraiva', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Murillo O', 'Initials': 'MO', 'LastName': 'Antunes', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Kalil Filho', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Vagner M', 'Initials': 'VM', 'LastName': 'Junior', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Alexandre M', 'Initials': 'AM', 'LastName': 'Soeiro', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Alexandre P', 'Initials': 'AP', 'LastName': 'Tognon', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Viviane C', 'Initials': 'VC', 'LastName': 'Veiga', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Priscilla A', 'Initials': 'PA', 'LastName': 'Martins', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Diogo D F', 'Initials': 'DDF', 'LastName': 'Moia', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Bruna S', 'Initials': 'BS', 'LastName': 'Sampaio', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Silvia R L', 'Initials': 'SRL', 'LastName': 'Assis', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Ronaldo V P', 'Initials': 'RVP', 'LastName': 'Soares', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Luciana P A', 'Initials': 'LPA', 'LastName': 'Piano', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Kleber', 'Initials': 'K', 'LastName': 'Castilho', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Roberta G R A P', 'Initials': 'RGRAP', 'LastName': 'Momesso', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Frederico', 'Initials': 'F', 'LastName': 'Monfardini', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Helio P', 'Initials': 'HP', 'LastName': 'Guimarães', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Ponce de Leon', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Majori', 'Initials': 'M', 'LastName': 'Dulcine', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Marcia R T', 'Initials': 'MRT', 'LastName': 'Pinheiro', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Levent M', 'Initials': 'LM', 'LastName': 'Gunay', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'J Jasper', 'Initials': 'JJ', 'LastName': 'Deuring', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Luiz V', 'Initials': 'LV', 'LastName': 'Rizzo', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Tamas', 'Initials': 'T', 'LastName': 'Koncz', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': 'Otavio', 'Initials': 'O', 'LastName': 'Berwanger', 'Affiliation': 'From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2101643'] 1301,34143241,Cognitive and motor task performance under single- and dual-task conditions: effects of consecutive versus concurrent practice.,"The concurrent execution of two or more tasks simultaneously results in performance decrements in one or both conducted tasks. The practice of dual-task (DT) situations has been shown to decrease performance decrements. The purpose of this study was to investigate the effects of consecutive versus concurrent practice on cognitive and motor task performance under single-task (ST) and DT conditions. Forty-five young adults (21 females, 24 males) were randomly assigned to either a consecutive practice (INT consecutive) group, a concurrent practice (INT concurrent) group or a control (CON) group (i.e., no practice). Both INT groups performed 2 days of acquisition, i.e., practicing a cognitive and a motor task either consecutively or concurrently. The cognitive task required participants to perform an auditory stroop task and the number of correct responses was used as outcome measure. In the motor task, participants were asked to stand on a stabilometer and to keep the platform as close to horizontal as possible. The time in balance was calculated for further analysis. Pre- and post-practice testing included performance assessment under ST (i.e., cognitive task only, motor task only) and DT (i.e., cognitive and motor task simultaneously) test conditions. Pre-practice testing revealed no significant group differences under ST and DT test conditions neither for the cognitive nor the motor task measure. During acquisition, both INT groups improved their cognitive and motor task performance. The post-practice testing showed significantly better cognitive and motor task values under ST and DT test conditions for the two INT groups compared to the CON group. Further comparisons between the two INT groups revealed better motor but not cognitive task values in favor of the INT consecutive practice group (ST: p = 0.022; DT: p = 0.002). We conclude that consecutive and concurrent practice resulted in better cognitive (ST condition) and motor (ST and DT test conditions) task performance than no practice. In addition, consecutive practice resulted in superior motor task performance (ST and DT test conditions) compared to concurrent practice and is, therefore, recommended when executing DT practice schedules.",2021,The post-practice testing showed significantly better cognitive and motor task values under ST and DT test conditions for the two INT groups compared to the CON group.,"['Forty-five young adults (21 females, 24 males']","['concurrent practice (INT concurrent) group or a control (CON', 'Cognitive and motor task performance under single- and dual-task conditions', 'cognitive task required participants to perform an auditory stroop task', 'CON']","['superior motor task performance (ST and DT test conditions', 'cognitive and motor task performance', 'cognitive and motor task values under ST and DT test conditions', 'time in balance', 'cognitive and motor task performance under single-task (ST) and DT conditions', 'better cognitive (ST condition) and motor (ST and DT test conditions) task performance', 'performance assessment under ST (i.e., cognitive task only, motor task only) and DT (i.e., cognitive and motor task simultaneously) test conditions', 'cognitive task values']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}]","[{'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0449910', 'cui_str': 'Test conditions'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}]",45.0,0.0666796,The post-practice testing showed significantly better cognitive and motor task values under ST and DT test conditions for the two INT groups compared to the CON group.,"[{'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Beurskens', 'Affiliation': 'Department of Health and Social Affairs, FHM Bielefeld - University of Applied Sciences, Bielefeld, Germany. beurskens@fh-mittelstand.de.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Brueckner', 'Affiliation': 'Division of Movement and Training Sciences/Biomechanics of Sport, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Hagen', 'Initials': 'H', 'LastName': 'Voigt', 'Affiliation': 'Division of Movement and Training Sciences/Biomechanics of Sport, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Muehlbauer', 'Affiliation': 'Division of Movement and Training Sciences/Biomechanics of Sport, University of Duisburg-Essen, Essen, Germany.'}]",Experimental brain research,['10.1007/s00221-021-06130-8'] 1302,34140351,Vocal music listening enhances post-stroke language network reorganization.,"Listening to vocal music has been recently shown to improve language recovery in stroke survivors. The neuroplasticity mechanisms supporting this effect are, however, still unknown. Using data from a three-arm single-blind randomized controlled trial including acute stroke patients (N=38) and a 3-month follow-up, we set out to compare the neuroplasticity effects of daily listening to self-selected vocal music, instrumental music, and audiobooks on both brain activity and structural connectivity of the language network. Using deterministic tractography we show that the 3-month intervention induced an enhancement of the microstructural properties of the left frontal aslant tract (FAT) for the vocal music group as compared to the audiobook group. Importantly, this increase in the strength of the structural connectivity of the left FAT correlated with improved language skills. Analyses of stimulus-specific activation changes showed that the vocal music group exhibited increased activations in the frontal termination points of the left FAT during vocal music listening as compared to the audiobook group from acute to 3-month post-stroke stage. The increased activity correlated with the structural neuroplasticity changes in the left FAT. These results suggest that the beneficial effects of vocal music listening on post-stroke language recovery are underpinned by structural neuroplasticity changes within the language network and extend our understanding of music-based interventions in stroke rehabilitation. Significance statement Post-stroke language deficits have a devastating effect on patients and their families. Current treatments yield highly variable outcomes and the evidence for their long-term effects is limited. Patients often receive insufficient treatment that are predominantly given outside the optimal time window for brain plasticity. Post-stroke vocal music listening improves language outcome which is underpinned by neuroplasticity changes within the language network. Vocal music listening provides a complementary rehabilitation strategy which could be safely implemented in the early stages of stroke rehabilitation and seems to specifically target language symptoms and recovering language network.",2021,Analyses of stimulus-specific activation changes showed that the vocal music group exhibited increased activations in the frontal termination points of the left FAT during vocal music listening as compared to the audiobook group from acute to 3-month post-stroke stage.,['acute stroke patients (N=38'],"['vocal music listening', 'daily listening to self-selected vocal music, instrumental music, and audiobooks', 'Vocal music listening']","['brain activity and structural connectivity of the language network', 'strength of the structural connectivity of the left FAT correlated with improved language skills', 'increased activity']","[{'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0474395', 'cui_str': 'Behavior showing increased motor activity'}]",,0.078545,Analyses of stimulus-specific activation changes showed that the vocal music group exhibited increased activations in the frontal termination points of the left FAT during vocal music listening as compared to the audiobook group from acute to 3-month post-stroke stage.,"[{'ForeName': 'Aleksi J', 'Initials': 'AJ', 'LastName': 'Sihvonen', 'Affiliation': 'Cognitive Brain Research Unit, Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland aleksi.sihvonen@helsinki.fi.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Ripollés', 'Affiliation': 'Department of Psychology, New York University, USA.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Leo', 'Affiliation': 'Cognitive Brain Research Unit, Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland.'}, {'ForeName': 'Jani', 'Initials': 'J', 'LastName': 'Saunavaara', 'Affiliation': 'Department of Medical Physics, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Riitta', 'Initials': 'R', 'LastName': 'Parkkola', 'Affiliation': 'Department of Radiology, Turku University Hospital and University of Turku, Finland.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Rodríguez-Fornells', 'Affiliation': 'Department of Cognition, Development and Education Psychology, University of Barcelona, Spain.'}, {'ForeName': 'Seppo', 'Initials': 'S', 'LastName': 'Soinila', 'Affiliation': 'Division of Clinical Neurosciences, Department of Neurology, Turku University Hospital and University of Turku, Finland.'}, {'ForeName': 'Teppo', 'Initials': 'T', 'LastName': 'Särkämö', 'Affiliation': 'Cognitive Brain Research Unit, Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland.'}]",eNeuro,['10.1523/ENEURO.0158-21.2021'] 1303,34391275,The effect of foot massage on the level of consciousness and delirium of intensive care patients: A randomized single-blind controlled trial.,"INTRODUCTION Depressed level of consciousness and delirium are associated with multiple complications in cognitive, perceptual and sensory functions in the patients of the intensive care units. The present study aimed to determine the effect of foot massage by a nurse and patient's family on the level of consciousness and delirium in patients admitted to the intensive care units (ICU). METHODS This was a randomized parallel single-blind controlled trial. Seventy-five ICU were assigned in three groups (massage by a nurse, massage by patient's family and control group) by stratified block randomization method. Both feet were massaged with Swedish massage (10 min) once a day for six days by a nurse or patient's family. Delirium and level of consciousness was measured before, and post-intervention. RESULTS The mean level of consciousness in all the three groups increased significantly one-week post-intervention. However, there was no significant difference in the level of consciousness among the three groups during the study. The frequency of delirium in the massage group by the family was 20% before the intervention, which decreased to 12% after intervention. In the massage group by a nurse and control group, 16% of the samples had delirium before the intervention. After the intervention, the prevalence of delirium was 8% in the massage group by a nurse, and it decreased to 12% in the control group, none of which was statistically significant. CONCLUSION The use of Swedish foot massage did not change the level of consciousness and delirium of patients admitted to the ICU.",2021,The mean level of consciousness in all the three groups increased significantly one-week post-intervention.,"['patients admitted to the intensive care units (ICU', 'patients of the intensive care units', 'Seventy-five ICU', 'intensive care patients', 'patients admitted to the ICU']","['foot massage', 'Swedish massage', 'Swedish foot massage']","['level of consciousness and delirium', 'frequency of delirium', 'mean level of consciousness', 'Delirium and level of consciousness', 'prevalence of delirium', 'level of consciousness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C4319621', 'cui_str': '75'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0038996', 'cui_str': 'Swedish language'}]","[{'cui': 'C0234425', 'cui_str': 'Level of consciousness'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}]",75.0,0.0285282,The mean level of consciousness in all the three groups increased significantly one-week post-intervention.,"[{'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Momeni', 'Affiliation': 'Nursing Research Center, Razi Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran. Electronic address: momeni.ma8@gmail.com.'}, {'ForeName': 'Mansour', 'Initials': 'M', 'LastName': 'Arab', 'Affiliation': 'Faculty of Nursing and Midwifery, Bam University of Medical Sciences, Bam, Iran. Electronic address: marab112004@yahoo.com.'}, {'ForeName': 'Mahlagha', 'Initials': 'M', 'LastName': 'Dehghan', 'Affiliation': 'Nursing Research Center, Kerman University of Medical Sciences, Kerman, Iran. Electronic address: m_dehghan@kmu.ac.ir.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Ahmadinejad', 'Affiliation': 'Kerman University of Medical Sciences, Kerman, Iran. Electronic address: mehdia50@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.008'] 1304,33814126,"Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.","OBJECTIVE To compare ovarian response and reproductive outcomes in oocyte donors undergoing pituitary suppression with medroxyprogesterone acetate (MPA) versus those undergoing conventional treatment with a gonadotropin-releasing hormone (GnRH) antagonist. DESIGN A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes. The reproductive outcomes of the recipients were retrospectively analyzed later. SETTING A university-affiliated private in vitro fertilization center. PATIENT(S) We randomly divided 318 donors into 2 groups in a 1:1 ratio. The oocytes obtained were assigned to 364 recipients. One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm). Transvaginal ultrasound was performed, and serum estradiol, luteinizing hormone, and progesterone levels were recorded during monitoring. The following additional parameters were analyzed: endocrine profile (in follicular fluid), number of metaphase II oocytes, and pregnancy outcome. INTERVENTION(S) The donors included in the study group were stimulated using recombinant follicle-stimulating hormone and MPA at 10 mg/day, simultaneously begun on cycle day 2 or 3. Ovulation was induced using a GnRH agonist when dominant follicles matured. A short protocol with ganirelix at 0.25 mg/day was used for the control group. Oocytes were assigned to the recipients, followed by routine in vitro fertilization procedures in which 1 embryo was usually transferred. MAIN OUTCOME MEASURE(S) The primary outcome measure was the numbers of oocytes and metaphase II oocytes retrieved. The secondary outcomes were the incidence of premature luteinizing hormone surge, serum and follicular fluid hormone profiles, and clinical pregnancy outcomes in the recipient group. RESULT(S) The number of oocytes retrieved was 21.4 ± 11.7 in the MPA group and 21.2 ± 9.2 in the antagonist group (mean difference 0.14; 95% confidence interval -2.233, 2.517). The total dose of recombinant follicle-stimulating hormone, duration of OS, and endocrine profiles of the serum and follicular fluids were comparable in the 2 groups. No early ovulation was observed in either group. No statistically significant differences with respect to implantation rate (68.1% in the MPA group vs. 62% in the antagonist group), clinical pregnancy rate (64.5% in the MPA group vs. 57.8 in the antagonist group), ongoing pregnancy rate (55.4% in the MPA group vs. 48.5% in the antagonist group), live birth rate (55.1% in the MPA group vs. 48.5% in the antagonist group), or cumulative live birth rate (73.8% in the MPA group vs. 70.7% in the antagonist group) were observed between the groups. CONCLUSION(S) The administration of MPA resulted in oocyte retrieval rates, endocrine profiles, viable embryo numbers, and pregnancy outcomes similar to those achieved with the GnRH antagonist. Therefore, MPA can be recommended for OS in oocyte donation because it permits a more patient-friendly approach. CLINICAL TRIAL REGISTRATION NUMBER NCT03300960.",2021,"No statistically significant differences with respect to implantation rate (68.1% in the MPA group vs. 62% in the antagonist group), clinical pregnancy rate (64.5% in the MPA group vs. 57.8 in the antagonist group), ongoing pregnancy rate (55.4% in the MPA group vs. 48.5% in the antagonist group), live birth rate (55.1% in the MPA group vs. 48.5% in the antagonist group), or cumulative live birth rate (73.8% in the MPA group vs. 70.7% in the antagonist group) were observed between the groups. ","['A university-affiliated private in\xa0vitro fertilization center', 'October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes', 'One hundred sixty-one donors', 'oocyte donors undergoing pituitary suppression with']","['gonadotropin-releasing hormone antagonist', 'gonadotropin-releasing hormone (GnRH) antagonist', 'MPA', 'recombinant follicle-stimulating hormone and MPA', 'medroxyprogesterone acetate (MPA', 'Medroxyprogesterone acetate', 'GnRH antagonist']","['incidence of premature luteinizing hormone surge, serum and follicular fluid hormone profiles, and clinical pregnancy outcomes', 'numbers of oocytes and metaphase II oocytes retrieved', 'live birth rate', 'number of oocytes', 'cumulative live birth rate', 'ongoing pregnancy rate', 'oocyte retrieval rates, endocrine profiles, viable embryo numbers, and pregnancy outcomes', 'early ovulation', 'total dose of recombinant follicle-stimulating hormone, duration of OS, and endocrine profiles of the serum and follicular fluids', 'Ovulation', 'clinical pregnancy rate', 'endocrine profile (in follicular fluid), number of metaphase II oocytes, and pregnancy outcome', 'serum estradiol, luteinizing hormone, and progesterone levels', 'implantation rate']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0449803', 'cui_str': 'Number of oocytes'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C3267027', 'cui_str': 'Oocyte donor'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}]","[{'cui': 'C1268855', 'cui_str': 'Gonadotropin releasing hormone receptor antagonist-containing product'}, {'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}, {'cui': 'C0202022', 'cui_str': 'Follicle stimulating hormone measurement'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0016431', 'cui_str': 'Liquor Folliculi'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0449803', 'cui_str': 'Number of oocytes'}, {'cui': 'C1621812', 'cui_str': 'Metaphase'}, {'cui': 'C0029045', 'cui_str': 'Oocyte'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0404268', 'cui_str': 'Oocyte recovery'}, {'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0443348', 'cui_str': 'Viable'}, {'cui': 'C0013935', 'cui_str': 'Embryos'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0029965', 'cui_str': 'Ovulation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0202022', 'cui_str': 'Follicle stimulating hormone measurement'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0949385', 'cui_str': 'Ovarian Stimulation'}, {'cui': 'C0474672', 'cui_str': 'Serum estradiol measurement'}, {'cui': 'C0428409', 'cui_str': 'Progesterone level'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]",,0.417625,"No statistically significant differences with respect to implantation rate (68.1% in the MPA group vs. 62% in the antagonist group), clinical pregnancy rate (64.5% in the MPA group vs. 57.8 in the antagonist group), ongoing pregnancy rate (55.4% in the MPA group vs. 48.5% in the antagonist group), live birth rate (55.1% in the MPA group vs. 48.5% in the antagonist group), or cumulative live birth rate (73.8% in the MPA group vs. 70.7% in the antagonist group) were observed between the groups. ","[{'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Giles', 'Affiliation': 'IVI-RMA, Valencia, Spain; IVI Foundation, Instituto de Investigación Sanitaria Hospital Universitario y Politécnico La Fe, Valencia, Spain. Electronic address: juan.giles@ivirma.com.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Alama', 'Affiliation': 'IVI-RMA, Valencia, Spain; IVI Foundation, Instituto de Investigación Sanitaria Hospital Universitario y Politécnico La Fe, Valencia, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Gamiz', 'Affiliation': 'IVI-RMA, Valencia, Spain; IVI Foundation, Instituto de Investigación Sanitaria Hospital Universitario y Politécnico La Fe, Valencia, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Vidal', 'Affiliation': 'IVI-RMA, Valencia, Spain; IVI Foundation, Instituto de Investigación Sanitaria Hospital Universitario y Politécnico La Fe, Valencia, Spain.'}, {'ForeName': 'Paloma', 'Initials': 'P', 'LastName': 'Badia', 'Affiliation': 'IVI-RMA, Valencia, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Pellicer', 'Affiliation': 'IVI Foundation, Instituto de Investigación Sanitaria Hospital Universitario y Politécnico La Fe, Valencia, Spain; IVI-RMA, Rome, Italy; Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain; Department of Genomic and Systems Reproductive Medicine, IVI-RMA IVI Foundation, Valencia, Spain.'}, {'ForeName': 'Ernesto', 'Initials': 'E', 'LastName': 'Bosch', 'Affiliation': 'IVI-RMA, Valencia, Spain; IVI Foundation, Instituto de Investigación Sanitaria Hospital Universitario y Politécnico La Fe, Valencia, Spain.'}]",Fertility and sterility,['10.1016/j.fertnstert.2021.02.036'] 1305,33814028,Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study.,"Invasive meningococcal disease has high morbidity and mortality, with infants and young children among those at greatest risk. This phase III, open-label, randomised study in toddlers aged 12-23 months evaluated the immunogenicity and safety of meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT), a tetanus toxoid conjugated vaccine against meningococcal serogroups A, C, W and Y, when coadministered with paediatric vaccines (measles, mumps and rubella [MMR]; varicella [V]; 6-in-1 combination vaccine against diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type b [DTaP-IPV-HepB-Hib] and pneumococcal conjugate vaccine [PCV13])(NCT03205371). Immunogenicity to each meningococcal serogroup was assessed by serum bactericidal antibody assay using human complement (hSBA). Vaccine safety profiles were described up to 30 days post-vaccination. A total of 1183 participants were enrolled. The proportion with seroprotection (hSBA ≥1:8) to each meningococcal serogroup at Day 30 was comparable between the MenACYW-TT and MenACYW-TT + MMR + V groups (≥92 and ≥96%, respectively), between the MenACYW-TT and MenACYW-TT + DTaP-IPV-HepB-Hib groups (≥90% for both) and between the MenACYW-TT and MenACYW-TT + PCV13 groups (≥91 and ≥84%, respectively). The safety profiles of MenACYW-TT, and MMR + V, DTaP-IPV-HepB-Hib, and PCV13, with or without MenACYW-TT, were generally comparable. Coadministration of MenACYW-TT with paediatric vaccines in toddlers had no clinically relevant effect on the immunogenicity and safety of any of the vaccines.",2021,,['Toddlers'],"['Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT', 'Paediatric Vaccines']",['Immunogenicity and Safety'],"[{'cui': 'C0682053', 'cui_str': 'Toddler'}]","[{'cui': 'C0127526', 'cui_str': 'Meningococcal polysaccharide vaccine'}, {'cui': 'C0039620', 'cui_str': 'Tetanus vaccine'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0800439,,"[{'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Dhingra', 'Affiliation': 'Global Clinical Sciences, Sanofi Pasteur, Swiftwater, PA, USA.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Namazova-Baranova', 'Affiliation': 'Institute of Pediatrics, Central Clinical Hospital of the Russian Academy of Science, Moscow, Russia.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Arredondo-Garcia', 'Affiliation': 'Instituto Nacional de Pediatría Clinical Research Unit, Mexico City, Mexico.'}, {'ForeName': 'K-H', 'Initials': 'KH', 'LastName': 'Kim', 'Affiliation': ""Department of Pediatrics, Ewha Woman's University College of Medicine, Seoul, South Korea.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Limkittikul', 'Affiliation': 'Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Jantarabenjakul', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Perminova', 'Affiliation': 'City Children Clinical Outpatient Hospital #5, Perm, Russia.'}, {'ForeName': 'I A R', 'Initials': 'IAR', 'LastName': 'Kobashi', 'Affiliation': 'Centro de Investigación Clínica del Pacífico, Guerrero, Mexico.'}, {'ForeName': 'C-W', 'Initials': 'CW', 'LastName': 'Bae', 'Affiliation': 'Kyung Hee University Hospital at Gangdong, Seoul, Korea.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ojeda', 'Affiliation': 'Global Clinical Sciences, Sanofi Pasteur, Mexico City, Mexico.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Global Clinical Sciences, Sanofi Pasteur, Singapore, Singapore.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Chansinghakul', 'Affiliation': 'Global Clinical Sciences, Sanofi Pasteur, Bangkok, Thailand.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': ""B'Chir"", 'Affiliation': ""Global Biostatistical Sciences, Sanofi Pasteur, Marcy l'Etoile, France.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Neveu', 'Affiliation': 'Global Pharmacovigilance, Sanofi Pasteur, Swiftwater, PA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bonaparte', 'Affiliation': 'Global Clinical Immunology, Sanofi Pasteur, Swiftwater, PA, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Jordanov', 'Affiliation': 'Global Clinical Sciences, Sanofi Pasteur, Swiftwater, PA, USA.'}]",Epidemiology and infection,['10.1017/S0950268821000698'] 1306,33783553,"Randomized, placebo-controlled trial of orally administered vitamin K1 for warfarin-associated coagulopathy in Chinese patients with mechanical heart valves.","PURPOSE Warfarin-associated coagulopathy commonly occurs in patients undergoing treatment with this anticoagulant. This trial aimed to determine the efficacy of using low-dose orally administered vitamin K 1 to lower international normalized ratio (INR) values into the target range in a cohort of Chinese patients with mechanical heart valves. METHODS This was a double-blind, placebo-controlled, randomized trial. Chinese patients with mechanical heart valves who were undergoing warfarin treatment and who had INR values from 4.0 to 10.0 without bleeding were the subjects of this study. These patients were randomized into two treatment groups and were orally administered either vitamin K 1 (2.5 mg) or placebo. Warfarin was discontinued in both groups until INR values were ≤ 2.5. INR values on the day following treatment were the primary study outcome, with INR values on the following days and adverse clinical events over a 3-month follow-up serving as secondary study outcomes. RESULTS In total, 80 patients were enrolled in the present study, and 40 patients each were assigned to the placebo and vitamin K1 treatment groups. Patients administered vitamin K 1 exhibited a quick reduction in INR values relative to patients administered placebo (29 of 40 [72.5%] vs. 0 of 44 [0%] patients exhibiting INR values from 1.5-2.5 on the day following treatment, respectively, p = 0.000). Lower bleeding incidence was observed among patients administered vitamin K 1 relative to those administered placebo during follow-up (4 [10%] vs. 12 [30%] patients, respectively, p = 0.045). There were no instances of thromboembolic complications or warfarin resistance in either group. CONCLUSION Low-dose oral vitamin K 1 can be effectively administered to Chinese patients with mechanical heart valves taking warfarin to rapidly reduce elevated INR values.",2021,"Patients administered vitamin K 1 exhibited a quick reduction in INR values relative to patients administered placebo (29 of 40 [72.5%] vs. 0 of 44 [0%] patients exhibiting INR values from 1.5-2.5 on the day following treatment, respectively, p = 0.000).","['Chinese patients with mechanical heart valves who were undergoing warfarin treatment and who had INR values from 4.0 to 10.0 without bleeding were the subjects of this study', 'Chinese patients with mechanical heart valves taking', 'Chinese patients with mechanical heart valves', '80 patients were enrolled in the present study, and 40 patients each were assigned to the', 'patients undergoing treatment with this anticoagulant']","['vitamin K1', 'Warfarin', 'vitamin K', 'placebo', 'placebo and vitamin K1', 'vitamin K 1 (2.5\xa0mg) or placebo', 'warfarin']","['international normalized ratio (INR) values', 'Lower bleeding incidence', 'adverse clinical events', 'INR values', 'thromboembolic complications or warfarin resistance', 'exhibiting INR values', 'INR values relative']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018829', 'cui_str': 'Prosthetic heart'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}]","[{'cui': 'C0031862', 'cui_str': 'Vitamin K 1'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0042878', 'cui_str': 'Vitamin K'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3844011', 'cui_str': '2.5'}]","[{'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0750384', 'cui_str': 'Coumarin Resistance'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0080103', 'cui_str': 'Relative'}]",80.0,0.541619,"Patients administered vitamin K 1 exhibited a quick reduction in INR values relative to patients administered placebo (29 of 40 [72.5%] vs. 0 of 44 [0%] patients exhibiting INR values from 1.5-2.5 on the day following treatment, respectively, p = 0.000).","[{'ForeName': 'Heng', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiovascular Surgery, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Department of Cardiovascular Surgery, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, China.'}, {'ForeName': 'Xue-Lian', 'Initials': 'XL', 'LastName': 'Ao', 'Affiliation': 'Department of Ultrasound, West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Yi-Jun', 'Initials': 'YJ', 'LastName': 'Dong', 'Affiliation': 'Department of Thoracic Neoplasm, West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Dong', 'Affiliation': 'Department of Cardiovascular Surgery, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, China. donglikn199@163.com.'}]",European journal of clinical pharmacology,['10.1007/s00228-021-03127-8'] 1307,33784802,"Effect of intravenous dexamethasone on the duration of postoperative analgesia for popliteal sciatic nerve block: a randomized, double-blind, placebo-controlled study.","BACKGROUND Intravenous (IV) dexamethasone prolongs the duration of a peripheral nerve block; however, there is little available information about its optimal effective dose. This study aimed to evaluate the effects of three different doses of IV dexamethasone on the duration of postoperative analgesia to determine the optimal effective dose for a sciatic nerve block. METHODS Patients scheduled for foot and ankle surgery were randomly assigned to receive normal saline or IV dexamethasone (2.5 mg, 5 mg, or 10 mg). An ultrasound-guided popliteal sciatic nerve block was performed using 0.75% ropivacaine (20 ml) before general anesthesia. The duration of postoperative analgesia was the primary outcome, and pain scores, use of rescue analgesia, onset time, adverse effects, and patient satisfaction were assessed as secondary outcomes. RESULTS Compared with the control group, the postoperative analgesic duration of the sciatic nerve block was prolonged in groups receiving IV dexamethasone 10 mg (P < 0.001), but not in the groups receiving IV dexamethasone 2.5 mg or 5 mg. The use of rescue analgesics was significantly different among the four groups 24 h postoperatively (P = 0.001) and similar thereafter. However, pain scores were not significantly different among the four groups 24 h postoperatively. There were no statistically significant differences in the other secondary outcomes among the four groups. CONCLUSIONS This study demonstrated that compared to the controls, only IV dexamethasone 10 mg increased the duration of postoperative analgesia following a sciatic nerve block for foot and ankle surgery without the occurrence of adverse events.",2021,The use of rescue analgesics was significantly different among the 4 groups 24 h postoperatively (P = 0.004) and similar thereafter.,"['Methods\n\n\nPatients scheduled for foot and ankle surgery', 'popliteal sciatic nerve block']","['dexamethasone', 'intravenous dexamethasone', 'normal saline or IV dexamethasone', 'IV dexamethasone', 'placebo', '\n\n\nIntravenous (IV) dexamethasone', 'Ultrasound-guided popliteal sciatic nerve block was performed using 0.75% ropivacaine']","['postoperative analgesic duration of sciatic nerve block', 'duration of peripheral nerve block', 'pain scores', 'duration of postoperative analgesia', 'pain scores, use of rescue analgesics, block onset time, incidence of postoperative nausea and vomiting, adverse effects, and patient satisfaction']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0188412', 'cui_str': 'Operative procedure on ankle'}, {'cui': 'C0442037', 'cui_str': 'Popliteal'}, {'cui': 'C0394735', 'cui_str': 'Injection of anesthetic agent into sciatic nerve'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0442037', 'cui_str': 'Popliteal'}, {'cui': 'C0394735', 'cui_str': 'Injection of anesthetic agent into sciatic nerve'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C4068882', 'cui_str': '0.75'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0394735', 'cui_str': 'Injection of anesthetic agent into sciatic nerve'}, {'cui': 'C0198807', 'cui_str': 'Peripheral block anesthesia'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0449244', 'cui_str': 'Time of onset'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",,0.418002,The use of rescue analgesics was significantly different among the 4 groups 24 h postoperatively (P = 0.004) and similar thereafter.,"[{'ForeName': 'Byung-Gun', 'Initials': 'BG', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Inha University School of Medicine, Incheon, Korea.'}, {'ForeName': 'Woojoo', 'Initials': 'W', 'LastName': 'Lee', 'Affiliation': 'Department of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, Korea.'}, {'ForeName': 'Jang Ho', 'Initials': 'JH', 'LastName': 'Song', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Inha University School of Medicine, Incheon, Korea.'}, {'ForeName': 'Chunwoo', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Inha University School of Medicine, Incheon, Korea.'}, {'ForeName': 'Gyung A', 'Initials': 'GA', 'LastName': 'Heo', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Inha University School of Medicine, Incheon, Korea.'}, {'ForeName': 'Hongseok', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Inha University School of Medicine, Incheon, Korea.'}]",Korean journal of anesthesiology,['10.4097/kja.20640'] 1308,33238154,A Causal Role for Gastric Rhythm in Human Disgust Avoidance.,"Rotten food, maggots, bodily waste-all elicit disgust in humans. Disgust promotes survival by encouraging avoidance of disease vectors 1 but is also implicated in prejudice toward minority groups; avoidance of environmentally beneficial foods, such as insect protein; and maladaptive avoidance behavior in neuropsychiatric conditions. 2-5 Unlike fear, pathological disgust is not improved substantially by exposure therapy clinically, 6 nor in experimental work does behavioral avoidance of disgusting images habituate following prolonged exposure. 7 , 8 Under normal physiological conditions, perception of disgusting stimuli disrupts myoelectrical rhythms in the stomach, 9-13 inducing gastric dysrhythmias that correlate with neural signatures of disgust. 11 However, the causal role of gastric rhythm in disgust avoidance is unknown. We manipulated gastric rhythm using domperidone, a peripheral dopamine D2/D3 antagonist and common anti-emetic, at a dose (10 mg) that acts to convert gastric dysrhythmias to normal rhythms. 9 In a preregistered, randomized, double-blind, placebo-controlled crossover design in 25 healthy volunteers (aged 18-25), we measured the effects of domperidone on core disgust avoidance, using eye tracking to measure implicit (oculomotor) avoidance of disgusting images (feces) before and after an ""exposure"" intervention (monetary reinforcement for looking at disgusting images). 7 , 8 We find that domperidone significantly reduces oculomotor disgust avoidance following incentivized exposure. This suggests that domperidone may weaken the ""immunity"" of disgust to habituation, putatively by reducing gastric dysrhythmias during incentivized engagement with disgusting stimuli. This indicates a causal role for disgust-related visceral changes in disgust avoidance, supporting the hypothesis that physiological homeostasis contributes to emotional experience.",2021,We find that domperidone significantly reduces oculomotor disgust avoidance following incentivized exposure.,"['11', '25 healthy volunteers (aged 18-25']","['eye tracking to measure implicit (oculomotor) avoidance of disgusting images (feces) before and after an ""exposure"" intervention (monetary reinforcement for looking at disgusting images', 'placebo', 'domperidone']",['oculomotor disgust avoidance'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0450335', 'cui_str': '18/25'}]","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0683283', 'cui_str': 'Disgust'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0035007', 'cui_str': 'Psychological Reinforcement'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013015', 'cui_str': 'Domperidone'}]","[{'cui': 'C0683283', 'cui_str': 'Disgust'}]",25.0,0.0848097,We find that domperidone significantly reduces oculomotor disgust avoidance following incentivized exposure.,"[{'ForeName': 'Camilla L', 'Initials': 'CL', 'LastName': 'Nord', 'Affiliation': 'Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, Cambridge CB2 7EF, UK. Electronic address: camilla.nord@mrc-cbu.cam.ac.uk.'}, {'ForeName': 'Edwin S', 'Initials': 'ES', 'LastName': 'Dalmaijer', 'Affiliation': 'Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, Cambridge CB2 7EF, UK. Electronic address: edwin.dalmaijer@mrc-cbu.cam.ac.uk.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Armstrong', 'Affiliation': 'Department of Psychology, Whitman College, 345 Boyer Avenue, Walla Walla, WA 99362, USA.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Baker', 'Affiliation': 'Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, Cambridge CB2 7EF, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Dalgleish', 'Affiliation': 'Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, Cambridge CB2 7EF, UK; Cambridgeshire and Peterborough NHS Foundation Trust.'}]",Current biology : CB,['10.1016/j.cub.2020.10.087'] 1309,33243443,"A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.","OBJECTIVE This randomized open-label phase II study evaluated the safety and clinical activity of EP-100 plus weekly paclitaxel in patients with recurrent ovarian cancer expressing positive LHRH receptor. METHODS In a limited ""run-in"" dose escalation phase for EP-100, six patients were treated with ascending dose levels (13 mg/m 2 , 20 mg/m 2 , 30 mg/m 2 ). In the randomized phase, patients received weekly paclitaxel (80 mg/m 2 intravenously) plus twice weekly EP-100 (30 mg/m 2 intravenously; combination arm) or weekly paclitaxel alone (80 mg/m 2 intravenously; paclitaxel arm). The primary study endpoint was overall response rate (ORR). RESULTS Forty-four patients were then randomized to either the experimental combination arm (n = 23) or the standard of care paclitaxel monotherapy arm (n = 21). The ORR was 35% (95%CI 16%-57%) for the combination arm and 33% (95% CI 15%-57%) for the paclitaxel arm. An interesting observation from an unplanned analysis was that a subset of patients with target liver lesions showed a greater overall response rate to the combination (69%) compared to paclitaxel alone (16%). The frequency of treatment-related grade 3-4 adverse events was similar between treatment arms: 48% vs 43% for the combination and paclitaxel arms, respectively. CONCLUSIONS ORR in the EP-100 combination arm was similar to that in the group treated with paclitaxel alone; however, a subset of patients with liver metastases appeared to benefit from the combination. The addition of EP-100 did not appear to augment the adverse event profile of paclitaxel and was well tolerated.",2021,"The frequency of treatment-related grade 3-4 adverse events was similar between treatment arms: 48% vs 43% for the combination and paclitaxel arms, respectively. ","['patients with recurrent ovarian cancer expressing positive LHRH receptor', 'Forty-four patients', 'refractory or recurrent ovarian cancer']","['paclitaxel', 'paclitaxel alone', 'standard of care paclitaxel monotherapy', 'paclitaxel (80\xa0mg/m 2 intravenously) plus twice weekly EP-100', 'paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone', 'EP-100 plus weekly paclitaxel']","['overall response rate', 'overall response rate (ORR', 'ORR', 'tolerated', 'frequency of treatment-related grade 3-4 adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278689', 'cui_str': 'Recurrent ovarian cancer'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0034811', 'cui_str': 'Gonadoliberin receptor'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0034811', 'cui_str': 'Gonadoliberin receptor'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",6.0,0.109529,"The frequency of treatment-related grade 3-4 adverse events was similar between treatment arms: 48% vs 43% for the combination and paclitaxel arms, respectively. ","[{'ForeName': 'Anca', 'Initials': 'A', 'LastName': 'Chelariu-Raicu', 'Affiliation': 'Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Alpa', 'Initials': 'A', 'LastName': 'Nick', 'Affiliation': 'Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Urban', 'Affiliation': 'Department of Gynecologic Oncology, University of Washington Medical Center and Seattle Cancer Care Alliance, Seattle, WA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Gordinier', 'Affiliation': 'Department of Gynecologic Oncology, Norton Cancer Institute, Louisville, KY, USA.'}, {'ForeName': 'Carola', 'Initials': 'C', 'LastName': 'Leuschner', 'Affiliation': 'Esperance Pharmaceuticals, Inc., Houston, TX, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Bavisotto', 'Affiliation': 'Esperance Pharmaceuticals, Inc., Houston, TX, USA.'}, {'ForeName': 'Graziela Zibetti Dal', 'Initials': 'GZD', 'LastName': 'Molin', 'Affiliation': 'Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'Whisnant', 'Affiliation': 'Esperance Pharmaceuticals, Inc., Houston, TX, USA.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Coleman', 'Affiliation': 'Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany. Electronic address: robert.coleman@usoncology.com.'}]",Gynecologic oncology,['10.1016/j.ygyno.2020.11.013'] 1310,33246494,Assessing the effect of hyperbaric oxygen therapy in breast cancer patients with late radiation toxicity (HONEY trial): a trial protocol using a trial within a cohort design.,"BACKGROUND Breast cancer treatment with radiotherapy can induce late radiation toxicity, characterized by pain, fibrosis, edema, impaired arm mobility, and poor cosmetic outcome. Hyperbaric oxygen therapy (HBOT) has been proposed as treatment for late radiation toxicity; however, high-level evidence of effectiveness is lacking. As HBOT is standard treatment and reimbursed by insurers, performing classic randomized controlled trials is difficult. The ""Hyperbaric OxygeN therapy on brEast cancer patients with late radiation toxicity"" (HONEY) trial aims to evaluate the effectiveness of HBOT on late radiation toxicity in breast cancer patients using the trial within cohorts (TwiCs) design. METHODS The HONEY trial will be conducted within the Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaluation (UMBRELLA). Within UMBRELLA, breast cancer patients referred for radiotherapy to the University Medical Centre Utrecht are eligible for inclusion. Patients consent to collection of clinical data and patient-reported outcomes and provide broad consent for randomization into future intervention studies. Patients who meet the HONEY in- and exclusion criteria (participation ≥ 12 months in UMBRELLA, moderate/severe breast or chest wall pain, completed primary breast cancer treatment except hormonal treatment, no prior treatment with HBOT, no contraindications for HBOT, no clinical signs of metastatic or recurrent disease) will be randomized to HBOT or control group on a 2:1 ratio (n = 120). Patients in the control group will not be informed about participation in the trial. Patients in the intervention arm will undergo 30-40 HBOT treatment sessions in a high pressure chamber (2.4 atmospheres absolute) where they inhale 100% oxygen through a mask. Cohort outcome measures (i.e., physical outcomes, quality of life, fatigue, and cosmetic satisfaction) of the HBOT group will be compared to the control group at 3 months follow-up. DISCUSSION This pragmatic trial within the UMBELLA cohort was designed to evaluate the effectiveness of HBOT on late radiation toxicity in breast cancer patients using the TwiCs design. Use of the TwiCs design is expected to address issues encountered in classic randomized controlled trials, such as contamination (i.e., HBOT in the control group) and disappointment bias, and generate information about acceptability of HBOT. TRIAL REGISTRATION ClinicalTrials.gov. NCT04193722 . Registered on 10 December 2019.",2020,This pragmatic trial within the UMBELLA cohort was designed to evaluate the effectiveness of HBOT on late radiation toxicity in breast cancer patients using the TwiCs design.,"['breast cancer patients referred for radiotherapy to the University Medical Centre Utrecht are eligible for inclusion', 'breast cancer patients using the trial within cohorts (TwiCs) design', 'breast cancer patients with late radiation toxicity (HONEY trial', 'Patients who meet the HONEY in- and exclusion criteria (participation ≥\u200912\u2009months in UMBRELLA, moderate/severe breast or chest wall pain, completed primary breast cancer treatment except hormonal treatment, no prior treatment with HBOT, no contraindications for HBOT, no clinical signs of metastatic or recurrent disease', 'brEast cancer patients with late radiation toxicity"" (HONEY', 'breast cancer patients using the TwiCs design']","['radiotherapy', 'Hyperbaric oxygen therapy (HBOT', 'Hyperbaric OxygeN therapy', 'HBOT', 'hyperbaric oxygen therapy']","['late radiation toxicity', 'physical outcomes, quality of life, fatigue, and cosmetic satisfaction']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0420378', 'cui_str': 'Referred for radiotherapy'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C1510432', 'cui_str': 'Radiation sickness'}, {'cui': 'C0019906', 'cui_str': 'Honey'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0008035', 'cui_str': 'Chest wall pain'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0277556', 'cui_str': 'Recurrent disease'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}]","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C1510432', 'cui_str': 'Radiation sickness'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0780113,This pragmatic trial within the UMBELLA cohort was designed to evaluate the effectiveness of HBOT on late radiation toxicity in breast cancer patients using the TwiCs design.,"[{'ForeName': 'M C T', 'Initials': 'MCT', 'LastName': 'Batenburg', 'Affiliation': 'Department of Radiation Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CZ, Utrecht, the Netherlands. m.c.t.batenburg-3@umcutrecht.nl.'}, {'ForeName': 'H J G D', 'Initials': 'HJGD', 'LastName': 'van den Bongard', 'Affiliation': 'Department of Radiation Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CZ, Utrecht, the Netherlands.'}, {'ForeName': 'C E', 'Initials': 'CE', 'LastName': 'Kleynen', 'Affiliation': 'Department of Radiation Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CZ, Utrecht, the Netherlands.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Maarse', 'Affiliation': 'Department of Plastic, Reconstructive and Hand Surgery, University Medical Centre Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Witkamp', 'Affiliation': 'Department of Surgery, University Medical Centre Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ernst', 'Affiliation': 'Department of Surgery, Alexander Monro Ziekenhuis, Bilthoven, the Netherlands.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Doeksen', 'Affiliation': 'Department of Surgery, St. Antonius Ziekenhuis, Nieuwegein, the Netherlands.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'van Dalen', 'Affiliation': 'Department of Surgery, Diakonessenhuis, Utrecht, the Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Sier', 'Affiliation': 'Department of Surgery, St. Antonius Ziekenhuis, Nieuwegein, the Netherlands.'}, {'ForeName': 'E J P', 'Initials': 'EJP', 'LastName': 'Schoenmaeckers', 'Affiliation': 'Department of Surgery, Meander Medisch Centrum, Amersfoort, the Netherlands.'}, {'ForeName': 'I O', 'Initials': 'IO', 'LastName': 'Baas', 'Affiliation': 'Department of Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'H M', 'Initials': 'HM', 'LastName': 'Verkooijen', 'Affiliation': 'Imaging Division, University Medical Centre Utrecht, Utrecht, the Netherlands.'}]",Trials,['10.1186/s13063-020-04869-z'] 1311,33249498,Switching to Progressively Reduced Nicotine Content Cigarettes in Smokers With Low Socioeconomic Status: A Double-Blind Randomized Clinical Trial.,"INTRODUCTION The Food and Drug Administration issued an advanced notice of proposed rulemaking for setting a product standard for nicotine levels in cigarettes, with an emphasis on minimally or non-addicting very low nicotine content (VLNC). METHODS A 33 week, two-arm, double-blind randomized trial conducted in Hershey, Pennsylvania, USA and Washington, DC, USA included adult daily cigarette smokers (≥5 cigarettes per day) with less than a college degree, and who had no plans to quit within the next six months. Participants were randomized to either reduced nicotine content (RNC) study cigarettes tapered every three weeks to a final VLNC (0.2 mg/cigarette) for six weeks or to usual nicotine content (UNC) study cigarettes (11.6 mg/cigarette). Outcomes included acceptability of study cigarettes measured by attrition (primary outcome), compliance, reduction in cigarette dependence and tobacco biomarkers, and post-intervention cessation. RESULTS The RNC (n = 122) versus UNC (n = 123) group had higher attrition (adjusted Hazard Ratio 3.4; 95% confidence interval [CI] 1.99 to 5.81). At the end of the intervention, cotinine levels were 50% lower in the RNC group (mean group difference -137 ng/mL; 95% CI -172, -102). The RNC group smoked fewer CPD (-4.1; 95% CI -6.44, -1.75) and had lower carbon monoxide levels (-4.0 ppm; 95% CI -7.7, -0.4). Forty seven percent (29/62) of the RNC group were biochemically-confirmed compliant with smoking VLNC cigarettes (mean cotinine = 8.9 ng/ml). At three month follow-up, only compliant VLNC smokers quit with an assisted quit attempt (N = 6/22, 27%). CONCLUSIONS This study supports a VLNC standard in cigarettes. IMPLICATIONS Differential dropout and noncompliance indicate some smokers had difficulty transitioning to cigarettes with reduced nicotine. These smokers will benefit from supplemental nicotine in medicinal or noncombustible tobacco products if a nicotine reduction standard is established. Other smokers successfully transitioned to very low nicotine content cigarettes exclusively and substantially reduced their exposure to nicotine.",2021,The RNC group smoked fewer CPD,"['A 33-week, two-arm, double-blind randomized trial conducted in Hershey, Pennsylvania, USA and Washington, DC, USA included adult daily cigarette smokers (≥5 cigarettes per day) with less than a college degree, and who had no plans to quit within the next 6 months', 'Forty seven percent (29/62) of the RNC group were biochemically-confirmed compliant with smoking VLNC cigarettes ', 'n= 122) vs. UNC (n=123) group', 'Smokers with Low Socioeconomic Status']","['Reduced Nicotine Content (RNC) study cigarettes tapered every 3 weeks to a final VLNC (0.2\xa0mg/cigarette) for six weeks or to Usual Nicotine Content (UNC) study cigarettes', 'Nicotine Content Cigarettes', 'RNC', 'CPD']","['cotinine levels', 'acceptability of study cigarettes measured by attrition (primary outcome), compliance, reduction in cigarette dependence and tobacco biomarkers, and post-intervention cessation', 'lower carbon monoxide levels', 'higher attrition']","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0566588', 'cui_str': 'Compliant'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0442811', 'cui_str': 'Very low'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0441640', 'cui_str': 'Tapering - action'}, {'cui': 'C0585333', 'cui_str': 'Triweekly'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0442811', 'cui_str': 'Very low'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0055816', 'cui_str': 'citrate phosphate dextrose'}]","[{'cui': 'C0010194', 'cui_str': 'Cotinine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0205250', 'cui_str': 'High'}]",,0.187935,The RNC group smoked fewer CPD,"[{'ForeName': 'Nicolle M', 'Initials': 'NM', 'LastName': 'Krebs', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Junjia', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Wasserman', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Kuprewicz', 'Affiliation': 'Department of Psychiatry, Georgetown University, Washington, DC.'}, {'ForeName': 'Diane J', 'Initials': 'DJ', 'LastName': 'Martinez', 'Affiliation': 'Public Health Division, Arlington County Department of Human Services, Arlington, VA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Veldheer', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Livelsberger', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Modesto', 'Affiliation': 'Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Reinhart', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Trushin', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Samantha M', 'Initials': 'SM', 'LastName': 'Reilly', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Liao', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Alyse', 'Initials': 'A', 'LastName': 'Fazzi', 'Affiliation': 'Department of Pharmacy, Investigational Drug Service Pharmacy, Penn State Health, Hershey, PA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Bascom', 'Affiliation': 'Department of Medicine, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Richie', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Foulds', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Horn', 'Affiliation': 'Department of Population Health Sciences, Virginia Tech Carilion Research Institute, Roanoke, VA.'}, {'ForeName': 'Joshua E', 'Initials': 'JE', 'LastName': 'Muscat', 'Affiliation': 'Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, PA.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa247'] 1312,33248978,Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease: PICCOLETO II Randomized Clinical Trial.,"OBJECTIVES This study sought to compare the performance of a novel drug-coated balloon (DCB) (Elutax SV, Aachen Resonance, Germany), with an everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California) in patients with de novo lesions. BACKGROUND Small vessel coronary artery disease (SVD) represents one of the most attractive fields of application for DCB. To date, several devices have been compared with drug-eluting stents in this setting, with different outcomes. METHODS The PICCOLETO II (Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment) trial was an international, investigator-driven, multicenter, open-label, prospective randomized controlled trial where patients with de novo SVD lesions were randomized to DCB or EES. Primary study endpoint was in-lesion late lumen loss (LLL) at 6 months (independent core laboratory), with the noninferiority between the 2 arms hypothesized. Secondary endpoints were minimal lumen diameter, percent diameter stenosis at angiographic follow-up, and the occurrence of major adverse cardiac events at 12 months. RESULTS Between May 2015 and May 2018, a total of 232 patients were enrolled at 5 centers. After a median of 189 (interquartile range: 160 to 202) days, in-lesion LLL was significantly lower in the DCB group (0.04 vs. 0.17 mm; p = 0.001 for noninferiority; p = 0.03 for superiority). Percent diameter stenosis and minimal lumen diameter were not significantly different. At 12-month clinical follow-up, major adverse cardiac events occurred in 7.5% of the DES group and in 5.6% of the DCB group (p = 0.55). There was a numerically higher incidence of spontaneous myocardial infarction (4.7% vs. 1.9%; p = 0.23) and vessel thrombosis (1.8% vs. 0%; p = 0.15) in the DES arm. CONCLUSIONS In this multicenter randomized clinical trial in patients with de novo SVD lesions, a new-generation DCB was found superior to EES in terms of LLL as the angiographic pattern and comparable in terms of clinical outcome. (Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment [PICCOLETO II]; NCT03899818).",2020,"At 12-month clinical follow-up, major adverse cardiac events occurred in 7.5% of the DES group and in 5.6% of the DCB group (p = 0.55).","['Small Coronary Vessel Disease Treatment', 'patients with de novo lesions', 'patients with de novo SVD lesions', 'Small Coronary Vessel Disease', 'Between May 2015 and May 2018, a total of 232 patients were enrolled at 5 centers']","['DCB', 'DES', 'DCB or EES', 'novel drug-coated balloon (DCB) (Elutax SV, Aachen Resonance, Germany), with an everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California', 'Drug-Coated Balloon Versus Drug-Eluting Stent']","['Percent diameter stenosis and minimal lumen diameter', 'vessel thrombosis', 'minimal lumen diameter, percent diameter stenosis at angiographic follow-up, and the occurrence of major adverse cardiac events', 'adverse cardiac events', 'lesion LLL', 'spontaneous myocardial infarction', 'lesion late lumen loss (LLL']","[{'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0010075', 'cui_str': 'Coronary Vessels'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0225988', 'cui_str': 'Structure of small blood vessel (organ)'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0011702', 'cui_str': '4-(4-Amino-4-Carboxybutyl)-1-(5-Amino-5-Carboxypentyl)-3,5-bis(3-Amino-3-Carboxypropyl)pyridinium'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0231881', 'cui_str': 'Resonance'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0524461', 'cui_str': 'Structure of lumen of body system'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}]",232.0,0.123235,"At 12-month clinical follow-up, major adverse cardiac events occurred in 7.5% of the DES group and in 5.6% of the DCB group (p = 0.55).","[{'ForeName': 'Bernardo', 'Initials': 'B', 'LastName': 'Cortese', 'Affiliation': 'Cardiovascular Research Team, San Carlo Clinic, Milano, Italy. Electronic address: bcortese@gmail.com.'}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Di Palma', 'Affiliation': 'Cardiovascular Research Team, San Carlo Clinic, Milano, Italy.'}, {'ForeName': 'Marcos Garcia', 'Initials': 'MG', 'LastName': 'Guimaraes', 'Affiliation': 'Cardiology Department, Hospital de la Princesa, Madrid, Spain.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Piraino', 'Affiliation': 'Interventional Cardiology, Giaccone Hospital, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Pedro Silva', 'Initials': 'PS', 'LastName': 'Orrego', 'Affiliation': 'Interventional Cardiology, ASST Fatebenefratelli-Sacco, Milano, Italy.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Buccheri', 'Affiliation': 'Interventional Cardiology, San Giovanni di Dio Hospital, Trapani, Italy.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Rivero', 'Affiliation': 'Cardiology Department, Hospital de la Princesa, Madrid, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Perotto', 'Affiliation': 'Interventional Cardiology, ASST Fatebenefratelli-Sacco, Milano, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Zambelli', 'Affiliation': 'Interventional Cardiology, Giaccone Hospital, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Alfonso', 'Affiliation': 'Cardiology Department, Hospital de la Princesa, Madrid, Spain.'}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2020.08.035'] 1313,33252379,"Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.","BACKGROUND Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs. METHODS We carried out a 48-week, randomized, controlled, open-label non-inferiority trial at 12 sites in China. Adults on the World Health Organization (WHO)-recommended first-line treatment for >6 months with a plasma viral load >1000 copies/mL were enrolled and randomly assigned (1:1) to receive albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or the WHO-recommended second-line treatment (NRTI group). The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 weeks. Non-inferiority was prespecified with a margin of 12%. RESULTS At the time of analysis, week 24 data were available for 83 and 92 patients, and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups, respectively. At 48 weeks, 80.4% of patients in the ABT group and 66.0% of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL, meeting the criteria for non-inferiority. For the per-protocol population, the superiority of albuvirtide over NRTI was demonstrated. The frequency of grade 3 to 4 adverse events was similar in the two groups; the most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration. Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT group. CONCLUSIONS The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug. This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02369965; https://www.clinicaltrials.gov.Chinese Clinical Trial Registry No. ChiCTR-TRC-14004276; http://www.chictr.org.cn/enindex.aspx.",2020,"The frequency of grade 3 to 4 adverse events was similar in the two groups; the most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration.","['patients with first-line treatment failure', 'HIV-1-infected adults already treated with antiretroviral drugs', 'Adults on the World Health Organization (WHO)-recommended first-line treatment for >6 months with a plasma viral load >1000 copies/mL', 'antiretroviral-experienced adults with human immunodeficiency virus-1', '12 sites in China']","['ritonavir-boosted lopinavir', 'tenofovir disoproxil fumarate', 'albuvirtide plus lopinavir-ritonavir', 'long-acting fusion inhibitor albuvirtide', 'albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or the WHO-recommended second-line treatment (NRTI group']","['safety and efficacy', 'diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration', 'Efficacy and safety', 'proportion of patients with a plasma viral load', 'frequency of grade 3 to 4 adverse events', 'Renal function', 'HIV-1 RNA levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0599685', 'cui_str': 'Antiretroviral-containing product'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C3493164', 'cui_str': 'albuvirtide'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0939237', 'cui_str': 'lopinavir and ritonavir'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C1275666', 'cui_str': 'Fusion inhibitor'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}, {'cui': 'C0045246', 'cui_str': ""2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid""}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C1710038', 'cui_str': 'Second line treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0369499', 'cui_str': 'Human immunodeficiency virus 1 RNA'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.193702,"The frequency of grade 3 to 4 adverse events was similar in the two groups; the most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration.","[{'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Su', 'Affiliation': 'Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.'}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Yao', 'Affiliation': 'Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China.'}, {'ForeName': 'Qing-Xia', 'Initials': 'QX', 'LastName': 'Zhao', 'Affiliation': 'Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan 450061, China.'}, {'ForeName': 'Wei-Ping', 'Initials': 'WP', 'LastName': 'Cai', 'Affiliation': ""Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China.""}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Institute of HIV/AIDS, The First Hospital of Changsha, Changsha, Hunan 410005, China.'}, {'ForeName': 'Hong-Zhou', 'Initials': 'HZ', 'LastName': 'Lu', 'Affiliation': 'Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Yuan-Yuan', 'Initials': 'YY', 'LastName': 'Chen', 'Affiliation': 'Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan 450061, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ""Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China.""}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': ""Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China.""}, {'ForeName': 'Yu-Huang', 'Initials': 'YH', 'LastName': 'Zheng', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.'}, {'ForeName': 'Ling-Hua', 'Initials': 'LH', 'LastName': 'Li', 'Affiliation': ""Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China.""}, {'ForeName': 'Jin-Feng', 'Initials': 'JF', 'LastName': 'Chen', 'Affiliation': ""Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China.""}, {'ForeName': 'Jian-Hua', 'Initials': 'JH', 'LastName': 'Yu', 'Affiliation': 'Department of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang 310023, China.'}, {'ForeName': 'Biao', 'Initials': 'B', 'LastName': 'Zhu', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310003, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'National Clinical Research Center for Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China.'}, {'ForeName': 'Yong-Tao', 'Initials': 'YT', 'LastName': 'Sun', 'Affiliation': ""Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, China.""}, {'ForeName': 'Wen-Hui', 'Initials': 'WH', 'LastName': 'Lun', 'Affiliation': 'Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Xia', 'Affiliation': 'Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.'}, {'ForeName': 'Li-Jun', 'Initials': 'LJ', 'LastName': 'Sun', 'Affiliation': 'Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.'}, {'ForeName': 'Li-Li', 'Initials': 'LL', 'LastName': 'Dai', 'Affiliation': 'Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.'}, {'ForeName': 'Tai-Yi', 'Initials': 'TY', 'LastName': 'Jiang', 'Affiliation': 'Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.'}, {'ForeName': 'Mei-Xia', 'Initials': 'MX', 'LastName': 'Wang', 'Affiliation': 'Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.'}, {'ForeName': 'Qing-Shan', 'Initials': 'QS', 'LastName': 'Zheng', 'Affiliation': 'Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.'}, {'ForeName': 'Hai-Yan', 'Initials': 'HY', 'LastName': 'Peng', 'Affiliation': 'Beijing Co-CRO Medical Development Co., Ltd., Beijing 100711, China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Beijing Co-CRO Medical Development Co., Ltd., Beijing 100711, China.'}, {'ForeName': 'Rong-Jian', 'Initials': 'RJ', 'LastName': 'Lu', 'Affiliation': 'Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China.'}, {'ForeName': 'Jian-Hua', 'Initials': 'JH', 'LastName': 'Hu', 'Affiliation': 'Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Xing', 'Affiliation': 'State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.'}, {'ForeName': 'Yi-Ming', 'Initials': 'YM', 'LastName': 'Shao', 'Affiliation': 'State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Xie', 'Affiliation': 'Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China.'}, {'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.'}, {'ForeName': 'Fu-Jie', 'Initials': 'FJ', 'LastName': 'Zhang', 'Affiliation': 'Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Chinese medical journal,['10.1097/CM9.0000000000001273'] 1314,33257497,New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.,"OBJECTIVES American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) is a composite endpoint to assess the likelihood of improvement in diffuse systemic sclerosis. ACR-CRISS is a weighted score and includes five core set measures: modified Rodnan skin score, FVC% predicted, health assessment questionnaire-disability index, and patient and clinician global assessments. METHODS We analysed core set measures from 354 participants who participated in three placebo-controlled trials. We generated 10 development datasets, randomly selected from 2/3 of the participants, stratified by study and treatment group. The remaining participants (1/3 of the participants) formed the validation sets. Risk differences (RDs) between active and placebo treatments were calculated by averaging over the replicate datasets; bootstrap 95% CIs for the RDs to estimate the magnitude of treatment effects. RESULTS In the development sets (n=237), the proportion of participants in the active group had statistically higher improvement in >1 of 5 core set measures versus the placebo group. For example, the proportion who improved by ≥20% in ≥3 core set measures was 49.4% in the active versus338.9% in the placebo; RD: 10.5%, 95% CI4.9 % to 16.1%. In the validation sets (n=117), the proportion who improved by ≥20% in ≥3 core set measures was 50.3% in the active versus35.63% in the placebo (RD:114.8%, 95% CI 3.1% to225.7%). Similar trends were seen with larger percentage cut-offs. CONCLUSION Revised CRISS, as assessed by the proportion of participants who improved by a certain percentage in ≥3 of 5 core set measures, is a potential new composite outcome measure.",2020,"In the development sets (n=237), the proportion of participants in the active group had statistically higher improvement in >1 of 5 core set measures versus the placebo group.","['354 participants who participated in three placebo-controlled trials', 'early diffuse cutaneous systemic sclerosis', 'American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS']",['placebo'],"['modified Rodnan skin score, FVC% predicted, health assessment questionnaire-disability index, and patient and clinician global assessments']","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1258104', 'cui_str': 'Progressive systemic sclerosis'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0036421', 'cui_str': 'Systemic sclerosis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C4728203', 'cui_str': 'Modified Rodnan skin score'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",354.0,0.173049,"In the development sets (n=237), the proportion of participants in the active group had statistically higher improvement in >1 of 5 core set measures versus the placebo group.","[{'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Khanna', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA khannad@med.umich.edu.'}, {'ForeName': 'Suiyuan', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Celia J F', 'Initials': 'CJF', 'LastName': 'Lin', 'Affiliation': 'Genentech Inc, South San Francisco, California, USA.'}, {'ForeName': 'Cathie', 'Initials': 'C', 'LastName': 'Spino', 'Affiliation': 'Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.'}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2020-219100'] 1315,33252964,Alcohol-involved sexual aggression: Emotion regulation as a mechanism of behavior change.,"OBJECTIVE Sexual aggression remains a significant public health problem, with the majority of sexual assaults involving alcohol. Founded upon an experimental medicine approach to behavior change, the current study used a proximal change experiment to target and test emotion regulation (ER) as a mechanism underlying alcohol-involved sexual aggression. METHOD Heavy episodic drinking men aged 21-30 with a sexual assault perpetration history (N = 209) were randomly assigned to a brief, online, ER-focused cognitive restructuring or mindfulness intervention or to control. Intervention effects were evaluated during sober and intoxicated states through laboratory-based alcohol administration (target BrAC = .08%). Intoxicated and sober participants completed a proximal change protocol that included implementing ER skills during a sexual aggression analogue that assessed relevant emotions and intentions. RESULTS Path analysis demonstrated that relative to control, the cognitive restructuring intervention improved emotional modulation and emotional clarity, resulting in lower sexual arousal and anger, respectively, followed by decreased sexual coercion intentions. The mindfulness intervention yielded mixed results, predicting decreased sexual aggression intentions compared to control but also predicting stronger coercive tactic intentions in intoxicated men with more severe sexual aggression histories. Both interventions improved emotional acceptance relative to control, but only for sober men. CONCLUSIONS Overall, the current study demonstrated that ER-focused interventions improved proximal ER skills associated with reduced sexual aggression intentions, signifying ER as an important mechanism for changing sexually aggressive behavior. Because intervention efficacy varied by intoxication state, further research is needed to assess the effectiveness of ER interventions targeting real-world alcohol-involved sexual aggression. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"The mindfulness intervention yielded mixed results, predicting decreased sexual aggression intentions compared to control but also predicting stronger coercive tactic intentions in intoxicated men with more severe sexual aggression histories.",['Heavy episodic drinking men aged 21-30 with a sexual assault perpetration history (N = 209'],"['online, ER-focused cognitive restructuring or mindfulness intervention or to control']","['sexual coercion intentions', 'sexual aggression intentions', 'emotional acceptance', 'proximal ER skills', 'emotional modulation and emotional clarity, resulting in lower sexual arousal and anger']","[{'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0237236', 'cui_str': 'Sexual assault'}, {'cui': 'C0019664', 'cui_str': 'History'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0150173', 'cui_str': 'Cognitive restructuring'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0009236', 'cui_str': 'Coercion'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0233953', 'cui_str': 'Sexual aggression'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0486588', 'cui_str': 'Clarity (property)'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0233972', 'cui_str': 'Sexual excitation'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}]",209.0,0.0311135,"The mindfulness intervention yielded mixed results, predicting decreased sexual aggression intentions compared to control but also predicting stronger coercive tactic intentions in intoxicated men with more severe sexual aggression histories.","[{'ForeName': 'Kelly Cue', 'Initials': 'KC', 'LastName': 'Davis', 'Affiliation': 'Edson College of Nursing and Health Innovation, Arizona State University.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Neilson', 'Affiliation': 'Department of Psychology, Morehead State University.'}, {'ForeName': 'Mitchell', 'Initials': 'M', 'LastName': 'Kirwan', 'Affiliation': 'Edson College of Nursing and Health Innovation, Arizona State University.'}, {'ForeName': 'Nolan', 'Initials': 'N', 'LastName': 'Eldridge', 'Affiliation': 'Edson College of Nursing and Health Innovation, Arizona State University.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'George', 'Affiliation': 'Department of Psychology, University of Washington.'}, {'ForeName': 'Cynthia A', 'Initials': 'CA', 'LastName': 'Stappenbeck', 'Affiliation': 'Department of Psychology, Georgia State University.'}]","Health psychology : official journal of the Division of Health Psychology, American Psychological Association",['10.1037/hea0001048'] 1316,34122679,Nomogram for Predicting the Relationship between the Extent of Visceral Pleural Invasion and Survival in Non-Small-Cell Lung Cancer.,"Objective Although visceral pleural invasion (VPI) has already been incorporated into the TNM staging system, few studies have been conducted to evaluate the prognostic value of the extent of VPI for the survival of non-small-cell lung cancer (NSCLC) patients. Thus, we utilized the Surveillance, Epidemiology, and End Results (SEER) database to assess the correlation between the extent of VPI and survival in NSCLC. Methods We identified and incorporated the extent of VPI to build a prognostic nomogram in this study. Patients in the SEER database diagnosed with NSCLC ( n  = 87,045) from 2010 to 2015 were further analyzed and randomly assigned into either the training group ( n  = 60,933) or validation group ( n  = 26,112). Clinical variables were calculated by means of multivariate Cox regressions and incorporated into the predictive model. Subsequently, the accuracy and discrimination of nomogram were further assessed through the concordance index (C-index), calibration curves, and Kaplan-Meier curves. Results Multivariate analysis demonstrated that the extent of visceral pleural invasion was an independent and unfavorable prognostic factor. The C-indexes of the training and validation groups were 0.772 (95% CI: 0.770-0.774) and 0.769 (95% CI: 0.765-0.773), respectively, which revealed that the nomogram had sufficient credibility and stable predictive accuracy. The calibration curve displayed consistency between the actual and predictive values in both training and validation groups. Conclusion The prognostic nomogram with the extent of VPI could offer an accurate risk evaluation for patients with NSCLC. Independent external validation of this research should be conducted in the future.",2021,The C-indexes of the training and validation groups were 0.772,"['Patients in the SEER database diagnosed with NSCLC ( n \u2009=\u200987,045) from 2010 to 2015', 'patients with NSCLC']",[],"['concordance index (C-index), calibration curves, and Kaplan-Meier curves', 'visceral pleural invasion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0014507', 'cui_str': 'Epidemiology'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}]",[],"[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0006751', 'cui_str': 'Calibration'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C1522720', 'cui_str': 'Pleural'}, {'cui': 'C1269955', 'cui_str': 'Tumour invasion'}]",,0.199318,The C-indexes of the training and validation groups were 0.772,"[{'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'The Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi 833000, Xinjiang, China.'}, {'ForeName': 'Pei', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'The Second Affiliated Hospital of Xinjiang Medical University, Urumqi 833000, Xinjiang, China.'}, {'ForeName': 'Fengsen', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'The Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi 833000, Xinjiang, China.'}]",Canadian respiratory journal,['10.1155/2021/8816860'] 1317,34391292,Triceps surae muscle-tendon unit mechanical property changes during 10 minutes of streching.,"OBJECTIVE To verify the effect of 10-min static stretching on the triceps surae mechanical properties. DESIGN Quasi-experimental one-group pre test-post test study compared the time points of before, after, and minute by minute of one session of triceps surae passive static stretching. METHODS 15 participants performed a 10-min plantar flexor passive static stretching on the isokinetic dynamometer. We evaluated passive torque and myotendinous junction (MTJ) displacement before, minute by minute, and after the intervention. In contrast, we evaluated the range of motion (ROM), passive torque, MTJ displacement, and hysteresis before and after the intervention. Paired t-test compared pre and post-intervention time points. Passive torque and MTJ displacement in the minute-by-minute evaluations were compared by repeated measures one-way ANOVA with a Bonferroni post-hoc test. RESULTS ROM increased (effect size d = 0.56) and passive torque and muscle-tendon unit stiffness decreased (effect size d = 0.65 and d = 0.73, respectively) post-stretching. There was a reduction only in passive torque in the minute-by-minute evaluation, mainly at minutes five and seven. CONCLUSIONS passive torque decreased over a 10-min static stretching session of the ankle plantar flexors, followed by a ROM increase and muscle-tendon unit, a stiffness decrease.",2021,"There was a reduction only in passive torque in the minute-by-minute evaluation, mainly at minutes five and seven. ",['15 participants performed a'],"['10-min plantar flexor passive static stretching on the isokinetic dynamometer', '10-min static stretching']","['range of motion (ROM), passive torque, MTJ displacement, and hysteresis', 'passive torque and myotendinous junction (MTJ) displacement', 'passive torque', 'passive torque and muscle-tendon unit stiffness', 'ROM', 'Passive torque and MTJ displacement']","[{'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C1720875', 'cui_str': 'Static Stretching'}, {'cui': 'C0180572', 'cui_str': 'Dynamometer'}]","[{'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0584646', 'cui_str': 'Musculotendinous junction'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0039508', 'cui_str': 'Tendon structure'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}]",15.0,0.0754243,"There was a reduction only in passive torque in the minute-by-minute evaluation, mainly at minutes five and seven. ","[{'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Borges', 'Affiliation': 'Escola de Educação Física, Fisioterapia e Dança, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Kinesiology and Kinesiotherapy Research Group, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Anelize', 'Initials': 'A', 'LastName': 'Cini', 'Affiliation': 'Escola de Educação Física, Fisioterapia e Dança, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Kinesiology and Kinesiotherapy Research Group, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: anelizecini@yahoo.com.br.'}, {'ForeName': 'Francesca Chaida', 'Initials': 'FC', 'LastName': 'Sonda', 'Affiliation': 'Escola de Educação Física, Fisioterapia e Dança, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Biomechanics and Kinesiology Research Group, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Souza da Rocha', 'Affiliation': 'Escola de Educação Física, Fisioterapia e Dança, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Biomechanics and Kinesiology Research Group, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Cassiele Janina', 'Initials': 'CJ', 'LastName': 'Felappi', 'Affiliation': 'Escola de Educação Física, Fisioterapia e Dança, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Kinesiology and Kinesiotherapy Research Group, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Marco Aurélio', 'Initials': 'MA', 'LastName': 'Vaz', 'Affiliation': 'Escola de Educação Física, Fisioterapia e Dança, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Biomechanics and Kinesiology Research Group, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Cláudia Silveira', 'Initials': 'CS', 'LastName': 'Lima', 'Affiliation': 'Escola de Educação Física, Fisioterapia e Dança, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Kinesiology and Kinesiotherapy Research Group, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.05.003'] 1318,34145468,Letter to the Editor: Yoga-An Alternative Form of Therapy in Patients with Blunt Chest Trauma: a Randomized Controlled Trial.,,2021,,['Patients with Blunt Chest Trauma'],['Letter to the Editor: Yoga-An Alternative Form of Therapy'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C0039980', 'cui_str': 'Chest injury'}]","[{'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],,0.118114,,"[{'ForeName': 'Fatih', 'Initials': 'F', 'LastName': 'Özden', 'Affiliation': 'Elderly Care Department, Köyceğiz Vocational School of Health Services, Muğla Sıtkı Koçman University, 48800, Köyceğiz, Muğla, Turkey. fatihozden@mu.edu.tr.'}]",World journal of surgery,['10.1007/s00268-021-06195-0'] 1319,34391267,A psychophysical study comparing massage to conditioned pain modulation: A single blind randomized controlled trial in healthy participants.,"INTRODUCTION Pain-inducing massage results in greater pain inhibition than pain free massage, suggesting a mechanism dependent on conditioned pain modulation (CPM). The purpose of this study was to test the hypothesis that pain inducing massage produces similar magnitude of reduction in pain sensitivity as a cold pressor task and that baseline conditioned pain modulation efficiency predicts pain inducing massage related hypoalgesia. METHODS Sixty healthy participants were randomly assigned to receive either pain inducing massage to the neck, cold pressor task to the hand, or pain free massage to the neck. Participants also underwent pre and immediate post-intervention quantitative sensory testing. A repeated measures ANCOVA determined between group differences in pain sensitivity changes. RESULTS Pain inducing massage used as a conditioning stimulus resulted in comparable experimental pain sensitivity changes as a cold pressor task (p > 0.05). Pain intensity during the intervention demonstrated a weak correlation (r = 0.20, p = 0.12) with changes in pain sensitivity at a remote site. Individuals with an efficient CPM at baseline who received the pain inducing massage displayed greater increases in pressure pain threshold compared to individuals with a less efficient CPM indicating the potential benefit of treatment stratification by mechanism. CONCLUSION Although pain inducing massage resulted in less self-reported pain than a cold pressor task, both resulted in similar magnitude of the CPM response, suggesting shared underlying mechanisms. Understanding mechanisms of interventions can move us closer to mechanistic based treatments for pain which is consistent with a personalized medicine approach to care.",2021,"Although pain inducing massage resulted in less self-reported pain than a cold pressor task, both resulted in similar magnitude of the CPM response, suggesting shared underlying mechanisms.","['Sixty healthy participants', 'healthy participants']","['massage to conditioned pain modulation', 'pain inducing massage to the neck, cold pressor task to the hand, or pain free massage to the neck']","['experimental pain sensitivity changes', 'pressure pain', 'pain sensitivity', 'pain sensitivity changes', 'Pain intensity']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0908489', 'cui_str': 'Pain-Free'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",60.0,0.150457,"Although pain inducing massage resulted in less self-reported pain than a cold pressor task, both resulted in similar magnitude of the CPM response, suggesting shared underlying mechanisms.","[{'ForeName': 'Abigail T', 'Initials': 'AT', 'LastName': 'Wilson', 'Affiliation': 'University of Florida, College of Public Health & Health Professions, Department of Physical Therapy, Box 100154, UFHSC, Gainesville, FL, 32610-0154, USA. Electronic address: abigail.wilson@phhp.ufl.edu.'}, {'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Riley', 'Affiliation': 'University of Florida College of Dentistry, Interim Associate Dean of Faculty Affairs, Director, Pain Clinical Research Unit, Pain Research & Intervention Center of Excellence, UF CTSI, University of Florida, Health Center Office, D2-148, Gainesville, FL, 32610-0404, USA. Electronic address: jriley@dental.ufl.edu.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Bishop', 'Affiliation': 'University of Florida, College of Public Health & Health Professions, Department of Physical Therapy, Box 100154, UFHSC, Gainesville, FL, 32610-0154, USA. Electronic address: bish@phhp.ufl.edu.'}, {'ForeName': 'Jason M', 'Initials': 'JM', 'LastName': 'Beneciuk', 'Affiliation': 'University of Florida, College of Public Health & Health Professions, Department of Physical Therapy, Box 100154, UFHSC, Gainesville, FL, 32610-0154, USA; College of Public Health and Health Professions (University of Florida) Research Collaboration, USA. Electronic address: beneciuk@phhp.ufl.edu.'}, {'ForeName': 'Mutsa', 'Initials': 'M', 'LastName': 'Godza', 'Affiliation': 'University of Florida, College of Public Health & Health Professions, Department of Physical Therapy, Box 100154, UFHSC, Gainesville, FL, 32610-0154, USA. Electronic address: mgodza@ufl.edu.'}, {'ForeName': 'Yenisel', 'Initials': 'Y', 'LastName': 'Cruz-Almeida', 'Affiliation': 'University of Florida Term Professor, Colleges of Dentistry and Medicine, Associate Director, UF Pain Research & Intervention Center of Excellence, UF CTSI. PO Box 103628, 1329 SW 16th Street, Ste 5180, Gainesville, FL, USA. Electronic address: cryeni@ufl.edu.'}, {'ForeName': 'Joel E', 'Initials': 'JE', 'LastName': 'Bialosky', 'Affiliation': 'University of Florida, College of Public Health & Health Professions, Department of Physical Therapy, Box 100154, UFHSC, Gainesville, FL, 32610-0154, USA; College of Public Health and Health Professions (University of Florida) Research Collaboration, USA. Electronic address: bialosky@phhp.ufl.edu.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.02.014'] 1320,34391265,Kinesiotape on quadriceps and gluteus in counter movement jump and sprint in soccer players.,"BACKGROUND Kinesiotape (KT) is a technique commonly used in sports practice. It may be beneficial in enhancing muscle function by additional cutaneous afferent stimulation. The objective of this study was to analyse the effect of KT on countermovement jump (CMJ) and 20-m sprints (sp) immediately and 24 h after its application on the quadriceps and gluteus maximus. METHODS 37 male soccer players (19.7 ± 0.9 years old) were randomly assigned to one of 3 groups: experimental group: KT activation (KTact), placebo group: sham tape (KTst), and control group (CG). Participants performed a 30-min preliminary warm-up, after which they conducted CMJ and 20-m sp tests. These tests were repeated later (with KT application or not) and after 24 h. RESULTS Intergroup results found no significant differences either post-test (CMJ, p = 0.115; sp, p = 0.307) or after 24 h (p = 0.053). Intragroup results showed no significant results for CMJ, although 20-m sp seemed to display significant differences in the (KTst) (p = 0.002, post-hoc: 0.015 in pre_sp vs post_sp) and the (KTact) (0.021, in post-hoc: 0.007 in pre_sp vs post_sp), with a moderate effect in pre_sp vs post_sp (0.66) in the (KTact) after KT was applied. CONCLUSION KT application on the gluteus maximus and quadriceps in young soccer players increases the sprint execution time immediately and 24 h after application, even that the sprint execution time had not been grater that one tenth of the second (0.08 s). It also has no effect on CMJ.",2021,"RESULTS Intergroup results found no significant differences either post-test (CMJ, p = 0.115; sp, p = 0.307) or after 24 h (p = 0.053).","['soccer players', 'young soccer players', '37 male soccer players (19.7\xa0±\xa00.9 years old']","['CMJ', 'Kinesiotape (KT', 'KT activation (KTact), placebo group: sham tape (KTst), and control group (CG', 'Kinesiotape', 'KT', 'KT application']",['sprint execution time'],"[{'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C4505491', 'cui_str': 'Kinesiotape'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C1278561', 'cui_str': 'Judicial execution'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",37.0,0.0545572,"RESULTS Intergroup results found no significant differences either post-test (CMJ, p = 0.115; sp, p = 0.307) or after 24 h (p = 0.053).","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Reina Abellán', 'Affiliation': 'Department of Physiotherapy, Catholic University of Murcia, Murcia, Spain.'}, {'ForeName': 'Juan L', 'Initials': 'JL', 'LastName': 'Yuste', 'Affiliation': 'Department of Plastic, Musical and Dynamic Expression (Area of Didactics of Body Expression), University of Murcia, Murcia, Spain.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Mora Cabrera', 'Affiliation': 'Department of Physiotherapy, Catholic University of Murcia, Murcia, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Gómez-Tomás', 'Affiliation': 'Department of Physiotherapy, Catholic University of Murcia, Murcia, Spain. Electronic address: cgomez@ucam.edu.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.02.021'] 1321,34391264,The effects of an 8-week knitting program on osteoarthritis symptoms in elderly women: A pilot randomized controlled trial.,"BACKGROUND Exercise therapy is effective in reducing symptoms and disability associated with hand osteoarthritis (HOA) but often has low adherence. An intervention consisting in a meaningful occupation, such as knitting, may improve adherence to treatment. This pilot randomized controlled trial (RCT) studied the adherence and clinical effectiveness of a knitting program in older females suffering from HOA to evaluate the acceptability of this intervention and assess the feasibility of a larger-scale RCT. METHODS Single-blind, two-arm pilot RCT with a parallel group design with 37 participants (18 control, 19 intervention). Control participants were given an educational pamphlet and assigned to a waiting list. The knitting program (8-week duration) had two components: bi-weekly 20-min group knitting sessions and daily 20-min home knitting session on the 5 remaining weekdays. Measures included knitting adherence (implementation outcomes) as well as stiffness, pain, functional status, hand physical activity level, patient's global impression of change, health-related quality of life, self-efficacy, and grip strength (clinical outcomes measured throughout the 8-week program and 4 weeks after the intervention). RESULTS Our protocol is feasible and the intervention was acceptable and enjoyable for participants, who showed high adherence. No difference was observed between the two groups for any of the clinical outcome measures (all p > .05). CONCLUSION Knitting is a safe and accessible activity for older women with HOA. However, our 8-week knitting program did not result in improvements in any of our outcome measures. Knitting for a longer period and/or with higher frequency may yield better outcomes.",2021,"No difference was observed between the two groups for any of the clinical outcome measures (all p > .05). ","['37 participants (18 control, 19 intervention', 'elderly women', 'older females suffering from HOA', 'older women with HOA']","['educational pamphlet and assigned to a waiting list', 'knitting program', 'Exercise therapy']","['osteoarthritis symptoms', ""knitting adherence (implementation outcomes) as well as stiffness, pain, functional status, hand physical activity level, patient's global impression of change, health-related quality of life, self-efficacy, and grip strength (clinical outcomes""]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0263746', 'cui_str': 'Degenerative joint disease of hand'}]","[{'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]","[{'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",37.0,0.0398206,"No difference was observed between the two groups for any of the clinical outcome measures (all p > .05). ","[{'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Leonard', 'Affiliation': ""Faculté de médecine et des sciences de la santé, École de réadaptation, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada. Electronic address: guillaume.leonard2@usherbrooke.ca.""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Paquet', 'Affiliation': 'Physiotherapy Program, School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: npaquet@uottawa.ca.'}, {'ForeName': 'Paulette', 'Initials': 'P', 'LastName': 'Guitard', 'Affiliation': 'Occupational Therapy Program, School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: guitardp@uottawa.ca.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Toupin-April', 'Affiliation': ""Occupational Therapy Program, School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada; Children's Hospital of Eastern Ontario Research Institute, Department of Pediatrics, Faculty of Medicine, Ottawa, Ontario, Canada. Electronic address: ktoupina@uottawa.ca.""}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Cavallo', 'Affiliation': 'School of Rehabilitation Sciences, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: sabrina.cavallo@umontreal.ca.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Paterson', 'Affiliation': 'The Arthritis Society, Ottawa Office, Ontario Division, Ottawa, Ontario, Canada. Electronic address: gpaterson@arthritis.ca.'}, {'ForeName': 'Sibel Z', 'Initials': 'SZ', 'LastName': 'Aydin', 'Affiliation': 'Rheumatologist, Ottawa Hospital, Ottawa, Ontario, Canada. Electronic address: Saydin@toh.ca.'}, {'ForeName': 'Sibel', 'Initials': 'S', 'LastName': 'Bakirci', 'Affiliation': 'Rheumatologist, Ottawa Hospital, Ottawa, Ontario, Canada. Electronic address: bakircisibel@gmail.com.'}, {'ForeName': 'Alexia', 'Initials': 'A', 'LastName': 'Coulombe-Lévêque', 'Affiliation': ""Faculté de médecine et des sciences de la santé, École de réadaptation, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada. Electronic address: alexia.coulombe-leveque@usherbrooke.ca.""}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Brosseau', 'Affiliation': 'Physiotherapy Program, School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: lbrossea@uottawa.ca.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.001'] 1322,34391263,Effect of finding-oriented manual therapy techniques on muscle activity and postural control in patients with chronic ankle instability - A randomized controlled feasibility study.,"INTRODUCTION Previous studies have analyzed the effects of manual therapy techniques (MTT) in patients with chronic ankle instability (CAI). Clinicians treat patients according the finding-oriented MTT approach. This approach is seldom pursued in research. The purpose of this study was to evaluate the feasibility and efficacy of finding-oriented MTT applications in patients with CAI. METHOD In this randomized controlled, blinded assessor crossover feasibility trial, participants were randomized to receive nine finding-oriented MTT treatments or no treatment during a three-week period, followed by a six-day washout period after which participants were crossed-over. Criteria under evaluation were adherence and attrition rates, safety (adverse events (AEs)) and acceptability and preliminary effects of finding-oriented MTT on muscular activity (measured by surface Electromyography (sEMG)) and on dynamic balance (measured by time to stabilization (TTS) and the modified Star Excursion Balance Test (modified STBT)). RESULTS Seven women and two men (mean age: 26 ± 6.1 years) with CAI enrolled in this feasibility study. Success criteria showed a high adherence (90%) and low attrition rate (10%). All data could be used for analysis. AEs such as tingling in the foot during a short time frame were reported after four finding-oriented MTT interventions. Preliminary effect sizes showed divergence and few statistically significant results for sEMG. CONCLUSION The participants were adherent to the finding-oriented MTT intervention. The acceptability of data recording and data analysis was good. In addition, the study protocol should be adapted by adding a 10-min warm up period, a participant familiarization to TTS and modified STBT, and test repetitions.",2021,"Preliminary effect sizes showed divergence and few statistically significant results for sEMG. ","['Seven women and two men (mean age: 26\xa0±\xa06.1 years) with CAI enrolled in this feasibility study', 'patients with CAI', 'patients with chronic ankle instability ', 'patients with chronic ankle instability (CAI']","['manual therapy techniques (MTT', 'finding-oriented manual therapy techniques']","['feasibility and efficacy', 'low attrition rate', 'muscle activity and postural control', 'adherence and attrition rates, safety (adverse events (AEs)) and acceptability and preliminary effects of finding-oriented MTT on muscular activity (measured by surface Electromyography (sEMG)) and on dynamic balance (measured by time to stabilization (TTS) and the modified Star Excursion Balance Test (modified STBT']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3840097', 'cui_str': 'Chronic ankle instability'}, {'cui': 'C0015730', 'cui_str': 'Feasibility Studies'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0439611', 'cui_str': 'Preliminary'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0430815', 'cui_str': 'Surface EMG'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0282064', 'cui_str': 'Stars, Celestial'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0662049', 'cui_str': 'STBT'}]",7.0,0.123805,"Preliminary effect sizes showed divergence and few statistically significant results for sEMG. ","[{'ForeName': 'Slavko', 'Initials': 'S', 'LastName': 'Rogan', 'Affiliation': 'Division of Physiotherapy, Department of Health Professions, University of Applied Sciences Bern, Bern, Switzerland; Akademie für Integrative Physiotherapie und Trainingslehre, Grenzach-Wyhlen, Germany; Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Belgium. Electronic address: slavko.rogan@bfh.ch.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Taeymans', 'Affiliation': 'Division of Physiotherapy, Department of Health Professions, University of Applied Sciences Bern, Bern, Switzerland; Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Belgium.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Eggertswyler', 'Affiliation': 'Division of Physiotherapy, Department of Health Professions, University of Applied Sciences Bern, Bern, Switzerland.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Zuber', 'Affiliation': 'Division of Physiotherapy, Department of Health Professions, University of Applied Sciences Bern, Bern, Switzerland.'}, {'ForeName': 'Patric', 'Initials': 'P', 'LastName': 'Eichelberger', 'Affiliation': 'Division of Physiotherapy, Department of Health Professions, University of Applied Sciences Bern, Bern, Switzerland.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.018'] 1323,34148714,Three-dimensional ultrasound assessment of effects of therapies on carotid atherosclerosis using vessel wall thickness maps.,"We present a new method for assessing the effects of therapies on atherosclerosis, by measuring the weighted average of carotid vessel-wall-plus-plaque thickness change (ΔVWT¯ Weighted ) in 120 patients randomized to pomegranate juice/extract versus placebo. Three-dimensional ultrasound images were acquired at baseline and one year after. Three-dimensional VWT maps were reconstructed and then projected onto a carotid template to obtain two-dimensional VWT maps. Anatomic correspondence on the two-dimensional VWT maps was optimized to reduce misalignment for the same subject and across subjects. A weight was computed at each point on the two-dimensional VWT map to highlight anatomic locations likely to exhibit plaque progression/regression, resulting in ΔVWT¯ Weighted for each subject. The weighted average of VWT-Change measured from the two-dimensional VWT maps with correspondence alignment (ΔVWT¯ Weighted,MDL ) detected a significant difference between the pomegranate and placebo groups (P = 0.008). This method improves the cost-effectiveness of proof-of-concept studies involving new therapies for atherosclerosis.",2021,Anatomic correspondence on the two-dimensional VWT maps was optimized to reduce misalignment for the same subject and across subjects.,['120 patients randomized to'],['pomegranate juice/extract versus placebo'],['weighted average of VWT-Change'],"[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1327962', 'cui_str': 'POMEGRANATE JUICE'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",120.0,0.077846,Anatomic correspondence on the two-dimensional VWT maps was optimized to reduce misalignment for the same subject and across subjects.,"[{'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Electrical Engineering, City University of Hong Kong, Hong Kong.'}, {'ForeName': 'J David', 'Initials': 'JD', 'LastName': 'Spence', 'Affiliation': 'Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, London, Ontario, Canada.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Chiu', 'Affiliation': 'Department of Electrical Engineering, City University of Hong Kong, Hong Kong. Electronic address: bcychiu@cityu.edu.hk.'}]",Ultrasound in medicine & biology,['10.1016/j.ultrasmedbio.2021.04.015'] 1324,34147854,"Do you see what I see? The influence of self-objectification on appearance anxiety, intrinsic motivation, interoceptive awareness, and physical performance.","Self-objectification negatively impacts body image, mental health, and cognitive performance outcomes in women and has been correlated with poorer physical performance. The purpose of this study was to determine if trying on a swimsuit (versus a sweater) impacted state self-objectification, body shame, social physique anxiety, intrinsic motivation, bodily awareness, and physical performance in university women. Female undergraduate students (N = 52) were randomly assigned to try on either a swimsuit (objectification condition) or sweater (control condition) and complete measures of self-objectification, body shame, appearance anxiety, intrinsic motivation, and interoceptive awareness, and perform a series of balance tasks. Women in the swimsuit condition reported higher state self-objectification, body-related shame and appearance anxiety, and lower intrinsic motivation compared to women in the sweater condition. In addition, women in the swimsuit condition restricted body movements during a 1-legged stand balance task. Consistent with objectification theory, women may have made smaller physical movements in an attempt to hide or cover up the body. Findings could have implications for promoting positive experiences during physical activity for women, such as in sport, exercise or rehabilitation settings.",2021,"Women in the swimsuit condition reported higher state self-objectification, body-related shame and appearance anxiety, and lower intrinsic motivation compared to women in the sweater condition.","['Female undergraduate students (N = 52', 'university women']","['swimsuit (objectification condition) or sweater (control condition) and complete measures of self-objectification, body shame, appearance anxiety, intrinsic motivation, and interoceptive awareness, and perform a series of balance tasks']","['Self-objectification negatively impacts body image, mental health, and cognitive performance outcomes', 'state self-objectification, body shame, social physique anxiety, intrinsic motivation, bodily awareness, and physical performance', 'appearance anxiety, intrinsic motivation, interoceptive awareness, and physical performance', 'higher state self-objectification, body-related shame and appearance anxiety, and lower intrinsic motivation', 'body movements']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0542352', 'cui_str': 'Pullover'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0036938', 'cui_str': 'Shame'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0392350', 'cui_str': 'Intrinsic motivation'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205549', 'cui_str': 'Series'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0036938', 'cui_str': 'Shame'}, {'cui': 'C0424611', 'cui_str': 'Physique type'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0392350', 'cui_str': 'Intrinsic motivation'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]",52.0,0.00599974,"Women in the swimsuit condition reported higher state self-objectification, body-related shame and appearance anxiety, and lower intrinsic motivation compared to women in the sweater condition.","[{'ForeName': 'Michelle A', 'Initials': 'MA', 'LastName': 'Dimas', 'Affiliation': 'Brock University, 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada.'}, {'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Galway', 'Affiliation': 'Brock University, 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada.'}, {'ForeName': 'Kimberley L', 'Initials': 'KL', 'LastName': 'Gammage', 'Affiliation': 'Brock University, 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada. Electronic address: kgammage@brocku.ca.'}]",Body image,['10.1016/j.bodyim.2021.05.010'] 1325,34147766,Reductions in guilt cognitions following prolonged exposure and/or sertraline predict subsequent improvements in PTSD and depression.,"BACKGROUND AND OBJECTIVES Reduction of trauma related negative cognitions, such as guilt, is thought to be a mechanism of change within PTSD treatments like prolonged exposure (PE). Research suggests PE can directly address guilt cognitions. However, whether pharmacotherapies for PTSD can remains unclear. METHODS Data from a randomized controlled trial of PE plus placebo (PE + PLB), sertraline plus enhanced medication management (SERT + EMM), and their combination (PE + SERT) in 195 Veterans from recent wars was analyzed. RESULTS The unadjusted means and mixed-effects model showed guilt decreased significantly over the follow-up time as expected; however, contrary to our hypothesis, PE conditions were not associated with greater reductions in guilt than the SERT + EMM condition. As hypothesized, week 12 reduction in guilt predicted post-treatment (weeks 24-52) reduction in PTSD and depression, but not impairments in function. LIMITATIONS Generalizability of findings is limited by the sample being comprised of combat Veterans who were predominantly male, not on SSRI at study entry, willing to be randomized to therapy or medication, and reporting low levels of guilt. To reduce differences in provider attention, SERT + EMM was administered over 30 min to include psychoeducation and active listening; it is unknown if this contributed to effects on guilt. CONCLUSIONS PE + PLB, SERT + EMM, and PE + SERT were equally associated with reduction in trauma related guilt. Reducing trauma related guilt may be a pathway to reducing PTSD and posttraumatic depression symptoms. Further study is needed to determine how best to treat trauma related guilt and to understand the mechanisms by which guilt improves across different treatments for PTSD.",2021,"The unadjusted means and mixed-effects model showed guilt decreased significantly over the follow-up time as expected; however, contrary to our hypothesis, PE conditions were not associated with greater reductions in guilt than the SERT + EMM condition.","['195 Veterans from recent wars was analyzed', 'sample being comprised of combat Veterans who were predominantly male, not on SSRI at study entry']","['sertraline', 'PE plus placebo (PE\xa0+\xa0PLB), sertraline plus enhanced medication management (SERT\xa0+\xa0EMM), and their combination (PE\xa0+\xa0SERT']","['PTSD and depression', 'guilt', 'guilt cognitions']","[{'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0043027', 'cui_str': 'War'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0150270', 'cui_str': 'Management of drug regimen'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0018379', 'cui_str': 'Feeling guilt'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.146684,"The unadjusted means and mixed-effects model showed guilt decreased significantly over the follow-up time as expected; however, contrary to our hypothesis, PE conditions were not associated with greater reductions in guilt than the SERT + EMM condition.","[{'ForeName': 'Carolyn B', 'Initials': 'CB', 'LastName': 'Allard', 'Affiliation': 'VA San Diego Healthcare System, 3350 Villa La Jolla Drive, San Diego, CA, 92161, USA; California School of Professional Psychology, Alliant International University, Daley Hall, 10455 Pomerado Rd, San Diego, CA, 92131, USA. Electronic address: Carolyn.Allard@alliant.edu.'}, {'ForeName': 'Sonya B', 'Initials': 'SB', 'LastName': 'Norman', 'Affiliation': 'VA San Diego Healthcare System, 3350 Villa La Jolla Drive, San Diego, CA, 92161, USA; National Center for PTSD, VA Medical Center, 215 North Main st, White River Junction, VT, 05009, USA; University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093, USA; VA Center of Excellence for Stress and Mental Health, 3350 La Jolla Village Drive, MC116B, San Diego, CA, 92161, USA. Electronic address: snorman@health.ucsd.edu.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Straus', 'Affiliation': 'VA San Diego Healthcare System, 3350 Villa La Jolla Drive, San Diego, CA, 92161, USA; University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093, USA. Electronic address: Elizabeth.Straus@va.gov.'}, {'ForeName': 'H Myra', 'Initials': 'HM', 'LastName': 'Kim', 'Affiliation': 'VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA; University of Michigan, Consulting for Statistics, Computing and Analytics Research, 3550 Rackham, 950 E. Washington Street, Ann Arbor, MI, 48109, USA. Electronic address: myrakim@umich.edu.'}, {'ForeName': 'Murray B', 'Initials': 'MB', 'LastName': 'Stein', 'Affiliation': 'VA San Diego Healthcare System, 3350 Villa La Jolla Drive, San Diego, CA, 92161, USA; University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093, USA. Electronic address: mstein@health.ucsd.edu.'}, {'ForeName': 'Naomi M', 'Initials': 'NM', 'LastName': 'Simon', 'Affiliation': 'Massachusetts General Hospital, Department of Psychiatry, One Bowdoin Square, 6th Floor, Boston, MA, 02114, USA; New York University Grossman School of Medicine, Department of Psychiatry, One Park Avenue 8th Floor, New York, NY, 10016, USA. Electronic address: Naomi.Simon@nyulangone.org.'}, {'ForeName': 'Sheila A M', 'Initials': 'SAM', 'LastName': 'Rauch', 'Affiliation': 'VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA; Atlanta VA Medical Center, 1670 Clairmont Road, Decatur, GA, 30033, USA; Emory University School of Medicine, 12 Executive Park, 3rd Floor, Atlanta, GA, 30029, USA. Electronic address: sheila.a.m.rauch@emory.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2021.101666'] 1326,34151817,Effect of Age on Clinical Trial Outcome in Participants with Probable Alzheimer's Disease.,"BACKGROUND Age may affect treatment outcome in trials of mild probable Alzheimer's disease (AD). OBJECTIVE We examined age as a moderator of outcome in an exploratory study of deep brain stimulation targeting the fornix (DBS-f) region in participants with AD. METHODS Forty-two participants were implanted with DBS electrodes and randomized to double-blind DBS-f stimulation (""on"") or sham DBS-f (""off"") for 12 months. RESULTS The intervention was safe and well tolerated. However, the selected clinical measures did not differentiate between the ""on"" and ""off"" groups in the intent to treat (ITT) population. There was a significant age by time interaction with the Alzheimer's Disease Assessment Scale; ADAS-cog-13 (p = 0.028). Six of the 12 enrolled participants < 65 years old (50%) markedly declined on the ADAS-cog-13 versus only 6.7%of the 30 participants≥65 years old regardless of treatment assignment (p = 0.005). While not significant, post-hoc analyses favored DBS-f ""off"" versus ""on"" over 12 months in the < 65 age group but favored DBS-f ""on"" versus ""off"" in the≥65 age group on all clinical metrics. On the integrated Alzheimer's Disease rating scale (iADRS), the effect size contrasting DBS-f ""on"" versus ""off"" changed from +0.2 (favoring ""off"") in the < 65 group to -0.52 (favoring ""on"") in the≥65 age group. CONCLUSION The findings highlight issues with subject selection in clinical trials for AD. Faster disease progression in younger AD participants with different AD sub-types may influence the results. Biomarker confirmation and genotyping to differentiate AD subtypes is important for future clinical trials.",2021,There was a significant age by time interaction with the Alzheimer's Disease Assessment Scale; ADAS-cog-13 (p = 0.028).,"[""Participants with Probable Alzheimer's Disease"", 'participants with AD', 'Forty-two participants were implanted with', ""mild probable Alzheimer's disease (AD""]","['DBS electrodes and randomized to double-blind DBS-f stimulation (""on"") or sham DBS-f (""off']","[""integrated Alzheimer's Disease rating scale (iADRS"", 'safe and well tolerated', ""time interaction with the Alzheimer's Disease Assessment Scale; ADAS-cog-13""]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}]","[{'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0013812', 'cui_str': 'Electrode'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0152334', 'cui_str': 'Cerebral fornix structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0001457', 'cui_str': 'Adenosine deaminase'}, {'cui': 'C0009738', 'cui_str': 'Congo'}]",12.0,0.815665,There was a significant age by time interaction with the Alzheimer's Disease Assessment Scale; ADAS-cog-13 (p = 0.028).,"[{'ForeName': 'Steven D', 'Initials': 'SD', 'LastName': 'Targum', 'Affiliation': 'Functional Neuromodulation Ltd., Minneapolis MN, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Fosdick', 'Affiliation': 'Functional Neuromodulation Ltd., Minneapolis MN, USA.'}, {'ForeName': 'Kristen E', 'Initials': 'KE', 'LastName': 'Drake', 'Affiliation': 'Functional Neuromodulation Ltd., Minneapolis MN, USA.'}, {'ForeName': 'Paul B', 'Initials': 'PB', 'LastName': 'Rosenberg', 'Affiliation': ""Memory and Alzheimer's Treatment Center & Alzheimer's Disease Research Center, Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.""}, {'ForeName': 'Anna D', 'Initials': 'AD', 'LastName': 'Burke', 'Affiliation': 'Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Wolk', 'Affiliation': 'Penn Memory Center, Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Kelly D', 'Initials': 'KD', 'LastName': 'Foote', 'Affiliation': 'Departments of and Neurosurgery and Neurology, University of Florida, Fixel Institute for Neurological Diseases, Gainesville, FL, USA.'}, {'ForeName': 'Wael F', 'Initials': 'WF', 'LastName': 'Asaad', 'Affiliation': 'Department of Neurosurgery, Rhode Island Hospital and the Alpert Medical School of Brown University, Providence, RI, USA.'}, {'ForeName': 'Marwan', 'Initials': 'M', 'LastName': 'Sabbagh', 'Affiliation': 'Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland, OH, USA.'}, {'ForeName': 'Gwenn S', 'Initials': 'GS', 'LastName': 'Smith', 'Affiliation': ""Memory and Alzheimer's Treatment Center & Alzheimer's Disease Research Center, Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.""}, {'ForeName': 'Andres M', 'Initials': 'AM', 'LastName': 'Lozano', 'Affiliation': 'Department of Surgery (Neurosurgery), University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Constantine G', 'Initials': 'CG', 'LastName': 'Lyketsos', 'Affiliation': ""Memory and Alzheimer's Treatment Center & Alzheimer's Disease Research Center, Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.""}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-210530'] 1327,34151792,Hippocampal Functional Connectivity and Memory Performance After Exercise Intervention in Older Adults with Mild Cognitive Impairment.,"BACKGROUND Exercise training (ET) has neuroprotective effects in the hippocampus, a key brain region for memory that is vulnerable to age-related dysfunction. OBJECTIVE We investigated the effects of ET on functional connectivity (FC) of the hippocampus in older adults with mild cognitive impairment (MCI) and a cognitively normal (CN) control group. We also assessed whether the ET-induced changes in hippocampal FC (Δhippocampal-FC) are associated with changes in memory task performance (Δmemory performance). METHODS 32 older adults (77.0±7.6 years; 16 MCI and 16 CN) participated in the present study. Cardiorespiratory fitness tests, memory tasks (Rey Auditory Verbal Learning Test (RAVLT) and Logical Memory Test (LM)), and resting-state fMRI were administered before and after a 12-week walking ET intervention. We utilized a seed-based correlation analysis using the bilateral anterior and posterior hippocampi as priori seed regions of interest. The associations of residualized ET-induced Δhippocampal-FC and Δmemory performance were assessed using linear regression. RESULTS There were significant improvements in RAVLT Trial 1 and LM test performance after ET across participants. At baseline, MCI, compared to CN, demonstrated significantly lower posterior hippocampal FC. ET was associated with increased hippocampal FC across groups. Greater ET-related anterior and posterior hippocampal FC with right posterior cingulate were associated with improved LM recognition performance in MCI participants. CONCLUSION Our findings indicate that hippocampal FC is significantly increased following 12-weeks of ET in older adults and, moreover, suggest that increased hippocampal FC may reflect neural network plasticity associated with ET-related improvements in memory performance in individuals diagnosed with MCI.",2021,"Greater ET-related anterior and posterior hippocampal FC with right posterior cingulate were associated with improved LM recognition performance in MCI participants. ","['32 older adults (77.0±7.6 years; 16 MCI and 16 CN) participated in the present study', 'individuals diagnosed with MCI', 'older adults with mild cognitive impairment (MCI) and a cognitively normal (CN) control group', 'Older Adults with Mild Cognitive Impairment', 'older adults']","['ET', 'Exercise training (ET', 'Exercise Intervention']","['functional connectivity (FC', 'LM recognition performance', 'memory task performance (Δmemory performance', 'Cardiorespiratory fitness tests, memory tasks (Rey Auditory Verbal Learning Test (RAVLT) and Logical Memory Test (LM)), and resting-state fMRI', 'Hippocampal Functional Connectivity and Memory Performance', 'memory performance', 'hippocampal FC', 'hippocampal FC (Δhippocampal-FC', 'posterior hippocampal FC']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C4505058', 'cui_str': 'Rey Auditory Verbal Learning Test'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C1285654', 'cui_str': 'Memory performance'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}]",32.0,0.031604,"Greater ET-related anterior and posterior hippocampal FC with right posterior cingulate were associated with improved LM recognition performance in MCI participants. ","[{'ForeName': 'Junyeon', 'Initials': 'J', 'LastName': 'Won', 'Affiliation': 'Department of Kinesiology, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Callow', 'Affiliation': 'Department of Kinesiology, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Gabriel S', 'Initials': 'GS', 'LastName': 'Pena', 'Affiliation': 'Department of Kinesiology, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Leslie S', 'Initials': 'LS', 'LastName': 'Jordan', 'Affiliation': 'Department of Kinesiology, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Naomi A', 'Initials': 'NA', 'LastName': 'Arnold-Nedimala', 'Affiliation': 'Department of Kinesiology, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Kristy A', 'Initials': 'KA', 'LastName': 'Nielson', 'Affiliation': 'Department of Psychology, Marquette University, Milwaukee, WI, USA.'}, {'ForeName': 'J Carson', 'Initials': 'JC', 'LastName': 'Smith', 'Affiliation': 'Department of Kinesiology, University of Maryland, College Park, MD, USA.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-210051'] 1328,33246430,Effectiveness of Alberta Family Integrated Care on infant length of stay in level II neonatal intensive care units: a cluster randomized controlled trial.,"BACKGROUND Parents of infants in neonatal intensive care units (NICUs) are often unintentionally marginalized in pursuit of optimal clinical care. Family Integrated Care (FICare) was developed to support families as part of their infants' care team in level III NICUs. We adapted the model for level II NICUs in Alberta, Canada, and evaluated whether the new Alberta FICare™ model decreased hospital length of stay (LOS) in preterm infants without concomitant increases in readmissions and emergency department visits. METHODS In this pragmatic cluster randomized controlled trial conducted between December 15, 2015 and July 28, 2018, 10 level II NICUs were randomized to provide Alberta FICare™ (n = 5) or standard care (n = 5). Alberta FICare™ is a psychoeducational intervention with 3 components: Relational Communication, Parent Education, and Parent Support. We enrolled mothers and their singleton or twin infants born between 32 0/7 and 34 6/7 weeks gestation. The primary outcome was infant hospital LOS. We used a linear regression model to conduct weighted site-level analysis comparing adjusted mean LOS between groups, accounting for site geographic area (urban/regional) and infant risk factors. Secondary outcomes included proportions of infants with readmissions and emergency department visits to 2 months corrected age, type of feeding at discharge, and maternal psychosocial distress and parenting self-efficacy at discharge. RESULTS We enrolled 654 mothers and 765 infants (543 singletons/111 twin cases). Intention to treat analysis included 353 infants/308 mothers in the Alberta FICare™ group and 365 infants/306 mothers in the standard care group. The unadjusted difference between groups in infant hospital LOS (1.96 days) was not statistically significant. Accounting for site geographic area and infant risk factors, infant hospital LOS was 2.55 days shorter (95% CI, - 4.44 to - 0.66) in the Alberta FICare™ group than standard care group, P = .02. Secondary outcomes were not significantly different between groups. CONCLUSIONS Alberta FICare™ is effective in reducing preterm infant LOS in level II NICUs, without concomitant increases in readmissions or emergency department visits. A small number of sites in a single jurisdiction and select group infants limit generalizability of findings. TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT02879799 , retrospectively registered August 26, 2016.",2020,"Secondary outcomes were not significantly different between groups. ","['December 15, 2015 and July 28, 2018, 10 level II NICUs were randomized to', 'enrolled mothers and their singleton or twin infants born between 32 0/7 and 34 6/7 weeks gestation', '353 infants/308 mothers in the Alberta FICare™ group and 365 infants/306 mothers in the standard care group', '654 mothers and 765 infants (543 singletons/111 twin cases', 'Parents of infants in neonatal intensive care units (NICUs', 'infant length of stay in level II neonatal intensive care units']","['Family Integrated Care (FICare', 'Alberta Family Integrated Care', 'provide Alberta FICare™ (n\xa0=\u20095) or standard care']","['proportions of infants with readmissions and emergency department visits to 2\u2009months corrected age, type of feeding at discharge, and maternal psychosocial distress and parenting self-efficacy at discharge', 'site geographic area and infant risk factors, infant hospital LOS', 'infant hospital LOS', 'preterm infant LOS', 'hospital length of stay (LOS']","[{'cui': 'C0441926', 'cui_str': 'Level II'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0001914', 'cui_str': 'Alberta'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0041427', 'cui_str': 'Twin sibling'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0455806', 'cui_str': 'Infant length'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0001914', 'cui_str': 'Alberta'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]",654.0,0.17207,"Secondary outcomes were not significantly different between groups. ","[{'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Benzies', 'Affiliation': 'Faculty of Nursing, University of Calgary, Calgary, AB, T2N 1N4, Canada. benzies@ucalgary.ca.'}, {'ForeName': 'Khalid', 'Initials': 'K', 'LastName': 'Aziz', 'Affiliation': 'Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Vibhuti', 'Initials': 'V', 'LastName': 'Shah', 'Affiliation': 'Faculty of Medicine, University of Toronto, and Mount Sinai Hospital, Toronto, ON, Canada.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Faris', 'Affiliation': 'Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Wanrudee', 'Initials': 'W', 'LastName': 'Isaranuwatchai', 'Affiliation': 'Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Scotland', 'Affiliation': 'Neonatal Intensive Care Unit, Rockyview General Hospital, Alberta Health Services, Calgary, AB, Canada.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Larocque', 'Affiliation': ""Northern Alberta Neonatal Program, Stollery Children's Hospital, Edmonton, AB, Canada.""}, {'ForeName': 'Kelly J', 'Initials': 'KJ', 'LastName': 'Mrklas', 'Affiliation': 'Strategic Clinical Networks™, System Innovation and Programs, Alberta Health Services, Calgary, AB, Canada.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Naugler', 'Affiliation': 'Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'H Thomas', 'Initials': 'HT', 'LastName': 'Stelfox', 'Affiliation': 'Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Chari', 'Affiliation': 'Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Amuchou Singh', 'Initials': 'AS', 'LastName': 'Soraisham', 'Affiliation': 'Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Albert Richard', 'Initials': 'AR', 'LastName': 'Akierman', 'Affiliation': 'Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Ernest', 'Initials': 'E', 'LastName': 'Phillipos', 'Affiliation': 'Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Harish', 'Initials': 'H', 'LastName': 'Amin', 'Affiliation': 'Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Hoch', 'Affiliation': 'Department of Public Health Sciences, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Zanoni', 'Affiliation': 'Faculty of Nursing, University of Calgary, Calgary, AB, T2N 1N4, Canada.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Kurilova', 'Affiliation': 'Faculty of Nursing, University of Calgary, Calgary, AB, T2N 1N4, Canada.'}, {'ForeName': 'Abhay', 'Initials': 'A', 'LastName': 'Lodha', 'Affiliation': 'Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC pediatrics,['10.1186/s12887-020-02438-6'] 1329,33250012,Does forward head posture change subacromial space in active or passive arm elevation?,"Objectives : Forward head posture (FHP) is one of the most common musculoskeletal disorders that appears to affect the shoulder joint through the shared muscles between the head and neck area and the shoulder girdle. The present study compared the acromiohumeral distance between individuals with normal head and neck alignment and those with moderate and severe FHP in active and passive arm elevation. Methods : Based on the craniovertebral angle, 60 volunteers were selected and equally distributed among three groups, including group one with normal head and neck alignment, group two with moderate FHP and group three with severe FHP. The space between the humeral head and the acromion was measured in 10°, 45° and 60° of active and passive arm elevation as the acromiohumeral distance. Results : The acromiohumeral distance was only different between the three groups at 45° arm elevation angle, and this difference was significant between groups one and three. In active and passive arm elevation, increased arm elevation angle reduced the subacromial space significantly. Also, in each arm elevation angle, the subacromial space differed significantly between the active and passive arm elevations. Conclusions : The acromiohumeral distance was significantly lower in the severe FHP group than the group with normal head and neck alignment in the 45° active arm elevation angle, which could be due to the changed tension in tissues between active and passive arm elevation and also the maximum muscle activity in the 45° active arm elevation angle.",2021,"The acromiohumeral distance was significantly lower in the severe FHP group than the group with normal head and neck alignment in the 45° active arm elevation angle, which could be due to the changed tension in tissues between active and passive arm elevation and also the maximum muscle activity in the 45° active arm elevation angle.","['individuals with normal head and neck alignment and those with moderate and severe FHP in active and passive arm elevation', '60 volunteers were selected and equally distributed among three groups, including group one with normal head and neck alignment, group two with moderate FHP and group three with severe FHP']",['head posture (FHP'],"['acromiohumeral distance', 'subacromial space']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C1536116', 'cui_str': 'Head posture abnormal'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C1536116', 'cui_str': 'Head posture abnormal'}, {'cui': 'C0439780', 'cui_str': 'Forward'}]","[{'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}]",60.0,0.0449527,"The acromiohumeral distance was significantly lower in the severe FHP group than the group with normal head and neck alignment in the 45° active arm elevation angle, which could be due to the changed tension in tissues between active and passive arm elevation and also the maximum muscle activity in the 45° active arm elevation angle.","[{'ForeName': 'Behdokht', 'Initials': 'B', 'LastName': 'Dehqan', 'Affiliation': 'Department of Physiotherapy, Rehabilitation Faculty, Semnan University of Medical Sciences, Semnan, Iran.'}, {'ForeName': 'Cyrus Taghizadeh', 'Initials': 'CT', 'LastName': 'Delkhoush', 'Affiliation': 'Department of Physiotherapy, Rehabilitation Faculty, Semnan University of Medical Sciences, Semnan, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Mirmohammadkhani', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Ehsani', 'Affiliation': 'Department of Physiotherapy, Rehabilitation Faculty, Semnan University of Medical Sciences, Semnan, Iran.'}]",The Journal of manual & manipulative therapy,['10.1080/10669817.2020.1854010'] 1330,33249220,Application of Midazolam Injection in Patients with Intraoperative Nerve Block Anesthesia and Sedation Assisted by Imaging Guidance.,"OBJECTIVE In the present study, we explored the clinical effect of midazolam as an adjuvant analgesic and tranquilizer after brachial plexus block anesthesia with the aid of imaging guidance. METHODS We selected 106 patients who had undergone elective unilateral upper extremity surgery from January 2017 to December 2019 and randomly divided them into groups A and B, with 53 cases in each group. All the patients had undergone brachial plexus block anesthesia. Group A received imidazole-assisted sedation, and group B received fentanyl plus midazolam-assisted sedation. Under ultrasound-guided intermuscular sulcus brachial plexus block, we observed and recorded the ultrasound anatomical images before injection, including the distance from the lower edge of the upper, middle, and lower trunk of the forearm brachial plexus to the skin. We also recorded the anesthesia and operation times, effects of the anesthetic block, and incidence of adverse reactions. RESULTS The distance from the lower edge of each nerve trunk to the skin averaged 1.002 cm for the upper stem, 1.598 cm for the middle stem, and 2.26 cm for the lower stem. The average anesthesia procedure time was 3 minutes, 56 seconds and was within 3-5 minutes for 92% of the procedures. The anesthesia effect was excellent, good, and poor in 81%, 11%, and 6%, respectively, and ineffective for 2% and effective for 92%. CONCLUSIONS The ultrasound-guided inferior intermuscular sulcus approach for brachial plexus block is suitable for unilateral upper extremity radial hand surgery. For surgery involving the upper extremity ulnar hand side, a larger dose (concentration) of local anesthetic should be used within a safe range and/or an additional ulnar nerve block might be necessary. Midazolam adjuvant medication can have a good sedative and amnestic effect in brachial plexus block anesthesia, helping to reduce pain and inhibit the increase in stress levels.",2021,"The anaesthesia effect was 81% excellent, 11% good, 6% poor, 2% ineffective, and 92% effective.","['106 patients who underwent elective unilateral upper extremity surgery from January 2017 to December 2019', 'unilateral upper extremity hand radial surgery', 'Patients with Intraoperative Nerve Block Anesthesia and Sedation Assisted by Medical Image']","['Ultrasound guided inferior intermuscular sulcus approach brachial plexus block', 'midazolam', 'imidazole Lon assisted sedation', 'Midazolam adjuvant medication', 'fentanyl + midazolam assisted sedation', 'Midazolam Injection', 'brachial plexus block anaesthesia']","['anaesthesia effect', 'average operation time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0198802', 'cui_str': 'Nerve block anesthesia'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0394697', 'cui_str': 'Injection of anesthetic agent into brachial plexus'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0020923', 'cui_str': 'Imidazole'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C4051556', 'cui_str': 'Midazolam Injection'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}]","[{'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.0140007,"The anaesthesia effect was 81% excellent, 11% good, 6% poor, 2% ineffective, and 92% effective.","[{'ForeName': 'Xiaolin', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Xiaoxiao', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Han', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Xinhua', 'Initials': 'X', 'LastName': 'Zhuang', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Rundong', 'Initials': 'R', 'LastName': 'Tang', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Yongsheng', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: yongshengxu6@sina.com.'}]",World neurosurgery,['10.1016/j.wneu.2020.11.101'] 1331,33256456,Effects of transcutaneous electrical acupuncture point stimulation on peripheral capillary oxygen saturation in elderly patients undergoing colonoscopy with sedation: a prospective randomized controlled trial.,"INTRODUCTION This study investigated whether transcutaneous electrical acupuncture point stimulation (TEAS) at PC6 can reduce the proportion of elderly patients experiencing a drop of ⩾4% in peripheral capillary oxygen saturation (SpO 2 ) while undergoing colonoscopy under sedation. METHODS A total of 32 elderly patients (aged ⩾ 65 years) scheduled for colonoscopy were randomly assigned in a 1:1 ratio to receive either real or sham TEAS (treatment or control groups, respectively). Each patient received oxygen (2 L/min) delivered routinely via nasal cannula. The treatment group was given TEAS at PC6 for 20 min at 2 Hz frequency and 6 mA intensity; the control group underwent the same procedures but with zero frequency/intensity. SpO 2 and other physiological parameters were measured prior to sedation and colonoscopy (baseline) and at seven other timepoints through departure from recovery. Depth of anesthesia was measured using a Narcotrend monitor. RESULTS Significantly fewer patients in the treatment group experienced a ⩾4% decrease from baseline SpO 2 (2/16) than patients in the control group (10/16; p = 0.004). The two groups were comparable with regard to respiratory rate, systolic and diastolic blood pressures, mean arterial pressure, and heart rate. CONCLUSION TEAS applied at PC6 with 2 Hz frequency was feasible and may be helpful in reducing the rate of hypoxia in elderly patients during colonoscopy. Trial registration number: NCT03775122 (ClinicalTrials.gov).",2021,Significantly fewer patients in the treatment group experienced a ⩾4% decrease from baseline SpO 2 (2/16) than patients in the control group (10/16; p = 0.004).,"['elderly patients during colonoscopy', '32 elderly patients (aged\u2009⩾\u200965\u2009years) scheduled for colonoscopy', 'elderly patients experiencing a drop of ⩾4% in peripheral capillary oxygen saturation (SpO 2 ) while undergoing colonoscopy under sedation', 'elderly patients undergoing colonoscopy with sedation']","['TEAS', 'TEAS at PC6', 'transcutaneous electrical acupuncture point stimulation', 'oxygen (2\u2009L/min) delivered routinely via nasal cannula', 'real or sham TEAS', 'transcutaneous electrical acupuncture point stimulation (TEAS) at PC6']","['rate of hypoxia', 'Depth of anesthesia', 'respiratory rate, systolic and diastolic blood pressures, mean arterial pressure, and heart rate', 'peripheral capillary oxygen saturation']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0428178', 'cui_str': 'Capillary oxygen saturation measurement'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}]","[{'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0135624', 'cui_str': 'PC6 extract'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0439393', 'cui_str': 'L/min'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0474710', 'cui_str': 'Depth of anesthesia'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0428178', 'cui_str': 'Capillary oxygen saturation measurement'}]",32.0,0.182575,Significantly fewer patients in the treatment group experienced a ⩾4% decrease from baseline SpO 2 (2/16) than patients in the control group (10/16; p = 0.004).,"[{'ForeName': 'Yongming', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Gong', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Xiaorong', 'Initials': 'X', 'LastName': 'Huai', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.'}, {'ForeName': 'Xiyao', 'Initials': 'X', 'LastName': 'Gu', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Diansan', 'Initials': 'D', 'LastName': 'Su', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Weifeng', 'Initials': 'W', 'LastName': 'Yu', 'Affiliation': 'Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Xie', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.'}]",Acupuncture in medicine : journal of the British Medical Acupuncture Society,['10.1177/0964528420960479'] 1332,34118653,Music therapy enhances preterm infant's signs of engagement and sustains maternal singing in the NICU.,"Hospitalized preterm infants are exposed to stressful stimuli and early parental separation, which can undermine their long-term development and mother-infant bonding. Family-centered music therapy can enable positive mother-infant interactions, mediated by maternal infant-directed singing. This study aimed to investigate the effects of music therapy on preterm infant's signs of engagement, namely Eye Opening (EO) and Smiling (SM), and maternal vocalizations. Participants were 30 mother-preterm infant dyads in a Brazilian Neonatal Intensive Care Unit (NICU), divided into a Music Therapy Group (MTG) and a Comparison Group (CG). The MTG participated in 6 sessions of the Music Therapy Intervention for the Mother-Preterm Infant Dyad (MUSIP), with the aim of supporting maternal singing with the infant. Prior to discharge, all mothers were filmed during a Non-singing (NS) and Singing (S) interactional condition; in the S condition, mothers were explicitly asked to address their infants by singing. Results of video and audio analysis showed that infants in the MTG displayed greater Eye Opening (EO) frequency compared to CG, but only when they were in an initial awake state at test, suggesting that music therapy can potentialize infants' alertness, by increasing their disposition and chances of being engaged in the interaction with the mother. Non-religious mothers appeared to sing significantly more in the MTG than in the CG. These preliminary findings indicate that music therapy in the NICU could promote infant's signs of engagement during interactions and can sustain maternal singing, especially with non-religious mothers in Brazil.",2021,"Results of video and audio analysis showed that infants in the MTG displayed greater Eye Opening (EO) frequency compared to CG, but only when they were in an initial awake state at test, suggesting that music therapy can potentialize infants' alertness, by increasing their disposition and chances of being engaged in the interaction with the mother. Non-religious mothers appeared to sing significantly more in the MTG than in the CG.","['Participants were 30 mother-preterm infant dyads in a Brazilian Neonatal Intensive Care Unit (NICU), divided into a', 'Hospitalized preterm infants']","['music therapy', 'Music Therapy Intervention', 'Family-centered music therapy', 'Music Therapy Group (MTG) and a Comparison Group (CG', 'Music therapy']","['Eye Opening (EO) frequency', ""preterm infant's signs of engagement and sustains maternal singing"", ""preterm infant's signs of engagement, namely Eye Opening (EO) and Smiling (SM), and maternal vocalizations""]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}]","[{'cui': 'C0026868', 'cui_str': 'Music therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0037363', 'cui_str': 'Smiling'}, {'cui': 'C0042932', 'cui_str': 'Singing, Animal'}]",30.0,0.0354503,"Results of video and audio analysis showed that infants in the MTG displayed greater Eye Opening (EO) frequency compared to CG, but only when they were in an initial awake state at test, suggesting that music therapy can potentialize infants' alertness, by increasing their disposition and chances of being engaged in the interaction with the mother. Non-religious mothers appeared to sing significantly more in the MTG than in the CG.","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Palazzi', 'Affiliation': 'Psychology Institute, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil. Electronic address: palazziambra@gmail.com.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Filippa', 'Affiliation': ""Department of Psychology and University Hospital, University of Geneva, Switzerland; Department of Social Sciences, University of Valle d'Aosta, Italy.""}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Meschini', 'Affiliation': 'S. Stefano Rehabilitation Institute, P. P. Picena, MC, Italy.'}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Piccinini', 'Affiliation': 'Psychology Institute, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.'}]",Infant behavior & development,['10.1016/j.infbeh.2021.101596'] 1333,34118609,Randomized trial of high-dose pyridoxine in combination with standard hormonal therapy in West syndrome.,"OBJECTIVE To determine whether high-dose, oral pyridoxine in combination with standard adrenocorticotropic hormone (ACTH) therapy has superior effectiveness than ACTH therapy alone in increasing cessation of epileptic spasms for children with West syndrome. METHODS This study was an open-label, randomized controlled trial with masked endpoint assessments. Eligible children with West syndrome, age ranged 3-18 months, were randomized into the intervention (n = 43) and the standard arm (n = 37) of therapy. The intervention group received oral pyridoxine at 100-300 mg/kg/day in addition to standard therapy of intramuscular ACTH at 150 IU/m 2 /day. Primary effectiveness outcome was a complete cessation of spasms at two weeks and sustained till six weeks. RESULTS Comparison of effectiveness measures between intervention and standard groups were : complete cessation of epileptic spasms (48.8% vs 58.3%; group difference -9.6%; 95% confidence interval [CI] -30% to 12.3%; p = 0.4), median EEG scores (Q1-Q3) by Jeavons Score at six weeks [3 (1-5) vs 3 (1-5); p = 0.6], median motor scores (Q1-Q3) by DASII (Development Assessment Scales for Indian Infants) at 12 weeks [35 (29-49) vs 42 (34.3-63.8), p = 0.04], and median mental scores (Q1-Q3) by DASII at 12 weeks [35 (29.5-46) vs 41.5 (31.3-60), p = 0.02]. Adverse events were comparable in both arms. CONCLUSIONS There was no evidence to suggest the superiority of high-dose pyridoxine in combination with ACTH versus ACTH alone for the treatment of West syndrome, considering the limitations of the study design.",2021,"Adverse events were comparable in both arms. ","['Eligible children with West syndrome, age ranged 3-18 months', 'children with West syndrome', 'West syndrome']","['pyridoxine', 'standard hormonal therapy', 'standard adrenocorticotropic hormone (ACTH) therapy', 'oral pyridoxine at 100-300\xa0mg/kg/day in addition to standard therapy of intramuscular ACTH', 'ACTH versus ACTH', 'ACTH therapy alone']","['median EEG scores (Q1-Q3) by Jeavons Score', 'Adverse events', 'median motor scores (Q1-Q3) by DASII (Development Assessment Scales', 'median mental scores', 'complete cessation of epileptic spasms', 'complete cessation of spasms at two weeks and sustained till six weeks']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0034272', 'cui_str': 'pyridoxine'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C3665414', 'cui_str': 'mg/kg/day'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1527366', 'cui_str': 'Salaam Seizures'}, {'cui': 'C0026821', 'cui_str': 'Cramp'}, {'cui': 'C4082118', 'cui_str': 'Two weeks'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0439230', 'cui_str': 'week'}]",,0.100242,"Adverse events were comparable in both arms. ","[{'ForeName': 'Arundhati', 'Initials': 'A', 'LastName': 'Banerjee', 'Affiliation': 'Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Jitendra Kumar', 'Initials': 'JK', 'LastName': 'Sahu', 'Affiliation': 'Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: jsh2003@gmail.com.'}, {'ForeName': 'Naveen', 'Initials': 'N', 'LastName': 'Sankhyan', 'Affiliation': 'Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Smita', 'Initials': 'S', 'LastName': 'Pattanaik', 'Affiliation': 'Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Renu', 'Initials': 'R', 'LastName': 'Suthar', 'Affiliation': 'Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Arushi Gahlot', 'Initials': 'AG', 'LastName': 'Saini', 'Affiliation': 'Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Lokesh', 'Initials': 'L', 'LastName': 'Saini', 'Affiliation': 'Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Sandeep', 'Initials': 'S', 'LastName': 'Negi', 'Affiliation': 'Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Prahbhjot', 'Initials': 'P', 'LastName': 'Malhi', 'Affiliation': 'Child Psychology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Pratibha', 'Initials': 'P', 'LastName': 'Singhi', 'Affiliation': 'Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}]",Seizure,['10.1016/j.seizure.2021.05.012'] 1334,34118568,"Application of a new serratus anterior plane block in modified radical mastectomy under ultrasound guidance: A prospective, randomized controlled trial.","STUDY OBJECTIVES Post-operative pain is a significant concern following modified radical mastectomy in breast cancer patients. The serratus anterior plane block has recently been described as an effective technique for post-operative analgesia of modified radical mastectomy. The purpose of this study was to evaluate the analgesic efficacy and safety of a new serratus anterior plane (SAP) block for post-operative pain of mastectomy. DESIGN A randomized controlled trial. SETTING Single university teaching hospital, from October 2019 to April 2020. PATIENTS Eighty-seven female breast cancer patients aged 30-81 years scheduled for unilateral modified radical mastectomy. INTERVENTIONS Participants were randomly allocated to receive either general anesthesia plus SAP block (SAP block group, n = 43) or general anesthesia alone (Control group, n = 44). A single injection of 20 ml of 0.5% ropivacaine was administered into fascial plane between the pectoralis major and the serratus anterior in SAP block group. In the Control group, no block intervention was applied. MEASUREMENTS The primary outcome measure of the study was the VAS pain scores at different time-points (1, 6, 12, 24, 48 h) after modified radical mastectomy whereas the secondary outcome measures were the consumption of opioid analgesics. MAIN RESULTS Breast cancer patients in SAP block group had lower VAS pain scores compared with the Control group during the early post-operative period (1 h and 6 h after modified radical mastectomy), both at rest and with movement. In addition, the consumption of propofol was similar in two groups (P = 0.406), and the consumption of sufentanil and remifentanil in SAP block group were significantly lower than that of Control group (P = 0.000 and P = 0.000, respectively). CONCLUSIONS SAP block significantly attenuated post-operative pain and decreased opioids consumption in breast cancer patients undergoing modified radical mastectomy. TRIAL REGISTRATION This trial is registered in the Chinese Clinical Trial Registry (ChiCTR1900026989).",2021,"In addition, the consumption of propofol was similar in two groups (P = 0.406), and the consumption of sufentanil and remifentanil in SAP block group were significantly lower than that of Control group (P = 0.000 and P = 0.000, respectively). ","['modified radical mastectomy under ultrasound guidance', 'breast cancer patients', 'breast cancer patients undergoing modified radical mastectomy', 'Single university teaching hospital, from October 2019 to April 2020', 'Breast cancer patients in', 'Eighty-seven female breast cancer patients aged 30-81\xa0years scheduled for']","['new serratus anterior plane (SAP) block', 'ropivacaine', 'unilateral modified radical mastectomy', 'new serratus anterior plane block', 'SAP block', 'general anesthesia plus SAP block (SAP block group, n\xa0=\xa043) or general anesthesia alone (Control group, n\xa0=\xa044', 'modified radical mastectomy']","['VAS pain scores', 'analgesic efficacy and safety', 'consumption of sufentanil and remifentanil', 'consumption of opioid analgesics', 'consumption of propofol', 'opioids consumption']","[{'cui': 'C0024883', 'cui_str': 'Modified radical mastectomy'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C4517895', 'cui_str': '87'}, {'cui': 'C0235653', 'cui_str': 'Malignant neoplasm of female breast'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0224349', 'cui_str': 'Structure of serratus anterior muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0024883', 'cui_str': 'Modified radical mastectomy'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]",,0.304134,"In addition, the consumption of propofol was similar in two groups (P = 0.406), and the consumption of sufentanil and remifentanil in SAP block group were significantly lower than that of Control group (P = 0.000 and P = 0.000, respectively). ","[{'ForeName': 'Weixiang', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Guangtao', 'Initials': 'G', 'LastName': 'Luo', 'Affiliation': 'Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. Electronic address: luoguangtao@outlook.com.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Hu', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Yuanhai', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. Electronic address: liyuanhai-1@163.com.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110377'] 1335,34121224,"Real-time continuous glucose monitoring in preterm infants (react): An International, open-label, randomised, controlled trial.",,2021,,['preterm infants (react'],[],[],"[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C4224854', 'cui_str': 'React'}]",[],[],,0.0941968,,"[{'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Dinu', 'Affiliation': 'Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Rozance', 'Affiliation': 'University of Colorado, Aurora, CO, USA.'}]","Acta paediatrica (Oslo, Norway : 1992)",['10.1111/apa.15946'] 1336,34126540,Serum vanadium concentrations in different sports modalities.,"AIMS The aim of this study was to compare serum vanadium (V) concentrations between athletes of different sports modalities and people who did not practise physical exercise regularly. METHODS One hundred and twenty-one subjects divided into a control group (CG; n = 37; 1.75 ± 0.03 m; 79.45 ± 10.20 kg; 24.72 ± 6.06 years) and an athletes' group (AG; n = 84; 1.77 ± 0.05 m; 66.34 ± 6.12 kg; 19.57 ± 1.95 years) participated in this research. AG were classified by sports modality: aerobic (AE; n = 26), anaerobic (ANA; n = 22); aerobic-anaerobic (AE-ANA; n = 36). Serum V concentrations were analysed by inductively coupled plasma mass spectrometry. RESULTS AG showed higher V concentrations compared to CG (p < 0.01). AE obtained higher concentrations compared to ANA and AE-ANA (p < 0.05). CONCLUSIONS Physical training could increase serum V levels. Specifically, aerobic sports modalities could increase serum V levels to a greater extent than other sports modalities.",2021,"AE obtained higher concentrations compared to ANA and AE-ANA (p < 0.05). ","[""One hundred and twenty-one subjects divided into a control group (CG; n\u2009=\u200937; 1.75\u2009±\u20090.03\u2009m; 79.45\u2009±\u200910.20\u2009kg; 24.72\u2009±\u20096.06 years) and an athletes' group (AG; n\u2009=\u200984; 1.77\u2009±\u20090.05\u2009m; 66.34\u2009±\u20096.12\u2009kg; 19.57\u2009±\u20091.95 years) participated in this research"", 'athletes of different sports modalities and people who did not practise physical exercise regularly']",['Physical training'],"['Serum V concentrations', 'serum V levels', 'Serum vanadium concentrations', 'serum vanadium (V) concentrations']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517514', 'cui_str': '1.75'}, {'cui': 'C4517402', 'cui_str': '0.03'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0042306', 'cui_str': 'Vanadium'}]",121.0,0.0384104,"AE obtained higher concentrations compared to ANA and AE-ANA (p < 0.05). ","[{'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Toro-Román', 'Affiliation': 'Department of Physiology, School of Sport Sciences, University of Extremadura, Avenida de la Universidad s/n, 10003 Cáceres, Extremadura, Spain. Electronic address: vtororom@alumnos.unex.es.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Bartolomé', 'Affiliation': 'Department of Physiology, School of Sport Sciences, University of Extremadura, Avenida de la Universidad s/n, 10003 Cáceres, Extremadura, Spain. Electronic address: ignbs.1991@gmail.com.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Siquier-Coll', 'Affiliation': 'Movement, Brain and Health (MOBhe) Research Group, Center of Higher Education Alberta Giménez, affiliated to Comillas Pontifical University, Costa de Saragossa 16, 07013 Palma, Mallorca, Balearic Islands, Spain. Electronic address: jesussiquier@cesag.org.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Alves', 'Affiliation': 'Department of Sport Science, Faculty of Education, Pontifical University of Salamanca, C/Henry Collet, 52-70, CP: 37007 Salamanca, Spain. Electronic address: fjalvesva@upsa.es.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Grijota', 'Affiliation': 'Faculty of Language and Education, University of Nebrija, Campus La Berzosa, Calle del Hostal, 28248, Hoyo de Manzanares, Madrid, Spain. Electronic address: fgrijota@nebrija.es.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Muñoz', 'Affiliation': 'Department of Physiology, School of Sport Sciences, University of Extremadura, Avenida de la Universidad s/n, 10003 Cáceres, Extremadura, Spain. Electronic address: diegomun@unex.es.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Maynar-Mariño', 'Affiliation': 'Department of Physiology, School of Sport Sciences, University of Extremadura, Avenida de la Universidad s/n, 10003 Cáceres, Extremadura, Spain. Electronic address: mmaynar@unex.es.'}]",Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),['10.1016/j.jtemb.2021.126808'] 1337,34126432,Evaluation of Long-Term Clinical Outcomes and Patient Satisfaction Rate Following Low Intensity Shock Wave Therapy in Men With Erectile Dysfunction: A Minimum 5-Year Follow-Up on a Prospective Open-Label Single-Arm Clinical Study.,"INTRODUCTION Low intensity extracorporeal shock wave therapy (LIESWT) improves erectile function (EF) in men with vascular erectile dysfunction (ED) but longer-term outcomes remain unknown. AIM To evaluate the clinical outcomes of LIESWT at a minimum 5-year follow-up. METHODS This is an open-label single-arm prospective study involved men with vascular ED who received LIESWT. MAIN OUTCOME MEASURE Changes in patient demographics, IIEF-5 and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) scores, as well as overall satisfaction score (on a 5-point scale) were reviewed at 12, 24, 48, and 60 months after completion of LIESWT. A chi-square contingency analysis was used to examine the relationship between erectile function score and treatment satisfaction, with statistical significance set at 5%. RESULTS The mean follow-up period was 69.9 (63-82; median 76) months. The mean IIEF-5 scores for pretreatment and after treatment at 12, 24, 48, and 60 months were 14.8, 17.6, 16.8, 16.5, and 16.5 while the percentages of patients who reported an improvement in IIEF-5 score by 5 points were 60%, 45%, 40%, and 40%; and EDITS scores >50% were recorded in 70%, 55%, 50%, and 48% of patients at 12, 24, 48, and 60 months post-LIESWT. Ten patients required medical therapy and 2 patients opted for penile prosthesis implantation. The overall satisfaction rate appeared sustained subsequent follow-up (score 4 out of 5; 68% vs 50% vs 40% vs 40% at 12, 24, 48, and 60 months). There were minor time-limited, but no significant adverse event reported. CONCLUSION This long-term study showed the observed clinical improvement in EF continues to deteriorate but appears to plateau at 40% clinical efficacy at 48-60 months after completion of LIESWT. The absence of penile pain and deformity at 5-year follow-up supports the long-term safety data of LIESWT in men with ED. Chung E, Cartmill R. Evaluation of Long-Term Clinical Outcomes and Patient Satisfaction Rate Following Low Intensity Shock Wave Therapy in Men With Erectile Dysfunction: A Minimum 5-Year Follow-Up on a Prospective Open-Label Single-Arm Clinical Study. Sex Med 2021;9:100384.",2021,Following Low Intensity Shock Wave Therapy in Men,"['men with ED', 'With Erectile Dysfunction', 'Men', 'men with vascular erectile dysfunction (ED) but', 'men with vascular ED who received LIESWT']","['Low intensity extracorporeal shock wave therapy (LIESWT', 'penile prosthesis implantation', 'Low Intensity Shock Wave Therapy']","['overall satisfaction score', 'mean IIEF-5 scores', 'overall satisfaction rate', 'erectile function score and treatment satisfaction', 'patient demographics, IIEF-5 and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS', 'erectile function (EF', 'IIEF-5 score', 'Patient Satisfaction Rate']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0242350', 'cui_str': 'Impotence'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C1737238', 'cui_str': 'Extracorporeal shock wave therapy'}]","[{'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C1737238', 'cui_str': 'Extracorporeal shock wave therapy'}, {'cui': 'C0403319', 'cui_str': 'Insertion of penile prosthesis'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030847', 'cui_str': 'Penile erection'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0242350', 'cui_str': 'Impotence'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",,0.0746092,Following Low Intensity Shock Wave Therapy in Men,"[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Chung', 'Affiliation': 'The University of Queensland, Department of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia; AndroUrology Centre, Brisbane, QLD, Australia; AndroUrology Centre, Sydney, NSW, Australia. Electronic address: ericchg@hotmail.com.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Cartmill', 'Affiliation': 'The University of Queensland, Department of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia.'}]",Sexual medicine,['10.1016/j.esxm.2021.100384'] 1338,34391284,The addition of thoracic mobilization to aerobic exercise did not alter autonomic function and pain pressure threshold acutely in asymptomatic young people: A randomized controlled trial.,"OBJECTIVE To analyze the influence of acute aerobic exercise (AE) plus thoracic mobilization in pain perception and autonomic nervous system response in healthy adults. DESIGN Randomized clinical trial. METHODS Forty-eight asymptomatic adults were allocated into one of three groups: 1) Aerobic Exercise (AE), 2) Aerobic Exercise + Mobilization (AE + M), and 3) Placebo. Participants from groups AE and AE + M ran for 5 min on a treadmill with a 75-85% of age-predicted heart rate. Participants from AE + M group also received a rotatory thoracic passive accessory intervertebral mobilization at T4 after running. Participants from the Placebo group received placebo mobilization. We mesured the autonomic system modulation through Heart Rate Variability (HRV) (time-domain, frequency-domain, and non-linear variables). We measured Pressure Pain Threshold (PPT) with a handheld digital algometer. RESULTS While aerobic exercise increased the sympathetic outflow and reduced the HRV, the addition of vertebral mobilization to exercise had no further effect on autonomic system modulation. There was no change in PPT in any group. Besides, there was no correlation between HRV and PPT. CONCLUSION Thoracic mobilization did not increase the sympathetic response induced by aerobic exercise. Moreover, exercise alone or exercise plus thoracic mobilization did not change the PPT.",2021,"While aerobic exercise increased the sympathetic outflow and reduced the HRV, the addition of vertebral mobilization to exercise had no further effect on autonomic system modulation.","['Forty-eight asymptomatic adults', 'healthy adults', 'asymptomatic young people']","['Aerobic Exercise (AE), 2', 'aerobic exercise', 'Aerobic Exercise\xa0+\xa0Mobilization (AE\xa0+\xa0M), and 3) Placebo', 'rotatory thoracic passive accessory intervertebral mobilization', 'placebo mobilization', 'Placebo', 'acute aerobic exercise (AE) plus thoracic mobilization', 'exercise alone or exercise plus thoracic mobilization']","['PPT', 'sympathetic outflow', 'Pressure Pain Threshold (PPT', 'autonomic function and pain pressure threshold acutely', 'autonomic system modulation', 'pain perception and autonomic nervous system response', 'sympathetic response', 'Heart Rate Variability (HRV) (time-domain, frequency-domain, and non-linear variables']","[{'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0442106', 'cui_str': 'Intervertebral'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0032334', 'cui_str': 'podofilox'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0439828', 'cui_str': 'Variable'}]",48.0,0.170336,"While aerobic exercise increased the sympathetic outflow and reduced the HRV, the addition of vertebral mobilization to exercise had no further effect on autonomic system modulation.","[{'ForeName': 'Mariana D V', 'Initials': 'MDV', 'LastName': 'Pessoa', 'Affiliation': 'Physical Therapy Department, Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil. Electronic address: marianadvalentina@gmail.com.'}, {'ForeName': 'Francisco X', 'Initials': 'FX', 'LastName': 'de Araujo', 'Affiliation': 'Physical Therapy Department, Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil; Centro Universitário Ritter dos Reis (UniRitter) - Laureate International Universities, Porto Alegre, Brazil. Electronic address: franciscoxaraujo@gmail.com.'}, {'ForeName': 'Maurício S', 'Initials': 'MS', 'LastName': 'Schell', 'Affiliation': 'Physical Therapy Department, Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil. Electronic address: mschell.fisio@gmail.com.'}, {'ForeName': 'Marcelo F', 'Initials': 'MF', 'LastName': 'Silva', 'Affiliation': 'Physical Therapy Department, Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil. Electronic address: Marcelofs@ufcspa.edu.br.'}, {'ForeName': 'Fabricio Edler', 'Initials': 'FE', 'LastName': 'Macagnan', 'Affiliation': 'Physical Therapy Department, Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil. Electronic address: fmacagnan@hotmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.008'] 1339,34131001,Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g BRCA Advanced Breast Cancer (BROCADE3 Crossover).,"PURPOSE Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (g BRCA )-associated breast cancer enrolled in the BROCADE3 trial who received crossover veliparib monotherapy after disease progression on placebo plus carboplatin/paclitaxel. PATIENTS AND METHODS Eligible patients ( N = 513) were randomized 2:1 to veliparib plus carboplatin/paclitaxel or placebo plus carboplatin/paclitaxel; patients had variable platinum-free intervals (PFI) at progression. In the placebo arm, patients were eligible to receive crossover veliparib monotherapy (300-400 mg twice daily continuous). Antitumor activity and adverse events were assessed during crossover veliparib treatment. BRCA reversion mutations at crossover were analyzed retrospectively using next-generation sequencing on plasma circulating tumor DNA (ctDNA). RESULTS Seventy-five patients in the placebo plus carboplatin/paclitaxel arm received ≥1 dose of crossover veliparib postprogression (mean treatment duration: 154 days). Eight of 50 (16%) patients with measurable disease had a RECIST v1.1 response. Activity was greater in patients with PFI ≥180 days compared with <180 days [responses in 23.1% (3/13) vs. 13.5% (5/37) of patients]. BRCA reversion mutations that restored protein function were detected in ctDNA from 4 of 28 patients tested, and the mean duration of crossover veliparib monotherapy was <1 month in these 4 patients versus 7.49 months in patients lacking reversion mutations. The most frequent adverse events were nausea (61%), vomiting (29%), and fatigue (24%). CONCLUSIONS Crossover veliparib monotherapy demonstrated limited antitumor activity in patients who experienced disease progression on placebo plus carboplatin/paclitaxel. PFI appeared to affect veliparib activity. BRCA reversion mutations may promote cross-resistance and limit veliparib activity following progression on platinum.",2021,Activity was greater in patients with PFI {greater than or equal to}180 days compared with <180 days (responses in 23.1% [3/13] vs 13.5% [5/37] of patients). ,"['patients who experienced disease progression on', 'gBRCA Advanced Breast Cancer', 'patients with advanced HER2-negative g BRCA', 'N=513', 'Eligible patients ', 'Seventy-five patients in the', 'patients had variable platinum-free intervals (PFIs) at progression']","['veliparib plus carboplatin/paclitaxel or placebo plus carboplatin/paclitaxel', 'Carboplatin/Paclitaxel', 'Veliparib Monotherapy', 'placebo plus carboplatin/paclitaxel', 'placebo', 'crossover veliparib monotherapy']","['Antitumor activity and adverse events', 'Activity', 'antitumor activity', 'protein function', 'vomiting', 'fatigue', 'nausea', 'BRCA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]","[{'cui': 'C1958300', 'cui_str': 'veliparib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",513.0,0.195582,Activity was greater in patients with PFI {greater than or equal to}180 days compared with <180 days (responses in 23.1% [3/13] vs 13.5% [5/37] of patients). ,"[{'ForeName': 'Shannon L', 'Initials': 'SL', 'LastName': 'Puhalla', 'Affiliation': 'University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania. puhallasl@upmc.edu.'}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Diéras', 'Affiliation': 'Institut Curie, Paris, France.'}, {'ForeName': 'Banu K', 'Initials': 'BK', 'LastName': 'Arun', 'Affiliation': 'The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Bella', 'Initials': 'B', 'LastName': 'Kaufman', 'Affiliation': 'Sheba Medical Center, Tel Hashomer, Israel.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Wildiers', 'Affiliation': 'University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Hyo S', 'Initials': 'HS', 'LastName': 'Han', 'Affiliation': 'Moffitt Cancer Center, Tampa, Florida.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Ayoub', 'Affiliation': ""Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.""}, {'ForeName': 'Vered', 'Initials': 'V', 'LastName': 'Stearns', 'Affiliation': 'The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'City of Hope Cancer Center, Duarte, California.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Helsten', 'Affiliation': 'University of California San Diego Moores Cancer Center, La Jolla, California.'}, {'ForeName': 'Bridget', 'Initials': 'B', 'LastName': 'Riley-Gillis', 'Affiliation': 'AbbVie Inc., North Chicago, Illinois.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Murphy', 'Affiliation': 'AbbVie Inc., North Chicago, Illinois.'}, {'ForeName': 'Madan G', 'Initials': 'MG', 'LastName': 'Kundu', 'Affiliation': 'AbbVie Inc., North Chicago, Illinois.'}, {'ForeName': 'Meijing', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'AbbVie Inc., North Chicago, Illinois.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Maag', 'Affiliation': 'AbbVie Inc., North Chicago, Illinois.'}, {'ForeName': 'Christine K', 'Initials': 'CK', 'LastName': 'Ratajczak', 'Affiliation': 'AbbVie Inc., North Chicago, Illinois.'}, {'ForeName': 'Cyril Y', 'Initials': 'CY', 'LastName': 'Ramathal', 'Affiliation': 'AbbVie Inc., North Chicago, Illinois.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Friedlander', 'Affiliation': 'Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney, New South Wales, Australia.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-21-0748'] 1340,34129743,Effect of orofacial physiotherapeutic and hygiene interventions on oral health-related quality of life in patients with Parkinson's disease: A randomised controlled trial.,"BACKGROUND Parkinson's disease (PD) has a negative effect on oral health and orofacial function, but the subjective experience of orofacial symptoms and their impact on the quality of life is not fully investigated. In addition, knowledge of how to improve the subjective oral symptoms is lacking. OBJECTIVES To assess the self-reported orofacial function and oral health in patients with PD. Furthermore, to investigate the effect of interventions for improvement of oral hygiene and function on oral health-related quality of life (OHRQoL). METHODS A randomised controlled study with delayed intervention was conducted in 29 patients with moderate to advanced PD. Patients were instructed in a standardised exercise programme for the jaw and orofacial muscles and given an individualised oral hygiene programme. The effect on self-reported orofacial function and OHRQoL was measured after 2 and 4 months using the Nordic Orofacial Test-Screening (NOT-S), the oral health impact profile (OHIP-14), self-reported drooling score and subjective mastication ability. RESULTS Self-reported oral health and function before the intervention was significantly correlated to the severity and duration of PD. The NOT-S and drooling score were significantly improved by the interventions after 2 months and the OHIP-14 after 4 months. CONCLUSION The interventions improve the self-reported orofacial function and OHRQoL. These simple interventions can be implemented in the allied multidisciplinary health care surrounding the PD patient.",2021,"The NOT-S and drooling score were significantly improved by the interventions after 2 months and the OHIP-14 after 4 months. ","['29 patients with moderate to advanced PD', ""Parkinson's disease (PD"", ""patients with Parkinson's disease"", 'patients with PD']","['orofacial physiotherapeutic and hygiene interventions', 'standardised exercise program for the jaw and orofacial muscles and given an individualized oral hygiene program', 'delayed intervention']","['NOT-S and drooling score', 'oral health impact profile (OHIP-14), self-reported drooling score and subjective mastication ability', 'oral hygiene and function on oral health related quality of life (OHRQoL', 'orofacial function and OHRQoL', 'self-reported orofacial function and OHRQoL', 'severity and duration of PD', 'oral health related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0022359', 'cui_str': 'Jaw'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}]","[{'cui': 'C0013132', 'cui_str': 'Dribbling from mouth'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0024888', 'cui_str': 'Mastication'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]",29.0,0.0350666,"The NOT-S and drooling score were significantly improved by the interventions after 2 months and the OHIP-14 after 4 months. ","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Baram', 'Affiliation': 'Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Merete', 'Initials': 'M', 'LastName': 'Karlsborg', 'Affiliation': 'Department of Neurology, Bispebjerg University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Esben Boeskov', 'Initials': 'EB', 'LastName': 'Øzhayat', 'Affiliation': 'Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Merete', 'Initials': 'M', 'LastName': 'Bakke', 'Affiliation': 'Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}]",Journal of oral rehabilitation,['10.1111/joor.13214'] 1341,34134048,Prenatal household air pollutant exposure is associated with reduced size and gestational age at birth among a cohort of Ghanaian infants.,"BACKGROUND Low birth weight and prematurity are important risk factors for death and disability, and may be affected by prenatal exposure to household air pollution (HAP). METHODS We investigate associations between maternal exposure to carbon monoxide (CO) during pregnancy and birth outcomes (birth weight, birth length, head circumference, gestational age, low birth weight, small for gestational age, and preterm birth) among 1288 live-born infants in the Ghana Randomized Air Pollution and Health Study (GRAPHS). We evaluate whether evidence of malaria during pregnancy, as determined by placental histopathology, modifies these associations. RESULTS We observed effects of CO on birth weight, birth length, and gestational age that were modified by placental malarial status. Among infants from pregnancies without evidence of placental malaria, each 1 ppm increase in CO was associated with reduced birth weight (-53.4 g [95% CI: -84.8, -21.9 g]), birth length (-0.3 cm [-0.6, -0.1 cm]), gestational age (-1.0 days [-1.8, -0.2 days]), and weight-for-age Z score (-0.08 standard deviations [-0.16, -0.01 standard deviations]). These associations were not observed in pregnancies with evidence of placental malaria. Each 1 ppm increase in maternal exposure to CO was associated with elevated odds of low birth weight (LBW, OR 1.14 [0.97, 1.33]) and small for gestational age (SGA, OR 1.14 [0.98, 1.32]) among all infants. CONCLUSIONS Even modest reductions in exposure to HAP among pregnant women could yield substantial public health benefits, underscoring a need for interventions to effectively reduce exposure. Adverse associations with HAP were discernible only among those without evidence of placental malaria, a key driver of impaired fetal growth in this malaria-endemic area.",2021,"Adverse associations with HAP were discernible only among those without evidence of placental malaria, a key driver of impaired fetal growth in this malaria-endemic area.","['pregnant women', '53.4', '1288 live-born infants in the Ghana Randomized Air Pollution and Health Study (GRAPHS']",['maternal exposure to carbon monoxide (CO'],"['weight-for-age Z score', 'birth weight ', 'CO', 'birth outcomes (birth weight, birth length, head circumference, gestational age, low birth weight, small for gestational age, and preterm birth', 'birth weight, birth length, and gestational age', 'maternal exposure to CO', 'birth length']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0017516', 'cui_str': 'Ghana'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0001873', 'cui_str': 'Air pollution'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0243033', 'cui_str': 'Maternal Exposure'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C1286282', 'cui_str': 'Birth outcome'}, {'cui': 'C0419415', 'cui_str': 'Birth length'}, {'cui': 'C0262499', 'cui_str': 'Head circumference'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0235991', 'cui_str': 'Small for gestational age'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0243033', 'cui_str': 'Maternal Exposure'}]",,0.390892,"Adverse associations with HAP were discernible only among those without evidence of placental malaria, a key driver of impaired fetal growth in this malaria-endemic area.","[{'ForeName': 'Ashlinn K', 'Initials': 'AK', 'LastName': 'Quinn', 'Affiliation': 'Fogarty International Center, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Irene Apewe', 'Initials': 'IA', 'LastName': 'Adjei', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}, {'ForeName': 'Kenneth Ayuurebobi', 'Initials': 'KA', 'LastName': 'Ae-Ngibise', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}, {'ForeName': 'Oscar', 'Initials': 'O', 'LastName': 'Agyei', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}, {'ForeName': 'Ellen Abrafi', 'Initials': 'EA', 'LastName': 'Boamah-Kaali', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Burkart', 'Affiliation': 'University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Carrión', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Steven N', 'Initials': 'SN', 'LastName': 'Chillrud', 'Affiliation': 'Mailman School of Public Health, Columbia University, New York, NY, USA; Lamont-Doherty Earth Observatory of Columbia University, Palisades, NY, USA.'}, {'ForeName': 'Carlos F', 'Initials': 'CF', 'LastName': 'Gould', 'Affiliation': 'Mailman School of Public Health, Columbia University, New York, NY, USA.'}, {'ForeName': 'Stephaney', 'Initials': 'S', 'LastName': 'Gyaase', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}, {'ForeName': 'Darby W', 'Initials': 'DW', 'LastName': 'Jack', 'Affiliation': 'Mailman School of Public Health, Columbia University, New York, NY, USA.'}, {'ForeName': 'Seyram', 'Initials': 'S', 'LastName': 'Kaali', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}, {'ForeName': 'Patrick L', 'Initials': 'PL', 'LastName': 'Kinney', 'Affiliation': 'Boston University School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Alison G', 'Initials': 'AG', 'LastName': 'Lee', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Mohammed Nuhu', 'Initials': 'MN', 'LastName': 'Mujtaba', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}, {'ForeName': 'Felix Boakye', 'Initials': 'FB', 'LastName': 'Oppong', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}, {'ForeName': 'Seth', 'Initials': 'S', 'LastName': 'Owusu-Agyei', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana; Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana.'}, {'ForeName': 'Abena', 'Initials': 'A', 'LastName': 'Yawson', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}, {'ForeName': 'Blair J', 'Initials': 'BJ', 'LastName': 'Wylie', 'Affiliation': 'Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: bwylie@bidmc.harvard.edu.'}, {'ForeName': 'Kwaku Poku', 'Initials': 'KP', 'LastName': 'Asante', 'Affiliation': 'Kintampo Health Research Centre, Kintampo, Ghana.'}]",Environment international,['10.1016/j.envint.2021.106659'] 1342,34153272,"Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial.","BACKGROUND Respiratory complications are an important cause of postoperative morbidity. We aimed to investigate whether continuous positive airway pressure (CPAP) administered immediately after major abdominal surgery could prevent postoperative morbidity. METHODS PRISM was an open-label, randomised, phase 3 trial done at 70 hospitals across six countries. Patients aged 50 years or older who were undergoing elective major open abdominal surgery were randomly assigned (1:1) to receive CPAP within 4 h of the end of surgery or usual postoperative care. Patients were randomly assigned using a computer-generated minimisation algorithm with inbuilt concealment. The primary outcome was a composite of pneumonia, endotracheal re-intubation, or death within 30 days after randomisation, assessed in the intention-to-treat population. Safety was assessed in all patients who received CPAP. The trial is registered with the ISRCTN registry, ISRCTN56012545. FINDINGS Between Feb 8, 2016, and Nov 11, 2019, 4806 patients were randomly assigned (2405 to the CPAP group and 2401 to the usual care group), of whom 4793 were included in the primary analysis (2396 in the CPAP group and 2397 in the usual care group). 195 (8·1%) of 2396 patients in the CPAP group and 197 (8·2%) of 2397 patients in the usual care group met the composite primary outcome (adjusted odds ratio 1·01 [95% CI 0·81-1·24]; p=0·95). 200 (8·9%) of 2241 patients in the CPAP group had adverse events. The most common adverse events were claustrophobia (78 [3·5%] of 2241 patients), oronasal dryness (43 [1·9%]), excessive air leak (36 [1·6%]), vomiting (26 [1·2%]), and pain (24 [1·1%]). There were two serious adverse events: one patient had significant hearing loss and one patient had obstruction of their venous catheter caused by a CPAP hood, which resulted in transient haemodynamic instability. INTERPRETATION In this large clinical effectiveness trial, CPAP did not reduce the incidence of pneumonia, endotracheal re-intubation, or death after major abdominal surgery. Although CPAP has an important role in the treatment of respiratory failure after surgery, routine use of prophylactic post-operative CPAP is not recommended. FUNDING National Institute for Health Research, Barts Charity, Intersurgical, Association of Anaesthetists, and Sapienza Università di Roma.",2021,"The most common adverse events were claustrophobia (78 [3·5%] of 2241 patients), oronasal dryness (43 [1·9%]), excessive air leak (36 [1·6%]), vomiting (26 [1·2%]), and pain (24 [1·1%]).","['Patients aged 50 years or older who were undergoing elective major open abdominal surgery', '195 (8·1%) of 2396 patients in the CPAP group and 197 (8·2%) of 2397 patients in the usual care group met the composite primary outcome ', 'Between Feb 8, 2016, and Nov 11, 2019, 4806 patients were randomly assigned (2405 to the CPAP group and 2401 to the usual care group), of whom 4793 were included in the primary analysis (2396 in the CPAP group and 2397 in the usual care group', '70 hospitals across six countries', 'after major abdominal surgery (PRISM']","['continuous positive airway pressure (CPAP', 'Postoperative continuous positive airway pressure', 'computer-generated minimisation algorithm with inbuilt concealment', 'CPAP', 'CPAP within 4 h of the end of surgery or usual postoperative care']","['excessive air leak', 'transient haemodynamic instability', 'composite of pneumonia, endotracheal re-intubation, or death within 30 days after randomisation, assessed in the intention-to-treat population', 'hearing loss', 'incidence of pneumonia, endotracheal re-intubation, or death', 'pneumonia, re-intubation, and death', 'oronasal dryness', 'adverse events', 'vomiting', 'pain', 'Safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0454664', 'cui_str': 'Country'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0032786', 'cui_str': 'Postoperative care'}]","[{'cui': 'C0442802', 'cui_str': 'Excessive'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0332234', 'cui_str': 'Leaking'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0948268', 'cui_str': 'Hemodynamic instability'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0011053', 'cui_str': 'Deafness'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",4806.0,0.238398,"The most common adverse events were claustrophobia (78 [3·5%] of 2241 patients), oronasal dryness (43 [1·9%]), excessive air leak (36 [1·6%]), vomiting (26 [1·2%]), and pain (24 [1·1%]).","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(21)00089-8'] 1343,33254239,The clinical and cost effectiveness of splints for thumb base osteoarthritis: a randomized controlled clinical trial.,"OBJECTIVES To investigate the clinical effectiveness, efficacy and cost effectiveness of splints (orthoses) in people with symptomatic basal thumb joint OA (BTOA). METHODS A pragmatic, multicentre parallel group randomized controlled trial at 17 National Health Service (NHS) hospital departments recruited adults with symptomatic BTOA and at least moderate hand pain and dysfunction. We randomized participants (1:1:1) using a computer-based minimization system to one of three treatment groups: a therapist supported self-management programme (SSM), a therapist supported self-management programme plus a verum thumb splint (SSM+S), or a therapist supported self-management programme plus a placebo thumb splint (SSM+PS). Participants were blinded to group allocation, received 90 min therapy over 8 weeks and were followed up for 12 weeks from baseline. Australian/Canadian (AUSCAN) hand pain at 8 weeks was the primary outcome, using intention to treat analysis. We calculated costs of treatment. RESULTS We randomized 349 participants to SSM (n = 116), SSM+S (n = 116) or SSM+PS (n = 117) and 292 (84%) provided AUSCAN Osteoarthritis Hand Index hand pain scores at the primary end point (8 weeks). All groups improved, with no mean treatment difference between groups: SSM+S vs SSM -0.5 (95% CI: -1.4, 0.4), P = 0.255; SSM+PS vs SSM -0.1 (95% CI: -1.0, 0.8), P = 0.829; and SSM+S vs SSM+PS -0.4 (95% CI: -1.4, 0.5), P = 0.378. The average 12-week costs were: SSM £586; SSM+S £738; and SSM+PS £685. CONCLUSION There was no additional benefit of adding a thumb splint to a high-quality evidence-based, supported self-management programme for thumb OA delivered by therapists. TRIAL REGISTRATION ISRCTN 54744256 (http://www.isrctn.com/ISRCTN54744256).",2021,"All groups improved, with no mean treatment difference between groups:","['17 National Health Service (NHS) hospital departments recruited adults with symptomatic BTOA and at least moderate hand pain and dysfunction', '349 participants to SSM (n\u2009=\u2009116', 'thumb base osteoarthritis', 'people with symptomatic basal thumb joint OA (BTOA']","['therapist supported self-management programme (SSM), a therapist supported self-management programme plus a verum thumb splint (SSM+S), or a therapist supported self-management programme plus a placebo thumb splint (SSM+PS', 'SSM+S', 'splints (orthoses', 'SSM+S vs SSM+PS', 'SSM+PS']",['AUSCAN Osteoarthritis Hand Index hand pain scores'],"[{'cui': 'C0027462', 'cui_str': 'National Health Services'}, {'cui': 'C0019961', 'cui_str': 'Hospital department'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0459473', 'cui_str': 'Thumb joint structure'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0239833', 'cui_str': 'Hand pain'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0040067', 'cui_str': 'Thumb structure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0040067', 'cui_str': 'Thumb structure'}, {'cui': 'C0038009', 'cui_str': 'Splint'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0263746', 'cui_str': 'Degenerative joint disease of hand'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0239833', 'cui_str': 'Hand pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",349.0,0.242708,"All groups improved, with no mean treatment difference between groups:","[{'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Adams', 'Affiliation': 'Health Sciences, University of Southampton, Southampton.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Barratt', 'Affiliation': 'Health Sciences, University of Southampton, Southampton.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Rombach', 'Affiliation': 'Oxford Clinical Trials Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Oxford.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Arden', 'Affiliation': 'Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Southampton, Oxford.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Barbosa Bouças', 'Affiliation': 'Department of Life Sciences, Brunel University London, Uxbridge.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bradley', 'Affiliation': 'Hand Therapy Unit, Poole Hospital NHS Trust, Poole.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Doherty', 'Affiliation': 'Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Southampton, Oxford.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Dutton', 'Affiliation': 'Oxford Clinical Trials Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Oxford.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Gooberman-Hill', 'Affiliation': 'Elizabeth Blackwell Institute for Health Research, University of Bristol, Bristol.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Hislop-Lennie', 'Affiliation': 'Health Sciences, University of Southampton, Southampton.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Hutt-Greenyer', 'Affiliation': 'Patient and Public Involvement Group Health Sciences, University of Southampton, Southampton.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Jansen', 'Affiliation': 'Pulvertaft Hand Centre, Royal Derby Hospital, Derby.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'Luengo-Fernadez', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Williams', 'Affiliation': 'Department of Sport, Health Sciences and Social Work, Oxford Brookes University, Oxford.'}, {'ForeName': 'Krysia', 'Initials': 'K', 'LastName': 'Dziedzic', 'Affiliation': 'Primary Care Centre of Excellence Versus Arthritis, School of Primary Community and Social Care, Keele University, Staffordshire.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa726'] 1344,33254235,Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.,"OBJECTIVE The primary objectives of two phase II studies of fostamatinib were to evaluate efficacy (OSKIRA-Asia-1: NCT01569074) and long-term safety/tolerability (OSKIRA-Asia-1X: NCT01640054) in patients from Asia with active RA despite MTX treatment. METHODS OSKIRA-Asia-1 was a 12-week, multicentre, double-blind, placebo-controlled, parallel-group study. Patients were randomized to receive one of four fostamatinib doses (groups A-D; n = 31, 33, 33, 33) or placebo (group E; n = 33). OSKIRA-Asia-1X was a long-term extension study (100 mg fostamatinib qd) of patients who completed OSKIRA-Asia-1. RA signs and symptoms were measured by ACR response criteria and DAS based on a 28-joint count. Physical function status was assessed with the HAQ-Disability Index. Safety findings were monitored. RESULTS In OSKIRA-Asia-1, fostamatinib revealed numerical improvements in ACR 20% response (ACR20) at week 12 in group A (100 mg bid) and group B (100 mg bid, then 150 mg qd) vs placebo. Statistically significant improvements in ACR20 and ACR50 at week 8 and in ACR70 at week 12, and statistically significant achievement in low disease activity (defined as DAS based on a 28-joint count ≤3.2 based on C-reactive protein) occurred in groups A and B. Improvement in physical function was numerically higher in group A. The most common adverse events were hypertension, diarrhoea and neutropenia. In OSKIRA-Asia-1X, the most common adverse events were nasopharyngitis, hypertension, RA and neutropenia. CONCLUSION Fostamatinib achieved both statistically and clinically significant improvements in RA signs and symptoms. The safety and tolerability of fostamatinib (plus MTX) were consistent with previous studies. TRIAL REGISTRATION OSKIRA-Asia-1 trial registration: https://clinicaltrials.gov, NCT01569074; OSKIRA-Asia-1X trial registration: https://clinicaltrials.gov, NCT01640054.",2021,"Statistically significant improvements in ACR20 and ACR50 at week 8 and in ACR70 at week 12, and statistically significant achievement in low disease activity (defined as DAS based on a 28-joint count ≤3.2 based on C-reactive protein) occurred in groups A and B. Improvement in physical function was numerically higher in group A.","['patients from Asia with active RA despite MTX treatment', 'rheumatoid arthritis patients with an inadequate response to']","['methotrexate', 'fostamatinib (plus MTX', 'placebo']","['low disease activity', 'safety and tolerability', 'ACR20 and ACR50', 'nasopharyngitis, hypertension, RA and neutropenia', 'RA signs and symptoms', 'physical function', 'Safety and efficacy', 'hypertension, diarrhoea and neutropenia', 'Physical function status', 'HAQ-Disability Index']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C2713632', 'cui_str': 'fostamatinib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0102923', 'cui_str': 'ametantrone'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.151731,"Statistically significant improvements in ACR20 and ACR50 at week 8 and in ACR70 at week 12, and statistically significant achievement in low disease activity (defined as DAS based on a 28-joint count ≤3.2 based on C-reactive protein) occurred in groups A and B. Improvement in physical function was numerically higher in group A.","[{'ForeName': 'Yoshiya', 'Initials': 'Y', 'LastName': 'Tanaka', 'Affiliation': 'The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Millson', 'Affiliation': 'AstraZeneca R&D, Macclesfield, UK.'}, {'ForeName': 'Shigeru', 'Initials': 'S', 'LastName': 'Iwata', 'Affiliation': 'The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.'}, {'ForeName': 'Shingo', 'Initials': 'S', 'LastName': 'Nakayamada', 'Affiliation': 'The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa732'] 1345,33258114,Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.,"BACKGROUND An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE). METHODS Patients with HAE-1/2 received either lanadelumab 150 mg every 4 weeks (q4wks; n = 28), 300 mg q4wks (n = 29), 300 mg every 2 weeks (q2wks; n = 27), or placebo (n = 41) for 26 weeks (days 0-182). The Angioedema Quality of Life Questionnaire (AE-QoL) was administered monthly, consisting of four domain (functioning, fatigue/mood, fears/shame, nutrition) and total scores. The generic EQ-5D-5L questionnaire was administered on days 0, 98, and 182. Comparisons were made between placebo and (a) all lanadelumab-treated patients and (b) individual lanadelumab groups for changes in scores (day 0-182) and proportions achieving the minimal clinically important difference (MCID, -6) in AE-QoL total score. RESULTS Compared with the placebo group, the lanadelumab total group demonstrated significantly greater improvements in AE-QoL total and domain scores (mean change, -13.0 to -29.3; p < 0.05 for all); the largest improvement was in functioning. A significantly greater proportion of the lanadelumab total group achieved the MCID (70% vs 37%; p = 0.001). The lanadelumab 300 mg q2wks group had the highest proportion (81%; p = 0.001) and was 7.2 times more likely to achieve the MCID than the placebo group. Mean EQ-5D-5L scores at day 0 were high in all groups, indicating low impairment, with no significant changes at day 182. CONCLUSION Patients with HAE-1/2 experienced significant and clinically meaningful improvements in HRQoL measured by AE-QoL following lanadelumab treatment in the HELP Study.",2021,The lanadelumab 300 mg q2wks group had the highest proportion (81%; P=.001) and was 7.2 times more likely to achieve the MCID than the placebo group.,"['patients with hereditary angioedema in the HELP Study', 'Patients with HAE-1/2 received either', 'patients with hereditary angioedema (HAE']","['lanadelumab', 'placebo']","['MCID', 'Mean EQ-5D-5L scores', 'health-related quality of life (HRQoL', 'Angioedema Quality of Life Questionnaire (AE-QoL', 'HRQoL', 'health-related quality of life', 'AE-QoL total and domain scores', 'generic EQ-5D-5L questionnaire', 'proportions achieving the minimal clinically important difference (MCID, -6) in AE-QoL total score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019243', 'cui_str': 'Hereditary angioedema'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0580272', 'cui_str': '1/2'}]","[{'cui': 'C4505508', 'cui_str': 'lanadelumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0002994', 'cui_str': 'Angioedema'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C4277733', 'cui_str': 'Minimal Clinically Important Difference'}]",,0.0794152,The lanadelumab 300 mg q2wks group had the highest proportion (81%; P=.001) and was 7.2 times more likely to achieve the MCID than the placebo group.,"[{'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Lumry', 'Affiliation': 'Allergy Asthma Research Associates Research Center, Dallas, TX, USA.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Weller', 'Affiliation': 'Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Magerl', 'Affiliation': 'Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Aleena', 'Initials': 'A', 'LastName': 'Banerji', 'Affiliation': 'Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Hilary J', 'Initials': 'HJ', 'LastName': 'Longhurst', 'Affiliation': ""Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, and University College London Hospitals, London, UK.""}, {'ForeName': 'Marc A', 'Initials': 'MA', 'LastName': 'Riedl', 'Affiliation': 'Division of Rheumatology, Allergy & Immunology, University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Hannah B', 'Initials': 'HB', 'LastName': 'Lewis', 'Affiliation': 'ICON plc, London, UK.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Lu', 'Affiliation': 'Takeda Pharmaceutical Company Limited, Lexington, MA, USA.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Devercelli', 'Affiliation': 'Takeda Pharmaceutical Company Limited, Lexington, MA, USA.'}, {'ForeName': 'Gagan', 'Initials': 'G', 'LastName': 'Jain', 'Affiliation': 'Takeda Pharmaceutical Company Limited, Lexington, MA, USA.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Maurer', 'Affiliation': 'Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Allergy,['10.1111/all.14680'] 1346,34118436,Menstrual phase does not influence ventilatory responses to group III/IV afferent signaling in eumenorrheic young females.,"Estrogen can reduce sympathetic activity, but its effects on minute ventilation (V E ) with group III/IV afferent activation remain unclear. This study examined the influence of estrogen on V E during lower-extremity exercise with group III/IV activation. Females completed two identical visits in follicular and ovulatory menstrual phases. Nine participants (age 25 ± 4 years) performed three minutes of baseline steady-state cycle ergometry and then group III/IV afferents were further activated with proximal thigh cuffs inflated to 20, 60, and 100 mmHg (randomized) for two minutes and five minutes of cycling between each occlusion. Metaboreflex was isolated by post-exercise circulatory occlusion. Ventilation was measured continuously and rating of perceived exertion (RPE) was recorded for each stage. During rest and exercise, V E (p < 0.001) and tidal volume (V T ) (p = 0.033) were higher in the follicular than ovulatory phase. Minute ventilation, V T , and respiratory rate (R R ) with ergoreflex and metaboreflex activation were similar across phases. With cuff occlusion of 100 mmHg, V E increased from baseline by 26.3 ± 7.0 L/min in the follicular phase (p < 0.001) and by 25.3±7.7 L/min in the ovulatory phase (p < 0.001), with no difference between phases (p> 0.05); R R and V T increased similarly with occlusion, also with no phase differences. In eumenorrheic females, menstrual phase influences ventilation but not ventilatory responses to group III/IV isolation.",2021,"During rest and exercise, V E (p < 0.001) and tidal volume (V T ) (p = 0.033) were higher in the follicular than ovulatory phase.","['Eumenorrheic Young Females', 'Nine participants (age 25\u2009±\u20094 years']","['Estrogen', 'baseline steady-state cycle ergometry']","['Minute ventilation, V T , and respiratory rate (R R ) with ergoreflex and metaboreflex activation', 'V E', 'sympathetic activity', 'Metaboreflex', 'tidal volume (V T ', 'rating of perceived exertion (RPE']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0085143', 'cui_str': 'Ergometry'}]","[{'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0231963', 'cui_str': 'Volume of expired gas'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}]",,0.0430072,"During rest and exercise, V E (p < 0.001) and tidal volume (V T ) (p = 0.033) were higher in the follicular than ovulatory phase.","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Lee', 'Affiliation': 'Division of Physical Therapy, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, United States. Electronic address: leex4357@umn.edu.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Vera', 'Affiliation': 'Division of Rehabilitation Science, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, United States; Department of Health and Human Performance, University of Wisconsin - River Falls, 1110 S. Main St., River Falls, WI, 54022, United States.'}, {'ForeName': 'Ninitha', 'Initials': 'N', 'LastName': 'Asirvatham-Jeyaraj', 'Affiliation': 'Department of Biotechnology, Indian Institute of Technology Madras, Chennai, 6000036, India.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Chantigian', 'Affiliation': 'Division of Physical Therapy, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, United States.'}, {'ForeName': 'Mia', 'Initials': 'M', 'LastName': 'Larson', 'Affiliation': 'Lillehei Clinical Research Unit, University of Minnesota, Cancer & Cardiovascular Research Center, 2231 6th St. E, Minneapolis, MN, 55455, United States.'}, {'ForeName': 'Manda', 'Initials': 'M', 'LastName': 'Keller-Ross', 'Affiliation': 'Division of Physical Therapy, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, United States; Division of Rehabilitation Science, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, United States.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2021.103712'] 1347,34118367,The impact of gender on researchers' assessment: A randomized controlled trial.,"OBJECTIVES This randomized controlled trial aimed to test whether women or men would be preferred with identical curriculum vitae (CV); and the impact of the career stage in the evaluators' choice. STUDY DESIGN AND SETTING A simulated post-doctoral process was carried forward to be assessed for judgment. Level 1 and 2 Brazilian fellow researchers in the field of Dentistry were invited to act as external reviewers in a post-doctoral process and were randomly assigned to receive a CV from a woman or a man. They were required to rate the CV from 0 to 10 in scientific contribution, leadership potential, ability to work in groups, and international experience. RESULTS For all categories of CVs evaluated, CVs from men received higher scores compared to the CVs from women. Robust variance Poisson regressions demonstrated that men were more likely to receive higher scores in all categories, despite applicants' career stage. For example, CVs from men were nearly three quarters more likely to be seen as having leadership potential than equivalent CVs from women. CONCLUSION Gender bias is powerfully prevalent in academia in the dentistry field, despite researchers' career stage. Actions like implicit bias training must be urgently implemented to avoid (or at least decrease) that more women are harmed.",2021,"Robust variance Poisson regressions demonstrated that men were more likely to receive higher scores in all categories, despite applicants' career stage.",['women or men'],['identical curriculum vitae (CV'],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0592257', 'cui_str': 'Vita-E'}]",[],,0.307949,"Robust variance Poisson regressions demonstrated that men were more likely to receive higher scores in all categories, despite applicants' career stage.","[{'ForeName': 'Marina Christ', 'Initials': 'MC', 'LastName': 'Franco', 'Affiliation': 'Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus, 501 Smyth Rd, Ottawa, Canada; Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas, 457 Gonçalves Chaves Street, Pelotas, Brazil. Electronic address: mchrist@ohri.ca.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Helal', 'Affiliation': 'Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus, 501 Smyth Rd, Ottawa, Canada; Universidade do Extremo Sul Catarinense, 1105 Universitária Avenue, Criciúma, Santa Catarina, Brazil.'}, {'ForeName': 'Maximiliano Sérgio', 'Initials': 'MS', 'LastName': 'Cenci', 'Affiliation': 'Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas, 457 Gonçalves Chaves Street, Pelotas, Brazil.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Moher', 'Affiliation': 'Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus, 501 Smyth Rd, Ottawa, Canada.'}]",Journal of clinical epidemiology,['10.1016/j.jclinepi.2021.05.026'] 1348,34125089,Validation of a Psychosocial Intervention on Body Image in Older People: An Experimental Design.,"For most people, body satisfaction is crucial to develop both a positive self-concept and self-esteem, and therefore, it can influence mental health and well-being. This idea has been tested with younger people, but no studies explore whether body image interventions are useful when people age. This research validates a specific program designed for older people (IMAGINA Specific Body Image Program). This is done by employing a mixed experimental design, with between-subject and within-subject comparisons that focus on body satisfaction before and after experimental treatment, comparing two groups. Using this experimental methodology makes it possible to identify the effect of the intervention in a group of 176 people. The score obtained with the Body Shape Questionnaire (BSQ) was the dependent variable, and the IMAGINA program was the independent one. As for age, gender, relationship status, season, and residence environment, these were controlled variables. There were significant differences in body satisfaction between the two programs, obtaining better results with IMAGINA. The controlled variables had a much less significant effect than the treatment. Therefore, it is possible to improve body satisfaction in older adults through interventions similar to the one presented here.",2021,"There were significant differences in body satisfaction between the two programs, obtaining better results with IMAGINA.","['176 people', 'Older People', 'older people', 'older adults']",['Psychosocial Intervention'],"['body satisfaction', 'Body Shape Questionnaire (BSQ']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0451032', 'cui_str': 'Body shape questionnaire'}]",,0.00619078,"There were significant differences in body satisfaction between the two programs, obtaining better results with IMAGINA.","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Sánchez-Cabrero', 'Affiliation': 'Department of Social Sciences and Applied Languages, Alfonso X El Sabio University; rcabrero@uax.es.'}, {'ForeName': 'Ana C', 'Initials': 'AC', 'LastName': 'León-Mejía', 'Affiliation': 'Department of Psychology of Education and Psychobiology, International University of La Rioja (UNIR).'}, {'ForeName': 'Amaya', 'Initials': 'A', 'LastName': 'Arigita-García', 'Affiliation': 'Department of Social Sciences and Applied Languages, Alfonso X El Sabio University.'}]",Journal of visualized experiments : JoVE,['10.3791/62506'] 1349,34127852,"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.","Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R agonist and found it had comparable efficacy to injectable peptidic GLP-1R agonists in a humanized mouse model. We then completed a placebo-controlled, randomized, double-blind, multiple ascending-dose phase 1 study ( NCT03538743 ), in which we enrolled 98 patients with T2D on background metformin and randomized them to receive multiple ascending doses of danuglipron or placebo for 28 d, across eight cohorts. The primary outcomes were assessment of adverse events (AEs), safety laboratory tests, vital signs and 12-lead electrocardiograms. Most AEs were mild, with nausea, dyspepsia and vomiting most commonly reported. There were no clinically meaningful AEs in laboratory values across groups. Heart rate generally increased with danuglipron treatment at day 28, but no heart-rate AEs were reported. Systolic blood pressure was slightly decreased and changes in diastolic blood pressure were similar with danuglipron treatment at day 28, compared with placebo. There were no clinically meaningful electrocardiogram findings. In this study in T2D, danuglipron was generally well tolerated, with a safety profile consistent with the mechanism of action of GLP-1R agonism.",2021,"Systolic blood pressure was slightly decreased and changes in diastolic blood pressure were similar with danuglipron treatment at day 28, compared with placebo.","['type 2 diabetes', '98 patients with T2D on background']","['Danuglipron (PF-06882961', 'danuglipron or placebo', 'metformin', 'placebo', 'glucagon-like peptide-1 receptor (GLP-1R']","['Systolic blood pressure', 'adverse events (AEs), safety laboratory tests, vital signs and 12-lead electrocardiograms', 'nausea, dyspepsia and vomiting', 'diastolic blood pressure', 'glycemic lowering and body weight loss', 'Heart rate']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0378073', 'cui_str': 'GLP-1R Receptor'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0430456', 'cui_str': '12 lead ECG'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",98.0,0.415346,"Systolic blood pressure was slightly decreased and changes in diastolic blood pressure were similar with danuglipron treatment at day 28, compared with placebo.","[{'ForeName': 'Aditi R', 'Initials': 'AR', 'LastName': 'Saxena', 'Affiliation': 'Pfizer Worldwide Research and Development, Cambridge, MA, USA. aditi.saxena@pfizer.com.'}, {'ForeName': 'Donal N', 'Initials': 'DN', 'LastName': 'Gorman', 'Affiliation': 'Pfizer Worldwide Research and Development, Cambridge, UK.'}, {'ForeName': 'Ryan M', 'Initials': 'RM', 'LastName': 'Esquejo', 'Affiliation': 'Pfizer Worldwide Research and Development, Cambridge, MA, USA.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Bergman', 'Affiliation': 'Pfizer Worldwide Research and Development, Cambridge, MA, USA.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Chidsey', 'Affiliation': 'Pfizer Worldwide Research and Development, Cambridge, MA, USA.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Buckeridge', 'Affiliation': 'Pfizer Worldwide Research and Development, Cambridge, MA, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Griffith', 'Affiliation': 'Pfizer Worldwide Research and Development, Cambridge, MA, USA.'}, {'ForeName': 'Albert M', 'Initials': 'AM', 'LastName': 'Kim', 'Affiliation': 'Pfizer Worldwide Research and Development, Cambridge, MA, USA.'}]",Nature medicine,['10.1038/s41591-021-01391-w'] 1350,34126630,"Effects of cranberry beverages on oxidative stress and gut microbiota in subjects with Helicobacter pylori infection: a randomized, double-blind, placebo-controlled trial.","Helicobacter pylori-induced oxidative stress plays an important role in gastric diseases. H. pylori disturbs gut microbiota. The objective is to investigate the effects of cranberry beverages on oxidative stress biomarkers and gut microbiota in H. pylori positive subjects. 171 H. pylori positive participants were randomly assigned to one of the three groups: high-dose (HCb; 480 mL cranberry beverage), low-dose (LCb; 240 mL cranberry beverage plus 240 mL placebo) and placebo (480 mL). Subjects consumed the beverages daily for 4 weeks. Fasting blood samples were analyzed for oxidative stress biomarkers. The intestinal microbiome was analyzed by 16S rRNA sequencing. Compared with the placebo, HCb resulted in a significantly higher increase of total antioxidant capacity (mean ± SD: 1.39 ± 1.69 IU mL-1vs. 0.34 ± 1.73 IU mL-1; p < 0.001) and a higher decrease of the lipid peroxidation product malondialdehyde (-7.29 ± 10.83 nmol mg-1vs. -0.84 ± 15.66 nmol mg-1; p = 0.025). A significant dose-dependent effect on the elevation of superoxide dismutase was observed (p < 0.001). Microbiome data showed that consuming HCb and LCb led to a significant reduction of Pseudomonas (p < 0.05). In conclusion, the current research showed that consuming cranberry beverages significantly improved the antioxidant status in H. pylori positive subjects, which may be related to the reshaping of gut microbiota.",2021,Microbiome data showed that consuming HCb and LCb led to a significant reduction of Pseudomonas (p < 0.05).,"['171 H. pylori positive participants', 'H. pylori positive subjects', 'subjects with Helicobacter pylori infection']","['placebo', 'high-dose (HCb; 480 mL cranberry beverage), low-dose (LCb; 240 mL cranberry beverage plus 240 mL placebo) and placebo', 'placebo, HCb', 'cranberry beverages']","['elevation of superoxide dismutase', 'oxidative stress and gut microbiota', 'Fasting blood samples', 'antioxidant status', 'oxidative stress biomarkers and gut microbiota', 'total antioxidant capacity', 'lipid peroxidation product malondialdehyde']","[{'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0850666', 'cui_str': 'Infection caused by Helicobacter pylori'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0019432', 'cui_str': 'Hexachlorobenzene'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0453273', 'cui_str': 'Cranberry preparation'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023775', 'cui_str': 'Lipid peroxidation'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}]",171.0,0.546569,Microbiome data showed that consuming HCb and LCb led to a significant reduction of Pseudomonas (p < 0.05).,"[{'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Gao', 'Affiliation': 'Binzhou Medical University Hospital, 661 Huanghe Second Road, Binzhou, Shandong, China.'}, {'ForeName': 'Meiling', 'Initials': 'M', 'LastName': 'Hou', 'Affiliation': ''}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Pan', 'Affiliation': ''}, {'ForeName': 'Chengxia', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Chongxiu', 'Initials': 'C', 'LastName': 'Sun', 'Affiliation': ''}, {'ForeName': 'Mengru', 'Initials': 'M', 'LastName': 'Jia', 'Affiliation': ''}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Xiong', 'Affiliation': ''}, {'ForeName': 'Aiguo', 'Initials': 'A', 'LastName': 'Ma', 'Affiliation': ''}]",Food & function,['10.1039/d1fo00467k'] 1351,34126249,Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.,"OBJECTIVE To describe predominantly persistent subretinal fluid (SRF) in eyes receiving ranibizumab or bevacizumab for neovascular age-related macular degeneration and to compare visual acuity (VA) to eyes with nonpersistent SRF. DESIGN Cohort within randomized clinical trial. PARTICIPANTS Comparison of Age-related Macular Degeneration Treatments Trials patients assigned to pro re nata treatment. METHODS Graders evaluated monthly OCT scans for SRF. Predominantly persistent SRF through week 12 was defined as SRF at baseline and weeks 4, 8, and 12. Predominantly persistent SRF through 1 or 2 years was defined as SRF in 80% or more of visits by years 1 or 2, respectively. Linear regression models including baseline predictors of VA and predominantly persistent intraretinal fluid (IRF) were used to evaluate mean differences in vision outcomes. PRIMARY OUTCOME MEASURES Predominantly persistent SRF through year 1, adjusted VA score and VA change, and foveal SRF thickness. RESULTS Among 406 eyes with baseline SRF, SRF persisted in 108 eyes (26.6%) through week 12, in 94 eyes (23.2%) through year 1, and in 77 eyes (19.0%) through year 2. Adjusted VA means at year 1 were similar between eyes with predominantly persistent versus non persistent SRF by week 12 (68.1 vs. 70.2 letters; P = 0.18), year 1 (67.6 vs. 70.2 letters; P = 0.11), and year 2 (71.4 vs. 70.9 letters; P = 0.78). Adjusted changes in mean VA at year 1 were similar between eyes with predominantly persistent versus nonpersistent SRF by week 12 (6.3 vs. 7.6 letters; P = 0.38), year 1 (5.5 vs. 7.8 letters; P = 0.14), and year 2 (8.1 vs. 7.7 letters; P = 0.78). Among eyes with predominantly persistent SRF through year 1, foveal SRF was absent in 46 eyes (48.9%), thickness was 1 to 200 μm in 48 eyes (50.0%) and more than 200 μm in 1 eye (1.1%) at year 1. CONCLUSIONS Eyes with predominantly persistent and nonpersistent SRF through week 12, year 1, or year 2 showed similar VA outcomes after adjustment for baseline covariates and persistent IRF. At the foveal center, predominantly persistent SRF was most commonly absent or present in small quantities.",2021,"Adjusted VA means (letters) at year 1 were similar between eyes with predominantly persistent vs. non-persistent SRF by week 12, (68.1 vs. 70.2; P=0.18), year 1 (67.6 vs. 70.2; P=0.11), and year 2 (71.4 vs. 70.9; P=0.78).",['for neovascular age-related macular degeneration and compare visual acuity (VA) to eyes with non-persistent SRF'],"['ranibizumab or bevacizumab', 'pro re nata (PRN) treatment']","['SRF thickness', 'optical coherence tomography scans']","[{'cui': 'C0271084', 'cui_str': 'Exudative age-related macular degeneration'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0067792', 'cui_str': 'N-acetyltryptophanamide'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}]",406.0,0.209368,"Adjusted VA means (letters) at year 1 were similar between eyes with predominantly persistent vs. non-persistent SRF by week 12, (68.1 vs. 70.2; P=0.18), year 1 (67.6 vs. 70.2; P=0.11), and year 2 (71.4 vs. 70.9; P=0.78).","[{'ForeName': 'Jason Q', 'Initials': 'JQ', 'LastName': 'Core', 'Affiliation': 'Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Maxwell', 'Initials': 'M', 'LastName': 'Pistilli', 'Affiliation': 'Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Ebenezer', 'Initials': 'E', 'LastName': 'Daniel', 'Affiliation': 'Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Juan E', 'Initials': 'JE', 'LastName': 'Grunwald', 'Affiliation': 'Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Cynthia A', 'Initials': 'CA', 'LastName': 'Toth', 'Affiliation': 'Department of Ophthalmology, Duke University, Durham, North Carolina.'}, {'ForeName': 'Glenn J', 'Initials': 'GJ', 'LastName': 'Jaffe', 'Affiliation': 'Department of Ophthalmology, Duke University, Durham, North Carolina.'}, {'ForeName': 'Peiying', 'Initials': 'P', 'LastName': 'Hua', 'Affiliation': 'Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'Martin', 'Affiliation': 'Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, and National Eye Institute, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Gui-Shuang', 'Initials': 'GS', 'LastName': 'Ying', 'Affiliation': 'Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Maureen G', 'Initials': 'MG', 'LastName': 'Maguire', 'Affiliation': 'Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: maguirem@pennmedicine.upenn.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology. Retina,['10.1016/j.oret.2021.06.003'] 1352,34391283,Immediate effects of the high-velocity low-amplitude thrust on the heart rate autonomic modulation of judo athletes.,"INTRODUCTION There is controversy about the repercussions of high speed-low amplitude thrust (HVLAT) manipulation in the thoracic region on the autonomic nervous system. OBJECTIVE To evaluate the immediate effects of the HVLAT in the high thoracic region on the heart rate autonomic modulation of judo athletes. METHODS In the experimental study, thirty-eight healthy men divided into 2 groups (Judo athletes and non-athletes) having heart rate variability (HRV) collected beat-to-beat using a cardio-pacemater during all stages of the manipulation: i) rest, ii) time 1 (participant positioning), iii) time 2 (positioning of the participant together with the therapist), iv) HVLAT manipulation, v) post 5min, vi) post 10min and vii) post 15min HVLAT. Systolic blood pressure (SBP), diastolic blood pressure (DBP), breath frequency (BF), and HRV were also analyzed. RESULTS A higher sympathetic modulation was observed with an increase in the standard deviation of successive normal R-R intervals (SDNN) and SD2 indices representing the total variability, however, there was no significant statistical difference in the root mean square of the mean squared differences (RMSSD), percentual of interval differences of successive NN intervals greater than 50 ms (pNN50), and SD1 variables, which represent the parasympathetic nervous system. CONCLUSION HVLAT manipulation was able to decrease HRV during manipulation, reflecting sympathetic hyperactivity. However, the return of the HRV indices to the baseline conditions in the first minutes of recovery in Judo athletes and non-athletes reflected the safety of the application of the manipulation in these conditions studied.",2021,"A higher sympathetic modulation was observed with an increase in the standard deviation of successive normal R-R intervals (SDNN) and SD2 indices representing the total variability, however, there was no significant statistical difference in the root","['thirty-eight healthy men divided into 2 groups (Judo athletes and non-athletes) having heart rate variability (HRV) collected beat-to-beat using a cardio-pacemater during all stages of the manipulation: i) rest, ii) time 1 (participant positioning), iii', 'judo athletes']","['high-velocity low-amplitude', 'HVLAT', 'HVLAT manipulation']","['HRV during manipulation, reflecting sympathetic hyperactivity', 'mean square of the mean squared differences (RMSSD), percentual of interval differences of successive NN intervals', 'Systolic blood pressure (SBP), diastolic blood pressure (DBP), breath frequency (BF), and HRV', 'standard deviation of successive normal R-R intervals (SDNN) and SD2 indices', 'sympathetic modulation']","[{'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0079650', 'cui_str': 'Judo'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}]","[{'cui': 'C0010343', 'cui_str': 'Croatia'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0424295', 'cui_str': 'Hyperactive behavior'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}]",38.0,0.0560437,"A higher sympathetic modulation was observed with an increase in the standard deviation of successive normal R-R intervals (SDNN) and SD2 indices representing the total variability, however, there was no significant statistical difference in the root","[{'ForeName': 'Vanessa Alves', 'Initials': 'VA', 'LastName': 'Leite', 'Affiliation': 'Grupo de Pesquisa em Avaliação e Reabilitação Cardiorrespiratória (GECARE), Departamento de Fisioterapia, Universidade Federal do Rio de Janeiro, Brazil; Programa de Pós-graduação em Educação Física / Escola de Educação Física e Desportos (EEFD), Universidade Federal do Rio de Janeiro (UFRJ), Brazil.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'da Costa Silva', 'Affiliation': 'Grupo de Pesquisa em Avaliação e Reabilitação Cardiorrespiratória (GECARE), Departamento de Fisioterapia, Universidade Federal do Rio de Janeiro, Brazil.'}, {'ForeName': 'Alef', 'Initials': 'A', 'LastName': 'Gustavo de Oliveira', 'Affiliation': 'Grupo de Pesquisa em Avaliação e Reabilitação Cardiorrespiratória (GECARE), Departamento de Fisioterapia, Universidade Federal do Rio de Janeiro, Brazil.'}, {'ForeName': 'Wallace', 'Initials': 'W', 'LastName': 'Machado', 'Affiliation': 'Grupo de Pesquisa em Avaliação e Reabilitação Cardiorrespiratória (GECARE), Departamento de Fisioterapia, Universidade Federal do Rio de Janeiro, Brazil; Programa de Pós-graduação em Educação Física / Escola de Educação Física e Desportos (EEFD), Universidade Federal do Rio de Janeiro (UFRJ), Brazil.'}, {'ForeName': 'Michel Silva', 'Initials': 'MS', 'LastName': 'Reis', 'Affiliation': 'Grupo de Pesquisa em Avaliação e Reabilitação Cardiorrespiratória (GECARE), Departamento de Fisioterapia, Universidade Federal do Rio de Janeiro, Brazil; Programa de Pós-graduação em Educação Física / Escola de Educação Física e Desportos (EEFD), Universidade Federal do Rio de Janeiro (UFRJ), Brazil; Programa de Pós-graduação em Cardiologia, Instituto do Coração Edson Saad, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil. Electronic address: msreis@hucff.ufrj.br.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.006'] 1353,34111359,Community Health Worker Asthma Interventions for Children: Results From a Clinically Integrated Randomized Comparative Effectiveness Trial (2016‒2019).,"Objectives. To compare asthma control for children receiving either community health worker (CHW) or certified asthma educator (AE-C) services. Methods. The Asthma Action at Erie Trial is a comparative effectiveness trial that ran from 2016 to 2019 in Cook County, Illinois. Participants (aged 5‒16 years with uncontrolled asthma) were randomized to 10 home visits from clinically integrated asthma CHWs or 2 in-clinic sessions from an AE-C. Results. Participants (n = 223) were mainly Hispanic (85%) and low-income. Both intervention groups showed significant improvement in asthma control scores over time. Asthma control was maintained after interventions ended. The CHW group experienced a greater improvement in asthma control scores. One year after intervention cessation, the CHW group had a 42% reduction in days of activity limitation relative to the AE-C group (b = 0.58; 95% confidence interval = 0.35, 0.96). Conclusions. Both interventions were associated with meaningful improvements in asthma control. Improvements continued for 1 year after intervention cessation and were stronger with the CHW intervention. Public Health Implications. Clinically integrated asthma CHW and AE-C services that do not provide home environmental remediation equipment may improve and sustain asthma control.",2021,"One year after intervention cessation, the CHW group had a 42% reduction in days of activity limitation relative to the AE-C group (b=0.58; 95% confidence interval=0.35, 0.96. ","['Participants (aged 5-16 years with uncontrolled asthma', 'children receiving either community health worker (CHW) or certified asthma educator (AE-C) services. Methods', 'ran from 2016 to 2019 in Cook County, Illinois', 'Participants (n=223) were mainly Hispanic (85%) and low-income', 'Children']",['10 home visits from clinically integrated asthma CHWs or 2 in-clinic sessions from an AE-C. Results'],"['activity limitation relative', 'asthma control scores']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C0020898', 'cui_str': 'Illinois'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}]","[{'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",223.0,0.0437673,"One year after intervention cessation, the CHW group had a 42% reduction in days of activity limitation relative to the AE-C group (b=0.58; 95% confidence interval=0.35, 0.96. ","[{'ForeName': 'Molly A', 'Initials': 'MA', 'LastName': 'Martin', 'Affiliation': 'Molly A. Martin is with the Department of Pediatrics and the Institute for Health and Research Policy at the University of Illinois at Chicago. Oksana Pugach and Genesis Rosales are with the Institute for Health and Research Policy at the University of Illinois at Chicago. Giselle Mosnaim is with Northshore University Health System, Evanston, IL. Sally Weinstein is with the Department of Psychiatry at the University of Illinois at Chicago. Angkana Roy is with Erie Family Health Center, Chicago. Andrea A. Pappalardo is with the Department of Pediatrics at the University of Illinois at Chicago. Surrey Walton is with the College of Pharmacy at the University of Illinois at Chicago.'}, {'ForeName': 'Oksana', 'Initials': 'O', 'LastName': 'Pugach', 'Affiliation': 'Molly A. Martin is with the Department of Pediatrics and the Institute for Health and Research Policy at the University of Illinois at Chicago. Oksana Pugach and Genesis Rosales are with the Institute for Health and Research Policy at the University of Illinois at Chicago. Giselle Mosnaim is with Northshore University Health System, Evanston, IL. Sally Weinstein is with the Department of Psychiatry at the University of Illinois at Chicago. Angkana Roy is with Erie Family Health Center, Chicago. Andrea A. Pappalardo is with the Department of Pediatrics at the University of Illinois at Chicago. Surrey Walton is with the College of Pharmacy at the University of Illinois at Chicago.'}, {'ForeName': 'Giselle', 'Initials': 'G', 'LastName': 'Mosnaim', 'Affiliation': 'Molly A. Martin is with the Department of Pediatrics and the Institute for Health and Research Policy at the University of Illinois at Chicago. Oksana Pugach and Genesis Rosales are with the Institute for Health and Research Policy at the University of Illinois at Chicago. Giselle Mosnaim is with Northshore University Health System, Evanston, IL. Sally Weinstein is with the Department of Psychiatry at the University of Illinois at Chicago. Angkana Roy is with Erie Family Health Center, Chicago. Andrea A. Pappalardo is with the Department of Pediatrics at the University of Illinois at Chicago. Surrey Walton is with the College of Pharmacy at the University of Illinois at Chicago.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Weinstein', 'Affiliation': 'Molly A. Martin is with the Department of Pediatrics and the Institute for Health and Research Policy at the University of Illinois at Chicago. Oksana Pugach and Genesis Rosales are with the Institute for Health and Research Policy at the University of Illinois at Chicago. Giselle Mosnaim is with Northshore University Health System, Evanston, IL. Sally Weinstein is with the Department of Psychiatry at the University of Illinois at Chicago. Angkana Roy is with Erie Family Health Center, Chicago. Andrea A. Pappalardo is with the Department of Pediatrics at the University of Illinois at Chicago. Surrey Walton is with the College of Pharmacy at the University of Illinois at Chicago.'}, {'ForeName': 'Genesis', 'Initials': 'G', 'LastName': 'Rosales', 'Affiliation': 'Molly A. Martin is with the Department of Pediatrics and the Institute for Health and Research Policy at the University of Illinois at Chicago. Oksana Pugach and Genesis Rosales are with the Institute for Health and Research Policy at the University of Illinois at Chicago. Giselle Mosnaim is with Northshore University Health System, Evanston, IL. Sally Weinstein is with the Department of Psychiatry at the University of Illinois at Chicago. Angkana Roy is with Erie Family Health Center, Chicago. Andrea A. Pappalardo is with the Department of Pediatrics at the University of Illinois at Chicago. Surrey Walton is with the College of Pharmacy at the University of Illinois at Chicago.'}, {'ForeName': 'Angkana', 'Initials': 'A', 'LastName': 'Roy', 'Affiliation': 'Molly A. Martin is with the Department of Pediatrics and the Institute for Health and Research Policy at the University of Illinois at Chicago. Oksana Pugach and Genesis Rosales are with the Institute for Health and Research Policy at the University of Illinois at Chicago. Giselle Mosnaim is with Northshore University Health System, Evanston, IL. Sally Weinstein is with the Department of Psychiatry at the University of Illinois at Chicago. Angkana Roy is with Erie Family Health Center, Chicago. Andrea A. Pappalardo is with the Department of Pediatrics at the University of Illinois at Chicago. Surrey Walton is with the College of Pharmacy at the University of Illinois at Chicago.'}, {'ForeName': 'Andrea A', 'Initials': 'AA', 'LastName': 'Pappalardo', 'Affiliation': 'Molly A. Martin is with the Department of Pediatrics and the Institute for Health and Research Policy at the University of Illinois at Chicago. Oksana Pugach and Genesis Rosales are with the Institute for Health and Research Policy at the University of Illinois at Chicago. Giselle Mosnaim is with Northshore University Health System, Evanston, IL. Sally Weinstein is with the Department of Psychiatry at the University of Illinois at Chicago. Angkana Roy is with Erie Family Health Center, Chicago. Andrea A. Pappalardo is with the Department of Pediatrics at the University of Illinois at Chicago. Surrey Walton is with the College of Pharmacy at the University of Illinois at Chicago.'}, {'ForeName': 'Surrey', 'Initials': 'S', 'LastName': 'Walton', 'Affiliation': 'Molly A. Martin is with the Department of Pediatrics and the Institute for Health and Research Policy at the University of Illinois at Chicago. Oksana Pugach and Genesis Rosales are with the Institute for Health and Research Policy at the University of Illinois at Chicago. Giselle Mosnaim is with Northshore University Health System, Evanston, IL. Sally Weinstein is with the Department of Psychiatry at the University of Illinois at Chicago. Angkana Roy is with Erie Family Health Center, Chicago. Andrea A. Pappalardo is with the Department of Pediatrics at the University of Illinois at Chicago. Surrey Walton is with the College of Pharmacy at the University of Illinois at Chicago.'}]",American journal of public health,['10.2105/AJPH.2021.306272'] 1354,34131798,Does increasing the number of channels during neuromuscular electrical stimulation reduce fatigability and produce larger contractions with less discomfort?,"PURPOSE Neuromuscular electrical stimulation (NMES) is often delivered at frequencies that recruit motor units (MUs) at unphysiologically high rates, leading to contraction fatigability. Rotating NMES pulses between multiple electrodes recruits subpopulations of MUs from each site, reducing MU firing rates and fatigability. This study was designed to determine whether rotating pulses between an increasing number of stimulation channels (cathodes) reduces contraction fatigability and increases the ability to generate torque during NMES. A secondary outcome was perceived discomfort. METHODS Fifteen neurologically intact volunteers completed four sessions. NMES was delivered over the quadriceps through 1 (NMES 1 ), 2 (NMES 2 ), 4 (NMES 4 ) or 8 (NMES 8 ) channels. Fatigability was assessed over 100 contractions (1-s on/1-s off) at an initial contraction amplitude that was 20% of a maximal voluntary contraction. Torque-frequency relationships were characterized over six frequencies from 20 to 120 Hz. RESULTS NMES 4 and NMES 8 resulted in less decline in peak torque (42 and 41%) over the 100 contractions than NMES 1 and NMES 2 (53 and 50% decline). Increasing frequency from 20 to 120 Hz increased torque by 7, 13, 21 and 24% MVC, for NMES 1 , NMES 2 , NMES 4 and NMES 8 , respectively. Perceived discomfort was highest during NMES 8 . CONCLUSION NMES 4 and NMES 8 reduced contraction fatigability and generated larger contractions across a range of frequencies than NMES 1 and NMES 2 . NMES 8 produced the most discomfort, likely due to small electrodes and high current density. During NMES, more is not better and rotating pulses between four channels may be optimal to reduce contraction fatigability and produce larger contractions with minimal discomfort compared to conventional NMES configurations.",2021,NMES 4 and NMES 8 reduced contraction fatigability and generated larger contractions across a range of frequencies than NMES 1 and NMES 2 .,['Fifteen neurologically intact volunteers completed four sessions'],"['NMES', 'Neuromuscular electrical stimulation (NMES']","['Hz increased torque', 'Fatigability', 'discomfort', 'Perceived discomfort', 'contraction fatigability and generated larger contractions', 'peak torque']","[{'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}]","[{'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0231230', 'cui_str': 'Fatigability'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0444505', 'cui_str': 'Peak'}]",,0.0524776,NMES 4 and NMES 8 reduced contraction fatigability and generated larger contractions across a range of frequencies than NMES 1 and NMES 2 .,"[{'ForeName': 'Trevor S', 'Initials': 'TS', 'LastName': 'Barss', 'Affiliation': 'Human Neurophysiology Laboratory, Faculty of Kinesiology, Sport, and Recreation, University of Alberta, 4-219 Van Vliet Complex, Edmonton, AB, T6G 2H9, Canada.'}, {'ForeName': 'Bailey W M', 'Initials': 'BWM', 'LastName': 'Sallis', 'Affiliation': 'Human Neurophysiology Laboratory, Faculty of Kinesiology, Sport, and Recreation, University of Alberta, 4-219 Van Vliet Complex, Edmonton, AB, T6G 2H9, Canada.'}, {'ForeName': 'Dylan J', 'Initials': 'DJ', 'LastName': 'Miller', 'Affiliation': 'Human Neurophysiology Laboratory, Faculty of Kinesiology, Sport, and Recreation, University of Alberta, 4-219 Van Vliet Complex, Edmonton, AB, T6G 2H9, Canada.'}, {'ForeName': 'David F', 'Initials': 'DF', 'LastName': 'Collins', 'Affiliation': 'Human Neurophysiology Laboratory, Faculty of Kinesiology, Sport, and Recreation, University of Alberta, 4-219 Van Vliet Complex, Edmonton, AB, T6G 2H9, Canada. dcollins@ualberta.ca.'}]",European journal of applied physiology,['10.1007/s00421-021-04742-0'] 1355,34131763,Effect of Music on Outcomes of Birth Asphyxia: A Randomized Controlled Trial.,"INTRODUCTION Birth asphyxia may cause neuro-developmental impairment in the affected newborns especially those who had hypoxic-ischemic encephalopathy. Music therapy has been observed to help in reducing pain and stress in newborns and improve neurodevelopmental outcome. OBJECTIVES The objective of this study is to determine the effects of music therapy on the outcomes of birth asphyxia. METHODS A randomized controlled trial involving 3095 newborns born between January 2013 and August 2019 with birth asphyxia was conducted in the neonatal intensive care unit of Burdwan Medical College. They were distributed in two groups-A (received music therapy along with coventional management) and B (only received conventional management), using computer-generated randomization. Pain score was assessed during any painful procedure and the neurodevelopmental outcome was measured at 3rd, 6th, 12th, 18th and 24th months. p < 0.01 was considered statistically significant. RESULTS A total of 3095 newborns were included with a mean gestation of 34.3 ± 2.1 weeks and 56.7% of them were male. Mean hospital stay, oxygen dependency, requirement of mechanical ventilation and incidence of apnea were significantly lesser among newborns of group A. Newborns of group B showed a significantly higher mean pain score, whereas newborns in Group A exhibited significantly greater mental and motor neurodevelopmental quotients. CONCLUSIONS Music therapy was observed to help in reducing hospital stay, oxygen dependency, incidences of apnea, pain during procedures and also resulted in better neurodevelopmental outcome. However, before generalizing the findings, further multi-centric research should be undertaken.",2021,"Mean hospital stay, oxygen dependency, requirement of mechanical ventilation and incidence of apnea were significantly lesser among newborns of group A. Newborns of group B showed a significantly higher mean pain score, whereas newborns in Group A exhibited significantly greater mental and motor neurodevelopmental quotients. ","['3095 newborns born between January 2013 and August 2019 with birth asphyxia was conducted in the neonatal intensive care unit of Burdwan Medical College', 'Birth Asphyxia', 'A total of 3095 newborns were included with a mean gestation of 34.3\u2009±\u20092.1\u2009weeks and 56.7% of them were male']","['Music', 'music therapy', 'music therapy along with coventional management) and B (only received conventional management', 'Music therapy']","['Pain score', 'mean pain score', 'hospital stay, oxygen dependency, incidences of apnea, pain', 'mental and motor neurodevelopmental quotients', 'Mean hospital stay, oxygen dependency, requirement of mechanical ventilation and incidence of apnea', 'pain and stress']","[{'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0004045', 'cui_str': 'Asphyxia, in liveborn infant'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C4068876', 'cui_str': '2.1'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0026868', 'cui_str': 'Music therapy'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",3095.0,0.082952,"Mean hospital stay, oxygen dependency, requirement of mechanical ventilation and incidence of apnea were significantly lesser among newborns of group A. Newborns of group B showed a significantly higher mean pain score, whereas newborns in Group A exhibited significantly greater mental and motor neurodevelopmental quotients. ","[{'ForeName': 'Mithun Chandra', 'Initials': 'MC', 'LastName': 'Konar', 'Affiliation': 'Pediatrics Department, Burdwan Medical College, Burdwan, West Bengal 713104, India.'}, {'ForeName': 'Kamirul', 'Initials': 'K', 'LastName': 'Islam', 'Affiliation': 'Pediatrics Department, Burdwan Medical College, Burdwan, West Bengal 713104, India.'}, {'ForeName': 'Archan', 'Initials': 'A', 'LastName': 'Sil', 'Affiliation': 'Pediatrics Department, Burdwan Medical College, Burdwan, West Bengal 713104, India.'}, {'ForeName': 'Kaustav', 'Initials': 'K', 'LastName': 'Nayek', 'Affiliation': 'Pediatrics Department, Burdwan Medical College, Burdwan, West Bengal 713104, India.'}, {'ForeName': 'Kanailal', 'Initials': 'K', 'LastName': 'Barik', 'Affiliation': 'Pediatrics Department, Burdwan Medical College, Burdwan, West Bengal 713104, India.'}]",Journal of tropical pediatrics,['10.1093/tropej/fmab009'] 1356,34131726,"A randomised, multi-center, open trial comparing a semi-automated closed vitrification system with a manual open system in women undergoing IVF.","STUDY QUESTION What are outcome and procedural differences when using the semi-automated closed Gavi® device versus the manual open Cryotop® method for vitrification of pronuclear (2PN) stage oocytes within an IVF program? SUMMARY ANSWER A semi-automated closed vitrification method gives similar clinical results as compared to an exclusively manual, open system but higher procedure duration and less staff convenience. WHAT IS KNOWN ALREADY A semi-automated closed vitrification device has been introduced to the market, however, little evaluation of its performance in a clinical setting has been conducted so far. STUDY DESIGN, SIZE, DURATION This prospective, randomised, open non-inferiority trial was conducted at three German IVF centers (10/2017-12/2018). Randomization was performed on day of fertilization check, stratified by center and by indication for vitrification (surplus 2PN oocytes in the context of a fresh embryo transfer (ET) cycle or 'freeze-all' of 2PN oocytes). PARTICIPANT/MATERIAL, SETTING, METHODS The study population included subfertile women, aged 18-40 years, undergoing IVF or ICSI treatment after ovarian stimulation, with 2PN oocytes available for vitrification. The primary outcome was survival rate of 2PN oocytes at first warming procedure in a subsequent cycle and non-inferiority of 2PN survival was to be declared if the lower bound 95% CI of the mean difference in survival rate excluded a difference larger than 9.5%; secondary, descriptive outcomes included embryo development, pregnancy and live birth rate, procedure time and staff convenience. MAIN RESULTS AND THE ROLE OF CHANCE The randomised patient population consisted of 149 patients, and the per-protocol population (patients with warming of 2PN oocytes for culture and planned ET) was 118 patients. The survival rate was 94.0% (±13.5) and 96.7% (±9.7) in the Gavi® and the Cryotop® group (weighted mean difference -1.6%, 95% CI -4.7 to 1.4, P = 0.28), respectively, indicating non-inferiority of the Gavi® vitrification/warming method for the primary outcome. Embryo development and the proportion of top-quality embryos was similar in the two groups, as were the pregnancy and live birth rate. Mean total procedure duration (vitrification and warming) was higher in the Gavi® group (81 ± 39 min vs 47 ± 15 min, mean difference 34 min, 95% CI 19 to 48). Staff convenience assessed by eight operators in a questionnaire was lower for the Gavi® system. The majority of respondents preferred the Cryotop® method because of practicality issues. LIMITATIONS, REASON FOR CAUTION The study was performed in centers with long experience of manual vitrification, and the relative performance of the Gavi® system as well as the staff convenience may be higher in settings with less experience in the manual procedure. Financial costs of the two procedures were not measured along the trial. WIDER IMPLICATIONS OF THE FINDINGS With increasing requirements for standardization of procedures and tissue safety, a semi-automated closed vitrification method may constitute a suitable alternative technology to the established manual open vitrification method given the equivalent clinical outcomes demonstrated herein. STUDY FUNDING/COMPETING INTERESTS The trial received no direct financial funding. The Gavi® instrument, Gavi® consumables and staff training were provided for free by the distributor (Merck, Darmstadt, Germany) during the study period. The manufacturer of the Gavi® instrument had no influence on study protocol, study conduct, data analysis, data interpretation or manuscript writing. J.H. has received honoraria and/or non-financial support from Ferring, Merck and Origio. G.G. has received honoraria and/or non-financial support from Abbott, Ferring, Finox, Gedeon Richter, Guerbet, Merck, MSD, ObsEva, PregLem, ReprodWissen GmbH and Theramex. The remaining authors have no competing interests. TRIAL REGISTRATION NUMBER ClinicalTrials.gov NCT03287479. TRIAL REGISTRATION DATE 19 September 2017. DATE OF FIRST PATIENT’S ENROLMENT 10 October 2017.",2021,"A semi-automated closed vitrification method gives similar clinical results as compared to an exclusively manual, open system but higher procedure duration and less staff convenience. ","['three German IVF centers (10/2017-12/2018', 'centers with long experience of manual vitrification, and the relative performance of the Gavi® system as well as the staff convenience may be higher in settings with less experience in the manual procedure', 'study population included subfertile women, aged 18-40\u2009years, undergoing IVF or ICSI treatment after ovarian stimulation, with 2PN oocytes available for vitrification', '’S ENROLMENT\n\n\n10 October 2017', '19 September 2017', 'women undergoing IVF', '149 patients, and the per-protocol population (patients with warming of 2PN oocytes for culture and planned ET) was 118 patients']",['semi-automated closed vitrification system with a manual open system'],"['Financial costs', 'pregnancy and live birth rate', 'embryo development, pregnancy and live birth rate, procedure time and staff convenience', 'survival rate of 2PN oocytes at first warming procedure in a subsequent cycle and non-inferiority of 2PN survival', 'survival rate', 'proportion of top-quality embryos', 'Mean total procedure duration (vitrification and warming']","[{'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C2936610', 'cui_str': 'Glass Transition'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0949385', 'cui_str': 'Ovarian Stimulation'}, {'cui': 'C0029045', 'cui_str': 'Oocyte'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C4517542', 'cui_str': '118'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C2936610', 'cui_str': 'Glass Transition'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0013936', 'cui_str': 'Embryo Development'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0029045', 'cui_str': 'Oocyte'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0013935', 'cui_str': 'Embryos'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C2936610', 'cui_str': 'Glass Transition'}]",,0.292953,"A semi-automated closed vitrification method gives similar clinical results as compared to an exclusively manual, open system but higher procedure duration and less staff convenience. ","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hajek', 'Affiliation': 'Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Luebeck, Germany.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Baron', 'Affiliation': 'Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Luebeck, Germany.'}, {'ForeName': 'Nathallie', 'Initials': 'N', 'LastName': 'Sandi-Monroy', 'Affiliation': 'Kinderwunsch-Zentrum Ulm, Ulm, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Schansker', 'Affiliation': 'Universitaeres Kinderwunschzentrum Kiel, Kiel, Germany.'}, {'ForeName': 'Beate', 'Initials': 'B', 'LastName': 'Schoepper', 'Affiliation': 'Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Luebeck, Germany.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Depenbusch', 'Affiliation': 'Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Luebeck, Germany.'}, {'ForeName': 'Askan', 'Initials': 'A', 'LastName': 'Schultze-Mosgau', 'Affiliation': 'Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Luebeck, Germany.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Neumann', 'Affiliation': 'Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Luebeck, Germany.'}, {'ForeName': 'Friedrich', 'Initials': 'F', 'LastName': 'Gagsteiger', 'Affiliation': 'Kinderwunsch-Zentrum Ulm, Ulm, Germany.'}, {'ForeName': 'Soeren', 'Initials': 'S', 'LastName': 'von Otte', 'Affiliation': 'Universitaeres Kinderwunschzentrum Kiel, Kiel, Germany.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Griesinger', 'Affiliation': 'Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Luebeck, Germany.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/deab140'] 1357,34160288,Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial.,"Current markers of iron deficiency (ID), such as ferritin and hemoglobin, have shortcomings, and hepcidin and erythroferrone (ERFE) could be of clinical relevance in relation to early assessment of ID. Here, we evaluate whether exposure to altitude-induced hypoxia (2,320 m) alone, or in combination with recombinant human erythropoietin (rHuEPO) treatment, affects hepcidin and ERFE levels before alterations in routine ID biomarkers and stress erythropoiesis manifest. Two interventions were completed, each comprising a 4-wk baseline, a 4-wk intervention at either sea level or altitude, and a 4-wk follow-up. Participants ( n = 39) were randomly assigned to 20 IU·kg body wt -1 rHuEPO or placebo injections every second day for 3 wk during the two intervention periods. Venous blood was collected weekly. Altitude increased ERFE ( P ≤ 0.001) with no changes in hepcidin or routine iron biomarkers, making ERFE of clinical relevance as an early marker of moderate hypoxia. rHuEPO treatment at sea level induced a similar pattern of changes in ERFE ( P < 0.05) and hepcidin levels ( P < 0.05), demonstrating the impact of accelerated erythropoiesis and not of other hypoxia-induced mechanisms. Compared with altitude alone, concurrent rHuEPO treatment and altitude exposure induced additive changes in hepcidin ( P < 0.05) and ERFE ( P ≤ 0.001) parallel with increases in hematocrit ( P < 0.001), demonstrating a relevant range of both hepcidin and ERFE. A poor but significant correlation between hepcidin and ERFE was found ( R 2 = 0.13, P < 0.001). The findings demonstrate that hepcidin and ERFE are more rapid biomarkers of changes in iron demands than routine iron markers. Finally, ERFE and hepcidin may be sensitive markers in an antidoping context.",2021,"Altitude increased ERFE (P≤0.001) with no changes in hepcidin or routine iron biomarkers, making ERFE of clinical relevance as an early marker of moderate hypoxia.",['Participants (n=39'],"['hepcidin and ERFE', 'rHuEPO', 'altitude-induced hypoxia (2,320 m) alone, or in combination with recombinant human erythropoietin (rHuEPO', '20 IU·kg bw -1 rHuEPO or placebo', 'altitude and recombinant human erythropoietin']","['Venous blood', 'Altitude increased ERFE', 'hepcidin and ERFE', 'iron metabolism']",[],"[{'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0002349', 'cui_str': 'Altitude'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0229667', 'cui_str': 'Venous blood'}, {'cui': 'C0002349', 'cui_str': 'Altitude'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}]",39.0,0.0582371,"Altitude increased ERFE (P≤0.001) with no changes in hepcidin or routine iron biomarkers, making ERFE of clinical relevance as an early marker of moderate hypoxia.","[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Breenfeldt Andersen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Thomas C', 'Initials': 'TC', 'LastName': 'Bonne', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Bejder', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Jung', 'Affiliation': 'Department of Medicine and Pathology, Center for Iron Disorders, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.'}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Ganz', 'Affiliation': 'Department of Medicine and Pathology, Center for Iron Disorders, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.'}, {'ForeName': 'Elizabeta', 'Initials': 'E', 'LastName': 'Nemeth', 'Affiliation': 'Department of Medicine and Pathology, Center for Iron Disorders, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.'}, {'ForeName': 'Niels Vidiendal', 'Initials': 'NV', 'LastName': 'Olsen', 'Affiliation': 'Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jesús Rodríguez', 'Initials': 'JR', 'LastName': 'Huertas', 'Affiliation': 'Department of Physiology, Faculty of Sport Sciences, Institute of Nutrition and Food Technology, Biomedical Research Centre, University of Granada, Armilla, Spain.'}, {'ForeName': 'Nikolai Baastrup', 'Initials': 'NB', 'LastName': 'Nordsborg', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00070.2021'] 1358,34159344,Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention.,"Background Casirivimab and imdevimab (REGEN-COV™) markedly reduces risk of hospitalization or death in high-risk individuals with Covid-19. Here we explore the possibility that subcutaneous REGEN-COV prevents SARS-CoV-2 infection and subsequent Covid-19 in individuals at high risk of contracting SARS-CoV-2 by close exposure in a household with a documented SARS-CoV-2-infected individual. Methods Individuals ≥12 years were enrolled within 96 hours of a household contact being diagnosed with SARS-CoV-2 and randomized 1:1 to receive 1200 mg REGEN-COV or placebo via subcutaneous injection. The primary efficacy endpoint was the proportion of participants without evidence of infection (SARS-CoV-2 RT-qPCR- negative) or prior immunity (seronegative) who subsequently developed symptomatic SARS-CoV-2 infection during a 28-day efficacy assessment period. Results Subcutaneous REGEN-COV significantly prevented symptomatic SARS-CoV-2 infection compared with placebo (81.4% risk reduction; 11/753 [1.5%] vs. 59/752 [7.8%], respectively; P<0.0001), with 92.6% risk reduction after the first week (2/753 [0.3%] vs. 27/752 [3.6%], respectively). REGEN-COV also prevented overall infections, either symptomatic or asymptomatic (66.4% risk reduction). Among infected participants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV vs. placebo (1.2 vs. 3.2 weeks, respectively), and the duration of time with high viral load (>10 4 copies/mL) was lower (0.4 vs. 1.3 weeks, respectively). REGEN-COV was generally well tolerated. Conclusions Administration of subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in uninfected household contacts of infected individuals. Among individuals who became infected, REGEN-COV reduced the duration of symptomatic disease, decreased maximal viral load, and reduced the duration of detectable virus. ( ClinicalTrials.gov number, NCT04452318 .).",2021,"Subcutaneous REGEN-COV significantly prevented symptomatic SARS-CoV-2 infection compared with placebo (81.4% risk reduction; 11/753 [1.5%] vs. 59/752 [7.8%], respectively; P<0.0001), with 92.6% risk reduction after the first week (2/753 [0.3%] vs. 27/752 [3.6%], respectively).","['Methods\n\n\nIndividuals ≥12 years were enrolled within 96 hours of a household contact being diagnosed with SARS-CoV-2', 'high-risk individuals with Covid-19']","['placebo', '\n\n\nCasirivimab and imdevimab (REGEN-COV™', '1200 mg REGEN-COV or placebo']","['proportion of participants without evidence of infection (SARS-CoV-2 RT-qPCR- negative) or prior immunity (seronegative) who subsequently developed symptomatic SARS-CoV-2 infection during a 28-day efficacy assessment period', 'maximal viral load', 'tolerated', 'duration of symptomatic disease', 'symptomatic SARS-CoV-2 infection', 'duration of time with high viral load', 'median time to resolution of symptoms', 'risk of hospitalization or death']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4517548', 'cui_str': '1200'}]","[{'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0020964', 'cui_str': 'Immune status'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.445069,"Subcutaneous REGEN-COV significantly prevented symptomatic SARS-CoV-2 infection compared with placebo (81.4% risk reduction; 11/753 [1.5%] vs. 59/752 [7.8%], respectively; P<0.0001), with 92.6% risk reduction after the first week (2/753 [0.3%] vs. 27/752 [3.6%], respectively).","[{'ForeName': 'Meagan P', 'Initials': 'MP', 'LastName': ""O'Brien"", 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Forleo-Neto', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Bret J', 'Initials': 'BJ', 'LastName': 'Musser', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Flonza', 'Initials': 'F', 'LastName': 'Isa', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Kuo-Chen', 'Initials': 'KC', 'LastName': 'Chan', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Neena', 'Initials': 'N', 'LastName': 'Sarkar', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Katharine J', 'Initials': 'KJ', 'LastName': 'Bar', 'Affiliation': 'Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Ruanne V', 'Initials': 'RV', 'LastName': 'Barnabas', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, WA, USA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Dan H', 'Initials': 'DH', 'LastName': 'Barouch', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Myron S', 'Initials': 'MS', 'LastName': 'Cohen', 'Affiliation': 'Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'Hurt', 'Affiliation': 'Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Dale R', 'Initials': 'DR', 'LastName': 'Burwen', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.'}, {'ForeName': 'Mary A', 'Initials': 'MA', 'LastName': 'Marovich', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.'}, {'ForeName': 'Peijie', 'Initials': 'P', 'LastName': 'Hou', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Ingeborg', 'Initials': 'I', 'LastName': 'Heirman', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Davis', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Kenneth C', 'Initials': 'KC', 'LastName': 'Turner', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Ramesh', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Mahmood', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Andrea T', 'Initials': 'AT', 'LastName': 'Hooper', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Jennifer D', 'Initials': 'JD', 'LastName': 'Hamilton', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Yunji', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Purcell', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Baum', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Christos A', 'Initials': 'CA', 'LastName': 'Kyratsous', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Krainson', 'Affiliation': 'Clinical Trials of Florida, LLC, Miami, FL, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Perez-Perez', 'Affiliation': 'Medical Research of Westchester, Miami, FL, USA.'}, {'ForeName': 'Rizwana', 'Initials': 'R', 'LastName': 'Mohseni', 'Affiliation': 'Catalina Research Institute, LLC, Montclair, CA, USA.'}, {'ForeName': 'Bari', 'Initials': 'B', 'LastName': 'Kowal', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'A Thomas', 'Initials': 'AT', 'LastName': 'DiCioccio', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Stahl', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Lipsich', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Ned', 'Initials': 'N', 'LastName': 'Braunstein', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Herman', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'George D', 'Initials': 'GD', 'LastName': 'Yancopoulos', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Weinreich', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}]",medRxiv : the preprint server for health sciences,['10.1101/2021.06.14.21258567'] 1359,34164675,Randomised controlled trial of the effects of increased energy intake on menstrual recovery in exercising women with menstrual disturbances: the 'REFUEL' study.,"STUDY QUESTION Does increased daily energy intake lead to menstrual recovery in exercising women with oligomenorrhoea (Oligo) or amenorrhoea (Amen)? SUMMARY ANSWER A modest increase in daily energy intake (330 ± 65 kcal/day; 18 ± 4%) is sufficient to induce menstrual recovery in exercising women with Oligo/Amen. WHAT IS KNOWN ALREADY Optimal energy availability is critical for normal reproductive function, but the magnitude of increased energy intake necessary for menstrual recovery in exercising women, along with the associated metabolic changes, is not known. STUDY DESIGN, SIZE, DURATION The REFUEL study (trial # NCT00392873) is the first randomised controlled trial to assess the effectiveness of 12 months of increased energy intake on menstrual function in 76 exercising women with menstrual disturbances. Participants were randomised (block method) to increase energy intake 20-40% above baseline energy needs (Oligo/Amen + Cal, n = 40) or maintain energy intake (Oligo/Amen Control, n = 36). The study was performed from 2006 to 2014. PARTICIPANTS/MATERIALS, SETTING, METHODS Participants were Amen and Oligo exercising women (age = 21.0 ± 0.3 years, BMI = 20.8 ± 0.2 kg/m2, body fat = 24.7 ± 0.6%) recruited from two universities. Detailed assessment of menstrual function was performed using logs and measures of daily urinary ovarian steroids. Body composition and metabolic outcomes were assessed every 3 months. MAIN RESULTS AND THE ROLE OF CHANCE Using an intent-to-treat analysis, the Oligo/Amen + Cal group was more likely to experience menses during the intervention than the Oligo/Amen Control group (P = 0.002; hazard ratio [CI] = 1.91 [1.27, 2.89]). In the intent-to-treat analysis, the Oligo/Amen + Cal group demonstrated a greater increase in energy intake, body weight, percent body fat and total triiodothyronine (TT3) compared to the Oligo/Amen Control group (P < 0.05). In a subgroup analysis where n = 22 participants were excluded (ambiguous baseline menstrual cycle, insufficient time in intervention for menstrual recovery classification), 64% of the Oligo/Amen + Cal group exhibited improved menstrual function compared with 19% in the Oligo/Amen Control group (χ2, P = 0.001). LIMITATIONS, REASONS FOR CAUTION While we had a greater than expected dropout rate for the 12-month intervention, it was comparable to other shorter interventions of 3-6 months in duration. Menstrual recovery defined herein does not account for quality of recovery. WIDER IMPLICATIONS OF THE FINDINGS Expanding upon findings in shorter, non-randomised studies, a modest increase in daily energy intake (330 ± 65 kcal/day; 18 ± 4%) is sufficient to induce menstrual recovery in exercising women with Oligo/Amen. Improved metabolism, as demonstrated by a modest increase in body weight (4.9%), percent body fat (13%) and TT3 (16%), was associated with menstrual recovery. STUDY FUNDING/COMPETING INTEREST(S) This research was supported by the U.S. Department of Defense: U.S. Army Medical Research and Material Command (Grant PR054531). Additional research assistance provided by the Penn State Clinical Research Center was supported by the National Center for Advancing Translation Sciences, National Institutes of Health, through Grant UL1 TR002014. M.P.O. was supported in part by the Loretta Anne Rogers Chair in Eating Disorders at University of Toronto and University Health Network. All authors report no conflict of interest. TRIAL REGISTRATION NUMBER NCT00392873. TRIAL REGISTRATION DATE October 2006. DATE OF FIRST PATIENT’S ENROLMENT September 2006.",2021,"Amen + Cal group demonstrated a greater increase in energy intake, body weight, percent body fat and total triiodothyronine (TT3) compared to the Oligo/Amen Control group (P < 0.05).","['2006 to 2014', 'Participants were Amen and Oligo exercising women (age\u2009=\u200921.0\u2009±\u20090.3 years, BMI\u2009=\u200920.8\u2009±\u20090.2\u2009kg/m2, body fat\u2009=\u200924.7\u2009±\u20090.6%) recruited from two universities', '76 exercising women with menstrual disturbances', 'exercising women with Oligo', 'exercising women with menstrual disturbances', 'exercising women with oligomenorrhoea (Oligo) or amenorrhoea (Amen']","['12\u2009months of increased energy intake', 'increase energy intake 20-40% above baseline energy needs (Oligo/Amen + Cal, n\u2009=\u200940) or maintain energy intake (Oligo/Amen Control, n\u2009=\u200936', 'increased energy intake']","['menstrual recovery', 'menstrual function', 'energy intake, body weight, percent body fat and total triiodothyronine (TT3', 'daily energy intake', 'body weight', 'percent body fat', 'Body composition and metabolic outcomes']","[{'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0028953', 'cui_str': 'Oligonucleotide'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025345', 'cui_str': 'Disorder of menstruation'}, {'cui': 'C0028949', 'cui_str': 'Oligomenorrhea'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0455769', 'cui_str': 'Increased energy'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0028953', 'cui_str': 'Oligonucleotide'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0025344', 'cui_str': 'Menstruation'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0041014', 'cui_str': 'liothyronine'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",22.0,0.177759,"Amen + Cal group demonstrated a greater increase in energy intake, body weight, percent body fat and total triiodothyronine (TT3) compared to the Oligo/Amen Control group (P < 0.05).","[{'ForeName': 'Mary Jane', 'Initials': 'MJ', 'LastName': 'De Souza', 'Affiliation': 'Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Mallinson', 'Affiliation': 'Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Nicole C A', 'Initials': 'NCA', 'LastName': 'Strock', 'Affiliation': 'Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Kristen J', 'Initials': 'KJ', 'LastName': 'Koltun', 'Affiliation': 'Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Marion P', 'Initials': 'MP', 'LastName': 'Olmsted', 'Affiliation': 'Centre for Mental Health, University Health Network and University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Emily A', 'Initials': 'EA', 'LastName': 'Ricker', 'Affiliation': 'Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Scheid', 'Affiliation': 'Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Heather C', 'Initials': 'HC', 'LastName': 'Allaway', 'Affiliation': 'Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Mallinson', 'Affiliation': 'School of Public Affairs, Pennsylvania State University-Harrisburg, Middletown, PA, USA.'}, {'ForeName': 'Prabhani', 'Initials': 'P', 'LastName': 'Kuruppumullage Don', 'Affiliation': 'Department of Statistics, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Nancy I', 'Initials': 'NI', 'LastName': 'Williams', 'Affiliation': 'Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/deab149'] 1360,34162641,Internet-assisted cognitive behavioural therapy with telephone coaching for anxious Finnish children aged 10-13 years: study protocol for a randomised controlled trial.,"INTRODUCTION Childhood anxiety is common, causes significant functional impairment and may lead to psychosocial problems by adulthood. Although cognitive behavioural therapy (CBT) is effective for treating anxiety, its availability is limited by the lack of trained CBT therapists and easily accessible local services. To address the challenges in both recognition and treatment, this study combines systematic anxiety screening in the general population with a randomised controlled trial (RCT) on internet-assisted CBT (ICBT) with telephone coaching. Child, family and intervention-related factors are studied as possible predictors or moderators, together with the COVID-19 pandemic. METHODS AND ANALYSIS The study is an open two-parallel group RCT, stratified by sex, that compares ICBT with telephone coaching to an education control. Children aged 10-13 are screened at yearly school healthcare check-ups using five items from the Screen for Child Anxiety Related Disorders (SCARED) Questionnaire. The families of children who screen positive for anxiety are contacted to assess the family's eligibility for the RCT. The inclusion criteria include scoring at least 22 points in the 41-item SCARED Questionnaire. The primary outcome is the SCARED child and parent reports. The secondary outcomes include the impact of anxiety, quality of life, comorbidity, peer relationships, perceptions of school, parental well-being and service use. Additional measures include demographics and life events, anxiety disorder diagnoses, as well as therapeutic partnerships, the use of the programme and general satisfaction among the intervention group. ETHICS AND DISSEMINATION The study has been approved by the research ethics board of the Hospital District of South West Finland and local authorities. Participation is voluntary and based on informed consent. The anonymity of the participants will be protected and the results will be published in a scientific journal and disseminated to healthcare professionals and the general public. TRIAL REGISTRATION NUMBER ClinicalTrials.gov NCT03310489, pre-results, initially released on 30 September 2017.",2021,"The study is an open two-parallel group RCT, stratified by sex, that compares ICBT with telephone coaching to an education control.","['anxious Finnish children aged 10-13 years', 'Children aged 10-13 are screened at yearly school healthcare check-ups using five items from the Screen for Child Anxiety Related Disorders (SCARED) Questionnaire']","['ICBT with telephone coaching to an education control', 'Internet-assisted cognitive behavioural therapy with telephone coaching', 'cognitive behavioural therapy (CBT', 'internet-assisted CBT (ICBT) with telephone coaching']","['impact of anxiety, quality of life, comorbidity, peer relationships, perceptions of school, parental well-being and service use', 'demographics and life events, anxiety disorder diagnoses, as well as therapeutic partnerships, the use of the programme and general satisfaction', 'SCARED child and parent reports']","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0016134', 'cui_str': 'Finnish language'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0420160', 'cui_str': 'History and physical examination, school'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0557155', 'cui_str': 'Life event observable'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0684224', 'cui_str': 'Report'}]",,0.0756249,"The study is an open two-parallel group RCT, stratified by sex, that compares ICBT with telephone coaching to an education control.","[{'ForeName': 'Terhi', 'Initials': 'T', 'LastName': 'Luntamo', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Tarja', 'Initials': 'T', 'LastName': 'Korpilahti-Leino', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Terja', 'Initials': 'T', 'LastName': 'Ristkari', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Sanna', 'Initials': 'S', 'LastName': 'Hinkka-Yli-Salomäki', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Marjo', 'Initials': 'M', 'LastName': 'Kurki', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Atte', 'Initials': 'A', 'LastName': 'Sinokki', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Kaisa', 'Initials': 'K', 'LastName': 'Lamminen', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Kristiina', 'Initials': 'K', 'LastName': 'Saanakorpi', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Saarinen', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Marjukka', 'Initials': 'M', 'LastName': 'Maunuksela', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Saana', 'Initials': 'S', 'LastName': 'Sourander', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Toivonen', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Zadkova', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Miia', 'Initials': 'M', 'LastName': 'Suilamo', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Casagrande', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Palmroth', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sourander', 'Affiliation': 'Department of Child Psychiatry, University of Turku and Turku University Hospital; INVEST Research Flagship Center, University of Turku, Finland andsou@utu.fi.'}]",BMJ open,['10.1136/bmjopen-2020-045474'] 1361,34126053,"Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.","BACKGROUND SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme 2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed to test our hypothesis that discontinuation of chronic treatment with ACE-inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) mitigates the course o\f recent-onset COVID-19. METHODS ACEI-COVID was a parallel group, randomised, controlled, open-label trial done at 35 centres in Austria and Germany. Patients aged 18 years and older were enrolled if they presented with recent symptomatic SARS-CoV-2 infection and were chronically treated with ACEIs or ARBs. Patients were randomly assigned 1:1 to discontinuation or continuation of RAS inhibition for 30 days. Primary outcome was the maximum sequential organ failure assessment (SOFA) score within 30 days, where death was scored with the maximum achievable SOFA score. Secondary endpoints were area under the death-adjusted SOFA score (AUC SOFA ), mean SOFA score, admission to the intensive care unit, mechanical ventilation, and death. Analyses were done on a modified intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT04353596. FINDINGS Between April 20, 2020, and Jan 20, 2021, 204 patients (median age 75 years [IQR 66-80], 37% females) were randomly assigned to discontinue (n=104) or continue (n=100) RAS inhibition. Within 30 days, eight (8%) of 104 died in the discontinuation group and 12 (12%) of 100 patients died in the continuation group (p=0·42). There was no significant difference in the primary endpoint between the discontinuation and continuation group (median [IQR] maximum SOFA score 0·00 (0·00-2·00) vs 1·00 (0·00-3·00); p=0·12). Discontinuation was associated with a significantly lower AUC SOFA (0·00 [0·00-9·25] vs 3·50 [0·00-23·50]; p=0·040), mean SOFA score (0·00 [0·00-0·31] vs 0·12 [0·00-0·78]; p=0·040), and 30-day SOFA score (0·00 [10-90th percentile, 0·00-1·20] vs 0·00 [0·00-24·00]; p=0·023). At 30 days, 11 (11%) in the discontinuation group and 23 (23%) in the continuation group had signs of organ dysfunction (SOFA score ≥1) or were dead (p=0·017). There were no significant differences for mechanical ventilation (10 (10%) vs 8 (8%), p=0·87) and admission to intensive care unit (20 [19%] vs 18 [18%], p=0·96) between the discontinuation and continuation group. INTERPRETATION Discontinuation of RAS-inhibition in COVID-19 had no significant effect on the maximum severity of COVID-19 but may lead to a faster and better recovery. The decision to continue or discontinue should be made on an individual basis, considering the risk profile, the indication for RAS inhibition, and the availability of alternative therapies and outpatient monitoring options. FUNDING Austrian Science Fund and German Center for Cardiovascular Research.",2021,"At 30 days, 11 (11%) in the discontinuation group and 23 (23%) in the continuation group had signs of organ dysfunction (SOFA score ≥1) or were dead (p=0·017).","['35 centres in Austria and Germany', 'Patients aged 18 years and older were enrolled if they presented with recent symptomatic SARS-CoV-2 infection and were chronically treated with', 'Between April 20, 2020, and Jan 20, 2021, 204 patients (median age 75 years [IQR 66-80], 37% females']","['discontinue', 'ACEIs or ARBs', 'renin-angiotensin-system inhibitors', 'ACE-inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs']","['maximum sequential organ failure assessment (SOFA) score within 30 days, where death was scored with the maximum achievable SOFA score', 'mean SOFA score', '30-day SOFA score', 'area under the death-adjusted SOFA score (AUC SOFA ), mean SOFA score, admission to the intensive care unit, mechanical ventilation, and death', 'mechanical ventilation', 'signs of organ dysfunction (SOFA score ≥1']","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0004348', 'cui_str': 'Austria'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0003018', 'cui_str': 'Angiotensin'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C3494459', 'cui_str': 'Sequential organ failure assessment score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}]",,0.148922,"At 30 days, 11 (11%) in the discontinuation group and 23 (23%) in the continuation group had signs of organ dysfunction (SOFA score ≥1) or were dead (p=0·017).","[{'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Bauer', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: axel.bauer@i-med.ac.at.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schreinlechner', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Nikolay', 'Initials': 'N', 'LastName': 'Sappler', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Dolejsi', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Tilg', 'Affiliation': 'Department of Internal Medicine I, Gastroenterology, Hepatology, and Endocrinology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Benedikt A', 'Initials': 'BA', 'LastName': 'Aulinger', 'Affiliation': 'Medizinische Klinik und Poliklinik II, LMU University Hospital Munich, Munich, Germany.'}, {'ForeName': 'Günter', 'Initials': 'G', 'LastName': 'Weiss', 'Affiliation': 'Department of Internal Medicine II, Infectious Diseases, Immunology, Rheumatology and Pneumology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Bellmann-Weiler', 'Affiliation': 'Department of Internal Medicine II, Infectious Diseases, Immunology, Rheumatology and Pneumology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Adolf', 'Affiliation': 'Medizinische Klinik und Poliklinik IV, LMU University Hospital Munich, Munich, Germany.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Wolf', 'Affiliation': 'Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Pirklbauer', 'Affiliation': 'Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Graziadei', 'Affiliation': 'Department of Internal Medicine, Hospital Hall in Tirol, Hall in Tirol, Austria.'}, {'ForeName': 'Hannes', 'Initials': 'H', 'LastName': 'Gänzer', 'Affiliation': 'Department of Internal Medicine, Hospital Schwaz, Schwaz, Austria.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'von Bary', 'Affiliation': 'Department of Internal Medicine I, Rotkreuzklinikum Munich, Munich, Germany.'}, {'ForeName': 'Andreas E', 'Initials': 'AE', 'LastName': 'May', 'Affiliation': 'Department of Internal Medicine, Hospital Memmingen, Memmingen, Germany.'}, {'ForeName': 'Ewald', 'Initials': 'E', 'LastName': 'Wöll', 'Affiliation': 'Department of Internal Medicine, Hospital Zams, Zams, Austria.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'von Scheidt', 'Affiliation': 'Department of Internal Medicine I, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Tienush', 'Initials': 'T', 'LastName': 'Rassaf', 'Affiliation': 'Department of Cardiology and Vascular Medicine, West German Heart- and Vascular Center, University Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Duerschmied', 'Affiliation': 'University Heart Center Freiburg, Department of Cardiology and Angiology I, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Brenner', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kääb', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research, Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Metzler', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Joannidis', 'Affiliation': 'Division of Intensive Care and Emergency Medicine, Department Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Hans-Ulrich', 'Initials': 'HU', 'LastName': 'Kain', 'Affiliation': 'Department of Internal Medicine, Hospital Mühldorf, Mühldorf, Germany.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Kaiser', 'Affiliation': 'Department of Internal Medicine, Hospital St Johann in Tirol, St Johann in Tirol, Austria.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Schwinger', 'Affiliation': 'Department of Internal Medicine, Hospital Weiden, Weiden, Germany.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Witzenbichler', 'Affiliation': 'Department of Internal Medicine, Hospital Dachau, Dachau, Germany.'}, {'ForeName': 'Hannes', 'Initials': 'H', 'LastName': 'Alber', 'Affiliation': 'Department of Internal Medicine and Cardiology, Klinikum Klagenfurt am Woerthersee, Klagenfurt, Austria.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Straube', 'Affiliation': 'Department of Cardiology and Internal Intensive Care Medicine, Munich Clinic Bogenhausen and Schwabing, Munich, Germany.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Hartmann', 'Affiliation': 'Department of Internal Medicine I (Cardiology), University Hospital Aachen, Aachen, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Achenbach', 'Affiliation': 'Department of Cardiology and Angiology, University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'von Bergwelt-Baildon', 'Affiliation': 'Medizinische Klinik und Poliklinik III, LMU University Hospital Munich, Munich, Germany.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'von Stülpnagel', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria; Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research, Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Schoenherr', 'Affiliation': 'Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Forer', 'Affiliation': 'Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Embacher-Aichhorn', 'Affiliation': 'Competence Center for Clinical Trials, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Mansmann', 'Affiliation': 'Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-University Munich, Germany.'}, {'ForeName': 'Konstantinos D', 'Initials': 'KD', 'LastName': 'Rizas', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research, Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Massberg', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research, Munich Heart Alliance, Munich, Germany. Electronic address: steffen.massberg@med.uni-muenchen.de.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(21)00214-9'] 1362,34126052,Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.,"BACKGROUND As oral pre-exposure prophylaxis (PrEP) becomes the standard of prevention globally, its potential effect on HIV incidence in clinical trials of new prevention interventions is unknown, particularly for trials among women. In a trial measuring HIV incidence in African women, oral PrEP was incorporated into the standard of prevention in the trial's last year. We assessed the effect of on-site access to PrEP on HIV incidence in this natural experiment. METHODS We did a nested interrupted time-series study using data from the ECHO trial. At 12 sites in four countries (Eswatini, Kenya, South Africa, and Zambia), women (aged 16-35 years) were randomly assigned to receive one of three contraceptives between Dec 14, 2015, and Sept 12, 2017, and followed up quarterly for up to 18 months to determine the effect of contraceptive method on HIV acquisition. Women were eligible if they wanted long-acting contraception, were medically qualified to receive study contraceptives, and had not used any of the study contraceptives in the past 6 months. The present analyses are limited to nine South African sites where on-site access to oral PrEP was implemented between March 13 and June 12, 2018. Using an interrupted time-series design, we compared HIV incidence before versus after PrEP access, limited to quarterly study visits at which on-site PrEP access was available to at least some participants and, in a sensitivity analysis, to the 180 days before and after access. The outcome was incident HIV infection, detected using two rapid HIV tests done in parallel for each participant at every scheduled follow-up visit. This study is registered on ClinicalTrials.gov, NCT02550067. FINDINGS 2124 women were followed up after on-site PrEP access began, of whom 543 (26%) reported PrEP use. A total of 12 HIV seroconversions were observed in 556 person-years (incidence 2·16%) after on-site PrEP access, compared with 133 HIV seroconversions in 2860 person-years (4·65%) before PrEP access (adjusted incidence rate ratio [IRR] 0·45, 95% CI 0·25-0·82, p=0·0085). Similar results were also observed when limiting the analysis to 180 days before versus after PrEP access. A total of 46 HIV seroconversions were observed in 919 person-years within 180 days before PrEP access, compared with 11 seroconversions in 481 person-years in the 180 days following PrEP access (incidence 5·00 vs 2·29 per 100 person-years; IRR 0·43, 95% CI 0·22-0·88, p=0·012). INTERPRETATION On-site access to PrEP as part of standard of prevention in a clinical trial among women in South Africa was associated with halving HIV incidence, when approximately a quarter of women started PrEP. Providing access to on-site PrEP could decrease incidence in HIV prevention trials. These data are also among the first to show in any setting that access to PrEP is associated with decreased HIV acquisition among South African women. FUNDING Bill & Melinda Gates Foundation, United States Agency for International Development, President's Emergency Plan for AIDS Relief, the Swedish International Development Cooperation Agency, South African Medical Research Council, and United Nations Population Fund.",2021,"A total of 12 HIV seroconversions were observed in 556 person-years (incidence 2·16%) after on-site PrEP access, compared with 133 HIV seroconversions in 2860 person-years (4·65%) before PrEP access (adjusted incidence rate ratio [IRR] 0·45, 95% CI 0·25-0·82, p=0·0085).","['South African women', 'African women', 'Women were eligible if they wanted long-acting contraception, were medically qualified to receive study contraceptives, and had not used any of the study contraceptives in the past 6 months', '2124 women', 'At 12 sites in four countries (Eswatini, Kenya, South Africa, and Zambia), women (aged 16-35 years']","['oral PrEP', 'oral pre-exposure prophylaxis (PrEP']",['HIV acquisition'],"[{'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0700589', 'cui_str': 'Contraception'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009871', 'cui_str': 'Contraceptive agent'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0445107', 'cui_str': 'Not used'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0038983', 'cui_str': 'Swaziland'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C0043445', 'cui_str': 'Zambia'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]",2124.0,0.208477,"A total of 12 HIV seroconversions were observed in 556 person-years (incidence 2·16%) after on-site PrEP access, compared with 133 HIV seroconversions in 2860 person-years (4·65%) before PrEP access (adjusted incidence rate ratio [IRR] 0·45, 95% CI 0·25-0·82, p=0·0085).","[{'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Donnell', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA; University of Washington, Seattle, WA, USA. Electronic address: deborah@fredhutch.org.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Beesham', 'Affiliation': 'MatCH Research Unit (MRU), Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa.'}, {'ForeName': 'Julia D', 'Initials': 'JD', 'LastName': 'Welch', 'Affiliation': 'FHI 360, Durham, NC, USA.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Heffron', 'Affiliation': 'University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Pleaner', 'Affiliation': 'Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Kidoguchi', 'Affiliation': 'University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Thesla', 'Initials': 'T', 'LastName': 'Palanee-Phillips', 'Affiliation': 'Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Khatija', 'Initials': 'K', 'LastName': 'Ahmed', 'Affiliation': 'Setshaba Research Centre, Tshwane, South Africa.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Baron', 'Affiliation': 'Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Bukusi', 'Affiliation': 'University of Washington, Seattle, WA, USA; Center for Microbiology Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Louw', 'Affiliation': 'Madibeng Centre for Research, Brits, South Africa; Department of Family Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Mastro', 'Affiliation': 'FHI 360, Durham, NC, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Smit', 'Affiliation': 'MatCH Research Unit (MRU), Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa.'}, {'ForeName': 'Joanne R', 'Initials': 'JR', 'LastName': 'Batting', 'Affiliation': 'Effective Care Research Unit (ECRU), Universities of the Witwatersrand, Fort Hare and Eastern Cape Department of Health, East London, South Africa.'}, {'ForeName': 'Mookho', 'Initials': 'M', 'LastName': 'Malahleha', 'Affiliation': 'Setshaba Research Centre, Tshwane, South Africa.'}, {'ForeName': 'Veronique C', 'Initials': 'VC', 'LastName': 'Bailey', 'Affiliation': 'Setshaba Research Centre, Tshwane, South Africa.'}, {'ForeName': 'Mags', 'Initials': 'M', 'LastName': 'Beksinska', 'Affiliation': 'MatCH Research Unit (MRU), Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Rees', 'Affiliation': 'Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Jared M', 'Initials': 'JM', 'LastName': 'Baeten', 'Affiliation': 'University of Washington, Seattle, WA, USA; Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The lancet. HIV,['10.1016/S2352-3018(21)00048-5'] 1363,34129715,"Evaluation of different materials used for sealing of implant abutment access channel and the peri-implant sulcus microbiota: A 6-month, randomized controlled trial.","OBJECTIVE Peri-implantitis has been attributed to a myriad of factors, including microleakage at the abutment-implant interface. Implant abutment access channel sealing materials (IACSM) are readily used in implant dentistry, with little evidence on their effect on microleakage. This study aims to evaluate the effect of IACSM on the microbial composition in the implant access channel and the peri-implant sulcus. METHODS A total of n = 8 patients (64 implants) were included in this single-blinded, randomized controlled trial, whereas four different materials (cotton, polytetrafluoroethylene [PTFE], synthetic foam, or polyvinyl siloxane [PVS]) were randomly placed as an IACSM. Following 6 months, microbial analysis was completed on the IACSM and samples from the peri-implant sulci via PCR and high-throughput sequencing. Bacterial samples on the IACSM and in the peri-implant sulci were classified according to Socransky's microbial complexes. RESULTS There was a preponderance of early colonizing bacteria within the IACSM, while the peri-implant sulci were dominated by Orange complex bacteria. The proportion of Red and Orange complex members on the IACSM was significantly less than in the peri-implant sulci. The proportion of Green, Yellow, and Blue complex members found on the IACSM was significantly greater than in the peri-implant sulci. Atopobium, a diverse species not included in the microbial complexes, was frequently detected in the peri-implant sulcus samples. CONCLUSIONS No detectable effects of IACSM on the microbial community in the peri-implant sulcus or on the IACSM were identified. Variation of bacterial species was most dependent on the individual patient. No significant differences were found in the periodontal parameters between the different treatment groups.",2021,No detectable effects of IACSM on the microbial community in the peri-implant sulcus or on the IACSM were identified.,"['A total of n=8 patients (64 implants', 'Peri-implant Sulcus Microbiota']","['IACSM', 'Implant abutment access channel sealing materials (IACSM', 'materials (cotton, Polytetrafluroethylene (PTFE), synthetic foam or Polyvinyl siloxane (PVS']","['IACSM', 'periodontal parameters', 'proportion of Green, Yellow, and Blue complex members']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}]","[{'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0439799', 'cui_str': 'Channel'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0010196', 'cui_str': 'Gossypium'}, {'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0078267', 'cui_str': 'vinyl polysiloxane'}]","[{'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0439799', 'cui_str': 'Channel'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0221205', 'cui_str': 'Yellow color'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0680022', 'cui_str': 'Member of'}]",8.0,0.0633154,No detectable effects of IACSM on the microbial community in the peri-implant sulcus or on the IACSM were identified.,"[{'ForeName': 'Caroline V', 'Initials': 'CV', 'LastName': 'Rubino', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Brandon G', 'Initials': 'BG', 'LastName': 'Katz', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Langlois', 'Affiliation': 'School of Marine and Atmospheric Sciences, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Howard H', 'Initials': 'HH', 'LastName': 'Wang', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Julio A', 'Initials': 'JA', 'LastName': 'Carrion', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Stephen G', 'Initials': 'SG', 'LastName': 'Walker', 'Affiliation': 'Department of Oral Biology and Pathology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Jackie L', 'Initials': 'JL', 'LastName': 'Collier', 'Affiliation': 'School of Marine and Atmospheric Sciences, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Vincent J', 'Initials': 'VJ', 'LastName': 'Iacono', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Srinivas R', 'Initials': 'SR', 'LastName': 'Myneni', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA.'}]",Clinical oral implants research,['10.1111/clr.13787'] 1364,34137474,Examining depression scores as predictors and moderators of treatment outcomes in patients with binge-eating disorder.,"OBJECTIVE A substantial proportion of patients with binge-eating disorder (BED) do not derive sufficient benefits from available evidence-based psychological interventions. We examined depression scores as predictors and moderators of response to cognitive-behavioral therapy (CBT) and behavioral weight-loss (BWL) for BED. We explored associations between changes in depression scores and changes in treatment outcomes. METHOD Ninety adults with BED with obesity were randomized to CBT or BWL (6 months) and were evaluated independently throughout treatment, at posttreatment, and 12-month follow-up after treatments (18 months post-randomization). Pre-treatment depression scores, early changes in depression, and changes in depression from pre- to post-treatment were tested as predictors/moderators of outcomes (binge-eating frequency and eating-disorder psychopathology). RESULTS Baseline depression scores did not predict nor moderate outcomes at post-treatment or 12-month follow-up. Changes in depression scores (both early and throughout treatment) were not associated significantly with changes in binge-eating frequency or eating-disorder psychopathology at post-treatment or 12-month follow-up. DISCUSSION Findings suggest depression scores do not predict nor moderate acute- or longer-term outcomes in patients with BED receiving CBT or BWL. Findings reinforce need to improve treatments for BED overall, although they provide confidence that patients with elevated depression scores derive benefits from existing CBT and BWL interventions.",2021,"Changes in depression scores (both early and throughout treatment) were not associated significantly with changes in binge-eating frequency or eating-disorder psychopathology at post-treatment or 12-month follow-up. ","['patients with binge-eating disorder', 'patients with binge-eating disorder (BED', 'Ninety adults with BED with obesity', 'patients with BED receiving CBT or BWL']",['CBT or BWL'],"['Pre-treatment depression scores, early changes in depression, and changes in depression', 'cognitive-behavioral therapy (CBT) and behavioral weight-loss (BWL', 'outcomes (binge-eating frequency and eating-disorder psychopathology', 'binge-eating frequency or eating-disorder psychopathology', 'depression scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0596170', 'cui_str': 'Binge eating disorder'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0006370', 'cui_str': 'Binge Eating'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}]",90.0,0.0363348,"Changes in depression scores (both early and throughout treatment) were not associated significantly with changes in binge-eating frequency or eating-disorder psychopathology at post-treatment or 12-month follow-up. ","[{'ForeName': 'Carlos M', 'Initials': 'CM', 'LastName': 'Grilo', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Ralitza', 'Initials': 'R', 'LastName': 'Gueorguieva', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Pittman', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.'}]",The International journal of eating disorders,['10.1002/eat.23569'] 1365,34133958,Comparison of clinical and histologic findings in daylight photodynamic therapy for skin field cancerization: A randomized controlled four-arm study on physical methods-assisted delivery of methyl aminolevulinate.,"BACKGROUND Daylight photodynamic therapy (DL-PDT) has similar efficacy to conventional photodynamic therapy in treating actinic keratosis (AKs). Good clinical outcomes have been reported when associated with physical methods such as microneedles, but a comparison of different methods and histologic studies is lacking. OBJECTIVES To evaluate clinical and histologic modifications induced by standard DL-PDT and compare with DL-PDT associated with physical methods in treating skin field cancerization of the face. METHODS Forty patients with photodamaged skin and at least one AK lesion on the face were randomly distributed into four groups, ten patients in each (I: Standard DL-PDT; II: DL-PDT + microneedles; III: DL-PDT + CO2 laser; IV: DL-PDT + microdermabrasion) and underwent two DL-PDT sessions with methyl aminolevulinate cream and 2-hour daylight exposure. Skin biopsies were performed on all patients before and 3 months after. All fragments were stained using the hematoxylin-eosin, orcein, and picrosirius. RESULTS All 40 patients completed the study. Group III had a higher AK-clearance after 1 (p = 0,002) and 3 (p = 0,034) months, but it was similar in every group at 6 months (p = 0,441). Group III and IV had better clinical global improvement on texture, pigmentation and fine lines. In the groups associated with physical methods, the improvement of the keratinocytes' atypia and solar elastosis were remarkable. Only group III showed a significant reduction in solar elastosis (p = 0.034) and increased collagen type I (p = 0.028) after treatment. CONCLUSION DL-PDT-associated with physical methods had better clinical and histologic results. AK-clearance were significantly higher after 1 and 3 months with pretreatment-CO2 laser. Photorejuvenation were more evident with pretreatment-CO2 laser and microdermabrasion. Pretreatment-CO2 laser showed a significant reduction in solar elastosis and increase of collagen type 1. These results pointed to the pretreatment with laser as a potentially better option for skin field cancerization of the face.",2021,"Only group III showed a significant reduction in solar elastosis (p=0.034) and increased collagen type I (p=0.028) after treatment. ","['skin field cancerization', 'Forty patients with photodamaged skin and at least one AK lesion on the face', 'All 40 patients completed the study']","['methyl aminolevulinate', 'conventional photodynamic therapy', 'standard DL-PDT and compare with DL-PDT', 'DL-PDT\u202f+\u202fCO2 laser; IV: DL-PDT\u202f+\u202fmicrodermabrasion) and underwent two DL-PDT sessions with methyl aminolevulinate cream and 2-hour daylight exposure', 'Daylight photodynamic therapy (DL-PDT', 'daylight photodynamic therapy', 'Pretreatment-CO2 laser']","['higher AK-clearance', 'clinical global improvement on texture, pigmentation, and fine lines', 'collagen type I', ""keratinocytes' atypia and solar elastosis"", 'solar elastosis', 'AK-clearance', 'Skin biopsies']","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1698818', 'cui_str': 'Photodamaged skin'}, {'cui': 'C0743775', 'cui_str': 'Lesion of face'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C1134467', 'cui_str': 'methyl 5-aminolevulinate'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0449582', 'cui_str': 'With texture'}, {'cui': 'C0031911', 'cui_str': 'Pigmentation'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}, {'cui': 'C0022567', 'cui_str': 'Keratinocyte'}, {'cui': 'C0263415', 'cui_str': 'Solar degeneration'}, {'cui': 'C0150866', 'cui_str': 'Biopsy of skin'}]",40.0,0.0235624,"Only group III showed a significant reduction in solar elastosis (p=0.034) and increased collagen type I (p=0.028) after treatment. ","[{'ForeName': 'Camila de Oliveira', 'Initials': 'CO', 'LastName': 'Bento', 'Affiliation': 'Department of Clinical Medicine - Dermatology, Universidade Federal Fluminense, Brazil. Electronic address: camiladeobento@hotmail.com.'}, {'ForeName': 'Luciana', 'Initials': 'L', 'LastName': 'Pantaleão', 'Affiliation': 'Department of Pathology, Universidade Federal Fluminense, Brazil.'}, {'ForeName': 'Mariana Boechat', 'Initials': 'MB', 'LastName': 'de Souza', 'Affiliation': 'Department of Clinical Medicine - Dermatology, Universidade Federal Fluminense, Brazil.'}, {'ForeName': 'Enoi Aparecida Guedes', 'Initials': 'EAG', 'LastName': 'Vilar', 'Affiliation': 'Department of Pathology, Universidade Federal Fluminense, Brazil.'}, {'ForeName': 'Ronir Raggio', 'Initials': 'RR', 'LastName': 'Luiz', 'Affiliation': 'Department of Biostatistics, Universidade Federal do Rio de Janeiro, Brazil.'}, {'ForeName': 'Porphirio José Soares', 'Initials': 'PJS', 'LastName': 'Filho', 'Affiliation': 'Department of Pathology, Universidade Federal Fluminense, Brazil.'}, {'ForeName': 'Ronaldo Altenburg Odebrecht Curi', 'Initials': 'RAOC', 'LastName': 'Gismondi', 'Affiliation': 'Department of Clinical Medicine, Universidade Federal Fluminense, Brazil.'}, {'ForeName': 'Maria Claudia Almeida', 'Initials': 'MCA', 'LastName': 'Issa', 'Affiliation': 'Department of Clinical Medicine - Dermatology, Universidade Federal Fluminense, Brazil.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102404'] 1366,34391280,Impact of two different pulmonary rehabilitation methods in children with down syndrome.,"PURPOSE To investigate and compare the effect of proprioceptive neuromuscular facilitation of respiratory muscles with that of inspiratory muscle training as a preventive measure on respiratory muscle strength, chest expansion, spirometry, and functional capacity in children with Down syndrome. METHODS Forty-five Down syndrome participants with an age ranged from 10 to 13 years were enrolled. There were distributed into three groups. The study group A (n = 15) underwent proprioceptive neuromuscular facilitation of respiratory muscles while study group B (n = 15) underwent inspiratory muscle training. Third group C (n = 15) was a control group. The three groups received aerobic exercises using the bicycle ergometer for 20 min, 5 times/week for 12 successive weeks. The treatment program for both study groups was conducted for 20-30 min, 5 times/week for 12 successive weeks. Measurements of respiratory muscle strength (MIP, MEP), chest expansion, spirometry test (VC, FEV1, PEFR, MVV) and 6 min walk test were measured pre and post treatment. RESULTS The post treatment mean values of all investigated variables were significantly increased in both study groups with higher effect to group underwent proprioceptive neuromuscular facilitation of respiratory muscles. CONCLUSION Both proprioceptive neuromuscular facilitation of respiratory muscles and inspiratory muscle training are effective in children with Down syndrome on improving respiratory muscle strength, chest expansion, spirometry and functional capacity with superior effect of proprioceptive neuromuscular facilitation.",2021,"The post treatment mean values of all investigated variables were significantly increased in both study groups with higher effect to group underwent proprioceptive neuromuscular facilitation of respiratory muscles. ","['children with Down syndrome', 'children with down syndrome', 'Forty-five', 'Down syndrome participants with an age ranged from 10 to 13 years were enrolled']","['aerobic exercises using the bicycle ergometer', 'inspiratory muscle training', 'proprioceptive neuromuscular facilitation of respiratory muscles while study group B (n\xa0=\xa015) underwent inspiratory muscle training']","['respiratory muscle strength (MIP, MEP), chest expansion, spirometry test (VC, FEV1, PEFR, MVV) and 6\xa0min walk test', 'respiratory muscle strength, chest expansion, spirometry, and functional capacity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0013080', 'cui_str': 'Trisomy 21'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0180749', 'cui_str': 'Bicycle ergometer'}, {'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0376579', 'cui_str': 'Macrophage Inflammatory Proteins'}, {'cui': 'C0054871', 'cui_str': 'Cathepsin L'}, {'cui': 'C0231902', 'cui_str': 'Chest expansion'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0030735', 'cui_str': 'Peak expiratory flow rate'}, {'cui': 'C0024967', 'cui_str': 'Maximum voluntary ventilation'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}]",45.0,0.012958,"The post treatment mean values of all investigated variables were significantly increased in both study groups with higher effect to group underwent proprioceptive neuromuscular facilitation of respiratory muscles. ","[{'ForeName': 'Rasha A', 'Initials': 'RA', 'LastName': 'Mohamed', 'Affiliation': 'Department of Physical Therapy for Growth and Developmental Disorders in Children and Its Surgery, Faculty of Physical Therapy, Cairo University, Egypt. Electronic address: dr.rashapt@gmail.com.'}, {'ForeName': 'El Sayed H', 'Initials': 'ESH', 'LastName': 'Mohamed', 'Affiliation': 'Cardiopulmonary Disorders, Physical Therapy Department, Buraydah Private Colleges, Saudi Arabia. Electronic address: dr.elsayedhassanpt@gmail.com.'}, {'ForeName': 'Suzan M', 'Initials': 'SM', 'LastName': 'Habshy', 'Affiliation': 'Cardiopulmonary Disorders, Physical Therapy Department, Abu-Reesh Mounira Hospitals, Cairo, Egypt. Electronic address: maya.sameh.menese@gmail.com.'}, {'ForeName': 'Sobhy M', 'Initials': 'SM', 'LastName': 'Aly', 'Affiliation': 'Department of Biomechanics, Faculty of Physical Therapy, Cairo University, Egypt. Electronic address: drsobhyaly@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.009'] 1367,34142950,"Evaluation of bioequivalence between generic and brand-name clozapine in Chinese schizophrenic patients: A randomized, two-period, crossover study.","OBJECTIVE Clozapine is the most effective therapy for schizophrenia. This study compared the bioequivalence of a generic formulation of clozapine (ChangZhou Pharmaceutical Factory Co. Ltd. Jiangsu, China) to the brand name formulation (Clozaril, HLS Therapeutics, Inc., Philadelphia, PA, USA) after multiple doses in Chinese schizophrenic patients. MATERIALS AND METHODS This was a randomized, open-label, multiple-dose, 2-way crossover study in which patients with schizophrenia received the generic clozapine or Clozaril 100 mg twice daily for 10 days before crossing over to the alternate formulation for the next 10 days. Blood samples were collected at regular intervals during each treatment period, and plasma concentration of clozapine was determined by high-performance liquid chromatography. RESULTS 26 patients were enrolled, of whom 24 completed the study and were included in the steady-state analyses. The mean AUC 0-12 was 6,003.29 h×ng/mL for generic clozapine and 6,347.53 h×ng/mL for Clozaril. The mean C max,ss was 698.52 ng/mL for generic clozapine and 739.75 ng/mL for Clozaril. The ratio of the adjusted geometric means and its 90% CI of the ratios for AUC 0-12 was 96.24% (89.60 - 103.36%), and for C max,ss was 95.90% (88.91 - 103.44%). A total of 66 adverse events were reported by 22 (84.62%) subjects. Among them, 34 occurred in 17 (65.38%) patients during dosing of generic clozapine, and 32 occurred in 16 (61.54%) patients during dosing of brand-name clozapine. CONCLUSION The result demonstrated that the generic clozapine was bioequivalent to brand-name clozapine (Clozaril). This would provide physicians with reassurance that patients who receive the studied generic clozapine will achieve similar plasma drug concentrations to those of brand-name clozapine (Clozaril).",2021,"The mean AUC 0-12 was 6,003.29 h×ng/mL for generic clozapine and 6,347.53 h×ng/mL for Clozaril.","['patients with schizophrenia', 'Chinese schizophrenic patients', '26 patients were enrolled, of whom 24 completed the study and were included in the steady-state analyses']","['clozapine', 'generic and brand-name clozapine', 'Clozapine', 'generic clozapine or Clozaril', 'clozapine (Clozaril', 'generic clozapine']","['Blood samples', 'plasma concentration of clozapine']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0009079', 'cui_str': 'Clozapine'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0719386', 'cui_str': 'Clozaril'}]","[{'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009079', 'cui_str': 'Clozapine'}]",26.0,0.0384739,"The mean AUC 0-12 was 6,003.29 h×ng/mL for generic clozapine and 6,347.53 h×ng/mL for Clozaril.","[{'ForeName': 'Xiding', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Qiangyong', 'Initials': 'Q', 'LastName': 'Yan', 'Affiliation': ''}, {'ForeName': 'Lingfeng', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Fan', 'Affiliation': ''}, {'ForeName': 'Jindong', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Haishan', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Hualin', 'Initials': 'H', 'LastName': 'Cai', 'Affiliation': ''}, {'ForeName': 'Ronghua', 'Initials': 'R', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Pingfei', 'Initials': 'P', 'LastName': 'Fang', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203864'] 1368,34141717,"A High-Protein, Low Glycemic Index Diet Suppresses Hunger but Not Weight Regain After Weight Loss: Results From a Large, 3-Years Randomized Trial (PREVIEW).","Background: Previous studies have shown an increase in hunger during weight-loss maintenance (WLM) after diet-induced weight loss. Whether a combination of a higher protein, lower glycemic index (GI) diet and physical activity (PA) can counteract this change remains unclear. Aim: To compare the long-term effects of two diets [high protein (HP)-low GI vs. moderate protein (MP)-moderate GI] and two PA programs [high intensity (HI) vs. moderate intensity (MI)] on subjective appetite sensations during WLM after ≥8% weight loss (WL). Methods: Data derived from the 3-years PREVIEW randomized intervention study. An 8-weeks WL phase using a low-energy diet was followed by a 148-weeks randomized WLM phase. For the WLM phase, participants were assigned to one of the four groups: HP-MI, HP-HI, MP-MI, and MP-HI. Available data from 2,223 participants with overweight or obesity (68% women; BMI ≥ 25 kg/m 2 ). Appetite sensations including satiety, hunger, desire to eat, and desire to eat something sweet during the two phases (at 0, 8 weeks and 26, 52, 104, and 156 weeks) were assessed based on the recall of feelings during the previous week using visual analogue scales. Differences in changes in appetite sensations from baseline between the groups were determined using linear mixed models with repeated measures. Results: There was no significant diet × PA interaction. From 52 weeks onwards, decreases in hunger were significantly greater in HP-low GI than MP-moderate GI ( P time × diet = 0.018, P dietgroup = 0.021). Although there was no difference in weight regain between the diet groups ( P time × diet = 0.630), hunger and satiety ratings correlated with changes in body weight at most timepoints. There were no significant differences in appetite sensations between the two PA groups. Decreases in hunger ratings were greater at 52 and 104 weeks in HP-HI vs. MP-HI, and greater at 104 and 156 weeks in HP-HI vs. MP-MI. Conclusions: This is the first long-term, large-scale randomized intervention to report that a HP-low GI diet was superior in preventing an increase in hunger, but not weight regain, during 3-years WLM compared with a MP-moderate GI diet. Similarly, HP-HI outperformed MP-HI in suppressing hunger. The role of exercise intensity requires further investigation. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT01777893.",2021,"From 52 weeks onwards, decreases in hunger were significantly greater in HP-low GI than MP-moderate GI ( P time","['2,223 participants with overweight or obesity (68% women; BMI ≥ 25 kg/m 2 ']","['HP-low GI diet', 'two diets [high protein (HP)-low GI vs. moderate protein (MP)-moderate GI] and two PA programs [high intensity (HI) vs. moderate intensity (MI']","['appetite sensations', 'weight regain', 'hunger and satiety ratings', 'hunger', 'subjective appetite sensations', 'hunger during weight-loss maintenance (WLM', 'body weight', 'glycemic index (GI) diet and physical activity (PA', 'hunger ratings', 'Appetite sensations including satiety, hunger, desire to eat, and desire to eat something sweet']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}]",2223.0,0.0338757,"From 52 weeks onwards, decreases in hunger were significantly greater in HP-low GI than MP-moderate GI ( P time","[{'ForeName': 'Ruixin', 'Initials': 'R', 'LastName': 'Zhu', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Fogelholm', 'Affiliation': 'Department of Food and Nutrition, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Larsen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Sally D', 'Initials': 'SD', 'LastName': 'Poppitt', 'Affiliation': 'Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Marta P', 'Initials': 'MP', 'LastName': 'Silvestre', 'Affiliation': 'Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Pia S', 'Initials': 'PS', 'LastName': 'Vestentoft', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Elli', 'Initials': 'E', 'LastName': 'Jalo', 'Affiliation': 'Department of Food and Nutrition, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Navas-Carretero', 'Affiliation': 'Department of Nutrition, University of Navarra, Pamplona, Spain.'}, {'ForeName': 'Maija', 'Initials': 'M', 'LastName': 'Huttunen-Lenz', 'Affiliation': 'Institute for Nursing Science, University of Education Schwäbisch Gmünd, Schwäbisch Gmünd, Germany.'}, {'ForeName': 'Moira A', 'Initials': 'MA', 'LastName': 'Taylor', 'Affiliation': ""Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, Nottingham, United Kingdom.""}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Stratton', 'Affiliation': 'Applied Sports, Technology, Exercise and Medicine (A-STEM) Research Centre, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Swindell', 'Affiliation': 'Applied Sports, Technology, Exercise and Medicine (A-STEM) Research Centre, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Niina E', 'Initials': 'NE', 'LastName': 'Kaartinen', 'Affiliation': 'Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Lam', 'Affiliation': 'NetUnion sarl, Lausanne, Switzerland.'}, {'ForeName': 'Teodora', 'Initials': 'T', 'LastName': 'Handjieva-Darlenska', 'Affiliation': 'Department of Pharmacology and Toxicology, Medical University of Sofia, Sofia, Bulgaria.'}, {'ForeName': 'Svetoslav', 'Initials': 'S', 'LastName': 'Handjiev', 'Affiliation': 'Department of Pharmacology and Toxicology, Medical University of Sofia, Sofia, Bulgaria.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Schlicht', 'Affiliation': 'Exercise and Health Sciences, University of Stuttgart, Stuttgart, Germany.'}, {'ForeName': 'J Alfredo', 'Initials': 'JA', 'LastName': 'Martinez', 'Affiliation': 'Department of Nutrition, University of Navarra, Pamplona, Spain.'}, {'ForeName': 'Radhika V', 'Initials': 'RV', 'LastName': 'Seimon', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Sainsbury', 'Affiliation': 'School of Human Sciences (Exercise and Sports Science), Faculty of Science, The University of Western Australia, Crawley, WA, Australia.'}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Macdonald', 'Affiliation': ""Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, MRC/ARUK Centre for Musculoskeletal Ageing Research, ARUK Centre for Sport, Exercise and Osteoarthritis, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham, United Kingdom.""}, {'ForeName': 'Margriet S', 'Initials': 'MS', 'LastName': 'Westerterp-Plantenga', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'Brand-Miller', 'Affiliation': 'School of Life and Environmental Sciences and Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Raben', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}]",Frontiers in nutrition,['10.3389/fnut.2021.685648'] 1369,34139459,Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis.,"Fingolimod is an oral medication for multiple sclerosis that sequesters certain subsets of lymphocytes in lymph nodes, reducing egress into blood and their subsequent CNS migration. The initial multi-site randomized Phase III controlled trials found rates of infection similar to those in control groups. However, post-marketing surveillance has revealed an association with several opportunistic infections, including cryptococcosis. We report a case of fingolimod-related cryptococcal meningoencephalitis and IRIS after drug discontinuation and suggest a surveillance and risk mitigation strategy.",2021,"Fingolimod is an oral medication for multiple sclerosis that sequesters certain subsets of lymphocytes in lymph nodes, reducing egress into blood and their subsequent CNS migration.",['patient with multiple sclerosis'],['Fingolimod'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C1699926', 'cui_str': 'fingolimod'}]",[],,0.0383296,"Fingolimod is an oral medication for multiple sclerosis that sequesters certain subsets of lymphocytes in lymph nodes, reducing egress into blood and their subsequent CNS migration.","[{'ForeName': 'Fernando X', 'Initials': 'FX', 'LastName': 'Cuascut', 'Affiliation': 'Maxine Mesinger Multiple Sclerosis Comprehensive Care Center, Department of Neurology, Baylor College of Medicine, Houston, Texas, United States. Electronic address: Fernando.Cuascut@bcm.edu.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Alkabie', 'Affiliation': 'Maxine Mesinger Multiple Sclerosis Comprehensive Care Center, Department of Neurology, Baylor College of Medicine, Houston, Texas, United States.'}, {'ForeName': 'George J', 'Initials': 'GJ', 'LastName': 'Hutton', 'Affiliation': 'Maxine Mesinger Multiple Sclerosis Comprehensive Care Center, Department of Neurology, Baylor College of Medicine, Houston, Texas, United States.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2021.103072'] 1370,34138672,The FIFA 11+ Shoulder Injury Prevention Program Was Effective in Reducing Upper Extremity Injuries Among Soccer Goalkeepers: A Randomized Controlled Trial.,"BACKGROUND Soccer is one of the most popular sports worldwide. Goalkeepers are more likely to injure their upper limbs, particularly their shoulders, than outfield players. To reduce upper extremity injuries, the FIFA 11+ Shoulder Injury Prevention Program (FIFA 11+S) was developed. PURPOSE The purpose of this study was to assess the effectiveness of the FIFA 11+S program in reducing the incidence of upper extremity injuries among amateur soccer goalkeepers. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS A total of 726 goalkeepers, who were blinded to study intent, were randomly assigned to the experimental group (n = 360) or control group (n = 366). The experimental group was instructed to perform the FIFA 11+S program before all training sessions for 1 season (6 months). The control group was instructed to continue performing their usual routine warm-up program before training sessions for 1 season. Primary outcomes included the incidence of upper extremity injury and incidence of mechanism, type, and severity of injury measured using injury risk ratios (IRR); compliance with the experimental and control interventions was also recorded. RESULTS A total of 50 injuries (0.62 injuries per 1000 exposure-hours) were reported in the experimental group, and 122 injuries (1.94 injuries/1000 hours) were reported in the control group. The FIFA 11+S program reduced the total number of upper extremity injuries by 68% (IRR = 0.32 [95% CI, 0.27-0.34]) compared with the usual warm-up. The FIFA 11+S program reduced the incidence of contact injury (IRR = 0.30 [95% CI, 0.25-0.31]), noncontact injury (IRR = 0.40 [95% CI, 0.35-0.43]), initial injury (IRR = 0.34 [95% CI, 0.29-0.36]), recurrent injury (IRR = 0.20 [95% CI, 0.17-0.21]), and overuse injury (IRR = 0.40 [95% CI, 0.35-0.43]). Participants in the experimental group demonstrated a significant decrease in injuries of minor (IRR = 0.32 [95% CI, 0.27-0.34]) and moderate severity (IRR = 0.33 [95% CI, 0.29-0.35]) compared with the control group. We noted no difference in compliance between the experimental and control groups (80% vs 73%, respectively; P = .92). CONCLUSION The FIFA 11+S program resulted in 50% fewer upper extremity injuries among soccer goalkeepers, compared with a regular warm-up. REGISTRATION ACTRN12618001080213 (Australian New Zealand Clinical Trials Registry).",2021,Participants in the experimental group demonstrated a significant decrease in injuries of minor (IRR = 0.32,"['A total of 726 goalkeepers', 'Soccer Goalkeepers', 'amateur soccer goalkeepers']","['FIFA 11+ Shoulder Injury Prevention Program', 'FIFA 11+S program']","['incidence of upper extremity injury and incidence of mechanism, type, and severity of injury measured using injury risk ratios (IRR); compliance', 'noncontact injury', 'injuries of minor (IRR = 0.32', 'incidence of contact injury', 'compliance', 'upper extremity injuries', 'recurrent injury', 'moderate severity', 'total number of upper extremity injuries']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}]","[{'cui': 'C0149776', 'cui_str': 'Injury of shoulder region'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0003794', 'cui_str': 'Injury of upper extremity'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0582456', 'cui_str': 'At risk for injury'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C4517448', 'cui_str': '0.32'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",,0.114835,Participants in the experimental group demonstrated a significant decrease in injuries of minor (IRR = 0.32,"[{'ForeName': 'Wesam Saleh A', 'Initials': 'WSA', 'LastName': 'Al Attar', 'Affiliation': 'Department of Physical Therapy, College of Applied Medical Sciences, Umm Al Qura University, Makkah, Saudi Arabia.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Faude', 'Affiliation': 'Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Bizzini', 'Affiliation': 'Human Performance Lab, Schulthess Clinic, Zürich, Switzerland.'}, {'ForeName': 'Saud', 'Initials': 'S', 'LastName': 'Alarifi', 'Affiliation': 'Department of Physical Therapy, King Abdulaziz Medical City, Riyadh, Saudi Arabia.'}, {'ForeName': 'Hosam', 'Initials': 'H', 'LastName': 'Alzahrani', 'Affiliation': 'Department of Physical Therapy, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.'}, {'ForeName': 'Raed S', 'Initials': 'RS', 'LastName': 'Almalki', 'Affiliation': 'Department of Physical Therapy, College of Applied Medical Sciences, Umm Al Qura University, Makkah, Saudi Arabia.'}, {'ForeName': 'Riyadh G', 'Initials': 'RG', 'LastName': 'Banjar', 'Affiliation': 'Department of Physical Therapy, College of Applied Medical Sciences, Umm Al Qura University, Makkah, Saudi Arabia.'}, {'ForeName': 'Ross H', 'Initials': 'RH', 'LastName': 'Sanders', 'Affiliation': 'Discipline of Exercise and Sport Science, Faculty of Medicine and Health Sciences, University of Sydney, Sydney, Australia.'}]",The American journal of sports medicine,['10.1177/03635465211021828'] 1371,34138667,"No Treatment Benefits of Local Administration of Insulin-like Growth Factor-1 in Addition to Heavy Slow Resistance Training in Tendinopathic Human Patellar Tendons: A Randomized, Double-Blind, Placebo-Controlled Trial With 1-Year Follow-up.","BACKGROUND Heavy slow resistance (HSR) training is currently recommended as part of the treatment of patellar tendon tendinopathy. However, treatment success is not reached in all patients, and combinations of different treatments could be beneficial. Local administration of insulin-like growth factor-1 (IGF-1) in humans has been shown to quickly stimulate tendon collagen synthesis. PURPOSE To study whether IGF-1 injections combined with HSR training enhance tendon synthesis, tissue structure, and patient satisfaction versus saline injection combined with HSR training in patients with patellar tendinopathy. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS Forty patients (age 18-50 years) with unilateral patellar tendinopathy undertook HSR training (3 times a week for 12 weeks) and received intratendinous IGF-1 injections (1 mg IGF-1 per dose) or isotonic saline injections (sham injections) at baseline and after 1 and 2 weeks of training. The primary outcome was collagen synthesis parameters after 12 weeks (primary endpoint). The secondary outcomes were patient-reported outcomes (scores on the Victorian Institute of Sport Assessment-Patella [VISA-P] and visual analog scale [VAS] for pain) and structural changes before the initiation of treatment and at week 3, week 12, and 1 year after the initiation of treatment. RESULTS Analysis of the patellar tendon biopsy specimens at 12 weeks showed that collagen mRNA and total RNA were increased in the tendinopathic tendons compared with the contralateral healthy tendons regardless of treatment with IGF-1 or saline. Similarly, no difference between the groups was seen in tendon thickness and Doppler activity at week 12 or at 1-year follow-up. The combination of HSR training and IGF-1 injections significantly improved VISA-P and VAS pain scores after 3 weeks, whereas the overall responses after 12 weeks and at 1-year follow-up were identical in the 2 groups. CONCLUSION Although a small, immediate clinical response to IGF-1 injections was seen when combined with training, no additional long-term effect of intratendinous IGF-1 was observed on structural and clinical outcomes in patients with patellar tendinopathy. REGISTRATION NCT01834989 (ClinicalTrials.gov identifier).",2021,"Similarly, no difference between the groups was seen in tendon thickness and Doppler activity at week 12 or at 1-year follow-up.","['patellar tendon tendinopathy', 'Forty patients (age 18-50 years) with unilateral patellar tendinopathy undertook HSR training (3 times a week for 12 weeks) and received', 'Tendinopathic Human Patellar Tendons', 'patients with patellar tendinopathy']","['Heavy slow resistance (HSR) training', 'saline injection combined with HSR training', 'IGF-1 injections combined with HSR training', 'insulin-like growth factor-1 (IGF-1', 'IGF-1 or saline', 'HSR training and IGF-1 injections', 'Insulin-like Growth Factor-1', 'Placebo', 'intratendinous IGF-1 injections (1 mg IGF-1 per dose) or isotonic saline injections']","['collagen mRNA and total RNA', 'tendon thickness and Doppler activity', 'patient-reported outcomes (scores on the Victorian Institute of Sport Assessment-Patella [VISA-P] and visual analog scale [VAS] for pain) and structural changes before the initiation of treatment', 'collagen synthesis parameters', 'tendon synthesis, tissue structure, and patient satisfaction', 'VISA-P and VAS pain scores']","[{'cui': 'C0206332', 'cui_str': 'Structure of patellar ligament'}, {'cui': 'C0151936', 'cui_str': 'Disorder of tendon'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0595620', 'cui_str': 'Intratendinous route'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0454287', 'cui_str': 'Isotonic exercise'}]","[{'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0039508', 'cui_str': 'Tendon structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0554756', 'cui_str': 'Doppler studies'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}, {'cui': 'C1318881', 'cui_str': 'Infection due to vancomycin intermediate Staphylococcus aureus'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",,0.29695,"Similarly, no difference between the groups was seen in tendon thickness and Doppler activity at week 12 or at 1-year follow-up.","[{'ForeName': 'Jens L', 'Initials': 'JL', 'LastName': 'Olesen', 'Affiliation': 'Center for General Practice at Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Hansen', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Ida F', 'Initials': 'IF', 'LastName': 'Turtumoygard', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Rikke', 'Initials': 'R', 'LastName': 'Hoffner', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Schjerling', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Christensen', 'Affiliation': 'Department of Occupational Therapy and Physiotherapy, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Christopher L', 'Initials': 'CL', 'LastName': 'Mendias', 'Affiliation': 'Hospital for Special Surgery, New York, New York, USA.'}, {'ForeName': 'Peter S', 'Initials': 'PS', 'LastName': 'Magnusson', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kjaer', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}]",The American journal of sports medicine,['10.1177/03635465211021056'] 1372,34144460,"Anxiety of families after first unprovoked or first febrile seizure - A prospective, randomized pilot study.","OBJECTIVES Parents of children with a first unprovoked seizure report high levels of stress and anxiety. Little is known however about interventions that might help to reduce anxiety. We aimed to evaluate anxiety of parents and children after a first unprovoked seizure and assess the anxiety-reducing effect of a semi-structured follow-up in a first seizure clinic (FSC). In comparison, parents of children with febrile seizures are also evaluated, as an example of anxiety evolution without follow-up intervention after provoked seizures. STUDY DESIGN In this prospective, interventional study, patients presenting with a first unprovoked seizure were randomized to early care (EC) with follow-up in FSC within 3 weeks and late care (LC), follow-up in FSC after 4 months. Anxiety levels of parents and patients were scored with the State Trait Anxiety Inventory (STAI) after the initial seizure (T0), 3 and 12 months (T1, T2). To assess the effect of the semi-structured follow-up, anxiety scores were compared between the two groups at baseline, at T1 (i.e., after intervention in EC but prior to intervention in LC) and at T2. Parents of children with febrile seizures (FS) were prospectively followed up without intervention. RESULTS Fifty two patients were included (EC n = 18, LC n = 18, FS n = 15). Initial state anxiety in parents was high in all groups. At T1 (i. e. after intervention in EC but not LC) state anxiety was significantly higher in LC (52.2 (16.7) vs. 33.3 (5.3), p < 0.01). This effect persisted after 12 months, despite intervention in LC in the meantime (39.0 (11.7) vs. 28.8 (6.2); p < 0.01)). The effect in children was similar (T1: 40.6 (8.3) vs. 29.8 (5.1); p < 0.05 and T2: 33.5 (4.7) vs. 24.7 (3.6); p < 0.01). State anxiety in FS decreased within 3 months without intervention (50.0 (14.5) to 33.7 (9.2)). CONCLUSIONS A timely and structured follow-up in a FSC offers effective and sustained reduction of anxiety-levels after first unprovoked seizure in children. In contrast, anxiety after a first febrile seizure decreases over time without additional intervention.",2021,"At T1 (i. e. after intervention in EC but not LC) state anxiety was significantly higher in LC (52.2 (16.7) vs. 33.3 (5.3), p < 0.01).","['Parents of children with febrile seizures (FS', 'Fifty', 'two patients were included (EC n\u202f=\u202f18, LC n\u202f=\u202f18, FS n\u202f=\u202f15', 'patients presenting with a first unprovoked seizure', 'Parents of children with a first unprovoked seizure report high levels of stress and anxiety']","['early care (EC) with follow-up in FSC within 3\u202fweeks and late care (LC), follow-up in FSC']","['LC) state anxiety', 'State anxiety in FS', 'Anxiety levels', 'State Trait Anxiety Inventory (STAI', 'anxiety scores', 'anxiety-levels', 'Initial state anxiety']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009952', 'cui_str': 'Febrile convulsion'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C3838759', 'cui_str': 'Seizure clinic'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205087', 'cui_str': 'Late'}]","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}, {'cui': 'C0009952', 'cui_str': 'Febrile convulsion'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205265', 'cui_str': 'Initial'}]",52.0,0.0127605,"At T1 (i. e. after intervention in EC but not LC) state anxiety was significantly higher in LC (52.2 (16.7) vs. 33.3 (5.3), p < 0.01).","[{'ForeName': 'Kerstin Alexandra', 'Initials': 'KA', 'LastName': 'Klotz', 'Affiliation': 'Department of Neuropediatrics and Muscle Disorders, Center for Pediatrics, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Mathildenstraße 1, 79106 Freiburg, Germany; Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Breisacher Straße 153, 79106 Freiburg, Germany; Epilepsy Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Straße 64, 79106 Freiburg, Germany. Electronic address: kerstin.alexandra.klotz@uniklinik-freiburg.de.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Özcan', 'Affiliation': 'Department of Neuropediatrics and Muscle Disorders, Center for Pediatrics, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Mathildenstraße 1, 79106 Freiburg, Germany.'}, {'ForeName': 'Yusuf', 'Initials': 'Y', 'LastName': 'Sag', 'Affiliation': 'Department of Neuropediatrics and Muscle Disorders, Center for Pediatrics, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Mathildenstraße 1, 79106 Freiburg, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Schönberger', 'Affiliation': 'Department of Neuropediatrics and Muscle Disorders, Center for Pediatrics, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Mathildenstraße 1, 79106 Freiburg, Germany; Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Breisacher Straße 153, 79106 Freiburg, Germany; Epilepsy Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Straße 64, 79106 Freiburg, Germany. Electronic address: jan.schoenberger@uniklinik-freiburg.de.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Kaier', 'Affiliation': 'Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Stefan-Meier-Straße 26, 79104 Freiburg, Germany. Electronic address: Kaier@imbi.uni-freiburg.de.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Jacobs', 'Affiliation': ""Alberta Children's Hospital, Alberta Children's Research Institute, Hodgekiss Brain Institute, University of Calgary, Section of Pediatric Neurology, Alberta, Canada; Department of Neuropediatrics and Muscle Disorders, Center for Pediatrics, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Mathildenstraße 1, 79106 Freiburg, Germany. Electronic address: julia.jacobs@gmx.de.""}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2021.108120'] 1373,34144438,Sonification of combined action observation and motor imagery: Effects on corticospinal excitability.,"Action observation and motor imagery are valuable strategies for motor learning. Their simultaneous use (AOMI) increases neural activity, with related benefits for motor learning, compared to the two strategies alone. In this study, we explored how sonification influences AOMI. Twenty-five participants completed a practice block based on AOMI, motor imagery and physical execution of the same action. Participants were divided into two groups: An experimental group that practiced with sonification during AOMI (sAOMI), and a control group, which did not receive any extrinsic feedback. Corticospinal excitability at rest and during action observation and AOMI was assessed before and after practice, with and without sonification sound, to test the development of an audiomotor association. The practice block increased corticospinal excitability in all testing conditions, but sonification did not affect this. In addition, we found no differences in action observation and AOMI, irrespective of sonification. These results suggest that, at least for simple tasks, sonification of AOMI does not influence corticospinal excitability; In these conditions, sonification may have acted as a distractor. Future studies should further explore the relationship between task complexity, value of auditory information and action, to establish whether sAOMI is a valuable for motor learning.",2021,"Their simultaneous use (AOMI) increases neural activity, with related benefits for motor learning, compared to the two strategies alone.",[],"['experimental group that practiced with sonification during AOMI (sAOMI), and a control group, which did not receive any extrinsic feedback', 'combined action observation and motor imagery']","['corticospinal excitability', 'action observation and AOMI, irrespective of sonification', 'Corticospinal excitability']",[],"[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}]","[{'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]",25.0,0.0340893,"Their simultaneous use (AOMI) increases neural activity, with related benefits for motor learning, compared to the two strategies alone.","[{'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Castro', 'Affiliation': 'Research Unit of Neurophysiology and Neuroengineering of Human-Technology Interaction (Next Lab), Università Campus Bio-Medico di Roma, Rome, Italy; Centre for Cognitive Neuroscience, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, UK. Electronic address: f.castro@unicampus.it.'}, {'ForeName': 'Paulina Anna', 'Initials': 'PA', 'LastName': 'Bryjka', 'Affiliation': 'Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, UK.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Di Pino', 'Affiliation': 'Research Unit of Neurophysiology and Neuroengineering of Human-Technology Interaction (Next Lab), Università Campus Bio-Medico di Roma, Rome, Italy.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Vuckovic', 'Affiliation': 'School of Engineering, College of Engineering and Science, James Watt Building (south) University of Glasgow, Glasgow G12 8QQ, UK.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Nowicky', 'Affiliation': 'Centre for Cognitive Neuroscience, Department of Clinical Sciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, UK.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Bishop', 'Affiliation': 'Centre for Cognitive Neuroscience, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, UK.'}]",Brain and cognition,['10.1016/j.bandc.2021.105768'] 1374,34169235,The effect of head cooling and remote ischemic conditioning on patients with traumatic brain injury.,"Cerebral impairment caused by an external force to the head is known as traumatic brain injury (TBI). The aim of this study was to determine the role of local hypothermia and remote ischemic conditioning (RIC) on oxidative stress, inflammatory response after TBI, and other involved variables. The present study is a clinical trial on 84 patients with TBI who were divided into 4 groups. The head cooling for 1.5 to 6 hr was performed in the first three days after TBI. RIC intervention was performed within the golden time after TBI in the form of four 5-min cycles with full cuff and 5 min of emptying of cuff. The group receiving the head cooling technique recovered better than the group receiving the RIC technique. Generally, combination of the two interventions of head cooling and RIC techniques is more effective on the improvement of clinical status of patients than each separate technique.",2021,The group receiving the head cooling technique recovered better than the group receiving the RIC technique.,"['patients with traumatic brain injury', '84 patients with TBI who were divided into 4 groups']","['head cooling and remote ischemic conditioning', 'local hypothermia and remote ischemic conditioning (RIC', 'RIC intervention', 'head cooling technique']","['oxidative stress, inflammatory response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}]","[{'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0020672', 'cui_str': 'Hypothermia'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0242606', 'cui_str': 'Oxidative stress'}]",84.0,0.0127213,The group receiving the head cooling technique recovered better than the group receiving the RIC technique.,"[{'ForeName': 'Fardin', 'Initials': 'F', 'LastName': 'Hodoodi', 'Affiliation': 'Department of Physiology and Pharmacology, Schoole of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Allah-Tavakoli', 'Affiliation': 'Department of Physiology and Pharmacology, Schoole of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran.'}, {'ForeName': 'Farzad', 'Initials': 'F', 'LastName': 'Tajik', 'Affiliation': 'Department of Clinical Research Sciences, Department of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran.'}, {'ForeName': 'Iman', 'Initials': 'I', 'LastName': 'Fatemi', 'Affiliation': 'Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Moghadam Ahmadi', 'Affiliation': 'Department of Neurology, Department of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran.'}]",iScience,['10.1016/j.isci.2021.102472'] 1375,34166195,An Accessible Training Device for Children With Cerebral Palsy.,"Walking and balance capabilities can be improved upon using repetitive ankle dorsiflexion exercises. Here we developed two types of pedal switches incorporated with training devices to improve their walking and balance performance of children with cerebral palsy. The first type of pedal switch can be used to operate a home appliance, while the second type of pedal switch can connect them to web games. Pedal switches can be used for home rehabilitation. This randomized controlled trial included patients in the intervention (n = 24) and control (n = 24) groups who completed 15 weeks of ankle training. The experimental group performed ankle dorsiflexion using a pressure-activated pedal switch connected to the web games. The control group performed ankle dorsiflexion exercises using a pedal switch that operated a home appliance (a fan). Standing balance and walking performance were estimated using the Zebris FDM system, a pressure force platform, the Pediatric Balance Scale score, and the 1-minute walk test. The pre- and posttest data were analyzed using analysis of variance and analysis of covariance, which revealed that the intervention group had more significant improvements in sway patterns and balance and walking. The developed facility of a modified pedal switch integrated with web games can achieve better exercise adherence to promote balance and walking performance than that with home appliances. Maintaining motivation in children with cerebral palsy plays a very important role in the rehabilitation process.",2021,The developed facility of a modified pedal switch integrated with web games can achieve better exercise adherence to promote balance and walking performance than that with home appliances.,"['children with cerebral palsy', 'Children with Cerebral Palsy', 'patients in the intervention (n = 24) and control (n = 24) groups who completed 15 weeks of ankle training']","['ankle dorsiflexion exercises using a pedal switch that operated a home appliance (a fan', 'ankle dorsiflexion using a pressure-activated pedal switch connected to the web games']","['Pediatric Balance Scale score', 'sway patterns and balance and walking', 'Standing balance and walking performance']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0231770', 'cui_str': 'Dorsiflexion of foot'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1542418', 'cui_str': 'Appliance'}, {'cui': 'C0441039', 'cui_str': 'Fan'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}]",24.0,0.0121722,The developed facility of a modified pedal switch integrated with web games can achieve better exercise adherence to promote balance and walking performance than that with home appliances.,"[{'ForeName': 'Guoqing', 'Initials': 'G', 'LastName': 'Wan', 'Affiliation': ''}, {'ForeName': 'Hsieh-Chun', 'Initials': 'HC', 'LastName': 'Hsieh', 'Affiliation': ''}, {'ForeName': 'Chien-Heng', 'Initials': 'CH', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Hung-Yu', 'Initials': 'HY', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Chien-Yu', 'Initials': 'CY', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Wen-Hsin', 'Initials': 'WH', 'LastName': 'Chiu', 'Affiliation': ''}]",IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society,['10.1109/TNSRE.2021.3092199'] 1376,34166100,"Training Surgeons to Perform Arthroscopic All-Inside Meniscal Repair: A Randomized Controlled Trial Evaluating the Effectiveness of a Novel Cognitive Task Analysis Teaching Tool, Imperial College London/University College London Meniscus Repair Cognitive Task Analysis (IUMeRCTA).","BACKGROUND All-inside meniscal repair is an increasingly common technique for the surgical treatment of meniscal tears. There are currently no standardized techniques for training residents in this procedure. Cognitive task analysis (CTA) is a method of analyzing and standardizing key steps in a procedure that allows training to be conducted in a validated and reproducible manner. PURPOSE (1) To design a digital CTA teaching tool for a standardized all-inside meniscal repair. (2) To evaluate whether CTA-trained residents would perform better in a meniscal repair task compared with a control group who underwent traditional apprenticeship methods of training. STUDY DESIGN Controlled laboratory study. METHODS Three expert knee surgeons were interviewed using a modified Delphi method to generate a consensus among the ideal technical steps, cognitive decision points, and common errors and solutions for an all-inside meniscal repair. This written information was then combined with visual and audio components and integrated onto a digital platform to create the Imperial College London/University College London Meniscus Repair Cognitive Task Analysis (IUMeRCTA) tool. Eighteen novice residents were randomized into an intervention group (digital CTA tool) and control group (equipment instruction manual). Both groups performed an all-inside meniscal repair on high-fidelity, phantom knee models and were assessed by expert surgeons, blinded to the interventions, using a validated global rating scale (GRS). After a power calculation, median GRS scores were compared between groups using the Mann-Whitney U test; significance was set at P < .05. RESULTS For the IUMeRCTA tool design, the procedure was divided into 55 steps across 9 phases: (1) preoperative planning, (2) theater and patient setup, (3) portal placement, (4) meniscal examination, (5) tear reduction, (6) suture planning, (7) suture insertion, (8) repair completion, and (9) postoperative care and rehabilitation. For the trial, the intervention group (mean ± SD GRS, 32 ± 2.9) performed significantly better than did the control group (GRS, 24 ± 3.3; P < .001). CONCLUSION This is the first CTA tool to demonstrate objective benefits in training novices to perform an arthroscopic all-inside meniscal repair. CLINICAL RELEVANCE The IUMeRCTA tool is an easily accessible and effective adjunct to traditional teaching that enhances learning the all-inside meniscal repair for novice surgeons.",2021,The IUMeRCTA tool is an easily accessible and effective adjunct to traditional teaching that enhances learning the all-inside meniscal repair for novice surgeons.,"['Three expert knee surgeons', 'Eighteen novice residents']","['Novel Cognitive Task Analysis Teaching Tool, Imperial College London/University College London Meniscus Repair Cognitive Task Analysis (IUMeRCTA', 'preoperative planning, (2) theater and patient setup, (3) portal placement, (4) meniscal examination, (5) tear reduction, (6) suture planning, (7) suture insertion, (8) repair completion, and (9) postoperative care and rehabilitation', 'CTA-trained residents', 'Arthroscopic All-Inside Meniscal Repair', 'control group who underwent traditional apprenticeship methods of training', 'Cognitive task analysis (CTA', 'intervention group (digital CTA tool) and control group (equipment instruction manual', 'modified Delphi method to generate a consensus among the ideal technical steps, cognitive decision points, and common errors and solutions for an all-inside meniscal repair']","['median GRS scores', 'global rating scale (GRS']","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0556033', 'cui_str': 'Work analysis'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0407887', 'cui_str': 'Repair of meniscus'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0475307', 'cui_str': 'Theatre'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0948455', 'cui_str': 'Suture insertion'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0032786', 'cui_str': 'Postoperative care'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0391549,The IUMeRCTA tool is an easily accessible and effective adjunct to traditional teaching that enhances learning the all-inside meniscal repair for novice surgeons.,"[{'ForeName': 'Urvi', 'Initials': 'U', 'LastName': 'Karamchandani', 'Affiliation': 'Department of Surgery and Cancer, Imperial College London, London, UK.'}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Bhattacharyya', 'Affiliation': 'Department of Surgery and Cancer, Imperial College London, London, UK.'}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Department of Orthopaedics, University College London Hospitals NHS Trust, UK.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Oussedik', 'Affiliation': 'Department of Orthopaedics, University College London Hospitals NHS Trust, UK.'}, {'ForeName': 'Rajarshi', 'Initials': 'R', 'LastName': 'Bhattacharya', 'Affiliation': 'Department of Surgery and Cancer, Imperial College London, London, UK.'}, {'ForeName': 'Chinmay', 'Initials': 'C', 'LastName': 'Gupte', 'Affiliation': 'Department of Surgery and Cancer, Imperial College London, London, UK.'}]",The American journal of sports medicine,['10.1177/03635465211021652'] 1377,34391239,Acute effect of different duration times of application of myofascial release on quadriceps femoris strength: A randomized clinical trial.,"OBJECTIVES To evaluate the effect of Miofascial Release (MFR) on knee extensors strength, at different duration times of application. METHOD 51 healthy individuals were randomly assigned to one of three groups (3min, 5min or placebo) in this randomized clinical trial. The knee extensors strength was assessed in two conditions: pre and post-intervention, using an isokinetic dynamometer, at speeds of 60° and 120°/s. MFR was applied on the anterior surface of the thigh for 3min or 5 min, according to the experimental groups. The placebo group underwent through the application of a non-therapeutic gel, associated with 3min of a light touch on the skin. Peak torque, total work and mean power were the isokinetic variables analyzed through a multivariate analysis of variance (MANOVA) with p ≤ 0.05. RESULTS Our findings suggest a main effect and interaction between moments (pre and post-intervention) and speeds (60° and 120°/s) for total work and mean power (p < 0.01). Likewise, main effect and interaction of speed were observed for peak torque (p < 0.01). There were no significant differences for the other analyzed variables. CONCLUSION No significant main effect of MFR were detected in any of the proposed application time on peak torque, total work and mean power, in the knee extensors, compared to the placebo group.",2021,"No significant main effect of MFR were detected in any of the proposed application time on peak torque, total work and mean power, in the knee extensors, compared to the placebo group.","['51 healthy individuals', 'quadriceps femoris strength']","['placebo', 'MFR', 'Miofascial Release (MFR']","['Peak torque, total work and mean power', 'knee extensors strength', 'peak torque, total work and mean power, in the knee extensors', 'peak torque', 'MFR']","[{'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}]",51.0,0.0348119,"No significant main effect of MFR were detected in any of the proposed application time on peak torque, total work and mean power, in the knee extensors, compared to the placebo group.","[{'ForeName': 'Tamires Cristina', 'Initials': 'TC', 'LastName': 'Campos de Almeida', 'Affiliation': 'Post-Graduate Program in Rehabilitation Sciences, Augusto Motta University (UNISUAM), Rio de Janeiro, Brazil.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Paes', 'Affiliation': 'Post-Graduate Program in Rehabilitation Sciences, Augusto Motta University (UNISUAM), Rio de Janeiro, Brazil; Almirante Adalberto Nunes Physical Education Center (CEFAN), Navy of Brazil, Brazil.'}, {'ForeName': 'Maurício', 'Initials': 'M', 'LastName': 'Soares', 'Affiliation': 'Post-Graduate Program in Rehabilitation Sciences, Augusto Motta University (UNISUAM), Rio de Janeiro, Brazil; Almirante Adalberto Nunes Physical Education Center (CEFAN), Navy of Brazil, Brazil.'}, {'ForeName': 'Guilherme', 'Initials': 'G', 'LastName': 'de Freitas Fonseca', 'Affiliation': 'Post-Graduate Program in Exercise Science and Sports University of Rio de Janeiro State (UERJ), Rio de Janeiro, Brazil.'}, {'ForeName': 'Maicom', 'Initials': 'M', 'LastName': 'Lima', 'Affiliation': 'Post-Graduate Program in Rehabilitation Sciences, Augusto Motta University (UNISUAM), Rio de Janeiro, Brazil; Almirante Adalberto Nunes Physical Education Center (CEFAN), Navy of Brazil, Brazil.'}, {'ForeName': 'Júlio Guilherme', 'Initials': 'JG', 'LastName': 'Silva', 'Affiliation': 'Federal University of Rio de Janeiro - Medical School - Physiotherapy Department, Rio de Janeiro, Brazil. Electronic address: jgsilva@hucff.ufrj.br.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.02.026'] 1378,34138499,"Continued root development of immature permanent teeth after regenerative endodontics with or without a collagen membrane: A randomized, controlled clinical trial.","BACKGROUND Recent studies evaluated the efficacy of a collagen membrane (Bio-Gide) to promote root development in regenerative endodontics (REPs). However, the influence of etiology and tooth type on the results was not assessed. AIMS To evaluate the quantitative and qualitative effect of a collagen membrane (Bio-Gide), with and without the effect of etiology and tooth type, in promoting root development in immature teeth after REPs. DESIGN Eighty nonvital immature teeth were divided randomly into two groups (40 teeth in each group). REPs were performed with (experimental group) and without (control group) a collagen membrane. All teeth were subjected to regular clinical and radiographical follow-up. RESULTS Seventy-six teeth were included in the final analyses. The average follow-up periods were 33.1 ± 21.8 months for the control group and 28.1± 18.6 months for the experimental group. Quantitative analysis of root development in the experimental group showed a greater increase in dentin wall thickness in the middle one-third of the root compared to the control group, with or without the effect of etiology and tooth type. Six types of root development were observed. There was no significant difference in the type of tooth development between the two groups. CONCLUSION The use of a collagen membrane could promote an increase in dentin wall thickness in the middle one-third of the root, and it had no significant effect in terms of the type of subsequent root development.",2021,"Quantitative analysis of root development in the experimental group showed a greater increase in dentin wall thickness in the middle one-third of the root compared to the control group, with or without the effect of etiology and tooth type.","['Eighty nonvital immature teeth', 'Seventy-six teeth were included in the final analyses', 'immature teeth after regenerative endodontics (REPs']",['collagen membrane (Bio-Gide'],"['type of tooth development', 'dentin wall thickness']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0205252', 'cui_str': 'Immature'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4704832', 'cui_str': 'Regenerative Endodontics'}]","[{'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0539912', 'cui_str': 'Bio-Gide'}]","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0028877', 'cui_str': 'Odontogenesis'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",76.0,0.0268114,"Quantitative analysis of root development in the experimental group showed a greater increase in dentin wall thickness in the middle one-third of the root compared to the control group, with or without the effect of etiology and tooth type.","[{'ForeName': 'Xijun', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'Department of Pediatric Dentistry, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Pediatric Dentistry, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Chufang', 'Initials': 'C', 'LastName': 'Peng', 'Affiliation': 'Department of Pediatric Dentistry, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}]",International journal of paediatric dentistry,['10.1111/ipd.12853'] 1379,34142415,"Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.","AIMS Over decades, left ventricular assist device (LVAD) technology has transitioned from less durable bulky pumps to smaller continuous-flow pumps which have substantially improved long-term outcomes and quality of life. Contemporary LVAD therapy is beleaguered by haemocompatibility-related adverse events including thrombosis, stroke and bleeding. A fully magnetically levitated pump, the HeartMate 3 (HM3, Abbott, USA) LVAD, has been shown to be superior to the older HeartMate II (HMII, Abbott, USA) pump by improving haemocompatibility. Experience with the HM3 LVAD suggests near elimination of de-novo pump thrombosis, a marked reduction in stroke rates, and only a modest decrease in bleeding complications. Since the advent of continuous-flow LVAD therapy, patients have been prescribed a combination of aspirin and anticoagulation therapy on the presumption that platelet activation and perturbations to the haemostatic axis determine their necessity. Observational studies in patients implanted with the HM3 LVAD who suffer bleeding have suggested a signal of reduced subsequent bleeding events with withdrawal of aspirin. The notion of whether antiplatelet therapy can be avoided in an effort to reduce bleeding complications has now been advanced. METHODS To evaluate this hypothesis and its clinical benefits, the Antiplatelet Removal and Hemocompatibility Events with the HeartMate 3 Pump (ARIES HM3) has been introduced as the first-ever international prospective, randomized, double-blind and placebo-controlled, non-inferiority trial in a patient population implanted with a LVAD. CONCLUSION This paper reviews the biological and clinical role of aspirin (100 mg) with LVADs and discusses the rationale and design of the ARIES HM3 trial.",2021,"Experience with the HM3 LVAD suggests near elimination of de-novo pump thrombosis, a significant reduction in stroke rates, and only a modest decrease in bleeding complications.","['patient population implanted with a LVAD', 'patients implanted with the HM3 LVAD who suffer bleeding']","['USA) LVAD', 'HM3 LVAD', 'HeartMate 3 Pump (ARIES HM3', 'Placebo', 'Aspirin', 'placebo', 'aspirin']","['bleeding complications', 'stroke rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0085842', 'cui_str': 'Ventricular assist device'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]","[{'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",,0.257857,"Experience with the HM3 LVAD suggests near elimination of de-novo pump thrombosis, a significant reduction in stroke rates, and only a modest decrease in bleeding complications.","[{'ForeName': 'Mandeep R', 'Initials': 'MR', 'LastName': 'Mehra', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Daniel L', 'Initials': 'DL', 'LastName': 'Crandall', 'Affiliation': 'Clinical Affairs Heart Failure, Abbott, Chicago, IL, USA.'}, {'ForeName': 'Finn', 'Initials': 'F', 'LastName': 'Gustafsson', 'Affiliation': 'Cardiology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Ulrich P', 'Initials': 'UP', 'LastName': 'Jorde', 'Affiliation': 'Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Bronx, NY, USA.'}, {'ForeName': 'Jason N', 'Initials': 'JN', 'LastName': 'Katz', 'Affiliation': 'Division of Cardiology, Duke University, Durham, NC, USA.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Netuka', 'Affiliation': 'Department of Cardiovascular Surgery, IKEM, Prague, Czech Republic.'}, {'ForeName': 'Nir', 'Initials': 'N', 'LastName': 'Uriel', 'Affiliation': 'Heart Failure, Heart Transplant & Mechanical Circulatory Support, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Jean M', 'Initials': 'JM', 'LastName': 'Connors', 'Affiliation': ""Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Poornima', 'Initials': 'P', 'LastName': 'Sood', 'Affiliation': 'Clinical Affairs Heart Failure, Abbott, Chicago, IL, USA.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Heatley', 'Affiliation': 'Global Biometrics, Abbott, Chicago, IL, USA.'}, {'ForeName': 'Francis D', 'Initials': 'FD', 'LastName': 'Pagani', 'Affiliation': 'Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA.'}]",European journal of heart failure,['10.1002/ejhf.2275'] 1380,34142409,Randomized controlled trial comparing magnetic marker localization (MaMaLoc) with wire-guided localization in the treatment of early-stage breast cancer.,"Wire-guided localization (WGL) is the standard of care in the surgical treatment of nonpalpable breast tumors. In this study, we compare the use of a new magnetic marker localization (MaMaLoc) technique to WGL in the treatment of early-stage breast cancer patients. Open-label, single-center, randomized controlled trial comparing MaMaLoc (intervention) to WGL (control) in women with early-stage breast cancer. Primary outcome was surgical usability measured using the System Usability Scale (SUS, 0-100 score). Secondary outcomes were patient reported, clinical, and pathological outcomes such as retrieval rate, operative time, resected specimen weight, margin status, and reoperation rate. Thirty-two patients were analyzed in the MaMaLoc group and 35 in the WGL group. Patient and tumor characteristics were comparable between groups. No in situ complications occurred. Retrieval rate was 100% in both groups. Surgical usability was higher for MaMaLoc: 70.2 ± 8.9 vs. 58.1 ± 9.1, p < 0.001. Patients reported higher overall satisfaction with MaMaLoc (median score 5/5) versus WGL (score 4/5), p < 0.001. The use of magnetic marker localization (MaMaLoc) for early-stage breast cancer is effective and has higher surgical usability than standard WGL.",2021,The use of magnetic marker localization (MaMaLoc) for early-stage breast cancer is effective and has higher surgical usability than standard WGL.,"['early-stage breast cancer patients', 'women with early-stage breast cancer', 'early-stage breast cancer', 'Thirty-two patients were analyzed in the MaMaLoc group and 35 in the WGL group']","['magnetic marker localization (MaMaLoc', 'MaMaLoc (intervention) to WGL (control', 'Wire-guided localization (WGL', 'new magnetic marker localization (MaMaLoc) technique to WGL', 'magnetic marker localization (MaMaLoc) with wire-guided localization']","['Surgical usability', 'patient reported, clinical, and pathological outcomes such as retrieval rate, operative time, resected specimen weight, margin status, and reoperation rate', 'overall satisfaction with MaMaLoc', 'surgical usability measured using the System Usability Scale (SUS, 0-100\xa0score', 'Retrieval rate']","[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0037710', 'cui_str': 'Auditory localization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0181089', 'cui_str': 'Guide wire'}]","[{'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0037710', 'cui_str': 'Auditory localization'}, {'cui': 'C0181089', 'cui_str': 'Guide wire'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0037710', 'cui_str': 'Auditory localization'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0574518', 'cui_str': 'Susu language'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.354589,The use of magnetic marker localization (MaMaLoc) for early-stage breast cancer is effective and has higher surgical usability than standard WGL.,"[{'ForeName': 'Gerson M', 'Initials': 'GM', 'LastName': 'Struik', 'Affiliation': 'Department of Surgery, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.'}, {'ForeName': 'Bram', 'Initials': 'B', 'LastName': 'Schermers', 'Affiliation': 'Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Ingeborg', 'Initials': 'I', 'LastName': 'Mares', 'Affiliation': 'Department of Surgery, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.'}, {'ForeName': 'Harold E', 'Initials': 'HE', 'LastName': 'Lont', 'Affiliation': 'Department of Surgery, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.'}, {'ForeName': 'Jennifer W', 'Initials': 'JW', 'LastName': 'Bradshaw', 'Affiliation': 'Department of Radiology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Ten Haken', 'Affiliation': 'Technical Medical Centre, University of Twente, Enschede, The Netherlands.'}, {'ForeName': 'Theo J M', 'Initials': 'TJM', 'LastName': 'Ruers', 'Affiliation': 'Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Jurgen E M', 'Initials': 'JEM', 'LastName': 'Mourik', 'Affiliation': 'Department of Medical Physics, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.'}, {'ForeName': 'Erwin', 'Initials': 'E', 'LastName': 'Birnie', 'Affiliation': 'Department of Statistics and Education, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.'}, {'ForeName': 'Taco M A L', 'Initials': 'TMAL', 'LastName': 'Klem', 'Affiliation': 'Department of Surgery, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.'}]",The breast journal,['10.1111/tbj.14262'] 1381,34391272,The influence of rotational movement exercise on the abdominal muscle thickness and trunk mobility - Randomized control trial.,"BACKGROUND Trunk rotations are important functional movements which form the foundations of human motion pattern, especially in the functions of walking and running. They prevent the functional impairments and structural lesions resulting from axial overloading in static positions such as sitting. OBJECTIVES The aim of the study was to assess the influence of rotational movement training exercises on the abdominal muscle thickness and spinal mobility range. STUDY DESIGN Randomized controlled trial. METHODS The study involved 73 individuals aged 18-45. The subjects were randomly divided into two groups. The study group (TG) comprised 40 people who performed rotational movement exercises over the period of 4 weeks (16 training sessions). In the control group (CG) the training was not applied. Changes in the thickness of selected abdominal muscles on ultrasound imaging were evaluated, as well as trunk mobility, based on the trunk lateral flexion test. RESULTS The analysis of the obtained data has demonstrated a statistically significant increase in the thickness of the abdominal internal (IO) (p < 0.05) and external oblique muscles (EO) (p < 0.001) in the study group (TG) between measurements I and II, and measurements I and III. A similar increase in the thickness was found in the summation measurement of TrA + IO + EO. Bilateral increase in the trunk lateral flexion range in the frontal plane has also been noted. CONCLUSIONS Rotational movement training of the trunk leads to an increase in the thickness of the abdominal oblique muscles. Rotational movement exercise training increases trunk mobility in the frontal plane.",2021,"The analysis of the obtained data has demonstrated a statistically significant increase in the thickness of the abdominal internal (IO) (p < 0.05) and external oblique muscles (EO) (p < 0.001) in the study group (TG) between measurements I and II, and measurements I and III.","['40 people who performed', '73 individuals aged 18-45']","['Rotational movement training', 'rotational movement exercises', 'Rotational movement exercise training', 'rotational movement exercise', 'rotational movement training exercises']","['trunk mobility', 'thickness of the abdominal internal (IO', 'external oblique muscles (EO', 'trunk lateral flexion range']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0224375', 'cui_str': 'External Oblique Muscle'}, {'cui': 'C0439791', 'cui_str': 'Lateral flexion'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]",73.0,0.0715804,"The analysis of the obtained data has demonstrated a statistically significant increase in the thickness of the abdominal internal (IO) (p < 0.05) and external oblique muscles (EO) (p < 0.001) in the study group (TG) between measurements I and II, and measurements I and III.","[{'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Niewiadomy', 'Affiliation': 'Department of Balneoclimatology and Biological Regeneration, School of Health Sciences in Katowice, Medical University of Silesia in Katowice, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Szuścik-Niewiadomy', 'Affiliation': 'Department of Adapted Physical Activity and Sport, School of Health Sciences in Katowice, Medical University of Silesia in Katowice, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Kuszewski', 'Affiliation': 'Institute of Physiotherapy and Health Sciences, The Jerzy Kukuczka Academy of Physical Education in Katowice, Poland.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Kurpas', 'Affiliation': 'School of Health Sciences in Katowice, Medical University of Silesia in Katowice, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Kochan', 'Affiliation': 'Institute of Physiotherapy and Health Sciences, The Jerzy Kukuczka Academy of Physical Education in Katowice, Poland. Electronic address: m.kochan@awf.katowice.pl.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.05.008'] 1382,34144603,Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial.,"OBJECTIVES Methotrexate is widely used at low dosages (LD-MTX) for non-oncologic indications and is associated with a variety of adverse effects (AEs). We sought to determine whether concentrations of the active metabolite, MTX polyglutamates (MTX-PGs) 1-5, correlate with AEs. METHOD We examined data from the LD-MTX arm of the randomized double-blind Cardiovascular Inflammation Reduction Trial (CIRT). All AEs were blindly adjudicated and monitoring laboratories were tested centrally. The MTX-PGs 1-5 were assessed in one reference laboratory using liquid chromatography-tandem mass spectrometry. Based on prior literature, MTX-PGs 3-5 were chosen as the exposure of interest and quartiles of MTX-PGs 3-5 were assessed for their relationship with all AEs and each pre-specified category of AE using adjusted Cox proportional hazards regression. RESULTS Of the 2391 subjects randomized to LD-MTX, MTX-PG levels were available for 1319 subjects (median dosage 16.1 mg/week) from the 8 month visit. We followed these subjects for a median of 2.2 years [interquartile range (IQR) 1.5-2.9]. Higher MTX-PG3-5 levels were related to an increased risk of anaemia [compared with quartile 1 (Q1); hazard ratio (HR) for Q4 1.27 (95% CI 0.98, 1.65), P for trend = 0.05] and a decreased risk of thrombocytopenia [HR for Q4 0.52 (95% CI 0.32, 0.84), P for trend = 0.05]. MTX-PG3-5 levels >134 nmol/l were associated with an increased risk of liver abnormalities [HR 1.36 (95% CI 1.08, 1.72)]. CONCLUSIONS Higher MTX- PG3-5 levels were modestly associated with LD-MTX AEs, including anaemia and liver function abnormalities, but a reduced risk of thrombocytopenia and haemorrhage. CLINICAL TRIAL REGISTRATION NCT01594333.",2021,Higher MTX-PG3-5 levels were related to an increased risk of anaemia [compared with quartile 1 (Q1); hazard ratio (HR) for Q4 1.27,['2391 subjects randomized to'],"['Methotrexate', 'LD-MTX']","['risk of thrombocytopenia [HR', 'risk of thrombocytopenia and haemorrhage', 'MTX-PG levels', 'risk of anaemia', 'risk of liver abnormalities', 'anaemia and liver function abnormalities']",[],"[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}]",2391.0,0.352629,Higher MTX-PG3-5 levels were related to an increased risk of anaemia [compared with quartile 1 (Q1); hazard ratio (HR) for Q4 1.27,"[{'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': ""Division of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Selhub', 'Affiliation': 'USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Jacques', 'Affiliation': 'USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.'}, {'ForeName': 'Nina P', 'Initials': 'NP', 'LastName': 'Paynter', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Jean G', 'Initials': 'JG', 'LastName': 'MacFadyen', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Glynn', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Ridker', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Solomon', 'Affiliation': ""Division of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital, Boston, MA, USA.""}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa650'] 1383,34145182,Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder.,,2021,,['Adults With Posttraumatic Stress Disorder'],['Vortioxetine Versus Placebo'],['Cognition and Functional Capacity'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}]","[{'cui': 'C3661282', 'cui_str': 'vortioxetine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}]",,0.184457,,"[{'ForeName': 'Dante', 'Initials': 'D', 'LastName': 'Durand', 'Affiliation': ''}, {'ForeName': 'Tess Moore', 'Initials': 'TM', 'LastName': 'Calcagno', 'Affiliation': ''}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': ''}, {'ForeName': 'D Jeffrey', 'Initials': 'DJ', 'LastName': 'Newport', 'Affiliation': ''}, {'ForeName': 'Charles B', 'Initials': 'CB', 'LastName': 'Nemeroff', 'Affiliation': ''}, {'ForeName': 'Boadie W', 'Initials': 'BW', 'LastName': 'Dunlop', 'Affiliation': ''}, {'ForeName': 'Philip D', 'Initials': 'PD', 'LastName': 'Harvey', 'Affiliation': ''}]",Journal of clinical psychopharmacology,['10.1097/JCP.0000000000001414'] 1384,34148764,Twelve-Month Efficacy of an Obesity Prevention Program Targeting Hispanic Families With Preschoolers From Low-Income Backgrounds.,"OBJECTIVE Assess effects of an obesity prevention program promoting eating self-regulation and healthy preferences in Hispanic preschool children. DESIGN Randomized controlled trial with pretest, posttest, 6- and 12-month assessments. Fourteen waves, each lasting 7 weeks. SETTING Families recruited from Head Start across 2 sites. PARTICIPANTS Two hundred fifty-five families randomized into prevention (n = 136) or control (n = 119). INTERVENTION Prevention received curriculum; control received no curriculum. MAIN OUTCOME MEASURE(S) Feeding knowledge/practices/styles (parent); body mass index percentile, eating self-regulation, trying new foods, and fruit/vegetable consumption (child). ANALYSIS Multilevel analyses for nested data (time points within families; families within waves) and multinomial regression. RESULTS Program increased mothers' repeated presentation of new foods (P < 0.05), measured portion sizes (P < 0.05), child involvement in food preparation (P < 0.001), feeding responsiveness (P < 0.001), knowledge of best feeding practices (P < 0.001), and feeding efficacy (P < 0.05); reduced feeding misconceptions (P < 0.01) and uninvolved feeding (P < 0.01). Effects on child eating behavior were minimal. At 12 months, children in the prevention group were less likely to have overweight (P < 0.05) or obesity (P < 0.05). CONCLUSIONS AND IMPLICATIONS Program effects emphasize the importance of feeding approaches in reducing childhood obesity.",2021,"RESULTS Program increased mothers' repeated presentation of new foods (P < 0.05), measured portion sizes (P < 0.05), child involvement in food preparation (P < 0.001), feeding responsiveness (P < 0.001), knowledge of best feeding practices (P < 0.001), and feeding efficacy (P < 0.05); reduced feeding misconceptions (P < 0.01) and uninvolved feeding (P < 0.01).","['Two hundred fifty-five families randomized into prevention (n\u202f=\u202f136) or control (n\u202f=\u202f119', 'Families recruited from Head Start across 2 sites', 'Hispanic preschool children', 'Hispanic Families']","['Feeding knowledge/practices/styles (parent', 'Obesity Prevention Program', 'obesity prevention program', 'Prevention received curriculum; control received no curriculum']","['portion sizes', 'feeding responsiveness', 'child involvement in food preparation', 'feeding misconceptions', 'feeding efficacy', 'knowledge of best feeding practices', 'child eating behavior', ""mothers' repeated presentation of new foods"", 'uninvolved feeding']","[{'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}]","[{'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C3658326', 'cui_str': 'Portion Size'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205429', 'cui_str': 'Uninvolved'}]",255.0,0.0160399,"RESULTS Program increased mothers' repeated presentation of new foods (P < 0.05), measured portion sizes (P < 0.05), child involvement in food preparation (P < 0.001), feeding responsiveness (P < 0.001), knowledge of best feeding practices (P < 0.001), and feeding efficacy (P < 0.05); reduced feeding misconceptions (P < 0.01) and uninvolved feeding (P < 0.01).","[{'ForeName': 'Sheryl O', 'Initials': 'SO', 'LastName': 'Hughes', 'Affiliation': ""USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX. Electronic address: shughes@bcm.edu.""}, {'ForeName': 'Thomas G', 'Initials': 'TG', 'LastName': 'Power', 'Affiliation': 'Department of Human Development, Washington State University, Pullman, WA.'}, {'ForeName': 'Ashley D', 'Initials': 'AD', 'LastName': 'Beck', 'Affiliation': 'Spokane Regional Health District, Spokane, WA.'}, {'ForeName': 'Drew', 'Initials': 'D', 'LastName': 'Betz', 'Affiliation': 'Whatcom County Extension, Washington State University, Bellingham, WA.'}, {'ForeName': 'L Suzanne', 'Initials': 'LS', 'LastName': 'Goodell', 'Affiliation': 'Department of Food, Bioprocessing, and Nutrition Sciences, North Carolina State University, Raleigh, NC.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Hopwood', 'Affiliation': 'Pullman Regional Hospital, Pullman, WA.'}, {'ForeName': 'J Andrea', 'Initials': 'JA', 'LastName': 'Jaramillo', 'Affiliation': ""USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX.""}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Lanigan', 'Affiliation': 'Department of Human Development, Washington State University, Vancouver, WA.'}, {'ForeName': 'AnaMaria Diaz', 'Initials': 'AD', 'LastName': 'Martinez', 'Affiliation': 'Franklin County Extension, Washington State University, Pasco, WA.'}, {'ForeName': 'Nilda', 'Initials': 'N', 'LastName': 'Micheli', 'Affiliation': ""USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX.""}, {'ForeName': 'Yadira Olivera', 'Initials': 'YO', 'LastName': 'Guerrero', 'Affiliation': 'Yakima County Extension, Washington State University, Union Gap, WA.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Overath', 'Affiliation': 'Kitsap County Extension, Washington State University, Bremerton, WA.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Parker', 'Affiliation': 'Department of Human Development, Washington State University Extension, Seattle, WA.'}, {'ForeName': 'Guadalupe', 'Initials': 'G', 'LastName': 'Ramos', 'Affiliation': 'Department of Preventive Medicine, University of Southern California, Los Angeles, CA.'}, {'ForeName': 'Yuri P', 'Initials': 'YP', 'LastName': 'Thompson', 'Affiliation': 'College of Education, Department of Psychological, Health, and Learning Sciences, University of Houston, Houston, TX.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Papaioannou', 'Affiliation': ""USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX.""}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Johnson', 'Affiliation': 'Department of Pediatrics, Section of Nutrition, University of Colorado School of Medicine, Aurora, CO.'}]",Journal of nutrition education and behavior,['10.1016/j.jneb.2021.04.460'] 1385,34147954,"The effects of combined sternocleidomastoid muscle stretching and massage on pain, disability, endurance, kinesiophobia, and range of motion in individuals with chronic neck pain: A randomized, single-blind study.","BACKGROUND The effect of interventions to the Sternocleidomastoid (SCM)-muscle, as an important element of neck movement which is overactive in individuals with chronic neck pain (CNP), are unknown. OBJECTIVE The aim of the current study is to investigate the effects of SCM stretching and massage on pain, range of motion (ROM), endurance, disability, and kinesiophobia in individuals with CNP. METHODS In this study, individuals with CNP were randomized 1:1 to parallel SCM-Group (n = 30) or control group (CG) (n = 30). Conventional physiotherapy was applied to CG. In addition to the same interventions applied to the CG, classical massage and stretching exercises were applied to the SCM-muscle in the SCM-Group. Treatment sessions were administered three times each week for a total of 5 weeks. Pain, endurance, ROM, disability, and kinesiophobia were evaluated. Both prior to and immediately following the treatments. Mixed-model repeated measured ANOVAs were then employed to determine if a group*time interaction existed on the effects of the treatment on each outcome variable for each group as the between-subjects variable and time as the within-subjects variables. RESULTS Improvements in pain, disability, ROM(extension, left-lateral flexion, and right/left-rotation), and endurance were found to be greater in the SCM-Group compared to the CG (p < 0.05). Changes in flexion and right-lateral flexion ROM and kinesiophobia did not significantly differ between the groups (p > 0.05). CONCLUSION Stretching exercises and massage applied to the SCM-muscle, together with conventional physiotherapy, can reduce pain and disability, and increase ROM and endurance in individuals with CNP. This treatment may therefore be considered for use as an alternative method in treating CNP. The study was registered in ClinicalTrials.gov (NCT04345042).",2021,"Changes in flexion and right-lateral flexion ROM and kinesiophobia did not significantly differ between the groups (p > 0.05). ","['individuals with CNP', 'individuals with chronic neck pain', 'individuals with chronic neck pain (CNP']","['combined sternocleidomastoid muscle stretching and massage', 'SCM stretching and massage', 'CG, classical massage and stretching exercises', 'parallel SCM-Group (n\xa0=\xa030) or control group (CG', 'Stretching exercises and massage', 'Conventional physiotherapy']","['Changes in flexion and right-lateral flexion ROM and kinesiophobia', 'pain, range of motion (ROM), endurance, disability, and kinesiophobia', 'pain, disability, endurance, kinesiophobia, and range of motion', 'pain and disability, and increase ROM and endurance', 'Pain, endurance, ROM, disability, and kinesiophobia', 'pain, disability, ROM(extension, left-lateral flexion, and right/left-rotation), and endurance']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0224153', 'cui_str': 'Structure of sternocleidomastoid muscle'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0450415', 'cui_str': 'Lateral to the right'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0450414', 'cui_str': 'Lateral to the left'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}]",,0.0313224,"Changes in flexion and right-lateral flexion ROM and kinesiophobia did not significantly differ between the groups (p > 0.05). ","[{'ForeName': 'Buket', 'Initials': 'B', 'LastName': 'Büyükturan', 'Affiliation': 'Kırşehir Ahi Evran University, Schol of Physical Therapy and Rehabilitation, Kırşehir, Turkey. Electronic address: fztkaya04@hotmail.com.'}, {'ForeName': 'Senem', 'Initials': 'S', 'LastName': 'Şaş', 'Affiliation': 'Erciyes University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Kayseri, Turkey. Electronic address: senemsas@gmail.com.'}, {'ForeName': 'Caner', 'Initials': 'C', 'LastName': 'Kararti', 'Affiliation': 'Kırşehir Ahi Evran University, Schol of Physical Therapy and Rehabilitation, Kırşehir, Turkey. Electronic address: fzt.caner.92@gmail.com.'}, {'ForeName': 'Öznur', 'Initials': 'Ö', 'LastName': 'Büyükturan', 'Affiliation': 'Kırşehir Ahi Evran University, Schol of Physical Therapy and Rehabilitation, Kırşehir, Turkey. Electronic address: fzt_oznur@hotmail.com.'}]",Musculoskeletal science & practice,['10.1016/j.msksp.2021.102417'] 1386,34153543,"Effect of Photodynamic therapy and Er,Cr: YSGG laser on bond strength of bleached enamel to composite resin.","OBJECTIVE The purpose of the present study was bleached enamel reversal using conventional ascorbic acid (AA) and contemporary methods including Photodynamic therapy (PDT), Er, Cr: YSGG (ECL) on bond integrity to composite resin. MATERIAL AND METHOD Forty sound permanent mandibular premolars were collected from a dental clinical setting and disinfected. All forty samples were mounted vertically in a rubber mold exposing only the clinical crown. All samples were bleached using Opalescence Boost Professional Teeth Whitening. After the bleaching procedure, each sample was randomly allocated into four groups according to surface treatment. Samples in group 1 were treated with methylene blue photosensitizer (MBP). Samples in group 2 were exposed to 10% sodium ascorbate. Samples in group 3 were treated with Er, Cr: YSGG laser (ECL). Samples in group 4 were not treated (control). All Samples were treated with 37% phosphoric acid and a bonding agent was applied. A bulk-fill composite was cured to all specimens and all samples were treated in a thermocycler. Specimens were placed in a universal testing machine for shear bond strength (SBS) testing. Descriptive statistics were associated by analysis of variance (ANOVA) and Tukey's post hoc test maintaining level of significance (p<0.05) RESULTS: The lowest SBS scores were achieved in the bleached enamel (BE) group (15.25±1.745 MPa). Whereas, the highest bond integrity was attained by AA group (32.23±1.854 MPa). Samples treated with ECL (31.87±1.659 MPa) and AA (32.23±1.854) were comparable (p>0.05). Samples treated with PDT exhibited significantly different SBS (22.41±1.258) compared to other experimental groups CONCLUSION: ECL showed a reversal effect of BE compared to AA and has the potential to be used in clinical settings. BE reversal using MBP needs further investigation.",2021,Samples treated with PDT exhibited significantly different SBS (22.41±1.258) compared to other experimental groups CONCLUSION: ECL showed a reversal effect of BE compared to AA and has the potential to be used in clinical settings.,"['All forty samples were mounted vertically in a rubber mould exposing only the clinical crown', 'bleached enamel to composite resin', 'Forty sound permanent mandibular premolars were collected from a dental clinical setting and disinfected']","['ECL', 'Er, Cr: YSGG laser (ECL', 'conventional ascorbic acid (AA) and contemporary methods Photodynamic therapy (PDT), Er, Cr: YSGG (ECL', 'sodium ascorbate', 'Photodynamic therapy and Er,Cr: YSGG laser', 'methylene blue photosensitizer (MBP', 'phosphoric acid']","['highest bond integrity', 'lowest SBS scores']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0181909', 'cui_str': 'Mount'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0369241', 'cui_str': 'Filamentous fungus'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0010384', 'cui_str': 'Crown'}, {'cui': 'C0303749', 'cui_str': 'Bleach'}, {'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C0009570', 'cui_str': 'Composite Resins'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}]","[{'cui': 'C0879167', 'cui_str': 'Yttrium-Scandium-Gallium Garnet Lasers'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0887557', 'cui_str': 'Sodium Ascorbate'}, {'cui': 'C0025746', 'cui_str': 'Methylene blue'}, {'cui': 'C0162713', 'cui_str': 'Photosensitizing agent'}, {'cui': 'C0031700', 'cui_str': 'Phosphoric acid'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0175735', 'cui_str': 'Scissors'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",40.0,0.0232908,Samples treated with PDT exhibited significantly different SBS (22.41±1.258) compared to other experimental groups CONCLUSION: ECL showed a reversal effect of BE compared to AA and has the potential to be used in clinical settings.,"[{'ForeName': 'Fayez Hussain', 'Initials': 'FH', 'LastName': 'Niazi', 'Affiliation': 'Department of Restorative and Prosthetic Dentistry, College of Dentistry, Dar Al Uloom University, Riyadh, Saudi Arabia. Electronic address: fayezniazi92@gmail.com.'}, {'ForeName': 'Zeeshan', 'Initials': 'Z', 'LastName': 'Qamar', 'Affiliation': 'Department of OMFS and Diagnostic Sciences, Riyadh Elm University, Riyadh, Saudi Arabia; Department of Oral Biology, Liaquat College of Medicine and Dentistry, Karachi, Pakistan.'}, {'ForeName': 'Syed Bilal', 'Initials': 'SB', 'LastName': 'Tanvir', 'Affiliation': 'Visiting Researcher center of Immunobiology, Blizard Institute, Barts and London School of medicine and dentistry London United Kingdom.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Noushad', 'Affiliation': 'Dept of Restorative and Prosthetic Dentistry, College of Dentistry, Dar Al Uloom University, Riyadh, Saudi Arabia; Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.'}, {'ForeName': 'Omar Bandar Al', 'Initials': 'OBA', 'LastName': 'Dossary', 'Affiliation': 'Faculty of dentistry, Visions Colleges, Riyadh Saudi Arabia.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102405'] 1387,34153529,Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study.,"BACKGROUND Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are gut hormones secreted in response to food ingestion, and they have been suggested to regulate bone turnover. In humans, exogenous GIP and GLP-2 acutely inhibit bone resorption as measured by circulating levels of carboxy-terminal type 1 collagen crosslinks (CTX). OBJECTIVE The objective was to study the individual and combined acute effects of GIP and GLP-2 on bone turnover in postmenopausal women during nighttime - a period of increased bone resorption. METHODS Using a randomized, placebo-controlled, double-blinded, crossover design, each participant (n = 9) received on four separate study days: GIP, GLP-2, GIP + GLP-2, and placebo (saline) as subcutaneous injections at bedtime. Main outcomes were levels of CTX and procollagen type 1 N-terminal propeptide (P1NP). RESULTS Compared with placebo, GIP and GLP-2 alone significantly inhibited bone resorption (measured by CTX). GIP rapidly reduced CTX levels in the period from 45 to 120 min after injection, while GLP-2 had a more delayed effect with reduced CTX levels in the period from 120 to 240 min after injection. Combining GIP and GLP-2 showed complementary effects resulting in a sustained inhibition of CTX with reduced levels from 45 to 240 min after injection. Furthermore, GIP acutely increased bone formation (measured by P1NP). CONCLUSION Both GIP and GLP-2 reduced CTX during the night and had complementary effects when combined.",2021,"Main outcomes were levels of CTX and procollagen type 1 N-terminal propeptide (P1NP). ","['postmenopausal women', 'postmenopausal women during nighttime - a period of increased bone resorption']","['Subcutaneous GIP and GLP-2', 'GIP and GLP-2', 'GIP, GLP-2, GIP+GLP-2, and placebo (saline', 'placebo, GIP and GLP-2', 'placebo', 'Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2']","['bone formation', 'CTX levels', 'bone turnover', 'bone resorption', 'levels of CTX and procollagen type 1 N-terminal propeptide (P1NP']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4721411', 'cui_str': 'Osteolysis'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0912332', 'cui_str': 'Glucagon-like peptide 2'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0033235', 'cui_str': 'Procollagen'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}]",,0.139149,"Main outcomes were levels of CTX and procollagen type 1 N-terminal propeptide (P1NP). ","[{'ForeName': 'Kirsa', 'Initials': 'K', 'LastName': 'Skov-Jeppesen', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Veedfald', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark; Department of Endocrinology, Hvidovre University Hospital, Kettegaard Alle 30, 2650 Hvidovre, Denmark.'}, {'ForeName': 'Sten', 'Initials': 'S', 'LastName': 'Madsbad', 'Affiliation': 'Department of Endocrinology, Hvidovre University Hospital, Kettegaard Alle 30, 2650 Hvidovre, Denmark.'}, {'ForeName': 'Jens Juul', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.'}, {'ForeName': 'Mette Marie', 'Initials': 'MM', 'LastName': 'Rosenkilde', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.'}, {'ForeName': 'Bolette', 'Initials': 'B', 'LastName': 'Hartmann', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark. Electronic address: bhartmann@sund.ku.dk.'}]",Bone,['10.1016/j.bone.2021.116065'] 1388,34152835,"Feasibility, Acceptability, and Preliminary Effectiveness of a Compassion-Centered Team Intervention to Improve Clinical Research Coordinator Resilience and Well-Being.","PURPOSE Oncology clinical research coordinators (CRCs) and team-based coordinator care are critical for the success of clinical trials. However, CRCs typically report elevated anxiety and burnout and many oncology centers have high levels of coordinator attrition. To address the need for a team-based intervention to reduce burnout and promote resilience and cohesion among CRCs, we developed a compassion-centered, team-based intervention, Compassion-Centered Spiritual Health Team Intervention (CCSH-TI). METHODS Participants were CRCs working in disease-specific teams within a comprehensive cancer center. CRCs were randomly assigned by team to either participate in four 60-minute sessions of CCSH-TI or receive the intervention after the study. To evaluate whether CCSH-TI is feasible and acceptable, we used a mixed-method approach including self-report questionnaires and a focus group. To evaluate the impact of CCSH-TI, we assessed self-reported resilience, well-being, burnout, and team civility before and immediately after the intervention period (ClinicalTrials.gov identifier: NCT04060901). RESULTS Attendance varied by team, but all teams had rates more than 60%. Coordinators rated high levels of credibility of CCSH-TI to improve burnout, and the majority reported that they received benefits, particularly in resilience and stress management, indicating acceptability. Coordinators randomly assigned to CCSH-TI reported an increase in resilience compared with coordinators randomly assigned to the wait-list group (F(41) = 4.53, P = .039). CONCLUSION Data from this pilot study indicate that CCSH-TI may be a feasible, credible, acceptable, and effective intervention to augment individual resilience among CRCs. However, the quantitative and qualitative data suggest that more comprehensive and systematic programming is necessary to truly mitigate burnout.",2021,"Coordinators randomly assigned to CCSH-TI reported an increase in resilience compared with coordinators randomly assigned to the wait-list group (F(41) = 4.53, P = .039). ",['Participants were CRCs working in disease-specific teams within a comprehensive cancer center'],"['CCSH-TI', 'Compassion-Centered Team Intervention']",[],"[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0686997', 'cui_str': 'Spiritual health of patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0400874,"Coordinators randomly assigned to CCSH-TI reported an increase in resilience compared with coordinators randomly assigned to the wait-list group (F(41) = 4.53, P = .039). ","[{'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Mascaro', 'Affiliation': 'Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Patricia K', 'Initials': 'PK', 'LastName': 'Palmer', 'Affiliation': 'Department of Spiritual Health, Emory University Woodruff Health Sciences Center, Atlanta, GA.'}, {'ForeName': 'Marcia J', 'Initials': 'MJ', 'LastName': 'Ash', 'Affiliation': 'Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Peacock', 'Affiliation': 'Department of Spiritual Health, Emory University Woodruff Health Sciences Center, Atlanta, GA.'}, {'ForeName': 'Anuja', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Cam', 'Initials': 'C', 'LastName': 'Escoffery', 'Affiliation': 'Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Raison', 'Affiliation': 'Department of Spiritual Health, Emory University Woodruff Health Sciences Center, Atlanta, GA.'}]",JCO oncology practice,['10.1200/OP.21.00120'] 1389,34152787,Do baseline resilience profiles moderate the effects of a resilience-enhancing intervention for adolescents with type I diabetes?,"OBJECTIVE Resilience processes include modifiable individual and family-based skills and behaviors and are associated with better health and emotional outcomes for youth with Type I diabetes (T1D). There is likely heterogeneity among adolescents with T1D based on differing profiles of resilience processes. At-risk adolescents with lower levels of modifiable skills and assets may benefit more from psychosocial skill-building interventions, compared to adolescents who already have strong resilience processes. This article identified whether there are subgroups of adolescents with T1D based on resilience process profiles and assessed differences in glycemic control, diabetes management behaviors, and distress at baseline. It also evaluated subgroups as moderators of the efficacy of a psychosocial skill-building program. METHOD Two hundred sixty-four adolescents with T1D (14 to 18 years) were randomly assigned to a resilience-promoting program (N = 133) or diabetes education control (N = 131). Data were collected at seven time points over 3 years and analyzed with latent profile analysis and latent growth curve modeling. RESULTS There were two subgroups with high- versus low-resilience processes. The low-resilience subgroup exhibited more distress, higher HbA1c, less glucose monitoring, and fewer diabetes management behaviors at baseline. Differences persisted over 3 years. Subgroup membership did not moderate the efficacy of a resilience-promoting program compared to control. The resilience program resulted in lower distress regardless of subgroup. CONCLUSIONS There is heterogeneity in resilience process profiles, which are associated with clinically meaningful differences in distress, diabetes management, and glycemic control. Findings can be used to identify at-risk teenagers and inform a targeted approach to care. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"The low-resilience subgroup exhibited more distress, higher HbA1c, less glucose monitoring, and fewer diabetes management behaviors at baseline.","['youth with Type I diabetes (T1D', 'Two hundred sixty-four adolescents with T1D (14 to 18 years', 'adolescents with type I diabetes']","['resilience-enhancing intervention', 'resilience-promoting program (N = 133) or diabetes education control']","['distress, higher HbA1c, less glucose monitoring, and fewer diabetes management behaviors']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",264.0,0.0505233,"The low-resilience subgroup exhibited more distress, higher HbA1c, less glucose monitoring, and fewer diabetes management behaviors at baseline.","[{'ForeName': 'Jenna B', 'Initials': 'JB', 'LastName': 'Shapiro', 'Affiliation': 'Pritzker Department of Psychiatry and Behavioral Health.'}, {'ForeName': 'Fred B', 'Initials': 'FB', 'LastName': 'Bryant', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Grayson N', 'Initials': 'GN', 'LastName': 'Holmbeck', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Korey K', 'Initials': 'KK', 'LastName': 'Hood', 'Affiliation': 'Division of Endocrinology and Diabetes.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Weissberg-Benchell', 'Affiliation': 'Pritzker Department of Psychiatry and Behavioral Health.'}]","Health psychology : official journal of the Division of Health Psychology, American Psychological Association",['10.1037/hea0001076'] 1390,34154490,"The effectiveness of using an abdominal binder during colonoscopy: a randomized, double-blind, sham-controlled trial.","BACKGROUND Prolongation of cecal intubation time (CIT) directly affects the comfort of the patient and the colonoscopist. In this study, the effectiveness of using an abdominal binder (AB) during colonoscopy on procedure time and colonoscopy outcomes was investigated. METHODS We conducted a parallel randomized double-blind sham-device-controlled study of patients who underwent elective outpatient colonoscopy between 1 May 2020, and 31 August 2020. Participants were randomly assigned to AB ( n  = 173) and sham binder (SB) ( n  = 173) groups. The primary outcome was CIT. Secondary outcomes were the need for auxiliary maneuvers, the cecum intubation length (CIL) of the colonoscope, visual analog scale (VAS) score, narcotic analgesic dose, and colonoscopy results. Moreover, subgroup analysis was performed in terms of age and obesity indices. RESULTS A total of 346 patients were enrolled in the study. The mean CIT was similar between groups (AB group 240 secs, control group 250 secs, p  > .05). Manual pressure requirement was less in the AB group (27 vs. 36%, p  = .069). VAS score and the need for extra narcotic analgesic drugs were prominently lower in the AB group ( p  < .001, p  = .016, respectively). In the subgroup analyses, in participants at the age of <60 and waist-to-height ratio (WHtR) ≥0.5, manual pressure requirements were significantly shorter in the AB group ( p  = .017, p  = .032, respectively). CONCLUSION AB use in selected patients may be advantageous during colonoscopy because it reduces the need for analgesics and post-procedure pain, and reduces the need for auxiliary maneuvers in relatively young and obese patients.",2021,"The mean CIT was similar between groups (AB group 240 secs, control group 250 secs, p  > .05).","['patients who underwent elective outpatient colonoscopy between 1 May 2020, and 31 August 2020', 'relatively young and obese patients', '346 patients were enrolled in the study']","['abdominal binder during colonoscopy', 'sham binder (SB', 'abdominal binder (AB']","['need for auxiliary maneuvers, the cecum intubation length (CIL) of the colonoscope, visual analog scale (VAS) score, narcotic analgesic dose, and colonoscopy results', 'mean CIT', 'Manual pressure requirement', 'VAS score and the need for extra narcotic analgesic drugs', 'manual pressure requirements']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0179303', 'cui_str': 'Abdominal binder'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0179302', 'cui_str': 'Binder'}]","[{'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0007531', 'cui_str': 'Cecum structure'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0180022', 'cui_str': 'Colonoscope'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0027409', 'cui_str': 'Analgesics, Narcotic'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",346.0,0.600128,"The mean CIT was similar between groups (AB group 240 secs, control group 250 secs, p  > .05).","[{'ForeName': 'Beslen', 'Initials': 'B', 'LastName': 'Goksoy', 'Affiliation': 'Department of General Surgery, Sancaktepe Şehit Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Mevlut', 'Initials': 'M', 'LastName': 'Kiyak', 'Affiliation': 'Department of Gastroenterology, Sancaktepe Şehit Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2021.1941238'] 1391,34156877,"Outcomes of Arthroscopic Nerve Release in Patients Treated for Large or Massive Rotator Cuff Tears and Associated Suprascapular Neuropathy: A Prospective, Randomized, Double-Blinded Clinical Trial.","BACKGROUND Suprascapular neuropathy has been observed in the setting of rotator cuff tears (RCTs), but its association with these tears and their treatment are unclear. HYPOTHESIS Arthroscopic suprascapular nerve release during rotator cuff repair will not alter the outcomes of neuropathy. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS A total of 42 patients with large/massive reparable RCTs and suprascapular neuropathy were recruited and followed up at 6 and 12 months. Electrophysiological results as well as Disabilities of the Arm, Shoulder and Hand (DASH), American Shoulder and Elbow Surgeons (ASES), and Constant scores were evaluated at selected time periods. Patients were randomly assigned to 2 groups. Patients in the control group underwent arthroscopic repair of the rotator cuff without combined arthroscopic release of the superior transverse scapular ligament; in the second group, the superior transverse ligament was released. The primary outcome was to examine full suprascapular nerve recovery through electrophysiological changes between groups. The secondary/tertiary outcomes were analysis of clinical outcomes and assessment of the relation between RCT size and the degree of suprascapular nerve recovery. Patients, clinical staff members, and the neurologist were blinded to the type of surgical procedure. RESULTS Of 42 patients, 37 completed the follow-up at 12 months (median age, 64 years [range, 50-75 years]). Overall, 17 of 19 (89.5%) patients in the control group and 15 of 18 (83.3%) patients in the nerve release group had full nerve recovery, with no significant difference between the 2 groups. Clinically, all patients in both groups showed a significant improvement ( P < .001), but no significant difference was observed between the 2 groups in terms of 12-month postoperative scores (control group: DASH: median, 5 [range, 0-21]; ASES: median, 88 [range, 83-98]; Constant: median, 86 [range, 70-98]) (nerve release group: DASH: median, 6 [range, 0-25]; ASES: median, 90 [range, 83-98]; Constant: median, 88 [range, 75-98]). Also, no significant difference was found between the 2 groups regarding other secondary and tertiary outcomes. CONCLUSION Combined arthroscopic release of the superior transverse scapular ligament and rotator cuff repair in patients with large/massive RCTs and suprascapular neuropathy did not produce statistically significant improved outcomes compared with repair of the rotator cuff alone. REGISTRATION NCT02318381 (ClinicalTrials.gov identifier).",2021,"Clinically, all patients in both groups showed a significant improvement ( P < .001), but no significant difference was observed between the 2 groups in terms of 12-month postoperative scores (control group: DASH: median, 5 [range, 0-21]; ASES: median, 88 [range, 83-98]; Constant: median, 86 [range, 70-98])","['42 patients with large/massive reparable RCTs and suprascapular neuropathy', '42 patients', '90 [range, 83-98]; Constant: median, 88 [range, 75-98', 'Patients Treated for Large or Massive Rotator Cuff Tears and Associated Suprascapular Neuropathy']","['Arthroscopic Nerve Release', 'arthroscopic repair of the rotator cuff without combined arthroscopic release of the superior transverse scapular ligament']","['12-month postoperative scores', 'full suprascapular nerve recovery through electrophysiological changes', 'full nerve recovery', 'Disabilities of the Arm, Shoulder and Hand (DASH), American Shoulder and Elbow Surgeons (ASES), and Constant scores', 'RCT size and the degree of suprascapular nerve recovery']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0522501', 'cui_str': 'Massive'}, {'cui': 'C0263912', 'cui_str': 'Rotator cuff syndrome'}, {'cui': 'C3662000', 'cui_str': 'Suprascapular neuropathy'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]","[{'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0085515', 'cui_str': 'Structure of rotator cuff including muscles and tendons'}, {'cui': 'C0225059', 'cui_str': 'Structure of superior transverse scapular ligament'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0228878', 'cui_str': 'Structure of suprascapular nerve'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",42.0,0.183253,"Clinically, all patients in both groups showed a significant improvement ( P < .001), but no significant difference was observed between the 2 groups in terms of 12-month postoperative scores (control group: DASH: median, 5 [range, 0-21]; ASES: median, 88 [range, 83-98]; Constant: median, 86 [range, 70-98])","[{'ForeName': 'Nikolaos Platon', 'Initials': 'NP', 'LastName': 'Sachinis', 'Affiliation': 'First Orthopaedic Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Sotirios', 'Initials': 'S', 'LastName': 'Papagiannopoulos', 'Affiliation': 'Third Neurology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Sarris', 'Affiliation': 'Third Orthopaedic Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Pericles', 'Initials': 'P', 'LastName': 'Papadopoulos', 'Affiliation': 'Second Orthopaedic Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}]",The American journal of sports medicine,['10.1177/03635465211021834'] 1392,34160597,"Antibiotic eluting envelopes: evidence, technology, and defining high-risk populations.","Cardiovascular implantable electronic devices (CIED) are effective and important components of modern cardiovascular care. Despite the dramatic improvements in the functionality and reliability of these devices, over time patients are at risk for developing several morbidities, the most feared of which are local and systemic infections. Despite significant financial investment and aggressive therapy with hospitalization, intravenous antibiotics, and transvenous lead extraction, the outcomes include a 1-year mortality rate as high as 25%. This risk of infection has increased over time, likely due to the increased complexity of the surgical interventions required to insert and replace these devices. The only way to reduce this morbidity and mortality is to prevent these infections, and other than preoperative antibiotics, there were little data supporting effective therapy until the WRAP-IT trial provided randomized data showing that pocket infections can be reduced by 60% at 12 months and major CIED infections reduced by 40% at 1 year with the use of the absorbable antibiotic eluting envelope in patient CIED procedures at high risk of infection. Not all CIED procedures are at high risk of infection and justify the use of the envelope, but cost-effectiveness data support the use of the antibiotic envelope particularly in patients with defibrillator replacements, revisions, and upgrades, such as to a resynchronization device and in patients with prior CIED infection, history of immunocompromise, two or more prior procedures, or a history of renal dysfunction.",2021,"Not all CIED procedures are at high risk of infection and justify the use of the envelope, but cost-effectiveness data support the use of the antibiotic envelope particularly in patients with defibrillator replacements, revisions, and upgrades, such as to a resynchronization device and in patients with prior CIED infection, history of immunocompromise, two or more prior procedures, or a history of renal dysfunction.",[],['Cardiovascular implantable electronic devices (CIED'],"['1-year mortality rate', 'morbidity and mortality']",[],"[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",,0.0660044,"Not all CIED procedures are at high risk of infection and justify the use of the envelope, but cost-effectiveness data support the use of the antibiotic envelope particularly in patients with defibrillator replacements, revisions, and upgrades, such as to a resynchronization device and in patients with prior CIED infection, history of immunocompromise, two or more prior procedures, or a history of renal dysfunction.","[{'ForeName': 'Thomas D', 'Initials': 'TD', 'LastName': 'Callahan', 'Affiliation': 'Cardiac Electrophysiology and Pacing, Department of Cardiovascular Medicine, Cleveland Clinic 9500 Euclid Avenue, J2-2 Cleveland, OH 44195, USA.'}, {'ForeName': 'Khaldoun G', 'Initials': 'KG', 'LastName': 'Tarakji', 'Affiliation': 'Cardiac Electrophysiology and Pacing, Department of Cardiovascular Medicine, Cleveland Clinic 9500 Euclid Avenue, J2-2 Cleveland, OH 44195, USA.'}, {'ForeName': 'Bruce L', 'Initials': 'BL', 'LastName': 'Wilkoff', 'Affiliation': 'Cardiac Electrophysiology and Pacing, Department of Cardiovascular Medicine, Cleveland Clinic 9500 Euclid Avenue, J2-2 Cleveland, OH 44195, USA.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euab019'] 1393,34160577,Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.,"Importance The prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains poor after surgery. Neoadjuvant chemoradiotherapy (NCRT) has been shown to potentially improve survival. Objective To compare the treatment efficacy of NCRT plus surgery with surgery alone for long-term survival among patients with locally advanced ESCC. Design, Setting, and Participants The Neoadjuvant Chemoradiotherapy for Esophageal Cancer 5010 study was a multicenter open-label randomized phase 3 clinical trial that enrolled patients between June 1, 2007, and December 31, 2014. Follow-up ended on December 31, 2019. The study was conducted at 8 centers in China. A total of 451 patients aged 18 to 70 years with thoracic ESCC stage T1-4N1M0/T4N0M0 were enrolled and randomized. Data were analyzed from December 1, 2019, to June 30, 2020. Interventions Patients randomized to receive NCRT plus surgery (NCRT group) received preoperative chemotherapy (25 mg/m2 of vinorelbine on days 1 and 8 and 75 mg/m2 of cisplatin on day 1 or 25 mg/m2 of cisplatin on days 1 to 4) every 3 weeks for 2 cycles and concurrent radiotherapy (40.0 Gy, administered in 20 fractions of 2.0 Gy for 5 days per week) followed by surgery. Patients randomized to receive surgery alone (surgery group) underwent surgery after randomization. Main Outcomes and Measures The primary end point was overall survival in the intention-to-treat population. The secondary end point was disease-free survival. Results A total of 451 patients (mean [SD] age, 56.5 [7.0] years; 367 men [81.4%]) were randomized to the NCRT (n = 224) and surgery (n = 227) groups and were eligible for the intention-to-treat analysis. By December 31, 2019, 224 deaths had occurred. The median follow-up was 53.5 months (interquartile range, 18.2-87.4 months). Patients receiving NCRT plus surgery had prolonged overall survival compared with those receiving surgery alone (hazard ratio, 0.74; 95% CI, 0.57-0.97; P = .03), with a 5-year survival rate of 59.9% (95% CI, 52.9%-66.1%) vs 49.1% (95% CI, 42.3%-55.6%), respectively. Patients in the NCRT group compared with the surgery group also had prolonged disease-free survival (hazard ratio, 0.60; 95% CI, 0.45-0.80; P < .001), with a 5-year survival rate of 63.6% (95% CI, 56.0%-70.2%) vs 43.0% (95% CI, 36.0%-49.7%), respectively. Conclusions and Relevance In this randomized clinical trial, treatment with NCRT plus surgery significantly improved long-term overall survival and disease-free survival and therefore may be considered a standard of care for patients with locally advanced ESCC. Trial Registration ClinicalTrials.gov Identifier: NCT01216527.",2021,"Patients receiving NCRT plus surgery had prolonged overall survival compared with those receiving surgery alone (hazard ratio, 0.74; 95% CI, 0.57-0.97; P = .03), with a 5-year survival rate of 59.9% (95% CI, 52.9%-66.1%) vs 49.1% (95% CI, 42.3%-55.6%), respectively.","['patients with locally advanced esophageal squamous cell carcinoma (ESCC', 'enrolled patients between June 1, 2007, and December 31, 2014', 'patients with locally advanced ESCC', 'Locally Advanced Esophageal Squamous Cell Carcinoma', '8 centers in China', ' 367 men [81.4', '451 patients (mean [SD] age, 56.5 [7.0] years', '451 patients aged 18 to 70 years with thoracic ESCC stage T1-4N1M0/T4N0M0']","['concurrent radiotherapy', 'NCRT plus surgery with surgery alone', 'Neoadjuvant chemoradiotherapy (NCRT', 'Neoadjuvant Chemoradiotherapy', 'NCRT plus surgery', 'Neoadjuvant Chemoradiotherapy Plus Surgery', 'NCRT', 'surgery alone (surgery group) underwent surgery after randomization', 'NCRT plus surgery (NCRT group) received preoperative chemotherapy (25 mg/m2 of vinorelbine on days 1 and 8 and 75 mg/m2 of cisplatin on day 1 or 25 mg/m2 of cisplatin']","['overall survival', 'disease-free survival', 'prolonged disease-free survival', '5-year survival rate', 'long-term overall survival and disease-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0279626', 'cui_str': 'Squamous cell carcinoma of esophagus'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C5191282', 'cui_str': '451'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}, {'cui': 'C0078257', 'cui_str': 'vinorelbine'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]",451.0,0.65111,"Patients receiving NCRT plus surgery had prolonged overall survival compared with those receiving surgery alone (hazard ratio, 0.74; 95% CI, 0.57-0.97; P = .03), with a 5-year survival rate of 59.9% (95% CI, 52.9%-66.1%) vs 49.1% (95% CI, 42.3%-55.6%), respectively.","[{'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Yuping', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Thoracic Surgery, Cancer Hospital of Shantou University Medical College, Shantou, China.'}, {'ForeName': 'Chengchu', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': 'Department of Thoracic Surgery, Taizhou Hospital, Wenzhou Medical University, Linhai, China.'}, {'ForeName': 'Wentao', 'Initials': 'W', 'LastName': 'Fang', 'Affiliation': 'Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Zhentao', 'Initials': 'Z', 'LastName': 'Yu', 'Affiliation': 'Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.'}, {'ForeName': 'Weimin', 'Initials': 'W', 'LastName': 'Mao', 'Affiliation': 'Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Jiaqing', 'Initials': 'J', 'LastName': 'Xiang', 'Affiliation': 'Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.'}, {'ForeName': 'Yongtao', 'Initials': 'Y', 'LastName': 'Han', 'Affiliation': 'Department of Thoracic Surgery, Sichuan Cancer Hospital, Chengdu, China.'}, {'ForeName': 'Zhijian', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.'}, {'ForeName': 'Haihua', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.'}, {'ForeName': 'Jiaming', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Qingsong', 'Initials': 'Q', 'LastName': 'Pang', 'Affiliation': 'Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Zheng', 'Affiliation': 'Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Huanjun', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Geng', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Department of Thoracic Surgery, Cancer Hospital of Shantou University Medical College, Shantou, China.'}, {'ForeName': 'Baofu', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': 'Department of Thoracic Surgery, Taizhou Hospital, Wenzhou Medical University, Linhai, China.'}, {'ForeName': 'Teng', 'Initials': 'T', 'LastName': 'Mao', 'Affiliation': 'Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Kong', 'Affiliation': 'Department of Thoracic Surgery, Taizhou Hospital, Wenzhou Medical University, Linhai, China.'}, {'ForeName': 'Xufeng', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Lin', 'Affiliation': 'Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Mengzhong', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Fu', 'Affiliation': 'Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}]",JAMA surgery,['10.1001/jamasurg.2021.2373'] 1394,34174778,"The Effect of a Wordless, Animated, Social Media Video Intervention on COVID-19 Prevention: Online Randomized Controlled Trial.","BACKGROUND Innovative approaches to the dissemination of evidence-based COVID-19 health messages are urgently needed to counter social media misinformation about the pandemic. To this end, we designed a short, wordless, animated global health communication video (the CoVideo), which was rapidly distributed through social media channels to an international audience. OBJECTIVE The objectives of this study were to (1) establish the CoVideo's effectiveness in improving COVID-19 prevention knowledge, and (2) establish the CoVideo's effectiveness in increasing behavioral intent toward COVID-19 prevention. METHODS In May and June 2020, we enrolled 15,163 online participants from the United States, Mexico, the United Kingdom, Germany, and Spain. We randomized participants to (1) the CoVideo arm, (2) an attention placebo control (APC) arm, and (3) a do-nothing arm, and presented 18 knowledge questions about preventive COVID-19 behaviors, which was our first primary endpoint. To measure behavioral intent, our second primary endpoint, we randomized participants in each arm to five list experiments. RESULTS Globally, the video intervention was viewed 1.2 million times within the first 10 days of its release and more than 15 million times within the first 4 months. Knowledge in the CoVideo arm was significantly higher (mean 16.95, 95% CI 16.91-16.99) than in the do-nothing (mean 16.86, 95% CI 16.83-16.90; P<.001) arm. We observed high baseline levels of behavioral intent to perform many of the preventive behaviors featured in the video intervention. We were only able to detect a statistically significant impact of the CoVideo on one of the five preventive behaviors. CONCLUSIONS Despite high baseline levels, the intervention was effective at boosting knowledge of COVID-19 prevention. We were only able to capture a measurable change in behavioral intent toward one of the five COVID-19 preventive behaviors examined in this study. The global reach of this health communication intervention and the high voluntary engagement of trial participants highlight several innovative features that could inform the design and dissemination of public health messages. Short, wordless, animated videos, distributed by health authorities via social media, may be an effective pathway for rapid global health communication during health crises. TRIAL REGISTRATION German Clinical Trials Register DRKS00021582; https://tinyurl.com/6r4zkbbn. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.1186/s13063-020-04942-7.",2021,"Knowledge in the CoVideo arm was significantly higher (mean = 16.95; 95% CI: 16.91, 16.99) than in the do-nothing (mean = 16.86; 95% CI: 16.83, 16.90; p < 0.001) arm.","['15,163 adults in the USA, Mexico, UK, Germany, and Spain', 'German Clinical Trials Register (www.drks.de) on May 12th, 2020', 'enrolled 15,163 online participants from the United States of America, Mexico, United Kingdom, Germany, and Spain']","['attention placebo control (APC) arm, and (iii) a do-nothing arm', 'wordless, animated, social media video intervention']",['COVID-19 prevention'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0002454', 'cui_str': 'America'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]",15163.0,0.131359,"Knowledge in the CoVideo arm was significantly higher (mean = 16.95; 95% CI: 16.91, 16.99) than in the do-nothing (mean = 16.86; 95% CI: 16.83, 16.90; p < 0.001) arm.","[{'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Vandormael', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Adam', 'Affiliation': 'Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States.'}, {'ForeName': 'Merlin', 'Initials': 'M', 'LastName': 'Greuel', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Gates', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Favaretti', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Violetta', 'Initials': 'V', 'LastName': 'Hachaturyan', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Till', 'Initials': 'T', 'LastName': 'Bärnighausen', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}]",JMIR public health and surveillance,['10.2196/29060'] 1395,34144680,The effects of different accumulated pressure-time integral stimuli on plantar blood flow in people with diabetes mellitus.,"BACKGROUND Exercise, especially weight-bearing exercise (e.g. walking), may affect plantar tissue viability due to prolonged repetitive high vertical and high shear pressure stimulus on the plantar tissue, and further induce development of diabetic foot ulcers (DFUs). This study aimed to investigate the effects of different accumulated pressure-time integral (APTI) stimuli induced by walking on plantar skin blood flow (SBF) responses in people with diabetes mellitus (DM). METHODS A repeated measures design was used in this study. Two walking protocols (low APTI (73,000 kPa·s) and high APTI (73,000 × 1.5 kPa·s)) were randomly assigned to ten people with DM and twenty people without DM. The ratio of SBF measured by laser Doppler flowmetry after walking to that before (normalized SBF) was used to express the SBF responses. RESULTS After low APTI, plantar SBF of people with DM showed a similar response to people without DM (P = 0.91). However, after high APTI, people with DM had a significantly lower plantar SBF compared to people without DM (P < 0.05). In people with DM, plantar SBF in the first 2 min after both APTI stimuli significantly decreased compared to plantar SBF before walking (P < 0.05). CONCLUSIONS People with DM had a normal SBF response after low APTI walking but had an impaired SBF response after high APTI walking, which suggests that they should avoid weight-bearing physical activity with intensity more than 73,000 kPa·s and should rest for more than 2 min after weight-bearing physical activity to allow a full vasodilatory response to reduce risk of DFUs.",2021,"After low APTI, plantar SBF of people with DM showed a similar response to people without DM (P = 0.91).","['people with diabetes mellitus (DM', 'people with diabetes mellitus']","['Two walking protocols (low APTI (73,000\u2009kPa·s) and high APTI', 'accumulated pressure-time integral stimuli', 'accumulated pressure-time integral (APTI) stimuli induced by walking']","['plantar skin blood flow (SBF) responses', 'SBF response', 'plantar blood flow', 'normal SBF response', 'plantar SBF before walking', 'plantar SBF', 'ratio of SBF']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443238', 'cui_str': 'Integral'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0558145', 'cui_str': 'Skin appearance normal'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.00622943,"After low APTI, plantar SBF of people with DM showed a similar response to people without DM (P = 0.91).","[{'ForeName': 'Yijie', 'Initials': 'Y', 'LastName': 'Duan', 'Affiliation': ""Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, People's Republic of China.""}, {'ForeName': 'Weiyan', 'Initials': 'W', 'LastName': 'Ren', 'Affiliation': ""Key Laboratory of Human Motion Analysis and Rehabilitation Technology of the Ministry of Civil Affairs, National Research Center for Rehabilitation Technical Aids, Beijing, People's Republic of China.""}, {'ForeName': 'Liqiang', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': ""Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, People's Republic of China.""}, {'ForeName': 'Wenqiang', 'Initials': 'W', 'LastName': 'Ye', 'Affiliation': ""Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, People's Republic of China.""}, {'ForeName': 'Yih-Kuen', 'Initials': 'YK', 'LastName': 'Jan', 'Affiliation': ""Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, People's Republic of China. yjan@illinois.edu.""}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Pu', 'Affiliation': ""Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, People's Republic of China. pufangbme@buaa.edu.cn.""}]",BMC musculoskeletal disorders,['10.1186/s12891-021-04437-9'] 1396,34143996,"Partner-delivered HIV self-test kits with and without financial incentives in antenatal care and index patients with HIV in Malawi: a three-arm, cluster-randomised controlled trial.","BACKGROUND Secondary distribution of HIV self-testing (HIVST) kits by patients attending clinic services to their partners could improve the rate of HIV diagnosis. We aimed to investigate whether secondary administration of HIVST kits, with or without an additional financial incentive, via women receiving antenatal care (ANC) or via people newly diagnosed with HIV (ie, index patients) could improve the proportion of male partners tested or the number of people newly diagnosed with HIV. METHODS We did a three-arm, open-label, pragmatic, cluster-randomised trial of 27 health centres (clusters), eligible if they were a government primary health centre providing ANC, HIV testing, and ART services, across four districts of Malawi. We recruited women (aged ≥18 years) attending their first ANC visit and whose male partner was available, not already taking ART, and not already tested for HIV during this pregnancy (ANC cohort), and people (aged ≥18 years) with newly diagnosed HIV during routine clinic HIV testing who had at least one sexual contact not already known to be HIV-positive (index cohort). Centres were randomly assigned (1:1:1), using a public selection of computer-generated random allocations, to enhanced standard of care (including an invitation for partners to attend HIV testing services), HIVST only, or HIVST plus a US$10 financial incentive for retesting. The primary outcome for the ANC cohort was the proportion of male partners reportedly tested, as ascertained by interview with women in this cohort at day 28. The primary outcome for the index cohort was the geometric mean number of new HIV-positive people identified per facility within 28 days of enrolment, as measured by observed HIV test results. Cluster-level summaries compared intervention with standard of care by intention to treat. This trial is registered with ClinicalTrials.gov, NCT03705611. FINDINGS Between Sept 8, 2018, and May 2, 2019, nine clusters were assigned to each trial arm, resulting in 4544 eligible women in the ANC cohort (1447 [31·8%] in the standard care group, 1465 [32·2%] in the HIVST only group, and 1632 [35·9%] in HIVST plus financial incentive group) and 708 eligible patients in the index cohort (234 [33·1%] in the standard care group, 169 [23·9%] in the HIVST only group, and 305 [42·9%] in the HIVST plus financial incentive group). 4461 (98·2%) of 4544 eligible women in the ANC cohort and 645 (91·1%) of 708 eligible patients in the index cohort were recruited, of whom 3378 (75·7%) in the ANC cohort and 439 (68·1%) in the index cohort were interviewed after 28 days. In the ANC cohort, the mean proportion of reported partner testing per cluster was 35·0% (SD 10·0) in the standard care group, 73·0% in HIVST only group (13·1, adjusted risk ratio [RR] 1·71, 95% CI 1·48-1·98; p<0·0001), and 65·2% in the HIVST plus financial incentive group (11·6, adjusted RR 1·62, 1·45-1·81; p<0·0001). In the index cohort, the geometric mean number of new HIV-positive sexual partners per cluster was 1·35 (SD 1·62) for the standard care group, 1·91 (1·78) for the HIVST only group (incidence rate ratio adjusted for number eligible as an offset in the negative binomial model 1·65, 95% CI 0·49-5·55; p=0·3370), and 3·20 (3·81) for the HIVST plus financial incentive group (3·11, 0·99-9·77; p=0·0440). Four self-resolving, temporary marital separations occurred due to disagreement in couples regarding HIV self-test kits. INTERPRETATION Although administration of HIVST kits in the ANC cohort, even when offered alongside a financial incentive, did not identify significantly more male patients with HIV than did standard care, out-of-clinic options for HIV testing appear more acceptable to many male partners of women with HIV, increasing test uptake. Viewed in the current context, this approach might allow continuation of services despite COVID-19-related lockdowns. FUNDING Unitaid, through the Self-Testing Africa Initiative.",2021,"Although administration of HIVST kits in the ANC cohort, even when offered alongside a financial incentive, did not identify significantly more male patients with HIV than did standard care, out-of-clinic options for HIV testing appear more acceptable to many male partners of women with HIV, increasing test uptake.","['4461 (98·2%) of 4544 eligible women in the ANC cohort and', '645 (91·1%) of 708 eligible patients in the index cohort were recruited, of whom 3378 (75·7%) in the ANC cohort and 439 (68·1%) in the index cohort were interviewed after 28 days', 'people newly diagnosed with HIV (ie, index patients', 'patients attending clinic services to their partners', '27 health centres (clusters), eligible if they were a government primary health centre providing ANC, HIV testing, and ART services, across four districts of Malawi', 'male patients with HIV', 'antenatal care and index patients with HIV in Malawi', '4544 eligible women in the ANC cohort (1447 [31·8%] in the standard care group, 1465 [32·2%] in the HIVST only group, and 1632 [35·9%] in HIVST plus financial incentive group) and 708 eligible patients in the index cohort (234 [33·1%] in the standard care group, 169 [23·9%] in the HIVST only group, and 305 [42·9%] in the HIVST plus financial incentive group', 'recruited women (aged ≥18 years) attending their first ANC visit and whose male partner was available, not already taking ART, and not already tested for HIV during this pregnancy (ANC cohort), and people (aged ≥18 years) with newly diagnosed HIV during routine clinic HIV testing who had at least one sexual contact not already known to be HIV-positive (index cohort']","['Partner-delivered HIV self-test kits with and without financial incentives', 'HIV self-testing (HIVST) kits', 'HIVST kits, with or without an additional financial incentive, via women receiving antenatal care (ANC', 'HIVST kits', 'public selection of computer-generated random allocations, to enhanced standard of care (including an invitation for partners to attend HIV testing services), HIVST only, or HIVST plus a US$10 financial incentive for retesting']","['geometric mean number of new HIV-positive people identified per facility within 28 days of enrolment, as measured by observed HIV test results', 'mean proportion of reported partner testing per cluster']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0730261', 'cui_str': 'Attending clinic'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C4517703', 'cui_str': '305'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}]","[{'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1272835', 'cui_str': 'Test kit'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0031222', 'cui_str': 'Personnel Selection'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}]",4544.0,0.284597,"Although administration of HIVST kits in the ANC cohort, even when offered alongside a financial incentive, did not identify significantly more male patients with HIV than did standard care, out-of-clinic options for HIV testing appear more acceptable to many male partners of women with HIV, increasing test uptake.","[{'ForeName': 'Augustine T', 'Initials': 'AT', 'LastName': 'Choko', 'Affiliation': 'TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi. Electronic address: augutc@gmail.com.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Fielding', 'Affiliation': 'Department of Infectious Disease Epidemiology and MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Cheryl C', 'Initials': 'CC', 'LastName': 'Johnson', 'Affiliation': 'Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK; Global HIV, Hepatitis and STI Programme, WHO, Geneva, Switzerland.'}, {'ForeName': 'Moses K', 'Initials': 'MK', 'LastName': 'Kumwenda', 'Affiliation': 'TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Chilongosi', 'Affiliation': 'Population Services International, Lilongwe, Malawi.'}, {'ForeName': 'Rachel C', 'Initials': 'RC', 'LastName': 'Baggaley', 'Affiliation': 'Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Nyirenda', 'Affiliation': 'Department of HIV-AIDS, Ministry of Health, Lilongwe, Malawi.'}, {'ForeName': 'Linda A', 'Initials': 'LA', 'LastName': 'Sande', 'Affiliation': 'TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi; Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Desmond', 'Affiliation': 'TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Hatzold', 'Affiliation': 'Population Services International, Johannesburg, South Africa.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Neuman', 'Affiliation': 'Department of Infectious Disease Epidemiology and MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Elizabeth L', 'Initials': 'EL', 'LastName': 'Corbett', 'Affiliation': 'TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.'}]",The Lancet. Global health,['10.1016/S2214-109X(21)00175-3'] 1397,34145803,"A randomized comparative evaluation of local infiltration analgesia, extended nerve blocks, and conventional analgesia in pain management after total knee arthroplasty.","OBJECTIVES The aim of this study was to analyze the postoperative effects of extended nerve blocks and local infiltration analgesia (LIA) on postoperative pain control, muscle weakness, and blood loss after total knee arthroplasty (TKA). PATIENTS AND METHODS Between February 24 th 2020 and July 10 th 2020, a total of 161 patients (55 males, 106 females; median age: 69.0 years [IQR 63.0-75.0], range, 41 to 81 years) who underwent primary TKA were randomly allocated into three parallel groups according to their concomitant procedure in a double-blind fashion: (i) those to whom nerve blockade was performed after competition of surgery under the duration of spinal anesthesia (n=50); (ii) those to whom LIA was performed during surgery (n=52), and (iii) control group (n=59). The content of LIA was 10-10 mL of 20 mg lidocaine with 0.01 mg adrenalin and 100 mg ropivacaine, 1 mL (30 mg) ketorolac, and 5 mL (500 mg) tranexamic acid was diluted by 50 mL 0.9% NaCl under aseptic conditions. Outcome parameters were the evaluation of pain until the evening of first postoperative day (24 to 36 h), mobilization, and blood loss within the first three postoperative days. RESULTS The pain was maximal between 4 and 8 h postoperatively, when the effect of the spinal anesthetic drugs disappeared. During this critical period, tolerable pain (Numerical Rating Scale, NRS ≤3) was observed in 52%, 42%, and 19% of nerve blockade in LIA and control groups, respectively. None of the patients complained of high-intensity pain (NRS >8) in the LIA group, which was a significant difference from the block and control groups (10% and 14%, p<0.008, respectively). There was no significant muscle weakness associated with the use of this extended block. The decrease in hemoglobin level was significantly lower in the LIA group than in the control and block groups (odds ratio [OR]: 0.379, 95% confidence interval [CI]: 0.165-0.874 for nerve blockade vs. LIA, OR: 1.189, 95% CI: 0.491-2.880 for nerve blockade vs. control, OR: 0.319, 95% CI: 0.140-0.727, respectively). The common language effect size for pain in each referred interval in each group and for decrease of hemoglobin between the first and third postoperative days fell between 0.507 and 0.680. CONCLUSION This study demonstrates that LIA technique offers a fast and safe treatment option for pain relief after TKA. No clinically relevant muscle weakness was observed among groups according to field block applications. Significant advantages were also achieved in blood loss.",2021,"None of the patients complained of high-intensity pain (NRS >8) in the LIA group, which was a significant difference from the block and control groups (10% and 14%, p<0.008, respectively).","['pain management after total knee arthroplasty', 'after total knee arthroplasty (TKA', 'Between February 24 th 2020 and July 10 th 2020, a total of 161 patients (55 males, 106 females; median age: 69.0 years [IQR 63.0-75.0], range, 41 to 81 years) who underwent primary TKA']","['lidocaine', 'local infiltration analgesia, extended nerve blocks, and conventional analgesia', 'LIA technique', 'LIA', 'extended nerve blocks and local infiltration analgesia (LIA', 'ropivacaine, 1 mL (30 mg) ketorolac', 'concomitant procedure in a double-blind fashion: (i) those to whom nerve blockade was performed after competition of surgery under the duration of spinal anesthesia (n=50); (ii) those to whom LIA', 'tranexamic acid']","['evaluation of pain until the evening of first postoperative day (24 to 36 h), mobilization, and blood loss', 'postoperative pain control, muscle weakness, and blood loss', 'hemoglobin level', 'blood loss', 'high-intensity pain', 'pain', 'hemoglobin', 'tolerable pain (Numerical Rating Scale, NRS ≤3', 'pain relief', 'muscle weakness']","[{'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205225', 'cui_str': 'Principal'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030552', 'cui_str': 'Paresis'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}]",161.0,0.120127,"None of the patients complained of high-intensity pain (NRS >8) in the LIA group, which was a significant difference from the block and control groups (10% and 14%, p<0.008, respectively).","[{'ForeName': 'Csaba', 'Initials': 'C', 'LastName': 'Kopitkó', 'Affiliation': 'Department of Anesthesiology and Intensive Therapy, Uzsoki Str. Teaching Hospital, 1145 Budapest, Hungary. kopcsab2@gmail.com.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Czermann', 'Affiliation': ''}, {'ForeName': 'Mátyás', 'Initials': 'M', 'LastName': 'Orosz', 'Affiliation': ''}, {'ForeName': 'György', 'Initials': 'G', 'LastName': 'Hangody', 'Affiliation': ''}, {'ForeName': 'Dániel', 'Initials': 'D', 'LastName': 'Kiss', 'Affiliation': ''}, {'ForeName': 'Zsuzsanna', 'Initials': 'Z', 'LastName': 'Szabó', 'Affiliation': ''}, {'ForeName': 'László', 'Initials': 'L', 'LastName': 'Hangody', 'Affiliation': ''}]",Joint diseases and related surgery,['10.52312/jdrs.2021.68'] 1398,34145796,External validity of randomized clinical trial studying preventing depressive symptoms following acute coronary syndrome.,"OBJECTIVE The objective of the current study was to quantitatively explore aspects of external validity, both researcher's choices (eligibility) and patient's choices (consent), of a recently conducted clinical trial. METHODS A cohesive comparison between the MEDACIS trial (NCT02451293) database and a national quality and research database was conducted. Comparisons between both participants and nonconsenting patients (patient consent) and participants and noneligible patients (researcher selection) were performed. Comparisons of outcomes were depressive and anxiety symptoms, demographics, and somatic or psychiatric comorbidity. RESULTS Noneligible patients had significantly higher levels of depressive symptoms and anxiety and were older and more likely to suffer from unstable angina pectoris. Furthermore, noneligible patients were less likely to be married, had a lower educational level, used more medication, and had a higher frequency of comorbidity. Nonconsenting patients had significantly higher levels of depressive symptoms and anxiety and were older and more likely to be females compared to participants. CONCLUSION Significant differences were present between noneligible patients and participants; however, more troublingly significant differences were shown between nonconsenting patients and participants. The presence of depressive symptoms and anxiety has a significant impact on patients' willingness to give informed consent in clinical trials in cardiology with a focus on psychological outcomes.",2021,"Nonconsenting patients had significantly higher levels of depressive symptoms and anxiety and were older and more likely to be females compared to participants. ",['acute coronary syndrome'],[],"['depressive symptoms', 'depressive symptoms and anxiety', 'depressive and anxiety symptoms, demographics, and somatic or psychiatric comorbidity']","[{'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}]",[],"[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1257909', 'cui_str': 'Diploid Cell'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}]",,0.192416,"Nonconsenting patients had significantly higher levels of depressive symptoms and anxiety and were older and more likely to be females compared to participants. ","[{'ForeName': 'Michael Tvilling', 'Initials': 'MT', 'LastName': 'Madsen', 'Affiliation': 'Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.'}, {'ForeName': 'Knud', 'Initials': 'K', 'LastName': 'Juel', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Simonsen', 'Affiliation': 'Psychiatric Research Unit, Slagelse, Denmark.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Gögenur', 'Affiliation': 'Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.'}, {'ForeName': 'Ann Dorthe Olsen', 'Initials': 'ADO', 'LastName': 'Zwisler', 'Affiliation': 'REHPA - Danish Knowledge Center for Rehabilitation and Palliative Care, Odense University Hospital, University of Southern Denmark, Odense, Denmark.'}]",Brain and behavior,['10.1002/brb3.2132'] 1399,34391270,Effects of sling-based manual therapy on cervicothoracic junction in patients with neck pain and forward head posture: A randomized clinical trial.,"OBJECTIVE The purpose of this study was to investigate the effect of 4 weeks of sling-based manual therapy on the cervicothoracic junction (CTJ) area in patients with neck pain and forward head posture. DESIGN Single-blind randomized controlled trial. SETTING Outpatient, Chonbuk National University hospital, Republic of Korea. SUBJECTS A total of 22 participants with neck pain (Numeric Pain Rating Scale >3) and forward head posture (craniovertebral angle <51) were randomly assigned to a CTJ group or a control group (n = 11 each). INTERVENTION In the control group, joint mobilization and motor control training was applied for the upper cervical spine (C0-C1). The CTJ group applied the same intervention to the upper cervical spine and cervicothoracic junction (C7-T3). MAIN MEASURES Numeric pain rating scale and neck disability index, craniovertebral angle, active range of motion, and muscle activity were evaluated before and after 4 weeks of intervention. RESULT The CTJ group participants showed significant improvement in the craniovertebral angle and cervical extension range after the intervention than the control group (P = 0.025, P = 0.001). While both groups presented significant differences after the intervention regarding Numeric pain rating scale, neck disability index, and muscle activity (sternocleidomastoid and anterior scalene muscle), there were no statistically significant differences between the groups (P > 0.05). CONCLUSION Our results suggest that the CTJ and the upper cervical region in patients with neck pain and forward head posture represent an area which if approached by manual therapy, improves cervical mobility and posture.",2021,"The CTJ group participants showed significant improvement in the craniovertebral angle and cervical extension range after the intervention than the control group (P = 0.025, P = 0.001).","['22 participants with neck pain (Numeric Pain Rating Scale >3) and forward head posture (craniovertebral angle <51', 'Outpatient, Chonbuk National University hospital, Republic of Korea', 'patients with neck pain and forward head posture']","['joint mobilization and motor control training', 'CTJ', 'sling-based manual therapy']","['Numeric pain rating scale, neck disability index, and muscle activity (sternocleidomastoid and anterior scalene muscle', 'craniovertebral angle and cervical extension range', 'Numeric pain rating scale and neck disability index, craniovertebral angle, active range of motion, and muscle activity', 'cervical mobility and posture']","[{'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C1536116', 'cui_str': 'Head posture abnormal'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0231588', 'cui_str': 'Physiatric mobilization of joint'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0450195', 'cui_str': 'Cervicothoracic'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0454525', 'cui_str': 'Manual therapy'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0224153', 'cui_str': 'Structure of sternocleidomastoid muscle'}, {'cui': 'C0224173', 'cui_str': 'Structure of scalenus anterior muscle'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}]",22.0,0.0373188,"The CTJ group participants showed significant improvement in the craniovertebral angle and cervical extension range after the intervention than the control group (P = 0.025, P = 0.001).","[{'ForeName': 'Suhn-Yeop', 'Initials': 'SY', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, College of Health and Medical Science, Daejeon University, Republic of Korea. Electronic address: kimsy@dju.kr.'}, {'ForeName': 'Chang-Man', 'Initials': 'CM', 'LastName': 'An', 'Affiliation': 'Department of Physical Therapy, Chonbuk National University Hospital, Republic of Korea. Electronic address: dks3597@hanmail.net.'}, {'ForeName': 'Yoon-Sang', 'Initials': 'YS', 'LastName': 'Cha', 'Affiliation': 'Department of Physical Therapy, Chonbuk National University Hospital, Republic of Korea. Electronic address: chajeb92@gmail.com.'}, {'ForeName': 'Dae-Hyun', 'Initials': 'DH', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, Chonbuk National University Hospital, Republic of Korea. Electronic address: biceps4079@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.007'] 1400,34146646,Health gains through loss frames: Testing the effectiveness of message framing on citizens' use of nutritional warnings.,"The aim of the present work was twofold: (i) to evaluate the effect of nutritional warnings and health-related packaging cues (nutrient claim and images of natural foods) on consumers' food choices, and (ii) to evaluate the influence of two types of messages (gain-framed and loss-framed) aimed at encouraging the use of such warnings and packaging cues on food choices. A total of 510 participants were recruited using an advertisement on Facebook and Instagram targeted at Uruguayan adult users. Participants were randomly allocated to one of three experimental groups: control (n = 167), loss-framed messages (n = 177) and gain-framed messages (n = 166). Then, they completed a choice-conjoint task involving packages of crackers differing in three variables: nutritional warnings (present vs. absent), nutrient claim (present vs. absent) and images of seeds and wheat (present vs. absent). Warnings were the most relevant package element driving choices, even when participants were not exposed to any type of message. Exposure to loss-framed messages led to changes in the relative importance attached to the package characteristics, whereas gain-framed messages did not. Graphic pieces conveying messages encouraging the use of nutritional warnings by stressing the negative consequences of excessive consumption of sugar, fat, and sodium increased the relative importance attached to nutritional warnings and decreased the relative importance attached to health-related cues (nutrient claims and images of seeds and wheat). These results suggest that public awareness campaigns aimed at encouraging citizens to use nutritional warnings should emphasize the negative health consequences of excessive intake of sugar, fat, and sodium.",2021,"Then, they completed a choice-conjoint task involving packages of crackers differing in three variables: nutritional warnings (present vs. absent), nutrient claim (present vs. absent) and images of seeds and wheat (present vs. absent).",['510 participants were recruited using an advertisement on Facebook and Instagram targeted at Uruguayan adult users'],"['control (n\u202f=\u202f167), loss-framed messages (n\u202f=\u202f177) and gain-framed messages']",[],"[{'cui': 'C4517800', 'cui_str': '510'}, {'cui': 'C0949214', 'cui_str': 'Advertisements'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}]",[],510.0,0.0188337,"Then, they completed a choice-conjoint task involving packages of crackers differing in three variables: nutritional warnings (present vs. absent), nutrient claim (present vs. absent) and images of seeds and wheat (present vs. absent).","[{'ForeName': 'Jimena', 'Initials': 'J', 'LastName': 'Eguren', 'Affiliation': 'Centro de Investigación Básica en Psicología, Facultad de Psicología, Universidad de la República, Tristán Narvaja, CP 11200, Montevideo, Uruguay.'}, {'ForeName': 'Lucía', 'Initials': 'L', 'LastName': 'Antúnez', 'Affiliation': 'Sensometrics & Consumer Science, Instituto Polo Tecnológico de Pando, Facultad de Química, Universidad de la República, By Pass de Rutas 8 y 101 s/n. CP 91000. Pando, Canelones, Uruguay.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Otterbring', 'Affiliation': 'School of Business and Law, Department of Management, University of Agder, Universitetsveien 17, 4630 Kristiansand, Norway, & Institute of Retail Economics, Regeringsgatan 60, 103 29, Stockholm, Sweden.'}, {'ForeName': 'María Rosa', 'Initials': 'MR', 'LastName': 'Curutchet', 'Affiliation': 'Observatorio de Seguridad Alimentaria y Nutricional, Instituto Nacional de Alimentación, Piedras 165, CP 11000, Montevideo, Uruguay.'}, {'ForeName': 'Gastón', 'Initials': 'G', 'LastName': 'Ares', 'Affiliation': 'Centro de Investigación Básica en Psicología, Facultad de Psicología, Universidad de la República, Tristán Narvaja, CP 11200, Montevideo, Uruguay; Sensometrics & Consumer Science, Instituto Polo Tecnológico de Pando, Facultad de Química, Universidad de la República, By Pass de Rutas 8 y 101 s/n. CP 91000. Pando, Canelones, Uruguay. Electronic address: gares@fq.edu.uy.'}]",Appetite,['10.1016/j.appet.2021.105469'] 1401,34146464,Developing teamwork skills in baccalaureate nursing students: impact of TeamSTEPPS ® training and simulation.,"OBJECTIVES Examine the impact of TeamSTEPPS ® training and simulation experiences on student knowledge and teamwork attitudes in a baccalaureate-nursing program. METHODS This study used a quasi-experimental, pre-test, post-test design. The intervention included a workshop followed by 2 days of simulation experiences. Participants included a total of 46 nursing students. Instruments included the TeamSTEPPS learning benchmark and the Teamwork Attitudes Questionnaire (T-TAQ). RESULTS Scores on the learning benchmark increased following the intervention. In addition, changes in subscores of teamwork strategies, leadership, situation monitoring, and mutual support on the T-TAQ indicate an improvement in student attitudes toward teamwork. CONCLUSIONS Incorporating TeamSTEPPS ® strategies into undergraduate education can be effective in increasing student knowledge and improving attitudes toward interdisciplinary teamwork.",2021,"RESULTS Scores on the learning benchmark increased following the intervention.","['baccalaureate nursing students', 'Participants included a total of 46 nursing students']","['TeamSTEPPS ®', 'TeamSTEPPS ® training and simulation experiences']","['student knowledge and teamwork attitudes', 'learning benchmark', 'TeamSTEPPS learning benchmark and the Teamwork Attitudes Questionnaire (T-TAQ']","[{'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0525063', 'cui_str': 'Best Practice Analysis'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",46.0,0.0225468,"RESULTS Scores on the learning benchmark increased following the intervention.","[{'ForeName': 'Debbie A', 'Initials': 'DA', 'LastName': 'Greene', 'Affiliation': 'Undergraduate Nursing Programs, School of Nursing, Georgia College & State University, 231\xa0W Hancock Street, Campus Box\xa0063, Milledgeville, GA 31061, USA.'}, {'ForeName': 'Josie L', 'Initials': 'JL', 'LastName': 'Doss', 'Affiliation': 'School of Nursing, Georgia College & State University, Milledgeville, GA, USA.'}]",International journal of nursing education scholarship,['10.1515/ijnes-2020-0077'] 1402,34391252,Effects of myofascial release on flexibility and electromyographic activity of the lumbar erector spinae muscles in healthy individuals.,"OBJECTIVE To investigate the effects of myofascial release on the flexibility and electromyographic activity of the lumbar erector spinae muscle in healthy individuals. METHODS Ten healthy subjects were recruited to an intervention protocol of myofascial release techniques: (1) superficial myofascial release; (2) deep myofascial release apply along 10 sessions, twice a week, with 40 min per sessions. The outcomes evaluated were flexibility (Toe-Touch Test) and electromyography activity (EMG) of the lumbar erector spinae muscle (Iliocostalis and Longissimus bilaterally) during the movement of extension-flexion of the trunk. Paired t-test was used to compare the electromyographic outcomes, while the Wilcoxon test was used to compare the flexibility outcomes. RESULTS The myofascial release techniques increased the flexibility (p = 0.005; r = 0.88) and have no influence over the electromyographic activity of the right iliocostalis (p = 0.179; r = 0.43), right longissimus (p = 0.877; r = 0.05), left iliocostalis (p = 0.386; r = 0.29) and left longissimus (p = 0.418; r = 0.27). CONCLUSIONS The application of myofascial release techniques increase flexibility and did not influence over the electromyographic activity of the lumbar erector spinae muscles in healthy individuals. Further studies should include a larger sample with a sham group and/or compare EMG activity of the lumbar erector spinae muscles with patients with low back pain during the movement of extension-flexion of the trunk.",2021,"The myofascial release techniques increased the flexibility (p = 0.005; r = 0.88) and have no influence over the electromyographic activity of the right iliocostalis (p = 0.179; r = 0.43),","['Ten healthy subjects', 'healthy individuals']","['myofascial release', 'right longissimus ', 'intervention protocol of myofascial release techniques: (1) superficial myofascial release; (2) deep myofascial release']","['left longissimus ', 'flexibility and electromyographic activity', 'flexibility', 'flexibility (Toe-Touch Test) and electromyography activity (EMG) of the lumbar erector spinae muscle (Iliocostalis and Longissimus bilaterally) during the movement of extension-flexion of the trunk', 'flexibility outcomes', 'left iliocostalis', 'electromyographic activity of the right iliocostalis']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0695600', 'cui_str': 'Myofascial release'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0224306', 'cui_str': 'Structure of longissimus muscle'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0205125', 'cui_str': 'Deep'}]","[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0224306', 'cui_str': 'Structure of longissimus muscle'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0040357', 'cui_str': 'Toe structure'}, {'cui': 'C0152054', 'cui_str': 'Touch'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205090', 'cui_str': 'Right'}]",10.0,0.0177973,"The myofascial release techniques increased the flexibility (p = 0.005; r = 0.88) and have no influence over the electromyographic activity of the right iliocostalis (p = 0.179; r = 0.43),","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Rodrigues', 'Affiliation': 'Universidade do Vale do Rio dos Sinos (UNISINOS), São Leopoldo, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Patricia Cilene', 'Initials': 'PC', 'LastName': ""Freitas Sant'Anna"", 'Affiliation': 'Universidade do Vale do Rio dos Sinos (UNISINOS), São Leopoldo, Rio Grande do Sul, Brazil. Electronic address: pcfsantanna@gmail.com.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'La Torre', 'Affiliation': 'Universidade do Vale do Rio dos Sinos (UNISINOS), São Leopoldo, Rio Grande do Sul, Brazil.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Dhein', 'Affiliation': 'Centro Universitário da Serra Gaúcha (FSG), Caxias do Sul, Rio Grande do Sul, Brazil.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.015'] 1403,34148244,"Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D 2 /D 3 receptor antagonist, in patients with gastroparesis.","BACKGROUND Gastroparesis is a chronic gastric motility disorder. Dopamine D 2 /D 3 receptor antagonists metoclopramide and domperidone are current treatment options but are associated with central nervous system and cardiovascular safety concerns, respectively, precluding chronic use. Trazpiroben (TAK-906), a dopamine D 2 /D 3 receptor antagonist, is under development for chronic treatment of moderate-to-severe gastroparesis. Nonclinical data suggest trazpiroben will have D 2 /D 3 receptor antagonism comparable with metoclopramide or domperidone. AIMS To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (effect on prolactin and gastric function) of twice-daily trazpiroben (5, 25 and 100 mg) in participants with gastroparesis. METHODS This phase 2a pilot study evaluated gastric emptying using the gastric emptying breath test, with metoclopramide as an internal control. Gastric accommodation and gastroparesis symptoms were assessed using the nutrient drink test and American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary, respectively. RESULTS Overall, 51 participants were enrolled. Trazpiroben was well tolerated, demonstrating a favourable safety profile without cardiovascular or central nervous system adverse events. All trazpiroben doses were rapidly absorbed and eliminated (t 1/2z 4-5 hours), and D 2 /D 3 receptor target engagement confirmed by increased serum prolactin (peaking at trazpiroben 25 mg). No effect on gastric emptying was demonstrated with trazpiroben or metoclopramide (P > 0.05), although benefits in volume-to-fullness were seen at trazpiroben 5 mg (P > 0.05) and 25 mg (88.5 vs -26.3 mL; P = 0.019), and nonsignificant numerical aggregate symptom score improvements were observed with trazpiroben 25 mg vs placebo (P = 0.182). CONCLUSIONS Trazpiroben was well tolerated with a favourable safety profile, supporting its further development for the treatment of gastroparesis. ClinicalTrials.gov identifier: NCT03268941.",2021,"No effect on gastric emptying was demonstrated with trazpiroben or metoclopramide (P > 0.05), although benefits in volume-to-fullness were seen at trazpiroben 5 mg (P > 0.05) and 25 mg (88.5 vs -26.3 mL; P = 0.019), and nonsignificant numerical aggregate symptom score improvements were observed with trazpiroben 25 mg vs placebo (P = 0.182). ","['patients with gastroparesis', '51 participants were enrolled', 'participants with gastroparesis']","['metoclopramide or domperidone', 'Trazpiroben', 'domperidone', 'metoclopramide', 'trazpiroben', 'trazpiroben (TAK-906', 'twice-daily trazpiroben', 'Trazpiroben (TAK-906), a dopamine D 2 /D', 'trazpiroben or metoclopramide', 'placebo', 'Dopamine D 2 /D']","['nutrient drink test and American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary, respectively', 'benefits in volume-to-fullness', 'gastric emptying', 'safety, tolerability, pharmacokinetics and pharmacodynamics (effect on prolactin and gastric function', 'serum prolactin', 'Gastric accommodation and gastroparesis symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}]","[{'cui': 'C0025853', 'cui_str': 'Metoclopramide'}, {'cui': 'C0013015', 'cui_str': 'Domperidone'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}, {'cui': 'C0326926', 'cui_str': 'Cardinalis cardinalis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439650', 'cui_str': 'Fullness'}, {'cui': 'C0017127', 'cui_str': 'Gastric emptying'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0033371', 'cui_str': 'Prolactin'}, {'cui': 'C0232538', 'cui_str': 'Gastric function'}, {'cui': 'C1277972', 'cui_str': 'Serum prolactin measurement'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}]",51.0,0.092557,"No effect on gastric emptying was demonstrated with trazpiroben or metoclopramide (P > 0.05), although benefits in volume-to-fullness were seen at trazpiroben 5 mg (P > 0.05) and 25 mg (88.5 vs -26.3 mL; P = 0.019), and nonsignificant numerical aggregate symptom score improvements were observed with trazpiroben 25 mg vs placebo (P = 0.182). ","[{'ForeName': 'Braden', 'Initials': 'B', 'LastName': 'Kuo', 'Affiliation': 'Harvard School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Scimia', 'Affiliation': 'Takeda Pharmaceuticals International Co., Cambridge, MA, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Dukes', 'Affiliation': 'Takeda Pharmaceuticals International Co., Cambridge, MA, USA.'}, {'ForeName': 'Wenwen', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Takeda Pharmaceuticals International Co., Cambridge, MA, USA.'}, {'ForeName': 'Saurabh', 'Initials': 'S', 'LastName': 'Gupta', 'Affiliation': 'Takeda Pharmaceuticals International Co., Cambridge, MA, USA.'}, {'ForeName': 'Chunlin', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Takeda Pharmaceuticals International Co., Cambridge, MA, USA.'}, {'ForeName': 'Emil', 'Initials': 'E', 'LastName': 'Chuang', 'Affiliation': 'Takeda Pharmaceuticals International Co., Cambridge, MA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Camilleri', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.16451'] 1404,34147568,"VR outreach and meat reduction advocacy: The role of presence, empathic concern and speciesism in predicting meat reduction intentions.","The industrial farming and slaughtering of animals may be considered one of the most pressing ethical problems of our time, yet consumers remain empathically disconnected from food animals and continue to eat meat. Therefore, animal advocacy groups have started using virtual reality (VR) outreach to promote consumers' concern for food animals and persuade them to eat less meat. In this study, we examined whether a short 360° documentary depicting the life cycle of factory farmed pigs (from their lives on the farm to their death in the slaughterhouse) experienced in a VR format versus in a regular video format increases participants' intentions to eat less meat via an increased feeling of presence and empathic concern. Using a single factor experimental design, we randomly allocated participants (n = 84 after data-cleaning) to answer a questionnaire following one of both conditions (VR versus video documentary, each n = 42). Results confirmed our hypothesized serial mediation model; VR (versus video) had a positive influence on presence and additionally on empathic concern, leading to higher intentions of reduced meat consumption among participants. Yet, VR (versus video) also had a direct, negative effect on empathy when controlling for presence, so no total effect of medium format on intentions to reduce meat could be found. This counter-effect of VR on empathic concern could be explained by an increased level of speciesism among participants exposed to the VR (versus video) documentary, a finding that is consistent with prior literature on speciesism, cognitive dissonance and dissociation, and requires further confirmatory investigation. Limitations and implications for theory and practice of the study are considered.",2021,"This counter-effect of VR on empathic concern could be explained by an increased level of speciesism among participants exposed to the VR (versus video) documentary, a finding that is consistent with prior literature on speciesism, cognitive dissonance and dissociation, and requires further confirmatory investigation.","[""short 360° documentary depicting the life cycle of factory farmed pigs (from their lives on the farm to their butcher in the slaughterhouse) experienced in a VR format versus in a regular video format increases participants' intentions to eat less meat via an increased feeling of presence and empathic concern""]","['virtual reality (VR) outreach', 'VR outreach and meat reduction advocacy']",[],"[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0023675', 'cui_str': 'Life Cycle'}, {'cui': 'C0442614', 'cui_str': 'Factory'}, {'cui': 'C0557759', 'cui_str': 'Farming environment'}, {'cui': 'C0039005', 'cui_str': 'Suidae'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C1301627', 'cui_str': 'Format'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0150312', 'cui_str': 'Present'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0150446', 'cui_str': 'Advocacy'}]",[],,0.0535448,"This counter-effect of VR on empathic concern could be explained by an increased level of speciesism among participants exposed to the VR (versus video) documentary, a finding that is consistent with prior literature on speciesism, cognitive dissonance and dissociation, and requires further confirmatory investigation.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Herrewijn', 'Affiliation': 'Center for Persuasive Communication, Department of Communication Sciences, Ghent University, Korte Meer 7(-9-11), 9000, Ghent, Belgium. Electronic address: laura.herrewijn@ugent.be.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'De Groeve', 'Affiliation': 'Center for Persuasive Communication, Department of Communication Sciences, Ghent University, Korte Meer 7(-9-11), 9000, Ghent, Belgium.'}, {'ForeName': 'Verolien', 'Initials': 'V', 'LastName': 'Cauberghe', 'Affiliation': 'Center for Persuasive Communication, Department of Communication Sciences, Ghent University, Korte Meer 7(-9-11), 9000, Ghent, Belgium.'}, {'ForeName': 'Liselot', 'Initials': 'L', 'LastName': 'Hudders', 'Affiliation': 'Center for Persuasive Communication, Department of Communication Sciences, Ghent University, Korte Meer 7(-9-11), 9000, Ghent, Belgium; Department of Marketing, Innovation and Organisation, Ghent University, Tweekerkenstraat 2, 9000, Ghent, Belgium.'}]",Appetite,['10.1016/j.appet.2021.105455'] 1405,34151413,A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.,"BACKGROUND AND OBJECTIVES Islatravir (MK-8591) is a novel nucleoside analogue in development for the treatment and prevention of HIV-1 infection. Doravirine is a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection. This study evaluated the pharmacokinetics, safety, and tolerability of islatravir and doravirine coadministration in a double-blind, placebo-controlled, randomized, fixed-sequence study. METHODS Adult participants without HIV infection were administered oral doravirine 100 mg (n = 10) or placebo (n = 4) once daily (QD) for 5 days, immediately followed by oral islatravir 2.25 mg (n = 10) or placebo QD (n = 4) for 14 days; islatravir 2.25 mg and doravirine 100 mg QD, or placebo QD, were then coadministered for 5 days. Pharmacokinetic and safety data were collected. RESULTS Doravirine geometric least-squares mean ratios (90% confidence intervals (CIs)) of (doravirine + islatravir)/doravirine for the area under the plasma drug concentration-time curve over 24 h (AUC 0-24h ), maximum plasma concentration (C max ), and plasma concentration at 24 h post-dose (C 24h ) were not meaningfully impacted. Islatravir geometric least-squares mean ratios (90% CI) of (islatravir + doravirine)/islatravir for AUC 0-24h and C max were both close to unity, 1.06 (1.01, 1.12) and 1.08 (0.91, 1.27), respectively. All study regimens were generally well tolerated. CONCLUSION These results indicate that coadministration of islatravir and doravirine had no clinically meaningful effect on the pharmacokinetics of either drug, and support further clinical investigation of islatravir in combination with doravirine for the treatment of HIV-1 infection.",2021,"Islatravir geometric least-squares mean ratios (90% CI) of (islatravir + doravirine)/islatravir for AUC 0-24h and C max were both close to unity, 1.06 (1.01, 1.12) and 1.08 (0.91, 1.27), respectively.","['Adult participants without HIV infection', 'Adults Without HIV']","['islatravir 2.25\xa0mg and doravirine 100\xa0mg QD, or placebo QD', 'doravirine', 'Doravirine', 'doravirine + islatravir)/doravirine', 'islatravir and doravirine coadministration', 'Islatravir (MK-8591) and Doravirine', 'placebo QD', 'placebo', 'oral doravirine 100\xa0mg (n\xa0=\xa010) or placebo']","['Islatravir geometric least-squares mean ratios', 'Pharmacokinetic and safety data', 'tolerated', 'pharmacokinetics, safety, and tolerability', 'maximum plasma concentration (C max ), and plasma concentration']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]","[{'cui': 'C4068875', 'cui_str': '2.25'}, {'cui': 'C4723295', 'cui_str': 'DORAVIRINE 100 MG'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4045491', 'cui_str': 'DORAVIRINE'}, {'cui': 'C4549592', 'cui_str': 'MK-8591'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",,0.296982,"Islatravir geometric least-squares mean ratios (90% CI) of (islatravir + doravirine)/islatravir for AUC 0-24h and C max were both close to unity, 1.06 (1.01, 1.12) and 1.08 (0.91, 1.27), respectively.","[{'ForeName': 'Randolph P', 'Initials': 'RP', 'LastName': 'Matthews', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, 07033, USA. randolph.matthews@merck.com.'}, {'ForeName': 'Deanne', 'Initials': 'D', 'LastName': 'Jackson Rudd', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, 07033, USA.'}, {'ForeName': 'Kerry L', 'Initials': 'KL', 'LastName': 'Fillgrove', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, 07033, USA.'}, {'ForeName': 'Saijuan', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, 07033, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Tomek', 'Affiliation': 'Celerion, Lincoln, NE, USA.'}, {'ForeName': 'S Aubrey', 'Initials': 'SA', 'LastName': 'Stoch', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, 07033, USA.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Iwamoto', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, 07033, USA.'}]",Clinical drug investigation,['10.1007/s40261-021-01046-1'] 1406,34391250,Influence of age and lymphedema on the postural balance of women undergoing breast cancer treatment.,"INTRODUCTION Breast cancer affects women of different ages, and comorbidities resulting from treatment can affect postural stability. The study aimed to evaluate the influence of age and lymphedema on the postural balance of women undergoing breast cancer treatment. METHODS The study included 77 women undergoing breast cancer treatment, divided into different groups: 37 young adult women divided into 17 with lymphedema (GYL) and 20 young adults without lymphedema (GY); 40 elderly women, 20 elderly women with lymphedema (GEL) and 20 elderly women without lymphedema (GE). Mini Balance Evaluation Systems Test (Mini BESTest) and Falls Efficacy Scale - International (FES-I) were used. RESULTS Mini BESTest and FES-I between the groups showed that GE and GEL had a significant difference to GY. Mini BESTest Total and Time Up and Go TUG-Double Task showed that GE has a significant difference to GYL, with GE and GEL having lower scores. Moderate negative correlation in the GEL between FES-I and Mini BESTest. In the age correlation between the Mini BESTest, FES-I, TUG, and double task TUG, a moderate positive correlation was observed for TUG. GEL showed a moderate positive correlation for FES-I and double-task TUG, strong for TUG, and moderate negative correlation with Mini BESTest. Correlation of the volume difference between the limb affected and not affected by lymphedema and the FES-I, Mini BESTest, TUG, and TUG double task, GYL showed moderate negative correlation for TUG. CONCLUSION Age and lymphedema influenced the dynamic postural balance of women undergoing breast cancer treatment.",2021,"Mini BESTest Total and Time Up and Go TUG-Double Task showed that GE has a significant difference to GYL, with GE and GEL having lower scores.","['77 women undergoing breast cancer treatment, divided into different groups: 37 young adult women divided into 17 with lymphedema (GYL) and 20 young adults without lymphedema (GY); 40 elderly women, 20 elderly women with lymphedema (GEL) and 20 elderly women without lymphedema (GE', 'women undergoing breast cancer treatment']","['FES', 'GEL']","['Mini Balance Evaluation Systems Test (Mini BESTest) and Falls Efficacy Scale - International (FES-I', 'dynamic postural balance']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0524338', 'cui_str': 'Elderly woman'}]","[{'cui': 'C0525959', 'cui_str': '16-fluoroestradiol, (16alpha, 17beta)-isomer, (18F)-labeled'}, {'cui': 'C0017243', 'cui_str': 'Gel'}]","[{'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0525959', 'cui_str': '16-fluoroestradiol, (16alpha, 17beta)-isomer, (18F)-labeled'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C1256755', 'cui_str': 'Postural balance'}]",77.0,0.159034,"Mini BESTest Total and Time Up and Go TUG-Double Task showed that GE has a significant difference to GYL, with GE and GEL having lower scores.","[{'ForeName': 'Cristina Faustino', 'Initials': 'CF', 'LastName': 'Cuviena', 'Affiliation': 'Postgraduate Program in Rehabilitation and Functional Performance, Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Brazil.'}, {'ForeName': 'Carla Silva', 'Initials': 'CS', 'LastName': 'Perez', 'Affiliation': 'Postgraduate Program in Rehabilitation and Functional Performance, Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Brazil.'}, {'ForeName': 'Victória Carrer', 'Initials': 'VC', 'LastName': 'Nardo', 'Affiliation': 'Postgraduate Program in Rehabilitation and Functional Performance, Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Brazil.'}, {'ForeName': 'Lais Mara', 'Initials': 'LM', 'LastName': 'Siqueira das Neves', 'Affiliation': 'Postgraduate Program in Rehabilitation and Functional Performance, Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Brazil.'}, {'ForeName': 'Flávia Belavenuto', 'Initials': 'FB', 'LastName': 'Rangon', 'Affiliation': 'Postgraduate Program in Rehabilitation and Functional Performance, Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Brazil.'}, {'ForeName': 'Elaine Caldeira de Oliveira', 'Initials': 'ECO', 'LastName': 'Guirro', 'Affiliation': 'Postgraduate Program in Rehabilitation and Functional Performance, Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Brazil. Electronic address: ecguirro@fmrp.usp.br.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.02.024'] 1407,34153228,Lavender Aromatherapy as a Nurse-Driven Intervention for Preoperative Anxiety.,"OBJECTIVE To explore potential clinical applications, based on evidence and a nurse-driven test of change, of using lavender aromatherapy for preoperative anxiety as an intervention complementary to standard preoperative care. DESIGN A pre- versus postaromatherapy comparison using a visual analog scale (VAS). SETTING The preoperative department at a level 2 trauma hospital with 544 beds. PARTICIPANTS Forty-four surgical patients, including 29 female participants and 15 male participants. INTERVENTION/MEASUREMENTS Participants reported their anxiety on a VAS before receiving a lavender aromatherapy inhaler. Anxiety scores were measured again after receiving the lavender aromatherapy and shortly before participants left the preoperative area for surgery. A pre-post comparison of the two VAS anxiety measurements before and after receiving the lavender aromatherapy was completed, analyzed, and is discussed. RESULTS Mean anxiety scores were calculated for the pre- and postaromatherapy groups. Forty-eight percent of female participants (n = 29) reported a decrease in their anxiety after receiving preoperative lavender aromatherapy. Female participants reported higher preoperative anxiety scores and a larger decrease in their mean anxiety scores after receiving lavender aromatherapy when compared to male participants. CONCLUSION The use of a nurse-driven complementary intervention in the preoperative area was associated with a decrease in mean anxiety scores among female patients about to undergo elective surgery. However, cause and effect cannot be determined because of a lack of a control group and randomization. Opportunities exist with support from seasoned staff for nurses to incorporate safe, evidence-based complementary interventions into the current standard of care for preoperative anxiety.",2021,"Female participants reported higher preoperative anxiety scores and a larger decrease in their mean anxiety scores after receiving lavender aromatherapy when compared to male participants. ","['The preoperative department at a level 2 trauma hospital witsth 544 beds', 'Forty-four surgical patients, including 29 female participants and 15 male participants', 'female patients about to undergo elective surgery']","['lavender aromatherapy inhaler', 'nurse-driven complementary intervention', 'preoperative lavender aromatherapy', 'lavender aromatherapy', 'Lavender Aromatherapy']","['visual analog scale (VAS', 'preoperative anxiety scores', 'Mean anxiety scores', 'anxiety', 'mean anxiety scores', 'Anxiety scores']","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0456948', 'cui_str': 'Level 2'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}]","[{'cui': 'C0524903', 'cui_str': 'Lavender'}, {'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0021461', 'cui_str': 'Inhaler'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",44.0,0.0230468,"Female participants reported higher preoperative anxiety scores and a larger decrease in their mean anxiety scores after receiving lavender aromatherapy when compared to male participants. ","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Koehler', 'Affiliation': ''}]",Nursing for women's health,['10.1016/j.nwh.2021.05.005'] 1408,34153143,Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism.,"Targeting interleukin-6 (IL-6) is a promising strategy to counteract antibody-mediated rejection (ABMR). In inflammatory states, IL-6 antagonism was shown to modulate cytochrome P450 (CYP), but its impact on drug metabolism in ABMR treatment was not addressed so far. We report a sub-study of a phase 2 trial of anti-IL-6 antibody clazakizumab in late ABMR (ClinicalTrials.gov, NCT03444103). Twenty kidney transplant recipients were randomized to clazakizumab versus placebo (4-weekly doses; 12 weeks), followed by a 9-month extension where all recipients received clazakizumab. To study CYP2C19/CYP3A4 metabolism, we administered pantoprazole (20 mg intravenously) at prespecified time points. Dose-adjusted C 0 levels (C 0 /D ratio) of tacrolimus (n = 13) and cyclosporin A (CyA, n = 6) were monitored at 4-weekly intervals. IL-6 and C-reactive protein were not elevated at baseline, the latter was then suppressed to undetectable levels under clazakizumab. IL-6 blockade had no clinically meaningful impact on pantoprazole pharmacokinetics (area under the curve; baseline versus week 52: 3.16 [2.21-7.84] versus 4.22 [1.99-8.18] μg/ml*h, P = 0.36) or calcineurin inhibitor C 0 /D ratios (tacrolimus: 1.49 [1.17-3.20] versus 1.37 [0.98-2.42] ng/ml/mg, P = 0.21; CyA: 0.69 [0.57-0.85] versus 1.08 [0.52-1.38] ng/ml/mg, P = 0.47). We conclude that IL-6 blockade in ABMR - in absence of systemic inflammation - may have no meaningful effect on CYP metabolism.",2021,IL-6,"['late antibody-mediated kidney transplant rejection', 'Twenty kidney transplant recipients']","['anti-IL-6 antibody clazakizumab', 'pantoprazole', 'clazakizumab versus placebo', 'clazakizumab', 'IL-6', 'tacrolimus', 'cyclosporin A', 'Anti-interleukin-6 antibody clazakizumab']","['pantoprazole pharmacokinetics', 'ratios']","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0238217', 'cui_str': 'Renal transplant rejection'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C4077748', 'cui_str': 'clazakizumab'}, {'cui': 'C0081876', 'cui_str': 'pantoprazole'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0010592', 'cui_str': 'Cyclosporine'}]","[{'cui': 'C0081876', 'cui_str': 'pantoprazole'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",6.0,0.188742,IL-6,"[{'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Mühlbacher', 'Affiliation': 'Department of General Surgery, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schörgenhofer', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Konstantin', 'Initials': 'K', 'LastName': 'Doberer', 'Affiliation': 'Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Dürr', 'Affiliation': 'Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Klemens', 'Initials': 'K', 'LastName': 'Budde', 'Affiliation': 'Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Farsad', 'Initials': 'F', 'LastName': 'Eskandary', 'Affiliation': 'Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Katharina A', 'Initials': 'KA', 'LastName': 'Mayer', 'Affiliation': 'Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Schranz', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Ely', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Reiter', 'Affiliation': 'Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Chong', 'Affiliation': 'Vitaeris Inc. (a subsidiary of CSL Behring, King of Prussia, PA, USA), Vancouver, BC, Canada.'}, {'ForeName': 'Scott H', 'Initials': 'SH', 'LastName': 'Adler', 'Affiliation': 'CSL Behring, King of Prussia, PA, USA.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Jilma', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Georg A', 'Initials': 'GA', 'LastName': 'Böhmig', 'Affiliation': 'Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.'}]",Transplant international : official journal of the European Society for Organ Transplantation,['10.1111/tri.13954'] 1409,34155082,The Effects of Oral Energy-Dense Supplements on Nutritional Status in Nondiabetic Maintenance Hemodialysis Patients: A Randomized Controlled Trial.,"BACKGROUND AND OBJECTIVES Fat-based energy-dense nutritional supplements may offer benefits over protein- or carbohydrate-dense supplements for patients receiving dialysis because of the adverse metabolic consequences of the latter. We conducted a randomized controlled trial to assess the effects of the short-term use of a fat-based nutritional supplement on various measures of nutritional status in patients receiving maintenance hemodialysis who have low dietary energy intake. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We enrolled nondiabetic patients receiving hemodialysis for >3 months who had inadequate dietary energy intake (<30 kcal/kg per day). The participants were randomly assigned in a 1:1 ratio to receive an oral fat-based energy-dense supplement (300 kcal daily) or routine care for 12 weeks ( n =120 per group). The primary outcome was the change in phase angle measured by bioelectrical impedance analysis, a marker of cell integrity and body cell mass, from the baseline to week 12. The secondary outcomes were changes in quality of life. Other outcomes included laboratory nutritional indicators and physical examinations. RESULTS The average age of the total population was 47 (SD: 12) years, and 55% were men. The median of dialysis vintage was 43.4 (22.5-76.3) months; 240 participants were randomly assigned to the intervention ( n =120) or control group ( n =120). In total, 228 (95%) participants completed the trial. The change in phase angle did not differ significantly between the intervention and control groups (estimate, 0.0; 95% confidence interval, -0.1 to 0.1 versus estimate, 0.0; 95% confidence interval, -0.1 to 0.1; estimated difference, 0.0; 95% confidence interval -0.2 to 0.2; P =0.99). None of the 19 domains of quality of life differed between the groups. Adverse events were reported in 23 (19%) participants in the control group and 40 (33%) participants in the intervention group. CONCLUSIONS In nondiabetic patients on maintenance hemodialysis, short-term administration of fat-based energy-dense nutritional supplement has no clinically significant effect on nutritional status as measured by phase angle. PODCAST This article contains a podcast at https://https://www.asn-online.org/media/podcast/CJASN/2021_08_03_CJN16821020.mp3.",2021,"The change in phase angle did not differ significantly between the intervention and the control groups (estimate (95% confidence interval [CI]): 0.0 (-0.1, 0.1) vs. 0.0 (-0.1, 0.1); estimated difference, 0.0; 95% [CI], -0.2 to 0.2; P =0.99).","['enrolled nondiabetic patients receiving hemodialysis for more than 3 months and had inadequate dietary energy intake (<30kcal/kg/d', 'Nondiabetic Maintenance Hemodialysis Patients', 'patients receiving maintenance hemodialysis who have low dietary energy intake', 'SD: 12) years and 55% were male', '240 participants', 'patients receiving dialysis because of the adverse metabolic consequences of the latter', 'nondiabetic maintenance hemodialysis patients']","['Fat-based energy-dense nutritional supplements', 'oral fat-based energy-dense supplement (300kcal daily) or routine care', 'fat-based nutritional supplement', 'Oral Energy-Dense Supplements']","['median of dialysis vintage', 'Nutritional Status', 'laboratory nutritional indicators and physical examinations', 'Adverse events', 'change in phase angle, measured by bioelectrical impedance analysis, a marker of cell integrity and body cell mass', 'quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C2315964', 'cui_str': 'Inadequate dietary energy intake'}, {'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}]","[{'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439794', 'cui_str': 'Dense'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0162536', 'cui_str': 'Biolectric Impedance'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",240.0,0.190046,"The change in phase angle did not differ significantly between the intervention and the control groups (estimate (95% confidence interval [CI]): 0.0 (-0.1, 0.1) vs. 0.0 (-0.1, 0.1); estimated difference, 0.0; 95% [CI], -0.2 to 0.2; P =0.99).","[{'ForeName': 'Yaya', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Xianhui', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Junzhi', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ""Division of Nephrology, Huadu District People's Hospital of Guangzhou, Guangzhou, China.""}, {'ForeName': 'Yaozhong', 'Initials': 'Y', 'LastName': 'Kong', 'Affiliation': ""Division of Nephrology, The First People's Hospital of Foshan, Foshan, China.""}, {'ForeName': 'Qijun', 'Initials': 'Q', 'LastName': 'Wan', 'Affiliation': ""Division of Nephrology, Shenzhen Second People's Hospital, Shenzhen, China.""}, {'ForeName': 'Huiqin', 'Initials': 'H', 'LastName': 'Tao', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Aiqun', 'Initials': 'A', 'LastName': 'Liu', 'Affiliation': 'Division of Nephrology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Youbao', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Zizhen', 'Initials': 'Z', 'LastName': 'Lin', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Yanhuan', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Zihan', 'Initials': 'Z', 'LastName': 'Lei', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Liang', 'Affiliation': 'National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China nfyylm@163.com.'}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.16821020'] 1410,34157385,Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial.,"BACKGROUND Randomized trials are generally performed from a frequentist perspective, which can conflate absence of evidence with evidence of absence. The RECOVERY trial evaluated convalescent plasma for patients hospitalized with coronavirus disease 2019 (COVID-19) and concluded that there was no evidence of an effect. Re-analysis from a Bayesian perspective is warranted. METHODS Outcome data were extracted from the RECOVERY trial by serostatus and time of presentation. A Bayesian re-analysis with a wide variety of priors (vague, optimistic, sceptical, and pessimistic) was performed, calculating the posterior probability for: any benefit, an absolute risk difference of 0.5% (small benefit, number needed to treat 200), and an absolute risk difference of one percentage point (modest benefit, number needed to treat 100). RESULTS Across all patients, when analysed with a vague prior, the likelihood of any benefit or a modest benefit with convalescent plasma was estimated to be 64% and 18%, respectively. The estimated chance of any benefit was 95% if presenting within 7 days of symptoms, or 17% if presenting after this. In patients without a detectable antibody response at presentation, the chance of any benefit was 85%. However, it was only 20% in patients with a detectable antibody response at presentation. CONCLUSIONS Bayesian re-analysis suggests that convalescent plasma reduces mortality by at least one percentage point among the 39% of patients who present within 7 days of symptoms, and that there is a 67% chance of the same mortality reduction in the 38% who are seronegative at the time of presentation. This is in contrast to the results in people who already have antibodies when they present. This biologically plausible finding bears witness to the advantage of Bayesian analyses over misuse of hypothesis tests to inform decisions.",2021,,[],[],[],[],[],[],,0.466561,,"[{'ForeName': 'F W', 'Initials': 'FW', 'LastName': 'Hamilton', 'Affiliation': 'MRC-IEU Integrative Epidemiology Unit, University of Bristol, Bristol, UK; Infection Science, North Bristol NHS Trust, Bristol, UK. Electronic address: Fergus.hamilton@bristol.ac.uk.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Lee', 'Affiliation': 'Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Canada.'}, {'ForeName': 'D T', 'Initials': 'DT', 'LastName': 'Arnold', 'Affiliation': 'Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Lilford', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Hemming', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2021.06.034'] 1411,34183429,Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.,"OBJECTIVE To directly compare the efficacy and safety of a fixed-ratio combination, of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi), with those of a premix insulin analog, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine) (BIAsp 30) as treatment advancement in type 2 diabetes suboptimally controlled on basal insulin plus oral antihyperglycemic drugs (OADs). RESEARCH DESIGN AND METHODS In SoliMix, a 26-week, open-label, multicenter study, adults with suboptimally controlled basal insulin-treated type 2 diabetes (HbA 1c ≥7.5% and ≤10%) were randomized to once-daily iGlarLixi or twice-daily BIAsp 30. Primary efficacy end points were noninferiority in HbA 1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi versus BIAsp 30. RESULTS Both primary efficacy end points were met: after 26 weeks, baseline HbA 1c (8.6%) was reduced by 1.3% with iGlarLixi and 1.1% with BIAsp 30, meeting noninferiority (least squares [LS] mean difference -0.2% [97.5% CI -0.4, -0.1]; P < 0.001). iGlarLixi was also superior to BIAsp 30 for body weight change (LS mean difference -1.9 kg [95% CI -2.3, -1.4]) and percentage of participants achieving HbA 1c <7% without weight gain and HbA 1c <7% without weight gain and without hypoglycemia (all P < 0.001). iGlarLixi was also superior versus BIAsp 30 for HbA 1c reduction ( P < 0.001). Incidence and rates of American Diabetes Association level 1 and 2 hypoglycemia were lower with iGlarLixi versus BIAsp 30. CONCLUSIONS Once-daily iGlarLixi provided better glycemic control with weight benefit and less hypoglycemia than twice-daily premix BIAsp 30. iGlarLixi is a more efficacious, simpler, and well-tolerated alternative to premix BIAsp 30 in suboptimally controlled type 2 diabetes requiring treatment beyond basal insulin plus OAD therapy. VIDEO 1: diacare;dc21-0393v4/F1F1f1Infographic available at https://care.diabetesjournals.org/content/dc21-0393-infographic.",2021,iGlarLixi was also superior versus BIAsp 30 for HbA 1c reduction (p<0.001).,"['suboptimally controlled basal insulin-treated type 2 diabetes', 'randomized adults with suboptimally controlled basal insulin-treated type 2 diabetes (HbA 1c ≥7.5 % and ≤10 %) to', 'type 2 diabetes suboptimally controlled on basal insulin plus oral antihyperglycemic drugs (OADs']","['iGlarLixi versus premix BIAsp', 'once-daily iGlarLixi or twice-daily BIAsp 30', 'Advancing therapy', 'iGlarLixi', 'fixed-ratio combination, iGlarLixi, with a premix insulin analog (BIAsp 30']","['efficacy and safety', 'Incidence and rates of ADA Level 1 and 2 hypoglycemia', 'weight gain and without hypoglycemia', 'non-inferiority in HbA 1c reduction', 'hypoglycemia']","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C2003521', 'cui_str': 'insulin aspart, insulin aspart protamine drug combination 30:70'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0001457', 'cui_str': 'Adenosine deaminase'}, {'cui': 'C0456947', 'cui_str': 'Level 1'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.322884,iGlarLixi was also superior versus BIAsp 30 for HbA 1c reduction (p<0.001).,"[{'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Rosenstock', 'Affiliation': 'Dallas Diabetes Research Center at Medical City, Dallas, TX juliorosenstock@dallasdiabetes.com.'}, {'ForeName': 'Rifat', 'Initials': 'R', 'LastName': 'Emral', 'Affiliation': 'Department of Endocrinology and Metabolic Diseases, Ankara University Faculty of Medicine, Ankara, Turkey.'}, {'ForeName': 'Leobardo', 'Initials': 'L', 'LastName': 'Sauque-Reyna', 'Affiliation': 'Instituto de Diabetes Obesidad y Nutrición S.C., Cuernavaca, Morelos, Mexico.'}, {'ForeName': 'Viswanathan', 'Initials': 'V', 'LastName': 'Mohan', 'Affiliation': ""Dr. Mohan's Diabetes Specialities Centre & Madras Diabetes Research Foundation, IDF Centre of Excellence in Diabetes Care & ICMR Centre for Advanced Research on Diabetes, Chennai, India.""}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Trescolí', 'Affiliation': 'Hospital Universitario de La Ribera, Alzira, Spain.'}, {'ForeName': 'Saud', 'Initials': 'S', 'LastName': 'Al Sifri', 'Affiliation': 'Al Hada Military Hospital, Taif, Saudi Arabia.'}, {'ForeName': 'Nebojsa', 'Initials': 'N', 'LastName': 'Lalic', 'Affiliation': 'Faculty of Medicine of the University of Belgrade, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia.'}, {'ForeName': 'Agustina', 'Initials': 'A', 'LastName': 'Alvarez', 'Affiliation': 'Sanofi, Buenos Aires, Argentina.'}, {'ForeName': 'Pascaline', 'Initials': 'P', 'LastName': 'Picard', 'Affiliation': 'IviData LIFE SCIENCES, Levallois-Perret, France.'}, {'ForeName': 'Mireille', 'Initials': 'M', 'LastName': 'Bonnemaire', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Nacima', 'Initials': 'N', 'LastName': 'Demil', 'Affiliation': 'Diabetes Medical Operation Department, Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Rory J', 'Initials': 'RJ', 'LastName': 'McCrimmon', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc21-0393'] 1412,34182611,"Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease.","AIMS This 3-part, randomised, phase 1 first-in-human study (NCT03436316) investigated the safety, tolerability and pharmacokinetics (PK) of AZD8154, a dual phosphoinositide 3-kinase (PI3K) γδ inhibitor developed as a novel inhaled anti-inflammatory treatment for respiratory disease. METHODS Healthy men, and women of nonchildbearing potential, were enrolled to receive single and multiple ascending inhaled doses of AZD8154 in parts 1 and 3 of the study, respectively, while part 2 characterised the systemic PK after a single intravenous (IV) dose. In part 1, participants received 0.1-7.7 mg AZD8154 in 6 cohorts. In part 2, participants were given 0.15 mg AZD8154 as an IV infusion. In part 3, AZD8154 was given in 3 cohorts of 0.6, 1.8 and 3.1 mg, with a single dose on Day 1 followed by repeated once-daily doses on Days 4-12. RESULTS In total, 78 volunteers were randomised. All single inhaled, single IV and multiple inhaled doses were shown to be well tolerated without any safety concerns. A population PK model, using nonlinear mixed-effect modelling, was developed to describe the PK of AZD8154. The terminal mean half-life of AZD8154 was 18.0-32.0 hours. The geometric mean of the absolute pulmonary bioavailability of AZD8154 via the inhaled route was 94.1%. CONCLUSION AZD8154 demonstrated an acceptable safety profile, with no reports of serious adverse events and no clinically significant drug-associated safety concerns reported in healthy volunteers. AZD8154 demonstrated prolonged lung retention and a half-life supporting once-daily dosing.",2021,"CONCLUSION AZD8154 demonstrated an acceptable safety profile, with no reports of serious adverse events and no clinically significant drug-associated safety concerns reported in healthy volunteers.","['healthy volunteers', 'Healthy men, and women of non-childbearing potential', '78 volunteers were randomised']",['single and multiple ascending inhaled doses of AZD8154'],"['prolonged lung retention', 'Characterisation of pharmacokinetics, safety and tolerability', 'geometric mean of the absolute pulmonary bioavailability of AZD8154', 'safety, tolerability and pharmacokinetics (PK']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}]",78.0,0.151432,"CONCLUSION AZD8154 demonstrated an acceptable safety profile, with no reports of serious adverse events and no clinically significant drug-associated safety concerns reported in healthy volunteers.","[{'ForeName': 'Muhammad Waqas', 'Initials': 'MW', 'LastName': 'Sadiq', 'Affiliation': 'Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Asimus', 'Affiliation': 'Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, Sweden.'}, {'ForeName': 'Maria G', 'Initials': 'MG', 'LastName': 'Belvisi', 'Affiliation': 'Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Wayne', 'Initials': 'W', 'LastName': 'Brailsford', 'Affiliation': 'Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Fransson', 'Affiliation': 'Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Rainard', 'Initials': 'R', 'LastName': 'Fuhr', 'Affiliation': 'Parexel Early Phase Clinical Unit, Berlin, Germany.'}, {'ForeName': 'Anette', 'Initials': 'A', 'LastName': 'Hagberg', 'Affiliation': 'Patient Safety, Respiratory & Immunology, Chief Medical Office, R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Hashemi', 'Affiliation': 'Early Biostats & Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Jellesmark Jensen', 'Affiliation': 'Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Jonsson', 'Affiliation': 'Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Keen', 'Affiliation': 'Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Körnicke', 'Affiliation': 'Parexel Early Phase Clinical Unit, Berlin, Germany.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Kristensson', 'Affiliation': 'Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Jukka', 'Initials': 'J', 'LastName': 'Mäenpää', 'Affiliation': 'Patient Safety, Respiratory & Immunology, Chief Medical Office, R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Necander', 'Affiliation': 'Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Szilárd', 'Initials': 'S', 'LastName': 'Nemes', 'Affiliation': 'Early Biostats & Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Betts', 'Affiliation': 'Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}]",British journal of clinical pharmacology,['10.1111/bcp.14956'] 1413,34181750,Randomised clinical trial: adjunctive induction therapy with oral effervescent budesonide in newly diagnosed coeliac disease.,"BACKGROUND The healing of the mucosal lesion in patients with coeliac disease is slow. AIM To determine whether concurrent budesonide and gluten-free diet hasten small bowel healing and symptomatic improvement in patients with newly diagnosed coeliac disease. METHODS In a pilot, randomised, double-blind trial, effects on Marsh grading and quantitative duodenal morphometry of 10 weeks' effervescent budesonide (initially 9 mg/day) or placebo were assessed after 8 and 52 weeks. Multiple clinical measures and adverse events were assessed. RESULTS Nineteen patients were randomised to budesonide and 18 to placebo. No differences (all P > 0.32) were observed for the week-8 mucosal response (Marsh 0 or 1) (budesonide: 37% vs placebo: 28%), week-8 remission (Marsh 0) (32% vs 17%), week-52 response (63% vs 44%) and week-52 remission (42% vs 33%). Likewise, the improvement from baseline in villous-height : crypt-depth ratio was not different for the treatment groups. There were no statistically significant differences in clinical measures or adverse events between the treatment groups. No corticosteroid adverse effects were observed. In a post hoc analysis of all patients, Marsh 3C was present at the diagnostic biopsy in 1/9 achieving mucosal remission at 8 weeks versus 18/23 not (P < 0.001) and mean villous-height : crypt-depth ratio was 1.06 (SD: 0.73) versus 0.46 (0.38) (P = 0.005). CONCLUSIONS In this pilot trial, induction therapy with budesonide had no significant effect on mucosal healing in patients with coeliac disease concurrently initiated on a gluten-free diet. Mucosal remission at 8 weeks occurred in approximately one in four patients and was associated with less severe histological lesions at diagnosis.",2021,"Likewise, the improvement from baseline in villous-height : crypt-depth ratio was not different for the treatment groups.","['Nineteen patients', 'patients with coeliac disease concurrently initiated on a gluten-free diet', 'patients with coeliac disease', 'patients with newly diagnosed coeliac disease', 'newly diagnosed coeliac disease']","['effervescent budesonide', 'budesonide and gluten-free diet', 'adjunctive induction therapy with oral effervescent budesonide', 'placebo', 'budesonide']","['mucosal remission', 'week-52 remission', 'adverse events', 'week-8 mucosal response', 'mean villous-height\xa0:\xa0crypt-depth ratio', 'clinical measures or adverse events', 'mucosal healing', 'Mucosal remission', 'week-52 response', 'severe histological lesions', 'corticosteroid adverse effects']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007570', 'cui_str': 'Celiac disease'}, {'cui': 'C0344351', 'cui_str': 'Gluten free diet'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0344351', 'cui_str': 'Gluten free diet'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",19.0,0.199741,"Likewise, the improvement from baseline in villous-height : crypt-depth ratio was not different for the treatment groups.","[{'ForeName': 'Evan D', 'Initials': 'ED', 'LastName': 'Newnham', 'Affiliation': 'Departments of Gastroenterology and Hepatology, Eastern Health, Melbourne, Vic., Australia.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Clayton-Chubb', 'Affiliation': 'Departments of Gastroenterology and Hepatology, Eastern Health, Melbourne, Vic., Australia.'}, {'ForeName': 'Meena', 'Initials': 'M', 'LastName': 'Nagarethinam', 'Affiliation': 'Departments of Gastroenterology and Hepatology, Eastern Health, Melbourne, Vic., Australia.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Hosking', 'Affiliation': 'Pathology, Eastern Health, Box Hill, Vic., Australia.'}, {'ForeName': 'Peter R', 'Initials': 'PR', 'LastName': 'Gibson', 'Affiliation': 'Departments of Gastroenterology and Hepatology, Eastern Health, Melbourne, Vic., Australia.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.16446'] 1414,34185116,The relationship between adrenocortical candidate gene expression and clinical response to hydrocortisone in patients with septic shock.,"PURPOSE To determine if adrenocortical gene expression is associated with clinical outcomes or response to corticosteroid treatment in septic shock. METHODS A pre-specified nested cohort study of a randomised controlled trial of hydrocortisone compared to placebo in septic shock. Blood was collected for RNAseq analysis prior to treatment with hydrocortisone or placebo. The expression of adrenocortical candidate genes related to pituitary releasing hormones, mineralocorticoid and glucocorticoid receptors, intracellular glucocorticoid metabolism and transport proteins was measured. RESULTS From May 2014 to April 2017, 671 patients were enrolled in the nested cohort study, from which 494 samples were available for analysis. We found no evidence of an association between candidate gene expression levels and either 90-day mortality, 28-day mortality or time to shock reversal. We observed evidence of a significant interaction between expression and treatment group for time to shock reversal in two genes; GLCCI1 (HR 3.81, 95%CI 0.57-25.47 vs. HR 0.64, 95%CI 0.13-3.07 for hydrocortisone and placebo respectively, p for interaction 0.008) and BHSD1 (HR 0.55, 95%CI 0.28-1.09 vs. HR 1.32 95%CI 0.67-2.60, p for interaction 0.01). CONCLUSIONS In patients with septic shock, there is no association between adrenocortical candidate gene expression and mortality. Patients with higher expression of GLCCI1 who received hydrocortisone achieved shock resolution faster than those receiving placebo; conversely, patients who had higher expression of BHSD1 who received hydrocortisone achieved shock resolution slower than those who received placebo. Variation in gene expression may be a mechanism for heterogeneity of treatment response to corticosteroids in septic shock.",2021,"Patients with higher expression of GLCCI1 who received hydrocortisone achieved shock resolution faster than those receiving placebo; conversely, patients who had higher expression of BHSD1 who received hydrocortisone achieved shock resolution slower than those who received placebo.","['septic shock', 'From May 2014 to April 2017, 671 patients were enrolled in the nested cohort study, from which 494 samples were available for analysis', 'patients with septic shock']","['hydrocortisone or placebo', 'placebo', 'hydrocortisone', 'hydrocortisone and placebo']","['shock resolution faster', '90-day mortality, 28-day mortality or time to shock reversal', 'shock resolution', 'BHSD1']","[{'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",671.0,0.507044,"Patients with higher expression of GLCCI1 who received hydrocortisone achieved shock resolution faster than those receiving placebo; conversely, patients who had higher expression of BHSD1 who received hydrocortisone achieved shock resolution slower than those who received placebo.","[{'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Cohen', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia. cohenjeremy@me.com.'}, {'ForeName': 'Antje', 'Initials': 'A', 'LastName': 'Blumenthal', 'Affiliation': 'University of Queensland Diamantina Institute, University of Queensland, St Lucia, Australia.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Cuellar-Partida', 'Affiliation': 'University of Queensland Diamantina Institute, University of Queensland, St Lucia, Australia.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Evans', 'Affiliation': 'University of Queensland Diamantina Institute, University of Queensland, St Lucia, Australia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Finfer', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Ljungberg', 'Affiliation': 'University of Queensland Diamantina Institute, University of Queensland, St Lucia, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Myburgh', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Peach', 'Affiliation': 'University of Queensland Diamantina Institute, University of Queensland, St Lucia, Australia.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Powell', 'Affiliation': 'Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute, Sydney, Australia.'}, {'ForeName': 'Dorrilyn', 'Initials': 'D', 'LastName': 'Rajbhandari', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Rhodes', 'Affiliation': ""St George's Hospital, London, UK.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Senabouth', 'Affiliation': 'Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute, Sydney, Australia.'}, {'ForeName': 'Balasubramanian', 'Initials': 'B', 'LastName': 'Venkatesh', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}]",Intensive care medicine,['10.1007/s00134-021-06464-5'] 1415,34391173,Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China.,"BACKGROUND Tenofovir disoproxil fumarate has been recommended for pre-exposure prophylaxis (PrEP) to prevent HIV infection. Several studies have shown short but potent intermittent PrEP could provide comparable protection to daily PrEP in men, suggesting such dosing strategy might be useful in Chinese as well. The objective of this study was to evaluate the impact of different dosing strategies on plasma concentrations of tenofovir. METHODS An open label study in 40 Chinese healthy volunteers, randomized to receive the WHO-recommended dose of tenofovir (300mg) at four different dosing intervals: twice weekly for 4 weeks; once daily for 4 weeks with one missing dose in weeks 2-4; once daily for 4 weeks with two missing doses in weeks 2-4; and once every other day for 12 days. Plasma samples were collected at pre-dose, weekly trough and 24h post last dose and assayed using HPLC-UV. RESULTS The tenofovir trough concentrations were below the lower limit of quantification with the twice weekly regimen. The trough concentrations (24h dosing interval) at the steady state were 51.7±12.1ng/ml and 53.5±13.8ng/ml (mean±SD) in the once daily groups. Missing doses, once or twice weekly, had no significant impact on trough concentrations. Prolongation of dosing interval to 48h resulted with concentrations at 24h and 48h (trough) of ∼40 and 20ng/ml, respectively. CONCLUSIONS Intermittent tenofovir regimens resulted with remarkably low plasma concentrations in Chinese participants. Missing doses did not affect trough concentrations significantly.",2021,Missing doses did not affect trough concentrations significantly.,"['40 Chinese healthy volunteers', 'Chinese participants', 'HIV pre-exposure prophylaxis in China']","['tenofovir', 'Tenofovir disoproxil fumarate']","['low plasma concentrations', 'plasma concentrations of tenofovir', 'trough concentrations', 'tenofovir trough concentrations']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1096319', 'cui_str': 'Prophylaxis against HIV infection'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C0444506', 'cui_str': 'Trough'}]",40.0,0.0951109,Missing doses did not affect trough concentrations significantly.,"[{'ForeName': 'Jingchuan', 'Initials': 'J', 'LastName': 'Shang', 'Affiliation': 'Department of Pharmaceutical Analysis and Pharmacology, Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Tan', 'Affiliation': 'Department of Pharmaceutical Analysis and Pharmacology, Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Junqing', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Pharmaceutical Analysis and Pharmacology, Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Yan', 'Affiliation': 'Department of Pharmaceutical Analysis and Pharmacology, Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Xiaoni', 'Initials': 'X', 'LastName': 'Zhong', 'Affiliation': 'School of Public Health, Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'School of Public Health, Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Bayan', 'Initials': 'B', 'LastName': 'Alnajebi', 'Affiliation': 'Department of Pharmacy Practice, University at Buffalo, Buffalo, New York 14214, United States.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Ma', 'Affiliation': 'Department of Pharmacy Practice, University at Buffalo, Buffalo, New York 14214, United States. Electronic address: qingma@buffalo.edu.'}, {'ForeName': 'Ailong', 'Initials': 'A', 'LastName': 'Huang', 'Affiliation': 'Key Laboratory of Molecular Biology and Infectious Diseases, Chongqing Medical University, Chongqing 400016, China. Electronic address: ahuang1964@163.com.'}]",Journal of infection and public health,['10.1016/j.jiph.2021.07.018'] 1416,34153798,Acute mild dim light at night slightly modifies sleep but does not affect glucose homeostasis in healthy men.,"OBJECTIVE We evaluated the effect of acute mild light exposure at night on sleep architecture and glucose homeostasis. PATIENTS/METHODS Twenty healthy normal-weight men took part in two conditions of a randomized, controlled, balanced cross-over experimental study: i) two-consecutive nights with 8-h of sleep under dLAN (<5 lux) or ii) total darkness (CON). Sleep was evaluated by polysomnography. In the morning following 'night2', glucose homeostasis was assessed by an intravenous glucose tolerance test (ivGTT) with consecutive measures of glucose, insulin, and c-peptide. Plasma cortisol was measured at night before sleep, after morning awakening, and during mid-afternoon hours. RESULTS There was no significant difference in total sleep time, sleep efficiency, and sleep latency between conditions (all p > 0.66). However, NREM sleep stage N3 latency was prolonged after dLAN (p = 0.02) and NREM sleep stage 2 was decreased after two nights with dLAN (p = 0.04). During the first sleep hour, power in slow-oscillations, slow-waves, and delta bands diminished after dLAN (all p < 0.04). Glucose, insulin, and c-peptide were not altered by dLAN (all p > 0.14). Cortisol was reduced in the afternoon after 'night1' and in the morning after 'night2' (both p < 0.03). CONCLUSIONS dLAN slightly disturbed sleep architecture and quality without impairment of glucose homeostasis. Longer exposure to chronic dLAN might be needed to unmask its hypothesized metabolic consequences.",2021,"There was no significant difference in total sleep time, sleep efficiency, and sleep latency between conditions (all p > 0.66).","['Twenty healthy normal-weight men took part in two conditions of a randomized, controlled, balanced cross-over experimental study', 'healthy men']","['dLAN', 'dLAN ', 'sleep under dLAN (<5 lux) or ii) total darkness (CON']","['Sleep', 'glucose homeostasis', 'Plasma cortisol', 'NREM sleep stage N3 latency', 'sleep architecture and quality without impairment of glucose homeostasis', 'NREM sleep stage 2', 'total sleep time, sleep efficiency, and sleep latency', 'Glucose, insulin, and c-peptide', 'Cortisol']","[{'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0024176', 'cui_str': 'Luxembourg'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010986', 'cui_str': 'Darkness'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C1281899', 'cui_str': 'Plasma cortisol measurement'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C4505222', 'cui_str': 'Sleep Onset Latency'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}]",20.0,0.037585,"There was no significant difference in total sleep time, sleep efficiency, and sleep latency between conditions (all p > 0.66).","[{'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Chamorro', 'Affiliation': 'Institute for Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany; Department of Nutrition, University of Chile, Santiago, Chile.'}, {'ForeName': 'Britta', 'Initials': 'B', 'LastName': 'Wilms', 'Affiliation': 'Institute for Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany; German Center for Diabetes Research, München-Neuherberg, Germany.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Holst', 'Affiliation': 'Institute for Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Röhl', 'Affiliation': 'Institute for Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Mölle', 'Affiliation': 'Center of Brain, Behavior & Metabolism, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Knaak', 'Affiliation': 'Institute for Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Svenja', 'Initials': 'S', 'LastName': 'Meyhöfer', 'Affiliation': 'Institute for Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany; German Center for Diabetes Research, München-Neuherberg, Germany.'}, {'ForeName': 'Hendrik', 'Initials': 'H', 'LastName': 'Lehnert', 'Affiliation': 'Institute for Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany; University of Salzburg, Salzburg, Austria.'}, {'ForeName': 'Sebastian M', 'Initials': 'SM', 'LastName': 'Schmid', 'Affiliation': 'Institute for Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany; German Center for Diabetes Research, München-Neuherberg, Germany. Electronic address: sebastian.schmid@uni-luebeck.de.'}]",Sleep medicine,['10.1016/j.sleep.2021.05.038'] 1417,34156965,Improving Electronic Survey Response Rates Among Cancer Center Patients During the COVID-19 Pandemic: Mixed Methods Pilot Study.,"BACKGROUND Surveys play a vital role in cancer research. During the COVID-19 pandemic, the use of electronic surveys is crucial to improve understanding of the patient experience. However, response rates to electronic surveys are often lower compared with those of paper surveys. OBJECTIVE The aim of this study was to determine the best approach to improve response rates for an electronic survey administered to patients at a cancer center during the COVID-19 pandemic. METHODS We contacted 2750 patients seen at Moffitt Cancer Center in the prior 5 years via email to complete a survey regarding their experience during the COVID-19 pandemic, with patients randomly assigned to a series of variations of prenotifications (ie, postcard, letter) or incentives (ie, small gift, modest gift card). In total, eight combinations were evaluated. Qualitative interviews were conducted to understand the level of patient understanding and burden with the survey, and quantitative analysis was used to evaluate the response rates between conditions. RESULTS A total of 262 (9.5%) patients completed the survey and 9 participated in a qualitative interview. Interviews revealed minimal barriers in understanding or burden, which resulted in minor survey design changes. Compared to sending an email only, sending a postcard or letter prior to the email improved response rates from 3.7% to 9.8%. Similarly, inclusion of an incentive significantly increased the response rate from 5.4% to 16.7%, especially among racial (3.0% to 12.2%) and ethnic (6.4% to 21.0%) minorities, as well as among patients with low socioeconomic status (3.1% to 14.9%). CONCLUSIONS Strategies to promote effective response rates include prenotification postcards or letters as well as monetary incentives. This work can inform future survey development to increase response rates for electronic surveys, particularly among hard-to-reach populations.",2021,"Similarly, inclusion of an incentive significantly increased response the rate from 5.4% to 16.7%, especially among racial (3.0% to 12.2%) and ethnic minorities (6.4% to 21.0%) as well as patients with low socioeconomic status (3.1% to 14.9%). ","['Cancer Center Patients', 'A total of 262 (9.5%) patients completed the survey, and 9 participated in a qualitative interview', 'patients at a cancer center during the COVID-19 pandemic', '2,750 patients seen at Moffitt Cancer Center in the prior five years via email to complete a survey regarding their experience during the COVID-19 pandemic']",[],['response rates'],"[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0347984', 'cui_str': 'During'}]",[],[],8.0,0.0597273,"Similarly, inclusion of an incentive significantly increased response the rate from 5.4% to 16.7%, especially among racial (3.0% to 12.2%) and ethnic minorities (6.4% to 21.0%) as well as patients with low socioeconomic status (3.1% to 14.9%). ","[{'ForeName': 'Cassandra A', 'Initials': 'CA', 'LastName': 'Hathaway', 'Affiliation': 'Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.'}, {'ForeName': 'Melody N', 'Initials': 'MN', 'LastName': 'Chavez', 'Affiliation': 'Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, FL, United States.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Kadono', 'Affiliation': 'The AltaMed Institute for Health Equity, Los Angeles, CA, United States.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Ketcher', 'Affiliation': 'Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.'}, {'ForeName': 'Dana E', 'Initials': 'DE', 'LastName': 'Rollison', 'Affiliation': 'Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.'}, {'ForeName': 'Erin M', 'Initials': 'EM', 'LastName': 'Siegel', 'Affiliation': 'Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.'}, {'ForeName': 'Anita R', 'Initials': 'AR', 'LastName': 'Peoples', 'Affiliation': 'Huntsman Cancer Institute, Salt Lake City, UT, United States.'}, {'ForeName': 'Cornelia M', 'Initials': 'CM', 'LastName': 'Ulrich', 'Affiliation': 'Huntsman Cancer Institute, Salt Lake City, UT, United States.'}, {'ForeName': 'Frank J', 'Initials': 'FJ', 'LastName': 'Penedo', 'Affiliation': 'Departments of Medicine and Psychology, University of Miami, Coral Gables, FL, United States.'}, {'ForeName': 'Shelley S', 'Initials': 'SS', 'LastName': 'Tworoger', 'Affiliation': 'Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.'}, {'ForeName': 'Brian D', 'Initials': 'BD', 'LastName': 'Gonzalez', 'Affiliation': 'Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.'}]",JMIR cancer,['10.2196/30265'] 1418,34164794,"Safety and Pharmacokinetics of HTL0018318, a Novel M 1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects.","INTRODUCTION HTL0018318 is a selective muscarinic M 1 receptor partial agonist under development for the symptomatic treatment of dementias, including Alzheimer's disease. Clinically, HTL0018318 would likely be used alone or in conjunction with cholinesterase inhibitors (e.g. donepezil). OBJECTIVE We investigated the safety, tolerability, and pharmacokinetics of HTL0018318 given alone and in combination with donepezil. METHODS This was a randomized, double-blind, placebo-controlled trial in 42 (to deliver 36 with combination treatment) healthy elderly subjects investigating the effects of oral HTL0018318 15 and 25 mg given alone and combined with donepezil 10 mg at steady state on adverse events (AEs), vital signs, saliva production, sleep quality, pulmonary function, subjective feelings, and pharmacokinetics. RESULTS AEs were reported by lower percentages of subjects after HTL0018318 alone than after donepezil alone. There was no increase in the percentage of subjects reporting AEs after co-administration than after donepezil alone. Supine systolic blood pressure was 1.6 mmHg (95% confidence interval [CI] -3.1 to -0.1) lower after HTL0018318 alone than after combination treatment. This was comparable with results from placebo alone: 1.7 mmHg (95% CI -3.2 to 0.2) lower than with combination treatment. Supine pulse rate was 3.3 bpm (95% CI 1.5-5.1) higher after HTL0018318 alone than with co-administration. HTL0018318 and donepezil did not meaningfully affect each other's pharmacokinetics. CONCLUSION HTL0018318 was well tolerated when given alone and in combination with donepezil. HTL0018318 and donepezil do not demonstrate pharmacokinetic or pharmacodynamic interactions, indicating that HTL0018318 can be safely administered in combination with donepezil. CLINICAL TRIAL REGISTRATION Netherlands Trial register identifier NL5915, registered on 28 October 2016.",2021,Supine pulse rate was 3.3 bpm (95% CI 1.5-5.1) higher after HTL0018318 alone than with co-administration.,"['42 (to deliver 36 with combination treatment) healthy elderly subjects', 'Healthy Elderly Subjects']","['oral HTL0018318 15 and 25 mg given alone and combined with donepezil', 'donepezil', 'Donepezil at Steady State', 'placebo', 'cholinesterase inhibitors (e.g. donepezil']","['safety, tolerability, and pharmacokinetics', 'adverse events (AEs), vital signs, saliva production, sleep quality, pulmonary function, subjective feelings, and pharmacokinetics', 'tolerated', 'Supine pulse rate', 'percentage of subjects reporting AEs', 'Supine systolic blood pressure']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0527316', 'cui_str': 'donepezil'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0008425', 'cui_str': 'Cholinesterase inhibitor'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",,0.378205,Supine pulse rate was 3.3 bpm (95% CI 1.5-5.1) higher after HTL0018318 alone than with co-administration.,"[{'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Bakker', 'Affiliation': 'Centre for Human Drug Research (CDHR), Leiden, The Netherlands. cbakker@chdr.nl.'}, {'ForeName': 'Jasper', 'Initials': 'J', 'LastName': 'van der Aart', 'Affiliation': 'Centre for Human Drug Research (CDHR), Leiden, The Netherlands.'}, {'ForeName': 'Geert', 'Initials': 'G', 'LastName': 'Labots', 'Affiliation': 'Centre for Human Drug Research (CDHR), Leiden, The Netherlands.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Liptrot', 'Affiliation': 'Sosei Heptares, Cambridge, UK.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Cross', 'Affiliation': 'Cross Pharma Consulting Ltd, Cambridge, UK.'}, {'ForeName': 'Erica S', 'Initials': 'ES', 'LastName': 'Klaassen', 'Affiliation': 'Centre for Human Drug Research (CDHR), Leiden, The Netherlands.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Dickinson', 'Affiliation': 'Sosei Heptares, Cambridge, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Tasker', 'Affiliation': 'Sosei Heptares, Cambridge, UK.'}, {'ForeName': 'Geert Jan', 'Initials': 'GJ', 'LastName': 'Groeneveld', 'Affiliation': 'Centre for Human Drug Research (CDHR), Leiden, The Netherlands.'}]",Drugs in R&D,['10.1007/s40268-021-00352-5'] 1419,34162752,The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.,"Toll-like receptor 7 (TLR7) agonists, in combination with other therapies, can induce sustained control of simian-human immunodeficiency virus (SHIV) or simian immunodeficiency virus (SIV) in nonhuman primates. Here, we report the results of a randomized, double-blind, placebo-controlled phase 1b clinical trial of an oral TLR7 agonist, vesatolimod, in HIV-1-infected controllers on antiretroviral therapy (ART). We randomized participants 2:1 to receive vesatolimod ( n = 17) or placebo ( n = 8) once every other week for a total of 10 doses while continuing on ART. ART was then interrupted, and the time to viral rebound was analyzed using the Kaplan-Meier method. Vesatolimod was associated with induction of immune cell activation, decreases in intact proviral DNA during ART, and a modest increase in time to rebound after ART was interrupted. The delayed viral rebound was predicted by the lower intact proviral DNA at the end of vesatolimod treatment (13 days after the final dose). Inferred pathway analysis suggested increased dendritic cell and natural killer cell cross-talk and an increase in cytotoxicity potential after vesatolimod dosing. Larger clinical studies will be necessary to assess the efficacy of vesatolimod-based combination therapies aimed at long-term control of HIV infection.",2021,The delayed viral rebound was predicted by the lower intact proviral DNA at the end of vesatolimod treatment (13 days after the final dose).,[],"['placebo', 'vesatolimod', 'oral TLR7 agonist, vesatolimod']","['cytotoxicity potential', 'dendritic cell and natural killer cell cross-talk', 'delayed viral rebound']",[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4519174', 'cui_str': 'vesatolimod'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0971207', 'cui_str': 'TLR7 protein, human'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0003315', 'cui_str': 'Immunologic Accessory Cells'}, {'cui': 'C0022688', 'cui_str': 'NK-cell'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0521026', 'cui_str': 'viruses'}]",,0.449735,The delayed viral rebound was predicted by the lower intact proviral DNA at the end of vesatolimod treatment (13 days after the final dose).,"[{'ForeName': 'Devi', 'Initials': 'D', 'LastName': 'SenGupta', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Brinson', 'Affiliation': 'Central Texas Clinical Research, Austin, TX, USA.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'DeJesus', 'Affiliation': 'Orlando Immunology Center, Orlando, FL, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Mills', 'Affiliation': ""Men's Health Foundation, West Hollywood, CA, USA.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Shalit', 'Affiliation': 'Peter Shalit MD and Associates, Seattle, WA, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Guo', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Yanhui', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Wallin', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Liao', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Humeniuk', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Begley', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Romas', 'Initials': 'R', 'LastName': 'Geleziunas', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Mellors', 'Affiliation': 'University of Pittsburgh, Pittsburg, PA, USA.'}, {'ForeName': 'Terri', 'Initials': 'T', 'LastName': 'Wrin', 'Affiliation': 'Monogram Biosciences, South San Francisco, CA, USA.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Jones', 'Affiliation': 'University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Milush', 'Affiliation': 'University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'April L', 'Initials': 'AL', 'LastName': 'Ferre', 'Affiliation': 'University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Barbara L', 'Initials': 'BL', 'LastName': 'Shacklett', 'Affiliation': 'University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Greg M', 'Initials': 'GM', 'LastName': 'Laird', 'Affiliation': 'Accelevir Diagnostics, Baltimore, MD, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Moldt', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Vendrame', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Diana M', 'Initials': 'DM', 'LastName': 'Brainard', 'Affiliation': 'Gilead Sciences Inc., Foster City, CA, USA.'}, {'ForeName': 'Moti', 'Initials': 'M', 'LastName': 'Ramgopal', 'Affiliation': 'Midway Specialty Care Center, Fort Pierce, FL, USA.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Deeks', 'Affiliation': 'University of California San Francisco, San Francisco, CA, USA. steven.deeks@ucsf.edu.'}]",Science translational medicine,['10.1126/scitranslmed.abg3071'] 1420,34162188,Real Life Data of Treat and Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age-related Macular Degeneration Patients: 3-Year Results.,"PURPOSE To compare functional and anatomic outcome of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) treatments in neovascular age-related macular degeneration by using the treat and extend (TE) protocol. METHODS In this retrospective chart study, treatment naïve 74 eyes of 74 age-related macular degeneration patients treated with IVR and IVA (38 eyes in IVR and 36 eyes in IVA group) with TE protocol were included. Following three consecutive monthly intravitreal injections, TE protocol was applied to each group. Patients were followed up for at least 36 months. Mean change in best-corrected visual acuity (BCVA), central macula thickness (CMT) and injection numbers over 3 years were compared. RESULTS Among 36 months period, the mean number of injections was 17 ± 4 for both groups (p > 0.05). In terms of CMT, there was no statistically significant difference between groups at 36 months compared to baseline. A decrease of 72.55 ± 39.37 μm in CMT was detected in IVR group, whereas the decrease was 70.58 ± 33.96 μm in IVA group (p > 0.05). There was a significant increase in BCVA at 36 months of measurements. In addition, BCVA demonstrated an increase of 4.1 ± 0.44 letters in IVR group and 4.36 ± 0.67 letters in IVA group after 36 months compared to the baseline (p > 0.05). CONCLUSIONS Both IVR and IVA injections provided significant improvements and stability in BCVA and CMT, however there was no significant difference between IVR and IVA injections with TE protocol of 36 months.",2021,"Among 36 months period, the mean number of injection was 17±4 for both groups (p>0.05).","['treatment naïve 74 eyes of 74 nAMD patients treated with IVR and IVA (38 eyes in IVR and 36 eyes in IVA group) with TE protocol were included', 'neovascular age related macular degeneration (nAMD', 'Wet Age Related Macular Degeneration Patients']","['intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA', 'BCVA', 'Intravitreal Ranibizumab and Aflibercept Therapy']","['corrected visual acuity (BCVA), central macula thickness (CMT) and injection numbers', 'mean number of injection', 'BCVA', 'stability in BCVA and CMT']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0271084', 'cui_str': 'Exudative age-related macular degeneration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3888896', 'cui_str': 'Wet age-related macular degeneration'}]","[{'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0227662', 'cui_str': 'Structure of macula densa'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",74.0,0.0887332,"Among 36 months period, the mean number of injection was 17±4 for both groups (p>0.05).","[{'ForeName': 'Ozgul', 'Initials': 'O', 'LastName': 'Ugurtay', 'Affiliation': 'Department of Ophthalmology, T. C. Demiroglu Bilim University Medical Faculty, Istanbul, Turkey.'}, {'ForeName': 'Alev', 'Initials': 'A', 'LastName': 'Kockar', 'Affiliation': 'Department of Ophthalmology, T. C. Demiroglu Bilim University Medical Faculty, Istanbul, Turkey.'}, {'ForeName': 'Elvan Alper', 'Initials': 'EA', 'LastName': 'Sengul', 'Affiliation': 'Department of Ophthalmology, T. C. Demiroglu Bilim University Medical Faculty, Istanbul, Turkey.'}]",Korean journal of ophthalmology : KJO,['10.3341/kjo.2020.0109'] 1421,34165201,The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.,"BACKGROUND Obesity may affect efficacy and safety of biologic treatments for ulcerative colitis (UC). Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. AIMS To assess efficacy and safety of tofacitinib in patients with UC, by baseline body mass index (BMI). METHODS This post hoc analysis evaluated patients with UC receiving placebo or tofacitinib from the 8-week OCTAVE Induction 1 and 2 (NCT01465763, NCT01458951) and 52-week OCTAVE Sustain (NCT01458574) studies. Patients were stratified by BMI at OCTAVE Induction 1 and 2 baseline (<25, 25 to <30 and ≥30 kg/m 2 ). Outcomes included remission, endoscopic improvement, clinical response, sustained steroid-free remission, Inflammatory Bowel Disease Questionnaire total score and Short Form-36 Health Survey scores. Adverse events were evaluated. RESULTS At Week 8 of OCTAVE Induction 1 and 2, and Week 52 of OCTAVE Sustain, higher proportions of patients receiving tofacitinib 5 or 10 mg twice daily (b.d.) achieved clinical response vs placebo, regardless of baseline BMI subgroup (all P < 0.05). Proportions of patients achieving efficacy endpoints were generally similar across BMI subgroups; in univariate and multivariate regression analyses, BMI was not a significant predictor (all P ≥ 0.05; univariate BMI [continuous] odds ratio for remission: 0.98 [95% confidence interval 0.95, 1.02]). There was no consistent trend between BMI and adverse events. Among patients receiving tofacitinib 10 mg b.d. in OCTAVE Induction 1 and 2, serious infections were numerically greater in the BMI ≥30 subgroup (3.2%) vs other subgroups (0.4%). Limitations included small patient numbers in the BMI ≥30 subgroup. CONCLUSIONS Efficacy and safety of tofacitinib were similar in patients with UC regardless of baseline BMI.",2021,"Outcomes included remission, endoscopic improvement, clinical response, sustained steroid-free remission, Inflammatory Bowel Disease Questionnaire total score and Short Form-36 Health Survey scores.","['patients with UC regardless of baseline BMI', 'ulcerative colitis (UC', 'patients with UC, by baseline body mass index (BMI']","['tofacitinib', 'Tofacitinib', 'placebo or tofacitinib']","['remission, endoscopic improvement, clinical response, sustained steroid-free remission, Inflammatory Bowel Disease Questionnaire total score and Short Form-36 Health Survey scores', 'efficacy and safety', 'BMI and adverse events', 'serious infections', 'Adverse events', 'clinical response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C2930696', 'cui_str': 'tofacitinib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",,0.167154,"Outcomes included remission, endoscopic improvement, clinical response, sustained steroid-free remission, Inflammatory Bowel Disease Questionnaire total score and Short Form-36 Health Survey scores.","[{'ForeName': 'Francis A', 'Initials': 'FA', 'LastName': 'Farraye', 'Affiliation': 'Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Taha', 'Initials': 'T', 'LastName': 'Qazi', 'Affiliation': 'Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Paulo G', 'Initials': 'PG', 'LastName': 'Kotze', 'Affiliation': 'IBD Outpatient Clinics, Colorectal Surgery Unit, Cajuru University Hospital, Pontifical Catholic University of Paraná (PUCPR), Curitiba, Brazil.'}, {'ForeName': 'Gregory T', 'Initials': 'GT', 'LastName': 'Moore', 'Affiliation': 'Department of Gastroenterology, Monash Health, Melbourne, Vic., Australia.'}, {'ForeName': 'Rajiv', 'Initials': 'R', 'LastName': 'Mundayat', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Nervin', 'Initials': 'N', 'LastName': 'Lawendy', 'Affiliation': 'Pfizer Inc, Collegeville, PA, USA.'}, {'ForeName': 'Puza P', 'Initials': 'PP', 'LastName': 'Sharma', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Donna T', 'Initials': 'DT', 'LastName': 'Judd', 'Affiliation': 'Pfizer Inc, Collegeville, PA, USA.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.16439'] 1422,34165199,Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension.,"BACKGROUND Portal hypertension is the main determinant of clinical decompensation in patients with liver cirrhosis. In preclinical data metformin lowers portal pressure, but there are no clinical data for this beneficial effect. AIMS To investigate the acute effects of metformin on hepatic venous pressure gradient (HVPG) and liver perfusion. METHODS In a randomised, double-blinded study design, we investigated 32 patients with cirrhosis before and 90 minutes after ingestion of 1000-mg metformin (n = 16) or placebo (n = 16). Liver vein catherisation was performed to evaluate HVPG and indocyanine green (ICG) infusion for investigation of hepatic blood flow. RESULTS The mean relative change in HVPG was -16% (95% CI: -28% to -4%) in the metformin group compared with 4% (95% CI: -6% to 14%) in the placebo group (time × group interaction, P = 0.008). In patients with baseline HVPG ≥12 mm Hg clinically significant improvements in HVPG (HVPG <12 mm Hg or a >20% reduction in HVPG) were observed in 46% (6/13) of metformin-treated and in 8% (1/13) of placebo-treated patients (P = 0.07). There were no changes or differences in systemic blood pressure, heart rate, hepatic plasma and blood flow, hepatic ICG clearance, hepatic O 2 uptake or inflammation markers between groups. CONCLUSIONS A single oral metformin dose acutely reduces HVPG in patients with portal hypertension without affecting systemic or liver hemodynamics or inflammatory biomarkers. This offers a promising perspective of a safe and inexpensive treatment option that should be investigated in larger-scale clinical studies with long-term outcomes in patients with cirrhosis and portal hypertension.",2021,A single oral metformin dose acutely reduces HVPG in patients with portal hypertension without affecting systemic or liver hemodynamics or inflammatory biomarkers.,"['patients with liver cirrhosis', 'patients with cirrhosis and portal hypertension', 'n\xa0=\xa016', '32 patients with cirrhosis before and 90\xa0minutes after ingestion of 1000-mg metformin (n\xa0=\xa016) or', 'patients with portal hypertension without affecting systemic or liver hemodynamics or inflammatory biomarkers', 'patients with baseline']","['HVPG', 'placebo', 'metformin', 'HVPG and indocyanine green (ICG) infusion']","['HVPG', 'systemic blood pressure, heart rate, hepatic plasma and blood flow, hepatic ICG clearance, hepatic O 2 uptake or inflammation markers', 'mean relative change in HVPG', 'HVPG ', 'hepatic venous pressure gradient (HVPG) and liver perfusion', 'portal pressure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C0020541', 'cui_str': 'Portal hypertension'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C4049263', 'cui_str': 'Hepatic venous pressure gradient'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0021234', 'cui_str': 'Indocyanine Green'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C4049263', 'cui_str': 'Hepatic venous pressure gradient'}, {'cui': 'C1272641', 'cui_str': 'Systemic arterial pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0021234', 'cui_str': 'Indocyanine Green'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0193410', 'cui_str': 'Perfusion of liver'}, {'cui': 'C0162523', 'cui_str': 'Portal Venous Pressure'}]",32.0,0.447703,A single oral metformin dose acutely reduces HVPG in patients with portal hypertension without affecting systemic or liver hemodynamics or inflammatory biomarkers.,"[{'ForeName': 'Nikolaj', 'Initials': 'N', 'LastName': 'Rittig', 'Affiliation': 'Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Niels Kristian', 'Initials': 'NK', 'LastName': 'Aagaard', 'Affiliation': 'Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Gerda Elisabeth', 'Initials': 'GE', 'LastName': 'Villadsen', 'Affiliation': 'Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Thomas Damgaard', 'Initials': 'TD', 'LastName': 'Sandahl', 'Affiliation': 'Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Jessen', 'Affiliation': 'Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Grønbaek', 'Affiliation': 'Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'George', 'Affiliation': 'Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.16460'] 1423,34167959,Strength of Association between Infarct Volume and Clinical Outcome Depends on the Magnitude of Infarct Size: Results from the ESCAPE-NA1 Trial.,"BACKGROUND AND PURPOSE Infarct volume is an important predictor of clinical outcome in acute stroke. We hypothesized that the association of infarct volume and clinical outcome changes with the magnitude of infarct size. MATERIALS AND METHODS Data were derived from the Safety and Efficacy of Nerinetide in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1) trial, in which patients with acute stroke with large-vessel occlusion were randomized to endovascular treatment plus either nerinetide or a placebo. Infarct volume was manually segmented on 24-hour noncontrast CT or DWI. The relationship between infarct volume and good outcome, defined as mRS 0-2 at 90 days, was plotted. Patients were categorized on the basis of visual grouping at the curve shoulders of the infarct volume/outcome plot. The relationship between infarct volume and adjusted probability of good outcome was fitted with linear or polynomial functions as appropriate in each group. RESULTS We included 1099 individuals in the study. Median infarct volume at 24 hours was 24.9 mL (interquartile range [IQR] = 6.6-92.2 mL). On the basis of the infarct volume/outcome plot, 4 infarct volume groups were defined (IQR = 0-15 mL, 15.1-70 mL, 70.1-200 mL, >200 mL). Proportions of good outcome in the 4 groups were 359/431 (83.3%), 219/337 (65.0%), 71/201 (35.3%), and 16/130 (12.3%), respectively. In small infarcts (IQR = 0-15 mL), no relationship with outcome was appreciated. In patients with intermediate infarct volume (IQR = 15-200 mL), there was progressive importance of volume as an outcome predictor. In infarcts of > 200 mL, outcomes were overall poor. CONCLUSIONS The relationship between infarct volume and clinical outcome varies nonlinearly with the magnitude of infarct size. Infarct volume was linearly associated with decreased chances of achieving good outcome in patients with moderate-to-large infarcts, but not in those with small infarcts. In very large infarcts, a near-deterministic association with poor outcome was seen.",2021,"Infarct volume was linearly associated with decreased chances of achieving good outcome in patients with moderate-to-large infarcts, but not in those with small infarcts.","['patients with acute stroke with large-vessel occlusion', 'Subjects', '1099 individuals in the study']",['endovascular treatment plus either nerinetide or a placebo'],"['Infarct volume', 'Median infarct volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0225990', 'cui_str': 'Large blood vessel structure'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",1099.0,0.0838308,"Infarct volume was linearly associated with decreased chances of achieving good outcome in patients with moderate-to-large infarcts, but not in those with small infarcts.","[{'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Ospel', 'Affiliation': 'Department of Clinical Neurosciences (J.M.O., M.D.H., B.K.M., A.D., W.Q., A.M., M.A., C.Z., M.G.), University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Hill', 'Affiliation': 'Department of Clinical Neurosciences (J.M.O., M.D.H., B.K.M., A.D., W.Q., A.M., M.A., C.Z., M.G.), University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'B K', 'Initials': 'BK', 'LastName': 'Menon', 'Affiliation': 'Department of Clinical Neurosciences (J.M.O., M.D.H., B.K.M., A.D., W.Q., A.M., M.A., C.Z., M.G.), University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Demchuk', 'Affiliation': 'Department of Clinical Neurosciences (J.M.O., M.D.H., B.K.M., A.D., W.Q., A.M., M.A., C.Z., M.G.), University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'McTaggart', 'Affiliation': 'Department of Interventional Radiology (R.M., M. Jayaraman), Warren Alpert Medical School of Brown University, Providence, Rhode Island.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Nogueira', 'Affiliation': 'Department of Neurology (R.N., D.H.), Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Poppe', 'Affiliation': ""Centre Hospitalier de l'Université de Montréal (A.P., D.R.), Montreal, Quebec, Canada.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Haussen', 'Affiliation': 'Department of Neurology (R.N., D.H.), Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Qiu', 'Affiliation': 'Department of Clinical Neurosciences (J.M.O., M.D.H., B.K.M., A.D., W.Q., A.M., M.A., C.Z., M.G.), University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Mayank', 'Affiliation': 'Department of Clinical Neurosciences (J.M.O., M.D.H., B.K.M., A.D., W.Q., A.M., M.A., C.Z., M.G.), University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Almekhlafi', 'Affiliation': 'Department of Clinical Neurosciences (J.M.O., M.D.H., B.K.M., A.D., W.Q., A.M., M.A., C.Z., M.G.), University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Zerna', 'Affiliation': 'Department of Clinical Neurosciences (J.M.O., M.D.H., B.K.M., A.D., W.Q., A.M., M.A., C.Z., M.G.), University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Joshi', 'Affiliation': 'Department of Radiology (M.D.H., B.K.M., A.D., M.A., M. Joshi, M.G.), University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Jayaraman', 'Affiliation': 'Department of Interventional Radiology (R.M., M. Jayaraman), Warren Alpert Medical School of Brown University, Providence, Rhode Island.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Roy', 'Affiliation': ""Centre Hospitalier de l'Université de Montréal (A.P., D.R.), Montreal, Quebec, Canada.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Rempel', 'Affiliation': 'University of Alberta Hospital (J.R., B.B.), Edmonton, Alberta, Canada.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Buck', 'Affiliation': 'University of Alberta Hospital (J.R., B.B.), Edmonton, Alberta, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Tymianski', 'Affiliation': 'NoNO Inc (M.T.), Toronto, Ontario, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Goyal', 'Affiliation': 'Department of Clinical Neurosciences (J.M.O., M.D.H., B.K.M., A.D., W.Q., A.M., M.A., C.Z., M.G.), University of Calgary, Calgary, Alberta, Canada mgoyal@ucalgary.ca.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",AJNR. American journal of neuroradiology,['10.3174/ajnr.A7183'] 1424,34391247,Impact of yoga in facilitating muscular functioning among asymptomatic male cricket players: Longitudinal randomized controlled study.,"BACKGROUND Cricket is one of the prominent global team sports. With an emergence of Twenty20 tournaments, the physical preparation of elite cricket players has become complex with high match injury incidence. Yoga as a body-mind training is associated with having positive effects on a person's physical and psychological conditions, bringing in better mind-body equilibrium. OBJECTIVES Evaluating the impact of yoga in facilitating muscular functioning and mindfulness among asymptomatic male cricket players. METHOD First-class domestic male cricket players in the age group of 18-35 years were randomized into yoga group n=42 and wait-list control group n=40. Players received the yoga module for five days per week for a duration of six weeks. Primary outcome measures of muscular functioning were core stability, flexibility, range of motion, static balance, dynamic balance and proprioception of the ankle. Assessments were held at baseline, immediate post-intervention, and a follow-up after six months of intervention. RESULTS A statistical significance with p < .001 was observed for most of the variables at T2 and T3. Comparison of the model fit shows a highly significant p < 0.001 difference between the model as compared to the baseline model among most of the variables. CONCLUSION This yoga module was appropriate for enhancing muscular functioning variables of this study. Continuous practice of this yoga module can reinforce sustainable benefits for male cricket players.",2021,"Comparison of the model fit shows a highly significant p < 0.001 difference between the model as compared to the baseline model among most of the variables. ","['male cricket players', 'First-class domestic male cricket players in the age group of 18-35 years', 'asymptomatic male cricket players']",['yoga group n=42 and wait-list control group n=40'],"['muscular functioning were core stability, flexibility, range of motion, static balance, dynamic balance and proprioception of the ankle']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0018288', 'cui_str': 'Cricket'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0003063', 'cui_str': 'Domestic Animals'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}]",,0.0238311,"Comparison of the model fit shows a highly significant p < 0.001 difference between the model as compared to the baseline model among most of the variables. ","[{'ForeName': 'Manasa R', 'Initials': 'MR', 'LastName': 'Rao', 'Affiliation': ""Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA Deemed-to-be University), Division of Yoga and Physical Sciences, #19, 'Eknath Bhavan', Gavipuram circle, Kempegowda Nagar, Bengaluru, 560019, India. Electronic address: mansarao@gmail.com.""}, {'ForeName': 'Ravi Kumar', 'Initials': 'RK', 'LastName': 'Itagi', 'Affiliation': ""Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA Deemed-to-be University), Division of Yoga and Physical Sciences, #19, 'Eknath Bhavan', Gavipuram circle, Kempegowda Nagar, Bengaluru, 560019, India. Electronic address: itagi.ravi@gmail.com.""}, {'ForeName': 'T M', 'Initials': 'TM', 'LastName': 'Srinivasan', 'Affiliation': ""Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA Deemed-to-be University), Division of Yoga and Physical Sciences, #19, 'Eknath Bhavan', Gavipuram circle, Kempegowda Nagar, Bengaluru, 560019, India. Electronic address: tmsrini@gmail.com.""}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.02.022'] 1425,34174496,"The risk of postpartum hemorrhage when lowering the oxytocin dose in planned cesarean section, a pilot study.","OBJECTIVES Oxytocin is the drug of choice in preventing postpartum hemorrhage (PPH). The aim was to compare the peroperative- and total blood loss within two hours and PPH after planned cesarean section (CS) when receiving 2.5 IU vs 5.0 IU of oxytocin in different risk groups for PPH. STUDY DESIGN A pilot study including 927 women undergoing planned CS where women receiving 2.5 IU of oxytocin were compared to women receiving 5.0 IU of oxytocin. MAIN OUTCOME MEASURES Data comparing peroperative blood loss, total blood loss within two hours and PPH were analyzed. RESULTS The women receiving 2.5 IU of oxytocin had a slightly higher peroperative blood loss, compared to the 5.0 IU group (476 ml vs 426 ml, p = 0.029). The total blood loss two hours after surgery showed no significant difference between the groups (626 ml vs 595 ml, p = 0.230). In the 2.5 IU group 13% had a blood loss ≥ 1000 ml vs 10% in the 5 IU group (aOR 1.64, 95% CI = 1.05-2.56). When the women considered to be at high risk for postpartum hemorrhage were excluded, we found no difference in the likelihood for postpartum hemorrhage between the groups (aOR 1.13, 95% CI = 0.64-1.99). CONCLUSIONS Women undergoing planned CS and receiving 2.5 IU of oxytocin had a slightly higher risk for postpartum hemorrhage in this study. However, a lower dose of 2.5 IU of oxytocin seems to be a safe option in planned CS for women without known risk factors for postpartum hemorrhage, but further research is needed to confirm these findings.",2021,"The total blood loss two hours after surgery showed no significant difference between the groups (626 ml vs 595 ml, p = 0.230).",['927 women undergoing'],"['oxytocin', 'planned CS', 'Oxytocin']","['blood loss\xa0≥', 'peroperative blood loss', 'total blood loss', 'peroperative blood loss, total blood loss within two hours and PPH', 'risk of postpartum hemorrhage', 'peroperative- and total blood loss', 'postpartum hemorrhage']","[{'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0232100', 'cui_str': 'Exsanguination'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",927.0,0.294737,"The total blood loss two hours after surgery showed no significant difference between the groups (626 ml vs 595 ml, p = 0.230).","[{'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Stålberg', 'Affiliation': ""Department of Obstetrics and Gynecology in Norrköping and Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Sweden.""}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Josefsson', 'Affiliation': ""Department of Obstetrics and Gynecology in Linköping and Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Sweden.""}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Bladh', 'Affiliation': ""Department of Obstetrics and Gynecology in Linköping and Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Sweden.""}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Lilliecreutz', 'Affiliation': ""Department of Obstetrics and Gynecology in Linköping and Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Sweden. Electronic address: caroline.lilliecreutz@regionostergotland.se.""}]",Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives,['10.1016/j.srhc.2021.100641'] 1426,34179981,Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement.,"AIMS The aims of the study were to compare clinical outcomes and valve durability after 8 years of follow-up in patients with symptomatic severe aortic valve stenosis at low surgical risk treated with either transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR). METHODS AND RESULTS In the NOTION trial, patients with symptomatic severe aortic valve stenosis were randomized to TAVI or SAVR. Clinical status, echocardiography, structural valve deterioration, and failure were assessed using standardized definitions. In total, 280 patients were randomized to TAVI (n = 145) or SAVR (n = 135). Baseline characteristics were similar, including mean age of 79.1 ± 4.8 years and a mean STS score of 3.0 ± 1.7%. At 8-year follow-up, the estimated risk of the composite outcome of all-cause mortality, stroke, or myocardial infarction was 54.5% after TAVI and 54.8% after SAVR (P = 0.94). The estimated risks for all-cause mortality (51.8% vs. 52.6%; P = 0.90), stroke (8.3% vs. 9.1%; P = 0.90), or myocardial infarction (6.2% vs. 3.8%; P = 0.33) were similar after TAVI and SAVR. The risk of structural valve deterioration was lower after TAVI than after SAVR (13.9% vs. 28.3%; P = 0.0017), whereas the risk of bioprosthetic valve failure was similar (8.7% vs. 10.5%; P = 0.61). CONCLUSIONS In patients with severe aortic valve stenosis at low surgical risk randomized to TAVI or SAVR, there were no significant differences in the risk for all-cause mortality, stroke, or myocardial infarction, as well as the risk of bioprosthetic valve failure after 8 years of follow-up. CLINICAL TRIAL REGISTRATION URL: http://www.ClinicalTrials.gov. Unique identifier: NCT01057173.",2021,"The estimated risks for all-cause mortality (51.8% vs. 52.6%; P = 0.90), stroke (8.3% vs. 9.1%; P = 0.90), or myocardial infarction (6.2% vs. 3.8%; P = 0.33) were similar after TAVI and SAVR.","['patients with severe aortic valve stenosis at low surgical risk', 'patients with symptomatic severe aortic valve stenosis', '280 patients were randomized to', 'patients with aortic valve stenosis at low surgical risk randomized to', 'patients with symptomatic severe aortic valve stenosis at low surgical risk treated with either']","['TAVI', 'transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR', 'transcatheter vs. surgical aortic valve replacement', 'SAVR', 'TAVI or SAVR']","['risk of bioprosthetic valve failure', 'clinical outcomes and valve durability', 'mortality, stroke, or myocardial infarction', 'stroke', 'risk of structural valve deterioration', 'Clinical status, echocardiography, structural valve deterioration, and failure', 'myocardial infarction', 'risk for all-cause mortality, stroke, or myocardial infarction, as well as the risk of bioprosthetic valve failure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003507', 'cui_str': 'Aortic valve stenosis'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0442343', 'cui_str': 'Transcatheter approach'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C4285833', 'cui_str': 'Structural valve deterioration'}, {'cui': 'C0449440', 'cui_str': 'Clinical status'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}]",280.0,0.12047,"The estimated risks for all-cause mortality (51.8% vs. 52.6%; P = 0.90), stroke (8.3% vs. 9.1%; P = 0.90), or myocardial infarction (6.2% vs. 3.8%; P = 0.33) were similar after TAVI and SAVR.","[{'ForeName': 'Troels Højsgaard', 'Initials': 'TH', 'LastName': 'Jørgensen', 'Affiliation': 'Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark.'}, {'ForeName': 'Hans Gustav Hørsted', 'Initials': 'HGH', 'LastName': 'Thyregod', 'Affiliation': 'Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark.'}, {'ForeName': 'Nikolaj', 'Initials': 'N', 'LastName': 'Ihlemann', 'Affiliation': 'Department of Cardiology, Odense University Hospital, J. B. Winsløws Vej 4, 5000 Odense, Denmark.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Nissen', 'Affiliation': 'Department of Cardiology, Odense University Hospital, J. B. Winsløws Vej 4, 5000 Odense, Denmark.'}, {'ForeName': 'Petur', 'Initials': 'P', 'LastName': 'Petursson', 'Affiliation': 'Department of Cardiology, Sahlgrenska University Hospital, Blå stråket 5, 413 45 Gothenburg, Sweden.'}, {'ForeName': 'Bo Juel', 'Initials': 'BJ', 'LastName': 'Kjeldsen', 'Affiliation': 'Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, J. B. Winsløws Vej 4, 5000 Odense, Denmark.'}, {'ForeName': 'Daniel Andreas', 'Initials': 'DA', 'LastName': 'Steinbrüchel', 'Affiliation': 'Department of Medicine, Nykoebing F Hospital and University of Southern Denmark, J. B. Winsløws Vej 4, 5000 Odense, Denmark.'}, {'ForeName': 'Peter Skov', 'Initials': 'PS', 'LastName': 'Olsen', 'Affiliation': 'Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Søndergaard', 'Affiliation': 'Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark.'}]",European heart journal,['10.1093/eurheartj/ehab375'] 1427,34183431,Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.,"OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared outcomes according to baseline glycemic status. RESEARCH DESIGN AND METHODS We enrolled participants with CKD, estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73 m 2 , and urinary albumin-to-creatinine ratio 200-5,000 mg/g. The primary composite end point was sustained eGFR decline ≥50%, end-stage kidney disease, or kidney or cardiovascular death. RESULTS Of 4,304 participants, 738 had normoglycemia, 660 had prediabetes, and 2,906 had type 2 diabetes. The effect of dapagliflozin on the primary outcome was consistent ( P for interaction = 0.19) in normoglycemia (hazard ratio [HR] 0.62 [95% CI 0.39, 1.01]), prediabetes (HR 0.37 [0.21, 0.66]), and type 2 diabetes (HR 0.64 [0.52, 0.79]). We found no evidence for effect modification on any outcome. Adverse events were similar, with no major hypoglycemia or ketoacidosis in participants with normoglycemia or prediabetes. CONCLUSIONS Dapagliflozin safely reduced kidney and cardiovascular events independent of baseline glycemic status.",2021,"The effect of dapagliflozin on the primary outcome was consistent ( P for interaction = 0.19) in normoglycemia (hazard ratio [HR] 0.62 [95% CI 0.39, 1.01]), prediabetes (HR 0.37 [0.21, 0.66]), and type 2 diabetes (HR 0.64 [0.52, 0.79]).","['participants with chronic kidney disease (CKD) with and without diabetes', '4,304 participants', 'We enrolled participants with CKD, estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m 2 , and urinary albumin-to-creatinine ratio 200-5,000 mg/g', ' 738 had normoglycemia, 660 had prediabetes, and 2,906 had type 2 diabetes', 'Chronic Kidney Disease (DAPA-CKD']","['dapagliflozin versus placebo', 'dapagliflozin', 'Dapagliflozin by Baseline Glycemic Status', 'Dapagliflozin']","['hypoglycemia or ketoacidosis', 'Efficacy and Safety', 'normoglycemia', 'sustained eGFR decline ≥50%, end-stage kidney disease, or kidney or cardiovascular death', 'Adverse events', 'kidney and cardiovascular events']","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1300563', 'cui_str': 'g/kg'}, {'cui': 'C4517845', 'cui_str': '660'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0011880', 'cui_str': 'Diabetic ketoacidosis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",,0.408283,"The effect of dapagliflozin on the primary outcome was consistent ( P for interaction = 0.19) in normoglycemia (hazard ratio [HR] 0.62 [95% CI 0.39, 1.01]), prediabetes (HR 0.37 [0.21, 0.66]), and type 2 diabetes (HR 0.64 [0.52, 0.79]).","[{'ForeName': 'Frederik', 'Initials': 'F', 'LastName': 'Persson', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark frederik.persson@regionh.dk.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rossing', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Priya', 'Initials': 'P', 'LastName': 'Vart', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Chertow', 'Affiliation': 'Departments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA.'}, {'ForeName': 'Fan Fan', 'Initials': 'FF', 'LastName': 'Hou', 'Affiliation': 'Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, Guangzhou, China.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Jongs', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, U.K.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Correa-Rotter', 'Affiliation': 'National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico.'}, {'ForeName': 'Harpreet S', 'Initials': 'HS', 'LastName': 'Bajaj', 'Affiliation': 'LMC Diabetes and Endocrinology, Brampton, Ontario, Canada.'}, {'ForeName': 'Bergur V', 'Initials': 'BV', 'LastName': 'Stefansson', 'Affiliation': 'Late-stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Toto', 'Affiliation': 'Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Anna Maria', 'Initials': 'AM', 'LastName': 'Langkilde', 'Affiliation': 'Late-stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Wheeler', 'Affiliation': 'Department of Renal Medicine, University College London, London, U.K.'}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc21-0300'] 1428,34182189,Management of pregnancies with suspected preeclampsia based on 6-hour vs 24-hour urine protein collection-a randomized double-blind controlled pilot trial.,"BACKGROUND Traditionally, the diagnosis of preeclampsia requires elevated blood pressure measurements and proteinuria demonstrated in a 24-hour urine collection. This prolonged urine collection is associated with patient discomfort, a delay in diagnosis, and in some cases, hospitalization for further management of outcomes. OBJECTIVE We aimed to assess the feasibility, reliability, and association between maternal and neonatal outcomes of pregnancies managed according to a 6-hour vs 24-hour urine protein collection for suspected preeclampsia. STUDY DESIGN This was a randomized controlled trial conducted at a tertiary university hospital between January 2019 and January 2021 (ClinicalTrials.gov Identifier: NCT03724786). Patients who were hospitalized for preeclampsia workup were asked to participate and randomized at a 1:1 ratio to 6- and 24-hour urine protein collection groups. Both groups collected urine for 24 hours, during which the collection was also tested after 6-hours. After 24 hours, both results were reviewed by one of the research staff, and either the 6- or 24-hour collection result was reported to the patient's managing physician and was documented in the patient's medical record. Both patient and the managing physician were blinded to group allocation. Unblinding was undertaken in cases of a discrepancy between the results (1 of 2 results of >300 mg protein), and the results were analyzed by intention to treat. The primary study outcome was defined as a composite of adverse maternal outcomes. The sample size was set empirically as per proof on concept design. RESULTS During the study period, 115 patients participated in the trial, 101 of whom completed the follow-up and were analyzed-51 in the 6-hour group and 50 in the 24-hour group. Patient demographics were similar between the study groups. Unblinding occurred in 7 cases in the 6-hour group, in which the initial 6-hour result ranged from 168 to 475 mg. The rates of composite adverse maternal outcomes were 15.6% and 12.0% in the 6- and 24-hour groups, respectively (P=.59). No significant difference was demonstrated in the rate of adverse neonatal outcomes, cesarean delivery, induction of labor, gestational age at delivery, betamethasone treatment, or neonatal birthweight. CONCLUSION Managing pregnancies suspected of preeclampsia with a 6-hour urine protein collection is feasible and associated with similar maternal and neonatal outcomes. In cases where the 6-hour result is in the 168 to 475 mg range, we propose completing a 24-hour collection.",2021,"No significant difference was demonstrated in the rate of adverse neonatal outcomes, cesarean delivery, labor induction, gestational age at delivery, Betamethasone treatment or neonatal birthweight. ","['tertiary university hospital between 01/2019 and 01/2021', '115 patients participated in the trial, 101 of whom completed the follow up and were analyzed - 51 in the 6-hour group and 50 in the 24-hour group', 'Patients who were hospitalized for preeclampsia workup', 'pregnancies with suspected preeclampsia']",[],"['rate of composite adverse maternal outcome', 'rate of adverse neonatal outcomes, cesarean delivery, labor induction, gestational age at delivery, Betamethasone treatment or neonatal birthweight', 'composite of adverse maternal outcomes']","[{'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1292428', 'cui_str': '6 hours'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}]",[],"[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}]",115.0,0.314295,"No significant difference was demonstrated in the rate of adverse neonatal outcomes, cesarean delivery, labor induction, gestational age at delivery, Betamethasone treatment or neonatal birthweight. ","[{'ForeName': 'Hadas Ganer', 'Initials': 'HG', 'LastName': 'Herman', 'Affiliation': 'Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: hadassganer@yahoo.com.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Barda', 'Affiliation': 'Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Hadas', 'Initials': 'H', 'LastName': 'Miremberg', 'Affiliation': 'Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Noa', 'Initials': 'N', 'LastName': 'Gonen', 'Affiliation': 'Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Torem', 'Affiliation': 'Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Ilia', 'Initials': 'I', 'LastName': 'Kleiner', 'Affiliation': 'Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Bar', 'Affiliation': 'Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Eran', 'Initials': 'E', 'LastName': 'Weiner', 'Affiliation': 'Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}]",American journal of obstetrics & gynecology MFM,['10.1016/j.ajogmf.2021.100429'] 1429,34186232,The effects of narrative exposure therapy on COVID-19 patients with post-traumatic stress symptoms: A randomized controlled trial.,"BACKGROUND With the global attack of Coronavirus Disease 2019 (COVID-19), cases with Post-traumatic Stress Disorder (PTSD) have been increasing steadily, which seriously affects the quality of life of patients and as such, seeking effective treatments is an urgent matter. Narrative Exposure Therapy (NET) is a typical cognitive behavioral therapy targeting trauma-related psychological disorders and may be an effective intervention. METHODS A total of 111 COVID-19 patients near the discharge stage with positive screening results for posttraumatic stress symptoms (PTSS) were randomly assigned (1:1) to either the study group or the control group. The study group received NET and personalized psychological intervention, while the control group only received personalized psychological intervention. PTSS, depression, anxiety and sleep quality were measured pre- and post-intervention to evaluate the effect of NET. This trial was registered with the International Standard Randomized Clinical Trial Registry (No. ChiCTR2000039369). RESULTS NET participants showed a significantly greater PTSS reduction in comparison with the control group after the intervention. Improvement in sleep quality, anxiety and depression after the intervention were pronounced but not significantly different between the two treatment groups. LIMITATIONS The assessors weren't blinded for the convenience of measurement and protection of participants' psychological security. CONCLUSIONS NET likely had a positive impact on PTSS of COVID-19 patients. Clinical staff should consider applying NET to improve the psychological well-being of patients who have experienced an epidemic such as COVID-19.",2021,"Improvement in sleep quality, anxiety and depression after the intervention were pronounced but not significantly different between the two treatment groups. ","['111 COVID-19 patients near the discharge stage with positive screening results for posttraumatic stress symptoms (PTSS', 'cases with Post-traumatic Stress Disorder (PTSD', 'COVID-19 patients with post-traumatic stress symptoms']","['Narrative Exposure Therapy (NET', 'narrative exposure therapy', 'NET and personalized psychological intervention, while the control group only received personalized psychological intervention']","['sleep quality, anxiety and depression', 'PTSS, depression, anxiety and sleep quality', 'PTSS reduction']","[{'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",111.0,0.0845712,"Improvement in sleep quality, anxiety and depression after the intervention were pronounced but not significantly different between the two treatment groups. ","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': ""Bachelor of Nursing, Wuhan University School of Health Sciences, Xiangzhou District People's Hospital in Hubei Province, China.""}, {'ForeName': 'Yuxin', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Bachelor of Nursing, Wuhan University School of Health Sciences, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Associate Professor, Wuhan University School of Health Sciences, China. Electronic address: junz@whu.edu.cn.'}, {'ForeName': 'Dingwen', 'Initials': 'D', 'LastName': 'Sun', 'Affiliation': ""Associate chief physician, Vice President of Xiangzhou District People's Hospital, Xiangyang city, Hubei Province, China.""}, {'ForeName': 'Xuefei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Bachelor of Nursing; Wuhan University School of Health Sciences, Xiangyang Central Hospital in Hubei Province, China.'}, {'ForeName': 'Gaizhi', 'Initials': 'G', 'LastName': 'Fu', 'Affiliation': ""Associate professor of nursing, Director of psychological Outpatient Department, Xiangzhou District People's Hospital, Xiangyang city, Hubei Province, China.""}, {'ForeName': 'Daorong', 'Initials': 'D', 'LastName': 'Mo', 'Affiliation': ""Associate professor of nursing; Xiangzhou District People's Hospital, Xiangyang city, Hubei Province, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Wen', 'Affiliation': ""Associate professor of nursing, Xiangzhou District People's Hospital, Xiangyang city, Hubei Province, China.""}, {'ForeName': 'Xuexia', 'Initials': 'X', 'LastName': 'Xiao', 'Affiliation': 'Associate professor of nursing, Xiangyang Hospital of Traditional Chinese Medicine in Hubei Province, China.'}, {'ForeName': 'Lingai', 'Initials': 'L', 'LastName': 'Kong', 'Affiliation': 'Bachelor of Public health, Wuhan University School of Health Sciences, China.'}]",Journal of affective disorders,['10.1016/j.jad.2021.06.019'] 1430,34191104,Letter to the editor: The extended pessary interval for care (EPIC) study: a failed randomized clinical trial.,,2021,,[],[],[],[],[],[],,0.364703,,"[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Azarkish', 'Affiliation': 'Tropical and Communicable Diseases Research Center, Department of Midwifery, Iranshahr University of Medical Sciences, Iranshahr, Iran.'}, {'ForeName': 'Roksana', 'Initials': 'R', 'LastName': 'Janghorban', 'Affiliation': 'Department of Midwifery, School of Nursing and Midwifery, Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Janghorban@sums.ac.ir.'}]",International urogynecology journal,['10.1007/s00192-021-04895-8'] 1431,33984593,Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.,"BACKGROUND Hepatocellular carcinoma (HCC) is a common malignant tumor with limited treatment options. Conventional antitumor therapy combined with traditional Chinese medicine (TCM) to limit tumor progression has gradually become the focus of complementary and alternative therapies for HCC treatment. The Fuzheng Jiedu Xiaoji formulation (FZJDXJ) alleviates the clinical symptoms of patients and inhibits tumor progression, but its curative effect still requires extensive clinical research and mechanistic analysis. PURPOSE To explore the effectiveness of FZJDXJ in HCC patients and investigate its biological function and mechanism underlying anticancer therapy. METHODS This randomized controlled clinical trial enrolled 291 HCC patients receiving transcatheter arterial chemoembolization (TACE) therapy; patients received either FZJDXJ combined with standard treatment, or standard treatment alone, for 48 weeks. Statistical analyses were performed according to survival time at the end of the trial. The main constituents of the FZJDXJ extracts were identified and evaluated using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) and molecular docking. The antitumor effects of FZJDXJ and its specific biological mechanism of action were studied. RESULTS After 48 weeks of treatment, one-year overall survival (OS) and progression-free survival (PFS) were significantly different between the two groups. Co-administration of FZJDXJ and TACE prolonged the OS of HCC patients, especially in BCLC A or B stage. FZJDXJ and TACE treatment effectively extended the PFS of patients, especially in the BCLC B stage. HPLC-MS/MS identified 1619 active constituents of FZJDXJ, including formononetin, chlorogenic acid (CGA), caffeic acid, luteolin, gallic acid, diosgenin, ergosterol endoperoxide, and lupeol, which may function through the AKT/CyclinD1/p21/p27 pathways. Through molecular docking, CGA and gallic acid could effectively combine with Thr308, an important phosphorylation site of AKT1. FZJDXJ inhibited tumor growth in nude mice. In vitro, FZJDXJ-mediated serum inhibited the proliferation, migration, and invasion of liver cancer cells, and promoted cell apoptosis. CONCLUSION Clinically, FZJDXJ combined with TACE therapy significantly prolonged OS and PFS and reduced the mortality rate of HCC patients. Mechanistically, FZJDXJ effectively inhibited the proliferation and migration of liver cancer cells through the modulation of the AKT/CyclinD1/p21/p27 pathways, and may be a promising TCM drug for anti-HCC therapy.",2021,"Clinically, FZJDXJ combined with TACE therapy significantly prolonged OS and PFS and reduced the mortality rate of HCC patients.","['HCC patients', '291 HCC patients receiving']","['Conventional antitumor therapy combined with traditional Chinese medicine (TCM', 'FZJDXJ and TACE', 'FZJDXJ', 'transcatheter arterial chemoembolization (TACE) therapy', 'FZJDXJ combined with standard treatment, or standard treatment alone', 'Fuzheng Jiedu Xiaoji formulation (FZJDXJ', 'FZJDXJ combined with TACE therapy', 'Fuzheng Jiedu Xiaoji formulation']","['overall survival (OS) and progression-free survival (PFS', 'hepatocellular carcinoma progression', 'proliferation and migration of liver cancer cells', 'proliferation, migration, and invasion of liver cancer cells', 'mortality rate', 'survival time', 'prolonged OS and PFS', 'formononetin, chlorogenic acid (CGA), caffeic acid, luteolin, gallic acid, diosgenin, ergosterol endoperoxide, and lupeol']","[{'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C2711393', 'cui_str': 'Transarterial chemoembolization of hepatic artery'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C2605428', 'cui_str': 'fuzheng jiedu'}, {'cui': 'C4044186', 'cui_str': 'xiaoji'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0334094', 'cui_str': 'Proliferation'}, {'cui': 'C0237731', 'cui_str': 'Human Migration'}, {'cui': 'C0345904', 'cui_str': 'Malignant neoplasm of liver'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C1269955', 'cui_str': 'Tumour invasion'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0060656', 'cui_str': 'formononetin'}, {'cui': 'C0008240', 'cui_str': 'Chlorogenic acid'}, {'cui': 'C0054433', 'cui_str': 'caffeic acid'}, {'cui': 'C0065264', 'cui_str': ""3',4',5,7-Tetrahydroxyflavone""}, {'cui': 'C0016979', 'cui_str': 'Gallic acid'}, {'cui': 'C0012497', 'cui_str': 'Diosgenin'}, {'cui': 'C0059520', 'cui_str': 'ergosterol-5,8-peroxide'}, {'cui': 'C0065254', 'cui_str': 'lupeol'}]",291.0,0.0726142,"Clinically, FZJDXJ combined with TACE therapy significantly prolonged OS and PFS and reduced the mortality rate of HCC patients.","[{'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Feng', 'Affiliation': 'Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xieqiong', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': 'Department of Infectious Diseases, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China.'}, {'ForeName': 'Xiaomin', 'Initials': 'X', 'LastName': 'Ji', 'Affiliation': 'Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Le', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Fangyuan', 'Initials': 'F', 'LastName': 'Gao', 'Affiliation': 'Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yuxin', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Bingbing', 'Initials': 'B', 'LastName': 'Zhu', 'Affiliation': 'Department of Gastroenterology, The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'XianBo', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Electronic address: wangxb@ccmu.edu.cn.'}]",Phytomedicine : international journal of phytotherapy and phytopharmacology,['10.1016/j.phymed.2021.153575'] 1432,34193436,"Preventive Care in Type 2 Diabetes: Results of a Randomized, Controlled Trial in Community Pharmacies.",,2021,,['Type 2 Diabetes'],[],[],"[{'cui': 'C0441730', 'cui_str': 'Type 2'}]",[],[],,0.370921,,"[{'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Prax', 'Affiliation': 'Molecular & Clinical Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Schmiedel', 'Affiliation': 'Kur-Apotheke, Bad Windsheim, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Hepp', 'Affiliation': 'Institute of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Helmut', 'Initials': 'H', 'LastName': 'Schlager', 'Affiliation': 'Scientific Institute for Prevention in Health Care, Munich, Germany.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Friedland', 'Affiliation': 'Molecular & Clinical Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany kfriedla@uni-mainz.de.'}]",Diabetes care,['10.2337/dc20-2319'] 1433,34157632,"Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.","OBJECTIVE Intravenous ferric carboxymaltose (FCM) has been shown to be efficacious in treating restless legs syndrome (RLS) symptoms in non-anemic patients. The aim of this study was to evaluate the effectiveness of FCM in treating RLS symptoms in patients who also had an iron deficiency anemia (IDA). METHODS This is a randomized, double-blinded, placebo-controlled study. Subjects with RLS and IDA were enrolled. Subjects received an infusion of either 1500 mg FCM or placebo in Phase I. The primary outcomes were a change-from-baseline at week six on the International Restless Legs Syndrome Study Group scale (IRLS). Phase II of the study involved long-term (52 weeks) follow-up, for those who responded to treatment in the prior phase, with the potential for further treatment if symptoms returned. RESULTS We enrolled 29 RLS patients with IDA (15 FCM and 14 placebo). At week six post-infusion, FCM compared to placebo group showed significant improvement from baseline in IRLS score (-13.47 ± 7.38 vs. 1.36 ± 3.59). Among secondary outcome variables, quality of sleep showed significant improvement from baseline in the FCM group. 61% of subjects remained off RLS medications at the Phase II, week-52 endpoint. There were no serious adverse events observed in the study. CONCLUSION The study showed significant efficacy and safety of FCM 1500 mg treatment both in the short term (6 weeks) and long term (52 weeks) in RLS patients with IDA.",2021,The primary outcomes were a change-from-baseline at week six on the International Restless Legs Syndrome Study Group scale (IRLS).,"['restless legs syndrome patients with iron deficiency anemia', 'Subjects with RLS and IDA were enrolled', 'patients who also had an iron deficiency anemia (IDA', 'RLS patients with IDA', '29 RLS patients with IDA (15 FCM and 14 placebo']","['FCM', 'ferric carboxymaltose', 'FCM or placebo', 'placebo', 'ferric carboxymaltose (FCM']","['efficacy and safety', 'IRLS score', 'quality of sleep', 'serious adverse events', 'change-from-baseline at week six on the International Restless Legs Syndrome Study Group scale (IRLS']","[{'cui': 'C0035258', 'cui_str': 'Restless legs'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}, {'cui': 'C2001867', 'cui_str': 'ferric carboxymaltose'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2001867', 'cui_str': 'ferric carboxymaltose'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035258', 'cui_str': 'Restless legs'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439230', 'cui_str': 'week'}]",29.0,0.290396,The primary outcomes were a change-from-baseline at week six on the International Restless Legs Syndrome Study Group scale (IRLS).,"[{'ForeName': 'Hyoeun', 'Initials': 'H', 'LastName': 'Bae', 'Affiliation': 'Department of Neurology, Keimyung University School of Medicine, Daegu, South Korea.'}, {'ForeName': 'Yong Won', 'Initials': 'YW', 'LastName': 'Cho', 'Affiliation': 'Department of Neurology, Keimyung University School of Medicine, Daegu, South Korea. Electronic address: neurocho@gmail.com.'}, {'ForeName': 'Keun Tae', 'Initials': 'KT', 'LastName': 'Kim', 'Affiliation': 'Department of Neurology, Keimyung University School of Medicine, Daegu, South Korea.'}, {'ForeName': 'Richard P', 'Initials': 'RP', 'LastName': 'Allen', 'Affiliation': 'Department of Neurology, Johns Hopkins University, Hopkins Bayview Medical Center, Baltimore, MD, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Earley', 'Affiliation': 'Department of Neurology, Johns Hopkins University, Hopkins Bayview Medical Center, Baltimore, MD, USA.'}]",Sleep medicine,['10.1016/j.sleep.2021.05.036'] 1434,34157617,Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial.,"AIM This is the first randomised study to evaluate toxicity and survival outcomes of two neoadjuvant chemoradiotherapy (CRT) regimens for patients with localised oesophageal adenocarcinoma (OAC) or gastro-oesophageal junction (GOJ) adenocarcinoma. The initial results showed comparable toxicity between regimens and pathological complete response (pCR) rate favouring CarPacRT. Herein, we report survival, progression patterns, and long-term toxicity after a median follow-up of 40.7 months. METHODS NeoSCOPE was an open-label, UK multicentre, randomised, phase II trial. Eighty-five patients with resectable OAC or GOJ adenocarcinoma, ≥cT3 and/or ≥cN1 (TNM v7), suitable for neoadjuvant CRT, were recruited between October 2013 and February 2015. Patients were randomised to OxCapRT (oxaliplatin 85 mg/m 2 on Days 1, 15, and 29; capecitabine 625 mg/m 2 orally twice daily on days of radiotherapy [RT]) or CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m 2 on Days 1, 8, 15, 22, and 29). RT dose was 45 Gy/25 fractions/5 weeks. Both arms received induction chemotherapy (two cycles oxaliplatin 130 mg/m 2 on Day 1, capecitabine 625 mg/m 2 orally twice daily on Days 1-21) before CRT. Surgery was performed 6-8 weeks after CRT. The primary end-point was pCR. Secondary end-points were toxicity, progression-free survival (PFS), overall survival (OS), and patterns of progression. RESULTS Eighty-five patients were recruited from 17 UK centres. The median OS was 41.7 months (95% confidence interval [CI] 19.6 to not reached) in the OxCapRT arm and was not reached in the CarPacRT arm (multivariable hazard ratio [HR] = 0.48, 95% CIs: 0.24-0.95, P = 0.035). The median PFS was 32.6 months (95% CIs: 17.1 to not reached) in the OxCapRT arm and was not reached in the CarPacRT arm (multivariable HR = 0.54, 95% CIs: 0.29-1.01, P = 0.053). In both arms, the distant progression was twice as common as locoregional progression. CONCLUSIONS OS and PFS favoured neoadjuvant CarPacRT over OxCapRT. Distant was more common than locoregional progression; therefore, priority should be given to optimising the systemic treatment component. CLINICAL TRIAL INFORMATION EudraCT Number: 2012-000640-10; ClinicalTrials.gov: NCT01843829.",2021,"The median OS was 41.7 months (95% confidence interval [CI] 19.6 to not reached) in the OxCapRT arm and was not reached in the CarPacRT arm (multivariable hazard ratio [HR] = 0.48, 95% CIs:","['resectable oesophageal adenocarcinoma (NeoSCOPE', 'EudraCT Number: 2012-000640-10', 'Eighty-five patients with resectable OAC or GOJ adenocarcinoma, ≥cT3 and/or ≥cN1 (TNM v7), suitable for neoadjuvant CRT, were recruited between October 2013 and February 2015', 'Eighty-five patients were recruited from 17 UK centres', 'patients with localised oesophageal adenocarcinoma (OAC) or gastro-oesophageal junction (GOJ) adenocarcinoma']","['capecitabine 625', 'NeoSCOPE', 'radiotherapy [RT]) or CarPacRT (carboplatin AUC2', 'oxaliplatin', 'OxCapRT', 'induction chemotherapy (two cycles oxaliplatin 130', 'Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation', 'neoadjuvant chemoradiotherapy (CRT', ' paclitaxel']","['toxicity between regimens and pathological complete response (pCR) rate favouring CarPacRT', 'toxicity and survival outcomes', 'toxicity, progression-free survival (PFS), overall survival (OS), and patterns of progression', 'survival, progression patterns, and long-term toxicity', 'median PFS', 'median OS']","[{'cui': 'C0279628', 'cui_str': 'Adenocarcinoma of esophagus'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}, {'cui': 'C0039694', 'cui_str': 'Tetranitromethane'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C4517838', 'cui_str': '625'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C3179010', 'cui_str': 'Induction chemotherapy'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",85.0,0.363415,"The median OS was 41.7 months (95% confidence interval [CI] 19.6 to not reached) in the OxCapRT arm and was not reached in the CarPacRT arm (multivariable hazard ratio [HR] = 0.48, 95% CIs:","[{'ForeName': 'Somnath', 'Initials': 'S', 'LastName': 'Mukherjee', 'Affiliation': 'Oxford Institute for Radiation Oncology, Oxford University, Oxford, OX3 7DQ, UK; Department of Oncology, Oxford University Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Hurt', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, CF14 4YS, UK. Electronic address: hurtcn@cardiff.ac.uk.'}, {'ForeName': 'Ganesh', 'Initials': 'G', 'LastName': 'Radhakrishna', 'Affiliation': 'Christie Hospital, Christie NHS Foundation Trust, Manchester, M20 4BX, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Gwynne', 'Affiliation': 'South West Wales Cancer Centre, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Bateman', 'Affiliation': 'Clinical Oncology, University Hospital Southampton, Southampton, SO16 6YD, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Gollins', 'Affiliation': 'North Wales Cancer Treatment Centre, Betsi Cadwaladr University Health Board, Rhyl, LL18 5UJ, UK.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Hawkins', 'Affiliation': 'Cancer Institute, University College London, London, WC1E 6DD, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Canham', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, CF14 4YS, UK.'}, {'ForeName': 'Heike I', 'Initials': 'HI', 'LastName': 'Grabsch', 'Affiliation': 'Department of Pathology, Maastricht University Medical Center, Maastricht, the Netherlands; Leeds Institute of Medical Research, University of Leeds, Leeds, LS9 7TF, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Falk', 'Affiliation': 'Bristol Haematology and Oncology Centre, University Hospitals Bristol, Bristol, BS2 8ED, UK.'}, {'ForeName': 'Ricky A', 'Initials': 'RA', 'LastName': 'Sharma', 'Affiliation': 'Cancer Institute, University College London, London, WC1E 6DD, UK.'}, {'ForeName': 'Ruby', 'Initials': 'R', 'LastName': 'Ray', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, CF14 4YS, UK.'}, {'ForeName': 'Rajarshi', 'Initials': 'R', 'LastName': 'Roy', 'Affiliation': 'Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust, Hull, HU16 5JQ, UK.'}, {'ForeName': 'Catrin', 'Initials': 'C', 'LastName': 'Cox', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, CF14 4YS, UK.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Maynard', 'Affiliation': 'Department of Oncology, Oxford University Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.'}, {'ForeName': 'Lisette', 'Initials': 'L', 'LastName': 'Nixon', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, CF14 4YS, UK.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Sebag-Montefiore', 'Affiliation': 'Leeds Institute of Medical Research, University of Leeds, Leeds, LS9 7TF, UK.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Maughan', 'Affiliation': 'Oxford Institute for Radiation Oncology, Oxford University, Oxford, OX3 7DQ, UK.'}, {'ForeName': 'Gareth O', 'Initials': 'GO', 'LastName': 'Griffiths', 'Affiliation': 'Southampton Clinical Trials Unit, University of Southampton, Southampton, SO16 6YD, UK.'}, {'ForeName': 'Tom D L', 'Initials': 'TDL', 'LastName': 'Crosby', 'Affiliation': 'Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, CF14 2TL, UK.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.05.020'] 1435,34160184,Personalized Behavioral Nutrition Among Older Asian Americans: Study Protocol.,"BACKGROUND Metabolomics profiling is an objective assessment of metabolic responses to intricate dietary patterns. However, few studies have investigated the potential benefits associated with personalized behavioral nutrition (PBN) interventions incorporating the metabolomics approach for improving diabetes outcomes for older Asian Americans with Type 2 diabetes. OBJECTIVE This article describes the protocol for a pilot study testing self-management of a nutrition intervention-provided personalized dietary advice incorporating metabolites phenotypic feedback and digital self-monitoring of diet and blood glucose. METHODS A total of 60 older Asian Americans will be randomized into two groups: a PBN group and a control group. Participants in the PBN group will receive personalized dietary advice based on dietary and phenotypic feedback-used metabolic profiles. This study aims to examine the feasibility and preliminary effects of the PBN on diabetes outcomes. RESULTS The study began in September 2020, with estimated complete data collection by late 2021. DISCUSSION Findings from this pilot study will inform future research for developing personalized nutrition interventions for people with Type 2 diabetes.",2021,"OBJECTIVE This article describes the protocol for a pilot study testing self-management of a nutrition intervention-provided personalized dietary advice incorporating metabolites phenotypic feedback and digital self-monitoring of diet and blood glucose. ","['September 2020, with estimated complete data collection by late 2021', 'older Asian Americans with Type 2 diabetes', '60 older Asian Americans', 'people with Type 2 diabetes', 'Older Asian Americans']","['Personalized Behavioral Nutrition', 'personalized behavioral nutrition (PBN) interventions', 'PBN', 'nutrition intervention-provided personalized dietary advice incorporating metabolites phenotypic feedback and digital self-monitoring of diet and blood glucose', 'personalized dietary advice based on dietary and phenotypic feedback-used metabolic profiles']",[],"[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0003988', 'cui_str': 'Asian Americans'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}]",[],60.0,0.0374153,"OBJECTIVE This article describes the protocol for a pilot study testing self-management of a nutrition intervention-provided personalized dietary advice incorporating metabolites phenotypic feedback and digital self-monitoring of diet and blood glucose. ","[{'ForeName': 'Jisook', 'Initials': 'J', 'LastName': 'Ko', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Du', 'Affiliation': ''}, {'ForeName': 'Rozmin', 'Initials': 'R', 'LastName': 'Jiwani', 'Affiliation': ''}, {'ForeName': 'Chengdong', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': ''}]",Nursing research,['10.1097/NNR.0000000000000514'] 1436,34160182,Effect of Nurse Practitioner Interventions on Hospitalizations in the Community Transitions Intervention Trial.,"BACKGROUND Despite improvements in hypertension treatment in the United States, Black and Hispanic individuals experience poor blood pressure control and have worse hypertension-related outcomes compared to Whites. OBJECTIVE The aim of the study was to determine the effect on hospitalization of supplementing usual home care (UHC) with two hypertension-focused transitional care interventions-one deploying nurse practitioners (NPs) and the other NPs plus health coaches. METHODS We examined post hoc the effect of two hypertension-focused NP interventions on hospitalizations in the Community Transitions Intervention trial-a three-arm, randomized controlled trial comparing the effectiveness of (a) UHC with (b) UHC plus a 30-day NP transitional care intervention or (c) UHC plus NP plus 60-day health coach intervention. RESULTS The study comprised 495 participants: mean age = 66 years; 57% female; 70% Black, non-Hispanic; 30% Hispanic. At the 3- and 12-month follow-up, all three groups showed a significant decrease in the average number of hospitalizations compared to baseline. The interventions were not significantly different from UHC. CONCLUSION The results of this post hoc analysis show that, during the study period, decreases in hospitalizations in the intervention groups were comparable to those in UHC, and deploying NPs provided no detectable value added. Future research should focus on testing ways to optimize UHC services.",2021,"At the 3- and 12-month follow-up, all three groups showed a significant decrease in the average number of hospitalizations compared to baseline.","['495 participants: mean age = 66 years; 57% female; 70% Black, non-Hispanic; 30% Hispanic']","['supplementing usual home care (UHC) with two hypertension-focused transitional care interventions-one deploying nurse practitioners (NPs', 'Nurse Practitioner Interventions', 'UHC with (b) UHC plus a 30-day NP transitional care intervention or (c) UHC plus NP plus 60-day health coach intervention', 'two hypertension-focused NP interventions']","['hospitalizations', 'average number of hospitalizations']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0204977', 'cui_str': 'Home care of patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0028657', 'cui_str': 'Nurse practitioner'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2317129', 'cui_str': 'Health coach'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",495.0,0.0425516,"At the 3- and 12-month follow-up, all three groups showed a significant decrease in the average number of hospitalizations compared to baseline.","[{'ForeName': 'Zainab Toteh', 'Initials': 'ZT', 'LastName': 'Osakwe', 'Affiliation': ''}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Barrón', 'Affiliation': ''}, {'ForeName': 'Margaret V', 'Initials': 'MV', 'LastName': 'McDonald', 'Affiliation': ''}, {'ForeName': 'Penny H', 'Initials': 'PH', 'LastName': 'Feldman', 'Affiliation': ''}]",Nursing research,['10.1097/NNR.0000000000000508'] 1437,34163157,Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.,"Background A pre-specified meta-analysis of individual patient data from the 52-week METREX and METREO trials, which investigated mepolizumab for chronic obstructive pulmonary disease (COPD) in patients with blood eosinophil counts ≥150 cells/µL (screening) or ≥300 cells/µL (prior year) and frequent exacerbations, enables more robust characterization of mepolizumab efficacy in COPD and exploration of the relationship between blood eosinophil count and treatment responses. Methods In METREX (117106/NCT02105948) and METREO (117113/NCT02105961), randomized patients received mepolizumab or placebo added to existing inhaled corticosteroid (ICS)-based triple maintenance therapy. The annual rate of moderate/severe exacerbations (primary endpoint) was compared between subcutaneous (SC) mepolizumab 100 mg versus placebo (primary comparison of interest) and all doses (100 mg and 300 mg SC) versus placebo in patients with blood eosinophil counts ≥150 cells/µL at screening or ≥300 cells/µL in the prior year. Secondary/other endpoints included time to first moderate/severe exacerbation, exacerbations leading to emergency department visit/hospitalization and health-related quality of life (HRQoL). A predictive model of the relationship between screening blood eosinophil counts and exacerbation rates included data from all randomized patients. Results In total, 1510 patients were randomized in METREX and METREO and 1136 patients were included in the pre-specified meta-analysis. From the meta-analysis, mepolizumab 100 mg SC significantly reduced annual moderate/severe exacerbation rates versus placebo by 18% (rate ratio: 0.82; 95% confidence interval: 0.71, 0.95; p=0.006) and delayed time to first moderate/severe exacerbation (hazard ratio: 0.80 [0.68, 0.94]; p=0.006). Mepolizumab 100 mg SC versus placebo numerically reduced exacerbations leading to ED visits/hospitalization and improved HRQoL. A modelling approach demonstrated increasing efficacy for moderate/severe exacerbations with increasing screening blood eosinophil count; this relationship was more pronounced for exacerbations requiring oral corticosteroids (post hoc). The all-doses comparison had similar results. Conclusion Mepolizumab reduces exacerbations in patients with eosinophil-associated COPD. Results suggest that blood eosinophil counts (≥150 cells/µL at screening or ≥300 cells/µL in the prior year) allow for identification of patients with COPD who experience exacerbations while treated with maximal ICS-based triple maintenance therapy who are likely to benefit from mepolizumab.",2021,Mepolizumab 100 mg SC versus placebo numerically reduced exacerbations leading to ED visits/hospitalization and improved HRQoL. A modelling approach demonstrated increasing efficacy for moderate/severe exacerbations with increasing screening blood eosinophil count; this relationship was more pronounced for exacerbations requiring oral corticosteroids (post hoc).,"['patients with eosinophil-associated COPD', '1510 patients were randomized in METREX and METREO and 1136 patients were included in the pre-specified meta-analysis', 'chronic obstructive pulmonary disease (COPD) in patients with blood eosinophil counts ≥150 cells/µL (screening) or ≥300 cells/µL (prior year) and frequent exacerbations', 'patients with blood eosinophil counts ≥150 cells/µL at screening or ≥300 cells/µL in the prior year']","['mepolizumab or placebo added to existing inhaled corticosteroid (ICS)-based triple maintenance therapy', 'maximal ICS-based triple maintenance therapy', 'Mepolizumab', 'mepolizumab', 'placebo', 'subcutaneous (SC) mepolizumab 100 mg versus placebo']","['time to first moderate/severe exacerbation, exacerbations leading to emergency department visit/hospitalization and health-related quality of life (HRQoL', 'annual moderate/severe exacerbation rates', 'annual rate of moderate/severe exacerbations', 'delayed time to first moderate/severe exacerbation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C5191065', 'cui_str': '1136'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0282458', 'cui_str': 'Meta-Analysis'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0969324', 'cui_str': 'mepolizumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C4058343', 'cui_str': 'mepolizumab 100 MG'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0522486', 'cui_str': 'Delay time'}]",1510.0,0.292265,Mepolizumab 100 mg SC versus placebo numerically reduced exacerbations leading to ED visits/hospitalization and improved HRQoL. A modelling approach demonstrated increasing efficacy for moderate/severe exacerbations with increasing screening blood eosinophil count; this relationship was more pronounced for exacerbations requiring oral corticosteroids (post hoc).,"[{'ForeName': 'Ian D', 'Initials': 'ID', 'LastName': 'Pavord', 'Affiliation': 'Nuffield Department of Medicine and Oxford Respiratory NIHR BRC, University of Oxford, Oxford, UK.'}, {'ForeName': 'Kenneth R', 'Initials': 'KR', 'LastName': 'Chapman', 'Affiliation': 'Asthma & Airway Centre, UHN and University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Bafadhel', 'Affiliation': 'Nuffield Department of Medicine and Oxford Respiratory NIHR BRC, University of Oxford, Oxford, UK.'}, {'ForeName': 'Frank C', 'Initials': 'FC', 'LastName': 'Sciurba', 'Affiliation': 'Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Eric S', 'Initials': 'ES', 'LastName': 'Bradford', 'Affiliation': 'Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Schweiker Harris', 'Affiliation': 'Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.'}, {'ForeName': 'Bhabita', 'Initials': 'B', 'LastName': 'Mayer', 'Affiliation': 'Clinical Statistics, GSK, Brentford, Middlesex, UK.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Rubin', 'Affiliation': 'Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.'}, {'ForeName': 'Steven W', 'Initials': 'SW', 'LastName': 'Yancey', 'Affiliation': 'Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.'}, {'ForeName': 'Pierluigi', 'Initials': 'P', 'LastName': 'Paggiaro', 'Affiliation': 'Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy.'}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S294333'] 1438,34161616,Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.,"Eliglustat, an oral substrate reduction therapy, is approved for eligible adults with Gaucher disease type 1. In the Phase 3 ENGAGE trial of previously untreated adults with Gaucher disease type 1, eliglustat-treated patients had statistically significant improvements in organ volumes and hematologic parameters compared with placebo in the 9-month primary analysis. We report final outcomes by time on eliglustat among all patients who participated in the ENGAGE trial and extension. No patient deteriorated clinically or withdrew due to adverse events; 39/40 patients entered the open-label extension period and 34/40 (85%) remained in the trial until completion or switching to commercial eliglustat after its approval (2.3-6 years). Clinically meaningful improvements in Gaucher disease manifestations were seen in all patients concomitant with reductions in pathological lipid substrate levels (glucosylceramide and glucosylsphingosine). Among patients with 4.5 years of eliglustat exposure, mean spleen volume decreased by 66% (from 17.1 to 5.8 multiples of normal [MN], n = 13), mean liver volume decreased by 23% (from 1.5 to 1.1 MN, n = 13), mean hemoglobin increased 1.4 g/dl (from 11.9 to 13.4 g/dl, n = 12), mean platelet count increased by 87% (from 67.6 to 122.6 × 10 9 /L, n = 12), median chitotriosidase decreased by 82% (from 13 394 to 2312 nmol/h/ml, n = 11), median glucosylceramide decreased by 79% (from 11.5 to 2.4 μg/ml, n = 11), median glucosylsphingosine decreased by 84% (from 518.5 to 72.1 ng/ml, n = 10), and mean spine T-score increased from -1.07 (osteopenia) to -0.53 (normal) (n = 9). The magnitude of improvement in Gaucher disease manifestations and biomarkers over time was similar among the full trial cohort. Eliglustat was well-tolerated and led to clinically significant improvements in previously untreated patients with Gaucher disease type 1 during 4.5 years of treatment.",2021,No patient deteriorated clinically or withdrew due to adverse events; 39/40 patients entered the open-label extension period and 34/40 (85%) remained in the trial until completion or switching to commercial eliglustat after its approval (2.3 to 6 years).,"['patients who participated in the ENGAGE trial and extension', 'eligible adults with Gaucher disease type 1']","['oral substrate reduction therapy', 'Eliglustat Therapy', 'placebo']","['organ volumes and hematologic parameters', 'n=13)mean liver volume', 'median chitotriosidase', 'mean spleen volume', 'mean spine T-score', 'mean platelet count', 'median glucosylsphingosine', 'Gaucher manifestations and disease biomarkers', 'pathological lipid substrate levels (glucosylceramide and glucosylsphingosine', 'mean hemoglobin', 'median glucosylceramide']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1961835', 'cui_str': ""Gaucher's disease type I""}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3272698', 'cui_str': 'eliglustat'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1565449', 'cui_str': 'Organ Volume'}, {'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0008145', 'cui_str': 'Chitinase'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037993', 'cui_str': 'Splenic structure'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0074996', 'cui_str': 'sphingosyl beta-glucoside'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017770', 'cui_str': 'Glucocerebroside'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",,0.059389,No patient deteriorated clinically or withdrew due to adverse events; 39/40 patients entered the open-label extension period and 34/40 (85%) remained in the trial until completion or switching to commercial eliglustat after its approval (2.3 to 6 years).,"[{'ForeName': 'Pramod K', 'Initials': 'PK', 'LastName': 'Mistry', 'Affiliation': 'Yale University School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Lukina', 'Affiliation': 'National Research Center for Hematology, Moscow, Russia.'}, {'ForeName': 'Hadhami', 'Initials': 'H', 'LastName': 'Ben Turkia', 'Affiliation': 'Hôpital La Rabta, Tunis, Tunisia.'}, {'ForeName': 'Suma P', 'Initials': 'SP', 'LastName': 'Shankar', 'Affiliation': 'Emory University, Atlanta, Georgia, USA.'}, {'ForeName': 'Hagit', 'Initials': 'H', 'LastName': 'Baris Feldman', 'Affiliation': 'The Genetics Institute, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Marwan', 'Initials': 'M', 'LastName': 'Ghosn', 'Affiliation': 'Hôtel-Dieu de France University Hospital, Beirut, Lebanon.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Mehta', 'Affiliation': 'The Royal Free Hospital, London, UK.'}, {'ForeName': 'Seymour', 'Initials': 'S', 'LastName': 'Packman', 'Affiliation': 'UCSF School of Medicine, San Francisco, California, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Lau', 'Affiliation': 'New York University School of Medicine, New York, New York, USA.'}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Petakov', 'Affiliation': 'Clinical Center of Serbia, Belgrade University Medical School, Belgrade, Serbia.'}, {'ForeName': 'Sarit', 'Initials': 'S', 'LastName': 'Assouline', 'Affiliation': 'Jewish General Hospital, Montreal, Quebec, Canada.'}, {'ForeName': 'Manisha', 'Initials': 'M', 'LastName': 'Balwani', 'Affiliation': 'Icahn School of Medicine at Mt. Sinai Hospital, New York, New York, USA.'}, {'ForeName': 'Sumita', 'Initials': 'S', 'LastName': 'Danda', 'Affiliation': 'Christian Medical College, Vellore, India.'}, {'ForeName': 'Evgueniy', 'Initials': 'E', 'LastName': 'Hadjiev', 'Affiliation': 'University Hospital Alexandrovska, Sofia, Bulgaria.'}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Ortega', 'Affiliation': 'OCA Hospital, Monterrey, Mexico.'}, {'ForeName': 'Meredith C', 'Initials': 'MC', 'LastName': 'Foster', 'Affiliation': 'Sanofi Genzyme, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Sebastiaan J M', 'Initials': 'SJM', 'LastName': 'Gaemers', 'Affiliation': 'Sanofi Genzyme, Amsterdam, The Netherlands.'}, {'ForeName': 'M Judith', 'Initials': 'MJ', 'LastName': 'Peterschmitt', 'Affiliation': 'Sanofi Genzyme, Cambridge, Massachusetts, USA.'}]",American journal of hematology,['10.1002/ajh.26276'] 1439,32777010,Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.,"Importance The goal of preclinical Alzheimer disease (AD) clinical trials is to move diagnosis and treatment to presymptomatic stages, which will require biomarker testing and disclosure. Objective To assess the short-term psychological outcomes of disclosing amyloid positron emission tomography results to older adults who did not have cognitive impairment. Design, Setting, and Participants This observational study included participants who were screening for a multisite randomized clinical trial that began on February 28, 2014, and is anticipated to be completed in 2022. Participants aged 65 to 85 years who had no known cognitive impairments underwent an amyloid positron emission tomography scan and learned their result from an investigator who used a protocol-specified process that included prescan education and psychological assessments. This report compares participants with elevated amyloid levels with at least 1 available outcome measure with participants who did not have elevated amyloid levels who enrolled in an observational cohort study and received further evaluations. Data were collected from April 2014 to December 2017 and analyzed from March 2019 to October 2019. Exposures A personal biomarker result described as either an elevated or not elevated amyloid level. Main Outcomes and Measures To assess the immediate and short-term psychological outcome of disclosure, the following validated measures were used: the Geriatric Depression Scale, the state items from the State-Trait Anxiety Inventory, and the Columbia Suicide Severity Rating Scale, as well as the Concerns About AD Scale and the Future Time Perspective Scale to assess changes in participants' perceived risk for AD and perceived remaining life span, respectively. Results A total of 1167 participants with elevated amyloid levels and 538 participants with not elevated amyloid levels were included. Participants had a mean (SD) age of 71.5 (4.7) years, 1025 (60.1%) were women, and most were white (1611 [94.5%]) and non-Latino (1638 [96.1%]). Compared with participants who learned that they had a not elevated amyloid result, individuals who learned of an elevated amyloid result were no more likely to experience short-term increases in depression (mean [SD] change in the Geriatric Depression Scale score, 0.02 [1.3] vs 0.04 [1.3]; P = .90), anxiety (mean [SD] change in State-Trait Anxiety Inventory score, -0.02 [3.2] vs -0.15 [3.0]; P = .65), or suicidality (mean [SD] change in the Columbia Suicide Severity Rating Scale score, 0.0 [0.4] vs -0.01 [0.5]; P = .67). Participants with elevated amyloid levels had increased Concern About AD scores (raw change in scores: elevated amyloid group, 0.8 [3.9]; not elevated amyloid group, -0.4 [3.8]; P < .001). Participants with not elevated amyloid levels experienced a slight increase in Future Time Perspective score(mean [SD] score, 1.15 [7.4] points; P < .001); there was no change in time perspective among those receiving an elevated amyloid result (mean [SD] score, 0.33 [7.8] points). Conclusions and Relevance In this observational preclinical AD study, participants who learned they had elevated amyloid levels did not experience short-term negative psychological sequelae compared with persons who learned they did not have elevated amyloid levels.",2020,"Participants with elevated amyloid levels had increased Concern About AD scores (raw change in scores: elevated amyloid group, 0.8 [3.9]; not elevated amyloid group, -0.4 [3.8]; P < .001).","['participants who were screening for a multisite randomized clinical trial that began on February 28, 2014, and is anticipated to be completed in 2022', 'Participants had a mean (SD) age of 71.5 (4.7) years, 1025 (60.1%) were women, and most were white ', 'participants with elevated amyloid levels with at least 1 available outcome measure with participants who did not have elevated amyloid levels who enrolled in an observational cohort study and received further evaluations', '1167 participants with elevated amyloid levels and 538 participants with not elevated amyloid levels were included', 'Data were collected from April 2014 to December 2017 and analyzed from March 2019 to October 2019', 'Participants aged 65 to 85 years who had no known cognitive impairments underwent an amyloid positron emission tomography scan and learned their result from an investigator who used a protocol-specified process that included prescan education and psychological assessments', 'older adults who did not have cognitive impairment']",['amyloid positron emission tomography'],"['Geriatric Depression Scale score', 'State-Trait Anxiety Inventory score', 'anxiety', 'depression', ""immediate and short-term psychological outcome of disclosure, the following validated measures were used: the Geriatric Depression Scale, the state items from the State-Trait Anxiety Inventory, and the Columbia Suicide Severity Rating Scale, as well as the Concerns About AD Scale and the Future Time Perspective Scale to assess changes in participants' perceived risk for AD and perceived remaining life span, respectively"", 'Columbia Suicide Severity Rating Scale score', 'Concern About AD scores', 'Future Time Perspective score(mean [SD] score']","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0204452', 'cui_str': 'Psychological assessment'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}]","[{'cui': 'C0451184', 'cui_str': 'Geriatric depression scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C3888485', 'cui_str': 'Columbia suicide severity rating scale'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0040226', 'cui_str': 'Time Perception'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0870809', 'cui_str': 'Lifespan'}]",1167.0,0.508404,"Participants with elevated amyloid levels had increased Concern About AD scores (raw change in scores: elevated amyloid group, 0.8 [3.9]; not elevated amyloid group, -0.4 [3.8]; P < .001).","[{'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Grill', 'Affiliation': 'Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine.'}, {'ForeName': 'Rema', 'Initials': 'R', 'LastName': 'Raman', 'Affiliation': ""Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, San Diego.""}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Ernstrom', 'Affiliation': ""Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, San Diego.""}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Sultzer', 'Affiliation': 'Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Burns', 'Affiliation': ""University of Kansas Alzheimer's Disease Center, Kansas City.""}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Donohue', 'Affiliation': ""Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, San Diego.""}, {'ForeName': 'Keith A', 'Initials': 'KA', 'LastName': 'Johnson', 'Affiliation': 'Division of Molecular Imaging and Nuclear Medicine, Department of Radiology, Massachusetts General Hospital, Boston.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Aisen', 'Affiliation': ""Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, San Diego.""}, {'ForeName': 'Reisa A', 'Initials': 'RA', 'LastName': 'Sperling', 'Affiliation': ""Harvard Medical School, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Karlawish', 'Affiliation': 'Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA neurology,['10.1001/jamaneurol.2020.2734'] 1440,34167770,"Epicardial fat tissue, coronary arterial calcification and mortality in patients with advanced chronic kidney disease and hemodialysis.","INTRODUCTION AND OBJECTIVES Epicardial and mediastinal adipose tissue (EAT, MAT) are linked to metabolic syndrome and coronary artery disease. Patients with chronic kidney disease (CKD) have thicker EAT. We assessed if EAT and MAT could be associated with increased mortality and cardiovascular events in patients with advanced CKD and haemodialysis therapy. METHODS A post-hoc study was performed. We analyzed a prospective series of 104 cases. EAT thickness was quantified by a multislice synchronized computed tomography (MSCT). RESULTS The follow-up period was 112.68 (109.94-115.42) months. The optimal cut-off point of EAT for prediction of total mortality was 11.45 mm (92.86% and 43.75%). EAT thickness was associated with serum albumin levels, serum triglyceride levels, phosphorus and calcium phosphate product. The EAT was greater in haemodialysis patients compared to those with advanced CKD (P < .001). Patients with diabetes mellitus had greater EAT and MAT thickness (P = .018). At the end of follow up, the survival average time of patients with EAT thickness <11.45 mm was 97.48 months vs. 76.65 months for thickness > 11.45 mm (P = .007). CONCLUSIONS A higher EAT and MAT thickness was associated with increased mortality. Furthermore, EAT was associated with lower free survival time to fatal and non-fatal cardiovascular events. The measurement of EAT and MAT by MSCT could be a prognostic tool to predict cardiovascular events and mortality risk in advanced CKD patients.",2021,Patients with diabetes mellitus had greater EAT and MAT thickness (P = .018).,"['104 cases', 'Patients with chronic kidney disease (CKD', 'Patients with diabetes mellitus', 'patients with advanced chronic kidney disease and hemodialysis', 'patients with advanced CKD and haemodialysis therapy', 'advanced CKD patients']","['EAT and MAT', 'multislice synchronized computed tomography (MSCT', 'Epicardial and mediastinal adipose tissue (EAT, MAT']","['Epicardial fat tissue, coronary arterial calcification and mortality', 'total mortality', 'survival average time', 'EAT and MAT thickness', 'free survival time to fatal and non-fatal cardiovascular events', 'EAT thickness', 'EAT', 'mortality and cardiovascular events', 'mortality', 'serum albumin levels, serum triglyceride levels, phosphorus and calcium phosphate product']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0066317', 'cui_str': 'methylallyl trisulfide'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0442016', 'cui_str': 'Epicardial'}, {'cui': 'C0025066', 'cui_str': 'Mediastinal'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}]","[{'cui': 'C0442016', 'cui_str': 'Epicardial'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1168153', 'cui_str': 'Arterial calcification'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0066317', 'cui_str': 'methylallyl trisulfide'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0523465', 'cui_str': 'Albumin measurement, serum'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0006711', 'cui_str': 'calcium phosphate'}]",,0.0287292,Patients with diabetes mellitus had greater EAT and MAT thickness (P = .018).,"[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Cano Megías', 'Affiliation': 'Endocrinología y Nutrición, Hospital Universitario de Guadalajara, Guadalajara, Spain. Electronic address: mcanomegias@sescam.jccm.es.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Guisado Vasco', 'Affiliation': 'Medicina interna, hospital universitario Quironsalud Madrid. Pozuelo de Alarcón. Universidad Europea (Madrid). Spain.'}, {'ForeName': 'Hanane', 'Initials': 'H', 'LastName': 'Bouarich', 'Affiliation': 'Nefrología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Lara Aguilera', 'Affiliation': 'Radiología, Hospital Universitario Príncipe de Asturias, Spain.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'de Arriba-de la Fuente', 'Affiliation': 'Nefrología, Hospital Universitario de Guadalajara, Guadalajara, Spain.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Rodríguez-Puyol', 'Affiliation': 'Nefrología, Fundación de Investigación, Hospital Universitario Príncipe de Asturias, Spain.'}]",Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia,['10.1016/j.nefroe.2020.09.008'] 1441,34165999,To be mindful of the breath or pain: Comparing two brief preoperative mindfulness techniques for total joint arthroplasty patients.,"OBJECTIVE Total joint arthroplasty (TJA) often reduces pain and improves function, but it is also a risk factor for the development of chronic pain and postoperative opioid use. To protect against these untoward postsurgical outcomes, TJA patients need better, non-pharmacological pain management strategies. This study compared two, promising, mindfulness-based pain management techniques. METHOD We conducted a single-site, three-arm, parallel-group randomized controlled study conducted at an orthopedic clinic among patients undergoing TJA of the knee or hip. TJA patients (N = 118, M age = 65, female = 73, Caucasian = 110) were randomized to either a preoperative mindfulness of breath (MoB), mindfulness of pain (MoP), or cognitive-behavioral pain psychoeducation (CB) intervention, approximately 3 weeks before surgery. Each intervention was delivered in a single, 20-min session during a 2-hr, preoperative education program. Change in pain intensity was the sole preoperative outcome. The postoperative outcomes, pain intensity, pain interference, and opioid use were assessed on the 2nd, 3rd, 7th, 14th, 21st, and 28th postoperative days. RESULTS MoB was found to most effectively decrease preoperative pain scores, F(2, 89) = 5.28, p = .007, while MoP resulted in the least amount of postoperative pain intensity, F(8, 94) = 3.21, p = .003, and interference, F(8, 94) = 2.52, p = .016). Both MoB and MoP decreased postoperative opioid use relative to CB, F(8, 83) = 16.66, p < .001. CONCLUSION A brief preoperative MBI may be able to prevent both postoperative pain and opioid use. Moreover, the MBIs used in this study are highly feasible, capable of being delivered by nearly any healthcare provider, and requiring minimal clinic time given their brevity. As such, embedding MBIs in surgical care pathways has considerable potential. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"5.28, p = .007, while MoP resulted in the least amount of postoperative pain intensity, F(8, 94) =","['TJA patients (N = 118, M age = 65, female = 73, Caucasian = 110', 'patients undergoing TJA of the knee or hip', 'total joint arthroplasty patients']","['Total joint arthroplasty (TJA', 'preoperative mindfulness of breath (MoB), mindfulness of pain (MoP), or cognitive-behavioral pain psychoeducation (CB) intervention']","['pain intensity', 'breath or pain', 'preoperative pain scores', 'postoperative pain intensity, F(8, 94) ', 'postoperative outcomes, pain intensity, pain interference, and opioid use']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",110.0,0.0472526,"5.28, p = .007, while MoP resulted in the least amount of postoperative pain intensity, F(8, 94) =","[{'ForeName': 'Adam W', 'Initials': 'AW', 'LastName': 'Hanley', 'Affiliation': 'Center on Mindfulness and Integrative Health Intervention Development (C-MIIND), University of Utah.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Gililland', 'Affiliation': 'Department of Orthopaedic Surgery, University of Utah.'}, {'ForeName': 'Eric L', 'Initials': 'EL', 'LastName': 'Garland', 'Affiliation': 'Center on Mindfulness and Integrative Health Intervention Development (C-MIIND), University of Utah.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000657'] 1442,34170839,Effect of Community-Based Kangaroo Mother Care Package on Neonatal Mortality Among Preterm and Low Birthweight Infants in Rural Pakistan: Protocol for a Cluster Randomized Controlled Trial.,"BACKGROUND Neonatal mortality due to preterm birth and low birthweight remains a significant challenge in Pakistan. Kangaroo mother care (KMC) is a unique, low-cost intervention proven to reduce neonatal mortality and morbidity and increase exclusive breastfeeding rates. However, KMC has not been attempted in community settings in Pakistan. We aim to implement and evaluate the effectiveness of a community-based KMC package to reduce neonatal morbidity and mortality among preterm and low birthweight (LBW) infants, which will provide evidence for policy development and the large-scale implementation of KMC across the country. OBJECTIVE The primary objective of this trial is to reduce neonatal mortality among preterm and LBW infants. The secondary objectives are growth (measured as weight gain), reduced incidence of possible serious bacterial infection, and increased exclusive breastfeeding and continued breastfeeding practices. METHODS We designed a community-based cluster randomized controlled trial in one rural district of Pakistan. Stable, LBW babies (weighing 1200 grams to 2500 grams) are included in the study. The community KMC package, consisting of the KMC kit, information and counseling material, and community mobilization through KMC champions (village volunteers), was designed after preliminary research in the same geographical location and implemented in intervention clusters. The standard essential newborn care is offered in the control clusters. Infants are recruited and followed up by independent teams of data collectors. Data are collected on the duration of skin-to-skin contact, growth, breastfeeding practices, morbidities, neonatal mortality, and neurodevelopment status. Data analysis will be conducted based on the intention to treat principle. The Cox regression model will be used to assess the primary outcome of neonatal mortality. The secondary outcomes will be evaluated using linear or logistic regression. RESULTS The Ethics Review Committee of Aga Khan University, Pakistan, approved the study protocol in February 2017. Data collection began in August 2019 and will be completed in December 2021. Data analyses are yet to be completed. CONCLUSIONS This intervention may be effective in preventing sepsis and subsequently improve survival in LBW newborns in Pakistan and other low-income and middle-income countries worldwide. TRIAL REGISTRATION clinicaltrials.gov NCT03545204; https://clinicaltrials.gov/ct2/show/NCT03545204. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/28156.",2021,"Kangaroo mother care (KMC) is a unique, low-cost intervention proven to reduce neonatal mortality and morbidity and increase exclusive breastfeeding rates.","['preterm and low birthweight infants in rural Pakistan', 'preterm/low birthweight infants', 'one rural district of Pakistan', 'village volunteers', 'Aga Khan University, Pakistan in February 2017', 'low birth weight babies']","['community-based kangaroo mother care package', 'Kangaroo mother care (KMC', 'KMC kit, information and counseling material and community mobilization through KMC champion']","['neonatal mortality and morbidity', 'neonatal morbidity and mortality', 'neonatal mortality', 'duration of skin-to-skin contact, growth, breastfeeding practices, morbidities, neonatal mortality and neurodevelopment status', 'weight gain, reduction in incidence of possible serious bacterial infection (PSBI), increased exclusive breastfeeding and continued breastfeeding practices']","[{'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0071561', 'cui_str': 'polyethylene glycol-glutaminase-asparaginase'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C1963897', 'cui_str': 'Low birth weight baby'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1257803', 'cui_str': 'Kangaroo-Mother Care'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}]","[{'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0332149', 'cui_str': 'Possible'}, {'cui': 'C0004623', 'cui_str': 'Bacterial infectious disease'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0242205', 'cui_str': 'Breastfeeding, Exclusive'}]",1.0,0.116374,"Kangaroo mother care (KMC) is a unique, low-cost intervention proven to reduce neonatal mortality and morbidity and increase exclusive breastfeeding rates.","[{'ForeName': 'Shabina', 'Initials': 'S', 'LastName': 'Ariff', 'Affiliation': 'Department of Paediatrics & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Atif', 'Initials': 'A', 'LastName': 'Habib', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Zahid', 'Initials': 'Z', 'LastName': 'Memon', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Tayyaba', 'Initials': 'T', 'LastName': 'Arshad', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Tariq', 'Initials': 'T', 'LastName': 'Samejo', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Ikram', 'Initials': 'I', 'LastName': 'Maznani', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Umer', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Amjad', 'Initials': 'A', 'LastName': 'Hussain', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Arjumand', 'Initials': 'A', 'LastName': 'Rizvi', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Imran', 'Initials': 'I', 'LastName': 'Ahmed', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Sajid Bashir', 'Initials': 'SB', 'LastName': 'Soofi', 'Affiliation': 'Department of Paediatrics & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Zulfiqar A', 'Initials': 'ZA', 'LastName': 'Bhutta', 'Affiliation': 'Center of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.'}]",JMIR research protocols,['10.2196/28156'] 1443,34170736,Impact of nurse-initiated education on HeartScore in patients with hypertension: a randomised trial.,"BACKGROUND People with hypertension experience significant damage to major organs due to insufficient management of cardiovascular risk factors. AIMS To assess the impact of nurse-led educational interventions on the total cardiovascular risk among people with hypertension. METHOD the study was an interventional randomised study. The sample ( n =92) was randomly assigned to the either the control or intervention group. The HeartScore tool was used to assess patients' total cardiovascular risk between December 2017 and March 2018. FINDINGS 56.6% of the control group and 55.4% of the intervention group were women, with a mean age of 64.4 years and 66.2 years respectively ( P >0.05). Total cholesterol reduced in both groups; however, improvement was greater in the intervention group ( P <0.05). Total cardiovascular risk fell in the intervention group from 4.75 to 4.33 ( P >0.05), while the control group saw an increase in risk from 10.03 to 12.65 ( P =0.035). CONCLUSION Nurse-led educational interventions should be incorporated in the usual care of patients with hypertension, in order to achieve the best management of the condition.",2021,"Total cholesterol reduced in both groups; however, improvement was greater in the intervention group ( P <0.05).","['people with hypertension', ""patients' total cardiovascular risk between December 2017 and March 2018"", 'patients with hypertension']","['Nurse-led educational interventions', 'nurse-initiated education', 'nurse-led educational interventions']","['Total cholesterol', 'Total cardiovascular risk fell', 'total cardiovascular risk']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}]",,0.0108633,"Total cholesterol reduced in both groups; however, improvement was greater in the intervention group ( P <0.05).","[{'ForeName': 'Anastasia A', 'Initials': 'AA', 'LastName': 'Chatziefstratiou', 'Affiliation': 'Postdoctorate Student, Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Nikolaos V', 'Initials': 'NV', 'LastName': 'Fotos', 'Affiliation': 'Assistant Professor, Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Giakoumidakis', 'Affiliation': 'Nurse, Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Hero', 'Initials': 'H', 'LastName': 'Brokalaki', 'Affiliation': 'Emeritus Professor, Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece.'}]",British journal of nursing (Mark Allen Publishing),['10.12968/bjon.2021.30.12.722'] 1444,34175638,Serratus anterior plane block reduces the prevalence of chronic postsurgical pain after modified radical mastectomy: A randomized controlled trial.,"STUDY OBJECTIVE To determine whether ultrasound-guided serratus anterior plane block (SAPB) is associated with decreased prevalence of chronic postsurgical pain (CPSP) after modified radical mastectomy. DESIGN Randomized, double-blind, placebo-controlled study. SETTING University hospital. PATIENTS We enrolled 198 patients aged 18-65 years with American Society of Anesthesiologists physical status I to II, undergoing unilateral modified radical mastectomy. INTERVENTIONS Patients were randomly allocated to receive SAPB with 30 ml of 0.5% ropivacaine (SAPB group) or 0.9% normal saline (Control group). MEASUREMENTS The primary outcome was the prevalence of CPSP three months after surgery. Secondary outcomes were area under the curve of the numeric rating scale pain scores over 24 h, postoperative 24-h morphine consumption, quality of recovery, length of post-anesthesia care unit stay, postoperative nausea and vomiting, dizziness, SAPB-related adverse events, the prevalence of CPSP at six months, and pain-related function at three and six months. MAIN RESULTS Preoperative SAPB with 0.5% ropivacaine reduced the prevalence of CPSP at three postoperative months from 46/89 (51.7%) to 22/90 (25.6%), relative risk (95% confidence interval): 0.47 (0.31-0.72), P < 0.001. The prevalence of CPSP was reduced at six months from 37/89 (41.6%) to 17/90 (18.9%), relative risk (95% confidence interval): 0.72 (0.58-0.88), P = 0.001. Moreover, SAPB decreased the area under the curve of the numeric rating scale pain scores over 24 h, shortened the length of post-anesthesia care unit stay, reduced postoperative 24-h morphine consumption and the occurrence of postoperative nausea and vomiting, and improved quality of recovery and patient satisfaction, with P < 0.05 for all. No SAPB-related complications occurred. CONCLUSIONS Preoperative SAPB with ropivacaine improved acute postoperative analgesia and quality of recovery and decreased the prevalence of CPSP at three and six months after modified radical mastectomy.",2021,"The prevalence of CPSP was reduced at six months from 37/89 (41.6%) to 17/90 (18.9%), relative risk (95% confidence interval): 0.72","['University hospital', '198 patients aged 18-65\xa0years with American Society of Anesthesiologists physical status']","['ultrasound-guided serratus anterior plane block (SAPB', 'ropivacaine', 'unilateral modified radical mastectomy', 'placebo', 'SAPB with 30\xa0ml of 0.5% ropivacaine (SAPB group) or 0.9% normal saline (Control group', 'modified radical mastectomy']","['relative risk', 'length of post-anesthesia care unit stay, reduced postoperative 24-h morphine consumption and the occurrence of postoperative nausea and vomiting, and improved quality of recovery and patient satisfaction', 'area under the curve of the numeric rating scale pain scores over 24\xa0h, postoperative 24-h morphine consumption, quality of recovery, length of post-anesthesia care unit stay, postoperative nausea and vomiting, dizziness, SAPB-related adverse events, the prevalence of CPSP at six months, and pain-related function', 'acute postoperative analgesia and quality of recovery', 'chronic postsurgical pain (CPSP', 'prevalence of CPSP', 'numeric rating scale pain scores', 'chronic postsurgical pain']","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0224349', 'cui_str': 'Structure of serratus anterior muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0024883', 'cui_str': 'Modified radical mastectomy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0439166', 'cui_str': '% normal'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0034871', 'cui_str': 'Postoperative anesthesia care unit'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0224349', 'cui_str': 'Structure of serratus anterior muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}]",198.0,0.764061,"The prevalence of CPSP was reduced at six months from 37/89 (41.6%) to 17/90 (18.9%), relative risk (95% confidence interval): 0.72","[{'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Qian', 'Affiliation': ""Department of Anesthesiology, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.""}, {'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': ""Department of Anesthesiology, Xiang'an Branch, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.""}, {'ForeName': 'Xincheng', 'Initials': 'X', 'LastName': 'Liao', 'Affiliation': 'Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.'}, {'ForeName': 'Junbei', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Lin', 'Affiliation': ""Department of Anesthesiology, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China. Electronic address: eyao717@sina.com.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': 'Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China. Electronic address: linying_789@126.com.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110410'] 1445,34175582,"The ability and safety of community-based health workers to safely initiate lifesaving therapies for pre-eclampsia in Ogun State, Nigeria: An analysis of 260 community treatments with MgSO 4 and/or methyldopa.","OBJECTIVES To evaluate community-based health workers' ability to identify cases of hypertension in pregnancy, safely deliver methyldopa and magnesium sulphate and make referrals when appropriate. STUDY DESIGN This was part of Nigeria Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomized controlled trial (NCT01911494). Community-based Health Workers (CHW) recruited pregnant women from five Local Government Areas (clusters) and used mobile health aid for clinical assessment of pre-eclampsia. MAIN OUTCOME MEASURES The primary outcome was the number of adverse events that occurred after the administration of magnesium sulphate and/or methyldopa to pregnant women by CHWs. FINDINGS Of 8790 women receiving mobile health-guided care, community-based health workers in Nigeria provided 309 women with hypertension (4.2% of delivered women), and safely administered 142 doses of intramuscular magnesium sulphate. Community Heath Extension Workers (CHEWs) and nurses gave fifty-two and sixty-seven doses of intramuscular magnesium sulphate respectively, twenty-three doses were given by other health care workers (midwives, community health officers, health assistants). The high rate of administration by nurses can be explained by turf protection as well as their seniority within the health system. Also, CHEWs and nurses gave 124 doses of oral methyldopa and 126 urgent referrals were completed. There were no complications related to administration of treatment or referral. INTERPRETATION These findings demonstrate the ability of community-based health workers to safely administer methyldopa and intramuscular magnesium sulphate. The use of task-sharing, therefore, could drastically reduce the three delays (triage, transport and treatment) associated with high maternal mortality and morbidity in rural communities in low- and middle-income countries.",2021,"The use of task-sharing, therefore, could drastically reduce the three delays (triage, transport and treatment) associated with high maternal mortality and morbidity in rural communities in low- and middle-income countries.","['health care workers (midwives, community health officers, health assistants', 'Community-based Health Workers (CHW) recruited pregnant women from five Local Government Areas (clusters', 'Community Heath Extension Workers (CHEWs) and nurses gave fifty-two and sixty-seven doses of', 'rural communities in low- and middle-income countries', 'pre-eclampsia in Ogun State, Nigeria', '8790 women receiving mobile health-guided care, community-based health workers in Nigeria provided 309 women with hypertension (4.2% of delivered women', '260 community treatments with MgSO 4 and/or']","['methyldopa and intramuscular magnesium sulphate', 'methyldopa', 'oral methyldopa', 'magnesium sulphate and/or methyldopa', 'intramuscular magnesium sulphate', 'methyldopa and magnesium sulphate']",['number of adverse events'],"[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0026083', 'cui_str': 'Professional midwife'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0237758', 'cui_str': 'Non-commissioned officer'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0011327', 'cui_str': 'Dental assistant'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0026788', 'cui_str': 'Government, Local'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0086944', 'cui_str': 'Rural Communities'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0028075', 'cui_str': 'Nigeria'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C4517669', 'cui_str': '260'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0025741', 'cui_str': 'Methyldopa'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0024480', 'cui_str': 'Magnesium Sulfate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",309.0,0.0919044,"The use of task-sharing, therefore, could drastically reduce the three delays (triage, transport and treatment) associated with high maternal mortality and morbidity in rural communities in low- and middle-income countries.","[{'ForeName': 'Akinmade A', 'Initials': 'AA', 'LastName': 'Adepoju', 'Affiliation': 'Centre for Research in Reproductive Health, Sagamu, Ogun State, Nigeria. Electronic address: a_adepoju@hotmail.co.uk.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Vidler', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Rm V3-339 West 28th Avenue, Vancouver, British Columbia V5Z 4H4, Canada.'}, {'ForeName': 'Adebayo A', 'Initials': 'AA', 'LastName': 'Akadri', 'Affiliation': 'Department of Obstetrics and Gynaecology, Babcock University Teaching Hospital, Ilishan-Remo, Ogun State, Nigeria.'}, {'ForeName': 'Ebun', 'Initials': 'E', 'LastName': 'Jaiyesimi', 'Affiliation': 'Centre for Research in Reproductive Health, Sagamu, Ogun State, Nigeria.'}, {'ForeName': 'Chimaobi C', 'Initials': 'CC', 'LastName': 'Nwankpa', 'Affiliation': 'Department of Obstetrics and Gynaecology, Babcock University Teaching Hospital, Ilishan-Remo, Ogun State, Nigeria.'}, {'ForeName': 'Oluwafayokemi O', 'Initials': 'OO', 'LastName': 'Odubena', 'Affiliation': 'Department of Obstetrics and Gynaecology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria.'}, {'ForeName': 'Sumedha', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Rm V3-341 West 28th Avenue, Vancouver, British Columbia V5Z 4H4, Canada.'}, {'ForeName': 'Larry', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Rm V3-337 West 28th Avenue, Vancouver, British Columbia V5Z 4H4, Canada.'}, {'ForeName': 'Domena', 'Initials': 'D', 'LastName': 'Tu', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Rm V3-339 West 28th Avenue, Vancouver, British Columbia V5Z 4H4, Canada.'}, {'ForeName': 'Sharla', 'Initials': 'S', 'LastName': 'Drebit', 'Affiliation': 'BC Emergency Medicine Network, Department of Emergency Medicine, University of British Columbia, Rm 11235 11th Floor, 2775 Laurel St, Vancouver, British Columbia V5Z 1M9, Canada.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Payne', 'Affiliation': ""School of Population and Public Health, University of British Columbia, Women's Health Research Institute, Rm H203 - West 28th Avenue, Vancouver, British Columbia V5Z 4H4, Canada.""}, {'ForeName': 'David O', 'Initials': 'DO', 'LastName': 'Akeju', 'Affiliation': 'Department of Sociology, University of Lagos, Lagos, Nigeria.'}, {'ForeName': 'Zulfiqar', 'Initials': 'Z', 'LastName': 'Bhutta', 'Affiliation': 'Program for Global Pediatric Research, Hospital for Sick Children, Toronto, Canada; Division of Women & Child Health, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Magee', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK.""}, {'ForeName': 'Hannah L', 'Initials': 'HL', 'LastName': 'Nathan', 'Affiliation': ""Department to Women and Children's Health, King's College London, London, UK.""}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Shennan', 'Affiliation': ""Department to Women and Children's Health, King's College London, London, UK.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Sotunsa', 'Affiliation': 'Department of Obstetrics and Gynaecology, Babcock University Teaching Hospital, Ilishan-Remo, Ogun State, Nigeria.'}, {'ForeName': 'Olalekan O', 'Initials': 'OO', 'LastName': 'Adetoro', 'Affiliation': 'Centre for Research in Reproductive Health, Sagamu, Ogun State, Nigeria.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'von Dadelszen', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK.""}, {'ForeName': 'Olukayode A', 'Initials': 'OA', 'LastName': 'Dada', 'Affiliation': 'Centre for Research in Reproductive Health, Sagamu, Ogun State, Nigeria.'}, {'ForeName': 'Olaokun', 'Initials': 'O', 'LastName': 'Soyinka', 'Affiliation': 'Ministry of Health, Ogun State, Nigeria.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pregnancy hypertension,['10.1016/j.preghy.2021.05.005'] 1446,34176722,"Effect of Oral CNSA-001 (sepiapterin, PTC923) on gastric accommodation in women with diabetic gastroparesis: A randomized, placebo-controlled, Phase 2 trial.","AIMS Diabetic gastroparesis may be associated with impaired nitric oxide metabolism and reduced tetrahydrobiopterin (BH 4 ) synthesis. Oral treatment with CNSA-001 (sepiapterin, currently known as PTC923) increased BH 4 levels in humans in a previous study. This Phase 2 study evaluated CNSA-001 in women with diabetic gastroparesis. METHODS Non-pregnant diabetic women with moderate/severe symptomatic gastroparesis, delayed gastric emptying, and impaired gastric accommodation (nutrient satiety testing) were randomized to 10mg/kg BID CNSA-001 or matching placebo for 14days. The primary endpoint was change in gastric accommodation (maximal tolerated liquid meal volume) at 14- and 28-days' follow-up. RESULTS Gastric accommodation improved in CNSA-001-treated vs. placebo-treated subjects at 28days (least squares mean [LSM] difference: 98 [95% CI 36 to 161], p=0.0042). Subjects' ratings of bloating, fullness, nausea, and pain were lower vs. baseline in the CNSA-001 group at 14 and 28days, though these improvements were not observed consistently in placebo-treated subjects. There were no significant group differences in upper gastrointestinal symptom scores, and in gastric emptying breath test parameters. CNSA-001 was well tolerated, with no withdrawals for adverse events. CONCLUSIONS CNSA-001 improved gastric accommodation in women with diabetic gastroparesis. Further evaluation of CNSA-001 in gastroparesis is warranted; ClinicalTrials.gov number, NCT03712124.",2021,"Subjects' ratings of bloating, fullness, nausea, and pain were lower vs. baseline in the CNSA-001 group at 14 and 28days, though these improvements were not observed consistently in placebo-treated subjects.","['Non-pregnant diabetic women with moderate/severe symptomatic gastroparesis, delayed gastric emptying, and impaired gastric accommodation (nutrient satiety testing', 'women with diabetic gastroparesis']","['kg BID CNSA-001 or matching placebo', 'Oral CNSA-001 (sepiapterin, PTC923', 'CNSA-001 (sepiapterin', 'CNSA-001-treated vs. placebo', 'CNSA-001', 'placebo']","[""Subjects' ratings of bloating, fullness, nausea, and pain"", 'change in gastric accommodation (maximal tolerated liquid meal volume', 'Gastric accommodation', 'upper gastrointestinal symptom scores', 'gastric accommodation', 'gastric emptying breath test parameters']","[{'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0267176', 'cui_str': 'Gastroparesis with diabetes mellitus'}]","[{'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0074349', 'cui_str': 'Sepiapterin'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0439650', 'cui_str': 'Fullness'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0857493', 'cui_str': 'Upper gastrointestinal symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006153', 'cui_str': 'Breath test'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",,0.152873,"Subjects' ratings of bloating, fullness, nausea, and pain were lower vs. baseline in the CNSA-001 group at 14 and 28days, though these improvements were not observed consistently in placebo-treated subjects.","[{'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Abell', 'Affiliation': 'University of Louisville, KY, USA.'}, {'ForeName': 'Lazaro M', 'Initials': 'LM', 'LastName': 'Garcia', 'Affiliation': 'LMG Research, Miami, FL, USA.'}, {'ForeName': 'Gregory J', 'Initials': 'GJ', 'LastName': 'Wiener', 'Affiliation': 'GW Research Inc., Chula Vista, CA, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Wo', 'Affiliation': 'Indiana University Hospital, Indianapolis, IN, USA.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Bulat', 'Affiliation': 'Johns Hopkins Center for Neurogastroenterology, Baltimore, MD, USA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Smith', 'Affiliation': 'PTC Therapeutics Inc., South Plainfield, NJ, USA. Electronic address: nsmith@ptcbio.com.com.'}]",Journal of diabetes and its complications,['10.1016/j.jdiacomp.2021.107961'] 1447,34161745,Body mass-normalized moderate dose of dietary nitrate intake improves endothelial function and walking capacity in patients with peripheral artery disease.,"Peripheral artery disease (PAD) is characterized by the accumulation of atherosclerotic plaques in the lower extremity conduit arteries, which impairs blood flow and walking capacity. Dietary nitrate has been used to reduce blood pressure (BP) and improve walking capacity in PAD. However, a standardized dose for PAD has not been determined. Therefore, we sought to determine the effects of a body mass-normalized moderate dose of nitrate (0.11 mmol nitrate/kg) as beetroot juice on serum nitrate/nitrite, vascular function, walking capacity, and tissue oxygen utilization capacity in patients with PAD. A total of 11 patients with PAD received either nitrate supplement or placebo in a randomized crossover design. Total serum nitrate/nitrite, resting BP, brachial and popliteal artery endothelial function (flow-mediated dilation, FMD), arterial stiffness (pulse-wave velocity, PWV), augmentation index (AIx), maximal walking distance and time, claudication onset time, and skeletal muscle oxygen utilization were measured pre- and postnitrate and placebo intake. There were significant group × time interactions ( P < 0.05) for serum nitrate/nitrite, FMD, BP, walking distance and time, and skeletal muscle oxygen utilization. The nitrate group showed significantly increased serum nitrate/nitrite (Δ1.32 μM), increased brachial and popliteal FMD (Δ1.3% and Δ1.7%, respectively), reduced peripheral and central systolic BP (Δ-4.7 mmHg and Δ-8.2 mmHg, respectively), increased maximal walking distance (Δ92.7 m) and time (Δ56.3 s), and reduced deoxygenated hemoglobin during walking. There were no changes in PWV, AIx, or claudication ( P > 0.05). These results indicate that a body-mass normalized moderate dose of nitrate may be effective and safe for reducing BP, improving endothelial function, and improving walking capacity in patients with PAD.",2021,"The nitrate group showed significantly increased serum nitrate/nitrite (Δ1.32μM), increased brachial and popliteal FMD (Δ1.3% and Δ1.7%, respectively), reduced peripheral and central systolic BP (Δ-4.7mmHg and Δ-8.2mmHg, respectively), increased maximal walking distance (Δ92.7m) and time (Δ56.3s), and reduced deoxygenated hemoglobin during walking.","['11 patients with PAD', 'patients with peripheral artery disease', 'patients with PAD']","['dietary nitrate intake', 'nitrate supplement or placebo']","['serum nitrate/nitrite, vascular function, walking capacity, and tissue oxygen utilization capacity', 'PWV, AIx, or claudication (p>0.05', 'walking capacity', 'maximal walking distance (Δ92.7m) and time (Δ56.3s), and reduced deoxygenated hemoglobin', 'Total serum nitrate/nitrite, resting BP, brachial and popliteal artery endothelial function (flow-mediated dilation, FMD), arterial stiffness (pulse-wave velocity, PWV), augmentation index (AIx), maximal walking distance and time, claudication onset time, and skeletal muscle oxygen utilization', 'serum nitrate/nitrite, FMD, BP, walking distance and time, and skeletal muscle oxygen utilization', 'serum nitrate/nitrite (Δ1.32μM), increased brachial and popliteal FMD', 'BP, improving endothelial function', 'endothelial function and walking capacity', 'reduced peripheral and central systolic BP', 'blood pressure (BP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0028137', 'cui_str': 'Nitrite salt'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0057437', 'cui_str': 'Deoxyhemoglobin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0032649', 'cui_str': 'Structure of popliteal artery'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0016052', 'cui_str': 'Fibromuscular dysplasia'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0449244', 'cui_str': 'Time of onset'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0442037', 'cui_str': 'Popliteal'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",11.0,0.0175328,"The nitrate group showed significantly increased serum nitrate/nitrite (Δ1.32μM), increased brachial and popliteal FMD (Δ1.3% and Δ1.7%, respectively), reduced peripheral and central systolic BP (Δ-4.7mmHg and Δ-8.2mmHg, respectively), increased maximal walking distance (Δ92.7m) and time (Δ56.3s), and reduced deoxygenated hemoglobin during walking.","[{'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Pekas', 'Affiliation': 'School of Health & Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'TeSean K', 'Initials': 'TK', 'LastName': 'Wooden', 'Affiliation': 'School of Health & Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'Santosh K', 'Initials': 'SK', 'LastName': 'Yadav', 'Affiliation': 'Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.'}, {'ForeName': 'Song-Young', 'Initials': 'SY', 'LastName': 'Park', 'Affiliation': 'School of Health & Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00121.2021'] 1448,34165604,Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine.,"To re-analyse the clinical outcomes and interferon (IFN) activity data from the JOQUER trial, a phase III trial investigating hydroxychloroquine (HCQ) in patients with primary Sjögren's syndrome (pSS), after stratifying patients into putative pathobiological subgroups utilizing the Newcastle Sjögren's Stratification Tool (NSST) based on patient-reported symptoms of dryness, pain, fatigue, anxiety and depression. 107 patients were assigned to one of four subgroups using NSST at baseline-the high symptom burden (HSB), pain dominant with fatigue (PDF), dryness dominant with fatigue (DDF) and low symptom burden (LSB). Endpoints were re-analysed after stratification, testing for treatment differences within subgroups and adjusting for baseline differences using a repeated measures covariate model. The HSB subgroup (n = 32) showed a relative improvement in ESSPRI of 1.49 points (95% CI 0.54-2.43; p = 0.002) within 12 weeks in patients taking HCQ compared to placebo, with no further changes after 24 weeks. For the LSB subgroup (n = 14), the ESSPRI worsened in the placebo but not the HCQ arm after 12 weeks (mean difference 1.44, 95% CI 0.05-2.83, p = 0.042). Neither the HSB nor the LSB patients showed significant changes in IFN activity at 24 weeks. There were no significant differences in ESSPRI in the PDF (n = 39) and DDF (n = 22) patients taking HCQ. However, significant reductions in overall IFN score at 24 weeks were seen in both PDF (difference at 24 weeks; 6.41, 95% CI, 2.48-10.34, p = 0.002) and DDF (difference at 24 weeks; 7.23, 95% CI, 1.85-12.6, p = 0.009) without improvement in ESSPRI. Although the JOQUER trial reported no overall benefit from HCQ in pSS patients, stratification suggests that both HSB and LSB subgroups may respond to HCQ. However, these patients may benefit through mechanisms other than the reduction of IFN activities.",2021,There were no significant differences in ESSPRI in the PDF (n = 39) and DDF (n = 22) patients taking HCQ.,"['107 patients', ""patients with primary Sjögren's syndrome (pSS), after stratifying patients into putative pathobiological subgroups utilizing the Newcastle Sjögren's Stratification Tool (NSST) based on patient-reported""]","['interferon', 'placebo', 'hydroxychloroquine (HCQ', 'hydroxychloroquine']","['DDF', 'symptoms of dryness, pain, fatigue, anxiety and depression', 'IFN activity', 'ESSPRI', 'overall IFN score', 'symptom burden (HSB), pain dominant with fatigue (PDF), dryness dominant with fatigue (DDF) and low symptom burden (LSB']","[{'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0151449', 'cui_str': ""Primary Sjögren's syndrome""}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0027983', 'cui_str': 'Newcastle disease'}, {'cui': 'C1527336', 'cui_str': ""Sjögren's syndrome""}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",107.0,0.628501,There were no significant differences in ESSPRI in the PDF (n = 39) and DDF (n = 22) patients taking HCQ.,"[{'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Collins', 'Affiliation': 'Musculoskeletal Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Lendrem', 'Affiliation': 'Musculoskeletal Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Wason', 'Affiliation': 'Faculty of Medical Sciences, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Tarn', 'Affiliation': 'Musculoskeletal Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Howard-Tripp', 'Affiliation': 'Musculoskeletal Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Bodewes', 'Affiliation': 'Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.'}, {'ForeName': 'Marjan A', 'Initials': 'MA', 'LastName': 'Versnel', 'Affiliation': 'Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.'}, {'ForeName': 'Jacques-Eric', 'Initials': 'JE', 'LastName': 'Gottenberg', 'Affiliation': 'Department of Rheumatology, National Reference Centre for Rare Systemic Autoimmune Diseases, Strasbourg University Hospital, CNRS, IBMC, Université de Strasbourg, UPR 3572, Strasbourg, France.'}, {'ForeName': 'Raphaele', 'Initials': 'R', 'LastName': 'Seror', 'Affiliation': 'Centre for Immunology of Viral Infections and Autoimmune Diseases, INSERM, UMR 1184, Université Paris- Saclay, Paris, France.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Mariette', 'Affiliation': 'Centre for Immunology of Viral Infections and Autoimmune Diseases, INSERM, UMR 1184, Université Paris- Saclay, Paris, France.'}, {'ForeName': 'Wan-Fai', 'Initials': 'WF', 'LastName': 'Ng', 'Affiliation': 'Musculoskeletal Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. wan-fai.ng@newcastle.ac.uk.'}]",Rheumatology international,['10.1007/s00296-021-04927-y'] 1449,34391248,Pilates-based core exercise improves health-related quality of life in people living with chronic low back pain: A pilot study.,"PURPOSE To investigate the effects of Pilates exercise on improving health-related quality of life in people living with chronic low back pain. METHODS This was a single-blind, randomised clinical trial. Thirty-nine physically active subjects aged between 30 and 70 years with nonspecific chronic low back pain for more than three months were recruited. The study employed a pretest-posttest design, with a 4 -, 8 -, and 26-week follow-up. For eight weeks, the intervention group participated in a group-supervised, mat-based Pilates program, while the control group received the usual pharmacologic and rehabilitation standard of care, including patient education on chronic low back pain. The primary outcome was self-perceived health status measured using the EQ-5D questionnaire in a structured form and a visual analogue scale. Secondary outcomes included intensity of pain and degree of disability. RESULTS By the end of the 8-week Pilates program, the intervention group achieved a better health-related quality of life on the EQ-5D visual analogue score than the control group. In assessing the trends in each individual group regarding pain, the intervention group demonstrated an earlier pain reduction than the control group that lasted until the end of the trial. CONCLUSIONS An 8-week supervised Pilates-based core exercise program is an effective therapeutic modality for improving self-perceived health status in patients with chronic low back pain. This finding could inform clinicians of better alternatives when they suggest exercise interventions for chronic low back pain.",2021,"In assessing the trends in each individual group regarding pain, the intervention group demonstrated an earlier pain reduction than the control group that lasted until the end of the trial. ","['patients with chronic low back pain', 'people living with chronic low back pain', 'Thirty-nine physically active subjects aged between 30 and 70 years with nonspecific chronic low back pain for more than three months were recruited']","['Pilates exercise', 'supervised Pilates-based core exercise program', 'exercise interventions', 'group-supervised, mat-based Pilates program, while the control group received the usual pharmacologic and rehabilitation standard of care, including patient education', 'Pilates-based core exercise']","['self-perceived health status measured using the EQ-5D questionnaire in a structured form and a visual analogue scale', 'health-related quality of life', 'health-related quality of life on the EQ-5D visual analogue score', 'earlier pain reduction', 'intensity of pain and degree of disability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C4082119', 'cui_str': 'Three months'}]","[{'cui': 'C1321049', 'cui_str': 'Pilates exercise'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0066317', 'cui_str': 'methylallyl trisulfide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030688', 'cui_str': 'Patient education'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0231170', 'cui_str': 'Disability'}]",39.0,0.0276241,"In assessing the trends in each individual group regarding pain, the intervention group demonstrated an earlier pain reduction than the control group that lasted until the end of the trial. ","[{'ForeName': 'Chen-Ya', 'Initials': 'CY', 'LastName': 'Yang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Taichung Veterans General Hospital, Chiayi and Wanqiao Branch, Chiayi, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.'}, {'ForeName': 'Yun-An', 'Initials': 'YA', 'LastName': 'Tsai', 'Affiliation': 'Neural Regeneration and Repair Division, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Pi-Keng', 'Initials': 'PK', 'LastName': 'Wu', 'Affiliation': 'Department of Rehabilitation, Keelung Hospital, Ministry of Health and Welfare, Keelung, Taiwan.'}, {'ForeName': 'Sih-Ying', 'Initials': 'SY', 'LastName': 'Ho', 'Affiliation': 'Taipei Veterans General Hospital Yuanshan Branch, Yilan, Taiwan.'}, {'ForeName': 'Chih-Yi', 'Initials': 'CY', 'LastName': 'Chou', 'Affiliation': 'College of Medicine, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Shih-Fong', 'Initials': 'SF', 'LastName': 'Huang', 'Affiliation': 'Neural Regeneration and Repair Division, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan. Electronic address: shihfongh@yahoo.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.006'] 1450,34168334,Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.,"More than half of the world's population lives in areas at risk for dengue virus infection. A vaccine will be pivotal to controlling spread, however, the only licensed vaccine, Dengvaxia, has been shown to increase the risk of severe disease in a subset of individuals. Vaccine efforts are hampered by a poor understanding of antibody responses, including those generated by vaccines, and whether antibody titers can be used as a marker of protection from infection or disease. Here we present the results of an ancillary study to a phase III vaccine study (n = 611). All participants received three doses of either Dengvaxia or placebo and were followed for 6 years. We performed neutralization tests on annual samples and during confirmed dengue episodes (n = 16,508 total measurements). We use mathematical models to reconstruct long-term antibody responses to vaccination and natural infection, and to identify subclinical infections. There were 87 symptomatic infections reported, and we estimated that there were a further 351 subclinical infections. Cumulative vaccine efficacy was positive for both subclinical and symptomatic infection, although the protective effect of the vaccine was concentrated in the first 3 years following vaccination. Among individuals with the same antibody titer, we found no difference between the risk of subsequent infection or disease between placebo and vaccine recipients, suggesting that antibody titers are a good predictor of both protection and disease risk.",2021,"Cumulative vaccine efficacy was positive for both subclinical and symptomatic infection, although the protective effect of the vaccine was concentrated in the first 3 years following vaccination.",[],"['Dengvaxia or placebo', 'Dengvaxia vaccine', 'placebo']",['Cumulative vaccine efficacy'],[],"[{'cui': 'C5196214', 'cui_str': 'Dengvaxia'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.164944,"Cumulative vaccine efficacy was positive for both subclinical and symptomatic infection, although the protective effect of the vaccine was concentrated in the first 3 years following vaccination.","[{'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Salje', 'Affiliation': 'Department of Genetics, University of Cambridge, Cambridge, UK. hs743@cam.ac.uk.'}, {'ForeName': 'Maria Theresa', 'Initials': 'MT', 'LastName': 'Alera', 'Affiliation': 'Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.'}, {'ForeName': 'Mary Noreen', 'Initials': 'MN', 'LastName': 'Chua', 'Affiliation': 'Chong Hua Hospital, Cebu City, Philippines.'}, {'ForeName': 'Taweewun', 'Initials': 'T', 'LastName': 'Hunsawong', 'Affiliation': 'Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.'}, {'ForeName': 'Damon', 'Initials': 'D', 'LastName': 'Ellison', 'Affiliation': 'Bacterial Disease Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.'}, {'ForeName': 'Anon', 'Initials': 'A', 'LastName': 'Srikiatkhachorn', 'Affiliation': 'Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Jarman', 'Affiliation': 'Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.'}, {'ForeName': 'Gregory D', 'Initials': 'GD', 'LastName': 'Gromowski', 'Affiliation': 'Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Rodriguez-Barraquer', 'Affiliation': 'University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Cauchemez', 'Affiliation': 'Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Paris, France.'}, {'ForeName': 'Derek A T', 'Initials': 'DAT', 'LastName': 'Cummings', 'Affiliation': 'Department of Biology, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Macareo', 'Affiliation': 'Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.'}, {'ForeName': 'In-Kyu', 'Initials': 'IK', 'LastName': 'Yoon', 'Affiliation': 'Coalition for Epidemic Preparedness Innovations, Washington, DC, USA.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Fernandez', 'Affiliation': 'Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Rothman', 'Affiliation': 'Institute for Immunology and Informatics, Department of Cell and Molecular Biology, University of Rhode Island, Providence, RI, USA.'}]",Nature medicine,['10.1038/s41591-021-01392-9'] 1451,34167763,Effectiveness of an mHealth system on access to eye health services in Kenya: a cluster-randomised controlled trial.,"BACKGROUND There is limited access to eye health services in many low-income and middle-income populations. We aimed to assess the effectiveness in increasing service utilisation of the Peek Community Eye Health (Peek CEH) system, a smartphone-based referral system comprising decision support algorithms (Peek Community Screening app), SMS reminders, and real-time reporting. METHODS In this cluster-randomised controlled trial of eye health in Kenya, community unit clusters were defined as one health centre and its catchment population. Clusters were randomly allocated (1:1) to receive Peek CEH and referral (intervention group) or standard care via periodic health centre-based outreach clinics and onward referral (control group). Individuals in the intervention group were assessed at home by screeners and those referred were asked to present for triage assessment in a central location. They received regular SMS reminders. In both groups, community sensitisation was done followed by a triage clinic at the cluster health centre 4 weeks after sensitisation. During triage, individuals in both groups were assessed and treated and, if necessary, referred to a specific hospital. Individuals in the intervention group received further SMS reminders. The primary outcome was the mean attendance rate (the number of people per 10 000 population) at triage of those with confirmed eye conditions, as assessed at 4 weeks after sensitisation in the intention-to-treat population. We estimated the intervention effect using a Student's t-test on cluster-level rates. This trial is registered with Pan African Clinical Trial Registry, number 201807329096632. FINDINGS Between Nov 26, 2018, and June 7, 2019, of the 85 community units in Trans Nzoia County, Kenya, 49 were excluded. We randomly allocated 18 community units each to the intervention group (68 348 individuals) and the control group (60 243 individuals). 9387 individuals from the intervention group and 3070 from the control group attended triage assessment. The mean attendance rate at triage by individuals with eye problems was 1429 (92% CI 1228-1629) in the intervention group and 522 (418-625) in the control group (rate difference 906 per 10 000 [95% CI 689-1124; p<0·0001]). INTERPRETATION The Peek CEH system increased primary care attendance by people with eye problems compared with standard approaches, indicating the potential of this mobile health package to increase service uptake and guide appropriate task sharing. FUNDING The Queen Elizabeth Diamond Jubilee Trust and Wellcome Trust.",2021,The mean attendance rate at triage by individuals with eye problems was 1429 (92% CI 1228-1629) in the intervention group and 522 (418-625) in the control group (rate difference 906 per 10 000,"['Kenya', '9387 individuals from the intervention group and 3070 from the control group attended triage assessment', 'Between Nov 26, 2018, and June 7, 2019, of the 85 community units in Trans Nzoia County, Kenya, 49 were excluded', 'eye health in Kenya, community unit clusters were defined as one health centre and its catchment population']","['mHealth system', 'SMS reminders', 'regular SMS reminders', 'Peek CEH and referral (intervention group) or standard care via periodic health centre-based outreach clinics and onward referral (control group']",['mean attendance rate'],"[{'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0040861', 'cui_str': 'Triage'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C4505266', 'cui_str': 'One Health Concept'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0795864', 'cui_str': 'Smith-Magenis syndrome'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0084113', 'cui_str': 'polyetheretherketone'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0332182', 'cui_str': 'Periodic'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0581047', 'cui_str': 'Outreach clinic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}]",,0.0804258,The mean attendance rate at triage by individuals with eye problems was 1429 (92% CI 1228-1629) in the intervention group and 522 (418-625) in the control group (rate difference 906 per 10 000,"[{'ForeName': 'Hillary', 'Initials': 'H', 'LastName': 'Rono', 'Affiliation': 'International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK; Kitale County Referral and Teaching Hospital, Kitale, Kenya; Peek Vision, Berkhamsted, Hertfordshire, UK. Electronic address: hillary.rono@lshtm.ac.uk.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Bastawrous', 'Affiliation': 'International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK; Peek Vision, Berkhamsted, Hertfordshire, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Macleod', 'Affiliation': 'MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Mamboleo', 'Affiliation': 'Kitale County Referral and Teaching Hospital, Kitale, Kenya.'}, {'ForeName': 'Cosmas', 'Initials': 'C', 'LastName': 'Bunywera', 'Affiliation': 'Peek Vision, Berkhamsted, Hertfordshire, UK.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Wanjala', 'Affiliation': 'Kitale County Referral and Teaching Hospital, Kitale, Kenya.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Gichuhi', 'Affiliation': 'Department of Ophthalmology, Kenyatta National Hospital, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Burton', 'Affiliation': 'International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK; Moorfields Eye Hospital NHS Trust, London, UK.'}]",The Lancet. Digital health,['10.1016/S2589-7500(21)00083-2'] 1452,34166970,The effects of intensity on a phonological treatment for anomia in post-stroke aphasia.,"INTRODUCTION The evidence regarding optimal treatment intensity is mixed, and differing definitions have further confounded existing findings. The primary objective of this study was to compare the efficacy of Phonological Components Analysis (PCA) treatment for anomia delivered at intense and non-intense schedules, using a well-controlled design. The number of teaching episodes and active ingredients of therapy are important considerations when defining intensity. We hypothesized that an active ingredient of PCA is the self-generation of phonological components during therapy sessions. Our secondary aim was to examine whether component generation predicted treatment outcome. METHODS Sixteen adults (M = 52.63 years old, SD = 11.40) with chronic post-stroke aphasia (M = 4.52 years post-onset, SD = 5.55) were randomly assigned to intensive (IT) or standard (ST) PCA treatment conditions. Cumulative treatment intensity in both conditions was equivalent: ST participants received PCA 1 hour/day, 3 days/week for 10 weeks, whereas IT participants received PCA 3 hours/day, 4 days/week for 2.5 weeks. The primary outcome was naming accuracy on a set of treated and (matched) untreated words, measured pre- and post-treatment, and at four- and eight-week follow-ups. RESULTS IT and ST conditions were similarly efficacious. However, secondary analyses suggest an advantage for the IT condition in naming of the treated words immediately post-treatment, but not at follow-ups. The self-generation of phonological components emerged as a significant positive predictor of naming accuracy for both the treated and untreated words. However, this relationship did not reach significance once baseline anomia severity was accounted for. CONCLUSIONS Although replication in a larger sample is warranted, results suggest that PCA treatment is similarly efficacious when delivered at different intensities. Other factors related to the quality of treatment (i.e., active ingredients such as cue-generation) may play an important role in determining treatment efficacy and must also be considered when comparing treatment intensities.",2021,The self-generation of phonological components emerged as a significant positive predictor of naming accuracy for both the treated and untreated words.,"['Sixteen adults (M\xa0=\xa052.63 years old, SD\xa0=\xa011.40) with chronic post-stroke aphasia (M\xa0=\xa04.52 years post-onset, SD\xa0=\xa05.55', 'anomia in post-stroke aphasia']","['Phonological Components Analysis (PCA', 'PCA', 'intensive (IT) or standard (ST) PCA treatment conditions']","['naming accuracy on a set of treated and (matched) untreated words, measured pre- and post-treatment']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0003537', 'cui_str': 'Aphasia'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0003113', 'cui_str': 'Anomic aphasia'}]","[{'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0027365', 'cui_str': 'Name'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",16.0,0.0696423,The self-generation of phonological components emerged as a significant positive predictor of naming accuracy for both the treated and untreated words.,"[{'ForeName': 'Tijana', 'Initials': 'T', 'LastName': 'Simic', 'Affiliation': ""Department of Speech-Language Pathology, University of Toronto, 160-500 University Avenue, Toronto, ON M5G 1V7, Canada; Rehabilitation Sciences Institute, University of Toronto, 500 University Avenue, Toronto, ON M5G 1V7, Canada; Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, 600 Peter Morand Cres., Suite 206, Ottawa, ON K1G 5Z3, Canada; KITE Research Institute, Toronto Rehab, University Health Network, 550 University Avenue, Toronto, ON M5G 2A2, Canada; Department of Psychology, Université de Montréal, 90 Vincent d'Indy Avenue, Montreal, QC H2V 2S9, Canada; Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal (CRIUGM), 4545 Queen Mary Rd., Montreal, QC H3W 1W4, Canada. Electronic address: tijana.simic@umontreal.ca.""}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Leonard', 'Affiliation': 'Department of Speech-Language Pathology, University of Toronto, 160-500 University Avenue, Toronto, ON M5G 1V7, Canada; Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, 600 Peter Morand Cres., Suite 206, Ottawa, ON K1G 5Z3, Canada; School of Rehabilitation Sciences, University of Ottawa, 451 Smyth Rd., Ottawa, ON K1H 8M5, Canada.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Laird', 'Affiliation': 'Department of Speech-Language Pathology, University of Toronto, 160-500 University Avenue, Toronto, ON M5G 1V7, Canada; KITE Research Institute, Toronto Rehab, University Health Network, 550 University Avenue, Toronto, ON M5G 2A2, Canada.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Stewart', 'Affiliation': 'KITE Research Institute, Toronto Rehab, University Health Network, 550 University Avenue, Toronto, ON M5G 2A2, Canada.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Rochon', 'Affiliation': 'Department of Speech-Language Pathology, University of Toronto, 160-500 University Avenue, Toronto, ON M5G 1V7, Canada; Rehabilitation Sciences Institute, University of Toronto, 500 University Avenue, Toronto, ON M5G 1V7, Canada; Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, 600 Peter Morand Cres., Suite 206, Ottawa, ON K1G 5Z3, Canada; KITE Research Institute, Toronto Rehab, University Health Network, 550 University Avenue, Toronto, ON M5G 2A2, Canada.'}]",Journal of communication disorders,['10.1016/j.jcomdis.2021.106125'] 1453,34391243,The effect of the Kinesio Tape on the muscle power performance of elite weightlifters.,"INTRODUCTION To investigate the effect of the Kinesio Tape on the muscle power of the elite weightlifters. METHODS A randomized controlled trial, single blind. Forty-two male weightlifters were randomly assigned to the experimental Kinesio Tape and sham Kinesio Tape groups of the study. The participants then performed a single leg vertical jump and a single leg horizontal jump with three attempts of each to obtain the measurement of muscle power. Outcome measures were included single-leg vertical countermovement jump, estimated peak power, and single-leg horizontal countermovement jump. RESULT Significant effect of Kinesio Tape on horizontal jumps distance among the weightlifters in the experimental group (p = 0.002). The study showed that the vertical jump height (p = 0.433), estimated peak power (p = 0.542) and horizontal jump distance (p = 0.841) measurements did not improve significantly between the groups at level p = 0.05. CONCLUSION There is a small and better improvement noticed on the outcome measurements after Kinesio Tape application, which may be considered clinical importance for the sport. However, there was no statistically significant effect of Kinesio Tape between the groups.",2021,"The study showed that the vertical jump height (p = 0.433), estimated peak power (p = 0.542) and horizontal jump distance (p = 0.841) measurements did not improve significantly between the groups at level","['elite weightlifters', 'Forty-two male weightlifters']","['experimental Kinesio Tape and sham Kinesio Tape', 'single leg vertical jump and a single leg horizontal jump', 'Kinesio Tape']","['horizontal jump distance', 'estimated peak power', 'single-leg vertical countermovement jump, estimated peak power, and single-leg horizontal countermovement jump', 'vertical jump height', 'horizontal jumps distance']","[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C4505491', 'cui_str': 'Kinesiotape'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0205126', 'cui_str': 'Horizontal'}]","[{'cui': 'C0205126', 'cui_str': 'Horizontal'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}]",42.0,0.0956071,"The study showed that the vertical jump height (p = 0.433), estimated peak power (p = 0.542) and horizontal jump distance (p = 0.841) measurements did not improve significantly between the groups at level","[{'ForeName': 'MajedA', 'Initials': 'M', 'LastName': 'Alabbad', 'Affiliation': 'Department of Physical Therapy, College of Applied Medical Science, University of Imam Abdulrahman bin Alfaisal, Dammam, Saudi Arabia; Department of Physical Therapy, Medical Rehabilitation Department in Qatif Central Hospital, Ministry of Health, Qatif, Saudi Arabia. Electronic address: majed2031@gmail.com.'}, {'ForeName': 'QassimI', 'Initials': 'Q', 'LastName': 'Muaidi', 'Affiliation': 'Department of Physical Therapy, College of Applied Medical Science, University of Imam Abdulrahman bin Alfaisal, Dammam, Saudi Arabia. Electronic address: qmuaidi@uod.edu.sa.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.02.027'] 1454,34391242,"Fascial therapy, strength exercises and taping in soccer players with recurrent ankle sprains: A randomized controlled trial.","INTRODUCTION Recurrent ankle sprains are common in soccer players, characterized by restricted range of motion, pain, and decreased proprioception, strength, and postural control. The objective was to evaluate the effectiveness of a fascial therapy and strength training program, combined with kinesiotaping, in improving ankle range of motion, pain, strength and stability in footballers with recurrent sprains. METHOD A simple blind randomized clinical trial was conducted on soccer players. Thirty-six federated footballers were recruited and randomized to the two study groups. The experimental group received an intervention using myofascial techniques applied to the subastragaline joint, eccentric training with an isoinertial device and neuromuscular taping. The control group was administered an intervention using myofascial techniques on the subastragaline joint and eccentric training with an isoinertial device. The results were recorded for all players at baseline, after 4 weeks of intervention, and at the end of the 4-week follow-up period. RESULTS Subsequent to intervention and follow-up, we found statistically significant improvements in the experimental group in ankle mobility, strength and stability. The control group exhibited improvements in all study variables. No differences in the improvement of variables were found based on the allocation of athletes to one group or another. CONCLUSION The combination of fascial therapy and eccentric strength training with an isoinertial device improves ankle mobility, strength and stability in footballers with recurrent ankle sprains. The use of taping techniques failed to provide a greater improvement of the study variables when combined with manual therapy and strength techniques.",2021,The use of taping techniques failed to provide a greater improvement of the study variables when combined with manual therapy and strength techniques.,"['footballers with recurrent sprains', 'soccer players with recurrent ankle sprains', 'soccer players', 'Thirty-six federated footballers', 'footballers with recurrent ankle sprains']","['fascial therapy and eccentric strength training', 'Fascial therapy, strength exercises and taping', 'intervention using myofascial techniques on the subastragaline joint and eccentric training with an isoinertial device', 'fascial therapy and strength training program, combined with kinesiotaping', 'intervention using myofascial techniques applied to the subastragaline joint, eccentric training with an isoinertial device and neuromuscular taping']","['ankle mobility, strength and stability', 'ankle range of motion, pain, strength and stability']","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0038045', 'cui_str': 'Sprain'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0160087', 'cui_str': 'Sprain of ankle'}, {'cui': 'C4319606', 'cui_str': '36'}]","[{'cui': 'C0015641', 'cui_str': 'Fascial'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1632850', 'cui_str': 'Apply'}]","[{'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0576183', 'cui_str': 'Ankle joint - range of movement'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.0148752,The use of taping techniques failed to provide a greater improvement of the study variables when combined with manual therapy and strength techniques.,"[{'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Allois', 'Affiliation': 'Department of Physiotherapy, Faculty of Sport Sciences, European University of Madrid, Spain.'}, {'ForeName': 'Adriano', 'Initials': 'A', 'LastName': 'Niglia', 'Affiliation': 'Department of Physiotherapy, Faculty of Sport Sciences, European University of Madrid, Spain.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Pernice', 'Affiliation': 'Department of Physiotherapy, Faculty of Sport Sciences, European University of Madrid, Spain.'}, {'ForeName': 'Rubén', 'Initials': 'R', 'LastName': 'Cuesta-Barriuso', 'Affiliation': 'Department of Physiotherapy, Faculty of Sport Sciences, European University of Madrid, Spain; Real Fundación Victoria Eugenia, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: ruben.cuestab@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.022'] 1455,34391234,"Instrument assisted soft tissue mobilization (IASTM) versus stretching: A comparison in effectiveness on hip active range of motion, muscle torque and power in people with hamstring tightness.","BACKGROUND Instrument-assisted soft tissue mobilization (IASTM) is a new technique that has been known to be effective in reducing muscle tightness in athletics. However, little is known about its effect on the range of motion, muscle power, and torque compared to manual stretching among non-athletics. Thus, the study was aimed to compare the effectiveness between IASTM and manual stretching in improving hip flexion active range of motion (ROM), muscle torque and power on hamstring muscle complex (HMC) tightness in one session. METHOD Twenty-three young male college students with unilateral hamstring tightness measured via straight leg raising (SLR) test (<65°) were randomly assigned to one of two groups. Twelve participants received the application of IASTM (group 1), and eleven received manual stretching (group 2). Hip flexion active ROM was measured via goniometer, the torque & power of the hamstring muscle were measured using Humac isokinetic dynamometer, before and after both interventions. (ISRCTN17693345). RESULTS There was no significant difference in the improvement of hip flexion active ROM (69.6 ± 6.6 vs 72.5 ± 7.9, p = .34), HMC torque (63.7 ± 14.5 vs 53.2 ± 16.3, p = .14), and HMC power (47.8 ± 11.8 vs 40.9 ± 16.3, p = .34) between group 1 and group 2 respectively. When a comparison was made within each group, significant improvements in hip active flexion ROM was found in both groups (p's < .001), and HMC power was significantly improved in group 1 (p = .04) but not in group 2. CONCLUSION The current study findings demonstrate that IASTM was as effective as manual stretching in improving hip flexion active ROM, muscle torque and power among non-athletic people with HMC tightness.",2021,"There was no significant difference in the improvement of hip flexion active ROM (69.6 ± 6.6 vs 72.5 ± 7.9,","['people with hamstring tightness', 'Twenty-three young male college students with unilateral hamstring tightness measured via straight leg raising (SLR) test (<65°']","['Instrument-assisted soft tissue mobilization (IASTM', 'IASTM', 'manual stretching', 'Instrument assisted soft tissue mobilization (IASTM) versus stretching', 'IASTM and manual stretching']","['hip flexion active ROM, muscle torque and power', 'HMC torque', 'hip active range of motion, muscle torque and power', 'hip active flexion ROM', 'HMC power', 'hip flexion active ROM', 'hip flexion active range of motion (ROM), muscle torque and power on hamstring muscle complex (HMC) tightness', 'Hip flexion active ROM']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439816', 'cui_str': 'Tightness sensation quality'}, {'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0019421', 'cui_str': 'Heterosexuality'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0686940', 'cui_str': 'Soft tissue mobilization'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}]","[{'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0439816', 'cui_str': 'Tightness sensation quality'}]",23.0,0.0254252,"There was no significant difference in the improvement of hip flexion active ROM (69.6 ± 6.6 vs 72.5 ± 7.9,","[{'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Osailan', 'Affiliation': 'Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia. Electronic address: a.osailan@psau.edu.sa.'}, {'ForeName': 'Abdulaziz', 'Initials': 'A', 'LastName': 'Jamaan', 'Affiliation': 'Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.'}, {'ForeName': 'Khalid', 'Initials': 'K', 'LastName': 'Talha', 'Affiliation': 'Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.'}, {'ForeName': 'Mshari', 'Initials': 'M', 'LastName': 'Alhndi', 'Affiliation': 'Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.001'] 1456,34391233,"Effects of 12-week whole-body vibration exercise on fatigue, functional ability and quality of life in women with systemic lupus erythematosus: A randomized controlled trial.","BACKGROUND Systemic lupus erythematosus (SLE) is a complex rheumatic autoimmune disease characterized by periods of exacerbations that can present damage in organs with important clinical manifestations. OBJECTIVE The aim of this study was to evaluate the effect of 12-week whole-body vibration exercise (WBVE) on the fatigue, functional ability and quality of life of women with systemic lupus erythematosus (SLE) in chronic glucocorticoids use (CGU). METHODS Twenty-one women were allocated randomly in the WBVE group or isometry group. The participants of WBVE group were positioned on the vibrating platform with 130° knee flexion and received the intervention twice a week for 12 weeks. The isometry group performed the same position and time, but without the stimulus of mechanical vibration. Fatigue, functional ability and the quality of life were evaluated at weeks 0, 6, and 12. RESULTS From a sample of seventy-seven individuals, seventeen participants completed the study, 8 in WBVE group and 9 in isometry group. Fatigue reduced in the WBVE group at 6 and 12 weeks of intervention (p = 0.04) and (p = 0.03) respectively. There was a significant improvement in the functional ability evaluated by the Health Assessment Questionnaire in the WBVE group compared to the isometry group (p = 0.03). CONCLUSION WBVE would be a useful intervention for control of fatigue and improvement of the functional ability of women with SLE in CGU.",2021,Fatigue reduced in the WBVE group at 6 and 12 weeks of intervention (p = 0.04) and (p = 0.03) respectively.,"['Twenty-one women', 'From a sample of seventy-seven individuals, seventeen participants completed the study, 8 in WBVE group and 9 in isometry group', 'women with systemic lupus erythematosus', 'women with SLE in CGU', 'women with systemic lupus erythematosus (SLE']","['12-week whole-body vibration exercise (WBVE', '12-week whole-body vibration exercise', 'WBVE']","['Fatigue, functional ability and the quality of life', 'Health Assessment Questionnaire', 'Fatigue', 'functional ability', 'fatigue, functional ability and quality of life']","[{'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}]",21.0,0.0535098,Fatigue reduced in the WBVE group at 6 and 12 weeks of intervention (p = 0.04) and (p = 0.03) respectively.,"[{'ForeName': 'Patrícia', 'Initials': 'P', 'LastName': 'Lopes-Souza', 'Affiliation': 'Laboratório de Vibrações Mecânicas e Práticas Integrativas, Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Programa de Pós-Graduação em Ciências Médicas, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ Brazil. Electronic address: patricia.souza@inca.gov.br.'}, {'ForeName': 'Carla Fontoura', 'Initials': 'CF', 'LastName': 'Dionello', 'Affiliation': 'Laboratório de Vibrações Mecânicas e Práticas Integrativas, Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Programa de Pós-Graduação em Ciências Médicas, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ Brazil. Electronic address: carla_dionello@yahoo.com.br.'}, {'ForeName': 'Camila Leite', 'Initials': 'CL', 'LastName': 'Bernardes-Oliveira', 'Affiliation': 'Laboratório de Vibrações Mecânicas e Práticas Integrativas, Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Programa de Pós-Graduação em Ciências Médicas, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ Brazil. Electronic address: camilalbernardes@hotmail.com.'}, {'ForeName': 'Eloá', 'Initials': 'E', 'LastName': 'Moreira-Marconi', 'Affiliation': 'Laboratório de Vibrações Mecânicas e Práticas Integrativas, Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Programa de Pós-Graduação em Fisiopatologia Clínica e Experimental, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. Electronic address: eloamarconi@gmail.com.'}, {'ForeName': 'Renata Marques', 'Initials': 'RM', 'LastName': 'Marchon', 'Affiliation': 'Laboratório de Vibrações Mecânicas e Práticas Integrativas, Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Mestrado Profissional em Saúde, Medicina Laboratorial e Tecnologia Forense, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. Electronic address: remarchon_fisio@hotmail.com.'}, {'ForeName': 'Ygor', 'Initials': 'Y', 'LastName': 'Teixeira-Silva', 'Affiliation': 'Laboratório de Vibrações Mecânicas e Práticas Integrativas, Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Programa de Pós-Graduação em Ciências Médicas, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ Brazil. Electronic address: silvarogy@hotmail.com.'}, {'ForeName': 'Laisa Liane', 'Initials': 'LL', 'LastName': 'Paineiras-Domingos', 'Affiliation': 'Laboratório de Vibrações Mecânicas e Práticas Integrativas, Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Programa de Pós-Graduação em Ciências Médicas, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ Brazil; Faculdade Bezerra de Araújo, Rio de Janeiro, RJ, Brazil. Electronic address: laisanit@gmail.com.'}, {'ForeName': 'Danúbia', 'Initials': 'D', 'LastName': 'da Cunha Sá-Caputo', 'Affiliation': 'Laboratório de Vibrações Mecânicas e Práticas Integrativas, Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Programa de Pós-Graduação em Ciências Médicas, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ Brazil; Faculdade Bezerra de Araújo, Rio de Janeiro, RJ, Brazil. Electronic address: dradanubia@gmail.com.'}, {'ForeName': 'Vinicius Layter', 'Initials': 'VL', 'LastName': 'Xavier', 'Affiliation': 'Departamento de Estatística, Instituto de Matemática e Estatística, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: viniciuslx@ime.uerj.br.'}, {'ForeName': 'Anke', 'Initials': 'A', 'LastName': 'Bergmann', 'Affiliation': 'Programa de Epidemiologia Clínica, Instituto Nacional de Câncer (INCA), Brazil. Electronic address: abergmann@inca.gov.br.'}, {'ForeName': 'Evandro Mendes', 'Initials': 'EM', 'LastName': 'Klumb', 'Affiliation': 'Programa de Pós-Graduação em Ciências Médicas, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ Brazil; Departamento de Reumatologia do Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. Electronic address: klumb@uol.com.br.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Bernardo-Filho', 'Affiliation': 'Laboratório de Vibrações Mecânicas e Práticas Integrativas, Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. Electronic address: bernardofilhom@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.01.015'] 1457,34174189,"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.","BACKGROUND The addition of camrelizumab to gemcitabine and cisplatin showed promising activity as first-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma in a phase 1 trial. We therefore compared camrelizumab plus gemcitabine and cisplatin with placebo plus gemcitabine and cisplatin in a randomised phase 3 trial. METHODS In this randomised, double-blind, phase 3 trial done at 28 hospitals in China, patients were eligible if they were aged 18-75 years, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and had previously untreated recurrent or metastatic nasopharyngeal carcinoma. Patients were randomly assigned (1:1; using an interactive web-response system with a block size of four) to receive either camrelizumab (200 mg on day 1) or matching placebo intravenously, plus gemcitabine and cisplatin (gemcitabine 1000 mg/m 2 on days 1 and 8; cisplatin 80 mg/m 2 on day 1) intravenously every 3 weeks for four to six cycles, followed by maintenance therapy with camrelizumab or placebo, until radiographic progression, unacceptable toxicity, start of new anticancer treatment, investigator decision, or withdrawal of consent. Stratification factors used in randomisation were liver metastases, previous radical concurrent chemoradiotherapy, and ECOG performance status. The allocation sequence was generated by an independent randomisation group. The primary endpoint was progression-free survival per independent review committee. The significance threshold for independent review committee-assessed progression-free survival was p=0·0086 (one-sided) at the interim analysis. Efficacy and safety analyses included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03707509, and is closed for enrolment but is ongoing. FINDINGS Between Nov 13, 2018, and Nov 29, 2019, 343 patients were screened and 263 were eligible and were randomly assigned to the camrelizumab group (n=134) or placebo group (n=129). At the prespecified interim analysis (June 15, 2020), independent review committee-assessed progression-free survival was significantly longer in the camrelizumab group (median 9·7 months [95% CI 8·3-11·4]) than in the placebo group (median 6·9 months [5·9-7·3]; hazard ratio 0·54 [95% CI 0·39-0·76]; one-sided p=0·0002). As of Dec 31, 2020, the most common grade 3 or worse adverse events of any cause were decreased white blood cell count (89 [66%] of 134 patients in the camrelizumab group vs 90 [70%] of 129 patients in the placebo group), decreased neutrophil count (86 [64%] vs 85 [66%]), anaemia (53 [40%] vs 57 [44%]), and decreased platelet count (53 [40%] vs 52 [40%]). Serious adverse events were reported in 59 (44%) of 134 patients in the camrelizumab group and 48 (37%) of 129 patients in the placebo group. Treatment-related deaths occurred in five (4%) patients in the camrelizumab group (two unknown cause of death, one multiple organ dysfunction syndrome, one pharyngeal haemorrhage, and one arrhythmia) and one (<1%) patient in the placebo group (unknown cause of death). INTERPRETATION Our findings suggest that camrelizumab plus gemcitabine and cisplatin could be a new standard of care for patients with recurrent or metastatic nasopharyngeal carcinoma in the first-line setting. Longer follow-up is needed to confirm this conclusion. FUNDING Jiangsu Hengrui Pharmaceuticals (formerly Jiangsu Hengrui Medicine). TRANSLATION For the Chinese translation of the abstract see Supplementary Materials section.",2021,"As of Dec 31, 2020, the most common grade 3 or worse adverse events of any cause were decreased white blood cell count (89 [66%] of 134 patients in the camrelizumab group vs 90 [70%] of 129 patients in the placebo group), decreased neutrophil count (86 [64%] vs 85 [66%]), anaemia (53 [40%] vs 57 [44%]), and decreased platelet count (53 [40%] vs 52 [40%]).","['patients with recurrent or metastatic nasopharyngeal carcinoma in the first-line setting', 'Between Nov 13, 2018, and Nov 29, 2019, 343 patients were screened and 263 were eligible', '28 hospitals in China, patients were eligible if they were aged 18-75 years, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and had previously untreated recurrent or metastatic nasopharyngeal carcinoma', 'recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st', 'patients with recurrent or metastatic nasopharyngeal carcinoma in a phase 1 trial', 'patients who received at least one dose of study drug']","['gemcitabine and cisplatin', 'camrelizumab to gemcitabine and cisplatin', 'cisplatin 80 mg', 'camrelizumab', 'camrelizumab plus gemcitabine and cisplatin with placebo plus gemcitabine and cisplatin', 'camrelizumab plus gemcitabine and cisplatin', 'Camrelizumab versus placebo', 'camrelizumab (200 mg on day 1) or matching placebo intravenously, plus gemcitabine and cisplatin (gemcitabine 1000', 'placebo', 'camrelizumab or placebo']","['death', 'neutrophil count', 'platelet count', 'progression-free survival', 'deaths', 'anaemia', 'white blood cell count', 'death, one multiple organ dysfunction syndrome, one pharyngeal haemorrhage, and one arrhythmia', 'Serious adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C2931822', 'cui_str': 'Nasopharyngeal carcinoma'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517671', 'cui_str': '263'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C4521397', 'cui_str': 'US Military Commissioned Officer O6'}, {'cui': 'C0205435', 'cui_str': 'First'}, {'cui': 'C0439559', 'cui_str': 'Phase 1'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C4682408', 'cui_str': 'camrelizumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1883310', 'cui_str': '1000'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0200633', 'cui_str': 'Neutrophil count'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0026766', 'cui_str': 'Multiple organ failure'}, {'cui': 'C0576995', 'cui_str': 'Pharyngeal hemorrhage'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",343.0,0.453277,"As of Dec 31, 2020, the most common grade 3 or worse adverse events of any cause were decreased white blood cell count (89 [66%] of 134 patients in the camrelizumab group vs 90 [70%] of 129 patients in the placebo group), decreased neutrophil count (86 [64%] vs 85 [66%]), anaemia (53 [40%] vs 57 [44%]), and decreased platelet count (53 [40%] vs 52 [40%]).","[{'ForeName': 'Yunpeng', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Qu', 'Affiliation': 'Guangxi Medical University Affiliated Tumor Hospital, Nanning, China.'}, {'ForeName': 'Jingao', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Jiangxi Cancer Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Chaosu', 'Initials': 'C', 'LastName': 'Hu', 'Affiliation': 'Fudan University Shanghai Cancer Center, Shanghai, China.'}, {'ForeName': 'Mingjun', 'Initials': 'M', 'LastName': 'Xu', 'Affiliation': 'First Affiliated Hospital of Gannan Medical University, Ganzhou, China.'}, {'ForeName': 'Weidong', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Guangzhou Medical University Affiliated Oncology Hospital, Guangzhou, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Zhou', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Liangfang', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Xiangya Hospital Central South University, Changsha, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Jinyi', 'Initials': 'J', 'LastName': 'Lang', 'Affiliation': 'Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Guangyuan', 'Initials': 'G', 'LastName': 'Hu', 'Affiliation': 'Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Zhanxiong', 'Initials': 'Z', 'LastName': 'Luo', 'Affiliation': ""Liuzhou People's Hospital, Liuzhou, China.""}, {'ForeName': 'Zhichao', 'Initials': 'Z', 'LastName': 'Fu', 'Affiliation': '900th Hospital of The Joint Logistics Team, PLA, Fuzhou, China.'}, {'ForeName': 'Shenhong', 'Initials': 'S', 'LastName': 'Qu', 'Affiliation': ""Guangxi Zhuang Autonomous Region People's Hospital, Nanning, China.""}, {'ForeName': 'Weineng', 'Initials': 'W', 'LastName': 'Feng', 'Affiliation': ""The First People's Hospital of Foshan, Foshan, China.""}, {'ForeName': 'Xiaozhong', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Shaojun', 'Initials': 'S', 'LastName': 'Lin', 'Affiliation': 'Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.'}, {'ForeName': 'Weimin', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'General Hospital of Southern Theatre Command, Guangzhou, China.'}, {'ForeName': 'Xiaojiang', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Yunnan Cancer Hospital, Kunming, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Beijing Cancer Hospital, Beijing, China.'}, {'ForeName': 'Zhixiong', 'Initials': 'Z', 'LastName': 'Lin', 'Affiliation': 'Cancer Hospital of Shantou University Medical College, Shantou, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Lin', 'Affiliation': 'The First Affiliated Hospital of Xiamen University, Xiamen, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Lei', 'Affiliation': ""Zhongshan People's Hospital, Zhongshan, China.""}, {'ForeName': 'Jianting', 'Initials': 'J', 'LastName': 'Long', 'Affiliation': 'The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Jinsheng', 'Initials': 'J', 'LastName': 'Hong', 'Affiliation': 'The First Affiliated Hospital of Fujian Medical University/Key Laboratory of Radiation Biology, Fuzhou, China.'}, {'ForeName': 'Xiaoming', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Lingzhi', 'Initials': 'L', 'LastName': 'Zeng', 'Affiliation': ""Jiujiang No.1 People's Hospital of Nanchang University, Jiujiang, China.""}, {'ForeName': 'Peiguo', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': 'Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.'}, {'ForeName': 'Xiaohui', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Jiangsu Hengrui Pharmaceuticals, Shanghai, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Yang', 'Affiliation': 'Jiangsu Hengrui Pharmaceuticals, Shanghai, China.'}, {'ForeName': 'Xiaojing', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Jiangsu Hengrui Pharmaceuticals, Shanghai, China.'}, {'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Zou', 'Affiliation': 'Jiangsu Hengrui Pharmaceuticals, Shanghai, China.'}, {'ForeName': 'Wenfeng', 'Initials': 'W', 'LastName': 'Fang', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address: zhangli@sysucc.org.cn.'}]",The Lancet. Oncology,['10.1016/S1470-2045(21)00302-8'] 1458,34175565,Effectiveness of team-based learning on postpartum hemorrhage in midwifery students in Indonesia: A quasi-experimental study.,"BACKGROUND Poor quality of care by midwives in Indonesia has become a barrier to improving maternal health. To eliminate this barrier, reforming the educational system (i.e., teaching and learning processes) is an urgent concern. Herein, we propose the use of team-based learning (TBL) as an active learning strategy to enhance knowledge of postpartum hemorrhage (PPH) and learning satisfaction of midwifery students in Indonesia. OBJECTIVES To assess and compare knowledge of PPH, long-term retention of knowledge, and learning satisfaction of midwifery students attending a TBL class versus a didactic lecture on PPH topics. METHODS A quasi-experimental design was used. The participants were second-year diploma level midwifery students who have (a) no TBL experience, (b) completed the previous semester, and (c) graduated from senior high school (without nursing background). We recruited 118 participants. The midwifery students in the intervention group participated 3 times in the TBL class (90 min), whereas those in the control group participated in the didactic lecture on PPH topics. An unpaired t-test was used to evaluate differences between groups. ANOVA was used to evaluate differences within groups. RESULTS A total of 115 participants (intervention = 62, control = 53) were finally evaluated. The demographic data and pre-test scores were not significantly different between the 2 groups. The mean knowledge of PPH scores were significantly higher in the TBL students than in the control students at post-test, 2 weeks post-test, 6 weeks post-test, and 12 weeks post-test (all p < .001). The nursing student satisfaction scale score was significantly higher in the intervention group than in the control group. CONCLUSION The findings showed that TBL is an effective active learning strategy to improve knowledge of PPH of Indonesian midwifery students before clinical practice exposure. Further long-term evaluation (e.g., 1 semester) of the effectiveness of TBL is warranted.",2021,"The mean knowledge of PPH scores were significantly higher in the TBL students than in the control students at post-test, 2 weeks post-test, 6 weeks post-test, and 12 weeks post-test (all p < .001).","['midwifery students attending a TBL class versus a', '115 participants (intervention\xa0=\xa062, control\xa0=\xa053', 'midwifery students in Indonesia', '118 participants', 'participants were second-year diploma level midwifery students who have (a) no TBL experience, (b) completed the previous semester, and (c) graduated from senior high school (without nursing background']","['didactic lecture on PPH topics', 'team-based learning (TBL', 'team-based learning', 'didactic lecture', 'TBL']","['mean knowledge of PPH scores', 'postpartum hemorrhage', 'demographic data and pre-test scores', 'nursing student satisfaction scale score']","[{'cui': 'C0026082', 'cui_str': 'Midwifery'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0588053', 'cui_str': 'Graduate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]","[{'cui': 'C0376683', 'cui_str': 'Lectures'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",118.0,0.0344416,"The mean knowledge of PPH scores were significantly higher in the TBL students than in the control students at post-test, 2 weeks post-test, 6 weeks post-test, and 12 weeks post-test (all p < .001).","[{'ForeName': 'Yunefit', 'Initials': 'Y', 'LastName': 'Ulfa', 'Affiliation': ""Graduate School of Nursing Science, St. Luke's International University, Tokyo, Japan. Electronic address: 17dn901@slcn.ac.jp.""}, {'ForeName': 'Yukari', 'Initials': 'Y', 'LastName': 'Igarashi', 'Affiliation': ""Graduate School of Nursing Science, St. Luke's International University, Tokyo, Japan. Electronic address: yukari@slcn.ac.jp.""}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Takahata', 'Affiliation': ""Graduate School of Nursing Science, St. Luke's International University, Tokyo, Japan. Electronic address: kaoritakahata@slcn.ac.jp.""}, {'ForeName': 'Eri', 'Initials': 'E', 'LastName': 'Shishido', 'Affiliation': ""Graduate School of Nursing Science, St. Luke's International University, Tokyo, Japan. Electronic address: eri-shishido@slcn.ac.jp.""}, {'ForeName': 'Shigeko', 'Initials': 'S', 'LastName': 'Horiuchi', 'Affiliation': ""Graduate School of Nursing Science, St. Luke's International University, Tokyo, Japan. Electronic address: shigeko-horiuchi@slcn.ac.jp.""}]",Nurse education today,['10.1016/j.nedt.2021.105015'] 1459,34214863,Self-disclosure is associated with adrenocortical attunement between new acquaintances.,"Adrenocortical attunement-similarity in hypothalamic-pituitary-adrenal (HPA) axis activity-has been well-documented in close relationships (e.g., between romantic partners, parents and children, and close friends). However, little is known about adrenocortical attunement during early relationship formation. In the current study, we examine dyadic adrenocortical attunement during a guided conversation in which two new acquaintances (N = 140 people, 70 dyads), who were university students or adults in the community, answered questions about themselves. Dyads were randomly assigned to answer questions designed to elicit dyad members to reveal a high or low amount of personal information (i.e., to self-disclose at high or low levels). We collected saliva samples (assayed for cortisol) before and after the conversation, and we coded behavioral self-disclosure-the extent to which people revealed their thoughts, feelings, and facts about themselves-during the conversation. As expected, dyads who were assigned to ask and answer high self-disclosure questions disclosed more than those assigned to ask and answer low self-disclosure questions. In addition, greater self-disclosure during the conversation was associated with greater similarity in cortisol change-that is, dyad members who revealed more about themselves experienced more similar cortisol changes in response to their conversation. This work reveals one social process through which adrenocortical attunement occurs during early relationship formation, and, in doing so, describes how our physiological functioning is linked to those around us-even people we have just met.",2021,"As expected, dyads who were assigned to ask and answer high self-disclosure questions disclosed more than those assigned to ask and answer low self-disclosure questions.","['dyadic adrenocortical attunement during a guided conversation in which two new acquaintances (N\xa0=\xa0140 people, 70 dyads), who were university students or adults in the community, answered questions about themselves']",[],['greater self-disclosure'],"[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0337609', 'cui_str': 'Acquaintance'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}]",[],"[{'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0036596', 'cui_str': 'Self Disclosure'}]",140.0,0.04974,"As expected, dyads who were assigned to ask and answer high self-disclosure questions disclosed more than those assigned to ask and answer low self-disclosure questions.","[{'ForeName': 'Katherine R', 'Initials': 'KR', 'LastName': 'Thorson', 'Affiliation': 'Dept. of Psychology, 3009 Broadway, Barnard College of Columbia University, New York, NY, USA. Electronic address: kthorson@barnard.edu.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Ketay', 'Affiliation': 'Department of Psychology, University of Hartford, West Hartford, CT, USA.'}, {'ForeName': 'Ashlin R K', 'Initials': 'ARK', 'LastName': 'Roy', 'Affiliation': 'Department of Neurology, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Keith M', 'Initials': 'KM', 'LastName': 'Welker', 'Affiliation': 'Department of Psychology, University of Massachusetts Boston, Boston, MA, USA.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2021.105323'] 1460,34171709,"Combination of real-time needle-tip pressure sensing and minimal intensity stimulation limits unintentional intraneural injection during an ultrasound-guided peripheral nerve block procedure: A randomized, parallel group, controlled trial.","STUDY OBJECTIVE Ultrasound guidance does not eliminate the risk of intraneural injection, which must be avoided during PNB. Combining ultrasound guidance (USG), nerve stimulation (NS), and injection pressure monitoring is advocated to prevent nerve injury during PNB. We hypothesized that combining patient-tailored dynamic NS and real-time pressure sensing (RTPS) could reduce the incidence of intraneural injection and nerve puncture during USG PNB compared with a traditional fixed thresholds (Control) procedure. DESIGN Randomized, prospective study. SETTING Operating room. PATIENTS One hundred ASA physical status I to III patients undergoing orthopedic surgery. INTERVENTIONS Patient anesthetized using axillary, sciatic or femoral USG PNB were randomized to the PresStim group (Dynamic RTPS and NS set at 1.5 mA then decreased; n = 50) or Control group (fixed thresholds for in-line pressure mechanical manometer and NS at 0.2 mA; n = 50). MEASUREMENTS Procedural ultrasound images and videos were recorded, stored and reviewed in random order by two experts in ultrasound-guided PNB blinded to the group. They noted the needle-to-nerve relationship and intraneural injection for all blocked nerves. MAIN RESULTS One hundred and twenty-three USG PNBs were performed (56 axillary brachial plexus blocks, 40 femoral nerve blocks and 27 sciatic popliteal nerve blocks); 235 blocked nerves and videos were recorded and analyzed (PresStim, 118; Control, 117). Less paresthesia was noted in the PresStim group (12.7%) compared with the Control group (18.8%). The risk of intraneural injection was significantly higher in the Control group (odds ratio [OR], 17.1; 95% confidence interval [CI], 2.2-135, P = 0.007). The risk of nerve puncture (OR, 22.7; 95% CI, 2.9-175, p = 0.003) and needle-nerve contact (OR, 4.7; 95% CI, 2.4-9.5, p < 0.001) was significantly higher in the Control group than the PresStim group. CONCLUSIONS Under the conditions of the study, dynamic triple monitoring combining RTPS, NS and USG decreases intraneural injection and unintentional needle-nerve contact and puncture during a PNB procedure.",2021,"The risk of nerve puncture (OR, 22.7; 95% CI, 2.9-175, p = 0.003) and needle-nerve contact (OR, 4.7; 95% CI, 2.4-9.5, p < 0.001) was significantly higher in the Control group than the PresStim group. ","['III patients undergoing orthopedic surgery', 'One hundred ASA physical status', 'One hundred and twenty-three USG PNBs were performed (56 axillary brachial plexus blocks, 40 femoral nerve blocks and 27 sciatic popliteal nerve blocks); 235 blocked nerves and videos were recorded and analyzed (PresStim, 118; Control, 117']","['real-time needle-tip pressure sensing and minimal intensity stimulation limits unintentional intraneural injection', 'combining patient-tailored dynamic NS and real-time pressure sensing (RTPS', 'Combining ultrasound guidance (USG), nerve stimulation (NS), and injection pressure monitoring', 'Patient anesthetized using axillary, sciatic or femoral USG PNB', 'PresStim group (Dynamic RTPS and NS set at 1.5\xa0mA then decreased; n\xa0=\xa050) or Control group (fixed thresholds for in-line pressure mechanical manometer and NS at 0.2\xa0mA; n\xa0=\xa050']","['needle-nerve contact', 'Less paresthesia', 'risk of nerve puncture', 'risk of intraneural injection']","[{'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0394701', 'cui_str': 'Brachial plexus block by axillary approach'}, {'cui': 'C0394739', 'cui_str': 'Local anesthetic femoral nerve block'}, {'cui': 'C0446826', 'cui_str': 'Popliteal nerve'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C1283932', 'cui_str': 'Unintentional'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C1720436', 'cui_str': 'Under anesthesia'}, {'cui': 'C0004454', 'cui_str': 'Axillary'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0303973', 'cui_str': 'p-nitrobiphenyl'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C2720530', 'cui_str': 'Manometer'}, {'cui': 'C4517436', 'cui_str': '0.2'}]","[{'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]",235.0,0.0944402,"The risk of nerve puncture (OR, 22.7; 95% CI, 2.9-175, p = 0.003) and needle-nerve contact (OR, 4.7; 95% CI, 2.4-9.5, p < 0.001) was significantly higher in the Control group than the PresStim group. ","[{'ForeName': 'Adrien', 'Initials': 'A', 'LastName': 'Coudray', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Lapeyronie University Hospital, 34295 Montpellier Cedex 5, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Choquet', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Lapeyronie University Hospital, 34295 Montpellier Cedex 5, France.'}, {'ForeName': 'Fabien', 'Initials': 'F', 'LastName': 'Swisser', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Lapeyronie University Hospital, 34295 Montpellier Cedex 5, France.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Hochman', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Lapeyronie University Hospital, 34295 Montpellier Cedex 5, France; Department of Restorative Dentistry, Stony Brook School of Dental Medicine, NY, New York, United States of America.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Bringuier', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Lapeyronie University Hospital, 34295 Montpellier Cedex 5, France; Department of Medical Statistics, Montpellier University Hospital, 34295 Montpellier Cedex 5, France.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Capdevila', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Lapeyronie University Hospital, 34295 Montpellier Cedex 5, France; Inserm Unit 1051 Montpellier NeuroSciences Institute, Montpellier University, 34295 Montpellier Cedex 5, France. Electronic address: x-capdevila@chu-montpellier.fr.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110420'] 1461,34171694,A comparison of an absorbable nasal implant versus functional rhinoplasty for nasal obstruction.,"PURPOSE An absorbable nasal implant for the treatment lateral nasal wall collapse was approved for use in patients with nasal obstruction. It remains to be seen whether this treatment is equivalent to open techniques for the treatment of nasal valve incompetence from collapsibility. MATERIALS AND METHODS Two groups were analyzed for the study. One group had surgery which included the implant, septoplasty, and inferior turbinate submucous reduction and the other group had a variety of functional rhinoplasty techniques for lateral wall insufficiency in addition to septoplasty and inferior turbinate submucous reduction. NOSE and SNOT-22 were used to demonstrate pre and post-operative changes. RESULTS Ninety total patients were identified. Fifty patients underwent insertion of an absorbable nasal implant and 40 underwent a traditional open technique to stabilize the LNW. For the implant group the mean NOSE score was 63.4 (SD 24) and post-operative was 22.9 (SD 19.9), in addition, the SNOT-22 score was 38.8 (SD 19.8) and post-operative was 18.5 (SD 15.2). For the open rhinoplasty group, the mean NOSE score was 57.9 (SD 23.2) and post-operative was 17.6 (SD 16.4). The SNOT-22 score was 33.6 (SD 14.9) and post-operative score was 11.5 (SD 15.2) The delta between pre and post-operative NOSE and SNOT-22 test were not different at an average of 3.95 months post-operatively between the groups (NOSE, P = 0.94 and SNOT-22, p = 0.53). CONCLUSION In patients with multiple structural causes of nasal obstruction, including lateral wall insufficiency, insertion of an absorbable nasal implant, to support the LNW, seems to be equally effective as functional rhinoplasty techniques over a 4 month timeframe.",2021,"The delta between pre and post-operative NOSE and SNOT-22 test were not different at an average of 3.95 months post-operatively between the groups (NOSE, P = 0.94 and SNOT-22, p = 0.53). ","['Fifty patients underwent insertion of an', 'nasal obstruction', 'Ninety total patients were identified', 'patients with multiple structural causes of nasal obstruction, including lateral wall insufficiency, insertion of an absorbable nasal implant', 'patients with nasal obstruction']","['absorbable nasal implant versus functional rhinoplasty', 'absorbable nasal implant and 40 underwent a traditional open technique to stabilize the LNW', 'absorbable nasal implant']","['mean NOSE score', 'SNOT-22 score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0027429', 'cui_str': 'Nasal obstruction'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0496828', 'cui_str': 'Malignant neoplasm of lateral wall of urinary bladder'}, {'cui': 'C0231179', 'cui_str': 'Insufficiency'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]","[{'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0035467', 'cui_str': 'Rhinoplasty'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0184512', 'cui_str': 'Stabilized'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C5197690', 'cui_str': 'SNOT-22'}]",90.0,0.0257948,"The delta between pre and post-operative NOSE and SNOT-22 test were not different at an average of 3.95 months post-operatively between the groups (NOSE, P = 0.94 and SNOT-22, p = 0.53). ","[{'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Olson', 'Affiliation': 'Texas Center for Facial Plastic and Laser Surgery, San Antonio, TX, USA. Electronic address: olson.michael@mayo.edu.'}, {'ForeName': 'Jose E', 'Initials': 'JE', 'LastName': 'Barrera', 'Affiliation': 'Texas Center for Facial Plastic and Laser Surgery, San Antonio, TX, USA. Electronic address: office@drjosebarrera.com.'}]",American journal of otolaryngology,['10.1016/j.amjoto.2021.103118'] 1462,34174097,Estimating vaccine efficacy over time after a randomized study is unblinded.,"The COVID-19 pandemic due to the novel coronavirus SARS CoV-2 has inspired remarkable breakthroughs in the development of vaccines against the virus and the launch of several phase 3 vaccine trials in Summer 2020 to evaluate vaccine efficacy (VE). Trials of vaccine candidates using mRNA delivery systems developed by Pfizer-BioNTech and Moderna have shown substantial VEs of 94-95%, leading the US Food and Drug Administration to issue Emergency Use Authorizations and subsequent widespread administration of the vaccines. As the trials continue, a key issue is the possibility that VE may wane over time. Ethical considerations dictate that trial participants be unblinded and those randomized to placebo be offered study vaccine, leading to trial protocol amendments specifying unblinding strategies. Crossover of placebo subjects to vaccine complicates inference on waning of VE. We focus on the particular features of the Moderna trial and propose a statistical framework based on a potential outcomes formulation within which we develop methods for inference on potential waning of VE over time and estimation of VE at any postvaccination time. The framework clarifies assumptions made regarding individual- and population-level phenomena and acknowledges the possibility that subjects who are more or less likely to become infected may be crossed over to vaccine differentially over time. The principles of the framework can be adapted straightforwardly to other trials.",2021,The COVID-19 pandemic due to the novel coronavirus SARS CoV-2 has inspired remarkable breakthroughs in the development of vaccines against the virus and the launch of several phase 3 vaccine trials in Summer 2020 to evaluate vaccine efficacy (VE).,[],['placebo'],[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.408217,The COVID-19 pandemic due to the novel coronavirus SARS CoV-2 has inspired remarkable breakthroughs in the development of vaccines against the virus and the launch of several phase 3 vaccine trials in Summer 2020 to evaluate vaccine efficacy (VE).,"[{'ForeName': 'Anastasios A', 'Initials': 'AA', 'LastName': 'Tsiatis', 'Affiliation': 'Department of Statistics, North Carolina State University, Raleigh, NC, USA.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Davidian', 'Affiliation': 'Department of Statistics, North Carolina State University, Raleigh, NC, USA.'}]",Biometrics,['10.1111/biom.13509'] 1463,34175782,Instagram Sexualization: When posts make you feel dissatisfied and wanting to change your body.,"Instagram is a visually centered social media that involves the presence of sexualized imagery posted by users. Such Instagram sexualization may have a negative impact on women's body image. The present study examined whether exposure to Instagram sexualization, namely posts of sexualized women along with appearance-related comments, affected women's body satisfaction and cosmetic surgery intentions. In doing so, it also considered the moderating role of Instagram Addiction Proclivity (IAP). Young Italian female participants (N = 247) were randomly exposed to one of four video conditions resulting from the combination of either sexualized or non-sexualized women's pictures on Instagram, paired with appearance or neutral comments. In the sexualized picture condition participants' body dissatisfaction increased compared to pre-exposure levels and to the non-sexualized picture condition. The type of comments did not affect participants' body satisfaction. Moreover, IAP predicted cosmetic surgery intentions and moderated their reactions to Instagram content. Indeed, the higher the IAP, the higher the cosmetic surgery intentions of participants viewing sexualized pictures with neutral comments and non-sexualized pictures with body appearance comments. These findings suggest that female Instagram users should be aware of the negative impacts of viewing sexualized imagery as well as the role that IAP may play.",2021,In the sexualized picture condition participants' body dissatisfaction increased compared to pre-exposure levels and to the non-sexualized picture condition.,"['female Instagram users', 'Young Italian female participants (N = 247']","[""sexualized or non-sexualized women's pictures on Instagram, paired with appearance or neutral comments"", 'Instagram Sexualization']","['body dissatisfaction', 'cosmetic surgery intentions']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0022275', 'cui_str': 'Italian language'}]","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0282411', 'cui_str': 'Editorial Comment'}]","[{'cui': 'C2732632', 'cui_str': 'Dissatisfaction with body image'}, {'cui': 'C0079169', 'cui_str': 'Cosmetic Surgery'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",247.0,0.0211608,In the sexualized picture condition participants' body dissatisfaction increased compared to pre-exposure levels and to the non-sexualized picture condition.,"[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Guizzo', 'Affiliation': 'University of Surrey, School of Psychology, Stag Hill Campus, GU2 7HX, Guildford, United Kingdom; University of Padova, Department of Developmental and Social Psychology, Via Venezia 8, 35131, Padova, Italy. Electronic address: f.guizzo@surrey.ac.uk.'}, {'ForeName': 'Natale', 'Initials': 'N', 'LastName': 'Canale', 'Affiliation': 'University of Padova, Department of Developmental and Social Psychology, Via Venezia 8, 35131, Padova, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Fasoli', 'Affiliation': 'University of Surrey, School of Psychology, Stag Hill Campus, GU2 7HX, Guildford, United Kingdom; Centro de Investigação e Intervenção Social do Instituto Universitário de Lisboa, ISCTE-IUL, Av. das Forças Armadas, 1649-026, Lisboa, Portugal.'}]",Body image,['10.1016/j.bodyim.2021.06.005'] 1464,34180949,Home Health Management of Parkinson Disease Deep Brain Stimulation: A Randomized Clinical Trial.,"Importance The travel required to receive deep brain stimulation (DBS) programming causes substantial burden on patients and limits who can access DBS therapy. Objective To evaluate the efficacy of home health DBS postoperative management in an effort to reduce travel burden and improve access. Design, Settings, and Participants This open-label randomized clinical trial was conducted at University of Florida Health from November 2017 to April 2020. Eligible participants had a diagnosis of Parkinson disease (PD) and were scheduled to receive DBS independently of the study. Consenting participants were randomized 1:1 to receive either standard of care or home health postoperative DBS management for 6 months after surgery. Primary caregivers, usually spouses, were also enrolled to assess caregiver strain. Interventions The home health postoperative management was conducted by a home health nurse who chose DBS settings with the aid of the iPad-based Mobile Application for PD DBS system. Prior to the study, the home health nurse had no experience providing DBS care. Main Outcomes and Measures The primary outcome was the number of times each patient traveled to the movement disorders clinic during the study period. Secondary outcomes included changes from baseline on the Unified Parkinson's Disease Rating Scale part III. Results Approximately 75 patients per year were scheduled for DBS. Of the patients who met inclusion criteria over the entire study duration, 45 either declined or were excluded for various reasons. Of the 44 patients enrolled, 19 of 21 randomized patients receiving the standard of care (mean [SD] age, 64.1 [10.0] years; 11 men) and 23 of 23 randomized patients receiving home health who underwent a minimum of 1 postoperative management visit (mean [SD] age, 65.0 [10.9] years; 13 men) were included in analysis. The primary outcome revealed that patients randomized to home health had significantly fewer clinic visits than the patients in the standard of care arm (mean [SD], 0.4 [0.8] visits vs 4.8 [0.4] visits; P < .001). We found no significant differences between the groups in the secondary outcomes measuring the efficacy of DBS. No adverse events occurred in association with the study procedure or devices. Conclusions and Relevance This study provides evidence supporting the safety and feasibility of postoperative home health DBS management. Trial Registration ClinicalTrials.gov Identifier: NCT02474459.",2021,"The primary outcome revealed that patients randomized to home health had significantly fewer clinic visits than the patients in the standard of care arm (mean [SD], 0.4 [0.8] visits vs 4.8 [0.4] visits; P < .001).","['44 patients enrolled, 19 of 21 randomized patients receiving the standard of care (mean [SD] age, 64.1 [10.0] years; 11 men) and 23 of 23 randomized patients receiving home health who underwent a minimum of 1 postoperative management visit (mean [SD] age, 65.0 [10.9] years; 13 men', 'Eligible participants had a diagnosis of Parkinson disease (PD) and were scheduled to receive DBS independently of the study', 'Parkinson Disease Deep Brain Stimulation', 'University of Florida Health from November 2017 to April 2020', 'Consenting participants', 'patients who met inclusion criteria over the entire study duration, 45 either declined or were excluded for various reasons', 'patients and limits who can access DBS therapy']","['standard of care or home health postoperative DBS management', 'deep brain stimulation (DBS) programming']","[""Unified Parkinson's Disease Rating Scale"", 'efficacy of DBS', 'adverse events', 'number of times each patient traveled to the movement disorders clinic', 'clinic visits']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1317851', 'cui_str': 'Home health care'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0016253', 'cui_str': 'Florida'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1317851', 'cui_str': 'Home health care'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449809', 'cui_str': 'Number of times'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040802', 'cui_str': 'Travel'}, {'cui': 'C3839502', 'cui_str': 'Movement disorder clinic'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}]",44.0,0.319387,"The primary outcome revealed that patients randomized to home health had significantly fewer clinic visits than the patients in the standard of care arm (mean [SD], 0.4 [0.8] visits vs 4.8 [0.4] visits; P < .001).","[{'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Duffley', 'Affiliation': 'Scientific Computing and Imaging Institute, University of Utah, Salt Lake City.'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Lutz', 'Affiliation': 'School of Nursing, University of North Carolina-Wilmington, Wilmington.'}, {'ForeName': 'Aniko', 'Initials': 'A', 'LastName': 'Szabo', 'Affiliation': 'Division of Biostatistics, Institute for Health & Equity, Medical College of Wisconsin, Milwaukee.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Wright', 'Affiliation': 'Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville.'}, {'ForeName': 'Christopher W', 'Initials': 'CW', 'LastName': 'Hess', 'Affiliation': 'Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville.'}, {'ForeName': 'Adolfo', 'Initials': 'A', 'LastName': 'Ramirez-Zamora', 'Affiliation': 'Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Zeilman', 'Affiliation': 'Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Chiu', 'Affiliation': 'Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville.'}, {'ForeName': 'Kelly D', 'Initials': 'KD', 'LastName': 'Foote', 'Affiliation': 'Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Okun', 'Affiliation': 'Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Butson', 'Affiliation': 'Scientific Computing and Imaging Institute, University of Utah, Salt Lake City.'}]",JAMA neurology,['10.1001/jamaneurol.2021.1910'] 1465,34182998,Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.,"BACKGROUND In the Phase III KRONOS study, triple therapy with budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) was shown to reduce exacerbations and improve lung function versus glycopyrronium/formoterol fumarate dihydrate (GFF) MDI in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD). However, whether the benefits related to the ICS component of BGF are driven by patients with high blood eosinophil counts (EOS) and/or airway reversibility has not been previously studied. METHODS KRONOS was a Phase III, double-blind, parallel-group, multicenter, randomized, controlled study of patients with moderate-to-very-severe COPD. Patients were randomized 2:2:1:1 to receive BGF 320/14.4/10 μg, GFF 14.4/10 μg, budesonide/formoterol fumarate dihydrate (BFF) MDI 320/10 μg via a single Aerosphere inhaler, or open-label budesonide/formoterol fumarate dihydrate dry powder inhaler 400/12 μg (BUD/FORM DPI; Symbicort Turbuhaler) twice-daily for 24 weeks. Efficacy outcomes included in this post-hoc analysis were change from baseline in morning pre-dose trough FEV 1 over weeks 12-24 and the rate of moderate-to-severe and severe COPD exacerbations. Adverse events in the non-reversible subgroup are also reported. RESULTS Of 1896 patients analyzed, 948 (50%) were non-reversible and had EOS < 300 cells/mm 3 . In this group, BGF significantly improved morning pre-dose trough FEV 1 versus BFF and BUD/FORM (least squares mean treatment difference, 95% confidence interval [CI] 69 mL [39, 99], unadjusted p < 0.0001 and 51 mL [20, 81], unadjusted p = 0.0011, respectively) and was comparable to GFF. BGF also significantly reduced annual moderate-to-severe exacerbation rates versus GFF (rate ratio [95% CI] 0.53 [0.37, 0.76], unadjusted p = 0.0005), with numerical reductions observed versus BFF and BUD/FORM. These results were similar for the overall study population. Safety findings were generally similar between non-reversible patients with EOS < 300 cells/mm 3 and the overall population. CONCLUSIONS In patients with moderate-to-very-severe COPD without airway reversibility and EOS < 300 cells/mm 3 , BGF significantly improved morning pre-dose trough FEV 1 versus BFF and BUD/FORM and significantly reduced the rate of moderate-to-severe exacerbations versus GFF. These findings demonstrate that BGF can provide benefits for a broad range of patients with COPD, and that the overall findings of the KRONOS primary analysis were not driven by patients with reversible airflow obstruction or high eosinophil counts. Trial registration ClinicalTrials.gov, NCT02497001. Registered 14 July 2015, https://clinicaltrials.gov/ct2/show/NCT02497001.",2021,"Safety findings were generally similar between non-reversible patients with EOS < 300 cells/mm 3 and the overall population. ","['1896 patients analyzed, 948 (50%) were non-reversible and had EOS\u2009<\u2009300 cells/mm 3 ', 'patients with COPD', 'patients with airway reversibility and high eosinophil counts', 'patients with moderate-to-very-severe COPD', 'patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD']","['budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI', 'BGF', 'budesonide/glycopyrronium/formoterol', 'BGF 320/14.4/10\xa0μg, GFF 14.4/10\xa0μg, budesonide/formoterol fumarate dihydrate (BFF) MDI 320/10\xa0μg via a single Aerosphere inhaler, or open-label budesonide/formoterol fumarate dihydrate dry powder inhaler 400/12\xa0μg', 'mL', 'glycopyrronium/formoterol fumarate dihydrate (GFF) MDI']","['rate of moderate-to-severe exacerbations', 'rate of moderate-to-severe and severe COPD exacerbations', 'BGF significantly improved morning pre-dose trough FEV 1 versus BFF and BUD/FORM', 'Adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205343', 'cui_str': 'Reversible'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0449261', 'cui_str': 'Reversibility'}, {'cui': 'C0014457', 'cui_str': 'Eosinophilia'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C3641272', 'cui_str': 'Very severe'}]","[{'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C3814772', 'cui_str': 'glycopyrronium'}, {'cui': 'C0771469', 'cui_str': 'Formoterol fumarate'}, {'cui': 'C0993596', 'cui_str': 'Metered dose inhaler'}, {'cui': 'C0060657', 'cui_str': 'formoterol'}, {'cui': 'C1579393', 'cui_str': 'Formoterol fumarate dihydrate'}, {'cui': 'C1276807', 'cui_str': 'formoterol and budesonide'}, {'cui': 'C0016801', 'cui_str': 'Fumarates'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021461', 'cui_str': 'Inhaler'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1967611', 'cui_str': 'Dry powder inhaler'}]","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0730607', 'cui_str': 'Severe chronic obstructive pulmonary disease'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0439565', 'cui_str': 'Pre-dose'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C1276807', 'cui_str': 'formoterol and budesonide'}, {'cui': 'C0016801', 'cui_str': 'Fumarates'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.295764,"Safety findings were generally similar between non-reversible patients with EOS < 300 cells/mm 3 and the overall population. ","[{'ForeName': 'Shigeo', 'Initials': 'S', 'LastName': 'Muro', 'Affiliation': 'Department of Respiratory Medicine, Nara Medical University Graduate School of Medicine, 840 Shijo-cho, Kashihara-shi, Nara, 634-8521, Japan. smuro@naramed-u.ac.jp.'}, {'ForeName': 'Hisatoshi', 'Initials': 'H', 'LastName': 'Sugiura', 'Affiliation': 'Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Darken', 'Affiliation': 'AstraZeneca, Wilmington, DE, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dorinsky', 'Affiliation': 'AstraZeneca, Durham, NC, USA.'}]",Respiratory research,['10.1186/s12931-021-01773-1'] 1466,34391225,Effects of proprioceptive training on ankle muscle strength in fencers: A clinical trial.,"BACKGROUND Fencing is a combat sport, which depends of lower limbs muscular strength and neuromuscular function. Because of that, approximately half of all injuries occur in lower limbs, especially in ankle. Thus, the objective of this study was to verify the influence of a twelve-week proprioceptive training program on ankle muscular strength and muscular balance in fencers. METHODS The study was a clinical trial, with 19 fencing athletes from 14 to 35-year-old. The main outcome was ankle invertors, evertors, plantiflexors and dorsiflexors muscular strength and ankle muscle balance. The study was performed in six stages: familiarization of muscular strength test in isokinetic dynamometer; pre-intervention; intervention; post-intervention; three- and six-months follow-up. At pre-intervention stage, the muscular strength was evaluated. At intervention stage, the athletes performed 12-week proprioceptive training program, three times a week. At post-intervention, three- and the six-months follow-ups, same pre-intervention test was performed. RESULTS The proprioceptive training improved front leg ankle dorsiflexor strength at three- and six-months follow-ups compared to pre-intervention. Furthermore, training increased the front leg dorsiflexors/plantiflexors conventional ratio at three- and six-months follow-ups compared to pre-intervention; and evertors/invertors conventional ratio at three-months follow-up compared to pre-intervention; and evertors/invertors functional ratio at post-intervention and three- and six-months follow-ups compared to pre-intervention. CONCLUSIONS The improvement and/or maintenance of ankle muscle strength occurred in intervention group seems to be due to stimulus provided by proprioceptive training, with ankle dorsiflexors being the most stimulated group.",2021,The proprioceptive training improved front leg ankle dorsiflexor strength at three- and six-months follow-ups compared to pre-intervention.,"['fencers', '19 fencing athletes from 14 to 35-year-old']","['muscular strength test in isokinetic dynamometer; pre-intervention; intervention; post-intervention; three- and six-months follow-up', 'proprioceptive training program', 'proprioceptive training']","['ankle muscle strength', 'front leg ankle dorsiflexor strength', 'ankle muscular strength and muscular balance', 'ankle invertors, evertors, plantiflexors and dorsiflexors muscular strength and ankle muscle balance', 'front leg dorsiflexors/plantiflexors conventional ratio']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0180572', 'cui_str': 'Dynamometer'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0016555', 'cui_str': 'Forelimb'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",19.0,0.00675749,The proprioceptive training improved front leg ankle dorsiflexor strength at three- and six-months follow-ups compared to pre-intervention.,"[{'ForeName': 'Vasconcelos', 'Initials': 'V', 'LastName': 'Gabriela', 'Affiliation': 'Laboratório de Pesquisa do Exercício/ Universidade Federal do Rio Grande do Sul(UFRGS), Porto Alegre, RS, Brazil. Electronic address: vasconcelosgs@gmail.com.'}, {'ForeName': 'Grazioli', 'Initials': 'G', 'LastName': 'Rafael', 'Affiliation': 'Laboratório de Pesquisa do Exercício/ Universidade Federal do Rio Grande do Sul(UFRGS), Porto Alegre, RS, Brazil.'}, {'ForeName': 'Minozzo', 'Initials': 'M', 'LastName': 'Felipe', 'Affiliation': 'Laboratório de Pesquisa do Exercício/ Universidade Federal do Rio Grande do Sul(UFRGS), Porto Alegre, RS, Brazil.'}, {'ForeName': 'Lima', 'Initials': 'L', 'LastName': 'Cláudia', 'Affiliation': 'Laboratório de Pesquisa do Exercício/ Universidade Federal do Rio Grande do Sul(UFRGS), Porto Alegre, RS, Brazil.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.01.011'] 1467,34391221,The acute mechanism of the self-massage-induced effects of using a foam roller.,"INTRODUCTION Maintaining flexibility, often defined as range of motion (ROM), is important. Recently, self-massage using a foam roller (FR) has been used in clinical and/or sports settings to effectively and immediately improve ROM. Many studies have found significant increases in ROM following the FR intervention; however, the mechanism of the effect is unclear. We aimed to clarify this mechanism regarding the ROM effects following the FR intervention by evaluating local tissue and autonomic nervous system responses. METHOD The study employed a crossover design that included a comparison between non-intervention (CON trial: left leg) and intervention (FR trial: right leg) groups. Fourteen volunteers participated. Nine outcomes (passive maximum ankle ROM [ROM with a specified and non-specified passive strength], tissue hardness, skin temperature, water contents, circumference, blood flow velocity, pressure pain threshold, autonomic nervous system, and heart rate) were investigated before (PRE) and 0 min (POST0), 20 min (POST20), 40 min (POST40), and 60 min (POST60) post intervention. RESULTS Skin temperature, impedance, and circumference changed significantly following the intervention, and increased ROM with non-specified strength was observed. DISCUSSION Although we found that the FR intervention influenced skin temperature, impedance, circumference, and ROM, adaptability to the intervention may differ depending on an individual's characteristics. Females and/or individuals with a high body water content could obtain greater positive ROM effects than males and/or individuals with a low body water content. CONCLUSION These findings suggest that the FR intervention may be an effective method to improve ROM, with alterations of skin temperature, impedance, and circumference.",2021,"Females and/or individuals with a high body water content could obtain greater positive ROM effects than males and/or individuals with a low body water content. ",['Fourteen volunteers participated'],['FR intervention'],"['positive ROM effects', 'ROM, with alterations of skin temperature, impedance, and circumference', 'ROM with non-specified strength', 'Nine outcomes (passive maximum ankle ROM [ROM with a specified and non-specified passive strength], tissue hardness, skin temperature, water contents, circumference, blood flow velocity, pressure pain threshold, autonomic nervous system, and heart rate) were investigated before (PRE) and 0\xa0min (POST0), 20\xa0min (POST20), 40\xa0min (POST40), and 60\xa0min (POST60) post intervention', 'skin temperature, impedance, circumference, and ROM, adaptability', 'Skin temperature, impedance, and circumference', 'ROM', 'ROM effects']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0326180', 'cui_str': 'Coraciidae'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0162537', 'cui_str': 'Impedance'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0576183', 'cui_str': 'Ankle joint - range of movement'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0005798', 'cui_str': 'Blood Flow Velocity'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",14.0,0.00697078,"Females and/or individuals with a high body water content could obtain greater positive ROM effects than males and/or individuals with a low body water content. ","[{'ForeName': 'Akane', 'Initials': 'A', 'LastName': 'Yoshimura', 'Affiliation': 'Graduate School of Sport Sciences, Waseda University, Japan. Electronic address: 0906akane@gmail.com.'}, {'ForeName': 'Yuta', 'Initials': 'Y', 'LastName': 'Sekine', 'Affiliation': 'Faculty of Modern Life, Teikyo Heisei University, Japan. Electronic address: y.sekine@thu.ac.jp.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Schleip', 'Affiliation': 'Department of Sport and Health Sciences, Technical University of Munich, Germany. Electronic address: robert.schleip@tum.de.'}, {'ForeName': 'Atsuya', 'Initials': 'A', 'LastName': 'Furusyo', 'Affiliation': 'Graduate School of Sport Sciences, Waseda University, Japan. Electronic address: f.atsuya1996@gmail.com.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Yamazaki', 'Affiliation': 'Graduate School of Sport Sciences, Waseda University, Japan. Electronic address: k.yamazaki.at@gmail.com.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Inami', 'Affiliation': 'Institute of Physical Education, Keio University, Japan. Electronic address: inamit@keio.jp.'}, {'ForeName': 'Mitsuyoshi', 'Initials': 'M', 'LastName': 'Murayama', 'Affiliation': 'Institute of Physical Education, Keio University, Japan. Electronic address: murayama@z3.keio.jp.'}, {'ForeName': 'Norikazu', 'Initials': 'N', 'LastName': 'Hirose', 'Affiliation': 'Faculty of Sport Sciences, Waseda University, 3-4-1, Higashifushimi, Nishitokyo City, Tokyo, 2020021, Japan. Electronic address: toitsu_hirose@waseda.jp.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.02.012'] 1468,34391194,A soft baby carrier intervention enhances amygdala responses to infant crying in fathers: A randomized controlled trial.,"New fathers may grow into their parental role through active involvement in childcare. Spending time in physical contact with the child may promote an adaptive transition to fatherhood. In this randomized controlled trial, we tested the effects of a baby carrier intervention on fathers' hormonal and neural functioning. Using functional magnetic resonance imaging (fMRI), we examined whether infant carrying affects neural reactivity to infant crying in first-time fathers, taking into account the role of the hormone oxytocin as a mediating mechanism and fathers' own childhood experiences as a potential moderating factor. Sixty first-time fathers (infant age M = 11.18 weeks, SD = 2.08) were randomly assigned to a baby carrier intervention group (n = 32 fathers) or a control group (n = 28 fathers). Fathers in the intervention group were instructed to use a baby carrier for three weeks, whereas fathers in the control group were instructed to use a baby seat. Before and after the intervention salivary oxytocin was measured and neural reactivity to infant crying was assessed using fMRI. Results showed that the infant carrier intervention increased amygdala reactivity to infant crying compared to the infant seat users. This effect was most pronounced in fathers with experiences of childhood abuse. The carrier intervention did not affect fathers' oxytocin levels. Our findings indicate that spending time in physical contact with the infant may promote attention to and accurate perception of infant signals, in particular in fathers with more adverse childhood experiences. Soft baby carriers may, therefore, facilitate an adaptive transition to fatherhood.",2021,The carrier intervention did not affect fathers' oxytocin levels.,"['infant crying in fathers', 'fathers with experiences of childhood abuse', ""fathers' hormonal and neural functioning"", 'Sixty first-time fathers (infant age M\xa0=\xa011.18 weeks, SD\xa0=\xa02.08']","['baby carrier intervention', 'functional magnetic resonance imaging (fMRI', 'hormone oxytocin', 'soft baby carrier intervention']","['neural reactivity to infant crying', ""fathers' oxytocin levels"", 'amygdala reactivity to infant crying']","[{'cui': 'C0581876', 'cui_str': 'Crying infant'}, {'cui': 'C0015671', 'cui_str': 'Father'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0221134', 'cui_str': 'Blood group antigen M'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4517626', 'cui_str': '2.08'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0205358', 'cui_str': 'Soft'}]","[{'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0581876', 'cui_str': 'Crying infant'}, {'cui': 'C0015671', 'cui_str': 'Father'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}]",,0.0917428,The carrier intervention did not affect fathers' oxytocin levels.,"[{'ForeName': 'Madelon M E', 'Initials': 'MME', 'LastName': 'Riem', 'Affiliation': 'Behavioural Science Institute, Radboud University, The Netherlands; Clinical Child & Family Studies, Faculty of Behavioral and Movement Sciences, Vrije Universiteit, Amsterdam, The Netherlands. Electronic address: Madelon.hendricx-riem@ru.nl.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Lotz', 'Affiliation': 'Clinical Child & Family Studies, Faculty of Behavioral and Movement Sciences, Vrije Universiteit, Amsterdam, The Netherlands; Leiden Institute for Brain and Cognition, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Lisa I', 'Initials': 'LI', 'LastName': 'Horstman', 'Affiliation': 'Clinical Child & Family Studies, Faculty of Behavioral and Movement Sciences, Vrije Universiteit, Amsterdam, The Netherlands; Leiden Institute for Brain and Cognition, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Maaike', 'Initials': 'M', 'LastName': 'Cima', 'Affiliation': 'Behavioural Science Institute, Radboud University, The Netherlands.'}, {'ForeName': 'Martine W F T', 'Initials': 'MWFT', 'LastName': 'Verhees', 'Affiliation': 'Clinical Child & Family Studies, Faculty of Behavioral and Movement Sciences, Vrije Universiteit, Amsterdam, The Netherlands.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Alyousefi-van Dijk', 'Affiliation': 'Clinical Child & Family Studies, Faculty of Behavioral and Movement Sciences, Vrije Universiteit, Amsterdam, The Netherlands; Leiden Institute for Brain and Cognition, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Marinus H', 'Initials': 'MH', 'LastName': 'van IJzendoorn', 'Affiliation': 'Department of Psychology, Education and Child Studies, Erasmus University Rotterdam, The Netherlands; Research Department of Clinical, Educational and Health Psychology, Faculty of Brain Sciences, UCL, University of London, UK.'}, {'ForeName': 'Marian J', 'Initials': 'MJ', 'LastName': 'Bakermans-Kranenburg', 'Affiliation': 'Clinical Child & Family Studies, Faculty of Behavioral and Movement Sciences, Vrije Universiteit, Amsterdam, The Netherlands.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2021.105380'] 1469,34189814,Admission computed tomography radiomic signatures outperform hematoma volume in predicting baseline clinical severity and functional outcome in the ATACH-2 trial intracerebral hemorrhage population.,"BACKGROUND AND PURPOSE Radiomics provides a framework for automated extraction of high-dimensional feature sets from medical images. We aimed to determine radiomics signature correlates of admission clinical severity and medium-term outcome from intracerebral hemorrhage (ICH) lesions on baseline head computed tomography (CT). METHODS We used the ATACH-2 (Antihypertensive Treatment of Acute Cerebral Hemorrhage II) trial dataset. Patients included in this analysis (n = 895) were randomly allocated to discovery (n = 448) and independent validation (n = 447) cohorts. We extracted 1130 radiomics features from hematoma lesions on baseline noncontrast head CT scans and generated radiomics signatures associated with admission Glasgow Coma Scale (GCS), admission National Institutes of Health Stroke Scale (NIHSS), and 3-month modified Rankin Scale (mRS) scores. Spearman's correlation between radiomics signatures and corresponding target variables was compared with hematoma volume. RESULTS In the discovery cohort, radiomics signatures, compared to ICH volume, had a significantly stronger association with admission GCS (0.47 vs. 0.44, p = 0.008), admission NIHSS (0.69 vs. 0.57, p < 0.001), and 3-month mRS scores (0.44 vs. 0.32, p < 0.001). Similarly, in independent validation, radiomics signatures, compared to ICH volume, had a significantly stronger association with admission GCS (0.43 vs. 0.41, p = 0.02), NIHSS (0.64 vs. 0.56, p < 0.001), and 3-month mRS scores (0.43 vs. 0.33, p < 0.001). In multiple regression analysis adjusted for known predictors of ICH outcome, the radiomics signature was an independent predictor of 3-month mRS in both cohorts. CONCLUSIONS Limited by the enrollment criteria of the ATACH-2 trial, we showed that radiomics features quantifying hematoma texture, density, and shape on baseline CT can provide imaging correlates for clinical presentation and 3-month outcome. These findings couldtrigger a paradigm shift where imaging biomarkers may improve current modelsfor prognostication, risk-stratification, and treatment triage of ICH patients.",2021,"In multiple regression analysis adjusted for known predictors of ICH outcome, the radiomics signature was an independent predictor of 3-month mRS in both cohorts. ",['Patients included in this analysis (n=895) were randomly allocated to discovery (n=448) and independent validation (n=447) cohorts'],[],"['admission NIHSS', 'admission GCS', 'NIHSS', '3-month mRS scores', 'admission Glasgow Coma Scale (GCS), admission National Institutes of Health Stroke Scale (NIHSS), and 3-month modified Rankin Scale (mRS) scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]",[],"[{'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",895.0,0.113039,"In multiple regression analysis adjusted for known predictors of ICH outcome, the radiomics signature was an independent predictor of 3-month mRS in both cohorts. ","[{'ForeName': 'Stefan P', 'Initials': 'SP', 'LastName': 'Haider', 'Affiliation': 'Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': 'Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USA.'}, {'ForeName': 'Abhi', 'Initials': 'A', 'LastName': 'Jain', 'Affiliation': 'Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Hishan', 'Initials': 'H', 'LastName': 'Tharmaseelan', 'Affiliation': 'Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Elisa R', 'Initials': 'ER', 'LastName': 'Berson', 'Affiliation': 'Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Tal', 'Initials': 'T', 'LastName': 'Zeevi', 'Affiliation': 'Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Shahram', 'Initials': 'S', 'LastName': 'Majidi', 'Affiliation': 'Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Filippi', 'Affiliation': 'Department of Radiology, Tufts University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Iseke', 'Affiliation': 'Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Gross', 'Affiliation': 'Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Julian N', 'Initials': 'JN', 'LastName': 'Acosta', 'Affiliation': 'Department of Neurology, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Ajay', 'Initials': 'A', 'LastName': 'Malhotra', 'Affiliation': 'Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Kim', 'Affiliation': 'Department of Neurology, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Lauren H', 'Initials': 'LH', 'LastName': 'Sansing', 'Affiliation': 'Department of Neurology, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Guido J', 'Initials': 'GJ', 'LastName': 'Falcone', 'Affiliation': 'Department of Neurology, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Kevin N', 'Initials': 'KN', 'LastName': 'Sheth', 'Affiliation': 'Department of Neurology, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Seyedmehdi', 'Initials': 'S', 'LastName': 'Payabvash', 'Affiliation': 'Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.'}]",European journal of neurology,['10.1111/ene.15000'] 1470,34391110,Virtual reality promotes greater improvements than video-stimulation screen on perceptual-cognitive skills in young soccer athletes.,"Background The literature has shown the positive effect of virtual reality (VR) in percepto-cognitive skills. However, the literature lacks findings about at what extent VR would be better than video. Purpose This study aimed to analyze the chronic effect of VR and video-stimulation screen training on passing decision-making, visual search behavior, and inhibitory control performance in young soccer athletes. Method A total of 26 young soccer players underwent an 8-week training protocol after being randomly assigned to the VR (n = 13) or video-screen (VID, n = 13) group. Passing decision-making, visual search behavior, and inhibitory control performance were measured before and after both interventions. Results A group x time interaction was found for decision-making performance (p < 0.01) and visual search behavior (p < 0.01). Both groups improved both decision-making performance (p < 0.01) and visual search behavior (p < 0.01); however, greater improvements were verified in VR (p < 0.01). Both VR and VID improved inhibitory control (p < 0.01), but no group interaction effect was observed (p > 0.05). Conclusion Our results suggest that VR leads to greater improvements in decision-making and visual search behavior in young soccer athletes than VID.",2021,"Both groups improved both decision-making performance (p < 0.01) and visual search behavior (p < 0.01); however, greater improvements were verified in VR (p < 0.01).","['26 young soccer players', 'young soccer athletes']","['video-stimulation screen', 'VR and video-stimulation screen training']","['decision-making performance', 'decision-making and visual search behavior', 'visual search behavior', 'inhibitory control', 'Passing decision-making, visual search behavior, and inhibitory control performance', 'perceptual-cognitive skills', 'passing decision-making, visual search behavior, and inhibitory control performance']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0003624', 'cui_str': 'Searching Behavior'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",26.0,0.00914693,"Both groups improved both decision-making performance (p < 0.01) and visual search behavior (p < 0.01); however, greater improvements were verified in VR (p < 0.01).","[{'ForeName': 'Leonardo S', 'Initials': 'LS', 'LastName': 'Fortes', 'Affiliation': 'Associate Graduate Program in Physical Education, Federal University of Paraiba, João Pessoa, Brazil. Electronic address: leodesousafortes@hotmail.com.'}, {'ForeName': 'Sebastião S', 'Initials': 'SS', 'LastName': 'Almeida', 'Affiliation': 'Psychology Departament, University of São Paulo, Ribeirão Preto, Brazil.'}, {'ForeName': 'Gibson M', 'Initials': 'GM', 'LastName': 'Praça', 'Affiliation': 'Sports Department, Federal University of Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'José R A', 'Initials': 'JRA', 'LastName': 'Nascimento-Júnior', 'Affiliation': 'Physical Education Departament, Federal University of Vale do São Francisco, Petrolina, Brazil.'}, {'ForeName': 'Dalton', 'Initials': 'D', 'LastName': 'Lima-Junior', 'Affiliation': 'Associate Graduate Program in Physical Education, Federal University of Paraiba, João Pessoa, Brazil.'}, {'ForeName': 'Bruno Teixeira', 'Initials': 'BT', 'LastName': 'Barbosa', 'Affiliation': 'Associate Graduate Program in Physical Education, Federal University of Paraiba, João Pessoa, Brazil.'}, {'ForeName': 'Maria E C', 'Initials': 'MEC', 'LastName': 'Ferreira', 'Affiliation': 'Associate Graduate Program in Physical Education, Federal University of Juiz de Fora, Juiz de Fora, Brazil.'}]",Human movement science,['10.1016/j.humov.2021.102856'] 1471,34186473,A qualitative exploration of patient experiences of medication for sciatica.,"BACKGROUND Sciatica is often a painful and disabling condition, with medication routinely the first line of management. It is important to describe patients experiences of taking medication for sciatica, the reasons for commencing and reasons for cessation, the effects of the medication in symptom management and any other potential positive or deleterious effects. OBJECTIVES To describe patient experiences of medication for the relief of symptoms of sciatica. STUDY DESIGN Qualitative analysis of data from a mixed-methods randomised controlled pilot study. METHODS A total of 46 semi-structured interviews were conducted with 33 consenting participants (19 female) recruited from 14 GP practices. A purposive sampling strategy ensured a range of age, severity of pain and disability. Interviews were recorded and transcribed verbatim prior to thematic analysis, which aimed to identify the important, interesting or divergent views within the data. FINDINGS Participant experiences of pain were often severe with significant disability and fear. The use of a combination of medications was common, including the use of opioids and other medication inconsistent with national (NICE) guidance. Most participants found medication ineffective and reported significant side-effects, often necessitating cessation of the drugs or the use of alternatives. Despite the regularity of participants stopping all medication for sciatica, their pain levels still significantly eased over the 6-month period of the study. CONCLUSIONS The study highlighted a lack of perceived effectiveness for prescribed medication, often with concomitant side-effects. Clinicians should be cognisant of the fears that patients hold in terms of the cause and severity of sciatica, as well as fears of prescribed medication.",2021,"Most participants found medication ineffective and reported significant side-effects, often necessitating cessation of the drugs or the use of alternatives.","['patient experiences of medication for sciatica', 'A total of 46 semi-structured interviews were conducted with 33 consenting participants (19 female) recruited from 14\xa0GP practices']",[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0036396', 'cui_str': 'Sciatica'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],[],46.0,0.0689757,"Most participants found medication ineffective and reported significant side-effects, often necessitating cessation of the drugs or the use of alternatives.","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Reddington', 'Affiliation': 'Therapy Services Outpatient Department Northern General Hospital Herries Road Sheffield, S5 7AU, UK. Electronic address: Michael.reddington1@nhs.net.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Baxter', 'Affiliation': 'Section of Public Health ScHARR, University of Sheffield 30 Regents Court Sheffield, S1 4DA, UK. Electronic address: s.k.baxter@sheffield.ac.uk.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Walters', 'Affiliation': 'Designs, Trials and Statistics, ScHARR, University of Sheffield, 30 Regents Court, Sheffield, S1 4DA, UK. Electronic address: S.J.Walters@sheffield.ac.uk.'}]",Musculoskeletal science & practice,['10.1016/j.msksp.2021.102419'] 1472,34391078,Changes in craving following acute aerobic exercise in adults with alcohol use disorder.,"AIMS Exercise is increasingly being studied as treatment for alcohol use disorder (AUD). We examined the effects of an acute bout of exercise on alcohol craving, heterogeneity of response, and factors associated with reductions in craving. METHODS Within the context of a randomized controlled trial, we conducted an exploratory, single-arm study. In total, 117 adults with AUD (52.7 years; SD = 12.3; 68.4% female) and indications of alcohol craving (Desire for Alcohol Questionnaire, DAQ-short version total score >8) were included. The intervention was a 12-min sub-maximal fitness test performed on a cycle ergometer. We examined changes in participant's self-rated desire for alcohol immediately before and after exercise. Personal, clinical, and exercise-related factors associated with reductions (≥0.5 SD) in craving were identified using hierarchical logistic regression. RESULTS In the total sample craving reduced from pre-to post-exercise (p < 0.001, g = 0.60 [0.40-0.79]). Three groups were observed: those whose craving decreased (70.1%; p < 0.001, g = 1.12 [0.85-1.40]), increased (16.2%; p < 0.001, g = 1.08 [0.51-1.64]), or did not change (13.7%). Forty percent experienced clinically meaningful reductions in craving (≥0.5 SD). In fully adjusted models, two factors were associated with these reductions: higher pre-exercise cravings (OR = 1.15 [1.07-1.23], p < 0.001) and lower cardiorespiratory fitness (OR = 0.88 [0.79-1.00], p = 0.043). CONCLUSIONS In most adults with AUD, short bouts of moderately intense aerobic exercise helps reduce cravings for alcohol. Those with higher cravings and lower cardiorespiratory fitness are most likely to benefit.",2021,"In the total sample craving reduced from pre-to post-exercise (p < 0.001, g = 0.60 [0.40-0.79]).","['117 adults with AUD (52.7 years; SD\xa0=\xa012.3; 68.4% female) and indications of alcohol craving (Desire for Alcohol Questionnaire, DAQ-short version total score >8) were included', 'adults with alcohol use disorder']","['acute aerobic exercise', 'aerobic exercise']","['pre-exercise cravings', 'total sample craving', 'lower cardiorespiratory fitness', 'craving']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C5191283', 'cui_str': '12.3'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0556385', 'cui_str': 'Craving for alcohol'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0611631', 'cui_str': 'DAQ'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}]",117.0,0.035919,"In the total sample craving reduced from pre-to post-exercise (p < 0.001, g = 0.60 [0.40-0.79]).","[{'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Hallgren', 'Affiliation': 'Epidemiology of Psychiatric Conditions, Substance Use and Social Environment (EPiCSS), Department of Global Public Health Sciences, Karolinska Institutet, Stockholm, 171 77, Sweden. Electronic address: mats.hallgren@ki.se.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Herring', 'Affiliation': 'Physical Activity for Health Research Cluster, Health Research Institute, Department of Physical Education and Sport Sciences, University of Limerick, Ireland.'}, {'ForeName': 'Davy', 'Initials': 'D', 'LastName': 'Vancampfort', 'Affiliation': 'Department of Rehabilitation Sciences, University of Leuven, University Psychiatric Center, Katholieke Universiteit Leuven, Belgium.'}, {'ForeName': 'Minh Tuan', 'Initials': 'MT', 'LastName': 'Hoang', 'Affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Andersson', 'Affiliation': 'Epidemiology of Psychiatric Conditions, Substance Use and Social Environment (EPiCSS), Department of Global Public Health Sciences, Karolinska Institutet, Stockholm, 171 77, Sweden; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Health Care Services, Sweden.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Andreasson', 'Affiliation': 'Epidemiology of Psychiatric Conditions, Substance Use and Social Environment (EPiCSS), Department of Global Public Health Sciences, Karolinska Institutet, Stockholm, 171 77, Sweden; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Health Care Services, Sweden.'}, {'ForeName': 'Ana M', 'Initials': 'AM', 'LastName': 'Abrantes', 'Affiliation': 'Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, USA.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2021.08.007'] 1473,34391038,An experimental demonstration of the positive consequences of guiding students to conceptualize education as connection.,"INTRODUCTION Educators often struggle to sustain students' motivation during adolescence. Students may view school tasks as insignificant because learning, achievement, and success feel detached from valued social connections. Previous findings in the study of development demonstrate that young people derive meaning from key sources of social support and connection. Finding ways to link how students approach their educational goals to meaningful social connections may strengthen responses to daily learning opportunities with positive implications for achievement. METHOD A randomized-controlled experiment and daily diary survey evaluated the consequences of guiding students to conceptualize educational pursuits as linked to their social connections. A group of ninth-grade students in the United States (N = 39; 58.97 % girls, 30.77 % boys, 2.56 % non-binary, 7.69 % did not disclose) were randomly assigned to one of two brief programs designed to cultivate goals and motivation. RESULTS Participants randomly assigned to a healthy achievement condition (including an emphasis on the importance of social support and connection as part of achievement and success) reported more productive responses to daily academic difficulty than participants in a standard motivation condition on a daily diary survey over one year after the program. This led to an indirect increase in actual daily support, which was associated with earning higher grades. CONCLUSIONS The results suggest that a reconceptualization of education as an endeavor grounded in social connection would help keep students engaged in learning.",2021,A randomized-controlled experiment and daily diary survey evaluated the consequences of guiding students to conceptualize educational pursuits as linked to their social connections.,"['A group of ninth-grade students in the United States (N\xa0=\xa039; 58.97\xa0% girls, 30.77\xa0% boys, 2.56\xa0% non-binary, 7.69\xa0% did not disclose']",[],[],"[{'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0205443', 'cui_str': 'Ninth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C1299585', 'cui_str': 'Does not'}]",[],[],,0.0336296,A randomized-controlled experiment and daily diary survey evaluated the consequences of guiding students to conceptualize educational pursuits as linked to their social connections.,"[{'ForeName': 'Mesmin', 'Initials': 'M', 'LastName': 'Destin', 'Affiliation': 'Northwestern University, United States. Electronic address: m-destin@northwestern.edu.'}, {'ForeName': 'Régine', 'Initials': 'R', 'LastName': 'Debrosse', 'Affiliation': 'McGill University, United States.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Silverman', 'Affiliation': 'Northwestern University, United States.'}]",Journal of adolescence,['10.1016/j.adolescence.2021.08.003'] 1474,34197281,"Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.","Safe and effective vaccines are still urgently needed to cope with the ongoing COVID-19 pandemic. Recently, we developed a recombinant COVID-19 vaccine (V-01) containing fusion protein (IFN-PADRE-RBD-Fc dimer) as antigen verified to induce protective immunity against SARS-CoV-2 challenge in pre-clinical study, which supported progression to Phase I clinical trials in humans. A Randomized, double-blind, placebo-controlled Phase I clinical trial was initiated at the Guangdong Provincial Center for Disease Control and Prevention (Gaozhou, China) in February 2021. Healthy adults aged between 18 and 59 years and over 60 years were sequentially enrolled and randomly allocated into three subgroups (1:1:1) either to receive the vaccine (10, 25, and 50 μg) or placebo (V-01: Placebo = 4:1) intramuscularly with a 21-day interval by a sentinel and dose escalation design. The data showed a promising safety profile with approximately 25% vaccine-related overall adverse events (AEs) within 30 days and no grade 3 or worse AEs. Besides, V-01 provoked rapid and strong immune responses, elicited substantially high-titre neutralizing antibodies and anti-RBD IgG peaked at day 35 or 49 after first dose, presented with encouraging immunogenicity at low dose (10 μg) subgroup and elderly participants, which showed great promise to be used as all-aged (18 and above) vaccine against COVID-19. Taken together, our preliminary findings indicate that V-01 is safe and well tolerated, capable of inducing rapid and strong immune responses, and warrants further testing in Phase II/III clinical trials.",2021,The data showed promising safety profile with approximately 25% vaccine related overall adverse events within 30 days and no grade 3 or worse adverse events.,"['Guangdong Provincial Center for Disease Control and Prevention (Gaozhou, China) in February, 2021', 'Healthy adults aged between 18 and 59 years and over 60 years', 'healthy adults']","['vaccine', 'recombinant COVID-19 vaccine (V-01) containing fusion protein (IFN-PADRE-RBD-Fc dimer', 'placebo (V-01: Placebo=4:1', 'placebo', 'recombinant interferon-armed RBD dimer vaccine (V-01']","['Safety and immunogenicity', 'overall adverse events', 'titre neutralizing antibodies and anti-RBD IgG']","[{'cui': 'C0007670', 'cui_str': 'Centers for Disease Control and Prevention (U.S.)'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0162768', 'cui_str': 'Fusion protein'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C1522002', 'cui_str': 'RRM Motif'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0282682', 'cui_str': 'Blocking antibody'}, {'cui': 'C1522002', 'cui_str': 'RRM Motif'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}]",2021.0,0.579326,The data showed promising safety profile with approximately 25% vaccine related overall adverse events within 30 days and no grade 3 or worse adverse events.,"[{'ForeName': 'Jikai', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.""}, {'ForeName': 'Zhongyu', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': ""National Institutes for Food and Drug Control, Beijing, People's Republic of China.""}, {'ForeName': 'Jianfeng', 'Initials': 'J', 'LastName': 'He', 'Affiliation': ""Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, People's Republic of China.""}, {'ForeName': 'Yuyi', 'Initials': 'Y', 'LastName': 'Liao', 'Affiliation': ""Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.""}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.""}, {'ForeName': 'Rongjuan', 'Initials': 'R', 'LastName': 'Pei', 'Affiliation': ""Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Fang', 'Affiliation': ""National Institutes for Food and Drug Control, Beijing, People's Republic of China.""}, {'ForeName': 'Peiyu', 'Initials': 'P', 'LastName': 'Zeng', 'Affiliation': ""Gaozhou Center for Disease Control and Prevention, Maoming, People's Republic of China.""}, {'ForeName': 'Renfeng', 'Initials': 'R', 'LastName': 'Fan', 'Affiliation': ""Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.""}, {'ForeName': 'Zhiqiang', 'Initials': 'Z', 'LastName': 'Ou', 'Affiliation': ""Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.""}, {'ForeName': 'Jinglong', 'Initials': 'J', 'LastName': 'Deng', 'Affiliation': ""Gaozhou Center for Disease Control and Prevention, Maoming, People's Republic of China.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': ""Gaozhou Center for Disease Control and Prevention, Maoming, People's Republic of China.""}, {'ForeName': 'Wuxiang', 'Initials': 'W', 'LastName': 'Guan', 'Affiliation': ""Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.""}, {'ForeName': 'Yuanqin', 'Initials': 'Y', 'LastName': 'Min', 'Affiliation': ""Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.""}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Deng', 'Affiliation': ""Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.""}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Peng', 'Affiliation': ""Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, People's Republic of China.""}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': ""Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.""}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Feng', 'Affiliation': ""LivzonBio Inc., Zhuhai, People's Republic of China.""}, {'ForeName': 'Baobao', 'Initials': 'B', 'LastName': 'Xin', 'Affiliation': ""LivzonBio Inc., Zhuhai, People's Republic of China.""}]",Emerging microbes & infections,['10.1080/22221751.2021.1951126'] 1475,34197242,Efficacy and safety of tranexamic acid in hip fracture surgery: A comparative study of 613 patients.,"BACKGROUND Blood loss is a major concern in the frail elderly patient undergoing hip fracture surgery. The objective of this study was to investigate the efficacy of tranexamic acid in reducing blood loss and allogenic blood transfusions. The study also investigated the safety profile by comparing rates of thromboembolic events. METHODS A total of 613 patients with hip fractures were included in the study. Patients received 1g of tranexamic acid on induction of anaesthesia. Postoperative haemoglobin was measured on day one. Blood loss was calculated, and blood transfusion was recorded. RESULTS Tranexamic acid use resulted in a higher mean postoperative haemoglobin (110.3 ± 15.9 vs 106.8 ± 16.2; p  = 0.023) and reduced mean estimated blood loss (571.3 ± 150.4 vs 678.3 ± 201.2; p  = 0.001). There was also a significantly reduced number of transfusions in tranexamic acid group (13% vs 28%; p  = 0.002). There was no difference in rates of deep vein thrombosis (4 vs 3; p  = 0.98) or pulmonary embolism (2 vs 2; p  = 1). CONCLUSION The use of tranexamic acid is effective in reduction of blood loss and rates of blood transfusion, without an apparent increase in adverse thromboembolic events.",2021,"The use of tranexamic acid is effective in reduction of blood loss and rates of blood transfusion, without an apparent increase in adverse thromboembolic events.","['613 patients with hip fractures', 'frail elderly patient undergoing hip fracture surgery', 'hip fracture surgery', '613 patients']","['Tranexamic acid', 'tranexamic acid']","['Blood loss', 'blood loss and rates of blood transfusion', 'rates of deep vein thrombosis', 'Efficacy and safety', 'mean postoperative haemoglobin', 'blood loss and allogenic blood transfusions', 'number of transfusions', 'pulmonary embolism', 'Postoperative haemoglobin', 'adverse thromboembolic events', 'blood transfusion', 'mean estimated blood loss']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C3160876', 'cui_str': 'Allogenic blood transfusion'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}]",613.0,0.0673006,"The use of tranexamic acid is effective in reduction of blood loss and rates of blood transfusion, without an apparent increase in adverse thromboembolic events.","[{'ForeName': 'Mutaz', 'Initials': 'M', 'LastName': 'AlSumadi', 'Affiliation': 'Countess of Chester Hospital NHS Foundation Trust, Chester, UK.'}, {'ForeName': 'Aatif', 'Initials': 'A', 'LastName': 'Mahmood', 'Affiliation': 'Countess of Chester Hospital NHS Foundation Trust, Chester, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Whittam', 'Affiliation': 'Countess of Chester Hospital NHS Foundation Trust, Chester, UK.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Kharma', 'Affiliation': 'School of Psychology, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Rami', 'Initials': 'R', 'LastName': 'Ashour', 'Affiliation': 'Countess of Chester Hospital NHS Foundation Trust, Chester, UK.'}, {'ForeName': 'Ronan', 'Initials': 'R', 'LastName': 'Banim', 'Affiliation': 'Countess of Chester Hospital NHS Foundation Trust, Chester, UK.'}]",Journal of perioperative practice,['10.1177/17504589211002090'] 1476,34219218,Shaping classroom social experiences through collaborative small-group discussions.,"BACKGROUND Students form interpersonal and intrapersonal classroom social experiences with peers. While diverse intervention programmes have been developed, few have integrated social-emotional learning into academic activities to maximize the potential for learning and development. AIMS This study examined the effects of collaborative small-group discussions on students' classroom social experiences at the interpersonal and intrapersonal levels. SAMPLE The study included 250 students (M age  = 10.98, female = 52%) and six teachers from 12 English language arts fifth-grade classrooms in two public schools in the United States. METHODS Students were assigned to one of three conditions: Collaborative Social Reasoning (CSR), Read-Aloud (RA), or Regular Instruction (RI). Students in the CSR condition participated in recurrent collaborative small-group discussions about stories related to complex social-moral issues, including friendship, social exclusion, ethics of care, and responsibility. Students in the RA condition read the same stories without discussions. RESULTS Collaborative Social Reasoning students were more socially accepted by peers and were less aggressive to others compared to students in the other conditions. RA students revealed more aggressive behaviour than other groups. In a post-intervention interview, CSR students reported improved communication and group work strategies, ability to maintain harmonious relationships, and class participation. A higher proportion of CSR students in the CSR than the other conditions reported experiencing positive change in classroom relationships. Teacher interviews were used in conjunction with student interviews to triangulate conclusions from qualitative interview data. CONCLUSION Findings suggest effective ways to structure collaborative small-group discussions to foster positive classroom social experiences with peers.",2021,"In a post-intervention interview, CSR students reported improved communication and group work strategies, ability to maintain harmonious relationships, and class participation.","[""students' classroom social experiences at the interpersonal and intrapersonal levels"", '250 students (M age \xa0=\xa010.98, female\xa0=\xa052%) and six teachers from 12 English language arts fifth-grade classrooms in two public schools in the United States', 'Students form interpersonal and intrapersonal classroom social experiences with peers', 'Students']","['Collaborative Social Reasoning (CSR), Read-Aloud (RA), or Regular Instruction (RI', 'collaborative small-group discussions']",['aggressive behaviour'],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0557800', 'cui_str': 'Public school'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205431', 'cui_str': 'Formed'}]","[{'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}]","[{'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}]",250.0,0.0322459,"In a post-intervention interview, CSR students reported improved communication and group work strategies, ability to maintain harmonious relationships, and class participation.","[{'ForeName': 'Tzu-Jung', 'Initials': 'TJ', 'LastName': 'Lin', 'Affiliation': 'Department of Educational Studies, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Kraatz', 'Affiliation': 'Department of Educational Studies, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Seung Yon', 'Initials': 'SY', 'LastName': 'Ha', 'Affiliation': 'Department of Educational Studies, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Ming-Yi', 'Initials': 'MY', 'LastName': 'Hsieh', 'Affiliation': 'Office of Educational Innovation and Evaluation, Kansas State University, Manhattan, Kansas, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Glassman', 'Affiliation': 'Department of Educational Studies, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Manisha', 'Initials': 'M', 'LastName': 'Nagpal', 'Affiliation': 'Department of Educational Studies, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Sallade', 'Affiliation': 'University of Cincinnati, Ohio, USA.'}, {'ForeName': 'Sangin', 'Initials': 'S', 'LastName': 'Shin', 'Affiliation': 'Department of Educational Studies, The Ohio State University, Columbus, Ohio, USA.'}]",The British journal of educational psychology,['10.1111/bjep.12442'] 1477,34218046,Treatment of subcutaneous nodules after infusion of apomorphine; a biopsy-controlled study comparing 4 frequently used therapies.,"This study aimed to provide clinical evidence for existing treatments of subcutaneous nodules after subcutaneous infusion of apomorphine, using a biopsy-controlled prospective crossover design of four treatments. We demonstrated that dilution of apomorphine significantly improved patient satisfaction, while subcutaneous hydrocortisone reduced nodule size, however with no differences in the histopathology.",2021,"We demonstrated that dilution of apomorphine significantly improved patient satisfaction, while subcutaneous hydrocortisone reduced nodule size, however with no differences in the histopathology.",[],['apomorphine'],['patient satisfaction'],[],"[{'cui': 'C0003596', 'cui_str': 'Apomorphine'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",,0.0800533,"We demonstrated that dilution of apomorphine significantly improved patient satisfaction, while subcutaneous hydrocortisone reduced nodule size, however with no differences in the histopathology.","[{'ForeName': 'Robbert W K', 'Initials': 'RWK', 'LastName': 'Borgemeester', 'Affiliation': 'Department of Neurology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands. Electronic address: r.w.k.borgemeester@umcg.nl.'}, {'ForeName': 'Gilles F H', 'Initials': 'GFH', 'LastName': 'Diercks', 'Affiliation': 'Department of Pathology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands. Electronic address: g.f.h.diercks@umcg.nl.'}, {'ForeName': 'Teus', 'Initials': 'T', 'LastName': 'van Laar', 'Affiliation': 'Department of Neurology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands. Electronic address: t.van.laar@umcg.nl.'}]",Parkinsonism & related disorders,['10.1016/j.parkreldis.2021.06.024'] 1478,34217920,Effects of pre-bedtime blue-light exposure on ratio of deep sleep in healthy young men.,"This study aimed to investigate the effects of pre-bedtime blue-light exposure on ratio of deep sleep and sleep quality. In this study, 11 healthy young men were exposed to three conditions for 1 h before bedtime: 1) incandescent light, 2) blue-light, or 3) blue light-blocking glasses on. The following morning, subjective sleep quality was measured using the Oguri-Shirakawa-Azumi Sleep Inventory. Sleep time, ratio of sleep, ratio of deep sleep, and body movements during sleep were measured using a mat sleep-scan (sleep scan, SL- 504; TANITA Corp., Japan) and an ambulatory portable sleep study system (LS-140; Fukuda Denshi Co. Ltd., Japan). Ratio of deep sleep was significantly decreased in the blue-light exposure group compared to the groups with incandescent light and blue light-blocking glasses (p < 0.01), There were no differences noted in sleep time or body movements among the three groups. These results suggest that blue-light exposure to affects sleep quality by reducing the ratio of deep sleep.",2021,"Ratio of deep sleep was significantly decreased in the blue-light exposure group compared to the groups with incandescent light and blue light-blocking glasses (p < 0.01), There were no differences noted in sleep time or body movements among the three groups.","['11 healthy young men', 'healthy young men']","['incandescent light, 2) blue-light, or 3) blue light-blocking glasses on', 'pre-bedtime blue-light exposure']","['ratio of deep sleep and sleep quality', 'ratio of deep sleep', 'sleep time or body movements', 'subjective sleep quality', 'sleep quality', 'Ratio of deep sleep', 'Sleep time, ratio of sleep, ratio of deep sleep, and body movements during sleep']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0303896', 'cui_str': 'Blue light'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0015421', 'cui_str': 'Eyeglasses'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0587116', 'cui_str': 'During sleep'}]",11.0,0.0313572,"Ratio of deep sleep was significantly decreased in the blue-light exposure group compared to the groups with incandescent light and blue light-blocking glasses (p < 0.01), There were no differences noted in sleep time or body movements among the three groups.","[{'ForeName': 'Masao', 'Initials': 'M', 'LastName': 'Ishizawa', 'Affiliation': 'Department of Occupational Therapy, Yamagata College of Medical Arts & Sciences, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Uchiumi', 'Affiliation': 'Department of Occupational Therapy, Yamagata College of Medical Arts & Sciences, Japan.'}, {'ForeName': 'Miki', 'Initials': 'M', 'LastName': 'Takahata', 'Affiliation': 'Area of Occupational Therapy, Graduate School of Health Sciences, Yamagata Prefectural University of Health Sciences, Japan.'}, {'ForeName': 'Michiyasu', 'Initials': 'M', 'LastName': 'Yamaki', 'Affiliation': 'Area of Occupational Therapy, Graduate School of Health Sciences, Yamagata Prefectural University of Health Sciences, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Sato', 'Affiliation': 'Area of Occupational Therapy, Graduate School of Health Sciences, Yamagata Prefectural University of Health Sciences, Japan. Electronic address: tsato@yachts.ac.jp.'}]",Sleep medicine,['10.1016/j.sleep.2021.05.046'] 1479,34176392,"Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers.","BACKGROUND Balovaptan is a potent, selective vasopressin 1a receptor antagonist. The early-phase pharmacokinetics (PK) of balovaptan are reported. RESEARCH DESIGN AND METHODS Two Phase 1 studies (overall N = 93) assessed single- and multiple-dose balovaptan PK in healthy adults. One ( N  = 16) assessed absolute oral bioavailability (10 mg or 50 mg) vs a [ 13 C]-balovaptan microdose. The other ( N  = 77) explored single- (0.5-76 mg) and multiple-dose (14 days; 12-52 mg/day) - randomized 6:2 balovaptan:placebo per dose - PK, dose proportionality, and the effect of food on single-dose (32 mg) C max and AUC inf . RESULTS Absolute balovaptan bioavailability was high (103-116%). Steady-state (Day 14) balovaptan PK was approximately dose proportional with a half-life of 45-47 hours, but single-dose C max increased more than dose proportionally and half-life was inversely dose-proportional - a discordance partially attributable to a dose-and-time-dependent volume of distribution. Accumulation (Day 1-Day 14) was inversely dose-proportional (~3.5 [12 mg] to ~1.8 [52 mg]). There was no relevant effect of a high-fat meal on single-dose balovaptan exposure. There were no safety signals: 2/93 subjects discontinued for adverse events. CONCLUSIONS Balovaptan was well tolerated at single (≤76 mg) and multiple (≤52 mg/day) doses, with a PK profile supportive of once-daily administration without food restrictions. TRIAL REGISTRATION ClinicalTrials.gov NCT03764449; NCT01418963.",2021,"Steady-state (Day 14) balovaptan PK was approximately dose proportional with a half-life of 45-47 hours, but single-dose C max increased more than dose proportionally and half-life was inversely dose-proportional -- a discordance partially attributable to a dose-and-time-dependent volume of distribution.","['healthy volunteers', 'healthy adults']","['balovaptan placebo', ' ', 'Balovaptan']","['absolute oral bioavailability', 'Absolute balovaptan bioavailability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}]",,0.0818194,"Steady-state (Day 14) balovaptan PK was approximately dose proportional with a half-life of 45-47 hours, but single-dose C max increased more than dose proportionally and half-life was inversely dose-proportional -- a discordance partially attributable to a dose-and-time-dependent volume of distribution.","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Derks', 'Affiliation': 'Roche Pharma Research & Early Development, Roche Innovation Center Welwyn, Roche Products Ltd, Welwyn Garden City, UK.'}, {'ForeName': 'Sian', 'Initials': 'S', 'LastName': 'Lennon-Chrimes', 'Affiliation': 'Roche Pharma Research & Early Development, Roche Innovation Center Welwyn, Roche Products Ltd, Welwyn Garden City, UK.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Guenther', 'Affiliation': 'Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Squassante', 'Affiliation': 'Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Wandel', 'Affiliation': 'Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Szczesny', 'Affiliation': 'Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Paehler', 'Affiliation': 'Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.'}, {'ForeName': 'Heidemarie', 'Initials': 'H', 'LastName': 'Kletzl', 'Affiliation': 'Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.'}]",Expert opinion on investigational drugs,['10.1080/13543784.2021.1948009'] 1480,34391232,Immediate analgesic effect of transcutaneous electrical nerve stimulation (TENS) and interferential current (IFC) on chronic low back pain: Randomised placebo-controlled trial.,"OBJECTIVE To compare the immediate analgesic effect of transcutaneous nerve stimulation (TENS) and interferential current (IFC), with different combinations of parameters, in individuals with chronic low back pain (CLBP). METHODOLOGY 280 individuals with CLBP were included in the study, both genders, randomized in 8 groups: GI2KHz/100Hz, GI2KHz/2Hz, GI4KHz/100Hz, GI4KHz/2Hz, placebo interferential group (GIP), GT100Hz, GT2Hz, and placebo TENS group (GTP). All individuals underwent a single application of TENS or IFC for 30min. The assessments were carried out prior to the intervention, as well as immediately after, with the following outcomes: pain intensity (Numeric Pain Rating Scale-NPRS), qualitative pain characteristics (McGill Pain Questionnaire-MPQ), and pressure pain threshold (PPT) by pressure algometry (PA) in 4 points of the low back region. RESULTS In the intergroup comparison of NPRS, all intervention groups showed greater pain reduction compared to GTP (p < 0.05). In the total MPQ score, the groups that obtained significant results (p < 0.05) when compared to GTP were GT100Hz and GT2Hz, while the groups GT100Hz and GI4KHz/100Hz were significant when compared to GIP. In the PA, GI4KHz/100Hz showed an increase in the PPT in all points compared to GTP and GI2KHz/100Hz. CONCLUSION Both TENS and IFC presented immediate analgesic effect in CLBP, with emphasis on the interferential current of 4 KHz modulated at 100Hz.",2021,"In the total MPQ score, the groups that obtained significant results (p < 0.05) when compared to GTP were GT100Hz and GT2Hz, while the groups GT100Hz and GI4KHz/100Hz were significant when compared to GIP.","['individuals with chronic low back pain (CLBP', '280 individuals with CLBP were included in the study, both genders, randomized in 8 groups', 'chronic low back pain']","['transcutaneous electrical nerve stimulation (TENS) and interferential current (IFC', 'GI2KHz/100Hz, GI2KHz/2Hz, GI4KHz/100Hz, GI4KHz/2Hz, placebo interferential group (GIP), GT100Hz, GT2Hz, and placebo TENS group (GTP', 'transcutaneous nerve stimulation (TENS) and interferential current (IFC', 'TENS or IFC', 'placebo']","['pain reduction', 'total MPQ score', 'pain intensity (Numeric Pain Rating Scale-NPRS), qualitative pain characteristics (McGill Pain Questionnaire-MPQ), and pressure pain threshold (PPT) by pressure algometry (PA) in 4 points of the low back region']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0040654', 'cui_str': 'Percutaneous electrical nerve stimulation'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018353', 'cui_str': 'Guanosine triphosphate'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C1286315', 'cui_str': 'Characteristic of pain'}, {'cui': 'C0024985', 'cui_str': 'McGill pain chart questionnaire'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0004600', 'cui_str': 'Back'}]",280.0,0.0554324,"In the total MPQ score, the groups that obtained significant results (p < 0.05) when compared to GTP were GT100Hz and GT2Hz, while the groups GT100Hz and GI4KHz/100Hz were significant when compared to GIP.","[{'ForeName': 'Lucas Vinicius', 'Initials': 'LV', 'LastName': 'Dias', 'Affiliation': 'Physical Therapy at the Federal University of Paraná (UFPR), Brazil.'}, {'ForeName': 'Marina Aleixo', 'Initials': 'MA', 'LastName': 'Cordeiro', 'Affiliation': 'Physical Therapy at the Federal University of Paraná (UFPR), Brazil.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'Schmidt de Sales', 'Affiliation': 'Physical Therapy at the Federal University of Paraná (UFPR), Brazil.'}, {'ForeName': 'Matheus Matheus Bieberbach Rodrigues', 'Initials': 'MMBR', 'LastName': 'Dos Santos', 'Affiliation': 'Physical Therapy at the Federal University of Paraná (UFPR), Brazil.'}, {'ForeName': 'Raciele I G', 'Initials': 'RIG', 'LastName': 'Korelo', 'Affiliation': 'Department of Prevention and Rehabilitation in Physical Therapy at UFPR, Brazil.'}, {'ForeName': 'Audrin Said', 'Initials': 'AS', 'LastName': 'Vojciechowski', 'Affiliation': 'The Physical Education Postgraduate Program at UFPR, Brazil.'}, {'ForeName': 'Ana Carolina Brandt', 'Initials': 'ACB', 'LastName': 'de Mace do', 'Affiliation': 'Department of Prevention and Rehabilitation in Physical Therapy at UFPR, Brazil. Electronic address: acbrandtmacedo@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.005'] 1481,34391230,Effects of lymphatic drainage therapy on autonomic nervous system responses in healthy subjects: A single blind randomized controlled trial.,"OBJECTIVES This study aimed to determine effects of lymphatic drainage therapy (LDT) on autonomic nervous system (ANS) responses by comparing including Hoffmann reflex (H reflex), heart rate variability (HRV), salivary alpha-amylase (sAA) and muscle tone (via straight leg raise (SLR)) in healthy participants. METHODS A single blind randomized controlled trial evaluating sixty-six healthy participants including 58 females and 8 males aged between 40 and 65 years. All participants were blinded and randomized to either experimental group (EXP: LDT) or control group (CT: rest). LDT was applied to participants 45 min in experimental group. The LDT is light movement applied by an experienced physical therapist, starting from neck, deep abdomen, and along to the leg. While for the control group, participants received 45 min supine on the treatment table. Tests for evaluating ANS such as Hoffmann reflex (H reflex), heart rate variability (HRV), salivary alpha-amylase (sAA) and straight leg raise (SLR) were assessed at pre and post intervention. RESULTS The findings demonstrated that H reflex decreased significantly after applying LDT; within and between groups (p < 0.05). Whereas, it increased significantly in control group. First tension (R1) indicated by participants during SLR significantly improved within both groups. However, there were no significant differences of HRV and sAA in either LDT or control groups. CONCLUSION This study demonstrated that LDT decreased autonomic activity via decreased spinal reflex excitability and tension in healthy participants.",2021,The findings demonstrated that H reflex decreased significantly after applying LDT; within and between groups (p < 0.05).,"['sixty-six healthy participants including 58 females and 8 males aged between 40 and 65 years', 'healthy subjects', 'healthy participants']","['lymphatic drainage therapy', 'experimental group (EXP: LDT) or control group (CT: rest', 'LDT', 'lymphatic drainage therapy (LDT']","['H reflex', 'autonomic nervous system (ANS) responses', 'spinal reflex excitability and tension', 'Hoffmann reflex (H reflex), heart rate variability (HRV), salivary alpha-amylase (sAA) and muscle tone (via straight leg raise (SLR', 'autonomic nervous system responses', 'Hoffmann reflex (H reflex), heart rate variability (HRV), salivary alpha-amylase (sAA) and straight leg raise (SLR', 'First tension (R1', 'HRV and sAA', 'autonomic activity']","[{'cui': 'C4517841', 'cui_str': '66'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0398480', 'cui_str': 'Drainage of lymphatics'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0035253', 'cui_str': 'Rest'}]","[{'cui': 'C0034929', 'cui_str': 'Reflex'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C2350322', 'cui_str': 'Salivary alpha-Amylases'}, {'cui': 'C0026841', 'cui_str': 'Muscle Tension'}, {'cui': 'C0422926', 'cui_str': 'Straight leg raise test response'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",66.0,0.0769291,The findings demonstrated that H reflex decreased significantly after applying LDT; within and between groups (p < 0.05).,"[{'ForeName': 'Agsipa', 'Initials': 'A', 'LastName': 'Honguten', 'Affiliation': 'Faculty of Physical Therapy, Mahidol University, 999 Phuttamonthon 4 Road, Salaya, Phuttamonthon, Nakhon Pathom, 73170, Thailand. Electronic address: agsipa@hotmail.com.'}, {'ForeName': 'Keerin', 'Initials': 'K', 'LastName': 'Mekhora', 'Affiliation': 'Faculty of Physical Therapy, Mahidol University, 999 Phuttamonthon 4 Road, Salaya, Phuttamonthon, Nakhon Pathom, 73170, Thailand. Electronic address: keerin.mek@mahidol.ac.th.'}, {'ForeName': 'Sopa', 'Initials': 'S', 'LastName': 'Pichaiyongwongdee', 'Affiliation': 'Faculty of Physical Therapy, Mahidol University, 999 Phuttamonthon 4 Road, Salaya, Phuttamonthon, Nakhon Pathom, 73170, Thailand. Electronic address: sopa.pic@mahidol.ac.th.'}, {'ForeName': 'Sirikarn', 'Initials': 'S', 'LastName': 'Somprasong', 'Affiliation': 'Faculty of Physical Therapy, Mahidol University, 999 Phuttamonthon 4 Road, Salaya, Phuttamonthon, Nakhon Pathom, 73170, Thailand. Electronic address: sirikarn.som@mahidol.ac.th.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.019'] 1482,34391226,"Does sensorimotor training influence neuromuscular responses, balance, and quality of life in diabetics without a history of diabetic distal polyneuropathy?","OBJECTIVE To evaluate the effect of supervised and home sensorimotor training on static postural balance (SPB), quality of life (QL), and neuromuscular responses of Type 2 Diabetics (DM-2). DESIGN Randomized controlled blind study with DM-2 patients, between 45 and 64 years old, of both sexes, divided into 3 groups: Control Group - CG (n = 27), Home Training Group - HTG (n = 27), and Supervised Training Group - STG (n = 26). The subjects were evaluated before and at the end of 3 months of treatment, with a four-week follow-up. The intervention was held twice a week, for 45 min, divided into three phases: warm-up, sensorimotor training, and cool-down. The primary outcome was SPB, using the force platform. Secondary outcome: questionnaires and clinical measures related to diabetic foot and knee flexor-extensors using isokinetic dynamometry. RESULTS In the baseline, the characteristics were similar between groups and between times. Tactile and vibratory sensitivity demonstrated the absence of symptoms of peripheral neuropathy in diabetic patients. In the intra-group comparison, there was a significant increase in the classification without symptoms of diabetic distal polyneuropathy in the HTG and STG groups (p < 0.05) and there were no significant effects on other clinical outcomes and QL and SPB, muscle strength, and sense of knee joint position. CONCLUSION The intervention showed no improvement in SPB, QL, and other clinical outcomes of DM-2 patients. Thus, no differences were found between the groups, considering that the patients did not present clinical characteristics of diabetic distal polyneuropathy.",2021,"In the intra-group comparison, there was a significant increase in the classification without symptoms of diabetic distal polyneuropathy in the HTG and STG groups (p < 0.05) and there were no significant effects on other clinical outcomes and QL and SPB, muscle strength, and sense of knee joint position. ","['diabetics without a history of diabetic distal polyneuropathy', 'diabetic patients', 'DM-2 patients, between 45 and 64 years old, of both sexes, divided into 3 groups']","['Home Training Group - HTG (n\xa0=\xa027), and Supervised Training Group - STG', 'sensorimotor training', 'Control Group - CG', 'supervised and home sensorimotor training']","['clinical outcomes and QL and SPB, muscle strength, and sense of knee joint position', 'neuromuscular responses, balance, and quality of life', 'SPB, QL', 'classification without symptoms of diabetic distal polyneuropathy', 'diabetic distal polyneuropathy', 'static postural balance (SPB), quality of life (QL), and neuromuscular responses of Type 2 Diabetics (DM-2', 'diabetic foot and knee flexor-extensors using isokinetic dynamometry', 'Tactile and vibratory sensitivity']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0152025', 'cui_str': 'Polyneuropathy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C1256755', 'cui_str': 'Postural balance'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0152025', 'cui_str': 'Polyneuropathy'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0206172', 'cui_str': 'Diabetic foot'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0439815', 'cui_str': 'Tactile'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",,0.00433731,"In the intra-group comparison, there was a significant increase in the classification without symptoms of diabetic distal polyneuropathy in the HTG and STG groups (p < 0.05) and there were no significant effects on other clinical outcomes and QL and SPB, muscle strength, and sense of knee joint position. ","[{'ForeName': 'Ariane Hidalgo', 'Initials': 'AH', 'LastName': 'Mansano Pletsch', 'Affiliation': 'Laboratory of Physiotherapeutic Resources, Postgraduate Program in Rehabilitation and Functional Performance, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Nathalia Cristina', 'Initials': 'NC', 'LastName': 'de Souza Borges', 'Affiliation': 'Laboratory of Physiotherapeutic Resources, Postgraduate Program in Rehabilitation and Functional Performance, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Duany Maria', 'Initials': 'DM', 'LastName': 'Villar', 'Affiliation': 'Laboratory of Physiotherapeutic Resources, Postgraduate Program in Rehabilitation and Functional Performance, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Ana Laura', 'Initials': 'AL', 'LastName': 'Franzini Sutilo', 'Affiliation': 'Laboratory of Physiotherapeutic Resources, Postgraduate Program in Rehabilitation and Functional Performance, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Elaine Caldeira', 'Initials': 'EC', 'LastName': 'de Oliveira Guirro', 'Affiliation': 'Laboratory of Physiotherapeutic Resources, Postgraduate Program in Rehabilitation and Functional Performance, University of São Paulo, Ribeirão Preto, SP, Brazil; Department of Biomechanics, Medicine and Rehabilitation, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Francisco José Albuquerque', 'Initials': 'FJA', 'LastName': 'de Paula', 'Affiliation': 'Department of Clinical Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Rinaldo Roberto', 'Initials': 'RR', 'LastName': 'de Jesus Guirro', 'Affiliation': 'Laboratory of Physiotherapeutic Resources, Postgraduate Program in Rehabilitation and Functional Performance, University of São Paulo, Ribeirão Preto, SP, Brazil; Department of Biomechanics, Medicine and Rehabilitation, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil. Electronic address: rguirro@fmrp.usp.br.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.01.012'] 1483,34182060,Progress and limitations of current surface registration methods when measuring natural enamel wear.,"OBJECTIVES Our ability to detect dental wear on sequential scans is improving. This experiment aimed to determine if widely used surface registration methods were sufficiently accurate to distinguish differences between intervention groups on early wear lesions. METHODS Baseline measurements were taken on human molar buccal enamel samples (n = 96) with a confocal scanning profilometer (Taicaan, UK). Samples were randomly assigned to subgroups of brushing (30 linear strokes 300 g force) before or after an acid challenge (10 min citric acid 0.3% immersion) for four test dentifrices (medium abrasivity NaF, medium abrasivity SnF 2 , low abrasivity NaF and a water control). Post-experimental profilometry was repeated. 3D step height was analysed using WearCompare (www.leedsdigitaldentistry.co.uk/wearcompare, UK). Percentage Sa change was calculated using Boddies (Taicaan Technologies, Southampton, UK). Data were analysed in SPSS (IBM, USA). RESULTS The mean 3D step height (SD) observed when samples were brushed before the erosive challenge was -2.33 µm (3.46) and after was -3.5 µm (5.6). No significant differences were observed between timing of toothbrushing or dentifrice used. The mean % Sa change for the low abrasivity group (water control and low abrasivity NaF) was -10.7% (16.8%) and +28.0% (42.0%) for the medium abrasivity group (medium abrasivity NaF and SnF 2 ). CONCLUSIONS Detectable wear scars were observed at early stages of wear progression. However standard deviations were high and the experiment was underpowered to detect significant changes. Brushing with a low abrasivity dentifrice or water control produced a smoother surface whereas brushing with a high abrasivity dentifrice produced a rougher surface. CLINICAL SIGNIFICANCE The methodology currently used to align sequential scans of teeth and measure change is too imprecise to measure early wear on natural enamel surfaces unless a large sample size is used. Further improvements are required before we can fully assess early wear processes on natural teeth using profilometry.",2021,"Brushing with a low abrasivity dentifrice or water control produced a smoother surface whereas brushing with a high abrasivity dentifrice produced a rougher surface. ","['Baseline measurements were taken on human molar buccal enamel samples (n=96) with a confocal scanning profilometer (Taicaan, UK']","['acid challenge (10 min citric acid 0.3% immersion) for four test dentifrices (medium abrasivity NaF, medium abrasivity SnF 2 , low abrasivity NaF and a water control']","['Percentage Sa change', 'mean % Sa change', 'mean 3D step height (SD']","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}]","[{'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0055819', 'cui_str': 'Citric Acid'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0020940', 'cui_str': 'Immersion'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0011427', 'cui_str': 'Dentifrice'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0037508', 'cui_str': 'Sodium Fluoride'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0427127', 'cui_str': 'Step height'}]",,0.0316426,"Brushing with a low abrasivity dentifrice or water control produced a smoother surface whereas brushing with a high abrasivity dentifrice produced a rougher surface. ","[{'ForeName': 'Saoirse', 'Initials': 'S', 'LastName': ""O'Toole"", 'Affiliation': ""Centre for Clinical, Oral and Translational Sciences, Faculty for Dental, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, SE1 9RT, UK; Department of Prosthodontics, Faculty for Dental, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, SE1 9RT, UK. Electronic address: Saoirse.otoole@kcl.ac.uk.""}, {'ForeName': 'Polyvios', 'Initials': 'P', 'LastName': 'Charalambous', 'Affiliation': ""Centre for Clinical, Oral and Translational Sciences, Faculty for Dental, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, SE1 9RT, UK.""}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Almatrafi', 'Affiliation': ""Department of Prosthodontics, Faculty for Dental, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, SE1 9RT, UK.""}, {'ForeName': 'Sandeep', 'Initials': 'S', 'LastName': 'Mukar', 'Affiliation': ""Department of Prosthodontics, Faculty for Dental, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, SE1 9RT, UK.""}, {'ForeName': 'Sherif', 'Initials': 'S', 'LastName': 'Elsharkawy', 'Affiliation': ""Centre for Clinical, Oral and Translational Sciences, Faculty for Dental, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, SE1 9RT, UK; Department of Prosthodontics, Faculty for Dental, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, SE1 9RT, UK.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Bartlett', 'Affiliation': ""Centre for Clinical, Oral and Translational Sciences, Faculty for Dental, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, SE1 9RT, UK; Department of Prosthodontics, Faculty for Dental, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, SE1 9RT, UK.""}]",Journal of dentistry,['10.1016/j.jdent.2021.103738'] 1484,34181880,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.","BACKGROUND To date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK). METHODS We did a phase 2, open-label, randomised, controlled trial on adults aged 18-60 years, vaccinated with a single dose of ChAdOx1-S 8-12 weeks before screening, and no history of SARS-CoV-2 infection. Participants were randomly assigned (2:1) to receive either BNT162b2 (0·3 mL) via a single intramuscular injection (intervention group) or continue observation (control group). The primary outcome was 14-day immunogenicity, measured by immunoassays for SARS-CoV-2 trimeric spike protein and receptor binding domain (RBD). Antibody functionality was assessed using a pseudovirus neutralisation assay, and cellular immune response using an interferon-γ immunoassay. The safety outcome was 7-day reactogenicity, measured as solicited local and systemic adverse events. The primary analysis included all participants who received at least one dose of BNT162b2 and who had at least one efficacy evaluation after baseline. The safety analysis included all participants who received BNT162b2. This study is registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739), and is ongoing. FINDINGS Between April 24 and 30, 2021, 676 individuals were enrolled and randomly assigned to either the intervention group (n=450) or control group (n=226) at five university hospitals in Spain (mean age 44 years [SD 9]; 382 [57%] women and 294 [43%] men). 663 (98%) participants (n=441 intervention, n=222 control) completed the study up to day 14. In the intervention group, geometric mean titres of RBD antibodies increased from 71·46 BAU/mL (95% CI 59·84-85·33) at baseline to 7756·68 BAU/mL (7371·53-8161·96) at day 14 (p<0·0001). IgG against trimeric spike protein increased from 98·40 BAU/mL (95% CI 85·69-112·99) to 3684·87 BAU/mL (3429·87-3958·83). The interventional:control ratio was 77·69 (95% CI 59·57-101·32) for RBD protein and 36·41 (29·31-45·23) for trimeric spike protein IgG. Reactions were mild (n=1210 [68%]) or moderate (n=530 [30%]), with injection site pain (n=395 [88%]), induration (n=159 [35%]), headache (n=199 [44%]), and myalgia (n=194 [43%]) the most commonly reported adverse events. No serious adverse events were reported. INTERPRETATION BNT162b2 given as a second dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile. FUNDING Instituto de Salud Carlos III. TRANSLATIONS For the French and Spanish translations of the abstract see Supplementary Materials section.",2021,"The interventional:control ratio was 77·69 (95% CI 59·57-101·32) for RBD protein and 36·41 (29·31-45·23) for trimeric spike protein IgG. Reactions were mild (n=1210 [68%]) or moderate (n=530 [30%]), with injection site pain (n=395 [88%]), induration (n=159 [35%]), headache (n=199 [44%]), and myalgia (n=194 [43%]) the most commonly reported adverse events.","['ChAdOx1-S-primed participants (CombiVacS', 'Between April 24 and 30, 2021, 676 individuals were enrolled and randomly assigned to either the intervention group (n=450) or control group (n=226) at five university hospitals in Spain (mean age 44 years [SD 9]; 382 [57%] women and 294', 'participants who received at least one dose of BNT162b2 and who had at least one efficacy evaluation after baseline', '663 (98%) participants (n=441 intervention, n=222 control) completed the study up to day 14', 'participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK', 'adults aged 18-60 years, vaccinated with a single dose of ChAdOx1-S 8-12 weeks before screening, and no history of SARS-CoV-2 infection']","['EudraCT', 'BNT162b2 (Comirnaty, BioNTech, Mainz, Germany', 'BNT162b2 (0·3 mL) via a single intramuscular injection (intervention group) or continue observation (control group']","['injection site pain', 'myalgia', 'Antibody functionality', 'adverse events', 'IgG against trimeric spike protein', 'solicited local and systemic adverse events', 'headache', 'Immunogenicity and reactogenicity', 'serious adverse events', '14-day immunogenicity, measured by immunoassays for SARS-CoV-2 trimeric spike protein and receptor binding domain (RBD', 'immunogenicity and reactogenicity', 'geometric mean titres of RBD antibodies']","[{'cui': 'C0331021', 'cui_str': 'Ligustrum vulgare'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517750', 'cui_str': '382'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332122', 'cui_str': 'No history of'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]","[{'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021492', 'cui_str': 'Intramuscular injection'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0151828', 'cui_str': 'Injection site pain'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0020980', 'cui_str': 'Immunoassay method'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}]",676.0,0.394691,"The interventional:control ratio was 77·69 (95% CI 59·57-101·32) for RBD protein and 36·41 (29·31-45·23) for trimeric spike protein IgG. Reactions were mild (n=1210 [68%]) or moderate (n=530 [30%]), with injection site pain (n=395 [88%]), induration (n=159 [35%]), headache (n=199 [44%]), and myalgia (n=194 [43%]) the most commonly reported adverse events.","[{'ForeName': 'Alberto M', 'Initials': 'AM', 'LastName': 'Borobia', 'Affiliation': 'Servicio de Farmacología Clínica, Departamento de Farmacología y Terapéutica, Facultad de Medicina, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Antonio J', 'Initials': 'AJ', 'LastName': 'Carcas', 'Affiliation': 'Servicio de Farmacología Clínica, Departamento de Farmacología y Terapéutica, Facultad de Medicina, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Mayte', 'Initials': 'M', 'LastName': 'Pérez-Olmeda', 'Affiliation': 'Laboratorio de Serología, Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Castaño', 'Affiliation': 'Hospital Universitario de Cruces, Biocruces Bizkaia HRI, UPV/EHU, OSAKIDETZA, CIBERDEM, CIBERER, Endo-ERN, Barakaldo-Bilbao, Spain.'}, {'ForeName': 'María Jesús', 'Initials': 'MJ', 'LastName': 'Bertran', 'Affiliation': 'Servicio de Medicina Preventiva y Epidemiología, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'García-Pérez', 'Affiliation': 'Unidad de Inmunopatología del SIDA, Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Campins', 'Affiliation': ""Servicio de Medicina Preventiva y Epidemiología, Servicio de Farmacología Clínica, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Portolés', 'Affiliation': 'Servicio de Farmacología Clínica, Hospital Clínico San Carlos, IdISSC, Departamento de Farmacología y Toxicología, Universidad Complutense de Madrid, Madrid, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'González-Pérez', 'Affiliation': 'Laboratorio de Referencia en Inmunología, Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'María Teresa', 'Initials': 'MT', 'LastName': 'García Morales', 'Affiliation': 'Instituto de Investigación Sanitaria Hospital 12 de Octubre, CIBER de Epidemiología y Salud Pública, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.'}, {'ForeName': 'Eunate', 'Initials': 'E', 'LastName': 'Arana-Arri', 'Affiliation': 'Hospital Universitario de Cruces, Biocruces Bizkaia HRI, UPV/EHU, OSAKIDETZA, CIBERDEM, CIBERER, Endo-ERN, Barakaldo-Bilbao, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Aldea', 'Affiliation': 'Servicio de Medicina Preventiva y Epidemiología, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Díez-Fuertes', 'Affiliation': 'Unidad de Inmunopatología del SIDA, Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Inmaculada', 'Initials': 'I', 'LastName': 'Fuentes', 'Affiliation': ""Unidad de Soporte a la Investigación Clínica, Vall d'Hebron Institut de Recerca, Servicio de Farmacología Clínica, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Ascaso', 'Affiliation': 'Servicio de Farmacología Clínica, Hospital Clínico San Carlos, IdISSC, Departamento de Farmacología y Toxicología, Universidad Complutense de Madrid, Madrid, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Lora', 'Affiliation': 'Instituto de Investigación Sanitaria Hospital 12 de Octubre, CIBER de Epidemiología y Salud Pública, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.'}, {'ForeName': 'Natale', 'Initials': 'N', 'LastName': 'Imaz-Ayo', 'Affiliation': 'Hospital Universitario de Cruces, Biocruces Bizkaia HRI, UPV/EHU, OSAKIDETZA, CIBERDEM, CIBERER, Endo-ERN, Barakaldo-Bilbao, Spain.'}, {'ForeName': 'Lourdes E', 'Initials': 'LE', 'LastName': 'Barón-Mira', 'Affiliation': 'Servicio de Medicina Preventiva y Epidemiología, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Agustí', 'Affiliation': ""Departmento de Farmacología, Terapéutica y Toxicología, Servicio de Farmacología Clínica, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Pérez-Ingidua', 'Affiliation': 'Servicio de Farmacología Clínica, Hospital Clínico San Carlos, IdISSC, Departamento de Farmacología y Toxicología, Universidad Complutense de Madrid, Madrid, Spain.'}, {'ForeName': 'Agustín', 'Initials': 'A', 'LastName': 'Gómez de la Cámara', 'Affiliation': 'Instituto de Investigación Sanitaria Hospital 12 de Octubre, CIBER de Epidemiología y Salud Pública, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.'}, {'ForeName': 'José Ramón', 'Initials': 'JR', 'LastName': 'Arribas', 'Affiliation': 'Servicio de Medicina Interna, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Ochando', 'Affiliation': 'Laboratorio de Referencia en Inmunología, Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Alcamí', 'Affiliation': 'Unidad de Inmunopatología del SIDA, Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Cristóbal', 'Initials': 'C', 'LastName': 'Belda-Iniesta', 'Affiliation': 'Centro Nacional de Microbiología, and Evaluation and Promotion of Research, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: cbelda@isciii.es.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Frías', 'Affiliation': 'Servicio de Farmacología Clínica, Departamento de Farmacología y Terapéutica, Facultad de Medicina, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain. Electronic address: jesus.frias@uam.es.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(21)01420-3'] 1485,34184930,A Randomized Clinical Trial of Standard versus Expanded Cultures to Diagnose Urinary Tract Infections in Women.,"PURPOSE We compared urinary tract infection (UTI) symptom resolution rates at 7-10 days in symptomatic women randomized to treatment based on standard urine culture (SUC) versus expanded quantitative urine culture (EQUC) results. MATERIALS AND METHODS Women ≥18 years old who responded ""yes"" to ""do you feel you have a UTI?"" agreed to urethral catheterization, and followup. Symptoms were assessed using the validated UTI Symptom Assessment (UTISA) questionnaire. Culture method was randomized 2:1 (SUC:EQUC); antibiotics were prescribed to women with positive cultures. The primary outcome, UTI symptom resolution, was determined 7-10 days following enrollment on all participants regardless of treatment. RESULTS Demographic data were similar between groups. Of the SUC and EQUC groups 63% and 74% had positive cultures (p=0.10), respectively. Of participants with positive cultures 97% received antibiotics. Primary outcome data were provided by 215 of 225 participants (SUC 143 [95%], EQUC 72 [97%]). At the primary outcome assessment, 64% and 69% in the SUC and EQUC groups, respectively, reported UTI symptom resolution (p=0.46); UTISA scores improved from baseline in the EQUC arm compared to the SUC arm (p=0.04). In the subset of women predominated by non- Escherichia coli (76), there was a trend toward more symptom resolution in the EQUC arm (21%, p=0.08). CONCLUSIONS Symptom resolution was similar for the overall population ( E. coli and non- E. coli ) of women treated for UTI symptoms based on SUC or EQUC. Although the sample size limits conclusions regarding the utility of EQUC in women with non- E. coli uropathogens, the detected trend indicates that this understudied clinical subset warrants further study.",2021,"(UTI) symptom resolution rates at 7-10 days in symptomatic women randomized to treatment based on standard urine culture (SUC) versus expanded quantitative urine culture (EQUC) results. ","['Women ≥18 years old who responded ""yes"" to ""do you feel you have a UTI?"" agreed to urethral catheterization, and follow-up', 'Women', 'women with positive cultures']","['Standard Versus Expanded Cultures', 'EQUC', 'antibiotics', 'standard urine culture (SUC) versus expanded quantitative urine culture (EQUC']","['UTI) symptom resolution rates', 'validated UTI Symptom Assessment (UTISA) questionnaire', 'UTISA scores', 'urinary tract infection', 'UTI symptom resolution', 'symptom resolution']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1298907', 'cui_str': 'Yes'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0042019', 'cui_str': 'Catheterization, Urinary'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C1294291', 'cui_str': 'Quantitative urine culture'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0430404', 'cui_str': 'Urine culture'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",225.0,0.493435,"(UTI) symptom resolution rates at 7-10 days in symptomatic women randomized to treatment based on standard urine culture (SUC) versus expanded quantitative urine culture (EQUC) results. ","[{'ForeName': 'Hayley C', 'Initials': 'HC', 'LastName': 'Barnes', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Departments of Urology & Obstetrics/Gynecology, Loyola University Medical Center, Maywood, Illinois.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Wolff', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Departments of Urology & Obstetrics/Gynecology, Loyola University Medical Center, Maywood, Illinois.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Abdul-Rahim', 'Affiliation': 'Department of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Harrington', 'Affiliation': 'Department of Pathology, Loyola University Chicago, Maywood, Illinois.'}, {'ForeName': 'E E', 'Initials': 'EE', 'LastName': 'Hilt', 'Affiliation': 'Department of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois.'}, {'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Price', 'Affiliation': 'Department of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Halverson', 'Affiliation': 'Department of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois.'}, {'ForeName': 'B R', 'Initials': 'BR', 'LastName': 'Hochstedler', 'Affiliation': 'Department of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Pham', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Departments of Urology & Obstetrics/Gynecology, Loyola University Medical Center, Maywood, Illinois.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Acevedo-Alvarez', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Departments of Urology & Obstetrics/Gynecology, Loyola University Medical Center, Maywood, Illinois.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Joyce', 'Affiliation': 'Department of Public Health Sciences, Loyola University Chicago, Maywood, Illinois.'}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Fitzgerald', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Departments of Urology & Obstetrics/Gynecology, Loyola University Medical Center, Maywood, Illinois.'}, {'ForeName': 'P C', 'Initials': 'PC', 'LastName': 'Schreckenberger', 'Affiliation': 'Department of Pathology, Loyola University Chicago, Maywood, Illinois.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Brubaker', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, La Jolla, California.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Wolfe', 'Affiliation': 'Department of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Mueller', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Departments of Urology & Obstetrics/Gynecology, Loyola University Medical Center, Maywood, Illinois.'}]",The Journal of urology,['10.1097/JU.0000000000001949'] 1486,34391128,The Sobriety Treatment and Recovery Teams program for families with parental substance use: Comparison of child welfare outcomes through 12 months post-intervention.,"BACKGROUND The 2018 Family First Prevention Services Act (FFPSA) shifted child welfare funding to interventions proven effective in preserving families with parental substance use and child welfare involvement. The Sobriety Treatment and Recovery Teams (START) program serves this population with FFPSA aligned goals. OBJECTIVE This study was the first to test the sustained effects of START from the initial CPS report through 12-months post-intervention. PARTICIPANTS AND SETTING Children (n = 784) receiving START services in four sites were compared to 784 children receiving child welfare treatment as usual (TAU). METHODS Using child welfare administrative data, children in START were matched to children in TAU using propensity score matching. Outcomes were tested during the intervention period, and at six- and 12-months post-intervention using comparative statistics and multilevel logistic regression. RESULTS The odds of START children being placed in out-of-home care (OOHC) during the intervention period were half those of children in TAU (20.3% vs. 35.2%, p < .001, OR = 0.47, 95% CI [0.37, 0.59]). When placed in OOHC, START children were more likely to be reunified with their parents (p = .042, OR = 1.44, 95% CI [0.99, 1.62]). At 12-months post-intervention, 68.5% of START and 56.0% of TAU-served children remained free from both OOHC placement and child abuse and neglect (after multilevel clustering adjustment: p < .001, OR = 1.85, 95% CI [1.41, 2.43]). CONCLUSION The primary impact of START was significantly reduced rates of OOHC placement, with results sustained through 12-months post-intervention and after accounting for family clusters and site differences.",2021,"When placed in OOHC, START children were more likely to be reunified with their parents (p = .042, OR = ","['Using child welfare administrative data', '784 children receiving', 'Children (n\xa0']",['child welfare treatment as usual (TAU'],"['OOHC placement and child abuse and neglect', 'rates of OOHC placement']","[{'cui': 'C0008093', 'cui_str': 'Child Well Being'}, {'cui': 'C1292785', 'cui_str': 'Administrative action'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0008093', 'cui_str': 'Child Well Being'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0204977', 'cui_str': 'Home care of patient'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0008060', 'cui_str': 'Child abuse'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}]",784.0,0.0523973,"When placed in OOHC, START children were more likely to be reunified with their parents (p = .042, OR = ","[{'ForeName': 'Ruth A', 'Initials': 'RA', 'LastName': 'Huebner', 'Affiliation': 'Kentucky Department of Community Based Services, Retired Professor Eastern Kentucky University, United States of America. Electronic address: ruthhuebner@hotmail.com.'}, {'ForeName': 'Martin T', 'Initials': 'MT', 'LastName': 'Hall', 'Affiliation': 'Kent School of Social Work, University of Louisville, Louisville, KY, United States of America. Electronic address: martin.hall@louisville.edu.'}, {'ForeName': 'Mathew T', 'Initials': 'MT', 'LastName': 'Walton', 'Affiliation': 'Office of Health Data and Analytics, Division of Analytics, Frankfort, KY 40621, United States of America. Electronic address: matthew.walton@ky.gov.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Smead', 'Affiliation': 'University of Kentucky College of Social Work, Department for Community Based Services, United States of America. Electronic address: erine.smead@ky.gov.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Willauer', 'Affiliation': 'National START Training and Technical Assistance Program, Children and Family Futures, Inc., Lake Forest, CA 92630, United States of America. Electronic address: twillauer@cffutures.org.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Posze', 'Affiliation': 'National START Training and Technical Assistance Program, Children and Family Futures, Inc., Lake Forest, CA 92630, United States of America. Electronic address: lposze@cffutures.org.'}]",Child abuse & neglect,['10.1016/j.chiabu.2021.105260'] 1487,34186278,Ultrasound-guided retrolaminar block versus ilioinguinal nerve block for postoperative analgesia in children undergoing inguinal herniotomy: A randomized controlled trial.,"STUDY OBJECTIVE Ultrasound-guided retrolaminar block (RLB) is a new, safe and technically easy nerve block. To our knowledge, no studies have evaluated its analgesic efficacy in pediatric patients. This study aimed to compare the postoperative analgesic efficacy of RLB and ilioinguinal nerve block (INB) in pediatric patients undergoing unilateral inguinal herniotomy. DESIGN Superiority, prospective, randomized, double-blinded, controlled study. SETTING Operating rooms and wards of Mansoura University Children's Hospital, Egypt. PATIENTS Sixty-five patients aged 2 to 6 years undergoing unilateral inguinal herniotomy were enrolled. INTERVENTIONS In the ultrasound-guided RLB group (n = 30), we injected 0.5 mL/kg bupivacaine 0.25% into the retrolaminar space between the lamina of T12 and the paraspinal muscles and in ultrasound-guided INB group (n = 30), 0.5 mL/kg bupivacaine 0.25% was injected for INB. MEASUREMENTS The primary outcome measure was the number of patients requiring ibuprofen as rescue analgesia and the secondary outcome measures were intraoperative hemodynamic changes and the postoperative FLACC (Face, Legs, Activity, Cry, Consolability) score. MAIN RESULTS The number of patients who needed rescue analgesia in the first postoperative 24 h was significantly lower (P = 0.023) in the RLB group [5 (16%)] than the INB group [13 (43%)]. The mean (SD) arterial blood pressure and heart rate were significantly higher (P < 0.001) during sac traction in the INB group [74.07 (2.99), 97.33 (6.98)] than the RLB group [67.73 (3.55), 90.79 (5.13)]. The postoperative FLACC scores at 4, 6, 12, and 24 h were significantly lower (P < 0.05) in the RLB group than in the INB group. CONCLUSION Retrolaminar block is superior to ilioinguinal nerve block in providing postoperative analgesia in pediatric patients undergoing unilateral inguinal herniotomy.",2021,The number of patients who needed rescue analgesia in the first postoperative 24 h was significantly lower (P = 0.023) in the RLB group [5 (16%)] than the INB group [13 (43%)].,"['children undergoing inguinal herniotomy', 'pediatric patients', 'Sixty-five patients aged 2 to 6\xa0years undergoing unilateral inguinal herniotomy were enrolled', 'pediatric patients undergoing unilateral inguinal herniotomy', ""Operating rooms and wards of Mansoura University Children's Hospital, Egypt""]","['Ultrasound-guided retrolaminar block versus ilioinguinal nerve block', 'Retrolaminar block', 'RLB and ilioinguinal nerve block (INB', 'bupivacaine', 'Ultrasound-guided retrolaminar block (RLB']","['analgesic efficacy', 'postoperative FLACC scores', 'number of patients requiring ibuprofen as rescue analgesia', 'mean (SD) arterial blood pressure and heart rate', 'intraoperative hemodynamic changes and the postoperative FLACC (Face, Legs, Activity, Cry, Consolability) score']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018246', 'cui_str': 'Inguinal'}, {'cui': 'C0405600', 'cui_str': 'Simple excision of inguinal hernial sac'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0405602', 'cui_str': 'Unilateral inguinal herniotomy'}, {'cui': 'C0029064', 'cui_str': 'Operating theatre'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0013715', 'cui_str': 'Egypt'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0394766', 'cui_str': 'Local anesthetic block of ilioinguinal nerve'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0010399', 'cui_str': 'Crying'}]",65.0,0.304716,The number of patients who needed rescue analgesia in the first postoperative 24 h was significantly lower (P = 0.023) in the RLB group [5 (16%)] than the INB group [13 (43%)].,"[{'ForeName': 'Mahmoud M', 'Initials': 'MM', 'LastName': 'Alseoudy', 'Affiliation': 'Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Electronic address: drs3ody.mansora@mans.edu.eg.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Abdelbaser', 'Affiliation': 'Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110421'] 1488,34186271,Moderators of cognitive insight outcome in metacognitive training for first-episode psychosis.,"Metacognitive training (MCT) is a promising treatment for improving cognitive insight associated with delusional beliefs in individuals with psychotic disorders. The aim of this study was to examine potential moderators of cognitive insight in individuals with first-episode psychosis (FEP) who received either MCT or psychoeducation. The present study was based on data from a randomized control trial comparing MCT to psychoeducation. Baseline sociodemographic and clinical characteristics in a sample of 122 patients with FEP were examined as potential moderators of the self-reflectiveness and self-certainty dimensions of cognitive insight using the SPSS PROCESS macro. The only variable that moderated self-reflectiveness at the post-treatment evaluation was age of onset (b = -0.27, p = .025). The effect of MCT in reducing self-certainty was stronger in women (b = -3.26, p = .018) and in individuals with average or above average baseline self-esteem (b = -0.30, p = .007). Overall, our findings support the generalization of MCT to a variety of sociodemographic and clinical profiles. While some patient profiles may require targeted interventions such as MCT to improve cognitive insight, others may do equally as well with less demanding interventions such as a psychoeducational group.",2021,"The effect of MCT in reducing self-certainty was stronger in women (b = -3.26, p = .018) and in individuals with average or above average baseline self-esteem (b = -0.30, p = .007).","['individuals with first-episode psychosis (FEP', 'first-episode psychosis', '122 patients with FEP', 'individuals with psychotic disorders']","['MCT', 'Metacognitive training (MCT', 'MCT or psychoeducation', 'metacognitive training']",['self-certainty'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205423', 'cui_str': 'Certain'}]",122.0,0.0637449,"The effect of MCT in reducing self-certainty was stronger in women (b = -3.26, p = .018) and in individuals with average or above average baseline self-esteem (b = -0.30, p = .007).","[{'ForeName': 'César', 'Initials': 'C', 'LastName': 'González-Blanch', 'Affiliation': 'Mental Health Centre, University Hospital Marqués de Valdecilla, Santander, Spain; IDIVAL, Valdecilla Biomedical Research Institute, Santander, Spain. Electronic address: cesar.gonzalezblanch@scsalud.es.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Birulés', 'Affiliation': 'Parc Sanitari Sant Joan de Déu, Barcelona, Spain; MERITT, Institut de Recerca Sant Joan de Déu, Barcelona, Spain; Universitat de Barcelona (UB), Barcelona, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Pousa', 'Affiliation': ""Salut Mental Parc Taulí. Sabadell (Barcelona), Hospital Universitari, UAB Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Psychiatry, Hospital de La Santa Creu I Sant Pau, Institut D'Investigació Biomèdica-Sant Pau (IIB-Sant Pau), Barcelona, Spain.""}, {'ForeName': 'María Luisa', 'Initials': 'ML', 'LastName': 'Barrigon', 'Affiliation': 'Department of Psychiatry, IIS-Fundación Jiménez Díaz Hospital, Madrid, Spain; Department of Psychiatry, Universidad Autonoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'López-Carrilero', 'Affiliation': 'Parc Sanitari Sant Joan de Déu, Barcelona, Spain; Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain; MERITT, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Lorente-Rovira', 'Affiliation': 'Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain; Psychiatry Service, Hospital Clinico Universitario, Valencia, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Ayesa-Arriola', 'Affiliation': 'IDIVAL, Valdecilla Biomedical Research Institute, Santander, Spain; Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Setien-Suero', 'Affiliation': 'Department of Methods and Experimental Psychology, Faculty of Psychology and Education, University of Deusto, Bilbao, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Barajas', 'Affiliation': ""Department of Research, Centre D'Higiene Mental Les Corts, Barcelona, Spain; Serra Húnter Programme, Government of Catalonia, Spain; Department of Clinical and Health Psychology, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.""}, {'ForeName': 'Eva M', 'Initials': 'EM', 'LastName': 'Grasa', 'Affiliation': ""Department of Psychiatry, Hospital de La Santa Creu I Sant Pau, Institut D'Investigació Biomèdica-Sant Pau (IIB-Sant Pau), Barcelona, Spain; Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.""}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Ruiz-Delgado', 'Affiliation': 'UGC Salud Mental Hospital Regional de Malaga, Malaga, Spain.'}, {'ForeName': 'Fermín', 'Initials': 'F', 'LastName': 'González-Higueras', 'Affiliation': 'Comunidad Terapéutica Jaén, Servicio Andaluz de Salud. Jaen, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Cid', 'Affiliation': ""Mental Health & Addiction Research Group, IdiBGi, Institut D'Assistencia Sanitàri, Girona, Spain.""}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Ochoa', 'Affiliation': 'Parc Sanitari Sant Joan de Déu, Barcelona, Spain; Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain; MERITT, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2021.06.040'] 1489,34196106,Circulating platelet-derived extracellular vesicles are decreased after remote ischemic preconditioning in patients with coronary disease: A randomized controlled trial.,"BACKGROUND Brief nonharmful ischemia, remote ischemic preconditioning (RIPC) has been proposed to confer benefit to patients with coronary artery disease via unknown mechanisms. OBJECTIVES We aimed to investigate the effect of RIPC on circulating levels of extracellular vesicles (EVs) and global coagulation and fibrinolytic factors in patients with coronary disease. PATIENTS/METHODS Blood samples were taken from 60 patients presenting for coronary angiography enrolled in a randomized, controlled trial before and after RIPC (3 × 5 min administration of 200 mmHg sphygmomanometer on the arm, n = 31) or sham (n = 29) treatment. Most patients (n = 48) had significant coronary artery disease and all were taking at least one antiplatelet agent. RESULTS Remote ischemic preconditioning significantly decreased circulating levels of EVs expressing platelet markers CD41 and CD61 detected by flow cytometry in plasma, whereas no such effect was found on EVs expressing phosphatidylserine, CD62P, CD45, CD11b, CD144, CD31 + /CD41 - , or CD235a. RIPC had no effect on the overall hemostatic potential assay or circulating antigen levels of tissue plasminogen activator, urokinase, plasminogen activator inhibitor-1, or plasminogen. Sham treatment had no effect on any studied parameter. Statin use inhibited the effect of RIPC on CD61 + EVs, diabetes modified the effect of RIPC on CD45 + and CD11b + EVs, and hypertension modified the effect of RIPC on CD235a + EVs. CONCLUSIONS Remote ischemic preconditioning decreased circulating levels of platelet-derived EVs in patients with coronary disease taking conventional antiplatelet therapy. This may reflect increased EV clearance/uptake or change in production. Clinical variables may alter the effectiveness of RIPC.",2021,"RIPC had no effect on the overall hemostatic potential (OHP) assay or circulating antigen levels of tissue plasminogen activator, urokinase, plasminogen activator inhibitor-1, or plasminogen.","['patients with coronary disease', 'Most patients (n=48) had significant coronary artery disease and all were taking at least one antiplatelet agent', 'patients with coronary artery disease (CAD) via unknown mechanisms', 'patients with coronary disease taking conventional antiplatelet therapy', 'Blood samples were taken from 60 patients presenting for coronary angiography enrolled']","['ischemic preconditioning (RIPC', 'RIPC']","['overall hemostatic potential (OHP) assay or circulating antigen levels of tissue plasminogen activator, urokinase, plasminogen activator inhibitor-1, or plasminogen', 'circulating levels of EV expressing platelet markers CD41 and CD61', 'EV expressing phosphatidylserine, CD62P, CD45, CD11b, CD144, CD31+/CD41-, or CD235a', 'circulating levels of extracellular vesicles (EV) and global coagulation and fibrinolytic factors']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010068', 'cui_str': 'Coronary Heart Disease'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0085826', 'cui_str': 'Antiplatelet agent'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0085532', 'cui_str': 'Coronary angiography'}]","[{'cui': 'C0376466', 'cui_str': 'Ischemic Pre-Conditioning'}, {'cui': 'C0205157', 'cui_str': 'Remote'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0430420', 'cui_str': 'Antigen assay'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0042071', 'cui_str': 'Urokinase'}, {'cui': 'C0030190', 'cui_str': 'Plasminogen activator inhibitor-1'}, {'cui': 'C0032140', 'cui_str': 'Plasminogen'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3894683', 'cui_str': 'Extracellular Vesicles'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0032191', 'cui_str': 'Lymphocyte antigen CD41'}, {'cui': 'C0245726', 'cui_str': 'Lymphocyte antigen CD61'}, {'cui': 'C0031623', 'cui_str': 'Phosphatidylserine'}, {'cui': 'C0134835', 'cui_str': 'Lymphocyte antigen CD62'}, {'cui': 'C0054961', 'cui_str': 'Lymphocyte antigen CD45'}, {'cui': 'C1136310', 'cui_str': 'Lymphocyte antigen CD11b'}, {'cui': 'C0017955', 'cui_str': 'Glycophorin A'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0040044', 'cui_str': 'Thrombolytic therapy'}]",60.0,0.0832184,"RIPC had no effect on the overall hemostatic potential (OHP) assay or circulating antigen levels of tissue plasminogen activator, urokinase, plasminogen activator inhibitor-1, or plasminogen.","[{'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Reddel', 'Affiliation': 'ANZAC Research Institute, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.'}, {'ForeName': 'Gabrielle J', 'Initials': 'GJ', 'LastName': 'Pennings', 'Affiliation': 'ANZAC Research Institute, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.'}, {'ForeName': 'Jerrett K', 'Initials': 'JK', 'LastName': 'Lau', 'Affiliation': 'ANZAC Research Institute, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.'}, {'ForeName': 'Vivien M', 'Initials': 'VM', 'LastName': 'Chen', 'Affiliation': 'ANZAC Research Institute, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.'}, {'ForeName': 'Leonard', 'Initials': 'L', 'LastName': 'Kritharides', 'Affiliation': 'ANZAC Research Institute, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.15441'] 1490,34197228,Intermittent short-arm centrifugation is a partially effective countermeasure against upright balance deterioration following 60-day head-down tilt bed rest.,"This study investigated whether artificial gravity (AG), induced by short-radius centrifugation, mitigated deterioration in standing balance and anticipatory postural adjustments (APAs) of trunk muscles following 60-day head-down tilt bed rest. Twenty-four participants were allocated to one of three groups: control group ( n = 8); 30-min continuous AG daily ( n = 8); and intermittent 6 × 5 min AG daily ( n = 8). Before and immediately after bed rest, standing balance was assessed in four conditions: eyes open and closed on both stable and foam surfaces. Measures including sway path, root mean square, and peak sway velocity, sway area, sway frequency power, and sway density curve were extracted from the center of pressure displacement. APAs were assessed during rapid arm movements using intramuscular or surface electromyography electrodes of the rectus abdominis; obliquus externus and internus abdominis; transversus abdominis; erector spinae at L1, L2, L3, and L4 vertebral levels; and deep lumbar multifidus muscles. The relative latency between the EMG onset of the deltoid and each of the trunk muscles was calculated. All three groups had poorer balance performance in most of the parameters (all P < 0.05) and delayed APAs of the trunk muscles following bed rest (all P < 0.05). Sway path and sway velocity were deteriorated, and sway frequency power was less in those who received intermittent AG than in the control group (all P < 0.05), particularly in conditions with reduced proprioceptive feedback. These data highlight the potential of intermittent AG to mitigate deterioration of some aspects of postural control induced by gravitational unloading, but no protective effects on trunk muscle responses were observed. NEW & NOTEWORTHY This study presents novel insights into the effect of artificial gravity (AG) on the deterioration of standing balance and anticipatory postural adjustments (APAs) of trunk muscles induced by 60-day strict head-down bed rest. The results indicated severe balance dysfunction and delayed APAs during rapid arm movement. AG partially mitigated the deterioration in standing balance and may thus be considered as a potential countermeasure for future planetary surface explorations. Optimization of AG protocols might enhance effects.",2021,All three groups had poorer balance performance in most of the parameters (all P<0.05) and delayed APAs of the trunk muscles following bed rest (all P<0.05).,['Twenty-four participants'],"['artificial gravity (AG', '60-day head-down tilt bed rest']","['trunk muscle responses', 'sway path, root-mean-square, and peak sway velocity, sway area, sway frequency power, and sway density curve', 'Sway path and sway velocity', 'poorer balance performance', 'standing balance and anticipatory postural adjustments (APAs) of trunk muscles', 'sway frequency power']","[{'cui': 'C3715070', 'cui_str': '24'}]","[{'cui': 'C0242678', 'cui_str': 'Gravity, Artificial'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242683', 'cui_str': 'Head-Down Tilt'}, {'cui': 'C0004910', 'cui_str': 'Bedrest'}]","[{'cui': 'C0581755', 'cui_str': 'Skeletal muscle structure of trunk'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0234964', 'cui_str': 'Poor balance'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}]",24.0,0.0203194,All three groups had poorer balance performance in most of the parameters (all P<0.05) and delayed APAs of the trunk muscles following bed rest (all P<0.05).,"[{'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'De Martino', 'Affiliation': 'Aerospace Medicine and Rehabilitation Laboratory, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Sauro E', 'Initials': 'SE', 'LastName': 'Salomoni', 'Affiliation': 'National Health and Medical Research Council Centre for Clinical Research Excellence in Spinal Pain, Injury and Health, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Hodges', 'Affiliation': 'National Health and Medical Research Council Centre for Clinical Research Excellence in Spinal Pain, Injury and Health, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Hides', 'Affiliation': 'School of Health Sciences and Social Work, Griffith University, Nathan Campus, Brisbane, Australia.'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'Lindsay', 'Affiliation': 'Aerospace Medicine and Rehabilitation Laboratory, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Dorothée', 'Initials': 'D', 'LastName': 'Debuse', 'Affiliation': 'Aerospace Medicine and Rehabilitation Laboratory, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Winnard', 'Affiliation': 'Aerospace Medicine and Rehabilitation Laboratory, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Elliott', 'Affiliation': 'Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Hoggarth', 'Affiliation': 'Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Beard', 'Affiliation': 'National Institute for Health Research Oxford Biomedical Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Cook', 'Affiliation': 'National Institute for Health Research Oxford Biomedical Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Ekman', 'Affiliation': 'European Astronaut Centre, Space Medicine Team (HRE-OM), European Space Agency, Cologne, Germany.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Hinterwaldner', 'Affiliation': 'European Astronaut Centre, Space Medicine Team (HRE-OM), European Space Agency, Cologne, Germany.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Scott', 'Affiliation': 'European Astronaut Centre, Space Medicine Team (HRE-OM), European Space Agency, Cologne, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Weber', 'Affiliation': 'European Astronaut Centre, Space Medicine Team (HRE-OM), European Space Agency, Cologne, Germany.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Caplan', 'Affiliation': 'Aerospace Medicine and Rehabilitation Laboratory, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00180.2021'] 1491,34197227,Cardiac baroreflex dysfunction in patients with pulmonary arterial hypertension at rest and during orthostatic stress: role of the peripheral chemoreflex.,"The baroreflex integrity in early-stage pulmonary arterial hypertension (PAH) remains uninvestigated. A potential baroreflex impairment could be functionally relevant and possibly mediated by enhanced peripheral chemoreflex activity. Thus, we investigated 1 ) the cardiac baroreflex in nonhypoxemic PAH; 2 ) the association between baroreflex indexes and peak aerobic capacity [i.e., peak oxygen consumption (V̇o 2peak )]; and 3 ) the peripheral chemoreflex contribution to the cardiac baroreflex. Nineteen patients and 13 age- and sex-matched healthy adults (HA) randomly inhaled either 100% O 2 (peripheral chemoreceptor inhibition) or 21% O 2 (control session) while at rest and during a repeated sit-to-stand maneuver. Beat-by-beat analysis of R-R intervals and systolic blood pressure provided indexes of cardiac baroreflex sensitivity (cBRS) and effectiveness (cBEI). The PAH group had lower cBEI for all sequences (cBEI ALL ) at rest [means ± SD: PAH = 0.5 ± 0.2 vs. HA = 0.7 ± 0.1 arbitrary units (a.u.), P = 0.02] and lower cBRS ALL (PAH = 6.8 ± 7.0 vs. HA = 9.7 ± 5.0 ms·mmHg -1 , P < 0.01) and cBEI ALL (PAH = 0.4 ± 0.2 vs. HA= 0.6 ± 0.1 a.u., P < 0.01) during the sit-to-stand maneuver versus the HA group. The cBEI during the sit-to-stand maneuver was independently correlated to V̇o 2peak (partial r  = 0.45, P < 0.01). Hyperoxia increased cBRS and cBEI similarly in both groups at rest and during the sit-to-stand maneuver. Therefore, cardiac baroreflex dysfunction was observed under spontaneous and, most notably, provoked blood pressure fluctuations in nonhypoxemic PAH, was not influenced by the peripheral chemoreflex, and was associated with lower V̇o 2peak , suggesting that it could be functionally relevant. NEW & NOTEWORTHY Does the peripheral chemoreflex play a role in cardiac baroreflex dysfunction in patients with pulmonary arterial hypertension (PAH)? Here we provide new evidence of cardiac baroreflex dysfunction under spontaneous and, most notably, provoked blood pressure fluctuations in patients with nonhypoxemic PAH. Importantly, impaired cardiac baroreflex effectiveness during provoked blood pressure fluctuations was independently associated with poorer functional capacity. Finally, our results indicated that the peripheral chemoreflex did not mediate cardiac baroreflex dysfunction among those patients.",2021,Hyperoxia increased cBRS and cBEI similarly in both groups at rest and during the sit-to-stand maneuver.,"['Nineteen patients and 13 age- and sex-matched healthy adults (HA) randomly', 'patients with pulmonary arterial hypertension at rest and during orthostatic stress', 'early-stage pulmonary arterial hypertension (PAH']","['inhaled either 100% O 2 (peripheral chemoreceptors inhibition) or 21% O 2 (control session), while at rest and during a repeated sit-to-stand maneuver']","['cardiac baroreflex dysfunction', 'baroreflex integrity', 'baroreflex indexes and peak aerobic capacity', 'Hyperoxia increased cBRS and cBEI', 'lower cBEI ALL', 'Beat-by-beat analysis of R-R intervals and systolic blood pressure provided indexes of cardiac baroreflex sensitivity (cBRS) and effectiveness (cBEI', 'Cardiac baroreflex dysfunction']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C2973725', 'cui_str': 'Pulmonary arterial hypertension'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0030123', 'cui_str': '4-Aminohippuric Acid'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0008010', 'cui_str': 'Chemoreceptive Cells'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0560801', 'cui_str': 'Does stand from sitting'}]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0206162', 'cui_str': 'Baroreceptor reflex'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",19.0,0.0233785,Hyperoxia increased cBRS and cBEI similarly in both groups at rest and during the sit-to-stand maneuver.,"[{'ForeName': 'Marcelle', 'Initials': 'M', 'LastName': 'Paula-Ribeiro', 'Affiliation': 'Postgraduate Program in Translational Medicine, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}, {'ForeName': 'Indyanara C', 'Initials': 'IC', 'LastName': 'Ribeiro', 'Affiliation': 'Postgraduate Program in Pulmonary Medicine and Pulmonary Vascular Group, Division of Respiratory Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}, {'ForeName': 'Liliane C', 'Initials': 'LC', 'LastName': 'Aranda', 'Affiliation': 'Postgraduate Program in Pulmonary Medicine and Pulmonary Vascular Group, Division of Respiratory Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}, {'ForeName': 'Talita M', 'Initials': 'TM', 'LastName': 'Silva', 'Affiliation': 'Postgraduate Program in Pulmonary Medicine and Pulmonary Vascular Group, Division of Respiratory Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}, {'ForeName': 'Camila M', 'Initials': 'CM', 'LastName': 'Costa', 'Affiliation': 'Postgraduate Program in Pulmonary Medicine and Pulmonary Vascular Group, Division of Respiratory Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}, {'ForeName': 'Roberta P', 'Initials': 'RP', 'LastName': 'Ramos', 'Affiliation': 'Postgraduate Program in Pulmonary Medicine and Pulmonary Vascular Group, Division of Respiratory Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}, {'ForeName': 'Jaquelina', 'Initials': 'J', 'LastName': 'Ota-Arakaki', 'Affiliation': 'Postgraduate Program in Pulmonary Medicine and Pulmonary Vascular Group, Division of Respiratory Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}, {'ForeName': 'Sergio L', 'Initials': 'SL', 'LastName': 'Cravo', 'Affiliation': 'Department of Physiology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}, {'ForeName': 'Luiz E', 'Initials': 'LE', 'LastName': 'Nery', 'Affiliation': 'Postgraduate Program in Pulmonary Medicine and Pulmonary Vascular Group, Division of Respiratory Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Stickland', 'Affiliation': 'Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Bruno M', 'Initials': 'BM', 'LastName': 'Silva', 'Affiliation': 'Postgraduate Program in Translational Medicine, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00152.2021'] 1492,34225066,Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.,"BACKGROUND Despite endocrine therapy being the mainstay of treatment for hormone receptor positive (HR+)/HER2- metastatic breast cancer, patients at risk of visceral crisis or doubt for endocrine sensitivity are still offered first-line chemotherapy. Maintenance hormonal therapy is generally offered at the discontinuation of chemotherapy. The MAINtenance Afinitor study is a randomised, phase III trial comparing maintenance everolimus combined with aromatase inhibitors (AIs) versus AI monotherapy in patients with disease control after first-line chemotherapy. METHODS Patients with stable disease, partial response or complete response after first-line chemotherapy were randomised to everolimus plus AIs (exemestane or letrozole or anastrozole) or to AIs alone. Primary aim was progression-free survival (PFS). Secondary aims included response rate, safety and overall survival (OS). RESULTS In total, 110 patients were randomised to everolimus + AIs (n = 52) or to AIs (n = 58). Median PFS was 11.0 months (95% confidence interval [CI] 8.1-13.8) in the everolimus + AI arm and 7.2 months (95% CI 4.7-10.9) in the AI monotherapy arm (hazard ratio [HR] 0.71, 95% CI 0.47-1.06). Objective response rate was 22.4% in everolimus + AI arm and 19.2% in AI monotherapy arm. A higher proportion of disease progression as best response was reported in the AI monotherapy arm (28.8% versus 14.3%). Median OS was 35.7 months (95% CI 26.0-47.8) in the combination arm versus 33.5 (95% CI 26.4-42.7) in the AI alone arm (HR 1.0, 95% CI 0.61-1.62). CONCLUSIONS EVE + AIs did not significantly impact on the outcome of metastatic breast cancer patients deemed suitable for first-line chemotherapy. Also taking into account treatment tolerability, maintenance endocrine therapy remains the standard. TRIAL REGISTRATION EudraCT: 2013-004153-24.",2021,"Median OS was 35.7 months (95% CI 26.0-47.8) in the combination arm versus 33.5 (95% CI 26.4-42.7) in the AI alone arm (HR 1.0, 95% CI 0.61-1.62). ","['patients with disease control after first-line chemotherapy', 'metastatic breast cancer patients', '110\xa0patients', 'Patients with stable disease, partial response or complete response after first-line chemotherapy']","['endocrine therapy', 'Everolimus plus aromatase inhibitors', 'Maintenance hormonal therapy', 'everolimus plus AIs (exemestane or letrozole or anastrozole', 'maintenance everolimus combined with aromatase inhibitors (AIs) versus AI monotherapy']","['response rate, safety\xa0and overall survival (OS', 'disease progression', 'Median OS', 'Median PFS', 'Objective response rate', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}]","[{'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0039585', 'cui_str': 'Androgen resistance syndrome'}, {'cui': 'C0851344', 'cui_str': 'exemestane'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0290883', 'cui_str': 'anastrozole'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]",,0.279741,"Median OS was 35.7 months (95% CI 26.0-47.8) in the combination arm versus 33.5 (95% CI 26.4-42.7) in the AI alone arm (HR 1.0, 95% CI 0.61-1.62). ","[{'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Guarneri', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy. Electronic address: valentina.guarneri@unipd.it.'}, {'ForeName': 'Carlo Alberto', 'Initials': 'CA', 'LastName': 'Giorgi', 'Affiliation': 'Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.'}, {'ForeName': 'Saverio', 'Initials': 'S', 'LastName': 'Cinieri', 'Affiliation': 'Department of Oncology, Di Summa - Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Carmelo', 'Initials': 'C', 'LastName': 'Bengala', 'Affiliation': 'Medical Oncology, Ospedale Misericordia, Azienda Toscana Sud-Est, Grosseto, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Mariani', 'Affiliation': 'Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Bisagni', 'Affiliation': 'Department of Oncology and Advanced Technologies, Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Frassoldati', 'Affiliation': 'Clinical Oncology, Department of Morphology, Surgery and Experimental Medicine, S. Anna University Hospital, Ferrara, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Zamagni', 'Affiliation': 'Medical Oncology Unit, Addarii Institute of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.'}, {'ForeName': 'Costanza', 'Initials': 'C', 'LastName': 'De Rossi', 'Affiliation': ""Medical Oncology, Ospedale dell'Angelo, AULSS3 Serenissima, Mestre, Italy.""}, {'ForeName': 'Vito', 'Initials': 'V', 'LastName': 'Amoroso', 'Affiliation': 'Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Andreetta', 'Affiliation': 'Department of Oncology, ASUFC Udine University Hospital, Udine, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Ferro', 'Affiliation': 'Breast Center, Santa Chiara Hospital, Trento, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Zambelli', 'Affiliation': 'Unit of Oncology, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Gori', 'Affiliation': 'Medical Oncology, IRCCS Ospedale Sacro Cuore-Don Calabria, Negrar di Valpolicella, Italy.'}, {'ForeName': 'Ornella', 'Initials': 'O', 'LastName': 'Garrone', 'Affiliation': 'Breast Unit, Medical Oncology AO S. Croce and Carle Teaching Hospital, Cuneo, Italy.'}, {'ForeName': 'Maria Vittoria', 'Initials': 'MV', 'LastName': 'Dieci', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Orlando', 'Affiliation': 'Department of Oncology, Di Summa - Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Pastina', 'Affiliation': 'Medical Oncology, Ospedale Misericordia, Azienda Toscana Sud-Est, Grosseto, Italy.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Beninato', 'Affiliation': 'Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Moretti', 'Affiliation': 'Department of Oncology and Advanced Technologies, Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Genovesi', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.'}, {'ForeName': 'Margherita', 'Initials': 'M', 'LastName': 'Cinefra', 'Affiliation': 'Department of Oncology, Di Summa - Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Vicini', 'Affiliation': 'Department of Medical and Surgical Sciences for Children and Adults, Statistics Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Magni', 'Affiliation': 'Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.'}, {'ForeName': 'Gian L', 'Initials': 'GL', 'LastName': 'De Salvo', 'Affiliation': 'Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.'}, {'ForeName': 'PierFranco', 'Initials': 'P', 'LastName': 'Conte', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.05.008'] 1493,34187756,"Transcutaneous auricular vagus nerve stimulation influences gastric motility: A randomized, double-blind trial in healthy individuals.","BACKGROUND Transcutaneous auricular vagus nerve stimulation (taVNS) has been investigated regarding its therapeutic properties in several several conditions such as epilepsy, migraine and major depressive disorder and was shown to access similar neural pathways as invasive vagus nerve stimulation. While the vagus nerve's role in gut motility is physiologically established, the effect of taVNS has scarcely been investigated in humans and yielded conflicting results. Real-time gastric magnetic resonance imaging (rtMRI) is an established reproducible method to investigate gastric motility non-invasively. OBJECTIVE To investigate the influence of taVNS on gastric motility of healthy participants using rtMRI. METHODS We conducted a randomized, double-blind study using high-frequency (HF) stimulation at 25Hz or low-frequency (LF) taVNS at 1Hz after ingestions of a standardized meal in 57 healthy participants. The gastric motility index (GMI) was determined by measuring the amplitude and velocity of the peristaltic waves using rtMRI. RESULTS After HF taVNS, GMI was significantly higher than after LF stimulation (p = 0.005), which was mainly attributable to a higher amplitude of the peristaltic waves (p = 0.003). CONCLUSION We provide evidence that 4-h of taVNS influences gastric motility in healthy human participants for the first time using rtMRI. HF stimulation is associated with higher amplitudes of peristaltic waves in the gastric antrum compared to LF stimulation. Further studies are needed to investigate the effect of different frequencies of taVNS and its therapeutic properties in conditions with impaired gastric motility.",2021,"After HF taVNS, GMI was significantly higher than after LF stimulation (p = 0.005), which was mainly attributable to a higher amplitude of the peristaltic waves (p = 0.003). ","['influences gastric motility', 'healthy participants using rtMRI', '57 healthy participants', 'healthy human participants', 'healthy individuals']","['Transcutaneous auricular vagus nerve stimulation (taVNS', 'Real-time gastric magnetic resonance imaging (rtMRI', 'taVNS', 'Transcutaneous auricular vagus nerve stimulation', 'high-frequency (HF) stimulation at 25Hz or low-frequency (LF) taVNS at 1Hz after ingestions of a standardized meal']","['gastric motility index (GMI', 'gastric motility']","[{'cui': 'C0232572', 'cui_str': 'Gastric motility'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C1522191', 'cui_str': 'Otic route'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0232572', 'cui_str': 'Gastric motility'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",57.0,0.104071,"After HF taVNS, GMI was significantly higher than after LF stimulation (p = 0.005), which was mainly attributable to a higher amplitude of the peristaltic waves (p = 0.003). ","[{'ForeName': 'Kenan', 'Initials': 'K', 'LastName': 'Steidel', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Krause', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany; Center for Mind, Brain and Behavior, CMBB, Philipps-University Marburg, Marburg, Germany; Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Menzler', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany; Center for Mind, Brain and Behavior, CMBB, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Strzelczyk', 'Affiliation': 'Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University Frankfurt, Frankfurt am Main, Germany; Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Germany; Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Ilka', 'Initials': 'I', 'LastName': 'Immisch', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Fuest', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Gorny', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Mross', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Hakel', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Schmidt', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Timmermann', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany; Center for Mind, Brain and Behavior, CMBB, Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Rosenow', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany; Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University Frankfurt, Frankfurt am Main, Germany; Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Bauer', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany; Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University Frankfurt, Frankfurt am Main, Germany; Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Knake', 'Affiliation': 'Epilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg, Germany; Center for Mind, Brain and Behavior, CMBB, Philipps-University Marburg, Marburg, Germany; Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Germany. Electronic address: knake@med.uni-marburg.de.'}]",Brain stimulation,['10.1016/j.brs.2021.06.006'] 1494,34187716,Effect of foot-ankle flexibility and resistance exercise in the secondary prevention of plantar foot diabetic ulcer.,"AIMS The study aimed to evaluate the effects of foot-ankle flexibility and resistance exercises on the recurrence rate of plantar foot diabetic ulcers, HbA1c levels, diabetic neuropathy examination (DNE) scores, ankle brachial index (ABI), and walking speed within 12 and 24weeks. METHODS We conducted a double-blind randomized clinical trial. Fifty patients with recently healed plantar foot diabetic ulcers were randomized to an intervention group that performed foot-ankle flexibility and resistance exercise three times a week in their home (n=25) or a control group (n=25). Both groups were given foot care education. Outcomes were assessed at plantar foot diabetic ulcer recurrence or at 12 and 24weeks whichever came first. Outcome measures included plantar foot diabetic ulcer recurrence, changes of HbA1c levels, DNE scores, ankle brachial index ABI, and walking speed. RESULTS There were significant difference between groups in ulcer recurrence at either 12weeks (intervention 8%, control 68%, RR 0.288; 95% CI 0.156-0.534, P=0.000) within 12weeks. or 24weeks (intervention 16%, control 72%, RR 0.222; 95% CI 0.088-0.564, P=0.000).). There were significant differences in the DNE score delta (P=0.000) and walking speed delta (P=0.000), but there were no significant differences in the HbA1c delta and ABI delta between groups at either 12 or 24weeks. CONCLUSIONS Foot-ankle flexibility and resistance exercises can reduce the recurrence of plantar foot diabetic ulcer incidence and improve diabetic neuropathy and walking speed. Clinical trial number: NCT04624516.",2021,"There were significant differences in the DNE score delta (P=0.000) and walking speed delta (P=0.000), but there were no significant differences in the HbA1c delta and ABI delta between groups at either 12 or 24weeks. ","['plantar foot diabetic ulcer', 'Fifty patients with recently healed plantar foot diabetic ulcers']","['foot-ankle flexibility and resistance exercise', 'foot-ankle flexibility and resistance exercises', 'Foot-ankle flexibility and resistance exercises', 'intervention group that performed foot-ankle flexibility and resistance exercise three times a week in their home (n=25) or a control group']","['ulcer recurrence', 'diabetic neuropathy and walking speed', 'walking speed delta', 'plantar foot diabetic ulcer recurrence', 'DNE score delta', 'HbA1c delta and ABI delta', 'plantar foot diabetic ulcer recurrence, changes of HbA1c levels, DNE scores, ankle brachial index ABI, and walking speed', 'recurrence rate of plantar foot diabetic ulcers, HbA1c levels, diabetic neuropathy examination (DNE) scores, ankle brachial index (ABI), and walking speed within 12 and 24weeks']","[{'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0743150', 'cui_str': 'Diabetic ulcer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0556987', 'cui_str': 'Three times weekly'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0011882', 'cui_str': 'Diabetic neuropathy'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0743150', 'cui_str': 'Diabetic ulcer'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C1328319', 'cui_str': 'Ankle brachial pressure index'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",50.0,0.0378233,"There were significant differences in the DNE score delta (P=0.000) and walking speed delta (P=0.000), but there were no significant differences in the HbA1c delta and ABI delta between groups at either 12 or 24weeks. ","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Suryani', 'Affiliation': 'Nursing Study Program, St. Elisabeth School Health Science (STIKES St.Elisabeth), Semarang, Indonesia; Medicine Faculty, Diponegoro University, Semarang, Indonesia. Electronic address: mariahandoko22@gmail.com.'}, {'ForeName': 'Widiastuti', 'Initials': 'W', 'LastName': 'Samekto', 'Affiliation': 'Medicine Faculty, Diponegoro University, Semarang, Indonesia; St. Elisabeth Hospital, Semarang, Indonesia.'}, {'ForeName': '', 'Initials': '', 'LastName': 'Heri-Nugroho', 'Affiliation': 'Medicine Faculty, Diponegoro University, Semarang, Indonesia; St. Elisabeth Hospital, Semarang, Indonesia; Kariadi Hospital, Semarang, Indonesia.'}, {'ForeName': 'Hardhono', 'Initials': 'H', 'LastName': 'Susanto', 'Affiliation': 'Medicine Faculty, Diponegoro University, Semarang, Indonesia.'}, {'ForeName': 'Luky', 'Initials': 'L', 'LastName': 'Dwiantoro', 'Affiliation': 'Medicine Faculty, Diponegoro University, Semarang, Indonesia.'}]",Journal of diabetes and its complications,['10.1016/j.jdiacomp.2021.107968'] 1495,34194225,"Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.","Introduction Concerns have been raised about the practical use and clinical benefits of medications and inhalers in older patients with chronic obstructive pulmonary disease (COPD). Here, we report analyses according to age from five clinical trials evaluating medications administered using the ELLIPTA dry-powder inhaler (DPI). Methods Efficacy and safety according to age groups (<65 and ≥65 years) were assessed using data from five clinical trials in patients ≥40 years of age with symptomatic COPD. There was a mix of pre-specified and post hoc analyses of two 24-week trials with fluticasone furoate (FF)/vilanterol (VI) 100/25 µg; one 24-week trial with umeclidinium (UMEC) 62.5 µg; and two 12-week trials with UMEC 62.5 µg + FF/VI 100/25 µg. The primary endpoint was trough forced expiratory volume in 1 second (FEV 1 ) obtained 23 and 24 hours after dosing on the last day of the study. Results A total of 2876 patients <65 years of age and 2148 patients ≥65 years of age were enrolled across all studies of whom 1333 and 1111 patients, respectively, received treatment at the doses presented. Statistically significant and clinically meaningful treatment differences in improvement from baseline in mean trough FEV 1 were reported for active comparators versus placebo at study end for both <65 and ≥65 years subgroups (FF/VI vs placebo: 143 mL and 111 mL; UMEC vs placebo: 110 mL and 123 mL; UMEC + FF/VI vs placebo + FF/VI: 136 mL and 105 mL; p<0.001 for all comparisons). The incidence of adverse events reported for active treatments was similar between age groups. Conclusion These data provide evidence to support the use of FF/VI, UMEC, or UMEC + FF/VI, all delivered via the ELLIPTA DPI, to treat older (≥65 years) and younger (<65 years) patients with COPD.",2021,Statistically significant and clinically meaningful treatment differences in improvement from baseline in mean trough FEV 1 were reported for active comparators versus placebo at study end for both <65 and ≥65 years subgroups (FF/VI vs placebo: 143 mL and 111 mL; UMEC vs placebo: 110 mL and 123 mL; UMEC + FF/VI vs placebo + FF/VI: 136 mL and 105 mL; p<0.001 for all comparisons).,"['Patients with Chronic Obstructive Pulmonary Disease', 'older patients with chronic obstructive pulmonary disease (COPD', 'older (≥65 years) and younger (<65 years) patients with COPD', '2876 patients <65 years of age and 2148 patients ≥65 years of age were enrolled across all studies of whom 1333 and 1111 patients, respectively, received treatment at the doses presented', 'age groups (<65 and ≥65 years) were assessed using data from five clinical trials in patients ≥40 years of age with symptomatic COPD']","['Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI', 'umeclidinium (UMEC', 'UMEC 62.5 µg + FF/VI 100/25 µg', 'placebo', 'ELLIPTA dry-powder inhaler (DPI', 'fluticasone furoate (FF)/vilanterol']","['trough forced expiratory volume', 'incidence of adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}]","[{'cui': 'C1948374', 'cui_str': 'fluticasone furoate'}, {'cui': 'C2935023', 'cui_str': 'vilanterol'}, {'cui': 'C3661274', 'cui_str': 'umeclidinium'}, {'cui': 'C4517836', 'cui_str': '62.5'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1967611', 'cui_str': 'Dry powder inhaler'}, {'cui': 'C0082607', 'cui_str': 'fluticasone'}]","[{'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",2876.0,0.849853,Statistically significant and clinically meaningful treatment differences in improvement from baseline in mean trough FEV 1 were reported for active comparators versus placebo at study end for both <65 and ≥65 years subgroups (FF/VI vs placebo: 143 mL and 111 mL; UMEC vs placebo: 110 mL and 123 mL; UMEC + FF/VI vs placebo + FF/VI: 136 mL and 105 mL; p<0.001 for all comparisons).,"[{'ForeName': 'Nicola A', 'Initials': 'NA', 'LastName': 'Hanania', 'Affiliation': 'Airways Clinical Research Center, Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Caveney', 'Affiliation': 'US Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USA.'}, {'ForeName': 'Tedi', 'Initials': 'T', 'LastName': 'Soule', 'Affiliation': 'US Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USA.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Tombs', 'Affiliation': 'Precise Approach Ltd, Contingent Worker on Assignment at GlaxoSmithKline, Brentford, Middlesex, UK.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Lettis', 'Affiliation': 'Statistics, GlaxoSmithKline, Brentford, Middlesex, UK.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Crim', 'Affiliation': 'R&D, GlaxoSmithKline, Research Triangle Park, NC, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Mannino', 'Affiliation': 'Department of Preventive Medicine and Environmental Health, University of Kentucky, College of Public Health, Lexington, KY, USA.'}, {'ForeName': 'Hitesh', 'Initials': 'H', 'LastName': 'Patel', 'Affiliation': 'US Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USA.'}, {'ForeName': 'Isabelle H', 'Initials': 'IH', 'LastName': 'Boucot', 'Affiliation': 'Statistics, GlaxoSmithKline, Brentford, Middlesex, UK.'}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S302864'] 1496,34198135,The influence of perceived stress and self-control on efficacy of repeated transcranial direct current stimulation in non-treatment-seeking smokers.,"INTRODUCTION Transcranial direct current stimulation (tDCS) has recently been raising interest in its therapeutic impact on tobacco use disorder. This study investigates the effects of repeated frontal tDCS (anode: F3, cathode: F4) on cigarette consumption, craving and executive functions. MATERIAL AND METHODS In a randomized sham-controlled trial, 24 individuals received active (2.0 mA) and 20 individuals received sham stimulation (0.3 mA) for 20 min on five consecutive days. The participants indicated their tobacco cravings, answered questionnaires and completed neuropsychological tasks at various time points throughout the study. Carbon monoxide (CO) levels and the daily numbers of consumed cigarettes were recorded. RESULTS Both intervention groups experienced a significant decrease in the daily number of smoked cigarettes, CO levels, and craving after the stimulation, however, there were no improvements in executive functions. These results did not differ significantly between both intervention groups. Additionally, in the active group, a higher level of perceived stress and a lower level of self-control were linked to a lower cigarette consumption, respectively a higher reduction of the level of CO. CONCLUSION This study does not support the hypotheses that tDCS reduces cigarette consumption, attenuates substance craving, or improves executive functions beyond the placebo effect. Our subgroup analysis suggests that high levels of perceived stress and low self-control may be predictors for a successful reduction in cigarette consumption. Furthermore, the placebo effect might be rather high for light smokers, whereas heavy smokers seem to benefit more from the specific effects of tDCS. CLINICAL TRIAL REGISTRATION NUMBER NCT03691805.",2021,"This study does not support the hypotheses that tDCS reduces cigarette consumption, attenuates substance craving, or improves executive functions beyond the placebo effect.","['non-treatment-seeking smokers', '24 individuals received active (2.0 mA) and 20 individuals received']","['transcranial direct current stimulation', 'Transcranial direct current stimulation (tDCS', 'sham stimulation', 'repeated frontal tDCS (anode: F3, cathode: F4', 'placebo']","['daily number of smoked cigarettes, CO levels, and craving', 'cigarette consumption, craving and executive functions', 'higher level of perceived stress and a lower level of self-control', 'cigarette consumption, attenuates substance craving', 'Carbon monoxide (CO) levels and the daily numbers of consumed cigarettes', 'tobacco cravings, answered questionnaires and completed neuropsychological tasks', 'executive functions']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0003103', 'cui_str': 'Anode'}, {'cui': 'C0007441', 'cui_str': 'Cathode'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0459840', 'cui_str': 'Cigarette consumption'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",24.0,0.104419,"This study does not support the hypotheses that tDCS reduces cigarette consumption, attenuates substance craving, or improves executive functions beyond the placebo effect.","[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Müller', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Yury', 'Initials': 'Y', 'LastName': 'Shevchenko', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany; Research Methods, Assessment, and iScience, University of Konstanz, Universitätsstraße 10, D-78464, Konstanz, Germany.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Gerhardt', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Falk', 'Initials': 'F', 'LastName': 'Kiefer', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany; Mannheim Center for Translational Neurosciences (MCTN), Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany; Feuerlein Center on Translational Addiction Medicine, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Vollstädt-Klein', 'Affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany; Mannheim Center for Translational Neurosciences (MCTN), Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany. Electronic address: s.vollstaedt-klein@zi-mannheim.de.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2021.108861'] 1497,34214661,Inhaled nasopharyngeal nitric oxide concentrations during unilateral nostril breathing - A pilot study.,"The yogic pranayama technique of unilateral nostril breathing (UNB) has previously demonstrated improvements in language and anxiety in stroke sufferers, as well as reduced blood pressure and increased heart rate in normal healthy adults. The nose typically passes different amounts of air through each nostril with the greater amount of air passing through the 'patent' side, and a lesser amount through the 'congested' side. Each side of the nose periodically takes turns at carrying the dominant tidal air flow in what is termed the' nasal cycle'. The nasal sinuses are a rich source of inhaled nitric oxide, a colourless and odourless gas that acts as a bronchodilator, vasodilator, and neurotransmitter. Nasal derived nitric oxide (NO) may contribute to the benefits attributed to UNB. This investigation seeks to assess the influence the nasal cycle has on inhaled nasopharyngeal NO concentrations during UNB by comparing unobstructed bilateral nostril breathing to patent-side and congested-side UNB in healthy individuals demonstrating a nasal cycle. After determining the patent and congested nasal sides in healthy adult volunteers, and sampling air at both nostrils, nasopharyngeal inhaled NO concentrations were then assessed during normal nasal at-rest tidal breathing during three different nasal breathing states: first both nostrils, then allocated in randomised order, patent side only, and congested side with only UNB. Nasopharyngeal NO concentrations were found to be consistently higher on both exhalation and inhalation during congested side UNB, when compared with either unilateral patent side UNB or breathing through both nostrils.",2021,"NO concentrations were found to be consistently higher on both exhalation and inhalation during congested side UNB, when compared with either unilateral patent side UNB or breathing through both nostrils.","['healthy individuals demonstrating a nasal cycle', 'normal healthy adults', 'healthy adult volunteers']","['Nasopharyngeal', 'unilateral nostril breathing (UNB']","['Inhaled nasopharyngeal nitric oxide concentrations', 'blood pressure and increased heart rate']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0027442', 'cui_str': 'Nasopharyngeal'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0595944', 'cui_str': 'Both anterior nares'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0027442', 'cui_str': 'Nasopharyngeal'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}]",,0.0245434,"NO concentrations were found to be consistently higher on both exhalation and inhalation during congested side UNB, when compared with either unilateral patent side UNB or breathing through both nostrils.","[{'ForeName': 'Tim H A', 'Initials': 'THA', 'LastName': 'Stassen', 'Affiliation': 'Zuyd University of Applied Sciences, Maastricht, the Netherlands.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Bartley', 'Affiliation': 'BioDesign Lab, School of Engineering, Computer and Mathematical Sciences, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'White', 'Affiliation': 'BioDesign Lab, School of Engineering, Computer and Mathematical Sciences, Auckland University of Technology, Auckland, New Zealand. Electronic address: david.white@aut.ac.nz.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2021.103734'] 1498,34214639,Wow! They really like celeriac! Kindergarten teachers' experiences of an intervention to increase 1-year-olds' acceptance of vegetables.,"Exposure to varied foods in early life is important for short- and long-term health and development. Strategically introducing toddlers to new vegetables is not a common practice in Norwegian kindergartens. Therefore, we developed, conducted, and evaluated a web-based cluster randomised kindergarten intervention, Pre-schoolers' Food Courage 2.0. The purpose of the current qualitative study was to explore kindergarten teachers' experience of implementing this intervention and what they thought facilitated the positive impact of the intervention reported in the quantitative evaluation. Ten individual telephonic interviews with kindergarten teachers who took part in the intervention study were conducted using a semi-structured interview guide. Data were transcribed verbatim and subjected to thematic analysis. Five main themes were identified: 1) One-year-olds love food and renewal of the menus was inspiring; 2) One-year-olds are surprisingly willing to try and accept novel foods; 3) Novel food at meals stimulate social interaction; and 4) The Sapere method is a fun and explorative activity for 1-year-olds. These four themes were the features perceived as the effective elements of the intervention by the kindergarten teachers. The fifth main theme was: 5) Sustained impact on kindergarten teachers' practices and beliefs. The kindergarten teachers found the intervention easy to implement, and they were surprised by the foods 1-year-olds like and how the intervention increased their food acceptance. This age window of opportunity seems to be underused in kindergartens. By using the strategies described in the intervention, kindergarten staff effectively took advantage of this opportunity and consequently, child and kindergarten staff behaviour in relation to food was enhanced. Interventions targeting healthy feeding practices may potentially have a long-term public health impact by increasing food variety and vegetable intake in toddlers. TRIAL REGISTRATION: ISRCTN98064772.",2021,Interventions targeting healthy feeding practices may potentially have a long-term public health impact by increasing food variety and vegetable intake in toddlers.,"['toddlers', 'Ten individual telephonic interviews with kindergarten teachers who took part in the intervention study were conducted using a semi-structured interview guide']",[],"[""kindergarten teachers' practices and beliefs"", ""1-year-olds' acceptance of vegetables""]","[{'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0335008', 'cui_str': 'Pre-primary education teacher'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]",[],"[{'cui': 'C0335008', 'cui_str': 'Pre-primary education teacher'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}]",,0.0184781,Interventions targeting healthy feeding practices may potentially have a long-term public health impact by increasing food variety and vegetable intake in toddlers.,"[{'ForeName': 'Sissel H', 'Initials': 'SH', 'LastName': 'Helland', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sport Sciences, University of Agder, Norway. Electronic address: sissel.h.helland@uia.no.'}, {'ForeName': 'Nina C', 'Initials': 'NC', 'LastName': 'Øverby', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sport Sciences, University of Agder, Norway. Electronic address: nina.c.overby@uia.no.'}, {'ForeName': 'Eli Anne', 'Initials': 'EA', 'LastName': 'Myrvoll Blomkvist', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sport Sciences, University of Agder, Norway. Electronic address: eli.ablomkvist@uia.no.'}, {'ForeName': 'Elisabet R', 'Initials': 'ER', 'LastName': 'Hillesund', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sport Sciences, University of Agder, Norway. Electronic address: elisabet.r.hillesund@uia.no.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Strömmer', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, UK. Electronic address: ss3@mrc.soton.ac.uk.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Barker', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sport Sciences, University of Agder, Norway; MRC Lifecourse Epidemiology Unit, University of Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust, UK. Electronic address: meb@mrc.soton.ac.uk.'}, {'ForeName': 'Tormod', 'Initials': 'T', 'LastName': 'Bjørkkjær', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sport Sciences, University of Agder, Norway. Electronic address: tormod.bjorkkjar@uia.no.'}]",Appetite,['10.1016/j.appet.2021.105581'] 1499,34214614,Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial.,"BACKGROUND AND PURPOSE The phase III FLAME trial (NCT01168479) showed an increase in five-year biochemical disease-free survival, with no significant increase in toxicity when adding a focal boost to external beam radiotherapy (EBRT) for localized prostate cancer [Kerkmeijer et al. JCO 2021]. The aim of this study was to investigate the association between delivered radiation dose to the anorectum and gastrointestinal (GI) toxicity (grade ≥2). MATERIAL AND METHODS All patients in the FLAME trial were analyzed, irrespective of treatment arm. The dose-effect relation of the anorectal dose parameters (D2cm 3 and D50%) and GI toxicity grade ≥2 in four years of follow-up was assessed using a mixed model analysis for repeated measurements, adjusted for age, cardiovascular disease, diabetes mellitus, T-stage, baseline toxicity grade ≥1, hormonal therapy and institute. RESULTS A dose-effect relation for D2cm 3 and D50% was observed with adjusted odds ratios of 1.17 (95% CI 1.13-1.21, p < 0.0001) and 1.20 (95% CI 1.14-1.25, p < 0.0001) for GI toxicity, respectively. CONCLUSION Although there was no difference in toxicity between study arms, a higher radiation dose to the anorectum was associated with a statistically significant increase in GI toxicity following EBRT for prostate cancer. This dose-effect relation was present for both large and small anorectal volumes. Therefore, further increase in dose to the anorectum should be weighed against the benefit of focal dose escalation for prostate cancer.",2021,"Although there was no difference in toxicity between study arms, a higher radiation dose to the anorectum was associated with a statistically significant increase in GI toxicity following EBRT for prostate cancer.","['localized prostate cancer', 'All patients in the FLAME trial']","['external beam radiotherapy (EBRT', 'external beam radiotherapy']","['five-year biochemical disease-free survival', 'GI toxicity', 'toxicity', 'GI toxicity grade ≥2', 'anorectum and gastrointestinal (GI) toxicity (grade ≥2']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0419095', 'cui_str': 'Teleradiotherapy procedure'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C1142499', 'cui_str': 'Gastrointestinal toxicity'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0441800', 'cui_str': 'Grade'}]",,0.132476,"Although there was no difference in toxicity between study arms, a higher radiation dose to the anorectum was associated with a statistically significant increase in GI toxicity following EBRT for prostate cancer.","[{'ForeName': 'Veerle H', 'Initials': 'VH', 'LastName': 'Groen', 'Affiliation': 'University Medical Center Utrecht, Radiation Oncology, The Netherlands.'}, {'ForeName': 'Nicolaas P A', 'Initials': 'NPA', 'LastName': 'Zuithoff', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, The Netherlands.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'van Schie', 'Affiliation': 'The Netherlands Cancer Institute, Radiation Oncology, Amsterdam, The Netherlands.'}, {'ForeName': 'Evelyn M', 'Initials': 'EM', 'LastName': 'Monninkhof', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, The Netherlands.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Kunze-Busch', 'Affiliation': 'Radboud University Medical Centre, Radiation Oncology, Nijmegen, The Netherlands.'}, {'ForeName': 'Hans C J', 'Initials': 'HCJ', 'LastName': 'de Boer', 'Affiliation': 'University Medical Center Utrecht, Radiation Oncology, The Netherlands.'}, {'ForeName': 'Jochem', 'Initials': 'J', 'LastName': 'van der Voort van Zyp', 'Affiliation': 'University Medical Center Utrecht, Radiation Oncology, The Netherlands.'}, {'ForeName': 'Floris J', 'Initials': 'FJ', 'LastName': 'Pos', 'Affiliation': 'The Netherlands Cancer Institute, Radiation Oncology, Amsterdam, The Netherlands.'}, {'ForeName': 'Robert Jan', 'Initials': 'RJ', 'LastName': 'Smeenk', 'Affiliation': 'Radboud University Medical Centre, Radiation Oncology, Nijmegen, The Netherlands.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Haustermans', 'Affiliation': 'University Hospitals Leuven, Radiation Oncology, Belgium.'}, {'ForeName': 'Sofie', 'Initials': 'S', 'LastName': 'Isebaert', 'Affiliation': 'University Hospitals Leuven, Radiation Oncology, Belgium.'}, {'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Draulans', 'Affiliation': 'University Hospitals Leuven, Radiation Oncology, Belgium.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Depuydt', 'Affiliation': 'University Hospitals Leuven, Radiation Oncology, Belgium.'}, {'ForeName': 'Helena M', 'Initials': 'HM', 'LastName': 'Verkooijen', 'Affiliation': 'University Medical Center, Imaging Division, Utrecht, The Netherlands.'}, {'ForeName': 'Uulke A', 'Initials': 'UA', 'LastName': 'van der Heide', 'Affiliation': 'The Netherlands Cancer Institute, Radiation Oncology, Amsterdam, The Netherlands.'}, {'ForeName': 'Linda G W', 'Initials': 'LGW', 'LastName': 'Kerkmeijer', 'Affiliation': 'University Medical Center Utrecht, Radiation Oncology, The Netherlands; Radboud University Medical Centre, Radiation Oncology, Nijmegen, The Netherlands. Electronic address: linda.kerkmeijer@radboudumc.nl.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2021.06.033'] 1500,34217036,Promoviendo una Alimentación Saludable (PAS) results: Engaging Latino families in eating disorder treatment.,"Latinos/as are underrepresented in eating disorders clinical trials. This study compared results of a culturally adapted individual cognitive-behavioral treatment (CBT) for binge-spectrum eating disorders that included or excluded a family enhanced module (CBT + FE), in a proof-of-principle pilot study with a sample of Latina adults and one family member per patient. Twenty-five patients (M age  = 37 yrs) and 25 family members (M age  = 40 yrs) were randomized to CBT (n = 13) or CBT+ FE (n = 12). DSM-IV eating disorder diagnoses were: 48% (n = 12) bulimia nervosa, 28% (n = 7) binge-eating disorder, and 24% (n = 6) eating disorder not otherwise specified. Effect sizes favored CBT + FE on adherence and retention, and scores on treatment satisfaction and therapeutic alliance were high, indicating treatment acceptability. In spite of the hypothesis that family outcomes such as support, familism, cohesion, pride, family cultural conflict, burden, and marital satisfaction (in couples) would be superior in CBT + FE, the preliminary data were inconclusive and results were mixed. The hypothesis that eating disorder outcomes including global eating psychopathology, binge eating, and purging would improve in CBT + FE was not supported. There was some evidence that patients in CBT improved more particularly on binge eating, otherwise the groups had no differences. In conclusion, the results suggest that CBT + FE could enhance treatment adherence and retention, although this did not automatically translate to better family and symptom outcomes.",2021,"There was some evidence that patients in CBT improved more particularly on binge eating, otherwise the groups had no differences.","['DSM-IV eating disorder diagnoses were: 48% (n\xa0=\xa012) bulimia nervosa, 28% (n\xa0=\xa07) binge-eating disorder, and 24% (n\xa0=\xa06) eating disorder not otherwise specified', '37\xa0yrs) and 25 family members (M age \xa0=\xa040\xa0yrs', 'binge-spectrum eating disorders that included or excluded a family enhanced module (CBT\xa0+\xa0FE), in a proof-of-principle pilot study with a sample of Latina adults and one family member per patient', 'Latino families in eating disorder treatment', 'Twenty-five patients (M age \xa0']","['CBT', 'Promoviendo una Alimentación Saludable (PAS', 'CBT+ FE', 'CBT\xa0+\xa0FE', 'culturally adapted individual cognitive-behavioral treatment (CBT']","['binge eating', 'global eating psychopathology, binge eating', 'support, familism, cohesion, pride, family cultural conflict, burden, and marital satisfaction', 'adherence and retention, and scores on treatment satisfaction and therapeutic alliance']","[{'cui': 'C0220952', 'cui_str': 'DSM-IV'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C2267227', 'cui_str': 'Bulimia nervosa'}, {'cui': 'C0596170', 'cui_str': 'Binge eating disorder'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0556981', 'cui_str': '% proof'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3715062', 'cui_str': '25'}]","[{'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0030125', 'cui_str': 'aminosalicylic acid'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0006370', 'cui_str': 'Binge Eating'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0814487', 'cui_str': 'Therapeutic Alliance'}]",,0.0701988,"There was some evidence that patients in CBT improved more particularly on binge eating, otherwise the groups had no differences.","[{'ForeName': 'Mae Lynn', 'Initials': 'ML', 'LastName': 'Reyes-Rodríguez', 'Affiliation': 'Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States of America. Electronic address: maelynn_reyes@med.unc.edu.'}, {'ForeName': 'Hunna J', 'Initials': 'HJ', 'LastName': 'Watson', 'Affiliation': 'Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States of America; Division of Paediatrics, The University of Western Australia, Perth, Australia; School of Psychology, Curtin University, Perth, Australia.'}, {'ForeName': 'Tosha Woods', 'Initials': 'TW', 'LastName': 'Smith', 'Affiliation': 'Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Donald H', 'Initials': 'DH', 'LastName': 'Baucom', 'Affiliation': 'Department of Psychology, University of North Carolina, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Cynthia M', 'Initials': 'CM', 'LastName': 'Bulik', 'Affiliation': 'Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States of America; Department of Nutrition, University of North Carolina, Chapel Hill, NC, United States of America; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}]",Eating behaviors,['10.1016/j.eatbeh.2021.101534'] 1501,34217031,Stability recovery performance in adults over a wide age range: A multicentre reliability analysis using different lean-and-release test protocols.,"The ability to effectively increase the base of support is crucial to prevent from falling due to stability disturbances and has been commonly assessed using the forward-directed lean-and-release test. With this multicentre study we examined whether the assessment of stability recovery performance using two different forward lean-and-release test protocols is reliable in adults over a wide age range. Ninety-seven healthy adults (age from 21 to 80 years) were randomly assigned to one out of two lean angle protocols: gradual increase to maximal forward-lean angle (maximal lean angle; n = 43; seven participants were excluded due to marker artefacts) or predefined lean angle (single lean angle; n = 26; 21 participants needed to be excluded due to multiple stepping after release or marker artefacts). Both protocols were repeated after 0.5 h and 48 h to investigate intra- and inter-session reliability. Stability recovery performance was examined using the margin of stability at release (MoS RL ) and touchdown (MoS TD ) and increase in base of support (BoS TD ). Intraclass correlation coefficients (confidence intervals at 95%) for the maximal lean angle and for the single lean angle were respectively 0.93 (0.89-0.96) and 0.94 (0.89-0.97) in MoS RL , 0.85 (0.77-0.91) and 0.67 (0.48-0.82) in MoS TD and 0.88 (0.81-0.93) and 0.80 (0.66-0.90) in BoS TD , with equivalence being revealed for each parameter between all three measurements (p < 0.01). We concluded that the assessment of stability recovery performance parameters in adults over a wide age range with the means of the forward lean-and-release test is reliable, independent of the used lean angle protocol.",2021,"Intraclass correlation coefficients (confidence intervals at 95%) for the maximal lean angle and for the single lean angle were respectively 0.93 (0.89-0.96) and 0.94 (0.89-0.97) in MoS RL , 0.85 (0.77-0.91) and 0.67 (0.48-0.82) in MoS TD and 0.88 (0.81-0.93) and 0.80 (0.66-0.90) in BoS TD , with equivalence being revealed for each parameter between all three measurements (p < 0.01).","['maximal lean angle; n\xa0=\xa043; seven participants were excluded due to marker artefacts) or predefined lean angle (single lean angle; n\xa0=\xa026; 21 participants needed to be excluded due to multiple stepping after release or marker artefacts', 'adults over a wide age range', 'Ninety-seven healthy adults (age from 21 to 80\xa0years']",['lean angle protocols: gradual increase to maximal forward-lean angle'],"['margin of stability at release (MoS RL ) and touchdown (MoS TD ) and increase in base of support (BoS TD ', 'Stability recovery performance']","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0085089', 'cui_str': 'Artifact'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439073', 'cui_str': '97'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439833', 'cui_str': 'Gradual'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439780', 'cui_str': 'Forward'}]","[{'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0026574', 'cui_str': 'mos Oncogenes'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0265514', 'cui_str': 'Dermatofibrosis lenticularis disseminata'}]",97.0,0.0834464,"Intraclass correlation coefficients (confidence intervals at 95%) for the maximal lean angle and for the single lean angle were respectively 0.93 (0.89-0.96) and 0.94 (0.89-0.97) in MoS RL , 0.85 (0.77-0.91) and 0.67 (0.48-0.82) in MoS TD and 0.88 (0.81-0.93) and 0.80 (0.66-0.90) in BoS TD , with equivalence being revealed for each parameter between all three measurements (p < 0.01).","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Werth', 'Affiliation': 'Sport and Exercise Science Research Centre, School of Applied Sciences, London South Bank University, London, United Kingdom. Electronic address: werthj2@lsbu.ac.uk.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bohm', 'Affiliation': 'Department of Training and Movement Sciences, Humboldt-Universität zu Berlin, Berlin, Germany; Berlin School of Movement Science, Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Klenk', 'Affiliation': 'Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Baden-Wurttemberg, Germany; Department of Clinical Gerontology, Robert-Bosch-Hospital, Stuttgart, Germany; IB University for Applied Health and Social Sciences, Study Centre Stuttgart, Stuttgart, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'König', 'Affiliation': 'Sport and Exercise Science Research Centre, School of Applied Sciences, London South Bank University, London, United Kingdom.'}, {'ForeName': 'K S', 'Initials': 'KS', 'LastName': 'Sczuka', 'Affiliation': 'Department of Clinical Gerontology, Robert-Bosch-Hospital, Stuttgart, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Schroll', 'Affiliation': 'Department of Training and Movement Sciences, Humboldt-Universität zu Berlin, Berlin, Germany; Berlin School of Movement Science, Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Epro', 'Affiliation': 'Sport and Exercise Science Research Centre, School of Applied Sciences, London South Bank University, London, United Kingdom.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mandla-Liebsch', 'Affiliation': 'Department of Training and Movement Sciences, Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Rapp', 'Affiliation': 'Department of Clinical Gerontology, Robert-Bosch-Hospital, Stuttgart, Germany.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Potthast', 'Affiliation': 'Institute of Biomechanics and Orthopaedics, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Arampatzis', 'Affiliation': 'Department of Training and Movement Sciences, Humboldt-Universität zu Berlin, Berlin, Germany; Berlin School of Movement Science, Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Karamanidis', 'Affiliation': 'Sport and Exercise Science Research Centre, School of Applied Sciences, London South Bank University, London, United Kingdom.'}]",Journal of biomechanics,['10.1016/j.jbiomech.2021.110584'] 1502,34222543,The Effect of Applying the Information-Motivation-Behavioral Skills Model on Treatment Adherence in Patients with Cardiovascular Disease: A Quasi-Experimental Study.,"Background Non-adherence complicates the management of patients with cardiovascular disease. This study aimed to determine the effect of applying the information-motivation-behavioral skills (IMB) model on the treatment adherence among these patients. Methods This quasi-experimental study was conducted on 112 patients with cardiovascular disease in Nemazee and Al-zahra hospitals in Shiraz, Iran, from October 2019 to July 2020. Eligible patients were selected and divided into intervention and control groups. The intervention was based on an integration of IMB model constructs and included 10 motivational-educational sessions for three months, followed by telephone consultations for six months. Data were collected before, and three and six months after the end of the motivational-educational sessions using adherence questionnaire in patients with chronic diseases, and adherence in chronic disease scale for medication adherence. Data were analyzed using SPSS 22, and descriptive statistics, chi-square, independent t-test, and repeated measure ANOVA were performed. P<0.05 was considered significant. Results The intervention and control groups were homogenous based on demographic characteristics. Repeated measure ANOVA findings revealed an increasing trend in the mean scores of the intervention group in treatment adherence from 51.10±3.20 at baseline to 66.40±5.50 three months and 73.80±6.80 six months after the end of the intervention (P<0.001). Furthermore, based on repeated measure ANOVA findings, the mean score of the intervention group in medication adherence significantly increased from 20.10+3 at baseline to 24.10+2.40 three months and 24.50+3.20 six months after the end of the intervention (P<0.001). Conclusion Applying the IMB model promoted adherence to treatment and medication among patients with cardiovascular disease. Therefore, such interventions are recommended for these patients.",2021,Repeated measure ANOVA findings revealed an increasing trend in the mean scores of the intervention group in treatment adherence from 51.10±3.20 at baseline to 66.40±5.50 three months and 73.80±6.80 six months after the end of the intervention (P<0.001).,"['patients with chronic diseases, and adherence in chronic disease scale for medication adherence', '112 patients with cardiovascular disease in Nemazee and Al-zahra hospitals in Shiraz, Iran, from October 2019 to July 2020', 'patients with cardiovascular disease', 'Patients with Cardiovascular Disease', 'Eligible patients', 'these patients']","['Information-Motivation-Behavioral Skills Model', 'information-motivation-behavioral skills (IMB) model']","['medication adherence', 'mean scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",112.0,0.0194429,Repeated measure ANOVA findings revealed an increasing trend in the mean scores of the intervention group in treatment adherence from 51.10±3.20 at baseline to 66.40±5.50 three months and 73.80±6.80 six months after the end of the intervention (P<0.001).,"[{'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Zahmatkeshan', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mahnaz', 'Initials': 'M', 'LastName': 'Rakhshan', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Ladan', 'Initials': 'L', 'LastName': 'Zarshenas', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Community Based Psychiatric Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Kojuri', 'Affiliation': 'Clinical Education Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Khademian', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",International journal of community based nursing and midwifery,['10.30476/ijcbnm.2021.88987.1563'] 1503,34051009,The gut microbiota associated with high-Gleason prostate cancer.,"We have found that intestinal bacteria and their metabolites, short-chain fatty acids (SCFAs), promote cancer growth in prostate cancer (PCa) mouse models. To clarify the association between gut microbiota and PCa in humans, we analyzed the gut microbiota profiles of men with suspected PCa. One hundred and fifty-two Japanese men undergoing prostate biopsies (96 with cancer and 56 without cancer) were included in the study and randomly divided into two cohorts: a discovery cohort (114 samples) and a test cohort (38 samples). The gut microbiota was compared between two groups, a high-risk group (men with Grade group 2 or higher PCa) and a negative + low-risk group (men with negative biopsy or Grade group 1 PCa), using 16S rRNA gene sequencing. The relative abundances of Rikenellaceae, Alistipes, and Lachnospira, all SCFA-producing bacteria, were significantly increased in high-risk group. In receiver operating characteristic curve analysis, the index calculated from the abundance of 18 bacterial genera which were selected by least absolute shrinkage and selection operator regression detected high-risk PCa in the discovery cohort with higher accuracy than the prostate specific antigen test (area under the curve [AUC] = 0.85 vs 0.74). Validation of the index in the test cohort showed similar results (AUC = 0.81 vs 0.67). The specific bacterial taxa were associated with high-risk PCa. The gut microbiota profile could be a novel useful marker for the detection of high-risk PCa and could contribute to the carcinogenesis of PCa.",2021,"The relative abundances of Rikenellaceae, Alistipes, and Lachnospira, all SCFA-producing bacteria, were significantly increased in high-risk group.","['One hundred and fifty-two Japanese men undergoing prostate biopsies (96 with cancer and 56 without cancer', 'men with suspected PCa']",[],"['relative abundances of Rikenellaceae, Alistipes, and Lachnospira, all SCFA-producing bacteria']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0194804', 'cui_str': 'Biopsy of prostate'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1277615', 'cui_str': 'Suspected prostate cancer'}]",[],"[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C1080664', 'cui_str': 'Rikenellaceae'}, {'cui': 'C1490417', 'cui_str': 'Alistipes'}, {'cui': 'C0317586', 'cui_str': 'Lachnospira'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}]",152.0,0.157576,"The relative abundances of Rikenellaceae, Alistipes, and Lachnospira, all SCFA-producing bacteria, were significantly increased in high-risk group.","[{'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Matsushita', 'Affiliation': 'Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.'}, {'ForeName': 'Kazutoshi', 'Initials': 'K', 'LastName': 'Fujita', 'Affiliation': 'Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Motooka', 'Affiliation': 'Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Hatano', 'Affiliation': 'Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.'}, {'ForeName': 'Shota', 'Initials': 'S', 'LastName': 'Fukae', 'Affiliation': 'Department of Urology, Osaka Police Hospital, Osaka, Japan.'}, {'ForeName': 'Norihiko', 'Initials': 'N', 'LastName': 'Kawamura', 'Affiliation': 'Department of Urology, Osaka General Medical Center, Osaka, Japan.'}, {'ForeName': 'Eisuke', 'Initials': 'E', 'LastName': 'Tomiyama', 'Affiliation': 'Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.'}, {'ForeName': 'Yujiro', 'Initials': 'Y', 'LastName': 'Hayashi', 'Affiliation': 'Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.'}, {'ForeName': 'Eri', 'Initials': 'E', 'LastName': 'Banno', 'Affiliation': 'Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Takao', 'Affiliation': 'Department of Urology, Osaka General Medical Center, Osaka, Japan.'}, {'ForeName': 'Shingo', 'Initials': 'S', 'LastName': 'Takada', 'Affiliation': 'Department of Urology, Osaka Police Hospital, Osaka, Japan.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Yachida', 'Affiliation': 'Department of Cancer Genome Informatics, Graduate School of Medicine, Osaka University, Suita, Japan.'}, {'ForeName': 'Hirotsugu', 'Initials': 'H', 'LastName': 'Uemura', 'Affiliation': 'Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Japan.'}, {'ForeName': 'Shota', 'Initials': 'S', 'LastName': 'Nakamura', 'Affiliation': 'Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.'}, {'ForeName': 'Norio', 'Initials': 'N', 'LastName': 'Nonomura', 'Affiliation': 'Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.'}]",Cancer science,['10.1111/cas.14998'] 1504,34224671,"Effect of general practitioner-led versus surgeon-led colon cancer survivorship care, with or without eHealth support, on quality of life (I CARE): an interim analysis of 1-year results of a randomised, controlled trial.","BACKGROUND Colon cancer is associated with an increased risk of physical and psychosocial morbidity, even after treatment. General practitioner (GP) care could be beneficial to help to reduce this morbidity. We aimed to assess quality of life (QOL) in patients who received GP-led survivorship care after treatment for colon cancer compared with those who received surgeon-led care. Furthermore, the effect of an eHealth app (Oncokompas) on QOL was assessed in both patient groups. METHODS We did a pragmatic two-by-two factorial, open-label, randomised, controlled trial at eight hospitals in the Netherlands. Eligible patients were receiving primary surgical treatment for stage I-III colon cancer or rectosigmoid carcinoma and qualified for routine follow-up according to Dutch national guidelines. Patients were randomly assigned (1:1:1:1)-via computer-generated variable block randomisation stratified by age and tumour stage-to survivorship care overseen by a surgeon, survivorship care overseen by a surgeon with access to Oncokompas, survivorship care overseen by a GP, or survivorship care overseen by a GP with access to Oncokompas. Blinding of the trial was not possible. The primary endpoint of the trial was QOL at 5 years, as measured by the change from baseline in the European Organistion for Research and Treatment of Cancer QLQ-C30 summary score. Here, we report an unplanned interim analysis of QOL at the 12-month follow-up. Grouped comparisons were done (ie, both GP-led care groups were compared with both surgeon-led groups, and both Oncokompas groups were compared with both no Oncokompas groups). Differences in change of QOL between trial groups were estimated with linear mixed-effects models. A change of ten units was considered clinically meaningful. Analysis was by intention to treat. This trial is registered with the Netherlands Trial Register, NTR4860. FINDINGS Between March 26, 2015, and Nov 21, 2018, 353 patients were enrolled and randomly assigned. There were 50 early withdrawals (27 patient decisions and 23 GP withdrawals). Of the remaining 303 participants, 79 were assigned to surgeon-led care, 83 to surgeon-led care with Oncokompas, 73 to GP-led care, and 68 to GP-led care with Oncokompas. Median follow-up was 12·2 months (IQR 12·0-13·0) in all groups. At baseline, QOL was high in all trial groups. At 12 months, there was no clinically meaningful difference in change from baseline in QOL between the GP-led care groups and the surgeon-led care groups (difference in summary score -2·3 [95% CI -5·0 to 0·4]) or between the Oncokompas and no Oncokompas groups (-0·1 [-2·8 to 2·6]). INTERPRETATION In terms of QOL, GP-led survivorship care can be considered as an alternative to surgeon-led care within the first year after colon cancer treatment. Other outcomes, including patient and physician preferences, will be important for decisions about the type of survivorship care. FUNDING Dutch Cancer Society (KWF).",2021,"At 12 months, there was no clinically meaningful difference in change from baseline in QOL between the GP-led care groups and the surgeon-led care groups (difference in summary score -2·3","['eight hospitals in the Netherlands', 'Between March 26, 2015, and Nov 21, 2018, 353 patients were enrolled and randomly assigned', 'Of the remaining 303 participants, 79 were assigned to surgeon-led care, 83 to surgeon-led care with Oncokompas, 73 to GP-led care, and 68 to GP-led care with Oncokompas', 'Eligible patients were receiving primary surgical treatment for stage I-III colon cancer or rectosigmoid carcinoma and qualified for routine follow-up according to Dutch national guidelines', 'patients who received GP-led survivorship care after treatment for colon cancer compared with those who received surgeon-led care']","['general practitioner-led versus surgeon-led colon cancer survivorship care, with or without eHealth support', 'computer-generated variable block randomisation stratified by age and tumour stage-to survivorship care overseen by a surgeon, survivorship care overseen by a surgeon with access to Oncokompas, survivorship care overseen by a GP, or survivorship care overseen by a GP with access to Oncokompas']","['quality of life (QOL', 'quality of life (I CARE', 'European Organistion for Research and Treatment of Cancer QLQ-C30 summary score', 'QOL', 'risk of physical and psychosocial morbidity']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C1327709', 'cui_str': 'Rectosigmoid cancer'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0475455', 'cui_str': 'T - Tumor stage'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",353.0,0.190963,"At 12 months, there was no clinically meaningful difference in change from baseline in QOL between the GP-led care groups and the surgeon-led care groups (difference in summary score -2·3","[{'ForeName': 'Julien A M', 'Initials': 'JAM', 'LastName': 'Vos', 'Affiliation': 'Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, Netherlands. Electronic address: j.a.m.vos@amsterdamumc.nl.'}, {'ForeName': 'Laura A M', 'Initials': 'LAM', 'LastName': 'Duineveld', 'Affiliation': 'Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Thijs', 'Initials': 'T', 'LastName': 'Wieldraaijer', 'Affiliation': 'Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Wind', 'Affiliation': 'Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Wim B', 'Initials': 'WB', 'LastName': 'Busschers', 'Affiliation': 'Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Edanur', 'Initials': 'E', 'LastName': 'Sert', 'Affiliation': 'Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Pieter J', 'Initials': 'PJ', 'LastName': 'Tanis', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Cancer Centre Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.'}, {'ForeName': 'Irma M', 'Initials': 'IM', 'LastName': 'Verdonck-de Leeuw', 'Affiliation': 'Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, Netherlands; Cancer Centre Amsterdam, Amsterdam UMC, Amsterdam, Netherlands; Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, and Department of Clinical, Neuro- and Developmental Psychology (Clinical Psychology Section), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Henk C P M', 'Initials': 'HCPM', 'LastName': 'van Weert', 'Affiliation': 'Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, Netherlands.'}, {'ForeName': 'Kristel M', 'Initials': 'KM', 'LastName': 'van Asselt', 'Affiliation': 'Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(21)00273-4'] 1505,34229888,AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.,"BACKGROUND Eliciting durable humoral immunity with sufficient breadth and magnitude is important for HIV-1 vaccine design. The HVTN 114 vaccine trial evaluated different boost regimens administered after a 7-year rest period in participants previously enrolled in HVTN 205, who received either three MVA/HIV62B (MMM) or two DNA and two MVA/HIV62B (DDMM) injections; both vaccines expressed multiple HIV-1 antigens in non-infectious virus-like-particles. The primary objective of HVTN 114 was to assess the impact of a heterologous gp120 protein AIDSVAX B/E boost on the magnitude, breadth and durability of vaccine-induced immune responses. METHODS We enrolled 27 participants from HVTN 205 into five groups. Eight participants who previously received MMM were randomized and boosted with either MVA/HIV62B alone (T1; n = 4) or MVA/HIV62B and AIDSVAX B/E (T2; n = 4). Nineteen participants who received DDMM were randomized and boosted with MVA/HIV62B alone (T3; n = 6), MVA/HIV62B and AIDSVAX B/E (T4; n = 6), or AIDSVAX B/E alone (T5; n = 7). Boosts were at months 0 and 4. Participants were followed for safety and immunogenicity for 10 months and were pooled for analysis based on the regimen: MVA-only (T1 + T3), MVA + AIDSVAX (T2 + T4), and AIDSVAX-only (T5). RESULTS All regimens were safe and well-tolerated. Prior to the boost vaccination, binding antibody and CD4+T-cell responses were observed 7 years after HVTN 205 vaccinations. Late boosting with AIDSVAX, with or without MVA, resulted in high binding antibody responses to gp120 and V1V2 epitopes, with increased magnitude and breadth compared to those observed in HVTN 205. Late boosting with MVA, with or without AIDSVAX, resulted in increased gp140 and gp41 antibody responses and higher CD4+T-cell responses to Env and Gag. CONCLUSIONS Late boosting with AIDSVAX, alone or in combination with MVA, can broaden binding antibody responses and increase T-cell responses even years following the original MVA/HIV62B with or without DNA-priming vaccine.",2021,"Late boosting with MVA, with or without AIDSVAX, resulted in increased gp140 and gp41 antibody responses and higher CD4+T-cell responses to Env and Gag. ","['participants previously enrolled in HVTN 205, who received either', 'Eight participants who previously received MMM', '27 participants from HVTN 205 into five groups', 'Nineteen participants who received DDMM']","['MVA, with or without AIDSVAX', 'three MVA/HIV62B (MMM) or two DNA and two MVA/HIV62B', 'MVA\xa0+\xa0AIDSVAX (T2\xa0+\xa0T4), and AIDSVAX-only (T5', 'AIDSVAX', 'AIDSVAX, alone or in combination with MVA', 'MVA/HIV62B alone (T3; n\xa0=\xa06), MVA/HIV62B and AIDSVAX B/E (T4; n\xa0=\xa06), or AIDSVAX B/E alone', 'MVA/HIV62B alone (T1; n\xa0=\xa04) or MVA/HIV62B and AIDSVAX B/E']","['safe and well-tolerated', 'gp140 and gp41 antibody responses and higher CD4+T-cell responses', 'safety and immunogenicity', 'high binding antibody responses']","[{'cui': 'C0026987', 'cui_str': 'Myelofibrosis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0450337', 'cui_str': '19'}]","[{'cui': 'C0052712', 'cui_str': 'AVM protocol'}, {'cui': 'C0675907', 'cui_str': 'AIDSVAX'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}]","[{'cui': 'C0061830', 'cui_str': 'GP 140'}, {'cui': 'C0019692', 'cui_str': 'Envelope Protein gp41, HIV'}, {'cui': 'C0003261', 'cui_str': 'Antibody Production'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}]",27.0,0.1364,"Late boosting with MVA, with or without AIDSVAX, resulted in increased gp140 and gp41 antibody responses and higher CD4+T-cell responses to Env and Gag. ","[{'ForeName': 'Yunda', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Kelly E', 'Initials': 'KE', 'LastName': 'Seaton', 'Affiliation': 'Duke Center for Human Systems Immunology, Duke University Departments of Surgery, Immunology, Pathology, Molecular Genetics and Microbiology, Durham, NC, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Casapia', 'Affiliation': 'Asociacion Civil Selva Amazonica, Universidad Nacional de la Amazonia, Iquitos, Peru. Urbanizacion Jardin 27, Iquitos, Peru. Electronic address: mcasapia@acsaperu.org.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Polakowski', 'Affiliation': 'Division of AIDS, NIAID, Rockville, MD, USA.'}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'De Rosa', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Cohen', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Chenchen', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Marnie', 'Initials': 'M', 'LastName': 'Elizaga', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Paez', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Maurine D', 'Initials': 'MD', 'LastName': 'Miner', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Colleen F', 'Initials': 'CF', 'LastName': 'Kelley', 'Affiliation': 'Department of Medicine, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Maenza', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Keefer', 'Affiliation': 'Infectious Diseases Division, Department of Medicine, University of Rochester, Rochester, NY, USA.'}, {'ForeName': 'Javier R', 'Initials': 'JR', 'LastName': 'Lama', 'Affiliation': 'Asociacion Civil Impacta Salud y Educacion, Lima, Peru.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Sobieszczyk', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, Columbia University Irving Medical Center, NYC, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Buchbinder', 'Affiliation': 'Bridge HIV, San Francisco Department of Public Health, San Francisco, CA, USA.'}, {'ForeName': 'Lindsey R', 'Initials': 'LR', 'LastName': 'Baden', 'Affiliation': ""Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Carter', 'Initials': 'C', 'LastName': 'Lee', 'Affiliation': 'Global Solutions for Infectious Diseases, Lafayette, CA, USA.'}, {'ForeName': 'Vineeta', 'Initials': 'V', 'LastName': 'Gulati', 'Affiliation': 'Global Solutions for Infectious Diseases, Lafayette, CA, USA.'}, {'ForeName': 'Faruk', 'Initials': 'F', 'LastName': 'Sinangil', 'Affiliation': 'Global Solutions for Infectious Diseases, Lafayette, CA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Montefiori', 'Affiliation': 'Department of Surgery and Duke Human Vaccine Institute, Duke University, Durham, NC, USA.'}, {'ForeName': 'M Juliana', 'Initials': 'MJ', 'LastName': 'McElrath', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Georgia D', 'Initials': 'GD', 'LastName': 'Tomaras', 'Affiliation': 'Duke Center for Human Systems Immunology, Duke University Departments of Surgery, Immunology, Pathology, Molecular Genetics and Microbiology, Durham, NC, USA.'}, {'ForeName': 'Harriet L', 'Initials': 'HL', 'LastName': 'Robinson', 'Affiliation': 'GeoVax, Atlanta, GA, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Goepfert', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: pgoepfert@uabmc.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Vaccine,['10.1016/j.vaccine.2021.06.066'] 1506,34234425,Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial.,"Introduction Limited prospective evidence is available to guide selection of first-line maintenance therapy in patients with COPD. This pre-specified analysis of the EMAX trial explored the efficacy and safety of dual- versus mono-bronchodilator therapy in maintenance-naïve and maintenance-treated patients. Methods The 24-week EMAX trial evaluated lung function, symptoms (including rescue medication use), exacerbations, and safety with umeclidinium/vilanterol, umeclidinium, and salmeterol in symptomatic patients at low exacerbation risk who were not receiving inhaled corticosteroids. Maintenance-naïve and maintenance-treated subgroups were defined by maintenance bronchodilator use 30 days before screening. Results The analysis included 749 (31%) maintenance-naïve and 1676 (69%) maintenance-treated patients. For both subgroups, improvements from baseline in trough FEV 1 at Week 24 (primary endpoint) were greater with umeclidinium/vilanterol versus umeclidinium (mean difference [95% CI]; maintenance-naïve: 44 mL [1, 87]; maintenance-treated: 77 mL [50, 104]), and salmeterol (maintenance-naïve: 128 mL [85, 171]; maintenance-treated: 145 mL [118, 172]), and in rescue medication inhalations/day over 24 weeks versus umeclidinium (maintenance-naïve: -0.44 [-0.73, -0.16]; maintenance-treated: -0.28 [-0.45, -0.12]) and salmeterol (maintenance-naïve: -0.37 [-0.66, -0.09]; maintenance-treated: -0.25 [-0.41, -0.08]). In maintenance-naïve patients, umeclidinium/vilanterol numerically improved scores at Week 24 for Transition Dyspnea Index versus umeclidinium (0.37 [-0.21, 0.96]) and versus salmeterol (0.47 [-0.10, 1.05]) and Evaluating Respiratory Symptoms-COPD versus umeclidinium (-0.26 [-1.04, 0.53]) and versus salmeterol (-0.58 [-1.36, 0.20]), with similar improvements seen in maintenance-treated patients. All treatments were well tolerated across both subgroups. Conclusion Similar to maintenance-treated patients, maintenance-naïve patients receiving umeclidinium/vilanterol showed greater improvements in lung function and symptoms compared with patients receiving umeclidinium or salmeterol. These findings provide support for the consideration of dual bronchodilator treatment in symptomatic maintenance-naïve patients with COPD.",2021,"For both subgroups, improvements from baseline in trough FEV 1 at Week 24 (primary endpoint) were greater with umeclidinium/vilanterol versus umeclidinium (mean difference [95% CI]; maintenance-naïve: 44 mL [1, 87];","['patients with COPD', 'maintenance-naïve and maintenance-treated patients', 'symptomatic patients at low exacerbation risk who were not receiving inhaled corticosteroids', 'Maintenance-Naïve Patients with Symptomatic COPD', 'symptomatic maintenance-naïve patients with COPD']","['salmeterol (maintenance-naïve', 'dual- versus mono-bronchodilator therapy', 'salmeterol', 'Dual Bronchodilator Therapy']","['lung function, symptoms (including rescue medication use), exacerbations, and safety with umeclidinium/vilanterol, umeclidinium, and salmeterol', 'efficacy and safety', 'lung function and symptoms', 'Evaluating Respiratory Symptoms-COPD versus umeclidinium']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]","[{'cui': 'C0073992', 'cui_str': 'salmeterol'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0021345', 'cui_str': 'Infectious mononucleosis'}, {'cui': 'C0578554', 'cui_str': 'Inhaled bronchodilator therapy'}]","[{'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3709478', 'cui_str': 'umeclidinium / vilanterol'}, {'cui': 'C3661274', 'cui_str': 'umeclidinium'}, {'cui': 'C0073992', 'cui_str': 'salmeterol'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]",,0.190056,"For both subgroups, improvements from baseline in trough FEV 1 at Week 24 (primary endpoint) were greater with umeclidinium/vilanterol versus umeclidinium (mean difference [95% CI]; maintenance-naïve: 44 mL [1, 87];","[{'ForeName': 'Leif', 'Initials': 'L', 'LastName': 'Bjermer', 'Affiliation': 'Respiratory Medicine and Allergology, Lund University, Lund, Sweden.'}, {'ForeName': 'Isabelle H', 'Initials': 'IH', 'LastName': 'Boucot', 'Affiliation': 'Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Maltais', 'Affiliation': 'Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Canada.'}, {'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Kerwin', 'Affiliation': 'Clinical Research Institute of Southern Oregon, Medford, OR, USA.'}, {'ForeName': 'Ian P', 'Initials': 'IP', 'LastName': 'Naya', 'Affiliation': 'Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Tombs', 'Affiliation': 'Precise Approach Ltd, contingent worker on assignment at GSK, Stockley Park West, Uxbridge, Middlesex, UK.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Jones', 'Affiliation': 'Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Compton', 'Affiliation': 'Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Lipson', 'Affiliation': 'Respiratory Clinical Sciences, GSK, Collegeville, PA, USA.'}, {'ForeName': 'Claus F', 'Initials': 'CF', 'LastName': 'Vogelmeier', 'Affiliation': 'Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany.'}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S291751'] 1507,34239299,Long-Term Benefits of Adding a Pedometer to Pulmonary Rehabilitation for COPD: The Randomized Controlled STAR Trial.,"Purpose This Stay Active after Rehabilitation (STAR) study examined the effects of a pedometer-based behavioral intervention for individuals with COPD during three weeks of inpatient pulmonary rehabilitation (PR) on patients' physical activity levels six weeks and six months after PR, including steps (primary outcome), moderate-intensity physical activity, and sedentary time as well as patient quality of life, symptoms, and other psychological and clinical variables. Patients and Methods Rehabilitation patients with COPD wore a triaxial accelerometer (ActiGraph wGT3X) for seven days two weeks before (T0) as well as six weeks (T3) and six months (T4) after PR. In addition to the three-week inpatient PR (control group, CG), the randomly allocated intervention group (IG) received a brief pedometer-based behavioral intervention with the application of the following behavior-change techniques: performing the behavior, individual goal-setting, self-monitoring, and feedback. The effects were analyzed using analysis of covariance with an intention-to-treat approach. Results A total of 327 patients (69% male, age: 58 years, FEV 1 (%): 53.5, six-minute walk distance: 447.8 m) were randomly allocated to either the IG (n = 167) or CG (n = 160). Although both groups increased their daily steps after PR (IG: M T3-T0 = 1152, CG: M T3-T0 = 745; IG: M T4-T0 = 795, CG: M T4-T0 = 300), the slightly higher increases in daily steps in the IG compared to the CG at T3 (Δ388 steps, d = 0.16) and T4 (Δ458 steps, d = 0.15) were not statistically significant (p > 0.05 for all). Patients in both groups showed moderate to high pre-post-changes in terms of secondary outcomes, but no advantage favoring the IG was found. Conclusion The results show that adding a pedometer-based behavioral intervention to standard German three-week inpatient PR for COPD patients did not result in more physical activity in terms of steps and moderate-intensity physical activity or less sedentary time. However, both groups (IG and CG) showed remarkably enhanced physical activity levels six weeks and six months after PR, as well as improvements in other secondary outcomes (eg, quality of life).",2021,"Although both groups increased their daily steps after PR (IG: M T3-T0 = 1152, CG: M T3-T0 = 745; IG: M T4-T0 = 795, CG:","['Patients and Methods\n\n\nRehabilitation patients with COPD wore a', 'individuals with COPD during three weeks of inpatient pulmonary rehabilitation (PR) on patients', 'COPD', '327 patients (69% male, age: 58 years, FEV 1 (%): 53.5, six-minute walk distance: 447.8 m']","['CG', 'brief pedometer-based behavioral intervention with the application of the following behavior-change techniques: performing the behavior, individual goal-setting, self-monitoring, and feedback', 'triaxial accelerometer (ActiGraph wGT3X', 'pedometer-based behavioral intervention']","['moderate-intensity physical activity, and sedentary time as well as patient quality of life, symptoms, and other psychological and clinical variables', 'physical activity', 'physical activity levels', 'daily steps', 'quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4082109', 'cui_str': 'Three weeks'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0150598', 'cui_str': 'Goal setting'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}]",327.0,0.0204855,"Although both groups increased their daily steps after PR (IG: M T3-T0 = 1152, CG: M T3-T0 = 745; IG: M T4-T0 = 795, CG:","[{'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Geidl', 'Affiliation': 'Department of Sport Science and Sport, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Carl', 'Affiliation': 'Department of Sport Science and Sport, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schuler', 'Affiliation': 'Institute for Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.'}, {'ForeName': 'Eriselda', 'Initials': 'E', 'LastName': 'Mino', 'Affiliation': 'Department of Sport Science and Sport, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Lehbert', 'Affiliation': 'Klinik Bad Reichenhall, Centre for Rehabilitation, Pulmonology, and Orthopaedics, Bad Reichenhall, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wittmann', 'Affiliation': 'Klinik Bad Reichenhall, Centre for Rehabilitation, Pulmonology, and Orthopaedics, Bad Reichenhall, Germany.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Pfeifer', 'Affiliation': 'Department of Sport Science and Sport, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Konrad', 'Initials': 'K', 'LastName': 'Schultz', 'Affiliation': 'Klinik Bad Reichenhall, Centre for Rehabilitation, Pulmonology, and Orthopaedics, Bad Reichenhall, Germany.'}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S304976'] 1508,34204359,Effect of Glutamine Supplementation on Muscular Damage Biomarkers in Professional Basketball Players.,"Scientific evidence supports the role of L-glutamine in improving immune function. This could suggest a possible role of L-glutamine in recovery after intense exercise. To this end, the present report aimed to study if oral L-glutamine supplementation could attenuate muscle damage in a group of players of a mainly eccentric sport discipline such as basketball. Participants ( n = 12) were supplemented with 6 g/day of glutamine (G group) or placebo (P group) for 40 days in a crossover study design (20 days with glutamine + 20 days with placebo and vice versa). Blood samples were obtained at the beginning and at the end of each period and markers from exercise-induced muscle damage were determined. The glutamine supplemented group displayed significantly low values of aspartate transaminase, creatine kinase and myoglobin in blood, suggesting less muscle damage compared to the placebo. In addition, adrenocorticotropic hormone levels were lower in the glutamine supplemented group than in the placebo. As a result, the circulating cortisol levels did not increase at the end of the study in the glutamine supplemented group. Altogether, the results indicate that glutamine could help attenuate exercise-induced muscle damage in sport disciplines with predominantly eccentric actions.",2021,"The glutamine supplemented group displayed significantly low values of aspartate transaminase, creatine kinase and myoglobin in blood, suggesting less muscle damage compared to the placebo.","['a group of players of a mainly eccentric sport discipline such as basketball', 'Participants ( n = 12', 'Professional Basketball Players']","['Glutamine Supplementation', 'glutamine + 20 days with placebo', 'glutamine (G group) or placebo', 'placebo', 'glutamine', 'oral L-glutamine supplementation']","['Blood samples', 'low values of aspartate transaminase, creatine kinase and myoglobin in blood', 'adrenocorticotropic hormone levels', 'Muscular Damage Biomarkers', 'circulating cortisol levels']","[{'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0004818', 'cui_str': 'Basketball'}]","[{'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0027078', 'cui_str': 'Myoglobin'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0201835', 'cui_str': 'Adrenocorticotropic hormone measurement'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}]",12.0,0.089548,"The glutamine supplemented group displayed significantly low values of aspartate transaminase, creatine kinase and myoglobin in blood, suggesting less muscle damage compared to the placebo.","[{'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Córdova-Martínez', 'Affiliation': 'Departamento Bioquímica, Biología Molecular y Fisiología, Facultad de Ciencias de la Salud, GIR: ""Ejercicio Físico y Envejecimiento"" Universidad Valladolid, Campus Universitario ""Los Pajaritos"", 42004 Soria, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Caballero-García', 'Affiliation': 'Departamento de Anatomía y Radiología, Facultad de Ciencias de la Salud, GIR: ""Ejercicio Físico y Envejecimiento"" Universidad Valladolid, Campus Universitario ""Los Pajaritos"", 42004 Soria, Spain.'}, {'ForeName': 'Hugo J', 'Initials': 'HJ', 'LastName': 'Bello', 'Affiliation': 'Departamento Matemáticas, Escuela de Ingeniería de la Industria Forestal, Agronómica y de la Bioenergía, GIR: ""Ejercicio Físico y Envejecimiento"" Universidad Valladolid, Campus Universitario ""Los Pajaritos"", 42004 Soria, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pérez-Valdecantos', 'Affiliation': 'Departamento Bioquímica, Biología Molecular y Fisiología, Facultad de Ciencias de la Salud, GIR: ""Ejercicio Físico y Envejecimiento"" Universidad Valladolid, Campus Universitario ""Los Pajaritos"", 42004 Soria, Spain.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Roche', 'Affiliation': 'Instituto de Bioingeniería y Departamento de Biología Aplicada-Nutrición, Universidad Miguel Hernández, 03202 Elche, Spain.'}]",Nutrients,['10.3390/nu13062073'] 1509,34210411,Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization.,"BACKGROUND The benefit of optimal medical therapy (OMT) on 5-year outcomes in patients with 3-vessel disease and/or left main disease after percutaneous coronary intervention or coronary artery bypass grafting (CABG) was demonstrated in the randomized SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) trial. OBJECTIVES The objective of this analysis is to assess the impact of the status of OMT at 5 years on 10-year mortality after percutaneous coronary intervention or CABG. METHODS This is a subanalysis of the SYNTAXES (Synergy Between PCI With Taxus and Cardiac Surgery Extended Survival) study, which evaluated for up to 10 years the vital status of patients who were originally enrolled in the SYNTAX trial. OMT was defined as the combination of 4 types of medications: at least 1 antiplatelet drug, statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and beta-blocker. After stratifying participants by the number of individual OMT agents at 5 years and randomized treatment, a landmark analysis was conducted to assess the association between treatment response and 10-year mortality. RESULTS In 1,472 patients, patients on OMT at 5 years had a significantly lower mortality at 10 years compared with those on ≤2 types of medications (13.1% vs 19.9%; adjusted HR: 0.470; 95% CI: 0.292-0.757; P = 0.002) but had a mortality similar to those on 3 types of medications. Furthermore, patients undergoing CABG with the individual OMT agents, antiplatelet drug and statin, at 5 years had lower 10-year mortality than those without. CONCLUSIONS In patients with 3-vessel and/or left main disease undergoing percutaneous coronary intervention or CABG, medication status at 5 years had a significant impact on 10-year mortality. Patients on OMT with guideline-recommended pharmacologic therapy at 5 years had a survival benefit. (Synergy Between PCI With Taxus and Cardiac Surgery: SYNTAX Extended Survival [SYNTAXES]; NCT03417050; Taxus Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries [SYNTAX]; NCT00114972).",2021,"In 1,472 patients, patients on OMT at 5 years had a significantly lower mortality at 10 years compared with those on ≤2 types of medications (13.1% vs 19.9%; adjusted HR: 0.470; 95% CI: 0.292-0.757; P = 0.002) but had a mortality similar to those on 3 types of medications.","['patients with 3-vessel and/or left main disease undergoing percutaneous coronary intervention or CABG, medication status at 5 years', 'patients with 3-vessel disease', 'up to 10 years the vital status of patients who were originally enrolled in the SYNTAX trial']","['statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and beta-blocker', 'Optimal Medical Therapy', 'optimal medical therapy (OMT', 'percutaneous coronary intervention or coronary artery bypass grafting (CABG', 'PCI']","['OMT', '10-year mortality', '10-Year Mortality', 'survival benefit', 'mortality', '5-year outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0034787', 'cui_str': 'Angiotensin receptor'}, {'cui': 'C0001645', 'cui_str': 'Beta adrenergic receptor antagonist'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}]","[{'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",1472.0,0.0818795,"In 1,472 patients, patients on OMT at 5 years had a significantly lower mortality at 10 years compared with those on ≤2 types of medications (13.1% vs 19.9%; adjusted HR: 0.470; 95% CI: 0.292-0.757; P = 0.002) but had a mortality similar to those on 3 types of medications.","[{'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Kawashima', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway, Galway, Ireland; Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: https://twitter.com/HideyukiKawash2.'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway, Galway, Ireland; National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address: patrick.serruys@nuigalway.ie.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Ono', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway, Galway, Ireland; Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway, Galway, Ireland; Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': ""O'Leary"", 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway, Galway, Ireland.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Mack', 'Affiliation': 'Department of Cardiothoracic Surgery, Baylor Scott and White Health, Dallas, Texas, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Holmes', 'Affiliation': 'Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Morice', 'Affiliation': 'Hôpital Privé Jacques Cartier, Ramsay Générale de Santé, Massy, France.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Head', 'Affiliation': 'Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands.'}, {'ForeName': 'Arie Pieter', 'Initials': 'AP', 'LastName': 'Kappetein', 'Affiliation': 'Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands.'}, {'ForeName': 'Daniel J F M', 'Initials': 'DJFM', 'LastName': 'Thuijs', 'Affiliation': 'Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands.'}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Milojevic', 'Affiliation': 'Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands; Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia.'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Noack', 'Affiliation': 'University Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany.'}, {'ForeName': 'Friedrich-Wilhelm', 'Initials': 'FW', 'LastName': 'Mohr', 'Affiliation': 'University Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany.'}, {'ForeName': 'Piroze M', 'Initials': 'PM', 'LastName': 'Davierwala', 'Affiliation': 'University Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany.'}, {'ForeName': 'Faisal', 'Initials': 'F', 'LastName': 'Sharif', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway, Galway, Ireland.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'McEvoy', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway, Galway, Ireland.'}, {'ForeName': 'Yoshinobu', 'Initials': 'Y', 'LastName': 'Onuma', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway, Galway, Ireland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2021.04.087'] 1510,34210409,Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.,"BACKGROUND The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular (CV) events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). OBJECTIVES The aim of this work was to report the effects of the combination on overall and cause-specific mortality. METHODS The COMPASS trial enrolled 27,395 patients of whom 18,278 were randomized to the combination (n = 9,152) or aspirin alone (n = 9,126). Deaths were adjudicated by a committee blinded to treatment allocation. Previously identified high-risk baseline features were polyvascular disease, chronic kidney disease, mild or moderate heart failure, and diabetes. RESULTS During a median of 23 months of follow-up (maximum 47 months), 313 patients (3.4%) allocated to the combination and 378 patients (4.1%) allocated to aspirin alone died (hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0.71-0.96; P = 0.01). Compared with aspirin, the combination reduced CV death (160 [1.7%] vs 203 [2.2%]; HR: 0.78; 95% CI: 0.64-0.96; P = 0.02) but not non-CV death. There were fewer deaths following MI, stroke, and CV procedures, as well as fewer sudden cardiac, other, and unknown causes of CV deaths and coronary heart disease deaths. Patients with 0, 1, 2, and 3 or 4 high-risk features at baseline had 4.2, 4.8, 25.0, and 53.9 fewer deaths, respectively, per 1000 patients treated for 30 months. CONCLUSIONS The combination of rivaroxaban and aspirin compared with aspirin reduced overall and CV mortality with consistent reductions in cause specific CV mortality in patients with chronic CAD or PAD. The absolute mortality benefits are greater with increasing baseline risk. (Cardiovascular Outcomes for People Using Anticoagulant Strategies [COMPASS]; NCT01776424).",2021,"Compared with aspirin, the combination reduced CV death (160 [1.7%] vs 203 [2.2%]; HR: 0.78; 95% CI: 0.64-0.96; P = 0.02) but not non-CV death.","['patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD', 'Patients with 0, 1, 2, and 3 or 4 high-risk features at baseline had 4.2, 4.8, 25.0, and 53.9 fewer deaths, respectively, per 1000 patients treated for 30\xa0months', 'patients with chronic CAD or PAD', '27,395 patients of whom 18,278 were randomized to the combination (n\xa0=\xa09,152) or', 'Patients With Chronic Coronary or Peripheral Artery Disease']","['aspirin alone', 'rivaroxaban and aspirin', 'rivaroxaban', 'aspirin', 'Rivaroxaban Plus Aspirin']","['overall and CV mortality', 'deaths following MI, stroke, and CV procedures', 'major adverse cardiovascular (CV) events', 'CV deaths and coronary heart disease deaths', 'CV death', 'absolute mortality benefits', 'specific CV mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C4517765', 'cui_str': '4.8'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0189573', 'cui_str': 'Procedure on cardiovascular system'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0205369', 'cui_str': 'Specific'}]",27395.0,0.299162,"Compared with aspirin, the combination reduced CV death (160 [1.7%] vs 203 [2.2%]; HR: 0.78; 95% CI: 0.64-0.96; P = 0.02) but not non-CV death.","[{'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Eikelboom', 'Affiliation': 'Population Health Research Institute, Hamilton Ontario, Canada; Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: eikelbj@mcmaster.ca.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Keith A A', 'Initials': 'KAA', 'LastName': 'Fox', 'Affiliation': 'Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Bosch', 'Affiliation': 'Population Health Research Institute, Hamilton Ontario, Canada; School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Connolly', 'Affiliation': 'Population Health Research Institute, Hamilton Ontario, Canada; Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Sonia S', 'Initials': 'SS', 'LastName': 'Anand', 'Affiliation': 'Population Health Research Institute, Hamilton Ontario, Canada; Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Avezum', 'Affiliation': 'International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Berkowitz', 'Affiliation': 'Bayer US, LLC, Whippany, New Jersey, USA.'}, {'ForeName': 'Kelley R H', 'Initials': 'KRH', 'LastName': 'Branch', 'Affiliation': 'University of Washington Medical Center, Seattle, Washington, USA.'}, {'ForeName': 'Gilles R', 'Initials': 'GR', 'LastName': 'Dagenais', 'Affiliation': 'Institut Universitaire de Cardiologie et Pneumologie de Québec, Université Laval, Québec, Québec, Canada.'}, {'ForeName': 'Camilo', 'Initials': 'C', 'LastName': 'Félix', 'Affiliation': 'Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador.'}, {'ForeName': 'Tomasz J', 'Initials': 'TJ', 'LastName': 'Guzik', 'Affiliation': 'Department of Internal and Agricultural Medicine, Jagiellonian University, Collegium Medicum, Krakow, Poland; British Heart Foundation Centre for Cardiovascular Research, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Hart', 'Affiliation': 'Population Health Research Institute, Hamilton Ontario, Canada; Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'ForeName': 'Aldo P', 'Initials': 'AP', 'LastName': 'Maggioni', 'Affiliation': 'Italian Association of Hospital Cardiologists Research Center, Florence, Italy.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Muehlhofer', 'Affiliation': 'Bayer AG, Wuppertal, Germany.'}, {'ForeName': 'Mukul', 'Initials': 'M', 'LastName': 'Sharma', 'Affiliation': 'Population Health Research Institute, Hamilton Ontario, Canada; Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Shestakovska', 'Affiliation': 'Population Health Research Institute, Hamilton Ontario, Canada.'}, {'ForeName': 'Salim', 'Initials': 'S', 'LastName': 'Yusuf', 'Affiliation': 'Population Health Research Institute, Hamilton Ontario, Canada; Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2021.04.083'] 1511,34216380,Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment.,"BACKGROUND The EORTC QLU-C10D is a preference-based measure derived from the EORTC QLQ-C30. For use in economic evaluations, country-specific value sets are needed. This study aimed to generate an EORTC QLU-C10 value set for Spain. METHODS A sample of the Spanish general population completed an online discrete choice experiment. An attribute-balanced incomplete block design was used to select 960 choice tasks, with a total of 1920 health states. Each participant was randomly assigned 16 choice sets without replacement. Data were modelled using generalized estimating equations and mixed logistic regressions. RESULTS A total of 1625 panel members were invited to participate, 1010 of whom were included in the study. Dimension decrements were generally monotonic with larger disutilities at increased severity levels. Dimensions associated with larger decrements were physical functioning and pain, while the dimension with the smallest decrement was sleep disturbances. The PITS state (i.e. worst attainable health) for the Spanish population is - 0.043. CONCLUSIONS This study generated the first Spanish value set for the QLU-C10D. This can facilitate cost-utility analyses when applied to data collected with the EORTC QLQ-C30.",2021,"Dimensions associated with larger decrements were physical functioning and pain, while the dimension with the smallest decrement was sleep disturbances.","['A total of 1625 panel members were invited to participate, 1010 of whom were included in the study']",[],"['physical functioning and pain', 'sleep disturbances']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}]",,0.0578377,"Dimensions associated with larger decrements were physical functioning and pain, while the dimension with the smallest decrement was sleep disturbances.","[{'ForeName': 'Aureliano Paolo', 'Initials': 'AP', 'LastName': 'Finch', 'Affiliation': 'Research Centre on Health and Social Care Management (CERGAS), Bocconi University, Via Sarfatti 25, S1 4DT, Milan, Italy. finc8@hotmail.com.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Gamper', 'Affiliation': 'Division of Psychiatry I, Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Norman', 'Affiliation': 'School of Public Health, Curtin University, Perth, Australia.'}, {'ForeName': 'Rosalie', 'Initials': 'R', 'LastName': 'Viney', 'Affiliation': 'Centre for Health Economics Research and Evaluation (CHERE), UTS Business School, University of Technology Sydney (UTS), Sydney, NSW, Australia.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Holzner', 'Affiliation': 'Division of Psychiatry I, Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'King', 'Affiliation': 'School of Psychology, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Kemmler', 'Affiliation': 'Division of Psychiatry II, Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",PharmacoEconomics,['10.1007/s40273-021-01058-x'] 1512,34214867,Efficacy and safety of Cerebrolysin after futile recanalisation therapy in patients with severe stroke.,"INTRODUCTION Golden standard of acute stroke treatment is recanalisation therapy. However, opening the occluded blood vessel sometimes does not show the expected clinical result or leads to haemorrhagic complications. As neuroinflammation and neurotoxicity play an important role in the pathophysiology of stroke, neuroprotective agents might preserve brain tissue after futile recanalisation. PATIENTS AND METHODS After recanalisation therapy and not later than 24 h after symptoms onset, patients with initial NIHSS of ≥ 8 were assigned to the investigational and control group. The investigational group received intravenous Cerebrolysin as add-on therapy. The primary objective was to assess the clinical efficacy of Cerebrolysin. The secondary objective was to investigate its effect on haemorrhagic transition and to confirm its safety profile. RESULTS Baseline characteristics of patients showed no significant differences between the two groups. No difference could be detected between the two groups in the mRS scale though the Cerebrolysin group showed descriptive superiority over the control group. We found a statistically significant difference considering haemorrhagic transition and mortality rate in favour of the Cerebrolysin group. DISCUSSION The multimodal neurotrophic agent Cerebrolysin holds promise to impact on the late consequences of a reperfusion syndrome. Its influence on reducing neuroinflammation, promoting neuronal cell viability and neurogenesis as well as the stabilising effect on the blood-brain barrier suggests a protective effect on the neurovascular unit even when no recanalisation occurs. We confirmed the excellent safety profile of Cerebrolysin. CONCLUSION Cerebrolysin as add-on therapy might be beneficial and safe for patients with acute stroke in terms of lowering risk for haemorrhagic complications after recanalisation therapy.",2021,No difference could be detected between the two groups in the mRS scale though the Cerebrolysin group showed descriptive superiority over the control group.,"['patients with initial NIHSS of ≥\xa08', 'patients with severe stroke', 'patients with acute stroke']","['intravenous Cerebrolysin', 'Cerebrolysin']","['haemorrhagic transition and mortality rate', 'clinical efficacy of Cerebrolysin', 'Efficacy and safety', 'mRS scale', 'haemorrhagic transition']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0055108', 'cui_str': 'cerebrolysin'}]","[{'cui': 'C0333275', 'cui_str': 'Hemorrhagic'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0055108', 'cui_str': 'cerebrolysin'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0367566,No difference could be detected between the two groups in the mRS scale though the Cerebrolysin group showed descriptive superiority over the control group.,"[{'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Poljakovic', 'Affiliation': 'University Hospital Zagreb, Departement of Neurology, ESO Comprehensive Stroke Center, Croatia. Electronic address: zdravka.po@gmail.com.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Supe', 'Affiliation': 'University Hospital Zagreb, Departement of Neurology, ESO Comprehensive Stroke Center, Croatia.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ljevak', 'Affiliation': 'University Hospital Zagreb, Departement of Neurology, ESO Comprehensive Stroke Center, Croatia.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Starcevic', 'Affiliation': 'University Hospital Zagreb, Departement of Neurology, ESO Comprehensive Stroke Center, Croatia.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Peric', 'Affiliation': 'University Hospital Zagreb, Departement of Neurology, ESO Comprehensive Stroke Center, Croatia.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Blazevic', 'Affiliation': 'University Hospital Zagreb, Departement of Neurology, ESO Comprehensive Stroke Center, Croatia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Krbot-Skoric', 'Affiliation': 'University Hospital Zagreb, Departement of Neurology, ESO Comprehensive Stroke Center, Croatia.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Jovanovic', 'Affiliation': 'University Hospital Zagreb, Departement of Neuroradiology, ESO Comprehensive Stroke Center, Croatia.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Ozretic', 'Affiliation': 'University Hospital Zagreb, Departement of Neuroradiology, ESO Comprehensive Stroke Center, Croatia.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2021.106767'] 1513,34216862,Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.,"OBJECTIVES Acute pain management in patients with opioid use disorder who are maintained on methadone presents unique challenges due to high levels of opioid tolerance in this population. This randomized controlled study assessed the analgesic and abuse liability effects of escalating doses of acute intravenous (IV) hydromorphone versus placebo utilizing a validated experimental pain paradigm, quantitative sensory testing (QST). METHODS Individuals (N = 8) without chronic pain were maintained on 80-100 mg/day of oral methadone. Participants received four IV, escalating/incremental doses of hydromorphone over 270 min (32 mg total) or four placebo doses within a session test day. Test sessions were scheduled at least one week apart. QST and abuse liability measures were administered at baseline and after each injection. RESULTS No significant differences between the hydromorphone and placebo control conditions on analgesic indices for any QST outcomes were detected. Similarly, no differences on safety or abuse liability indices were detected despite the high doses of hydromorphone utilized. Few adverse events were detected, and those reported were mild in severity. CONCLUSIONS The findings demonstrate that methadone-maintained individuals are highly insensitive to the analgesic effects of high-dose IV hydromorphone and may require very high doses of opioids, more efficacious opioids, or combined non-opioid analgesic strategies to achieve adequate analgesia.",2021,No significant differences between the hydromorphone and placebo control conditions on analgesic indices for any QST outcomes were detected.,"['Individuals (N = 8) without chronic pain', 'patients with opioid use disorder who are maintained on']","['methadone', 'oral methadone', 'Methadone', 'hydromorphone', 'acute intravenous (IV) hydromorphone versus placebo', 'placebo']","['safety or abuse liability indices', 'analgesic and abuse liability effects', 'QST and abuse liability measures']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]","[{'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0012306', 'cui_str': 'Hydromorphone'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0430838', 'cui_str': 'Quantitative sensory test'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.186688,No significant differences between the hydromorphone and placebo control conditions on analgesic indices for any QST outcomes were detected.,"[{'ForeName': 'Gabrielle', 'Initials': 'G', 'LastName': 'Agin-Liebes', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry and Behavioral Sciences, 401 Parnassus Ave, San Francisco, CA, 94143, USA; Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, Ward 95, San Francisco, CA, 94110, USA. Electronic address: gabrielle.agin-liebes@ucsf.edu.'}, {'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'Huhn', 'Affiliation': 'Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'Strain', 'Affiliation': 'Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.'}, {'ForeName': 'George E', 'Initials': 'GE', 'LastName': 'Bigelow', 'Affiliation': 'Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Smith', 'Affiliation': 'Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'Edwards', 'Affiliation': ""Harvard Medical School, Brigham and Women's Hospital, Department of Anesthesiology, Perioperative, and Pain Medicine, 75 Francis St, Boston, MA, 02115, USA.""}, {'ForeName': 'Valerie A', 'Initials': 'VA', 'LastName': 'Gruber', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry and Behavioral Sciences, 401 Parnassus Ave, San Francisco, CA, 94143, USA; Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, Ward 95, San Francisco, CA, 94110, USA.'}, {'ForeName': 'D Andrew', 'Initials': 'DA', 'LastName': 'Tompkins', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry and Behavioral Sciences, 401 Parnassus Ave, San Francisco, CA, 94143, USA; Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, Ward 95, San Francisco, CA, 94110, USA. Electronic address: david.tompkins@ucsf.edu.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2021.108869'] 1514,34216838,Bone turnover marker responses to sleep restriction and weekend recovery sleep.,"BACKGROUND Prior data demonstrated three weeks of sleep restriction and concurrent circadian disruption uncoupled bone turnover markers (BTMs), indicating decreased bone formation and no change or increased bone resorption. The effect of insufficient sleep with or without ad libitum weekend recovery sleep on BTMs is unknown. METHODS BTMs were measured in stored serum from 20 healthy adults randomized to one of three study groups consisting of a control group (N = 3 men; 9 h/night) or one of two nocturnal sleep restriction groups in an inpatient laboratory environment. One Sleep Restriction group (""SR""; N = 9; 4 women) had 5 h sleep opportunity per night for nine nights. The other sleep restriction group had an opportunity for ad libitum Weekend Recovery sleep (""WR""; N = 8; 4 women) after four nights of 5 h sleep opportunity per night. Food intake was energy balanced at baseline and ad libitum thereafter. Fasted morning BTM levels and hourly 24 h melatonin levels were obtained on study days 3 (baseline), 5 (after 1 night of sleep restriction for WR and SR), and 11 (after a sleep restricted workweek with weekend recovery sleep in WR or 7 nights of sleep restriction in SR). Linear mixed-effects modeling was used to examine the effect of study duration (e.g., change over time), study condition, age, and sex on BTMs. Pearson correlations were used to determine associations between changes in BTMs and changes in weight and morning circadian misalignment (i.e., duration of high melatonin levels after wake time). RESULTS There was no significant difference between the three study groups in change over time (p ≥ 0.4 for interaction between assigned group and time for all BTMs), adjusted for age and sex. There was no significant change in N-terminal propeptide of procollagen type I (P1NP), osteocalcin, or C-telopeptide of type I collagen (CTX) from baseline to day 11 (all p ≥ 0.3). In women <25 years old, there was a non-significant decline in P1NP from day 3 to day 5 (= -15.74 ± 7.80 ng/mL; p = 0.06). Change in weight and morning circadian misalignment from baseline to day 11 were correlated with statistically non-significant changes in BTMs (all p ≤ 0.05). CONCLUSION In this small secondary analysis, we showed that nine nights of prescribed sleep restriction with or without weekend recovery sleep and ad libitum food intake did not alter BTMs. It is possible that age, sex, weight change and morning circadian misalignment modify the effects of sleep restriction on bone metabolism.",2021,There was no significant change in N-terminal propeptide of procollagen type,['20 healthy adults'],['control group (N\u202f=\u202f3 men; 9\u202fh/night) or one of two nocturnal sleep restriction groups in an inpatient laboratory environment'],"['I (P1NP), osteocalcin, or C-telopeptide of type', 'N-terminal propeptide of procollagen type', 'Change in weight and morning circadian misalignment', 'BTMs', 'bone resorption', 'BTMs and changes in weight and morning circadian misalignment (i.e., duration of high melatonin levels', 'Fasted morning BTM levels and hourly 24\u202fh melatonin levels']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0029419', 'cui_str': 'Osteocalcin'}, {'cui': 'C0631180', 'cui_str': 'C-telopeptide'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0033235', 'cui_str': 'Procollagen'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C1275957', 'cui_str': 'Misalignment'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0558292', 'cui_str': 'Hourly'}]",20.0,0.0695278,There was no significant change in N-terminal propeptide of procollagen type,"[{'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Depner', 'Affiliation': 'Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, USA; Department of Health and Kinesiology, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Rice', 'Affiliation': 'Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado, Aurora, CO, USA.'}, {'ForeName': 'Emma J', 'Initials': 'EJ', 'LastName': 'Tussey', 'Affiliation': 'Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Eckel', 'Affiliation': 'Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Bryan C', 'Initials': 'BC', 'LastName': 'Bergman', 'Affiliation': 'Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Janine A', 'Initials': 'JA', 'LastName': 'Higgins', 'Affiliation': 'Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Melanson', 'Affiliation': 'Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Division of Geriatric Medicine, University of Colorado Anschutz Medical Campus, and Eastern Colorado VA Geriatric, Research, Education, and Clinical Center (GRECC), Aurora, CO, USA.'}, {'ForeName': 'Wendy M', 'Initials': 'WM', 'LastName': 'Kohrt', 'Affiliation': 'Division of Geriatric Medicine, University of Colorado Anschutz Medical Campus, and Eastern Colorado VA Geriatric, Research, Education, and Clinical Center (GRECC), Aurora, CO, USA.'}, {'ForeName': 'Kenneth P', 'Initials': 'KP', 'LastName': 'Wright', 'Affiliation': 'Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, USA; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Swanson', 'Affiliation': 'Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: Christine.Swanson@CUAnschutz.edu.'}]",Bone,['10.1016/j.bone.2021.116096'] 1515,34219679,Non-invasive electrical brain stimulation for vision restoration after stroke: An exploratory randomized trial (REVIS).,"BACKGROUND Occipital strokes often cause permanent homonymous hemianopia leading to significant disability. In previous studies, non-invasive electrical brain stimulation (NIBS) has improved vision after optic nerve damage and in combination with training after stroke. OBJECTIVE We explored different NIBS modalities for rehabilitation of hemianopia after chronic stroke. METHODS In a randomized, double-blinded, sham-controlled, three-armed trial, altogether 56 patients with homonymous hemianopia were recruited. The three experiments were: i) repetitive transorbital alternating current stimulation (rtACS, n = 8) vs. rtACS with prior cathodal transcranial direct current stimulation over the intact visual cortex (tDCS/rtACS, n = 8) vs. sham (n = 8); ii) rtACS (n = 9) vs. sham (n = 9); and iii) tDCS of the visual cortex (n = 7) vs. sham (n = 7). Visual functions were evaluated before and after the intervention, and after eight weeks follow-up. The primary outcome was change in visual field assessed by high-resolution and standard perimetries. The individual modalities were compared within each experimental arm. RESULTS Primary outcomes in Experiments 1 and 2 were negative. Only significant between-group change was observed in Experiment 3, where tDCS increased visual field of the contralesional eye compared to sham. tDCS/rtACS improved dynamic vision, reading, and visual field of the contralesional eye, but was not superior to other groups. rtACS alone increased foveal sensitivity, but was otherwise ineffective. All trial-related procedures were tolerated well. CONCLUSIONS This exploratory trial showed safety but no main effect of NIBS on vision restoration after stroke. However, tDCS and combined tDCS/rtACS induced improvements in visually guided performance that need to be confirmed in larger-sample trials.NCT01418820 (clinicaltrials.gov).",2021,"Only significant between-group change was observed in Experiment 3, where tDCS increased visual field of the contralesional eye compared to sham.","['vision restoration after stroke', '56 patients with homonymous hemianopia were recruited']","['repetitive transorbital alternating current stimulation (rtACS, n\u200a=\u200a8) vs. rtACS with prior cathodal transcranial direct current stimulation over the intact visual cortex (tDCS/rtACS, n\u200a=\u200a8) vs. sham (n\u200a=\u200a8); ii) rtACS (n\u200a=\u200a9) vs. sham (n\u200a=\u200a9); and iii) tDCS of the visual cortex', 'invasive electrical brain stimulation (NIBS', 'NIBS', 'invasive electrical brain stimulation', 'tDCS and combined tDCS/rtACS', 'tDCS/rtACS', 'rtACS']","['change in visual field assessed by high-resolution and standard perimetries', 'vision restoration', 'Visual functions', 'dynamic vision, reading, and visual field of the contralesional eye', 'foveal sensitivity', 'tDCS increased visual field of the contralesional eye']","[{'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0271202', 'cui_str': 'Homonymous hemianopia'}]","[{'cui': 'C0442367', 'cui_str': 'Transorbital approach'}, {'cui': 'C0442830', 'cui_str': 'Alternating current'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0042817', 'cui_str': 'Visual Cortex'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0302825', 'cui_str': 'Electrical Stimulation of the Brain'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0031061', 'cui_str': 'Perimetry'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C1719911', 'cui_str': 'Foveal sensitivity'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",56.0,0.294573,"Only significant between-group change was observed in Experiment 3, where tDCS increased visual field of the contralesional eye compared to sham.","[{'ForeName': 'Silja', 'Initials': 'S', 'LastName': 'Räty', 'Affiliation': 'HUS Neurocenter, Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Borrmann', 'Affiliation': 'Institute of Medical Psychology, Otto-v.-Guericke University of Magdeburg Medical Faculty, Magdeburg, Germany.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Granata', 'Affiliation': 'Institute of Neurology, Policlinic A. Gemelli Foundation-IRCCS, Rome, Italy.'}, {'ForeName': 'Lizbeth', 'Initials': 'L', 'LastName': 'Cárdenas-Morales', 'Affiliation': 'Institute of Medical Psychology, Otto-v.-Guericke University of Magdeburg Medical Faculty, Magdeburg, Germany.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Schoenfeld', 'Affiliation': 'Clinic of Neurorehabilitation, Kliniken Schmieder, Heidelberg, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sailer', 'Affiliation': 'MEDIAN Klinik NRZ Magdeburg, An-Institut für Neurorehabilitation, Otto-von-Guericke University, Magdeburg, Germany.'}, {'ForeName': 'Katri', 'Initials': 'K', 'LastName': 'Silvennoinen', 'Affiliation': 'HUS Neurocenter, Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Juha', 'Initials': 'J', 'LastName': 'Holopainen', 'Affiliation': 'Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'De Rossi', 'Affiliation': 'National Centre of Services and Research for the Prevention of Blindness and Rehabilitation of Low Vision Patients - IAPB, Italian Branch, Rome, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Antal', 'Affiliation': 'HUS Neurocenter, Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Paolo M', 'Initials': 'PM', 'LastName': 'Rossini', 'Affiliation': 'Department Neuroscience & Neurorehabilitation, IRCCS San Raffaele-Pisana, Rome, Italy.'}, {'ForeName': 'Turgut', 'Initials': 'T', 'LastName': 'Tatlisumak', 'Affiliation': 'Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Bernhard A', 'Initials': 'BA', 'LastName': 'Sabel', 'Affiliation': 'Institute of Medical Psychology, Otto-v.-Guericke University of Magdeburg Medical Faculty, Magdeburg, Germany.'}]",Restorative neurology and neuroscience,['10.3233/RNN-211198'] 1516,34218071,Effect of educational intervention on clinical reasoning skills in nursing: A quasi-experimental study.,"This study evaluated the effect of an educational intervention based on virtual clinical simulation and problem-based learning using a mobile application in a clinical nursing education context as a tool to improve clinical reasoning skills of students on the second year of nursing graduation. A prospective quasi-experimental study was conducted in the year 2018, and assessments were performed before and after the educational intervention. A random convenience sample (n = 32) of nursing students in the second year of a public university in Brazil was divided equally into experimental and control groups. The experimental group underwent educational intervention about clinical reasoning skills and measured the quality of the Diagnostician Nurse software by LORI 2.0 instrument. The control group experienced the conventional class on clinical reasoning skills. Four clinical cases were used to assess reasoning skills before and after the educational intervention. The data were analyzed using descriptive and inferential statistics. The experimental group showed a statistically significant difference regarding the prioritization of nursing diagnoses (p = 0.014) and a higher final score. There was a statistically significant difference in performance between the pre- and post-test in the grades of the students who participated in the intervention (p = 0.003). The control group also showed statistical significance in the score attributed to the clinical reasoning process (p = 0.015). In addition, the Diagnostician Nurse software had excellent usability and quality evaluations (SUS 87.81 and LORI 4.66, respectively). It is concluded that educational intervention based on virtual clinical simulation and learning problems using the Diagnostician Nurse software is effective as a tool to improve clinical reasoning skills and can support early detection of patients. The educational intervention developed was of high quality and attractive and improved students' motivation for the teaching-learning process.",2021,The experimental group showed a statistically significant difference regarding the prioritization of nursing diagnoses (p = 0.014) and a higher final score.,"['students on the second year of nursing graduation', 'nursing', 'A random convenience sample (n\xa0=\xa032) of nursing students in the second year of a public university in Brazil']","['educational intervention based on virtual clinical simulation and problem-based learning using a mobile application', 'educational intervention about clinical reasoning skills and measured the quality of the Diagnostician Nurse software by LORI 2.0 instrument', 'educational intervention', 'conventional class on clinical reasoning skills']","['excellent usability and quality evaluations', 'performance', 'prioritization of nursing diagnoses', ""high quality and attractive and improved students' motivation"", 'clinical reasoning skills']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0037585', 'cui_str': 'Software'}, {'cui': 'C0326002', 'cui_str': 'Lory'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0028684', 'cui_str': 'Nursing diagnosis'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}]",,0.0132848,The experimental group showed a statistically significant difference regarding the prioritization of nursing diagnoses (p = 0.014) and a higher final score.,"[{'ForeName': 'Jéssica Dantas de Sá', 'Initials': 'JDS', 'LastName': 'Tinôco', 'Affiliation': 'Nursing Department, State University of Rio Grande do Norte, Caicó, Rio Grande do Norte, Brazil. Electronic address: jessicadantas@uern.br.'}, {'ForeName': 'Marcelly Santos', 'Initials': 'MS', 'LastName': 'Cossi', 'Affiliation': 'Nursing Department, State University of Rio Grande do Norte, Caicó, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Maria Isabel da Conceição Dias', 'Initials': 'MIDCD', 'LastName': 'Fernandes', 'Affiliation': 'Nursing Department, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Anderson Cruz', 'Initials': 'AC', 'LastName': 'Paiva', 'Affiliation': 'Metrópole Digital Institute - IMD, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Marcos Venícios de Oliveira', 'Initials': 'MVO', 'LastName': 'Lopes', 'Affiliation': 'Department of Nursing and in the Post-graduate Program in Nursing, Federal University of Ceará, Fortaleza, Ceará, Brazil.'}, {'ForeName': 'Ana Luisa Brandão de Carvalho', 'Initials': 'ALBC', 'LastName': 'Lira', 'Affiliation': 'Nursing Department and in the Post-Graduate Program in Nursing, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.'}]",Nurse education today,['10.1016/j.nedt.2021.105027'] 1517,34218069,"Use of an interactive multimedia e-book to improve nursing students'' sexual harassment prevention knowledge, prevention strategies, coping behavior, and learning motivation: A randomized controlled study.","BACKGROUND Nursing essentially involves working closely with patients both physically and psychologically. Nurses, particularly inexperienced nursing students, are often at great risk of sexual harassment. OBJECTIVES To evaluate the effects of a clinical-based sexual harassment prevention e-book on nursing students' knowledge, prevention strategies, coping behaviors, and learning motivation. DESIGN A randomized, controlled, experimental study. SETTING Nursing Department at a private university in Taiwan. PARTICIPANTS Senior nursing students who had finished the required professional internship or were undergoing community nursing or psychiatric nursing internship. METHODS Participants were randomly allocated to intervention (e-book, n = 33) and control (video and brochure, n = 33) groups. They were asked to complete a structured questionnaire before, after, and 2 weeks after the intervention to evaluate their sexual harassment knowledge, prevention strategies, coping behaviors, and learning motivation. RESULTS In the posttest, the e-book group scored significantly higher in the sexual harassment prevention knowledge (p < .05), sexual harassment prevention strategy (p < .01), and ARCS motivation (p < .001) subscales than the control group, but not in the coping behavior subscale. In terms of group and time effects, knowledge, coping behavior, prevention strategy, and motivation scores were all significantly different in the first posttest (p < .001). In the second posttest, coping behavior and ARCS motivation scores remained significantly different (p < .01). CONCLUSION The interactive multimedia e-book effectively improved the sexual harassment prevention knowledge and competence of nursing students. This method can be employed as a supplementary material in nursing education, internship guidance, and nursing on-the-job education.",2021,"In the posttest, the e-book group scored significantly higher in the sexual harassment prevention knowledge (p < .05), sexual harassment prevention strategy (p < .01), and ARCS motivation (p < .001) subscales than the control group, but not in the coping behavior subscale.","['Nursing Department at a private university in Taiwan', 'Senior nursing students who had finished the required professional internship or were undergoing community nursing or psychiatric nursing internship', 'Participants', 'nursing students']","['clinical-based sexual harassment prevention e-book', 'interactive multimedia e-book']","['time effects, knowledge, coping behavior, prevention strategy, and motivation scores', 'coping behavior subscale', 'coping behavior and ARCS motivation scores', 'sexual harassment prevention knowledge', 'ARCS motivation', 'sexual harassment prevention strategy']","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C1706059', 'cui_str': 'Finish'}, {'cui': 'C0237690', 'cui_str': 'Internship'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0033870', 'cui_str': 'Nursing, Psychiatric'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0162790', 'cui_str': 'Sexual harassment'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0006002', 'cui_str': 'Book'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1859722', 'cui_str': 'Arthrogryposis, renal dysfunction, and cholestasis 1'}, {'cui': 'C0162790', 'cui_str': 'Sexual harassment'}, {'cui': 'C0001857', 'cui_str': 'AIDS related complex'}]",33.0,0.0154297,"In the posttest, the e-book group scored significantly higher in the sexual harassment prevention knowledge (p < .05), sexual harassment prevention strategy (p < .01), and ARCS motivation (p < .001) subscales than the control group, but not in the coping behavior subscale.","[{'ForeName': 'Ting-Shan', 'Initials': 'TS', 'LastName': 'Chang', 'Affiliation': 'Department of Public Health, China Medical University, Taichung 406040, Taiwan.'}, {'ForeName': 'Yu-Kuei', 'Initials': 'YK', 'LastName': 'Teng', 'Affiliation': 'School of Nursing, College of Health Care, China Medical University, Taichung 406040, Taiwan; Department of Nursing, China Medical University Hospital, Taichung 404332, Taiwan.'}, {'ForeName': 'Shao-Yun', 'Initials': 'SY', 'LastName': 'Chien', 'Affiliation': 'School of Nursing, University of Washington, Seattle, WA 98195, USA.'}, {'ForeName': 'Ya-Ling', 'Initials': 'YL', 'LastName': 'Tzeng', 'Affiliation': 'School of Nursing, College of Health Care, China Medical University, Taichung 406040, Taiwan; Department of Nursing, China Medical University Hospital, Taichung 404332, Taiwan. Electronic address: tyaling@mail.cmu.edu.tw.'}]",Nurse education today,['10.1016/j.nedt.2021.104883'] 1518,34225174,Can improvements in sleep quality positively affect serum adiponectin-levels in patients with obstructive sleep apnea?,"BACKGROUND Assess if changes in sleep quality (Sleep Quality Index, SQI) based on cardiopulmonary coupling-analysis (CPC) impacts serum adiponectin-levels in patients with cardiovascular disease (CVD). METHODS Secondary analysis of electrocardiogram (ECG) data from the Heart Biomarker Evaluation in Apnea Treatment study (HeartBEAT), a multicenter, controlled trial in patients with CVD and moderate-severe sleep apnea, randomly assigned to intervention of Continuous Positive Airway Pressure (CPAP), Nocturnal Supplemental Oxygen (NSO) or Healthy Lifestyle and Sleep Hygiene Education (HLSE; control group). Participants with good-quality ECG-signal (n = 241) were included. RESULTS Improving CPC-sleep quality was associated with net average improvements in serum adiponectin-levels 2.69 μg/ml (p = 0.005) irrespective of therapy initiated. After controlling for confounders, a unit increase in SQI was associated with increase in serum adiponectin-levels 0.071 μg/ml (p = 0.012) and decrease in insulin-levels 0.197 μIU/ml (p = 0.0018). Similarly, a percentage point increase in sleep apnea indicator (SAI) was associated with decrease in serum adiponectin-levels of 0.071 μg/ml (p = 0.017) and increase in insulin-levels of 0.218 μIU/ml (p = 0.020). A percentage point increase in CPC-sleep fragmentation (eLFC BB ) had a predicted increase in glucose-levels 0.371 mg/dl (p = 0.009) and insulin-levels 0.284 μIU/ml (p = 0.010). In patients receiving CPAP-therapy, a difference in serum adiponictin levels of 3.82 μg/ml (p = 0.025) is observed comparing patients in which SQI-improved to patients that SQI-declined during the study period. The difference is mostly due to a decrease in serum adiponectin levels in patients that decline in SQI (-3.20 μg/ml). CONCLUSION Improvements in sleep quality were associated with higher serum adiponectin-levels, and improved measures of glycemic metabolism which may have beneficial effects on metabolic syndrome and cardiovascular health. CLINICAL TRIAL REGISTRATION NAME AND NUMBER The Heart Biomarker Evaluation in Apnea Treatment (HeartBEAT) study is registered at https://clinicaltrials.gov/ct2/show/NCT01086800.",2021,A percentage point increase in CPC-sleep fragmentation (eLFC BB ) had a predicted increase in glucose-levels 0.371 ,"['Participants with good-quality ECG-signal (n\xa0=\xa0241) were included', 'patients with obstructive sleep apnea', 'patients with cardiovascular disease (CVD', 'patients with CVD and moderate-severe sleep apnea']","['cardiopulmonary coupling-analysis (CPC', 'intervention of Continuous Positive Airway Pressure (CPAP), Nocturnal Supplemental Oxygen (NSO) or Healthy Lifestyle and Sleep Hygiene Education (HLSE; control group']","['CPC-sleep fragmentation (eLFC BB ', 'insulin-levels', 'glucose-levels 0.371', 'SQI', 'insulin-levels 0.197 μIU', 'serum adiponectin levels', 'sleep quality (Sleep Quality Index, SQI', 'serum adiponictin levels', 'sleep quality', 'CPC-sleep quality', 'serum adiponectin-levels', 'sleep apnea indicator (SAI']","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0037315', 'cui_str': 'Sleep apnea'}]","[{'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C4277672', 'cui_str': 'Good Sleep Habits'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0751507', 'cui_str': 'Sleep Fragmentation'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C0001910', 'cui_str': 'Albanian language'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037315', 'cui_str': 'Sleep apnea'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}]",241.0,0.0377831,A percentage point increase in CPC-sleep fragmentation (eLFC BB ) had a predicted increase in glucose-levels 0.371 ,"[{'ForeName': 'Solveig', 'Initials': 'S', 'LastName': 'Magnusdottir', 'Affiliation': 'MyCardio LLC, SleepImage®, 3003 E 3rd Avenue, Denver, CO 80206, USA. Electronic address: Solveig.magnusdottir@sleepimage.com.'}, {'ForeName': 'Robert Joseph', 'Initials': 'RJ', 'LastName': 'Thomas', 'Affiliation': 'Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. Electronic address: rthomas1@bidmc.harvard.edu.'}, {'ForeName': 'Hugi', 'Initials': 'H', 'LastName': 'Hilmisson', 'Affiliation': 'MyCardio LLC, SleepImage®, 3003 E 3rd Avenue, Denver, CO 80206, USA. Electronic address: hugi.hilmisson@sleepimage.com.'}]",Sleep medicine,['10.1016/j.sleep.2021.05.032'] 1519,34229042,Video game and motor-cognitive dual-task training could be suitable treatments to improve dual-task interference in older adults.,"The objective of study was to investigate the effects of video game training in comparison with traditional motor-cognitive dual-task training on dual-task interference in older adults. Sixty older adults were allocated to the video game (intervention group) or the motor-cognitive dual-task training (control group). The outcome measures were dual-task cost (DTC) of linear metrics (Standard deviation (SD) of amplitude and velocity) and DTC of nonlinear metrics (approximate entropy, Lyapunov and correlation dimension) acquired from postural sway time series from both the mediolateral (ML) and anteroposterior (AP) directions. The results revealed in both groups, dual-task cost of SD of amplitude and velocity as well as Lyapunov were significantly decreased in post-training and follow-up compared with pre-training (p < 0.017), while there was no significant difference between the groups. Video game and motor-cognitive dual-task training could be recommended as suitable treatments to improve dual-task interference.",2021,"The results revealed in both groups, dual-task cost of SD of amplitude and velocity as well as Lyapunov were significantly decreased in post-training and follow-up compared with pre-training (p<0.017), while there was no significant difference between the groups.","['Sixty older adults', 'older adults']","['video game (intervention group) or the motor-cognitive dual-task training (control group', 'Video game and motor-cognitive dual-task training', 'traditional motor-cognitive dual-task training', 'video game training']","['dual-task cost of SD of amplitude and velocity as well as Lyapunov', 'dual-task cost (DTC) of linear metrics (Standard deviation (SD) of amplitude and velocity) and DTC of nonlinear metrics (approximate entropy, Lyapunov and correlation dimension) acquired from postural sway time series from both the mediolateral (ML) and anteroposterior (AP) directions', 'dual-task interference']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0376522', 'cui_str': 'Entropy'}, {'cui': 'C0010101', 'cui_str': 'Correlation Studies'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0439661', 'cui_str': 'Acquired'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205549', 'cui_str': 'Series'}, {'cui': 'C0441992', 'cui_str': 'Mediolateral'}, {'cui': 'C0439755', 'cui_str': 'Directions'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}]",60.0,0.0126345,"The results revealed in both groups, dual-task cost of SD of amplitude and velocity as well as Lyapunov were significantly decreased in post-training and follow-up compared with pre-training (p<0.017), while there was no significant difference between the groups.","[{'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Bagheri', 'Affiliation': 'Physical Therapy Department, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Roya', 'Initials': 'R', 'LastName': 'Khanmohammadi', 'Affiliation': 'Physical Therapy Department, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: rkhanmohammadi@Sina.tums.ac.ir.'}, {'ForeName': 'Gholamreza', 'Initials': 'G', 'LastName': 'Olyaei', 'Affiliation': 'Physical Therapy Department, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Talebian', 'Affiliation': 'Physical Therapy Department, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Reza Hadian', 'Affiliation': 'Physical Therapy Department, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Marziyeh', 'Initials': 'M', 'LastName': 'Najafi', 'Affiliation': 'Physical Therapy Department, Tehran University of Medical Sciences, Tehran, Iran.'}]",Neuroscience letters,['10.1016/j.neulet.2021.136099'] 1520,34231375,Impact of high-salt versus low-salt intake on the response of sympathetic baroreflex sensitivity to orthostasis in women with a history of normal pregnancy.,"Previous studies have demonstrated that sympathetic baroreflex sensitivity (BRS) increases during orthostatic stress in humans. We recently showed that dietary salt intake affects sympathetic neural control in healthy premenopausal women. This study aimed to determine whether salt loading versus salt reduction would impact sympathetic BRS during orthostasis in premenopausal women with a history of normal pregnancy. Nine healthy women [42 ± 3 (SD) yr] were given a standardized isocaloric high-salt (250 mEq sodium/day) or low-salt (50 mEq sodium/day) diet for 1 wk each (∼2 mo apart with the order randomized), whereas water intake was ad libitum. Laboratory testing was performed following each high- and low-salt period in the midluteal phase of the menstrual cycle. Hemodynamics and muscle sympathetic nerve activity (MSNA) were measured at baseline (supine; 2 min) and during a graded head-up tilt (30° for 5 min and 60° for 20 min). Sympathetic BRS was assessed during baseline and head-up tilt. Hemodynamics were not different between salt conditions during baseline or tilt. Both supine and upright MSNA indices were lower in high salt than low salt (all P < 0.05), however, there was no interaction effect ( P = 0.507-0.996). On moving from supine to upright, sympathetic BRS remained unchanged in high salt but increased in low salt ( P = 0.028 for interaction). Thus, salt loading diminishes the responsiveness of sympathetic BRS during orthostasis compared with salt reduction in healthy premenopausal women with prior normal pregnancy. Whether this is one underlying mechanism for salt-induced development of hypertension during ambulation remains to be determined.",2021,"Both supine and upright MSNA indices were lower in high salt than low salt (all P<0.05); however, there was no interaction effect (P=0.507-0.996).","['healthy premenopausal women', 'premenopausal women with a history of normal pregnancy', 'humans', 'Nine healthy women [42±3 (SD) yr', 'women with a history of normal pregnancy', 'healthy premenopausal women with prior normal pregnancy']","['high salt versus low salt intake', 'salt loading versus salt reduction', 'standardized isocaloric high salt (250 mEq sodium/day) or low salt (50 mEq sodium/day) diet', 'dietary salt intake']","['Hemodynamics and muscle sympathetic nerve activity (MSNA', 'Sympathetic BRS']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0232989', 'cui_str': 'Normal pregnancy'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0332152', 'cui_str': 'Before'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0439152', 'cui_str': 'mEq'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0425431', 'cui_str': 'Dietary salt intake'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0459521', 'cui_str': 'Sympathetic nerve structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0206162', 'cui_str': 'Baroreceptor reflex'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",9.0,0.0210635,"Both supine and upright MSNA indices were lower in high salt than low salt (all P<0.05); however, there was no interaction effect (P=0.507-0.996).","[{'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Takeda', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}, {'ForeName': 'Abigail S L', 'Initials': 'ASL', 'LastName': 'Stickford', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}, {'ForeName': 'Stuart A', 'Initials': 'SA', 'LastName': 'Best', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}, {'ForeName': 'Jeung-Ki', 'Initials': 'JK', 'LastName': 'Yoo', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Hissen', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}, {'ForeName': 'Yu-Lun', 'Initials': 'YL', 'LastName': 'Liu', 'Affiliation': 'The University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Fu', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00069.2021'] 1521,34237250,"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.","BACKGROUND Patients with radioiodine-refractory differentiated thyroid cancer (DTC) previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy have aggressive disease and no available standard of care. The aim of this study was to evaluate the tyrosine kinase inhibitor cabozantinib in this patient population. METHODS In this global, randomised, double-blind, placebo-controlled, phase 3 trial, patients aged 16 years and older with radioiodine-refractory DTC (papillary or follicular and their variants) and an Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (2:1) to oral cabozantinib (60 mg once daily) or matching placebo, stratified by previous lenvatinib treatment and age. The randomisation scheme used stratified permuted blocks of block size six and an interactive voice-web response system; both patients and investigators were masked to study treatment. Patients must have received previous lenvatinib or sorafenib and progressed during or after treatment with up to two VEGFR tyrosine kinase inhibitors. Patients receiving placebo could cross over to open-label cabozantinib on disease progression confirmed by blinded independent radiology committee (BIRC). The primary endpoints were objective response rate (confirmed response per Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1) in the first 100 randomly assigned patients (objective response rate intention-to-treat [OITT] population) and progression-free survival (time to earlier of disease progression per RECIST version 1.1 or death) in all patients (intention-to-treat [ITT] population), both assessed by BIRC. This report presents the primary objective response rate analysis and a concurrent preplanned interim progression-free survival analysis. The study is registered with ClinicalTrials.gov, NCT03690388, and is no longer enrolling patients. FINDINGS Between Feb 27, 2019, and Aug 18, 2020, 227 patients were assessed for eligibility, of whom 187 were enrolled from 164 clinics in 25 countries and randomly assigned to cabozantinib (n=125) or placebo (n=62). At data cutoff (Aug 19, 2020) for the primary objective response rate and interim progression-free survival analyses, median follow-up was 6·2 months (IQR 3·4-9·2) for the ITT population and 8·9 months (7·1-10·5) for the OITT population. An objective response in the OITT population was achieved in ten (15%; 99% CI 5·8-29·3) of 67 patients in the cabozantinib group versus 0 (0%; 0-14·8) of 33 in the placebo (p=0·028) but did not meet the prespecified significance level (α=0·01). At interim analysis, the primary endpoint of progression-free survival was met in the ITT population; cabozantinib showed significant improvement in progression-free survival over placebo: median not reached (96% CI 5·7-not estimable [NE]) versus 1·9 months (1·8-3·6); hazard ratio 0·22 (96% CI 0·13-0·36; p<0·0001). Grade 3 or 4 adverse events occurred in 71 (57%) of 125 patients receiving cabozantinib and 16 (26%) of 62 receiving placebo, the most frequent of which were palmar-plantar erythrodysaesthesia (13 [10%] vs 0), hypertension (11 [9%] vs 2 [3%]), and fatigue (ten [8%] vs 0). Serious treatment-related adverse events occurred in 20 (16%) of 125 patients in the cabozantinib group and one (2%) of 62 in the placebo group. There were no treatment-related deaths. INTERPRETATION Our results show that cabozantinib significantly prolongs progression-free survival and might provide a new treatment option for patients with radioiodine-refractory DTC who have no available standard of care. FUNDING Exelixis.",2021,"There were no treatment-related deaths. ","['patients with radioiodine-refractory DTC who have no available standard of care', 'patients aged 16 years and older with radioiodine-refractory DTC (papillary or follicular and their variants) and an Eastern Cooperative Oncology Group performance status of 0 or 1', 'refractory differentiated thyroid cancer (COSMIC-311', 'Between Feb 27, 2019, and Aug 18, 2020, 227 patients were assessed for eligibility, of whom 187 were enrolled from 164 clinics in 25 countries and randomly assigned to cabozantinib (n=125) or', 'patient population', 'Patients with radioiodine-refractory differentiated thyroid cancer (DTC']","['lenvatinib or sorafenib', 'radioiodine', 'oral cabozantinib (60 mg once daily) or matching placebo', 'vascular endothelial growth factor receptor (VEGFR)-targeted therapy', 'placebo']","['Grade 3 or 4 adverse events', 'objective response rate intention-to-treat [OITT] population) and progression-free survival (time to earlier of disease progression per RECIST version 1.1 or death', 'response rate and interim progression-free survival analyses', 'hazard ratio 0·22', 'progression-free survival', 'palmar-plantar erythrodysaesthesia', 'adverse events', 'fatigue', 'objective response rate (confirmed response per Response Evaluation Criteria in Solid Tumours [RECIST', 'hypertension']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2828294', 'cui_str': 'iodide ion I-131'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C4722172', 'cui_str': 'Primary differentiated carcinoma of thyroid gland'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205312', 'cui_str': 'Papillary'}, {'cui': 'C0439682', 'cui_str': 'Follicular'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0056409', 'cui_str': 'Cosmic composite resin'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C4517618', 'cui_str': '187'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205615', 'cui_str': 'Well differentiated'}, {'cui': 'C0007115', 'cui_str': 'Malignant tumor of thyroid gland'}]","[{'cui': 'C2986924', 'cui_str': 'lenvatinib'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C2828294', 'cui_str': 'iodide ion I-131'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0148199', 'cui_str': 'Vascular Endothelial Growth Factor Receptor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C4517491', 'cui_str': '1.1'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1184147', 'cui_str': 'Palmar'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",227.0,0.768166,"There were no treatment-related deaths. ","[{'ForeName': 'Marcia S', 'Initials': 'MS', 'LastName': 'Brose', 'Affiliation': 'Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: marcia.brose@pennmedicine.upenn.edu.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Robinson', 'Affiliation': 'Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Steven I', 'Initials': 'SI', 'LastName': 'Sherman', 'Affiliation': 'Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Jolanta', 'Initials': 'J', 'LastName': 'Krajewska', 'Affiliation': 'Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.'}, {'ForeName': 'Chia-Chi', 'Initials': 'CC', 'LastName': 'Lin', 'Affiliation': 'Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Vaisman', 'Affiliation': 'Instituto Nacional de Câncer, Rio de Janeiro, Brazil.'}, {'ForeName': 'Ana O', 'Initials': 'AO', 'LastName': 'Hoff', 'Affiliation': 'Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Hitre', 'Affiliation': 'Department of Medical Oncology and Clinical Pharmacology ""B"", Országos Onkológiai Intézet, Budapest, Hungary.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Bowles', 'Affiliation': 'Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Hernando', 'Affiliation': ""Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Faoro', 'Affiliation': 'Exelixis, Alameda, CA, USA.'}, {'ForeName': 'Kamalika', 'Initials': 'K', 'LastName': 'Banerjee', 'Affiliation': 'Exelixis, Alameda, CA, USA.'}, {'ForeName': 'Jennifer W', 'Initials': 'JW', 'LastName': 'Oliver', 'Affiliation': 'Exelixis, Alameda, CA, USA.'}, {'ForeName': 'Bhumsuk', 'Initials': 'B', 'LastName': 'Keam', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.'}, {'ForeName': 'Jaume', 'Initials': 'J', 'LastName': 'Capdevila', 'Affiliation': ""Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.""}]",The Lancet. Oncology,['10.1016/S1470-2045(21)00332-6'] 1522,34243101,"Beneficial effects of a nano formulation of pomegranate seed oil, GranaGard, on the cognitive function of multiple sclerosis patients.","BACKGROUND Though often neglected, cognitive impairment is a common feature of multiple sclerosis in 43-70% of patients. None of the novel MS treatment seems to substantially affect or restore cognitive disability in MS. GranaGard (Granalix Bio Technologies LTD) is a food supplement shown to prevent neuronal death in several animal models of neurological diseases. Capsules of GranaGard comprise a self-emulsion nano formulation of pomegranate seed oil (PSO). This oil contains 80-90% of Punicic Acid (PA), one of the strongest natural antioxidants. In animal experiments, administration of GranaGard results in conjugation with linoleic acid (CLA), the main metabolite of PA, which is a well-known neuroprotective agent. AIMS To investigate whether GranaGard administration has an effect on the cognitive state of MS patients. METHODS This is a single center, randomized double blind clinical trial that started in May 2018. The study included 30 MS patients; half of them (Group-A) were given GranaGard for the first three months and then placebo pills containing soybean oil for additional three months. Patients in Group-B received placebo for the first three months, and GranaGard for the following three months. GranaGard was administrated in addition to their immunomodulatory MS-treatments. Subsequently, all patients received GranaGard for additional six months. Patients were required to visit the neurologist at baseline (inclusion, visit 1) and at 3 months after treatment-initiation at each cycle of the trial (visits 2 and 3). During the follow up visits, clinical and cognitive examinations were performed, including Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC: 25 ft walking test, 9 PEG hole test & PASAT). Cognitive tests included The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery: 1) Symbol Digit Modalities Test (SDMT); 2) California Verbal Learning Test - Second Edition (CVLT-II); 3) and Brief Visuospatial Memory Test - Revised (BVMT-R). Cognitive outcomes were normalized to the healthy population and expressed as z-scores, depended on age, gender and education. Short quality of life and fatigue questionnaires (SF-12, MFIS-5) were also provided by the participants. RESULTS No serious adverse effects, related to the product, were observed during the study period. All patients receiving GranaGard reported a ''positive'' effect in their ADL while using the product. While there were no significant differences in the clinical parameters of disability (EDSS scores) between the treatment groups, there was a trend of beneficial effect of GranaGard, on the verbal testing during the first 3-month period of treatment. The z score for CVLT-II, significantly increased (from 0.891 to 1.415, p = 0.012, Wilcoxon rank test) at 3-months in the group of patients who were treated with GranaGard, as compared to baseline. A similar (but not statistically significant) trend was seen also in the BVMTr testing during the same 3 months-period, whereas there was no change in the SDMT. The overall average z-score of all three cognitive functions was significantly improved in the three months of Granagard treatment (-0.0077 at 3 months vs 0.462 at baseline, p = 0.034, Wilcoxon rank test). During the same 3-months period there were no significant changes in the placebo-treated group. For the patients receiving GranaGard in the initial 3 months, the value of z score of CVLT-II remained high (z = 1.415) also at the following three months (while they received placebo), suggesting a longer lasting effect for at least 3 months after discontinuation of the drug. CONCLUSION This is the first study in which GranaGard, a brain targeted nano-formulation of PSO, was tested in humans. Our results in this small pilot, controlled trial provide indications that GranaGard administration to MS patients might improve/stabilize cognitive disability. Larger studies with longer duration, are needed to confirm these initial observations.",2021,"The overall average z-score of all three cognitive functions was significantly improved in the three months of Granagard treatment (-0.0077 at 3 months vs 0.462 at baseline, p = ","['multiple sclerosis patients', 'Multiple Sclerosis (BICAMS) battery']","['nano formulation of pomegranate seed oil, GranaGard', 'Punicic Acid (PA', 'GranaGard administration', 'linoleic acid (CLA', 'GranaGard (Granalix Bio Technologies LTD', 'Symbol Digit Modalities Test (SDMT', 'placebo', 'placebo pills containing soybean oil']","['BVMTr testing', 'Short quality of life and fatigue questionnaires (SF-12, MFIS-5', 'clinical parameters of disability (EDSS scores', 'stabilize cognitive disability', 'Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC: 25\xa0ft walking test, 9 PEG hole test & PASAT', 'Cognitive outcomes', 'restore cognitive disability', 'overall average z-score of all three cognitive functions', '2) California Verbal Learning Test - Second Edition (CVLT-II); 3) and Brief Visuospatial Memory Test - Revised (BVMT-R']","[{'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}]","[{'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C3256645', 'cui_str': 'POMEGRANATE SEED OIL'}, {'cui': 'C1956989', 'cui_str': 'punicic acid'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0023749', 'cui_str': 'Linoleic acid'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C1136140', 'cui_str': 'Long-Term Depression, Neurophysiologic'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0037732', 'cui_str': 'Soybean Oil'}]","[{'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0184512', 'cui_str': 'Stabilized'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0589055', 'cui_str': 'California verbal learning test'}, {'cui': 'C0441795', 'cui_str': 'Second edition'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}]",30.0,0.0784336,"The overall average z-score of all three cognitive functions was significantly improved in the three months of Granagard treatment (-0.0077 at 3 months vs 0.462 at baseline, p = ","[{'ForeName': 'Panayiota', 'Initials': 'P', 'LastName': 'Petrou', 'Affiliation': 'Multiple sclerosis Center and cell therapies Unit, Unit and Laboratory of Neuroimmunology and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Jerusalem.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Ginzberg', 'Affiliation': 'Multiple sclerosis Center and cell therapies Unit, Unit and Laboratory of Neuroimmunology and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Jerusalem.'}, {'ForeName': 'Orli', 'Initials': 'O', 'LastName': 'Binyamin', 'Affiliation': 'Multiple sclerosis Center and cell therapies Unit, Unit and Laboratory of Neuroimmunology and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Jerusalem.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Karussis', 'Affiliation': 'Multiple sclerosis Center and cell therapies Unit, Unit and Laboratory of Neuroimmunology and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Jerusalem. Electronic address: dimitriosk@ekmd.huji.ac.il.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2021.103103'] 1523,34198131,Nicotine acutely alters temporal properties of resting brain states.,"BACKGROUND Nicotine-dependent individuals have altered activity in neurocognitive networks such as the default mode (DMN), salience (SN) and central executive networks (CEN). One theory suggests that, among chronic tobacco smokers, nicotine abstinence drives more DMN-related internal processing while nicotine replacement suppresses DMN and enhances SN and CEN. Whether acute nicotine impacts network dynamics in non-smokers is, however, unknown. METHODS In a randomized double-blind crossover study, 17 healthy non-smokers (8 females) were administered placebo and nicotine (2-mg lozenge) on two different days prior to collecting resting-state functional magnetic resonance imaging (fMRI). Previously defined brain states in 462 individuals that spatially overlap with well-characterized resting-state networks including the DMN, SN, and CEN were applied to compute state-specific dynamics at rest: total time spent in state, persistence in each state after entry, and frequency of state transitions. We examined whether nicotine acutely alters these resting-state dynamics. RESULTS A significant drug-by-state interaction emerged; post-hoc analyses clarified that, relative to placebo, nicotine suppressed time spent in a frontoinsular-DMN state (posterior cingulate cortex, medial prefrontal cortex, anterior insula, striatum and orbitofrontal cortex) and enhanced time spent in a SN state (anterior cingulate cortex and insula). No significant findings were observed for persistence and frequency. CONCLUSIONS In non-smokers, nicotine biases resting-state brain function away from the frontoinsular-DMN and toward the SN, which may reduce internally focused cognition and enhance salience processing. While past work suggests nicotine impacts DMN activity, the current work shows nicotinic influences on a specific DMN-like network that has been linked with rumination and depression.",2021,"Previously defined brain states in 462 individuals that spatially overlap with well-characterized resting-state networks including the DMN, SN, and CEN were applied to compute state-specific dynamics at rest: total time spent in state, persistence in each state after entry, and frequency of state transitions.","['non-smokers', '462 individuals that spatially overlap with well-characterized resting-state networks including the DMN, SN, and CEN', 'chronic tobacco smokers', '17 healthy non-smokers (8 females']","['placebo and nicotine (2-mg lozenge) on two different days prior to collecting resting-state functional magnetic resonance imaging (fMRI', 'nicotine', 'placebo, nicotine', 'Nicotine']","['persistence and frequency', 'frontoinsular-DMN state (posterior cingulate cortex, medial prefrontal cortex, anterior insula, striatum and orbitofrontal cortex) and enhanced time spent in a SN state (anterior cingulate cortex and insula']","[{'cui': 'C0337672', 'cui_str': 'Non-smoker'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0185027', 'cui_str': 'Imbrication'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0012431', 'cui_str': 'N-nitrosodimethylamine'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C4505217', 'cui_str': 'Smokers, Tobacco'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0991564', 'cui_str': 'Lozenge'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0546816', 'cui_str': 'Persistence'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0012431', 'cui_str': 'N-nitrosodimethylamine'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0175191', 'cui_str': 'Posterior Cingulate Gyri'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0228259', 'cui_str': 'Anterior insula'}, {'cui': 'C0010097', 'cui_str': 'Corpus striatum structure'}, {'cui': 'C0152301', 'cui_str': 'Structure of orbital gyrus'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}]",17.0,0.201988,"Previously defined brain states in 462 individuals that spatially overlap with well-characterized resting-state networks including the DMN, SN, and CEN were applied to compute state-specific dynamics at rest: total time spent in state, persistence in each state after entry, and frequency of state transitions.","[{'ForeName': 'Kainan S', 'Initials': 'KS', 'LastName': 'Wang', 'Affiliation': 'McLean Imaging Center, McLean Hospital, Belmont, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: kwang23@mclean.harvard.edu.'}, {'ForeName': 'Kaelyn', 'Initials': 'K', 'LastName': 'Brown', 'Affiliation': 'McLean Imaging Center, McLean Hospital, Belmont, MA, USA; Harvard University, Cambridge, MA, USA.'}, {'ForeName': 'Blaise B', 'Initials': 'BB', 'LastName': 'Frederick', 'Affiliation': 'McLean Imaging Center, McLean Hospital, Belmont, MA, USA; Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Lauren V', 'Initials': 'LV', 'LastName': 'Moran', 'Affiliation': 'McLean Imaging Center, McLean Hospital, Belmont, MA, USA; Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Olson', 'Affiliation': 'McLean Imaging Center, McLean Hospital, Belmont, MA, USA; Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Diego A', 'Initials': 'DA', 'LastName': 'Pizzagalli', 'Affiliation': 'McLean Imaging Center, McLean Hospital, Belmont, MA, USA; Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Roselinde H', 'Initials': 'RH', 'LastName': 'Kaiser', 'Affiliation': 'Department of Psychology and Neuroscience, University of Colorado, Boulder, CO, USA.'}, {'ForeName': 'Amy C', 'Initials': 'AC', 'LastName': 'Janes', 'Affiliation': 'McLean Imaging Center, McLean Hospital, Belmont, MA, USA; Harvard Medical School, Boston, MA, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2021.108846'] 1524,34215316,Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.,"OBJECTIVE To evaluate the effectiveness of bazedoxifene in preventing bone loss in patients with rheumatoid arthritis (RA) receiving low-dose glucocorticoids (GCs). METHODS In this randomized, controlled, open-label study, we assigned postmenopausal women with osteopenia who had been receiving low-dose GCs for RA to two groups: a group receiving bazedoxifene (20 mg/day) with elemental calcium 1200 mg and vitamin D 800 IU daily (bazedoxifene group) and a group receiving the same doses of calcium and vitamin D only (control group). As primary outcome, bone mineral density (BMD) change in the lumbar spine (L-spine) from baseline to 48 weeks was assessed. Changes in BMD in the femur, trabecular bone score, bone turnover markers, and development of fracture were assessed as secondary outcomes. For intention-to-treat analysis, 20 completed data sets were created by applying multiple imputations by chained equations. RESULTS A total of 114 patients (57 patients in each group) were recruited. A significant increase in L-spine BMD (0.015 g/cm 2 , P = 0.007) was observed in the bazedoxifene group, and the increase was significantly higher than in the control group (0.013, 95% CI 0.0003-0.026, P = 0.047). Reductions in bone turnover markers in the bazedoxifene group were significantly greater than in the control group. Only one fracture was observed in the bazedoxifene group, while four fractures developed in the control group. CONCLUSION In postmenopausal patients with RA receiving low-dose GCs, bazedoxifene improved BMD and reduced bone turnover markers. However, the change in BMD did not exceed the least significant change. TRIAL REGISTRATION ClinicalTrials.gov, NCT02602704 .",2021,"A significant increase in L-spine BMD (0.015 g/cm 2 , P = 0.007) was observed in the bazedoxifene group, and the increase was significantly higher than in the control group (0.013, 95% CI 0.0003-0.026, P = 0.047).","['postmenopausal women with osteopenia who had been receiving low-dose GCs for RA to two groups: a group receiving', 'rheumatoid arthritis patients', 'patients with rheumatoid arthritis (RA) receiving low-dose glucocorticoids (GCs', 'postmenopausal patients with RA receiving low-dose', '114 patients (57 patients in each group) were recruited']","['bazedoxifene', 'GCs, bazedoxifene', 'bazedoxifene (20\u2009mg/day) with elemental calcium 1200\u2009mg and vitamin D 800\u2009IU daily (bazedoxifene group) and a group receiving the same doses of calcium and vitamin D only (control group']","['bone turnover markers', 'L-spine BMD', 'Changes in BMD in the femur, trabecular bone score, bone turnover markers, and development of fracture', 'bone loss', 'BMD and reduced bone turnover markers', 'change in BMD', 'bone mineral density (BMD) change in the lumbar spine (L-spine']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4708785', 'cui_str': '114'}]","[{'cui': 'C2346970', 'cui_str': 'bazedoxifene'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C4517548', 'cui_str': '1200'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0222660', 'cui_str': 'Trabecular substance of bone'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",114.0,0.0841292,"A significant increase in L-spine BMD (0.015 g/cm 2 , P = 0.007) was observed in the bazedoxifene group, and the increase was significantly higher than in the control group (0.013, 95% CI 0.0003-0.026, P = 0.047).","[{'ForeName': 'Soo-Kyung', 'Initials': 'SK', 'LastName': 'Cho', 'Affiliation': 'Hanyang University Hospital for Rheumatic Diseases, 222-1 wangsimni-ro, Seongdong-gu, Seoul, 04763, South Korea.'}, {'ForeName': 'Hyoungyoung', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Hanyang University Hospital for Rheumatic Diseases, 222-1 wangsimni-ro, Seongdong-gu, Seoul, 04763, South Korea.'}, {'ForeName': 'Jiyoung', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Clinical Research Center for Rheumatoid Arthritis (CRCRA), 222 wangsimni-ro, Seongdong-gu, Seoul, 04763, South Korea.'}, {'ForeName': 'Eunwoo', 'Initials': 'E', 'LastName': 'Nam', 'Affiliation': 'Hanyang University Hospital for Rheumatic Diseases, 222-1 wangsimni-ro, Seongdong-gu, Seoul, 04763, South Korea.'}, {'ForeName': 'Seunghun', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Radiology, Hanyang University College of Medicine, 222 wangsimni-ro, Seongdong-gu, Seoul, 04763, South Korea.'}, {'ForeName': 'Yun Young', 'Initials': 'YY', 'LastName': 'Choi', 'Affiliation': 'Department of Nuclear Medicine, Hanyang University College of Medicine, 222 wangsimni-ro, Seongdong-gu, Seoul, 04763, South Korea.'}, {'ForeName': 'Yoon-Kyoung', 'Initials': 'YK', 'LastName': 'Sung', 'Affiliation': 'Hanyang University Hospital for Rheumatic Diseases, 222-1 wangsimni-ro, Seongdong-gu, Seoul, 04763, South Korea. sungyk@hanyang.ac.kr.'}]",Arthritis research & therapy,['10.1186/s13075-021-02564-1'] 1525,34216524,Visit-to-visit office blood pressure variability combined with Framingham risk score to predict all-cause mortality: A post hoc analysis of the systolic blood pressure intervention trial.,"We aim to determine if visit-to-visit blood pressure variability (BPV) adds prognostic value for all-cause mortality independently of the Framingham risk score (FRS) in the systolic blood pressure intervention trial (SPRINT). We defined BPV as variability independent of the mean (VIM) and the difference of maximum minus minimum (MMD) of the systolic blood pressure (SBP). Multivariable Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI). Based on FRS stratification, there were 1035, 2911, and 4050 participants in the low-, intermediate-, and high-risk groups, respectively. During the trial, 230 deaths occurred since the 12th month with an average follow-up of 2.5 years. In continuous analysis, 1-SD increase of SBP VIM and MMD were significantly associated with all-cause mortality (HR 1.18, 95% CI 1.05-1.32, p = .005; and HR 1.21, 95% CI 1.09-1.35, p < .001, respectively). In category analysis, the highest quintile of BPV compared with the lowest quintile had significantly higher risk of all-cause mortality. Cross-tabulation analysis showed that the 3rd tertile of SBP VIM in the high-risk group had the highest HR of all-cause mortality in total population (HR 4.99; 95% CI 1.57-15.90; p = .007), as well as in intensive-therapy group (HR 7.48; 95% CI 1.01-55.45; p = .05) analyzed separately. Cross-tabulation analysis of SBP MMD had the same pattern as VIM showed above. In conclusion, visit-to-visit BPV was an independent predictor of all-cause mortality, when accounting for conventional risk factors or FRS. BPV combined with FRS conferred an increased risk for all-cause mortality in the SPRINT trial.",2021,"In continuous analysis, 1-SD increase of SBP VIM and MMD were significantly associated with all-cause mortality (HR 1.18, 95% CI 1.05-1.32, p = .005; and HR 1.21, 95% CI 1.09-1.35, p < .001, respectively).",[],"['BPV combined with FRS', 'visit-to-visit blood pressure variability (BPV']","['mortality', 'maximum minus minimum (MMD) of the systolic blood pressure (SBP', 'SBP VIM', 'SBP VIM and MMD']",[],"[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0332288', 'cui_str': 'Without'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0332291', 'cui_str': 'Independent of'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.202776,"In continuous analysis, 1-SD increase of SBP VIM and MMD were significantly associated with all-cause mortality (HR 1.18, 95% CI 1.05-1.32, p = .005; and HR 1.21, 95% CI 1.09-1.35, p < .001, respectively).","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': 'Department of Cardiovascular Medicine, Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Key Lab of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Clinical Research Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xinping', 'Initials': 'X', 'LastName': 'Ren', 'Affiliation': 'Department of Ultrasound, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiovascular Medicine, Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Key Lab of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yulin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'State Key Laboratory of Medical Genomics, Clinical Trial Center, Department of Endocrinology and Metabolism, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Ya', 'Initials': 'Y', 'LastName': 'Miao', 'Affiliation': 'State Key Laboratory of Medical Genomics, Clinical Trial Center, Department of Endocrinology and Metabolism, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Chang-Sheng', 'Initials': 'CS', 'LastName': 'Sheng', 'Affiliation': 'Department of Cardiovascular Medicine, Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Key Lab of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Jingyan', 'Initials': 'J', 'LastName': 'Tian', 'Affiliation': 'State Key Laboratory of Medical Genomics, Clinical Trial Center, Department of Endocrinology and Metabolism, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}]","Journal of clinical hypertension (Greenwich, Conn.)",['10.1111/jch.14314'] 1526,34217029,The effects of the Start-Up NurseS program on nursing students using management strategy simulation.,"BACKGROUND Korea's rising youth unemployment, resulting from a long-term economic downturn, has fostered a conducive environment for entrepreneurship. The global healthcare market is expanding rapidly, and entrepreneurship in the nursing sector is also predicted to grow. OBJECTIVES The objective of this study was to analyze the effects of the Start-Up NurseS program, developed using a management strategy simulation technique, on entrepreneurial attitude, entrepreneurial intention, entrepreneurial self-efficacy, entrepreneurship, and entrepreneurship education demand among nursing students. DESIGN A randomized control trial with repeated measures. SETTINGS Four nursing departments in two metropolitan cities. PARTICIPANTS We assigned 34 nursing students to the experimental group and 33 to the comparison group. METHODS Nursing students in the experimental group participated in the Start-Up NurseS program for four weeks. Post-intervention data were collected three times: immediately after the program, at four weeks, and at eight weeks. RESULTS Entrepreneurial attitude, entrepreneurial intention, entrepreneurial self-efficacy, and entrepreneurship were more positive in the experimental group than in the control group. In the former, entrepreneurial attitude, entrepreneurial intention, entrepreneurial self-efficacy, and entrepreneurship showed significant differences immediately after the program, four weeks later, and eight weeks later. CONCLUSIONS The program had a significant effect on improving nursing start-up competency and can be expanded to various nursing fields.",2021,"Entrepreneurial attitude, entrepreneurial intention, entrepreneurial self-efficacy, and entrepreneurship were more positive in the experimental group than in the control group.","['Nursing students in the experimental group participated in the Start-Up NurseS program for four weeks', 'We assigned 34 nursing students to the experimental group and 33 to the comparison group', 'nursing students using management strategy simulation', 'nursing students', 'Four nursing departments in two metropolitan cities']",['Start-Up NurseS program'],"['Entrepreneurial attitude, entrepreneurial intention, entrepreneurial self-efficacy, and entrepreneurship']","[{'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0008848', 'cui_str': 'Cities'}]","[{'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0085116', 'cui_str': 'Entrepreneurship'}]",34.0,0.0242905,"Entrepreneurial attitude, entrepreneurial intention, entrepreneurial self-efficacy, and entrepreneurship were more positive in the experimental group than in the control group.","[{'ForeName': 'Ji Young', 'Initials': 'JY', 'LastName': 'Lim', 'Affiliation': 'Department of Nursing, Inha University, Incheon, Republic of Korea.'}, {'ForeName': 'Juhang', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Nursing, Far East University, Chungbuk, Republic of Korea. Electronic address: jukim@kdu.ac.kr.'}, {'ForeName': 'Seulki', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': ""Department of Nursing, Seoul Women's College of Nursing, Seoul, Republic of Korea.""}]",Nurse education today,['10.1016/j.nedt.2021.105020'] 1527,34218214,"Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.","BACKGROUND AND AIMS Sodium-glucose cotransporter-2 inhibitors, glucose-lowering drugs that increase urinary glucose excretion, have been shown to reduce CV events in patients with type 2 diabetes (T2D), despite the fact that these agents increase blood levels of the proatherogenic low density lipoprotein cholesterol (LDL-C). It has been hypothesized that hemoconcentration due to osmotic diuresis, effects on calculated LDL particle size, or a modulation of lipoprotein subfractions may play a role in this context but to date the underlying mechanisms remain largely unexplored. Therefore, the present study examined effects of empagliflozin on LDL-C and lipoprotein subfractions including calculated LDL particle size and composition. METHODS In this placebo-controlled, randomized, double blind study, patients with T2D were randomized to empagliflozin 10 mg (n = 20) or placebo (n = 22). Composition of lipoprotein subfractions was assessed before and after 3 months of treatment. Lipoproteins were separated using a combined ultracentrifugation-precipitation method (β-quantification). RESULTS Empagliflozin increased LDL-C after 3 months of treatment (from baseline: 103 ± 36 mg/dL to 112 ± 47 mg/dL; p < 0.001) while no difference was recorded after day 1 or day 3 of treatment. The increase of LDL-C was paralleled by an increase of total cholesterol (baseline: 169 ± 41 mg/dL, 3 months: 185 ± 48 mg/dL; p = 0.001). Analyses of lipoprotein subfractions revealed LDL phospholipids and LDL apolipoprotein B to be increased by empagliflozin after 3 months of treatment while calculated LDL particle size was not affected. In addition empagliflozin increased free fatty acid concentrations. CONCLUSIONS Empagliflozin treatment of patients with T2D increased LDL-C and LDL apolipoprotein B levels but had no effect on calculated LDL particle size.",2021,Analyses of lipoprotein subfractions revealed LDL phospholipids and LDL apolipoprotein B to be increased by empagliflozin after 3 months of treatment while calculated LDL particle size was not affected.,"['patients with type 2 diabetes', 'patients with T2D', 'patients with type 2 diabetes (T2D']","['placebo', 'Empagliflozin', 'empagliflozin']","['free fatty acid concentrations', 'LDL-C and LDL apolipoprotein B levels', 'LDL-C', 'lipoprotein subfractions', 'total cholesterol', 'Composition of lipoprotein subfractions', 'LDL phospholipids and LDL apolipoprotein B']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}]","[{'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0003593', 'cui_str': 'Apolipoprotein B'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0031676', 'cui_str': 'Phospholipids'}]",,0.229383,Analyses of lipoprotein subfractions revealed LDL phospholipids and LDL apolipoprotein B to be increased by empagliflozin after 3 months of treatment while calculated LDL particle size was not affected.,"[{'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Rau', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Thiele', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Niels-Ulrik', 'Initials': 'NU', 'LastName': 'Korbinian Hartmann', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Möllmann', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Wied', 'Affiliation': 'Department of Medical Statistics, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Department of Internal Medicine III, University Hospital Saarland, Saarland University, Homburg/Saar, Germany.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Scharnagl', 'Affiliation': 'Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Winfried', 'Initials': 'W', 'LastName': 'März', 'Affiliation': 'Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria; Department of Internal Medicine 5, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany; Synlab Academy, Synlab Holding Germany GmbH, Mannheim, Germany.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Marx', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany. Electronic address: nmarx@ukaachen.de.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lehrke', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}]",Atherosclerosis,['10.1016/j.atherosclerosis.2021.06.915'] 1528,34218211,Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis.,"This post hoc analysis was conducted to evaluate the efficacy, tolerability, and health-related quality of life during long-term adjunctive brivaracetam (BRV) treatment in adult patients with focal to bilateral tonic-clonic seizures (FBTCS). Patients (≥ 16 years) were included in this post hoc analysis if they were randomized to BRV or placebo in double-blind, placebo-controlled (N01252 [NCT00490035], N01253 [NCT00464269], N01358 [NCT01261325]; core) trials, and received adjunctive BRV in the corresponding long-term follow-up (N01125 [NCT00175916], N01199 [NCT00150800], N01379 [NCT01339559]) trials, and reported FBTCS during the 8-week prospective baseline (core trial). Efficacy (concomitant levetiracetam excluded) and tolerability (concomitant levetiracetam included) were assessed from the first day of BRV in patients who initiated BRV at 50-200 mg/day. Two hundred and eighty-four patients reported FBTCS during baseline (core trials) and were included in the Efficacy Set. Patients (mean age of 37.0 years; 51.8% male; mean epilepsy duration of 22.4 years; median baseline frequency of 2.8 FBTCS per 28 days) received BRV for a median treatment duration of 2.5 years (range< 0.1-11.3) at a median modal dose of 150 mg/day. BRV was discontinued by 175 (61.6%) patients, most commonly (≥ 10% of patients) due to adverse event (18.3%), lack of efficacy (18.3%), and consent withdrawn (11.6%); the median time to discontinuation of BRV due to any reason was 358.5 days. The Kaplan-Meier (KM)-estimated retention on BRV at 1, 3, and 5 years, were 69.3%, 48.2%, and 37.3%, respectively. The KM-estimated proportion of patients not discontinuing BRV due to lack of efficacy or adverse event were 80.0%, 63.9%, and 57.2% at 1, 3, and 5 years, respectively. Overall, the median percentage reduction in FBTCS frequency from baseline was 76.2%, and the 50% and 75% responder rates for FBTCS were 68.7% and 50.7%, respectively, which were sustained over time across completer cohorts. Sustained 50%, 75%, and 100% response in FBTCS from day 1 of adjunctive BRV treatment during the entire first year was estimated for 32.5%, 21.1%, and 15.0% of patients, respectively (KM analysis), and showed maintenance or improvement in the response to BRV over time. For patients with ≥ 1 year of BRV exposure, 51.3% were free from FBTCS for ≥ 1 year during any time of the treatment period, and 22.8% of patients did not report FBTCS during the first year from the first day of treatment. Clinically meaningful improvements in total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score were reported by 43.6% and 46.4% of patients after 1 and 2 years of treatment, respectively. The largest improvements in the QOLIE-31-P score, with > 50% of patients reporting a clinically meaningful improvement, were observed in the seizure worry and daily activities/social functioning subscales after 1 and 2 years of BRV treatment. Overall, 278/313 (88.8%; Safety Set) patients reported at least one treatment-emergent adverse event (TEAE), 170 (54.3%) had a drug-related TEAE, 88 (28.1%) had a serious TEAE, and 55 (17.6%) discontinued BRV due to a TEAE. Overall, long-term adjunctive BRV was generally well tolerated and reduced the frequency of FBTCS in adults, with 22.8% of patients (who completed ≥ 1 year of treatment) not reporting any FBTCS during the first year from the first day of BRV treatment.",2021,"Overall, long-term adjunctive BRV was generally well tolerated and reduced the frequency of FBTCS in adults, with 22.8% of patients (who completed ≥ 1 year of treatment) not reporting any FBTCS during the first year from the first day of BRV treatment.","['adults with focal to bilateral tonic-clonic (secondary generalized) seizures', 'Two hundred and eighty-four patients reported FBTCS during baseline (core trials) and were included in the Efficacy Set', 'Patients (≥ 16 years', 'Patients (mean age of 37.0 years; 51.8% male; mean epilepsy duration of 22.4 years; median baseline frequency of 2.8 FBTCS per 28 days) received BRV for a median treatment duration of 2.5 years (range < 0.1-11.3) at a median modal dose of 150 mg/day', 'adult patients with focal to bilateral tonic-clonic seizures (FBTCS']","['placebo', 'long-term adjunctive brivaracetam (BRV', 'BRV or placebo', 'adjunctive brivaracetam']","['efficacy or adverse event', 'adjunctive BRV', 'QOLIE-31-P score', 'FBTCS frequency', 'seizure worry and daily activities/social functioning subscales', 'total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score', 'median time to discontinuation of BRV', 'Kaplan-Meier (KM)-estimated retention on BRV', 'frequency of FBTCS', 'efficacy, tolerability, and health-related quality of life', 'adverse event', 'BRV', 'serious TEAE', 'lack of efficacy']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C3543842', 'cui_str': 'TONICS'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}]",284.0,0.243966,"Overall, long-term adjunctive BRV was generally well tolerated and reduced the frequency of FBTCS in adults, with 22.8% of patients (who completed ≥ 1 year of treatment) not reporting any FBTCS during the first year from the first day of BRV treatment.","[{'ForeName': 'Brian D', 'Initials': 'BD', 'LastName': 'Moseley', 'Affiliation': 'Department of Neurology & Rehabilitation Medicine, University of Cincinnati, 260 Stetson Street, Suite 2300, Cincinnati, OH, 45267-0525, USA. Electronic address: briandmoseley@gmail.com.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Dimova', 'Affiliation': 'UCB Pharma, Allée de la Recherche 60, B-1070, Brussels, Belgium. Electronic address: svetlana.dimova@ucb.com.'}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Elmoufti', 'Affiliation': 'UCB Pharma, 8010 Arco Corporate Dr, Raleigh, NC, 27617, USA. Electronic address: sami.elmoufti@ucb.com.'}, {'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Laloyaux', 'Affiliation': 'UCB Pharma, Allée de la Recherche 60, B-1070, Brussels, Belgium. Electronic address: cedric.laloyaux@ucb.com.'}, {'ForeName': 'Ali A', 'Initials': 'AA', 'LastName': 'Asadi-Pooya', 'Affiliation': 'Shiraz Epilepsy Research Center, Shiraz University of Medical Sciences, Zand St, Shiraz, Iran; Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, 909 Walnut St #3, Philadelphia, PA, 19107, USA. Electronic address: aliasadipooya@yahoo.com.'}]",Epilepsy research,['10.1016/j.eplepsyres.2021.106694'] 1529,34223671,The results of health-related quality of life assessment depend on the prevailing rhythm at the assessment: Experience from the CAPTAF trial (Catheter Ablation Compared with Pharmacological Therapy for Atrial Fibrillation).,"AIMS To assess whether the prevailing rhythm at the time of replying to symptom and health-related quality of life (HR-QoL) questionnaires impacts the findings. METHOD A total of 150 patients from the randomized Catheter Ablation Compared with Pharmacological Therapy for Atrial Fibrillation-trial, comparing atrial fibrillation (AF) ablation versus drugs, were included. The effect of the prevailing rhythm on the outcome results of the HR-QoL 36-Item Short-Form Health Survey, the symptom severity questionnaire (SSQ), and the European Heart Rhythm Association (EHRA) score for classification of AF-related symptoms was assessed. RESULTS AF as the prevailing rhythm was independently associated with a significantly lower Vitality score; 18.4 points lower (95% confidence interval -32.7 to -4.1, p = .01) compared with sinus rhythm when adjusted for AF burden, median duration of episode, number of episodes, beta-blocker use, type of AF, and sex. The presence of AF did not affect the General Health score compared with sinus rhythm, nor did it influence symptoms assessed by the SSQ or EHRA score. CONCLUSION The observation that the presence of AF versus sinus rhythm when conducting HR-QoL tests had a negative impact on its outcome, leaving symptom-related questionnaires unaffected, implies that the prevailing rhythm should be taken into account when results of HR-QoL questionnaires are interpreted.",2021,"RESULTS AF as the prevailing rhythm was independently associated with a significantly lower Vitality (VT) score; 18.4 points lower (95% CI -32.7- -4.1, p=0.01) compared with sinus rhythm when adjusted for AF burden, median duration of episode, number of episodes, beta-blocker use, type of AF, and sex.","['150 patients from the randomized CAPTAF-trial, comparing atrial fibrillation (AF) ablation versus drugs, were included']",[],"['HR-QoL 36-Item Short-Form Health Survey, the symptom severity questionnaire (SSQ), and the European Heart Rhythm Association (EHRA) score', 'prevailing rhythm at the time of replying to symptom and health-related quality of life (HR-QoL) questionnaires', 'lower Vitality (VT) score', 'General Health (GH) score', 'AF burden, median duration of episode, number of episodes, beta-blocker use, type of AF, and sex']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",[],"[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0232187', 'cui_str': 'Cardiac rhythm type'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3152857', 'cui_str': 'Prevail'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0001645', 'cui_str': 'Beta adrenergic receptor antagonist'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}]",150.0,0.0325691,"RESULTS AF as the prevailing rhythm was independently associated with a significantly lower Vitality (VT) score; 18.4 points lower (95% CI -32.7- -4.1, p=0.01) compared with sinus rhythm when adjusted for AF burden, median duration of episode, number of episodes, beta-blocker use, type of AF, and sex.","[{'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Jansson', 'Affiliation': 'Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Schwieler', 'Affiliation': 'Department of Cardiology, Karolinska University Hospital, Solna, Stockholm, Sweden.'}, {'ForeName': 'Lennart', 'Initials': 'L', 'LastName': 'Bergfeldt', 'Affiliation': 'Department of Molecular and Clinical Medicine/Cardiology, Department of Cardiology, Institute of Medicine, Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg and Region Västra Götaland, Gothenburg, Sweden.'}, {'ForeName': 'Göran', 'Initials': 'G', 'LastName': 'Kennebäck', 'Affiliation': 'Department of Cardiology, Karolinska University Hospital, Solna, Stockholm, Sweden.'}, {'ForeName': 'Steen M', 'Initials': 'SM', 'LastName': 'Jensen', 'Affiliation': 'Department of Public Health and Clinical Medicine, Heart Centre, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Sciaraffia', 'Affiliation': 'Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Blomström-Lundqvist', 'Affiliation': 'Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}]",Journal of cardiovascular electrophysiology,['10.1111/jce.15147'] 1530,34224858,Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action.,"Mastiha is a natural nutritional supplement with known anti-inflammatory properties. Non-alcoholic fatty liver disease (NAFLD) and Inflammatory bowel disease (IBD) are immune mediated inflammatory diseases that share common pathophysiological features. Mastiha has shown beneficial effects in both diseases. MicroRNAs have emerged as key regulators of inflammation and their modulation by phytochemicals have been extensively studied over the last years. Therefore, the aim of this study was to investigate whether a common route exists in the anti-inflammatory activity of Mastiha, specifically through the regulation of miRNA levels. Plasma miR-16, miR-21 and miR-155 were measured by Real-Time PCR before and after two double blinded and placebo-controlled randomized clinical trials with Mastiha. In IBD and particularly in ulcerative colitis patients in relapse, miR-155 increased in the placebo group (p = 0.054) whereas this increase was prevented by Mastiha. The mean changes were different in the two groups even after adjusting for age, sex and BMI (p = 0.024 for IBD and p = 0.042). Although the results were not so prominent in NAFLD, miR-155 displayed a downward trend in the placebo group (p = 0.054) whereas the levels did not changed significantly in the Mastiha group in patients with less advanced fibrosis. Our results propose a regulatory role for Mastiha in circulating levels of miR-155, a critical player in T helper-17 (Th17) differentiation and function.",2021,"In IBD and particularly in ulcerative colitis patients in relapse, miR-155 increased in the placebo group (p=0.054) whereas this increase was prevented by Mastiha.",[],['placebo'],"['Plasma miR-16, miR-21 and miR-155', 'relapse, miR-155']",[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C1101610', 'cui_str': 'MicroRNA'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]",,0.198795,"In IBD and particularly in ulcerative colitis patients in relapse, miR-155 increased in the placebo group (p=0.054) whereas this increase was prevented by Mastiha.","[{'ForeName': 'Charalampia', 'Initials': 'C', 'LastName': 'Amerikanou', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Efstathia', 'Initials': 'E', 'LastName': 'Papada', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Aristea', 'Initials': 'A', 'LastName': 'Gioxari', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Ilias', 'Initials': 'I', 'LastName': 'Smyrnioudis', 'Affiliation': 'Chios Mastic Gum Growers Association, Chios, Greece.'}, {'ForeName': 'Stamatia-Angeliki', 'Initials': 'SA', 'LastName': 'Kleftaki', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Evdokia', 'Initials': 'E', 'LastName': 'Valsamidou', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Bruns', 'Affiliation': 'Sanofi Research and Development, Industriepark Hoechst, D-65926 Frankfurt, Germany.'}, {'ForeName': 'Rajarshi', 'Initials': 'R', 'LastName': 'Banerjee', 'Affiliation': 'Perspectum Ltd, Oxford, UK.'}, {'ForeName': 'Maria Giovanna', 'Initials': 'MG', 'LastName': 'Trivella', 'Affiliation': 'ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Institute of Clinical Physiology National Research Council, Pisa, Italy.'}, {'ForeName': 'Natasa', 'Initials': 'N', 'LastName': 'Milic', 'Affiliation': 'Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.'}, {'ForeName': 'Milica', 'Initials': 'M', 'LastName': 'Medić-Stojanoska', 'Affiliation': 'Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Vojvodina, Novi Sad, Serbia.'}, {'ForeName': 'Amalia', 'Initials': 'A', 'LastName': 'Gastaldelli', 'Affiliation': 'Institute of Clinical Physiology National Research Council, Pisa, Italy.'}, {'ForeName': 'Aimo', 'Initials': 'A', 'LastName': 'Kannt', 'Affiliation': 'Sanofi Research and Development, Industriepark Hoechst, D-65926 Frankfurt, Germany; Fraunhofer Institute of Translational Medicine and Pharmacology ITMP, Frankfurt, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'George V', 'Initials': 'GV', 'LastName': 'Dedoussis', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece. Electronic address: dedousi@hua.gr.'}, {'ForeName': 'Andriana C', 'Initials': 'AC', 'LastName': 'Kaliora', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece. Electronic address: akaliora@hua.gr.'}]",Pharmacological research,['10.1016/j.phrs.2021.105753'] 1531,34224791,How different time intervals between repeated applications of CPP-ACP fluoride varnish effect smooth surface enamel demineralization?,"OBJECTIVES To evaluate the preventive effects of different time intervals between repeated applications of the CPP-ACP fluoride varnish on enamel demineralization. METHODS Human teeth were sectioned and randomly allocated to three groups: 4-week, 6-week, and 12-week (N = 22/group). Baseline images of the enamel surfaces were obtained using the FluoreCam recording the area, intensity, and impact of baseline enamel demineralization. All groups received fluoride varnish applications at the beginning of the experiment. The varnish was reapplied every 4 or 6 weeks in the 4-week and 6-week groups, respectively. Following each application, the groups underwent thermo-cycling, tooth brushing and pH cycling to simulate the time effect. After 12 weeks, the enamel surfaces were reimaged using the FluoreCam. Within and between-group differences in the area, intensity and impact of demineralization were evaluated. RESULTS At baseline, there were no significant between-group differences for area, intensity, or impact. Statistically significant (p<0.001) enamel demineralization occurred over time within each group. There were significant between-group differences in the changes that occurred in area (P = 0.004), impact (P = 0.022), but not intensity. The 12-week had significantly larger areas of demineralization than the 6-week (P = 0.041) and 4-week (P = 0.001) groups. Changes in impact was significantly (P = 0.007) greater in the 12-week group than 4-week group, but not greater than the 6-week group. There were no statistically significant differences between 4- and 6-week groups in the changes of area, intensity, or impact. CONCLUSION Reapplication of the CPP-ACP fluoride varnish every 4-6 weeks, is more effective in reducing enamel demineralization compared to every 12 weeks.",2021,"Changes in impact was significantly (P=0.007) greater in the 12-week group than 4-week group, but not greater than the 6-week group.",['Human teeth'],"['fluoride varnish applications', 'CPP-ACP fluoride varnish']","['larger areas of demineralization', 'enamel demineralization', 'changes of area, intensity, or impact', 'area, intensity and impact of demineralization']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}]","[{'cui': 'C0016326', 'cui_str': 'Fluoride Varnishes'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C1120338', 'cui_str': 'casein phosphopeptide-amorphous calcium phosphate nanocomplex'}]","[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0700185', 'cui_str': 'Decalcified structure'}, {'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]",,0.0245524,"Changes in impact was significantly (P=0.007) greater in the 12-week group than 4-week group, but not greater than the 6-week group.","[{'ForeName': 'Moufida', 'Initials': 'M', 'LastName': 'Abufarwa', 'Affiliation': 'Department of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, TX 75246, United States. Electronic address: mofifya@gmail.com.'}, {'ForeName': 'Amal', 'Initials': 'A', 'LastName': 'Noureldin', 'Affiliation': 'Department of Public Health Sciences, Texas A&M University College of Dentistry, Dallas, TX 75246, United States.'}, {'ForeName': 'Phillip M', 'Initials': 'PM', 'LastName': 'Campbell', 'Affiliation': 'Department of Orthodontics. Texas A&M University College of Dentistry, Dallas, TX 75246, United States. Electronic address: pmc4747@sbcglobal.net.'}, {'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': 'Buschang', 'Affiliation': 'Department of Orthodontics. Texas A&M University College of Dentistry, Dallas, TX 75246, United States. Electronic address: phbuschang@tamu.edu.'}]",Journal of dentistry,['10.1016/j.jdent.2021.103742'] 1532,34227708,Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.,"BACKGROUND Tegoprazan is a novel, fast- and long-acting potassium-competitive acid blocker that suppresses gastric acid secretion, which could benefit patients with non-erosive reflux disease (NERD), a type of gastroesophageal reflux disease. AIM To evaluate the efficacy and safety profiles of tegoprazan compared with those of a placebo in Korean patients with NERD. METHODS In this phase 3, double-blind, placebo-controlled, multicentre study, 324 Korean patients with NERD were randomised into three treatment groups: tegoprazan 50 mg, tegoprazan 100 mg and placebo. These drugs were provided once daily for 4 weeks. The primary endpoint was the proportion of patients with complete resolution of major symptoms (both heartburn and regurgitation) for the last 7 days of the 4-week treatment period. Other outcomes related to efficacy, safety and tolerability were also evaluated. RESULTS Among all, 42.5% (45/106), 48.5% (48/99) and 24.2% (24/99) of patients showed complete resolution of major symptoms at week 4 after receiving tegoprazan 50 mg, tegoprazan 100 mg, and placebo, respectively. Both doses of tegoprazan showed superior efficacy than the placebo (P = 0.0058 and P = 0.0004, respectively). The complete resolution rates of heartburn and proportions of heartburn-free days (as other efficacy outcomes) were significantly higher in both tegoprazan groups than in the placebo group (P < 0.05 for all). No significant difference in the incidence of treatment-emergent adverse events were noted. CONCLUSIONS Tegoprazan 50 and 100 mg showed superior therapeutic efficacy compared with the placebo, as well as a favourable safety profile in patients with NERD. Registration number: ClinicalTrials.gov identifier NCT02556021.",2021,"Both doses of tegoprazan showed superior efficacy than the placebo (P = 0.0058 and P = 0.0004, respectively).","['patients with non-erosive reflux disease (NERD), a type of gastroesophageal reflux disease', 'patients with NERD', 'Korean patients with NERD', 'non-erosive reflux disease', '324 Korean patients with NERD']","['tegoprazan', 'tegoprazan and placebo', 'Tegoprazan', 'tegoprazan 100\xa0mg and placebo', 'placebo']","['efficacy and safety profiles', 'proportion of patients with complete resolution of major symptoms (both heartburn and regurgitation', 'incidence of treatment-emergent adverse events', 'superior therapeutic efficacy', 'complete resolution of major symptoms', 'complete resolution rates of heartburn and proportions of heartburn-free days', 'superior efficacy', 'efficacy, safety and tolerability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2242528', 'cui_str': 'Non-erosive reflux disease'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C4517713', 'cui_str': '324'}]","[{'cui': 'C4726822', 'cui_str': 'tegoprazan'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0018834', 'cui_str': 'Heartburn'}, {'cui': 'C0232605', 'cui_str': 'Regurgitates after swallowing'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",324.0,0.35257,"Both doses of tegoprazan showed superior efficacy than the placebo (P = 0.0058 and P = 0.0004, respectively).","[{'ForeName': 'Seung Han', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Kwang Bum', 'Initials': 'KB', 'LastName': 'Cho', 'Affiliation': 'Daegu, South Korea.'}, {'ForeName': 'Hoon Jai', 'Initials': 'HJ', 'LastName': 'Chun', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Sang Woo', 'Initials': 'SW', 'LastName': 'Lee', 'Affiliation': 'Ansan, South Korea.'}, {'ForeName': 'Joong Goo', 'Initials': 'JG', 'LastName': 'Kwon', 'Affiliation': 'Daegu, South Korea.'}, {'ForeName': 'Dong Ho', 'Initials': 'DH', 'LastName': 'Lee', 'Affiliation': 'Seongnam, South Korea.'}, {'ForeName': 'Sang Gyun', 'Initials': 'SG', 'LastName': 'Kim', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Hwoon-Yong', 'Initials': 'HY', 'LastName': 'Jung', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Ji Won', 'Initials': 'JW', 'LastName': 'Kim', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Joon Seong', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Hyojin', 'Initials': 'H', 'LastName': 'Park', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Suck Chei', 'Initials': 'SC', 'LastName': 'Choi', 'Affiliation': 'Iksan, South Korea.'}, {'ForeName': 'Sam Ryong', 'Initials': 'SR', 'LastName': 'Jee', 'Affiliation': 'Busan, South Korea.'}, {'ForeName': 'Hyun-Soo', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Kwangju, South Korea.'}, {'ForeName': 'Kwang Hyun', 'Initials': 'KH', 'LastName': 'Ko', 'Affiliation': 'Seongnam, South Korea.'}, {'ForeName': 'Seun Ja', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Busan, South Korea.'}, {'ForeName': 'Yong Chan', 'Initials': 'YC', 'LastName': 'Lee', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Soo Heon', 'Initials': 'SH', 'LastName': 'Park', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Ah Rong', 'Initials': 'AR', 'LastName': 'Kim', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Eun Ji', 'Initials': 'EJ', 'LastName': 'Kim', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Hyun Wook', 'Initials': 'HW', 'LastName': 'Park', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Bong Tae', 'Initials': 'BT', 'LastName': 'Kim', 'Affiliation': 'Seoul, South Korea.'}, {'ForeName': 'Geun Seog', 'Initials': 'GS', 'LastName': 'Song', 'Affiliation': 'Seoul, South Korea.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.16477'] 1533,34229064,A new technique to analyse threshold-intensities based on time dependent change-points in the ratio of minute ventilation and end-tidal partial pressure of carbon-dioxide production.,"The aim of this study was to test the utility and effectiveness of an alternative computational approach to threshold-intensities based on time dependent change-points in minute ventilation divided by end-tidal partial pressure of CO 2 (V E /P ET CO 2 ) to reveal whether respiratory compensation point (RCP) is a third ventilatory threshold, or not. Ten recreationally active young adults and ten well-trained athletes volunteered to take part in this study. Following incremental ramp tests, gas exchange threshold (GET) and respiratory compensation point (RCP) were respectively evaluated by the slopes of VCO 2 -VO 2 and V E -VCO 2 using the Innocor system automatically. Respiratory threshold (RT) was analysed based on time dependent change-points in the V E /P ET CO 2 using binary segmentation algorithm. Additionally, those intersections were analysed independently by two experienced investigators using a visual identification technique in a double-blind design. According to the results, in the recreationally active group, there were the first (GET 1 ) and the second (GET 2 ) gas exchange thresholds which were identical with the RT 1 (139 W; 1.9 L⋅min -1 of VO 2 ; 1.73 L⋅min -1 of VCO 2 ; 49.9 L⋅min -1 of V E versus 139 W; 1.88 L⋅min -1 ; 1.7 L⋅min -1 ; 49 L⋅min -1 , respectively) and RT 2 (186 W; 2.39 L⋅min -1 of VO 2 ; 2.44 L⋅min -1 of VCO 2 ; 66 L⋅min -1 of V E versus 187 W; 2.41 L⋅min -1 ; 2.49 L⋅min -1 ; 65.7 L⋅min -1 , respectively). However, there were three threshold intensities which were determined by GET 1 , GET 2 , and RCP in well-trained athletes. Additionally, RT 1 , RT 2 , and RT 3 were determined as valid surrogates of the GET 1 (194 W; 2.56 L⋅min -1 of VO 2 ; 1.99 L⋅min -1 of VCO 2 ; 57.5 L⋅min -1 of V E versus 192 W; 2.61 L⋅min -1 ; 1.99 Lmin -1 ; 57.7 L⋅min -1 , respectively), GET 2 (267 W; 3.6 L⋅min -1 of VO 2 ; 3.29 L⋅min -1 of VCO 2 ; 94.5 L⋅min -1 of V E versus 266 W; 3.58 L⋅min -1 ; 3.26 L⋅min -1 ; 93.4 L⋅min -1 , respectively), and RCP (324 W; 4.05 L⋅min -1 of VO 2 ; 4.13 L⋅min -1 of VCO 2 ; 124 L⋅min -1 of V E versus 322 W; 4.02 L⋅min -1 ; 4.07 L⋅min -1 ; 122 L⋅min -1 , respectively) in well-trained athletes. There were high levels of agreements between the power outputs determined by traditional techniques and newly proposed change-points in RT. All markers were strongly correlated (p < 0.001). It was shown that RT technique can provide an accurate threshold determination. Furthermore, the RCP was observed as a third threshold-intensity for well-trained athletes but not for recreationally active young adults.",2021,"Furthermore, the RCP was observed as a third threshold-intensity for well-trained athletes but not for recreationally active young adults.",['Ten recreationally active young adults and ten well-trained athletes volunteered to take part in this study'],['GET'],"['Respiratory threshold (RT', 'gas exchange threshold (GET) and respiratory compensation point (RCP']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}]",,0.0455054,"Furthermore, the RCP was observed as a third threshold-intensity for well-trained athletes but not for recreationally active young adults.","[{'ForeName': 'Ozgur', 'Initials': 'O', 'LastName': 'Ozkaya', 'Affiliation': 'Department of Coaching Education, Faculty of Sport Sciences, Ege University, 35050, Bornova, Izmir, Turkey. Electronic address: ozgur.ozkaya@ege.edu.tr.'}, {'ForeName': 'Gorkem A', 'Initials': 'GA', 'LastName': 'Balci', 'Affiliation': 'Department of Coaching Education, Faculty of Sport Sciences, Ege University, 35050, Bornova, Izmir, Turkey.'}, {'ForeName': 'Hakan', 'Initials': 'H', 'LastName': 'As', 'Affiliation': 'Department of Sports and Health Sciences, Institution of Health Sciences, Ege University, 35050, Bornova, Izmir, Turkey.'}, {'ForeName': 'Engin', 'Initials': 'E', 'LastName': 'Yildiztepe', 'Affiliation': 'Department of Statistics, Faculty of Science, Dokuz Eylul University, 35390, Buca, Izmir, Turkey.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2021.103735'] 1534,34229063,Neurocognitive mechanisms underlying improvement of prosocial responses by a novel implicit compassion promotion task.,"Compassion is closely associated with prosocial behavior. Although there is growing interest in developing strategies that cultivate compassion, most available strategies rely on effortful reflective processes. Furthermore, few studies have investigated neurocognitive mechanisms underlying compassion-dependent improvement of prosocial responses. We devised a novel implicit compassion promotion task that operates based on association learning and examined its prosocial effects in two independent experiments. In Experiment 1, healthy adults were assigned to either the compassion or control group. For the intervention task, the compassion group completed word fragments that were consistently related to compassionate responses toward others; in contrast, the control group completed word fragments related to emotionally neutral responses toward others. Following the intervention task, we measured attentional biases to fearful, sad, and happy faces. Prosocial responses were assessed using two measures of helping: the pen-drop test and the helping intentions rating test. In Experiment 2, independent groups of healthy adults completed the same intervention tasks used in Experiment 1. Inside a functional MRI scanner, participants rated empathic care and distress based on either distressful or neutral video clips. Outside the scanner, we assessed the degree of helping intentions toward the victims depicted in the distressful clips. The results of Experiment 1 showed that the compassion promotion task reduced attentional vigilance to fearful faces, which in turn mediated a compassion promotion task-dependent increase in helping intentions. In Experiment 2, relative to the control group, the compassion group showed reduced empathic distress and increased activity in the medial orbitofrontal cortex in response to others' suffering. Furthermore, increased functional connectivity of the medial orbitofrontal and inferior parietal cortex, predicted by reduced empathic distress, explained the increase in helping intentions. These results suggest the potential of implicit compassion promotion intervention to modulate compassion-related and prosocial responses as well as highlight the brain activation and connectivity related to these responses, contributing to our understanding of the neurocognitive mechanisms underlying compassion-dependent prosocial improvement.",2021,"In Experiment 2, relative to the control group, the compassion group showed reduced empathic distress and increased activity in the medial orbitofrontal cortex in response to others' suffering.",['healthy adults'],"['implicit compassion promotion intervention', 'distressful or neutral video clips']","['empathic distress and increased activity', 'Prosocial responses', 'functional connectivity of the medial orbitofrontal and inferior parietal cortex', 'empathic distress', 'attentional biases to fearful, sad, and happy faces', 'helping intentions', 'attentional vigilance to fearful faces']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0175722', 'cui_str': 'Clip'}]","[{'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0474395', 'cui_str': 'Behavior showing increased motor activity'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0030560', 'cui_str': 'Parietal lobe structure'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0043012', 'cui_str': 'Wakefulness'}]",,0.0169093,"In Experiment 2, relative to the control group, the compassion group showed reduced empathic distress and increased activity in the medial orbitofrontal cortex in response to others' suffering.","[{'ForeName': 'Shin Ah', 'Initials': 'SA', 'LastName': 'Kim', 'Affiliation': 'Department of Brain and Cognitive Engineering, Korea University, Seoul, South Korea.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Hamann', 'Affiliation': 'Department of Psychology, Emory University, Atlanta GA, USA.'}, {'ForeName': 'Sang Hee', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Department of Brain and Cognitive Engineering, Korea University, Seoul, South Korea. Electronic address: sangheekim.ku@gmail.com.'}]",NeuroImage,['10.1016/j.neuroimage.2021.118333'] 1535,34229057,Inhaled nitric oxide in adults with in-hospital cardiac arrest: A feasibility study.,"BACKGROUND While inhaled nitric oxide (iNO) has revealed benefit in cardiac arrest in an animal model, no published data has yet demonstrated the impact of iNO in humans with cardiac arrest. METHODS In this pilot study, we administered iNO, along with standard post-resuscitative care, in adults with in-hospital cardiac arrest (IHCA) following achievement of return of spontaneous circulation (ROSC) at an academic tertiary medical center. Patients receiving iNO were compared to age-matched controls with IHCA receiving standard care from an institutional registry. The primary outcome was survival to discharge; secondary outcome was favorable neurologic outcome, defined by a Glasgow Outcome Score of 4 or 5. Propensity-score (PS) matching analysis was performed between patients receiving iNO versus controls. RESULTS Twenty adults with IHCA receiving iNO were compared to 199 controls with IHCA. Similar age, Charlson comorbidity index, and initial rhythm were noted in both groups. Patients receiving iNO had higher rates of survival to discharge compared to controls (35% vs 11%, p < 0.0001) but no difference in favorable neurologic outcome (15% vs 9%, p = 0.39) in the unmatched population. In the PS-matched analysis, patients receiving iNO had higher survival to discharge (35% vs 20%, p = 0.0344) than the control group but no difference in favorable neurologic outcome (15% vs 20%, p = 0.13) were noted between both groups. CONCLUSIONS In this pilot study, iNO was associated with significantly higher rates of survival to discharge but not favorable neurologic outcome among patients with IHCA compared to controls. This benefit was also observed in the PS-matched analysis. A large scale randomized controlled trial comparing standard of care supplemented with iNO to standard of care alone is warranted in patients with cardiac arrest (Funded by Stony Brook University Renaissance School of Medicine, ClinicalTrials.gov number, NCT04134078).",2021,"Patients receiving iNO had higher rates of survival to discharge compared to controls (35% vs 11%, p<0.0001) but no difference in favorable neurologic outcome (15% vs 9%, p=0.39) in the unmatched population.","['Twenty adults with IHCA receiving iNO were compared to 199 controls with IHCA', 'patients with cardiac arrest', 'Patients receiving iNO were compared to age-matched controls with IHCA receiving standard care from an institutional registry', 'humans with cardiac arrest', 'Adults with In-Hospital Cardiac Arrest', 'adults with in-hospital cardiac arrest (IHCA) following achievement of return of spontaneous circulation (ROSC) at an academic tertiary medical center']","['care supplemented with iNO to standard of care alone', 'Inhaled Nitric Oxide', 'nitric oxide (iNO']","['favorable neurologic outcome', 'survival to discharge', 'Charlson comorbidity score, and initial rhythm', 'survival to discharge; secondary outcome was favorable neurologic outcome, defined by a Glasgow Outcome Score of 4 or 5', 'rates of survival to discharge']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C3539106', 'cui_str': 'Defined'}]",199.0,0.373323,"Patients receiving iNO had higher rates of survival to discharge compared to controls (35% vs 11%, p<0.0001) but no difference in favorable neurologic outcome (15% vs 9%, p=0.39) in the unmatched population.","[{'ForeName': 'Jignesh K', 'Initials': 'JK', 'LastName': 'Patel', 'Affiliation': 'Resuscitation Research Group, Division of Pulmonary, Critical Care and Sleep Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA. Electronic address: jignesh.patel@stonybrookmedicine.edu.'}, {'ForeName': 'Elinor', 'Initials': 'E', 'LastName': 'Schoenfeld', 'Affiliation': 'Division of Epidemiology and Biostatistics, Department of Family, Population, and Preventive Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hou', 'Affiliation': 'Division of Epidemiology and Biostatistics, Department of Family, Population, and Preventive Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Singer', 'Affiliation': 'Department of Emergency Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Rakowski', 'Affiliation': 'Resuscitation Research Group, Division of Pulmonary, Critical Care and Sleep Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA.'}, {'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Ahmad', 'Affiliation': 'Resuscitation Research Group, Division of Pulmonary, Critical Care and Sleep Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA.'}, {'ForeName': 'Rajeev', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Resuscitation Research Group, Division of Pulmonary, Critical Care and Sleep Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA.'}, {'ForeName': 'Puja B', 'Initials': 'PB', 'LastName': 'Parikh', 'Affiliation': 'Division of Cardiology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Smaldone', 'Affiliation': 'Resuscitation Research Group, Division of Pulmonary, Critical Care and Sleep Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA.'}]",Nitric oxide : biology and chemistry,['10.1016/j.niox.2021.07.001'] 1536,34233204,"Indirect Resin Composite Inlays Cemented with a Self-adhesive, Self-etch or a Conventional Resin Cement Luting Agent: A 5 Years Prospective Clinical Evaluation.","OBJECTIVE The aim of this study was to clinically evaluate the 5-years clinical performance of indirect resin composite inlays luted with three different resin cement strategies in MOD Class II restorations. MATERIALS AND METHODS A randomized clinical trial was conducted following CONSORT guidelines. Forty patients with three large cavities indicated for indirect MOD Class II restorations were enrolled in the current study. Then, 120 indirect resin composite inlay restorations (SR Nexco) were placed and luted with three different resin cement strategies (n=40); an etch-and-rinse (Variolink N), self-etch (Panavia F2.0) and self-adhesive (RelyX Unicem). These restorations were evaluated to the periods of 1 week (baseline), 1, 3 and 5 years using modified USPHS criteria. Statistical analyses were performed with Wilcoxon and Friedman tests with level of significance set at 0.05. RESULTS The outcome of the clinical trial showed that, there was neither loss of restorations nor recurrent caries after 5 years for all luting cements groups. Both self-etch Panavia F2.0 and self-adhesive RelyX Unicem resin cements exhibited significant differences between the evaluation periods regarding to marginal discoloration and marginal adaptation (p=0.03). At baseline, only 8 cases of etch-and-rinse (Variolink N) resin cement group exhibited post-operative sensitivity which were relieved after short time (p=0.04). CONCLUSION All the three resin cement strategies tested, showed acceptable clinical performance after 5-years recall period. In time, etch-and-rinse resin cement group showed better clinical performance regarding marginal discoloration and marginal adaptation at 5-years recall period. Clinical Relevance statement:In vitro and in vivo studies reveal contradictory evidence of the clinical performance of indirect resin composite inlays luted with different resin cement strategies. Thus, this study revealed that etch-and-rinse resin cement still has the best prognosis for adhesive luting of indirect resin composite inlays.",2021,RelyX Unicem resin cements exhibited significant differences between the evaluation periods regarding to marginal discoloration and marginal adaptation (p=0.03).,"['MOD Class II restorations', 'Forty patients with three large cavities indicated for indirect MOD Class II restorations were enrolled in the current study', 'Indirect Resin Composite Inlays Cemented with a Self-adhesive, Self-etch or a Conventional Resin Cement Luting Agent']","['120 indirect resin composite inlay restorations (SR Nexco) were placed and luted with three different resin cement strategies (n=40); an etch-and-rinse (Variolink N), self-etch (Panavia F2.0) and self-adhesive ']","['loss of restorations nor recurrent caries', 'marginal discoloration and marginal adaptation', 'clinical performance regarding marginal discoloration and marginal adaptation']","[{'cui': 'C0441886', 'cui_str': 'Class 2'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009570', 'cui_str': 'Composite Resins'}, {'cui': 'C0021513', 'cui_str': 'Dental Inlays'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0001516', 'cui_str': 'Adhesive'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0376523', 'cui_str': 'Resin Cement'}, {'cui': 'C0450442', 'cui_str': 'Agent'}]","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}, {'cui': 'C0009570', 'cui_str': 'Composite Resins'}, {'cui': 'C0399076', 'cui_str': 'Restoration, inlay'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}, {'cui': 'C0376523', 'cui_str': 'Resin Cement'}, {'cui': 'C1701810', 'cui_str': 'Rinse'}, {'cui': 'C0534004', 'cui_str': 'Variolink'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0001516', 'cui_str': 'Adhesive'}]","[{'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0332572', 'cui_str': 'Abnormal color'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",40.0,0.08739,RelyX Unicem resin cements exhibited significant differences between the evaluation periods regarding to marginal discoloration and marginal adaptation (p=0.03).,"[{'ForeName': 'Radwa I', 'Initials': 'RI', 'LastName': 'Eltoukhy', 'Affiliation': 'Operative Dentistry Dept., Faculty of Dentistry, Mansoura University, Algomhoria Street, Mansoura, Aldakhlia, Egypt Po (box) 35516. Electronic address: Eltoukhyr333@gmail.com.'}, {'ForeName': 'Ali A', 'Initials': 'AA', 'LastName': 'Elkaffas', 'Affiliation': 'Operative Dentistry Dept., Faculty of Dentistry, Mansoura University, Algomhoria Street, Mansoura, Aldakhlia, Egypt Po (box) 35516. Electronic address: Dr.aly.atef@gmail.com.'}, {'ForeName': 'Ashraf I', 'Initials': 'AI', 'LastName': 'Ali', 'Affiliation': 'Operative Dentistry Dept., Faculty of Dentistry, Mansoura University, Algomhoria Street, Mansoura, Aldakhlia, Egypt Po (box) 35516. Electronic address: ashraf@mans.edu.eg.'}, {'ForeName': 'Salah H', 'Initials': 'SH', 'LastName': 'Mahmoud', 'Affiliation': 'Operative Dentistry Dept., Faculty of Dentistry, Mansoura University, Algomhoria Street, Mansoura, Aldakhlia, Egypt Po (box) 35516. Electronic address: Salahmahmoud2010@yahoo.com.'}]",Journal of dentistry,['10.1016/j.jdent.2021.103740'] 1537,34246175,Long-term effects of shoe mileage on knee and ankle joints muscle co-contraction during walking in females with genu varus.,"BACKGROUND Shoe mileage may influence the risk of sustaining injuries during walking. RESEARCH QUESTION What are the effects of shoe mileage on knee and ankle muscle co-contraction during walking in females with genu varus? METHODS Fifteen healthy and 15 women diagnosed with genu varus received a new pair of running shoes. They were asked to wear these shoes over 6 months. Pre and post intervention, muscle activities of the dominant limb were recorded during a walking test at preferred gait speed. Two dependent variables were assessed to examine muscle co-contraction: (1) directed co-contraction ratios of agonists and antagonists, and (2) general joint muscle co-contraction. FINDINGS Results demonstrated significant main effects of the ""shoe"" factor for general ankle co-contraction during the push-off phase (p = 0.013, d = 1.503). Irrespective of experimental group, paired comparisons revealed significantly lower general ankle co-contraction during the push-off phase after the intervention. A significant main effects of ""shoe"" for general knee co-contraction during loading phase (p = 0.025, d = 0.895) was also observed. In both groups, paired comparison revealed significantly lower general knee co-contraction during the push-off phase in the post condition. We did not find any significant main effect of group nor group-by-shoe interaction for general ankle co-contraction during the stance phase. Likewise, we did not observe any significant main effect of ""shoe"", ""group"" and ""group-by-shoe"" interaction for mediolateral directed knee co-contraction during stance phase of walking (p > 0.05). SIGNIFICANCE Our findings showed that the shoe mileage but not the genu varus condition affects the general and directed co-contraction of the muscles stabilizing the knee and ankle joints. Together with the observed findings on ankle and knee muscle co-contraction, it is essential to change running shoes after a long wearing time in both healthy and genu varus females.",2021,We did not find any significant main effect of group nor group-by-shoe interaction for general ankle co-contraction during the stance phase.,"['Fifteen healthy and 15 women diagnosed with genu varus received a', 'females with genu varus']","['new pair of running shoes', 'shoe mileage']","['muscle co-contraction: (1) directed co-contraction ratios of agonists and antagonists, and (2) general joint muscle co-contraction', 'general ankle co-contraction', 'general knee co-contraction', 'muscle activities of the dominant limb', 'shoe"" factor for general ankle co-contraction during the push-off phase']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0544755', 'cui_str': 'Bandy legged'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C0036988', 'cui_str': 'Shoes'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0036988', 'cui_str': 'Shoes'}, {'cui': 'C0580841', 'cui_str': 'Does push'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]",15.0,0.0280644,We did not find any significant main effect of group nor group-by-shoe interaction for general ankle co-contraction during the stance phase.,"[{'ForeName': 'Amir Ali', 'Initials': 'AA', 'LastName': 'Jafarnezhadgero', 'Affiliation': 'Department of Sport Management and Biomechanics, Faculty of Education Sciences and Psychology, University of Mohaghegh Ardabili, Ardabil, Iran. Electronic address: a.jafarnezhad@uma.ac.ir.'}, {'ForeName': 'Milad', 'Initials': 'M', 'LastName': 'Piran Hamlabadi', 'Affiliation': 'Department of Sport Management and Biomechanics, Faculty of Education Sciences and Psychology, University of Mohaghegh Ardabili, Ardabil, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Anvari', 'Affiliation': 'Department of Sport Management and Biomechanics, Faculty of Education Sciences and Psychology, University of Mohaghegh Ardabili, Ardabil, Iran.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Zago', 'Affiliation': 'Department of Mechanics, Politecnico di Milano, Lecco, Italy. Electronic address: matteo2.zago@polimi.it.'}]",Gait & posture,['10.1016/j.gaitpost.2021.07.004'] 1538,34246153,"Effectiveness of a smartphone-based, augmented reality exposure app to reduce fear of spiders in real-life: A randomized controlled trial.","Although in vivo exposure therapy is highly effective in the treatment of specific phobias, only a minority of patients seeks therapy. Exposure to virtual objects has been shown to be better tolerated, equally efficacious, but the technology has not been made widely accessible yet. We developed an augmented reality (AR) application (app) to reduce fear of spiders and performed a randomized controlled trial comparing the effects of our app (six 30-min sessions at home over a two-week period) with no intervention. Primary outcome was subjective fear, measured by a Subjective Units of Distress Scale (SUDS) in a Behavioural Approach Test (BAT) in a real-life spider situation at six weeks follow-up. Between Oct 7, 2019, and Dec 6, 2019, 66 individuals were enrolled and randomized. The intervention led to significantly lower subjective fear in the BAT compared to the control group (intervention group, baseline: 7.12 [SD 2.03] follow-up: 5.03 [SD 2.19] vs. control group, baseline: 7.06 [SD 2.34], follow-up 6.24 [SD 2.21]; adjusted group difference -1.24, 95 % CI -2.17 to -0.31; Cohen's d = 0.57, p = 0.010). The repeated use of the AR app reduces subjective fear in a real-life spider situation, providing a low-threshold and low-cost treatment for fear of spiders.",2021,"The intervention led to significantly lower subjective fear in the BAT compared to the control group (intervention group, baseline: 7.12 [SD 2.03] follow-up: 5.03 [SD 2.19] vs. control group, baseline: 7.06 [SD 2.34], follow-up 6.24",['66 individuals were enrolled and randomized'],"['augmented reality (AR) application (app', 'smartphone-based, augmented reality exposure app']","['subjective fear', 'fear of spiders in real-life', 'subjective fear, measured by a Subjective Units of Distress Scale (SUDS) in a Behavioural Approach Test (BAT) in a real-life spider situation']","[{'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C5197824', 'cui_str': 'Mixed Reality'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0392331', 'cui_str': 'Arachnophobia'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0037913', 'cui_str': 'Order Araneae'}]",66.0,0.0462397,"The intervention led to significantly lower subjective fear in the BAT compared to the control group (intervention group, baseline: 7.12 [SD 2.03] follow-up: 5.03 [SD 2.19] vs. control group, baseline: 7.06 [SD 2.34], follow-up 6.24","[{'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Zimmer', 'Affiliation': 'Division of Cognitive Neuroscience, Faculty of Psychology, University of Basel, CH, Switzerland; Transfaculty Research Platform, University of Basel, CH, Switzerland.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': 'Division of Cognitive Neuroscience, Faculty of Psychology, University of Basel, CH, Switzerland; Transfaculty Research Platform, University of Basel, CH, Switzerland.'}, {'ForeName': 'Merle K', 'Initials': 'MK', 'LastName': 'Ibach', 'Affiliation': 'Division of Cognitive Neuroscience, Faculty of Psychology, University of Basel, CH, Switzerland; Transfaculty Research Platform, University of Basel, CH, Switzerland.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Fehlmann', 'Affiliation': 'Division of Cognitive Neuroscience, Faculty of Psychology, University of Basel, CH, Switzerland; Transfaculty Research Platform, University of Basel, CH, Switzerland.'}, {'ForeName': 'Nathalie S', 'Initials': 'NS', 'LastName': 'Schicktanz', 'Affiliation': 'Division of Cognitive Neuroscience, Faculty of Psychology, University of Basel, CH, Switzerland; Transfaculty Research Platform, University of Basel, CH, Switzerland.'}, {'ForeName': 'Dorothée', 'Initials': 'D', 'LastName': 'Bentz', 'Affiliation': 'Division of Cognitive Neuroscience, Faculty of Psychology, University of Basel, CH, Switzerland; Transfaculty Research Platform, University of Basel, CH, Switzerland.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Michael', 'Affiliation': 'Division of Clinical Psychology and Psychotherapy, Department of Psychology, Saarland University, D, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Papassotiropoulos', 'Affiliation': 'Division of Molecular Neuroscience, Faculty of Psychology, University of Basel, CH, Switzerland; Life Sciences Training Facility, Department Biozentrum, University of Basel, CH, Switzerland; University Psychiatric Clinics Basel, CH, Switzerland; Transfaculty Research Platform, University of Basel, CH, Switzerland.'}, {'ForeName': 'Dominique J F', 'Initials': 'DJF', 'LastName': 'de Quervain', 'Affiliation': 'Division of Cognitive Neuroscience, Faculty of Psychology, University of Basel, CH, Switzerland; University Psychiatric Clinics Basel, CH, Switzerland; Transfaculty Research Platform, University of Basel, CH, Switzerland. Electronic address: dominique.dequervain@unibas.ch.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2021.102442'] 1539,34247582,The impact of physical exercises with elements of dance movement therapy on the upper limb grip strength and functional performance of elderly wheelchair users living in nursing homes - a randomized control trial.,"INTRODUCTION Over the last few decades, the quality of care and the quality of life of nursing home (NH) residents have significantly improved, but insufficient physical activity and social involvement still represent substantial challenges in modern nursing facilities. The main aim of this research was to assess the influence of physical exercises with dance movement therapy (DMT) elements on strength and other fitness components of the upper limbs and the overall functional performance of NH residents in wheelchairs compared to standard exercise programmes and usual care. METHOD The study participants were persons aged 68-85 who lived in NH and used manual wheelchairs as a primary means of mobility. Individuals meeting the inclusion criteria were assigned to one of the three groups: Group 1, basic exercise/BE group (n = 55); group 2, physical exercises with elements of dance movement therapy/PED group (n = 55); and group 3, control group, usual care/CO group (n = 55). The intervention for both exercising groups consisted of a 30-min session, two times a week, for 12 weeks in total. Outcome assessments were performed at baseline, 12 weeks after baseline (immediately after the intervention) and 24 weeks after baseline (12 weeks after the intervention). The main outcome was observed for hand grip strength (HGS), while secondary outcomes for box and block test (BBT), arm curl test (ACT), back scratch test (BS), chair sit-and-reach (CSR), peak expiratory flow (PEF), Barthel Index (BI), Berg Balance Scale (BBS) and the range of motion of the shoulder. RESULTS Prior to the start of the exercise programmes, all the tested groups were homogeneous. After 12 weeks the PED group presented higher statistically significant scores in HGS L , BBT, ACT, BS, CSR, BI, BBS: p < 0.001 and HGS R : p = 0.01, compared to the BE group. After 24 weeks from the beginning of the intervention the comparison between the PED group and the BE group showed statistically significant differences (p < 0.001) in favour of PED group in almost all areas: HGS R , HGS L , BBT: ACT, PEF, BS, CSR, BI. After 12 and 24 weeks both intervention groups performed better than the CO in all measures except for Katz ADL and shoulder extension. CONCLUSION Twelve weeks of physical exercises had beneficial effects on the strength and fitness of the upper limbs and overall functional performance in both exercise groups. This study demonstrated that group performing physical exercises with elements of DMT obtained statistically better scores in the majority of analysed domains than other groups. TRIAL REGISTRATION The study was registered in the Sri Lanka Clinical Trials Registry (Registration Number - SLCTR/2018/014 - Date of Registration 16/05/2018. Accessed on https://slctr.lk/trials/1045 ).",2021,"After 12 and 24 weeks both intervention groups performed better than the CO in all measures except for Katz ADL and shoulder extension. ","['elderly wheelchair users living in nursing homes', 'participants were persons aged 68-85 who lived in NH and used manual wheelchairs as a primary means of mobility', 'NH residents in wheelchairs compared to standard exercise programmes and usual care']","['basic exercise/BE group (n\u2009=\u200955); group 2, physical exercises with elements of dance movement therapy/PED group (n\u2009=\u200955); and group 3, control group, usual care/CO', 'physical exercises with elements of dance movement therapy', 'physical exercises with dance movement therapy (DMT', 'physical exercises']","['hand grip strength (HGS), while secondary outcomes for box and block test (BBT), arm curl test (ACT), back scratch test (BS), chair sit-and-reach (CSR), peak expiratory flow (PEF), Barthel Index (BI), Berg Balance Scale (BBS) and the range of motion of the shoulder', 'strength and fitness of the upper limbs and overall functional performance', 'HGS L , BBT, ACT, BS, CSR, BI, BBS', 'Katz ADL and shoulder extension', 'HGS R , HGS L , BBT: ACT, PEF, BS, CSR, BI']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0853966', 'cui_str': 'Wheelchair user'}, {'cui': 'C0425205', 'cui_str': 'Lives in a nursing home'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0184423', 'cui_str': 'Manual wheelchair'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0043143', 'cui_str': 'Wheelchair'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0013879', 'cui_str': 'Chemical element'}, {'cui': 'C0010963', 'cui_str': 'Dance'}, {'cui': 'C0454279', 'cui_str': 'Movement therapy'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0010474', 'cui_str': ""Curling's ulcers""}, {'cui': 'C0430562', 'cui_str': 'Scratch test'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]",,0.0320412,"After 12 and 24 weeks both intervention groups performed better than the CO in all measures except for Katz ADL and shoulder extension. ","[{'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Wołoszyn', 'Affiliation': 'Institute of Health Sciences, Medical College of Rzeszow University, Warzywna 1A Street, 35-310, Rzeszów, Poland. natalia.woloszyn@op.pl.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Wiśniowska-Szurlej', 'Affiliation': 'Institute of Health Sciences, Medical College of Rzeszow University, Warzywna 1A Street, 35-310, Rzeszów, Poland.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Grzegorczyk', 'Affiliation': 'Institute of Medicine, Medical College of Rzeszow University, Warzywna 1A Street, 35-310, Rzeszów, Poland.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Kwolek', 'Affiliation': 'Institute of Health Sciences, Medical College of Rzeszow University, Warzywna 1A Street, 35-310, Rzeszów, Poland.'}]",BMC geriatrics,['10.1186/s12877-021-02368-7'] 1540,34214683,Anthocyanin complex niosome gel accelerates oral wound healing: In vitro and clinical studies.,"An anthocyanin complex (AC), composed of extracts of purple waxy corn and blue butterfly pea petals, and AC niosomes, bilayered vesicles of non-ionic surfactants, were compared in in vitro and clinical studies. Cultured fibroblasts subjected to a scratch wound were monitored for cell viability, cell migration, nuclear morphology and protein expression. Scratched cells showed accelerated wound healing activity, returning to normal 24 h after treatment with AC niosomes (0.002 mg/mL). Western blots and immunocytochemistry indicated upregulation of type I, III and IV collagens, fibronectin and laminins in AC niosome-treated scratched cells. A randomized block placebo-controlled double-blind clinical trial in 60 volunteers (18-60 years old) with oral wounds indicated that AC niosome gel accelerated wound closure, reduced pain due to the oral wounds and improved participants' quality of life more than AC gel, triamcinolone gel and placebo gel. These data are consistent with enhanced delivery of AC to fibroblasts by use of niosomes. AC niosomes activated fibroblasts within wounded regions and accelerated wound healing, indicating that AC niosomes have therapeutic potential.",2021,"Western blots and immunocytochemistry indicated upregulation of type I, III and IV collagens, fibronectin and laminins in AC niosome-treated scratched cells.","['60 volunteers (18-60years old) with oral wounds indicated that AC niosome gel accelerated wound closure, reduced pain due to the oral wounds and improved participants']","['AC gel, triamcinolone gel and placebo gel', 'placebo', 'Anthocyanin complex niosome gel']","['wound healing activity', 'cell viability, cell migration, nuclear morphology and protein expression', 'upregulation of type I, III and IV collagens, fibronectin and laminins', 'oral wound healing', 'quality of life']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C1720782', 'cui_str': 'Niosomes'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]","[{'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1720782', 'cui_str': 'Niosomes'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0007620', 'cui_str': 'Cell Viability'}, {'cui': 'C1622501', 'cui_str': 'Cell Migration'}, {'cui': 'C0332437', 'cui_str': 'Associated morphology'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0041904', 'cui_str': 'Up-Regulation (Physiology)'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0016055', 'cui_str': 'Fibronectin'}, {'cui': 'C0022984', 'cui_str': 'Glycoprotein GP-2'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",60.0,0.128717,"Western blots and immunocytochemistry indicated upregulation of type I, III and IV collagens, fibronectin and laminins in AC niosome-treated scratched cells.","[{'ForeName': 'Teerasak', 'Initials': 'T', 'LastName': 'Damrongrungruang', 'Affiliation': 'Department of Oral Diagnosis, Faculty of Dentistry, Khon Kaen University, Thailand. Electronic address: dteera@kku.ac.th.'}, {'ForeName': 'Jarin', 'Initials': 'J', 'LastName': 'Paphangkorakit', 'Affiliation': 'Department of Oral Biology, Faculty of Dentistry, Khon Kaen University, Thailand. Electronic address: jarin@kku.ac.th.'}, {'ForeName': 'Sucharat', 'Initials': 'S', 'LastName': 'Limsitthichaikoon', 'Affiliation': 'College of Pharmacy, Rangsit University, Thailand. Electronic address: sucharat.l@rsu.ac.th.'}, {'ForeName': 'Bhattaranitch', 'Initials': 'B', 'LastName': 'Khampaenjiraroch', 'Affiliation': 'Division of Thai Traditional Medicine, Udon Thani Rajabhat University, Thailand. Electronic address: akapa_excellent@hotmail.com.'}, {'ForeName': 'Michael Jonathan', 'Initials': 'MJ', 'LastName': 'Davies', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen N, Denmark. Electronic address: davies@sund.ku.dk.'}, {'ForeName': 'Bunleu', 'Initials': 'B', 'LastName': 'Sungthong', 'Affiliation': 'Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand. Electronic address: bunleu.s@msu.ac.th.'}, {'ForeName': 'Aroonsri', 'Initials': 'A', 'LastName': 'Priprem', 'Affiliation': 'Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand; Melatonin Research Group, Khon Kaen University, Thailand. Electronic address: apriprem@gmail.com.'}]","Nanomedicine : nanotechnology, biology, and medicine",['10.1016/j.nano.2021.102423'] 1541,34219000,"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.","BACKGROUND In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, and a clinically meaningful overall survival (OS) effect in PD-L1-positive aTNBC. The phase III KEYNOTE-355 trial adding pembrolizumab to chemotherapy for aTNBC showed similar PFS effects. IMpassion131 evaluated first-line atezolizumab-paclitaxel in aTNBC. PATIENTS AND METHODS Eligible patients [no prior systemic therapy or ≥12 months since (neo)adjuvant chemotherapy] were randomised 2:1 to atezolizumab 840 mg or placebo (days 1, 15), both with paclitaxel 90 mg/m 2 (days 1, 8, 15), every 28 days until disease progression or unacceptable toxicity. Stratification factors were tumour PD-L1 status, prior taxane, liver metastases and geographical region. The primary endpoint was investigator-assessed PFS, tested hierarchically first in the PD-L1-positive [immune cell expression ≥1%, VENTANA PD-L1 (SP142) assay] population, and then in the ITT population. OS was a secondary endpoint. RESULTS Of 651 randomised patients, 45% had PD-L1-positive aTNBC. At the primary PFS analysis, adding atezolizumab to paclitaxel did not improve investigator-assessed PFS in the PD-L1-positive population [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.60-1.12; P = 0.20; median PFS 6.0 months with atezolizumab-paclitaxel versus 5.7 months with placebo-paclitaxel]. In the PD-L1-positive population, atezolizumab-paclitaxel was associated with more favourable unconfirmed best overall response rate (63% versus 55% with placebo-paclitaxel) and median duration of response (7.2 versus 5.5 months, respectively). Final OS results showed no difference between arms (HR 1.11, 95% CI 0.76-1.64; median 22.1 months with atezolizumab-paclitaxel versus 28.3 months with placebo-paclitaxel in the PD-L1-positive population). Results in the ITT population were consistent with the PD-L1-positive population. The safety profile was consistent with known effects of each study drug. CONCLUSION Combining atezolizumab with paclitaxel did not improve PFS or OS versus paclitaxel alone. CLINICALTRIALS.GOV: NCT03125902.",2021,"Final OS results showed no difference between arms (HR 1.11, 95% CI 0.76-1.64; median 22.1 months with atezolizumab-paclitaxel versus 28.3 months with placebo-paclitaxel in the PD-L1-positive population).","['Of 651 randomised patients, 45% had PD-L1-positive aTNBC', 'Eligible patients [no prior systemic therapy or ≥12 months since (neo)adjuvant chemotherapy', 'unresectable locally advanced/metastatic triple-negative breast cancer']","['atezolizumab with first-line nanoparticle albumin-bound-paclitaxel', 'atezolizumab 840 mg or placebo', 'paclitaxel with or without atezolizumab', 'pembrolizumab', 'placebo-paclitaxel', 'atezolizumab-paclitaxel', 'paclitaxel', 'atezolizumab with paclitaxel', 'atezolizumab to paclitaxel']","['median duration of response', 'investigator-assessed PFS, tested hierarchically first in the PD-L1-positive [immune cell expression', 'overall response rate', 'progression-free survival (PFS) benefit']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C3539878', 'cui_str': 'Triple-negative breast cancer'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C4708913', 'cui_str': '840'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.689646,"Final OS results showed no difference between arms (HR 1.11, 95% CI 0.76-1.64; median 22.1 months with atezolizumab-paclitaxel versus 28.3 months with placebo-paclitaxel in the PD-L1-positive population).","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Miles', 'Affiliation': 'Mount Vernon Cancer Centre, Northwood, UK. Electronic address: David.miles@doctors.org.uk.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Gligorov', 'Affiliation': 'Medical Oncology Department, Institut Universitaire de Cancérologie Assistance Publique-Hôpitaux de Paris-Sorbonne Université, Paris, France.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'André', 'Affiliation': 'Department of Medical Oncology, Gustave Roussy, Université Paris Sud, Villejuif, France.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cameron', 'Affiliation': 'University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Schneeweiss', 'Affiliation': 'Division of Gynecologic Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Barrios', 'Affiliation': 'Latin American Cooperative Oncology Group, Porto Alegre RS, Brazil.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Xu', 'Affiliation': 'National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Wardley', 'Affiliation': 'National Institute for Health Research Manchester Clinical Research Facility at The Christie NHS Foundation Trust, Manchester, UK; Outreach Research & Innovation Group, Manchester, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Kaen', 'Affiliation': 'Centro Oncológico Riojano Integral and Universidad Nacional de La Rioja, La Rioja, Argentina.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Andrade', 'Affiliation': 'Clinical Oncology, Santa Casa de Misericórdia da Bahia, Salvador, Brazil.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Semiglazov', 'Affiliation': 'NN Petrov Research Institute of Oncology, St. Petersburg, Russia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Reinisch', 'Affiliation': 'Kliniken Essen-Mitte, Essen, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Product Development Oncology, Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Patre', 'Affiliation': 'Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Morales', 'Affiliation': 'Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Patel', 'Affiliation': 'Patient-Centered Outcomes Research, Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kaul', 'Affiliation': 'Product Development Oncology, Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Barata', 'Affiliation': 'Pharma Development Biostatistics Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': ""O'Shaughnessy"", 'Affiliation': 'Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.05.801'] 1542,34217774,"Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.","AIM We evaluated the effect of the latest GLP-1 RA semaglutide on tongue fat storage in obese women. DESIGN We conducted a randomized single-blind, pilot study. METHODS Twenty-five obese women with polycystic ovary syndrome (PCOS) (33.7 ± 5.3 years, body mass index (BMI) 36.1 ± 3.9 kg/m2, mean ± SD) were randomized to semaglutide 1.0 mg or placebo for 16 weeks. We quantified tongue volume and its fat tissue and fat proportion by magnetic resonance imaging. RESULTS Tongue fat tissue and fat proportion significantly reduced after semaglutide vs placebo (-1.94 ± 5.51 vs. + 3.12 ± 4.87 cm 3 , p = 0.022, and -0.02 ± 0.07 vs. 0.04 ± 0.06, p = 0.010, respectively). Correlation analysis revealed that these reductions were associated with those in body weight, BMI and waist circumference (p = 0.010 for all). CONCLUSIONS This is the first study confirming the beneficial effect of semaglutide on tongue structure in obese women with PCOS. Further studies are needed to assess the clinical importance of such findings.",2021,"RESULTS Tongue fat tissue and fat proportion significantly reduced after semaglutide vs placebo (-1.94±5.51 vs. +3.12±4.87 cm 3 , p=0.022, and -0.02±0.07 vs. 0.04±0.06, p=0.010, respectively).","[' Twenty-five obese women with polycystic ovary syndrome (PCOS) (33.7±5.3 years, body mass index (BMI) 36.1±3.9 kg/m2, mean ± SD', 'obese women', 'obese women with PCOS']","['latest GLP-1 RA semaglutide', 'Semaglutide', 'semaglutide', 'semaglutide 1.0 mg or placebo', 'placebo']","['Tongue fat tissue and fat proportion', 'body weight, BMI and waist circumference']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}]",25.0,0.064113,"RESULTS Tongue fat tissue and fat proportion significantly reduced after semaglutide vs placebo (-1.94±5.51 vs. +3.12±4.87 cm 3 , p=0.022, and -0.02±0.07 vs. 0.04±0.06, p=0.010, respectively).","[{'ForeName': 'Mojca', 'Initials': 'M', 'LastName': 'Jensterle', 'Affiliation': 'Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Slovenia.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Ferjan', 'Affiliation': 'Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Slovenia.'}, {'ForeName': 'Andrej', 'Initials': 'A', 'LastName': 'Vovk', 'Affiliation': 'Center for Clinical Physiology, Faculty of Medicine, University of Ljubljana, Slovenia.'}, {'ForeName': 'Tadej', 'Initials': 'T', 'LastName': 'Battelino', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, University of Ljubljana, Slovenia.'}, {'ForeName': 'Manfredi', 'Initials': 'M', 'LastName': 'Rizzo', 'Affiliation': 'Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Italy.'}, {'ForeName': 'Andrej', 'Initials': 'A', 'LastName': 'Janež', 'Affiliation': 'Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Slovenia. Electronic address: andrej.janez@kclj.si.'}]",Diabetes research and clinical practice,['10.1016/j.diabres.2021.108935'] 1543,34222540,"The Effect of Benson's Relaxation Technique on Pain Intensity, Belief, Perception, and Acceptance in adult Hemophilia Patients: A Randomized Controlled Trial.","Background Most hemophilia patients experience pain in their lives. Some complementary interventions might affect pain belief. This study aimed to determine the effect of Benson's relaxation technique on pain intensity, pain belief and perception, and pain acceptance in hemophilia patients. Methods In this clinical trial study, 80 hemophilia patients were divided into an intervention (relaxation technique) and a control (routine care) group based on block randomization. This study was conducted in the hemophilia center of Shahid Dastgheib hospital affiliated to Shiraz University of Medical Sciences from October to December 2018. The intervention group listened to a voice containing relaxation technique twice a day for eight weeks. Numeric rating scale, pain belief and perception inventory, and chronic pain acceptance questionnaires were completed at the beginning and eight weeks after the intervention. Data were analyzed by SPSS 21 using independent t-test, Paired-t-test, Chi-square, Mann-Whitney U test, and ANCOVA. P-value <0.05 was considered as significant. Results After the intervention, the mean scores of pain intensity, pain belief and perception inventory, and pain acceptance in the intervention group were 4.26±2.17, -13.35±1.50, and 67.24±9.49 and in the control groups were 5.85±2.61, -2±1.70, and 56.57±11.04, respectively. After the intervention, a difference was found between the groups regarding the mean score of pain intensity (P=0.007), pain belief and perception inventory (P<0.001) and its subscales (P<0.05) as well as total pain acceptance (P<0.001). Conclusion This study showed relaxation technique can be applied to reduce these patients' pain intensity, improve their pain belief and perception, and enhance their pain acceptance. Trial Registration Number IRCT20180311039037N1.",2021,"After the intervention, the mean scores of pain intensity, pain belief and perception inventory, and pain acceptance in the intervention group were 4.26±2.17, -13.35±1.50, and 67.24±9.49 and in the control groups were 5.85±2.61, -2±1.70, and 56.57±11.04, respectively.","['hemophilia patients', 'hemophilia center of Shahid Dastgheib hospital affiliated to Shiraz University of Medical Sciences from October to December 2018', '\n\n\nMost hemophilia', '80 hemophilia patients', 'patients experience pain in their lives', 'adult Hemophilia Patients']","[""Benson's Relaxation Technique"", 'intervention (relaxation technique) and a control (routine care) group based on block randomization', 'intervention group listened to a voice containing relaxation technique', ""Benson's relaxation technique""]","['Pain Intensity, Belief, Perception, and Acceptance', 'Numeric rating scale, pain belief and perception inventory, and chronic pain acceptance questionnaires', 'total pain acceptance', 'pain intensity, pain belief and perception, and pain acceptance', 'mean score of pain intensity', 'pain belief', 'pain belief and perception inventory', 'mean scores of pain intensity, pain belief and perception inventory, and pain acceptance']","[{'cui': 'C0019069', 'cui_str': 'Hereditary factor VIII deficiency disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0035029', 'cui_str': 'Relaxation technique'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",80.0,0.0689206,"After the intervention, the mean scores of pain intensity, pain belief and perception inventory, and pain acceptance in the intervention group were 4.26±2.17, -13.35±1.50, and 67.24±9.49 and in the control groups were 5.85±2.61, -2±1.70, and 56.57±11.04, respectively.","[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Molazem', 'Affiliation': 'Community Based Psychiatric Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Madineh', 'Initials': 'M', 'LastName': 'Alizadeh', 'Affiliation': 'Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Masoume', 'Initials': 'M', 'LastName': 'Rambod', 'Affiliation': 'Community Based Psychiatric Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",International journal of community based nursing and midwifery,['10.30476/ijcbnm.2021.87937.1471'] 1544,34221210,Benefits Conferred by Peer-Support Nursing Intervention to Pulmonary Function and Quality of Life in Nonsmoking Patients with COPD.,"Objective Peer support is a concept of substantial significance to health scientists and practitioners today due to its focus shifting from disease treatment to health promotion. Effective incorporation peer relationships in support-enhancing interventions could improve quality care and health outcomes. More and more cases of chronic obstructive pulmonary disease (COPD) have been diagnosed in nonsmokers. In this study, the effects of peer-support nursing intervention on the pulmonary function and quality of life of nonsmoking patients with COPD were investigated. Methods A total of 100 COPD nonsmoking patients admitted to our hospital from October 2018 to October 2020 were selected as study subjects. All nonsmoking patients were in accordance with the guidelines of COPD diagnosis and treatment issued by the Respiratory Medicine Branch of Chinese Medical Association, and they were not in the habit of smoking. According to the different interventions, the nonsmoking patients were divided into the control group ( n  = 50) and the observation group ( n  = 50). Among them, nonsmoking patients in the control group received routine care, and nonsmoking patients in the observation group received routine care and peer-support nursing. The difference on the scores of social support, self-management efficacy, healthy lifestyle, and the distance of six-minute walking were to be compared between the two groups before and after the intervention. Results There was no significant statistical difference on the general information between the two groups in terms of age, gender, and course of disease ( P > 0.05). Before intervention, the social support score involving subjective support, objective support, utilization of support, and total score revealed slight difference between the two groups ( P > 0.05). However, after the intervention, the subjective support, utilization of support, and total score remained statistically different between the two groups ( P < 0.05), and the objective support showed no significant difference between the two groups ( P > 0.05). Before intervention, there was no statistical difference in the self-management efficacy scores such as positive attitude, stress reduction, self-decision-making, and total score between the two groups ( P > 0.05). After the intervention, the two groups indicated statistical difference in the self-management efficacy scores ( P < 0.05). Before intervention, there was no significant difference between the two groups in the healthy lifestyle score in terms of health responsibility, self-realization, interpersonal support, and stress management ( P > 0.05), and the abovementioned outcome measures indicated significant difference between the two groups after intervention ( P < 0.05). There was no statistical difference in six-minute walking distance between the two groups before the intervention ( P > 0.05), but after the intervention, the observation group revealed a significantly longer distance of six-minute walking compared to the control group ( P < 0.05). Conclusion These data suggest that peer-support nursing intervention can effectively improve pulmonary function and quality of life of nonsmoking patients with COPD.",2021,"There was no significant statistical difference on the general information between the two groups in terms of age, gender, and course of disease ( P > 0.05).","['Nonsmoking Patients with COPD', 'All nonsmoking patients were in accordance with the guidelines of COPD diagnosis and treatment issued by the Respiratory Medicine Branch of Chinese Medical Association, and they were not in the habit of smoking', '100 COPD nonsmoking patients admitted to our hospital from October 2018 to October 2020 were selected as study subjects', 'nonsmoking patients with COPD', 'nonsmoking patients']","['peer-support nursing intervention', 'routine care and peer-support nursing', 'Peer-Support Nursing Intervention', 'routine care']","['healthy lifestyle score', 'longer distance of six-minute walking', 'pulmonary function and quality of life', 'six-minute walking distance', 'scores of social support, self-management efficacy, healthy lifestyle, and the distance of six-minute walking', 'self-management efficacy scores', 'Pulmonary Function and Quality of Life', 'chronic obstructive pulmonary disease (COPD', 'self-management efficacy scores such as positive attitude, stress reduction, self-decision-making, and total score', 'health responsibility, self-realization, interpersonal support, and stress management', 'social support score involving subjective support, objective support, utilization of support, and total score', 'quality care and health outcomes', 'general information', 'subjective support, utilization of support, and total score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0034060', 'cui_str': 'Pulmonary medicine'}, {'cui': 'C1253959', 'cui_str': 'Branch of'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}]",100.0,0.00582427,"There was no significant statistical difference on the general information between the two groups in terms of age, gender, and course of disease ( P > 0.05).","[{'ForeName': 'Xiaoling', 'Initials': 'X', 'LastName': 'Yao', 'Affiliation': ""Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.""}, {'ForeName': 'Xiaoyu', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Yuan', 'Affiliation': ""Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.""}, {'ForeName': 'Zhikang', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': ""Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.""}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': ""Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.""}, {'ForeName': 'Hongyan', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': ""Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.""}]",Canadian respiratory journal,['10.1155/2021/7450979'] 1545,34229078,"A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjects.","OBJECTIVE Recombinant human albumin (rHA) is an alternative to human serum albumin (HSA) for treating ascites in cirrhosis patients. This study was to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics/pharmacodynamics (PK/PD) of rHA in healthy subjects to guide the design for further clinical trials. METHODS Healthy subjects aged 18-55 years were enrolled in this double-blinded, first-in-human, placebo-controlled single ascending dose (SAD) (1.25, 5, 10, 20, or 30g) and positive-controlled multiple-dose study (3-day treatment of 10g/day for three cycles every three weeks). The safety was assessed by adverse events (AEs). Antibodies (IgE and IgD) and cytokines were analyzed for immunogenicity. Serum albumin levels and changes in plasma colloid osmotic pressure (PCOP) and hematocrit (HCT) were measured for PK/PD analysis. RESULTS rHA was well tolerated as all AEs were assessed as mild or moderate. No severe allergy or difference in the incidence of AEs was observed among the different cohorts in the SAD study or in the different cycles in the multiple-dose study. The incidence of AEs was similar for the rHA and HSA cohort. Antibodies or cytokines showed no changes after drug administration. As expected, serum albumin levels and PCOP increases, and HCT ratio decreases were dose-related with significant differences (p < 0.01). No differences were observed between rHA and HSA. CONCLUSION rHA is safe and well-tolerated in healthy Chinese subjects. rHA and HSA exhibited similar safety, tolerability, and PK/PD profiles. The results support further evaluation of rHA treatment in cirrhotic patients with ascites. The clinical trial registration numbers are CTR20191221 (http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml).",2021,No severe allergy or difference in the incidence of AEs was observed among the different cohorts in the SAD study or in the different cycles in the multiple-dose study.,"['cirrhotic patients with ascites', 'cirrhosis patients', 'Healthy subjects aged 18-55 years', 'Healthy Subjects', 'healthy subjects', 'healthy Chinese subjects']","['Novel Recombinant Human Albumin', 'rHA', 'Recombinant human albumin (rHA', 'placebo-controlled single ascending dose (SAD']","['serum albumin levels and PCOP increases, and HCT ratio decreases', 'incidence of AEs', 'Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics', 'safety, tolerability, immunogenicity, and pharmacokinetics/pharmacodynamics (PK/PD', 'Serum albumin levels and changes in plasma colloid osmotic pressure (PCOP) and hematocrit (HCT', 'safety, tolerability, and PK/PD profiles', 'safe and well-tolerated', 'Antibodies (IgE and IgD) and cytokines']","[{'cui': 'C0439686', 'cui_str': 'Cirrhotic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003962', 'cui_str': 'Ascites'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0304925', 'cui_str': 'Albumin Human, USP'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C0523465', 'cui_str': 'Albumin measurement, serum'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0009361', 'cui_str': 'Colloids'}, {'cui': 'C1168413', 'cui_str': 'Osmotic pressure increased'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0029393', 'cui_str': 'Osmotic pressure'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0020843', 'cui_str': 'Immunoglobulin D'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}]",,0.1555,No severe allergy or difference in the incidence of AEs was observed among the different cohorts in the SAD study or in the different cycles in the multiple-dose study.,"[{'ForeName': 'Cuiyun', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China. Electronic address: lcy2442929@jlu.edu.cn.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Xiang', 'Affiliation': 'Tonghua Anrate Biopharmaceuticals Co., Ltd., Tonghua, Jilin, 134100, China. Electronic address: xiang_wei@anrate.cn.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China. Electronic address: wumin1987@jlu.edu.cn.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China. Electronic address: zhanghong2015@jlu.edu.cn.'}, {'ForeName': 'Jianqiu', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'Tonghua Anrate Biopharmaceuticals Co., Ltd., Tonghua, Jilin, 134100, China. Electronic address: cheng_jianqiu@anrate.cn.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Yang', 'Affiliation': 'Tonghua Anrate Biopharmaceuticals Co., Ltd., Tonghua, Jilin, 134100, China. Electronic address: yang_tao@anrate.cn.'}, {'ForeName': 'Jiajia', 'Initials': 'J', 'LastName': 'Mai', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China. Electronic address: 2272135673@qq.com.'}, {'ForeName': 'Xiumei', 'Initials': 'X', 'LastName': 'Chi', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China. Electronic address: chixm@jlu.edu.cn.'}, {'ForeName': 'Xiuzhu', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China. Electronic address: xiuzhugao@jlu.edu.cn.'}, {'ForeName': 'Yanhua', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China. Electronic address: dingyanh@jlu.edu.cn.'}, {'ForeName': 'Junqi', 'Initials': 'J', 'LastName': 'Niu', 'Affiliation': 'Department of Hepatology, First Hospital, Jilin University, Changchun, 130021, Jilin, China. Electronic address: junqiniu@jlu.edu.cn.'}]",European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,['10.1016/j.ejps.2021.105923'] 1546,34176180,Effect of conscious sedation and deep sedation on the vagal response characteristics during ganglionated plexus ablation.,"INTRODUCTION We aimed to determine the effects of conscious and deep sedation on vagal response (VR) characteristics during ganglionated plexus (GP) ablation. METHODS Forty consecutive patients undergoing GP ablation for vasovagal syncope were divided to receive conscious sedation with midazolam (Group 1, n = 29) or deep sedation with the midazolam-propofol combination (Group 2, n = 11). VR was defined on three levels. R-R interval increase of >50% (Level 1); R-R interval increase of 20%-50% (Level 2); and R-R interval increase of <20% (Level 3). RESULTS The ratio of Level 1 VR during ablation on left superior and inferior GPs was significantly lower in Group 2 (p < .0001 and p = .034, respectively). Once the cut-off for VR was decreased to Level 2, the ratio of (+) VR was similar between groups during ablation of left-sided GPs. Positive VR in any level was lower than 20% during ablation of right-sided GPs. CONCLUSIONS The autonomic tone might be affected in different ways by the level or type of intravenous sedation. Awareness of anesthesia-related differences may be important if GP ablation will be performed by using VR characteristics during ablation.",2021,"The ratio of Level 1 VR during ablation on left superior and inferior GPs was significantly lower in Group 2 (p < .0001 and p = .034, respectively).","['ganglionated plexus ablation', 'Forty consecutive patients undergoing GP ablation for vasovagal syncope']","['conscious sedation and deep sedation', 'conscious and deep sedation', 'conscious sedation with midazolam', 'deep sedation with the midazolam-propofol combination']","['autonomic tone', 'vagal response (VR) characteristics', 'ratio of (+) VR', 'ratio of Level 1 VR during ablation on left superior and inferior GPs', 'Positive VR']","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042420', 'cui_str': 'Vasovagal syncope'}]","[{'cui': 'C0079159', 'cui_str': 'Conscious sedation'}, {'cui': 'C1956064', 'cui_str': 'Sedation, Deep'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0456947', 'cui_str': 'Level 1'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0272302', 'cui_str': 'Gray platelet syndrome'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",40.0,0.0432311,"The ratio of Level 1 VR during ablation on left superior and inferior GPs was significantly lower in Group 2 (p < .0001 and p = .034, respectively).","[{'ForeName': 'Tolga', 'Initials': 'T', 'LastName': 'Aksu', 'Affiliation': 'Department of Cardiology, Yeditepe University Hospital, Istanbul, Turkey.'}, {'ForeName': 'Kivanc', 'Initials': 'K', 'LastName': 'Yalin', 'Affiliation': 'Department of Cardiology, Istanbul-Cerrahpasa University Hospital, Istanbul, Turkey.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'John', 'Affiliation': 'Department of Cardiology, Medical University of South Carolina, Mt Pleasant, South Carolina, USA.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Osorio', 'Affiliation': 'Department of Cardiology, Arrhythmia Institute at Grandview, Birmingham, Alabama, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Winterfield', 'Affiliation': 'Department of Cardiology, Medical University of South Carolina, Mt Pleasant, South Carolina, USA.'}, {'ForeName': 'Dursun', 'Initials': 'D', 'LastName': 'Aras', 'Affiliation': 'Department of Cardiology, Ankara City Hospital, Ankara, Turkey.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Gopinathannair', 'Affiliation': 'Department of Cardiology, Kansas City Heart Rhythm Institute and Research Foundation, Kansas City, Missouri, USA.'}]",Journal of cardiovascular electrophysiology,['10.1111/jce.15133'] 1547,34233928,The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.,"OBJECTIVE Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve albuminuria in patients with high cardiorenal risk. We report albuminuria change in the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) cardiovascular outcome trial, which included populations with lower cardiorenal risk. RESEARCH DESIGN AND METHODS DECLARE-TIMI 58 randomized 17,160 patients with type 2 diabetes, creatinine clearance >60 mL/min, and either atherosclerotic cardiovascular disease (CVD; 40.6%) or risk-factors for CVD (59.4%) to dapagliflozin or placebo. Urinary albumin-to-creatinine ratio (UACR) was tested at baseline, 6 months, 12 months, and yearly thereafter. The change in UACR over time was measured as a continuous and categorical variable (≤15, >15 to <30, ≥30 to ≤300, and >300 mg/g) by treatment arm. The composite cardiorenal outcome was a ≥40% sustained decline in the estimated glomerular filtration rate (eGFR) to <60 mL/min/1.73 m 2 , end-stage kidney disease, and cardiovascular or renal death; specific renal outcome included all except cardiovascular death. RESULTS Baseline UACR was available for 16,843 (98.15%) participants: 9,067 (53.83%) with ≤15 mg/g, 2,577 (15.30%) with >15 to <30 mg/g, 4,030 (23.93%) with 30-300 mg/g, and 1,169 (6.94%) with >300 mg/g. Measured as a continuous variable, UACR improved from baseline to 4.0 years with dapagliflozin, compared with placebo, across all UACR and eGFR categories (all P < 0.0001). Sustained confirmed ≥1 category improvement in UACR was more common in dapagliflozin versus placebo (hazard ratio 1.45 [95% CI 1.35-1.56], P < 0.0001). Cardiorenal outcome was reduced with dapagliflozin for subgroups of UACR ≥30 mg/g ( P < 0.0125, P interaction = 0.033), and the renal-specific outcome was reduced for all UACR subgroups ( P < 0.05, P interaction = 0.480). CONCLUSIONS In DECLARE-TIMI 58, dapagliflozin demonstrated a favorable effect on UACR and renal-specific outcome across baseline UACR categories, including patients with normal albumin excretion. The results suggest a role for SGLT2i also in the primary prevention of diabetic kidney disease.",2021,"Cardiorenal outcome was reduced with dapagliflozin for subgroups of UACR ≥30 mg/g ( P < 0.0125, P int eraction = 0.033), and the renal-specific outcome was reduced for all UACR subgroups ( P < 0.05, P interaction = 0.480). ","['DECLARE-TIMI 58 randomized 17,160 patients with type 2 diabetes, creatinine clearance', 'patients with high cardiorenal risk', 'included populations with lower cardiorenal risk']","['dapagliflozin or placebo', 'SGLT2i', 'Sodium-glucose cotransporter 2 inhibitors (SGLT2i', 'Dapagliflozin', 'dapagliflozin', 'placebo']","['estimated glomerular filtration rate (eGFR', 'renal-specific outcome', 'Urinary albumin-to-creatinine ratio (UACR', 'Cardiorenal outcome', 'stage kidney disease, and cardiovascular or renal death; specific renal outcome included all except cardiovascular death', 'UACR and renal-specific outcome', 'UACR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205251', 'cui_str': 'Low'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",17160.0,0.317967,"Cardiorenal outcome was reduced with dapagliflozin for subgroups of UACR ≥30 mg/g ( P < 0.0125, P int eraction = 0.033), and the renal-specific outcome was reduced for all UACR subgroups ( P < 0.05, P interaction = 0.480). ","[{'ForeName': 'Ofri', 'Initials': 'O', 'LastName': 'Mosenzon', 'Affiliation': 'Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel ofrim@hadassah.org.il.'}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Wiviott', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.""}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Jamie P', 'Initials': 'JP', 'LastName': 'Dwyer', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Avivit', 'Initials': 'A', 'LastName': 'Cahn', 'Affiliation': 'Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Erica L', 'Initials': 'EL', 'LastName': 'Goodrich', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.""}, {'ForeName': 'Aliza', 'Initials': 'A', 'LastName': 'Rozenberg', 'Affiliation': 'Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Meir', 'Initials': 'M', 'LastName': 'Schechter', 'Affiliation': 'Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Ilan', 'Initials': 'I', 'LastName': 'Yanuv', 'Affiliation': 'Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Sabina A', 'Initials': 'SA', 'LastName': 'Murphy', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.""}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Zelniker', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.""}, {'ForeName': 'Ingrid A M', 'Initials': 'IAM', 'LastName': 'Gause-Nilsson', 'Affiliation': 'BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Anna Maria', 'Initials': 'AM', 'LastName': 'Langkilde', 'Affiliation': 'BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Fredriksson', 'Affiliation': 'BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Johansson', 'Affiliation': 'BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.""}, {'ForeName': 'Lawrence A', 'Initials': 'LA', 'LastName': 'Leiter', 'Affiliation': ""Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Darren K', 'Initials': 'DK', 'LastName': 'McGuire', 'Affiliation': 'Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'John P H', 'Initials': 'JPH', 'LastName': 'Wilding', 'Affiliation': 'Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, U.K.'}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Sabatine', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.""}, {'ForeName': 'Itamar', 'Initials': 'I', 'LastName': 'Raz', 'Affiliation': 'Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.'}]",Diabetes care,['10.2337/dc21-0076'] 1548,34235906,Histologic and histomorphometric analysis of connective tissue grafts harvested by the parallel incision method: a pilot randomized controlled trial comparing macro- and microsurgical approaches.,"OBJECTIVE The aim of this pilot randomized controlled trial was to assess the efficacy of macro- and microsurgical procedures in removing the epithelial tissue layer of subepithelial connective grafts (SCTGs) harvested by the parallel incision method. METHOD AND MATERIALS Sixteen patients were randomized to receive macro-SCTG harvesting (n = 10, control group) or micro-SCTG harvesting (n = 10, test group) by the parallel incision technique. Histologic and histomorphometric analysis of the SCTG evaluated the percentage remnant of epithelium and connective tissue. The presence of remnant portions of the epithelium was identified in eight samples (three in the macro- and five in the microsurgery groups). RESULTS Sixteen participants with 20 sites were included and 20 SCTG were collected and analyzed. SCTG harvested by microsurgical approaches displayed more portions of remnant epithelium compared to the conventional removal (50% versus 30%). There were no significant differences in mean remnant epithelial thickness for test (147.3 ± 89.3 μm) and control (209.0 ± 127.5 μm) groups (P = .57). Likewise, nonsignificant differences were identified in terms of the connective tissue thickness (macrosurgery: 1,511.0 ± 1,160.0 μm; microsurgery: 1,472.0 ± 1,063.0 μm) between groups (P = .96). CONCLUSION The samples harvested by microsurgery had greater remaining epithelial portions than those harvested by macrosurgery, and similar connective layer thickness.",2021,There were no significant differences in mean remnant epithelial thickness for test (147.3 ± 89.3 μm) and control (209.0 ± 127.5 μm) groups (P = .57).,"['Sixteen participants with 20 sites were included and 20 SCTG', 'Sixteen patients']","['parallel incision technique', 'connective tissue grafts harvested by the parallel incision method', 'macro-SCTG harvesting (n = 10, control group) or micro-SCTG harvesting', 'macro- and microsurgical procedures', 'macro- and microsurgical approaches']","['mean remnant epithelial thickness', 'connective tissue thickness', 'portions of remnant epithelium', 'remaining epithelial portions']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009780', 'cui_str': 'Connective tissue'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0026035', 'cui_str': 'Microsurgery'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0009780', 'cui_str': 'Connective tissue'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0014609', 'cui_str': 'Epithelium'}]",16.0,0.0768489,There were no significant differences in mean remnant epithelial thickness for test (147.3 ± 89.3 μm) and control (209.0 ± 127.5 μm) groups (P = .57).,"[{'ForeName': 'Sérgio', 'Initials': 'S', 'LastName': 'Kahn', 'Affiliation': ''}, {'ForeName': 'Ilana Tajra Evangelista', 'Initials': 'ITE', 'LastName': 'Araújo', 'Affiliation': ''}, {'ForeName': 'Alexandra Tavares', 'Initials': 'AT', 'LastName': 'Dias', 'Affiliation': ''}, {'ForeName': 'Alex Balduíno de', 'Initials': 'AB', 'LastName': 'Souza', 'Affiliation': ''}, {'ForeName': 'Leandro', 'Initials': 'L', 'LastName': 'Chambrone', 'Affiliation': ''}, {'ForeName': 'Gustavo Vicentis de Oliveira', 'Initials': 'GVO', 'LastName': 'Fernandes', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.b1702145'] 1549,34235827,Effect of different initial anticoagulant strategies on short-term outcome of patients with symptomatic DVT in China.,"PURPOSE In ambulant patients with lower limb DVT managed with Warfarin, there is a need for initial treatment and short time ""bridging"" with a rapidly acting anticoagulant until there is a stable therapeutic INR. In this study, results from bridging with subcutaneous low molecular weight heparin (LMWH) or oral Rivaroxaban were compared. METHODS One hundred and twenty-four patients received LMWH and 98 patients received Rivaroxaban, both in addition to Warfarin. Patients were assessed at 1 and 4 weeks after treatment initiation for thrombus progression, bleeding, clinic attendance and INR. FINDINGS The treatment groups were well matched. There were no significant differences between the treatment groups for any of the end-points at either 1 week or 4 weeks. IMPLICATIONS In ambulant patients with DVT treated with Warfarin both Rivaroxaban and LMWH are suitable for use in the early phase of Warfarin treatment until therapeutic INR is achieved. Rivaroxaban is a suitable alternative to LMWH for patients who prefer not to have injections.",2021,"There were no significant differences between the treatment groups for any of the endpoints at either 1 or 4 weeks. ","['ambulant patients with DVT treated with', 'ambulant patients with lower limb DVT managed with', '124 patients received', 'patients who prefer not to have injections', 'patients with symptomatic DVT in China']","['subcutaneous low molecular weight heparin (LMWH) or oral Rivaroxaban', 'Rivaroxaban, both in addition to warfarin', 'warfarin both Rivaroxaban and LMWH', 'Rivaroxaban', 'LMWH', 'warfarin']","['thrombus progression, bleeding, clinic attendance and INR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0019139', 'cui_str': 'Low molecular weight heparin'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}]","[{'cui': 'C0087086', 'cui_str': 'Thrombus'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}]",124.0,0.04253,"There were no significant differences between the treatment groups for any of the endpoints at either 1 or 4 weeks. ","[{'ForeName': 'Fenling', 'Initials': 'F', 'LastName': 'Fan', 'Affiliation': ""Department of Cardiovascular Medicine, the First Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Yifan', 'Initials': 'Y', 'LastName': 'Zou', 'Affiliation': ""School of Economics and Finance, Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Youson', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Cardiovascular Medicine, the First Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': ""Department of Cardiovascular Medicine, the First Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Yuping', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Cardiovascular Medicine, the First Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Song', 'Affiliation': ""Department of Cardiovascular Medicine, the First Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Anthony M', 'Initials': 'AM', 'LastName': 'Dart', 'Affiliation': 'Baker Institute & Cardiovascular Medicine, The Alfred, Melbourne, VIC, Australia.'}, {'ForeName': 'Yuliang', 'Initials': 'Y', 'LastName': 'Zou', 'Affiliation': ""Department of Gynecology and Obstetrics, the First Hospital of Xi'an Jiaotong University, Xi'an, China.""}]",International journal of clinical practice,['10.1111/ijcp.14619'] 1550,34237655,"Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study.","Sodium oxybate (SMO) has been approved in Italy and Austria for the maintenance of abstinence in alcohol dependent (AD) patients. Although SMO is well tolerated in AD patients, cases of abuse and misuse have been reported outside the therapeutic setting. Here we report on a phase IIb double-blind, randomized, placebo-controlled trial for the maintenance of abstinence in AD patients with a new abuse and misuse deterrent formulation of SMO. A total of 509 AD patients were randomized to 12 weeks of placebo or one of four SMO doses (0.75, 1.25, 1.75 or 2.25 g t.i.d.) followed by a one-week medication-free period. The primary endpoint was the percentage of days abstinent (PDA) at end of treatment. An unexpectedly high placebo response (mean 73%, median 92%) was observed. This probably compromised the demonstration of efficacy in the PDA, but several secondary endpoints showed statistically significant improvements. A post-hoc subgroup analysis based on baseline severity showed no improvements in the mild group, but statistically significant improvements in the severe group: PDA: mean difference +15%, Cohen's d = 0.42; abstinence: risk difference +18%, risk ratio = 2.22. No safety concerns were reported. Although the primary endpoint was not significant in the overall population, several secondary endpoints were significant in the intent-to-treat population and post-hoc results showed that treatment with SMO was associated with a significant improvement in severe AD patients which is consistent with previous findings. New trials are warranted that take baseline severity into consideration.",2021,No safety concerns were reported.,"['A total of 509 AD patients', 'AD patients with a new abuse and misuse deterrent formulation of SMO']","['sodium oxybate', 'Sodium oxybate (SMO', 'placebo', 'SMO']",['percentage of days abstinent (PDA'],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0581116', 'cui_str': 'Dependent patient'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0037537', 'cui_str': 'Sodium Oxybate'}]","[{'cui': 'C0037537', 'cui_str': 'Sodium Oxybate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0457801', 'cui_str': 'Non - drinker'}]",509.0,0.687532,No safety concerns were reported.,"[{'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Guiraud', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Meibergdreef 5, Amsterdam, Netherlands; D&A Pharma, Paris, France. Electronic address: j.guiraud@da-pharma.com.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Addolorato', 'Affiliation': 'Alcohol Use Disorder and Alcohol Related Disease Unit, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy; Internal Medicine Unit, Columbus-Gemelli Hospital, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Henri-Jean', 'Initials': 'HJ', 'LastName': 'Aubin', 'Affiliation': 'French Institute of Health and Medical Research (Inserm), Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Paris, France; Addiction Research and Treatment Center, Paul Brousse Hospital, Paris-Sud University, Villejuif, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Batel', 'Affiliation': 'Addiction unit of Charente, Camille Claudel Hospital, 16400 La Couronne, France.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'de Bejczy', 'Affiliation': 'Section of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Caputo', 'Affiliation': 'Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy; Center for the Study and Treatment of Alcohol-Related Diseases, Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy; Center for the Study and Treatment of Chronic Inflammatory Bowel Diseases (IBD) and Gastroenterological Manifestations of Rare Diseases, Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy; Department of Internal Medicine, Santissima Annunziata Hospital, Cento (Ferrara), University of Ferrara, 44042 Ferrara, Italy.'}, {'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Goudriaan', 'Affiliation': 'Amsterdam University Medical Centers, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Amsterdam, Netherlands; Arkin, Dept. of Research and Quality of Care, Amsterdam, Netherlands, & Amsterdam Public Health Research Institute, Netherlands.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Gual', 'Affiliation': 'Psychiatry Department, Neurosciences Institute, Hospital Clinic, IDIBAPS, Barcelona, Spain.'}, {'ForeName': 'Otto', 'Initials': 'O', 'LastName': 'Lesch', 'Affiliation': 'Department of Social Psychiatry, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Icro', 'Initials': 'I', 'LastName': 'Maremmani', 'Affiliation': 'Santa Chiara University Hospital, University of Pisa, Italy.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Perney', 'Affiliation': 'Addiction Medicine, Hospital Grau-du-Roi, Nimes, France.'}, {'ForeName': 'Roch', 'Initials': 'R', 'LastName': 'Poulnais', 'Affiliation': 'D&A Pharma, Paris, France.'}, {'ForeName': 'Quentin', 'Initials': 'Q', 'LastName': 'Raffaillac', 'Affiliation': 'D&A Pharma, Paris, France.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Soderpalm', 'Affiliation': 'Section of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Spanagel', 'Affiliation': 'Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany.'}, {'ForeName': 'Henriette', 'Initials': 'H', 'LastName': 'Walter', 'Affiliation': 'Department of Social Psychiatry, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'van den Brink', 'Affiliation': 'Amsterdam University Medical Centers, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Amsterdam, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2021.06.003'] 1551,34237553,The effects of Animal Assisted Therapy on autonomic and endocrine activity in adults with autism spectrum disorder: A randomized controlled trial.,"OBJECTIVE Stress and its sequelae are very common in adults with autism spectrum disorder (ASD) without an intellectual disability (ID). Animal-assisted therapy (AAT) has shown physiological stress-reductive effects in children with ASD. The aim of the current study was to examine the acute psychophysiological response to an AAT session, and to examine the longer-term stress-physiological effects of the intervention, up until 10 weeks post-treatment, in comparison to waiting-list controls. METHOD A randomized controlled trial with pre-intervention (T0), post-intervention (T1: 10 weeks) and follow-up (T2: 20 weeks) measurements of neuroendocrine and cardiovascular measures, was conducted in 53 adults with ASD (N = 27 in intervention arm; N = 26 in control arm). Within the intervention group, stress-physiological data were collected during the 5th therapy session (acute effects). Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity. RESULTS The AAT interventional session was significantly associated with reduced cortisol levels (β = -0.41, p = .010), while parasympathetic and sympathetic cardiovascular activity remained unaltered. No significant changes were found for stress-physiological measures at post-treatment time points. CONCLUSIONS Acute stress reduction, reflected in significant reduction in cortisol levels, was found during an AAT session in adults with ASD, without ID. More research is needed to explore to what extent the specific factors of AAT have contributed to the decrease in cortisol and whether stress reduction is possible for the longer-term.",2021,"The AAT interventional session was significantly associated with reduced cortisol levels (β = -0.41, p = .010), while parasympathetic and sympathetic cardiovascular activity remained unaltered.","['53 adults with ASD (N\xa0=\xa027 in intervention arm', 'adults with autism spectrum disorder (ASD) without an intellectual disability (ID', 'adults with ASD', 'adults with autism spectrum disorder', 'children with ASD']","['pre-intervention (T0), post-intervention', 'Animal-assisted therapy (AAT', 'Animal Assisted Therapy']","['cortisol, alpha-amylase, heart rate variability and sympathetic activity', 'reduced cortisol levels', 'acute psychophysiological response', 'stress-physiological data', 'autonomic and endocrine activity', 'stress-physiological measures', 'cortisol levels', 'parasympathetic and sympathetic cardiovascular activity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C3714756', 'cui_str': 'Intellectual disability'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0150133', 'cui_str': 'Animal-assisted therapy'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0002245', 'cui_str': 'alpha-Amylase'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0449430', 'cui_str': 'Physiological stress'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",53.0,0.0519969,"The AAT interventional session was significantly associated with reduced cortisol levels (β = -0.41, p = .010), while parasympathetic and sympathetic cardiovascular activity remained unaltered.","[{'ForeName': 'Carolien', 'Initials': 'C', 'LastName': 'Wijker', 'Affiliation': 'GGZ Oost Brabant, Berlicumseweg 8, 5248 NT Rosmalen, the Netherlands; Faculty of Psychology, Open University of the Netherlands, the Netherlands. Electronic address: carolien.wijker@ou.nl.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Kupper', 'Affiliation': 'CoRPS - Center of Research on Psychological and Somatic disorders, Department of Medical & Clinical Psychology, Tilburg University, Tilburg, the Netherlands.'}, {'ForeName': 'Ruslan', 'Initials': 'R', 'LastName': 'Leontjevas', 'Affiliation': 'Faculty of Psychology, Open University of the Netherlands, the Netherlands.'}, {'ForeName': 'Annelies', 'Initials': 'A', 'LastName': 'Spek', 'Affiliation': 'Autism Center of Expertise, Eemnes, the Netherlands.'}, {'ForeName': 'Marie-Jose', 'Initials': 'MJ', 'LastName': 'Enders-Slegers', 'Affiliation': 'Faculty of Psychology, Open University of the Netherlands, the Netherlands.'}]",General hospital psychiatry,['10.1016/j.genhosppsych.2021.05.003'] 1552,34236794,A Retrospective Study of Coronary Artery Bypass Grafting with Low-Thermal Plasma Dissection Device Compared to Conventional Monopolar Electrosurgery.,"INTRODUCTION The objective of this study is to compare the effects of conventional monopolar electrosurgery (CMES) and low-thermal plasma kinetic cautery (PKC) on complications such as bleeding, abnormal wound healing, pain, and drainage in patients who underwent on-pump coronary artery bypass grafting (CABG). METHODS This retrospective clinical study included 258 patients undergoing CABG; the patients were randomized to PKC (PEAK PlasmaBlade, n=153) and CMES (n=105) groups. The patients' clinical data were examined retrospectively for biochemical variables, postoperative drainage, post-surgery erythrocyte suspension transfusion count, surgical site pain examined with visual analogue scale (VAS), and wound healing. Two-sided P-value > 0.05 was considered as statistically significant. RESULTS The median post-surgery erythrocyte suspension transfusion number was significantly lower with PKC compared to CMES (0 [0-1] vs. 1 [1-4], respectively, P<0.001). Mean postoperative drain output and time until removal of drain tubes were significantly lower with PKC compared to CMES (300±113 vs. 547±192 and 1.95±1.5 vs. 2.44±1.8; P<0.001 and P=0.025, respectively). Mean VAS score for spontaneous and cough-induced pain were significantly lower with PKC compared to CMES (1.98±1.51 vs. 3.94± 2.09 and 3.76±1.46 vs. 5.6±1.92; P<0.001 for both comparisons). Reoperation due to bleeding was significantly higher with CMES compared to PKC (0 vs. 11 [7.2%], P=0.001). CONCLUSION Use of PKC during CABG considerably reduces postoperative drainage, need for blood transfusion, reoperation due to bleeding, and postoperative pain. PCK appears to be a good alternative to CMES for CABG.",2021,Mean VAS score for spontaneous and cough-induced pain were significantly lower with PKC compared to CMES (1.98±1.51 vs. 3.94± 2.09 and 3.76±1.46 vs. 5.6±1.92; P<0.001 for both comparisons).,"['patients who underwent on-pump coronary artery bypass grafting (CABG', '258 patients undergoing CABG; the patients were randomized to PKC (PEAK PlasmaBlade, n=153) and CMES (n=105) groups']","['CMES', 'PCK', 'Conventional Monopolar Electrosurgery', 'conventional monopolar electrosurgery (CMES) and low-thermal plasma kinetic cautery (PKC', 'Coronary Artery Bypass Grafting with Low-Thermal Plasma Dissection Device']","['median post-surgery erythrocyte suspension transfusion number', 'Reoperation due to bleeding', 'complications such as bleeding, abnormal wound healing, pain, and drainage', 'biochemical variables, postoperative drainage, post-surgery erythrocyte suspension transfusion count, surgical site pain examined with visual analogue scale (VAS), and wound healing', 'Mean VAS score for spontaneous and cough-induced pain', 'Mean postoperative drain output and time until removal of drain tubes', 'postoperative drainage, need for blood transfusion, reoperation due to bleeding, and postoperative pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0007471', 'cui_str': 'Cauterization - action'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0012002', 'cui_str': 'Diathermy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0012002', 'cui_str': 'Diathermy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C2936479', 'cui_str': 'Thermal Plasma'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0007471', 'cui_str': 'Cauterization - action'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0012737', 'cui_str': 'Dissection - action'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0332850', 'cui_str': 'Operative site'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0411815', 'cui_str': 'Removal of drain'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]",258.0,0.0521687,Mean VAS score for spontaneous and cough-induced pain were significantly lower with PKC compared to CMES (1.98±1.51 vs. 3.94± 2.09 and 3.76±1.46 vs. 5.6±1.92; P<0.001 for both comparisons).,"[{'ForeName': 'Dincer', 'Initials': 'D', 'LastName': 'Uysal', 'Affiliation': 'Department of Cardiovascular Surgery, Suleyman Demirel Universitesi Tip Fakultesi, Isparta, Turkey.'}, {'ForeName': 'Erdogan', 'Initials': 'E', 'LastName': 'Ibrisim', 'Affiliation': 'Department of Cardiovascular Surgery, Suleyman Demirel Universitesi Tip Fakultesi, Isparta, Turkey.'}]",Brazilian journal of cardiovascular surgery,['10.21470/1678-9741-2020-0386'] 1553,34253180,Describing people with cognitive impairment and their complex treatment needs during routine care in the hospital - cross-sectional results of the intersec-CM study.,"BACKGROUND Cognitive impairment is an important determinant in health care. In the acute hospital setting cognition has a strong impact on treatment and care. Cognitive impairment can negatively affect diagnostics and treatment success. However, little is known about the individual situation and specific risks of people with cognitive impairments during hospital stays. The aim of the present research is to describe and analyze the treatment needs of people with cognitive impairments in acute hospital care. METHODS The analyses use baseline data of the ongoing multisite, longitudinal, randomized controlled intervention trial intersec-CM (Supporting elderly people with cognitive impairment during and after hospital stays with Intersectoral Care Management), which recruited 402 participants at baseline. We assessed sociodemographic aspects, cognitive status, functional status, frailty, comorbidities, level of impairment, formal diagnosis of dementia, geriatric diagnoses, delirium, depression, pharmacological treatment, utilization of health care services and health care related needs. RESULTS The sample under examination had been on average mildly cognitively impaired (MMSE M = 22.3) and had a mild to moderate functional impairment (Barthel Index M = 50.4; HABAM M = 19.1). The Edmonton Frail Scale showed a mean of 7.4 and half of the patients (52.3%) had been assigned a care level. About 46.9% had a geriatric diagnosis, 3.0% had a diagnosis of dementia. According to DSM-V 19.2% of the patients had at least one main symptom of depression. The mean number of regularly taken drugs per patient was 8.2. Utilization of health care services prior to the hospital stay was rather low. On average, the sample showed 4.38 care related needs in general, of which 0.60 needs were unaddressed at the time of assessment. CONCLUSIONS Descriptive analyses highlight an in-depth insight into impairments and different care needs of people with cognitive impairments. The results emphasize the need for gender-specific analyses as well as an increased attention to the heterogeneity of needs of people with cognitive impairments related to specific wards, settings and regions where they are admitted. Our results indicate also that people with cognitive impairments represent a high proportion of older patients in acute hospital care. TRIAL REGISTRATION The intersec-CM trial is registered at ClinicalTrials.gov ( NCT03359408 ).",2021,The Edmonton Frail Scale showed a mean of 7.4 and half of the patients (52.3%) had been assigned a care level.,"['elderly people with cognitive impairment during and after hospital stays with Intersectoral Care Management), which recruited 402 participants at baseline', 'people with cognitive impairments during hospital stays', 'people with cognitive impairments in acute hospital care', 'people with cognitive impairments']",[],"['diagnosis of dementia', 'Edmonton Frail Scale', 'sociodemographic aspects, cognitive status, functional status, frailty, comorbidities, level of impairment, formal diagnosis of dementia, geriatric diagnoses, delirium, depression, pharmacological treatment, utilization of health care services and health care related needs', 'mean number of regularly taken drugs']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]",[],"[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",402.0,0.0856949,The Edmonton Frail Scale showed a mean of 7.4 and half of the patients (52.3%) had been assigned a care level.,"[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Kracht', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE), site Rostock/ Greifswald, Greifswald, Germany. friederike.kracht@dzne.de.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Boekholt', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE), site Rostock/ Greifswald, Greifswald, Germany. melanie.boekholt@dzne.de.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Schumacher-Schönert', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE), site Rostock/ Greifswald, Greifswald, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Nikelski', 'Affiliation': 'Evangelisches Klinikum Bethel, Campus Bielefeld-Bethel, Division of Geriatric Psychiatry, Universitätsklinikum OWL der Universität Bielefeld, Bielefeld, Germany.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Chikhradze', 'Affiliation': 'Institute of General Practice and Family Medicine (AM RUB), Faculty of Medicine, Ruhr University Bochum (RUB), Bochum, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Lücker', 'Affiliation': 'Institute for Community Medicine, Section of Epidemiology of Health Care and Community Health, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'H C', 'Initials': 'HC', 'LastName': 'Vollmar', 'Affiliation': 'Institute of General Practice and Family Medicine (AM RUB), Faculty of Medicine, Ruhr University Bochum (RUB), Bochum, Germany.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Hoffmann', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE), site Rostock/ Greifswald, Greifswald, Germany.'}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Kreisel', 'Affiliation': 'Evangelisches Klinikum Bethel, Campus Bielefeld-Bethel, Division of Geriatric Psychiatry, Universitätsklinikum OWL der Universität Bielefeld, Bielefeld, Germany.'}, {'ForeName': 'J R', 'Initials': 'JR', 'LastName': 'Thyrian', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE), site Rostock/ Greifswald, Greifswald, Germany. rene.thyrian@dzne.de.'}]",BMC geriatrics,['10.1186/s12877-021-02298-4'] 1554,34252374,"Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.","BACKGROUND The optimal perioperative chemotherapeutic regimen for locally advanced gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and postoperative S-1 and oxaliplatin (SOX) compared with postoperative capecitabine and oxaliplatin (CapOx) in patients with locally advanced gastric cancer undergoing D2 gastrectomy. METHODS We did this open-label, phase 3, superiority and non-inferiority, randomised trial at 27 hospitals in China. We recruited antitumour treatment-naive patients aged 18 years or older with historically confirmed cT4a N+ M0 or cT4b Nany M0 gastric or gastro-oesophageal junction adenocarcinoma, with Karnofsky performance score of 70 or more. Patients undergoing D2 gastrectomy were randomly assigned (1:1:1) via an interactive web response system, stratified by participating centres and Lauren classification, to receive adjuvant CapOx (eight postoperative cycles of intravenous oxaliplatin 130 mg/m 2 on day one of each 21 day cycle plus oral capecitabine 1000 mg/m 2 twice a day), adjuvant SOX (eight postoperative cycles of intravenous oxaliplatin 130 mg/m 2 on day one of each 21 day cycle plus oral S-1 40-60 mg twice a day), or perioperative SOX (intravenous oxaliplatin 130 mg/m 2 on day one of each 21 day plus oral S-1 40-60 mg twice a day for three cycles preoperatively and five cycles postoperatively followed by three cycles of S-1 monotherapy). The primary endpoint, assessed in the modified intention-to-treat population, 3-year disease-free survival to assess the superiority of perioperative-SOX compared with adjuvant-SOX and the non-inferiority (hazard ratio non-inferiority margin of 1·33) of adjuvant-SOX compared with adjuvant-CapOx. Safety analysis were done in patients who received at least one dose of the assigned treatment. This study is registered with ClinicalTrials.gov, NCT01534546. FINDINGS Between Aug 15, 2012, and Feb 28, 2017, 1094 patients were screened and 1022 (93%) were included in the modified intention-to-treat population, of whom 345 (34%) patients were assigned to the adjuvant-CapOx, 340 (33%) patients to the adjuvant-SOX group, and 337 (33%) patients to the perioperative-SOX group. 3-year disease-free survival was 51·1% (95% CI 45·5-56·3) in the adjuvant-CapOx group, 56·5% (51·0-61·7) in the adjuvant-SOX group, and 59·4% (53·8-64·6) in the perioperative-SOX group. The hazard ratio (HR) was 0·77 (95% CI 0·61-0·97; Wald p=0·028) for the perioperative-SOX group compared with the adjuvant-CapOx group and 0·86 (0·68-1·07; Wald p=0·17) for the adjuvant-SOX group compared with the adjuvant-CapOx group. The most common grade 3-4 adverse events was neutropenia (32 [12%] of 258 patients in the adjuvant-CapOx group, 21 [8%] of 249 patients in the adjuvant-SOX group, and 30 [10%] of 310 patients in the perioperative-SOX group). Serious adverse events were reported in seven (3%) of 258 patients in adjuvant-CapOx group, two of which were related to treatment; eight (3%) of 249 patients in adjuvant-SOX group, two of which were related to treatment; and seven (2%) of 310 patients in perioperative-SOX group, four of which were related to treatment. No treatment-related deaths were reported. INTERPRETATION Perioperative-SOX showed a clinically meaningful improvement compared with adjuvant-CapOx in patients with locally advanced gastric cancer who had D2 gastrectomy; adjuvant-SOX was non-inferior to adjuvant-CapOx in these patients. Perioperative-SOX could be considered a new treatment option for patients with locally advanced gastric cancer. FUNDING National Key Research and Development Program of China, Beijing Scholars Program 2018-2024, Peking University Clinical Scientist Program, Taiho, Sanofi-Aventis, and Hengrui Pharmaceutical. TRANSLATION For the Chinese translation of the abstract see Supplementary Materials section.",2021,"3-year disease-free survival was 51·1% (95% CI 45·5-56·3) in the adjuvant-CapOx group, 56·5% (51·0-61·7) in the adjuvant-SOX group, and 59·4% (53·8-64·6) in the perioperative-SOX group.","['Between Aug 15, 2012, and Feb 28, 2017, 1094 patients were screened and 1022 (93%) were included in the modified intention-to-treat population, of whom 345 (34%) patients were assigned to the adjuvant-CapOx, 340 (33%) patients to the adjuvant-SOX group, and 337 (33%) patients to the perioperative-SOX group', 'locally advanced gastric cancer', 'patients with locally advanced gastric cancer undergoing D2 gastrectomy', '27 hospitals in China', 'Patients undergoing D2 gastrectomy', 'patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE', 'patients with locally advanced gastric cancer', 'patients with locally advanced gastric cancer who had D2 gastrectomy', 'patients aged 18 years or older with historically confirmed cT4a N+ M0 or cT4b Nany M0 gastric or gastro-oesophageal junction adenocarcinoma, with Karnofsky performance score of 70 or more']","['oral S-1 40-60 mg twice a day), or perioperative SOX (intravenous oxaliplatin', 'adjuvant-CapOx', 'interactive web response system, stratified by participating centres and Lauren classification, to receive adjuvant CapOx (eight postoperative cycles of intravenous oxaliplatin 130 mg/m 2 on day one of each 21 day cycle plus oral capecitabine', 'Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine', 'postoperative capecitabine and oxaliplatin (CapOx', 'oxaliplatin 130', 'perioperative and postoperative S-1 and oxaliplatin (SOX', 'antitumour treatment-naive']","['neutropenia', 'modified intention-to-treat population, 3-year disease-free survival', 'Serious adverse events', '3-year disease-free survival', 'hazard ratio (HR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C4517730', 'cui_str': '340'}, {'cui': 'C0879262', 'cui_str': 'S 1 (combination)'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}, {'cui': 'C3714811', 'cui_str': 'Resolved'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0206065', 'cui_str': 'Karnofsky performance status'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0879262', 'cui_str': 'S 1 (combination)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",1094.0,0.201869,"3-year disease-free survival was 51·1% (95% CI 45·5-56·3) in the adjuvant-CapOx group, 56·5% (51·0-61·7) in the adjuvant-SOX group, and 59·4% (53·8-64·6) in the perioperative-SOX group.","[{'ForeName': 'Xiaotian', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Han', 'Initials': 'H', 'LastName': 'Liang', 'Affiliation': 'Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.'}, {'ForeName': 'Ziyu', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Yingwei', 'Initials': 'Y', 'LastName': 'Xue', 'Affiliation': 'Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin, China.'}, {'ForeName': 'Yanong', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Gastric Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.'}, {'ForeName': 'Zhiwei', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Department of Gastric Surgery, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Jiren', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Zhaode', 'Initials': 'Z', 'LastName': 'Bu', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Yian', 'Initials': 'Y', 'LastName': 'Du', 'Affiliation': 'Department of Gastric Surgery and Department of Hepatopancreatobiliary Surgery, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Xinbao', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Gastric Surgery and Department of Hepatopancreatobiliary Surgery, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Aiwen', 'Initials': 'A', 'LastName': 'Wu', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Guoli', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of General surgery, Nanjing Jinling Hospital, Nanjing, China.'}, {'ForeName': 'Xiangqian', 'Initials': 'X', 'LastName': 'Su', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Xiao', 'Affiliation': 'Department of General Surgery, Beijing Hospital, Beijing, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Cui', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of General Surgery, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Xiaojiang', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Yanbing', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Lianhai', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Chengxue', 'Initials': 'C', 'LastName': 'Dang', 'Affiliation': ""Department of Oncology Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Yulong', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Zhongtao', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yihong', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Guangzhou, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.'}, {'ForeName': 'Huanqiu', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of General Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Yuxian', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': 'Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.'}, {'ForeName': 'Changsong', 'Initials': 'C', 'LastName': 'Qi', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Peiwu', 'Initials': 'P', 'LastName': 'Yu', 'Affiliation': 'Department of General Surgery, The First Hospital Affiliated to Army Medical University, Chongqing, China.'}, {'ForeName': 'Guanbao', 'Initials': 'G', 'LastName': 'Zhu', 'Affiliation': 'Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Suo', 'Affiliation': 'Department of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Baoqing', 'Initials': 'B', 'LastName': 'Jia', 'Affiliation': 'Department of General Surgery, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Leping', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Jinan, China.'}, {'ForeName': 'Changming', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': 'Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Yingjiang', 'Initials': 'Y', 'LastName': 'Ye', 'Affiliation': ""Department of General Surgery, Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Huimian', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Department of Gastrointestinal Oncology Surgery, The First Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of General Surgery, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Yannan', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Jian-Yu', 'Initials': 'JY', 'LastName': 'E', 'Affiliation': 'Wilmer Eye Institute, Johns Hopkins University School of Medicine and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Xiangji', 'Initials': 'X', 'LastName': 'Ying', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yao', 'Affiliation': 'Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China. Electronic address: shenlin@bjmu.edu.cn.'}, {'ForeName': 'Jiafu', 'Initials': 'J', 'LastName': 'Ji', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China. Electronic address: jijiafu@hsc.pku.edu.cn.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(21)00297-7'] 1555,34254832,Acute plate fixation of displaced midshaft clavicular fractures is not associated with earlier return of normal shoulder function when union is achieved.,"AIMS It is unclear whether acute plate fixation facilitates earlier return of normal shoulder function following a displaced mid-shaft clavicular fracture compared with nonoperative management when union occurs. The primary aim of this study was to establish whether acute plate fixation was associated with a greater return of normal shoulder function when compared with nonoperative management in patients who unite their fractures. The secondary aim was to investigate whether there were identifiable predictors associated with return of normal shoulder function in patients who achieve union with nonoperative management. METHODS Patient data from a randomized controlled trial were used to compare acute plate fixation with nonoperative management of united fractures. Return of shoulder function was based on the age- and sex-matched Disabilities of the Arm, Shoulder and Hand (DASH) scores for the cohort. Independent predictors of an early recovery of normal shoulder function were investigated using a separate prospective series of consecutive nonoperative displaced mid-shaft clavicular fractures recruited over a two-year period (aged ≥ 16 years). Patient demographics and functional recovery were assessed over the six months post-injury using a standardized protocol. RESULTS Data from the randomized controlled trial consisted of 86 patients who underwent operative fixation compared with 76 patients that united with nonoperative treatment. The recovery of normal shoulder function, as defined by a DASH score within the predicted 95% confidence interval for each respective patient, was similar between each group at six weeks (operative 26.7% vs nonoperative 25.0%, p = 0.800), three months (52.3% vs 44.2%, p = 0.768), and six months post-injury (86.0% vs 90.8%, p = 0.349). The mean DASH score and return to work were also comparable at each timepoint. In the prospective cohort, 86.5% (n = 173/200) achieved union by six months post-injury (follow-up rate 88.5%, n = 200/226). Regression analysis found that no specific patient, injury, or fracture predictor was associated with an early return of function at six or 12 weeks. CONCLUSION Return of normal shoulder function was comparable between acute plate fixation and nonoperative management when union was achieved. One in two patients will have recovery of normal shoulder function at three months, increasing to nine out of ten patients at six months following injury when union occurs, irrespective of initial treatment. Cite this article: Bone Jt Open  2021;2(7):522-529.",2021,"Regression analysis found that no specific patient, injury, or fracture predictor was associated with an early return of function at six or 12 weeks. ","['consecutive nonoperative displaced mid-shaft clavicular fractures recruited over a two-year period (aged ≥ 16 years', 'patients who unite their fractures', 'patients who achieve union with nonoperative management', '86 patients who underwent operative fixation compared with 76 patients that united with nonoperative treatment']",[],"['normal shoulder function', 'recovery of normal shoulder function', 'mean DASH score and return to work', 'Patient demographics and functional recovery', 'DASH score']","[{'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0337141', 'cui_str': 'Shaft'}, {'cui': 'C0159658', 'cui_str': 'Fracture of clavicle'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0166872', 'cui_str': 'Unite resin'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",[],"[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0425105', 'cui_str': 'Returned to work'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0599766', 'cui_str': 'Recovery of Function'}]",2.0,0.0332901,"Regression analysis found that no specific patient, injury, or fracture predictor was associated with an early return of function at six or 12 weeks. ","[{'ForeName': 'Jamie A', 'Initials': 'JA', 'LastName': 'Nicholson', 'Affiliation': 'Department of Orthopaedic Surgery, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Nick D', 'Initials': 'ND', 'LastName': 'Clement', 'Affiliation': 'Department of Orthopaedic Surgery, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Clelland', 'Affiliation': 'Department of Orthopaedic Surgery, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Deborah J', 'Initials': 'DJ', 'LastName': 'MacDonald', 'Affiliation': 'Department of Orthopaedic Surgery, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'A Hamish R W', 'Initials': 'AHRW', 'LastName': 'Simpson', 'Affiliation': 'Department of Orthopaedic Surgery, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'C Mike', 'Initials': 'CM', 'LastName': 'Robinson', 'Affiliation': 'Department of Orthopaedic Surgery, University of Edinburgh, Edinburgh, UK.'}]",Bone & joint open,['10.1302/2633-1462.27.BJO-2021-0049.R1'] 1556,34257740,Effect of the Wii Sports Resort on Mobility and Health-Related Quality of Life in Moderate Stroke.,"Background Stroke is a common cerebral circulatory disorder that has several sequelae that affect the daily life of patients as well as their quality of life and the lives of people close to them. Video games are being used in the rehabilitation process to address these sequelae and their benefits are shown on physical activity and in the cognition area. However, their effects on daily life activities and quality of life are not known. This study was aimed to test the effect of the Nintendo Wii Sports Resort on mobility and health-related quality of life among patients who have suffered a moderate stroke. Methods A prepost design study was conducted with 30 moderately impaired stroke patients aged 65 ± 15. The study lasted eight weeks. 15 participated in the intervention group and the others belong to the control group. They were assessed in mobility (Timed Get Up and Go Test-TUG) and health-related quality of life (SF-36 Health Questionnaire). Parametric test and effect sizes were used to analyze the change in outcomes and to compare groups. Results There were no differences at baseline between the groups. After the intervention, the intervention group had experienced a greater change according to the size of the effect on the variables concerning TUG ( d = 1.32), physical function ( d = 1.32), social function ( d = 0.71), and Physical Component Summary ( d = 0.75). On the other hand, the control group had a significant change in mental health according to effect size; however, this effect is not statistically relevant ( d = 0.88; CI 95% = -3.74 to 5.50). Conclusions The results on mobility and health-related quality of life indicate an improvement in both groups. However, according to the effect sizes and its confidence of interval, the intervention group achieved better results than the control group. Although more studies are needed in this area, the results are encouraging for improving mobility and health-related quality of life after stroke.",2021,"However, according to the effect sizes and its confidence of interval, the intervention group achieved better results than the control group.","['30 moderately impaired stroke patients aged 65 ± 15', 'Moderate Stroke', 'patients who have suffered a moderate stroke']","['Wii Sports Resort', 'Nintendo Wii Sports Resort']","['Mobility and Health-Related Quality of Life', 'social function', 'mobility (Timed Get Up and Go Test-TUG) and health-related quality of life (SF-36 Health Questionnaire', 'daily life activities and quality of life', 'mental health', 'physical function', 'mobility and health-related quality of life']","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0038039', 'cui_str': 'Sport'}]","[{'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1303170', 'cui_str': 'Get up and go test'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",30.0,0.0143783,"However, according to the effect sizes and its confidence of interval, the intervention group achieved better results than the control group.","[{'ForeName': 'Iratxe', 'Initials': 'I', 'LastName': 'Unibaso-Markaida', 'Affiliation': 'Faculty of Psychology at University of Deusto, 48007 Bilbao, Basque Country, Spain.'}, {'ForeName': 'Ioseba', 'Initials': 'I', 'LastName': 'Iraurgi', 'Affiliation': 'Faculty of Psychology at University of Deusto, 48007 Bilbao, Basque Country, Spain.'}]",Behavioural neurology,['10.1155/2021/6635298'] 1557,34224994,"An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial.","INTRODUCTION Coronavirus disease 2019 (COVID-19) has been a serious obstacle in front of public health. Interferon-beta 1a (IFN-β 1a) has been used to treat patients with COVID-19. We aimed to compare the effectiveness of high-dose IFN-β 1a compared to low dose IFN-β 1a in severe COVID-19 cases. METHODS In this randomized, controlled, and clinical trial, eligible patients with confirmed SARS-CoV-2 infections were randomly assigned to receive one of the two following therapeutic regimens: The intervention group was treated with high-dose IFN-β 1a (Recigen) (Subcutaneous injections of 88 μg (24 million IU) on days 1, 3, 6) + lopinavir /ritonavir (Kaletra) (400 mg/100 mg twice a day for 10 days, orally) and the control group was treated with low-dose IFN-β 1a (Recigen) (Subcutaneous injections of 44 μg (12 million IU) on days 1, 3, 6) + lopinavir /ritonavir (Kaletra) (400 mg/100 mg twice a day for 10 days, orally). RESULT A total of 168 COVID- 19 confirmed patients underwent randomization; 83 were assigned to the intervention group and 85 were assigned to the control group. Median Time To Clinical Improvement (TTIC) for cases treated with low-dose IFN-β1a was shorter than that for cases treated with high-dose IFN-β1a (6 vs 10 days; P = 0.018). The mortality rates in intervention and control group were 41% and 36.5%, respectively. CONCLUSION The use of high-dose IFN-β 1a did not improve TTCI in hospitalized patients with moderate to severe COVID-19. Also, it did not have any significant effect on mortality reduction compared with treating with low-dose IFN-β 1a. TRIAL REGISTRATION This trial has been registered as ClinicalTrials.gov, NCT04521400.",2021,To Clinical Improvement (TTIC) for cases treated with low-dose IFN-β1a was shorter than that for cases treated with high-dose IFN-β1a (6 vs 10 days; P = 0.018).,"['A total of 168 COVID- 19 confirmed patients underwent randomization; 83', 'patients with COVID-19', 'in severe COVID-19', 'eligible patients with confirmed SARS-CoV-2 infections', 'hospitalized patients with moderate to severe COVID-19']","['interferon beta 1-a', 'Interferon-beta 1a (IFN-β 1a', 'high-dose IFN-β 1a (Recigen) (Subcutaneous injections of 88\xa0μg (24 million IU) on days 1, 3, 6)\xa0+\xa0lopinavir /ritonavir (Kaletra', 'control group was treated with low-dose IFN-β 1a (Recigen) (Subcutaneous injections of 44\xa0μg (12 million IU) on days 1, 3, 6)\xa0+\xa0lopinavir /ritonavir (Kaletra']","['mortality rates', 'Median Time', 'mortality reduction']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319556', 'cui_str': '168'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C0254119', 'cui_str': 'Interferon beta-1a'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous injection'}, {'cui': 'C1881839', 'cui_str': '1000000'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C0939357', 'cui_str': 'Kaletra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.0763617,To Clinical Improvement (TTIC) for cases treated with low-dose IFN-β1a was shorter than that for cases treated with high-dose IFN-β1a (6 vs 10 days; P = 0.018).,"[{'ForeName': 'Ilad', 'Initials': 'I', 'LastName': 'Alavi Darazam', 'Affiliation': 'Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON. Electronic address: ilad13@yahoo.com.'}, {'ForeName': 'Firouze', 'Initials': 'F', 'LastName': 'Hatami', 'Affiliation': 'Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Mahdi Rabiei', 'Affiliation': 'Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON.'}, {'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Amin Pourhoseingholi', 'Affiliation': 'SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON; Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Minoosh', 'Initials': 'M', 'LastName': 'Shabani', 'Affiliation': 'Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON.'}, {'ForeName': 'Shervin', 'Initials': 'S', 'LastName': 'Shokouhi', 'Affiliation': 'Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Mardani', 'Affiliation': 'Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Moradi', 'Affiliation': 'SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON; Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Farid', 'Initials': 'F', 'LastName': 'Javandoust Gharehbagh', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON.'}, {'ForeName': 'Nasrinsadat', 'Initials': 'N', 'LastName': 'Mirtalaee', 'Affiliation': 'Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON.'}, {'ForeName': 'Halimeh', 'Initials': 'H', 'LastName': 'Negahban', 'Affiliation': 'Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Amirdosara', 'Affiliation': 'SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON; Anesthesiology Research Center Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Zangi', 'Affiliation': 'Brain Mapping Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Hajiesmaeili', 'Affiliation': 'SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON; Anesthesiology Research Center Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Muhanna', 'Initials': 'M', 'LastName': 'Kazempour', 'Affiliation': 'SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON; Brain Mapping Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Navid', 'Initials': 'N', 'LastName': 'Shafigh', 'Affiliation': 'SBMU (Shahid Beheshti University of Medical Sciences) Task Force on the COVIFERON; Anesthesiology Research Center Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",International immunopharmacology,['10.1016/j.intimp.2021.107916'] 1558,34224930,Sleep disturbances and related disordered breathing after hip replacement surgery: A randomised controlled trial.,"INTRODUCTION Mechanisms of postoperative sleep architecture disturbances and sleep-disordered breathing are uncertain. The authors hypothesised that patients undergoing surgery under regional anaesthesia without opioids used for postoperative analgesia would experience lesser changes in these parameters than patients operated under general anaesthesia with per- and postoperative opioids. PATIENTS AND METHODS After ethical approval and informed consent, patients undergoing total hip replacement were included in a prospective, randomised trial comparing 3 groups of patients: (1) S-LPB group receiving spinal anaesthesia and postoperative analgesia by lumbar plexus block; (2) GA-PCA group receiving general anaesthesia and postoperative analgesia by morphine patient-controlled analgesia; (3) GA-LPB group receiving general anaesthesia and postoperative analgesia by lumbar plexus block. Outcome measurements were polysomnographic parameters of sleep architecture and sleep-disordered breathing. RESULTS Eighteen patients completed the 5-night study protocol (preoperative night: N-1, postoperative nights: N1 to N4). The percentage of rapid eye movement (REM) sleep decreased by 49% and 47% during N1 in the GA-PCA and GA-LPB groups respectively. A rebound phenomenon of more than 40% in the GA-PCA group and 25% in the GA-LPB group was observed during N2 and N3. Apnoea hypopnoea index (AHI) and the number of arousals per hour were significantly increased during N2 and N3 when compared with N-1 in the GA-groups. No sleep architecture disturbances and no sleep-disordered breathing were measured in the S-LPB group. CONCLUSION Postoperative sleep architecture and breathing pattern were disturbed in GA groups. Both were preserved under spinal anaesthesia associated with a free opioid postoperative analgesia.",2021,The percentage of rapid eye movement (REM) sleep decreased by 49% and 47% during N1 in the GA-PCA and GA-LPB groups respectively.,"['patients undergoing surgery under regional anaesthesia without', 'Sleep disturbances and related disordered breathing after hip replacement surgery', 'Eighteen patients completed the 5-night study protocol (preoperative night: N-1, postoperative nights: N1 to N4', 'patients undergoing total hip replacement']","['opioids', 'S-LPB group receiving spinal anaesthesia and postoperative analgesia by lumbar plexus block; 2) GA-PCA group receiving general anaesthesia and postoperative analgesia by morphine patient-controlled analgesia; 3) GA-LPB group receiving general anaesthesia and postoperative analgesia by lumbar plexus block', 'GA-PCA']","['sleep architecture disturbances and no sleep-disordered breathing', 'percentage of rapid eye movement (REM) sleep', 'polysomnographic parameters of sleep architecture and sleep-disordered breathing', 'Apnoea hypopnoea index (AHI) and the number of arousals per hour']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0392806', 'cui_str': 'Insertion of hip prosthesis'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C2599718', 'cui_str': 'Clinical Trial Protocols'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0394731', 'cui_str': 'Lumbar plexus block'}, {'cui': 'C0030131', 'cui_str': 'p-Chloramphetamine'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0015413', 'cui_str': 'Eye Movements'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0564385', 'cui_str': '/hour'}]",,0.0209367,The percentage of rapid eye movement (REM) sleep decreased by 49% and 47% during N1 in the GA-PCA and GA-LPB groups respectively.,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Charier', 'Affiliation': 'Department of Anaesthesiology and Critical Care Medicine, Centre Hospitalier Universitaire (CHU) Saint-Etienne, Université Jean Monnet Saint-Etienne, Saint-Etienne, F-42055, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Court-Fortune', 'Affiliation': 'Pneumology and Thoracic Oncology Department, Centre Hospitalier Universitaire (CHU) Saint-Etienne, Université Jean Monnet Saint-Etienne, Saint-Etienne, F-42055, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Pereira', 'Affiliation': 'Biostatistic Unit, Direction de la Recherche Clinique (DRCI), Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, F-63003, France.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Molliex', 'Affiliation': 'Department of Anaesthesiology and Critical Care Medicine, Centre Hospitalier Universitaire (CHU) Saint-Etienne, Université Jean Monnet Saint-Etienne, Saint-Etienne, F-42055, France. Electronic address: serge.molliex@chu-st-etienne.fr.'}]","Anaesthesia, critical care & pain medicine",['10.1016/j.accpm.2021.100927'] 1559,34224918,Mild intermittent hypoxia exposure induces metabolic and molecular adaptations in men with obesity.,"OBJECTIVE Recent studies suggest that hypoxia exposure may improve glucose homeostasis, but well-controlled human studies are lacking. We hypothesized that mild intermittent hypoxia (MIH) exposure decreases tissue oxygen partial pressure (pO 2 ) and induces metabolic improvements in people who are overweight/obese. METHODS In a randomized, controlled, single-blind crossover study, 12 men who were overweight/obese were exposed to MIH (15 % O 2 , 3 × 2 h/day) or normoxia (21 % O 2 ) for 7 consecutive days. Adipose tissue (AT) and skeletal muscle (SM) pO 2 , fasting/postprandial substrate metabolism, tissue-specific insulin sensitivity, SM oxidative capacity, and AT and SM gene/protein expression were determined. Furthermore, primary human myotubes and adipocytes were exposed to oxygen levels mimicking the hypoxic and normoxic AT and SM microenvironments. RESULTS MIH decreased systemic oxygen saturation (92.0 ± 0.5 % vs 97.1 ± 0.3, p < 0.001, respectively), AT pO 2 (21.0 ± 2.3 vs 36.5 ± 1.5 mmHg, p < 0.001, respectively), and SM pO 2 (9.5 ± 2.2 vs 15.4 ± 2.4 mmHg, p = 0.002, respectively) compared to normoxia. In addition, MIH increased glycolytic metabolism compared to normoxia, reflected by enhanced fasting and postprandial carbohydrate oxidation (p AUC  = 0.002) and elevated plasma lactate concentrations (p AUC  = 0.005). Mechanistically, hypoxia exposure increased insulin-independent glucose uptake compared to standard laboratory conditions (~50 %, p < 0.001) and physiological normoxia (~25 %, p = 0.019) through AMP-activated protein kinase in primary human myotubes but not in primary human adipocytes. MIH upregulated inflammatory/metabolic pathways and downregulated extracellular matrix-related pathways in AT but did not alter systemic inflammatory markers and SM oxidative capacity. MIH exposure did not induce significant alterations in AT (p = 0.120), hepatic (p = 0.132) and SM (p = 0.722) insulin sensitivity. CONCLUSIONS Our findings demonstrate for the first time that 7-day MIH reduces AT and SM pO 2 , evokes a shift toward glycolytic metabolism, and induces adaptations in AT and SM but does not induce alterations in tissue-specific insulin sensitivity in men who are overweight/obese. Future studies are needed to investigate further whether oxygen signaling is a promising target to mitigate metabolic complications in obesity. CLINICAL TRIAL REGISTRATION This study is registered at the Netherlands Trial Register (NL7120/NTR7325).",2021,"MIH upregulated inflammatory/metabolic pathways and downregulated extracellular matrix-related pathways in AT, but did not alter systemic inflammatory markers and SM oxidative capacity.","['12 men with overweight/obesity', 'Men with Obesity', 'people with overweight/obesity', 'men with overweight/obesity']",['mild intermittent hypoxia (MIH) exposure'],"['elevated plasma lactate concentrations', 'enhanced fasting and postprandial carbohydrate oxidation', 'Adipose tissue (AT) and skeletal muscle (SM) pO 2 , fasting/postprandial substrate metabolism, tissue-specific insulin sensitivity, SM oxidative capacity and AT and SM gene/protein expression', 'metabolic improvements', 'physiological normoxia', 'hepatic', 'tissue oxygen partial pressure', 'Mechanistically, hypoxia exposure increased insulin-independent glucose uptake', 'glycolytic metabolism', 'systemic oxygen saturation']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0297199', 'cui_str': 'PO-2'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0030604', 'cui_str': 'Partial pressure'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0020459', 'cui_str': 'Hyperinsulinism'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}]",12.0,0.149165,"MIH upregulated inflammatory/metabolic pathways and downregulated extracellular matrix-related pathways in AT, but did not alter systemic inflammatory markers and SM oxidative capacity.","[{'ForeName': 'Rens L J', 'Initials': 'RLJ', 'LastName': 'van Meijel', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Max A A', 'Initials': 'MAA', 'LastName': 'Vogel', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Johan W E', 'Initials': 'JWE', 'LastName': 'Jocken', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Lars M M', 'Initials': 'LMM', 'LastName': 'Vliex', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Joey S J', 'Initials': 'JSJ', 'LastName': 'Smeets', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Hoebers', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Joris', 'Initials': 'J', 'LastName': 'Hoeks', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Essers', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Paul F M', 'Initials': 'PFM', 'LastName': 'Schoffelen', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands; Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Henrike', 'Initials': 'H', 'LastName': 'Sell', 'Affiliation': 'Paul-Langerhans-Group for Integrative Physiology, German Diabetes Center, Dusseldorf, Germany.'}, {'ForeName': 'Sander', 'Initials': 'S', 'LastName': 'Kersten', 'Affiliation': 'Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, Wageningen, the Netherlands.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'M A Rouschop', 'Affiliation': 'Maastricht Radiation Oncology (MaastRO) Laboratory, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Ellen E', 'Initials': 'EE', 'LastName': 'Blaak', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands.'}, {'ForeName': 'Gijs H', 'Initials': 'GH', 'LastName': 'Goossens', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center(+), Maastricht, the Netherlands. Electronic address: G.Goossens@maastrichtuniversity.nl.'}]",Molecular metabolism,['10.1016/j.molmet.2021.101287'] 1560,34227246,Attention training in children with autism spectrum disorder improves academic performance: A double-blind pilot application of the computerized progressive attentional training program.,"Atypical attention has been reported in individuals with autism spectrum disorder (ASD) with studies pointing to an increase in attention deficit and hyperactivity disorder-like symptomatology. Individuals with ASD may also present academic difficulties and it is possible that they face a double-barrier for academic attainment from both core ASD symptomatology and from attention atypicalities, which are directly linked to academic performance. This raises the possibility that academic difficulties in ASD may benefit from cognitive training targeting attention. To test this possibility, we used the computerized progressive attentional training (CPAT) intervention in a double-blind, active control with follow-up intervention study in Brazil. The CPAT is a computerized attention training program that was recently piloted with schoolchildren with ASD in the UK. Twenty-six participants (8-14 years) with ASD in the São Paulo's ASD Reference Unit were assigned to either the CPAT (n = 14) or active control group (n = 12), which were matched at baseline. Two 45-min intervention sessions per week were conducted over a 2-month period. School performance, attention, fluid intelligence, and behavior were assessed before, immediately after and 3 months following the intervention. Significant group by time interactions show improvements in math, reading, writing and attention that were maintained at follow-up for the CPAT (but not the active control) group, while parents of children from both groups tended to report behavioral improvements. We conclude that attention training has the potential to reduce obstacles for academic attainment in ASD. Combined with the previous pilot study, the current results point to the generality of the approach, which leads to similar outcomes in different cultural and social contexts. LAY ABSTRACT: Attention difficulties tend to occur in ASD and are linked to academic performance. In this study, we demonstrate that school performance in math, reading and writing in children with ASD can improve following an intervention that trains basic attention skills (the CPAT intervention). The improvements we report are stable and were maintained 3-months following the intervention. This study, which was conducted in a public-health setting in Brazil, extends previous research in schools in the UK pointing to the cross-cultural and cross-settings efficacy of the intervention.",2021,"Significant group by time interactions show improvements in math, reading, writing and attention that were maintained at follow-up for the CPAT (but not the active control) group, while parents of children from both groups tended to report behavioral improvements.","['children with autism spectrum disorder improves academic performance', 'Individuals with ASD', 'schoolchildren with ASD in the UK', 'individuals with autism spectrum disorder (ASD', ""Twenty-six participants (8-14\u2009years) with ASD in the São Paulo's ASD Reference Unit"", 'children with ASD']","['computerized progressive attentional training (CPAT) intervention', 'computerized progressive attentional training program', 'attention training', 'CPAT', 'Attention training']","['School performance, attention, fluid intelligence, and behavior', 'math, reading, writing and attention']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439148', 'cui_str': 'Unit'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0556509', 'cui_str': 'Attention training'}]","[{'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0021704', 'cui_str': 'Intelligence'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0024934', 'cui_str': 'Mathematics'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0018582', 'cui_str': 'Handwriting'}]",26.0,0.0283861,"Significant group by time interactions show improvements in math, reading, writing and attention that were maintained at follow-up for the CPAT (but not the active control) group, while parents of children from both groups tended to report behavioral improvements.","[{'ForeName': 'Mayra Muller', 'Initials': 'MM', 'LastName': 'Spaniol', 'Affiliation': 'Developmental Disorders Program, Mackenzie Presbyterian University, São Paulo, Brazil.'}, {'ForeName': 'Carmel', 'Initials': 'C', 'LastName': 'Mevorach', 'Affiliation': 'School of Psychology and the Centre for Human Brain Health, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Lilach', 'Initials': 'L', 'LastName': 'Shalev', 'Affiliation': 'School of Education and the Sagol School of Neuroscience, Tel-Aviv University, Israel.'}, {'ForeName': 'Maria Cristina T V', 'Initials': 'MCTV', 'LastName': 'Teixeira', 'Affiliation': 'Developmental Disorders Program, Mackenzie Presbyterian University, São Paulo, Brazil.'}, {'ForeName': 'Rosane', 'Initials': 'R', 'LastName': 'Lowenthal', 'Affiliation': 'Mental Health Department, Santa Casa School of Medical Sciences, São Paulo, Brazil.'}, {'ForeName': 'Cristiane Silvestre', 'Initials': 'CS', 'LastName': 'de Paula', 'Affiliation': 'Developmental Disorders Program, Mackenzie Presbyterian University, São Paulo, Brazil.'}]",Autism research : official journal of the International Society for Autism Research,['10.1002/aur.2566'] 1561,34230002,The combination of endoluminal radiofrequency ablation and metal stent implantation for the treatment of malignant biliary stenosis - Randomized study.,"PURPOSE To analyse whether endobiliary radiofrequency ablation prior metal stent insertion in malignant biliary stenosis show improved survival or stent patency. METHODS 76 patients with histologically proven malignant biliary stenosis have been enrolled in a prospective, randomized study. In control arm, 40 patients underwent self-expandable metal stent insertion. In experimental arm, the endoluminal ablation with a bipolar radiofrequency catheter was performed immediately before stent insertion. A subgroup analysis of cholangiocarcinoma was performed (22 vs 21 patients). The objective of the study was to determine the rate of complications, duration of the stent patency and the survival of patients (Kaplan-Meier analysis). RESULTS No major complications related to the stent insertion and the endoluminal ablation were found. The mean primary stent patency was 5.2 (95% CI 0.7-12.8) vs 4.8 months (95% CI 0.8-18.2) months (p = 0.79) in control and experimental group, respectively, in the subgroup analysis with cholangiocarcinoma 4.5 (95% CI 0.8-10.3) and 9.6 (95% CI 5.2-11.2) months (p = 0.029). The median survival since the insertion of the stent was 6.8 (95 %CI 3.0-10.6) vs 5.2 (95 %CI 2.4-7.9) months (p = 0.495) and since the initial drainage 9.8 (95 %CI 6.9-12.7) vs 9.1 (95 %CI 5.4-12.7) months (p = 0.720) in the control and experimental arm. CONCLUSION Endobiliary radiofrequency ablation prior metal stent insertion showed increased patency rate only in patients with cholangiocarcinoma, on the other hand, no improvement in survival was demonstrated in this randomized clinical study.",2021,"CONCLUSION Endobiliary radiofrequency ablation prior metal stent insertion showed increased patency rate only in patients with cholangiocarcinoma, on the other hand, no improvement in survival was demonstrated in this randomized clinical study.","['76 patients with histologically proven malignant biliary stenosis', '40 patients underwent']","['self-expandable metal stent insertion', 'endoluminal radiofrequency ablation and metal stent implantation', 'endoluminal ablation with a bipolar radiofrequency catheter', 'endobiliary radiofrequency ablation prior metal stent insertion']","['rate of complications, duration of the stent patency', 'survival or stent patency', 'patency rate', 'median survival since the insertion of the stent', 'survival', 'mean primary stent patency']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0205282', 'cui_str': 'Malignant'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}]","[{'cui': 'C4042807', 'cui_str': 'Self Expandable Metallic Stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0441290', 'cui_str': 'Metal stent'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0332152', 'cui_str': 'Before'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0449591', 'cui_str': 'Stent patency'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205225', 'cui_str': 'Principal'}]",76.0,0.169317,"CONCLUSION Endobiliary radiofrequency ablation prior metal stent insertion showed increased patency rate only in patients with cholangiocarcinoma, on the other hand, no improvement in survival was demonstrated in this randomized clinical study.","[{'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Andrasina', 'Affiliation': 'Department of Radiology and Nuclear Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic.'}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Rohan', 'Affiliation': 'Department of Radiology and Nuclear Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic. Electronic address: rohan.tomas@fnbrno.cz.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Panek', 'Affiliation': 'Department of Radiology and Nuclear Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Kovalcikova', 'Affiliation': 'Institute of Biostatistics and Analyses, Masaryk University, Brno 625 00, Czech Republic.'}, {'ForeName': 'Lumir', 'Initials': 'L', 'LastName': 'Kunovsky', 'Affiliation': 'Department of Surgery, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic; Department of Gastroenterology and Internal Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic.'}, {'ForeName': 'Lenka', 'Initials': 'L', 'LastName': 'Ostrizkova', 'Affiliation': 'Department of Hematooncology, Oncology and Internal Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic.'}, {'ForeName': 'Vlastimil', 'Initials': 'V', 'LastName': 'Valek', 'Affiliation': 'Department of Radiology and Nuclear Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic.'}]",European journal of radiology,['10.1016/j.ejrad.2021.109830'] 1562,34229292,"Impact of opioid-free anaesthesia on postoperative nausea, vomiting and pain after gynaecological laparoscopy - A randomised controlled trial.","STUDY OBJECTIVE Opioid-free anaesthesia may enhance postoperative recovery by reducing opioid-related side effects such as nausea, hyperalgesia or tolerance. The objective was to investigate the impact of multimodal opioid-free general anaesthesia on postoperative nausea, vomiting, pain and morphine consumption compared to the traditional opioid-based approach. DESIGN This study was conducted as a prospective parallel-group randomised controlled trial. SETTING Perioperative Care. PATIENTS 152 adult women undergoing elective inpatient gynaecological laparoscopy. INTERVENTIONS Patients were randomly assigned for opioid-free anaesthesia (Group OF) with dexmedetomidine, esketamine and sevoflurane or to have opioid-based anaesthesia (Group C) with sufentanil and sevoflurane. MEASUREMENTS Primary outcome was the occurrence of nausea within 24 h after surgery. Patients were assessed for the incidence and severity of PONV, postoperative pain and morphine consumption and recovery characteristics. MAIN RESULTS Patients in both groups had comparable clinical and surgical data. 69.7% of patients in the control group and 68.4% of patients in the opioid-free group met the primary endpoint (OR 1.06, 95% Confidence Interval (CI) (0.53; 2.12) p = 0.86). The incidence of clinically important PONV defined by the PONV impact scale was 8.1% (Group C) vs 10.5% (OF); p = 0.57). Antiemetic requirements, pain scores and morphine consumption were equivalent in both groups. Postoperative sedation was significantly increased in group OF (p < 0.001), and the median length of stay at the post-anaesthesia care unit was 69.0 min (46.5-113.0) vs 50.0 (35.3-77.0) minutes in the control group (p < 0.001). CONCLUSIONS Opioid-free multimodal general anaesthesia is feasible but did not decrease the incidence of PONV, or reduce pain scores and morphine consumption compared to an opioid-containing anaesthetic regimen.",2021,"CONCLUSIONS Opioid-free multimodal general anaesthesia is feasible but did not decrease the incidence of PONV, or reduce pain scores and morphine consumption compared to an opioid-containing anaesthetic regimen.",['152 adult women undergoing elective inpatient gynaecological laparoscopy'],"['dexmedetomidine, esketamine and sevoflurane or to have opioid-based anaesthesia', 'multimodal opioid-free general anaesthesia', 'opioid-free anaesthesia', 'sufentanil and sevoflurane']","['median length of stay', 'occurrence of nausea', 'Postoperative sedation', 'postoperative nausea, vomiting and pain', 'incidence of PONV, or reduce pain scores and morphine consumption', 'postoperative nausea, vomiting, pain and morphine consumption', 'nausea, hyperalgesia or tolerance', 'Antiemetic requirements, pain scores and morphine consumption', 'incidence and severity of PONV, postoperative pain and morphine consumption and recovery characteristics', 'PONV impact scale']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C2825616', 'cui_str': 'esketamine'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0520904', 'cui_str': 'Postoperative nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesia'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic agent'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",152.0,0.366367,"CONCLUSIONS Opioid-free multimodal general anaesthesia is feasible but did not decrease the incidence of PONV, or reduce pain scores and morphine consumption compared to an opioid-containing anaesthetic regimen.","[{'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Massoth', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, A1, 48149 Münster, Germany. Electronic address: Christina.Massoth@ukmuenster.de.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Schwellenbach', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, Florence-Nightingale-Hospital, Kreuzbergstraße 79, 40489 Düsseldorf, Germany.'}, {'ForeName': 'Khaschayar', 'Initials': 'K', 'LastName': 'Saadat-Gilani', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, A1, 48149 Münster, Germany.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Weiss', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, A1, 48149 Münster, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pöpping', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, A1, 48149 Münster, Germany.'}, {'ForeName': 'Mira', 'Initials': 'M', 'LastName': 'Küllmar', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, A1, 48149 Münster, Germany.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Wenk', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, Florence-Nightingale-Hospital, Kreuzbergstraße 79, 40489 Düsseldorf, Germany.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110437'] 1563,34229284,Intermittent Theta Burst Stimulation in Veterans with Mild Alcohol Use Disorder.,"BACKGROUND Alcohol use disorder (AUD) is highly comorbid with depression and posttraumatic stress disorder (PTSD) and can complicate their treatment. Transcranial magnetic stimulation is a promising treatment for these disorders, yet prior research often excluded AUD patients out of concern for safety or poorer outcomes. To this end, we revisited a prior study of intermittent theta burst stimulation (iTBS) for PTSD, to evaluate whether mild AUD impacted safety and clinical outcomes. METHODS Fifty veterans with PTSD (n=17, with comorbid AUD) received 10 days of sham-controlled iTBS, followed by 10 unblinded sessions. Stimulation was delivered at 80% of the motor threshold for 1800 pulses to the right dorsolateral prefrontal cortex. Safety, PTSD and depressive outcomes were evaluated with repeated measures analysis of variance, to examine the effects of time, treatment group and comorbid AUD. RESULTS iTBS was safe, although AUD patients reported more adverse events, regardless of whether they received active or sham stimulation. Regarding clinical outcomes, patients with AUD who received active stimulation demonstrated a greater rate of improvement in depression symptoms than those without comorbid AUD. The presence of AUD did not impact PTSD symptom change. LIMITATIONS Limitations include a modest sample size and use of a categorical, rather than continuous, index of AUD diagnosis. CONCLUSION While these results require replication, they indicate that iTBS is likely safe in patients with mild comorbid AUD. We propose that comorbid AUD should not preclude clinical use of iTBS, and that iTBS should be further investigated as a novel treatment option for AUD.",2021,"RESULTS iTBS was safe, although AUD patients reported more adverse events, regardless of whether they received active or sham stimulation.","['patients with AUD who received', 'Fifty veterans with PTSD (n=17, with comorbid AUD', 'patients with mild comorbid AUD', 'Veterans with Mild Alcohol Use Disorder']","['Intermittent Theta Burst Stimulation', 'sham-controlled iTBS', 'iTBS', 'Transcranial magnetic stimulation', 'active stimulation', 'intermittent theta burst stimulation (iTBS']","['Safety, PTSD and depressive outcomes', 'adverse events', 'depression symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",,0.0556342,"RESULTS iTBS was safe, although AUD patients reported more adverse events, regardless of whether they received active or sham stimulation.","[{'ForeName': 'Melanie L', 'Initials': 'ML', 'LastName': 'Bozzay', 'Affiliation': 'VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Healthcare System; Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island 02908, United States.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Brigido', 'Affiliation': 'VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Healthcare System.'}, {'ForeName': 'Mascha', 'Initials': 'M', 'LastName': ""van 't Wout-Frank"", 'Affiliation': 'VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Healthcare System; Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island 02908, United States.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Aiken', 'Affiliation': 'VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Healthcare System.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Swift', 'Affiliation': 'VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Healthcare System; Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island 02908, United States.'}, {'ForeName': 'Noah S', 'Initials': 'NS', 'LastName': 'Philip', 'Affiliation': 'VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Healthcare System; Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island 02908, United States. Electronic address: Noah_Philip@brown.edu.'}]",Journal of affective disorders,['10.1016/j.jad.2021.06.039'] 1564,34233727,"Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial.","BACKGROUND Tapering or stopping biological disease-modifying anti-rheumatic drugs has been proposed for patients with rheumatoid arthritis (RA) in remission, but it frequently results in high rates of recurrence. This study evaluates the efficacy and safety of tacrolimus (TAC) as maintenance therapy in patients with established RA in remission after receiving combination therapy with tumor necrosis factor inhibitor (TNFi) and methotrexate (MTX). METHODS This 24-week, prospective, open-label trial included patients who received TNFi and MTX at stable doses for ≥24 weeks and had low disease activity (LDA), measured by Disease Activity Score-28 for ≥12 weeks. Patients selected one of two arms: maintenance (TNFi plus MTX) or switched (TAC plus MTX). The primary outcome was the difference in the proportion of patients maintaining LDA at week 24, which was assessed using a logistic regression model. Adverse events were monitored throughout the study period. RESULTS In efficacy analysis, 80 and 34 patients were included in the maintenance and switched arms, respectively. At week 24, LDA was maintained in 99% and 91% of patients in the maintenance and switched arms, respectively (odds ratio, 0.14; 95% confidence interval, 0.01-1.59). Drug-related adverse effects tended to be more common in the switched arm than in the maintenance arm (20.9% versus 7.1%, respectively) but were well-tolerated. CONCLUSION This controlled study tested a novel treatment strategy of switching from TNFi to TAC in RA patients with sustained LDA, and the findings suggested that TNFi can be replaced with TAC in most patients without the patients experiencing flare-ups for at least 24 weeks. TRIAL REGISTRATION Korea CDC CRIS, KCT0005868 . Registered 4 February 2021-retrospectively registered.",2021,"At week 24, LDA was maintained in 99% and 91% of patients in the maintenance and switched arms, respectively (odds ratio, 0.14; 95% confidence interval, 0.01-1.59).","['RA patients with sustained LDA', 'patients with rheumatoid arthritis (RA', 'at stable doses for ≥24\u2009weeks and had low disease activity (LDA), measured by Disease Activity Score-28 for ≥12\u2009weeks', 'patients with established RA in remission after receiving combination therapy with tumor necrosis factor inhibitor (TNFi) and methotrexate (MTX']","['TNFα inhibitor to tacrolimus', 'tacrolimus (TAC', 'maintenance (TNFi plus MTX) or switched (TAC plus MTX', 'TNFα inhibitors and methotrexate', 'TNFi and MTX']","['efficacy and safety', 'proportion of patients maintaining LDA', 'Adverse events']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C4509670', 'cui_str': 'Rheumatoid arthritis in remission'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C3537192', 'cui_str': 'TNF Antagonists'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C3537192', 'cui_str': 'TNF Antagonists'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.156531,"At week 24, LDA was maintained in 99% and 91% of patients in the maintenance and switched arms, respectively (odds ratio, 0.14; 95% confidence interval, 0.01-1.59).","[{'ForeName': 'Sang Youn', 'Initials': 'SY', 'LastName': 'Jung', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.'}, {'ForeName': 'Jung Hee', 'Initials': 'JH', 'LastName': 'Koh', 'Affiliation': ""Division of Rheumatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, the Catholic University of Korea, Seoul, South Korea.""}, {'ForeName': 'Ki-Jo', 'Initials': 'KJ', 'LastName': 'Kim', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine, St. Vincent Hospital, the Catholic University of Korea, Seoul, South Korea.'}, {'ForeName': 'Yong-Wook', 'Initials': 'YW', 'LastName': 'Park', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, South Korea.'}, {'ForeName': 'Hyung-In', 'Initials': 'HI', 'LastName': 'Yang', 'Affiliation': 'College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.'}, {'ForeName': 'Sung Jae', 'Initials': 'SJ', 'LastName': 'Choi', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, South Korea.'}, {'ForeName': 'Jisoo', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Chan-Bum', 'Initials': 'CB', 'LastName': 'Choi', 'Affiliation': 'Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.'}, {'ForeName': 'Wan-Uk', 'Initials': 'WU', 'LastName': 'Kim', 'Affiliation': ""Division of Rheumatology, Department of Internal Medicine, Seoul St Mary's Hospital, Center for Integrative Rheumatoid Transcriptomics and Dynamics, College of Medicine, the Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, South Korea. wan725@catholic.ac.kr.""}]",Arthritis research & therapy,['10.1186/s13075-021-02566-z'] 1565,34235909,"Two-year outcomes following the adjunctive use of InGaAsP and Er,Cr:YSGG lasers in nonsurgical periodontal therapy in patients with stages III and IV periodontitis.","OBJECTIVE To evaluate the clinical outcomes 2 years after the adjunctive use of an InGaAsP diode and Er,Cr:YSGG laser for nonsurgical treatment of severe periodontitis. METHOD AND MATERIALS Forty-two patients (45.31 ± 9.78 years old, n = 22 females, n = 23 smokers) with stage III or IV grade B periodontitis were randomly treated either with laser (InGaAsP + Er,Cr:YSGG) adjunctive to subgingival debridement (test group, n = 21) or with subgingival debridement alone (control group, n = 21). Subjects in the test group received a second laser treatment in residual sites 2 months after the initial laser therapy. At baseline, and at 12 and 24 months after therapy, periodontal clinical parameters were evaluated. The primary outcome variable was the number of residual deep sites at 12 months (probing depth [PD] ≥ 6 mm). RESULTS One and two years after nonsurgical periodontal treatment, both groups yielded statistically significant clinical improvements. The adjunctive use of InGaAsP and Er,Cr:YSGG laser to mechanical debridement resulted in statistically significantly higher clinical (PD, clinical attachment level, bleeding on probing, number of sites with PD ≥ 5 mm, PD ≥ 6 mm, PD ≥ 7 mm) improvements (P < .05) compared to subgingival debridement alone both at 12 and 24 months after therapy. CONCLUSION In patients with stage III or IV grade B periodontitis, InGaAsP and Er,Cr:YSGG used adjunctively to subgingival debridement may additionally improve the clinical outcomes compared to mechanical debridement alone over a period of 24 months.",2021,"One and two years after nonsurgical periodontal treatment, both groups yielded statistically significant clinical improvements.","['patients with stages III and IV periodontitis', 'Forty-two patients (45.31 ± 9.78 years old, n = 22 females, n = 23 smokers) with stage III or IV grade B periodontitis']","['InGaA\ufeffsP and Er,Cr:YSGG laser', 'second laser treatment', 'InGaAsP and Er,Cr:YSGG lasers', 'laser (InGaAsP + Er,Cr:YSGG) adjunctive to subgingival debridement\ufeff (test group, n = 21) or with \ufeffsubgingival debridement alone (control', 'InGaAsP diode and Er,Cr:YSGG laser']","['number of residual deep sites at 12 months (probing depth [PD] ≥ 6 mm', 'higher clinical (PD, clinical attachment level, bleeding on probing, number of sites']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0441806', 'cui_str': 'Grade B'}]","[{'cui': 'C0879167', 'cui_str': 'Yttrium-Scandium-Gallium Garnet Lasers'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0595817', 'cui_str': 'Subgingival route'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0445108', 'cui_str': 'Number of sites'}]",42.0,0.0369852,"One and two years after nonsurgical periodontal treatment, both groups yielded statistically significant clinical improvements.","[{'ForeName': 'Codruta Elena', 'Initials': 'CE', 'LastName': 'Ciurescu', 'Affiliation': ''}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Gutknecht', 'Affiliation': ''}, {'ForeName': 'Vlad Alexandru', 'Initials': 'VA', 'LastName': 'Ciurescu', 'Affiliation': ''}, {'ForeName': 'Anca', 'Initials': 'A', 'LastName': 'Gheorghiu', 'Affiliation': ''}, {'ForeName': 'Rene', 'Initials': 'R', 'LastName': 'Franzen', 'Affiliation': ''}, {'ForeName': 'Nicole B', 'Initials': 'NB', 'LastName': 'Arweiler', 'Affiliation': ''}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Sculean', 'Affiliation': ''}, {'ForeName': 'Raluca', 'Initials': 'R', 'LastName': 'Cosgarea', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.b1702285'] 1566,34235908,Efficacy of buccal versus intranasal route of administration of midazolam spray in behavior management of preschool dental patients.,"OBJECTIVE To assess the efficacy of aerosolized midazolam, introduced through buccal versus intranasal mucosa in managing uncooperative children undergoing dental treatment. METHOD AND MATERIALS A crossover randomized controlled clinical trial included 36 children aged 3 to 5 years, rated I or II according to the Frankl scale and ASA I or II. Each child fulfilled the requirement of having a dental condition that needed treatment in two dental settings. They were randomly assigned to one of two groups; either buccal or intranasal aerosolized midazolam was administered at the first visit. The alternate route was implemented with a 1-week washout period in the second visit. Drug acceptance and time until optimum sedation were measured. Crying, sleeping, head resistance, and child overall behavior were assessed using modified Houpt scale. RESULTS In total, 34 patients (95 %) were drowsy on optimum sedation. There was a statistically higher acceptance of buccal midazolam (P < .001). Onset of optimum sedation was more rapid for the intranasal group, with a mean of 15.50 ± 4.226 minutes (P < .001), while in the buccal group the mean was 22.97 ± 4.582 minutes. No statistical differences were recorded between the two groups in all behavior rating scales, except for crying where the intranasal group was statistically higher (P = .010). Regarding the overall behavior, there was no significant difference recorded between the two groups (P = .204). CONCLUSION Aerosolized buccal midazolam was more tolerated by the patients. However, intranasal aerosolized midazolam had a more rapid onset of sedation. Both buccal and intranasal administrations of aerosolized midazolam are safe and effective.",2021,"No statistical differences were recorded between the two groups in all behavior rating scales, except for crying where the intranasal group was statistically higher (P = .010).","['uncooperative children undergoing dental treatment', 'preschool dental patients', '36 children aged 3 to 5 years, rated I or II according to the Frankl scale and ASA I or II']","['buccal or intranasal aerosolized midazolam', 'Aerosolized buccal midazolam', 'aerosolized midazolam', 'buccal', 'intranasal aerosolized midazolam', 'midazolam spray']","['Drug acceptance and time until optimum sedation', 'rapid onset of sedation', 'Crying, sleeping, head resistance, and child overall behavior', 'behavior rating scales, except for crying', 'acceptance of buccal midazolam', 'drowsy on optimum sedation']","[{'cui': 'C0424350', 'cui_str': 'Uncooperative behavior'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011331', 'cui_str': 'Dental care'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0475483', 'cui_str': 'Behavior rating scale'}, {'cui': 'C0332300', 'cui_str': 'Except for'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}]",36.0,0.0332037,"No statistical differences were recorded between the two groups in all behavior rating scales, except for crying where the intranasal group was statistically higher (P = .010).","[{'ForeName': 'Yousr N', 'Initials': 'YN', 'LastName': 'Mowafy', 'Affiliation': ''}, {'ForeName': 'Nadia A', 'Initials': 'NA', 'LastName': 'Wahba', 'Affiliation': ''}, {'ForeName': 'Tamer M', 'Initials': 'TM', 'LastName': 'Gho Neim', 'Affiliation': ''}, {'ForeName': 'Ghada M', 'Initials': 'GM', 'LastName': 'Mahmoud', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.b1702197'] 1567,34238446,Long-Term Effects of an Intensive Prevention Program After Acute Myocardial Infarction.,"Effective long-term prevention after myocardial infarction (MI) is crucial to reduce recurrent events. In this study the effects of a 12-months intensive prevention program (IPP), based on repetitive contacts between non-physician ""prevention assistants"" and patients, were evaluated. Patients after MI were randomly assigned to the IPP versus usual care (UC). Effects of IPP on risk factor control, clinical events and costs were investigated after 24 months. In a substudy efficacy of short reinterventions after more than 24 months (""Prevention Boosts"") was analyzed. IPP was associated with a significantly better risk factor control compared to UC after 24 months and a trend towards less serious clinical events (12.5% vs 20.9%, log-rank p = 0.06). Economic analyses revealed that already after 24 months cost savings due to event reduction outweighted the costs of the prevention program (costs per patient 1,070 € in IPP vs 1,170 € in UC). Short reinterventions (""Prevention Boosts"") more than 24 months after MI further improved risk factor control, such as LDL cholesterol and blood pressure lowering. In conclusion, IPP was associated with numerous beneficial effects on risk factor control, clinical events and costs. The study thereby demonstrates the efficacy of preventive long-term concepts after MI, based on repetitive contacts between non-physician coworkers and patients.",2021,"IPP was associated with a significantly better risk factor control compared to UC after 24 months and a trend towards less serious clinical events (12.5% vs 20.9%, log-rank p = 0.06).",['Patients after MI'],"['Intensive Prevention Program', 'IPP versus usual care (UC', '12-months intensive prevention program (IPP', 'IPP']","['serious clinical events', 'IPP', 'risk factor control, such as LDL cholesterol and blood pressure lowering', 'risk factor control, clinical events and costs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}]","[{'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.0177855,"IPP was associated with a significantly better risk factor control compared to UC after 24 months and a trend towards less serious clinical events (12.5% vs 20.9%, log-rank p = 0.06).","[{'ForeName': 'Rico', 'Initials': 'R', 'LastName': 'Osteresch', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Bremen, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Fach', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Bremen, Germany.'}, {'ForeName': 'Fabian-Simon', 'Initials': 'FS', 'LastName': 'Frielitz', 'Affiliation': 'Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Meyer', 'Affiliation': 'Department of Cardiology, University Hospital Oldenburg, Oldenburg, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Schmucker', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Bremen, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Rühle', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Bremen, Germany.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Retzlaff', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Bremen, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Hadwiger', 'Affiliation': 'Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Härle', 'Affiliation': 'Department of Cardiology, University Hospital Oldenburg, Oldenburg, Germany.'}, {'ForeName': 'Albrecht', 'Initials': 'A', 'LastName': 'Elsässer', 'Affiliation': 'Department of Cardiology, University Hospital Oldenburg, Oldenburg, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Katalinic', 'Affiliation': 'Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Eitel', 'Affiliation': 'Medical Clinic II, Lübeck University Heart Center, Lübeck, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Hambrecht', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Bremen, Germany.'}, {'ForeName': 'Harm', 'Initials': 'H', 'LastName': 'Wienbergen', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Bremen, Germany; Medical Clinic II, Lübeck University Heart Center, Lübeck, Germany. Electronic address: harm.wienbergen@klinikum-bremen-ldw.de.'}]",The American journal of cardiology,['10.1016/j.amjcard.2021.05.034'] 1568,34238445,Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis.,"It remains inconclusive whether the additional low-density lipoprotein cholesterol (LDL-C) lowering effects of ezetimibe added to statin on coronary atherosclerosis and clinical outcomes are similar to those of statin monotherapy in the setting of comparable LDL-C reduction. We aimed to determine whether there were distinguishable differences in their effects on coronary atherosclerosis with intermediate stenosis between the combination of moderate-intensity statin plus ezetimibe and high-intensity statin monotherapy. Forty-one patients with stable angina undergoing percutaneous coronary intervention were randomized to receive either atorvastatin 10 mg plus ezetimibe 10 mg (ATO10/EZE10) or atorvastatin 40 mg alone (ATO40). The intermediate lesions were evaluated using a near-infrared spectroscopy-intravascular ultrasonography at baseline and after 12 months in 37 patients. The primary endpoint was percent atheroma volume (PAV). Mean LDL-C levels were significantly reduced by 40% and 38% from baseline in the ATO10/EZE10 group (n = 18, from 107 mg/dL to 61 mg/dL) and ATO40 group (n = 19, from 101 mg/dL to 58 mg/dL), respectively, without between-group difference. The absolute change of PAV was -2.9% in the ATO10/EZE10 group and -3.2% in the ATO40 group. The mean difference (95% confidence interval) for the absolute change in PAV between the 2 groups was 0.5% (-2.4% to 2.8%), which did not exceed the pre-defined non-inferiority margin of 5%. There was no significant reduction in lipid core burden index in both groups. In conclusion, the combination of atorvastatin 10 mg and ezetimibe 10 mg showed comparable LDL-C lowering and regression of coronary atherosclerosis in the intermediate lesions, compared with atorvastatin 40 mg alone.",2021,"The mean difference (95% confidence interval) for the absolute change in PAV between the 2 groups was 0.5% (-2.4% to 2.8%), which did not exceed the pre-defined non-inferiority margin of 5%.",['Forty-one patients with stable angina undergoing percutaneous coronary intervention'],"['ezetimibe and high-intensity statin monotherapy', 'ATO10/EZE10', 'atorvastatin 10 mg plus ezetimibe 10 mg (ATO10/EZE10) or atorvastatin 40 mg alone (ATO40', 'Atorvastatin', 'atorvastatin', 'Ezetimibe (10 mg) Combination Compared to Atorvastatin', 'ezetimibe']","['Coronary Atherosclerosis', 'percent atheroma volume (PAV', 'absolute change of PAV', 'lipid core burden index', 'Mean LDL-C levels', 'PAV', 'LDL-C lowering and regression of coronary atherosclerosis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0340288', 'cui_str': 'Stable angina'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C1379772', 'cui_str': 'atorvastatin 10 MG'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1166438', 'cui_str': 'ezetimibe 10 MG'}, {'cui': 'C1616508', 'cui_str': 'atorvastatin 40 MG [Lipitor]'}, {'cui': 'C0286651', 'cui_str': 'atorvastatin'}]","[{'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0264956', 'cui_str': 'Atheroma'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0684321', 'cui_str': 'Regression - mental defense mechanism'}]",41.0,0.0830404,"The mean difference (95% confidence interval) for the absolute change in PAV between the 2 groups was 0.5% (-2.4% to 2.8%), which did not exceed the pre-defined non-inferiority margin of 5%.","[{'ForeName': 'Pyung Chun', 'Initials': 'PC', 'LastName': 'Oh', 'Affiliation': 'Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Albert Youngwoo', 'Initials': 'AY', 'LastName': 'Jang', 'Affiliation': 'Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Kyungeun', 'Initials': 'K', 'LastName': 'Ha', 'Affiliation': 'Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Minsu', 'Initials': 'M', 'LastName': 'Kim', 'Affiliation': 'Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Jeonggeun', 'Initials': 'J', 'LastName': 'Moon', 'Affiliation': 'Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Soon Yong', 'Initials': 'SY', 'LastName': 'Suh', 'Affiliation': 'Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Kyounghoon', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Seung Hwan', 'Initials': 'SH', 'LastName': 'Han', 'Affiliation': 'Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Woong Chol', 'Initials': 'WC', 'LastName': 'Kang', 'Affiliation': 'Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea. Electronic address: kangwch@gilhospital.com.'}]",The American journal of cardiology,['10.1016/j.amjcard.2021.05.039'] 1569,34238436,Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities.,"BACKGROUND Rhythm control strategies for atrial fibrillation (AF), including catheter ablation, are substantially underused in racial/ethnic minorities in North America. OBJECTIVES This study sought to describe outcomes in the CABANA trial as a function of race/ethnicity. METHODS CABANA randomized 2,204 symptomatic participants with AF to ablation or drug therapy including rate and/or rhythm control drugs. Only participants in North America were included in the present analysis, and participants were subgrouped as racial/ethnic minority or nonminority with the use of National Institutes of Health definitions. The primary endpoint was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. RESULTS Of 1,280 participants enrolled in CABANA in North America, 127 (9.9%) were racial and ethnic minorities. Compared with nonminorities, racial and ethnic minorities were younger with median age 65.6 versus 68.5 years, respectively, and had more symptomatic heart failure (37.0% vs 22.0%), hypertension (92.1% vs 76.8%, respectively), and ejection fraction <40% (20.8% vs 7.1%). Racial/ethnic minorities treated with ablation had a 68% relative reduction in the primary endpoint (adjusted hazard ratio [aHR]: 0.32; 95% confidence interval [CI]: 0.13-0.78) and a 72% relative reduction in all-cause mortality (aHR: 0.28; 95% CI: 0.10-0.79). Primary event rates in racial/ethnic minority and nonminority participants were similar in the ablation arm (4-year Kaplan-Meier event rates 12.3% vs 9.9%); however, racial and ethnic minorities randomized to drug therapy had a much higher event rate than nonminority participants (27.4% vs. 9.4%). CONCLUSION Among racial or ethnic minorities enrolled in the North American CABANA cohort, catheter ablation significantly improved major clinical outcomes compared with drug therapy. These benefits, which were not seen in nonminority participants, appear to be due to worse outcomes with drug therapy. (Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial [CABANA]; NCT00911508).",2021,Racial/ethnic minorities treated with ablation had a 68% relative reduction in the primary endpoint (adjusted hazard ratio [aHR]: 0.32; 95% confidence interval [CI]: 0.13-0.78) and a 72% relative reduction in all-cause mortality (aHR: 0.28; 95% CI: 0.10-0.79).,"['2,204 symptomatic participants with AF to ablation or drug therapy including rate and/or rhythm control drugs', 'Atrial Fibrillation in Racial and Ethnic Minorities', '1,280 participants enrolled in CABANA in North America, 127 (9.9%) were racial and ethnic minorities', 'Only participants in North America were included in the present analysis, and participants were subgrouped as racial/ethnic minority or nonminority with the use of National Institutes of Health definitions']",['Ablation Versus Drug Therapy'],"['composite of death, disabling stroke, serious bleeding, or cardiac arrest', 'symptomatic heart failure', 'event rate', 'hypertension']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0013168', 'cui_str': 'Drug Control'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C3539107', 'cui_str': 'Definition'}]","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",2204.0,0.250521,Racial/ethnic minorities treated with ablation had a 68% relative reduction in the primary endpoint (adjusted hazard ratio [aHR]: 0.32; 95% confidence interval [CI]: 0.13-0.78) and a 72% relative reduction in all-cause mortality (aHR: 0.28; 95% CI: 0.10-0.79).,"[{'ForeName': 'Kevin L', 'Initials': 'KL', 'LastName': 'Thomas', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA. Electronic address: kevin.thomas@duke.edu.'}, {'ForeName': 'Hussein R', 'Initials': 'HR', 'LastName': 'Al-Khalidi', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Adam P', 'Initials': 'AP', 'LastName': 'Silverstein', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Kristi H', 'Initials': 'KH', 'LastName': 'Monahan', 'Affiliation': ""Mayo Clinic-St Mary's Campus, Rochester, Minnesota, USA.""}, {'ForeName': 'Tristram D', 'Initials': 'TD', 'LastName': 'Bahnson', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Jeanne E', 'Initials': 'JE', 'LastName': 'Poole', 'Affiliation': 'University of Washington Medical Center, Seattle, Washington, USA.'}, {'ForeName': 'Daniel B', 'Initials': 'DB', 'LastName': 'Mark', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Packer', 'Affiliation': ""Mayo Clinic-St Mary's Campus, Rochester, Minnesota, USA.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2021.04.092'] 1570,34255649,Use of a Virtual Reality Simulator for Tendon Repair Training: Randomized Controlled Trial.,"BACKGROUND Virtual reality (VR) simulators have become widespread tools for training medical students and residents in medical schools. Students using VR simulators are provided with a 3D human model to observe the details by using multiple senses and they can participate in an environment that is similar to reality. OBJECTIVE The aim of this study was to promote a new approach consisting of a shared and independent study platform for medical orthopedic students, to compare traditional tendon repair training with VR simulation of tendon repair, and to evaluate future applications of VR simulation in the academic medical field. METHODS In this study, 121 participants were randomly allocated to VR or control groups. The participants in the VR group studied the tendon repair technique via the VR simulator, while the control group followed traditional tendon repair teaching methods. The final assessment for the medical students involved performing tendon repair with the ""Kessler tendon repair with 2 interrupted tendon repair knots"" (KS) method and the ""Bunnell tendon repair with figure 8 tendon repair"" (BS) method on a synthetic model. The operative performance was evaluated using the global rating scale. RESULTS Of the 121 participants, 117 participants finished the assessment and 4 participants were lost to follow-up. The overall performance (a total score of 35) of the VR group using the KS method and the BS method was significantly higher (P<.001) than that of the control group. Thus, participants who received VR simulator training had a significantly higher score on the global rating scale than those who received traditional tendon repair training (P<.001). CONCLUSIONS Our study shows that compared with the traditional tendon repair method, the VR simulator for learning tendon suturing resulted in a significant improvement of the medical students in the time in motion, flow of operation, and knowledge of the procedure. Therefore, VR simulator development in the future would most likely be beneficial for medical education and clinical practice. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR2100046648; http://www.chictr.org.cn/hvshowproject.aspx?id=90180.",2021,The overall performance (a total score of 35) of the VR group using the KS method and the BS method was significantly higher (P<.001) than that of the control group.,"['medical orthopedic students', '121 participants', '117 participants finished the assessment and 4 participants were lost to follow-up', 'training medical students and residents in medical schools']","['VR simulator training', 'traditional tendon repair training with VR simulation of tendon repair', 'traditional tendon repair training', 'Virtual reality (VR) simulators', 'tendon repair with the ""Kessler tendon repair with 2 interrupted tendon repair knots"" (KS) method and the ""Bunnell tendon repair with figure 8 tendon repair"" (BS) method on a synthetic model', 'Virtual Reality Simulator', 'tendon repair technique via the VR simulator, while the control group followed traditional tendon repair teaching methods']","['global rating scale', 'operative performance', 'overall performance', 'time in motion, flow of operation, and knowledge of the procedure']","[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1706059', 'cui_str': 'Finish'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1302313', 'cui_str': 'Lost to follow-up'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0036378', 'cui_str': 'Medical School'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0565350', 'cui_str': 'Plastic repair of tendon'}, {'cui': 'C0443239', 'cui_str': 'Interrupted'}, {'cui': 'C0560032', 'cui_str': 'knot'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0039403', 'cui_str': 'Teaching Methods'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",121.0,0.0511735,The overall performance (a total score of 35) of the VR group using the KS method and the BS method was significantly higher (P<.001) than that of the control group.,"[{'ForeName': 'Tsz-Ngai', 'Initials': 'TN', 'LastName': 'Mok', 'Affiliation': 'Institute of Orthopedics Diseases and Center for Joint Surgery and Sports Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.'}, {'ForeName': 'Junyuan', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Institute of Orthopedics Diseases and Center for Joint Surgery and Sports Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.'}, {'ForeName': 'Jinghua', 'Initials': 'J', 'LastName': 'Pan', 'Affiliation': 'Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.'}, {'ForeName': 'Wai-Kit', 'Initials': 'WK', 'LastName': 'Ming', 'Affiliation': 'Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China.'}, {'ForeName': 'Qiyu', 'Initials': 'Q', 'LastName': 'He', 'Affiliation': 'Pediatric Cardiac Surgery Centre, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Tat-Hang', 'Initials': 'TH', 'LastName': 'Sin', 'Affiliation': 'Institute of Orthopedics Diseases and Center for Joint Surgery and Sports Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.'}, {'ForeName': 'Jialin', 'Initials': 'J', 'LastName': 'Deng', 'Affiliation': 'Institute of Orthopedics Diseases and Center for Joint Surgery and Sports Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.'}, {'ForeName': 'Jieruo', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Institute of Orthopedics Diseases and Center for Joint Surgery and Sports Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.'}, {'ForeName': 'Zhengang', 'Initials': 'Z', 'LastName': 'Zha', 'Affiliation': 'Institute of Orthopedics Diseases and Center for Joint Surgery and Sports Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.'}]",JMIR serious games,['10.2196/27544'] 1571,34259636,The Effects of Immersive Virtual Reality in Reducing Public Stigma of Mental Illness in the University Population of Hong Kong: Randomized Controlled Trial.,"BACKGROUND Public stigma in mental health often brings various adverse effects on people with mental illness. Researchers have been developing different interventions in combating public stigma. OBJECTIVE This study investigates the effects of immersive virtual reality (IVR) in reducing the public stigma of mental illness using a single-blinded randomized control trial. METHODS A pre-post experimental design with a 1-week follow-up was conducted. Participants (N=206) were recruited through the mass mail system of The Chinese University of Hong Kong and randomized into 3 conditions: immersive animation, text, and control. In the immersive animation condition (n=72), participants experienced the simulation of daily life and the stigma experienced as an animated story protagonist with mixed anxiety and depressive disorder with IVR. In the text condition (n=65), participants experienced an identical story to the immersive animation condition with first-person audio narration using the same virtual reality headset. In the control condition (n=69), participants watched a video about planets with IVR. All participants received interventions with a researcher-assisted Oculus Go virtual reality headset. Participants' public stigma was measured through self-administered online questionnaires and compared across conditions and at different time points using repeated measures analysis of variance. Simple and sequential mediation analyses on the relationship of condition (immersive animation vs text) and follow-up public stigma with possible mediators, including sense of embodiment and story transportation, were conducted using PROCESS. RESULTS Public stigma did not differ significantly across conditions at pre-experiment (P>.99). In the immersive animation and text conditions, public stigma was significantly reduced at postexperiment and at the 1-week follow-up compared to pre-experiment (all with P<.001). Public stigma in the control condition at postexperiment and follow-up remained unchanged compared with pre-experiment (P=.69). Immersive animation had significantly lower public stigma than the control at postexperiment (P=.003) and follow-up (P=.02). Text also had lower public stigma than the control at postexperiment (P=.007) and follow-up (P=.03). However, immersive animation did not significantly differ from text in public stigma at postexperiment and follow-up (both P>.99). In simple mediation models, both sense of embodiment (95% CI -0.22 to 0.46) and story transportation (95% CI -0.18 to 0.00) were not significant mediators. In the sequential mediation model, both sense of embodiment and story transportation were significant sequential mediators. Sense of embodiment was positively associated with story transportation (P<.001), while story transportation was negatively associated with public stigma (P<.001). The indirect effect of the sequential mediation model was significant (95% CI -0.38 to -0.11). CONCLUSIONS This study provides novel findings and a rigorous comparison in understanding the effects of IVR on public stigma. The findings showed that IVR and text with audio narration performed similarly and significantly in stigma reduction. Sense of embodiment and story transportation were found to be sequentially associated with public stigma reduction. TRIAL REGISTRATION Centre for Clinical Research and Biostatistics Clinical Trial Registry CUHK_Ccrb00638; https://www2.ccrb.cuhk.edu.hk/registry/public/632.",2021,Immersive animation had significantly lower public stigma than the control at postexperiment (P=.003) and follow-up (P=.02).,"['University Population of Hong Kong', 'Participants (N=206) were recruited through the mass mail system of The Chinese University of Hong Kong and randomized into 3 conditions', 'people with mental illness']","['immersive animation, text, and control', 'identical story to the immersive animation condition with first-person audio narration using the same virtual reality headset', 'Immersive Virtual Reality', 'interventions with a researcher-assisted Oculus Go virtual reality headset', 'immersive virtual reality (IVR', 'immersive animation condition']","['public stigma of mental illness', 'story transportation', 'Public Stigma of Mental Illness', 'stigma reduction', 'Public stigma', 'public stigma']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}]","[{'cui': 'C0376650', 'cui_str': 'Animation'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}]","[{'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0040756', 'cui_str': 'Transportation'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",206.0,0.0730184,Immersive animation had significantly lower public stigma than the control at postexperiment (P=.003) and follow-up (P=.02).,"[{'ForeName': 'Anna S Y', 'Initials': 'ASY', 'LastName': 'Yuen', 'Affiliation': 'Department of Psychology, The Chinese University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Winnie W S', 'Initials': 'WWS', 'LastName': 'Mak', 'Affiliation': 'Department of Psychology, The Chinese University of Hong Kong, Hong Kong, Hong Kong.'}]",Journal of medical Internet research,['10.2196/23683'] 1572,34259635,Assessing the Contribution of Self-Monitoring Through a Commercial Weight Loss App: Mediation and Predictive Modeling Study.,"BACKGROUND Electronic self-monitoring technology has the potential to provide unique insights into important behaviors for inducing weight loss. OBJECTIVE The aim of this study is to investigate the effects of electronic self-monitoring behavior (using the commercial Lose It! app) and weight loss interventions (with differing amounts of counselor feedback and support) on 4- and 12-month weight loss. METHODS In this secondary analysis of the Fit Blue study, we compared the results of two interventions of a randomized controlled trial. Counselor-initiated participants received consistent support from the interventionists, and self-paced participants received assistance upon request. The participants (N=191), who were active duty military personnel, were encouraged to self-monitor their diet and exercise with the Lose It! app or website. We examined the associations between intervention assignment and self-monitoring behaviors. We conducted a mediation analysis of the intervention assignment for weight loss through multiple mediators-app use (calculated from the first principal component [PC] of electronically collected variables), number of weigh-ins, and 4-month weight change. We used linear regression to predict weight loss at 4 and 12 months, and the accuracy was measured using cross-validation. RESULTS On average, the counselor-initiated-treatment participants used the app more frequently than the self-paced-treatment participants. The first PC represented app use frequencies, the second represented calories recorded, and the third represented reported exercise frequency and exercise caloric expenditure. We found that 4-month weight loss was partially mediated through app use (ie, the first PC; 60.3%) and the number of weigh-ins (55.8%). However, the 12-month weight loss was almost fully mediated by 4-month weight loss (94.8%). Linear regression using app data from the first 8 weeks, the number of self-weigh-ins at 8 weeks, and baseline data explained approximately 30% of the variance in 4-month weight loss. App use frequency (first PC; P=.001), self-monitored caloric intake (second PC; P=.001), and the frequency of self-weighing at 8 weeks (P=.008) were important predictors of 4-month weight loss. Predictions for 12-month weight with the same variables produced an R 2 value of 5%; only the number of self-weigh-ins was a significant predictor of 12-month weight loss. The R 2 value using 4-month weight loss as a predictor was 31%. Self-reported exercise did not contribute to either model (4 months: P=.77; 12 months: P=.15). CONCLUSIONS We found that app use and daily reported caloric intake had a substantial impact on weight loss prediction at 4 months. Our analysis did not find evidence of an association between participant self-monitoring exercise information and weight loss. As 12-month weight loss was completely mediated by 4-month weight loss, intervention targets should focus on promoting early and frequent dietary intake self-monitoring and self-weighing to promote early weight loss, which leads to long-term success. TRIAL REGISTRATION ClinicalTrials.gov NCT02063178; https://clinicaltrials.gov/ct2/show/NCT02063178.",2021,"App use frequency (first PC; P=.001), self-monitored caloric intake (second PC; P=.001), and the frequency of self-weighing at 8 weeks (P=.008) were important predictors of 4-month weight loss.","['participants (N=191), who were active duty military personnel, were encouraged to self-monitor their diet and exercise with the Lose It']","['Counselor-initiated participants received consistent support from the interventionists, and self-paced participants received assistance upon request', 'electronic self-monitoring behavior']","['weight loss', '12-month weight loss', '4-month weight loss', 'weight loss prediction', 'self-monitored caloric intake', 'number of weigh-ins, and 4-month weight change', 'frequency of self-weighing', 'weight loss interventions', 'exercise frequency and exercise caloric expenditure']","[{'cui': 'C3831794', 'cui_str': 'Active duty military'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C1571885', 'cui_str': 'Professional counselor'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0556455', 'cui_str': 'Frequency of exercise'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015316', 'cui_str': 'Expenditures'}]",,0.047183,"App use frequency (first PC; P=.001), self-monitored caloric intake (second PC; P=.001), and the frequency of self-weighing at 8 weeks (P=.008) were important predictors of 4-month weight loss.","[{'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Farage', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Simmons', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}, {'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Kocak', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Klesges', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}, {'ForeName': 'G Wayne', 'Initials': 'GW', 'LastName': 'Talcott', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}, {'ForeName': 'Phyllis', 'Initials': 'P', 'LastName': 'Richey', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Hare', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}, {'ForeName': 'Karen C', 'Initials': 'KC', 'LastName': 'Johnson', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}, {'ForeName': 'Saunak', 'Initials': 'S', 'LastName': 'Sen', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Krukowski', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.'}]",JMIR mHealth and uHealth,['10.2196/18741'] 1573,34264439,Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.,"PURPOSE In LOTUS (NCT02162719), adding the oral AKT inhibitor ipatasertib to first-line paclitaxel for locally advanced/metastatic triple-negative breast cancer (aTNBC) improved progression-free survival (PFS; primary endpoint), with an enhanced effect in patients with PIK3CA/AKT1/PTEN-altered tumors (FoundationOne next-generation sequencing [NGS] assay). We report final overall survival (OS) results. METHODS Eligible patients had measurable previously untreated aTNBC. Patients were stratified by prior (neo)adjuvant therapy, chemotherapy-free interval, and tumor immunohistochemistry PTEN status, and were randomized 1:1 to paclitaxel 80 mg/m 2 (days 1, 8, 15) plus ipatasertib 400 mg or placebo (days 1-21) every 28 days until disease progression or unacceptable toxicity. OS (intent-to-treat [ITT], immunohistochemistry PTEN-low, and PI3K/AKT pathway-activated [NGS PIK3CA/AKT1/PTEN-altered] populations) was a secondary endpoint. RESULTS Median follow-up was 19.0 versus 16.0 months in the ipatasertib-paclitaxel versus placebo-paclitaxel arms, respectively. In the ITT population (n = 124), median OS was numerically longer with ipatasertib-paclitaxel than placebo-paclitaxel (hazard ratio 0.80, 95% CI 0.50-1.28; median 25.8 vs 16.9 months, respectively; 1-year OS 83% vs 68%). Likewise, median OS favored ipatasertib-paclitaxel in the PTEN-low (n = 48; 23.1 vs 15.8 months; hazard ratio 0.83) and PIK3CA/AKT1/PTEN-altered (n = 42; 25.8 vs 22.1 months; hazard ratio 1.13) subgroups. The ipatasertib-paclitaxel safety profile was unchanged. CONCLUSIONS Final OS results show a numerical trend favoring ipatasertib-paclitaxel and median OS exceeding 2 years with ipatasertib-paclitaxel. Overall, results are consistent with the reported PFS benefit; interpretation within biomarker-defined subgroups is complicated by small sample sizes and TNBC heterogeneity.",2021,"In the ITT population (n = 124), median OS was numerically longer with ipatasertib-paclitaxel than placebo-paclitaxel (hazard ratio 0.80, 95% CI 0.50-1.28; median 25.8 vs 16.9 months, respectively; 1-year OS 83% vs 68%).","['Patients were stratified by prior (neo)adjuvant therapy, chemotherapy-free\xa0interval, and tumor immunohistochemistry PTEN status', 'inoperable locally advanced/metastatic triple-negative breast cancer', 'Eligible patients had measurable previously untreated aTNBC']","['placebo', 'paclitaxel 80\xa0mg/m 2 (days 1, 8, 15) plus ipatasertib 400\xa0mg or placebo', 'placebo-paclitaxel', 'paclitaxel']",['median OS'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C1430988', 'cui_str': 'PTEN protein, human'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205187', 'cui_str': 'Inoperable'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C3539878', 'cui_str': 'Triple-negative breast cancer'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3712838', 'cui_str': '2-(4-chlorophenyl)-1-(4-(7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one'}, {'cui': 'C3816746', 'cui_str': '400'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.561052,"In the ITT population (n = 124), median OS was numerically longer with ipatasertib-paclitaxel than placebo-paclitaxel (hazard ratio 0.80, 95% CI 0.50-1.28; median 25.8 vs 16.9 months, respectively; 1-year OS 83% vs 68%).","[{'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Dent', 'Affiliation': 'Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. rebecca.dent@duke-nus.edu.sg.'}, {'ForeName': 'Mafalda', 'Initials': 'M', 'LastName': 'Oliveira', 'Affiliation': ""Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Isakoff', 'Affiliation': 'Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Seock-Ah', 'Initials': 'SA', 'LastName': 'Im', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Espié', 'Affiliation': 'Department of Medical Oncology, Breast Disease Center, Hospital Saint Louis, Paris, France.'}, {'ForeName': 'Sibel', 'Initials': 'S', 'LastName': 'Blau', 'Affiliation': 'Oncology Division, Northwest Medical Specialties, Puyallup, WA, USA.'}, {'ForeName': 'Antoinette R', 'Initials': 'AR', 'LastName': 'Tan', 'Affiliation': 'Department of Solid Tumor and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Saura', 'Affiliation': ""Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Wongchenko', 'Affiliation': 'Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Xu', 'Affiliation': 'Biostatistics, Genentech, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Bradley', 'Affiliation': 'Pharma Development, Roche Products Ltd, Welwyn Garden City, UK.'}, {'ForeName': 'Sarah-Jayne', 'Initials': 'SJ', 'LastName': 'Reilly', 'Affiliation': 'Pharma Development, Roche Products Ltd, Welwyn Garden City, UK.'}, {'ForeName': 'Aruna', 'Initials': 'A', 'LastName': 'Mani', 'Affiliation': 'Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Sung-Bae', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Breast cancer research and treatment,['10.1007/s10549-021-06143-5'] 1574,34228774,Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.,"Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes. Data Sources Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts. Study Selection Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria. Data Extraction and Synthesis In this prospective meta-analysis, risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I2 statistic. The primary analysis was an inverse variance-weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality. Main Outcomes and Measures The primary outcome measure was all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days. Results A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P = .003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P < .001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P = .52) for sarilumab. The summary ORs for the association with mortality compared with usual care or placebo in those receiving corticosteroids were 0.77 (95% CI, 0.68-0.87) for tocilizumab and 0.92 (95% CI, 0.61-1.38) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16). Conclusions and Relevance In this prospective meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality. Trial Registration PROSPERO Identifier: CRD42021230155.",2021,"Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16). ","['A total of 10\u202f930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included', '72 potentially eligible trials, 27 (37.5%) met study selection criteria', 'patients hospitalized for COVID-19, administration of', 'Patients Hospitalized for COVID-19', 'Study Selection\n\n\nEligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom', 'patients hospitalized for COVID-19']","['tocilizumab', 'IL-6 antagonists', 'IL-6 antagonists nor any other immunomodulators except corticosteroids', 'usual care or placebo', 'placebo']","['mortality risk', 'Mortality', 'Data Extraction and Synthesis', 'cause mortality', 'progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517742', 'cui_str': '37.5'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0242801', 'cui_str': 'Selection Criteria'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0031222', 'cui_str': 'Personnel Selection'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C1609165', 'cui_str': 'tocilizumab'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0001551', 'cui_str': 'Immunologic adjuvant'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0442886', 'cui_str': 'Secondary infection'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",10930.0,0.35147,"Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16). ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Manu', 'Initials': 'M', 'LastName': 'Shankar-Hari', 'Affiliation': ""Guy's and St Thomas' NHS Foundation Trust, ICU Support Offices, St Thomas' Hospital, London, England.""}, {'ForeName': 'Claire L', 'Initials': 'CL', 'LastName': 'Vale', 'Affiliation': 'University College London, MRC Clinical Trials Unit at UCL, London, England.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Godolphin', 'Affiliation': 'University College London, MRC Clinical Trials Unit at UCL, London, England.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fisher', 'Affiliation': 'University College London, MRC Clinical Trials Unit at UCL, London, England.'}, {'ForeName': 'Julian P T', 'Initials': 'JPT', 'LastName': 'Higgins', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Spiga', 'Affiliation': 'University of Bristol, Bristol, England.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Savovic', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.'}, {'ForeName': 'Jayne', 'Initials': 'J', 'LastName': 'Tierney', 'Affiliation': 'University College London, MRC Clinical Trials Unit at UCL, London, England.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Baron', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Centre for Clinical Epidemiology, Hôpital Hôtel-Dieu, Paris, France.'}, {'ForeName': 'Julie S', 'Initials': 'JS', 'LastName': 'Benbenishty', 'Affiliation': 'Department of Nursing, Hadassah Hebrew University Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Lindsay R', 'Initials': 'LR', 'LastName': 'Berry', 'Affiliation': 'Berry Consultants, Austin, Texas.'}, {'ForeName': 'Niklas', 'Initials': 'N', 'LastName': 'Broman', 'Affiliation': 'Turku University Hospital, Department of Infectious Diseases, Turku, Finland.'}, {'ForeName': 'Alexandre Biasi', 'Initials': 'AB', 'LastName': 'Cavalcanti', 'Affiliation': 'BP-A Beneficência Portuguesa de São Paulo, Rua Maestro Cardim, São Paulo, Brazil.'}, {'ForeName': 'Roos', 'Initials': 'R', 'LastName': 'Colman', 'Affiliation': 'Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Stefanie L', 'Initials': 'SL', 'LastName': 'De Buyser', 'Affiliation': 'Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Lennie P G', 'Initials': 'LPG', 'LastName': 'Derde', 'Affiliation': 'Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Pere', 'Initials': 'P', 'LastName': 'Domingo', 'Affiliation': 'Department of Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Sharifah Faridah', 'Initials': 'SF', 'LastName': 'Omar', 'Affiliation': 'Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Fernandez-Cruz', 'Affiliation': 'Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.'}, {'ForeName': 'Thijs', 'Initials': 'T', 'LastName': 'Feuth', 'Affiliation': 'Department of Pulmonary Diseases, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Garcia', 'Affiliation': 'Infectious Diseases Department, Hospital Clinic Barcelona-IDIBAPS, Barcelona, Spain.'}, {'ForeName': 'Rosario', 'Initials': 'R', 'LastName': 'Garcia-Vicuna', 'Affiliation': 'Rheumatology, Hospital Universitario La Princesa IIS-IP, Madrid, Spain.'}, {'ForeName': 'Isidoro', 'Initials': 'I', 'LastName': 'Gonzalez-Alvaro', 'Affiliation': 'Rheumatology, Hospital Universitario La Princesa IIS-IP, Madrid, Spain.'}, {'ForeName': 'Anthony C', 'Initials': 'AC', 'LastName': 'Gordon', 'Affiliation': 'Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, England.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Haynes', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, England.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Hermine', 'Affiliation': 'Department of Hematology, Necker Hospital, Paris, France.'}, {'ForeName': 'Peter W', 'Initials': 'PW', 'LastName': 'Horby', 'Affiliation': 'Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, England.'}, {'ForeName': 'Nora K', 'Initials': 'NK', 'LastName': 'Horick', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital, Boston.'}, {'ForeName': 'Kuldeep', 'Initials': 'K', 'LastName': 'Kumar', 'Affiliation': 'Medanta-The Medicity, Institute of Liver Transplantation and Regenerative Medicine, Gurugram, India.'}, {'ForeName': 'Bart N', 'Initials': 'BN', 'LastName': 'Lambrecht', 'Affiliation': 'VIB Center for Inflammation Research, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'Landray', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, England.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Leal', 'Affiliation': 'Infectious Diseases Department, Hospital Clinic Barcelona-IDIBAPS, Barcelona, Spain.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Lederer', 'Affiliation': 'Regeneron Pharmaceuticals Inc, Tarrytown, New York.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Lorenzi', 'Affiliation': 'Berry Consultants, Austin, Texas.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Mariette', 'Affiliation': 'Centre for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Saclay, INSERM UMR1184, Le Kremlin-Bicêtre, Paris, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Merchante', 'Affiliation': 'Unit of Infectious Diseases and Microbiology, Valme University Hospital, Institute of Biomedicine of Sevilla, Seville, Spain.'}, {'ForeName': 'Nor Arisah', 'Initials': 'NA', 'LastName': 'Misnan', 'Affiliation': 'Hospital Sungai Buloh, Ministry of Health, Buloh, Malaysia.'}, {'ForeName': 'Shalini V', 'Initials': 'SV', 'LastName': 'Mohan', 'Affiliation': 'Genentech, South San Francisco, California.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Nivens', 'Affiliation': 'Regeneron Pharmaceuticals Inc, Tarrytown, New York.'}, {'ForeName': 'Jarmo', 'Initials': 'J', 'LastName': 'Oksi', 'Affiliation': 'Turku University Hospital, Department of Infectious Diseases, Turku, Finland.'}, {'ForeName': 'Jose A', 'Initials': 'JA', 'LastName': 'Perez-Molina', 'Affiliation': 'Hospital Universitario Ramón y Cajal IRYCIS, Infectious Diseases Department, Madrid, Spain.'}, {'ForeName': 'Reuven', 'Initials': 'R', 'LastName': 'Pizov', 'Affiliation': 'Department of Anesthesilogy Critical Care and Pain Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Porcher', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Centre for Clinical Epidemiology, Hôpital Hôtel-Dieu, Paris, France.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Postma', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, University Hospital Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Reena', 'Initials': 'R', 'LastName': 'Rajasuriar', 'Affiliation': 'Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Athimalaipet V', 'Initials': 'AV', 'LastName': 'Ramanan', 'Affiliation': 'Department of Paediatric Rheumatology, University Hospitals Bristol, NHS Foundation Trust, Bristol, England.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Ravaud', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Centre for Clinical Epidemiology, Hôpital Hôtel-Dieu, Paris, France.'}, {'ForeName': 'Pankti D', 'Initials': 'PD', 'LastName': 'Reid', 'Affiliation': 'Department of Medicine (Rheumatology), University of Chicago Medical Center, Chicago, Illinois.'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Rutgers', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, University Hospital Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Aranzazu', 'Initials': 'A', 'LastName': 'Sancho-Lopez', 'Affiliation': 'Department of Clinical Pharmacology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.'}, {'ForeName': 'Todd B', 'Initials': 'TB', 'LastName': 'Seto', 'Affiliation': ""Center for Outcomes Research and Evaluation, Queen's Medical Center, Honolulu, Hawaii.""}, {'ForeName': 'Sumathi', 'Initials': 'S', 'LastName': 'Sivapalasingam', 'Affiliation': 'Regeneron Pharmaceuticals Inc, Tarrytown, New York.'}, {'ForeName': 'Arvinder Singh', 'Initials': 'AS', 'LastName': 'Soin', 'Affiliation': 'Medanta-The Medicity, Institute of Liver Transplantation and Regenerative Medicine, Gurugram, India.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Staplin', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, England.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Stone', 'Affiliation': 'Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston.'}, {'ForeName': 'Garth W', 'Initials': 'GW', 'LastName': 'Strohbehn', 'Affiliation': 'VA Ann Arbor, Center for Clinical Management and Research, Ann Arbor, Michigan.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Sunden-Cullberg', 'Affiliation': 'Department of Infectious Diseases, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Torre-Cisneros', 'Affiliation': 'Maimonides Institute for Biomedical Research of Cordoba/Reina Sofia University Hospital/University of Córdoba, Córdoba, Spain.'}, {'ForeName': 'Larry W', 'Initials': 'LW', 'LastName': 'Tsai', 'Affiliation': 'Genentech, South San Francisco, California.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'van Hoogstraten', 'Affiliation': 'Global Medical Affairs, Sanofi-Genzyme, Bridgewater, New Jersey.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'van Meerten', 'Affiliation': 'Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Viviane Cordeiro', 'Initials': 'VC', 'LastName': 'Veiga', 'Affiliation': 'BP-A Beneficência Portuguesa de São Paulo, Rua Maestro Cardim, São Paulo, Brazil.'}, {'ForeName': 'Peter E', 'Initials': 'PE', 'LastName': 'Westerweel', 'Affiliation': 'Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.'}, {'ForeName': 'Srinivas', 'Initials': 'S', 'LastName': 'Murthy', 'Affiliation': 'Department of Pediatrics, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Janet V', 'Initials': 'JV', 'LastName': 'Diaz', 'Affiliation': 'Clinical Unit, Health Emergencies Programme, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Marshall', 'Affiliation': ""Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Jonathan A C', 'Initials': 'JAC', 'LastName': 'Sterne', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.'}]",JAMA,['10.1001/jama.2021.11330'] 1575,34236209,Unattainable equipoise in randomized controlled trials : staff views of a feasibility study of surgical treatments for segmental tibial fractures.,"AIMS To explore staff experiences of a multicentre pilot randomized controlled trial (RCT) comparing intramedullary nails and circular frame external fixation for segmental tibial fractures. METHODS A purposeful sample of 19 staff (nine surgeons) involved in the study participated in an interview. Interviews explored participants' experience and views of the study and the treatments. The interviews drew on phenomenology, were face-to-face or by telephone, and were analyzed using thematic analysis. RESULTS The findings identify that for the treatment of segmental tibial fractures equipoise was a theoretical ideal that was most likely unattainable in clinical practice. This was conveyed through three themes: the ambiguity of equipoise, where multiple definitions of equipoise and a belief in community equipoise were evident; an illusion of equipoise, created by strong treatment preferences and variation in collective surgical skills; and treating the whole patient, where the complexity and severity of the injury required a patient-centred approach and doing the best for the individual patient took priority over trial recruitment. CONCLUSION Equipoise can be unattainable for rare injuries such as segmental tibial fractures, where there are substantially different surgical treatments requiring specific expertise, high levels of complexity, and a concern for poor outcomes. Surgeons are familiar with community equipoise. However, a shared understanding of factors that limit the feasibility of RCTs may identify instances where community equipoise is unlikely to translate into practice. Cite this article: Bone Jt Open  2021;2(7):486-492.",2021,"Equipoise can be unattainable for rare injuries such as segmental tibial fractures, where there are substantially different surgical treatments requiring specific expertise, high levels of complexity, and a concern for poor outcomes.","['A purposeful sample of 19 staff (nine surgeons) involved in the study participated in an interview', 'segmental tibial fractures']",['intramedullary nails and circular frame external fixation'],[],"[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0205122', 'cui_str': 'Segmental'}, {'cui': 'C0040185', 'cui_str': 'Fracture of tibia'}]","[{'cui': 'C0021885', 'cui_str': 'Bone nailing'}, {'cui': 'C1282913', 'cui_str': 'Circular'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C0407333', 'cui_str': 'External skeletal fixation procedure'}]",[],,0.110632,"Equipoise can be unattainable for rare injuries such as segmental tibial fractures, where there are substantially different surgical treatments requiring specific expertise, high levels of complexity, and a concern for poor outcomes.","[{'ForeName': 'Emma Elizabeth', 'Initials': 'EE', 'LastName': 'Phelps', 'Affiliation': 'Kadoorie, Oxford Trauma and Emergency Care, Nuffield Department Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Tutton', 'Affiliation': 'Kadoorie, Oxford Trauma and Emergency Care, Nuffield Department Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Costa', 'Affiliation': 'Kadoorie, Oxford Trauma and Emergency Care, Nuffield Department Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Hing', 'Affiliation': ""Department of Trauma and Orthopaedics, St George's University Hospitals NHS Foundation Trust, London, UK.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Bone & joint open,['10.1302/2633-1462.27.BJO-2021-0055.R1'] 1576,34237775,Erratum: Randomized Trials of Retosiban versus Placebo or Atosiban in Spontaneous Preterm Labor.,,2021,,['Spontaneous Preterm Labor'],['Retosiban versus Placebo or Atosiban'],[],"[{'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0022876', 'cui_str': 'Premature labor'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0164398', 'cui_str': 'Atosiban'}]",[],,0.446368,,"[{'ForeName': 'George', 'Initials': 'G', 'LastName': 'Saade', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Shennan', 'Affiliation': ""Department of Women and Children's Health, King's College London, St Thomas' Hospital, London, UK.""}, {'ForeName': 'Kathleen J', 'Initials': 'KJ', 'LastName': 'Beach', 'Affiliation': 'Department of Maternal and Fetal Medicine, GSK, Research Triangle Park, North Carolina.'}, {'ForeName': 'Eran', 'Initials': 'E', 'LastName': 'Hadar', 'Affiliation': 'Helen Schneider Hospital for Women, Rabin Medical Center, Petach-Tikva, Israel.'}, {'ForeName': 'Barbara V', 'Initials': 'BV', 'LastName': 'Parilla', 'Affiliation': 'Department of Obstetrics and Gynecology, Advocate Lutheran General Hospital, Park Ridge, Illinois.'}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Snidow', 'Affiliation': 'Alternative Discovery and Development, GSK, Research Triangle Park, North Carolina.'}, {'ForeName': 'Marcy', 'Initials': 'M', 'LastName': 'Powell', 'Affiliation': 'Central Safety Department, GSK, Research Triangle Park, North Carolina.'}, {'ForeName': 'Timothy H', 'Initials': 'TH', 'LastName': 'Montague', 'Affiliation': 'Clinical Statistics, Quantitative Sciences, GSK, Collegeville, Pennsylvania.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Clinical Statistics, Quantitative Sciences, GSK, Collegeville, Pennsylvania.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Komatsu', 'Affiliation': 'Maternal and Neonatal Health Unit, Alternative Discovery & Development, R&D, GSK, Research Triangle Park, North Carolina.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'McKain', 'Affiliation': 'Pharmacovigilance, PPD, Wilmington, North Carolina.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Thornton', 'Affiliation': 'Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}]",American journal of perinatology,['10.1055/s-0041-1731633'] 1577,34237249,"Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.","BACKGROUND There is paucity of investigations into immunotherapy or targeted therapy for postoperative locally recurrent pancreatic cancer. We aimed to assess the efficacy of stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib in these patients. METHODS In this open-label, randomised, controlled, phase 2 study, participants were recruited from Changhai Hospital affiliated to Naval Medical University, Shanghai, China. Eligible patients were aged 18 years or older with histologically confirmed pancreatic ductal adenocarcinoma characterised by mutant KRAS and positive immunohistochemical staining of PD-L1, Eastern Cooperative Oncology Group performance status of 0 or 1, and documented local recurrence after surgery followed by chemotherapy (mFOLFIRINOX or 5-fluorouracil). Eligible participants were randomly assigned (1:1) using an interactive voice or web response system, without stratification, to receive SBRT with doses ranging from 35-40 Gy in five fractions, intravenous pembrolizumab 200 mg once every 3 weeks, and oral trametinib 2 mg once daily or SBRT (same regimen) and intravenous gemcitabine (1000 mg/m 2 ) on day 1 and 8 of a 21-day cycle for eight cycles until disease progression, death, unacceptable toxicity, or consent withdrawal. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the as-treated population in all participants who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT02704156, and is now complete. FINDINGS Between Oct 10, 2016, and Oct 28, 2017, 198 patients were screen, of whom 170 patients were enrolled and randomly assigned to receive SBRT plus pembrolizumab and trametinib (n=85) or SBRT plus gemcitabine (n=85). As of the clinical cutoff date (Nov 30, 2020), median follow-up was 23·3 months (IQR 20·5-27·4). Median overall survival was 24·9 months (23·3-26·5) with SBRT plus pembrolizumab and trametinib and 22·4 months (95% CI 21·2-23·6) with SBRT plus gemcitabine (hazard ratio [HR] 0·60 [95% CI 0·44-0·82]; p=0·0012). The most common grade 3 or 4 adverse effects were increased alanine aminotransferase or aspartate aminotransferase (ten [12%] of 85 in SBRT plus pembrolizumab and trametinib group vs six [7%] of 85 in SBRT plus gemcitabine group), increased blood bilirubin (four [5%] vs none), neutropenia (one [1%] vs nine [11%]), and thrombocytopenia (one [1%] vs four [5%]). Serious adverse events were reported by 19 (22%) participants in the SBRT plus pembrolizumab and trametinib group and 12 (14%) in the SBRT plus gemcitabine group. No treatment-related deaths occurred. INTERPRETATION The combination of SBRT plus pembrolizumab and trametinib could be a novel treatment option for patients with locally recurrent pancreatic cancer after surgery. Phase 3 trials are needed to confirm our findings. FUNDING Shanghai Shenkang Center and Changhai Hospital. TRANSLATION For the Chinese translation of the abstract see Supplementary Materials section.",2021,Serious adverse events were reported by 19 (22%) participants in the SBRT plus pembrolizumab and trametinib group and 12 (14%) in the SBRT plus gemcitabine group.,"['locally recurrent pancreatic cancer after surgical resection', '0·60', 'Eligible patients were aged 18 years or older with histologically confirmed pancreatic ductal adenocarcinoma characterised by mutant KRAS and positive immunohistochemical staining of PD-L1, Eastern Cooperative Oncology Group performance status of 0 or 1, and documented local recurrence after surgery followed by', 'participants were recruited from Changhai Hospital affiliated to Naval Medical University, Shanghai, China', 'postoperative locally recurrent pancreatic cancer', 'Eligible participants', 'Between Oct 10, 2016, and Oct 28, 2017, 198 patients were screen, of whom 170 patients', 'patients with locally recurrent pancreatic cancer after surgery']","['Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine', 'interactive voice or web response system, without stratification, to receive SBRT with doses ranging from 35-40 Gy in five fractions, intravenous pembrolizumab 200 mg once every 3 weeks, and oral trametinib 2 mg once daily or SBRT (same regimen) and intravenous gemcitabine', 'immunotherapy', 'chemotherapy (mFOLFIRINOX or 5-fluorouracil', 'SBRT plus pembrolizumab and trametinib (n=85) or SBRT plus gemcitabine', 'SBRT plus pembrolizumab', 'SBRT plus gemcitabine', 'stereotactic body radiotherapy (SBRT) plus pembrolizumab', 'gemcitabine']","['overall survival', 'alanine aminotransferase or aspartate aminotransferase', 'neutropenia', 'Median overall survival', 'thrombocytopenia', 'Serious adverse events', 'Safety', 'blood bilirubin']","[{'cui': 'C0854777', 'cui_str': 'Pancreatic carcinoma recurrent'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C1335302', 'cui_str': 'Ductal adenocarcinoma of pancreas'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0487602', 'cui_str': 'Staining method'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517599', 'cui_str': '170'}]","[{'cui': 'C1720823', 'cui_str': 'Stereotactic Body Radiotherapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C2697961', 'cui_str': 'trametinib'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0585333', 'cui_str': 'Triweekly'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3644516', 'cui_str': 'trametinib 2 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0863174', 'cui_str': 'Blood bilirubin'}]",198.0,0.116554,Serious adverse events were reported by 19 (22%) participants in the SBRT plus pembrolizumab and trametinib group and 12 (14%) in the SBRT plus gemcitabine group.,"[{'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.'}, {'ForeName': 'Yangsen', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': 'Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.'}, {'ForeName': 'Wenyu', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Surgery, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Ju', 'Affiliation': 'Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.'}, {'ForeName': 'Xianzhi', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.'}, {'ForeName': 'Lingong', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.'}, {'ForeName': 'Yusheng', 'Initials': 'Y', 'LastName': 'Ye', 'Affiliation': 'Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Jin', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Surgery, Changhai Hospital affiliated to Naval Medical University, Shanghai, China. Electronic address: jingang@hotmail.com.'}, {'ForeName': 'Huojun', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China. Electronic address: chyyzhj@163.com.'}]",The Lancet. Oncology,['10.1016/S1470-2045(21)00286-2'] 1578,34243100,Pilot randomized controlled trial of an attachment- and trauma-focused intervention for kinship caregivers.,"BACKGROUND Kinship care placements are increasing in many Western countries, however families in kinship care are underserved partly due to the lack of evidence-based interventions addressing their unique needs. OBJECTIVE We conducted a pilot randomized controlled trial (RCT) to examine research feasibility and the acceptability, fidelity, and preliminary outcomes of an attachment- and trauma-focused intervention for kinship caregivers in Australia. PARTICIPANTS AND SETTING Participants included 26 kinship caregivers (M age  = 55.00 years; 54% grandparents) with youth (M age  = 10.58 years; 38% female), and 19 practitioners from child protection, out-of-home care and other services. METHOD Kinship caregivers were randomized to Connect for Kinship Parents (Connect-KP) or care-as-usual (CAU), and completed assessments at baseline, post-intervention, and 6-month follow-up. Placement changes were evaluated at 6-month follow-up. A subset of practitioners received both training and supervision in implementing Connect-KP, and their videorecorded sessions were coded for fidelity. RESULTS Practitioners rated the training highly and demonstrated excellent fidelity to program content and process. Results supported the research feasibility and all kinship caregivers reported high levels of program satisfaction and had very high attendance and completion rates. Direction of effects favored Connect-KP vs. CAU for all nine caregiver and youth outcomes, with the largest effects observed for significant reductions in caregiver strain, caregiver psychological aggression, and youth affect suppression following intervention. At 6-month follow-up, more youth from CAU (15%) vs. Connect-KP (0%) experienced an unplanned placement change. CONCLUSIONS Our findings show promise of Connect-KP as a potentially effective intervention that can be successfully implemented in child welfare services, and provide impetus for a larger-scale RCT.",2021,"Our findings show promise of Connect-KP as a potentially effective intervention that can be successfully implemented in child welfare services, and provide impetus for a larger-scale RCT.","['kinship caregivers', 'Kinship caregivers', 'kinship caregivers in Australia', 'Participants included 26 kinship caregivers (M age \xa0', '10.58\xa0years; 38% female), and 19 practitioners from child protection, out-of-home care and other services', '55.00\xa0years; 54% grandparents) with youth (M age \xa0']","['attachment- and trauma-focused intervention', 'Connect-KP vs. CAU', 'Connect for Kinship Parents (Connect-KP) or care-as-usual (CAU']","['unplanned placement change', 'caregiver strain, caregiver psychological aggression, and youth affect suppression']","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0204977', 'cui_str': 'Home care of patient'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0337471', 'cui_str': 'Grandparent'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]","[{'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}]",,0.0552323,"Our findings show promise of Connect-KP as a potentially effective intervention that can be successfully implemented in child welfare services, and provide impetus for a larger-scale RCT.","[{'ForeName': 'Dave S', 'Initials': 'DS', 'LastName': 'Pasalich', 'Affiliation': 'Research School of Psychology, Australian National University, Australia. Electronic address: dave.pasalich@anu.edu.au.'}, {'ForeName': 'Marlene M', 'Initials': 'MM', 'LastName': 'Moretti', 'Affiliation': 'Department of Psychology, Simon Fraser University, Canada.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Hassall', 'Affiliation': 'Research School of Psychology, Australian National University, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Curcio', 'Affiliation': 'Community Services Directorate, ACT Government, Australia.'}]",Child abuse & neglect,['10.1016/j.chiabu.2021.105178'] 1579,34243077,Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial).,"BACKGROUND The aim of this ancillary study of the SARAH trial is to compare health-related quality of life (HRQoL) in patients with locally advanced or inoperable hepatocellular carcinoma (HCC) treated with transarterial radioembolisation (TARE) or sorafenib. METHODS This study included randomised patients who received either TARE or at least one dose of sorafenib with no major deviation in the protocol and who had at least one QoL follow-up assessment in addition to the baseline evaluation. QoL was assessed from the date of randomisation using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire, until disease progression or other reasons for stopping study participation. Data were analysed using linear mixed and time-dependent models. RESULTS A total of 285 patients were included (122 and 163, in the TARE and sorafenib groups, respectively). Questionnaire completion rates were similar (77.5% versus 80.4%, in the TARE and sorafenib groups, respectively, p = 0.25). Longitudinal HRQoL analysis showed a significant treatment and time effects for fatigue and global health status, and significant treatment, time and treatment by time interaction effects for appetite loss, diarrhoea and social functioning. The median time to deterioration for the global health status was 3.9 months (95% confidence interval [CI] 3.7-4.3) versus 2.6 months (95% CI 2.0-3.0) in the TARE and sorafenib groups, respectively. CONCLUSIONS HRQoL was preserved longer with TARE than with sorafenib in locally advanced HCC. These data could be used to optimise management of patients with advanced or inoperable HCC.",2021,"Questionnaire completion rates were similar (77.5% versus 80.4%, in the TARE and sorafenib groups, respectively, p = 0.25).","['A total of 285 patients were included (122 and 163, in the TARE and sorafenib groups, respectively', 'locally advanced hepatocellular carcinoma', 'patients with advanced or inoperable HCC', 'patients with locally advanced or inoperable hepatocellular carcinoma (HCC) treated with']","['transarterial radioembolisation (TARE) or sorafenib', 'TARE', 'sorafenib with no major deviation in the protocol and who had at least one QoL', 'radioembolisation or sorafenib', 'sorafenib']","['Questionnaire completion rates', 'median time to deterioration for the global health status', 'Health-related quality of life', 'appetite loss, diarrhoea and social functioning', 'health-related quality of life (HRQoL']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0522522', 'cui_str': 'Transarterial approach'}, {'cui': 'C2985560', 'cui_str': 'Radioembolisation'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0205187', 'cui_str': 'Inoperable'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0522522', 'cui_str': 'Transarterial approach'}, {'cui': 'C2985560', 'cui_str': 'Radioembolisation'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}]",285.0,0.104724,"Questionnaire completion rates were similar (77.5% versus 80.4%, in the TARE and sorafenib groups, respectively, p = 0.25).","[{'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Pereira', 'Affiliation': ""INSERM, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, F-75015 Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Unité de Recherche Clinique, Paris, France. Electronic address: helena.pereira@aphp.fr.""}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Bouattour', 'Affiliation': ""Université de Paris, Centre de Recherche de l'Inflammation (CRI), INSERM U1149, F-75018 Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Beaujon, Clichy, France.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Dioguardi Burgio', 'Affiliation': ""Université de Paris, Centre de Recherche de l'Inflammation (CRI), INSERM U1149, F-75018 Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Beaujon, Clichy, France.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Assenat', 'Affiliation': 'Centre Hospitalier Universitaire de Montpellier, Hôpital Saint Eloi, Montpellier, France.'}, {'ForeName': 'Jules', 'Initials': 'J', 'LastName': 'Grégory', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Beaujon, Clichy, France.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Bronowicki', 'Affiliation': 'Centre Hospitalier Universitaire de Nancy, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Chatellier', 'Affiliation': ""INSERM, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, F-75015 Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Unité de Recherche Clinique, Paris, France.""}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Vilgrain', 'Affiliation': ""Université de Paris, Centre de Recherche de l'Inflammation (CRI), INSERM U1149, F-75018 Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Beaujon, Clichy, France.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.05.032'] 1580,34243076,Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.,"BACKGROUND Addition of veliparib to carboplatin-paclitaxel, with continuation of veliparib monotherapy if carboplatin-paclitaxel was discontinued, improved progression-free survival (PFS) in patients with germline BRCA-associated locally advanced/metastatic HER2- breast cancer and ≤2 lines of previous cytotoxic therapy for metastatic disease in BROCADE3. A pre-planned subgroup analysis evaluated efficacy and safety in patients without previous cytotoxic therapy for metastatic disease. METHODS Patients were randomised 2:1 to receive veliparib (120 mg orally BID) or placebo on days -2 to 5. Carboplatin (AUC 6) was administered on day 1, and paclitaxel (80 mg/m 2 ) on days 1, 8 and 15 (21-day cycles). Patients discontinuing carboplatin-paclitaxel for reasons besides progression could continue veliparib/placebo monotherapy (300 mg BID, increasing to 400 mg BID if tolerated) until progression. The primary end-point was PFS assessed by investigator. RESULTS Of 509 patients in the intention-to-treat population (98.6% female; mean age 47, standard deviation 11), 413 (81%) had no previous cytotoxic therapy for metastatic disease (274, veliparib; 139, placebo). In the first-line subgroup, median PFS was 16.6 months (95% confidence interval [CI] 13.4-18.7) versus 13.1 months (95% CI 11.4-14.5) for the veliparib versus control groups (hazard ratio 0.70, 95% CI 0.54-0.89, P = .004). More patients were alive and progression-free at 2 years (36% versus 23.2%) and 3 years (27.9% versus 13.3%) in the veliparib versus control group. Adverse events unrelated to progression leading to study drug discontinuation occurred in 25 (9.1%) and 8 (5.8%) patients. CONCLUSIONS Veliparib with carboplatin-paclitaxel led to durable disease control among first-line patients, suggesting a benefit of this treatment approach in early lines. CLINICAL TRIAL REGISTRATION NCT02163694.",2021,More patients were alive and progression-free at 2 years (36% versus 23.2%) and 3 years (27.9% versus 13.3%) in the veliparib versus control group.,"['Patients', 'patients with HER2- advanced germline BRCA+ breast cancer', 'patients without previous cytotoxic therapy for metastatic disease', '509 patients in the intention-to-treat population (98.6% female; mean age 47, standard deviation 11), 413 (81%) had no previous cytotoxic therapy for metastatic disease (274, veliparib; 139, placebo', 'patients with germline BRCA-associated locally advanced/metastatic HER2- breast cancer and ≤2 lines of previous cytotoxic therapy for metastatic disease in BROCADE3']","['Carboplatin (AUC 6', 'Veliparib with carboplatin-paclitaxel', 'veliparib', 'veliparib to carboplatin-paclitaxel', 'paclitaxel', 'placebo', 'first-line veliparib and carboplatin-paclitaxel', 'carboplatin-paclitaxel']","['efficacy and safety', 'median PFS', 'Efficacy and safety', 'progression-free survival (PFS', 'alive and progression-free', 'PFS assessed by investigator']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0304497', 'cui_str': 'Cytotoxic agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C1958300', 'cui_str': 'veliparib'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0205132', 'cui_str': 'Linear'}]","[{'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C1958300', 'cui_str': 'veliparib'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205132', 'cui_str': 'Linear'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}]",,0.533315,More patients were alive and progression-free at 2 years (36% versus 23.2%) and 3 years (27.9% versus 13.3%) in the veliparib versus control group.,"[{'ForeName': 'Banu K', 'Initials': 'BK', 'LastName': 'Arun', 'Affiliation': 'Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: barun@mdanderson.org.'}, {'ForeName': 'Hyo S', 'Initials': 'HS', 'LastName': 'Han', 'Affiliation': 'Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.'}, {'ForeName': 'Bella', 'Initials': 'B', 'LastName': 'Kaufman', 'Affiliation': 'Department of Oncology, Breast Oncology Institute, Sheba Medical Center, Tel-Aviv, Israel.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Wildiers', 'Affiliation': 'Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Friedlander', 'Affiliation': 'Prince of Wales Clinical School, University of New South Wales, Sydney, Australia, Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Ayoub', 'Affiliation': ""Department of Hematology and Oncology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Shannon L', 'Initials': 'SL', 'LastName': 'Puhalla', 'Affiliation': 'Division of Hematology/Oncology, Department of Medicine, UPMC Cancer Centers, Pittsburgh, PA, USA.'}, {'ForeName': 'Katherine M', 'Initials': 'KM', 'LastName': 'Bell-McGuinn', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Bach', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Madan G', 'Initials': 'MG', 'LastName': 'Kundu', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Christine K', 'Initials': 'CK', 'LastName': 'Ratajczak', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Maag', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Diéras', 'Affiliation': 'Department of Medical Oncology, Institut Curie, Paris, France, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.05.037'] 1581,34243767,Simulation in physiotherapy students for clinical decisions during interaction with people with low back pain: randomised controlled trial.,"BACKGROUND Low back pain (LBP) is a condition with a high global prevalence, which is getting health professionals' attention, including physiotherapists as they must have the skills to provide treatment that increases the patient's quality of life. Clinical simulations could be a pedagogic strategy that facilitates adequate training for students to acquire skills to improve their professional reasoning in this clinical situation. OBJECTIVE This study sought to determine the effects of clinical simulations with simulated patients (SP) on the physiotherapy students' clinical decision-making within a role-playing (RP) scenario while caring of LBP patients. METHODS This experimental study included 42 participants from two Colombian universities, randomized into two groups (SP, n = 21; RP, n = 21). The clinical skill of performing the Objective Structured Clinical Examination (OSCE-LBP) was evaluated while students cared for patients with LBP; after that, a pedagogical method was conducted that included clinical simulation and, finally, the OSCE-LBP was applied again to compare both groups. RESULTS Changes occurred in the OSCE-LBP among both groups of students: the scores increased (0.66 and 0.59 in RP and SP, respectively), and neither of the two was superior (p value 0.01; 95%CI - 0.21 to 0.23). CONCLUSION Both types of simulation favor decision-making in professional reasoning in physiotherapy students during interactions with individuals with LBP. Trial registration https://clinicaltrials.gov/ct2/show/NCT04428892 Identifying number: NCT04428892. It was retrospectively registered.",2021,"RESULTS Changes occurred in the OSCE-LBP among both groups of students: the scores increased (0.66 and 0.59 in RP and SP, respectively), and neither of the two was superior (p value 0.01; 95%CI - 0.21 to 0.23). ","['physiotherapy students during interactions with individuals with LBP', 'physiotherapy students for clinical decisions during interaction with people with low back pain', 'students cared for patients with LBP', '42 participants from two Colombian universities', ""simulated patients (SP) on the physiotherapy students' clinical decision-making within a role-playing (RP) scenario while caring of LBP patients""]",['LBP'],['OSCE-LBP'],"[{'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0035822', 'cui_str': 'Role play technique'}]","[{'cui': 'C0024031', 'cui_str': 'Low back pain'}]","[{'cui': 'C0024031', 'cui_str': 'Low back pain'}]",42.0,0.0658809,"RESULTS Changes occurred in the OSCE-LBP among both groups of students: the scores increased (0.66 and 0.59 in RP and SP, respectively), and neither of the two was superior (p value 0.01; 95%CI - 0.21 to 0.23). ","[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Sandoval-Cuellar', 'Affiliation': 'Universidad de Boyacá, Tunja, Colombia. carolinasandoval@uniboyaca.edu.co.'}, {'ForeName': 'Margareth Lorena', 'Initials': 'ML', 'LastName': 'Alfonso-Mora', 'Affiliation': 'Universidad de La Sabana, Chía, Colombia.'}, {'ForeName': 'Adriana Lucia', 'Initials': 'AL', 'LastName': 'Castellanos-Garrido', 'Affiliation': 'Universidad de La Sabana, Chía, Colombia.'}, {'ForeName': 'Angélica', 'Initials': 'A', 'LastName': 'Del Pilar Villarraga-Nieto', 'Affiliation': 'Center of Clinical Simulation, Universidad de La Sabana, Chía, Colombia.'}, {'ForeName': 'Ruth Liliana', 'Initials': 'RL', 'LastName': 'Goyeneche-Ortegón', 'Affiliation': 'Universidad de Boyacá, Tunja, Colombia.'}, {'ForeName': 'Martha Lucia', 'Initials': 'ML', 'LastName': 'Acosta-Otalora', 'Affiliation': 'Universidad de La Sabana, Chía, Colombia.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Del Pilar Castellanos-Vega', 'Affiliation': 'Universidad de Boyacá, Tunja, Colombia.'}, {'ForeName': 'Elisa Andrea', 'Initials': 'EA', 'LastName': 'Cobo-Mejía', 'Affiliation': 'Universidad de Boyacá, Tunja, Colombia.'}]",BMC medical education,['10.1186/s12909-021-02812-7'] 1582,34247512,Effects of Experimental Sleep Restriction on Ambulatory and Sleep Blood Pressure in Healthy Young Adults: A Randomized Crossover Study.,[Figure: see text].,2021,"24-hour mean BP was higher (adjusted mean difference, day 12: 2.1 mm Hg [95% CI, 0.6-3.6], corrected P =0.016), endothelial function was attenuated ( P <0.001), and plasma norepinephrine increased ( P =0.011).","['20 healthy young participants (aged 23.4±4.8 years, 9 females', 'Healthy Young Adults']","['Experimental Sleep Restriction', 'acclimation, 9 days of sleep restriction (4 hours of sleep/night) or control sleep', 'prolonged sleep restriction']","['24-hour BP, wakefulness, and sleep BP', 'sleep systolic BP', '24-hour ambulatory blood pressure (BP', 'endothelial function', '24-hour mean BP', 'Ambulatory and Sleep Blood Pressure', 'plasma norepinephrine', '24-hour BP (primary outcome) and cardiovascular biomarkers', 'deep sleep, BP']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1292426', 'cui_str': '4 hours'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0234452', 'cui_str': 'Prolonged sleep'}]","[{'cui': 'C1282173', 'cui_str': '24 hour blood pressure'}, {'cui': 'C0043012', 'cui_str': 'Wakefulness'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}]",20.0,0.10727,"24-hour mean BP was higher (adjusted mean difference, day 12: 2.1 mm Hg [95% CI, 0.6-3.6], corrected P =0.016), endothelial function was attenuated ( P <0.001), and plasma norepinephrine increased ( P =0.011).","[{'ForeName': 'Naima', 'Initials': 'N', 'LastName': 'Covassin', 'Affiliation': 'Department of Cardiovascular Medicine (N.C., J.B., P.S., V.K.S.), Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Bukartyk', 'Affiliation': 'Department of Cardiovascular Medicine (N.C., J.B., P.S., V.K.S.), Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Prachi', 'Initials': 'P', 'LastName': 'Singh', 'Affiliation': 'Department of Cardiovascular Medicine (N.C., J.B., P.S., V.K.S.), Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Calvin', 'Affiliation': 'Department of Cardiovascular Medicine, Mayo Clinic Health System, Eau Claire, WI (A.D.C.).'}, {'ForeName': 'Erik K', 'Initials': 'EK', 'LastName': 'St Louis', 'Affiliation': 'Center for Sleep Medicine, Department of Neurology (E.K.S.L.), Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Virend K', 'Initials': 'VK', 'LastName': 'Somers', 'Affiliation': 'Department of Cardiovascular Medicine (N.C., J.B., P.S., V.K.S.), Mayo Clinic, Rochester, MN.'}]","Hypertension (Dallas, Tex. : 1979)",['10.1161/HYPERTENSIONAHA.121.17622'] 1583,34253233,Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial.,"BACKGROUND Re-excision due to positive margins following breast-conserving surgery (BCS) negatively affects patient outcomes and healthcare costs. The inability to visualize margin involvement is a significant challenge in BCS. 5-Aminolevulinic acid hydrochloride (5-ALA HCl), a non-fluorescent oral prodrug, causes intracellular accumulation of fluorescent porphyrins in cancer cells. This single-center Phase II randomized controlled trial evaluated the safety, feasibility, and diagnostic accuracy of a prototype handheld fluorescence imaging device plus 5-ALA for intraoperative visualization of invasive breast carcinomas during BCS. METHODS Fifty-four patients were enrolled and randomized to receive no 5-ALA or oral 5-ALA HCl (15 or 30 mg/kg). Forty-five patients (n = 15/group) were included in the analysis. Fluorescence imaging of the excised surgical specimen was performed, and biopsies were collected from within and outside the clinically demarcated tumor border of the gross specimen for blinded histopathology. RESULTS In the absence of 5-ALA, tissue autofluorescence imaging lacked tumor-specific fluorescent contrast. Both 5-ALA doses caused bright red tumor fluorescence, with improved visualization of tumor contrasted against normal tissue autofluorescence. In the 15 mg/kg 5-ALA group, the positive predictive value (PPV) for detecting breast cancer inside and outside the grossly demarcated tumor border was 100.0% and 55.6%, respectively. In the 30 mg/kg 5-ALA group, the PPV was 100.0% and 50.0% inside and outside the demarcated tumor border, respectively. No adverse events were observed, and clinical feasibility of this imaging device-5-ALA combination approach was confirmed. CONCLUSIONS This is the first known clinical report of visualization of 5-ALA-induced fluorescence in invasive breast carcinoma using a real-time handheld intraoperative fluorescence imaging device. TRIAL REGISTRATION Clinicaltrials.gov identifier NCT01837225 . Registered 23 April 2013.",2021,"Both 5-ALA doses caused bright red tumor fluorescence, with improved visualization of tumor contrasted against normal tissue autofluorescence.","['Fifty-four patients', 'Forty-five patients (n = 15/group', 'detects grossly occult breast cancer']","['breast-conserving surgery (BCS', 'prototype handheld fluorescence imaging device plus 5-ALA', 'no 5-ALA or oral 5-ALA HCl', 'Intraoperative fluorescence imaging with aminolevulinic acid', '5-ALA', '5-ALA-induced fluorescence', '5-Aminolevulinic acid hydrochloride (5-ALA HCl']","['positive predictive value (PPV', 'safety, feasibility, and diagnostic accuracy', 'adverse events', 'PPV']","[{'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0028794', 'cui_str': 'Occultism'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C0430876', 'cui_str': 'Ophthalmic fluorescence imaging'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002563', 'cui_str': 'Aminolevulinic Acid'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0876231', 'cui_str': 'Aminolevulinic acid hydrochloride'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",54.0,0.27135,"Both 5-ALA doses caused bright red tumor fluorescence, with improved visualization of tumor contrasted against normal tissue autofluorescence.","[{'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Ottolino-Perry', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Anam', 'Initials': 'A', 'LastName': 'Shahid', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'DeLuca', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Son', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Mayleen', 'Initials': 'M', 'LastName': 'Sukhram', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Fannong', 'Initials': 'F', 'LastName': 'Meng', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Zhihui Amy', 'Initials': 'ZA', 'LastName': 'Liu', 'Affiliation': 'Biostatistics Department, University Health Network, 610 University Ave, Toronto, M5T 2M9, Ontario, Canada.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Rapic', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Nayana Thalanki', 'Initials': 'NT', 'LastName': 'Anantha', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Shirley C', 'Initials': 'SC', 'LastName': 'Wang', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Chamma', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Gibson', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Medeiros', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Safa', 'Initials': 'S', 'LastName': 'Majeed', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Chu', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Wignall', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Pizzolato', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Cheryl F', 'Initials': 'CF', 'LastName': 'Rosen', 'Affiliation': 'Dermatology Department, Toronto Western Hospital, University Health Network, 399 Bathurst St, Toronto, M5T 2S8, Ontario, Canada.'}, {'ForeName': 'Liis Lindvere', 'Initials': 'LL', 'LastName': 'Teene', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Starr-Dunham', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Kulbatski', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Panzarella', 'Affiliation': 'Biostatistics Department, University Health Network, 610 University Ave, Toronto, M5T 2M9, Ontario, Canada.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Done', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Alexandra M', 'Initials': 'AM', 'LastName': 'Easson', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Wey L', 'Initials': 'WL', 'LastName': 'Leong', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada.'}, {'ForeName': 'Ralph S', 'Initials': 'RS', 'LastName': 'DaCosta', 'Affiliation': 'Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, 101 College Street, Toronto, M5G 1L7, Ontario, Canada. rdacosta@uhnresearch.ca.'}]",Breast cancer research : BCR,['10.1186/s13058-021-01442-7'] 1584,34256795,"A randomized clinical trial to assess the effectiveness of pre- and post-surgical pelvic floor physiotherapy for bowel symptoms, pelvic floor function, and quality of life of patients with rectal cancer: CARRET protocol.","BACKGROUND There is scarcity of trials about preventative strategies for low anterior resection syndrome (LARS) in rectal cancer patients. The aim of this study is to evaluate the effectiveness of a pre- and post-surgical pelvic floor rehabilitation program on the bowel symptoms, pelvic floor function, and quality of life of rectal cancer patients. METHODS A randomized controlled trial with parallel groups (pelvic floor rehabilitation versus control group), with a blinded evaluator. PARTICIPANTS AND SETTING 56 stage I to III rectal cancer patients aged from 18 to 80 years old undergoing sphincter preservation surgery at Hospital del Salvador and who have a sufficient knowledge of Spanish. MAIN OUTCOME MEASURES ICIQ-B questionnaire for intestinal symptoms, high-resolution anorectal manometry (Alacer Multiplex 24-channel manometry equipment) for anorectal function, pelvic floor muscle strength test with Oxford Modified Scale, and a quality of life test with the EORTC QLQ C30 questionnaire. The evaluations will be carried out at five stages: before surgery, before and after the pelvic floor rehabilitation, and during a 3-month and 1-year follow-up. INTERVENTIONS one pre-rehabilitation session and 9 to 12 sessions of pelvic floor rehabilitation, including patient education, pelvic floor muscle exercises, pelvic floor electromyography biofeedback, and capacitive and sensory rectal training with a balloon probe. Rehabilitation will begin 3-5 weeks before the ileostomy is removed (four sessions) and around 3 weeks after stoma removal (5-8 sessions). DISCUSSION We expect the program to improve the bowel symptoms, pelvic floor function, and quality of life of rectal cancer patients. TRIAL REGISTRATION Australian New Zealand Clinical Trials Register ACTRN12620000040965 . Registered on 21 January 2020.",2021,"PARTICIPANTS AND SETTING 56 stage I to III rectal cancer patients aged from 18 to 80 years old undergoing sphincter preservation surgery at Hospital del Salvador and who have a sufficient knowledge of Spanish. ","['patients with rectal cancer', '56 stage I to III rectal cancer patients aged from 18 to 80\u2009years old undergoing sphincter preservation surgery at Hospital del Salvador and who have a sufficient knowledge of Spanish', 'rectal cancer patients']","['pre- and post-surgical pelvic floor rehabilitation program', 'one pre-rehabilitation session and 9 to 12 sessions of pelvic floor rehabilitation, including patient education, pelvic floor muscle exercises, pelvic floor electromyography biofeedback, and capacitive and sensory rectal training with a balloon probe', 'pre- and post-surgical pelvic floor physiotherapy']","['bowel symptoms, pelvic floor function, and quality of life', 'ICIQ-B questionnaire for intestinal symptoms, high-resolution anorectal manometry (Alacer Multiplex 24-channel manometry equipment']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008628', 'cui_str': 'Chromosomal deletion'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030688', 'cui_str': 'Patient education'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0205052', 'cui_str': 'Rectal'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}]","[{'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0374190', 'cui_str': 'Anorectal manometry'}, {'cui': 'C0439799', 'cui_str': 'Channel'}, {'cui': 'C0024751', 'cui_str': 'Manometry'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}]",,0.169727,"PARTICIPANTS AND SETTING 56 stage I to III rectal cancer patients aged from 18 to 80 years old undergoing sphincter preservation surgery at Hospital del Salvador and who have a sufficient knowledge of Spanish. ","[{'ForeName': 'Cinara', 'Initials': 'C', 'LastName': 'Sacomori', 'Affiliation': ""Universidad Bernardo O'Higgins, Escuela de Kinesiología, Santiago, Chile. csacomori@yahoo.com.br.""}, {'ForeName': 'Luz Alejandra', 'Initials': 'LA', 'LastName': 'Lorca', 'Affiliation': 'Hospital del Salvador, Servicio de Medicina Física y Rehabilitación, Santiago, Chile.'}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'Martinez-Mardones', 'Affiliation': 'Hospital del Salvador, Servicio de Cirugía y Servicio de Coloproctologia, Santiago, Chile.'}, {'ForeName': 'Roberto Ignacio', 'Initials': 'RI', 'LastName': 'Salas-Ocaranza', 'Affiliation': 'Hospital del Salvador, Servicio de Cirugía y Servicio de Coloproctologia, Santiago, Chile.'}, {'ForeName': 'Guillermo Patricio', 'Initials': 'GP', 'LastName': 'Reyes-Reyes', 'Affiliation': 'Hospital del Salvador, Servicio de Cirugía y Servicio de Coloproctologia, Santiago, Chile.'}, {'ForeName': 'Marta Natalia', 'Initials': 'MN', 'LastName': 'Pizarro-Hinojosa', 'Affiliation': 'Hospital del Salvador, Servicio de Medicina Física y Rehabilitación, Santiago, Chile.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Plasser-Troncoso', 'Affiliation': 'Hospital del Salvador, Servicio de Cirugía y Servicio de Coloproctologia, Santiago, Chile.'}]",Trials,['10.1186/s13063-021-05396-1'] 1585,34255698,Supportive Accountability and Mobile App Use in a Tobacco Control Intervention Targeting Low-Income Minority Mothers Who Smoke: Observational Study.,"BACKGROUND Smartphone mobile apps are frequently used in standalone or multimodal smoking cessation interventions. However, factors that impede or improve app usage are poorly understood. OBJECTIVE This study used the supportive accountability model to investigate factors that influence app usage in the context of a trial designed to reduce maternal smoking in low-income and predominantly minority communities. METHODS We conducted a secondary analysis of data (N=181) from a randomized controlled trial that included a smoking cessation app (QuitPal-m). Supportive accountability was measured by the number of times a participant was advised by their cessation counselor to use QuitPal-m. Participants reported app use helpfulness and barriers. Investigators tracked reported phone and technical problems that impeded app use. RESULTS Most participants rated the app as very helpful (103/155, 66.5%), but daily use declined rapidly over time. App use was positively related to the level of perceived app helpfulness (P=.02) and education (P=.002) and inversely related to perceived barriers (P=.003), phone technical problems (P<.001), and cigarettes smoked per day at the end of treatment (P<.001). Participants used the app a greater proportion of the days following app advice than those preceding app advice (0.45 versus 0.34; P<.001). The positive relation between counselor app advice and app usage 24 hours after receiving advice was stronger among smokers with no plan to quit than in those planning to quit (P=.03), independent of education and phone or app problems. CONCLUSIONS Findings show the utility of supportive accountability for increasing smoking cessation app use in a predominantly low-income, minority population, particularly if quit motivation is low. Results also highlight the importance of addressing personal and phone/technical barriers in addition to adding supportive accountability. TRIAL REGISTRATION ClinicalTrials.gov NCT02602288; https://clinicaltrials.gov/ct2/show/NCT02602288.",2021,"App use was positively related to the level of perceived app helpfulness (P=.02) and education (P=.002) and inversely related to perceived barriers (P=.003), phone technical problems (P<.001), and cigarettes smoked per day at the end of treatment (P<.001).","['low-income and predominantly minority communities', 'Targeting Low-Income Minority Mothers']","['smoking cessation app (QuitPal-m', 'Tobacco Control Intervention']","['phone technical problems', 'level of perceived app helpfulness', 'Supportive accountability']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0078889', 'cui_str': 'Accountability'}]",,0.0791757,"App use was positively related to the level of perceived app helpfulness (P=.02) and education (P=.002) and inversely related to perceived barriers (P=.003), phone technical problems (P<.001), and cigarettes smoked per day at the end of treatment (P<.001).","[{'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Lepore', 'Affiliation': 'Department of Social and Behavioral Sciences, Temple University, Philadelphia, PA, United States.'}, {'ForeName': 'Bradley N', 'Initials': 'BN', 'LastName': 'Collins', 'Affiliation': 'Department of Social and Behavioral Sciences, Temple University, Philadelphia, PA, United States.'}, {'ForeName': 'Howard W', 'Initials': 'HW', 'LastName': 'Killam', 'Affiliation': 'User Centered Design Inc, Ashburn, VA, United States.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Barry', 'Affiliation': 'User Centered Design Inc, Ashburn, VA, United States.'}]",JMIR mHealth and uHealth,['10.2196/28175'] 1586,34255667,Correction: A Direct-to-Public Peer Support Program (Big White Wall) Versus Web-Based Information to Aid the Self-management of Depression and Anxiety: Results and Challenges of an Automated Randomized Controlled Trial.,[This corrects the article DOI: 10.2196/23487.].,2021,[This corrects the article DOI: 10.2196/23487.].,['Depression and Anxiety'],['Direct-to-Public Peer Support Program (Big White Wall'],[],"[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0205380', 'cui_str': 'Walled'}]",[],,0.0621826,[This corrects the article DOI: 10.2196/23487.].,"[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Morriss', 'Affiliation': 'Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Kaylor-Hughes', 'Affiliation': 'Department of General Practice, University of Melbourne, Melbourne, United Kingdom.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Rawsthorne', 'Affiliation': 'Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Coulson', 'Affiliation': 'School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Simpson', 'Affiliation': 'Research Delivery Team, Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, United Kingdom.'}, {'ForeName': 'Boliang', 'Initials': 'B', 'LastName': 'Guo', 'Affiliation': 'Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Marilyn', 'Initials': 'M', 'LastName': 'James', 'Affiliation': 'School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Lathe', 'Affiliation': 'Centre for Longitudinal Studies, University College London, London, United Kingdom.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Moran', 'Affiliation': 'School of Medicine, University of Bristol, Bristol, United Kingdom.'}, {'ForeName': 'Laila J', 'Initials': 'LJ', 'LastName': 'Tata', 'Affiliation': 'School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Williams', 'Affiliation': 'Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom.'}]",Journal of medical Internet research,['10.2196/31543'] 1587,34237313,Vagal nerve stimulation as a possible non-invasive treatment for chronic widespread pain in Gulf Veterans with Gulf War Illness.,"AIMS Widespread pain and headache are common in Gulf War Illness with suboptimal treatments available. We tested the efficacy of non-invasive, transcutaneous vagal nerve stimulation (nVNS) for relief of widespread pain and migraine in Gulf War Veterans with GWI. MAIN METHODS A 10-week double-blind, randomized controlled trial of nVNS used the gammaCore (ElectroCore, Inc.) compared to sham stimulation with the same device followed by a 10-week open-label follow up with active nVNS. The primary outcome was a numerical pain rating at the end of the blinded period. Secondary outcomes included physical function, migraine frequency and severity, and impression of change during the blinded and open-label periods. Two-factor MANOVA models tested for significant differences between groups from baseline to end of the blinded period and during the open-label period. KEY FINDINGS Among 27 participants enrolled and issued a nVNS device, there was a slight improvement in pain ratings from baseline to the end of the blinded phase [6.18 (±0.82) vs. 5.05 (±2.3); p = 0.040] which did not differ between active and sham nVNS. Physical function was also slightly improved overall without group differences. There were no significant changes in migraine frequency or severity during the blinded period. Twenty participants started in the open-label phase; no statistically significant changes in pain, physical function, migraine measures, or impression of change were noted during this phase. SIGNIFICANCE Veterans with GWI actively treated with nVNS reported no improvement in either widespread pain or migraine frequency or severity relative to Veterans with GWI who received sham nVNS.",2021,"Twenty participants started in the open-label phase; no statistically significant changes in pain, physical function, migraine measures, or impression of change were noted during this phase. ","['27 participants enrolled and issued a nVNS device', 'Veterans with GWI actively treated with', 'Gulf Veterans with Gulf War Illness', 'Gulf War Veterans with GWI']","['gammaCore (ElectroCore, Inc', 'Vagal nerve stimulation', 'non-invasive, transcutaneous vagal nerve stimulation (nVNS', 'nVNS']","['pain ratings', 'widespread pain or migraine frequency or severity relative', 'pain, physical function, migraine measures, or impression of change', 'physical function, migraine frequency and severity, and impression of change during the blinded and open-label periods', 'numerical pain rating', 'migraine frequency or severity', 'Physical function']","[{'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C1449761', 'cui_str': 'Persian Gulf War, 1991'}, {'cui': 'C0221423', 'cui_str': 'Illness'}]","[{'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205219', 'cui_str': 'Diffuse'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",27.0,0.532857,"Twenty participants started in the open-label phase; no statistically significant changes in pain, physical function, migraine measures, or impression of change were noted during this phase. ","[{'ForeName': 'Benjamin H', 'Initials': 'BH', 'LastName': 'Natelson', 'Affiliation': 'Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Aaron J', 'Initials': 'AJ', 'LastName': 'Stegner', 'Affiliation': 'Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Kinesiology, University of Wisconsin-Madison, Madison, WI, USA.. Electronic address: astegner@wisc.edu.'}, {'ForeName': 'Gudrun', 'Initials': 'G', 'LastName': 'Lange', 'Affiliation': 'Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Khan', 'Affiliation': 'Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Blate', 'Affiliation': 'Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Anays', 'Initials': 'A', 'LastName': 'Sotolongo', 'Affiliation': 'War Related Illness and Injury Study Center, VA New Jersey Health Care System, East Orange, NJ, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'DeLuca', 'Affiliation': 'War Related Illness and Injury Study Center, VA New Jersey Health Care System, East Orange, NJ, USA.'}, {'ForeName': 'William W', 'Initials': 'WW', 'LastName': 'Van Doren', 'Affiliation': 'War Related Illness and Injury Study Center, VA New Jersey Health Care System, East Orange, NJ, USA.'}, {'ForeName': 'Drew A', 'Initials': 'DA', 'LastName': 'Helmer', 'Affiliation': 'Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston TX, USA.'}]",Life sciences,['10.1016/j.lfs.2021.119805'] 1588,34236930,Diagnostic Accuracy of the AzBio Speech Recognition in Noise Test.,"Purpose The goal of this study was to determine the ability of the AzBio speech recognition in noise (SRN) test to distinguish between groups of participants with and without a self-reported SRN disorder and a self-reported signal-to-noise ratio (SNR) loss. Method Fifty-four native English-speaking young adults with normal pure-tone thresholds (≤ 25 dB HL, 0.25-6.0 kHz) participated. Individuals who reported hearing difficulty in a noisy restaurant (Reference Standard 1) were placed in the SRN disorder group. SNR loss groups were created based on the self-report of the ability to hear Hearing in Noise Test (HINT) sentences in steady-state speech-shaped noise, four-talker babble, and 20-talker babble in a controlled listening environment (Reference Standard 2). Participants with HINT thresholds poorer than or equal to the median were assigned to the SNR loss group. Results The area under the curve from the receiver operating characteristics curves revealed that the AzBio test was not a significant predictor of an SRN disorder, or an SNR loss using the steady-state noise Reference Standard 2 condition. However, the AzBio was a significant predictor of an SNR loss using the four-talker babble and 20-talker babble Reference Standard 2 conditions ( p < .05). The AzBio was a significant predictor of an SNR loss when using the average HINT thresholds across the three Reference Standard 2 masker conditions (area under the curve = .79, p = .001). Conclusions The AzBio test was not a significant predictor of a self-reported SRN disorder or a self-reported SNR loss in steady-state noise. However, it was a significant predictor of a self-reported SNR loss in babble noise and the average across all noise conditions. A battery of reference standard tests with a range of maskers in a controlled listening environment is recommended for diagnostic accuracy evaluations of SRN tests.",2021,The AzBio test was not a significant predictor of a self-reported SRN disorder or a self-reported SNR loss in steady-state noise.,"['Individuals who reported hearing difficulty in a noisy restaurant (Reference Standard 1) were placed in the SRN disorder group', 'groups of participants with and without a self-reported SRN disorder and a self-reported signal-to-noise ratio (SNR) loss', 'Participants with HINT thresholds poorer than or equal to the median were assigned to the SNR loss group', 'Method Fifty-four native English-speaking young adults with normal pure-tone thresholds (≤ 25 dB HL, 0.25-6.0 kHz) participated']",[],['SNR loss'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1313969', 'cui_str': 'Hearing difficulty'}, {'cui': 'C0035255', 'cui_str': 'Restaurant'}, {'cui': 'C0034925', 'cui_str': 'Standards, Reference'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0439498', 'cui_str': 'dB HL'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0556965', 'cui_str': 'kHz'}]",[],"[{'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}]",54.0,0.0634801,The AzBio test was not a significant predictor of a self-reported SRN disorder or a self-reported SNR loss in steady-state noise.,"[{'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Vermiglio', 'Affiliation': 'Department of Communication Sciences and Disorders, East Carolina University, Greenville, NC.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Leclerc', 'Affiliation': 'Department of Communication Sciences and Disorders, East Carolina University, Greenville, NC.'}, {'ForeName': 'Meagan', 'Initials': 'M', 'LastName': 'Thornton', 'Affiliation': 'Department of Communication Sciences and Disorders, East Carolina University, Greenville, NC.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Osborne', 'Affiliation': 'Department of Communication Sciences and Disorders, East Carolina University, Greenville, NC.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Bonilla', 'Affiliation': 'Department of Communication Sciences and Disorders, East Carolina University, Greenville, NC.'}, {'ForeName': 'Xiangming', 'Initials': 'X', 'LastName': 'Fang', 'Affiliation': 'Department of Biostatistics, East Carolina University, Greenville, NC.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2021_JSLHR-20-00453'] 1589,34242627,Cost-effectiveness of behavioral and pelvic floor muscle therapy combined with midurethral sling surgery vs surgery alone among women with mixed urinary incontinence: results of the Effects of Surgical Treatment Enhanced With Exercise for Mixed Urinary Incontinence randomized trial.,"BACKGROUND Urinary incontinence is prevalent among women, and it has a substantial economic impact. Mixed urinary incontinence, with both stress and urgency urinary incontinence symptoms, has a greater adverse impact on quality of life and is more complex to treat than either stress or urgency urinary incontinence alone. Studies evaluating the cost-effectiveness of treating both the stress and urgency urinary incontinence components simultaneously are lacking. OBJECTIVE Cost-effectiveness was assessed between perioperative behavioral and pelvic floor muscle therapies combined with midurethral sling surgery and midurethral sling surgery alone for the treatment of women with mixed urinary incontinence. The impact of baseline severe urgency urinary incontinence symptoms on cost-effectiveness was assessed. STUDY DESIGN This prospective economic evaluation was performed concurrently with the Effects of Surgical Treatment Enhanced with Exercise for Mixed Urinary Incontinence randomized trial that was conducted from October 2013 to April 2016. Participants included 480 women with moderate-to-severe stress and urgency urinary incontinence symptoms and at least 1 stress urinary incontinence episode and 1 urgency urinary incontinence episode on a 3-day bladder diary. The primary within-trial analysis was from the healthcare sector and societal perspectives, with a 1-year time horizon. Costs were in 2019 US dollars. Effectiveness was measured in quality-adjusted life-years and reductions in urinary incontinence episodes per day. Incremental cost-effectiveness ratios of combined treatment vs midurethral sling surgery alone were calculated, and cost-effectiveness acceptability curves were generated. Analysis was performed for the overall study population and subgroup of women with Urogenital Distress Inventory irritative scores of ≥50th percentile. RESULTS The costs for combined treatment were higher than the cost for midurethral sling surgery alone from both the healthcare sector perspective ($5100 [95% confidence interval, $5000-$5190] vs $4470 [95% confidence interval, $4330-$4620]; P<.01) and the societal perspective ($9260 [95% confidence interval, $8590-$9940] vs $8090 [95% confidence interval, $7630-$8560]; P<.01). There was no difference between combined treatment and midurethral sling surgery alone in quality-adjusted life-years (0.87 [95% confidence interval, 0.86-0.89] vs 0.87 [95% confidence interval, 0.86-0.89]; P=.90) or mean reduction in urinary incontinence episodes per day (-4.76 [95% confidence interval, -4.51 to 5.00] vs -4.50 [95% confidence interval, -4.25 to 4.75]; P=.13). When evaluating the overall study population, from both the healthcare sector and societal perspectives, midurethral sling surgery alone was superior to combined treatment. The probability that combined treatment is cost-effective compared with midurethral sling surgery alone is ≤28% from the healthcare sector and ≤19% from the societal perspectives for a willingness-to-pay value of ≤$150,000 per quality-adjusted life-years. For women with baseline Urogenital Distress Inventory irritative scores of ≥50th percentile, combined treatment was cost-effective compared with midurethral sling surgery alone from both the healthcare sector and societal perspectives. The probability that combined treatment is cost-effective compared with midurethral sling surgery alone for this subgroup is ≥90% from both the healthcare sector and societal perspectives, at a willingness-to-pay value of ≥$150,000 per quality-adjusted life-years. CONCLUSION Overall, perioperative behavioral and pelvic floor muscle therapies combined with midurethral sling surgery was not cost-effective compared with midurethral sling surgery alone for the treatment of women with mixed urinary incontinence. However, combined treatment was of good value compared with midurethral sling surgery alone for women with baseline severe urgency urinary incontinence symptoms.",2021,"For women with baseline Urogenital Distress Inventory-irritative scores ≥50th percentile, combined treatment was cost effective compared to midurethral sling surgery alone from both the health care sector and societal perspectives.","['women with severe baseline urgency symptoms', 'women with mixed urinary incontinence', 'women with Urogenital Distress Inventory-irritative scores ≥50th percentile', 'October 2013 through April 2016', 'Participants included 480 women with moderate-to-severe stress and urgency-incontinence symptoms and at least 1 stress and 1 urgency incontinence episode on a 3-day bladder diary', 'Mixed Urinary Incontinence', 'Women With Mixed Urinary Incontinence']","['perioperative behavioral and pelvic floor muscle therapy combined with midurethral sling surgery versus surgery alone', 'Behavioral and Pelvic Floor Muscle Therapy Combined With Midurethral Sling Surgery vs Surgery Alone', 'midurethral sling surgery', 'midurethral sling surgery alone']","['quality-adjusted life-years (QALYs) and reductions in urinary-incontinence episodes/day', 'cost-effectiveness acceptability curves', 'Incremental cost-effectiveness ratios']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0869256', 'cui_str': 'Mixed urinary incontinence'}, {'cui': 'C0042066', 'cui_str': 'Structure of genitourinary system'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0430970', 'cui_str': 'Urinary frequency volume chart'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C3179501', 'cui_str': 'Mid-Urethral Slings'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",480.0,0.165878,"For women with baseline Urogenital Distress Inventory-irritative scores ≥50th percentile, combined treatment was cost effective compared to midurethral sling surgery alone from both the health care sector and societal perspectives.","[{'ForeName': 'Heidi S', 'Initials': 'HS', 'LastName': 'Harvie', 'Affiliation': 'Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA. Electronic address: hharvie@pennmedicine.upenn.edu.'}, {'ForeName': 'Vivian W', 'Initials': 'VW', 'LastName': 'Sung', 'Affiliation': 'Department of Obstetrics and Gynecology, Women and Infants Hospital, the Warren Alpert Medical School of Brown University, Providence, RI.'}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Neuwahl', 'Affiliation': 'Social, Statistical, and Environmental Sciences, RTI International, Research Triangle Park, NC.'}, {'ForeName': 'Amanda A', 'Initials': 'AA', 'LastName': 'Honeycutt', 'Affiliation': 'Social, Statistical, and Environmental Sciences, RTI International, Research Triangle Park, NC.'}, {'ForeName': 'Isuzu', 'Initials': 'I', 'LastName': 'Meyer', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Chermansky', 'Affiliation': 'Department of Urology, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Menefee', 'Affiliation': 'Department of Obstetrics and Gynecology, Kaiser Permanente San Diego, San Diego, CA.'}, {'ForeName': 'Whitney K', 'Initials': 'WK', 'LastName': 'Hendrickson', 'Affiliation': 'Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC.'}, {'ForeName': 'Gena C', 'Initials': 'GC', 'LastName': 'Dunivan', 'Affiliation': 'Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, NM.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Mazloomdoost', 'Affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Sarah J', 'Initials': 'SJ', 'LastName': 'Bass', 'Affiliation': 'Social, Statistical, and Environmental Sciences, RTI International, Research Triangle Park, NC.'}, {'ForeName': 'Marie G', 'Initials': 'MG', 'LastName': 'Gantz', 'Affiliation': 'Social, Statistical, and Environmental Sciences, RTI International, Research Triangle Park, NC.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2021.06.099'] 1590,34242512,A Transabdominal Robotic Purse-String Suture Technique for Transanal Total Mesorectal Excision.,"Introduction: Transanal total mesorectal excision (TaTME) is a novel technique that overcomes the problem of access to the deep pelvis during radical surgery for mid-rectal and lower rectal cancer. Although TaTME has several important steps, the creation of the distal purse-string suture following TaTME plays an important role in ensuring the integrity of the colorectal anastomosis. However, this procedure represents a major technical challenge for the surgeon. Robot-assisted surgery may make this suturing procedure easier than laparoscopic surgery because it permits intuitive wrist movements and a three-dimensional view. The aim of the present study was to investigate the usefulness of transabdominal robotic purse-string suture during anastomosis in TaTME. Methods: Twenty-seven patients, who underwent anastomosis using a single stapling technique (SST) during the TaTME of mid-rectal or lower rectal cancer, were enrolled in the study. The patients were allocated to two groups: 11 patients underwent transabdominal robotic purse-string suturing (the Robot group) and 16 patients underwent transanal purse-string suturing (the Transanal group). The characteristics and short-term surgical outcomes of the participants were compared between the two groups. Results: The Robot group tended to have a shorter purse-string suturing time (541 ± 206 seconds versus 729 ± 310 seconds; P  = .07). Regarding the shape of the ""donut"" after SST anastomosis, in the Transanal group, 5 of the 16 participants had incomplete donuts with muscular defects and required additional suturing, whereas in the Robot group, all the participants had complete donuts ( P  = .04). Conclusions: Transabdominal robotic purse-string suturing may facilitate the suturing procedure and contribute to reliable anastomosis.",2021,Results: The Robot group tended to have a shorter purse-string suturing time (541 ± 206 seconds versus 729 ± 310 seconds; P  = .07).,"['Twenty-seven patients, who underwent anastomosis using a single stapling technique (SST) during the TaTME of mid-rectal or lower rectal cancer, were enrolled in the study']","['transabdominal robotic purse-string suturing', 'TaTME', 'Robot-assisted surgery', 'Transanal total mesorectal excision (TaTME', 'Transabdominal Robotic Purse-String Suture Technique', 'Transabdominal robotic purse-string suturing', 'transanal purse-string suturing', 'transabdominal robotic purse-string suture']","['shorter purse-string suturing time', 'incomplete donuts with muscular defects and required additional suturing']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332853', 'cui_str': 'Anastomosis'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0185012', 'cui_str': 'Closure by staple'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0205052', 'cui_str': 'Rectal'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205496', 'cui_str': 'Abdominal approach'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0443313', 'cui_str': 'Stringing'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0589371', 'cui_str': 'Transanal approach'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0038968', 'cui_str': 'Suturing techniques'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0443313', 'cui_str': 'Stringing'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0243067', 'cui_str': 'defects'}]",,0.0709998,Results: The Robot group tended to have a shorter purse-string suturing time (541 ± 206 seconds versus 729 ± 310 seconds; P  = .07).,"[{'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Tokunaga', 'Affiliation': 'Department of Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.'}, {'ForeName': 'Hideya', 'Initials': 'H', 'LastName': 'Kashihara', 'Affiliation': 'Department of Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Higashijima', 'Affiliation': 'Department of Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.'}, {'ForeName': 'Kozo', 'Initials': 'K', 'LastName': 'Yoshikawa', 'Affiliation': 'Department of Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.'}, {'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Nishi', 'Affiliation': 'Department of Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.'}, {'ForeName': 'Chie', 'Initials': 'C', 'LastName': 'Takasu', 'Affiliation': 'Department of Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.'}, {'ForeName': 'Shohei', 'Initials': 'S', 'LastName': 'Eto', 'Affiliation': 'Department of Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Yoshimoto', 'Affiliation': 'Department of Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.'}, {'ForeName': 'Mitsuo', 'Initials': 'M', 'LastName': 'Shimada', 'Affiliation': 'Department of Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.'}]",Journal of laparoendoscopic & advanced surgical techniques. Part A,['10.1089/lap.2021.0286'] 1591,34245234,Prescription Opioids Higher Among Knee Arthroplasty Recipients Randomized to Inpatient Rehabilitation.,"OBJECTIVE To determine whether the purchase of prescription opioids was lower among people randomized to inpatient rehabilitation (IR) compared with those discharged directly home following total knee arthroplasty (TKA). METHOD A secondary analysis of a previous clinical trial in which participants were randomized 3 to 5 days after -surgery to 10 days of IR and a home program or to a home program alone. The primary outcome for this secondary analysis was the purchase of opioid-based pain relief up to 10-weeks after surgery, which was captured via patient diaries. Between-group differences were analyzed using a χ 2 test and relative risk (RR) (95% confidence interval [CI]). We report this outcome alongside the main outcomes observed at 10 weeks for the original study (6-minute walk test, index joint pain, and function) for context. RESULTS At 10 weeks, 158 participants were available for follow-up; 120 (76%) provided diaries, with 113 providing generic or brand names for the pain relief purchased. In the IR group, 60% (33/55) reported the purchase of opioid-based medications after discharge compared with 34% (20/58) in the home group (χ 2 = 7.4; P = 0.007); thus, the risk of purchasing opioids for those in the IR group was almost double (RR, 1.7 [95% CI, 1.1-2.6]). No significant or meaningful between-group differences in index joint pain, function, or mobility were observed. CONCLUSION Contrary to what was hypothesized, IR is a strong driver of opioid purchase after discharge from the hospital following TKA.",2021,"No significant or meaningful between-group differences in index joint pain, function, or mobility were observed. ","['158 participants were available for follow-up; 120 (76%) provided diaries, with 113 providing generic or brand names for the pain relief purchased']",['IR and a home program or to a home program alone'],"['risk of purchasing opioids', 'original study (6-minute walk test, index joint pain, and function) for context', 'purchase of opioid-based medications after discharge', 'purchase of opioid-based pain relief up to 10-weeks after surgery, which was captured via patient diaries', 'index joint pain, function, or mobility']","[{'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0027365', 'cui_str': 'Name'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}]","[{'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449255', 'cui_str': 'Context'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}]",158.0,0.465208,"No significant or meaningful between-group differences in index joint pain, function, or mobility were observed. ","[{'ForeName': 'Justine M', 'Initials': 'JM', 'LastName': 'Naylor', 'Affiliation': 'Liverpool Hospital, Liverpool, New South Wales, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Buhagiar', 'Affiliation': 'Bethany Centre, Parramatta, New South Wales, Australia.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Johns', 'Affiliation': 'The Rehabilitation Medicine Group, Moorabbin, Victoria, Australia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Penm', 'Affiliation': 'University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Adie', 'Affiliation': 'St. George Private Hospital, Kogarah, New South Wales, Australia.'}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Harris', 'Affiliation': 'Liverpool Hospital, Liverpool, New South Wales, Australia.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Xuan', 'Affiliation': 'Ingham Institute, Liverpool, New South Wales, Australia.'}]",ACR open rheumatology,['10.1002/acr2.11304'] 1592,34244316,"Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial.","BACKGROUND The effects of convalescent plasma (CP) therapy hospitalised patients with coronavirus disease 2019 (COVID-19) remain uncertain. This study investigates the effect CP on clinical improvement in these patients. METHODS This is an investigator-initiated, randomised, parallel arm, open-label, superiority clinical trial. Patients were randomly (1:1) assigned to two infusions of CP plus standard of care (SOC) or SOC alone. The primary outcome was the proportion of patients with clinical improvement 28 days after enrolment. RESULTS A total of 160 (80 in each arm) patients (66.3% were critically ill and 33.7%, severe) completed the trial. The median age was 60.5 years (interquartile range [IQR], 48-68), 58.1% were men and the median time from symptom onset to randomisation was 10 days (IQR, 8-12). Neutralising antibodies titres >1:80 were present in 133 (83.1%) patients at baseline. The proportion of patients with clinical improvement on day 28 was 61.3% in the CP+SOC and 65.0% in the SOC group (difference, -3.7%; 95% Confidence Interval [CI], -18.8%-11.3%). The results were similar in the subgroups of severe and critically ill. There was no significant difference between CP+SOC and SOC groups in prespecified secondary outcomes, including 28-day mortality, days alive and free of respiratory support and duration of invasive ventilatory support. Inflammatory and other laboratorial markers values on days 3, 7 and 14 were similar between groups. CONCLUSIONS CP+SOC did not result in a higher proportion of clinical improvement on at day 28 in hospitalised patients with COVID-19 compared to SOC alone.",2021,"There was no significant difference between CP+SOC and SOC groups in prespecified secondary outcomes, including 28-day mortality, days alive and free of respiratory support and duration of invasive ventilatory support.","['hospitalised patients with coronavirus disease 2019 (COVID-19) remain uncertain', 'hospitalised patients', 'A total of 160 (80 in each arm) patients (66.3% were critically ill and 33.7%, severe) completed the trial', 'The median age was 60.5\u2005years (interquartile range [IQR], 48-68), 58.1% were men and the median time from symptom onset to randomisation was 10\u2005days (IQR, 8-12']","['CP plus standard of care (SOC) or SOC alone', 'convalescent plasma (CP) therapy']","['proportion of patients with clinical improvement', 'proportion of patients with clinical improvement 28\u2005days after enrolment', '28-day mortality, days alive and free of respiratory support and duration of invasive ventilatory support', 'Convalescent plasma', 'Neutralising antibodies titres']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0087130', 'cui_str': 'Uncertain'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0740326', 'cui_str': 'Convalescent'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0740326', 'cui_str': 'Convalescent'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0475463', 'cui_str': 'Neutralizing antibody'}, {'cui': 'C0475208', 'cui_str': 'Titer'}]",,0.298858,"There was no significant difference between CP+SOC and SOC groups in prespecified secondary outcomes, including 28-day mortality, days alive and free of respiratory support and duration of invasive ventilatory support.","[{'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Sekine', 'Affiliation': 'Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Arns', 'Affiliation': 'Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Bruna R', 'Initials': 'BR', 'LastName': 'Fabro', 'Affiliation': 'Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Murillo M', 'Initials': 'MM', 'LastName': 'Cipolatt', 'Affiliation': 'Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Rafael R G', 'Initials': 'RRG', 'LastName': 'Machado', 'Affiliation': 'Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Edison L', 'Initials': 'EL', 'LastName': 'Durigon', 'Affiliation': 'Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Edino', 'Initials': 'E', 'LastName': 'Parolo', 'Affiliation': 'Critical Care Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'José Augusto S', 'Initials': 'JAS', 'LastName': 'Pellegrini', 'Affiliation': 'Critical Care Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Marina V', 'Initials': 'MV', 'LastName': 'Viana', 'Affiliation': 'Critical Care Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Patrícia', 'Initials': 'P', 'LastName': 'Schwarz', 'Affiliation': 'Critical Care Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Thiago C', 'Initials': 'TC', 'LastName': 'Lisboa', 'Affiliation': 'Critical Care Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'José Miguel S', 'Initials': 'JMS', 'LastName': 'Dora', 'Affiliation': 'Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Brazil.'}, {'ForeName': 'Júlia P', 'Initials': 'JP', 'LastName': 'Portich', 'Affiliation': 'Clinical Hematology and Bone Marrow Transplantation Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Alessandra A', 'Initials': 'AA', 'LastName': 'Paz', 'Affiliation': 'Clinical Hematology and Bone Marrow Transplantation Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Silla', 'Affiliation': 'Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Brazil.'}, {'ForeName': 'Almeri M', 'Initials': 'AM', 'LastName': 'Balsan', 'Affiliation': 'Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Felipe da-Silva', 'Initials': 'FD', 'LastName': 'Schirmer', 'Affiliation': 'Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Juliana P M', 'Initials': 'JPM', 'LastName': 'Franz', 'Affiliation': 'Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Luciana M', 'Initials': 'LM', 'LastName': 'da-Silveira', 'Affiliation': 'Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Raquel C', 'Initials': 'RC', 'LastName': 'Breunig', 'Affiliation': 'Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Viviana', 'Initials': 'V', 'LastName': 'Petersen', 'Affiliation': 'Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Monalisa', 'Initials': 'M', 'LastName': 'Sosnoski', 'Affiliation': 'Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Nanci F', 'Initials': 'NF', 'LastName': 'Mesquita', 'Affiliation': 'Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Fabiana Caroline Z', 'Initials': 'FCZ', 'LastName': 'Volpato', 'Affiliation': 'Laboratório de Diagnóstico de SARS-CoV-2, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Sganzerla', 'Affiliation': 'Research Projects Office, Hospital Moinhos de Vento (HMV), Porto Alegre, Brazil.'}, {'ForeName': 'Maicon', 'Initials': 'M', 'LastName': 'Falavigna', 'Affiliation': 'Research Projects Office, Hospital Moinhos de Vento (HMV), Porto Alegre, Brazil.'}, {'ForeName': 'Regis G', 'Initials': 'RG', 'LastName': 'Rosa', 'Affiliation': 'Intensive Care Service, Hospital Moinhos de Vento, Porto Alegre, Brazil.'}, {'ForeName': 'Alexandre P', 'Initials': 'AP', 'LastName': 'Zavascki', 'Affiliation': 'Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Brazil.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The European respiratory journal,['10.1183/13993003.01471-2021'] 1593,34243938,Comparison of Ticagrelor Versus Clopidogrel on Cerebrovascular Microembolic Events and Platelet Inhibition during Transcatheter Aortic Valve Implantation.,"The impact of the antiplatelet regimen and the extent of associated platelet inhibition on cerebrovascular microembolic events during transcatheter aortic valve implantation (TAVI) are unknown. Our aim was to evaluate the effects of ticagrelor versus clopidogrel and of platelet inhibition on the number of cerebrovascular microembolic events in patients undergoing TAVI. Patients scheduled for TAVI were randomized previous to the procedure to either aspirin and ticagrelor or to aspirin and clopidogrel. Platelet inhibition was expressed in P2Y12 reaction units (PRU) and percentage of inhibition. High intensity transient signals (HITS) were assessed with transcranial Doppler (TCD). Safety outcomes were recorded according to the VARC-2 definitions. Among 90 patients randomized, 6 had an inadequate TCD signal. The total number of procedural HITS was lower in the ticagrelor group (416.5 [324.8, 484.2]) (42 patients) than in the clopidogrel group (723.5 [471.5, 875.0]) (42 patients), p <0.001. After adjusting for the duration of the procedure, diabetes, extra-cardiac arteriopathy, BMI, hypertension, aortic valve calcium content, procedural ACT, and pre-implantation balloon valvuloplasty, patients on ticagrelor had on average 256.8 (95% CI: [-335.7, -176.5]) fewer total procedural HITS than patients on clopidogrel. Platelet inhibition was greater with ticagrelor 26 [10, 74.5] PRU than with clopidogrel 207.5 (120 to 236.2) PRU, p <0.001, and correlated significantly with procedural HITS (r = 0.5, p <0.05). In conclusion, ticagrelor resulted in fewer procedural HITS, compared with clopidogrel, in patients undergoing TAVI, while achieving greater platelet inhibition.",2021,"Platelet inhibition was greater with ticagrelor 26 [10, 74.5] PRU than with clopidogrel 207.5 (120 to 236.2) PRU, p <0.001, and correlated significantly with procedural HITS (r = 0.5, p <0.05).","['Transcatheter Aortic Valve Implantation', 'patients undergoing TAVI', '90 patients randomized, 6 had an inadequate TCD signal', 'Patients scheduled for TAVI']","['aspirin and ticagrelor or to aspirin and clopidogrel', 'ticagrelor', 'Ticagrelor Versus Clopidogrel', 'transcranial Doppler (TCD', 'transcatheter aortic valve implantation (TAVI', 'clopidogrel']","['High intensity transient signals (HITS', 'Platelet inhibition', 'Cerebrovascular Microembolic Events and Platelet Inhibition', 'total number of procedural HITS', 'platelet inhibition', 'duration of the procedure, diabetes, extra-cardiac arteriopathy, BMI, hypertension, aortic valve calcium content, procedural ACT, and pre-implantation balloon valvuloplasty', 'cerebrovascular microembolic events']","[{'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0206077', 'cui_str': 'Transcranial doppler ultrasonography'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0206077', 'cui_str': 'Transcranial doppler ultrasonography'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0852949', 'cui_str': 'Disorder of artery'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0003501', 'cui_str': 'Aortic valve structure'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0004708', 'cui_str': 'Balloon Valvotomy'}]",90.0,0.0710224,"Platelet inhibition was greater with ticagrelor 26 [10, 74.5] PRU than with clopidogrel 207.5 (120 to 236.2) PRU, p <0.001, and correlated significantly with procedural HITS (r = 0.5, p <0.05).","[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Vavuranakis', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece; Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: mikevavuranakis@gmail.com.'}, {'ForeName': 'Charalampos', 'Initials': 'C', 'LastName': 'Kalantzis', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.'}, {'ForeName': 'Vassilis', 'Initials': 'V', 'LastName': 'Voudris', 'Affiliation': 'Onassis Cardiac Surgery Center, Kallithea, Greece.'}, {'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Kosmas', 'Affiliation': 'Onassis Cardiac Surgery Center, Kallithea, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Kalogeras', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece; Department of Cardiology, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.'}, {'ForeName': 'Efstratios', 'Initials': 'E', 'LastName': 'Katsianos', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.'}, {'ForeName': 'Evaggelos', 'Initials': 'E', 'LastName': 'Oikonomou', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece; Department of Cardiology, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.'}, {'ForeName': 'Gerasimos', 'Initials': 'G', 'LastName': 'Siasos', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece; Department of Cardiology, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Aznaouridis', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Toutouzas', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.'}, {'ForeName': 'Myrsini', 'Initials': 'M', 'LastName': 'Stasinopoulou', 'Affiliation': 'Agios Savvas - Anticancer Hospital, Athens, Greece.'}, {'ForeName': 'Argyro', 'Initials': 'A', 'LastName': 'Tountopoulou', 'Affiliation': 'Aiginiteio University Hospital, Athens, Greece.'}, {'ForeName': 'Evangelia', 'Initials': 'E', 'LastName': 'Bei', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.'}, {'ForeName': 'Carmen M', 'Initials': 'CM', 'LastName': 'Moldovan', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Vrachatis', 'Affiliation': 'General Hospital of Athens ""G. Gennimatas"", Athens, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Iakovou', 'Affiliation': 'Onassis Cardiac Surgery Center, Kallithea, Greece.'}, {'ForeName': 'Theodore G', 'Initials': 'TG', 'LastName': 'Papaioannou', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Tousoulis', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.'}, {'ForeName': 'Thorsten M', 'Initials': 'TM', 'LastName': 'Leucker', 'Affiliation': 'Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Manolis', 'Initials': 'M', 'LastName': 'Vavuranakis', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece; Department of Cardiology, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.'}]",The American journal of cardiology,['10.1016/j.amjcard.2021.05.047'] 1594,34245960,Randomized Study of Wound Drainage on Early Complications After Lymph Node Dissection for Melanoma.,"INTRODUCTION The complication rate after axillary lymph node dissection (ALND) and inguinal lymph node dissection (ILND) in melanoma patients is high. The aim of this randomized non-inferiority study was to evaluate the effect of postoperative wound drainage on early complications after ALND and ILND. MATERIALS AND METHODS Between 2018 and 2020, 104 stage III melanoma patients operated on with ALND or ILND were randomized to a study group with complete wound drain removal 3 wk after surgery or a control group with progressive drain removal. The primary end point was overall early complications graded according to the modified Clavien-Dindo classification. Secondary endpoints were length of hospital stay and prognostic factors for early complications. RESULTS Of the 99 patients analyzed, ALND was performed in 58 patients and ILND in 41 patients. Overall, 62 patients (62.6%) developed early complications: 30 in the study group and 32 in the control group (P = 0.53). The confidence interval for the difference in proportions of patients without early complications in the two groups was -0.27 to 0.11 (P = 0.42), hence non-inferiority could be claimed. Length of hospital stay was 5 d in the study group compared to 6 in the control group (P < 0.01). ILND was associated with increased risk of early complications compared to ALND (75.6% versus 53.4%, P = 0.04). CONCLUSIONS Complete drain removal 3 wk after ALN and ILND in stage III melanoma patients did not increase the risk of early complications compared to progressive drain removal.",2021,"ILND was associated with increased risk of early complications compared to ALND (75.6% versus 53.4%, P = 0.04). ","['99 patients analyzed', 'stage III melanoma patients', 'Between 2018 and 2020, 104 stage III melanoma patients operated on with ALND or ILND', '58 patients and ILND in 41 patients']","['complete wound drain removal 3 wk after surgery or a control group with progressive drain removal', 'Complete drain removal', 'postoperative wound drainage', 'Wound Drainage', 'ILND']","['Early Complications', 'overall early complications graded according to the modified Clavien-Dindo classification', 'Length of hospital stay', 'length of hospital stay and prognostic factors for early complications', 'early complications', 'risk of early complications', 'complication rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0193867', 'cui_str': 'Excision of axillary lymph nodes'}, {'cui': 'C0729596', 'cui_str': 'Inguinal lymph node group'}, {'cui': 'C0012737', 'cui_str': 'Dissection - action'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0411815', 'cui_str': 'Removal of drain'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0406834', 'cui_str': 'Wound discharge finding'}, {'cui': 'C0729596', 'cui_str': 'Inguinal lymph node group'}, {'cui': 'C0012737', 'cui_str': 'Dissection - action'}]","[{'cui': 'C0231243', 'cui_str': 'Early complication'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1514474', 'cui_str': 'Prognostic Factors'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",58.0,0.135315,"ILND was associated with increased risk of early complications compared to ALND (75.6% versus 53.4%, P = 0.04). ","[{'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Frich', 'Affiliation': 'Section of oncologic plastic surgery, Department of Plastic and Reconstructive Surgery, Oslo University Hospital Radiumhospitalet, Oslo, Norway. Electronic address: lfrich@ous-hf.no.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hermann', 'Affiliation': 'Section of oncologic plastic surgery, Department of Plastic and Reconstructive Surgery, Oslo University Hospital Radiumhospitalet, Oslo, Norway.'}, {'ForeName': 'Åshild', 'Initials': 'Å', 'LastName': 'Berentzen', 'Affiliation': 'Section of oncologic plastic surgery, Department of Plastic and Reconstructive Surgery, Oslo University Hospital Radiumhospitalet, Oslo, Norway.'}, {'ForeName': 'Truls', 'Initials': 'T', 'LastName': 'Ryder', 'Affiliation': 'Section of oncologic plastic surgery, Department of Plastic and Reconstructive Surgery, Oslo University Hospital Radiumhospitalet, Oslo, Norway.'}]",The Journal of surgical research,['10.1016/j.jss.2021.05.005'] 1595,34245918,"Thalamic deep brain stimulation for Tourette Syndrome: A naturalistic trial with brief randomized, double-blinded sham-controlled periods.","BACKGROUND There is still a lack of controlled studies to prove efficacy of thalamic deep brain stimulation for Tourette's Syndrome. OBJECTIVES In this controlled trial, we investigated the course of tic severity, comorbidities and quality of life during thalamic stimulation and whether changes in tic severity can be assigned to ongoing compared to sham stimulation. METHODS We included eight adult patients with medically refractory Tourette's syndrome. Bilateral electrodes were implanted in the centromedian-parafascicular-complex and the nucleus ventro-oralis internus. Tic severity, quality of life and comorbidities were assessed before surgery as well as six and twelve months after. Short randomized, double-blinded sham-controlled crossover sequences with either active or sham stimulation were implemented at both six- and twelve-months' assessments. The primary outcome measurement was the difference in the Yale Global Tic Severity Scale tic score between active and sham stimulation. Adverse events were systematically surveyed for all patients to evaluate safety. RESULTS Active stimulation resulted in significantly higher tic reductions than sham stimulation (F = 79.5; p = 0.001). Overall quality of life and comorbidities improved significantly in the open-label-phase. Over the course of the trial two severe adverse events occurred that were resolved without sequelae. CONCLUSION Our results provide evidence that thalamic stimulation is effective in improving tic severity and overall quality of life. Crucially, the reduction of tic severity was primarily driven by active stimulation. Further research may focus on improving stimulation protocols and refining patient selection to improve efficacy and safety of deep brain stimulation for Tourette's Syndrome.",2021,"RESULTS Active stimulation resulted in significantly higher tic reductions than sham stimulation (F = 79.5; p = 0.001).","[""eight adult patients aged with medically refractory Tourette's syndrome"", 'Tourette Syndrome']",['Thalamic deep brain stimulation'],"['tic severity and overall quality of life', 'tic severity', 'severe adverse events', 'Adverse events', 'tic reductions', 'Tic severity, quality of life and comorbidities', 'Overall quality of life and comorbidities', 'Yale Global Tic Severity Scale tic score between active and sham stimulation']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0040517', 'cui_str': ""Gilles de la Tourette's syndrome""}]","[{'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}]","[{'cui': 'C0040188', 'cui_str': 'Tic disorder'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C4720888', 'cui_str': 'Yale global tic severity scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]",8.0,0.569091,"RESULTS Active stimulation resulted in significantly higher tic reductions than sham stimulation (F = 79.5; p = 0.001).","[{'ForeName': 'Juan Carlos', 'Initials': 'JC', 'LastName': 'Baldermann', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany. Electronic address: juan.baldermann@uk-koeln.de.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Kuhn', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany; Department of Psychiatry, Psychotherapy, and Psychosomatics, Johanniter Hospital Oberhausen, Oberhausen, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Schüller', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.'}, {'ForeName': 'Sina', 'Initials': 'S', 'LastName': 'Kohl', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Andrade', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Functional Neurosurgery and Stereotaxy, Cologne, Germany.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Schleyken', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.'}, {'ForeName': 'Reinhild', 'Initials': 'R', 'LastName': 'Prinz-Langenohl', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre, Cologne, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hellmich', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Medical Statistics and Computational Biology, Cologne, Germany.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Barbe', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Timmermann', 'Affiliation': 'University Hospital Giessen and Marburg, Department of Neurology, Campus Marburg, Marburg, Germany; Center for Mind, Brain and Behaviour, Marburg, Germany.'}, {'ForeName': 'Veerle', 'Initials': 'V', 'LastName': 'Visser-Vandewalle', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Functional Neurosurgery and Stereotaxy, Cologne, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Huys', 'Affiliation': 'University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.'}]",Brain stimulation,['10.1016/j.brs.2021.07.003'] 1596,34247009,The effects of flipped classroom characterized by situational and collaborative learning in a community nursing course: A quasi-experimental design.,"BACKGROUND Since traditional teaching could not help to develop competences, flipped classroom has caught the sight of researchers. Despite the uptake of flipped classroom in other disciplines, there is a dearth of evidence available about the use in nursing curricula. In addition, there is no consensus on how to best implement a flipped classroom. OBJECTIVE This study aimed to (1) develop a flipped classroom underpinned by constructivism theory and (2) to verify its effectiveness. DESIGN This study adopted a quasi-experimental design. SETTING AND PARTICIPANTS This study was conducted in 2018 spring semester at a University in East China with 6th semester undergraduate nursing students in four parallel classes in Community Nursing Course. METHODS A flipped classroom characterized by situational and collaborative learning was developed and carried out with two classes (intervention group, n = 98). In-class lectures was applied for the other two classes (control group, n = 90). Course examination score, experience (course experience questionnaire, CEQ), and students' appraisal were used to verify the effectiveness of flipped classroom. RESULTS Compared to control group, the examination score was higher for intervention group. As for the four domains of CEQ, good teaching domain rating was lower, learning burden domain rating was higher for the intervention group. There was no statistical difference in classroom quality and harvest domains. More students in intervention group chose the course helped them in developing ""critical thinking"" and ""self-cognition and evaluation"" abilities. Satisfaction rating of groups was not statistically different. CONCLUSIONS Flipped classroom was efficient in improving students' academic performance and promoting development of higher-level thinking abilities; however, it failed in improving students' satisfaction and course experience. These findings suggest that active learning strategies such as situational and collaborative learning of group problem solving and discussion should be integrated into nursing curriculum and refinement to flipped classroom are needed to create students' buy-in.",2021,"More students in intervention group chose the course helped them in developing ""critical thinking"" and ""self-cognition and evaluation"" abilities.",['2018 spring semester at a University in East China with 6th semester undergraduate nursing students in four parallel classes in Community Nursing Course'],['flipped classroom characterized by situational and collaborative learning'],"['Satisfaction rating', 'learning burden domain rating', ""students' academic performance"", ""Course examination score, experience (course experience questionnaire, CEQ), and students' appraisal"", 'classroom quality and harvest domains', 'examination score']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0540654', 'cui_str': 'Casper Protein'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C4505156', 'cui_str': 'Collaborative Learning'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332306', 'cui_str': 'Quality'}]",,0.0399536,"More students in intervention group chose the course helped them in developing ""critical thinking"" and ""self-cognition and evaluation"" abilities.","[{'ForeName': 'Yujing', 'Initials': 'Y', 'LastName': 'Dong', 'Affiliation': 'School of Nursing, Nanjing University of Chinese Medicine, 138 Xianlin RD, Nanjing, Jiangsu Province, China. Electronic address: yujingdong@njucm.edu.cn.'}, {'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Yin', 'Affiliation': 'School of Nursing, Nanjing University of Chinese Medicine, 138 Xianlin RD, Nanjing, Jiangsu Province, China.'}, {'ForeName': 'Shizheng', 'Initials': 'S', 'LastName': 'Du', 'Affiliation': 'School of Nursing, Nanjing University of Chinese Medicine, 138 Xianlin RD, Nanjing, Jiangsu Province, China.'}, {'ForeName': 'Aihong', 'Initials': 'A', 'LastName': 'Wang', 'Affiliation': 'School of Nursing, Nanjing University of Chinese Medicine, 138 Xianlin RD, Nanjing, Jiangsu Province, China.'}]",Nurse education today,['10.1016/j.nedt.2021.105037'] 1597,34246994,Comparative effectiveness of endoscopic versus microscopic transsphenoidal surgery for patients with growth hormone secreting pituitary adenoma: An emulated trial.,"INTRODUCTION Previous studies failed to show the benefit of endoscopic surgery over microscopic surgery in terms of early endocrine remission. This study was to investigate whether early endocrine outcomes in patients with GH-secreting pituitary adenoma underwent endoscopic transsphenoidal surgery would be better than those operated by microscopic surgery. METHODS An acromegaly database collected from 2010 to 2019 in a single institution was used to emulate a randomized trial. Adult patients operated by a transsphenoidal approach using either endoscope or microscope were included. The primary outcome was endocrine remission based on insulin-like growth factor-1 (IGF-1) at six-month follow-up after surgery. We used inverse probability weighting to construct a pseudo population from which the treatment effect was estimated. RESULTS In the original cohort, 1118 patients underwent transsphenoidal surgery (424 with an endoscopic approach and 694 with a microscopic approach). Patients treated with endoscopic surgery were more likely to be previously surgical treated and to have an invasive tumor than patients who underwent microscopic surgery. In the pseudo population, the proportion of endocrine remission was 54.9% in the endoscopic group and 42.0% in the microscopic group (odds ratio, 1.68; 95% CI, 1.27-2.23). This finding was consistent and robust across several sensitivity analyses. CONCLUSIONS Among patients with growth hormone secreting pituitary adenoma who underwent transsphenoidal surgery, endoscopic surgery was associated with higher early endocrine remission than microscopic surgery.",2021,"Among patients with growth hormone secreting pituitary adenoma who underwent transsphenoidal surgery, endoscopic surgery was associated with higher early endocrine remission than microscopic surgery.","['patients with growth hormone secreting pituitary adenoma', 'patients with growth hormone secreting pituitary adenoma who underwent', 'patients with GH-secreting pituitary adenoma underwent', 'An acromegaly database collected from 2010 to 2019 in a single institution was used to emulate a randomized trial', '1118 patients underwent transsphenoidal surgery (424 with an endoscopic approach and 694 with a microscopic approach', 'Adult patients operated by a transsphenoidal approach using either endoscope or microscope were included']","['endoscopic surgery over microscopic surgery', 'endoscopic surgery', 'endoscopic versus microscopic transsphenoidal surgery', 'endoscopic transsphenoidal surgery', 'transsphenoidal surgery, endoscopic surgery']","['proportion of endocrine remission', 'endocrine remission based on insulin-like growth factor-1 (IGF-1', 'endocrine remission']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0346302', 'cui_str': 'Somatotroph adenoma'}, {'cui': 'C0001206', 'cui_str': 'Acromegaly'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205508', 'cui_str': 'Transsphenoidal approach'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0205288', 'cui_str': 'Microscopic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0014243', 'cui_str': 'Endoscope'}, {'cui': 'C0181839', 'cui_str': 'Microscope'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0282493', 'cui_str': 'Endoscopy with surgical procedure'}, {'cui': 'C0205288', 'cui_str': 'Microscopic'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0205508', 'cui_str': 'Transsphenoidal approach'}]","[{'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}]",1118.0,0.0559662,"Among patients with growth hormone secreting pituitary adenoma who underwent transsphenoidal surgery, endoscopic surgery was associated with higher early endocrine remission than microscopic surgery.","[{'ForeName': 'Nidan', 'Initials': 'N', 'LastName': 'Qiao', 'Affiliation': 'Department of Neurosurgery, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China; Medical Science in Clinical Investigation, Harvard Medical School, Boston, USA; Neurosurgical Institute of Fudan University, Shanghai, China; Shanghai Pituitary Tumor Center, Shanghai, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Shen', 'Affiliation': 'Department of Neurosurgery, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China; Neurosurgical Institute of Fudan University, Shanghai, China.'}, {'ForeName': 'Wenqiang', 'Initials': 'W', 'LastName': 'He', 'Affiliation': 'Department of Neurosurgery, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China; Neurosurgical Institute of Fudan University, Shanghai, China; Shanghai Pituitary Tumor Center, Shanghai, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'He', 'Affiliation': 'Department of Endocrinology, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China.'}, {'ForeName': 'Zhaoyun', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China.'}, {'ForeName': 'Hongying', 'Initials': 'H', 'LastName': 'Ye', 'Affiliation': 'Department of Endocrinology, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China.'}, {'ForeName': 'Xuefei', 'Initials': 'X', 'LastName': 'Shou', 'Affiliation': 'Department of Neurosurgery, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China; Neurosurgical Institute of Fudan University, Shanghai, China; Shanghai Pituitary Tumor Center, Shanghai, China.'}, {'ForeName': 'Yongfei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Neurosurgery, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China; Neurosurgical Institute of Fudan University, Shanghai, China; Shanghai Pituitary Tumor Center, Shanghai, China. Electronic address: eamns@hotmail.com.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Neurosurgery, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China; Neurosurgical Institute of Fudan University, Shanghai, China; Shanghai Pituitary Tumor Center, Shanghai, China; State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: zhaoyaohs@hotmail.com.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2021.106781'] 1598,34246993,Oxygen desaturation and adverse outcomes in acute stroke: Secondary analysis of the HeadPoST study.,"OBJECTIVE Uncertainty exists over the prognostic significance of low arterial oxygen saturation (SaO 2 ) in acute stroke. We aimed to determine the strength of association of SaO 2 and adverse outcomes among participants of the international Head Positioning in acute Stroke Trial (HeadPoST). METHODS Post-hoc analyzes of HeadPoST, a pragmatic cluster-crossover randomized trial of lying flat versus sitting up head positioning in 11,093 patients (age ≥18 years) with acute stroke at 114 hospitals in 9 countries during 2015-2016. Associations of the lowest recorded SaO 2 level, as a continuous measure and as a cut-point for desaturation (SaO 2 <93%), in the first 24 h and clinical outcomes of death or dependency (modified Rankin scale [mRS] scores 3-6) and any serious adverse event (SAE) at 90 days, were assessed in generalized linear mixed models adjusted for baseline and in-hospital management confounders. RESULTS There was an inverse J-shaped association between SaO 2 and death or dependency, with a nadir for optimal outcome at 96-97%. Patients with SaO 2 desaturation were older, and had greater neurological impairment, premorbid disability and cardiorespiratory disease. Desaturation was not clearly associated with death or dependency (adjusted odds ratio [aOR] 1.19, 95% confidence interval [CI] 0.95-1.48) but was with SAEs (aOR 1.34, 95% CI 1.07-1.68), without heterogeneity by head position, cardiac-respiratory comorbidity, or other pre-specified subgroups. CONCLUSIONS Any change in SaO 2 outside of 96-97% is associated with poorer outcome after acute stroke. CLINICAL TRIAL REGISTRATION HeadPoST is registered at ClinicalTrials.gov (NCT02162017).",2021,"Desaturation was not clearly associated with death or dependency (adjusted odds ratio [aOR] 1.19, 95% confidence interval [CI] 0.95-1.48) but was with SAEs (aOR 1.34, 95% CI 1.07-1.68), without heterogeneity by head position, cardiac-respiratory comorbidity, or other pre-specified subgroups. ","['acute stroke', 'Patients with SaO 2 desaturation were older, and had greater neurological impairment, premorbid disability and cardiorespiratory disease', 'participants of the international Head Positioning in acute Stroke Trial (HeadPoST', '11,093 patients (age ≥18 years) with acute stroke at 114 hospitals in 9 countries during 2015-2016']","['HeadPoST', 'lying flat versus sitting up head positioning']","['Oxygen desaturation and adverse outcomes', 'death or dependency', 'death or dependency (modified Rankin scale [mRS] scores 3-6) and any serious adverse event (SAE', 'Desaturation']","[{'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1862322', 'cui_str': 'Southeast Asian ovalocytosis'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0454664', 'cui_str': 'Country'}]","[{'cui': 'C0023668', 'cui_str': 'Liechtenstein'}, {'cui': 'C0205324', 'cui_str': 'Flat'}, {'cui': 'C0560837', 'cui_str': 'Does sit up'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0442759', 'cui_str': '3/6'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",11093.0,0.380709,"Desaturation was not clearly associated with death or dependency (adjusted odds ratio [aOR] 1.19, 95% confidence interval [CI] 0.95-1.48) but was with SAEs (aOR 1.34, 95% CI 1.07-1.68), without heterogeneity by head position, cardiac-respiratory comorbidity, or other pre-specified subgroups. ","[{'ForeName': 'Menglu', 'Initials': 'M', 'LastName': 'Ouyang', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia; The George Institute China at Peking University Health Science Center, Beijing, China.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Roffe', 'Affiliation': 'Stroke Research, School of Medicine, Keele University, Staffordshire, UK.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Billot', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Song', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia; The George Institute China at Peking University Health Science Center, Beijing, China.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Muñoz-Venturelli', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia; Unidad de Neurología Vascular, Servicio de Neurología, Departmento de Neurología y Psiquiatría, Clínica Alemana de Santiago, Chile; Clinical Research Center, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile.'}, {'ForeName': 'Pablo M', 'Initials': 'PM', 'LastName': 'Lavados', 'Affiliation': 'Unidad de Neurología Vascular, Servicio de Neurología, Departmento de Neurología y Psiquiatría, Clínica Alemana de Santiago, Chile.'}, {'ForeName': 'Thompson', 'Initials': 'T', 'LastName': 'Robinson', 'Affiliation': 'Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.'}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Middleton', 'Affiliation': ""Nursing Research Institute, St Vincent's Health (Sydney) Australia, Australian Catholic University, Sydney, Australia.""}, {'ForeName': 'Verónica V', 'Initials': 'VV', 'LastName': 'Olavarría', 'Affiliation': 'Unidad de Neurología Vascular, Servicio de Neurología, Departmento de Neurología y Psiquiatría, Clínica Alemana de Santiago, Chile.'}, {'ForeName': 'Caroline L', 'Initials': 'CL', 'LastName': 'Watkins', 'Affiliation': 'Faculty of Health and Care, University of Central Lancashire, Preston, Lancashire, UK.'}, {'ForeName': 'Tsong-Hai', 'Initials': 'TH', 'LastName': 'Lee', 'Affiliation': 'Stroke Center and Department of Neurology, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan.'}, {'ForeName': 'Alejandro M', 'Initials': 'AM', 'LastName': 'Brunser', 'Affiliation': 'Unidad de Neurología Vascular, Servicio de Neurología, Departmento de Neurología y Psiquiatría, Clínica Alemana de Santiago, Chile.'}, {'ForeName': 'Octavio M', 'Initials': 'OM', 'LastName': 'Pontes-Neto', 'Affiliation': 'Stroke Service - Neurology Division, Department of Neuroscience and Behavioral Sciences, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Maree L', 'Initials': 'ML', 'LastName': 'Hackett', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia; Faculty of Health and Care, University of Central Lancashire, Preston, Lancashire, UK.'}, {'ForeName': 'Craig S', 'Initials': 'CS', 'LastName': 'Anderson', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia; The George Institute China at Peking University Health Science Center, Beijing, China; Neurology Department, Royal Prince Alfred Hospital, Sydney Health Partners, Sydney, Australia; Heart Health Research Center, Beijing, China. Electronic address: canderson@georgeinstitute.org.au.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2021.106796'] 1599,34265255,"Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial.","BACKGROUND Corticosteroid injections and physiotherapy exercise programmes are commonly used to treat rotator cuff disorders but the treatments' effectiveness is uncertain. We aimed to compare the clinical effectiveness and cost-effectiveness of a progressive exercise programme with a single session of best practice physiotherapy advice, with or without corticosteroid injection, in adults with a rotator cuff disorder. METHODS In this pragmatic, multicentre, superiority, randomised controlled trial (2 × 2 factorial), we recruited patients from 20 UK National Health Service trusts. We included patients aged 18 years or older with a rotator cuff disorder (new episode within the past 6 months). Patients were excluded if they had a history of significant shoulder trauma (eg, dislocation, fracture, or full-thickness tear requiring surgery), neurological disease affecting the shoulder, other shoulder conditions (eg, inflammatory arthritis, frozen shoulder, or glenohumeral joint instability), received corticosteroid injection or physiotherapy for shoulder pain in the past 6 months, or were being considered for surgery. Patients were randomly assigned (centralised computer-generated system, 1:1:1:1) to progressive exercise (≤6 sessions), best practice advice (one session), corticosteroid injection then progressive exercise, or corticosteroid injection then best practice advice. The primary outcome was the Shoulder Pain and Disability Index (SPADI) score over 12 months, analysed on an intention-to-treat basis (statistical significance set at 1%). The trial was registered with the International Standard Randomised Controlled Trial Register, ISRCTN16539266, and EuDRACT, 2016-002991-28. FINDINGS Between March 10, 2017, and May 2, 2019, we screened 2287 patients. 708 patients were randomly assigned to progressive exercise (n=174), best practice advice (n=174), corticosteroid injection then progressive exercise (n=182), or corticosteroid injection then best practice advice (n=178). Over 12 months, SPADI data were available for 166 (95%) patients in the progressive exercise group, 164 (94%) in the best practice advice group, 177 (97%) in the corticosteroid injection then progressive exercise group, and 175 (98%) in the corticosteroid injection then best practice advice group. We found no evidence of a difference in SPADI score between progressive exercise and best practice advice when analysed over 12 months (adjusted mean difference -0·66 [99% CI -4·52 to 3·20]). We also found no evidence of a difference between corticosteroid injection compared with no injection when analysed over 12 months (-1·11 [-4·47 to 2·26]). No serious adverse events were reported. INTERPRETATION Progressive exercise was not superior to a best practice advice session with a physiotherapist in improving shoulder pain and function. Subacromial corticosteroid injection provided no long-term benefit in patients with rotator cuff disorders. FUNDING UK National Institute for Health Research Technology Assessment Programme.",2021,We found no evidence of a difference in SPADI score between progressive exercise and best practice advice when analysed over 12 months (adjusted mean difference -0·66,"['adults with a rotator cuff disorder', 'patients with rotator cuff disorders', '2287 patients', 'Between March 10, 2017, and May 2, 2019', 'patients with rotator cuff disorders (GRASP', 'patients aged 18 years or older with a rotator cuff disorder (new episode within the past 6 months', 'Patients were excluded if they had a history of significant shoulder trauma (eg, dislocation, fracture, or full-thickness tear requiring surgery', '2\u2009×\u20092 factorial), we recruited patients from 20 UK National Health Service trusts', '708 patients']","['progressive exercise', 'Subacromial corticosteroid injection', 'Corticosteroid injections and physiotherapy exercise programmes', 'practice advice (n=174), corticosteroid injection then progressive exercise (n=182), or corticosteroid injection then best practice advice', 'Progressive exercise compared with best practice advice, with or without corticosteroid injection', 'progressive exercise (≤6 sessions), best practice advice (one session), corticosteroid injection then progressive exercise, or corticosteroid injection', 'practice physiotherapy advice, with or without corticosteroid injection', 'corticosteroid injection or physiotherapy', 'progressive exercise programme']","['Shoulder Pain and Disability Index (SPADI) score', 'SPADI score between progressive exercise and best practice advice', 'clinical effectiveness and cost-effectiveness', 'shoulder pain and function', 'serious adverse events']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0085515', 'cui_str': 'Structure of rotator cuff including muscles and tendons'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0565959', 'cui_str': 'New episode'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0439809', 'cui_str': 'Full thickness'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0027462', 'cui_str': 'National Health Services'}, {'cui': 'C0237935', 'cui_str': 'Trust'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}]","[{'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",708.0,0.220873,We found no evidence of a difference in SPADI score between progressive exercise and best practice advice when analysed over 12 months (adjusted mean difference -0·66,"[{'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Hopewell', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Electronic address: sally.hopewell@csm.ox.ac.uk.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Keene', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Ioana R', 'Initials': 'IR', 'LastName': 'Marian', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Melina', 'Initials': 'M', 'LastName': 'Dritsaki', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Heine', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Cureton', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Dutton', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Dakin', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Carr', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Willie', 'Initials': 'W', 'LastName': 'Hamilton', 'Affiliation': 'College of Medicine and Health, University of Exeter, Exeter, UK.'}, {'ForeName': 'Zara', 'Initials': 'Z', 'LastName': 'Hansen', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Anju', 'Initials': 'A', 'LastName': 'Jaggi', 'Affiliation': 'Royal National Orthopaedic Hospital NHS Trust, Stanmore, Middlesex, UK.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Littlewood', 'Affiliation': 'Department of Health Professions, Manchester Metropolitan University, Manchester, UK.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Barker', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Alastair', 'Initials': 'A', 'LastName': 'Gray', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Lamb', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; College of Medicine and Health, University of Exeter, Exeter, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(21)00846-1'] 1600,34264700,Exploring the relations between interpersonal risk and adolescent suicidality during treatment.,"OBJECTIVE Despite considerable evidence that supports perceived burdensomeness (PB) and thwarted belongingness (TB) as risk factors for suicidal ideation (SI), far less is known about the direction of effects between these constructs in treatments for suicidal adolescents. The present study examined bidirectional relations between PB, TB, and adolescents' suicidal ideation (SI) during a 16-week randomized clinical trial. METHOD 129 depressed and suicidal adolescents completed PB, TB, and SI measures at three time points: baseline (T1), mid-treatment (T2), and treatment completion (T3). Random-intercept cross-lagged panel models (RI-CLPM) examined within-subject direction of effects between interpersonal variables (PB & TB) and suicidal ideation (SI) in the first and second halves of treatment. RESULTS Within-subjects, autoregressive paths indicated significant carryover in PB and SI. In the first half of treatment, a significant cross-lagged path indicated that T1 PB predicted change in T2 SI, and in the last half of treatment change in T2 SI predicted change in T3 PB. There were no significant auto-regressive or cross-lagged effects for TB. CONCLUSIONS In the first half of treatment, baseline PB predicted fewer reductions in SI suggesting that PB initially moderated adolescents' response to treatment. However, in the last half of treatment, initial reductions in SI predicted subsequent reductions in PB suggesting that adolescents' initial response to treatment decreased their perceptions of burdening others. The clinical and treatment implications of these bidirectional findings are discussed. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"In the first half of treatment, baseline PB predicted fewer reductions in SI suggesting that PB initially moderated adolescents' response to treatment.","['129 depressed and suicidal adolescents completed', 'suicidal adolescents']",[],"[""adolescents' suicidal ideation (SI"", 'interpersonal risk and adolescent suicidality', 'PB, TB, and SI measures', 'PB and SI', 'interpersonal variables (PB & TB) and suicidal ideation (SI', 'T1 PB predicted change in T2 SI']","[{'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0438696', 'cui_str': 'Suicidal'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",129.0,0.106443,"In the first half of treatment, baseline PB predicted fewer reductions in SI suggesting that PB initially moderated adolescents' response to treatment.","[{'ForeName': 'Caroline H', 'Initials': 'CH', 'LastName': 'Abbott', 'Affiliation': 'Department of Psychological and Brain Sciences.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Zisk', 'Affiliation': 'Department of Psychological and Brain Sciences.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Herres', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Guy S', 'Initials': 'GS', 'LastName': 'Diamond', 'Affiliation': 'Department of Counseling and Family Therapy.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Krauthamer Ewing', 'Affiliation': 'Department of Counseling and Family Therapy.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Kobak', 'Affiliation': 'Department of Psychological and Brain Sciences.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000656'] 1601,34244155,Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo.,"The inflammation-resolving and insulin-sensitizing properties of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids have potential to augment effects of weight loss on breast cancer risk. In a feasibility study, 46 peri/postmenopausal women at increased risk for breast cancer with a body mass index (BMI) of 28 kg/m 2 or greater were randomized to 3.25 g/day combined EPA and DHA (ω-3-FA) or placebo concomitantly with initiation of a weight-loss intervention. Forty-five women started the intervention. Study discontinuation for women randomized to ω-3-FA and initiating the weight-loss intervention was 9% at 6 months and thus satisfied our main endpoint, which was feasibility. Between baseline and 6 months significant change ( P < 0.05 ) was observed in 12 of 25 serum metabolic markers associated with breast cancer risk for women randomized to ω-3-FA, but only four for those randomized to placebo. Weight loss (median of 10% for trial initiators and 12% for the 42 completing 6 months) had a significant impact on biomarker modulation. Median loss was similar for placebo (-11%) and ω-3-FA (-13%). No significant change between ω-3-FA and placebo was observed for individual biomarkers, likely due to sample size and effect of weight loss. Women randomized to ω-3-FA exhibiting more than 10% weight loss at 6 months showed greatest biomarker improvement including 6- and 12-month serum adiponectin, insulin, omentin, and C-reactive protein (CRP), and 12-month tissue adiponectin. Given the importance of a favorable adipokine profile in countering the prooncogenic effects of obesity, further evaluation of high-dose ω-3-FA during a weight-loss intervention in obese high-risk women should be considered. PREVENTION RELEVANCE: This study examines biomarkers of response that may be modulated by omega-3 fatty acids when combined with a weight-loss intervention. While focused on obese, postmenopausal women at high risk for development of breast cancer, the findings are applicable to other cancers studied in clinical prevention trials.",2021,"Between baseline and 6 months significant change (P<0.05) was observed in 12 of 25 serum metabolic markers associated with breast cancer risk for women randomized to ω-3-FA, but only four for those randomized to placebo.","['45 women started the intervention', 'obese high-risk women', '46 peri or postmenopausal women at increased risk for breast cancer with a BMI of 28 kg/m2 or greater', 'Women Undergoing a Weight Loss Intervention Randomized to']","['EPA and DHA (ω-3-FA) or placebo', 'ω-3-FA', 'High Dose ω-3 Fatty Acids vs Placebo', 'eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids', 'ω-3-FA and placebo', 'placebo']","['weight loss', 'biomarker improvement including 6- and 12-month serum adiponectin, insulin, omentin and CRP, and 12-month tissue adiponectin', 'biomarker modulation', 'Median loss', 'Weight loss']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0968453', 'cui_str': 'ITLN1 protein, human'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",45.0,0.188118,"Between baseline and 6 months significant change (P<0.05) was observed in 12 of 25 serum metabolic markers associated with breast cancer risk for women randomized to ω-3-FA, but only four for those randomized to placebo.","[{'ForeName': 'Carol J', 'Initials': 'CJ', 'LastName': 'Fabian', 'Affiliation': 'Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas. cfabian@kumc.edu.'}, {'ForeName': 'Christie A', 'Initials': 'CA', 'LastName': 'Befort', 'Affiliation': 'Department of Population Health, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Teresa A', 'Initials': 'TA', 'LastName': 'Phillips', 'Affiliation': 'Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Nydegger', 'Affiliation': 'Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Amy L', 'Initials': 'AL', 'LastName': 'Kreutzjans', 'Affiliation': 'Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Kandy R', 'Initials': 'KR', 'LastName': 'Powers', 'Affiliation': 'Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Trina', 'Initials': 'T', 'LastName': 'Metheny', 'Affiliation': 'Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Jennifer R', 'Initials': 'JR', 'LastName': 'Klemp', 'Affiliation': 'Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Carlson', 'Affiliation': 'Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Debra K', 'Initials': 'DK', 'LastName': 'Sullivan', 'Affiliation': 'Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Carola M', 'Initials': 'CM', 'LastName': 'Zalles', 'Affiliation': 'Department of Pathology, Boca Raton Regional Hospital, Boca Raton, Florida.'}, {'ForeName': 'Erin D', 'Initials': 'ED', 'LastName': 'Giles', 'Affiliation': 'Department of Nutrition, Agriculture and Life Sciences, Texas A&M University, College Station, Texas.'}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Hursting', 'Affiliation': 'Department of Nutrition and Nutrition Research Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Jinxiang', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Bruce F', 'Initials': 'BF', 'LastName': 'Kimler', 'Affiliation': 'Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas.'}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-20-0656'] 1602,34246118,"Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial.","This Phase III, long-term, open-label extension (OLE) trial (EP0009; NCT01832038) was conducted to evaluate the long-term safety, tolerability, and efficacy of adjunctive lacosamide (100-400 mg/day) in Chinese and Japanese people with epilepsy (PWE) (16-70 years) who had completed a double-blind, randomized, placebo-controlled trial of adjunctive lacosamide (EP0008; NCT01710657). PWE entered the OLE trial on 200 mg/day lacosamide and up to 3 concomitant antiseizure medications. Dose adjustments were permitted to optimize tolerability and seizure reduction. Safety variables were treatment-emergent adverse events (TEAEs) and discontinuations due to TEAEs. Efficacy variables were percent change in focal seizure frequency per 28 days from Baseline of the double-blind trial, ≥50 % and ≥75 % responder rates, seizure-freedom, and proportion of PWE on lacosamide monotherapy. Overall, 473 PWE (74.0 % Chinese and 26.0 % Japanese) were enrolled; 238 (50.3 %) PWE completed the trial and 235 (49.7 %) discontinued, most commonly due to lack of efficacy (81 [17.1 %]), adverse events (55 [11.6 %]), and consent withdrawn (49 [10.4 %]). During the trial, PWE received lacosamide for a median of 1016.0 days (∼3 years), with a total exposure of 1454.8 person-years; 321 (67.9 %) PWE received lacosamide for >24 months, and 246 (52.0 %) for >36 months. The median modal dose of lacosamide was 300 mg/day. Overall, 410/473 (86.7 %) PWE reported TEAEs, 244 (51.6 %) had a TEAE that was considered drug-related, and 49 (10.4 %) discontinued due to a TEAE. The most common TEAEs (≥20 % of PWE) were nasopharyngitis, dizziness, and upper respiratory tract infection. The median reduction in focal seizure frequency per 28 days from Baseline was 57.1 %, and the ≥50 % and ≥75 % responder rates were 57.1 % (269/471) and 29.7 % (140/471), respectively. Among PWE who completed 12, 24, and 36 months of treatment, the 12-, 24-, and 36-month seizure-freedom rates were 3.5 % (13/375), 3.4 % (11/321), and 2.0 % (5/247), respectively. Among PWE exposed to lacosamide for ≥6 months and ≥12 months, the proportions of PWE that maintained continuous monotherapy for ≥6 months and ≥12 months were 5.0 % (21/421) and 5.0 % (19/378), respectively. Overall, lacosamide was well-tolerated as long-term adjunctive therapy in Chinese and Japanese PWE and uncontrolled focal seizures, with improvements in seizure reduction maintained over 36 months of treatment.",2021,"The median reduction in focal seizure frequency per 28 days from Baseline was 57.1 %, and the ≥50 % and ≥75 % responder rates were 57.1 % (269/471) and 29.7 % (140/471), respectively.","['Chinese and Japanese adults with epilepsy and focal seizures', 'Chinese and Japanese people with epilepsy (PWE) (16-70 years) who had completed a double-blind, randomized']","['placebo', 'adjunctive lacosamide', 'lacosamide']","['36-month seizure-freedom rates', 'adverse events', 'adverse events (TEAEs) and discontinuations due to TEAEs', 'tolerability and seizure reduction', 'focal seizure frequency', 'Safety and efficacy', 'seizure reduction', 'long-term safety, tolerability, and efficacy', 'nasopharyngitis, dizziness, and upper respiratory tract infection', 'median reduction in focal seizure frequency']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0893761', 'cui_str': 'lacosamide'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.463848,"The median reduction in focal seizure frequency per 28 days from Baseline was 57.1 %, and the ≥50 % and ≥75 % responder rates were 57.1 % (269/471) and 29.7 % (140/471), respectively.","[{'ForeName': 'Yushi', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'NHO Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Aoi-ku, Shizuoka, 420-8688, Japan. Electronic address: yshinoue@gmail.com.'}, {'ForeName': 'Weiping', 'Initials': 'W', 'LastName': 'Liao', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou Medical University, 250 Changgang East Road, Guangzhou, Guangdong, 510260, China. Electronic address: wpliao@163.net.'}, {'ForeName': 'Xuefeng', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'The First Affiliated Hospital of Chongqing Medical University, No.1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China. Electronic address: xfyp@163.com.'}, {'ForeName': 'Xinlu', 'Initials': 'X', 'LastName': 'Du', 'Affiliation': 'UCB Pharma, 14 Taikoo Wan Road, Taikoo, Hong Kong, China. Electronic address: Chinaduxinlu@163.com.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Tennigkeit', 'Affiliation': 'UCB Pharma, Alfred-Nobel-Straße 10, 40789, Monheim am Rhein, Germany. Electronic address: Frank.Tennigkeit@ucb.com.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Sasamoto', 'Affiliation': 'UCB Pharma, Shinjuku Grand Tower, 8-17-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan. Electronic address: Hiroshi.Sasamoto@ucb.com.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Osakabe', 'Affiliation': 'UCB Pharma, Shinjuku Grand Tower, 8-17-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan. Electronic address: Toru.Osakabe@ucb.com.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Hoshii', 'Affiliation': 'UCB Pharma, Shinjuku Grand Tower, 8-17-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan. Electronic address: Naoki.Hoshii@ucb.com.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Yuen', 'Affiliation': 'UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC, 27617, United States. Electronic address: Nancy.Yuen@ucb.com.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Hong', 'Affiliation': 'Huashan Hospital Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040, China. Electronic address: profzhong@sina.com.'}]",Epilepsy research,['10.1016/j.eplepsyres.2021.106705'] 1603,34245667,A randomized trial investigating clinical outcomes and stent-related symptoms after placement of a complete intra-ureteric stent on a string versus conventional stent placement.,"OBJECTIVE To compare stent-related symptoms (SRS) associated with conventional ureteric JJ stent (CUS) placement and SRS associated with placement of a modified complete intra-ureteric stent (CIUS) with extraction suture, designed to minimize SRS, using the validated Ureteral Stent Symptom Questionnaire (USSQ). MATERIALS AND METHODS We randomized 124 patients who had undergone uncomplicated ureteroscopic lithotripsy into a CIUS and a CUS placement group. USSQ scores were evaluated on postoperative days 1 and 7 (just before stent removal) and 4 weeks after stent removal (control values). Pain scores on a visual analogue scale (VAS) after stent removal were also recorded. Subdomain analysis of all SRS and stent-related complications were also compared. RESULTS No significant intergroup differences were found in the domain scores for urinary symptoms (P = 0.74), pain (P = 0.32), general health (P = 0.27), work (P = 0.24), or additional problems (P = 0.29). However, a statistically significant difference was noted in VAS scores (P = 0.015). Analysis of subdomains of USSQ item scores showed the CIUS group had significantly better scores for urge incontinence (1.21 vs 1.00; P ≤ 0.001), discomfort on voiding (2.07 vs 1.50; P ≤ 0.001), difficulties with respect to light physical activity (1.131 vs 1.00; P ≤ 0.001), fatigue (1.84 vs 1.57; P = 0.002), feeling comfortable (3.68 vs 3.16; P = 0.003), need for extra help (1.96 vs 1.00; P ≤ 0.001), and change in duration of work (4.27 vs 1.86; P ≤ 0.001). However, the patients in the CIUS group were sexually inactive for the time during which the stent was indwelling (mean: 7.34 days). There was no difference in complication rates between the two groups. CONCLUSION The use of a CIUS with strings after Ureteroscopy decreases SRS.",2021,"No significant intergroup differences were found in the domain scores of urinary symptoms (P = 0.74), pain (P = 0.32), general health (P = 0.27), work (P = 0.24), or additional problems (P = 0.29).",['We randomized 124 patients after uncomplicated'],"['ureteroscopic lithotripsy into complete intraureteral stent (CIUS) and conventional DJ stent (CUS) placement group', 'Intraureteral Stent on a String versus Conventional Stent Placement']","['domain scores of urinary symptoms', 'Pain scores', 'USSQ scores', 'feeling comfortable', 'urge incontinence', 'discomfort on voiding', 'visual analogue scale (VAS', 'pain', 'light physical activity', 'complication rate', 'fatigue', 'general health', 'VAS scores']","[{'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0023878', 'cui_str': 'Lithotripsy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0522776', 'cui_str': 'Placement of stent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443313', 'cui_str': 'Stringing'}]","[{'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0426359', 'cui_str': 'Urinary symptoms'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0183518', 'cui_str': 'Ureteric stent'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0150045', 'cui_str': 'Urge incontinence of urine'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",124.0,0.116236,"No significant intergroup differences were found in the domain scores of urinary symptoms (P = 0.74), pain (P = 0.32), general health (P = 0.27), work (P = 0.24), or additional problems (P = 0.29).","[{'ForeName': 'Milap', 'Initials': 'M', 'LastName': 'Shah', 'Affiliation': 'Department of Urology and Renal Transplant, Kasturba Medical College, MAHE, Manipal, Karnataka, India.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Pillai', 'Affiliation': 'Department of Urology and Renal Transplant, Kasturba Medical College, MAHE, Manipal, Karnataka, India.'}, {'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Chawla', 'Affiliation': 'Department of Urology and Renal Transplant, Kasturba Medical College, MAHE, Manipal, Karnataka, India.'}, {'ForeName': 'Jean J M C H', 'Initials': 'JJMCH', 'LastName': 'de la Rosette', 'Affiliation': 'Istanbul Medipol Mega University Hospital, Istanbul, Turkey.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Laguna', 'Affiliation': 'Istanbul Medipol Mega University Hospital, Istanbul, Turkey.'}, {'ForeName': 'Suraj', 'Initials': 'S', 'LastName': 'Jayadeva Reddy', 'Affiliation': 'Department of Urology and Renal Transplant, Kasturba Medical College, MAHE, Manipal, Karnataka, India.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Taori', 'Affiliation': 'Department of Urology and Renal Transplant, Kasturba Medical College, MAHE, Manipal, Karnataka, India.'}, {'ForeName': 'Padmaraj', 'Initials': 'P', 'LastName': 'Hegde', 'Affiliation': 'Department of Urology and Renal Transplant, Kasturba Medical College, MAHE, Manipal, Karnataka, India.'}, {'ForeName': 'Sitaram', 'Initials': 'S', 'LastName': 'Mummalaneni', 'Affiliation': 'Department of Urology and Renal Transplant, Kasturba Medical College, MAHE, Manipal, Karnataka, India.'}]",BJU international,['10.1111/bju.15540'] 1604,34245666,"Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia.","OBJECTIVES To assess the contraceptive efficacy, bleeding pattern and safety of a combined oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. DESIGN Multicenter, open-label, phase 3 trial. SETTING Sixty-nine sites in Europe and Russia. POPULATION Sexually active women aged 18-50 years with regular menstrual cycles and body mass index ≤35 kg/m 2 . METHODS E4/DRSP was administered in a 24 active/4 placebo regimen for up to 13 cycles. Visits were scheduled during Cycles 2, 4, 7 and 10 and after completing treatment during which adverse events (AEs) were collected. Participants recorded medication intake, vaginal bleeding/spotting, use of other contraceptive methods and sexual intercourse on a daily diary. MAIN OUTCOME MEASURES Pearl Index (PI) for women 18-35 years (overall and method-failure), bleeding pattern and AEs. RESULTS A total of 1553 women aged 18-50 years, including 1353 from 18 to 35 years old, received the study medication. PI was 0.47 pregnancies/100 woman-years (95% CI 0.15-1.11); method failure PI was 0.29 pregnancies/100 woman-years (95% CI 0.06-0.83). Scheduled bleeding/spotting occurred in 91.9-94.4% of women over Cycles 1 to 12 and lasted a median of 4-5 days per cycle. The percentage of women with unscheduled bleeding/spotting episodes decreased from 23.5% in Cycle 1 to <16% from Cycle 6 onwards. The most common AEs were headache (7.7%), metrorrhagia (5.5%), vaginal haemorrhage (4.8%) and acne (4.2%). One treatment-related serious AE was reported, a lower extremity venous thromboembolism. One-hundred and forty-one (9.1%) women discontinued study participation because of treatment-related adverse events. CONCLUSION E4/DRSP provides effective contraception, a predictable bleeding pattern and a favourable safety profile. TWEETABLE ABSTRACT A phase 3 trial with E4/DRSP shows high contraceptive efficacy, a predictable bleeding pattern and favourable safety profile.",2021,"The most common AEs were headache (7.7%), metrorrhagia (5.5%), vaginal haemorrhage (4.8%) and acne (4.2%).","['One-hundred forty-one (9.1', 'Europe and Russia', 'Sexually active women aged 18-50 years with regular menstrual cycles and body mass index ≤35 kg/m 2 ', 'Sixty-nine sites in Europe and Russia', '1,553 women aged 18-50 years, including 1,353 from 18-35 years old, received study medication']","['Estetrol-Drospirenone combination oral contraceptive', 'combined oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP', 'placebo', 'E4/DRSP']","['contraceptive efficacy, bleeding pattern, and safety', 'extremity venous thromboembolism', 'percentage of women with unscheduled bleeding/spotting episodes', 'medication intake, vaginal bleeding/spotting, use of other contraceptive methods, and sexual intercourse on a daily diary', 'Pearl Index (PI) for women 18-35 years (overall and method-failure), bleeding pattern, and adverse events', 'metrorrhagia', 'headache', 'vaginal haemorrhage', 'Scheduled bleeding/spotting']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0035970', 'cui_str': 'Russian federation - Europe'}, {'cui': 'C0241028', 'cui_str': 'Sexually active'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0025329', 'cui_str': 'Normal menstrual cycle'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0014899', 'cui_str': '15 alpha-Hydroxyestriol'}, {'cui': 'C0043822', 'cui_str': 'drospirenone'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0009906', 'cui_str': 'Oral Contraceptives, Combined'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009871', 'cui_str': 'Contraceptive agent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3854240', 'cui_str': 'Unscheduled'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C2979982', 'cui_str': 'Vaginal bleeding'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0700589', 'cui_str': 'Contraception'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0025874', 'cui_str': 'Intermenstrual bleeding - irregular'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]",1553.0,0.156861,"The most common AEs were headache (7.7%), metrorrhagia (5.5%), vaginal haemorrhage (4.8%) and acne (4.2%).","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Gemzell-Danielsson', 'Affiliation': ""Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Apter', 'Affiliation': 'VL-Medi Clinical Research Centre, Helsinki, Finland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Zatik', 'Affiliation': 'Gynaecological Praxis St Anna, Debrecen, Hungary.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Weyers', 'Affiliation': 'Department of Obstetrics and Gynaecology, University Hospital, Gent, Belgium.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Piltonen', 'Affiliation': 'Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Suturina', 'Affiliation': 'Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Apolikhina', 'Affiliation': 'Kulakov National Medical Research Centre for Obstetrics, Gynaecology, and Perinatology, Moscow, Russia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Jost', 'Affiliation': 'Estetra SRL, an affiliate Company of Mithra Pharmaceuticals, Liège, Belgium.'}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Creinin', 'Affiliation': 'Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, USA.'}, {'ForeName': 'J-M', 'Initials': 'JM', 'LastName': 'Foidart', 'Affiliation': 'Estetra SRL, an affiliate Company of Mithra Pharmaceuticals, Liège, Belgium.'}]",BJOG : an international journal of obstetrics and gynaecology,['10.1111/1471-0528.16840'] 1605,34247259,Authors' Reply: Yoga-An Alternative form of Therapy in Patients with Blunt Chest Trauma: A Randomized Controlled Trial.,,2021,,['Patients with Blunt Chest Trauma'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C0039980', 'cui_str': 'Chest injury'}]",[],[],,0.103156,,"[{'ForeName': 'Mallikarjun', 'Initials': 'M', 'LastName': 'Gunjiganvi', 'Affiliation': 'Specialty of Trauma Surgery, Apex Trauma Center, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.'}, {'ForeName': 'Subodh', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Division of Trauma Surgery and Critical Care, JPN Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India. subodh6@gmail.com.'}]",World journal of surgery,['10.1007/s00268-021-06237-7'] 1606,34247040,The effect of moderate wine consumption on cytokine secretion by peripheral blood mononuclear cells: A randomized clinical study in coronary heart disease patients.,"Many studies conclude that wine consumption is related to lower risk for cardiovascular diseases partially through the amelioration of inflammatory biomarkers. The aim of the present study was to examine the effects of wine consumption on the inflammatory response and to compare these effects with the consumption of similar amount of alcohol without the wine micro-constituents in cardiovascular disease patients. Therefore, a randomized, single-blind, controlled, three-arm parallel intervention study was designed. Cardiovascular disease patients were randomly assigned to one of the three groups. In Group A participants consumed no alcohol, in Group B (ethanol group) and Group C (wine group) participants consumed 27 g of alcohol per day. Biological samples were collected at the beginning, on the 4th and 8th week and several biomarkers were measured. Peripheral blood mononuclear cells that were isolated from patients were incubated under basal and inflammatory conditions for 4 and 24 h and the secretion of interleukin 1β (IL-1β) and tumor necrosis factor α (TNFα) was measured. No significant difference was observed among the three groups before the initiation or during the intervention in the most soluble biomarkers. Higher TNFα secretion by peripheral blood mononuclear cells was observed at basal conditions in the ethanol group both at 4 and 24 h of incubation versus baseline secretion. Furthermore, lower secretion of the ΤNFα was observed after 8 weeks of intake in the wine group versus the ethanol group, both at 4 and 24 h of incubation. In conclusion, the light to moderate wine consumption for 8 weeks revealed an attenuation of the ethanol consumption effect on cytokine secretion at basal conditions from the patients' peripheral blood mononuclear cells.",2021,"Furthermore, lower secretion of the ΤNFα was observed after 8 weeks of intake in the wine group versus the ethanol group, both at 4 and 24 h of incubation.","['Cardiovascular disease patients', 'cardiovascular disease patients', 'coronary heart disease patients']","['no alcohol, in Group B (ethanol group) and Group C (wine group) participants consumed 27\xa0g of alcohol per day', 'wine consumption', 'moderate wine consumption', 'alcohol without the wine micro-constituents']","['secretion of interleukin 1β (IL-1β) and tumor necrosis factor α (TNFα', 'cytokine secretion', 'Higher TNFα secretion by peripheral blood mononuclear cells', 'lower secretion of the ΤNFα', 'Peripheral blood mononuclear cells']","[{'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0043188', 'cui_str': 'Wine'}, {'cui': 'C0456640', 'cui_str': '27G'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0729650', 'cui_str': 'Constituents'}]","[{'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",,0.0310002,"Furthermore, lower secretion of the ΤNFα was observed after 8 weeks of intake in the wine group versus the ethanol group, both at 4 and 24 h of incubation.","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Fragopoulou', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, 70 Eleftheriou Venizelou Avenue Kallithea, 17671 Athens, Greece. Electronic address: efragop@hua.gr.'}, {'ForeName': 'Chrysa', 'Initials': 'C', 'LastName': 'Argyrou', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, 70 Eleftheriou Venizelou Avenue Kallithea, 17671 Athens, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Detopoulou', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, 70 Eleftheriou Venizelou Avenue Kallithea, 17671 Athens, Greece.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Tsitsou', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, 70 Eleftheriou Venizelou Avenue Kallithea, 17671 Athens, Greece.'}, {'ForeName': 'Sotiria', 'Initials': 'S', 'LastName': 'Seremeti', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, 70 Eleftheriou Venizelou Avenue Kallithea, 17671 Athens, Greece.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Yannakoulia', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, 70 Eleftheriou Venizelou Avenue Kallithea, 17671 Athens, Greece.'}, {'ForeName': 'Smaragdi', 'Initials': 'S', 'LastName': 'Antonopoulou', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, 70 Eleftheriou Venizelou Avenue Kallithea, 17671 Athens, Greece.'}, {'ForeName': 'Genovefa', 'Initials': 'G', 'LastName': 'Kolovou', 'Affiliation': 'Cardiology Department, Onassis Cardiac Surgery Center, Athens. Greece.'}, {'ForeName': 'Petros', 'Initials': 'P', 'LastName': 'Kalogeropoulos', 'Affiliation': 'Department of Cardiology, General Ongology Hospital, Kifisias Greece.'}]",Cytokine,['10.1016/j.cyto.2021.155629'] 1607,34246974,Machine learning-based diagnosis support system for differentiating between clinical anxiety and depression disorders.,"In light of the need for objective mechanism-based diagnostic tools, the current research describes a novel diagnostic support system aimed to differentiate between anxiety and depression disorders in a clinical sample. Eighty-six psychiatric patients with clinical anxiety and/or depression were recruited from a public hospital and assigned to one of the experimental groups: Depression, Anxiety, or Mixed. The control group included 25 participants with no psychiatric diagnosis. Participants performed a battery of six cognitive-behavioral tasks assessing biases of attention, expectancies, memory, interpretation and executive functions. Data were analyzed with a machine-learning (ML) random forest-based algorithm and cross-validation techniques. The model assigned participants to clinical groups based solely on their aggregated cognitive performance. By detecting each group's unique performance pattern and the specific measures contributing to the prediction, the ML algorithm predicted diagnosis classification in two models: (I) anxiety/depression/mixed vs. control (76.81% specificity, 69.66% sensitivity), and (II) anxiety group vs. depression group (80.50% and 66.46% success rates in classifying anxiety and depression, respectively). The findings demonstrate that the cognitive battery can be utilized as a support system for psychiatric diagnosis alongside the clinical interview. This implicit tool, which is not based on self-report, is expected to enable the clinician to achieve increased diagnostic specificity and precision. Further, this tool may increase the confidence of both clinician and patient in the diagnosis by equipping them with an objective assessment tool. Finally, the battery provides a profile of biased cognitions that characterizes the patient, which in turn enables more fine-tuned, individually-tailored therapy.",2021,"Participants performed a battery of six cognitive-behavioral tasks assessing biases of attention, expectancies, memory, interpretation and executive functions.","['Eighty-six psychiatric patients with clinical anxiety and/or depression were recruited from a public hospital and assigned to one of the experimental groups: Depression, Anxiety, or Mixed', '25 participants with no psychiatric diagnosis']",['Machine learning-based diagnosis support system'],"['six cognitive-behavioral tasks assessing biases of attention, expectancies, memory, interpretation and executive functions']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0748064', 'cui_str': 'Psychiatric in-patient'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0020022', 'cui_str': 'Public Hospitals'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0376338', 'cui_str': 'Psychiatric Diagnosis'}]","[{'cui': 'C0376284', 'cui_str': 'Machine Learning'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0748877', 'cui_str': 'Social Support System'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0459471', 'cui_str': 'Interpretation'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",86.0,0.0518868,"Participants performed a battery of six cognitive-behavioral tasks assessing biases of attention, expectancies, memory, interpretation and executive functions.","[{'ForeName': 'Thalia', 'Initials': 'T', 'LastName': 'Richter', 'Affiliation': 'Department of Psychology, School of Psychological Sciences, University of Haifa, Mount Carmel Haifa, Israel. Electronic address: thalia.richter173@gmail.com.'}, {'ForeName': 'Barak', 'Initials': 'B', 'LastName': 'Fishbain', 'Affiliation': 'Faculty of Civil and Environmental Engineering, Technion - Israel Institute of Technology, Haifa, Israel.'}, {'ForeName': 'Eyal', 'Initials': 'E', 'LastName': 'Fruchter', 'Affiliation': 'Brus Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.'}, {'ForeName': 'Gal', 'Initials': 'G', 'LastName': 'Richter-Levin', 'Affiliation': 'Department of Psychology, School of Psychological Sciences, University of Haifa, Mount Carmel Haifa, Israel.'}, {'ForeName': 'Hadas', 'Initials': 'H', 'LastName': 'Okon-Singer', 'Affiliation': 'Department of Psychology, School of Psychological Sciences, University of Haifa, Mount Carmel Haifa, Israel.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2021.06.044'] 1608,34246917,Does alcohol affect emotional face processing via interoceptive pathways?,"BACKGROUND Our brain uses interoceptive signals from the body to shape how we perceive emotions in others; however, whether interoceptive signals can be manipulated to alter emotional perceptions is unknown. Alcohol has acute effects both on emotional processing and on the physiological substrates supporting interoception. In this registered report, we examine whether alcohol administration triggers physiological changes that alter interoceptive signals and manipulate emotional face processing. Such knowledge will broaden understanding of the mechanisms by which alcohol affects emotional face processing. METHODS Participants (n = 36) will be administered an alcohol or placebo beverage. Cardiovascular physiology will be recorded before and after administration. Participants will complete two behavioral tasks in which they view emotional faces presented in synchrony with different phases of the cardiac cycle (i.e., systole, diastole). This manipulation creates an index of how interoceptive signals amplify emotional face processing. HYPOTHESES We hypothesize that, compared to placebo, alcohol administration will disrupt the cardiac amplification of emotional face processing. We further explore whether this disruption depends on the nature and magnitude of changes in cardiovascular physiology after alcohol administration.",2021,"In this registered report, we examine whether alcohol administration triggers physiological changes that alter interoceptive signals and manipulate emotional face processing.",['Participants (n\u2009=\u200936'],"['alcohol or placebo beverage', 'alcohol', 'placebo, alcohol administration']",['Cardiovascular physiology'],[],"[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0007227', 'cui_str': 'Cardiovascular function'}]",36.0,0.136488,"In this registered report, we examine whether alcohol administration triggers physiological changes that alter interoceptive signals and manipulate emotional face processing.","[{'ForeName': 'Mateo', 'Initials': 'M', 'LastName': 'Leganes-Fonteneau', 'Affiliation': 'Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ, USA; Cardiac Neuroscience Laboratory, Center of Alcohol and Substance Use Studies, Rutgers University, New Brunswick, NJ, USA. Electronic address: mateo.leganes@rutgers.edu.'}, {'ForeName': 'Marsha E', 'Initials': 'ME', 'LastName': 'Bates', 'Affiliation': 'Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ, USA; Cardiac Neuroscience Laboratory, Center of Alcohol and Substance Use Studies, Rutgers University, New Brunswick, NJ, USA. Electronic address: mebates@smithers.rutgers.edu.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Pawlak', 'Affiliation': 'Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ, USA; Cardiac Neuroscience Laboratory, Center of Alcohol and Substance Use Studies, Rutgers University, New Brunswick, NJ, USA.'}, {'ForeName': 'Jennifer F', 'Initials': 'JF', 'LastName': 'Buckman', 'Affiliation': 'Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ, USA; Cardiac Neuroscience Laboratory, Center of Alcohol and Substance Use Studies, Rutgers University, New Brunswick, NJ, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2021.108845'] 1609,34251414,Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).,"Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. In this phase 3 trial, untreated older AML patients were randomized to cytarabine (100 mg/m2 per day on days 4-10) and daunorubicin (60 mg/m2 per day on days 4-6) followed by cytarabine consolidation (2000 mg/m2 per day on days 4-8) with (arm A) or without (arm B) G3139 (7 mg/m2 per day on days 1-10 [induction] or days 1-8 [consolidation]). A total of 506 patients were enrolled. No differences in toxicity were observed between arms. Estimated overall survival (OS) at 1 year was 43% for arm A and 40% for arm B (1-sided log rank P = .13), with no differences in disease-free (DFS; P = .26) or event-free survival (P = .80). Subgroup analyses showed patients age <70 years in arm A had improved OS by 1 month vs those in arm B (P = .04), and patients with secondary AML in arm A had better DFS vs those in arm B (P = .04). We conclude that addition of G3139 to chemotherapy failed to improve outcomes of older AML patients. However, more effective means of inhibiting BCL2 are showing promising results in combination with chemotherapy in AML. This trial was registered at www.clinicaltrials.gov as #NCT00085124.",2021,Estimated overall survival (OS) at 1 year was 43% for arm A and 40% for arm B (1-sided log rank P =,"['untreated older AML patients', 'older AML patients', '506 patients were enrolled']","['cytarabine consolidation', 'cytarabine', 'daunorubicin', 'G3139, cytarabine, and daunorubicin induction with cytarabine', 'chemotherapy']","['disease-free (DFS; P = .26) or event-free survival', 'toxicity', 'OS', 'Estimated overall survival (OS', 'BCL2 downregulation']","[{'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0521530', 'cui_str': 'Lung consolidation'}, {'cui': 'C0011015', 'cui_str': 'Daunorubicin'}, {'cui': 'C1144384', 'cui_str': 'G-3139 oligonucleotide'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0023434', 'cui_str': 'Chronic lymphocytic leukemia'}, {'cui': 'C0024299', 'cui_str': 'Malignant lymphoma'}, {'cui': 'C0013081', 'cui_str': 'Down-regulation'}]",506.0,0.0657658,Estimated overall survival (OS) at 1 year was 43% for arm A and 40% for arm B (1-sided log rank P =,"[{'ForeName': 'Alison R', 'Initials': 'AR', 'LastName': 'Walker', 'Affiliation': 'Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Marcucci', 'Affiliation': 'Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Yin', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Blum', 'Affiliation': 'Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Stock', 'Affiliation': 'University of Chicago Comprehensive Cancer Center, Chicago, IL.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Kohlschmidt', 'Affiliation': 'Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH.'}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Mrózek', 'Affiliation': 'Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Carroll', 'Affiliation': 'Department of Genetics, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Ann-Kathrin', 'Initials': 'AK', 'LastName': 'Eisfeld', 'Affiliation': 'Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Eunice S', 'Initials': 'ES', 'LastName': 'Wang', 'Affiliation': 'Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.'}, {'ForeName': 'Sawyer', 'Initials': 'S', 'LastName': 'Jacobson', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Jonathan E', 'Initials': 'JE', 'LastName': 'Kolitz', 'Affiliation': 'Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY.'}, {'ForeName': 'Mohan', 'Initials': 'M', 'LastName': 'Thakuri', 'Affiliation': 'Southeast Clinical Oncology Research Consortium, National Cancer Institute Community Oncology Research Program, Cancer Care of Western North Carolina, Asheville, NC.'}, {'ForeName': 'Grerk', 'Initials': 'G', 'LastName': 'Sutamtewagul', 'Affiliation': 'Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Vij', 'Affiliation': 'Division of Hematology and Oncology, Washington University School of Medicine, St Louis, MO.'}, {'ForeName': 'Robert K', 'Initials': 'RK', 'LastName': 'Stuart', 'Affiliation': 'Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; and.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Byrd', 'Affiliation': 'Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Clara D', 'Initials': 'CD', 'LastName': 'Bloomfield', 'Affiliation': 'Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Stone', 'Affiliation': 'Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Larson', 'Affiliation': 'University of Chicago Comprehensive Cancer Center, Chicago, IL.'}]",Blood advances,['10.1182/bloodadvances.2021004233'] 1610,34252783,Adolescent depressed mood and difficulties with emotion regulation: Concurrent trajectories of change.,"INTRODUCTION Adolescent depression is a significant mental health concern. Emotion regulation difficulties have been associated with subsequent depressive symptoms, though different facets of emotion regulation are rarely compared. This study examined the degree to which trajectories of change in different facets of emotion regulation (goal-directed behavior, impulse control, and regulation strategies) and depressive symptoms were associated across twelve months in a clinical adolescent sample. METHODS Participants included 110 adolescents from the US who were enrolled in a randomized trial that tested a cognitive-behavioral treatment for youth with co-occurring mental health and substance use concerns (M age  = 15.71 years; 57.3% male). Assessments were conducted at baseline, 3-, 6-, and 12-month follow-ups. Three separate bivariate latent basis growth curve analyses were conducted. Correlations between latent intercepts and latent slopes, as well as overall model fit, were examined. RESULTS Impulse control and goal-directed behavior were each associated with depressive symptoms at baseline. Additionally, change in impulse control over time was significantly associated with change in depressive symptoms. However, the same was not true for goal-directed behavior. Overall fit indices for models of emotion regulation strategies were below acceptable levels and thus could not be interpreted. CONCLUSIONS Findings from the present study indicate that adolescents' depressive symptoms appear to improve as their perceived ability to control impulses improves. These results suggest that addressing impulse control difficulties may be an important step in treating adolescent depression and co-occurring disorders.",2021,"Overall fit indices for models of emotion regulation strategies were below acceptable levels and thus could not be interpreted. ","['Participants included 110 adolescents from the US who were enrolled', ""adolescents' depressive symptoms"", 'for youth with co-occurring mental health and substance use concerns (M age \xa0=\xa015.71 years; 57.3% male']",['cognitive-behavioral treatment'],['depressive symptoms'],"[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",110.0,0.102831,"Overall fit indices for models of emotion regulation strategies were below acceptable levels and thus could not be interpreted. ","[{'ForeName': 'Annamarie B', 'Initials': 'AB', 'LastName': 'Defayette', 'Affiliation': 'Department of Psychology, George Mason University, 4400 University Drive, 3F5, Fairfax, VA, USA, 22030. Electronic address: abaile25@gmu.edu.'}, {'ForeName': 'Emma D', 'Initials': 'ED', 'LastName': 'Whitmyre', 'Affiliation': 'Department of Psychology, George Mason University, 4400 University Drive, 3F5, Fairfax, VA, USA, 22030.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'López', 'Affiliation': 'Department of Psychology, George Mason University, 4400 University Drive, 3F5, Fairfax, VA, USA, 22030.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Brown', 'Affiliation': 'Department of Psychology, University of South Florida, 4202 E. Fowler Avenue, PCD 4118G, Tampa, FL, USA, 33620.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Wolff', 'Affiliation': 'Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Box G-BH, 700 Butler Drive, Providence, RI, USA, 02906.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Spirito', 'Affiliation': 'Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Box G-BH, 700 Butler Drive, Providence, RI, USA, 02906.'}, {'ForeName': 'Christianne', 'Initials': 'C', 'LastName': 'Esposito-Smythers', 'Affiliation': 'Department of Psychology, George Mason University, 4400 University Drive, 3F5, Fairfax, VA, USA, 22030.'}]",Journal of adolescence,['10.1016/j.adolescence.2021.07.001'] 1611,34251886,The T-Tilt Position: A Novel Modified Patient Position to Improve Stone-free Rates in Retrograde Intrarenal Surgery.,"PURPOSE Residual fragments following retrograde intrarenal surgery can lead to future stone episodes. The lower pole of the kidney presents a unique challenge as it is the most difficult location for retrograde intrarenal surgery. We investigated a modified patient position to increase stone-free rate by analyzing presence of residual fragments. We randomized patients into standard position and the T-Tilt position (15˚ Trendelenburg and 15˚ airplane away from the surgical side kidney). MATERIALS AND METHODS In this prospective, randomized study, patients were randomized into the standard or T-Tilt position. Demographics, comorbidities and operative parameters were collected. Stone-free rate was determined with renal ultrasound and x-ray at 1-month followup. Postoperative complications were recorded up to 1 month. Variables were compared using Kruskal-Wallis test for continuous variables and chi-square test for categorical variables. RESULTS A total of 138 patients were analyzed: 75 standard patients and 63 T-Tilt patients. The groups had similar patient and stone factors. The most common stone position was the lower pole (68.0% standard, 74.6% T-Tilt). Stone-free rates were significantly different: standard position was 76.7% and T-Tilt position was 92.1% (p=0.015). Stone-free rates for isolated lower pole stones were significantly different as well: standard position was 68.2% vs T-Tilt position was 95.6% (p <0.001). Clavien-Dindo scores did not differ significantly (p=0.262). CONCLUSIONS The T-Tilt patient position was associated with higher stone-free rates. It is an atraumatic, cost-effective technique. These results suggest that modifying patient positioning during retrograde intrarenal surgery improves stone-free rates.",2021,Stone-free rates for isolated lower pole stones were significantly different as well: standard position was 68.2% vs. T-Tilt position was 95.6% (p <0.001).,['138 patients were analyzed: 75 standard patients and 63 T-Tilt patients'],['standard position and the T-Tilt position (15˚ Trendelenburg and 15˚ airplane away from the surgical side kidney'],"['Clavien-Dindo scores', 'Stone-free rate', 'Postoperative complications', 'stone-free rates', 'Stone-free rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0683901', 'cui_str': 'Airplanes'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}]",138.0,0.0560429,Stone-free rates for isolated lower pole stones were significantly different as well: standard position was 68.2% vs. T-Tilt position was 95.6% (p <0.001).,"[{'ForeName': 'Christine W', 'Initials': 'CW', 'LastName': 'Liaw', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Johnathan A', 'Initials': 'JA', 'LastName': 'Khusid', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Blair', 'Initials': 'B', 'LastName': 'Gallante', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jake N', 'Initials': 'JN', 'LastName': 'Bamberger', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'William M', 'Initials': 'WM', 'LastName': 'Atallah', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Mantu', 'Initials': 'M', 'LastName': 'Gupta', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}]",The Journal of urology,['10.1097/JU.0000000000001948'] 1612,34251882,"Early Weightbearing Versus Nonweightbearing After Operative Treatment of an Ankle Fracture: A Multicenter, Noninferiority, Randomized Controlled Trial.","BACKGROUND Acute ankle fractures can occur during sports activities, and unstable ankle fractures are commonly treated operatively. However, controversy exists about the optimal time to allow weightbearing. HYPOTHESIS Early weightbearing after the stable fixation of an ankle fracture is not inferior to nonweightbearing in terms of ankle function assessed at 12 months after injury. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS A total of 258 patients were assessed for eligibility. Of these patients, 194 were randomly allocated to either the early weightbearing group (95 patients who were allowed weightbearing at 2 weeks postoperatively) or the nonweightbearing group (99 patients who were not allowed weightbearing until 6 weeks postoperatively). The primary outcome measure was the mean difference in the Olerud-Molander ankle score (OMAS) between the groups, assessed at the 12-month follow-up examination. The secondary outcome measures were the time to return to preinjury activities and patients' subjective satisfaction. Complications such as hardware loosening or failure, fracture displacement, and nonunion were evaluated. RESULTS The mean difference in the OMAS for the early weightbearing group compared with the nonweightbearing group was 1.6 (95% CI, -1.9 to 5.0) in the intention-to-treat analysis. The lower limit of the 95% CI (-1.9) exceeded the noninferiority margin of -8, indicating that early weightbearing was not inferior to nonweightbearing. The difference in the proportion of patients who were satisfied or very satisfied with their treatment was not statistically significant (84.3% vs 76.2%; P = .19); however, the time taken to return to preinjury activities was shorter with early weightbearing than with nonweightbearing (9.1 ± 3.0 vs 11.0 ± 3.0 weeks; P < .001). No cases of nonunion were observed in either group. CONCLUSION Early weightbearing after the operative treatment of an unstable ankle fracture was not inferior to nonweightbearing in terms of OMAS assessed at 12 months after injury. The patients' subjective satisfaction was similar between the groups, although the time taken to return to preinjury activities was shorter in the early weightbearing group. REGISTRATION NCT02029170 (ClinicalTrials.gov identifier).",2021,"No cases of nonunion were observed in either group. ",['A total of 258 patients were assessed for eligibility'],['Early Weightbearing Versus Nonweightbearing'],"['time taken to return to preinjury activities', 'mean difference in the Olerud-Molander ankle score (OMAS', 'OMAS', 'subjective satisfaction', ""time to return to preinjury activities and patients' subjective satisfaction"", 'nonunion', 'hardware loosening or failure, fracture displacement, and nonunion']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0333050', 'cui_str': 'Loosening'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0585059', 'cui_str': 'Fracture with displacement'}]",258.0,0.191323,"No cases of nonunion were observed in either group. ","[{'ForeName': 'Jae Yong', 'Initials': 'JY', 'LastName': 'Park', 'Affiliation': 'Department of Orthopedic Surgery, Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang-si, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Bom Soo', 'Initials': 'BS', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, Inha University Hospital, Incheon, Republic of Korea.'}, {'ForeName': 'Yu Mi', 'Initials': 'YM', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, Sanbon Hospital, Wonkwang University College of Medicine, Gunpo-si, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Jae Ho', 'Initials': 'JH', 'LastName': 'Cho', 'Affiliation': 'Department of Orthopedic Surgery, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon-si, Gangwon-do, Republic of Korea.'}, {'ForeName': 'Young Rak', 'Initials': 'YR', 'LastName': 'Choi', 'Affiliation': 'Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hyong Nyun', 'Initials': 'HN', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.'}]",The American journal of sports medicine,['10.1177/03635465211026960'] 1613,34251865,Randomized controlled trial of technology-assisted case management in low-income adults with type 2 diabetes: Effect on quality of life and blood pressure.,"INTRODUCTION A novel randomized controlled trial tested the efficacy of a technology-assisted case management program in a low income, rural population previously where nurses titrated medication over the phone instead of in a clinic. The primary analysis showed significant improvement in glycemic control at 6 months post-randomization decreasing hemoglobin A1c by 1%. This study aimed to test if the intervention was also effective at decreasing blood pressure without compromising quality of life. METHODS A total of 113 adults with poorly controlled diabetes (hemoglobin A1c ≥ 8%) were randomly assigned to the technology-assisted case management intervention or usual care. Participants received a 2-in-1 telehealth system to monitor glycemic and blood pressure control, which was uploaded daily to a central server. A nurse case manager was trained to titrate medication under physician supervision every 2 weeks based on the readings. Outcomes were blood pressure and quality of life (12-item Short-Form Health Survey) at 6 months. Baseline adjusted mixed models using a random intercept were used to evaluate change at 6 months for the technology-assisted case management intervention group compared to usual care. RESULTS There were no statistically significant differences in systolic blood pressure, physical component of quality of life, or mental component of quality of life between the technology-assisted case management and control group. However, there was a significant change in diastolic blood pressure over time, with the technology-assisted case management group decreasing at 6 months ( p  = .05), whereas the control group remained stable. CONCLUSIONS Technology-assisted case management by a nurse with medication titration under physician supervision was efficacious in improving diastolic blood pressure without compromising quality of life in low-income rural adults with diabetes.",2021,"There were no statistically significant differences in systolic blood pressure, physical component of quality of life, or mental component of quality of life between the technology-assisted case management and control group.","['low-income rural adults with diabetes', '113 adults with poorly controlled diabetes (hemoglobin A1c\u2009≥\u20098', 'low-income adults with type 2 diabetes']","['technology-assisted case management program', 'technology-assisted case management intervention group compared to usual care', 'technology-assisted case management intervention or usual care', 'technology-assisted case management', '2-in-1 telehealth system to monitor glycemic and blood pressure control, which was uploaded daily to a central server']","['hemoglobin A1c', 'diastolic blood pressure', 'glycemic control', 'systolic blood pressure, physical component of quality of life, or mental component of quality of life', 'blood pressure and quality of life (12-item Short-Form Health Survey', 'quality of life and blood pressure', 'blood pressure without compromising quality of life']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0085971', 'cui_str': 'Case management'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1705194', 'cui_str': 'Computer network server'}]","[{'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}]",113.0,0.0200352,"There were no statistically significant differences in systolic blood pressure, physical component of quality of life, or mental component of quality of life between the technology-assisted case management and control group.","[{'ForeName': 'Leonard E', 'Initials': 'LE', 'LastName': 'Egede', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine, 5506Medical College of Wisconsin, USA.'}, {'ForeName': 'Aprill Z', 'Initials': 'AZ', 'LastName': 'Dawson', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine, 5506Medical College of Wisconsin, USA.'}, {'ForeName': 'Rebekah J', 'Initials': 'RJ', 'LastName': 'Walker', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine, 5506Medical College of Wisconsin, USA.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Garraci', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine, 5506Medical College of Wisconsin, USA.'}, {'ForeName': 'Rebecca G', 'Initials': 'RG', 'LastName': 'Knapp', 'Affiliation': 'Department of Public Health Services, College of Medicine, 2345Medical University of South Carolina, USA.'}]",Journal of telemedicine and telecare,['10.1177/1357633X211028491'] 1614,34256810,The effectiveness of a psycho-education intervention on mental health literacy in communities affected by the COVID-19 pandemic-a cluster randomized trial of 24 villages in central Uganda-a research protocol.,"BACKGROUND Literature shows a high prevalence of psychological distress (PD) as well as common mental disorders (CMD) such as major depressive disorders (MDD), generalized anxiety disorders (GAD), post-traumatic stress disorders (PTSD), and substance misuse disorders (SUD) among people exposed to disasters and pandemics like the COVID-19. Moreover, CMD are associated with increased mortality (mainly through suicide) and morbidity (loss of productivity). A number of countries have made deliberate efforts to identify and manage CMD in light of COVID-19. However, low levels of mental health literacy (MHL) manifested by the individual's unawareness of CMD symptoms, limited human and mental health infrastructure resources, and high levels of mental illness stigma (MIS) are barriers to integration of mental health care in general health care during pandemics and epidemics such as the COVID-19. OBJECTIVES For the proposed study, we will determine effectiveness of a psycho-education intervention delivered by village health team (VHT) members. METHODS We will employ a cluster randomized trial design in 24 villages in central Uganda. We will collect baseline data to and document the prevalence of MHL, PD, MDD, PTSD, GAD, and SUD. We will distribute information education and communication materials (IEC) aimed at improving MHL to 420 adult individuals in the intervention arm (n = 12 villages). In the control arm (n = 12 villages), VHTs will distribute ministry of health COVID-19 information leaflets to 420 participants. Within 7 days of distributing the materials, research assistants will conduct a follow-up interview and assess for the same parameters (MHL, PD, MDD, PTSD, GAD, and SUD). We will use an intention to treat analysis to estimate the effectiveness of the psycho-education intervention. DISCUSSION Findings from this research will guide policy and practice regarding the integration of mental health services in the community in the context of epidemic preparedness and response. TRIAL REGISTRATION ClinicalTrials.gov NCT04616989 . Registered on 05 November 2020.",2021,We will distribute information education and communication materials (IEC) aimed at improving MHL to 420 adult individuals in the intervention arm (n = 12 villages).,"['mental health literacy in communities affected by the COVID-19 pandemic-a cluster randomized trial of 24 villages in central Uganda-a research protocol', '420 adult individuals in the intervention arm (n = 12 villages', '24 villages in central Uganda']",['psycho-education intervention'],"['prevalence of MHL, PD, MDD, PTSD, GAD, and SUD', 'mortality (mainly through suicide) and morbidity (loss of productivity']","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C4517774', 'cui_str': '420'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038661', 'cui_str': 'Suicide'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}]",,0.064776,We will distribute information education and communication materials (IEC) aimed at improving MHL to 420 adult individuals in the intervention arm (n = 12 villages).,"[{'ForeName': 'Dickens', 'Initials': 'D', 'LastName': 'Akena', 'Affiliation': 'Department of Psychiatry, Makerere University College of Health Sciences, Kampala, Uganda. akendickens@yahoo.co.uk.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Kiguba', 'Affiliation': 'Department of Pharmacology, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Wilson W', 'Initials': 'WW', 'LastName': 'Muhwezi', 'Affiliation': 'Department of Psychiatry, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Brendan', 'Initials': 'B', 'LastName': 'Kwesiga', 'Affiliation': 'Health Systems Strengthening Cluster, World Health Organization, Kenya Country Office, Nairobi, Kenya.'}, {'ForeName': 'Gwendolyne', 'Initials': 'G', 'LastName': 'Kigozi', 'Affiliation': 'Grants office, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Noeline', 'Initials': 'N', 'LastName': 'Nakasujja', 'Affiliation': 'Department of Psychiatry, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Hafsa', 'Initials': 'H', 'LastName': 'Lukwata', 'Affiliation': 'Department of Mental Health, Ministry of Health of Uganda, Kampala, Uganda.'}]",Trials,['10.1186/s13063-021-05391-6'] 1615,34256800,Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.,"BACKGROUND The type I interferon (IFN) gene signature is present in a subgroup of patients with early rheumatoid arthritis (RA). Protein levels of IFNα have not been measured in RA and it is unknown whether they associate with clinical characteristics or treatment effect. METHODS Patients with early untreated RA (n = 347) were randomized to methotrexate combined with prednisone, certolizumab-pegol, abatacept, or tocilizumab. Plasma IFNα protein levels were determined by single molecular array (Simoa) before and 24 weeks after treatment initiation and were related to demographic and clinical factors including clinical disease activity index, disease activity score in 28 joints, swollen and tender joint counts, and patient global assessment. RESULTS IFNα protein positivity was found in 26% of the patients, and of these, 92% were double-positive for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). IFNα protein levels were reduced 24 weeks after treatment initiation, and the absolute change was similar irrespective of treatment. IFNα protein positivity was associated neither with disease activity nor with achievement of CDAI remission 24 weeks after randomization. CONCLUSION IFNα protein positivity is present in a subgroup of patients with early RA and associates with double-positivity for autoantibodies but not with disease activity. Pre-treatment IFNα positivity did not predict remission in any of the treatment arms, suggesting that the IFNα system is distinct from the pathways of TNF, IL-6, and T-cell activation in early RA. A spin-off study of the NORD-STAR randomized clinical trial, NCT01491815 (ClinicalTrials), registered 12/08/2011, https://clinicaltrials.gov/ct2/show/NCT01491815 .",2021,"treatment IFNα positivity did not predict remission in any of the treatment arms, suggesting that the IFNα system is distinct from the pathways of TNF, IL-6, and T-cell activation in early RA.","['patients with early rheumatoid arthritis (RA', 'Patients with early untreated RA (n = 347']","['interferon', 'methotrexate combined with prednisone, certolizumab-pegol, abatacept, or tocilizumab']","['IFNα protein positivity', 'IFNα protein levels', 'clinical disease activity index, disease activity score in 28 joints, swollen and tender joint counts, and patient global assessment', 'Plasma IFNα protein levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}]","[{'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1872109', 'cui_str': 'certolizumab pegol'}, {'cui': 'C1619966', 'cui_str': 'abatacept'}, {'cui': 'C1609165', 'cui_str': 'tocilizumab'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0428479', 'cui_str': 'Protein level - finding'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0451530', 'cui_str': 'Tender joint count'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]",347.0,0.479376,"treatment IFNα positivity did not predict remission in any of the treatment arms, suggesting that the IFNα system is distinct from the pathways of TNF, IL-6, and T-cell activation in early RA.","[{'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Stockfelt', 'Affiliation': 'Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, S-405 30, Gothenburg, Sweden. marit.stockfelt@gu.se.'}, {'ForeName': 'Anna-Carin', 'Initials': 'AC', 'LastName': 'Lundell', 'Affiliation': 'Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, S-405 30, Gothenburg, Sweden.'}, {'ForeName': 'Merete Lund', 'Initials': 'ML', 'LastName': 'Hetland', 'Affiliation': 'Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Mikkel', 'Initials': 'M', 'LastName': 'Østergaard', 'Affiliation': 'Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Till', 'Initials': 'T', 'LastName': 'Uhlig', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Marte Schrumpf', 'Initials': 'MS', 'LastName': 'Heiberg', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Espen A', 'Initials': 'EA', 'LastName': 'Haavardsholm', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Nurmohamed', 'Affiliation': 'Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Lampa', 'Affiliation': 'Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Nordström', 'Affiliation': 'Department of Medicine and Rheumatology, Helsinki University and University Hospital, Helsinki, Finland.'}, {'ForeName': 'Kim Hørslev', 'Initials': 'KH', 'LastName': 'Petersen', 'Affiliation': 'Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark.'}, {'ForeName': 'Bjorn', 'Initials': 'B', 'LastName': 'Gudbjornsson', 'Affiliation': 'Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland.'}, {'ForeName': 'Gerdur', 'Initials': 'G', 'LastName': 'Gröndal', 'Affiliation': 'Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Aldridge', 'Affiliation': 'Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, S-405 30, Gothenburg, Sweden.'}, {'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Andersson', 'Affiliation': 'Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, S-405 30, Gothenburg, Sweden.'}, {'ForeName': 'Kaj', 'Initials': 'K', 'LastName': 'Blennow', 'Affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Zetterberg', 'Affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'van Vollenhoven', 'Affiliation': 'Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centres, Amsterdam, The Netherlands.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Rudin', 'Affiliation': 'Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, S-405 30, Gothenburg, Sweden.'}]",Arthritis research & therapy,['10.1186/s13075-021-02556-1'] 1616,34273811,Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.,"BACKGROUND In the ARAMIS trial, darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT significantly improved metastasis-free survival (MFS), overall survival (OS) and time to pain progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Herein, we present analyses of patient-reported health-related quality of life (HRQoL) outcomes. PATIENTS AND METHODS This double-blind, placebo-controlled, phase III trial randomised patients with nmCRPC and prostate-specific antigen doubling time ≤10 months to darolutamide 600 mg (n = 955) twice daily or matched placebo (n = 554) while continuing ADT. The primary end-point was MFS; the secondary end-points included OS and time to pain progression. In this analysis, HRQoL was assessed by the time to deterioration using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) prostate cancer subscale (PCS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer Module (EORTC QLQ-PR25) subscales. RESULTS Darolutamide significantly prolonged time to deterioration of FACT-P PCS versus placebo (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.70-0.91; P = 0.0005) at the primary analysis (cut-off date: 3rd September 2018). Time to deterioration of EORTC QLQ-PR25 outcomes showed statistically significant delays with darolutamide versus placebo for urinary (HR 0.64, 95% CI 0.54-0.76; P < 0.0001) and bowel (HR 0.78, 95% CI 0.66-0.92; P = 0.0027) symptoms. Time to worsening of hormonal treatment-related symptoms was similar between the two groups. CONCLUSION In patients with nmCRPC who are generally asymptomatic, darolutamide maintained HRQoL by significantly delaying time to deterioration of prostate cancer-specific quality of life and disease-related symptoms versus placebo.",2021,"Time to deterioration of EORTC QLQ-PR25 outcomes showed statistically significant delays with darolutamide versus placebo for urinary (HR 0.64, 95% CI 0.54-0.76; P < 0.0001) and bowel (HR 0.78, 95% CI 0.66-0.92; P = 0.0027) symptoms.","['patients with non-metastatic castration-resistant prostate cancer (nmCRPC', 'patients with non-metastatic castration-resistant prostate cancer', 'patients with nmCRPC and prostate-specific antigen doubling time\xa0≤10 months to']","['darolutamide 600\xa0mg (n\xa0=\xa0955) twice daily or matched placebo (n\xa0=\xa0554) while continuing ADT', 'Darolutamide', 'placebo', 'darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT']","['Darolutamide and health-related quality of life', 'Time to worsening of hormonal treatment-related symptoms', 'metastasis-free survival (MFS), overall survival (OS) and time to pain progression', 'health-related quality of life (HRQoL) outcomes', 'Functional Assessment of Cancer Therapy-Prostate (FACT-P) prostate cancer subscale (PCS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer Module (EORTC QLQ-PR25) subscales', 'MFS; the secondary end-points included OS and time to pain progression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C4547776', 'cui_str': 'darolutamide'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C4547776', 'cui_str': 'darolutamide'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0451149', 'cui_str': 'EORTC - Quality of life questionnaire'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",,0.56156,"Time to deterioration of EORTC QLQ-PR25 outcomes showed statistically significant delays with darolutamide versus placebo for urinary (HR 0.64, 95% CI 0.54-0.76; P < 0.0001) and bowel (HR 0.78, 95% CI 0.66-0.92; P = 0.0027) symptoms.","[{'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Smith', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address: smith.matthew@mgh.harvard.edu.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Shore', 'Affiliation': 'Carolina Urologic Research Center, Myrtle Beach, SC, USA.'}, {'ForeName': 'Teuvo L', 'Initials': 'TL', 'LastName': 'Tammela', 'Affiliation': 'Tampere University Hospital and Tampere University, Tampere, Finland.'}, {'ForeName': 'Albertas', 'Initials': 'A', 'LastName': 'Ulys', 'Affiliation': 'National Cancer Institute, Vilnius, Lithuania.'}, {'ForeName': 'Egils', 'Initials': 'E', 'LastName': 'Vjaters', 'Affiliation': 'Stradins Clinical University Hospital, Riga.'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Polyakov', 'Affiliation': 'N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus.'}, {'ForeName': 'Mindaugas', 'Initials': 'M', 'LastName': 'Jievaltas', 'Affiliation': 'Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.'}, {'ForeName': 'Murilo', 'Initials': 'M', 'LastName': 'Luz', 'Affiliation': 'Hospital Erasto Gaertner, Curitiba, Brazil.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Alekseev', 'Affiliation': 'National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russia.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Kuss', 'Affiliation': 'Clinical Statistics, Bayer AG, Berlin, Germany.'}, {'ForeName': 'Marie-Aude', 'Initials': 'MA', 'LastName': 'Le Berre', 'Affiliation': 'Bayer Healthcare SAS, Loos, France.'}, {'ForeName': 'Ateesha F', 'Initials': 'AF', 'LastName': 'Mohamed', 'Affiliation': 'Bayer Healthcare, Whippany, NJ, USA.'}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Odom', 'Affiliation': 'Research Triangle Institute, Durham, NC, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Bartsch', 'Affiliation': 'Research Triangle Institute, Durham, NC, USA.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Snapir', 'Affiliation': 'Orion Corporation Orion Pharma, Espoo, Finland.'}, {'ForeName': 'Toni', 'Initials': 'T', 'LastName': 'Sarapohja', 'Affiliation': 'Orion Corporation Orion Pharma, Espoo, Finland.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Fizazi', 'Affiliation': 'Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.06.010'] 1617,34273797,The Impact of a Mobile Phone Application for Retention of Bleeding Control Skills.,"BACKGROUND The American College of Surgeons Bleeding Control Course (B-Con) empowers bystanders with hemorrhage control skills to manage prehospital emergencies, but demonstrates poor skill retention. The point of care use of a free Stop the Bleed mobile phone application on the retention of hemorrhage control skills from the B-Con Course was explored. METHODS Convenience sample of college students previously trained in B-Con were randomized into mobile application (MA) or control groups. The use of a mobile application during a simulated emergency scenario with tourniquet and situational awareness skills was assessed. Wound packing skill retention without intervention was also assessed. Survey data allowed for comparison of participant perceptions of skills with actual performances. RESULTS MA (n = 30) was superior to control (n = 32) in correct tourniquet application (62.5% versus 30.0%; P = 0.01) with longer placement times (163 sec versus 95 sec; P < 0.001) and in calling 911 (31.3% versus 3.3%, P = 0.004). Participants maintain inflated perceptions of their skills, but generally feel underprepared for a future bleeding emergency. CONCLUSIONS Mobile apps improve tourniquet and situational awareness skills and may serve as potential aids to improve bystander hemorrhage control skills in real-time, but require further prospective investigation into its use.",2021,"RESULTS MA (n = 30) was superior to control (n = 32) in correct tourniquet application (62.5% versus 30.0%; P = 0.01) with longer placement times (163 sec versus 95 sec; P < 0.001) and in calling 911 (31.3% versus 3.3%, P = 0.004).","['Convenience sample of college students previously trained in B-Con', 'American College of Surgeons Bleeding Control Course']",['mobile application (MA) or control groups'],"['Retention of Bleeding Control Skills', 'correct tourniquet application', 'tourniquet and situational awareness skills']","[{'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0149533', 'cui_str': 'Control of hemorrhage'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}]","[{'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0149533', 'cui_str': 'Control of hemorrhage'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0204731', 'cui_str': 'Application of tourniquet'}, {'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}]",,0.0269407,"RESULTS MA (n = 30) was superior to control (n = 32) in correct tourniquet application (62.5% versus 30.0%; P = 0.01) with longer placement times (163 sec versus 95 sec; P < 0.001) and in calling 911 (31.3% versus 3.3%, P = 0.004).","[{'ForeName': 'Nicholas B', 'Initials': 'NB', 'LastName': 'Dadario', 'Affiliation': 'Department of Emergency Medicine, White Plains Hospital, White Plains, New York; Department of Medicine, Rutgers Robert Wood Johnson School of Medicine, Rutgers University, New Brunswick, New Jersey. Electronic address: nbd37@rwjms.rutgers.edu.'}, {'ForeName': 'Rachel C Santana', 'Initials': 'RCS', 'LastName': 'Felipes', 'Affiliation': 'Department of Emergency Medicine, White Plains Hospital, White Plains, New York; Department of Biological Sciences, Binghamton University, Binghamton, New York.'}, {'ForeName': 'Joseph V', 'Initials': 'JV', 'LastName': 'Cooney', 'Affiliation': 'Department of Emergency Medicine, White Plains Hospital, White Plains, New York; Department of Biological Sciences, Binghamton University, Binghamton, New York.'}, {'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Stephenson', 'Affiliation': 'Department of Biological Sciences, Binghamton University, Binghamton, New York.'}, {'ForeName': 'Nicholas H', 'Initials': 'NH', 'LastName': 'Shleiwet', 'Affiliation': 'Department of Biological Sciences, Binghamton University, Binghamton, New York; Department of Dental Medicine, Columbia University College of Dental Medicine, New York City, New York.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Liang', 'Affiliation': 'Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Farrukh N', 'Initials': 'FN', 'LastName': 'Jafri', 'Affiliation': 'Department of Emergency Medicine, White Plains Hospital, White Plains, New York; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.'}]",The Journal of surgical research,['10.1016/j.jss.2021.06.021'] 1618,34273682,Effects of Euterpe edulis Martius on inflammatory responses to high-intensity intermittent exercise: Crossover randomized trial.,"OBJECTIVE High-intensity intermittent exercise (HIIE) may enhance the antiinflammatory status. The juçara fruit juice (JFJ) has well-established antioxidant and antiinflammatory properties. This study investigated the effect of JFJ consumption on the inflammatory response to HIIE in physically active subjects. METHODS In a randomized crossover design, 15 men were assigned to drink 250 mL of either JFJ or water (control) 1 h before a cycling HIIE session (seven sets of 60 s at 100% peak power output; 75 s recovery between sets). Blood samples were obtained before and at 0, 30, and 60 min post-HIIE, and the serum was analyzed for interleukin (IL)-6, IL-1β, IL-8, IL-10, tumor necrosis factor-α, and cortisol. RESULTS After HIIE, the IL-6 levels were higher than baseline (percent change) at 30 min (P = 0.041) and 60 min (P = 0.038) for the control, but were unaffected by JFJ. IL-10 was higher in the JFJ group than in the control at 30 min (d = ‒0.63). Tumor necrosis factor-α was lower than baseline at 30 min for the control (d = ‒0.71) and at 60 min for the JFJ group (d = ‒0.60). For control, cortisol increased to higher than the baseline at 30 and 60 min (d = 0.54 and d = 0.76, respectively). For the JFJ group, the cortisol levels were significantly higher than the baseline at 30 min (P = 0.022). Performance during sprints was higher in the JFJ group than in the control (P = 0.002). In the control group, performance was with both IL-6 (semipartial correlation; sr = -0.59, large effect size) and cortisol at 0 h (sr = -0.52, large effect size). CONCLUSIONS JFJ intake attenuated the antiinflammatory response to HIIE, possibly resulting from a lower degree of muscle stress.",2021,Performance during sprints was higher in the JFJ group than in the control (P = 0.002).,"['15 men', 'physically active subjects']","['Euterpe edulis Martius', 'JFJ', 'drink 250 mL of either JFJ or water (control) 1 h before a cycling HIIE session', 'juçara fruit juice (JFJ', 'JFJ consumption', 'High-intensity intermittent exercise (HIIE']","['inflammatory responses', 'Blood samples', 'IL-10', 'Tumor necrosis factor-α', 'interleukin (IL)-6, IL-1β, IL-8, IL-10, tumor necrosis factor-α, and cortisol', 'cortisol levels', 'IL-6 levels']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}]","[{'cui': 'C1193660', 'cui_str': 'Euterpe edulis'}, {'cui': 'C0452453', 'cui_str': 'Fruit juice'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",15.0,0.155622,Performance during sprints was higher in the JFJ group than in the control (P = 0.002).,"[{'ForeName': 'Bruna Cunha', 'Initials': 'BC', 'LastName': 'Mendes', 'Affiliation': 'Nutrition Postgraduate Program, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil. Electronic address: bruna.mendes@posgrad.ufsc.br.'}, {'ForeName': 'Cândice Laís Knöner', 'Initials': 'CLK', 'LastName': 'Copetti', 'Affiliation': 'Nutrition Postgraduate Program, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.'}, {'ForeName': 'Vilma Simões Pereira', 'Initials': 'VSP', 'LastName': 'Panza', 'Affiliation': 'Nutrition Postgraduate Program, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.'}, {'ForeName': 'Lucas B R', 'Initials': 'LBR', 'LastName': 'Orssatto', 'Affiliation': 'School of Exercise and Nutrition Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia.'}, {'ForeName': 'Julia Salvan', 'Initials': 'JS', 'LastName': 'da Rosa', 'Affiliation': 'Pharmacy Postgraduate Program, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Diefenthaeler', 'Affiliation': 'Physical Education Postgraduate Program, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.'}, {'ForeName': 'Eduardo Monguilhott', 'Initials': 'EM', 'LastName': 'Dalmarco', 'Affiliation': 'Pharmacy Postgraduate Program, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.'}, {'ForeName': 'Patricia Faria Di', 'Initials': 'PFD', 'LastName': 'Pietro', 'Affiliation': 'Nutrition Postgraduate Program, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.'}, {'ForeName': 'Débora Kurrle', 'Initials': 'DK', 'LastName': 'Rieger', 'Affiliation': 'Nutrition Postgraduate Program, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2021.111344'] 1619,34275872,Comparison of community-led distribution of HIV self-tests kits with distribution by paid distributors: a cluster randomised trial in rural Zimbabwean communities.,"BACKGROUND We compared community-led versus an established community-based HIV self-testing (HIVST) model in rural Zimbabwe using a cluster-randomised trial. METHODS Forty village groups were randomised 1:1 using restricted randomisation to community-led HIVST, where communities planned and implemented HIVST distribution for 4 weeks, or paid distribution (PD), where distributors were paid US$50 to distribute kits door-to-door over 4 weeks. Individual level primary outcomes compared household survey responses by arm 4 months post-intervention for: (1) newly diagnosed HIV during/within 4 months following HIVST distribution, (2) linkage to confirmatory testing, pre-exposure prophylaxis or voluntary medical male circumcision during/within 4 months following HIVST distribution. Participants were not masked to allocation; analysis used masked data. Trial analysis used random-effects logistic regression.Distribution costs compared: (1) community-led HIVST, (2) PD HIVST and (3) PD costs when first implemented in 2016/2017. RESULTS From October 2018 to August 2019, 27 812 and 36 699 HIVST kits were distributed in community-led and PD communities, respectively. We surveyed 11 150 participants and 5683 were in community-led arm. New HIV diagnosis was reported by 211 (3.7%) community-led versus 197 (3.6%) PD arm participants, adjusted OR (aOR) 1.1 (95% CI 0.72 to 1.56); 318 (25.9%) community-led arm participants linked to post-test services versus 361 (23.9%) in PD arm, aOR 1.1 (95% CI 0.75 to 1.49.Cost per HIVST kit distributed was US$6.29 and US$10.25 for PD and community-led HIVST, both lower than 2016/2017 costs for newly implemented PD (US$14.52). No social harms were reported. CONCLUSIONS Community-led HIVST can perform as well as paid distribution, with lower costs in the first year. These costs may reduce with programme maturity/learning. TRIAL REGISTRATION NUMBER PACTR201811849455568.",2021,"No social harms were reported. ","['From October 2018 to August 2019', 'We surveyed 11 150 participants and 5683 were in community-led arm', 'rural Zimbabwean communities', 'Forty village groups', '27 812 and 36 699 HIVST kits']","['HIV self-tests kits with distribution by paid distributors', 'community-led versus an established community-based HIV self-testing (HIVST) model', 'community-led HIVST, where communities planned and implemented HIVST distribution for 4 weeks, or paid distribution (PD), where distributors were paid US$50 to distribute kits door-to-door over 4 weeks']","['New HIV diagnosis', 'Distribution costs compared: (1) community-led HIVST, (2) PD HIVST and (3) PD costs']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1272835', 'cui_str': 'Test kit'}, {'cui': 'C0522509', 'cui_str': 'With distribution'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0557698', 'cui_str': 'Door'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]",11150.0,0.198001,"No social harms were reported. ","[{'ForeName': 'Euphemia Lindelwe', 'Initials': 'EL', 'LastName': 'Sibanda', 'Affiliation': 'CeSHHAR Zimbabwe, Harare, Zimbabwe euphemia@ceshhar.co.zw.'}, {'ForeName': 'Collin', 'Initials': 'C', 'LastName': 'Mangenah', 'Affiliation': 'CeSHHAR Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Neuman', 'Affiliation': 'Department of Infectious Disease Epidemiology and MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Tumushime', 'Affiliation': 'CeSHHAR Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Constancia', 'Initials': 'C', 'LastName': 'Watadzaushe', 'Affiliation': 'CeSHHAR Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Miriam N', 'Initials': 'MN', 'LastName': 'Mutseta', 'Affiliation': 'Department of Sexual Reproductive Health Rights and Innovations, Population Services International Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Galven', 'Initials': 'G', 'LastName': 'Maringwa', 'Affiliation': 'CeSHHAR Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Dirawo', 'Affiliation': 'CeSHHAR Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Fielding', 'Affiliation': 'Department of Infectious Disease Epidemiology and MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Johnson', 'Affiliation': 'HIV, Hepatitis and STI Department, World Health Organisation, Geneva, Switzerland.'}, {'ForeName': 'Getrude', 'Initials': 'G', 'LastName': 'Ncube', 'Affiliation': 'AIDS and TB Unit, Ministry of Health and Child Care, Harare, Zimbabwe.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Taegtmeyer', 'Affiliation': 'Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Hatzold', 'Affiliation': 'Population Services International, Washington, District of Columbia, USA.'}, {'ForeName': 'Elizabeth Lucy', 'Initials': 'EL', 'LastName': 'Corbett', 'Affiliation': 'Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Fern', 'Initials': 'F', 'LastName': 'Terris-Prestholt', 'Affiliation': 'Department of Global Health & Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Frances M', 'Initials': 'FM', 'LastName': 'Cowan', 'Affiliation': 'CeSHHAR Zimbabwe, Harare, Zimbabwe.'}]",BMJ global health,['10.1136/bmjgh-2021-005000'] 1620,34275869,Pragmatic economic evaluation of community-led delivery of HIV self-testing in Malawi.,"INTRODUCTION Community-based strategies can extend coverage of HIV testing and diagnose HIV at earlier stages of infection but can be costly to implement. We evaluated the costs and effects of community-led delivery of HIV self-testing (HIVST) in Mangochi District, Malawi. METHODS This economic evaluation was based within a pragmatic cluster-randomised trial of 30 group village heads and their catchment areas comparing the community-led HIVST intervention in addition to the standard of care (SOC) versus the SOC alone. The intervention involved mobilising community health groups to lead 7-day HIVST campaigns including distribution of HIVST kits. The SOC included facility-based HIV testing services. Primary costings estimated economic costs of the intervention and SOC from the provider perspective, with costs annualised and measured in 2018 US$. A postintervention survey captured individual-level data on HIV testing events, which were combined with unit costs from primary costings, and outcomes. The incremental cost per person tested HIV-positive and associated uncertainty were estimated. RESULTS Overall, the community-led HIVST intervention costed $138 624 or $5.70 per HIVST kit distributed, with test kits and personnel the main contributing costs. The SOC costed $263 400 or $4.57 per person tested. Individual-level provider costs were higher in the community-led HIVST arm than the SOC arm (adjusted mean difference $3.77, 95% CI $2.44 to $5.10; p<0.001), while the intervention effect on HIV positivity varied based on adjustment for previous diagnosis. The incremental cost per person tested HIV positive was $324 but increased to $1312 and $985 when adjusting for previously diagnosed self-testers or self-testers on treatment, respectively. Community-led HIVST demonstrated low probability of being cost-effective against plausible willingness-to-pay values, with HIV positivity a key determinant. CONCLUSION Community-led HIVST can provide HIV testing at a low additional unit cost. However, adding community-led HIVST to the SOC was not likely to be cost-effective, especially in contexts with low prevalence of undiagnosed HIV. TRIAL REGISTRATION NUMBER NCT03541382.",2021,"Individual-level provider costs were higher in the community-led HIVST arm than the SOC arm (adjusted mean difference $3.77, 95% CI $2.44 to $5.10; p<0.001), while the intervention effect on HIV positivity varied based on adjustment for previous diagnosis.","['30 group village heads and their catchment areas comparing the community-led', 'Malawi']","['HIVST campaigns including distribution of HIVST kits', 'community-led delivery of HIV self-testing (HIVST', 'HIVST intervention in addition to the standard of care (SOC) versus the SOC alone']","['incremental cost per person tested HIV positive', 'economic costs', 'Individual-level provider costs', 'HIV positivity']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0007403', 'cui_str': 'Health Catchment Area'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0013556', 'cui_str': 'Economics'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0825557,"Individual-level provider costs were higher in the community-led HIVST arm than the SOC arm (adjusted mean difference $3.77, 95% CI $2.44 to $5.10; p<0.001), while the intervention effect on HIV positivity varied based on adjustment for previous diagnosis.","[{'ForeName': 'Pitchaya P', 'Initials': 'PP', 'LastName': 'Indravudh', 'Affiliation': 'Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK pitchaya.indravudh@lshtm.ac.uk.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Fielding', 'Affiliation': 'Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Linda A', 'Initials': 'LA', 'LastName': 'Sande', 'Affiliation': 'Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Hendramoorthy', 'Initials': 'H', 'LastName': 'Maheswaran', 'Affiliation': 'Institute of Population Health Sciences, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Saviour', 'Initials': 'S', 'LastName': 'Mphande', 'Affiliation': 'Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Moses K', 'Initials': 'MK', 'LastName': 'Kumwenda', 'Affiliation': 'Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Chilongosi', 'Affiliation': 'Population Services International Malawi, Lilongwe, Malawi.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Nyirenda', 'Affiliation': 'Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi.'}, {'ForeName': 'Cheryl C', 'Initials': 'CC', 'LastName': 'Johnson', 'Affiliation': 'Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, WHO, Geneva, Switzerland.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Hatzold', 'Affiliation': 'Population Services International, Washington, DC, USA.'}, {'ForeName': 'Elizabeth L', 'Initials': 'EL', 'LastName': 'Corbett', 'Affiliation': 'Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Fern', 'Initials': 'F', 'LastName': 'Terris-Prestholt', 'Affiliation': 'Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}]",BMJ global health,['10.1136/bmjgh-2020-004593'] 1621,34275868,Does community-based distribution of HIV self-tests increase uptake of HIV testing? Results of pair-matched cluster randomised trial in Zambia.,"OBJECTIVES Ending HIV by 2030 is a global priority. Achieving this requires alternative HIV testing strategies, such as HIV self-testing (HIVST) to reach all individuals with HIV testing services (HTS). We present the results of a trial evaluating the impact of community-based distribution of HIVST in community and facility settings on the uptake of HTS in rural and urban Zambia. DESIGN Pair-matched cluster randomised trial. METHODS In catchment areas of government health facilities, OraQuick HIVST kits were distributed by community-based distributors (CBDs) over 12 months in 2016-2017. Within matched pairs, clusters were randomised to receive the HIVST intervention or standard of care (SOC). Individuals aged ≥16 years were eligible for HIVST. Within communities, CBDs offered HIVST in high traffic areas, door to door and at healthcare facilities. The primary outcome was self-reported recent testing within the previous 12 months measured using a population-based survey. RESULTS In six intervention clusters (population 148 541), 60 CBDs distributed 65 585 HIVST kits. A recent test was reported by 66% (1622/2465) in the intervention arm compared with 60% (1456/2429) in SOC arm (adjusted risk ratio 1.08, 95% CI 0.94 to 1.24; p=0.15). Uptake of the HIVST intervention was low: 24% of respondents in the intervention arm (585/2493) used an HIVST kit in the previous 12 months. No social harms were identified during implementation. CONCLUSION Despite distributing a large number of HIVST kits, we found no evidence that this community-based HIVST distribution intervention increased HTS uptake. Other models of HIVST distribution, including secondary distribution and community-designed distribution models, provide alternative strategies to reach target populations. TRIAL REGISTRATION NUMBER ClinicalTrials.gov Registry (NCT02793804).",2021,"A recent test was reported by 66% (1622/2465) in the intervention arm compared with 60% (1456/2429) in SOC arm (adjusted risk ratio 1.08, 95% CI 0.94 to 1.24; p=0.15).","['rural and urban Zambia', 'Individuals aged ≥16 years were eligible for HIVST', 'individuals with HIV testing services (HTS']","['HIVST intervention', 'HIVST kits', 'HIVST intervention or standard of care (SOC']","['self-reported recent testing within the previous 12 months measured using a population-based survey', 'HTS uptake']","[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0043445', 'cui_str': 'Zambia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0557854', 'cui_str': 'Services'}]",148541.0,0.209748,"A recent test was reported by 66% (1622/2465) in the intervention arm compared with 60% (1456/2429) in SOC arm (adjusted risk ratio 1.08, 95% CI 0.94 to 1.24; p=0.15).","[{'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Neuman', 'Affiliation': 'Department of Infectious Disease Epidemiology, MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK Melissa.Neuman@lshtm.ac.uk.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Hensen', 'Affiliation': 'Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Alwyn', 'Initials': 'A', 'LastName': 'Mwinga', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Namwinga', 'Initials': 'N', 'LastName': 'Chintu', 'Affiliation': 'Society for Family Health, Lusaka, Zambia.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Fielding', 'Affiliation': 'Department of Infectious Disease Epidemiology, MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Nixon', 'Initials': 'N', 'LastName': 'Handima', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Hatzold', 'Affiliation': 'Population Services International, Cape Town, South Africa.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Johnson', 'Affiliation': 'Global HIV, Hepatitis and STI Programme, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Chama', 'Initials': 'C', 'LastName': 'Mulubwa', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Mutinta', 'Initials': 'M', 'LastName': 'Nalubamba', 'Affiliation': 'Society for Family Health, Lusaka, Zambia.'}, {'ForeName': 'Eveline', 'Initials': 'E', 'LastName': 'Otte Im Kampe', 'Affiliation': 'Department of Infectious Disease Epidemiology, MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Musonda', 'Initials': 'M', 'LastName': 'Simwinga', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Smith', 'Affiliation': 'Society for Family Health, Lusaka, Zambia.'}, {'ForeName': 'Dickson', 'Initials': 'D', 'LastName': 'Tsamwa', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Elizabeth Lucy', 'Initials': 'EL', 'LastName': 'Corbett', 'Affiliation': 'Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Ayles', 'Affiliation': 'Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.'}]",BMJ global health,['10.1136/bmjgh-2020-004543'] 1622,34275209,Effects of simvastatin on white matter integrity in healthy middle-aged adults.,"BACKGROUND The brain is the most cholesterol-rich organ and myelin contains 70% of total brain cholesterol. Statins are potent cholesterol-lowing medications used by millions of adults for prevention of vascular disease, yet the effect of statins on cholesterol-rich brain white matter (WM) is largely unknown. METHODS We used longitudinal neuroimaging data acquired from 73 healthy, cognitively unimpaired, statin-naïve, middle-aged adults during an 18-month randomized controlled trial of simvastatin 40 mg daily (n = 35) or matching placebo (n = 38). ANCOVA models (covariates: age, sex, APOE-ɛ4) tested the effect of treatment group on percent change in WM, gray matter (GM), and WM hyperintensity (WMH) neuroimaging measures at each study visit. Mediation analysis tested the indirect effects of simvastatin on WM microstructure through change in serum total cholesterol levels. RESULTS At 18 months, the simvastatin group showed a significant preservation in global WM fractional anisotropy (β = 0.88%, 95% CI 0.27 to 1.50, P = 0.005), radial diffusivity (β = -1.10%, 95% CI -2.13 to -0.06, P = 0.039), and WM volume (β = 0.72%, 95% CI 0.13 to 1.32, P = 0.018) relative to the placebo group. There was no significant effect of simvastatin on GM or WMH volume. Change in serum total cholesterol mediated approximately 30% of the effect of simvastatin on WM microstructure. CONCLUSIONS Simvastatin treatment in healthy, middle-aged adults resulted in preserved WM microstructure and volume at 18 months. The partial mediation by serum cholesterol reduction suggests both peripheral and central mechanisms. Future studies are needed to determine whether these effects persist and translate to cognitive outcomes. TRIAL REGISTRATION NCT00939822 (ClinicalTrials.gov).",2021,"At 18 months, the simvastatin group showed a significant preservation in global WM fractional anisotropy (β = 0.88%, 95% CI 0.27 to 1.50, P = 0.005), radial diffusivity (β = -1.10%, 95% CI -2.13 to -0.06, P = 0.039), and WM volume (β = 0.72%, 95% CI 0.13 to 1.32, P = 0.018) relative to the placebo group.","['healthy, middle-aged adults', 'healthy middle-aged adults', '73 healthy, cognitively unimpaired, statin-naïve, middle-aged adults']","['simvastatin', 'placebo', 'simvastatin 40\xa0mg daily (n\xa0=\xa035) or matching placebo', 'Simvastatin']","['WM, gray matter (GM), and WM hyperintensity (WMH) neuroimaging measures', 'serum total cholesterol levels', 'radial diffusivity', 'global WM fractional anisotropy', 'white matter integrity', 'serum total cholesterol', 'GM or WMH volume']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}]","[{'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0989916', 'cui_str': 'Simvastatin 40 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1445957', 'cui_str': 'Serum total cholesterol measurement'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",,0.159845,"At 18 months, the simvastatin group showed a significant preservation in global WM fractional anisotropy (β = 0.88%, 95% CI 0.27 to 1.50, P = 0.005), radial diffusivity (β = -1.10%, 95% CI -2.13 to -0.06, P = 0.039), and WM volume (β = 0.72%, 95% CI 0.13 to 1.32, P = 0.018) relative to the placebo group.","[{'ForeName': 'Nicholas M', 'Initials': 'NM', 'LastName': 'Vogt', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Jack F V', 'Initials': 'JFV', 'LastName': 'Hunt', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Van Hulle', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Nagesh', 'Initials': 'N', 'LastName': 'Adluru', 'Affiliation': 'Waisman Laboratory for Brain Imaging and Behavior, Waisman Center, University of Wisconsin-Madison, Madison, Wisconsin.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Chappell', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Karen K', 'Initials': 'KK', 'LastName': 'Lazar', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Jacobson', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Benjamin P', 'Initials': 'BP', 'LastName': 'Austin', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Asthana', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Sterling C', 'Initials': 'SC', 'LastName': 'Johnson', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Barbara B', 'Initials': 'BB', 'LastName': 'Bendlin', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}, {'ForeName': 'Cynthia M', 'Initials': 'CM', 'LastName': 'Carlsson', 'Affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.""}]",Annals of clinical and translational neurology,['10.1002/acn3.51421'] 1623,34250814,Metabolic and cardiovascular adaptations to an 8-week lifestyle weight loss intervention in younger and older obese men.,"The number of older obese adults is increasing worldwide. Whether obese adults show similar health benefits in response to lifestyle interventions at different ages is unknown. The study enrolled 25 obese men (BMI 31-39 kg/m2) in two arms according to age (30-40 and 60-70 years old). Participants underwent an 8-week intervention with moderate calorie restriction (~20% below individual energy requirements) and supervised endurance training resulting in ~5% weight loss. Body composition was measured using dual energy X-Ray absorptiometry. Insulin sensitivity was assessed during a hypersinsulinemic euglycemic clamp. Cardiometabolic profile was derived from blood parameters. Subcutaneous fat and vastus lateralis muscle biopsies were used for ex vivo analyses. Two-way repeated-measure ANOVA and linear mixed models were used to evaluate the response to lifestyle intervention and comparison between the two groups. Fat mass was decreased and bone mass was preserved in the two groups after intervention. Muscle mass decreased significantly in older obese men. Cardiovascular risk (Framingham risk score, plasma triglyceride and cholesterol) and insulin sensitivity were greatly improved to a similar extent in the two age groups after intervention. Changes in adipose tissue and skeletal muscle transcriptomes were marginal. Analysis of the differential response to the lifestyle intervention showed tenuous differences between age groups. These data suggest that lifestyle intervention combining calorie restriction and exercise shows similar beneficial effects on cardiometabolic risk and insulin sensitivity in younger and older obese men. However, attention must be paid to potential loss of muscle mass in response to weight loss in older obese men.",2021,"Cardiovascular risk (Framingham risk score, plasma triglyceride and cholesterol) and insulin sensitivity were greatly improved to a similar extent in the two age groups after intervention.","['older obese adults', 'younger and older obese men', '25 obese men (BMI 31-39 kg/m2) in two arms according to age (30-40 and 60-70 years old', 'older obese men', 'obese adults']","['lifestyle weight loss intervention', '8-week intervention with moderate calorie restriction (~20% below individual energy requirements) and supervised endurance training']","['Insulin sensitivity', 'Cardiovascular risk (Framingham risk score, plasma triglyceride and cholesterol) and insulin sensitivity', 'Cardiometabolic profile', 'cardiometabolic risk and insulin sensitivity', 'adipose tissue and skeletal muscle transcriptomes', 'Fat mass', 'Body composition', 'bone mass', 'Muscle mass']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0489460', 'cui_str': 'Energy requirement'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}]","[{'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0583329', 'cui_str': 'Plasma triglyceride measurement'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C3178810', 'cui_str': 'Transcriptomes'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}]",25.0,0.00787776,"Cardiovascular risk (Framingham risk score, plasma triglyceride and cholesterol) and insulin sensitivity were greatly improved to a similar extent in the two age groups after intervention.","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Vion', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Sramkova', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Montastier', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Marie-Adeline', 'Initials': 'MA', 'LastName': 'Marques', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Caspar-Bauguil', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Thibaut', 'Initials': 'T', 'LastName': 'Duparc', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Laurent O', 'Initials': 'LO', 'LastName': 'Martinez', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Bourlier', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Harant', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Larrouy', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Nabila', 'Initials': 'N', 'LastName': 'Moussaoui', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Bonnel', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Celine', 'Initials': 'C', 'LastName': 'Vindis', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Dray', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Valet', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Jean Sebastien', 'Initials': 'JS', 'LastName': 'Saulnier-Blache', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Schanstra', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Thalamas', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Viguerie', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Moro', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Langin', 'Affiliation': 'Institute of Metabolic and Cardiovascular Diseases, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR 1297, F-CRIN/FORCE network, Toulouse, France.'}]",American journal of physiology. Endocrinology and metabolism,['10.1152/ajpendo.00109.2021'] 1624,34252387,Rationale and design of a digital trial using smartphones to detect subclinical atrial fibrillation in a population at risk: The eHealth-based bavarian alternative detection of Atrial Fibrillation (eBRAVE-AF) trial.,"Current guidelines recommend opportunistic screening for subclinical atrial fibrillation (AF) taking advantage of e-health-based technologies. However, the efficacy of a fully scalable e-health-based strategy for AF detection in a head-to-head comparison with routine symptom-based screening is unknown. eBRAVE-AF is an investigator-initiated, digital, prospective, randomized, siteless, open-label, cross-over study to evaluate an e-health-based strategy for detection of AF in a real-world setting. 67,488 policyholders of a large German health insurance company (Versicherungskammer Bayern, Germany) selected by age ≥ 50 years and a CHA 2 DS 2 -VASc score ≥ 1 (females ≥2) are invited to participate. Subjects with known AF or on treatment with oral anticoagulation are excluded. After obtaining electronic informed consent, at least 4,400 participants will be randomly assigned to an e-health-based screening strategy or routine symptom-based screening. The e-health-based strategy consists of repetitive one-minute photoplethysmographic (PPG) pulse wave assessments using a certified smartphone app (Preventicus Heartbeats, Preventicus, Jena, Germany), followed by a confirmatory 14-day ECG patch (CardioMem CM 100 XT, Getemed, Teltow, Germany) in case of abnormal findings. After 6 months, participants are crossed over to the other study arm. Primary endpoint is the incidence of newly diagnosed AF leading to oral anticoagulation indicated by an independent physician. Clinical follow-up will be at least 12 months. In both groups, follow-up is performed by 4-week app-based questionnaires, personal contact in case of abnormal findings, and matching with claim-based insurance data and medical reports. At time of writing enrollment is completed. First results are expected to be available in mid-2021.",2021,"In both groups, follow-up is performed by 4-week app-based questionnaires, personal contact in case of abnormal findings, and matching with claim-based insurance data and medical reports.","['67,488 policyholders of a large German health insurance company (Versicherungskammer Bayern, Germany) selected by age ≥ 50 years and a CHA 2 DS 2 -VASc score ≥ 1 (females ≥2) are invited to participate', 'Subjects with known AF or on treatment with oral anticoagulation are excluded']",['e-health-based screening strategy or routine symptom-based screening'],['incidence of newly diagnosed AF leading to oral anticoagulation indicated by an independent physician'],"[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0574369', 'cui_str': 'Chamorro language'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0031831', 'cui_str': 'Physician'}]",,0.0651192,"In both groups, follow-up is performed by 4-week app-based questionnaires, personal contact in case of abnormal findings, and matching with claim-based insurance data and medical reports.","[{'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Freyer', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'von Stülpnagel', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Spielbichler', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Nikolay', 'Initials': 'N', 'LastName': 'Sappler', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Wenner', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schreinlechner', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Aresa', 'Initials': 'A', 'LastName': 'Krasniqi', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Amira', 'Initials': 'A', 'LastName': 'Behroz', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Eiffener', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Zens', 'Affiliation': 'Kliniken Ostallgaeu-Kaufbeuren, Fuessen Hospital, Germany.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Dolejsi', 'Affiliation': 'Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Massberg', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Konstantinos D', 'Initials': 'KD', 'LastName': 'Rizas', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Bauer', 'Affiliation': 'Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany; Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: axel.bauer@i-med.ac.at.'}]",American heart journal,['10.1016/j.ahj.2021.06.008'] 1625,34252001,Postactivation performance enhancement (PAPE) of sprint acceleration performance.,"Postactivation performance enhancement (PAPE) is a principle that an acute bout of high-intensity voluntary exercise is followed by an enhancement in strength, speed or power production. This study intended to show a direct correlation between intensity, specificity and the outcome of a maximal task of sprint accelerations compared to a previously defined weighted plyometric intervention. In a randomised controlled, double-blind trial, professional footballers undertook 20 m maximal sprint accelerations at a baseline and at 2 and 6 min post-intervention after 1 of 3 interventions; 2 repetitions of 20 m sprint accelerations (S), 3 × 10 alternative leg weighted bounding (P) and control (C). Relative to the baseline there was a significant improvement for S over 10 and 20 m at 2 min of 0.12m.s -1 and 0.11m.s -1 and 6 min of 0.11m.s -1 and 0.12m.s -1 . Relative to the baseline P also had a significant improvement over 10 and 20 m at 2 min 0.09m.s -1 and 0.09m.s -1 and 6 min of 0.11m.s -1 and 0.09m.s -1 . There was a significant improvement in C between 2 and 6 min post-intervention at 10 and 20 m of 0.06m.s -1 and 0.08m.s -1 . This finding suggests a maximal sprint acceleration may enhance the outcome of a subsequent maximal sprint acceleration at 2 min, but the latter results could not be directly attributed to the interventions as previous testing is likely to have influenced these outcomes.",2021,There was also a significant improvement in C between 2 and 6 minutes post-intervention at 10m and 20m of 0.06m .,[],"['Postactivation performance enhancement (PAPE', '20m sprint accelerations (S), 3x10 alternative leg weighted bounding (P) and control (C']",['Postactivation performance enhancement (PAPE) of sprint acceleration performance'],[],"[{'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}]",,0.155614,There was also a significant improvement in C between 2 and 6 minutes post-intervention at 10m and 20m of 0.06m .,"[{'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Brink', 'Affiliation': 'Faculty of Health Sciences, Centre for Exercise Science and Sports Medicine, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Demitri', 'Initials': 'D', 'LastName': 'Constantinou', 'Affiliation': 'Faculty of Health Sciences, Centre for Exercise Science and Sports Medicine, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Torres', 'Affiliation': 'Faculty of Health Sciences, Centre for Exercise Science and Sports Medicine, University of the Witwatersrand, Johannesburg, South Africa.'}]",European journal of sport science,['10.1080/17461391.2021.1955012'] 1626,34256114,Effect of intermittent hypoxic conditioning on inflammatory biomarkers in older adults.,"Ageing is associated with chronic low-grade inflammation and with a decrease in muscle mass and strength. The aim of the study was to evaluate the effect of a resistance training programme in conditions of intermittent hypoxia on inflammatory biomarkers in older people. A total of 54 older adults (aged 65-75 years), who voluntarily participated in the study, were randomly divided into three groups: the control (CON) group, the resistance training normoxia (RTN) group that performed resistance training in normoxia and resistance training hypoxia (RTH) group that trained under hypoxic conditions at a simulated altitude of 2500 m above sea level. The training programme that was carried out during 24 weeks was similar in both experimental groups and consisted of a full-body workout with elastic bands and kettlebells (three sets x 12-15 reps). Blood inflammatory parameters (CRP, VCAM-1, IL-6, IL-8 and IL-10) were analysed before and after the intervention. After the resistance training programme, a significant decrease in CRP and IL-8 levels was observed, as well as an increase in IL-10 levels, both in normoxia and hypoxia. These results show that resistance training, either in conditions of normoxia or hypoxia, is useful to deal with the chronic inflammation associated with ageing.",2021,"Blood inflammatory parameters (CRP, VCAM-1, IL-6, IL-8 and IL-10) were analysed before and after the intervention.","['54 older adults (aged 65-75\u202fyears), who voluntarily participated in the study', 'older people', 'older adults']","['resistance training programme', 'intermittent hypoxic conditioning', 'resistance training normoxia (RTN) group that performed resistance training in normoxia and resistance training hypoxia (RTH) group that trained under hypoxic conditions at a simulated altitude of 2500\u202fm above sea level', 'control (CON']","['CRP and IL-8 levels', 'IL-10 levels, both in normoxia and hypoxia', 'Blood inflammatory parameters (CRP, VCAM-1, IL-6, IL-8 and IL-10', 'inflammatory biomarkers']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0002349', 'cui_str': 'Altitude'}, {'cui': 'C4319601', 'cui_str': '2500'}, {'cui': 'C0036493', 'cui_str': 'Sea'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0078056', 'cui_str': 'Lymphocyte antigen CD106'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",54.0,0.0105529,"Blood inflammatory parameters (CRP, VCAM-1, IL-6, IL-8 and IL-10) were analysed before and after the intervention.","[{'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Timon', 'Affiliation': 'University of Extremadura, Faculty of Sport Sciences, Cáceres, Spain. Electronic address: rtimon@unex.es.'}, {'ForeName': 'Ismael', 'Initials': 'I', 'LastName': 'Martínez-Guardado', 'Affiliation': 'University of Extremadura, Faculty of Sport Sciences, Cáceres, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Camacho-Cardeñosa', 'Affiliation': 'University of Extremadura, Faculty of Sport Sciences, Cáceres, Spain.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Villa-Andrada', 'Affiliation': 'University of Extremadura, Faculty of Sport Sciences, Cáceres, Spain.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Olcina', 'Affiliation': 'University of Extremadura, Faculty of Sport Sciences, Cáceres, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Camacho-Cardeñosa', 'Affiliation': 'University of Extremadura, Faculty of Sport Sciences, Cáceres, Spain.'}]",Experimental gerontology,['10.1016/j.exger.2021.111478'] 1627,34256041,Safety and efficacy of short-term structured resistance exercise in Gulf War Veterans with chronic unexplained muscle pain: A randomized controlled trial.,"AIMS Chronic widespread musculoskeletal pain (CMP) is a primary condition of Veterans suffering from Gulf War illness. This study evaluated the influence of resistance exercise training (RET) on symptoms, mood, perception of improvement, fitness, and total physical activity in Gulf War Veterans (GWV) with CMP. MAIN METHODS Fifty-four GWV with CMP were randomly assigned to 16 weeks of RET (n = 28) or wait-list control (n = 26). Supervised exercise was performed twice weekly starting at a low intensity. Outcomes, assessed at baseline, 6, 11 and 17 weeks and 6- and 12-months post-intervention, were: pain, fatigue, mood, sleep quality, perception of improvement, and physical activity via self-report and accelerometry. Muscular strength was assessed at baseline, 8 and 16 weeks. Accelerometer data yielded estimates of time spent in sedentary, light, and moderate-to-vigorous physical activities. Analyses used separate linear mixed models with group and time point as fixed effects. All models, except for perceived improvement, included baseline values as a covariate. KEY FINDINGS Participants assigned to RET completed 87% of training sessions and exhibited strength increases between 16 and 34% for eight lifts tested (Hedges' g range: 0.47-0.78). The treatment by time interaction for perceived improvement (F 1,163  = 16.94, p < 0.001) was characterized by greater perceived improvement since baseline for RET at each time point, until the 12-month follow-up. Effects were not significant for other outcomes (p > 0.05). RET caused no adverse events. SIGNIFICANCE After 16 weeks of RET, GWV with CMP reported improvements in their condition and exhibited increases in muscular strength, without symptom exacerbation or reductions in total physical activity.",2021,"The treatment by time interaction for perceived improvement (F 1,163  = 16.94, p < 0.001) was characterized by greater perceived improvement since baseline for RET at each time point, until the 12-month follow-up.","['Gulf War Veterans (GWV) with CMP', 'Veterans suffering from Gulf War illness', 'Fifty-four GWV with CMP', 'Gulf War Veterans with chronic unexplained muscle pain']","['resistance exercise training (RET', 'Supervised exercise', 'RET', 'short-term structured resistance exercise', 'wait-list control']","['muscular strength', 'total physical activity', 'Safety and efficacy', 'pain, fatigue, mood, sleep quality, perception of improvement, and physical activity via self-report and accelerometry', 'time spent in sedentary, light, and moderate-to-vigorous physical activities', 'exhibited strength increases', 'symptoms, mood, perception of improvement, fitness, and total physical activity', 'Muscular strength']","[{'cui': 'C1449761', 'cui_str': 'Persian Gulf War, 1991'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205219', 'cui_str': 'Diffuse'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal pain'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0441677', 'cui_str': 'Accelerometry'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0562344,"The treatment by time interaction for perceived improvement (F 1,163  = 16.94, p < 0.001) was characterized by greater perceived improvement since baseline for RET at each time point, until the 12-month follow-up.","[{'ForeName': 'Aaron J', 'Initials': 'AJ', 'LastName': 'Stegner', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, WI, United States of America; University of Wisconsin-Madison, Madison, WI, United States of America. Electronic address: astegner@wisc.edu.'}, {'ForeName': 'Neda E', 'Initials': 'NE', 'LastName': 'Almassi', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, WI, United States of America; University of Wisconsin-Madison, Madison, WI, United States of America.'}, {'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Dougherty', 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.'}, {'ForeName': 'Laura D', 'Initials': 'LD', 'LastName': 'Ellingson', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, WI, United States of America; Western Oregon University, Monmouth, OR, United States of America.'}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Gretzon', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, WI, United States of America; University of Wisconsin-Madison, Madison, WI, United States of America.'}, {'ForeName': 'Jacob B', 'Initials': 'JB', 'LastName': 'Lindheimer', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, WI, United States of America; University of Wisconsin-Madison, Madison, WI, United States of America.'}, {'ForeName': 'Jacob V', 'Initials': 'JV', 'LastName': 'Ninneman', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, WI, United States of America; University of Wisconsin-Madison, Madison, WI, United States of America.'}, {'ForeName': 'Stephanie M', 'Initials': 'SM', 'LastName': 'Van Riper', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, WI, United States of America; University of Wisconsin-Madison, Madison, WI, United States of America.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': ""O'Connor"", 'Affiliation': 'University of Georgia, Athens, GA, United States of America.'}, {'ForeName': 'Dane B', 'Initials': 'DB', 'LastName': 'Cook', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, WI, United States of America; University of Wisconsin-Madison, Madison, WI, United States of America.'}]",Life sciences,['10.1016/j.lfs.2021.119810'] 1628,34256038,A randomized phase II remote study to assess Bacopa for Gulf War Illness associated cognitive dysfunction: Design and methods of a national study.,"AIMS Gulf War Illness (GWI) is a chronic, debilitating, multi-symptom condition affecting as many as one-third of the nearly 700,000 U.S. troops deployed to the Middle East during the 1990-1991 Gulf War (GW). The treatment of GWI relies on symptom management. A common challenge in studying the efficacy of interventions for symptom management is participant recruitment related to factors such as the burden of travelling to study sites and the widespread dispersion of Veterans with GWI. The goal of this study is to assess the efficacy of a novel low-risk therapeutic agent, Bacopa monnieri, for cognitive function in Veterans with GWI and to evaluate the utility of a remote patient-centric study design developed to promote recruitment and minimize participant burden. MAIN METHODS To promote effective participant recruitment, we developed a remote patient-centric study design. Participants will be recruited online through social media and through a web-based research volunteer list of GW Veterans. An online assessment platform will be used, and laboratory blood draws will be performed at clinical laboratory sites that are local to participants. Furthermore, the assigned intervention will be mailed to each participant. SIGNIFICANCE These study design adaptations will open participation to Veterans nearly nationwide and reduce administrative costs while maintaining methodologic rigor and participant safety in a randomized, placebo-controlled phase II clinical trial.",2021,"The goal of this study is to assess the efficacy of a novel low-risk therapeutic agent, Bacopa monnieri, for cognitive function in Veterans with GWI and to evaluate the utility of a remote patient-centric study design developed to promote recruitment and minimize participant burden. ","['Veterans with GWI', 'Participants will be recruited online through social media and through a web-based research volunteer list of GW Veterans']",['placebo'],[],"[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C1449761', 'cui_str': 'Persian Gulf War, 1991'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0692972,"The goal of this study is to assess the efficacy of a novel low-risk therapeutic agent, Bacopa monnieri, for cognitive function in Veterans with GWI and to evaluate the utility of a remote patient-centric study design developed to promote recruitment and minimize participant burden. ","[{'ForeName': 'Amanpreet K', 'Initials': 'AK', 'LastName': 'Cheema', 'Affiliation': 'Institute for Neuro Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States; Department of Nutrition, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States; Halmos College of Natural Sciences and Oceanography, Nova Southeastern University, Fort Lauderdale, FL, United States. Electronic address: acheema@nova.edu.'}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Wiener', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States.'}, {'ForeName': 'Rebecca B', 'Initials': 'RB', 'LastName': 'McNeil', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States.'}, {'ForeName': 'Maria M', 'Initials': 'MM', 'LastName': 'Abreu', 'Affiliation': 'Institute for Neuro Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States; Miami VA Healthcare System, Miami, FL, United States.'}, {'ForeName': 'Travis', 'Initials': 'T', 'LastName': 'Craddock', 'Affiliation': 'Institute for Neuro Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States; Department of Psychology and Neuroscience, Nova Southeastern University, Fort Lauderdale, FL, United States; Department of Computer Science, Nova Southeastern University, Fort Lauderdale, FL, United States.'}, {'ForeName': 'Mary A', 'Initials': 'MA', 'LastName': 'Fletcher', 'Affiliation': 'Institute for Neuro Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States; Miami VA Healthcare System, Miami, FL, United States.'}, {'ForeName': 'Drew A', 'Initials': 'DA', 'LastName': 'Helmer', 'Affiliation': 'Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, United States; Department of Medicine, Baylor College of Medicine, Houston, TX, United States.'}, {'ForeName': 'J Wesson', 'Initials': 'JW', 'LastName': 'Ashford', 'Affiliation': 'War Related Illness & Injury Study Center (WRIISC), VA Palo Alto Health Care System, Palo Alto, CA, United States; Department of Psychiatry & Behavioral Sciences, College of Medicine, Stanford University, Palo Alto, CA, United States.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Sullivan', 'Affiliation': 'Department of Environmental Health, Boston University School of Public Health, Boston, MA, United States.'}, {'ForeName': 'Nancy G', 'Initials': 'NG', 'LastName': 'Klimas', 'Affiliation': 'Institute for Neuro Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States; Miami VA Healthcare System, Miami, FL, United States.'}]",Life sciences,['10.1016/j.lfs.2021.119819'] 1629,34256014,Gut-microbiota-targeted diets modulate human immune status.,"Diet modulates the gut microbiome, which in turn can impact the immune system. Here, we determined how two microbiota-targeted dietary interventions, plant-based fiber and fermented foods, influence the human microbiome and immune system in healthy adults. Using a 17-week randomized, prospective study (n = 18/arm) combined with -omics measurements of microbiome and host, including extensive immune profiling, we found diet-specific effects. The high-fiber diet increased microbiome-encoded glycan-degrading carbohydrate active enzymes (CAZymes) despite stable microbial community diversity. Although cytokine response score (primary outcome) was unchanged, three distinct immunological trajectories in high-fiber consumers corresponded to baseline microbiota diversity. Alternatively, the high-fermented-food diet steadily increased microbiota diversity and decreased inflammatory markers. The data highlight how coupling dietary interventions to deep and longitudinal immune and microbiome profiling can provide individualized and population-wide insight. Fermented foods may be valuable in countering the decreased microbiome diversity and increased inflammation pervasive in industrialized society.",2021,The high-fiber diet increased microbiome-encoded glycan-degrading carbohydrate active enzymes (CAZymes) despite stable microbial community diversity.,['healthy adults'],[],['microbiota diversity and decreased inflammatory markers'],"[{'cui': 'C0686750', 'cui_str': 'Well adult'}]",[],"[{'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",,0.0191515,The high-fiber diet increased microbiome-encoded glycan-degrading carbohydrate active enzymes (CAZymes) despite stable microbial community diversity.,"[{'ForeName': 'Hannah C', 'Initials': 'HC', 'LastName': 'Wastyk', 'Affiliation': 'Department of Bioengineering, Stanford School of Medicine, Stanford, CA 94305, USA.'}, {'ForeName': 'Gabriela K', 'Initials': 'GK', 'LastName': 'Fragiadakis', 'Affiliation': 'Microbiology & Immunology, Stanford School of Medicine, Stanford, CA 94305, USA.'}, {'ForeName': 'Dalia', 'Initials': 'D', 'LastName': 'Perelman', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford School of Medicine, Stanford, CA 94305, USA.'}, {'ForeName': 'Dylan', 'Initials': 'D', 'LastName': 'Dahan', 'Affiliation': 'Microbiology & Immunology, Stanford School of Medicine, Stanford, CA 94305, USA.'}, {'ForeName': 'Bryan D', 'Initials': 'BD', 'LastName': 'Merrill', 'Affiliation': 'Microbiology & Immunology, Stanford School of Medicine, Stanford, CA 94305, USA.'}, {'ForeName': 'Feiqiao B', 'Initials': 'FB', 'LastName': 'Yu', 'Affiliation': 'Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.'}, {'ForeName': 'Madeline', 'Initials': 'M', 'LastName': 'Topf', 'Affiliation': 'Microbiology & Immunology, Stanford School of Medicine, Stanford, CA 94305, USA.'}, {'ForeName': 'Carlos G', 'Initials': 'CG', 'LastName': 'Gonzalez', 'Affiliation': 'Department of Chemical and Systems Biology, Stanford School of Medicine, Stanford University, Stanford, CA 94305, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Van Treuren', 'Affiliation': 'Microbiology & Immunology, Stanford School of Medicine, Stanford, CA 94305, USA.'}, {'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': 'Microbiology & Immunology, Stanford School of Medicine, Stanford, CA 94305, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Robinson', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford School of Medicine, Stanford, CA 94305, USA.'}, {'ForeName': 'Joshua E', 'Initials': 'JE', 'LastName': 'Elias', 'Affiliation': 'Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.'}, {'ForeName': 'Erica D', 'Initials': 'ED', 'LastName': 'Sonnenburg', 'Affiliation': 'Microbiology & Immunology, Stanford School of Medicine, Stanford, CA 94305, USA; Center for Human Microbiome Studies, Stanford School of Medicine, Stanford University, Stanford, CA 94305, USA. Electronic address: erica.sonnenburg@stanford.edu.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Gardner', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford School of Medicine, Stanford, CA 94305, USA. Electronic address: cgardner@stanford.edu.'}, {'ForeName': 'Justin L', 'Initials': 'JL', 'LastName': 'Sonnenburg', 'Affiliation': 'Microbiology & Immunology, Stanford School of Medicine, Stanford, CA 94305, USA; Center for Human Microbiome Studies, Stanford School of Medicine, Stanford University, Stanford, CA 94305, USA. Electronic address: jsonnenburg@stanford.edu.'}]",Cell,['10.1016/j.cell.2021.06.019'] 1630,34263648,"Cardioprotective effect of saffron total glycoside tablets in patients with breast cancer receiving anthracycline-based chemotherapy: study protocol for a multicentre, randomised, parallel, double-blind, placebo-controlled clinical trial.","BACKGROUND Breast cancer is the most common cancer worldwide. Anthracyclines, alone or in combination with other chemotherapeutic agents, are the most effective chemotherapy agents against breast cancer. However, the dose-dependent cardiotoxicity of anthracyclines is a serious drawback in clinical treatment. Considerable efforts have been made to establish suggestions to avoid anthracycline-induced cardiotoxicity. Crocin extracted from saffron has potential cardioprotective effects against anthracycline-induced cardiotoxicity. The aim of this study was to estimate the cardioprotective effects and safety of saffron total glycoside tablets relative to placebo in patients with breast cancer undergoing anthracycline-based chemotherapy. METHODS This is a multicentre, randomised, double-blind, placebo-controlled clinical trial. A sample of 200 participants (100 per group) with breast cancer will be randomly assigned to receive either saffron total glycoside tablet or placebo (four tablets each time, three times each day) for 6 months. Each participant will be interviewed three times: baseline (visit 1), after 3 months (visit 2), and after 6 months (visit 3). The primary outcome is to confirm if administration of saffron total glycoside tablets reduces the rate of cardiotoxicity relative to that with placebo. Secondary outcomes include new arrhythmic events, and cardiac troponin I and N-terminal pro-B-type natriuretic peptide levels. The quantity, quality, and severity of the adverse events will be carefully documented. DISCUSSION We look forward to obtaining high-quality evidence that can be used to formulate clinical practice guidelines. Thus, the findings of this study are expected to help fill the current gap in cardiotoxicity prevention drugs. TRIAL REGISTRATION This trial was published in the Chinese Clinical Trial Registry (No. ChiCTR2000041134, registered on 19th December 2020).",2021,"Secondary outcomes include new arrhythmic events, and cardiac troponin I and N-terminal pro-B-type natriuretic peptide levels.","['patients with breast cancer undergoing anthracycline-based chemotherapy', 'patients with breast cancer receiving', '200 participants (100 per group) with breast cancer']","['Anthracyclines, alone or in combination with other chemotherapeutic agents', 'anthracycline-based chemotherapy', 'saffron total glycoside tablets', 'placebo', 'saffron total glycoside tablet or placebo']","['rate of cardiotoxicity relative', 'quantity, quality, and severity of the adverse events', 'new arrhythmic events, and cardiac troponin I and N-terminal pro-B-type natriuretic peptide levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C3653881', 'cui_str': 'Other chemotherapeutics'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0162753', 'cui_str': 'Saffron Stain'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0007158', 'cui_str': 'Glycoside'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0876994', 'cui_str': 'Cardiotoxicity'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0883409', 'cui_str': 'Cardiac troponin I'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",200.0,0.825277,"Secondary outcomes include new arrhythmic events, and cardiac troponin I and N-terminal pro-B-type natriuretic peptide levels.","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Su', 'Affiliation': ""Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Xiang-Ying', 'Initials': 'XY', 'LastName': 'Li', 'Affiliation': ""Xingtai People's Hospital, Xingtai, China.""}, {'ForeName': 'Yi-Jun', 'Initials': 'YJ', 'LastName': 'Zhang', 'Affiliation': 'The First Affiliated Hospital, Hebei North University, Zhangjiakou, China.'}, {'ForeName': 'Yong-Sheng', 'Initials': 'YS', 'LastName': 'Liu', 'Affiliation': ""Jiaozuo Fourth People's Hospital, Jiaozuo, China.""}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Yuan', 'Affiliation': ""Dezhou Second People's Hospital, Dezhou, China.""}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': ""Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': ""Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Heng-Wen', 'Initials': 'HW', 'LastName': 'Chen', 'Affiliation': ""Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Xing-Jiang', 'Initials': 'XJ', 'LastName': 'Xiong', 'Affiliation': ""Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Yong-Hong', 'Initials': 'YH', 'LastName': 'Gao', 'Affiliation': 'Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Yan-Wei', 'Initials': 'YW', 'LastName': 'Xing', 'Affiliation': ""Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}]",Annals of palliative medicine,['10.21037/apm-21-444'] 1631,34263647,"Immediate effects of Zhongji point acupuncture on pelvic floor structure in female patients with stress urinary incontinence: a randomized, single-blind, and sham-controlled clinical trial protocol.","BACKGROUND Stress urinary incontinence (SUI) is defined as involuntary leakage of urine from the external urethra due to increased abdominal pressure, for example, upon sneezing, coughing, or exercise. Acupuncture is an effective therapy for patients with SUI, although objective evidence of its benefits or mechanism of action is limited. Patients with SUI often harbor structural changes of pelvic floor, the parameters of which are measurable from various perspectives and in multiple dimensions, dynamically and comprehensively, through transperineal ultrasound (TPUS). The status of such changes may then be assessed following acupuncture procedures. In the present investigation, TPUS serves to gauge the immediate effects of acupuncture on pelvic floor structures in female patients with SUI. METHODS This protocol calls for a prospective, randomized, controlled, and single-blinded study of 72 female patients with SUI, each randomly assigned as test or control group members. The test group is subjected to one-time acupuncture at the Zhongji (RN3) acupoint for a period of 10 min, whereas the control group undergoes sham acupuncture in the same manner. In both groups, TPUS imaging of pelvic floor is performed before, during, and immediately after acupuncture procedures. Bladder neck mobility (BND), urethral rotation angle (URA), retrovesical angle (RVA), lowest point of bladder (BN-S), and presence/absence of urethral funneling or bladder bulging are then recorded as outcome measures. DISCUSSION Above efforts are intended to assess real-time pelvic floor structural changes in women undergoing acupuncture for SUI. The subsequent findings may help objectively document the efficacy of acupuncture in this setting and clarify its mechanism of action. TRIAL REGISTRATION Registration with the Chinese Clinical Trial Registry (ChiCTR200041559) (http://www.chictr.org.cn/edit.aspx?pid=64591&htm=4), was effective December 29, 2020. DATES OF STUDY 12/19/2020 to 06/30/2022.",2021,"Bladder neck mobility (BND), urethral rotation angle (URA), retrovesical angle (RVA), lowest point of bladder (BN-S), and presence/absence of urethral funneling or bladder bulging are then recorded as outcome measures. ","['72 female patients with SUI', 'female patients with stress urinary incontinence', 'female patients with SUI', 'women undergoing acupuncture for SUI', 'patients with SUI']","['acupuncture', 'acupuncture at the Zhongji (RN3) acupoint', 'Zhongji point acupuncture', 'control group undergoes sham acupuncture', 'Acupuncture']","['Bladder neck mobility (BND), urethral rotation angle (URA), retrovesical angle (RVA), lowest point of bladder (BN-S), and presence/absence of urethral funneling or bladder bulging are then recorded as outcome measures', 'pelvic floor structure']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0227716', 'cui_str': 'Structure of neck of urinary bladder'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0041967', 'cui_str': 'Urethral'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}]",72.0,0.112172,"Bladder neck mobility (BND), urethral rotation angle (URA), retrovesical angle (RVA), lowest point of bladder (BN-S), and presence/absence of urethral funneling or bladder bulging are then recorded as outcome measures. ","[{'ForeName': 'Li-Xin', 'Initials': 'LX', 'LastName': 'Guan', 'Affiliation': 'Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Xiu-Ling', 'Initials': 'XL', 'LastName': 'Song', 'Affiliation': 'Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Xuhui Hospital, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Xuhui Hospital, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Lu-Min', 'Initials': 'LM', 'LastName': 'Liu', 'Affiliation': 'Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Bing-Li', 'Initials': 'BL', 'LastName': 'Chen', 'Affiliation': 'Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Yue-Lai', 'Initials': 'YL', 'LastName': 'Chen', 'Affiliation': 'Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}]",Annals of palliative medicine,['10.21037/apm-21-662'] 1632,34263641,Specific survival nomograms based on SEER database for small intestine adenocarcinoma.,"BACKGROUND Small intestine cancers, as an extremely rare tumor type, account only for 3% of all gastrointestinal tumors. Small intestine adenocarcinoma (SIA), representing approximately one-third of all small bowel cancers, has received relatively little attention, both in research efforts and clinical cognizance. Owing to anatomical proximity and rarity, small bowel adenocarcinomas are frequently grouped with colorectal adenocarcinomas. Therefore, a large SIA patient cohort is needed to develop and validate new nomogram prognostic models specific to SIA patients. METHODS Patients diagnosed with SIA between 2004 and 2016 were extracted from the Surveillance, Epidemiology, and Final Results (SEER) database. All patients were randomly assigned to the training cohort and the validation cohort (2:1). The basic clinical information, detailed pathological staging, and treatment information of the patients were included in the analysis. Nomograms were shaped following the evaluations of the Cox regression model and verified using the decision curve analysis (DCA), time-dependent receiver operating characteristic (ROC) curves, concordance index (C-index), and calibration curves. RESULTS The entire group comprised 6,947 patients with small intestine adenocarcinoma. According to the results of the multivariate Cox regression analysis, ten variables, including marital status, age, pathological grade, tumor location, T (tumor), N (nodes), M (metastasis) stage, surgery, chemotherapy, and regional nodes examined (RNE), were independent predictors of both of overall survival (OS) and cancer-specific survival (CSS). All significant variables were used to create the nomograms for OS and CSS. Various methods verified the reliability of the nomograms. The C-indexes of the OS and CSS nomogram were 0.756 (95% CI, 0.748-0.764) and 0.771 (95% CI, 0.761-0.781) in the training cohort and 0.748 (95% CI, 0.736-0.760) and 0.767 (95% CI, 0.752-0.781) in the validation cohort. The calibration curve showed good agreement between the nomogram prediction and actual survival. DCA indicated a clear net benefit of these new forecasting models. CONCLUSIONS This study built and verified nomograms to predict OS and CSS for rare SIA, which appear to be excellent tools to augment the clinically available evidence to facilitate the discussion between SIA patients and clinicians regarding therapeutic choice.",2021,"The C-indexes of the OS and CSS nomogram were 0.756 (95% CI, 0.748-0.764) and 0.771 (95% CI, 0.761-0.781) in the training cohort and 0.748 (95% CI, 0.736-0.760) and 0.767 (95% CI, 0.752-0.781) in the validation cohort.","['small intestine adenocarcinoma', '6,947 patients with small intestine adenocarcinoma', 'Small intestine adenocarcinoma (SIA), representing approximately one-third of all small bowel cancers', 'Patients diagnosed with SIA between 2004 and 2016 were extracted from the Surveillance, Epidemiology, and Final Results (SEER) database']",['DCA'],"['overall survival (OS) and cancer-specific survival (CSS', 'decision curve analysis (DCA), time-dependent receiver operating characteristic (ROC) curves, concordance index (C-index), and calibration curves', 'marital status, age, pathological grade, tumor location, T (tumor), N (nodes), M (metastasis) stage, surgery, chemotherapy, and regional nodes examined (RNE']","[{'cui': 'C0278803', 'cui_str': 'Adenocarcinoma of small intestine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0153425', 'cui_str': 'Malignant tumor of small intestine'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0014507', 'cui_str': 'Epidemiology'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}]","[{'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0006751', 'cui_str': 'Calibration'}, {'cui': 'C0024819', 'cui_str': 'Marital status'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0007591', 'cui_str': 'Cell division phase'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}]",6947.0,0.12985,"The C-indexes of the OS and CSS nomogram were 0.756 (95% CI, 0.748-0.764) and 0.771 (95% CI, 0.761-0.781) in the training cohort and 0.748 (95% CI, 0.736-0.760) and 0.767 (95% CI, 0.752-0.781) in the validation cohort.","[{'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, China; Department of General Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Chenglong', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Yuqiang', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, China; Department of General Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Wenxue', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': ""Department of Rheumatology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China; Department of Cardiology, Xiangya Hospital, Central South University, Changsha, China.""}, {'ForeName': 'Lilan', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': 'Department of Thoracic surgery, Fujian Provincial Hospital, Fuzhou, China.'}, {'ForeName': 'Cenap', 'Initials': 'C', 'LastName': 'Güngör', 'Affiliation': 'Department of General Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Fengbo', 'Initials': 'F', 'LastName': 'Tan', 'Affiliation': 'Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, China.'}]",Annals of palliative medicine,['10.21037/apm-21-600'] 1633,34263623,Low dose intraoperative ketamine infusion with multilevel paravertebral block for pain after video-assisted thoracic surgery: a randomized-controlled study.,"BACKGROUND Intraoperative low-dose ketamine infusion has been reported to be an effective adjuvant to opioids for postoperative pain control without major side effects, but it has not been tested in video-assisted thoracic surgery (VATS). The aim of this study was to examine the effect of low-dose intraoperative intravenous ketamine infusion on 24-hour morphine requirement and acute postoperative pain following VATS for lung resection. METHODS This study was a single center, randomized, double-blind, placebo-controlled study. Thirty-two patients undergoing elective VATS for lung resection in a university hospital were included. Patients were randomly allocated (1:1 ratio) to receive either intraoperative low-dose ketamine (0.2 mg/kg/h) or normal saline infusion starting from intubation to the beginning of chest closure. All patients received multilevel thoracic paravertebral block (TPVB) and morphine was administered postoperatively via the patient-controlled analgesia pump using the same protocol. Time to first analgesia, postoperative cumulative morphine doses at 10, 30 minutes, and the consecutive 1, 2, 6, 12, 18, and 24 hours were recorded. Pain intensity during rest and deep breathing were also assessed by numeric rating scale (NRS) score at 1- and 24-hour postoperatively. RESULTS There was no significant difference in median (P25, P75) cumulative 24-hour morphine requirement between the ketamine and the control groups [15 (5.5, 29.5) vs. 22.5 (15.3, 40.8) mg, P=0.090]. Patients in ketamine group had significantly longer median pain free time than the control group (27 vs. 2 minutes, P=0.006). No difference in overall NRS score at rest or during deep breathing at 1- and 24-hour postoperatively was demonstrated (P=0.861). CONCLUSIONS Intraoperative low dose ketamine infusion in addition to TPVB does not reduce postoperative morphine consumption or pain intensity but may prolong pain free time in patients undergoing VATS for lung resection.",2021,"No difference in overall NRS score at rest or during deep breathing at 1- and 24-hour postoperatively was demonstrated (P=0.861). ","['patients undergoing VATS for lung resection', 'following VATS for lung resection', 'pain after video-assisted thoracic surgery', 'Thirtytwo patients undergoing elective VATS for lung resection in a university hospital were included']","['ketamine infusion with multilevel paravertebral block', 'multilevel thoracic paravertebral block (TPVB) and morphine', 'intraoperative low-dose ketamine', 'normal saline infusion starting from intubation', 'ketamine', 'placebo']","['overall NRS score', '24-hour morphine requirement and acute postoperative pain', 'Time to first analgesia, postoperative cumulative morphine doses', 'median pain free time', 'median (P25, P75) cumulative 24-hour morphine requirement', 'numeric rating scale (NRS) score', 'Pain intensity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039986', 'cui_str': 'Thoracic surgery'}, {'cui': 'C0396565', 'cui_str': 'Lung excision'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C2215257', 'cui_str': 'Acute postoperative pain'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0908489', 'cui_str': 'Pain-Free'}, {'cui': 'C0215955', 'cui_str': 'LCN2 protein, human'}, {'cui': 'C1259013', 'cui_str': 'IL2RB protein, human'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",,0.563951,"No difference in overall NRS score at rest or during deep breathing at 1- and 24-hour postoperatively was demonstrated (P=0.861). ","[{'ForeName': 'Sirilak', 'Initials': 'S', 'LastName': 'Suksompong', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Nophanan', 'Initials': 'N', 'LastName': 'Chaikittisilpa', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Suthatip', 'Initials': 'S', 'LastName': 'Wanchiange', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Suppachai', 'Initials': 'S', 'LastName': 'Poolsuppasit', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Punnarerk', 'Initials': 'P', 'LastName': 'Thongcharoen', 'Affiliation': 'Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Panop', 'Initials': 'P', 'LastName': 'Limratana', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}]",Annals of palliative medicine,['10.21037/apm-21-766'] 1634,34261468,Assessing the impact of an educational intervention program based on the theory of planned behavior on the nutritional behaviors of adolescents and young adults with PCOS in Iran: a field trial study.,"BACKGROUND Polycystic ovary syndrome is the most common endocrine disorder among adolescents and adults. Given the importance of healthy nutritional behaviors in management of this disease, the present study was conducted to determine the impact of an educational intervention program based on the theory of planned behavior on the nutritional behaviors of adolescents and young adults with polycystic ovary syndrome. METHODS In this field trial study, 72 participants aged between 15 and 21 years old from four gynecology clinics in Shiraz, Iran, were assigned into the intervention and control groups. Educational intervention program was implemented based on the theory of planned behavior over 4 sessions during two weeks. The data collection tools were researcher-made questionnaires of demographic information, knowledge assessment, and assessment of theory of planned behavior constructs, as well as a questionnaire for assessing consumption of food groups, fast food, and snacks. The data were collected at two stages (once at baseline and once three months after the intervention), and then the changes in knowledge, attitude, subjective norms, the perceived behavioral control, behavioral intention, and nutritional behavior were analyzed using descriptive and inferential statistical methods (t-test, Chi-square, Mann- Whitney U, and Wilcoxon tests; as well as one- way ANOVA, repeated measures ANOVA, and ANCOVA, respectively). RESULTS Statistically significant increases were observed in the mean scores of knowledge, attitude, subjective norms, the perceived behavioral control, behavioral intention, and nutritional behavior in the intervention group by passing three months from the intervention compared to the scores before the intervention (P < 0.001). However, these differences were not statistically significant in the control group (P > 0.05). Moreover, the mean scores of knowledge, attitude, subjective norms, perceived behavioral control, behavioral intention, and nutritional behavior had no statistically significant difference before the intervention between the two groups; however, this was statistically significant by passing three months from the intervention (P < 0.001). CONCLUSION Considering the effect of an educational intervention program based on the theory of planned behavior on creating healthy nutritional behaviors in adolescents and young adults with polycystic ovary syndrome, it is recommended to use it in order to improve the nutritional health of them. TRIAL REGISTRATION IRCT, IRCT20160224026756N6. Registered 18 Aug 2018, https://en.irct.ir/user/trial/32693/view.",2021,"Statistically significant increases were observed in the mean scores of knowledge, attitude, subjective norms, the perceived behavioral control, behavioral intention, and nutritional behavior in the intervention group by passing three months from the intervention compared to the scores before the intervention (P < 0.001).","['72 participants aged between 15 and 21\xa0years old from four gynecology clinics in Shiraz, Iran', 'adolescents and young adults with polycystic ovary syndrome', 'adolescents and adults', 'adolescents and young adults with PCOS in Iran']","['Educational intervention program', 'educational intervention program']","['mean scores of knowledge, attitude, subjective norms, perceived behavioral control, behavioral intention, and nutritional behavior', 'knowledge, attitude, subjective norms, the perceived behavioral control, behavioral intention, and nutritional behavior', 'healthy nutritional behaviors', 'mean scores of knowledge, attitude, subjective norms, the perceived behavioral control, behavioral intention, and nutritional behavior']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3839674', 'cui_str': 'Gynecology clinic'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",72.0,0.01054,"Statistically significant increases were observed in the mean scores of knowledge, attitude, subjective norms, the perceived behavioral control, behavioral intention, and nutritional behavior in the intervention group by passing three months from the intervention compared to the scores before the intervention (P < 0.001).","[{'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Hajivandi', 'Affiliation': 'Department of Nursing and Midwifery, Kazerun Medical Sciences Branch, Islamic Azad University, Kazerun, Iran.'}, {'ForeName': 'Mahnaz', 'Initials': 'M', 'LastName': 'Noroozi', 'Affiliation': 'Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran. noroozi@nm.mui.ac.ir.'}, {'ForeName': 'Firoozeh', 'Initials': 'F', 'LastName': 'Mostafavi', 'Affiliation': 'Department of Health Education and Promotion, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Ekramzadeh', 'Affiliation': 'Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",BMC pediatrics,['10.1186/s12887-021-02784-z'] 1635,34261437,Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome.,"BACKGROUND AND OBJECTIVE Recently, dietary restriction of fermentable carbohydrates (a low-FODMAP diet) in combination with a gluten-free diet (GFD) has been proposed to reduce the symptoms in irritable bowel syndrome (IBS) patients. Different studies reported that IBS has been associated with dysbiosis in the gut microbiota. Additionally, a few studies have reported inflammation in the gastrointestinal (GI) system of adults with IBS. In this study, we aimed to investigate the effects of low FODMAP-gluten free diet (LF-GFD) on clinical symptoms, intestinal microbiota diversity, and fecal calprotectin (FC) level in Iranian patients with IBS. DESIGN In this clinical trial study, 42 patients with IBS (Rome IV criteria) underwent LF-GFD intervention for 6 weeks. Symptoms were assessed using the IBS symptom severity scoring (IBS-SSS), and fecal samples were collected at baseline and after intervention and analyzed by quantitative 16 S rRNA PCR assay. The diversity of gut microbiota compared before and after 6 weeks of dietary intervention. FC was also analyzed by the ELISA method. RESULTS Thirty patients (mean age 37.8 ± 10.7 years) completed the 6-week diet. The IBS-SSS was significantly (P = 0.001) reduced after LF-GFD intervention compared to the baseline. Significant microbial differences before and after intervention were noticed in fecal samples. A significant increase was found in Bacteroidetes, and the Firmicutes to Bacteroidetes (F/B) ratio was significantly (P = 0.001) decreased after the dietary intervention. The value of FC was significantly decreased after 6 weeks of dietary intervention (P = 0.001). CONCLUSIONS Our study suggests that patients with IBS under an LF-GFD had a significant improvement in IBS symptoms severity, with reduced FC level following normalization of their gut microbiota composition. Further rigorous trials are needed to establish a long-term efficacy and safety of this dietary intervention for personalized nutrition in IBS. Clinical Trial Registry Number: IRCT20100524004010N26.",2021,The IBS-SSS was significantly (P = 0.001) reduced after LF-GFD intervention compared to the baseline.,"['Iranian patients with irritable bowel syndrome', '42 patients with IBS (Rome IV criteria) underwent', 'Thirty patients (mean age 37.8\u2009±\u200910.7 years', 'patients with IBS under an LF-GFD', 'adults with IBS', 'irritable bowel syndrome (IBS) patients', 'Iranian patients with IBS']","['gluten-free diet (GFD', 'low FODMAP-gluten free diet', 'LF-GFD intervention', 'low FODMAP-gluten free diet (LF-GFD']","['Bacteroidetes, and the Firmicutes to Bacteroidetes (F/B', 'IBS symptoms severity', 'fecal samples', 'FC level', 'FC', 'value of FC', 'IBS-SSS', 'gut microbiota alterations and symptom severity', 'IBS symptom severity scoring (IBS-SSS), and fecal samples', 'clinical symptoms, intestinal microbiota diversity, and fecal calprotectin (FC) level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191365', 'cui_str': '10.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0344351', 'cui_str': 'Gluten free diet'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0344351', 'cui_str': 'Gluten free diet'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0037052', 'cui_str': 'Sick sinus syndrome'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",42.0,0.0268907,The IBS-SSS was significantly (P = 0.001) reduced after LF-GFD intervention compared to the baseline.,"[{'ForeName': 'Kaveh', 'Initials': 'K', 'LastName': 'Naseri', 'Affiliation': 'Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Dabiri', 'Affiliation': 'Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Rostami-Nejad', 'Affiliation': 'Celiac Disease Department, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. m.rostamii@gmail.com.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Yadegar', 'Affiliation': 'Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Shahid Arabi Ave., Yemen St., Velenjak, Tehran, Iran. a.yadegar@sbmu.ac.ir.'}, {'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Houri', 'Affiliation': 'Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Shahid Arabi Ave., Yemen St., Velenjak, Tehran, Iran.'}, {'ForeName': 'Meysam', 'Initials': 'M', 'LastName': 'Olfatifar', 'Affiliation': 'Celiac Disease Department, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Sadeghi', 'Affiliation': 'Celiac Disease Department, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeede', 'Initials': 'S', 'LastName': 'Saadati', 'Affiliation': 'Celiac Disease Department, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Ciacci', 'Affiliation': 'Gastrointestinal Unit, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, Università di Salerno, Via Allende, 84081, Salerno, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Iovino', 'Affiliation': 'Gastrointestinal Unit, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, Università di Salerno, Via Allende, 84081, Salerno, Italy.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Zali', 'Affiliation': 'Celiac Disease Department, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",BMC gastroenterology,['10.1186/s12876-021-01868-5'] 1636,34261364,"Effects of remifentanil on pharyngeal swallowing and esophageal motility - no impact of different bolus volumes, and partial antagonism by methylnaltrexone.","Background Remifentanil impairs swallowing, and disturbed accommodation to bolus volume may be one of the underlying causes. It is not fully understood whether remifentanil-induced swallowing dysfunction is mediated by peripheral or central mechanisms. Aims To investigate if remifentanil-induced swallowing dysfunction is dependent on the bolus volume and whether the effect of remifentanil could be counteracted by methylnaltrexone, a peripherally acting opioid antagonist. Methods Nineteen healthy volunteers were included in this double-blinded, randomized, placebo-controlled, crossover study. Study participants received target-controlled remifentanil infusions and placebo infusions in a randomized order. Methylnaltrexone was administered by intravenous injection of doses of 0.3 mg/kg. Recordings of pressure and impedance data were acquired using a combined manometry and impedance solid state catheter. Data was analyzed from three series of bolus swallows, baseline, during remifentanil exposure, and 15 min after methylnaltrexone. Results Remifentanil induced significant effects on multiple pharyngeal and esophageal function parameters. No significant differences in remifentanil-induced swallowing dysfunction related to different bolus volumes were found. Pharyngeal effects of remifentanil were not significantly counteracted by methylnaltrexone, whereas on the distal esophageal level, effects on distension pressures were counteracted. Conclusions Changes in pharyngeal and esophageal pressure flow variables were consistent with previous results on remifentanil-induced swallowing dysfunction, and uniform across all bolus volumes. The effects of remifentanil on the pharyngeal level and on the proximal esophagus appear to be predominantly centrally mediated, whereas the effects of remifentanil on the distal esophagus may be mediated by both central and peripheral mechanisms.",2021,"Pharyngeal effects of remifentanil were not significantly counteracted by methylnaltrexone, whereas on the distal esophageal level, effects on distension pressures were counteracted.",['Methods Nineteen healthy volunteers'],"['Remifentanil', 'remifentanil infusions and placebo infusions', ' Remifentanil', 'placebo', 'Methylnaltrexone', 'remifentanil']","['pharyngeal swallowing and esophageal motility', 'multiple pharyngeal and esophageal function parameters', 'Pharyngeal effects', 'remifentanil-induced swallowing dysfunction', 'distal esophageal level, effects on distension pressures']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0066411', 'cui_str': 'methylnaltrexone'}]","[{'cui': 'C0031354', 'cui_str': 'Pharyngeal structure'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1531882', 'cui_str': 'Esophageal function'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",19.0,0.0882349,"Pharyngeal effects of remifentanil were not significantly counteracted by methylnaltrexone, whereas on the distal esophageal level, effects on distension pressures were counteracted.","[{'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Cajander', 'Affiliation': 'Department of Anesthesiology and Intensive Care, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Taher I', 'Initials': 'TI', 'LastName': 'Omari', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Cock', 'Affiliation': 'Department of Gastroenterology and Hepatology, Flinders Medical Centre, Southern Adelaide Local Health Network, and College of Medicine and Public Health, Flinders University, South Australia.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Magnuson', 'Affiliation': 'Clinical Epidemiology and Biostatistics, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Scheinin', 'Affiliation': 'Institute of Biomedicine, University of Turku, and Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Savilampi', 'Affiliation': 'Department of Anesthesiology and Intensive Care, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.'}]",American journal of physiology. Gastrointestinal and liver physiology,['10.1152/ajpgi.00137.2021'] 1637,34280820,Exercise-induced increases in Anandamide and BDNF during extinction consolidation contribute to reduced threat following reinstatement: Preliminary evidence from a randomized controlled trial.,"INTRODUCTION We recently demonstrated that moderate-intensity aerobic exercise delivered during the consolidation of fear extinction learning reduced threat expectancy during a test of extinction recall among women with posttraumatic stress disorder (PTSD). These findings suggest that exercise may be a potential candidate for improving the efficacy of exposure-based therapies, which are hypothesized to work via the mechanisms of fear extinction learning. The purpose of this secondary analysis was to examine whether exercise-induced increases in circulating concentrations of candidate biomarkers: endocannabinoids (anandamide [AEA]; 2-arachidonoylglycerol [2-AG], brain-derived neurotrophic factor (BDNF), and homovanillic acid (HVA), mediate the effects of exercise on extinction recall. METHODS Participants (N = 35) completed a 3-day fear acquisition (day 1), extinction (day 2), and extinction recall (day 3) protocol, in which participants were randomly assigned to complete either moderate-intensity aerobic exercise (EX) or a light-intensity control (CON) condition following extinction training (day 2). Blood was obtained prior to and following EX or CON. Threat expectancy ratings during tests of extinction recall (i.e., initial fear recall and fear recall following reinstatement) were obtained 24 h following EX or CON. Mediation was tested using linear-mixed effects models and bootstrapping of the indirect effect. RESULTS Circulating concentrations of AEA and BDNF (but not 2-AG and HVA) were found to mediate the relationship between moderate-intensity aerobic exercise and reduced threat expectancy ratings following reinstatement (AEA 95% CI: -0.623 to -0.005; BDNF 95% CI: -0.941 to -0.005). CONCLUSIONS Exercise-induced increases in peripheral AEA and BDNF appear to play a role in enhancing consolidation of fear extinction learning, thereby leading to reduced threat expectancies following reinstatement among women with PTSD. Future mechanistic research examining these and other biomarkers (e.g., brain-based biomarkers) is warranted.",2021,"Threat expectancy ratings during tests of extinction recall (i.e., initial fear recall and fear recall following reinstatement) were obtained 24 h following EX or CON.","['Participants (N\xa0=\xa035) completed a', 'women with PTSD', 'women with posttraumatic stress disorder (PTSD']","['moderate-intensity aerobic exercise (EX) or a light-intensity control (CON) condition following extinction training', '3-day fear acquisition (day 1), extinction (day 2), and extinction recall (day 3) protocol']","['threat expectancy ratings', 'peripheral AEA and BDNF', 'circulating concentrations of candidate biomarkers: endocannabinoids (anandamide [AEA]; 2-arachidonoylglycerol [2-AG], brain-derived neurotrophic factor (BDNF), and homovanillic acid (HVA', 'extinction recall (i.e., initial fear recall and fear recall following reinstatement', 'Anandamide and BDNF']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0015347', 'cui_str': 'Psychological Extinction'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1172779', 'cui_str': 'Endocannabinoid'}, {'cui': 'C0211726', 'cui_str': 'anandamide'}, {'cui': 'C0299477', 'cui_str': 'glyceryl 2-arachidonate'}, {'cui': 'C0019903', 'cui_str': 'Homovanillic acid'}, {'cui': 'C0178681', 'cui_str': 'Homovanillate'}, {'cui': 'C0015347', 'cui_str': 'Psychological Extinction'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]",,0.0384587,"Threat expectancy ratings during tests of extinction recall (i.e., initial fear recall and fear recall following reinstatement) were obtained 24 h following EX or CON.","[{'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Crombie', 'Affiliation': 'University of Wisconsin, Department of Psychiatry, 6001 Research Park Boulevard, Madison, WI 53719-1176, United States. Electronic address: kmcrombie@wisc.edu.'}, {'ForeName': 'Anneliis', 'Initials': 'A', 'LastName': 'Sartin-Tarm', 'Affiliation': 'University of Wisconsin, Department of Psychiatry, 6001 Research Park Boulevard, Madison, WI 53719-1176, United States.'}, {'ForeName': 'Kyrie', 'Initials': 'K', 'LastName': 'Sellnow', 'Affiliation': 'University of Wisconsin, Department of Psychiatry, 6001 Research Park Boulevard, Madison, WI 53719-1176, United States.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Ahrenholtz', 'Affiliation': 'University of Wisconsin, Department of Psychiatry, 6001 Research Park Boulevard, Madison, WI 53719-1176, United States.'}, {'ForeName': 'Sierra', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'University of Wisconsin, Department of Psychiatry, 6001 Research Park Boulevard, Madison, WI 53719-1176, United States.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Matalamaki', 'Affiliation': 'University of Wisconsin, Department of Psychiatry, 6001 Research Park Boulevard, Madison, WI 53719-1176, United States.'}, {'ForeName': 'Neda E', 'Initials': 'NE', 'LastName': 'Almassi', 'Affiliation': 'University of Wisconsin, Department of Kinesiology, 285 Med Sci, 1300 University Ave, Madison, WI 53706-1121, United States.'}, {'ForeName': 'Cecilia J', 'Initials': 'CJ', 'LastName': 'Hillard', 'Affiliation': 'Medical College of Wisconsin, Neuroscience Research Center, Department of Pharmacology and Toxicology, 8701 Watertown Plank Rd., Milwaukee, WI 53226, United States.'}, {'ForeName': 'Kelli F', 'Initials': 'KF', 'LastName': 'Koltyn', 'Affiliation': 'University of Wisconsin, Department of Kinesiology, 285 Med Sci, 1300 University Ave, Madison, WI 53706-1121, United States.'}, {'ForeName': 'Tom G', 'Initials': 'TG', 'LastName': 'Adams', 'Affiliation': 'University of Kentucky, Department of Psychology, 105 Kastle Hill, Lexington, KY 40506-0044, United States; Yale School of Medicine, Department of Psychiatry, 300 George St., New Haven, CT 06511, United States; National Center for PTSD, Clinical Neurosciences Division, VA CT Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, United States.'}, {'ForeName': 'Josh M', 'Initials': 'JM', 'LastName': 'Cisler', 'Affiliation': 'University of Texas at Austin, Department of Psychiatry and Behavioral Sciences, 1601 Trinity St, Bldg B, Austin, TX 78712, United States.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2021.105355'] 1638,34280784,Effects of general versus subarachnoid anaesthesia on circadian melatonin rhythm and postoperative delirium in elderly patients undergoing hip fracture surgery: A prospective cohort clinical trial.,"BACKGROUND Circadian rhythm disturbance is common postoperatively in older patients with hip fractures, which may contribute to the development of postoperative delirium (POD). As a reliable biomarker of endogenous circadian rhythms, melatonin regulates the sleep-wake cycle and environmental adaptation, and its secretory rhythm may be modified by anaesthesia and surgery. This study compared the impact of subarachnoid anaesthesia (SA) and general anaesthesia (GA), on the peak of melatonin secretion (primary outcome), the circadian rhythm of melatonin, cortisol and sleep, and the POD incidence (secondary outcome). METHODS In this prospective cohort observational study, hip fracture surgery patients were enrolled and assigned to receive either SA or GA. Postoperative plasma melatonin and cortisol levels were dynamically measured every six hours on seven time-points, and the circadian rhythm parameters including mesor, amplitude, and acrophase were calculated. Subjective and objective sleep assessments were performed by sleep diaries and sleep trackers, respectively. The Confusion Assessment Method was used twice daily by a specific geriatrician to screen for POD occurrence. FINDINGS In a cohort of 138 patients who underwent hip fracture surgery, the circadian rhythm disruption of the patients in the GA group (n=69) was greater than the SA group (n=69). Compared with SA, GA provided the lower peak concentration, mesor, and amplitude of melatonin secretion on postoperative day 1 (p < 0.05). Patients in the GA group experienced higher awakenings, more sleep deprivation, and poor sleep quality on surgery day (p < 0.05). A proportion of 12 patients in the SA group (17.4%) and 24 patients in the GA group (34.8%) experienced POD (p = 0.020). INTERPRETATION These results suggest that SA may be superior to GA in elderly patients undergoing hip fracture surgery as SA is associated with less impairment of the melatonin rhythm and sleep patterns, and fewer POD occurrences.",2021,"Compared with SA, GA provided the lower peak concentration, mesor, and amplitude of melatonin secretion on postoperative day 1 (p < 0.05).","['138 patients who underwent hip fracture surgery, the circadian rhythm disruption of the patients in the GA group (n=69) was greater than the SA group (n=69', 'older patients with hip fractures', 'elderly patients undergoing hip fracture surgery', 'hip fracture surgery patients']","['SA or GA', 'SA', 'SA, GA', 'subarachnoid anaesthesia', 'subarachnoid anaesthesia (SA) and general anaesthesia (GA']","['Postoperative plasma melatonin and cortisol levels', 'circadian rhythm of melatonin, cortisol and sleep, and the POD incidence (secondary outcome', 'higher awakenings, more sleep deprivation, and poor sleep quality', 'circadian rhythm parameters including mesor, amplitude, and acrophase', 'POD', 'Subjective and objective sleep assessments', 'circadian melatonin rhythm and postoperative delirium', 'peak concentration, mesor, and amplitude of melatonin secretion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0008810', 'cui_str': 'Circadian rhythm'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0038527', 'cui_str': 'Subarachnoid space structure'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0038527', 'cui_str': 'Subarachnoid space structure'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0008810', 'cui_str': 'Circadian rhythm'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C4721772', 'cui_str': 'Postoperative delirium'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1720052', 'cui_str': 'Awakening'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0235162', 'cui_str': 'Difficulty sleeping'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0036536', 'cui_str': 'secretion'}]",138.0,0.0819521,"Compared with SA, GA provided the lower peak concentration, mesor, and amplitude of melatonin secretion on postoperative day 1 (p < 0.05).","[{'ForeName': 'Yanan', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'Yajie', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, 31 Xinjiekou East Street, Xicheng District, Beijing 100035, China.'}, {'ForeName': 'Xixi', 'Initials': 'X', 'LastName': 'Jia', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'Wenchao', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, 31 Xinjiekou East Street, Xicheng District, Beijing 100035, China.'}, {'ForeName': 'Geng', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, 31 Xinjiekou East Street, Xicheng District, Beijing 100035, China.'}, {'ForeName': 'Yunyang', 'Initials': 'Y', 'LastName': 'Jia', 'Affiliation': 'Department of Orthopaedics & Traumatology, Beijing Jishuitan Hospital, 31 Xinjiekou East Street, Xicheng District, Beijing 100035, China.'}, {'ForeName': 'Xiaoxiao', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Research Center of Clinical Epidemiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shandong University, Shandong 250012, China.'}, {'ForeName': 'Weitian', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'College of Veterinary Medicine, China Agricultural University, No.2, Yuanmingyuan West Road, Haidian District, Beijing 100193, China.'}, {'ForeName': 'Xinping', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Geriatrics, Beijing Jishuitan Hospital, 31 Xinjiekou East Street, Xicheng District, Beijing 100035, China.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Cai', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, 31 Xinjiekou East Street, Xicheng District, Beijing 100035, China.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'Yongzheng', 'Initials': 'Y', 'LastName': 'Han', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'Xinning', 'Initials': 'X', 'LastName': 'Mi', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'Chengmei', 'Initials': 'C', 'LastName': 'Shi', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China.'}, {'ForeName': 'John Q', 'Initials': 'JQ', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, University of Missouri Kansas City, School of Medicine, Kansas 64110, MO, USA.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Vuylsteke', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Royal Papworth Hospital NHS Foundation Trust, CB2 0AY Cambridge, UK.'}, {'ForeName': 'Xiangyang', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China. Electronic address: puthmzk@bjmu.edu.cn.'}, {'ForeName': 'Zhengqian', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China. Electronic address: zhengqianli@bjmu.edu.cn.'}]",EBioMedicine,['10.1016/j.ebiom.2021.103490'] 1639,34280733,Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study.,"AIMS the objectives of this study are to reveal the potential side effects after taking the covid19 vaccines, associated risk factors with severe side effects, and to compare the three COVID-19 vaccines available in Iraq (Sinopharm, AstraZeneca-Oxford and Pfizer- BioNTech). METHODS a randomized cross-sectional study was conducted in April 2021. A standardized questionnaire platform was utilized to collect information about the Iraqi population. RESULTS 1012 were enrolled in the study, 60.2% were male and 39.8% were female. 84% were symptomatic post vaccination. Young aged participants, females, participants with history of COVID19 infection, those with comorbid diseases and AstraZeneca vaccine receivers were statistically significant risk factors for having adverse reactions post vaccination, P value (0.03, 0.028, 0.007, 0.019 and 0.0001) respectively. Regarding severity of symptoms, most symptoms were mild and moderate. Residency in Kurdistan Region of Iraq and AstraZeneca vaccine were the statistically significant risk factors for getting severe symptoms P value < 0.0001 of both. Females were an associated risk factor for D-dimer elevation P value = 0.05. CONCLUSION fatigue, injection site reactions, fever, myalgia, headache and chills were the most reported side effects. Most symptoms were mild to moderate in term of severity.",2021,Residency in Kurdistan Region of Iraq and AstraZeneca vaccine were the statistically significant risk factors for getting severe symptoms P value ,"['Iraqi population', 'Young aged participants, females, participants with history of COVID19 infection, those with comorbid diseases and AstraZeneca vaccine receivers', '1012 were enrolled in the study, 60.2% were male and 39.8% were female']",['COVID19 vaccines'],"['fatigue, injection site reactions, fever, myalgia, headache and chills']","[{'cui': 'C1556087', 'cui_str': 'Iraqi'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0085593', 'cui_str': 'Chill'}]",1012.0,0.0559672,Residency in Kurdistan Region of Iraq and AstraZeneca vaccine were the statistically significant risk factors for getting severe symptoms P value ,"[{'ForeName': 'Hind B', 'Initials': 'HB', 'LastName': 'Almufty', 'Affiliation': 'Department of Clinical Pharmacy, College of Pharmacy, University of Duhok, Duhok, 42001, Iraq. Electronic address: hind.bahzad@uod.ac.'}, {'ForeName': 'Shinah A', 'Initials': 'SA', 'LastName': 'Mohammed', 'Affiliation': 'Department of Clinical Pharmacy, College of Pharmacy, University of Duhok, Duhok, 42001, Iraq. Electronic address: Shinah.mohemmad@uod.ac.'}, {'ForeName': 'Arshad M', 'Initials': 'AM', 'LastName': 'Abdullah', 'Affiliation': 'Department of Clinical Pharmacy, College of Pharmacy, University of Duhok, Duhok, 42001, Iraq. Electronic address: arshad.abdullah@uod.ac.'}, {'ForeName': 'Muayad A', 'Initials': 'MA', 'LastName': 'Merza', 'Affiliation': 'Department of Clinical Pharmacy, College of Pharmacy, University of Duhok, Duhok, 42001, Iraq. Electronic address: muayad.merza@uod.ac.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2021.102207'] 1640,34280724,Organic mineral supplementation on differential protein profile of Osmanabadi bucks (Capra hircus).,"The present study aimed to determine the differential protein profile of seminal plasma proteins of bucks supplemented with trace minerals. Forty bucks of uniform size and body weight were assigned as ten groups (n = 4). The control group (T1) was fed with the control diet (concentration mixture and roughages) whereas the remaining groups were supplemented the control diet with Zn20 mg (T2), Zn40 mg (T3), Zn60 mg (T4), Cu12.5 mg (T5), Cu25 mg (T6), Cu37.5 mg (T7), Zn20 mg + Cu12.5 mg (T8), Zn40 mg + Cu25 mg (T9), and Zn60 mg + Cu37.5 mg (T10) for eight months. Seminal plasma proteins from each group were subjected to two-dimensional electrophoresis and fifteen differential proteins were selected based on differential expression, subjected to identification using Nano-LC-MS/MS (LTQ-Qrbitrap-MS). The identified proteins were Triacylglycerol lipase, EGF like repeats and discoidin domains 3, Lipocalin, Iodothyronine deiodinase, Transcription factor AP2-delta, 60S ribosomal protein L13, IST1 factor associated with ESCRT-III, Lysozyme, Uncharacterized protein (BRI3-binding protein), Uncharacterized protein, Histone deacetylase 11, General transcription factor IIF subunit 2, Nudix hydrolase 6, Protein kinase cAMP-activated catalytic subunit beta and Elongin C. The organic Cu supplemented group is the better than the organic Zn and organic Zn + Cu supplemented groups.",2021,The organic Cu supplemented group is the better than the organic Zn and organic Zn + Cu supplemented groups.,['Forty bucks of uniform size and body weight'],"['organic Zn and organic Zn + Cu', 'Zn40 mg + Cu25 mg (T9), and Zn60 mg + Cu37.5 mg (T10', 'Organic mineral supplementation']","['Triacylglycerol lipase, EGF like repeats and discoidin domains 3, Lipocalin, Iodothyronine deiodinase, Transcription factor AP2-delta, 60S']","[{'cui': 'C0852885', 'cui_str': 'Bucking'}, {'cui': 'C0205375', 'cui_str': 'Uniform'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0556112', 'cui_str': 'Mineral supplement'}]","[{'cui': 'C0023764', 'cui_str': 'Lipase'}, {'cui': 'C0242275', 'cui_str': 'Epidermal Growth Factor'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C4277651', 'cui_str': 'Discoidin Domains'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}, {'cui': 'C0021995', 'cui_str': 'Iodothyronine Deiodinase'}, {'cui': 'C0059296', 'cui_str': 'AP-2 Enhancer Binding Protein'}, {'cui': 'C0439097', 'cui_str': 'Delta'}]",,0.0162252,The organic Cu supplemented group is the better than the organic Zn and organic Zn + Cu supplemented groups.,"[{'ForeName': 'Backialakshmi', 'Initials': 'B', 'LastName': 'Sekar', 'Affiliation': 'Reproductive Physiology Laboratory, Animal Physiology Division, ICAR-National Institute of Animal Nutrition and Physiology, Bangalore, Karnataka, 560030, India; Department of Biotechnology, Jain University, Bengaluru, Karnataka, 560078, India.'}, {'ForeName': 'Arunachalam', 'Initials': 'A', 'LastName': 'Arangasamy', 'Affiliation': 'Reproductive Physiology Laboratory, Animal Physiology Division, ICAR-National Institute of Animal Nutrition and Physiology, Bangalore, Karnataka, 560030, India. Electronic address: arangasamyars@gmail.com.'}, {'ForeName': 'Sharanya Jeevendra', 'Initials': 'SJ', 'LastName': 'Naidu', 'Affiliation': 'Reproductive Physiology Laboratory, Animal Physiology Division, ICAR-National Institute of Animal Nutrition and Physiology, Bangalore, Karnataka, 560030, India; Department of Biochemistry, Jain University, Bengaluru, Karnataka, 560078, India.'}, {'ForeName': 'Ippala Janardhan', 'Initials': 'IJ', 'LastName': 'Reddy', 'Affiliation': 'Reproductive Physiology Laboratory, Animal Physiology Division, ICAR-National Institute of Animal Nutrition and Physiology, Bangalore, Karnataka, 560030, India.'}, {'ForeName': 'Raghavendra', 'Initials': 'R', 'LastName': 'Bhatta', 'Affiliation': 'Director, ICAR-National Institute of Animal Nutrition and Physiology, Bangalore, Karnataka, 560030, India.'}]",Reproductive biology,['10.1016/j.repbio.2021.100533'] 1641,34256276,tACS as a promising therapeutic option for improving cognitive function in mild cognitive impairment: A direct comparison between tACS and tDCS.,"Neuromodulation has gained attention as a potential non-pharmacological intervention for mild cognitive impairment (MCI). However, no studies have directly compared the effects of transcranial alternating current stimulation (tACS) with transcranial direct current stimulation (tDCS) on MCI patients. We aimed to identify the more promising and efficient therapeutic option between tACS and tDCS for cognitive enhancement in MCI patients. We compared the effects of gamma-tACS with tDCS on cognitive function and electroencephalography (EEG) in MCI patients. In this sham-controlled, double-blinded, repeated-measures study with the order of the stimulation counterbalanced across patients (n = 20), both gamma-tACS (40 H z) and tDCS were administered at the same intensity (2 mA) in the dorsolateral prefrontal cortex for 30 min. Cognitive tests (Stroop and Trail-Making-Test [TMT]) and EEG were performed before and after single-session stimulation. Gamma-tACS improved the Stroop-color in comparison with tDCS (p = .044) and sham (p = .010) and enhanced the TMT-B in comparison with sham (p = .021). However, tDCS was not significantly different from sham in changes of any cognitive test scores. In EEG analysis, gamma-tACS increased beta activity in comparison with sham and tDCS, whereas tDCS decreased delta and theta activity in comparison with sham. Gamma-tACS also increased beta 2 source activity in the anterior cingulate, compared to sham. The cognitive benefits of tACS in MCI patients appeared superior to those of tDCS. tACS facilitated cognitive function by increasing beta activity, while tDCS delayed the progression of MCI symptoms by decreasing slow-frequency activity. Thus, tACS could be used as a new therapeutic option for MCI.",2021,Gamma-tACS improved the Stroop-color in comparison with tDCS (p = .044) and sham (p = .010) and enhanced the TMT-B in comparison with sham (p = .021).,"['MCI patients', 'mild cognitive impairment (MCI', 'mild cognitive impairment']","['tACS', 'gamma-tACS with tDCS', 'transcranial alternating current stimulation (tACS) with transcranial direct current stimulation (tDCS', 'gamma-tACS']","['tDCS decreased delta and theta activity', 'beta activity', 'Cognitive tests (Stroop and Trail-Making-Test [TMT]) and EEG', 'cognitive function and electroencephalography (EEG']","[{'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0017011', 'cui_str': 'Gamma radiation'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.0499721,Gamma-tACS improved the Stroop-color in comparison with tDCS (p = .044) and sham (p = .010) and enhanced the TMT-B in comparison with sham (p = .021).,"[{'ForeName': 'Jiheon', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea; Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon, Republic of Korea.'}, {'ForeName': 'Hansol', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon, Republic of Korea.'}, {'ForeName': 'Hyewon', 'Initials': 'H', 'LastName': 'Jeong', 'Affiliation': 'Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon, Republic of Korea.'}, {'ForeName': 'Daeyoung', 'Initials': 'D', 'LastName': 'Roh', 'Affiliation': 'Department of Psychiatry, Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea; Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon, Republic of Korea.'}, {'ForeName': 'Do Hoon', 'Initials': 'DH', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea; Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon, Republic of Korea. Electronic address: dohkim@hallym.ac.kr.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2021.07.012'] 1642,34256006,Effect of Hearing Aid Technology Level and Individual Characteristics on Listener Outcome Measures.,"Purpose The purpose of the study was to determine the effect of hearing aid technology level on listener outcome measures. In addition, we aimed to determine if individual characteristics such as noise acceptance and the demands of the listening environment impacted performance and preference. Method A repeated-measures, single-blinded research design was utilized. Twenty-four adults recruited by mail from The University of Tennessee Health Science Center Audiology Clinic participated in this experiment (15 men and nine women). Participants completed two 2-week trial periods using Unitron T Moxi Fit FLEX:TRIAL devices programmed as basic or premium technology levels. A data-logging feature, Log It All (LIA), quantified the demands of the listening environment. At the end of each trial, outcome measures were obtained using Pascoe's High-Frequency Word List, the Hearing in Noise Test, the Quick Speech-in-Noise Test, the Acceptable Noise Level (ANL), the Speech, Spatial and Qualities of Hearing short form, satisfaction ratings, and preference. Results Results for ANL, satisfaction in large groups, and LIA total coverage were significantly improved for the premium devices. Participants who preferred the premium devices received significant improvement with premium devices on the ANL and the speech in small group and speech in large group satisfaction ratings, whereas participants who preferred the basic devices did not receive significant improvement with premium devices on any outcome measure. Participants in more demanding listening environments received significant improvement with premium devices on the ANL, whereas participants in less demanding listening environments did not receive significant improvement with premium devices on any outcome measure. Conclusions Group data revealed similar outcomes between technology levels on most measures; however, noise acceptance and satisfaction for speech in a large group were significantly improved when using the premium devices. Individual characteristics such as noise acceptance and listening demands may be useful when comparing hearing aid technology levels for a given patient.",2021,"Participants who preferred the premium devices received significant improvement with premium devices on the ANL and the speech in small group and speech in large group satisfaction ratings, whereas participants who preferred the basic devices did not receive significant improvement with premium devices on any outcome measure.",['Twenty-four adults recruited by mail from The University of Tennessee Health Science Center Audiology Clinic participated in this experiment (15 men and nine women'],"['hearing aid technology level', 'Unitron T Moxi Fit FLEX']","['LIA total coverage', ""Pascoe's High-Frequency Word List, the Hearing in Noise Test, the Quick Speech-in-Noise Test, the Acceptable Noise Level (ANL), the Speech, Spatial and Qualities of Hearing short form, satisfaction ratings, and preference"", 'noise acceptance and satisfaction for speech']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0039514', 'cui_str': 'Tennessee'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C3838745', 'cui_str': 'Audiology clinic'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0018768', 'cui_str': 'Hearing aid'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0036572', 'cui_str': 'Seizure'}]","[{'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}]",24.0,0.0839077,"Participants who preferred the premium devices received significant improvement with premium devices on the ANL and the speech in small group and speech in large group satisfaction ratings, whereas participants who preferred the basic devices did not receive significant improvement with premium devices on any outcome measure.","[{'ForeName': 'Patrick N', 'Initials': 'PN', 'LastName': 'Plyler', 'Affiliation': 'Department of Audiology and Speech Pathology, The University of Tennessee Health Science Center, Knoxville.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hausladen', 'Affiliation': 'Department of Audiology and Speech Pathology, The University of Tennessee Health Science Center, Knoxville.'}, {'ForeName': 'Micaela', 'Initials': 'M', 'LastName': 'Capps', 'Affiliation': 'Department of Audiology and Speech Pathology, The University of Tennessee Health Science Center, Knoxville.'}, {'ForeName': 'Mary Alice', 'Initials': 'MA', 'LastName': 'Cox', 'Affiliation': 'Department of Audiology and Speech Pathology, The University of Tennessee Health Science Center, Knoxville.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2021_JSLHR-21-00111'] 1643,34255711,A Mobile-Based Intervention to Increase Self-esteem in Students With Depressive Symptoms: Randomized Controlled Trial.,"BACKGROUND Depressive symptoms are one of the most common and ever-increasing mental health problems among students worldwide. Conventional treatment options, particularly psychotherapy, do not reach all students in need of help. Internet- and mobile-based interventions are promising alternatives for narrowing the treatment gap. OBJECTIVE In the framework of a randomized controlled trial, we aim to investigate the effectiveness, acceptance, and side effects of a self-help smartphone app (MCT & More) based on cognitive behavioral therapy, mindfulness, acceptance and commitment therapy, and metacognitive training in a sample of students with self-reported depressive symptoms. Furthermore, we were interested in examining the influence of treatment expectations and attitudes toward internet- and mobile-based interventions on treatment adherence and effectiveness. METHODS A total of 400 students were recruited via open access websites and randomized to either the intervention group (n=200), who received access to the self-help smartphone app MCT & More for a period of 4 weeks, or to a wait-list control group (n=200). The Patient Health Questionnaire-9 (depression) served as the primary outcome parameter, and the Rosenberg Self-esteem Scale (self-esteem) and the global item of the World Health Organization Quality of Life-abbreviated version (quality of life) served as the secondary outcome parameters. The Attitudes Towards Psychological Online Interventions was used to measure attitudes toward internet- and mobile-based interventions. Outcome expectations were assessed using the Patient Questionnaire on Therapy Expectation and Evaluation, and side effects were assessed using the Inventory for Assessing Negative Effects of Psychotherapy. RESULTS Per-protocol (PP), complete-case, and intention-to-treat analyses showed a significantly higher reduction in depressive symptoms (PP: F 1222 =3.98; P=.047; d=0.26) and a significantly higher increase in self-esteem (PP: F 1220 =8.79; P=.003; d=0.77) in the intervention group than in the wait-list control group. Most participants regularly used the self-help smartphone app (91/120, 75.8%, at least once a week). The more positive the attitude toward internet- and mobile-based interventions (r=0.260; P=.004) and the more positive the outcome expectation (r=0.236; P=.009), the more frequently the self-help smartphone app was used. CONCLUSIONS The effectiveness of the self-help smartphone app MCT & More was demonstrated among students with depressive symptoms compared with a wait-list control group. The app could be offered regularly as a low-threshold intervention to enhance students' health. TRIAL REGISTRATION German Clinical Trials Register DRKS00020941; https://tinyurl.com/pr84w6er.",2021,The effectiveness of the self-help smartphone app MCT & More was demonstrated among students with depressive symptoms compared with a wait-list control group.,"['students with self-reported depressive symptoms', 'Students With Depressive Symptoms', 'A total of 400 students were recruited via open access websites and randomized to either the intervention group (n=200), who received', 'students with depressive symptoms']","['Internet- and mobile-based interventions', 'self-help smartphone app (MCT & More) based on cognitive behavioral therapy, mindfulness, acceptance and commitment therapy, and metacognitive training', 'access to the self-help smartphone app MCT & More for a period of 4 weeks, or to a wait-list control group', 'Mobile-Based Intervention']","['Self-esteem', 'Rosenberg Self-esteem Scale (self-esteem) and the global item of the World Health Organization Quality of Life-abbreviated version (quality of life', 'Patient Questionnaire on Therapy Expectation and Evaluation, and side effects', 'depressive symptoms', 'effectiveness, acceptance, and side effects', 'self-esteem']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0026687', 'cui_str': 'Mucociliary clearance'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0582666', 'cui_str': 'Rosenberg self-esteem scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}]",400.0,0.0460722,The effectiveness of the self-help smartphone app MCT & More was demonstrated among students with depressive symptoms compared with a wait-list control group.,"[{'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Bruhns', 'Affiliation': 'University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.'}, {'ForeName': 'Thies', 'Initials': 'T', 'LastName': 'Lüdtke', 'Affiliation': 'University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Moritz', 'Affiliation': 'University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Bücker', 'Affiliation': 'University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.'}]",JMIR mHealth and uHealth,['10.2196/26498'] 1644,34255703,A Mobile Phone-Based Life-Skills Training Program for Substance Use Prevention Among Adolescents: Cluster-Randomized Controlled Trial.,"BACKGROUND Life skills are abilities for adaptive and positive behavior that enable individuals to deal effectively with the demands and challenges of everyday life. Life-skills training programs conducted within the school curriculum are effective in preventing the onset and escalation of substance use among adolescents. However, their dissemination is impeded due to their large resource requirements. Life-skills training provided via mobile phones may provide a more economic and scalable approach. OBJECTIVE The goal of this study was to test the appropriateness (ie, acceptance, use, and evaluation) and short-term efficacy of a mobile phone-based life-skills training program to prevent substance use among adolescents within a controlled trial. METHODS The study design was a two-arm, parallel-group, cluster-randomized controlled trial with assessments at baseline and follow-up assessments after 6 and 18 months. This report includes outcomes measured up to the 6-month follow-up. The efficacy of the intervention was tested in comparison to an assessment-only control group. The automated intervention program SmartCoach included online feedback and individually tailored text messages provided over 22 weeks. The contents were based on social cognitive theory and addressed self-management skills, social skills, and substance use resistance skills. Linear mixed models and generalized linear mixed models, as well as logistic or linear regressions, were used to investigate changes between baseline and 6-month follow-up in the following outcomes: 30-day prevalence rates of problem drinking, tobacco use, and cannabis use as well as quantity of alcohol use, quantity of cigarettes smoked, cannabis use days, perceived stress, well-being, and social skills. RESULTS A total of 1759 students from 89 Swiss secondary and upper secondary school classes were invited to participate in the study. Of these, 1473 (83.7%) students participated in the study; the mean age was 15.4 years (SD 1.0) and 55.2% (813/1473) were female. Follow-up assessments at 6 months were completed by 1233 (83.7%) study participants. On average, program participants responded to half (23.6 out of 50) of the prompted activities. Program evaluations underlined its appropriateness for the target group of secondary school students, with the majority rating the program as helpful and individually tailored. The results concerning the initial effectiveness of this program based on 6-month follow-up data are promising, with three of nine outcomes of the intention-to-treat analyses showing beneficial developments of statistical significance (ie, quantity of alcohol use, quantity of tobacco use, and perceived stress; P<.05) and another three outcomes (ie, problem drinking prevalence, cannabis use days, and social skills) showing beneficial developments of borderline significance (P<.10). CONCLUSIONS The results showed good acceptance of this intervention program that could be easily and economically implemented in school classes. Initial results on program efficacy indicate that it might be effective in both preventing or reducing substance use and fostering life skills; however, data from the final 18-month follow-up assessments will be more conclusive. TRIAL REGISTRATION ISRCTN Registry ISRCTN41347061; https://doi.org/10.1186/ISRCTN41347061.",2021,"The contents were based on social cognitive theory and addressed self-management skills, social skills, and substance use resistance skills.","['students participated in the study; the mean age was 15.4 years (SD 1.0) and 55.2% (813/1473) were female', 'adolescents within a controlled trial', 'A total of 1759 students from 89 Swiss secondary and upper secondary school classes were invited to participate in the study', 'Adolescents']",['mobile phone-based life-skills training program'],"['30-day prevalence rates of problem drinking, tobacco use, and cannabis use as well as quantity of alcohol use, quantity of cigarettes smoked, cannabis use days, perceived stress, well-being, and social skills']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517579', 'cui_str': '15.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0241315', 'cui_str': 'Swiss'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0556562', 'cui_str': 'Life skills training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0040335', 'cui_str': 'Tobacco use'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0679005', 'cui_str': 'Social Abilities'}]",1759.0,0.0147584,"The contents were based on social cognitive theory and addressed self-management skills, social skills, and substance use resistance skills.","[{'ForeName': 'Severin', 'Initials': 'S', 'LastName': 'Haug', 'Affiliation': 'Swiss Research Institute for Public Health and Addiction at Zurich University, Zurich, Switzerland.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Paz Castro', 'Affiliation': 'Swiss Research Institute for Public Health and Addiction at Zurich University, Zurich, Switzerland.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Wenger', 'Affiliation': 'Swiss Research Institute for Public Health and Addiction at Zurich University, Zurich, Switzerland.'}, {'ForeName': 'Michael Patrick', 'Initials': 'MP', 'LastName': 'Schaub', 'Affiliation': 'Swiss Research Institute for Public Health and Addiction at Zurich University, Zurich, Switzerland.'}]",JMIR mHealth and uHealth,['10.2196/26951'] 1645,34259164,Developing and Implementing a Web-Based Psychotherapy Program to Address Mental Health Challenges Among Patients Receiving Oncologic and Palliative Care: Protocol for an Open-Label Randomized Controlled Trial.,"BACKGROUND The demand for mental health care, particularly for depression and anxiety, is 3-fold greater among patients receiving oncologic and palliative care than for the general population. This population faces unique barriers, making them more susceptible to mental health challenges. Various forms of psychotherapy have been deemed effective in addressing mental health challenges in this population, including supportive psychotherapy, cognitive behavioral therapy, problem-based therapy, and mindfulness; however, their access to traditional face-to-face psychotherapy resources is limited owing to their immunocompromised status, making frequent hospital visits dangerous. Additionally, patients can face hospital fatigue from numerous appointments and investigations or may live in remote areas, which makes commutes both physically and financially challenging. Web-based psychotherapy is a promising solution to address these accessibility barriers. Moreover, web-based psychotherapy has been proven effective in addressing depression and anxiety in other populations and may be implementable among patients receiving oncologic and palliative care. OBJECTIVE The study will investigate the feasibility and effectiveness of web-based psychotherapy among patients receiving oncologic and palliative care, who have comorbid depression or anxiety. We hypothesized that this program will be a viable and efficacious treatment modality compared to current treatment modalities in addressing depression and anxiety symptoms in this population. METHODS Participants (n=60) with depression or anxiety will be recruited from oncology and palliative care settings in Kingston (Ontario, Canada). Participants will be randomly allocated to receive either 8 weeks of web-based psychotherapy plus treatment as usual (treatment arm) or treatment as usual exclusively (control arm). The web-based psychotherapy program will incorporate cognitive behavioral therapy, mindfulness, and problem-solving skills, and homework assignments with personalized feedback from a therapist. All web-based programs will be delivered through a secure platform specifically designed for web-based psychotherapy delivery. To evaluate treatment efficacy, all participants will complete standardized symptomology questionnaires at baseline, midpoint (week 4), and posttreatment. RESULTS The study received ethics approval in February 2021 and began recruiting participants in April 2021. Participant recruitment has been conducted through social media advertisements, physical advertisements, and physician referrals. To date, 11 participants (treatment, n=5; control, n=4; dropout, n=2) have been recruited. Data collection and analysis are expected to conclude by December 2021 and January 2022, respectively. Linear regression (for continuous outcomes) will be conducted with interpretive qualitative methods. CONCLUSIONS Our findings can be incorporated into clinical policy and help develop more accessible mental health treatment options for patients receiving oncologic and palliative care. Asynchronous and web-based psychotherapy delivery is a more accessible, scalable, and financially feasible treatment that could have major implications on the health care system. TRIAL REGISTRATION ClinicalTrials.gov NCT04664270; https://clinicaltrials.gov/ct2/show/NCT04664270. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/30735.",2021,"Asynchronous and web-based psychotherapy delivery is a more accessible, scalable, and financially feasible treatment that could have major implications on the health care system. ","['Participants (n=60) with depression or anxiety will be recruited from oncology and palliative care settings in Kingston (Ontario, Canada', 'patients receiving oncologic and palliative care than for the general population', '11 participants (treatment, n=5; control, n=4; dropout, n=2) have been recruited', 'patients receiving oncologic and palliative care, who have comorbid depression or anxiety', 'patients receiving oncologic and palliative care', 'February 2021 and began recruiting participants in April 2021', 'Patients Receiving Oncologic and Palliative Care']","['psychotherapy', 'web-based psychotherapy', 'Asynchronous and web-based psychotherapy delivery', 'psychotherapy plus treatment as usual (treatment arm) or treatment as usual exclusively (control arm']",[],"[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205478', 'cui_str': 'Oncologic'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439581', 'cui_str': 'Asynchronous'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],,0.0514483,"Asynchronous and web-based psychotherapy delivery is a more accessible, scalable, and financially feasible treatment that could have major implications on the health care system. ","[{'ForeName': 'Nazanin', 'Initials': 'N', 'LastName': 'Alavi', 'Affiliation': ""Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Callum', 'Initials': 'C', 'LastName': 'Stephenson', 'Affiliation': ""Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Shadé', 'Initials': 'S', 'LastName': 'Miller', 'Affiliation': ""Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Payam', 'Initials': 'P', 'LastName': 'Khalafi', 'Affiliation': ""Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Israa', 'Initials': 'I', 'LastName': 'Sinan', 'Affiliation': ""Faculty of Arts and Science, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Kain', 'Affiliation': ""Department of Medicine, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'McDougall', 'Affiliation': 'Supportive Care Program, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Kingston, ON, Canada.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Davies', 'Affiliation': 'Supportive Care Program, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Kingston, ON, Canada.'}, {'ForeName': 'Debora', 'Initials': 'D', 'LastName': 'Stark', 'Affiliation': 'Supportive Care Program, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Kingston, ON, Canada.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Tompkins', 'Affiliation': 'Supportive Care Program, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Kingston, ON, Canada.'}, {'ForeName': 'Jasleen', 'Initials': 'J', 'LastName': 'Jagayat', 'Affiliation': ""Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Omrani', 'Affiliation': 'OPTT Inc, Toronto, ON, Canada.'}, {'ForeName': 'Amirhossein', 'Initials': 'A', 'LastName': 'Shirazi', 'Affiliation': ""Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Dianne', 'Initials': 'D', 'LastName': 'Groll', 'Affiliation': ""Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Soares', 'Affiliation': ""Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.""}]",JMIR research protocols,['10.2196/30735'] 1646,34258913,Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy.,"We evaluated the lipidomic profile of patients with very high-risk atherosclerotic cardiovascular disease (ASCVD) by ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-MS). A total of 64 patients with a very high risk of ASCVD were recruited and randomLy divided into the atorvastatin group (20 mg, every night, 4 weeks) or the combined group (evolocumab, 140 mg, once every 2 weeks on top of atorvastatin (20 mg per day)). The level of serum lipids was detected before and after treatment for 4 weeks. The lipid classes of triacylglycerols, cholesteryl esters, and sphingomyelins were analyzed using an ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry system. There were 32 patients in each group. After 4 weeks of treatment, the levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in both groups and the level of lipoprotein-a (Lp-a) in the combined group were lower. In the combined treatment group, the levels of TC, LDL-C, and Lp-a decreased significantly ( P < 0.05) after 4 weeks of treatment. Most of the lipid classes in plasma decreased in the combined group at 4 weeks, especially sphingolipids. Only 1 patient had an adverse event (a rash) in the combined group, which improved after anti-allergic treatment. PCSK9 inhibitors can rapidly and effectively reduce most lipid classes in patients with very-high-risk ASCVD.",2021,"Only 1 patient had an adverse event (a rash) in the combined group, which improved after anti-allergic treatment.","['patients with very high-risk atherosclerotic cardiovascular disease (ASCVD) by ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-MS', 'patients with very-high-risk ASCVD', 'patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy', '64 patients with a very high risk of ASCVD']","['atorvastatin', 'PCSK9 inhibitors', 'combined group (evolocumab']","['levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C', 'level of serum lipids', 'adverse event (a rash', 'lipid classes of triacylglycerols, cholesteryl esters, and sphingomyelins', 'levels of TC, LDL-C, and Lp']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442804', 'cui_str': 'Very high'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0008565', 'cui_str': 'Liquid chromatography measurement'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0037813', 'cui_str': 'Mass spectrometry measurement'}, {'cui': 'C4521460', 'cui_str': 'PCSK9 inhibitor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C4521460', 'cui_str': 'PCSK9 inhibitor'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3529352', 'cui_str': 'evolocumab'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0428462', 'cui_str': 'Measurement of serum lipid level'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0008387', 'cui_str': 'Cholesterol ester'}, {'cui': 'C0037906', 'cui_str': 'Sphingomyelin'}]",64.0,0.0409512,"Only 1 patient had an adverse event (a rash) in the combined group, which improved after anti-allergic treatment.","[{'ForeName': 'Kui', 'Initials': 'K', 'LastName': 'Huang', 'Affiliation': 'Department of Cardiology, Tianjin Chest Hospital, 300222 Tianjin, China.'}, {'ForeName': 'Xiao-Qin', 'Initials': 'XQ', 'LastName': 'Wen', 'Affiliation': 'Department of Cardiology, Tianjin Hospital, 300211 Tianjin, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Ren', 'Affiliation': 'Department of Cardiology, Tianjin Chest Hospital, 300222 Tianjin, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Department of Cardiology, Tianjin Chest Hospital, 300222 Tianjin, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Gao', 'Affiliation': 'Department of Cardiology, Tianjin Hospital, 300211 Tianjin, China.'}]",Reviews in cardiovascular medicine,['10.31083/j.rcm2202052'] 1647,34264195,Barriers to the Use of Web-Based Mental Health Programs for Preventing Depression: Qualitative Study.,"BACKGROUND Depression has a profound impact on population health. Although using web-based mental health programs to prevent depression has been found to be effective in decreasing depression incidence, there are obstacles preventing their use, as reflected by the low rates of use and adherence. OBJECTIVE The aims of the study are to understand the barriers to using web-based mental health programs for the prevention of depression and the possible dangers or concerns regarding the use of such programs. METHODS BroMatters and HardHat were two randomized controlled trials (RCTs) that evaluated the effectiveness of e-mental health programs for preventing workplace depression. In the BroMatters RCT, only working men who were at high risk of having a major depressive episode were included. The participants were assigned to either the control group or 1 of 2 intervention groups. The control participants had access to the general depression information on the BroMatters website. Intervention group 1 had access to BroMatters and BroHealth-the depression prevention program. Intervention group 2 had access to BroMatters and BroHealth along with weekly access to a qualified coach through telephone calls. The HardHat trial targeted both men and women at high risk of having a major depressive episode. The participants in the intervention group were given access to the HardHat depression prevention program (which included a web-based coach), whereas HardHat access was only granted to the control group once the study was completed. This qualitative study recruited male participants from the intervention groups of the two RCTs. A total of 2 groups of participants were recruited from the BroMatters study (after a baseline interview: n=41; 1 month after the RCT: n=20; 61/744, 8.2%), and 1 group was recruited from the HardHat RCT 1 month after the initial quantitative interview (9/103, 8.7%). Semistructured interviews were performed with the participants (70/847, 8.3%) and analyzed using content analysis. RESULTS There were both personal and program-level barriers to program use. The three personal barriers included time, stress level, and the perception of depression prevention. Content, functionality, and dangers were the program-level barriers to the use of web-based mental health programs. Large amounts of text and functionality issues within the programs decreased participants' engagement. The dangers associated with web-based mental health programs included privacy breaches and inadequate help for severe symptoms. CONCLUSIONS There are personal and program-level barriers to the use of web-based mental health programs. The stigmatization of help seeking for depression symptoms affects the time spent on the program, as does the public perception of depression. Certain barriers may be mitigated by program updates, whereas others may require a complete shift in the perception of depression prevention.",2021,"Content, functionality, and dangers were the program-level barriers to the use of web-based mental health programs.","['A total of 2 groups of participants were recruited from the BroMatters study (after a baseline interview: n=41; 1 month after the RCT', 'working men who were at high risk of having a major depressive episode were included', 'male participants from the intervention groups of the two RCTs', 'BroMatters and HardHat', 'men and women at high risk of having a major depressive episode']","['e-mental health programs', 'Intervention group 2 had access to BroMatters and BroHealth along with weekly access to a qualified coach through telephone calls', 'HardHat depression prevention program (which included a web-based coach', 'Intervention group 1 had access to BroMatters and BroHealth', 'Web-Based Mental Health Programs']","['time, stress level, and the perception of depression prevention']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0024517', 'cui_str': 'Major depression, single episode'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]",,0.016196,"Content, functionality, and dangers were the program-level barriers to the use of web-based mental health programs.","[{'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Eccles', 'Affiliation': 'The Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Nannarone', 'Affiliation': 'The Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Lashewicz', 'Affiliation': 'Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, ON, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Attridge', 'Affiliation': 'Attridge Consulting, Inc, Minneapolis, MN, United States.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Marchand', 'Affiliation': 'School of Industrial Relations, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Aiken', 'Affiliation': 'Faculty of Health, Dalhousie University, Halifax, NS, Canada.'}, {'ForeName': 'Kendall', 'Initials': 'K', 'LastName': 'Ho', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'JianLi', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'The Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.'}]",JMIR formative research,['10.2196/16949'] 1648,34264128,Postprandial superior mesenteric artery blood flow is related to changes in peripheral pulse wave harmonics and heart rate: implications for wearable technology?,"Postprandial superior mesenteric artery (SMA) blood flow is associated with the caloric content of a meal. Whether spectral analysis of a peripheral pulse wave or heart rate can model postprandial SMA blood flow is unclear. We hypothesized that altering the caloric content of a meal would evoke dose-response increases in postprandial SMA hyperemia and distinct changes in the pulse wave harmonic spectrum and heart rate. Twenty healthy subjects (10 male, 26 ± 10 yr) completed a randomized cross-over trial, comparing three meals (280, 560, or 840 kcal) on SMA blood flow (Doppler ultrasound), heart rate, and the first to seventh harmonic amplitudes (derived from a finger pulse wave). Supine SMA diameter and blood velocity were collected at baseline and every 15 min throughout 2 h of postprandial recovery. SMA blood flow was smaller across all time points following meal 1 (280 kcal) compared with both meal 2 (560 kcal) and meal 3 (840 kcal) (all P < 0.001), while meal 2 had attenuated responses compared with meal 3 at 60, 90, 105, and 120 min postprandial (all P < 0.01). Distinct changes in heart rate and the amplitude of second to fifth harmonics were observed between meals (all P < 0.05). The changes in harmonic spectrum or heart rate explained 66-69% (adjusted r 2 ) of the variance in postprandial SMA blood flow. These results provide proof-of-concept that easily obtained and noninvasive postprandial harmonic profiles or heart rate may be used to explain changes in SMA blood flow and exploited for the development of wearable technology to noninvasively track caloric intake. NEW & NOTEWORTHY We studied the superior mesenteric artery (SMA) blood flow responses to three meals of varying caloric value and examined whether these responses could be modeled using changes in heart rate or the peripheral pulse wave harmonic spectrum. We found that both inputs could explain 66-69% of the SMA blood flow variance over 2 h of postprandial recovery. Noninvasive methods may be able to predict SMA blood flow and thus used to measure caloric intake.",2021,Distinct changes in heart rate and the amplitude of 2 nd to 5 th harmonics were observed between meals (All p<0.05).,"['Twenty healthy subjects (10 male, 26±10 yrs']",[],"['postprandial SMA blood flow', 'SMA blood flow', 'Supine SMA diameter and blood velocity', 'Postprandial superior mesenteric artery (SMA) blood flow', 'SMA blood flow (Doppler ultrasound), heart rate', 'heart rate and the amplitude of 2 nd to 5 th harmonics', 'postprandial SMA hyperemia', 'harmonic spectrum or heart rate']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}]",[],"[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0162861', 'cui_str': 'Superior mesenteric artery structure'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C1531610', 'cui_str': 'Blood velocity'}, {'cui': 'C0162481', 'cui_str': 'Doppler ultrasound'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0020452', 'cui_str': 'Hyperemia'}]",,0.0205738,Distinct changes in heart rate and the amplitude of 2 nd to 5 th harmonics were observed between meals (All p<0.05).,"[{'ForeName': 'Eamon', 'Initials': 'E', 'LastName': 'Abdullah', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Jordan B', 'Initials': 'JB', 'LastName': 'Lee', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Karambir', 'Initials': 'K', 'LastName': 'Notay', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Millar', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00903.2020'] 1649,34261530,Intradermal acupuncture for rheumatoid arthritis: study protocol for a randomised controlled trial.,"BACKGROUND Rheumatoid arthritis (RA) is a common autoimmune disease that severely impacts quality of life. Currently available medications for the treatment of RA have adverse side effects. Emerging evidence suggests that intradermal acupuncture (IA) is feasible and safe for patients, but its application in RA patients has not been examined. Our study aims to explore the efficacy and safety of IA for the treatment of RA. METHODS This study is a randomised, sham-controlled, patient-outcome assessor-statistician blind trial that aims to evaluate the effects of IA in patients with RA. We will recruit 132 patients aged ≥ 18 years with a diagnosis of RA. Patients will be randomly allocated with a 1:1 ratio to IA or sham IA groups. Both groups will receive basic treatment and nursing routines for RA. The experimental group will receive actual IA treatment, whereas the control group will receive sham IA treatment. All patients will receive one course of treatment (i.e., four consecutive treatment sessions with an intervening 1-day interval). Primary outcomes will be traditional Chinese medicine (TCM) syndromes before and after a treatment course and Health Assessment Questionnaire (HAQ) scores. Secondary outcomes will be disease activity score 28 (DAS28) and levels of serum C-reactive protein (CRP). Outcome measures will be collected pre- and post-treatment. DISCUSSION This study aims to provide high-quality evidence for the efficacy and safety of IA for treating RA. In addition, the results will provide references for selection of acupoints for other syndromes in clinical practice. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR2000038028 . Registered on 8 September 2020.",2021,Secondary outcomes will be disease activity score 28 (DAS28) and levels of serum C-reactive protein (CRP).,"['rheumatoid arthritis', 'patients with RA', '132 patients aged ≥ 18 years with a diagnosis of RA']","['intradermal acupuncture (IA', 'Intradermal acupuncture']","['traditional Chinese medicine (TCM) syndromes before and after a treatment course and Health Assessment Questionnaire (HAQ) scores', 'efficacy and safety', 'disease activity score 28 (DAS28) and levels of serum C-reactive protein (CRP']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C1522475', 'cui_str': 'Intradermal route'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",132.0,0.518048,Secondary outcomes will be disease activity score 28 (DAS28) and levels of serum C-reactive protein (CRP).,"[{'ForeName': 'Huifang', 'Initials': 'H', 'LastName': 'Luo', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Peng', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Ma', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Zhihua', 'Initials': 'Z', 'LastName': 'Wei', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Changsong', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Mingying', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Peiwu', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Department of Spleen and Stomach Diseases, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China. fau20@126.com.'}, {'ForeName': 'Xiangwei', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China. 1327758056@qq.com.'}]",Trials,['10.1186/s13063-021-05416-0'] 1650,34260969,CRTpowerdist: An R package to calculate attained power and construct the power distribution for cross-sectional stepped-wedge and parallel cluster randomized trials.,"BACKGROUND The attained power, calculated conditional on the realized allocation, of a clinical trial may differ from the expected power, obtained pre-randomization through averaging over all potential allocations that could be generated by the randomization algorithm (RA). For example, a two-arm trial using a RA that is expected to allocate 20 participants to each arm will attain less than the expected power if by chance it allocates 25 and 15 participants to the arms. Cluster randomized trials with unequal cluster sizes have elevated risk of realizing an allocation that yields an attained power much lower than the expected power when modest numbers of clusters are randomized. METHOD We developed the R package CRTpowerdist, which implements both simulations and approximate analytic formulae to calculate the attained powers associated with different realized allocations and constructs the pre-randomization power distribution associated with the RA to facilitate assessing the risk of obtaining inadequate power. The package covers unequal cluster-size, cross-sectional stepped-wedge and parallel cluster randomized trials, with or without stratification. Allowed outcome types are: continuous (Gaussian), binary (Binomial) and count (Poisson). The analytic formulae-based calculations are also implemented in a Shiny app. RESULTS The functionality of the CRTpowerdist is illustrated for each type of trial design. The examples show how to obtain the attained power, the power distribution, and the risk of low attained power, using both simulation and analytic formulae. CONCLUSION For cluster randomized trials with unequal cluster sizes, the CRTpowerdist package can assist users in identifying an appropriate randomization algorithm by enabling the user to assess the risk that a randomization algorithm will lead to an allocation with inadequate attained power. The Shiny app makes these assessments accessible to researchers who are unable or do not wish to use the CRTpowerdist package.",2021,"Cluster randomized trials with unequal cluster sizes have elevated risk of realizing an allocation that yields an attained power much lower than the expected power when modest numbers of clusters are randomized. ",['CRTpowerdist'],[],[],[],[],[],,0.0782454,"Cluster randomized trials with unequal cluster sizes have elevated risk of realizing an allocation that yields an attained power much lower than the expected power when modest numbers of clusters are randomized. ","[{'ForeName': 'Yongdong', 'Initials': 'Y', 'LastName': 'Ouyang', 'Affiliation': ""School of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, BC Canada V6T 1Z3; Centre for Health Evaluation & Outcome Sciences, 588 - 1081 Burrard Street, St. Paul's Hospital Vancouver, BC Canada V6Z 1Y6. Electronic address: douyang@cheos.ubc.ca.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': ""School of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, BC Canada V6T 1Z3; Centre for Health Evaluation & Outcome Sciences, 588 - 1081 Burrard Street, St. Paul's Hospital Vancouver, BC Canada V6Z 1Y6.""}, {'ForeName': 'Mohammad Ehsanul', 'Initials': 'ME', 'LastName': 'Karim', 'Affiliation': ""School of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, BC Canada V6T 1Z3; Centre for Health Evaluation & Outcome Sciences, 588 - 1081 Burrard Street, St. Paul's Hospital Vancouver, BC Canada V6Z 1Y6.""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Gustafson', 'Affiliation': 'Department of Statistics, University of British Columbia, 3182 Earth Sciences Building, 2207 Main Mall Vancouver, BC Canada V6T 1Z4.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Wong', 'Affiliation': ""School of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, BC Canada V6T 1Z3; Centre for Health Evaluation & Outcome Sciences, 588 - 1081 Burrard Street, St. Paul's Hospital Vancouver, BC Canada V6Z 1Y6.""}]",Computer methods and programs in biomedicine,['10.1016/j.cmpb.2021.106255'] 1651,34266463,Comparison of walking variations during treadmill walking test between neurogenic and vascular claudication: a crossover study.,"BACKGROUND Lumbar spinal stenosis (LSS) and peripheral arterial disease (PAD) are two distinct conditions characterized by similar symptoms including leg pain and walking limitations due to claudication. Differentiation between both origins can be difficult and characteristics such as symptom manifestations, time to relief in rest position and pain localization should be considered when determining diagnosis and the treatment plan. The objectives of this study were to compare changes in walking time to symptom change during treadmill tests and self-reported outcomes measures related to claudication, kinesophobia and global health between individuals with LSS, PAD and non-specific low back pain (nLBP). METHOD Fifty-five patients (23 with LSS, 14 with PAD and 18 with nLBP) were recruited from May 2018 to March 2020 to complete a treadmill walking test involving two 5-min walking tasks (Upright and Forward Leaning Trunk (FLT) Walking tasks). The speed was set at 1.9 km/h (1.2 mph), and each task was followed by a 5-min rest period. Walking time to symptom change and Total walking time were recorded during each walking task. Patients were asked to complete four questionnaires related to the impact of claudication, walking impairment, kinesiophobia and global health. One-way ANOVAs were performed to compare walking time difference from the Upright to the FLT walking tasks and to compare questionnaires results between groups. RESULTS One-way ANOVAs showed a significant difference between groups regarding difference in Walking time to symptom change between both tasks (F = 4.12, p = 0.022). The LSS group improved its Walking time to symptom change from the Upright to the FLT walking tasks more than the PAD (p = 0.34) and the nLBP group (p = 0.12). The nLBP group was less impacted by claudication and less impaired during walking compared to the LSS and PAD groups (ps < 0.001). The nLBP group also had less kinesiophobia than the LSS one (p < 0.001), but was similar to the PAD group. The global health rating was not statistically different between groups (p = 0.118). CONCLUSION The test was able to distinguish neurogenic from vascular or nLBP related claudication. However, further studies are needed to validate this new treadmill walking test. TRIAL REGISTRATION clinicaltrials.gov ( NCT04058171 ), Registered August 15, 2019 -Registered during recruitment.",2021,The nLBP group was less impacted by claudication and less impaired during walking compared to the LSS and PAD groups (ps < 0.001).,"['individuals with LSS, PAD and non-specific low back pain (nLBP', 'Fifty-five patients (23 with LSS, 14 with PAD and 18 with nLBP) were recruited from May 2018 to March 2020 to complete a', 'neurogenic and vascular claudication', 'Lumbar spinal stenosis (LSS) and peripheral arterial disease (PAD']","['LSS', 'walking variations during treadmill walking test', 'treadmill walking test involving two 5-min walking tasks (Upright and Forward Leaning Trunk (FLT) Walking tasks']","['Walking time to symptom change and Total walking time', 'kinesiophobia', 'global health rating', 'Walking time to symptom change', 'claudication, kinesophobia and global health']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0158288', 'cui_str': 'Spinal stenosis of lumbar region'}, {'cui': 'C0085096', 'cui_str': 'Peripheral vascular disease'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0450382', 'cui_str': '55'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}]","[{'cui': 'C0158288', 'cui_str': 'Spinal stenosis of lumbar region'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}]",,0.0233385,The nLBP group was less impacted by claudication and less impaired during walking compared to the LSS and PAD groups (ps < 0.001).,"[{'ForeName': 'Mariève', 'Initials': 'M', 'LastName': 'Houle', 'Affiliation': ""Département des Sciences de l'activité physique, Université du Québec à Trois-Rivières, 3351, boul. des Forges, C.P. 500, Trois-Rivières, QC, G8Z 4M3, Canada. marieve.houle@uqtr.ca.""}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': ""O'Shaughnessy"", 'Affiliation': 'Département de Chiropratique, Université du Québec à Trois-Rivières, 3351, boul. des Forges, C.P. 500, Trois-Rivières, QC, G8Z 4M3, Canada.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Tétreau', 'Affiliation': ""Département des Sciences de l'activité physique, Université du Québec à Trois-Rivières, 3351, boul. des Forges, C.P. 500, Trois-Rivières, QC, G8Z 4M3, Canada.""}, {'ForeName': 'Claude-Édouard', 'Initials': 'CÉ', 'LastName': 'Châtillon', 'Affiliation': 'Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-et-du-Centre-du-Québec (CIUSSS MCQ), 1991 Boulevard du Carmel, Trois-Rivières, QC, G8Z 3R9, Canada.'}, {'ForeName': 'Andrée-Anne', 'Initials': 'AA', 'LastName': 'Marchand', 'Affiliation': 'Département de Chiropratique, Université du Québec à Trois-Rivières, 3351, boul. des Forges, C.P. 500, Trois-Rivières, QC, G8Z 4M3, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Descarreaux', 'Affiliation': ""Département des Sciences de l'activité physique, Université du Québec à Trois-Rivières, 3351, boul. des Forges, C.P. 500, Trois-Rivières, QC, G8Z 4M3, Canada.""}]",Chiropractic & manual therapies,['10.1186/s12998-021-00382-5'] 1652,34264782,Chronic Sequelae After Muscle Strain Injuries: Influence of Heavy Resistance Training on Functional and Structural Characteristics in a Randomized Controlled Trial.,"BACKGROUND Muscle strain injury leads to a high risk of recurrent injury in sports and can cause long-term symptoms such as weakness and pain. Scar tissue formation after strain injuries has been described, yet what ultrastructural changes might occur in the chronic phase of this injury have not. It is also unknown if persistent symptoms and morphological abnormalities of the tissue can be mitigated by strength training. PURPOSE To investigate if heavy resistance training improves symptoms and structural abnormalities after strain injuries. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS A total of 30 participants with long-term weakness and/or pain after a strain injury of the thigh or calf muscles were randomized to eccentric heavy resistance training of the injured region or control exercises of the back and abdominal muscle. Isokinetic (hamstring) or isometric (calf) muscle strength was determined, muscle cross-sectional area measured, and pain and function evaluated. Scar tissue ultrastructure was determined from biopsy specimens taken from the injured area before and after the training intervention. RESULTS Heavy resistance training over 3 months improved pain and function, normalized muscle strength deficits, and increased muscle cross-sectional area in the previously injured region. No systematic effect of training was found upon pathologic infiltration of fat and blood vessels into the previously injured area. Control exercises had no effect on strength, cross-sectional area, or scar tissue but a positive effect on patient-related outcome measures, such as pain and functional scores. CONCLUSION Short-term strength training can improve sequelae symptoms and optimize muscle function even many years after a strain injury, but it does not seem to influence the overall structural abnormalities of the area with scar tissue. REGISTRATION NCT02152098 (ClinicalTrials.gov identifier).",2021,"Control exercises had no effect on strength, cross-sectional area, or scar tissue but a positive effect on patient-related outcome measures, such as pain and functional scores. ","['After Muscle Strain Injuries', '30 participants with long-term weakness and/or pain after a strain injury of the thigh or calf muscles']","['Heavy resistance training', 'Short-term strength training', 'eccentric heavy resistance training of the injured region or control exercises of the back and abdominal muscle', 'heavy resistance training', 'Heavy Resistance Training', 'Control exercises']","['pain and function, normalized muscle strength deficits, and increased muscle cross-sectional area', 'Scar tissue ultrastructure', 'Isokinetic (hamstring) or isometric (calf) muscle strength was determined, muscle cross-sectional area measured, and pain and function evaluated', 'pathologic infiltration of fat and blood vessels', 'Chronic Sequelae', 'strength, cross-sectional area, or scar tissue', 'pain and functional scores']","[{'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C3714552', 'cui_str': 'Debility'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0448482', 'cui_str': 'Posterior crural muscle structure'}]","[{'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0000739', 'cui_str': 'Skeletal muscle structure of abdomen'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0241158', 'cui_str': 'Scar of skin'}, {'cui': 'C0041623', 'cui_str': 'ultrastructure'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0243088', 'cui_str': 'sequels'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",30.0,0.0506814,"Control exercises had no effect on strength, cross-sectional area, or scar tissue but a positive effect on patient-related outcome measures, such as pain and functional scores. ","[{'ForeName': 'Monika L', 'Initials': 'ML', 'LastName': 'Bayer', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.'}, {'ForeName': 'Maren', 'Initials': 'M', 'LastName': 'Hoegberget-Kalisz', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.'}, {'ForeName': 'Rene B', 'Initials': 'RB', 'LastName': 'Svensson', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.'}, {'ForeName': 'Mikkel H', 'Initials': 'MH', 'LastName': 'Hjortshoej', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.'}, {'ForeName': 'Jens L', 'Initials': 'JL', 'LastName': 'Olesen', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.'}, {'ForeName': 'Janus D', 'Initials': 'JD', 'LastName': 'Nybing', 'Affiliation': 'Department of Radiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Boesen', 'Affiliation': 'Department of Radiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.'}, {'ForeName': 'S Peter', 'Initials': 'SP', 'LastName': 'Magnusson', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kjaer', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.'}]",The American journal of sports medicine,['10.1177/03635465211026623'] 1653,34264757,Play and Learn for Surgeons: A Serious Game to Educate Medical Residents in Uterine Artery Ligation Surgery.,"Objective: Postpartum hemorrhage (PPH) is a leading cause of maternal mortality. Surgical interventions, such as uterine artery ligation and utero-ovarian arteries ligation (UAL and UOAL), are considered as effective methods to control PPH. Owing to PPH's severe outcomes, various educational tools have been developed to train surgical residents. A potential educational medium for this purpose could be serious digital games. In this pilot study, we assessed the usability and effectiveness of a serious game to promote the surgical skills of UAL/UOAL among obstetrics and gynecology (OB/GYN) residents. Methods: We designed and developed the Play and Learn for Surgeons (PLS) game to train OB/GYN residents. We assessed and compared the usability challenges of PLS before and after revising the game. To assess the effectiveness of PLS, residents were allocated randomly in control and intervention groups. Surgical skills of the residents were assessed pre- and post-test using the Objective Structured Assessment of Technical Skills checklist. Setting: This pilot study took place at the OB/GYN wards of Omolbanin Hospital (Mashhad University of Medical Sciences) and Imam Ali Hospital (Zahedan University of Medical Sciences) in Iran. Participants: Thirteen subject matter experts (nine OB/GYN experts and four senior clinical assistants) participated in the user interface design and usability assessment of PLS. Total of 46 OB/GYN residents participated in the educational effectiveness analysis of PLS. All participants were female with mean ages of 40.6, 29.9 and 28.0 years for OB/GYN experts, assistants, and residents, accordingly. Results: All participants completed the study. PLS significantly improved the skills of residents for UAL ( P -value = 0.018) and UOAL ( P -value <0.001) procedures. Conclusion: Serious games can be an effective and affordable approach in training OB/GYN residents for UAL and UOAL procedures. Approval number: (# IR.MUMS.fm.REC.1396.345) Trial registration number: (# IRCT2017092436366N1).",2021,PLS significantly improved the skills of residents for UAL ( P -value = 0.018) and UOAL ( P -value <0.001) procedures. ,"['Surgeons', 'All participants were female with mean ages of 40.6, 29.9 and 28.0 years for OB/GYN experts, assistants, and residents, accordingly', 'Educate Medical Residents in Uterine Artery Ligation Surgery', 'OB/GYN wards of Omolbanin Hospital (Mashhad University of Medical Sciences) and Imam Ali Hospital (Zahedan University of Medical Sciences) in Iran', 'Participants']","['Play and Learn for Surgeons (PLS) game to train OB/GYN residents', 'uterine artery ligation and utero-ovarian arteries ligation (UAL and UOAL']","['skills of residents for UAL', 'UOAL', 'usability and effectiveness']","[{'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C0011327', 'cui_str': 'Dental assistant'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0226378', 'cui_str': 'Structure of uterine artery'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0521321', 'cui_str': 'Imam'}, {'cui': 'C0242488', 'cui_str': 'Acute lung injury'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0226378', 'cui_str': 'Structure of uterine artery'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0226411', 'cui_str': 'Structure of ovarian artery'}]","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",46.0,0.0474816,PLS significantly improved the skills of residents for UAL ( P -value = 0.018) and UOAL ( P -value <0.001) procedures. ,"[{'ForeName': 'Nahid', 'Initials': 'N', 'LastName': 'Sharifzadeh', 'Affiliation': 'Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Tabesh', 'Affiliation': 'Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Kharrazi', 'Affiliation': 'Department of Health Policy and Management, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Tara', 'Affiliation': 'Department of Obstetrics and Gynecology, Neonatal Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Kiani', 'Affiliation': 'Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Marjan', 'Initials': 'M', 'LastName': 'Rasoulian Kasrineh', 'Affiliation': 'Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Mirteimouri', 'Affiliation': 'Department of Obstetrics and Gynecology, Neonatal Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mahmood', 'Initials': 'M', 'LastName': 'Tara', 'Affiliation': 'Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Games for health journal,['10.1089/g4h.2020.0220'] 1654,34269042,A randomized controlled trial on the plaque-removing efficacy of a low-abrasive air-polishing system to improve oral health care.,"OBJECTIVES While air polishing with abrasive powders has been proved efficient for sub- and supragingival application, only few studies concerning the quality of supragingival biofilm removal using the low-abrasive erythritol powder (EP) exist. The aim of the present randomized controlled trial was to clinically compare the efficacy of supragingival air polishing using EP in comparison with the rubber cup method, and to juxtapose the corresponding biofilm regrowth rates. METHOD AND MATERIALS Thirty-two young adults, suspending oral hygiene for 48 hours, were enrolled in the present double-blind short-term investigation. Using a split-mouth design, tooth polishing was conducted by means of either air polishing or rubber cups with prophylaxis paste (control). While 16 participants received air polishing in the second and fourth quadrants (and rubber cup prophylaxis in the first and third ones), the reverse sequence was applied with the remaining 16 subjects. Biofilms were assessed using the modified Quigley-Hein index (QHI), and QHI sum scores achieved both prior to and immediately after the polishing procedure, as well as 24 hours later, were assessed using a two-way analysis of variance (ANOVA), followed by Tukey's HSD to test multiple pairwise comparisons. RESULTS Both methods revealed a significant reduction of QHI scores (P < .001). Compared to the rubber cup method, air polishing resulted in significantly lower scores, both after tooth cleaning and after 24 hours (P < .001). CONCLUSIONS Supragingival biofilm removal by means of air polishing combined with low-abrasive erythritol seems to be more efficacious than the traditional polishing method, and should improve oral health care.",2021,"Compared to the rubber cup method, air polishing resulted in significantly lower scores, both after tooth cleaning and after 24 hours (P < .001). ","['Thirty-two young adults, suspending oral hygiene for 48 hours']","['supragingival air polishing using EP', 'low\ufeff-abrasive air-polishing system', 'air polishing or rubber cups with prophylaxis paste (control', 'air polishing']","['modified Quigley-Hein index (QHI), and QHI sum scores', 'QHI scores', 'oral health care']","[{'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0038959', 'cui_str': 'Suspending Agents'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0439586', 'cui_str': '48 hours'}]","[{'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0032376', 'cui_str': 'Polish language'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0030634', 'cui_str': 'Pastes'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}]",32.0,0.0597333,"Compared to the rubber cup method, air polishing resulted in significantly lower scores, both after tooth cleaning and after 24 hours (P < .001). ","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wolgin', 'Affiliation': ''}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Frankenhauser', 'Affiliation': ''}, {'ForeName': 'Natallia', 'Initials': 'N', 'LastName': 'Shakavets', 'Affiliation': ''}, {'ForeName': 'Klaus-Dieter', 'Initials': 'KD', 'LastName': 'Bastendorf', 'Affiliation': ''}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Lussi', 'Affiliation': ''}, {'ForeName': 'Andrej Michael', 'Initials': 'AM', 'LastName': 'Kielbassa', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.b1763661'] 1655,34271401,Social connectedness as a mediator for horticultural therapy's biological effect on community-dwelling older adults: Secondary analyses of a randomized controlled trial.,"BACKGROUND Elevated levels of inflammatory marker and a lack of social connectedness are two prominent risk factors for developing dementia and depression. Horticultural therapy (HT) has been shown to improve social connectedness and inflammatory markers. However, the underpinning mechanisms of HT remained unknown. Within this study, we hypothesized that improved social connectedness mediates the effects of HT on IL-6 levels. METHODS The present study is a secondary analysis of a randomized controlled trial investigating the bio-psycho-social effects of HT. Social connectedness was operationalized as positive relationships with others (PRWO), a sub-scale of the Ryff's scale of psychological well-being. IL-6 was quantified using a commercial ELISA kit. Outcomes were assessed at baseline, 3-month and 6-month post-intervention. Mediation analyses with bootstrapping were run to investigate our primary hypothesis. All analyses were controlled for covariates. RESULTS We recruited 59 participants (78% women; 67.10 ± 4.31 years). 29 participants partook in HT and 30 participants were included in the waitlist control group. At baseline, social connectedness was significantly correlated with IL-6 levels (β = -0.12, 95% CI = -0.21 to -0.03, p = 0.008). Furthermore, social connectedness at 3-month significantly mediated the effects of HT on IL-6 levels at 6-month (β = 0.32, 95% CI = 0.09 to 0.54, p = 0.005; β = -0.25, 95% CI = -0.45 to -0.05, p = 0.016). CONCLUSIONS These findings highlight the critical roles of social connectedness as a social determinant of health in eliciting HT's biological effects. When administering HT, interventionalists should consider social connectedness as a modifiable factor for ameliorating increased inflammation in older adults.",2021,"At baseline, social connectedness was significantly correlated with IL-6 levels (β = -0.12, 95% CI = ","['59 participants (78% women; 67.10\xa0±\xa04.31 years', 'community-dwelling older adults', '29 participants partook in HT and 30 participants were included in the waitlist control group', 'older adults']","['Horticultural therapy (HT', 'HT']","['IL-6', 'IL-6 levels']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0454057', 'cui_str': 'Horticultural therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0454057', 'cui_str': 'Horticultural therapy'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",59.0,0.247097,"At baseline, social connectedness was significantly correlated with IL-6 levels (β = -0.12, 95% CI = ","[{'ForeName': 'Ted Kheng Siang', 'Initials': 'TKS', 'LastName': 'Ng', 'Affiliation': 'Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, 119228, Singapore. Electronic address: a0047115@u.nus.edu.'}, {'ForeName': 'Daniel R Y', 'Initials': 'DRY', 'LastName': 'Gan', 'Affiliation': 'Real Estate Foundation Postdoctoral Fellow at the Gerontology Research Centre, Simon Fraser University, #2800-515 West Hastings St, Vancouver, B.C, V6B 5K3, Canada.'}, {'ForeName': 'Rathi', 'Initials': 'R', 'LastName': 'Mahendran', 'Affiliation': 'Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, 119228, Singapore; Department of Psychological Medicine, National University Hospital, 1E Kent Ridge Road, NUHS Tower Block, 119228, Singapore; Academic Development Department, Duke-NUS Medical School, 8 College Road, Singapore.'}, {'ForeName': 'Ee Heok', 'Initials': 'EH', 'LastName': 'Kua', 'Affiliation': 'Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, 119228, Singapore; Department of Psychological Medicine, National University Hospital, 1E Kent Ridge Road, NUHS Tower Block, 119228, Singapore.'}, {'ForeName': 'Roger C-M', 'Initials': 'RC', 'LastName': 'Ho', 'Affiliation': 'Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, 119228, Singapore; Department of Psychological Medicine, National University Hospital, 1E Kent Ridge Road, NUHS Tower Block, 119228, Singapore.'}]",Social science & medicine (1982),['10.1016/j.socscimed.2021.114191'] 1656,34271366,No effect of calcium and vitamin D intake on maternal blood pressure in a healthy pregnant population.,"OBJECTIVES Clinical studies have reported an inverse relationship between calcium and vitamin D intake and hypertensive disorders of pregnancy (HDP). The aim of this study was to investigate if there was an association between calcium/vitamin D intake, and vitamin D (25OHD) status, and maternal blood pressure (BP), during pregnancy and at 5-year follow-up. STUDY DESIGN This was an observational study of 415 women who participated in the ROLO (Randomised cOntrolled trial of LOw glycaemic index diet for the prevention of recurrence of macrosomia) study. Maternal BP measurements were taken during each trimester and at 5-year follow-up. Calcium and vitamin D intake were determined at each trimester and 25OHD was measured in early and late pregnancy. RESULTS Over two-thirds of the cohort were vitamin D sufficient (25OHD > 30 nmol/L) and had adequate calcium intake (>750 mg/day). There was no correlation between calcium intake or vitamin D intake and maternal BP in trimester 1 to 3 or at 5-year follow-up. Vitamin D status at 13 weeks' gestation negatively correlated with mean arterial pressure in trimester 1 (r = -0.152, p = 0.044). There was no correlation however between 25OHD at 28 weeks' gestation and BP at 28 or 34 weeks' gestation or 25OHD and BP at 5-year follow-up. CONCLUSIONS In a healthy population of women with adequate calcium and vitamin D intake, no clinically significant correlation existed between calcium and vitamin D and maternal BP.",2021,"There was no correlation however between 25OHD at 28 weeks' gestation and BP at 28 or 34 weeks' gestation or 25OHD and BP at 5-year follow-up. ","['415 women who participated in the ROLO (Randomised cOntrolled trial of', 'hypertensive disorders of pregnancy (HDP', 'healthy pregnant population']","['LOw glycaemic index diet', 'calcium and vitamin D intake']","['Calcium and vitamin D intake', 'mean arterial pressure', 'maternal blood pressure', 'Vitamin D status', 'calcium intake or vitamin D intake and maternal BP', 'calcium/vitamin D intake, and vitamin D (25OHD) status, and maternal blood pressure (BP', 'calcium and vitamin D and maternal BP', 'Maternal BP measurements']","[{'cui': 'C4517772', 'cui_str': '415'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0852260', 'cui_str': 'Hypertension associated disorders of pregnancy'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0564439', 'cui_str': 'Vitamin D intake'}]","[{'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0564439', 'cui_str': 'Vitamin D intake'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0489458', 'cui_str': 'Calcium intake'}, {'cui': 'C0719107', 'cui_str': 'Calcium and vitamin D product'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}]",415.0,0.15702,"There was no correlation however between 25OHD at 28 weeks' gestation and BP at 28 or 34 weeks' gestation or 25OHD and BP at 5-year follow-up. ","[{'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Forde', 'Affiliation': ""Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland. Electronic address: hannahforde@gmail.com.""}, {'ForeName': 'Rachel K', 'Initials': 'RK', 'LastName': 'Crowley', 'Affiliation': ""Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland; UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.""}, {'ForeName': 'Malachi J', 'Initials': 'MJ', 'LastName': 'McKenna', 'Affiliation': ""Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland; UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.""}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Kilbane', 'Affiliation': ""Department of Clinical Chemistry, St Vincent's University Hospital, Dublin, Ireland.""}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Conway', 'Affiliation': 'UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Ciara M', 'Initials': 'CM', 'LastName': 'McDonnell', 'Affiliation': ""Department of Paediatric Endocrinology & Diabetes, Children's Health Ireland, Temple Street Hospital, Dublin, Ireland.""}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Twomey', 'Affiliation': ""Department of Clinical Chemistry, St Vincent's University Hospital, Dublin, Ireland.""}, {'ForeName': 'Fionnuala M', 'Initials': 'FM', 'LastName': 'McAuliffe', 'Affiliation': ""Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland; UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.""}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2021.07.005'] 1657,34271362,Impact of innovative pelvic floor muscle training on quality-adjusted life years (QALYs) in women with stress urinary incontinence treated by duloxetine.,"OBJECTIVES The aim of this study was to measure the impact of innovative pelvic floor muscle training (iPFMT) on Quality-Adjusted Life Years (QALYs) in women with stress urinary incontinence (SUI) treated by duloxetine. STUDY DESIGN This analysis is part of the DULOXING study conducted between February 2019 and 2020. The control group received oral duloxetine treatment (40 mg BID), and the experimental group received oral duloxetine treatment (40 mg BID) and iPFMT with lumbopelvic stabilization. SUI was analysed at baseline and in the final period according to the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF). The QALYs gained were calculated by multiplying life expectancy (LE) by a weighting factor (QALYs = LE * WF). RESULTS The study included 158 women, of whom 129 were fully analysed (81.6%). The mean life expectancy was 26.3 ± 11.8 years for the control group and 29.0 ± 11.7 years for the experimental group. The mean baseline ICIQ-UI SF scores were 15.2 ± 1.7 vs 15.1 ± 1.5, and the final ICIQ-UI SF scores were 9.8 ± 4.2 vs 8.3 ± 3.8, in the control vs the experimental group, respectively (p < 0.05). The mean baseline WF was 0.27 ± 0.08 vs 0.28 ± 0.07, and the final WF was 0.53 ± 0.20 vs 0.60 ± 0.18, in the control vs the experimental group, respectively (p < 0.05). Before treatment, the number of QALYs during life expectancy in the control vs the experimental group was 7.53 ± 4.24 vs 8.30 ± 4.01. The number of QALYs during life expectancy in control vs the experimental group increased following treatment: 15.03 ± 7.63 vs 17.90 ± 7.86 (p < 0.05). CONCLUSIONS Combination treatment with duloxetine and iPFMT statistically significantly increased the number of QALYs and reduced the degree of urinary incontinence in women with stress urinary incontinence.",2021,"The number of QALYs during life expectancy in control vs the experimental group increased following treatment: 15.03 ± 7.63 vs 17.90 ± 7.86 (p < 0.05). ","['158 women, of whom 129 were fully analysed (81.6', 'women with stress urinary incontinence treated by', 'women with stress urinary incontinence (SUI) treated by', 'study conducted between February 2019 and 2020', 'women with stress urinary incontinence']","['oral duloxetine treatment', 'duloxetine and iPFMT', 'duloxetine', 'innovative pelvic floor muscle training (iPFMT', 'iPFMT with lumbopelvic stabilization', 'innovative pelvic floor muscle training']","['number of QALYs', 'Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF', 'urinary incontinence', 'number of QALYs during life expectancy', 'mean life expectancy', 'quality-adjusted life years (QALYs', 'final ICIQ-UI SF scores', 'mean baseline ICIQ-UI SF scores', 'Quality-Adjusted Life Years (QALYs']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0245561', 'cui_str': 'duloxetine'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0023671', 'cui_str': 'Life Expectancy'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",158.0,0.0539587,"The number of QALYs during life expectancy in control vs the experimental group increased following treatment: 15.03 ± 7.63 vs 17.90 ± 7.86 (p < 0.05). ","[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Svihra', 'Affiliation': 'Department of Urology, Jessenius Faculty of Medicine, Martin, Comenius University Bratislava, Slovak Republic. Electronic address: jan.svihra@uniba.sk.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Hagovska', 'Affiliation': 'Department of Physiatry, Balneology, and Medical Rehabilitation, Faculty of Medicine, PJ Safarik University, Kosice, Slovak Republic.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Breza', 'Affiliation': 'National Institute of Pediatric Diseases, Department of Pediatric Urology, Faculty of Medicine, Comenius University Bratislava, Slovak Republic.'}, {'ForeName': 'Jozef', 'Initials': 'J', 'LastName': 'Dubravicky', 'Affiliation': 'Department of Urology, University Hospital Bratislava, Slovak Republic.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Vargovcak', 'Affiliation': 'Outpatient Clinic of Urology, Railway Hospital, Kosice, Slovak Republic.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Svihra', 'Affiliation': 'Department of Urology, Jessenius Faculty of Medicine, Martin, Comenius University Bratislava, University Hospital Martin, Slovak Republic.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Luptak', 'Affiliation': 'Department of Urology, Jessenius Faculty of Medicine, Martin, Comenius University Bratislava, Slovak Republic.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2021.06.025'] 1658,34271337,Exploring the relationship between childhood adversity and adult depression: A risk versus strengths-oriented approach.,"BACKGROUND Previous research suggests a dose-response relationship between adverse childhood experiences (ACEs) and adult depression. Both constructs are also known correlates of child maltreatment risk. OBJECTIVES This study examines the relationship between a cumulative count of ACEs and adult depressive symptoms in a sample of families at risk for child maltreatment. The study also aims to determine if a new childhood caregiving environment (CCE) scale predicts adult depressive symptoms as well as or better than the traditional ACE score in this high-risk population, and whether it holds potential as a service needs assessment tool for the child maltreatment prevention field. PARTICIPANTS AND SETTING Baseline survey data from a randomized control trial testing a child maltreatment prevention program in Milwaukee, Wisconsin were used. The sample (n = 618) included caregivers reported to and investigated by child protective services (CPS) for allegations of abuse or neglect. METHODS Ordinary least squares regression was used to look at the relationship between the number of ACEs, scores on the CCE scale, and adult depressive symptoms. Exploratory factor analysis was used to examine the CCE scale items in comparison to ACEs. RESULTS A high ACE score was associated with more depressive symptomatology (B = 0.82, p < 0.001). Conversely, adults with higher scores on the CCE scale had fewer depressive symptoms (B = -0.30, p < 0.001). There was also preliminary evidence that the CCE scale may tap into similar underlying constructs as ACEs. CONCLUSIONS Given that the CCE measure favors strengths-oriented question items, it may be a promising alternative to the risk-oriented ACE score in assessing parental childhood adversities known to be associated with the maltreatment of one's own children, and as an approach for identifying service needs related to childhood trauma in a maltreatment prevention context.",2021,"A high ACE score was associated with more depressive symptomatology (B = 0.82, p < 0.001).","['sample of families at risk for child maltreatment', 'The sample (n\xa0=\xa0618) included caregivers reported to and investigated by child protective services (CPS) for allegations of abuse or neglect', 'Baseline survey data from a randomized control trial testing a child maltreatment prevention program in Milwaukee, Wisconsin were used']",['new childhood caregiving environment (CCE) scale'],"['cumulative count of ACEs and adult depressive symptoms', 'CCE scale, and adult depressive symptoms', 'depressive symptoms', 'depressive symptomatology', 'CCE scale items']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0008060', 'cui_str': 'Child abuse'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0681158', 'cui_str': 'Child Welfare Agencies'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}, {'cui': 'C0282121', 'cui_str': 'Baseline Survey'}, {'cui': 'C0282440', 'cui_str': 'Randomized Controlled Trials as Topic'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0043193', 'cui_str': 'Wisconsin'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]","[{'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C4296616', 'cui_str': 'Adverse Childhood Experiences'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.164542,"A high ACE score was associated with more depressive symptomatology (B = 0.82, p < 0.001).","[{'ForeName': 'Marissa', 'Initials': 'M', 'LastName': 'Abbott', 'Affiliation': 'Sandra Rosenbaum School of Social Work, University of Wisconsin-Madison, Madison, WI, USA; Institute for Research on Poverty, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: mcabbott@wisc.edu.'}, {'ForeName': 'Kristen S', 'Initials': 'KS', 'LastName': 'Slack', 'Affiliation': 'Sandra Rosenbaum School of Social Work, University of Wisconsin-Madison, Madison, WI, USA; Institute for Research on Poverty, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: ksslack@wisc.edu.'}]",Child abuse & neglect,['10.1016/j.chiabu.2021.105207'] 1659,34284726,Effect of 12-weeks elastic band resistance training on MyomiRs and osteoporosis markers in elderly women with Osteosarcopenic obesity: a randomized controlled trial.,"BACKGROUND Interorgan communication networks established during exercise in several different tissues can be mediated by several exercise-induced factors. Therefore, the present study aimed to investigate the effects of resistance-type training using elastic band-induced changes of myomiRs (i.e., miR-206 and miR-133), vitamin D, CTX-I, ALP, and FRAX® score in elderly women with osteosarcopenic obesity (OSO). METHODS In this randomized controlled trial, 63 women (aged 65-80 years) with Osteosarcopenic Obesity were recruited and assessed, using a dual-energy X-ray absorptiometry instrument. The resistance-type training via elastic bands was further designed three times per week for 12-weeks. The main outcomes were Fracture Risk Assessment Tool score, bone mineral content, bone mineral density, vitamin D, alkaline phosphatase, C-terminal telopeptides of type I collagen, expression of miR-206 and miR-133. RESULTS There was no significant difference between the study groups in terms of the Fracture Risk Assessment Tool score (p = 0.067), vitamin D (p = 0.566), alkaline phosphatase (p = 0.334), C-terminal telopeptides of type I collagen (p = 0.067), microR-133 (p = 0.093) and miR-206 (p = 0.723). CONCLUSION Overall, the results of this study illustrated 12-weeks of elastic band resistance training causes a slight and insignificant improvement in osteoporosis markers in women affected with Osteosarcopenic Obesity. TRIAL REGISTRATION Randomized controlled trial (RCT) (Iranian Registry of Clinical Trials, trial registration number: IRCT20180627040260N1 . Date of registration: 27/11/2018.",2021,"There was no significant difference between the study groups in terms of the Fracture Risk Assessment Tool score (p = 0.067), vitamin D (p = 0.566), alkaline phosphatase (p = 0.334), C-terminal telopeptides of type I collagen (p = 0.067), microR-133 (p = 0.093) and miR-206 (p = 0.723). ","['63 women (aged 65-80\u2009years) with Osteosarcopenic Obesity', 'elderly women with osteosarcopenic obesity (OSO', 'women affected with Osteosarcopenic Obesity', 'elderly women with Osteosarcopenic obesity']","['elastic band resistance training', '12-weeks elastic band resistance training']","['vitamin D', 'myomiRs (i.e., miR-206 and miR-133), vitamin D, CTX-I, ALP, and FRAX® score', 'MyomiRs and osteoporosis markers', 'osteoporosis markers', 'alkaline phosphatase', 'Fracture Risk Assessment Tool score', 'Fracture Risk Assessment Tool score, bone mineral content, bone mineral density, vitamin D, alkaline phosphatase, C-terminal telopeptides of type']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C0001721', 'cui_str': 'Affect'}]","[{'cui': 'C0221839', 'cui_str': 'Orthodontic band, elastic'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C1101610', 'cui_str': 'MicroRNA'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0631180', 'cui_str': 'C-telopeptide'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0005963', 'cui_str': 'Bone Mineral Content'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]",63.0,0.131938,"There was no significant difference between the study groups in terms of the Fracture Risk Assessment Tool score (p = 0.067), vitamin D (p = 0.566), alkaline phosphatase (p = 0.334), C-terminal telopeptides of type I collagen (p = 0.067), microR-133 (p = 0.093) and miR-206 (p = 0.723). ","[{'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Banitalebi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Majid Mardaniyan', 'Initials': 'MM', 'LastName': 'Ghahfarrokhi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Mortaza', 'Initials': 'M', 'LastName': 'Dehghan', 'Affiliation': 'Clinical Research Development Unit, Kashani Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran. dehghan_mortaza@yahoo.com.'}]",BMC geriatrics,['10.1186/s12877-021-02374-9'] 1660,34284154,Two-year evaluation of a multifamily psychoeducational program (PROTEC) in the family burden and prognosis of bipolar patients.,"INTRODUCTION Bipolar disorder causes a significant burden on the lives of patients and their families. The family is one of the targets for therapeutic intervention, related to the prognosis in patients with bipolar disorder. AIM To assess the effectiveness of a multifamily psychoeducational program for people with bipolar disorder, in the family burden: objective and subjective and in the variables related to the course of the patients with bipolar disorder (symptoms, adherence, functionality, hospitalizations), comparing it with a control group (CG). MATERIALS AND METHODS A total of 148 relatives of bipolar patients and 148 bipolar patients were recruited. The sample was randomized (experimental group [EG] and CG) and with single-blind evaluations (baseline, at 5 months and one year). Clinical and sociodemographic variables were collected from families and patients (family burden self-report scale, Strauss-Carpenter Scale, Global Assessment of Functioning, Morisky Green adherence Scale). Both, EG and CG received 8 multifamily sessions, applied exclusively on the relatives of patients with bipolar disorder, but in the EG a psychoeducational treatment was carried out and in the CG only playful and current topics were discussed. Bivariate and logistic regression models were used, among others. RESULTS The caregivers and patients of the EG and CG did not differ in any of the baseline variables (sociodemographic and clinical) (P>.001). In the total sample, the baseline objective burden was light (mean 0.6±0.4) and the subjective ones was medium-moderate (mean 1.1±0.3). During the follow-up, in relation to the variables of the caregivers, there was a greater reduction in the objective burden in the EG compared to the CG (5 months P=.006; one year P=.002). It was found that the objective burden (P=.006) and the subjective burden (P=.003) were significantly reduced over a year in EG but not in the CG. During the follow-up, the patients whose caregivers belonged to the EG showed a greater increase in the frequency of social activity (P=.008), in the work activity (P=.002), and global functioning (P=.002), and reduced their symptoms (P≤.001). Longitudinal analyses, over a year, showed that patients in the EG had a greater improvement in functionality compared to patients in the CG (P=.001). After the intervention, adherence to pharmacological treatment improved more in EG than in the CG (P≤.001). Regarding hospitalizations, any patients in the CG were hospitalized during the 5 months after the intervention, while 27.8% of the patients in the CG were hospitalized (P≤.001); the difference between groups remained significant in the long term (one year: P≤.001; 2 years: P≤.001). There were no significant differences between groups in the pharmacological treatment of the patients in any of the evaluations. CONCLUSIONS The multifamily psychoeducational intervention group improved the family burden after the intervention. Likewise, bipolar patients, whose families attended the EG, improved significantly, over a year, the functionality, the frequency of social contacts, the work status, the adherence to treatment, and reduced their symptoms. In addition, in the EG, the percentage of hospitalizations during the 2 years of follow-up was significantly reduced.",2021,It was found that the objective burden (p: 0.006) and the subjective burden (p: 0.003) were significantly reduced over a year in E.G but not in the C.G.,"['people with bipolar disorder', 'families and patients (ECF', 'patients with bipolar disorder (symptoms, adherence, functionality, hospitalizations', 'patients with bipolar disorder', '148 relatives of bipolar patients and 148 bipolar patients were recruited']","['multifamily psychoeducational program', 'multifamily psychoeducational intervention']","['work activity', 'frequency of social activity', 'percentage of hospitalizations', 'global functioning', 'functionality', 'Family burden self-report scale, Strauss Carpenter Scale, GAF; global assessment of functioning, Morisky Green adherence Scale', 'objective burden', 'adherence to pharmacological treatment improved more in E. G', 'subjective burden']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0336362', 'cui_str': 'Carpenter, general'}, {'cui': 'C1565805', 'cui_str': 'FGF9 protein, human'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}]",148.0,0.0207794,It was found that the objective burden (p: 0.006) and the subjective burden (p: 0.003) were significantly reduced over a year in E.G but not in the C.G.,"[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Barbeito', 'Affiliation': 'Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja (UNIR), Logroño, La Rioja, España; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) G10, Vitoria-Gasteiz, Álava, España. Electronic address: sara.barbeito@unir.net.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Vega', 'Affiliation': 'Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) G10, Vitoria-Gasteiz, Álava, España; Universidad del País Vasco, Leioa, Bizkaia, España; Instituto de Investigación Sanitaria Bioaraba, Vitoria-Gasteiz, Álava, España.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Ruiz de Azúa', 'Affiliation': 'Universidad del País Vasco, Leioa, Bizkaia, España.'}, {'ForeName': 'Itxaso', 'Initials': 'I', 'LastName': 'González-Ortega', 'Affiliation': 'Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) G10, Vitoria-Gasteiz, Álava, España; Instituto de Investigación Sanitaria Bioaraba, Vitoria-Gasteiz, Álava, España.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Alberich', 'Affiliation': 'Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) G10, Vitoria-Gasteiz, Álava, España; Instituto de Investigación Sanitaria Bioaraba, Vitoria-Gasteiz, Álava, España.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'González-Pinto', 'Affiliation': 'Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) G10, Vitoria-Gasteiz, Álava, España; Universidad del País Vasco, Leioa, Bizkaia, España; Instituto de Investigación Sanitaria Bioaraba, Vitoria-Gasteiz, Álava, España.'}]",Revista de psiquiatria y salud mental,['10.1016/j.rpsm.2021.07.002'] 1661,34284152,Efficacy of the Unified Protocol for the treatment of comorbid alcohol use and anxiety disorders: Study protocol and methods.,"Alcohol Use Disorder (AUD) and anxiety disorders (ANX) are each highly prevalent and frequently co-occur, resulting in a complex clinical presentation. The existing literature to date has not yet identified how to best treat comorbid AUD/ANX, partially due to limitations in understanding what factors and mechanisms are implicated in their co-occurrence. This manuscript describes the rationale and methods for an ongoing randomized-controlled trial designed to evaluate the efficacy of a cognitive behavioral intervention, the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP), compared to Take Control (TC), a psychosocial and motivational treatment serving as a control condition in this study, for comorbid AUD/ANX. Sixty individuals with comorbid AUD/ANX will be randomized to UP or TC, and complete assessments at pre- and post-treatment, as well as one- and six-month follow-up points. We hypothesize that the UP, compared to TC, will result in significantly greater reductions in drinking-related outcomes, as well as anxiety and depressive-related outcomes. Additionally, the current study is designed to evaluate exploratory aims to contribute to our theoretical understanding of why AUD and ANX frequently co-occur. Specifically, we will examine the relationship between changes in AUD and ANX symptoms in relation to changes in emotional disorder mechanisms, such as emotion regulation. Because the UP is a transdiagnostic treatment that specifically targets underlying components of emotional disorders generally, it may be well suited to effectively target comorbid AUD/ANX.",2021,"We hypothesize that the UP, compared to TC, will result in significantly greater reductions in drinking-related outcomes, as well as anxiety and depressive-related outcomes.","['comorbid alcohol use and anxiety disorders', 'Sixty individuals with comorbid AUD/ANX']",['cognitive behavioral intervention'],[],"[{'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}]","[{'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]",[],60.0,0.0630407,"We hypothesize that the UP, compared to TC, will result in significantly greater reductions in drinking-related outcomes, as well as anxiety and depressive-related outcomes.","[{'ForeName': 'Todd J', 'Initials': 'TJ', 'LastName': 'Farchione', 'Affiliation': 'The Center for Anxiety and Related Disorders, Boston University, 900 Commonwealth Avenue, 2nd Floor, Boston, MA 02215, United States of America. Electronic address: tfarchio@bu.edu.'}, {'ForeName': 'Hayley E', 'Initials': 'HE', 'LastName': 'Fitzgerald', 'Affiliation': 'The Center for Anxiety and Related Disorders, Boston University, 900 Commonwealth Avenue, 2nd Floor, Boston, MA 02215, United States of America.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Curreri', 'Affiliation': 'The Center for Anxiety and Related Disorders, Boston University, 900 Commonwealth Avenue, 2nd Floor, Boston, MA 02215, United States of America.'}, {'ForeName': 'Amy C', 'Initials': 'AC', 'LastName': 'Janes', 'Affiliation': 'McLean Imaging Center, McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States of America; Department of Psychiatry, Harvard Medical School, Boston, MA 02215, United States of America.'}, {'ForeName': 'Matthew W', 'Initials': 'MW', 'LastName': 'Gallagher', 'Affiliation': 'Department of Psychology, Texas Institute for MeasurementEvaluation, and Statistics, University of Houston, 4849 Calhoun Rd, Rm 483, Houston, TX, 77004, United States of America.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Sbi', 'Affiliation': 'The Center for Anxiety and Related Disorders, Boston University, 900 Commonwealth Avenue, 2nd Floor, Boston, MA 02215, United States of America.'}, {'ForeName': 'Elizabeth H', 'Initials': 'EH', 'LastName': 'Eustis', 'Affiliation': 'The Center for Anxiety and Related Disorders, Boston University, 900 Commonwealth Avenue, 2nd Floor, Boston, MA 02215, United States of America.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Barlow', 'Affiliation': 'The Center for Anxiety and Related Disorders, Boston University, 900 Commonwealth Avenue, 2nd Floor, Boston, MA 02215, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106512'] 1662,34284099,CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.,"BACKGROUND Guidelines regarding whether tamoxifen should be prescribed based on women's cytochrome P450 2D6 (CYP2D6) genotypes are conflicting and have caused confusion. This study aims to investigate if CYP2D6 metabolizer status is associated with tamoxifen-related endocrine symptoms, tamoxifen discontinuation, and mammographic density change. PATIENTS AND METHODS We used data from 1440 healthy women who participated the KARISMA dose determination trial. Endocrine symptoms were measured using a modified Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) questionnaire. Change in mammographic density was measured and used as a proxy for tamoxifen response. Participants were genotyped and categorized as poor, intermediate, normal, or ultrarapid CYP2D6 metabolizers. RESULTS The median endoxifen level per mg oral tamoxifen among poor, intermediate, normal and ultrarapid CYP2D6 metabolizers were 0.18 ng/ml, 0.38 ng/ml, 0.56 ng/ml and 0.67 ng/ml, respectively. Ultrarapid CYP2D6 metabolizers were more likely than other groups to report a clinically relevant change in cold sweats, hot flash, mood swings, being irritable, as well as the overall modified FACT-ES score, after taking tamoxifen. The 6-month tamoxifen discontinuation rates among poor, intermediate, normal, and ultrarapid CYP2D6 metabolizers were 25.7%, 23.6%, 28.6%, and 44.4%, respectively. Among those who continued and finished the 6-month tamoxifen intervention, the mean change in dense area among poor, intermediate, normal, and ultrarapid CYP2D6 metabolizers were -0.8 cm 2 , -4.5 cm 2 , -4.1 cm 2 , and -8.0 cm 2 respectively. CONCLUSIONS Poor CYP2D6 metabolizers are likely to experience an impaired response to tamoxifen, measured through mammographic density reduction. In contrast, ultrarapid CYP2D6 metabolizers are at risk for exaggerated response with pronounced adverse effects that may lead to treatment discontinuation.",2021,"Ultrarapid CYP2D6 metabolizers were more likely than other groups to report a clinically relevant change in cold sweats, hot flash, mood swings, being irritable, as well as the overall modified FACT-ES score, after taking tamoxifen.","['1,440 healthy women who participated the KARISMA dose determination trial']",['tamoxifen'],"['median endoxifen level', 'modified Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) questionnaire', 'CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Drug Response', 'mammographic density', 'Endocrine symptom']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0039286', 'cui_str': 'Tamoxifen'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0048311', 'cui_str': '4-hydroxy-N-desmethyltamoxifen'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0057223', 'cui_str': 'Cytochrome p450 CYP2D6 enzyme'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1268717', 'cui_str': 'Mammographic breast density'}]",1440.0,0.0743215,"Ultrarapid CYP2D6 metabolizers were more likely than other groups to report a clinically relevant change in cold sweats, hot flash, mood swings, being irritable, as well as the overall modified FACT-ES score, after taking tamoxifen.","[{'ForeName': 'W', 'Initials': 'W', 'LastName': 'He', 'Affiliation': ""Chronic Disease Research Institute, The Children's Hospital, and National Clinical Research Center for Child Health, School of Public Health, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; Department of Nutrition and Food Hygiene, School of Public Health, Zhejiang University, Hangzhou, Zhejiang, China; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Eriksson', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Eliasson', 'Affiliation': 'Department of Laboratory Medicine, Clinical Pharmacology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Grassmann', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bäcklund', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gabrielson', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hammarström', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Margolin', 'Affiliation': 'Department of Oncology, South General Hospital, Stockholm, Sweden; Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Thorén', 'Affiliation': 'Department of Oncology, South General Hospital, Stockholm, Sweden; Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Wengström', 'Affiliation': 'Department of Neurobiology, Care Science and Society, Division of Nursing and Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Borgquist', 'Affiliation': 'Department of Oncology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; Department of Clinical Sciences Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Hall', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Oncology, South General Hospital, Stockholm, Sweden. Electronic address: per.hall@ki.se.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Czene', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.07.005'] 1663,34284065,Food-related inhibitory control training reduces food liking but not snacking frequency or weight in a large healthy adult sample.,"Inhibitory control training has recently been used as an intervention to aid healthy eating and encourage weight loss. The aim of this pre-registered study was to explore the effects of training on food liking, food consumption and weight loss in a large (n = 366), predominantly healthy-weight sample. Participants received four training sessions within a week, in which they had to inhibit their responses to either energy-dense foods (active group) or non-food images (control group). Subjective food ratings, food consumption frequency and weight were measured pre- and post-training. At two-weeks post-training, the active group reported a greater reduction in liking for energy-dense foods, compared to the control group. Active participants also reported a significantly greater increase in healthy food liking, immediately post-training, relative to the control group. There was no statistically significant difference between groups for the change in consumption of trained foods or for weight loss. These findings are partially consistent with previous research conducted in smaller, more overweight samples. Exploratory analyses suggest that some effects of training may be driven by awareness effects. Methodological differences across findings and avenues for future investigation are discussed.",2021,"At two-weeks post-training, the active group reported a greater reduction in liking for energy-dense foods, compared to the control group.","['a large (n\u202f=\u202f366), predominantly healthy sample']","['Inhibitory control training', 'energy-dense foods (active group) or non-food images (control group', 'Food-related inhibitory control training']","['healthy food liking', 'Subjective food ratings, food consumption frequency and weight', 'liking for energy-dense foods', 'food liking, food consumption and weight loss', 'change in consumption of trained foods or for weight loss']","[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0453831', 'cui_str': 'High energy food'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}]","[{'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0453831', 'cui_str': 'High energy food'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}]",,0.00658027,"At two-weeks post-training, the active group reported a greater reduction in liking for energy-dense foods, compared to the control group.","[{'ForeName': 'Rachel C', 'Initials': 'RC', 'LastName': 'Adams', 'Affiliation': 'CUBRIC, School of Psychology, Cardiff University, Maindy Road, Cardiff, CF24 4HQ, UK; School of Psychology, Cardiff University, 70 Park Place, Cardiff, CF10 3AT, UK.'}, {'ForeName': 'Kate S', 'Initials': 'KS', 'LastName': 'Button', 'Affiliation': 'Department of Psychology, University of Bath, Claverton Down, Bath, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Hickey', 'Affiliation': 'School of Psychology, Cardiff University, 70 Park Place, Cardiff, CF10 3AT, UK.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Morrison', 'Affiliation': 'School of Psychology, Cardiff University, 70 Park Place, Cardiff, CF10 3AT, UK.'}, {'ForeName': 'Audra', 'Initials': 'A', 'LastName': 'Smith', 'Affiliation': 'School of Psychology, Cardiff University, 70 Park Place, Cardiff, CF10 3AT, UK.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Bolus', 'Affiliation': 'School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, EX4 4QG, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Coombs', 'Affiliation': 'School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, EX4 4QG, UK.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Randolph', 'Affiliation': 'School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, EX4 4QG, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Hunt', 'Affiliation': 'Department of Psychology, University of Bath, Claverton Down, Bath, UK.'}, {'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Kim', 'Affiliation': 'Department of Psychology, University of Bath, Claverton Down, Bath, UK.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Chambers', 'Affiliation': 'CUBRIC, School of Psychology, Cardiff University, Maindy Road, Cardiff, CF24 4HQ, UK; School of Psychology, Cardiff University, 70 Park Place, Cardiff, CF10 3AT, UK.'}, {'ForeName': 'Natalia S', 'Initials': 'NS', 'LastName': 'Lawrence', 'Affiliation': 'School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, EX4 4QG, UK. Electronic address: Natalia.Lawrence@exeter.ac.uk.'}]",Appetite,['10.1016/j.appet.2021.105601'] 1664,34287530,ASSESSMENT OF RECURRENT ANAL FISTULAS TREATMENT WITH PLATELET-RICH PLASMA.,"BACKGROUND Surgical treatment of recurrent anal fistulas can lead to numerous complications, including fecal incontinence. Therefore, sphincter preserving techniques are gaining more popularity. OBJECTIVE The aim of the study was to assess effectiveness of platelet-rich plasma (PRP) therapy in the patients with recurrent cryptoglandular anal fistulas. METHODS A cohort of 18 patients with anal fistulas was enrolled into a preliminary and prospective trial. They were divided into two groups consisting of eight and ten patients respectively. PRP was injected locally in all patients, however in the group II it was applied after 7 days drainage of fistulas with polyurethane foam or negative pressure wound therapy. On average, three doses of PRP were administered, but with the opportunity to double the number of applications if it was clinically justified. The patients were evaluated in an out-patient department after fortnight and then in 1, 6, and 12 months following the last PRP application. RESULTS Anal fistulas were closed in 4 (50%) patients from the group I and in 7 (70%) patients form the group II. Although, the difference between both groups was not statistically significant, PRP therapy should be preceded with fistulous tract drainage in all patients. Summarizing, that successful result was achieved in 11 (60%) patients from the entire group of 18 participants. CONCLUSION The rate of recurrent cryptoglandular anal fistulas closure reaching 60%, after topical treatment with PRP, exceeds the results of other sphincter-saving methods of treatment. Therefore, it might become a novel method of anal fistulas therapy.",2021,"The rate of recurrent cryptoglandular anal fistulas closure reaching 60%, after topical treatment with PRP, exceeds the results of other sphincter-saving methods of treatment.","['patients with recurrent cryptoglandular anal fistulas', '18 patients with anal fistulas']","['platelet-rich plasma (PRP) therapy', 'polyurethane foam or negative pressure wound therapy', 'PRP']","['Anal fistulas', 'rate of recurrent cryptoglandular anal fistulas closure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0149889', 'cui_str': 'Anorectal fistula'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0071696', 'cui_str': 'polyurethane foam'}, {'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}]","[{'cui': 'C0149889', 'cui_str': 'Anorectal fistula'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}]",18.0,0.0135839,"The rate of recurrent cryptoglandular anal fistulas closure reaching 60%, after topical treatment with PRP, exceeds the results of other sphincter-saving methods of treatment.","[{'ForeName': 'Jarosław', 'Initials': 'J', 'LastName': 'Cwaliński', 'Affiliation': 'Poznan University of Medical Sciences, Department of General, Endocrinological Surgery and Gastroenterological Oncology, Poznań, Poland.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Hermann', 'Affiliation': 'Poznan University of Medical Sciences, Department of General, Endocrinological Surgery and Gastroenterological Oncology, Poznań, Poland.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Paszkowski', 'Affiliation': 'Poznan University of Medical Sciences, Department of General, Endocrinological Surgery and Gastroenterological Oncology, Poznań, Poland.'}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Banasiewicz', 'Affiliation': 'Poznan University of Medical Sciences, Department of General, Endocrinological Surgery and Gastroenterological Oncology, Poznań, Poland.'}]",Arquivos de gastroenterologia,['10.1590/S0004-2803.202100000-32'] 1665,34289831,Effect of maternal education and encouragement on newborn care utilization: a health system intervention.,"BACKGROUND The objective of this health system interventional study was to determine the effect of delivering newborn-care-oriented education and encouragement on newborn care utilization. METHODS This study was performed in the urban health centers of the catchment area of Tehran Defined Population, which covered 10 of the 22 municipality districts of Tehran. The two catchment areas included 10,000 families in the intervention and 20,000 families in the control areas. As many as 4837 newborns (intervention = 1544, control = 3293) were enrolled and followed until the end of the second month of life. The utilization of the three newborn care visits, as recommended by national guidelines, was compared among the intervention and control groups. RESULTS As many as 877 (56.8%) newborns in the intervention group and 1214 (36.9%) in the control group received all their three newborn care visits. The mean number of newborn care visits was higher in the intervention group compared to the control group: 2.26 (0.99) versus 1.84 (1.07), p < 0.001. The number of newborns who did not attend any of their three newborn care visits was 143 (9.3%) in the intervention group and 468 (14.2%) in the control group. CONCLUSIONS The intervention improved newborn care utilization during the first 2 months after birth. It could be suggested that active follow-up be added to newborn care guidelines. Parents need to be informed of the necessity and benefits of newborn care and be encouraged to perform all three newborn care visits.",2021,"The utilization of the three newborn care visits, as recommended by national guidelines, was compared among the intervention and control groups. ","['4837 newborns (intervention\u2009=\u20091544, control\u2009=\u20093293', 'urban health centers of the catchment area of Tehran Defined Population, which covered 10 of the 22 municipality districts of Tehran', 'two catchment areas included 10,000 families in the intervention and 20,000 families in the control areas']","['newborn-care-oriented education and encouragement', 'maternal education and encouragement']","['newborn care utilization', 'mean number of newborn care visits', 'newborn care visits']","[{'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0041933', 'cui_str': 'Urban Health'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0007403', 'cui_str': 'Health Catchment Area'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0204792', 'cui_str': 'Routine care of newborn'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C0204792', 'cui_str': 'Routine care of newborn'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",3.0,0.010907,"The utilization of the three newborn care visits, as recommended by national guidelines, was compared among the intervention and control groups. ","[{'ForeName': 'Ali-Asghar', 'Initials': 'AA', 'LastName': 'Kolahi', 'Affiliation': 'Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Koodakyar Ave., Daneshju Blvd., Velenjak, Tehran, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Abbasi-Kangevari', 'Affiliation': 'Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Koodakyar Ave., Daneshju Blvd., Velenjak, Tehran, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Abadi', 'Affiliation': 'Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Koodakyar Ave., Daneshju Blvd., Velenjak, Tehran, Iran. a.abadi@sbmu.ac.ir.'}]",BMC pediatrics,['10.1186/s12887-021-02773-2'] 1666,34289820,"Growth and tolerance of healthy, term infants fed lower protein extensively hydrolyzed or amino acid-based formula: double-blind, randomized, controlled trial.","BACKGROUND Optimal protein level in hypoallergenic infant formulas is an area of ongoing investigation. The aim was to evaluate growth of healthy term infants who received extensively hydrolyzed (EH) or amino acid (AA)-based formulas with reduced protein. METHODS In this prospective, multi-center, double-blind, controlled, parallel group study, infants were randomized to receive a marketed EH casein infant formula at 2.8 g protein/100 kcal (Control) or one of two investigational formulas: EH casein formula at 2.4 g protein/100 kcal (EHF) or AA-based formula at 2.4 g total protein equivalents/100 kcal (AAF). Control and EHF each had 2 × 10 7  CFU Lactobacillus rhamnosus GG/100 kcal. Anthropometrics were measured and recall of formula intake, tolerance, and stool characteristics was collected at 14, 30, 60, 90, 120 days of age. Primary outcome was weight growth rate (g/day) between 14 and 120 days of age (analyzed by ANOVA). Medically confirmed adverse events were recorded throughout the study. RESULTS No group differences in weight or length growth rate from 14 to 120 days were detected. With the exception of significant differences at several study time points for males, no group differences were detected in mean head circumference growth rates. However, mean achieved weight, length, and head circumference demonstrated normal growth throughout the study period. No group differences in achieved weight or length (males and females) and head circumference (females) were detected and means were within the WHO growth 25th and 75th percentiles from 14 to 120 days of age. With the exception of Day 90, there were no statistically significant group differences in achieved head circumference for males; means remained between the WHO 50th and 75th percentiles for growth at Days 14, 30, and 60 and continued along the 75th percentile through Day 120. No differences in study discontinuation due to formula were detected. The number of participants for whom at least one adverse event was reported was similar among groups. CONCLUSIONS This study demonstrated hypoallergenic infant formulas at 2.4 g protein/100 kcal were safe, well-tolerated, and associated with appropriate growth in healthy term infants from 14 to 120 days of age. TRIAL REGISTRATION ClinicalTrials.gov, ClinicalTrials.gov Identifier: NCT01354366 . Registered 13 May 2011.",2021,"With the exception of significant differences at several study time points for males, no group differences were detected in mean head circumference growth rates.","['healthy term infants from 14 to 120\u2009days of age', 'healthy term infants who received']","['extensively hydrolyzed (EH) or amino acid (AA)-based formulas with reduced protein', 'marketed EH casein infant formula at 2.8\u2009g protein/100\u2009kcal (Control) or one of two investigational formulas: EH casein formula at 2.4\u2009g protein/100\u2009kcal (EHF) or AA-based formula at 2.4\u2009g total protein equivalents/100\u2009kcal (AAF']","['mean achieved weight, length, and head circumference demonstrated normal growth', 'head circumference', 'adverse events', 'mean head circumference growth rates', 'recall of formula intake, tolerance, and stool characteristics', 'weight growth rate', 'weight or length (males and females) and head circumference (females', 'adverse event', 'weight or length growth rate']","[{'cui': 'C0456128', 'cui_str': 'Term infant'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1318228', 'cui_str': 'Market'}, {'cui': 'C0007332', 'cui_str': 'Caseins'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C4517631', 'cui_str': '2.4'}, {'cui': 'C0555903', 'cui_str': 'Total protein measurement'}, {'cui': 'C0001034', 'cui_str': 'Acetylaminofluorene'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0262499', 'cui_str': 'Head circumference'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449249', 'cui_str': 'Growth rate'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0424639', 'cui_str': 'Height / growth measure'}]",,0.217602,"With the exception of significant differences at several study time points for males, no group differences were detected in mean head circumference growth rates.","[{'ForeName': 'Craig B', 'Initials': 'CB', 'LastName': 'Adams', 'Affiliation': 'Southeastern Pediatric Associates, 364 Honeysuckle Road, Dothan, AL, 36305, USA.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Johnston', 'Affiliation': ""Birmingham Pediatric Associates, 806 St Vincent's Drive, Suite 615, Birmingham, AL, 35205, USA.""}, {'ForeName': 'Harold', 'Initials': 'H', 'LastName': 'Deulofeut', 'Affiliation': ""Children's Medical Association, 8430 W Broward Blvd, Plantation, FL, 33324, USA.""}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Leader', 'Affiliation': 'Woburn Pediatric Associates Research Dept, 7 Alfred Street, Suite 220, Woburn, MA, 01801, USA.'}, {'ForeName': 'Robbie', 'Initials': 'R', 'LastName': 'Rhodes', 'Affiliation': 'Central Arkansas Pediatric Clinic, 2301 Springhill Road, Suite 200, Benton, AR, 72019, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Yeiser', 'Affiliation': 'Owensboro Pediatrics, 2200 East Parrish Ave, Owensboro, KY, 42303, USA.'}, {'ForeName': 'Cheryl L', 'Initials': 'CL', 'LastName': 'Harris', 'Affiliation': 'Medical Affairs and Scientific Affairs, Reckitt/Mead Johnson Nutrition Institute, Evansville, IN, 47721, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Wampler', 'Affiliation': 'Medical Affairs and Scientific Affairs, Reckitt/Mead Johnson Nutrition Institute, Evansville, IN, 47721, USA. jennifer.wampler@rb.com.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Hill', 'Affiliation': 'Medical Affairs and Scientific Affairs, Reckitt/Mead Johnson Nutrition Institute, Evansville, IN, 47721, USA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Cooper', 'Affiliation': 'Medical Affairs and Scientific Affairs, Reckitt/Mead Johnson Nutrition Institute, Evansville, IN, 47721, USA.'}]",BMC pediatrics,['10.1186/s12887-021-02617-z'] 1667,34261541,Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.,"BACKGROUND The interleukin-23p19-subunit inhibitor guselkumab effectively treats signs and symptoms of psoriatic arthritis (PsA). We evaluated the effect of guselkumab on fatigue. METHODS Across two phase 3 trials of guselkumab (DISCOVER-1, DISCOVER-2), patients with active PsA despite standard therapy were randomized to subcutaneous injections of guselkumab 100 mg every 4 weeks (Q4W, N = 373); guselkumab 100 mg at week 0, week 4, and then Q8W (N = 375); or placebo (N = 372) through week 24, after which patients in the placebo group crossed over to guselkumab Q4W. Fatigue was measured as a secondary endpoint using the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue instrument (range 0-52, higher scores indicate less fatigue). Least-squares mean changes in FACIT-Fatigue scores were compared between treatments using a mixed-effect model for repeated measures. Mediation analysis was used to adjust for indirect effects on fatigue deriving from improvement in other outcomes, including ≥20% improvement in American College of Rheumatology criteria (ACR20; prespecified), minimal disease activity (MDA; post hoc), or C-reactive protein (CRP; post hoc). RESULTS Baseline mean (SD) FACIT-Fatigue scores in DISCOVER-1 (N = 381) and DISCOVER-2 (N = 739), ranging from 29.1 (9.5) to 31.4 (10.1), indicated substantial levels of fatigue relative to the United States general population (43.6 [9.4]). Across studies, mean improvements, and proportions of patients with ≥4-point improvements, in FACIT-Fatigue scores at week 24 with guselkumab Q4W and Q8W (5.6-7.6 and 54-63%, respectively) were larger vs placebo (2.2-3.6 and 35-46%). Improvement in FACIT-Fatigue scores with guselkumab was sustained from week 24 to week 52, with moderate-to-large effect sizes (Cohen's d = 0.52-0.81 at week 24; 0.66-0.91 at week 52). Mediation analyses demonstrated that substantial proportions of the effects of guselkumab vs placebo on fatigue were direct effect, after adjusting for achievement of ACR20 (Q4W 69-70%, Q8W 12-36% direct effect) or MDA (72-92% across dosing regimens) response or for change in serum CRP concentrations (82-88% across dosing regimens). CONCLUSIONS In patients with active PsA, guselkumab 100 mg Q4W or Q8W led to clinically meaningful and sustained improvements in fatigue through 1 year. A substantial portion of the improvement in FACIT-Fatigue scores induced by guselkumab was independent of effects on the achievement of other select outcomes. TRIAL REGISTRATION Name of the registry: ClinicalTrials.gov Trial registrations: DISCOVER-1, NCT03162796; DISCOVER-2, NCT03158285 Date of registration: DISCOVER-1, May 22, 2017; DISCOVER-2, May 18, 2017 URLs of the trial registry record: DISCOVER-1, https://clinicaltrials.gov/ct2/show/NCT03162796?term=NCT03162796&draw=1&rank=1 DISCOVER-2, https://clinicaltrials.gov/ct2/show/NCT03158285?term=NCT03158285&draw=2&rank=1.",2021,"Improvement in FACIT-Fatigue scores with guselkumab was sustained from week 24 to week 52, with moderate-to-large effect sizes (Cohen's d = 0.52-0.81 at week 24; 0.66-0.91 at week 52).","['1120 patients with active psoriatic arthritis', 'patients with active PsA despite standard therapy']","['placebo', 'guselkumab vs placebo', 'guselkumab']","['serum CRP concentrations', 'Baseline mean (SD) FACIT-Fatigue scores', 'MDA', 'fatigue', 'FACIT-Fatigue scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0003872', 'cui_str': 'Psoriatic arthritis'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3852217', 'cui_str': 'guselkumab'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",372.0,0.253592,"Improvement in FACIT-Fatigue scores with guselkumab was sustained from week 24 to week 52, with moderate-to-large effect sizes (Cohen's d = 0.52-0.81 at week 24; 0.66-0.91 at week 52).","[{'ForeName': 'Proton', 'Initials': 'P', 'LastName': 'Rahman', 'Affiliation': 'Memorial University of Newfoundland, St. Johns, Newfoundland, Canada.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Mease', 'Affiliation': 'Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, USA.'}, {'ForeName': 'Philip S', 'Initials': 'PS', 'LastName': 'Helliwell', 'Affiliation': 'University of Leeds, Leeds, UK.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Deodhar', 'Affiliation': 'Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'Laure', 'Initials': 'L', 'LastName': 'Gossec', 'Affiliation': ""Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.""}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Kavanaugh', 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Alexa P', 'Initials': 'AP', 'LastName': 'Kollmeier', 'Affiliation': 'Janssen Research & Development, LLC, San Diego, CA, USA.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Hsia', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, 19436, USA.'}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Zhou', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, 19436, USA.'}, {'ForeName': 'Xiwu', 'Initials': 'X', 'LastName': 'Lin', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, 19436, USA.'}, {'ForeName': 'May', 'Initials': 'M', 'LastName': 'Shawi', 'Affiliation': 'Janssen Global Services, LLC, Horsham, PA, USA.'}, {'ForeName': 'Chetan S', 'Initials': 'CS', 'LastName': 'Karyekar', 'Affiliation': 'Janssen Global Services, LLC, Horsham, PA, USA.'}, {'ForeName': 'Chenglong', 'Initials': 'C', 'LastName': 'Han', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, 19436, USA. CHan3@its.jnj.com.'}]",Arthritis research & therapy,['10.1186/s13075-021-02554-3'] 1668,34260183,Editorial Comment: Optimal timing of a second postoperative voiding trial in women with incomplete bladder emptying after vaginal reconstructive surgery: a randomized trial.,,2021,,['women with incomplete bladder emptying after vaginal reconstructive surgery'],[],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0344365', 'cui_str': 'Incomplete emptying of bladder'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0524865', 'cui_str': 'Reconstruction - action'}]",[],[],,0.141182,,"[{'ForeName': 'Cássio L Z', 'Initials': 'CLZ', 'LastName': 'Riccetto', 'Affiliation': 'Divisão de Urologia Feminina, Faculdade de Ciências Médicas da Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil.'}]",International braz j urol : official journal of the Brazilian Society of Urology,['10.1590/S1677-5538.IBJU.2021.05.04'] 1669,34260182,Editorial Comment: Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals.,,2021,,"['26 Hospitals', 'Men Considering Prostate Surgery']",[],[],"[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0194790', 'cui_str': 'Operation on prostate'}]",[],[],,0.412625,,"[{'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Moreno-Palacios', 'Affiliation': 'Servicio Urología. UMAE Hospital de Especialidades CMN, Siglo XXI, IMSS, Ciudad de México.'}]",International braz j urol : official journal of the Brazilian Society of Urology,['10.1590/S1677-5538.IBJU.2021.05.03'] 1670,34260175,Efficacy of tamsulosin versus tadalafil as medical expulsive therapy on stone expulsion in patients with distal ureteral stones: A randomized double-blind clinical trial.,"PURPOSE To compare the effects of tadalafil, tamsulosin, and placebo as a medical expulsive therapy (MET) for distal ureteral calculi. MATERIALS AND METHODS This prospective randomized double-blind clinical trial was conducted on 132 renal colic patients with distal ureteric stones (≤10mm) over a period of 12 months. Patients were randomly divided into three groups. Patients in group A received tamsulosin 0.4mg, in group B received tadalafil 10mg, and in group C received placebo. Therapy was given for a maximum of 4 weeks. The rate of stone expulsion, duration of stone expulsion, the dose and the duration of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesic use, and adverse effects of drugs were recorded. RESULTS Demographic profiles were comparable between the 3 groups. Although the stone expulsion rate in group A (72.7%) was higher in comparison to group B(63.6%) and group C(56.8%), it was not considered statistically significant (P=0.294). Shorter mean time to stone expulsion was significantly observed in group A (17.75±75), than group B(21.13±1.17) and group C(22.25±1.18) (P=0.47). The mean number of analgesic use was 9.8±5.09 days in group A, 14.6±7.9 days in group B, and 12.6±22.25 days in group C, this difference was significant (P=0.004). The analgesic requirement (doses of NSAIDs and pethidine) in group A was significantly lower than other groups (P< 0.05). Also, patients in group A reported fewer headaches compared to other groups (P=0.011). CONCLUSION Tamsulosin as medical expulsive therapy is more effective for distal ureteric stones with less need for analgesics and less stone expulsion time than tadalafil.",2021,The analgesic requirement (doses of NSAIDs and pethidine) in group A was significantly lower than other groups (P< 0.05).,"['patients with distal ureteral stones', '132 renal colic patients with distal ureteric stones (≤10mm) over a period of 12 months']","['Tamsulosin', 'tadalafil, tamsulosin, and placebo', 'pethidine', 'placebo', 'tamsulosin', 'tadalafil']","['mean number of analgesic use', 'stone expulsion', 'stone expulsion time', 'rate of stone expulsion, duration of stone expulsion, the dose and the duration of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesic use, and adverse effects of drugs', 'analgesic requirement', 'stone expulsion rate', 'Shorter mean time to stone expulsion', 'headaches']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0041952', 'cui_str': 'Ureteric stone'}, {'cui': 'C0152169', 'cui_str': 'Renal colic'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C1176316', 'cui_str': 'tadalafil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025376', 'cui_str': 'Meperidine'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C1293107', 'cui_str': 'Expulsion'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0018681', 'cui_str': 'Headache'}]",132.0,0.102828,The analgesic requirement (doses of NSAIDs and pethidine) in group A was significantly lower than other groups (P< 0.05).,"[{'ForeName': 'Siavash', 'Initials': 'S', 'LastName': 'Falahatkar', 'Affiliation': 'Urology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.'}, {'ForeName': 'Ardalan', 'Initials': 'A', 'LastName': 'Akhavan', 'Affiliation': 'Urology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.'}, {'ForeName': 'Samaneh', 'Initials': 'S', 'LastName': 'Esmaeili', 'Affiliation': 'Urology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.'}, {'ForeName': 'Atiyeh', 'Initials': 'A', 'LastName': 'Amin', 'Affiliation': 'Urology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.'}, {'ForeName': 'Ehsan', 'Initials': 'E', 'LastName': 'Kazemnezhad', 'Affiliation': 'Urology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Jafari', 'Affiliation': 'Urology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.'}]",International braz j urol : official journal of the Brazilian Society of Urology,['10.1590/S1677-5538.IBJU.2020.1007'] 1671,34265569,The plasma antioxidant vitamin status of the INTAPP cohort examined: The unsuspected importance of β-carotene and γ-tocopherol in preeclampsia.,"OBJECTIVE Examine the levels of plasma antioxidant vitamins before and during a treatment with placebo or vitamin E + C supplement to prevent preeclampsia (PE). STUDY DESIGN Per-protocol analysis of a subset group of pregnant women (n = 295) from the International Trial of Antioxidants for the Prevention of PE (INTAPP) randomized case-control study. Normotensive receiving placebo or vitamins (n = 115 and 87 respectively) were compared to gestational hypertension (GH) without proteinuria (n = 30 and 27) and PE (n = 21 and 15). Vitamin quantification was performed at 12-18, 24-26 and 32-34 weeks of gestation. MAIN OUTCOME MEASURES Coenzyme (Co) Q 10 , β-carotene and vitamins E (α and γ forms) plasma levels. RESULTS Vitamin E + C supplementation was found to increase the α-tocopherol levels by 40% but was associated with a 57% decrease in the γ-tocopherol isoform for all study groups (p < 0.001). The β -carotene was lower in the PE than in the normotensive and GH groups (p < 0.001) while the level of CoQ 10 remained unaffected. CONCLUSIONS A more personalized approach that target the suboptimal levels of specific antioxidants without disturbing the α/γ-tocopherol ratio could be a more successful approach to counteract oxidative stress in PE.",2021,"The β -carotene was lower in the PE than in the normotensive and GH groups (p < 0.001) while the level of CoQ 10 remained unaffected. ","['n\xa0=\xa0115 and 87 respectively) were compared to gestational hypertension (GH) without proteinuria (n\xa0=\xa030 and 27) and PE (n\xa0=\xa021 and 15', 'preeclampsia', 'Per-protocol analysis of a subset group of pregnant women (n\xa0=\xa0295) from the International Trial of Antioxidants for the Prevention of PE (INTAPP) randomized case-control study']","['placebo or vitamins', 'β-carotene and γ-tocopherol', 'Coenzyme', 'placebo or vitamin E\xa0+\xa0C supplement', 'Vitamin E\xa0']","['preeclampsia (PE', 'Co) Q 10 , β-carotene and vitamins E (α and γ forms) plasma levels', 'plasma antioxidant vitamin status', 'Vitamin quantification', 'α-tocopherol levels']","[{'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0341934', 'cui_str': 'Transient hypertension of pregnancy'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0007328', 'cui_str': 'Case Control Studies'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0007269', 'cui_str': 'Carotene'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0009235', 'cui_str': 'Cofactors, Enzyme'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0009235', 'cui_str': 'Cofactors, Enzyme'}, {'cui': 'C0007269', 'cui_str': 'Carotene'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",295.0,0.450126,"The β -carotene was lower in the PE than in the normotensive and GH groups (p < 0.001) while the level of CoQ 10 remained unaffected. ","[{'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Bilodeau', 'Affiliation': 'Department of Medicine, Faculty of Medicine, Laval University, Quebec, Quebec, Canada; Endocrinology and Nephrology Research Axis, CHU of Quebec-Laval University, Quebec, Quebec, Canada. Electronic address: jean-francois.bilodeau@crchudequebec.ulaval.ca.'}, {'ForeName': 'Amélie', 'Initials': 'A', 'LastName': 'Gagné', 'Affiliation': 'Endocrinology and Nephrology Research Axis, CHU of Quebec-Laval University, Quebec, Quebec, Canada.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Greffard', 'Affiliation': 'Endocrinology and Nephrology Research Axis, CHU of Quebec-Laval University, Quebec, Quebec, Canada.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Audibert', 'Affiliation': 'Department of Obstetrics and Gynaecology, CHU of Sainte-Justine Research Center and Montreal University, Montreal, Quebec, Canada.'}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Fraser', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, CHU of Sherbrooke, Sherbrooke, Quebec, Canada.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Julien', 'Affiliation': 'Department of Medicine, Faculty of Medicine, Laval University, Quebec, Quebec, Canada; Endocrinology and Nephrology Research Axis, CHU of Quebec-Laval University, Quebec, Quebec, Canada.'}]",Pregnancy hypertension,['10.1016/j.preghy.2021.06.009'] 1672,34265044,Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial.,"BACKGROUND The role of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) has been addressed in some studies related to the current coronavirus disease-2019 (COVID-19) pandemic with possible higher severity and mortality in patients with hypertension. A triple-blind randomized controlled trial was designed to evaluate the effects of these medications on the COVID-19 progression. METHODS Patients were enrolled in this trial between April and September 2020. They were randomized in two groups. The former dosage of ACEis/ARBs was continued in one group while in another group, the ACEis/ARBs were replaced by amlodipine ± carvedilol according to the dose equivalents. The primary outcomes were length of stay in hospitals and intensive care units. Other outcomes include mechanical ventilation, non-invasive ventilation, readmission, and COVID-19 symptoms after discharge. RESULTS We randomized 64 patients with COVID-19 into two groups. Most patients were aged 66-80 and 46-65 years-old, 33 (51.6%) and 27 (42.2%), respectively. The study groups were nearly similar in baseline vital signs and characteristics. In addition, there was no significant difference in terms of recorded systolic and diastolic blood pressure measurements between groups. Furthermore, we did not find a significant difference between the days of intensive care unit or ward admission, the discharge rate, or readmission rates between the two groups. CONCLUSIONS This randomized triple-blind multi-centric clinical trial did not show any deleterious effects of ACEi/ARB medications in hypertensive COVID-19 patients.",2021,"Furthermore, we did not find a significant difference between the days of intensive care unit or ward admission, the discharge rate, or readmission rates between the two groups. ","['Patients were enrolled in this trial between April and September 2020', '64 patients with COVID-19 into two groups', 'hypertensive COVID-19 patients', 'Most patients were aged 66-80 and 46-65 years-old, 33 (51.6%) and 27 (42.2%), respectively', 'Hypertensive COVID-19 Patients', 'patients with hypertension']","['Renin-Angiotensin-Aldosterone Inhibitors', 'angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs', 'ACEi/ARB medications', 'amlodipine ± carvedilol']","['ACEis/ARBs', 'intensive care unit or ward admission, the discharge rate, or readmission rates', 'recorded systolic and diastolic blood pressure measurements', 'mechanical ventilation, non-invasive ventilation, readmission, and COVID-19 symptoms after discharge', 'length of stay in hospitals and intensive care units']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]","[{'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0003018', 'cui_str': 'Angiotensin'}, {'cui': 'C0002007', 'cui_str': 'Aldosterone receptor antagonist-containing product'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0034787', 'cui_str': 'Angiotensin receptor'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C0054836', 'cui_str': 'carvedilol'}]","[{'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0034787', 'cui_str': 'Angiotensin receptor'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]",64.0,0.183332,"Furthermore, we did not find a significant difference between the days of intensive care unit or ward admission, the discharge rate, or readmission rates between the two groups. ","[{'ForeName': 'Farhad', 'Initials': 'F', 'LastName': 'Najmeddin', 'Affiliation': 'Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Maedeh', 'Initials': 'M', 'LastName': 'Solhjoo', 'Affiliation': 'Pharmacy student, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Haleh', 'Initials': 'H', 'LastName': 'Ashraf', 'Affiliation': 'Department of Cardiology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran, Cardiac Primary Prevention Research Center (CPPRC), Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran, Research Development Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Salehi', 'Affiliation': 'Department of Infectious Disease, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Rasooli', 'Affiliation': 'Department of Emergency Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Morteza', 'Initials': 'M', 'LastName': 'Ghoghaei', 'Affiliation': 'Department of Internal Medicine, Sina Hospital, Tehran, Iran.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Soleimani', 'Affiliation': 'Department of Cardiology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Bahreini', 'Affiliation': 'Department of Emergency Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran Prehospital and Hospital Emergency Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}]",American journal of hypertension,['10.1093/ajh/hpab111'] 1673,34269813,Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial.,"Importance Azithromycin has been hypothesized to have activity against SARS-CoV-2. Objective To determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14. Design, Setting, and Participants Randomized clinical trial of azithromycin vs matching placebo conducted from May 2020 through March 2021. Outpatients from the US were enrolled remotely via internet-based surveys and followed up for 21 days. Eligible participants had a positive SARS-CoV-2 diagnostic test result (nucleic acid amplification or antigen) within 7 days prior to enrollment, were aged 18 years or older, and were not hospitalized at the time of enrollment. Among 604 individuals screened, 297 were ineligible, 44 refused participation, and 263 were enrolled. Participants, investigators, and study staff were masked to treatment randomization. Interventions Participants were randomized in a 2:1 fashion to a single oral 1.2-g dose of azithromycin (n = 171) or matching placebo (n = 92). Main Outcomes and Measures The primary outcome was absence of self-reported COVID-19 symptoms at day 14. There were 23 secondary clinical end points, including all-cause hospitalization at day 21. Results Among 263 participants who were randomized (median age, 43 years; 174 [66%] women; 57% non-Hispanic White and 29% Latinx/Hispanic), 76% completed the trial. The trial was terminated by the data and safety monitoring committee for futility after the interim analysis. At day 14, there was no significant difference in proportion of participants who were symptom free (azithromycin: 50%; placebo: 50%; prevalence difference, 0%; 95% CI, -14% to 15%; P > .99). Of 23 prespecified secondary clinical end points, 18 showed no significant difference. By day 21, 5 participants in the azithromycin group had been hospitalized compared with 0 in the placebo group (prevalence difference, 4%; 95% CI, -1% to 9%; P = .16). Conclusions and Relevance Among outpatients with SARS-CoV-2 infection, treatment with a single dose of azithromycin compared with placebo did not result in greater likelihood of being symptom free at day 14. These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection. Trial Registration ClinicalTrials.gov Identifier: NCT04332107.",2021,"At day 14, there was no significant difference in proportion of participants who were symptom free (azithromycin: 50%; placebo: 50%; prevalence difference, 0%; 95% CI, -14% to 15%; P > .99).","['263 participants who were randomized (median age, 43 years', 'Outpatients With SARS-CoV-2 Infection', 'outpatients with SARS-CoV-2 infection', 'Eligible participants had a positive SARS-CoV-2 diagnostic test result (nucleic acid amplification or antigen) within 7 days prior to enrollment, were aged 18 years or older, and were not hospitalized at the time of enrollment', 'Outpatients from the US were enrolled remotely via internet-based surveys and followed up for 21 days', '604 individuals screened, 297 were ineligible, 44 refused participation, and 263 were enrolled', '174 [66%] women; 57% non-Hispanic White and 29% Latinx/Hispanic), 76% completed the trial', 'outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14']","['Azithromycin', 'azithromycin', 'Oral Azithromycin vs Placebo', 'azithromycin (n\u2009=\u2009171) or matching placebo', 'oral azithromycin', 'placebo', 'azithromycin vs matching placebo']","['COVID-19 Symptoms', 'absence of self-reported COVID-19 symptoms']","[{'cui': 'C4517671', 'cui_str': '263'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}, {'cui': 'C0200932', 'cui_str': 'Nucleic acid amplification'}, {'cui': 'C0003320', 'cui_str': 'Antigen'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0017095', 'cui_str': 'Trash'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]",,0.870995,"At day 14, there was no significant difference in proportion of participants who were symptom free (azithromycin: 50%; placebo: 50%; prevalence difference, 0%; 95% CI, -14% to 15%; P > .99).","[{'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Oldenburg', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Benjamin A', 'Initials': 'BA', 'LastName': 'Pinsky', 'Affiliation': 'Department of Pathology, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Brogdon', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Cindi', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Ruder', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Zhong', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Fanice', 'Initials': 'F', 'LastName': 'Nyatigo', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Cook', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Hinterwirth', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Lebas', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Travis', 'Initials': 'T', 'LastName': 'Redd', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Arnold', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Thuy', 'Initials': 'T', 'LastName': 'Doan', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}]",JAMA,['10.1001/jama.2021.11517'] 1674,34268883,Blood pressure measurement: Should technique define targets?,"Accurate assessment of blood pressure (BP) is the cornerstone of hypertension management. The objectives of this study were to quantify the effect of medical personnel presence during BP measurement by automated oscillometric BP (AOBP) and to compare resting office BP by AOBP to daytime average BP by 24-h ambulatory BP monitoring (ABPM). This study is a prospective randomized cross-over trial, conducted in a referral population. Patients underwent measurements of casual and resting office BP by AOBP. Resting BP was measured as either unattended (patient alone in the room during resting and measurements) or as partially attended (nurse present in the room during measurements) immediately prior to and after 24-h ABPM. The primary outcome was the effect of unattended 5-min rest preceding AOBP assessment as the difference between casual and resting BP measured by the Omron HEM 907XL. Ninety patients consented and 78 completed the study. The mean difference between the casual and Omron unattended systolic BP was 7.0 mm Hg (95% confidence interval [CI] 4.5, 9.5). There was no significant difference between partially attended and unattended resting office systolic BP. Resting office BP (attended and partially attended) underestimated daytime systolic BP load from 24-h ABPM. The presence or absence of medical personnel does not impact casual office BP which is higher than resting office AOBP. The requirement for unattended rest may be dropped if logistically challenging. Casual and resting office BP readings by AOBP do not capture the complexity of information provided by the 24-h ABPM.",2021,There was no significant difference between partially attended and unattended resting office systolic BP.,['Ninety patients consented and 78 completed the study'],['medical personnel presence during BP measurement by automated oscillometric BP (AOBP'],"['systolic BP', 'daytime systolic BP load from 24-h ABPM', 'effect of unattended 5-min rest preceding AOBP assessment as the difference between casual and resting BP', 'Resting BP', 'Blood pressure measurement', 'unattended resting office systolic BP', 'blood pressure (BP']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0026426', 'cui_str': 'Blood pressure monitoring'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}, {'cui': 'C0442603', 'cui_str': 'Office'}]",90.0,0.0741126,There was no significant difference between partially attended and unattended resting office systolic BP.,"[{'ForeName': 'Swapnil', 'Initials': 'S', 'LastName': 'Hiremath', 'Affiliation': 'Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Ramsay', 'Affiliation': 'Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Ruzicka', 'Affiliation': 'Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.'}]","Journal of clinical hypertension (Greenwich, Conn.)",['10.1111/jch.14324'] 1675,34271194,Characterization of MRF genes and their tissue distributions and analysis of the effects of starvation and refeeding on the expression of these genes in Acipenser dabryanus muscle.,"The purpose of the study was to clone the sequences of myogenic regulatory factors in Acipenser dabryanus and explore the changes in their expression during starvation and refeeding in A. dabryanus muscle. One hundred twenty fish (60.532 ± 0.284 g) were randomly assigned to four groups (fasted for 0, 3, 7 or 14 d and then refed for 14 d). Our predictions showed that the coding sequences of myod1, myf5, myog and myf6 in A. dabryanus encoded 275, 248, 248 and 243 amino acids, respectively, and the expression of the four genes was the highest in muscle. During fasting, the expression of myod1 in muscle was significantly decreased in the 14 d group. The expressions of myf5 and myf6 were increased significantly at first and then decreased with prolonged starvation time. The expression of myog in the 14 d group was significantly decreased compared with other groups (P < 0.05). During refeeding, the highest values of myod1 and myf6 expression were found in the 3 d group (P < 0.05).The expressions of myf5 and myog in 0 d and 3 d group were significantly higher than those in 7 d and 14 d group (P < 0.05). These results indicate that myogenic regulatory factors (MRFs) play important roles in muscle growth and development in A. dabryanus. The inhibition of long-term starvation (14 d) on the expression of myogenic regulatory factors is probably one of the reasons why it can not achieve full compensation for growth.",2021,The expression of myog in the 14 d group was significantly decreased compared with other groups (P < 0.05).,['One hundred twenty fish (60.532\u202f±\u202f0.284\u202fg'],[],"['expression of myod1 in muscle', 'prolonged starvation time', 'expression of myog', 'highest values of myod1 and myf6 expression', 'expressions of myf5 and myf6']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0016163', 'cui_str': 'Fish'}]",[],"[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0038187', 'cui_str': 'Starvation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0135432,The expression of myog in the 14 d group was significantly decreased compared with other groups (P < 0.05).,"[{'ForeName': 'Xiao-Yun', 'Initials': 'XY', 'LastName': 'Wu', 'Affiliation': 'Fishery Institute, Sichuan Academy of Agricultural Sciences, Chengdu 611730, China.'}, {'ForeName': 'Jian-Sheng', 'Initials': 'JS', 'LastName': 'Lai', 'Affiliation': 'Fishery Institute, Sichuan Academy of Agricultural Sciences, Chengdu 611730, China.'}, {'ForeName': 'Ye-Yu', 'Initials': 'YY', 'LastName': 'Chen', 'Affiliation': 'Fishery Institute, Sichuan Academy of Agricultural Sciences, Chengdu 611730, China.'}, {'ForeName': 'Ya', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Fishery Institute, Sichuan Academy of Agricultural Sciences, Chengdu 611730, China.'}, {'ForeName': 'Ming-Jiang', 'Initials': 'MJ', 'LastName': 'Song', 'Affiliation': 'Fishery Institute, Sichuan Academy of Agricultural Sciences, Chengdu 611730, China.'}, {'ForeName': 'Fei-Yang', 'Initials': 'FY', 'LastName': 'Li', 'Affiliation': 'Fishery Institute, Sichuan Academy of Agricultural Sciences, Chengdu 611730, China.'}, {'ForeName': 'Qing-Chao', 'Initials': 'QC', 'LastName': 'Shi', 'Affiliation': 'Key Laboratory of Sichuan Province for Fishes Conservation and Utilization in the Upper Reaches of the Yangtze River, Neijiang Normal University, Neijiang 64100, China.'}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Gong', 'Affiliation': 'Fishery Institute, Sichuan Academy of Agricultural Sciences, Chengdu 611730, China. Electronic address: admiral671@163.com.'}]","Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology",['10.1016/j.cbpb.2021.110648'] 1676,34271161,Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry.,"BACKGROUND In the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial, vericiguat reduced the risk of mortality due to cardiovascular problems and of hospitalization due to heart failure (HF) among patients with HF with reduced ejection fraction (HFrEF) and recent worsening HF events (WHFEs). The representativeness of the VICTORIA population of patients with WHFE in clinical practice is unknown. METHODS AND RESULTS Patients with HF and ejection fraction <45% were identified in the Practice Innovation And Clinical Excellence (PINNACLE) registry and were stratified by the occurrence of WHFEs. Characteristics and outcomes of patients in the PINNACLE registry with and without WHFEs were compared to the VICTORIA population. Of the 14,180 PINNACLE patients identified with HFrEF, 26.5% had had a WHFE. The VICTORIA population was similar to PINNACLE patients with WHFEs in mean age (67.3 vs 66.7), ejection fraction (28.9% vs 28.3%), body mass index (26.8 vs 27.6), and comorbidity burden. The rate of hospitalization because of HF at 1 year was 29.6% in the placebo group of VICTORIA, compared to 35.8% in PINNACLE patients with WHFEs and 13.3% in patients without WHFEs. CONCLUSIONS The PINNACLE patients with WHFEs meeting the VICTORIA definition resembled the VICTORIA population in characteristics and outcomes, suggesting that VICTORIA's population may be generalizable to patients with WHFEs in clinical practice.",2021,"The rate of HF hospitalization at 1 year was 29.6% in the placebo group of VICTORIA, compared to 35.8% in PINNACLE patients with a WHFE and 13.3% in patients without a WHFE. ",['patients with heart failure with reduced ejection fraction (HFrEF) and a recent worsening heart failure event (WHFE'],['placebo'],"['cardiovascular mortality and heart failure (HF) hospitalization', 'rate of HF hospitalization', 'body mass index', 'ejection fraction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0441471', 'cui_str': 'Event'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]",14180.0,0.172947,"The rate of HF hospitalization at 1 year was 29.6% in the placebo group of VICTORIA, compared to 35.8% in PINNACLE patients with a WHFE and 13.3% in patients without a WHFE. ","[{'ForeName': 'Javed', 'Initials': 'J', 'LastName': 'Butler', 'Affiliation': 'Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi. Electronic address: jbutler4@umc.edu.'}, {'ForeName': 'Laurence M', 'Initials': 'LM', 'LastName': 'Djatche', 'Affiliation': 'Merck & Co., Kenilworth, New Jersey.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Lautsch', 'Affiliation': 'Merck & Co., Kenilworth, New Jersey.'}, {'ForeName': 'Lingfeng', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Merck & Co., Kenilworth, New Jersey.'}, {'ForeName': 'Mahesh J', 'Initials': 'MJ', 'LastName': 'Patel', 'Affiliation': 'Merck & Co., Kenilworth, New Jersey.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mentz', 'Affiliation': 'Department of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.'}]",Journal of cardiac failure,['10.1016/j.cardfail.2021.06.019'] 1677,34271135,"A multidimensional program including standing exercises, health education, and telephone support to reduce sedentary behavior in frail older adults: Randomized clinical trial.","OBJECTIVES The primary aim of this study was to evaluate the effect of a multidimensional program including home-based standing exercises, health education, and telephone support for the reduction of sedentary behavior in community-dwelling frail older adults. The secondary aim of this study was to evaluate the safety and adherence of the program. STUDY DESIGN A single-blind, randomized controlled trial. METHODS A total of 43 frail older adults were randomly assigned to the intervention and control groups. The intervention consisted of combined strategies including home-based standing exercises, health education, and telephone support for 16 weeks for frail older adults. The control group received orientation regarding the harmful effects of a sedentary lifestyle. Sedentary behavior was evaluated by total sedentary time, accumulated sedentary time in bouts of at least 10 min, and by the break in sedentary time, measured by an accelerometer used for at least 600 min/day for 4 days. Safety was assessed by self-reporting of possible adverse events. Adherence was assessed based on the number of days in which standing exercises were performed by the participants. Repeated measures ANOVA and Tukeys post hoc test were used to analyze the collected data. RESULTS The intervention group reduced the sedentary time by 30 min/day (p= 0.048), but without significant maintenance after 30 days of the program. Of the total number of participants, 82% (n = 14) of the intervention group participants showed more than 70% adherence to the program. The main adverse effects faced by the intervention group participants were tiredness (53%; n = 9) and lower limb pain (47%; n = 8). CONCLUSIONS The multidimensional program reduced sedentary behavior, was safe, and showed satisfactory adherence in frail older adults.",2021,"The intervention group reduced the sedentary time by 30 min/day (p = 0.048), but without significant maintenance after 30 days of the program.","['frail older adults', 'community-dwelling frail older adults', '43 frail older adults']","['standing exercises, health education, and telephone support', 'multidimensional program including home-based standing exercises, health education, and telephone support', 'combined strategies including home-based standing exercises, health education, and telephone support']","['sedentary behavior', 'sedentary time', 'Adherence', 'tiredness', 'limb pain', 'safety and adherence', 'Sedentary behavior', 'Safety']","[{'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C1532253', 'cui_str': 'Sedentary lifestyle'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0030196', 'cui_str': 'Pain in limb'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",43.0,0.035222,"The intervention group reduced the sedentary time by 30 min/day (p = 0.048), but without significant maintenance after 30 days of the program.","[{'ForeName': 'Fabiana C', 'Initials': 'FC', 'LastName': 'Tosi', 'Affiliation': 'Laboratory of Studies in Technology, Functionality and Aging of the Department of Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, SP, Brazil. Electronic address: tosi.fisio@usp.br.'}, {'ForeName': 'Sumika M', 'Initials': 'SM', 'LastName': 'Lin', 'Affiliation': 'Medical Investigation Laboratory on Ageing (LIM66), Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School, São Paulo, Brazil.'}, {'ForeName': 'Gisele C', 'Initials': 'GC', 'LastName': 'Gomes', 'Affiliation': 'Laboratory of Studies in Technology, Functionality and Aging of the Department of Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Aprahamian', 'Affiliation': 'Medical Investigation Laboratory on Ageing (LIM66), Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School, São Paulo, Brazil; Group of investigation on Multimorbidity and Mental Health in Aging (GIMMA), Geriatrics Division, Internal Medicine Department, Jundiaí Medical School, Jundiaí, Brazil; University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands.'}, {'ForeName': 'Naomi K', 'Initials': 'NK', 'LastName': 'Nakagawa', 'Affiliation': 'Laboratory of Studies in Technology, Functionality and Aging of the Department of Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Viveiro', 'Affiliation': 'Laboratory of Studies in Technology, Functionality and Aging of the Department of Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Jessica M R', 'Initials': 'JMR', 'LastName': 'Bacha', 'Affiliation': 'Laboratory of Studies in Technology, Functionality and Aging of the Department of Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Wilson', 'Initials': 'W', 'LastName': 'Jacob-Filho', 'Affiliation': 'Medical Investigation Laboratory on Ageing (LIM66), Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School, São Paulo, Brazil.'}, {'ForeName': 'Jose E', 'Initials': 'JE', 'LastName': 'Pompeu', 'Affiliation': 'Laboratory of Studies in Technology, Functionality and Aging of the Department of Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, SP, Brazil.'}]",Experimental gerontology,['10.1016/j.exger.2021.111472'] 1678,34275877,Innovative demand creation strategies to increase voluntary medical male circumcision uptake: a pragmatic randomised controlled trial in Zimbabwe.,"INTRODUCTION Reaching men aged 20-35 years, the group at greatest risk of HIV, with voluntary medical male circumcision (VMMC) remains a challenge. We assessed the impact of two VMMC demand creation approaches targeting this age group in a randomised controlled trial (RCT). METHODS We conducted a 2×2 factorial RCT comparing arms with and without two interventions: (1) standard demand creation augmented by human-centred design (HCD)-informed approach; (2) standard demand creation plus offer of HIV self-testing (HIVST). Interpersonal communication (IPC) agents were the unit of randomisation. We observed implementation of demand creation over 6 months (1 May to 31 October 2018), with number of men circumcised assessed over 7 months. The primary outcome was the number of men circumcised per IPC agent using the as-treated population of actual number of months each IPC agent worked. We conducted a mixed-methods process evaluation within the RCT. RESULTS We randomised 140 IPC agents, 35 in each arm. 132/140 (94.3%) attended study training and 105/132 (79.5%) reached at least one client during the trial period and were included in final analysis. There was no evidence that the HCD-informed intervention increased VMMC uptake versus no HCD-informed intervention (incident rate ratio (IRR) 0.87, 95% CI 0.38 to 2.02; p=0.75). Nor did offering men a HIVST kit at time of VMMC mobilisation (IRR 0.65, 95% CI 0.28 to 1.50; p=0.31). Among IPC agents that reported reaching at least one man with demand creation, both the HCD-informed intervention and HIVST were deemed useful. There were some challenges with trial implementation; <50% of IPC agents converted any men to VMMC, which undermined our ability to show an effect of demand creation and may reflect acceptability and feasibility of the interventions. CONCLUSION This RCT did not show evidence of an effect of HCD-informed demand intervention or HIVST on VMMC uptake. Findings will inform future design and implementation of demand creation evaluations. TRIAL REGISTRATION NUMBER PACTR201804003064160.",2021,This RCT did not show evidence of an effect of HCD-informed demand intervention or HIVST on VMMC uptake.,"['Reaching men aged 20-35 years, the group at greatest risk of HIV, with voluntary medical male circumcision (VMMC) remains a challenge', 'voluntary medical male circumcision uptake']",['without two interventions: (1) standard demand creation augmented by human-centred design (HCD)-informed approach; (2) standard demand creation plus offer of HIV self-testing (HIVST'],"['VMMC uptake versus no HCD-informed intervention (incident rate ratio (IRR', 'number of men circumcised per IPC agent using the as-treated population of actual number of months each IPC agent worked']","[{'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0008819', 'cui_str': 'Circumcision'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0441513', 'cui_str': 'Construction'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]","[{'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0008819', 'cui_str': 'Circumcision'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0083017', 'cui_str': 'insulin receptor-related receptor'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0920194', 'cui_str': 'Circumcised'}, {'cui': 'C0086792', 'cui_str': 'Personal Communication'}, {'cui': 'C0449881', 'cui_str': 'Agent used'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0043227', 'cui_str': 'Working'}]",,0.155928,This RCT did not show evidence of an effect of HCD-informed demand intervention or HIVST on VMMC uptake.,"[{'ForeName': 'Webster', 'Initials': 'W', 'LastName': 'Mavhu', 'Affiliation': 'Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe webster@ceshhar.co.zw.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Neuman', 'Affiliation': 'MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Hatzold', 'Affiliation': 'Population Services International, Washington, District of Columbia, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Buzuzi', 'Affiliation': 'Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Galven', 'Initials': 'G', 'LastName': 'Maringwa', 'Affiliation': 'Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Sungai T', 'Initials': 'ST', 'LastName': 'Chabata', 'Affiliation': 'Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Collin', 'Initials': 'C', 'LastName': 'Mangenah', 'Affiliation': 'Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Noah', 'Initials': 'N', 'LastName': 'Taruberekera', 'Affiliation': 'Population Services International Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Ngonidzashe', 'Initials': 'N', 'LastName': 'Madidi', 'Affiliation': 'Population Services International Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Malvern', 'Initials': 'M', 'LastName': 'Munjoma', 'Affiliation': 'Population Services International Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Getrude', 'Initials': 'G', 'LastName': 'Ncube', 'Affiliation': 'Ministry of Health and Child Care, Harare, Zimbabwe.'}, {'ForeName': 'Sinokuthemba', 'Initials': 'S', 'LastName': 'Xaba', 'Affiliation': 'Ministry of Health and Child Care, Harare, Zimbabwe.'}, {'ForeName': 'Owen', 'Initials': 'O', 'LastName': 'Mugurungi', 'Affiliation': 'Ministry of Health and Child Care, Harare, Zimbabwe.'}, {'ForeName': 'Cheryl C', 'Initials': 'CC', 'LastName': 'Johnson', 'Affiliation': 'HIV Department, World Health Organization, Geneve, Switzerland.'}, {'ForeName': 'Elizabeth L', 'Initials': 'EL', 'LastName': 'Corbett', 'Affiliation': 'Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Helen A', 'Initials': 'HA', 'LastName': 'Weiss', 'Affiliation': 'MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Fielding', 'Affiliation': 'MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Frances M', 'Initials': 'FM', 'LastName': 'Cowan', 'Affiliation': 'Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}]",BMJ global health,['10.1136/bmjgh-2021-006141'] 1679,34275501,Low dose depot oral vitamin D 3 v . daily oral vitamin D 3 for treating nutritional rickets: a randomised clinical trial.,"We aimed to compare the efficacy of daily v. low dose depot oral vitamin D3 for treating nutritional rickets. We conducted a randomised controlled trial in the department of paediatrics of a tertiary care hospital catering to semi-urban and rural population in Delhi, India. We randomised sixty-six children aged 3 months to 5 years with nutritional rickets to receive either daily oral vitamin D3 drops (3-12 months: 2000 IU; > 12 months to 5 years: 4000 IU; n 33) for 12 weeks duration or a single oral depot dose of vitamin D3 granules (3-12 months: 60 000 IU; > 12 months to 5 years: 150 000 IU; n 33). Participants in both groups had comparable demographic characteristics, laboratory features and radiological severity of rickets. Thirty-three participants in each group received the assigned intervention and all were followed up till 12 weeks. At 12 weeks follow-up, children in both groups showed a significant improvement in all biochemical parameters (serum Ca, P, alkaline phosphatase (ALP), parathormone and 25(OH) vitamin D levels) as well as radiological healing. At 12 weeks, the mean serum 25(OH) vitamin D levels (nmol/l) were statistically comparable in both groups (daily: 120·2 (sd 83·2), depot: 108 (sd 74), P = 0·43) and 31 (93·9 %) children in each group had radiological healing (Thacher score < 1·5). Two children in each group persisted to have raised ALP, and one child each in the daily group continued to have hypocalcaemia and hypophosphataemia at 12 weeks. Low dose oral depot vitamin D3 is an effective alternative to daily oral vitamin D3 for nutritional rickets.",2021,"At 12 weeks follow up, children in both groups showed a significant improvement in all biochemical parameters [serum calcium, phosphorus, alkaline phosphatase, parathormone and 25(OH) vitamin D levels] as well as radiological healing.","['Paediatrics department of a tertiary care hospital catering to semi-urban and rural population in Delhi, India', 'Treating Nutritional Rickets', '66 children aged 3 months to 5 years with nutritional rickets to receive either']","['vitamin D3', 'vitamin D3 granules', 'daily oral vitamin D3 drops', 'Low Dose Depot Oral Vitamin D3 Versus Daily Oral Vitamin D3']","['biochemical parameters [serum calcium, phosphorus, alkaline phosphatase, parathormone and 25(OH) vitamin D levels', 'demographic characteristics, laboratory features and radiological severity of rickets', 'radiological healing', 'raised alkaline phosphatase', 'mean (SD) serum 25(OH) vitamin D levels (nmol/L', 'hypocalcemia and hypophosphatemia']","[{'cui': 'C0587482', 'cui_str': 'Pediatric department'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0035962', 'cui_str': 'Rural Population'}, {'cui': 'C0086541', 'cui_str': 'Dry form of cutaneous leishmaniasis'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0035579', 'cui_str': 'Rickets'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}]","[{'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0020063', 'cui_str': 'PTH protein, human'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0035579', 'cui_str': 'Rickets'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0151849', 'cui_str': 'Alkaline phosphatase raised'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439282', 'cui_str': 'nmol/L'}, {'cui': 'C0020598', 'cui_str': 'Hypocalcemia'}, {'cui': 'C0085682', 'cui_str': 'Hypophosphatemia'}]",66.0,0.254512,"At 12 weeks follow up, children in both groups showed a significant improvement in all biochemical parameters [serum calcium, phosphorus, alkaline phosphatase, parathormone and 25(OH) vitamin D levels] as well as radiological healing.","[{'ForeName': 'Ravneet Kaur', 'Initials': 'RK', 'LastName': 'Saluja', 'Affiliation': 'Department of Paediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India.'}, {'ForeName': 'Pooja', 'Initials': 'P', 'LastName': 'Dewan', 'Affiliation': 'Department of Paediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Gomber', 'Affiliation': 'Department of Paediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India.'}, {'ForeName': 'Sri Venkata', 'Initials': 'SV', 'LastName': 'Madhu', 'Affiliation': 'Department of Endocrinology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India.'}, {'ForeName': 'Shuchi', 'Initials': 'S', 'LastName': 'Bhat', 'Affiliation': 'Department of Radiodiagnosis, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India.'}, {'ForeName': 'Piyush', 'Initials': 'P', 'LastName': 'Gupta', 'Affiliation': 'Department of Paediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India.'}]",The British journal of nutrition,['10.1017/S0007114521002713'] 1680,34274620,The auditory startle response in relation to outcome in functional movement disorders.,"BACKGROUND The auditory startle reflex (ASR) is enlarged in patients with functional movement disorders (FMD). OBJECTIVES To study whether the ASR relates to symptom reduction in FMD patients, who participated in a placebo controlled double blind treatment trial with Botulinum Neurotoxin (BoNT). METHODS Response to treatment in the BoNT study was assessed using the Clinical Global Impression - Improvement scale (CGI-I). The electromyography (EMG) muscle activity of 7 muscles following 110 dB tones was measured in 14 FMD patients before and after one-year treatment and compared to 11 matched controls. The early and a late (behaviorally affected) component of the ASR and the sympathetic skin response (SSR) were assessed. RESULTS 10 of 14 patients (71.4%) showed symptom improvement, which was believed to be mainly caused by placebo effects. The early total response probability of the ASR at baseline tended to be larger in patients compared to controls (p = 0.08), but normalized at follow-up (p = 0.84). The late total response probability was larger in patients vs. controls at baseline (p < 0.05), a trend that still was present at follow-up (p = 0.08). The SSR was higher in patients vs. controls at baseline (p < 0.01), and normalized at follow-up (p = 0.71). CONCLUSIONS On a group level 71.4% of the patients showed clinical symptom improvement after treatment. The early part of the ASR, most likely reflecting anxiety and hyperarousal, normalized in line with the clinical improvement. Interestingly, the augmented late component of the ASR remained enlarged suggesting persistent altered behavioral processing in functional patients despite motor improvement.",2021,"The late total response probability was larger in patients vs. controls at baseline (p < 0.05), a trend that still was present at follow-up (p = 0.08).","['FMD patients, who participated in a', 'patients with functional movement disorders (FMD']","['ASR', 'Botulinum Neurotoxin (BoNT', 'placebo', 'auditory startle reflex (ASR']","['Clinical Global Impression - Improvement scale (CGI-I', 'SSR', 'sympathetic skin response (SSR', 'early total response probability of the ASR', 'late total response probability', 'symptom improvement', 'clinical symptom improvement', 'auditory startle response']","[{'cui': 'C4273557', 'cui_str': 'Functional movement disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0038186', 'cui_str': 'Startle Reaction'}, {'cui': 'C1295507', 'cui_str': 'Bontoxilysin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0312646', 'cui_str': 'Finding related to response to skin test'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0038186', 'cui_str': 'Startle Reaction'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",14.0,0.0643684,"The late total response probability was larger in patients vs. controls at baseline (p < 0.05), a trend that still was present at follow-up (p = 0.08).","[{'ForeName': 'Y E M', 'Initials': 'YEM', 'LastName': 'Dreissen', 'Affiliation': 'Department of Neurology and Clinical Neurophysiology, Amsterdam University Medical Center, University of Amsterdam, the Netherlands.'}, {'ForeName': 'J H T M', 'Initials': 'JHTM', 'LastName': 'Koelman', 'Affiliation': 'Department of Neurology and Clinical Neurophysiology, Amsterdam University Medical Center, University of Amsterdam, the Netherlands.'}, {'ForeName': 'M A J', 'Initials': 'MAJ', 'LastName': 'Tijssen', 'Affiliation': 'Department of Neurology, University Medical Centre Groningen, University Groningen, the Netherlands. Electronic address: M.A.J.de.Koning-Tijssen@umcg.nl.'}]",Parkinsonism & related disorders,['10.1016/j.parkreldis.2021.07.012'] 1681,34274600,Neural mechanisms and predictors of SSRI and CBT treatment of anxiety: A randomized trial focused on emotion and cognitive processing.,"Anxiety disorders (ADs) are common and difficult to treat. While research suggests ADs are characterized by an imbalance between bottom-up and top-down attention processes and that effective treatments work by correcting this dysfunction, there is insufficient data to explain how and for whom treatments work. The late positive potential (LPP), an event-related potential reflecting elaborative processing of motivationally salient stimuli, is sensitive to both bottom-up and top-down processes. The present study examines the LPP in healthy controls (HC) and patients with ADs under low and high working memory (WM) load to assess its utility as a predictor and index of symptom reduction in patients who underwent cognitive behavioral therapy (CBT) or selective serotonin reuptake inhibitor (SSRI) treatment. The LPP when viewing negative and neutral distractor images and WM performance were assessed in 96 participants (40 HC, 32 CBT, 24 SSRI) during a letter recall task at Week 0 and in a subset of the study sample (23 CBT, 16 SSRI) at Week 12. Patients were randomly assigned to twelve weeks of CBT or SSRI treatment. Participants completed self-reported symptom measures at each time point. Greater Week 0 LPP to negative images under low WM load predicted greater symptom reduction in the SSRI, but not the CBT, group. Regression analyses examining the LPP to negative images as an index of symptom reduction revealed a smaller decrease in the LPP to negative images under low WM load was associated with less anxiety reduction across treatment modalities. Findings suggest the LPP during low WM load may serve as a cost-effective predictor and index of treatment outcome in ADs. Clinical Trials Registration: ClinicalTrials.gov (Identifier: NCT01903447).",2021,"LPP to negative images under low WM load predicted greater symptom reduction in the SSRI, but not the CBT, group.","['healthy controls (HC) and patients with ADs under low and high working memory (WM', 'patients who underwent', 'anxiety']","['CBT or SSRI', 'cognitive behavioral therapy (CBT) or selective serotonin reuptake inhibitor (SSRI) treatment', 'emotion and cognitive processing', 'LPP']","['viewing negative and neutral distractor images and WM performance', 'symptom reduction', 'anxiety reduction', 'late positive potential (LPP']","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0150135', 'cui_str': 'Alleviating anxiety'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",96.0,0.0519465,"LPP to negative images under low WM load predicted greater symptom reduction in the SSRI, but not the CBT, group.","[{'ForeName': 'Kerry L', 'Initials': 'KL', 'LastName': 'Kinney', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, United States; Department of Psychology, University of Illinois at Chicago, Chicago, IL, United States. Electronic address: kkinne6@uic.edu.'}, {'ForeName': 'Katie L', 'Initials': 'KL', 'LastName': 'Burkhouse', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, United States; Department of Psychology, University of Illinois at Chicago, Chicago, IL, United States.'}, {'ForeName': 'Fini', 'Initials': 'F', 'LastName': 'Chang', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, United States; Department of Psychology, University of Illinois at Chicago, Chicago, IL, United States.'}, {'ForeName': 'Annmarie', 'Initials': 'A', 'LastName': 'MacNamara', 'Affiliation': 'Department of Psychological and Brain Sciences, Texas A&M University, College Station, TX, United States.'}, {'ForeName': 'Heide', 'Initials': 'H', 'LastName': 'Klumpp', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, United States; Department of Psychology, University of Illinois at Chicago, Chicago, IL, United States; Department of Psychological and Brain Sciences, Texas A&M University, College Station, TX, United States.'}, {'ForeName': 'K Luan', 'Initials': 'KL', 'LastName': 'Phan', 'Affiliation': 'Department of Psychiatry and Behavioral Health, Ohio State University, Columbus, OH, United States.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2021.102449'] 1682,34274555,Acute consumption of pecans decreases angiopoietin-like protein-3 in healthy males: a secondary analysis of randomized controlled trials.,"Angiopoietin-like proteins (ANGPTL)-3 and -4 regulate lipid metabolism, but the effect of tree nuts of varying fatty acid composition on post-meal responses is unknown. The purpose of the study was to conduct a secondary analysis of two studies on ANGPTL3 and -4 responses to meals containing different tree nuts. We hypothesized that the pecan-containing meal would mitigate postprandial rises in ANGPTL3 compared to the traditional meal without nuts in males, but not females. In addition, we hypothesized that there would be no other differences between any other treatments in ANGPTL3 or -4 responses. The two studies were double-blind, randomized crossover trials. Twenty-two adults (10=male, 12=female) completed study 1, which compared meals containing pecans vs. no nuts (control), and thirty adults (14=male, 16=female) completed study 2, which compared meals containing black walnuts, English walnuts (EW), or no nuts (control). Blood was collected at fasting, 30, 60, 120, and 180min postprandially. In study 1, ANGPTL3 was suppressed more in pecan vs. control in males (iAUC: -579.4±219.4 vs. -128.4±87.1pg/mL/3h, P<.05). In study 2, there was no difference in ANGPTL3 between black walnuts vs. EW, but ANGPTL3 was suppressed more in control vs. black walnuts in females only (iAUC: -196.4±138.4 vs. 102.1±90.1pg/mL/3h, P<.05). There were no differences in ANGPTL4 between treatments. In conclusion, adding pecans to a meal decreased ANGPTL3 in males, but not females. These data highlight the importance of investigating the impact of nutrients and sex on postprandial ANGPTL3 ad -4 responses to better understand their ability to reduce cardiovascular disease risk.",2021,There were no differences in ANGPTL4 between treatments.,"['Twenty-two adults (10=male, 12=female) completed study 1, which compared meals containing pecans vs. no nuts (control), and thirty adults (14=male, 16=female) completed study 2, which compared', 'healthy males']","['meals containing different tree nuts', 'pecan-containing meal', 'meals containing black walnuts, English walnuts (EW), or no nuts (control']",[],"[{'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0946601', 'cui_str': 'Carya illinoinensis'}, {'cui': 'C0028723', 'cui_str': 'Nut'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C3714627', 'cui_str': 'Tree nut'}, {'cui': 'C0946601', 'cui_str': 'Carya illinoinensis'}, {'cui': 'C0330972', 'cui_str': 'Juglans nigra'}, {'cui': 'C0330974', 'cui_str': 'Juglans regia'}, {'cui': 'C0028723', 'cui_str': 'Nut'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],,0.100601,There were no differences in ANGPTL4 between treatments.,"[{'ForeName': 'Liana L', 'Initials': 'LL', 'LastName': 'Guarneiri', 'Affiliation': 'Department of Nutritional Sciences, University of Georgia, Athens, GA, USA.'}, {'ForeName': 'Mai O', 'Initials': 'MO', 'LastName': 'Spaulding', 'Affiliation': 'Department of Nutritional Sciences, University of Georgia, Athens, GA, USA.'}, {'ForeName': 'Alexis R', 'Initials': 'AR', 'LastName': 'Marquardt', 'Affiliation': 'Department of Nutritional Sciences, University of Georgia, Athens, GA, USA.'}, {'ForeName': 'Jamie A', 'Initials': 'JA', 'LastName': 'Cooper', 'Affiliation': 'Department of Nutritional Sciences, University of Georgia, Athens, GA, USA.'}, {'ForeName': 'Chad M', 'Initials': 'CM', 'LastName': 'Paton', 'Affiliation': 'Department of Nutritional Sciences, University of Georgia, Athens, GA, USA; Department of Food Science and Technology, University of Georgia, Athens, GA, USA. Electronic address: cpaton@uga.edu.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2021.06.001'] 1683,34274552,"Eight weeks of intermittent fasting versus calorie restriction does not alter eating behaviors, mood, sleep quality, quality of life and cognitive performance in women with overweight.","Human trials that compare intermittent fasting (IF) to calorie restriction (CR) with psychological, behavioral and cognition outcomes are limited. We hypothesized that there would be no difference between CR and IF on perceived eating behaviors, mood, sleep quality, quality of life (QOL) and cognition in women with overweight and obesity. In this prespecified secondary analysis of an open-label, single center, parallel assignment, randomized controlled trial, healthy women with overweight or obesity (N = 46, mean [SD] age 50 [9] years, BMI 32.9 [4.4] kg/m 2 ), without a diagnosed eating disorder and who were randomized into 2 weight loss groups (prescribed 70% of calculated energy requirements as IF or CR) were included. Measurements were assessed in both IF and CR groups following a 12-hour overnight fast during baseline and week 8 and additionally following a 24-hour fast in the IF group only at week 8. We observed that IF produced greater weight and body fat loss than CR (P < .001). We did not detect any statistical difference between groups for the change in dietary restraint, disinhibition, hunger, mood, sleep quality, and QOL. An increase in cognitive performance was found in both IF (P = .036) and CR (P = .006) groups in one of the cognitive tasks, but there was no statistical difference between groups. Perceived eating behaviors, mood, sleep quality and cognitive performance were not changed by an acute 24-hour fast within the IF group (all P > .05). IF may be a viable alternative to CR for weight loss, in the short-term, without adversely impacting eating behaviors, mood, sleep quality, QOL or cognition in healthy women with overweight or obesity. However, larger and long term trials are required.",2021,"We did not detect any statistical difference between groups for the change in dietary restraint, disinhibition, hunger, mood, sleep quality, and QOL.","['healthy women with overweight or obesity', 'women with overweight and obesity', '9] years, BMI 32.9 [4.4] kg/m 2 ), without a diagnosed eating disorder', 'women with overweight', 'N\xa0=\xa046, mean [SD] age 50']","['intermittent fasting versus calorie restriction', 'intermittent fasting (IF) to calorie restriction (CR']","['weight and body fat loss', 'eating behaviors, mood, sleep quality, QOL or cognition', 'cognitive performance', 'dietary restraint, disinhibition, hunger, mood, sleep quality, and QOL', 'Perceived eating behaviors, mood, sleep quality and cognitive performance', 'eating behaviors, mood, sleep quality, quality of life and cognitive performance', 'perceived eating behaviors, mood, sleep quality, quality of life (QOL) and cognition']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C4704881', 'cui_str': 'Intermittent Fasting'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0424630', 'cui_str': 'Loss of body fat - finding'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0035260', 'cui_str': 'Physical restraint'}, {'cui': 'C0234410', 'cui_str': 'Disinhibition'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",,0.0452008,"We did not detect any statistical difference between groups for the change in dietary restraint, disinhibition, hunger, mood, sleep quality, and QOL.","[{'ForeName': 'Xiao Tong', 'Initials': 'XT', 'LastName': 'Teong', 'Affiliation': 'Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia; Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.'}, {'ForeName': 'Amy T', 'Initials': 'AT', 'LastName': 'Hutchison', 'Affiliation': 'Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia; Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia; Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.'}, {'ForeName': 'Gary A', 'Initials': 'GA', 'LastName': 'Wittert', 'Affiliation': 'Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia; Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.'}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Lange', 'Affiliation': 'Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Siobhan', 'Initials': 'S', 'LastName': 'Banks', 'Affiliation': 'Behavior-Brain-Body Research Centre, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Leonie K', 'Initials': 'LK', 'LastName': 'Heilbronn', 'Affiliation': 'Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia; Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia. Electronic address: leonie.heilbronn@adelaide.edu.au.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2021.06.006'] 1684,34291590,Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up.,"BACKGROUND Visual hallucinations are common in patients with Parkinson's disease and represent probably the major independent predictor for cognitive deterioration and nursing home placement. OBJECTIVE To investigate if treatment of minor visual hallucinations in Parkinson's disease with rivastigmine delays the progression to psychosis. METHODS A multicenter, randomized, double-blind, placebo-controlled trial was conducted which aimed to recruit 168 patients with Parkinson's disease reporting minor visual hallucinations 4 weeks before it. Important exclusion criteria were Parkinson's disease dementia, current delirium, and treatment with antipsychotics or drugs that have significant anti-cholinergic side effects. Subjects were randomized to rivastigmine capsules, 3-6 mg twice a day, or placebo for 24 months. The primary outcome was the time to Parkinson's disease psychosis, which was defined as the need to start with antipsychotics. RESULTS The trial was stopped prematurely because of slow recruitment. Ninety-one patients were randomized: 46 patients were assigned to rivastigmine and 45 patients to placebo. No effect of rivastigmine could be demonstrated on the transition time to psychosis or dementia during the 24-month follow-up period. After 6 months of study treatment, cognition, mood, motor performance, and non-motor performance did not differ significantly between the rivastigmine-group and the placebo-group. CONCLUSIONS Because the study was terminated early, it was insufficiently powered to properly evaluate the primary outcome. The limited data of the study favor a wait and see approach instead of early treatment with rivastigmine in PD patients with minor VH.",2021,"After 6 months of study treatment, cognition, mood, motor performance, and non-motor performance did not differ significantly between the rivastigmine-group and the placebo-group. ","['PD patients with minor VH', ""168 patients with Parkinson's disease reporting minor visual hallucinations 4 weeks before it"", 'Ninety-one patients were randomized: 46 patients', ""patients with Parkinson's disease"", ""Parkinson's disease""]","['rivastigmine', 'placebo', 'rivastigmine capsules, 3-6\xa0mg twice a day, or placebo', 'Rivastigmine']","['cognition, mood, motor performance, and non-motor performance', ""time to Parkinson's disease psychosis"", 'transition time to psychosis or dementia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C4319556', 'cui_str': '168'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0233763', 'cui_str': 'Visual hallucinations'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C3816959', 'cui_str': '90'}]","[{'cui': 'C0649350', 'cui_str': 'rivastigmine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0442759', 'cui_str': '3/6'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3805119', 'cui_str': ""Parkinson's disease psychosis""}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]",168.0,0.581508,"After 6 months of study treatment, cognition, mood, motor performance, and non-motor performance did not differ significantly between the rivastigmine-group and the placebo-group. ","[{'ForeName': 'Tom J M', 'Initials': 'TJM', 'LastName': 'van Mierlo', 'Affiliation': 'Department of Neurology, Amsterdam Neuroscience, VU University Amsterdam, Amsterdam University, Medical Centers, Amsterdam, The Netherlands.'}, {'ForeName': 'Elisabeth M J', 'Initials': 'EMJ', 'LastName': 'Foncke', 'Affiliation': 'Department of Neurology, Amsterdam Neuroscience, VU University Amsterdam, Amsterdam University, Medical Centers, Amsterdam, The Netherlands.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Post', 'Affiliation': 'Department of Neurology and Centre of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain Cognition and Behaviour, Radboudumc, Nijmegen, The Netherlands.'}, {'ForeName': 'Ben A', 'Initials': 'BA', 'LastName': 'Schmand', 'Affiliation': 'Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Bastiaan R', 'Initials': 'BR', 'LastName': 'Bloem', 'Affiliation': 'Department of Neurology and Centre of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain Cognition and Behaviour, Radboudumc, Nijmegen, The Netherlands.'}, {'ForeName': 'Barbera', 'Initials': 'B', 'LastName': 'van Harten', 'Affiliation': 'Department of Neurology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.'}, {'ForeName': 'Gerrit', 'Initials': 'G', 'LastName': 'Tissingh', 'Affiliation': 'Department of Neurology, Zuyderland Medical Center, Heerlen, The Netherlands.'}, {'ForeName': 'Alexander G', 'Initials': 'AG', 'LastName': 'Munts', 'Affiliation': 'Department of Neurology, Spaarne Gasthuis, Haarlem, The Netherlands.'}, {'ForeName': 'Rob J', 'Initials': 'RJ', 'LastName': 'de Haan', 'Affiliation': 'Clinical Research Unit, Amsterdam Neuroscience, University of Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.'}, {'ForeName': 'Rob M A', 'Initials': 'RMA', 'LastName': 'de Bie', 'Affiliation': 'Department of Neurology, Amsterdam Neuroscience, University of Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Brain and behavior,['10.1002/brb3.2257'] 1685,34297496,Abelacimab for Prevention of Venous Thromboembolism.,"BACKGROUND The role of factor XI in the pathogenesis of postoperative venous thromboembolism is uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation. METHODS In this open-label, parallel-group trial, we randomly assigned 412 patients who were undergoing total knee arthroplasty to receive one of three regimens of abelacimab (30 mg, 75 mg, or 150 mg) administered postoperatively in a single intravenous dose or to receive 40 mg of enoxaparin administered subcutaneously once daily. The primary efficacy outcome was venous thromboembolism, detected by mandatory venography of the leg involved in the operation or objective confirmation of symptomatic events. The principal safety outcome was a composite of major or clinically relevant nonmajor bleeding up to 30 days after surgery. RESULTS Venous thromboembolism occurred in 13 of 102 patients (13%) in the 30-mg abelacimab group, 5 of 99 patients (5%) in the 75-mg abelacimab group, and 4 of 98 patients (4%) in the 150-mg abelacimab group, as compared with 22 of 101 patients (22%) in the enoxaparin group. The 30-mg abelacimab regimen was noninferior to enoxaparin, and the 75-mg and 150-mg abelacimab regimens were superior to enoxaparin (P<0.001). Bleeding occurred in 2%, 2%, and none of the patients in the 30-mg, 75-mg, and 150-mg abelacimab groups, respectively, and in none of the patients in the enoxaparin group. CONCLUSIONS This trial showed that factor XI is important for the development of postoperative venous thromboembolism. Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Anthos Therapeutics; ANT-005 TKA EudraCT number, 2019-003756-37.).",2021,Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding.,['412 patients who were undergoing total knee arthroplasty'],"['Abelacimab', 'enoxaparin', 'abelacimab']","['composite of major or clinically relevant nonmajor bleeding', 'Bleeding', 'venous thromboembolism, detected by mandatory venography of the leg involved in the operation or objective confirmation of symptomatic events', 'Venous thromboembolism']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0206460', 'cui_str': 'Enoxaparin'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0031545', 'cui_str': 'Venography'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",412.0,0.149867,Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding.,"[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Verhamme', 'Affiliation': 'From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.).'}, {'ForeName': 'B Alexander', 'Initials': 'BA', 'LastName': 'Yi', 'Affiliation': 'From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.).'}, {'ForeName': 'Annelise', 'Initials': 'A', 'LastName': 'Segers', 'Affiliation': 'From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.).'}, {'ForeName': 'Janeen', 'Initials': 'J', 'LastName': 'Salter', 'Affiliation': 'From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.).'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Bloomfield', 'Affiliation': 'From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.).'}, {'ForeName': 'Harry R', 'Initials': 'HR', 'LastName': 'Büller', 'Affiliation': 'From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.).'}, {'ForeName': 'Gary E', 'Initials': 'GE', 'LastName': 'Raskob', 'Affiliation': 'From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.).'}, {'ForeName': 'Jeffrey I', 'Initials': 'JI', 'LastName': 'Weitz', 'Affiliation': 'From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2105872'] 1686,34265777,A Randomized Clinical Trial of Cognitive-Behavioral Therapy for Insomnia to Augment Posttraumatic Stress Disorder Treatment in Survivors of Interpersonal Violence.,"INTRODUCTION Individuals exposed to interpersonal violence (IPV) commonly develop posttraumatic stress disorder (PTSD) with co-occurring depression and insomnia. Standard PTSD interventions such as cognitive processing therapy (CPT) do not typically lead to remission or improved insomnia. Cognitive behavioral therapy for insomnia (CBTi) improves insomnia in individuals with PTSD, but PTSD severity remains elevated. OBJECTIVE To determine whether sequential treatment of insomnia and PTSD is superior to treatment of only PTSD. METHODS In a 20-week trial, 110 participants exposed to IPV who had PTSD, depression and insomnia were randomized to CBTi followed by CPT or to attention control followed by CPT. Primary outcomes following CBTi (or control) were the 6-week change in score on the Insomnia Severity Index (ISI), the Clinician-Administered PTSD Scale (CAPS), and the Hamilton Rating Scale for Depression (HAM-D). Primary outcomes following CPT were the 20-week change in scores. RESULTS At 6 weeks, the CBTi condition had greater reductions in ISI, HAM-D, and CAPS scores than the attention control condition. At 20 weeks, participants in the CBTi+CPT condition had greater reductions in ISI, HAM-D, and CAPS scores compared to control+CPT. Effects were larger for insomnia and for depression than for PTSD. Similar patterns were observed with respect to clinical response and remission. A tipping point sensitivity analyses supported the plausibility of the findings. CONCLUSIONS The sequential delivery of CBTi and CPT had plausible, significant effects on insomnia, depression, and PTSD compared to CPT alone. The effects for PTSD symptoms were moderate and clinically meaningful.",2021,"The sequential delivery of CBTi and CPT had plausible, significant effects on insomnia, depression, and PTSD compared to CPT alone.","['Survivors of Interpersonal Violence', 'individuals with PTSD', '110 participants exposed to IPV who had PTSD, depression and insomnia', 'Individuals exposed to interpersonal violence (IPV) commonly develop posttraumatic stress disorder (PTSD) with co-occurring depression and insomnia']","['cognitive processing therapy (CPT', 'Cognitive-Behavioral Therapy', 'CPT', 'CBTi followed by CPT or to attention control followed by CPT', 'Cognitive behavioral therapy for insomnia (CBTi']","['insomnia, depression, and PTSD', '20-week change in scores', 'ISI, HAM-D, and CAPS scores', 'Insomnia Severity Index (ISI), the Clinician-Administered PTSD Scale (CAPS), and the Hamilton Rating Scale for Depression (HAM-D', 'clinical response and remission', 'CBTi (or control', 'insomnia and for depression']","[{'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}]","[{'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",110.0,0.0359951,"The sequential delivery of CBTi and CPT had plausible, significant effects on insomnia, depression, and PTSD compared to CPT alone.","[{'ForeName': 'Wilfred R', 'Initials': 'WR', 'LastName': 'Pigeon', 'Affiliation': 'Sleep and Neurophysiology Research Laboratory, Department of Psychiatry, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Hugh F', 'Initials': 'HF', 'LastName': 'Crean', 'Affiliation': 'US Department of Veterans Affairs Center of Excellence for Suicide Prevention, Finger Lakes Health Care System, Canandaigua, New York, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Cerulli', 'Affiliation': 'Susan B. Anthony Center and Laboratory of Interpersonal Violence and Victimization, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Autumn M', 'Initials': 'AM', 'LastName': 'Gallegos', 'Affiliation': 'Sleep and Neurophysiology Research Laboratory, Department of Psychiatry, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Todd M', 'Initials': 'TM', 'LastName': 'Bishop', 'Affiliation': 'Sleep and Neurophysiology Research Laboratory, Department of Psychiatry, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Kathi L', 'Initials': 'KL', 'LastName': 'Heffner', 'Affiliation': 'Sleep and Neurophysiology Research Laboratory, Department of Psychiatry, University of Rochester Medical Center, Rochester, New York, USA.'}]",Psychotherapy and psychosomatics,['10.1159/000517862'] 1687,34265658,Thoughts of social distancing experiences affect food intake and hypothetical binge eating: Implications for people in home quarantine during COVID-19.,"BACKGROND AND RATIONALE Social distance regulations have been suggested as one of the best ways to control and prevent the spread of COVID-19. Social connection and food are intertwined because both have played critical evolutionary roles in human survival. We tested whether the substitutability hypothesis in human motivation applies here in that cues signaling scarcity in one domain (e.g., social connection) might enhance the desire to acquire resources in another domain (e.g., food). METHODS We recruited 140 adults from Kaohsiung City (the largest city in southern Taiwan) to participate in a laboratory experiment. Participants were randomly assigned to receive either social distancing or neutral primes via an emotional-event recollection technique. The amount of ice cream eaten during a taste test and the self-reported likelihood of binge eating served as the dependent measures. RESULTS We found that, compared with controls, participants primed with social distancing consumed more ice cream in a taste test and reported a greater likelihood that they would engage in binge eating if they were placed in home quarantine. CONCLUSIONS We may be the first to provide experimental evidence that social distancing can enhance the desire for food. The link between social distancing and the desire for food is pertinent to understanding how strongly social distance regulations may influence weight gain. Our findings have far-reaching implications for weight control under social distance regulations for prevention and control of COVID-19.",2021,"We found that, compared with controls, participants primed with social distancing consumed more ice cream in a taste test and reported a greater likelihood that they would engage in binge eating if they were placed in home quarantine. ","['140 adults from Kaohsiung City (the largest city in southern Taiwan) to participate in a laboratory experiment', 'people in home quarantine during COVID-19']","['social distancing or neutral primes via an emotional-event recollection technique', 'social distancing consumed more ice cream']",['binge eating'],"[{'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0034386', 'cui_str': 'Quarantine'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}]","[{'cui': 'C0071973', 'cui_str': 'PRIME protocol'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0020747', 'cui_str': 'Ice cream'}]","[{'cui': 'C0006370', 'cui_str': 'Binge Eating'}]",140.0,0.0540661,"We found that, compared with controls, participants primed with social distancing consumed more ice cream in a taste test and reported a greater likelihood that they would engage in binge eating if they were placed in home quarantine. ","[{'ForeName': 'Yevvon', 'Initials': 'Y', 'LastName': 'Yi-Chi Chang', 'Affiliation': 'Department of Hospitality Management, Tunghai University, Taichung, 407224, Taiwan. Electronic address: yevvon@thu.edu.tw.'}, {'ForeName': 'Pai-Lu', 'Initials': 'PL', 'LastName': 'Wu', 'Affiliation': 'Center for Teacher Education, Cheng Shiu University, Kaohsiung, 83347, Taiwan. Electronic address: pailu@gcloud.csu.edu.tw.'}, {'ForeName': 'Wen-Bin', 'Initials': 'WB', 'LastName': 'Chiou', 'Affiliation': 'Institute of Education, National Sun Yat-sen University, Kaohsiung, 80424, Taiwan. Electronic address: wbchiou@mail.nsysu.edu.tw.'}]",Social science & medicine (1982),['10.1016/j.socscimed.2021.114218'] 1688,34265599,"Corrigendum to ""Open vs ultrasound guided tunneled central venous access in children: A randomised controlled study"": Journal of Surgical Research April 2021 (260) 284-292. JSURGRES-D-21-00792.",,2021,,['children'],"['Corrigendum to ""Open vs ultrasound guided tunneled central venous access']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0337138', 'cui_str': 'Tunnel'}, {'cui': 'C0444466', 'cui_str': 'Central venous'}, {'cui': 'C0444454', 'cui_str': 'Access'}]",[],,0.0631817,,"[{'ForeName': 'Soundappan S V', 'Initials': 'SSV', 'LastName': 'Soundappan', 'Affiliation': ""Department of Surgery, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; Division of Child and Adolescent Helath, Sydney Medical School, University of Sydney, NSW, Australia. Electronic address: s.soundappan@health.nsw.gov.au.""}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Lam', 'Affiliation': 'Tung Wah College, Hong Kong.'}, {'ForeName': 'Daniel T', 'Initials': 'DT', 'LastName': 'Cass', 'Affiliation': ""Department of Surgery, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; Division of Child and Adolescent Helath, Sydney Medical School, University of Sydney, NSW, Australia.""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Karpelowsky', 'Affiliation': ""Department of Surgery, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; Division of Child and Adolescent Helath, Sydney Medical School, University of Sydney, NSW, Australia.""}]",The Journal of surgical research,['10.1016/j.jss.2021.06.039'] 1689,34268884,Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study.,"The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, and rs72552763) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration ( T max ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06). The geometric mean ratios of the areas under the plasma concentration time-curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin-to-no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin-to-no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug-drug interaction between metformin and codeine seems plausible.",2021,"Concomitant oral and iv metformin increased the plasma levels of morphine, M3G and M6G.","['Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, rs72552763) were invited', 'healthy subjects - a cross-over study', 'D']","['codeine', 'metformin', 'metformin and codeine', 'Metformin', 'metformin with and without oral codeine intake', 'tablet codeine', 'tablet metformin', 'Concomitant oral and iv metformin']","['median absorption fraction of metformin', 'median T max', 'geometric mean ratios of the AUCs for morphine and its metabolites M3G and M6G for oral intake of metformin-to-no metformin', 'plasma levels of morphine, M3G and M6G']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4545384', 'cui_str': 'CYP2D6 normal metabolizer'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205419', 'cui_str': 'Variant'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}]","[{'cui': 'C0009214', 'cui_str': 'Codeine'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0798322,"Concomitant oral and iv metformin increased the plasma levels of morphine, M3G and M6G.","[{'ForeName': 'Ida', 'Initials': 'I', 'LastName': 'Kuhlmann', 'Affiliation': 'Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Nøddebo Nyrup', 'Affiliation': 'Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Tore', 'Initials': 'T', 'LastName': 'Bjerregaard Stage', 'Affiliation': 'Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Mette Marie', 'Initials': 'MM', 'LastName': 'Hougaard Christensen', 'Affiliation': 'Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Troels', 'Initials': 'T', 'LastName': 'Korshøj Bergmann', 'Affiliation': 'Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Damkier', 'Affiliation': 'Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Flemming', 'Initials': 'F', 'LastName': 'Nielsen', 'Affiliation': 'Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Højlund', 'Affiliation': 'Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Brøsen', 'Affiliation': 'Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.'}]",Clinical and translational science,['10.1111/cts.13107'] 1690,34272042,Unprotected Left Main Percutaneous Coronary Intervention With or Without Hemodynamic Support.,"Hemodynamic support is widely utilized for unprotected left main (ULM) percutaneous coronary interventions (PCI) despite lack of evidence from randomized studies and the risk of device-related complications. We aimed to compare ULMPCI with and without intra-aortic balloon pump (IABP) support. A single-center, retrospective analysis was performed for patients undergoing ULMPCI with and without IABP support. Clinical, procedural, in-hospital, and 30-day cardiovascular outcomes were compared. From 2003 through 2018, 217 patients underwent non-emergent ULMPCI, 55 with elective IABP support (IABP group), and 162 without support (No-IABP group). The study population comprised 56.4% men and 74.5% Caucasians in the IABP group and 53.7% men and 62.3% Caucasians in the No-IABP group. The mean age for IABP and No-IABP group patients was 75.75 ± 12.34 years and 73.47 ± 15.19 years, respectively (p = 0.315). Procedural success was achieved in 99% of IABP and 95.3% of No-IABP patients (p = 0.089). In-hospital and 30-day mortality was 5.5% for the IABP group and 5.6% for the No-IABP group (p = 0.977). Rates of major complications were statistically similar between the groups. Bailout IABP was required in 10% of No-IABP patients. Hospital and intensive care unit length of stay was statistically longer in the IABP group. In conclusion, ULMPCI without IABP support was not associated with increased mortality and major cardiovascular outcomes compared with supported patients and was associated with shorter hospital and intensive care unit stay. A randomized trial comparing unsupported versus supported ULMPCI is warranted to identify patients who would benefit from hemodynamic support.",2021,Rates of major complications were statistically similar between the groups.,"['patients undergoing ULMPCI with and without IABP support', 'patients who would benefit from hemodynamic support', 'study population comprised 56.4% men and 74.5% Caucasians in the IABP group and 53.7% men and 62.3% Caucasians in the No-IABP group', 'From 2003 through 2018, 217 patients underwent non-emergent ULMPCI, 55 with elective IABP support (IABP group), and 162 without support (No-IABP group']","['ULMPCI', 'IABP', 'Unprotected Left Main Percutaneous Coronary Intervention', 'ULMPCI with and without intra-aortic balloon pump (IABP']","['Rates of major complications', 'Bailout IABP', 'Procedural success', 'Hospital and intensive care unit length of stay', 'Clinical, procedural, in-hospital, and 30-day cardiovascular outcomes', '30-day mortality', 'mortality and major cardiovascular outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021860', 'cui_str': 'Cardioassist by aortic balloon pump'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517646', 'cui_str': '217'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C5191360', 'cui_str': '162'}]","[{'cui': 'C0021860', 'cui_str': 'Cardioassist by aortic balloon pump'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0336968', 'cui_str': 'Sky-diving'}, {'cui': 'C0021860', 'cui_str': 'Cardioassist by aortic balloon pump'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.0507063,Rates of major complications were statistically similar between the groups.,"[{'ForeName': 'Nauman', 'Initials': 'N', 'LastName': 'Khalid', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Corey', 'Initials': 'C', 'LastName': 'Shea', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Sarah Aftab', 'Initials': 'SA', 'LastName': 'Ahmad', 'Affiliation': 'Section of Cardiothoracic Surgery, St. Francis Medical Center, Monroe, Louisiana.'}, {'ForeName': 'Evan', 'Initials': 'E', 'LastName': 'Shlofmitz', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Jason P', 'Initials': 'JP', 'LastName': 'Wermers', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Toby', 'Initials': 'T', 'LastName': 'Rogers', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Hayder', 'Initials': 'H', 'LastName': 'Hashim', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Itsik', 'Initials': 'I', 'LastName': 'Ben-Dor', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Nelson L', 'Initials': 'NL', 'LastName': 'Bernardo', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Lowell F', 'Initials': 'LF', 'LastName': 'Satler', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Waksman', 'Affiliation': 'Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC. Electronic address: Ron.Waksman@MedStar.net.'}]",The American journal of cardiology,['10.1016/j.amjcard.2021.05.037'] 1691,34272041,"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.","BACKGROUND Guidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (IC), based on IMpassion130. We report the final overall survival (OS) and safety of that study as per the prespecified analysis plan. PATIENTS AND METHODS Patients were randomized to nP 100 mg/m 2 (days 1, 8, and 15 of a 28-day cycle) with atezolizumab 840 mg (A + nP) or placebo (P + nP; days 1 and 15), until progression or unacceptable toxicity. Coprimary endpoints were progression-free survival [intention-to-treat (ITT) and PD-L1 IC-positive populations] and OS (tested hierarchically in the ITT population and, if significant, in the PD-L1 IC-positive population). RESULTS Each arm comprised 451 patients; 666 (73.8%) had died by the final OS analysis cut-off (median follow-up, 18.8 months; interquartile range, 8.9-34.7 months). Median OS in the ITT population was 21.0 months [95% confidence interval (CI), 19.0-23.4 months] with A + nP, and 18.7 months (95% CI, 16.9-20.8 months) with P + nP [stratified hazard ratio (HR), 0.87; 95% CI, 0.75-1.02; P = 0.077]. Exploratory analysis in the PD-L1 IC-positive population showed a median OS of 25.4 months (95% CI, 19.6-30.7 months) with A + nP (n = 185) and 17.9 months (95% CI, 13.6-20.3 months) with P + nP (n = 184; stratified HR, 0.67; 95% CI, 0.53-0.86). Safety outcomes were consistent with previous analyses and the known toxicity profiles of each agent. Immune-mediated adverse events of special interest were reported in 58.7% and 41.6% of patients treated with A + nP and P + nP, respectively. CONCLUSION Although the OS benefit in the ITT population was not statistically significant, precluding formal testing, clinically meaningful OS benefit was observed with A + nP in PD-L1 IC-positive patients, consistent with prior interim analyses. This combination remained safe and tolerable with longer follow-up.",2021,"Although the OS benefit in the ITT population was not statistically significant, precluding formal testing,",['Patients'],"['atezolizumab 840 mg (A\xa0+ nP) or placebo', 'atezolizumab plus nab-paclitaxel', 'atezolizumab plus nab-paclitaxel (A\xa0+ nP']","['Median OS', 'progression-free survival [intention-to-treat (ITT) and PD-L1 IC-positive populations] and OS', 'clinically meaningful OS benefit', 'median OS', 'final overall survival (OS) and safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C4708913', 'cui_str': '840'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0439178', 'cui_str': '% positive cells'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.571777,"Although the OS benefit in the ITT population was not statistically significant, precluding formal testing,","[{'ForeName': 'L A', 'Initials': 'LA', 'LastName': 'Emens', 'Affiliation': 'University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, USA. Electronic address: emensla@upmc.edu.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Adams', 'Affiliation': 'New York University Langone Health, Perlmutter Cancer Center, New York, USA.'}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Barrios', 'Affiliation': 'Centro de Pesquisa Clínica, HSL, PUCRS, Porto Alegre, Brazil.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Diéras', 'Affiliation': 'Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Iwata', 'Affiliation': 'Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loi', 'Affiliation': 'Peter MacCallum Cancer Centre, Melbourne, Australia.'}, {'ForeName': 'H S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Schneeweiss', 'Affiliation': 'University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'E P', 'Initials': 'EP', 'LastName': 'Winer', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Henschel', 'Affiliation': 'F. Hoffmann-La Roche Ltd., Basel, Switzerland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Swat', 'Affiliation': 'Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kaul', 'Affiliation': 'Product Development Safety, Genentech, Inc., South San Francisco.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Molinero', 'Affiliation': 'Oncology Biomarker Development, Genentech, Inc., South San Francisco.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Product Development Data Sciences, Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'S Y', 'Initials': 'SY', 'LastName': 'Chui', 'Affiliation': 'Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Schmid', 'Affiliation': 'Barts Cancer Institute, Queen Mary University London, London, UK.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.05.355'] 1692,34272040,"Important news on nutritional support in cancer patients - but some EFFORT is still ahead: Referring to Bargetzi et al., 'Nutritional support during hospital stay reduces mortality in patients with different types of cancer: a secondary analysis of a prospective randomized trial'.",,2021,,['patients with different types of cancer'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]",[],[],,0.0341939,,"[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Arends', 'Affiliation': 'Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address: jann.arends@uniklinik-freiburg.de.'}, {'ForeName': 'E J', 'Initials': 'EJ', 'LastName': 'Roeland', 'Affiliation': 'Oregon Health and Sciences University, Knight Cancer Institute, Portland, USA.'}, {'ForeName': 'V E', 'Initials': 'VE', 'LastName': 'Baracos', 'Affiliation': 'Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.06.020'] 1693,34273681,Caffeine decreases ammonemia in athletes using a ketogenic diet during prolonged exercise.,"OBJECTIVES Both exercise and a ketogenic (low-carbohydrate) diet favor glycogen depletion and increase ammonemia, which can impair physical performance. Caffeine supplementation has been routinely used to improve exercise performance. Herein, the effect of xanthine was evaluated on ammonemia in cyclists who were placed on a ketogenic diet and engaged in prolonged exercise. METHODS Fourteen male cyclists followed a ketogenic diet for 2 d before and during the experimental trial. The cyclists were assigned to either the caffeine- (CEx; n = 7) or placebo-supplemented (LEx; n = 7) group. Blood samples were obtained during cycling and the recovery periods. RESULTS The CEx group showed a significant decrease (up to 25%) in blood ammonia at 60, 90, and 120 min after beginning exercise compared with the LEx group. A higher concentration of apparent blood urea was observed in the LEx group than in the CEx group at 60 to 90 min of exercise (~10%). In addition, a significant increase in blood glucose levels was evident at 30 min of exercise (~28%), and an increase in blood lactate levels was visible during the first 30 to 60 min of exercise (~80%) in the CEx group. CONCLUSIONS Our results suggest that the consumption of caffeine might attenuate the increase in ammonemia that occurs during exercise.",2021,A higher concentration of apparent blood urea was observed in the LEx group than in the CEx group at 60 to 90 min of exercise (~10%).,"['cyclists who were placed on a ketogenic diet and engaged in prolonged exercise', 'Fourteen male cyclists followed a', 'athletes using a ketogenic diet during prolonged exercise']","['Caffeine supplementation', 'xanthine', 'ketogenic diet', 'Caffeine', 'caffeine- (CEx; n\xa0=\xa07) or placebo-supplemented (LEx; n\xa0=\xa07) group', 'Both exercise and a ketogenic (low-carbohydrate) diet']","['exercise performance', 'Blood samples', 'blood lactate levels', 'blood glucose levels', 'concentration of apparent blood urea', 'blood ammonia']","[{'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0259972', 'cui_str': 'Ketogenic diet'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0043314', 'cui_str': 'xanthine'}, {'cui': 'C0259972', 'cui_str': 'Ketogenic diet'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0080188', 'cui_str': 'Lymphocyte antigen CD15'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0428445', 'cui_str': 'D-lactate measurement'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}, {'cui': 'C0428437', 'cui_str': 'Blood ammonia measurement'}]",14.0,0.00943537,A higher concentration of apparent blood urea was observed in the LEx group than in the CEx group at 60 to 90 min of exercise (~10%).,"[{'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Prado', 'Affiliation': 'Laboratory for Research in Physical Exercise and Metabolism, Federal University of Alagoas, Maceió, Brazil.'}, {'ForeName': 'Aníbal', 'Initials': 'A', 'LastName': 'Magalhães-Neto', 'Affiliation': 'Biological and Health Sciences Institute, Federal University of Mato Grosso, Barra do Garças, Brazil.'}, {'ForeName': 'José Rezende', 'Initials': 'JR', 'LastName': 'Neto', 'Affiliation': 'Department of Pharmacy, Federal University of Sergipe, Lagarto, Brazil.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Bassini', 'Affiliation': 'Laboratory of Protein Biochemistry, Federal University of State of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Luiz-Claudio', 'Initials': 'LC', 'LastName': 'Cameron', 'Affiliation': 'Laboratory of Protein Biochemistry, Federal University of State of Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: cameron@unirio.br.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2021.111377'] 1694,34273680,Comparison of short-term hypocaloric high-protein diets with a hypocaloric Mediterranean diet: Effect on body composition and health-related blood markers in overweight and sedentary young participants.,"OBJECTIVES The aim of the present study was to compare the short-term effects of a hypocaloric Mediterranean diet and two high protein diets, with and without whey protein supplementation, on body composition, lipidemic profile, and inflammation and muscle-damage blood indices in overweight, sedentary, young participants. METHODS Thirty-three young, overweight, male and female participants (mean ± SD age: 22.8 ± 4.8 y; body mass: 85.5 ± 10.2 kg; body fat percentage: 34.3% ± 8.1%) were randomly allocated to three different hypocaloric (-700 kcal/d) diets: a Mediterranean diet (MD; n = 10), a high-protein diet (HP; n = 10) diet, and a high-protein diet with whey supplementation (n = 10). The intervention lasted 6 wk. Body composition and biochemical indices were evaluated 1 wk before and after the nutritional interventions. RESULTS Body and fat mass were decreased in the MD and HP groups (-3.5% ± 1.1% and -5.9% ± 4.2% for body and fat mass respectively in MD, and -1.7% ± 1.2% and -2.0% ± 1.8% for body and fat mass respectively in HP;P < 0.05), with no significant decline of fat-free mass observed in the MD group. The MD group's diet beneficially altered the lipid profile (P < 0.05), but the HP and HPW groups' diets did not induce significant changes. Subclinical inflammation and muscle-damage indices significantly increased in the HP and HPW groups (7.4% ± 3.5% and 66.6% ± 40.1% for neutrophils and CRP respectively in HP, and 14.3% ± 6.4% and 266.6% ± 55.1% for neutrophils and CRP respectively in HPW; P < 0.05) but decreased in the MD group (1.8% ± 1.2% and -33.3% ± 10.1% for neutrophils and CRP respectivelyc; P < 0.05). Energy intake of carbohydrates and proteins were significantly related to the changes in body composition and biochemical blood markers (r = -0.389 and -0.889; P < 0.05). CONCLUSIONS Among the three hypocaloric diets, only the Mediterranean diet induced positive changes in body composition and metabolic profile in overweight, sedentary individuals.",2021,"Subclinical inflammation and muscle-damage indices significantly increased in the HP and HPW groups (7.4% ± 3.5% and 66.6% ± 40.1% for neutrophils and CRP respectively in HP, and 14.3% ± 6.4% and 266.6% ± 55.1% for neutrophils and CRP respectively in HPW; P < 0.05) but decreased in the MD group (1.8% ± 1.2% and -33.3% ± 10.1% for neutrophils and CRP respectivelyc; P < 0.05).","['overweight and sedentary young participants', 'overweight, sedentary, young participants', 'Thirty-three young, overweight, male and female participants (mean ± SD age: 22.8 ± 4.8 y; body mass: 85.5 ± 10.2 kg; body fat percentage: 34.3% ± 8.1']","['hypocaloric Mediterranean diet and two high protein diets, with and without whey protein supplementation', 'Mediterranean diet', 'hypocaloric Mediterranean diet', 'hypocaloric (-700 kcal/d) diets: a Mediterranean diet (MD; n\xa0=\xa010), a high-protein diet (HP; n\xa0=\xa010) diet, and a high-protein diet with whey supplementation', 'short-term hypocaloric high-protein diets']","['lipid profile', 'body composition, lipidemic profile, and inflammation and muscle-damage blood indices', 'body composition and metabolic profile', 'body composition and biochemical blood markers', 'Subclinical inflammation and muscle-damage indices', 'body composition and health-related blood markers', 'Body composition and biochemical indices', 'Body and fat mass']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517765', 'cui_str': '4.8'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C4517875', 'cui_str': '8.1'}]","[{'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C0425403', 'cui_str': 'Increased protein diet'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C0456649', 'cui_str': 'kcal/day'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]",33.0,0.00977281,"Subclinical inflammation and muscle-damage indices significantly increased in the HP and HPW groups (7.4% ± 3.5% and 66.6% ± 40.1% for neutrophils and CRP respectively in HP, and 14.3% ± 6.4% and 266.6% ± 55.1% for neutrophils and CRP respectively in HPW; P < 0.05) but decreased in the MD group (1.8% ± 1.2% and -33.3% ± 10.1% for neutrophils and CRP respectivelyc; P < 0.05).","[{'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Feidantsis', 'Affiliation': 'Department of Nutrition Sciences and Dietetics, Faculty of Health Sciences, International Hellenic University, Sindos, Greece; Laboratory of Animal Physiology, Department of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece. Electronic address: kfeidant@bio.auth.gr.'}, {'ForeName': 'Spyridon', 'Initials': 'S', 'LastName': 'Methenitis', 'Affiliation': 'Department of Nutrition Sciences and Dietetics, Faculty of Health Sciences, International Hellenic University, Sindos, Greece; Sports Performance Laboratory, School of Physical Education & Sports Science, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Kleopatra', 'Initials': 'K', 'LastName': 'Ketselidi', 'Affiliation': 'Department of Nutrition Sciences and Dietetics, Faculty of Health Sciences, International Hellenic University, Sindos, Greece; Department of Nutrition and Dietetics, School of Health Science & Education, Harokopio University of Athens, Athens, Greece.'}, {'ForeName': 'Kiriaki', 'Initials': 'K', 'LastName': 'Vagianou', 'Affiliation': 'Department of Nutrition Sciences and Dietetics, Faculty of Health Sciences, International Hellenic University, Sindos, Greece; Department of Nutrition and Dietetics, School of Health Science & Education, Harokopio University of Athens, Athens, Greece.'}, {'ForeName': 'Petros', 'Initials': 'P', 'LastName': 'Skepastianos', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health Sciences, International Hellenic University, Sindos, Greece.'}, {'ForeName': 'Apostolos', 'Initials': 'A', 'LastName': 'Hatzitolios', 'Affiliation': 'Diabetes Center, EASO Obesity Center, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Alexandros', 'Initials': 'A', 'LastName': 'Mourouglakis', 'Affiliation': 'Diabetes Center, EASO Obesity Center, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Athina', 'Initials': 'A', 'LastName': 'Kaprara', 'Affiliation': 'Laboratory of Sport Medicine, School of Physical Education and Sports Science, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Hassapidou', 'Affiliation': 'Department of Nutrition Sciences and Dietetics, Faculty of Health Sciences, International Hellenic University, Sindos, Greece.'}, {'ForeName': 'Tzortzis', 'Initials': 'T', 'LastName': 'Nomikos', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science & Education, Harokopio University of Athens, Athens, Greece.'}, {'ForeName': 'Sousana K', 'Initials': 'SK', 'LastName': 'Papadopoulou', 'Affiliation': 'Department of Nutrition Sciences and Dietetics, Faculty of Health Sciences, International Hellenic University, Sindos, Greece.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2021.111365'] 1695,34273635,Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.,"INTRODUCTION The effectiveness of umifenovir against COVID-19 is controversial; therefore, clinical trials are crucial to evaluate its efficacy. METHODS The study was conducted as a single-center, randomized, open-label clinical trial. Eligible moderate-severe hospitalized patients with confirmed SARS-Cov-2 infection were randomly segregated into intervention and control groups. The intervention group were treated with lopinavir/ritonavir (400 mg/100 mg bid for 10-14 days) + hydroxychloroquine (400 mg single dose) + interferon-β1a (Subcutaneous injections of 44 µg (12,000 IU) on days 1, 3, 5) + umifenovir (200 mg trice daily for 10 days), and the control group received lopinavir/ritonavir (same dose) + hydroxychloroquine (same dose) + interferon-β1a (same dose). RESULTS Of 1180 patients with positive RT-PCRs and positive chest CT scans, 101 patients were finally included in the trial; 50 were assigned to receive IFNβ1a + hydroxychloroquine + lopinavir/ritonavir group and 51 were managed to treat with IFNβ1a + hydroxychloroquine + lopinavir/ritonavir + umifenovir. Since all patients received the intended treatment as scheduled, the analysis just included as the ITT population. Time to clinical improvement (TTCI) did not hold a statistically significant difference between intervention and control groups (median, 9 days for intervention group versus 7 days for the control group; P: 0.22). Besides, Hazard Ratio for TTCI in the Cox regression model was 0.75 (95% CI: 0.45-1.23, P:0.25) which also confirmed that there was no statistically significant difference between the treatment group and the control group. The mortality was not statistically significant between the two groups (38% in controls vs 33.3% treatment group). CONCLUSIONS Our findings shed new lights on the facts that additional umifenovir has not been found to be effective in shortening the duration of SARS-CoV-2 in severe patients and improving the prognosis in non-ICU patients and mortality. TRIAL REGISTRATION The trial was confirmed by the Ethics in Medical Research Committee of the Shahid Beheshti University of Medical Sciences. signed informed consents were obtained from all the participants or their legally authorized representatives. This trial has been registered as ClinicalTrials.gov, NCT04350684.",2021,"The mortality was not statistically significant between the two groups (38% in controls vs 33.3% treatment group). ","['101 patients were finally included in the trial; 50', '1180 patients with positive RT-PCRs and positive chest CT scans', 'hospitalized moderate to severe COVID-19 patients', 'Eligible moderate-severe hospitalized patients with confirmed SARS-Cov-2 infection']","['IFNβ1a', 'lopinavir/ritonavir', 'lopinavir/ritonavir (same dose)\xa0+\xa0hydroxychloroquine (same dose)\xa0+\xa0interferon-β1a (same dose', '\xa0hydroxychloroquine\xa0+\xa0lopinavir/ritonavir', 'hydroxychloroquine\xa0+\xa0lopinavir/ritonavir\xa0+\xa0umifenovir', 'Umifenovir', 'hydroxychloroquine']","['mortality', 'Hazard Ratio for TTCI', 'Time to clinical improvement (TTCI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0202823', 'cui_str': 'CT of chest'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]","[{'cui': 'C0939237', 'cui_str': 'lopinavir and ritonavir'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0254211', 'cui_str': 'umifenovir'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",1180.0,0.136691,"The mortality was not statistically significant between the two groups (38% in controls vs 33.3% treatment group). ","[{'ForeName': 'Ilad', 'Initials': 'I', 'LastName': 'Alavi Darazam', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: ilad.alavi@sbmu.ac.ir.'}, {'ForeName': 'Shervin', 'Initials': 'S', 'LastName': 'Shokouhi', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Mardani', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohamad Amin', 'Initials': 'MA', 'LastName': 'Pourhoseingholi', 'Affiliation': 'Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Mahdi', 'Initials': 'MM', 'LastName': 'Rabiei', 'Affiliation': 'Clinical Research Development Unit of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Firouze', 'Initials': 'F', 'LastName': 'Hatami', 'Affiliation': 'Clinical Research Development Unit of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Minoosh', 'Initials': 'M', 'LastName': 'Shabani', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Moradi', 'Affiliation': 'Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Farid Javandoust', 'Initials': 'FJ', 'LastName': 'Gharehbagh', 'Affiliation': 'Clinical Research Development Unit of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seyed Sina Naghibi', 'Initials': 'SSN', 'LastName': 'Irvani', 'Affiliation': 'Clinical Research Development Unit of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Amirdosara', 'Affiliation': 'Anesthesiology Research Center Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Hajiesmaeili', 'Affiliation': 'Anesthesiology Research Center Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Omidvar', 'Initials': 'O', 'LastName': 'Rezaei', 'Affiliation': 'Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Khoshkar', 'Affiliation': 'Department of Surgery, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Legha', 'Initials': 'L', 'LastName': 'Lotfollahi', 'Affiliation': 'Department of Nephrology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Latif', 'Initials': 'L', 'LastName': 'Gachkar', 'Affiliation': 'Clinical Research Development Unit of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hadiseh Shabanpour', 'Initials': 'HS', 'LastName': 'Dehbsneh', 'Affiliation': 'Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Negar', 'Initials': 'N', 'LastName': 'Khalili', 'Affiliation': 'Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Azam', 'Initials': 'A', 'LastName': 'Soleymaninia', 'Affiliation': 'Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Akram Hoseyni', 'Initials': 'AH', 'LastName': 'Kusha', 'Affiliation': 'Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Maryam Taleb', 'Initials': 'MT', 'LastName': 'Shoushtari', 'Affiliation': 'Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Parham', 'Initials': 'P', 'LastName': 'Torabinavid', 'Affiliation': 'Clinical Research Development Unit of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",International immunopharmacology,['10.1016/j.intimp.2021.107969'] 1696,34274708,Predicting the physical activity of new parents who participated in a physical activity intervention.,"RATIONALE The demands of early parenthood may limit the pursuit of moderate-to-vigorous intensity physical activity (MVPA); thus, understanding the predictors of MVPA among this population could help build targeted intervention programs. OBJECTIVE The purpose of this study was to examine the correlates of MVPA, in the form of constructs subsumed within the theory of planned behavior (TPB) and multi-process action control (M-PAC) framework, among new parents participating in in a couple-based PA promotion randomized trial across a six-month period in the first year after birth. METHODS In total, 264 participants (132 couples) at the two-month point of parenting their first child were enrolled in the trial through advertisements. MVPA, TPB, and M-PAC constructs were assessed via self-report at baseline, and six-week, three-month, and six-month after baseline time-periods. RESULTS Dyadic path modeling of the TPB showed that intention only predicted MVPA for mothers and PBC did not predict MVPA. Most of the sample had intentions to be physically active, although the extent to which intentions predicted subsequent MVPA was dependent on mothers and fathers reported strength of planning, habits, and exercise identity (M-PAC variables). Intention was subsequently predicted by affective attitude and PBC for mothers and fathers. CONCLUSIONS Interventions targeting affective attitude and perceived behavioral control may assist in improving MVPA intentions of new parents; yet, additional intervention strategies to increase planning, habit, and especially exercise identity seems warranted for many parents to close the gap between intention and PA. The findings highlight the complementary approach of intention formation and intention translation theories among new parents.",2021,"Most of the sample had intentions to be physically active, although the extent to which intentions predicted subsequent MVPA was dependent on mothers and fathers reported strength of planning, habits, and exercise identity (M-PAC variables).","['new parents who participated in a physical activity intervention', '264 participants (132 couples) at the two-month point of parenting their first child were enrolled in the trial through advertisements', 'new parents participating in in a couple-based PA promotion']",['planned behavior (TPB) and multi-process action control (M-PAC) framework'],"['affective attitude and PBC', 'MVPA, TPB, and M-PAC constructs']","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0949214', 'cui_str': 'Advertisements'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}]","[{'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0008312', 'cui_str': 'Primary biliary cholangitis'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}]",264.0,0.0518314,"Most of the sample had intentions to be physically active, although the extent to which intentions predicted subsequent MVPA was dependent on mothers and fathers reported strength of planning, habits, and exercise identity (M-PAC variables).","[{'ForeName': 'Ryan E', 'Initials': 'RE', 'LastName': 'Rhodes', 'Affiliation': 'University of Victoria, School of Exercise Science, Physical and Health Education, Victoria, Canada. Electronic address: rhodes@uvic.ca.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Beauchamp', 'Affiliation': 'University of British Columbia, School of Kinesiology (Faculty of Education), Canada.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Quinlan', 'Affiliation': 'University of Victoria, School of Exercise Science, Physical and Health Education, Victoria, Canada.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Symons Downs', 'Affiliation': 'The Pennsylvania State University, Departments of Kinesiology and Obstetrics and Gynecology, University Park, USA.'}, {'ForeName': 'Darren E R', 'Initials': 'DER', 'LastName': 'Warburton', 'Affiliation': 'University of British Columbia, School of Kinesiology (Faculty of Education), Canada; Experimental Medicine Program (Faculty of Medicine), Vancouver, Canada.'}, {'ForeName': 'Chris M', 'Initials': 'CM', 'LastName': 'Blanchard', 'Affiliation': 'Dalhousie University, Faculty of Medicine, Halifax, Canada.'}]",Social science & medicine (1982),['10.1016/j.socscimed.2021.114221'] 1697,34274654,Identifying patients with malnutrition and improving use of nutrition interventions: A quality study in four US hospitals.,"OBJECTIVE This study investigated how specific nutrition interventions were implemented at four US hospitals, compared rates of malnutrition diagnosis and assessment between physicians and registered dietitian nutritionists (RDNs), and examined how these differences affected the nutrition intervention received during patients' hospital stay. METHODS Data on patients' nutrition status and nutrition interventions were collected from 16 669 hospital inpatient records. Data on intervention utilization for patients with differing nutrition assessments and diagnoses from different health care practitioners were compared using descriptive statistics and χ 2 tests. RESULTS The study found high levels of agreement between physician diagnosis and RDN assessment of malnutrition (88%). Much of this agreement related to patients identified as not malnourished. Of patients identified as malnourished by either physician diagnosis or RDN assessment, agreement was reached in 55.5% of patients. Less than half (46.3%) of patients identified as malnourished had a documented nutrition intervention. Oral nutritional supplements (ONS) were the most commonly used intervention, with 5.1% of patients receiving them. Patients identified as malnourished by physician diagnosis, but not by RDN assessment, were more likely to receive enteral and parenteral nutrition. Patients identified as malnourished by RDN assessment, but not by physician diagnosis, were more likely to have received ONS, meals and snacks, counseling, and food/nutrition-related medication management. CONCLUSION The high level of agreement on assessment and malnutrition diagnosis suggests positive levels of malnutrition care coordination at the study hospitals. However, significant room for improvement exists in providing interventions to inpatients diagnosed with malnourishment. Differences in interventions may reflect dissimilar approaches commonly used by different practitioners and should be a topic of future study.",2021,Less than half (46.3%) of patients identified as malnourished had a documented nutrition intervention.,"[""patients' nutrition status and nutrition interventions were collected from 16 669 hospital inpatient records"", 'patients with differing nutrition assessments and diagnoses from different health care practitioners']","['Oral nutritional supplements (ONS', 'nutrition interventions']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0239966', 'cui_str': 'Hospital patient'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0028708', 'cui_str': 'Assessment of nutritional status'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}]",[],,0.0133584,Less than half (46.3%) of patients identified as malnourished had a documented nutrition intervention.,"[{'ForeName': 'Sharen', 'Initials': 'S', 'LastName': 'Anghel', 'Affiliation': 'Overlook Medical Center, Atlantic Health System, Summit, New Jersey, United States.'}, {'ForeName': 'Kirk W', 'Initials': 'KW', 'LastName': 'Kerr', 'Affiliation': 'Abbott Nutrition, Columbus, Ohio, United States. Electronic address: kirk.kerr@abbott.com.'}, {'ForeName': 'Angel F', 'Initials': 'AF', 'LastName': 'Valladares', 'Affiliation': 'Avalere Health, Washington, DC, United States.'}, {'ForeName': 'Karl M', 'Initials': 'KM', 'LastName': 'Kilgore', 'Affiliation': 'Avalere Health, Washington, DC, United States.'}, {'ForeName': 'Suela', 'Initials': 'S', 'LastName': 'Sulo', 'Affiliation': 'Abbott Nutrition, Columbus, Ohio, United States.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2021.111360'] 1698,34278743,Type of exercise may influence postural adaptations in chemotherapy-induced peripheral neuropathy.,"OBJECTIVE Traditional posturography measurements characterize postural instability in patients with chemotherapy-induced peripheral neuropathy (CIPN), while underlying postural control mechanisms remain unclear. Taking a model-based approach can yield insights into these mechanisms. This study's aim was to characterize the modifications in postural control of CIPN patients associated with exercise in relation to the postural behavior of healthy control participants (hCON) via an exploratory approach. METHODS Thirty-one CIPN patients were randomly assigned to two interventions (balance plus moderate endurance training vs. moderate endurance training only) and exercised twice per week over 12 weeks. Baseline data were compared to 36 matched hCONs. We recorded spontaneous sway and postural reactions to platform tilts using Optotrak and a Kistler force platform pre- and post-intervention. Data interpretation relied on a model-based parameter identification procedure. RESULTS Spontaneous sway amplitudes were larger and postural reactions smaller, with a relative phase advance, in our pre-intervention patients than the hCONs. Post-intervention, spontaneous sway, and postural reactions were reduced and the sensory-motor ratio larger in both groups, while the postural reaction timing differed between groups. INTERPRETATION The abnormally small postural reactions in CIPN patients before the intervention can be interpreted as the consequence of abnormally strong velocity control-a strategy modification that may serve as a prediction mechanism to compensate for the lack of timely and accurate proprioceptive signals. While both groups reduced postural sway and showed an adapted sensory-motor ratio post-intervention, the interventions seemed to trigger different velocity control strategies. This study emphasizes the need for taking a more differentiated perspective on intervention effects. TRIAL REGISTRATION German Clinical Trials Register (DRKS) number: DRKS00005419, prospectively registered on November 19, 2013.",2021,"Post-intervention, spontaneous sway, and postural reactions were reduced and the sensory-motor ratio larger in both groups, while the postural reaction timing differed between groups. ","['chemotherapy-induced peripheral neuropathy', 'Thirty-one CIPN patients', 'healthy control participants (hCON) via an exploratory approach', 'patients with chemotherapy-induced peripheral neuropathy (CIPN']","['spontaneous sway and postural reactions to platform tilts using Optotrak and a Kistler force platform pre- and post-intervention', 'interventions (balance plus moderate endurance training vs. moderate endurance training only) and exercised twice per week over 12\xa0weeks']","['postural sway', 'spontaneous sway, and postural reactions', 'postural reaction timing', 'sensory-motor ratio larger']","[{'cui': 'C3873567', 'cui_str': 'Peripheral neuropathy due to and following chemotherapy'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0549177', 'cui_str': 'Large'}]",,0.0151781,"Post-intervention, spontaneous sway, and postural reactions were reduced and the sensory-motor ratio larger in both groups, while the postural reaction timing differed between groups. ","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Waibel', 'Affiliation': 'Department of Neurology and Neuroscience, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Wehrle', 'Affiliation': 'Department of Sport and Sport Science, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Müller', 'Affiliation': 'Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Bertz', 'Affiliation': 'Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Maurer', 'Affiliation': 'Department of Neurology and Neuroscience, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}]",Annals of clinical and translational neurology,['10.1002/acn3.51426'] 1699,34280356,"Efficacy of vitamin D supplementation among persons living with HIV/AIDS in São Paulo city, Brazil.","Hypovitaminosis D is now considered a pandemic, especially among more vulnerable populations and in HIV-infected subjects, with 80% presenting levels below 30 ng/mL. As there is no consensus on the more adequate dosage needed to correct such deficiency, the objective of this study was to evaluate 25 (OH) vitamin D supplementation in HIV-1 patients deficient of vitamin D. A total of 73 HIV-1-infected patients were included, drawn from a cohort of 435 patients; 37 patients were randomized to the active group, supplemented once a week with 50,000 UI vitamin D by mouth (group 1) and 36 to the placebo group (group 2). The study period ranged from June 2016 to September 2017. Variables involved in vitamin D metabolism and risk factors associated with hypovitaminosis were evaluated. The mean age was 45 years and 31.5 % were women. Vitamin D supplementation was effective in normalizing serum levels after six months in group 1 (mean 35 ng/mL compared to 21 ng/mL for the placebo group; p = 0.04). No patient reached blood levels considered toxic (>100 UI). Efavirenz use can negatively influence vitamin D levels and supplementation is necessary as a likely adjunct to improving CD4+ T cells, resulting in greater effectiveness of the treatment. A weekly oral dose of 50,000 IU of vitamin D was sufficient to normalize the vitamin deficiency, safely and with good adherence among persons living with HIV/AIDS in Brazil.",2021,Vitamin D supplementation was effective in normalizing serum levels after six months in group 1,"['HIV-infected subjects, with 80% presenting levels below 30', 'persons living with HIV/AIDS in São Paulo city, Brazil', 'The mean age was 45 years and 31.5 % were women', 'HIV-1 patients deficient of vitamin D. A total of 73 HIV-1-infected patients were included, drawn from a cohort of 435 patients; 37 patients', 'persons living with HIV/AIDS in Brazil']","['vitamin D supplementation', 'vitamin D', 'Efavirenz', 'Vitamin D supplementation', 'placebo']",['normalizing serum levels'],"[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0674428', 'cui_str': 'efavirenz'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",73.0,0.162934,Vitamin D supplementation was effective in normalizing serum levels after six months in group 1,"[{'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Almeida-Afonso', 'Affiliation': 'Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina, Departamento de Dermatologia, São Paulo, SP, Brazil; Centro de Referência em IST/AIDS, São Paulo, SP, Brazil.'}, {'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'Finamor', 'Affiliation': 'Centro de Referência em IST/AIDS, São Paulo, SP, Brazil.'}, {'ForeName': 'Luiz Augusto M', 'Initials': 'LAM', 'LastName': 'Fonseca', 'Affiliation': 'Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina, Departamento de Dermatologia, São Paulo, SP, Brazil.'}, {'ForeName': 'Ana P Rocha', 'Initials': 'APR', 'LastName': 'Veiga', 'Affiliation': 'Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina, Departamento de Dermatologia, São Paulo, SP, Brazil.'}, {'ForeName': 'Mariana A', 'Initials': 'MA', 'LastName': 'Monteiro', 'Affiliation': 'Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina, Departamento de Dermatologia, São Paulo, SP, Brazil.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Magri', 'Affiliation': 'Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina, Departamento de Dermatologia, São Paulo, SP, Brazil.'}, {'ForeName': 'Alberto Js', 'Initials': 'AJ', 'LastName': 'Duarte', 'Affiliation': 'Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina, Departamento de Dermatologia, São Paulo, SP, Brazil.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Casseb', 'Affiliation': 'Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina, Departamento de Dermatologia, São Paulo, SP, Brazil. Electronic address: jcasseb@usp.br.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,['10.1016/j.bjid.2021.101598'] 1700,34293510,The impact of modifying obsessive-compulsive beliefs about perfectionism.,"BACKGROUND AND OBJECTIVES Cognitive-behavioural models of obsessive-compulsive disorder (OCD) suggest that maladaptive beliefs about perfectionism play a key role in the development and maintenance of OCD. Cognitive-bias modification for interpretation bias (CBM-I) is an experimental procedure that can test this proposed causal relation. METHODS As such, the current study investigated whether multiple CBM-I sessions administered in different contexts can modify perfectionism biases. Undergraduate students high in OCD-related perfectionism beliefs were randomly allocated to either an experimental (n = 44) or control (n = 44) training condition and completed self-report and behavioural measures of perfectionism and OCD symptoms. RESULTS As predicted, relative to the control condition, participants in the experimental condition exhibited a significant decrease in perfectionism beliefs, from baseline to after one CBM-I training session, which was maintained at one-week follow-up. Contrary to hypotheses, there were no significant differences between conditions on measures of OCD symptoms and perfectionistic behaviour. LIMITATIONS Issues with the current study's behavioural measures may have precluded any differences between conditions. CONCLUSIONS Results underscore the need to further refine cognitive-behavioural models of OCD to understand the precise causal relation between beliefs and symptoms.",2021,"Contrary to hypotheses, there were no significant differences between conditions on measures of OCD symptoms and perfectionistic behaviour. ",['Undergraduate students high in OCD-related perfectionism beliefs'],['control (n\xa0=\xa044) training condition and completed self-report and behavioural measures of perfectionism and OCD symptoms'],"['OCD symptoms and perfectionistic behaviour', 'perfectionism beliefs']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",,0.0437969,"Contrary to hypotheses, there were no significant differences between conditions on measures of OCD symptoms and perfectionistic behaviour. ","[{'ForeName': 'Shiu F', 'Initials': 'SF', 'LastName': 'Wong', 'Affiliation': 'Department of Psychology, Concordia University, Canada. Electronic address: shiu.wong@concordia.ca.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Lim', 'Affiliation': 'School of Psychology, University of New South Wales, Australia.'}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Black', 'Affiliation': 'MRC Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom; Black Dog Institute, University of New South Wales, Australia.'}, {'ForeName': 'Jessica R', 'Initials': 'JR', 'LastName': 'Grisham', 'Affiliation': 'School of Psychology, University of New South Wales, Australia. Electronic address: jessicag@unsw.edu.au.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2021.101675'] 1701,34293461,Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance).,"BACKGROUND In colon cancer, tumor deposits (TD) are considered in assigning prognosis and staging only in the absence of lymph node metastasis (i.e., stage III pN1c tumors). We aimed at evaluating the prognostic value of the presence and the number of TD in patients with stage III, node-positive colon cancer. PATIENTS AND METHODS All participants from the CALGB/SWOG 80702 phase III trial were included in this post hoc analysis. Pathology reports were reviewed for the presence and the number of TD, lymphovascular and perineural invasion. Associations with disease-free survival (DFS) and overall survival (OS) were evaluated by multivariable Cox models adjusting for gender, treatment arm, T-stage, N-stage, lymphovascular invasion, perineural invasion and lymph node ratio. RESULTS Overall, 2028 patients were included, with 524 (26%) TD-positive and 1504 (74%) TD-negative tumors. Of the TD-positive patients, 80 (15.4%) were node negative (i.e., pN1c), 239 (46.1%) were pN1a/b (<4 positive lymph nodes) and 200 (38.6%) were pN2 (≥4 positive lymph nodes). The presence of TD was associated with poorer DFS (adjusted hazard ratio (aHR)= 1.63, 95%CI 1.33-1.98) and OS (aHR = 1.59, 95%CI 1.24-2.04). The negative effect of TD was observed for both pN1a/b and pN2 groups. Among TD-positive patients, the number of TD had a linear negative effect on DFS and OS. Combining TD and the number of lymph node metastases, 104 of 1470 (7.1%) pN1 patients were re-staged as pN2, with worse outcomes than patients confirmed as pN1 (3-year DFS rate: 80.5% versus 65.4%, P=.0003; 5-year OS rate: 87.9% versus 69.1%, P=<0.0001). DFS was not different between patients re-staged as pN2 and those initially staged as pN2 (3-year DFS rate: 62.3% versus 65.4%, P=.4895). CONCLUSIONS Combining the number of TD and the number of lymph node metastases improved the prognostication accuracy of TNM staging.",2021,"The presence of TD was associated with poorer DFS (adjusted hazard ratio (aHR)= 1.63, 95%CI 1.33-1.98) and OS (aHR = 1.59, 95%CI 1.24-2.04).","['All participants from the CALGB/SWOG 80702 phase III trial', '2028 patients were included, with 524 (26%) TD-positive and 1504 (74%) TD-negative tumors', 'patients with stage III, node-positive colon cancer', 'stage III colon cancer']",[],"['number of lymph node metastases', 'DFS and OS', 'disease-free survival (DFS) and overall survival (OS', 'DFS', '5-year OS rate']","[{'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C5197703', 'cui_str': 'Tumor Deposit'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0278480', 'cui_str': 'Carcinoma of colon, stage III'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0686619', 'cui_str': 'Secondary malignant neoplasm of lymph node'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",2028.0,0.161255,"The presence of TD was associated with poorer DFS (adjusted hazard ratio (aHR)= 1.63, 95%CI 1.33-1.98) and OS (aHR = 1.59, 95%CI 1.24-2.04).","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Cohen', 'Affiliation': 'Department of Health Science Research, Mayo Clinic, Rochester, MN, USA; Sorbonne Université, Department of Medical Oncology, Saint-Antoine Hospital, Paris, France; Sorbonne Université, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, F-75012 Paris, France. Electronic address: romain.cohen@aphp.fr.'}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Shi', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Meyers', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Jin', 'Affiliation': 'Division of Oncology, Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, MN, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Svrcek', 'Affiliation': 'Sorbonne Université, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, F-75012 Paris, France; Sorbonne Université, Department of Pathology, Saint-Antoine Hospital, Paris, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Fuchs', 'Affiliation': 'Genentech, South San Francisco, CA, USA; Division of Hematology and Medical Oncology, Department of Internal Medicine, Yale School of Medicine, and Yale Cancer Center, New Haven, CT, USA.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Couture', 'Affiliation': 'Hôtel-Dieu de Québec, Quebec, Canada.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Kuebler', 'Affiliation': 'Columbus NCI Community Clinical Oncology Research Program, Columbus, OH, USA.'}, {'ForeName': 'K K', 'Initials': 'KK', 'LastName': 'Ciombor', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bendell', 'Affiliation': 'Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'De Jesus-Acosta', 'Affiliation': 'John Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Kumar', 'Affiliation': 'Illinois Cancercare, P.C., Peoria, IL, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Lewis', 'Affiliation': 'Southeast Clinical Oncology Research, Cone Health Medical Group, Asheboro, NC, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Tan', 'Affiliation': 'Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Bertagnolli', 'Affiliation': ""Office of the Alliance Group Chair, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Philip', 'Affiliation': 'Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Blanke', 'Affiliation': ""SWOG Cancer Research Network Group Chair's Office, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA.""}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical Center, New York, NY, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Shields', 'Affiliation': 'Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Meyerhardt', 'Affiliation': 'Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, MA, USA.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.07.009'] 1702,34293413,"Multicomponent exercise to improve motor functions, cognition and well-being for nursing home residents who are unable to walk - A randomized controlled trial.","BACKGROUND Older nursing home residents are often characterized by multimorbidity and dependency in activities of daily living. Most exercise studies in this setting aim at residents who are still able to walk despite the huge group of residents that is unable to walk. Thus, little is known about the effectiveness to improve cognitive and motor functions as well as well-being within this target group, e.g., by use of chair-based exercises. The aim of this study was to determine the effects of a 16-week multicomponent chair-based exercise intervention on motor functions, cognition and well-being for nursing home residents who are unable to walk. METHODS A two-arm single-blinded multicenter randomized controlled trial integrated N = 52 nursing home residents with a mean age of 81 ± 11 years (63% female), randomly assigned to a training (n = 26, 16 weeks; twice a week; 60 min) or a wait-list control group (n = 26). The intervention followed the F.I.T.T. principles (frequency, intensity, time and type) and was continuously adapted to residents' performance level. The outcomes motor function (hand grip strength, sitting balance, manual dexterity), cognitive performance (cognitive status, working memory) and psychosocial resources (physical and mental well-being (SF12), satisfaction with life (SWLS), depressive symptoms (CES-D)) were assessed at baseline (pre-test) and after 16-weeks (post-treatment). Statistics were performed using ANOVA for repeated measures. RESULTS The results of the ANOVA showed significant improvements of the intervention group for hand grip strength (Pre: M = 12.67, SD = 5.28; Post: M = 13.86, SD = 4.79; Group × Time: F(1, 17) = 10.816, p = .002, η p 2 = 0.241), manual dexterity (Pre: M = 4.50, SD = 5.17; Post: M = 5.30, SD = 4.25; Group × Time: F(1, 7) = 9.193, p = .008, η p 2 = 0.365), cognition (Pre: M = 10.31, SD = 6.87; Post: M = 11.06, SD = 7.50; Group × Time: F(1, 15) = 12.687, p = .001, η p 2 = 0.284), and depression (Pre: M = 5.19, SD = 5.12; Post: M = 4.38, SD = 4.62; Group × Time: F(1, 14) = 5.135, p = .031, η p 2 = 0.150) while the values of the control group decreased. CONCLUSION The multicomponent chair-based intervention over 16 weeks was able to improve motor functions and cognition in nursing home residents who are unable to walk. Other psychological factors remained stable within the intervention group, which can be interpreted as a good result for this target group. All of the investigated parameters showed a significant decrease in the control group. The intervention seemed to cause physiological adaptations even in very old age. Study results encourage to further differentiate the heterogeneous group of nursing home residents concerning mobility aspects and to include chair-based interventions as feasible program to prevent further decline of functional performance and maintain independence in activities of daily living for a better physical and mental well-being.",2021,The multicomponent chair-based intervention over 16 weeks was able to improve motor functions and cognition in nursing home residents who are unable to walk.,"['Older nursing home residents', 'nursing home residents who are unable to walk', 'N\u202f=\u202f52 nursing home residents with a mean age of 81\u202f±\u202f11\u202fyears (63% female']","['Multicomponent exercise', 'multicomponent chair-based exercise intervention']","['manual dexterity', 'hand grip strength', 'motor functions, cognition and well-being', 'outcomes motor function (hand grip strength, sitting balance, manual dexterity), cognitive performance (cognitive status, working memory) and psychosocial resources (physical and mental well-being (SF12), satisfaction with life (SWLS), depressive symptoms (CES-D', 'depression (Pre']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0560046', 'cui_str': 'Unable to walk'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities'}, {'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0516712', 'cui_str': 'Balancing when sitting'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]",,0.0206986,The multicomponent chair-based intervention over 16 weeks was able to improve motor functions and cognition in nursing home residents who are unable to walk.,"[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Cordes', 'Affiliation': 'Institute of Human Movement Science, University of Hamburg, Mollerstr, 10, 20148 Hamburg, Germany. Electronic address: thomas.cordes@uni-hamburg.de.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Zwingmann', 'Affiliation': 'Institute of Human Movement Science and Health, Chemnitz University of Technology, 09126 Chemnitz, Germany. Electronic address: katharina.zwingmann@hsw.tu-chemnitz.de.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Rudisch', 'Affiliation': 'Department of Neuromotor Behavior and Exercise, Institute of Sport and Exercise Sciences, University of Muenster, Horstmarer Landweg 62 b, 48149 Muenster, Germany. Electronic address: julian.rudisch@uni-muenster.de.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Voelcker-Rehage', 'Affiliation': 'Institute of Human Movement Science and Health, Chemnitz University of Technology, 09126 Chemnitz, Germany; Department of Neuromotor Behavior and Exercise, Institute of Sport and Exercise Sciences, University of Muenster, Horstmarer Landweg 62 b, 48149 Muenster, Germany. Electronic address: claudia.voelcker-rehage@uni-muenster.de.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Wollesen', 'Affiliation': 'Institute of Human Movement Science, University of Hamburg, Mollerstr, 10, 20148 Hamburg, Germany; Biological Psychology and Neuroergonomics, TU Berlin, Fasanenstr. 1, 10623 Berlin, Germany. Electronic address: bettina.wollesen@uni-hamburg.de.'}]",Experimental gerontology,['10.1016/j.exger.2021.111484'] 1703,34298028,Effectiveness of financial incentives and message framing to improve clinic visits of people with moderate-high cardiovascular risk in a vulnerable population in Argentina: A cluster randomized trial.,"In Argentina, cardiovascular disease (CVD) represents the first cause of mortality, but effective coverage for CVD prevention is low. Strategies based on behavioral economics are emerging worldwide as key pieces to increase the effectiveness of CVD prevention approaches. The aim of this study was to evaluate whether the implementation of two strategies based on financial incentives and framing increased attendance to clinical visits as proposed by the national program for CVD risk factors management among the uninsured and poor population with moderate or high CVD risk in Argentina. We conducted a cluster randomized trial in nine primary care clinics (PCCs) in Argentina. Three PCCs were assigned to financial incentives, 3 to framing-text messages (SMS) and 3 to usual care. The incentive scheme included a direct incentive for attending the first clinical visit and the opportunity to participate in a lottery when attending a second clinical visit. The framing-text messages group received messages with a gain-frame format. The main outcome was the proportion of participants who attended the clinical visits. A total of 918 individuals with a risk ≥10% of suffering a CVD event within the next 10 years were recruited to participate in the study. The financial incentive group had a significantly higher percentage of participants who attended the first (59.0% vs 33.9%, p˂ 0.001) and the follow up visit (34.4% and 16.6%, p˂ 0.001) compared to control group. However, the framing-SMS group did not show significant differences compared to the control group. TRIAL REGISTRATION: This study is registered at www.clinicaltrials.govNCT03300154.",2021,"The financial incentive group had a significantly higher percentage of participants who attended the first (59.0% vs 33.9%, p˂ 0.001) and the follow up visit (34.4% and 16.6%, p˂ 0.001) compared to control group.","['uninsured and poor population with moderate or high CVD risk in Argentina', 'people with moderate-high cardiovascular risk in a vulnerable population in Argentina', '918 individuals with a risk ≥10% of suffering a CVD event within the next 10\u202fyears were recruited to participate in the study', 'nine primary care clinics (PCCs) in Argentina']",['financial incentives and message framing'],[],"[{'cui': 'C0087134', 'cui_str': 'Uninsured'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0003761', 'cui_str': 'Argentina'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0949366', 'cui_str': 'Vulnerable Populations'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}]","[{'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}]",[],918.0,0.0537735,"The financial incentive group had a significantly higher percentage of participants who attended the first (59.0% vs 33.9%, p˂ 0.001) and the follow up visit (34.4% and 16.6%, p˂ 0.001) compared to control group.","[{'ForeName': 'Rosana', 'Initials': 'R', 'LastName': 'Poggio', 'Affiliation': 'Department of Research in Chronic Diseases, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina. Electronic address: rpoggio@iecs.org.ar.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Prado', 'Affiliation': 'Department of Research in Chronic Diseases, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.'}, {'ForeName': 'Marilina', 'Initials': 'M', 'LastName': 'Santero', 'Affiliation': 'Department of Research in Chronic Diseases, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.'}, {'ForeName': 'Analía', 'Initials': 'A', 'LastName': 'Nejamis', 'Affiliation': 'Department of Research in Chronic Diseases, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Gutierrez', 'Affiliation': 'Department of Research in Chronic Diseases, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.'}, {'ForeName': 'Vilma', 'Initials': 'V', 'LastName': 'Irazola', 'Affiliation': 'Department of Research in Chronic Diseases, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.'}]",Preventive medicine,['10.1016/j.ypmed.2021.106738'] 1704,34271271,Transcutaneous electrical acupoint stimulation before surgery reduces chronic pain after mastectomy: A randomized clinical trial.,"STUDY OBJECTIVE Despite multiple interventions, the incidence of chronic pain after mastectomy could be as high as 50% after surgery. This study aimed to determine the efficacy of transcutaneous electrical acupoint stimulation (TEAS) before anesthesia induction in reducing chronic pain and to compare the effect of combined acupoint TEAS with that of single acupoint TEAS. DESIGN A multicenter randomized clinical trial. SETTING The study was conducted at six medical centers in China from May 2016 to April 2018. Final follow-up was on October 26, 2018. PARTICIPANTS Eligible patients were women scheduled for radical mastectomy under general anesthesia. INTERVENTIONS Patients were randomly and equally grouped into sham control (n = 188), single acupoint (PC6, n = 198), or combined acupoints (PC6 and CV17, n = 190) TEAS groups using a centralized computer-generated randomization system. TEAS was applied for 30 min before anesthesia induction. The sham-operated control group received electrode attachment but without stimulation. Anesthesiologists, surgeons, and outcome assessors were blinded to the interventions. MEASURES The primary endpoint was the incidence of chronic pain 6 months after surgery. Incidences were compared among the groups using the unadjusted χ 2 test. RESULTS Of the 576 randomized patients, 568 completed the trial. In the intention-to-treat analysis, post-mastectomy pain at 6 months was reported in 42 of 190 patients (22.1%) in the combined acupoints group, 65 of 188 patients (34.6%) in the sham-operated group (P = 0.007; relative risk [RR], 95% confidence interval [CI]: 0.68, 0.52-0.89), and 72 of 198 patients (36.4%) in the single acupoint group (P = 0.002; RR, 95% CI: 0.72, 0.55-0.93). Remifentanil consumption during surgery and postoperative nausea and vomiting at 24 h after surgery were lower in the combined acupoint group than that in the sham-operated group. CONCLUSION TEAS at combined acupoints before surgery was associated with reduced chronic pain 6 months after surgery. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT02741726. Registered on April 13, 2016.",2021,"Remifentanil consumption during surgery and postoperative nausea and vomiting at 24 h after surgery were lower in the combined acupoint group than that in the sham-operated group. ","['Eligible patients were women scheduled for radical mastectomy under general anesthesia', 'six medical centers in China from May 2016 to April 2018', '576 randomized patients', 'after mastectomy']","['Remifentanil', 'single acupoint (PC6, n\xa0=\xa0198), or combined acupoints (PC6 and CV17, n\xa0', 'sham-operated control group received electrode attachment but without stimulation', 'Transcutaneous electrical acupoint stimulation', 'combined acupoint TEAS', 'transcutaneous electrical acupoint stimulation (TEAS', 'centralized computer-generated randomization system', 'TEAS']","['incidence of chronic pain', 'chronic pain', 'postoperative nausea and vomiting']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0024884', 'cui_str': 'Radical mastectomy'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}]","[{'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0135624', 'cui_str': 'PC6 extract'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0450826', 'cui_str': 'CV17'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013812', 'cui_str': 'Electrode'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}]",576.0,0.675221,"Remifentanil consumption during surgery and postoperative nausea and vomiting at 24 h after surgery were lower in the combined acupoint group than that in the sham-operated group. ","[{'ForeName': 'Zhihong', 'Initials': 'Z', 'LastName': 'Lu', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China. Electronic address: deerlu23@163.com.""}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.""}, {'ForeName': 'Xude', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': ""Department of Anesthesiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China.'}, {'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Min', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Jiaqiang', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China.""}, {'ForeName': 'Weixian', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital of Guangdong University of Traditional Chinese Medicine, Guangzhou, Guangdong 510120, China.'}, {'ForeName': 'Jianfeng', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.""}, {'ForeName': 'Yonghui', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.""}, {'ForeName': 'Yaomin', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.""}, {'ForeName': 'Lanlan', 'Initials': 'L', 'LastName': 'Zheng', 'Affiliation': ""Department of Anesthesiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, China.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Liyuan', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China.""}, {'ForeName': 'Lini', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.""}, {'ForeName': 'Chong', 'Initials': 'C', 'LastName': 'Lei', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.""}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.""}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.""}, {'ForeName': 'Junbao', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.""}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': ""Department of Medical Statistics, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.""}, {'ForeName': 'Nian', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, China.""}, {'ForeName': 'Hailong', 'Initials': 'H', 'LastName': 'Dong', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.""}, {'ForeName': 'Lize', 'Initials': 'L', 'LastName': 'Xiong', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China; Department of Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence， Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China. Electronic address: lizexiong@tongji.edu.cn.""}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110453'] 1705,34271265,The effectiveness of a nurse-led home-based heart failure self-management programme (the HOM-HEMP) for patients with chronic heart failure: A three-arm stratified randomized controlled trial.,"BACKGROUND Although important, heart failure self-care remains a challenge for many patients. This study aimed to evaluate the effect of a nurse-led, home-based self-management psychosocial education intervention (HOM-HEMP). The primary outcome was patient's HF self-care in terms of maintenance, management and confidence. The secondary outcomes were cardiac self-efficacy, psychological wellbeing in terms of perceived social support, health related quality of life and levels of anxiety and depression. The clinical outcomes included New York Heart Association (NYHA) functional class and numbers of unplanned health service visits due to cardiac-related reasons. DESIGN A three-arm stratified randomized controlled trial was conducted (Clinical trial registration number: NCT03108235). METHODS A total of 213 participants admitted for heart failure were recruited from the inpatient wards of a tertiary public hospital in Singapore. They were randomly allocated to the control group, the experimental group A or the experimental group B. All participants received the usual care provided by the hospital. Participants in experimental groups A and B received the HOM-HEMP intervention, and those in experimental group B received an additional supplemental smartphone application. Data were collected at baseline, 6 weeks, 3 months and 6 months from baseline. RESULTS Compared to the control groups, participants in either of the experimental group had significantly higher levels of heart failure self-care maintenance (F = 4.222, p = 0.001), self-care confidence (F = 5.796, p < 0.001) and self-care management (p < 0.05) at 6-week, 3-month and 6-month follow-ups. In addition, both experimental groups had significantly higher levels of cardiac self-efficacy, better health related quality of life and lower depression levels than the control group after the study intervention. A higher proportion of participants in both experimental groups had a better New York Heart Association functional class at 6-week and 3-month follow-ups. Participants in the experimental group B also had significantly fewer cardiac-related unplanned hospital admissions and emergency room visits than the control group at 6-month follow-up. Results on perceived social support were not significant. The study outcomes in experimental group A and B were not significantly different at any of the post intervention follow-up. CONCLUSION The findings suggested that HOM-HEMP is an effective intervention for patients with heart failure in Singapore.",2021,"Compared to the control groups, participants in either of the experimental group had significantly higher levels of heart failure self-care maintenance (F = 4.222, p = 0.001), self-care confidence (F = 5.796, p < 0.001) and self-care management (p < 0.05) at 6-week, 3-month and 6-month follow-ups.","['patients with chronic heart failure', 'patients with heart failure in Singapore', '213 participants admitted for heart failure were recruited from the inpatient wards of a tertiary public hospital in Singapore']","['nurse-led, home-based self-management psychosocial education intervention (HOM-HEMP', 'HOM-HEMP', 'nurse-led home-based heart failure self-management programme (the HOM-HEMP', 'HOM-HEMP intervention']","['levels of heart failure self-care maintenance', 'New York Heart Association (NYHA) functional class and numbers of unplanned health service visits due to cardiac-related reasons', 'self-care confidence', 'cardiac self-efficacy, psychological wellbeing in terms of perceived social support, health related quality of life and levels of anxiety and depression', 'cardiac-related unplanned hospital admissions and emergency room visits', 'New York Heart Association functional class', 'cardiac self-efficacy, better health related quality of life and lower depression levels', 'self-care management', ""patient's HF self-care in terms of maintenance, management and confidence""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0020022', 'cui_str': 'Public Hospitals'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0162335', 'cui_str': 'HEMP'}, {'cui': 'C0225810', 'cui_str': 'Structure of base of heart'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",213.0,0.0737964,"Compared to the control groups, participants in either of the experimental group had significantly higher levels of heart failure self-care maintenance (F = 4.222, p = 0.001), self-care confidence (F = 5.796, p < 0.001) and self-care management (p < 0.05) at 6-week, 3-month and 6-month follow-ups.","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Level 2, Clinical Research Centre, Block MD, 11,10 Medical Drive 117597, Singapore. Electronic address: nurjiy@nus.edu.sg.'}, {'ForeName': 'Karen Wei Ling', 'Initials': 'KWL', 'LastName': 'Koh', 'Affiliation': 'National University Heart Centre Singapore, National University Hospital, Singapore. Electronic address: karen_wl_koh@nuhs.edu.sg.'}, {'ForeName': 'Hadassah Joann', 'Initials': 'HJ', 'LastName': 'Ramachandran', 'Affiliation': 'Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Level 2, Clinical Research Centre, Block MD, 11,10 Medical Drive 117597, Singapore. Electronic address: hadassah.joann.ramachandran@u.nus.edu.'}, {'ForeName': 'Hoang D', 'Initials': 'HD', 'LastName': 'Nguyen', 'Affiliation': 'School of Computing Science, University of Glasgow, Singapore. Electronic address: Harry.Nguyen@glasgow.ac.uk.'}, {'ForeName': 'Der Shin', 'Initials': 'S', 'LastName': 'Lim', 'Affiliation': 'Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Level 2, Clinical Research Centre, Block MD, 11,10 Medical Drive 117597, Singapore. Electronic address: nurlds@nus.edu.sg.'}, {'ForeName': 'Yee Kian', 'Initials': 'YK', 'LastName': 'Tay', 'Affiliation': 'Regional Health System, National University Health System, Singapore. Electronic address: Yee_Kian_TAY@nuhs.edu.sg.'}, {'ForeName': 'Shefaly', 'Initials': 'S', 'LastName': 'Shorey', 'Affiliation': 'Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Level 2, Clinical Research Centre, Block MD, 11,10 Medical Drive 117597, Singapore. Electronic address: nurssh@nus.edu.sg.'}, {'ForeName': 'Wenru', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Level 2, Clinical Research Centre, Block MD, 11,10 Medical Drive 117597, Singapore. Electronic address: nurww@nus.edu.sg.'}]",International journal of nursing studies,['10.1016/j.ijnurstu.2021.104026'] 1706,34271197,"The Effect of Psychosexual Education on Promoting Sexual Function, Genital Self-Image, and Sexual Distress among Women with Rokitansky Syndrome: A Randomized Controlled Clinical Trial.","STUDY OBJECTIVE To assess the effectiveness of psychosexual education on promoting sexual function and genital self-image and reducing sexual distress through e-learning among women with Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome. DESIGN Randomized controlled trial. SETTING Imam Khomeini Hospital ""Pelvic Floor Clinic"" in Tehran. PARTICIPANTS Thirty-eight 15- to 49-year-old women with MRKH syndrome who had undergone surgical or nonsurgical vaginal reconstruction techniques more than 6 months before the intervention were assigned to 2 parallel intervention and control groups of 19 each. INTERVENTIONS Psychosexual education was delivered through e-learning for the intervention group over an 8-week period, with no limitations of time and space. Sexual function, genital self-image, and sexual distress were evaluated at baseline, and at 4 and 8 weeks after the intervention. MAIN OUTCOME MEASURES The data collection tools included the Persian version of the Female Sexual Function Index, Female Genital Self-Image Scale, and the Revised Female Sexual Distress Scale. RESULTS The between group mean differences of sexual function, genital self-image, and sexual distress after 4 weeks (-1.2 [95% CI, -2.1 to -0.1], P = .025; -1.9 [95% CI, -2.9 to -0.9], P < .001; 4.2 [95% CI, 2.0-6.4], P < .001, respectively), as well as after 8 weeks (-1.8 [95% CI, -3.1 to -0.5], P = .009; -3.0 [95% CI, -4.5 to -1.5], P < .001; 6.7, 95% CI, 3.9-9.6], P <0.001, respectively) after baseline were significant. CONCLUSION Psychosexual education improved sexual function and genital self-image and reduced sexual distress in women with MRKH syndrome. Therefore, using this approach, we can raise individuals' sexual knowledge and skills and correct their sexual beliefs and attitudes.",2021,"Sexual function, genital self-image, and sexual distress were evaluated at baseline, 4 and 8 weeks after the intervention. ","['Women with Rokitansky Syndrome', ""Imam Khomeini Hospital's 'Pelvic Floor Clinic' in Tehran PARTICIPANTS"", 'Thirty-eight 15-49-year-old women with MRKH syndrome who had undergone surgical or non-surgical vaginal reconstruction techniques more than 6 months prior to the intervention', 'women with MRKH syndrome']","['Psychosexual Education', 'psychosexual education', 'Psychosexual education']","['sexual function & genital self-image and reduced sexual distress', 'sexual function & genital self-image and reducing sexual distress', 'Sexual function, genital self-image, and sexual distress', 'Persian version of the Female Sexual Function Index (FSFI), Female Genital Self-Image Scale (FGSIS), and the Revised Female Sexual Distress Scale (FSDS-R', 'Sexual Function, Genital Self-Image, and Sexual Distress', 'sexual function, genital self-image and sexual distress']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0521321', 'cui_str': 'Imam'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C3839594', 'cui_str': 'Pelvic floor clinic'}, {'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1698581', 'cui_str': 'Mayer-Rokitansky-Kuster-Hauser syndrome'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0195196', 'cui_str': 'Reconstruction of vagina'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C0242498', 'cui_str': 'Self-image'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0031188', 'cui_str': 'Persian language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0278098', 'cui_str': 'Female sexual function'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017421', 'cui_str': 'Female genital'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",,0.043187,"Sexual function, genital self-image, and sexual distress were evaluated at baseline, 4 and 8 weeks after the intervention. ","[{'ForeName': 'Nafiseh', 'Initials': 'N', 'LastName': 'Vosoughi', 'Affiliation': 'Department of Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Raziyeh', 'Initials': 'R', 'LastName': 'Maasoumi', 'Affiliation': 'Department of Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran; Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: r_masoumi@sina.tums.ac.ir.'}, {'ForeName': 'Ali Asghar', 'Initials': 'AA', 'LastName': 'Haeri Mehrizi', 'Affiliation': 'Health Metrics Research Center, Iranian Institute for Health Sciences Research, ACECR, Tehran, Iran.'}, {'ForeName': 'Zinat', 'Initials': 'Z', 'LastName': 'Ghanbari', 'Affiliation': 'Department of Obstetrics and Gynecology, Vali-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}]",Journal of pediatric and adolescent gynecology,['10.1016/j.jpag.2021.06.008'] 1707,34273551,"Bilingual problem-solving training for caregivers of adults with dementia: A randomized, factorial-design protocol for the CaDeS trial.","OBJECTIVE Caregivers of individuals with Alzheimer's disease and related dementias (ADRD) often experience debilitating caregiver burden and emotional distress. To address these negative emotional consequences of caregiving, we will test and refine a strategy training intervention - Problem-Solving Training (PST) - that promotes self-efficacy and reduces caregiver burden and depressive symptoms. Previous research supports efficacy of PST; however, we do not know exactly how many PST sessions are needed or if post-training ""boosters"" are required to maintain PST benefits. Additionally, we translated and culturally-adapted PST into ""Descubriendo Soluciones Juntos"" (DSJ), our novel intervention for Spanish-speaking caregivers. METHOD In this 2 × 2 factorial design randomized controlled trial, we will test remotely-delivered PST/DSJ sessions for both English- and Spanish-speaking caregivers of persons with ADRD to determine the optimal number of PST/DSJ sessions and ongoing ""booster"" sessions needed to best help caregivers navigate their current and future needs. AIMS 1) Compare the efficacy of three vs. six PST/DSJ sessions each with and without booster sessions for decreasing caregiver burden and depression and enhancing caregiver problem-solving; 2) Identify key factors associated with efficacy of PST/DSJ, including age, gender, primary language, relationship to care recipient, and uptake of the PST/DSJ strategy. RESULTS These results will establish guidelines needed for an evidence-based, culturally-adapted, and implementable problem-solving intervention to reduce caregiver stress and burden and improve caregiver health and well-being. CONCLUSION This work promotes inclusion of diverse and underserved populations and advances therapeutic behavioral interventions that improve the lives of caregivers of individuals with chronic conditions.",2021,"These results will establish guidelines needed for an evidence-based, culturally-adapted, and implementable problem-solving intervention to reduce caregiver stress and burden and improve caregiver health and well-being. ","[""Caregivers of individuals with Alzheimer's disease and related dementias (ADRD) often experience debilitating caregiver burden and emotional distress"", 'for both English- and Spanish-speaking caregivers of persons with AD/ADRD', 'caregivers of adults with dementia', 'caregivers of individuals with chronic conditions']","['PST', 'Bilingual problem-solving training', 'PST/DSJ sessions']",[],"[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0543432', 'cui_str': 'Problem solving training'}]",[],,0.101849,"These results will establish guidelines needed for an evidence-based, culturally-adapted, and implementable problem-solving intervention to reduce caregiver stress and burden and improve caregiver health and well-being. ","[{'ForeName': 'ShannonB', 'Initials': 'S', 'LastName': 'Juengst', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States of America; Department of Applied Clinical Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States of America. Electronic address: Shannon.Juengst@UTSouthwestern.edu.'}, {'ForeName': 'Charlene', 'Initials': 'C', 'LastName': 'Supnet', 'Affiliation': 'Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States of America.'}, {'ForeName': 'Chung Lin Novelle', 'Initials': 'CLN', 'LastName': 'Kew', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States of America; Department of Applied Clinical Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States of America.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Silva', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States of America.'}, {'ForeName': 'Marlene', 'Initials': 'M', 'LastName': 'Vega', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States of America; Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States of America.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Han', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Texas A&M University, 212 Adriance Lab Road, College Station, TX 77843, United States of America; Center for Population Health and Aging, Texas A&M University, 212 Adriance Lab Road, College Station, TX 77843, United States of America.'}, {'ForeName': 'Brendan', 'Initials': 'B', 'LastName': 'Kelley', 'Affiliation': 'Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States of America.'}, {'ForeName': 'Matthew Lee', 'Initials': 'ML', 'LastName': 'Smith', 'Affiliation': 'Center for Population Health and Aging, Texas A&M University, 212 Adriance Lab Road, College Station, TX 77843, United States of America; Department of Environmental and Occupational Health, School of Public Health, Texas A&M University, 212 Adriance Lab Road, College Station, TX 77843, United States of America.'}, {'ForeName': 'Gladys', 'Initials': 'G', 'LastName': 'Maestre', 'Affiliation': 'School of Medicine, University of Texas Rio Grande Valley, One West University Boulevard, Brownsville, TX 78520, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106506'] 1708,34273498,Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial.,"OBJECTIVE To determine the efficacy and safety of add-on dry powder for inhalation (DPI) of combined anti-TB agents prepared as a particulate system (study group) compared with placebo DPI (control group) in patients diagnosed with pulmonary TB. METHODS This study was a randomized, placebo-controlled, double-blinded parallel design. Subjects were pulmonary TB patients, new or re-treatment, aged 18 years or older. The eligible patients were randomly allocated (1:1) to either the study group or the control group using stratified blocked randomization. The add-on DPI of combined anti-TB therapy (each capsule contained isoniazid 5 mg, rifampicin 2 mg, pyrazinamide 16 mg, and levofloxacin 2 mg) was used throughout the course of the standard oral anti-TB treatment. The primary outcome was Mycobacterium tuberculosis (MTB) sputum culture conversion measured after receiving treatment for eight weeks. Secondary outcomes were clinical signs and symptoms of pulmonary TB and adverse drug reactions (ADRs) related to anti-TB agents. The percentages of patients who achieved the primary outcome were compared (95% confidence interval). All analyses were performed using the modified intention-to-treat principle. RESULTS 91 patients were randomly allocated: 44 to the study group and 47 to the control group. Important baseline data (%peak expiratory flow rate, chest X-ray findings, resistance to anti-TB agents, renal and liver function tests) were similar between the two groups. Although the percentages of patients who achieved the primary outcome were similar in both groups (34/44 [77.3%] in the study group and (34/47 [72.3%] in the control group; relative risk [RR] 1.07, 95% CI 0.84-1.36; p = 0.589), the study group patients seemed to achieve the primary outcome earlier than the control group (22/44 [50.0%] vs 15/47 [31.9%]; RR 1.57, 95% CI 0.94-2.61; p = 0.079) at the end of week 4. Cough was significantly lower in the study group than in the control group (23/44 [52.3%] vs 43/47 [91.5%]; RR 0.57, 95% CI 0.43-0.77; p < 0.001) at week 4 of treatment. Hemoptysis was found in approximately half of each group at baseline. The percentage of patients having hemoptysis was substantially reduced at week 2 of treatment (5 [11.4%] in the study group and 11 [23.0%] in the control group, p = 0.132). Regarding safety outcomes, no dyspnea or severe ADRs were reported. Adverse events (AEs) related to oral anti-TB agents, (e.g. liver function tests) were in normal ranges in most patients in both groups during the treatment. The incidences of common AEs reported (e.g. anorexia, dizziness, numbness, arthralgia, rash, and itching) were similar between the two groups, while the incidences of nausea and vomiting were significantly lower in the study group than the control group (38.6% vs 74.5%, p = 0.001, and 43.2% vs 66.0%, p = 0.029, respectively). CONCLUSIONS Add-on combined anti-TB DPI therapy to the standard oral anti-TB treatment did not increase MTB sputum culture conversion at two months of treatment. However, the percentage of patients having cough in the study group was significantly lower than in the control group at two months after treatment. A reduction in cough might represent adequate response to treatment, and result in a decreased risk of spread of infection. Combined anti-TB DPI therapy was safe. Further study investigated in a larger sample using higher strengths of DPI therapy is required.",2021,"Cough was significantly lower in the study group than in the control group (23/44 [52.3%] vs 43/47 [91.5%]; RR 0.57, 95% CI 0.43-0.77; p < 0.001) at week 4 of treatment.","['91 patients were randomly allocated: 44 to the study group and 47 to the control group', 'Pulmonary Tuberculosis', 'patients diagnosed with pulmonary TB', 'Subjects were pulmonary TB patients, new or re-treatment, aged 18 years or older']","['isoniazid 5 mg, rifampicin 2 mg, pyrazinamide 16 mg, and levofloxacin', 'Combined anti-TB DPI therapy', 'Combined Isoniazid-Rifampicin-Pyrazinamide-Levofloxacin Dry Powder Inhaler', 'placebo DPI (control group', 'placebo']","['efficacy and safety', 'Efficacy and Safety', 'nausea and vomiting', 'Mycobacterium tuberculosis (MTB) sputum culture conversion', 'peak expiratory flow rate, chest X-ray findings, resistance to anti-TB agents, renal and liver function tests', 'anorexia, dizziness, numbness, arthralgia, rash, and itching', 'percentage of patients having hemoptysis', 'Cough', 'MTB sputum culture conversion', 'Adverse events (AEs) related to oral anti-TB agents, (e.g. liver function tests', 'Hemoptysis', 'percentage of patients having cough', 'clinical signs and symptoms of pulmonary TB and adverse drug reactions (ADRs) related to anti-TB agents', 'safety outcomes, no dyspnea or severe ADRs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0041327', 'cui_str': 'Pulmonary tuberculosis'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0022209', 'cui_str': 'isoniazid'}, {'cui': 'C0035608', 'cui_str': 'Rifampin'}, {'cui': 'C0034239', 'cui_str': 'Pyrazinamide'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0991575', 'cui_str': 'Powder for inhalation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1967611', 'cui_str': 'Dry powder inhaler'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0026926', 'cui_str': 'Mycobacterium tuberculosis'}, {'cui': 'C0523174', 'cui_str': 'Microbial culture of sputum'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0030735', 'cui_str': 'Peak expiratory flow rate'}, {'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0003448', 'cui_str': 'Antituberculosis agent'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0023901', 'cui_str': 'Hepatic function panel'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0020580', 'cui_str': 'Hypesthesia'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0019079', 'cui_str': 'Hemoptysis'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0041327', 'cui_str': 'Pulmonary tuberculosis'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",91.0,0.232215,"Cough was significantly lower in the study group than in the control group (23/44 [52.3%] vs 43/47 [91.5%]; RR 0.57, 95% CI 0.43-0.77; p < 0.001) at week 4 of treatment.","[{'ForeName': 'Nisa', 'Initials': 'N', 'LastName': 'Laohapojanart', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, 90112, Thailand. Electronic address: nisa.l@chulahospital.org.'}, {'ForeName': 'Chaveewan', 'Initials': 'C', 'LastName': 'Ratanajamit', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, 90112, Thailand. Electronic address: chaveewan.r@psu.ac.th.'}, {'ForeName': 'Kamon', 'Initials': 'K', 'LastName': 'Kawkitinarong', 'Affiliation': 'Tuberculosis Research Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. Electronic address: kamonkaw@hotmail.com.'}, {'ForeName': 'Teerapol', 'Initials': 'T', 'LastName': 'Srichana', 'Affiliation': 'Drug Delivery System Excellence Center and Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, 90112, Thailand. Electronic address: teerapol.s@psu.ac.th.'}]",Pulmonary pharmacology & therapeutics,['10.1016/j.pupt.2021.102056'] 1709,34275866,Effect of door-to-door distribution of HIV self-testing kits on HIV testing and antiretroviral therapy initiation: a cluster randomised trial in Malawi.,"INTRODUCTION Reaching high coverage of HIV testing remains essential for HIV diagnosis, treatment and prevention. We evaluated the effectiveness and safety of door-to-door distribution of HIV self-testing (HIVST) kits in rural Malawi. METHODS This cluster randomised trial, conducted between September 2016 and January 2018, used restricted 1:1 randomisation to allocate 22 health facilities and their defined areas to door-to-door HIVST alongside the standard of care (SOC) or the SOC alone. The study population included residents (≥16 years). HIVST kits were provided door-to-door by community-based distribution agents (CBDAs) for at least 12 months. The primary outcome was recent HIV testing (in the last 12 months) measured through an endline survey. Secondary outcomes were lifetime HIV testing and cumulative 16-month antiretroviral therapy (ART) initiations, which were captured at health facilities. Social harms were reported through community reporting systems. Analysis compared cluster-level outcomes by arm. RESULTS Overall, 203 CBDAs distributed 273 729 HIVST kits. The endline survey included 2582 participants in 11 HIVST clusters and 2908 participants in 11 SOC clusters. Recent testing was higher in the HIVST arm (68.5%, 1768/2582) than the SOC arm (48.9%, 1422/2908), with adjusted risk difference (RD) of 16.1% (95% CI 6.5% to 25.7%). Lifetime testing was also higher in the HIVST arm (86.9%, 2243/2582) compared with the SOC arm (78.5%, 2283/2908; adjusted RD 6.3%, 95% CI 2.3% to 10.3%). Differences were most pronounced for adolescents aged 16-19 years (adjusted RD 18.6%, 95% CI 7.3% to 29.9%) and men (adjusted RD 10.2%, 95% CI 3.1% to 17.2%). Cumulative incidence of ART initiation was 1187.2 and 909.0 per 100 000 population in the HIVST and SOC arms, respectively (adjusted RD 309.1, 95% CI -95.5 to 713.7). Self-reported HIVST use was 42.5% (1097/2582), with minimal social harms reported. CONCLUSION Door-to-door HIVST increased recent and lifetime testing at population level and showed high safety, underscoring potential for HIVST to contribute to HIV elimination goals in priority settings. TRIAL REGISTRATION NUMBER NCT02718274.",2021,"Self-reported HIVST use was 42.5% (1097/2582), with minimal social harms reported. ","['2582 participants in 11 HIVST clusters and 2908 participants in 11 SOC clusters', 'September 2016 and January 2018, used restricted 1:1 randomisation to allocate 22 health facilities and their defined areas to door-to-door HIVST alongside the standard of care (SOC) or the SOC alone', 'study population included residents (≥16 years', 'rural Malawi']","['HIV self-testing kits', 'HIV self-testing (HIVST) kits']","['lifetime HIV testing and cumulative 16-month antiretroviral therapy (ART) initiations, which were captured at health facilities', 'Cumulative incidence of ART initiation', 'Lifetime testing', 'recent HIV testing']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205171', 'cui_str': 'Singular'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}]","[{'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0332185', 'cui_str': 'Recent'}]",,0.395777,"Self-reported HIVST use was 42.5% (1097/2582), with minimal social harms reported. ","[{'ForeName': 'Pitchaya P', 'Initials': 'PP', 'LastName': 'Indravudh', 'Affiliation': 'Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK pitchaya.indravudh@lshtm.ac.uk.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Fielding', 'Affiliation': 'Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Chilongosi', 'Affiliation': 'Population Services International, Blantyre, Malawi.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Nzawa', 'Affiliation': 'Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Neuman', 'Affiliation': 'Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Moses K', 'Initials': 'MK', 'LastName': 'Kumwenda', 'Affiliation': 'Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Nyirenda', 'Affiliation': 'Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi.'}, {'ForeName': 'Cheryl C', 'Initials': 'CC', 'LastName': 'Johnson', 'Affiliation': 'Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneve, Switzerland.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Taegtmeyer', 'Affiliation': 'Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Desmond', 'Affiliation': 'Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Hatzold', 'Affiliation': 'Population Services International, Washington, DC, USA.'}, {'ForeName': 'Elizabeth L', 'Initials': 'EL', 'LastName': 'Corbett', 'Affiliation': 'Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}]",BMJ global health,['10.1136/bmjgh-2020-004269'] 1710,34275457,The longitudinal association between the use of antihypertensive medications and 24-hour sleep in nursing homes: results from the randomized controlled COSMOS trial.,"BACKGROUND Antihypertensive medication use and sleep problems are highly prevalent in nursing home patients. While it is hypothesized that blood pressure and antihypertensive medication use can affect sleep, this has not been investigated in depth in this population. Alongside a multicomponent intervention including a systematic medication review, we aimed to investigate the longitudinal association between antihypertensive medication use, blood pressure and day- and night-time sleep over 4 months. METHODS This study was based on secondary analyses from the multicomponent cluster randomized controlled COSMOS trial, in which the acronym denotes the intervention: COmmuncation, Systematic pain assessment and treatment, Medication review, Organization of activities and Safety. We included baseline and 4-month follow-up data from a subgroup of nursing home patients who wore actigraphs (n = 107). The subgroup had different levels of blood pressure, from low (< 120) to high (≥ 141). Assessments included blood pressure, antihypertensive medication use, and sleep parameters as assessed by actigraphy. RESULTS We found a significant reduction in total sleep time at month four in the intervention group compared to the control group. When analysing the control group alone, we found a significant association between antihypertensive medication use and increased daytime sleep. We also found negative associations between blood pressure, antihypertensive medication use and sleep onset latency in the control group. CONCLUSIONS Our results suggest a correlation between excessive daytime sleep and antihypertensive medication use. These findings should be followed up with further research, and with clinical caution, as antihypertensive medications are frequently used in nursing homes, and sleep problems may be especially detrimental for this population. TRIAL REGISTRATION The trial is registered at clinicaltrials.gov ( NCT02238652 ).",2021,We found a significant reduction in total sleep time at month four in the intervention group compared to the control group.,"['nursing homes', 'nursing home patients', 'nursing home patients who wore actigraphs (n\u2009=\u2009107']",['antihypertensive medications'],"['blood pressure and day- and night-time sleep', 'total sleep time', 'blood pressure, antihypertensive medication use, and sleep parameters as assessed by actigraphy', 'blood pressure, antihypertensive medication use and sleep onset latency', 'daytime sleep', 'blood pressure']","[{'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517529', 'cui_str': '107'}]","[{'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C4505222', 'cui_str': 'Sleep Onset Latency'}, {'cui': 'C4075948', 'cui_str': 'Sleeps during day'}]",,0.035735,We found a significant reduction in total sleep time at month four in the intervention group compared to the control group.,"[{'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Flo-Groeneboom', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. Elisabeth.flo@uib.no.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Elvegaard', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Gulla', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Bettina S', 'Initials': 'BS', 'LastName': 'Husebo', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.'}]",BMC geriatrics,['10.1186/s12877-021-02317-4'] 1711,34274907,Effects of Dexmedetomidine on Patients Undergoing Laparoscopic Surgery for Colorectal Cancer.,"BACKGROUND Pneumoperitoneum during laparoscopic surgery has a systemic impact on the renal system and might contribute to acute kidney injury or postoperative renal dysfunction. However, effective preventive strategies are still lacking. We aimed to explore the effects of dexmedetomidine (DEX) on kidney and other organ function in patients undergoing elective laparoscopic surgery for colorectal cancer. MATERIALS AND METHODS Fifty-six patients were randomly enrolled into the Control or DEX group. The DEX group received 1 µg kg -1 DEX intravenously within 10 min followed by a maintenance dose of 0.5 µg kg -1 h -1 infused until 30 min before closing the peritoneum. In the Control group, 0.9% sodium chloride was administered as a placebo. The primary outcome was serum neutrophil gelatinase-associated lipocalin (NGAL) levels reflecting kidney injury. Secondary outcomes included variables reflecting the kidney, intestinal injury and systemic inflammatory response. RESULTS NGAL levels were significantly lower in the DEX group than in the Control group at 1 d and 5 d postoperatively (107.5 ± 55.6 ng mL -1 versus 179.5 ± 78.2 ng mL -1 ; 70.3 ± 45.8 ng mL -1 versus 135.2 ± 59.6 ng mL -1 , P < 0.001), while the BUN and Cr levels showed no differences between the groups. Serum DAO activity was significantly lower in the DEX group patients 24 h after surgery. Moreover, I-FABP levels were markedly lower at 2 h and 24 h postoperatively in the DEX group than in the Control group (P < 0.001). CONCLUSIONS Perioperative DEX administration may potentially confer kidney and intestinal protection during laparoscopic surgery for colorectal cancer patients.",2021,"RESULTS NGAL levels were significantly lower in the DEX group than in the Control group at 1 d and 5 d postoperatively (107.5 ± 55.6 ng mL -1 versus 179.5 ± 78.2 ng mL -1 ; 70.3 ± 45.8 ng mL -1 versus 135.2 ± 59.6 ng mL -1 , P < 0.001), while the BUN and Cr levels showed no differences between the groups.","['Fifty-six patients', 'Patients Undergoing Laparoscopic Surgery for Colorectal Cancer', 'patients undergoing elective laparoscopic surgery for colorectal cancer', 'colorectal cancer patients']","['Dexmedetomidine', 'sodium chloride', 'DEX', 'Control or DEX', 'dexmedetomidine (DEX', 'placebo']","['variables reflecting the kidney, intestinal injury and systemic inflammatory response', 'BUN and Cr levels', 'NGAL levels', 'serum neutrophil gelatinase-associated lipocalin (NGAL) levels reflecting kidney injury', 'FABP levels', 'Serum DAO activity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0215955', 'cui_str': 'LCN2 protein, human'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0206528', 'cui_str': 'Gelatinase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}, {'cui': 'C0160420', 'cui_str': 'Injury of kidney'}, {'cui': 'C0023139', 'cui_str': 'Lauric acid'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",56.0,0.164937,"RESULTS NGAL levels were significantly lower in the DEX group than in the Control group at 1 d and 5 d postoperatively (107.5 ± 55.6 ng mL -1 versus 179.5 ± 78.2 ng mL -1 ; 70.3 ± 45.8 ng mL -1 versus 135.2 ± 59.6 ng mL -1 , P < 0.001), while the BUN and Cr levels showed no differences between the groups.","[{'ForeName': 'Wenqin', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Changde City, Changde, China.""}, {'ForeName': 'Fengling', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, Affiliated Dongguan People's Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, China.""}, {'ForeName': 'Xianxue', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Changde City, Changde, China.""}, {'ForeName': 'Hongbo', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Changde City, Changde, China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Mo', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Changde City, Changde, China.""}, {'ForeName': 'Daobo', 'Initials': 'D', 'LastName': 'Pan', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Changde City, Changde, China.""}, {'ForeName': 'Shihong', 'Initials': 'S', 'LastName': 'Wen', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: wenshihong2006@aliyun.com.'}, {'ForeName': 'Aiguo', 'Initials': 'A', 'LastName': 'Zhou', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Changde City, Changde, China. Electronic address: zag0736@163.com.""}]",The Journal of surgical research,['10.1016/j.jss.2021.06.043'] 1712,34274848,The effects of massage velocity on heart rate and heart rate variability in healthy infants: A randomized crossover study.,"BACKGROUND Infant massage, in which mothers stroke their infant's skin slowly and gently, can cause pleasant sensations in the infant that can be affected by the velocity of massage. However, the massage velocity at which infants feel the most pleasant sensations remains unclear. OBJECTIVE To investigate the effects of massage velocity on heart rate (HR) and HR variability (HRV) in healthy infants. METHOD Twenty-two infant-mother dyads two to seven months of age were recruited. Mothers stroked their infant's skin at three massage velocities (5.0, 7.5, and 10.0 cm/s) in a randomized order for 15 min. The rhythm of massage velocity was calculated according to the length of three body areas. The massage velocity of the mothers was regulated using a metronome. HR and HRV (high frequency [HF] and low frequency [LF]) were measured at rest and during massage for each velocity. The effects on pleasantness were evaluated using percent change in median baseline value compared with median values for the three massage velocities. Statistical analysis was performed using analysis of variance mixed effect models to exclude ""period"" and ""carryover"" effects during massage. RESULTS When measuring HF, massage (7.5 cm/s) caused a significant increase in pleasantness compared with 10.0 cm/s (p = 0.04). The HR and LF/HF ratio were not significantly changed between velocities. CONCLUSION Results of this study suggested that a massage velocity of 7.5 cm/s was the most pleasant for infants. Future research should investigate the relationship between an infant massage by optimal velocity and infant development in longitudinal studies.",2021,"When measuring HF, massage (7.5 cm/s) caused a significant increase in pleasantness compared with 10.0 cm/s (p = 0.04).","['healthy infants', 'Twenty-two infant-mother dyads two to seven months of age were recruited']",['massage velocity'],"['heart rate and heart rate variability', 'HR and LF/HF ratio', 'rhythm of massage velocity', 'HR and HRV (high frequency [HF] and low frequency [LF', 'heart rate (HR) and HR variability (HRV', 'pleasantness']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}]",,0.0230401,"When measuring HF, massage (7.5 cm/s) caused a significant increase in pleasantness compared with 10.0 cm/s (p = 0.04).","[{'ForeName': 'Chiori', 'Initials': 'C', 'LastName': 'Kamiya', 'Affiliation': 'Division of Developmental Neuroscience, United Graduate School of Child Development, Osaka University, Osaka, Japan.'}, {'ForeName': 'Akimitsu', 'Initials': 'A', 'LastName': 'Miyake', 'Affiliation': 'Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.'}, {'ForeName': 'Tomomi', 'Initials': 'T', 'LastName': 'Yamada', 'Affiliation': 'Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Ohmi', 'Affiliation': 'Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Osaka, Japan.'}, {'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Watanabe', 'Affiliation': ""Department of Children and Women's Health, Osaka University Graduate School of Medicine, Osaka, Japan. Electronic address: watanabe@sahs.med.osaka-u.ac.jp.""}]",Infant behavior & development,['10.1016/j.infbeh.2021.101604'] 1713,34274407,Differential loss of β-cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study.,"AIMS To compare OGTT-derived estimates of β-cell function between youth and adults with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes after treatment discontinuation in RISE. METHODS Youth (n = 89) and adults (n = 132) were randomized to 3 months glargine followed by 9 months metformin (G/M) or 12 months metformin (MET). Insulin sensitivity and β-cell responses were estimated from 3-hour OGTTs over 21 months. Linear mixed models tested for differences by time and age group within each treatment arm. RESULTS After treatment withdrawal, HbA1c increased in both youth and adults with a larger net increase in G/M youth vs. adults at 21 months. Among youth, β-cell function decreased starting at 12 months in G/M and 15 months in MET. Among adults, β-cell function remained relatively stable although insulin secretion rates decreased in G/M at 21 months. At 21 months vs. baseline β-cell function declined to a greater extent in youth vs. adults in both the G/M and MET treatment arms. CONCLUSIONS After treatment withdrawal youth demonstrated progressive decline in β-cell function after stopping treatment with either G/M or MET. In contrast, β-cell function in adults remained stable despite an increase in HbA1c over time. ClinicalTrials.gov Identifier: NCT01779375 and NCT01779362 at clinical trials.gov.",2021,"After treatment withdrawal, HbA1c increased in both youth and adults with a larger net increase in G/M youth vs. adults at 21 months.","['youth and adults with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes after treatment discontinuation in RISE', 'Youth (n=89) and adults (n=132', 'Youth vs. Adults']",['glargine followed by 9 months metformin (G/M) or 12 months metformin (MET'],"['Insulin sensitivity and β-cell responses', 'β-cell function', 'Differential Loss of β-cell Function', 'insulin secretion rates']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0151671', 'cui_str': 'Glucose tolerance decreased'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0035853', 'cui_str': 'Rose'}]","[{'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0007613', 'cui_str': 'Physiology, Cell'}, {'cui': 'C0443199', 'cui_str': 'Differential'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}]",132.0,0.226326,"After treatment withdrawal, HbA1c increased in both youth and adults with a larger net increase in G/M youth vs. adults at 21 months.","[{'ForeName': 'Kristina M', 'Initials': 'KM', 'LastName': 'Utzschneider', 'Affiliation': 'VA Puget Sound Health Care System, Seattle, WA, United States; Department of Medicine, University of Washington, Seattle, WA, United States.'}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Tripputi', 'Affiliation': 'George Washington University Biostatistics Center, Rockville, MD, United States.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Kozedub', 'Affiliation': 'VA Puget Sound Health Care System, Seattle, WA, United States.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Barengolts', 'Affiliation': 'Jesse Brown VA Medical Center, Chicago, IL, United States.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Caprio', 'Affiliation': 'Department of Pediatrics, Yale University, New Haven, CT, United States.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Cree-Green', 'Affiliation': ""University of Colorado Anschutz Medical Campus/Children's Hospital Colorado, Denver, CO, United States.""}, {'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Edelstein', 'Affiliation': 'George Washington University Biostatistics Center, Rockville, MD, United States.'}, {'ForeName': 'Laure', 'Initials': 'L', 'LastName': 'El Ghormli', 'Affiliation': 'George Washington University Biostatistics Center, Rockville, MD, United States.'}, {'ForeName': 'Tamara S', 'Initials': 'TS', 'LastName': 'Hannon', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, IN, United States.'}, {'ForeName': 'Kieren J', 'Initials': 'KJ', 'LastName': 'Mather', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, IN, United States.'}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Palmer', 'Affiliation': 'VA Puget Sound Health Care System, Seattle, WA, United States; Department of Medicine, University of Washington, Seattle, WA, United States.'}, {'ForeName': 'Kristen J', 'Initials': 'KJ', 'LastName': 'Nadeau', 'Affiliation': ""University of Colorado Anschutz Medical Campus/Children's Hospital Colorado, Denver, CO, United States.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes research and clinical practice,['10.1016/j.diabres.2021.108948'] 1714,34278942,The effects of concurrent biomechanical biofeedback on rowing performance at different stroke rates.,"The aims of this study were to assess the effects of stroke rate (SR) on the ability of trained rowers to: a) comply with concurrent biomechanical biofeedback on knee-back-elbow joint sequencing; and b) transfer any changes to competition-intensity conditions (maximal rowing task). Following a five-minute maximal rowing task (Baseline), 30 trained rowers were randomised to four groups. Two groups rowed at high SRs (90% maximum SR with biofeedback ( BFb 90 ) or control), while others rowed at low SRs (60% maximum SR with biofeedback ( BFb 60 ) or control) for 3 sessions. All rowers then completed another maximal rowing task (Transfer). Rowers complied with the biofeedback at both SRs, which promoted coordinative changes to knee-elbow motions during the pull. During Transfer, control rowers did not improve whereas those receiving biofeedback covered significantly greater distances (increase from Baseline: BFb 60   = 6 ± 5%; BFb 90  = 5 ± 4%; p < 0.05). However, movement adaptations were temporally different between SRs and were better maintained into Transfer by those that rowed at higher rates. This indicated biofeedback specificity, as transference of modified movement patterns appeared better when acquisition and transfer conditions were similar. These findings have practical implications for assimilating biofeedback into training programmes.",2021,"During Transfer, control rowers did not improve whereas those receiving biofeedback covered significantly greater distances (increase from Baseline: BFb 60   = 6 ± 5%; BFb 90  = 5 ± 4%; p < 0.05).",['30 trained rowers'],"['concurrent biomechanical biofeedback', 'biomechanical biofeedback']","['stroke rate (SR', 'rowing performance']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}]","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",,0.06575,"During Transfer, control rowers did not improve whereas those receiving biofeedback covered significantly greater distances (increase from Baseline: BFb 60   = 6 ± 5%; BFb 90  = 5 ± 4%; p < 0.05).","[{'ForeName': 'Anthony J', 'Initials': 'AJ', 'LastName': 'Gorman', 'Affiliation': 'School of Sport & Exercise Science, College of Social Science, University of Lincoln, Lincoln, UK.'}, {'ForeName': 'Alexander P', 'Initials': 'AP', 'LastName': 'Willmott', 'Affiliation': 'School of Sport & Exercise Science, College of Social Science, University of Lincoln, Lincoln, UK.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Mullineaux', 'Affiliation': 'School of Sport & Exercise Science, College of Social Science, University of Lincoln, Lincoln, UK.'}]",Journal of sports sciences,['10.1080/02640414.2021.1954349'] 1715,34280575,Incorporating systems-level stakeholder perspectives into the clinical trial design of school-supervised asthma therapy.,"RATIONALE Few evidence-based public health interventions are adopted in practice, in part due to a disconnect between the outcomes measured in clinical trials and the outcomes important to stakeholders that determine implementation in real-world practice. AsthmaLink is a school-supervised asthma therapy program which partners pediatric providers, school nurses, and families. To inform the design of a cluster randomized controlled trial of AsthmaLink, we elicited systems-level stakeholder input. METHODS Maximum variation sampling was used to recruit 18 stakeholders to participate in semi-structured interviews that were recorded, transcribed, and open coded: Department of Public Health officials (n = 4), school officials (n = 4), pediatric practice managers (n = 3), health insurance officials (n = 4), and legislators (n = 3). Thematic analysis was used to identify common themes related to stakeholder priorities for clinical trial design and perceived barriers to AsthmaLink adoption. RESULTS Stakeholder groups identified common priorities for the clinical trial design, including examination of the extent to which AsthmaLink (1) reduces health care utilization, (2) is cost effective (2) addresses health disparities, (3) reduces school absenteeism, and (4) educates families about asthma. Stakeholder groups reported potential barriers to AsthmaLink adoption, including challenges pertaining to (1) securing resources, staffing, and reimbursement, (2) variability across school districts, and (3) standing out amidst multiple programs vying for resources. CONCLUSIONS Systems-level stakeholder input informed refinements to the clinical trial design of a school-supervised therapy program including outcome and implementation measures and choice of study population. Incorporating systems-level stakeholder perspectives into clinical trial design is critical to achieve adoption of evidence-based interventions into practice.",2021,"Stakeholder groups reported potential barriers to AsthmaLink adoption, including challenges pertaining to (1) securing resources, staffing, and reimbursement, (2) variability across school districts, and (3) standing out amidst multiple programs vying for resources. ","['18 stakeholders to participate in semi-structured interviews that were recorded, transcribed, and open coded: Department of Public Health officials (n\u202f=\u202f4), school officials (n\u202f=\u202f4), pediatric practice managers (n\u202f=\u202f3), health insurance officials (n\u202f=\u202f4), and legislators (n\u202f=\u202f3']",['AsthmaLink'],"['cost effective (2) addresses health disparities, (3) reduces school absenteeism, and (4) educates families about asthma']","[{'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0007465', 'cui_str': 'Cause of death'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0402422', 'cui_str': 'Practice manager'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}]",[],"[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}]",,0.224316,"Stakeholder groups reported potential barriers to AsthmaLink adoption, including challenges pertaining to (1) securing resources, staffing, and reimbursement, (2) variability across school districts, and (3) standing out amidst multiple programs vying for resources. ","[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Trivedi', 'Affiliation': 'Division of Pulmonary Medicine, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA. Electronic address: michelle.trivedi@umassmemorial.org.'}, {'ForeName': 'Shushmita', 'Initials': 'S', 'LastName': 'Hoque', 'Affiliation': 'University of Massachusetts Medical School, Worcester, MA, USA.'}, {'ForeName': 'Janki', 'Initials': 'J', 'LastName': 'Luther', 'Affiliation': 'Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Spano', 'Affiliation': 'Division of Pulmonary Medicine, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Shillan', 'Affiliation': 'University of Massachusetts Medical School, Worcester, MA, USA.'}, {'ForeName': 'Hallie', 'Initials': 'H', 'LastName': 'Pearl', 'Affiliation': 'Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Seay', 'Affiliation': 'University of Massachusetts Medical School, Worcester, MA, USA.'}, {'ForeName': 'Wanda', 'Initials': 'W', 'LastName': 'Phipatanakul', 'Affiliation': ""Division of Asthma, Allergy, and Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Lynn B', 'Initials': 'LB', 'LastName': 'Gerald', 'Affiliation': 'Department of Health Promotion Sciences, University of Arizona Mel and Enid Zuckerman College of Public Health, Tucson, AZ, USA; Asthma and Airway Disease Research Center, University of Arizona, Tucson, AZ, USA.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Pbert', 'Affiliation': 'Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106510'] 1716,34280509,Resistance training improves nerve conduction and arterial stiffness in older adults with diabetic distal symmetrical polyneuropathy: A randomized controlled trial.,"Diabetes is the main cause of peripheral neuropathy where older patients are at increased risk of diabetic distal symmetrical polyneuropathy (DSPN) due to age-related nerve degeneration and vascular changes. The aim of the study was to investigate the effect of resistance training on nerve conduction, measures of neuropathy and arterial stiffness in older patients with DSPN. In a randomized controlled trial, thirty-four older adults with type-2 diabetes and peripheral neuropathy were enrolled and randomly assigned to experimental and control groups. The experimental group carried out circuit resistance training (1-3 rounds, 11 exercises, 10-15 reps, 50%-60% of 1RM, 3 times per week) for 12 weeks. Measurements were performed at baseline and 48 h after the intervention. Measures of DSPN including Michigan neuropathy screening instrument (MNSI), Michigan diabetic neuropathy score (MDNS), motor nerve action potential amplitude (APA), sensory and motor nerve conduction velocity (NCV) improved following intervention (p < 0.001, p = 0.001, p = 0.034, p = 0.001, and p = 0.001, respectively). Sensory APA did not change after the intervention (p = 0.139). Cardio-ankle vascular index (CAVI) and ankle-brachial index (ABI) improved in the experimental group compared with the control group (p = 0.014 and p = 0.033, respectively). In addition, HbA1C decreased following the 12-week resistance training program (p = 0.002). Older adults with DSPN respond positively to resistance training by improved neuropathy symptoms, nerve conduction, arterial stiffness and glucose regulation. Resistance training offers a positive intervention that can abate the progression of DSPN in older adults.",2021,"Older adults with DSPN respond positively to resistance training by improved neuropathy symptoms, nerve conduction, arterial stiffness and glucose regulation.","['older adults with diabetic distal symmetrical polyneuropathy', 'older patients with DSPN', 'thirty-four older adults with type-2 diabetes and peripheral neuropathy', 'Older adults with', 'older adults']","['resistance training', 'circuit resistance training', 'DSPN', 'Resistance training']","['DSPN including Michigan neuropathy screening instrument (MNSI), Michigan diabetic neuropathy score (MDNS), motor nerve action potential amplitude (APA), sensory and motor nerve conduction velocity (NCV', 'HbA1C', 'nerve conduction and arterial stiffness', 'Cardio-ankle vascular index (CAVI) and ankle-brachial index (ABI', 'neuropathy symptoms, nerve conduction, arterial stiffness and glucose regulation', 'nerve conduction, measures of neuropathy and arterial stiffness', 'Sensory APA']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0152025', 'cui_str': 'Polyneuropathy'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0152025', 'cui_str': 'Polyneuropathy'}]","[{'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0152025', 'cui_str': 'Polyneuropathy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025939', 'cui_str': 'Michigan'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0011882', 'cui_str': 'Diabetic neuropathy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0429382', 'cui_str': 'Nerve action potential amplitude'}, {'cui': 'C0001272', 'cui_str': 'Action Potentials'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0457379', 'cui_str': 'Motor nerve conduction velocity'}, {'cui': 'C0429381', 'cui_str': 'Nerve conduction velocity'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0027788', 'cui_str': 'Nerve conduction'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C4034558', 'cui_str': 'Cardio-ankle vascular index'}, {'cui': 'C1328319', 'cui_str': 'Ankle brachial pressure index'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",34.0,0.0308251,"Older adults with DSPN respond positively to resistance training by improved neuropathy symptoms, nerve conduction, arterial stiffness and glucose regulation.","[{'ForeName': 'Farhad', 'Initials': 'F', 'LastName': 'Gholami', 'Affiliation': 'Faculty of Sport Sciences, Shahrood University of Technology, Shahrood, Semnan, Iran. Electronic address: Gholami-fa@shahroodut.ac.ir.'}, {'ForeName': 'Raziyeh', 'Initials': 'R', 'LastName': 'Khaki', 'Affiliation': 'Faculty of Sport Sciences, Shahrood University of Technology, Shahrood, Semnan, Iran.'}, {'ForeName': 'Batool', 'Initials': 'B', 'LastName': 'Mirzaei', 'Affiliation': 'Faculty of Sport Sciences, Shahrood University of Technology, Shahrood, Semnan, Iran.'}, {'ForeName': 'Glyn', 'Initials': 'G', 'LastName': 'Howatson', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, UK; Water Research Group, North West University, Potchefstroom, South Africa.'}]",Experimental gerontology,['10.1016/j.exger.2021.111481'] 1717,34280468,Simplification of complex insulin therapy: a story of dogma and therapeutic resignation.,"The combination of rapid-acting plus long-acting insulins has been the cornerstone of therapy of patients with type 1 diabetes mellitus (T1DM) and has also become the gold standard of insulin therapy in type 2 diabetes (T2DM). A significant proportion of T2DM patients are overtreated, with potential harms of insulin therapy exceeding its benefits. Treatment simplification aims to decrease the complexity of insulin regimens, including, but not limited to fewer administration times and fewer blood glucose checks. Few small studies in T2DM patients with good glycemic control have shown that glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotrasporter-2 (SGLT-2) inhibitors can be a safe and effective alternative to bolus insulin, if basal insulin administration is continued. Two larger and controlled trials have thrown some light about simplification of complex insulin regimens in patients with T2DM and poor glycemic control. Although different in their design (randomized controlled trial versus pragmatic trial), their results provide evidence that it is possible to switch from a basal bolus insulin regimen to a combination of basal insulin plus either a GLP-1RA or a daily gliflozin pill, with same or better glycemic control, less injections, less insulin doses, less hypoglycemia and increased satisfaction of therapy. The dogma about the untouchability of basal bolus insulin regimen has been confuted.",2021,"Treatment simplification aims to decrease the complexity of insulin regimens, including, but not limited to fewer administration times and fewer blood glucose checks.","['patients with T2DM and poor glycemic control', 'T2DM patients with good glycemic control', 'patients with type 1 diabetes mellitus (T1DM']",['complex insulin therapy'],['blood glucose checks'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0342299', 'cui_str': 'Poor glycemic control'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}]","[{'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}]",,0.0621367,"Treatment simplification aims to decrease the complexity of insulin regimens, including, but not limited to fewer administration times and fewer blood glucose checks.","[{'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Giugliano', 'Affiliation': 'Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy; Ph.D. of Translational Medicine, Chair of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy. Electronic address: dario.giugliano@unicampania.it.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Scappaticcio', 'Affiliation': 'Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy; Ph.D. of Translational Medicine, Chair of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Longo', 'Affiliation': 'Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy; Ph.D. of Translational Medicine, Chair of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Caruso', 'Affiliation': 'Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy; Ph.D. of Translational Medicine, Chair of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Maria Ida', 'Initials': 'MI', 'LastName': 'Maiorino', 'Affiliation': 'Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Bellastella', 'Affiliation': 'Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Esposito', 'Affiliation': 'Ph.D. of Translational Medicine, Chair of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy; Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania ""L. Vanvitelli"", Naples, Italy.'}]",Diabetes research and clinical practice,['10.1016/j.diabres.2021.108958'] 1718,34301203,Effectiveness of a programable body-worn digital hearing aid for older adults in a developing country: a randomized controlled trial with a cross-over design.,"BACKGROUND Hearing aids are important assistive devices for hearing rehabilitation. However, the cost of commonly available commercial hearing aids is often higher than the average monthly income of individuals in some developing countries. Therefore, there is a great need to locally produce cheaper, but still effective, hearing aids. The Thai-produced P02 hearing aid was designed to meet this requirement. OBJECTIVE To compare the effectiveness of the P02 hearing aid with two common commercially available digital hearing aids (Clip-II™ and Concerto Basic®). METHODS A prospective, randomized controlled trial with a cross-over design was conducted from October 2012 to September 2014 in a rural Thai community. There were 73 participants (mean age of 73.7 ± 7.3 years) included in this study with moderate to severe hearing loss who were assessed for hearing aid performance, including probe microphone real-ear measurement, functional gain, speech discrimination, and participant satisfaction with the overall quality of perceived sound and the design of the device. RESULTS There were no statistically significant differences in functional gain or speech discrimination among the three hearing aids evaluated (p-value > 0.05). Real-ear measurements of the three hearing aids met the target curve in 93% of the participants. The best real-ear measurement of the hearing aid following the target curve was significantly lower than that of Clip-II™ and Concerto Basic® (p-value < 0.05) at high frequency. However, participants rated the overall quality of sound higher for the P02 hearing aid than that of Clip-II™ but lower than that of Concerto Basic® (p-value > 0.05). Participants revealed that the P02 hearing aid provided the highest satisfaction ratings for design and user-friendliness with statistical significance (p-value < 0.05). CONCLUSION The P02 hearing aid was an effective device for older Thai adults with hearing disabilities. Additionally, its modern design, simplicity of use, and ease of maintenance were attractive to this group of individuals. These benefits support the rehabilitation potential of this hearing aid model and its positive impact on the quality of life of older adults in developing countries. TRIAL REGISTRATION This study was registered under Clinicaltrial.gov NCT01902914 . Date of registration: July 18, 2013.",2021,"Participants revealed that the P02 hearing aid provided the highest satisfaction ratings for design and user-friendliness with statistical significance (p-value < 0.05). ","['older Thai adults with hearing disabilities', '73 participants (mean age of 73.7\u2009±\u20097.3\u2009years) included in this study with moderate to severe hearing loss who were assessed for hearing aid performance, including probe microphone real-ear measurement, functional gain, speech discrimination, and participant satisfaction with the overall quality of perceived sound and the design of the device', 'October 2012 to September 2014 in a rural Thai community', 'older adults in a developing country']","['Clip-II™ and Concerto', 'programable body-worn digital hearing aid', 'P02 hearing aid with two common commercially available digital hearing aids (Clip-II™ and Concerto Basic®']",['functional gain or speech discrimination'],"[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0039724', 'cui_str': 'Thai language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0018768', 'cui_str': 'Hearing aid'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C1709026', 'cui_str': 'Microphone'}, {'cui': 'C0013443', 'cui_str': 'Ear structure'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037820', 'cui_str': 'Speech Discrimination'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0011750', 'cui_str': 'Less-Developed Countries'}]","[{'cui': 'C0175722', 'cui_str': 'Clip'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037820', 'cui_str': 'Speech Discrimination'}]",,0.0552591,"Participants revealed that the P02 hearing aid provided the highest satisfaction ratings for design and user-friendliness with statistical significance (p-value < 0.05). ","[{'ForeName': 'Pornthep', 'Initials': 'P', 'LastName': 'Kasemsiri', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.'}, {'ForeName': 'Kwanchanok', 'Initials': 'K', 'LastName': 'Yimtae', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand. kwayim@kku.ac.th.'}, {'ForeName': 'Panida', 'Initials': 'P', 'LastName': 'Thanawirattananit', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.'}, {'ForeName': 'Pasin', 'Initials': 'P', 'LastName': 'Israsena', 'Affiliation': 'National Electronics and Computer Technology Center (NECTEC), National Science and Technology Development Agency (NSTDA), Prathumthani, Thailand.'}, {'ForeName': 'Anukool', 'Initials': 'A', 'LastName': 'Noymai', 'Affiliation': 'National Electronics and Computer Technology Center (NECTEC), National Science and Technology Development Agency (NSTDA), Prathumthani, Thailand.'}, {'ForeName': 'Supawan', 'Initials': 'S', 'LastName': 'Laohasiriwong', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.'}, {'ForeName': 'Patravoot', 'Initials': 'P', 'LastName': 'Vatanasapt', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.'}, {'ForeName': 'Pipop', 'Initials': 'P', 'LastName': 'Siripaopradith', 'Affiliation': 'Phuwieng Hospital, Ministry of Public Health, Khon Kaen, Thailand.'}, {'ForeName': 'Pritaporn', 'Initials': 'P', 'LastName': 'Kingkaew', 'Affiliation': 'Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand.'}]",BMC geriatrics,['10.1186/s12877-021-02325-4'] 1719,34299902,Comparison Study of the Histomorphometric Results after Socket Preservation with PRF and Allograft Used for Socket Preservation-Randomized Controlled Trials.,"The aim of the present clinical study was to assess and compare the histomorphometric results and efficacy of freeze-dried bone allograft (FDBA) in combination with platelet-rich fibrin (PRF), and PRF as a sole grafting material for socket preservation. Ninety patients in need of tooth extraction and implant restoration were included in this study. The participants were randomly divided into three groups based on post-extraction clinical protocol: socket preservation procedure with allograft in combination with a PRF membrane (PRFm), PRF as a sole grafting material, and a control group. A total of 90 implants were placed four months post-extraction. During the surgical re-entry a bone biopsy was harvested with a trephine drill. Histological samples were prepared and analyzed for percentage vital bone and connective tissue. One-way ANOVA with Bonferroni post-hoc analysis were used to assess the results. Both test groups revealed a significantly higher percentage of vital bone formation compared to the control group. No statistically significant differences regarding vital bone formation and connective tissue quantity between the tested groups were observed (FDBA + PRFm: 3.29 ± 13.03%; and PRF: 60.79 ± 9.72%). From a clinical and histological point of view, both materials in the test groups are suitable for the filling of post-extraction sockets without bone defects. Both of the tested groups revealed a significantly higher percentage of vital bone formation compared to the control group.",2021,No statistically significant differences regarding vital bone formation and connective tissue quantity between the tested groups were observed (FDBA + PRFm: 3.29 ± 13.03%; and PRF: 60.79 ± 9.72%).,['Ninety patients in need of tooth extraction and implant restoration'],"['post-extraction clinical protocol: socket preservation procedure with allograft in combination with a PRF membrane (PRFm), PRF as a sole grafting material, and a control group', 'freeze-dried bone allograft (FDBA', 'platelet-rich fibrin (PRF), and PRF']","['vital bone formation and connective tissue quantity', 'vital bone formation']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0040440', 'cui_str': 'Tooth extraction'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0008971', 'cui_str': 'Clinical Protocol'}, {'cui': 'C0224517', 'cui_str': 'Gomphosis structure'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C4505052', 'cui_str': 'Leukocyte- and Platelet-Rich Fibrin'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0033374', 'cui_str': 'Prolactin releasing factor'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0016698', 'cui_str': 'Lyophilization'}, {'cui': 'C0407564', 'cui_str': 'Allogeneic bone graft'}]","[{'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0009780', 'cui_str': 'Connective tissue'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}]",90.0,0.0203095,No statistically significant differences regarding vital bone formation and connective tissue quantity between the tested groups were observed (FDBA + PRFm: 3.29 ± 13.03%; and PRF: 60.79 ± 9.72%).,"[{'ForeName': 'Vasilena', 'Initials': 'V', 'LastName': 'Ivanova', 'Affiliation': 'Oral Surgery Department, Faculty of Dental Medicine, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Chenchev', 'Affiliation': 'Center of Dental Implantology Research Institute, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Zlatev', 'Affiliation': 'CAD/CAM Center of Dental Medicine, Research Institute at the Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.'}, {'ForeName': 'Eitan', 'Initials': 'E', 'LastName': 'Mijiritsky', 'Affiliation': 'Head and Neck Maxillofacial Surgery, Tel-Aviv Sourasky Medical Center, Department of Otoryngology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 699350, Israel.'}]",International journal of environmental research and public health,['10.3390/ijerph18147451'] 1720,34299895,Does Dynamic Tailoring of A Narrative-Driven Exergame Result in Higher User Engagement among Adolescents? Results from A Cluster-Randomized Controlled Trial.,"Physical activity interventions for youth are direly needed given low adherence to physical activity guidelines, but many interventions suffer from low user engagement. Exergames that require bodily movement while played may provide an engaging form of physical activity intervention but are not perceived as engaging to all. This study aimed to evaluate whether dynamic tailoring in a narrative-driven mobile exergame for adolescents played in leisure settings, can create higher user engagement compared to a non-tailored exergame. A cluster-randomized controlled trial assessed differences in user engagement between a dynamically tailored (based on an accelerometer sensor integrated in a T-shirt) and non-tailored condition. In total, 94 participants (M age = 14.61 ± 1.93; 35% female) participated and were assigned to one of the two conditions. User engagement was measured via a survey and game metric data. User engagement was low in both conditions. Narrative sensation was higher in the dynamically tailored condition, but the non-tailored condition showed longer play-time. User suggestions to create a more appealing game included simple and more colorful graphics, avoiding technical problems, more variety and shorter missions and multiplayer options. Less cumbersome or more attractive sensing options than the smart T-shirt may offer a more engaging solution, to be tested in future research.",2021,"Narrative sensation was higher in the dynamically tailored condition, but the non-tailored condition showed longer play-time.","['In total, 94 participants (M age = 14.61 ± 1.93; 35% female', 'adolescents played in leisure settings']",['Physical activity interventions'],['Narrative sensation'],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0086542', 'cui_str': 'Leisure'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}]",94.0,0.0650742,"Narrative sensation was higher in the dynamically tailored condition, but the non-tailored condition showed longer play-time.","[{'ForeName': 'Ayla', 'Initials': 'A', 'LastName': 'Schwarz', 'Affiliation': 'Consumption and Healthy Lifestyles, Faculty of Social Sciences, Wageningen University & Research, 6708 PB Wageningen, The Netherlands.'}, {'ForeName': 'Greet', 'Initials': 'G', 'LastName': 'Cardon', 'Affiliation': 'Department of Movement and Sport Sciences, Ghent University, 9000 Ghent, Belgium.'}, {'ForeName': 'Sebastien', 'Initials': 'S', 'LastName': 'Chastin', 'Affiliation': 'School of Health and Life Science, Caledonian University, Glasgow G4 0BA, UK.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Stragier', 'Affiliation': 'IMEC-MICT, Department of Communication Sciences, Ghent University, 9000 Ghent, Belgium.'}, {'ForeName': 'Lieven', 'Initials': 'L', 'LastName': 'De Marez', 'Affiliation': 'IMEC-MICT, Department of Communication Sciences, Ghent University, 9000 Ghent, Belgium.'}, {'ForeName': '', 'Initials': '', 'LastName': 'Consortium SmartLife', 'Affiliation': 'KnowledgeBizConsulting, and Faculdade de Ciências e Tecnologia, Universidade NOVA, 1099-085 Lisbon, Portugal.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'DeSmet', 'Affiliation': 'Research Center for the Promotion of Health, Prosocial Behavior and Wellbeing PACE, Faculty of Psychological and Educational Sciences, Université Libre de Bruxelles, 1050 Brussels, Belgium.'}]",International journal of environmental research and public health,['10.3390/ijerph18147444'] 1721,34299891,Effectiveness of Swimming Program in Adolescents with Down Syndrome.,"The aim of this study was to estimate the influence of a 33-week swimming program on aerobic capacity, muscle strength, balance, flexibility, and body composition of adolescents with Down syndrome (DS). Twenty-two adolescents diagnosed with DS were randomly allocated into the training group (T) and the control group (C). The T group participated in 33 weeks of water-based exercise and a swimming program while the control group maintained their normal daily activity. Following thirty-three weeks of swimming program, body mass, body fat, and BMI of the T group decreased significantly (from 56.8 ± 7.97 kg to 55.0 ± 7.11 kg, from 15.1 ± 4.47 kg to 13.2 ± 3.92 kg, and from 25.1 ± 2.37 to 24.0 ± 2.05, respectively) while a significant increase was recorded in C (from 57.3 ± 8.43 kg to 59.7 ± 8.29 kg, from 14.5 ± 2.76 kg to 16.0 ± 3.11 kg, and from 25.4 ± 2.46 to 26.0 ± 2.72, respectively). Moreover, significant improvement in aerobic capacity in the T group was noted; VO 2 max (mL/kg/min) increased by 16.3% in T and decreased by 4.8% in C. Improvement in static arm strength, trunk strength and endurance/functional strength were noted in T, while the parameters did not change in C. The speed of arm movement, balance and flexibility did not change following the intervention. Also, the aquatic skills improved significantly in the training group. Changes in C were not significant. The results of our study indicate that 33-week swimming program significantly improved health status and swimming skills in adolescents with DS.",2021,"Following thirty-three weeks of swimming program, body mass, body fat, and BMI of the T group decreased significantly (from 56.8 ± 7.97 kg to 55.0 ± 7.11 kg, from 15.1 ± 4.47 kg to 13.2 ± 3.92 kg, and from 25.1 ± 2.37 to 24.0 ± 2.05, respectively) while a significant increase was recorded in C (from 57.3 ± 8.43 kg to 59.7 ± 8.29 kg, from 14.5 ± 2.76 kg to 16.0 ± 3.11 kg, and from 25.4 ± 2.46 to 26.0 ± 2.72, respectively).","['Twenty-two adolescents diagnosed with DS', 'Adolescents with Down Syndrome', 'adolescents with Down syndrome (DS', 'adolescents with DS']","['water-based exercise and a swimming program while the control group maintained their normal daily activity', '33-week swimming program', 'Swimming Program']","['health status and swimming skills', 'aerobic capacity', 'aquatic skills', 'static arm strength, trunk strength and endurance/functional strength', 'aerobic capacity, muscle strength, balance, flexibility, and body composition', 'speed of arm movement, balance and flexibility']","[{'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0013080', 'cui_str': 'Trisomy 21'}]","[{'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0039003', 'cui_str': 'Swimming'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0039003', 'cui_str': 'Swimming'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]",22.0,0.00904638,"Following thirty-three weeks of swimming program, body mass, body fat, and BMI of the T group decreased significantly (from 56.8 ± 7.97 kg to 55.0 ± 7.11 kg, from 15.1 ± 4.47 kg to 13.2 ± 3.92 kg, and from 25.1 ± 2.37 to 24.0 ± 2.05, respectively) while a significant increase was recorded in C (from 57.3 ± 8.43 kg to 59.7 ± 8.29 kg, from 14.5 ± 2.76 kg to 16.0 ± 3.11 kg, and from 25.4 ± 2.46 to 26.0 ± 2.72, respectively).","[{'ForeName': 'Alicja', 'Initials': 'A', 'LastName': 'Naczk', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Physical Culture in Gorzow Wielkopolski, University School of Physical Education in Poznan, 66-400 Gorzow Wielkopolski, Poland.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Gajewska', 'Affiliation': 'Department of Developmental Neurology, Poznan University of Medical Sciences, 60-355 Poznan, Poland.'}, {'ForeName': 'Mariusz', 'Initials': 'M', 'LastName': 'Naczk', 'Affiliation': 'Institute of Health Sciences, Collegium Medicum, University of Zielona Gora, 65-417 Zielona Gora, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph18147441'] 1722,34303223,Closeness-inducing discussions with a romantic partner increase cortisol and testosterone.,"Despite progress in understanding the social neuroendocrinology of close relationship processes, most work has focused on negative experiences, such as relationship conflict or stress. As a result, much less is known about the neuroendocrine implications of positive, emotionally intimate relationship experiences. In the current study, we randomly assigned 105 dating or married couples to a 30-minute semi-structured discussion task that was designed to elicit either high or low levels of closeness. Participants provided pre- and post-task saliva samples (to assess cortisol and testosterone) and post-task reports of self-disclosure, closeness, attraction, positive and negative affect, and stress. Participants found the discussion conditions comparably positive and enjoyable, but those in the high-closeness condition reported that they disclosed marginally more and felt marginally closer to their partners than those in the low-closeness condition. Participants also showed larger increases in cortisol and testosterone during the high (versus low) closeness discussion, and self-reported disclosure mediated these increases in cortisol and testosterone. Self-reported closeness and other theoretically plausible mediators, such as sexual attraction and excitement, did not mediate changes in either hormone. Taken together, the current findings contribute to our understanding of neuroendocrine changes associated with emotionally intimate relationship experiences. We consider possible explanations for the hormone changes we observed and offer directions for future research on the neuroendocrine implications of close relationship experiences.",2021,"Self-reported closeness and other theoretically plausible mediators, such as sexual attraction and excitement, did not mediate changes in either hormone.",[],['30-minute semi-structured discussion task'],"['cortisol and testosterone', 'cortisol and testosterone) and post-task reports of self-disclosure, closeness, attraction, positive and negative affect, and stress']",[],"[{'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0036596', 'cui_str': 'Self Disclosure'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",105.0,0.0895222,"Self-reported closeness and other theoretically plausible mediators, such as sexual attraction and excitement, did not mediate changes in either hormone.","[{'ForeName': 'Kristi', 'Initials': 'K', 'LastName': 'Chin', 'Affiliation': 'University of Michigan, USA. Electronic address: krischin@umich.edu.'}, {'ForeName': 'Zachary A', 'Initials': 'ZA', 'LastName': 'Reese', 'Affiliation': 'University of Michigan, USA.'}, {'ForeName': 'Esra', 'Initials': 'E', 'LastName': 'Ascigil', 'Affiliation': 'University of Michigan, USA.'}, {'ForeName': 'Lester', 'Initials': 'L', 'LastName': 'Sim', 'Affiliation': 'University of Michigan, USA.'}, {'ForeName': 'Robin S', 'Initials': 'RS', 'LastName': 'Edelstein', 'Affiliation': 'University of Michigan, USA.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2021.105357'] 1723,34302941,Resistance exercise training at different loads in frail and healthy older adults: A randomised feasibility trial.,"OBJECTIVES This trial aimed to determine the feasibility of recruitment, retention, adherence, and safety of a resistance training (RT) intervention to skeletal muscle failure in both frail and non-frail older adults. DESIGN An 8-week randomised feasibility trial. SETTING AND PARTICIPANTS Older adults, with and without frailty, recruited from both clinics and community. METHODS Recruitment was based on the number of participants enrolled from those provided with a Patient Information Sheet (PIS). Retention was based on the number of participants who completed the trial. Adherence was based on the number of RT sessions attended out of 16. Outcomes included frailty (Fried criteria), muscle strength (maximal voluntary contraction), functional abilities (Short Physical Performance battery), quality of life (EQ-5D-5L), activities of daily living (LIADL) and safety (diary). RESULTS Recruitment target (n = 60) was achieved within 15 months, 58 were randomised to high (n = 30) or low repetition-load (n = 28) groups. Mean age of participants was 72 years (range 65-93). Adherence and retention rate for the RT intervention was ≥70%. There was one serious adverse experience due to the RT intervention. There were no differences (P > 0.05) in effects of RT on outcome variables between low and high repetition-load groups. CONCLUSIONS AND IMPLICATIONS Recruitment of frail people was challenging. Older adults performing supervised RT to skeletal muscle failure was feasible and safe, with appropriate caution, and the repetition-load did not appear to influence its efficacy. Future research into the effectiveness of this simplified model of RT is warranted.",2021,"There were no differences (P > 0.05) in effects of RT on outcome variables between low and high repetition-load groups. ","['Older adults', 'Recruitment was based on the number of participants enrolled from those provided with a Patient Information Sheet (PIS', 'both frail and non-frail older adults', 'frail and healthy older adults', 'Mean age of participants was 72\u202fyears (range 65-93', 'Older adults, with and without frailty, recruited from both clinics and community']","['Resistance exercise training', 'resistance training (RT) intervention']","['Adherence and retention rate', 'frailty (Fried criteria), muscle strength (maximal voluntary contraction), functional abilities (Short Physical Performance battery), quality of life (EQ-5D-5L), activities of daily living (LIADL) and safety (diary']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439643', 'cui_str': 'Sheets'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C1510451', 'cui_str': 'French fries'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}]",,0.0940396,"There were no differences (P > 0.05) in effects of RT on outcome variables between low and high repetition-load groups. ","[{'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Marshall-McKenna', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Evan', 'Initials': 'E', 'LastName': 'Campbell', 'Affiliation': 'Healthcare Improvement Scotland, Glasgow, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Ho', 'Affiliation': 'Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 8RZ, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Banger', 'Affiliation': 'Biomedical Engineering, Graham Hills Building, University of Strathclyde, Glasgow G1 1QE, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Ireland', 'Affiliation': 'Clinical Research Facility, Glasgow Royal Infirmary, Glasgow, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Rowe', 'Affiliation': 'Biomedical Engineering, Graham Hills Building, University of Strathclyde, Glasgow G1 1QE, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'McAlpine', 'Affiliation': 'Department of Medicine for the Elderly, Glasgow Royal Infirmary, Glasgow, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'McArthur', 'Affiliation': 'Department of Medicine for the Elderly, Glasgow Royal Infirmary, Glasgow, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Terence J', 'Initials': 'TJ', 'LastName': 'Quinn', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, United Kingdom of Great Britain and Northern Ireland; Department of Medicine for the Elderly, Glasgow Royal Infirmary, Glasgow, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Stuart R', 'Initials': 'SR', 'LastName': 'Gray', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, United Kingdom of Great Britain and Northern Ireland; Department of Health Promotion and Rehabilitation, Lithuanian Sports University, Kaunas, Lithuania. Electronic address: stuart.gray@glasgow.ac.uk.'}]",Experimental gerontology,['10.1016/j.exger.2021.111496'] 1724,34302899,Exploring qualities of ethnically diverse parents related to the healthy home environment of toddlers.,"Parents serve as role models and household policy makers for their children's home social environment. Also, parents may influence the home physical environment through the provision of resources to support their children's dietary, activity, and sleep behaviors. Understanding the parental characteristics related to children's home environment may allow for tailoring obesity interventions to families' needs. This study aimed to explore parental qualities (general parenting styles, parent feeding practices, and parental BMI) related to healthy home food, physical activity, media and sleep environment of toddlers. A total of 50 multi-ethnic parents with toddler age children who were enrolled in a randomized pilot study of a wellness program completed the Structure and Control in Parent Feeding (SCPF) questionnaire and Comprehensive General Parenting Questionnaire (CGPQ). Parental BMI was calculated using self-reported weight and height data. The Healthy Home Survey, the Home Food Inventory, the Sleep Environment Questionnaire, and items developed for this study were standardized and summed to create home food, physical activity, screen media, and sleep environment scores; high scores reflected healthier environments. To examine the relationships between parental qualities and the home environment, Pearson's correlation test was performed. Parental BMI and overall healthy home environment were inversely associated (r = -0.306; p = 0.032). Structure in general parenting and parental feeding practice were positively correlated with the overall healthy home environment (r = 0.336; p = 0.026) and healthy home food environment (r = 0.415; p = 0.003), respectively. The coercive control general parenting was inversely related to overall healthy home environment score (r = -0.333; p = 0.022). Based on the findings from this study, parents who provide clear communication, set consistent rules, avoid pressure to control their child's behavior, and have lower BMI tend to live in a home environment that support children's health behaviors.",2021,"Structure in general parenting and parental feeding practice were positively correlated with the overall healthy home environment (r = 0.336; p = 0.026) and healthy home food environment (r = 0.415; p = 0.003), respectively.","['50 multi-ethnic parents with toddler age children', 'ethnically diverse parents related to the healthy home environment of toddlers']","['parental qualities (general parenting styles, parent feeding practices, and parental BMI', 'wellness program completed the Structure and Control in Parent Feeding (SCPF) questionnaire and Comprehensive General']","['Parental BMI', 'overall healthy home environment score', 'Parental BMI and overall healthy home environment', 'Parenting Questionnaire (CGPQ']","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0043113', 'cui_str': 'Wellness Programs'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}]",50.0,0.00794606,"Structure in general parenting and parental feeding practice were positively correlated with the overall healthy home environment (r = 0.336; p = 0.026) and healthy home food environment (r = 0.415; p = 0.003), respectively.","[{'ForeName': 'Aliye B', 'Initials': 'AB', 'LastName': 'Cepni', 'Affiliation': 'Department of Health and Human Performance, University of Houston, USA. Electronic address: abcepni@uh.edu.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Taylor', 'Affiliation': 'Department of Psychological, Health, and Learning Sciences, University of Houston, USA. Electronic address: aataylo4@central.uh.edu.'}, {'ForeName': 'Debbe', 'Initials': 'D', 'LastName': 'Thompson', 'Affiliation': ""USDA/ARS Children's Nutrition Research Center & Department of Pediatrics, Baylor College of Medicine, USA. Electronic address: dit@bcm.edu.""}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Moran', 'Affiliation': ""USDA/ARS Children's Nutrition Research Center & Department of Pediatrics, Baylor College of Medicine, USA. Electronic address: Nancy.Moran@bcm.edu.""}, {'ForeName': 'Norma', 'Initials': 'N', 'LastName': 'Olvera', 'Affiliation': 'Department of Psychological, Health, and Learning Sciences, University of Houston, USA; Latino Health Disparities Lab, University of Houston, USA. Electronic address: NOlvera@central.uh.edu.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Health and Human Performance, University of Houston, USA; HEALTH Research Institute, University of Houston, USA. Electronic address: dpoconno@central.uh.edu.'}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Johnston', 'Affiliation': 'Department of Health and Human Performance, University of Houston, USA. Electronic address: cajohn25@central.uh.edu.'}, {'ForeName': 'Tracey A', 'Initials': 'TA', 'LastName': 'Ledoux', 'Affiliation': 'Department of Health and Human Performance, University of Houston, USA. Electronic address: taledoux@uh.edu.'}]",Appetite,['10.1016/j.appet.2021.105608'] 1725,34302882,Effects of transcranial random noise stimulation timing on corticospinal excitability and motor function.,"Although transcranial random noise stimulation (tRNS) to the primary motor cortex (M1) increases corticospinal excitability and improves motor function, the effects of tRNS timing have not been clarified when combined with motor training. The purpose of this study was to clarify the effects of different tRNS timing on corticospinal excitability and motor function. We applied tRNS to the left M1 using a frequency of 0.1-640 Hz for 10 min to 15 healthy subjects. Subjects performed visuomotor tracking tasks with right hand for 10 min and participated in the following four conditions based on the timing of tRNS: (1) ""before"" condition, tRNS was performed before motor training; (2) ""during"" condition, tRNS was performed during motor training; (3) ""after"" condition, tRNS was performed after motor training; and (4) sham condition, the control group. Motor evoked potential (MEP) amplitudes were recorded from the right first dorsal interosseous muscle using transcranial magnetic stimulation. MEP amplitudes were assessed by baseline followed by three sessions at 10 min intervals. The motor function was assessed before and after tRNS and motor training. The MEP amplitude increased after tRNS in the before and during conditions but not in the after condition. Motor function after motor training improved in all conditions, but there were no significant differences between these conditions. The present study revealed that the timing of tRNS affects corticospinal excitability but not motor learning.",2021,"Motor function after motor training improved in all conditions, but there were no significant differences between these conditions.",['15 healthy subjects'],"['transcranial random noise stimulation', 'transcranial random noise stimulation (tRNS', 'visuomotor tracking tasks with right hand for 10\u2009min']","['MEP amplitudes', 'Motor function', 'Motor evoked potential (MEP) amplitudes', 'corticospinal excitability and motor function', 'MEP amplitude', 'motor function']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C3852967', 'cui_str': 'Transcranial Random Noise Stimulation'}, {'cui': 'C0230370', 'cui_str': 'Structure of right hand'}, {'cui': 'C0439232', 'cui_str': 'min'}]","[{'cui': 'C0282617', 'cui_str': 'Motor Evoked Potentials'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}]",15.0,0.0198263,"Motor function after motor training improved in all conditions, but there were no significant differences between these conditions.","[{'ForeName': 'Haruki', 'Initials': 'H', 'LastName': 'Hoshi', 'Affiliation': 'Graduate School of Health and Welfare, Niigata University of Health and Welfare, 1398 Shimami-cho, Kita-Ku, Niigata-City, Niigata 950-3198, Japan; TMG Asaka Medical Center, 1340-1 Mizonuma, Asaka-City, Saitama 351-0023, Japan. Electronic address: hpm18012@nuhw.ac.jp.'}, {'ForeName': 'Sho', 'Initials': 'S', 'LastName': 'Kojima', 'Affiliation': 'Institute for Human Movement and Medical Sciences, Niigata University of Health and Welfare, 1398 Shimami-cho, Kita-Ku, Niigata-City, Niigata 950-3198, Japan. Electronic address: kojima@nuhw.ac.jp.'}, {'ForeName': 'Naofumi', 'Initials': 'N', 'LastName': 'Otsuru', 'Affiliation': 'Institute for Human Movement and Medical Sciences, Niigata University of Health and Welfare, 1398 Shimami-cho, Kita-Ku, Niigata-City, Niigata 950-3198, Japan. Electronic address: otsuru@nuhw.ac.jp.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Onishi', 'Affiliation': 'Institute for Human Movement and Medical Sciences, Niigata University of Health and Welfare, 1398 Shimami-cho, Kita-Ku, Niigata-City, Niigata 950-3198, Japan. Electronic address: onishi@nuhw.ac.jp.'}]",Behavioural brain research,['10.1016/j.bbr.2021.113479'] 1726,34274496,"Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial.","BACKGROUND Clopidogrel and aspirin are key intervention for acute ischemic stroke (AIS) and transient ischemic attack (TIA). However, with increased clinical application, many patients have shown clopidogrel resistance (CR) and/or aspirin resistance (AR) that affect antiplatelet therapy on AIS/TIA. At present, there is no research reported on personalized antiplatelet therapy guidelines for patients with CR and/or AR. Our study aims to assess the effect of personalized antiplatelet therapy based on CYP2C19 genotype and urine 11-dhTxB2 tests in patients with AIS or TIA. METHODS This is a multi-center randomized controlled trial. Eligible patients with AIS/TIA from 14 comprehensive hospitals in Jiangxi province will be recruited after obtaining informed consent. Participants will be randomly divided into the intervention group and the control group at a ratio of 1:1. personalized antiplatelet therapy based on the CYP2C19 genotype/urine11-dhTxB2 tests will be given to the intervention group. Demographics, disease history, laboratory investigations, therapys, physiological tests, imaging reports and other clinical features will be collected. Clinical outcomes including stroke recurrence, Modified Rankin Scale (mRS) score, bleeding events and all-cause mortality will be assessed at the 1st, 3rd, 6th, and 12th-month post-discharge. DISCUSSION Our study will conduct free antiplatelet resistance tests and personalized antiplatelet therapy for AIS/TIA patients with CR/AR, ultimately evaluating personalized therapy effectiveness through one-year follow-up. The research results will help to assess the impact of personalized antiplatelet therapy on the prognosis of stroke, thus providing reference for precise clinical treatment.",2021,"Clinical outcomes including stroke recurrence, Modified Rankin Scale (mRS) score, bleeding events and all-cause mortality will be assessed at the 1st, 3rd, 6th, and 12th-month post-discharge. ","['Eligible patients with AIS/TIA from 14 comprehensive hospitals in Jiangxi province', 'patients with AIS or TIA', 'acute ischemic stroke and transient ischemic attack', 'patients with CR and/or AR', 'AIS/TIA patients with CR/AR']","['clopidogrel/aspirin resistance tests', 'Clopidogrel and aspirin', 'personalized antiplatelet therapy']","['clopidogrel resistance (CR) and/or aspirin resistance (AR', 'CYP2C19 genotype and urine 11-dhTxB2 tests', 'stroke recurrence, Modified Rankin Scale (mRS) score, bleeding events and all-cause mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0960580', 'cui_str': 'CYP2C19 protein, human'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.0754899,"Clinical outcomes including stroke recurrence, Modified Rankin Scale (mRS) score, bleeding events and all-cause mortality will be assessed at the 1st, 3rd, 6th, and 12th-month post-discharge. ","[{'ForeName': 'Jiajing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, 461BaYi Road, Nanchang 330006, PR China.'}, {'ForeName': 'Mengqi', 'Initials': 'M', 'LastName': 'Han', 'Affiliation': 'Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, 461BaYi Road, Nanchang 330006, PR China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Kuang', 'Affiliation': 'Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, 461BaYi Road, Nanchang 330006, PR China. Electronic address: kuangjie@ncu.edu.cn.'}, {'ForeName': 'Jianglong', 'Initials': 'J', 'LastName': 'Tu', 'Affiliation': 'Department of Neurology, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Starcevich', 'Affiliation': 'School of Community Health Sciences, University of Nevada, Reno, 89557 Nevada, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Gao', 'Affiliation': 'School of Community Health Sciences, University of Nevada, Reno, 89557 Nevada, USA.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Peng', 'Affiliation': 'Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, 461BaYi Road, Nanchang 330006, PR China.'}, {'ForeName': 'Shujuan', 'Initials': 'S', 'LastName': 'Yin', 'Affiliation': 'Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, 461BaYi Road, Nanchang 330006, PR China.'}, {'ForeName': 'Jibiao', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, 461BaYi Road, Nanchang 330006, PR China.'}, {'ForeName': 'Xiaolin', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, 461BaYi Road, Nanchang 330006, PR China.'}, {'ForeName': 'Weijie', 'Initials': 'W', 'LastName': 'Jia', 'Affiliation': 'Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, 461BaYi Road, Nanchang 330006, PR China.'}, {'ForeName': 'Yifan', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, 461BaYi Road, Nanchang 330006, PR China.'}, {'ForeName': 'Yingping', 'Initials': 'Y', 'LastName': 'Yi', 'Affiliation': 'Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang 330006, PR China. Electronic address: yyp66@126.com.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106507'] 1727,34274494,The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial.,"More than 3000 clinical trials related to COVID-19 have been registered through clinicaltrials.gov. With so many trials, there is a risk that many will be inconclusive due to being underpowered or due to an inability to recruit patients. At academic medical centers, multiple trials are competing for the same resources; the success of one may come at the expense of another. The COVID-19 Outpatient Pragmatic Protocol Study (COPPS) is a flexible phase 2, multi-site, randomized, blinded trial based at Stanford University designed to overcome these issues by simultaneously evaluating multiple COVID-19 treatments in the outpatient setting in one common platform with shared controls. This approach reduces the overall number of patients required for statistical power, while improving the likelihood that any enrolled patient receives active treatment. The platform study has two main domains designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding (Viral Domain), measured with self-collected nasal swabs, or improve clinical outcomes (Clinical Domain), measured through self-reported symptomology data. Data are collected on both domains for all participants enrolled. Participants are followed over a 28-day period. COPPS has the advantage of pragmatism created around its workflow that is also appealing to potential participants because of a lower probability of inactive treatment. At the conclusion of this clinical trial we expect to have identified potentially effective therapeutic strategy/ies for treating COVID-19 in the outpatient setting, which will have a transformative impact on medicine and public health.",2021,"The platform study has two main domains designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding (Viral Domain), measured with self-collected nasal swabs, or improve clinical outcomes (Clinical Domain), measured through self-reported symptomology data.",[],['COPPS'],[],[],"[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],,0.393335,"The platform study has two main domains designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding (Viral Domain), measured with self-collected nasal swabs, or improve clinical outcomes (Clinical Domain), measured through self-reported symptomology data.","[{'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Bunning', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Haley', 'Initials': 'H', 'LastName': 'Hedlin', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Purington', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Vandana', 'Initials': 'V', 'LastName': 'Sundaram', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Kristopher', 'Initials': 'K', 'LastName': 'Kapphahn', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Yingjie', 'Initials': 'Y', 'LastName': 'Weng', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Cunanan', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Maldonado', 'Affiliation': 'Divison of Infectious Diseases, Department of Pediatrics, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Upinder', 'Initials': 'U', 'LastName': 'Singh', 'Affiliation': 'Divison of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Chaitan', 'Initials': 'C', 'LastName': 'Khosla', 'Affiliation': 'Department of Chemical Engineering, Stanford Unviersity, Stanford, CA, USA; Stanford ChEM-H, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': ""O'Hara"", 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Nicolls', 'Affiliation': 'Divison of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Springman', 'Affiliation': 'Illuma Biosciences LLC, Punta Gorda, FL, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Parsonnet', 'Affiliation': 'Divison of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA; Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Rogers', 'Affiliation': 'Divison of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Levitt', 'Affiliation': 'Divison of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Manisha', 'Initials': 'M', 'LastName': 'Desai', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA. Electronic address: manishad@stanford.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106509'] 1728,34278925,The effects of endurance exercise combined with high-temperature head-out water immersion on serum concentration of brain-derived neurotrophic factor in healthy young men.,"OBJECTIVES To evaluate acute changes in serum brain-derived neurotrophic factor (BDNF) concentration following combined endurance exercise and heat stress through head-out water immersion (HOI). SETTING Observational study with crossover design. METHODS Ten healthy young male participants performed HOI at 40 °C (40 °C HOI) or continuous cycling at 60% of maximal oxygen uptake while immersed in 40 °C (40 °C HOI-ex) or 23 °C water (23 °C HOI-ex) for 15 min. Serum BDNF, cortisol and lactate concentrations, and core temperature (T core ) were measured pre, immediately post, and 15 and 30 min post-immersion. RESULTS BDNF concentration increased immediately and 15 min after 40 °C HOI-ex, but not after 40 °C or 23 °C HOI-ex. No changes in T core concentration were observed during 23 °C HOI-ex (Pre; 37.3 °C ± 0.3 °C, Post; 37.8 °C ± 0.2 °C, Post 15; 37.4 °C ± 0.3 °C, Post 30; 37.2 °C ± 0.2 °C). T core increased significantly post, post 15, and post 30 min of 40 °C HOI (Pre; 37.1 °C ± 0.4 °C, Post; 38.8 °C ± 0.5 °C, Post 15; 37.9 °C ± 0.4 °C, Post 30; 37.9 °C ± 0.2 °C) and 40 °C HOI-ex (Pre; 37.2 °C ± 0.2 °C, Post; 40.2 °C ± 0.7 °C, Post 15; 38.9 °C ± 0.5 °C, Post 30; 38.3 °C ± 0.5 °C). T core was higher in 40 °C HOI-ex compared with 40 °C HOI and 23 °C HOI-ex immediately post and post 15 min. Plasma lactate and cortisol were significantly higher in 40 °C HOI-ex compared with 40 °C HOI and 23 °C HOI-ex after immersion ( p  = 0.001). CONCLUSION While 15 min HOI alone or thermoneutral exercise do not increase BDNF concentration, both combined may form a time-efficient strategy to acutely elevate BDNF.",2021,Plasma lactate and cortisol were significantly higher in 40 °C HOI-ex compared with 40 ,"['healthy young men', 'Ten healthy young male participants performed']","['endurance exercise combined with high-temperature head-out water immersion', 'combined endurance exercise and heat stress through head-out water immersion (HOI', 'HOI at 40\u2009°C (40\u2009°C HOI) or continuous cycling at 60% of maximal oxygen uptake while immersed in 40\u2009°C']","['serum concentration of brain-derived neurotrophic factor', 'T core concentration', 'BDNF concentration', 'Plasma lactate and cortisol', 'Serum BDNF, cortisol and lactate concentrations, and core temperature (T core ']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0020940', 'cui_str': 'Immersion'}, {'cui': 'C0282507', 'cui_str': 'Stress Disorders, Heat'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}]",10.0,0.023201,Plasma lactate and cortisol were significantly higher in 40 °C HOI-ex compared with 40 ,"[{'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Ohko', 'Affiliation': 'Department of Rehabilitation and Care, Seijoh University, Aichi, Japan.'}, {'ForeName': 'Yasunori', 'Initials': 'Y', 'LastName': 'Umemoto', 'Affiliation': 'Department of Rehabilitation Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan.'}, {'ForeName': 'Yuta', 'Initials': 'Y', 'LastName': 'Sakurai', 'Affiliation': 'Research Center of Sports Medicine and Balneology, Nachikatsuura Balneologic Town Hospital, Tenma-Nachikatuurachou, Japan.'}, {'ForeName': 'Shouhei', 'Initials': 'S', 'LastName': 'Araki', 'Affiliation': 'Research Center of Sports Medicine and Balneology, Nachikatsuura Balneologic Town Hospital, Tenma-Nachikatuurachou, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Kojima', 'Affiliation': 'Department of Rehabilitation Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan.'}, {'ForeName': 'Yoshiichiro', 'Initials': 'Y', 'LastName': 'Kamijo', 'Affiliation': 'Department of Rehabilitation Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan.'}, {'ForeName': 'Kota', 'Initials': 'K', 'LastName': 'Murai', 'Affiliation': 'Department of Rehabilitation Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Yasuoka', 'Affiliation': 'Department of Rehabilitation Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan.'}, {'ForeName': 'Fumihiro', 'Initials': 'F', 'LastName': 'Tajima', 'Affiliation': 'Department of Rehabilitation Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan.'}]","International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group",['10.1080/02656736.2021.1922761'] 1729,34280667,Comparison of blended versus traditional classrooms among undergraduate nursing students: A quasi-experimental study.,"BACKGROUND Blended learning is a relatively new educational approach that has been introduced into higher education in Palestine. While it has many advantages, there is no empirical evidence, nor any case studies from Palestine to support the use of blended learning over traditional classroom. OBJECTIVES To compare students' learning outcomes, learning perceptions of their educational environment, and satisfaction of blended learning versus traditional classroom. DESIGN A quasi-experimental study. SETTING A public university in Palestine. PARTICIPANTS 102 Bachelor of Science in nursing students enrolled on the maternal health course. METHODS Students freely chose to register for the blended teaching section (49 students) or traditional classroom (53 students), then the teaching method for each section was assigned. Student demographics, course component grades, perceptions of the educational environment, measured by the Arabic version of Dundee Ready Education Environment Measurement (DREEM) inventory, and degree of satisfaction were collected in this study. Descriptive statistics and the Independent Sample t-test were used to analyze the data. RESULTS The sample included 49 students in the blended teaching section and 53 students in the traditional section. Overall DREEM scores, Student Perceptions of Learning, and Student Perceptions of Teachers were significantly higher for students taught with the blended method compared to traditional classroom settings. The total DREEM scores were between 101 and 151 for both sections, indicating that all students, regardless of teaching method, had more positive than negative perceptions of their educational environment. Moreover, there was no significant difference in scores and total course GPA (Grade Point Average), both with and without assignment grades, or between blended and traditional learning in first, second and final exams. However, students taught with the blended format scored significantly higher in assignments than students taught the traditional classroom. CONCLUSIONS Blended learning can be a useful educational approach in nursing education and Palestinian universities may consider using it for nursing courses.",2021,"Overall DREEM scores, Student Perceptions of Learning, and Student Perceptions of Teachers were significantly higher for students taught with the blended method compared to traditional classroom settings.","['49 students in the blended teaching section and 53 students in the traditional section', 'Students freely chose to register for the blended teaching section (49 students) or traditional classroom (53 students), then the teaching method for each section was assigned', 'undergraduate nursing students', 'A public university in Palestine', '102 Bachelor of Science in nursing students enrolled on the maternal health course']","['blended learning versus traditional classroom', 'blended versus traditional classrooms']","['total DREEM scores', 'scores and total course GPA', 'Overall DREEM scores, Student Perceptions of Learning, and Student Perceptions of Teachers', 'Student demographics, course component grades, perceptions of the educational environment, measured by the Arabic version of Dundee Ready Education Environment Measurement (DREEM) inventory, and degree of satisfaction']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0039403', 'cui_str': 'Teaching Methods'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0337600', 'cui_str': 'Bachelor'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0024921', 'cui_str': 'Maternal Health'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0017955', 'cui_str': 'Glycophorin A'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0574175', 'cui_str': 'Arabic language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0594298,"Overall DREEM scores, Student Perceptions of Learning, and Student Perceptions of Teachers were significantly higher for students taught with the blended method compared to traditional classroom settings.","[{'ForeName': 'Eman', 'Initials': 'E', 'LastName': 'Alshawish', 'Affiliation': 'Nursing and Midwifery Department, Faculty of Medicine and Health Sciences, An-Najah National University, New Campus Building: 17 Office 2170, Nablus, Palestine. Electronic address: alshawish@najah.edu.'}, {'ForeName': 'Majeda M', 'Initials': 'MM', 'LastName': 'El-Banna', 'Affiliation': 'The George Washington University School of Nursing, 45085 University Drive, Innovation Hall 201-G, Ashburn, VA 20147, United States of America. Electronic address: melbanna@gwu.edu.'}, {'ForeName': 'Intima', 'Initials': 'I', 'LastName': 'Alrimawi', 'Affiliation': 'School of Nursing and Health Professions, Trinity Washington University, 125 Michigan Ave, NE, Washington, DC 20017, United States of America. Electronic address: AlrimawiI@trinitydc.edu.'}]",Nurse education today,['10.1016/j.nedt.2021.105049'] 1730,34280591,Couples' Use of Online Stress Management and Resiliency Training for Sexual Health Concerns: A Randomized Controlled Trial.,"INTRODUCTION Mindfulness is a promising intervention for female sexual dysfunction (FSD); however, of the mindfulness interventions studied, few treat the woman and her partner. AIM We developed a brief online mindfulness, resilience, and psychoeducation intervention, Stress Management and Resiliency Training for Sexuality (Sex SMART), for women with sexual health concerns and their partners. METHODS Women with female sexual interest/arousal disorder and their partners were recruited between February 24, 2015, and October 6, 2016, and randomized to treatment or control groups (received educational pamphlets). The treatment intervention comprised of an online SMART and sexual health psychoeducation module. MAIN OUTCOME MEASURES The Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS-R), Sexual Desire Inventory-2 (SDI-2), Revised Dyadic Adjustment Scale (RDAS), International Index of Erectile Function (IIEF), and other subjective measures were used to assess sexual function and sexual distress at baseline and 12 weeks. RESULTS The study included 60 women and their partners (30 couples in each group). In both groups, sexual function by total FSFI scores and sexual distress scores significantly improved at 12 weeks compared with baseline, with no significant between-group differences (FSFI effect estimate for Sex SMART vs control = +1.4 (90% CI [-0.6 to +3.4]; P=.13). Both participants and partners randomized to the intervention reported significantly improved attitude and feelings, comfort as a sexual person, and subjective sexual functioning at 12 weeks. The findings provide preliminary evidence for efficacy of an online intervention for couples with sexual health problems. CONCLUSIONS A brief online mindfulness, resilience, and psychoeducation-based intervention showed no significant improvement in many outcomes (FSFI, FSDS-R, SDI-2, RDAS) of sexual health versus controls. Although this is the first online randomized controlled trial to evaluate a mindfulness-based therapy intervention, it was limited by its lack of population diversity and high attrition rate. Significant improvements in subjective sexual health and partner sexual function by the International Index of Erectile Function were reported only in the intervention group. Rullo JE, Sood R, Fokken SC, et al. Couples' Use of Online Stress Management and Resiliency Training for Sexual Health Concerns: A Randomized Controlled Trial. Sex Med 2021;9:100404.",2021,"In both groups, sexual function by total FSFI scores and sexual distress scores significantly improved at 12 weeks compared with baseline, with no significant between-group differences (FSFI effect estimate for Sex SMART vs control = +1.4 (90% CI [-0.6 to +3.4]; P=.13).","['women with sexual health concerns and their partners', 'female sexual dysfunction (FSD', 'Women with female sexual interest/arousal disorder and their partners were recruited between February 24, 2015, and October 6, 2016', 'Sexual Health Concerns', 'couples with sexual health problems', '60 women and their partners (30 couples in each group']","['Online Stress Management and Resiliency Training', 'psychoeducation intervention, Stress Management and Resiliency Training for Sexuality (Sex SMART', 'online intervention', 'online SMART and sexual health psychoeducation module', 'control groups (received educational pamphlets']","['Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS-R), Sexual Desire Inventory-2 (SDI-2), Revised Dyadic Adjustment Scale (RDAS), International Index of Erectile Function (IIEF), and other subjective measures', 'subjective sexual health and partner sexual function', 'sexual function and sexual distress', 'many outcomes (FSFI, FSDS-R, SDI-2, RDAS) of sexual health', 'International Index of Erectile Function', 'sexual function by total FSFI scores and sexual distress scores', 'attitude and feelings, comfort as a sexual person, and subjective sexual functioning']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C1112442', 'cui_str': 'Female sexual dysfunction'}, {'cui': 'C0424400', 'cui_str': 'Erotic interest'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C3898714', 'cui_str': 'Internet Intervention'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}]","[{'cui': 'C0278098', 'cui_str': 'Female sexual function'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0023618', 'cui_str': 'Libido'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C2960541', 'cui_str': 'International index of erectile function'}, {'cui': 'C0030847', 'cui_str': 'Penile erection'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0036911', 'cui_str': 'Sexual partners'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",60.0,0.021302,"In both groups, sexual function by total FSFI scores and sexual distress scores significantly improved at 12 weeks compared with baseline, with no significant between-group differences (FSFI effect estimate for Sex SMART vs control = +1.4 (90% CI [-0.6 to +3.4]; P=.13).","[{'ForeName': 'Jordan E', 'Initials': 'JE', 'LastName': 'Rullo', 'Affiliation': ""Menopause and Women's Sexual Health Clinic, Rochester, Minnesota; Department of Clinical Psychology, The University of Utah, Salt Lake City, Utah. Electronic address: jordan.rullo@psych.utah.edu.""}, {'ForeName': 'Richa', 'Initials': 'R', 'LastName': 'Sood', 'Affiliation': ""Menopause and Women's Sexual Health Clinic, Rochester, Minnesota; Center for Women's Health, Rochester, Minnesota.""}, {'ForeName': 'Shawn C', 'Initials': 'SC', 'LastName': 'Fokken', 'Affiliation': 'Division of General Internal Medicine, Rochester, Minnesota.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Sood', 'Affiliation': 'Viterbo University, La Crosse, Wisconsin.'}, {'ForeName': 'Karla S', 'Initials': 'KS', 'LastName': 'Frohmader', 'Affiliation': 'Center for Individualized Medicine, Rochester, Minnesota.'}, {'ForeName': 'Ivana T', 'Initials': 'IT', 'LastName': 'Croghan', 'Affiliation': 'Division of General Internal Medicine, Rochester, Minnesota; Division of Epidemiology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Darrell R', 'Initials': 'DR', 'LastName': 'Schroeder', 'Affiliation': 'Division of Biomedical Statistics and Informatics, Rochester, Minnesota.'}, {'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': 'Faubion', 'Affiliation': ""Center for Women's Health, Rochester, Minnesota; Division of General Internal Medicine, Mayo Clinic, Jacksonville, Florida.""}]",Sexual medicine,['10.1016/j.esxm.2021.100404'] 1731,34285350,Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative.,"BACKGROUND Decipher Biopsy is a commercially available gene expression classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently, there are no prospective data evaluating its clinical utility. We seek to assess the clinical utility of Decipher Biopsy in localized PCa patients. METHODS A multi-institutional study of 855 men who underwent Decipher Biopsy testing between February 2015 and October 2019. All patients were tracked through the prospective Michigan Urological Surgery Improvement Collaborative and linked to the Decipher Genomics Resource Information Database (GRID ® ; NCT02609269). Patient matching was performed by an independent third-party (ArborMetrix Inc.) using two or more unique identifiers. Cumulative incidence curves for time to treatment (TTT) and time to failure (TTF) were constructed using Kaplan-Meier estimates. Multivariable Cox proportional hazard models were used to evaluate the independent association of high-risk Decipher scores with the conversion from AS to radical therapy and treatment failure (biochemical failure or receipt of salvage therapy). RESULTS AND LIMITATIONS Eight hundred fifty-five patients underwent Decipher Biopsy testing during the study period. Of the 855 men, 264 proceeded to AS (31%), and 454 (53%) received radical therapy. In men electing AS, after adjusting for NCCN risk group, age, PSA, prostate volume, body mass index, and percent positive cores, a high-risk Decipher score was independently associated with shorter TTT (HR 2.51, 95% CI 1.52-4.13 p < 0.001). Similarly, in patients that underwent radical therapy, a high-risk Decipher score was independently associated with TTF (HR 2.98, 95% CI 1.22-7.29, p = 0.01) on multivariable analysis. Follow-up time was a limitation. CONCLUSION In a prospective statewide registry, high-risk Decipher Biopsy score was strongly and independently associated with conversion from AS to definitive treatment and treatment failure. These real-world data support the clinical utility of Decipher Biopsy. An ongoing phase 3 randomized trial (NCT04396808) will provide level 1 evidence of the clinical impact of Decipher biopsy testing.",2021,"In men electing AS, after adjusting for NCCN risk group, age, PSA, prostate volume, body mass index, and percent positive cores, a high-risk Decipher score was independently associated with shorter TTT (HR 2.51, 95% CI 1.52-4.13 p < 0.001).","['localized prostate cancer', '855 men who underwent Decipher Biopsy testing between February 2015 and October 2019', '855 men, 264 proceeded to AS (31%), and 454 (53%) received', 'localized PCa patients', 'Eight hundred fifty-five patients underwent Decipher Biopsy testing during the study period', 'newly diagnosed prostate cancer (PCa']","['Decipher Biopsy testing', 'radical therapy']","['Cumulative incidence curves for time to treatment (TTT) and time to failure (TTF', 'high-risk Decipher score']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C4517782', 'cui_str': '454'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0450382', 'cui_str': '55'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C3494202', 'cui_str': 'Time to Treatment'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",855.0,0.070805,"In men electing AS, after adjusting for NCCN risk group, age, PSA, prostate volume, body mass index, and percent positive cores, a high-risk Decipher score was independently associated with shorter TTT (HR 2.51, 95% CI 1.52-4.13 p < 0.001).","[{'ForeName': 'Randy A', 'Initials': 'RA', 'LastName': 'Vince', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA. virandy@med.umich.edu.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Jiang', 'Affiliation': 'Department of Biostatics, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Ji', 'Initials': 'J', 'LastName': 'Qi', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Tosoian', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Takele', 'Affiliation': 'Edward Via College of Osteopathic Medicine, Blacksburg, VA, USA.'}, {'ForeName': 'Felix Y', 'Initials': 'FY', 'LastName': 'Feng', 'Affiliation': 'Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Linsell', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Johnson', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Sughand', 'Initials': 'S', 'LastName': 'Shetty', 'Affiliation': 'Oakland University William Beaumont School of Medicine, Auburn Hills, MI, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Hurley', 'Affiliation': 'Oakland University William Beaumont School of Medicine, Auburn Hills, MI, USA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Miller', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Arvin', 'Initials': 'A', 'LastName': 'George', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Khurshid', 'Initials': 'K', 'LastName': 'Ghani', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Fionna', 'Initials': 'F', 'LastName': 'Sun', 'Affiliation': 'Oakland University William Beaumont School of Medicine, Auburn Hills, MI, USA.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Seymore', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Dess', 'Affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Jackson', 'Affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Schipper', 'Affiliation': 'Department of Biostatics, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Spratt', 'Affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Todd M', 'Initials': 'TM', 'LastName': 'Morgan', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, MI, USA.'}]",Prostate cancer and prostatic diseases,['10.1038/s41391-021-00428-y'] 1732,34285282,Concomitant oral intake of purified clinoptilolite tuff (G-PUR) reduces enteral lead uptake in healthy humans.,"Lead exposure can cause substantial organ damage. Enteral lead absorption may be reduced by concomitant intake of clinoptilolite tuff, a zeolite from natural sources. This study aimed to assess the effect of purified clinoptilolite tuff (G-PUR) on enteral lead uptake in adults using stable lead isotope 204 Pb as a tracer. In this randomized, placebo-controlled, double-blind, parallel-group study, 42 healthy participants were randomized to receive oral G-PUR 2.0 g, 2 * 2.0 g, or placebo, together with 2.5 µg of 204 Pb in water. The enrichment of 204 Pb caused by the tracer in blood and urine was measured by mass spectrometry. G-PUR was well tolerated. The mean maximum 204 Pb enrichment of 0.505% of total blood lead was significantly higher (p < 0.0001) in the placebo group compared to G-PUR 2.0 g (0.073%) or G-PUR 2 * 2.0 g (0.057%) group. Normalized 204 Pb AUC 0-192 was 86.5, 11.9, and 8.5% * h without and with G-PUR 2.0 g, and G-PUR 2 * 2.0 g, respectively (p < 0.0001 vs. placebo). This smaller 204 Pb exposure was paralleled by a reduced urinary excretion in subjects receiving G-PUR. Concomitant oral intake of purified clinoptilolite tuff reduced enteral uptake of 204 Pb in healthy humans by approximately 90%. The reduced bioavailability is demonstrable by a decrease of 204 Pb tracer enrichment in blood and urine.Trial registration: clinicaltrials.gov identifier: NCT04138693, registered 24/10/2019.",2021,The mean maximum 204 Pb enrichment of 0.505% of total blood lead was significantly higher (p < 0.0001) in the placebo group compared to G-PUR 2.0 g (0.073%) or G-PUR 2,"['healthy humans', 'adults using stable lead isotope 204 Pb as a tracer', '42 healthy participants']","['purified clinoptilolite tuff (G-PUR', 'oral G-PUR 2.0\xa0g, 2 * 2.0\xa0g, or placebo', 'placebo']","['urinary excretion', 'tolerated', 'reduced bioavailability', 'total blood lead', 'enteral uptake of']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0303230', 'cui_str': 'Lead isotope'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0661172', 'cui_str': 'clinoptilolite'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0853362', 'cui_str': 'Blood lead'}, {'cui': 'C1304890', 'cui_str': 'Enteral'}]",42.0,0.163495,The mean maximum 204 Pb enrichment of 0.505% of total blood lead was significantly higher (p < 0.0001) in the placebo group compared to G-PUR 2.0 g (0.073%) or G-PUR 2,"[{'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Samekova', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.'}, {'ForeName': 'Christa', 'Initials': 'C', 'LastName': 'Firbas', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Irrgeher', 'Affiliation': 'Department of General, Analytical and Physical Chemistry, Montanuniversität Leoben, Franz-Josef-Straße 18, 8700, Leoben, Austria.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Opper', 'Affiliation': 'Department of General, Analytical and Physical Chemistry, Montanuniversität Leoben, Franz-Josef-Straße 18, 8700, Leoben, Austria.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Prohaska', 'Affiliation': 'Department of General, Analytical and Physical Chemistry, Montanuniversität Leoben, Franz-Josef-Straße 18, 8700, Leoben, Austria.'}, {'ForeName': 'Anika', 'Initials': 'A', 'LastName': 'Retzmann', 'Affiliation': 'Department of General, Analytical and Physical Chemistry, Montanuniversität Leoben, Franz-Josef-Straße 18, 8700, Leoben, Austria.'}, {'ForeName': 'Cornelius', 'Initials': 'C', 'LastName': 'Tschegg', 'Affiliation': 'Glock Health, Science and Research GmbH, Hausfeldstraße 17, 2232, Deutsch-Wagram, Austria.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Meisslitzer', 'Affiliation': 'Glock Health, Science and Research GmbH, Hausfeldstraße 17, 2232, Deutsch-Wagram, Austria.'}, {'ForeName': 'Anastassiya', 'Initials': 'A', 'LastName': 'Tchaikovsky', 'Affiliation': 'Glock Health, Science and Research GmbH, Hausfeldstraße 17, 2232, Deutsch-Wagram, Austria.'}, {'ForeName': 'Ghazaleh', 'Initials': 'G', 'LastName': 'Gouya', 'Affiliation': 'Gouya Insights, Elisabethstrasse 22/12, 1010, Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Freissmuth', 'Affiliation': 'Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Währingerstrasse 13a, Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wolzt', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. michael.wolzt@meduniwien.ac.at.'}]",Scientific reports,['10.1038/s41598-021-94245-x'] 1733,34284333,Musical enjoyment does not enhance walking speed in healthy adults during music-based auditory cueing.,"BACKGROUND Rhythmic Auditory Stimulation (RAS) involves synchronizing footsteps to music or a metronome to improve gait speed and stability in patients with neurological disorders, such as Parkinson's disease. However, responses to RAS vary across individuals, perhaps because of differences in enjoyment of the music or in musical abilities. RESEARCH QUESTION Intuitively, musical enjoyment may influence gait responses to RAS, but enjoyment has not been systematically manipulated nor the effects empirically assessed. In addition, differences in beat perception ability are likely to influence gait responses to music, particularly when synchronizing to the beat. Therefore, we asked: how does music enjoyment alter gait, and do gait parameters differ between individuals with good versus poor beat perception ability, specifically when instructed to 'walk freely' versus 'synchronize to the beat'? METHOD Young adults and older adults walked on a pressure sensor walkway in silence and to music that they had rated as either high or low in enjoyment, as well as a metronome. All stimuli were presented at 15 % faster than baseline cadence. Participants either walked freely to the music or synchronized to the beat. RESULTS Music enjoyment had no significant effects on gait in either younger or older adults. Compared to baseline, younger adults walked faster (by taking longer strides) to music than the metronome, whereas older adults walked faster (by taking more steps per minute) to the metronome than music. When instructed to synchronize vs. walk freely, young adults walked faster, but older adults walked slower. Finally, regardless of instruction type, young adults with poor beat perception took shorter and slower strides to the music, whereas older adults with poor beat perception took slower strides to the music. SIGNIFICANCE Beat perception ability, instruction type, and age affect gait more than music enjoyment does, and thus should be considered when optimizing RAS outcomes.",2021,"Compared to baseline, younger adults walked faster (by taking longer strides) to music than the metronome, whereas older adults walked faster (by taking more steps per minute) to the metronome than music.","[""patients with neurological disorders, such as Parkinson's disease"", 'young adults with poor beat perception took shorter and slower strides to the music, whereas older adults with poor beat perception took slower strides to the music', 'healthy adults', 'Young adults and older adults walked on a pressure sensor walkway in silence and to music that they had rated as either high or low in enjoyment, as well as a metronome']","['Musical enjoyment', 'Rhythmic Auditory Stimulation (RAS']",['gait speed and stability'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027765', 'cui_str': 'Disorder of nervous system'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0183210', 'cui_str': 'Sensor device'}]","[{'cui': 'C0679105', 'cui_str': 'Pleasure'}, {'cui': 'C0001164', 'cui_str': 'Stimulation, Acoustic'}]","[{'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",,0.0349919,"Compared to baseline, younger adults walked faster (by taking longer strides) to music than the metronome, whereas older adults walked faster (by taking more steps per minute) to the metronome than music.","[{'ForeName': 'Brittany S', 'Initials': 'BS', 'LastName': 'Roberts', 'Affiliation': 'Brain and Mind Institute, University of Western Ontario, Canada. Electronic address: brober57@uwo.ca.'}, {'ForeName': 'Emily A', 'Initials': 'EA', 'LastName': 'Ready', 'Affiliation': 'Department of Psychology, University of Western Ontario, Canada. Electronic address: eready2@uwo.ca.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Grahn', 'Affiliation': 'Brain and Mind Institute, University of Western Ontario, Canada; Department of Psychology, University of Western Ontario, Canada. Electronic address: jgrahn@uwo.ca.'}]",Gait & posture,['10.1016/j.gaitpost.2021.04.008'] 1734,34284321,Budget Impact of Restrictive Strategy Versus Usual Care for Cholecystectomy (SECURE-trial).,"OBJECTIVES A cost-effectiveness analysis of a multicenter randomized-controlled trial comparing restrictive strategy versus usual care in patients with gallstones showed that savings by restrictive strategy could not compensate for the lower proportion of pain-free patients. However, four subgroups based on combined stratification factors resulted in less cholecystectomies and more pain-free patients in restrictive strategy (female-low volume-BMI > 30, female-low volume-BMI25-30, female-high volume-BMI25-30, and male-low volume-BMI < 25). The aim of this study was to explore the budget impact from a hospital healthcare perspective of implementation of restrictive strategy in these subgroups. METHODS Data of the SECURE-trial were used to calculate the hospital budget impact with a time horizon of four years. Based on a study into practice variation, about 19% of hospitals treat patients according restrictive strategy. This represents the proportion of patients treated according restrictive strategy at the start of budget period. Three subanalyses were performed: a scenario analysis in which 30% of patients fall under a restrictive strategy in clinical practice, a sensitivity analysis in which we calculated the budget impact with the low and high 95% confidence limits of the expected future number of patients, a subgroup analysis in which restrictive strategy was also implemented in two additional subgroups (male-high volume-BMI < 25 and female-high volume-BMI >30). RESULTS Budget impact analysis showed savings of €6.7-€15.6 million (2.2%-5.6%) for the period 2021-2024/2025 by implementing the restrictive strategy in the four subgroups and provision of usual care in other patients. Sensitivity analysis with 30% of patients already in the restrictive strategy at the start of the budget period, resulted in savings between €5.4 million and €14.0 million (1.7%-5.0%). CONCLUSION Performing a restrictive strategy for selection of cholecystectomy in subgroups of patients and provision of usual care in other patients will result in a lower overall hospital budget needed to treat patients with abdominal pain and gallstones. TRIAL REGISTRATION The Netherlands National Trial Register NTR4022. Registered on June 5, 2013.",2021,"However, four subgroups based on combined stratification factors resulted in less cholecystectomies and more pain-free patients in restrictive strategy (female-low volume-BMI > 30, female-low volume-BMI25-30, female-high volume-BMI25-30, and male-low volume-BMI < 25).","['two additional subgroups (male-high volume-BMI < 25 and female-high volume-BMI >30', 'patients with gallstones']","['Restrictive Strategy Versus Usual Care', 'restrictive strategy versus usual care']",[],"[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008350', 'cui_str': 'Biliary calculus'}]",[],[],3.0,0.0198697,"However, four subgroups based on combined stratification factors resulted in less cholecystectomies and more pain-free patients in restrictive strategy (female-low volume-BMI > 30, female-low volume-BMI25-30, female-high volume-BMI25-30, and male-low volume-BMI < 25).","[{'ForeName': 'Carmen S S', 'Initials': 'CSS', 'LastName': 'Latenstein', 'Affiliation': 'Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands. Electronic address: carmen.latenstein@radboudumc.nl.'}, {'ForeName': 'Aafke H', 'Initials': 'AH', 'LastName': 'van Dijk', 'Affiliation': 'Department of Surgery, Amsterdam UMC - University of Amsterdam, Amsterdam, the Netherlands, the Netherlands.'}, {'ForeName': 'Sarah Z', 'Initials': 'SZ', 'LastName': 'Wennmacker', 'Affiliation': 'Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands.'}, {'ForeName': 'Joost P H', 'Initials': 'JPH', 'LastName': 'Drenth', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands.'}, {'ForeName': 'Gert P', 'Initials': 'GP', 'LastName': 'Westert', 'Affiliation': 'IQ healthcare, Radboud University Medical Centre, Nijmegen, the Netherlands.'}, {'ForeName': 'Cornelis J H M', 'Initials': 'CJHM', 'LastName': 'van Laarhoven', 'Affiliation': 'Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands.'}, {'ForeName': 'Marja A', 'Initials': 'MA', 'LastName': 'Boermeester', 'Affiliation': 'Department of Surgery, Amsterdam UMC - University of Amsterdam, Amsterdam, the Netherlands, the Netherlands.'}, {'ForeName': 'Marcel G W', 'Initials': 'MGW', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Epidemiology and Data Science, Amsterdam UMC - University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Philip R', 'Initials': 'PR', 'LastName': 'de Reuver', 'Affiliation': 'Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands. Electronic address: philip.dereuver@radboudumc.nl.'}]",The Journal of surgical research,['10.1016/j.jss.2021.06.033'] 1735,34283660,"Effect of whole-body resistance training at different load intensities on circulating inflammatory biomarkers, body fat, muscular strength, and physical performance in postmenopausal women.","The primary purpose of this study was to identify the impact of whole-body resistance training (RT) at different load intensities on adipokines, adhesion molecules, and extracellular heat shock proteins in postmenopausal women. As secondary purpose, we analyzed the impact of RT at different load intensities on body fat, muscular strength, and physical performance. Forty participants were randomized into lower-load intensity RT (LIRT, n = 20, 30-35 repetition maximum in the first set of each exercise) or higher-load intensity RT (HIRT, n = 20, 8-12 repetition maximum in the first set of each exercise). Adipokines (adiponectin and leptin), adhesion molecules (MCP-1 and ICAM-1), extracellular heat shock proteins (HO-1 and eHSP60), body fat, muscular strength (1RM), and physical performance [400-meter walking test (400-M) and 6-minute walking test (6MWT)] were analyzed at baseline and after 12-weeks RT. There was a significant time-by-group interaction for eHSP60 ( P = 0.049) and 400-M ( P = 0.003), indicating superiority of HIRT ( d = 0.47 and 0.55). However, both groups similarly improved adiponectin, ICAM-1, HO-1, body fat, 1RM, and 6MWT ( P < 0.05). Our study suggests that load intensity does not seem to determine the RT effect on several obesity-related pro-inflammatory and chemotactic compounds, body fat, 1RM, and 6MWT in postmenopausal women, although a greater improvement has been revealed for eHSP60 and 400-M in HIRT. Novelty: Higher-load intensity resistance training improves eHSP60 and 400-M in postmenopausal women. Resistance training improves the inflammatory profile, body fat, muscle strength, and 6MWT, regardless of load intensity.",2021,There was a significant time-by-group interaction for eHSP60,"['Forty participants', 'postmenopausal women']","['eHSP60', 'Resistance training', 'whole-body resistance training', 'lower-load intensity RT (LIRT, n = 20, 30-35 repetition maximum in the first set of each exercise) or higher-load intensity RT (HIRT, n = 20, 8-12 repetition maximum in the first set of each exercise', 'whole-body resistance training (RT']","['Adipokines (adiponectin and leptin), adhesion molecules (MCP-1 and ICAM-1), extracellular heat shock proteins (HO-1 and eHSP60), body fat, muscular strength (1RM), and physical performance [400-meter walking test (400-M) and 6-minute walking test (6MWT', 'inflammatory profile, body fat, muscle strength, and 6MWT, regardless of load intensity', 'body fat, muscular strength, and physical performance', 'circulating inflammatory biomarkers, body fat, muscular strength, and physical performance', 'adiponectin, ICAM-1, HO-1, body fat, 1RM, and 6MWT']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C1955907', 'cui_str': 'Adipokine'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0007578', 'cui_str': 'Cell Adhesion Molecules'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0063695', 'cui_str': 'Lymphocyte antigen CD54'}, {'cui': 'C0521119', 'cui_str': 'Extracellular'}, {'cui': 'C0018850', 'cui_str': 'Heat-Shock Protein'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",40.0,0.0125746,There was a significant time-by-group interaction for eHSP60,"[{'ForeName': 'Marcelo A S', 'Initials': 'MAS', 'LastName': 'Carneiro', 'Affiliation': 'Applied Physiology, Nutrition and Exercise Research Group, Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Gersiel N de', 'Initials': 'GN', 'LastName': 'Oliveira Júnior', 'Affiliation': 'Applied Physiology, Nutrition and Exercise Research Group, Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Jairo F R', 'Initials': 'JFR', 'LastName': 'de Sousa', 'Affiliation': 'Applied Physiology, Nutrition and Exercise Research Group, Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Claudio L', 'Initials': 'CL', 'LastName': 'Orsatti', 'Affiliation': 'Applied Physiology, Nutrition and Exercise Research Group, Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Eddie F C', 'Initials': 'EFC', 'LastName': 'Murta', 'Affiliation': 'Research Institute of Oncology, Departament of Gynecology and Obstetrics, Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Márcia A', 'Initials': 'MA', 'LastName': 'Michelin', 'Affiliation': 'Research Institute of Oncology, Departament of Gynecology and Obstetrics, Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Edilson S', 'Initials': 'ES', 'LastName': 'Cyrino', 'Affiliation': 'Metabolism, Nutrition and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Paraná, Brazil.'}, {'ForeName': 'Fábio L', 'Initials': 'FL', 'LastName': 'Orsatti', 'Affiliation': 'Applied Physiology, Nutrition and Exercise Research Group, Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2020-0746'] 1736,34288015,The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.,"BACKGROUND Little is known about how benign prostatic hyperplasia (BPH) develops and why patients respond differently to medical therapy designed to reduce lower urinary tract symptoms (LUTS). The Medical Therapy of Prostatic Symptoms (MTOPS) trial randomized men with symptoms of BPH and followed response to medical therapy for up to 6 years. Treatment with a 5α-reductase inhibitor (5ARI) or an alpha-adrenergic receptor antagonist (α-blocker) reduced the risk of clinical progression, while men treated with combination therapy showed a 66% decrease in risk of progressive disease. However, medical therapies for BPH/LUTS are not effective in many patients. The reasons for nonresponse or loss of therapeutic response in the remaining patients over time are unknown. A better understanding of why patients fail to respond to medical therapy may have a major impact on developing new approaches for the medical treatment of BPH/LUTS. Prostaglandins (PG) act on G-protein-coupled receptors (GPCRs), where PGE 2 and PGF 2 elicit smooth muscle contraction. Therefore, we measured PG levels in the prostate tissue of BPH/LUTS patients to assess the possibility that this signaling pathway might explain the failure of medical therapy in BPH/LUTS patients. METHOD Surgical BPH (S-BPH) was defined as benign prostatic tissue collected from the transition zone (TZ) of patients who failed medical therapy and underwent surgical intervention to relieve LUTS. Control tissue was termed Incidental BPH (I-BPH). I-BPH was TZ obtained from men undergoing radical prostatectomy for low-volume, low-grade prostatic adenocarcinoma (PCa, Gleason score ≤ 7) confined to the peripheral zone. All TZ tissue was confirmed to be cancer-free. S-BPH patients divided into four subgroups: patients on α-blockers alone, 5ARI alone, combination therapy (α-blockers plus 5ARI), or no medical therapy (none) before surgical resection. I-BPH tissue was subgrouped by prior therapy (either on α-blockers or without prior medical therapy before prostatectomy). We measured prostatic tissue levels of prostaglandins (PGF 2α , PGI 2 , PGE 2 , PGD 2 , and TxA 2 ), quantitative polymerase chain reaction levels of mRNAs encoding enzymes within the PG synthesis pathway, cellular distribution of COX1 (PTGS1) and COX2 (PTGS2), and tested the ability of PGs to contract bladder smooth muscle in an in vitro assay. RESULTS All PGs were significantly elevated in TZ tissues from S-BPH patients (n = 36) compared to I-BPH patients (n = 15), regardless of the treatment subgroups. In S-BPH versus I-BPH, mRNA for PG synthetic enzymes COX1 and COX2 were significantly elevated. In addition, mRNA for enzymes that convert the precursor PGH 2 to metabolite PGs were variable: PTGIS (which generates PGI 2 ) and PTGDS (PGD 2 ) were significantly elevated; nonsignificant increases were observed for PTGES (PGE 2 ), AKR1C3 (PGF 2α ), and TBxAS1 (TxA 2 ). Within the I-BPH group, men responding to α-blockers for symptoms of BPH but requiring prostatectomy for PCa did not show elevated levels of COX1, COX2, or PGs. By immunohistochemistry, COX1 was predominantly observed in the prostatic stroma while COX2 was present in scattered luminal cells of isolated prostatic glands in S-BPH. PGE 2 and PGF 2α induced contraction of bladder smooth muscle in an in vitro assay. Furthermore, using the smooth muscle assay, we demonstrated that α-blockers that inhibit alpha-adrenergic receptors do not appear to inhibit PG stimulation of GPCRs in bladder muscle. Only patients who required surgery to relieve BPH/LUTS symptoms showed significantly increased tissue levels of PGs and the PG synthetic enzymes. CONCLUSIONS Treatment of BPH/LUTS by inhibition of alpha-adrenergic receptors with pharmaceutical α-blockers or inhibiting androgenesis with 5ARI may fail because of elevated paracrine signaling by prostatic PGs that can cause smooth muscle contraction. In contrast to patients who fail medical therapy for BPH/LUTS, control I-BPH patients do not show the same evidence of elevated PG pathway signaling. Elevation of the PG pathway may explain, in part, why the risk of clinical progression in the MTOPS study was only reduced by 34% with α-blocker treatment.",2021,"Only patients who required surgery to relieve BPH/LUTS symptoms showed significantly increased tissue levels of PGs and the PG synthetic enzymes. ","['Surgical BPH (S-BPH) was defined as benign prostatic tissue collected from the transition zone (TZ) of patients who failed medical therapy and underwent surgical intervention to relieve LUTS', 'Prostatic Symptoms (MTOPS) trial randomized men with symptoms of BPH and followed response to medical therapy for up to 6 years', 'patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms']","['α-blockers alone, 5ARI alone, combination therapy (α-blockers plus 5ARI), or no medical therapy (none) before surgical resection', '5α-reductase inhibitor (5ARI) or an alpha-adrenergic receptor antagonist (α-blocker', 'radical prostatectomy']","['prostatic tissue levels of prostaglandins (PGF 2α , PGI 2 , PGE 2 , PGD 2 , and TxA 2 ), quantitative polymerase chain reaction levels of mRNAs encoding enzymes within the PG synthesis pathway, cellular distribution of COX1 (PTGS1) and COX2 (PTGS2', 'risk of progressive disease', 'tissue levels of PGs and the PG synthetic enzymes', 'COX1, COX2, or PGs']","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0005001', 'cui_str': 'Hypertrophy, Benign Prostatic'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0332303', 'cui_str': 'Relieved by'}, {'cui': 'C0574785', 'cui_str': 'Lower urinary tract symptoms'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0030016', 'cui_str': 'Oxidoreductase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0001641', 'cui_str': 'Alpha adrenergic receptor antagonist'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}]","[{'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0033554', 'cui_str': 'Prostaglandin'}, {'cui': 'C0033561', 'cui_str': 'F series prostaglandin'}, {'cui': 'C0523816', 'cui_str': 'Pepsinogen I measurement'}, {'cui': 'C0033559', 'cui_str': 'E series prostaglandin'}, {'cui': 'C0033558', 'cui_str': 'PGD'}, {'cui': 'C0040057', 'cui_str': 'Thromboxane A>2<'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0014442', 'cui_str': 'Enzyme'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C1565830', 'cui_str': 'PTGS1 protein, human'}, {'cui': 'C1565860', 'cui_str': 'PTGS2 protein, human'}, {'cui': 'C0387583', 'cui_str': 'Cyclooxygenase 2'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0031619', 'cui_str': 'Glycerol Phosphoglycerides'}]",,0.0180433,"Only patients who required surgery to relieve BPH/LUTS symptoms showed significantly increased tissue levels of PGs and the PG synthetic enzymes. ","[{'ForeName': 'RenJie', 'Initials': 'R', 'LastName': 'Jin', 'Affiliation': 'Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Douglas W', 'Initials': 'DW', 'LastName': 'Strand', 'Affiliation': 'Department of Urology, UT Southwestern, Dallas, Texas, USA.'}, {'ForeName': 'Connor M', 'Initials': 'CM', 'LastName': 'Forbes', 'Affiliation': 'Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Case', 'Affiliation': 'Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Justin M M', 'Initials': 'JMM', 'LastName': 'Cates', 'Affiliation': 'Department of Pathology,\xa0Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': 'Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Marisol', 'Initials': 'M', 'LastName': 'Ramirez-Solano', 'Affiliation': 'Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Ginger L', 'Initials': 'GL', 'LastName': 'Milne', 'Affiliation': 'Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Sanchez', 'Affiliation': 'Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Zunyi Y', 'Initials': 'ZY', 'LastName': 'Wang', 'Affiliation': 'Department of Surgical Science, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA.'}, {'ForeName': 'Dale E', 'Initials': 'DE', 'LastName': 'Bjorling', 'Affiliation': 'Department of Surgical Science, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA.'}, {'ForeName': 'Nicole L', 'Initials': 'NL', 'LastName': 'Miller', 'Affiliation': 'Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Matusik', 'Affiliation': 'Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}]",The Prostate,['10.1002/pros.24190'] 1737,34289408,Using marginal structural models to analyze randomized clinical trials with non-adherence and lost to follow up.,"BACKGROUND In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment. METHODS Inverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix. RESULTS Out of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21). CONCLUSION Concordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials.",2021,"RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21). ","['Out of 488 participants, 174 (36']","['theophylline vs. placebo', 'montelukast vs. placebo', 'ITT analysis (theophylline vs. montelukast', 'placebo', 'Marginal Structural Models (MSMs']",['adjusted relative risks (RR'],"[{'cui': 'C4517604', 'cui_str': '174'}]","[{'cui': 'C0039771', 'cui_str': 'Theophylline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0298130', 'cui_str': 'montelukast'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0026349', 'cui_str': 'Models, Structural'}]","[{'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}]",488.0,0.640567,"RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21). ","[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Lancet', 'Affiliation': 'Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York, New York, NY. Electronic address: Elizabeth.Lancet13@sphmail.cuny.edu.'}, {'ForeName': 'Luisa N', 'Initials': 'LN', 'LastName': 'Borrell', 'Affiliation': 'Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York, New York, NY.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Holbrook', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Morabia', 'Affiliation': 'Barry Commoner Center for Health and the Environment, Queens College, City University of New York, Flushing, NY.'}]",Annals of epidemiology,['10.1016/j.annepidem.2021.07.001'] 1738,34292298,Home-Use Evaluation of a Wearable Collision Warning Device for Individuals With Severe Vision Impairments: A Randomized Clinical Trial.,"Importance There is scant rigorous evidence about the real-world mobility benefit of electronic mobility aids. Objective To evaluate the effect of a collision warning device on the number of contacts experienced by blind and visually impaired people in their daily mobility. Design, Setting, and Participants In this double-masked randomized clinical trial, participants used a collision warning device during their daily mobility over a period of 4 weeks. A volunteer sample of 31 independently mobile individuals with severe visual impairments, including total blindness and peripheral visual field restrictions, who used a long cane or guide dog as their habitual mobility aid completed the study. The study was conducted from January 2018 to December 2019. Interventions The device automatically detected collision hazards using a chest-mounted video camera. It randomly switched between 2 modes: active mode (intervention condition), where it provided alerts for detected collision threats via 2 vibrotactile wristbands, and silent mode (control condition), where the device still detected collisions but did not provide any warnings to the user. Scene videos along with the collision warning information were recorded by the device. Potential collisions detected by the device were reviewed and scored, including contacts with the hazards, by 2 independent reviewers. Participants and reviewers were masked to the device operation mode. Main Outcomes and Measures Rate of contacts per 100 hazards per hour, compared between the 2 device modes within each participant. Modified intention-to-treat analysis was used. Results Of the 31 included participants, 18 (58%) were male, and the median (range) age was 61 (25-73) years. A total of 19 participants (61%) had a visual acuity (VA) of light perception or worse, and 28 (90%) reported a long cane as their habitual mobility aid. The median (interquartile range) number of contacts was lower in the active mode compared with silent mode (9.3 [6.6-14.9] vs 13.8 [6.9-24.3]; difference, 4.5; 95% CI, 1.5-10.7; P < .001). Controlling for demographic characteristics, presence of VA better than light perception, and fall history, the rate of contacts significantly reduced in the active mode compared with the silent mode (β = 0.63; 95% CI, 0.54-0.73; P < .001). Conclusions and Relevance In this study involving 31 visually impaired participants, the collision warnings were associated with a reduced rate of contacts with obstacles in daily mobility, indicating the potential of the device to augment habitual mobility aids. Trial Registration ClinicalTrials.gov Identifier: NCT03057496.",2021,"In this study involving 31 visually impaired participants, the collision warnings were associated with a reduced rate of contacts with obstacles in daily mobility, indicating the potential of the device to augment habitual mobility aids. ","['31 included participants, 18 (58%) were male, and the median (range) age was 61 (25-73) years', 'January 2018 to December 2019', 'A volunteer sample of 31 independently mobile individuals with severe visual impairments, including total blindness and peripheral visual field restrictions, who used a long cane or guide dog as their habitual mobility aid completed the study', 'Individuals With Severe Vision Impairments', '31 visually impaired participants, the collision warnings', 'A total of 19 participants (61%) had a visual acuity (VA) of light perception or worse, and 28 (90%) reported a long cane as their habitual mobility aid']","['Wearable Collision Warning Device', 'collision warning device']","['Measures\n\n\nRate of contacts per 100 hazards per hour', 'median (interquartile range) number of contacts', 'rate of contacts']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1301509', 'cui_str': 'Severe visual impairment'}, {'cui': 'C1879328', 'cui_str': 'Blindness - both eyes'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C1283235', 'cui_str': 'Long cane'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0012984', 'cui_str': 'Canis lupus familiaris'}, {'cui': 'C3495449', 'cui_str': 'Mobility aid'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C3665347', 'cui_str': 'Visual impairment'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0564385', 'cui_str': '/hour'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",31.0,0.351682,"In this study involving 31 visually impaired participants, the collision warnings were associated with a reduced rate of contacts with obstacles in daily mobility, indicating the potential of the device to augment habitual mobility aids. ","[{'ForeName': 'Shrinivas', 'Initials': 'S', 'LastName': 'Pundlik', 'Affiliation': 'Schepens Eye Research Institute of Mass Eye and Ear, Boston, Massachusetts.'}, {'ForeName': 'Vilte', 'Initials': 'V', 'LastName': 'Baliutaviciute', 'Affiliation': 'Schepens Eye Research Institute of Mass Eye and Ear, Boston, Massachusetts.'}, {'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Moharrer', 'Affiliation': 'Schepens Eye Research Institute of Mass Eye and Ear, Boston, Massachusetts.'}, {'ForeName': 'Alex R', 'Initials': 'AR', 'LastName': 'Bowers', 'Affiliation': 'Schepens Eye Research Institute of Mass Eye and Ear, Boston, Massachusetts.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Luo', 'Affiliation': 'Schepens Eye Research Institute of Mass Eye and Ear, Boston, Massachusetts.'}]",JAMA ophthalmology,['10.1001/jamaophthalmol.2021.2624'] 1739,34304069,Comparison of greater occipital nerve and supra orbital nerve blocks methods in the treatment of acute migraine attack: A randomized double-blind controlled trial.,"OBJECTIVE The main goal of this investigation is to compare the Greater Occipital Nerve (GON) and Supra Orbital Nerve (SON) block methods used in the treatment of migraine attacks in the ED with each other, in combination, and with a placebo. METHODS This study was planned as a single center, prospective, double-blind, randomized control study. The patients were divided into 4 groups: GON, SON, Combined, and Placebo. Groups were named according to the nerve areas that were blocked. Therefore1% lidocaine for nerve blockade and 0.9% NaCl for placebo effect was used. Along with the time of admission, baseline pain scale values, as well as recordings at 30 and 60 min in addition to the Visual Analog Scale (VAS) at the 120th min. and Likert-Type (LT) Verbal scale at the 120th min. were measured. The primary outcome of this study was a change in the VAS and LT values at the 0-120th minute after treatment RESULTS: In this study, 128 patients in 4 groups were included in the analysis. In the GON group, SON group, and Combined group, the change observed at the 120th minute scores compared to baseline VAS scores was higher than Placebo group [OR (95% CI) = -17.4 (-24.8, -9.9), 32.1 (23.8, 40.3), 49.5 (41.9, 57), respectively]. In inter-group comparison, it was found that the VAS and LT scores of the Combined group and the GON group improved at a higher rate than the SON group CONCLUSIONS: SON blockade, GON blockade, and a combination of these two blockades are effective treatment methods in acute migraine attack. Performing a GON or Combined blockade for migraine attack causes greater pain reduction than SON blockade.",2021,"In inter-group comparison, it was found that the VAS and LT scores of the Combined group and the GON group improved at a higher rate than the SON group CONCLUSIONS:","['128 patients in 4 groups were included in the analysis', 'acute migraine attack']","['Supra Orbital Nerve (SON) block methods', 'GON, SON, Combined, and Placebo', 'lidocaine', 'Placebo', 'greater occipital nerve and supra orbital nerve blocks methods', 'GON']","['VAS and LT values', 'time of admission, baseline pain scale values', 'VAS and LT scores', 'baseline VAS scores', 'and Likert-Type (LT) Verbal scale', 'Visual Analog Scale (VAS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1740836', 'cui_str': 'Acute migraine'}, {'cui': 'C0004063', 'cui_str': 'Assault'}]","[{'cui': 'C0228714', 'cui_str': 'Structure of supraorbital nerve'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0228814', 'cui_str': 'Greater occipital nerve'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",128.0,0.379669,"In inter-group comparison, it was found that the VAS and LT scores of the Combined group and the GON group improved at a higher rate than the SON group CONCLUSIONS:","[{'ForeName': 'Nihat M', 'Initials': 'NM', 'LastName': 'Hokenek', 'Affiliation': 'Department of Emergency Medicine, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey. Electronic address: nihathokenek@gmail.com.'}, {'ForeName': 'Duygu', 'Initials': 'D', 'LastName': 'Ozer', 'Affiliation': 'Department of Neurology, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey.'}, {'ForeName': 'Erdal', 'Initials': 'E', 'LastName': 'Yılmaz', 'Affiliation': 'Department of Emergency Medicine, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey.'}, {'ForeName': 'Nurhayat', 'Initials': 'N', 'LastName': 'Baskaya', 'Affiliation': 'Department of Emergency Medicine, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey.'}, {'ForeName': 'Ummahan Dalkilinc', 'Initials': 'UD', 'LastName': 'Hokenek', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey.'}, {'ForeName': 'Rohat', 'Initials': 'R', 'LastName': 'Ak', 'Affiliation': 'Department of Emergency Medicine, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey.'}, {'ForeName': 'Ramazan', 'Initials': 'R', 'LastName': 'Guven', 'Affiliation': 'Department of Emergency Medicine, Basaksehir Cam ve Sakura Hospital, İstanbul, Turkey.'}, {'ForeName': 'Mehmet O', 'Initials': 'MO', 'LastName': 'Erdogan', 'Affiliation': 'Department of Emergency Medicine, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey.'}, {'ForeName': 'Lewis Aaron', 'Initials': 'LA', 'LastName': 'Mepham', 'Affiliation': 'School of Medicine, University of Bahcesehir, İstanbul, Turkey.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2021.106821'] 1740,34309859,Prevention of infant eczema by neonatal bacille Calmette-Guérin vaccination: The MIS BAIR randomized controlled trial.,"BACKGROUND Bacille Calmette-Guérin (BCG) vaccine could play a role in counteracting the rising prevalence of atopic diseases, through its beneficial off-target effects. We aimed to determine whether neonatal BCG vaccination reduces the incidence of eczema in infants. METHODS Randomized controlled trial with 1272 infants allocated to receive BCG-Denmark or no BCG at birth. The primary outcome was the 12-month incidence of eczema based on 3-monthly questionnaires. Eczema was also assessed at a 12-month clinic visit. ClinicalTrial.gov: NCT01906853. RESULTS The 12-month eczema incidence was 32.2% in the BCG group compared with 36.6% in the control group (adjusted risk difference (aRD) -4.3%, 95% CI -9.9% to 1.3%, multiple imputation model). In addition, comparing infants in the BCG group with the control group, 15.7% vs. 19.2% had eczema lesions at the 12-month visit (aRD -3.5%, 95% CI -8.0% to 1.0%); 35.7% vs. 39.0% reported using topical steroids (aRD -3.3, 95% CI -9.2 to 2.7); and 7.3% vs. 10.2% had severe eczema scores (aRD -3.0%, 95% CI -8.8% to 2.7%). In 344 high-risk infants (two atopic parents), the 12-month eczema incidence was 35.3% in the BCG group compared with 46.8% in the control group (aRD -11.5%, 95% CI -21.9% to -1.2%; number needed to treat 8.7, 95% CI 4.6 to 83.3). CONCLUSION There is insufficient evidence to recommend neonatal BCG vaccination in all infants for the prevention of eczema in the first year of life; however, a modest beneficial effect was observed among high-risk infants. A single dose of BCG-Denmark soon after birth could reduce the incidence of eczema in infants with two atopic parents.",2021,"There is insufficient evidence to recommend neonatal BCG vaccination in all infants for the prevention of eczema in the first year of life; however, a modest beneficial effect was observed among high-risk infants.","['1272 infants allocated to receive BCG-Denmark or no BCG at birth', 'infants with two atopic parents', 'infants', '344 high-risk infants (two atopic parents']","['neonatal Bacillus Calmette-Guérin vaccination', 'Bacille Calmette-Guérin (BCG) vaccine', 'neonatal BCG vaccination']","['12-month incidence of eczema based on 3-monthly questionnaires', 'severe eczema scores', 'incidence of eczema', 'eczema lesions', 'Eczema', '12-month eczema incidence']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C1744681', 'cui_str': 'Congenital'}, {'cui': 'C0392707', 'cui_str': 'Atopy'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0419437', 'cui_str': 'High risk infant'}]","[{'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0004587', 'cui_str': 'Bacillus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",2.0,0.436971,"There is insufficient evidence to recommend neonatal BCG vaccination in all infants for the prevention of eczema in the first year of life; however, a modest beneficial effect was observed among high-risk infants.","[{'ForeName': 'Laure F', 'Initials': 'LF', 'LastName': 'Pittet', 'Affiliation': ""Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Nicole L', 'Initials': 'NL', 'LastName': 'Messina', 'Affiliation': ""Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Kaya', 'Initials': 'K', 'LastName': 'Gardiner', 'Affiliation': ""Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Bridget', 'Initials': 'B', 'LastName': 'Freyne', 'Affiliation': ""Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Abruzzo', 'Affiliation': ""Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Kate L', 'Initials': 'KL', 'LastName': 'Francis', 'Affiliation': ""Clinical Epidemiology & Biostatistics Unit, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Morrison', 'Affiliation': ""Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Christel', 'Initials': 'C', 'LastName': 'Zufferey', 'Affiliation': ""Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Vuillermin', 'Affiliation': 'School of Medicine, Deakin University, Geelong, Victoria, Australia.'}, {'ForeName': 'Katrina J', 'Initials': 'KJ', 'LastName': 'Allen', 'Affiliation': ""Formerly Centre for Food and Allergy Research, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Anne-Louise', 'Initials': 'AL', 'LastName': 'Ponsonby', 'Affiliation': ""Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'Robins-Browne', 'Affiliation': ""Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Shann', 'Affiliation': 'Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.'}, {'ForeName': 'Katie L', 'Initials': 'KL', 'LastName': 'Flanagan', 'Affiliation': 'School of Health Sciences, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Rod', 'Initials': 'R', 'LastName': 'Phillips', 'Affiliation': 'Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Donath', 'Affiliation': 'Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Casalaz', 'Affiliation': 'Neonatal Intensive Care Unit, Mercy Hospital for Women, Heidelberg, Victoria, Australia.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Curtis', 'Affiliation': ""Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}]",Allergy,['10.1111/all.15022'] 1741,34309839,High-flow nasal cannula versus face mask for preoxygenation in obese patients: A randomised controlled trial.,"BACKGROUND Preoxygenation efficacy with high-flow nasal cannula (HFNC) in obese patients is not clearly established. The primary aim of this study was to compare heated, humidified, high-flow nasal cannula with face mask for preoxygenation in this population. METHODS We conducted a single-centre, randomised, controlled trial. Forty subjects with BMI ≥ 35 kg m -2 were randomly assigned to receive 5.0 min of preoxygenation with face mask and 7 cm H 2 O of PEEP (PEEP group) or HFNC at 70 L min -1 (HF group). Following induction, bag-mask ventilation continued until laryngoscopy, whereas HFNC was maintained before and during intubation. The primary outcomes were end-tidal fraction of oxygen (EtO 2 ) at 2.5 and 5.0 min duration of preoxygenation. Secondary outcomes included PaO 2 and PaCO 2 at 2.5 and 5.0 min of preoxygenation and at intubation. RESULTS Mean (±SD) EtO 2 was 0.89 (±0.04) versus 0.90 (±0.05) after 2.5 min (95% CI for mean difference -0.02, 0.04) and 0.93 (±0.02) versus 0.91 (±0.02) after 5.0 min of preoxygenation (95% CI for mean difference -0.03, -0.002) in the PEEP (n = 18) and HF group (n = 20), respectively. All subjects reached an EtO 2  ≥ 0.85 at 5.0 min. There were no differences in mean PaO 2 or PaCO 2 during preoxygenation. Subjects in the HF group had a mean (±SD) apnoea time of 199 (±38) s, but no desaturation (SpO 2  < 100%) occurred. CONCLUSIONS Face mask with PEEP was superior to HFNC for preoxygenation in obese subjects. HFNC provided adequate preoxygenation quality in all subjects and may be considered as an alternative to face mask in selected patients. TRIAL REGISTRATION #ISRCTN37375068 (www.isrctn.com).",2021,"EtO 2 was 0.89 (±0.04) vs. 0.90 (±0.05) after 2.5 min (95% CI for mean difference -0.02, 0.04) and 0.93 (±0.02) vs 0.91 (±0.02) after 5.0 min of preoxygenation (95% CI for mean difference -0.03, -0.002) in the PEEP (n=18) and HF group (n=20) respectively.","['obese subjects', 'Forty subjects with BMI≥35 kg m -2', 'obese patients']","['PEEP', 'preoxygenation with face-mask and 7 cmH 2 O of PEEP (PEEP group) or HFNC', 'High flow nasal cannula versus face-mask', 'high flow nasal cannula (HFNC', 'HFNC', 'heated, humidified, high flow nasal cannula with face-mask']","['PaO 2 and PaCO 2 at 2.5 and 5.0 min of preoxygenation and at intubation', 'mean (±SD) apnoea time of 199 (±38) seconds but no desaturation', 'Mean (±SD', 'adequate preoxygenation quality', 'tidal fraction of oxygen (EtO 2 ']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1532718', 'cui_str': 'kg-m'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0412792', 'cui_str': 'Preoxygenation'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0949658', 'cui_str': 'Primary familial hypertrophic cardiomyopathy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}]","[{'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C1097282', 'cui_str': '2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0412792', 'cui_str': 'Preoxygenation'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0218234', 'cui_str': 'CBFA2T1 protein, human'}]",40.0,0.299943,"EtO 2 was 0.89 (±0.04) vs. 0.90 (±0.05) after 2.5 min (95% CI for mean difference -0.02, 0.04) and 0.93 (±0.02) vs 0.91 (±0.02) after 5.0 min of preoxygenation (95% CI for mean difference -0.03, -0.002) in the PEEP (n=18) and HF group (n=20) respectively.","[{'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Rosén', 'Affiliation': 'Department of Surgical Sciences, Section of Anaesthesiology and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Frykholm', 'Affiliation': 'Department of Surgical Sciences, Section of Anaesthesiology and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Diddi', 'Initials': 'D', 'LastName': 'Fors', 'Affiliation': 'Department of Surgical Sciences, Section of Anaesthesiology and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13960'] 1742,34309111,Association Between Caregiver-Oncologist Discordance in Patient's Life Expectancy Estimates and Caregiver Perceived Autonomy Support by the Oncologist.,"BACKGROUND Caregiver perceived autonomy support by the oncologist is important for caregiver well-being and may be affected by the patient's survival. We determined the association of caregiver-oncologist discordance in patient's life expectancy estimates with perceived autonomy support over time and whether the association differed by patient survival status. MATERIALS AND METHODS We used data from a geriatric assessment cluster-randomized trial (URCC 13070) that recruited patients aged at least 70 years with incurable cancer considering or receiving treatment, their caregivers, and their oncologists. At baseline, caregivers and oncologists were asked to estimate patient's life expectancy (0-6 months, 7-12 months, 1-2 years, 2-5 years, and >5 years; any difference in response was considered discordant). At 4-6 weeks, 3 months, and 6 months, caregivers completed the Health Care Climate Questionnaire (HCCQ), which measured perceived autonomy support by the oncologist. Generalized estimating equation modeling was conducted to assess the association of baseline caregiver-oncologist discordance with longitudinal HCCQ scores, stratified by patient 6-month survival status. RESULTS Discordant life expectancy estimates were present in 72.0% of dyads. In multivariate analyses, caregiver-oncologist discordance in patient's life expectancy estimates was associated with higher caregiver HCCQ scores. In stratified analysis, caregiver-oncologist discordance was associated with lower caregiver HCCQ scores (β = -3.46; 95% CI, -4.64 to -2.29) among patients who died within 6 months but with higher caregiver HCCQ scores (β = 1.33; 95% CI, 0.63-2.04) among patients who survived beyond 6 months. CONCLUSION Interventions aimed at mitigating discordance need to consider its association with caregiver perceived autonomy support and patient's survival in order to better inform caregiver expectations. IMPLICATIONS FOR PRACTICE Among patients who died within the first 6 months, caregivers who estimated a different length of life for the patient compared with oncologists were more likely to report lower support from the oncologist, whereas the opposite relationship was seen within patients who survived beyond the first 6 months. When designing interventions to improve caregiver understanding of the patient's prognosis, its relationship with caregiver-perceived support and patient's survival needs to be considered.",2021,"In multivariate analyses, caregiver-oncologist discordance in patient's life expectancy estimates was associated with higher HCCQ scores.","['patients aged ≥70 with incurable cancer considering or receiving treatment, their caregivers, and oncologists']",[],"['caregiver HCCQ scores', 'length of life', ""patient's life expectancy"", 'Health Care Climate Questionnaire (HCCQ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0259990', 'cui_str': 'Oncologists'}]",[],"[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0008946', 'cui_str': 'Climate'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023980', 'cui_str': 'Longevity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023671', 'cui_str': 'Life Expectancy'}]",,0.274972,"In multivariate analyses, caregiver-oncologist discordance in patient's life expectancy estimates was associated with higher HCCQ scores.","[{'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Tuch', 'Affiliation': 'Department of Aged Care, Alfred Health, Melbourne, Australia.'}, {'ForeName': 'Chandrika', 'Initials': 'C', 'LastName': 'Sanapala', 'Affiliation': 'Division of Hematology/Oncology, Department of Medicine, James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Supriya G', 'Initials': 'SG', 'LastName': 'Mohile', 'Affiliation': 'Division of Hematology/Oncology, Department of Medicine, James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Paul R', 'Initials': 'PR', 'LastName': 'Duberstein', 'Affiliation': 'Department of Health Behavior, Society, and Policy, Rutgers School of Public Health, Piscataway, New Jersey, USA.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Soto-Perez-de-Celis', 'Affiliation': 'Department of Geriatrics, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.'}, {'ForeName': 'Huiwen', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Department of Surgery, Cancer Control, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Culakova', 'Affiliation': 'Department of Surgery, Cancer Control, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Flannery', 'Affiliation': 'School of Nursing, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Yousefi-Nooraie', 'Affiliation': 'Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Ronald M', 'Initials': 'RM', 'LastName': 'Epstein', 'Affiliation': 'Department of Family Medicine, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'McHugh', 'Affiliation': 'Division of Hematology/Oncology, Department of Medicine, James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Aarne', 'Affiliation': 'SCOREboard Advisory Group, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology/Oncology, Department of Medicine, James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Jodi', 'Initials': 'J', 'LastName': 'Geer', 'Affiliation': 'Metro Minnesota Community Oncology Research Program, St. Louis Park, Minnesota, USA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': ""O'Rourke"", 'Affiliation': 'National Cancer Institute Community Oncology Research Program (NCORP) of the Carolinas (Greenville Health System NCORP), Greenville, South Carolina, USA.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Vogelzang', 'Affiliation': 'Nevada Cancer Research Foundation NCORP, Las Vegas, Nevada, USA.'}, {'ForeName': 'Kah Poh', 'Initials': 'KP', 'LastName': 'Loh', 'Affiliation': 'Division of Hematology/Oncology, Department of Medicine, James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.'}]",The oncologist,['10.1002/onco.13913'] 1743,34281485,"Telephone-based peer support intervention to reduce depressive symptoms in women with coronary heart disease, a randomized controlled trial in Germany.","Depressive symptoms in patients with coronary heart disease (CHD) predict adverse outcomes regarding e.g. cardiovascular complications. We trained women with CHD to support female peers through telephone-based counseling and tested whether depressive symptoms can be reduced, and perceived social support can be improved by the intervention over six months. 108 women with CHD and self-reported depressive or anxiety symptoms were included in a randomized controlled trial. The intervention group was offered immediate telephone-based peer support for six months, while the waiting list control group received the intervention with a 6-months delay. Primary outcomes were depressive symptoms and perceived social support immediately after the intervention period and at 6-months-follow-up. 40% of the women made use of the peer support. During the first six months, both groups showed a reduction in depressive symptoms (IIG: t(169) = -1.79, p = .08; WCG: t(169) = -2.76, p = .007) and a significant improvement in social support (IIG: t(175) = 3.54, p < .001; WCG: t(175) = 3.36, p < .001). We found no significant group × time interactions. There was no influence of telephone-based peer support on depressive symptoms and social support. We discuss potential causes for both lack of specific treatment effects and the general improvement over time in both groups.",2021,"WCG: t(169) = -2.76, p = .007) and a significant improvement in social support (IIG: t(175) = 3.54, p < .001; WCG: t(175) = 3.36, p < .001).","['108 women with CHD and self-reported depressive or anxiety symptoms', 'trained women with CHD to support female peers through', 'women with coronary heart disease', 'patients with coronary heart disease (CHD']","['immediate telephone-based peer support for six months, while the waiting list control group received the intervention with a 6-months delay', 'Telephone-based peer support intervention', 'telephone-based counseling']","['depressive symptoms and perceived social support', 'depressive symptoms', 'Depressive symptoms', 'social support', 'depressive symptoms and social support']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037438', 'cui_str': 'Social support'}]",108.0,0.0480544,"WCG: t(169) = -2.76, p = .007) and a significant improvement in social support (IIG: t(175) = 3.54, p < .001; WCG: t(175) = 3.36, p < .001).","[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Kyaw Tha Tun', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Centre, Göttingen, Germany.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Nagel', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Centre, Göttingen, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Bosbach', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Centre, Göttingen, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Bock', 'Affiliation': 'KKH Allianz, Statutory Health Insurance, Hannover, Germany.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Kielblock', 'Affiliation': 'KKH Allianz, Statutory Health Insurance, Hannover, Germany.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Siegmund-Schultze', 'Affiliation': 'Medicoles Healthcare Advise, Hannover, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Herrmann-Lingen', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Centre, Göttingen, Germany.'}]",Women & health,['10.1080/03630242.2021.1953208'] 1744,34284255,An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.,"PURPOSE Angiosarcomas represents a diverse group of aggressive high-grade vascular tumours with limited therapeutic options. We sought to determine the safety and efficacy of regorafenib, a small-molecule multikinase inhibitor, in the treatment of metastatic or locally advanced unresectable angiosarcoma. PATIENTS AND METHODS In this single-arm multicentre, open-label phase II clinical trial, 31 patients were enrolled and received regorafenib 160 mg PO daily for 21 days of a 28-day cycle. The primary endpoint for the study was progression-free survival at 4 months. Secondary endpoints included overall survival, response rate, and safety. Patients (≥18 years) with an Eastern Cooperative Oncology Group (ECOG) score of 0-1, a life expectancy of at least 4 months who had progressed on at least one but no more than 4 prior lines of therapy were eligible. RESULTS Of the 23 patients evaluable for efficacy, 2 had a complete response (8.7%), and 2 had a partial response (8.7%), for a total overall response rate of 17.4%. Median PFS was 5.5 months, and 12/23 patients (52.2%) had a PFS of greater than 4 months. 10/31 (32.3%) patients evaluable for toxicity had a grade 3 or higher adverse events. CONCLUSIONS Regorafenib is a safe and active treatment for refractory metastatic and unresectable angiosarcoma. Rates of adverse events were comparable to prior studies of regorafenib for other tumour types. Regorafenib, the single agent, could be considered as therapy for patients with metastatic or unresectable AS.",2021,"RESULTS Of the 23 patients evaluable for efficacy","['aggressive high-grade vascular tumours with limited therapeutic options', '31 patients were enrolled and received', 'metastatic or locally advanced unresectable angiosarcoma', '23 patients evaluable for efficacy', 'Patients (≥18 years) with an Eastern Cooperative Oncology Group (ECOG) score of 0-1, a life expectancy of at least 4 months who had progressed on at least one but no more than 4 prior lines of therapy were eligible', 'patients with metastatic or unresectable AS']","['Regorafenib', 'regorafenib', 'regorafenib 160\xa0mg PO']","['toxicity', 'progression-free survival', 'safety and efficacy', 'total overall response rate', 'Median PFS', 'partial response', 'Rates of adverse events', 'overall survival, response rate, and safety']","[{'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0018923', 'cui_str': 'Hemangiosarcoma'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023671', 'cui_str': 'Life Expectancy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C4319554', 'cui_str': '160'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",31.0,0.0743338,"RESULTS Of the 23 patients evaluable for efficacy","[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Agulnik', 'Affiliation': 'Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago IL, USA. Electronic address: magulnik@coh.org.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Schulte', 'Affiliation': 'Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago IL, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Robinson', 'Affiliation': 'Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Angela C', 'Initials': 'AC', 'LastName': 'Hirbe', 'Affiliation': ""Siteman Cancer Center, St Louis, MO, USA; Washington University in St. Louis School of Medicine, St Louis MO, USA; St Louis Children's Hospital, Department id Pediatrics, St Louis, MO, 63110, USA.""}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Kozak', 'Affiliation': 'Department of Radiation Oncology, Mercy Health System, Janesville, WI, USA.'}, {'ForeName': 'Sant P', 'Initials': 'SP', 'LastName': 'Chawla', 'Affiliation': 'Sarcoma Oncology Center, Santa Monica, CA, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Attia', 'Affiliation': 'Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Alfred', 'Initials': 'A', 'LastName': 'Rademaker', 'Affiliation': 'Department of Preventive Medicine, Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Preventive Medicine, Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Abbinanti', 'Affiliation': 'Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago IL, USA.'}, {'ForeName': 'Rasima', 'Initials': 'R', 'LastName': 'Cehic', 'Affiliation': 'Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago IL, USA.'}, {'ForeName': 'Varun', 'Initials': 'V', 'LastName': 'Monga', 'Affiliation': 'Department of Hematology/Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Milhem', 'Affiliation': 'Department of Hematology/Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Okuno', 'Affiliation': 'Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Brian A', 'Initials': 'BA', 'LastName': 'Van Tine', 'Affiliation': ""Siteman Cancer Center, St Louis, MO, USA; Washington University in St. Louis School of Medicine, St Louis MO, USA; St Louis Children's Hospital, Department id Pediatrics, St Louis, MO, 63110, USA.""}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.06.027'] 1745,34284064,"Effects of diurnal exercise timing on appetite, energy intake and body composition: A parallel randomized trial.","OBJECTIVE To determine the effect of diurnal exercise timing on appetite, energy intake and body composition in individuals with overweight or obesity. METHODS Forty sedentary, individuals with overweight or obesity (17 males, 23 females; age: 51 ± 13 years; BMI: 30.9 ± 4.2 kg/m 2 ) were randomly allocated to complete a 12-week supervised multi-modal exercise training program performed either in the morning (amEX) or evening (pmEX). Outcome measures included appetite in response to a standardised test meal, daily energy intake (EI), body weight and body composition. Measures of dietary behaviour were assessed at baseline and post-intervention, along with habitual physical activity, sleep quality and sleep quantity. Significance was set at p ≤ .05 and Hedge's g effect sizes were calculated. RESULTS Regardless of timing, exercise training increased perceived fullness (AUC; g = 0.82-1.67; both p < .01), decreased daily EI (g = 0.73-0.93; both p < .01) and body-fat (g = 0.29-0.32; both p <. 01). The timing of exercise did not change the daily EI or body-fat response to training (all p ≥ .27), however, perceived fullness increased in the amEX group (p ≤ .01). DISINHIBITION: (g = 0.35-1.95; p ≤ .01) and Hunger (g = 0.05-0.4; p = .02) behaviours decreased following exercise training, with Disinhibition demonstrating greater improvements in the pmEX group (p = .01). Objective and subjective sleep quantity increased with training (all p ≤ .01), but sleep quality was not reported to change. CONCLUSIONS Multi-modal exercise training improved body composition and some appetite outcomes, although changes were inconsistent and largely independent of exercise-timing. In the absence of dietary manipulation, the effect of diurnal exercise timing on appetite and body composition appear trivial compared to the overall benefits of exercise participation.",2021,"Objective and subjective sleep quantity increased with training (all p ≤ .01), but sleep quality was not reported to change. ","['Forty sedentary, individuals with overweight or obesity (17 males, 23 females; age: 51\u202f±\u202f13 years; BMI: 30.9\u202f±\u202f4.2\u202fkg/m 2 ', 'individuals with overweight or obesity']","['exercise training', 'diurnal exercise', 'Multi-modal exercise training', 'supervised multi-modal exercise training program performed either in the morning (amEX) or evening (pmEX']","['daily EI or body-fat response to training', 'appetite in response to a standardised test meal, daily energy intake (EI), body weight and body composition', 'body-fat', 'Objective and subjective sleep quantity', 'appetite, energy intake and body composition', 'dietary behaviour', 'perceived fullness', 'sleep quality', 'body composition and some appetite outcomes', 'habitual physical activity, sleep quality and sleep quantity', 'perceived fullness (AUC']","[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517758', 'cui_str': '4.2'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0587117', 'cui_str': 'Evening'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0439650', 'cui_str': 'Fullness'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",40.0,0.00507151,"Objective and subjective sleep quantity increased with training (all p ≤ .01), but sleep quality was not reported to change. ","[{'ForeName': 'Shaun Y M', 'Initials': 'SYM', 'LastName': 'Teo', 'Affiliation': 'Discipline of Exercise Science, Murdoch University, Australia; The Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Australia. Electronic address: y.teo@murdoch.edu.au.'}, {'ForeName': 'Jill A', 'Initials': 'JA', 'LastName': 'Kanaley', 'Affiliation': 'Department of Nutrition & Exercise Physiology, University of Missouri, USA. Electronic address: kanaleyj@missouri.edu.'}, {'ForeName': 'Kym J', 'Initials': 'KJ', 'LastName': 'Guelfi', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Australia. Electronic address: kym.guelfi@uwa.edu.au.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Dimmock', 'Affiliation': 'Department of Psychology, James Cook University, Australia. Electronic address: james.dimmock@jcu.edu.au.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Jackson', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Australia; Telethon Kids Institute, Australia. Electronic address: ben.jackson@uwa.edu.au.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Fairchild', 'Affiliation': 'Discipline of Exercise Science, Murdoch University, Australia; The Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Australia. Electronic address: t.fairchild@murdoch.edu.au.'}]",Appetite,['10.1016/j.appet.2021.105600'] 1746,34283917,"Development of a Videogame for the Promotion of Active Aging Through Depression Prevention, Healthy Lifestyle Habits, and Cognitive Stimulation for Middle-to-Older Aged Adults.","Objective: The objective of this pilot study was to analyze the efficacy on perceived health and the feasibility of a multicomponent psychological intervention to promote active aging through depression prevention, healthy lifestyle habits, and cognitive stimulation in middle-to-older adulthood administered through an interactive multimedia online videogame with a complementary smartphone app. Materials and Methods: Twenty-five participants from the general population aged 45 or older with computer and smartphone access and no difficulties in communication, sensory or mental health condition (64.0% women, mean age 54.9 years) participated in the intervention, which consisted of eight modules with tasks between sessions. The multicomponent intervention consisted of three components (depression prevention, healthy lifestyle habits, and cognitive stimulation) and was administered using an interactive online multimedia videogame (graphic adventure type), with a complementary smartphone app. Perceived health, dropouts, adherence to the intervention (performed modules and completed intersession tasks), and engagement were independently assessed. Results: After the intervention, participants exhibited significant improvement in their scores for General Health, Physical Functioning, Social Functioning, and Mental Health, with effect sizes ranging from small ( d  = 0.38) to medium ( d  = 0.59). The dropout rate was only 8%. The mean number of completed modules was 7.5 (SD = 1.8), and the mean number of tasks performed was 232.4 (out of 259) (SD = 15.4). Participants were highly satisfied ( M  = 27.7; SD = 3.1) and engaged ( M  = 42.7; SD = 4.7) with the intervention. Conclusion: The results support the efficacy and feasibility of using the videogame to promote active aging, and they encourage further evaluation through a randomized-controlled clinical trial. ClinicalTrials.gov NCT03643237.",2021,"After the intervention, participants exhibited significant improvement in their scores for General Health, Physical Functioning, Social Functioning, and Mental Health, with effect sizes ranging from small ( d  = 0.38) to medium ( d  = 0.59).","['Twenty-five participants from the general population aged 45 or older with computer and smartphone access and no difficulties in communication, sensory or mental health condition (64.0% women, mean age 54.9 years', 'Middle-to-Older Aged Adults', 'middle-to-older adulthood administered through an interactive multimedia online videogame with a complementary smartphone app', 'Participants were highly satisfied ( M \u2009=\u200927.7; SD\u2009=\u20093.1) and engaged ( M \u2009=\u200942.7; SD\u2009=\u20094.7) with the intervention']","['multicomponent psychological intervention', 'multicomponent intervention consisted of three components (depression prevention, healthy lifestyle habits, and cognitive stimulation) and was administered using an interactive online multimedia videogame (graphic adventure type), with a complementary smartphone app']","['Perceived health, dropouts, adherence to the intervention (performed modules and completed intersession tasks), and engagement', 'General Health, Physical Functioning, Social Functioning, and Mental Health', 'dropout rate', 'mean number of completed modules']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0700597', 'cui_str': 'Adulthood'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4517683', 'cui_str': '3.1'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0150174', 'cui_str': 'Cognitive stimulation'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",25.0,0.031872,"After the intervention, participants exhibited significant improvement in their scores for General Health, Physical Functioning, Social Functioning, and Mental Health, with effect sizes ranging from small ( d  = 0.38) to medium ( d  = 0.59).","[{'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Otero', 'Affiliation': 'Department of Psychology, University of A Coruña, A Coruña, Spain.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Cotardo', 'Affiliation': 'Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Blanco', 'Affiliation': 'Department of Evolutionary and Educational Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Fernando L', 'Initials': 'FL', 'LastName': 'Vázquez', 'Affiliation': 'Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Santiago de Compostela, Spain.'}]",Games for health journal,['10.1089/g4h.2020.0165'] 1747,34288591,Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial.,"OBJECTIVE The delivery of healthcare at home has expanded to intravenous infusions of monoclonal antibodies. A recently developed model of care for home infusions of natalizumab for people with relapsing-remitting multiple sclerosis was evaluated. This pilot study of home infusions of natalizumab and usual care (attendance in a hospital out-patients' clinic) compared safety, feasibility, patient satisfaction, effectiveness and costs. METHODS In this randomised AB/BA crossover trial, 37 adults were randomised to usual care (n = 19) or home infusions (n = 18). After three infusions, patients crossed over to the alternate treatment for another three infusions. Patient safety outcomes and adherence, satisfaction, quality of life, disability and costs were compared. RESULTS No adverse events were recorded from 207 infusions from 35 patients across both home and clinic infusions. There was no difference in adherence (p = 0.71) and infection rates (p = 0.84) between home and clinic settings. Satisfaction with ""convenience"" of home infusions was significantly greater (p = 0.008) but there were no differences in quality of life measures. Excluding pharmacy, costs were A$74 lower per infusion at home, including A$16 of patients"" out-of-pocket costs. INTERPRETATION There were no differences in safety and effectiveness between clinic and home infusions of natalizumab. The home infusions were shown to be feasible, more convenient and less expensive than usual care. Larger scale studies are required to verify these preliminary findings, particularly around safety and management of hypersensitivity adverse events in the home setting and for equivalence of clinical outcomes.",2021,There was no difference in adherence (p = 0.71) and infection rates (p = 0.84) between home and clinic settings.,"['37 adults', ""in a hospital out-patients' clinic"", 'people with relapsing-remitting multiple sclerosis', 'people with multiple sclerosis']","['natalizumab and usual care (attendance', 'natalizumab']","['infection rates', 'safety and effectiveness', 'safety, feasibility, patient satisfaction, effectiveness and costs', 'adverse events', 'adherence', 'Patient safety outcomes and adherence, satisfaction, quality of life, disability and costs', 'quality of life measures']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C1172734', 'cui_str': 'natalizumab'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}]","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",37.0,0.0221698,There was no difference in adherence (p = 0.71) and infection rates (p = 0.84) between home and clinic settings.,"[{'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Schultz', 'Affiliation': 'Adelaide Nursing School, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Thomas', 'Affiliation': 'Post Op Care at Home (Pty Ltd), Adelaide, South Australia, Australia.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Georgiou', 'Affiliation': 'Medical Day Treatment Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Mahasen S', 'Initials': 'MS', 'LastName': 'Juaton', 'Affiliation': 'Adelaide Nursing School, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Lynette', 'Initials': 'L', 'LastName': 'Cusack', 'Affiliation': 'Adelaide Nursing School, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Simon', 'Affiliation': 'Medical Day Treatment Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Kerisha', 'Initials': 'K', 'LastName': 'Naidoo', 'Affiliation': 'Biogen Australia and New Zealand, Sydney, New South Wales, Australia.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Webb', 'Affiliation': 'Neurology & Stroke Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Karnon', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.'}, {'ForeName': 'Janakan', 'Initials': 'J', 'LastName': 'Ravindran', 'Affiliation': 'Neurology & Stroke Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}]",Annals of clinical and translational neurology,['10.1002/acn3.51410'] 1748,34287695,Elective intervention for unruptured cranial arteriovenous malformations in relation to ARUBA trial: a National Inpatient Sample study.,"BACKGROUND In 2014, A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) concluded that medical management alone for cranial arteriovenous malformations (AVMs) had better clinical outcomes than interventional treatment. The impact of the ARUBA study on changes in the rates of intervention and outcomes is unknown. Thus, we investigated whether the conclusions from ARUBA may have influenced treatment modalities and outcomes of unruptured AVMs. METHODS The National Inpatient Sample (NIS) was queried between 2006 and 2018, for adult patients with an AVM who were admitted on an elective basis. Interventions included open, endovascular, and stereotactic surgeries. Join-point regression was used to assess differences in slopes of treatment rate for each modality before and after the time-point. Logistic regression was used to assess the odds of non-routine discharge and hemorrhage between the two time-points for each treatment modality. Linear regression was used to assess the mean length of stay (LOS) for each treatment modality between the two time-points. RESULTS A total of 40,285 elective admissions for AVMs were identified between 2006 and 2018. The rate of intervention was higher pre-ARUBA (n = 15,848; 63.8%) compared to post-ARUBA (n = 6985; 45.2%; difference in slope - 8.24%, p < 0.001). The rate of open surgery decreased, while endovascular and stereotactic surgeries remained the same, after the ARUBA trial time-point (difference in slopes - 8.24%, p < 0.001; - 1.74%, p = 0.055; 0.20%, p = 0.22, respectively). For admissions involving interventions, the odds of non-routine discharge were higher post-ARUBA (OR 1.24; p = 0.043); the odds of hemorrhage were lower post-ARUBA (OR 0.69; p = 0.025). There was no statistical difference in length of stay between the two time-points (p = 0.22). CONCLUSION The rate of intervention decreased, the rate of non-routine discharge increased, and rate of hemorrhage decreased post-ARUBA, suggesting that it may have influenced treatment practices for unruptured AVMs.",2021,"The rate of open surgery decreased, while endovascular and stereotactic surgeries remained the same, after the ARUBA trial time-point (difference in slopes - 8.24%, p < 0.001; - 1.74%, p = 0.055; 0.20%, p = 0.22, respectively).","['cranial arteriovenous malformations (AVMs', 'Unruptured Brain Arteriovenous Malformations (ARUBA', 'The National Inpatient Sample (NIS) was queried between 2006 and 2018, for adult patients with an AVM who were admitted on an elective basis', '40,285 elective admissions for AVMs were identified between 2006 and 2018']",['Elective intervention'],"['rate of non-routine discharge', 'length of stay', 'odds of hemorrhage', 'mean length of stay (LOS', 'rate of open surgery', 'rate of intervention']","[{'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0003857', 'cui_str': 'Congenital arteriovenous malformation'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C3543841', 'cui_str': 'Query'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205396', 'cui_str': 'Identified'}]","[{'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0348025', 'cui_str': 'Open approach'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",40285.0,0.173204,"The rate of open surgery decreased, while endovascular and stereotactic surgeries remained the same, after the ARUBA trial time-point (difference in slopes - 8.24%, p < 0.001; - 1.74%, p = 0.055; 0.20%, p = 0.22, respectively).","[{'ForeName': 'Waseem', 'Initials': 'W', 'LastName': 'Wahood', 'Affiliation': 'Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, 3200 University Drive, Davie, FL, 3328, USA. ww412@mynsu.nova.edu.'}, {'ForeName': 'A Yohan', 'Initials': 'AY', 'LastName': 'Alexander', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Ronan J', 'Initials': 'RJ', 'LastName': 'Doherty', 'Affiliation': 'School of Medicine, Trinity College Dublin, The University of Dublin, Dublin, Ireland.'}, {'ForeName': 'Archis', 'Initials': 'A', 'LastName': 'Bhandarkar', 'Affiliation': 'Alix School of Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Lanzino', 'Affiliation': 'Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Bydon', 'Affiliation': 'Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Waleed', 'Initials': 'W', 'LastName': 'Brinjikji', 'Affiliation': 'Department of Radiology, Mayo Clinic, Rochester, MN, USA.'}]",Acta neurochirurgica,['10.1007/s00701-021-04936-7'] 1749,34292510,Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC 4 E Trial.,"BACKGROUND AND OBJECTIVE Influenza-like illness (ILI) leads to a substantial disease burden every winter in Europe; however, oseltamivir is not frequently prescribed to ILI patients in the primary-care setting. An open-label, multi-country, multi-season, randomised controlled trial investigated the effectiveness of oseltamivir for treating ILI in 15 European countries. We aimed to evaluate whether patients presenting with ILI in primary care and being managed with the addition of oseltamivir to usual care had lower average direct and indirect costs compared to patients with usual care alone. METHODS Resource use data were extracted from participants' daily diaries. Itemised country-specific unit costs were collected through official tariffs, pharmacies or literature. Costs were converted to 2018 values. The null hypothesis was tested based on one-sided credible intervals (CrIs) obtained by bootstrapping. Base-case analysis estimated direct cost and productivity losses using itemised costed resource use and the human capital approach. Scenario analyses with self-reported spending rather than itemised costing were also performed. RESULTS Patients receiving oseltamivir (N = 1306) reported fewer healthcare visits, medication uses, hospital attendances and paid-work hours lost than the other patients (N = 1298). Excluding the oseltamivir cost, the average direct costs were lower in patients treated with oseltamivir from all perspectives, but these differences were not statistically significant (perspective of patient: €17 [0-95% Crl: 16-19] vs. €24 [5-100% Crl: 18-29]; healthcare provider: €37 [28-67] vs. €44 [25-55]; healthcare payers: €54 [45-85] vs. €68 [45-81]; and society: €423 [399-478] vs. €451 [390-478]). Scenario and age-group analyses confirmed these findings, but with some between-country differences. CONCLUSION The average direct and indirect costs were consistently lower in patients treated with oseltamivir than in patients without from four perspectives (excluding the oseltamivir cost). However, these differences were not statistically significant.",2021,The average direct and indirect costs were consistently lower in patients treated with oseltamivir than in patients without from four perspectives (excluding the oseltamivir cost).,"['15 European countries', '15 European Countries', 'patients presenting with ILI in primary care and being managed with the addition of oseltamivir to usual care had lower average direct and indirect costs compared to patients with usual care alone']","['Influenza-Like Illness Treated with and Without Oseltamivir', 'oseltamivir']","['healthcare visits, medication uses, hospital attendances and paid-work hours lost', 'average direct costs', 'average direct and indirect costs']","[{'cui': 'C0454713', 'cui_str': 'European country'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0392171', 'cui_str': 'Influenza-like symptoms'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0874161', 'cui_str': 'Oseltamivir'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]","[{'cui': 'C0392171', 'cui_str': 'Influenza-like symptoms'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0874161', 'cui_str': 'Oseltamivir'}]","[{'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}]",,0.0809975,The average direct and indirect costs were consistently lower in patients treated with oseltamivir than in patients without from four perspectives (excluding the oseltamivir cost).,"[{'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium. xiao.li@uantwerpen.be.'}, {'ForeName': 'Joke', 'Initials': 'J', 'LastName': 'Bilcke', 'Affiliation': 'Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium.'}, {'ForeName': 'Alike W', 'Initials': 'AW', 'LastName': 'van der Velden', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Bongard', 'Affiliation': 'The Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Bruyndonckx', 'Affiliation': 'Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BIOSTAT), Data Science Institute (DSI), Hasselt University, Hasselt, Belgium.'}, {'ForeName': 'Pär-Daniel', 'Initials': 'PD', 'LastName': 'Sundvall', 'Affiliation': 'Primary Health Care, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Nicolay J', 'Initials': 'NJ', 'LastName': 'Harbin', 'Affiliation': 'Antibiotic Center for Primary Care, Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Coenen', 'Affiliation': 'Department of Family Medicine and Population Health (FAMPOP), Vaccine and Infectious Disease Institute (VAXINFECTIO), Laboratory of Medical Microbiology, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Francis', 'Affiliation': 'School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Pascale', 'Initials': 'P', 'LastName': 'Bruno', 'Affiliation': ""Département de Santé Publique, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Garcia-Sangenis', 'Affiliation': ""Drug Study Unit, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain.""}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Glinz', 'Affiliation': 'Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Kosiek', 'Affiliation': ""Family Doctors' Clinic, Lodz, Poland.""}, {'ForeName': 'Réka', 'Initials': 'R', 'LastName': 'Mikó-Pauer', 'Affiliation': 'DRC Drug Research Center LLC, Balatonfüred, Hungary.'}, {'ForeName': 'Ruta', 'Initials': 'R', 'LastName': 'Radzeviciene Jurgute', 'Affiliation': 'FDC Mano šeimos gydytojas, Klaipeda, Lithuania.'}, {'ForeName': 'Bohumil', 'Initials': 'B', 'LastName': 'Seifert', 'Affiliation': 'First Faculty of Medicine, Institute of General Practice, Charles University in Prague, Prague, Czech Republic.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Tsakountakis', 'Affiliation': 'Malia Surgery, Kastelli HC, Heraklio, Greece.'}, {'ForeName': 'Rune', 'Initials': 'R', 'LastName': 'Aabenhus', 'Affiliation': 'Section and Research Unit of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Butler', 'Affiliation': 'The Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Beutels', 'Affiliation': 'Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium.'}]",Clinical drug investigation,['10.1007/s40261-021-01057-y'] 1750,34292119,Factors influencing the use of different methods of consent in a randomized acute stroke trial: The Third International Stroke Trial (IST-3).,"BACKGROUND Obtaining informed consent in people with acute stroke is complex since many, as a direct result of their stroke, lose capacity to make important decisions. Furthermore, reperfusion interventions are time dependent necessitating rapid consent. We developed four different consent approaches to facilitate recruitment of a broad range of patients in the Third International Stroke Trial (IST-3). AIMS To describe the clinical characteristics of patients recruited by different consent methods and the association between these methods and time from stroke onset to randomization. METHODS IST-3 was a randomized controlled trial of thrombolysis for acute ischemic stroke. Clinicians could use one of four consent procedures: written consent, witnessed consent, assent, or a waiver of consent. We analyzed the relationship between consent procedure and baseline variables. The effect of consent procedure on delay time from onset to randomization was determined using analysis of variance to adjust for confounding effects. RESULTS Of the 3035 patients recruited, the method of consent was known for 3034 (99.9%), and it was written in 985 subjects (32.5%), witnessed verbal consent in 280 (9.2%), assent by relative in 1727 (56.9%), and waiver of consent in 42 subjects (1.4%). Assent was required in 63.4% for those presenting 0-3 h from stroke onset (written consent in 25.3%). Patients with more severe neurological deficits (or with a non-lacunar hemispheric stroke syndrome) were less likely to give written consent. Mean delay between onset and randomization varied significantly between consent types (one-way analysis of variance: F = 15.7 on 3 df, p < 0.0001) (longest at 4.06 h for signed consent and 3.46 h for waiver of consent). CONCLUSIONS Acute stroke trials requiring written informed consent would result in substantial selection bias. Flexible consent methods will ensure a broad range of patients are recruited, enabling trial results to be widely generalizable. Registration: This study's registered number is ISRCTN25765518.",2021,"Mean delay between onset and randomisation varied significantly between consent types (one way anova : F=15.7 on 3 df, P<0.0001) (longest at 4.06 hours for signed consent and 3.46 hours for waiver of consent).Conclusions Acute stroke trials requiring written informed consent would result in substantial selection bias.","['Patients with more severe neurological deficits (or with a non-lacunar hemispheric stroke syndrome', 'people with acute stroke', 'acute ischaemic stroke', '3035 patients recruited, the method of consent was known for 3034 (99.9%) and it was: written in 985 subjects (24%), witnessed verbal consent in 280 (9.2%), assent by relative in 1727 (56.9%), and waiver of consent in 42 subjects (1.4']",['thrombolysis'],"['delay time', 'Mean delay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0205139', 'cui_str': 'Hemispheric'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C4517914', 'cui_str': '99.9'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C5191219', 'cui_str': '9.2'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C4517503', 'cui_str': '1.4'}]","[{'cui': 'C0520997', 'cui_str': 'Thrombolysis'}]","[{'cui': 'C0522486', 'cui_str': 'Delay time'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",3035.0,0.131245,"Mean delay between onset and randomisation varied significantly between consent types (one way anova : F=15.7 on 3 df, P<0.0001) (longest at 4.06 hours for signed consent and 3.46 hours for waiver of consent).Conclusions Acute stroke trials requiring written informed consent would result in substantial selection bias.","[{'ForeName': 'Richard I', 'Initials': 'RI', 'LastName': 'Lindley', 'Affiliation': 'Westmead Applied Research Centre, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Kane', 'Affiliation': 'Department of Stroke Medicine, Royal Sussex Country Hospital, Sussex University Hospitals Trust, Brighton, UK.'}, {'ForeName': 'Geoff', 'Initials': 'G', 'LastName': 'Cohen', 'Affiliation': 'Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Peter Ag', 'Initials': 'PA', 'LastName': 'Sandercock', 'Affiliation': 'Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.'}]",International journal of stroke : official journal of the International Stroke Society,['10.1177/17474930211037123'] 1751,34290065,"Non-invasive, vagus nerve stimulation to reduce ileus after colorectal surgery: protocol for a feasibility trial with nested mechanistic studies.","INTRODUCTION Ileus is a common and distressing condition characterised by gut dysfunction after surgery. While a number of interventions have aimed to curtail its impact on patients and healthcare systems, ileus is still an unmet challenge. Electrical stimulation of the vagus nerve is a promising new treatment due to its role in modulating the neuro-immune axis through a novel anti-inflammatory reflex. The protocol for a feasibility study of non-invasive vagus nerve stimulation (nVNS), and a programme of mechanistic and qualitative studies, is described. METHODS AND ANALYSIS This is a participant-blinded, parallel-group, randomised, sham-controlled feasibility trial (IDEAL Stage 2b) of self-administered nVNS. One hundred forty patients planned for elective, minimally invasive, colorectal surgery will be randomised to four schedules of nVNS before and after surgery. Feasibility outcomes include assessments of recruitment and attrition, adequacy of blinding and compliance to the intervention. Clinical outcomes include bowel function and length of hospital stay. A series of mechanistic substudies exploring the impact of nVNS on inflammation and bowel motility will inform the design of the final stimulation schedule. Semistructured interviews with participants will explore experiences and perceptions of the intervention, while interviews with patients who decline participation will explore barriers to recruitment. ETHICS AND DISSEMINATION The protocol has been approved by the Tyne and Wear South National Health Service (NHS) Research Ethics Committee (19/NE/0217) on 2 July 2019. Feasibility, mechanistic and qualitative findings will be disseminated to national and international partners through peer-reviewed publications, academic conferences, social media channels and stakeholder engagement activities. The findings will build a case for or against progression to a definitive randomised assessment as well as informing key elements of study design. TRIAL REGISTRATION NUMBER ISRCTN62033341.",2021,"One hundred forty patients planned for elective, minimally invasive, colorectal surgery will be randomised to four schedules of nVNS before and after surgery.","['One hundred forty patients planned for elective, minimally invasive, colorectal surgery']","['self-administered nVNS', 'non-invasive vagus nerve stimulation (nVNS', 'nVNS']","['bowel function and length of hospital stay', 'recruitment and attrition, adequacy of blinding and compliance to the intervention']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}]","[{'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",,0.247209,"One hundred forty patients planned for elective, minimally invasive, colorectal surgery will be randomised to four schedules of nVNS before and after surgery.","[{'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Chapman', 'Affiliation': ""Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK s.chapman@leeds.ac.uk.""}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Naylor', 'Affiliation': 'West Riding of Yorkshire Ileostomy Association, Leeds, UK.'}, {'ForeName': 'Carolyn J', 'Initials': 'CJ', 'LastName': 'Czoski Murray', 'Affiliation': 'Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.'}, {'ForeName': 'Damian', 'Initials': 'D', 'LastName': 'Tolan', 'Affiliation': 'Leeds Teaching Hospitals NHS Trust, Leeds, UK.'}, {'ForeName': 'Deborah D', 'Initials': 'DD', 'LastName': 'Stocken', 'Affiliation': 'Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Jayne', 'Affiliation': ""Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.""}]",BMJ open,['10.1136/bmjopen-2020-046313'] 1752,34290063,Peer mentorship to improve self-management of hip and knee osteoarthritis: a randomised feasibility trial.,"OBJECTIVE To determine the feasibility of conducting a randomised controlled trial (RCT) of a peer mentorship intervention to improve self-management of osteoarthritis (OA). DESIGN Six-month parallel group non-blinded randomised feasibility trial. SETTING One secondary care and one primary care UK National Health Service Trust. PARTICIPANTS Fifty adults aged ≥55 years old with hip and/or knee OA. INTERVENTIONS Participants were allocated 1:1 to the intervention or control group using an online randomisation service. Intervention group participants received usual care (information resources) and up to eight community-based self-management support sessions delivered by a peer mentor (trained volunteer with hip and/or knee OA). Control group participants received usual care only. OUTCOME MEASURES Key feasibility outcomes were participant and peer mentor recruitment and attrition, intervention completion and the sample size required for a definitive RCT. Based on these feasibility outcomes, four success criteria for proceeding to a definitive RCT were prespecified. Patient-reported outcomes were collected via questionnaires at baseline, 8 weeks and 6 months. RESULTS Ninety-six individuals were screened, 65 were eligible and 50 were randomised (25 per group). Of the 24 participants who commenced the intervention, 20 completed it. Four participants did not complete the 6-month questionnaire. Twenty-one individuals were eligible for the peer mentor role, 15 were trained and 5 withdrew prior to being matched with a participant. No intervention-related harms occurred. Allowing for 20% attrition, the sample size required for a definitive RCT was calculated as 170 participants. The intervention group showed improvements in self-management compared with the control group. CONCLUSIONS The feasibility outcomes achieved the prespecified criteria for proceeding to an RCT. The exploratory analyses suggest peer mentorship may improve OA self-management. An RCT of the OA peer mentorship intervention is therefore warranted with minor modifications to the intervention and trial procedures. TRIAL REGISTRATION NUMBER ISRCTN:50675542.",2021,"The intervention group showed improvements in self-management compared with the control group. ","['hip and knee osteoarthritis', '24 participants who commenced the intervention, 20 completed it', 'osteoarthritis (OA', 'Fifty adults aged ≥55 years old with hip and/or knee OA', 'One secondary care and one primary care UK National Health Service Trust', 'Twenty-one individuals were eligible for the peer mentor role, 15 were trained and 5 withdrew prior to being matched with a participant', 'Ninety-six individuals were screened, 65 were eligible and 50 were randomised (25 per group']","['usual care (information resources) and up to eight community-based self-management support sessions delivered by a peer mentor (trained volunteer with hip and/or knee OA', 'intervention or control group using an online randomisation service', 'peer mentorship intervention', 'Peer mentorship', 'usual care only']","['self-management', 'peer mentor recruitment and attrition, intervention completion and the sample size required for a definitive RCT']","[{'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C3494402', 'cui_str': 'Secondary Care'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0027462', 'cui_str': 'National Health Services'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0025369', 'cui_str': 'Mentors'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1512759', 'cui_str': 'Information Resources'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0025369', 'cui_str': 'Mentors'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0025370', 'cui_str': 'Mentorships'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0025369', 'cui_str': 'Mentors'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C0443196', 'cui_str': 'Definitive'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",50.0,0.10901,"The intervention group showed improvements in self-management compared with the control group. ","[{'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Anderson', 'Affiliation': 'School of Healthcare, University of Leeds, Leeds, UK A.Anderson@leeds.ac.uk.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Lavender', 'Affiliation': 'School of Healthcare, University of Leeds, Leeds, UK.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Dusabe-Richards', 'Affiliation': 'School of Healthcare, University of Leeds, Leeds, UK.'}, {'ForeName': 'Teumzghi F', 'Initials': 'TF', 'LastName': 'Mebrahtu', 'Affiliation': 'School of Healthcare, University of Leeds, Leeds, UK.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'McGowan', 'Affiliation': 'School of Healthcare, University of Leeds, Leeds, UK.'}, {'ForeName': 'Philip G', 'Initials': 'PG', 'LastName': 'Conaghan', 'Affiliation': 'Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Biomedical Research Centre, University of Leeds, Leeds, UK.'}, {'ForeName': 'Sarah R', 'Initials': 'SR', 'LastName': 'Kingsbury', 'Affiliation': 'Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Biomedical Research Centre, University of Leeds, Leeds, UK.'}, {'ForeName': 'Gerry', 'Initials': 'G', 'LastName': 'Richardson', 'Affiliation': 'Centre for Health Economics, University of York, York, UK.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Antcliff', 'Affiliation': 'School of Healthcare, University of Leeds, Leeds, UK.'}, {'ForeName': 'Gretl A', 'Initials': 'GA', 'LastName': 'McHugh', 'Affiliation': 'School of Healthcare, University of Leeds, Leeds, UK.'}]",BMJ open,['10.1136/bmjopen-2020-045389'] 1753,34290045,Hiding unhealthy heart outcomes in a low-fat diet trial: the Women's Health Initiative Randomized Controlled Dietary Modification Trial finds that postmenopausal women with established coronary heart disease were at increased risk of an adverse outcome if they consumed a low-fat 'heart-healthy' diet.,"The Women's Health Initiative Randomized Controlled Dietary Modification Trial (WHIRCDMT) was designed to test whether the US Department of Agriculture's 1977 Dietary Guidelines for Americans protects against coronary heart disease (CHD) and other chronic diseases. The only significant finding in the original 2006 WHIRCDMT publication was that postmenopausal women with CHD randomised to a low-fat 'heart-healthy' diet in 1993 were at 26% greater risk of developing additional CHD events compared with women with CHD eating the control diet. A 2017 WHIRCDMT publication includes data for an additional 5 years of follow-up. It finds that CHD risk in this subgroup of postmenopausal women had increased further to 47%-61%. The authors present three post-hoc rationalisations to explain why this finding is 'inadmissible': (1) only women in this subgroup were less likely to adhere to the prescribed dietary intervention; (2) their failure to follow the intervention diet increased their CHD risk; and (3) only these women were more likely to not have received cholesterol-lowering drugs. These rationalisations appear spurious. Rather these findings are better explained as a direct consequence of postmenopausal women with features of insulin resistance (IR) eating a low-fat high-carbohydrate diet for 13 years. All the worst clinical features of IR, including type 2 diabetes mellitus (T2DM) in some, can be 'reversed' by the prescription of a high-fat low-carbohydrate diet. The Women's Health Study has recently reported that T2DM (10.71-fold increased risk) and other markers of IR including metabolic syndrome (6.09-fold increased risk) were the most powerful predictors of future CHD development in women; blood low-density lipoprotein-cholesterol concentration was a poor predictor (1.38-fold increased risk). These studies challenge the prescription of the low-fat high-carbohydrate heart-healthy diet, at least in postmenopausal women with IR, especially T2DM. According to the medical principle of 'first do no harm', this practice is now shown to be not evidence-based, making it scientifically unjustifiable, perhaps unethical.",2021,The Women's Health Initiative Randomized Controlled Dietary Modification Trial (WHIRCDMT) was designed to test whether the US Department of Agriculture's 1977 Dietary Guidelines for Americans protects against coronary heart disease (CHD) and other chronic diseases.,"['Americans protects against coronary heart disease (CHD) and other chronic diseases', 'postmenopausal women with IR, especially T2DM', 'postmenopausal women with established coronary heart disease', 'postmenopausal women with features of insulin resistance (IR) eating a low-fat high-carbohydrate diet for 13 years']",[],[],"[{'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0259835', 'cui_str': 'High carbohydrate diet'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],[],,0.0394414,The Women's Health Initiative Randomized Controlled Dietary Modification Trial (WHIRCDMT) was designed to test whether the US Department of Agriculture's 1977 Dietary Guidelines for Americans protects against coronary heart disease (CHD) and other chronic diseases.,"[{'ForeName': 'Timothy David', 'Initials': 'TD', 'LastName': 'Noakes', 'Affiliation': 'Applied Design, Cape Peninsula University of Technology, Bellville, South Africa timothy.noakes@uct.ac.za.'}]",Open heart,['10.1136/openhrt-2021-001680'] 1754,34294478,Longitudinal assessment of nonavalent vaccine HPV types in a sample of sexually active African American women from ten U.S. Cities.,"BACKGROUND Chronic infection with high-risk human papillomavirus is a necessary cause for cervical carcinogenesis. This study examined prevalence of nonavalent vaccine preventable HPV types over four months among sexually active women in the United States. METHODS This sub-study obtained meta-data for 80 of the 1,365 women (18-25 years), enrolled in the BRAVO study, a randomized, open-label trial of home screening and treatment of asymptomatic bacterial vaginosis at high-risk for sexually transmitted infections conducted between 2008 and 2013. Participants were randomized to treatment or standard-of-care, and followed every 2-months for 12 months. Stored vaginal swabs from the first three visits were tested for the nine vaccine preventable HPV types using quantitative PCR. Prevalence and associated 95% confidence intervals for the HPV types were assessed using R (version 3.6.1). RESULTS The average age of the participants was 21.5 (SD ± 2.11) years, with 60% having ever been pregnant and all were African-American. Majority (71%) reported ≥ two sex partners in the prior year with 89% having unprotected vaginal sex and 45% having a new sex partner in the prior year. About 30% had ≥ one of the nine nonavalent vaccine HPV types at all three time points over a period of four months, 15% at two of any three visits, 19% at one of the three visits and 36% were negative for all nine vaccine HPV types at all time points. The most frequently detected HPV vaccine types were 52, 58, 16, and 18. The prevalence of any vaccine HPV types, and high-risk HPV types was 63.8% and 58.8%, respectively. CONCLUSIONS Our findings suggest that HPV vaccination which is currently recommended for all unvaccinated persons through age 26 years, is likely to be more beneficial than previously thought as nonavalent HPV vaccine was not available during the time these data were collected.",2021,"The prevalence of any vaccine HPV types, and high-risk HPV types was 63.8% and 58.8%, respectively. ","['The average age of the participants was 21.5 (SD\xa0±\xa02.11) years, with 60% having ever been pregnant and all were African-American', 'sexually active women in the United States', 'unvaccinated persons through age 26\xa0years', 'sexually active African American women from ten U.S. Cities', '80 of the 1,365 women (18-25\xa0years), enrolled in the BRAVO study, a randomized, open-label trial of home screening and treatment of asymptomatic bacterial vaginosis at high-risk for sexually transmitted infections conducted between 2008 and 2013']","['HPV vaccination', 'nonavalent vaccine HPV types']","['prevalence of any vaccine HPV types, and high-risk HPV types']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0241028', 'cui_str': 'Sexually active'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0450335', 'cui_str': '18/25'}, {'cui': 'C0443160', 'cui_str': 'Bravo'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0085166', 'cui_str': 'Bacterial vaginosis'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0201679', 'cui_str': 'Human papillomavirus typing'}]","[{'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0201679', 'cui_str': 'Human papillomavirus typing'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]",,0.123318,"The prevalence of any vaccine HPV types, and high-risk HPV types was 63.8% and 58.8%, respectively. ","[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Madhivanan', 'Affiliation': 'Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA; College of Medicine, University of Arizona, Tucson, USA; University of Arizona Comprehensive Cancer Center, Tucson, USA. Electronic address: pmadhivanan@arizona.edu.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Krupp', 'Affiliation': 'Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA; University of Arizona Comprehensive Cancer Center, Tucson, USA. Electronic address: kkrupp@arizona.edu.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Coudray', 'Affiliation': 'Robert Stempel College of Public Health and Social Work, Florida International University, Miami, USA; College of Medicine, University of Central Florida, Orlando, USA. Electronic address: Makella.Coudray@ucf.edu.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Colbert', 'Affiliation': 'Herbert Wertheim College of Medicine, Florida International University, Miami, USA. Electronic address: bmc48@miami.edu.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Ruiz-Perez', 'Affiliation': 'Bioinformatic Research Group (BioRG), School of Computing and Information Sciences, Florida International University, Miami, USA. Electronic address: druiz072@cs.fiu.edu.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Cui', 'Affiliation': 'University of Arizona Comprehensive Cancer Center, Tucson, USA. Electronic address: HCui@uacc.arizona.edu.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Bokulich', 'Affiliation': 'Laboratory of Food Systems Biotechnology, Institute of Food, Nutrition and Health, ETH Zurich, Switzerland. Electronic address: Nicholas.Bokulich@hest.ethz.ch.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Narasimhan', 'Affiliation': 'Herbert Wertheim College of Medicine, Florida International University, Miami, USA. Electronic address: giri@cs.fiu.edu.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Mathee', 'Affiliation': 'Herbert Wertheim College of Medicine, Florida International University, Miami, USA. Electronic address: matheek@fiu.edu.'}, {'ForeName': 'R L', 'Initials': 'RL', 'LastName': 'Cook', 'Affiliation': 'College of Public Health and Health Professions, University of Florida, Gainesville, USA. Electronic address: cookrl@ufl.edu.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Schwebke', 'Affiliation': 'College of Medicine, University of Birmingham, Alabama, USA. Electronic address: janeschwebke@gmail.com.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Roe', 'Affiliation': 'Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA; University of Arizona Comprehensive Cancer Center, Tucson, USA. Electronic address: droe@arizona.edu.'}]",Vaccine,['10.1016/j.vaccine.2021.07.026'] 1755,34299719,"Effects and Responsiveness of a Multicomponent Intervention on Body Composition, Physical Fitness, and Leptin in Overweight/Obese Adolescents.","Physical exercise reduces the biochemical markers of obesity, but the effects of multicomponent interventions on these markers should be explored. The present study aimed to elucidate how overweight/obese adolescents respond to a multicomponent program approach on body composition, physical fitness, and inflammatory markers, using a quasi-experimental study with 33 overweight/obesity adolescents (control group (CG) = 16; intervention group (IG) = 17). The intervention consisted of 24 weeks with physical exercises and nutritional and psychological guidance. Both groups were evaluated at the pre/post-intervention moments on body mass index (BMI); body fat (%Fat); waist circumference (WC); waist/hip ratio (WHR); waist-to-height ratio (WHtR), cardiorespiratory fitness (CRF); abdominal strength, flexibility; leptin; interleukin 6; interleukin 10; and tumor necrosis factor-alpha. Mixed-analysis of variance and generalized estimation equations were used for statistical analysis. There was an interaction effect between groups and time on %Fat ( p = 0.002), WC ( p = 0.023), WHR ( p < 0.001), WHtR ( p = 0.035), CRF ( p = 0.050), and leptin ( p = 0.026). Adolescents were classified as 82.4% responders for %Fat, 70.6% for WC, 88.2% for WHR, and 70.6% for CRF. Further, there was an association between changes in %Fat ( p = 0.033), WC ( p = 0.032), and WHR ( p = 0.033) between responders and non-responders with CRF in the IG. There was a positive effect on body composition, physical fitness, and leptin. In addition, reductions in body composition parameters were explained by CRF improvements.",2021,"There was an interaction effect between groups and time on %Fat ( p = 0.002), WC ( p = 0.023), WHR ( p < 0.001), WHtR ( p = 0.035), CRF ( p = 0.050), and leptin ( p = 0.026).","['Overweight/Obese Adolescents', '33 overweight/obesity adolescents (control group (CG) = 16; intervention group (IG) = 17', 'overweight/obese adolescents']","['physical exercises and nutritional and psychological guidance', 'multicomponent program approach', 'Multicomponent Intervention', 'Physical exercise']","['body composition, physical fitness, and leptin', 'WHR', 'body mass index (BMI); body fat (%Fat); waist circumference (WC); waist/hip ratio (WHR); waist-to-height ratio (WHtR), cardiorespiratory fitness (CRF); abdominal strength, flexibility; leptin; interleukin 6; interleukin 10; and tumor necrosis factor-alpha', 'CRF', 'Body Composition, Physical Fitness, and Leptin', 'WHtR', 'body composition parameters']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1821269', 'cui_str': 'Waist to Height Ratio'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",33.0,0.0130184,"There was an interaction effect between groups and time on %Fat ( p = 0.002), WC ( p = 0.023), WHR ( p < 0.001), WHtR ( p = 0.035), CRF ( p = 0.050), and leptin ( p = 0.026).","[{'ForeName': 'Leticia', 'Initials': 'L', 'LastName': 'Borfe', 'Affiliation': 'Graduate Program in Human Movement Sciences, Federal University of Rio Grande do Sul, Porto Alegre 90690-200, Brazil.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Brand', 'Affiliation': 'Graduate Program on Health Promotion, University of Santa Cruz do Sul, Santa Cruz do Sul 96816-501, Brazil.'}, {'ForeName': 'Letícia de Borba', 'Initials': 'LB', 'LastName': 'Schneiders', 'Affiliation': 'Graduate Program on Health Promotion, University of Santa Cruz do Sul, Santa Cruz do Sul 96816-501, Brazil.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Mota', 'Affiliation': 'Research Center in Physical Activity, Health and Leisure, Faculty of Sports, University of Porto, 4200-450 Porto, Portugal.'}, {'ForeName': 'Claudia Regina', 'Initials': 'CR', 'LastName': 'Cavaglieri', 'Affiliation': 'Department of Adapted Physical Activity Studies, University State Campinas, Campinas 13083-851, Brazil.'}, {'ForeName': 'Neiva', 'Initials': 'N', 'LastName': 'Leite', 'Affiliation': 'Department of Physical Education, University of Paraná, Curitiba 81690-100, Brazil.'}, {'ForeName': 'Jane Dagmar Pollo', 'Initials': 'JDP', 'LastName': 'Renner', 'Affiliation': 'Department of Life Sciences and Graduate Program on Health Promotion, University of Santa Cruz do Sul, Santa Cruz do Sul 96816-501, Brazil.'}, {'ForeName': 'Cézane Priscila', 'Initials': 'CP', 'LastName': 'Reuter', 'Affiliation': 'Department of Health Sciences and Graduate Program on Health Promotion, University of Santa Cruz do Sul, Santa Cruz do Sul 96816-501, Brazil.'}, {'ForeName': 'Anelise Reis', 'Initials': 'AR', 'LastName': 'Gaya', 'Affiliation': 'Graduate Program in Human Movement Sciences, Federal University of Rio Grande do Sul, Porto Alegre 90690-200, Brazil.'}]",International journal of environmental research and public health,['10.3390/ijerph18147267'] 1756,34299702,Effects of Time-Restricted Feeding on Supramaximal Exercise Performance and Body Composition: A Randomized and Counterbalanced Crossover Study in Healthy Men.,"Using a crossover design, we explored the effects of both short- and long-term time-restricted feeding (TRF) vs. regular diet on Wingate (WnT) performance and body composition in well-trained young men. Twelve healthy male physical education students were included (age: 22.4 ± 2.8 years, height: 174.0 ± 7.1 cm, body mass: 73.6 ± 9.5 kg, body mass index: 24.2 ± 2.0 kg/m 2 ). The order of dieting was randomized and counterbalanced, and all participants served as their own controls. TRF was limited to an 8-h eating window and non-TRF involved a customary meal pattern. Participants performed WnT tests and body composition scans at baseline, post-one and post-four weeks of the assigned diet. Before testing, participants were asked to fill out a dietary record over four consecutive days and were instructed to continue their habitual training throughout the study. Energy intake and macronutrient distribution were similar at baseline in both conditions. WnT mean power and total work output increased post-four weeks of TRF. Both conditions were similarly effective in increasing fat-free mass after four weeks of intervention. However, there was no correlation between change in fat-free mass and WnT mean power after TRF. TRF did not elicit any changes in WnT performance or body composition one week post-intervention. Thus, long-term TRF can be used in combination with regular training to improve supramaximal exercise performance in well-trained men.",2021,WnT mean power and total work output increased post-four weeks of TRF.,"['Healthy Men', 'Twelve healthy male physical education students were included (age: 22.4 ± 2.8 years, height: 174.0 ± 7.1 cm, body mass: 73.6 ± 9.5 kg, body mass index: 24.2 ± 2.0 kg/m 2 ', 'well-trained men', 'well-trained young men']","['Time-Restricted Feeding', 'regular training', 'TRF', 'short- and long-term time-restricted feeding (TRF) vs. regular diet']","['Energy intake and macronutrient distribution', 'Supramaximal Exercise Performance and Body Composition', 'Wingate (WnT) performance and body composition', 'WnT mean power and total work output', 'supramaximal exercise performance']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C4704883', 'cui_str': 'Time Restricted Feeding'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0040162', 'cui_str': 'Thyrotropin-Releasing Hormone'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0184625', 'cui_str': 'Normal diet'}]","[{'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}]",12.0,0.0192397,WnT mean power and total work output increased post-four weeks of TRF.,"[{'ForeName': 'Joana M', 'Initials': 'JM', 'LastName': 'Correia', 'Affiliation': 'Laboratório de Função Neuromuscular, Faculdade de Motricidade Humana, Universidade de Lisboa, Estrada da Costa, 1499-002 Cruz Quebrada-Dafundo, Portugal.'}, {'ForeName': 'Inês', 'Initials': 'I', 'LastName': 'Santos', 'Affiliation': 'CIDEFES-Centro de Investigação em Desporto, Educação Física, Exercício e Saúde, Universidade Lusófona, Campo Grande 376, 1749-024 Lisboa, Portugal.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Pezarat-Correia', 'Affiliation': 'Laboratório de Função Neuromuscular, Faculdade de Motricidade Humana, Universidade de Lisboa, Estrada da Costa, 1499-002 Cruz Quebrada-Dafundo, Portugal.'}, {'ForeName': 'Cláudia', 'Initials': 'C', 'LastName': 'Minderico', 'Affiliation': 'CIPER-Centro Interdisciplinar Para o Estudo da Performance Humana, Faculdade de Motricidade Humana, Universidade de Lisboa, Estrada da Costa, 1499-002 Cruz Quebrada-Dafundo, Portugal.'}, {'ForeName': 'Brad J', 'Initials': 'BJ', 'LastName': 'Schoenfeld', 'Affiliation': 'Department of Health Sciences, CUNY Lehman College, Bronx, NY 10468, USA.'}, {'ForeName': 'Goncalo V', 'Initials': 'GV', 'LastName': 'Mendonca', 'Affiliation': 'Laboratório de Função Neuromuscular, Faculdade de Motricidade Humana, Universidade de Lisboa, Estrada da Costa, 1499-002 Cruz Quebrada-Dafundo, Portugal.'}]",International journal of environmental research and public health,['10.3390/ijerph18147227'] 1757,34299697,"A Multicentre, Randomised, Controlled Trial of a Combined Clinical Treatment for First-Episode Psychosis.","INTRODUCTION There is evidence that early intervention contributes to improving the prognosis and course of first-episode psychosis (FEP). However, further randomised treatment clinical trials are needed. OBJECTIVES The aim of this study was to compare the efficacy of a combined clinical treatment involving Cognitive Behavioural Therapy (CBT) as an adjunctive to treatment-as-usual (TAU) (CBT+TAU) versus TAU alone for FEP. PATIENTS AND METHODS In this multicentre, single-blind, randomised controlled trial, 177 participants were randomly allocated to either CBT+TAU or TAU. The primary outcome was post-treatment patient functioning. RESULTS The CBT+TAU group showed a greater improvement in functioning, which was measured using the Global Assessment Functioning (GAF) and Functioning Assessment Short Test (FAST), compared to the TAU group post-treatment. The CBT+TAU participants exhibited a greater decline in depressive, negative, and general psychotic symptoms; a better awareness of the disease and treatment adherence; and a greater increase in brain-derived neurotrophic factor levels than TAU participants. CONCLUSIONS Early intervention based on a combined clinical treatment involving CBT as an adjunctive to standard treatment may improve clinical and functional outcomes in FEP.",2021,"The CBT+TAU group showed a greater improvement in functioning, which was measured using the Global Assessment Functioning (GAF) and Functioning Assessment Short Test (FAST), compared to the TAU group post-treatment.","['First-Episode Psychosis', '177 participants']","['CBT+TAU or TAU', 'Cognitive Behavioural Therapy (CBT']","['post-treatment patient functioning', 'depressive, negative, and general psychotic symptoms', 'Global Assessment Functioning (GAF) and Functioning Assessment Short Test (FAST', 'brain-derived neurotrophic factor levels']","[{'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0871189', 'cui_str': 'Psychotic symptom'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",177.0,0.238992,"The CBT+TAU group showed a greater improvement in functioning, which was measured using the Global Assessment Functioning (GAF) and Functioning Assessment Short Test (FAST), compared to the TAU group post-treatment.","[{'ForeName': 'Itxaso', 'Initials': 'I', 'LastName': 'González-Ortega', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Vega', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Echeburúa', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Alberich', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Fernández-Sevillano', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Barbeito', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Vicent', 'Initials': 'V', 'LastName': 'Balanzá-Martínez', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Vieta', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Lorente-Rovira', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Luengo', 'Affiliation': 'Department of Psychiatry, Clinic University Hospital of Valencia, INCLIVA, 46010 Valencia, Spain.'}, {'ForeName': 'Ester', 'Initials': 'E', 'LastName': 'Cerrillo', 'Affiliation': 'Department of Psychiatry, Bellvitge University Hospital, IDIBELL, 08907 Barcelona, Spain.'}, {'ForeName': 'José Manuel', 'Initials': 'JM', 'LastName': 'Crespo', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Matute', 'Affiliation': 'Achucarro Basque Centre for Neurosciences, University of the Basque Country, 48940 Leioa, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'González-Pinto', 'Affiliation': 'Centre for Biomedical Research in the Mental Health Network (CIBERSAM), 28029 Madrid, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18147239'] 1758,34299009,Influence of Cannabinoid Receptor 1 Genetic Variants on the Subjective Effects of Smoked Cannabis.,"As many jurisdictions consider relaxing cannabis legislation and usage is increasing in North America and other parts of the world, there is a need to explore the possible genetic differences underlying the subjective effects of cannabis. This pilot study investigated specific genetic variations within the cannabinoid receptor 1 ( CNR1 ) gene for association with the subjective effects of smoked cannabis. Data were obtained from a double-blinded, placebo-controlled clinical trial studying the impact of cannabis intoxication on driving performance. Participants randomized to the active cannabis group who consented to secondary genetic analysis ( n = 52) were genotyped at the CNR1 rs1049353 and rs2023239 polymorphic areas. Maximum value and area under the curve (AUC) analyses were performed on subjective measures data. Analysis of subjective effects by genotype uncovered a global trend towards greater subjective effects for rs1049353 T-allele- and rs2023239 C-allele-carrying subjects. However, significant differences attributed to allelic identity were only documented for a subset of subjective effects. Our findings suggest that rs1049353 and rs2023239 minor allele carriers experience augmented subjective effects during acute cannabis intoxication.",2021,Analysis of subjective effects by genotype uncovered a global trend towards greater subjective effects for rs1049353 T-allele- and rs2023239 C-allele-carrying subjects.,"['Participants randomized to the active cannabis group who consented to secondary genetic analysis ( n = 52) were genotyped at the CNR1 rs1049353 and rs2023239 polymorphic areas', 'Smoked Cannabis']",['placebo'],['Maximum value and area under the curve (AUC) analyses'],"[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0679560', 'cui_str': 'Genetic test'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",52.0,0.0685916,Analysis of subjective effects by genotype uncovered a global trend towards greater subjective effects for rs1049353 T-allele- and rs2023239 C-allele-carrying subjects.,"[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Murphy', 'Affiliation': 'Centre for Addiction and Mental Health, Translational Addiction Research Laboratory, University of Toronto, 33 Ursula Franklin Street, Toronto, ON M5S 2S1, Canada.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Matheson', 'Affiliation': 'Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Mann', 'Affiliation': 'Centre for Addiction and Mental Health, Institute for Mental Health Policy Research, Toronto, ON M6J 1H4, Canada.'}, {'ForeName': 'Bruna', 'Initials': 'B', 'LastName': 'Brands', 'Affiliation': 'Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Wickens', 'Affiliation': 'Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.'}, {'ForeName': 'Arun K', 'Initials': 'AK', 'LastName': 'Tiwari', 'Affiliation': 'Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, CAMH, Toronto, ON M5T 1R8, Canada.'}, {'ForeName': 'Clement C', 'Initials': 'CC', 'LastName': 'Zai', 'Affiliation': 'Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, CAMH, Toronto, ON M5T 1R8, Canada.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Kennedy', 'Affiliation': 'Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, CAMH, Toronto, ON M5T 1R8, Canada.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Le Foll', 'Affiliation': 'Centre for Addiction and Mental Health, Translational Addiction Research Laboratory, University of Toronto, 33 Ursula Franklin Street, Toronto, ON M5S 2S1, Canada.'}]",International journal of molecular sciences,['10.3390/ijms22147388'] 1759,34312159,Acute effects of the food preservative propionic acid on glucose metabolism in humans.,"INTRODUCTION Propionic acid (PA) is a common food preservative generally recognized as safe by the US Food and Drug Administration; however, exogenous PA has effects on glucose metabolism that are not fully understood. Our preclinical studies demonstrated exogenous PA increases glucagon, norepinephrine, and endogenous glucose production (EGP). RESEARCH DESIGN AND METHODS We performed a randomized, placebo-controlled, crossover study in 28 healthy men and women to determine the effect of PA (1500 mg calcium propionate) on these factors. Subjects had two study visits, each preceded by a 1 week, PA-free diet. During each visit, glucose, insulin, glucagon, norepinephrine, epinephrine, and EGP were assessed for 2 hours after oral administration of PA/placebo under resting conditions (protocol 1) and during either a euglycemic (~85-90 mg/dL) or hypoglycemic (~65-70 mg/dL) hyperinsulinemic clamp (protocol 2). RESULTS PA, as compared with placebo, significantly increased: (1) glucagon and norepinephrine during protocol 1; (2) glucagon, norepinephrine, and epinephrine under euglycemic conditions in protocol 2; and (3) norepinephrine, epinephrine, and EGP under hypoglycemic conditions in protocol 2. CONCLUSION Oral consumption of PA leads to inappropriate activation of the insulin counterregulatory hormonal network. This inappropriate stimulation highlights PA as a potential metabolic disruptor.",2021,"RESULTS PA, as compared with placebo, significantly increased:","['humans', '28 healthy men and women']","['norepinephrine, epinephrine, and EGP', 'PA/placebo', 'hypoglycemic (~65-70\u2009mg/dL) hyperinsulinemic clamp (protocol 2', 'PA (1500 mg calcium propionate', 'food preservative propionic acid', 'glucagon and norepinephrine during protocol 1; (2) glucagon, norepinephrine, and epinephrine', 'placebo', 'Propionic acid (PA']","['glucose metabolism', 'glucagon, norepinephrine, and endogenous glucose production (EGP', 'glucose, insulin, glucagon, norepinephrine, epinephrine, and EGP']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0033482', 'cui_str': 'Propanoic Acids'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0108141', 'cui_str': 'calcium propionate'}, {'cui': 'C0016485', 'cui_str': 'Food preservative'}, {'cui': 'C0017687', 'cui_str': 'Glucagon'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0017687', 'cui_str': 'Glucagon'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}]",28.0,0.143773,"RESULTS PA, as compared with placebo, significantly increased:","[{'ForeName': 'Gail K', 'Initials': 'GK', 'LastName': 'Adler', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA gadler@bwh.harvard.edu.""}, {'ForeName': 'Ezra S', 'Initials': 'ES', 'LastName': 'Hornik', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Murray', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Shreya', 'Initials': 'S', 'LastName': 'Bhandari', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Yogesh', 'Initials': 'Y', 'LastName': 'Yadav', 'Affiliation': 'Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.'}, {'ForeName': 'Mahyar', 'Initials': 'M', 'LastName': 'Heydarpour', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Basu', 'Affiliation': 'Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Garg', 'Affiliation': 'Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Tirosh', 'Affiliation': 'Division of Endocrinology, Sheba Medical Center and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}]",BMJ open diabetes research & care,['10.1136/bmjdrc-2021-002336'] 1760,34312146,Why do strategies to strengthen primary health care succeed in some places and fail in others? Exploring local variation in the effectiveness of a community health worker managed digital health intervention in rural India.,"INTRODUCTION Digital health interventions (DHIs) have huge potential as support modalities to identify and manage cardiovascular disease (CVD) risk in resource-constrained settings, but studies assessing them show modest effects. This study aims to identify variation in outcomes and implementation of SMARTHealth India, a cluster randomised trial of an ASHA-managed digitally enabled primary healthcare (PHC) service strengthening strategy for CVD risk management, and to explain how and in what contexts the intervention was effective. METHODS We analysed trial outcome and implementation data for 18 PHC centres and collected qualitative data via focus groups with ASHAs (n=14) and interviews with ASHAs, PHC facility doctors and fieldteam mangers (n=12) Drawing on principles of realist evaluation and an explanatory mixed-methods design we developed mechanism-based explanations for observed outcomes. RESULTS There was substantial between-cluster variation in the primary outcome (overall: I 2 =62.4%, p<=0.001). The observed heterogeneity in trial outcomes was not attributable to any single factor. Key mechanisms for intervention effectiveness were community trust and acceptability of doctors' and ASHAs' new roles, and risk awareness. Enabling local contexts were seen to evolve over time and in response to the intervention. These included obtaining legitimacy for ASHAs' new roles from trusted providers of curative care; ASHAs' connections to community and to qualified providers; their responsiveness to community needs; and the accessibility, quality and appropriateness of care provided by higher level medical providers, including those outside of the implementing (public) subsystem. CONCLUSION Local contextual factors were significant influences on the effectiveness of this DHI-enabled PHC service strategy intervention. Local adaptions need to be planned for, monitored and responded to over time. By identifying plausible explanations for variation in outcomes between clusters, we identify potential strategies to strengthen such interventions.",2021,"Key mechanisms for intervention effectiveness were community trust and acceptability of doctors' and ASHAs' new roles, and risk awareness.","['rural India', '18 PHC centres and collected qualitative data via focus groups with ASHAs (n=14) and interviews with ASHAs, PHC facility doctors and fieldteam mangers']","['community health worker managed digital health intervention', 'Digital health interventions (DHIs', 'ASHA-managed digitally enabled primary healthcare (PHC) service strengthening strategy']",[],"[{'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0031831', 'cui_str': 'Physician'}]","[{'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0557854', 'cui_str': 'Services'}]",[],,0.121506,"Key mechanisms for intervention effectiveness were community trust and acceptability of doctors' and ASHAs' new roles, and risk awareness.","[{'ForeName': 'Gill', 'Initials': 'G', 'LastName': 'Schierhout', 'Affiliation': 'The George Institute for Global Health, Newtown, New South Wales, Australia.'}, {'ForeName': 'Devarsetty', 'Initials': 'D', 'LastName': 'Praveen', 'Affiliation': 'The George Institute for Global Health India, Hyderabad, India dpraveen@georgeinstitute.org.in.'}, {'ForeName': 'Bindu', 'Initials': 'B', 'LastName': 'Patel', 'Affiliation': 'The George Institute for Global Health, Newtown, New South Wales, Australia.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'The George Institute for Global Health, Newtown, New South Wales, Australia.'}, {'ForeName': 'Kishor', 'Initials': 'K', 'LastName': 'Mogulluru', 'Affiliation': 'The George Institute for Global Health India, New Delhi, Delhi, India.'}, {'ForeName': 'Mohammed Abdul', 'Initials': 'MA', 'LastName': 'Ameer', 'Affiliation': 'The George Institute for Global Health India, Hyderberad, India.'}, {'ForeName': 'Anushka', 'Initials': 'A', 'LastName': 'Patel', 'Affiliation': 'The George Institute for Global Health, Newtown, New South Wales, Australia.'}, {'ForeName': 'Gari D', 'Initials': 'GD', 'LastName': 'Clifford', 'Affiliation': 'Department of Biomedical Informatics and Biomedical Engineering, Emory University, Atlanta, Georgia, USA.'}, {'ForeName': 'Rohina', 'Initials': 'R', 'LastName': 'Joshi', 'Affiliation': 'The George Institute for Global Health, Newtown, New South Wales, Australia.'}, {'ForeName': 'Stephane', 'Initials': 'S', 'LastName': 'Heritier', 'Affiliation': 'Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Pallab', 'Initials': 'P', 'LastName': 'Maulik', 'Affiliation': 'UNSW, Sydney, New South Wales, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Peiris', 'Affiliation': 'The George Institute for Global Health, Newtown, New South Wales, Australia.'}]",BMJ global health,['10.1136/bmjgh-2021-005003'] 1761,34292335,Evaluation of a Clinical Decision Support Strategy to Increase Seasonal Influenza Vaccination Among Hospitalized Children Before Inpatient Discharge.,"Importance Hospitalized children are at increased risk of influenza-related complications, yet influenza vaccine coverage remains low among this group. Evidence-based strategies about vaccination of vulnerable children during all health care visits are especially important during the COVID-19 pandemic. Objective To design and evaluate a clinical decision support (CDS) strategy to increase the proportion of eligible hospitalized children who receive a seasonal influenza vaccine prior to inpatient discharge. Design, Setting, and Participants This quality improvement study was conducted among children eligible for the seasonal influenza vaccine who were hospitalized in a tertiary pediatric health system providing care to more than half a million patients annually in 3 hospitals. The study used a sequential crossover design from control to intervention and compared hospitalizations in the intervention group (2019-2020 season with the use of an intervention order set) with concurrent controls (2019-2020 season without use of an intervention order set) and historical controls (2018-2019 season with use of an order set that underwent intervention during the 2019-2020 season). Interventions A CDS intervention was developed through a user-centered design process, including (1) placing a default influenza vaccine order into admission order sets for eligible patients, (2) a script to offer the vaccine using a presumptive strategy, and (3) just-in-time education for clinicians addressing vaccine eligibility in the influenza order group with links to further reference material. The intervention was rolled out in a stepwise fashion during the 2019-2020 influenza season. Main Outcomes and Measures Proportion of eligible hospitalizations in which 1 or more influenza vaccines were administered prior to discharge. Results Among 17 740 hospitalizations (9295 boys [52%]), the mean (SD) age was 8.0 (6.0) years, and the patients were predominantly Black (n = 8943 [50%]) or White (n = 7559 [43%]) and mostly had public insurance (n = 11 274 [64%]). There were 10 997 hospitalizations eligible for the influenza vaccine in the 2019-2020 season. Of these, 5449 (50%) were in the intervention group, and 5548 (50%) were concurrent controls. There were 6743 eligible hospitalizations in 2018-2019 that served as historical controls. Vaccine administration rates were 31% (n = 1676) in the intervention group, 19% (n = 1051) in concurrent controls, and 14% (n = 912) in historical controls (P < .001). In adjusted analyses, the odds of receiving the influenza vaccine were 3.25 (95% CI, 2.94-3.59) times higher in the intervention group and 1.28 (95% CI, 1.15-1.42) times higher in concurrent controls than in historical controls. Conclusions and Relevance This quality improvement study suggests that user-centered CDS may be associated with significantly improved influenza vaccination rates among hospitalized children. Stepwise implementation of CDS interventions was a practical method that was used to increase quality improvement rigor through comparison with historical and concurrent controls.",2021,"In adjusted analyses, the odds of receiving the influenza vaccine were 3.25 (95% CI, 2.94-3.59) times higher in the intervention group and 1.28 (95% CI, 1.15-1.42) times higher in concurrent controls than in historical controls. ","['Among 17\u202f740 hospitalizations (9295 boys [52%]), the mean (SD) age was 8.0 (6.0) years, and the patients were predominantly Black (n\u2009=\u20098943 [50%]) or White (n\u2009=\u20097559 [43%]) and mostly had public insurance (n\u2009=\u200911\u202f274 [64', 'hospitalized children', 'children eligible for the seasonal influenza vaccine who were hospitalized in a tertiary pediatric health system providing care to more than half a million patients annually in 3 hospitals', '6743 eligible hospitalizations in 2018-2019 that served as historical controls', 'intervention group (2019-2020 season with the use of an intervention order set) with concurrent controls (2019-2020 season without use of an intervention order set) and historical controls (2018-2019 season with use of an order set that underwent intervention during the 2019-2020 season', 'There were 10\u202f997 hospitalizations eligible for the influenza vaccine in the 2019-2020 season', 'Hospitalized Children Before Inpatient Discharge', 'eligible hospitalized children who receive a seasonal influenza vaccine prior to inpatient discharge']",['CDS intervention'],"['influenza vaccination rates', 'Vaccine administration rates', 'Seasonal Influenza Vaccination', 'Main Outcomes and Measures\n\n\nProportion of eligible hospitalizations']","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0021672', 'cui_str': 'Insurance'}, {'cui': 'C0008098', 'cui_str': 'Children, Hospitalized'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C1881839', 'cui_str': '1000000'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0332152', 'cui_str': 'Before'}]","[{'cui': 'C4042765', 'cui_str': 'Decision Support, Clinical'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0042200', 'cui_str': 'Influenza vaccination'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",,0.02715,"In adjusted analyses, the odds of receiving the influenza vaccine were 3.25 (95% CI, 2.94-3.59) times higher in the intervention group and 1.28 (95% CI, 1.15-1.42) times higher in concurrent controls than in historical controls. ","[{'ForeName': 'Evan W', 'Initials': 'EW', 'LastName': 'Orenstein', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'ElSayed-Ali', 'Affiliation': 'Department of Pediatrics, Washington University in St Louis, St Louis, Missouri.'}, {'ForeName': 'Swaminathan', 'Initials': 'S', 'LastName': 'Kandaswamy', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Masterson', 'Affiliation': ""Division of Hospital Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia.""}, {'ForeName': 'Reena', 'Initials': 'R', 'LastName': 'Blanco', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Pareen', 'Initials': 'P', 'LastName': 'Shah', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Lantis', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Kolwaite', 'Affiliation': ""Division of Emergency Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia.""}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Dawson', 'Affiliation': ""Division of Hospital Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia.""}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'Ray', 'Affiliation': ""Division of Hospital Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia.""}, {'ForeName': 'Christy', 'Initials': 'C', 'LastName': 'Bryant', 'Affiliation': ""Division of Hospital Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia.""}, {'ForeName': 'Srikant', 'Initials': 'S', 'LastName': 'Iyer', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Andi L', 'Initials': 'AL', 'LastName': 'Shane', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Jernigan', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.17809'] 1762,34292309,Expanding Evidence for Clinical Care of Older Adults: Beyond Clinical Trial Traditions and Finding New Approaches.,,2021,,['Older Adults'],[],[],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}]",[],[],,0.237223,,"[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Steinman', 'Affiliation': 'Division of Geriatrics, Department of Medicine, University of California, San Francisco.'}, {'ForeName': 'Cynthia M', 'Initials': 'CM', 'LastName': 'Boyd', 'Affiliation': 'Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Kenneth E', 'Initials': 'KE', 'LastName': 'Schmader', 'Affiliation': 'Division of Geriatrics, Department of Medicine, Duke University, Durham, North Carolina.'}]",JAMA,['10.1001/jama.2021.12134'] 1763,34292305,Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group.,"Importance Brain tumors are the leading cause of disease-related death in children. Medulloblastoma is the most common malignant embryonal brain tumor, and strategies to increase survival are needed. Objective To evaluate therapy intensification with carboplatin as a radiosensitizer and isotretinoin as a proapoptotic agent in children with high-risk medulloblastoma in a randomized clinical trial and, with a correlative biology study, facilitate planned subgroup analysis according to World Health Organization consensus molecular subgroups of medulloblastoma. Design, Setting, and Participants A randomized clinical phase 3 trial was conducted from March 2007 to September 2018. Analysis was completed in September 2020. Patients aged 3 to 21 years with newly diagnosed high-risk medulloblastoma from Children's Oncology Group institutions within the US, Canada, Australia, and New Zealand were included. High-risk features included metastasis, residual disease, or diffuse anaplasia. Interventions Patients were randomized to receive 36-Gy craniospinal radiation therapy and weekly vincristine with or without daily carboplatin followed by 6 cycles of maintenance chemotherapy with cisplatin, cyclophosphamide, and vincristine with or without 12 cycles of isotretinoin during and following maintenance. Main Outcomes and Measures The primary clinical trial end point was event-free survival, using the log-rank test to compare arms. The primary biology study end point was molecular subgroup classification by DNA methylation array. Results Of 294 patients with medulloblastoma, 261 were evaluable after central radiologic and pathologic review; median age, 8.6 years (range, 3.3-21.2); 183 (70%) male; 189 (72%) with metastatic disease; 58 (22%) with diffuse anaplasia; and 14 (5%) with greater than 1.5-cm2 residual disease. For all participants, the 5-year event-free survival was 62.9% (95% CI, 55.6%-70.2%) and overall survival was 73.4% (95% CI, 66.7%-80.1%). Isotretinoin randomization was closed early owing to futility. Five-year event-free survival was 66.4% (95% CI, 56.4%-76.4%) with carboplatin vs 59.2% (95% CI, 48.8%-69.6%) without carboplatin (P = .11), with the effect exclusively observed in group 3 subgroup patients: 73.2% (95% CI, 56.9%-89.5%) with carboplatin vs 53.7% (95% CI, 35.3%-72.1%) without (P = .047). Five-year overall survival differed by molecular subgroup (P = .006): WNT pathway activated, 100% (95% CI, 100%-100%); SHH pathway activated, 53.6% (95% CI, 33.0%-74.2%); group 3, 73.7% (95% CI, 61.9%-85.5%); and group 4, 76.9% (95% CI, 67.3%-86.5%). Conclusions and Relevance In this randomized clinical trial, therapy intensification with carboplatin improved event-free survival by 19% at 5 years for children with high-risk group 3 medulloblastoma. These findings further support the value of an integrated clinical and molecular risk stratification for medulloblastoma. Trial Registration ClinicalTrials.gov Identifier: NCT00392327.",2021,"Five-year overall survival differed by molecular subgroup (P = .006): WNT pathway activated, 100% (95% CI, 100%-100%); SHH pathway activated, 53.6% (95% CI, 33.0%-74.2%); group 3, 73.7% (95% CI, 61.9%-85.5%); and group 4, 76.9% (95% CI, 67.3%-86.5%). ","[""Children's Oncology Group"", ""Patients aged 3 to 21 years with newly diagnosed high-risk medulloblastoma from Children's Oncology Group institutions within the US, Canada, Australia, and New Zealand were included"", 'children with high-risk group 3 medulloblastoma', 'March 2007 to September 2018', '294 patients with medulloblastoma, 261 were evaluable after central radiologic and pathologic review; median age, 8.6 years (range, 3.3-21.2); 183 (70%) male; 189 (72%) with metastatic disease; 58 (22%) with diffuse anaplasia; and 14 (5%) with greater than 1.5-cm2 residual disease', 'children with high-risk medulloblastoma', 'Children']","['Carboplatin and Isotretinoin', 'High-risk Medulloblastoma', 'carboplatin', '36-Gy craniospinal radiation therapy and weekly vincristine with or without daily carboplatin followed by 6 cycles of maintenance chemotherapy with cisplatin, cyclophosphamide, and vincristine with or without 12 cycles of isotretinoin during and following maintenance']","['overall survival', 'free survival', '5-year event-free survival', 'event-free survival']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0025149', 'cui_str': 'Medulloblastoma'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0034599', 'cui_str': 'Radiology - specialty'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C4517879', 'cui_str': '8.6'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4517688', 'cui_str': '3.3'}, {'cui': 'C4517615', 'cui_str': '183'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1320479', 'cui_str': 'Diffuse anaplasia'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0439479', 'cui_str': 'sq. cm'}, {'cui': 'C0543478', 'cui_str': 'Residual Tumour'}]","[{'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0022265', 'cui_str': 'Isotretinoin'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0025149', 'cui_str': 'Medulloblastoma'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0481504', 'cui_str': 'Maintenance Chemotherapy'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}]",294.0,0.699432,"Five-year overall survival differed by molecular subgroup (P = .006): WNT pathway activated, 100% (95% CI, 100%-100%); SHH pathway activated, 53.6% (95% CI, 33.0%-74.2%); group 3, 73.7% (95% CI, 61.9%-85.5%); and group 4, 76.9% (95% CI, 67.3%-86.5%). ","[{'ForeName': 'Sarah E S', 'Initials': 'SES', 'LastName': 'Leary', 'Affiliation': ""Cancer and Blood Disorders Center, Seattle Children's, Seattle, Washington.""}, {'ForeName': 'Roger J', 'Initials': 'RJ', 'LastName': 'Packer', 'Affiliation': ""Center for Neuroscience and Behavioral Health, Children's National Hospital, Washington, DC.""}, {'ForeName': 'Yimei', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Billups', 'Affiliation': ""Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Kyle S', 'Initials': 'KS', 'LastName': 'Smith', 'Affiliation': ""Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Alok', 'Initials': 'A', 'LastName': 'Jaju', 'Affiliation': ""Department of Radiology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois.""}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Heier', 'Affiliation': 'Department of Radiology, NYP/Weill Cornell Medical Center, New York, New York.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Burger', 'Affiliation': 'Sidney Kimmel Cancer Center, Department of Pathology, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Walsh', 'Affiliation': ""Division of Neuropsychology, Children's National Hospital, Washington, DC.""}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Han', 'Affiliation': ""Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Embry', 'Affiliation': 'Pediatric Hematology/Oncology, UT Health San Antonio, San Antonio, Texas.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hadley', 'Affiliation': ""Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Kumar', 'Affiliation': ""Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Michalski', 'Affiliation': 'Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Hwang', 'Affiliation': ""Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC.""}, {'ForeName': 'Amar', 'Initials': 'A', 'LastName': 'Gajjar', 'Affiliation': ""Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Ian F', 'Initials': 'IF', 'LastName': 'Pollack', 'Affiliation': ""Department of Neurosurgery, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.""}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Fouladi', 'Affiliation': ""Pediatric Hematology & Oncology, Nationwide Children's Hospital, Columbus, Ohio.""}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Northcott', 'Affiliation': ""Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Olson', 'Affiliation': ""Cancer and Blood Disorders Center, Seattle Children's, Seattle, Washington.""}]",JAMA oncology,['10.1001/jamaoncol.2021.2224'] 1764,34291862,eFOCUS 2: A randomised crossover trial of smartphone fundoscopy and direct ophthalmoscopy aiming to improve optic disc interpretation by medical students with e-learning support.,"BACKGROUND Ophthalmoscopy and its interpretation are complex. We aimed to compare the diagnostic accuracy of smartphone fundoscopy with traditional direct ophthalmoscopy for optic disc interpretation, with e-learning support. METHODS We conducted a randomised, crossover study of 102 medical students. Students were offered e-learning for optic disc interpretation. A fundoscopy objective structured clinical examination was conducted after an introductory lecture and 10-min practical training session on smartphone fundoscopy and traditional ophthalmoscopy. Participants examined patients and simulator slides with a randomised crossover between smartphone [D-eye (Padova, Italy) or iExaminer (Welch Allyn, Macquarie Park, Australia)] and traditional ophthalmoscopy (Welch Allyn). Optic discs were graded independently by three masked ophthalmologists. The primary outcome was the ability to interpret an optic disc as normal or abnormal. Secondary outcomes included other optic disc aspects; student preferences; and e-learning performance. RESULTS Students' agreement with the gold standard for an abnormal or normal disc was significantly greater using a smartphone (74.4%) than with direct ophthalmoscopy (68.1%, p = 0.032). More students preferred smartphone (74%) over direct ophthalmoscopy (26%, p < 0.001). E-learning led to an improvement in optic disc interpretation scores (mean improvement = 4.5%, 95% CI = 3.7-5.2, p < 0.001). CONCLUSIONS Medical students are more accurate at recognising an abnormal optic disc using smartphone fundoscopy than traditional direct ophthalmoscopy, and have a strong preference for smartphone fundoscopy. E-learning may improve the interpretation of optic disc abnormalities. Smartphone fundoscopy may mitigate some technical challenges of fundoscopy and reinvigorate use of this valuable clinical examination.",2021,"More students preferred smartphone (74%) over direct ophthalmoscopy (26%, p<0.001).","['Participants examined patients and simulator slides', 'medical students with e-learning support', '102 medical students']","['smartphone fundoscopy with traditional direct ophthalmoscopy', 'smartphone fundoscopy and direct ophthalmoscopy', 'smartphone (D-eye [Padova, Italy] or iExaminer [Welch Allyn, Macquarie Park, Australia]) and traditional ophthalmoscopy (Welch Allyn']","['Optic discs', 'abnormal or normal disc', 'ability to interpret an optic disc as normal or abnormal', 'optic disc aspects; student preferences; and e-learning performance', 'optic disc interpretation scores']","[{'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0332246', 'cui_str': 'Sliding'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0029090', 'cui_str': 'Ophthalmoscopy'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C1444581', 'cui_str': 'Direct ophthalmoscopy'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0237771', 'cui_str': 'Parks, Recreational'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0029127', 'cui_str': 'Optic disc structure'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C1285553', 'cui_str': 'Interprets'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0582590', 'cui_str': 'Learning performance'}, {'cui': 'C0459471', 'cui_str': 'Interpretation'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",102.0,0.121217,"More students preferred smartphone (74%) over direct ophthalmoscopy (26%, p<0.001).","[{'ForeName': 'Hamish P', 'Initials': 'HP', 'LastName': 'Dunn', 'Affiliation': 'Northern Clinical School, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Marks', 'Affiliation': 'Northern Clinical School, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.'}, {'ForeName': 'Kai Z', 'Initials': 'KZ', 'LastName': 'Teo', 'Affiliation': 'Northern Clinical School, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.'}, {'ForeName': 'Stewart M', 'Initials': 'SM', 'LastName': 'Dunn', 'Affiliation': 'Northern Clinical School, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.'}, {'ForeName': 'Paul R', 'Initials': 'PR', 'LastName': 'Healey', 'Affiliation': 'Northern Clinical School, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'White', 'Affiliation': 'Northern Clinical School, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.'}]",Clinical & experimental ophthalmology,['10.1111/ceo.13977'] 1765,34290069,Comparison of antimicrobial efficacy of Calcipex and Metapex in endodontic treatment of chronic apical periodontitis: a randomised controlled trial study protocol.,"INTRODUCTION Various intracanal medicaments have been used in cases of chronic apical periodontitis for appropriate disinfection of the root canal system to eliminate microbes especially from the inaccessible areas. Calcium hydroxide is the most common intracanal medicament available in various forms, but its effectiveness with or without iodoform using microbial culture is unknown. Therefore, our aim is to compare the antimicrobial efficacy of Calcipex and Metapex in endodontic treatment of teeth presenting with chronic apical periodontitis by assessing the bacterial load reduction. METHOD AND ANALYSIS 60 single rooted teeth of patients with diagnosis of chronic apical periodontitis will be selected and the canals debrided chemomechanically. The patients will be randomised into two groups: Calcipex and Metapex. The first sample (S1) for bacterial culture will be taken before placement of intracanal medicament and the second sample (S2) will be taken after 7 days, before final obturation from the canal and sent to lab for culture. Colony-forming unit will be evaluated. Paired t-test will be used to assess difference between antimicrobial efficacies within the group of medicaments. Independent sample t-test will be used to assess antimicrobial efficacies between groups. Level of significance will be kept at 0.05. ETHICS AND DISSEMINATION Approval from Aga Khan University Hospital Ethical review committee is taken. Findings will be reported according to the Standard Protocol Items for Randomised Trials guidelines. Research findings will be disseminated through annual reports, peer-reviewed journals and conferences. TRIAL REGISTRATION NUMBER NCT04336709.",2021,"INTRODUCTION Various intracanal medicaments have been used in cases of chronic apical periodontitis for appropriate disinfection of the root canal system to eliminate microbes especially from the inaccessible areas.","['teeth presenting with chronic apical periodontitis', 'chronic apical periodontitis', '60 single rooted teeth of patients with diagnosis of chronic apical periodontitis will be selected and the canals debrided chemomechanically']","['Calcium hydroxide', 'Calcipex and Metapex']","['antimicrobial efficacy', 'antimicrobial efficacies']","[{'cui': 'C0457755', 'cui_str': 'Tooth presence - finding'}, {'cui': 'C0392492', 'cui_str': 'Asymptomatic periapical periodontitis'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0086881', 'cui_str': 'Pulp canal'}]","[{'cui': 'C0006701', 'cui_str': 'calcium hydroxide'}, {'cui': 'C1567041', 'cui_str': 'Metapex'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0847831,"INTRODUCTION Various intracanal medicaments have been used in cases of chronic apical periodontitis for appropriate disinfection of the root canal system to eliminate microbes especially from the inaccessible areas.","[{'ForeName': 'Momina Anis', 'Initials': 'MA', 'LastName': 'Motiwala', 'Affiliation': 'Operative Dentistry, Surgery, The Aga Khan University Hospital Main Campus, Karachi, Pakistan momina_anis@live.com.'}, {'ForeName': 'Saqib', 'Initials': 'S', 'LastName': 'Habib', 'Affiliation': 'Operative Dentistry, Surgery, The Aga Khan University Hospital Main Campus, Karachi, Pakistan.'}, {'ForeName': 'Robia', 'Initials': 'R', 'LastName': 'Ghafoor', 'Affiliation': 'Operative Dentistry, Surgery, The Aga Khan University Hospital Main Campus, Karachi, Pakistan.'}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Irfan', 'Affiliation': 'Pathology and laboratory medicine, The Aga Khan University Hospital Main Campus, Karachi, Pakistan.'}]",BMJ open,['10.1136/bmjopen-2021-048947'] 1766,34297465,Ultrasound-guided injection of intralesional steroids in acute hidradenitis suppurativa lesions: A prospective study.,"The management of hidradenitis suppurativa (HS) flares with intralesional steroids lacks strong scientific evidence but limited data suggest that it may be useful. The objective of this study is to assess the clinical and ultrasound responses of HS flares to ultrasound-guided injections of intralesional triamcinolone (40 mg/ml) with a dilution 1:4 versus 1:2 at 30-day (t1), 60-day (t2), and 90-day (t3) follow-up. We recruited patients with ≤3 acute lesions, unresponsive to topical therapy. At baseline we assessed lesions clinically and by ultra-high frequency ultrasound (48 or 70 MHz) and randomly performed an ultrasound-guided injection of triamcinolone. Assessments were repeated at t1, t2, and t3 follow-up, re-injecting the lesion in the case of no or partial response. We treated 49 lesions: 38.8% showed improvements at t1; 46.9% at t2; 6% at t3; and 8.3% showed no clinical and ultrasound improvements. Long-term follow-up data confirmed a statistically significant reduction in Visual Analogue Scale (VAS)-pain, Dermatology Life Quality Index (DLQI), and HS-Physician Global Assessment (HS-PGA), as well as edema and vascular signals. No adverse effects were reported. Our study suggests that ultrasound-injections with a 1:2 dilution are beneficial for HS flares that do not respond to topical treatment and should be included in the therapeutic algorithm.",2021,"Long-term follow-up data confirmed a statistically significant reduction in VAS-pain, Dermatology Life Quality Index (DLQI), and HS-Physician Global Assessment (HS-PGA), as well as edema and vascular signals.","['acute hidradenitis suppurativa lesions', 'patients with ≤3 acute lesions, unresponsive to topical therapy']","['intralesional triamcinolone', 'triamcinolone', 'ultra-high frequency ultrasound (48 or 70MHz', 'Ultrasound-guided injection of intralesional steroids']","['VAS-pain, Dermatology Life Quality Index (DLQI), and HS-Physician Global Assessment (HS-PGA), as well as edema and vascular signals', 'adverse effects']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0162836', 'cui_str': 'Hidradenitis suppurativa'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C1512955', 'cui_str': 'Intralesional route'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index'}, {'cui': 'C0162836', 'cui_str': 'Hidradenitis suppurativa'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",,0.0543277,"Long-term follow-up data confirmed a statistically significant reduction in VAS-pain, Dermatology Life Quality Index (DLQI), and HS-Physician Global Assessment (HS-PGA), as well as edema and vascular signals.","[{'ForeName': 'Michela', 'Initials': 'M', 'LastName': 'Iannone', 'Affiliation': 'Department of Dermatology, University of Pisa, Pisa.'}, {'ForeName': 'Agata', 'Initials': 'A', 'LastName': 'Janowska', 'Affiliation': 'Department of Dermatology, University of Pisa, Pisa.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Oranges', 'Affiliation': 'Department of Dermatology, University of Pisa, Pisa.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Balderi', 'Affiliation': 'Department of Dermatology, University of Pisa, Pisa.'}, {'ForeName': 'Bianca Benedetta', 'Initials': 'BB', 'LastName': 'Benincasa', 'Affiliation': 'Department of Dermatology, University of Pisa, Pisa.'}, {'ForeName': 'Saverio', 'Initials': 'S', 'LastName': 'Vitali', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Tonini', 'Affiliation': 'Department of Dermatology, University of Pisa, Pisa.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Morganti', 'Affiliation': 'Department of Clinical and Experimental Medicine, Section of Statistics, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Romanelli', 'Affiliation': 'Department of Dermatology, University of Pisa, Pisa.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Dini', 'Affiliation': 'Department of Dermatology, University of Pisa, Pisa.'}]",Dermatologic therapy,['10.1111/dth.15068'] 1767,34299864,Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off.,"OBJECTIVE To provide health-related quality of life (HRQoL) data to support health technology assessment (HTA) and reimbursement decisions in Romania, by developing a country-specific value set for the EQ-5D-3L questionnaire. METHODS We used the cTTO method to elicit health state values using a computer-assisted personal interviewing approach. Interviews were standardized following the most recent version of the EQ-VT protocol developed by the EuroQoL Foundation. Thirty EQ-5D-3L health states were randomly assigned to respondents in blocks of three. Econometric modeling was used to estimate values for all 243 states described by the EQ-5D-3L. RESULTS Data from 1556 non-institutionalized adults aged 18 years and older, selected from a national representative sample, were used to build the value set. All tested models were logically consistent; the final model chosen to generate the value set was an interval regression model. The predicted EQ-5D-3L values ranged from 0.969 to 0.399, and the relative importance of EQ-5D-3L dimensions was in the following order: mobility, pain/discomfort, self-care, anxiety/depression, and usual activities. CONCLUSIONS These results can support reimbursement decisions and allow regional cross-country comparisons between health technologies. This study lays a stepping stone in the development of a health technology assessment process more driven by locally relevant data in Romania.",2021,This study lays a stepping stone in the development of a health technology assessment process more driven by locally relevant data in Romania.,"['1556 non-institutionalized adults aged 18 years and older, selected from a national representative sample', 'Thirty EQ-5D-3L health states']",[],"['predicted EQ-5D-3L values', 'mobility, pain/discomfort, self-care, anxiety/depression, and usual activities']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1301808', 'cui_str': 'State'}]",[],"[{'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",1556.0,0.0612563,This study lays a stepping stone in the development of a health technology assessment process more driven by locally relevant data in Romania.,"[{'ForeName': 'Marian Sorin', 'Initials': 'MS', 'LastName': 'Paveliu', 'Affiliation': 'Romanian Academic Society, 020071 Bucharest, Romania.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Olariu', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE2 4AX, UK.'}, {'ForeName': 'Raluca', 'Initials': 'R', 'LastName': 'Caplescu', 'Affiliation': 'Department of Statistics and Econometrics, Bucharest University of Economic Studies, 010374 Bucharest, Romania.'}, {'ForeName': 'Yemi', 'Initials': 'Y', 'LastName': 'Oluboyede', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE2 4AX, UK.'}, {'ForeName': 'Ileana-Gabriela', 'Initials': 'IG', 'LastName': 'Niculescu-Aron', 'Affiliation': 'Department of Statistics and Econometrics, Bucharest University of Economic Studies, 010374 Bucharest, Romania.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Ernu', 'Affiliation': 'Romanian Academic Society, 020071 Bucharest, Romania.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Vale', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE2 4AX, UK.'}]",International journal of environmental research and public health,['10.3390/ijerph18147415'] 1768,34299814,Factors Associated with Physical Activity among People with Hypertension in a Rural Area in Bangladesh: Baseline Data from a Cluster Randomized Control Trial.,"The health benefits of physical activity (PA) are well recognized, and PA levels vary in different populations. The study aimed to investigate PA levels and associated sociodemographic factors among people with hypertension in a rural area in Bangladesh. Baseline data were part of a cluster randomized controlled trial of 307 adults aged 30-75 years to study the effectiveness of PA and lifestyle changes in lowering blood pressure. The outcome variables were PA at work, commuter, recreation, metabolic equivalent task (MET)-minute per week and sitting time. Total 68 (22.1%) people participated in vigorous-intensity activity, 23 (7.5%) participated in moderate-intensity sports. Overall, 83% of people were physically active more than 600 MET-min. Women (OR 2.95, 95% CI, 1.36-6.39) compared to men, and people with no education (OR 4.47, 95% CI, 1.62-12.33) compared to people with secondary school certificates or above were less physically active. Of total PA, 63% were work-related, and 1% were recreation-related for women, and these figures were 55% and 3% for men. The study reports that vigorous-intensity PA is low, and recreation time is minimal. Routine PA, especially for women and people with low education levels, should be encouraged to increase PA to manage hypertension.",2021,"Women (OR 2.95, 95% CI, 1.36-6.39) compared to men, and people with no education (OR 4.47, 95% CI, 1.62-12.33) compared to people with secondary school certificates or above were less physically active.","['Total 68 (22.1', 'People with Hypertension in a Rural Area in Bangladesh', '307 adults aged 30-75 years', 'people with hypertension in a rural area in Bangladesh', 'women and people with low education levels', 'people participated in vigorous-intensity activity, 23 (7.5%) participated in moderate-intensity sports']",[],"['PA at work, commuter, recreation, metabolic equivalent task (MET)-minute per week and sitting time', 'lowering blood pressure']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0038039', 'cui_str': 'Sport'}]",[],"[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0034872', 'cui_str': 'Recreation'}, {'cui': 'C2355577', 'cui_str': 'Metabolic Equivalent'}, {'cui': 'C0702093', 'cui_str': '/minute'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}]",307.0,0.0414362,"Women (OR 2.95, 95% CI, 1.36-6.39) compared to men, and people with no education (OR 4.47, 95% CI, 1.62-12.33) compared to people with secondary school certificates or above were less physically active.","[{'ForeName': 'Fakir M Amirul', 'Initials': 'FMA', 'LastName': 'Islam', 'Affiliation': 'School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC 3122, Australia.'}]",International journal of environmental research and public health,['10.3390/ijerph18147365'] 1769,34298492,A comparison of the effectiveness of three types of trunk orthoses on the balance performance of older people with osteoporotic hyperkyphosis: A cross-over study.,"BACKGROUND Orthotic immobilization is an early treatment for osteoporotic vertebral fracture at the hyperkyphotic thoracic spine. OBJECTIVE This exploratory study compared the immediate impact of three types of trunk orthoses on the balance parameters of older people with osteoporosis hyperkyphosis. METHODS Twenty older people (aged 60-65 years) with osteoporosis kyphosis and a history of falls participated in a pilot cross-over study. Four randomized comparisons were carried out, including either soft, semi-rigid, and rigid trunk orthoses worn on the participants compared to ""no orthosis"" as the control condition. Kyphosis angle, Forward Reach Test, Timed Up and Go test, and postural stability during standing on a force plate were recorded and compared between study conditions using one-way repeated measures analysis of variance test. RESULTS All orthoses significantly reduced the kyphosis angle (p < 0.01). None of the orthoses has a significant change in the Timed Up and Go test (p > 0.01). Rigid orthosis significantly reduced the forward reach compared to ""no orthosis"" (p = 0.003, 95% CI: 1.08-6.3 cm). None of the orthosis induced a significant change in postural sway velocity in anteroposterior and mediolateral directions compared to the control condition (p > 0.01). CONCLUSION These findings suggest that using rigid orthosis in older people with osteoporosis hyperkyphosis reduces the balance performance.",2021,None of the orthoses has a significant change in the Timed Up and Go test (p > 0.01).,"['older people with osteoporosis hyperkyphosis', 'older people with osteoporotic hyperkyphosis', 'osteoporotic vertebral fracture at the hyperkyphotic thoracic spine', 'Twenty older people (aged 60-65 years) with osteoporosis kyphosis and a history of falls participated in a pilot cross-over study']","['trunk orthoses', 'rigid trunk orthoses worn on the participants compared to ""no orthosis"" as the control condition']","['kyphosis angle', 'balance performance', 'postural sway velocity', 'Kyphosis angle, Forward Reach Test, Timed Up and Go test, and postural stability']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0022821', 'cui_str': 'Kyphosis deformity of spine'}, {'cui': 'C0080179', 'cui_str': 'Fracture of vertebral column'}, {'cui': 'C0581269', 'cui_str': 'Thoracic spine structure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1561668', 'cui_str': 'History of fall'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}]","[{'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0026837', 'cui_str': 'Muscle rigidity'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0022821', 'cui_str': 'Kyphosis deformity of spine'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",20.0,0.0272557,None of the orthoses has a significant change in the Timed Up and Go test (p > 0.01).,"[{'ForeName': 'Mohamad-Rasoul', 'Initials': 'MR', 'LastName': 'Karimian', 'Affiliation': 'Student Research Committee, School of Rehabilitation Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Yeowell', 'Affiliation': 'Department of Health Professions, Manchester Metropolitan University, Manchester, UK.'}, {'ForeName': 'Shirin', 'Initials': 'S', 'LastName': 'Saberi', 'Affiliation': 'Musculoskeletal Research Center, School of Rehabilitation Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Sadeghi-Demneh', 'Affiliation': 'Musculoskeletal Research Center, School of Rehabilitation Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: sadeghi@rehab.mui.ir.'}]",Musculoskeletal science & practice,['10.1016/j.msksp.2021.102430'] 1770,34298402,A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata.,"BACKGROUND Alopecia areata (AA) is a chronic autoimmune disorder. Finding the best treatment regimen for it remains a challenge. Currently, one of the best documented treatment modalities for AA is topical immunotherapy. AIM To evaluate the safety and efficacy of combined DPCP and anthralin versus standard protocol (DPCP alone). METHODS A prospective randomized clinical trial was conducted on 50 patients with Alopecia areata who received DPCP alone (group D) or in combination with anthralin (group D/A). Percentage of hair regrowth after 6 months of treatment and the incidence of drug-related adverse effects were evaluated and compared between the two groups. RESULTS Complete hair regrowth was observed among three patients in each group (18.75% in Group D and 15.79% in Group D/A) after 6 months. Moreover, 25% and 31% of patients in group D and 21% and 47% of patients in group D/A had > 75% and > 50% hair regrowth respectively at the end of the study (P-value: 0.696). In addition, earlier age of onset, chronicity of lesions, nail involvement, facial hair loss and extensive lesions at baseline were associated with poor clinical outcome. CONCLUSION DPCP and anthralin was as effective as DPCP alone and anthralin did not add to the effect of DPCP in treating AA.",2021,"CONCLUSION DPCP and anthralin was as effective as DPCP alone and anthralin did not add to the effect of DPCP in treating AA.","['50 patients with Alopecia areata who received', 'treating moderate to severe alopecia areata']","['combined DPCP and anthralin versus standard protocol (DPCP alone', 'diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone', 'DPCP alone (group D) or in combination with anthralin']","['safety and efficacy', 'Complete hair regrowth', 'chronicity of lesions, nail involvement, facial hair loss and extensive lesions', 'Percentage of hair regrowth', 'incidence of drug-related adverse effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002170', 'cui_str': 'Alopecia'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0058379', 'cui_str': 'diphenylcyclopropenone'}, {'cui': 'C0003166', 'cui_str': 'Anthralin'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0441838', 'cui_str': 'Group D'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0547045', 'cui_str': 'Chronicity'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0221980', 'cui_str': 'Structure of hair of face'}, {'cui': 'C0205231', 'cui_str': 'Extensive'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",50.0,0.088343,"CONCLUSION DPCP and anthralin was as effective as DPCP alone and anthralin did not add to the effect of DPCP in treating AA.","[{'ForeName': 'Narges', 'Initials': 'N', 'LastName': 'Ghandi', 'Affiliation': 'Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences,Tehran 1199663911, Iran; Department of Dermatology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran 1199663911, Iran.'}, {'ForeName': 'Romina', 'Initials': 'R', 'LastName': 'Daneshmand', 'Affiliation': 'Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences,Tehran 1199663911, Iran.'}, {'ForeName': 'Parvaneh', 'Initials': 'P', 'LastName': 'Hatami', 'Affiliation': 'Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences,Tehran 1199663911, Iran. Electronic address: phatami@alumnus.tums.ac.ir.'}, {'ForeName': 'Robabeh', 'Initials': 'R', 'LastName': 'Abedini', 'Affiliation': 'Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences,Tehran 1199663911, Iran; Department of Dermatology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran 1199663911, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Nasimi', 'Affiliation': 'Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences,Tehran 1199663911, Iran; Department of Dermatology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran 1199663911, Iran.'}, {'ForeName': 'Zeinab', 'Initials': 'Z', 'LastName': 'Aryanian', 'Affiliation': 'Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences,Tehran 1199663911, Iran; Department of Dermatology, Babol University of Medical Sciences, Babol 4717647745, Iran. Electronic address: z_aryanian@yahoo.com.'}, {'ForeName': 'Terrence M', 'Initials': 'TM', 'LastName': 'Vance', 'Affiliation': 'Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, RI, USA; Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA.'}]",International immunopharmacology,['10.1016/j.intimp.2021.107971'] 1771,34298148,Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial.,"In order to assess whether previous hepatic IR (Hepatic-IR fasting ) and beta-cell functionality could modulate type 2 diabetes remission and the need for starting glucose-lowering treatment, newly-diagnosed type 2 diabetes participants who had never received glucose-lowering treatment (190 out of 1002) from the CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (a prospective, randomized and controlled clinical trial), were randomized to consume a Mediterranean or a low-fat diet. Type 2 diabetes remission was defined according to the American Diabetes Association recommendation for levels of HbA1c, fasting plasma glucose and 2h plasma glucose after oral glucose tolerance test, and having maintained them for at least 2 consecutive years. Patients were classified according to the median of Hepatic-IR fasting and beta-cell functionality, measured as the disposition index (DI) at baseline. Cox proportional hazards regression determined the potential for Hepatic-IR fasting and DI indexes as predictors of diabetes remission and the probability of starting pharmacological treatment after a 5-year follow-up. Low-Hepatic-IR fasting or high-DI patients had a higher probability of diabetes remission than high-Hepatic-IR fasting or low-DI subjects (HR:1.79; 95% CI 1.06-3.05; and HR:2.66; 95% CI 1.60-4.43, respectively) after a dietary intervention with no pharmacological treatment and no weight loss. The combination of low-Hepatic-IR fasting and high-DI presented the highest probability of remission (HR:4.63; 95% CI 2.00-10.70). Among patients maintaining diabetes, those with high- Hepatic-IR fasting and low-DI showed the highest risk of starting glucose-lowering therapy (HR:3.24;95% CI 1.50-7.02). Newly-diagnosed type 2 diabetes patients with better beta-cell functionality and lower Hepatic-IR fasting had a higher probability of type 2 diabetes remission in a dietary intervention without pharmacological treatment or weight loss, whereas among patients not achieving remission, those with worse beta-cell functionality and higher Hepatic-IR fasting index had the highest risk of starting glucose-lowering treatment after 5 years of follow-up.",2021,TRANSLATIONAL SIGNIFICANCE: Patients with lower hepatic insulin resistance and better beta cell functionality had a higher probability of remission without significant weight loss or pharmacological treatment.,['newly-diagnosed type 2 diabetes participants who had never received glucose-lowering treatment (190 out of 1002'],['Mediterranean or a low-fat diet'],"['weight loss', 'median of Hepatic-IR fasting and beta-cell functionality', 'probability of diabetes remission', 'levels of HbA1c, fasting plasma glucose and 2h plasma glucose', 'highest risk of starting glucose-lowering therapy']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517622', 'cui_str': '190'}]","[{'cui': 'C0242970', 'cui_str': 'Low fat diet'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0030281', 'cui_str': 'Structure of beta Cell of islet'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",1002.0,0.0716499,TRANSLATIONAL SIGNIFICANCE: Patients with lower hepatic insulin resistance and better beta cell functionality had a higher probability of remission without significant weight loss or pharmacological treatment.,"[{'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Roncero-Ramos', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Francisco M', 'Initials': 'FM', 'LastName': 'Gutierrez-Mariscal', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Gomez-Delgado', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Villasanta-Gonzalez', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Jose D', 'Initials': 'JD', 'LastName': 'Torres-Peña', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Silvia De La', 'Initials': 'S', 'LastName': 'Cruz-Ares', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Oriol A', 'Initials': 'OA', 'LastName': 'Rangel-Zuñiga', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Raul M', 'Initials': 'RM', 'LastName': 'Luque', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain; Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Cordoba, Spain; Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Cordoba, Spain.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Ordovas', 'Affiliation': 'Nutrition and Genomics Laboratory, J.M.-US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts; IMDEA Alimentacion, CNIC, Madrid, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Delgado-Lista', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Perez-Martinez', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Camargo', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Alcalá-Diaz', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lopez-Miranda', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain. Electronic address: jlopezmir@uco.es.'}]",Translational research : the journal of laboratory and clinical medicine,['10.1016/j.trsl.2021.07.001'] 1772,34298114,Long-term cost-effectiveness of glass hybrid versus composite in permanent molars.,"OBJECTIVES We assessed the long-term cost-effectiveness of glass hybrid (GH) versus composite (CO) for restoring permanent molars using a health economic modelling approach. METHODS A multi-national (Croatia, Serbia, Italy, Turkey) split-mouth randomized trial comparing GH and CO in occlusal-proximal two-surfaced cavities in permanent molars (n=180/360 patients/molars) provided data on restoration failure and allocation probabilities (i.e. failure requiring re-restoration, repair or endodontic therapy). Using Markov modelling, we followed molars over the lifetime of an initially 12-years-old individual. Our health outcome was the time a tooth was retained. A mixed-payers' perspective within German healthcare was used to determine costs (in Euro 2018) using fee item catalogues. Monte-Carlo-microsimulations, univariate and probabilistic sensitivity analyses were conducted. Incremental cost-effectiveness ratios (ICER)s and cost-effectiveness-acceptability were quantified. RESULTS In the base-case scenario, CO was more effective (tooth retention for a mean (SD) 54.4 (1.7) years) but also more costly (694 (54) Euro) than GH (53.9 (1.7) years; 614 (56 Euro). The ICER was 158 Euro/year, i.e. payers needed to be willing to invest 158 Euro per additional year of tooth retention when using CO. In a sensitivity analysis, this finding was confirmed or GH found more effective and less costly. CONCLUSION CO was more costly and limitedly more effective than GH, and while there is uncertainty around our findings, GH is likely a cost-effectiveness option for restoring permanent molars. CLINICAL SIGNIFICANCE When considering the long-term (life-time) cost-effectiveness, GH showed cost savings but CO was limitedly more effective. Overall, cost-effectiveness differences seems limited or in favour of GH.",2021,"In the base-case scenario, CO was more effective (tooth retention for a mean (SD) 54.4 (1.7) years) but also more costly (694 (54) Euro) than GH (53.9 (1.7) years; 614 (56 Euro).","['occlusal-proximal two-surfaced cavities in permanent molars (n=180/360 patients/molars) provided data on restoration failure and allocation probabilities (i.e. failure requiring re-restoration, repair or endodontic therapy', 'Permanent Molars']","['glass hybrid (GH) versus composite (CO', 'GH and CO', 'Glass Hybrid versus Composite']","['effective (tooth retention', 'cost savings', 'Incremental cost-effectiveness ratios (ICER)s and cost-effectiveness-acceptability']","[{'cui': 'C0447303', 'cui_str': 'Structure of occlusal surface of tooth'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0332274', 'cui_str': 'Endodontic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0015421', 'cui_str': 'Eyeglasses'}, {'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C0205199', 'cui_str': 'Composite'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0085550', 'cui_str': 'Cost Savings'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",,0.0519615,"In the base-case scenario, CO was more effective (tooth retention for a mean (SD) 54.4 (1.7) years) but also more costly (694 (54) Euro) than GH (53.9 (1.7) years; 614 (56 Euro).","[{'ForeName': 'Falk', 'Initials': 'F', 'LastName': 'Schwendicke', 'Affiliation': 'Department of Oral Diagnostics, Digital Health and Health Services Research, Charité - Universitätsmedizin Berlin, Germany. Electronic address: falk.schwendicke@charite.de.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Basso', 'Affiliation': 'Center of Minimally Invasive, Aesthetic and Digital Oral Rehabilitation (CROMED), IRCCS Galeazzi Orthopaedic Institute, University of Milan, Milan, Italy.'}, {'ForeName': 'Dejan', 'Initials': 'D', 'LastName': 'Markovic', 'Affiliation': 'Department of Pediatric and Preventive Dentistry, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.'}, {'ForeName': 'Lezize Sebnem', 'Initials': 'LS', 'LastName': 'Turkun', 'Affiliation': 'Department of Restorative Dentistry, Ege University School of Dentistry, Izmir, Turkey.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Miletić', 'Affiliation': 'Department of Endodontics and Restorative Dentistry, School of Dental Medicine, University of Zagreb, Croatia.'}]",Journal of dentistry,['10.1016/j.jdent.2021.103751'] 1773,34298029,"Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users.","BACKGROUND Recent data suggest that glial cells may be involved in the analgesic effects and abuse liability of opioids. Preclinical studies have demonstrated that mu-opioid-receptor-selective agonists, such as oxycodone, activate glia and increase the release of cytokines, causing a suppression of opioid-induced analgesic effects. Preclinical studies also show that certain medications, such as the broad-spectrum tetracycline antibiotic minocycline, inhibit opioid-induced glial activation and thereby enhance the analgesic effects of opioids. Importantly, minocycline reduces the rewarding effects of opioids at the same doses that it enhances opioid-induced analgesia. AIMS The purpose of the present study was to assess the effects of acute administration of minocycline on the subjective, physiological, and analgesic effects of oxycodone in human research volunteers. DESIGN This study was a within-subject, randomized, double-blind outpatient study. Participants completed five separate sessions in which they received 0, 100, or 200 mg minocycline (MINO) simultaneously with either 0 or 40 mg oxycodone (OXY). The subjective, physiological, and analgesic effects of OXY were measured before and repeatedly after drug administration. SETTINGS AND PARTICIPANTS Participants were between 21 and 45 years of age, non-treatment seeking, non-dependent recreational opioid users (N = 12). This study was conducted between 2013 and 2014 at the New York State Psychiatric Institute in New York, NY. FINDINGS MINO 100 and 200 mg were safe and well-tolerated in combination with OXY 40 mg. MINO 200 mg administered with OXY 40 mg attenuated OXY-induced positive subjective effects such as ""Good Effect"" and ""Liking"" compared to OXY alone. MINO did not alter the physiological or analgesic effects of OXY. CONCLUSIONS MINO may attenuate the abuse liability of mu-opioid-receptor-selective agonists.",2021,"MINO did not alter the physiological or analgesic effects of OXY. ","['Participants were between 21 and 45\u202fyears of age', 'non-dependent, recreational opioid users', '2013 and 2014 at the New York State Psychiatric Institute in New York, NY', 'human research volunteers']","['oxycodone', 'minocycline', 'Minocycline', 'minocycline (MINO) simultaneously with either 0 or 40\u202fmg oxycodone (OXY']","['safe and well-tolerated', 'subjective, physiological, and analgesic effects of OXY', 'physiological or analgesic effects of OXY']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0026187', 'cui_str': 'Minocycline'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}]",,0.0297965,"MINO did not alter the physiological or analgesic effects of OXY. ","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Mogali', 'Affiliation': 'Division on Substance Use Disorders, New York State Psychiatric Institute, Department of Psychiatry, Vagelos College of Physicians and Surgeons of Columbia University, 1051 Riverside Dr., Unit 66, New York, NY 10032, United States of America. Electronic address: shanthi.mogali@nyspi.columbia.edu.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Askalsky', 'Affiliation': 'NYU Langone School of Medicine, Department of Psychiatry, New York, NY 10016, United States of America.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Madera', 'Affiliation': 'Weill Cornell Medical College, 515 East 71st Street, New York, NY 10021, United States of America.'}, {'ForeName': 'J D', 'Initials': 'JD', 'LastName': 'Jones', 'Affiliation': 'Division on Substance Use Disorders, New York State Psychiatric Institute, Department of Psychiatry, Vagelos College of Physicians and Surgeons of Columbia University, 1051 Riverside Dr., Unit 66, New York, NY 10032, United States of America.'}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Comer', 'Affiliation': 'Division on Substance Use Disorders, New York State Psychiatric Institute, Department of Psychiatry, Vagelos College of Physicians and Surgeons of Columbia University, 1051 Riverside Dr., Unit 66, New York, NY 10032, United States of America.'}]","Pharmacology, biochemistry, and behavior",['10.1016/j.pbb.2021.173241'] 1774,34301673,A cluster randomised controlled trial to evaluate the impact of a gender transformative intervention on intimate partner violence against women in newly formed neighbourhood groups in Tanzania.,"INTRODUCTION Violence against women is a global public health concern; around a quarter of women will experience intimate partner physical or sexual violence during their lifetime. We assessed the impact of a gender transformative intervention for women designed to prevent intimate partner violence (IPV). METHODS We conducted a cluster randomised controlled trial in Mwanza city, Tanzania, among women in newly formed neighbourhood groups to evaluate a 10-session participatory intervention that aims to empower women, prevent IPV and promote healthy relationships. Following a baseline interview, groups were randomly assigned (1:1 ratio) to the intervention or control arm. An intention-to-treat analysis was conducted to assess the impact of the intervention on the main outcomes, assessed 24 months postintervention. These included past-year physical IPV and sexual IPV (primary); past-year emotional abuse; and acceptability and tolerance of IPV. RESULTS Between September 2015 and February 2017, 1265 women were recruited in 66 neighbourhoods and randomly allocated to intervention (n=627 women in 33 neighbourhoods) or control (n=638 women in 33 neighbourhoods). Assessment of outcomes was completed for 551 (88%) intervention and 575 (90%) control women. Among intervention women, 113 (21%) reported physical IPV compared with 117 (20%) control women (adjusted OR (aOR) 0.98, 95% CI 0.72 to 1.33, p=0.892), and 109 (20%) intervention women reported sexual IPV compared with 121 (21%) control women (aOR 0.98, 95% CI 0.72 to 1.32, p=0.881). Intervention women reported less emotional abuse (aOR 0.74, 95% CI 0.56 to 0.98, p=0.035), and were less likely to express attitudes accepting of IPV (aOR 0.49, 95% CI 0.36 to 0.66, p<0.001), and beliefs that IPV is a private matter (aOR 0.54, 95% CI 0.38 to 0.78, p=0.001), or should be tolerated (aOR 0.48, 95% CI 0.34 to 0.66, p<0.001). CONCLUSION These results indicate that the intervention was effective in reducing emotional abuse and positively impacting attitudes and beliefs condoning IPV, but was not sufficient to reduce physical or sexual IPV. TRIAL REGISTRATION NUMBER NCT02592252.",2021,"Intervention women reported less emotional abuse (aOR 0.74, 95% CI 0.56 to 0.98, p=0.035), and were less likely to express attitudes accepting of IPV (aOR 0.49, 95% CI 0.36 to 0.66, p<0.001), and beliefs that IPV is a private matter (aOR 0.54, 95% CI 0.38 to 0.78, p=0.001), or should be tolerated (aOR 0.48, 95% CI 0.34 to 0.66, p<0.001). ","['Mwanza city, Tanzania, among women in newly formed neighbourhood groups', 'Between September 2015 and February 2017', 'women designed to prevent intimate partner violence (IPV', 'intimate partner violence against women in newly formed neighbourhood groups in Tanzania', '1265 women were recruited in 66 neighbourhoods and randomly allocated to intervention (n=627 women in 33 neighbourhoods) or control (n=638 women in 33 neighbourhoods']","['10-session participatory intervention', 'gender transformative intervention']","['physical IPV', 'emotional abuse', 'attitudes accepting of IPV', 'physical or sexual IPV', 'tolerated', 'sexual IPV']","[{'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0039298', 'cui_str': 'Tanzania'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0079399', 'cui_str': 'Gender'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0730557', 'cui_str': 'Emotional abuse'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}]",1265.0,0.126615,"Intervention women reported less emotional abuse (aOR 0.74, 95% CI 0.56 to 0.98, p=0.035), and were less likely to express attitudes accepting of IPV (aOR 0.49, 95% CI 0.36 to 0.66, p<0.001), and beliefs that IPV is a private matter (aOR 0.54, 95% CI 0.38 to 0.78, p=0.001), or should be tolerated (aOR 0.48, 95% CI 0.34 to 0.66, p<0.001). ","[{'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Harvey', 'Affiliation': 'Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK sheila.harvey@lshtm.ac.uk.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Abramsky', 'Affiliation': 'Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Gerry', 'Initials': 'G', 'LastName': 'Mshana', 'Affiliation': 'Sexual and Reproductive Health, National Institute for Medical Research Mwanza Research Centre, Mwanza, Mwanza, Tanzania.'}, {'ForeName': 'Christian Holm', 'Initials': 'CH', 'LastName': 'Hansen', 'Affiliation': 'Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Grace J', 'Initials': 'GJ', 'LastName': 'Mtolela', 'Affiliation': 'Mwanza Intervention Trials Unit, National Institute for Medical Research Mwanza Research Centre, Mwanza, Tanzania.'}, {'ForeName': 'Flora', 'Initials': 'F', 'LastName': 'Madaha', 'Affiliation': 'Mwanza Intervention Trials Unit, National Institute for Medical Research Mwanza Research Centre, Mwanza, Tanzania.'}, {'ForeName': 'Ramadhan', 'Initials': 'R', 'LastName': 'Hashim', 'Affiliation': 'Mwanza Intervention Trials Unit, National Institute for Medical Research Mwanza Research Centre, Mwanza, Tanzania.'}, {'ForeName': 'Imma', 'Initials': 'I', 'LastName': 'Kapinga', 'Affiliation': 'Mwanza Intervention Trials Unit, National Institute for Medical Research Mwanza Research Centre, Mwanza, Tanzania.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Watts', 'Affiliation': 'Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Shelley', 'Initials': 'S', 'LastName': 'Lees', 'Affiliation': 'Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Saidi', 'Initials': 'S', 'LastName': 'Kapiga', 'Affiliation': 'Mwanza Intervention Trials Unit, National Institute for Medical Research Mwanza Research Centre, Mwanza, Tanzania.'}]",BMJ global health,['10.1136/bmjgh-2020-004555'] 1775,34301655,"Protocol of a tailored educational intervention for general practitioners on potentially inappropriate medications among older patients at community healthcare institutions in Beijing, China: a cluster-randomised controlled trial.","INTRODUCTION Prescribing of potentially inappropriate medications (PIMs) has become a prominent issue of public concern among elderly patients. However, no research has involved interventions on PIMs of Chinese elderly patients seeking care at primary healthcare. This study aims to evaluate the effectiveness of a tailored educational intervention programme for general practitioners (GPs), aiming at reducing the occurrence of PIMs in elderly patients. METHODS AND ANALYSIS This is a parallel group, controlled, cluster-randomised trial, with blinded evaluation of outcomes and data analysis, and un-blinded intervention. Twenty primary community healthcare stations (CHSs) in Dongcheng district in Beijing will be randomised to intervention and control arm with an allocation ratio of 1:1. GPs in CHSs randomised to the intervention arm will receive a two-component intervention: general training of PIMs and distribution of PIMs handbook. GPs in the control arm will assess and manage patients according to the institutions' routine practice. The primary outcome is the change in PIMs patient visit rate. ETHICS AND DISSEMINATION Ethics committee approval of this study was obtained from Peking University Institution Review Board (IRB00001052-19074). The findings will be published in scientific and conference presentations. TRIAL REGISTRATION NUMBER ChiCTR2100047788.",2021,Twenty primary community healthcare stations (CHSs) in Dongcheng district in Beijing will be randomised to intervention and control arm with an allocation ratio of 1:1.,"['general practitioners (GPs', 'elderly patients', 'Twenty primary community healthcare stations (CHSs) in Dongcheng district in Beijing', 'Chinese elderly patients seeking care at primary healthcare', 'older patients at community healthcare institutions in Beijing, China']","['tailored educational intervention programme', 'tailored educational intervention', 'potentially inappropriate medications (PIMs']",['change in PIMs patient visit rate'],"[{'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0086034', 'cui_str': 'Community Healthcare'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4042848', 'cui_str': 'PIM List'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4042848', 'cui_str': 'PIM List'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",20.0,0.268134,Twenty primary community healthcare stations (CHSs) in Dongcheng district in Beijing will be randomised to intervention and control arm with an allocation ratio of 1:1.,"[{'ForeName': 'Mengyuan', 'Initials': 'M', 'LastName': 'Fu', 'Affiliation': 'Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Haishaerjiang', 'Initials': 'H', 'LastName': 'Wushouer', 'Affiliation': 'Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Nie', 'Affiliation': 'Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.'}, {'ForeName': 'Xinyan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Department of Pharmacy Administration, Dongcheng Health Service Management Center, Beijing, China.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Guan', 'Affiliation': 'Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China guanxiaodong@pku.edu.cn.'}, {'ForeName': 'Luwen', 'Initials': 'L', 'LastName': 'Shi', 'Affiliation': 'Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.'}]",BMJ open,['10.1136/bmjopen-2020-046942'] 1776,34313843,Oral acetaminophen as an adjunct to continuous epidural infusion and patient-controlled epidural analgesia in laboring parturients: a randomized controlled trial.,"BACKGROUND Intravenous acetaminophen is safe and effective as an adjunct to labor analgesia with combined spinal-epidural (CSE) analgesia and patient-controlled epidural analgesia (PCEA). Oral acetaminophen is a much cheaper and safe option but has not been studied as an adjunct to labor analgesia till date. The aim of the present study is to evaluate the effect of oral acetaminophen as an adjunct in patients receiving local anesthetic-opioid combination using CSE analgesia. METHOD In this ethically approved randomized double-blind placebo-controlled trial, 60 consenting parturients were randomly allocated to two groups of 30 each: acetaminophen (who received oral acetaminophen 1 g) or placebo, 45 min before the procedure. CSE was administered as per hospital protocol. All the patients received continuous epidural infusion (CEI) of levobupivacaine 0.1% and fentanyl 2 mcg/mL at 5 ml/h and PCEA boluses of 5 mL of the same drug with a lockout interval of 15 min if needed. The primary outcome was hourly mean consumption of levobupivacaine and fentanyl mixture (mL/h). Secondary outcomes included pain score, sensory and motor block, hemodynamic parameters of mother, duration of the second stage of labor, mode of delivery, maternal satisfaction, Apgar scores, fetal heart rate, and adverse effects. RESULTS The mean drug consumption per hour was significantly less in the acetaminophen group than in the placebo group (7.66 mL/h, SD 2.01 vs. 9.01 mL/h, SD 2.83; p = 0.04). The requirement for bolus was also significantly less in the acetaminophen group than in the placebo group (median 2.5, IQR 3 vs. median 3.5, IQR 2; p = 0.04). CONCLUSION The use of 1 g of oral acetaminophen could be a cheap, safe, and effective adjunct to CEI plus PCEA in labor analgesia.",2021,"The mean drug consumption per hour was significantly less in the acetaminophen group than in the placebo group (7.66 mL/h, SD 2.01 vs. 9.01 mL/h, SD 2.83; p = 0.04).","['60 consenting parturients', 'patients receiving local anesthetic-opioid combination using CSE analgesia', 'laboring parturients']","['acetaminophen (who received oral acetaminophen 1\xa0g) or placebo', 'continuous epidural infusion (CEI) of levobupivacaine 0.1% and fentanyl 2 mcg/mL at 5\xa0ml/h and PCEA', 'CSE', 'acetaminophen', 'placebo', 'Oral acetaminophen']","['pain score, sensory and motor block, hemodynamic parameters of mother, duration of the second stage of labor, mode of delivery, maternal satisfaction, Apgar scores, fetal heart rate, and adverse effects', 'mean drug consumption per hour', 'hourly mean consumption of levobupivacaine and fentanyl mixture (mL/h']","[{'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0022864', 'cui_str': 'Labor'}]","[{'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0439391', 'cui_str': 'mL/h'}, {'cui': 'C1301707', 'cui_str': 'Patient controlled epidural analgesia'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0022872', 'cui_str': 'Second stage of labor'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0003533', 'cui_str': 'Finding of Apgar score'}, {'cui': 'C0018811', 'cui_str': 'Fetal heart rate'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0564385', 'cui_str': '/hour'}, {'cui': 'C0558292', 'cui_str': 'Hourly'}, {'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0439391', 'cui_str': 'mL/h'}]",60.0,0.553442,"The mean drug consumption per hour was significantly less in the acetaminophen group than in the placebo group (7.66 mL/h, SD 2.01 vs. 9.01 mL/h, SD 2.83; p = 0.04).","[{'ForeName': 'Reecha', 'Initials': 'R', 'LastName': 'Panghal', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India.'}, {'ForeName': 'Sukanya', 'Initials': 'S', 'LastName': 'Mitra', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India. drsmitra12@yahoo.com.'}, {'ForeName': 'Jasveer', 'Initials': 'J', 'LastName': 'Singh', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India.'}, {'ForeName': 'Rashi', 'Initials': 'R', 'LastName': 'Sarna', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Bharti', 'Initials': 'B', 'LastName': 'Goel', 'Affiliation': 'Department of Obstetrics and Gynaecology, Government Medical College and Hospital, Chandigarh, India.'}]",Journal of anesthesia,['10.1007/s00540-021-02975-z'] 1777,34315062,"Effect of multi-disciplinary teaching on learning satisfaction, self-confidence level and learning performance in the nursing students.","AIM The aim of this study was to design a multidisciplinary teaching method that combines game-based learning with a clinical situation-based teaching program and to test learning motivation, learning satisfaction and self-confidence. BACKGROUND Research has suggested that game-based learning and clinical situation-based teaching can effectively capture student attention and stimulate student learning motivation as well as increase learning satisfaction and self-confidence. DESIGN The randomized and experimental design used in this study was a pretest-posttest control group design. METHODS This study recruited participants from a technical college in the north of Taiwan. The experimental group (receiving multidisciplinary teaching) comprised 48 participants and the control group (receiving traditional teaching) comprised 50 participants. Participants took a pretest before the multidisciplinary teaching intervention, received a total of 12 weeks of intervention and then took a posttest within 1 week of the end of the course. These participants completed a questionnaire regarding learning satisfaction, confidence and learning performance. RESULTS The multidisciplinary teaching intervention improved learning satisfaction (t = 7.36, p < 0.001), self-confidence (t = 7.34, p < 0.001) and learning performance (t = 6.66, p < 0.001). Multidisciplinary teaching interventions can improve learning satisfaction, self-confidence and learning performance among nursing students. CONCLUSIONS Multidisciplinary teaching should be promoted in the context of nursing teaching and students have the multidisciplinary learning.",2021,"The multidisciplinary teaching intervention improved learning satisfaction (t = 7.36, p < 0.001), self-confidence (t = 7.34, p < 0.001) and learning performance (t = 6.66, p < 0.001).","['recruited participants from a technical college in the north of Taiwan', 'nursing students']","['multidisciplinary teaching method that combines game-based learning with a clinical situation-based teaching program', 'multidisciplinary teaching', 'Multidisciplinary teaching interventions', 'control group (receiving traditional teaching', 'multi-disciplinary teaching']","['learning satisfaction, self-confidence level and learning performance', 'learning satisfaction', 'learning performance', 'learning satisfaction, self-confidence and learning performance', 'self-confidence']","[{'cui': 'C0557810', 'cui_str': 'Technical college'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}]","[{'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0039403', 'cui_str': 'Teaching Methods'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0582590', 'cui_str': 'Learning performance'}]",50.0,0.16078,"The multidisciplinary teaching intervention improved learning satisfaction (t = 7.36, p < 0.001), self-confidence (t = 7.34, p < 0.001) and learning performance (t = 6.66, p < 0.001).","[{'ForeName': 'Yueh-Min', 'Initials': 'YM', 'LastName': 'Liu', 'Affiliation': 'Department of Nursing, Ching Kuo Institute of Management and Health, No.336, Fuxing Road., Zhongshan Dist., Keelung City, Taiwan, ROC. Electronic address: yuehmin@ems.cku.edu.tw.'}, {'ForeName': 'Yi-Chou', 'Initials': 'YC', 'LastName': 'Hou', 'Affiliation': 'Division of Nephrology, Department of Medicine, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, No.362, Zhongzheng Road., Xindian Dist., New Taipei City, Taiwan, ROC. Electronic address: athletics910@gmail.com.'}]",Nurse education in practice,['10.1016/j.nepr.2021.103128'] 1778,34293634,Home-based early stimulation program targeting visual and motor functions for preterm infants with delayed tracking: Feasibility of a Randomized Clinical Trial.,"AIMS To verify the feasibility of a home-based early stimulation program targeting visual and motor functions in preterm infants with delayed visual tracking. METHOD We applied a randomized controlled trial. We included thirty low-risk preterm infants, from both genders, with delayed visual tracking, gestational between 28-37 weeks, and age at entrance between 1-2 months of corrected age, and absence of visual impairments. Infants were divided into two groups as follows: a) standard care group (SC) that received general orientation about sensory and motor development (16 infants); b) experimental group, that received a four-week home-based early stimulation program targeting visual and motor functions (ESPVM) applied by the caregivers (14 infants). The feasibility outcomes were retention and loss rates, adherence, adverse events, and stress signals. We obtained preliminary data by comparing visual tracking, motor development, and sensory behavior between groups at the end of the intervention. RESULTS Retention rate was high, 90 % of the caregivers provided ESPVM at least 22 days, and 70 % provided SC at least 17 days. No adverse events were reported. At the end of intervention, the ESPVM group presented higher frequencies of complete visual tracking for cards 7 (ESPVM = 57.3 %, SC = 6.3 %, p = 0.006) and 8 (ESPVM = 64.3 %, SC = 12.2 %, p = 0.013), and lower scores for total sensory profile (ESPVM: median = 58, range = 46-69; SC: median = 71, range = 54-90; p = 0.016). The groups were similar for motor development. CONCLUSIONS The protocol was feasible, and the results encourage a larger randomized controlled trial.",2021,"At the end of intervention, the ESPVM group presented higher frequencies of complete visual tracking for cards 7 (ESPVM = 57.3 %, SC = 6.3 %, p = 0.006) and 8 (ESPVM = 64.3 %, SC = 12.2 %, p = 0.013), and lower scores for total sensory profile (ESPVM: median = 58, range = 46-69; SC: median = 71, range = 54-90; p = 0.016).","['preterm infants with delayed tracking', 'thirty low-risk preterm infants, from both genders, with delayed visual tracking, gestational between 28-37 weeks, and age at entrance between 1-2 months of corrected age, and absence of visual impairments', 'preterm infants with delayed visual tracking']","['home-based early stimulation program', 'standard care group (SC) that received general orientation about sensory and motor development (16 infants); b) experimental group, that received a four-week home-based early stimulation program targeting visual and motor functions (ESPVM', 'ESPVM', 'Home-based early stimulation program targeting visual and motor functions']","['retention and loss rates, adherence, adverse events, and stress signals', 'adverse events', 'frequencies of complete visual tracking', 'total sensory profile', 'Retention rate', 'visual tracking, motor development, and sensory behavior']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0337095', 'cui_str': 'Entrance'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0042798', 'cui_str': 'Dim vision'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2732625', 'cui_str': 'Sensory profile'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",30.0,0.0407875,"At the end of intervention, the ESPVM group presented higher frequencies of complete visual tracking for cards 7 (ESPVM = 57.3 %, SC = 6.3 %, p = 0.006) and 8 (ESPVM = 64.3 %, SC = 12.2 %, p = 0.013), and lower scores for total sensory profile (ESPVM: median = 58, range = 46-69; SC: median = 71, range = 54-90; p = 0.016).","[{'ForeName': 'Giovana', 'Initials': 'G', 'LastName': 'Pascoali Rodovanski', 'Affiliation': 'Department of Health Science, Federal University of Santa Catarina, Araranguá, SC, Brazil.'}, {'ForeName': 'Bruna Aparecida', 'Initials': 'BA', 'LastName': 'Bêz Reus', 'Affiliation': 'Department of Health Science, Federal University of Santa Catarina, Araranguá, SC, Brazil.'}, {'ForeName': 'Angela Vitória', 'Initials': 'AV', 'LastName': 'Cechinel Damiani', 'Affiliation': 'Department of Health Science, Federal University of Santa Catarina, Araranguá, SC, Brazil.'}, {'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'Franco Mattos', 'Affiliation': 'Department of Health Science, Federal University of Santa Catarina, Araranguá, SC, Brazil.'}, {'ForeName': 'Rafaela Silva', 'Initials': 'RS', 'LastName': 'Moreira', 'Affiliation': 'Department of Health Science, Federal University of Santa Catarina, Araranguá, SC, Brazil.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Neves Dos Santos', 'Affiliation': 'Department of Health Science, Federal University of Santa Catarina, Araranguá, SC, Brazil. Electronic address: adrianaft04@gmail.com.'}]",Research in developmental disabilities,['10.1016/j.ridd.2021.104037'] 1779,34293624,Effect of Guo Qing Yi Tang combined with Western medicine cluster therapy on acute pancreatitis.,"BACKGROUND This study evaluated the effect of Guo Qing Yi Tang (GQYT) combined with Western medicine cluster therapy on acute pancreatitis (AP). METHODS A total of 138 AP patients were recruited and divided into the observation group (68 patients) and control group (70 patients). The control group was treated with cluster therapy alone, while the observation group was treated with trans-jejunum feeding of GQYT combined with cluster therapy. Blood samples were taken before the treatment and 24 h, 72 h, and 1 week after the treatment. The serum concentrations of Di amine oxidase(DAO), Endotoxin(ET), D-lactic acid, Intestinal trefoil factor(ITF), MFG-E8, TNF-α, IL-1β, IL-6, and IL-8 were determined by using spectrophotometry and enzyme-linked immunosorbent assay. The concentrations of urinary lactulose and mannitol (L/M) were determined by high-performance liquid chromatography, and the urinary L/M value was calculated. RESULTS Compared with the control group, the observation group had shorter hospital stay, faster recovery, significantly lower APACHE II score, and higher complete response rate (94.12%) after 1 week of treatment (P < 0.05). Moreover, the indicators related to intestinal mucosal barrier function (DAO, MFG-8, L/M) and inflammatory cytokines (TNF-α, IL-6, IL-8) were significantly reduced in the observation group after 1 week of treatment (P < 0.05). CONCLUSION GQYT combined with cluster therapy for the treatment of AP has definite curative effect and rapid onset, reduces the level of inflammatory factors, and improves intestinal mucosal barrier function and APACHE II score. Thus, it has obvious clinical therapeutic advantages and can be used as a new therapeutic regimen for AP.",2021,"Compared with the control group, the observation group had shorter hospital stay, faster recovery, significantly lower APACHE II score, and higher complete response rate (94.12%) after 1 week of treatment (P < 0.05).","['138 AP patients were recruited and divided into the observation group (68 patients) and control group (70 patients', 'acute pancreatitis (AP', 'acute pancreatitis']","['cluster therapy alone, while the observation group was treated with trans-jejunum feeding of GQYT combined with cluster therapy', 'Guo Qing Yi Tang (GQYT) combined with Western medicine cluster therapy', 'Guo Qing Yi Tang combined with Western medicine cluster therapy']","['complete response rate', 'intestinal mucosal barrier function and APACHE II score', 'intestinal mucosal barrier function (DAO, MFG-8, L/M) and inflammatory cytokines (TNF-α, IL-6, IL-8', 'shorter hospital stay', 'serum concentrations of Di amine oxidase(DAO), Endotoxin(ET), D-lactic acid, Intestinal trefoil factor(ITF), MFG-E8, TNF-α, IL-1β, IL-6, and IL-8 were determined by using spectrophotometry and enzyme-linked immunosorbent assay', 'concentrations of urinary lactulose and mannitol (L/M']","[{'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0022378', 'cui_str': 'Jejunal'}, {'cui': 'C0018330', 'cui_str': 'Guanosine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0489438', 'cui_str': 'APACHE II score'}, {'cui': 'C0019587', 'cui_str': 'Amine oxidase (copper-containing)'}, {'cui': 'C0022957', 'cui_str': 'Lactulose'}, {'cui': 'C0024730', 'cui_str': 'Mannitol'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0002508', 'cui_str': 'Amine'}, {'cui': 'C0014264', 'cui_str': 'Bacterial endotoxin'}, {'cui': 'C3658295', 'cui_str': 'Propanoic Acid, 2-Hydroxy-, (2R)-'}, {'cui': 'C0950061', 'cui_str': 'Trefoil'}, {'cui': 'C0146550', 'cui_str': 'Trefoil Factor Family Proteins'}, {'cui': 'C0388561', 'cui_str': 'MFGE8 protein, human'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0037805', 'cui_str': 'Spectrophotometric measurement'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}]",138.0,0.0102469,"Compared with the control group, the observation group had shorter hospital stay, faster recovery, significantly lower APACHE II score, and higher complete response rate (94.12%) after 1 week of treatment (P < 0.05).","[{'ForeName': 'Ying-Jie', 'Initials': 'YJ', 'LastName': 'Chen', 'Affiliation': ""Department of Critical Care Medicine, Jinjiang Hospital of Traditional Chinese Medicine, Jinjiang 362200, Fujian province, People's Republic of China. Electronic address: chenyj@fjtcm.edu.cn.""}, {'ForeName': 'Ming-Zhi', 'Initials': 'MZ', 'LastName': 'Chen', 'Affiliation': ""Department of Critical Care Medicine, Jinjiang Hospital of Traditional Chinese Medicine, Jinjiang 362200, Fujian province, People's Republic of China. Electronic address: cmz_1973@126.com.""}, {'ForeName': 'Hong-Wei', 'Initials': 'HW', 'LastName': 'Zhang', 'Affiliation': ""Department of Critical Care Medicine, Jinjiang Hospital of Traditional Chinese Medicine, Jinjiang 362200, Fujian province, People's Republic of China.""}, {'ForeName': 'Gui-Song', 'Initials': 'GS', 'LastName': 'Wu', 'Affiliation': ""Department of Critical Care Medicine, Jinjiang Hospital of Traditional Chinese Medicine, Jinjiang 362200, Fujian province, People's Republic of China.""}, {'ForeName': 'Sen-Ren', 'Initials': 'SR', 'LastName': 'Guo', 'Affiliation': ""Department of Critical Care Medicine, Jinjiang Hospital of Traditional Chinese Medicine, Jinjiang 362200, Fujian province, People's Republic of China.""}]",The American journal of emergency medicine,['10.1016/j.ajem.2021.07.004'] 1780,34299807,Screen Time Parenting Practices and Associations with Preschool Children's TV Viewing and Weight-Related Outcomes.,"The purpose of this study was to examine associations between screen time (ST) parenting practices and 2-5-year-old children's TV viewing and weight status. Data were collected from 252 parent-child dyads enrolled in a randomized parent-focused childhood obesity prevention trial from 2009-2012. ST parenting practices were assessed at baseline using a validated parent-reported survey. Parent-reported child TV viewing and objectively measured anthropometrics were assessed at baseline, post-intervention (35 weeks), and follow-up (59 weeks). Marginal effect models were developed to test the association between baseline ST parenting practices and children's TV viewing, BMI z-score, and waist circumference across all time points. Limiting/monitoring ST was associated with decreased weekly TV viewing (β = -1.79, 95% CI: -2.61; -0.95), while exposure to TV was associated with more weekly TV viewing over 59 weeks (β = 1.23, 95% CI: 0.71; 1.75). Greater parent use of ST as a reward was associated with increased child BMI z-score (β = 0.15, 95% CI: 0.03; 0.27), while limiting/monitoring ST was associated with decreased BMI z-score (β = -0.16, 95% CI: -0.30; -0.01) and smaller waist circumference (β = -0.55, 95% CI: -1.04; -0.06) over the study period. These findings suggest that modifying parent ST practices may be an important strategy to reduce ST and promote healthy weight in young children.",2021,"Greater parent use of ST as a reward was associated with increased child BMI z-score (β = 0.15, 95% CI: 0.03; 0.27), while limiting/monitoring ST was associated with decreased BMI z-score (β = -0.16, 95% CI: -0.30; -0.01) and smaller waist circumference (β =",['252 parent-child dyads enrolled in a randomized parent-focused childhood obesity prevention trial from 2009-2012'],[],"[""screen time (ST) parenting practices and 2-5-year-old children's TV viewing and weight status"", 'ST parenting practices', 'BMI z-score', 'child BMI z-score', 'smaller waist circumference', ""baseline ST parenting practices and children's TV viewing, BMI z-score, and waist circumference""]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C2362324', 'cui_str': 'Childhood obesity'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C4704787', 'cui_str': 'Screen Time'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0449911', 'cui_str': 'View'}]",,0.0837414,"Greater parent use of ST as a reward was associated with increased child BMI z-score (β = 0.15, 95% CI: 0.03; 0.27), while limiting/monitoring ST was associated with decreased BMI z-score (β = -0.16, 95% CI: -0.30; -0.01) and smaller waist circumference (β =","[{'ForeName': 'Cody D', 'Initials': 'CD', 'LastName': 'Neshteruk', 'Affiliation': 'Department of Population Health Sciences, School of Medicine, Duke University, 200 Morris Street, Durham, NC 27701, USA.'}, {'ForeName': 'Gina L', 'Initials': 'GL', 'LastName': 'Tripicchio', 'Affiliation': 'Department of Social and Behavioral Sciences, Temple University, Philadelphia, PA 19122, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Lobaugh', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.'}, {'ForeName': 'Amber E', 'Initials': 'AE', 'LastName': 'Vaughn', 'Affiliation': 'Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'ForeName': 'Courtney T', 'Initials': 'CT', 'LastName': 'Luecking', 'Affiliation': 'Department of Dietetics and Human Nutrition, University of Kentucky, Lexington, KY 40506, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Mazzucca', 'Affiliation': 'Prevention Research Center, Washington University in St. Louis, St. Louis, MO 63130, USA.'}, {'ForeName': 'Dianne S', 'Initials': 'DS', 'LastName': 'Ward', 'Affiliation': 'Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph18147359'] 1781,34299804,Development of a Mobile Application of Internet-Based Support Program on Parenting Outcomes for Primiparous Women.,"Primiparous women usually experience various parenting problems after childbirth that have negative effects on the well-being of mothers and infants. Although e-Support technology could provide an innovative and easily accessible intervention approach, mobile-phone interventions remain limited for Chinese primiparous women. Therefore, a new mobile application (APP) called the ""Internet-based Support Program"" (""ISP"") was designed, incorporating the self-efficacy theory and the social-exchange theory for Chinese first-time mothers to improve their levels of maternal self-efficacy (MSE), social support, and satisfaction, as well as to reduce their postpartum depression symptoms. The research was conducted to develop and optimize the ""ISP"" APP for new mothers via a theory-, evidence-, and person-based approach. Five modules of ""learning forum"", ""communication forum"", ""ask-the-expert forum"", ""baby home forum"", and ""reminder forum"" were included in the APP to meet various parenting needs of first-time mothers; and its contents and functions were validated by the experts and primiparous women. The majority of participants gave positive feedback on the APP's perceived ease of use and usefulness. The ""ISP"" APP was the first designed for Chinese primiparous women, and a multicenter randomized controlled trial (RCT) will be conducted to measure its effectiveness on parenting outcomes.",2021,The majority of participants gave positive feedback on the APP's perceived ease of use and usefulness.,"['Primiparous women usually experience various parenting problems after childbirth', 'Chinese primiparous women', 'Primiparous Women']",['Internet-Based Support Program'],"['maternal self-efficacy (MSE), social support, and satisfaction', 'Parenting Outcomes']","[{'cui': 'C0033150', 'cui_str': 'Para 1'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1446387', 'cui_str': 'Parenting problems'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0168895,The majority of participants gave positive feedback on the APP's perceived ease of use and usefulness.,"[{'ForeName': 'Xilin', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Health Science Centre, Shenzhen University, Shenzhen 518060, China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Health Science Centre, Shenzhen University, Shenzhen 518060, China.'}, {'ForeName': 'Ziwen', 'Initials': 'Z', 'LastName': 'Ye', 'Affiliation': 'Health Science Centre, Shenzhen University, Shenzhen 518060, China.'}, {'ForeName': 'Lingling', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Health Science Centre, Shenzhen University, Shenzhen 518060, China.'}, {'ForeName': 'Xujuan', 'Initials': 'X', 'LastName': 'Zheng', 'Affiliation': 'Health Science Centre, Shenzhen University, Shenzhen 518060, China.'}]",International journal of environmental research and public health,['10.3390/ijerph18147354'] 1782,34299780,Bioactive Compounds of Porcine Hearts and Aortas May Improve Cardiovascular Disorders in Humans.,"Functional foods promote health benefits in human metabolism, with bioactive compounds acting as therapeutic agents. The aim was to investigate the biological effects of a pâté made of pork hearts and aortas, minced, sterilised and packed in tins. Adults (61-66 years old) with a body mass index of 26.4-60.7 kg/m 2 (n = 36) were randomly divided into two groups: one group consumed a low-calorie diet (LCD), while the other consumed an LCD with the developed meat product (MP) for 28-30 days. Serum biochemical parameters, anthropometry and blood pressure were measured. Consumption of an LCD + MP by experimental group participants helped to maintain reduced cholesterol levels. The difference in total cholesterol was significantly different ( p = 0.018) from that of the control group, mainly due to the difference in low-density lipoprotein cholesterol ( p = 0.005). Six peptides with potential cholesterol-binding properties and four peptides with potential antioxidant activity were identified in the MP, while elevation of the content of two peptides with potential angiotensin-converting enzyme-inhibitory activity was detected in patients' plasma. Intervention with the MP can be considered as a supportive therapy to the main treatment for medical cardiovascular diseases due to a positive effect on serum cholesterol.",2021,"The difference in total cholesterol was significantly different ( p = 0.018) from that of the control group, mainly due to the difference in low-density lipoprotein cholesterol ( p = 0.005).","['Adults (61-66 years old) with a body mass index of 26.4-60.7 kg/m 2 (n = 36', 'Humans']","['LCD + MP', 'low-calorie diet (LCD), while the other consumed an LCD with the developed meat product (MP']","['Cardiovascular Disorders', 'low-density lipoprotein cholesterol', 'cholesterol levels', 'total cholesterol', 'Serum biochemical parameters, anthropometry and blood pressure']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C1690006', 'cui_str': 'Lattice corneal dystrophy Type I'}, {'cui': 'C2930544', 'cui_str': 'Calorie restricted diet'}, {'cui': 'C0025018', 'cui_str': 'Meat products'}]","[{'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",36.0,0.0264086,"The difference in total cholesterol was significantly different ( p = 0.018) from that of the control group, mainly due to the difference in low-density lipoprotein cholesterol ( p = 0.005).","[{'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Chernukha', 'Affiliation': 'V. M. Gorbatov Federal Research Center for Food Systems of RAS, Experimental Clinic and Research Laboratory for Bioactive Substances of Animal Origin, Talalikhina St. 26, Moscow 109316, Russia.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Kotenkova', 'Affiliation': 'V. M. Gorbatov Federal Research Center for Food Systems of RAS, Experimental Clinic and Research Laboratory for Bioactive Substances of Animal Origin, Talalikhina St. 26, Moscow 109316, Russia.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Derbeneva', 'Affiliation': 'Federal Research Center of Nutrition, Biotechnology and Food Safety, Department of Cardiovascular Pathology, Kashirskoe Sh. 21, Moscow 115446, Russia.'}, {'ForeName': 'Daniil', 'Initials': 'D', 'LastName': 'Khvostov', 'Affiliation': 'V. M. Gorbatov Federal Research Centre for Food Systems of RAS, Laboratory of Molecular Biology and Bioinformatics, Talalikhina St. 26, Moscow 109316, Russia.'}]",International journal of environmental research and public health,['10.3390/ijerph18147330'] 1783,34299775,Neurophysiological Stress Response and Mood Changes Induced by High-Intensity Interval Training: A Pilot Study.,"This pilot study, conducted in advance of a future definitive randomized controlled trial, aimed to investigate the feasibility of using a HIIT-based intervention to induce neurophysiological stress responses that could be associated with possible changes in mood. Twenty-five active male college students with an average age of 21.7 ± 2.1 years, weight 72.6 ± 8.4 kg, height 177 ± 6.1 cm, and BMI: 23.1 ± 1.4 kg/m 2 took part in this quasi-experimental pilot study in which they were evaluated in two different sessions. In the first session, subjects performed a graded exercise test to determine the cycling power output corresponding to VO 2peak . The second session consisted of (a) pre-intervention assessment (collection of blood samples for measuring plasma corticotropin and cortisol levels, and application of POMS questionnaire to evaluate mood states); (b) exercise intervention (10 × 1-min of cycling at VO 2peak power output); (c) post-intervention assessment, and (d) 30-min post-intervention evaluation. Significant post-exercise increases in corticotropin and cortisol plasma levels were observed whereas mood states decreased significantly at this assessment time-point. However, a significant increase in mood was found 30-min after exercise. Finally, significant relationships between increases in stress hormones concentrations and changes in mood states after intense exercise were observed. In conclusion, our HIIT-based intervention was feasible to deliver and acceptable to participants. A single bout of HIIT induced acute changes in mood states that seems to be associated with hypothalamic-pituitary-adrenal axis activation.",2021,Significant post-exercise increases in corticotropin and cortisol plasma levels were observed whereas mood states decreased significantly at this assessment time-point.,"['Twenty-five active male college students with an average age of 21.7 ± 2.1 years, weight 72.6 ± 8.4 kg, height 177 ± 6.1 cm, and BMI: 23.1 ± 1.4 kg/m 2 took part in this quasi-experimental pilot study in which they were evaluated in two different sessions']","['exercise intervention (10 × 1-min of cycling at VO 2peak power output); (c) post-intervention assessment, and (d) 30-min post-intervention evaluation', 'HIIT-based intervention']","['plasma corticotropin and cortisol levels, and application of POMS questionnaire to evaluate mood states', 'stress hormones concentrations and changes in mood states', 'mood', 'corticotropin and cortisol plasma levels', 'Neurophysiological Stress Response and Mood Changes']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191366', 'cui_str': '21.7'}, {'cui': 'C4068876', 'cui_str': '2.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517503', 'cui_str': '1.4'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C1281899', 'cui_str': 'Plasma cortisol measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",25.0,0.00637125,Significant post-exercise increases in corticotropin and cortisol plasma levels were observed whereas mood states decreased significantly at this assessment time-point.,"[{'ForeName': 'Inmaculada C', 'Initials': 'IC', 'LastName': 'Martínez-Díaz', 'Affiliation': 'Department of Physical Education and Sport, University of Seville, E-41013 Seville, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Carrasco', 'Affiliation': 'Department of Physical Education and Sport, University of Seville, E-41013 Seville, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18147320'] 1784,34298398,ω-3 fatty acid alleviates virus-induced myocardial injury by regulating TLR4 and TLR3 expression.,"The specific pathogenesis of viral-induced myocardial injury is unclear. TLR regulation plays an important role in virus-induced myocardial injury. The therapeutic effect and possible mechanism of omega-3 fatty acids in patients with viral-induced myocardial injury must be investigated. The study population was randomly divided into three groups: a healthy control group (n = 50); general treatment group (n = 40); and general treatment with ω-3 polyunsaturated fatty acid group (n = 36). We detected the mRNA levels of TLR3 and TLR4, downstream signal pathway proteins, inflammatory factors, oxidative stress markers, and myocardial enzymes in patients and healthy controls. ω-3 fatty acid therapy in patients with virus-induced myocardial injury significantly regulates the expression of TLR3 and TLR4 and their downstream signal protein, increases antioxidant expression, reduces the secretion of inflammatory factors, alleviates myocardial injury, and improves cardiac function. This provides a new strategy to treat virus-induced myocardial injury.",2021,"ω-3 fatty acid therapy in patients with virus-induced myocardial injury significantly regulates the expression of TLR3 and TLR4 and their downstream signal protein, increases antioxidant expression, reduces the secretion of inflammatory factors, alleviates myocardial injury, and improves cardiac function.","['patients with viral-induced myocardial injury', 'patients with virus-induced myocardial injury', 'patients and healthy controls']","['omega-3 fatty acids', 'healthy control group (n\xa0=\xa050); general treatment group (n\xa0=\xa040); and general treatment with ω-3 polyunsaturated fatty acid', 'ω-3 fatty acid therapy']","['mRNA levels of TLR3 and TLR4, downstream signal pathway proteins, inflammatory factors, oxidative stress markers, and myocardial enzymes', 'cardiac function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0199174', 'cui_str': 'General treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1313494', 'cui_str': 'TLR3 protein, human'}, {'cui': 'C1321919', 'cui_str': 'TLR4 protein, human'}, {'cui': 'C0522506', 'cui_str': 'Downstream'}, {'cui': 'C0037080', 'cui_str': 'Signal Pathways'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0014442', 'cui_str': 'Enzyme'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}]",,0.0331814,"ω-3 fatty acid therapy in patients with virus-induced myocardial injury significantly regulates the expression of TLR3 and TLR4 and their downstream signal protein, increases antioxidant expression, reduces the secretion of inflammatory factors, alleviates myocardial injury, and improves cardiac function.","[{'ForeName': 'Zhang', 'Initials': 'Z', 'LastName': 'Ping', 'Affiliation': ""Department of Neurology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang 330006, Jiangxi, People's Republic of China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Lang', 'Affiliation': ""Department of Cardiology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, No, 92 Aiguo Road, Donghu District, Nanchang, Jiangxi, People's Republic of China.""}, {'ForeName': 'Zhan', 'Initials': 'Z', 'LastName': 'Yuliang', 'Affiliation': ""Department of Cardiology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, No, 92 Aiguo Road, Donghu District, Nanchang, Jiangxi, People's Republic of China.""}, {'ForeName': 'Huang', 'Initials': 'H', 'LastName': 'Xiao', 'Affiliation': ""Department of Cardiology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, No, 92 Aiguo Road, Donghu District, Nanchang, Jiangxi, People's Republic of China.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Shao', 'Affiliation': ""Department of Cardiology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, No, 92 Aiguo Road, Donghu District, Nanchang, Jiangxi, People's Republic of China. Electronic address: shaoliang021224@hotmail.com.""}]",International immunopharmacology,['10.1016/j.intimp.2021.107973'] 1785,34298389,Motion degradation in optic nerve MRI: A randomized intraindividual comparison study of eye states.,"PURPOSE MRI is a powerful tool for optic nerve assessment, but image quality can be degraded by artifacts related to ocular motion. The purpose of this investigation was to evaluate the effect of undergoing MRI with eyes open versus closed on the degree of motion degradation affecting the optic nerves. METHOD Patients undergoing 3 Tesla orbital MRI were randomized to undergo the coronal STIR sequence with eyes open and focused on a standardized fixation point, blinking as needed, or with eyes closed. The sequence was then performed again with the other instruction set. Two neuroradiologists rated the intraorbital optic nerves for motion artifact on a 5-point scale (higher numbers reflecting greater motion artifact) in 2 locations of each nerve. Differences were evaluated by the clustered Wilcoxon signed rank test. RESULTS Seventy-seven orbits were included. Interrater reliability was high (weighted kappa = 0.78). The anterior intraorbital optic nerves were rated with less motion artifact when eyes were open and focused during acquisition than when closed (p = 0.006), but this was not the case for the posterior intraorbital optic nerve (p = 0.69). For example, at the anterior intraorbital optic nerve, motion artifact of mean grade better than 2 was seen in 60% of eyes-open vs. 32% of eyes-closed acquisitions, while mean grade 4 or worse was seen in 4% of eyes-open vs. 12% of eyes-closed acquisitions. CONCLUSION Undergoing orbital MRI with eyes open and focused rather than closed reduces motion artifact at the anterior intraorbital segment of the optic nerve.",2021,"The anterior intraorbital optic nerves were rated with less motion artifact when eyes were open and focused during acquisition than when closed (p = 0.006), but this was not the case for the posterior intraorbital optic nerve (p = 0.69).","['Patients undergoing 3 Tesla orbital MRI', 'Seventy-seven orbits were included', 'optic nerve MRI']","['coronal STIR sequence with eyes open and focused on a standardized fixation point, blinking as needed, or with eyes closed']",['Interrater reliability'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0699036', 'cui_str': 'Orbital'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0029180', 'cui_str': 'Orbital cavity'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0029130', 'cui_str': 'Optic nerve structure'}]","[{'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0266574', 'cui_str': 'Ablepharon'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0005757', 'cui_str': 'Blinking'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0587267', 'cui_str': 'Closed'}]","[{'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}]",77.0,0.0228656,"The anterior intraorbital optic nerves were rated with less motion artifact when eyes were open and focused during acquisition than when closed (p = 0.006), but this was not the case for the posterior intraorbital optic nerve (p = 0.69).","[{'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Deng', 'Affiliation': 'Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: fdeng@mgh.harvard.edu.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Reinshagen', 'Affiliation': 'Department of Radiology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA. Electronic address: katherine_reinshagen@meei.harvard.edu.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Li', 'Affiliation': 'Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: mdli@mgh.harvard.edu.'}, {'ForeName': 'Amy F', 'Initials': 'AF', 'LastName': 'Juliano', 'Affiliation': 'Department of Radiology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA. Electronic address: amy_juliano@meei.harvard.edu.'}]",European journal of radiology,['10.1016/j.ejrad.2021.109865'] 1786,34298279,"Intranasal oxytocin, testosterone reactivity, and human competitiveness.","Competitiveness is an essential feature of human social interactions. Despite an extensive body of research on the underlying psychological and cultural factors regulating competitive behavior, the role of biological factors remains poorly understood. Extant research has focused primarily on sex hormones, with equivocal findings. Here, we examined if intranasal administration of the neuropeptide oxytocin (OT) - a key regulator of human social behavior and cognition - interacts with changes in endogenous testosterone (T) levels in regulating the willingness to engage in competition. In a double-blind placebo-control design, 204 subjects (102 females) self-administrated OT or placebo and were assessed for their willingness to compete via an extensively-validated economic laboratory competition paradigm, in which, before completing a set of incentivized arithmetic tasks, subjects are asked to decide what percentage of their payoffs will be based on tournament paying-scheme. Salivary T concentrations (n = 197) were measured throughout the task to assess endogenous reactivity. Under both OT and placebo, T-reactivity during competition was not associated with competitiveness in females. However, in males, the association between T-reactivity and competitiveness was OT-dependent. That is, males under placebo demonstrated a positive correlation between T-reactivity and the willingness to engage in competition, while no association was observed in males receiving OT. The interaction between OT, T-reactivity, and sex on competitive preferences remained significant even after controlling for potential mediators such as performance, self-confidence, and risk-aversion, suggesting that this three-way interaction effect was specific to competitive motivation rather than to other generalized processes. These findings deepen our understanding of the biological processes underlying human preferences for competition and extend the evidence base for the interplay between hormones in affecting human social behavior.",2021,"Under both OT and placebo, T-reactivity during competition was not associated with competitiveness in females.",['204 subjects (102 females'],"['self-administrated OT or placebo', 'neuropeptide oxytocin (OT', 'placebo', 'OT and placebo']","['Salivary T concentrations', 'Intranasal oxytocin, testosterone reactivity, and human competitiveness', 'endogenous testosterone (T) levels']","[{'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0027895', 'cui_str': 'Neuropeptide'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement'}]",197.0,0.0747096,"Under both OT and placebo, T-reactivity during competition was not associated with competitiveness in females.","[{'ForeName': 'Boaz R', 'Initials': 'BR', 'LastName': 'Cherki', 'Affiliation': 'Psychology Department, The Hebrew University of Jerusalem, Mount Scopus Campus, Mt. Scopus, Jerusalem 9190501, Israel; The Federmann Center for the Study of Rationality, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 9190401, Israel.'}, {'ForeName': 'Eyal', 'Initials': 'E', 'LastName': 'Winter', 'Affiliation': 'The Federmann Center for the Study of Rationality, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 9190401, Israel; Economics Department, The Hebrew University of Jerusalem, Mount Scopus Campus, Mt. Scopus, Jerusalem 9190501, Israel; Management School, University of Lancaster, Lancaster LA1 4YX, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mankuta', 'Affiliation': 'Hadassah Medical Center, Department of Labor and Delivery, Kiryat Hadassah, Jerusalem 9112001, Israel.'}, {'ForeName': 'Salomon', 'Initials': 'S', 'LastName': 'Israel', 'Affiliation': 'Psychology Department, The Hebrew University of Jerusalem, Mount Scopus Campus, Mt. Scopus, Jerusalem 9190501, Israel. Electronic address: salomon.israel@mail.huji.ac.il.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2021.105352'] 1787,34298274,"Pharmacist led intervention towards management of type 2 diabetes mellitus and assessment of patient satisfaction of care - A prospective, randomized controlled study.","BACKGROUND Diabetes mellitus, a metabolic disorder characterized by hyperglycaemia is due to impaired insulin secretion and deficiency. Though effective current drug therapies are available for diabetes, yet glycaemic maintenance remains a challenge without medication adherence. This necessitates a holistic approach to improve clinical outcomes for a better patient health care. METHODS A prospective, interventional, randomized controlled study was conducted among 97 type 2 diabetic patients for 6 months. The primary outcome measures included patient satisfaction of care assessment by diabetes treatment satisfaction questionnaire (DTSQ) and medication adherence by medication adherence rating scale (MARS). Secondary outcomes included assessment of knowledge, attitude, and perception and laboratory parameters. The collected data was analyzed using paired and unpaired T-test. RESULTS Of 97 patients randomized to group A (n = 49) and group B (n = 48), there were 3 and 1 drop-out in group A and B, respectively. The mean age of patients was found to be 56.82 ± 4.06 years. At the 6 th month follow up, significant improvement of glycaemic parameters was observed in group A vs B. Mean MARS and DTSQ scores also improved in group A vs. B (P-value <0.05). CONCLUSION Pharmacist-provided counselling improves patient compliance, quality of life and satisfaction of care in diabetic patients.",2021,"At the 6 th month follow up, significant improvement of glycaemic parameters was observed in group A vs B. Mean MARS and DTSQ scores also improved in group A vs. B (P-value <0.05). ","['diabetic patients', '97 type 2 diabetic patients for 6 months', '97 patients randomized to group A (n\xa0=\xa049) and group B (n\xa0=\xa048']",['Pharmacist led intervention'],"['Mean MARS and DTSQ scores', 'assessment of knowledge, attitude, and perception and laboratory parameters', 'glycaemic parameters', 'patient compliance, quality of life and satisfaction of care', 'patient satisfaction of care assessment by diabetes treatment satisfaction questionnaire (DTSQ) and medication adherence by medication adherence rating scale (MARS']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451116', 'cui_str': 'Diabetes treatment satisfaction questionnaire'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1321605', 'cui_str': 'Compliance behavior'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",97.0,0.0171198,"At the 6 th month follow up, significant improvement of glycaemic parameters was observed in group A vs B. Mean MARS and DTSQ scores also improved in group A vs. B (P-value <0.05). ","[{'ForeName': 'Manithottiyle Angelo', 'Initials': 'MA', 'LastName': 'Simon', 'Affiliation': 'Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medical & Health Sciences, SRM Institute of Science and Technology, Kattankulathur, 603 203, Chengalpattu (DT), Tamil Nadu, India.'}, {'ForeName': 'Bandaru Yeswanth', 'Initials': 'BY', 'LastName': 'Raja', 'Affiliation': 'Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medical & Health Sciences, SRM Institute of Science and Technology, Kattankulathur, 603 203, Chengalpattu (DT), Tamil Nadu, India.'}, {'ForeName': 'Paulin C', 'Initials': 'PC', 'LastName': 'Varughese', 'Affiliation': 'Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medical & Health Sciences, SRM Institute of Science and Technology, Kattankulathur, 603 203, Chengalpattu (DT), Tamil Nadu, India.'}, {'ForeName': 'Linda Mary', 'Initials': 'LM', 'LastName': 'Daniel', 'Affiliation': 'Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medical & Health Sciences, SRM Institute of Science and Technology, Kattankulathur, 603 203, Chengalpattu (DT), Tamil Nadu, India.'}, {'ForeName': 'Kolli', 'Initials': 'K', 'LastName': 'Sowjanya', 'Affiliation': 'Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medical & Health Sciences, SRM Institute of Science and Technology, Kattankulathur, 603 203, Chengalpattu (DT), Tamil Nadu, India.'}, {'ForeName': 'Kumar J', 'Initials': 'KJ', 'LastName': 'S', 'Affiliation': 'Department of General Medicine, SRM Medical College Hospital and Research Centre, Faculty of Medical & Health Sciences, SRM Institute of Science and Technology, Kattankulathur, 603203, Chengalpattu (DT), Tamil Nadu, India.'}, {'ForeName': 'Sarumathy', 'Initials': 'S', 'LastName': 'S', 'Affiliation': 'Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medical & Health Sciences, SRM Institute of Science and Technology, Kattankulathur, 603 203, Chengalpattu (DT), Tamil Nadu, India. Electronic address: saruprabakar@gmail.com.'}, {'ForeName': 'Kiran Kumar', 'Initials': 'KK', 'LastName': 'Rathinam', 'Affiliation': 'Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medical & Health Sciences, SRM Institute of Science and Technology, Kattankulathur, 603 203, Chengalpattu (DT), Tamil Nadu, India.'}, {'ForeName': 'Pravin', 'Initials': 'P', 'LastName': 'Kumar J', 'Affiliation': 'Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medical & Health Sciences, SRM Institute of Science and Technology, Kattankulathur, 603 203, Chengalpattu (DT), Tamil Nadu, India.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2021.102208'] 1788,34301734,Effects of Patient-Initiated Visits on Patient Satisfaction and Clinical Outcomes in a Type 1 Diabetes Outpatient Clinic: A 2-Year Randomized Controlled Study.,"OBJECTIVE We investigated the effects of replacing regular outpatient follow-up through prescheduled visits with patient-initiated visits on patient satisfaction and clinical variables of type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS A 24-month randomized controlled trial in which adults with T1D were allocated to either patient-initiated unlimited access to outpatient visits or usual care through regular prescheduled visits. The primary outcome was seven patient-reported experience measures of patient satisfaction focused on benefit of consultation and accessibility of the outpatient clinic. Secondary outcomes included clinical variables of diabetes and use of staff resources. RESULTS We enrolled 357 outpatients (intervention, n = 178; control, n = 179). After 24 months, participants in the intervention group experienced more benefit from consultations compared with baseline within groups ( P < 0.05) and fewer unnecessary visits compared with control subjects ( P < 0.05). Patient needs covered and satisfaction with the outpatient clinic were high and unchanged in both groups, and accessibility was increased (three questions, all P < 0.05). A calculated seven-item patient satisfaction sum score favored the intervention group over control subjects ( P < 0.001). There were no significant changes in glycated hemoglobin (HbA 1c ), LDL, blood pressure, and complication status. The mean number of outpatient visits over 24 months (± SD) was lower in the intervention group compared with control subjects (4.4 ± 2.8 vs. 6.3 ± 2.7; P < 0.001), while the number of telephone contacts was higher (3.1 ±3.4 vs. 2.5 ± 3.2; P < 0.001). CONCLUSIONS Patient satisfaction remained high or improved with patient-initiated on-demand use of the diabetes outpatient clinic, with no decline in the quality of diabetes care, and a reduction in the use of staff resources.",2021,"The mean number of outpatient visits over 24 months (± SD) was lower in the intervention group compared with control subjects (4.4 ± 2.8 vs. 6.3 ± 2.7; P < 0.001), while the number of telephone contacts was higher (3.1 ±3.4 vs. 2.5 ± 3.2; P < 0.001). ","['adults with T1D', 'Type 1 Diabetes Outpatient Clinic', '357 outpatients (intervention, n = 178; control, n = 179']","['patient-initiated unlimited access to outpatient visits or usual care through regular prescheduled visits', 'replacing regular outpatient follow-up through prescheduled visits with patient-initiated visits', 'Patient-Initiated Visits']","['number of telephone contacts', 'unnecessary visits', 'benefit of consultation and accessibility of the outpatient clinic', 'mean number of outpatient visits over 24 months (± SD', 'clinical variables of diabetes and use of staff resources', 'glycated hemoglobin, LDL, blood pressure, and complication status']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517609', 'cui_str': '179'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",357.0,0.0864752,"The mean number of outpatient visits over 24 months (± SD) was lower in the intervention group compared with control subjects (4.4 ± 2.8 vs. 6.3 ± 2.7; P < 0.001), while the number of telephone contacts was higher (3.1 ±3.4 vs. 2.5 ± 3.2; P < 0.001). ","[{'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Drøjdahl Ryg', 'Affiliation': 'Medical Department, Endocrinology, Hospital South West Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark nina.droejdahl.ryg@rsyd.dk.'}, {'ForeName': 'Jeppe', 'Initials': 'J', 'LastName': 'Gram', 'Affiliation': 'Medical Department, Endocrinology, Hospital South West Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Haghighi', 'Affiliation': 'Medical Department, Endocrinology, Hospital South West Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark.'}, {'ForeName': 'Claus Bogh', 'Initials': 'CB', 'LastName': 'Juhl', 'Affiliation': 'Medical Department, Endocrinology, Hospital South West Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark.'}]",Diabetes care,['10.2337/dc20-3083'] 1789,34299972,Psychoeducation Improved Illness Perception and Expressed Emotion of Family Caregivers of Patients with Schizophrenia.,"Social interventions such as psychoeducation, in conjunction with appropriate antipsychotic medications, positively impact schizophrenic patients' recovery. The aim of this 12-week study was to compare standard Indonesian mental healthcare for schizophrenia with psychoeducation-enriched care for family members, investigating both family and patient parameters. Sixty-four family participants meeting pre-set criteria were recruited from various online Indonesian community forums, social media, seminars/gathering events, and inpatient visits. Each family member was the main care provider for one patient with a schizophrenia diagnosis. Family participants were randomly allocated to one of two groups (control or intervention); both groups received equal personal time and attention from staff but the control group lacked the specific psychoeducational aspect of the intervention. In comparison with the control group, pre- and post-evaluation revealed significant positive effects in the intervention group for illness perception (F (ave) = 124.85; d (ave) = 2.72) and expressed emotion (OR (ave) = 0.39) among family members. For the patients, there was a significant positive effect on medication adherence (F (1, 62) = 21.54; p < 0.001, d (intervention) = 1.31) if their family members were in the intervention group. Partial least-squares path modeling revealed that low expressed emotion in family members was positively correlated with high medication adherence (β = -0.718; p < 0.001) in patients. This study provides evidence for the patient and family benefits of family psychoeducation on schizophrenia in a diverse Indonesian population.",2021,"In comparison with the control group, pre- and post-evaluation revealed significant positive effects in the intervention group for illness perception (F (ave) = 124.85; d (ave) = 2.72) and expressed emotion (OR (ave) = 0.39) among family members.","['Sixty-four family participants meeting pre-set criteria were recruited from various online Indonesian community forums, social media, seminars/gathering events, and inpatient visits', 'Patients with Schizophrenia', 'Family participants']",['equal personal time and attention from staff but the control group lacked the specific psychoeducational aspect of the intervention'],"['illness perception', 'medication adherence', 'Illness Perception and Expressed Emotion of Family Caregivers']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0021248', 'cui_str': 'Indonesian language'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]","[{'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0302826', 'cui_str': 'Expressed Emotion'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}]",64.0,0.019676,"In comparison with the control group, pre- and post-evaluation revealed significant positive effects in the intervention group for illness perception (F (ave) = 124.85; d (ave) = 2.72) and expressed emotion (OR (ave) = 0.39) among family members.","[{'ForeName': 'Watari', 'Initials': 'W', 'LastName': 'Budiono', 'Affiliation': 'Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya (Ubaya), Surabaya 60293, Indonesia.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Kantono', 'Affiliation': 'Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya (Ubaya), Surabaya 60293, Indonesia.'}, {'ForeName': 'Franciscus Cahyo', 'Initials': 'FC', 'LastName': 'Kristianto', 'Affiliation': 'Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya (Ubaya), Surabaya 60293, Indonesia.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Avanti', 'Affiliation': 'Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya (Ubaya), Surabaya 60293, Indonesia.'}, {'ForeName': 'Fauna', 'Initials': 'F', 'LastName': 'Herawati', 'Affiliation': 'Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya (Ubaya), Surabaya 60293, Indonesia.'}]",International journal of environmental research and public health,['10.3390/ijerph18147522'] 1790,34299917,Impact of the Childcare Physical Activity (PLAY) Policy on Young Children's Physical Activity and Sedentary Time: A Pilot Clustered Randomized Controlled Trial.,"Background : The importance of daily physical activity is crucial for healthy development during the early years. Currently, a formal written physical activity policy is lacking in Canadian childcare centers, but holds promise for offering consistent physical activity opportunities. With eight recommendations, the Childcare PLAY policy is an evidence-informed, institutional-level document, targeting children's physical activity, outdoor play, and sedentary time. The purpose of this study was to examine the impact of the Childcare Physical Activity (PLAY) policy on the physical activity and sedentary time of young children (18 months-4 years) in childcare. Methods : Nine childcare centers in London, Ontario participated in the cluster, randomized controlled trial. The centers in the control condition ( n = 4) continued their typical daily routines, while the centers in the intervention condition ( n = 5) implemented the PLAY policy for eight weeks. To assess physical activity levels, toddlers and preschoolers wore ActiGraph wGT3X-BT accelerometers for five consecutive days during childcare hours, at baseline, mid- and post-intervention, and at the six-month follow-up. Raw accelerometry data were converted to 15 s epochs, and age- and device-specific cut-points were applied. The participants with two or more days of at least 5 h/day of wear-time at baseline, and at one additional time point, were included in the linear mixed-effects models. An adjusted alpha ( p < 0.017) was used to account for multiple comparison bias. Results : A total of 148 children (31.92 ± 7.41 months) had valid accelerometry data. The intervention resulted in a significant increase in light physical activity among the participants in the experimental group at the six-month follow-up (+1.07 min/h, an 11.16% increase; p = 0.0017). The intervention did not have a statistically significant effect on the total physical activity, moderate-to-vigorous physical activity, or sedentary time. Conclusions : The findings indicate that the Childcare PLAY policy was effective at increasing the toddlers' and preschoolers' light physical activity. This pilot intervention appears promising for supporting some improved movement behaviors among children in childcare settings; however, additional investigations are needed to explore the feasibility and effectiveness with larger and more-diverse samples.",2021,"The intervention did not have a statistically significant effect on the total physical activity, moderate-to-vigorous physical activity, or sedentary time. ","['Nine childcare centers in London, Ontario participated in the cluster', '148 children (31.92 ± 7.41 months) had valid accelerometry data', 'children in childcare settings', ""Young Children's Physical Activity and Sedentary Time"", 'Canadian childcare centers', 'young children (18 months-4 years) in childcare']","['Childcare Physical Activity (PLAY) Policy', ' ', 'Childcare Physical Activity (PLAY) policy']","['physical activity levels, toddlers and preschoolers wore ActiGraph wGT3X-BT accelerometers', 'total physical activity, moderate-to-vigorous physical activity, or sedentary time', 'light physical activity', ""toddlers' and preschoolers' light physical activity""]","[{'cui': 'C0008070', 'cui_str': 'Child day care center'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0441677', 'cui_str': 'Accelerometry'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0242456', 'cui_str': 'Policy'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0023693', 'cui_str': 'Light'}]",148.0,0.036893,"The intervention did not have a statistically significant effect on the total physical activity, moderate-to-vigorous physical activity, or sedentary time. ","[{'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Szpunar', 'Affiliation': 'Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, ON N6A 3K7, Canada.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Driediger', 'Affiliation': 'School of Kinesiology, Faculty of Health Sciences, University of Western Ontario, London, ON N6A 3K7, Canada.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Johnson', 'Affiliation': 'Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, ON N6A 3K7, Canada.'}, {'ForeName': 'Leigh M', 'Initials': 'LM', 'LastName': 'Vanderloo', 'Affiliation': 'Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, ON N6A 3K7, Canada.'}, {'ForeName': 'Shauna M', 'Initials': 'SM', 'LastName': 'Burke', 'Affiliation': 'Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, ON N6A 3K7, Canada.'}, {'ForeName': 'Jennifer D', 'Initials': 'JD', 'LastName': 'Irwin', 'Affiliation': 'Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, ON N6A 3K7, Canada.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Shelley', 'Affiliation': 'Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, ON N6A 3K7, Canada.'}, {'ForeName': 'Brian W', 'Initials': 'BW', 'LastName': 'Timmons', 'Affiliation': 'Child Health & Exercise Medicine Program, Department of Pediatrics, McMaster University, Hamilton, ON L8S 4L8, Canada.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Tucker', 'Affiliation': 'Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, ON N6A 3K7, Canada.'}]",International journal of environmental research and public health,['10.3390/ijerph18147468'] 1791,34303267,A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.,"BACKGROUND In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin. This study evaluated whether irinotecan/5-fluorouracil (5-FU; mFOLFIRI) was superior to oxaliplatin/5-FU (mFOLFOX) as a second-line treatment in BTC. PATIENTS AND METHODS Patients diagnosed with BTC with disease progression after prior gemcitabine/cisplatin were randomised (1:1) to either mFOLFOX (control arm) or mFOLFIRI (experimental arm). Randomisation was stratified by tumour location (intrahepatic versus extrahepatic versus gallbladder versus ampulla of Vater) and ECOG performance status (0, 1 versus 2). The primary endpoint was the overall survival (OS) rate at 6 months. RESULTS In total, 120 patients were enrolled and 118 patients were randomised (mFOLFOX n = 59, mFOLFIRI n = 59). The baseline characteristics were well balanced between the two arms. The tumour location was intrahepatic bile duct in 48 patients (40.7%), extrahepatic bile duct in 29 patients (24.6%), gallbladder in 35 patients (29.7%) and ampulla of Vater in 6 patients (5.1%). At a median follow-up duration of 25.8 months, the 6-month OS rate was 54.1% in mFOLFOX and 44.1% in mFOLFIRI (p = 0.677). The median OS was 6.3 months (95% CI, 4.4-8.2) in mFOLFOX and 5.7 months (95% CI, 4.7-6.7) in mFOLFIRI (p = 0.677). The median progression-free survival was 2.8 months (95% CI, 2.3-3.3) in mFOLFOX and 2.1 months (95% CI, 1.1-3.1) in mFOLFIRI (p = 0.974). Of the 101 evaluable patients, the objective response rate and disease control rate were 5.9% and 66.7% in mFOLFOX and 4.0% and 64.0% in mFOLFIRI (p = 0.663 and p = 0.778, respectively). Peripheral neuropathy (37.5% versus 5.2%) and thrombocytopenia (35.7% versus 15.5%) in mFOLFOX and vomiting (19.0% versus 1.8%) and cholangitis (10.3% versus 0.0%) in mFOLFIRI occurred more frequently. No chemotherapy-related death was reported. CONCLUSION In the second-line treatment of BTC, mFOLFIRI was not superior to mFOLFOX. However, mFOLFIRI was tolerable and showed comparable efficacy to mFOLFOX. Adverse events were different between the two arms. CLINICALTRIALS. GOV IDENTIFIER NCT03464968.",2021,"The median progression-free survival was 2.8 months (95% CI, 2.3-3.3) in mFOLFOX and 2.1 months (95% CI, 1.1-3.1) in mFOLFIRI (p = 0.974).","['Patients diagnosed with BTC with disease progression after prior', '120 patients were enrolled and 118 patients', 'locally advanced or metastatic biliary tract cancer refractory to first-line']","['gemcitabine/cisplatin', 'gemcitabine/cisplatin chemotherapy', 'oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy', 'oxaliplatin/5-FU (mFOLFOX', 'irinotecan/5-fluorouracil (5-FU; mFOLFIRI', 'mFOLFOX (control arm) or mFOLFIRI']","['objective response rate and disease control rate', 'extrahepatic bile duct', '6-month OS rate', 'median progression-free survival', 'Peripheral neuropathy', 'overall survival (OS) rate', 'Adverse events', 'cholangitis', 'mFOLFOX and vomiting', 'median OS', 'thrombocytopenia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0750952', 'cui_str': 'Malignant tumor of biliary tract'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0205132', 'cui_str': 'Linear'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0206187', 'cui_str': 'Extrahepatic duct structure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0008311', 'cui_str': 'Cholangitis'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}]",120.0,0.154161,"The median progression-free survival was 2.8 months (95% CI, 2.3-3.3) in mFOLFOX and 2.1 months (95% CI, 1.1-3.1) in mFOLFIRI (p = 0.974).","[{'ForeName': 'In Sil', 'Initials': 'IS', 'LastName': 'Choi', 'Affiliation': 'Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, South Korea.'}, {'ForeName': 'Ki Hwan', 'Initials': 'KH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, South Korea.'}, {'ForeName': 'Ju Hyun', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.'}, {'ForeName': 'Koung Jin', 'Initials': 'KJ', 'LastName': 'Suh', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.'}, {'ForeName': 'Ji-Won', 'Initials': 'JW', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.'}, {'ForeName': 'Jin Hyun', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, South Korea.'}, {'ForeName': 'Yu Jung', 'Initials': 'YJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.'}, {'ForeName': 'Jin-Soo', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, South Korea.'}, {'ForeName': 'Jee Hyun', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.'}, {'ForeName': 'Jin Won', 'Initials': 'JW', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea. Electronic address: jwkim@snubh.org.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.06.019'] 1792,34321453,Efficacy of Single Level Versus Double Levels Surgery of Percutaneous Disc Nucleoplasty (PDN) Approach in Treating Lumbar Disc Herniation.,"BACKGROUND Although percutaneous disc nucleoplasty (PDN) has been widely applied in treating lumbar disc herniation (LDH) in recent years, the efficacy of surgical levels for PDN on LDH has been reported in limited studies. This study aimed to explore and compare the efficacy of surgical levels (single level vs double level) of PDN in treating LDH. MATERIAL AND METHODS All patients diagnosed with LDH from January 2012 to December 2014 in our hospital who underwent PDN were included in this study. Patients were divided into a single-level group and double-level group based on the number of discs/surgical treatment levels. The improvement of visual analog scale (VAS) score, patient satisfaction, and reoperation occurrence were compared between the 2 groups. RESULTS Of 105 total patients, 75 patients were treated with single-level treatment and 30 patients with double-level treatment. VAS for leg pain and patient satisfaction scores in the double-level group were worse than those in the single-level group at 6 months after surgery (P<0.05). Among all 105 patients, the incidence of reoperation was 11.4%. Also, there was a marked difference in reoperation occurrence at 6 months after surgery between the single-level (6.7%) and double-level (23.3%) groups; however, the difference was not statistically significant (P=0.05). CONCLUSIONS PDN is a safe and minimal-invasive approach, which could effectively treat LDH. The number of surgical levels might be an important factor influencing the efficacy of PND. Caution should be exercised to strictly follow the clinical indications for nucleoplasty.",2021,VAS for leg pain and patient satisfaction scores in the double-level group were worse than those in the single-level group at 6 months after surgery (P<0.05).,"['105 total patients', '75 patients were treated with single-level treatment and 30 patients with double-level treatment', 'All patients diagnosed with LDH from January 2012 to December 2014 in our hospital who underwent PDN were included in this study', 'Treating Lumbar Disc Herniation']","['PDN', 'Single Level Versus Double Levels Surgery of Percutaneous Disc Nucleoplasty (PDN) Approach', 'VAS', 'percutaneous disc nucleoplasty (PDN']","['incidence of reoperation', 'double-level', 'reoperation occurrence', 'leg pain and patient satisfaction scores', 'visual analog scale (VAS) score, patient satisfaction, and reoperation occurrence']","[{'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0281899', 'cui_str': 'Prolapsed lumbar intervertebral disc'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0023222', 'cui_str': 'Pain in lower limb'}, {'cui': 'C0451370', 'cui_str': 'Patient satisfaction score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",75.0,0.230376,VAS for leg pain and patient satisfaction scores in the double-level group were worse than those in the single-level group at 6 months after surgery (P<0.05).,"[{'ForeName': 'Haidong', 'Initials': 'H', 'LastName': 'Yin', 'Affiliation': 'Department of Orthopedics, Panyu Hospital of Chinese Medicine, Guangzhou, Guangdong, China (mainland).'}, {'ForeName': 'Xinmei', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiovascular Medicine, Shunde Hospital, Southern Medical University, Foshan, Guangdong, China (mainland).'}, {'ForeName': 'Zhiping', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': 'Department of Spinal Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Department of Cardiovascular Medicine, Shunde Hospital, Southern Medical University, Foshan, Guangdong, China (mainland).'}, {'ForeName': 'Qingan', 'Initials': 'Q', 'LastName': 'Zhu', 'Affiliation': 'Department of Spinal Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).'}]",Medical science monitor : international medical journal of experimental and clinical research,['10.12659/MSM.930000'] 1793,34321436,Preliminary Efficacy of an Emotion Regulation Intervention on Physical Activity and Depressive and Anxious Symptoms in Individuals in Cardiac Rehabilitation.,"BACKGROUND For the 720 000 Americans expected to experience a new acute cardiac event this year, cardiac rehabilitation is an important part of recovery. Symptoms of depression and anxiety undermine recovery efforts, leaving recovering patients at risk for diminished functional capacity and heightened risk of mortality. Poor emotion regulation can worsen symptoms of depression and anxiety and hinder recovery efforts. OBJECTIVE The purpose of this randomized controlled trial was to evaluate the early efficacy testing of a theoretically based emotion regulation treatment (Regulating Emotions to Improve Self-management of Nutrition, Exercise, and Stress [RENEwS]) designed to assist survivors of an acute cardiac event in cardiac rehabilitation to optimize recovery. METHODS Survivors of an acute cardiac event in cardiac rehabilitation (n = 30, 83% men) were randomized to five 1-hour in-person group sessions of RENEwS or a phone-based attention-control group. Participants completed measures of depression and anxiety symptoms at 3 time points. Moderate to vigorous physical activity (MVPA) was objectively measured for 7 days at each time point using waist-worn actigraphy monitors. Between-group differences were calculated using analysis of variance with Cohen f effect sizes calculated to evaluate initial efficacy. RESULTS There was no statistically significant difference in depression, anxiety, or MVPA over time based on group assignment (all P > .05). Compared with attention control participants, in RENEwS participants, preliminary effects showed greater reductions in depression (Cohen f = 0.34) and anxiety (Cohen f = 0.40) symptoms but only modest improvements in MVPA from baseline to 5 months (Cohen f = 0.08). CONCLUSIONS Findings show that RENEwS is a promising emotion regulation intervention to enhance cardiac rehabilitation and potentially decrease symptoms of depression and anxiety.",2021,"There was no statistically significant difference in depression, anxiety, or MVPA over time based on group assignment (all P > .05).","['720 000 Americans', 'Individuals in Cardiac Rehabilitation', 'Survivors of an acute cardiac event in cardiac rehabilitation (n = 30, 83% men']","['Emotion Regulation Intervention', 'theoretically based emotion regulation treatment (Regulating Emotions', 'person group sessions of RENEwS or a phone-based attention-control group']","['Physical Activity and Depressive and Anxious Symptoms', 'anxiety', 'vigorous physical activity (MVPA', 'depression', 'depression, anxiety, or MVPA', 'MVPA', 'depression and anxiety symptoms']","[{'cui': 'C4517865', 'cui_str': '720'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C4552344', 'cui_str': 'Acute cardiac event'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}]",720000.0,0.0616626,"There was no statistically significant difference in depression, anxiety, or MVPA over time based on group assignment (all P > .05).","[{'ForeName': 'Kelly L', 'Initials': 'KL', 'LastName': 'Wierenga', 'Affiliation': 'Kelly L. Wierenga, PhD, RN Assistant Professor, Indiana University School of Nursing, Indianapolis. David M. Fresco, PhD Professor of Psychiatry, Research Professor, Institute for Social Research, The University of Michigan, Ann Arbor. Megan Alder, BSN, RN Predoctoral Trainee, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio. Abdus Sattar, PhD Associate Professor, Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio. Shirley M. Moore, PhD, RN, FAAN Edward J. and Louise Mellen Professor of Nursing Emerita, Distinguished University Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Fresco', 'Affiliation': ''}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Alder', 'Affiliation': ''}, {'ForeName': 'Abdus', 'Initials': 'A', 'LastName': 'Sattar', 'Affiliation': ''}, {'ForeName': 'Shirley M', 'Initials': 'SM', 'LastName': 'Moore', 'Affiliation': ''}]",The Journal of cardiovascular nursing,['10.1097/JCN.0000000000000837'] 1794,34320459,"Associations between exercise, inflammation and symptom severity in those with mental health disorders.","AIM This study aimed to investigate the effects of 6-weeks of moderate intensity aerobic exercise on markers of inflammation and symptom severity in those undergoing management of a mental health disorder. METHOD Twenty six participants were allocated into two groups, those reporting as apparently healthy (AH, n = 13) or those undergoing the management of a mental health disorder (MI, n = 13). Following a baseline testing and familiarization session, participants commenced the 6-week aerobic training intervention, involving stationary cycling at 65% heart rate reserve for 35 min progressing to 70% for 40 min. Measures of aerobic fitness (VO 2peak ), anthropometric variables, symptom questionnaires and venous blood were collect pre- and post-intervention. Venous blood was assessed for nod-like receptor pyrin containing-3, interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), IL-1β, C-reactive protein (CRP) and brain-derived neurotropic factor (BDNF). RESULTS There were no baseline differences between groups, however following the intervention the AH demonstrated lower TNF-α (p = 0.049) than the MI group. Within change was observed for the MI group with an increase in VO 2peak (p = 0.049) and declines in symptom severity (p = 0.00-0.005). Significant correlations between variables indicated a positive association between body fat, body fat percentage, CRP and symptom severity (p = 0.01-0.04). Conversely, symptom severity and CRP were inversely associated with VO 2peak values (p = 0.02-0.04). CONCLUSION Six-weeks of moderate intensity aerobic exercise increases VO 2peak and reduces symptom severity in those currently undergoing management of a mental health disorder. Further, there may be a physiological link between aerobic capacity, symptom severity, inflammation and adiposity, however greater exploration is required.",2021,Within change was observed for the MI group with an increase in VO 2peak (p = 0.049) and declines in symptom severity (p = 0.00-0.005).,"['Twenty six participants were allocated into two groups, those reporting as apparently healthy (AH, n\xa0=\xa013) or those undergoing the management of a mental health disorder (MI, n\xa0=\xa013', 'those undergoing management of a mental health disorder', 'those with mental health disorders']","['aerobic training intervention', 'moderate intensity aerobic exercise']","['symptom severity', 'body fat, body fat percentage, CRP and symptom severity', 'Venous blood', 'nod-like receptor pyrin containing-3, interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), IL-1β, C-reactive protein (CRP) and brain-derived neurotropic factor (BDNF', 'VO 2peak', 'aerobic fitness (VO 2peak ), anthropometric variables, symptom questionnaires and venous blood', 'symptom severity and CRP', 'TNF-α']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0229667', 'cui_str': 'Venous blood'}, {'cui': 'C4277661', 'cui_str': 'NLR Protein'}, {'cui': 'C0665818', 'cui_str': 'Marenostrin'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",26.0,0.0258991,Within change was observed for the MI group with an increase in VO 2peak (p = 0.049) and declines in symptom severity (p = 0.00-0.005).,"[{'ForeName': 'Tegan E', 'Initials': 'TE', 'LastName': 'Hartmann', 'Affiliation': 'School of Exercise Science, Sport and Health, Charles Sturt University, Bathurst, NSW, Australia. Electronic address: thartmann@csu.edu.au.'}, {'ForeName': 'Caroline V', 'Initials': 'CV', 'LastName': 'Robertson', 'Affiliation': 'School of Exercise Science, Sport and Health, Charles Sturt University, Bathurst, NSW, Australia.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Miller', 'Affiliation': 'School of Exercise Science, Sport and Health, Charles Sturt University, Bathurst, NSW, Australia.'}, {'ForeName': 'Jayden R', 'Initials': 'JR', 'LastName': 'Hunter', 'Affiliation': 'Holsworth Research Initiative, La Trobe University, Bendigo, VIC, Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Skein', 'Affiliation': 'School of Exercise Science, Sport and Health, Charles Sturt University, Bathurst, NSW, Australia.'}]",Cytokine,['10.1016/j.cyto.2021.155648'] 1795,34299987,Effects of a Physical Education Program on Physical Activity and Emotional Well-Being among Primary School Children.,"(1) Background: It has been identified that schools that adopt at least two hours a week of physical education and plan specific contents and activities can achieve development goals related to physical level, such as promoting health, well-being, and healthy lifestyles, on a personal level, including bodily awareness and confidence in physical skills, as well as a general sense of well-being, greater security and self-esteem, sense of responsibility, patience, courage, and mental balance. The purpose of this study was to establish the effect of physical education programs on the physical activity and emotional well-being of primary school children. (2) Methods: The experimental group comprised 45 girls and 44 boys aged 6-7 years (First Grade) and 48 girls and 46 boys aged 8-9 years (Second Grade), while the control group comprised 43 girls and 46 boys aged 6-7 years (First Grade) and 47 girls and 45 boys aged 8-9 years (Second Grade). All children attended the same school. The Children's Physical Activity Questionnaire was used, which is based on the Children's Leisure Activities Study Survey questionnaire, which includes activities specific to young children (e.g., ""playing in a playhouse""). Emotional well-being status was explored by estimating three main dimensions: somatic anxiety, personality anxiety, and social anxiety. The Revised Children's Manifest Anxiety Scale (RCMAS) was used. (3) Results: When analysing the pre-test results of physical activity of the 6-7- and 8-9-year-old children, it turned out that both the First Grade (92.15 MET, min/week) and Second Grade (97.50 MET, min/week) participants in the experimental group were physically active during physical education lessons. When exploring the results of somatic anxiety in EG (4.95 ± 1.10 points), both before and after the experiment, we established that somatic anxiety in EG was 4.55 ± 1.00 points after the intervention program, demonstrating lower levels of depression, seclusion, somatic complaints, aggression, and delinquent behaviours (F = 4.785, p < 0.05, P = 0.540). (4) Conclusions: We established that the properly constructed and purposefully applied eight-month physical education program had positive effects on the physical activity and emotional well-being of primary school children (6-7 and 8-9 years) in three main dimensions: somatic anxiety, personality anxiety, and social anxiety. Our findings suggest that the eight-month physical education program intervention was effective at increasing levels of physical activity. Changes in these activities may require more intensive behavioural interventions with children or upstream interventions at the family and societal levels, as well as at the school environment level. These findings have relevance for researchers, policy makers, public health practitioners, and doctors who are involved in health promotion, policy making, and commissioning services.",2021,"When exploring the results of somatic anxiety in EG (4.95 ± 1.10 points), both before and after the experiment, we established that somatic anxiety in EG was 4.55 ± 1.00 points after the intervention program, demonstrating lower levels of depression, seclusion, somatic complaints, aggression, and delinquent behaviours (F = 4.785, p < 0.05, P = 0.540).","['primary school children (6-7 and 8-9 years) in three main dimensions: somatic anxiety, personality anxiety, and social anxiety', 'primary school children', '45 girls and 44 boys aged 6-7 years (First Grade) and 48 girls and 46 boys aged 8-9 years (Second Grade), while the control group comprised 43 girls and 46 boys aged 6-7 years (First Grade) and 47 girls and 45 boys aged 8-9 years (Second Grade', 'Primary School Children']","['Physical Education Program', 'physical education programs']","['levels of depression, seclusion, somatic complaints, aggression, and delinquent behaviours', 'physical activity', ""Revised Children's Manifest Anxiety Scale (RCMAS"", 'Physical Activity and Emotional Well', 'levels of physical activity', 'somatic anxiety, personality anxiety, and social anxiety']","[{'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C1257909', 'cui_str': 'Diploid Cell'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0204742', 'cui_str': 'Secluding patient'}, {'cui': 'C1257909', 'cui_str': 'Diploid Cell'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0522174', 'cui_str': 'Delinquent behavior'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0024720', 'cui_str': 'Manifest Anxiety Scale'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}]",,0.0137757,"When exploring the results of somatic anxiety in EG (4.95 ± 1.10 points), both before and after the experiment, we established that somatic anxiety in EG was 4.55 ± 1.00 points after the intervention program, demonstrating lower levels of depression, seclusion, somatic complaints, aggression, and delinquent behaviours (F = 4.785, p < 0.05, P = 0.540).","[{'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Kliziene', 'Affiliation': 'Educational Research Group, Institute of Social Science and Humanity, Kaunas University of Technology, Kaunas 44249, Lithuania.'}, {'ForeName': 'Ginas', 'Initials': 'G', 'LastName': 'Cizauskas', 'Affiliation': 'Department of Mechanical Engineering, Faculty of Mechanical Engineering and Design, Kaunas University of Technology, Kaunas 51424, Lithuania.'}, {'ForeName': 'Saule', 'Initials': 'S', 'LastName': 'Sipaviciene', 'Affiliation': 'Department of Applied Biology and Rehabilitation, Lithuanian Sports University, Kaunas 44221, Lithuania.'}, {'ForeName': 'Roma', 'Initials': 'R', 'LastName': 'Aleksandraviciene', 'Affiliation': 'Department of Coaching Science, Lithuanian Sports University, Kaunas 44221, Lithuania.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Zaicenkoviene', 'Affiliation': 'Department of Coaching Science, Lithuanian Sports University, Kaunas 44221, Lithuania.'}]",International journal of environmental research and public health,['10.3390/ijerph18147536'] 1796,34303029,Effects of multiple sessions of antimicrobial photodynamic therapy (aPDT) in the treatment of periodontitis in patients with uncompensated type 2 diabetes: A randomized controlled clinical study.,"BACKGROUND The aim of this study was to compare, through clinical and microbiological analysis, the use of multiple applications of aPDT as an adjuvant therapy to non-surgical periodontal treatment of stage III and IV grade C periodontitis in type 2 diabetic (DM2) patients. METHODS Thirty-four patients with non-compensated DM2 and periodontitis were randomly divided into two groups: SRP Group (n = 17): scaling and root planing (SRP); and SRP+aPDT Group (n = 17): SRP followed by 3 consecutive aPDT applications, immediately, 48 and 96 h after in pockets with probing depth (PD) ≥5 mm. In SRP+aPDT, after 1 min of irrigation with methylene blue (10 mg/ml), the sites were irradiated with a 660 nm diode laser for 50 s (157 J/cm 2 , 4.7 J, 100 mW). Porphyromonas gingivalis (P. gingivalis) and Prevotella intermedia (P. intermedia) were quantified by real-time qPCR. Periodontal clinical and microbiological data (baseline, 90 and 180 days) were statistically analyzed (α = 5%). RESULTS There was a significant reduction in PD and bleeding on probing at 90 and 180 days post-treatment in both groups (p<0.05). The SRP+aPDT group presented a significant reduction in the number of residual pockets at 90 and 180 days (p<0.05). The SRP+aPDT group presented reduced PD means in deep pockets 180 days post-treatment (p<0.05). No differences were observed in P. gingivalis and P. intermedia levels (p>0.05). CONCLUSION The results of present study indicate that the use of multiples aPDT sessions as adjuvant therapy in the periodontal treatment of uncompensated diabetic patients with periodontitis promotes additional clinical benefits.",2021,The SRP+aPDT group presented a significant reduction in the number of residual pockets at 90 and 180 days (p<0.05).,"['non-surgical periodontal treatment of stage III and IV grade C periodontitis in type 2 diabetic (DM2) patients', 'uncompensated diabetic patients with periodontitis', 'Thirty-four patients with non-compensated DM2 and periodontitis', 'periodontitis in patients with uncompensated type 2 diabetes']","['SRP+aPDT', 'antimicrobial photodynamic therapy (aPDT', 'scaling and root planning (SRP); and SRP+aPDT', 'aPDT', 'methylene blue', 'SRP', 'multiples aPDT sessions']","['Periodontal clinical and microbiological data', 'PD and bleeding', 'PD means', 'P. gingivalis and P. intermedia levels', 'number of residual pockets']","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0441807', 'cui_str': 'Grade C'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205433', 'cui_str': 'Uncompensated'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205432', 'cui_str': 'Compensated'}, {'cui': 'C1300562', 'cui_str': 'dm2'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0627220', 'cui_str': ""P(1)-(adenosine-5')-P(5)-(thymidine-5')-pentaphosphate""}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0025746', 'cui_str': 'Methylene blue'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}]","[{'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0446035', 'cui_str': 'Candida intermedia'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}]",34.0,0.0327016,The SRP+aPDT group presented a significant reduction in the number of residual pockets at 90 and 180 days (p<0.05).,"[{'ForeName': 'Marina Módolo', 'Initials': 'MM', 'LastName': 'Cláudio', 'Affiliation': 'Department of Diagnostic and Surgery, Periodontics Division, São Paulo State University - UNESP, Dentistry School of Araçatuba, Araçatuba, SP, Brazil.'}, {'ForeName': 'Marta Aparecida Alberton', 'Initials': 'MAA', 'LastName': 'Nuernberg', 'Affiliation': 'Department of Diagnostic and Surgery, Periodontics Division, São Paulo State University - UNESP, Dentistry School of Araçatuba, Araçatuba, SP, Brazil.'}, {'ForeName': 'João Victor Soares', 'Initials': 'JVS', 'LastName': 'Rodrigues', 'Affiliation': 'Department of Diagnostic and Surgery, Periodontics Division, São Paulo State University - UNESP, Dentistry School of Araçatuba, Araçatuba, SP, Brazil.'}, {'ForeName': 'Lícia Clara Garcia', 'Initials': 'LCG', 'LastName': 'Belizário', 'Affiliation': 'Department of Diagnostic and Surgery, Periodontics Division, São Paulo State University - UNESP, Dentistry School of Araçatuba, Araçatuba, SP, Brazil.'}, {'ForeName': 'Júlia Arruda', 'Initials': 'JA', 'LastName': 'Batista', 'Affiliation': 'Department of Diagnostic and Surgery, Periodontics Division, São Paulo State University - UNESP, Dentistry School of Araçatuba, Araçatuba, SP, Brazil.'}, {'ForeName': 'Cristiane', 'Initials': 'C', 'LastName': 'Duque', 'Affiliation': 'Department of Preventive and Restorative Dentistry, São Paulo State University - UNESP, Dentistry School of Araçatuba, Araçatuba, SP, Brazil.'}, {'ForeName': 'Valdir Gouveia', 'Initials': 'VG', 'LastName': 'Garcia', 'Affiliation': 'Latin American Institute of Dental Research and Teaching (ILAPEO), Curitiba, PR, Brazil.'}, {'ForeName': 'Letícia Helena', 'Initials': 'LH', 'LastName': 'Theodoro', 'Affiliation': 'Department of Diagnostic and Surgery, Periodontics Division, São Paulo State University - UNESP, Dentistry School of Araçatuba, Araçatuba, SP, Brazil. Electronic address: leticia.theodoro@unesp.br.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102451'] 1797,34303017,Response to Omalizumab in Black and White Patients with Allergic Asthma.,"BACKGROUND Higher asthma burden is more likely to be experienced by Black than White patients. In clinical research, underrepresentation of minority populations is observed. OBJECTIVE To estimate response to omalizumab in Black and White patients in North America with moderate to severe asthma. METHODS Data from placebo-controlled (EXTRA) and single-armed (PROSPERO) omalizumab studies were used for this post hoc analysis. We used a Poisson regression model to examine exacerbation rates. An analysis of covariance model was used to estimate placebo-corrected change in FEV 1 and Asthma Quality of Life Questionnaire (AQLQ) by racial group. RESULTS This analysis included 631 White and 176 Black patients from EXTRA and 567 White and 130 Black patients from PROSPERO. In EXTRA, placebo-corrected exacerbation rate reductions (relative rate change [95% confidence interval], 22.6% [2.0-38.9%] vs 22.0% [-18.0% to 48.4%]) and FEV 1 improvements were similar for White and Black patients. There was a trend toward greater AQLQ improvements for Black versus White patients (least squares mean treatment differences: 0.0 vs 0.3, 0.6 vs 0.4, and 0.6 vs 0.2 at weeks 16, 32, and 48, respectively) throughout the study. In PROSPERO, on-study exacerbation rates (0.76 [0.65-0.88] vs 0.77 [0.56-1.10]) and AQLQ improvements (least squares mean change from baseline: 1.2 vs 1.2 and 1.3 vs 1.2 at month 6 and end of study, respectively) were similar for White versus Black patients. A trend toward greater FEV 1 improvement was observed in White versus Black patients throughout the study. CONCLUSIONS This analysis of EXTRA and PROSPERO suggests that Black and White patients with moderate to severe asthma experience similar improvements in exacerbations, FEV 1 , and AQLQ with omalizumab.",2021,"In EXTRA, placebo-corrected exacerbation rate reductions (relative rate change [95% CI], 22.6% [2.0-38.9%] vs 22.0% [-18.0%, 48.4%]) and FEV 1 improvements were similar for White and Black patients.","['631 White/176 Black patients from EXTRA and 567 White/130 Black patients from PROSPERO', 'Black and White patients in North America with moderate-to-severe asthma', 'Black and White Patients with Allergic Asthma']","['Omalizumab', 'placebo-controlled', 'omalizumab']","['AQLQ improvements (LSM change', 'FEV 1 and Asthma Quality of Life Questionnaire (AQLQ', 'exacerbation rates', 'AQLQ improvements', 'exacerbation rate reductions']","[{'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0155877', 'cui_str': 'Allergic asthma'}]","[{'cui': 'C0966225', 'cui_str': 'omalizumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",631.0,0.263109,"In EXTRA, placebo-corrected exacerbation rate reductions (relative rate change [95% CI], 22.6% [2.0-38.9%] vs 22.0% [-18.0%, 48.4%]) and FEV 1 improvements were similar for White and Black patients.","[{'ForeName': 'Stanley J', 'Initials': 'SJ', 'LastName': 'Szefler', 'Affiliation': ""Pediatric Asthma Research Program, Breathing Institute, Children's Hospital Colorado, and University of Colorado School of Medicine, Aurora, Colo.""}, {'ForeName': 'Elina', 'Initials': 'E', 'LastName': 'Jerschow', 'Affiliation': 'Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Bongin', 'Initials': 'B', 'LastName': 'Yoo', 'Affiliation': 'Genentech, Inc., South San Francisco, Calif.'}, {'ForeName': 'Pranathi', 'Initials': 'P', 'LastName': 'Janampally', 'Affiliation': 'Genentech, Inc., South San Francisco, Calif.'}, {'ForeName': 'Hooman', 'Initials': 'H', 'LastName': 'Pazwash', 'Affiliation': 'Genentech, Inc., South San Francisco, Calif.'}, {'ForeName': 'Cecile T J', 'Initials': 'CTJ', 'LastName': 'Holweg', 'Affiliation': 'Genentech, Inc., South San Francisco, Calif. Electronic address: holweg.cecile@gene.com.'}, {'ForeName': 'Golda', 'Initials': 'G', 'LastName': 'Hudes', 'Affiliation': 'Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2021.07.013'] 1798,34303000,The impact of multimodal cognitive rehabilitation on executive functions in older adults with traumatic brain injury.,"OBJECTIVES This study evaluated the impact of a 12-week, 24-session multimodal group cognitive rehabilitation intervention, the Cognitive Enrichment Program (CEP), on executive functioning and resumption of daily activities after traumatic brain injury (TBI) in older individuals as compared with an active control group that received individual holistic rehabilitation as usual care. METHODS In total, 37 patients with a TBI and aged 57 to 90 years were assigned to experimental (n = 23) and control (n = 14) groups in a semi-randomized, controlled, before-after intervention trial with follow-up at 6 months, with blinded outcome measurement. The CEP's executive function module included planning, problem solving, and goal management training as well as strategies focusing on self-awareness. Efficacy was evaluated by neuropsychological tests (Six Elements Task-Adapted [SET-A], D-KEFS Sorting test and Stroop four-color version); generalization was measured by self-reporting questionnaires about daily functioning (Dysexecutive Functioning Questionnaire, forsaken daily activities). RESULTS ANCOVA results showed significant group-by-time interactions; the experimental group showed a statistically significant improvement on Tackling the 6 subtasks and Avoiding rule-breaking measures of the SET-A, with medium effect sizes. The generalization measure, the Dysexecutive Functioning Questionnaire, showed a significant reduction in experimental patient-significant other difference on the Executive cognition subscale. The number of forsaken daily activities was reduced in the experimental versus control group, which was not significant immediately after the CEP but was significant 6 months later. CONCLUSIONS Our study shows that older adults with TBI can improve their executive functioning, with a positive impact on everyday activities, after receiving multimodal cognitive training with the CEP. ClinicalTrials.gov Identifier: NCT04590911.",2021,"The number of forsaken daily activities was reduced in the experimental versus control group, which was not significant immediately after the CEP but was significant 6 months later. ","['37 patients with a TBI and age 57 to 90 years', 'older adults with TBI', 'older adults with traumatic brain injury', 'older individuals']","['individual holistic rehabilitation as usual care', '24-session multimodal group cognitive rehabilitation intervention, the Cognitive Enrichment Program (CEP', 'multimodal cognitive rehabilitation']","['neuropsychological tests (Six Elements Task-Adapted [SET-A], D-KEFS Sorting test and Stroop four-color version); generalization', 'Executive cognition subscale', 'Dysexecutive Functioning Questionnaire', 'self-reporting questionnaires about daily functioning (Dysexecutive Functioning Questionnaire, forsaken daily activities', 'Tackling the 6 subtasks and Avoiding rule-breaking measures', 'Efficacy', 'number of forsaken daily activities', 'executive functions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0013879', 'cui_str': 'Chemical element'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0017324', 'cui_str': 'Generalization (Psychology)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0522637', 'cui_str': 'Measuring ruler'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",37.0,0.0187811,"The number of forsaken daily activities was reduced in the experimental versus control group, which was not significant immediately after the CEP but was significant 6 months later. ","[{'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Cisneros', 'Affiliation': ""Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR)-IURDPM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, QC, Canada; Department of Psychology, Université de Montréal, Montreal, QC, Canada. Electronic address: eduardo.cisneros@umontreal.ca.""}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Beauséjour', 'Affiliation': ""Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR)-IURDPM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, QC, Canada; Department of Psychology, Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'de Guise', 'Affiliation': ""Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR)-IURDPM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, QC, Canada; Department of Psychology, Université de Montréal, Montreal, QC, Canada; Research Institute of the Montreal University Hospital Centre, Montreal, QC, Canada.""}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Belleville', 'Affiliation': 'Department of Psychology, Université de Montréal, Montreal, QC, Canada; Research Centre of the Institut universitaire de gériatrie de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'McKerral', 'Affiliation': ""Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR)-IURDPM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, QC, Canada; Department of Psychology, Université de Montréal, Montreal, QC, Canada. Electronic address: michelle.mckerral@umontreal.ca.""}]",Annals of physical and rehabilitation medicine,['10.1016/j.rehab.2021.101559'] 1799,34302986,HIV Engage-A randomized controlled efficacy trial of an acceptance-based behavioral therapy intervention to improve retention in care for HIV treatment naïve patients: Study protocol.,"INTRODUCTION People with HIV (PWH) who are not consistently retained in medical care, particularly when they are first diagnosed, are at risk for: delayed antiretroviral therapy (ART) initiation, suboptimal ART adherence, unsuppressed viremia, and mortality. Suboptimal retention means effective ART cannot be leveraged to prevent onward HIV transmission. To address this, we developed and previously pilot tested the HIV Engage intervention-a novel behavioral approach to enhance retention in HIV care using acceptance-based behavioral therapy (ABBT)-and established feasibility and acceptability of this approach. In the current study, we investigate the efficacy of ABBT compared to an attention-matched control condition in a full-scale randomized controlled efficacy trial. METHODS Two hundred seventy HIV care naïve patients from geographically diverse clinics will be recruited and equally randomized to receive (a) the HIV Engage intervention, consisting of two 20-30 min ABBT sessions delivered in-person or remotely, or (b) an attention-matched HIV education control condition. Primary outcomes are number of HIV care appointments kept and HIV viral load suppression. Secondary outcomes are higher self-reported ART adherence, HIV status disclosure, increased social support, and reductions in perceived HIV stigma. Hypothesized mediators include acceptance of one's HIV diagnosis and willingness to disclose serostatus. We will also assess for epidemiologically-linked moderators of the treatment effect. CONCLUSIONS ABBT represents a novel, potentially promising approach to enhance retention in ongoing HIV care among treatment naïve PWH. This study will contribute significant actionable data establishing the impact, mediational mechanisms, and effect modifiers of ABBT.",2021,"Secondary outcomes are higher self-reported ART adherence, HIV status disclosure, increased social support, and reductions in perceived HIV stigma.","['HIV treatment naïve patients', 'People with HIV (PWH', 'Two hundred seventy HIV care naïve patients from geographically diverse clinics']","['ABBT', 'acceptance-based behavioral therapy intervention', 'HIV Engage intervention, consisting of two 20-30\u202fmin ABBT sessions delivered in-person or remotely, or (b) an attention-matched HIV education control condition']","['higher self-reported ART adherence, HIV status disclosure, increased social support, and reductions in perceived HIV stigma', 'number of HIV care appointments kept and HIV viral load suppression']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0458074', 'cui_str': 'HIV status'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C1168369', 'cui_str': 'HIV viral load'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}]",270.0,0.110828,"Secondary outcomes are higher self-reported ART adherence, HIV status disclosure, increased social support, and reductions in perceived HIV stigma.","[{'ForeName': 'Ethan', 'Initials': 'E', 'LastName': 'Moitra', 'Affiliation': 'Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: ethan_moitra@brown.edu.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Chan', 'Affiliation': 'Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA; Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA.'}, {'ForeName': 'Patricia E', 'Initials': 'PE', 'LastName': 'Molina', 'Affiliation': 'Department of Physiology, School of Medicine, Louisiana State University - Health Sciences Center, New Orleans, LA, USA.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Ernst', 'Affiliation': 'Department of Psychiatry, School of Medicine, Louisiana State University - Health Sciences Center, New Orleans, LA, USA.'}, {'ForeName': 'Tekeda F', 'Initials': 'TF', 'LastName': 'Ferguson', 'Affiliation': 'Department of Physiology, School of Medicine, Louisiana State University - Health Sciences Center, New Orleans, LA, USA; Department of Epidemiology, School of Public Health, Louisiana State University - Health Sciences Center, New Orleans, LA, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Mimiaga', 'Affiliation': 'Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA; Department of Psychiatry & Biobehavioral Sciences, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.'}, {'ForeName': 'Debra S', 'Initials': 'DS', 'LastName': 'Herman', 'Affiliation': 'Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA; Behavioral Medicine and Addictions Research Unit, Butler Hospital, Providence, RI, USA.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Stein', 'Affiliation': 'Behavioral Medicine and Addictions Research Unit, Butler Hospital, Providence, RI, USA; Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, MA, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106514'] 1800,34304002,"""Impact of pentaglobin in severe COVID 19 pneumonia- a prospective study.""","BACKGROUND The current COVID-19 pandemic has become a global public health crisis and presents a serious challenge in treatment of severe COVID pneumonia patients. With an imperative need for an effective treatment, we aimed to study the effectiveness of Pentaglobin, an intravenous immunoglobin in the treatment of severe Covid-19 pneumonia patients. METHODS This is an open-label non-randomised controlled study. Patients in the study group (n = 17) received Pentaglobin in addition to standard therapy and the control group (n = 19) received only the standard of care treatment. Severity of illness were quantified by severity scores and inflammatory laboratory parameters were compared between the two groups. RESULTS The average length of hospital stay in pentaglobin group were 12.35 ± 6.98 days compared to 10.94 ± 4.62 days in standard treatment group with mean difference of 1.4 days (p value = 0.4). Pentaglobin did not provide an added advantage in terms of reducing the duration of hospital stay. There was no significant difference between both the groups in terms of requirement of invasive ventilation (p = 0.56) and mortality (p = 0.86). CT Severity score (OR = 1.39 95% CI = 1.09-1.77, P = 0.01), APACHE II score (OR = 1.16 95% CI = 0.99-1.35, P = 0.05) and the SOFA score (OR = 2.11 95% CI = 1.13-3.93, P = 0.02) were independent predictors of mortality. CONCLUSION The administration of pentaglobin in COVID -19 patients has no significant effect in reducing the risk of mechanical ventilation or death, in disease worsening or in reduction of inflammation.",2021,There was no significant difference between both the groups in terms of requirement of invasive ventilation (p = 0.56) and mortality (p = 0.86).,"['severe COVID 19 pneumonia- a prospective study', 'severe Covid-19 pneumonia patients', 'severe COVID pneumonia patients']","['pentaglobin', 'immunoglobin', 'Pentaglobin', 'Pentaglobin in addition to standard therapy and the control group (n\xa0=\xa019) received only the standard of care treatment']","['SOFA score', 'risk of mechanical ventilation or death', 'duration of hospital stay', 'Severity of illness', 'average length of hospital stay', 'mortality', 'requirement of invasive ventilation', 'CT Severity score']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0070286', 'cui_str': 'pentaglobulin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}]",,0.0508135,There was no significant difference between both the groups in terms of requirement of invasive ventilation (p = 0.56) and mortality (p = 0.86).,"[{'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Joshi', 'Affiliation': 'Department of Cardiology U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.'}, {'ForeName': 'Kamal', 'Initials': 'K', 'LastName': 'Sharma', 'Affiliation': 'Department of Cardiology U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.'}, {'ForeName': 'Senthilraj', 'Initials': 'S', 'LastName': 'Thangasami', 'Affiliation': 'Department of Cardiology U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India. Electronic address: sencon85@yahoo.co.in.'}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Department of Cardiology U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.'}, {'ForeName': 'Iva', 'Initials': 'I', 'LastName': 'Patel', 'Affiliation': 'Department of Cardiology U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.'}]",International immunopharmacology,['10.1016/j.intimp.2021.107968'] 1801,34309668,Comparison of HIV Screening Strategies in the Emergency Department: A Randomized Clinical Trial.,"Importance The National HIV Strategic Plan for the US recommends HIV screening in emergency departments (EDs). The most effective approach to ED-based HIV screening remains unknown. Objective To compare strategies for HIV screening when integrated into usual ED practice. Design, Setting, and Participants This randomized clinical trial included patients visiting EDs at 4 US urban hospitals between April 2014 and January 2016. Patients included were ages 16 years or older, not critically ill or mentally altered, not known to have an HIV positive status, and with an anticipated length of stay 30 minutes or longer. Data were analyzed through March 2021. Interventions Consecutive patients underwent concealed randomization to either nontargeted screening, enhanced targeted screening using a quantitative HIV risk prediction tool, or traditional targeted screening as adapted from the Centers for Disease Control and Prevention. Screening was integrated into clinical practice using opt-out consent and fourth-generation antigen-antibody assays. Main Outcomes and Measures New HIV diagnoses using intention-to-treat analysis, absolute differences, and risk ratios (RRs). Results A total of 76 561 patient visits were randomized; median (interquartile range) age was 40 (28-54) years, 34 807 patients (51.2%) were women, and 26 776 (39.4%) were Black, 22 131 (32.6%) non-Hispanic White, and 14 542 (21.4%) Hispanic. A total of 25 469 were randomized to nontargeted screening; 25 453, enhanced targeted screening; and 25 639, traditional targeted screening. Of the nontargeted group, 6744 participants (26.5%) completed testing and 10 (0.15%) were newly diagnosed; of the enhanced targeted group, 13 883 participants (54.5%) met risk criteria, 4488 (32.3%) completed testing, and 7 (0.16%) were newly diagnosed; and of the traditional targeted group, 7099 participants (27.7%) met risk criteria, 3173 (44.7%) completed testing, and 7 (0.22%) were newly diagnosed. When compared with nontargeted screening, targeted strategies were not associated with a higher rate of new diagnoses (enhanced targeted and traditional targeted combined: difference, -0.01%; 95% CI, -0.04% to 0.02%; RR, 0.7; 95% CI, 0.30 to 1.56; P = .38; and enhanced targeted only: difference, -0.01%; 95% CI, -0.04% to 0.02%; RR, 0.70; 95% CI, 0.27 to 1.84; P = .47). Conclusions and Relevance Targeted HIV screening was not superior to nontargeted HIV screening in the ED. Nontargeted screening resulted in significantly more tests performed, although all strategies identified relatively low numbers of new HIV diagnoses. Trial Registration ClinicalTrials.gov Identifier: NCT01781949.",2021,"When compared with nontargeted screening, targeted strategies were not associated with a higher rate of new diagnoses (enhanced targeted and traditional targeted combined: difference, -0.01%; 95% CI, -0.04% to 0.02%; RR, 0.7; 95% CI, 0.30 to 1.56; P = .38; and enhanced targeted only: difference, -0.01%; 95% CI, -0.04% to 0.02%; RR, 0.70; 95% CI, 0.27 to 1.84; P = .47). ","['A total of 25\u202f469', '6744 participants (26.5%) completed testing and 10 (0.15%) were newly diagnosed; of the enhanced targeted group, 13\u202f883 participants (54.5%) met risk criteria, 4488 (32.3%) completed testing, and 7 (0.16%) were newly diagnosed; and of the traditional targeted group, 7099 participants (27.7%) met risk criteria, 3173 (44.7%) completed testing, and 7 (0.22%) were newly diagnosed', 'patients visiting EDs at 4 US urban hospitals between April 2014 and January 2016', 'Emergency Department', 'A total of 76\u202f561 patient visits were randomized; median (interquartile range) age was 40 (28-54) years, 34\u202f807 patients (51.2%) were women, and 26\u202f776 (39.4%) were Black, 22\u202f131 (32.6%) non-Hispanic White, and 14\u202f542 (21.4%) Hispanic', 'Patients included were ages 16 years or older, not critically ill or mentally altered, not known to have an HIV positive status, and with an anticipated length of stay 30 minutes or longer']","['nontargeted screening, enhanced targeted screening using a quantitative HIV risk prediction tool, or traditional targeted screening as adapted from the Centers for Disease Control and Prevention', 'nontargeted screening; 25\u202f453, enhanced targeted screening; and 25\u202f639, traditional targeted screening', 'HIV Screening Strategies']","['Main Outcomes and Measures\n\n\nNew HIV diagnoses using intention-to-treat analysis, absolute differences, and risk ratios (RRs', 'rate of new diagnoses']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C4068886', 'cui_str': '0.15'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C4517431', 'cui_str': '0.16'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0020029', 'cui_str': 'Urban Hospitals'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439673', 'cui_str': 'Unknown'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0205166', 'cui_str': 'Long'}]","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0007670', 'cui_str': 'Centers for Disease Control and Prevention (U.S.)'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C2585997', 'cui_str': 'New diagnosis'}]",25469.0,0.447864,"When compared with nontargeted screening, targeted strategies were not associated with a higher rate of new diagnoses (enhanced targeted and traditional targeted combined: difference, -0.01%; 95% CI, -0.04% to 0.02%; RR, 0.7; 95% CI, 0.30 to 1.56; P = .38; and enhanced targeted only: difference, -0.01%; 95% CI, -0.04% to 0.02%; RR, 0.70; 95% CI, 0.27 to 1.84; P = .47). ","[{'ForeName': 'Jason S', 'Initials': 'JS', 'LastName': 'Haukoos', 'Affiliation': 'Department of Emergency Medicine, Denver Health Medical Center, Denver, Colorado.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Lyons', 'Affiliation': 'Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Rothman', 'Affiliation': 'Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Douglas A E', 'Initials': 'DAE', 'LastName': 'White', 'Affiliation': 'Department of Emergency Medicine, Highland Hospital, Oakland, California.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Hopkins', 'Affiliation': 'Department of Emergency Medicine, Denver Health Medical Center, Denver, Colorado.'}, {'ForeName': 'Meggan', 'Initials': 'M', 'LastName': 'Bucossi', 'Affiliation': 'Department of Emergency Medicine, Denver Health Medical Center, Denver, Colorado.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Ruffner', 'Affiliation': 'Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Rachel M', 'Initials': 'RM', 'LastName': 'Ancona', 'Affiliation': 'Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Yu-Hsiang', 'Initials': 'YH', 'LastName': 'Hsieh', 'Affiliation': 'Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Peterson', 'Affiliation': 'Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Signer', 'Affiliation': 'Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Toerper', 'Affiliation': 'Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Mustapha', 'Initials': 'M', 'LastName': 'Saheed', 'Affiliation': 'Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Pfeil', 'Affiliation': 'Department of Emergency Medicine, Highland Hospital, Oakland, California.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Todorovic', 'Affiliation': 'Department of Emergency Medicine, Highland Hospital, Oakland, California.'}, {'ForeName': 'Alia A', 'Initials': 'AA', 'LastName': 'Al-Tayyib', 'Affiliation': 'Department of Epidemiology, Colorado School of Public Health, Aurora.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Bradley-Springer', 'Affiliation': 'Division of Infectious Diseases, University of Colorado School of Medicine, Aurora.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Campbell', 'Affiliation': 'Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado.'}, {'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Gardner', 'Affiliation': 'Denver Public Health, Denver, Colorado.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Rowan', 'Affiliation': 'Denver Public Health, Denver, Colorado.'}, {'ForeName': 'Allison L', 'Initials': 'AL', 'LastName': 'Sabel', 'Affiliation': 'Department of Patient Safety and Quality, Denver Health, Denver, Colorado.'}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Thrun', 'Affiliation': 'Denver Public Health, Denver, Colorado.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA network open,['10.1001/jamanetworkopen.2021.17763'] 1802,34312921,Gastric emptying time of two different quantities of clear fluids in children: A double-blinded randomized controlled study.,"BACKGROUND Perioperative pulmonary aspiration risk increases with increased preoperative gastric volume; hence traditionally, healthy children are kept fasted overnight before surgery. Current guidelines recommend 2-h clear fluids fasting prior to anesthesia. However, emerging evidence favors allowing 3 ml/kg clear fluids up to 1-h before anesthesia. We compared the gastric volume and gastric emptying time after ingestion of 3 ml/kg and 5 ml/kg of clear fluids. METHODS The present study enrolled 44 children, aged between 6 and 14 years. On the day of surgery, baseline gastric volume was estimated using ultrasound and patients were randomly allocated into two groups of equal number, that is, Group 3 and Group 5 (patients received 3 ml/kg and 5 ml/kg 5% Dextrose respectively). Repeated gastric ultrasound was performed at every 5 min until the gastric volume reached baseline levels. The primary objective of the study was to compare gastric emptying time. Secondary objectives included comparison of antral cross-sectional area and gastric volume. RESULTS The demographic profile, preoperative fasting duration for clear fluids, and baseline gastric volume were comparable between groups. In both groups, compared to baseline the antral cross-sectional area and gastric volume increased significantly following fluid ingestion and then decreased exponentially to reach baseline within 1-h. The median (IQR) (range) gastric emptying time (minutes) [35.0 (28.8, 40.0) (20.0-45.0) in group 3 and 40.0 (28.8, 45.0) (20.0-50.0) in group 5] and emptying half-time (minutes) [17.0 (15.7, 21.5) (14.4-24.0) in group 3 and 18.6 (16.0, 22.0) (15.1-23.8) in group 5] were comparable [median difference -5 (95% CI -7.8 to 2.1) and -1.5 (95% CI -2.3 to 1.0), respectively] (p = .16 and p = .44, respectively). CONCLUSION As the gastric volume returned to baseline within 1-h even after ingesting 5 ml/kg clear fluids, the preoperative fasting time can be reduced to 1-h and healthy children undergoing elective procedure can be safely allowed to drink up to 5 ml/kg clear fluids.",2021,"In both groups, compared to baseline the ACSA and gastric volume increased significantly following fluid ingestion and then decreased exponentially to reach baseline within 1-hour.","['healthy children', 'enrolled forty-four children, aged between 6 and 14 years', 'children']",[],"['gastric emptying time', 'median (IQR) (range)gastric emptying time', 'gastric volume and gastric emptying time', 'comparison of antral cross-sectional area (ACSA) and gastric volume', 'Gastric emptying time', 'ACSA and gastric volume', 'demographic profile, preoperative fasting duration for clear fluids and baseline gastric volume', 'baseline gastric volume']","[{'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],"[{'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0293352', 'cui_str': 'Antral'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0453847', 'cui_str': 'Clear fluid'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",44.0,0.0841257,"In both groups, compared to baseline the ACSA and gastric volume increased significantly following fluid ingestion and then decreased exponentially to reach baseline within 1-hour.","[{'ForeName': 'Sunny', 'Initials': 'S', 'LastName': 'Taye', 'Affiliation': 'Department of Anaesthesiology and Critical Care, AIIMS, Jodhpur, India.'}, {'ForeName': 'Sadik', 'Initials': 'S', 'LastName': 'Mohammed', 'Affiliation': 'Department of Anaesthesiology and Critical Care, AIIMS, Jodhpur, India.'}, {'ForeName': 'Pradeep', 'Initials': 'P', 'LastName': 'Bhatia', 'Affiliation': 'Department of Anaesthesiology and Critical Care, AIIMS, Jodhpur, India.'}, {'ForeName': 'Mritunjay', 'Initials': 'M', 'LastName': 'Kumar', 'Affiliation': 'Department of Anaesthesiology, Pain Medicine and Critical Care, AIIMS, New Delhi, India.'}, {'ForeName': 'Swati', 'Initials': 'S', 'LastName': 'Chhabra', 'Affiliation': 'Department of Anaesthesiology and Critical Care, AIIMS, Jodhpur, India.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Kumar', 'Affiliation': 'Department of Anaesthesiology and Critical Care, AIIMS, Jodhpur, India.'}, {'ForeName': 'Kamlesh', 'Initials': 'K', 'LastName': 'Kumari', 'Affiliation': 'Department of Anaesthesiology and Critical Care, AIIMS, Jodhpur, India.'}]",Paediatric anaesthesia,['10.1111/pan.14261'] 1803,34311206,Factors associated with obtaining employment among opioid use disorder patients enrolled in a therapeutic workplace intervention.,"BACKGROUND Unemployment is a common problem among adults who have substance use disorder that often persists during treatment and recovery. We identified patient characteristics that were associated with obtaining employment among unemployed adults in opioid use disorder treatment. METHODS This analysis used data from participants (N = 91) who were enrolled in a randomized controlled trial evaluating the effectiveness of a therapeutic workplace in promoting drug abstinence and employment. After a 3-month training period (Phase 1), participants were randomly assigned to a study group and could work for 12 months with an employment specialist who assisted participants in obtaining employment (Phase 2). A logistic regression model was used to identify patient characteristics that were associated with obtaining employment. RESULTS Of the 91 participants, 39 (42.9 %) obtained employment. Compared to participants who did not obtain employment, participants who obtained employment worked more days in the therapeutic workplace during the training period (Phase 1) [OR (95 % CI) = 1.072 (1.015-1.132), p = .014], provided more opiate- and cocaine-negative urine samples while seeking employment [OR (95 % CI) = 1.015 (1.002-1.027), p = .025], and reported not usually being unemployed at study intake [OR (95 % CI) = 0.229 (0.080-0.652), p = .007]. CONCLUSIONS Our analyses suggest that among unemployed adults in opioid use disorder treatment, those with the lowest rates of therapeutic workplace attendance, lowest rates of drug abstinence while seeking employment, and relatively long histories of unemployment are the least likely to obtain employment. These relations are potentially addressable at a practical level, and future research could build on these findings to improve the effectiveness of employment-based interventions.",2021,"Compared to participants who did not obtain employment, participants who obtained employment worked more days in the therapeutic workplace during the training period (Phase 1) [OR (95 % CI) = 1.072 (1.015-1.132), p = .014], provided more opiate- and cocaine-negative urine samples while seeking employment [OR (95 % CI) = 1.015 (1.002-1.027), p = .025], and reported not usually being unemployed at study intake [OR (95 % CI) = 0.229 (0.080-0.652), p = .007]. ","['participants (N\u2009=\u200991', 'adults who have substance use disorder', 'unemployed adults in opioid use disorder treatment']","['employment specialist who assisted participants in obtaining employment (Phase 2', 'therapeutic workplace intervention']",[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0041674', 'cui_str': 'Unemployed'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0628148,"Compared to participants who did not obtain employment, participants who obtained employment worked more days in the therapeutic workplace during the training period (Phase 1) [OR (95 % CI) = 1.072 (1.015-1.132), p = .014], provided more opiate- and cocaine-negative urine samples while seeking employment [OR (95 % CI) = 1.015 (1.002-1.027), p = .025], and reported not usually being unemployed at study intake [OR (95 % CI) = 0.229 (0.080-0.652), p = .007]. ","[{'ForeName': 'August F', 'Initials': 'AF', 'LastName': 'Holtyn', 'Affiliation': 'Johns Hopkins University School of Medicine, USA. Electronic address: aholtyn1@jhmi.edu.'}, {'ForeName': 'Forrest', 'Initials': 'F', 'LastName': 'Toegel', 'Affiliation': 'Johns Hopkins University School of Medicine, USA.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Novak', 'Affiliation': 'Johns Hopkins University School of Medicine, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Silverman', 'Affiliation': 'Johns Hopkins University School of Medicine, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2021.108907'] 1804,34311182,"Acupuncture, seizure frequency, and quality of life in temporal lobe epilepsy.","OBJECTIVE To assess seizure frequency and quality of life (QOL) in a group of adults with temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) before and after 10 weeks of systemic acupuncture sessions and compare the results with a group of patients with TLE-HS not undergoing acupuncture. METHODS The Quality of Life in Epilepsy Inventory (QOLIE-31) and the initial and final seizure frequency of 26 adult patients with TLE-HS who underwent acupuncture sessions for 10 consecutive weeks were assessed. The data were compared to those of 26 patients with TLE-HS not submitted to acupuncture, with p < 0.05. RESULTS There was a clinically significant effect in reducing the mean number of seizures per month in the follow-up period of patients submitted or not to acupuncture (no intervention group and intervention group, effect size: -0.94 and -1.01, respectively). In the last four weeks of follow-up, there was a significant difference between the no intervention and intervention groups (0.5 [0-2] and 0 [0-4]; p = 0.018). When using minimally important change (MIC) threshold data for the QOLIE-31 between the final and initial scores, with the Cantril Ladder Scale as anchoring, it was observed that, in the intervention group, large clinically significant effects were seen for all dimensions, except for cognitive function, medication effect, and social function, which presented medium effects. In the follow-up, the variation of the QOLIE-31 scores was positive for both groups; however, it was higher in all dimensions in the intervention group, indicating a better QOL. CONCLUSION There was a reduction in the mean number of seizures per month in all patients during the follow-up period. Acupuncture significantly reduced the number of seizures in the intervention group in the final phase of the study. QOL improvements occurred in all patients, however, more significantly in the intervention group.",2021,"There was a clinically significant effect in reducing the mean number of seizures per month in the follow-up period of patients submitted or not to acupuncture (no intervention group and intervention group, effect size:","['adults with temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) before and after 10\u202fweeks of', '26 adult patients with TLE-HS who underwent']","['acupuncture', 'systemic acupuncture sessions', 'acupuncture sessions', 'Acupuncture', 'TLE-HS not undergoing acupuncture']","['number of seizures', 'seizure frequency and quality of life (QOL', 'Quality of Life in Epilepsy Inventory (QOLIE-31', 'Acupuncture, seizure frequency, and quality of life in temporal lobe epilepsy', 'cognitive function, medication effect, and social function', 'Cantril Ladder Scale', 'mean number of seizures', 'QOL improvements', 'QOLIE-31 scores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0014556', 'cui_str': 'Temporal lobe epilepsy'}, {'cui': 'C1504404', 'cui_str': 'Hippocampal sclerosis'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0014556', 'cui_str': 'Temporal lobe epilepsy'}, {'cui': 'C1504404', 'cui_str': 'Hippocampal sclerosis'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0014556', 'cui_str': 'Temporal lobe epilepsy'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1319171', 'cui_str': 'Medication response'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0336762', 'cui_str': 'Ladder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",26.0,0.0583175,"There was a clinically significant effect in reducing the mean number of seizures per month in the follow-up period of patients submitted or not to acupuncture (no intervention group and intervention group, effect size:","[{'ForeName': 'Gilvano Amorim', 'Initials': 'GA', 'LastName': 'Oliveira', 'Affiliation': 'Health Sciences, Centro de Ciência da Vida, Pontifical Catholic University of Campinas, Campinas, SP, Brazil. Electronic address: gilvano.oliveira@puc-campinas.edu.br.'}, {'ForeName': 'Gloria M A S', 'Initials': 'GMAS', 'LastName': 'Tedrus', 'Affiliation': 'The Health Sciences Program, Centro de Ciência da Vida, Pontifical Catholic University of Campinas, Campinas, SP, Brazil.'}, {'ForeName': 'Luciana Bertoldi', 'Initials': 'LB', 'LastName': 'Nucci', 'Affiliation': 'The Health Sciences Program, Centro de Ciência da Vida, Pontifical Catholic University of Campinas, Campinas, SP, Brazil.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2021.108213'] 1805,34310694,Handling oxygenation targets in ICU patients with COVID-19-Protocol and statistical analysis plan in the HOT-COVID trial.,"BACKGROUND Coronavirus disease (COVID-19) primarily affects the lungs and lower airways and may present as hypoxaemic respiratory failure requiring admission to an intensive care unit (ICU) for supportive treatment. Here, supplemental oxygen remains essential for COVID-19 patient management, but the optimal dosage is not defined. We hypothesize that targeting an arterial partial pressure of oxygen of 8 kPa throughout ICU admission is superior to targeting 12 kPa. METHODS The Handling Oxygenation Targets in ICU patients with COVID-19 (HOT-COVID) trial, is an investigator-initiated, pragmatic, multicentre, randomized, parallel-group trial comparing a lower oxygenation target versus a higher oxygenation target in adult ICU patients with COVID-19. The primary outcome is days alive without life-support (use of mechanical ventilation, renal replacement therapy or vasoactive therapy) at day 90. Secondary outcomes are 90-day and 1-year mortality, serious adverse events in the ICU and days alive and out of hospital in the 90-day period, health-related quality-of-life at 1 year, and health economic analyses. One-year follow-up of cognitive and pulmonary function is planned in a subgroup of Danish patients. We will include 780 patients to detect or reject an absolute increase in days alive without life-support of 7 days with an α of 5% and a β of 20%. An interim analysis is planned after 90-day follow-up of 390 patients. CONCLUSIONS The HOT-COVID trial will provide patient-important data on the effect of two oxygenation targets in ICU patients with COVID-19 and hypoxia. This protocol paper describes the background, design and statistical analysis plan for the trial.",2021,"Secondary outcomes are 90-day and 1-year mortality, serious adverse events in the ICU and days alive and out of hospital in the 90-day period, health-related quality-of-life at 1 year, and health economic analyses.","['ICU patients with COVID-19 and hypoxia', 'ICU patients with COVID-19 - protocol and statistical analysis plan in the HOT-COVID trial', 'ICU patients with COVID-19 (HOT-COVID) trial', 'adult ICU patients with COVID-19', '390 patients', '780 patients to detect or reject an absolute increase in days alive without life-support of seven days with an α of 5% and a β of 20']",[],"['days alive without life-support (use of mechanical ventilation, renal replacement therapy, or vasoactive therapy', '90-day and 1-year mortality, serious adverse events in the ICU and days alive and out of hospital in the 90-day period, health-related quality-of-life at 1 year, and health economic analyses']","[{'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0018578', 'cui_str': 'Handling (Psychology)'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0587445', 'cui_str': 'Adult intensive care unit'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C4319517', 'cui_str': 'Order rejected'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0521300', 'cui_str': 'Life support procedure'}, {'cui': 'C0205453', 'cui_str': '7'}]",[],"[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0521300', 'cui_str': 'Life support procedure'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0013560', 'cui_str': 'Medical Economics'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",780.0,0.273885,"Secondary outcomes are 90-day and 1-year mortality, serious adverse events in the ICU and days alive and out of hospital in the 90-day period, health-related quality-of-life at 1 year, and health economic analyses.","[{'ForeName': 'Frederik', 'Initials': 'F', 'LastName': 'Mølgaard Nielsen', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lass Klitgaard', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Crescioli', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Rosborg Aagaard', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Anne Sofie', 'Initials': 'AS', 'LastName': 'Andreasen', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Herlev Hospital, Herlev, Denmark.'}, {'ForeName': 'Lone', 'Initials': 'L', 'LastName': 'Musaeus Poulsen', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Zealand University Hospital, Køge, Denmark.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Siegemund', 'Affiliation': 'Department of Intensive Care, Basel University Hospital, Basel, Switzerland.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Craveiro Brøchner', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Kolding Hospital, Kolding, Denmark.'}, {'ForeName': 'Morten H', 'Initials': 'MH', 'LastName': 'Bestle', 'Affiliation': 'Collaboration for Research in Intensive Care (CRIC, Copenhagen, Denmark.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Andi Iversen', 'Affiliation': 'Department of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Björn A', 'Initials': 'BA', 'LastName': 'Brand', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Oslo University Hospital, Rikshospitalet, Norway.'}, {'ForeName': 'Jon Henrik', 'Initials': 'JH', 'LastName': 'Laake', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Randers Hospital, Randers, Denmark.'}, {'ForeName': 'Thorbjørn', 'Initials': 'T', 'LastName': 'Grøfte', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hildebrandt', 'Affiliation': 'Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Theis', 'Initials': 'T', 'LastName': 'Lange', 'Affiliation': 'Collaboration for Research in Intensive Care (CRIC, Copenhagen, Denmark.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Perner', 'Affiliation': 'Collaboration for Research in Intensive Care (CRIC, Copenhagen, Denmark.'}, {'ForeName': 'Olav', 'Initials': 'O', 'LastName': 'Lilleholt Schjørring', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Bodil', 'Initials': 'B', 'LastName': 'Steen Rasmussen', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13956'] 1806,34314856,Assessing the impact of medically tailored meals and medical nutrition therapy on type 2 diabetes: Protocol for Project MiNT.,"BACKGROUND Research has shown that among people with type 2 diabetes mellitus, reduction in hemoglobin A1c (HbA1c) prevents long term complications. Medically tailored meals (MTM) and telehealth-delivered medical nutrition therapy (tele-MNT) are promising strategies for patient-centered diabetes care. OBJECTIVES Project MiNT will determine whether provision of MTM with and without the addition of telehealth-delivered medical nutrition therapy improves HbA1c and is cost effective for patients with type 2 diabetes mellitus. METHODS Patients with poorly controlled type 2 diabetes mellitus (HbA1c >8%) will be recruited from Jefferson Health. Eligible patients will be randomized to one of three arms: 1) usual care, 2) 12 weeks of home-delivered MTM, or 3) MTM + 12 months of tele-MNT. All participants (n = 600) will complete three follow-up assessments at 3, 6, and 12 months. The primary outcome is change in HbA1c at 6 months. Secondary outcomes include change in HbA1c at 3 and 12 months and cost-effectiveness of the intervention at 6 and 12 months. Conclusion Findings from Project MiNT will inform MTM coverage and financing decisions, how to structure services for scalability and system-wide integration, and the role of these services in reducing health disparities.",2021,"Medically tailored meals (MTM) and telehealth-delivered medical nutrition therapy (tele-MNT) are promising strategies for patient-centered diabetes care. ","['type 2 diabetes', 'Patients with poorly controlled type 2 diabetes mellitus (HbA1c >8%) will be recruited from Jefferson Health', 'people with type 2 diabetes mellitus', 'patients with type 2 diabetes mellitus', 'Eligible patients']","['medically tailored meals and medical nutrition therapy', 'Medically tailored meals (MTM) and telehealth-delivered medical nutrition therapy (tele-MNT', 'usual care, 2) 12\u202fweeks of home-delivered MTM, or 3) MTM\u202f+\u202f12\u202fmonths of tele-MNT']","['change in HbA1c at 3 and 12\u202fmonths and cost-effectiveness', 'change in HbA1c at 6\u202fmonths']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C1257928', 'cui_str': 'Medical Nutrition Therapy'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",600.0,0.0547855,"Medically tailored meals (MTM) and telehealth-delivered medical nutrition therapy (tele-MNT) are promising strategies for patient-centered diabetes care. ","[{'ForeName': 'Kristin L', 'Initials': 'KL', 'LastName': 'Rising', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut Street, Suite 300, Philadelphia, PA 19107, USA; Center for Connected Care, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Walnut St, Suite 704, Philadelphia, PA 19107, USA; College of Nursing, Thomas Jefferson University, 901 Walnut Street, Philadelphia, PA 19107, USA. Electronic address: Kristin.rising@jefferson.edu.'}, {'ForeName': 'Mackenzie', 'Initials': 'M', 'LastName': 'Kemp', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut Street, Suite 300, Philadelphia, PA 19107, USA; Center for Connected Care, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Walnut St, Suite 704, Philadelphia, PA 19107, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Davidson', 'Affiliation': 'College of Health Sciences, Nutrition Department, West Chester University, 855 South New Street, West Chester, PA 19383, USA.'}, {'ForeName': 'Judd E', 'Initials': 'JE', 'LastName': 'Hollander', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut Street, Suite 300, Philadelphia, PA 19107, USA; Center for Connected Care, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Walnut St, Suite 704, Philadelphia, PA 19107, USA.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Jabbour', 'Affiliation': 'Department of Endocrinology, Sidney Kimmel Medical College, Thomas Jefferson University, 211 S 9(th) St, Unit 600, Philadelphia, PA 19107, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Jutkowitz', 'Affiliation': 'Department of Health Services, Policy & Practice, Brown University School of Public Health, 121 South Main Street, Providence, RI 02912, USA; Providence Veterans Affairs (VA) Medical Center, Center of Innovation in Long Term Services and Supports, 830 Chalkstone Avenue, Providence, RI 02908, USA.'}, {'ForeName': 'Benjamin E', 'Initials': 'BE', 'LastName': 'Leiby', 'Affiliation': 'Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Chestnut Street, Suite 401, Philadelphia, PA 19107, USA.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Marco', 'Affiliation': 'Department of Endocrinology, Sidney Kimmel Medical College, Thomas Jefferson University, 211 S 9(th) St, Unit 600, Philadelphia, PA 19107, USA.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'McElwee', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut Street, Suite 300, Philadelphia, PA 19107, USA.'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Mills', 'Affiliation': 'Department of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Walnut Street, Suite 401, Philadelphia, PA 19107, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pizzi', 'Affiliation': 'Center for Health Outcomes, Policy, & Economics, Rutgers University, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.'}, {'ForeName': 'Rhea E', 'Initials': 'RE', 'LastName': 'Powell', 'Affiliation': 'Division of Internal Medicine, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 833 Chestnut Street, Suite 701, Philadelphia, PA 19107, USA; Mathematica, 600 Alexander Park, Suite 100, Princeton, NJ 08543, USA.'}, {'ForeName': 'Anna Marie', 'Initials': 'AM', 'LastName': 'Chang', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut Street, Suite 300, Philadelphia, PA 19107, USA; Center for Connected Care, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Walnut St, Suite 704, Philadelphia, PA 19107, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106511'] 1807,34321133,Awareness of and reactions to health and environmental harms of red meat among parents in the United States.,"OBJECTIVE Evidence of the health and environmental harms of red meat is growing, yet little is known about which harms may be most impactful to include in meat reduction messages. This study examined which harms consumers are most aware of and which most discourage them from wanting to eat red meat. DESIGN Within-subjects randomised experiment. Participants responded to questions about their awareness of, and perceived discouragement in response to, eight health and eight environmental harms of red meat presented in random order. Discouragement was assessed on a 1-to-5 Likert-type scale. SETTING Online survey. PARTICIPANTS 544 US parents. RESULTS A minority of participants reported awareness that red meat contributes to health harms (ranging from 8 % awareness for prostate cancer to 28 % for heart disease) or environmental harms (ranging from 13 % for water shortages and deforestation to 22 % for climate change). Among specific harms, heart disease elicited the most discouragement (mean = 2·82 out of 5), followed by early death (mean = 2·79) and plants and animals going extinct (mean = 2·75), though most harms elicited similar discouragement (range of means, 2·60-2·82). In multivariable analyses, participants who were younger, identified as Black, identified as politically liberal, had higher general perceptions that red meat is bad for health and had higher usual red meat consumption reported being more discouraged from wanting to eat red meat in response to health and environmental harms (all P < 0·05). CONCLUSIONS Messages about a variety of health and environmental harms of red meat could inform consumers and motivate reductions in red meat consumption.",2021,"In multivariable analyses, participants who were younger, identified as Black, identified as politically liberal, had higher general perceptions that red meat is bad for health, and had higher usual red meat consumption reported being more discouraged from wanting to eat red meat in response to health and environmental harms (all p<0.05). ","['parents in the United States', '544 US parents']",[],[],"[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C1301808', 'cui_str': 'State'}]",[],[],544.0,0.0754438,"In multivariable analyses, participants who were younger, identified as Black, identified as politically liberal, had higher general perceptions that red meat is bad for health, and had higher usual red meat consumption reported being more discouraged from wanting to eat red meat in response to health and environmental harms (all p<0.05). ","[{'ForeName': 'Anna H', 'Initials': 'AH', 'LastName': 'Grummon', 'Affiliation': 'Harvard Center for Population and Development Studies, Harvard TH Chan School of Public Health, Cambridge, MA, USA.'}, {'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Goodman', 'Affiliation': 'Department of Global Health, Harvard TH Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Lindsay M', 'Initials': 'LM', 'LastName': 'Jaacks', 'Affiliation': 'Global Academy of Agriculture and Food Security, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Lindsey Smith', 'Initials': 'LS', 'LastName': 'Taillie', 'Affiliation': 'Department of Nutrition, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.'}, {'ForeName': 'Christina A', 'Initials': 'CA', 'LastName': 'Chauvenet', 'Affiliation': 'Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.'}, {'ForeName': 'Meg G', 'Initials': 'MG', 'LastName': 'Salvia', 'Affiliation': 'Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Eric B', 'Initials': 'EB', 'LastName': 'Rimm', 'Affiliation': 'Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA.'}]",Public health nutrition,['10.1017/S1368980021003098'] 1808,34326299,"Effect of Transcranial Direct Current Stimulation on Walking Speed, Functional Strength, and Balance in Older Adults: A Randomized, Double-Blind Controlled Trial.","BACKGROUND The purpose of this study was to investigate the immediate effect of transcranial direct current stimulation (tDCS) on walking speed, functional strength of lower limbs, and balance in healthy older adults. Through this study, we intend to introduce a new method to improve the physical function of older adults. MATERIAL AND METHODS This was a randomized, controlled, double-blind study in which participants and evaluators were blinded. Among 57 healthy adults (aged 65 years or older), 31 underwent tDCS, while 26 received sham stimulation. For the pre-test, participants performed a 10-meter walk test, functional strength test of lower limbs, and static and dynamic balance tests. Next, the primary motor cortex area was subjected to tDCS for 20 min. Tests were repeated as post-tests. RESULTS There were significant differences in group-by-time interaction for 10-meter walk speed, functional strength of lower limbs, and static balance on the left side (P<0.05). There was not a significant group-by-time interaction for dynamic and static balance on the right side (P>0.05). There were significant differences in the main effect of time for 10-meter walk speed, functional strength of lower limbs, static balance on the right side, and dynamic balance (P<0.05). CONCLUSIONS Results showed tDCS was effective in improving gait and functional strength of the lower limbs in older adults. We recommend tDCS as a safe and effective way to improve motor performance and increase physical function, including walking and functional strength of lower limbs, in older adults.",2021,"There were significant differences in group-by-time interaction for 10-meter walk speed, functional strength of lower limbs, and static balance on the left side (P<0.05).","['healthy older adults', '57 healthy adults (aged 65 years or older), 31 underwent tDCS, while 26 received sham stimulation', 'older adults', 'Older Adults']","['transcranial direct current stimulation (tDCS', 'tDCS', 'Transcranial Direct Current Stimulation']","['10-meter walk test, functional strength test of lower limbs, and static and dynamic balance tests', 'walking speed, functional strength of lower limbs, and balance', 'Walking Speed, Functional Strength, and Balance', 'gait and functional strength', '10-meter walk speed, functional strength of lower limbs, and static balance on the left side', 'motor performance and increase physical function, including walking and functional strength of lower limbs', 'main effect of time for 10-meter walk speed, functional strength of lower limbs, static balance on the right side, and dynamic balance']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205090', 'cui_str': 'Right'}]",57.0,0.134094,"There were significant differences in group-by-time interaction for 10-meter walk speed, functional strength of lower limbs, and static balance on the left side (P<0.05).","[{'ForeName': 'Donghyun', 'Initials': 'D', 'LastName': 'Yi', 'Affiliation': 'Department of Physical Therapy, Graduate School of Sahmyook University, Seoul, South Korea.'}, {'ForeName': 'YuJung', 'Initials': 'Y', 'LastName': 'Sung', 'Affiliation': 'Department of Physical Therapy, Graduate School of Sahmyook University, Seoul, South Korea.'}, {'ForeName': 'JongEun', 'Initials': 'J', 'LastName': 'Yim', 'Affiliation': 'Department of Physical Therapy, Sahmyook University, Seoul, South Korea.'}]",Medical science monitor : international medical journal of experimental and clinical research,['10.12659/MSM.932623'] 1809,34326283,Poorer Muscle Quality and Quantity with ART Initiation is Associated with Greater Inflammation and Immune Activation.,"BACKGROUND We have previously shown that initiation of antiretroviral therapy (ART) is associated with a decrease in skeletal muscle density (greater fat accumulation), suggesting that gains in lean body mass seen in many ART studies may reflect gains in low quality, fatty muscle. Here we explore whether skeletal muscle density and area are associated with markers of inflammation and immune activation. METHODS ART-naïve PWH were randomized to raltegravir or ritonavir-boosted atazanavir or darunavir, each with tenofovir disoproxil fumarate/emtricitabine. Abdominal Computed Tomography (CT) scans from baseline and week 96 were re-analyzed for psoas density and area and correlations explored with inflammation (IL-6, hs-CRP) and immune activation (sCD14, sCD163, %CD38+HLADR+ on CD4+ or CD8+ T-cells). RESULTS 222 participants had available inflammation/immune activation markers and paired CT scans. At baseline, lower psoas density (greater fat) correlated with higher IL-6 (r -0.26, p<0.001) and sCD163 (r -0.15, p=0.03) and lower lean psoas area correlated with higher IL-6, hs-CRP, sCD14, sCD163, and %CD38+HLADR+ on CD4+ T-cells (r= -0.30 to 0.13); all p≤0.05). From baseline to week 96, greater % decrease in total psoas density (more fat) correlated with greater increase in IL-6 (r -0.14; p=0.04); greater % decrease in lean psoas area correlated greater increases in IL-6, sCD14, sCD163, and %CD38+HLADR+ on CD8+ T-cells (r -0.15 to -0.18; all p<0.04). CONCLUSIONS Greater fat infiltration within the psoas muscle (lower density) and greater loss in lean psoas muscle area were associated with higher inflammation and immune activation, which may portend important effects on muscle function and cardiometabolic risk.",2021,"At baseline, lower psoas density (greater fat) correlated with higher IL-6 (r -0.26, p<0.001) and sCD163 (r -0.15, p=0.03) and lower lean psoas area correlated with higher IL-6, hs-CRP, sCD14, sCD163, and %CD38+HLADR+ on CD4+ T-cells (","['ART-naïve PWH', '222 participants had available inflammation/immune activation markers and paired CT scans']","['antiretroviral therapy (ART', 'raltegravir or ritonavir-boosted atazanavir or darunavir, each with tenofovir disoproxil fumarate/emtricitabine', 'Abdominal Computed Tomography (CT) scans']","['IL-6', 'sCD163', 'total psoas density', 'Poorer Muscle Quality and Quantity with ART Initiation', 'IL-6, sCD14, sCD163, and %CD38+HLADR+ on CD8+ T-cells', 'lower psoas density', 'lean psoas area', 'lower lean psoas area correlated with higher IL-6, hs-CRP, sCD14, sCD163, and %CD38+HLADR+ on CD4+ T-cells ']","[{'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}]","[{'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C1871526', 'cui_str': 'raltegravir'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C1145759', 'cui_str': 'Atazanavir'}, {'cui': 'C1435444', 'cui_str': 'darunavir'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}]",222.0,0.0865034,"At baseline, lower psoas density (greater fat) correlated with higher IL-6 (r -0.26, p<0.001) and sCD163 (r -0.15, p=0.03) and lower lean psoas area correlated with higher IL-6, hs-CRP, sCD14, sCD163, and %CD38+HLADR+ on CD4+ T-cells (","[{'ForeName': 'Arianna', 'Initials': 'A', 'LastName': 'Kousari', 'Affiliation': 'University of Colorado Anschutz Medical Campus; Aurora, CO Harvard T.H. Chan School of Public Health; Boston, MA Johns Hopkins; Baltimore, MD University of California Los Angeles; Los Angeles, CA Case Western Reserve; Cleveland, OH University of Wisconsin; Madison, WI University of Texas Houston; Houston, TX.'}, {'ForeName': 'Carlee', 'Initials': 'C', 'LastName': 'Moser', 'Affiliation': ''}, {'ForeName': 'Maxine', 'Initials': 'M', 'LastName': 'Olefsky', 'Affiliation': ''}, {'ForeName': 'Todd T', 'Initials': 'TT', 'LastName': 'Brown', 'Affiliation': ''}, {'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Currier', 'Affiliation': ''}, {'ForeName': 'Grace A', 'Initials': 'GA', 'LastName': 'McComsey', 'Affiliation': ''}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Scherzinger', 'Affiliation': ''}, {'ForeName': 'James H', 'Initials': 'JH', 'LastName': 'Stein', 'Affiliation': ''}, {'ForeName': 'Jordan E', 'Initials': 'JE', 'LastName': 'Lake', 'Affiliation': ''}, {'ForeName': 'Kristine M', 'Initials': 'KM', 'LastName': 'Erlandson', 'Affiliation': ''}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002776'] 1810,34325186,The effect of erector spinae plane block on postoperative analgesia and respiratory function in patients undergoing laparoscopic cholecystectomy: A double-blind randomized controlled trial.,"STUDY OBJECTIVE Laparoscopic cholecystectomy (LC) causes moderate-to-severe postoperative pain. Postoperative pain is one of the leading contributors to respiratory dysfunction following surgery. This study investigated the effect of erector spinae plane (ESP) block on postoperative analgesia and respiratory function in patients undergoing LC. DESIGN Prospective, randomized, controlled trial. SETTING University of Health Science. PATIENTS Sixty-eight adult patients undergoing LC. INTERVENTIONS Both groups received a standardized analgesia protocol. Patients assigned to the ESP block group received an additional bilateral ESP block. MEASUREMENTS The primary outcome was assessed as postoperative pain intensity associated with a lower opioid requirement and significant respiratory function improvement. MAIN RESULTS Numerical rating scale (NRS) scores both at rest and during coughing were significantly lower in the ESP block group than in the control group at all time intervals (p < 0.001 in each) except for hour 2 postoperatively (p = 0.06 and p = 0.13, respectively). Tramadol consumption at 2 h and 24 h postoperatively was significantly lower in the ESP block group than in the controls (p < 0.001 for each). There was significant preservation in forced expiratory volume in the first second (FEV 1 ) and forced vital capacity (FVC) in the ESP group in comparison to the control group at 2 and 24 h after surgery (p < 0.05 in each). FEV 1 /FVC and peak expiratory flow rate (PEFR) values were similar in each time interval. CONCLUSIONS Bilateral ESP blocks provides adequate analgesia, allowing for a lower opioid requirement and significant respiratory function improvement after LC; therefore, we concluded that ESP block could be added to the multimodal analgesia protocol in LC.",2021,Tramadol consumption at 2 h and 24 h postoperatively was significantly lower in the ESP block group than in the controls (p < 0.001 for each).,"['patients undergoing LC', 'University of Health Science', 'Sixty-eight adult patients undergoing LC', 'patients undergoing laparoscopic cholecystectomy']","['erector spinae plane (ESP) block', 'ESP block', 'Laparoscopic cholecystectomy (LC', 'standardized analgesia protocol', 'erector spinae plane block', 'additional bilateral ESP block']","['Tramadol consumption', 'Postoperative pain', 'postoperative pain intensity associated with a lower opioid requirement and significant respiratory function improvement', 'postoperative analgesia and respiratory function', 'FEV 1 /FVC and peak expiratory flow rate (PEFR) values', 'forced expiratory volume in the first second (FEV 1 ) and forced vital capacity (FVC', 'Numerical rating scale (NRS) scores both at rest and during coughing']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}]","[{'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0042834', 'cui_str': 'Vital capacity'}, {'cui': 'C0030735', 'cui_str': 'Peak expiratory flow rate'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}]",68.0,0.314843,Tramadol consumption at 2 h and 24 h postoperatively was significantly lower in the ESP block group than in the controls (p < 0.001 for each).,"[{'ForeName': 'Munise', 'Initials': 'M', 'LastName': 'Yildiz', 'Affiliation': 'University of Health Science, Konya City Hospital, Department of Anesthesiology and Reanimation, Konya, Turkey. Electronic address: drmunise@hotmail.com.'}, {'ForeName': 'Betul', 'Initials': 'B', 'LastName': 'Kozanhan', 'Affiliation': 'University of Health Science, Konya City Hospital, Department of Anesthesiology and Reanimation, Konya, Turkey.'}, {'ForeName': 'Mehmet S', 'Initials': 'MS', 'LastName': 'Iyisoy', 'Affiliation': 'Necmettin Erbakan University, Department of Medical Education and Informatics, Konya, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Canıtez', 'Affiliation': 'Abdulkadir Yuksel City Hospital, Department of Anesthesiology and Reanimation, Gaziantep, Turkey.'}, {'ForeName': 'Nergis', 'Initials': 'N', 'LastName': 'Aksoy', 'Affiliation': 'University of Health Science, Konya City Hospital, Department of General Surgery, Konya, Turkey.'}, {'ForeName': 'Aysenur', 'Initials': 'A', 'LastName': 'Eryigit', 'Affiliation': 'University of Health Science, Konya City Hospital, Department of Anesthesiology and Reanimation, Konya, Turkey.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110403'] 1811,34304826,Effect of high-intensity interval training in adolescents with asthma: The eXercise for Asthma with Commando Joe's® (X4ACJ) trial.,"BACKGROUND Higher levels of cardiorespiratory fitness are associated with reduced asthma severity and increased quality of life in those with asthma. Therefore, the purpose of this study was to evaluate the effectiveness of a 6-month high-intensity interval training (HIIT) intervention in adolescents with and without asthma. METHODS A total of 616 adolescents (334 boys; 13.0 ± 1.1 years, 1.57 ± 0.10 m, 52.6 ± 12.9 kg, mean ± SD), including 155 with asthma (78 boys), were recruited as part of a randomized controlled trial from 5 schools (4 control and 1 intervention). The 221 intervention participants (116 boys; 47 asthma) completed 6 months of school-based HIIT (30 min, 3 times per week, 10-30 s bouts at >90% age-predicted maximum heart rate with equal rest). At baseline, mid-intervention, post-intervention, and 3-month follow-up, measurements for 20-m shuttle run, body mass index (BMI), lung function, Pediatric Quality of Life Inventory, Paediatric Asthma Quality of Life Questionnaire, and Asthma Control Questionnaire were collected. Additionally, 69 adolescents (39 boys (of the 36 with asthma there were 21 boys)) also completed an incremental ramp test. For analysis, each group's data (intervention and control) were divided into those with and without asthma. RESULTS Participants with asthma did not differ from their peers in any parameter of aerobic fitness, at any time-point, but were characterized by a greater BMI. The intervention elicited a significant improvement in maximal aerobic fitness but no change in sub-maximal parameters of aerobic fitness, lung function, or quality of life irrespective of asthma status. Those in the intervention group maintained their BMI, whereas BMI significantly increased in the control group throughout the 6-month period. CONCLUSION HIIT represents an effective tool for improving aerobic fitness and maintaining BMI in adolescents, irrespective of asthma status. HIIT was well-tolerated by those with asthma, who evidenced a similar aerobic fitness to their healthy peers and responded equally well to a HIIT program.",2021,"The intervention elicited a significant improvement in maximal aerobic fitness but no change in sub-maximal parameters of aerobic fitness, lung function, or quality of life irrespective of asthma status.","['adolescents with asthma', '69 adolescents (39 boys (of the 36 with asthma there were 21 boys)) also completed an incremental ramp test', '221 intervention participants (116 boys; 47 asthma', 'A total of 616 adolescents (334 boys; 13.0 ± 1.1 years, 1.57 ± 0.10 m, 52.6 ± 12.9 kg, mean ± SD), including 155 with asthma (78 boys', 'adolescents with and without asthma']","['high-intensity interval training', '6-month high-intensity interval training (HIIT) intervention']","['aerobic fitness, lung function, or quality of life irrespective of asthma status', 'maximal aerobic fitness', 'aerobic fitness and maintaining BMI', 'BMI', '20-m shuttle run, body mass index (BMI), lung function, Pediatric Quality of Life Inventory, Paediatric Asthma Quality of Life Questionnaire, and Asthma Control Questionnaire', 'quality of life']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034646', 'cui_str': 'Ramp'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517729', 'cui_str': '334'}, {'cui': 'C4517491', 'cui_str': '1.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}]",616.0,0.0470507,"The intervention elicited a significant improvement in maximal aerobic fitness but no change in sub-maximal parameters of aerobic fitness, lung function, or quality of life irrespective of asthma status.","[{'ForeName': 'Charles O N', 'Initials': 'CON', 'LastName': 'Winn', 'Affiliation': 'Swansea University Medical School, Singleton Campus, Swansea University, Swansea SA2 8PP, UK; Applied Sports Technology, Exercise and Medicine (A-STEM) Research Centre, College of Engineering, Bay Campus, Swansea University, Swansea SA1 8EN, UK.'}, {'ForeName': 'Kelly A', 'Initials': 'KA', 'LastName': 'Mackintosh', 'Affiliation': 'Applied Sports Technology, Exercise and Medicine (A-STEM) Research Centre, College of Engineering, Bay Campus, Swansea University, Swansea SA1 8EN, UK.'}, {'ForeName': 'William T B', 'Initials': 'WTB', 'LastName': 'Eddolls', 'Affiliation': 'Applied Sports Technology, Exercise and Medicine (A-STEM) Research Centre, College of Engineering, Bay Campus, Swansea University, Swansea SA1 8EN, UK.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Stratton', 'Affiliation': 'Applied Sports Technology, Exercise and Medicine (A-STEM) Research Centre, College of Engineering, Bay Campus, Swansea University, Swansea SA1 8EN, UK.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Wilson', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, England NR4 7TJ, UK.'}, {'ForeName': 'Melitta A', 'Initials': 'MA', 'LastName': 'McNarry', 'Affiliation': 'Applied Sports Technology, Exercise and Medicine (A-STEM) Research Centre, College of Engineering, Bay Campus, Swansea University, Swansea SA1 8EN, UK. Electronic address: m.mcnarry@swansea.ac.uk.'}, {'ForeName': 'Gwyneth A', 'Initials': 'GA', 'LastName': 'Davies', 'Affiliation': 'Swansea University Medical School, Singleton Campus, Swansea University, Swansea SA2 8PP, UK. Electronic address: gwyneth.davies@swansea.ac.uk.'}]",Journal of sport and health science,['10.1016/j.jshs.2019.05.009'] 1812,34304301,"Effectiveness of Pelargonium sidoides in pediatric patients diagnosed with uncomplicated upper respiratory tract infection: a single-blind, randomized, placebo-controlled study.","Upper respiratory tract infections (URTIs) are a condition characterized by upper airway inflammation often caused by viruses in humans. The present study aimed to assess the effectiveness of the liquid herbal drug preparation from the root extracts of Pelargonium sidoides in improving symptoms of uncomplicated URTIs. One hundred sixty-four patients with URTI were randomized and given either verum containing the root extracts of Pelargonium sidoides (n = 82) or a matching placebo (n = 82) in a single-blind manner for 7 days. The median total scores of all symptoms (TSS) showed a significant decreasing trend in the group treated with the root extracts derived from Pelargonium sidoides compared to the placebo group from day 0 to day 7 (TSS significantly decreased by 0.85 points in the root extract group compared to a decrease of 0.62 points, p = 0.018). ""Cough frequency"" showed a significant improvement from day 0 to day 3 (p = 0.023). There was also detected a significant recovery in ""sneezing"" on day 3 via Brunner-Langer model, and it was detected that the extract administration given in the first 24 h onset of the symptoms had provided a significant improvement in day 0 to day 3 (difference of TSS 0.18 point, p = 0.011).Conclusion: The findings of the study revealed that the Pelargonium sidoides extracts are effective in relieving the symptom burden in the duration of the disease. It may be regarded as an alternative option for the management of URTIs. What is Known: • Upper respiratory tract infections (URTIs), an inflammation on the upper airways, are the most common infectious disease in children. • Pelargonium sidoides, a traditional medicinal plant native to South Africa, is one of the ornamental geraniums that is thought to be effective in treating URTIs What is New: • It may be revealed that the dried root extract of Pelargonium sidoides compared with placebo might be an alternative treatment in improving the symptoms such as dry cough, sneezing, and relieving cough frequency. • The administration of the root extract at the onset of URTIs' signs may be regarded as an adjunctive option for the management of URTIs due to its effectiveness in decreasing the symptom burden of the disease.",2021,The median total scores of all symptoms (TSS) showed a significant decreasing trend in the group treated with the root extracts derived from Pelargonium sidoides compared to the placebo group from day 0 to day 7,"['One hundred sixty-four patients with URTI', 'children', 'pediatric patients diagnosed with uncomplicated upper respiratory tract infection']","['verum containing the root extracts of Pelargonium sidoides (n\u2009=\u200982) or a matching placebo', 'placebo', 'Pelargonium sidoides']","['sneezing', 'median total scores of all symptoms (TSS', 'Cough frequency']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}]","[{'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0330888', 'cui_str': 'Pelargonium'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0037383', 'cui_str': 'Sneezing'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",164.0,0.0274774,The median total scores of all symptoms (TSS) showed a significant decreasing trend in the group treated with the root extracts derived from Pelargonium sidoides compared to the placebo group from day 0 to day 7,"[{'ForeName': 'Şule', 'Initials': 'Ş', 'LastName': 'Gökçe', 'Affiliation': ""Department of General Pediatrics, Faculty of Medicine, Childrens' Hospital, Ege University, Bornova, Izmir, Turkey. sule.gokce@yahoo.com.""}, {'ForeName': 'Burçe Emine', 'Initials': 'BE', 'LastName': 'Dörtkardeşler', 'Affiliation': ""Department of General Pediatrics, Faculty of Medicine, Childrens' Hospital, Ege University, Bornova, Izmir, Turkey.""}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Yurtseven', 'Affiliation': ""Department of Pediatric Emergency, Faculty of Medicine, Childrens' Hospital, Ege University, Bornova, Izmir, Turkey.""}, {'ForeName': 'Zafer', 'Initials': 'Z', 'LastName': 'Kurugöl', 'Affiliation': ""Department of Pediatric Infection, Faculty of Medicine, Childrens' Hospital, Ege University, Bornova, Izmir, Turkey.""}]",European journal of pediatrics,['10.1007/s00431-021-04211-y'] 1813,34304054,"Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.","AIM The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC). Overall survival (OS) data were immature at the time of the primary analysis. METHODS In total, 487 patients from 53 institutions with previously untreated mCRC were randomly assigned (1:1) to receive either mFOLFOX6/CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group; 3- or 4-week regimen). The final OS data were analysed from follow-up data collected until 30th September 2017. RESULTS With a median follow-up period of 48.7 months, median survival times were 32.6 and 34.3 months (hazard ratio [HR]: 0.89, 95% confidence interval [CI]: 0.72-1.10, P = 0.293) and median PFS durations were 10.8 and 14.0 months in the control and experimental groups, respectively (HR: 0.86, 95% CI: 0.71-1.04, P < 0.0001 for non-inferiority). In patients with left-sided RAS wild-type tumours, median PFS durations were 11.4 and 16.9 months in the control and experimental groups, respectively (HR: 0.68, 95% CI: 0.48-0.96, P = 0.028). CONCLUSION S-1 and irinotecan plus bevacizumab resulted in comparable OS and non-inferior PFS with that of mFOLFOX6/CapeOX plus bevacizumab treatment as first-line chemotherapy for patients with mCRC. We recommend the use of S-1 and irinotecan plus bevacizumab as a standard first-line regimen independent of tumour sidedness or RAS status in mCRC. TRIAL REGISTRATION UMIN-CTR: 000007834.",2021,"CONCLUSION S-1 and irinotecan plus bevacizumab resulted in comparable OS and non-inferior PFS with that of mFOLFOX6/CapeOX plus bevacizumab treatment as first-line chemotherapy for patients with mCRC.","['patients with mCRC', 'metastatic colorectal cancer (TRICOLORE', 'metastatic colorectal cancer (mCRC', '487 patients from 53 institutions with previously untreated mCRC']","['S-1 and irinotecan plus bevacizumab', 'bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX', 'mFOLFOX6/CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab', '5-fluorouracil, leucovorin\xa0and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab', 'mFOLFOX6/CapeOX plus bevacizumab']","['median PFS durations', 'median survival times', 'Overall survival (OS) data']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}]","[{'cui': 'C0879262', 'cui_str': 'S 1 (combination)'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",487.0,0.243387,"CONCLUSION S-1 and irinotecan plus bevacizumab resulted in comparable OS and non-inferior PFS with that of mFOLFOX6/CapeOX plus bevacizumab treatment as first-line chemotherapy for patients with mCRC.","[{'ForeName': 'Tadamichi', 'Initials': 'T', 'LastName': 'Denda', 'Affiliation': 'Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan.'}, {'ForeName': 'Atsuo', 'Initials': 'A', 'LastName': 'Takashima', 'Affiliation': 'Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Makio', 'Initials': 'M', 'LastName': 'Gamoh', 'Affiliation': 'Osaki Citizen Hospital, Japan.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Iwanaga', 'Affiliation': 'Department of Medical Oncology, Japanese Red Cross Kitami Hospital, Hokkaido, Japan.'}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Komatsu', 'Affiliation': 'Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Hokkaido, Japan.'}, {'ForeName': 'Masanobu', 'Initials': 'M', 'LastName': 'Takahashi', 'Affiliation': 'Department of Medical Oncology, Tohoku University Hospital, Miyagi, Japan.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Nakamura', 'Affiliation': 'Aizawa Comprehensive Cancer Center, Aizawa Hospital, Nagano, Japan.'}, {'ForeName': 'Hisatsugu', 'Initials': 'H', 'LastName': 'Ohori', 'Affiliation': 'Department of Medical Oncology, Japanese Red Cross Ishinomaki Hospital, Miyagi, Japan.'}, {'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Sakashita', 'Affiliation': 'Department of Internal Medicine, Showa University Northern Yokohama Hospital, Kanagawa, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Tsuda', 'Affiliation': 'Department of Gastroenterological Oncology, Hyogo Cancer Center, Hyogo, Japan.'}, {'ForeName': 'Yoshimitsu', 'Initials': 'Y', 'LastName': 'Kobayashi', 'Affiliation': 'Gastroenterology and Medical Oncology, KKR Sapporo Medical Center, Hokkaido, Japan.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Baba', 'Affiliation': 'Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.'}, {'ForeName': 'Masanori', 'Initials': 'M', 'LastName': 'Kotake', 'Affiliation': 'Department of Surgery, Kouseiren Takaoka Hospital, Toyama, Japan.'}, {'ForeName': 'Chikashi', 'Initials': 'C', 'LastName': 'Ishioka', 'Affiliation': 'Department of Medical Oncology, Tohoku University Hospital, Miyagi, Japan.'}, {'ForeName': 'Yasuhide', 'Initials': 'Y', 'LastName': 'Yamada', 'Affiliation': 'Comprehensive Cancer Center, National Center for Global Health and Medicine, Tokyo, Japan; Department of Medical Oncology, Hamamatsu University, Shizuoka, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Sato', 'Affiliation': 'Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Yuki', 'Affiliation': 'Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Morita', 'Affiliation': 'Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Takahashi', 'Affiliation': 'Department of Medical Oncology, Tohoku University Hospital, Miyagi, Japan.'}, {'ForeName': 'Tatsuro', 'Initials': 'T', 'LastName': 'Yamaguchi', 'Affiliation': 'Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. Electronic address: tatsuro@yamaguchi.email.ne.jp.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Shimada', 'Affiliation': 'Department of Internal Medicine, Division of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.06.013'] 1814,34304046,Autonomic responses to facial expression tasks in children with autism spectrum disorders: Cross-section study.,"BACKGROUND The autonomic nervous system has an influence on emotions and behavior modulation, however, the relationship between autonomic modulation impairment and the autism spectrum disorder (ASD) is yet to be fully described. AIMS To evaluate the autonomic responses of children with and without ASD through the non-linear, and linear heart rate variability (HRV) measures, and assess the correlation between these responses, the severity and behavioral symptoms of autism. METHODS AND PROCEDURES 27 children diagnosed with ASD (EG = experimental group) and 28 matching controls (CG = control group) were evaluated. The HRV was evaluated in 15 min sections at the following moments: I) Resting condition; II) During facial expression tasks; and III) Recovery. The severity and behavioral symptoms of autism were evaluated by the Childhood Autism Rating Scale (CARS) and Autistic Behaviors Checklist (ABC) scales. OUTCOMES AND RESULTS The facial expression tasks influenced the activity of the autonomic nervous system in both groups, however the EG experienced more autonomic changes. These changes were mostly evidenced by the non-linear indices. Also, the CARS and ABC scales showed significant correlations with HRV indices. CONCLUSIONS AND IMPLICATIONS Children with ASD presented an autonomic modulation impairment, mostly identified by the non-linear indices of HRV. Also, this autonomic impairment is associated with the severity and behavioral symptoms of autism.",2021,"The facial expression tasks influenced the activity of the autonomic nervous system in both groups, however the EG experienced more autonomic changes.","['children with and without ASD', 'Children with ASD', '27 children diagnosed with ASD (EG\u202f=\u202fexperimental group) and 28 matching controls (CG\u202f=\u202fcontrol group', 'children with autism spectrum disorders']",['facial expression tasks'],"['severity and behavioral symptoms of autism', 'autonomic responses', 'Childhood Autism Rating Scale (CARS) and Autistic Behaviors Checklist (ABC) scales', 'HRV', 'autonomic changes']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}]","[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0004941', 'cui_str': 'Behavioral Symptoms'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0856975', 'cui_str': 'Autistic behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",27.0,0.0338286,"The facial expression tasks influenced the activity of the autonomic nervous system in both groups, however the EG experienced more autonomic changes.","[{'ForeName': 'Caroline Nunes', 'Initials': 'CN', 'LastName': 'Gonzaga', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}, {'ForeName': 'Heloisa Balotari', 'Initials': 'HB', 'LastName': 'Valente', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil. Electronic address: helobalov@hotmail.com.'}, {'ForeName': 'Ana Laura', 'Initials': 'AL', 'LastName': 'Ricci-Vitor', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}, {'ForeName': 'Maria Júlia Lopez', 'Initials': 'MJL', 'LastName': 'Laurino', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}, {'ForeName': 'Lorena Altafin', 'Initials': 'LA', 'LastName': 'Santos', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}, {'ForeName': 'Mileide Cristina', 'Initials': 'MC', 'LastName': 'Stoco-Oliveira', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}, {'ForeName': 'Mariana Viana', 'Initials': 'MV', 'LastName': 'Rodrigues', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}, {'ForeName': 'Armênio Alcântara', 'Initials': 'AA', 'LastName': 'Ribeiro', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}, {'ForeName': 'Tânia Cristina', 'Initials': 'TC', 'LastName': 'Bofi', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}, {'ForeName': 'Augusto Cesinando', 'Initials': 'AC', 'LastName': 'de Carvalho', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}, {'ForeName': 'Luiz Carlos Marques', 'Initials': 'LCM', 'LastName': 'Vanderlei', 'Affiliation': 'São Paulo State University (UNESP), School of Technology and Sciences, Presidente Prudente. Rua Roberto Simonsen, 305 - Centro Educacional, Presidente Prudente, SP, CEP: 19060-900, Brazil.'}]",Research in developmental disabilities,['10.1016/j.ridd.2021.104034'] 1815,34304029,Pilot RCT of the Attempted Suicide Short Intervention Program (ASSIP) adapted for rapid delivery during hospitalization to adult suicide attempt patients with substance use problems.,"OBJECTIVE The Attempted Suicide Short Intervention Program (ASSIP) was adapted for hospital delivery and to address substance use problems as well as evaluated for feasibility, acceptability, and therapist fidelity in a series of preparatory steps (n = 28) and in a pilot randomized controlled trial, RCT (n = 34). METHOD In the RCT, patients with suicide attempts and substance use problem(s) with sufficient lengths of stay to deliver three ASSIP therapy sessions in hospital were randomized to adapted ASSIP or treatment as usual control. A blinded assessor identified suicide reattempts over 6-month follow-up with the Columbia-Suicide Severity Rating Scale (C-SSRS) and a comprehensive multi-source method. Treatment process measures and the Scale for Suicidal Ideation (SSI) were also administered. RESULTS Median hospital stay was 13 days. ASSIP subjects reported high satisfaction with the treatment and high therapeutic alliance. Study therapists showed high fidelity to the modified ASSIP intervention. Repetition of suicide attempt was common in both study groups including a combined 9 (26%) subjects with reattempt based on C-SSRS and 13 (38%) subjects with reattempt based on multiple sources. CONCLUSIONS Adult suicide attempt patients with substance use problems who require lengthy hospitalizations are at exceptionally high risk and may require additional strategies to lower risk.",2021,"The Attempted Suicide Short Intervention Program (ASSIP) was adapted for hospital delivery and to address substance use problems as well as evaluated for feasibility, acceptability, and therapist fidelity in a series of preparatory steps (n = 28) and in a pilot randomized controlled trial, RCT (n = 34). ","['adult suicide attempt patients with substance use problems', 'study groups including a combined 9 (26%) subjects with reattempt based on C-SSRS and 13 (38%) subjects with reattempt based on multiple sources']","['RCT', 'ASSIP therapy sessions', 'Suicide Short Intervention Program (ASSIP', 'ASSIP']","['Scale for Suicidal Ideation (SSI', 'feasibility, acceptability, and therapist fidelity', 'Columbia-Suicide Severity Rating Scale (C-SSRS', 'Repetition of suicide attempt', 'Median hospital stay']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038663', 'cui_str': 'Suicide attempt'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3888485', 'cui_str': 'Columbia suicide severity rating scale'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449416', 'cui_str': 'Source'}]","[{'cui': 'C0038663', 'cui_str': 'Suicide attempt'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0038661', 'cui_str': 'Suicide'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C3888485', 'cui_str': 'Columbia suicide severity rating scale'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0038663', 'cui_str': 'Suicide attempt'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",,0.0132107,"The Attempted Suicide Short Intervention Program (ASSIP) was adapted for hospital delivery and to address substance use problems as well as evaluated for feasibility, acceptability, and therapist fidelity in a series of preparatory steps (n = 28) and in a pilot randomized controlled trial, RCT (n = 34). ","[{'ForeName': 'Kenneth R', 'Initials': 'KR', 'LastName': 'Conner', 'Affiliation': 'University of Rochester Medical Center, Rochester, NY, USA. Electronic address: kenneth_conner@urmc.rochester.edu.'}, {'ForeName': 'Jaclyn C', 'Initials': 'JC', 'LastName': 'Kearns', 'Affiliation': 'Department of Psychology, University of Rochester, Rochester, NY, USA. Electronic address: jaclyn.kearns@rochester.edu.'}, {'ForeName': 'Erika C', 'Initials': 'EC', 'LastName': 'Esposito', 'Affiliation': 'Department of Psychology, University of Rochester, Rochester, NY, USA.'}, {'ForeName': 'Edmund', 'Initials': 'E', 'LastName': 'Pizzarello', 'Affiliation': 'University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Wiegand', 'Affiliation': 'University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Britton', 'Affiliation': 'University of Rochester Medical Center, Rochester, NY, USA; Center of Excellence for Suicide Prevention, Finger Lakes VA Healthcare System, Canandaigua, NY, USA.'}, {'ForeName': 'Konrad', 'Initials': 'K', 'LastName': 'Michel', 'Affiliation': 'University Hospital of Psychiatry, Bern, Switzerland.'}, {'ForeName': 'Anja C', 'Initials': 'AC', 'LastName': 'Gysin-Maillart', 'Affiliation': 'Translational Research Centre, University Hospital of Psychiatry, University of Bern, Switzerland; Unit for Clinical Suicide Research, Department of Clinical Sciences, Psychiatry, Faculty of Medicine, Lund University, Sweden; University of Leipzig, Department of Medical Psychology and Medical Sociology, Germany.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Goldston', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.'}]",General hospital psychiatry,['10.1016/j.genhosppsych.2021.07.002'] 1816,34304028,360° Video virtual reality exposure therapy for public speaking anxiety: A randomized controlled trial.,"Public speaking anxiety (PSA) is a prevalent condition which is highly interrelated with social anxiety. PSA can be effectively treated with exposure therapy. Virtual reality exposure therapy (VRET) is increasingly being explored as a novel and cost-effective mode of treatment. No previous randomized controlled trial has examined whether stand-alone 360° video VRET is an effective intervention for treating PSA and interrelated disorder relevant fears. Further, studies have not explored whether 360° video content influences VRET outcomes. Participants with high PSA (n = 51) were randomly allocated to: 360° video VRET incorporating stimuli of audiences (360°Audience) (n = 17), 360° video VRET incorporating stimuli of empty rooms (360°Empty) (n = 16) and no treatment control (n = 18). Outcomes were measured over five time-points. Mixed ANOVA revealed a significant interaction between time and intervention group for PSA, social anxiety and fear of negative evaluation (FNE). Within-group analysis demonstrated there was a significant pre-intervention to post-intervention reduction across measures for both 360° video VRET groups: PSA 360°Audience (η p 2 = .90, p<.001), 360°Empty (η p 2 = .71, p < .001); social anxiety 360°Audience (η p 2 = .49, p=.002), 360°Empty (η p 2 = .39, p = .009); FNE 360°Audience (η p 2 = .59, p<.001), 360°Empty (η p 2 = .43, p = .006). Active intervention participants showed significant improvement from pre-intervention to 10-week follow-up on all measures. Findings illustrate that 360° video VRET is an efficacious way to significantly reduce PSA, social anxiety and FNE.",2021,Within-group analysis demonstrated there was a significant pre-intervention to post-intervention reduction across measures for both 360° video VRET groups:,"['360°', '360° video VRET incorporating stimuli of empty rooms', 'Participants with high PSA (n = 51', 'public speaking anxiety']","['Virtual reality exposure therapy (VRET', '360° video VRET incorporating stimuli of audiences', 'Video virtual reality exposure therapy']","['social anxiety 360°Audience', 'PSA, social anxiety and fear of negative evaluation (FNE', 'PSA, social anxiety and FNE']","[{'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C3494470', 'cui_str': 'Virtual Reality Therapy'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C3494470', 'cui_str': 'Virtual Reality Therapy'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}]","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]",51.0,0.0179838,Within-group analysis demonstrated there was a significant pre-intervention to post-intervention reduction across measures for both 360° video VRET groups:,"[{'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Reeves', 'Affiliation': 'Queens University Belfast, United Kingdom.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Elliott', 'Affiliation': 'Northern Health and Social Care Trust, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Curran', 'Affiliation': 'Queens University Belfast, United Kingdom.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Dyer', 'Affiliation': 'Northern Health and Social Care Trust, United Kingdom.'}, {'ForeName': 'Donncha', 'Initials': 'D', 'LastName': 'Hanna', 'Affiliation': 'Queens University Belfast, United Kingdom. Electronic address: donncha.hanna@qub.ac.uk.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2021.102451'] 1817,34309665,Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.,"Importance Although bevacizumab is a standard of care in combination treatments for metastatic colorectal cancer (mCRC), its clinical benefit has been limited. Objective To determine whether sequential scheduling of bevacizumab administration in combination with chemotherapy improves treatment efficacy in patients with mCRC, in keeping with the tumor vascular normalization hypothesis. Design, Setting, and Participants This open-label, randomized clinical phase 3 trial was conducted from May 8, 2012, to December 9, 2015, at 3 Italian centers. Patients aged 18 to 75 years with unresectable, previously untreated, or single line-treated mCRC were recruited. Follow-up was completed December 31, 2019, and data were analyzed from February 26 to July 24, 2020. Interventions Patients received 12 biweekly cycles of standard oxaliplatin-based regimens (modified FOLFOX-6 [levo-folinic acid, fluorouracil, and oxaliplatin]/modified CAPOX [capecitabine and oxaliplatin]) plus bevacizumab administered either on the same day as chemotherapy (standard arm) or 4 days before chemotherapy (experimental arm). Main Outcomes and Measures The primary end point was the objective response rate (ORR) measured with Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included progression-free survival, overall survival, safety, and quality of life (QOL). Results Overall, 230 patients (136 men [59.1%]; median age, 62.3 [interquartile range, 53.3-67.6] years) were randomly assigned to the standard arm (n = 115) or the experimental arm (n = 115). The median duration of follow-up was 68.3 (95% CI, 61.0-70.0) months. No difference in ORR (57.4% [95% CI, 47.8%-66.6%] in the standard arm and 56.5% [95% CI, 47.0-65.7] in the experimental arm; P = .89) or progression-free survival (10.5 [95% CI, 9.1-12.3] months in the standard arm and 11.7 [95% CI, 9.9-12.9] months in the experimental arm; P = .15) was observed. However, the median overall survival was 29.8 (95% CI, 22.5-41.1) months in the experimental arm compared with 24.1 (95% CI, 18.6-29.8) months in the standard arm (adjusted hazard ratio, 0.73; 95% CI, 0.54-0.99; P = .04). Moreover, the experimental arm was associated with a significant reduction in the rate of severe diarrhea (6 [5.3%] vs 19 [16.5%]; P = .006) and nausea (2 [1.8%] vs 8 [7.0%]; P = .05) and improved physical functioning (mean [SD] change from baseline, 0.65 [1.96] vs -7.41 [2.95] at 24 weeks; P = .02), and constipation scores (mean [SD] change from baseline, -17.2 [3.73] vs -0.62 [4.44]; P = .003). Conclusions and Relevance In this randomized clinical trial, sequential administration of bevacizumab plus chemotherapy did not improve ORR, the primary end point. However, the overall survival advantage, fewer adverse effects, and better health-related QOL associated with sequential bevacizumab administration might provide the basis for exploring antiangiogenic combination treatments with innovative perspectives. Trial Registration EudraCT Identifier: 2011-004997-27; ClinicalTrials.gov Identifier: NCT01718873.",2021,"No difference in ORR (57.4% [95% CI, 47.8%-66.6%] in the standard arm and 56.5% [95% CI, 47.0-65.7] in the experimental arm; P = .89) or progression-free survival (10.5 [95% CI, 9.1-12.3] months in the standard arm and 11.7 [95% CI, 9.9-12.9] months in the experimental arm; P = .15) was observed.","['Patients', 'Patients aged 18 to 75 years with unresectable, previously untreated, or single line-treated mCRC were recruited', 'patients with mCRC, in keeping with the tumor vascular normalization hypothesis', 'With Metastatic Colorectal Cancer', '230 patients (136 men [59.1%]; median age, 62.3 [interquartile range, 53.3-67.6] years', 'metastatic colorectal cancer (mCRC']","['Bevacizumab', 'bevacizumab', 'Standard Oxaliplatin-Based Regimens', 'chemotherapy', 'bevacizumab plus chemotherapy', 'standard oxaliplatin-based regimens (modified FOLFOX-6 [levo-folinic acid, fluorouracil, and oxaliplatin]/modified CAPOX [capecitabine and oxaliplatin]) plus bevacizumab']","['objective response rate (ORR', 'progression-free survival', 'rate of severe diarrhea', 'physical functioning', 'progression-free survival, overall survival, safety, and quality of life (QOL', 'overall survival advantage', 'constipation scores', 'median overall survival', 'nausea', 'median duration of follow-up', 'ORR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1443924', 'cui_str': 'Severe diarrhea'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",,0.635979,"No difference in ORR (57.4% [95% CI, 47.8%-66.6%] in the standard arm and 56.5% [95% CI, 47.0-65.7] in the experimental arm; P = .89) or progression-free survival (10.5 [95% CI, 9.1-12.3] months in the standard arm and 11.7 [95% CI, 9.9-12.9] months in the experimental arm; P = .15) was observed.","[{'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Avallone', 'Affiliation': 'Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Piccirillo', 'Affiliation': 'Clinical Trials Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Guglielmo', 'Initials': 'G', 'LastName': 'Nasti', 'Affiliation': 'Innovative Therapy for Abdominal Metastases, IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Rosati', 'Affiliation': 'Medical Oncology Unit, S. Carlo Hospital, Potenza, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Carlomagno', 'Affiliation': 'Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Di Gennaro', 'Affiliation': 'Experimental Pharmacology Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Carmela', 'Initials': 'C', 'LastName': 'Romano', 'Affiliation': 'Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Tatangelo', 'Affiliation': 'Pathology Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Vincenza', 'Initials': 'V', 'LastName': 'Granata', 'Affiliation': 'Radiology Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Antonino', 'Initials': 'A', 'LastName': 'Cassata', 'Affiliation': 'Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Lucrezia', 'Initials': 'L', 'LastName': 'Silvestro', 'Affiliation': 'Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'De Stefano', 'Affiliation': 'Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Aloj', 'Affiliation': 'Nuclear Medicine Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Vicario', 'Affiliation': 'Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Nappi', 'Affiliation': 'Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Leone', 'Affiliation': 'Experimental Pharmacology Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Bilancia', 'Affiliation': 'Medical Oncology Unit, S. Carlo Hospital, Potenza, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Arenare', 'Affiliation': 'Clinical Trials Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Petrillo', 'Affiliation': 'Radiology Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Secondo', 'Initials': 'S', 'LastName': 'Lastoria', 'Affiliation': 'Nuclear Medicine Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Ciro', 'Initials': 'C', 'LastName': 'Gallo', 'Affiliation': 'Università della Campania Luigi Vanvitelli, Napoli, Italy.'}, {'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Botti', 'Affiliation': 'Pathology Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Delrio', 'Affiliation': 'Colorectal Oncological Surgery, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Izzo', 'Affiliation': 'Colorectal Oncological Surgery, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Perrone', 'Affiliation': 'Clinical Trials Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Budillon', 'Affiliation': 'Experimental Pharmacology Unit, Istituto Nazionale Tumori-IRCCS, Fondazione G. Pascale, Napoli, Italy.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.18475'] 1818,34309619,Assessment of Optimal Patient Selection for Endovascular Thrombectomy Beyond 6 Hours After Symptom Onset: A Pooled Analysis of the AURORA Database.,"Importance The optimal imaging approach for identifying patients who may benefit from endovascular thrombectomy (EVT) beyond 6 hours after they were last known well is unclear. Six randomized clinical trials (RCTs) have evaluated the efficacy of EVT vs standard medical care among patients with ischemic stroke. Objective To assess the benefits of EVT among patients with 3 baseline imaging profiles using a pooled analysis of RCTs. Data Sources The AURORA (Analysis of Pooled Data from Randomized Studies of Thrombectomy More Than 6 Hours After Last Known Well) Collaboration pooled patient-level data from the included clinical trials. Study Selection An online database search identified RCTs of endovascular stroke therapy published between January 1, 2010, and March 1, 2021, that recruited patients with ischemic stroke who were randomized between 6 and 24 hours after they were last known well. Data Extraction/Synthesis Data from the final locked database of each study were provided. Data were pooled, and analyses were performed using mixed-effects modeling with fixed effects for parameters of interest. Main Outcomes and Measures The primary outcome was reduction in disability measured by the modified Rankin Scale at 90 days. An evaluation was also performed to examine whether the therapeutic response differed based on imaging profile among patients who received treatment based on the time they were last known well. Treatment benefits were assessed among a clinical mismatch subgroup, a target perfusion mismatch subgroup, and an undetermined profile subgroup. The primary end point was assessed among these subgroups and during 3 treatment intervals (tercile 1, 360-574 minutes [6.0-9.5 hours]; tercile 2, 575-762 minutes [9.6-12.7 hours]; and tercile 3, 763-1440 minutes [12.8-24.0 hours]). Results Among 505 eligible patients, 266 (mean [SD] age, 68.4 [13.8] years; 146 women [54.9%]) were assigned to the EVT group and 239 (mean [SD] age, 68.7 [13.7] years; 126 men [52.7%]) were assigned to the control group. Among 295 patients in the clinical mismatch subgroup and 359 patients in the target perfusion mismatch subgroup, EVT was associated with reductions in disability at 90 days vs no EVT (clinical mismatch subgroup, odds ratio [OR], 3.57; 95% CI, 2.29-5.57; P < .001; target perfusion mismatch subgroup, OR, 3.13; 95% CI, 2.10-4.66; P = .001). Statistically significant benefits were observed in all 3 terciles for both subgroups, with the highest OR observed for tercile 3 (clinical mismatch subgroup, OR, 4.95; 95% CI, 2.20-11.16; P < .001; target perfusion mismatch subgroup, OR, 5.01; 95% CI, 2.37-10.60; P < .001). A total of 132 patients (26.1%) had an undetermined imaging profile and no significant treatment benefit (OR, 1.59; 95% CI, 0.82-3.06; P = .17). The interaction between treatment effects for the clinical and target perfusion mismatch subgroups vs the undetermined profile subgroup was significant (OR, 2.28; 95% CI, 1.11-4.70; P = .03). Conclusions and Relevance In this study, EVT was associated with similar benefit among patients in the clinical mismatch and target perfusion mismatch subgroups during the 6- to 24-hour treatment interval. These findings support EVT as a treatment for patients meeting the criteria for either of the imaging mismatch profiles within the 6- to 24-hour interval.",2021,"A total of 132 patients (26.1%) had an undetermined imaging profile and no significant treatment benefit (OR, 1.59; 95% CI, 0.82-3.06; P = .17).","['patients with ischemic stroke', 'patients with ischemic stroke who were randomized between 6 and 24 hours after they were last known well', '505 eligible patients, 266 (mean [SD] age, 68.4 [13.8] years; 146 women [54.9%]) were assigned to the EVT group and 239 (mean [SD] age, 68.7 [13.7] years; 126 men [52.7', 'patients with 3 baseline imaging profiles using a pooled analysis of RCTs', '295 patients in the clinical mismatch subgroup and 359 patients in the target perfusion mismatch subgroup']",['EVT'],"['disability', 'reduction in disability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0205170', 'cui_str': 'Good'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517561', 'cui_str': '13.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0162578', 'cui_str': 'Removal of thrombus'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0206034', 'cui_str': 'Trials, Randomized Clinical'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}]","[{'cui': 'C0162578', 'cui_str': 'Removal of thrombus'}]","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",505.0,0.333589,"A total of 132 patients (26.1%) had an undetermined imaging profile and no significant treatment benefit (OR, 1.59; 95% CI, 0.82-3.06; P = .17).","[{'ForeName': 'Gregory W', 'Initials': 'GW', 'LastName': 'Albers', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.'}, {'ForeName': 'Maarten G', 'Initials': 'MG', 'LastName': 'Lansberg', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Brown', 'Affiliation': 'Bright Research Partners, Minneapolis, Minnesota.'}, {'ForeName': 'Ashutosh P', 'Initials': 'AP', 'LastName': 'Jadhav', 'Affiliation': 'Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona.'}, {'ForeName': 'Diogo C', 'Initials': 'DC', 'LastName': 'Haussen', 'Affiliation': 'Department of Neurology, Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Sheila O', 'Initials': 'SO', 'LastName': 'Martins', 'Affiliation': 'Federal University of Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Leticia C', 'Initials': 'LC', 'LastName': 'Rebello', 'Affiliation': 'Department of Neurology, Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Demchuk', 'Affiliation': 'Department of Clinical Neurosciences, Calgary Stroke Program, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Mayank', 'Initials': 'M', 'LastName': 'Goyal', 'Affiliation': 'Department of Clinical Neurosciences, Calgary Stroke Program, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ribo', 'Affiliation': ""Stroke Unit, Department of Neurology, Hospital Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Aquilla S', 'Initials': 'AS', 'LastName': 'Turk', 'Affiliation': 'Department of Neurosurgery, Prisma Health-Upstate, Greenville, South Carolina.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Liebeskind', 'Affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles.'}, {'ForeName': 'Jeremy J', 'Initials': 'JJ', 'LastName': 'Heit', 'Affiliation': 'Department of Radiology and Stanford Stroke Center, Stanford University, Stanford, California.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Marks', 'Affiliation': 'Department of Radiology and Stanford Stroke Center, Stanford University, Stanford, California.'}, {'ForeName': 'Tudor G', 'Initials': 'TG', 'LastName': 'Jovin', 'Affiliation': 'Department of Neurology, Cooper University Health Care, Camden, New Jersey.'}, {'ForeName': 'Raul G', 'Initials': 'RG', 'LastName': 'Nogueira', 'Affiliation': 'Department of Neurology, Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA neurology,['10.1001/jamaneurol.2021.2319'] 1819,34309563,Acceptability of Intervention Design Factors in mHealth Intervention Research: Experimental Factorial Study.,"BACKGROUND With the growing interest in mobile health (mHealth), behavioral medicine researchers are increasingly conducting intervention studies that use mobile technology (eg, to support healthy behavior change). Such studies' scientific premises are often sound, yet there is a dearth of implementational data on which to base mHealth research methodologies. Notably, mHealth approaches must be designed to be acceptable to research participants to support meaningful engagement, but little empirical data about design factors influencing acceptability in such studies exist. OBJECTIVE This study aims to evaluate the impact of two common design factors in mHealth intervention research-requiring multiple devices (eg, a study smartphone and wrist sensor) relative to requiring a single device and providing individually tailored feedback as opposed to generic content-on reported participant acceptability. METHODS A diverse US adult convenience sample (female: 104/255, 40.8%; White: 208/255, 81.6%; aged 18-74 years) was recruited to complete a web-based experiment. A 2×2 factorial design (number of devices×nature of feedback) was used. A learning module explaining the necessary concepts (eg, behavior change interventions, acceptability, and tailored content) was presented, followed by four vignettes (representing each factorial cell) that were presented to participants in a random order. The vignettes each described a hypothetical mHealth intervention study featuring different combinations of the two design factors (requiring a single device vs multiple devices and providing tailored vs generic content). Participants rated acceptability dimensions (interest, benefit, enjoyment, utility, confidence, difficulty, and overall likelihood of participating) for each study presented. RESULTS Reported interest, benefit, enjoyment, confidence in completing study requirements, and perceived utility were each significantly higher for studies featuring tailored (vs generic) content, and the overall estimate of the likelihood of participation was significantly higher. Ratings of interest, benefit, and perceived utility were significantly higher for studies requiring multiple devices (vs a single device); however, multiple device studies also had significantly lower ratings of confidence in completing study requirements, and participation was seen as more difficult and was associated with a lower estimated likelihood of participation. The two factors did not exhibit any evidence of statistical interactions in any of the outcomes tested. CONCLUSIONS The results suggest that potential research participants are sensitive to mHealth design factors. These mHealth intervention design factors may be important for initial perceptions of acceptability (in research or clinical settings). This, in turn, may be associated with participant (eg, self) selection processes, differential compliance with study or treatment processes, or retention over time.",2021,"Ratings of interest, benefit, and perceived utility were significantly higher for studies requiring multiple devices (vs a single device); however, multiple device studies also had significantly lower ratings of confidence in completing study requirements, and participation was seen as more difficult and was associated with a lower estimated likelihood of participation.","['A diverse US adult convenience sample (female: 104/255, 40.8%; White: 208/255, 81.6%; aged 18-74 years', 'mHealth Intervention Research']",[],"['acceptability dimensions (interest, benefit, enjoyment, utility, confidence, difficulty, and overall likelihood of participating']","[{'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}]",[],"[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",,0.0902091,"Ratings of interest, benefit, and perceived utility were significantly higher for studies requiring multiple devices (vs a single device); however, multiple device studies also had significantly lower ratings of confidence in completing study requirements, and participation was seen as more difficult and was associated with a lower estimated likelihood of participation.","[{'ForeName': 'Frank T', 'Initials': 'FT', 'LastName': 'Materia', 'Affiliation': ""Division of Health Services and Outcomes Research, Children's Mercy Kansas City, Kansas City, MO, United States.""}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Smyth', 'Affiliation': 'Departments of Biobehavioral Health and Medicine, The Pennsylvania State University, University Park, PA, United States.'}]",JMIR mHealth and uHealth,['10.2196/23303'] 1820,34309480,An Audio-Recorded Hypnosis Intervention for Chronic Pain Management in Cancer Survivors: A Randomized Controlled Pilot Study.,"This pilot study evaluated the feasibility, acceptability, and potential efficacy of a 4-week hypnosis audio-recording intervention in cancer survivors with chronic pain. Forty participants were randomly assigned to treatment ( n = 21) or wait-list ( n = 19) conditions. Pain intensity ratings were lower at Week 4 for both groups. The effect size for pain reduction in the treatment group was d = 0.25 from baseline to 4 weeks, and the interaction effect (Time x Group) was F = .024; η 2 p  = .001. The small interaction effect may be due to the availability of only one recording and large variability in dose. Qualitative data indicated that the intervention's benefits included participation in self-care, improved relaxation, and an opportunity to focus on oneself in a positive way. Further efficacy testing of an audio-recording intervention in a fully powered clinical trial is warranted.",2021,Pain intensity ratings were lower at Week 4 for both groups.,"['cancer survivors with chronic pain', 'Forty participants', 'Cancer Survivors']","['Audio-Recorded Hypnosis Intervention', 'hypnosis audio-recording intervention', 'audio-recording intervention']","['feasibility, acceptability, and potential efficacy', 'pain reduction', 'Pain intensity ratings']","[{'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}]","[{'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",40.0,0.0703507,Pain intensity ratings were lower at Week 4 for both groups.,"[{'ForeName': 'Linda H', 'Initials': 'LH', 'LastName': 'Eaton', 'Affiliation': 'School of Nursing and Health Studies, University of Washington Bothell, USA.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Beck', 'Affiliation': 'College of Nursing, University of Utah, Salt Lake City, USA.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Jensen', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, USA.'}]",The International journal of clinical and experimental hypnosis,['10.1080/00207144.2021.1951119'] 1821,34305798,Robot-Assisted Arm Training in Stroke Individuals With Unilateral Spatial Neglect: A Pilot Study.,"Background: Robot-assisted arm training (RAT) is an innovative exercise-based therapy that provides highly intensive, adaptive, and task-specific training, yet its effects for stroke individuals with unilateral spatial neglect remain to be explored. The study was aimed to investigate the effects of RAT on unilateral spatial neglect, arm motor function, activities of daily living, and social participation after stroke. Methods: In a pilot randomized controlled trial, individuals with unilateral spatial neglect after right hemisphere stroke were equally allocated to intervention group and control group, 45-min training daily, 5 days/week, for 4 weeks. Outcome measures included the Behavioral Inattention Test-conventional section (BIT-C), Catherine Bergego Scale (CBS), Fugl-Meyer Assessment for Upper Extremity (FMA-UE), Modified Barthel Index (MBI), and World Health Organization Disability Assessment Schedule Version 2.0 (WHODAS 2.0). Results: From November 2018 to February 2021, 20 stroke patients (mean age 47.40 ± 8.47) were enrolled in the study. Robot-assisted arm training was feasible and safe for individuals with unilateral spatial neglect. Both groups had significant improvements in all outcome measures. Participants assigned to RAT therapy had significantly greater improvements in BIT-C (difference, 7.70; 95% CI, 0.55-14.85, P = 0.04), FMA-UE (difference, 5.10; 95% CI, 1.52-8.68, P = 0.01), and WHODAS 2.0 (difference, -7.30; 95% CI, -12.50 to -2.10, P = 0.01). However, the change scores on CBS and MBI demonstrated no significance between the groups. Conclusion: Our findings provide preliminary support for introducing robot-assisted arm training to remediate unilateral spatial neglect after stroke. The training program focusing on neglect of contralateral space and affected upper extremity may be effective in neglect symptoms, motor function recovery, and social participation, while not generalizing into improvements in activities of daily living. Clinical Trial Registration : Chinese Clinical Trial Registry (http://www.chictr.org.cn/) on 17 October 2019, identifier: ChiCTR1900026656.",2021,"Participants assigned to RAT therapy had significantly greater improvements in BIT-C (difference, 7.70; 95% CI, 0.55-14.85, P = 0.04), FMA-UE (difference, 5.10; 95% CI, 1.52-8.68, P = 0.01), and WHODAS 2.0 (difference, -7.30; 95% CI, -12.50 to -2.10, P = 0.01).","['Results: From November 2018 to February 2021', '20 stroke patients (mean age 47.40 ± 8.47) were enrolled in the study', 'Stroke Individuals With Unilateral Spatial Neglect', 'individuals with unilateral spatial neglect after right hemisphere stroke', 'individuals with unilateral spatial neglect']","['intervention group and control group, 45-min training daily', 'RAT', 'Robot-assisted arm training (RAT', 'Robot-assisted arm training', 'Robot-Assisted Arm Training', 'RAT therapy']","['CBS and MBI', 'BIT-C', 'Behavioral Inattention Test-conventional section (BIT-C), Catherine Bergego Scale (CBS), Fugl-Meyer Assessment for Upper Extremity (FMA-UE), Modified Barthel Index (MBI), and World Health Organization Disability Assessment Schedule Version 2.0 (WHODAS 2.0', 'FMA-UE', 'unilateral spatial neglect, arm motor function, activities of daily living, and social participation']","[{'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}, {'cui': 'C0228175', 'cui_str': 'Right cerebral hemisphere structure'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C2985547', 'cui_str': 'Scintimammography'}, {'cui': 'C0045724', 'cui_str': '2-(4-ethoxybenzyl)-1-diethylaminoethyl-5-isothiocyanatobenzimidazole'}, {'cui': 'C0475484', 'cui_str': 'Behavioral inattention test'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0451124', 'cui_str': 'Disability assessment schedule'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0814554', 'cui_str': 'Social Participation'}]",,0.0278216,"Participants assigned to RAT therapy had significantly greater improvements in BIT-C (difference, 7.70; 95% CI, 0.55-14.85, P = 0.04), FMA-UE (difference, 5.10; 95% CI, 1.52-8.68, P = 0.01), and WHODAS 2.0 (difference, -7.30; 95% CI, -12.50 to -2.10, P = 0.01).","[{'ForeName': 'Ze-Jian', 'Initials': 'ZJ', 'LastName': 'Chen', 'Affiliation': 'Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Ming-Hui', 'Initials': 'MH', 'LastName': 'Gu', 'Affiliation': 'Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'He', 'Affiliation': 'State Key Lab of Digital Manufacturing Equipment and Technology, Institute of Rehabilitation and Medical Robotics, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Cai-Hua', 'Initials': 'CH', 'LastName': 'Xiong', 'Affiliation': 'State Key Lab of Digital Manufacturing Equipment and Technology, Institute of Rehabilitation and Medical Robotics, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Xiao-Lin', 'Initials': 'XL', 'LastName': 'Huang', 'Affiliation': 'Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}]",Frontiers in neurology,['10.3389/fneur.2021.691444'] 1822,34312205,Last Year of Life Study-Cologne (LYOL-C) (Part II): study protocol of a prospective interventional mixed-methods study in acute hospitals to analyse the implementation of a trigger question and patient question prompt sheets to optimise patient-centred care.,"INTRODUCTION The Last Year of Life Study-Cologne Part I (LYOL-C I) has identified general hospital units as the most important checkpoints for transitions in the last year of life of patients. Yet, satisfaction with hospitals, as reported by bereaved relatives, is the lowest of all health service providers. Thus, the LYOL-C Part II (LYOL-C II) focuses on optimising patient-centred care in acute hospitals for patients identified to be in their last year of life. LYOL-C II aims to test an intervention for hospitals by using a two-sided (healthcare professionals (HCPs) and patients) trigger question-based intervention to 'shake' the system in a minimally invasive manner. METHODS AND ANALYSIS Prospective interventional mixed-methods study following a two-phase approach: phase I, individual interviews with HCPs and patient representatives to design the intervention to maximise ease of implementation and phase II, exploratory study with two arms and a prepost design with patients in their last year of life. The intervention will consist of the Surprise Question and the German version of the Supportive and Palliative Care Indicators Tool (SPICT-DE) for HCPs to identify patients and provide patient-centred care, plus question prompt sheets for patients, encouraging them to initiate discussions with their HCPs. Data on transitions, changes in therapy, quality of care, palliative care integration and death of patients will be analysed. Furthermore, a staff survey (pre/post) and guided interviews with staff, patients and relatives (post) will be conducted. Finally, a formative socioeconomic impact assessment to provide evidence regarding the sustainability of the intervention will be performed. ETHICS AND DISSEMINATION The study was approved by the Ethics Committee of the Faculty of Medicine of the University of Cologne (#20-1431). Results will be published in peer-reviewed journals and presented at national and international conferences. TRIAL REGISTRATION NUMBER DRKS00022378.",2021,"Thus, the LYOL-C Part II (LYOL-C II) focuses on optimising patient-centred care in acute hospitals for patients identified to be in their last year of life.","['Faculty of Medicine of the University of Cologne (#20-1431', 'hospitals by using a two-sided (healthcare professionals (HCPs) and patients']","[""trigger question-based intervention to 'shake' the system in a minimally invasive manner""]","['therapy, quality of care, palliative care integration and death']","[{'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040822', 'cui_str': 'Tremor'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.0453686,"Thus, the LYOL-C Part II (LYOL-C II) focuses on optimising patient-centred care in acute hospitals for patients identified to be in their last year of life.","[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Strupp', 'Affiliation': 'Department of Palliative Medicine, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany julia.strupp@uk-koeln.de.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Kasdorf', 'Affiliation': 'Department of Palliative Medicine, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Dust', 'Affiliation': 'Department of Palliative Medicine, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.'}, {'ForeName': 'Kira Isabel', 'Initials': 'KI', 'LastName': 'Hower', 'Affiliation': 'Institute of Medical Sociology, Health Services Research and Rehabilitation Science (IMVR), Faculty of Human Sciences and Faculty of Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Seibert', 'Affiliation': 'Department of Business Administration and Health Care Management, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Werner', 'Affiliation': 'Faculty of Management, Economics and Social Sciences, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Ludwig', 'Initials': 'L', 'LastName': 'Kuntz', 'Affiliation': 'Department of Business Administration and Health Care Management, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Schulz-Nieswandt', 'Affiliation': 'Faculty of Management, Economics and Social Sciences, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Meyer', 'Affiliation': 'PMV Research Group, Department of Child and Adolescence Psychiatry, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Pfaff', 'Affiliation': 'Institute of Medical Sociology, Health Services Research and Rehabilitation Science (IMVR), Faculty of Human Sciences and Faculty of Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hellmich', 'Affiliation': 'Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Voltz', 'Affiliation': 'Department of Palliative Medicine, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2021-048681'] 1823,34312191,Impact evaluation of the Care Tipping Point Initiative in Nepal: study protocol for a mixed-methods cluster randomised controlled trial.,"INTRODUCTION Girl child, early and forced marriage (CEFM) persists in South Asia, with long-term consequences for girls. CARE's Tipping Point Initiative (TPI) addresses the causes of CEFM by challenging repressive gender norms and inequalities. The TPI engages different participant groups on programmatic topics and supports community dialogue to build girls' agency, shift inequitable power relations, and change community norms sustaining CEFM. METHODS/ANALYSIS The Nepal TPI impact evaluation has an integrated, mixed-methods design. The quantitative evaluation is a three-arm, cluster randomised controlled trial (control; Tipping Point Programme (TPP); TPP+ with emphasised social norms change). Fifty-four clusters of ~200 households were selected from two districts (27:27) with probability proportional to size and randomised. A household census ascertained eligible study participants, including unmarried girls and boys 12-16 years (1242:1242) and women and men 25+ years (270:270). Baseline participation was 1134 girls, 1154 boys, 270 women and 270 men. Questionnaires covered agency; social networks/norms; and discrimination/violence. Thirty in-depth interviews, 8 key-informant interviews and 32 focus group discussions were held across eight TPP/TPP+ clusters. Guides covered gender roles/aspirations; marriage decisions; girls' safety/mobility; collective action; perceived shifts in child marriage; and norms about girls. Monitoring involves qualitative interviews, focus groups and session/event observations over two visits. Qualitative analyses follow a modified grounded theory approach. Quantitative analyses apply intention to treat, regression-based difference-in-difference strategies to assess impacts on primary (married, marriage hazard) and secondary outcomes, targeted endline tracing and regression-based methods to address potential selection bias. ETHICS/DISSEMINATION The Nepal Social Welfare Council approved CARE Nepal to operate in the study districts. Emory (IRB00109419) and the Nepal Health Research Council (161-2019) approved the study. We follow UNICEF and CARE guidelines for ethical research involving children and gender-based violence. Study materials are here or available on request. We will share findings through clinicaltrials.gov, CARE reports/briefs and publications. TRIAL REGISTRATION NUMBER NCT04015856.",2021,CARE's Tipping Point Initiative (TPI) addresses the causes of CEFM by challenging repressive gender norms and inequalities.,"['Fifty-four clusters of ~200 households were selected from two districts (27:27) with probability proportional to size and randomised', '1134 girls, 1154 boys, 270\u2009women and 270 men', 'A household census ascertained eligible study participants, including unmarried girls and boys 12-16 years (1242:1242) and women and men 25+ years (270:270']",['Care Tipping Point Initiative'],['Questionnaires covered agency; social networks/norms; and discrimination/violence'],"[{'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0205351', 'cui_str': 'Proportional'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0007663', 'cui_str': 'Census'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0424093', 'cui_str': 'Initiative'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C0042693', 'cui_str': 'Violence'}]",,0.282414,CARE's Tipping Point Initiative (TPI) addresses the causes of CEFM by challenging repressive gender norms and inequalities.,"[{'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Yount', 'Affiliation': 'Global Health & Sociology, Emory University School of Public Health, Atlanta, Georgia, USA kyount@emory.edu.'}, {'ForeName': 'Cari Jo', 'Initials': 'CJ', 'LastName': 'Clark', 'Affiliation': 'Global Health, Emory University School of Public Health, Atlanta, Georgia, USA.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Bergenfeld', 'Affiliation': 'Global Health, Emory University School of Public Health, Atlanta, Georgia, USA.'}, {'ForeName': 'Zara', 'Initials': 'Z', 'LastName': 'Khan', 'Affiliation': 'Global Health, Emory University School of Public Health, Atlanta, Georgia, USA.'}, {'ForeName': 'Yuk Fai', 'Initials': 'YF', 'LastName': 'Cheong', 'Affiliation': 'Psychology, Emory University, Atlanta, Georgia, USA.'}, {'ForeName': 'Sadhvi', 'Initials': 'S', 'LastName': 'Kalra', 'Affiliation': 'Gender Justice Team, CARE USA, Atlanta, Georgia, USA.'}, {'ForeName': 'Sudhindra', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Interdisciplinary Analysts (IDA), Kathmandu, Nepal.'}, {'ForeName': 'Shuvechha', 'Initials': 'S', 'LastName': 'Ghimire', 'Affiliation': 'Interdisciplinary Analysts (IDA), Kathmandu, Nepal.'}, {'ForeName': 'Ruchira T', 'Initials': 'RT', 'LastName': 'Naved', 'Affiliation': 'International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Kausar', 'Initials': 'K', 'LastName': 'Parvin', 'Affiliation': 'International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Mahfuz', 'Initials': 'M', 'LastName': 'Al Mamun', 'Affiliation': 'International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Aloka', 'Initials': 'A', 'LastName': 'Talukder', 'Affiliation': 'International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Laterra', 'Affiliation': 'Health Equity and Rights Team, CARE USA, Atlanta, Georgia, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Sprinkel', 'Affiliation': 'Gender Justice Team, CARE USA, Atlanta, Georgia, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2020-042032'] 1824,34312190,"A prospective, phase II, single-centre, cross-sectional, randomised study investigating Dehydroepiandrosterone supplementation and its Profile in Trauma: ADaPT.","INTRODUCTION The improvements in short-term outcome after severe trauma achieved through early resuscitation and acute care can be offset over the following weeks by an acute systemic inflammatory response with immuneparesis leading to infection, multiorgan dysfunction/multiorgan failure (MOF) and death. Serum levels of the androgen precursor dehydroepiandrosterone (DHEA) and its sulfate ester DHEAS, steroids with immune-enhancing activity, are low after traumatic injury at a time when patients are catabolic and immunosuppressed. Addressing this deficit and restoring the DHEA(S) ratio to cortisol may provide a range of physiological benefits, including immune modulatory effects. OBJECTIVE Our primary objective is to establish a dose suitable for DHEA supplementation in patients after acute trauma to raise circulating DHEA levels to at least 15 nmol/L. Secondary objectives are to assess if DHEA supplementation has any effect on neutrophil function, metabolic and cytokine profiles and which route of administration (oral vs sublingual) is more effective in restoring circulating levels of DHEA, DHEAS and downstream androgens. METHODS AND ANALYSIS A prospective, phase II, single-centre, cross-sectional, randomised study investigating Dehydroepiandrosterone supplementation and its profile in trauma, with a planned recruitment between April 2019 and July 2021, that will investigate DHEA supplementation and its effect on serum DHEA, DHEAS and downstream androgens in trauma. A maximum of 270 patients will receive sublingual or oral DHEA at 50, 100 or 200 mg daily over 3 days. Females aged ≥50 years with neck of femur fracture and male and female major trauma patients, aged 16-50 years with an injury severity score ≥16, will be recruited. ETHICS AND DISSEMINATION This protocol was approved by the West Midlands - Coventry and Warwickshire Research Ethics Committee (Reference 18/WM/0102) on 8 June 2018. Results will be disseminated via peer-reviewed publications and presented at national and international conferences. TRIAL REGISTRATION This trial is registered with the European Medicines Agency (EudraCT: 2016-004250-15) and ISRCTN (12961998). It has also been adopted on the National Institute of Health Research portfolio (CPMS ID:38158). TRIAL PROGRESSION The study recruited its first patient on 2 April 2019 and held its first data monitoring committee on 8 November 2019. DHEA dosing has increased to 100 mg in both male cohorts and remains on 50 mg in across all female groups.",2021,"Serum levels of the androgen precursor dehydroepiandrosterone (DHEA) and its sulfate ester DHEAS, steroids with immune-enhancing activity, are low after traumatic injury at a time when patients are catabolic and immunosuppressed.","['patients after acute trauma', 'Females aged ≥50 years with neck of femur fracture and male and female major trauma patients, aged 16-50 years with an injury severity score ≥16', '270 patients will receive', 'trauma, with a planned recruitment between April 2019 and July 2021', 'The study recruited its first patient on 2 April 2019 and held its first data monitoring committee on 8 November 2019']","['DHEA', 'sublingual or oral DHEA', 'Dehydroepiandrosterone supplementation', 'DHEA supplementation']","['infection, multiorgan dysfunction/multiorgan failure (MOF) and death', 'Serum levels of the androgen precursor dehydroepiandrosterone (DHEA', 'serum DHEA, DHEAS and downstream androgens in trauma']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0015806', 'cui_str': 'Fracture of neck of femur'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0332677', 'cui_str': 'Major injury'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0021504', 'cui_str': 'Injury severity score'}, {'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205435', 'cui_str': 'First'}]","[{'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0026766', 'cui_str': 'Multiple organ failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0002844', 'cui_str': 'Androgen'}, {'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C0522506', 'cui_str': 'Downstream'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]",,0.232065,"Serum levels of the androgen precursor dehydroepiandrosterone (DHEA) and its sulfate ester DHEAS, steroids with immune-enhancing activity, are low after traumatic injury at a time when patients are catabolic and immunosuppressed.","[{'ForeName': 'Conor', 'Initials': 'C', 'LastName': 'Bentley', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK conor.bentley@nhs.net.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Potter', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Kamal Makram', 'Initials': 'KM', 'LastName': 'Yakoub', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Brock', 'Affiliation': 'D3B, CRUK Clinical Trials Unit, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Homer', 'Affiliation': 'D3B, CRUK Clinical Trials Unit, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Toman', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Angela E', 'Initials': 'AE', 'LastName': 'Taylor', 'Affiliation': 'Institute of Metabolism and Systems Research, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.'}, {'ForeName': 'Fozia', 'Initials': 'F', 'LastName': 'Shaheen', 'Affiliation': 'Institute of Metabolism and Systems Research, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.'}, {'ForeName': 'Lorna C', 'Initials': 'LC', 'LastName': 'Gilligan', 'Affiliation': 'Institute of Metabolism and Systems Research, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.'}, {'ForeName': 'Amrita', 'Initials': 'A', 'LastName': 'Athwal', 'Affiliation': 'D3B, CRUK Clinical Trials Unit, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Barton', 'Affiliation': 'D3B, CRUK Clinical Trials Unit, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Carrera', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Young', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Amisha', 'Initials': 'A', 'LastName': 'Desai', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'McGee', 'Affiliation': 'Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Ermogenous', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Gurneet', 'Initials': 'G', 'LastName': 'Sur', 'Affiliation': 'D3B, CRUK Clinical Trials Unit, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.'}, {'ForeName': 'Carolyn A', 'Initials': 'CA', 'LastName': 'Greig', 'Affiliation': 'School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Hazeldine', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Wiebke', 'Initials': 'W', 'LastName': 'Arlt', 'Affiliation': 'Institute of Metabolism and Systems Research, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.'}, {'ForeName': 'Janet M', 'Initials': 'JM', 'LastName': 'Lord', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Foster', 'Affiliation': 'NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK.'}]",BMJ open,['10.1136/bmjopen-2020-040823'] 1825,34328396,'I need a break': the effect of choice of rest break duration on vigilance.,"Vigilance is the ability to sustain attention for an extended period of time and to respond to infrequently occurring critical signals. One of the most replicable findings within the vigilance literature is the performance decrement; the decline in performance as time on task increases. In an effort to attenuate the decrement, and decrease the workload and stress associated with vigilance, the present study investigated the role of choice of rest break duration on vigilance performance, perceived workload, and stress. Participants were assigned to one of three conditions: (1) choice condition, (2) no-choice condition (yoked-control), and (3) a no-break control condition. Participants completed a sensory vigilance task and common measures of workload and stress. A vigilance decrement was observed in all conditions. Participants in the choice condition exhibited more conservative responses and fewer false alarms than the no-choice condition. Across all conditions, task engagement and worry decreased, and distress increased. Practitioner Summary: This study shows the impact of rest breaks and autonomy on vigilance task performance. The findings suggest that resource theory is a plausible explanation for the vigilance decrement. Additionally, providing a choice in rest break length changes the operator's criterion following the break. Abbreviations: TSA: transportation security administration; SART: sustained attention to response task; ERP: event-related potential; S-DT: self-determination theory; ISI: interstimulus interval; DSSQ: dundee stress state questionnaire; CFQ: cognitive failures questionnaire; BP: boredom proneness; NASA-TLX: NASA task load index; IMI: intrinsic motivation inventory.",2021,Participants in the choice condition exhibited more conservative responses and fewer false alarms than the no-choice condition.,[],"['choice condition, 2) no-choice condition (yoked-control), and 3) a no-break control condition']","['vigilance performance, perceived workload, and stress', 'sensory vigilance task and common measures of workload and stress', 'conservative responses', 'vigilance task performance']",[],"[{'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0043012', 'cui_str': 'Wakefulness'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}]",,0.0614778,Participants in the choice condition exhibited more conservative responses and fewer false alarms than the no-choice condition.,"[{'ForeName': 'Grace E', 'Initials': 'GE', 'LastName': 'Waldfogle', 'Affiliation': 'Performance Research Laboratory, Psychology Department, University of Central Florida, Orlando, FL, USA.'}, {'ForeName': 'Allison E', 'Initials': 'AE', 'LastName': 'Garibaldi', 'Affiliation': 'Performance Research Laboratory, Psychology Department, University of Central Florida, Orlando, FL, USA.'}, {'ForeName': 'Alexis R', 'Initials': 'AR', 'LastName': 'Neigel', 'Affiliation': 'Performance Research Laboratory, Psychology Department, University of Central Florida, Orlando, FL, USA.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Szalma', 'Affiliation': 'Performance Research Laboratory, Psychology Department, University of Central Florida, Orlando, FL, USA.'}]",Ergonomics,['10.1080/00140139.2021.1960428'] 1826,34327851,Gut Microbiota Composition is Associated with Responses to Peanut Intervention in Multiple Parameters Among Adults with Metabolic Syndrome Risk.,"INTRODUCTION Peanuts are widely consumed as a meal ingredient and a snack, and are commonly considered as a healthy food based on their nutrient profile. Peanut consumption has been associated with a lower risk of metabolic syndrome (MetS) in epidemiological studies. This study aims to investigate whether consuming peanuts affects the gut microbiota in adults with risk of MetS and whether the intervention effect of peanuts is associated with gut microbiota composition. METHODS AND RESULTS This study analyzes the gut microbiota of subjects from a 12-week randomized clinical trial comparing consumption of either peanuts or isocaloric carbohydrate bars. It is observed that there is high inter-individual variability on multiple clinical and anthropometrical parameters in response to peanut consumption. Meanwhile, the gut microbiota composition is also highly person-specific and have minor changes when compared laterally or longitudinally. This study employs a machine-learning algorithm and establishes prediction models using the microbiome data and the responsiveness data of different parameters in subjects with peanut intervention. As a result, it is found that the improvement of MetS risk and numerous parameters, including diastolic blood pressure, body weight, waist circumference, and fasting blood glucose level can be predicted for responsiveness with high accuracy that has a value of area under curve over 0.70 by receiver operating characteristic analysis. CONCLUSION Together, the findings of this study suggest that individual gut microbiota configuration may modulate host metabolism and alter an individual's response to peanut intervention, thus highlighting the importance of personalized nutrition.",2021,We observed that there was high inter-individual variability on multiple clinical and anthropometrical parameters in response to peanut consumption.,"['Adults with Metabolic Syndrome Risk', 'adults with risk of metabolic syndrome', 'subjects with peanut intervention']","['consumption of either peanuts or isocaloric carbohydrate bars', 'Peanut Intervention']","['diastolic blood pressure, body weight, waist circumference, and fasting blood glucose level']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0001643', 'cui_str': 'Beta-2 adrenergic receptor'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}]",,0.0406022,We observed that there was high inter-individual variability on multiple clinical and anthropometrical parameters in response to peanut consumption.,"[{'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.'}, {'ForeName': 'Lingling', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.'}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.'}, {'ForeName': 'Meiqin', 'Initials': 'M', 'LastName': 'Huang', 'Affiliation': 'CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.'}, {'ForeName': 'Jingyu', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.'}, {'ForeName': 'Vasanti', 'Initials': 'V', 'LastName': 'Malik', 'Affiliation': 'Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, 02115, USA.'}, {'ForeName': 'Xiaoran', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, 02115, USA.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Lin', 'Affiliation': 'CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.'}]",Molecular nutrition & food research,['10.1002/mnfr.202001051'] 1827,34327346,"Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial.","Background We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. Methods This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8-11 months of age). Poliovirus neutralizing antibodies were measured in sera collected prior to the first sIPV dose and one month after the last dose. Findings We enrolled 560 infants; 536 (95.7%) completed the study. Final seropositivity rates were >98% for all three serotypes in both study arms. There were no statistically significant differences in seropositivity between the 2-dose and the 3-dose schedule. Final median reciprocal titres of polio antibodies were high overall (>1:768 for all serotypes) and statistically significantly higher in 2-dose recipients compared with 3-dose recipients ( p  < 0.001). Interpretation This study offers evidence that two doses of sIPV administered at 4 and 8-11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. Median reciprocal titres of polio antibodies were high overall, and were more related to the interval between doses than the number of doses, with the longer interval of the 2-dose schedule producing higher reciprocal titres than the shorter-interval 3-dose schedule. The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule. Countries planning to use an IPV-only schedule in the post-eradication era can consider this 2-dose sIPV option as an immunogenic and dose-sparing strategy. Funding World Health Organization (from a grant from International PolioPlus Committee, Rotary International, Evanston, IL, USA).",2021,The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule.,"['We enrolled 560 infants; 536 (95.7%) completed the study', '16 vaccination clinics in Shandong province', 'China']","['Sabin-strain inactivated poliovirus vaccine (sIPV', 'sIPV', 'Sabin inactivated poliovirus vaccine']","['seropositivity', 'reciprocal titres', 'Final seropositivity rates', 'Median reciprocal titres of polio antibodies', 'Poliovirus neutralizing antibodies', 'Final median reciprocal titres of polio antibodies', 'Immunogenicity']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0338051', 'cui_str': 'Vaccination clinic'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0036106', 'cui_str': 'Salk Vaccine'}]","[{'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0032371', 'cui_str': 'Acute poliomyelitis'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0206435', 'cui_str': 'Human poliovirus'}, {'cui': 'C0282682', 'cui_str': 'Blocking antibody'}]",560.0,0.281708,The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule.,"[{'ForeName': 'Yamin', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Xu', 'Affiliation': 'Shandong Provincial Center for Disease Control and Prevention, Jinan, China.'}, {'ForeName': 'Vishali', 'Initials': 'V', 'LastName': 'Jeyaseelan', 'Affiliation': 'Polio Eradication Department, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Zhifang', 'Initials': 'Z', 'LastName': 'Ying', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Ondrej', 'Initials': 'O', 'LastName': 'Mach', 'Affiliation': 'Polio Eradication Department, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Sutter', 'Affiliation': 'Polio Eradication Department, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Wen', 'Affiliation': 'Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Lance', 'Initials': 'L', 'LastName': 'Rodewald', 'Affiliation': 'Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Changgui', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Dezhou prefecture-level Center for Disease Control and Prevention, Dezhou, Shandong, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': 'Liaocheng prefecture-level Center for Disease Control and Prevention, Liaocheng, Shandong, China.'}, {'ForeName': 'Zundong', 'Initials': 'Z', 'LastName': 'Yin', 'Affiliation': 'Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Zijian', 'Initials': 'Z', 'LastName': 'Feng', 'Affiliation': 'Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Aiqiang', 'Initials': 'A', 'LastName': 'Xu', 'Affiliation': 'Shandong Provincial Center for Disease Control and Prevention, Jinan, China.'}, {'ForeName': 'Zhijie', 'Initials': 'Z', 'LastName': 'An', 'Affiliation': 'Chinese Center for Disease Control and Prevention, Beijing, China.'}]",The Lancet regional health. Western Pacific,['10.1016/j.lanwpc.2021.100133'] 1828,34327293,"Cost-Effectiveness of Technology-Assisted Case Management in Low-Income, Rural Adults with Type 2 Diabetes.","Objective: The objective of this study was to examine whether delivering technology-assisted case management (TACM) with medication titration by nurses under physician supervision is cost effective compared with usual care (standard office procedures) in low-income rural adults with type 2 diabetes. Methods: One hundred and thirteen low-income, rural adults with type 2 diabetes and hemoglobin A1c (HbA1c) ≥8%, were randomized to a TACM intervention or usual care. Effectiveness was measured as differences in HbA1c between the TACM and usual care groups at 6 months. Total cost per patient included intervention or usual care cost, medical care cost, and income loss associated with lost workdays. The total cost per patient and HbA1c were used to estimate a joint distribution of incremental cost and incremental effect of TACM compared with usual care. Incremental cost-effectiveness ratios (ICERs) were estimated to summarize the cost-effectiveness of the TACM intervention relative to usual care to decrease HbA1c by 1%. Results: Costs due to intervention, primary care, other health care, emergency room visits, and workdays missed showed statistically significant differences between the groups (usual care $1,360.49 vs. TACM $5,379.60, p =0.004), with an absolute cost difference of $4,019.11. Based on the intervention cost per patient and the change in HbA1c, the median bootstrapped ICERs was estimated to be $6,299.04 (standard error=731.71) per 1% decrease in HbA1c. Conclusion: Based on these results, a 1% decrease in HbA1c can be obtained with the TACM intervention at an approximate cost of $6,300; therefore, it is a cost-effective option for treating vulnerable populations of adults with type 2 diabetes.",2021,"a 1% decrease in HbA1c can be obtained with the TACM intervention at an approximate cost of $6,300; therefore, it is a cost-effective option for treating vulnerable populations of adults with type 2 diabetes.","['Low-Income, Rural Adults with Type 2 Diabetes', 'low-income rural adults with type 2 diabetes', 'adults with type 2 diabetes', 'One hundred and thirteen low-income, rural adults with type 2 diabetes and hemoglobin A1c (HbA1c) ≥8']","['technology-assisted case management (TACM', 'TACM intervention', 'Technology-Assisted Case Management', 'usual care (standard office procedures', 'TACM', 'TACM intervention or usual care']","['Effectiveness', 'Costs due to intervention, primary care, other health care, emergency room visits, and workdays missed', 'Incremental cost-effectiveness ratios (ICERs', 'median bootstrapped ICERs', 'Total cost per patient included intervention or usual care cost, medical care cost, and income loss associated with lost workdays']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0085971', 'cui_str': 'Case management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0086600', 'cui_str': 'Costs, Medical Care'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]",,0.0124997,"a 1% decrease in HbA1c can be obtained with the TACM intervention at an approximate cost of $6,300; therefore, it is a cost-effective option for treating vulnerable populations of adults with type 2 diabetes.","[{'ForeName': 'Leonard E', 'Initials': 'LE', 'LastName': 'Egede', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Clara E', 'Initials': 'CE', 'LastName': 'Dismuke', 'Affiliation': 'Health Economics Resource Center (HERC), VA Palo Alto Health Care System, Palo Alto, California, USA.'}, {'ForeName': 'Rebekah J', 'Initials': 'RJ', 'LastName': 'Walker', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Joni S', 'Initials': 'JS', 'LastName': 'Williams', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Eiler', 'Affiliation': 'Center for Advancing Population Science, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.'}]",Health equity,['10.1089/heq.2020.0134'] 1829,34330252,The use of Web-based interactive technology to promote HPV vaccine uptake among young females: a randomized controlled trial.,"BACKGROUND Currently no study has investigated whether Web-based interactive technology can influence females to adopt healthy behaviors. We investigated how and under what conditions do Web-based interactivity influence vaccination intentions among young females. METHODS In this randomized controlled trail, we conduct a 2 (mode of information presentation: narrative vs. data visualization) × 2 (interactivity: interactive information vs. noninteractive information) between-groups design. A total of 180 Chinese female undergraduate students who had never received HPV vaccination were randomly allocated to 4 experimental groups. Each participant was assessed for their information avoidance behavior and vaccination intention. The hypotheses were tested using a moderated mediation model. All analyses were performed using SPSS version 22.0 with probability set at 0.05 alpha level. RESULTS The indirect relationship between interactivity and behavioral intention though information avoidance was moderated by the mode of presentation. Under the narrative condition, interactivity (vs. non-interactivity) decreased information avoidance and increased the intention to receive HPV vaccination (B = -.23, SE = 0.10, P < 0.05). However, under data visualization condition, no significant difference was observed between the effects of interactivity and non-interactivity on intention. CONCLUSION The findings suggest that when young females experience difficulties in manipulating or understanding HPV-related information, their information-avoidance behavior is likely to increase. Rather than use interactive statistical or graphical information, young females are more likely to be persuaded by interactive narratives.",2021,"Under the narrative condition, interactivity (vs. non-interactivity) decreased information avoidance and increased the intention to receive HPV vaccination (B = -.23, SE = 0.10, P < 0.05).","['180 Chinese female undergraduate students who had never received HPV vaccination', 'young females']","['data visualization)\u2009×\u20092 (interactivity: interactive information vs. noninteractive information', 'Web-based interactive technology']","['information avoidance', 'intention to receive HPV vaccination', 'interactivity and non-interactivity on intention']","[{'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C4704817', 'cui_str': 'Data Visualization'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]","[{'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",180.0,0.0249991,"Under the narrative condition, interactivity (vs. non-interactivity) decreased information avoidance and increased the intention to receive HPV vaccination (B = -.23, SE = 0.10, P < 0.05).","[{'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ""School of Industrial Design, Hubei University of Technology, 28 Nanli Road, Wuhan, 430068, People's Republic of China.""}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': ""School of Journalism and Culture Communication, Zhongnan University of Economics and Law, 182 Nanhu Avenue, Wuhan, 430073, People's Republic of China. Z0004810@zuel.edu.cn.""}]",BMC women's health,['10.1186/s12905-021-01417-y'] 1830,34329963,Simulation-based education and the effect of multiple simulation sessions - A randomised controlled study.,"BACKGROUND Simulation-based education may improve clinical decision-making skills and supplement clinical placement of nursing students to prepare them for real healthcare settings. Exposing students to several simulation sessions could maximise learning, but longitudinal randomised studies are lacking regarding the effects of simulation-based education. OBJECTIVE In this randomised study, we followed a class of nursing students to assess the effect of multiple simulations on the students' self-reported clinical decision-making skills and self-confidence. DESIGN A randomised controlled trial, collecting data four times throughout a 3-year nursing program; at the beginning of the second semester as baseline and at the end of each of the following academic years. Students experienced either a single (control) or a double (intervention) set of simulation scenarios in four simulation days, including several simulation scenarios for each session. SETTING A university in Norway, 2018-2020. PARTICIPANTS The study included 146 baccalaureate nursing students who volunteered to participate. METHODS The participants completed two validated instruments, the 24-item Nurse Decision-Making Instrument and the Self-Confidence Scale, and demographic data were collected. Analysis of covariance and linear mixed-effect models were applied to analyse the effect of the double compared to the single scenario simulations. RESULTS Complete data were obtained for 71 participants. The results showed no significant differences between double vs single scenario sessions on clinical decision-making scores (B = -0.2; 95% confidence interval, -2.1 to 1.7; p = 0.806) or self-confidence score (B = -0.1; 95% confidence interval, -0.4 to 0.2; p = 0.467). However, the overall self-confidence scores increased significantly over time. CONCLUSION In this randomised study, we found no effects of double vs single scenario simulations on clinical decision-making or self-confidence scores among nursing students during their 3-year program.",2021,"The results showed no significant differences between double vs single scenario sessions on clinical decision-making scores (B = -0.2; 95% confidence interval, -2.1 to 1.7; p = 0.806) or self-confidence score (B = -0.1; 95% confidence interval, -0.4 to 0.2; p = 0.467).","['A university in Norway, 2018-2020', 'nursing students during their 3-year program', '146 baccalaureate nursing students who volunteered to participate']",['double vs single scenario simulations'],"['overall self-confidence scores', 'self-confidence score', '24-item Nurse Decision-Making Instrument and the Self-Confidence Scale, and demographic data', 'clinical decision-making scores', 'clinical decision-making or self-confidence scores']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0028423', 'cui_str': 'Norway'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0037179', 'cui_str': 'Single person'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C4042877', 'cui_str': 'Medical Decision-Making'}]",146.0,0.314266,"The results showed no significant differences between double vs single scenario sessions on clinical decision-making scores (B = -0.2; 95% confidence interval, -2.1 to 1.7; p = 0.806) or self-confidence score (B = -0.1; 95% confidence interval, -0.4 to 0.2; p = 0.467).","[{'ForeName': 'Alette H', 'Initials': 'AH', 'LastName': 'Svellingen', 'Affiliation': 'Centre of Diaconia and Professional Practice, VID Specialized University, Oslo, Norway; Faculty of Health Studies, VID Specialized University, Bergen, Norway. Electronic address: Alette.Svellingen@vid.no.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Forstrønen', 'Affiliation': 'Faculty of Health Studies, VID Specialized University, Bergen, Norway. Electronic address: Astrid.Forstronen@vid.no.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Assmus', 'Affiliation': 'Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway. Electronic address: Jorg.Assmus@helse-bergen.no.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Røykenes', 'Affiliation': 'Faculty of Health Studies, VID Specialized University, Bergen, Norway. Electronic address: Kari.Roykenes@vid.no.'}, {'ForeName': 'Guttorm', 'Initials': 'G', 'LastName': 'Brattebø', 'Affiliation': 'Department of Anaesthesia & Intensive Care, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway. Electronic address: Guttorm.Brattebo@helse-bergen.no.'}]",Nurse education today,['10.1016/j.nedt.2021.105059'] 1831,34329947,Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial.,"BACKGROUND The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast Saccharomyces boulardii have been suggested to improve left ventricular ejection fraction (LVEF). METHODS In a multicentre, prospective randomized open label, blinded end-point trial, we randomized patients with LVEF <40% and New York Heart Association functional class II or III, despite optimal medical therapy, to treatment (1:1:1) with the probiotic yeast Saccharomyces boulardii, the antibiotic rifaximin, or standard of care (SoC) only. The primary endpoint, the baseline-adjusted LVEF at three months, was assessed in an intention-to-treat analysis. FINDINGS We enrolled a total of 151 patients. After three months' treatment, the LVEF did not differ significantly between the SoC arm and the rifaximin arm (mean difference was -1•2 percentage points; 95% CI -3•2 - 0•7; p=0•22) or between the SoC arm and the Saccharomyces boulardii arm (mean difference -0•2 percentage points; 95% CI -2•2 - 1•9; p=0•87). We observed no significant between-group differences in changes in microbiota diversity, TMAO, or C-reactive protein. INTERPRETATION Three months' treatment with Saccharomyces boulardii or rifaximin on top of SoC had no significant effect on LVEF, microbiota diversity, or the measured biomarkers in our population with HF. FUNDING The trial was funded by the Norwegian Association for Public Health, the Blix foundation, Stein Erik Hagen's Foundation for Clinical Heart Research, Ada og Hagbart Waages humanitære og veldedige stiftelse, Alfasigma, and Biocodex.",2021,"After three months' treatment, the LVEF did not differ significantly between the SoC arm and the rifaximin arm (mean difference was -1•2 percentage points; 95% CI -3•2 - 0•7; p=0•22) or between the SoC arm and the Saccharomyces boulardii arm (mean difference -0•2 percentage points; 95% CI -2•2 - 1•9; p=0•87).","['151 patients', 'heart failure with reduced ejection fraction', 'patients with LVEF <40% and New York Heart Association functional class II or III, despite optimal medical therapy, to treatment (1:1:1) with the']","['Saccharomyces boulardii or rifaximin', 'probiotic yeast', 'Rifaximin or Saccharomyces boulardii', 'Saccharomyces boulardii', 'probiotic yeast Saccharomyces boulardii, the antibiotic rifaximin, or standard of care (SoC) only']","['left ventricular ejection fraction (LVEF', 'LVEF, microbiota diversity', 'LVEF', 'microbiota diversity, TMAO, or C-reactive protein', 'intention-to-treat analysis', 'baseline-adjusted LVEF']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0441886', 'cui_str': 'Class 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0772093', 'cui_str': 'Saccharomyces boulardii'}, {'cui': 'C0073374', 'cui_str': 'rifaximin'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0036025', 'cui_str': 'Saccharomyces cerevisiae'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0077194', 'cui_str': 'trimethyloxamine'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}]",151.0,0.200969,"After three months' treatment, the LVEF did not differ significantly between the SoC arm and the rifaximin arm (mean difference was -1•2 percentage points; 95% CI -3•2 - 0•7; p=0•22) or between the SoC arm and the Saccharomyces boulardii arm (mean difference -0•2 percentage points; 95% CI -2•2 - 1•9; p=0•87).","[{'ForeName': 'Ayodeji', 'Initials': 'A', 'LastName': 'Awoyemi', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, 0424 Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Department of Cardiology, Oslo University Hospital Ullevål, 0424 Oslo, Norway. Electronic address: a.o.awoyemi@medisin.uio.no.'}, {'ForeName': 'Cristiane', 'Initials': 'C', 'LastName': 'Mayerhofer', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Department of Cardiology, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway.'}, {'ForeName': 'Alex S', 'Initials': 'AS', 'LastName': 'Felix', 'Affiliation': 'Instituto Nacional de Cardiologia, 22240-006 Rio de Janeiro, Brazil.'}, {'ForeName': 'Johannes R', 'Initials': 'JR', 'LastName': 'Hov', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway; Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammation Medicine and Transplantation, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway; Section of Gastroenterology, Department of Transplantation Medicine, Division of Surgery, Inflammation Medicine and Transplantation, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway.'}, {'ForeName': 'Samuel D', 'Initials': 'SD', 'LastName': 'Moscavitch', 'Affiliation': 'Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, 21040-900, Brazil.'}, {'ForeName': 'Knut Tore', 'Initials': 'KT', 'LastName': 'Lappegård', 'Affiliation': 'Division of Internal Medicine, Nordlandssykehuset, 8005 Bodø, Norway; Institute of Clinical Medicine, University of Tromsø, 9037 Tromsø, Norway.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Hovland', 'Affiliation': 'Division of Internal Medicine, Nordlandssykehuset, 8005 Bodø, Norway; Institute of Clinical Medicine, University of Tromsø, 9037 Tromsø, Norway.'}, {'ForeName': 'Sigrun', 'Initials': 'S', 'LastName': 'Halvorsen', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Department of Cardiology, Oslo University Hospital Ullevål, 0424 Oslo, Norway.'}, {'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Halvorsen', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway.'}, {'ForeName': 'Ida', 'Initials': 'I', 'LastName': 'Gregersen', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway.'}, {'ForeName': 'Asbjørn', 'Initials': 'A', 'LastName': 'Svardal', 'Affiliation': 'Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.'}, {'ForeName': 'Rolf K', 'Initials': 'RK', 'LastName': 'Berge', 'Affiliation': 'Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.'}, {'ForeName': 'Simen H', 'Initials': 'SH', 'LastName': 'Hansen', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammation Medicine and Transplantation, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Götz', 'Affiliation': 'Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammation Medicine and Transplantation, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Holm', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway; Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammation Medicine and Transplantation, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway.'}, {'ForeName': 'Pål', 'Initials': 'P', 'LastName': 'Aukrust', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway; Section of Clinical Immunology and Infectious diseases, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.'}, {'ForeName': 'Sissel', 'Initials': 'S', 'LastName': 'Åkra', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, 0424 Oslo, Norway.'}, {'ForeName': 'Ingebjørg', 'Initials': 'I', 'LastName': 'Seljeflot', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, 0424 Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Department of Cardiology, Oslo University Hospital Ullevål, 0424 Oslo, Norway.'}, {'ForeName': 'Svein', 'Initials': 'S', 'LastName': 'Solheim', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, 0424 Oslo, Norway; Department of Cardiology, Oslo University Hospital Ullevål, 0424 Oslo, Norway.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Lorenzo', 'Affiliation': 'Instituto Nacional de Cardiologia, 22240-006 Rio de Janeiro, Brazil.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Gullestad', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Department of Cardiology, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway; KG Jebsen Center for Cardiac Research, University of Oslo, 0450 Oslo, Norway.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Trøseid', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0450 Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway; Section of Clinical Immunology and Infectious diseases, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.'}, {'ForeName': 'Kaspar', 'Initials': 'K', 'LastName': 'Broch', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway; KG Jebsen Center for Cardiac Research, University of Oslo, 0450 Oslo, Norway.'}]",EBioMedicine,['10.1016/j.ebiom.2021.103511'] 1832,34329898,Weight gain in children after adenotonsillectomy: undesirable weight gain or catch-up growth?,"OBJECTIVE/BACKGROUND Obesity and obstructive sleep apnea (OSA) are consequential conditions with significant overlap in the pediatric population. Early studies documented catch-up growth in underweight children after adenotonsillectomy, but more recent studies suggested that normal and even overweight children may experience excess weight gain after adenotonsillectomy. We performed a secondary analysis of Childhood Adenotonsillectomy Trial (CHAT) data to test whether there was an effect of early adenotonsillectomy on undesirable weight gain, defined as an increase in body mass index (BMI) Z score in an already overweight or obese child or a change from baseline normal or underweight to a follow up BMI Z score classified as overweight. PATIENTS/METHODS We included 398 children with moderate OSA and complete anthropomorphic data randomized to adenotonsillectomy versus watchful waiting with supportive care. Pearson's χ 2 and independent t tests were used to compare demographic, activity, sleep and anthropomorphic characteristics between children who did and did not experience undesirable weight gain over seven months. Logistic regression was used to test for an association between adenotonsillectomy and undesirable weight gain, both unadjusted and adjusted for age, sex, Black race, average parent-reported weekly activity level, mother's body mass index, average nightly sleep duration and either baseline or follow up AHI (in separate models). RESULTS Forty three percent (n = 172) experienced undesirable weight gain. A similar percentage of children in both arms experienced undesirable weight gain (45% adenotonsillectomy vs 41% watchful waiting). Neither unadjusted nor adjusted regression analysis demonstrated a significant effect of adenotonsillectomy on undesirable weight gain. CONCLUSION Adenotonsillectomy may not be an independent risk factor for undesirable weight gain in children.",2021,"Neither unadjusted nor adjusted regression analysis demonstrated a significant effect of adenotonsillectomy on undesirable weight gain. ","['398 children with moderate OSA and complete anthropomorphic data randomized to', 'Forty three percent (n\xa0', 'children', 'children after adenotonsillectomy', 'Obesity and obstructive sleep apnea', 'already overweight or obese child or a change from baseline normal or underweight to a follow up BMI Z score classified as overweight', 'underweight children after adenotonsillectomy']","['adenotonsillectomy', 'adenotonsillectomy versus watchful waiting with supportive care']","['Weight gain', 'undesirable weight gain', 'weight gain or catch-up growth', 'body mass index (BMI) Z score', 'weight gain', 'demographic, activity, sleep and anthropomorphic characteristics']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0008902', 'cui_str': 'Classification'}]","[{'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0344211', 'cui_str': 'Support'}]","[{'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0231617', 'cui_str': 'Catch'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",398.0,0.0560869,"Neither unadjusted nor adjusted regression analysis demonstrated a significant effect of adenotonsillectomy on undesirable weight gain. ","[{'ForeName': 'Erin M', 'Initials': 'EM', 'LastName': 'Kirkham', 'Affiliation': 'Department of Otolaryngology: Head & Neck Surgery, The University of Michigan, Ann Arbor, MI, USA. Electronic address: ekirkham@umich.edu.'}, {'ForeName': 'Aleda M', 'Initials': 'AM', 'LastName': 'Leis', 'Affiliation': 'Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Ronald D', 'Initials': 'RD', 'LastName': 'Chervin', 'Affiliation': 'Sleep Disorders Center and Department of Neurology, University of Michigan, Ann Arbor, MI, USA.'}]",Sleep medicine,['10.1016/j.sleep.2021.07.010'] 1833,34312872,The effect of timing of orthodontic therapy on the outcomes of regenerative periodontal surgery in patients with stage IV periodontitis: A multicenter randomized trial.,"AIM To compare the outcomes after early (4 weeks post surgery) or late (6 months post surgery) orthodontic therapy (OT) following regenerative surgery of intra-bony defects (IDs). MATERIALS AND METHODS In a multi-center, parallel-group, randomized clinical trial, 43 patients with stage IV periodontitis were randomized to receive either early (n = 23) or late OT (n = 20) following regenerative surgery of IDs. Primary outcome was change in clinical attachment level (CAL) in one target ID at 12 months after surgery. Secondary outcomes were changes of probing pocket depth (PPD), bleeding on probing (BOP), and frequency of pocket closure. RESULTS No statistically significant differences between groups could be observed for CAL gain (5.4 mm [±2.1 mm] for early; 4.5 mm [±1.7 mm] for late OT). PPD was reduced by 4.2 mm (±1.9 mm) in the early group and by 3.9 mm (±1.5 mm) in the late group (p > .05). Pocket closure (PPD ≤ 4 mm) was obtained in 91% of defects in early compared to 85% in late OT. CONCLUSION In the inter-disciplinary treatment of periodontitis stage IV, OT can be initiated already 4 weeks after regenerative surgery of IDs with favourable results, thus reducing the overall treatment time.",2021,"Secondary outcomes were changes of probing pocket depth (PPD), bleeding on probing (BOP), and frequency of pocket closure. ","['43 patients with stage IV periodontitis', 'patients with stage IV periodontitis']","['late (6 months post-surgically) orthodontic therapy (OT', 'orthodontic therapy', 'late OT']","['PPD', 'clinical attachment level (CAL', 'CAL gain', 'changes of probing pocket depth (PPD), bleeding on probing (BOP), and frequency of pocket closure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}]","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}]",43.0,0.295958,"Secondary outcomes were changes of probing pocket depth (PPD), bleeding on probing (BOP), and frequency of pocket closure. ","[{'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Jepsen', 'Affiliation': 'Department of Periodontology, Operative and Preventive Dentistry, University Hospital of Bonn, Bonn, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Tietmann', 'Affiliation': 'Private Practice for Periodontology, Aachen, Germany.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Kutschera', 'Affiliation': 'Department of Orthodontics, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Wüllenweber', 'Affiliation': 'Private Practice for Orthodontics, Aachen, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Jäger', 'Affiliation': 'Department of Orthodontics, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Cardaropoli', 'Affiliation': 'Private Practice, Torino, Italy.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Gaveglio', 'Affiliation': 'Private Practice, Torino, Italy.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Sanz Sanchez', 'Affiliation': 'ETEP Research Group, University Complutense of Madrid, Madrid, Spain.'}, {'ForeName': 'Conchita', 'Initials': 'C', 'LastName': 'Martin', 'Affiliation': 'BIOCRAN Research Group, University Complutense of Madrid, Madrid, Spain.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Fimmers', 'Affiliation': 'Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Jepsen', 'Affiliation': 'Department of Periodontology, Operative and Preventive Dentistry, University Hospital of Bonn, Bonn, Germany.'}]",Journal of clinical periodontology,['10.1111/jcpe.13528'] 1834,34311338,"Response to the letter to editors by Gray et al. (2021) regarding ""Ethical issues with Zhang et al. (2017) a randomised controlled trial in comparing maternal and neonatal outcomes between hands-and-knees delivery position and supine position in China"".",,2021,,['hands-and-knees delivery position and supine position in China'],[],[],"[{'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C0008115', 'cui_str': 'China'}]",[],[],,0.0783218,,"[{'ForeName': 'Wenzhi', 'Initials': 'W', 'LastName': 'Cai', 'Affiliation': 'Shenzhen hospital of Southern Medical University, Shenzhen, China.'}]",Midwifery,['10.1016/j.midw.2021.103034'] 1835,34311336,"Safety and acceptance of ""Vibwife"", a new moving mattress to support mobilization during labor: Result of a clinical study.","OBJECTIVE To examine the safety and acceptance ""Vibwife"", a new moving mattress to support mobilization of pregnant women during labor. DESIGN The study was a prospective medical device clinical study without a control group. The study was designed in intervention phases, with safety evaluation by a safety review board after each intervention phase. SETTING The study took place at the University Hospital of Basel, Switzerland. PARTICIPANTS 50 women were included with a low risk singleton pregnancy > 37 th weeks during the first stage of labor. INTERVENTION Evaluation of the safety and acceptance of women, midwives and physicians during the first stage of labor. The intervention was carried out in 3 phases. In the first phase five women in labor used the device for 10 minutes, the next 10 women for 20 minutes, and finally the next 35 women for 30 minutes. MEASUREMENTS Measurement included capturing Adverse Events (AEs) (including Adverse Device Effects (ADEs)), Serious Adverse Events (SAEs) and recording vital parameters before, during, and after intervention, as well as CTG before and after intervention. Acceptance by women, midwives and physicians was measured by questionnaires with a 4-point Likert scale and pain intensity by a discrete Visual Analogue Scale (VAS) from 0-10. FINDINGS No SAE occurred during the trial. A total of 32 AEs occurred in 25 women during the intervention or in the 30 minutes follow-up. The most frequently observed AEs were modification of blood pressure and CTG abnormalities. None of the 32 AEs led to sequels of any kind. The relationship between AEs occurrence and the use of the medical device was viewed as certain in 2 cases (6.2%), possible or likely in 8 cases (25%), and unlikely or unrelated in 22 cases (68, 7%). Overall, women, midwives and physicians reported high satisfaction with their use of the device. KEY CONCLUSIONS AND IMPLICATIONS FOR PRACTICE The medical device ""Vibwife"" was judged as safe for women. Acceptance among women and health personnel was good. Considering the potential benefits of mobilization during labor, this new medical device could be a very interesting adjunct to other obstetrical tools. Particularly, women whose mobility is restrained by epidural anesthesia while giving birth could be very suitable candidates. To answer the question of efficacy, a randomized-controlled trial is required.",2021,None of the 32 AEs led to sequels of any kind.,"['50 women were included with a low risk singleton pregnancy > 37 th weeks during the first stage of labor', 'women, midwives and physicians during the first stage of labor', 'pregnant women during labor']",[],"['4-point Likert scale and pain intensity by a discrete Visual Analogue Scale (VAS', 'blood pressure and CTG abnormalities', 'capturing Adverse Events (AEs) (including Adverse Device Effects (ADEs)), Serious Adverse Events (SAEs) and recording vital parameters']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0022871', 'cui_str': 'First stage of labor'}, {'cui': 'C0026083', 'cui_str': 'Professional midwife'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0022864', 'cui_str': 'Labor'}]",[],"[{'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",50.0,0.0503648,None of the 32 AEs led to sequels of any kind.,"[{'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Monod', 'Affiliation': 'University Hospital Basel, Department of Obstetrics and Gynecology, Spitalstrasse 21, 4031 Basel, Switzerland. Electronic address: cecile.monod@usb.ch.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Granado', 'Affiliation': 'University Hospital Basel, Department of Obstetrics and Gynecology, Spitalstrasse 21, 4031 Basel, Switzerland. Electronic address: cristina.granado@usb.ch.'}, {'ForeName': 'Doris', 'Initials': 'D', 'LastName': 'Mueller', 'Affiliation': 'University Hospital Basel, Department of Obstetrics and Gynecology, Spitalstrasse 21, 4031 Basel, Switzerland. Electronic address: doris.mueller@usb.ch.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Gisin', 'Affiliation': 'University Hospital Basel, Department of Obstetrics and Gynecology, Spitalstrasse 21, 4031 Basel, Switzerland. Electronic address: martina.gisin@usb.ch.'}, {'ForeName': 'Jean-Jacques', 'Initials': 'JJ', 'LastName': 'Ries', 'Affiliation': 'University Hospital Basel, Department of Obstetrics and Gynecology, Spitalstrasse 21, 4031 Basel, Switzerland. Electronic address: jeanjacques.ries@usb.ch.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Horn', 'Affiliation': 'University Hospital Basel, Department of Obstetrics and Gynecology, Spitalstrasse 21, 4031 Basel, Switzerland. Electronic address: stephanie.toth@usb.ch.'}, {'ForeName': 'Tobias E', 'Initials': 'TE', 'LastName': 'Erlanger', 'Affiliation': 'University Basel, Department of Clinical Research, Clinical Trial Unit, c/o University Hospital Basel, Spitalstrasse 12, 4031 Basel, Switzerland. Electronic address: tobias.erlanger@usb.ch.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Hoesli', 'Affiliation': 'University Hospital Basel, Department of Obstetrics and Gynecology, Spitalstrasse 21, 4031 Basel, Switzerland. Electronic address: irene.hoesli@usb.ch.'}]",Midwifery,['10.1016/j.midw.2021.103096'] 1836,34311303,Spatial sonification of letters on tablets to stimulate literacy skills and handwriting in 5 y-o children: A pilot study.,"We evaluate the effects of multisensory training on letters, including sonification of graphic symbols. We used ""spatial sonification"" where letter handwriting movements recorded in a two dimensional plan, vertical and horizontal, are systematically assigned to two acoustic features, spectral composition for the horizontal axis and frequency for the vertical axis. Forty-six kindergarten children were recruited. They were randomly assigned to three multisensory training groups: with sonification (Son) of letters, with a melody unrelated to the shape of the letters (Mel) and without any sound (Sil). We observed a significant effect of training, with the Son group performing better than the other groups in the reading and spelling tasks. We also observed a modification of two kinematic cues (time and in-air time) during handwriting, also in the Son group. We conclude that letter sonification could act as a binder between the visual and auditory dimensions of the letter. The processes underlying this benefit are discussed in the light of the Act-In model, a cognition memory model.",2021,"We observed a significant effect of training, with the Son group performing better than the other groups in the reading and spelling tasks.","['5 y-o children', 'Forty-six kindergarten children']","['multisensory training groups: with sonification (Son) of letters, with a melody unrelated to the shape of the letters (Mel) and without any sound (Sil', 'multisensory training']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0445356', 'cui_str': 'Unrelated'}, {'cui': 'C0332479', 'cui_str': 'Shape finding'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0257766', 'cui_str': 'SILV protein, human'}]",[],46.0,0.0142231,"We observed a significant effect of training, with the Son group performing better than the other groups in the reading and spelling tasks.","[{'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Ecalle', 'Affiliation': ""Laboratoire d'Etude des Mécanismes Cognitifs (EA 3082), MSH LSE USR CNRS 2005, Université Lyon2, France; LabEx Cortex ANR-11-LABX-0042, Université de Lyon, France. Electronic address: ecalle.jean@wanadoo.fr.""}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Boisson', 'Affiliation': ""Laboratoire d'Etude des Mécanismes Cognitifs (EA 3082), MSH LSE USR CNRS 2005, Université Lyon2, France; LabEx Cortex ANR-11-LABX-0042, Université de Lyon, France.""}, {'ForeName': 'Hélène', 'Initials': 'H', 'LastName': 'Labat', 'Affiliation': 'Laboratoire Paragraphe, Université de Cergy-Pontoise, Université Paris 8, France.'}, {'ForeName': 'Rémy', 'Initials': 'R', 'LastName': 'Versace', 'Affiliation': ""Laboratoire d'Etude des Mécanismes Cognitifs (EA 3082), MSH LSE USR CNRS 2005, Université Lyon2, France; LabEx Cortex ANR-11-LABX-0042, Université de Lyon, France.""}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Magnan', 'Affiliation': ""Laboratoire d'Etude des Mécanismes Cognitifs (EA 3082), MSH LSE USR CNRS 2005, Université Lyon2, France; LabEx Cortex ANR-11-LABX-0042, Université de Lyon, France.""}]",Human movement science,['10.1016/j.humov.2021.102844'] 1837,34311300,Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201.,"BACKGROUND There is no standard chemotherapy for esophageal squamous cell carcinoma (ESCC) refractory to first-line fluoropyrimidine- and platinum-based chemotherapy. We therefore performed a randomized, selection-design phase II trial to compare docetaxel (DTX) and paclitaxel (PTX) in this setting. PATIENTS AND METHODS Eligible patients were randomly assigned to receive either DTX (70 mg/m 2 on day 1 of each 21-day cycle) or PTX (100 mg/m 2 on days 1, 8, 15, 22, 29 and 36 of each 49-day cycle). The primary end-point was overall survival (OS), and secondary end-points included progression-free survival (PFS), time to treatment failure (TTF), response rate (RR) and safety. RESULTS Seventy-eight eligible patients (N = 39 in each group) were included for efficacy analysis. OS was significantly longer in the PTX group than in the DTX group (median, 8.8 versus 7.3 months; hazard ratio [HR], 0.62; P = 0.047). A significant benefit of PTX over DTX was also apparent in PFS (median, 4.4 versus 2.1 months; HR, 0.49; P = 0.002) and TTF (median, 3.8 versus 2.1 months; HR, 0.45; P < 0.001). RR (25.6% versus 7.7%, P = 0.065) were higher in the PTX group than in the DTX group. Compared to the PTX group, neutropenia (28% versus 80%) and leukopenia (28% versus 76%) of grade ≥3 as well as febrile neutropenia (0% vs. 46%, P < 0.0001) occurred more frequently in the DTX group. CONCLUSION PTX showed a significantly better efficacy as well as a more manageable toxicity compared with DTX. CLINICAL TRIAL REGISTRATION UMIN000007940.",2021,"RR (25.6% versus 7.7%, P = 0.065) were higher in the PTX group than in the DTX group.","['Seventy-eight eligible patients (N\xa0', 'patients with esophageal squamous cell carcinoma refractory to', 'Eligible patients', 'esophageal squamous cell carcinoma (ESCC) refractory to first-line']","['fluoropyrimidine- and platinum-based chemotherapy', 'docetaxel versus paclitaxel', 'DTX', 'fluoropyrimidine- and platinum-based chemotherapy: OGSG1201', 'PTX', 'standard chemotherapy', 'docetaxel (DTX) and paclitaxel (PTX']","['manageable toxicity', 'neutropenia', 'OS', 'leukopenia', 'PFS', 'TTF', 'RR', 'overall survival (OS), and secondary end-points included progression-free survival (PFS), time to treatment failure (TTF), response rate (RR)\xa0and safety', 'febrile neutropenia']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0279626', 'cui_str': 'Squamous cell carcinoma of esophagus'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0205132', 'cui_str': 'Linear'}]","[{'cui': 'C3536920', 'cui_str': 'Platinum compounds'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0216817', 'cui_str': 'dendrotoxin K'}, {'cui': 'C0030899', 'cui_str': 'Pentoxifylline'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C4087167', 'cui_str': 'Tumour treating fields therapy'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3494202', 'cui_str': 'Time to Treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}]",78.0,0.16196,"RR (25.6% versus 7.7%, P = 0.065) were higher in the PTX group than in the DTX group.","[{'ForeName': 'Sachiko', 'Initials': 'S', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Osaka, 541-8567, Japan. Electronic address: yamamoto-sa@mc.pref.osaka.jp.'}, {'ForeName': 'Hisato', 'Initials': 'H', 'LastName': 'Kawakami', 'Affiliation': 'Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Osaka, 589-8511, Japan. Electronic address: kawakami_h@med.kindai.ac.jp.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Kii', 'Affiliation': 'Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-0801, Japan. Electronic address: in2058@osaka-med.ac.jp.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Department of Gastroenterology, Saitama Cancer Center, Kitaadachi-gun, Saitama, 362-0806, Japan. Electronic address: hirhara@cancer-c.pref.saitama.jp.'}, {'ForeName': 'Ryohei', 'Initials': 'R', 'LastName': 'Kawabata', 'Affiliation': 'Department of Surgery, Osaka Rosai Hospital, Sakai, Osaka, 591-8025, Japan; Department of Surgery, Sakai City Medical Center, Sakai, Osaka, 593-8304, Japan. Electronic address: r-kawabata@umin.ac.jp.'}, {'ForeName': 'Junji', 'Initials': 'J', 'LastName': 'Kawada', 'Affiliation': 'Department of Surgery, Osaka General Medical Center, Osaka, Osaka, 558-8558, Japan. Electronic address: j-kawada@umin.ac.jp.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Takeno', 'Affiliation': 'Department of Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, 660-8511, Japan. Electronic address: takeno-atsushi@kansaih.johas.go.jp.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Matsuyama', 'Affiliation': 'Department of Surgery, Yao Municipal Hospital, Yao, Osaka, 581-0069, Japan. Electronic address: matsuyama-j@higashiosaka-hosp.jp.'}, {'ForeName': 'Shugo', 'Initials': 'S', 'LastName': 'Ueda', 'Affiliation': 'Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Osaka, 530-8480, Japan. Electronic address: shu-ueda@kitano-hp.or.jp.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Okita', 'Affiliation': 'Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan; Department of Clinical Oncology, Kagawa University Faculty of Medicine, Kita-gun, Kagawa, 761-0793, Japan. Electronic address: yokita@med.kagawa-u.ac.jp.'}, {'ForeName': 'Shunji', 'Initials': 'S', 'LastName': 'Endo', 'Affiliation': 'Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Osaka, 578-8588, Japan. Electronic address: endo-s@med.kawasaki-m.ac.jp.'}, {'ForeName': 'Yutaka', 'Initials': 'Y', 'LastName': 'Kimura', 'Affiliation': 'Department of Surgery, Sakai City Medical Center, Sakai, Osaka, 593-8304, Japan; Department of Surgery, Kindai University Faculty of Medicine, Osakasayama, Osaka, 589-8511, Japan. Electronic address: you-kimura@med.kindai.ac.jp.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Yanagihara', 'Affiliation': 'Department of Medical Oncology, Kansai Electric Power Hospital, Osaka, Osaka, 553-0003, Japan. Electronic address: kazuhiro@kuhp.kyoto-u.ac.jp.'}, {'ForeName': 'Tatsuya', 'Initials': 'T', 'LastName': 'Okuno', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Graduate School of Medicine, Kobe University, Kobe, Hyogo, 650-0017, Japan. Electronic address: t-okuno@pg7.so-net.ne.jp.'}, {'ForeName': 'Yukinori', 'Initials': 'Y', 'LastName': 'Kurokawa', 'Affiliation': 'Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. Electronic address: ykurokawa@gesurg.med.osaka-u.ac.jp.'}, {'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Shimokawa', 'Affiliation': 'Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, Wakayama, Wakayama, 641-8510, Japan. Electronic address: shimokaw@wakayama-med.ac.jp.'}, {'ForeName': 'Taroh', 'Initials': 'T', 'LastName': 'Satoh', 'Affiliation': 'Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. Electronic address: taroh@cfs.med.osaka-u.ac.jp.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.06.035'] 1838,34311292,Effect of Repeated simulation experience on perceived self-efficacy among undergraduate nursing students.,"INTRODUCTION Simulation is an innovative teaching pedagogy commonly used in nursing education. Simulation-based nursing education increases the clinical competency of nursing students. However, it is unknown if the repetitive practice of skills through simulation results in long-term retention of both low- and high-complexity skills. OBJECTIVES The objective of the study was to evaluate the effect of repeated simulation experience post debriefing on the undergraduate nursing students' self-efficacy. METHODS A quasi-experimental one-group repeated measures design was used. A convenience sample involving undergraduate nursing students enrolled in ""Nursing Care for Childbearing Families"" and ""Nursing Care for Child-rearing Families"" (N = 126) were chosen. A self-reported Self-efficacy Likert scale was used to measure the student's self-efficacy. RESULTS Findings showed drop in self-efficacy following the first simulation with a significant improvement of the students' self-efficacy following a repeated simulation experience. CONCLUSION This finding could inspire nursing faculty to adopt the repeated simulation experience that will allow the students to master the case scenario and clinical skills while enhancing self-efficacy.",2021,"RESULTS Findings showed drop in self-efficacy following the first simulation with a significant improvement of the students' self-efficacy following a repeated simulation experience. ","['nursing students', 'undergraduate nursing students', 'undergraduate nursing students enrolled in ""Nursing Care for Childbearing Families"" and ""Nursing Care for Child-rearing Families']","['Simulation-based nursing education', 'Repeated simulation experience', 'repeated simulation experience post debriefing']","['self-efficacy', 'Self-efficacy Likert scale', ""students' self-efficacy""]","[{'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0028678', 'cui_str': 'nursing'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013636', 'cui_str': 'Nursing Education'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C0038492', 'cui_str': 'Student'}]",126.0,0.0279131,"RESULTS Findings showed drop in self-efficacy following the first simulation with a significant improvement of the students' self-efficacy following a repeated simulation experience. ","[{'ForeName': 'Koukab Abdullah', 'Initials': 'KA', 'LastName': 'Al Gharibi', 'Affiliation': 'Nursing Education Clinical Simulation Unit, College of Nursing, Sultan Qaboos University, Al khoudh, Muscat, P.O box 66, 123, Oman. Electronic address: kawkab@squ.edu.om.'}, {'ForeName': 'Nola', 'Initials': 'N', 'LastName': 'Schmidt', 'Affiliation': 'Valparaiso University College of Nursing, 836 LaPorte Ave, Valparaiso, IN 46383, United States of America. Electronic address: Nola.Schmidt@valpo.edu.'}, {'ForeName': 'Judie', 'Initials': 'J', 'LastName': 'Arulappan', 'Affiliation': 'Department of Maternal and Child health, College of Nursing, Sultan Qaboos University, Al Khoudh, P.O box -66, 123 Muscat, Oman. Electronic address: judie@squ.edu.om.'}]",Nurse education today,['10.1016/j.nedt.2021.105057'] 1839,34313697,Effect of Systemic Hydrocortisone Initiated 7 to 14 Days After Birth in Ventilated Preterm Infants on Mortality and Neurodevelopment at 2 Years' Corrected Age: Follow-up of a Randomized Clinical Trial.,,2021,,['Ventilated Preterm Infants'],['Systemic Hydrocortisone'],['Mortality and Neurodevelopment'],"[{'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.275189,,"[{'ForeName': 'Nienke M', 'Initials': 'NM', 'LastName': 'Halbmeijer', 'Affiliation': ""Department of Neonatology, Emma Children's Hospital Amsterdam UMC, Amsterdam, the Netherlands.""}, {'ForeName': 'Wes', 'Initials': 'W', 'LastName': 'Onland', 'Affiliation': ""Department of Neonatology, Emma Children's Hospital Amsterdam UMC, Amsterdam, the Netherlands.""}, {'ForeName': 'Filip', 'Initials': 'F', 'LastName': 'Cools', 'Affiliation': 'Department of Neonatology, Universitair Ziekenhuis Brussel, Jette, Belgium.'}, {'ForeName': 'Renate', 'Initials': 'R', 'LastName': 'Swarte', 'Affiliation': 'Department of Neonatology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands.'}, {'ForeName': 'Marja', 'Initials': 'M', 'LastName': 'van der Heide-Jalving', 'Affiliation': 'Department of Neonatology, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Maruschka P', 'Initials': 'MP', 'LastName': 'Merkus', 'Affiliation': 'Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Anton H', 'Initials': 'AH', 'LastName': 'van Kaam', 'Affiliation': ""Department of Neonatology, Emma Children's Hospital Amsterdam UMC, Amsterdam, the Netherlands.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2021.9380'] 1840,34313687,Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial.,"Importance Adoption of guideline-directed medical therapy for patients with heart failure is variable. Interventions to improve guideline-directed medical therapy have failed to consistently achieve target metrics, and limited data exist to inform efforts to improve heart failure quality of care. Objective To evaluate the effect of a hospital and postdischarge quality improvement intervention compared with usual care on heart failure outcomes and care. Design, Setting, and Participants This cluster randomized clinical trial was conducted at 161 US hospitals and included 5647 patients (2675 intervention vs 2972 usual care) followed up after a hospital discharge for acute heart failure with reduced ejection fraction (HFrEF). The trial was performed from 2017 to 2020, and the date of final follow-up was August 31, 2020. Interventions Hospitals (n = 82) randomized to a hospital and postdischarge quality improvement intervention received regular education of clinicians by a trained group of heart failure and quality improvement experts and audit and feedback on heart failure process measures (eg, use of guideline-directed medical therapy for HFrEF) and outcomes. Hospitals (n = 79) randomized to usual care received access to a generalized heart failure education website. Main Outcomes and Measures The coprimary outcomes were a composite of first heart failure rehospitalization or all-cause mortality and change in an opportunity-based composite score for heart failure quality (percentage of recommendations followed). Results Among 5647 patients (mean age, 63 years; 33% women; 38% Black; 87% chronic heart failure; 49% recent heart failure hospitalization), vital status was known for 5636 (99.8%). Heart failure rehospitalization or all-cause mortality occurred in 38.6% in the intervention group vs 39.2% in usual care (adjusted hazard ratio, 0.92 [95% CI, 0.81 to 1.05). The baseline quality-of-care score was 42.1% vs 45.5%, respectively, and the change from baseline to follow-up was 2.3% vs -1.0% (difference, 3.3% [95% CI, -0.8% to 7.3%]), with no significant difference between the 2 groups in the odds of achieving a higher composite quality score at last follow-up (adjusted odds ratio, 1.06 [95% CI, 0.93 to 1.21]). Conclusions and Relevance Among patients with HFrEF in hospitals randomized to a hospital and postdischarge quality improvement intervention vs usual care, there was no significant difference in time to first heart failure rehospitalization or death, or in change in a composite heart failure quality-of-care score. Trial Registration ClinicalTrials.gov Identifier: NCT03035474.",2021,"Heart failure rehospitalization or all-cause mortality occurred in 38.6% in the intervention group vs 39.2% in usual care (adjusted hazard ratio, 0.92 [95% CI, 0.81 to 1.05).","['5647 patients (mean age, 63 years; 33% women; 38% Black; 87% chronic heart failure', 'Patients With Heart Failure With Reduced Ejection Fraction', 'Interventions\n\n\nHospitals (n\u2009', 'patients with HFrEF in hospitals', 'patients with heart failure', '2017 to 2020, and the date of final follow-up was August 31, 2020', '161 US hospitals and included 5647 patients (2675 intervention vs 2972 usual care) followed up after a hospital discharge for acute heart failure with reduced ejection fraction (HFrEF']","['usual care received access to a generalized heart failure education website', 'hospital and postdischarge quality improvement intervention received regular education of clinicians by a trained group of heart failure and quality improvement experts and audit and feedback on heart failure process measures (eg, use of guideline-directed medical therapy for HFrEF', 'Hospital and Postdischarge Quality Improvement Intervention', 'guideline-directed medical therapy', 'hospital and postdischarge quality improvement intervention']","['composite quality score', 'time to first heart failure rehospitalization or death', 'heart failure hospitalization), vital status', 'composite of first heart failure rehospitalization or all-cause mortality and change in an opportunity-based composite score for heart failure quality (percentage of recommendations followed', 'Heart failure rehospitalization or all-cause mortality', 'Clinical Outcomes and Quality of Care', 'baseline quality-of-care score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0264714', 'cui_str': 'Acute heart failure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]","[{'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1828111', 'cui_str': 'Heart failure education'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C2936612', 'cui_str': 'Quality Improvement'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0086850', 'cui_str': 'Process Measures'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",5647.0,0.27936,"Heart failure rehospitalization or all-cause mortality occurred in 38.6% in the intervention group vs 39.2% in usual care (adjusted hazard ratio, 0.92 [95% CI, 0.81 to 1.05).","[{'ForeName': 'Adam D', 'Initials': 'AD', 'LastName': 'DeVore', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Bradi B', 'Initials': 'BB', 'LastName': 'Granger', 'Affiliation': 'Duke University School of Nursing, Durham, North Carolina.'}, {'ForeName': 'Gregg C', 'Initials': 'GC', 'LastName': 'Fonarow', 'Affiliation': 'Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, California.'}, {'ForeName': 'Hussein R', 'Initials': 'HR', 'LastName': 'Al-Khalidi', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Nancy M', 'Initials': 'NM', 'LastName': 'Albert', 'Affiliation': 'Nursing Institute and Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Eldrin F', 'Initials': 'EF', 'LastName': 'Lewis', 'Affiliation': 'Division of Cardiovascular Medicine, Stanford University, Palo Alto, California.'}, {'ForeName': 'Javed', 'Initials': 'J', 'LastName': 'Butler', 'Affiliation': 'Department of Medicine, University of Mississippi Medical Center, Jackson.'}, {'ForeName': 'Ileana L', 'Initials': 'IL', 'LastName': 'Piña', 'Affiliation': 'Wayne State University and Detroit Medical Center, Detroit, Michigan.'}, {'ForeName': 'Larry A', 'Initials': 'LA', 'LastName': 'Allen', 'Affiliation': 'Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado School of Medicine, Aurora.'}, {'ForeName': 'Clyde W', 'Initials': 'CW', 'LastName': 'Yancy', 'Affiliation': 'Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Lauren B', 'Initials': 'LB', 'LastName': 'Cooper', 'Affiliation': 'Department of Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, Virginia.'}, {'ForeName': 'G Michael', 'Initials': 'GM', 'LastName': 'Felker', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Kaltenbach', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'A Thomas', 'Initials': 'AT', 'LastName': 'McRae', 'Affiliation': 'Centennial Heart, Nashville, Tennessee.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Lanfear', 'Affiliation': 'Henry Ford Heart and Vascular Institute, Department of Medicine, Cardiovascular Division, Henry Ford Hospital, Detroit, Michigan.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Harrison', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Maghee', 'Initials': 'M', 'LastName': 'Disch', 'Affiliation': 'American College of Cardiology, Washington, DC.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Ariely', 'Affiliation': 'Center for Advanced Hindsight, Duke University, Durham, North Carolina.'}, {'ForeName': 'Julie M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'Center for Advanced Hindsight, Duke University, Durham, North Carolina.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'Granger', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Adrian F', 'Initials': 'AF', 'LastName': 'Hernandez', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.'}]",JAMA,['10.1001/jama.2021.8844'] 1841,34313686,Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial.,"Importance Determination of optimal treatment durations for common infectious diseases is an important strategy to preserve antibiotic effectiveness. Objective To determine whether 7 days of treatment is noninferior to 14 days when using ciprofloxacin or trimethoprim/sulfamethoxazole to treat urinary tract infection (UTI) in afebrile men. Design, Setting, and Participants Randomized, double-blind, placebo-controlled noninferiority trial of afebrile men with presumed symptomatic UTI treated with ciprofloxacin or trimethoprim/sulfamethoxazole at 2 US Veterans Affairs medical centers (enrollment, April 2014 through December 2019; final follow-up, January 28, 2020). Of 1058 eligible men, 272 were randomized. Interventions Participants continued the antibiotic prescribed by their treating clinician for 7 days of treatment and were randomized to receive continued antibiotic therapy (n = 136) or placebo (n = 136) for days 8 to 14 of treatment. Main Outcomes and Measures The prespecified primary outcome was resolution of UTI symptoms by 14 days after completion of active antibiotic treatment. A noninferiority margin of 10% was selected. The as-treated population (participants who took ≥26 of 28 doses and missed no more than 2 consecutive doses) was used for the primary analysis, and a secondary analysis included all patients as randomized, regardless of treatment adherence. Secondary outcomes included recurrence of UTI symptoms and/or adverse events within 28 days of stopping study medication. Results Among 272 patients (median [interquartile range] age, 69 [62-73] years) who were randomized, 100% completed the trial and 254 (93.4%) were included in the primary as-treated analysis. Symptom resolution occurred in 122/131 (93.1%) participants in the 7-day group vs 111/123 (90.2%) in the 14-day group (difference, 2.9% [1-sided 97.5% CI, -5.2% to ∞]), meeting the noninferiority criterion. In the secondary as-randomized analysis, symptom resolution occurred in 125/136 (91.9%) participants in the 7-day group vs 123/136 (90.4%) in the 14-day group (difference, 1.5% [1-sided 97.5% CI, -5.8% to ∞]) Recurrence of UTI symptoms occurred in 13/131 (9.9%) participants in the 7-day group vs 15/123 (12.9%) in the 14-day group (difference, -3.0% [95% CI, -10.8% to 6.2%]; P = .70). Adverse events occurred in 28/136 (20.6%) participants in the 7-day group vs 33/136 (24.3%) in the 14-day group. Conclusions and Relevance Among afebrile men with suspected UTI, treatment with ciprofloxacin or trimethoprim/sulfamethoxazole for 7 days was noninferior to 14 days of treatment with regard to resolution of UTI symptoms by 14 days after antibiotic therapy. The findings support the use of a 7-day course of ciprofloxacin or trimethoprim/sulfamethoxazole as an alternative to a 14-day course for treatment of afebrile men with UTI. Trial Registration ClinicalTrials.gov identifier: NCT01994538.",2021,"Recurrence of UTI symptoms occurred in 13/131 (9.9%) participants in the 7-day group vs 15/123 (12.9%) in the 14-day group (difference, -3.0% [95% CI, -10.8% to 6.2%]; P = .70).","['1058 eligible men, 272 were randomized', 'afebrile men with UTI', '272 patients (median [interquartile range] age, 69 [62-73] years) who were randomized, 100% completed the trial and 254 (93.4%) were included in the primary as-treated analysis', 'at 2 US Veterans Affairs medical centers (enrollment, April 2014 through December 2019; final follow-up, January 28, 2020', 'afebrile men with presumed symptomatic UTI treated with', 'afebrile men with suspected UTI, treatment with', 'afebrile men', 'Afebrile Men With Urinary Tract Infection']","['continued antibiotic therapy', 'placebo', 'ciprofloxacin or trimethoprim/sulfamethoxazole', 'Antibiotic Therapy']","['Symptom resolution', 'resolution of UTI symptoms', 'Adverse events', 'Resolution of Symptoms', 'recurrence of UTI symptoms and/or adverse events', 'symptom resolution', 'Recurrence of UTI symptoms']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0277797', 'cui_str': 'Apyrexial'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C1277624', 'cui_str': 'Suspected UTI (urinary tract infection)'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0041041', 'cui_str': 'Trimethoprim'}, {'cui': 'C0038689', 'cui_str': 'Sulfamethoxazole'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",1058.0,0.442264,"Recurrence of UTI symptoms occurred in 13/131 (9.9%) participants in the 7-day group vs 15/123 (12.9%) in the 14-day group (difference, -3.0% [95% CI, -10.8% to 6.2%]; P = .70).","[{'ForeName': 'Dimitri M', 'Initials': 'DM', 'LastName': 'Drekonja', 'Affiliation': 'Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Trautner', 'Affiliation': 'Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Amundson', 'Affiliation': 'Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kuskowski', 'Affiliation': 'University of Minnesota Medical School, Minneapolis.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Johnson', 'Affiliation': 'Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota.'}]",JAMA,['10.1001/jama.2021.9899'] 1842,34314993,Psychosocial functioning in integrated treatment of co-occurring posttraumatic stress disorder and alcohol use disorder.,"Co-occurring posttraumatic stress disorder and alcohol use disorder (PTSD/AUD) is associated with poorer psychosocial functioning than either disorder alone; however, it is unclear if psychosocial functioning improves in treatment for PTSD/AUD. This study examined if psychosocial functioning improved in integrated treatments for PTSD/AUD, and if changes in PTSD severity and percentage heavy drinking days (PHDD) during treatment were associated with functioning outcomes. 119 veterans with PTSD/AUD randomized to receive either Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure or Seeking Safety completed measures of functioning (Medical Outcomes Survey SF-36), PTSD (Clinician Administered PTSD Scale for DSM-5), and alcohol use (Timeline Follow-Back) at baseline, posttreatment, 3- and 6-month follow-ups. Our findings suggest that psychosocial functioning improved to a statistically significant degree with no significant differences between conditions. Reductions in PTSD severity during treatment were associated with psychosocial functioning improvements, whereas reductions in PHDD were associated with improvement in role impairment at posttreatment. Although psychosocial functioning improves to a statistically significant degree in interventions designed to treat PTSD/AUD, these improvements do not represent clinically meaningful improvements in patients' abilities to navigate important roles. Findings underscore the need to study how to best treat psychosocial functioning impairment in PTSD/AUD.",2021,Our findings suggest that psychosocial functioning improved to a statistically significant degree with no significant differences between conditions.,['119 veterans with PTSD/AUD'],[],"['psychosocial functioning', 'PTSD severity', 'PTSD severity and percentage heavy drinking days (PHDD', 'functioning (Medical Outcomes Survey SF-36), PTSD (Clinician Administered PTSD Scale for DSM-5), and alcohol use (Timeline Follow-Back', 'Psychosocial functioning']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}]",[],"[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0556347', 'cui_str': 'Drinking day'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0145943', 'cui_str': 'TimeLine'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]",119.0,0.0764619,Our findings suggest that psychosocial functioning improved to a statistically significant degree with no significant differences between conditions.,"[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lyons', 'Affiliation': 'San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120, USA; V.A. San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA, 92161, USA.'}, {'ForeName': 'Kaitlyn E', 'Initials': 'KE', 'LastName': 'Panza', 'Affiliation': 'V.A. San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA, 92161, USA; Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive #9116B, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Helm', 'Affiliation': 'San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120, USA; Psychology Department, San Diego State University, 5500 Campanile Dr, San Diego, CA, 92182, USA.'}, {'ForeName': 'Abigail C', 'Initials': 'AC', 'LastName': 'Angkaw', 'Affiliation': 'San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120, USA; V.A. San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA, 92161, USA; Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive #9116B, La Jolla, CA, 92093, USA; Center of Excellence for Stress and Mental Health/VA San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA, 92161, USA; National Center for PTSD, 215 North Main St, White River Junction, VT, 05009, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Straus', 'Affiliation': 'V.A. San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA, 92161, USA.'}, {'ForeName': 'Sonya B', 'Initials': 'SB', 'LastName': 'Norman', 'Affiliation': 'V.A. San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA, 92161, USA; Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive #9116B, La Jolla, CA, 92093, USA; Center of Excellence for Stress and Mental Health/VA San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA, 92161, USA; National Center for PTSD, 215 North Main St, White River Junction, VT, 05009, USA. Electronic address: snorman@ucsd.edu.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2021.07.036'] 1843,34314941,Effect of synchronous online vs. face-to-face cardiopulmonary resuscitation training on chest compression quality: A pilot randomized manikin study.,"OBJECTIVES The aim of the study was to compare the effect of synchronous online and face-to-face cardiopulmonary resuscitation (CPR) training on chest compressions quality in a manikin model. METHODS A total of 118 fourth-year medical students participated in this study. The participants were divided into two groups: the online synchronous teaching group and the face-to-face group. Then, the participants were further randomly distributed to 1 of 2 feedback groups: online synchronous teaching and training with feedback devices (TF, n = 30) or without feedback devices (TN, n = 29) and face-to-face teaching and training with feedback devices (FF, n = 30) or without feedback devices (FN, n = 29). In the FN group and FF group, instructors delivered a 45-min CPR training program and gave feedback and guidance during training on site. In the TN group and TF group, the participants were trained with an online lecture via Tencent Meeting live broadcasting. Finally, participants performed a 2-min continuous chest compression (CC) during a simulated cardiopulmonary arrest scene without the audiovisual feedback (AVF) device. The outcome measures included CC depth, CC rate, proportions of appropriate depth (50-60 mm) and CC rate (100-120/min), percentage of correct hand location position, and percentage of complete chest recoil. RESULTS There was little difference in the CC quality between the synchronous online training groups and the face-to-face training groups. There was no statistically significant difference in CC quality between the TN group and FN group. There were also no statistically significant differences between the TF and FF groups in terms of correct hand position, CC depth, appropriate CC depth, complete chest recoil or CC rate. However, the FF group had a higher appropriate CC rate than the TF group (p = 0.045). In the face-to-face training groups, the AVF device group had a significantly greater CC depth, appropriate CC depth, CC rate, and appropriate CC rate. However, there was a lack of statistically significant differences in terms of correct hand position (p = 0.191) and appropriate CC depth (p = 0.123). In the synchronous online training groups, the AVF device had little effect on the CC rate (p = 0.851) and increased the appropriate CC rate, but the difference was not statistically significant (p = 0.178). CONCLUSIONS Synchronous online training with an AVF device would be a potential alternative approach to face-to-face chest compression training. Synchronous online training with AVF devices seems to be a suitable replacement for face-to-face training to offer adequate bystander CPR chest compression training.",2021,There was little difference in the CC quality between the synchronous online training groups and the face-to-face training groups.,['A total of 118 fourth-year medical students participated in this study'],"['online synchronous teaching and training with feedback devices (TF, n = 30) or without feedback devices (TN, n = 29) and face-to-face teaching and training with feedback devices (FF, n = 30) or without feedback devices', '45-min CPR training program', 'online synchronous teaching group and the face-to-face group', 'synchronous online and face-to-face cardiopulmonary resuscitation (CPR) training', '2-min continuous chest compression (CC) during a simulated cardiopulmonary arrest scene without the audiovisual feedback (AVF) device', 'synchronous online vs. face-to-face cardiopulmonary resuscitation training']","['CC depth, CC rate, proportions of appropriate depth (50-60 mm) and CC rate (100-120/min), percentage of correct hand location position, and percentage of complete chest recoil', 'correct hand position, CC depth, appropriate CC depth, complete chest recoil or CC rate', 'chest compression quality', 'CC quality', 'appropriate CC rate', 'CC depth, appropriate CC depth, CC rate, and appropriate CC rate', 'CC rate', 'chest compressions quality']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0600228', 'cui_str': 'Cardiorespiratory arrest'}]","[{'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332306', 'cui_str': 'Quality'}]",118.0,0.00567548,There was little difference in the CC quality between the synchronous online training groups and the face-to-face training groups.,"[{'ForeName': 'Lian', 'Initials': 'L', 'LastName': 'Lin', 'Affiliation': 'Emergency Center, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China.'}, {'ForeName': 'Shaozhou', 'Initials': 'S', 'LastName': 'Ni', 'Affiliation': 'Emergency Center, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China; Hubei Clinical Research Center for Emergency and Resuscitation, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'Emergency Center, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China.'}, {'ForeName': 'Zhongxiang', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Emergency Center, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zeng', 'Affiliation': 'Emergency Center, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China.'}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'Jin', 'Affiliation': 'Emergency Center, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China; Hubei Clinical Research Center for Emergency and Resuscitation, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China. Electronic address: redjin@whu.edu.cn.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Emergency Center, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China; Hubei Clinical Research Center for Emergency and Resuscitation, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China. Electronic address: doctoryanzhao@whu.edu.cn.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2021.07.009'] 1844,34314906,Granisetron or ondansentron to prevent hypotension after spinal anesthesia for elective cesarean delivery: A randomized placebo-controlled trial.,"STUDY OBJECTIVE This study aimed to compare the effects of high doses of ondansetron and granisetron before spinal anesthesia on hemodynamic parameters in patients undergoing elective cesarean section. DESIGN A double-blinded randomized placebo-controlled trial. SETTING Operating room. PATIENTS A total of 120 parturients with term pregnancy undergoing elective cesarean section with combined spinal-epidural anesthesia were included. INTERVENTIONS Three groups (n = 40 for each group) were formed by randomization. Five minutes before the anesthesia procedure, Group I received 8 mg intravenous (IV) ondansetron diluted in 10 ml normal saline, Group II received IV 3 mg granisetron diluted in 10 ml normal saline, and Group III received IV 10 ml normal saline. MEASUREMENTS Following intrathecal drug administration, intraoperative hemodynamic changes were recorded every 2 min for 20 min and then every 5 min until the end of the operation. MAIN RESULTS Twenty patients (50%) in Group I, 12 patients (30%) in Group II, and 29 patients (72.5%) in Group III had hypotension requiring treatment with IV ephedrine (P = 0.001). The ephedrine requirement in Group III was significantly higher than in Groups I (P = 0.033) and II (P < 0.001). Also, the ephedrine requirement in Group II was lower than in Group I, but the difference was not statistically significant (P = 0.055). The mean arterial pressure for the three groups differed in the 10th, 18th, and 60th minutes. The number of patients with nausea or vomiting was lower in Groups I and II than in Group III (P < 0.001). At 5 min, the Apgar scores were higher than 8 for all neonates. Postoperative scores for the visual analogue scale were similar for all groups. CONCLUSIONS It was concluded that prophylactic IV administration of 3 mg of granisetron or 8 mg of ondansetron before spinal anesthesia results in a significantly lower ephedrine requirement compared to placebo.",2021,The ephedrine requirement in Group III was significantly higher than in Groups I (P = 0.033) and II (P < 0.001).,"['120 parturients with term pregnancy undergoing elective cesarean section with combined spinal-epidural anesthesia were included', 'patients undergoing elective cesarean section', 'after spinal anesthesia for elective cesarean delivery']","['granisetron diluted in 10\xa0ml normal saline, and Group III received IV 10\xa0ml normal saline', 'granisetron', 'IV ephedrine', 'ondansetron', 'Granisetron or ondansentron', 'placebo', 'ondansetron and granisetron']","['number of patients with nausea or vomiting', 'mean arterial pressure', 'Postoperative scores for the visual analogue scale', 'intraoperative hemodynamic changes', 'Apgar scores', 'hypotension', 'ephedrine requirement', 'hemodynamic parameters']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0232991', 'cui_str': 'Term pregnancy'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}]","[{'cui': 'C0061863', 'cui_str': 'Granisetron'}, {'cui': 'C1720119', 'cui_str': 'Dilute'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0014479', 'cui_str': 'Ephedrine'}, {'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0003533', 'cui_str': 'Finding of Apgar score'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0014479', 'cui_str': 'Ephedrine'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",120.0,0.283009,The ephedrine requirement in Group III was significantly higher than in Groups I (P = 0.033) and II (P < 0.001).,"[{'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Aksoy', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Ataturk University, Erzurum, Turkey; Anesthesiology Clinical Research Office, Ataturk University, Erzurum, Turkey. Electronic address: drmaksoy@hotmail.com.'}, {'ForeName': 'Aysenur', 'Initials': 'A', 'LastName': 'Dostbil', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Ataturk University, Erzurum, Turkey; Anesthesiology Clinical Research Office, Ataturk University, Erzurum, Turkey.'}, {'ForeName': 'Ayse Nur', 'Initials': 'AN', 'LastName': 'Aksoy', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Health Sciences, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.'}, {'ForeName': 'Ilker', 'Initials': 'I', 'LastName': 'Ince', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Ataturk University, Erzurum, Turkey; Anesthesiology Clinical Research Office, Ataturk University, Erzurum, Turkey.'}, {'ForeName': 'Zehra', 'Initials': 'Z', 'LastName': 'Bedir', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Health Sciences, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.'}, {'ForeName': 'Ozgur', 'Initials': 'O', 'LastName': 'Ozmen', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Ataturk University, Erzurum, Turkey; Anesthesiology Clinical Research Office, Ataturk University, Erzurum, Turkey.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110469'] 1845,34319359,Effect of Targeted Behavioral Science Messages on COVID-19 Vaccination Registration Among Employees of a Large Health System: A Randomized Trial.,,2021,,['Employees of a Large Health System'],['Targeted Behavioral Science Messages'],['COVID-19 Vaccination Registration'],"[{'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0004940', 'cui_str': 'Behavioral Sciences'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",,0.163926,,"[{'ForeName': 'Henri C', 'Initials': 'HC', 'LastName': 'Santos', 'Affiliation': 'Behavioral Insights Team, Steele Institute for Health Innovation, Geisinger Health System, Danville, Pennsylvania.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Goren', 'Affiliation': 'Behavioral Insights Team, Steele Institute for Health Innovation, Geisinger Health System, Danville, Pennsylvania.'}, {'ForeName': 'Christopher F', 'Initials': 'CF', 'LastName': 'Chabris', 'Affiliation': 'Behavioral Insights Team, Steele Institute for Health Innovation, Geisinger Health System, Danville, Pennsylvania.'}, {'ForeName': 'Michelle N', 'Initials': 'MN', 'LastName': 'Meyer', 'Affiliation': 'Behavioral Insights Team, Steele Institute for Health Innovation, Geisinger Health System, Danville, Pennsylvania.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.18702'] 1846,34315799,SYMPERHEART: an intervention to support symptom perception in persons with heart failure and their informal caregiver: a feasibility quasi-experimental study protocol.,"INTRODUCTION Symptom perception in heart failure (HF) has been identified as crucial for effective self-care, and is related to patient and health system outcomes. There is uncertainty regarding the feasibility and acceptability of symptom perception support and doubts regarding how to include informal caregivers. This study aims to test the feasibility, acceptability and outcome responsiveness of an intervention supporting symptom perception in persons with HF and their informal caregiver. METHODS AND ANALYSIS A feasibility study with a quasi-experimental pretest and post-test single group design is conducted. The convenience sample consists of 30 persons with HF, their informal caregivers and six nurses. SYMPERHEART is an evidence-informed intervention that targets symptom perception by educational and support components. Feasibility is measured by time-to-recruit; time-to-deliver; eligibility rate; intervention delivery fidelity rate. Acceptability is measured by rate of consent, retention rate, treatment acceptability and the engagement in the intervention components. Outcome responsiveness includes: HF self-care (via the Self-care of Heart Failure Index V.7.2); perception of HF symptom burden (via the Heart Failure Somatic Perception Scale V.3); health status (via the Kansas City Cardiomyopathy Questionnaire-12); caregivers' contribution to HF self-care (via the Caregiver Contribution to Self-Care of Heart Failure Index 2); caregivers' burden (via the Zarit Burden Interview). Clinical outcomes include HF events, hospitalisation reason and length of hospital stay. Descriptive statistics will be used to report feasibility, acceptability, patient-reported outcomes (PRO) and clinical outcomes. PRO and caregiver-reported outcome responsiveness will be reported with mean absolute change and effect sizes. ETHICS AND DISSEMINATION The study is conducted according to the Declaration of Helsinki. The Human Research Ethics Committee of the Canton of Vaud, Switzerland, has approved the study. Written informed consent from persons with HF and informal caregivers are obtained. Results will be published via peer reviewed and professional journals, and further disseminated via congresses. TRIAL REGISTRATION NUMBER ISRCTN18151041.",2021,Outcome responsiveness includes: HF self-care (via the Self-care of Heart Failure Index V.7.2); perception of HF symptom burden (via the Heart Failure Somatic Perception Scale V.3); health status (via the Kansas City Cardiomyopathy Questionnaire-12); caregivers' contribution to HF self-care (via the Caregiver Contribution to Self-Care of Heart Failure Index 2); caregivers' burden (via the Zarit Burden Interview).,"['30 persons with HF, their informal caregivers and six nurses', 'persons with HF and their informal caregiver', 'heart failure (HF', 'persons with heart failure and their informal caregiver', 'persons with HF and informal caregivers']",[],"['HF events, hospitalisation reason and length of hospital stay', 'Acceptability', 'rate of consent, retention rate, treatment acceptability', ""HF self-care (via the Self-care of Heart Failure Index V.7.2); perception of HF symptom burden (via the Heart Failure Somatic Perception Scale V.3); health status (via the Kansas City Cardiomyopathy Questionnaire-12); caregivers' contribution to HF self-care (via the Caregiver Contribution to Self-Care of Heart Failure Index 2); caregivers' burden (via the Zarit Burden Interview""]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C1319882', 'cui_str': 'Informal caregiver'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}]",[],"[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1257909', 'cui_str': 'Diploid Cell'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]",30.0,0.250528,Outcome responsiveness includes: HF self-care (via the Self-care of Heart Failure Index V.7.2); perception of HF symptom burden (via the Heart Failure Somatic Perception Scale V.3); health status (via the Kansas City Cardiomyopathy Questionnaire-12); caregivers' contribution to HF self-care (via the Caregiver Contribution to Self-Care of Heart Failure Index 2); caregivers' burden (via the Zarit Burden Interview).,"[{'ForeName': 'Gabrielle Cécile', 'Initials': 'GC', 'LastName': 'Santos', 'Affiliation': 'School of Health Sciences Fribourg, HES-SO University of Applied Sciences and Arts Western Switzerland, Fribourg, Switzerland gabrielle.santos@hefr.ch.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Liljeroos', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, Linköping University, Linkoping, Sweden.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Hullin', 'Affiliation': 'Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.'}, {'ForeName': 'Kris', 'Initials': 'K', 'LastName': 'Denhaerynck', 'Affiliation': 'Institute of Nursing Science, Department of Public Health, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Wicht', 'Affiliation': ""Service d'Aide et de Soins à Domicile de la Sarine, Fribourg, Switzerland.""}, {'ForeName': 'Corrine Y', 'Initials': 'CY', 'LastName': 'Jurgens', 'Affiliation': 'William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Schäfer-Keller', 'Affiliation': 'School of Health Sciences Fribourg, HES-SO University of Applied Sciences and Arts Western Switzerland, Fribourg, Switzerland.'}]",BMJ open,['10.1136/bmjopen-2021-052208'] 1847,34315793,"Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity.","INTRODUCTION Retinopathy of prematurity (ROP) is a vascular proliferative disorder that occurs in preterm infants. Existing treatments are only indicated in severe ROP cases due to the high invasiveness and the potential risk of irreversible side effects. We previously elucidated that ripasudil, a selective inhibitor of the Rho-associated protein kinase, has the ability to inhibit abnormal retinal neovascularisation in animal models. In addition, ripasudil eye drops (Glanatec ophthalmic solution 0.4%) have been already used for the treatment of glaucoma. Since eye drop therapy is less invasive, early intervention for ROP is possible. The purpose of this phase I/II trial is to evaluate the safety and efficacy of ripasudil eye drops for preterm infants with ROP. METHODS AND ANALYSIS This is a multicentre, open-label, single-arm phase I/II trial. To evaluate the safety and efficacy of ripasudil as much as possible, ripasudil will be administered to all enrolled preterm infants with zone I/II, stage 1, or worse ROP. The safety and efficacy of ripasudil in treated patients will be assessed in comparison to a historical control group. Because this is the first trial of ripasudil in preterm infants, a dose-escalation study (once daily for 1 week, then two times per day for 2 weeks) will be conducted in phase I. After obtaining approval from the independent data and safety monitoring board to continue the trial after the completion of phase I, phase II will be conducted. In phase II, ripasudil eye drops will be administered two times per day for 12 weeks. The primary endpoint in phase II is also safety. Efficacy and pharmacokinetics will be evaluated as secondary endpoints. ETHICS AND DISSEMINATION This study protocol was approved by the institutional review board at each of the participating centres. Data will be presented at international conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBERS NCT04621136 and jRCT2071200047.",2021,"After obtaining approval from the independent data and safety monitoring board to continue the trial after the completion of phase I, phase II will be conducted.","['preterm infants with ROP', 'preterm infants', 'enrolled preterm infants with zone I/II, stage 1, or worse ROP']",['ripasudil eye drops'],"['safety and efficacy', 'Efficacy and pharmacokinetics', 'Retinopathy of prematurity (ROP']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0035344', 'cui_str': 'Retinopathy of prematurity'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}]","[{'cui': 'C4045501', 'cui_str': 'ripasudil'}, {'cui': 'C0015399', 'cui_str': 'Eye drops'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0035344', 'cui_str': 'Retinopathy of prematurity'}]",,0.0355357,"After obtaining approval from the independent data and safety monitoring board to continue the trial after the completion of phase I, phase II will be conducted.","[{'ForeName': 'Mitsuru', 'Initials': 'M', 'LastName': 'Arima', 'Affiliation': 'Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan m-arima@eye.med.kyushu-u.ac.jp.'}, {'ForeName': 'Hirosuke', 'Initials': 'H', 'LastName': 'Inoue', 'Affiliation': 'Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Shintaro', 'Initials': 'S', 'LastName': 'Nakao', 'Affiliation': 'Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Misumi', 'Affiliation': 'Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Suzuki', 'Affiliation': 'Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Itsuka', 'Initials': 'I', 'LastName': 'Matsushita', 'Affiliation': 'Ophthalmology, University of Occupational and Environmental Health, Kitakyushu, Japan.'}, {'ForeName': 'Shunsuke', 'Initials': 'S', 'LastName': 'Araki', 'Affiliation': 'Pediatrics, University of Occupational and Environmental Health, Kitakyushu, Japan.'}, {'ForeName': 'Chiemi', 'Initials': 'C', 'LastName': 'Yamashiro', 'Affiliation': 'Ophthalmology, Yamaguchi University Graduate School of Medicine, Ube, Japan.'}, {'ForeName': 'Kazumasa', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Ochiai', 'Affiliation': 'Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Yoshida', 'Affiliation': 'Ophthalmology, Fukuoka Dental College, Fukuoka, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Hirose', 'Affiliation': 'Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Junji', 'Initials': 'J', 'LastName': 'Kishimoto', 'Affiliation': 'Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Todaka', 'Affiliation': 'Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Shunji', 'Initials': 'S', 'LastName': 'Hasegawa', 'Affiliation': 'Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Kimura', 'Affiliation': 'Ophthalmology, Yamaguchi University Graduate School of Medicine, Ube, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Kusuhara', 'Affiliation': 'Pediatrics, University of Occupational and Environmental Health, Kitakyushu, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Kondo', 'Affiliation': 'Ophthalmology, University of Occupational and Environmental Health, Kitakyushu, Japan.'}, {'ForeName': 'Shouichi', 'Initials': 'S', 'LastName': 'Ohga', 'Affiliation': 'Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Koh-Hei', 'Initials': 'KH', 'LastName': 'Sonoda', 'Affiliation': 'Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}]",BMJ open,['10.1136/bmjopen-2020-047003'] 1848,34315730,"Effect of peer-distributed HIV self-test kits on demand for biomedical HIV prevention in rural KwaZulu-Natal, South Africa: a three-armed cluster-randomised trial comparing social networks versus direct delivery.","STUDY OBJECTIVE We investigated two peer distribution models of HIV self-testing (HIVST) in HIV prevention demand creation compared with trained young community members (peer navigators). METHODS We used restricted randomisation to allocate 24 peer navigator pairs (clusters) in KwaZulu-Natal 1:1:1: (1) standard of care ( SOC): peer navigators distributed clinic referrals, pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) information to 18-30 year olds. (2) peer navigator direct distribution (PND): Peer navigators distributed HIVST packs (SOC plus two OraQuick HIVST kits) (3) incentivised peer networks (IPN): peer navigators recruited young community members (seeds) to distribute up to five HIVST packs to 18-30 year olds within their social networks. Seeds received 20 Rand (US$1.5) for each recipient who distributed further packs. The primary outcome was PrEP/ART linkage, defined as screening for PrEP/ART eligibility within 90 days of pack distribution per peer navigator month (pnm) of outreach, in women aged 18-24 (a priority for HIV prevention). Investigators and statisticians were blinded to allocation. Analysis was intention to treat. Total and unit costs were collected prospectively. RESULTS Between March and December 2019, 4163 packs (1098 SOC, 1480 PND, 1585 IPN) were distributed across 24 clusters. During 144 pnm, 272 18-30 year olds linked to PrEP/ART (1.9/pnm). Linkage rates for 18-24-year-old women were lower for IPN (n=26, 0.54/pnm) than PND (n=45, 0.80/pnm; SOC n=49, 0.85/pnm). Rate ratios were 0.68 (95% CI 0.28 to 1.66) for IPN versus PND, 0.64 (95% CI 0.26 to 1.62) for IPN versus SOC and 0.95 (95% CI 0.38 to 2.36) for PND versus SOC. In 18-30 year olds, PND had significantly more linkages than IPN (2.11 vs 0.88/pnm, RR 0.42, 95% CI 0.18 to 0.98). Cost per pack distributed was cheapest for IPN (US$36) c.f. SOC (US$64). Cost per person linked to PrEP/ART was cheaper in both peer navigator arms compared with IPN. DISCUSSION HIVST did not increase demand for PrEP/ART. Incentivised social network distribution reached large numbers with HIVST but resulted in fewer linkages compared with PrEP/ART promotion by peer navigators. TRIAL REGISTRATION NUMBER NCT03751826.",2021,"Linkage rates for 18-24-year-old women were lower for IPN (n=26, 0.54/pnm) than PND (n=45, 0.80/pnm; SOC n=49, 0.85/pnm).","['24 peer navigator pairs (clusters) in KwaZulu-Natal 1:1:1', 'During 144 pnm, 272 18-30\u2009year olds linked to PrEP/ART (1.9/pnm', 'rural KwaZulu-Natal, South Africa', 'trained young community members (peer navigators', '18-24-year-old women were lower for IPN (n=26, 0.54/pnm) than PND (n=45, 0.80/pnm; SOC n=49, 0.85/pnm']","['peer-distributed HIV self-test kits', 'HIVST', 'PrEP', 'peer navigators distributed clinic referrals, pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) information', '2) peer navigator direct distribution (PND): Peer navigators distributed HIVST packs (SOC plus two OraQuick HIVST kits) (3) incentivised peer networks (IPN): peer navigators recruited young community members (seeds) to distribute up to five HIVST packs to 18-30\u2009year olds within their social networks', 'HIV self-testing (HIVST']","['PrEP/ART linkage, defined as screening for PrEP/ART eligibility within 90 days of pack distribution per peer navigator month (pnm) of outreach', 'Linkage rates', 'Rate ratios', 'Total and unit costs']","[{'cui': 'C0454729', 'cui_str': 'Natal'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1879344', 'cui_str': 'Biliary papillomatosis'}, {'cui': 'C1956415', 'cui_str': 'Paroxysmal nocturnal dyspnea'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1272835', 'cui_str': 'Test kit'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.28544,"Linkage rates for 18-24-year-old women were lower for IPN (n=26, 0.54/pnm) than PND (n=45, 0.80/pnm; SOC n=49, 0.85/pnm).","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Shahmanesh', 'Affiliation': 'Institute for Global Health, University College London, London, UK m.shahmanesh@ucl.ac.uk.'}, {'ForeName': 'T Nondumiso', 'Initials': 'TN', 'LastName': 'Mthiyane', 'Affiliation': 'Africa Health Research Institute, Durban, Kwa-Zulu Natal, South Africa.'}, {'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Herbsst', 'Affiliation': 'Africa Health Research Institute, Durban, Kwa-Zulu Natal, South Africa.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Neuman', 'Affiliation': 'MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, London, UK.'}, {'ForeName': 'Oluwafemi', 'Initials': 'O', 'LastName': 'Adeagbo', 'Affiliation': 'Africa Health Research Institute, Durban, Kwa-Zulu Natal, South Africa.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Mee', 'Affiliation': 'London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, London, London, UK.'}, {'ForeName': 'Natsayi', 'Initials': 'N', 'LastName': 'Chimbindi', 'Affiliation': 'Africa Health Research Institute, Durban, Kwa-Zulu Natal, South Africa.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Smit', 'Affiliation': 'Africa Health Research Institute, Durban, Kwa-Zulu Natal, South Africa.'}, {'ForeName': 'Nonhlanhla', 'Initials': 'N', 'LastName': 'Okesola', 'Affiliation': 'Africa Health Research Institute, Durban, Kwa-Zulu Natal, South Africa.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Harling', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'Nuala', 'Initials': 'N', 'LastName': 'McGrath', 'Affiliation': 'Africa Health Research Institute, Durban, Kwa-Zulu Natal, South Africa.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Sherr', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Seeley', 'Affiliation': 'Department of Global Health &Development, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Hasina', 'Initials': 'H', 'LastName': 'Subedar', 'Affiliation': 'South African National Department of Health, Pretoria, South Africa.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Johnson', 'Affiliation': 'HIV, Hepatitis and STI Department, World Health Organisation, Geneva, Switzerland.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Hatzold', 'Affiliation': 'Population Services International, Washington, District of Columbia, USA.'}, {'ForeName': 'Fern', 'Initials': 'F', 'LastName': 'Terris-Prestholt', 'Affiliation': 'Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, London, UK.'}, {'ForeName': 'Frances M', 'Initials': 'FM', 'LastName': 'Cowan', 'Affiliation': 'Centre for Sexual Health HIV/AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Elizabeth Lucy', 'Initials': 'EL', 'LastName': 'Corbett', 'Affiliation': 'Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.'}]",BMJ global health,['10.1136/bmjgh-2020-004574'] 1849,34332432,Effectiveness of assertive case management for patients with suicidal intent.,"The aim of this study was to examine the effectiveness of assertive case management intervention in preventing suicidal behaviour in self-poisoning patients. We conducted a secondary analysis of data from the ACTION-J study. Participants were self-poisoning patients with clear suicide intent admitted to emergency departments and with a primary psychiatric diagnosis (as per DSM-IV-TR axis 1). Patients were randomly assigned either to assertive case management or enhanced usual care. The primary outcome measure was the incidence of a first recurrent suicide attempt within 6 months. This study is registered at ClinicalTrials.gov (NCT00736918) and UMIN-CTR (C000000444). There were 297 self-poisoning patients in the intervention group and 295 in the control group. The primary outcome was significantly lower in the intervention group than in the control group. The incidence of a first recurrent suicide attempt within 1 and 3 months was also significantly lower in the intervention group, as was the number of overall self-harm episodes over the entire study period. Furthermore, the number of non-suicidal self-harm episodes and suicide attempts was significantly lower in the intervention group. Assertive case management is effective when promptly introduced in a hospital setting as an intervention following a suicide attempt, particularly for self-poisoning patients.",2021,"The incidence of a first recurrent suicide attempt within 1 and 3 months was also significantly lower in the intervention group, as was the number of overall self-harm episodes over the entire study period.","['297 self-poisoning patients in the intervention group and 295 in the control group', 'patients with suicidal intent', 'self-poisoning patients', 'Participants were self-poisoning patients with clear suicide intent admitted to emergency departments and with a primary psychiatric diagnosis (as per DSM-IV-TR axis 1']","['assertive case management intervention', 'assertive case management', 'assertive case management or enhanced usual care']","['number of overall self-harm episodes', 'suicidal behaviour', 'incidence of a first recurrent suicide attempt within 6 months', 'incidence of a first recurrent suicide attempt', 'number of non-suicidal self-harm episodes and suicide attempts']","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0032343', 'cui_str': 'Poisoning'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0582496', 'cui_str': 'Suicidal intent'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0038661', 'cui_str': 'Suicide'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0376338', 'cui_str': 'Psychiatric Diagnosis'}, {'cui': 'C0220952', 'cui_str': 'DSM-IV'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}]","[{'cui': 'C0085971', 'cui_str': 'Case management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0085271', 'cui_str': 'Self-injurious behavior'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C1760428', 'cui_str': 'Suicidal behavior'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0038663', 'cui_str': 'Suicide attempt'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0438696', 'cui_str': 'Suicidal'}]",,0.0256993,"The incidence of a first recurrent suicide attempt within 1 and 3 months was also significantly lower in the intervention group, as was the number of overall self-harm episodes over the entire study period.","[{'ForeName': 'Masami', 'Initials': 'M', 'LastName': 'Inui-Yukawa', 'Affiliation': 'Department of Psychiatry, Kitasato University, School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Miyaoka', 'Affiliation': 'Department of Psychiatry, Kitasato University, School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Psychiatry, Tokai University, School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. Electronic address: key@is.icc.u-tokai.ac.jp.'}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Kamijo', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan.'}, {'ForeName': 'Michiko', 'Initials': 'M', 'LastName': 'Takai', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan.'}, {'ForeName': 'Naohiro', 'Initials': 'N', 'LastName': 'Yonemoto', 'Affiliation': 'Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashimachi, Kodaira, Tokyo 187-8553 187-8551, Japan.; Department of Public Health, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.'}, {'ForeName': 'Chiaki', 'Initials': 'C', 'LastName': 'Kawanishi', 'Affiliation': 'Department of Neuropsychiatry, Sapporo Medical University Graduate School of Medicine, S-1, W-17, Chuo-ku, Sapporo 060-8556, Japan.'}, {'ForeName': 'Kotaro', 'Initials': 'K', 'LastName': 'Otsuka', 'Affiliation': 'Department of Neuropsychiatry, School of Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan.'}, {'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Tachikawa', 'Affiliation': 'Department of Disaster and Community Psychiatry, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.'}, {'ForeName': 'Yoshio', 'Initials': 'Y', 'LastName': 'Hirayasu', 'Affiliation': 'Hirayasu Hospital, 346 Kyouzuka, Urasoe, Okinawa 901-2553, Japan.'}]",Psychiatry research,['10.1016/j.psychres.2021.114125'] 1850,34332374,Social Cognition and Interaction Training (SCIT) versus Training in Affect Recognition (TAR) in patients with schizophrenia: A randomized controlled trial.,"INTRODUCTION Training in Affect Recognition (TAR) is a ""targeted"" and computer-aided program that has been shown to effectively attenuate facial affect recognition deficits and improve social functioning in patients with schizophrenia. Social Cognition and Interaction Training (SCIT) is a group ""broad-based"" intervention, that has also been shown to improve emotion recognition, theory of mind (ToM), and social functioning. To date, no study has compared the efficacy of two different social cognitive interventions. OBJECTIVES We aim to compare the efficacy of TAR and SCIT on schizophrenia patients' performance on facial affect recognition, theory of mind, attributional style and social functioning before, after treatment, and three months thereafter. METHODS One hundred outpatients with a diagnosis of schizophrenia were randomly assigned to the TAR or SCIT condition and completed pre- (T0) and posttreatment (T1) assessments and a 3-month follow up (T2) of emotion recognition (ER-40), theory of mind (Hinting Task), attributional style (AIHQ) and social functioning (PSP). RESULTS The entire sample, receiving TAR or SCIT, showed improvements in theory of mind, attributional style, clinical symptoms and social functioning. This effect was maintained at three-months. The TAR intervention was more efficacious than the SCIT program in improving the recognition of facial emotions (ER-40). The TAR intervention also demonstrated a lower drop-out rate than the SCIT intervention. CONCLUSIONS There were improvements in social cognition, symptomatology and functioning of patients in the entire sample, receiving SCIT or TAR. Both TAR and SCIT appear as valuable treatments for people with schizophrenia and social cognitive deficits.",2021,"There were improvements in social cognition, symptomatology and functioning of patients in the entire sample, receiving SCIT or TAR.","['patients with schizophrenia', 'One hundred outpatients with a diagnosis of schizophrenia', 'people with schizophrenia and social cognitive deficits']","['Social Cognition and Interaction Training (SCIT) versus Training in Affect Recognition (TAR', 'TAR intervention', 'TAR and SCIT', 'TAR or SCIT condition and completed pre- (T0) and posttreatment (T1) assessments and a 3-month follow up (T2) of emotion recognition (ER-40), theory of mind (Hinting Task), attributional style (AIHQ) and social functioning (PSP', 'Social Cognition and Interaction Training (SCIT']","['theory of mind, attributional style, clinical symptoms and social functioning', 'social cognition, symptomatology and functioning', ""schizophrenia patients' performance on facial affect recognition, theory of mind, attributional style and social functioning"", 'recognition of facial emotions (ER-40']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009241', 'cui_str': 'Cognitive disorder'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0935573', 'cui_str': 'Theory of Mind'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0038868', 'cui_str': 'Progressive supranuclear palsy'}]","[{'cui': 'C0935573', 'cui_str': 'Theory of Mind'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",100.0,0.0182048,"There were improvements in social cognition, symptomatology and functioning of patients in the entire sample, receiving SCIT or TAR.","[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Lahera', 'Affiliation': 'University of Alcalá, IRyCIS, Madrid, Spain; Príncipe de Asturias University Hospital, Alcalá, Madrid, Spain; CIBERSAM (Biomedical Research Networking Centre in Mental Health), Madrid, Spain. Electronic address: guillermo.lahera@uah.es.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Reboreda', 'Affiliation': 'University Complex of Ferrol, A Coruña, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Vallespí', 'Affiliation': '""Actur Sur"" Mental Health Center, Zaragoza, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Vidal', 'Affiliation': '""Les Corts"" Mental Health Center, Barcelona, Spain.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'López', 'Affiliation': '""Les Corts"" Mental Health Center, Barcelona, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Aznar', 'Affiliation': '""Les Corts"" Mental Health Center, Barcelona, Spain.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Fernández', 'Affiliation': 'Ramón y Cajal University Hospital, Madrid, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Escolar', 'Affiliation': 'Ramón y Cajal University Hospital, Madrid, Spain.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Martínez-Alés', 'Affiliation': 'Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Rodriguez-Jimenez', 'Affiliation': 'CIBERSAM (Biomedical Research Networking Centre in Mental Health), Madrid, Spain; Department of Psychiatry, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas 12), Madrid, Spain.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Halverson', 'Affiliation': 'Department of Psychology and Neuroscience, University of North Carolina - Chapel Hill, USA.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Frommann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Germany.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Wölwer', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Germany.'}, {'ForeName': 'D L', 'Initials': 'DL', 'LastName': 'Penn', 'Affiliation': 'Department of Psychology and Neuroscience, University of North Carolina - Chapel Hill, USA; Australian Catholic University, School of Behavioural and Health Sciences, Melbourne, VIC, Australia.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2021.07.029'] 1851,34311135,Assessment of Lactobacillus casei rhamnosus (LGG) therapy in children with biliary atresia - Randomized placebo controlled trial.,"BACKGROUND The role of microbiota in biliary atresia (BA) remains unclear. The aim of our study was to assess efficacy and safety of LGG treatment in children with BA after HPE with special focus on bacterial cholangitis (BCH) and quantitative assessment of the gut microbiota composition and metabolism. METHODS We performed double-blind placebo controlled trial with patients randomized into treatment group who received LGG (n = 14) and placebo (n = 16). The gut microbiota and short-chain fatty acids (SCFA) were assessed at baseline and after 6 months of treatment. Clinical and laboratory parameters including episodes of bacterial cholangitis (BCH) were collected during the study period and after 2-year follow-up. Additionally, stool composition of BA patients was compared with healthy age-matched control group. RESULTS There were lower concentration of SCFA in children with BA compared to control group and significant increase in the number of Enterococcus bacteria. After 6 months of treatment, neither laboratory parameters nor gut microbiota composition differed between LGG group and placebo. PP analysis results were similar to ITT analysis, no significant differences between study and control group. Overall, there were 11 (36%) patients who developed at least one episode of bacterial cholangitis; 3 (21%) in the LGG group compared to 8 (50%) placebo group (p = 0.14). Bacterial cultures were positive in 22% of cases and recurrence after the first episode was observed in 27% of patients. The level of total bilirubin decreased below 2 mg/dl after 6 months of the study in 6 (42.8%) patients in the LGG group and in 8 (50%) patients in the placebo group (p = 0.73). During 2-year follow-up 6 out of 14 patients (42.8%) in the LGG group and 11 out of 16 placebo patients (68.7%) underwent liver transplantation (p = 0.27). CONCLUSIONS Patients with BA present with specific microbiota profiles and decreased SCFA what gives opportunities to implement novel therapeutic options based on modulation of  microbiota. Whether LGG is an effective therapy needs to be studied in a larger group with similar outcome parameters.",2021,"During 2-year follow-up 6 out of 14 patients (42.8%) in the LGG group and 11 out of 16 placebo patients (68.7%) underwent liver transplantation (p=0.27). ","['children with BA after HPE with special focus on bacterial cholangitis (BCH', 'n=16', 'children with biliary atresia - randomized']","['placebo', 'LGG', 'Lactobacillus casei rhamnosus (LGG) therapy']","['concentration of SCFA', 'number of Enterococcus bacteria', 'episodes of bacterial cholangitis (BCH', 'efficacy and safety', 'gut microbiota and short-chain fatty acids (SCFA', 'level of total bilirubin', 'gut microbiota composition', 'stool composition', 'episode of bacterial cholangitis', 'liver transplantation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005411', 'cui_str': 'Congenital biliary atresia'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0275553', 'cui_str': 'Bacterial cholangitis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1629836', 'cui_str': 'Lactobacillus rhamnosus GG'}, {'cui': 'C0317597', 'cui_str': 'Lactobacillus casei rhamnosus'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0085494', 'cui_str': 'Genus Enterococcus'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0275553', 'cui_str': 'Bacterial cholangitis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}]",14.0,0.196707,"During 2-year follow-up 6 out of 14 patients (42.8%) in the LGG group and 11 out of 16 placebo patients (68.7%) underwent liver transplantation (p=0.27). ","[{'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Orłowska', 'Affiliation': ""Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, ul. Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.""}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Czubkowski', 'Affiliation': ""Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, ul. Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.""}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Wołochowska', 'Affiliation': ""Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, ul. Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.""}, {'ForeName': 'Dorota', 'Initials': 'D', 'LastName': 'Jarzębicka', 'Affiliation': ""Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, ul. Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland. Electronic address: d.jarzebicka@ipczd.pl.""}, {'ForeName': 'Ilona', 'Initials': 'I', 'LastName': 'Motyl', 'Affiliation': 'Faculty of Biotechnology and Food Sciences, Łódź University of Technology, Łódź, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Socha', 'Affiliation': ""Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, ul. Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.""}]",Clinics and research in hepatology and gastroenterology,['10.1016/j.clinre.2021.101753'] 1852,34311119,Cognitive behavioural therapy versus health education for sleep disturbance and fatigue after acquired brain injury: A pilot randomised trial.,"BACKGROUND Sleep disturbance and fatigue are highly prevalent after acquired brain injury (ABI) and are associated with poor functional outcomes. Cognitive behavioural therapy (CBT) is a promising treatment for sleep and fatigue problems after ABI, although comparison with an active control is needed to establish efficacy. OBJECTIVES We compared CBT for sleep disturbance and fatigue (CBT-SF) with a health education (HE) intervention to control for non-specific therapy effects. METHODS In a parallel-group, pilot randomised controlled trial, 51 individuals with traumatic brain injury (n = 22) and stroke (n = 29) and clinically significant sleep and/or fatigue problems were randomised 2:1 to 8 weeks of a CBT-SF (n = 34) or HE intervention (n = 17), both adapted for cognitive impairments. Participants were assessed at baseline, post-treatment, and 2 and 4 months post-treatment. The primary outcome was the Pittsburgh Sleep Quality Index; secondary outcomes included measures of fatigue, sleepiness, mood, quality of life, activity levels, self-efficacy and actigraphy sleep measures. RESULTS The CBT-SF led to significantly greater improvements in sleep quality as compared with HE, during treatment and at 2 months [95% confidence interval (CI) -24.83; -7.71], as well as significant reductions in fatigue maintained at all time points, which were not evident with HE (95% CI -1.86; 0.23). HE led to delayed improvement in sleep quality at 4 months post-treatment and in depression (95% CI -1.37; -0.09) at 2 months post-treatment. CBT-SF led to significant gains in self-efficacy (95% CI 0.15; 0.53) and mental health (95% CI 1.82; 65.06). CONCLUSIONS CBT-SF can be an effective treatment option for sleep disturbance and fatigue after ABI, over and above HE. HE may provide delayed benefit for sleep, possibly by improving mood. TRIAL REGISTRATION Australia New Zealand Clinical Trials Registry: ACTRN12617000879369 (registered 15/06/2017) and ACTRN12617000878370 (registered 15/06/2017).",2021,"The CBT-SF led to significantly greater improvements in sleep quality as compared with HE, during treatment and at 2 months [95% confidence interval (CI) -24.83; -7.71], as well as significant reductions in fatigue maintained at all time points, which were not evident with HE (95% CI -1.86; 0.23).","['51 individuals with traumatic brain injury (n=22) and stroke (n=29) and clinically significant sleep and/or fatigue problems', 'sleep disturbance and fatigue after acquired brain injury']","['Cognitive behavioural therapy versus health education', 'HE intervention', 'CBT', 'Cognitive behavioural therapy (CBT', 'CBT-SF']","['self-efficacy', 'mental health', 'fatigue maintained', 'sleep quality', 'Pittsburgh Sleep Quality Index; secondary outcomes included measures of fatigue, sleepiness, mood, quality of life, activity levels, self-efficacy and actigraphy sleep measures']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",51.0,0.337035,"The CBT-SF led to significantly greater improvements in sleep quality as compared with HE, during treatment and at 2 months [95% confidence interval (CI) -24.83; -7.71], as well as significant reductions in fatigue maintained at all time points, which were not evident with HE (95% CI -1.86; 0.23).","[{'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Ymer', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia; Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia; Department of Psychology, Epworth Rehabilitation, Melbourne, VIC, Australia. Electronic address: lucy.ymer1@monash.edu.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'McKay', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia; Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia; Department of Psychology, Epworth Rehabilitation, Melbourne, VIC, Australia.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Wong', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia; Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia; School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Frencham', 'Affiliation': 'Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Grima', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia; Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Tran', 'Affiliation': 'Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Nguyen', 'Affiliation': 'Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia; Department of Psychology, Epworth Rehabilitation, Melbourne, VIC, Australia.'}, {'ForeName': 'Moira', 'Initials': 'M', 'LastName': 'Junge', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Jade', 'Initials': 'J', 'LastName': 'Murray', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia; Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Gershon', 'Initials': 'G', 'LastName': 'Spitz', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia; Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'Ponsford', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia; Monash Epworth Rehabilitation Research Centre, Melbourne, VIC, Australia.'}]",Annals of physical and rehabilitation medicine,['10.1016/j.rehab.2021.101560'] 1853,34311098,INERTIA: A pilot study of the impact of progressive resistance training on blood pressure control in older adults with sarcopenia.,"Sarcopenia, and high blood pressure are highly prevalent, preventable conditions that pose significant burden for older adults and on the healthcare system. Current prevention and treatment of high blood pressure in sarcopenia, by non-pharmacological approaches remain limited and are far from optimal. Clinical trials and mechanistic studies provide encouraging evidence of a plausible therapeutic effect of progressive resistance training (PRT) on blood pressure in younger, and pre-hypertensive and hypertensive older adults. The impact of PRT on blood pressure has not been empirically tested in older adults with sarcopenia. This pilot study aims to provide effect size confidence intervals, clinical trial and intervention feasibility data, and procedural materials for a full-scale randomized controlled trial that will determine the efficacy of PRT intervention as a therapeutic strategy for blood pressure control in older adults with sarcopenia. Participants (N = 90) will be randomized to receive exercise educational materials or the PRT intervention consisting of 24 supervised exercise sessions over 12-weeks. Follow-up assessments will occur at 12-weeks and one-year later. The primary outcome is systolic blood pressure and diastolic blood pressure, analyzed separately. Microvascular mechanisms linking muscle (perfusion, strength, function) to changes in blood pressure will be explored at baseline and 12-weeks. This study will provide new evidence for the therapeutic effect of PRT as a non-pharmacological strategy for improving blood pressure. Insights gained may also inform of the potential role of muscle strength as a novel target for blood pressure control, and future exercise prescription guidelines related to muscle strengthening in high-risk older adults.",2021,"Microvascular mechanisms linking muscle (perfusion, strength, function) to changes in blood pressure will be explored at baseline and 12-weeks.","['high-risk older adults', 'younger, and pre-hypertensive and hypertensive older adults', 'older adults with sarcopenia', 'Participants (N\u202f=\u202f90']","['PRT intervention', 'progressive resistance training', 'progressive resistance training (PRT', 'exercise educational materials or the PRT intervention consisting of 24 supervised exercise sessions', 'PRT']","['blood pressure control', 'systolic blood pressure and diastolic blood pressure', 'blood pressure']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",90.0,0.087969,"Microvascular mechanisms linking muscle (perfusion, strength, function) to changes in blood pressure will be explored at baseline and 12-weeks.","[{'ForeName': 'Deepika', 'Initials': 'D', 'LastName': 'Laddu', 'Affiliation': 'University of Illinois at Chicago, Department of Physical Therapy, College of Applied Health Sciences, 1919 W. Taylor Street, Room 434 (MC 898), Chicago, IL 60612, United States of America. Electronic address: dladdu@uic.edu.'}, {'ForeName': 'Hajwa', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'University of Illinois at Chicago, Center for Clinical and Translational Science, Biostatistics Core, 914 S. Wood Street, Room 233, Chicago, IL 60612, United States of America. Electronic address: hkim288@uic.edu.'}, {'ForeName': 'Shane A', 'Initials': 'SA', 'LastName': 'Phillips', 'Affiliation': 'University of Illinois at Chicago, Department of Physical Therapy, College of Applied Health Sciences, 1919 W. Taylor Street, Room 746 (MC 898), Chicago, IL 60612, United States. Electronic address: shanep@uic.edu.'}, {'ForeName': 'Ma', 'Initials': 'M', 'LastName': 'Jun', 'Affiliation': 'University of Illinois at Chicago, Department of Medicine, 1747 W. Roosevelt Rd, Room 586 (MC 275), Chicago, IL 60608, United States. Electronic address: maj2015@uic.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106516'] 1854,34311059,Effects of virtual reality versus conventional balance training on balance of the elderly.,"OBJECTIVE The aging population is growing in the world, and the reduction in physical function caused by this is an important issue that, particularly, causes a disorder of balance and an increased risk of falling. This study aimed at the comparison between the effects of virtual reality training (VRT) and Conventional balance training (CBT) on the balance of the elderly. METHODS The present study was conducted on 36 elderly (men and women) who are living in nursing homes. Participants were randomly divided into three groups: virtual reality training (6 males, 6 females; age = 66.5 ± 3.8 years), Conventional balance training (6 males, 6 females; age = 67.5 ± 3.1 years), and control (5 males, 7 females; age = 66.7 ± 3.2 years). Each group participated in a 60-min session, 3 times per week, for 9 weeks. To assess the participants' balance, the balance tests were used on single-leg stance (SLS) with open and closed eyes, Functional reach test (FRT), Timed up and Go Test (TUG), and Fullerton Advance Balance Scale (FABS). Data analysis was done using paired t-test and analysis of covariance by SPSS software version 24 at the significant level (P = 0.05). RESULTS In both groups (VRT, CBT), SLS with open and closed eyes, FRT, TUG, and FABS were significantly improved (P˂0.05). After the intervention, changes in both groups were similar (P > 0.05), which indicates that neither VRT and CBT training methods were superior to the other. CONCLUSION According to the results of this study, it seems that a virtual reality training program can be used as a new training method to improve the elderly's balance in daily programs of nursing homes.",2021,"After the intervention, changes in both groups were similar (P > 0.05), which indicates that neither VRT and CBT training methods were superior to the other. ","['36 elderly (men and women) who are living in nursing homes', '6 males, 6 females; age\u202f=\u202f66.5\u202f±\u202f3.8\u202fyears', '6 males, 6 females; age\u202f=\u202f67.5\u202f±\u202f3.1\u202fyears), and control (5 males, 7 females; age\u202f=\u202f66.7\u202f±\u202f3.2\u202fyears']","['virtual reality training (VRT) and Conventional balance training (CBT', 'virtual reality versus conventional balance training', 'Conventional balance training', 'virtual reality training']","['balance of the elderly', 'SLS with open and closed eyes, FRT, TUG, and FABS', 'single-leg stance (SLS) with open and closed eyes, Functional reach test (FRT), Timed up and Go Test (TUG), and Fullerton Advance Balance Scale (FABS']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0425205', 'cui_str': 'Lives in a nursing home'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517683', 'cui_str': '3.1'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517843', 'cui_str': '66.7'}, {'cui': 'C4517687', 'cui_str': '3.2'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C1998271', 'cui_str': 'Functional reach test'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",36.0,0.00418989,"After the intervention, changes in both groups were similar (P > 0.05), which indicates that neither VRT and CBT training methods were superior to the other. ","[{'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Yousefi Babadi', 'Affiliation': 'Faculty of Physical Education and Sport Sciences, Department of Sport Injuries & Corrective Exercises, University of Guilan, Rasht, Iran. Electronic address: saeed.yoosefi@gmail.com.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Daneshmandi', 'Affiliation': 'Faculty of Physical Education and Sport Sciences, Department of Sport Injuries & Corrective Exercises, University of Guilan, Rasht, Iran.'}]",Experimental gerontology,['10.1016/j.exger.2021.111498'] 1855,34311022,Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial.,"AIMS Non-Alcoholic Fatty Liver Disease (NAFLD) and type 2 diabetes (T2D) share pathophysiological mechanisms and possible therapeutic strategies. We evaluated the effects of 1-year treatment with pioglitazone or sulphonylureas on indirect indices of NAFLD in people with T2D and the role of insulin-resistance and glucotoxicity in determining these effects. METHODS Patients with T2D (n = 195) aged 50-75 years, poorly controlled with metformin 2 g/day, were randomly allocated to add-on pioglitazone (n = 98) or sulphonylureas (n = 97) within the TOSCA.IT trial. Plasma insulin, glucose, and liver enzymes were measured at baseline and after 1-year. Indirect indices of NAFLD (Liver Fat Equation [LFE], Hepatic Steatosis Index [HSI], and Index of NASH [ION]), and insulin resistance (HOMA-IR, Visceral Adiposity Index [VAI] and adipose tissue Insulin Resistance [ADIPO-IR]) were calculated. RESULTS Indices of NAFLD improved after pioglitazone, but not after sulphonylureas; differences between changes (1-year minus baseline) were respectively: -1.76 ± 3.84 vs. 0.28 ± 3.75 for LFE; -1.35 ± 2.78 vs. -0.27 ± 2.63 for HSI; -9.75 ± 43 vs. 3.24 ± 31 for ION; p < 0.05 for all. Indices of insulin resistance decreased after pioglitazone, but not after sulphonylureas: -0.95 ± 4.57 vs. 0.37 ± 3.34 for HOMA-IR, p = 0.032; -1.25 ± 4.11 vs. 1.36 ± 5.43 for ADIPO-IR, p = 0.001; -0.53 ± 1.88 vs. 0.03 ± 2.36 for VAI, p = 0.074. Changes in NAFLD indices were similar with different doses of pioglitazone (15, 30, or 45 mg/day), and were independent of blood glucose control. CONCLUSIONS One-year treatment with pioglitazone even at low dosage significantly improved liver steatosis and inflammation, systemic and adipose tissue insulin resistance in patients with T2D. The beneficial effects of pioglitazone on NAFLD were independent of blood glucose control.",2021,"Indices of insulin resistance decreased after pioglitazone, but not after sulphonylureas: -0.95±4.57 vs. 0.37±3.34 for HOMA-IR, p=0.032; -1.25±4.11 vs. 1.36±5.43 for ADIPO-IR, p=0.001; -0.53±1.88 vs. 0.03±2.36 for VAI, p=0.074.","['people with T2D', 'patients with T2D', 'n=98) or sulphonylureas (n=97) within the TOSCA.IT trial', 'patients with T2D (n=195) aged 50-75 years, poorly controlled with metformin 2 g/day']","['pioglitazone', 'LFE', 'Pioglitazone']","['Indirect indices of NAFLD (Liver Fat Equation [LFE], Hepatic Steatosis Index [HSI], and Index of NASH [ION]), and insulin resistance (HOMA-IR, Visceral Adiposity Index [VAI] and adipose tissue Insulin Resistance [ADIPO-IR', 'liver steatosis and inflammation, systemic and adipose tissue insulin resistance', 'NAFLD', 'NAFLD indices', 'Plasma insulin, glucose, and liver enzymes', 'Indices of insulin resistance', 'blood glucose control']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038766', 'cui_str': 'Sulfonylurea'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}]","[{'cui': 'C0071097', 'cui_str': 'pioglitazone'}]","[{'cui': 'C0439852', 'cui_str': 'Indirect'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0015695', 'cui_str': 'Fatty Liver'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",195.0,0.237807,"Indices of insulin resistance decreased after pioglitazone, but not after sulphonylureas: -0.95±4.57 vs. 0.37±3.34 for HOMA-IR, p=0.032; -1.25±4.11 vs. 1.36±5.43 for ADIPO-IR, p=0.001; -0.53±1.88 vs. 0.03±2.36 for VAI, p=0.074.","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Della Pepa', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Russo', 'Affiliation': 'Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, Pisa, Italy; University of Siena, Siena, Italy.'}, {'ForeName': 'Marilena', 'Initials': 'M', 'LastName': 'Vitale', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Fabrizia', 'Initials': 'F', 'LastName': 'Carli', 'Affiliation': 'Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, Pisa, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Vetrani', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Masulli', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Riccardi', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Vaccaro', 'Affiliation': 'Department of Pharmacy, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Amalia', 'Initials': 'A', 'LastName': 'Gastaldelli', 'Affiliation': 'Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, Pisa, Italy. Electronic address: amalia@ifc.cnr.it.'}, {'ForeName': 'Angela A', 'Initials': 'AA', 'LastName': 'Rivellese', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Electronic address: rivelles@unina.it.'}, {'ForeName': 'Lutgarda', 'Initials': 'L', 'LastName': 'Bozzetto', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.'}]",Diabetes research and clinical practice,['10.1016/j.diabres.2021.108984'] 1856,34311004,Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial.,"INTRODUCTION The success of intensification and personalisation of the curative treatment of non-small cell lung cancer (NSCLC) is strongly associated with the precision in radiotherapy. Here, we evaluate the impact of radiotherapy protocol adherence in a prospective multicentre trial. METHODS In the open-label, randomised, controlled PET-Plan trial, patients with inoperable NSCLC were randomized at a 1:1 ratio regarding the target volume delineation informed by 1 F-FDG PET and CT plus elective nodal irradiation (arm A) or target volumes informed by PET alone (arm B) and received iso-toxically dose-escalated concurrent chemoradiation. The prospectively organised quality assurance program (RTQA) included individual case review by predefined criteria. For evaluation, protocol adherence was scored as per protocol (pP), with minor (miD), intermediate (inD) and major (maD) deviations. In order to exclude biases through patients who discontinued treatment, patients who received ≥60 Gy were additionally analysed. RESULTS Between 05/2009-11/2016, 205 patients were randomized, 204 patients started treatment according to protocol of which 31 (15%) patients had maD. Patients with maD had an inferior overall survival (OS) (HR 2.9, 95% CI 1.8-4.4, p < 0.0001) and a higher risk of loco-regional progression (HR 5.7, 95% CI 2.7-11.1, p < 0.0001). These results were significant also in the subgroup of patients receiving ≥ 60 Gy. Patients with maD concerning normal tissue delineation and/or dose constraints had a worse OS (p = 0.006) although no higher incidence of grade ≥ 3 toxicities. CONCLUSIONS Non-adherence to the radiotherapy protocol was associated with an inferior OS and loco-regional control. These results underline the importance of RTQA.",2021,"Patients with maD concerning normal tissue delineation and/or dose constraints had a worse OS (p=0.006) although no higher incidence of grade ≥ 3 toxicities. ","['patients with locally advanced NSCLC treated with concurrent chemoradiation', 'patients with inoperable NSCLC', 'non-small cell lung cancer (NSCLC', 'Between 05/2009 -11/2016']","['radiotherapy protocol adherence', 'FDG PET and CT plus elective nodal irradiation (arm A) or target volumes informed by PET alone (arm B) and received iso-toxically dose-escalated concurrent chemoradiation']","['higher risk of loco-regional progression', 'inferior overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0205187', 'cui_str': 'Inoperable'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C3641247', 'cui_str': 'FDG PET scan'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0443268', 'cui_str': 'Nodal'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0911936', 'cui_str': 'isovaleronitrile'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}]","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",205.0,0.0974424,"Patients with maD concerning normal tissue delineation and/or dose constraints had a worse OS (p=0.006) although no higher incidence of grade ≥ 3 toxicities. ","[{'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Gkika', 'Affiliation': 'Department of Radiation Oncology, Medical Center, University of Freiburg, Germany; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine, University of Freiburg, Germany. Electronic address: eleni.gkika@uniklinik-freiburg.de.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Schimek-Jasch', 'Affiliation': 'Department of Radiation Oncology, Medical Center, University of Freiburg, Germany; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Kremp', 'Affiliation': 'Department of Radiotherapy and Radiation Oncology, Saarland University Medical Center and Faculty of Medicine, Homburg/Saar, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Lenz', 'Affiliation': 'Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Germany.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Stockinger', 'Affiliation': 'Department of Radiation Oncology, University Hospital Mainz, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Schaefer-Schuler', 'Affiliation': 'Department of Nuclear Medicine, Saarland University Medical Center and Faculty of Medicine, Homburg/Saar, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Mix', 'Affiliation': 'Faculty of Medicine, University of Freiburg, Germany; Department of Nuclear Medicine, Medical Center, University of Freiburg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Küsters', 'Affiliation': 'Department of Radiation Oncology, Kliniken Maria Hilf, Mönchengladbach, Germany.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Tosch', 'Affiliation': 'Department of Nuclear Medicine, Helios University Hospital Wuppertal, Germany; Department of Medicine, Faculty of Health, University of Witten/Herdecke, Witten, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hehr', 'Affiliation': 'Department of Radiation Oncology, Marienhospital, Stuttgart, Germany.'}, {'ForeName': 'Susanne Martina', 'Initials': 'SM', 'LastName': 'Eschmann', 'Affiliation': 'Department of Nuclear Medicine, Marienhospital, Stuttgart, Germany.'}, {'ForeName': 'Yves-Pierre', 'Initials': 'YP', 'LastName': 'Bultel', 'Affiliation': 'Department of Radiation Oncology, Klinikum Mutterhaus der Boromäerinnen, Trier, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hass', 'Affiliation': 'Department of Radiation Oncology, University Hospital Magdeburg, Germany.'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Fleckenstein', 'Affiliation': 'Department of Radiotherapy and Radiation Oncology, Saarland University Medical Center and Faculty of Medicine, Homburg/Saar, Germany.'}, {'ForeName': 'Alexander Henry', 'Initials': 'AH', 'LastName': 'Thieme', 'Affiliation': 'Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Germany.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Dieckmann', 'Affiliation': 'Department of Radiotherapy, Vienna General Hospital, Medical University of Vienna, Austria.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Miederer', 'Affiliation': 'Department of Nuclear Medicine, University Hospital Mainz, Germany.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Holl', 'Affiliation': 'Department of Nuclear Medicine, Helios Kliniken Schwerin, Germany.'}, {'ForeName': 'Hans Christian', 'Initials': 'HC', 'LastName': 'Rischke', 'Affiliation': 'Department of Radiation Oncology, Medical Center, University of Freiburg, Germany; Faculty of Medicine, University of Freiburg, Germany; Department of Nuclear Medicine, Saarland University Medical Center and Faculty of Medicine, Homburg/Saar, Germany.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Adebahr', 'Affiliation': 'Department of Radiation Oncology, Medical Center, University of Freiburg, Germany; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Jochem', 'Initials': 'J', 'LastName': 'König', 'Affiliation': 'Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Hospital of Mainz, Germany.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Binder', 'Affiliation': 'Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Germany.'}, {'ForeName': 'Anca-Ligia', 'Initials': 'AL', 'LastName': 'Grosu', 'Affiliation': 'Department of Radiation Oncology, Medical Center, University of Freiburg, Germany; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Ursula', 'Initials': 'U', 'LastName': 'Nestle', 'Affiliation': 'Department of Radiation Oncology, Medical Center, University of Freiburg, Germany; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine, University of Freiburg, Germany; Department of Nuclear Medicine, Medical Center, University of Freiburg, Germany.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2021.07.017'] 1857,34314843,Examining the influence of mental stress on balance perturbation responses in older adults.,"BACKGROUND Reach-to-grasp responses following balance perturbations are important to fall prevention but are often ineffective in older adults. The ability to shift attention from an ongoing cognitive task to balance related processes has been shown to influence reach-to-grasp effectiveness in older adults. However, the added influence of stress and anxiety - known to negatively affect attention shifting ability - has not yet been explored in relation to recovery from balance perturbations. Given that fear and anxiety over falling is a key fall risk factor, an understanding of how such a negative mental state may affect postural reactions is important. This study aimed to investigate the effect of varied induced emotional states on reach-to-grasp balance responses in older adults. METHODS Healthy older adults (mean age 70.5 ± 5.38 years) stood laterally between 2 handrails with contact sensors. A safety harness with an integrated loadcell was worn to prevent falls and measure the amount of harness assistance (expressed as percent body weight). With instructions to grasp one rail to restore balance, participants' balance was laterally disturbed using surface translations under three randomized conditions: no cognitive task, neutral (verb generation) task, and mental stress task with negative prompts (paced auditory serial addition). The primary outcome was frequency of protective grasps. Secondary outcomes included frequency of harness assistance during trials with grasp errors as well as wrist movement time, trajectory distance, and peak velocity. RESULTS Perceived level of distress was highest for the mental stress task compared to no task (p < 0.001) and neutral task conditions (p = 0.008). The mental stress task resulted in the lowest percentage of protective grasps (p < 0.001) in response to balance perturbations. Closer examination of trials that resulted in grasp errors (i.e., collisions or overshoots), revealed increased harness assistance and reduced peak velocity of wrist movement (p < 0.001) under the mental stress condition compared to grasp errors that occurred under the no task or neutral task condition. DISCUSSION AND CONCLUSION Distressing mental thoughts immediately prior to a balance perturbation lead to reduced effectiveness in reach-to-grasp balance responses compared to no or neutral cognitive tasks and should be considered as a possible fall risk factor.",2021,"RESULTS Perceived level of distress was highest for the mental stress task compared to no task (p < 0.001) and neutral task conditions (p = 0.008).","['Healthy older adults (mean age 70.5\xa0±', 'older adults']","['cognitive task, neutral (verb generation) task, and mental stress task with negative prompts (paced auditory serial addition']","['frequency of harness assistance during trials with grasp errors as well as wrist movement time, trajectory distance, and peak velocity', 'neutral task conditions', 'harness assistance and reduced peak velocity of wrist movement', 'level of distress', 'frequency of protective grasps']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0038443', 'cui_str': 'Psychological Stress'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C3873748', 'cui_str': 'Harness'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0231303', 'cui_str': 'Distress'}]",,0.0240657,"RESULTS Perceived level of distress was highest for the mental stress task compared to no task (p < 0.001) and neutral task conditions (p = 0.008).","[{'ForeName': 'Ruth Y', 'Initials': 'RY', 'LastName': 'Akinlosotu', 'Affiliation': 'University of Maryland School of Medicine, Department of Physical Therapy and Rehabilitation Science, Baltimore, MD 21201, USA. Electronic address: Ruakinlosotu@umaryland.edu.'}, {'ForeName': 'Nesreen', 'Initials': 'N', 'LastName': 'Alissa', 'Affiliation': 'University of Maryland School of Medicine, Department of Physical Therapy and Rehabilitation Science, Baltimore, MD 21201, USA. Electronic address: nesreen.alissa@som.umaryland.edu.'}, {'ForeName': 'Shari R', 'Initials': 'SR', 'LastName': 'Waldstein', 'Affiliation': 'Department of Psychology, University of Maryland Baltimore County, Baltimore, MD 21250, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: waldstei@umbc.edu.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Creath', 'Affiliation': 'Department of Exercise Science, Lebanon Valley College, Annville, PA 17003, USA. Electronic address: creath@lvc.edu.'}, {'ForeName': 'George F', 'Initials': 'GF', 'LastName': 'Wittenberg', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, Human Engineering Research Laboratory, VA Pittsburgh Healthcare System, USA; Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Electronic address: geowitt@pitt.edu.'}, {'ForeName': 'Kelly P', 'Initials': 'KP', 'LastName': 'Westlake', 'Affiliation': 'University of Maryland School of Medicine, Department of Physical Therapy and Rehabilitation Science, Baltimore, MD 21201, USA. Electronic address: kwestlake@som.umaryland.edu.'}]",Experimental gerontology,['10.1016/j.exger.2021.111495'] 1858,34314816,Greater efficacy of a combination of conservative therapies for thumb base OA in individuals with lower radial subluxation - a pre-planned subgroup analysis of the COMBO trial.,"OBJECTIVE To investigate heterogeneous effects of a combination of conservative therapies compared with an education comparator for thumb base (TB) osteoarthritis (OA) according to clinically relevant characteristics. METHODS Pre-planned subgroup analysis of the COMBO trial (n = 204) which compared a combination of education on self-management and ergonomic principles, a prefabricated neoprene splint, hand exercises, and diclofenac sodium gel, with education alone for radiographic and symptomatic TB OA. Primary outcomes were change in pain (visual analogue scale [VAS], 0-100 mm) and hand function (Functional Index for Hand Osteoarthritis questionnaire, 0-30) from baseline to week-6. Other outcomes were grip and tip-pinch strength and patient's global assessment (PGA) (VAS, 0-100 mm). Possible treatment effect modifiers were the presence of interphalangeal joint pain, erosive hand OA, radiographic thumb carpometacarpal joint subluxation (higher vs equal or lower than the sample mean), and baseline radiographic OA severity (Kellgren Lawrence grade). Linear regression models were fitted, adding interaction terms for each subgroup of interest. RESULTS The treatment effects of the combined intervention at 6 weeks were greater in participants with lower joint subluxation compared with those with greater subluxation (pain -11.6 [95%CI -22.2, -9.9] and 2.6 [-5.5, 10.7], respectively, difference between the subluxation groups 14.2 units (95% CI 2.3, 26.1), p-value 0.02; and PGA -14.0 [-22.4, -5.5] and 1.5 [-6.2, 9.3), respectively, difference between the subluxation groups 15.5 units (95% CI 4.2, 26.8), p-value 0.03). There was no statistically significant heterogeneity for the other subgroups. CONCLUSION A combination of conservative therapies may provide greater benefits over 6 weeks in individuals with lower joint subluxation, although the clinical relevance is uncertain given the wide confidence intervals. Treatment strategies may need to be customized for those with greater joint subluxation. TRIAL REGISTRATION NUMBER ACTRN 12616000353493.",2021,"The treatment effects of the combined intervention at 6 weeks were greater in participants with lower joint subluxation compared with those with greater subluxation (pain -11.6 [95%CI -22.2, -9.9] and 2.6 [-5.5, 10.7], respectively, difference between the subluxation groups 14.2 units (95% CI 2.3, 26.1), p-value 0.02; and PGA -14.0 [-22.4, -5.5] and 1.5 [-6.2, 9.3), respectively, difference between the subluxation groups 15.5 units (95% CI 4.2, 26.8), p-value 0.03).","['individuals with lower radial subluxation - a pre-planned subgroup analysis of the COMBO trial', 'individuals with lower joint subluxation']","['prefabricated neoprene splint, hand exercises, and diclofenac sodium gel, with education alone', 'conservative therapies']","['baseline radiographic OA severity (Kellgren Lawrence grade', ""grip and tip-pinch strength and patient's global assessment (PGA) (VAS, 0-100mm"", 'change in pain (visual analogue scale [VAS], 0-100 mm) and hand function (Functional Index for Hand Osteoarthritis questionnaire, 0-30', 'interphalangeal joint pain, erosive hand OA, radiographic thumb carpometacarpal joint subluxation']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0149977', 'cui_str': 'Pulled elbow'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332768', 'cui_str': 'Subluxation of joint'}]","[{'cui': 'C0027673', 'cui_str': 'Neoprene'}, {'cui': 'C0038009', 'cui_str': 'Splint'}, {'cui': 'C0454330', 'cui_str': 'Hand exercises'}, {'cui': 'C0700583', 'cui_str': 'Diclofenac sodium'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0429273', 'cui_str': 'Tip pinch'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0562230', 'cui_str': 'Hand functions'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0263746', 'cui_str': 'Degenerative joint disease of hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1563055', 'cui_str': 'Interphalangeal joint structure'}, {'cui': 'C0439679', 'cui_str': 'Erosive'}, {'cui': 'C0040067', 'cui_str': 'Thumb structure'}, {'cui': 'C0224620', 'cui_str': 'Carpometacarpal joint structure'}, {'cui': 'C0332768', 'cui_str': 'Subluxation of joint'}]",204.0,0.150883,"The treatment effects of the combined intervention at 6 weeks were greater in participants with lower joint subluxation compared with those with greater subluxation (pain -11.6 [95%CI -22.2, -9.9] and 2.6 [-5.5, 10.7], respectively, difference between the subluxation groups 14.2 units (95% CI 2.3, 26.1), p-value 0.02; and PGA -14.0 [-22.4, -5.5] and 1.5 [-6.2, 9.3), respectively, difference between the subluxation groups 15.5 units (95% CI 4.2, 26.8), p-value 0.03).","[{'ForeName': 'L A', 'Initials': 'LA', 'LastName': 'Deveza', 'Affiliation': 'Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia. Electronic address: leticia.alle@sydney.edu.au.'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Robbins', 'Affiliation': 'Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Duong', 'Affiliation': 'Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Fu', 'Affiliation': 'Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Wajon', 'Affiliation': 'Macquarie University Clinic, Macquarie Hand Therapy, Macquarie University, New South Wales, Australia.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Eyles', 'Affiliation': 'Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Jongs', 'Affiliation': 'Physiotherapy Department, Royal North Shore Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'E A', 'Initials': 'EA', 'LastName': 'Riordan', 'Affiliation': 'Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'W M', 'Initials': 'WM', 'LastName': 'Oo', 'Affiliation': 'Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Hunter', 'Affiliation': 'Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.'}]",Osteoarthritis and cartilage,['10.1016/j.joca.2021.07.010'] 1859,34319247,Efficacy and Safety of Text Messages Targeting Adherence to Cardiovascular Medications in Secondary Prevention: TXT2HEART Colombia Randomized Controlled Trial.,"BACKGROUND Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide, with a prevalence of approximately 100 million patients. There is evidence that antiplatelet agents and antihypertensive medications could reduce the risk of new vascular events in this population; however, treatment adherence is very low. An SMS text messaging intervention was recently developed based on behavior change techniques to increase adherence to pharmacological treatment among patients with a history of ASCVD. OBJECTIVE This study aims to evaluate the efficacy and safety of an SMS text messaging intervention to improve adherence to cardiovascular medications in patients with ASCVD. METHODS A randomized controlled clinical trial for patients with a prior diagnosis of cardiovascular events, such as acute myocardial infarction, unstable angina, cerebrovascular disease, or peripheral artery disease, in one center in Colombia was conducted. Patients randomized to the intervention arm were assigned to receive SMS text messages daily for the first 4 weeks, 5 SMS text messages on week 5, 3 SMS text messages each in weeks 6 and 7, and 1 SMS text message weekly from week 8 until week 52. In contrast, patients in the control arm received a monthly SMS text message reminding them of the next study appointment and the importance of the study, requesting information about changes in their phone number, and thanking them for participating in the study. The primary endpoint was the change in low-density lipoprotein cholesterol (LDL-C) levels, whereas the secondary endpoints were the changes in thromboxane B2 levels, heart rate, systolic and diastolic blood pressure, medication adherence, cardiac and noncardiac mortality, and hospitalization. Linear regression analyses and bivariate tests were performed. RESULTS Of the 930 randomized patients, 805 (86.5%) completed follow-up and were analyzed for the primary endpoint. There was no evidence that the intervention changed the primary outcome (LDL-C levels; P=.41) or any of the secondary outcomes evaluated (all P>.05). There was also no evidence that the intervention was associated with adverse events. CONCLUSIONS In this study, there was no evidence that a behavior modification intervention delivered by SMS text messaging improved LDL-C levels, blood pressure levels, or adherence at 12 months. More research is needed to evaluate whether different SMS text messaging strategies, including personalized messages and different timings, are effective; future studies should include mixed methods to better understand why, for whom, and in which context (eg, health system or social environment) SMS text messaging interventions work (or not) to improve adherence in patients with ASCVD. TRIAL REGISTRATION ClinicalTrials.gov NCT03098186; https://clinicaltrials.gov/ct2/show/NCT03098186. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.1136/bmjopen-2018-028017.",2021,There was no evidence that the intervention changed the primary outcome (LDL-C levels; P=.41) or any of the secondary outcomes evaluated (all P>.05).,"['patients with a prior diagnosis of cardiovascular events, such as acute myocardial infarction, unstable angina, cerebrovascular disease, or peripheral artery disease, in one center in Colombia was conducted', 'patients with a history of ASCVD', 'patients with ASCVD', 'approximately 100 million patients']","['SMS text messages daily for the first 4 weeks, 5 SMS text messages', 'SMS text messaging intervention', 'Text Messages']","['thromboxane B2 levels, heart rate, systolic and diastolic blood pressure, medication adherence, cardiac and noncardiac mortality, and hospitalization', 'efficacy and safety', 'change in low-density lipoprotein cholesterol (LDL-C) levels', 'LDL-C levels, blood pressure levels, or adherence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332132', 'cui_str': 'Prior diagnosis'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0002965', 'cui_str': 'Impending infarction'}, {'cui': 'C0007820', 'cui_str': 'Cerebrovascular disease'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C3245499', 'cui_str': 'Colombia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1881839', 'cui_str': '1000000'}]","[{'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0040059', 'cui_str': 'Thromboxane B>2<'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",930.0,0.132918,There was no evidence that the intervention changed the primary outcome (LDL-C levels; P=.41) or any of the secondary outcomes evaluated (all P>.05).,"[{'ForeName': 'Anderson', 'Initials': 'A', 'LastName': 'Bermon', 'Affiliation': 'Research Center, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.'}, {'ForeName': 'Ana Fernanda', 'Initials': 'AF', 'LastName': 'Uribe', 'Affiliation': 'Faculty of Psychology, Universidad Pontificia Bolivariana - Seccional Bucaramanga, Floridablanca, Colombia.'}, {'ForeName': 'Paula Fernanda', 'Initials': 'PF', 'LastName': 'Pérez-Rivero', 'Affiliation': 'Faculty of Psychology, Universidad Pontificia Bolivariana - Seccional Bucaramanga, Floridablanca, Colombia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Prieto-Merino', 'Affiliation': 'Epidemiology and Population Health Faculty, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Jose Federico', 'Initials': 'JF', 'LastName': 'Saaibi', 'Affiliation': 'Departament of Cardiovascular Surgery, Division of Vascular and Endovascular Surgery, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.'}, {'ForeName': 'Federico Arturo', 'Initials': 'FA', 'LastName': 'Silva', 'Affiliation': 'Neurovascular Science Group, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.'}, {'ForeName': 'Diana Ivonne', 'Initials': 'DI', 'LastName': 'Canon', 'Affiliation': 'Departament of Cardiology, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.'}, {'ForeName': 'Karol Melissa', 'Initials': 'KM', 'LastName': 'Castillo-Gonzalez', 'Affiliation': 'Research Center, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.'}, {'ForeName': 'Diana Isabel', 'Initials': 'DI', 'LastName': 'Cáceres-Rivera', 'Affiliation': 'Nursing Faculty, Universidad Cooperativa de Colombia, Bucaramanga, Colombia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Guio', 'Affiliation': 'Metabolism and Genoma Laboratory, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.'}, {'ForeName': 'Karen Janneth', 'Initials': 'KJ', 'LastName': 'Meneses-Castillo', 'Affiliation': 'Research Center, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Castillo-Meza', 'Affiliation': 'Research Center, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Atkins', 'Affiliation': 'Research Department of Epidemiology and Public Health, University College London, London, United Kingdom.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Horne', 'Affiliation': 'University College London School of Pharmacy, London, Colombia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Murray', 'Affiliation': 'Research Department of Primary Care and Population Health, University College London, London, United Kingdom.'}, {'ForeName': 'Norma Cecilia', 'Initials': 'NC', 'LastName': 'Serrano', 'Affiliation': 'Direction of Research, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Free', 'Affiliation': 'Epidemiology and Population Health Faculty, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Juan Pablo', 'Initials': 'JP', 'LastName': 'Casas', 'Affiliation': 'Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), Boston, MA, United States.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Perel', 'Affiliation': 'Centre for Global Chronic Conditions, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}]",JMIR mHealth and uHealth,['10.2196/25548'] 1860,34320651,Side-Effects 15 Years after Lymph Node Irradiation in Breast Cancer: Randomized EORTC Trial 22922/10925.,"BACKGROUND Uncertainty about the benefit/risk ratio of regional lymph node irradiation led to varying clinical protocols. We investigated long-term late side effects after internal mammary and medial supraclavicular (IM-MS) lymph node irradiation to improve shared decision-making. METHODS The multicentre EORTC trial (ClinicalTrials.gov, NCT00002851) randomized stage I-III breast cancer patients with involved axillary nodes and/or a medially located primary tumor. We analyzed late side effects, both longitudinally at every follow-up and cross-sectionally at 5-year intervals. All statistical tests were 2-sided. RESULTS Between 1996 and 2004, 46 departments from 13 countries accrued 4004 patients. Median follow-up was 15.7 years. Longitudinal follow-up data showed cumulative incidence rates at 15 years of 2.9% (95% confidence interval [CI] = 2.2%-3.8%) vs. 5.7% (95% CI = 4.7%-6.9%) (P<.001) for lung fibrosis, of 1.1% (95% CI = 0.7%-1.7%) vs. 1.9% (95% CI = 1.3%-2.6%) (P=.07) for cardiac fibrosis, and of 9.4% (95% CI = 8.0%-10.8%) vs. 11.1% (95% CI = 9.6%-12.7%) (P=.04) for any cardiac disease, when treated without or with IM-MS lymph node irradiation. There was no evidence for differences between left- and right-sided breast cancer (Wald chi-square test of treatment by breast side interaction, P=.33 and P=.35, for cardiac fibrosis and for any cardiac disease, respectively). The cumulative incidence probabilities of cross-sectionally reported side effects with a score of 2 or greater at 15 years were 0.1% (95% CI = 0.0%-0.5%) vs. 0.8% (95% CI = 0.4%-1.4%) for pulmonary (P=.02), 1.8% (95% CI = 1.1%-2.8%) vs. 2.6% (95% CI = 1.8%-3.7%) for cardiac (P=.15), and 0.0% (95% CI not evaluated) vs. 0.1% (95% CI = 0.0%-0.4%) for oesophageal (P=.16), respectively. No difference was observed in the incidence of second malignancies, contralateral breast cancer or cardiovascular deaths. CONCLUSIONS The incidence of late pulmonary side effects was statistically significantly higher after IM-MS lymph node irradiation, as were some of the cardiac events, without a difference between left- and right-sided treatments. Absolute rates and differences were very low, without increased non-breast cancer related mortality, even before introducing heart-sparing techniques.",2021,"Absolute rates and differences were very low, without increased non-breast cancer related mortality, even before introducing heart-sparing techniques.","['III breast cancer patients with involved axillary nodes and/or a medially located primary tumor', 'Between 1996 and 2004', 'Breast Cancer', ' 46 departments from 13 countries accrued 4004 patients']",['internal mammary and medial supraclavicular (IM-MS) lymph node irradiation'],"['incidence of second malignancies, contralateral breast cancer or cardiovascular deaths', 'oesophageal', 'cumulative incidence rates', 'lung fibrosis', 'incidence of late pulmonary side effects']","[{'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0729594', 'cui_str': 'Axillary lymph node group'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0454664', 'cui_str': 'Country'}]","[{'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0589496', 'cui_str': 'Supraclavicular approach'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0085183', 'cui_str': 'Second Primary Neoplasms'}, {'cui': 'C1096616', 'cui_str': 'Contralateral breast cancer'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0034069', 'cui_str': 'Fibrosis of lung'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",,0.356449,"Absolute rates and differences were very low, without increased non-breast cancer related mortality, even before introducing heart-sparing techniques.","[{'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Poortmans', 'Affiliation': 'Department of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium.'}, {'ForeName': 'Henk', 'Initials': 'H', 'LastName': 'Struikmans', 'Affiliation': 'Department of Radiation Oncology, Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'De Brouwer', 'Affiliation': 'Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Weltens', 'Affiliation': 'Department of Radiation Oncology, University Hospital Leuven, KU Leuven faculty of medicine, Leuven, Belgium.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Fortpied', 'Affiliation': 'European Organisation for Research and Treatment of Cancer (EORTC), Headquarters, Brussels, Belgium.'}, {'ForeName': 'Carine', 'Initials': 'C', 'LastName': 'Kirkove', 'Affiliation': 'Department of Radiation Oncology, University Hospital Saint Luc, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Budach', 'Affiliation': 'Department of Radiation Oncology, Charité-Universitaetsmedizin Berlin, corporate member of Free University Berlin, Humboldt-University Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Peignaux-Casasnovas', 'Affiliation': 'Department of Radiation Oncology, Centre Georges François Leclerc, Dijon, France.'}, {'ForeName': 'Femke', 'Initials': 'F', 'LastName': 'van der Leij', 'Affiliation': 'Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Ernest', 'Initials': 'E', 'LastName': 'Vonk', 'Affiliation': 'Institute for Radiation Oncology RISO, Deventer, The Netherlands.'}, {'ForeName': 'Mariacarla', 'Initials': 'M', 'LastName': 'Valli', 'Affiliation': 'Department of Radiation Oncology, Sant Anna Hospital, Como, Italy.'}, {'ForeName': 'Geertjan', 'Initials': 'G', 'LastName': 'van Tienhoven', 'Affiliation': 'Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Weidner', 'Affiliation': 'Department of Radiation Oncology, University Hospital, Tübingen, Germany.'}, {'ForeName': 'Georges', 'Initials': 'G', 'LastName': 'Noel', 'Affiliation': 'Department of Radiation Oncology, Centre Paul Strauss, Strasbourg, France.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Guckenberger', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Eveline', 'Initials': 'E', 'LastName': 'Koiter', 'Affiliation': 'Department of Radiation Oncology, Medisch Spectrum Twente, Enschede, The Netherlands.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'van Limbergen', 'Affiliation': 'Department of Radiation Oncology, University Hospital Leuven, KU Leuven faculty of medicine, Leuven, Belgium.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Engelen', 'Affiliation': 'Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Fourquet', 'Affiliation': 'Department of Radiation Oncology, Institut Curie, Paris, France.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Bartelink', 'Affiliation': 'Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the National Cancer Institute,['10.1093/jnci/djab113'] 1861,34320164,"The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19.",,2021,,[],[],[],[],[],[],,0.283699,,"[{'ForeName': 'Guilherme', 'Initials': 'G', 'LastName': 'Pessoa-Amorim', 'Affiliation': 'Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.'}, {'ForeName': 'Marion M', 'Initials': 'MM', 'LastName': 'Mafham', 'Affiliation': 'Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.'}]",Cardiovascular research,['10.1093/cvr/cvab239'] 1862,34320079,Exercise Training Improves Functions of Endothelial Progenitor Cells in Patients with Metabolic Syndrome.,"BACKGROUND Endothelial progenitor cells (EPCs) play an important role in maintaining endothelial function. Metabolic syndrome (MetS) is associated with EPC dysfunction. Although physical exercise has a beneficial impact on EPC activity, its mechanism is not completely clear yet. OBJECTIVE The purpose of this study is to investigate the effects of physical exercise on the functions of EPCs and the underlying mechanisms in patients with MetS. METHODS Volunteers with MetS were divided into exercise group (n=15) and control group (n=15). Before and after 8 weeks exercise training, EPCs were isolated from peripheral blood. Colony forming unit (CFU) assay, tube-formation assay, the protein expression of endothelial nitric oxide synthase (eNOS), phosphatidylinositol-3-kinase (PI3-K) and protein kinase B (AKT) were determined. A probability value <0.05 was considered to indicate statistical significance. RESULTS After 8 weeks, the number of CFUs was significantly increased in the exercise group compared to the control group (p<0.05). In addition, we observed a significant decrease of homeostasis model assessment for insulin resistance (HOMA-IR), endothelin-1, high-sensitive C-reactive protein, and homocysteine levels in the exercise group. Exercise intervention could also enhance tube-formation capacity of EPCs and increase phosphorylation level of eNOS, PI3-K and AKT. CONCLUSION Physical exercise enhanced the functions of EPCs. The mechanism may be related to exercise, activating the PI3-K/AKT/eNOS pathway.",2021,"Exercise intervention could also enhance tube-formation capacity of EPCs and increase phosphorylation level of eNOS, PI3-K and AKT. ","['Patients with Metabolic Syndrome', 'patients with MetS.\nMETHODS\n\n\nVolunteers with MetS']","['Exercise intervention', 'Physical exercise', 'physical exercise', 'Exercise Training', 'exercise group']","['Endothelial Progenitor Cells', 'homeostasis model assessment for insulin resistance (HOMA-IR), endothelin-1, high-sensitive C-reactive protein, and homocysteine levels', 'enhance tube-formation capacity of EPCs and increase phosphorylation level of eNOS, PI3-K and AKT', 'Metabolic syndrome (MetS', 'Colony forming unit (CFU) assay, tube-formation assay, the protein expression of endothelial nitric oxide synthase (eNOS), phosphatidylinositol-3-kinase (PI3-K) and protein kinase B (AKT', 'number of CFUs', 'functions of EPCs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}]","[{'cui': 'C3850017', 'cui_str': 'Circulating Endothelial Progenitor Cells'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0079281', 'cui_str': 'Endothelin Type 1'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C2242817', 'cui_str': 'Homocysteine measurement'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0031715', 'cui_str': 'Phosphorylation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0669365', 'cui_str': 'NOS3 protein, human'}, {'cui': 'C0044602', 'cui_str': '1-phosphatidylinositol 3-kinase'}, {'cui': 'C0164786', 'cui_str': 'c-akt Proto-Oncogene Protein'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0439158', 'cui_str': 'colonies'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",,0.00389356,"Exercise intervention could also enhance tube-formation capacity of EPCs and increase phosphorylation level of eNOS, PI3-K and AKT. ","[{'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Tan', 'Affiliation': 'Qinhuangdao First Hospital,Qinhuangdao - China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Qinhuangdao First Hospital,Qinhuangdao - China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Qinhuangdao First Hospital,Qinhuangdao - China.'}]",Arquivos brasileiros de cardiologia,['10.36660/abc.20200028'] 1863,34323666,Yoga for hypertensive patients: a study on barriers and facilitators of its implementation in primary care.,"BACKGROUND International guidelines for hypertension treatment recommend the use of yoga, particularly among low-risk patients. However, evidence is lacking on the implementation potential of health-worker-led yoga interventions in low-resource, primary care settings. OBJECTIVE To assess barriers to and facilitators of the implementation of a yoga intervention for hypertensive patients in primary care in Nepal. METHODS The study was conducted using focus group discussions, in-depth interviews, key informant interviews, and telephone interviews. Data were collected from the 'Yoga and Hypertension' (YoH) trial participants, YoH intervention implementers, and officials from the Ministry of Health and Population in Nepal. RESULTS Most YoH trial participants stated that: (1) it was easy to learn yoga during a five-day training period and practise it for three months at home; (2) practising yoga improved their health; and (3) group yoga sessions in a community centre would help them practise yoga more regularly. Most YoH intervention implementers stated that: (1) they were highly motivated to implement the intervention; (2) the cost of implementation was acceptable; (3) they did not need additional staff to effectively implement the intervention; (4) providing remuneration to the staff involved in the intervention would increase their motivation; and (5) the yoga programme was 'simple and easy to follow' and 'easily performed by participants of any age'. The government officials stated that: (1) yoga is considered as a key health promotional activity in Nepal; and (2) the integration of the yoga intervention into the existing health care programme would not be too challenging, because the existing personnel and other resources can be utilised. CONCLUSION While there is a good potential that a yoga intervention can be implemented in primary care, capacity development for health workers and the involvement of community yoga centres in the delivery of the interventions may be required to facilitate this implementation.",2021,", capacity development for health workers and the involvement of community yoga centres in the delivery of the interventions may be required to facilitate this implementation.","['primary care', ""Data were collected from the 'Yoga and Hypertension' (YoH) trial participants, YoH intervention implementers, and officials from the Ministry of Health and Population in Nepal"", 'hypertensive patients in primary care in Nepal', 'hypertensive patients', 'low-risk patients']",['yoga intervention'],[],"[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0027689', 'cui_str': 'Nepal'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.029749,", capacity development for health workers and the involvement of community yoga centres in the delivery of the interventions may be required to facilitate this implementation.","[{'ForeName': 'Raja Ram', 'Initials': 'RR', 'LastName': 'Dhungana', 'Affiliation': 'Institute for Health and Sport, Victoria University, Melbourne, Australia.'}, {'ForeName': 'Shiva Ram', 'Initials': 'SR', 'LastName': 'Khatiwoda', 'Affiliation': 'Patanjali Ayurveda Medical College and Research Center, Dhulikhel, Kathmandu, Nepal.'}, {'ForeName': 'Yadav', 'Initials': 'Y', 'LastName': 'Gurung', 'Affiliation': 'Child and Youth Health Research Center, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'Željko', 'Initials': 'Ž', 'LastName': 'Pedišić', 'Affiliation': 'Institute for Health and Sport, Victoria University, Melbourne, Australia.'}, {'ForeName': 'Maximilian', 'Initials': 'M', 'LastName': 'de Courten', 'Affiliation': 'Institute for Health and Sport, Victoria University, Melbourne, Australia.'}]",Global health action,['10.1080/16549716.2021.1952753'] 1864,34333826,A randomized prospective study of different dose regimens using the 308-nm excimer laser in the treatment of palmoplantar pustulosis.,"The objective of this study was to evaluate optimal treatment regimen of 308-nm excimer laser for palmoplantar pustulosis (PPP). 77 patients with PPP were randomly assigned to receive low dose (2-fold of MED as initial dose), medium dose (4-fold of MED as initial dose) and high dose group (6-fold of MED as initial dose) and the MED of each patient depended on the ultraviolet light sensitivity of individual's skin which ranged from 0.1 to 0.25 J/cm 2 . All group received 308-nm excimer laser treatment three times weekly for 8 weeks. Clinical evaluation based on the Palmoplantar Pustular Psoriasis Area and Severity Index (PP-PASI) and Dermatology Life Quality Index (DLQI) score. All treatment groups achieved satisfied efficacy at the end of the treatment period with more obvious reduction of PP-PASI score in high dose group (16.05 ± 4.26) than low and medium dose group (23.67 ± 7.16, p < 0.01; 22.04 ± 5.74, p < 0.01). Improvement of DLQI score was greatest at week 4 for all patients in each group, while DLQI improved more quickly in high/medium dose group than low dose group. Adverse effects of erythema, blistering and erosions were more common with the higher dose regimen. High dose of 308-nm excimer laser could achieve a better efficacy in PPP treatment, reduce the severity of the disease in patients and improve the life quality of patients. Meantime, the incidence of adverse reactions should be aware of and it's necessary to evaluate the skin and lesion type before the dose selection.",2021,"All treatment groups achieved satisfied efficacy at the end of the treatment period with more obvious reduction of PP-PASI score in high dose group (16.05 ± 4.26) than low and medium dose group (23.67 ± 7.16, P < 0.01; 22.04 ± 5.74, P < 0.01).","['77 patients with PPP', 'palmoplantar pustulosis (PPP', 'palmoplantar pustulosis']",['308-nm excimer laser'],"['satisfied efficacy', 'DLQI score', 'Adverse effects of erythema, blistering and erosions', 'PP-PASI score', 'Palmoplantar Pustular Psoriasis Area and Severity Index (PP-PASI) and Dermatology Life Quality Index (DLQI) score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031106', 'cui_str': 'Aggressive periodontitis'}, {'cui': 'C0030246', 'cui_str': 'Pustular psoriasis of palms and soles'}]","[{'cui': 'C0392265', 'cui_str': 'Excimer laser device'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0005758', 'cui_str': 'Blister'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer'}, {'cui': 'C0030246', 'cui_str': 'Pustular psoriasis of palms and soles'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C4706308', 'cui_str': 'DLQI (Dermatology Life Quality Index) score'}]",77.0,0.0215535,"All treatment groups achieved satisfied efficacy at the end of the treatment period with more obvious reduction of PP-PASI score in high dose group (16.05 ± 4.26) than low and medium dose group (23.67 ± 7.16, P < 0.01; 22.04 ± 5.74, P < 0.01).","[{'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Peng', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Yifan', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Wenjuan', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Yangfeng', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Xingzi', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Yu', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Jiajing', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Yuling', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.'}]",Dermatologic therapy,['10.1111/dth.15079'] 1865,34333503,Long Sleep Duration Associated With Cognitive Impairment in Chinese Community-Dwelling Older Adults.,"ABSTRACT We aimed to examine the association between sleep duration and impaired cognitive function in different cognitive domains in Chinese community-dwelling older adults. A total of 1591 participants (≥60 years) were divided into five groups: ≤6 hours (very short sleep duration), >6 to 7 hours (short sleep duration), ≥7 to 8 hours (moderate sleep duration), >8 to 9 hours (moderately long sleep duration), and >9 hours (long sleep duration), according to sleep duration. Cognitive function was assessed using the Mini-Mental State Examination. Long sleep duration significantly increased the likelihood of cognitive impairment. In addition to attention, long sleep duration was negatively related to poorer global cognition and other cognitive domain functions. With the stratification of age groups, long sleep duration was negatively associated with other cognitive domain functions except delayed recall in older elderly (≥75 years) people, but not in younger elderly (60-74 years) people. Long sleep duration was associated with higher rates of cognitive impairment, poorer global cognition, and declined orientation, memory, language ability, and executive function in Chinese community-dwelling older adults, which was more significant in older elderly people.",2021,"Long sleep duration was associated with higher rates of cognitive impairment, poorer global cognition, and declined orientation, memory, language ability, and executive function in Chinese community-dwelling older adults, which was more significant in older elderly people.","['older elderly (≥75 years) people, but not in younger elderly (60-74 years) people', 'Chinese Community-Dwelling Older Adults', '1591 participants (≥60 years', 'Chinese community-dwelling older adults']",[],"['likelihood of cognitive impairment', 'cognitive impairment, poorer global cognition, and declined orientation, memory, language ability, and executive function', 'Cognitive function']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0009462', 'cui_str': 'Community'}]",[],"[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",1591.0,0.0393262,"Long sleep duration was associated with higher rates of cognitive impairment, poorer global cognition, and declined orientation, memory, language ability, and executive function in Chinese community-dwelling older adults, which was more significant in older elderly people.","[{'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Shanghai University of Medicine and Health Science Affiliated First Rehabilitation Hospital Shanghai University of Traditional Chinese Medicine College of Rehabilitation Sciences, Shanghai University of Medicine and Health Sciences, Shanghai, China.'}, {'ForeName': 'Weibo', 'Initials': 'W', 'LastName': 'Ma', 'Affiliation': ''}, {'ForeName': 'Yaoxin', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Jingru', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Peipei', 'Initials': 'P', 'LastName': 'Han', 'Affiliation': ''}, {'ForeName': 'Yiwen', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Chenyu', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Fandi', 'Initials': 'F', 'LastName': 'Xie', 'Affiliation': ''}, {'ForeName': 'Shumeng', 'Initials': 'S', 'LastName': 'Niu', 'Affiliation': ''}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Guo', 'Affiliation': ''}]",The Journal of nervous and mental disease,['10.1097/NMD.0000000000001401'] 1866,34338876,A novel electrosurgical divider: performance in a self-controlled tonsillectomy study.,"PURPOSE Tonsillectomies are among the most common surgeries in otorhinolaryngology. A novel electrosurgical temperature-controlled instrument (device) promises rapid tonsillectomies and might reduce postoperative pain, but comparative studies to assess performance are warranted. METHODS This randomized self-controlled clinical trial was conducted from October 2019 to October 2020 at the Department of Otorhinolaryngology, Head and Neck Surgery of the Medical University of Vienna. Forty-eight patients underwent a tonsillectomy with the device on one side and using cold-steel with localized bipolar cauterization on the other side (control). Main outcomes were the time for tonsil removal (per side) and the time to stop bleeding (per side). Secondary measurements were postoperative pain, assessed once on day 0 and five times on days 1, 3, 5, 7, and 10. Postoperative bleeding episodes and consequences were recorded. RESULTS Device tonsillectomies were performed significantly faster than controls; the mean surgical time difference was 209 s (p < 0.001, 95% CI 129; 288). Intraoperative blood loss was significantly lower on the device side (all p < 0.05). Postoperative measurements of pain and bleeding were similar for both sides. Two return-to-theatre secondary bleeding events were recorded for the control side. CONCLUSION The novel electrosurgical temperature-controlled divider reduced the tonsillectomy surgical time and intraoperative blood loss, with no apparent negative effects on postoperative pain or bleeding, compared to a cold-steel tonsillectomy with localized bipolar cauterization. In time-restricted settings, the device could be beneficial, particularly after familiarization with device handling. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03793816.",2021,"A novel electrosurgical temperature-controlled instrument (device) promises rapid tonsillectomies and might reduce postoperative pain, but comparative studies to assess performance are warranted. ","['October 2019 to October 2020 at the Department of Otorhinolaryngology, Head and Neck Surgery\u2009of the Medical University of Vienna']","['electrosurgical temperature-controlled instrument (device) promises rapid tonsillectomies', 'cold-steel tonsillectomy with localized bipolar cauterization', 'tonsillectomy with the device on one side and using cold-steel with localized bipolar cauterization on the other side (control']","['postoperative pain or bleeding', 'Postoperative measurements of pain and bleeding', 'tonsillectomy surgical time and intraoperative blood loss', 'Intraoperative blood loss', 'postoperative pain', 'time for tonsil removal (per side) and the time to stop bleeding (per side', 'mean surgical time difference', 'Two return-to-theatre secondary bleeding events']","[{'cui': 'C0029892', 'cui_str': 'Otolaryngology'}, {'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0038239', 'cui_str': 'Steel'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0007471', 'cui_str': 'Cauterization - action'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0392752', 'cui_str': 'Localized'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0040421', 'cui_str': 'Tonsillar structure (palatine)'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0475307', 'cui_str': 'Theatre'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",48.0,0.164994,"A novel electrosurgical temperature-controlled instrument (device) promises rapid tonsillectomies and might reduce postoperative pain, but comparative studies to assess performance are warranted. ","[{'ForeName': 'Gerold', 'Initials': 'G', 'LastName': 'Besser', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. gerold.besser@meduniwien.ac.at.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Grasl', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.'}, {'ForeName': 'Elias L', 'Initials': 'EL', 'LastName': 'Meyer', 'Affiliation': 'Section for Medical Statistics, CeMSIIS, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Schnoell', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.'}, {'ForeName': 'Tina J', 'Initials': 'TJ', 'LastName': 'Bartosik', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.'}, {'ForeName': 'Faris F', 'Initials': 'FF', 'LastName': 'Brkic', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.'}, {'ForeName': 'Gregor', 'Initials': 'G', 'LastName': 'Heiduschka', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-021-07008-9'] 1867,34320288,A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection.,"BACKGROUND Primary cytomegalovirus (CMV) infection during pregnancy carries a risk of congenital infection and possible severe sequelae. There is no established intervention for preventing congenital CMV infection. METHODS In this multicenter, double-blind trial, pregnant women with primary CMV infection diagnosed before 24 weeks' gestation were randomly assigned to receive a monthly infusion of CMV hyperimmune globulin (at a dose of 100 mg per kilogram of body weight) or matching placebo until delivery. The primary outcome was a composite of congenital CMV infection or fetal or neonatal death if CMV testing of the fetus or neonate was not performed. RESULTS From 2012 to 2018, a total of 206,082 pregnant women were screened for primary CMV infection before 23 weeks of gestation; of the 712 participants (0.35%) who tested positive, 399 (56%) underwent randomization. The trial was stopped early for futility. Data on the primary outcome were available for 394 participants; a primary outcome event occurred in the fetus or neonate of 46 of 203 women (22.7%) in the group that received hyperimmune globulin and of 37 of 191 women (19.4%) in the placebo group (relative risk, 1.17; 95% confidence interval [CI] 0.80 to 1.72; P = 0.42). Death occurred in 4.9% of fetuses or neonates in the hyperimmune globulin group and in 2.6% in the placebo group (relative risk, 1.88; 95% CI, 0.66 to 5.41), preterm birth occurred in 12.2% and 8.3%, respectively (relative risk, 1.47; 95% CI, 0.81 to 2.67), and birth weight below the 5th percentile occurred in 10.3% and 5.4% (relative risk, 1.92; 95% CI, 0.92 to 3.99). One participant in the hyperimmune globulin group had a severe allergic reaction to the first infusion. Participants who received hyperimmune globulin had a higher incidence of headaches and shaking chills while receiving infusions than participants who received placebo. CONCLUSIONS Among pregnant women, administration of CMV hyperimmune globulin starting before 24 weeks' gestation did not result in a lower incidence of a composite of congenital CMV infection or perinatal death than placebo. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Center for Advancing Translational Sciences; ClinicalTrials.gov number, NCT01376778.).",2021,"Participants who received hyperimmune globulin had a higher incidence of headaches and shaking chills while receiving infusions than participants who received placebo. ","['From 2012 to 2018', '206,082 pregnant women were screened for primary CMV infection before 23 weeks of gestation; of the 712 participants (0.35%) who tested positive, 399 (56%) underwent randomization', ""pregnant women with primary CMV infection diagnosed before 24 weeks' gestation""]","['placebo', 'CMV hyperimmune globulin', 'Hyperimmune Globulin', 'hyperimmune globulin']","['birth weight', 'severe allergic reaction', 'Congenital Cytomegalovirus Infection', 'preterm birth', 'headaches and shaking chills', 'congenital CMV infection or perinatal death', 'fetus or neonate', 'composite of congenital CMV infection or fetal or neonatal death if CMV testing of the fetus or neonate was not performed', 'Death']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C4517451', 'cui_str': '0.35'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C0017649', 'cui_str': 'Globulin'}]","[{'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0158945', 'cui_str': 'Congenital cytomegalovirus infection'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0085593', 'cui_str': 'Chill'}, {'cui': 'C0701826', 'cui_str': 'Perinatal death'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0410916', 'cui_str': 'Newborn death'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0445106', 'cui_str': 'Not performed'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",206082.0,0.886239,"Participants who received hyperimmune globulin had a higher incidence of headaches and shaking chills while receiving infusions than participants who received placebo. ","[{'ForeName': 'Brenna L', 'Initials': 'BL', 'LastName': 'Hughes', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Rebecca G', 'Initials': 'RG', 'LastName': 'Clifton', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Dwight J', 'Initials': 'DJ', 'LastName': 'Rouse', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Saade', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Mara J', 'Initials': 'MJ', 'LastName': 'Dinsmoor', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Uma M', 'Initials': 'UM', 'LastName': 'Reddy', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Pass', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Allard', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Mallett', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Lida M', 'Initials': 'LM', 'LastName': 'Fette', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Gyamfi-Bannerman', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Varner', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Goodnight', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Alan T N', 'Initials': 'ATN', 'LastName': 'Tita', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Maged M', 'Initials': 'MM', 'LastName': 'Costantine', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Geeta K', 'Initials': 'GK', 'LastName': 'Swamy', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Ronald S', 'Initials': 'RS', 'LastName': 'Gibbs', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Edward K', 'Initials': 'EK', 'LastName': 'Chien', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Suneet P', 'Initials': 'SP', 'LastName': 'Chauhan', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Yasser Y', 'Initials': 'YY', 'LastName': 'El-Sayed', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Casey', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Parry', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Hyagriv N', 'Initials': 'HN', 'LastName': 'Simhan', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Napolitano', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Macones', 'Affiliation': ""From the Department of Obstetrics and Gynecology, Brown University, Providence, RI (B.L.H., D.J.R., D.A.); George Washington University Biostatistics Center, Washington, DC (R.G.C., L.M.F.); the University of Texas Medical Branch, Galveston (G.R.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas Southwestern Medical Center, Dallas (B.M.C.); Northwestern University, Chicago (M.J.D., G.M.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (U.M.R.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); the University of North Carolina at Chapel Hill, Chapel Hill (W.H.G.), and Duke University, Durham (G.K.S.) - both in North Carolina; the Department of Pediatrics (R.P.), University of Alabama at Birmingham (A.T.N.T.), Birmingham; Ohio State University, Columbus (M.M.C.), the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.S.G.); Case Western Reserve University, Cleveland (E.K.C.); Stanford University, Stanford, CA (Y.Y.E.-S.); the University of Pennsylvania, Philadelphia (S.P.), and the University of Pittsburgh, Pittsburgh (H.N.S.); Madigan Army Medical Center, Joint Base Lewis-McChord, WA (P.G.N.); and Washington University, St. Louis (G.A.M.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1913569'] 1868,34323337,"The effect of an orally-dosed Gynostemma pentaphyllum extract (ActivAMP®) on body composition in overweight, adult men and women: A double-blind, randomised, placebo-controlled study.","BACKGROUND The present study examined the effect of a herbal supplement containing a Gynostemma pentaphyllum (Gpp) extract (ActivAMP®) with respect to improving body composition in overweight males and females. METHODS One-hundred and seventeen men and women aged over 18 years completed 16 weeks of daily supplementation with either Gpp or a placebo. Participants underwent dual-energy X-rays to assess body composition (fat mass, lean mass and mass distribution), as well as anthropometric measures (weight, height, hip and waist circumference), in addition to blood tests to assess inflammatory and safety markers. RESULTS Following 16 weeks of treatment, the Gpp group had a significant reduction in total body weight, body mass index, total fat mass and gynoid fat mass compared to the placebo group. Blood measures showed plasma triglyceride, alanine aminotransferase and tumour necrosis factor-α to be statistically different between groups at week 16. Subgroup analysis of gender for fat distribution showed males in the Gpp group had a significant reduction in visceral fat compared to males in the placebo group and females in the Gpp group had a significant reduction in gynoid fat compared to the placebo group. CONCLUSIONS Gpp was capable of altering fat mass and fat distribution in overweight and obese males and females compared to a placebo.",2021,"Following 16 weeks of treatment the Gpp group had a significant reduction in total body weight, BMI, total fat mass and gynoid fat mass compared to the placebo group.","['overweight males and females', 'overweight, adult men and women', 'One-hundred and seventeen men and women aged over 18 completed 16 weeks of daily supplementation with either Gpp or a']","['orally-dosed Gynostemma pentaphyllum extract (ActivAMP®', 'placebo', 'herbal supplement containing a Gynostemma pentaphyllum (Gpp) extract (ActivAMP®', 'dual-energy X-rays']","['body composition', 'anthropometric measures (weight, height, hip and waist circumference) and blood tests to assess inflammatory and safety markers', 'visceral fat', 'gynoid fat', 'plasma triglyceride, ALT and TNF-α', 'total body weight, BMI, total fat mass and gynoid fat mass']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0950016', 'cui_str': 'Gynostemma pentaphyllum'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0950016', 'cui_str': 'Gynostemma pentaphyllum'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1504473', 'cui_str': 'Herbal Supplements'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0034571', 'cui_str': 'radiography'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0583329', 'cui_str': 'Plasma triglyceride measurement'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]",117.0,0.227034,"Following 16 weeks of treatment the Gpp group had a significant reduction in total body weight, BMI, total fat mass and gynoid fat mass compared to the placebo group.","[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Rao', 'Affiliation': 'RDC Clinical, Brisbane, QLD, Australia.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Clayton', 'Affiliation': 'Institute of Food, Brain and Behaviour, Oxford, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Briskey', 'Affiliation': 'RDC Clinical, Brisbane, QLD, Australia.'}]",Journal of human nutrition and dietetics : the official journal of the British Dietetic Association,['10.1111/jhn.12936'] 1869,34323334,Cost-effectiveness of a mobile phone text messaging program (KIDNEYTEXT) targeting dietary behaviours in people receiving haemodialysis.,"BACKGROUND There is little information available to inform the cost-effectiveness of eHealth interventions in improving patient health outcomes. A trial-based economic evaluation was undertaken aiming to inform the feasibility of conducting a mobile phone text messaging programme targeting dietary behaviours in people receiving haemodialysis. METHODS A trial-based economic evaluation from a health system perspective of a 6-month pilot randomised controlled trial was undertaken. One hundred and thirty patients receiving haemodialysis from six dialysis units across Sydney, Australia, were enrolled into the KIDNEYTEXT study. Usual care (inperson dietary counselling) was compared with usual care plus three semi-personalised dietary mobile phone text messages per week over a 6-month period. The outcomes of this economic evaluation included: cost of intervention, cost-effectiveness and marginal effects on total costs. RESULTS The cost of developing and maintaining the KIDNEYTEXT intervention was US $110 per participant. Total costs were US $1418 higher in the usual care arm compared to the intervention arm. The incremental benefits for quality-adjusted life adjusted years were 0.01 [95% confidence interval (CI) = -0.03 to 0.06] and dietary adherence (i.e., adherent to three or more dietary guidelines at 6 months) being 0.04 (95% CI = -0.15 to 0.24). The largest component of total costs was related to unplanned admissions to hospital. CONCLUSIONS Mobile phone text messages targeting dietary behaviours may be cost saving, at the same time as maintaining similar or improved dietary behaviours. A larger trial with a longer follow-up time is warranted.",2021,The incremental benefits for QALYs were 0.01,"['people receiving haemodialysis', '130 patients receiving haemodialysis from six dialysis units across Sydney, Australia were enrolled into the KIDNEYTEXT study']","['mobile phone text messaging program', 'Usual care (inperson dietary counselling', 'mobile phone text messaging program (KIDNEYTEXT']","['dietary adherence', 'Total costs', 'Cost-effectiveness', 'total costs', 'cost of intervention, cost-effectiveness and marginal effects on total costs']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1629858', 'cui_str': 'Dialysis unit'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.029779,The incremental benefits for QALYs were 0.01,"[{'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Dawson', 'Affiliation': 'Westmead Clinical School, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Howell', 'Affiliation': ""Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia.""}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Howard', 'Affiliation': 'Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Katrina L', 'Initials': 'KL', 'LastName': 'Campbell', 'Affiliation': 'Menzies Health Institute, Griffith University, Allied Health Services, Metro North Hospital and Health Service, Brisbane, QLD, Australia.'}, {'ForeName': 'Jonathan C', 'Initials': 'JC', 'LastName': 'Craig', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Tong', 'Affiliation': ""Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia.""}, {'ForeName': 'Vincent W', 'Initials': 'VW', 'LastName': 'Lee', 'Affiliation': 'Westmead Clinical School, The University of Sydney, Sydney, NSW, Australia.'}]",Journal of human nutrition and dietetics : the official journal of the British Dietetic Association,['10.1111/jhn.12937'] 1870,34323290,"Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.","OBJECTIVE To evaluate the efficacy and safety of two dosing regimens of fremanezumab in Japanese and Korean patients with episodic migraine. BACKGROUND Episodic migraine, which accounts for more than 90% of migraine cases, is inadequately addressed by widely available preventive therapies. Fremanezumab, a monoclonal antibody that selectively targets the trigeminal sensory neuropeptide calcitonin gene-related peptide involved in migraine pathogenesis, has demonstrated efficacy in international Phase 3 trials of patients with both chronic and episodic migraine. METHODS This Phase 3 randomized, placebo-controlled trial randomly assigned patients with episodic migraine to receive subcutaneous fremanezumab monthly (225 mg at baseline, week 4, and week 8), fremanezumab quarterly (675 mg at baseline and placebo at weeks 4 and 8), or matching placebo. The primary endpoint was the mean change from baseline in the monthly average number of migraine days during the 12-week treatment period after the first dose. RESULTS Of 357 patients enrolled (safety set, n = 356; full analysis set, n = 354), the least-squares mean (±standard error) reductions in the average number of migraine days per month during 12 weeks were significantly greater with fremanezumab monthly (-4.0 ± 0.4, n = 121) and fremanezumab quarterly (-4.0 ± 0.4, n = 117) than with placebo (-1.0 ± 0.4, n = 116; p < 0.0001 for both comparisons). The proportion of patients reaching at least a 50% reduction in the monthly average number of migraine days during the 12-week period after initial administration was also significantly improved with fremanezumab (fremanezumab monthly, 41.3%; fremanezumab quarterly, 45.3%; placebo, 11.2%; p < 0.0001 for both comparisons) as were other secondary endpoints (p < 0.001 for all comparisons between fremanezumab and placebo). Injection-site reactions were more common in fremanezumab-treated patients (fremanezumab monthly, 25.6%; fremanezumab quarterly, 29.7%; placebo, 21.4%). CONCLUSION Fremanezumab prevents episodic migraine in Japanese and Korean patients to a similar extent than in previously reported populations with no new safety concerns.",2021,Fremanezumab prevents episodic migraine in Japanese and Korean patients to a similar extent than in previously reported populations with no new safety concerns.,"['episodic migraine prevention', '357 patients', 'patients with both chronic and episodic migraine', 'Japanese and Korean patients', 'patients with episodic migraine to receive', 'Japanese and Korean patients with episodic migraine']","['subcutaneous fremanezumab', 'Fremanezumab', 'placebo', 'fremanezumab', 'fremanezumab quarterly (675\xa0mg at baseline and placebo']","['mean change from baseline in the monthly average number of migraine days', 'efficacy and safety', 'Efficacy and safety', 'episodic migraine', 'Injection-site reactions']","[{'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C4549503', 'cui_str': 'fremanezumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332179', 'cui_str': 'Trimonthly'}, {'cui': 'C4517854', 'cui_str': '675'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}]",357.0,0.583749,Fremanezumab prevents episodic migraine in Japanese and Korean patients to a similar extent than in previously reported populations with no new safety concerns.,"[{'ForeName': 'Fumihiko', 'Initials': 'F', 'LastName': 'Sakai', 'Affiliation': 'Saitama International Headache Center, Saitama Neuropsychiatric Institute, Saitama, Japan.'}, {'ForeName': 'Norihiro', 'Initials': 'N', 'LastName': 'Suzuki', 'Affiliation': 'Department of Neurology, Shonan Keiiku Hospital, Kanagawa, Japan.'}, {'ForeName': 'Byung-Kun', 'Initials': 'BK', 'LastName': 'Kim', 'Affiliation': 'Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Yoshihisa', 'Initials': 'Y', 'LastName': 'Tatsuoka', 'Affiliation': 'Department of Neurology, Tatsuoka Neurology Clinic, Kyoto, Japan.'}, {'ForeName': 'Noboru', 'Initials': 'N', 'LastName': 'Imai', 'Affiliation': 'Department of Neurology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Ning', 'Affiliation': 'Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Miki', 'Initials': 'M', 'LastName': 'Ishida', 'Affiliation': 'Specialty Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Nagano', 'Affiliation': 'Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Katsuhiro', 'Initials': 'K', 'LastName': 'Iba', 'Affiliation': 'Specialty Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Kondo', 'Affiliation': 'Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Koga', 'Affiliation': 'Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.'}]",Headache,['10.1111/head.14178'] 1871,34326046,HARMONY: a pragmatic cluster randomised controlled trial of a culturally competent systems intervention to prevent and reduce domestic violence among migrant and refugee families in general practice: study protocol.,"INTRODUCTION Domestic violence and abuse (DVA) is prevalent, harmful and more dangerous among diaspora communities because of the difficulty accessing DVA services, language and migration issues. Consequently, migrant/refugee women are common among primary care populations, but evidence for culturally competent DVA primary care practice is negligible. This pragmatic cluster randomised controlled trial aims to increase DVA identification and referral (primary outcomes) threefold and safety planning (secondary outcome) among diverse women attending intervention vs comparison primary care clinics. Additionally, the study plans to improve recording of DVA, ethnicity, and conduct process and economic evaluations. METHODS AND ANALYSIS Recruitment of ≤28 primary care clinics in Melbourne, Australia with high migrant/refugee communities. Eligible clinics need ≥1 South Asian general practitioner (GP) and one of two common software programmes to enable aggregated routine data extraction by GrHanite. Intervention staff undertake three DVA training sessions from a GP educator and bilingual DVA advocate/educator. Following training, clinic staff and DVA affected women 18+ will be supported for 12 months by the advocate/educator. Comparison clinics are trained in ethnicity and DVA data entry and offer routine DVA care. Data extraction of DV identification, safety planning and referral from routine GP data in both arms. Adjusted regression analysis by intention-to-treat by staff blinded to arm. Economic evaluation will estimate cost-effectiveness and cost-utility. Process evaluation interviews and analysis with primary care staff and women will be framed by Normalisation Process Theory to maximise understanding of sustainability. Harmony will be the first primary care trial to test a culturally competent model for the care of diverse women experiencing DVA. ETHICS AND DISSEMINATION Ethical approval from La Trobe University Human Ethics Committee (HEC18413) and dissemination by policy briefs, journal articles and conference and community presentations. TRIAL REGISTRATION NUMBER ANZCTR- ACTRN12618001845224; Pre-results.",2021,"Harmony will be the first primary care trial to test a culturally competent model for the care of diverse women experiencing DVA. ","['≤28 primary care clinics in Melbourne, Australia with high migrant/refugee communities', 'Eligible clinics need ≥1 South Asian general practitioner (GP', 'domestic violence among migrant and refugee families in general practice', 'diverse women attending intervention vs comparison primary care clinics']",[],"['recording of DVA, ethnicity, and conduct process and economic evaluations']","[{'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0026093', 'cui_str': 'Migrant'}, {'cui': 'C0034961', 'cui_str': 'Refugee'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0206073', 'cui_str': 'Domestic violence'}, {'cui': 'C1446393', 'cui_str': 'Refugee family'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],"[{'cui': 'C2355580', 'cui_str': 'Record of'}, {'cui': 'C0206073', 'cui_str': 'Domestic violence'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0150099', 'cui_str': 'Economic Evaluation'}]",18.0,0.21962,"Harmony will be the first primary care trial to test a culturally competent model for the care of diverse women experiencing DVA. ","[{'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Taft', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia a.taft@latrobe.edu.au.'}, {'ForeName': 'Felicity', 'Initials': 'F', 'LastName': 'Young', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Hegarty', 'Affiliation': 'Dept of General Practice, University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Yelland', 'Affiliation': 'Murdoch Childrens Research Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Mazza', 'Affiliation': 'General Practice, Monash University, Notting Hill, Victoria, Australia.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Boyle', 'Affiliation': 'HaBIC Research Information Technology Unit, Department of General Practice, University of Melbourne, Carlton, Victoria, Australia.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Norman', 'Affiliation': 'School of Population Health, Curtin University, Perth, Western Australia, Australia.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Garcia-Moreno', 'Affiliation': 'World Health Organisation, Geneva, Switzerland.'}, {'ForeName': 'Cattram Duong', 'Initials': 'CD', 'LastName': 'Nguyen', 'Affiliation': 'Pneumococcal Research, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Statistics, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Bijaya', 'Initials': 'B', 'LastName': 'Pokharel', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Allen', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Gene', 'Initials': 'G', 'LastName': 'Feder', 'Affiliation': 'Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK.'}]",BMJ open,['10.1136/bmjopen-2020-046431'] 1872,34325540,The use of Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 on oral health indexes in a school population: A pilot randomized clinical trial.,"To assess the effects of a probiotic upon oral health indices in adolescents and to establish relationships between these indices and dietary habits and oral hygiene. Twenty-seven adolescents between 12 and 18 years of age were randomized into two groups. The study group received tablets containing Lactobacillus reuteri DSM 17938 / ATCC 5289 for 28 days, while the control group received tablets without any bacteria. Streptococcus mutans, Lactobacillus sp., and salivary pH were assessed at baseline and at 7, 14, 21, 28, and 45 days. The plaque, gingivitis, and bleeding indices were recorded at baseline and at 14, 28, and 45 days. Dietary and oral hygiene habits were also evaluated by means of a questionnaire. A less marked rise in S. mutans was recorded in the study group. Improvements were observed in terms of plaque, gingivitis, and bleeding, though statistical significance was not reached. Oral pH increased in the study group, though not to a significant degree. Poorer eating habits were significantly correlated to increased plaque. The study parameters decreased with the two strains of L. reuteri DSM 17938 and ATCC PTA 5289 , though the results failed to reach statistical.",2021,"Improvements were observed in terms of plaque, gingivitis, and bleeding, though statistical significance was not reached.","['Twenty-seven adolescents between 12 and 18 years of age', 'a school population']","['DSM 17938 / ATCC', 'Lactobacillus reuteri DSM 17938 and ATCC PTA', 'probiotic', 'tablets containing Lactobacillus reuteri']","['plaque, gingivitis, and bleeding indices', 'Streptococcus mutans, Lactobacillus sp., and salivary pH', 'Poorer eating habits', 'plaque, gingivitis, and bleeding', 'Oral pH', 'Dietary and oral hygiene habits']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0317625', 'cui_str': 'Lactobacillus reuteri'}, {'cui': 'C0015522', 'cui_str': 'Coagulation factor XI'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0016468', 'cui_str': 'Eating Habits'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0018464', 'cui_str': 'Habits'}]",27.0,0.0257594,"Improvements were observed in terms of plaque, gingivitis, and bleeding, though statistical significance was not reached.","[{'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Borrell García', 'Affiliation': 'Department of Dentistry, Faculty of Health Sciences, CEU Cardenal Herrera University, Valencia, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Ribelles Llop', 'Affiliation': 'Department of Dentistry, Faculty of Health Sciences, CEU Cardenal Herrera University, Valencia, Spain.'}, {'ForeName': 'Maria Ángeles', 'Initials': 'MÁ', 'LastName': 'García Esparza', 'Affiliation': 'Department of Chemistry, Faculty of Health Sciences, CEU Cardenal Herrera University, Valencia, Spain.'}, {'ForeName': 'Antonio Juan', 'Initials': 'AJ', 'LastName': 'Flichy-Fernández', 'Affiliation': 'Department of Dentistry, Valencia University Medical and Dental School, Valencia, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Marqués Martínez', 'Affiliation': 'Department of Dentistry, Faculty of Health Sciences, CEU Cardenal Herrera University, Valencia, Spain.'}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Izquierdo Fort', 'Affiliation': 'Department of Periodontics, Valencia University Medical and Dental School, Valencia, Spain.'}]",International journal of immunopathology and pharmacology,['10.1177/20587384211031107'] 1873,34325040,A controlled clinical efficacy trial of multimodal cognitive rehabilitation on episodic memory functioning in older adults with traumatic brain injury.,"OBJECTIVES This study aimed to evaluate the impact of a 12-week, 24-session multimodal group cognitive intervention, the Cognitive Enrichment Program (CEP), on episodic memory in older adults with traumatic brain injury (TBI) compared to an active control group that received usual care in the form of individual holistic rehabilitation. METHODS In total, 37 patients with a TBI who were 57 to 90 years old were assigned to experimental (n = 23) and control (n = 14) groups in a semi-randomized, controlled, before-after intervention trial with follow-up at 6 months, with blinded outcome measurement. The CEP's Memory module consisted of memory strategies to promote encoding. Efficacy was evaluated by using Face-name association, Word list recall, and Text memory measures, and generalization was assessed with the Self-Evaluation Memory Questionnaire (SEMQ), the Psychological General Well-Being Index, and a satisfaction questionnaire. RESULTS ANCOVA mixed model repeated-measures analysis revealed a strong group-by-time interaction, with the experimental group showing statistically significant improvement on the Face-name association test, with a large effect size. We also found a statistically significant group-by-time interaction on 3 dimensions of the SEMQ generalization measure: the experimental group showed increased memorization of the content of Conversations, reduced Slips of attention, and increased memory of Political and social events, with medium to large effect sizes. The group also showed clinically significant improvements in psychological well-being. Scores on the satisfaction questionnaire indicated a perceived positive impact on daily life habits requiring memory abilities. CONCLUSIONS The CEP is a promising cognitive rehabilitation program for older individuals with TBI, showing high satisfaction in participants, that could improve their episodic memory functioning as well as enhance their psychological well-being. ClinicalTrials.gov Identifier: NCT04590911.",2021,"We also found a statistically significant group-by-time interaction on 3 dimensions of the SEMQ generalization measure: the experimental group showed increased memorization of the content of Conversations, reduced Slips of attention, and increased memory of Political and social events, with medium to large effect sizes.","['older individuals with TBI', 'older adults with traumatic brain injury (TBI', 'older adults with traumatic brain injury', '37 patients with a TBI who were 57 to 90 years old']","['usual care in the form of individual holistic rehabilitation', '24-session multimodal group cognitive intervention, the Cognitive Enrichment Program (CEP', 'multimodal cognitive rehabilitation', 'CEP']","['memorization of the content of Conversations, reduced Slips of attention, and increased memory of Political and social events', 'Face-name association, Word list recall, and Text memory measures, and generalization was assessed with the Self-Evaluation Memory Questionnaire (SEMQ), the Psychological General Well-Being Index, and a satisfaction questionnaire', 'episodic memory functioning', 'Efficacy', 'daily life habits requiring memory abilities']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}]","[{'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0337209', 'cui_str': 'Slipping'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0017324', 'cui_str': 'Generalization (Psychology)'}, {'cui': 'C0036591', 'cui_str': 'Self Assessment'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C2939150', 'cui_str': 'General wellbeing'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",37.0,0.0228405,"We also found a statistically significant group-by-time interaction on 3 dimensions of the SEMQ generalization measure: the experimental group showed increased memorization of the content of Conversations, reduced Slips of attention, and increased memory of Political and social events, with medium to large effect sizes.","[{'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Cisneros', 'Affiliation': ""Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR)-IURDPM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, QC, Canada; Department of Psychology, Université de Montréal, Montreal, QC, Canada. Electronic address: eduardo.cisneros@umontreal.ca.""}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'de Guise', 'Affiliation': ""Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR)-IURDPM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, QC, Canada; Department of Psychology, Université de Montréal, Montreal, QC, Canada; Research Institute of the Montreal University Hospital Centre, Montreal, QC, Canada.""}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Belleville', 'Affiliation': 'Department of Psychology, Université de Montréal, Montreal, QC, Canada; Research Centre of the Institut universitaire de gériatrie de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'McKerral', 'Affiliation': ""Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR)-IURDPM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, QC, Canada; Department of Psychology, Université de Montréal, Montreal, QC, Canada. Electronic address: michelle.mckerral@umontreal.ca.""}]",Annals of physical and rehabilitation medicine,['10.1016/j.rehab.2021.101563'] 1874,34325019,Impact of Early Cholecystectomy on the Cost of Treating Mild Gallstone Pancreatitis: Gallstone PANC Trial.,"BACKGROUND The Gallstone Pancreatitis: Admission vs Normal Cholecystectomy (Gallstone PANC) Trial demonstrated that cholecystectomy within 24 hours of admission (early) compared with after clinical resolution (control) for mild gallstone pancreatitis, significantly reduced 30-day length-of-stay (LOS) without increasing major postoperative complications. We assessed whether early cholecystectomy decreased 90-day healthcare use and costs. STUDY DESIGN A secondary economic evaluation of the Gallstone PANC Trial was performed from the healthcare system perspective. Costs for index admissions and all gallstone pancreatitis-related care 90 days post-discharge were obtained from the hospital accounting system and inflated to 2020 USD. Negative binomial regression models and generalized linear models with log-link and gamma distribution, adjusting for randomization strata, were used. Bayesian analysis with neutral prior was used to estimate the probability of cost reduction with early cholecystectomy. RESULTS Of 98 randomized patients, 97 were included in the analyses. Baseline characteristics were similar in early (n = 49) and control (n = 48) groups. Early cholecystectomy resulted in a mean absolute difference in LOS of -0.96 days (95% CI, -1.91 to 0.00, p = 0.05). Ninety-day mean total costs were $14,974 (early) vs $16,190 (control) (cost ratio [CR], 0.92; 95% CI, 0.73-1.15, p = 0.47), with a mean absolute difference of $1,216 less (95% CI, -$4,782 to $2,349, p = 0.50) per patient in the early group. On Bayesian analysis, there was an 81% posterior probability that early cholecystectomy reduced 90-day total costs. CONCLUSION In this single-center trial, early cholecystectomy for mild gallstone pancreatitis reduced 90-day LOS and had an 81% probability of reducing 90-day healthcare system costs.",2021,"Ninety-day mean total costs were $14,974 (early) versus $16,190 (control) (cost ratio [CR], 0.92; 95% CI, 0.73-1.15, p=0.47) with mean absolute difference of $1,216 less (95% CI, -$4,782 to $2,349, p = 0.50) per patient in the early group.",['98 randomized patients'],"['Early Cholecystectomy', 'cholecystectomy', 'Normal Cholecystectomy (Gallstone PANC']","['Ninety-day mean total costs', '90-day total costs', '30-day length-of-stay (LOS', '90-day healthcare utilization and costs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0008350', 'cui_str': 'Biliary calculus'}]","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",98.0,0.0223891,"Ninety-day mean total costs were $14,974 (early) versus $16,190 (control) (cost ratio [CR], 0.92; 95% CI, 0.73-1.15, p=0.47) with mean absolute difference of $1,216 less (95% CI, -$4,782 to $2,349, p = 0.50) per patient in the early group.","[{'ForeName': 'Kayla D', 'Initials': 'KD', 'LastName': 'Isbell', 'Affiliation': 'Department of Surgery; Center for Surgical Trials and Evidence-based Practice.'}, {'ForeName': 'Shuyan', 'Initials': 'S', 'LastName': 'Wei', 'Affiliation': 'Department of Surgery; Center for Surgical Trials and Evidence-based Practice.'}, {'ForeName': 'Shah-Jahan M', 'Initials': 'SM', 'LastName': 'Dodwad', 'Affiliation': 'Department of Surgery; Center for Surgical Trials and Evidence-based Practice.'}, {'ForeName': 'Elenir Bc', 'Initials': 'EB', 'LastName': 'Avritscher', 'Affiliation': 'Center for Clinical Research and Evidence-Based Medicine, McGovern Medical School at the University of Texas Health Science Center, Houston, TX.'}, {'ForeName': 'Krislynn M', 'Initials': 'KM', 'LastName': 'Mueck', 'Affiliation': 'Department of Surgery; Center for Surgical Trials and Evidence-based Practice.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Bernardi', 'Affiliation': 'Department of Surgery; Center for Surgical Trials and Evidence-based Practice.'}, {'ForeName': 'Gabrielle E', 'Initials': 'GE', 'LastName': 'Hatton', 'Affiliation': 'Department of Surgery; Center for Surgical Trials and Evidence-based Practice.'}, {'ForeName': 'Mike K', 'Initials': 'MK', 'LastName': 'Liang', 'Affiliation': 'University of Houston, HCA Healthcare Kingwood, Kingwood, TX.'}, {'ForeName': 'Tien C', 'Initials': 'TC', 'LastName': 'Ko', 'Affiliation': 'Department of Surgery.'}, {'ForeName': 'Lillian S', 'Initials': 'LS', 'LastName': 'Kao', 'Affiliation': 'Department of Surgery; Center for Surgical Trials and Evidence-based Practice; Center for Clinical Research and Evidence-Based Medicine, McGovern Medical School at the University of Texas Health Science Center, Houston, TX. Electronic address: Lillian.S.Kao@uth.tmc.edu.'}]",Journal of the American College of Surgeons,['10.1016/j.jamcollsurg.2021.06.023'] 1875,34340096,"Promotion on labor process and relief of the low back pain by relaxing pelvic muscle with Shangliao (BL 31) point injection in women using epidural analgesia during labor: A randomized, controlled, clinical trial.","BACKGROUND The purpose of this study was to explore the effects of combing Shangliao point injection with epidural analgesia on labor pain and birth process in women with low back pain and the possible mechanisms. METHODS 93 consecutive women were randomized to receive either Shangliao point injection combined with epidural analgesia or epidural analgesia. Another 14 women were recruited to explore the mechanisms and the transperineal ultrasound was performed accordingly. RESULTS The main result duration from epidural analgesia to baby delivery was significantly shorter in epidural analgesia and saline injection group than that in epidural analgesia group 307.0 (175.0-445.0) min VS 369.0 (254.0-563.0) min (P = 0.02). The verbal numerical rate scaling score in low back during the first contraction was significantly decreased 5.0 (4.0-7.0) after Shangliao point injections (P < 0.001). The consumption of ropivacaine per hour was significantly less in epidural analgesia and saline injection group than in epidural analgesia group (-0.4 mg, 95%CI: -0.1 to -1.8; P = 0.03). The angle of progression and anteroposterior diameter of the levator hiatus at rest and during valsalva were significantly increased after shangliao point injection (7.10°, 95%CI, 1.50~12.70; P = 0.02); (9.10°, 95%CI, 3.60~14.58; P < 0.01); (0.27 cm, 95%CI, 0.03~0.51; P = 0.03); (0.30 cm, 95%CI, 0.13~0.48; P < 0.01). CONCLUSIONS Shangliao point injection could shorten the time to baby delivery and rapidly relieve low back pain in addition to epidural analgesia, that may attribute to its function of relaxing the pelvic floor muscles and promote fetal head progress.",2021,"The consumption of ropivacaine per hour was significantly less in epidural analgesia and saline injection group than in epidural analgesia group (-0.4 mg, 95%CI: -0.1 to -1.8; P = 0.03).","['women using epidural analgesia during labor', 'women with low back pain and the possible mechanisms', 'Another 14 women', '93 consecutive women']","['Shangliao point injection combined with epidural analgesia or epidural analgesia', 'ropivacaine', 'combing Shangliao point injection with epidural analgesia', 'relaxing pelvic muscle with Shangliao (BL 31) point injection']","['labor pain and birth process', 'angle of progression and anteroposterior diameter of the levator hiatus at rest and during valsalva', 'epidural analgesia to baby delivery', 'verbal numerical rate scaling score']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0332149', 'cui_str': 'Possible'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}]","[{'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0376161', 'cui_str': 'Comb'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0448421', 'cui_str': 'Skeletal muscle structure of pelvis'}]","[{'cui': 'C0474368', 'cui_str': 'Labor pain'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",93.0,0.142969,"The consumption of ropivacaine per hour was significantly less in epidural analgesia and saline injection group than in epidural analgesia group (-0.4 mg, 95%CI: -0.1 to -1.8; P = 0.03).","[{'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Gu', 'Affiliation': 'Department of Anesthesiology, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Department of Anesthesiology, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China.'}, {'ForeName': 'Shuying', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Ni', 'Affiliation': 'Department of Anesthesiology, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, West China Hospital, Sichuan University, China. Electronic address: benbinliuhx@163.com.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2021.07.039'] 1876,34340007,A preliminary study on speech recognition in noise training for children with hearing loss.,"PURPOSE The current study is a preliminary study to examine whether children with hearing loss would benefit from a speech recognition in noise training. METHODS Twenty-five children who wore hearing aids, cochlear implants, or bimodal devices from 4 to 12 years old participated in the study (experimental, n = 16; control, n = 9). The experimental group received a speech-in-noise training that took sixteen 15-min sessions spanning 8 to 12 weeks. The task involves recognizing monosyllabic target words and sentence keywords with various contextual cues in a multi-talker babble. The target stimuli were spoken by two females and fixed at 65 dB SPL throughout the training while the masker varied adaptively. Pre- and post-training tests measured the speech recognition thresholds of monosyllabic words and sentences spoken by two males in the babble noise. The test targets were presented at 55, 65, and 80 dB SPL. RESULTS The experimental group improved for word and sentence recognition in noise after training (Mean Difference = 2.4-2.5 dB, 2.7-4.2 dB, respectively). Training benefits were observed at trained (65 dB SPL) and untrained levels (55 and 80 dB SPL). The amount of post-training improvement was comparable between children using hearing aids and cochlear implants. CONCLUSIONS This preliminary study showed that children with hearing loss could benefit from a speech recognition in noise training that may fit into the children's school schedules. Training at a conversational level (65 dB SPL) transfers the benefit to levels 10-15 dB softer or louder. Training with female target talkers transfers the benefit to male target talkers. Overall, speech in noise training brings practical benefits for school-age children with hearing loss.",2021,Training benefits were observed at trained (65 dB SPL) and untrained levels (55 and 80 dB SPL).,"['children with hearing loss', 'school-age children with hearing loss', 'Twenty-five children who wore hearing aids, cochlear implants, or bimodal devices from 4 to 12 years old participated in the study (experimental, n\xa0=\xa016; control, n\xa0=\xa09']","['noise training', 'dB softer or louder', 'speech-in-noise training']","['word and sentence recognition in noise', 'speech recognition thresholds of monosyllabic words and sentences spoken']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0009199', 'cui_str': 'Cochlear prosthesis'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0037817', 'cui_str': 'Speech'}]","[{'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}]",25.0,0.0166453,Training benefits were observed at trained (65 dB SPL) and untrained levels (55 and 80 dB SPL).,"[{'ForeName': 'Mengchao', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Communication Science and Disorders, University of Pittsburgh, 6035 Forbes Tower, Pittsburgh, PA, 15260, USA. Electronic address: mez52@pitt.edu.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Moncrieff', 'Affiliation': 'School of Communication Sciences and Disorders, University of Memphis, 4055 N. Park Loop, Memphis, TN, 38152, USA.'}, {'ForeName': 'Deborrah', 'Initials': 'D', 'LastName': 'Johnston', 'Affiliation': 'DePaul School for Hearing and Speech, 6202 Alder St, Pittsburgh, PA, 15206, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Parfitt', 'Affiliation': 'DePaul School for Hearing and Speech, 6202 Alder St, Pittsburgh, PA, 15206, USA.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Auld', 'Affiliation': 'DePaul School for Hearing and Speech, 6202 Alder St, Pittsburgh, PA, 15206, USA.'}]",International journal of pediatric otorhinolaryngology,['10.1016/j.ijporl.2021.110843'] 1877,34339988,Impact of ozone exposure on heart rate variability and stress hormones: A randomized-crossover study.,"The biological mechanisms underlying the associations between atmospheric ozone exposure and adverse cardiometabolic outcomes are yet to be identified. Imbalanced autonomic nervous system (ANS) as well as activations of the sympatho-adrenomedullary (SAM) and hypothalamic-pituitary-adrenal (HPA) axes are among possible early biological responses triggered by ozone, and may eventually lead to cardiometabolic abnormalities. To determine whether acute ozone exposure causes ANS imbalance and increases the secretion of neuroendocrine stress hormones, we conducted a randomized, double-blind, crossover trial, under controlled 2-hour exposure to either ozone (200 ppb) or clean air with intermittent exercise among 22 healthy young adults. Here we found that, compared to clean air exposure, acute ozone exposure significantly decreased the high-frequency band of heart rate variability, even after adjusting for heart rate and pre-exposure to ambient air pollutants and meteorological factors. Ozone exposure also significantly increased the serum levels of stress hormones, including corticotrophin-releasing factor, adrenocorticotropic hormone, adrenaline, and noradrenaline. Metabolomics analysis showed that acute ozone exposure led to alterations in stress hormones, systemic inflammation, oxidative stress, and energy metabolism. Our results suggest that acute ozone exposure may trigger ANS imbalance and activate the HPA and SAM axes, offering potential biological explanations for the adverse cardiometabolic effects following acute ozone exposure.",2021,"Ozone exposure also significantly increased the serum levels of stress hormones, including corticotrophin-releasing factor, adrenocorticotropic hormone, adrenaline, and noradrenaline.",['22 healthy young adults'],"['ozone exposure', 'ozone (200 ppb) or clean air with intermittent exercise']","['stress hormones, systemic inflammation, oxidative stress, and energy metabolism', 'heart rate variability and stress hormones', 'high-frequency band of heart rate variability', 'serum levels of stress hormones, including corticotrophin-releasing factor, adrenocorticotropic hormone, adrenaline, and noradrenaline']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0030106', 'cui_str': 'Ozone'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0032441', 'cui_str': 'Polybrominated biphenyl'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}]",22.0,0.071434,"Ozone exposure also significantly increased the serum levels of stress hormones, including corticotrophin-releasing factor, adrenocorticotropic hormone, adrenaline, and noradrenaline.","[{'ForeName': 'Cuiping', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China.'}, {'ForeName': 'Jingyu', 'Initials': 'J', 'LastName': 'Lin', 'Affiliation': 'Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Niu', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China.'}, {'ForeName': 'Weidong', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China.'}, {'ForeName': 'Jianfen', 'Initials': 'J', 'LastName': 'Wen', 'Affiliation': 'Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Lv', 'Affiliation': 'Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Cong', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China.'}, {'ForeName': 'Xihao', 'Initials': 'X', 'LastName': 'Du', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China.'}, {'ForeName': 'Qingli', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Cai', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China.'}, {'ForeName': 'Zhuohui', 'Initials': 'Z', 'LastName': 'Zhao', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China.'}, {'ForeName': 'Donghai', 'Initials': 'D', 'LastName': 'Liang', 'Affiliation': 'Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Ji', 'Affiliation': 'Nicholas School of the Environment, Duke University, Durham, NC, USA; Environmental Research Center, Duke Kunshan University, Kunshan, Jiangsu, China.'}, {'ForeName': 'Honglei', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Renjie', 'Initials': 'R', 'LastName': 'Chen', 'Affiliation': 'Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China. Electronic address: chenrenjie@fudan.edu.cn.'}, {'ForeName': 'Haidong', 'Initials': 'H', 'LastName': 'Kan', 'Affiliation': ""Department of Environmental Health, School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Fudan University, P.O. Box 249,130 Dong-An Road, Shanghai 200032, China; Children's Hospital of Fudan University, National Center for Children's Health, Shanghai, China. Electronic address: kanh@fudan.edu.cn.""}]",Journal of hazardous materials,['10.1016/j.jhazmat.2021.126750'] 1878,34346910,Effects of Acute High-Intensity Interval Training on Information Processing Speed.,"ABSTRACT Kendall, BJ, Siekirk, NJ, and Lai, Q. Effects of acute high-intensity interval training on information processing speed. J Strength Cond Res XX(X): 000-000, 2021-This study investigated the effects of acute exercise on reaction time (RT), premotor time (i.e., central processing), and motor time (i.e., peripheral processing) using surface electromyography to fractionate RT. Fifty-eight young adults (27 men, 31 women) between the age of 18 and 40 years participated in 2 testing sessions. During visit one, subjects performed a simple RT task under regular (i.e., consistent timing) and irregular (i.e., variable timing) foreperiods. Subjects were then randomized to either an aerobic-only high-intensity interval training (HIIT) group (HIIT-A), an aerobic/resistance HIIT group (HIIT-AR), or a resting control group (CG). Both exercise groups performed a 20-minute, digital video disc-delivered HIIT exercise protocol. After exercise or rest, when controlling for cardiovascular fitness, no statistical differences were observed for the regular foreperiod conditions (p > 0.05). For the irregular foreperiod conditions, the HIIT-A group (M = 219.8, SE = 6.5) and the HIIT-AR group (M = 218.2, SE = 5.8) had significantly faster mean RTs than the CG (M = 248.1, SE = 8.1). In addition, the HIIT-A (M = 172.1, SE = 4.6) and HIIT-AR exercise groups (M = 171.3, SE = 4.8) had significantly faster mean PMTs than the CG (M = 189.7, SE = 5.7). These findings suggest that tasks dependent on central processing may benefit from an acute bout of exercise.",2021,"After exercise or rest, when controlling for cardiovascular fitness, no statistical differences were observed for the regular foreperiod conditions (p > 0.05).","['Fifty-eight young adults (27 men, 31 women) between the age of 18 and 40 years participated in 2 testing sessions', ' 000-000']","['acute exercise', 'digital video disc-delivered HIIT exercise protocol', 'Acute High-Intensity Interval Training', 'aerobic-only high-intensity interval training (HIIT) group (HIIT-A), an aerobic/resistance HIIT group (HIIT-AR), or a resting control group (CG', 'J Strength Cond Res XX(X']","['reaction time (RT), premotor time (i.e., central processing), and motor time (i.e., peripheral processing']","[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]","[{'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}]","[{'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}]",58.0,0.012631,"After exercise or rest, when controlling for cardiovascular fitness, no statistical differences were observed for the regular foreperiod conditions (p > 0.05).","[{'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Kendall', 'Affiliation': 'Department of Kinesiology, Taylor University, Upland, Indiana; Division of Kinesiology, Health and Sport Studies, Wayne State University, Detroit, Michigan; and Department of Health Sciences and Kinesiology, Georgia Southern University, Statesboro, Georgia.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Siekirk', 'Affiliation': ''}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Lai', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000004029'] 1879,34322907,Effects of codeine on esophageal peristalsis in humans using high resolution manometry.,"BACKGROUND AND AIM Opioid receptors agonists have been demonstrated to impair lower esophageal sphincter (LES) relaxation and induce spastic esophageal dysmotility, but little was known for their impact on distension-induced secondary peristalsis. The aim of the study was to investigate the hypothesis whether acute administration of codeine can influence physiological characteristics of primary and secondary peristalsis in healthy adults. METHODS Eighteen healthy volunteers (13 men, mean age 27.5 years, aged 20-43 years) underwent high resolution manometry (HRM) with a catheter containing an injection port in mid-esophagus. Secondary peristalsis was performed with 10 and 20 mL rapid air injections. Two different sessions including acute administration of codeine (60 mg) or the placebo were randomly performed. RESULTS Codeine significantly increased 4-s integrated relaxation pressure (IRP-4s) (P = 0.003) and shortened distal latency (DL) (P = 0.003) of primary peristalsis. The IRP-4s of secondary peristalsis was also significantly higher after codeine than the placebo during air injections with 10 mL (P = 0.048) and 20 mL (P = 0.047). Codeine significantly increased the frequency of secondary peristalsis during air injections with 10 mL than the placebo (P = 0.007), but not for air injection with 20 mL (P = 0.305). CONCLUSIONS In addition to impair LES relaxation and reduce distal latency of primary peristalsis, codeine impairs LES relaxation of secondary peristalsis and increases secondary peristaltic frequency. Our study supports the notion in human esophagus that the impact of opioids on peristaltic physiology appears to be present in both primary and secondary peristalsis.",2021,"RESULTS Codeine significantly increased 4-second integrated relaxation pressure (IRP-4s) (P = 0.003) and shortens distal latency (DL) (P = 0.003) of primary peristalsis.","['humans using high resolution manometry', 'Eighteen healthy volunteers (13 men, mean age 27.5 years, aged 20-43 years) underwent', 'healthy adults']","['Codeine', 'codeine', 'high resolution manometry (HRM) with a catheter containing an injection port in mid-esophagus', 'placebo']","['IRP-4s of secondary peristalsis', 'distal latency', 'frequency of secondary peristalsis', 'shortens distal latency (DL', 'secondary peristaltic frequency', '4-second integrated relaxation pressure (IRP-4s']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0024751', 'cui_str': 'Manometry'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517674', 'cui_str': '27.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0009214', 'cui_str': 'Codeine'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0024751', 'cui_str': 'Manometry'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0452253', 'cui_str': 'Port'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0014876', 'cui_str': 'Esophageal structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0123987', 'cui_str': 'WNT2 protein, human'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0031133', 'cui_str': 'Peristalsis'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",18.0,0.140712,"RESULTS Codeine significantly increased 4-second integrated relaxation pressure (IRP-4s) (P = 0.003) and shortens distal latency (DL) (P = 0.003) of primary peristalsis.","[{'ForeName': 'Chien-Lin', 'Initials': 'CL', 'LastName': 'Chen', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Ming-Wun', 'Initials': 'MW', 'LastName': 'Wong', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Jui-Sheng', 'Initials': 'JS', 'LastName': 'Hung', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Shu-Wei', 'Initials': 'SW', 'LastName': 'Liang', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Tso-Tsai', 'Initials': 'TT', 'LastName': 'Liu', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Chih-Hsun', 'Initials': 'CH', 'LastName': 'Yi', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Lin', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Orr', 'Affiliation': 'Lynn Institute for Healthcare Research, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.'}, {'ForeName': 'Wei-Yi', 'Initials': 'WY', 'LastName': 'Lei', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}]",Journal of gastroenterology and hepatology,['10.1111/jgh.15641'] 1880,34326100,Interplay between worsening kidney function and cardiovascular events in patients with type 2 diabetes: an analysis from the ACCORD trial.,"INTRODUCTION Patients with type 2 diabetes (T2D) have an increased risk of worsening kidney function (WKF) over time compared with patients without diabetes. Data evaluating the inter-relation between WKF, cardiovascular risk, and clinical events are scarce. We aim to study the association of WKF with subsequent cardiovascular events and the probabilities of transition from WKF to hospitalization or death according to patients' risk. We have used a large population of patients with T2D and a high cardiovascular risk enrolled in the Action to Control Cardiovascular Risk in Diabetes Study. RESEARCH DESIGN AND METHODS Time-updated, joint, and multistate modeling were used. WKF was defined as an estimated glomerular filtration rate (eGFR) decline greater than 40% from baseline. A total of 10 251 patients were included, of whom 1213 (11.8%) presented WKF over a median (percentile 25-75 ) follow-up time of 5.0 (4.1-5.7) years. RESULTS Patients who experienced WKF were slightly older, more frequently women, and had longer diabetes duration. Patients experiencing WKF, regardless of baseline kidney function, had a higher risk of subsequent cardiovascular events, including the composite of cardiovascular death or hospitalization for heart failure (HHF), with ≈2-fold higher risk. Joint modeling showed that renal function deterioration frequently occurs even among patients who did not experience a cardiovascular event. In multistate models, patients with a medium-high cardiovascular risk (compared with those with a low cardiovascular risk) are at higher risk of HHF or cardiovascular death first (HR=4.76, 95% CI 3.63 to 6.23) than of WKF first (HR=1.37, 95% CI 1.21 to 1.56); remarkably, the risk of cardiovascular death or HHF is highest after a WKF event (HR=6.20, 95% CI 2.71 to 14.8). CONCLUSIONS In patients with T2D and a high cardiovascular risk, WKF occurs in more than 10% of patients and is independently associated with risk of subsequent cardiovascular events, irrespective of baseline eGFR. Preventing serious WKF and the transition from WKF to HHF or cardiovascular death is an important objective of future trials. TRIAL REGISTRATION NUMBER NCT00000620.",2021,"Patients experiencing WKF, regardless of baseline kidney function, had a higher risk of subsequent cardiovascular events, including the composite of cardiovascular death or hospitalization for heart failure (HHF), with ≈2-fold higher risk.","['patients with type 2 diabetes', 'Patients with type 2 diabetes (T2D', 'patients with a medium-high cardiovascular risk (compared with those with a low cardiovascular risk', 'patients with T2D and a high cardiovascular risk enrolled in the Action to Control Cardiovascular Risk in Diabetes Study', 'A total of 10 251 patients were included, of whom 1213 (11.8%) presented WKF over a median (percentile 25-75 ) follow-up time of 5.0 (4.1-5.7) years']",[],"['risk of cardiovascular death or HHF', 'renal function deterioration', 'risk of worsening kidney function (WKF', 'glomerular filtration rate (eGFR) decline', 'cardiovascular death or hospitalization for heart failure (HHF', 'HHF or cardiovascular death first ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C4517795', 'cui_str': '5.7'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}]",10251.0,0.128764,"Patients experiencing WKF, regardless of baseline kidney function, had a higher risk of subsequent cardiovascular events, including the composite of cardiovascular death or hospitalization for heart failure (HHF), with ≈2-fold higher risk.","[{'ForeName': 'João Pedro', 'Initials': 'JP', 'LastName': 'Ferreira', 'Affiliation': ""Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France j.ferreira@chru-nancy.fr.""}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Ferrao', 'Affiliation': 'Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Rossignol', 'Affiliation': ""Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.""}, {'ForeName': 'Faiez', 'Initials': 'F', 'LastName': 'Zannad', 'Affiliation': ""Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.""}, {'ForeName': 'Abhinav', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Division of Cardiology, DREAM-CV Lab, McGill University Health Centre, Montreal, Québec, Canada.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Vasques-Novoa', 'Affiliation': 'Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.'}, {'ForeName': 'Adelino', 'Initials': 'A', 'LastName': 'Leite-Moreira', 'Affiliation': 'Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.'}]",BMJ open diabetes research & care,['10.1136/bmjdrc-2021-002408'] 1881,34325483,Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial.,"BACKGROUND Combined withdrawal and early preventive medication was the most effective treatment for medication overuse headache (MOH) within the first 6 months in a previous study, but results from a longer follow-up period are lacking. OBJECTIVE (1) To measure the efficacy at 1 year of three different treatment approaches to MOH; (2) to compare withdrawal and early preventives (W+P), preventives with potential withdrawal therapy after 6 months (P+pW), and withdrawal with delayed potential preventives (W+pP); and (3) to identify predictors of chronic headache after 1 year. METHODS Patients with MOH and migraine and/or tension-type headache were randomly assigned to one of the three outpatient treatments. Headache calendar and questionnaires were filled out. Primary outcome was a reduction in headache days/month after 1 year. RESULTS Of 120 patients, 96 completed 1-year follow-up, and all were included in our analyses. Overall headache days/month were reduced from 24.6 (23.4-25.8) to 15.0 (13.0-17.0) (p < 0.0001), and only 11/96 patients (11%) relapsed. Reduction in monthly headache days was 10.3 days (95% CI: 6.7-13.9) in the W+P group, 10.8 days (95% CI: 7.6-14) in the P+pW group, and 7.9 days (95% CI: 5.1-10.7) in the W+pP group. No significant differences in treatment effect were seen between the three groups (p = 0.377). After 1 year, 39/96 (41%) had chronic headache. Predictors of chronic headache after 1 year were higher headache frequency (aOR 1.19; 1.09-1.31), more days with acute medication (aOR 1.11; 1.03-1.19), higher pain intensity (aOR 1.04; 1.01-1.08), and depression (aOR 4.7; 1.38-18.95), whereas higher self-rated health (aOR 0.61; 0.36-0.97) and high caffeine consumption (aOR 0.40; 0.16-0.96) were predictors of a lower risk of chronic headache. No adverse events were reported. CONCLUSIONS All treatment strategies proved effective in treating MOH with a low relapse rate. The W+P strategy leads to the fastest effect, confirming earlier treatment recommendations. Identification of predictors for chronic headache may help identify more complex patients.",2021,"Reduction in monthly headache days was 10.3 days (95% CI: 6.7-13.9) in the W+P group, 10.8 days (95% CI: 7.6-14) in the P+pW group, and 7.9 days (95% CI: 5.1-10.7) in the W+pP group.","['Patients with MOH and migraine and/or tension-type headache', 'Of 120 patients, 96 completed 1-year follow-up, and all were included in our analyses']","['withdrawal and early preventives (W+P), preventives with potential withdrawal therapy after 6\xa0months (P+pW), and withdrawal with delayed potential preventives (W+pP']","['depression', 'caffeine consumption', 'reduction in headache days/month after 1\xa0year', 'higher self-rated health', 'adverse events', 'higher pain intensity', 'chronic headache', 'Overall headache days/month', 'headache frequency']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0522254', 'cui_str': 'Analgesic overuse headache'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0033893', 'cui_str': 'Psychogenic headache'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0948365', 'cui_str': 'Caffeine consumption'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0556971', 'cui_str': 'days/month'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0151293', 'cui_str': 'Chronic Headache'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",120.0,0.105347,"Reduction in monthly headache days was 10.3 days (95% CI: 6.7-13.9) in the W+P group, 10.8 days (95% CI: 7.6-14) in the P+pW group, and 7.9 days (95% CI: 5.1-10.7) in the W+pP group.","[{'ForeName': 'Louise N', 'Initials': 'LN', 'LastName': 'Carlsen', 'Affiliation': 'Danish Headache Center, Rigshospitalet-Glostrup, Valdemar Hansens Vej 5, Glostrup, 2600, Denmark.'}, {'ForeName': 'Carolien', 'Initials': 'C', 'LastName': 'Rouw', 'Affiliation': 'Danish Headache Center, Rigshospitalet-Glostrup, Valdemar Hansens Vej 5, Glostrup, 2600, Denmark.'}, {'ForeName': 'Maria L', 'Initials': 'ML', 'LastName': 'Westergaard', 'Affiliation': 'Danish Headache Center, Rigshospitalet-Glostrup, Valdemar Hansens Vej 5, Glostrup, 2600, Denmark.'}, {'ForeName': 'Mia', 'Initials': 'M', 'LastName': 'Nielsen', 'Affiliation': 'Danish Headache Center, Rigshospitalet-Glostrup, Valdemar Hansens Vej 5, Glostrup, 2600, Denmark.'}, {'ForeName': 'Signe B', 'Initials': 'SB', 'LastName': 'Munksgaard', 'Affiliation': 'Danish Headache Center, Rigshospitalet-Glostrup, Valdemar Hansens Vej 5, Glostrup, 2600, Denmark.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Bendtsen', 'Affiliation': 'Danish Headache Center, Rigshospitalet-Glostrup, Valdemar Hansens Vej 5, Glostrup, 2600, Denmark.'}, {'ForeName': 'Rigmor H', 'Initials': 'RH', 'LastName': 'Jensen', 'Affiliation': 'Danish Headache Center, Rigshospitalet-Glostrup, Valdemar Hansens Vej 5, Glostrup, 2600, Denmark.'}]",Headache,['10.1111/head.14177'] 1882,34325236,The efficacy of incorporating mental imagery in cognitive restructuring techniques on reducing hostility: A randomized controlled trial.,"BACKGROUND AND OBJECTIVES Cognitive restructuring (CR) is an effective intervention for hostility. However, the number of patients who fail to benefit suggest that the efficacy of CR can be further improved. The present study investigated whether enhancing CR with mental imagery techniques can increase its efficacy. METHODS A high hostility sample (28% male, and 72% female) was randomized over one session of imagery enhanced CR (I-CR) (n = 34), traditional CR (n = 32) or an active control session (AC) (n = 21). Changes in hostile beliefs, aggressive tendencies, state anger and hostility traits were assessed pre- and post-treatment, and at one-week follow-up. RESULTS Results showed that both I-CR and CR efficaciously reduced hostile beliefs, aggressive tendencies and anger, to a stronger degree than AC. I-CR was more efficacious and sustainable over time than both CR and AC in reducing hostile beliefs and aggressive tendencies. LIMITATIONS This study was conducted using a small, non-treatment seeking sample. CONCLUSIONS Findings suggest that implementing imagery techniques in CR for hostile beliefs enhances its' efficacy.",2021,"I-CR was more efficacious and sustainable over time than both CR and AC in reducing hostile beliefs and aggressive tendencies. ","['A high hostility sample (28% male, and 72% female']","['traditional CR (n\xa0=\xa032) or an active control session (AC', 'mental imagery in cognitive restructuring techniques', 'Cognitive restructuring (CR']","['hostile beliefs and aggressive tendencies', 'hostile beliefs, aggressive tendencies and anger', 'hostility', 'hostile beliefs, aggressive tendencies, state anger and hostility traits']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020039', 'cui_str': 'Hostile behavior'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0150173', 'cui_str': 'Cognitive restructuring'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0020039', 'cui_str': 'Hostile behavior'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C1301808', 'cui_str': 'State'}]",,0.0323839,"I-CR was more efficacious and sustainable over time than both CR and AC in reducing hostile beliefs and aggressive tendencies. ","[{'ForeName': 'Martijn W', 'Initials': 'MW', 'LastName': 'van Teffelen', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands; Department of Anxiety Disorders, METggz Maastricht, the Netherlands. Electronic address: martijn.vanteffelen@maastrichtuniversity.nl.'}, {'ForeName': 'Marisol J', 'Initials': 'MJ', 'LastName': 'Voncken', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands.'}, {'ForeName': 'Frenk', 'Initials': 'F', 'LastName': 'Peeters', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands.'}, {'ForeName': 'Eline D', 'Initials': 'ED', 'LastName': 'Mollema', 'Affiliation': 'House of Schema Therapy, Maastricht, The Netherlands.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Lobbestael', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2021.101677'] 1883,34324933,"Hemodynamic impact of increasing time between fentanyl and propofol administration during anesthesia induction: a randomised, clinical trial.","BACKGROUND AND OBJECTIVE Anesthesia induction can produce severe propofol dose-dependent hypotension. Fentanyl coadministration reduces the catecholaminergic response to orotracheal intubation allowing propofol dose reduction. The aim of this study is to determine whether the hemodynamic response is improved by increasing the time between fentanyl and propofol administration and reducing the dose of the latter without increasing the time to achieve optimal hypnosis. METHODS After approval by the Research Ethics Committee, patients undergoing non-cardiac surgery with endotracheal intubation were randomized by a computer-generated table into six time-dose groups (1 or 2 minutes/1, 1.5, or 2 mg.kg -1 of propofol). Patients with high bronchoaspiration risk, a difficult airway, hemodynamic instability, or anesthetic allergies were excluded. After giving intravenous fentanyl (2 μg.kg -1 ), each group received different doses of propofol after 1 or 2 minutes. Noninvasive blood pressure (BP) and heart rate (HR) were measured at pre-induction, pre-intubation, and post-intubation. Time to hypnosis (bispectral index < 60) was also recorded. RESULTS Of the 192 recruited patients, 186 completed the study (1 min group n = 94; 2 min group n = 92). It was observed that HR and BP decreased after propofol administration and increased after intubation in all groups (p < 0.0001). In patients over 55 years, the 2 min - 2 mg.kg -1 group showed the greatest systolic BP reduction (36 ± 12%) at pre-intubation, while the 1 min - 1.5 mg.kg -1 group showed the least hemodynamic alteration between pre- and post-intubation (-4 ± 13%). No significant differences were found in younger patients or in the time to reach hypnosis between the six groups. While no cases of severe bradycardia were recorded, 5,4% of the sample required vasopressors. CONCLUSION Increasing the time between the administration of fentanyl and propofol by up to two minutes results in greater hypotension in patients over 55 years.",2021,"In patients over 55 years, the 2 min - 2 mg.kg -1 group showed the greatest systolic BP reduction (36 ± 12%) at pre-intubation, while the 1 min - 1.5 mg.kg -1 group showed the least hemodynamic alteration between pre- and post-intubation (-4 ± 13%).","['anesthesia induction', 'patients undergoing non-cardiac surgery with endotracheal intubation', 'Of the 192 recruited patients, 186 completed the study (1\u2009min group n\u2009=\u200994; 2\u2009min group n\u2009=\u200992', 'Patients with high bronchoaspiration risk, a difficult airway, hemodynamic instability, or anesthetic allergies were excluded']","['propofol', 'Fentanyl coadministration', 'fentanyl and propofol']","['catecholaminergic response', 'severe bradycardia', 'greatest systolic BP reduction', 'hemodynamic response', 'time to reach hypnosis', 'hypotension', 'HR and BP', 'least hemodynamic alteration', 'invasive blood pressure (BP) and heart rate (HR']","[{'cui': 'C0473960', 'cui_str': 'Induction of general anesthesia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0441848', 'cui_str': 'Group N'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0332218', 'cui_str': 'Difficult'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0948268', 'cui_str': 'Hemodynamic instability'}, {'cui': 'C0741020', 'cui_str': 'Allergy to anesthetic'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0428890', 'cui_str': 'Invasive arterial pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",192.0,0.0438742,"In patients over 55 years, the 2 min - 2 mg.kg -1 group showed the greatest systolic BP reduction (36 ± 12%) at pre-intubation, while the 1 min - 1.5 mg.kg -1 group showed the least hemodynamic alteration between pre- and post-intubation (-4 ± 13%).","[{'ForeName': 'Paula A', 'Initials': 'PA', 'LastName': 'Vullo', 'Affiliation': 'Hospital Central de la Defensa Gómez Ulla-IMIDEF, Critical Care and Pain Unit, Department of Anesthesia, Madrid, Spain. Electronic address: agosvullo@hotmail.com.'}, {'ForeName': 'María I', 'Initials': 'MI', 'LastName': 'Real Navacerrada', 'Affiliation': 'Hospital Universitario 12 de Octubre, Critical Care and Pain Unit, Department of Anesthesia, Madrid, Spain.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Navarro Suay', 'Affiliation': 'Hospital Central de la Defensa Gómez Ulla-IMIDEF, Critical Care and Pain Unit, Department of Anesthesia, Madrid, Spain.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2021.07.009'] 1884,34324930,Analgesic effect of intercostal nerve block given preventively or at the end of operation in video-assisted thoracic surgery: a randomized clinical trial.,"OBJECTIVE To compare the analgesic effect of intercostal nerve block (INB) with ropivacaine when given preventively or at the end of the operation in patients undergoing video-assisted thoracic surgery (VATS). METHODS A total of 50 patients undergoing VATS were randomly divided into two groups. The patients in the preventive analgesia group (PR group) were given INB with ropivacaine before the intrathoracic manipulation combined with patient-controlled analgesia (PCA). The patients in the post-procedural block group (PO group) were administered INB with ropivacaine at the end of the operation combined with PCA. To evaluate the analgesic effect, postoperative pain was assessed with the visual analogue scale (VAS) at rest and Prince Henry Pain Scale (PHPS) scale at 6, 12, 24, 48, and 72 hours after surgery. RESULTS At 6 h and 12 h post-surgery, the VAS at rest and PHPS scores in the PR group were significantly lower than those in the PO group. There were no significant differences in pain scores between two groups at 24, 48, and 72 hours post-surgery. CONCLUSION In patients undergoing VATS, preventive INB with ropivacaine provided a significantly better analgesic effect in the early postoperative period (at least through 12 h post-surgery) than did INB given at the end of surgery.",2021,"In patients undergoing VATS, preventive INB with ropivacaine provided a significantly better analgesic effect in the early postoperative period (at least through 12 h post-surgery) than did INB given at the end of surgery.","['patients undergoing video-assisted thoracic surgery (VATS', '50 patients undergoing VATS']","['ropivacaine', 'intercostal nerve block (INB', 'intrathoracic manipulation combined with patient-controlled analgesia (PCA', 'intercostal nerve block', 'video-assisted thoracic surgery']","['visual analogue scale (VAS) at rest and Prince Henry Pain Scale (PHPS) scale', 'analgesic effect', 'VAS at rest and PHPS scores', 'Analgesic effect', 'analgesic effect, postoperative pain', 'pain scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0196716', 'cui_str': 'Local anesthetic intercostal nerve block'}, {'cui': 'C0595836', 'cui_str': 'Intrathoracic route'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0582517', 'cui_str': 'henry'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",50.0,0.0914328,"In patients undergoing VATS, preventive INB with ropivacaine provided a significantly better analgesic effect in the early postoperative period (at least through 12 h post-surgery) than did INB given at the end of surgery.","[{'ForeName': 'Weizhang', 'Initials': 'W', 'LastName': 'Xiao', 'Affiliation': 'Affiliated Hospital of Nantong University, Department of Cardiothoracic Surgery, Nantong, China; Affiliated Hospital of Nantong University, Nantong Key Laboratory of Translational Medicine in Cardiothoracic Diseases, Nantong, China.'}, {'ForeName': 'Weiwei', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': 'Affiliated Hospital of Nantong University, Department of Anaesthesiology, Nantong, China.'}, {'ForeName': 'Xinming', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Affiliated Hospital of Nantong University, Department of Cardiothoracic Surgery, Nantong, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'Affiliated Hospital of Nantong University, Department of Cardiothoracic Surgery, Nantong, China.'}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Xue', 'Affiliation': 'Affiliated Hospital of Nantong University, Department of Cardiothoracic Surgery, Nantong, China.'}, {'ForeName': 'Jiahai', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Affiliated Hospital of Nantong University, Department of Cardiothoracic Surgery, Nantong, China; Affiliated Hospital of Nantong University, Nantong Key Laboratory of Translational Medicine in Cardiothoracic Diseases, Nantong, China. Electronic address: happysjh167@163.com.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2021.07.010'] 1885,34324910,"Impact of diagnostic labels and causal explanations for weight gain on diet intentions, cognitions and emotions: An experimental online study.","Disease labels and causal explanations for certain symptoms or conditions have been found to have both positive and negative outcomes. For example, a diagnosis of polycystic ovary syndrome could conceivably motivate a person to engage in weight management, which is the recommended first line treatment. Furthermore, doctors may feel more comfortable discussing weight when linked to a medical condition. However, such a diagnosis may elicit feelings of increased anxiety, perceived severity and reduced sense of control. Mixed findings are also evident for impacts of genetic explanations on psychosocial outcomes and behaviours. Using hypothetical scenarios presented in an online survey, participants were asked to imagine that they were visiting their general practitioner due to experiencing weight gain, irregular periods, and more pimples than usual. Participants were randomised to receive different diagnostic labels ('polycystic ovary syndrome', 'weight' or no label/description) and causal explanations (genetic or environmental) for their symptoms. Primary outcomes assessed included intention to eat a healthier diet and perceived personal control of weight (average score on scale 1-7 across 3 items). Secondary outcomes included weight stigma, blameworthiness, worry, perceived severity, self-esteem, belief diet will reduce risks and menu item choice. Participants were 545 females aged 18-45 years (mean = 33 years), living in Australia, recruited through a national online recruitment panel. The sample was overweight on average (BMI = 26.5). Participants reporting a PCOS diagnosis were excluded from analyses. We found no main effects of the label or explanation on intention to eat healthier or perceived personal control of weight. For secondary outcomes, those given the genetic explanation reported higher weight stigma (range 1-7; MD = 0.27, 95%CI: 0.011,0.522), greater worry (range 1-7; MD = 0.27, 95%CI: 0.037,0.496), lower self-esteem (range 10-40; MD = 1.26, 95%CI: 0.28 to 2.24) and perceived their weight as more severe (range 1-7; MD = 0.28; 95%CI: 0.05,0.52) than those given the environmental explanation, averaged over disease label given. These findings further highlight the deleterious effects of genetic explanations on psychosocial outcomes and reinforce the need for caution when communicating the aetiology of weight-related health issues.",2021,We found no main effects of the label or explanation on intention to eat healthier or perceived personal control of weight.,"['Participants were 545 females aged 18-45 years (mean\u202f=\u202f33 years), living in Australia, recruited through a national online recruitment panel']","[""diagnostic labels ('polycystic ovary syndrome, 'weight' or no label/description) and causal explanations (genetic or environmental""]","['weight gain on diet intentions, cognitions and emotions', 'intention to eat a healthier diet and perceived personal control of weight (average score on scale 1-7 across 3 items', 'weight stigma', 'weight stigma, blameworthiness, worry, perceived severity, self-esteem, belief diet will reduce risks and menu item choice', 'lower self-esteem']","[{'cui': 'C4517809', 'cui_str': '545'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0441833', 'cui_str': 'Groups'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0679136', 'cui_str': 'Low self-esteem'}]",545.0,0.159059,We found no main effects of the label or explanation on intention to eat healthier or perceived personal control of weight.,"[{'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': 'Wiser Healthcare, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia; Sydney Health Literacy Lab, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Ayre', 'Affiliation': 'Wiser Healthcare, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia; Sydney Health Literacy Lab, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Jansen', 'Affiliation': 'School of Public Health and Primary Care, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Cvejic', 'Affiliation': 'Wiser Healthcare, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia; Sydney Health Literacy Lab, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia.'}, {'ForeName': 'Kirsten J', 'Initials': 'KJ', 'LastName': 'McCaffery', 'Affiliation': 'Wiser Healthcare, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia; Sydney Health Literacy Lab, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Doust', 'Affiliation': 'Centre for Longitudinal and Life Course Research, School of Public Health, The University of Queensland, 4006, Australia.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Copp', 'Affiliation': 'Wiser Healthcare, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia; Sydney Health Literacy Lab, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, 2006, Australia. Electronic address: tessa.copp@sydney.edu.au.'}]",Appetite,['10.1016/j.appet.2021.105612'] 1886,34328695,Effect of prone position ventilation on right heart function in patients with acute respiratory distress syndrome.,"BACKGROUND Acute respiratory distress syndrome (ARDS) is a severe respiratory disease with a high mortality rate. It is characterized by acute onset of pulmonary edema, hypoxemia, and the need of mechanical ventilation. As the primary treatment, ventilation has been considered effective in treating patients with ARDS. Recently, numerous studies have shown that prone position ventilation demonstrates more efficacy compared with traditional supine position. However, the potential impact of the non-physiological prone position on patients remains unclear. Current study aims to evaluate the effect of prone position ventilation on right heart function in ARDS patients. METHODS Following Berlin Diagnostic Criteria, 80 eligible patients were recruited and randomly assigned into prone position ventilation group and supine position ventilation group. Different ventilation methods were implemented in these two groups. RESULTS Both positions showed the beneficial effects, as evidenced by decreased PV score and APACHE II score, enhanced blood gas index and right heart function parameters, and the prognosis analysis. However, compared with those receiving SPV treatment, the patients demonstrated greater benefits from PPV treatment, with significant differences in PV score (p < 0.01) and APACHE II score (p < 0.001), blood gas index such as PAPm (p < 0.05), and right heart function indicators (p < 0.05). CONCLUSION Prone position mechanical ventilation is more beneficial than supine position ventilation in improving the blood gas status of patients with moderate to severe ARDS, and it is more helpful to reduce the load on the right heart and promote the recovery of patients.",2021,"Both positions showed the beneficial effects, as evidenced by decreased PV score and APACHE II score, enhanced blood gas index and right heart function parameters, and the prognosis analysis.","['80 eligible patients', 'Acute respiratory distress syndrome (ARDS', 'patients with acute respiratory distress syndrome', 'patients with moderate to severe ARDS', 'ARDS patients']","['Prone position mechanical ventilation', 'prone position ventilation group and supine position ventilation group', 'supine position ventilation', 'prone position ventilation']","['PV score (p<0.01) and APACHE II score (p<0.001), blood gas index such as PAPm (p<0.05), and right heart function indicators (p<0.05', 'right heart function', 'PV score and APACHE II score, enhanced blood gas index and right heart function parameters']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0489438', 'cui_str': 'APACHE II score'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0225808', 'cui_str': 'Structure of right side of heart'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",80.0,0.0113106,"Both positions showed the beneficial effects, as evidenced by decreased PV score and APACHE II score, enhanced blood gas index and right heart function parameters, and the prognosis analysis.","[{'ForeName': 'Huaihai', 'Initials': 'H', 'LastName': 'Lu', 'Affiliation': 'Intensive Care Unit of Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.'}, {'ForeName': 'Pei', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Intensive Care Unit of Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.'}, {'ForeName': 'Xuefang', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Intensive Care Unit of Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.'}, {'ForeName': 'Liwei', 'Initials': 'L', 'LastName': 'Jin', 'Affiliation': 'Department of Geratology, Youfu Hospital of Hebei Province, Shijiazhuang, China.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, China.'}]",The clinical respiratory journal,['10.1111/crj.13431'] 1887,34328440,Wound Image Quality From a Mobile Health Tool for Home-Based Chronic Wound Management With Real-Time Quality Feedback: Randomized Feasibility Study.,"BACKGROUND Travel to clinics for chronic wound management is burdensome to patients. Remote assessment and management of wounds using mobile and telehealth approaches can reduce this burden and improve patient outcomes. An essential step in wound documentation is the capture of wound images, but poor image quality can have a negative influence on the reliability of the assessment. To date, no study has investigated the quality of remotely acquired wound images and whether these are suitable for wound self-management and telemedical interpretation of wound status. OBJECTIVE Our goal was to develop a mobile health (mHealth) tool for the remote self-assessment of digital ulcers (DUs) in patients with systemic sclerosis (SSc). We aimed to define and validate objective measures for assessing the image quality, evaluate whether an automated feedback feature based on real-time assessment of image quality improves the overall quality of acquired wound images, and evaluate the feasibility of deploying the mHealth tool for home-based chronic wound self-monitoring by patients with SSc. METHODS We developed an mHealth tool composed of a wound imaging and management app, a custom color reference sticker, and a smartphone holder. We introduced 2 objective image quality parameters based on the sharpness and presence of the color checker to assess the quality of the image during acquisition and enable a quality feedback mechanism in an advanced version of the app. We randomly assigned patients with SSc and DU to the 2 device groups (basic and feedback) to self-document their DU at home over 8 weeks. The color checker detection ratio (CCDR) and color checker sharpness (CCS) were compared between the 2 groups. We evaluated the feasibility of the mHealth tool by analyzing the usability feedback from questionnaires, user behavior and timings, and the overall quality of the wound images. RESULTS A total of 21 patients were enrolled, of which 15 patients were included in the image quality analysis. The average CCDR was 0.96 (191/199) in the feedback group and 0.86 (158/183) in the basic group. The feedback group showed significantly higher (P<.001) CCS compared to the basic group. The usability questionnaire results showed that the majority of patients were satisfied with the tool, but could benefit from disease-specific adaptations. The median assessment duration was <50 seconds in all patients, indicating the mHealth tool was efficient to use and could be integrated into the daily routine of patients. CONCLUSIONS We developed an mHealth tool that enables patients with SSc to acquire good-quality DU images and demonstrated that it is feasible to deploy such an app in this patient group. The feedback mechanism improved the overall image quality. The introduced technical solutions consist of a further step towards reliable and trustworthy digital health for home-based self-management of wounds.",2021,The introduced technical solutions consist of a further step towards reliable and trustworthy digital health for home-based self-management of wounds.,"['Home-Based Chronic Wound Management With Real-Time Quality Feedback', 'A total of 21 patients were enrolled, of which 15 patients were included in the image quality analysis', 'patients with SSc', 'patients with systemic sclerosis (SSc']",['CCS'],"['average CCDR', 'median assessment duration', 'color checker detection ratio (CCDR) and color checker sharpness (CCS', 'overall image quality']","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0886052', 'cui_str': 'Wound care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1297895', 'cui_str': 'Image quality analysis'}, {'cui': 'C0036421', 'cui_str': 'Systemic sclerosis'}]",[],"[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332306', 'cui_str': 'Quality'}]",15.0,0.0184693,The introduced technical solutions consist of a further step towards reliable and trustworthy digital health for home-based self-management of wounds.,"[{'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Mobile Health Systems Lab, Institute of Robotics and Intelligent Systems, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Mihai', 'Affiliation': 'Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Tüshaus', 'Affiliation': 'Mobile Health Systems Lab, Institute of Robotics and Intelligent Systems, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Scebba', 'Affiliation': 'Mobile Health Systems Lab, Institute of Robotics and Intelligent Systems, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Distler', 'Affiliation': 'Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Karlen', 'Affiliation': 'Mobile Health Systems Lab, Institute of Robotics and Intelligent Systems, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.'}]",JMIR mHealth and uHealth,['10.2196/26149'] 1888,34327467,C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV.,"Objective On-treatment levels of high sensitivity C-reactive protein (hsCRP) in statin-treated patients predict plaque progression and the prospective risk of atherosclerotic cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors produce additional LDL-C lowering, reduce plaque burden and improve cardiovascular outcomes in statin-treated patients. It is unknown whether residual systemic inflammation attenuates their favorable effects on plaque burden. Methods GLAGOV compared the effects of treatment for 78 weeks with evolocumab or placebo on progression of coronary atherosclerosis in statin-treated patients with coronary artery disease.Clinical demographics, biochemistry and changes in both the burden (percentage atheroma volume (PAV), total atheroma volume (TAV), n ​= ​413) and composition (n ​= ​162) of coronary plaque were evaluated in evolocumab-treated patients according to baseline hsCRP strata (<1, 1-3, >3 ​mg/L). Results The study cohort comprised 413 evolocumab-treated patients (32% low [<1 ​mg/L], 41% intermediate [1-3 ​mg/L] and 27% high [>3 ​mg/L] baseline hsCRP levels). Patients in the highest hsCRP stratum were more likely to be female and had a higher prevalence of diabetes, hypertension, and the metabolic syndrome. LDL-C levels were similar across the groups, however participants with higher hsCRP levels had higher triglyceride and lower HDL-C levels at baseline. At follow-up, the change in PAV from baseline (-0.87% [low] vs. -0.84% [intermediate] vs. -1.22% [high], p ​= ​0.46) and the proportion of patients experiencing any degree of regression (65.9% vs. 63.5% vs. 63.1%, p ​= ​0.88) was similar across hsCRP strata and when evaluated by levels of achieved LDL-C. There were no serial differences in plaque composition by hsCRP strata. Conclusion The ability of evolocumab to induce regression in statin-treated patients is not attenuated by the presence of enhanced systemic inflammation. This underscores the potential benefits of intensive lipid lowering, even in the presence of heightened inflammatory states.",2020,"LDL-C levels were similar across the groups, however participants with higher hsCRP levels had higher triglyceride and lower HDL-C levels at baseline.","['statin-treated patients with coronary artery disease', '413 evolocumab-treated patients (32% low [<1\xa0\u200bmg/L], 41% intermediate [1-3\xa0\u200bmg/L] and 27% high [>3\xa0\u200bmg/L] baseline hsCRP levels']","['evolocumab or placebo', 'high sensitivity C-reactive protein (hsCRP']","['burden (percentage atheroma volume (PAV), total atheroma volume (TAV), n\xa0\u200b=\xa0\u200b413) and composition (n\xa0\u200b=\xa0\u200b162) of coronary plaque', 'progression of coronary atherosclerosis', 'cardiovascular outcomes', 'triglyceride and lower HDL-C levels', 'LDL-C levels', 'plaque composition']","[{'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C3529352', 'cui_str': 'evolocumab'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}]","[{'cui': 'C3529352', 'cui_str': 'evolocumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0264956', 'cui_str': 'Atheroma'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}]",,0.0520201,"LDL-C levels were similar across the groups, however participants with higher hsCRP levels had higher triglyceride and lower HDL-C levels at baseline.","[{'ForeName': 'Adam J', 'Initials': 'AJ', 'LastName': 'Nelson', 'Affiliation': 'South Australian Health & Medical Research Institute, Adelaide, Australia.'}, {'ForeName': 'Rishi', 'Initials': 'R', 'LastName': 'Puri', 'Affiliation': 'Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Danielle M', 'Initials': 'DM', 'LastName': 'Brennan', 'Affiliation': 'Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Todd J', 'Initials': 'TJ', 'LastName': 'Anderson', 'Affiliation': 'Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Canada.'}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Cho', 'Affiliation': 'Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Christie M', 'Initials': 'CM', 'LastName': 'Ballantyne', 'Affiliation': 'Section of Cardiovascular Research, Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.'}, {'ForeName': 'John Jp', 'Initials': 'JJ', 'LastName': 'Kastelein', 'Affiliation': 'Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Koenig', 'Affiliation': 'Deutsches Herzzentrum München, Technische Universität München, Munich, DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.'}, {'ForeName': 'Helina', 'Initials': 'H', 'LastName': 'Kassahun', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Ransi M', 'Initials': 'RM', 'LastName': 'Somaratne', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Wasserman', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Nissen', 'Affiliation': 'Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Nicholls', 'Affiliation': 'Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Melbourne, Australia.'}]",American journal of preventive cardiology,['10.1016/j.ajpc.2020.100091'] 1889,34327070,Mobile Augmented Screening to Increase HIV Testing Among Emergency Department Patients as Young as 13 Years.,"Because adolescents and emerging adults are frequently not offered HIV testing, and often decline tests when offered, we developed and tested a tablet-based intervention to increase HIV test rates among emergency department (ED) patients aged 13-24 years. Pediatric and adult ED patients in a high volume New York City hospital (N = 295) were randomized to receive a face-to-face HIV test offer, or to complete a tablet-based intervention that contained an HIV test offer delivered via computer. Test rates in both conditions were then compared to historic test rates in the same ED during the previous six months. Among participants aged 19 years and younger who were offered HIV testing and declined before enrollment in the study, participants in the tablet-based condition were 1.7 times more likely to test for HIV compared to participants in the face-to-face condition. Participants aged 19 years and younger were three times as likely to test for HIV compared to patients the same age who were treated in the previous six months (26.39%, n = 71 study participants vs. 10.29%, n = 189 prior patients, OR = 3.13, [Formula: see text] 2 = 54.76, p < 0.001). Protocols designed to offer HIV testing to all eligible patients can significantly increase adolescent test rates compared to standard practice. Because tablets are equally effective compared to face-to-face offers, and in some cases more so, EDs may consider tablet-based interventions that require fewer staff resources and may integrate more easily into high-volume workflows.",2021,"Participants aged 19 years and younger were three times as likely to test for HIV compared to patients the same age who were treated in the previous six months (26.39%, n = 71 study participants vs. 10.29%, n = 189 prior patients, OR = 3.13, [Formula: see text]","['Pediatric and adult ED patients in a high volume New York City hospital (N = 295', 'emergency department (ED) patients aged 13-24 years', 'Emergency Department Patients as Young as 13 Years', 'Participants aged 19 years and younger were three times as likely to test for HIV compared to patients the same age who were treated in the previous six months (26.39%, n = 71 study participants vs. 10.29%, n = 189 prior patients, OR = 3.13, [Formula: see text', 'participants aged 19 years and younger who were offered HIV testing and declined before enrollment in the study, participants in the tablet-based condition were 1.7 times more likely to test for HIV compared to participants in the face-to-face condition']",[],['adolescent test rates'],"[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0027977', 'cui_str': 'New York City'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C5191364', 'cui_str': '3.13'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}]",[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",295.0,0.0816607,"Participants aged 19 years and younger were three times as likely to test for HIV compared to patients the same age who were treated in the previous six months (26.39%, n = 71 study participants vs. 10.29%, n = 189 prior patients, OR = 3.13, [Formula: see text]","[{'ForeName': 'Ian D', 'Initials': 'ID', 'LastName': 'Aronson', 'Affiliation': 'Research, Digital Health Empowerment, Brooklyn, USA.'}, {'ForeName': 'Jingru', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Measurement and Evaluation, Teachers College, Columbia University, New York, USA.'}, {'ForeName': 'Sonali', 'Initials': 'S', 'LastName': 'Rajan', 'Affiliation': 'Department of Health and Behavior Studies, Teachers College, Columbia University, New York, USA.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Bugaighis', 'Affiliation': 'Emergency Medicine, Columbia University Irving Medical Center, New York, USA.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Marsch', 'Affiliation': 'Center for Technology and Behavioral Health, Dartmouth College, Lebanon, USA.'}, {'ForeName': 'Mobolaji', 'Initials': 'M', 'LastName': 'Ibitoye', 'Affiliation': 'Institute for Population Research, The Ohio State University, Columbus, USA.'}, {'ForeName': 'Lauren S', 'Initials': 'LS', 'LastName': 'Chernick', 'Affiliation': 'Emergency Medicine, Columbia University Irving Medical Center, New York, USA.'}, {'ForeName': 'Don C', 'Initials': 'DC', 'LastName': 'Des Jarlais', 'Affiliation': 'Epidemiology, New York University School of Global Public Health, New York, USA.'}]",Cureus,['10.7759/cureus.15829'] 1890,34330211,"Effects of lower limb resistance exercise on muscle strength, physical fitness, and metabolism in pre-frail elderly patients: a randomized controlled trial.","BACKGROUND Few studies examined interventions in frail elderly in China, while the awareness of applying interventions to prevent frailty in pre-frail elderly is still lacking. This study aimed to explore the effects of lower limb resistance exercise in pre-frail elderly in China. METHODS This was a randomized controlled trial of patients with pre-frailty. The control group received routine care, while the exercise group received a 12-week lower limb resistance exercise based on routine care. The muscle strength in the lower limbs, physical fitness, and energy metabolism of the patients was evaluated at admission and after 12 weeks of intervention. RESULTS A total of 60 pre-frail elderly were included in this study. The patients were divided into the exercise group (n = 30) and control group (n = 30) by random grouping. There were 17 men and 13 women aged 65.3 ± 13.4 in the exercise group, and 15 men and 15 women aged 67.6 ± 11.9 years in the control groups. The Barthel index was 80.3 ± 10.6 and 85.1 ± 11.6, respectively. The characteristics of the two groups were not significantly different before intervention (all p > 0.05). The results of repeated measurement ANOVA showed that there was statistically significant in crossover effect of group * time (all p < 0.05), that is, the differences of quadriceps femoris muscle strength, 6-min walking test, 30-s sit-to-stand test, 8-ft ""up & go"" test, daily activity energy expenditure and metabolic equivalent between the intervention group and the control group changed with time, and the variation ranges were different. The main effects of time were statistically significant (all p < 0.05), namely, femoris muscle strength, 6-min walking test, 30-s sit-to-stand test, 8-ft ""up & go"" test, daily activity energy expenditure and metabolic equivalent of the intervention group and the control group were significantly different before and after intervention. The main effects of groups were statistically significant (p < 0.05), namely, femoris muscle strength, 6-min walking test, 30-s sit-to-stand test, daily activity energy expenditure and metabolic equivalent before and after intervention were significantly different between the intervention group and the control group, while there was no significant differences in 8-ft ""up & go"" test between groups. CONCLUSION Lower limb resistance exercise used for the frailty intervention could improve muscle strength, physical fitness, and metabolism in pre-frail elderly. TRIAL REGISTRATION ChiCTR, ChiCTR2000031099. Registered 22 March 2020, http://www.chictr.org.cn/edit.aspx?pid=51221&htm=4.",2021,"The main effects of time were statistically significant (all p < 0.05), namely, femoris muscle strength, 6-min walking test, 30-s sit-to-stand test, 8-ft ""up & go"" test, daily activity energy expenditure and metabolic equivalent of the intervention group and the control group were significantly different before and after intervention.","['pre-frail elderly in China', 'pre-frail elderly patients', 'A total of 60 pre-frail elderly', 'patients with pre-frailty', 'frail elderly in China', '17 men and 13 women aged 65.3\u2009±\u200913.4 in the exercise group, and 15 men and 15 women aged 67.6\u2009±\u200911.9\u2009years in the control groups']","['routine care, while the exercise group received a 12-week lower limb resistance exercise based on routine care', 'lower limb resistance exercise', 'Lower limb resistance exercise']","['quadriceps femoris muscle strength, 6-min walking test, 30-s sit-to-stand test, 8-ft ""up & go"" test, daily activity energy expenditure and metabolic equivalent', 'namely, femoris muscle strength, 6-min walking test, 30-s sit-to-stand test, 8-ft ""up & go"" test, daily activity energy expenditure and metabolic equivalent', 'muscle strength in the lower limbs, physical fitness, and energy metabolism', 'muscle strength, physical fitness, and metabolism', 'namely, femoris muscle strength, 6-min walking test, 30-s sit-to-stand test, daily activity energy expenditure and metabolic equivalent']","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517558', 'cui_str': '13.4'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0560801', 'cui_str': 'Does stand from sitting'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C2355577', 'cui_str': 'Metabolic Equivalent'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}]",,0.0160444,"The main effects of time were statistically significant (all p < 0.05), namely, femoris muscle strength, 6-min walking test, 30-s sit-to-stand test, 8-ft ""up & go"" test, daily activity energy expenditure and metabolic equivalent of the intervention group and the control group were significantly different before and after intervention.","[{'ForeName': 'Xiaoxing', 'Initials': 'X', 'LastName': 'Lai', 'Affiliation': 'Department of Health Care, Peking Union Medical College Hospital, Beijing, 100730, China. laixx86@163.com.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Bo', 'Affiliation': 'Department of Health Care, Peking Union Medical College Hospital, Beijing, 100730, China.'}, {'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'Department of Health Care, Peking Union Medical College Hospital, Beijing, 100730, China.'}, {'ForeName': 'Baoyu', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': 'Department of Health Care, Peking Union Medical College Hospital, Beijing, 100730, China.'}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'Department of Health Care, Peking Union Medical College Hospital, Beijing, 100730, China.'}, {'ForeName': 'Hongdi', 'Initials': 'H', 'LastName': 'Du', 'Affiliation': 'Department of Health Care, Peking Union Medical College Hospital, Beijing, 100730, China.'}, {'ForeName': 'Xiaopeng', 'Initials': 'X', 'LastName': 'Huo', 'Affiliation': 'Nursing Department, Peking Union Medical College Hospital, Beijing, 100730, China. huoxp001@126.com.'}]",BMC geriatrics,['10.1186/s12877-021-02386-5'] 1891,34329897,"Difference in background factors between responders to gabapentin enacarbil treatment and responders to placebo: pooled analyses of two randomized, double-blind, placebo-controlled studies in Japanese patients with restless legs syndrome.","OBJECTIVE Restless legs syndrome (RLS) is a sensorimotor disorder that is characterized by uncomfortable and unpleasant sensations mainly in the legs. Two placebo-controlled studies (Phase II/III and post-marketing) in Japanese patients with RLS failed to demonstrate the efficacy of gabapentin enacarbil (GE) 600 mg in the change from baseline in International Restless Legs Syndrome Rating Scale (IRLS) score at the end of the treatment period. The high response to placebo is thought to be a possible reason why the post-marketing study failed. The objectives of these post hoc analyses were to determine potential predictive factors associated with improvement in IRLS score with GE treatment and to identify subgroups with higher placebo responses. METHODS We combined data from the two Japanese studies and analyzed change from baseline in IRLS score in the pooled population and subgroups defined by several patient characteristics. Moreover, we calculated the variable importance of each factor and performed predictive enrichment analysis to identify an enrichable subpopulation with greater improvement by GE treatment. RESULTS The post hoc analyses suggested that higher baseline IRLS score (≥21) and higher body mass index (≥25 kg/m 2 ) were associated with higher placebo responses. On the other hand, positive family history of RLS, prior use of dopaminergic receptor agonists, and higher baseline ferritin level (≥50 ng/mL) were associated with higher responses to GE. CONCLUSIONS Our results suggest that patients with typical idiopathic RLS characteristics, including positive family history and no low ferritin level, would be expected to derive the greatest benefits from GE treatment.",2021,The post hoc analyses suggested that higher baseline IRLS score (≥21) and higher body mass index (≥25 kg/m 2 ) were associated with higher placebo responses.,"['Japanese patients with restless legs syndrome', 'Restless legs syndrome (RLS', 'Japanese patients with RLS']","['gabapentin enacarbil (GE', 'placebo']","['IRLS score', 'baseline ferritin level', 'International Restless Legs Syndrome Rating Scale (IRLS) score', 'baseline IRLS score (≥21) and higher body mass index']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035258', 'cui_str': 'Restless legs'}]","[{'cui': 'C2700226', 'cui_str': 'Gabapentin enacarbil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035258', 'cui_str': 'Restless legs'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0373607', 'cui_str': 'Ferritin measurement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",,0.422502,The post hoc analyses suggested that higher baseline IRLS score (≥21) and higher body mass index (≥25 kg/m 2 ) were associated with higher placebo responses.,"[{'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'Department of Somnology, Tokyo Medical University, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan; Japan Somnology Center, Neuropsychiatric Research Institute, 5-10-10, Yoyogi, Shibuya-ku, Tokyo, 151-0053, Japan. Electronic address: inoue@somnology.com.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Hirata', 'Affiliation': 'Dokkyo Medical University, 880, Kitakobayashi, Mibu, Shimotsugagun, Tochigi, 321-0293, Japan. Electronic address: hirata@dokkyomed.ac.jp.'}, {'ForeName': 'Yuya', 'Initials': 'Y', 'LastName': 'Hoshino', 'Affiliation': 'Data Science, Astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan. Electronic address: yuya.hoshino@astellas.com.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Yamaguchi', 'Affiliation': 'Data Science, Astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan. Electronic address: yusuke-yamaguchi@astellas.com.'}]",Sleep medicine,['10.1016/j.sleep.2021.07.004'] 1892,34329669,The processing characteristics of bodily expressions under the odor context: An ERP study.,"The recognition of facial expressions has been shown to be influenced by contextual odors. The aims of this study were (1) to investigate whether odor has a similar effect on the recognition of bodily expressions, and (2) to analyze the time-course of such effects. Sixty-nine adults were randomized into three groups to identify bodily expressions (happy, fearful, and neutral) in three odor environments (pleasant odor, unpleasant odor, and no odor). Event-related potentials (ERPs) induced by the viewing bodily expressions were analyzed. Behaviorally, the unpleasant odor context promoted the recognition of bodily expressions. The ERP results showed odor influences on bodily expression recognition in two phases. In a middle stage phase (150-200 ms post-stimulus onset), VPP amplitudes induced by bodily expressions were greater in an unpleasant odor context than in a pleasant odor context. In a mid-late stage phase (beyond 200 ms), an interaction between contextual odor and bodily expression type was observed. When exposed to an unpleasant contextual odor, N2 and LPP amplitudes related to fearful bodily expressions were smaller than when exposed to other odor contexts, showing the promoting effect of mood coherence effect. Behavioral and ERP evidence confirmed that contextual odor can modulate the visual processing of bodily expressions, with an overall promoting effect of an unpleasant odor on bodily expression processing (phase one) and a specific modulating influence of odors on affectively congruent/incongruent bodily expressions (phase two).",2021,"When exposed to an unpleasant contextual odor, N2 and LPP amplitudes related to fearful bodily expressions were smaller than when exposed to other odor contexts, showing the promoting effect of mood coherence effect.",['Sixty-nine adults'],"['bodily expressions (happy, fearful, and neutral) in three odor environments (pleasant odor, unpleasant odor, and no odor']","['visual processing of bodily expressions', 'Event-related potentials (ERPs', 'fearful bodily expressions', 'VPP amplitudes induced by bodily expressions', 'bodily expression recognition', 'recognition of bodily expressions']","[{'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0028884', 'cui_str': 'With odor'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0589087', 'cui_str': 'Visual processing'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0282171', 'cui_str': 'Event-related potentials'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0078414', 'cui_str': 'VP-P protocol'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}]",69.0,0.0372303,"When exposed to an unpleasant contextual odor, N2 and LPP amplitudes related to fearful bodily expressions were smaller than when exposed to other odor contexts, showing the promoting effect of mood coherence effect.","[{'ForeName': 'Danyang', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'School of Psychology, Shanghai University of Sport, Shanghai, 200438, China.'}, {'ForeName': 'Xiaochun', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'School of Psychology, Shanghai University of Sport, Shanghai, 200438, China. Electronic address: wangxiaochun@sus.edu.cn.'}]",Behavioural brain research,['10.1016/j.bbr.2021.113494'] 1893,34329567,In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers.,"Cetagliptin is an oral, potent, and newly developed selective inhibitor of dipeptidyl peptidase-4 (DPP-4). We evaluated the in vitro drug-drug interaction (DDI) potential of cetagliptin, as well as the pharmacokinetics of cetagliptin and metformin and the interaction between cetagliptin and metformin.Cetagliptin did not inhibit CYP1A2, CYP2C8, CYP2B6, CYP2C9, CYP2C19, and CYP3A4, only has a moderate inhibitory effect on CYP2D6, and did not induce CYP1A2, CYP2B6, and CYP3A4. Plasma protein binding of cetagliptin didn't have species differences or concentration dependence. Cetagliptin was a substrate for P-glycoprotein (P-gp).The 34 healthy subjects enrolled were randomly divided into two sequences (A and B) with 17 subjects in each sequence. Coadministration with metformin had no effect on cetagliptin AUC 0-120 (GMR, 99.25%; 90% CI, 95.96%-102.65%). There was a slightly increase in cetagliptin C max (GMR, 117.33%; 90% CI, 102.54%-134.25%). Coadministration with cetagliptin did not affect the metformin's AUC 0-24 (GMR, 108.54%; 90% CI, 101.41%-116.17%) or C max (GMR, 97.67%; 90% CI, 90.96%-104.89%).Based on in vitro study results, cetagliptin is unlikely to cause CYP-mediated, clinically relevant DDI. Although the possibility of transporter-mediated, clinically relevant DDI cannot be ruled out, there is little or no risk of side effects. Coadministration of cetagliptin and metformin had no clinically meaningful effect on the pharmacokinetics of each drug. There was no drug-drug interaction between cetagliptin and metformin. Both monotherapies and combination therapy were well tolerated. No serious AEs and hypoglycaemia was reported.",2021,"Coadministration with cetagliptin did not affect the metformin's AUC 0-24 (GMR, 108.54%; 90% CI, 101.41%∼116.17%) or C max (GMR, 97.67%; 90% CI, 90.96%∼104.89%).Based on in vitro study results, cetagliptin is unlikely to cause CYP-mediated, clinically relevant DDI.","['34 healthy subjects enrolled', 'Healthy Volunteers']","['metformin', 'Cetagliptin and Metformin', 'Cetagliptin', 'cetagliptin and metformin']","['cetagliptin AUC', 'cetagliptin C max', 'serious AEs and hypoglycemia', 'tolerated']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}]",34.0,0.0498017,"Coadministration with cetagliptin did not affect the metformin's AUC 0-24 (GMR, 108.54%; 90% CI, 101.41%∼116.17%) or C max (GMR, 97.67%; 90% CI, 90.96%∼104.89%).Based on in vitro study results, cetagliptin is unlikely to cause CYP-mediated, clinically relevant DDI.","[{'ForeName': 'Jinmiao', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Xusheng', 'Initials': 'X', 'LastName': 'Tian', 'Affiliation': 'CGeneTech (Suzhou, China) Co., Ltd, Suzhou, Jiangsu, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Tang', 'Affiliation': 'CGeneTech (Suzhou, China) Co., Ltd, Suzhou, Jiangsu, China.'}, {'ForeName': 'Xinyi', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'CGeneTech (Suzhou, China) Co., Ltd, Suzhou, Jiangsu, China.'}, {'ForeName': 'Zengyan', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': 'CGeneTech (Suzhou, China) Co., Ltd, Suzhou, Jiangsu, China.'}, {'ForeName': 'Juping', 'Initials': 'J', 'LastName': 'Ding', 'Affiliation': 'CGeneTech (Suzhou, China) Co., Ltd, Suzhou, Jiangsu, China.'}, {'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'CGeneTech (Suzhou, China) Co., Ltd, Suzhou, Jiangsu, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Yu', 'Affiliation': 'CGeneTech (Suzhou, China) Co., Ltd, Suzhou, Jiangsu, China.'}, {'ForeName': 'Jinsong', 'Initials': 'J', 'LastName': 'Ding', 'Affiliation': 'Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.'}]",Xenobiotica; the fate of foreign compounds in biological systems,['10.1080/00498254.2021.1963010'] 1894,34343658,Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.,"Outcomes for patients with systemic light-chain (AL) amyloidosis have improved over the last two decades with timely diagnosis, use of novel chemotherapeutic agents, risk stratification and better patient selection criteria before hematopoietic autologous stem cell transplant (ASCT). However, majority of patients have advanced stage disease at initial presentation and at relapse rendering them ineligible for intensive cytotoxic chemotherapy or ASCT. Daratumumab (Dara) with or without standard chemotherapy appears to be an excellent treatment option for newly diagnosed and relapsed refractory AL amyloidosis. This is largely due to its tolerable safety and remarkable efficacy as seen in multiple retrospective, small phase II studies as well as a phase III randomized controlled trial. Here we review published clinical trials and retrospective data of Dara in AL amyloidosis that explore its role as a valuable addition to the treatment armamentarium for this challenging disease.",2021,"Outcomes for patients with systemic light-chain (AL) amyloidosis have improved over the last two decades with timely diagnosis, use of novel chemotherapeutic agents, risk stratification and better patient selection criteria before hematopoietic autologous stem cell transplant (ASCT).","['patients with systemic light-chain (AL) amyloidosis', 'Patients with AL Amyloidosis']","['Daratumumab (Dara) with or without standard chemotherapy', 'intensive cytotoxic chemotherapy or ASCT']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0002726', 'cui_str': 'Amyloidosis'}, {'cui': 'C0268381', 'cui_str': 'AL amyloidosis'}]","[{'cui': 'C2346801', 'cui_str': 'daratumumab'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0304497', 'cui_str': 'Cytotoxic agent'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}]",[],,0.193693,"Outcomes for patients with systemic light-chain (AL) amyloidosis have improved over the last two decades with timely diagnosis, use of novel chemotherapeutic agents, risk stratification and better patient selection criteria before hematopoietic autologous stem cell transplant (ASCT).","[{'ForeName': 'Hamza', 'Initials': 'H', 'LastName': 'Hassan', 'Affiliation': 'Department of Hematology & Medical Oncology, Boston University School of Medicine, United States. Electronic address: hhassan@bu.edu.'}, {'ForeName': 'Faiz', 'Initials': 'F', 'LastName': 'Anwer', 'Affiliation': 'Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, United States.'}, {'ForeName': 'Anum', 'Initials': 'A', 'LastName': 'Javaid', 'Affiliation': 'Rawalpindi Medical University, Rawalpindi, Pakistan.'}, {'ForeName': 'Hamza', 'Initials': 'H', 'LastName': 'Hashmi', 'Affiliation': 'Department of Hematology Oncology, Medical University of South Carolina, United States.'}]",Critical reviews in oncology/hematology,['10.1016/j.critrevonc.2021.103435'] 1895,34343632,Functional and concurrent training do not impair immune function and improve functional fitness in postmenopausal women: A randomized controlled trial.,"PURPOSE To evaluate the effects of functional and concurrent training on immune function and functional fitness in postmenopausal women. MATERIALS AND METHODS A randomized controlled trial was performed on 108 women aged 60 or older who were randomly assigned among the groups: control group (CG: n = 40; 63.88 ± 3.64 years); functional training (FT: n = 32; 63.88 ± 3.79 years); and concurrent training (CT: n = 36; 64.83 ± 4.00 years). Immune function was measured by the expression of the T-lymphocyte function-related surface markers (CD28 and CD57). Functional fitness was assessed using physical tests similar to daily activities, i.e., five times sit to stand, timed up and go, and gallon-jug shelf-transfer. RESULTS Regarding immune function, there was only a time effect, without between-group differences. Specifically, FT and CT show a reduction and increase in CD4 + and CD8 + T cells, respectively, without impairment in the subpopulations analyzed, while CG showed a reduction in naive T cells (CD8 + CD28 + ). For functional fitness tests, there was a time × group interaction effect for all tests, the FT and CT were superior to the CG, with FT showing differences after the fourth week, while the CT showed this effect after the eighth week of intervention. CONCLUSION FT and CT do not impair immune function and similarly improve functional fitness in postmenopausal women. CLINICAL TRIALS REGISTRY RBR-2d56bt.",2021,"For functional fitness tests, there was a time × group interaction effect for all tests, the FT and CT were superior to the CG, with FT showing differences after the fourth week, while the CT showed this effect after the eighth week of intervention. ","['108 women aged 60 or older who were randomly assigned among the groups', 'postmenopausal women']","['FT and CT', 'control group (CG: n\u202f=\u202f40; 63.88\u202f±\u202f3.64\u202fyears); functional training (FT: n\u202f=\u202f32; 63.88\u202f±\u202f3.79\u202fyears); and concurrent training (CT', 'Functional and concurrent training', 'functional and concurrent training']","['immune function and functional fitness', 'naive T cells (CD8+CD28', 'Immune function', 'CD4+ and CD8+ T cells', 'expression of the T-lymphocyte function-related surface markers (CD28 and CD57', 'Functional fitness', 'functional fitness']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517695', 'cui_str': '3.64'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]","[{'cui': 'C1817756', 'cui_str': 'Immunologic function'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0075747', 'cui_str': 'Lymphocyte antigen CD28'}, {'cui': 'C0054965', 'cui_str': 'Lymphocyte antigen CD57'}]",108.0,0.0300158,"For functional fitness tests, there was a time × group interaction effect for all tests, the FT and CT were superior to the CG, with FT showing differences after the fourth week, while the CT showed this effect after the eighth week of intervention. ","[{'ForeName': 'José Carlos', 'Initials': 'JC', 'LastName': 'Aragão-Santos', 'Affiliation': 'Department of Physiology, Post Graduate Program in Physiology Sciences, Center of Biological and Health Sciences, Federal University of Sergipe, São Cristóvão, Brazil. Electronic address: prof.josecarlosaragao@gmail.com.'}, {'ForeName': 'Alan Bruno Silva', 'Initials': 'ABS', 'LastName': 'Vasconcelos', 'Affiliation': 'Department of Physiology, Post Graduate Program in Physiology Sciences, Center of Biological and Health Sciences, Federal University of Sergipe, São Cristóvão, Brazil.'}, {'ForeName': 'Antônio Gomes de', 'Initials': 'AG', 'LastName': 'Resende-Neto', 'Affiliation': 'Department of Physical Education, Post Graduate Program in Health Sciences, Center of Biological and Health Sciences, Federal University of Sergipe, Brazil.'}, {'ForeName': 'Lorranny Santana', 'Initials': 'LS', 'LastName': 'Rodrigues', 'Affiliation': 'Department of Physical Education, Post Graduate Program in Health Sciences, Center of Biological and Health Sciences, Federal University of Sergipe, Brazil.'}, {'ForeName': 'Nathanielly de Lima', 'Initials': 'NL', 'LastName': 'Silva', 'Affiliation': 'Department of Pharmacy, Post Graduate Program in Pharmaceutical Sciences, Center of Biological and Health Sciences, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil.'}, {'ForeName': 'Danilo Nobre', 'Initials': 'DN', 'LastName': 'Da Silva', 'Affiliation': 'Department of Pharmacy, Post Graduate Program in Pharmaceutical Sciences, Center of Biological and Health Sciences, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil.'}, {'ForeName': 'Dulce Marta', 'Initials': 'DM', 'LastName': 'Schimieguel', 'Affiliation': 'Department of Pharmacy, Post Graduate Program in Pharmaceutical Sciences, Center of Biological and Health Sciences, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil.'}, {'ForeName': 'Cristiane Bani', 'Initials': 'CB', 'LastName': 'Correa', 'Affiliation': 'Department of Morphology, Post Graduate Program in Health Sciences and Post Graduate Program in Physiology Sciences, Center of Biological and Health Sciences, Federal University of Sergipe, São Cristóvão, Brazil.'}, {'ForeName': 'Marzo Edir', 'Initials': 'ME', 'LastName': 'Da Silva-Grigoletto', 'Affiliation': 'Department of Physical Education, Post Graduate Program in Physical Education and Post Graduate Program in Physiology Sciences, Center of Biological and Health Sciences, Federal University of Sergipe, São Cristóvão, Brazil.'}]",Experimental gerontology,['10.1016/j.exger.2021.111504'] 1896,34324700,"Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.","OBJECTIVE To determine the efficacy and safety of fremanezumab administration in Japanese and Korean patients with chronic migraine (CM). BACKGROUND Available preventive treatments for CM are limited by various efficacy and safety issues. Fremanezumab, a monoclonal antibody that targets the calcitonin gene-related peptide pathway involved in migraine pathogenesis, has been shown to be effective and well tolerated in large-scale, international Phase 3 trials. METHODS Randomized, placebo-controlled trial of patients with CM who received subcutaneous fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8), fremanezumab quarterly (675 mg at baseline and placebo at weeks 4 and 8), or matching placebo. Primary endpoint was the mean change from baseline in the monthly (28-day) average number of headache days of at least moderate severity during the 12 weeks after the first dose. RESULTS Among 571 patients randomized (safety set, n = 569; full analysis set, n = 566), the least-squares mean (±standard error [SE]) reduction in the average number of headache days of at least moderate severity per month during 12 weeks was significantly greater with fremanezumab monthly (-4.1 ± 0.4) and fremanezumab quarterly (-4.1 ± 0.4) than with placebo (-2.4 ± 0.4). The difference from the placebo group in the mean change (95% confidence interval [CI]) was -1.7 days (-2.54, -0.80) for the fremanezumab monthly group and -1.7 days (-2.55, -0.82) for the fremanezumab quarterly group (p < 0.001 vs. placebo for both fremanezumab groups). The percentage of patients with a ≥50% reduction in the average number of headache days of at least moderate severity per month (response rate) was higher with fremanezumab monthly (29.0%) and fremanezumab quarterly (29.1%) than with placebo (13.2%) in addition to other improvements in secondary endpoints, including reduction of acute medication use (mean change from baseline during 12-week period ± SE: fremanezumab monthly, -3.7 ± 0.4; fremanezumab quarterly, -3.9 ± 0.4; placebo, -2.4 ± 0.4) and improvements in disability scores (mean change from baseline in six-item Headache Impact Test score at 4 weeks after third injection ± SE: fremanezumab monthly, -8.1 ± 0.7; fremanezumab quarterly, -8.0 ± 0.7; placebo, -6.5 ± 0.7). Fremanezumab was well tolerated with a similar incidence of adverse events including injection-site reactions as placebo (patients with at least one treatment-emergent adverse event: fremanezumab total, n = 232 [61.4%]; placebo, n = 118 [61.8%]). CONCLUSION Fremanezumab effectively prevents CM in Japanese and Korean patients and was well tolerated. No safety signal was detected.",2021,"Fremanezumab was well tolerated with a similar incidence of adverse events including injection-site reactions as placebo (patients with at least one treatment-emergent adverse event: fremanezumab total, n = 232 [61.4%]; placebo, n = 118 [61.8%]). ","['Japanese and Korean patients with chronic migraine (CM', '571 patients', 'patients with CM who received', 'chronic migraine prevention', 'Japanese and Korean patients']","['subcutaneous fremanezumab', 'Fremanezumab', 'placebo', 'fremanezumab', 'fremanezumab quarterly (675\xa0mg at baseline and placebo']","['efficacy and safety', 'reduction of acute medication use', 'mean change from baseline in the monthly (28-day) average number of headache days of at least moderate severity', 'Efficacy and safety', 'average number of headache days', 'tolerated', 'safety signal', 'disability scores']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1960870', 'cui_str': 'Transformed migraine'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C4549503', 'cui_str': 'fremanezumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332179', 'cui_str': 'Trimonthly'}, {'cui': 'C4517854', 'cui_str': '675'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",571.0,0.647458,"Fremanezumab was well tolerated with a similar incidence of adverse events including injection-site reactions as placebo (patients with at least one treatment-emergent adverse event: fremanezumab total, n = 232 [61.4%]; placebo, n = 118 [61.8%]). ","[{'ForeName': 'Fumihiko', 'Initials': 'F', 'LastName': 'Sakai', 'Affiliation': 'Saitama International Headache Center, Saitama Neuropsychiatric Institute, Saitama, Japan.'}, {'ForeName': 'Norihiro', 'Initials': 'N', 'LastName': 'Suzuki', 'Affiliation': 'Department of Neurology, Shonan Keiiku Hospital, Kanagawa, Japan.'}, {'ForeName': 'Byung-Kun', 'Initials': 'BK', 'LastName': 'Kim', 'Affiliation': 'Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Hisaka', 'Initials': 'H', 'LastName': 'Igarashi', 'Affiliation': 'Headache Care Unit, Department of Internal Medicine, Fujitsu Clinic, Kanagawa, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Hirata', 'Affiliation': 'Headache Center, Department of Neurology, Dokkyo Medical University, Tochigi, Japan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Takeshima', 'Affiliation': 'Headache Center, Department of Neurology, Tominaga Hospital, Osaka, Japan.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Ning', 'Affiliation': 'Specialty Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Shima', 'Affiliation': 'Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Miki', 'Initials': 'M', 'LastName': 'Ishida', 'Affiliation': 'Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Katsuhiro', 'Initials': 'K', 'LastName': 'Iba', 'Affiliation': 'Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Kondo', 'Affiliation': 'Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Koga', 'Affiliation': 'Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.'}]",Headache,['10.1111/head.14169'] 1897,34328290,Comparison of 1565-nm Nonablative Fractional Laser and 10600-nm Ablative Fractional Laser in the Treatment of Mild to Moderate Atrophic Acne Scars.,"BACKGROUND The 10,600-nm ablative fractional laser (AFL) is widely used for treating facial atrophic acne scars but with evident side effects. By contrast, the common Er:Glass non-AFL (NAFL) is safer but lacks of comparable outcomes. A novel 1,565 nm Er:Glass NAFL improves thermal energy delivery and could yield better outcomes. OBJECTIVE We aimed to compare the effectiveness and safety between the 1,565-nm NAFL and 10,600-nm AFL in treating mild-to-moderate facial atrophic acne scars. METHODS Nineteen patients with mild-to-moderate bilateral facial atrophic acne scars were enrolled in a randomized split-face trial, which involved 3-session procedures for each laser. The effectiveness and safety were evaluated by doctors and patients who were blinded to the treatment assignment. RESULTS Both lasers improved the acne scar profiles comparably. A marked reduction in erythema, crusting durations, and degree of pain were noted on the sides treated with the 1,565-nm NAFL, relative to those treated with the 10,600-nm AFL. CONCLUSION Both 1,565 nm-NAFL and 10,600-nm AFL can improve mild-to-moderate acne scars. Patients should never expect complete resolution. The 1,565-nm NAFL has less side effects.",2021,"A marked reduction in erythema, crusting durations, and degree of pain were noted on the sides treated with the 1,565-nm NAFL, relative to those treated with the 10,600-nm AFL. ","['Mild to Moderate Atrophic Acne Scars', 'Nineteen patients with mild-to-moderate bilateral facial atrophic acne scars', 'mild-to-moderate facial atrophic acne scars']","['10,600-nm ablative fractional laser (AFL', '1565-nm Nonablative Fractional Laser and 10600-nm Ablative Fractional Laser', '1,565-nm NAFL and 10,600-nm AFL', 'AFL']","['effectiveness and safety', 'facial atrophic acne scars', 'erythema, crusting durations, and degree of pain']","[{'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C1274728', 'cui_str': 'Atrophic acne scar'}, {'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}]","[{'cui': 'C0023089', 'cui_str': 'Laser device'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C1274728', 'cui_str': 'Atrophic acne scar'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0205204', 'cui_str': 'Crust'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",19.0,0.0725155,"A marked reduction in erythema, crusting durations, and degree of pain were noted on the sides treated with the 1,565-nm NAFL, relative to those treated with the 10,600-nm AFL. ","[{'ForeName': 'Xiaoxi', 'Initials': 'X', 'LastName': 'Cheng', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Shaanxi, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Yang', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Shaanxi, China.'}, {'ForeName': 'Yingjun', 'Initials': 'Y', 'LastName': 'Su', 'Affiliation': 'Department of Burns and Plastic Surgery, Fourth Medical Center of PLA General Hospital, Beijing, China.'}, {'ForeName': 'Yanqiu', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Shaanxi, China.'}, {'ForeName': 'Xianjie', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Shaanxi, China.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002771'] 1898,34328264,Efficacy of sonic versus manual toothbrushing after professional mechanical plaque removal: A 6-month randomized clinical trial.,"AIM The aim of this study was to compare the efficacy of two brushing methods (manual vs. sonic) in terms of plaque control after a session of professional mechanical plaque removal (PMPR). METHODS Subjects with gingivitis underwent a session of PMPR and were randomly assigned to sonic (SB) or manual brushing (MB). Oral hygiene instructions were provided at baseline (BL), 2 (T0a), 4 (T0b) and 6 weeks (T1) and 6 months (T2). Plaque Index (PI), Gingival Index (GI) and bleeding on probing (BoP) were measured at BL, T1 and T2. The proportion of sites with PI, GI and BoP was modelled at site level using a negative binomial regression fitted via generalized linear mixed model accounting for intra-patient correlation. RESULTS Thirty-two subjects were selected, 16 assigned to each group and 31 completed the study. PI, BoP and GI were comparable at BL. At T1, PI was successfully maintained at 6.21% for SB and 22.81% for MB, while at T2 reached 11.34% for SB and 28% for MB, favouring the SB group (p < 0.001). GI and BoP were significantly lower in the SB group at T1, with a BoP reduction for SB about 3 times higher than MB (p < 0.001). These parameters then levelled at T2 between the groups, with BOP reaching 0.14% versus 0.05% (p = 0.356) and GI 1.75% versus 3.52% (p = 0.020). CONCLUSION Sonic brushing seemed to maintain a lower PI score compared to a manual brush at 6 months. BoP and GI resulted comparable.",2021,"GI and BoP were significantly lower in the SB group at T1, with a BoP reduction for SB about 3 times higher than MB (p<0.001).","['32 subjects were selected,16 assigned to each group and 31 completed the study', 'Subjects with gingivitis underwent a session of PMPR', 'after professional mechanical plaque removal']","['sonic vs manual toothbrushing', 'sonic (SB) or manual brushing (MB', 'brushing methods (manual VS sonic']","['PI score', 'GI and BoP', 'PI, BoP and GI', 'proportion of sites with PI, GI and BoP', 'Plaque Index (PI), Gingival Index (GI) and Bleeding on Probing (BoP']","[{'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0040461', 'cui_str': 'Brushing of teeth'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C2945843', 'cui_str': 'Site of'}]",32.0,0.0910428,"GI and BoP were significantly lower in the SB group at T1, with a BoP reduction for SB about 3 times higher than MB (p<0.001).","[{'ForeName': 'Magda', 'Initials': 'M', 'LastName': 'Mensi', 'Affiliation': 'Section of Periodontics, School of Dentistry, Department of Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Scotti', 'Affiliation': 'Section of Periodontics, School of Dentistry, Department of Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Annamaria', 'Initials': 'A', 'LastName': 'Sordillo', 'Affiliation': 'Section of Periodontics, School of Dentistry, Department of Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Brognoli', 'Affiliation': 'Section of Periodontics, School of Dentistry, Department of Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Maria Paola', 'Initials': 'MP', 'LastName': 'Dominici', 'Affiliation': 'Section of Periodontics, School of Dentistry, Department of Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Calza', 'Affiliation': 'Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.'}]",International journal of dental hygiene,['10.1111/idh.12541'] 1899,34330073,Efficacy of IVRS-based mHealth intervention in reducing cardiovascular risk in metabolic syndrome: A cluster randomized trial.,"AIMS Efficacy of mobile-phone based intervention for reducing cardiovascular risk in metabolic syndrome (MetSyn). METHODS We screened adults 20-60 years in 10 villages in India for MetSyn using stratified cluster sampling. Lifestyle and biochemical risk factors were assessed. International Harmonized Criteria were used for diagnosis. Villages were randomized with 5 each in control and intervention groups. Interactive voice response system (IVRS) in Hindi was developed. In intervention clusters two messages for promotion of healthy lifestyle and medical treatment were broadcast daily over 12-months and risk factors reassessed. RESULTS 1012/1200(84%) persons were screened and MetSyn diagnosed in 286(28.3%). Villages were divided into 5 control(n = 136) and 5 intervention(n = 147) clusters. Baseline characteristics in both clusters were similar. Acceptability of intervention was >60% in 80% participants. At 12 months, significantly greater participants in intervention vs control clusters had healthier lifestyle (healthy diet 28.8vs14.7%, physical activity 25.9vs13.1%, tobacco 13.7vs32.5%), anthropometry (waist circumference 85.7 ± 6.3vs88.6 ± 14.0 cm, body mass index 21.9 ± 2.8vs23.1 ± 2.9 kg/m 2 ), systolic BP 123.6 ± 7.7vs128.6 ± 14.1 mmHg, fasting glucose 95.6 ± 19.4vs109.4 ± 43.7 mg/dl, cholesterol 175.5 ± 36.5vs186.4 ± 43.3 mg/dl, and triglycerides 147.6 ± 48.3vs159.5 ± 60.7 mg/dl (p < 0.01). Prevalence of metabolic syndrome declined in intervention group by 22.3%vs3.9%, p < 0.001). CONCLUSION An interactive voice response system based technology significantly reduced multiple cardiovascular risk factors and prevalence of metabolic syndrome.",2021,"Prevalence of metabolic syndrome declined in intervention group by 22.3%vs3.9%, p < 0.001). ","['metabolic syndrome', 'We screened adults 20-60 years in 10 villages in India for MetSyn using stratified cluster sampling', 'metabolic syndrome (MetSyn']","['mobile-phone based intervention', 'IVRS-based mHealth intervention', 'Interactive voice response system (IVRS']","['cardiovascular risk', 'systolic BP 123.6\xa0±\xa07.7vs128.6\xa0±', 'multiple cardiovascular risk factors and prevalence of metabolic syndrome', 'Lifestyle and biochemical risk factors', 'Prevalence of metabolic syndrome', 'fasting glucose 95.6\xa0±', 'healthier lifestyle']","[{'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}]","[{'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}]","[{'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}]",,0.0152779,"Prevalence of metabolic syndrome declined in intervention group by 22.3%vs3.9%, p < 0.001). ","[{'ForeName': 'Arvind K', 'Initials': 'AK', 'LastName': 'Sharma', 'Affiliation': 'Departments of Community Medicine, RUHS College of Medical Sciences, Jaipur, 302033, India. Electronic address: dranuaiiims@yahoo.com.'}, {'ForeName': 'Vaseem Naheed', 'Initials': 'VN', 'LastName': 'Baig', 'Affiliation': 'Departments of Community Medicine, RUHS College of Medical Sciences, Jaipur, 302033, India.'}, {'ForeName': 'Jitendra', 'Initials': 'J', 'LastName': 'Ahuja', 'Affiliation': 'Departments of Biochemistry, RUHS College of Medical Sciences, Jaipur, 302033, India.'}, {'ForeName': 'Sonali', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Departments of Biochemistry, RUHS College of Medical Sciences, Jaipur, 302033, India.'}, {'ForeName': 'Raja Babu', 'Initials': 'RB', 'LastName': 'Panwar', 'Affiliation': 'Academic Research Development Unit, Rajasthan University of Health Sciences, 302033, Jaipur, India.'}, {'ForeName': 'Vishwa Mohan', 'Initials': 'VM', 'LastName': 'Katoch', 'Affiliation': 'Academic Research Development Unit, Rajasthan University of Health Sciences, 302033, Jaipur, India.'}, {'ForeName': 'Rajeev', 'Initials': 'R', 'LastName': 'Gupta', 'Affiliation': 'Academic Research Development Unit, Rajasthan University of Health Sciences, 302033, Jaipur, India.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2021.06.019'] 1900,34331186,Comparison of Conventional Methods for Bowel Length Measurement in Laparoscopic Surgery to a Novel Computer-Assisted 3D Measurement System.,"PURPOSE Accurate laparoscopic bowel length measurement (LBLM), which is used primarily in metabolic surgery, remains a challenge. This study aims to three conventional methods for LBLM, namely using visual judgment (VJ), instrument markings (IM), or premeasured tape (PT) to a novel computer-assisted 3D measurement system (BMS). MATERIALS AND METHODS LBLM methods were compared using a 3D laparoscope on bowel phantoms regarding accuracy (relative error in percent, %), time in seconds (s), and number of bowel grasps. Seventy centimeters were measured seven times. As a control, the first, third, fifth, and seventh measurements were performed with VJ. The interventions IM, PT, and BMS were performed following a randomized order as the second, fourth, and sixth measurements. RESULTS In total, 63 people participated. BMS showed better accuracy (2.1±3.7%) compared to VJ (8.7±13.7%, p=0.001), PT (4.3±6.8%, p=0.002), and IM (11±15.3%, p<0.001). Participants performed LBLM in a similar amount of time with BMS (175.7±59.7s) and PT (166.5±63.6s, p=0.35), but VJ (64.0±24.0s, p<0.001) and IM (144.9±55.4s, p=0.002) were faster. Number of bowel grasps as a measure for the risk of bowel lesions was similar for BMS (15.8±3.0) and PT (15.9±4.6, p=0.861), whereas VJ required less (14.1±3.4, p=0.004) and IM required more than BMS (22.2±6.9, p<0.001). CONCLUSIONS PT had higher accuracy than VJ and IM, and lower number of bowel grasps than IM. BMS shows great potential for more reliable LBLM. Until BMS is available in clinical routine, PT should be preferred for LBLM.",2021,"BMS showed better accuracy (2.1±3.7%) compared to VJ (8.7±13.7%, p=0.001), PT (4.3±6.8%, p=0.002), and IM (11±15.3%, p<0.001).",['63 people participated'],"['laparoscopic bowel length measurement (LBLM', 'BMS', 'visual judgment (VJ), instrument markings (IM), or premeasured tape (PT) to a novel computer-assisted 3D measurement system (BMS']","['Number of bowel grasps', 'accuracy', 'time in seconds (s), and number of bowel grasps', 'risk of bowel lesions']","[{'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0522501', 'cui_str': 'Massive'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",70.0,0.0550706,"BMS showed better accuracy (2.1±3.7%) compared to VJ (8.7±13.7%, p=0.001), PT (4.3±6.8%, p=0.002), and IM (11±15.3%, p<0.001).","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Wagner', 'Affiliation': 'Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.'}, {'ForeName': 'Benjamin F B', 'Initials': 'BFB', 'LastName': 'Mayer', 'Affiliation': 'Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Bodenstedt', 'Affiliation': 'Division of Translational Surgical Oncology, National Center for Tumor Diseases, Partner-Site Dresden, Fetscherstraße 74, 01307, Dresden, Germany.'}, {'ForeName': 'Karl-Friedrich', 'Initials': 'KF', 'LastName': 'Kowalewski', 'Affiliation': 'Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Nickel', 'Affiliation': 'Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Speidel', 'Affiliation': 'Division of Translational Surgical Oncology, National Center for Tumor Diseases, Partner-Site Dresden, Fetscherstraße 74, 01307, Dresden, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Fischer', 'Affiliation': 'Department for General and Visceral Surgery, Hospital Mittelbaden, Balger Str. 50, 76532, Baden-Baden, Germany.'}, {'ForeName': 'Hannes G', 'Initials': 'HG', 'LastName': 'Kenngott', 'Affiliation': 'Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.'}, {'ForeName': 'Beat-Peter', 'Initials': 'BP', 'LastName': 'Müller-Stich', 'Affiliation': 'Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany. Beat.Mueller@med.uni-heidelberg.de.'}]",Obesity surgery,['10.1007/s11695-021-05620-6'] 1901,34332289,"Feasibility, acceptability, and potential effectiveness of an online expressive writing intervention for COVID-19 resilience.","BACKGROUND & PURPOSE The COVID-19 pandemic has negatively impacted mental health in the general population. In this trial, our objective was to assess whether a 6-week expressive writing intervention improves resilience in a sample from the general population in the midst of the COVID-19 pandemic. MATERIALS & METHODS This 6-week trial was conducted online. Eligible participants (n=63) were a sample of adults who self-identified as having been significantly affected by the COVID-19 pandemic. PRIMARY OUTCOME Connor-Davidson Resilience Scale (CD-RISC). SECONDARY OUTCOMES Perceived Stress Scale - 10-Item (PSS-10); Center for Epidemiologic Studies Depression Scale - Revised (CESD-R); Post-Traumatic Growth Inventory (PTGI). RESULTS Resilience measures (CD-RISC) increased from baseline (66.6 ± 14.9) to immediately post-intervention (73.0 ± 12.4; p=0.014; Cohen's d =0.31), and at a 1- month follow-up (72.9 ± 13.6; p=0.024; Cohen's d =0.28). Across the same timepoints, perceived stress scores (PSS-10) decreased from baseline (21.8 ± 6.6) to immediately post-intervention (18.3 ± 7.0; p=0.008; Cohen's d =0.41), and at the 1- month follow-up to (16.8 ± 6.7; p=0.0002; Cohen's d =0.56). Depression symptoms (CESD-R) decreased from baseline (23.3 ± 15.3) at 6 weeks (17.8 ± 15.4; p=0.058; Cohen's d =0.22), and 10 weeks (15.5 ± 12.7; p=0.004; Cohen's d =0.38). Posttraumatic growth (PTGI) increased from baseline (41.7 ± 23.4) at 6 weeks (55.8 ± 26.4; p=0.004; Cohen's d =0.44), and at the 1-month follow-up (55.9 ± 29.3; p=0.008; Cohen's d =0.49). CONCLUSION An online expressive writing intervention was effective at improving resilience in the midst of the COVID-19 pandemic. NCT#: NCT04589104.",2021,"Depression symptoms (CESD-R) decreased from baseline (23.3 ± 15.3) at 6 weeks (17.8 ± 15.4; p=0.058; Cohen's d =0.22), and 10 weeks (15.5 ± 12.7; p=0.004; Cohen's d =0.38).",['Eligible participants (n=63) were a sample of adults who self-identified as having been significantly affected by the COVID-19 pandemic'],"['expressive writing intervention', 'online expressive writing intervention']","['Perceived Stress Scale - 10-Item', 'stress scores (PSS-10', 'Resilience measures (CD-RISC', 'Feasibility, acceptability, and potential effectiveness', 'Connor-Davidson Resilience Scale (CD-RISC', 'Posttraumatic growth (PTGI', 'Depression symptoms (CESD-R']","[{'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}]","[{'cui': 'C0018582', 'cui_str': 'Handwriting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1099355', 'cui_str': 'RISC Multicomponent Nuclease'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4704809', 'cui_str': 'Posttraumatic Growth'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0043208', 'cui_str': ""Wolman's disease""}]",63.0,0.282608,"Depression symptoms (CESD-R) decreased from baseline (23.3 ± 15.3) at 6 weeks (17.8 ± 15.4; p=0.058; Cohen's d =0.22), and 10 weeks (15.5 ± 12.7; p=0.004; Cohen's d =0.38).","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Bechard', 'Affiliation': 'Duke Integrative Medicine, 3475 Erwin Road, Durham, NC, 27705, USA. Electronic address: elizabeth.matteson@gmail.com.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Evans', 'Affiliation': 'Duke Integrative Medicine, 3475 Erwin Road, Durham, NC, 27705, USA. Electronic address: jfevans77@gmail.com.'}, {'ForeName': 'Eunji', 'Initials': 'E', 'LastName': 'Cho', 'Affiliation': 'Vanderbilt University School of Nursing, 461 21st Avenue South, Nashville, TN, 37240, USA. Electronic address: eunji.cho@vanderbilt.edu.'}, {'ForeName': 'Yufen', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing, 1520 Clifton Road, Atlanta, GA, 30322, USA. Electronic address: yufen.lin@emory.edu.'}, {'ForeName': 'Arthi', 'Initials': 'A', 'LastName': 'Kozhumam', 'Affiliation': 'Duke University, Trinity College of Arts & Sciences, Box 90046, Durham, NC, 27708, USA. Electronic address: arthi.kozhumam@duke.edu.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Jones', 'Affiliation': 'Duke University, Trinity College of Arts & Sciences, Box 90046, Durham, NC, 27708, USA. Electronic address: jillkathleenjones@gmail.com.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Grob', 'Affiliation': 'Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA. Electronic address: sydneygrob@gmail.com.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Glass', 'Affiliation': 'Duke Integrative Medicine, 3475 Erwin Road, Durham, NC, 27705, USA. Electronic address: oliver.glass@duke.edu.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2021.101460'] 1902,34332269,Cognitive recovery in people with relapsing/remitting multiple sclerosis: A randomized clinical trial on virtual reality-based neurorehabilitation.,"BACKGROUND Multiple sclerosis (MS) can adversely affect several domains of cognitive function, including attention, information processing, memory and learning, executive functions and visuospatial skills. In recent years, technological innovations have proven effective in improving motor and cognitive impairment in neurological patients, including those affected by MS. OBJECTIVE The study aims to evaluate cognitive outcomes after rehabilitation training with the Virtual Reality rehabilitation system (VRRS) in patients suffering from MS. METHODS All patients were randomized into either the control group (CG: 15 patients) receiving conventional cognitive rehab or the experimental group (EG) using virtual reality (VR) (15 patients). Both groups underwent the same amount of cognitive training, 3 times a week for 8 weeks. They were submitted to neuropsychological assessment before (T0) and after the rehabilitation treatment (T1). RESULTS Our data showed that both conventional and VR cognitive rehabilitation approaches improved mood (p < 0.001) and visuospatial skills. However, only in the EG a significant improvement in specific cognitive domains (p < 0.001), including learning ability, short-term verbal memory, lexical access ability, as well as quality of life related to mental states, was found. CONCLUSIONS The present study demonstrated that VR can be a motivational and effective tool for cognitive recovery in MS patients.",2021,Our data showed that both conventional and VR cognitive rehabilitation approaches improved mood (p < 0.001) and visuospatial skills.,"['patients suffering from MS', 'All patients', 'people with relapsing/remitting multiple sclerosis']","['control group (CG: 15 patients) receiving conventional cognitive rehab or the experimental group (EG) using virtual reality (VR', 'rehabilitation training with the Virtual Reality rehabilitation system (VRRS']","['Cognitive recovery', 'visuospatial skills', 'cognitive outcomes', 'learning ability, short-term verbal memory, lexical access ability, as well as quality of life related to mental states', 'specific cognitive domains']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0439600', 'cui_str': 'Remitting'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0233832', 'cui_str': 'Learning ability'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",,0.0149729,Our data showed that both conventional and VR cognitive rehabilitation approaches improved mood (p < 0.001) and visuospatial skills.,"[{'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Leonardi', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Maggio', 'Affiliation': 'University of Catania, Department of Biomedical and Biotechnological Science, Italy.'}, {'ForeName': 'Margherita', 'Initials': 'M', 'LastName': 'Russo', 'Affiliation': 'AOU Papardo, Messina, Italy.'}, {'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Bramanti', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy.'}, {'ForeName': 'Francesca Antonia', 'Initials': 'FA', 'LastName': 'Arcadi', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy.'}, {'ForeName': 'Antonino', 'Initials': 'A', 'LastName': 'Naro', 'Affiliation': 'AOU Policlinico G. Martino, Messina, Italy.'}, {'ForeName': 'Rocco Salvatore', 'Initials': 'RS', 'LastName': 'Calabrò', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy. Electronic address: salbro77@tiscali.it.'}, {'ForeName': 'Rosaria', 'Initials': 'R', 'LastName': 'De Luca', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2021.106828'] 1903,34332159,A randomized crossover trial of HEPA air filtration to reduce cardiovascular risk for near highway residents: Methods and approach.,"BACKGROUND Near highway residents are exposed to elevated levels of traffic-related air pollution (TRAP), including ultrafine particles, which are associated with adverse health effects. The efficacy of using in-home air filtration units that reduce exposure and potentially yield health benefits has not been tested in a randomized controlled trial. METHODS We will conduct a randomized double-blind crossover trial of portable air filtration units for 200 adults 30 years and older who live in near-highway homes in Somerville, MA, USA. We will recruit participants from 172 households. The intervention periods will be one month of true or sham filtration, followed by a one-month wash out period and then a month of the alternate intervention. The primary health outcome will be systolic blood pressure (BP); secondary outcome measures will include diastolic and central BP, C-Reactive Protein (CRP) and D-dimer. Reasons for success or failure of the intervention will be evaluated in a subset of homes using indoor/outdoor monitoring for particulate pollution, personal monitoring, size and composition of particulate pollution, tracking of time spent in the room with the filter, and interviews for qualitative feedback. RESULTS This trial has begun recruitment and is expected to take 2-3 years to be completed. Recruitment has been particularly challenging because of additional precautions required by the COVID-19 pandemic. DISCUSSION This study has the potential to shed light on the value of using portable air filtration in homes close to highways to reduce exposure to TRAP and whether doing so has benefits for cardiovascular health.",2021,"The efficacy of using in-home air filtration units that reduce exposure and potentially yield health benefits has not been tested in a randomized controlled trial. ","['200 adults 30\u202fyears and older who live in near-highway homes in Somerville, MA, USA', 'near highway residents', 'participants from 172 households']","['HEPA air filtration', 'portable air filtration units']","['systolic blood pressure (BP); secondary outcome measures will include diastolic and central BP, C-Reactive Protein (CRP) and D-dimer', 'cardiovascular risk']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0567410', 'cui_str': 'Highway environment'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0020052', 'cui_str': 'Households'}]","[{'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0016107', 'cui_str': 'Filtration'}, {'cui': 'C0439148', 'cui_str': 'Unit'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",,0.189475,"The efficacy of using in-home air filtration units that reduce exposure and potentially yield health benefits has not been tested in a randomized controlled trial. ","[{'ForeName': 'Doug', 'Initials': 'D', 'LastName': 'Brugge', 'Affiliation': 'Department of Public Health Sciences, University of Connecticut, Farmington, CT 06032, United States of America.'}, {'ForeName': 'Shir', 'Initials': 'S', 'LastName': 'Lerman Ginzburg', 'Affiliation': 'UConn Health Department of Public Health Sciences, Farmington, CT 06032., United States of America. Electronic address: sginzburg@uchc.edu.'}, {'ForeName': 'Neelakshi', 'Initials': 'N', 'LastName': 'Hudda', 'Affiliation': 'Department of Civil and Environmental Engineering, Tufts University, Medford, MA, 02476, United States of America.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Sprague Martinez', 'Affiliation': 'Macro Department, Boston University School of Social Work, Boston, MA 02215, United States of America.'}, {'ForeName': 'Leigh', 'Initials': 'L', 'LastName': 'Meunier', 'Affiliation': 'UConn Health Department of Public Health Sciences, Farmington, CT 06032., United States of America.'}, {'ForeName': 'Scott P', 'Initials': 'SP', 'LastName': 'Hersey', 'Affiliation': 'Franklin W. Olin College of Engineering, Needham, MA 02492, United States of America.'}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Hochman', 'Affiliation': 'inTouch Technology Corp., Cambridge, MA 02142, United States of America.'}, {'ForeName': 'Douglas I', 'Initials': 'DI', 'LastName': 'Walker', 'Affiliation': 'Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029l, United States of America.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Echevarria', 'Affiliation': 'Welcome Project, Somerville, MA 02145, United States of America.'}, {'ForeName': 'Mohan', 'Initials': 'M', 'LastName': 'Thanikachalam', 'Affiliation': 'Tufts University School of Medicine, Public Health and Community Medicine, 136 Harrison Avenue, Boston, MA 02111, United States of America.'}, {'ForeName': 'John L', 'Initials': 'JL', 'LastName': 'Durant', 'Affiliation': 'Department of Civil and Environmental Engineering, Tufts University, Medford, MA 02476, United States of America.'}, {'ForeName': 'Wig', 'Initials': 'W', 'LastName': 'Zamore', 'Affiliation': 'Somerville Transportation Equity Partnership, Somerville, MA 02145, United States of America.'}, {'ForeName': 'Misha', 'Initials': 'M', 'LastName': 'Eliasziw', 'Affiliation': 'Department of Public Health and Community Medicine, Tufts University, Boston, MA 02111, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106520'] 1904,34332155,Accelerated theta burst stimulation for the treatment of depression: A randomised controlled trial.,"INTRODUCTION Theta burst pattern repetitive transcranial magnetic stimulation (TBS) is increasingly applied to treat depression. TBS's brevity is well-suited to application in accelerated schedules. Sizeable trials of accelerated TBS are lacking; and optimal TBS parameters such as stimulation intensity are not established. METHODS We conducted a three arm, single blind, randomised, controlled, multi-site trial comparing accelerated bilateral TBS applied at 80 % or 120 % of the resting motor threshold and left unilateral 10 Hz rTMS. 300 patients with treatment-resistant depression (TRD) were recruited. TBS arms applied 20 bilateral prefrontal TBS sessions over 10 days, while the rTMS arm applied 20 daily sessions of 10 Hz rTMS to the left prefrontal cortex over 4 weeks. Primary outcome was depression treatment response at week 4. RESULTS The overall treatment response rate was 43.7 % and the remission rate was 28.2 %. There were no significant differences for response (p = 0.180) or remission (p = 0.316) across the three groups. Response rates between accelerated bilateral TBS applied at sub- and supra-threshold intensities were not significantly different (p = 0.319). Linear mixed model analysis showed a significant effect of time (p < 0.01), but not rTMS type (p = 0.680). CONCLUSION This is the largest accelerated bilateral TBS study to date and provides evidence that it is effective and safe in treating TRD. The accelerated application of TBS was not associated with more rapid antidepressant effects. Bilateral sequential TBS did not have superior antidepressant effect to unilateral 10 Hz rTMS. There was no significant difference in antidepressant efficacy between sub- and supra-threshold accelerated bilateral TBS.",2021,There were no significant differences for response (p = 0.180) or remission (p = 0.316) across the three groups.,"['depression', '300 patients with treatment-resistant depression (TRD) were recruited']","['Accelerated theta burst stimulation', 'TBS', 'accelerated bilateral TBS', 'Theta burst pattern repetitive transcranial magnetic stimulation (TBS']","['antidepressant efficacy', 'remission rate', 'depression treatment response at week 4', 'overall treatment response rate']","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}]","[{'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}]","[{'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",300.0,0.0376243,There were no significant differences for response (p = 0.180) or remission (p = 0.316) across the three groups.,"[{'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare and Department of Psychiatry, Monash University, Camberwell, Victoria, Australia; Monash Alfred Psychiatry Research Centre, Department of Psychiatry, Monash University, Melbourne, Victoria, Australia; Alfred Mental and Addiction Health, Alfred Health, Melbourne, Victoria, Australia. Electronic address: leo.chen@monash.edu.'}, {'ForeName': 'Elizabeth H X', 'Initials': 'EHX', 'LastName': 'Thomas', 'Affiliation': 'Monash Alfred Psychiatry Research Centre, Department of Psychiatry, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Pakin', 'Initials': 'P', 'LastName': 'Kaewpijit', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare and Department of Psychiatry, Monash University, Camberwell, Victoria, Australia; Monash Alfred Psychiatry Research Centre, Department of Psychiatry, Monash University, Melbourne, Victoria, Australia; Bangkok Hospital, Bang Kapi, Bangkok, Thailand.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Miljevic', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare and Department of Psychiatry, Monash University, Camberwell, Victoria, Australia.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Hughes', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare and Department of Psychiatry, Monash University, Camberwell, Victoria, Australia.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Hahn', 'Affiliation': 'The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, South Australia, Australia.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Kato', 'Affiliation': 'The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, South Australia, Australia.'}, {'ForeName': 'Shane', 'Initials': 'S', 'LastName': 'Gill', 'Affiliation': 'The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, South Australia, Australia.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Clarke', 'Affiliation': 'The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, South Australia, Australia.'}, {'ForeName': 'Felicity', 'Initials': 'F', 'LastName': 'Ng', 'Affiliation': 'The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, South Australia, Australia; Discipline of Psychiatry, The University of Adelaide, South Australia, Australia.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Paterson', 'Affiliation': 'The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, South Australia, Australia; Discipline of Psychiatry, The University of Adelaide, South Australia, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Giam', 'Affiliation': 'Central Adelaide Local Health Network, South Australia, Australia.'}, {'ForeName': 'Shanthi', 'Initials': 'S', 'LastName': 'Sarma', 'Affiliation': 'Department of Mental Health, Gold Coast University Hospital, Southport, Queensland, Australia.'}, {'ForeName': 'Kate E', 'Initials': 'KE', 'LastName': 'Hoy', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare and Department of Psychiatry, Monash University, Camberwell, Victoria, Australia.'}, {'ForeName': 'Cherrie', 'Initials': 'C', 'LastName': 'Galletly', 'Affiliation': 'The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, South Australia, Australia; Discipline of Psychiatry, The University of Adelaide, South Australia, Australia; Northern Adelaide Local Health Network, South Australia, Australia.'}, {'ForeName': 'Paul B', 'Initials': 'PB', 'LastName': 'Fitzgerald', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare and Department of Psychiatry, Monash University, Camberwell, Victoria, Australia.'}]",Brain stimulation,['10.1016/j.brs.2021.07.018'] 1905,34334087,Effect of sensorimotor training on spatiotemporal parameters of gait among middle and older age adults with diabetic peripheral neuropathy.,"PURPOSE The study aimed to evaluate the effect of sensorimotor training on spatiotemporal parameters of gait among middle-aged and older adults with diabetic peripheral neuropathy (DPN). METHODS A randomised controlled study with four parallel arms (two intervention groups and two control groups) was conducted. Thirty-seven DPN patients were selected on the basis of inclusion and exclusion criteria. Of these, 16 middle-aged and 21 older adults were randomly allocated to the intervention and control groups. Participants in the intervention group were administered eight weeks (three days/week) of sensorimotor training along with diabetes and foot care education whereas participants in the control group received only diabetes and foot care education. Outcome measures involved spatiotemporal parameters of gait at self-paced and maximal-paced, measured before and after eight weeks. RESULTS Age difference was found to be significant in velocity ( p  ≤ 0.013) and stride length ( p  ≤ 0.017) at self-paced and maximal-paced walking. After the intervention, velocity was found to be a significant group effect and time × group interaction at self-paced ( p  = 0.003) and maximal-paced ( p  = 0.003) walking. Stride length ( p  = 0.006) was found to be a significant group effect and time × group interaction at self-paced only. Cadence ( p  = 0.041) and gait cycle ( p  = 0.05) were found to be significant time × group interaction only at maximal-paced walking. Stance ( p  ≤ 0.047) and double limb support ( p  ≤ 0.02) were found to be significant group effect and time × group interaction at self-paced and maximal-paced walking. CONCLUSION Sensorimotor training improves spatiotemporal parameters of gait after eight weeks in similar fashion in middle-aged and older age DPN patients, regardless of age.",2021,Stride length ( p  = 0.006) was found to be a significant group effect and time × group interaction at self-paced only.,"['16 middle-aged and 21 older adults', 'Thirty-seven DPN patients', 'middle-aged and older age DPN patients', 'middle-aged and older adults with diabetic peripheral neuropathy (DPN', 'gait among middle and older age adults with diabetic peripheral neuropathy']","['Sensorimotor training', 'sensorimotor training', 'sensorimotor training along with diabetes and foot care education whereas participants in the control group received only diabetes and foot care education']","['gait cycle', 'Cadence', 'velocity', 'double limb support', 'Stride length', 'spatiotemporal parameters of gait', 'stride length', 'spatiotemporal parameters of gait at self-paced and maximal-paced']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4319569', 'cui_str': '37'}, {'cui': 'C0740447', 'cui_str': 'Diabetic peripheral neuropathy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231337', 'cui_str': 'Senility'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1161230', 'cui_str': 'Foot care education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}]",37.0,0.0108546,Stride length ( p  = 0.006) was found to be a significant group effect and time × group interaction at self-paced only.,"[{'ForeName': 'Irshad', 'Initials': 'I', 'LastName': 'Ahmad', 'Affiliation': 'Diabetes Research Group, Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'Shalini', 'Initials': 'S', 'LastName': 'Verma', 'Affiliation': 'Diabetes Research Group, Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'Majumi Mohamad', 'Initials': 'MM', 'LastName': 'Noohu', 'Affiliation': 'Diabetes Research Group, Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'Mohd Ejaz', 'Initials': 'ME', 'LastName': 'Hussain', 'Affiliation': 'Diabetes Research Group, Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}]",Somatosensory & motor research,['10.1080/08990220.2021.1955671'] 1906,34333143,Effectiveness of photodynamic therapy on bonding strength and failure modes of fiber-posts in c-shaped treated root canals.,"AIM The present study aimed to assess the push-out bond strength (PBS) and failure modes of fiber-posts after photodynamic therapy (PDT) and Erbium yttrium scandium gallium garnet (Er,Cr:YSGG) in c-shaped canals. METHODS Sixty molars with c-shaped root configuration were studied. The endodontic prepared teeth specimen were equally randomized into four groups: i) photodynamic therapy (PDT); ii) Er,Cr:YSGG; iii) chlorhexidine and; iv) control group. Post root filling, 10 mm space was prepared for insertion of post in the root canals. The push-out bond strength was evaluated using Universal testing machine. Modes of failure were evaluated as adhesive, cohesive and admixed. Mean values were computed between groups using Kruskal-Wallis test followed by Bonferroni post hoc test. Comparison between two thirds of root sections were analyzed using Friedman test. P-value was set at 0.05 or less. RESULTS Specimens treated with PDT reported the highest mean PBS (8.56 ± 2.12 MPa), while the lowest PBS was observed in NaOCl group (6.92 ± 2.21 MPa). Thirteen failures were observed at the adhesive post interface, whereas 22 failures were found at the interface forming between the dentin surface and adhesive. Similarly, 9 failures were categorized as mixed. For PDT group, a sum of 3 failures and 4 failures were noted at the apical and cervical points. CONCLUSION The specimens treated with PDT showed the highest push out bond strength with least number of failures.in c-shaped root canals.",2021,The specimens treated with PDT showed the highest push out bond strength with least number of failures.in c-shaped root canals.,"['Sixty molars with c-shaped root configuration were studied', 'fiber-posts in c-shaped treated root canals']","['photodynamic therapy (PDT); ii', 'photodynamic therapy', 'push-out bond strength (PBS', 'photodynamic therapy (PDT) and Erbium yttrium scandium gallium garnet (Er,Cr:YSGG']","['lowest PBS', 'highest mean PBS', 'Mean values', 'bonding strength and failure modes']","[{'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0449830', 'cui_str': 'With configuration'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332479', 'cui_str': 'Shape finding'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}]","[{'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0580841', 'cui_str': 'Does push'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0014688', 'cui_str': 'Erbium'}, {'cui': 'C0043432', 'cui_str': 'Yttrium'}, {'cui': 'C0036274', 'cui_str': 'Scandium'}, {'cui': 'C0016980', 'cui_str': 'Gallium'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0580841', 'cui_str': 'Does push'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]",60.0,0.0462717,The specimens treated with PDT showed the highest push out bond strength with least number of failures.in c-shaped root canals.,"[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Hashem', 'Affiliation': 'Dental Health Department, College of Applied Medical Sciences, King Saud University, P.O Box 10219, Riyadh 11433, Saudi Arabia. Electronic address: mihashem@ksu.edu.sa.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Altinawi', 'Affiliation': 'Biomedical Technology Department, College of Applied Medical Sciences, King Saud University, P.O Box 10219, Riyadh 11433, Saudi Arabia.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Fouad', 'Affiliation': 'Applied Medical Science Department, CC, King Saud University, P.O Box 10219, Riyadh 11433, Saudi Arabia.'}, {'ForeName': 'Sajith', 'Initials': 'S', 'LastName': 'Vellappally', 'Affiliation': 'Dental Health Department, College of Applied Medical Sciences, King Saud University, P.O Box 10219, Riyadh 11433, Saudi Arabia.'}, {'ForeName': 'Aftab Ahmed', 'Initials': 'AA', 'LastName': 'Khan', 'Affiliation': 'Dental Health Department, College of Applied Medical Sciences, King Saud University, P.O Box 10219, Riyadh 11433, Saudi Arabia.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102469'] 1907,34332547,Central data monitoring in the multicentre randomised SafeBoosC-III trial - a pragmatic approach.,"BACKGROUND Data monitoring of clinical trials is a tool aimed at reducing the risks of random errors (e.g. clerical errors) and systematic errors, which include misinterpretation, misunderstandings, and fabrication. Traditional 'good clinical practice data monitoring' with on-site monitors increases trial costs and is time consuming for the local investigators. This paper aims to outline our approach of time-effective central data monitoring for the SafeBoosC-III multicentre randomised clinical trial and present the results from the first three central data monitoring meetings. METHODS The present approach to central data monitoring was implemented for the SafeBoosC-III trial, a large, pragmatic, multicentre, randomised clinical trial evaluating the benefits and harms of treatment based on cerebral oxygenation monitoring in preterm infants during the first days of life versus monitoring and treatment as usual. We aimed to optimise completeness and quality and to minimise deviations, thereby limiting random and systematic errors. We designed an automated report which was blinded to group allocation, to ease the work of data monitoring. The central data monitoring group first reviewed the data using summary plots only, and thereafter included the results of the multivariate Mahalanobis distance of each centre from the common mean. The decisions of the group were manually added to the reports for dissemination, information, correcting errors, preventing furture errors and documentation. RESULTS The first three central monitoring meetings identified 156 entries of interest, decided upon contacting the local investigators for 146 of these, which resulted in correction of 53 entries. Multiple systematic errors and protocol violations were identified, one of these included 103/818 randomised participants. Accordingly, the electronic participant record form (ePRF) was improved to reduce ambiguity. DISCUSSION We present a methodology for central data monitoring to optimise quality control and quality development. The initial results included identification of random errors in data entries leading to correction of the ePRF, systematic protocol violations, and potential protocol adherence issues. Central data monitoring may optimise concurrent data completeness and may help timely detection of data deviations due to misunderstandings or fabricated data.",2021,Central data monitoring may optimise concurrent data completeness and may help timely detection of data deviations due to misunderstandings or fabricated data.,['preterm infants'],[],[],"[{'cui': 'C0021294', 'cui_str': 'Premature infant'}]",[],[],,0.181333,Central data monitoring may optimise concurrent data completeness and may help timely detection of data deviations due to misunderstandings or fabricated data.,"[{'ForeName': 'Markus Harboe', 'Initials': 'MH', 'LastName': 'Olsen', 'Affiliation': 'Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. oel@oelfam.com.'}, {'ForeName': 'Mathias Lühr', 'Initials': 'ML', 'LastName': 'Hansen', 'Affiliation': 'Department of Neonatology, Juliane Marie Centre, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Sanam', 'Initials': 'S', 'LastName': 'Safi', 'Affiliation': 'Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Janus Christian', 'Initials': 'JC', 'LastName': 'Jakobsen', 'Affiliation': 'Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Gorm', 'Initials': 'G', 'LastName': 'Greisen', 'Affiliation': 'Department of Neonatology, Juliane Marie Centre, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Gluud', 'Affiliation': 'Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC medical research methodology,['10.1186/s12874-021-01344-4'] 1908,34332537,Impacts of tai chi exercise on functional fitness in community-dwelling older adults with mild degenerative knee osteoarthritis: a randomized controlled clinical trial.,"BACKGROUND Degenerative osteoarthritis (OA) often leads to pain and stiffness of the affected joints, which may affect the physical performance and decrease the quality of life of people with degenerative knee OA. Compared to traditional exercise, tai chi is a safe exercise with slow movements which can facilitate physical functioning and psychological well being, and might be suitable for improving the physical activities of older adults with knee OA. Therefore, this study investigated the impacts of tai chi exercise on the functional fitness of community-dwelling older adults with degenerative knee OA. METHODS Sixty-eight community-dwelling older adults with knee OA were recruited from the local community to participate in this randomized controlled clinical trial. All subjects were randomly assigned to either an TCE group that practiced tai chi exercise (TCE) (n = 36) or a control group (CON) (n = 32) that received regular health education programs twice per week for 12 weeks. Outcome measurements were determined using functional fitness tests before and after the intervention, including a 30-s chair stand (number of repeats), 30-s arm-curl (number of repeats), 2-min step (number of steps), chair sit-and-reach (reaching distance, cm), back-scratch flexibility (distance between hands, cm), single-leg stand (time, s), functional reach (reaching distance, cm), 8-foot up-and-go (time, s), and 10-m walk tests (time, s). Pre-post comparisons of functional fitness were analyzed using the ANCOVA test with SPSS software version 18.0. RESULTS Results revealed that participants' functional fitness in the TCE group had significantly higher adjusted mean post-tests scores than that in the CON group after the intervention, including the 8-foot up-and-go (s) (mean difference [MD]=-2.92 [-3.93, -1.91], p = 2.39*10 - 7 ), 30-s arm curl (MD = 4.75 (2.76, 6.73), p = 1.11*10 - 5 ), 2-min step (MD = 36.94 [23.53, 50.36], p = 7.08*10 - 7 ), 30-s chair stand (MD = 4.66 [2.97, 6.36], p = 6.96*10 - 7 ), functional-reach (MD = 5.86 [3.52, 8.20], p = 4.72*10 - 6 ), single-leg stand with eyes closed (MD = 3.44 [1.92, 4.97], p = 2.74*10 - 5 ), chair sit-and-reach (MD = 3.93 [1.72, 6.15], p = 0.001), and single-leg stand with eyes opened (MD = 17.07 [6.29, 27.85], p = 0.002), with large effect sizes (η²=0.14 ~ 0.34). CONCLUSIONS Community-dwelling older adults with knee OA in the TCE group had better functional fitness performances after the 12-week tai chi intervention than those receiving only health education.",2021,"Compared to traditional exercise, tai chi is a safe exercise with slow movements which can facilitate physical functioning and psychological well being, and might be suitable for improving the physical activities of older adults with knee OA.","['older adults with knee OA', 'Sixty-eight community-dwelling older adults with knee OA', 'community-dwelling older adults with mild degenerative knee osteoarthritis', 'people with degenerative knee OA', 'community-dwelling older adults with degenerative knee OA', 'Community-dwelling older adults']","['tai chi exercise', 'regular health education programs', 'TCE', 'TCE group that practiced tai chi exercise (TCE) (n\u2009=\u200936) or a control group (CON', 'CON']","['functional-reach', '30-s chair stand (number of repeats), 30-s arm-curl (number of repeats), 2-min step (number of steps), chair sit-and-reach (reaching distance, cm), back-scratch flexibility (distance between hands, cm), single-leg stand (time, s), functional reach (reaching distance, cm), 8-foot up-and-go (time, s), and 10-m walk tests (time, s). Pre-post comparisons of functional fitness', 'adjusted mean post-tests scores', 'functional fitness performances', 'functional fitness', 'quality of life']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0011164', 'cui_str': 'Degeneration'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0376403', 'cui_str': 'Tai-chi'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1321055', 'cui_str': 'Functional reach'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0010474', 'cui_str': ""Curling's ulcers""}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0311213', 'cui_str': 'Dermatitis verrucosa'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",68.0,0.0335585,"Compared to traditional exercise, tai chi is a safe exercise with slow movements which can facilitate physical functioning and psychological well being, and might be suitable for improving the physical activities of older adults with knee OA.","[{'ForeName': 'Po-Yin', 'Initials': 'PY', 'LastName': 'Chen', 'Affiliation': 'Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Chen-Yi', 'Initials': 'CY', 'LastName': 'Song', 'Affiliation': 'Department of Long-Term Care, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Hsin-Yen', 'Initials': 'HY', 'LastName': 'Yen', 'Affiliation': 'School of Gerontology Health Management, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Pi-Chu', 'Initials': 'PC', 'LastName': 'Lin', 'Affiliation': 'Master Program in Long-Term Care, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Su-Ru', 'Initials': 'SR', 'LastName': 'Chen', 'Affiliation': 'Post-Baccalaureate Program in Nursing and School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Liang-Hsuan', 'Initials': 'LH', 'LastName': 'Lu', 'Affiliation': 'Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Chen-Li', 'Initials': 'CL', 'LastName': 'Tien', 'Affiliation': 'School of Gerontology Health Management, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Xin-Miao', 'Initials': 'XM', 'LastName': 'Wang', 'Affiliation': 'Faculty of Humanities, Zhejiang Dong Fang Polytechnic Collage, Wenzhou, China.'}, {'ForeName': 'Chueh-Ho', 'Initials': 'CH', 'LastName': 'Lin', 'Affiliation': 'Master Program in Long-Term Care, College of Nursing, Taipei Medical University, 250 Wu-Xing Street, 11031, Taipei, Taiwan, Republic of China. chueh.ho@tmu.edu.tw.'}]",BMC geriatrics,['10.1186/s12877-021-02390-9'] 1909,34347542,Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.,"PURPOSE AcSé-ESMART is a proof-of-concept, phase I or II, platform trial, designed to explore targeted agents in a molecularly enriched cancer population. Arms A and B aimed to define the recommended phase II dose and activity of the CDK4/6 inhibitor ribociclib with topotecan and temozolomide (TOTEM) or everolimus, respectively, in children with recurrent or refractory malignancies. PATIENTS AND METHODS Ribociclib was administered orally once daily for 16 days after TOTEM for 5 days (arm A) or for 21 days with everolimus orally once daily continuously in a 28-day cycle (arm B). Dose escalation followed the continuous reassessment method, and activity assessment the Ensign design. Arms were enriched on the basis of molecular alterations in the cell cycle or PI3K/AKT/mTOR pathways. RESULTS Thirty-two patients were included, 14 in arm A and 18 in arm B, and 31 were treated. Fourteen patients had sarcomas (43.8%), and 13 brain tumors (40.6%). Main toxicities were leukopenia, neutropenia, and lymphopenia. The recommended phase II dose was ribociclib 260 mg/m 2 once a day, temozolomide 100 mg/m 2 once a day, and topotecan 0.5 mg/m 2 once a day (arm A) and ribociclib 175 mg/m 2 once a day and everolimus 2.5 mg/m 2 once a day (arm B). Pharmacokinetic analyses confirmed the drug-drug interaction of ribociclib on everolimus exposure. Two patients (14.3%) had stable disease as best response in arm A, and seven (41.2%) in arm B, including one patient with T-acute lymphoblastic leukemia with significant blast count reduction. Alterations considered for enrichment were present in 25 patients (81%) and in eight of nine patients with stable disease; the leukemia exhibited CDKN2A/B and PTEN deficiency. CONCLUSION Ribociclib in combination with TOTEM or everolimus was well-tolerated. The observed activity signals initiated a follow-up study of the ribociclib-everolimus combination in a population enriched with molecular alterations within both pathways.",2021,"Alterations considered for enrichment were present in 25 patients (81%) and in eight of nine patients with stable disease; the leukemia exhibited CDKN2A/B and PTEN deficiency. ","['Thirty-two patients were included, 14 in arm A and 18 in arm B, and 31 were treated', 'children with recurrent or refractory malignancies', 'Fourteen patients had sarcomas (43.8%), and 13 brain tumors (40.6', 'Children With Advanced Malignancies']","['ribociclib 175 mg/m 2 once a day and everolimus', 'temozolomide', 'everolimus', 'Ribociclib in combination with TOTEM or everolimus', 'Ribociclib in Combination With Topotecan-Temozolomide or Everolimus', 'CDK4/6 inhibitor ribociclib with topotecan and temozolomide (TOTEM) or everolimus']","['Main toxicities were leukopenia, neutropenia, and lymphopenia']","[{'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C1261473', 'cui_str': 'Sarcoma'}, {'cui': 'C0006118', 'cui_str': 'Neoplasm of brain'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}]","[{'cui': 'C4045494', 'cui_str': 'ribociclib'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0076080', 'cui_str': 'temozolomide'}, {'cui': 'C0146224', 'cui_str': 'Topotecan'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0024312', 'cui_str': 'Lymphocytopenia'}]",32.0,0.019189,"Alterations considered for enrichment were present in 25 patients (81%) and in eight of nine patients with stable disease; the leukemia exhibited CDKN2A/B and PTEN deficiency. ","[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Bautista', 'Affiliation': 'Hospital Niño Jesús, Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Madrid, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Paoletti', 'Affiliation': 'Gustave Roussy Cancer Campus, Biostatistics and Epidemiology Unit, INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, France.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Rubino', 'Affiliation': 'Gustave Roussy Cancer Campus, Clinical Research Direction, Villejuif, France.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Brard', 'Affiliation': 'Gustave Roussy Cancer Campus, Biostatistics and Epidemiology Unit, INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, France.'}, {'ForeName': 'Keyvan', 'Initials': 'K', 'LastName': 'Rezai', 'Affiliation': 'Institut Curie, Radio-Pharmacology Department, Saint Cloud, France.'}, {'ForeName': 'Souad', 'Initials': 'S', 'LastName': 'Nebchi', 'Affiliation': 'Gustave Roussy Cancer Campus, Biostatistics and Epidemiology Unit, INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Andre', 'Affiliation': 'Department of Pediatric Oncology, Hôpital de la Timone, AP-HM, Marseille, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Aerts', 'Affiliation': 'SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Institut Curie, PSL Research University, Paris, France.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'De Carli', 'Affiliation': 'Department of Pediatric Oncology, University Hospital, Angers, France.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'van Eijkelenburg', 'Affiliation': 'Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.'}, {'ForeName': 'Estelle', 'Initials': 'E', 'LastName': 'Thebaud', 'Affiliation': 'Department of Pediatric Oncology, Centre Hospitalier Universitaire, Nantes, France.'}, {'ForeName': 'Nadege', 'Initials': 'N', 'LastName': 'Corradini', 'Affiliation': 'Pediatric Oncology Department, Institut of Pediatric Hematology and Oncology, Centre Leon Berard, Lyon, France.'}, {'ForeName': 'Anne-Sophie', 'Initials': 'AS', 'LastName': 'Defachelles', 'Affiliation': 'Department of Pediatric Oncology, Oscar Lambret Cancer Center, Lille, France.'}, {'ForeName': 'Stephane', 'Initials': 'S', 'LastName': 'Ducassou', 'Affiliation': 'Centre Hospitalier Universitaire Pellegrin-Hôpital des Enfants, Bordeaux, France.'}, {'ForeName': 'Raphael J', 'Initials': 'RJ', 'LastName': 'Morscher', 'Affiliation': 'Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Vassal', 'Affiliation': 'Gustave Roussy Cancer Campus, Clinical Research Direction, Villejuif, France.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Geoerger', 'Affiliation': 'Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.21.01152'] 1910,34351285,Norm proximity and optimal social comparisons for energy conservation behavior.,"Bottom-up solutions targeting individual energy conservation behaviors can play an important role in mitigating climate change and other environmental problems. Information interventions using social comparisons have proven generally effective at improving conservation behaviors, yet are largely suboptimal and sometimes fail when not adequately designed for their specific context. Environmental managers and policy makers need guidance on behavioral intervention design to maximize effectiveness. This article reports the results of a randomized control trial field experiment that used social comparisons to influence individual electricity conservation behaviors in a unique experimental setting with homogeneous residential units and no economic incentive for subjects to conserve. Two treatment groups receiving information feedback with different social comparison reference points exhibited an average treatment effect of 6 % relative to a control group that did not receive feedback. Moreover, treated subjects whose baseline behavior was more proximate to their relevant comparison group norm exhibited stronger response to the treatment (greater than 10 %) than treated subjects whose baseline behavior was more distant from the relevant norm. These results demonstrate that individuals may be more responsive to social norms when provided with a relevant norm that is more proximate to their baseline behavior. Our findings have important practical implications for optimal design and implementation of behavioral interventions to improve environmental management and achieve energy policy goals.",2021,Bottom-up solutions targeting individual energy conservation behaviors can play an important role in mitigating climate change and other environmental problems.,[],['control group that did not receive feedback'],[],[],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]",[],,0.00911622,Bottom-up solutions targeting individual energy conservation behaviors can play an important role in mitigating climate change and other environmental problems.,"[{'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Callery', 'Affiliation': 'Bren School of Environmental Science & Management, University of California, Santa Barbara, CA, 93106, USA; Department of Economics, University of California, Santa Barbara, CA, 93106, USA. Electronic address: patrick.callery@carleton.ca.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Goodwin', 'Affiliation': 'Department of Economics, University of California, Santa Barbara, CA, 93106, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Moncayo', 'Affiliation': 'Department of Economics, University of California, Santa Barbara, CA, 93106, USA.'}]",Journal of environmental management,['10.1016/j.jenvman.2021.113332'] 1911,34331678,"Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.","BACKGROUND AND OBJECTIVE Daridorexant is a new dual orexin receptor antagonist currently in late-stage clinical development for the treatment of insomnia. This randomized, double-blind, placebo-controlled, four-period crossover study investigated the effect of daridorexant at a therapeutic and supratherapeutic dose on QT interval duration. METHODS Thirty-six healthy subjects received single oral doses of daridorexant (50 mg; 200 mg), moxifloxacin (400 mg; open label), and placebo. All treatments were administered at bedtime to mimic therapeutic practice. The primary analysis was based on linear mixed-effects concentration-QT modelling. Triplicate ECG data were extracted from Holter recordings at baseline and until 24 h post dosing at time points matching those for pharmacokinetic sampling. Plasma concentrations of daridorexant were determined over 24 h. RESULTS Assay sensitivity was demonstrated based on mean baseline- and placebo-corrected QT interval using Fridericia's formula (ΔΔQTcF) > 5 ms following moxifloxacin administration (p < 0.01). Following daridorexant administration, mean (90% confidence interval, CI) ΔΔQTcF was 1.40 ms (0.48; 2.32 ms) and 1.84 ms (-0.12; 3.79 ms) at the C max of 747 ng/mL (50 mg dose) and 1809 ng/mL (200 mg dose), respectively, i.e., the upper bounds of the CIs were < 10 ms defined as threshold of regulatory concern. Lack of relevant QT prolongation was confirmed by secondary by-time point analysis and absence of relevant findings in the categorical outlier analysis. Daridorexant was safe and well tolerated and its pharmacokinetics were consistent with previous data. CONCLUSION Daridorexant does not impair cardiac repolarization evidenced by absence of relevant QT prolongation at therapeutic and supratherapeutic doses. Clinical Trials Registration ID: NCT04250506.",2021,"CONCLUSION Daridorexant does not impair cardiac repolarization evidenced by absence of relevant QT prolongation at therapeutic and supratherapeutic doses.",['Thirty-six healthy subjects'],"['moxifloxacin (400\xa0mg; open label), and placebo', 'Daridorexant, a Dual Orexin Receptor Antagonist', 'daridorexant', 'placebo', 'Daridorexant', 'moxifloxacin']","['Assay sensitivity', 'Plasma concentrations of daridorexant', 'safe and well tolerated and its pharmacokinetics', 'Cardiac Repolarization', 'Lack of relevant QT prolongation', 'cardiac repolarization']","[{'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4046055', 'cui_str': 'Dual Orexin Receptor Antagonists'}]","[{'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}, {'cui': 'C0151878', 'cui_str': 'Prolonged QT interval'}]",36.0,0.376398,"CONCLUSION Daridorexant does not impair cardiac repolarization evidenced by absence of relevant QT prolongation at therapeutic and supratherapeutic doses.","[{'ForeName': 'Uta', 'Initials': 'U', 'LastName': 'Schilling', 'Affiliation': 'Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Henrich', 'Affiliation': 'Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'Muehlan', 'Affiliation': 'Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Krause', 'Affiliation': 'Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland.'}, {'ForeName': 'Jasper', 'Initials': 'J', 'LastName': 'Dingemanse', 'Affiliation': 'Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland. jasper.dingemanse@idorsia.com.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Ufer', 'Affiliation': 'Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland.'}]",Clinical drug investigation,['10.1007/s40261-021-01062-1'] 1912,34331676,Impact of probiotics supplement on the gut microbiota in neonates with antibiotic exposure: an open-label single-center randomized parallel controlled study.,"BACKGROUND Antibiotics, a common strategy used for neonatal infection, show consistent effect on the gut microbiota of neonates. Supplementation with probiotics has become increasingly popular in mitigating the loss of the gut microbiota. However, no clear consensus recommending the use of probiotics in the infection of neonates currently exists. This study examined the effects of probiotics on the gut microbiota of infectious neonates when used concurrently with or during the recovery period following antibiotic therapy. METHODS Fifty-five full-term neonates diagnosed with neonatal infections were divided into the following groups: NI (no intervention, antibiotic therapy only), PCA (probiotics used concurrently with antibiotics), and PAA (probiotics used after antibiotics). The NI group received antibiotic treatment (piperacillin-tazobactam) for 1 week and the PCA group received antibiotic treatment together with probiotics (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis) for 1 week. The PAA group received antibiotic treatment for 1 week followed by probiotics for 1 week. Fecal samples were collected at four time nodes: newborn, 1 week, 2 weeks, and 42 days after birth. The composition of the gut microbiota was determined by the high-throughput sequencing of 16S rRNA amplicons. RESULTS Antibiotic exposure was found to dramatically alter gut microbiota, with a significant decrease of Bifidobacterium and Lactobacillus. The use of probiotics did not restore the overall diversity of the gut microbiota. However, using probiotics simultaneously with the antibiotics was found to be beneficial for the gut microbiota as compared to delaying the use of probiotics to follow treatment with antibiotics, particularly in promoting the abundance of Bifidobacterium. CONCLUSIONS These results suggest that the early use of probiotics may have a potential ability to remodel the gut microbiota during recovery from antibiotic treatment. However, further study is required to fully understand the long-term effects including the clinical benefits.",2021,"RESULTS Antibiotic exposure was found to dramatically alter gut microbiota, with a significant decrease of Bifidobacterium and Lactobacillus.","['neonates with antibiotic exposure', 'Fifty-five full-term neonates diagnosed with neonatal infections']","['NI (no intervention, antibiotic therapy only), PCA (probiotics used concurrently with antibiotics), and PAA (probiotics used after antibiotics', 'antibiotic treatment (piperacillin-tazobactam', 'probiotics', 'probiotics supplement', 'antibiotic treatment together with probiotics (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis']","['Bifidobacterium and Lactobacillus', 'gut microbiota']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0450382', 'cui_str': '55'}, {'cui': 'C4551581', 'cui_str': 'Term baby'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0854706', 'cui_str': 'Neonatal infection'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0030131', 'cui_str': 'p-Chloramphetamine'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0267964', 'cui_str': 'Pancreatic acinar atrophy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0250480', 'cui_str': 'Piperacillin and tazobactam'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0314977', 'cui_str': 'Bifidobacterium longum'}, {'cui': 'C0022939', 'cui_str': 'Lactobacillus acidophilus'}, {'cui': 'C0085494', 'cui_str': 'Genus Enterococcus'}]","[{'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}]",55.0,0.0155989,"RESULTS Antibiotic exposure was found to dramatically alter gut microbiota, with a significant decrease of Bifidobacterium and Lactobacillus.","[{'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhong', 'Affiliation': ""Department of Pediatrics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Middle Yanchang Road, Shanghai, China.""}, {'ForeName': 'Xiang-Geng', 'Initials': 'XG', 'LastName': 'Wang', 'Affiliation': ""Department of Pediatrics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Middle Yanchang Road, Shanghai, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Pediatrics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Middle Yanchang Road, Shanghai, China.""}, {'ForeName': 'Yan-Jie', 'Initials': 'YJ', 'LastName': 'Chen', 'Affiliation': ""Department of Pediatrics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Middle Yanchang Road, Shanghai, China.""}, {'ForeName': 'Huan-Long', 'Initials': 'HL', 'LastName': 'Qin', 'Affiliation': 'Institute for Intestinal Diseases, Tongji University School of Medicine, No. 301 Middle Yanchang Road, Shanghai, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Yang', 'Affiliation': ""Department of Pediatrics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Middle Yanchang Road, Shanghai, China. yangrongtongji@163.com.""}]",World journal of pediatrics : WJP,['10.1007/s12519-021-00443-y'] 1913,34332023,Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: Extension phase of the GERIA-COVID study.,"BACKGROUND The objective of this extension phase of the quasi-experimental GERIA-COVID study was to determine whether vitamin D3 supplementation taken prior to or during COVID-19 was associated with better 3-month survival in geriatric patients hospitalized for COVID-19. METHODS Intervention group was defined as all participants supplemented with vitamin D3 prior to or during COVID-19 (n = 67). Supplements were either bolus vitamin D3 (ie, 50,000 IU per month, or 80,000 IU or 100,000 IU or 200,000 IU every 2-3 months), or daily supplementation with 800 IU. Comparator group involved those without vitamin D supplements (n = 28). Outcome was 3-month mortality. Covariables were age, sex, functional abilities, history of malignancies, cardiomyopathy, undernutrition, number of acute health issues, antibiotics use, systemic corticosteroids use, and 25(OH)D concentration. RESULTS 76.1 % (n = 51) of participants survived at 3 months in Intervention group, compared to only 53.6 % (n = 15) in Comparator group (P = 0.03). The fully-adjusted hazard ratio for 3-month mortality was HR = 0.23 [95 %CI: 0.09;0.58](P = 0.002) in Intervention group compared to Comparator group. Intervention group had also longer survival time (log-rank P = 0.008). CONCLUSIONS Vitamin D3 supplementation was associated with better 3-month survival in older COVID-19 patients.",2021,"RESULTS 76.1% (n = 51) of participants survived at 3 months in Intervention group, compared to only 53.6% (n = 15) in Comparator group (P = 0.03).","['older COVID-19 patients', 'geriatric patients', 'geriatric patients hospitalized for COVID-19']","['bolus vitamin D3', 'vitamin D3 supplementation', 'Vitamin D3 supplementation', 'Vitamin D supplementation', 'vitamin D supplements', 'vitamin D3 prior to or during COVID-19']","['3-month mortality', '3-month survival', 'longer survival time']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}]",,0.199593,"RESULTS 76.1% (n = 51) of participants survived at 3 months in Intervention group, compared to only 53.6% (n = 15) in Comparator group (P = 0.03).","[{'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Annweiler', 'Affiliation': 'School of Medicine, Health Faculty, University of Angers, Angers, France; Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France; UPRES EA 4638, University of Angers, Angers, France; Gérontopôle Autonomie Longévité des Pays de la Loire, France; Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, ON, Canada. Electronic address: Cedric.Annweiler@chu-angers.fr.'}, {'ForeName': 'Mélinda', 'Initials': 'M', 'LastName': 'Beaudenon', 'Affiliation': 'Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Simon', 'Affiliation': 'Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France.'}, {'ForeName': 'Mialy', 'Initials': 'M', 'LastName': 'Guenet', 'Affiliation': 'Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Otekpo', 'Affiliation': 'Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Célarier', 'Affiliation': 'Department of Clinical Gerontology, University Hospital of Saint-Etienne, Saint-Etienne, France; Chaire Santé des Ainés, University of Jean Monnet, Saint-Etienne, France; Gérontopôle Auvergne-Rhône-Alpes, Saint-Etienne, France.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Gautier', 'Affiliation': 'Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of steroid biochemistry and molecular biology,['10.1016/j.jsbmb.2021.105958'] 1914,34331964,The response to prolonged fasting in hypothalamic serotonin transporter availability is blunted in obesity.,"BACKGROUND AND AIMS Serotonergic and dopaminergic systems in the brain are essential for homeostatic and reward-associated regulation of food intake and systemic energy metabolism. It is largely unknown how fasting influences these systems or if such effects are altered in humans with obesity. We therefore aimed to evaluate the effects of fasting on hypothalamic/thalamic serotonin transporter (SERT) and striatal dopamine transporter (DAT) availability in lean subjects and subjects with obesity. METHODS In this randomized controlled cross-over trial, we assessed the effects of 12 vs 24 h of fasting on SERT and DAT availability in the hypothalamus/thalamus and striatum, respectively, using SPECT imaging in 10 lean men and 10 men with obesity. RESULTS As compared with the 12-h fast, a 24-h fast increased hypothalamic SERT availability in lean men, but not in men with obesity. We observed high inter-individual variation in the effects of fasting on thalamic SERT and striatal DAT, with no differences between lean men and those with obesity. In all subjects, fasting-induced increases in circulating free fatty acid (FFA) concentrations were associated with an increase in hypothalamic SERT availability and a decrease in striatal DAT availability. Multiple regression analysis showed that changes in plasma insulin and FFAs together accounted for 44% of the observed variation in striatal DAT availability. CONCLUSION Lean men respond to prolonged fasting by increasing hypothalamic SERT availability, whereas this response is absent in men with obesity. Inter-individual differences in the adaptations of the cerebral serotonergic and dopaminergic systems to fasting may, in part, be explained by changes in peripheral metabolic signals of fasting, including FFAs and insulin.",2021,"In all subjects, fasting-induced increases in circulating free fatty acid (FFA) concentrations were associated with an increase in hypothalamic SERT availability and a decrease in striatal DAT availability.","['10 lean men and 10 men with obesity', 'men with obesity', 'humans with obesity', 'lean subjects and subjects with obesity', 'lean men', 'Lean men']",[],"['striatal DAT availability', 'hypothalamic SERT availability', 'circulating free fatty acid (FFA) concentrations', 'plasma insulin and FFAs']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]",[],"[{'cui': 'C0114838', 'cui_str': 'Dopamine Transporter'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0020663', 'cui_str': 'Hypothalamic structure'}, {'cui': 'C0170657', 'cui_str': 'Serotonin Transporter'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}]",10.0,0.0466575,"In all subjects, fasting-induced increases in circulating free fatty acid (FFA) concentrations were associated with an increase in hypothalamic SERT availability and a decrease in striatal DAT availability.","[{'ForeName': 'Katy A', 'Initials': 'KA', 'LastName': 'van Galen', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Booij', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Anouk', 'Initials': 'A', 'LastName': 'Schrantee', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Sofie M', 'Initials': 'SM', 'LastName': 'Adriaanse', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Unga A', 'Initials': 'UA', 'LastName': 'Unmehopa', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Fliers', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Gary J', 'Initials': 'GJ', 'LastName': 'Schwartz', 'Affiliation': 'Fleischer Institute for Diabetes and Metabolism, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Ralph J', 'Initials': 'RJ', 'LastName': 'DiLeone', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Kasper W', 'Initials': 'KW', 'LastName': 'Ter Horst', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Susanne E', 'Initials': 'SE', 'LastName': 'la Fleur', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands; Laboratory of Endocrinology, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; Netherlands Institute for Neuroscience, An Institute of the Royal Netherlands Academy of Arts and Sciences (KNAW), Amsterdam, the Netherlands.'}, {'ForeName': 'Mireille J', 'Initials': 'MJ', 'LastName': 'Serlie', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands. Electronic address: m.j.serlie@amsterdamumc.nl.'}]",Metabolism: clinical and experimental,['10.1016/j.metabol.2021.154839'] 1915,34334431,Efficacy and safety of onabotulinumtoxinA with standardized occupational therapy for treatment of pediatric upper limb spasticity: Phase III placebo-controlled randomized trial.,"BACKGROUND This is the first large study of onabotulinumtoxinA as treatment for pediatric upper limb spasticity. OBJECTIVE Evaluate efficacy and safety of a single treatment with onabotulinumtoxinA plus occupational therapy (OT). METHODS In this registrational phase III, multinational study (NCT01603602), participants were randomized 1:1:1 to onabotulinumtoxinA 3 U/kg/OT, 6 U/kg/OT, or placebo/OT. Primary endpoint was average change from baseline at weeks 4 and 6 in Modified Ashworth Scale-Bohannon (MAS) score. Secondary endpoints included Modified Tardieu Scale (MTS), Clinical Global Impression of Change (CGI) and functional Goal Attainment Scale (GAS). RESULTS 235 participants were randomized. At weeks 4 and 6, onabotulinumtoxinA groups had greater mean reductions in MAS (both -1.9; p < 0.001) versus placebo (-1.2). OnabotulinumtoxinA doses improved dynamic tone per MTS. Mean CGI at weeks 4 and 6 was unchanged in the overall population, but improved in a post hoc analysis of patients with a single affected upper limb (UL) muscle group (elbow or wrist). GAS score for passive goals was significantly higher for 6 U/kg versus placebo at week 12. Most AEs were mild/moderate in severity; overall incidence was similar between groups. CONCLUSIONS OnabotulinumtoxinA (3 and 6 U/kg) was safe and effective in reducing upper limb spasticity in pediatric participants.",2021,"Mean CGI at weeks 4 and 6 was unchanged in the overall population, but improved in a post hoc analysis of patients with a single affected UL muscle group (elbow or wrist).","['pediatric upper limb spasticity', 'pediatric participants', '235 participants were randomized']","['onabotulinumtoxinA 3\u200aU/kg/OT, 6\u200aU/kg/OT, or placebo/OT', 'OnabotulinumtoxinA', 'onabotulinumtoxinA plus occupational therapy (OT', 'onabotulinumtoxinA', 'placebo', 'onabotulinumtoxinA with standardized occupational therapy']","['GAS score for passive goals', 'Modified Tardieu Scale (MTS), Clinical Global Impression of Change (CGI) and functional Goal Attainment Scale (GAS', 'Mean CGI', 'Efficacy and safety', 'upper limb spasticity', 'mean reductions in MAS', 'average change from baseline at weeks 4 and 6 in Modified Ashworth Scale-Bohannon (MAS) score', 'dynamic tone per MTS']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C1273957', 'cui_str': 'Upper limb spasticity'}]","[{'cui': 'C2719767', 'cui_str': 'OnabotulinumtoxinA'}, {'cui': 'C1300561', 'cui_str': 'U/kg'}, {'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1273957', 'cui_str': 'Upper limb spasticity'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}]",235.0,0.446402,"Mean CGI at weeks 4 and 6 was unchanged in the overall population, but improved in a post hoc analysis of patients with a single affected UL muscle group (elbow or wrist).","[{'ForeName': 'Rozalina', 'Initials': 'R', 'LastName': 'Dimitrova', 'Affiliation': 'Allergan, an AbbVie company, Irvine, CA, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'McCusker', 'Affiliation': 'Allergan, an AbbVie company, Irvine, CA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Gormley', 'Affiliation': ""Gillette Children's Specialty Healthcare, St Paul, MN, USA.""}, {'ForeName': 'Darcy', 'Initials': 'D', 'LastName': 'Fehlings', 'Affiliation': 'Holland Bloorview Kids Rehab Hospital, Department of Paediatrics, Toronto, ON, Canada.'}, {'ForeName': 'Katharine E', 'Initials': 'KE', 'LastName': 'Alter', 'Affiliation': 'Mount Washington Pediatric Hospital, Baltimore, MD, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Greaves', 'Affiliation': ""The Royal Children's Hospital, Melbourne, Victoria, Australia.""}, {'ForeName': 'Chengcheng', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Allergan, an AbbVie company, Madison, NJ, USA.'}, {'ForeName': 'Mitchell F', 'Initials': 'MF', 'LastName': 'Brin', 'Affiliation': 'Allergan, an AbbVie company, Irvine, CA, USA.'}]",NeuroRehabilitation,['10.3233/NRE-210071'] 1916,34333820,Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer.,"LESSONS LEARNED Limited evidence suggests an acceptable pharmacokinetic profile when enzalutamide is administered via a liquid formulation extracted from the commercially available liquid-filled soft-gelatin capsules. Tolerability may limit use in clinical practice. BACKGROUND Enzalutamide is an established standard-of-care treatment for advanced prostate cancer with a commercially available formulation that may be inconvenient for some patients. We proposed a study to evaluate the bioequivalence of a liquid formulation to provide an alternative method of administration. METHODS This was a single-dose, randomized, open-label, two-way crossover pilot bioequivalence study to compare two oral formulations of enzalutamide: four enzalutamide 40 mg liquid-filled soft-gelatin capsules (commercially available) administered whole versus enzalutamide 160 mg liquid (extracted from capsules) administered via oral syringe. To assess bioequivalence, patients were randomized to receive a single dose of one formulation, then cross over to receive the alternative formulation following a 42-day washout period; serial plasma samples were collected over the course of 24 hours, followed by collections at 3, 8, and 42 days after the dose for both formulations. Bioequivalence of the formulations was assessed via comparisons of area under the plasma concentration-time curve (AUC) calculations per U.S. Food and Drug Administration (FDA) guidance. The study also assessed the safety and tolerability of the formulations. RESULTS The study failed to meet proposed accrual, with only one patient enrolled, thus limiting the bioequivalence evaluation. Based on the data from a single patient, the drug exposure (measured by AUC) of enzalutamide and N-desmethyl enzalutamide (primary active metabolite) for the liquid formulation was 112% and 117%, respectively, compared with the capsule formulation. Although both formulations appeared well tolerated with no adverse events reported, the tolerability assessment questionnaire revealed an unpleasant taste of the liquid formulation. CONCLUSION Preliminary evidence suggests a similar pharmacokinetic profile when administering liquid extracted from enzalutamide soft-gelatin capsules compared with intact capsules in patients with prostate cancer.",2021,"Although both formulations appeared well tolerated with no adverse events reported, the tolerability assessment questionnaire revealed an unpleasant taste of the liquid formulation. ","['advanced prostate cancer', 'patients with prostate cancer', 'Prostate Cancer']","['enzalutamide', 'enzalutamide 40 mg liquid-filled soft-gelatin capsules (commercially available) administered whole versus enzalutamide 160 mg liquid (extracted from capsules) administered via oral syringe', 'Enzalutamide']","['plasma concentration-time curve (AUC) calculations per U.S. Food and Drug Administration (FDA) guidance', 'tolerability assessment questionnaire', 'safety and tolerability']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C3496794', 'cui_str': 'enzalutamide 40 MG'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0017237', 'cui_str': 'Gelatin'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0039142', 'cui_str': 'Syringe'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1441506', 'cui_str': 'Calculation technique'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0041714', 'cui_str': 'United States Food, Drug Administration'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0705514,"Although both formulations appeared well tolerated with no adverse events reported, the tolerability assessment questionnaire revealed an unpleasant taste of the liquid formulation. ","[{'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Cordes', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Keith T', 'Initials': 'KT', 'LastName': 'Schmidt', 'Affiliation': 'Clinical Pharmacology Program, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Cody J', 'Initials': 'CJ', 'LastName': 'Peer', 'Affiliation': 'Clinical Pharmacology Program, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Cindy H', 'Initials': 'CH', 'LastName': 'Chau', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Redmond', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Deneise', 'Initials': 'D', 'LastName': 'Francis', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Karzai', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Ravi A', 'Initials': 'RA', 'LastName': 'Madan', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Figg', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.'}]",The oncologist,['10.1002/onco.13919'] 1917,34333414,"Body Positivity, but not for everyone: The role of model size in exposure effects on women's mood, body satisfaction, and food choice.","Body Positivity (or 'BoPo') social media content may be beneficial for women's mood and body image, but concerns have been raised that it may reduce motivation for healthy behaviours. This study examines differences in women's mood, body satisfaction, and hypothetical food choices after viewing BoPo posts (featuring average or larger women) or a neutral travel control. Women (N = 167, 81.8 % aged 18-29) were randomly assigned in an online experiment to one of three conditions (BoPo-average, BoPo-larger, or Travel/Control) and viewed three Instagram posts for two minutes, before reporting their mood and body satisfaction, and selecting a meal from a hypothetical menu. Women who viewed the BoPo posts featuring average-size women reported more positive mood than the control group; women who viewed posts featuring larger women did not. There were no effects of condition on negative mood or body satisfaction. Women did not make less healthy food choices than the control in either BoPo condition; women who viewed the BoPo images of larger women showed a stronger association between hunger and calories selected. These findings suggest that concerns over BoPo promoting unhealthy behaviours may be misplaced, but further research is needed regarding women's responses to different body sizes.",2021,Women did not make less healthy food choices than the control in either BoPo condition; women who viewed the BoPo images of larger women showed a stronger association between hunger and calories selected.,"['Women who viewed the BoPo posts featuring average-size women', 'Women (N = 167, 81.8 % aged 18-29', ""women's mood, body satisfaction, and hypothetical food choices after viewing BoPo posts (featuring average or larger women) or a neutral travel control""]",[],"['negative mood or body satisfaction', 'positive mood']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0040802', 'cui_str': 'Travel'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",,0.0168191,Women did not make less healthy food choices than the control in either BoPo condition; women who viewed the BoPo images of larger women showed a stronger association between hunger and calories selected.,"[{'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Simon', 'Affiliation': 'Bariatric Surgery, Chelsea & Westminster Hospital, 369 Fulham Rd, Chelsea, London, SW10 9NH, UK.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Hurst', 'Affiliation': 'School of Psychology, University of Sussex, Falmer, Brighton, BN1 9QH, UK. Electronic address: m.hurst@sussex.ac.uk.'}]",Body image,['10.1016/j.bodyim.2021.07.001'] 1918,34333391,The effect of milk and rapeseed protein on growth factors in 7-8 year-old healthy children - A randomized controlled trial.,"OBJECTIVE Milk protein may stimulate linear growth through insulin-like growth factor-1 (IGF-1). However, the effect of plant proteins on growth factors is largely unknown. This study assesses the effect of combinations of milk and rapeseed protein versus milk protein alone on growth factors in children. DESIGN An exploratory 3-armed randomized, double-blind, controlled trial was conducted in 129 healthy 7-8 year-old Danish children. Children received 35 g milk and rapeseed protein (ratio 54:46 or 30:70) or 35 g milk protein per day for 4 weeks. The primary outcome was difference in IGF-1 changes between intervention groups after 4 weeks. Secondary outcomes included changes in IGF-1 after 1 week and changes in insulin-like growth factor binding protein-3 (IGFBP-3), IGF-1/IGFBP-3, insulin, height, weight and body composition after 1 and 4 weeks. Results were analysed by multiple linear mixed-effect models. RESULTS There were no differences in changes of plasma IGF-1, insulin-like growth factor binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio or insulin between groups after 1 or 4 weeks based on 89 complete cases (P > 0.10). IGF-1 increased by 13.7 (95% CI 9.7;17.7) ng/mL and 18.0 (14.0;22.0) ng/mL from baseline to week 1 and 4, respectively, a 16% increase during the intervention. Similarly, insulin increased by 31% (14; 50) and 33% (16; 53) from baseline to week 1 and 4. Fat-free mass index (FFMI) increments were higher with milk alone than rapeseed blends (P < 0.05), coinciding with a trend towards a lower height increment. Body mass index increased within all groups (P < 0.05), mainly due to an increase in FFMI (P < 0.01). CONCLUSION There were no differences in changes of growth factors between the combinations of milk and rapeseed protein and milk protein alone in healthy, well-nourished children with a habitual intake of milk. Within groups, growth factors increased considerably. Future studies are needed to investigate how intakes of plant and animal proteins affect childhood growth.",2021,"Body mass index increased within all groups (P < 0.05), mainly due to an increase in FFMI (P ","['children', '7-8\xa0year-old healthy children', '129 healthy 7-8\xa0year-old Danish children']","['milk and rapeseed protein', '35\xa0g milk and rapeseed protein (ratio 54:46 or 30:70) or 35\xa0g milk protein', 'milk and rapeseed protein versus milk protein alone']","['IGF-1', 'changes in IGF-1 after 1\xa0week and changes in insulin-like growth factor binding protein-3 (IGFBP-3), IGF-1/IGFBP-3, insulin, height, weight and body composition after 1 and 4\xa0weeks', 'plasma IGF-1, insulin-like growth factor binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio or insulin', 'Body mass index', 'growth factors', 'FFMI (P', 'Fat-free mass index (FFMI) increments', 'IGF-1 changes']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0010969', 'cui_str': 'Danish language'}]","[{'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0034670', 'cui_str': 'Brassica rapa'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0026138', 'cui_str': 'Milk protein'}]","[{'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0123707', 'cui_str': 'Insulin-like growth factor binding protein 3'}, {'cui': 'C0037657', 'cui_str': 'Somatomedin'}, {'cui': 'C0018284', 'cui_str': 'Growth factor'}, {'cui': 'C0443625', 'cui_str': 'Binding protein 3'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",129.0,0.0846779,"Body mass index increased within all groups (P < 0.05), mainly due to an increase in FFMI (P ","[{'ForeName': 'Benedikte', 'Initials': 'B', 'LastName': 'Grenov', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg C, Denmark. Electronic address: bgr@nexs.ku.dk.'}, {'ForeName': 'Anni', 'Initials': 'A', 'LastName': 'Larnkjær', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg C, Denmark. Electronic address: ala@nexs.ku.dk.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ritz', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg C, Denmark. Electronic address: ritz@nexs.ku.dk.'}, {'ForeName': 'Kim F', 'Initials': 'KF', 'LastName': 'Michaelsen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg C, Denmark. Electronic address: kfm@nexs.ku.dk.'}, {'ForeName': 'Camilla T', 'Initials': 'CT', 'LastName': 'Damsgaard', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg C, Denmark. Electronic address: ctd@nexs.ku.dk.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Mølgaard', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg C, Denmark. Electronic address: cm@nexs.ku.dk.'}]",Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society,['10.1016/j.ghir.2021.101418'] 1919,34333211,Effects of a nurse-led eHealth cardiac rehabilitation programme on health outcomes of patients with coronary heart disease: A randomised controlled trial.,"BACKGROUND The uptake of and adherence to cardiac rehabilitation remain suboptimal despite its apparent health benefits in modifying risk factors and slowing disease progression. eHealth refers to the use of information and communication technologies for health-related purposes. It is a promising approach for improving participation in cardiac rehabilitation by enabling instant contact, hypermedia information delivery, technology-monitored functionalities and individualised progress monitoring. AIMS To evaluate the effects of a nurse-led eHealth cardiac rehabilitation (NeCR) system on health behaviours, cardiac self-efficacy, anxiety and depression, health-related quality of life, risk parameters and unplanned use of care services for people with coronary heart disease. DESIGN A single-blinded randomised controlled trial design was used. METHODS The study randomly assigned 146 patients hospitalised for coronary heart disease to receive either the NeCR intervention or the usual care. Underpinned by social cognitive theory, the intervention commenced before hospital discharge with an in-person session by the nurse to identify individualised self-care needs, set goals and develop an action plan to enhance behavioural risk factor modification and orientate the patient to the use of the information and communication technology platform for cardiac rehabilitation. After discharge, the e-platform helped patients gain knowledge of disease management and monitor goal attainment for health behavioural changes. The nurse provided feedback on the patients' goal attainment and lifestyle modifications on a weekly basis in a small group format through the WeChat platform, thus also mobilising peer influence. Data for lifestyle behaviours, physiological risk parameters and clinical outcomes were collected at baseline and at 6 and 12 weeks post-intervention. RESULTS At 6 weeks post-intervention, participants in the intervention group showed significant improvement in the number of steps/day (β = 2628.48, p = .022), the number of minutes/week sitting (β = -640.30, p = .006) and their health-promoting lifestyle profile (β = 25.17, p < .001) compared with the control group. Improvements in the number of steps/day (β = 2520.00, p = .006), the number of minutes/week sitting (β = -719.73, p = .004) and health-promoting lifestyle (β = 16.09, p < .001) were sustained until the 12-week post-intervention endpoint. Moreover, participants showed significantly greater improvement in self-efficacy (β = 0.61, p = .005) and health-related quality of life (mean difference = 0.56, p < .001) than the control group at the study endpoint. CONCLUSIONS The findings of this study demonstrate the effectiveness of the NeCR intervention in modifying behavioural risk factors and improving health-related quality of life. These findings also provide insights into the application of eHealth nursing interventions to enhance the rehabilitation of patients with coronary heart disease. TRIAL REGISTRATION ChiCTR1800020411.",2021,"Moreover, participants showed significantly greater improvement in self-efficacy (β = 0.61, p = .005) and health-related quality of life (mean difference = 0.56,","['146 patients hospitalised for coronary heart disease to receive either the', 'people with coronary heart disease', 'patients with coronary heart disease']","['nurse-led eHealth cardiac rehabilitation (NeCR) system', 'nurse-led eHealth cardiac rehabilitation programme', 'NeCR intervention or the usual care', 'NeCR intervention']","['self-efficacy', 'health outcomes', 'health-promoting lifestyle profile', 'number of minutes/week sitting', 'behavioural risk factors and improving health-related quality of life', 'health-related quality of life', 'health behaviours, cardiac self-efficacy, anxiety and depression, health-related quality of life, risk parameters and unplanned use of care services', 'health-promoting lifestyle', 'number of steps/day (β\xa0']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C1562039', 'cui_str': 'Number of minutes'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",146.0,0.0231662,"Moreover, participants showed significantly greater improvement in self-efficacy (β = 0.61, p = .005) and health-related quality of life (mean difference = 0.56,","[{'ForeName': 'Jing Jing', 'Initials': 'JJ', 'LastName': 'Su', 'Affiliation': 'WHO Collaborating Centre for Community Health Services (WHOCC), School of Nursing, The Hong Kong Polytechnic University, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Doris Sau-Fung', 'Initials': 'DS', 'LastName': 'Yu', 'Affiliation': 'School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 4/F, William MW Mong Block, 21 Sassoon Road, Hong Kong Special Administrative Region, Pokfulam, Hong Kong, China. Electronic address: dyu1@hku.hk.'}]",International journal of nursing studies,['10.1016/j.ijnurstu.2021.104040'] 1920,34333202,"Snacks, nudges and asymmetric peer influence: Evidence from food choice experiments with children in Indonesia.","Many children in low- and middle-income countries are growing up during a rapid nutrition transition. Experimental evidence on food choice in developing countries is scarce, while it is unclear to what extent evidence from high-income countries can be generalized. Children participated in a snack choice experiment. We expose some children to emoji labels encouraging healthy snacks, while others observe healthy or unhealthy snacking by peers. While emoji labels moderately promote healthy snacking, the adverse effect of observing a peer eating the unhealthy snack is very large. The effect associated with observing a healthy peer is insignificant. Additionally, cross-randomized blocks of children watched a nutrition video to study the interaction of information provision and nudging. The video independently improves healthy choices but does not aid the emoji nudge and cannot counter the strong negative peer effect. We compare our findings to studies conducted in developed countries and discuss policy implications.",2021,The effect associated with observing a healthy peer is insignificant.,"['Children participated in a snack choice experiment', 'children in Indonesia']",[],"['healthy snacking', 'healthy choices']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}]",[],"[{'cui': 'C0008300', 'cui_str': 'Choice Behavior'}]",,0.0331327,The effect associated with observing a healthy peer is insignificant.,"[{'ForeName': 'Margarita de Vries', 'Initials': 'MV', 'LastName': 'Mecheva', 'Affiliation': 'The International Institute of Social Studies of Erasmus University Rotterdam, the Netherlands.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Rieger', 'Affiliation': 'The International Institute of Social Studies of Erasmus University Rotterdam, the Netherlands. Electronic address: rieger@iss.nl.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Sparrow', 'Affiliation': 'The International Institute of Social Studies of Erasmus University Rotterdam, the Netherlands; Development Economics Group, Wageningen University, the Netherlands.'}, {'ForeName': 'Erfi', 'Initials': 'E', 'LastName': 'Prafiantini', 'Affiliation': 'Department of Nutrition, Faculty of Medicine, Universitas Indonesia - Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Human Nutrition Research Center, Indonesian Medical Education and Research Institute (HNRC-IMERI), Faculty of Medicine, Universitas Indonesia, Indonesia.'}, {'ForeName': 'Rina', 'Initials': 'R', 'LastName': 'Agustina', 'Affiliation': 'Department of Nutrition, Faculty of Medicine, Universitas Indonesia - Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Human Nutrition Research Center, Indonesian Medical Education and Research Institute (HNRC-IMERI), Faculty of Medicine, Universitas Indonesia, Indonesia.'}]",Journal of health economics,['10.1016/j.jhealeco.2021.102508'] 1921,34342477,"Effect of telephone counselling on the knowledge, attitude and practices of contacts of confirmed COVID-19 cases in Egypt.","BACKGROUND The coronavirus disease 2019 (COVID-19) is an emerging respiratory illness. The World Health Organization declared it a public health emergency of international concern on 30 January 2020 and called for collaborative efforts, such as contact tracing and promoting the public awareness about COVID-19, and recommended prevention and control measures. AIM The aim of this study was to assess the effect of telephone counselling on the knowledge, attitude and practices (KAPs) of contacts of COVID-19 confirmed cases towards COVID-19 epidemiology and infection prevention and control measures. SETTING Ten areas in Sharkia Governorate, Egypt divided into six rural and four urban areas. METHODS A non-randomised controlled trial was conducted in Sharkia Governorate, Egypt, from 26 March 2020 to 12 April 2020 on 208 contacts of confirmed COVID-19 cases, divided equally into two groups: an experiment group that was exposed to telephone counselling by the researchers and a control group that was exposed to routine surveillance by local health authority. A semi-structured questionnaire was used to assess the KAP of both groups towards COVID-19 before and after intervention. RESULTS After intervention the percent of contacts who achieved good knowledge, positive attitudes and better practice scores in the experimental group was 91.3%, 57.8% and 71.2%, respectively, compared with 13.5%, 7.8% and 16.3%, respectively, in the control group. Male gender and working group were significantly associated with bad practice score. Furthermore, there was a statistically significant positive correlation between differences in knowledge, attitudes and practices of the experimental group before and after the intervention. CONCLUSION This study proved the effectiveness of telephone counselling in improving COVID-19-related KAP scores of contacts of confirmed COVID-19 cases.",2021,This study proved the effectiveness of telephone counselling in improving COVID-19-related KAP scores of contacts of confirmed COVID-19 cases.,"['Ten areas in Sharkia Governorate, Egypt divided into six rural and four urban areas', 'Sharkia Governorate, Egypt, from 26 March 2020 to 12 April 2020 on 208 contacts of confirmed COVID-19 cases']","['telephone counselling by the researchers and a control group that was exposed to routine surveillance by local health authority', 'telephone counselling']","['knowledge, attitude and practices (KAPs', 'good knowledge, positive attitudes and better practice scores', 'COVID-19-related KAP scores', 'knowledge, attitudes and practices', 'bad practice score']","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0013715', 'cui_str': 'Egypt'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0868928', 'cui_str': 'Case'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}]",,0.0325804,This study proved the effectiveness of telephone counselling in improving COVID-19-related KAP scores of contacts of confirmed COVID-19 cases.,"[{'ForeName': 'Randa M', 'Initials': 'RM', 'LastName': 'Said', 'Affiliation': 'Department of Family Medicine, Faculty of Medicine, Zagazig University, Zagazig. re_re99999@yahoo.com.'}, {'ForeName': 'Ghada M', 'Initials': 'GM', 'LastName': 'Salem', 'Affiliation': ''}]",African journal of primary health care & family medicine,['10.4102/phcfm.v13i1.2852'] 1922,34347057,Effect of Graphic Warning Labels on Cigarette Packs on US Smokers' Cognitions and Smoking Behavior After 3 Months: A Randomized Clinical Trial.,"Importance The US Food and Drug Administration's implementation of graphic warning labels (GWLs) on cigarette packs is under challenge in US courts. Objective To determine whether GWLs can affect US smokers' perceptions about their cigarettes or health consequences and changes in smoking behavior. Design, Setting, and Participants This study was a randomized clinical trial of the effect of a 3-month, real-world experience of cigarettes with GWL packaging. Community recruitment was done from September 2016 through December 2019 of daily smokers from San Diego, California, aged 21 to 65 years, who were not ready to quit. Participants were randomized to purchase and receive cigarettes in 1 of 3 pack designs: GWL, blank, or standard US pack. Data analysis was performed from July 2020 to February 2021. Interventions The study manufactured GWL cigarette packs (3 versions with Australian-licensed images) and packs devoid of marketing. For 3 months, participants purchased GWL, blank, or standard US pack cigarettes that were delivered to their home. Main Outcomes and Measures Smoking-related cognitions and behavior were queried by daily and weekly interactive text messages. Smoking behavior was self-reported before and after the intervention by 96% of randomized participants and was biochemically validated on a subsample. Results The study sample included 357 participants (195 women [54.6%]; mean [SD] age, 39.5 [11.9] years); 116 were randomized to the standard US pack group, 118 were randomized to the GWL pack group, and 125 were randomized to the blank pack group. Over the 3 months, participants who received the GWL packs had reduced positive perceptions of recent cigarettes smoked compared with participants who received the branded US pack (mean difference, -0.46 SD; 95% CI, -0.73 SD to -0.20 SD; P < .001). Health concerns increased in all groups, with a significant increase in the GWL group vs the US pack group (mean difference, 0.35 SD; 95% CI, 0.09 SD to 0.62 SD; P = .002). Quitting cognitions increased in all study groups, with a peak mean change of 0.60 SD for GWL participants vs 0.34 SD for US pack participants (mean difference, 0.55 SD; 95% CI, 0.28 SD to 0.81 SD; P < .001). GWL participants had slightly more cigarette abstinence periods per week than the US pack group, but the difference was not significant (adjusted odds ratio, 1.06; 95% CI, 0.99 to 1.13). At 3 months, there was no between-group difference in any smoking behavior. The blank pack group was similar to the US pack group on all measures. Conclusions and Relevance These findings suggest that the introduction of GWL packs appears to decrease positive perceptions of cigarettes and increase quitting cognitions in the short term. However, additional complementary tobacco control strategies may be necessary for GWL packs to be associated with reduced smoking behavior. Trial Registration ClinicalTrials.gov Identifier: NCT02676193.",2021,"GWL participants had slightly more cigarette abstinence periods per week than the US pack group, but the difference was not significant (adjusted odds ratio, 1.06; 95% CI, 0.99 to 1.13).","['357 participants (195 women [54.6%]; mean [SD] age, 39.5 [11.9] years); 116', 'Community recruitment was done from September 2016 through December 2019 of daily smokers from San Diego, California, aged 21 to 65 years, who were not ready to quit']","['Graphic Warning Labels', 'standard US pack', 'purchase and receive cigarettes in 1 of 3 pack designs: GWL, blank, or standard US pack', 'real-world experience of cigarettes with GWL packaging', 'GWL pack', 'GWL packs', 'GWLs']","['smoking behavior', 'Quitting cognitions', ""US Smokers' Cognitions and Smoking Behavior"", 'quitting cognitions', 'Smoking behavior', 'cigarette abstinence periods', 'Health concerns', 'positive perceptions of recent cigarettes smoked', 'Measures\n\n\nSmoking-related cognitions and behavior were queried by daily and weekly interactive text messages']","[{'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C3266136', 'cui_str': 'Smokes tobacco daily'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}]","[{'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1519383', 'cui_str': 'Smoking Behaviors'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C3543841', 'cui_str': 'Query'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]",357.0,0.354883,"GWL participants had slightly more cigarette abstinence periods per week than the US pack group, but the difference was not significant (adjusted odds ratio, 1.06; 95% CI, 0.99 to 1.13).","[{'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Strong', 'Affiliation': 'Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Pierce', 'Affiliation': 'Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Pulvers', 'Affiliation': 'Department of Psychology, California State University San Marcos, San Marcos.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Stone', 'Affiliation': 'Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Villaseñor', 'Affiliation': 'Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.'}, {'ForeName': 'Minya', 'Initials': 'M', 'LastName': 'Pu', 'Affiliation': 'Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.'}, {'ForeName': 'Claudiu V', 'Initials': 'CV', 'LastName': 'Dimofte', 'Affiliation': 'Department of Marketing, San Diego State University, San Diego, California.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'Leas', 'Affiliation': 'Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.'}, {'ForeName': 'Jesica', 'Initials': 'J', 'LastName': 'Oratowski', 'Affiliation': 'Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Brighton', 'Affiliation': 'Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Hurst', 'Affiliation': 'Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Kealey', 'Affiliation': 'Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.'}, {'ForeName': 'Ruifeng', 'Initials': 'R', 'LastName': 'Chen', 'Affiliation': 'Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Messer', 'Affiliation': 'Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.21387'] 1923,34345227,The Impacts of Subthalamic Nucleus-Deep Brain Stimulation (STN-DBS) on the Neuropsychiatric Function of Patients with Parkinson's Disease Using Image Features of Magnetic Resonance Imaging under the Artificial Intelligence Algorithms.,"This study was to explore the effect of subthalamic nucleus- (STN-) deep brain stimulation (DBS) on the neuropsychiatric function of Parkinson's disease (PD) patients using the magnetic resonance imaging (MRI) image analysis technology and the artificial intelligence (AI) algorithm. In this study, 40 PD patients admitted to our hospital from August 2018 to March 2020 were selected as the research objects, and they were divided into a control group and an observation group according to the random number table method, with 20 cases in each group. The patients in the control group were given oral treatment with levodopa tablets; and patients in the observation group were treated with STN-DBS + levodopa tablets. In patients, MRI examinations were performed before and after the treatment, and the image optimization processing algorithm under AI was adopted to process the images. The MRI imaging results of the two groups of patients were observed, analyzed, and compared before and after treatment; and the sports, cognition, and mental states of the two groups of patients were analyzed. It was believed that the MRI image before using the AI algorithm was blurry, and the image was clear after the noise reduction optimization process, which was convenient for observation. The data analysis revealed that the signal-to-noise ratio (SNR) after denoising (32.41) and structural similarity (SSIM) (0.79) had been improved. The results of the study suggested that the space occupation and bleeding symptoms of the two groups of patients were reduced after treatment, and those in the observation group were better than those of the control group; the incidences of dyskinesia and motor symptom fluctuations in the observation group were 5% and 0%, respectively, which were lower than those in the control group (35% and 25%, respectively). After treatment, the Unified Parkinson's Disease Rating Scale (UPDRS) score of the two groups of patients decreased, and it was lower in the observation group than in the control group; and the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Scale (MMSE) scores increased, and those in the observation group were higher in contrast to those in the control group (all P < 0.05). STN-DBS was beneficial to improve the clinical symptoms of patients and delay the progress of the disease, and MRI based on AI algorithms can effectively observe the changes in the neuropsychiatric function of patients, which was conducive to further clinical diagnosis and treatment.",2021,"The results of the study suggested that the space occupation and bleeding symptoms of the two groups of patients were reduced after treatment, and those in the observation group were better than those of the control group; the incidences of dyskinesia and motor symptom fluctuations in the observation group were 5% and 0%, respectively, which were lower than those in the control group (35% and 25%, respectively).","[""Patients with Parkinson's Disease"", '40 PD patients admitted to our hospital from August 2018 to March 2020', ""Parkinson's disease (PD) patients""]","['STN-DBS\u2009+\u2009levodopa tablets', 'Subthalamic Nucleus-Deep Brain Stimulation (STN-DBS', 'subthalamic nucleus- (STN-) deep brain stimulation (DBS', 'magnetic resonance imaging (MRI) image analysis technology and the artificial intelligence (AI) algorithm', 'levodopa tablets']","['space occupation and bleeding symptoms', ""Unified Parkinson's Disease Rating Scale (UPDRS) score"", 'signal-to-noise ratio (SNR', 'Montreal Cognitive Assessment (MoCA) and Mini-Mental State Scale (MMSE) scores', 'incidences of dyskinesia and motor symptom fluctuations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0038427', 'cui_str': 'Bruneomycin'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C1246645', 'cui_str': 'Levodopa Oral Tablet'}, {'cui': 'C0152355', 'cui_str': 'Nucleus of Luys'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0200765', 'cui_str': 'Image analysis'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}]","[{'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0013384', 'cui_str': 'Dyskinesia'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}]",,0.0438156,"The results of the study suggested that the space occupation and bleeding symptoms of the two groups of patients were reduced after treatment, and those in the observation group were better than those of the control group; the incidences of dyskinesia and motor symptom fluctuations in the observation group were 5% and 0%, respectively, which were lower than those in the control group (35% and 25%, respectively).","[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': ""Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China.""}, {'ForeName': 'Maode', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': ""Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China.""}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': ""Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China.""}, {'ForeName': 'Changwang', 'Initials': 'C', 'LastName': 'Du', 'Affiliation': ""Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China.""}, {'ForeName': 'Xudong', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': ""Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China.""}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': ""Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China.""}]",Contrast media & molecular imaging,['10.1155/2021/9915206'] 1924,34344230,Comparative effectiveness study of low versus high-intensity aerobic training with resistance training in community-dwelling older men with post-COVID 19 sarcopenia: A randomized controlled trial.,"OBJECTIVE To find and compare the clinical and psychological effects of low and high-intensity aerobic training combined with resistance training in community-dwelling older men with post-COVID-19 sarcopenia symptoms. DESIGN Randomized control trial. SETTING University physiotherapy clinic. PARTICIPANTS Men in the age range of 60-80 years with post-COVID-19 Sarcopenia. INTERVENTION All participants received resistance training for whatever time of the day that they received it, and that in addition they were randomized into two groups like low-intensity aerobic training group ( n  = 38) and high-intensity aerobic training group ( n  = 38) for 30 minutes/session, 1 session/day, 4 days/week for 8 weeks. OUTCOMES Clinical (muscle strength and muscle mass) and psychological (kinesiophobia and quality of life scales) measures were measured at the baseline, fourth week, the eighth week, and at six months follow-up. RESULTS The 2 × 4 group by time repeated measures MANOVA with corrected post-hoc tests for six dependent variables shows a significant difference between the groups ( P  < 0.001). At the end of six months follow up, the handgrip strength, -3.9 (95% CI -4.26 to -3.53), kinesiophobia level 4.7 (95% CI 4.24 to 5.15), and quality of life -10.4 (95% CI -10.81 to -9.9) shows more improvement ( P  < 0.001) in low-intensity aerobic training group than high-intensity aerobic training group, but in muscle mass both groups did not show any significant difference ( P  > 0.05). CONCLUSION Low-intensity aerobic training exercises are more effective in improving the clinical (muscle strength) and psychological (kinesiophobia and quality of life) measures than high-intensity aerobic training in post-COVID 19 Sarcopenia.",2021,"At the end of six months follow up, the handgrip strength, -3.9 (95% CI -4.26 to -3.53), kinesiophobia level 4.7 (95% CI 4.24 to 5.15), and quality of life -10.4 (95% CI -10.81 to -9.9) shows more improvement ( P  < 0.001) in low-intensity aerobic training group than high-intensity aerobic training group, but in muscle mass both groups did not show any significant difference ( P  > 0.05). ","['Men in the age range of 60-80\u2009years with post-COVID-19 Sarcopenia', 'University physiotherapy clinic', 'community-dwelling older men with post-COVID-19 sarcopenia symptoms', 'community-dwelling older men with post-COVID 19 sarcopenia']","['low versus high-intensity aerobic training with resistance training', 'low-intensity aerobic training group ( n \u2009=\u200938) and high-intensity aerobic training', 'low and high-intensity aerobic training combined with resistance training', 'resistance training', 'Low-intensity aerobic training exercises']","['Clinical (muscle strength and muscle mass) and psychological (kinesiophobia and quality of life', 'clinical (muscle strength) and psychological (kinesiophobia and quality of life) measures', 'kinesiophobia level', 'handgrip strength', 'quality of life', 'scales']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C3839152', 'cui_str': 'Physiotherapy clinic'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0185697,"At the end of six months follow up, the handgrip strength, -3.9 (95% CI -4.26 to -3.53), kinesiophobia level 4.7 (95% CI 4.24 to 5.15), and quality of life -10.4 (95% CI -10.81 to -9.9) shows more improvement ( P  < 0.001) in low-intensity aerobic training group than high-intensity aerobic training group, but in muscle mass both groups did not show any significant difference ( P  > 0.05). ","[{'ForeName': 'Gopal', 'Initials': 'G', 'LastName': 'Nambi', 'Affiliation': 'Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.'}, {'ForeName': 'Walid Kamal', 'Initials': 'WK', 'LastName': 'Abdelbasset', 'Affiliation': 'Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.'}, {'ForeName': 'Saud M', 'Initials': 'SM', 'LastName': 'Alrawaili', 'Affiliation': 'Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.'}, {'ForeName': 'Shereen H', 'Initials': 'SH', 'LastName': 'Elsayed', 'Affiliation': 'Department of Rehabilitation Sciences, Faculty of Health and Rehabilitation Sciences, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Anju', 'Initials': 'A', 'LastName': 'Verma', 'Affiliation': 'Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.'}, {'ForeName': 'Arul', 'Initials': 'A', 'LastName': 'Vellaiyan', 'Affiliation': 'Department of Nursing, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.'}, {'ForeName': 'Marwa M', 'Initials': 'MM', 'LastName': 'Eid', 'Affiliation': 'Department of Physical Therapy, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.'}, {'ForeName': 'Osama R', 'Initials': 'OR', 'LastName': 'Aldhafian', 'Affiliation': 'Department of Surgery, College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.'}, {'ForeName': 'Naif Bin', 'Initials': 'NB', 'LastName': 'Nwihadh', 'Affiliation': 'Department of Surgery, College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.'}, {'ForeName': 'Ayman K', 'Initials': 'AK', 'LastName': 'Saleh', 'Affiliation': 'Department of Surgery, College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.'}]",Clinical rehabilitation,['10.1177/02692155211036956'] 1925,34344218,Effect of individualized medical nutrition guidance on pregnancy outcomes in older pregnant women.,"OBJECTIVE We aimed to explore the effect of individualized medical nutrition guidance on pregnancy outcomes among older pregnant women. METHODS This was a prospective study using a randomized controlled trial design. We selected 820 older pregnant women and randomly divided them into a study group and control group (410 women each). The control group was given routine health education and nutrition guidance; the study group was provided individualized medical nutrition guidance. Gestational diabetes mellitus, hypertensive disorders of pregnancy, vaginal delivery rate, postpartum hemorrhage rate, gestational body weight, neonatal birth weight, and neonate transfer to the neonatal intensive care unit (NICU) were compared between the groups. RESULTS The incidence of gestational diabetes in the study group was significantly lower and the rate of vaginal delivery was significantly higher than those in the control group. The incidence of macrosomia, rate of neonatal transfer to the NICU, and rate of neonatal hyperbilirubinemia were significantly lower in the study group than those in the control group. CONCLUSIONS Individualized nutritional intervention for older pregnant women can effectively reduce the incidence of complications during pregnancy and childbirth and improve maternal and child outcomes.",2021,The incidence of gestational diabetes in the study group was significantly lower and the rate of vaginal delivery was significantly higher than those in the control group.,"['820 older pregnant women', 'older pregnant women']","['routine health education and nutrition guidance', 'individualized medical nutrition guidance', 'Individualized nutritional intervention']","['rate of vaginal delivery', 'incidence of gestational diabetes', 'incidence of macrosomia, rate of neonatal transfer to the NICU, and rate of neonatal hyperbilirubinemia', 'Gestational diabetes mellitus, hypertensive disorders of pregnancy, vaginal delivery rate, postpartum hemorrhage rate, gestational body weight, neonatal birth weight, and neonate transfer to the neonatal intensive care unit (NICU', 'pregnancy outcomes']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0158915', 'cui_str': 'Exceptionally large at birth'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0857007', 'cui_str': 'Neonatal hyperbilirubinemia'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}, {'cui': 'C0852260', 'cui_str': 'Hypertension associated disorders of pregnancy'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}]",820.0,0.0264034,The incidence of gestational diabetes in the study group was significantly lower and the rate of vaginal delivery was significantly higher than those in the control group.,"[{'ForeName': 'Chun-Ling', 'Initials': 'CL', 'LastName': 'Li', 'Affiliation': ""Health Care Department, Hebei Cangzhou Women And Children's Health, Cangzhou, China.""}, {'ForeName': 'Ying-Hua', 'Initials': 'YH', 'LastName': 'Wang', 'Affiliation': ""Health Care Department, Hebei Cangzhou Women And Children's Health, Cangzhou, China.""}, {'ForeName': 'Jun-Li', 'Initials': 'JL', 'LastName': 'Wang', 'Affiliation': 'Health Care Department, Hebei Cangxian Hospital, Cangzhou, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': ""Health Care Department, Hebei Cangzhou Women And Children's Health, Cangzhou, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': ""Health Care Department, Hebei Cangzhou Women And Children's Health, Cangzhou, China.""}]",The Journal of international medical research,['10.1177/03000605211033193'] 1926,34357153,Effectiveness of Yoga Lifestyle on Lipid Metabolism in a Vulnerable Population-A Community Based Multicenter Randomized Controlled Trial.,"Background: Dyslipidemia poses a high risk for cardiovascular disease and stroke in Type 2 diabetes (T2DM). There are no studies on the impact of a validated integrated yoga lifestyle protocol on lipid profiles in a high-risk diabetes population. Methods: Here, we report the results of lipid profile values of 11,254 (yoga 5932 and control 5322) adults (20-70 years) of both genders with high risk (≥60 on Indian diabetes risk score) for diabetes from a nationwide rural and urban community-based two group (yoga and conventional management) cluster randomized controlled trial. The yoga group practiced a validated integrated yoga lifestyle protocol (DYP) in nine day camps followed by daily one-hour practice. Biochemical profiling included glycated hemoglobin and lipid profiles before and after three months. Results: There was a significant difference between groups ( p < 0.001 ANCOVA) with improved serum total cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein in the yoga group compared to the control group. Further, the regulatory effect of yoga was noted with a significant decrease or increase in those with high or low values of lipids, respectively, with marginal or no change in those within the normal range. Conclusion: Yoga lifestyle improves and regulates (lowered if high, increased if low) the blood lipid levels in both genders of prediabetic and diabetic individuals in both rural and urban Indian communities.",2021,"Yoga lifestyle improves and regulates (lowered if high, increased if low) the blood lipid levels in both genders of prediabetic and diabetic individuals in both rural and urban Indian communities.","['11,254 (yoga 5932 and control 5322) adults (20-70 years) of both genders with high risk (≥60 on Indian diabetes risk score) for diabetes from a nationwide rural and urban community-based two group (yoga and conventional management) cluster randomized controlled trial']","['yoga group practiced a validated integrated yoga lifestyle protocol (DYP', 'Yoga Lifestyle']","['blood lipid levels', 'glycated hemoglobin and lipid profiles', 'Lipid Metabolism', 'serum total cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein']","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0018262', 'cui_str': 'Group Practice'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0428460', 'cui_str': 'Lipid level - finding'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}]",,0.0764824,"Yoga lifestyle improves and regulates (lowered if high, increased if low) the blood lipid levels in both genders of prediabetic and diabetic individuals in both rural and urban Indian communities.","[{'ForeName': 'Raghuram', 'Initials': 'R', 'LastName': 'Nagarathna', 'Affiliation': 'Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bengaluru 560105, India.'}, {'ForeName': 'Saurabh', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Neuroscience Research Lab, Department of Neurology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.'}, {'ForeName': 'Akshay', 'Initials': 'A', 'LastName': 'Anand', 'Affiliation': 'Neuroscience Research Lab, Department of Neurology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.'}, {'ForeName': 'Ishwara N', 'Initials': 'IN', 'LastName': 'Acharya', 'Affiliation': 'Central Council for Research in Yoga & Naturopathy (CCRYN), Delhi 110058, India.'}, {'ForeName': 'Amit Kumar', 'Initials': 'AK', 'LastName': 'Singh', 'Affiliation': 'Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bengaluru 560105, India.'}, {'ForeName': 'Suchitra S', 'Initials': 'SS', 'LastName': 'Patil', 'Affiliation': 'Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bengaluru 560105, India.'}, {'ForeName': 'Ramesh H', 'Initials': 'RH', 'LastName': 'Latha', 'Affiliation': 'Yoga Clinic, Bhopal 462026, India.'}, {'ForeName': 'Purnima', 'Initials': 'P', 'LastName': 'Datey', 'Affiliation': 'Arogya Rasahara Kendra, Bhopal 462024, India.'}, {'ForeName': 'Hongasandra Ramarao', 'Initials': 'HR', 'LastName': 'Nagendra', 'Affiliation': 'Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bengaluru 560105, India.'}]","Medicines (Basel, Switzerland)",['10.3390/medicines8070037'] 1927,34357081,"Metabolic Actions of a Supplement of Ilex Paraguariensis (An Extract of the Leaf Standardized to 2% I-Deoxinojirimcina), White Mulberry and Chromium Picolinate in Nondiabetic Subects with Dysglycemia: A Randomized Trial.","AIM To prove if a nutraceutical containing Ilex paraguariensis ( Ilex L. spp. Aquifoliales) (an extract of the leaf standardized to 2% I-deoxinojirimcina), white mulberry ( Morus spp., Moraceae), and chromium picolinate can be effective in improving glycemic status in subject with dysglycemia. METHODS We randomized patients to consume placebo or the nutraceutical, self-administered once a day, one tablet at breakfast, for 3 months. RESULTS A reduction in fasting plasma glucose, postprandial glucose, and glycated hemoglobin was observed with the nutraceutical combination, both compared to baseline and placebo. Data suggested a decrease in the Homeostasis Model Assessment index with the nutraceutical, both compared to baseline and placebo. The M value, an index of insulin sensitivity, obtained after nutraceutical treatment was higher compared to baseline. We recorded a decrease in total cholesterol, low-density lipoprotein-cholesterol, and triglycerides with the nutraceutical combination compared to baseline and placebo. A decrease in high-sensitivity C-reactive protein was observed with the nutraceutical combination compared to baseline and placebo. CONCLUSIONS A nutraceutical containing Ilex paraguariensis, white mulberry, and chromium picolinate can be helpful in improving glycemic status and lipid profile in dysglycemic subjects.",2021,"A reduction in fasting plasma glucose, postprandial glucose, and glycated hemoglobin was observed with the nutraceutical combination, both compared to baseline and placebo.","['dysglycemic subjects', 'Nondiabetic Subects with Dysglycemia']","['nutraceutical containing Ilex paraguariensis ( Ilex L. spp', 'placebo', 'Ilex Paraguariensis (An Extract of the Leaf Standardized to 2% I-Deoxinojirimcina), White Mulberry and Chromium Picolinate', 'chromium picolinate']","['glycemic status', 'glycemic status and lipid profile', 'fasting plasma glucose, postprandial glucose, and glycated hemoglobin', 'Homeostasis Model Assessment index', 'high-sensitivity C-reactive protein', 'M value, an index of insulin sensitivity', 'total cholesterol, low-density lipoprotein-cholesterol, and triglycerides with the nutraceutical combination']","[{'cui': 'C1960636', 'cui_str': 'Dysglycemia'}]","[{'cui': 'C1518478', 'cui_str': 'Nutriceuticals'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0874159', 'cui_str': 'Mate, Yerba'}, {'cui': 'C0330399', 'cui_str': 'Ilex'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0242724', 'cui_str': 'Leaves'}, {'cui': 'C0772361', 'cui_str': 'white mulberry extract'}, {'cui': 'C0163657', 'cui_str': 'CHROMIUM PICOLINATE'}]","[{'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C1518478', 'cui_str': 'Nutriceuticals'}]",,0.250083,"A reduction in fasting plasma glucose, postprandial glucose, and glycated hemoglobin was observed with the nutraceutical combination, both compared to baseline and placebo.","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Derosa', 'Affiliation': 'Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': ""D'Angelo"", 'Affiliation': 'Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Maffioli', 'Affiliation': 'Centre of Diabetes, Metabolic Diseases, and Dyslipidemias, University of Pavia, 27100 Pavia, Italy.'}]","Life (Basel, Switzerland)",['10.3390/life11070709'] 1928,34357009,Acute Exhaustive Exercise under Normoxic and Normobaric Hypoxic Conditions Differentially Regulates Angiogenic Biomarkers in Humans.,"Background and Objectives: Angiogenesis describes the outgrowth of new capillaries from already existing ones. Different biomarkers regulate this process. Physical exercise and hypoxia are key stimuli for the activation of different angiogenic molecules, such as the vascular endothelial growth factor (VEGF). matrix metalloproteases (MMPs)-2 and -9 or the extracellular matrix cleavage fragment endostatin. The present study aimed to investigate influences of short-term, intensive cycling exercise under both normoxic and normobaric hypoxic conditions on the mentioned parameters. Materials and Methods: Twelve male subjects (age: 23.3 ± 2.0 years) participated in the study. All subjects conducted four intensive cycling tests until individual exhaustion in a randomized order under the following conditions: normoxia, 2000 m, 3000 m and 4000 m above sea level. Blood samples were taken before (pre) and 10 min, 30 min, 60 min and 240 min post exercise and were analyzed by ELISA. Results: VEGF showed a significantly reduced concentration compared to the pre-value solely under 4000 m at 10 min post exercise. MMP-2 showed significantly reduced concentrations at 240 min post exercise under 4000 m. MMP-9 increased at 240 min post exercise under both 2000 m and 4000 m conditions. Endostatin was significantly increased at 10 min post exercise independently of the applied stimulus. Conclusions: The presented data show that intensive short-term exercise bouts facilitate the bioavailability of angiogenic, ECM (extracellular matrix)-related biomarkers. This finding is interesting for both health- and performance-related research as it demonstrates the positive effects of intensive short exercise interventions.",2021,MMP-2 showed significantly reduced concentrations at 240 min post exercise under 4000 m. MMP-9 increased at 240 min post exercise under both 2000 m and 4000 m conditions.,"['Twelve male subjects (age: 23.3 ± 2.0 years) participated in the study', 'Humans']",['intensive cycling exercise'],['Endostatin'],"[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0534628', 'cui_str': 'Endostatin'}]",12.0,0.0343864,MMP-2 showed significantly reduced concentrations at 240 min post exercise under 4000 m. MMP-9 increased at 240 min post exercise under both 2000 m and 4000 m conditions.,"[{'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Suhr', 'Affiliation': 'Exercise Physiology Research Group, Department of Movement Sciences, Biomedical Sciences Group, KU Leuven, 3000 Leuven, Belgium.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Knuth', 'Affiliation': 'The German Research Center of Elite Sport, German Sport University Cologne, 50933 Cologne, Germany.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Achtzehn', 'Affiliation': 'The German Research Center of Elite Sport, German Sport University Cologne, 50933 Cologne, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Mester', 'Affiliation': 'The German Research Center of Elite Sport, German Sport University Cologne, 50933 Cologne, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'de Marees', 'Affiliation': 'Department of Sports Medicine and Sports Nutrition, Ruhr-University Bochum, 44801 Bochum, Germany.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina57070727'] 1929,34356994,Robot-Assisted Gait Training in Patients with Multiple Sclerosis: A Randomized Controlled Crossover Trial.,"Background and Objectives: Gait disorders represent one of the most disabling aspects in multiple sclerosis (MS) that strongly influence patient quality of life. The improvement of walking ability is a primary goal for rehabilitation treatment. The aim of this study is to evaluate the effectiveness of robot-assisted gait training (RAGT) in association with physiotherapy treatment in patients affected by MS in comparison with ground conventional gait training. Study design: Randomized controlled crossover trial. Materials and Methods: Twenty-seven participants affected by MS with EDSS scores between 3.5 and 7 were enrolled, of whom seventeen completed the study. They received five training sessions per week over five weeks of conventional gait training with (experimental group) or without (control group) the inclusion of RAGT. The patients were prospectively evaluated before and after the first treatment session and, after the crossover phase, before and after the second treatment session. The evaluation was based on the 25-foot walk test (25FW, main outcome), 6 min walk test (6MWT), Tinetti Test, Modified Ashworth Scale, and modified Motricity Index for lower limbs. We also measured disability parameters using Functional Independence Measure and Quality of Life Index, and instrumental kinematic and gait parameters: knee extensor strength, double-time support, step length ratio; 17 patients reached the final evaluation. Results: Both groups significantly improved on gait parameters, motor abilities, and autonomy recovery in daily living activities with generally better results of RAGT over control treatment. In particular, the RAGT group improved more than control group in the 25FW ( p = 0.004) and the 6MWT ( p = 0.022). Conclusions: RAGT is a valid treatment option that in association with physiotherapy could induce positive effects in MS-correlated gait disorders. Our results showed greater effectiveness in recovering gait speed and resistance than conventional gait training.",2021,"In particular, the RAGT group improved more than control group in the 25FW ( p = 0.004) and the 6MWT ( p = 0.022). ","['patients affected by MS in comparison with ground conventional gait training', 'Twenty-seven participants affected by MS with EDSS scores between 3.5 and 7 were enrolled, of whom seventeen completed the study', 'Patients with Multiple Sclerosis']","['conventional gait training with (experimental group) or without (control group) the inclusion of RAGT', 'robot-assisted gait training (RAGT', 'Robot-Assisted Gait Training', 'RAGT']","['disability parameters using Functional Independence Measure and Quality of Life Index, and instrumental kinematic and gait parameters: knee extensor strength, double-time support, step length ratio', 'gait parameters, motor abilities, and autonomy recovery in daily living activities', '25-foot walk test (25FW, main outcome), 6 min walk test (6MWT), Tinetti Test, Modified Ashworth Scale, and modified Motricity Index for lower limbs', 'walking ability']","[{'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0303134', 'cui_str': 'Beryllium-7'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure'}, {'cui': 'C0451498', 'cui_str': 'Spitzer quality of life index'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0427126', 'cui_str': 'Step length'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451322', 'cui_str': 'Motricity index'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0559964', 'cui_str': 'Ability to walk'}]",27.0,0.015666,"In particular, the RAGT group improved more than control group in the 25FW ( p = 0.004) and the 6MWT ( p = 0.022). ","[{'ForeName': 'Cristiano', 'Initials': 'C', 'LastName': 'Sconza', 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Negrini', 'Affiliation': 'IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy.'}, {'ForeName': 'Berardo', 'Initials': 'B', 'LastName': 'Di Matteo', 'Affiliation': 'IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Borboni', 'Affiliation': 'Mechanical and Industrial Engineering Department, University of Brescia, 25121 Brescia, Italy.'}, {'ForeName': 'Gennaro', 'Initials': 'G', 'LastName': 'Boccia', 'Affiliation': 'Department of Clinical and Biological Sciences, University of Turin, 10124 Turin, Italy.'}, {'ForeName': 'Ignas', 'Initials': 'I', 'LastName': 'Petrikonis', 'Affiliation': 'Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, 50103 Kaunas, Lithuania.'}, {'ForeName': 'Edgaras', 'Initials': 'E', 'LastName': 'Stankevičius', 'Affiliation': 'Laboratory of Preclinical Drug Investigation, Institute of Cardiology, Lithuanian University of Health Sciences, 50166 Kaunas, Lithuania.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Casale', 'Affiliation': 'Rehabilitation and Pain Rehabilitation Unit, Department of High Technology, Habilita Care and Research Hospitals, 24040 Zingonia di Ciserano, Italy.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina57070713'] 1930,34356184,Substance Use Outcomes from Two Formats of a Cognitive-Behavioral Intervention for Aggressive Children: Moderating Roles of Inhibitory Control and Intervention Engagement.,"Although cognitive-behavioral interventions have reduced the risk of substance use, little is known about moderating factors in children with disruptive behaviors. This study examined whether aggressive preadolescents' inhibitory control and intervention engagement moderates the effect of group versus individual delivery on their substance use. Following screening for aggression in 4th grade, 360 children were randomly assigned to receive the Coping Power intervention in either group or individual formats. The sample was primarily African American (78%) and male (65%). Assessments were made of children's self-reported substance use from preintervention through a six-year follow-up after intervention, parent-reported inhibitory control at preintervention, and observed behavioral engagement in the group intervention. Multilevel growth modeling found lower increases in substance use slopes for children with low inhibitory control receiving individual intervention, and for children with higher inhibitory control receiving group intervention. Children with low inhibitory control but who displayed more positive behavioral engagement in the group sessions had slower increases in their substance use than did similar children without positive engagement. Aggressive children's level of inhibitory control can lead to tailoring of group versus individual delivery of intervention. Children's positive behavioral engagement in group sessions is a protective factor for children with low inhibitory control.",2021,Children with low inhibitory control but who displayed more positive behavioral engagement in the group sessions had slower increases in their substance use than did similar children without positive engagement.,"['360 children', 'Aggressive Children', 'children with low inhibitory control receiving individual intervention, and for children with higher inhibitory control receiving group intervention', 'The sample was primarily African American (78%) and male (65', 'children with disruptive behaviors', 'children with low inhibitory control']","['Coping Power intervention in either group or individual formats', 'Inhibitory Control and Intervention Engagement', 'Cognitive-Behavioral Intervention']","['positive behavioral engagement', 'substance use slopes']","[{'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0474416', 'cui_str': 'Disruptive behavior'}]","[{'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1301627', 'cui_str': 'Format'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}]",360.0,0.013802,Children with low inhibitory control but who displayed more positive behavioral engagement in the group sessions had slower increases in their substance use than did similar children without positive engagement.,"[{'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Lochman', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, AL 35487, USA.'}, {'ForeName': 'Caroline L', 'Initials': 'CL', 'LastName': 'Boxmeyer', 'Affiliation': 'Department of Psychiatry and Behavioral Medicine, University of Alabama, Tuscaloosa, AL 35487, USA.'}, {'ForeName': 'Chuong', 'Initials': 'C', 'LastName': 'Bui', 'Affiliation': 'Alabama Life Research Institute, University of Alabama, Tuscaloosa, AL 35487, USA.'}, {'ForeName': 'Estephan', 'Initials': 'E', 'LastName': 'Hakim', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, AL 35487, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Jones', 'Affiliation': 'Center for Youth Development and Intervention, University of Alabama, Tuscaloosa, AL 35487, USA.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Kassing', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, AL 35487, USA.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'McDonald', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, AL 35487, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Powell', 'Affiliation': 'Center for Youth Development and Intervention, University of Alabama, Tuscaloosa, AL 35487, USA.'}, {'ForeName': 'Lixin', 'Initials': 'L', 'LastName': 'Qu', 'Affiliation': 'Center for Youth Development and Intervention, University of Alabama, Tuscaloosa, AL 35487, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Dishion', 'Affiliation': 'REACH Institute, Department of Psychology, Arizona State University, Tempe, AZ 85281, USA.'}]",Brain sciences,['10.3390/brainsci11070950'] 1931,34356180,Transcranial Direct Current Stimulation (tDCS) for Depression during Pregnancy: Results from an Open-Label Pilot Study.,"INTRODUCTION Depression is the most common morbidity during pregnancy. Available first-line therapy options are limited and depressive disorders in pregnant women are often untreated, leading to negative effects on maternal and fetal health. OBJECTIVES The aim of this open-label pilot study is to extend evidence on the use of transcranial direct current stimulation (tDCS) as a treatment of antenatal depression and to point out options for the use of tDCS in this population. METHODS Six drug-free female patients with major depressive disorder during pregnancy (later than 10th gestational week) were included in this pilot study. Patients were treated with twice-daily tDCS (2 mA, 30 min, anode: F3, cathode: F4) over ten days during inpatient stay (Phase 1) and with once-daily tDCS over 10 days during an optional outpatient stay (Phase 2). Clinical (HAMD-21, BDI) and neuropsychological ratings (Trail Making Test A/B) were performed at baseline, after two and four weeks as well as an obstetric examination. RESULTS Six right-handed females (23-43 years, 12-33. gestational week) completed Phase 1; four patients additionally joined in Phase 2. tDCS was well tolerated and no adverse effects occurred. Clinical ratings showed an improvement of mean baseline HAMD-21 from 22.50 ± 7.56 to 13.67 ± 3.93 after week 2, and to 8.75 ± 4.99 after week 4. The mean baseline BDI was 26.00 ± 13.90 and declined to 11.17 ± 5.46 after week 2, and to 9.25 ± 3.30 after week 4. CONCLUSIONS Statistically significant changes in HAMD-21 and BDI were observed after Phase 1. One patient achieved remission in terms of HAMD in Phase 1. Although this small-scale study lacks sham control, it shows clinical improvement and absence of adverse events in this critical population.",2021,"Clinical ratings showed an improvement of mean baseline HAMD-21 from 22.50 ± 7.56 to 13.67 ± 3.93 after week 2, and to 8.75 ± 4.99 after week 4.","['Six drug-free female patients with major depressive disorder during pregnancy (later than 10th gestational week', 'pregnant women', 'Depression during Pregnancy', 'Six right-handed females (23-43 years, 12-33']","['tDCS', 'F3, cathode: F4', 'transcranial direct current stimulation (tDCS', 'twice-daily tDCS', 'Transcranial Direct Current Stimulation (tDCS']","['mean baseline BDI', 'Clinical (HAMD-21, BDI) and neuropsychological ratings (Trail Making Test A/B', 'tolerated and no adverse effects', 'HAMD-21 and BDI']","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0230370', 'cui_str': 'Structure of right hand'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0007441', 'cui_str': 'Cathode'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0006448', 'cui_str': 'Burundi'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0040604', 'cui_str': 'Trail making test'}, {'cui': 'C0853204', 'cui_str': 'No adverse effect'}]",,0.0320705,"Clinical ratings showed an improvement of mean baseline HAMD-21 from 22.50 ± 7.56 to 13.67 ± 3.93 after week 2, and to 8.75 ± 4.99 after week 4.","[{'ForeName': 'Anna Katharina', 'Initials': 'AK', 'LastName': 'Kurzeck', 'Affiliation': 'Department of Psychiatry, Hospital of the University of Munich, 80336 Munich, Germany.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Dechantsreiter', 'Affiliation': 'Department of Psychiatry, Hospital of the University of Munich, 80336 Munich, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Wilkening', 'Affiliation': 'Department of Psychiatry, Hospital of the University of Munich, 80336 Munich, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Kumpf', 'Affiliation': 'Department of Psychiatry, Hospital of the University of Munich, 80336 Munich, Germany.'}, {'ForeName': 'Tabea', 'Initials': 'T', 'LastName': 'Nenov-Matt', 'Affiliation': 'Department of Psychiatry, Hospital of the University of Munich, 80336 Munich, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Padberg', 'Affiliation': 'Department of Psychiatry, Hospital of the University of Munich, 80336 Munich, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Palm', 'Affiliation': 'Department of Psychiatry, Hospital of the University of Munich, 80336 Munich, Germany.'}]",Brain sciences,['10.3390/brainsci11070947'] 1932,34356168,Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center.,"Post-stroke spasticity frequently occurs in patients with stroke, and there is a need for more quality-of-life assessments for different therapies. We evaluated for the first time in Romania the quality of life among patients with post-stroke spasticity, comparing two therapies over a 6-month period: botulinum toxin type A (BOT) with conventional therapy (CON). We also assessed the reduction of spasticity and functionality secondary to the increase in the mobility in upper limbs. This study was based on a prospective, randomized design, including subjects with post-stroke spasticity (N = 34; 34-80 years of age): in the CON arm, patients received therapy against muscle spasticity and physiotherapy, and, in the BOT arm, patients received incobotulinumtoxin-A and additionally conventional treatment, if required. Among 34 treated subjects in the two arms, the quality of life was significantly higher after BOT therapy ( p < 0.001), represented by improvement in movement ( p < 0.001), usual activities ( p = 0.018), and distress ( p < 0.001). Improvements in muscle tone (Ashworth Scale) over 6 months of treatment period were greater in the BOT arm (100%) than in the CON arm (11.8%). These preliminary results suggested that incobotulinumtoxin-A increased quality of life by improving movement, daily activities, mental health, and muscle tone more effectively than conventional therapy and could form a basis for future comparator studies.",2021,"Among 34 treated subjects in the two arms, the quality of life was significantly higher after BOT therapy ( p < 0.001), represented by improvement in movement ( p < 0.001), usual activities ( p = 0.018), and distress ( p < 0.001).","['subjects with post-stroke spasticity (N = 34; 34-80 years of age', 'patients with stroke', 'Spastic Muscle Post-Stroke Patients', 'patients with post-stroke spasticity']","['therapy against muscle spasticity and physiotherapy', 'incobotulinumtoxin-A and additionally conventional treatment', 'botulinum toxin type A (BOT) with conventional therapy (CON', 'CON']","['quality of life by improving movement, daily activities, mental health, and muscle tone more effectively', 'distress', 'usual activities', 'Quality of Life Better', 'muscle tone (Ashworth Scale', 'quality of life']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0026841', 'cui_str': 'Muscle Tension'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0124628,"Among 34 treated subjects in the two arms, the quality of life was significantly higher after BOT therapy ( p < 0.001), represented by improvement in movement ( p < 0.001), usual activities ( p = 0.018), and distress ( p < 0.001).","[{'ForeName': 'Adina', 'Initials': 'A', 'LastName': 'Turcu-Stiolica', 'Affiliation': 'Department of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.'}, {'ForeName': 'Mihaela-Simona', 'Initials': 'MS', 'LastName': 'Subtirelu', 'Affiliation': 'Department of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.'}, {'ForeName': 'Ana-Maria', 'Initials': 'AM', 'LastName': 'Bumbea', 'Affiliation': 'Department of Physical and Rehabilitation Medicine, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.'}]",Brain sciences,['10.3390/brainsci11070934'] 1933,34356133,"Effects of Cognicise-Neurofeedback on Health Locus of Control, Depression, and Quantitative Electroencephalography Alpha Asymmetry in Elderly Women.","BACKGROUND With an increase in the aged population, there is a growing concern regarding the care of the elderly. This study aims to identify effects of cognicise-neurofeedback on health locus of control, depression, and quantitative electroencephalography (QEEG) alpha asymmetry in elderly women. METHODS A quasi-experimental control group pre-test-post-test design was used. Korean women aged 65 years or over at a senior welfare center were randomly allocated to the control ( n = 12) or experimental ( n = 19) groups from July to October 2019. The intervention consisted of cognicise (exercise with intensified cognitive activity) and neurofeedback twice a week for 10 weeks. The locus of control and depression were measured via self-reported questionnaires. QEEG alpha asymmetry was measured using BrainMaster. RESULTS Depression significantly decreased in the experimental group (t = 4.113, p = 0.001), while internality in the locus of control significantly decreased in the control group (t = 3.023, p = 0.012). On the other hand, QEEG alpha asymmetry index differences in F3-F4 between the pre-test and post-test were not significant in the experimental group (t = 0.491, p = 0.629) or control group (t = 0.413, p = 0.678). CONCLUSIONS Due to the coronavirus disease (COVID-19) pandemic, contact between the elderly and healthcare workers in the clinical practice field has become more restricted. These findings can help decrease negative emotions among elderly women in the community based on an integrated neuroscientific approach.",2021,"RESULTS Depression significantly decreased in the experimental group (t = 4.113, p = 0.001), while internality in the locus of control significantly decreased in the control group (t = 3.023, p = 0.012).","['elderly women', 'elderly women in the community based on an integrated neuroscientific approach', 'Elderly Women', 'Korean women aged 65 years or over at a senior welfare center']","['Cognicise-Neurofeedback', 'cognicise (exercise with intensified cognitive activity', 'cognicise-neurofeedback']","['Health Locus of Control, Depression, and Quantitative Electroencephalography Alpha Asymmetry', 'QEEG alpha asymmetry', 'health locus of control, depression, and quantitative electroencephalography (QEEG', 'negative emotions', 'Depression']","[{'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037440', 'cui_str': 'Social services'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0023953', 'cui_str': 'Locus of Control'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",,0.0215996,"RESULTS Depression significantly decreased in the experimental group (t = 4.113, p = 0.001), while internality in the locus of control significantly decreased in the control group (t = 3.023, p = 0.012).","[{'ForeName': 'Heewook', 'Initials': 'H', 'LastName': 'Weon', 'Affiliation': 'Department of Brain and Cognitive Science, Seoul University of Buddhism, Seoul 08559, Korea.'}, {'ForeName': 'Jieun', 'Initials': 'J', 'LastName': 'Yoo', 'Affiliation': 'College of Social Sciences, Yonsei University, Seoul 03722, Korea.'}, {'ForeName': 'Jumhwa', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Neuroscience Research Institute, Seoul University of Buddhism, Seoul 08559, Korea.'}, {'ForeName': 'Miso', 'Initials': 'M', 'LastName': 'Park', 'Affiliation': 'Neuroscience Research Institute, Seoul University of Buddhism, Seoul 08559, Korea.'}, {'ForeName': 'Haekyoung', 'Initials': 'H', 'LastName': 'Son', 'Affiliation': 'Department of Nursing, Eulji University, Seongnam-si 13135, Korea.'}]",Brain sciences,['10.3390/brainsci11070899'] 1934,34355544,The BACH project protocol: an international multicentre total Bile Acid Comparison and Harmonisation project and sub-study of the TURRIFIC randomised trial.,"OBJECTIVES Multicentre international trials relying on diagnoses derived from biochemical results may overlook the importance of assay standardisation from the participating laboratories. Here we describe a study protocol aimed at harmonising results from total bile acid determinations within the context of an international randomised controlled Trial of two treatments, URsodeoxycholic acid and RIFampicin, for women with severe early onset Intrahepatic Cholestasis of pregnancy (TURRIFIC), referred to as the Bile Acid Comparison and Harmonisation (BACH) study, with the aims of reducing inter-laboratory heterogeneity in total bile acid assays. METHODS We have simulated laboratory data to determine the feasibility of total bile acid recalibration using a reference set of patient samples with a consensus value approach and subsequently used regression-based techniques to transform the data. RESULTS From these simulations, we have demonstrated that mathematical recalibration of total bile acid results is plausible, with a high probability of successfully harmonising results across participating laboratories. CONCLUSIONS Standardisation of bile acid results facilitates the commutability of laboratory results and collation for statistical analysis. It may provide the momentum for broader application of the described techniques in the setting of large-scale multinational clinical trials dependent on results from non-standardised assays.",2021,"We have simulated laboratory data to determine the feasibility of total bile acid recalibration using a reference set of patient samples with a consensus value approach and subsequently used regression-based techniques to transform the data. ",['women with severe early onset Intrahepatic Cholestasis of pregnancy (TURRIFIC'],['URsodeoxycholic acid and RIFampicin'],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0268318', 'cui_str': 'Cholestasis of pregnancy'}]","[{'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C0035608', 'cui_str': 'Rifampin'}]",[],2.0,0.20477,"We have simulated laboratory data to determine the feasibility of total bile acid recalibration using a reference set of patient samples with a consensus value approach and subsequently used regression-based techniques to transform the data. ","[{'ForeName': 'Corey', 'Initials': 'C', 'LastName': 'Markus', 'Affiliation': 'Automated Laboratory, SA Pathology, Adelaide, Australia.'}, {'ForeName': 'Suzette', 'Initials': 'S', 'LastName': 'Coat', 'Affiliation': 'Robinson Research Institute, The University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Hanns-Ulrich', 'Initials': 'HU', 'LastName': 'Marschall', 'Affiliation': 'University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Williamson', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College, London, UK.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Dixon', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College, London, UK.""}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Fuller', 'Affiliation': 'Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Matthews', 'Affiliation': 'Flinders University International Centre for Point-of-Care Testing, Flinders Health and Medical Research Institute, Bedford Park, Australia.'}, {'ForeName': 'Wayne', 'Initials': 'W', 'LastName': 'Rankin', 'Affiliation': 'Chemical Pathology Directorate, SA Pathology, Adelaide, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Metz', 'Affiliation': 'Chemical Pathology Directorate, SA Pathology, Adelaide, Australia.'}, {'ForeName': 'William M', 'Initials': 'WM', 'LastName': 'Hague', 'Affiliation': 'Robinson Research Institute, The University of Adelaide, Adelaide, Australia.'}]",Clinical chemistry and laboratory medicine,['10.1515/cclm-2021-0496'] 1935,34334677,The Effect of Vibration on Pain During Heel Lance Procedures in Newborns: A Randomized Controlled Trial.,"BACKGROUND/SIGNIFICANCE The pain-reducing effect of applying vibration, which is used as a nonpharmacological method in pain management, is explained by the gate control theory developed by Melzack and Wall. Studies that are based on this theory have shown similar results to those of Melzack and Wall, indicating that pain-transmitting nerves are suppressed by vibrations, leading to higher pain thresholds. PURPOSE The study aimed to evaluate the effect of applying vibration to manage pain during heel lance procedures in newborns. METHODS This is a randomized, controlled experimental study. The study sample included 56 newborns determined using power analysis (vibration group = 28; control group = 28). For those in the vibration group, a vibrating device was used for approximately 30 seconds before the heel lance procedure and then continued throughout the procedure. No interventions were provided to the newborns in the control group. Pain in the newborns was evaluated by the nurse who performed the heel lance procedures, before the procedures and 15 to 20 seconds and 5 minutes after procedures, and by 2 specialists who viewed the video footage and conducted the Neonatal Infant Pain Scale examination. RESULTS The pain scores were significantly lower at 15 to 20 seconds and 5 minutes after the heel lance procedures in the group that received vibrations than in the control group (P < .05). IMPLICATIONS FOR PRACTICE The application of vibration, which is effective, nonpharmacological, and noninvasive, could help nurses manage pain in newborns as a nonpharmacological method. IMPLICATIONS FOR RESEARCH The number of studies that examine the effect that vibration has on pain associated with heel lance procedures in newborns is very limited, and it is recommended that further studies be conducted with larger sample sizes.",2021,"The pain scores were significantly lower at 15 to 20 seconds and 5 minutes after the heel lance procedures in the group that received vibrations than in the control group (P < .05). ","['newborns', '56 newborns determined using power analysis (vibration group = 28; control group = 28', 'Newborns']",['Vibration'],"['Pain', 'pain scores']","[{'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",56.0,0.0441291,"The pain scores were significantly lower at 15 to 20 seconds and 5 minutes after the heel lance procedures in the group that received vibrations than in the control group (P < .05). ","[{'ForeName': 'Nihal', 'Initials': 'N', 'LastName': 'Avan Antepli', 'Affiliation': 'Sanliurfa Birecik Cuma Gokdogan Primary Care Clinic No. 3, Turkey (Ms Avan Antepli); Department of Nursing, Faculty of Health Sciences, Gaziantep University, Gaziantep, Turkey (Dr Bilsin Kocamaz); and Department of Nursing, Faculty of Health Sciences, Gaziantep Islamic Science and Technology University, Gaziantep, Turkey (Dr Güngörmüs¸).'}, {'ForeName': 'Elif', 'Initials': 'E', 'LastName': 'Bilsin Kocamaz', 'Affiliation': ''}, {'ForeName': 'Zeynep', 'Initials': 'Z', 'LastName': 'Güngörmüs', 'Affiliation': ''}]",Advances in neonatal care : official journal of the National Association of Neonatal Nurses,['10.1097/ANC.0000000000000918'] 1936,34334668,Prospective Trial of Near-Infrared Spectroscopy for Continuous Noninvasive Monitoring of Free Fibular Flaps.,"INTRODUCTION Some free flaps develop postoperative vessel thrombosis, which influences the flap survival rate. Early discovery and identification of vascular crisis are critical to the success rate of flap salvage. The primary aims of this study were to determine the features of postoperative blood supply changes in fibular flaps with normal and abnormal blood flow, using near-infrared spectroscopy (NIRS), to monitor oxygenation and blood flow, and to characterize the probable risk factors for vascular crisis. METHODS Sixty-three consecutive patients undergoing reconstruction of unilateral mandibular defects with free fibular flaps at the Peking University School of Stomatology were included. Patients were divided into 2 groups, A (n = 38) and B (n = 25); fibular flaps in group A underwent continuous NIRS monitoring from immediately postoperatively until 7 days postoperatively (approximately 150 hours), whereas fibular flaps and opposite mandibles in group B underwent intermittent monitoring: once every 4 hours during the first 24 hours postoperatively and once every 12 hours from 24 to 168 hours postoperatively. RESULTS Six fibular flaps developed vascular thromboses: 4 were venous thromboses and 2 were arterial thromboses; 5 were rescued after exploration. Of 6 regional oxygen saturation (rSO2) values in the continuous monitoring group, 4 showed no significant differences at any time point compared with the intermittent monitoring group (P > 0.05). The rSO2 of the fibular flap was significantly different from that in the opposite mandible in the first 36 hours postoperatively (P < 0.05). This difference decreased over time. During the initial period of venous thrombosis, rSO2, deoxyhemoglobin, and oxygenated hemoglobin all rose slightly, then showed simultaneous rapid reduction. However, the magnitude of reduction was smaller for deoxyhemoglobin than for oxygenated hemoglobin. CONCLUSIONS Near-infrared spectroscopy can be used for noninvasive and reliable assessment of oxygenation and blood flow in free flaps through continuous, real-time monitoring. It is also portable, inexpensive, and simple to operate. In addition, the detection depth of NIRS is up to 2.0 cm, so it can be used to monitor buried flaps with depths <2.0 cm.",2021,Six fibular flaps developed vascular thromboses: 4 were venous thromboses and 2 were arterial thromboses; 5 were rescued after exploration.,['Sixty-three consecutive patients undergoing reconstruction of unilateral mandibular defects with free fibular flaps at the Peking University School of Stomatology were included'],"['deoxyhemoglobin', 'fibular flaps in group A underwent continuous NIRS monitoring', 'fibular flaps with normal and abnormal blood flow, using near-infrared spectroscopy (NIRS', 'fibular flaps and opposite mandibles in group B underwent intermittent monitoring', 'Near-Infrared Spectroscopy']","['venous thrombosis, rSO2, deoxyhemoglobin, and oxygenated hemoglobin', 'rSO2 of the fibular flap', 'regional oxygen saturation (rSO2) values', 'vascular thromboses', 'flap survival rate']","[{'cui': 'C4319614', 'cui_str': '63'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0441022', 'cui_str': 'Fibular flap'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0029167', 'cui_str': 'Medicine, Oral'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0057437', 'cui_str': 'Deoxyhemoglobin'}, {'cui': 'C0441022', 'cui_str': 'Fibular flap'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0376519', 'cui_str': 'Near-infrared spectroscopy'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0232340', 'cui_str': 'Abnormal vascular flow'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}]","[{'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}, {'cui': 'C0057437', 'cui_str': 'Deoxyhemoglobin'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0441022', 'cui_str': 'Fibular flap'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",63.0,0.0168468,Six fibular flaps developed vascular thromboses: 4 were venous thromboses and 2 were arterial thromboses; 5 were rescued after exploration.,"[{'ForeName': 'Si-Yuan', 'Initials': 'SY', 'LastName': 'Ouyang', 'Affiliation': 'From the Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology and National Clinical Research Center for Oral Diseases and National Engineering Laboratory for Digital and Material Technology of Stomatology and Beijing Key Laboratory of Digital Stomatolog, HaiDian District, Beijing, China Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, P.R. China.'}, {'ForeName': 'Zhi-Gang', 'Initials': 'ZG', 'LastName': 'Cai', 'Affiliation': ''}, {'ForeName': 'Xiao Feng', 'Initials': 'XF', 'LastName': 'Shan', 'Affiliation': ''}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ''}]",Annals of plastic surgery,['10.1097/SAP.0000000000002915'] 1937,34333191,The Feasibility of a Lifestyle Physical Activity Intervention for Black Women with Asthma.,"BACKGROUND Black women are disproportionately affected by both physical inactivity and asthma. Lifestyle physical activity (PA) interventions targeted for Black women with asthma are lacking. OBJECTIVE To assess the feasibility and acceptability as well as preliminary effects of a lifestyle PA intervention culturally tailored for Black women with asthma. METHODS Black women (age 18-70 years) with uncontrolled asthma (Asthma Control Test <20) were recruited. Outcome assessments at baseline and 24 weeks included measures of: feasibility and acceptability, asthma control, quality of life, health care use, and PA levels. Participants were randomized to the intervention (asthma education, Fitbit, monthly group sessions, text messages, individual step goals, and study manual) or enhanced usual care (EUC) (asthma education plus Fitbit) group. RESULTS Of the 53 women randomized (EUC = 28; intervention = 25), 92% remained in the intervention (23 of 25) and 76% completing the 24-week outcome assessment. Overall intervention satisfaction (mean score, 6.88 of 7) and individual components were high at 24 weeks. Mean change in asthma control questionnaire between groups was not significant at 24 weeks (intervention = -0.41 vs EUC = 0.03 [P = .08]; effect size = -0.38) but approached clinical significance (0.5). At 24 weeks, more women receiving the intervention had controlled asthma compared with EUC (36.84% vs 9.52%; P = .04). Clinically significant improvements (0.5) in quality of life were found in the intervention group (mean change: intervention = 0.58 vs EUC = 0.10; P = .10) at 24 weeks. CONCLUSIONS A culturally tailored lifestyle PA intervention is feasible and demonstrates improvements in asthma control and quality of life among Black women with asthma. These preliminary findings support the need for PA lifestyle interventions in urban Black women with asthma.",2021,Mean change in ACQ between groups was not significant at 24-weeks,"['AA women with asthma are lacking', 'urban AA women with asthma', '53 women randomized (EUC=28, Intervention=25', 'African American (AA) women', 'AA women (18-70 years old) with uncontrolled asthma (Asthma Control Test <20) were recruited', 'African American Women with Asthma', 'AA women with asthma']","['intervention (asthma education, Fitbit, monthly group sessions, text messages, individual step goals, study manual) or enhanced usual care (EUC; asthma education + Fitbit) group', 'Lifestyle Physical Activity Intervention', 'lifestyle PA intervention culturally-tailored', 'culturally-tailored lifestyle PA intervention', 'Lifestyle physical activity (PA) interventions']","['asthma control and quality of life', 'feasibility/acceptability, asthma control, quality of life, health care utilization, PA levels', 'feasibility/acceptability', 'Mean change in ACQ', 'quality of life', 'Overall intervention satisfaction']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C4048375', 'cui_str': 'Asthma control test'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1679754', 'cui_str': 'Asthma education'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]","[{'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0030672', 'cui_str': 'Health Care Utilization'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",53.0,0.0609597,Mean change in ACQ between groups was not significant at 24-weeks,"[{'ForeName': 'Sharmilee M', 'Initials': 'SM', 'LastName': 'Nyenhuis', 'Affiliation': 'Department of Medicine, University of Illinois at Chicago, Chicago, Ill. Electronic address: snyenhui@uic.edu.'}, {'ForeName': 'Nida', 'Initials': 'N', 'LastName': 'Shah', 'Affiliation': 'Department of Medicine, University of Illinois at Chicago, Chicago, Ill.'}, {'ForeName': 'Hajwa', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Center for Clinical and Translational Science, University of Illinois at Chicago, Chicago, Ill.'}, {'ForeName': 'David X', 'Initials': 'DX', 'LastName': 'Marquez', 'Affiliation': 'Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, Ill.'}, {'ForeName': 'JoEllen', 'Initials': 'J', 'LastName': 'Wilbur', 'Affiliation': 'Department of Women, Children and Family Nursing, Rush University, Chicago, Ill.'}, {'ForeName': 'Lisa K', 'Initials': 'LK', 'LastName': 'Sharp', 'Affiliation': 'Department of Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago, Chicago, Ill.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2021.07.028'] 1938,34333146,HPV-induced condylomata acuminata treated by Photodynamic Therapy in comparison with trichloroacetic acid: A randomized clinical trial.,"OBJECTIVES This is a randomized controlled clinical trial comparing Photodynamic Therapy (PDT) and the application of trichloracetic acid (TAA) in the treatment of HPV condyloma in the perianal and vulva regions. Design, Randomised controlled, open label, trial. They were allocated to each treatment following randomization by a computer program. SETTING Women Health Ambulatory in São Carlos city, São Paulo State in the Brazil. PARTICIPANTS 36 patients evaluated. 31 patients fulfilled the study requirements. INTERVENTION Photodynamic Therapy (PDT) versus trichloracetic acid (TAA). The PDT protocol used the prodrug methyl aminolevulinate incubated for 3 hours and irradiation at 630 nm (100 J/cm²). In the treatment using TAA, warts received a small amount of acid using a cotton swab. Both treatments were repeated weekly until the lesions disappeared completely or until 10 sessions were completed. MAIN OUTCOME MEASURE Clinical analysis. Follow-up between 12 and 30 months after the complete treatment. RESULTS A total of 16 patients were treated with PDT and 15 patients with TAA. A complete response rate of 60% for TAA and 63% for PDT, with a recurrence rate of 33% for TAA and 0% for PDT. CONCLUSION PDT appears not only to treat lesions due to physical destruction of condyloma and subclinical lesions, but also to modulate the immune system and/or also to decrease the local viral load, suggesting a lower recurrence compared to the TAA group.",2021,"Was reached a complete response rate of 60% for TAA and 63% for PDT, with a recurrence rate of 33% for TAA and 0% for PDT. ","['HPV condyloma in the perianal and vulva regions', 'Women Health Ambulatory in São Carlos city, São Paulo State in the Brazil', '16 patients were treated with PDT and 15 patients with TAA', '31 patients fulfilled the study requirements', '36 patients evaluated']","['trichloracetic acid (TAA', 'Trichloroacetic Acid', 'Photodynamic Therapy (PDT) versus trichloracetic acid (TAA', 'HPV-induced condylomata acuminata treated by Photodynamic Therapy', 'photodynamic Therapy (PDT']","['complete response rate', 'recurrence rate']","[{'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0009663', 'cui_str': 'Genital warts'}, {'cui': 'C0442158', 'cui_str': 'Perianal'}, {'cui': 'C0042993', 'cui_str': 'Vulval structure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0080339', 'cui_str': ""Woman's Health""}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0445462', 'cui_str': 'Carlos'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0040900', 'cui_str': 'Trichloroacetic acid'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0009663', 'cui_str': 'Genital warts'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",16.0,0.0618434,"Was reached a complete response rate of 60% for TAA and 63% for PDT, with a recurrence rate of 33% for TAA and 0% for PDT. ","[{'ForeName': 'Hilde Harb', 'Initials': 'HH', 'LastName': 'Buzzá', 'Affiliation': 'Sao Carlos Institute of Physics, University of Sao Paulo, Sao Carlos, SP, Brazil. Electronic address: hilde.buzza@gmail.com.'}, {'ForeName': 'Mirian Denise', 'Initials': 'MD', 'LastName': 'Stringasci', 'Affiliation': 'Sao Carlos Institute of Physics, University of Sao Paulo, Sao Carlos, SP, Brazil.'}, {'ForeName': 'Semira Silva', 'Initials': 'SS', 'LastName': 'de Arruda', 'Affiliation': 'Sao Carlos Institute of Physics, University of Sao Paulo, Sao Carlos, SP, Brazil; Biological and Health Sciences Center, Federal University of Sao Carlos, Sao Carlos, SP, Brazil.'}, {'ForeName': 'Rita Helena Schiavone', 'Initials': 'RHS', 'LastName': 'Crestana', 'Affiliation': 'Department of Medicine, Federal University of Sao Carlos, Sao Carlos, SP, Brazil.'}, {'ForeName': 'Cynthia Aparecida', 'Initials': 'CA', 'LastName': 'de Castro', 'Affiliation': 'Department of Morphology and Pathology, Federal University of Sao Carlos, Sao Carlos, SP, Brazil.'}, {'ForeName': 'Vanderlei Salvador', 'Initials': 'VS', 'LastName': 'Bagnato', 'Affiliation': 'Sao Carlos Institute of Physics, University of Sao Paulo, Sao Carlos, SP, Brazil; Hagler Fellow, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Natalia Mayumi', 'Initials': 'NM', 'LastName': 'Inada', 'Affiliation': 'Sao Carlos Institute of Physics, University of Sao Paulo, Sao Carlos, SP, Brazil.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102465'] 1939,34337893,Blood glucose concentration is unchanged during exposure to acute normobaric hypoxia in healthy humans.,"Normal blood [glucose] regulation is critical to support metabolism, particularly in contexts of metabolic stressors (e.g., exercise, high altitude hypoxia). Data regarding blood [glucose] regulation in hypoxia are inconclusive. We aimed to characterize blood [glucose] over 80 min following glucose ingestion during both normoxia and acute normobaric hypoxia. In a randomized cross-over design, on two separate days, 28 healthy participants (16 females; 21.8 ± 1.6 years; BMI 22.8 ± 2.5 kg/m 2 ) were randomly exposed to either NX (room air; fraction of inspired [F I ]O 2 ~0.21) or HX (F I O 2 ~0.148) in a normobaric hypoxia chamber. Measured F I O 2 and peripheral oxygen saturation were both lower at baseline in hypoxia (p < 0.001), which was maintained over 80 min, confirming the hypoxic intervention. Following a 10-min baseline (BL) under both conditions, participants consumed a standardized glucose beverage (75 g, 296 ml) and blood [glucose] and physiological variables were measured at BL intermittently over 80 min. Blood [glucose] was measured from finger capillary samples via glucometer. Initial fasted blood [glucose] was not different between trials (NX:4.8 ± 0.4 vs. HX:4.9 ± 0.4 mmol/L; p = 0.47). Blood [glucose] was sampled every 10 min (absolute, delta, and percent change) following glucose ingestion over 80 min, and was not different between conditions (p > 0.77). In addition, mean, peak, and time-to-peak responses during the 80 min were not different between conditions (p > 0.14). There were also no sex differences in these blood [glucose] responses in hypoxia. We conclude that glucose regulation is unchanged in young, healthy participants with exposure to acute steady-state normobaric hypoxia, likely due to counterbalancing mechanisms underlying blood [glucose] regulation in hypoxia.",2021,"Measured F I O 2 and peripheral oxygen saturation were both lower at baseline in hypoxia (p < 0.001), which was maintained over 80 min, confirming the hypoxic intervention.","['healthy humans', 'young, healthy participants with exposure to acute steady-state normobaric hypoxia', '28\xa0healthy participants (16 females; 21.8\xa0±\xa01.6\xa0years; BMI 22.8\xa0±\xa02.5\xa0kg/m 2 ']","['NX (room air; fraction of inspired [F I ]O 2 ~0.21) or HX (F I O 2 ~0.148) in a normobaric hypoxia chamber', 'standardized glucose beverage']","['Measured F I O 2 and peripheral oxygen saturation', 'Initial fasted blood [glucose', 'mean, peak, and time-to-peak responses', 'blood [glucose] responses', 'Blood [glucose', 'Blood glucose concentration']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517508', 'cui_str': '1.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C3844011', 'cui_str': '2.5'}]","[{'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}]","[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}]",,0.035154,"Measured F I O 2 and peripheral oxygen saturation were both lower at baseline in hypoxia (p < 0.001), which was maintained over 80 min, confirming the hypoxic intervention.","[{'ForeName': 'Jason S', 'Initials': 'JS', 'LastName': 'Chan', 'Affiliation': 'Department of Biology, Faculty of Science and Technology, Mount Royal University, Calgary, AB, Canada.'}, {'ForeName': 'Alexandra E', 'Initials': 'AE', 'LastName': 'Chiew', 'Affiliation': 'Department of Biology, Faculty of Science and Technology, Mount Royal University, Calgary, AB, Canada.'}, {'ForeName': 'Alexander N', 'Initials': 'AN', 'LastName': 'Rimke', 'Affiliation': 'Department of Biology, Faculty of Science and Technology, Mount Royal University, Calgary, AB, Canada.'}, {'ForeName': 'Garrick', 'Initials': 'G', 'LastName': 'Chan', 'Affiliation': 'Department of Biology, Faculty of Science and Technology, Mount Royal University, Calgary, AB, Canada.'}, {'ForeName': 'Zahrah H', 'Initials': 'ZH', 'LastName': 'Rampuri', 'Affiliation': 'Department of Biology, Faculty of Science and Technology, Mount Royal University, Calgary, AB, Canada.'}, {'ForeName': 'Mackenzie D', 'Initials': 'MD', 'LastName': 'Kozak', 'Affiliation': 'Department of Biology, Faculty of Science and Technology, Mount Royal University, Calgary, AB, Canada.'}, {'ForeName': 'Normand G', 'Initials': 'NG', 'LastName': 'Boulé', 'Affiliation': 'Alberta Diabetes Institute, Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Craig D', 'Initials': 'CD', 'LastName': 'Steinback', 'Affiliation': 'Alberta Diabetes Institute, Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Margie H', 'Initials': 'MH', 'LastName': 'Davenport', 'Affiliation': 'Alberta Diabetes Institute, Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Trevor A', 'Initials': 'TA', 'LastName': 'Day', 'Affiliation': 'Department of Biology, Faculty of Science and Technology, Mount Royal University, Calgary, AB, Canada.'}]",Physiological reports,['10.14814/phy2.14932'] 1940,34341340,"The Upworthy Research Archive, a time series of 32,487 experiments in U.S. media.","The pursuit of audience attention online has led organizations to conduct thousands of behavioral experiments each year in media, politics, activism, and digital technology. One pioneer of A/B tests was Upworthy.com, a U.S. media publisher that conducted a randomized trial for every article they published. Each experiment tested variations in a headline and image ""package,"" recording how many randomly-assigned viewers selected each variation. While none of these tests were designed to answer scientific questions, scientists can advance knowledge by meta-analyzing and data-mining the tens of thousands of experiments Upworthy conducted. This archive records the stimuli and outcome for every A/B test fielded by Upworthy between January 24, 2013 and April 30, 2015. In total, the archive includes 32,487 experiments, 150,817 experiment arms, and 538,272,878 participant assignments. The open access dataset is organized to support exploratory and confirmatory research, as well as meta-scientific research on ways that scientists make use of the archive.",2021,"The pursuit of audience attention online has led organizations to conduct thousands of behavioral experiments each year in media, politics, activism, and digital technology.",[],[],[],[],[],[],,0.0541258,"The pursuit of audience attention online has led organizations to conduct thousands of behavioral experiments each year in media, politics, activism, and digital technology.","[{'ForeName': 'J Nathan', 'Initials': 'JN', 'LastName': 'Matias', 'Affiliation': 'Cornell University Department of Communication, Ithaca, USA. nathan.matias@cornell.edu.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Munger', 'Affiliation': 'Penn State University Department of Political Science, State College, USA.'}, {'ForeName': 'Marianne Aubin', 'Initials': 'MA', 'LastName': 'Le Quere', 'Affiliation': 'Cornell University Department of Information Science, Ithaca, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Ebersole', 'Affiliation': 'University of Virginia, Charlottesville, USA.'}]",Scientific data,['10.1038/s41597-021-00934-7'] 1941,34342620,Effect of a Sedation and Ventilator Liberation Protocol vs Usual Care on Duration of Invasive Mechanical Ventilation in Pediatric Intensive Care Units: A Randomized Clinical Trial.,"Importance There is limited evidence on the optimal strategy for liberating infants and children from invasive mechanical ventilation in the pediatric intensive care unit. Objective To determine if a sedation and ventilator liberation protocol intervention reduces the duration of invasive mechanical ventilation in infants and children anticipated to require prolonged mechanical ventilation. Design, Setting, and Participants A pragmatic multicenter, stepped-wedge, cluster randomized clinical trial was conducted that included 17 hospital sites (18 pediatric intensive care units) in the UK sequentially randomized from usual care to the protocol intervention. From February 2018 to October 2019, 8843 critically ill infants and children anticipated to require prolonged mechanical ventilation were recruited. The last date of follow-up was November 11, 2019. Interventions Pediatric intensive care units provided usual care (n = 4155 infants and children) or a sedation and ventilator liberation protocol intervention (n = 4688 infants and children) that consisted of assessment of sedation level, daily screening for readiness to undertake a spontaneous breathing trial, a spontaneous breathing trial to test ventilator liberation potential, and daily rounds to review sedation and readiness screening and set patient-relevant targets. Main Outcomes and Measures The primary outcome was the duration of invasive mechanical ventilation from initiation of ventilation until the first successful extubation. The primary estimate of the treatment effect was a hazard ratio (with a 95% CI) adjusted for calendar time and cluster (hospital site) for infants and children anticipated to require prolonged mechanical ventilation. Results There were a total of 8843 infants and children (median age, 8 months [interquartile range, 1 to 46 months]; 42% were female) who completed the trial. There was a significantly shorter median time to successful extubation for the protocol intervention compared with usual care (64.8 hours vs 66.2 hours, respectively; adjusted median difference, -6.1 hours [interquartile range, -8.2 to -5.3 hours]; adjusted hazard ratio, 1.11 [95% CI, 1.02 to 1.20], P = .02). The serious adverse event of hypoxia occurred in 9 (0.2%) infants and children for the protocol intervention vs 11 (0.3%) for usual care; nonvascular device dislodgement occurred in 2 (0.04%) vs 7 (0.1%), respectively. Conclusions and Relevance Among infants and children anticipated to require prolonged mechanical ventilation, a sedation and ventilator liberation protocol intervention compared with usual care resulted in a statistically significant reduction in time to first successful extubation. However, the clinical importance of the effect size is uncertain. Trial Registration isrctn.org Identifier: ISRCTN16998143.",2021,"There was a significantly shorter median time to successful extubation for the protocol intervention compared with usual care (64.8 hours vs 66.2 hours, respectively; adjusted median difference, -6.1 hours [interquartile range, -8.2 to -5.3 hours]; adjusted hazard ratio, 1.11 [95% CI, 1.02 to 1.20], P = .02).","['infants and children', 'Pediatric Intensive Care Units', 'included 17 hospital sites (18 pediatric intensive care units) in the UK sequentially randomized from usual care to the protocol intervention', 'From February 2018 to October 2019, 8843 critically ill infants and children anticipated to require prolonged mechanical ventilation were recruited', '8843 infants and children (median age, 8 months [interquartile range, 1 to 46 months]; 42% were female) who completed the trial', 'n\u2009=\u20094688 infants and children']","['sedation level, daily screening for readiness to undertake a spontaneous breathing trial, a spontaneous breathing trial to test ventilator liberation potential, and daily rounds to review sedation and readiness screening and set patient-relevant targets', 'Sedation and Ventilator Liberation Protocol vs Usual Care', 'sedation and ventilator liberation protocol intervention', 'Pediatric intensive care units provided usual care (n\u2009=\u20094155 infants and children) or a sedation and ventilator liberation protocol intervention']","['shorter median time to successful extubation', 'calendar time and cluster (hospital site', 'time to first successful extubation', 'duration of invasive mechanical ventilation from initiation of ventilation until the first successful extubation', 'serious adverse event of hypoxia', 'Duration of Invasive Mechanical Ventilation', 'usual care; nonvascular device dislodgement', 'duration of invasive mechanical ventilation']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021710', 'cui_str': 'Pediatric intensive care unit'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C1828139', 'cui_str': 'Trial for spontaneous breathing'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0332490', 'cui_str': 'Round shape'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0021710', 'cui_str': 'Pediatric intensive care unit'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C1516147', 'cui_str': 'Calendars'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C1608950', 'cui_str': 'Device dislocation'}]",8843.0,0.107649,"There was a significantly shorter median time to successful extubation for the protocol intervention compared with usual care (64.8 hours vs 66.2 hours, respectively; adjusted median difference, -6.1 hours [interquartile range, -8.2 to -5.3 hours]; adjusted hazard ratio, 1.11 [95% CI, 1.02 to 1.20], P = .02).","[{'ForeName': 'Bronagh', 'Initials': 'B', 'LastName': 'Blackwood', 'Affiliation': ""Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Ireland.""}, {'ForeName': 'Lyvonne N', 'Initials': 'LN', 'LastName': 'Tume', 'Affiliation': 'School of Health and Society, University of Salford, Manchester, England.'}, {'ForeName': 'Kevin P', 'Initials': 'KP', 'LastName': 'Morris', 'Affiliation': ""Birmingham Women's and Children's NHS Foundation Trust, Birmingham, England.""}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Clarke', 'Affiliation': ""Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Ireland.""}, {'ForeName': 'Clíona', 'Initials': 'C', 'LastName': 'McDowell', 'Affiliation': 'Northern Ireland Clinical Trials Unit, Royal Hospitals, Belfast, Ireland.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Hemming', 'Affiliation': 'University of Birmingham, Birmingham, England.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Peters', 'Affiliation': 'Great Ormond Street Hospital, London, England.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'McIlmurray', 'Affiliation': ""Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Ireland.""}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Jordan', 'Affiliation': ""Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Ireland.""}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Agus', 'Affiliation': 'Northern Ireland Clinical Trials Unit, Royal Hospitals, Belfast, Ireland.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Murray', 'Affiliation': 'Northern Ireland Clinical Trials Unit, Royal Hospitals, Belfast, Ireland.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Parslow', 'Affiliation': 'Leeds Institute for Data Analytics, School of Medicine, University of Leeds, Leeds, England.'}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Walsh', 'Affiliation': 'Usher Institute of Population Health Sciences, University of Edinburgh, Edinburgh, Scotland.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Macrae', 'Affiliation': 'Royal Brompton Hospital, London, England.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Easter', 'Affiliation': 'University of Birmingham, Birmingham, England.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Feltbower', 'Affiliation': 'Leeds Institute for Data Analytics, School of Medicine, University of Leeds, Leeds, England.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'McAuley', 'Affiliation': ""Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Ireland.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2021.10296'] 1942,34342619,Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial.,"Importance Women with an early nonviable pregnancy of unknown location are at high risk of ectopic pregnancy and its inherent morbidity and mortality. Successful and timely resolution of the gestation, while minimizing unscheduled interventions, are important priorities. Objective To determine if active management is more effective in achieving pregnancy resolution than expectant management and whether the use of empirical methotrexate is noninferior to uterine evacuation followed by methotrexate if needed. Design, Setting, and Participants This multicenter randomized clinical trial recruited 255 hemodynamically stable women with a diagnosed persisting pregnancy of unknown location between July 25, 2014, and June 4, 2019, in 12 medical centers in the United States (final follow up, August 19, 2019). Interventions Eligible patients were randomized in a 1:1:1 ratio to expectant management (n = 86), active management with uterine evacuation followed by methotrexate if needed (n = 87), or active management with empirical methotrexate using a 2-dose protocol (n = 82). Main Outcomes and Measures The primary outcome was successful resolution of the pregnancy without change from initial strategy. The primary hypothesis tested for superiority of the active groups combined vs expectant management, and a secondary hypothesis tested for noninferiority of empirical methotrexate compared with uterine evacuation with methotrexate as needed using a noninferiority margin of -12%. Results Among 255 patients who were randomized (median age, 31 years; interquartile range, 27-36 years), 253 (99.2%) completed the trial. Ninety-nine patients (39%) declined their randomized allocation (26.7% declined expectant management, 48.3% declined uterine evacuation, and 41.5% declined empirical methotrexate) and crossed over to a different group. Compared with patients randomized to receive expectant management (n = 86), women randomized to receive active management (n = 169) were significantly more likely to experience successful pregnancy resolution without change in their initial management strategy (51.5% vs 36.0%; difference, 15.4% [95% CI, 2.8% to 28.1%]; rate ratio, 1.43 [95% CI, 1.04 to 1.96]). Among active management strategies, empirical methotrexate was noninferior to uterine evacuation followed by methotrexate if needed with regard to successful pregnancy resolution without change in management strategy (54.9% vs 48.3%; difference, 6.6% [1-sided 97.5% CI, -8.4% to ∞]). The most common adverse event was vaginal bleeding for all of the 3 management groups (44.2%-52.9%). Conclusions and Relevance Among patients with a persisting pregnancy of unknown location, patients randomized to receive active management, compared with those randomized to receive expectant management, more frequently achieved successful pregnancy resolution without change from the initial management strategy. The substantial crossover between groups should be considered when interpreting the results. Trial Registration ClinicalTrials.gov Identifier: NCT02152696.",2021,"The most common adverse event was vaginal bleeding for all of the 3 management groups (44.2%-52.9%). ","['Patients With a Persisting Pregnancy of Unknown Location', 'patients with a persisting pregnancy', '255 patients who were randomized (median age, 31 years; interquartile range, 27-36 years), 253 (99.2%) completed the trial', '255 hemodynamically stable women with a diagnosed persisting pregnancy of unknown location between July 25, 2014, and June 4, 2019, in 12 medical centers in the United States (final follow up, August 19, 2019']","['expectant management (n\u2009=\u200986), active management with uterine evacuation followed by methotrexate if needed (n\u2009=\u200987), or active management with empirical methotrexate', 'expectant management', 'methotrexate', 'Active vs Expectant Management Strategy']","['successful resolution of the pregnancy without change from initial strategy', 'experience successful pregnancy resolution', 'successful pregnancy resolution', 'vaginal bleeding', 'uterine evacuation', 'Successful Resolution of Pregnancy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3495853', 'cui_str': 'Pregnancy of unknown location'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0578150', 'cui_str': 'Hemodynamically stable'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0700325', 'cui_str': 'Patient status observation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C1282573', 'cui_str': 'Evacuation procedure'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0027552', 'cui_str': 'Needed'}]","[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C2979982', 'cui_str': 'Vaginal bleeding'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C1282573', 'cui_str': 'Evacuation procedure'}]",255.0,0.0621186,"The most common adverse event was vaginal bleeding for all of the 3 management groups (44.2%-52.9%). ","[{'ForeName': 'Kurt T', 'Initials': 'KT', 'LastName': 'Barnhart', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Karl R', 'Initials': 'KR', 'LastName': 'Hansen', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City.'}, {'ForeName': 'Mary D', 'Initials': 'MD', 'LastName': 'Stephenson', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Illinois at Chicago.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Usadi', 'Affiliation': 'Department of Obstetrics and Gynecology, Atrium Health, Charlotte, North Carolina.'}, {'ForeName': 'Anne Z', 'Initials': 'AZ', 'LastName': 'Steiner', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Marcelle I', 'Initials': 'MI', 'LastName': 'Cedars', 'Affiliation': 'Department of Obstetrics and Gynecology, University of California at San Francisco.'}, {'ForeName': 'Emily S', 'Initials': 'ES', 'LastName': 'Jungheim', 'Affiliation': 'Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Hoeger', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Rochester, Rochester, New York.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Krawetz', 'Affiliation': 'Department of Obstetrics and Gynecology and Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Benjie', 'Initials': 'B', 'LastName': 'Mills', 'Affiliation': 'Department of Obstetrics & Gynecology, Prisma Health, University of South Carolina School of Medicine-Greenville.'}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Alston', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado and Denver Health Medical Center, Denver.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Coutifaris', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Suneeta', 'Initials': 'S', 'LastName': 'Senapati', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Sarita', 'Initials': 'S', 'LastName': 'Sonalkar', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Diamond', 'Affiliation': 'Department of Obstetrics and Gynecology, Augusta University, Augusta, Georgia.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Wild', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City.'}, {'ForeName': 'Mitchell', 'Initials': 'M', 'LastName': 'Rosen', 'Affiliation': 'Department of Obstetrics and Gynecology, University of California at San Francisco.'}, {'ForeName': 'Mary D', 'Initials': 'MD', 'LastName': 'Sammel', 'Affiliation': 'Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora.'}, {'ForeName': 'Nanette', 'Initials': 'N', 'LastName': 'Santoro', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado, Denver.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Eisenberg', 'Affiliation': 'Fertility and Infertility Branch, National Institute of Child Health and Human Development, Rockville, Maryland.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': 'Department of Biostatistics, Yale University, New Haven, Connecticut.'}, {'ForeName': 'Heping', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Biostatistics, Yale University, New Haven, Connecticut.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2021.10767'] 1943,34342608,"Three-Dimensional Heads-up Cataract Surgery Using Femtosecond Laser: Efficiency, Efficacy, Safety, and Medical Education-A Randomized Clinical Trial.","Purpose To compare the efficiency, efficacy, and safety, as well as the educational value, of heads-up (three-dimensional visualization system-assisted) and traditional microscopic cataract surgery. Methods This randomized noninferiority trial enrolled 242 eyes of 201 patients who received femtosecond laser-assisted cataract surgery. The questionnaire study enrolled 26 medical interns and 39 medical students. Patients received surgery under either a three-dimensional visualization system (3D group, 117 eyes) or traditional microscope (TM group, 125 eyes) after random allocation. The primary outcome was surgical time. The noninferiority margin of surgical time was 60 seconds. Secondary outcomes included ultrasound power, phacoemulsification time, visual acuity, intraocular pressure, endothelial cell density, central corneal thickness, complications, and observer satisfaction scores for surgical procedures. Results Surgical time was 462.03 ± 80.36 seconds in the 3D group and 452.13 ± 76.63 seconds in the TM group (difference 9.90 seconds; 95% CI, -9.98 to 29.78; P = 0.365). Visual acuity and other perioperative parameters were comparable between the 3D group and the TM group (all P > 0.05). Incidences of both intraoperative and postoperative complications were low and not statistically different between groups (all P > 0.05). Across all observers, 3D surgery was superior to TM surgery for improving the degree of satisfaction (all P < 0.001). Conclusions The surgical efficiency of heads-up cataract surgery is not inferior to traditional microscopic surgery. Both methods achieved similar efficacy and safety outcomes. Moreover, heads-up cataract surgery showed a significant advantage in medical education. Translational Relevance Our findings show that heads-up cataract surgery has comparable efficiency, efficacy, and safety, as well as superior medical educational value, to TM surgery, which lays the foundation for promoting and popularizing this technology.",2021,Incidences of both intraoperative and postoperative complications were low and not statistically different between groups (all P > 0.05).,"['questionnaire study enrolled 26 medical interns and 39 medical students', '242 eyes of 201 patients who received']","['femtosecond laser-assisted cataract surgery', 'heads-up cataract surgery', 'surgery under either a three-dimensional visualization system (3D group, 117 eyes) or traditional microscope (TM']","['efficiency, efficacy, and safety', 'degree of satisfaction', 'Visual acuity and other perioperative parameters', 'Efficacy, Safety, and Medical Education', 'Incidences of both intraoperative and postoperative complications', 'Surgical time', 'ultrasound power, phacoemulsification time, visual acuity, intraocular pressure, endothelial cell density, central corneal thickness, complications, and observer satisfaction scores for surgical procedures', 'surgical time']","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C1293898', 'cui_str': 'Head up'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0181839', 'cui_str': 'Microscope'}]","[{'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0013631', 'cui_str': 'Medical Education'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell density'}, {'cui': 'C1720164', 'cui_str': 'Central corneal thickness'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]",242.0,0.166136,Incidences of both intraoperative and postoperative complications were low and not statistically different between groups (all P > 0.05).,"[{'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Song', 'Affiliation': 'Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Lifang', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Yueyang', 'Initials': 'Y', 'LastName': 'Zhong', 'Affiliation': 'Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Lu', 'Affiliation': 'Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Yao', 'Affiliation': 'Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.'}]",Translational vision science & technology,['10.1167/tvst.10.9.4'] 1944,34346165,"A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.","The study evaluated the safety, tolerability, pharmacokinetics (PK) and anti-drug antibody (ADA) of the recombinant human thymosin β4 (NL005) for single and multiple intravenous injections in healthy subjects. Seven cohorts, with 54 healthy subjects, were given a single intravenous dose of NL005 or placebo and were observed for 28 days. The cohorts received ascending doses of either 0.05, 0.25, 0.5, 2.0, 5.0, 12.5 or 25.0 μg/kg in the single-dose trial. A total of 30 healthy subjects were randomly enrolled in the multiple-dose trial, and 3 cohorts (0.5, 2.0 and 5.0 μg/kg) were administered once human thymosin β4 daily for 10 days and observed for 28 days. The adverse events were mild to moderate in intensity. There were no dose-limiting toxicities or serious adverse events. The plasma concentration, maximum peak concentration (C max ) and AUC of each dose group increased with the increase in the dose. The tendency of terminal clearance in each dose group was consistent, and there was no obvious accumulation after continuous administration. Thus, the drug can be concluded to be well tolerated and safe in healthy people and suitable for use in a clinical study for the treatment of acute myocardial infarction.",2021,"The plasma concentration, maximum peak concentration (C max ) and AUC of each dose group increased with the increase in the dose.","['healthy people', 'healthy Chinese volunteers', '30 healthy subjects', 'healthy subjects', 'Seven cohorts, with 54 healthy subjects']","['NL005 or placebo', 'recombinant human thymosin β4 (NL005', 'recombinant human thymosin β4']","['safety, tolerability, pharmacokinetics (PK) and anti-drug antibody (ADA', 'adverse events', 'tolerated and safe', 'plasma concentration, maximum peak concentration (C max ) and AUC', 'tendency of terminal clearance', 'dose-limiting toxicities or serious adverse events']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040106', 'cui_str': 'Thymosin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",30.0,0.103856,"The plasma concentration, maximum peak concentration (C max ) and AUC of each dose group increased with the increase in the dose.","[{'ForeName': 'Xinghe', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Phase I Clinical Trial Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Phase I Clinical Trial Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Qi', 'Affiliation': 'Phase I Clinical Trial Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Chunpu', 'Initials': 'C', 'LastName': 'Lei', 'Affiliation': 'Phase I Clinical Trial Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Pu', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Trial Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Phase I Clinical Trial Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Phase I Clinical Trial Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Haihong', 'Initials': 'H', 'LastName': 'Bai', 'Affiliation': 'Phase I Clinical Trial Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Chengquan', 'Initials': 'C', 'LastName': 'Han', 'Affiliation': 'Beijing Northland Biotech. Co., Ltd., Beijing, China.'}, {'ForeName': 'Yinjian', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Beijing Northland Biotech. Co., Ltd., Beijing, China.'}, {'ForeName': 'Jincan', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Beijing Northland Biotech. Co., Ltd., Beijing, China.'}]",Journal of cellular and molecular medicine,['10.1111/jcmm.16693'] 1945,34344312,A timed activity protocol to address sleep-wake disorders in home dwelling persons living with dementia: the healthy patterns clinical trial.,"BACKGROUND Sleep-wake disorders occur in most persons living with dementia and include late afternoon or evening agitation, irregular sleep-wake rhythms such as daytime hypersomnia, frequent night awakenings, and poor sleep efficiency. Sleep-wake disorders pose a great burden to family caregivers, and are the principal causes of distress, poor quality of life, and institutionalization. Regulating the sleep-wake cycle through the use of light and activity has been shown to alter core clock processes and suggests that a combination of cognitive, physical, and sensory-based activities, delivered at strategic times, may be an effective mechanism through which to reduce sleep-wake disorders. METHODS A definitive Phase III efficacy trial of the Healthy Patterns intervention, a home-based activity intervention designed to improve sleep-wake disorders and quality of life, is being conducted using a randomized two-group parallel design of 200 people living with dementia and their caregivers (dyads). Specific components of this one-month, home-based intervention involve 4 in-home visits and includes: 1) assessing individuals' functional status and interests; 2) educating caregivers on environmental cues to promote activity and sleep; and 3) training caregivers in using timed morning, afternoon, and evening activities based on circadian needs across the day. The patient focused outcomes of interest are quality of life, measures of sleep assessed by objective and subjective indicators including actigraphy, subjective sleep quality, and the presence of neuropsychiatric symptoms. Caregiver outcomes of interest are quality of life, burden, confidence using activities, and sleep disruption. Salivary measures of cortisol and melatonin are collected to assess potential intervention mechanisms. DISCUSSION The results from the ongoing study will provide fundamental new knowledge regarding the effects of timing activity participation based on diurnal needs and the mechanisms underlying timed interventions which can lead to a structured, replicable treatment protocol for use with this growing population of persons living with dementia. CLINICAL TRIAL REGISTRATION Clinicaltrials.gov # NCT03682185 at https://clinicaltrials.gov/ ; Date of clinical trial registration: 24 September 2018.",2021,"A definitive Phase III efficacy trial of the Healthy Patterns intervention, a home-based activity intervention designed to improve sleep-wake disorders and quality of life, is being conducted using a randomized two-group parallel design of 200 people living with dementia and their caregivers (dyads).","['persons living with dementia', 'home dwelling persons living with dementia', '200 people living with dementia and their caregivers (dyads']","['Healthy Patterns intervention, a home-based activity intervention', 'timed activity protocol']","['quality of life, measures of sleep assessed by objective and subjective indicators including actigraphy, subjective sleep quality, and the presence of neuropsychiatric symptoms', 'quality of life, burden, confidence using activities, and sleep disruption', 'sleep-wake disorders and quality of life']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C4042891', 'cui_str': 'Sleep Wake Disorders'}]",200.0,0.0535268,"A definitive Phase III efficacy trial of the Healthy Patterns intervention, a home-based activity intervention designed to improve sleep-wake disorders and quality of life, is being conducted using a randomized two-group parallel design of 200 people living with dementia and their caregivers (dyads).","[{'ForeName': 'Nancy A', 'Initials': 'NA', 'LastName': 'Hodgson', 'Affiliation': 'School of Nursing, University of Pennsylvania, Fagin Hall, Curie Blvd, Philadelphia, PA, 19102, USA. hodgsonn@nursing.upenn.edu.'}, {'ForeName': 'Nalaka', 'Initials': 'N', 'LastName': 'Gooneratne', 'Affiliation': 'School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Perez', 'Affiliation': 'School of Nursing, University of Pennsylvania, Fagin Hall, Curie Blvd, Philadelphia, PA, 19102, USA.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Talwar', 'Affiliation': 'School of Nursing, University of Pennsylvania, Fagin Hall, Curie Blvd, Philadelphia, PA, 19102, USA.'}, {'ForeName': 'Liming', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'School of Nursing, University of Pennsylvania, Fagin Hall, Curie Blvd, Philadelphia, PA, 19102, USA.'}]",BMC geriatrics,['10.1186/s12877-021-02397-2'] 1946,34344250,Manual training of mental rotation performance: Visual representation of rotating figures is the main driver for improvements.,"Studies have demonstrated that manual and mental rotation show common processes. Training studies have shown that a manual and concurrent visual rotation improves mental rotation performance. In this study, we separated the visual rotation from the manual rotation. In all, 121 participants were randomly assigned to visual training, manual rotation training, or manual training without rotational movement. Before and after the training session of 30 min, they had to solve a chronometric mental rotation test. Data were analysed with linear mixed models and showed an improvement in mental rotation performance for all groups. However, this improvement did not differ between groups. Due to the independence of the form and occurrence of the manual activity, this suggests that it is not the motor activity, but the concurrent visual rotation that leads to improvements in mental rotation tasks. Therefore, the visual component in mental rotation tasks has to be investigated in more detail.",2021,Data were analyzed with linear mixed models and showed an improvement in mental rotation performance for all groups.,['121 participants'],"['visual training, manual rotation training, or manual training without rotational movement']",['mental rotation performance'],[],"[{'cui': 'C0200244', 'cui_str': 'Visual training'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]","[{'cui': 'C0035868', 'cui_str': 'Rotation'}]",121.0,0.0478656,Data were analyzed with linear mixed models and showed an improvement in mental rotation performance for all groups.,"[{'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Jost', 'Affiliation': 'Faculty of Human Sciences, University of Regensburg, Regensburg, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Jansen', 'Affiliation': 'Faculty of Human Sciences, University of Regensburg, Regensburg, Germany.'}]",Quarterly journal of experimental psychology (2006),['10.1177/17470218211039494'] 1947,34343620,A randomized controlled pilot study of Yoga Skills Training versus an attention control delivered during chemotherapy administration.,"CONTEXT It is important to address fatigue and co-occurring symptoms during chemotherapy topreserve quality of life in patients with gastrointestinal (GI) cancer. OBJECTIVE To conduct a randomized controlled pilot study of a Yoga Skills Training (YST) intervention compared to an attention control (AC) among adults diagnosed with GI cancer. METHODS YST consisted of four 30-minute sessions delivered individually during chemotherapy plus home practice. AC provided empathic attention plus home diaries. Patient-reported (PROMIS T-score) assessments of fatigue, depressive symptoms, sleep disturbances, and psychological stress (Perceived Stress Scale) were collected at chemotherapy visits: baseline, Week 8, Week 10 and Week 14, and analyzed using a mixed effects model. Inflammatory cytokines were assessed at baseline and Week 10. RESULTS Forty-four of 77 adults approached agreed to participate (57%; YST n=23; AC n=21). Participants' mean age was 58 years and 48% were men. Participants randomized to YST reported a larger decline in fatigue (-2.4 difference, d=0.30) and depressive symptoms (-2.5 difference, d=0.30) than AC participants from baseline to Week 10 and sleep disturbances at Week 8 (-3.9 difference, d=0.50). Differences in magnitude of change in symptoms were consistent with or exceeded a minimally important difference. Psychological stress decreased more in the AC at Week 10 (d=0.30). Reductions in inflammatory cytokines (IL-6, sTNF R1) were larger in the YST group than AC. CONCLUSIONS YST showed promise for improving fatigue, depressive symptoms, sleep disturbances, and inflammation. YST is also feasible and reaches patients underrepresented in yoga research (i.e., GI cancer, men), thus warranting further examination.",2021,"Reductions in inflammatory cytokines (IL-6, sTNF R1) were larger in the YST group than AC. ","['adults diagnosed with GI cancer', ""Participants' mean age was 58 years and 48% were men"", 'patients with gastrointestinal (GI) cancer', 'Forty-four of 77 adults approached agreed to participate (57']","['attention control (AC', 'Yoga Skills Training (YST) intervention', 'chemotherapy plus home practice', 'YST', 'Yoga Skills Training']","['Inflammatory cytokines', 'sleep disturbances', 'Psychological stress', 'inflammatory cytokines (IL-6, sTNF R1', 'depressive symptoms', 'Patient-reported (PROMIS T-score) assessments of fatigue, depressive symptoms, sleep disturbances, and psychological stress (Perceived Stress Scale', 'fatigue', 'fatigue, depressive symptoms, sleep disturbances, and inflammation']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0685938', 'cui_str': 'Malignant neoplasm of gastrointestinal tract'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0038443', 'cui_str': 'Psychological Stress'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C4041113', 'cui_str': 'Assessment of fatigue'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",77.0,0.205742,"Reductions in inflammatory cytokines (IL-6, sTNF R1) were larger in the YST group than AC. ","[{'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Sohl', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: ssohl@wakehealth.edu.'}, {'ForeName': 'Janet A', 'Initials': 'JA', 'LastName': 'Tooze', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Emily Nance', 'Initials': 'EN', 'LastName': 'Johnson', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Sheila H', 'Initials': 'SH', 'LastName': 'Ridner', 'Affiliation': 'Vanderbilt University School of Nursing, Nashville, TN, USA.'}, {'ForeName': 'Russell L', 'Initials': 'RL', 'LastName': 'Rothman', 'Affiliation': 'Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Caio Rocha', 'Initials': 'CR', 'LastName': 'Lima', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Katherine C', 'Initials': 'KC', 'LastName': 'Ansley', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Wheeler', 'Affiliation': 'California State University, San Bernardino, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Nicklas', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Avis', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Lynne I', 'Initials': 'LI', 'LastName': 'Wagner', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC, USA.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2021.07.022'] 1948,34350546,"Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study.","BACKGROUND AND OBJECTIVES Osteoarthritis (OA) is a major public health burden. While knee and hip joints are most commonly affected, the glenohumoral (shoulder) joint is also frequently involved. We evaluated the pharmacokinetics and safety/tolerability of triamcinolone acetonide extended-release (TA-ER) and triamcinolone acetonide crystalline suspension (TAcs) in patients with shoulder OA. METHODS In this phase 2, randomized, open-label, single-dose study (NCT03382262), adults with moderately-to-severely symptomatic shoulder OA for ≥ 6 months randomly received a single ultrasound-guided intra-articular (IA) injection of TA-ER 32 mg or TAcs 40 mg. Safety was evaluated throughout 12 weeks post-injection; blood samples for pharmacokinetic evaluations were collected pre-injection and through Day 85 post-injection. RESULTS Among 25 randomized patients, 12 received TA-ER and 13 received TAcs. Most patients were female (60%), and all had moderate (72%) or severe (28%) shoulder OA. Adverse events (AEs) were reported by four (33%) patients following TA-ER and three (23%) following TAcs injection. No AE was serious or led to study discontinuation. Systemic exposure following TAcs was approximately 1.5-fold higher than that following TA-ER injection (geometric mean [GM] AUC 0-last 873,543 vs 557,602 h × pg/mL). GM C max was also higher in TAcs- than TA-ER-treated patients (2034 vs 1283 pg/mL). Bioequivalence testing confirmed lower systemic TA exposure following TA-ER than TAcs IA injection. CONCLUSION These pharmacokinetic data confirm protracted release of TA from TA-ER following IA injection in patients with shoulder OA. Lower peak and systemic TA exposure following TA-ER suggests TA-ER could potentially confer an improved systemic safety profile over TAcs. TRIAL REGISTRATION NUMBER NCT03382262 (December 22, 2017 retrospectively registered).",2021,"Systemic exposure following TAcs was approximately 1.5-fold higher than that following TA-ER injection (geometric mean [GM] AUC 0-last 873,543 vs 557,602 h × pg/mL).","['adults with moderately-to-severely symptomatic shoulder OA for ≥ 6 months randomly received a', 'patients with shoulder OA', 'Patients with Shoulder Osteoarthritis']","['Triamcinolone Acetonide', 'Triamcinolone', 'TA-ER and 13 received TAcs', 'triamcinolone acetonide extended-release (TA-ER) and triamcinolone acetonide crystalline suspension (TAcs', 'single ultrasound-guided intra-articular (IA) injection of TA-ER 32 mg or TAcs 40 mg']","['pharmacokinetics and safety/tolerability', 'systemic safety profile', 'Adverse events (AEs', 'GM C max', 'Safety']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0409939', 'cui_str': 'Osteoarthritis of glenohumeral joint'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0444626', 'cui_str': 'Crystal'}, {'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0442108', 'cui_str': 'Intra-articular'}, {'cui': 'C1960581', 'cui_str': 'Injection of triamcinolone'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",25.0,0.0841225,"Systemic exposure following TAcs was approximately 1.5-fold higher than that following TA-ER injection (geometric mean [GM] AUC 0-last 873,543 vs 557,602 h × pg/mL).","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hanson', 'Affiliation': 'BioSolutions Clinical Research Center, La Mesa, CA, USA.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Kivitz', 'Affiliation': 'Altoona Center for Clinical Research, Duncansville, PA, USA.'}, {'ForeName': 'Purvi', 'Initials': 'P', 'LastName': 'Mehra', 'Affiliation': 'ARTEMIS Institute for Clinical Research, San Diego, CA, USA.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Kwong', 'Affiliation': 'Harbor-UCLA Medical Center, Torrance, CA, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Cinar', 'Affiliation': 'Flexion Therapeutics, Inc., Burlington, MA, 01803, USA.'}, {'ForeName': 'Joelle', 'Initials': 'J', 'LastName': 'Lufkin', 'Affiliation': 'Flexion Therapeutics, Inc., Burlington, MA, 01803, USA.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Kelley', 'Affiliation': 'Flexion Therapeutics, Inc., Burlington, MA, 01803, USA. sdkelley@bwh.harvard.edu.'}]",Drugs in R&D,['10.1007/s40268-021-00348-1'] 1949,34348954,Developing a recovery-focused therapy for older people with bipolar disorder: a qualitative focus group study.,"OBJECTIVES As awareness of bipolar disorder (BD) increases and the world experiences a rapid ageing of the population, the number of people living with BD in later life is expected to rise substantially. There is no current evidence base for the effectiveness of psychological interventions for older adults with BD. This focus group study explored a number of topics to inform the development and delivery of a recovery-focused therapy (RfT) for older adults with BD. DESIGN A qualitative focus group study. SETTING Three focus groups were conducted at a university in the North West of England. PARTICIPANTS Eight people took part in the focus groups; six older adults with BD, one carer and one friend. RESULTS Participant's responses clustered into six themes: (1) health-related and age-related changes in later life, (2) the experience of BD in later life, (3) managing and coping with BD in later life, (4) recovery in later life, (5) seeking helping in the future and (6) adapting RfT for older people. CONCLUSIONS Participants reported a range of health-related and age-related changes and strategies to manage their BD. Participants held mixed views about using the term 'recovery' in later life. Participants were in agreement that certain adaptations were needed for delivering RfT for older adults, based on their experience of living with BD in later life. The data collected as part of the focus groups have led to a number of recommendations for delivering RfT for older adults with BD in a randomised controlled trial (Clinical Trial Registration: ISRCTN13875321).",2021,"As awareness of bipolar disorder (BD) increases and the world experiences a rapid ageing of the population, the number of people living with BD in later life is expected to rise substantially.","['older adults with BD', 'Eight people took part in the focus groups; six older adults with BD, one carer and one friend', 'Three focus groups were conducted at a university in the North West of England', 'older people with bipolar disorder']",['recovery-focused therapy (RfT'],"['later life, (3) managing and coping with BD in later life, (4) recovery in later life, (5) seeking helping']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}]",8.0,0.0990596,"As awareness of bipolar disorder (BD) increases and the world experiences a rapid ageing of the population, the number of people living with BD in later life is expected to rise substantially.","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Tyler', 'Affiliation': 'Division of Health Research, Lancaster University, Lancaster, UK e.tyler@lancaster.ac.uk.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Lobban', 'Affiliation': 'Division of Health Research, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Long', 'Affiliation': 'Division of Health Research, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Steven H', 'Initials': 'SH', 'LastName': 'Jones', 'Affiliation': 'Division of Health Research, Lancaster University, Lancaster, UK.'}]",BMJ open,['10.1136/bmjopen-2021-049829'] 1950,34353383,Favorable effects of the Dietary Approaches to Stop Hypertension diet on glucose tolerance and lipid profiles in gestational diabetes: a randomised clinical trial - Expression of concern.,,2021,,['gestational diabetes'],['Dietary Approaches to Stop Hypertension diet'],['glucose tolerance and lipid profiles'],"[{'cui': 'C0439671', 'cui_str': 'Gestational'}]","[{'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}]",,0.064193,,"[{'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': ''}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Tabassi', 'Affiliation': ''}, {'ForeName': 'Mansooreh', 'Initials': 'M', 'LastName': 'Samimi', 'Affiliation': ''}, {'ForeName': 'Taherh', 'Initials': 'T', 'LastName': 'Fahiminejad', 'Affiliation': ''}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Esmaillzadeh', 'Affiliation': ''}]",The British journal of nutrition,['10.1017/S0007114521002002'] 1951,34353381,"The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial - Expression of concern.",,2021,,['gestational diabetes'],"['placebo', 'synbiotic supplementation']",['insulin metabolism and lipid profiles'],"[{'cui': 'C0439671', 'cui_str': 'Gestational'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}]",,0.923011,,"[{'ForeName': 'Shahnaz', 'Initials': 'S', 'LastName': 'Ahmadi', 'Affiliation': ''}, {'ForeName': 'Mehri', 'Initials': 'M', 'LastName': 'Jamilian', 'Affiliation': ''}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Tajabadi-Ebrahimi', 'Affiliation': ''}, {'ForeName': 'Parvaneh', 'Initials': 'P', 'LastName': 'Jafari', 'Affiliation': ''}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': ''}]",The British journal of nutrition,['10.1017/S0007114521002026'] 1952,34353341,Feasibility of a home-based interdisciplinary rehabilitation program for patients with Post-Intensive Care Syndrome: the REACH study.,"BACKGROUND Survivors of critical illness experience long-term functional challenges, which are complex, heterogeneous, and multifactorial in nature. Although the importance of rehabilitation interventions after intensive care unit (ICU) discharge is universally recognized, evidence on feasibility and effectiveness of home-based rehabilitation programs is scarce and ambiguous. This study investigates the feasibility of an interdisciplinary rehabilitation program designed for patients with Post-Intensive Care Syndrome (PICS) who are discharged home. METHODS A mixed method, non-randomized, prospective pilot feasibility study was performed with a 6-month follow-up, comparing the intervention (REACH) with usual care. REACH was provided by trained professionals and included a patient-centered, interdisciplinary approach starting directly after hospital discharge. Primary outcomes were patient safety, satisfaction, adherence, referral need and health care usage. Secondary outcomes, measured at 3 timepoints, were functional exercise capacity, self-perceived health status, health-related quality of life (HRQoL), return to work and psychotrauma. Risk of undernutrition was assessed at baseline. RESULTS 43 patients with a median mechanical ventilation duration of 8 (IQR:10) days, were included in the study and 79.1% completed 6-month follow-up. 19 patients received the intervention, 23 received usual care. Groups were similar for gender distribution and ICU length of stay. No adverse events occurred. REACH participants showed higher satisfaction with treatment and reported more allied health professional visits, while the usual care group reported more visits to medical specialists. Qualitative analysis identified positive experiences among REACH-professionals related to providing state-of-the-art interventions and sharing knowledge and expertise within an interprofessional network. Similar recovery was seen between groups on all secondary outcomes, but neither group reached reference values for HRQoL at 6 months. Larger return to work rates were seen in the REACH group. Prevalence of undernutrition at hospital discharge was high in both groups (> 80%), warranting the need for careful tuning of physical therapy and nutritional interventions. CONCLUSIONS This study shows that providing early, home-based rehabilitation interventions for patients with PICS-related symptoms is feasible and perceived positively by patients and professionals. When provided in an interdisciplinary collaborative network state of the art, person-centered interventions can be tailored to individual needs potentially increasing patient satisfaction, adherence, and efficacy. Registered in the Dutch Trial register: NL7792: https://www.trialregister.nl/trial/7792 , registered 7-06-2019.",2021,Qualitative analysis identified positive experiences among REACH-professionals related to providing state-of-the-art interventions and sharing knowledge and expertise within an interprofessional network.,"['patients with Post-Intensive Care Syndrome (PICS) who are discharged home', 'patients with PICS-related symptoms', '43 patients with a median mechanical ventilation\xa0duration of 8 (IQR:10) days, were included in the study and 79.1% completed 6-month follow-up', 'patients with Post-Intensive Care Syndrome', '19 patients received the intervention, 23 received usual care']","['NL7792', 'interdisciplinary rehabilitation program', 'home-based interdisciplinary rehabilitation program']","['allied health professional visits', 'functional exercise capacity, self-perceived health status, health-related quality of life (HRQoL), return to work and psychotrauma', 'Larger return to work rates', 'Risk of undernutrition', 'Prevalence of undernutrition at hospital discharge', 'patient safety, satisfaction, adherence, referral need and health care usage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0454284', 'cui_str': 'Functional exercises'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0425105', 'cui_str': 'Returned to work'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0580715', 'cui_str': 'Referral needed'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0457083', 'cui_str': 'Usage'}]",43.0,0.0202842,Qualitative analysis identified positive experiences among REACH-professionals related to providing state-of-the-art interventions and sharing knowledge and expertise within an interprofessional network.,"[{'ForeName': 'Mel E', 'Initials': 'ME', 'LastName': 'Major', 'Affiliation': 'European School of Physiotherapy, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands. m.major@hva.nl.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Dettling-Ihnenfeldt', 'Affiliation': 'Department of Rehabilitation Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Movement Sciences, Meibergdreef 9, Amsterdam, The Netherlands.'}, {'ForeName': 'Stephan P J', 'Initials': 'SPJ', 'LastName': 'Ramaekers', 'Affiliation': 'Faculty of Health, Center of Expertise Urban Vitality, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands.'}, {'ForeName': 'Raoul H H', 'Initials': 'RHH', 'LastName': 'Engelbert', 'Affiliation': 'Faculty of Health, Center of Expertise Urban Vitality, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands.'}, {'ForeName': 'Marike', 'Initials': 'M', 'LastName': 'van der Schaaf', 'Affiliation': 'Faculty of Health, Center of Expertise Urban Vitality, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands.'}]","Critical care (London, England)",['10.1186/s13054-021-03709-z'] 1953,34353299,A randomised controlled trial of the Nextdoor Kind Challenge: a study protocol.,"BACKGROUND Community interventions are often promoted as a way of reducing loneliness and social isolation in our neighbourhoods. However, those community interventions are rarely examined within rigorous study designs. One strategy that holds the potential to reduce loneliness and can promote health and wellbeing is doing acts of kindness. The current study involves evaluating the impact of kindness acts on loneliness in community-dwelling individuals using an online social networking platform. METHODS This study is made up of three randomised controlled trials conducted in three countries. Each randomised controlled trial has two arms (intervention vs waitlist control) and is designed to compare the effectiveness of the KIND challenge, which involves doing at least one act of kindness per week within a four-week period. This study will recruit users of an online community, be randomised online, and will be conducted using online assessments. We will first explore the effects of the intervention on the primary outcome of loneliness, followed by secondary outcomes, social isolation, neighbour relationship quality and contact, mental health symptoms, stress, quality of life, and positive affect. Further, we will assess the feasibility, acceptability, and safety of the KIND Challenge. DISCUSSION This study, designed to evaluate the impact of kindness on the community, will be the first large scale randomised control trial conducted across three countries, Australia, UK, and USA. It will examine the potential of community-led interventions to reduce loneliness, improve social isolation, and promote neighbourhood cohesion, health, and wellbeing, which is especially crucial during the COVID-19 public health crisis. TRIAL REGISTRATION Clinical Trials Registry. NCT04398472 . Registered 21st May 2020.",2021,"It will examine the potential of community-led interventions to reduce loneliness, improve social isolation, and promote neighbourhood cohesion, health, and wellbeing, which is especially crucial during the COVID-19 public health crisis. ",['community-dwelling individuals using an online social networking platform'],[],"['social isolation, neighbour relationship quality and contact, mental health symptoms, stress, quality of life, and positive affect', 'feasibility, acceptability, and safety']","[{'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4704733', 'cui_str': 'Online Social Networking'}]",[],"[{'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C1553702', 'cui_str': 'Neighbor'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.152853,"It will examine the potential of community-led interventions to reduce loneliness, improve social isolation, and promote neighbourhood cohesion, health, and wellbeing, which is especially crucial during the COVID-19 public health crisis. ","[{'ForeName': 'Michelle H', 'Initials': 'MH', 'LastName': 'Lim', 'Affiliation': 'Iverson Health Innovation Research Institute, Swinburne University of Technology, Hawthorn, Victoria, Australia. mlim@swin.edu.au.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Qualter', 'Affiliation': 'Manchester Institute of Education, University of Manchester, Manchester, UK.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Hennessey', 'Affiliation': 'Manchester Institute of Education, University of Manchester, Manchester, UK.'}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Smith', 'Affiliation': 'University of Sydney, Camperdown, NSW, Australia.'}, {'ForeName': 'Taylah', 'Initials': 'T', 'LastName': 'Argent', 'Affiliation': 'Iverson Health Innovation Research Institute, Swinburne University of Technology, Hawthorn, Victoria, Australia.'}, {'ForeName': 'Julianne', 'Initials': 'J', 'LastName': 'Holt-Lunstad', 'Affiliation': 'Iverson Health Innovation Research Institute, Swinburne University of Technology, Hawthorn, Victoria, Australia.'}]",BMC public health,['10.1186/s12889-021-11489-y'] 1954,34353070,Observation of the effect of closed-loop health management based on an internet platform in patients with peritoneal dialysis: a randomized trial.,"BACKGROUND Peritoneal dialysis (PD) uses the peritoneum as the dialysis membrane. PD is a simple operation for self-treatment at home, and has become the preferred option for most patients with chronic renal failure (CRF). This study aimed to explore the effect of a closed-loop health management (CLHM) system based on an Internet platform in patients with PD. METHODS A total of 102 patients with PD who were admitted to Xuzhou Central Hospital from May 2019 to May 2020 were selected and randomly divided into two groups (n=51). The control group received routine care, and in the observation group a CLHM based on an Internet platform was introduced. The incidence of complications and changes in disease knowledge, nutritional status, quality of life (QOL) before and after the intervention were compared between groups. RESULTS The incidences of peritonitis, tunnel entrance infection, poor drainage, and hypokalemia in the observation group were lower than in the control group (P<0.05). The disease-related knowledge mastery scores of the observation group were higher than those in the control group after 3 months of intervention (P<0.05). Malnutrition-inflammation score (MIS) and serum creatinine (SCr) in the observation group were lower than in the control group after 3 months of intervention (P<0.05), and the body mass index (BMI), albumin (ALB), and hemoglobin (Hb) of the observation group were higher than those of the control group (P<0.05). The QOL scores of the observation group were higher than those of the control group after 3 months of intervention (P<0.05). CONCLUSIONS The application of a CLHM system based on an Internet platform to patients with PD could effectively reduce complications, and improve patients' knowledge of disease, nutritional status and QOL. TRIAL REGISTRATION ClinicalTrials.gov Identifier: ChiCTR2100046122.",2021,The disease-related knowledge mastery scores of the observation group were higher than those in the control group after 3 months of intervention (P<0.05).,"['patients with chronic renal failure (CRF', 'patients with PD.\nMETHODS\n\n\nA total of 102 patients with PD who were admitted to Xuzhou Central Hospital from May 2019 to May 2020', 'patients with peritoneal dialysis']","['routine care, and in the observation group a CLHM', 'Peritoneal dialysis (PD', 'closed-loop health management', 'PD', 'closed-loop health management (CLHM) system']","['incidences of peritonitis, tunnel entrance infection, poor drainage, and hypokalemia', 'incidence of complications and changes in disease knowledge, nutritional status, quality of life (QOL', 'body mass index (BMI), albumin (ALB), and hemoglobin (Hb', 'disease-related knowledge mastery scores', 'QOL scores', ""patients' knowledge of disease, nutritional status and QOL"", 'Malnutrition-inflammation score (MIS) and serum creatinine (SCr']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0031139', 'cui_str': 'Peritoneal dialysis'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0443183', 'cui_str': 'Closed loop'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0031139', 'cui_str': 'Peritoneal dialysis'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0031154', 'cui_str': 'Peritonitis'}, {'cui': 'C0337138', 'cui_str': 'Tunnel'}, {'cui': 'C0337095', 'cui_str': 'Entrance'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0020621', 'cui_str': 'Hypokalemia'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}]",102.0,0.02377,The disease-related knowledge mastery scores of the observation group were higher than those in the control group after 3 months of intervention (P<0.05).,"[{'ForeName': 'Fen', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Department of Renal Medicine, Xuzhou Central Hospital, Xuzhou, China.'}, {'ForeName': 'Yanfen', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Renal Medicine, Xuzhou Central Hospital, Xuzhou, China.'}, {'ForeName': 'Shuxia', 'Initials': 'S', 'LastName': 'Shi', 'Affiliation': 'Department of Renal Medicine, Xuzhou Central Hospital, Xuzhou, China.'}]",Annals of palliative medicine,['10.21037/apm-21-1402'] 1955,34353069,Effect analysis of kinetic energy progressive exercise in patients with acute myocardial infarction after percutaneous coronary intervention: a randomized trial.,"BACKGROUND Acute myocardial infarction (AMI) is the most common critical illness clinically. Percutaneous coronary intervention (PCI) can help patients with AMI by reopening their blocked blood vessels and improving clinical symptoms. Clinical practice has confirmed that rehabilitation training after PCI could significantly promote the recovery of patients' heart function, reduce cardiovascular events, and have a positive significance for prognosis. This study aimed to explore the effect of kinetic energy progressive exercise (PEKE) applied to patients with AMI after PCI. METHODS From April 2019 to April 2020, a total of 98 patients with AMI after PCI in our hospital were randomly allocated to PEKE group and routine intervention (RI) group. The RI group adopted routine intervention, while the PEKE group introduced PEKE intervention on the basis of the RI group. The incidence of adverse events (AEs), motor function, cardiac function, and quality of life (QoL) before and after intervention were compared between the two groups. RESULTS Compared with the RI group, the incidence of AEs in the PEKE group was significantly reduced (χ2=4.404, P=0.036). After 6 months of intervention, the maximum exercise load and metabolic equivalent of the PEKE group were greater than those of the RI group (t=7.114, 4.565; P=0.000, 0.000). After 6 months of intervention, the left ventricular ejection fraction (LVEF) of the PEKE group was greater than that of the RI group (t=6.826, P=0.000), and there were no significant differences in left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) compared with the RI group (t=1.253, 1.147; P=0.213, 0.254). After 6 months of intervention, the PEKE group's symptoms, physical function, cognitive function, psychosocial function, and satisfaction scores were greater than those in the RI group (t=5.991, 4.612, 7.165, 5.731, 5.468; P=0.000, 0.000, 0.000, 0.000, 0.000). CONCLUSIONS We applied PEKE was to AMI patients with after PCI, and it was shown to effectively reduce AEs, improve the patients' exercise ability and cardiac function, and improve their QoL. TRIAL REGISTRATION ClinicalTrials.gov Identifier: ChiCTR2100046123.",2021,"Compared with the RI group, the incidence of AEs in the PEKE group was significantly reduced (χ2=4.404, P=0.036).","['AMI patients with after PCI', 'patients with AMI after PCI.\nMETHODS\n\n\nFrom April 2019 to April 2020, a total of 98 patients with AMI after PCI in our hospital', 'patients with acute myocardial infarction after percutaneous coronary intervention']","['kinetic energy progressive exercise (PEKE', 'kinetic energy progressive exercise', 'PEKE group and routine intervention (RI) group', 'PEKE group introduced PEKE intervention', 'Percutaneous coronary intervention (PCI']","['maximum exercise load and metabolic equivalent', 'left ventricular ejection fraction (LVEF', 'incidence of AEs', 'symptoms, physical function, cognitive function, psychosocial function, and satisfaction scores', 'left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV', 'incidence of adverse events (AEs), motor function, cardiac function, and quality of life (QoL']","[{'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1292748', 'cui_str': 'Introduces'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2355577', 'cui_str': 'Metabolic Equivalent'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042509', 'cui_str': 'Ventricular End-Diastolic Volume'}, {'cui': 'C0080308', 'cui_str': 'Ventricular End-Systolic Volume'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",98.0,0.017585,"Compared with the RI group, the incidence of AEs in the PEKE group was significantly reduced (χ2=4.404, P=0.036).","[{'ForeName': 'Minghui', 'Initials': 'M', 'LastName': 'Jiang', 'Affiliation': 'Department of Cardiology, Xuzhou Central Hospital, Xuzhou, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Hua', 'Affiliation': 'Department of Coronary Care Unit, Xuzhou Central Hospital, Xuzhou, China.'}, {'ForeName': 'Xueping', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Coronary Care Unit, Xuzhou Central Hospital, Xuzhou, China.'}, {'ForeName': 'Liuqing', 'Initials': 'L', 'LastName': 'Qu', 'Affiliation': 'Department of Coronary Care Unit, Xuzhou Central Hospital, Xuzhou, China.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Coronary Care Unit, Xuzhou Central Hospital, Xuzhou, China.'}]",Annals of palliative medicine,['10.21037/apm-21-1478'] 1956,34353065,Study on the therapeutic effect of floating needle therapy combined with pressing acupoint embedding for female stress urinary incontinence after childbirth: a randomized trial.,"BACKGROUND Stress urinary incontinence is a common and widespread problem among women that can significantly reduce the quality of life of those affected and potentially result in limitations to the lives and activities of their friends and family members. We aimed to observe the effect of floating needle therapy combined with acupuncture point embedding in the treatment of female stress urinary incontinence after childbirth. METHODS A total of 64 postpartum female stress urinary incontinence patients who were treated and hospitalized in the Urology Clinic of the Ningbo Traditional Chinese Medicine Hospital of the Zhejiang Province from September 2020 to August 2021 were randomly allocated to the experimental group and the control group, each with 32 cases. The control group was treated with the drug midodrine combined with Kegel training, and the experimental group was treated with floating needle therapy combined with acupoint embedding. After 8 weeks of continuous treatment, the pelvic floor muscle strength, urinary incontinence score, and the improvement of urine leakage in the 1 h pad test were observed. We then evaluated the clinical efficacy of the 2 groups and the state of urinary incontinence at 3 months and 6 months as assessed by telephone follow-up. RESULTS After treatment, the pelvic floor muscle strength of the 2 groups had significantly increased, and both the urinary incontinence score and the urine leakage volume of the 1 h pad test were significantly reduced. The pelvic floor muscle strength of the experimental group was significantly higher than that of the control group after treatment, the urinary incontinence score and the amount of urine leakage of the 1 h pad test were significantly lower than those of the control group. The total effective rate of the experimental group was 90.63% (27/32), which was higher than that of the control group (71.88%, 23/32). CONCLUSIONS With the benefits of being both convenient and efficient, floating needle therapy combined with press-needle acupoint embedding is effective in treating female stress urinary incontinence after childbirth. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR2100047558.",2021,"After 8 weeks of continuous treatment, the pelvic floor muscle strength, urinary incontinence score, and the improvement of urine leakage in the 1 h pad test were observed.","['64 postpartum female stress urinary incontinence patients who were treated and hospitalized in the Urology Clinic of the Ningbo Traditional Chinese Medicine Hospital of the Zhejiang Province from September 2020 to August 2021', 'female stress urinary incontinence after childbirth']","['floating needle therapy combined with pressing acupoint embedding', 'floating needle therapy combined with acupuncture point embedding', 'midodrine combined with Kegel training, and the experimental group was treated with floating needle therapy combined with acupoint embedding']","['pelvic floor muscle strength', 'pelvic floor muscle strength, urinary incontinence score', 'urinary incontinence score and the urine leakage volume', 'urine leakage', 'total effective rate', 'urinary incontinence score and the amount of urine leakage']","[{'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C3812395', 'cui_str': 'Urology clinic'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]","[{'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0026078', 'cui_str': 'Midodrine'}, {'cui': 'C0262718', 'cui_str': 'Pelvic floor exercises'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0152245', 'cui_str': 'Extravasation of urine'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",64.0,0.021514,"After 8 weeks of continuous treatment, the pelvic floor muscle strength, urinary incontinence score, and the improvement of urine leakage in the 1 h pad test were observed.","[{'ForeName': 'Fengna', 'Initials': 'F', 'LastName': 'Chen', 'Affiliation': 'Department of Surgery, Ningbo Municipal Hospital of TCM Affiliated Hospital of Zhejiang Chinese Medicine University, Ningbo, China.'}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Nursing, Ningbo Municipal Hospital of TCM Affiliated Hospital of Zhejiang Chinese Medicine University, Ningbo, China.'}, {'ForeName': 'Weiming', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': 'Department of Anorectal Surgery, Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.'}, {'ForeName': 'Xuequn', 'Initials': 'X', 'LastName': 'Qian', 'Affiliation': 'Department of Nursing, Ningbo Municipal Hospital of TCM Affiliated Hospital of Zhejiang Chinese Medicine University, Ningbo, China.'}]",Annals of palliative medicine,['10.21037/apm-21-1382'] 1957,34353046,A randomised controlled study: efficacy of ICU nursing risk management combined with the cluster nursing model and its effect on quality of life and inflammatory factor levels of patients with acute respiratory distress syndrome and ventilator-associated pneumonia.,"BACKGROUND The purpose was to investigate the effect on quality of life and inflammatory factor levels of patients with acute respiratory distress syndrome (ARDS) and ventilator-associated pneumonia (VAP). METHODS A total of 110 ARDS patients with VAP were randomly divided into an experimental group and control group. The control group received routine nursing while the experimental group received ICU nursing risk management combined with the cluster nursing model to compare the clinical efficacy in the two groups of patients. RESULTS There were no significant differences in general information (P>0.05). The total clinical effective rate of patients in the experimental group was significantly higher than that of the control group (P<0.05). The Acute Physiology and Chronic Health Evaluation (APACHE II) scores of all patients after nursing were significantly lower than those before nursing (P<0.001), and the APACHE II score in the experimental group after nursing was significantly lower than that in the control group (P<0.001). The interleukin-8 (IL-8), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels of all patients after nursing were significantly lower than those before nursing (P<0.001), and the levels in the experimental group after nursing were significantly lower than those in the control group (P<0.001). The vital capacity (VC), total lung capacity (TLC), and forced expiratory volume 1 second (FEV1)/forced vital capacity (FVC) levels of all patients after nursing were significantly higher than those before nursing (P<0.001), and the levels in the experimental group after nursing were significantly higher than those in the control group (P<0.001). The MOS 36-item short form health survey (SF-36) scores of all patients after nursing were significantly higher than those before nursing (P<0.001), and the scores in the experimental group after nursing was higher than that in the control group (P<0.001). CONCLUSIONS ICU nursing risk management combined with the cluster nursing model can effectively and significantly reduce inflammatory reactions, improve pulmonary function, and enhance the quality of life of ARDS patients with VAP, making it worthy of promotion and application. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR2100048112.",2021,"The MOS 36-item short form health survey (SF-36) scores of all patients after nursing were significantly higher than those before nursing (P<0.001), and the scores in the experimental group after nursing was higher than that in the control group (P<0.001). ","['110 ARDS patients with VAP', 'patients with acute respiratory distress syndrome (ARDS) and ventilator-associated pneumonia (VAP', 'patients with acute respiratory distress syndrome and ventilator-associated pneumonia']","['routine nursing while the experimental group received ICU nursing risk management combined with the cluster nursing model', 'ICU nursing risk management combined with the cluster nursing model']","['inflammatory reactions', 'TNF-α) levels', 'quality of life and inflammatory factor levels', 'interleukin-8 (IL-8), interleukin-6 (IL-6), and tumor necrosis factor-α ', 'vital capacity (VC), total lung capacity (TLC), and forced expiratory volume 1 second (FEV1)/forced vital capacity (FVC) levels', 'Acute Physiology and Chronic Health Evaluation (APACHE II) scores', 'MOS 36-item short form health survey (SF-36) scores', 'total clinical effective rate', 'quality of life']","[{'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0035649', 'cui_str': 'Risk management'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0079849', 'cui_str': 'Model, Nursing'}]","[{'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0042834', 'cui_str': 'Vital capacity'}, {'cui': 'C0040509', 'cui_str': 'Total lung capacity'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0243030', 'cui_str': 'Acute physiology and chronic health evaluation'}, {'cui': 'C0243028', 'cui_str': 'Acute physiology and chronic health evaluation II'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",110.0,0.0373946,"The MOS 36-item short form health survey (SF-36) scores of all patients after nursing were significantly higher than those before nursing (P<0.001), and the scores in the experimental group after nursing was higher than that in the control group (P<0.001). ","[{'ForeName': 'Zhaojia', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': 'ICU, Wuhan Jinyintan Hospital, Wuhan, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Surgical, Wuhan Jinyintan Hospital, Wuhan, China.'}, {'ForeName': 'Rongjun', 'Initials': 'R', 'LastName': 'Xu', 'Affiliation': 'Supply Unit in Hospital, Wuhan Jinyintan Hospital, Wuhan, China.'}]",Annals of palliative medicine,['10.21037/apm-21-1192'] 1958,34352600,"Effect of aerobic water exercise during pregnancy on epidural use and pain: A multi-centre, randomised, controlled trial.","OBJECTIVE The physical and psychological benefits of exercise during pregnancy are well established. However, the impact of exercise on pain during labour and the use of epidural analgesia has been less explored. The main aim of this study was to analyse the effectiveness and safety of moderate aerobic water exercise by pregnant women on the subsequent use of epidural analgesia during labour, induction of labour, mode of delivery, and pain perception. DESIGN A multi-centre, parallel, randomised, evaluator blinded, controlled trial in a primary care setting. SETTING Primary care centres in a health district of a tertiary obstetric metropolitan hospital in Mallorca, Spain. PARTICIPANTS Pregnant women (14 to 20 weeks' gestation) who had low risk of complications. METHODS Three hundred and twenty pregnant women were randomly assigned to two groups: women who practiced moderate aquatic aerobic exercise with usual antenatal care, and those who received usual prenatal care alone. The gynaecologist, anaesthesiologist and midwife who assisted the women during labour were blinded to group allocations. Principal outcome: use of epidural analgesia during labour. Other outcomes: use of epidural analgesia before 6 cm cervical dilation, labour pain, type of delivery, time of active labour, episiotomy or perineal tear, and induction of labour. RESULTS The exercise program did not affect the use of epidural analgesia (OR = 0.79, 95% CI = 0.44 to 1.40), vaginal delivery (OR = 1.35, 95% CI = 0.73 to 2.41), or caesarean section (OR = 0.94, 95% CI = 0.47 to 1.89). However, women in the exercise group reported less pain during labour (mean difference: -0.6, 95% CI = -1.11 to -0.09). The two groups (moderate aquatic aerobic exercise versus usual antenatal care) showed no significant differences in maternal or newborn adverse events. CONCLUSION Aquatic aerobic exercise during pregnancy had no effect on the use of epidural analgesia during labour, whereas pain perception was lower after aquatic exercise compared to usual care in pregnancy. The intervention was safe for pregnant women and their newborns.",2021,"The two groups (moderate aquatic aerobic exercise versus usual antenatal care) showed no significant differences in maternal or newborn adverse events. ","['pregnant women', 'Three hundred and twenty pregnant women were randomly assigned to two groups: women who', ""Pregnant women (14 to 20 weeks' gestation) who had low risk of complications"", 'pregnant women and their newborns', 'Primary care centres in a health district of a tertiary obstetric metropolitan hospital in Mallorca, Spain']","['aquatic exercise', 'aerobic water exercise', 'epidural analgesia', 'moderate aerobic water exercise', 'aquatic aerobic exercise versus usual antenatal care', 'Aquatic aerobic exercise', 'practiced moderate aquatic aerobic exercise with usual antenatal care, and those who received usual prenatal care alone']","['epidural use and pain', 'vaginal delivery', 'caesarean section', 'epidural analgesia', 'maternal or newborn adverse events', 'labour pain, type of delivery, time of active labour, episiotomy or perineal tear, and induction of labour', 'effectiveness and safety', 'pain during labour', 'pain perception']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0020029', 'cui_str': 'Urban Hospitals'}, {'cui': 'C0454825', 'cui_str': 'Mallorca'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}]","[{'cui': 'C0592511', 'cui_str': 'Epidural route'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0474368', 'cui_str': 'Labor pain'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0233081', 'cui_str': 'Normal labor'}, {'cui': 'C0014586', 'cui_str': 'Episiotomy'}, {'cui': 'C0240713', 'cui_str': 'Laceration of perineum'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",320.0,0.0303428,"The two groups (moderate aquatic aerobic exercise versus usual antenatal care) showed no significant differences in maternal or newborn adverse events. ","[{'ForeName': 'María Del Carmen', 'Initials': 'MDC', 'LastName': 'Carrascosa', 'Affiliation': 'Mallorca Primary Health Care, Balearic Islands Health Services, Calle Escuela Graduada, 3, Palma 07002, Spain. Electronic address: mccarrascosa@ibsalut.caib.es.'}, {'ForeName': 'Araceli', 'Initials': 'A', 'LastName': 'Navas', 'Affiliation': 'Hospital Comarcal de Inca, Servei de Salut de les Illes Balears (Ib-salut), Carretera Vella de Llubí, s/n, Inca 07300, Spain.'}, {'ForeName': 'Catalina', 'Initials': 'C', 'LastName': 'Artigues', 'Affiliation': 'Mallorca Primary Health Care, Balearic Islands Health Services, Calle Escuela Graduada, 3, Palma 07002, Spain. Electronic address: cartigues@ibsalut.caib.es.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Ortas', 'Affiliation': 'Mallorca Primary Health Care, Balearic Islands Health Services, Calle Escuela Graduada, 3, Palma 07002, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Portells', 'Affiliation': 'Mallorca Primary Health Care, Balearic Islands Health Services, Calle Escuela Graduada, 3, Palma 07002, Spain. Electronic address: meportells@ibsalut.caib.es.'}, {'ForeName': 'Aina', 'Initials': 'A', 'LastName': 'Soler', 'Affiliation': ""Primary Care Research Unit of Mallorca, Balearic Islands Health Services, Calle Escuela Graduada, 3, Palma 07002, Spain; Insitut d'Investigació Sanitària Illes Balears (IdISBa), Carretera de Valldemossa, 79, Palma 07120, Spain. Electronic address: asoler@ibsalut.caib.es.""}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Bennasar-Veny', 'Affiliation': ""Insitut d'Investigació Sanitària Illes Balears (IdISBa), Carretera de Valldemossa, 79, Palma 07120, Spain; Nursing and Physiotherapy Department, Balearic Islands University, Carrertera de Valldemosa, Km 7,5, Palma 07122, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0, Madrid 28029, Spain. Electronic address: miquel.bennasar@uib.es.""}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Leiva', 'Affiliation': ""Primary Care Research Unit of Mallorca, Balearic Islands Health Services, Calle Escuela Graduada, 3, Palma 07002, Spain; Insitut d'Investigació Sanitària Illes Balears (IdISBa), Carretera de Valldemossa, 79, Palma 07120, Spain. Electronic address: aleiva@ibsalut.caib.es.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Midwifery,['10.1016/j.midw.2021.103105'] 1959,34352597,Effect of Healing Meditation on stress and eating behavior in overweight and obese women: A randomized clinical trial.,"BACKGROUND A randomized, parallel-controlled, blinded clinical trial was conducted to evaluate the effect of Healing Meditation on stress and eating behavior of women undergoing standard weight-loss treatment. MATERIALS AND METHODS An outpatient clinic in Brazil, 55 women with overweight and obesity were included and randomized: 27 for the Meditation Group, and 28 for the Control Group. Randomization was stratified by body mass index category and based on blocks of four. For eight weeks, in addition to the standard weight loss treatment, the Intervention Group underwent a Healing Meditation program, and the Control Group participated in a round table to observe compliance. Reduction in stress and changes in eating behavior were assessed at baseline, and in the 8th, and 16th week using the Perceived Stress Scale, the Dutch Eating Behavior Questionnaire, and Binge Eating Scale. RESULTS The sample mean age was 49 ± 11 years, 72.7% were obese, with a predominance of mixed (49.1%) and black (41.8%) ethnicity. After eight weeks, the Meditation Group showed a mean reduction in total stress of -17.4 (IC 95% -19.5 to -15.3 p < 0.001). In eating behavior, a mean reduction of -7.9 (p < 0.001) in external eating, of -11.4 (p < 0.0001) in emotional eating, and a rise of 9.6 (p < 0.0001) in restrained eating were found. Score levels remained stable between the 8th and 16th week. Binge eating had a mean variation of -22.2%(p = 0.011). CONCLUSION The addition of Healing Meditation to the standard weight-loss treatment may significantly reduce stress and produce positive changes in the eating behavior of overweight and obese women. TRIAL REGISTRATION RBR-7564FD.",2021,"In eating behavior, a mean reduction of -7.9 (p < 0.001) in external eating, of -11.4 (p < 0.0001) in emotional eating, and a rise of 9.6 (p < 0.0001) in restrained eating were found.","['55 women with overweight and obesity were included and randomized: 27 for the Meditation Group, and 28 for the Control Group', 'overweight and obese women', 'The sample mean age was 49\xa0±\xa011 years, 72.7% were obese, with a predominance of mixed (49.1%) and black (41.8%) ethnicity', 'women undergoing standard weight-loss treatment']","['Healing Meditation', 'Healing Meditation program']","['Reduction in stress and changes in eating behavior', 'emotional eating', 'Score levels', 'stress and eating behavior', 'Perceived Stress Scale, the Dutch Eating Behavior Questionnaire, and Binge Eating Scale', 'total stress', 'Binge eating']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0647859', 'cui_str': 'AM 49'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451027', 'cui_str': 'Binge eating scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0006370', 'cui_str': 'Binge Eating'}]",55.0,0.062421,"In eating behavior, a mean reduction of -7.9 (p < 0.001) in external eating, of -11.4 (p < 0.0001) in emotional eating, and a rise of 9.6 (p < 0.0001) in restrained eating were found.","[{'ForeName': 'Cynthia Vieira Sanches', 'Initials': 'CVS', 'LastName': 'Sampaio', 'Affiliation': 'Bahiana School of Medicine and Public Health, Bahia Foundation for the Development of Sciences, FBDC, Av. Tancredo Neves, 805-A. Centro Médico Iguatemi, sala 301, Caminho das Árvores, Salvador, Bahia, CEP: 41820-021, Brazil. Electronic address: cysampaio@gmail.com.'}, {'ForeName': 'Guilherme', 'Initials': 'G', 'LastName': 'Magnavita', 'Affiliation': 'Department of Psychiatry, Hospital Universitário Professor Edgard Santos, R. Dr. Augusto Viana, s/n -Canela, Salvador, Bahia, CEP: 40301-155, Brazil. Electronic address: Guilherme.magnavita@gmail.com.'}, {'ForeName': 'Ana Marice', 'Initials': 'AM', 'LastName': 'Ladeia', 'Affiliation': 'Bahiana School of Medicine and Public Health, Bahia Foundation for the Development of Sciences, FBDC, Rua Ceará 320. Edf. Mansão Calasans Neto apto 802, Pituba, Salvador, Bahia, 41820-021, Brazil. Electronic address: anamarice@bahiana.edu.br.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2021.101468'] 1960,34352596,"The effects of auricular acupressure on the sleep of the elderly using polysomnography, actigraphy and blood test: Randomized, single-blind, sham control.","AIM This study was conducted to examine the effects of auricular acupressure on sleep in elderly people with sleep disorders. METHODS This was a randomized, double-blind, sham-controlled study. The participants aged over 65 years old were randomly assigned to the experimental group (n = 21) and the sham control group (n = 21). The participants in the experimental group and the sham control group received auricular acupressure on sleep-disorder-related points or to sleep-disorder-unrelated points, respectively. The intervention was implemented for a total of eight weeks. To validate the effects of the treatment, polysomnography with the Alice portable sleep diagnostic system; actigraphy with Fitbit Alta; and melatonin, serotonin, and cortisol blood tests were conducted. RESULTS Non-Rapid Eye Movement sleep stage 3 duration change (Z = -2.187, p = .029) and Non-Rapid Eye Movement sleep stage 3 ratio change (Z = -2.423, p = .014), measured by polysomnography, of the experimental group showed a significant increase over time compared to the sham control group. CONCLUSIONS Auricular acupressure applied for eight weeks was found to be effective in increasing Non-Rapid Eye Movement sleep stage 3 duration and Non-Rapid Eye Movement sleep stage 3 ratio among sleep stages of the elderly. Consequently, it showed that auricular acupressure can be used as a proven nursing intervention method for sleep disorder in elders to increase deep sleep duration and ratio.",2021,"Rapid Eye Movement sleep stage 3 duration change (Z = -2.187, p = .029) and Non-Rapid Eye Movement sleep stage 3 ratio change (Z = -2.423, p = .014), measured by polysomnography, of the experimental group showed a significant increase over time compared to the sham control group. ","['elderly people with sleep disorders', 'participants aged over 65 years old']",['auricular acupressure'],['Rapid Eye Movement sleep stage 3 duration change'],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C1522191', 'cui_str': 'Otic route'}, {'cui': 'C0282614', 'cui_str': 'Acupressure'}]","[{'cui': 'C0037322', 'cui_str': 'Rapid eye movement sleep'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.16282,"Rapid Eye Movement sleep stage 3 duration change (Z = -2.187, p = .029) and Non-Rapid Eye Movement sleep stage 3 ratio change (Z = -2.423, p = .014), measured by polysomnography, of the experimental group showed a significant increase over time compared to the sham control group. ","[{'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Juyon', 'Affiliation': 'Ewha Womans University, Seoul, South Korea.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Bomi', 'Affiliation': 'Ewha Womans University, Seoul, South Korea.'}, {'ForeName': 'Park', 'Initials': 'P', 'LastName': 'Hyojung', 'Affiliation': 'College of Nursing, Ewha Womans University, Seoul, South Korea. Electronic address: hyojungp@ewha.ac.kr.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2021.101464'] 1961,34352588,"Randomized, double-blind, placebo-controlled trial to examine the safety, pharmacokinetics and effects of Epimedium prenylflavonoids, on bone specific alkaline phosphatase and the osteoclast adaptor protein TRAF6 in post-menopausal women.","BACKGROUND Fragility fractures due to menopausal osteoporosis are a major cause of morbidity and mortality. Osteoporotic medications have substantial side effects that limit long term use. HYPOTHESES Ingestion of a purified extract of Epimedium spp. (EP) is safe, can increase serum levels of prenylflavonoid metabolites, exert positive changes in bone specific alkaline phosphatase (BSAP), suppress of tumor necrosis factor receptor associated factor 6 (TRAF6) protein in osteoclast-precursor monocytes in peripheral blood and therefore have the potential to reduce post-menopausal bone loss. STUDY DESIGN & METHODS Healthy postmenopausal women were randomized in a double-blind fashion to consume either EP prenylflavonoid extract (740 mg daily) or placebo daily for 6 weeks. The main outcome measures were safety and pharmacokinetics of EP flavonoids. Fasting blood was collected at 3- and 6-weeks, and two weeks after stopping medication for safety evaluations and measurement of BSAP. Peripheral blood monocytes were harvested for measurement of TRAF6 levels. Serum levels of the EP metabolites icariin, icariside I & II, icaritin and desmethylicaritin were measured using tandem mass spectrometry, and non-compartmental pharmacokinetic analyses performed using WinNonlin software. RESULTS Between October 2018 and Jun 2020, 58 postmenopausal women, aged 57.9 ± 8.9 years, were randomized and completed the study. Consumption of EP prenylflavonoids was not associated with any significant adverse symptoms, with no changes in hepatic, hematological, and renal parameters observed. The main metabolites detected in sera after ingestion of EP prenylflavonoid capsules were desmethylicaritin, icaritin and icariside II. Icariin and icariside I were below detection levels. Ingestion of EP prenylflavonoids induced a median C max and AUC 0→∞ for desmethylicaritin of 60.9 nM, and 157.9 nM ×day, respectively; and were associated with higher levels of BSAP (p < 0.05) and a trend (p = 0.068) towards lower levels of TRAF6 in peripheral blood monocytes eight weeks after commencing prenylflavonoid ingestion. Prenylflavonoid metabolites were not detected in the sera of placebo participants. CONCLUSIONS Despite the widespread consumption of EP extracts, the safety, mechanisms of action of their bioactive compounds, and therapeutic indications in humans are unknown. Daily consumption of EP prenylflavonoids for six weeks was safe. The predominant metabolite in sera was desmethylicaritin. Rise in prenylflavonoid metabolites was associated with higher levels of the bone anabolic marker BSAP, suggesting potential therapeutic value for post-menopausal osteoporosis.",2021,"Serum levels of the EP metabolites icariin, icariside I & II, icaritin and desmethylicaritin were measured using tandem mass spectrometry, and non-compartmental pharmacokinetic analyses performed using WinNonlin software. ","['post-menopausal women', 'Between October 2018 and Jun 2020, 58 postmenopausal women, aged 57.9 ± 8.9 years', 'Healthy postmenopausal women']","['EP prenylflavonoid extract', 'purified extract of Epimedium spp', 'Epimedium prenylflavonoids', 'placebo', 'Icariin and icariside']","['Peripheral blood monocytes', 'median C max and AUC', 'hepatic, hematological, and renal parameters', 'levels of BSAP', 'Prenylflavonoid metabolites', 'Fasting blood', 'safety and pharmacokinetics of EP flavonoids', 'Serum levels of the EP metabolites icariin, icariside I & II, icaritin and desmethylicaritin']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0162508', 'cui_str': 'jun Oncogene'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1084567', 'cui_str': 'Epimedium'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0063273', 'cui_str': 'icariin'}]","[{'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0312399', 'cui_str': 'Alkaline phosphatase isoenzyme, bone fraction'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C1084567', 'cui_str': 'Epimedium'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0596577', 'cui_str': 'Flavonoid'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0063273', 'cui_str': 'icariin'}, {'cui': 'C2351736', 'cui_str': 'icariside I'}, {'cui': 'C1567768', 'cui_str': 'icaritin'}, {'cui': 'C1567769', 'cui_str': 'desmethylicaritin'}]",58.0,0.15314,"Serum levels of the EP metabolites icariin, icariside I & II, icaritin and desmethylicaritin were measured using tandem mass spectrometry, and non-compartmental pharmacokinetic analyses performed using WinNonlin software. ","[{'ForeName': 'Eu-Leong', 'Initials': 'EL', 'LastName': 'Yong', 'Affiliation': 'Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, 119228 Singapore. Electronic address: obgyel@nus.edu.sg.'}, {'ForeName': 'Wei Fun', 'Initials': 'WF', 'LastName': 'Cheong', 'Affiliation': 'Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, 119228 Singapore.'}, {'ForeName': 'Zhongwei', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': 'Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, 119228 Singapore; Institute of Molecular and Cell Biology, Agency of Science, Technology and Research, 138673 Singapore.'}, {'ForeName': 'Win Pa Pa', 'Initials': 'WPP', 'LastName': 'Thu', 'Affiliation': 'Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, 119228 Singapore.'}, {'ForeName': 'Amaury', 'Initials': 'A', 'LastName': 'Cazenave-Gassiot', 'Affiliation': 'Singapore Lipidomics Incubator, Life Sciences Institute, National University of Singapore, 117456 Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 117596 Singapore.'}, {'ForeName': 'Kok Yong', 'Initials': 'KY', 'LastName': 'Seng', 'Affiliation': 'Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117600 Singapore.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Logan', 'Affiliation': 'Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, 119228 Singapore.'}]",Phytomedicine : international journal of phytotherapy and phytopharmacology,['10.1016/j.phymed.2021.153680'] 1962,34357539,"Quality control questions on Amazon's Mechanical Turk (MTurk): A randomized trial of impact on the USAUDIT, PHQ-9, and GAD-7.","Crowdsourced psychological and other biobehavioral research using platforms like Amazon's Mechanical Turk (MTurk) is increasingly common - but has proliferated more rapidly than studies to establish data quality best practices. Thus, this study investigated whether outcome scores for three common screening tools would be significantly different among MTurk workers who were subject to different sets of quality control checks. We conducted a single-stage, randomized controlled trial with equal allocation to each of four study arms: Arm 1 (Control Arm), Arm 2 (Bot/VPN Check), Arm 3 (Truthfulness/Attention Check), and Arm 4 (Stringent Arm - All Checks). Data collection was completed in Qualtrics, to which participants were referred from MTurk. Subjects (n = 1100) were recruited on November 20-21, 2020. Eligible workers were required to claim U.S. residency, have a successful task completion rate > 95%, have completed a minimum of 100 tasks, and have completed a maximum of 10,000 tasks. Participants completed the US-Alcohol Use Disorders Identification Test (USAUDIT), the Patient Health Questionnaire (PHQ-9), and a screener for Generalized Anxiety Disorder (GAD-7). We found that differing quality control approaches significantly, meaningfully, and directionally affected outcome scores on each of the screening tools. Most notably, workers in Arm 1 (Control) reported higher scores than those in Arms 3 and 4 for all tools, and a higher score than workers in Arm 2 for the PHQ-9. These data suggest that the use, or lack thereof, of quality control questions in crowdsourced research may substantively affect findings, as might the types of quality control items.",2021,"Most notably, workers in Arm 1 (Control) reported higher scores than those in Arms 3 and 4 for all tools, and a higher score than workers in Arm 2 for the PHQ-9.","[""Amazon's Mechanical Turk (MTurk"", 'Eligible workers were required to claim U.S. residency, have a successful task completion rate > 95%, have completed a minimum of 100 tasks, and have completed a maximum of 10,000 tasks', 'Subjects (n = 1100) were recruited on November 20-21, 2020']","[""platforms like Amazon's Mechanical Turk (MTurk""]",[],"[{'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0337911', 'cui_str': 'Turks'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0035182', 'cui_str': 'Residency'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C4517537', 'cui_str': '1100'}]","[{'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0337911', 'cui_str': 'Turks'}]",[],1100.0,0.0744385,"Most notably, workers in Arm 1 (Control) reported higher scores than those in Arms 3 and 4 for all tools, and a higher score than workers in Arm 2 for the PHQ-9.","[{'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Agley', 'Affiliation': 'Prevention Insights, Department of Applied Health Science, School of Public Health Bloomington, Indiana University Bloomington, 809 E. 9th St, Bloomington, IN, 47405, USA. jagley@indiana.edu.'}, {'ForeName': 'Yunyu', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': 'School of Social Work, Indiana University Bloomington, Bloomington, IN, USA.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Nolan', 'Affiliation': 'Department of Environmental & Public Health Sciences, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Lilian', 'Initials': 'L', 'LastName': 'Golzarri-Arroyo', 'Affiliation': 'Biostatistics Consulting Center, School of Public Health Bloomington, Indiana University Bloomington, Bloomington, IN, USA.'}]",Behavior research methods,['10.3758/s13428-021-01665-8'] 1963,34357466,Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.,"Cisplatin is used to treat solid malignancies including head and neck cancer. However, nephrotoxicity limits its use. In this study, we looked for a possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity. We used novel biomarkers for early detection of nephrotoxicity. Sixty chemotherapy naïve head and neck cancer patients completed the study. Following complete history taking and thorough clinical examination, patients were randomly divided into three groups: 20 patients in each. Group I (control group) received cisplatin without pantoprazole, groups II and III received pantoprazole 80 mg and 40 mg, respectively, concurrently with cisplatin. Blood and urine samples were collected at baseline, and 48 h after the first and third cycles of cisplatin administration. Assessment of serum creatinine and soluble FasL (sFasL), as well as urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) was performed. Nephrotoxicity was detected in 6 patients in group I, none in group II and 3 patients in group III. Serum creatinine significantly increased at the end of treatment in group I compared to groups II and III. Group I also had significantly higher urinary KIM-1 and NGAL and serum sFasL compared to groups II and III after the first and third cycles. On the contrary, there was no significant difference between groups II and III. Pantoprazole prevented the increase in acute kidney injury biomarkers in cisplatin-treated patients. Therefore, it is a promising agent in reducing cisplatin-induced nephrotoxicity.Trial registration Clinical Trials.gov identifier: NCT04217512, registered in January 2020 "" retrospectively registered"".",2021,Group I also had significantly higher urinary KIM-1 and NGAL and serum sFasL compared to groups II and III after the first and third cycles.,"['treated patients', 'head and neck cancer patients', 'head and neck cancer', 'Sixty chemotherapy naïve head and neck cancer patients']","['cisplatin without pantoprazole', 'pantoprazole against cisplatin-induced nephrotoxicity', 'pantoprazole against cisplatin', 'Pantoprazole', 'cisplatin', 'Cisplatin', 'pantoprazole 80\xa0mg and 40\xa0mg, respectively, concurrently with cisplatin']","['Serum creatinine', 'urinary KIM-1 and NGAL and serum sFasL', 'serum creatinine and soluble FasL (sFasL), as well as urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1', 'Blood and urine samples', 'Nephrotoxicity', 'acute kidney injury biomarkers', 'nephrotoxicity']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0081876', 'cui_str': 'pantoprazole'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0595916', 'cui_str': 'Toxic nephropathy'}]","[{'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C1313407', 'cui_str': 'HAVCR1 protein, human'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0206528', 'cui_str': 'Gelatinase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1675724', 'cui_str': 'FASLG protein, human'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0595916', 'cui_str': 'Toxic nephropathy'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",,0.018665,Group I also had significantly higher urinary KIM-1 and NGAL and serum sFasL compared to groups II and III after the first and third cycles.,"[{'ForeName': 'Eman', 'Initials': 'E', 'LastName': 'Ghonaim', 'Affiliation': 'Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Governorate, Tanta, 31111, Egypt. eman.ghonim@pharm.tanta.edu.eg.'}, {'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'El-Haggar', 'Affiliation': 'Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Governorate, Tanta, 31111, Egypt.'}, {'ForeName': 'Suzy', 'Initials': 'S', 'LastName': 'Gohar', 'Affiliation': 'Oncology and Nuclear Medicine Department, Faculty of Medicine, Menoufia University, Yassin Abd-Elghaffar St. From Gamal Abdel Nasser ST., Shebin El-Kom, 32511, Menoufia, Egypt.'}]","Medical oncology (Northwood, London, England)",['10.1007/s12032-021-01558-y'] 1964,34357396,Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial.,"Importance Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptides (PACAPs) are structurally and functionally related, yet different in their migraine-inducing properties. It remains unclear whether the lack of migraine induction can be attributed to the only transient vasodilatory response after a 20-minute infusion of VIP. Objective To determine whether a 2-hour infusion of VIP would provoke migraine attacks. Design, Setting, and Participants A randomized, double-blind, placebo-controlled, crossover study was conducted between May and September 2020 at the Danish Headache Center in Copenhagen, Denmark. Patients were eligible for inclusion if they were ages 18 to 40 years, weighed between 50 and 90 kg, had a diagnosis of migraine without aura as defined by the International Classification of Headache Disorders, and had a migraine frequency of 1 to 6 attacks per month. Interventions Patients were randomly allocated to receive a 2-hour infusion of VIP or placebo on 2 different days. Main Outcomes and Measures The primary end point was the difference in incidence of experimentally induced migraine attacks during the observational period (0-12 hours) between VIP and placebo. Results Twenty-one patients (17 [81%] women and 4 [19%] men; mean [range] age, 25.9 [19-40] years) were recruited in the study. Fifteen patients (71%; 95% CI, 48%-89%) developed migraine attacks after VIP compared with 1 patient (5%; 95% CI, 0%-24%) who developed a migraine attack after placebo (P < .001). The VIP-induced migraine attacks mimicked patients' spontaneous attacks. The area under the curve (AUC) of headache intensity scores (0-12 hours), as well as the AUC of the superficial temporal artery diameter (0-180 minute) were significantly greater after VIP compared with placebo (AUC0-12h, P = .003; AUC0-180min, P < .001). Conclusions and Relevance A 2-hour infusion of VIP caused migraine attacks, suggesting an important role of VIP in migraine pathophysiology. VIP and its receptors could be potential targets for novel migraine drugs. Trial Registration ClinicalTrials.gov Identifier: NCT04260035.",2021,"Fifteen patients (71%; 95% CI, 48%-89%) developed migraine attacks after VIP compared with 1 patient (5%; 95% CI, 0%-24%) who developed a migraine attack after placebo (P < .001).","['Patients were eligible for inclusion if they were ages 18 to 40 years, weighed between 50 and 90 kg, had a diagnosis of migraine without aura as defined by the International Classification of Headache Disorders, and had a migraine frequency of 1 to 6 attacks per month', 'Twenty-one patients (17 [81%] women and 4 [19%] men; mean [range] age, 25.9 [19-40] years) were recruited in the study', 'May and September 2020 at the Danish Headache Center in Copenhagen, Denmark']","['Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptides (PACAPs', 'Vasoactive Intestinal Polypeptide', 'VIP or placebo', 'VIP', 'placebo']","['Migraine Headaches', 'AUC of the superficial temporal artery diameter', 'migraine attacks', 'migraine attack', 'area under the curve (AUC) of headache intensity scores', 'incidence of experimentally induced migraine attacks']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0338480', 'cui_str': 'Migraine without aura'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0393735', 'cui_str': 'Headache disorder'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0010969', 'cui_str': 'Danish language'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0042395', 'cui_str': 'vasoactive intestinal peptide'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0001492', 'cui_str': 'Adenylate cyclase'}, {'cui': 'C1305923', 'cui_str': 'Polypeptide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0226130', 'cui_str': 'Structure of superficial temporal artery'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]",15.0,0.387412,"Fifteen patients (71%; 95% CI, 48%-89%) developed migraine attacks after VIP compared with 1 patient (5%; 95% CI, 0%-24%) who developed a migraine attack after placebo (P < .001).","[{'ForeName': 'Lanfranco', 'Initials': 'L', 'LastName': 'Pellesi', 'Affiliation': 'Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mohammad Al-Mahdi', 'Initials': 'MA', 'LastName': 'Al-Karagholi', 'Affiliation': 'Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'De Icco', 'Affiliation': 'Headache Science & Neurorehabilitation Center, Istituto di Ricovero e Cura a Carattere Scientifico Mondino Foundation, Pavia, Italy.'}, {'ForeName': 'Hande', 'Initials': 'H', 'LastName': 'Coskun', 'Affiliation': 'Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Fatima Azzahra', 'Initials': 'FA', 'LastName': 'Elbahi', 'Affiliation': 'Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Lopez-Lopez', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Josefin', 'Initials': 'J', 'LastName': 'Snellman', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Hannibal', 'Affiliation': 'Department of Clinical Biochemistry, Bispebjerg Frederiksberg Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Faisal Mohammad', 'Initials': 'FM', 'LastName': 'Amin', 'Affiliation': 'Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Messoud', 'Initials': 'M', 'LastName': 'Ashina', 'Affiliation': 'Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.18543'] 1965,34357348,Progression of Postprandial Blood Plasma Phospholipids Following Acute Intake of Different Dairy Matrices: A Randomized Crossover Trial.,"Studies have indicated that the dairy matrix can affect postprandial responses of dairy products, but little is known about the effect on postprandial plasma phospholipid levels. This study investigated postprandial plasma phospholipid levels following consumption of four different dairy products that are similar in micro and macro nutrients, but different in texture and structure: cheddar cheese (Cheese), homogenized cheddar cheese (Hom. Cheese), micellar casein isolate with cream (MCI Drink) or a gel made from the MCI Drink (MCI Gel). The study was an acute randomized, crossover trial in human volunteers with four test days. Blood samples were collected during an 8 h postprandial period and the content of 53 plasma phospholipids was analysed using liquid chromatography-mass spectrometry (LC-MS). No meal-time interactions were revealed; however, for nine of the 53 phospholipids, a meal effect was found. Thus, the results indicated a lower plasma level of specific lyso-phosphatidylethanolamines (LPEs) and lyso-phosphatidylcholines (LPCs) following consumption of the MCI Gel compared to the MCI Drink and Hom. Cheese, which might be attributed to an effect of viscosity. However, further studies are needed in order to reveal more details on the effect of the dairy matrix on postprandial phospholipids.",2021,"No meal-time interactions were revealed; however, for nine of the 53 phospholipids, a meal effect was found.","['Acute Intake of Different Dairy Matrices', 'human volunteers with four test days']",['micellar casein isolate with cream (MCI Drink) or a gel made from the MCI Drink (MCI Gel'],['plasma level of specific lyso-phosphatidylethanolamines (LPEs) and lyso-phosphatidylcholines (LPCs'],"[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0020155', 'cui_str': 'Human Volunteers'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0007332', 'cui_str': 'Caseins'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0560005', 'cui_str': 'mCi'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0017243', 'cui_str': 'Gel'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0031618', 'cui_str': 'Phosphatidylethanolamines'}, {'cui': 'C1959616', 'cui_str': 'Lecithin'}]",,0.0342037,"No meal-time interactions were revealed; however, for nine of the 53 phospholipids, a meal effect was found.","[{'ForeName': 'Rebekka', 'Initials': 'R', 'LastName': 'Thøgersen', 'Affiliation': 'Department of Food Science, Aarhus University, Agro Food Park 48, DK-8200 Aarhus N, Denmark.'}, {'ForeName': 'Ida Emilie I', 'Initials': 'IEI', 'LastName': 'Lindahl', 'Affiliation': 'Department of Food Science, Aarhus University, Agro Food Park 48, DK-8200 Aarhus N, Denmark.'}, {'ForeName': 'Bekzod', 'Initials': 'B', 'LastName': 'Khakimov', 'Affiliation': 'Department of Food Science, University of Copenhagen, DK-1958 Frederiksberg C, Denmark.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Kjølbæk', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, DK-1958 Frederiksberg C, Denmark.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Juhl Jensen', 'Affiliation': 'Arla Foods Amba, DK-8200 Aarhus N, Denmark.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Astrup', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, DK-1958 Frederiksberg C, Denmark.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Hammershøj', 'Affiliation': 'Department of Food Science, Aarhus University, Agro Food Park 48, DK-8200 Aarhus N, Denmark.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Raben', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, DK-1958 Frederiksberg C, Denmark.'}, {'ForeName': 'Hanne Christine', 'Initials': 'HC', 'LastName': 'Bertram', 'Affiliation': 'Department of Food Science, Aarhus University, Agro Food Park 48, DK-8200 Aarhus N, Denmark.'}]",Metabolites,['10.3390/metabo11070454'] 1966,34357334,Metabolic Profiling of Plasma in Patients with Irritable Bowel Syndrome after a 4-Week Starch- and Sucrose-Reduced Diet.,"A 4-week dietary intervention with a starch- and sucrose-restricted diet (SSRD) was conducted in patients with irritable bowel syndrome (IBS) to examine the metabolic profile in relation to nutrient intake and gastrointestinal symptoms. IBS patients were randomized to SSRD intervention ( n = 69) or control continuing with their ordinary food habits ( n = 22). Food intake was registered and the questionnaires IBS-symptoms severity scale (IBS-SSS) and visual analog scale for IBS (VAS-IBS) were completed. Metabolomics untargeted analysis was performed by gas chromatography mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS) in positive and negative ionization modes. SSRD led to marked changes in circulating metabolite concentrations at the group level, most prominent for reduced starch intake and increased polyunsaturated fat, with small changes in the control group. On an individual level, the correlations were weak. The marked reduction in gastrointestinal symptoms did not correlate with the metabolic changes. SSRD was observed by clear metabolic effects mainly related to linoleic acid metabolism, fatty acid biosynthesis, and beta-oxidation.",2021,Food intake was registered and the questionnaires IBS-symptoms severity scale (IBS-SSS) and visual analog scale for IBS (VAS-IBS) were completed.,"['patients with irritable bowel syndrome (IBS', 'Patients with Irritable Bowel Syndrome after a 4-Week Starch- and Sucrose-Reduced Diet', 'IBS patients']","['dietary intervention with a starch- and sucrose-restricted diet (SSRD', 'SSRD', 'SSRD intervention', 'control continuing with their ordinary food habits']","['linoleic acid metabolism, fatty acid biosynthesis, and beta-oxidation', 'questionnaires IBS-symptoms severity scale (IBS-SSS) and visual analog scale for IBS (VAS-IBS', 'gastrointestinal symptoms', 'circulating metabolite concentrations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0016468', 'cui_str': 'Eating Habits'}]","[{'cui': 'C0023749', 'cui_str': 'Linoleic acid'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0005572', 'cui_str': 'bioformation'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0037052', 'cui_str': 'Sick sinus syndrome'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.0147029,Food intake was registered and the questionnaires IBS-symptoms severity scale (IBS-SSS) and visual analog scale for IBS (VAS-IBS) were completed.,"[{'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Stenlund', 'Affiliation': 'Umeå Plant Science Centre (UPSC), Department of Plant Physiology, Umeå University, 90187 Umeå, Sweden.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Nilholm', 'Affiliation': 'Department of Clinical Sciences, Lund University, 22100 Lund, Sweden.'}, {'ForeName': 'Elin', 'Initials': 'E', 'LastName': 'Chorell', 'Affiliation': 'Department of Public Health and Clinical Medicine, Umeå University, 90187 Umeå, Sweden.'}, {'ForeName': 'Bodil', 'Initials': 'B', 'LastName': 'Roth', 'Affiliation': 'Department of Clinical Sciences, Lund University, 22100 Lund, Sweden.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': ""D'Amato"", 'Affiliation': 'Gastrointestinal Genetics Laboratory, CIC bioGUNE-BRTA, 48160 Derio, Spain.'}, {'ForeName': 'Bodil', 'Initials': 'B', 'LastName': 'Ohlsson', 'Affiliation': 'Department of Clinical Sciences, Lund University, 22100 Lund, Sweden.'}]",Metabolites,['10.3390/metabo11070440'] 1967,34361372,"One-Abutment One-Time Effect on Peri-Implant Marginal Bone: A Prospective, Controlled, Randomized, Double-Blind Study.","OBJECTIVE To evaluate the peri-implant hard tissue change at 6 and 12 months after implant placement between definitive abutment placed at the same time of implant surgery, never removing it, and healing abutment disconnected and reconnected three times until the placement of the final rehabilitation. MATERIAL AND METHODS Each partial edentulous patient could receive between 1 and 4 platform-switched implants in the posterior regions. If the implants had primary stability-implant stability quotient (ISQ) equal to or greater than 50, they were randomized to the test group with the abutment inserted at the same time of implant placement (DA) or to the control group, receiving a healing abutment (PA). At 6 and 12 months after surgery, data related with vertical bone level changes (primary outcome) and other clinical parameters (implant mobility, bleeding on probing, probing depth, plaque index) were assessed. RESULTS 53 implants were included in the trial and completed 12 months follow-up (overall survival rate: 100%). All implants achieved primary stability, with an average ISQ value of 80.9 on the day of surgery. From surgery to 6 months, the mean bone loss was 0.14 ± 0.18 mm for the DA group and 0.23 ± 0.29 mm for the PA group, without statistical significance difference. Between 6 and 12 months, the mean bone loss was 0.14 ± 0.21 mm for the DA group and 0.21 ± 0.27 mm for the PA group, also without statistical significance between the two groups. There were no statistically significant differences ( p = 0.330) in total bone loss after 12 months between the control and the study groups. CONCLUSIONS The one abutment one time protocol has at least an equivalent effect on the peri-implant bone level changes when compared with the use of healing abutments that are disconnected and reconnected at least three times.",2021,"There were no statistically significant differences ( p = 0.330) in total bone loss after 12 months between the control and the study groups. ",[],"['implant placement (DA) or to the control group, receiving a healing abutment (PA']","['clinical parameters (implant mobility, bleeding on probing, probing depth, plaque index', 'total bone loss', 'mean bone loss', 'primary stability-implant stability quotient (ISQ']",[],"[{'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3266125', 'cui_str': 'Healing abutment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",53.0,0.0589734,"There were no statistically significant differences ( p = 0.330) in total bone loss after 12 months between the control and the study groups. ","[{'ForeName': 'Filipe', 'Initials': 'F', 'LastName': 'Moreira', 'Affiliation': 'Institute of Oral Implantology and Prosthodontics, Faculty of Medicine, University of Coimbra, 3000-075 Coimbra, Portugal.'}, {'ForeName': 'Salomão', 'Initials': 'S', 'LastName': 'Rocha', 'Affiliation': 'Institute of Oral Implantology and Prosthodontics, Faculty of Medicine, University of Coimbra and Center of Research and Innovation in Dental Sciences of the Faculty of Medicine of the University of Coimbra, 3000-075 Coimbra, Portugal.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Caramelo', 'Affiliation': 'Laboratory of Biostatistics and Medical Informatics (LBIM), Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.'}, {'ForeName': 'João P', 'Initials': 'JP', 'LastName': 'Tondela', 'Affiliation': 'Faculty of Medicine, University of Coimbra and Center of Research and Innovation in Dental Sciences of the Faculty of Medicine of the University of Coimbra, 3000-075 Coimbra, Portugal.'}]","Materials (Basel, Switzerland)",['10.3390/ma14154179'] 1968,34340243,Intravenous immunoglobulin for corticosteroid-resistant intestinal Henoch-Schönlein purpura: worth a controlled trial against corticosteroids?,"OBJECTIVES Henoch-Schönlein purpura (HScP) may present in children with severe, occasionally refractory, gastrointestinal (GI) involvement. The use of corticosteroids (CSs) is commonplace in the management of the disease, but to date no standardized protocol is available and, although rare, resistance to CS therapy may be challenging to clinicians. IVIG has been proposed as an effective alternative to CSs, but to date no controlled trial has been conducted to ascertain their real efficacy. We share our personal experience of successful IVIG treatment in two cases of GI HScP, comparing it with similar experiences reported in literature. METHODS Retrospective clinical data collection, comparison with available literature. RESULTS We describe two children with severe HScP GI vasculitis refractory to high-dose intravenous CSs that responded rapidly to IVIG administration, with complete recovery within a few days. Patient characteristics and response to IVIG administration were comparable to those of other previously reported cases. CONCLUSION Our observation confirms that IVIG may be useful in the treatment of CS-resistant HScP-related GI vasculitis in children, and highlights the need for more structured research, including a randomized trial against CSs, in order to ascertain their real effectiveness.",2021,"Our observation confirms that IVIG may be useful in the treatment of CS-resistant HScP-related GI vasculitis in children, and highlights the need for more structured research, including a randomized trial against CSs, in order to ascertain their real effectiveness.","['children with severe, occasionally refractory, gastrointestinal (GI) involvement', 'children with severe HScP GI vasculitis refractory to high-dose intravenous CSs']","['corticosteroids (CSs', 'Intravenous immunoglobulin']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0034152', 'cui_str': 'Henoch-Schönlein purpura'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]","[{'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}]",[],2.0,0.206248,"Our observation confirms that IVIG may be useful in the treatment of CS-resistant HScP-related GI vasculitis in children, and highlights the need for more structured research, including a randomized trial against CSs, in order to ascertain their real effectiveness.","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Morotti', 'Affiliation': 'SCDU of Pediatrics, Department of Health Sciences, Università degli Studi del Piemonte Orientale, Novara, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Bracciolini', 'Affiliation': 'Pediatrics and Pediatric Emergency Unit, The Children Hospital, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Caorsi', 'Affiliation': 'Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy.'}, {'ForeName': 'Lorella', 'Initials': 'L', 'LastName': 'Cattaneo', 'Affiliation': 'Pediatrics and Pediatric Emergency Unit, The Children Hospital, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Gattorno', 'Affiliation': 'Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Ravelli', 'Affiliation': 'Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Felici', 'Affiliation': 'Pediatrics and Pediatric Emergency Unit, The Children Hospital, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa743'] 1969,34340194,Effects of patient deterioration simulation using inattentional blindness for final year nursing students: A randomized controlled trial.,"BACKGROUND Patient deterioration should be detected early and responded appropriately for patient safety. It is necessary to strengthen situational awareness regarding patient deterioration. Inattentional blindness is a major factor that hinders situational awareness about patient deterioration in the clinical setting. OBJECTIVES To analyze the impact of patient deterioration simulation using inattentional blindness (PDS-IB) on situational awareness and patient safety competency-attitude among final year nursing students. DESIGN A randomized controlled trial. PARTICIPANTS Final year nursing students at a university in South Korea. METHODS Students were randomly assigned to an experimental or control group. The experimental group (n = 47) was given a PDS-IB. The control group (n = 44) received a simple patient deterioration simulation. Situational awareness and patient safety competency-attitude were measured at baseline, post intervention, and at 2 weeks follow-up. Data were analyzed using a two-way repeated measures ANOVA. RESULTS There were statistically significant group effects, time effects, and group and time interaction effects in situational awareness and patient safety competency-attitude. CONCLUSION PDS-IB is an effective educational strategy that increases situational awareness and patient safety competency-attitude in final year nursing students.",2021,"There were statistically significant group effects, time effects, and group and time interaction effects in situational awareness and patient safety competency-attitude. ","['Students', 'final year nursing students', 'Final year nursing students at a university in South Korea', 'inattentional blindness for final year nursing students']","['patient deterioration simulation using inattentional blindness (PDS-IB', 'patient deterioration simulation', 'simple patient deterioration simulation']","['situational awareness and patient safety competency-attitude', 'Situational awareness and patient safety competency-attitude']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0205352', 'cui_str': 'Simple'}]","[{'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}]",47.0,0.128581,"There were statistically significant group effects, time effects, and group and time interaction effects in situational awareness and patient safety competency-attitude. ","[{'ForeName': 'Jaewon', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Department of Nursing, Hannam University, Daejeon, South Korea.'}, {'ForeName': 'Kyoung-Ja', 'Initials': 'KJ', 'LastName': 'Kim', 'Affiliation': 'College of Medicine, Department of Nursing, Inha University, Inchon, South Korea. Electronic address: asteria43@inha.ac.kr.'}]",Nurse education today,['10.1016/j.nedt.2021.105080'] 1970,34340170,Mind's eye: The impact of spider presence and cognitive therapy on size estimation biases in spider phobia.,"The present study assessed the circumstances under which size estimation biases in spider phobia occur, and whether such biases are modifiable by treatment. Women with (n = 67) and without (n = 33) spider phobia approached a spider during a behavioral approach test (BAT). They provided size estimates of the spider both during and shortly after the BAT (with the spider in view, or not in view, respectively). Phobic women then received cognitive therapy or a placebo treatment and one week later they underwent a second BAT and provided size estimates of the same spider during and after the BAT. Phobic women reported larger size estimates than non-phobic women after, but not during, the BAT. Size estimates after, but not during, the BAT correlated with self-reported fear but not avoidance. Size estimates after, but not during, the BAT reduced from the first to second BAT in phobic women; an effect evident in both the cognitive therapy and placebo treatment conditions. Changes in size estimates were not associated with treatment-induced reductions in fear or avoidance. These results suggest that estimation biases in spider phobia are likely driven by non-perceptual processes. The clinical utility of size estimation measures is discussed.",2021,Changes in size estimates were not associated with treatment-induced reductions in fear or avoidance.,"['Phobic women', 'spider phobia', 'Women with (n = 67) and without (n = 33) spider phobia approached a spider during a behavioral approach test (BAT']","['cognitive therapy or a placebo', 'spider presence and cognitive therapy']",['fear or avoidance'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0392331', 'cui_str': 'Arachnophobia'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0037913', 'cui_str': 'Order Araneae'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0037913', 'cui_str': 'Order Araneae'}, {'cui': 'C0150312', 'cui_str': 'Present'}]","[{'cui': 'C0015726', 'cui_str': 'Fear'}]",67.0,0.131322,Changes in size estimates were not associated with treatment-induced reductions in fear or avoidance.,"[{'ForeName': 'Sophie H', 'Initials': 'SH', 'LastName': 'Li', 'Affiliation': 'School of Psychology, The University of New South Wales Australia, Sydney, New South Wales, Australia.'}, {'ForeName': 'Bronwyn M', 'Initials': 'BM', 'LastName': 'Graham', 'Affiliation': 'School of Psychology, The University of New South Wales Australia, Sydney, New South Wales, Australia. Electronic address: bgraham@psy.unsw.edu.au.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2021.102456'] 1971,34340163,A pilot study evaluating the effect of early physical therapy on pain and disabilities after breast cancer surgery: Prospective randomized control trail.,"BACKGROUND Morbidity of the shoulders after breast cancer (BC) surgery is a common side effect that includes; persistent pain, function limitation, and decreased range of motion (ROM). This study examines the effect of early physical therapy (PT) and patient's education on these morbidities. METHODS A prospective, randomized clinical trial was conducted at a single medical center from October 2018 until April 2019. Women scheduled for breast cancer surgery were divided into intervention or control as standard care. The intervention included a PT treatment that included exercise instructions from the first postoperative day. Pain levels, upper limb function, ROM, and complications were measured. RESULTS The study includes 157 women (mean age, 52.2 ± 12.9). Early PT reduced pain levels at the first month (NPRS 1.5 ± 1.2) and six months (NPRS 0.5 ± 0.8), compared with control (NPRS 2.1 ± 1.4, 1.0 ± 1.2), p = 0.019 and p = 0.011, respectively. Subdivision of the sample into small and extensive surgeries revealed additional positive effect for the intervention six months postoperatively on functional disabilities, p = 0.004 and p = 0.032 respectively. No complications attributable to the intervention were recorded. CONCLUSIONS Early PT and patient education reduces pain levels, and may improve function disabilities, without causing postoperative complications, although a larger study is needed to achieve unequivocal results.",2021,"Early PT reduced pain levels at the first month (NPRS 1.5 ± 1.2) and six months (NPRS 0.5 ± 0.8), compared with control (NPRS 2.1 ± 1.4, 1.0 ± 1.2), p = 0.019 and p = 0.011, respectively.","['shoulders after breast cancer (BC) surgery', 'single medical center from October 2018 until April 2019', 'Women scheduled for breast cancer surgery', 'pain and disabilities after breast cancer surgery', '157 women (mean age, 52.2\xa0±\xa012.9']","['early physical therapy (PT', 'early physical therapy']","['pain levels', 'Pain levels, upper limb function, ROM, and complications', 'range of motion (ROM']","[{'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517801', 'cui_str': '52.2'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}]","[{'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.025741,"Early PT reduced pain levels at the first month (NPRS 1.5 ± 1.2) and six months (NPRS 0.5 ± 0.8), compared with control (NPRS 2.1 ± 1.4, 1.0 ± 1.2), p = 0.019 and p = 0.011, respectively.","[{'ForeName': 'Ifat', 'Initials': 'I', 'LastName': 'Klein', 'Affiliation': 'Department of Physical Therapy, Assuta Medical Center, Tel Aviv, Israel; Department of Physical Therapy. Recanati School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.'}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Kalichman', 'Affiliation': 'Department of Physical Therapy. Recanati School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.'}, {'ForeName': 'Noy', 'Initials': 'N', 'LastName': 'Chen', 'Affiliation': 'Department of Physical Therapy, Assuta Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Susmallian', 'Affiliation': 'Department of Surgery, Assuta Medical Center, Tel Aviv, Israel; Faculty of Medicine, Ben Gurion University of the Negev, Beer Sheva, Israel. Electronic address: sergio9@bezeqint.net.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2021.07.013'] 1972,34345965,Viable and Heat-Killed Probiotic Strains Improve Oral Immunity by Elevating the IgA Concentration in the Oral Mucosa.,"Oral-nasal mucosal immunity plays a crucial role in protecting the body against bacterial and viral invasion. Safe probiotic products have been used to enhance human immunity and oral health. In this study, we verified the beneficial effects of mixed viable probiotic tablets, consisting of Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9, and Lactobacillus paracasei ET-66, and heat-killed probiotic tablets, consisting of L. salivarius subsp. salicinius AP-32 and L. paracasei ET-66, on oral immunity among 45 healthy participants. Participants were randomly divided into viable probiotic, heat-killed probiotic, and placebo groups. The administration of treatment lasted for 4 weeks. Saliva samples were collected at Weeks 0, 2, 4, and 6, and Lactobacillus, Bifidobacterium and Streptococcus mutans populations and IgA concentration were measured. IgA concentrations, levels of TGF-beta and IL-10 in PBMCs cells were quantified by ELISA method. Results showed that salivary IgA levels were significantly increased on administration of both the viable (119.30 ± 12.63%, ***P < 0.001) and heat-killed (116.78 ± 12.28%, ***P < 0.001) probiotics for 4 weeks. Among three probiotic strains, AP-32 would effectively increase the levels of TGF-beta and IL-10 in PBMCs. The oral pathogen Streptococcus mutans was significantly reduced on viable probiotic tablet administration (49.60 ± 31.01%, ***P < 0.001). The in vitro antibacterial test confirmed that viable probiotics effectively limited the survival rate of oral pathogens. Thus, this clinical pilot study demonstrated that oral probiotic tablets both in viable form or heat-killed form could exert beneficial effects on oral immunity via IL-10, TGB-beta mediated IgA secretion. The effective dosage of viable probiotic content in the oral tablet was 10 9 CFUs/g and the heat-killed oral tablet was 1 × 10 10 cells/g.",2021,"Among three probiotic strains, AP-32 would effectively increase the levels of TGF-beta and IL-10 in PBMCs.",['45 healthy participants'],"['salicinius AP-32 and L. paracasei ET-66', 'mixed viable probiotic tablets, consisting of Lactobacillus salivarius subsp', 'viable probiotic, heat-killed probiotic, and placebo']","['oral pathogen Streptococcus mutans', 'IgA concentrations, levels of TGF-beta and IL-10 in PBMCs cells', 'salivary IgA levels', 'levels of TGF-beta and IL-10', 'survival rate of oral pathogens']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0443348', 'cui_str': 'Viable'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0317593', 'cui_str': 'Lactobacillus salivarius'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0162388', 'cui_str': 'Killing'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0450254', 'cui_str': 'Pathogenic organism'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040690', 'cui_str': 'Platelet Transforming Growth Factor'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C1277748', 'cui_str': 'Salivary IgA measurement'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",45.0,0.0609304,"Among three probiotic strains, AP-32 would effectively increase the levels of TGF-beta and IL-10 in PBMCs.","[{'ForeName': 'Wen-Yang', 'Initials': 'WY', 'LastName': 'Lin', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan.'}, {'ForeName': 'Yi-Wei', 'Initials': 'YW', 'LastName': 'Kuo', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan.'}, {'ForeName': 'Ching-Wei', 'Initials': 'CW', 'LastName': 'Chen', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan.'}, {'ForeName': 'Yu-Fen', 'Initials': 'YF', 'LastName': 'Huang', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan.'}, {'ForeName': 'Chen-Hung', 'Initials': 'CH', 'LastName': 'Hsu', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan.'}, {'ForeName': 'Jia-Hung', 'Initials': 'JH', 'LastName': 'Lin', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan.'}, {'ForeName': 'Cheng-Ruei', 'Initials': 'CR', 'LastName': 'Liu', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan.'}, {'ForeName': 'Jui-Fen', 'Initials': 'JF', 'LastName': 'Chen', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan.'}, {'ForeName': 'Ko-Chiang', 'Initials': 'KC', 'LastName': 'Hsia', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan.'}, {'ForeName': 'Hsieh-Hsun', 'Initials': 'HH', 'LastName': 'Ho', 'Affiliation': 'Department of Research and Design, Bioflag Biotech Co., Ltd., 4F.C2, No. 17, Guoji Rd, Xinshi Dist, Tainan City, 744, Taiwan. sam.ho@bioflag.com.tw.'}]",Current microbiology,['10.1007/s00284-021-02569-8'] 1973,34344672,"New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial).","INTRODUCTION SARS-CoV-2 infection in Mexico has caused ~2.7 million confirmed cases; around 20%-25% of health workers will be infected by the virus at their workplace, with approximately 4.4% of mortality. High infectivity of SARS-CoV-2 is related with cell entry mechanism, through the ACE receptor. SARS-CoV-2 requires transmembrane protease serine 2 to cleave its spike glycoprotein and ensure fusion of host cell and virus membrane. We propose studying prophylactic treatment with hydroxychloroquine (HCQ) and bromhexine (BHH), which have been shown to be effective in preventing SARS-CoV-2 infection progression when administered in early stages. The aim of this study is to assess the efficacy of HCQ and BHH as prophylactic treatments for SARS-CoV-2 infection in healthy health workers exposed to the virus. METHODS AND ANALYSIS Double-blind randomised clinical trial, with parallel allocation at a 1:1 ratio with placebo, of low doses of HCQ plus BHH, for 60 days. Study groups will be defined as follows: (1) HCQ 200 mg/day+BHH 8 mg/8 hours versus (2) HCQ placebo plus BHH placebo. Primary endpoint will be efficacy of both interventions for the prevention of SARS-CoV-2 infection, determined by the risk ratio of infected personnel and the absolute risk. At least a 16% reduction in absolute risk is expected between the intervention and placebo groups; a minimum of 20% infection is expected in the placebo group. The sample size calculation estimated a total of 214 patients assigned: two groups of 107 participants each. ETHICS AND DISSEMINATION This protocol has been approved by the local Medical Ethics Committee (National Institute of Rehabilitation 'Luis Guillermo Ibarra Ibarra', approval number INRLGII/25/20) and by the Federal Commission for Protection against Sanitary Risks (COFEPRIS, approval number 203 300 410A0058/2020). The results of the study will be submitted for publication in peer-reviewed journals and disseminated through conferences. TRIAL REGISTRATION NUMBER NCT04340349.",2021,"INTRODUCTION SARS-CoV-2 infection in Mexico has caused ~2.7 million confirmed cases; around 20%-25% of health workers will be infected by the virus at their workplace, with approximately 4.4% of mortality.","['healthy health workers', '214 patients assigned: two groups of 107 participants each']","['hydroxychloroquine and bromhexine', 'HCQ 200 mg/day+BHH', 'placebo, of low doses of HCQ plus BHH', 'hydroxychloroquine (HCQ) and bromhexine (BHH', 'HCQ placebo plus BHH placebo', 'placebo', 'HCQ and BHH']","['absolute risk', 'efficacy of both interventions for the prevention of SARS-CoV-2 infection, determined by the risk ratio of infected personnel and the absolute risk']","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517529', 'cui_str': '107'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0006220', 'cui_str': 'Bromhexine'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}]",214.0,0.640967,"INTRODUCTION SARS-CoV-2 infection in Mexico has caused ~2.7 million confirmed cases; around 20%-25% of health workers will be infected by the virus at their workplace, with approximately 4.4% of mortality.","[{'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Granados-Montiel', 'Affiliation': 'Tissue Engineering and Regenerative Medicine Unit, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico juliogram@gmail.com.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Hazan-Lasri', 'Affiliation': 'Division of Traumatology, Emergencies and Bone Infections, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Franco-Cendejas', 'Affiliation': 'Department of Infectology Laboratory, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Chávez-Heres', 'Affiliation': 'Unit of Hospital Epidemiology Surveillance, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Phaedra', 'Initials': 'P', 'LastName': 'Silva-Bermudez', 'Affiliation': 'Tissue Engineering and Regenerative Medicine Unit, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Rocio', 'Initials': 'R', 'LastName': 'Aguilar-Gaytán', 'Affiliation': 'Tissue Engineering and Regenerative Medicine Unit, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Manzano-León', 'Affiliation': 'Basic Division Research, Instituto Nacional de Cancerologia, Mexico City, Mexico.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Méndez-Maldonado', 'Affiliation': 'Tissue Engineering and Regenerative Medicine Unit, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Alvarez-Arce', 'Affiliation': 'Tissue Engineering and Regenerative Medicine Unit, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Raigam Jafet', 'Initials': 'RJ', 'LastName': 'Martínez-Portilla', 'Affiliation': 'Clinical Research Division, National Institute of Perinatology, Mexico City, Mexico.'}]",BMJ open,['10.1136/bmjopen-2020-045190'] 1974,34344139,Considerations for crossover design in clinical study.,"This article introduces a crossover design that is often used in clinical studies, with the advantage of comparing treatment effects within one study subject. In particular, the advantages and disadvantages of the two-period, two-sequence crossover design (2 × 2 or AB/BA crossover design), which is widely used in clinical practice, are identified, and the elements necessary for analysis are introduced. This article explains the carryover effect, period effect, sequence effect, and period-by-treatment interaction in a crossover design and examines the analysis commands of SAS along with example data. After confirming the carryover effect using a general linear model, the treatment effect is analyzed using a linear mixed effect model.",2021,"After confirming the carryover effect using a general linear model, the treatment effect is analyzed using a linear mixed effect model.",[],[],[],[],[],[],,0.0370417,"After confirming the carryover effect using a general linear model, the treatment effect is analyzed using a linear mixed effect model.","[{'ForeName': 'Chi-Yeon', 'Initials': 'CY', 'LastName': 'Lim', 'Affiliation': 'Department of Biostatistics, Dongguk University College of Medicine, Goyang, Korea.'}, {'ForeName': 'Junyong', 'Initials': 'J', 'LastName': 'In', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.'}]",Korean journal of anesthesiology,['10.4097/kja.21165'] 1975,34347950,Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.,"BACKGROUND REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19). Whether subcutaneous REGEN-COV prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent Covid-19 in persons at high risk for infection because of household exposure to a person with SARS-CoV-2 infection is unknown. METHODS We randomly assigned, in a 1:1 ratio, participants (≥12 years of age) who were enrolled within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection to receive a total dose of 1200 mg of REGEN-COV or matching placebo administered by means of subcutaneous injection. At the time of randomization, participants were stratified according to the results of the local diagnostic assay for SARS-CoV-2 and according to age. The primary efficacy end point was the development of symptomatic SARS-CoV-2 infection through day 28 in participants who did not have SARS-COV-2 infection (as measured by reverse-transcriptase-quantitative polymerase-chain-reaction assay) or previous immunity (seronegativity). RESULTS Symptomatic SARS-CoV-2 infection developed in 11 of 753 participants in the REGEN-COV group (1.5%) and in 59 of 752 participants in the placebo group (7.8%) (relative risk reduction [1 minus the relative risk], 81.4%; P<0.001). In weeks 2 to 4, a total of 2 of 753 participants in the REGEN-COV group (0.3%) and 27 of 752 participants in the placebo group (3.6%) had symptomatic SARS-CoV-2 infection (relative risk reduction, 92.6%). REGEN-COV also prevented symptomatic and asymptomatic infections overall (relative risk reduction, 66.4%). Among symptomatic infected participants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV than with placebo (1.2 weeks and 3.2 weeks, respectively), and the duration of a high viral load (>10 4 copies per milliliter) was shorter (0.4 weeks and 1.3 weeks, respectively). No dose-limiting toxic effects of REGEN-COV were noted. CONCLUSIONS Subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household contacts of infected persons. Among the participants who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04452318.).",2021,"Among symptomatic infected participants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV than with placebo (1.2 weeks and 3.2 weeks, respectively), and the duration of a high viral load (>10 4 copies per milliliter) was shorter (0.4 weeks and 1.3 weeks, respectively).","['high-risk persons with coronavirus disease 2019 (Covid-19', 'participants (≥12 years of age) who were enrolled within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection to receive a']","['placebo', 'subcutaneous REGEN-COV', 'total dose of 1200 mg of REGEN-COV or matching placebo']","['Symptomatic SARS-CoV-2 infection', 'development of symptomatic SARS-CoV-2 infection', 'duration of symptomatic disease', 'symptomatic SARS-CoV-2 infection', 'median time to resolution of symptoms', 'duration of a high viral load', 'SARS-COV-2 infection (as measured by reverse-transcriptase-quantitative polymerase-chain-reaction assay) or previous immunity (seronegativity']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C4517548', 'cui_str': '1200'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0035379', 'cui_str': 'RNA-directed DNA polymerase'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0020964', 'cui_str': 'Immune status'}]",,0.641693,"Among symptomatic infected participants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV than with placebo (1.2 weeks and 3.2 weeks, respectively), and the duration of a high viral load (>10 4 copies per milliliter) was shorter (0.4 weeks and 1.3 weeks, respectively).","[{'ForeName': 'Meagan P', 'Initials': 'MP', 'LastName': ""O'Brien"", 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Forleo-Neto', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Bret J', 'Initials': 'BJ', 'LastName': 'Musser', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Flonza', 'Initials': 'F', 'LastName': 'Isa', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Kuo-Chen', 'Initials': 'KC', 'LastName': 'Chan', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Neena', 'Initials': 'N', 'LastName': 'Sarkar', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Katharine J', 'Initials': 'KJ', 'LastName': 'Bar', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Ruanne V', 'Initials': 'RV', 'LastName': 'Barnabas', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Dan H', 'Initials': 'DH', 'LastName': 'Barouch', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Myron S', 'Initials': 'MS', 'LastName': 'Cohen', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'Hurt', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Dale R', 'Initials': 'DR', 'LastName': 'Burwen', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Mary A', 'Initials': 'MA', 'LastName': 'Marovich', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Peijie', 'Initials': 'P', 'LastName': 'Hou', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Ingeborg', 'Initials': 'I', 'LastName': 'Heirman', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Davis', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Kenneth C', 'Initials': 'KC', 'LastName': 'Turner', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Ramesh', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Mahmood', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Andrea T', 'Initials': 'AT', 'LastName': 'Hooper', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Jennifer D', 'Initials': 'JD', 'LastName': 'Hamilton', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Yunji', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Purcell', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Baum', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Christos A', 'Initials': 'CA', 'LastName': 'Kyratsous', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Krainson', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Perez-Perez', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Rizwana', 'Initials': 'R', 'LastName': 'Mohseni', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Bari', 'Initials': 'B', 'LastName': 'Kowal', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'A Thomas', 'Initials': 'AT', 'LastName': 'DiCioccio', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Stahl', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Lipsich', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Ned', 'Initials': 'N', 'LastName': 'Braunstein', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Herman', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'George D', 'Initials': 'GD', 'LastName': 'Yancopoulos', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Weinreich', 'Affiliation': 'From Regeneron Pharmaceuticals, Tarrytown, NY (M.P.O., E.F.-N., B.J.M., F.I., K.-C.C., N. Sarkar, P.H., I.H., J.D.D., K.C.T., D.R., A.M., A.T.H., J.D.H., Y.K., L.A.P., A.B., C.A.K., B.K., A.T.D., N. Stahl, L.L., N.B., G.H., G.D.Y., D.M.W.); the Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia (K.J.B.); the Departments of Global Health and Epidemiology and the Division of Allergy and Infectious Diseases, University of Washington, and the Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center - both in Seattle (R.V.B.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (D.H.B.); the Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., C.B.H.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (D.R.B., M.A.M.); Clinical Trials of Florida (J.K.) and Medical Research of Westchester (R.P.-P.) - both in Miami; and the Catalina Research Institute, Montclair, CA (R.M.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2109682'] 1976,34360460,The Effect of Magnesium Supplementation on Endothelial Function: A Randomised Cross-Over Pilot Study.,"Evidence supports an association between low magnesium (Mg) intake and coronary heart disease and between Mg intake and endothelial function. The aim of this study was to assess the effect of one week of Mg supplementation on endothelial function, assessed by flow mediated dilatation (FMD). Nineteen healthy men and women completed this cross-over pilot study in which participants were randomised to take an over-the-counter magnesium supplement for one week or to follow their usual diet. Weight, FMD and blood pressure (BP) were taken on completion of each intervention and 24 h urine collections and blood samples were taken to assess compliance. Baseline serum Mg was within normal range for all participants. Urinary Mg and urinary magnesium-creatinine ratio (Mg/Cr) significantly increased between interventions, ( p = 0.03, p = 0.005, respectively). No significant differences in FMD or BP were found between the interventions. A significant negative correlation was seen between age and FMD (r = -0.496, p = 0.031). When adjusted for age, saturated fat was negatively associated with FMD ( p = 0.045). One week of Mg supplementation did not improve FMD in a healthy population.",2021,"Urinary Mg and urinary magnesium-creatinine ratio (Mg/Cr) significantly increased between interventions, ( p = 0.03, p = 0.005, respectively).",['Nineteen healthy men and women completed this cross-over pilot study in which participants'],"['Mg supplementation', 'Magnesium Supplementation']","['Endothelial Function', 'Weight, FMD and blood pressure (BP', 'endothelial function, assessed by flow mediated dilatation (FMD', 'FMD or BP', 'Urinary Mg and urinary magnesium-creatinine ratio (Mg/Cr', 'FMD']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}]","[{'cui': 'C1096534', 'cui_str': 'Magnesium supplement therapy'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",19.0,0.0452381,"Urinary Mg and urinary magnesium-creatinine ratio (Mg/Cr) significantly increased between interventions, ( p = 0.03, p = 0.005, respectively).","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Byrne', 'Affiliation': 'Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.'}, {'ForeName': 'Caitríona', 'Initials': 'C', 'LastName': 'Murphy', 'Affiliation': 'Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.'}, {'ForeName': 'Jennifer B', 'Initials': 'JB', 'LastName': 'Keogh', 'Affiliation': 'Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Clifton', 'Affiliation': 'Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.'}]",International journal of environmental research and public health,['10.3390/ijerph18158169'] 1977,34360425,Effects of Acute Beta-Alanine Ingestion and Immersion-Plus-Exercise on Connectedness to Nature and Perceived Pain.,"This double-blinded, placebo-controlled, crossover study examined the effect of induced painful sensation (via acute Beta Alanine (B-ALA) ingestion) on Love and Care of Nature (LCN), heart rate (HR), rating of perceived exertion (RPE), and McGill Pain Questionnaire (MPQ) during outdoor exercise. Twenty participants volunteered on consecutive days to complete a 0.8 km (0.5 mi) up-hill hike after consuming either B-ALA (6.4 g) or placebo. Immediately after consumption participants answered LCN, RPE, and MPQ questionnaires, immersed in a natural environment for 45 min, and then completed a hike as quickly as possible without running. No difference in HR ( p = 0.846), or RPE ( p = 0.606) were observed between treatments. Total MPQ scores increased with consumption of B-ALA ( p = 0.001). An increased LCN score was observed following exercise regardless of condition ( p = 0.035). The results demonstrate that acute B-ALA supplementation is effective in increasing perceived pain sensations. The results also demonstrate an increase in LCN in the presence of increased perceptions of pain sensations during exercise.",2021,"No difference in HR ( p = 0.846), or RPE ( p = 0.606) were observed between treatments.",['Twenty participants volunteered on consecutive days to complete a 0.8 km (0.5 mi) up-hill hike after consuming either B-ALA (6.4 g) or'],"['Acute Beta-Alanine Ingestion and Immersion-Plus-Exercise', 'placebo', 'induced painful sensation (via acute Beta Alanine (B-ALA) ingestion']","['Total MPQ scores', 'LCN', 'HR', 'pain sensations', 'Love and Care of Nature (LCN), heart rate (HR), rating of perceived exertion (RPE), and McGill Pain Questionnaire (MPQ', 'Connectedness to Nature and Perceived Pain', 'LCN score']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0442532', 'cui_str': 'Hill'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}, {'cui': 'C4517822', 'cui_str': '6.4'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0000392', 'cui_str': 'beta-Alanine'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0020940', 'cui_str': 'Immersion'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4305047', 'cui_str': 'McGill Pain Questionnaire score'}, {'cui': 'C0024028', 'cui_str': 'Love'}, {'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0024985', 'cui_str': 'McGill pain chart questionnaire'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0811812,"No difference in HR ( p = 0.846), or RPE ( p = 0.606) were observed between treatments.","[{'ForeName': 'R W', 'Initials': 'RW', 'LastName': 'Salatto', 'Affiliation': 'Department of Kinesiology and Nutrition Science, University of Nevada, Las Vegas, NV 89154, USA.'}, {'ForeName': 'Graham R', 'Initials': 'GR', 'LastName': 'McGinnis', 'Affiliation': 'Department of Kinesiology and Nutrition Science, University of Nevada, Las Vegas, NV 89154, USA.'}, {'ForeName': 'Dustin W', 'Initials': 'DW', 'LastName': 'Davis', 'Affiliation': 'Department of Kinesiology and Nutrition Science, University of Nevada, Las Vegas, NV 89154, USA.'}, {'ForeName': 'Bryson', 'Initials': 'B', 'LastName': 'Carrier', 'Affiliation': 'Department of Kinesiology and Nutrition Science, University of Nevada, Las Vegas, NV 89154, USA.'}, {'ForeName': 'Jacob W', 'Initials': 'JW', 'LastName': 'Manning', 'Affiliation': 'Department of Kinesiology and Outdoor Recreation, Southern Utah University, Cedar City, UT 84720, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'DeBeliso', 'Affiliation': 'Department of Kinesiology and Outdoor Recreation, Southern Utah University, Cedar City, UT 84720, USA.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Navalta', 'Affiliation': 'Department of Kinesiology and Nutrition Science, University of Nevada, Las Vegas, NV 89154, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph18158134'] 1978,34360360,Comparative Efficacy of Active Group Music Intervention versus Group Music Listening in Alzheimer's Disease.,"BACKGROUND Music interventions are promising therapies for the management of symptoms in Alzheimer's disease (AD). Globally, music interventions can be classified as active or receptive depending on the participation of the subjects. Active and receptive music tasks engage different brain areas that might result in distinctive clinical effects. This study aims to compare the clinical effects of two types of music interventions and a control activity. METHODS Ninety AD patients from six nursing homes participated in the study. Nursing homes were randomly and blindly assigned to receive either active music intervention, receptive music intervention, or the usual care. Effects on cognition, behaviour, daily living activities, and motor function were assessed. RESULTS Active music intervention improved cognition, behaviour, and functional state in a higher extent than both receptive music intervention and usual care. The effect size of active music intervention for cognitive deficits and behavioural symptoms was large (η 2 = 0.62 and 0.61, respectively), while for functional state, it was small-to-medium sized (η 2 = 0.18). Receptive music intervention had a stabilizing effect on behavioural symptoms compared to control intervention (mean change from baseline ± standard deviation = -0.76 ± 3.66 and 3.35 ± 3.29, respectively). In the active music intervention, the percentage of patients who showed improvement in cognitive deficits (85.7), behavioural symptoms (92.9), and functional state (46.4) was higher than in both receptive listening (11.8, 42.9, and 14.3, respectively) and control group (6.3, 12.2, and 17.1, respectively). CONCLUSIONS Active music intervention is useful to improve symptoms of AD and should be prescribed as a complement to the usual treatment.",2021,"In the active music intervention, the percentage of patients who showed improvement in cognitive deficits (85.7), behavioural symptoms (92.9), and functional state (46.4) was higher than in both receptive listening (11.8, 42.9, and 14.3, respectively) and control group (6.3, 12.2, and 17.1, respectively). ","['Ninety AD patients from six nursing homes participated in the study', 'Nursing homes', ""Alzheimer's Disease"", ""Alzheimer's disease (AD""]","['Active Group Music Intervention', 'music interventions', 'Receptive music intervention', 'Active music intervention', 'active music intervention', 'active music intervention, receptive music intervention, or the usual care']","['cognitive deficits and behavioural symptoms', 'behavioural symptoms', 'functional state', 'cognition, behaviour, and functional state', 'cognition, behaviour, daily living activities, and motor function', 'cognitive deficits']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009241', 'cui_str': 'Cognitive disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}]",90.0,0.0403592,"In the active music intervention, the percentage of patients who showed improvement in cognitive deficits (85.7), behavioural symptoms (92.9), and functional state (46.4) was higher than in both receptive listening (11.8, 42.9, and 14.3, respectively) and control group (6.3, 12.2, and 17.1, respectively). ","[{'ForeName': 'María', 'Initials': 'M', 'LastName': 'Gómez-Gallego', 'Affiliation': 'Clinical Neuroscience Research Group, Faculty of Health Sciences, Catholic University of Saint Anthony, 30100 Murcia, Spain.'}, {'ForeName': 'Juan Cándido', 'Initials': 'JC', 'LastName': 'Gómez-Gallego', 'Affiliation': 'Applied Economics Department, Faculty of Economics, University of Murcia, 30100 Murcia, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Gallego-Mellado', 'Affiliation': 'Espinardo Primary Health Care Centre, 30100 Murcia, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'García-García', 'Affiliation': 'Clinical Neuroscience Research Group, Faculty of Economics, Catholic University of Murcia, 30107 Murcia, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18158067'] 1979,34360315,Adolescents' Empowerment for Mental Health Literacy in School: A Pilot Study on ProLiSMental Psychoeducational Intervention.,"Adolescence is a critical life phase for mental health and anxiety an emerging challenge for adolescents. Psychoeducational interventions to promote mental health literacy (MHL) on anxiety in adolescents are needed. This study aimed to test the primary outcome of a future full-scale trial: improvement of adolescents' anxiety MHL components on recognition, prevention strategies, and self-help strategies. A sample of 38 adolescents, 24 (63.2%) females and 14 (36.8%) males, with an average age of 14.50 years (SD = 0.89) participated in this study. Each class was allocated to the intervention group (IG, n = 21) or the waiting list control group (WLCG, n = 17) with single-blinded randomization. MHL was assessed using the QuALiSMental. The ProLiSMental psychoeducational intervention consists of four or eight weekly sessions of 90 or 45 min for adolescents, using different active pedagogical methods and techniques. There also are initial and final sessions with adolescents, legal guardians, and teachers. There was a significant improvement with a small to relatively strong effect size in many dimensions of anxiety MHL components. This study suggests the progression to the full-scale trial and values the important role of mental health and psychiatric nurses in the adolescents' empowerment for MHL in schools.",2021,There was a significant improvement with a small to relatively strong effect size in many dimensions of anxiety MHL components.,"[""Adolescents' Empowerment for Mental Health Literacy in School"", ""mental health and psychiatric nurses in the adolescents' empowerment for MHL in schools"", 'adolescents', 'A sample of 38 adolescents, 24 (63.2%) females and 14 (36.8%) males, with an average age of 14.50 years (SD = 0.89) participated in this study']","['Psychoeducational interventions to promote mental health literacy (MHL', 'ProLiSMental Psychoeducational Intervention', 'intervention group (IG, n = 21) or the waiting list control group (WLCG, n = 17) with single-blinded randomization']",['MHL'],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0033870', 'cui_str': 'Nursing, Psychiatric'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}]",,0.0415674,There was a significant improvement with a small to relatively strong effect size in many dimensions of anxiety MHL components.,"[{'ForeName': 'Tânia', 'Initials': 'T', 'LastName': 'Morgado', 'Affiliation': 'Centro Hospitalar e Universitário de Coimbra-Hospital Pediátrico, Av. Afonso Romão, 3000-062 Coimbra, Portugal.'}, {'ForeName': 'Luís', 'Initials': 'L', 'LastName': 'Loureiro', 'Affiliation': 'Health Sciences Research Unit: Nursing, Escola Superior de Enfermagem de Coimbra, Av. Bissaya Barreto, 3004-011 Coimbra, Portugal.'}, {'ForeName': 'Maria Antónia', 'Initials': 'MA', 'LastName': 'Rebelo Botelho', 'Affiliation': 'Escola Superior de Enfermagem de Lisboa, Av. Dom João II, Lote 4.69.01, 1990-096 Lisboa, Portugal.'}, {'ForeName': 'Maria Isabel', 'Initials': 'MI', 'LastName': 'Marques', 'Affiliation': 'Health Sciences Research Unit: Nursing, Escola Superior de Enfermagem de Coimbra, Av. Bissaya Barreto, 3004-011 Coimbra, Portugal.'}, {'ForeName': 'José Ramón', 'Initials': 'JR', 'LastName': 'Martínez-Riera', 'Affiliation': 'Departamento Enfermeria Comunitaria, Medicina Preventiva y Salud Publica e Historia de la Ciencia, Universidad de Alicante, E-03080 Alicante, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Melo', 'Affiliation': 'Centre for Interdisiplinary Research in Health, Universidade Católica Portuguesa, 4169-005 Porto, Portugal.'}]",International journal of environmental research and public health,['10.3390/ijerph18158022'] 1980,34360187,Impact of the MooN Physical Education Program on the Socio-Emotional Competencies of Preadolescents.,"Few studies have analyzed emotional educational experiences through physical education interventions. The objective of this study was to evaluate the effects on socio-emotional competencies of a physical education intervention (i.e., the MooN program) based on the instructional model known as the sports education model (SEM), compared to a physical education intervention based on the traditional model of direct instruction (TM-DI) in preadolescents. The sample consisted of 170 students between 10 and 13 years old (mean age: M = 10.76; standard deviation: SD = 0.73). Participants were randomly assigned to the experimental group (SEM; n = 87) and the active control group (TM-DI; n = 83). In the experimental group, the SEM-based intervention was applied, while in the active control group, an intervention based on the TM-DI was developed. A quasi-experimental design with repeated pre-test and post-test measures and an active control group was used. The self-efficacy inventory for multiple intelligences (IAMI-40) was used to assess the children's socio-emotional competencies. The child perfectionism inventory was applied to evaluate the self-demand perfectionist efforts. The results confirmed that the MooN program (SEM intervention) promoted significant improvements in socio-emotional competencies. These findings support the potential of this physical education instructional model as an emotional education pathway for the socio-emotional improvement of preadolescent students.",2021,The self-efficacy inventory for multiple intelligences (IAMI-40) was used to assess the children's socio-emotional competencies.,"['Socio-Emotional Competencies of Preadolescents', 'preadolescent students', '170 students between 10 and 13 years old (mean age: M = 10.76; standard deviation: SD = 0.73']","['physical education intervention', 'MooN Physical Education Program', 'physical education intervention based on the traditional model of direct instruction (TM-DI']",['socio-emotional competencies'],"[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C1444711', 'cui_str': 'Pre-teen'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]","[{'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0079853', 'cui_str': 'Moon'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0086035', 'cui_str': 'Competence'}]",170.0,0.0141112,The self-efficacy inventory for multiple intelligences (IAMI-40) was used to assess the children's socio-emotional competencies.,"[{'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Luna', 'Affiliation': 'Department of Psychology, Faculty of Education, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Cejudo', 'Affiliation': 'Department of Psychology, Faculty of Education, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'Piqueras', 'Affiliation': 'Department of Health Psychology, Center for Applied Psychology, Faculty of Social and Health Sciences, Campus of Elche, Miguel Hernandez University of Elche (UMH), 03202 Elche, Spain.'}, {'ForeName': 'Débora', 'Initials': 'D', 'LastName': 'Rodrigo-Ruiz', 'Affiliation': 'Faculty of Education, International University of La Rioja (UNIR), 26006 Logroño, Spain.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Bajo', 'Affiliation': 'Department of Psychology, School of Medicine, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'ForeName': 'Juan-Carlos', 'Initials': 'JC', 'LastName': 'Pérez-González', 'Affiliation': 'Emotional Education Laboratory (EDUEMO Lab), National University of Distance Education (UNED), 28040 Madrid, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18157896'] 1981,34360184,Rating of Perceived Exertion as a Method to Determine Training Loads in Strength Training in Elderly Women: A Randomized Controlled Study.,"Objective : The aim of this study was to compare the effects of training using loads from a repetition maximum value (%1RM) and rating of perceived exertion (RPE) in elderly women. Methods : Twenty-five elderly women (60-75 years old) were randomly assigned to a group that trained using loads determined by 1RM test (G%; n = 12) or to a group that trained using loads determined by RPE (GPE; n = 13). Elderly women trained for 12 weeks using five exercises performed with 2-3 sets of 8-15 repetitions. Loads progressed from 45% to 75% of 1RM (G%) and from 13 to 18 from Rating Perceived Exertion of Borg Scale (GPE). The outcome measures, 1RM and maximum repetitions (RMs with 70% 1RM), were assessed before, between and after training programs. Results : Increased 1RM value and RMs were observed in both groups (20-42%, p < 0.001 and 56-76%, p < 0.001, respectively, for %G; and 17-56%, p < 0.001 and 47-106%, p < 0.001, respectively, for GPE), without differences between them. Conclusions : Prescribing loads using the RPE and 1RM might be similarly effective for training elderly women in order to promote strength gains. As a practical application, RPE could be an additional method to determine training loads. In spite of the promising results of the present study, it is not possible to state that the use of RPE is effective in monitoring loads during sub maximal strength training in elderly and more research must be carried out to confirm it.",2021,"Increased 1RM value and RMs were observed in both groups (20-42%, ","['elderly women', 'Elderly Women', 'Twenty-five elderly women (60-75 years old']","['RPE', 'training using loads from a repetition maximum value (%1RM) and rating of perceived exertion (RPE', 'trained using loads determined by 1RM test (G%; n = 12) or to a group that trained using loads determined by RPE (GPE']","['Rating Perceived Exertion of Borg Scale (GPE', '1RM and maximum repetitions (RMs with 70% 1RM', 'Increased 1RM value and RMs']","[{'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0449399', 'cui_str': 'Borg scale'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",25.0,0.00938235,"Increased 1RM value and RMs were observed in both groups (20-42%, ","[{'ForeName': 'Carlos Leandro', 'Initials': 'CL', 'LastName': 'Tiggemann', 'Affiliation': 'School of Physical Education, Centro Universitário da Serra Gaúcha, Caxias do Sul 95.020-472, Brazil.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Pietta-Dias', 'Affiliation': 'Exercise Research Laboratory, School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre 90.690-200, Brazil.'}, {'ForeName': 'Maira Cristina Wolf', 'Initials': 'MCW', 'LastName': 'Schoenell', 'Affiliation': 'Exercise Research Laboratory, School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre 90.690-200, Brazil.'}, {'ForeName': 'Matias', 'Initials': 'M', 'LastName': 'Noll', 'Affiliation': 'Goiano Federal Institute of Education, Science and Technology, Ceres 76.300-000, Brazil.'}, {'ForeName': 'Cristine Lima', 'Initials': 'CL', 'LastName': 'Alberton', 'Affiliation': 'Department of Sports, School of Physical Education, Federal University of Pelotas, Pelotas 96.055-630, Brazil.'}, {'ForeName': 'Ronei Silveira', 'Initials': 'RS', 'LastName': 'Pinto', 'Affiliation': 'Exercise Research Laboratory, School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre 90.690-200, Brazil.'}, {'ForeName': 'Luiz Fernando Martins', 'Initials': 'LFM', 'LastName': 'Kruel', 'Affiliation': 'Exercise Research Laboratory, School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre 90.690-200, Brazil.'}]",International journal of environmental research and public health,['10.3390/ijerph18157892'] 1982,34360178,Pace Controlled by a Steady-State Physiological Variable Is Associated with Better Performance in a 3000 M Run.,"This paper aims to test the hypothesis whereby freely chosen running pace is less effective than pace controlled by a steady-state physiological variable. Methods Eight runners performed four maximum-effort 3000 m time trials on a running track. The first time trial (TT1) was freely paced. In the following 3000 m time trials, the pace was controlled so that the average speed (TT2), average V˙O 2 (TT3) or average HR (TT4) recorded in TT1 was maintained throughout the time trial. Results: Physiologically controlled pace was associated with a faster time (mean ± standard deviation: 740 ± 34 s for TT3 and 748 ± 33 s for TT4, vs. 854 ± 53 s for TT1; p < 0.01), a lower oxygen cost of running (200 ± 5 and 220 ± 3 vs. 310 ± 5 mLO 2 ·kg -1 ·km -1 , respectively; p < 0.02), a lower cardiac cost (0.69 ± 0.08 and 0.69 ± 0.04 vs. 0.86 ± 0.09 beat·m -1 , respectively; p < 0.01), and a more positively skewed speed distribution (skewness: 1.7 ± 0.9 and 1.3 ± 0.6 vs. 0.2 ± 0.4, p < 0.05). Conclusion: Physiologically controlled pace (at the average V˙O 2 or HR recorded in a freely paced run) was associated with a faster time, a more favorable speed distribution and lower levels of physiological strain, relative to freely chosen pace. This finding suggests that non-elite runners do not spontaneously choose the best pace strategy.",2021,"Physiologically controlled pace was associated with a faster time (mean ± standard deviation: 740 ± 34 s for TT3 and 748 ± 33 s for TT4, vs. 854 ± 53 s for TT1; p < 0.01), a lower oxygen cost of running (200 ± 5 and 220 ± 3 vs. 310 ± 5 mLO 2 ·kg -1 ·km -1 , respectively; p < 0.02), a lower cardiac cost (0.69 ± 0.08 and 0.69 ± 0.04 vs. 0.86 ± 0.09 beat·m -1 , respectively; ",[],[],"['average speed (TT2), average V˙O 2 (TT3) or average HR (TT4', 'lower oxygen cost of running', 'lower cardiac cost']",[],[],"[{'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}]",8.0,0.118624,"Physiologically controlled pace was associated with a faster time (mean ± standard deviation: 740 ± 34 s for TT3 and 748 ± 33 s for TT4, vs. 854 ± 53 s for TT1; p < 0.01), a lower oxygen cost of running (200 ± 5 and 220 ± 3 vs. 310 ± 5 mLO 2 ·kg -1 ·km -1 , respectively; p < 0.02), a lower cardiac cost (0.69 ± 0.08 and 0.69 ± 0.04 vs. 0.86 ± 0.09 beat·m -1 , respectively; ","[{'ForeName': 'Claire A', 'Initials': 'CA', 'LastName': 'Molinari', 'Affiliation': ""Unité de Biologie Intégrative des Adaptations à l'Exercice, Université Paris-Saclay, Univ Evry, 91000 Evry-Courcouronnes, France.""}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Bresson', 'Affiliation': 'BillaTraining SAS, 32 Rue Paul Vaillant-Couturier, 94140 Alforville, France.'}, {'ForeName': 'Florent', 'Initials': 'F', 'LastName': 'Palacin', 'Affiliation': 'BillaTraining SAS, 32 Rue Paul Vaillant-Couturier, 94140 Alforville, France.'}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Billat', 'Affiliation': ""Unité de Biologie Intégrative des Adaptations à l'Exercice, Université Paris-Saclay, Univ Evry, 91000 Evry-Courcouronnes, France.""}]",International journal of environmental research and public health,['10.3390/ijerph18157886'] 1983,34360168,Effects of a Midwife-Coordinated Maternity Care Intervention (ChroPreg) vs. Standard Care in Pregnant Women with Chronic Medical Conditions: Results from a Randomized Controlled Trial.,"The proportion of childbearing women with pre-existing chronic medical conditions (CMC) is rising. In a randomized controlled trial, we aimed to evaluate the effects of a midwife-coordinated maternity care intervention (ChroPreg) in pregnant women with CMC. The intervention consisted of three main components: (1) Midwife-coordinated and individualized care, (2) Additional ante-and postpartum consultations, and (3) Specialized known midwives. The primary outcome was the total length of hospital stay (LOS). Secondary outcomes were patient-reported outcomes measuring psychological well-being and satisfaction with maternity care, health utilization, and maternal and infant outcomes. A total of 362 women were randomized to the ChroPreg intervention ( n = 131) or Standard Care ( n = 131). No differences in LOS were found between groups (median 3.0 days, ChroPreg group 0.1% lower LOS, 95% CI -7.8 to 7%, p = 0.97). Women in the ChroPreg group reported being more satisfied with maternity care measured by the Pregnancy and Childbirth Questionnaire (PCQ) compared with the Standard Care group (mean PCQ 104.5 vs. 98.2, mean difference 6.3, 95% CI 3.0-10.0, p < 0.0001). In conclusion, the ChroPreg intervention did not reduce LOS. However, women in the ChroPreg group were more satisfied with maternity care.",2021,"Women in the ChroPreg group reported being more satisfied with maternity care measured by the Pregnancy and Childbirth Questionnaire (PCQ) compared with the Standard Care group (mean PCQ 104.5 vs. 98.2, mean difference 6.3, 95% CI 3.0-10.0, p < 0.0001).","['childbearing women with pre-existing chronic medical conditions (CMC', 'pregnant women with CMC', 'A total of 362 women', 'Pregnant Women with Chronic Medical Conditions']","['Midwife-Coordinated Maternity Care Intervention (ChroPreg) vs. Standard Care', 'ChroPreg intervention', 'midwife-coordinated maternity care intervention (ChroPreg', 'Standard Care', 'Midwife-coordinated and individualized care, (2) Additional ante-and postpartum consultations, and (3) Specialized known midwives']","['total length of hospital stay (LOS', 'LOS', 'satisfied with maternity care', 'patient-reported outcomes measuring psychological well-being and satisfaction with maternity care, health utilization, and maternal and infant outcomes', 'Pregnancy and Childbirth Questionnaire (PCQ']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0026083', 'cui_str': 'Professional midwife'}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0740175', 'cui_str': 'Before values'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0205555', 'cui_str': 'Special'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",362.0,0.290772,"Women in the ChroPreg group reported being more satisfied with maternity care measured by the Pregnancy and Childbirth Questionnaire (PCQ) compared with the Standard Care group (mean PCQ 104.5 vs. 98.2, mean difference 6.3, 95% CI 3.0-10.0, p < 0.0001).","[{'ForeName': 'Mie G', 'Initials': 'MG', 'LastName': 'de Wolff', 'Affiliation': 'Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Midtgaard', 'Affiliation': 'Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Johansen', 'Affiliation': 'Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Ane L', 'Initials': 'AL', 'LastName': 'Rom', 'Affiliation': 'Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Rosthøj', 'Affiliation': 'Section of Biostatistics, Department of Public Health, University of Copenhagen, 1014 Copenhagen, Denmark.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Tabor', 'Affiliation': 'Center of Fetal Medicine and Pregnancy, Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Hanne K', 'Initials': 'HK', 'LastName': 'Hegaard', 'Affiliation': 'Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.'}]",International journal of environmental research and public health,['10.3390/ijerph18157875'] 1984,34360103,The Effects of Core Stabilization Exercise with the Abdominal Drawing-in Maneuver Technique versus General Strengthening Exercise on Lumbar Segmental Motion in Patients with Clinical Lumbar Instability: A Randomized Controlled Trial with 12-Month Follow-Up.,"Trunk stability exercises that focus on either deep or superficial muscles might produce different effects on lumbar segmental motion. This study compared outcomes in 34 lumbar instability patients in two exercises at 10 weeks and 12 months follow up. Participants were divided into either Core stabilization (deep) exercise, incorporating abdominal drawing-in maneuver technique (CSE with ADIM), or General strengthening (superficial) exercise (STE). Outcome measures were pain, muscle activation, and lumbar segmental motion. Participants in CSE with ADIM had significantly less pain than those in STE at 10 weeks. They showed significantly more improvement of abdominal muscle activity ratio than participants in STE at 10 weeks and 12 months follow-up. Participants in CSE with ADIM had significantly reduced sagittal translation at L4-L5 and L5-S1 compared with STE at 10 weeks. Participants in CSE with ADIM had significantly reduced sagittal translations at L4-L5 and L5-S1 compared with participants in STE at 10 weeks, whereas STE demonstrated significantly increased sagittal rotation at L4-L5. However, at 12 months follow-up, levels of lumbar sagittal translation were increased in both groups. CSE with ADIM which focuses on increasing deep trunk muscle activity can reduce lumbar segmental translation and should be recommended for lumbar instability.",2021,They showed significantly more improvement of abdominal muscle activity ratio than participants in STE at 10 weeks and 12 months follow-up.,"['34 lumbar instability patients in two exercises at 10 weeks and 12 months follow up', 'Patients with Clinical Lumbar Instability']","['Trunk stability exercises', 'Core Stabilization Exercise with the Abdominal Drawing-in Maneuver Technique versus General Strengthening Exercise', 'Core stabilization (deep) exercise, incorporating abdominal drawing-in maneuver technique (CSE with ADIM), or General strengthening (superficial) exercise (STE']","['sagittal rotation', 'Lumbar Segmental Motion', 'pain, muscle activation, and lumbar segmental motion', 'lumbar segmental motion', 'abdominal muscle activity ratio', 'pain', 'sagittal translations', 'levels of lumbar sagittal translation', 'sagittal translation']","[{'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0591126', 'cui_str': 'AT-10'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]","[{'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}]","[{'cui': 'C0205129', 'cui_str': 'Sagittal'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0205122', 'cui_str': 'Segmental'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0000739', 'cui_str': 'Skeletal muscle structure of abdomen'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0040712', 'cui_str': 'Translations'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",34.0,0.0811502,They showed significantly more improvement of abdominal muscle activity ratio than participants in STE at 10 weeks and 12 months follow-up.,"[{'ForeName': 'Rungthip', 'Initials': 'R', 'LastName': 'Puntumetakul', 'Affiliation': 'Research Center of Back, Neck, Other Joint Pain and Human Performance (BNOJPH), Khon Kaen University, Khon Kaen 40002, Thailand.'}, {'ForeName': 'Pongsatorn', 'Initials': 'P', 'LastName': 'Saiklang', 'Affiliation': 'Faculty of Physical Therapy, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.'}, {'ForeName': 'Weerasak', 'Initials': 'W', 'LastName': 'Tapanya', 'Affiliation': 'Department of Physical Therapy, School of Allied Health Sciences, University of Phayao, Phayao 56000, Thailand.'}, {'ForeName': 'Thiwaphon', 'Initials': 'T', 'LastName': 'Chatprem', 'Affiliation': 'Research Center of Back, Neck, Other Joint Pain and Human Performance (BNOJPH), Khon Kaen University, Khon Kaen 40002, Thailand.'}, {'ForeName': 'Jaturat', 'Initials': 'J', 'LastName': 'Kanpittaya', 'Affiliation': 'Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.'}, {'ForeName': 'Preeda', 'Initials': 'P', 'LastName': 'Arayawichanon', 'Affiliation': 'Department of Rehabilitation Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Boucaut', 'Affiliation': 'iCAHE (International Centre for Allied Health Evidence), School of Health Sciences (Physiotherapy), University of South Australia, Adelaide, SA 5001, Australia.'}]",International journal of environmental research and public health,['10.3390/ijerph18157811'] 1985,34360095,Effectiveness of Simulation-Based Empathy Enhancement Program for Caregivers (SEE-C) Evaluated by Older Adults Receiving Care.,"The aim of this study was to examine whether a Simulation-based Empathy Enhancement program for Caregivers of the Elderly (SEE-C) was effective in increasing program satisfaction and positive emotional changes of older adults. A total of 100 older adults living alone were randomly assigned to experimental and control groups. The experimental group was interviewed by caregivers who experienced SEE-C while the control group was interviewed by caregivers who did not experience SEE-C. In both elderly groups, post session satisfaction and affective state were assessed using a Session Evaluation Questionnaire (SEQ). Chi-square test and Mann-Whitney U test were conducted. The experimental group ( n = 49) reported significantly higher scores than the control group ( n = 51) for all three categories of SEQ: session-depth (Mann-Whitney U = 1651.5, p = 0.005), session-smoothness (Mann-Whitney U = 1803.0, p = 0.000), and emotion-positivity (Mann-Whitney U = 1783.0, p = 0.000). However, the experimental group had significantly lower scores for the arousal category of SEQ (Mann-Whitney U = 873.5, p = 0.009). SEE-C could have a positive impact on interviews for elderly care in terms of raising the satisfaction of the interviewee.",2021,"The experimental group ( n = 49) reported significantly higher scores than the control group ( n = 51) for all three categories of SEQ: session-depth (Mann-Whitney U = 1651.5, p = 0.005), session-smoothness (Mann-Whitney U = 1803.0, p = 0.000), and emotion-positivity (Mann-Whitney U =","['100 older adults living alone', 'Older Adults Receiving Care', 'Caregivers of the Elderly (SEE-C', 'Caregivers (SEE-C', 'older adults']","['caregivers who did not experience SEE-C', 'Simulation-based Empathy Enhancement program', 'Simulation-Based Empathy Enhancement Program']","['Session Evaluation Questionnaire (SEQ', 'arousal category of SEQ', 'emotion-positivity']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439044', 'cui_str': 'Lives alone'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",100.0,0.0143948,"The experimental group ( n = 49) reported significantly higher scores than the control group ( n = 51) for all three categories of SEQ: session-depth (Mann-Whitney U = 1651.5, p = 0.005), session-smoothness (Mann-Whitney U = 1803.0, p = 0.000), and emotion-positivity (Mann-Whitney U =","[{'ForeName': 'Kyuwon', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Industry Academic Cooperation Foundation Office, Yonsei University, Mirae Campus, 79, Ilsanchogyo-gil, Wonju 26425, Korea.'}, {'ForeName': 'Areum', 'Initials': 'A', 'LastName': 'Han', 'Affiliation': 'Department of Occupational Therapy, University of Alabama at Birmingham, SHPB 340, 1720 2nd Ave South, Birmingham, AL 35294, USA.'}, {'ForeName': 'Tae Hui', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph18157802'] 1986,34344675,Effects of an online-based motivational intervention to reduce problematic internet use and promote treatment motivation in internet gaming disorder and internet use disorder (OMPRIS): study protocol for a randomised controlled trial.,"INTRODUCTION In May 2019, the WHO classified internet gaming disorder (IGD) as a mental disorder in the upcoming International Classification of Diseases 11th Revision. However, individuals affected by IGD or internet use disorders (IUDs) are often not provided with adequate therapy due to a lack of motivation or absence of adequate local treatment options. To close the gap between individuals with IUDs and the care system, we conduct an online-based motivational intervention to reduce problematic internet use and promote treatment motivation in internet gaming disorder and internet use disorder (OMPRIS). METHODS AND ANALYSIS Within the randomised controlled trial, a total of n=162 participants will be allocated by sequential balancing randomisation to the OMPRIS intervention or a waitlist control group. The study includes an extensive diagnostic, followed by a 4-week psychological intervention based on motivational interviewing, (internet-related) addiction therapy, behavioural therapy techniques and additional social counselling. The primary outcome is the reduction of problematic internet use measured by the Assessment of Internet and Computer Game Addiction Scale. Secondary outcomes include time spent on the internet, motivation for change (Stages of Change Readiness and Treatment Eagerness Scale for Internet Use Disorder), comorbid mental symptoms (Patient Health Questionnaire-9, Generalized Anxiety Disorder Screener-7), quality of life (EuroQoL Standardised Measure of Health-related Quality of Life-5 Dimensions, General Life Satisfaction-1), self-efficacy (General Self-Efficacy Scale), personality traits (Big Five Inventory-10), therapeutic alliance (Helping Alliance Questionnaire) and health economic costs. The diagnosis of (comorbid) mental disorders is carried out with standardised clinical interviews. The measurement will be assessed before (T0), at midpoint (T1) and after the OMPRIS intervention (T2), representing the primary endpoint. Two follow-up assessments will be conducted after 6 weeks (T3) and 6 months (T4) after the intervention. The outcomes will be analysed primarily via analysis of covariance. Both intention-to-treat and per-protocol analyses will be conducted. ETHICS AND DISSEMINATION Participants will provide written informed consent. The trial has been approved by the Ethics Committee of the Faculty of Medicine, Ruhr University Bochum (approval number 19-6779). Findings will be disseminated through presentations, peer-reviewed journals and conferences. TRIAL REGISTRATION NUMBER DRKS00019925.",2021,"Secondary outcomes include time spent on the internet, motivation for change (Stages of Change Readiness and Treatment Eagerness Scale for Internet Use Disorder), comorbid mental symptoms (Patient Health Questionnaire-9, Generalized Anxiety Disorder Screener-7), quality of life (EuroQoL Standardised Measure of Health-related Quality of Life-5 Dimensions, General Life Satisfaction-1), self-efficacy (General Self-Efficacy Scale), personality traits (Big Five Inventory-10), therapeutic alliance (Helping Alliance Questionnaire) and health economic costs.","['internet gaming disorder and internet use disorder (OMPRIS', 'n=162 participants']","['OMPRIS intervention or a waitlist control group', 'psychological intervention based on motivational interviewing, (internet-related) addiction therapy, behavioural therapy techniques and additional social counselling', 'online-based motivational intervention']","['reduction of problematic internet use measured by the Assessment of Internet and Computer Game Addiction Scale', 'time spent on the internet, motivation for change (Stages of Change Readiness and Treatment Eagerness Scale for Internet Use Disorder), comorbid mental symptoms (Patient Health Questionnaire-9, Generalized Anxiety Disorder Screener-7), quality of life (EuroQoL Standardised Measure of Health-related Quality of Life-5 Dimensions, General Life Satisfaction-1), self-efficacy (General Self-Efficacy Scale), personality traits (Big Five Inventory-10), therapeutic alliance (Helping Alliance Questionnaire) and health economic costs']","[{'cui': 'C4760905', 'cui_str': 'Internet gaming disorder'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0474156', 'cui_str': 'Social counseling'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0870328', 'cui_str': 'Computer Games'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0424090', 'cui_str': 'Level of interest'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0233849', 'cui_str': 'Character trait finding'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0814487', 'cui_str': 'Therapeutic Alliance'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013560', 'cui_str': 'Medical Economics'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",162.0,0.0629603,"Secondary outcomes include time spent on the internet, motivation for change (Stages of Change Readiness and Treatment Eagerness Scale for Internet Use Disorder), comorbid mental symptoms (Patient Health Questionnaire-9, Generalized Anxiety Disorder Screener-7), quality of life (EuroQoL Standardised Measure of Health-related Quality of Life-5 Dimensions, General Life Satisfaction-1), self-efficacy (General Self-Efficacy Scale), personality traits (Big Five Inventory-10), therapeutic alliance (Helping Alliance Questionnaire) and health economic costs.","[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Dieris-Hirche', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, LWL University Hospital, Ruhr-University Bochum, Bochum, Germany jan.dieris-hirche@rub.de.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Bottel', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, LWL University Hospital, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Pape', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, LWL University Hospital, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Bert Theodor', 'Initials': 'BT', 'LastName': 'Te Wildt', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, LWL University Hospital, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Wölfling', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Mainz, Johannes Gutenberg University Mainz, Mainz, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Henningsen', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Rechts der Isar, Technical University Munich, Munich, Germany.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Timmesfeld', 'Affiliation': 'Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Neumann', 'Affiliation': 'Institute for Medicine Management, University of Duisburg-Essen, Duisburg, Germany.'}, {'ForeName': 'Silke', 'Initials': 'S', 'LastName': 'Neusser', 'Affiliation': 'Institute for Medicine Management, University of Duisburg-Essen, Duisburg, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Beckers', 'Affiliation': 'Competence Centre of Healthcare Telematics, Bochum, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Herpertz', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, LWL University Hospital, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2020-045840'] 1987,34343854,CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma.,"Biomarkers which can identify Diffuse Large B-Cell Lymphoma (DLBCL) likely to be refractory to first-line therapy are essential for selecting this population prior to therapy initiation to offer alternate therapeutic options that can improve prognosis. We tested the ability of a CT-based radiomics approach with machine learning to predict Primary Treatment Failure (PTF)-DLBCL from initial imaging evaluation. Twenty-six refractory patients were matched to 26 non-refractory patients, yielding 180 lymph nodes for analysis. Manual 3D delineation of the total node volume was performed by two independent readers to test the reproducibility. Then, 1218 hand-crafted radiomic features were extracted. The Random Forests machine learning approach was used as a classifier for constructing the prediction models. Seventy percent of the nodes were randomly assigned to a training set and the remaining 30% were assigned to an independent test set. The final model was tested on the dataset from the 2 readers, showing a mean accuracy, sensitivity and specificity of 73%, 62% and 82%, respectively, for distinguishing between refractory and non-refractory patients. The area under the receiver operating characteristic curve (AUC) was 0.83 and 0.79 for the two readers. We conclude that machine learning CT-based radiomics analysis is able to identify a priori PTF-DLBCL with a good accuracy.",2021,The area under the receiver operating characteristic curve (AUC) was 0.83 and 0.79 for the two readers.,"['Twenty-six refractory patients were matched to 26 non-refractory patients, yielding 180 lymph nodes for analysis']","['CT-based radiomics model with machine learning', 'machine learning CT-based radiomics analysis', 'CT-based radiomics approach with machine learning']","['area under the receiver operating characteristic curve (AUC', 'mean accuracy, sensitivity and specificity']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0376284', 'cui_str': 'Machine Learning'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0036668', 'cui_str': 'Sensitivity and Specificity'}]",26.0,0.0794426,The area under the receiver operating characteristic curve (AUC) was 0.83 and 0.79 for the two readers.,"[{'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Santiago', 'Affiliation': 'Jewish General Hospital - McGill University, Canada; Segal Cancer Centre and Lady Davis Institute for Medical Research, Canada.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Ortiz Jimenez', 'Affiliation': 'Jewish General Hospital - McGill University, Canada.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Forghani', 'Affiliation': 'Segal Cancer Centre and Lady Davis Institute for Medical Research, Canada; Augmented Intelligence & Precision Health Laboratory (AIPHL) of the Department of Radiology and the Research Institute of McGill University Health Centre, Canada; Gerald Bronfman Department of Oncology, Canada; McGill University, Canada. Electronic address: reza.forghani@mcgill.ca.'}, {'ForeName': 'Nikesh', 'Initials': 'N', 'LastName': 'Muthukrishnan', 'Affiliation': 'Segal Cancer Centre and Lady Davis Institute for Medical Research, Canada; Augmented Intelligence & Precision Health Laboratory (AIPHL) of the Department of Radiology and the Research Institute of McGill University Health Centre, Canada.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Del Corpo', 'Affiliation': 'McGill University, Canada.'}, {'ForeName': 'Shairabi', 'Initials': 'S', 'LastName': 'Karthigesu', 'Affiliation': 'McGill University, Canada.'}, {'ForeName': 'Muhammad Yahya', 'Initials': 'MY', 'LastName': 'Haider', 'Affiliation': 'McGill University, Canada.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Reinhold', 'Affiliation': 'Augmented Intelligence & Precision Health Laboratory (AIPHL) of the Department of Radiology and the Research Institute of McGill University Health Centre, Canada; McGill University, Canada.'}, {'ForeName': 'Sarit', 'Initials': 'S', 'LastName': 'Assouline', 'Affiliation': 'Jewish General Hospital - McGill University, Canada; Segal Cancer Centre and Lady Davis Institute for Medical Research, Canada.'}]",Translational oncology,['10.1016/j.tranon.2021.101188'] 1988,34343773,The prediction of morbidity related to vaginal delivery in nulliparous women - A secondary analysis from the genesis multicenter trial.,"OBJECTIVE In the prospective multicenter Genesis study, we developed a prediction model for Cesarean delivery (CD) in term nulliparous women. The objective of this secondary analysis was to determine whether the Genesis model has the potential to predict maternal and neonatal morbidity associated with vaginal delivery. STUDY DESIGN The national prospective Genesis trial recruited 2,336 nulliparous women with a vertex presentation between 39 + 0- and 40 + 6-weeks' gestation from seven tertiary centers. The prediction model used five parameters to assess the risk of CD: maternal age, maternal height, body mass index, fetal head circumference and fetal abdominal circumference. Simple and multiple logistic regression analyses were used to develop the Genesis model. The risk score calculated using this model were correlated with maternal and neonatal morbidity in women who delivered vaginally: postpartum hemorrhage (PPH), obstetric anal sphincter injury (OASI), shoulder dystocia, one- and five-minute Apgar score ≤ 7, neonatal intensive care (NICU) admission, cephalohematoma, fetal laceration, nerve palsy and fractures. The morbidities associated with spontaneous vaginal delivery were compared with those associated with operative vaginal delivery (OVD). The likelihood ratios for composite morbidity and the morbidity associated with OVD based on the Genesis risk scores were also calculated. RESULTS A total of 1,845 (79%) nulliparous women had a vaginal delivery. A trend of increasing intervention and morbidity was observed with increasing Genesis risk score, including OVD (p < 0.001), PPH (p < 0.008), NICU admission (p < 0.001), low Apgar score at one-minute (p < 0.001) and OASI (p = 0.009). The morbidity associated with OVD was significantly higher compared to spontaneous vaginal delivery, including NICU admission (p < 0.001), PPH (p = 0.022), birth injury (p < 0.001), shoulder dystocia (p = 0.002) and Apgar score of<7 at one-minute (p < 0.001). The positive likelihood ratios for composite outcomes (where the OVD was excluded) increases with increasing risk score from 1.005 at risk score of 5% to 2.507 for risk score of>50%. CONCLUSION In women who ultimately achieved a vaginal birth, we have shown more maternal and neonatal morbidity in the setting of a Genesis nomogram-determined high-risk score for intrapartum CD. Therefore, the Genesis prediction tool also has the potential to predict a more morbid vaginal delivery.",2021,"The risk score calculated using this model were correlated with maternal and neonatal morbidity in women who delivered vaginally: postpartum hemorrhage (PPH), obstetric anal sphincter injury (OASI), shoulder dystocia, one- and five-minute","[""2,336 nulliparous women with a vertex presentation between 39\xa0+\xa00- and 40\xa0+\xa06-weeks' gestation from seven tertiary centers"", 'A total of 1,845 (79', 'nulliparous women', 'nulliparous women had a vaginal delivery', 'term nulliparous women']",[],"['birth injury', 'Genesis risk scores', 'shoulder dystocia', 'OASI', 'PPH', 'morbidity associated with OVD', 'NICU admission', 'Genesis risk score, including OVD', 'Apgar score', 'risk score', 'Apgar score\xa0≤\xa07, neonatal intensive care (NICU) admission, cephalohematoma, fetal laceration, nerve palsy and fractures', 'risk of CD: maternal age, maternal height, body mass index, fetal head circumference and fetal abdominal circumference', 'Cesarean delivery (CD', 'low Apgar score', 'hemorrhage (PPH), obstetric anal sphincter injury (OASI), shoulder dystocia, one- and five-minute', 'operative vaginal delivery (OVD', 'maternal and neonatal morbidity']","[{'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0233260', 'cui_str': 'Vertex presentation'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]",[],"[{'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C4255166', 'cui_str': 'Genesis'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0269825', 'cui_str': 'Shoulder girdle dystocia'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0003533', 'cui_str': 'Finding of Apgar score'}, {'cui': 'C0021711', 'cui_str': 'Neonatal Intensive Care'}, {'cui': 'C0007722', 'cui_str': 'Cephalhematoma due to birth trauma'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0043246', 'cui_str': 'Laceration'}, {'cui': 'C0262576', 'cui_str': 'Nerve palsy'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0024915', 'cui_str': 'Maternal age'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0231117', 'cui_str': 'Fetal head structure'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C1300813', 'cui_str': 'Abdominal circumference'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C1142258', 'cui_str': 'Anal sphincter injury'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}]",2336.0,0.0965892,"The risk score calculated using this model were correlated with maternal and neonatal morbidity in women who delivered vaginally: postpartum hemorrhage (PPH), obstetric anal sphincter injury (OASI), shoulder dystocia, one- and five-minute","[{'ForeName': 'Khadijah I', 'Initials': 'KI', 'LastName': 'Ismail', 'Affiliation': 'Department of Obstetrics and Gynecology, Graduate Entry Medical School, University of Limerick, Limerick, Ireland. Electronic address: eirfah@yahoo.com.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Burke', 'Affiliation': 'Royal College of Surgeons in Ireland, Rotunda Hospital, Dublin, Ireland.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Burke', 'Affiliation': 'Department of Obstetrics and Gynecology, Graduate Entry Medical School, University of Limerick, Limerick, Ireland.'}, {'ForeName': 'Fionnuala', 'Initials': 'F', 'LastName': 'Breathnach', 'Affiliation': 'Royal College of Surgeons in Ireland, Rotunda Hospital, Dublin, Ireland.'}, {'ForeName': 'Fionnuala M', 'Initials': 'FM', 'LastName': 'McAuliffe', 'Affiliation': 'UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Morrison', 'Affiliation': 'National University of Ireland, Galway, Ireland.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Turner', 'Affiliation': 'UCD Center for Human Reproduction Coombe Women and Infants University Hospital, Dublin, Ireland.'}, {'ForeName': 'Samina', 'Initials': 'S', 'LastName': 'Dornan', 'Affiliation': 'Royal Jubilee Maternity Hospital, Belfast, Ireland.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Higgins', 'Affiliation': 'University College Cork, Cork University Maternity Hospital, Cork, Ireland.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Cotter', 'Affiliation': 'Department of Obstetrics and Gynecology, Graduate Entry Medical School, University of Limerick, Limerick, Ireland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Geary', 'Affiliation': 'UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'McParland', 'Affiliation': 'UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Daly', 'Affiliation': 'Coombe Women and Infants University Hospital, Dublin, Ireland.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Cody', 'Affiliation': 'Royal College of Surgeons in Ireland, Rotunda Hospital, Dublin, Ireland.'}, {'ForeName': 'Cecelia', 'Initials': 'C', 'LastName': 'Mulcahy', 'Affiliation': 'National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Pat', 'Initials': 'P', 'LastName': 'Dicker', 'Affiliation': 'Epidemiology & Public Health, Royal College of Surgeons in Ireland, Dublin, Ireland.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Tully', 'Affiliation': 'Royal College of Surgeons in Ireland, Rotunda Hospital, Dublin, Ireland.'}, {'ForeName': 'Fergal D', 'Initials': 'FD', 'LastName': 'Malone', 'Affiliation': 'Royal College of Surgeons in Ireland, Rotunda Hospital, Dublin, Ireland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2021.07.026'] 1989,34343772,Three-dimensional versus two-dimensional laparoscopic myomectomy: A randomized controlled trial.,"OBJECTIVE This study aimed to compare the surgical outcomes of three-dimensional (3D) and two-dimensional (2D) laparoscopic myomectomy. STUDY DESIGN A total of 64 patients with symptomatic uterine fibroids were randomly assigned to either the 3D (n = 32) group or the 2D group (n = 32). The primary outcomes were the operative blood loss and change in hemoglobin levels. The secondary outcome was operative time. RESULTS There were no differences in the baseline demographics between the two groups. The 3D and 2D groups were not significantly different in terms of operative blood loss (129.5 ± 86.5 mL vs. 140.9 ± 89.8 mL, P = 0.412), change in serum hemoglobin levels (1.4 ± 1.6 g/dL vs. 1.6 ± 1.6 g/dL, P = 0.553), and operative time (77.4 ± 37.8 min vs. 82.4 ± 35.4 min, P = 0.344). Furthermore, no differences were observed between the groups with regard to other surgical outcomes. CONCLUSION The 3D imaging system had no additional surgical benefit in laparoscopic myomectomy compared with to the conventional 2D imaging system.",2021,The 3D imaging system had no additional surgical benefit in laparoscopic myomectomy compared with to the conventional 2D imaging system.,['64 patients with symptomatic uterine fibroids'],"['three-dimensional (3D) and two-dimensional (2D) laparoscopic myomectomy', 'dimensional laparoscopic myomectomy', 'laparoscopic myomectomy']","['serum hemoglobin levels', 'operative time', 'operative blood loss', 'operative blood loss and change in hemoglobin levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}]","[{'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C2111517', 'cui_str': 'Laparoscopic myomectomy'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",64.0,0.42025,The 3D imaging system had no additional surgical benefit in laparoscopic myomectomy compared with to the conventional 2D imaging system.,"[{'ForeName': 'Taejong', 'Initials': 'T', 'LastName': 'Song', 'Affiliation': 'Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: taejong.song@gmail.com.'}, {'ForeName': 'Du-Young', 'Initials': 'DY', 'LastName': 'Kang', 'Affiliation': 'Department of Thoracic and Cardiovacular Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2021.07.036'] 1990,34348669,Longitudinal measurement invariance of the patient health questionnaire in a German sample.,"BACKGROUND The Patient Health Questionnaire-8 (PHQ-8) is a screening questionnaire of depressive symptoms. However, it is unknown whether it is equivalent across time and between groups of individuals. The aim of our paper was to test whether the PHQ-8 has the same meaning in two groups of individuals over time. METHODS Primary care patients were proactively recruited from three German cities. PHQ-8 data from a baseline assessment (n = 588), two assessments during the intervention (n = 246/225), and a six (n = 437) and 12 months (n = 447) follow-up assessment were first used to examine the factor structure of the PHQ-8 by confirmatory factor analysis (CFA). The best fitting factor solution was then used to test longitudinal invariance across time and between intervention and control group by Multiple Group CFA. RESULTS A two-factor structure consistently showed the best model fit. Only configural longitudinal invariance was evidenced when the baseline assessment was included in the analysis. Without the baseline assessment, strict longitudinal invariance was shown across the intervention and the follow-up assessments. Scalar invariance was established between the intervention and control group for the baseline assessment and strict invariance between groups and across the 6- and 12-month follow-up assessments. CONCLUSIONS The lack of longitudinal invariance might be attributed to various differences between the baseline assessments and all following assessments, e.g., assessment mode (iPad vs telephone), potential changes in symptom perception, and setting. TRIAL REGISTRATION DRKS0001163 5, date of trial registration: 20.01.2017; DRKS00011637 , date of trial registration: 25.01.2017.",2021,"Scalar invariance was established between the intervention and control group for the baseline assessment and strict invariance between groups and across the 6- and 12-month follow-up assessments. ","['Primary care patients were proactively recruited from three German cities', 'patient health questionnaire in a German sample']",['PHQ-8'],[],"[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}]",[],,0.105466,"Scalar invariance was established between the intervention and control group for the baseline assessment and strict invariance between groups and across the 6- and 12-month follow-up assessments. ","[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Moehring', 'Affiliation': 'Department of Social Medicine and Prevention, Institute of Community Medicine, University Medicine Greifswald, Walther-Rathenau-Str. 48, 17475, Greifswald, Germany. anne.moehring@med.uni-greifswald.de.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Guertler', 'Affiliation': 'Department of Social Medicine and Prevention, Institute of Community Medicine, University Medicine Greifswald, Walther-Rathenau-Str. 48, 17475, Greifswald, Germany.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Krause', 'Affiliation': 'Institute for Medical Psychology, University Medicine Greifswald, Walther-Rathenau-Str. 48, 17475, Greifswald, Germany.'}, {'ForeName': 'Gallus', 'Initials': 'G', 'LastName': 'Bischof', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Research Group S:TEP, University of Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany.'}, {'ForeName': 'Hans-Juergen', 'Initials': 'HJ', 'LastName': 'Rumpf', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Research Group S:TEP, University of Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany.'}, {'ForeName': 'Anil', 'Initials': 'A', 'LastName': 'Batra', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital of Tuebingen, Calwer Str. 14, 72076, Tuebingen, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Wurm', 'Affiliation': 'Department of Social Medicine and Prevention, Institute of Community Medicine, University Medicine Greifswald, Walther-Rathenau-Str. 48, 17475, Greifswald, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'John', 'Affiliation': 'Department of Social Medicine and Prevention, Institute of Community Medicine, University Medicine Greifswald, Walther-Rathenau-Str. 48, 17475, Greifswald, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Meyer', 'Affiliation': 'Department of Social Medicine and Prevention, Institute of Community Medicine, University Medicine Greifswald, Walther-Rathenau-Str. 48, 17475, Greifswald, Germany.'}]",BMC psychiatry,['10.1186/s12888-021-03390-0'] 1991,34348189,Addressing the punitive parent mode in schema therapy for borderline personality disorder: Short-term effects of the empty chair technique as compared to cognitive challenging.,"BACKGROUND AND OBJECTIVES In Schema Therapy (ST) for Borderline Personality Disorder (BPD) patients the empty chair technique (EC) is often used to diminish the 'punitive parent mode' (PP). The present study is a first attempt to assess whether EC is more effective in reducing the PP than a standard Cognitive Behavioral Therapy technique (CT). METHODS We utilized a counterbalanced, crossover design comparing one EC session to one CT session in twenty patients with a primary BPD diagnosis who had started ST. Before and after each intervention we assessed credibility, power, and valence of the PP-associated core belief and how much power patients felt over this core belief (dominance). Patients also completed a working alliance inventory. An interview was conducted to explore subjective views regarding the interventions. RESULTS Both techniques reduced power and credibility of the PP-associated core belief and increased dominance. CT reduced credibility more strongly than EC. Still, patients preferred EC as they felt it was better able to elicit feelings during the session and believed it would be more effective than CT when administered repeatedly. LIMITATIONS A complex technique was tested early in treatment and only once, effects might be different later in treatment and when applied repeatedly. Moreover, only short-term effects were assessed in a rather small sample. CONCLUSION Both EC and CT help combat the PP in BPD patients, with CT being more effective in reducing credibility after one session. However, patients preferred EC and suggest multiple sessions might be needed to truly elucidate differences between both techniques.",2021,"Both EC and CT help combat the PP in BPD patients, with CT being more effective in reducing credibility after one session.","['borderline personality disorder', 'twenty patients with a primary BPD diagnosis who had started ST']","['EC session to one CT session', 'Schema Therapy (ST', 'empty chair technique', 'EC', 'EC and CT', 'CT', 'standard Cognitive Behavioral Therapy technique (CT']","['power and credibility of the PP-associated core belief and increased dominance', 'credibility, power, and valence of the PP-associated core belief']","[{'cui': 'C0006012', 'cui_str': 'Borderline personality disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C5200813', 'cui_str': 'Schema Therapy'}]","[{'cui': 'C0582546', 'cui_str': 'Empty chair technique'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C5200813', 'cui_str': 'Schema Therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1287621', 'cui_str': 'Eye dominance - finding'}]",20.0,0.0111025,"Both EC and CT help combat the PP in BPD patients, with CT being more effective in reducing credibility after one session.","[{'ForeName': 'Frauke A T', 'Initials': 'FAT', 'LastName': 'van Maarschalkerweerd', 'Affiliation': 'Community Mental Health Center De Viersprong, Amsterdam, the Netherlands. Electronic address: f.vanmaarschalkerweerd@ggz-nhn.nl.'}, {'ForeName': 'Izabella M', 'Initials': 'IM', 'LastName': 'Engelmoer', 'Affiliation': 'Community Mental Health Center De Viersprong, Amsterdam, the Netherlands.'}, {'ForeName': 'Sem', 'Initials': 'S', 'LastName': 'Simon', 'Affiliation': 'Community Mental Health Center PsyQ, Amsterdam, the Netherlands.'}, {'ForeName': 'Arnoud', 'Initials': 'A', 'LastName': 'Arntz', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam, Amsterdam, the Netherlands.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2021.101678'] 1992,34347707,CT Radiomics for the Prediction of Synchronous Distant Metastasis in Clear Cell Renal Cell Carcinoma.,"PURPOSE The aim of this study was to construct and verify a computed tomography (CT) radiomics model for preoperative prediction of synchronous distant metastasis (SDM) in clear cell renal cell carcinoma (ccRCC) patients. METHODS Overall, 172 patients with ccRCC were enrolled in the present research. Contrast-enhanced CT images were manually sketched, and 2994 quantitative radiomic features were extracted. The radiomic features were then normalized and subjected to hypothesis testing. Least absolute shrinkage and selection operator (LASSO) was applied to dimension reduction, feature selection, and model construction. The performance of the predictive model was validated through analysis of the receiver operating characteristic curve. Multivariate and subgroup analyses were performed to verify the radiomic score as an independent predictor of SDM. RESULTS The patients randomized into a training (n = 104) and a validation (n = 68) cohort in a 6:4 ratio. Through dimension reduction using LASSO regression, 9 radiomic features were used for the construction of the SDM prediction model. The model yielded moderate performance in both the training (area under the curve, 0.89; 95% confidence interval, 0.81-0.97) and the validation cohort (area under the curve, 0.83; 95% confidence interval, 0.69-0.95). Multivariate analysis showed that the CT radiomic signature was an independent risk factor for clinical parameters of ccRCC. Subgroup analysis revealed a significant connection between the SDM and radiomic signature, except for the lower pole of the kidney subgroup. CONCLUSIONS The CT-based radiomics model could be used as a noninvasive, personalized approach for SDM prediction in patients with ccRCC.",2021,"The model yielded moderate performance in both the training (area under the curve, 0.89; 95% confidence interval, 0.81-0.97) and the validation cohort (area under the curve, 0.83; 95% confidence interval, 0.69-0.95).","['patients with ccRCC', '172 patients with ccRCC', 'clear cell renal cell carcinoma (ccRCC) patients']","['computed tomography (CT) radiomics model', 'CT Radiomics']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0279702', 'cui_str': 'Clear cell carcinoma of kidney'}, {'cui': 'C4517601', 'cui_str': '172'}]","[{'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]",[],172.0,0.0929324,"The model yielded moderate performance in both the training (area under the curve, 0.89; 95% confidence interval, 0.81-0.97) and the validation cohort (area under the curve, 0.83; 95% confidence interval, 0.69-0.95).","[{'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Wen', 'Affiliation': 'From the Departments of Medical Ultrasound Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region Department of GE Healthcare Global Research, GE Healthcare, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Rui-Zhi', 'Initials': 'RZ', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Da', 'Initials': 'D', 'LastName': 'Wan', 'Affiliation': ''}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Qin', 'Affiliation': ''}, {'ForeName': 'Yu-Ting', 'Initials': 'YT', 'LastName': 'Peng', 'Affiliation': ''}, {'ForeName': 'Yi-Qiong', 'Initials': 'YQ', 'LastName': 'Liang', 'Affiliation': ''}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xin-Rong', 'Initials': 'XR', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': ''}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': ''}]",Journal of computer assisted tomography,['10.1097/RCT.0000000000001211'] 1993,34351205,Testing the waters: An investigation of the impact of hot tubbing on experts from referral through testimony.,"OBJECTIVE The present research examined whether concurrent expert testimony (""hot tubbing"") and court-appointed testimony reduced adversarial allegiance in clinical experts' judgments compared with traditional adversarial expert testimony. HYPOTHESES We predicted Hypothesis 1: Defense experts would render more not responsible judgments and lower ratings of criminal responsibility than would prosecution experts; Hypothesis 2: Adversarial allegiance effects on experts' judgments would be heightened for adversarial experts and attenuated for concurrent experts over time; Hypothesis 3: Adversarial and concurrent experts would report higher dissonance than would court-appointed experts and adversarial experts' ratings would increase over time, concurrent experts' ratings would decrease, and court-appointed experts' ratings would remain unchanged. METHOD Clinicians and advanced clinical doctoral students conducted simulated criminal responsibility evaluations for the prosecution, defense, or court. We categorized participants as favoring the prosecution or defense based on their preexisting attitudes and randomly assigned them to the adversarial, concurrent, or court-appointed expert testimony conditions. Participants completed a dichotomous responsibility judgment, strength of responsibility ratings, and cognitive dissonance measure after initial evidence review (n = 93), report completion (n = 52), and testimony (n = 48). Concurrent experts generated a joint report outlining areas of agreement and disagreement before providing testimony. RESULTS Concurrent testimony did not eliminate adversarial allegiance. Adversarial and concurrent experts' perceptions of responsibility did not significantly differ (d = .04, 95% CI [-.64, .71]) or change over time (ηp2 = .03); however, prosecution experts-across testimony types-rated the defendant as significantly more responsible than did defense experts (d = 1.87, 95% CI [1.06, 2.67]). Concurrent and adversarial experts did not differ in their reports and minimally differed in testimony content. CONCLUSIONS Experts who initially favored the prosecution or defense showed adversarial allegiance regardless of expert testimony method, and we observed no attenuation of this bias over the course of their case involvement. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,Adversarial and concurrent experts' perceptions of responsibility did not significantly differ (,"['Testing the waters', 'Clinicians and advanced clinical doctoral students conducted simulated criminal responsibility evaluations for the prosecution, defense, or court']","['concurrent expert testimony (""hot tubbing"") and court-appointed testimony reduced adversarial allegiance']","['adversarial allegiance', 'dichotomous responsibility judgment, strength of responsibility ratings, and cognitive dissonance measure']","[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0699726', 'cui_str': 'Offenders'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0015325', 'cui_str': 'Expert Testimony'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]","[{'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0009242', 'cui_str': 'Cognitive Dissonance'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0739996,Adversarial and concurrent experts' perceptions of responsibility did not significantly differ (,"[{'ForeName': 'Jennifer T', 'Initials': 'JT', 'LastName': 'Perillo', 'Affiliation': 'Department of Psychology, Indiana University of Pennsylvania.'}, {'ForeName': 'Anthony D', 'Initials': 'AD', 'LastName': 'Perillo', 'Affiliation': 'Department of Psychology, Indiana University of Pennsylvania.'}, {'ForeName': 'Nikoleta M', 'Initials': 'NM', 'LastName': 'Despodova', 'Affiliation': 'Department of Psychology, The Graduate Center, City University of New York.'}, {'ForeName': 'Margaret Bull', 'Initials': 'MB', 'LastName': 'Kovera', 'Affiliation': 'Department of Psychology, The Graduate Center, City University of New York.'}]",Law and human behavior,['10.1037/lhb0000446'] 1994,34351204,"Race, witness credibility, and jury deliberation in a simulated drug trafficking trial.","OBJECTIVE The present study integrates several distinct lines of jury decision-making research by examining how the racial identities of the defendant and an informant witness interact in a federal drug conspiracy trial scenario and by assessing whether jurors' individual racial identity and jury group racial composition influence their judgments. HYPOTHESES We predicted that jurors would be biased against the Black defendant and would be more likely to convict after exposure to a White informant, among other hypotheses. METHOD We recruited 822 nonstudent jury-eligible participants assigned to 144 jury groups. Each group was assigned to one of four onditions where defendant race (Black or White) and informant race (Black or White) was manipulated. Each group watched a realistic audio-visual trial presentation, then deliberated as a group to render a verdict. RESULTS Contrary to expectations, the conditions depicting a Black defendant yielded lower conviction rates compared to those with a White defendant-at both the predeliberation individual (odds ratio [OR] = 1.54) and postdeliberation group level (OR = 2.91)-while the informant race did not influence verdict outcomes. We also found that jurors rated the government witnesses as more credible when the defendant was White compared to when he was Black. Credibility ratings and verdict outcomes were also predicted by jurors' own race, although juror race did not interact with the race conditions when predicting verdicts. CONCLUSIONS Jurors are sensitive to defendant race, and this sensitivity appears to strengthen after deliberation-but in a direction opposite to what was expected. One potential implication of our findings is that juries may operate as a check on system bias by applying greater scrutiny to law enforcement-derived evidence when the defendant is Black. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Contrary to expectations, the conditions depicting a Black defendant yielded lower conviction rates compared to those with a White defendant-at both the predeliberation individual (odds ratio [OR] = 1.54) and postdeliberation group level (OR = 2.91)-while",['822 nonstudent jury-eligible participants assigned to 144 jury groups'],[],"['conviction rates', 'Credibility ratings and verdict outcomes']","[{'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],"[{'cui': 'C1274040', 'cui_str': 'Result'}]",,0.165082,"Contrary to expectations, the conditions depicting a Black defendant yielded lower conviction rates compared to those with a White defendant-at both the predeliberation individual (odds ratio [OR] = 1.54) and postdeliberation group level (OR = 2.91)-while","[{'ForeName': 'Emily V', 'Initials': 'EV', 'LastName': 'Shaw', 'Affiliation': 'Department of Psychological Science, Law and Society, University of California-Irvine.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Lynch', 'Affiliation': 'Department of Criminology, Law and Society, University of California-Irvine.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Laguna', 'Affiliation': 'Department of Criminology, Law and Society, University of California-Irvine.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Frenda', 'Affiliation': 'Department of Psychology, California State University, Los Angeles.'}]",Law and human behavior,['10.1037/lhb0000449'] 1995,34352125,"The effect of triangular cross-section neck design on crestal bone stability in the anterior mandible: A randomized, controlled, split-mouth clinical trial.","OBJECTIVES This randomized controlled trial aimed to compare crestal bone loss (CBL) and buccal bone thickness (BBT) around triangular cross-section neck (TN) to round neck (RN) implants retaining mandibular overdentures one year after loading, using cone beam computed tomography (CBCT). MATERIAL AND METHODS Twenty edentulous patients receiving 40 implants with similar diameters were randomly assigned to the RN and TN groups. Clinical buccal bone thickness (CBBT) around the implants was measured with a caliper at baseline. A resonance frequency analyzer was used to measure the implant stability quotient (ISQ) at the baseline and two months after insertion. Pocket probing depths (PPD), plaque index (PI), and gingival index (GI) were also recorded at postoperative months 2, 6, and 12. CBCT was used to evaluate proximal CBL and BBT at three levels (0, -2, and -4 mm) one year after loading. RESULTS No implant loss was observed during the follow-up period. No significant differences in CBBT, ISQ values, and scores for PPD, PI, and GI between the two groups were observed at any time (p > .05). BBT was also comparable one year after loading (p > .05). The mean ± SD proximal CBL one year after loading was 0.58 ± 0.36 mm for TN and 0.91 ± 0.59 mm for RN (p < .01). CONCLUSIONS This study found better crestal bone preservation in the implants with the novel neck design than conventional neck design in the anterior mandible after a follow-up of one year. However, it may not be clinically noticeable.",2021,"No significant differences in CBBT, ISQ values, and scores for PPD, PI, and GI between the two groups were observed at any time (p > 0.05).","['Twenty edentulous patients receiving 40 implants with similar diameters', 'anterior mandible']","['CBCT', 'cone-beam computed tomography (CBCT', 'triangular cross-section neck design']","['crestal bone loss (CBL) and buccal bone thickness (BBT) around triangular cross-section neck (TN', 'proximal CBL and BBT', 'implant stability quotient (ISQ', 'implant loss', 'BBT', 'Pocket probing depths (PPD), plaque index (PI), and gingival index (GI', 'crestal bone preservation', 'crestal bone stability', 'CBBT, ISQ values, and scores for PPD, PI, and GI', 'mean ± SD proximal CBL', 'Clinical buccal bone thickness (CBBT']","[{'cui': 'C0026644', 'cui_str': 'Edentulous'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}]","[{'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C0205119', 'cui_str': 'Triangular'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205119', 'cui_str': 'Triangular'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",20.0,0.0553738,"No significant differences in CBBT, ISQ values, and scores for PPD, PI, and GI between the two groups were observed at any time (p > 0.05).","[{'ForeName': 'Berkay', 'Initials': 'B', 'LastName': 'Tokuc', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Kocaeli University, Kocaeli, Turkey.'}, {'ForeName': 'Bahadır', 'Initials': 'B', 'LastName': 'Kan', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Okan University, Istanbul, Turkey.'}]",Clinical oral implants research,['10.1111/clr.13821'] 1996,34351816,Acute endurance exercise stimulates circulating levels of mitochondrial derived peptides in humans.,"Mitochondrial derived peptides (MDPs) humanin (HN) and mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) are involved in cell survival, suppression of apoptosis and metabolism. Circulating levels of MDPs are altered in chronic diseases such as diabetes type 2 and chronic kidney disease. Whether acute resistance (RE) or endurance (EE) exercise modulates circulating levels of HN and MOTS-c in humans is unknown. Following familiarization, subjects were randomized to EE (n=10, 45 min cycling at 70% of estimated VO 2 max), RE (n=10, 4 sets x 7RM, leg press and knee extension), or control (CON, n=10). Skeletal muscle biopsies and blood samples were collected before and at 30 minutes and 3 hours following exercise. Plasma concentration of HN and MOTS-c, skeletal muscle MOTS-c as well as gene expression of exercise related genes were analyzed. Acute EE and RE promoted changes in skeletal muscle gene expression typically seen in response to each exercise modality (c-Myc, 45S pre-rRNA, PGC-1α-total and PGC-1α-ex1b). At rest, circulating levels of HN were positively correlated to MOTS-c levels and age. Plasma levels of MDPs were not correlated to fitness outcomes (VO 2 max, leg strength or muscle mitochondrial (mt) DNA copy number). Circulating levels of HN were significantly elevated by acute EE but not RE. MOTS-C levels showed a trend to increase after EE. These results indicate that plasma MDP levels are not related to fitness status but that acute EE increases circulating levels of MDPs, in particular HN.",2021,"Plasma levels of MDPs were not correlated to fitness outcomes (VO 2 max, leg strength or muscle mitochondrial (mt) DNA copy number).",['humans'],"['acute resistance (RE) or endurance (EE) exercise', 'Acute endurance exercise', 'Mitochondrial derived peptides (MDPs) humanin (HN', 'EE']","['Plasma levels of MDPs', 'Circulating levels of HN', 'fitness outcomes (VO 2 max, leg strength or muscle mitochondrial (mt) DNA copy number', 'plasma MDP levels', 'MOTS-C levels', 'Skeletal muscle biopsies and blood samples', 'circulating levels of HN', 'Plasma concentration of HN and MOTS-c, skeletal muscle MOTS-c']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0966511', 'cui_str': 'humanin'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0966511', 'cui_str': 'humanin'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0012929', 'cui_str': 'Mitochondrial DNA'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0052834', 'cui_str': 'B 30-muramyl dipeptide'}, {'cui': 'C2315740', 'cui_str': 'Biopsy of skeletal muscle'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0079941', 'cui_str': 'ORFs'}, {'cui': 'C0035701', 'cui_str': 'Ribosomal RNA'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}]",,0.0337094,"Plasma levels of MDPs were not correlated to fitness outcomes (VO 2 max, leg strength or muscle mitochondrial (mt) DNA copy number).","[{'ForeName': 'Ferdinand', 'Initials': 'F', 'LastName': 'von Walden', 'Affiliation': ""Division of Pediatric Neurology, Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.""}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Fernandez-Gonzalo', 'Affiliation': 'Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska Institutet, and Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Jessica Maria', 'Initials': 'JM', 'LastName': 'Norrbom', 'Affiliation': 'Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Eric B', 'Initials': 'EB', 'LastName': 'Emanuelsson', 'Affiliation': 'Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Vandre C', 'Initials': 'VC', 'LastName': 'Figueiredo', 'Affiliation': 'College of Health Sciences, University of Kentucky, Lexington, KY, United States.'}, {'ForeName': 'Eva-Karin', 'Initials': 'EK', 'LastName': 'Gidlund', 'Affiliation': 'Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Norrbrand', 'Affiliation': 'Division of Environmental Physiology, Swedish Aerospace Physiology Center, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': ""Division of Pediatric Neurology, Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.""}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Sandström', 'Affiliation': 'Department of Orthopaedics Eksjö, Region Jönköping County and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Hansson', 'Affiliation': 'Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska Institutet, and Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Junxiang', 'Initials': 'J', 'LastName': 'Wan', 'Affiliation': 'Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, United States.'}, {'ForeName': 'Pinchas', 'Initials': 'P', 'LastName': 'Cohen', 'Affiliation': 'Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, United States.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Alkner', 'Affiliation': 'Department of Orthopaedics Eksjö, Region Jönköping County and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00706.2019'] 1997,34356717,Stress and Psychopathology Reduction in Pregnant Women through Online Cognitive Behavioural Therapy during COVID-19: A Feasibility Study.,"BACKGROUND The global pandemic has affected the psychological health of the population, including pregnant women. Due to the difficulty of offering conventional therapies to reduce stress in this population, studies are needed to show the effect of online therapies. Therefore, the objective was to test the effect of online cognitive behavioural therapy in pregnant women during the pandemic on the main variables of stress and psychopathology. METHODS The sample consisted of 16 pregnant women who participated in a weekly cognitive behavioural intervention for 8 weeks. Prenatal concerns, general stress, stress vulnerability, resilience and psychopathology were assessed. RESULTS The results show a reduction in prenatal concerns, perceived stress, stress vulnerability and psychopathology, as well as an increase in resilience. CONCLUSIONS Online cognitive behavioural intervention may be effective in pregnant women, so it is important to conduct a randomised controlled trial to certify these findings.",2021,"The results show a reduction in prenatal concerns, perceived stress, stress vulnerability and psychopathology, as well as an increase in resilience. ","['Pregnant Women through', 'pregnant women', 'pregnant women during the pandemic on the main variables of stress and psychopathology', '16 pregnant women who participated in a weekly']","['online cognitive behavioural therapy', 'Online cognitive behavioural intervention', 'cognitive behavioural intervention', 'Online Cognitive Behavioural Therapy']","['Stress and Psychopathology Reduction', 'Prenatal concerns, general stress, stress vulnerability, resilience and psychopathology', 'prenatal concerns, perceived stress, stress vulnerability and psychopathology, as well as an increase in resilience']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",16.0,0.0746722,"The results show a reduction in prenatal concerns, perceived stress, stress vulnerability and psychopathology, as well as an increase in resilience. ","[{'ForeName': 'Jose A', 'Initials': 'JA', 'LastName': 'Puertas-Gonzalez', 'Affiliation': 'Mind, Brain and Behaviour Research Center (CIMCYC), 18071 Granada, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Mariño-Narvaez', 'Affiliation': 'Mind, Brain and Behaviour Research Center (CIMCYC), 18071 Granada, Spain.'}, {'ForeName': 'Borja', 'Initials': 'B', 'LastName': 'Romero-Gonzalez', 'Affiliation': 'Psychology Department, Faculty of Education, Campus Duques de Soria, University of Valladolid, 42004 Soria, Spain.'}, {'ForeName': 'Maria Isabel', 'Initials': 'MI', 'LastName': 'Peralta-Ramirez', 'Affiliation': 'Mind, Brain and Behaviour Research Center (CIMCYC), 18071 Granada, Spain.'}]","Behavioral sciences (Basel, Switzerland)",['10.3390/bs11070100'] 1998,34356589,Effects on Recovery of Pediatric Patients Undergoing Total Intravenous Anesthesia with Propofol versus Ketofol for Short-Lasting Laparoscopic Procedures.,"BACKGROUND Combining ketamine and propofol (ketofol) was suggested as a new concept for sedation and general anesthesia in pediatric populations for various conditions. The aim of the present study was to determine the effect of total intravenous anesthesia (TIVA) with propofol and ketofol on recovery after laparoscopic surgery in pediatric patients. METHODS Two hundred children with median age of 5 years who underwent laparoscopic surgery were randomized into two groups. Propofol 1% was used for induction and maintenance of anesthesia in group I, while ketamine-propofol combination (ketofol) was used in group II. Ketamine-propofol combination (ketofol) was prepared in the same applicator for group II. Ketofol ratios of 1:4 and 1:7 were used for induction and maintenance of anesthesia, respectively. A reduced McFarlan infusion dose was used in group I (1.2, 1.0, and 0.8 mL/kg/h for 15, 15, and 30 min, respectively), while a McFarlan infusion dose was used in group II (1.5, 1.3, and 1.1 mL/kg/h for 15, 15, and 30 min, respectively). Extubating time, duration of anesthesia, and length of stay in post-anesthesia care unit (PACU) were recorded. RESULTS Extubating time was significantly lower in the ketofol group than in the propofol group (240 s vs. 530 s; p < 0.00001). Significantly shorter duration of anesthesia (47 min vs. 60 min; p < 0.00001) as well as length of stay in the PACU (35 min vs. 100 min; p < 0.00001) were recorded in ketofol compared to the propofol group. Total fentanyl (100 µg (interquartile range, IQR 80, 125) vs. 50 µg (IQR 40, 60); p < 0.00001) and propofol (260 mg (IQR 200, 350) vs. 160 mg (IQR 120, 210); p < 0.00001) consumption per body weight were significantly lower in the ketofol group. CONCLUSIONS TIVA with ketamine-propofol combination (ketofol) using a reduced McFarlan dose regimen shortened extubating time, duration of anesthesia, as well as length of stay in the PACU in pediatric anesthesia after laparoscopic surgery.",2021,"p < 0.00001) and propofol (260 mg (IQR 200, 350) vs. 160 mg (IQR 120, 210); ","['pediatric anesthesia after laparoscopic surgery', 'Two hundred children with median age of 5 years who underwent laparoscopic surgery', 'pediatric patients', 'Pediatric Patients Undergoing Total Intravenous Anesthesia with Propofol versus Ketofol for Short-Lasting Laparoscopic Procedures']","['ketamine and propofol (ketofol', 'propofol', 'Propofol', 'total intravenous anesthesia (TIVA', 'Ketamine-propofol combination (ketofol', 'ketamine-propofol combination (ketofol', 'propofol and ketofol', 'Total fentanyl']","['Extubating time, duration of anesthesia, and length of stay in post-anesthesia care unit (PACU', 'length of stay in the PACU ', 'Extubating time', 'consumption per body weight', 'Ketofol ratios', 'duration of anesthesia']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0473965', 'cui_str': 'Total intravenous anesthesia'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0473965', 'cui_str': 'Total intravenous anesthesia'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0034871', 'cui_str': 'Postoperative anesthesia care unit'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",200.0,0.0255887,"p < 0.00001) and propofol (260 mg (IQR 200, 350) vs. 160 mg (IQR 120, 210); ","[{'ForeName': 'Ana Nevešćanin', 'Initials': 'AN', 'LastName': 'Biliškov', 'Affiliation': 'Department of Anesthesiology, Reanimatology and Intensive Care, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia.'}, {'ForeName': 'Božena', 'Initials': 'B', 'LastName': 'Ivančev', 'Affiliation': 'Department of Pediatric Surgery, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia.'}, {'ForeName': 'Zenon', 'Initials': 'Z', 'LastName': 'Pogorelić', 'Affiliation': 'Department of Pediatric Surgery, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia.'}]","Children (Basel, Switzerland)",['10.3390/children8070610'] 1999,34356551,Implementation of a Hybrid Educational Program between the Model of Personal and Social Responsibility (TPSR) and the Teaching Games for Understanding (TGfU) in Physical Education and Its Effects on Health: An Approach Based on Mixed Methods.,"The present study investigates the effect of an educational program hybridized between the Model of Personal and Social Responsibility (TPSR) and the Teaching Games for Understanding (TGfU) in physical education classes on the health and psychosocial variables of students, as well as knowing the advantages and disadvantages of its implementation by teachers. The applied program lasted 11 weeks in two Secondary Education centers with a total of four teachers (two in the experimental group and two in the control group) and 99 students (55 from the control group and 44 from the experimental group). We use research methodology Mixed Methods with a quasi-experimental design, where students completed a questionnaire before and after the educational program and teachers were interviewed at the end of the intervention. The results of the questionnaires indicate significant improvements in the experimental group over time in terms of the intention to be physically active, as well as in autonomous motivation, the self-determination index, the index of psychological mediators, personal and social responsibility, and enjoyment. Moreover, the interviews show positive opinions regarding the organizational capacity of the session using this methodology and the interest of teachers in continuing to apply it in the future, as well as the need for initial and ongoing training for proper implementation. In conclusion, the hybridization between the TPSR and TGfU model is presented as an effective alternative to be applied in the educational context with the aim of improving young peoples' intention to be physically active and psychological variables, such as motivation, responsibility, and enjoyment, in physical education classes.",2021,"The results of the questionnaires indicate significant improvements in the experimental group over time in terms of the intention to be physically active, as well as in autonomous motivation, the self-determination index, the index of psychological mediators, personal and social responsibility, and enjoyment.",['Health'],['educational program hybridized between the Model of Personal and Social Responsibility (TPSR) and the Teaching Games for Understanding (TGfU'],"['intention to be physically active, as well as in autonomous motivation, the self-determination index, the index of psychological mediators, personal and social responsibility, and enjoyment']","[{'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0037433', 'cui_str': 'Responsibility, Social'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}]","[{'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0036595', 'cui_str': 'Self Determination'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0037433', 'cui_str': 'Responsibility, Social'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}]",4.0,0.0105708,"The results of the questionnaires indicate significant improvements in the experimental group over time in terms of the intention to be physically active, as well as in autonomous motivation, the self-determination index, the index of psychological mediators, personal and social responsibility, and enjoyment.","[{'ForeName': 'Gregorio', 'Initials': 'G', 'LastName': 'García-Castejón', 'Affiliation': 'Department of Physical Activity and Sport, Faculty of Sport Sciences, University of Murcia, Santiago de la, Ribera, 30720 Murcia, Spain.'}, {'ForeName': 'Oleguer', 'Initials': 'O', 'LastName': 'Camerino', 'Affiliation': 'Biomedical Research Institute of Lleida (IRBLLeida), 25192 Lleida, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Castañer', 'Affiliation': 'Biomedical Research Institute of Lleida (IRBLLeida), 25192 Lleida, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Manzano-Sánchez', 'Affiliation': 'Department of Physical Activity and Sport, Faculty of Sport Sciences, University of Murcia, Santiago de la, Ribera, 30720 Murcia, Spain.'}, {'ForeName': 'José Francisco', 'Initials': 'JF', 'LastName': 'Jiménez-Parra', 'Affiliation': 'Department of Physical Activity and Sport, Faculty of Sport Sciences, University of Murcia, Santiago de la, Ribera, 30720 Murcia, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Valero-Valenzuela', 'Affiliation': 'Department of Physical Activity and Sport, Faculty of Sport Sciences, University of Murcia, Santiago de la, Ribera, 30720 Murcia, Spain.'}]","Children (Basel, Switzerland)",['10.3390/children8070573'] 2000,34356221,Nutritional Intervention Improves Nutrition Outcomes in Stomach and Colon Cancer Patients Receiving Chemotherapy: Finding from a Quasi-Experiment in Vietnam.,"BACKGROUND Evidence on the effects of nutritional interventions on gastrointestinal cancer patients receiving chemotherapy is not well documented. This study aims to assess the effects of nutritional intervention in patients diagnosed with stomach and colon cancer receiving chemotherapy in Vietnam. METHODS A quasi-experiment with intervention and control groups for pre- and post-intervention was carried out in cancer patients receiving chemotherapy in a university hospital in Vietnam. Patients in the intervention group were provided nutritional counseling, personalized specific dietary advice, and received oral nutrition supplements (ONSs) while patients in the control group only received nutrition counseling. RESULTS The weight in the intervention and control group after 2 months increased significantly by 1.4 ± 2.6 kg and 0.4 ± 2.3 kg, respectively. Muscle mass increased by 1.2 ± 4.1 cm in the intervention group, while those in the control group decreased by 0.55 ± 2.77 cm. There was no statistical significance between two groups after intervention in terms of Mid-Upper Arm Circumference (MUAC) and percentage of fat. The percentage of malnutrition based on the Scored Patient-Generated Subjective Global Assessment (PG-SGA) and Body Mass Index (BMI) declined after the intervention in both groups. According to the average treatment effect on the treated (ATT) using the propensity score matching and DiD method, participants receiving the intervention were more likely to have a higher score of weight (Coef = 0.84; 95%CI = 0.47; 2.16) and muscle mass (Coef = 1.08; 95%CI = 0.09; 2.06) between pre- and post-intervention. By contrast, the PG-SGA scores on treated participants were more likely to decrease after the intervention (Coef = -1.28; 95%CI = -4.39; -0.84). After matching, being female, living in rural areas, or having stomach cancer were still positively related to being moderately/severely malnourished by the PG-SGA, and these findings were statistically significant ( p < 0.05). CONCLUSION The nutritional interventions had a positive effect on weight gain, muscle mass, and reduced malnutrition. Further studies with a longer follow-up duration are needed to confirm the effects of the intervention.",2021,There was no statistical significance between two groups after intervention in terms of Mid-Upper Arm Circumference (MUAC) and percentage of fat.,"['patients diagnosed with stomach and colon cancer receiving chemotherapy in Vietnam', 'cancer patients receiving chemotherapy in a university hospital in Vietnam', 'Stomach and Colon Cancer Patients', 'gastrointestinal cancer patients receiving']","['Chemotherapy', 'nutritional interventions', 'Nutritional Intervention', 'chemotherapy', 'nutritional counseling, personalized specific dietary advice, and received oral nutrition supplements (ONSs) while patients in the control group only received nutrition counseling', 'nutritional intervention']","['percentage of malnutrition based on the Scored Patient-Generated Subjective Global Assessment (PG-SGA) and Body Mass Index (BMI', 'PG-SGA scores', 'Muscle mass', 'Mid-Upper Arm Circumference (MUAC) and percentage of fat', 'weight gain, muscle mass, and reduced malnutrition', 'Nutrition Outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0042658', 'cui_str': 'Vietnam'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0685938', 'cui_str': 'Malignant neoplasm of gastrointestinal tract'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3714365', 'cui_str': 'Nutrition counseling'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0451514', 'cui_str': 'Subjective global assessment'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0227158,There was no statistical significance between two groups after intervention in terms of Mid-Upper Arm Circumference (MUAC) and percentage of fat.,"[{'ForeName': 'Le Thi', 'Initials': 'LT', 'LastName': 'Huong', 'Affiliation': 'Nutrition and Dietetics Department, Hanoi Medical University Hospital, Hanoi 10000, Vietnam.'}, {'ForeName': 'Duong Thi', 'Initials': 'DT', 'LastName': 'Phuong', 'Affiliation': 'Nutrition and Dietetics Department, Hanoi Medical University Hospital, Hanoi 10000, Vietnam.'}, {'ForeName': 'Dang Kim', 'Initials': 'DK', 'LastName': 'Anh', 'Affiliation': 'Institute of Preventive Medicine and Public Health, Hanoi Medical University, Hanoi 10000, Vietnam.'}, {'ForeName': 'Phung Lam', 'Initials': 'PL', 'LastName': 'Toi', 'Affiliation': 'Health Strategy and Policy Institute, Ministry of Health, Hanoi 10000, Vietnam.'}, {'ForeName': 'Nguyen Le Tuan', 'Initials': 'NLT', 'LastName': 'Anh', 'Affiliation': 'Institute of Preventive Medicine and Public Health, Hanoi Medical University, Hanoi 10000, Vietnam.'}, {'ForeName': 'Trinh Le', 'Initials': 'TL', 'LastName': 'Huy', 'Affiliation': 'Oncology Department, Hanoi Medical University, Hanoi 10000, Vietnam.'}, {'ForeName': 'Nguyen Thuy', 'Initials': 'NT', 'LastName': 'Linh', 'Affiliation': 'Nutrition and Dietetics Department, Hanoi Medical University Hospital, Hanoi 10000, Vietnam.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare9070843'] 2001,34356210,Nursing-Intense Health Education Intervention for Persons with Type 2 Diabetes: A Quasi-Experimental Study.,"Type 2 diabetes mellitus (DM2) is a highly prevalent disease, the progression of which depends on high blood glucose levels, which are reflected in the level of glycosylated haemoglobin (HbA1c). Appropriate health education equips patients with the knowledge and skills to control their glucose and HbA1c levels to avoid long-term complications. This study was set up to compare the results of an intensive (360 min) educational intervention to improve HbA1c parameters in patients with DM2 with those of a usual 90 min intervention. For this purpose, healthcare personnel led a quasi-experimental study of 249 diabetics: 171 in the control group, and 78 in the intervention group. In the control group, the mean HbA1c value decreased from 6.97 to 6.75, while in intervention group it fell from 8.97 to 8.06. The before and after mean difference between both groups was compared with a Wilcoxon test, and the results statistically significant (W = 4530; p < 0.001), indicating a higher reduction of HbA1c in the intervention group. We concluded that the intensive health education provided by nurses during the consultation helped improve HBA1c levels in persons with DM2.",2021,"In the control group, the mean HbA1c value decreased from 6.97 to 6.75, while in intervention group it fell from 8.97 to 8.06.","['patients with DM2 with those of a usual 90 min intervention', 'persons with DM2', 'Persons with Type 2 Diabetes', 'Type 2 diabetes mellitus (DM2', '249 diabetics: 171 in the control group, and 78 in the intervention group']","['intensive (360 min) educational intervention', 'Nursing-Intense Health Education Intervention']","['mean HbA1c value', 'HBA1c levels', 'HbA1c parameters']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1300562', 'cui_str': 'dm2'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",,0.00911785,"In the control group, the mean HbA1c value decreased from 6.97 to 6.75, while in intervention group it fell from 8.97 to 8.06.","[{'ForeName': 'María Begoña', 'Initials': 'MB', 'LastName': 'Martos-Cabrera', 'Affiliation': 'Neonatal Intensive Care Unit, University Hospital San Cecilio, Avenida del Conocimiento, 18016 Granada, Spain.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Gómez-Urquiza', 'Affiliation': 'Faculty of Health Sciences, University of Granada, Avenida de la Ilustración, 60, 18016 Granada, Spain.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Cañadas-González', 'Affiliation': 'Support Device South Area of Cordoba, Andalusian Health Service, Av. Góngora, 9B, Cabra, 14940 Córdoba, Spain.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Romero-Bejar', 'Affiliation': 'Department of Statistics and Operational Research, University of Granada, 18071 Granada, Spain.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Suleiman-Martos', 'Affiliation': 'Faculty of Health Sciences, University of Granada, Avenida de la Ilustración, 60, 18016 Granada, Spain.'}, {'ForeName': 'Guillermo Arturo', 'Initials': 'GA', 'LastName': 'Cañadas-De la Fuente', 'Affiliation': 'Faculty of Health Sciences, University of Granada, Avenida de la Ilustración, 60, 18016 Granada, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Albendín-García', 'Affiliation': 'Casería de Montijo Health Center, Granada Metropolitan District, Andalusian Health Service, Calle Virgen de la Consolación, 12, 18015 Granada, Spain.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare9070832'] 2002,34356193,The Effect of Extra Educational Elements on the Confidence of Undergraduate Dental Students Learning to Administer Local Anaesthesia.,"Local anaesthesia is taught early in the practical part of dental programs. However, dental students express uncertainty and concern before their practical training in local anaesthesia. The aim of this study was to evaluate how extra educational elements in the teaching of local anaesthesia affect students' confidence using local anaesthesia. The students were divided into three groups (A, B and C). Group A received the same education that was used the previous year (i.e., four hours of theoretical lectures followed by four hours of practical exercises performed on a fellow student). Group B did their practical training on fellow students in groups of three, with each student taking turns performing, receiving and observing the procedure. Group C received training using an anatomically correct model before their practical training on a fellow student. After each training step, the students completed a questionnaire about their confidence administering local anaesthesia. The students experienced a significant increase in confidence after each educational step. Combining theory and practical instruction, including the use of anatomically correct models and peer instruction, improved students' confidence in administering local anaesthesia. The greatest increase in confidence was in the students placed in groups of three where each student performed, received and observed the procedure.",2021,"The greatest increase in confidence was in the students placed in groups of three where each student performed, received and observed the procedure.",['Undergraduate Dental Students Learning to Administer Local Anaesthesia'],"['Extra Educational Elements', 'Local anaesthesia', 'practical training', 'training using an anatomically correct model before their practical training']",[],"[{'cui': 'C0038493', 'cui_str': 'Dental Student'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}]","[{'cui': 'C0013879', 'cui_str': 'Chemical element'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]",[],,0.011085,"The greatest increase in confidence was in the students placed in groups of three where each student performed, received and observed the procedure.","[{'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Sjöström', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Umeå University, 90187 Umeå, Sweden.'}, {'ForeName': 'Malin', 'Initials': 'M', 'LastName': 'Brundin', 'Affiliation': 'Department of Endodontics, Umeå University, 90187 Umeå, Sweden.'}]",Dentistry journal,['10.3390/dj9070077'] 2003,34356191,Effects of Neurofeedback on the Working Memory of Children with Learning Disorders-An EEG Power-Spectrum Analysis.,"Learning disorders (LDs) are diagnosed in children impaired in the academic skills of reading, writing and/or mathematics. Children with LDs usually exhibit a slower resting-state electroencephalogram (EEG), corresponding to a neurodevelopmental lag. Frequently, children with LDs show working memory (WM) impairment, associated with an abnormal task-related EEG with overall slower EEG activity (more delta and theta power, and less gamma activity in posterior sites). These EEG patterns indicate inefficient neural resource management. Neurofeedback (NFB) treatments aimed at normalizing the resting-state EEG of LD children have shown improvements in cognitive-behavioral indices and diminished EEG abnormalities. Given the typical findings of WM impairment in children with LDs, we aimed to explore the effects of an NFB treatment on the WM of children with LDs by analyzing the WM-related EEG power spectrum. EEGs of 18 children (8-11 y.o.) with LDs were recorded, pre- and post-treatment, during performance of a Sternberg-type WM task. Thirty sessions of an NFB treatment (NFB-group, n = 10) or 30 sessions of a placebo-sham treatment (sham-group, n = 8) were administered. We analyzed the before and after treatment group differences for the behavioral performance and the WM-related EEG power spectrum. The NFB group showed faster response times in the WM task post-treatment. They also exhibited a decreased theta power and increased beta and gamma power at the frontal and posterior sites post-treatment. We explain these findings in terms of NFB improving the efficiency of neural resource management, maintenance of memory representations, and improved subvocal memory rehearsal.",2021,The NFB group showed faster response times in the WM task post-treatment.,"['children with LDs', '18 children (8-11 y.o.) with LDs', 'Children with Learning Disorders']","['NFB', 'Neurofeedback', 'Neurofeedback (NFB', 'NFB treatment (NFB-group, n = 10) or 30 sessions of a placebo-sham treatment']","['theta power and increased beta and gamma power', 'abnormal task-related EEG with overall slower EEG activity', 'slower resting-state electroencephalogram (EEG', 'cognitive-behavioral indices and diminished EEG abnormalities', 'subvocal memory rehearsal', 'working memory (WM) impairment']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0017011', 'cui_str': 'Gamma radiation'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0151611', 'cui_str': 'Electroencephalogram abnormal'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]",18.0,0.0280534,The NFB group showed faster response times in the WM task post-treatment.,"[{'ForeName': 'Benito J', 'Initials': 'BJ', 'LastName': 'Martínez-Briones', 'Affiliation': 'Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México Campus Juriquilla, Querétaro QE 76230, Mexico.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Bosch-Bayard', 'Affiliation': 'Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México Campus Juriquilla, Querétaro QE 76230, Mexico.'}, {'ForeName': 'Rolando J', 'Initials': 'RJ', 'LastName': 'Biscay-Lirio', 'Affiliation': 'Centro de Investigación en Matemáticas, Guanajuato GJ 36000, Mexico.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Silva-Pereyra', 'Affiliation': 'Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlanepantla, Estado de México MX 54090, Mexico.'}, {'ForeName': 'Lucero', 'Initials': 'L', 'LastName': 'Albarrán-Cárdenas', 'Affiliation': 'Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México Campus Juriquilla, Querétaro QE 76230, Mexico.'}, {'ForeName': 'Thalía', 'Initials': 'T', 'LastName': 'Fernández', 'Affiliation': 'Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México Campus Juriquilla, Querétaro QE 76230, Mexico.'}]",Brain sciences,['10.3390/brainsci11070957'] 2004,34359726,Randomized Trial Assessing the Impact of Routine Assessment of Health-Related Quality of Life in Patients with Head and Neck Cancer.,"The impact of routine assessment of health-related quality of life (HRQoL) on satisfaction with care and the HRQoL of patients with head and neck cancer (HNC) treated with radiotherapy was assessed. Patients with HNC were randomly assigned to two arms, with stratification on sex, cancer localization, and stage of the disease. In the intervention arm, the patients completed the EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires first before randomization, then before each medical appointment during radiotherapy (7 weeks), and then every 3 months until 1 year and at 2 years thereafter. In the control arm, the EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires were completed before randomization and at 1 year and 2 years thereafter. The primary endpoint was mean change in HRQoL at score at 2 years from baseline assessed by EQ VAS from the EuroQol questionnaire. The secondary endpoint was mean change in satisfaction with care at 2 years from baseline assessed by QLQ-SAT32. Two hundred patients with head and neck cancers were involved in this study (mean age, 58.83 years (range, 36.56-87.89)), of whom 100 were assigned to the intervention arm and 100 to the control arm. Patients in the intervention arm were reported to have a statistically significant increase in EQ VAS at 2 years ( p < 0.0001) and exceeded the minimal clinically important difference (mean change at 2 years from baseline = 10.46). In the two arms, mean differences between arms were not statistically significant, but minimal clinically important differences in favor of the intervention arm were found for EQ VAS (mean change difference (MD) = 5.84), satisfaction with care, in particular waiting times (MD = 10.85) and satisfaction with accessibility (MD = 6.52). Routine assessment of HRQoL improves HRQoL and satisfaction with care for patients with HNC treated with radiotherapy.",2021,Patients in the intervention arm were reported to have a statistically significant increase in EQ VAS at 2 years ( p < 0.0001) and exceeded the minimal clinically important difference (mean change at 2 years from baseline = 10.46).,"['patients with head and neck cancer (HNC) treated with', 'Patients with Head and Neck Cancer', 'patients with HNC treated with', 'Patients with HNC', 'Two hundred patients with head and neck cancers were involved in this study (mean age, 58.83 years (range, 36.56-87.89)), of whom 100 were assigned to the intervention arm and 100 to the control arm']","['radiotherapy', 'HRQoL', 'Routine Assessment of Health-Related Quality of Life']","['mean change in satisfaction with care', 'mean change in HRQoL', 'satisfaction with care, in particular waiting times', 'EQ VAS', 'EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",200.0,0.0471388,Patients in the intervention arm were reported to have a statistically significant increase in EQ VAS at 2 years ( p < 0.0001) and exceeded the minimal clinically important difference (mean change at 2 years from baseline = 10.46).,"[{'ForeName': 'Oumar', 'Initials': 'O', 'LastName': 'Billa', 'Affiliation': 'Georges-François Leclerc Cancer Centre-UNICANCER, Epidemiology and Quality of Life Unit, 21000 Dijon, France.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Bonnetain', 'Affiliation': 'Methodology and Quality of Life in Oncology Unit, Inserm UMR 1098, University Hospital of Besancon, 25000 Besancon, France.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Chamois', 'Affiliation': 'Georges-François Leclerc Cancer Centre-UNICANCER, Radiotherapy Department, 1 Rue Professeur Marion, 21000 Dijon, France.'}, {'ForeName': 'Angeline', 'Initials': 'A', 'LastName': 'Ligey', 'Affiliation': 'Centre Hospitalier Fleriat, 01012 Bourg-en-Bresse, France.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Ganansia', 'Affiliation': 'Paul Strauss Cancer Centre-Unicancer, 67000 Strasbourg, France.'}, {'ForeName': 'Georges', 'Initials': 'G', 'LastName': 'Noel', 'Affiliation': 'Paul Strauss Cancer Centre-Unicancer, 67000 Strasbourg, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Renard', 'Affiliation': 'Institut de cancérologie de Lorraine, 54519 Vandœuvre-lès-Nancy, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Maillard', 'Affiliation': 'Centre Bourgogne, 59000 Lille, France.'}, {'ForeName': 'Magali', 'Initials': 'M', 'LastName': 'Quivrin', 'Affiliation': 'Georges-François Leclerc Cancer Centre-UNICANCER, Radiotherapy Department, 1 Rue Professeur Marion, 21000 Dijon, France.'}, {'ForeName': 'Noémie', 'Initials': 'N', 'LastName': 'Vulquin', 'Affiliation': 'Georges-François Leclerc Cancer Centre-UNICANCER, Radiotherapy Department, 1 Rue Professeur Marion, 21000 Dijon, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Truntzer', 'Affiliation': 'Paul Strauss Cancer Centre-Unicancer, 67000 Strasbourg, France.'}, {'ForeName': 'Tienhan Sandrine', 'Initials': 'TS', 'LastName': 'Dabakuyo-Yonli', 'Affiliation': 'Georges-François Leclerc Cancer Centre-UNICANCER, Epidemiology and Quality of Life Unit, 21000 Dijon, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Maingon', 'Affiliation': 'Georges-François Leclerc Cancer Centre-UNICANCER, Radiotherapy Department, 1 Rue Professeur Marion, 21000 Dijon, France.'}]",Cancers,['10.3390/cancers13153826'] 2005,34359641,Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634.,"Docetaxel entrapped nanoparticle CPC634 is associated with dose-related skin toxicity that resembles conventional docetaxel (Cd)-related skin toxicity. This study compared the cutaneous pharmacokinetics and pharmacodynamics of docetaxel and CPC634. In this randomised cross-over study, patients with solid tumours received one cycle of CPC634 and Cd (both at 75 mg/m 2 ). Skin biopsies were taken at baseline and at day 8 of both cycles. Released and total docetaxel (released docetaxel plus entrapped docetaxel) concentrations and histopathological changes in the skin biopsies were evaluated. Twenty patients underwent paired skin biopsies for pharmacokinetic analysis and 10 patients had biopsies available for histopathological assessment. The total skin docetaxel concentration was 369% (95%CI: 229% to 569%, p < 0.001) higher after CPC634 administration compared to Cd while the released docetaxel concentrations were not statistically different (95%CI: -9% to 63%, p = 0.169). The CPC634 released docetaxel concentration in the skin was positively correlated with plasma concentrations (Pearson's correlation 0.48, p = 0.03). Histopathological examination revealed increased apoptosis, mitotic cells with nuclear atypia, and micronucleation with an enhanced Ki-67 index for both compounds. In conclusion, both CPC634 and Cd treatment result in docetaxel exposure in the skin causing cutaneous anti-mitotic effects such as micronucleation, which could induce an inflammatory reaction leading to skin toxicity.",2021,"p < 0.001) higher after CPC634 administration compared to Cd while the released docetaxel concentrations were not statistically different (95%CI: -9% to 63%, ","['Twenty patients underwent paired skin biopsies for pharmacokinetic analysis and 10 patients had biopsies available for histopathological assessment', 'patients with solid tumours']","['docetaxel (released docetaxel plus entrapped docetaxel', 'Docetaxel Skin Exposure and Micronucleation', 'CPC634 and Cd', 'docetaxel and CPC634', 'CPC634']","['apoptosis, mitotic cells with nuclear atypia, and micronucleation with an enhanced Ki-67 index', 'plasma concentrations', 'released docetaxel concentrations', 'Skin biopsies', 'total skin docetaxel concentration', 'Toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150866', 'cui_str': 'Biopsy of skin'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0162638', 'cui_str': 'Apoptosis'}, {'cui': 'C0230518', 'cui_str': 'Mitotic cell'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0150866', 'cui_str': 'Biopsy of skin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",20.0,0.0253536,"p < 0.001) higher after CPC634 administration compared to Cd while the released docetaxel concentrations were not statistically different (95%CI: -9% to 63%, ","[{'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Atrafi', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.'}, {'ForeName': 'Ruben A G', 'Initials': 'RAG', 'LastName': 'van Eerden', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.'}, {'ForeName': 'Stijn L W', 'Initials': 'SLW', 'LastName': 'Koolen', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'de Bruijn', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.'}, {'ForeName': 'Cristianne J F', 'Initials': 'CJF', 'LastName': 'Rijcken', 'Affiliation': 'Cristal Therapeutics, 6229 EV Maastricht, The Netherlands.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Hanssen', 'Affiliation': 'Cristal Therapeutics, 6229 EV Maastricht, The Netherlands.'}, {'ForeName': 'Ferry A L M', 'Initials': 'FALM', 'LastName': 'Eskens', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.'}, {'ForeName': 'Martijn P', 'Initials': 'MP', 'LastName': 'Lolkema', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Oomen-de Hoop', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Damman', 'Affiliation': 'Department of Pathology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.'}, {'ForeName': 'Ron H J', 'Initials': 'RHJ', 'LastName': 'Mathijssen', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.'}]",Cancers,['10.3390/cancers13153741'] 2006,34359609,"'Palliative-D'-Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial.","The aim of the 'Palliative-D' study was to test the hypothesis that correction of vitamin D deficiency reduces opioid use in cancer patients admitted to palliative care. A multicenter randomized, placebo-controlled, double-blind trial in three home-based palliative care facilities in Sweden was performed. Patients with advanced cancer and 25-hydroxyvitamin D < 50 nmol/L were randomized to vitamin D3 4000 IU/day or placebo for 12 weeks. The primary endpoint was the difference of long-acting opioid use (fentanyl ug/h) between the groups during 12 weeks, based on four time points. Secondary outcomes included changes in antibiotic use, fatigue and Quality of Life (QoL). A total of 244 patients were randomized, and 150 patients completed the 12 weeks. The major reason for drop-out was death due to cancer. The vitamin D-group had a significantly smaller increase of opioid doses compared to the placebo-group; beta coefficient -0.56 ( p = 0.03), i.e., 0.56 µg less fentanyl/h per week with vitamin D treatment. Vitamin D-reduced fatigue assessed with ESAS was -1.1 points after 12 weeks ( p < 0.01). Antibiotic use or QoL did not differ significantly between the groups. The treatment was safe and well-tolerated. In conclusion, correction of vitamin D deficiency may have positive effects on opioid use and fatigue in palliative cancer patients, but only in those with a survival time more than 12 weeks.",2021,"The vitamin D-group had a significantly smaller increase of opioid doses compared to the placebo-group; beta coefficient -0.56 ( p = 0.03), i.e., 0.56 µg less fentanyl/h per week with vitamin D treatment.","['three home-based palliative care facilities in Sweden was performed', 'palliative cancer patients', 'cancer patients admitted to palliative care', '244 patients were randomized, and 150 patients completed the 12 weeks', 'Palliative Cancer Patients', 'Patients with advanced cancer and 25-hydroxyvitamin D < 50 nmol/L']","['vitamin D3 4000 IU/day or placebo', 'Placebo', 'vitamin D deficiency', ""Palliative-D'-Vitamin D Supplementation"", 'placebo']","['difference of long-acting opioid use (fentanyl ug/h', 'changes in antibiotic use, fatigue and Quality of Life (QoL', 'Vitamin D-reduced fatigue assessed with ESAS', 'opioid doses', 'safe and well-tolerated', 'Antibiotic use or QoL']","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0587605', 'cui_str': 'Palliative care service'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C4517660', 'cui_str': '244'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0439282', 'cui_str': 'nmol/L'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C3842327', 'cui_str': '4000'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042870', 'cui_str': 'Vitamin D deficiency'}, {'cui': 'C0587605', 'cui_str': 'Palliative care service'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0439425', 'cui_str': 'ug/h'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",244.0,0.657401,"The vitamin D-group had a significantly smaller increase of opioid doses compared to the placebo-group; beta coefficient -0.56 ( p = 0.03), i.e., 0.56 µg less fentanyl/h per week with vitamin D treatment.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Helde Frankling', 'Affiliation': 'Department of Neurobiology, Care Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, SE-141 83 Huddinge, Sweden.'}, {'ForeName': 'Caritha', 'Initials': 'C', 'LastName': 'Klasson', 'Affiliation': 'Department of Neurobiology, Care Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, SE-141 83 Huddinge, Sweden.'}, {'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Sandberg', 'Affiliation': 'Stockholms Sjukhem, Palliative Medicine, SE-112 19 Stockholm, Sweden.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Nordström', 'Affiliation': 'Stockholms Sjukhem, Palliative Medicine, SE-112 19 Stockholm, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Warnqvist', 'Affiliation': 'Department of Environmental Medicine, Division of Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Bergqvist', 'Affiliation': 'Department of Surgery, Breast Centre, Capio St Gorans Hospital, SE-112 19 Stockholm, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bergman', 'Affiliation': 'Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, SE-141 86 Stockholm, Sweden.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Björkhem-Bergman', 'Affiliation': 'Department of Neurobiology, Care Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, SE-141 83 Huddinge, Sweden.'}]",Cancers,['10.3390/cancers13153707'] 2007,34359567,Effects of and Lessons Learned from an Internet-Based Physical Activity Support Program (with and without Physiotherapist Telephone Counselling) on Physical Activity Levels of Breast and Prostate Cancer Survivors: The PABLO Randomized Controlled Trial.,"BACKGROUND We developed an Internet-based physical activity (PA) support program (IPAS), which is embedded in a patient portal. We evaluated the effectiveness and costs of IPAS alone (online only) or IPAS combined with physiotherapist telephone counselling (blended care), compared to a control group. METHODS Breast or prostate cancer survivors, 3-36 months after completing primary treatment, were randomized to 6-months access to online only, blended care, or a control group. At baseline and 6-month post-baseline, minutes of moderate-to-vigorous PA (MVPA) were measured by accelerometers. Secondary outcomes were self-reported PA, fatigue, mood, health-related quality of life, attitude toward PA, and costs. (Generalized) linear models were used to compare the outcomes between groups. RESULTS We recruited 137 survivors (participation rate 11%). We did not observe any significant between-group differences in MVPA or secondary outcomes. Adherence was rather low and satisfaction scores were low to moderate, with better scores for blended care. Costs for both interventions were low. CONCLUSIONS Recruitment to the study was challenging and the interventions were less efficacious than anticipated, which led to lessons learned for future trials. Suggestions for future research are as follows: improved accessibility of the support program, increased frequency of support, and use of activity trackers.",2021,We did not observe any significant between-group differences in MVPA or secondary outcomes.,"['Breast or prostate cancer survivors, 3-36 months after completing primary treatment', 'Breast and Prostate Cancer Survivors', '137 survivors (participation rate 11']","['Internet-based physical activity (PA) support program (IPAS', '6-months access to online only, blended care, or a control group', 'IPAS alone (online only) or IPAS combined with physiotherapist telephone counselling (blended care', 'Lessons Learned from an Internet-Based Physical Activity Support Program (with and without Physiotherapist Telephone Counselling']","['self-reported PA, fatigue, mood, health-related quality of life, attitude toward PA, and costs', 'Physical Activity Levels']","[{'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}, {'cui': 'C4517569', 'cui_str': '137'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",137.0,0.0547131,We did not observe any significant between-group differences in MVPA or secondary outcomes.,"[{'ForeName': 'H J', 'Initials': 'HJ', 'LastName': 'van de Wiel', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Stuiver', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'May', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'van Grinsven', 'Affiliation': 'Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlands.'}, {'ForeName': 'N K', 'Initials': 'NK', 'LastName': 'Aaronson', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.'}, {'ForeName': 'H S A', 'Initials': 'HSA', 'LastName': 'Oldenburg', 'Affiliation': 'Division of Surgical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.'}, {'ForeName': 'H G', 'Initials': 'HG', 'LastName': 'van der Poel', 'Affiliation': 'Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.'}, {'ForeName': 'S N', 'Initials': 'SN', 'LastName': 'Koole', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.'}, {'ForeName': 'V P', 'Initials': 'VP', 'LastName': 'Retèl', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.'}, {'ForeName': 'W H', 'Initials': 'WH', 'LastName': 'van Harten', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.'}, {'ForeName': 'W G', 'Initials': 'WG', 'LastName': 'Groen', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.'}]",Cancers,['10.3390/cancers13153665'] 2008,34359017,Psychometric properties of the metacognitions about smartphone use questionnaire (MSUQ) in Chinese college students.,"AIMS Over the last ten years, several studies investigating the role of metacognitions in addictive behaviors, including technological addictions, have been published. Problematic Smartphone use has been conceptualized as a behavioural addiction and a psychometrically sound self-report measure to assess metacognitions about PSU has been recently published. The objective of this study was to evaluate some psychometric properties (e.g., factor structure, reliability, and validity) of the Chinese Metacognitions about Smartphone Use Questionnaire (Chinese MSUQ). METHODS A sample of 698 undergraduates (F = 54.70%, mean age = 19.89 ± 1.38 years) were enrolled in China. An exploratory factor analysis was first performed in a randomly allocated subsample of 349 participants. A confirmatory factor analysis was then computed on a second subsample of 349 participants to test its fitting with the identified factor structure. Internal consistency and predictive validity were verified. RESULTS The result of exploratory factor analysis showed a 2-factor structure, which consists of positive metacognitions concerning emotional and cognitive regulation and social advantages of smartphone use (MSUQ-PM) and negative metacognitions about uncontrollability and cognitive harm of smartphone use (MSUQ-NM). The confirmatory factor analysis indicated that the 2-factor structure of Chinese MSUQ had appropriate fit. Cronbach's Alphas ranged from 0.90 to 0.92. Additionally, regression analysis showed that MSUQ-PM and MSUQ-NM positively predicted PSU. Notably, MSUQ-NM is a stronger predictor of PSU compared with MSUQ-PM, with a rescaled importance of 86.36%. CONCLUSIONS The Chinese MSUQ has appropriate psychometric properties, suggesting it is a reliable instrument to assess metacognitions about smartphone use in the Chinese context.",2021,"The Chinese MSUQ has appropriate psychometric properties, suggesting it is a reliable instrument to assess metacognitions about smartphone use in the Chinese context.","['698 undergraduates (F\u202f=\u202f54.70%, mean age\u202f=\u202f19.89\u202f±\u202f1.38\u202fyears) were enrolled in China', '349 participants', 'Chinese college students']","['Chinese Metacognitions about Smartphone Use Questionnaire (Chinese MSUQ', 'smartphone use questionnaire (MSUQ']","['psychometric properties (e.g., factor structure, reliability, and validity', 'MSUQ-PM and MSUQ-NM positively predicted PSU', 'Internal consistency and predictive validity']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0589513', 'cui_str': 'Metacognition'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0033920', 'cui_str': 'Psychometric testing'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0042283', 'cui_str': 'Validity (Epidemiology)'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}]",698.0,0.0576868,"The Chinese MSUQ has appropriate psychometric properties, suggesting it is a reliable instrument to assess metacognitions about smartphone use in the Chinese context.","[{'ForeName': 'Zifu', 'Initials': 'Z', 'LastName': 'Shi', 'Affiliation': 'School of Educational Science, Hunan Normal University, Changsha, China; Cognition and Human Behavior Key Laboratory of Hunan Province, Changsha, China. Electronic address: shizf@hunnu.edu.cn.'}, {'ForeName': 'Huohong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'School of Educational Science, Hunan Normal University, Changsha, China; Cognition and Human Behavior Key Laboratory of Hunan Province, Changsha, China.'}, {'ForeName': 'Jinliang', 'Initials': 'J', 'LastName': 'Guan', 'Affiliation': 'School of Educational Science, Hunan Normal University, Changsha, China; Cognition and Human Behavior Key Laboratory of Hunan Province, Changsha, China.'}, {'ForeName': 'Yuntian', 'Initials': 'Y', 'LastName': 'Xie', 'Affiliation': 'School of Educational Science, Hunan Normal University, Changsha, China; Cognition and Human Behavior Key Laboratory of Hunan Province, Changsha, China.'}, {'ForeName': 'Sijing', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'School of Educational Science, Hunan Normal University, Changsha, China; Cognition and Human Behavior Key Laboratory of Hunan Province, Changsha, China.'}, {'ForeName': 'Xiaohao', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'School of Educational Science, Hunan Normal University, Changsha, China; Cognition and Human Behavior Key Laboratory of Hunan Province, Changsha, China.'}, {'ForeName': 'Baojuan', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'School of Educational Science, Hunan Normal University, Changsha, China; Cognition and Human Behavior Key Laboratory of Hunan Province, Changsha, China.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Shu', 'Affiliation': 'School of Educational Science, Hunan Normal University, Changsha, China; Cognition and Human Behavior Key Laboratory of Hunan Province, Changsha, China.'}]",Addictive behaviors,['10.1016/j.addbeh.2021.107041'] 2009,34358852,"Comment on: Application of a new serratus anterior plane block in modified radical mastectomy under ultrasound guidance: A prospective, randomized controlled trial.",,2021,,['modified radical mastectomy under ultrasound guidance'],['new serratus anterior plane block'],[],"[{'cui': 'C0024883', 'cui_str': 'Modified radical mastectomy'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0224349', 'cui_str': 'Structure of serratus anterior muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]",[],,0.0735348,,"[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Ferreira', 'Affiliation': 'Anesthesiology and Intensive Care Department, CHU Besançon, F-25000 Besançon, France. Electronic address: dferreira@chu-besancon.fr.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Vivot', 'Affiliation': 'Service de biostatistique et information médicale, Hôpital Saint Louis, AP-HP, Paris, France.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Berthier', 'Affiliation': 'Anesthesiology and Intensive Care Department, CHU Besançon, F-25000 Besançon, France.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110477'] 2010,34358773,A preliminary investigation of sound-field amplification as an inclusive classroom adjustment for children with and without Autism Spectrum Disorder.,"PURPOSE This study aimed to determine if sound-field amplification (SFA) could be used as an inclusive classroom adjustment to support primary school students with and without Autism Spectrum Disorder (ASD). METHODS A two-group, randomised controlled trial (RCT) with crossover was conducted involving 13 students with ASD (9 males, aged 7.6 to 8.4 years) and 17 typically progressing students without ASD (7 males, aged 7.6 to 9.3 years) from 10 primary schools in and near to Brisbane, Australia. Eighteen of these children had an SFA system in their classrooms in semester one and 12 in semester two of their fourth year of formal schooling (Year 3). Potential proximate benefits were assessed using teacher questionnaire and video analysis of student listening behaviours. Potential distant benefits were assessed using measures of phonological processing in quiet and in noise, attention, memory, and educational achievement. RESULTS Potential proximate benefits were observed for all students with teachers rating student listening behaviours higher with SFA versus without SFA. Potential distant benefits were observed for students with ASD who showed greater improvements in one area of phonological processing (blending nonsense words in noise) following SFA versus no SFA. No other potential proximate or distant benefits following SFA were observed. CONCLUSIONS SFA could be used as an inclusive classroom adjustment to support some primary school students with and without ASD by potentially putting those students in a better position to learn, but their learning must still take place over time and realistic expectations of what can reasonably be achieved by SFA alone are needed.",2021,"Potential distant benefits were assessed using measures of phonological processing in quiet and in noise, attention, memory, and educational achievement. ","['children with and without Autism Spectrum Disorder', '13 students with ASD (9 males, aged 7.6 to 8.4 years) and 17 typically progressing students without ASD (7 males, aged 7.6 to 9.3 years) from 10 primary schools in and near to Brisbane, Australia', 'students with ASD', 'primary school students with and without ASD', 'primary school students with and without Autism Spectrum Disorder (ASD']",['sound-field amplification (SFA'],"['phonological processing in quiet and in noise, attention, memory, and educational achievement', 'phonological processing']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}]","[{'cui': 'C0439654', 'cui_str': 'Quiet'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0013658', 'cui_str': 'Educational achievement'}]",13.0,0.0793645,"Potential distant benefits were assessed using measures of phonological processing in quiet and in noise, attention, memory, and educational achievement. ","[{'ForeName': 'Wayne J', 'Initials': 'WJ', 'LastName': 'Wilson', 'Affiliation': 'Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane, Australia; School of Health & Rehabilitation Sciences, The University of Queensland, Brisbane, Australia. Electronic address: w.wilson@uq.edu.au.'}, {'ForeName': 'Keely', 'Initials': 'K', 'LastName': 'Harper-Hill', 'Affiliation': 'Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane, Australia; School of Cultural and Professional Learning, Queensland University of Technology, Brisbane, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Armstrong', 'Affiliation': 'Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane, Australia; School of Health & Rehabilitation Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Cerys', 'Initials': 'C', 'LastName': 'Downing', 'Affiliation': 'Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane, Australia; School of Health & Rehabilitation Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Perrykkad', 'Affiliation': 'Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane, Australia; Cognition and Philosophy Lab, School of Philosophical, Historical and International Studies, Monash University, Melbourne, Australia.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Rafter', 'Affiliation': 'School of Education, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Ashburner', 'Affiliation': 'Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane, Australia; Autism Queensland, Brisbane, Australia.'}]",Journal of communication disorders,['10.1016/j.jcomdis.2021.106142'] 2011,34349267,"Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial.","We evaluated the safety and efficacy of fully closed-loop insulin therapy compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis. In an open-label, multinational, two-center, randomized crossover trial, 26 adults with type 2 diabetes requiring dialysis (17 men, 9 women, average age 68 ± 11 years (mean ± s.d.), diabetes duration of 20 ± 10 years) underwent two 20-day periods of unrestricted living, comparing the Cambridge fully closed-loop system using faster insulin aspart ('closed-loop') with standard insulin therapy and a masked continuous glucose monitor ('control') in random order. The primary endpoint was time in target glucose range (5.6-10.0 mmol l -1 ). Thirteen participants received closed-loop first and thirteen received control therapy first. The proportion of time in target glucose range (5.6-10.0 mmol l -1 ; primary endpoint) was 52.8 ± 12.5% with closed-loop versus 37.7 ± 20.5% with control; mean difference, 15.1 percentage points (95% CI 8.0-22.2; P < 0.001). Mean glucose was lower with closed-loop than control (10.1 ± 1.3 versus 11.6 ± 2.8 mmol l -1 ; P = 0.003). Time in hypoglycemia (<3.9 mmol l -1 ) was reduced with closed-loop versus control (median (IQR) 0.1 (0.0-0.4%) versus 0.2 (0.0-0.9%); P = 0.040). No severe hypoglycemia events occurred during the control period, whereas one severe hypoglycemic event occurred during the closed-loop period, but not during closed-loop operation. Fully closed-loop improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis. The trial registration number is NCT04025775.",2021,Fully closed-loop improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis.,"['Thirteen participants received', 'adults with type 2 diabetes requiring dialysis', 'adult outpatients with type 2 diabetes requiring dialysis', '26 adults with type 2 diabetes requiring dialysis (17 men, 9 women, average age 68\u2009±\u200911\u2009years (mean\u2009±\u2009s.d.), diabetes duration of 20\u2009±\u200910 years) underwent two 20-day periods of unrestricted living, comparing the']","['fully closed-loop insulin therapy', 'standard insulin therapy', 'closed-loop first and thirteen received control therapy first', 'Fully automated closed-loop glucose control', ""Cambridge fully closed-loop system using faster insulin aspart ('closed-loop') with standard insulin therapy and a masked continuous glucose monitor ('control""]","['time in target glucose range', 'severe hypoglycemia events', 'safety and efficacy', 'severe hypoglycemic event', 'proportion of time in target glucose range', 'Time in hypoglycemia', 'glucose control and reduced hypoglycemia', 'Mean glucose']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0443183', 'cui_str': 'Closed loop'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0123677', 'cui_str': 'Insulin, Aspart, Human'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4728082', 'cui_str': 'Severe hypoglycaemia'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",26.0,0.0443188,Fully closed-loop improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis.,"[{'ForeName': 'Charlotte K', 'Initials': 'CK', 'LastName': 'Boughton', 'Affiliation': ""Wellcome Trust - MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. cb2000@medschl.cam.ac.uk.""}, {'ForeName': 'Afroditi', 'Initials': 'A', 'LastName': 'Tripyla', 'Affiliation': 'Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Hartnell', 'Affiliation': 'Cambridge University Hospitals NHS Foundation Trust, Wolfson Diabetes and Endocrine Clinic, Cambridge, UK.'}, {'ForeName': 'Aideen', 'Initials': 'A', 'LastName': 'Daly', 'Affiliation': ""Wellcome Trust - MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Herzig', 'Affiliation': 'Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Malgorzata E', 'Initials': 'ME', 'LastName': 'Wilinska', 'Affiliation': ""Wellcome Trust - MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.""}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Czerlau', 'Affiliation': 'Department of Nephrology and Hypertension, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Fry', 'Affiliation': 'Department of Renal Medicine, Cambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Bally', 'Affiliation': 'Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Hovorka', 'Affiliation': ""Wellcome Trust - MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.""}]",Nature medicine,['10.1038/s41591-021-01453-z'] 2012,34348201,Home-based exercise training influences gut bacterial levels in multiple sclerosis.,"BACKGROUND Multiple sclerosis is associated with gut microbiome alterations. The current study aimed to investigate the effect of home-based exercise on gut bacteria in people with multiple sclerosis (MS). We also examined the association of exercise-induced gut bacterial modulation with circulating levels of inflammatory and anti-inflammatory cytokines. MATERIALS AND METHODS Forty-two people with MS (female/male: 31/11, expanded disability scale status <5) participated in this study and were divided into two groups: 6 months of home-based exercise (5 sessions per week) and controls. Before and after the intervention, the following parameters were assessed: gut microbiota, including faecalibacterium prausnitzii, akkermansia muciniphila, prevotella and bacteroides counts; cytokine levels including interleukin (IL)-10 and tumor necrosis factor-alpha (TNF-α); and psychosocial factors including anxiety, depression, and fatigue. RESULTS Home-based exercise significantly increased prevotella counts, and decreased akkermansia muciniphila counts (p < 0.05); however, there were no significant effects on faecalibacterium prausnitzii and bacteroides counts (p > 0.05). There were no significant effects of home-based exercise on circulating cytokine levels (p > 0.05). Moreover, home-based exercise was associated with significant improvements in anxiety and depression (p < 0.05); however, fatigue revealed no significant change (p > 0.05). Akkermansia muciniphila, prevotella and bacteroides count changes in response to the intervention were correlated with changes in IL-10 (r = -0.052, r = 0.67, and r = -0.55, respectively). CONCLUSION In general, our data revealed the effect of exercise on gut bacteria, especially prevotella, and akkermansia muciniphila counts, which can probably have a beneficial effect on MS disease pathology and course; however, the lack of changes in cytokines following exercise suggests the possible role of mechanisms other than modulation of circulating IL-10 and TNF- α levels.",2021,"RESULTS Home-based exercise significantly increased prevotella counts, and decreased akkermansia muciniphila counts (p < 0.05); however, there were no significant effects on faecalibacterium prausnitzii and bacteroides counts (p > 0.05).","['Forty-two people with MS (female/male: 31/11, expanded disability scale status <5) participated in this study', 'people with multiple sclerosis (MS', 'multiple sclerosis']","['Home-based exercise training', 'home-based exercise']","['IL-10', 'prevotella counts', 'akkermansia muciniphila counts', 'circulating cytokine levels', 'anxiety and depression', 'gut microbiota, including faecalibacterium prausnitzii, akkermansia muciniphila, prevotella and bacteroides counts; cytokine levels including interleukin (IL)-10 and tumor necrosis factor-alpha (TNF-α); and psychosocial factors including anxiety, depression, and fatigue', 'faecalibacterium prausnitzii and bacteroides counts']","[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0242946', 'cui_str': 'Prevotella'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C1490590', 'cui_str': 'Akkermansia muciniphila'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0317558', 'cui_str': 'Faecalibacterium prausnitzii'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0033963', 'cui_str': 'Psychosocial Factors'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",42.0,0.0130986,"RESULTS Home-based exercise significantly increased prevotella counts, and decreased akkermansia muciniphila counts (p < 0.05); however, there were no significant effects on faecalibacterium prausnitzii and bacteroides counts (p > 0.05).","[{'ForeName': 'Motahare', 'Initials': 'M', 'LastName': 'Mokhtarzade', 'Affiliation': 'Department of Physical Education and Sport Sciences, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Mahdieh', 'Initials': 'M', 'LastName': 'Molanouri Shamsi', 'Affiliation': 'Department of Physical Education and Sport Sciences, Tarbiat Modares University, Tehran, Iran. Electronic address: molanouri@modares.ac.ir.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Abolhasani', 'Affiliation': 'Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: dr_m_abolhasani@yahoo.com.'}, {'ForeName': 'Bita', 'Initials': 'B', 'LastName': 'Bakhshi', 'Affiliation': 'Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Mohammad Ali', 'Initials': 'MA', 'LastName': 'Sahraian', 'Affiliation': 'Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'LeBris S', 'Initials': 'LS', 'LastName': 'Quinn', 'Affiliation': 'Division of Gerontology and Geriatric Medicine, Department of Medicine, Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, University of Washington, Seattle, WA, 98108, USA.'}, {'ForeName': 'Raoof', 'Initials': 'R', 'LastName': 'Negaresh', 'Affiliation': 'Department of Physical Education and Sport Sciences, Tarbiat Modares University, Tehran, Iran.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2021.101463'] 2013,34348194,Effects of an expressive writing intervention in Chinese women undergoing pregnancy termination for fetal abnormality: A randomized controlled trial.,"OBJECTIVE To explore the efficacy of an expressive writing intervention on promoting psychological well-being of women who have had a diagnosis of fetal abnormality. DESIGN AND SETTING An open, randomized controlled trial with parallel group design was conducted at a tertiary hospital in China. 100 women were randomly assigned into either the expressive writing (EW) intervention group or the control group, and 80 women eventually took part in all the phases of the study. Psychological variables including post-traumatic growth (PTG), post-traumatic stress disorder (PTSD) and resilience were assessed at baseline, immediately after the intervention and 1-month follow-up. PARTICIPANTS Women who have had a diagnosis of fetal abnormalities and decided to terminate pregnancies. INTERVENTION Women in the intervention group were asked to write three 15 min essays in regard to their experiences with the fetal abnormalities. FINDINGS The intervention group had significantly higher level of PTG (p = 0.003) and lower level of PTSD symptoms (p = 0.023) immediately after the intervention, as compared with the control group. In 1-month follow-up, intervention participants demonstrated significant improvement in PTG (p = 0.014) but insignificant reduction for PTSD symptoms. No significant effects were observed in both groups in terms of changes over time in resilience. KEY CONCLUSIONS AND IMPLICATIONS FOR PRACTICE EW is efficacious for improving women's PTG and easing their symptoms of PTSD to some extent. Medical staff should pay more attention to this population's psychological status. In the future, EW interventions need to be conducted in larger samples with more severe symptoms of PTSD to validate its effectiveness. The efficacy of longer and more frequent writing interventions should also be investigated.",2021,"The intervention group had significantly higher level of PTG (p = 0.003) and lower level of PTSD symptoms (p = 0.023) immediately after the intervention, as compared with the control group.","['women who have had a diagnosis of fetal abnormality', '100 women', 'Chinese women undergoing pregnancy termination for fetal abnormality', 'tertiary hospital in China', 'Women who have had a diagnosis of fetal abnormalities and decided to terminate pregnancies']","['expressive writing intervention', 'expressive writing (EW) intervention']","['PTG', 'PTSD symptoms', 'changes over time in resilience', 'Psychological variables including post-traumatic growth (PTG), post-traumatic stress disorder (PTSD) and resilience', 'level of PTG', 'lower level of PTSD symptoms']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0392535', 'cui_str': 'Termination of pregnancy'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0018582', 'cui_str': 'Handwriting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",100.0,0.0781863,"The intervention group had significantly higher level of PTG (p = 0.003) and lower level of PTSD symptoms (p = 0.023) immediately after the intervention, as compared with the control group.","[{'ForeName': 'Jialu', 'Initials': 'J', 'LastName': 'Qian', 'Affiliation': ""Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Department of Obstetrics and Gynecology, Women's Hospital School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.""}, {'ForeName': 'Shiwen', 'Initials': 'S', 'LastName': 'Sun', 'Affiliation': ""Department of Obstetrics and Gynecology, Women's Hospital School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.""}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': ""Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Department of Obstetrics and Gynecology, Women's Hospital School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.""}, {'ForeName': 'Mengwei', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': ""Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Department of Obstetrics and Gynecology, Women's Hospital School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.""}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ""Department of Obstetrics and Gynecology, Women's Hospital School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: yuxy@zju.edu.cn.""}]",Midwifery,['10.1016/j.midw.2021.103104'] 2014,34352012,Primary care-based screening and management of depression amongst heavy drinking patients: Interim secondary outcomes of a three-country quasi-experimental study in Latin America.,"INTRODUCTION Implementation of evidence-based care for heavy drinking and depression remains low in global health systems. We tested the impact of providing community support, training, and clinical packages of varied intensity on depression screening and management for heavy drinking patients in Latin American primary healthcare. MATERIALS AND METHODS Quasi-experimental study involving 58 primary healthcare units in Colombia, Mexico and Peru randomized to receive: (1) usual care (control); (2) training using a brief clinical package; (3) community support plus training using a brief clinical package; (4) community support plus training using a standard clinical package. Outcomes were proportion of: (1) heavy drinking patients screened for depression; (2) screen-positive patients receiving appropriate support; (3) all consulting patients screened for depression, irrespective of drinking status. RESULTS 550/615 identified heavy drinkers were screened for depression (89.4%). 147/230 patients screening positive for depression received appropriate support (64%). Amongst identified heavy drinkers, adjusting for country, sex, age and provider profession, provision of community support and training had no impact on depression activity rates. Intensity of clinical package also did not affect delivery rates, with comparable performance for brief and standard versions. However, amongst all consulting patients, training providers resulted in significantly higher rates of alcohol measurement and in turn higher depression screening rates; 2.7 times higher compared to those not trained. CONCLUSIONS Training using a brief clinical package increased depression screening rates in Latin American primary healthcare. It is not possible to determine the effectiveness of community support on depression activity rates due to the impact of COVID-19.",2021,"Amongst identified heavy drinkers, adjusting for country, sex, age and provider profession, provision of community support and training had no impact on depression activity rates.","['heavy drinking patients', '147/230 patients screening positive for depression received appropriate support (64', 'Quasi-experimental study involving 58 primary healthcare units in Colombia, Mexico and Peru randomized to receive: (1', '550/615 identified heavy drinkers', 'Latin American primary healthcare', 'heavy drinking patients in Latin American primary healthcare']",['usual care (control); (2) training using a brief clinical package; (3) community support plus training using a brief clinical package; (4) community support plus training using a standard clinical package'],"['depression activity rates', 'proportion of: (1) heavy drinking patients screened for depression', 'depression screening rates', 'rates of alcohol measurement']","[{'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C2985410', 'cui_str': 'Controlled Clinical Trials, Non-Randomized'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C3245499', 'cui_str': 'Colombia'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0031238', 'cui_str': 'Peru'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0001969', 'cui_str': 'Alcohol intoxication'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0740218', 'cui_str': 'Depression screening'}, {'cui': 'C0202304', 'cui_str': 'Ethanol measurement'}]",58.0,0.0318919,"Amongst identified heavy drinkers, adjusting for country, sex, age and provider profession, provision of community support and training had no impact on depression activity rates.","[{'ForeName': 'Amy', 'Initials': 'A', 'LastName': ""O'Donnell"", 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Schulte', 'Affiliation': 'Center for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Manthey', 'Affiliation': 'Center for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Christiane Sybille', 'Initials': 'CS', 'LastName': 'Schmidt', 'Affiliation': 'Center for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Piazza', 'Affiliation': 'Mental Health, Alcohol, and Drug Research Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.'}, {'ForeName': 'Ines Bustamante', 'Initials': 'IB', 'LastName': 'Chavez', 'Affiliation': 'Mental Health, Alcohol, and Drug Research Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.'}, {'ForeName': 'Guillermina', 'Initials': 'G', 'LastName': 'Natera', 'Affiliation': 'Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, CDMX, Mexico.'}, {'ForeName': 'Natalia Bautista', 'Initials': 'NB', 'LastName': 'Aguilar', 'Affiliation': 'Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, CDMX, Mexico.'}, {'ForeName': 'Graciela Yazmín Sánchez', 'Initials': 'GYS', 'LastName': 'Hernández', 'Affiliation': 'Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, CDMX, Mexico.'}, {'ForeName': 'Juliana', 'Initials': 'J', 'LastName': 'Mejía-Trujillo', 'Affiliation': 'Corporación Nuevos Rumbos, Bogotá, Colombia.'}, {'ForeName': 'Augusto', 'Initials': 'A', 'LastName': 'Pérez-Gómez', 'Affiliation': 'Corporación Nuevos Rumbos, Bogotá, Colombia.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Gual', 'Affiliation': 'Addictions Unit, Psychiatry Dept, Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'de Vries', 'Affiliation': 'Department of Health Promotion, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Solovei', 'Affiliation': 'Department of Health Promotion, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Dasa', 'Initials': 'D', 'LastName': 'Kokole', 'Affiliation': 'Department of Health Promotion, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Kaner', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom.'}, {'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Kilian', 'Affiliation': 'Institute for Clinical Psychology and Psychotherapy, TU Dresden, Dresden, Germany.'}, {'ForeName': 'Jurgen', 'Initials': 'J', 'LastName': 'Rehm', 'Affiliation': 'Center for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Anderson', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Jané-Llopis', 'Affiliation': 'Department of Health Promotion, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.'}]",PloS one,['10.1371/journal.pone.0255594'] 2015,34356965,Short-Term Effects of a Conditioning Telerehabilitation Program in Confined Patients Affected by COVID-19 in the Acute Phase. A Pilot Randomized Controlled Trial.,"Background and objectives : The COVID-19 pandemic has become a challenge for health systems and, specifically, to physical therapists obligated to adapt their job and stop face-to-face consultations. In this situation, therapeutic exercise has been implemented in different COVID-19 patients. This study evaluated the feasibility and effectiveness of a novel therapeutic exercise program through telerehabilitation tools in COVID-19 patients with mild to moderate symptomatology in the acute stage. Materials and Methods : A total of 40 subjects were randomized an experimental group, based on muscle conditioning, and in a control group, who did not perform physical activity. Thirty-six subjects, 18 in each group, completed the one-week intervention. We measured the six-minute walking test, multidimensional dyspnoea-12, thirty seconds sit-to-stand test, and Borg Scale. Results : Both groups were comparable at baseline. Statistically significant improvement between groups ( p < 0.05) in favor of the experimental group was obtained. No differences between gender were found ( p > 0.05). Ninety percent adherence was found in our program. Conclusion : A one-week telerehabilitation program based on muscle toning exercise is effective, safe, and feasible in COVID-19 patients with mild to moderate symptomatology in the acute stage.",2021,Statistically significant improvement between groups ( p < 0.05) in favor of the experimental group was obtained.,"['40 subjects', 'COVID-19 patients with mild to moderate symptomatology in the acute stage']","['Materials and Methods ', 'novel therapeutic exercise program', 'Conditioning Telerehabilitation Program']",['feasibility and effectiveness'],"[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]","[{'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4042802', 'cui_str': 'Remote Rehabilitation'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",40.0,0.0137651,Statistically significant improvement between groups ( p < 0.05) in favor of the experimental group was obtained.,"[{'ForeName': 'Cleofas', 'Initials': 'C', 'LastName': 'Rodriguez-Blanco', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, 41009 Seville, Spain.'}, {'ForeName': 'Juan Jose', 'Initials': 'JJ', 'LastName': 'Gonzalez-Gerez', 'Affiliation': 'Department of Nursing, Physiotherapy and Medicine, University of Almeria, 04120 Almeria, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Bernal-Utrera', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, 41009 Seville, Spain.'}, {'ForeName': 'Ernesto', 'Initials': 'E', 'LastName': 'Anarte-Lazo', 'Affiliation': 'Doctoral Program in Health Sciences, University of Seville, 41009 Seville, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Perez-Ale', 'Affiliation': 'Physician in Intensive Medicine in the Spanish Army, Health Support in the Naval Base of Rota, 11520 Cádiz, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Saavedra-Hernandez', 'Affiliation': 'Department of Nursing, Physiotherapy and Medicine, University of Almeria, 04120 Almeria, Spain.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina57070684'] 2016,34356738,The Effect of Amoxicillin in Adult Patients Presenting to Primary Care with Acute Cough Predicted to Have Pneumonia or a Combined Viral-Bacterial Infection.,"While most cases of acute cough are self-limiting, antibiotics are prescribed to over 50%. This proportion is inappropriately high given that benefit from treatment with amoxicillin could only be demonstrated in adults with pneumonia (based on chest radiograph) or combined viral-bacterial infection (based on modern microbiological methodology). As routine use of chest radiographs and microbiological testing is costly, clinical prediction rules could be used to identify these patient subsets. In this secondary analysis of data from a multicentre randomised controlled trial in adults presenting to primary care with acute cough, we used prediction rules for pneumonia or combined infection and assessed the effect of amoxicillin in patients predicted to have pneumonia or combined infection on symptom duration, symptom severity and illness deterioration. In total, 2056 patients that fulfilled all inclusion criteria were randomised, 1035 to amoxicillin, 1021 to placebo. Neither patients with a predicted pneumonia nor patients with a predicted combined infection were significantly more likely to benefit from amoxicillin. While the studied clinical prediction rules may help primary care clinicians to reduce antibiotic prescribing for low-risk patients, they did not identify adult acute cough patients that would benefit from amoxicillin treatment.",2021,Neither patients with a predicted pneumonia nor patients with a predicted combined infection were significantly more likely to benefit from amoxicillin.,"['Adult Patients Presenting to Primary Care with Acute Cough Predicted to Have Pneumonia or a Combined Viral-Bacterial Infection', 'adults presenting to primary care with acute cough', 'adults with pneumonia (based on chest radiograph) or combined viral-bacterial infection (based on modern microbiological methodology', '2056 patients that fulfilled all inclusion criteria were randomised, 1035 to']","['amoxicillin', 'Amoxicillin', 'placebo']","['pneumonia or combined infection on symptom duration, symptom severity and illness deterioration']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0742857', 'cui_str': 'Acute cough'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0004623', 'cui_str': 'Bacterial infectious disease'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C1306645', 'cui_str': 'Plain radiography'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}, {'cui': 'C0969625', 'cui_str': 'methodology'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0221423', 'cui_str': 'Illness'}]",2056.0,0.190228,Neither patients with a predicted pneumonia nor patients with a predicted combined infection were significantly more likely to benefit from amoxicillin.,"[{'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Bruyndonckx', 'Affiliation': 'Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Data Science Institute (DSI), Hasselt University, 3500 Hasselt, Belgium.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Stuart', 'Affiliation': 'Aldermoor Health Centre, University of Southampton, Southampton SO16 5ST, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Little', 'Affiliation': 'Aldermoor Health Centre, University of Southampton, Southampton SO16 5ST, UK.'}, {'ForeName': 'Niel', 'Initials': 'N', 'LastName': 'Hens', 'Affiliation': 'Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Data Science Institute (DSI), Hasselt University, 3500 Hasselt, Belgium.'}, {'ForeName': 'Margareta', 'Initials': 'M', 'LastName': 'Ieven', 'Affiliation': 'Laboratory of Medical Microbiology, Vaccine & Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, 2610 Antwerp, Belgium.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Butler', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.'}, {'ForeName': 'Theo J M', 'Initials': 'TJM', 'LastName': 'Verheij', 'Affiliation': 'Julius Centre for Health, Sciences and Primary Care, University Medical Centre Utrecht, 3508 GA Utrecht, The Netherlands.'}, {'ForeName': 'Herman', 'Initials': 'H', 'LastName': 'Goossens', 'Affiliation': 'Laboratory of Medical Microbiology, Vaccine & Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, 2610 Antwerp, Belgium.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Coenen', 'Affiliation': 'Laboratory of Medical Microbiology, Vaccine & Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, 2610 Antwerp, Belgium.'}, {'ForeName': '', 'Initials': '', 'LastName': 'The Grace Project Group', 'Affiliation': ''}]","Antibiotics (Basel, Switzerland)",['10.3390/antibiotics10070817'] 2017,34356720,"Comparison on Well-Being, Engagement and Perceived School Climate in Secondary School Students with Learning Difficulties and Specific Learning Disorders: An Exploratory Study.","Reading and writing skills influence the social status of students, exerting effects not only on learning, but also on wellbeing. This study aimed to assess the impact of diagnosis of specific learning disorder on well-being in secondary-school students, comparing students with a diagnosis of specific learning disorder (SLD-group), students showing learning difficulties without diagnosis (LD-group) and students without learning difficulties (control-group). Students were tested with neuropsychological screening tests in order to identify learning difficulties and were further assessed by means of psychological and school well-being questionnaires. The results show that LD group perceive themselves as having a low sense of mastery and autonomy, less interest and engagement in daily activities and low peer social support than their schoolmates. This result highlights, for the LD group, a low well-being experience, which is not observed in the SLD and control groups. On the contrary, SLD group students do not differ from control group students in any dimensions except for the perceived parents' support and involvement in school life, in which the SLD group show the highest scores. This work underlines the importance of having a diagnosis as it seems to work as a protective factor for both the psychological and school well-being of the student.",2021,"On the contrary, SLD group students do not differ from control group students in any dimensions except for the perceived parents' support and involvement in school life, in which the SLD group show the highest scores.","['Secondary School Students with Learning Difficulties and Specific Learning Disorders', 'secondary-school students, comparing students with a diagnosis of specific learning disorder (SLD-group), students showing learning difficulties without diagnosis (LD-group) and students without learning difficulties (control-group']",[],"[""parents' support and involvement in school life"", 'Well-Being, Engagement and Perceived School Climate', 'low sense of mastery and autonomy, less interest and engagement in daily activities and low peer social support']","[{'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0424939', 'cui_str': 'Learning difficulties'}, {'cui': 'C4042933', 'cui_str': 'Specific Learning Disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0008946', 'cui_str': 'Climate'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0037438', 'cui_str': 'Social support'}]",,0.0242592,"On the contrary, SLD group students do not differ from control group students in any dimensions except for the perceived parents' support and involvement in school life, in which the SLD group show the highest scores.","[{'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Lombardi', 'Affiliation': 'Department of Psychology, Catholic University of Milan, 20123 Milano, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Traficante', 'Affiliation': 'Department of Psychology, Catholic University of Milan, 20123 Milano, Italy.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Bettoni', 'Affiliation': 'Department of Psychology, University of Milan-Bicocca, 20126 Milano, Italy.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Offredi', 'Affiliation': 'A.R.P. Associazione per la Ricerca in Psicologia Clinica, 20123 Milan, Italy.'}, {'ForeName': 'Mirta', 'Initials': 'M', 'LastName': 'Vernice', 'Affiliation': 'Dipartimento di Studi Umanistici, Università degli Studi di Urbino ""Carlo Bo"", 61029 Urbino, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Sarti', 'Affiliation': 'Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milano, Italy.'}]","Behavioral sciences (Basel, Switzerland)",['10.3390/bs11070103'] 2018,34356480,Ozone Gel in Chronic Periodontal Disease: A Randomized Clinical Trial on the Anti-Inflammatory Effects of Ozone Application.,"The search for new topical treatments able to display not only antimicrobial properties but also a multiplicity of other beneficial effects while expressing safe cytocompatibility toward host tissues is being progressively developed. Antiseptics represent an aid to the gold standard nonsurgical treatment Scaling-and-Root-Planing (SRP) for periodontal disease. This split-mouth study aims to assess the efficacy of the ozonized gel GeliO 3 (Bioemmei Srl, Vicenza, Italy) plus SRP (experimental treatment), with respect to SRP + chlorhexidine gel. Ten participants were treated with SRP + chlorhexidine gel (control sites) and with SRP + ozone gel (trial sites). After 1 (T 1 ) and 3 months (T 2 ) from baseline (T 0 ), patients were revisited. At each time-point, the following indexes were assessed: probing pocket depth (PPD), clinical attachment level (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BoP). It has been assessed that the use of the ozonized gel in addition to SRP did not show significant differences if compared to conventional SRP + chlorhexidine. Chlorhexidine was found to be more effective than ozone in reducing CAL and GI at T 2 . Ozone deserves consideration for its wide applicability in several clinical fields. In this connection, we also glance at the latest research on ozone therapy.",2021,"At each time-point, the following indexes were assessed: probing pocket depth (PPD), clinical attachment level (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BoP).",['Chronic Periodontal Disease'],"['SRP + chlorhexidine gel', 'Ozone Application', 'Chlorhexidine', 'ozonized gel GeliO', 'conventional SRP + chlorhexidine', 'SRP + chlorhexidine gel (control sites) and with SRP + ozone gel', 'Ozone Gel']","['probing pocket depth (PPD), clinical attachment level (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BoP']","[{'cui': 'C0266929', 'cui_str': 'Chronic periodontitis'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0085287', 'cui_str': 'Root planing of tooth'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0030106', 'cui_str': 'Ozone'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0796232', 'cui_str': 'Bohring Opitz syndrome'}]",10.0,0.064782,"At each time-point, the following indexes were assessed: probing pocket depth (PPD), clinical attachment level (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BoP).","[{'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Colombo', 'Affiliation': 'Section of Dentistry, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Piazzale Golgi 2, 27100 Pavia, Italy.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Gallo', 'Affiliation': 'Section of Dentistry, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Piazzale Golgi 2, 27100 Pavia, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Garofoli', 'Affiliation': 'Section of Dentistry, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Piazzale Golgi 2, 27100 Pavia, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Poggio', 'Affiliation': 'Section of Dentistry, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Piazzale Golgi 2, 27100 Pavia, Italy.'}, {'ForeName': 'Carla Renata', 'Initials': 'CR', 'LastName': 'Arciola', 'Affiliation': ""Laboratorio di Patologia delle Infezioni Associate all'Impianto, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Scribante', 'Affiliation': 'Section of Dentistry, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Piazzale Golgi 2, 27100 Pavia, Italy.'}]",Biology,['10.3390/biology10070625'] 2019,34356288,A Short Mindfulness Retreat for Students to Reduce Stress and Promote Self-Compassion: Pilot Randomised Controlled Trial Exploring Both an Indoor and a Natural Outdoor Retreat Setting.,"Here, we developed and examined a new way of disseminating mindfulness in nature to people without meditation experience, based on the finding that mindfulness conducted in natural settings may have added benefits. We evaluated a 5-day residential programme aiming to reduce stress and improve mental health outcomes. We compared an indoor and an outdoor version of the programme to a control group in a pilot randomised controlled trial (RCT). Sixty Danish university students experiencing moderate to high levels of stress were randomised into a residential mindfulness programme indoors ( n = 20), in nature ( n = 22), or a control group ( n = 18). Participants completed the Perceived Stress Scale and the Self-Compassion Scale (primary outcomes) along with additional secondary outcome measures at the start and end of the program and 3 months after. Stress was decreased with small to medium effect sizes post-intervention, although not statistically significant. Self-compassion increased post-intervention, but effect sizes were small and not significant. At follow-up, changes in stress were not significant, however self-compassion increased for both interventions with medium-sized effects. For the intervention groups, medium- to large-sized positive effects on trait mindfulness after a behavioural task were found post-intervention, and small- to medium-sized effects in self-reported mindfulness were seen at follow-up. Connectedness to Nature was the only outcome measure with an incremental effect in nature, exceeding the control with a medium-sized effect at follow-up. All participants in the nature arm completed the intervention, and so did 97% of the participants in all three arms. Overall, the results encourage the conduct of a larger-scale RCT, but only after adjusting some elements of the programme to better fit and take advantage of the potential benefits of the natural environment.",2021,"At follow-up, changes in stress were not significant, however self-compassion increased for both interventions with medium-sized effects.",['Sixty Danish university students experiencing moderate to high levels of stress'],['residential mindfulness programme indoors'],"['Perceived Stress Scale and the Self-Compassion Scale', 'self-compassion', 'Self-compassion', 'mental health outcomes', 'Stress and Promote Self-Compassion']","[{'cui': 'C0010969', 'cui_str': 'Danish language'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}]","[{'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}]",,0.0412168,"At follow-up, changes in stress were not significant, however self-compassion increased for both interventions with medium-sized effects.","[{'ForeName': 'Dorthe', 'Initials': 'D', 'LastName': 'Djernis', 'Affiliation': 'Department of Geosciences and Natural Resource Management, University of Copenhagen, DK-1958 Frederiksberg, Denmark.'}, {'ForeName': 'Mia S', 'Initials': 'MS', 'LastName': ""O'Toole"", 'Affiliation': 'Department of Psychology and Behavioural Sciences, Aarhus University, DK-8000 Aarhus, Denmark.'}, {'ForeName': 'Lone O', 'Initials': 'LO', 'LastName': 'Fjorback', 'Affiliation': 'Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus, Denmark.'}, {'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Svenningsen', 'Affiliation': 'Program for Mind and Body in Mental Health, Research Centre for Health and Welfare Technology, VIA University College, DK-8200 Aarhus, Denmark.'}, {'ForeName': 'Mimi Y', 'Initials': 'MY', 'LastName': 'Mehlsen', 'Affiliation': 'Department of Psychology and Behavioural Sciences, Aarhus University, DK-8000 Aarhus, Denmark.'}, {'ForeName': 'Ulrika K', 'Initials': 'UK', 'LastName': 'Stigsdotter', 'Affiliation': 'Department of Geosciences and Natural Resource Management, University of Copenhagen, DK-1958 Frederiksberg, Denmark.'}, {'ForeName': 'Jesper', 'Initials': 'J', 'LastName': 'Dahlgaard', 'Affiliation': 'Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus, Denmark.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare9070910'] 2020,34356287,Influences of Lavender Essential Oil Inhalation on Stress Responses during Short-Duration Sleep Cycles: A Pilot Study.,"Lavender essential oil (LEO) was reported to improve sleep quality. We investigated the influence of aromatherapy by testing the effects of LEO on stress responses during a short-duration sleep in a single-blind, randomized, crossover trial. The subjects were twelve healthy adults who were nonsmokers without any known disease and who were not prescribed medications, and nine of these completed the study. After the subjects had fallen asleep, they were sprayed with LEO using an aroma diffuser. Before and after 90 min of sleep, α-amylase, chromogranin A (CgA), and cortisol levels in saliva were measured as objective stress indicators, and the Japanese version of the UWIST Mood Adjective Checklist was used as a subjective indicator. A comparison of changes before and after sleep, with and without LEO, revealed that the cortisol level did not significantly change; however, α-amylase ( p < 0.05) and CgA ( p < 0.01) levels significantly decreased after LEO inhalation. A mood test indicated no change in mood before and after sleep, with or without LEO. Since α-amylase and CgA reflect the sympathetic nervous system response, these results indicate that LEO aromatherapy during a short-duration sleep cycle suppresses the stress response, especially that of the sympathetic nervous system.",2021,"A comparison of changes before and after sleep, with and without LEO, revealed that the cortisol level did not significantly change; however, α-amylase ( p < 0.05) and CgA ( p < 0.01) levels significantly decreased after LEO inhalation.","['subjects were twelve healthy adults who were nonsmokers without any known disease and who were not prescribed medications, and nine of these completed the study', 'Short-Duration Sleep Cycles']","['LEO', 'aromatherapy', 'Lavender Essential Oil Inhalation', 'Lavender essential oil (LEO', 'LEO aromatherapy']","['Stress Responses', 'sleep, α-amylase, chromogranin A (CgA), and cortisol levels in saliva', 'CgA', 'Japanese version of the UWIST Mood Adjective Checklist', 'stress responses', 'cortisol level', 'sleep quality']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0337672', 'cui_str': 'Non-smoker'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439593', 'cui_str': 'Short duration'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]","[{'cui': 'C0524903', 'cui_str': 'Lavender'}, {'cui': 'C0028910', 'cui_str': 'Volatile oil'}, {'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0002712', 'cui_str': 'Amylases'}, {'cui': 'C0055633', 'cui_str': 'Chromogranin A'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0451315', 'cui_str': 'Mood adjective checklist'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",12.0,0.0106462,"A comparison of changes before and after sleep, with and without LEO, revealed that the cortisol level did not significantly change; however, α-amylase ( p < 0.05) and CgA ( p < 0.01) levels significantly decreased after LEO inhalation.","[{'ForeName': 'Wakako', 'Initials': 'W', 'LastName': 'Yogi', 'Affiliation': 'Department of Physiology, School of Medicine, Showa University, Tokyo 142-8555, Japan.'}, {'ForeName': 'Mana', 'Initials': 'M', 'LastName': 'Tsukada', 'Affiliation': 'Department of Physiology, School of Medicine, Showa University, Tokyo 142-8555, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Sato', 'Affiliation': 'Department of Neurosurgery, School of Medicine, Showa University, Tokyo 142-8666, Japan.'}, {'ForeName': 'Takuji', 'Initials': 'T', 'LastName': 'Izuno', 'Affiliation': 'Department of Physiology, School of Medicine, Showa University, Tokyo 142-8555, Japan.'}, {'ForeName': 'Tatsuki', 'Initials': 'T', 'LastName': 'Inoue', 'Affiliation': 'Department of Physiology, School of Medicine, Showa University, Tokyo 142-8555, Japan.'}, {'ForeName': 'Yoshiki', 'Initials': 'Y', 'LastName': 'Tsunokawa', 'Affiliation': 'Department of Physiology, School of Medicine, Showa University, Tokyo 142-8555, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Okumo', 'Affiliation': 'Department of Physiology, School of Medicine, Showa University, Tokyo 142-8555, Japan.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Hisamitsu', 'Affiliation': 'Department of Physiology, School of Medicine, Showa University, Tokyo 142-8555, Japan.'}, {'ForeName': 'Masataka', 'Initials': 'M', 'LastName': 'Sunagawa', 'Affiliation': 'Department of Physiology, School of Medicine, Showa University, Tokyo 142-8555, Japan.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare9070909'] 2021,34356237,Influence of Lisdexamfetamine Dimesylate on Early Ejaculation-Results from a Double-Blind Randomized Clinical Trial.,"BACKGROUND Among male sexual dysfunctions, erectile dysfunction and early ejaculation have the highest prevalence rates. Here, we tested the influence of lisdexamfetamine dimesylate (Vyas ® ) on early ejaculation. To this end, we performed a double-blind randomized clinical trial among males with early ejaculation. METHODS A total of 46 males with early ejaculation (mean age: 35.23 years) and in stable marital relationships with regular weekly penile-vaginal intercourse were randomly assigned either to the lisdexamfetamine dimesylate condition (30 mg) or to the placebo condition. Compounds were taken about six hours before intended penile-vaginal intercourse. At baseline and four weeks later at the end of the study, participants completed a series of self-rating questionnaires covering early ejaculation. Female partners also rated participants' early ejaculation profile. RESULTS Compared to the placebo condition, dimensions of early ejaculation improved over time in the lisdexamfetamine condition, though improvements were also observed in the placebo condition. CONCLUSIONS Among male adults in stable marital relationships with regular weekly penile-vaginal intercourse, lisdexamfetamine dimesylate improved dimensions of early ejaculation. Given that improvements were also observed in the placebo condition, psychological factors such as increased attention to early ejaculation and favorable expectations of the compound should be considered.",2021,"Compared to the placebo condition, dimensions of early ejaculation improved over time in the lisdexamfetamine condition, though improvements were also observed in the placebo condition. ","['males with early ejaculation', 'male adults in stable marital relationships with regular weekly penile-vaginal intercourse', '46 males with early ejaculation (mean age: 35.23 years) and in stable marital relationships with regular weekly penile-vaginal intercourse', ""Female partners also rated participants' early ejaculation profile""]","['lisdexamfetamine dimesylate condition', 'placebo condition', 'lisdexamfetamine dimesylate', 'lisdexamfetamine dimesylate (Vyas ® ', 'placebo', 'Lisdexamfetamine Dimesylate']",['dimensions of early ejaculation'],"[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0013746', 'cui_str': 'Ejaculation'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0024818', 'cui_str': 'Marital Relationship'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0030851', 'cui_str': 'Penile structure'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}]","[{'cui': 'C1739826', 'cui_str': 'Lisdexamfetamine dimesylate'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0013746', 'cui_str': 'Ejaculation'}]",46.0,0.302538,"Compared to the placebo condition, dimensions of early ejaculation improved over time in the lisdexamfetamine condition, though improvements were also observed in the placebo condition. ","[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Haghighi', 'Affiliation': 'Behavioral Disorders and Substance Abuse Research Center, Hamadan University of Medical Sciences, Hamadan 6516848741, Iran.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Doostizadeh', 'Affiliation': 'Behavioral Disorders and Substance Abuse Research Center, Hamadan University of Medical Sciences, Hamadan 6516848741, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Jahangard', 'Affiliation': 'Behavioral Disorders and Substance Abuse Research Center, Hamadan University of Medical Sciences, Hamadan 6516848741, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Soltanian', 'Affiliation': 'Modeling of Non-Communicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan 6516848741, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Faryadres', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan 6516848741, Iran.'}, {'ForeName': 'Kenneth M', 'Initials': 'KM', 'LastName': 'Dürsteler', 'Affiliation': 'Psychiatric Clinics, Division of Substance Use Disorders, University of Basel, 4002 Basel, Switzerland.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Beatrix Brühl', 'Affiliation': 'Center for Affective, Stress and Sleep Disorders (ZASS), Psychiatric University Hospital Basel, 4002 Basel, Switzerland.'}, {'ForeName': 'Dena', 'Initials': 'D', 'LastName': 'Sadeghi-Bahmani', 'Affiliation': 'Center for Affective, Stress and Sleep Disorders (ZASS), Psychiatric University Hospital Basel, 4002 Basel, Switzerland.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Brand', 'Affiliation': 'Center for Affective, Stress and Sleep Disorders (ZASS), Psychiatric University Hospital Basel, 4002 Basel, Switzerland.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare9070859'] 2022,34356122,Rekindling Action Language: A Neuromodulatory Study on Parkinson's Disease Patients.,"Impairments of action semantics (a cognitive domain that critically engages motor brain networks) are pervasive in early Parkinson's disease (PD). However, no study has examined whether action semantic skills in persons with this disease can be influenced by non-invasive neuromodulation. Here, we recruited 22 PD patients and performed a five-day randomized, blinded, sham-controlled study to assess whether anodal transcranial direct current stimulation (atDCS) over the primary motor cortex, combined with cognitive training, can boost action-concept processing. On day 1, participants completed a picture-word association (PWA) task involving action-verb and object-noun conditions. They were then randomly assigned to either an atDCS ( n = 11, 2 mA for 20 m) or a sham tDCS ( n = 11, 2 mA for 30 s) group and performed an online PWA practice over three days. On day 5, they repeated the initial protocol. Relative to sham tDCS, the atDCS group exhibited faster reaction times for action (as opposed to object) concepts in the post-stimulation test. This result was exclusive to the atDCS group and held irrespective of the subjects' cognitive, executive, and motor skills, further attesting to its specificity. Our findings suggest that action-concept deficits in PD are distinctively grounded in motor networks and might be countered by direct neuromodulation of such circuits. Moreover, they provide new evidence for neurosemantic models and inform a thriving agenda in the embodied cognition framework.",2021,"Relative to sham tDCS, the atDCS group exhibited faster reaction times for action (as opposed to object) concepts in the post-stimulation test.","['Rekindling Action Language', '22 PD patients', ""Parkinson's Disease Patients"", ""early Parkinson's disease (PD""]","['anodal transcranial direct current stimulation (atDCS) over the primary motor cortex, combined with cognitive training, can boost action-concept processing', 'sham tDCS', 'picture-word association (PWA) task involving action-verb and object-noun conditions', 'atDCS']",['action semantic skills'],"[{'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C3495441', 'cui_str': 'Precentral Motor Cortex'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0036612', 'cui_str': 'Semantics'}]",,0.0842019,"Relative to sham tDCS, the atDCS group exhibited faster reaction times for action (as opposed to object) concepts in the post-stimulation test.","[{'ForeName': 'Diana M A', 'Initials': 'DMA', 'LastName': 'Suárez-García', 'Affiliation': 'Facultad de Psicología, Universidad del Valle, Santiago de Cali 76001, Colombia.'}, {'ForeName': 'Agustina', 'Initials': 'A', 'LastName': 'Birba', 'Affiliation': 'Cognitive Neuroscience Center (CNC), Universidad de San Andrés, Buenos Aires B1644BID, Argentina.'}, {'ForeName': 'Máximo', 'Initials': 'M', 'LastName': 'Zimerman', 'Affiliation': 'Cognitive Neuroscience Center (CNC), Universidad de San Andrés, Buenos Aires B1644BID, Argentina.'}, {'ForeName': 'Jesús A', 'Initials': 'JA', 'LastName': 'Diazgranados', 'Affiliation': 'Centro Médico de Atención Neurológica ""Neurólogos de Occidente"", Santiago de Cali 76001, Colombia.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Lopes da Cunha', 'Affiliation': 'Cognitive Neuroscience Center (CNC), Universidad de San Andrés, Buenos Aires B1644BID, Argentina.'}, {'ForeName': 'Agustín', 'Initials': 'A', 'LastName': 'Ibáñez', 'Affiliation': 'Cognitive Neuroscience Center (CNC), Universidad de San Andrés, Buenos Aires B1644BID, Argentina.'}, {'ForeName': 'Johan S', 'Initials': 'JS', 'LastName': 'Grisales-Cárdenas', 'Affiliation': 'Facultad de Psicología, Universidad del Valle, Santiago de Cali 76001, Colombia.'}, {'ForeName': 'Juan Felipe', 'Initials': 'JF', 'LastName': 'Cardona', 'Affiliation': 'Facultad de Psicología, Universidad del Valle, Santiago de Cali 76001, Colombia.'}, {'ForeName': 'Adolfo M', 'Initials': 'AM', 'LastName': 'García', 'Affiliation': 'Cognitive Neuroscience Center (CNC), Universidad de San Andrés, Buenos Aires B1644BID, Argentina.'}]",Brain sciences,['10.3390/brainsci11070887'] 2023,34356038,"Effect of robotic-assisted gait training on functional status, walking and quality of life in complete spinal cord injury.","The purpose of this study was to investigate the effect of robotic-assisted gait training (RAGT) on functional status and the quality of life in patients with subacute complete spinal cord injury (SCI). Thirty-seven patients with complete SCI were included in this study. All patients underwent conventional rehabilitation 5 days a week for 8 weeks. The patients were divided into two groups: those who received RAGT (group I, n = 17) and those who received only conventional rehabilitation (group II, n = 20) for 30 min twice a week for a total of 8 weeks. Evaluations were performed using the Walking Index SCI II (WISCI II) for ambulation, Functional Independence Measure (FIM) for functional status and Short Form 36 (SF-36) for the quality of life at the beginning and end of rehabilitation. The mean duration of injury was 3.5 ± 2.1 months in group I and 3.8 ± 2.6 months in group II (P > 0.05). Significant improvement was observed in both groups as per WISCI II and FIM scores (P < 0.05). However, no significant inter-group difference was noted in pre- and post-treatment FIM and WISCI II change scores (P > 0.05). In groups I and II, there was significant improvement only in physical activity scores of SF-36 compared with baseline scores (P < 0.05); however, other SF-36 subparameter scores did not differ significantly between pre- and post-treatment (P > 0.05). Treatment with RAGT has positive effects on functional independence, ambulation and the quality of life in patients with subacute complete SCI. RAGT combined with conventional therapy in patients with complete SCI may facilitate the improvement of patient condition more than conventional therapy alone.",2021,Significant improvement was observed in both groups as per WISCI II and FIM scores (P < 0.05).,"['patients with subacute complete SCI', 'Thirty-seven patients with complete SCI', 'patients with complete SCI', 'complete spinal cord injury', 'patients with subacute complete spinal cord injury (SCI']","['robotic-assisted gait training', 'RAGT combined with conventional therapy', 'robotic-assisted gait training (RAGT', 'RAGT', 'only conventional rehabilitation', 'conventional rehabilitation']","['mean duration of injury', 'physical activity scores of SF-36', 'functional independence, ambulation and the quality of life', 'SF-36 subparameter scores', 'pre- and post-treatment FIM and WISCI II change scores', 'Walking Index SCI II (WISCI II) for ambulation, Functional Independence Measure (FIM) for functional status and Short Form 36 (SF-36) for the quality of life', 'functional status and the quality of life', 'functional status, walking and quality of life', 'per WISCI II and FIM scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205365', 'cui_str': 'Subacute'}, {'cui': 'C3544168', 'cui_str': 'Complete spinal cord injury'}, {'cui': 'C4319569', 'cui_str': '37'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C4274266', 'cui_str': 'Functional Independence Measure score'}]",37.0,0.00379534,Significant improvement was observed in both groups as per WISCI II and FIM scores (P < 0.05).,"[{'ForeName': 'Çiğdem', 'Initials': 'Ç', 'LastName': 'Çinar', 'Affiliation': 'Physical Medicine and Rehabilitation Department, Physical Medicine and Rehabilitation Training Hospital, Istanbul, Turkey.'}, {'ForeName': 'Mustafa Aziz', 'Initials': 'MA', 'LastName': 'Yildirim', 'Affiliation': ''}, {'ForeName': 'Kadriye', 'Initials': 'K', 'LastName': 'Öneş', 'Affiliation': ''}, {'ForeName': 'Gökşen', 'Initials': 'G', 'LastName': 'Gökşenoğlu', 'Affiliation': ''}]",International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation,['10.1097/MRR.0000000000000486'] 2024,34355950,Eigenstate Entanglement: Crossover from the Ground State to Volume Laws.,"For the typical quantum many-body systems that obey the eigenstate thermalization hypothesis (ETH), we argue that the entanglement entropy of (almost) all energy eigenstates is described by a single crossover function. The ETH implies that the crossover functions can be deduced from subsystem entropies of thermal ensembles and have universal properties. These functions capture the full crossover from the ground-state entanglement regime at low energies and small subsystem size (area or log-area law) to the extensive volume-law regime at high energies or large subsystem size. For critical one-dimensional systems, a universal scaling function follows from conformal field theory and can be adapted for nonlinear dispersions. We use it to also deduce the crossover scaling function for Fermi liquids in d>1 dimensions. The analytical results are complemented by numerics for large noninteracting systems of fermions in d≤3 dimensions and have also been confirmed for bosonic systems and nonintegrable spin chains.",2021,"For critical one-dimensional systems, a universal scaling function follows from conformal field theory and can be adapted for nonlinear dispersions.",['Eigenstate Entanglement'],[],[],[],[],[],,0.0445477,"For critical one-dimensional systems, a universal scaling function follows from conformal field theory and can be adapted for nonlinear dispersions.","[{'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Miao', 'Affiliation': 'Department of Physics, Duke University, Durham, North Carolina 27708, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Barthel', 'Affiliation': 'Department of Physics, Duke University, Durham, North Carolina 27708, USA.'}]",Physical review letters,['10.1103/PhysRevLett.127.040603'] 2025,34354179,Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction.,"For cardiovascular disease prevention, statins alone or combined with ezetimibe have been recommended to achieve low-density lipoprotein cholesterol targets, but their effects on other lipids are less reported. This study was designed to examine lipid changes in subjects with ST-segment elevation myocardial infarction (STEMI) after two highly effective lipid-lowering therapies. Twenty patients with STEMI were randomized to be treated with rosuvastatin 20 mg QD or simvastatin 40 mg combined with ezetimibe 10 mg QD for 30 days. Fasting blood samples were collected on the first day (D1) and after 30 days (D30). Lipidomic analysis was performed using the Lipidyzer platform. Similar classic lipid profile was obtained in both groups of lipid-lowering therapies. However, differences with the lipidomic analysis were observed between D30 and D1 for most of the analyzed classes. Differences were noted with lipid-lowering therapies for lipids such as FA, LPC, PC, PE, CE, Cer, and SM, notably in patients treated with rosuvastatin. Correlation studies between classic lipid profiles and lipidomic results showed different information. These findings seem relevant, due to the involvement of these lipid classes in crucial mechanisms of atherosclerosis, and may account for residual cardiovascular risk.Randomized clinical trial: ClinicalTrials.gov, NCT02428374, registered on 28/09/2014.",2021,"Differences were noted with lipid-lowering therapies for lipids such as FA, LPC, PC, PE, CE, Cer, and SM, notably in patients treated with rosuvastatin.","['Twenty patients with STEMI', 'subjects with ST-segment elevation myocardial infarction (STEMI) after two highly effective lipid-lowering therapies', 'subjects with acute myocardial infarction']","['ezetimibe', 'rosuvastatin', 'rosuvastatin 20\xa0mg QD or simvastatin 40\xa0mg combined with ezetimibe 10\xa0mg QD', 'lipid-lowering therapies']","['Fasting blood samples', 'lipid changes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0585943', 'cui_str': 'Lipid-lowering therapy'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}]","[{'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C5136931', 'cui_str': 'rosuvastatin 20 MG [Ezallor]'}, {'cui': 'C0989916', 'cui_str': 'Simvastatin 40 MG'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1166438', 'cui_str': 'ezetimibe 10 MG'}, {'cui': 'C0585943', 'cui_str': 'Lipid-lowering therapy'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",20.0,0.0932891,"Differences were noted with lipid-lowering therapies for lipids such as FA, LPC, PC, PE, CE, Cer, and SM, notably in patients treated with rosuvastatin.","[{'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Klassen', 'Affiliation': 'Department of Chemistry, Federal University of Sao Paulo (UNIFESP), Diadema, SP, Brazil. aline.klassen@unifesp.br.'}, {'ForeName': 'Andrea Tedesco', 'Initials': 'AT', 'LastName': 'Faccio', 'Affiliation': 'Center for Multiplatform Metabolomics Studies (CEMM), Institute of Chemistry, University of Sao Paulo (USP), Sao Paulo, SP, Brazil.'}, {'ForeName': 'Carolina Raissa Costa', 'Initials': 'CRC', 'LastName': 'Picossi', 'Affiliation': 'Center for Multiplatform Metabolomics Studies (CEMM), Institute of Chemistry, University of Sao Paulo (USP), Sao Paulo, SP, Brazil.'}, {'ForeName': 'Priscilla Bento Matos Cruz', 'Initials': 'PBMC', 'LastName': 'Derogis', 'Affiliation': 'Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Carlos Eduardo', 'Initials': 'CE', 'LastName': 'Dos Santos Ferreira', 'Affiliation': 'Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Aline Soriano', 'Initials': 'AS', 'LastName': 'Lopes', 'Affiliation': 'Department of Chemistry, Federal University of Sao Paulo (UNIFESP), Diadema, SP, Brazil.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Sussulini', 'Affiliation': 'Department of Analytical Chemistry, Laboratory of Bioanalytics and Integrated Omics (LaBIOmics), Institute of Chemistry, University of Campinas (UNICAMP), P.O. Box 6154, Campinas, SP, 13083-970, Brazil.'}, {'ForeName': 'Elisa Castañeda Santa', 'Initials': 'ECS', 'LastName': 'Cruz', 'Affiliation': 'Department of Analytical Chemistry, Laboratory of Bioanalytics and Integrated Omics (LaBIOmics), Institute of Chemistry, University of Campinas (UNICAMP), P.O. Box 6154, Campinas, SP, 13083-970, Brazil.'}, {'ForeName': 'Rafaela Tudela', 'Initials': 'RT', 'LastName': 'Bastos', 'Affiliation': 'Department of Chemistry, Federal University of Sao Paulo (UNIFESP), Diadema, SP, Brazil.'}, {'ForeName': 'Stefanie Caroline', 'Initials': 'SC', 'LastName': 'Fontoura', 'Affiliation': 'Department of Chemistry, Federal University of Sao Paulo (UNIFESP), Diadema, SP, Brazil.'}, {'ForeName': 'Antonio Martins Figueiredo', 'Initials': 'AMF', 'LastName': 'Neto', 'Affiliation': 'Institute of Physics, University of Sao Paulo (USP), Sao Paulo, SP, Brazil.'}, {'ForeName': 'Marina Franco Maggi', 'Initials': 'MFM', 'LastName': 'Tavares', 'Affiliation': 'Center for Multiplatform Metabolomics Studies (CEMM), Institute of Chemistry, University of Sao Paulo (USP), Sao Paulo, SP, Brazil.'}, {'ForeName': 'Maria Cristina', 'Initials': 'MC', 'LastName': 'Izar', 'Affiliation': 'Division of Cardiology, Department of Medicine, Federal University of Sao Paulo (UNIFESP), Rua Loefgren 1350, São Paulo, SP, CEP 04040-001, Brazil.'}, {'ForeName': 'Francisco Antonio Helfenstein', 'Initials': 'FAH', 'LastName': 'Fonseca', 'Affiliation': 'Division of Cardiology, Department of Medicine, Federal University of Sao Paulo (UNIFESP), Rua Loefgren 1350, São Paulo, SP, CEP 04040-001, Brazil. fahfonseca@terra.com.br.'}]",Scientific reports,['10.1038/s41598-021-95455-z'] 2026,34354017,Effectiveness of training physical therapists in pain neuroscience education for patients with chronic spine pain: cluster-randomized trial.,"ABSTRACT Chronic spinal pain poses complex challenges for healthcare around the world and is in need of effective interventions. Pain Neuroscience Education (PNE) is a promising intervention hypothesized to improve pain and disability by changing individuals' beliefs, perceptions and expectations about pain. PNE has shown promise in small, controlled trials when implemented in tightly controlled situations. Exploration of promising interventions through more pragmatic methodologies is a crucial but under-studied step towards improving outcomes in routine clinical care. The purpose was to examine the impact of pragmatic PNE training on clinical outcomes in patients with chronic spine pain.The cluster-randomized clinical trial took place in 45 outpatient PT clinics. Participants included 108 physical therapists (45 clinics, 16 clusters) and 319 patients. Clusters of PT clinics were randomly assigned to either receive training in PNE or no intervention and continue with usual care (UC).We found no significant differences between groups for our primary outcome at 12 weeks, Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function computer adaptive test (CAT), (mean difference = 1.05 [95% CI: -0.73, 2.83], p=0.25). The PNE group demonstrated significant greater improvements in pain self-efficacy at 12 and 2 weeks compared to no intervention [mean difference = 3.65 (95% CI; 0.00 - 7.29), p=0.049 and = 3.08 95% CI: 0.07, - 6.09), p=0.045, respectively]. However, a similar percentage of participants in both control (41.1%) and treatment (44.4%) groups reported having received the treatment per fidelity question (yes or no to pain discussed as a perceived threat) at 2 weeks.Pragmatic PT PNE training and delivery failed to produce significant functional changes in patients with chronic spinal pain but did produce significant improvement in pain self-efficacy over usual care PT.",2021,"The PNE group demonstrated significant greater improvements in pain self-efficacy at 12 and 2 weeks compared to no intervention [mean difference = 3.65 (95% CI; 0.00 - 7.29), p=0.049 and = 3.08 95% CI: 0.07, - 6.09), p=0.045, respectively].","['45 outpatient PT clinics', 'patients with chronic spine pain', 'Clusters of PT clinics', 'patients with chronic spinal pain', 'Participants included 108 physical therapists (45 clinics, 16 clusters) and 319 patients']","['Pragmatic PT PNE training', 'training physical therapists', 'Patient-Reported Outcomes Measurement Information System (PROMIS', 'PNE', 'pragmatic PNE training', 'receive training in PNE or no intervention', 'Pain Neuroscience Education (PNE']","['Physical Function computer adaptive test (CAT', 'pain self-efficacy', 'pain and disability']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0423673', 'cui_str': 'Pain in spine'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}]","[{'cui': 'C3489398', 'cui_str': 'Peripheral neuroepithelioma'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0021428', 'cui_str': 'Information system'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0027910', 'cui_str': 'Neurosciences'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0007366', 'cui_str': 'Catalan language'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0231170', 'cui_str': 'Disability'}]",108.0,0.105829,"The PNE group demonstrated significant greater improvements in pain self-efficacy at 12 and 2 weeks compared to no intervention [mean difference = 3.65 (95% CI; 0.00 - 7.29), p=0.049 and = 3.08 95% CI: 0.07, - 6.09), p=0.045, respectively].","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Lane', 'Affiliation': 'Research Assistant Professor, Department of Physical Therapy & Athletic Training, University of Utah Department of Internal Medicine and Director, Population Health Research Study Design and Biostatistics Center, School of Medicine, University of Utah Biostatistician, Division of Epidemiology, School of Medicine, University of Utah Faculty, Doctor of Physical Therapy Program, Baylor University Department of Physical Therapy, Evidence in Motion, San Antonio, Texas Department of Physical Therapy, Brenau University Distinguished Professor and Associate Dean for Research, College of Health, University of Utah.'}, {'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Magel', 'Affiliation': ''}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Thackeray', 'Affiliation': ''}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Greene', 'Affiliation': ''}, {'ForeName': 'Nora F', 'Initials': 'NF', 'LastName': 'Fino', 'Affiliation': ''}, {'ForeName': 'Emilio J', 'Initials': 'EJ', 'LastName': 'Puentedura', 'Affiliation': ''}, {'ForeName': 'Adriaan', 'Initials': 'A', 'LastName': 'Louw', 'Affiliation': ''}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Maddox', 'Affiliation': ''}, {'ForeName': 'Julie M', 'Initials': 'JM', 'LastName': 'Fritz', 'Affiliation': ''}]",Pain,['10.1097/j.pain.0000000000002436'] 2027,34353477,"Effects of Empagliflozin Treatment on Cardiac Biomarkers in Adults With Metabolically Healthy Obesity: Results From a Randomized, Placebo-Controlled Clinical Trial.",,2021,,['Adults With Metabolically Healthy Obesity'],"['Placebo', 'Empagliflozin']",['Cardiac Biomarkers'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4042861', 'cui_str': 'Metabolically Benign Obesity'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",,0.259627,,"[{'ForeName': 'Sadiya S', 'Initials': 'SS', 'LastName': 'Khan', 'Affiliation': 'Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.'}, {'ForeName': 'Anubha', 'Initials': 'A', 'LastName': 'Agarwal', 'Affiliation': 'Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.'}, {'ForeName': 'Colby R', 'Initials': 'CR', 'LastName': 'Ayers', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Eunsook', 'Initials': 'E', 'LastName': 'Jin', 'Affiliation': 'Advanced Imaging Research Center and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Ian J', 'Initials': 'IJ', 'LastName': 'Neeland', 'Affiliation': 'University Hospitals Harrington Heart and Vascular Institute and Case Western Reserve University School of Medicine, Cleveland, OH.'}]",Mayo Clinic proceedings,['10.1016/j.mayocp.2021.06.012'] 2028,34353410,"The effects of selenium supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy: a randomised, double-blind, placebo-controlled trial - Expression of concern.",,2021,,['patients with diabetic nephropathy'],"['selenium supplementation', 'placebo']",['biomarkers of inflammation and oxidative stress'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011881', 'cui_str': 'Kidney disorder due to diabetes mellitus'}]","[{'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}]",,0.811313,,"[{'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': ''}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Kia', 'Affiliation': ''}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Soleimani', 'Affiliation': ''}, {'ForeName': 'Ali Akbar', 'Initials': 'AA', 'LastName': 'Mohammadi', 'Affiliation': ''}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': ''}]",The British journal of nutrition,['10.1017/S000711452100204X'] 2029,34353393,"Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial - Expression of concern.",,2021,,['patients with rheumatoid arthritis'],"['placebo', 'Synbiotic supplementation']",['clinical and metabolic responses'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}]",,0.95052,,"[{'ForeName': 'Batol', 'Initials': 'B', 'LastName': 'Zamani', 'Affiliation': ''}, {'ForeName': 'Shima', 'Initials': 'S', 'LastName': 'Farshbaf', 'Affiliation': ''}, {'ForeName': 'Hamid R', 'Initials': 'HR', 'LastName': 'Golkar', 'Affiliation': ''}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': ''}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': ''}]",The British journal of nutrition,['10.1017/S0007114521002051'] 2030,34353389,"Effects of magnesium supplementation on carotid intima-media thickness and metabolic profiles in diabetic haemodialysis patients: a randomised, double-blind, placebo-controlled trial - Expression of concern.",,2021,,['diabetic haemodialysis patients'],"['placebo', 'magnesium supplementation']",['carotid intima-media thickness and metabolic profiles'],"[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1096534', 'cui_str': 'Magnesium supplement therapy'}]","[{'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}]",,0.891231,,"[{'ForeName': 'Hamid Reza', 'Initials': 'HR', 'LastName': 'Talari', 'Affiliation': ''}, {'ForeName': 'Mehrafrouz', 'Initials': 'M', 'LastName': 'Zakizade', 'Affiliation': ''}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Soleimani', 'Affiliation': ''}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': ''}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Ghaderi', 'Affiliation': ''}, {'ForeName': 'Naghmeh', 'Initials': 'N', 'LastName': 'Mirhosseini', 'Affiliation': ''}, {'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Eslahi', 'Affiliation': ''}, {'ForeName': 'Mahtab', 'Initials': 'M', 'LastName': 'Babadi', 'Affiliation': ''}, {'ForeName': 'Mohammad Ali', 'Initials': 'MA', 'LastName': 'Mansournia', 'Affiliation': ''}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': ''}]",The British journal of nutrition,['10.1017/S0007114521002440'] 2031,34353386,"Selenium supplementation lowers insulin resistance and markers of cardio-metabolic risk in patients with congestive heart failure: a randomised, double-blind, placebo-controlled trial - Expression of concern.",,2021,,['patients with congestive heart failure'],"['Selenium supplementation', 'placebo']",['insulin resistance and markers of cardio-metabolic risk'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}]","[{'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.928838,,"[{'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Raygan', 'Affiliation': ''}, {'ForeName': 'Milad', 'Initials': 'M', 'LastName': 'Behnejad', 'Affiliation': ''}, {'ForeName': 'Vahidreza', 'Initials': 'V', 'LastName': 'Ostadmohammadi', 'Affiliation': ''}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': ''}, {'ForeName': 'Mohammad A', 'Initials': 'MA', 'LastName': 'Mansournia', 'Affiliation': ''}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Karamali', 'Affiliation': ''}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': ''}]",The British journal of nutrition,['10.1017/S0007114521002063'] 2032,34353382,"The favorable effects of long-term selenium supplementation on regression of cervical tissues and metabolic profiles of patients with cervical intraepithelial neoplasia: a randomised, double-blind, placebo-controlled trial - Expression of concern.",,2021,,['patients with cervical intraepithelial neoplasia'],"['selenium supplementation', 'placebo']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206708', 'cui_str': 'Cervical intraepithelial neoplasia'}]","[{'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.757916,,"[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Karamali', 'Affiliation': ''}, {'ForeName': 'Sepideh', 'Initials': 'S', 'LastName': 'Nourgostar', 'Affiliation': ''}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Zamani', 'Affiliation': ''}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Vahedpoor', 'Affiliation': ''}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': ''}]",The British journal of nutrition,['10.1017/S0007114521002014'] 2033,34357857,Procalcitonin kinetics to guide sequential invasive-noninvasive mechanical ventilation weaning in patients with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure: procalcitonin's adjunct role.,"How to identify the optimum switch point of sequential invasive and noninvasive ventilation is the focus of clinical attention on the patients suffering from acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated by acute respiratory failure (ARF). This study aims to explore the clinical significance of taking the change rate of procalcitonin (PCT) as identifying the timing of weaning on the mechanical ventilation for the patients of AECOPD followed by ARF as a complication. There were altogether 140 patients of AECOPD complicated with ARF, who were randomly selected and divided into a study group and a control group respectively. A change rate of serum PCT level exceeding 50% was taken as the switch point selection of tracheal intubation removal for the patients of the study group, while the 'pulmonary infection control (PIC) window' was done for those in the control group. With CRP, IL-6, TNF-a, PaCO 2, PaO 2, and Lac having been detected before and after treatment to them all, clinical indexes were obtained and compared between these two groups. The CRP, TNF-a, and IL-6 levels of the patients in the study group after treatment ( p < 0.05 ) were lower than those in the control group. There was no significant difference in PaCO 2, PaO 2, and Lac between these two groups before and after treatment ( p > 0.05 ). Even so, some other indexes available for the study group of patients were found to be lower than those for the control group ( p < 0.05 ) in the following aspects: duration of invasive ventilation support, total time of mechanical ventilation support, incidence rate of ventilator-associated pneumonia, 48-hour reintubation rate, incidence rate of upper gastrointestinal bleeding, hospitalization time of critical respiratory illness, total hospitalization time, RICU treatment cost, total treatment cost, and mortality. It is preferable to take the change rate of PCT level exceeding 50% as the switch point of weaning time in sequential mechanical ventilation rather than the PIC window. AbbreviationsAECOPD: acute exacerbation of chronic obstructive pulmonary disease; ARF: acute respiratory failure; PCT: procalcitonin; PaO 2 : the oxygen partial pressure; PaCO 2 : the partial pressure of carbon dioxide; TNF-a: serum tumor necrosis factor-a; IL-6: interleukin-6; CRP: serum C-reactive protein; PIC window: pulmonary infection control window; RICU: respiration and intensive care unit.",2021,"There was no significant difference in PaCO 2, PaO 2, and Lac between these two groups before and after treatment ( p > 0.05 ).","['patients suffering from acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated by acute respiratory failure (ARF', '140 patients of AECOPD complicated with ARF', 'patients with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure']","['sequential invasive-noninvasive mechanical ventilation weaning', 'sequential invasive and noninvasive ventilation']","['CRP, TNF-a, and IL-6 levels', 'PaCO 2, PaO 2, and Lac', 'CRP, IL-6, TNF-a, PaCO 2, PaO 2, and Lac having', 'change rate of PCT level', 'duration of invasive ventilation support, total time of mechanical ventilation support, incidence rate of ventilator-associated pneumonia, 48-hour reintubation rate, incidence rate of upper gastrointestinal bleeding, hospitalization time of critical respiratory illness, total hospitalization time, RICU treatment cost, total treatment cost, and mortality', 'serum PCT level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0340044', 'cui_str': 'Acute exacerbation of chronic obstructive airways disease'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0264490', 'cui_str': 'Acute respiratory failure'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C1868982', 'cui_str': 'Noninvasive mechanical ventilation'}, {'cui': 'C0043084', 'cui_str': 'Weaning'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}]","[{'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C1448177', 'cui_str': 'TNF protein, human'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1535922', 'cui_str': 'Procalcitonin'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0860359', 'cui_str': 'Reintubate'}, {'cui': 'C0041909', 'cui_str': 'Upper gastrointestinal bleeding'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0087112', 'cui_str': 'Treatment Costs'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.109374,"There was no significant difference in PaCO 2, PaO 2, and Lac between these two groups before and after treatment ( p > 0.05 ).","[{'ForeName': 'Shao-Hua', 'Initials': 'SH', 'LastName': 'Lin', 'Affiliation': 'Department of Infectious Diseases, Rongcheng Hospital Affiliated to Shandong First Medical University, Rongcheng, P.R.China.'}, {'ForeName': 'Ying-Ping', 'Initials': 'YP', 'LastName': 'He', 'Affiliation': 'Department of Human Resources, Rongcheng Hospital Affiliated to Shandong First Medical University, Rongcheng, P.R.China.'}, {'ForeName': 'Jun-Jie', 'Initials': 'JJ', 'LastName': 'Lian', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Rongcheng Hospital Affiliated to Shandong First Medical University, Rongcheng, P.R.China.'}, {'ForeName': 'Cun-Kun', 'Initials': 'CK', 'LastName': 'Chu', 'Affiliation': 'Library Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, P.R.China.'}]",The Libyan journal of medicine,['10.1080/19932820.2021.1961382'] 2034,34357781,E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.,"PURPOSE Endocrine therapy resistance in advanced breast cancer remains a significant clinical problem that may be overcome with the use of histone deacetylase inhibitors such as entinostat. The ENCORE301 phase II study reported improvement in progression-free survival (PFS) and overall survival (OS) with the addition of entinostat to the steroidal aromatase inhibitor (AI) exemestane in advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. PATIENTS AND METHODS E2112 is a multicenter, randomized, double-blind, placebo-controlled phase III study that enrolled men or women with advanced HR-positive, HER2-negative breast cancer whose disease progressed after nonsteroidal AI. Participants were randomly assigned to exemestane 25 mg by mouth once daily and entinostat (EE) or placebo (EP) 5 mg by mouth once weekly. Primary end points were PFS by central review and OS. Secondary end points included safety, objective response rate, and lysine acetylation change in peripheral blood mononuclear cells between baseline and cycle 1 day 15. RESULTS Six hundred eight patients were randomly assigned during March 2014-October 2018. Median age was 63 years (range 29-91), 60% had visceral disease, and 84% had progressed after nonsteroidal AI in metastatic setting. Previous treatments included chemotherapy (60%), fulvestrant (30%), and cyclin-dependent kinase inhibitor (35%). Most common grade 3 and 4 adverse events in the EE arm included neutropenia (20%), hypophosphatemia (14%), anemia (8%), leukopenia (6%), fatigue (4%), diarrhea (4%), and thrombocytopenia (3%). Median PFS was 3.3 months (EE) versus 3.1 months (EP; hazard ratio = 0.87; 95% CI, 0.67 to 1.13; P = .30). Median OS was 23.4 months (EE) versus 21.7 months (EP; hazard ratio = 0.99; 95% CI, 0.82 to 1.21; P = .94). Objective response rate was 5.8% (EE) and 5.6% (EP). Pharmacodynamic analysis confirmed target inhibition in entinostat-treated patients. CONCLUSION The combination of exemestane and entinostat did not improve survival in AI-resistant advanced HR-positive, HER2-negative breast cancer.",2021,"Median OS was 23.4 months (EE) versus 21.7 months (EP; hazard ratio = 0.99; 95% CI, 0.82 to 1.21; P = .94).","['Median age was 63 years (range 29-91), 60% had visceral disease, and 84% had progressed after nonsteroidal AI in metastatic setting', 'advanced breast cancer', 'Six hundred eight patients', 'entinostat-treated patients', 'Hormone Receptor-Positive Advanced Breast Cancer', 'enrolled men or women with advanced HR-positive, HER2-negative breast cancer whose disease progressed after nonsteroidal AI']","['steroidal aromatase inhibitor (AI) exemestane', 'fulvestrant', 'exemestane 25 mg by mouth once daily and entinostat (EE) or placebo (EP', 'placebo', 'exemestane', 'Endocrine Therapy Plus Entinostat or Placebo']","['neutropenia', 'Median OS', 'leukopenia', 'Median PFS', 'PFS by central review and OS', 'hypophosphatemia', 'Objective response rate', 'progression-free survival (PFS) and overall survival (OS', 'anemia', 'thrombocytopenia', 'fatigue', 'survival in AI-resistant advanced HR-positive, HER2-negative breast cancer', 'safety, objective response rate, and lysine acetylation change in peripheral blood mononuclear cells', 'diarrhea']","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2743752', 'cui_str': 'entinostat'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0851344', 'cui_str': 'exemestane'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C1125968', 'cui_str': 'exemestane 25 MG'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C2743752', 'cui_str': 'entinostat'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0085682', 'cui_str': 'Hypophosphatemia'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0024337', 'cui_str': 'Lysine'}, {'cui': 'C0001038', 'cui_str': 'Acetylation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",608.0,0.474629,"Median OS was 23.4 months (EE) versus 21.7 months (EP; hazard ratio = 0.99; 95% CI, 0.82 to 1.21; P = .94).","[{'ForeName': 'Roisin M', 'Initials': 'RM', 'LastName': 'Connolly', 'Affiliation': 'The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.'}, {'ForeName': 'Fengmin', 'Initials': 'F', 'LastName': 'Zhao', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Kathy D', 'Initials': 'KD', 'LastName': 'Miller', 'Affiliation': 'Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.'}, {'ForeName': 'Min-Jung', 'Initials': 'MJ', 'LastName': 'Lee', 'Affiliation': 'Center for Cancer Research, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Richard L', 'Initials': 'RL', 'LastName': 'Piekarz', 'Affiliation': 'Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Smith', 'Affiliation': 'The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.'}, {'ForeName': 'Ursa A', 'Initials': 'UA', 'LastName': 'Brown-Glaberman', 'Affiliation': 'University of New Mexico Cancer Center, Albuquerque, NM.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Winn', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, PA.'}, {'ForeName': 'Bryan A', 'Initials': 'BA', 'LastName': 'Faller', 'Affiliation': 'Heartland NCORP, Missouri Baptist Medical Centre, Saint Louis, MO.'}, {'ForeName': 'Adedayo A', 'Initials': 'AA', 'LastName': 'Onitilo', 'Affiliation': 'Marshfield Clinic, Marshfield, WI.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Burkard', 'Affiliation': 'University of Wisconsin Carbone Cancer Center, Madison, WI.'}, {'ForeName': 'George T', 'Initials': 'GT', 'LastName': 'Budd', 'Affiliation': 'Cleveland Clinic Foundation, Cleveland, OH.'}, {'ForeName': 'Ellis G', 'Initials': 'EG', 'LastName': 'Levine', 'Affiliation': 'Roswell Park Cancer Institute, Buffalo, NY.'}, {'ForeName': 'Melanie E', 'Initials': 'ME', 'LastName': 'Royce', 'Affiliation': 'New Mexico MU-NCORP, Albuquerque, NM.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Kaufman', 'Affiliation': 'University of Vermont Cancer Center, Burlington, VT.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Thomas', 'Affiliation': 'Wake Forest University, Winston Salem, NC.'}, {'ForeName': 'Jane B', 'Initials': 'JB', 'LastName': 'Trepel', 'Affiliation': 'Center for Cancer Research, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Antonio C', 'Initials': 'AC', 'LastName': 'Wolff', 'Affiliation': 'The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Sparano', 'Affiliation': 'Montefiore Medical Center, New York, NY.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.21.00944'] 2035,34363051,Home-based transcutaneous electrical acupoint stimulation for hypertension: a randomized controlled pilot trial.,"The aim of this trial was to evaluate the feasibility and effect of home-based transcutaneous electrical acupoint stimulation (TEAS) in patients with hypertension. In this randomized pilot trial, patients with hypertension were randomly assigned to the TEAS group or the usual care group. Participants in the usual care group were instructed to continue taking their antihypertensive drugs and received education on lifestyle modifications. In addition, participants in the TEAS group received 4 weekly sessions of noninvasive acupoint stimulation for 12 weeks at home. The primary outcome was the change in office systolic blood pressure at week 12 from baseline. Withdrawal from the study and adverse events associated with TEAS were also recorded. Sixty patients were randomized, with 30 patients in the TEAS group, of whom 1 was lost at week 36, and 30 patients in the usual care group, of whom 3 were lost by week 12. The reduction in systolic blood pressure at week 12 was greater in the TEAS group (-8.53 mm Hg; 95% CI [-13.37, -3.70 mm Hg]) than in the usual care group (-1.70 mm Hg; 95% CI [-4.29, -0.89 mm Hg]), with a between-group difference of -6.83 mm Hg (95% CI, [-12.23, -1.43 mm Hg]; P = 0.014). No TEAS-related adverse events occurred. In conclusion, home-based TEAS added to usual care for patients with hypertension was acceptable and safe and may be a potential treatment option. A larger randomized controlled trial of this intervention is warranted.",2021,"The reduction in systolic blood pressure at week 12 was greater in the TEAS group (-8.53 mm Hg; 95% CI [-13.37, -3.70 mm Hg]) than in the usual care group (-1.70 mm Hg; 95% CI [-4.29, -0.89 mm Hg]), with a between-group difference of -6.83 mm Hg (95% CI, [-12.23, -1.43 mm Hg]; P = 0.014).","['Sixty patients were randomized, with 30 patients in the TEAS group, of whom 1 was lost at week 36, and 30 patients in the usual care group, of whom 3 were lost by week 12', 'hypertension', 'patients with hypertension']","['continue taking their antihypertensive drugs and received education on lifestyle modifications', 'Home-based transcutaneous electrical acupoint stimulation', 'home-based transcutaneous electrical acupoint stimulation (TEAS', 'noninvasive acupoint stimulation', 'usual care group', 'TEAS']","['systolic blood pressure', 'change in office systolic blood pressure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0442603', 'cui_str': 'Office'}]",60.0,0.036338,"The reduction in systolic blood pressure at week 12 was greater in the TEAS group (-8.53 mm Hg; 95% CI [-13.37, -3.70 mm Hg]) than in the usual care group (-1.70 mm Hg; 95% CI [-4.29, -0.89 mm Hg]), with a between-group difference of -6.83 mm Hg (95% CI, [-12.23, -1.43 mm Hg]; P = 0.014).","[{'ForeName': 'Jian-Feng', 'Initials': 'JF', 'LastName': 'Tu', 'Affiliation': 'Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Dongcheng District, Beijing, China.'}, {'ForeName': 'Li-Qiong', 'Initials': 'LQ', 'LastName': 'Wang', 'Affiliation': 'International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Chaoyang District, Beijing, China.'}, {'ForeName': 'Jun-Hong', 'Initials': 'JH', 'LastName': 'Liu', 'Affiliation': 'Nanyuan Community Health Service Center, Fengtai District, Beijing, China.'}, {'ForeName': 'You-Sheng', 'Initials': 'YS', 'LastName': 'Qi', 'Affiliation': 'Nanyuan Community Health Service Center, Fengtai District, Beijing, China.'}, {'ForeName': 'Zhong-Xue', 'Initials': 'ZX', 'LastName': 'Tian', 'Affiliation': 'International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Chaoyang District, Beijing, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Chaoyang District, Beijing, China.'}, {'ForeName': 'Jing-Wen', 'Initials': 'JW', 'LastName': 'Yang', 'Affiliation': 'International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Chaoyang District, Beijing, China.'}, {'ForeName': 'Guang-Xia', 'Initials': 'GX', 'LastName': 'Shi', 'Affiliation': 'International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Chaoyang District, Beijing, China.'}, {'ForeName': 'Si-Bo', 'Initials': 'SB', 'LastName': 'Kang', 'Affiliation': 'International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Chaoyang District, Beijing, China.'}, {'ForeName': 'Cun-Zhi', 'Initials': 'CZ', 'LastName': 'Liu', 'Affiliation': 'Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Dongcheng District, Beijing, China. lcz623780@126.com.'}]",Hypertension research : official journal of the Japanese Society of Hypertension,['10.1038/s41440-021-00702-5'] 2036,34362859,An Examination of the Relationship Between Perfectionism and Neurological Functioning.,"Clinical perfectionism is the rigid pursuit of high standards, interfering with functioning. Little research has explored neural patterns in clinical perfectionism. The present study explores neural correlates of clinical perfectionism, before and after receiving ten 50-minute, weekly sessions of acceptance and commitment therapy (ACT), as compared to low-perfectionist controls, in specific cortical structures: the dorsolateral prefrontal cortex (DLPFC), medial prefrontal cortex (MPFC), right inferior parietal lobule (IPL). Participants in the perfectionist condition ( n = 43) were from a randomized controlled trial evaluating ACT for clinical perfectionism and low-perfectionist controls were undergraduate students ( n = 12). Participants completed three tasks (editing a passage, mirror image tracing, circle tracing) using functional near-infrared spectroscopy (fNIRS) to measure neural activation. Results indicate that ḥin the DLPFC and MPFC of the perfectionists whereas activation in the other tasks were relatively similar. There were no differences were observed in the right DLPFC, MPFC, and right IPL between the posttreatment perfectionist and nonperfectionist control groups. Our findings suggest an unclear relationship between neural activation and perfectionism.",2021,"There were no differences were observed in the right DLPFC, MPFC, and right IPL between the posttreatment perfectionist and nonperfectionist control groups.","['Participants in the perfectionist condition ( n = 43', 'for clinical perfectionism and low-perfectionist controls were undergraduate students ( n = 12']","['acceptance and commitment therapy (ACT', 'ACT']","['dorsolateral prefrontal cortex (DLPFC), medial prefrontal cortex (MPFC), right inferior parietal lobule (IPL', 'right DLPFC, MPFC, and right IPL']","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0152304', 'cui_str': 'Inferior parietal lobule structure'}]",43.0,0.064704,"There were no differences were observed in the right DLPFC, MPFC, and right IPL between the posttreatment perfectionist and nonperfectionist control groups.","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Petersen', 'Affiliation': 'Utah State University, Old Main Hill, Logan, UT Julie.Petersen@aggiemail.usu.edu.'}, {'ForeName': 'Clarissa W', 'Initials': 'CW', 'LastName': 'Ong', 'Affiliation': 'Utah State University, Old Main Hill, Logan, UT.'}, {'ForeName': 'Allison S', 'Initials': 'AS', 'LastName': 'Hancock', 'Affiliation': 'Utah State University, Old Main Hill, Logan, UT.'}, {'ForeName': 'Ronald B', 'Initials': 'RB', 'LastName': 'Gillam', 'Affiliation': 'Utah State University, Old Main Hill, Logan, UT.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Levin', 'Affiliation': 'Utah State University, Old Main Hill, Logan, UT.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Twohig', 'Affiliation': 'Utah State University, Old Main Hill, Logan, UT.'}]",Journal of cognitive psychotherapy,['10.1891/JCPSY-D-20-00037'] 2037,34362762,Automatic versus manual oxygen titration using a novel nasal high-flow device in medical inpatients with an acute illness: a randomised controlled trial.,"BACKGROUND Guideline recommendations state oxygen should be administered to acutely unwell patients to achieve a target oxygen saturation (SpO 2 ) range. The current practice of manual oxygen titration frequently results in SpO 2 outside of a prescribed range. The aim of this study was to assess the efficacy of automatic oxygen titration using a closed-loop feedback system to achieve SpO 2 within a prescribed target range METHODS: An open-label randomised parallel group trial was undertaken comparing automatic oxygen titration using a novel nasal high-flow device to manual oxygen titration using nasal high flow. Medical inpatients requiring oxygen therapy in Wellington Regional Hospital, New Zealand with a prescribed target SpO 2 range of 88%-92% or 92%-96% were recruited and randomised equally between the interventions for a period of 24 hours. The primary outcome was the proportion of time spent with SpO 2 within the prescribed range. RESULTS 20 patients were included in the analysis. Automatic oxygen titration resulted in a median (IQR) 96.2% (95.2-97.8) of time within the target range compared with 71% (59.4-88.3) with manual titration; difference (95% CI) 24.2% (7.9% to 35%), p<0.001. There was a reduction in the time spent with SpO 2 ≥2% above and ≥2% below range in the automatic titration group, although the point estimate for the differences were small; -1% (-8.2% to -0.04%), p=0.017 and -2.4% (-11.5% to 0.3%), p=0.05 respectively. CONCLUSIONS Nasal high-flow with automatic oxygen titration resulted in a greater proportion of time spent with SpO 2 in target range compared with manual titration. TRIAL REGISTRATION The trial was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12619000901101).",2021,"Automatic oxygen titration resulted in a median (IQR) 96.2% (95.2-97.8) of time within the target range compared with 71% (59.4-88.3) with manual titration; difference (95% CI) 24.2% (7.9% to 35%), p<0.001.","['20 patients were included in the analysis', 'medical inpatients with an acute illness', 'Medical inpatients requiring oxygen therapy in Wellington Regional Hospital, New Zealand with a prescribed target SpO 2 range of 88%-92% or 92%-96']","['automatic oxygen titration', 'novel nasal high-flow device to manual oxygen titration', 'Automatic versus manual oxygen titration using a novel nasal high-flow device']","['Automatic oxygen titration', 'proportion of time spent with SpO 2 within the prescribed range', 'time spent with SpO']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0453965', 'cui_str': 'Gum boots'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]",20.0,0.189285,"Automatic oxygen titration resulted in a median (IQR) 96.2% (95.2-97.8) of time within the target range compared with 71% (59.4-88.3) with manual titration; difference (95% CI) 24.2% (7.9% to 35%), p<0.001.","[{'ForeName': 'James', 'Initials': 'J', 'LastName': 'Harper', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand james.harper@mrinz.ac.nz.'}, {'ForeName': 'Nethmi', 'Initials': 'N', 'LastName': 'Kearns', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Bird', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Braithwaite', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Allie', 'Initials': 'A', 'LastName': 'Eathorne', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Shortt', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Weatherall', 'Affiliation': 'University of Otago Wellington, Wellington, New Zealand.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Beasley', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}]",BMJ open respiratory research,['10.1136/bmjresp-2020-000843'] 2038,34362409,The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) program: study protocol for a randomized controlled trial.,"BACKGROUND Community-based diabetes prevention programs varied widely in effectiveness, and the intervention strategy consisting of lifestyle interventions, stepwise addition of metformin, and financial incentives has not been studied in real-world clinical practice settings. The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) trial is a pragmatic trial that aims to compare the effectiveness of a community-based stepwise diabetes prevention program with added financial incentives (intervention) versus the standard of care (control) in reducing the risk of type 2 diabetes over 3 years among overweight or obese individuals with pre-diabetes. METHODS This is an open-label, 1:1 randomized controlled trial which aims to recruit 846 adult individuals with isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT), or both IFG and IGT from Singapore. Intervention arm participants attend 12 group-based sessions (2 nutrition workshops, 9 exercise sessions, and a goal-setting workshop) delivered at community sites (weeks 1 to 6), receive weekly physical activity and nutrition recommendations delivered by printed worksheets (weeks 7 to 12), and receive monthly health tips delivered by text messages (months 4 to 36). From month 6 onwards, intervention arm participants who remain at the highest risk of conversion to diabetes are prescribed metformin. Intervention arm participants are also eligible for a payment/rewards program with incentives tied to attendance at the group sessions and achievement of the weight loss target (5% of baseline weight). All participants are assessed at baseline, month 3, month 6, and every 6 months subsequently till month 36. The primary endpoint is the proportion of participants with diabetes at 3 years. Secondary endpoints include the mean change from baseline at 3 years in fasting plasma glucose, 2-hour plasma glucose, HbA1c, body weight, body mass index, physical activity, and dietary intake. DISCUSSION The Pre-DICTED trial will provide evidence of the effectiveness and feasibility of a community-based stepwise diabetes prevention program with added financial incentives for individuals with pre-diabetes in Singapore. The study will provide data for a future cost-effectiveness analysis, which will be used to inform policymakers of the value of a nationwide implementation of the diabetes prevention program. TRIAL REGISTRATION ClinicalTrials.gov NCT03503942 . Retrospectively registered on April 20, 2018. Protocol version: 5.0 Date: 1 March 2019.",2021,The Pre-DICTED trial will provide evidence of the effectiveness and feasibility of a community-based stepwise diabetes prevention program with added financial incentives for individuals with pre-diabetes in Singapore.,"['type 2 diabetes over 3\u2009years among overweight or obese individuals with', '846 adult individuals with isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT), or both IFG and IGT from Singapore', 'individuals with pre-diabetes in Singapore']","['community-based stepwise diabetes prevention program with added financial incentives (intervention) versus the standard of care (control', 'metformin', 'Intervention arm participants attend 12 group-based sessions (2 nutrition workshops, 9 exercise sessions, and a goal-setting workshop) delivered at community sites (weeks 1 to 6), receive weekly physical activity and nutrition recommendations delivered by printed worksheets (weeks 7 to 12), and receive monthly health tips delivered by text messages', 'community-based stepwise diabetes prevention program with added financial incentives']","['proportion of participants with diabetes at 3\u2009years', 'mean change from baseline at 3\u2009years in fasting plasma glucose, 2-hour plasma glucose, HbA1c, body weight, body mass index, physical activity, and dietary intake']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0151671', 'cui_str': 'Glucose tolerance decreased'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C1272092', 'cui_str': 'Impaired fasting glycaemia'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}]",,0.0652986,The Pre-DICTED trial will provide evidence of the effectiveness and feasibility of a community-based stepwise diabetes prevention program with added financial incentives for individuals with pre-diabetes in Singapore.,"[{'ForeName': 'Kar-Fu', 'Initials': 'KF', 'LastName': 'Yeung', 'Affiliation': 'Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore.'}, {'ForeName': 'Mihir', 'Initials': 'M', 'LastName': 'Gandhi', 'Affiliation': 'Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore.'}, {'ForeName': 'Amanda Yun Rui', 'Initials': 'AYR', 'LastName': 'Lam', 'Affiliation': 'Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.'}, {'ForeName': 'Selly', 'Initials': 'S', 'LastName': 'Julianty', 'Affiliation': 'SingHealth Duke-NUS Diabetes Centre, Singapore, Singapore.'}, {'ForeName': 'Alvin Yeow Meng', 'Initials': 'AYM', 'LastName': 'Chia', 'Affiliation': 'SingHealth Duke-NUS Diabetes Centre, Singapore, Singapore.'}, {'ForeName': 'Gilbert Choon Seng', 'Initials': 'GCS', 'LastName': 'Tan', 'Affiliation': 'SingHealth Duke-NUS Diabetes Centre, Singapore, Singapore.'}, {'ForeName': 'Su-Yen', 'Initials': 'SY', 'LastName': 'Goh', 'Affiliation': 'Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.'}, {'ForeName': 'Emily Tse Lin', 'Initials': 'ETL', 'LastName': 'Ho', 'Affiliation': 'Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.'}, {'ForeName': 'Angela Fang Yung', 'Initials': 'AFY', 'LastName': 'Koh', 'Affiliation': 'SingHealth Duke-NUS Diabetes Centre, Singapore, Singapore.'}, {'ForeName': 'Gavin Siew Wei', 'Initials': 'GSW', 'LastName': 'Tan', 'Affiliation': 'SingHealth Duke-NUS Diabetes Centre, Singapore, Singapore.'}, {'ForeName': 'Eugene Jin Wen', 'Initials': 'EJW', 'LastName': 'Shum', 'Affiliation': 'Regional Health System Office, SingHealth, Singapore, Singapore.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Finkelstein', 'Affiliation': 'Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.'}, {'ForeName': 'Tazeen H', 'Initials': 'TH', 'LastName': 'Jafar', 'Affiliation': 'Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.'}, {'ForeName': 'Yee Leong', 'Initials': 'YL', 'LastName': 'Teoh', 'Affiliation': 'Biostatistics, Singapore Clinical Research Institute, Singapore, Singapore.'}, {'ForeName': 'Rob M', 'Initials': 'RM', 'LastName': 'van Dam', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Whitton', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Thumboo', 'Affiliation': 'Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore.'}, {'ForeName': 'Yong Mong', 'Initials': 'YM', 'LastName': 'Bee', 'Affiliation': 'Department of Endocrinology, Singapore General Hospital, Singapore, Singapore. bee.yong.mong@singhealth.com.sg.'}]",Trials,['10.1186/s13063-021-05500-5'] 2039,34362375,"The effect of educational program based on beliefs, subjective norms and perceived behavior control on doing pap-smear test in sample of Iranian women.","OBJECTIVE Cervical cancer is considered treatable as long as it is detected early and managed effectively. Pap smear test is a screening tool that plays an important role in the early detection, prevention and can prevent any early cervical cell changes from becoming cancer. This study aims to survey the effect of educational programs based on beliefs, subjective norms, and perceived behavior control on doing the pap-smear test in a sample of Iranian women. MATERIALS AND METHODS This experimental interventional study was performed on 300 women admitted to Fasa City, Fars Province, Iran health centers in 2018-2019. A questionnaire consisting of demographic information, knowledge, Health Belief Model, and Theory of Planned Behavior constructs were used to measure on doing of Pap smear test in women before and after 6 months' educational intervention. RESULTS The results revealed that 6 months after the intervention, 108 women (72%) in the experimental group and only 9 women (6%) in the control group received the Pap smear test. CONCLUSIONS The current research results revealed that education based on the combination of the health Belief model and theory of planned behavior might be promoting participation and an increasing rate of receiving Pap smear tests in women.",2021,"Pap smear test is a screening tool that plays an important role in the early detection, prevention and can prevent any early cervical cell changes from becoming cancer.","['Iranian women', 'sample of Iranian women', '300 women admitted to Fasa City, Fars Province, Iran health centers in 2018-2019']","['educational program', 'educational programs']",[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0475309', 'cui_str': 'Health center'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}]",[],300.0,0.0261324,"Pap smear test is a screening tool that plays an important role in the early detection, prevention and can prevent any early cervical cell changes from becoming cancer.","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Khani Jeihooni', 'Affiliation': 'Nutrition Research Center, Department of Public Health, School of Health , Shiraz University of Medical Sciences, Shiraz, Iran. khani_1512@yahoo.com.'}, {'ForeName': 'Hanieh', 'Initials': 'H', 'LastName': 'Jormand', 'Affiliation': 'Department of Health Education and Promotion, School of Health, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Pooyan Afzali', 'Initials': 'PA', 'LastName': 'Harsini', 'Affiliation': 'Department of Public Health, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]",BMC women's health,['10.1186/s12905-021-01419-w'] 2040,34362359,Compliance with medical recommendations depending on the use of artificial intelligence as a diagnostic method.,"BACKGROUND Advanced analytics, such as artificial intelligence (AI), increasingly gain relevance in medicine. However, patients' responses to the involvement of AI in the care process remains largely unclear. The study aims to explore whether individuals were more likely to follow a recommendation when a physician used AI in the diagnostic process considering a highly (vs. less) severe disease compared to when the physician did not use AI or when AI fully replaced the physician. METHODS Participants from the USA (n = 452) were randomly assigned to a hypothetical scenario where they imagined that they received a treatment recommendation after a skin cancer diagnosis (high vs. low severity) from a physician, a physician using AI, or an automated AI tool. They then indicated their intention to follow the recommendation. Regression analyses were used to test hypotheses. Beta coefficients (ß) describe the nature and strength of relationships between predictors and outcome variables; confidence intervals [CI] excluding zero indicate significant mediation effects. RESULTS The total effects reveal the inferiority of automated AI (ß = .47, p = .001 vs. physician; ß = .49, p = .001 vs. physician using AI). Two pathways increase intention to follow the recommendation. When a physician performs the assessment (vs. automated AI), the perception that the physician is real and present (a concept called social presence) is high, which increases intention to follow the recommendation (ß = .22, 95% CI [.09; 0.39]). When AI performs the assessment (vs. physician only), perceived innovativeness of the method is high, which increases intention to follow the recommendation (ß = .15, 95% CI [- .28; - .04]). When physicians use AI, social presence does not decrease and perceived innovativeness increases. CONCLUSION Pairing AI with a physician in medical diagnosis and treatment in a hypothetical scenario using topical therapy and oral medication as treatment recommendations leads to a higher intention to follow the recommendation than AI on its own. The findings might help develop practice guidelines for cases where AI involvement benefits outweigh risks, such as using AI in pathology and radiology, to enable augmented human intelligence and inform physicians about diagnoses and treatments.",2021,"The total effects reveal the inferiority of automated AI (ß = .47,",['Participants from the USA (n\u2009=\u2009452'],"['hypothetical scenario where they imagined that they received a treatment recommendation after a skin cancer diagnosis (high vs. low severity) from a physician, a physician using AI, or an automated AI tool']",[],"[{'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0007114', 'cui_str': 'Malignant neoplasm of skin'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]",[],452.0,0.0253364,"The total effects reveal the inferiority of automated AI (ß = .47,","[{'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Soellner', 'Affiliation': 'Chair of Sport and Health Management, Technical University of Munich, Campus D - Uptown Munich, Georg-Brauchle-Ring 60/62, 80992, Munich, Germany.'}, {'ForeName': 'Joerg', 'Initials': 'J', 'LastName': 'Koenigstorfer', 'Affiliation': 'Chair of Sport and Health Management, Technical University of Munich, Campus D - Uptown Munich, Georg-Brauchle-Ring 60/62, 80992, Munich, Germany. joerg.koenigstorfer@tum.de.'}]",BMC medical informatics and decision making,['10.1186/s12911-021-01596-6'] 2041,34354551,Fuzzy C -Means Clustering Algorithm-Based Magnetic Resonance Imaging Image Segmentation for Analyzing the Effect of Edaravone on the Vascular Endothelial Function in Patients with Acute Cerebral Infarction.,"This paper aimed to discuss the denoising ability of magnetic resonance imaging (MRI) images based on fuzzy C-means clustering (FCM) algorithm and the influence of Butylphthalide combined with Edaravone treatment on nerve function and vascular endothelial function in patients with acute cerebral infarction (ACI). Based on FCM algorithm, Markov Random Field (MRF) model algorithm was introduced to obtain a novel algorithm (NFCM), which was compared with FCM and MRF algorithm in terms of misclassification rate (MCR) and difference of Kappa index (KI). 90 patients with ACI diagnosed in hospital from December 2018 to December 2019 were selected as subjects, who were divided into combined treatment group (conventional treatment + Edaravone + Butylphthalide) and Edaravone group (conventional treatment + Edaravone) randomly, each consisting of 45 cases. The National Institutes of Health Stroke Scale (NIHSS) score and endothelial function index level such as plasma nitric oxide (NO), human endothelin-1 (ET-1), and vascular endothelial cell growth factor (VEGF) were compared before and after treatment between the two groups. The results showed that the MCR of NFCM was evidently inferior to FCM and MRF, and the KI was notably higher relative to the other two algorithms. After treatment, the NIHSS score of the combined treatment group was (9.09 ± 1.86) points and that of Edaravone group was (14.97 ± 3.44) points, with evident difference between the two groups ( P < 0.05). After treatment, the NO of the combined treatment was (54.63 ± 4.85), and that of Edaravone group was (41.54 ± 5.27), which was considerably different ( P < 0.01), and the VEGF and ET-1 of combined treatment group were greatly inferior to Edaravone group ( P < 0.01). It was revealed that the novel algorithm based on FCM can obtain more favorable quality and segmentation accuracy of MRI images. Moreover, Butylphthalide combined with Edaravone treatment can effectively improve nerve function, vascular endothelial function, and short-term prognosis in ACI, which was safe and worthy of clinical adoption.",2021,"After treatment, the NIHSS score of the combined treatment group was (9.09 ± 1.86) points and that of Edaravone group was (14.97 ± 3.44) points, with evident difference between the two groups ( P < 0.05).","['90 patients with ACI diagnosed in hospital from December 2018 to December 2019 were selected as subjects', 'Patients with Acute Cerebral Infarction', 'patients with acute cerebral infarction (ACI']","['Butylphthalide combined with Edaravone treatment', 'magnetic resonance imaging (MRI', 'Butylphthalide combined with Edaravone', 'Edaravone', 'Fuzzy C', 'combined treatment group (conventional treatment\u2009+\u2009Edaravone\u2009+\u2009Butylphthalide) and Edaravone group (conventional treatment\u2009+\u2009Edaravone', 'Means']","['NIHSS score', 'nerve function and vascular endothelial function', 'Vascular Endothelial Function', 'misclassification rate (MCR) and difference of Kappa index (KI', 'nerve function, vascular endothelial function', 'VEGF and ET-1', 'Health Stroke Scale (NIHSS) score and endothelial function index level such as plasma nitric oxide (NO), human endothelin-1 (ET-1), and vascular endothelial cell growth factor (VEGF']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0047625', 'cui_str': '3-n-butylphthalide'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0070694', 'cui_str': 'edaravone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0541974', 'cui_str': 'Fuzzy head'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0439099', 'cui_str': 'Kappa'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1257792', 'cui_str': 'Vascular Endothelial Cells'}, {'cui': 'C0018284', 'cui_str': 'Growth factor'}, {'cui': 'C0079281', 'cui_str': 'Endothelin Type 1'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]",90.0,0.0463128,"After treatment, the NIHSS score of the combined treatment group was (9.09 ± 1.86) points and that of Edaravone group was (14.97 ± 3.44) points, with evident difference between the two groups ( P < 0.05).","[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Yin', 'Affiliation': ""Department of Encephalopathy, Qingdao Fifth People's Hospital, Qingdao 266002, China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Chang', 'Affiliation': ""Department of Encephalopathy, Qingdao Fifth People's Hospital, Qingdao 266002, China.""}, {'ForeName': 'Dongmei', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': ""Department of Encephalopathy, Qingdao Fifth People's Hospital, Qingdao 266002, China.""}, {'ForeName': 'Haifei', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': ""Department of Encephalopathy, Qingdao Fifth People's Hospital, Qingdao 266002, China.""}, {'ForeName': 'Aibing', 'Initials': 'A', 'LastName': 'Yin', 'Affiliation': ""Department of Encephalopathy, Qingdao Fifth People's Hospital, Qingdao 266002, China.""}]",Contrast media & molecular imaging,['10.1155/2021/4080305'] 2042,34353808,"Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: study protocol for the SAFO trial.","INTRODUCTION Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a frequent condition, with high mortality rates. There is a growing interest in identifying new therapeutic regimens able to reduce therapeutic failure and mortality observed with the standard of care of beta-lactam monotherapy. In vitro and small-scale studies have found synergy between cloxacillin and fosfomycin against S. aureus . Our aim is to test the hypothesis that cloxacillin plus fosfomycin achieves higher treatment success than cloxacillin alone in patients with MSSA bacteraemia. METHODS We will perform a superiority, randomised, open-label, phase IV-III, two-armed parallel group (1:1) clinical trial at 20 Spanish tertiary hospitals. Adults (≥18 years) with isolation of MSSA from at least one blood culture ≤72 hours before inclusion with evidence of infection, will be randomly allocated to receive either cloxacillin 2 g/4-hour intravenous plus fosfomycin 3 g/6-hour intravenous or cloxacillin 2 g/4-hour intravenous alone for 7 days. After the first week, sequential treatment and total duration of antibiotic therapy will be determined according to clinical criteria by the attending physician.Primary endpoints: (1) Treatment success at day 7, a composite endpoint comprising all the following criteria: patient alive, stable or with improved quick-Sequential Organ Failure Assessment score, afebrile and with negative blood cultures for MSSA at day 7. (2) Treatment success at test of cure (TOC) visit: patient alive and no isolation of MSSA in blood culture or at another sterile site from day 8 until TOC (12 weeks after randomisation).We assume a rate of treatment success of 74% in the cloxacillin group. Accepting alpha risk of 0.05 and beta risk of 0.2 in a two-sided test, 183 subjects will be required in each of the control and experimental groups to obtain statistically significant difference of 12% (considered clinically significant). ETHICS AND DISSEMINATION Ethical approval has been obtained from the Ethics Committee of Bellvitge University Hospital (AC069/18) and from the Spanish Medicines and Healthcare Product Regulatory Agency (AEMPS, AC069/18), and is valid for all participating centres under existing Spanish legislation. The results will be presented at international meetings and will be made available to patients and funders. TRIAL REGISTRATION NUMBER The protocol has been approved by AEMPS with the Trial Registration Number EudraCT 2018-001207-37. ClinicalTrials.gov Identifier: NCT03959345; Pre-results.",2021,There is a growing interest in identifying new therapeutic regimens able to reduce therapeutic failure and mortality observed with the standard of care of beta-lactam monotherapy.,"['adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia', 'Adults (≥18 years) with isolation of MSSA from at least one blood culture ≤72\u2009hours before inclusion with evidence of infection', 'patients with MSSA bacteraemia']","['cloxacillin', 'cloxacillin plus fosfomycin versus cloxacillin alone', 'cloxacillin plus fosfomycin', 'cloxacillin 2\u2009g/4-hour intravenous plus fosfomycin 3\u2009g/6-hour intravenous or cloxacillin']","['2) Treatment success at test of cure (TOC) visit: patient alive and no isolation of MSSA in blood culture', 'Treatment success at day 7, a composite endpoint comprising all the following criteria: patient alive, stable or with improved quick-Sequential Organ Failure Assessment score, afebrile and with negative blood cultures']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1635274', 'cui_str': 'Methicillin susceptible Staphylococcus aureus'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0200949', 'cui_str': 'Blood culture'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]","[{'cui': 'C0009077', 'cui_str': 'Cloxacillin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0016610', 'cui_str': 'Fosfomycin'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C1635274', 'cui_str': 'Methicillin susceptible Staphylococcus aureus'}, {'cui': 'C0200949', 'cui_str': 'Blood culture'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C3494459', 'cui_str': 'Sequential organ failure assessment score'}, {'cui': 'C0277797', 'cui_str': 'Apyrexial'}, {'cui': 'C0852859', 'cui_str': 'Blood culture negative'}]",183.0,0.200468,There is a growing interest in identifying new therapeutic regimens able to reduce therapeutic failure and mortality observed with the standard of care of beta-lactam monotherapy.,"[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Grillo', 'Affiliation': ""Department of Infectious Diseases, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.""}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Cuervo', 'Affiliation': ""Department of Infectious Diseases, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain guillermo.cuervo@bellvitgehospital.cat.""}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Carratala', 'Affiliation': ""Department of Infectious Diseases, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.""}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'San-Juan', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Aguado', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Morata', 'Affiliation': 'Department of Infectious Diseases, Hospital Clinic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Gomez-Zorrilla', 'Affiliation': 'Department of Infectious Diseases, Consorci Parc de Salut MAR de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Joaquín', 'Initials': 'J', 'LastName': 'López-Contreras', 'Affiliation': 'Department of Infectious diseases, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Oriol', 'Initials': 'O', 'LastName': 'Gasch', 'Affiliation': 'Infectious Diseases Department, Consorcio Corporacion Sanitaria Parc Tauli, Sabadell, Spain.'}, {'ForeName': 'Aina', 'Initials': 'A', 'LastName': 'Gomila-Grange', 'Affiliation': ""Institut d'Investigació i Innovació Parc Taulí, I3PT, Sabadell, Spain.""}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Iftimie', 'Affiliation': 'Department of Infection and Immunity, Hospital Universitari Sant Joan de Reus, Reus, Spain.'}, {'ForeName': 'Graciano', 'Initials': 'G', 'LastName': 'Garcia-Pardo', 'Affiliation': 'Departament of Preventive Medicine, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Calbo', 'Affiliation': 'Infectious Diseases Unit, Hospital Universitari MutuaTerrassa, Terrassa, Spain.'}, {'ForeName': 'Lucía', 'Initials': 'L', 'LastName': 'Boix-Palop', 'Affiliation': 'Infectious Diseases Unit, Hospital Universitari MutuaTerrassa, Terrassa, Spain.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Oriol', 'Affiliation': 'Department of Internal Medicine, Hospital de Sant Joan Despi Moises Broggi, Sant Joan Despi, Spain.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Jover-Sáenz', 'Affiliation': 'Territorial Unit of Nosocomial Infection, Hospital Universitari Arnau de Vilanova, Lleida, Spain.'}, {'ForeName': 'Luis Eduardo', 'Initials': 'LE', 'LastName': 'López-Cortés', 'Affiliation': 'Department of Infectious diseases, Hospital Universitario Virgen Macarena, Seville, Spain.'}, {'ForeName': 'Gorane', 'Initials': 'G', 'LastName': 'Euba', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario Cruces, Barakaldo, Spain.'}, {'ForeName': 'Malen', 'Initials': 'M', 'LastName': 'Aguirregabiria', 'Affiliation': 'Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.'}, {'ForeName': 'Maria Jose', 'Initials': 'MJ', 'LastName': 'Garcia-Pais', 'Affiliation': 'Internal Medicine, Hospital Universitario Lucus Augusti, Lugo, Spain.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Gioia', 'Affiliation': 'Department of Infectious diseases, Hospital Universitario Ramon y Cajal, Madrid, Spain.'}, {'ForeName': 'Jose Ramón', 'Initials': 'JR', 'LastName': 'Paño', 'Affiliation': 'Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Pedro-Botet', 'Affiliation': 'Hospital Universitari Germans Trias i Pujol, Badalona, Spain.'}, {'ForeName': 'Rosa Maria', 'Initials': 'RM', 'LastName': 'Benítez', 'Affiliation': 'Hospital Universitari Germans Trias i Pujol, Badalona, Spain.'}, {'ForeName': 'Maria Teresa', 'Initials': 'MT', 'LastName': 'Pérez-Rodríguez', 'Affiliation': 'Department of Internal Medicine and Infectious Diseases, Hospital Álvaro Cunqueiro, Vigo, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Meije', 'Affiliation': 'Hospital de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Maria Belén', 'Initials': 'MB', 'LastName': 'Loeches-Yagüe', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Gertrudis', 'Initials': 'G', 'LastName': 'Horna', 'Affiliation': 'Bellvitge Institute for Biomedical Research, IDIBELL, Barcelona, Spain.'}, {'ForeName': 'Damaris', 'Initials': 'D', 'LastName': 'Berbel', 'Affiliation': 'Bellvitge Institute for Biomedical Research, IDIBELL, Barcelona, Spain.'}, {'ForeName': 'Maria Ángeles', 'Initials': 'MÁ', 'LastName': 'Domínguez', 'Affiliation': 'Bellvitge Institute for Biomedical Research, IDIBELL, Barcelona, Spain.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Padullés', 'Affiliation': 'Bellvitge Institute for Biomedical Research, IDIBELL, Barcelona, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Cobo', 'Affiliation': 'Bellvitge Institute for Biomedical Research, IDIBELL, Barcelona, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Hereu', 'Affiliation': 'Bellvitge Institute for Biomedical Research, IDIBELL, Barcelona, Spain.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Videla', 'Affiliation': 'Bellvitge Institute for Biomedical Research, IDIBELL, Barcelona, Spain.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Tebe', 'Affiliation': 'University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Natàlia', 'Initials': 'N', 'LastName': 'Pallarés', 'Affiliation': 'University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Josep M', 'Initials': 'JM', 'LastName': 'Miro', 'Affiliation': 'Department of Infectious Diseases, Hospital Clinic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Pujol', 'Affiliation': ""Department of Infectious Diseases, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2021-051208'] 2043,34353802,Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial.,"INTRODUCTION Current antibiotic prescription for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is generally based on the Anthonisen criteria in The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guideline that have a potential risk of antibiotics overuse. The dilemma is to identify patients who are most likely to benefit from antibiotics while avoiding unnecessary antibiotic use. Procalcitonin (PCT), a more sensitive and specific biomarker of bacterial infection than other conventional laboratory tests, has the potential to determine those patients in whom antibiotics would be beneficial. It is unclear whether PCT-guided antibiotic therapy is safe and effective for patients hospitalised with AECOPD. The study hypothesis is that PCT-guided antibiotic therapy could reduce the antibiotic prescription rate for AECOPD, compared with the GOLD guideline recommendations, without negatively impacting the treatment success rate. METHODS AND ANALYSIS In this multicenter, open-label, randomised controlled trial, we aim to enrol 500 hospitalised patients with AECOPD that will be randomly assigned to either a PCT-guided group or a GOLD guideline-guided group. The coprimary endpoints are antibiotic prescription rate for AECOPD within 30 days post randomisation and treatment success rate at day 30 post randomisation. The secondary outcomes include: antibiotic prescription rate at day 1 post randomisation; hospital antibiotic exposure; length of hospital stay; rate of subsequent exacerbation and hospital readmission; overall mortality within 30 days post randomisation; changes in lung function and the score of COPD assessment test and modified Medical Research Council; and rate of intensive care unit admission. ETHICS AND DISSEMINATION This trial has been approved by the ethic committee of China-Japan Friendship Hospital. The findings of the study will be disseminated in peer-reviewed journals. If the results of the study are positive, PCT-guided antibiotic therapy is likely to change the guidelines for antibiotic recommendations for patients with AECOPD. TRIAL REGISTRATION NUMBER ClinicalTrials.gov: NCT04682899.",2021,"Procalcitonin (PCT), a more sensitive and specific biomarker of bacterial infection than other conventional laboratory tests, has the potential to determine those patients in whom antibiotics would be beneficial.","['patients hospitalised with AECOPD', 'enrol 500 hospitalised patients with AECOPD', 'patients with AECOPD', 'AECOPD inpatients', 'chronic obstructive pulmonary disease (AECOPD']","['Procalcitonin (PCT', 'PCT-guided group or a GOLD guideline-guided group', 'Procalcitonin-guided initiation of antibiotics', 'PCT-guided antibiotic therapy', 'antibiotic prescription']","['antibiotic prescription rate at day 1 post randomisation; hospital antibiotic exposure; length of hospital stay; rate of subsequent exacerbation and hospital readmission; overall mortality within 30 days post randomisation; changes in lung function and the score of COPD assessment test and modified Medical Research Council; and rate of intensive care unit admission', 'antibiotic prescription rate', 'antibiotic prescription rate for AECOPD within 30 days post randomisation and treatment success rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0340044', 'cui_str': 'Acute exacerbation of chronic obstructive airways disease'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]","[{'cui': 'C0072027', 'cui_str': 'Procalcitonin'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4284282', 'cui_str': 'COPD assessment test'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0340044', 'cui_str': 'Acute exacerbation of chronic obstructive airways disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",500.0,0.13778,"Procalcitonin (PCT), a more sensitive and specific biomarker of bacterial infection than other conventional laboratory tests, has the potential to determine those patients in whom antibiotics would be beneficial.","[{'ForeName': 'Lixue', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Department of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Jinxiang', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Pulmonary and Critical Care Medicine,Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Gu', 'Affiliation': 'Department of Pulmonary and Critical Care Medicine,National Center for Respiratory Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Weili', 'Initials': 'W', 'LastName': 'Sheng', 'Affiliation': 'Department of Pulmonary and Critical Care Medicine, Daxing teaching hospital of Capital Medical University, Beijing, China.'}, {'ForeName': 'Yeming', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Cao', 'Affiliation': 'Department of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, China caobin_ben@163.com.'}]",BMJ open,['10.1136/bmjopen-2021-049515'] 2044,34353294,A three-armed randomised controlled trial investigating the comparative impact of guidance on the efficacy of a web-based stress management intervention and health impairing and promoting mechanisms of prevention.,"BACKGROUND Web-based stress management interventions (SMI) fit increasingly digital lifestyles, reduce barriers of uptake and are easily scalable. SMIs might lower levels of stress in employees and thereby contribute to the prevention of depressive symptomatology. Different guidance formats can impact the efficacy of SMIs, with higher intensity assumed to result in larger effects. However, head-to-head comparisons of guidance formats are rare. This is the first trial to examine the impact of adherence-focused guidance compared to self-help on the efficacy of an occupational SMI compared to a wait list control condition. Additionally, it will be investigated if the SMI enfolds its impact on preventing depressive symptomatology by different pathways through reducing health impairing and increasing promoting factors. METHODS A three-armed randomised controlled trial (RCT) on an occupational SMI was conducted. 404 employees with elevated levels of perceived stress (PSS-10 ≥ 22) were randomly assigned to: adherence-focused guidance (AFG), self-help (SH) or a wait list control group (WLC). The primary outcome was perceived stress (PSS-10). Secondary outcomes included health- and work-related measures. A parallel mediation analysis with stress and resilience as mediators for the effect on depression (CES-D) was carried out. Data collection took place at baseline (T1), after 7 weeks (T2) and 6 months (T3). RESULTS The SMI was effective for all groups on the primary and secondary outcomes. For stress, analyses of covariance (ANCOVA) revealed significant group effects at T2 (F 2,400  = 36.08, P < .001) and T3 (F 2,400  = 37.04, P < .001) with large effect sizes for AFG (T2: d = 0.83; T3: d = 0.85) and SH (T2: d = 0.88; T3: d = 0.91) compared to WLC. No significant group differences were found for the efficacy between AFG and SH on the outcomes. Adherence in terms of completed modules was significantly higher for AFG compared to SH. The SMI's impact on depression was mediated by perceived stress: a 1 b 1  = - 0.77, 95% CI [- 1.26, - 0.34] and resilience: a 2 b 2  = - 0.62, 95% CI [- 1.05, - 0.26]. CONCLUSIONS The SMI was effective for reducing stress and improving other health- and work-related outcomes, irrespective of the guidance format. Results did not demonstrate superiority of adherence-focused guidance for the efficacy but for adherence in terms of completed modules. Among other reasons, better communication strategies about offered guidance and awareness-raising measures are discussed. Results from mediation analysis suggest that preventive SMIs should be designed to reach two goals: reducing the risk factor of stress and simultaneously increasing health promoting factors such as resilience. TRIAL REGISTRATION German Clinical Trial Registration (DRKS) DRKS00005687 , 6/6/2014.",2021,"The SMI was effective for reducing stress and improving other health- and work-related outcomes, irrespective of the guidance format.",['404 employees with elevated levels of perceived stress (PSS-10\u2009≥\u200922'],"['adherence-focused guidance (AFG), self-help (SH) or a wait list control group (WLC', 'Web-based stress management interventions (SMI', 'web-based stress management intervention']","['perceived stress (PSS-10', 'depression', 'health- and work-related measures', 'Adherence']","[{'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",404.0,0.0846834,"The SMI was effective for reducing stress and improving other health- and work-related outcomes, irrespective of the guidance format.","[{'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Nixon', 'Affiliation': 'Department of Health Psychology and Applied Biological Psychology, Institute of Psychology, Leuphana University of Lueneburg, Lueneburg, Germany.'}, {'ForeName': 'Leif', 'Initials': 'L', 'LastName': 'Boß', 'Affiliation': 'Department of Health Psychology and Applied Biological Psychology, Institute of Psychology, Leuphana University of Lueneburg, Lueneburg, Germany.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Heber', 'Affiliation': 'Department for Sport & Health Sciences, Technical University of Munich, Psychology & Digital Mental Health Care, Munich, Germany.'}, {'ForeName': 'David Daniel', 'Initials': 'DD', 'LastName': 'Ebert', 'Affiliation': 'GET.ON Institute for Online Health Trainings, Hamburg, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Lehr', 'Affiliation': 'Department of Health Psychology and Applied Biological Psychology, Institute of Psychology, Leuphana University of Lueneburg, Lueneburg, Germany. lehr@leuphana.de.'}]",BMC public health,['10.1186/s12889-021-11504-2'] 2045,34353073,Efficacy and safety of Intense pulsed light therapy for dry eye caused by meibomian gland dysfunction: a randomised trial.,"BACKGROUND This research explored the efficacy and safety of IPL in the treatment of dry eye caused by Meibomian gland dysfunction (MGD). METHODS A total of 132 patients with dry eye caused by MGD were enrolled in this study. The patients were randomly divided into either the experimental group or the control group by random number table. The experimental group (n=66) was treated with intense pulsed light (IPL), and the control group (n=66) was treated with palpebral gland massage combined with a hot compress. The efficacy, the incidence of adverse events, and patients' levels of satisfaction with treatment were compared between the 2 groups. The quality score of the palpebral gland, the height of the lacrimal river, and the change of tear secretion function were analyzed using a generalized linear equation at different time points. RESULTS The total effective rates of experimental group and control group were 90.2% and 80.0%, respectively, and the therapeutic effects of experimental group were better than those of the control group (P<0.05). In the generalized estimation equation, with the passing of time, the eyelid gland quality score for moderate and severe abnormality, the lacrimal river height measurements ≤0.35 mm, and the tear secretion measurements ≤5 mm all decreased (P<0.05). In addition, the moderate and severe abnormal eyelid gland quality score, the lacrimal river height measurements ≤0.35 mm and the tear secretion measurements≤5 mm of patients in the experimental group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse events between two groups during treatment (P>0.05). In the satisfaction survey, patients who received IPL treatment had higher levels of satisfaction at 7 days and 30 days than those control group (P<0.05). CONCLUSIONS IPL is more effective in the treatment of eyelid gland dysfunction dry eye than a traditional eyelid gland massage combined with a hot compress. IPL effectively improves eye function and alleviates clinical symptoms and has good safety; thus, it can be considered for clinical application and promotion. TRIAL REGISTRATION This study has been registered on the Chinese Clinical Trial Registry (ChiCTR2100045886).",2021,There was no significant difference in the incidence of adverse events between two groups during treatment (P>0.05).,['132 patients with dry eye caused by MGD'],"['palpebral gland massage combined with a hot compress', 'IPL', 'Intense pulsed light therapy', 'intense pulsed light (IPL']","['meibomian gland dysfunction', 'therapeutic effects', 'incidence of adverse events', 'Efficacy and safety', 'quality score of the palpebral gland, the height of the lacrimal river, and the change of tear secretion function', 'eye function and alleviates clinical symptoms', 'total effective rates', 'levels of satisfaction', 'moderate and severe abnormal eyelid gland quality score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C1275684', 'cui_str': 'Meibomian gland dysfunction'}]","[{'cui': 'C0015426', 'cui_str': 'Eyelid structure'}, {'cui': 'C1285092', 'cui_str': 'Gland structure'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0332260', 'cui_str': 'Compressing'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}]","[{'cui': 'C1275684', 'cui_str': 'Meibomian gland dysfunction'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015426', 'cui_str': 'Eyelid structure'}, {'cui': 'C1285092', 'cui_str': 'Gland structure'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0337050', 'cui_str': 'River'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0028853', 'cui_str': 'Ocular Physiological Phenomenon'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0459592', 'cui_str': 'Eyelid gland'}]",132.0,0.0218153,There was no significant difference in the incidence of adverse events between two groups during treatment (P>0.05).,"[{'ForeName': 'Shi', 'Initials': 'S', 'LastName': 'Yan', 'Affiliation': 'Ophthalmology Department, The Second Hospital of Shanxi Medical University, Taiyuan, China.'}, {'ForeName': 'Yaohong', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Ophthalmology Department, The Second Hospital of Shanxi Medical University, Taiyuan, China.'}]",Annals of palliative medicine,['10.21037/apm-21-1303'] 2046,34353042,Effects of comprehensive nursing intervention combined with respiratory functional exercises on pulmonary function and self-care ability in patients with pulmonary tuberculosis: results of a randomized trial.,"BACKGROUND This study was carried out based on the background that pulmonary tuberculosis seriously threatens people's physical health while the current treatment has certain limitations. METHODS A total of 150 patients with pulmonary tuberculosis who were admitted to Wuhan Jinyintan Hospital from January 2017 to December 2018 were selected as study participants. Patients were randomly divided into a control group (n=75) who were treated with routine nursing, and an experimental group (n=75) who were treated with comprehensive nursing intervention combined with respiratory functional exercises. Following treatment, the pulmonary function, self-care ability, and other indexes of the patients in both groups were compared and analyzed. RESULTS After nursing intervention, the pulmonary function and self-care ability of patients in the experimental group were significantly higher than those in the control group. The scores of the 6-minute walking distance (6MWD) and modified Medical Research Council (mMRC) dyspnea scale of patients in both groups were significantly higher after nursing intervention compared to before intervention. Furthermore, after intervention, the scores in the experimental group were significantly higher than those in the control group. The partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2), and the quality of life of patients in the experimental group after intervention were significantly better than those in the control group. CONCLUSIONS Comprehensive nursing intervention combined with respiratory functional exercises can significantly improve the pulmonary function, self-care ability, and quality of life of patients with pulmonary tuberculosis, with obvious clinical efficacy. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR2100048983.",2021,"Following treatment, the pulmonary function, self-care ability, and other indexes of the patients in both groups were compared and analyzed. ","['150 patients with pulmonary tuberculosis who were admitted to Wuhan Jinyintan Hospital from January 2017 to December 2018 were selected as study participants', 'patients with pulmonary tuberculosis', 'n=75) who were treated with routine nursing, and an experimental group (n=75) who were treated with']","['Comprehensive nursing intervention combined with respiratory functional exercises', 'control group', 'comprehensive nursing intervention combined with respiratory functional exercises']","['pulmonary function and self-care ability', 'pulmonary function, self-care ability, and quality of life', 'scores of the 6-minute walking distance (6MWD) and modified Medical Research Council (mMRC) dyspnea scale', 'partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2), and the quality of life', 'pulmonary function, self-care ability']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041327', 'cui_str': 'Pulmonary tuberculosis'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0454284', 'cui_str': 'Functional exercises'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0562734', 'cui_str': 'Ability to perform personal care activity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial'}, {'cui': 'C0030604', 'cui_str': 'Partial pressure'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}]",150.0,0.0380646,"Following treatment, the pulmonary function, self-care ability, and other indexes of the patients in both groups were compared and analyzed. ","[{'ForeName': 'Zhaojia', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': 'Intensive Care Unit, Wuhan Jinyintan Hospital, Wuhan, China.'}, {'ForeName': 'Wenwei', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Department of Tuberculosis, Wuhan Jinyintan Hospital, Wuhan, China.'}, {'ForeName': 'Xiaosong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Emergency, Wuhan Jinyintan Hospital, Wuhan, China.'}]",Annals of palliative medicine,['10.21037/apm-21-1178'] 2047,34353031,New pulmonary rehabilitation exercise for pulmonary fibrosis to improve the pulmonary function and quality of life of patients with idiopathic pulmonary fibrosis: a randomized control trial.,"BACKGROUND The aim of our study is to investigate the impact of the simple breathing exercises (LHP's respiratory rehabilitation for pulmonary fibrosis, LHP's RRPF) on patients with idiopathic pulmonary fibrosis (IPF). METHODS (I) The safety and effectiveness of LHP's RRPF were first verified in 20 healthy individuals. (II) A total of 101 patients with IPF administrated in Shanghai Pulmonary Hospital between January 2015 and May 2017 were screened, and 82 cases were randomly assigned to receive a 12-month LHP's RRPF program (exercise group) or usual medical care (control group). Lung function, chest X-ray, 6-minute walk distance (6MWD), quality of life (St. George's Respiratory Questionnaire, SGRQ), and EKG were measured at the 6th and 12th month during the trial. RESULTS At the 6th month visit, the exercise group showed improved SGRQ score and lung function parameters (FVC, FEV1, and DLCO). At the 12th months visit, the exercise group had significantly improved SGRQ score, 6MWD, and lung function (FVC, FEV1, and DLCO) compared to the control group (P<0.05). No obvious adverse events occurred in the exercise group. The incidence of acute exacerbation and one-year mortality were 7.69% and 2.56%, respectively in the exercise group, which were lower than those (20.9% and 9.3%, respectively) in the control group. CONCLUSIONS LHP's RRPF can delay the pulmonary function decline of patients with IPF and improve their quality of life. This breathing exercise may be an adjunct to pulmonary rehabilitation for IPF.",2021,"At the 12th months visit, the exercise group had significantly improved SGRQ score, 6MWD, and lung function (FVC, FEV1, and DLCO) compared to the control group (P<0.05).","['patients with idiopathic pulmonary fibrosis', 'I', '101 patients with IPF administrated in Shanghai Pulmonary Hospital between January 2015 and May 2017 were screened, and 82 cases', '20 healthy individuals', 'patients with idiopathic pulmonary fibrosis (IPF']","[""LHP's RRPF"", ""LHP's RRPF program (exercise group) or usual medical care (control group"", 'New pulmonary rehabilitation exercise', ""simple breathing exercises (LHP's respiratory rehabilitation""]","['pulmonary function and quality of life', 'incidence of acute exacerbation and one-year mortality', 'adverse events', ""Lung function, chest X-ray, 6-minute walk distance (6MWD), quality of life (St. George's Respiratory Questionnaire, SGRQ), and EKG"", 'SGRQ score, 6MWD, and lung function (FVC, FEV1, and DLCO', 'SGRQ score and lung function parameters (FVC, FEV1, and DLCO', 'quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0496675', 'cui_str': 'Medical care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",101.0,0.0148397,"At the 12th months visit, the exercise group had significantly improved SGRQ score, 6MWD, and lung function (FVC, FEV1, and DLCO) compared to the control group (P<0.05).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Medical College of Soochow University, Suzhou, China; Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Yiliang', 'Initials': 'Y', 'LastName': 'Su', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Weng', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Fen', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Wu', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Qiuhong', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Jin', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Aihong', 'Initials': 'A', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Statistics, Tongji University, School of Medicine, Shanghai, China.'}, {'ForeName': 'Huiping', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.'}]",Annals of palliative medicine,['10.21037/apm-21-71'] 2048,34352943,"Early postoperative treatment of mastectomy scars using a fractional carbon dioxide laser: a randomized, controlled, split-scar, blinded study.","BACKGROUND Mastectomy leaves unsightly scarring, which can be distressing to patients. Laser therapy for scar prevention has been consistently emphasized in recent studies showing that several types of lasers, including fractional ablation lasers, are effective for reducing scar formation. Nonetheless, there are few studies evaluating the therapeutic efficacy of ablative CO2 fractional lasers (ACFLs). METHODS This study had a randomized, comparative, prospective, split-scar design with blinded evaluation of mastectomy scars. Fifteen patients with mastectomy scars were treated using an ACFL. Half of each scar was randomized to ""A,"" while the other side was allocated to group ""B."" Laser treatment was conducted randomly. Scars were assessed using digital photographs of the scar and Vancouver scar scale (VSS) scores. Histological assessments were also done. RESULTS The mean VSS scores were 2.20±1.28 for the treatment side and 2.96±1.40 for the control side. There was a significant difference in the VSS score between the treatment side and the control side (P=0.002). The mean visual analog scale (VAS) scores were 4.13±1.36 for the treatment side and 4.67±1.53 for the control side. There was a significant difference in VAS score between the treatment side and the control side (P=0.02). CONCLUSIONS This study demonstrated that early scar treatment using an ACFL significantly improved the clinical results of the treatment compared to the untreated scar, and this difference was associated with patient satisfaction.",2021,"There was a significant difference in VAS score between the treatment side and the control side (P=0.02). ",['Fifteen patients with mastectomy scars'],"['ablative CO2 fractional lasers (ACFLs', 'fractional carbon dioxide laser', 'B."" Laser treatment', 'ACFL', 'Laser therapy', 'mastectomy scars']","['mean VSS scores', 'mean visual analog scale (VAS) scores', 'VSS score', 'digital photographs of the scar and Vancouver scar scale (VSS) scores', 'VAS score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}]","[{'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",15.0,0.0342305,"There was a significant difference in VAS score between the treatment side and the control side (P=0.02). ","[{'ForeName': 'Hyun Woo', 'Initials': 'HW', 'LastName': 'Shin', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Sangwoo', 'Initials': 'S', 'LastName': 'Suk', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Seoung Wan', 'Initials': 'SW', 'LastName': 'Chae', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Kun Chul', 'Initials': 'KC', 'LastName': 'Yoon', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Junekyu', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.'}]",Archives of plastic surgery,['10.5999/aps.2020.02495'] 2049,34352922,Maternal and Neonatal Outcomes in Nulliparous Participants Undergoing Labor Induction by Cervical Ripening Method.,"OBJECTIVE This study aimed to evaluate maternal and neonatal outcomes by method of cervical ripening for labor induction among low-risk nulliparous individuals. STUDY DESIGN This is a secondary analysis of a multicenter randomized trial of labor induction at 39 weeks versus expectant management in low-risk nulliparous participants. Participants undergoing cervical ripening for labor induction in either group were included. Participants were excluded for preripening membrane rupture, abruption, chorioamnionitis, fetal demise, or cervical dilation ≥3.5 cm. Cervical ripening was defined by the initial method used: prostaglandin only (PGE; referent), Foley with concurrent prostaglandin (Foley-PGE), Foley only (Foley), and Foley with concurrent oxytocin (Foley-oxytocin). Coprimary outcomes were adverse maternal and neonatal composites. Secondary outcomes included cesarean delivery and length of labor and delivery (L&D) stay. Multivariable analysis was used to adjust for patient characteristics. RESULTS Of 6,106 participants included in the trial, 2,376 (38.9%) met criteria for this analysis. Of these, 1,247 (52.4%) had cervical ripening with PGE, 290 (12.2%) had Foley-PGE, 385 (16.2%) had Foley, and 454 (19.1%) had Foley-oxytocin. The maternal composite outcome was similar among participants who received Foley-PGE (24.1%, adjusted relative risk [aRR] = 1.21, 95% confidence interval [CI]: 0.96-1.52), Foley (21.3%, aRR = 1.16, 95% CI: 0.92-1.45), or Foley-oxytocin (19.4%, aRR = 1.04, 95% CI: 0.83-1.29), compared with PGE (19.7%). The neonatal composite outcome was less frequent in participants who received the Foley-PGE (2.4%, aRR = 0.35, 95% CI: 0.16-0.75) or Foley (3.6%, aRR = 0.51, 95% CI: 0.29-0.89) but did not reach statistical significance for participants who received Foley-oxytocin (4.6%, aRR = 0.63, 95% CI: 0.40-1.01) compared with PGE only (6.8%). Participants who received Foley-PGE or Foley-oxytocin had a shorter L&D stay (adjusted mean difference = -1.97 hours, 95% CI: -3.45 to -0.49 and -5.92 hours, 95% CI: -7.07 to -4.77, respectively), compared with PGE. CONCLUSION In term low-risk nulliparous participants, Foley alone or concurrent with PGE is associated with a lower risk of adverse neonatal outcomes than with PGE alone. Length of L&D stay was the shortest with concurrent Foley-oxytocin. KEY POINTS · Adverse maternal outcomes are similar among different methods of cervical ripening in low-risk women.. · Adverse neonatal outcomes are less frequent with use of Foley alone or in combination with PGE.. · The use of Foley alone, or in combination with other agents, appears to be beneficial..",2021,"Participants who received Foley-PGE or Foley-oxytocin had a shorter L&D stay (adjusted mean difference = -1.97 hours, 95% CI: -3.45 to -0.49 and -5.92 hours, 95% CI: -7.07 to -4.77, respectively), compared with PGE. CONCLUSION ","['Participants were excluded for preripening membrane rupture, abruption, chorioamnionitis, fetal demise, or cervical dilation ≥3.5\u2009cm', '6,106 participants included in the trial, 2,376 (38.9%) met criteria for this analysis', 'Participants undergoing cervical ripening for labor induction in either group were included', 'Nulliparous Participants Undergoing Labor Induction by Cervical Ripening Method', 'low-risk nulliparous individuals', 'low-risk nulliparous participants']","['Foley-PGE', 'Foley-oxytocin', 'Foley-PGE or Foley-oxytocin', 'PGE', 'cervical ripening', 'Foley with concurrent prostaglandin (Foley-PGE), Foley only (Foley), and Foley with concurrent oxytocin (Foley-oxytocin']","['Foley-PGE', 'maternal composite outcome', 'neonatal composite outcome', 'Foley-oxytocin', 'shorter L&D stay', 'Length of L&D stay', 'Cervical ripening', 'adverse maternal and neonatal composites', 'cesarean delivery and length of labor and delivery (L&D) stay', 'cervical ripening', 'Adverse maternal outcomes']","[{'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0233308', 'cui_str': 'Spontaneous rupture of fetal membranes'}, {'cui': 'C0008495', 'cui_str': 'Chorioamnionitis'}, {'cui': 'C0015927', 'cui_str': 'Fetal death'}, {'cui': 'C0079103', 'cui_str': 'Cervical dilatation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0600454', 'cui_str': 'Cervical Ripening'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0033559', 'cui_str': 'E series prostaglandin'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0600454', 'cui_str': 'Cervical Ripening'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0033554', 'cui_str': 'Prostaglandin'}]","[{'cui': 'C0033559', 'cui_str': 'E series prostaglandin'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0566679', 'cui_str': 'Duration of labor'}, {'cui': 'C0600454', 'cui_str': 'Cervical Ripening'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}]",6106.0,0.501589,"Participants who received Foley-PGE or Foley-oxytocin had a shorter L&D stay (adjusted mean difference = -1.97 hours, 95% CI: -3.45 to -0.49 and -5.92 hours, 95% CI: -7.07 to -4.77, respectively), compared with PGE. CONCLUSION ","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Andrikopoulou', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University, New York, New York.'}, {'ForeName': 'Elisa T', 'Initials': 'ET', 'LastName': 'Bushman', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Madeline M', 'Initials': 'MM', 'LastName': 'Rice', 'Affiliation': 'The George Washington University Biostatistics Center, Washington, District of Columbia.'}, {'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Grobman', 'Affiliation': 'Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Uma M', 'Initials': 'UM', 'LastName': 'Reddy', 'Affiliation': 'The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Silver', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah.'}, {'ForeName': 'Yasser Y', 'Initials': 'YY', 'LastName': 'El-Sayed', 'Affiliation': 'Department of Obstetrics and Gynecology, Stanford University, Stanford, California.'}, {'ForeName': 'Dwight J', 'Initials': 'DJ', 'LastName': 'Rouse', 'Affiliation': 'Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island.'}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Saade', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Thorp', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Suneet P', 'Initials': 'SP', 'LastName': 'Chauhan', 'Affiliation': ""Department of Obstetrics and Gynecology, University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston, Texas.""}, {'ForeName': 'Maged M', 'Initials': 'MM', 'LastName': 'Costantine', 'Affiliation': 'Department of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Edward K', 'Initials': 'EK', 'LastName': 'Chien', 'Affiliation': 'Department of Obstetrics and Gynecology, MetroHealth Medical Center-Case Western Reserve University, Cleveland, Ohio.'}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Casey', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Sindhu K', 'Initials': 'SK', 'LastName': 'Srinivas', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Geeta K', 'Initials': 'GK', 'LastName': 'Swamy', 'Affiliation': 'Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina.'}, {'ForeName': 'Hyagriv N', 'Initials': 'HN', 'LastName': 'Simhan', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of perinatology,['10.1055/s-0041-1732379'] 2050,34352857,Intrapartum Resuscitation Interventions for Category II Fetal Heart Rate Tracings and Improvement to Category I.,"OBJECTIVE To evaluate intrapartum resuscitation interventions and improvement in category II fetal heart rate (FHR) tracings. METHODS This secondary analysis of a randomized trial of intrapartum fetal electrocardiographic ST-segment analysis included all participants with category II FHR tracings undergoing intrauterine resuscitation: maternal oxygen, intravenous fluid bolus, amnioinfusion, or tocolytic administration. Fetal heart rate pattern-recognition software was used to confirm category II FHR tracings 30 minutes before intervention and to analyze the subsequent 60 minutes. The primary outcome was improvement to category I within 60 minutes. Secondary outcomes included FHR tracing improvement to category I 30-60 minutes after the intervention and composite neonatal outcome. RESULTS Of 11,108 randomized participants, 2,251 (20.3%) had at least one qualifying intervention for category II FHR tracings: 63.7% improved to category I within 60 minutes and 50.5% improved at 30-60 minutes. Only 3.4% underwent cesarean delivery and 4.1% an operative vaginal delivery for nonreassuring fetal status within 60 minutes after the intervention. Oxygen administration was the most common intervention (75.4%). Among American College of Obstetricians and Gynecologists-defined subgroups that received oxygen, the absent FHR accelerations and absent-minimal FHR variability subgroup (n=332) was more likely to convert to category I within 60 minutes than the FHR accelerations or ""moderate FHR variability"" subgroup (n=1,919) (77.0% vs 63.0%, odds ratio [OR] 2.0, 95% CI 1.4-2.7). The incidence of composite neonatal adverse outcome for category II tracings was 2.9% (95% CI 2.2-3.7%) overall; 2.8% (95% CI 2.0-3.8%) for improvement to category I within 60 minutes (n=1,433); and 3.2% (95% CI 2.1-4.6%) for no improvement within 60 minutes (n=818). However, the group with improvement had 29% lower odds for higher level neonatal care (11.8% vs 15.9%, OR 0.71, 95% CI 0.55-0.91). CONCLUSION Nearly two thirds of category II FHR tracings improved to category I within 60 minutes of intervention with a relatively low overall rate of the composite neonatal adverse outcome. FUNDING SOURCE Funded in part by Neoventa Medical.",2021,"However, the group with improvement had 29% lower odds for higher level neonatal care (11.8% vs 15.9%, OR 0.71, 95% CI 0.55-0.91). ","['participants with category II FHR tracings undergoing intrauterine resuscitation: maternal', 'Of 11,108 randomized participants, 2,251 (20.3']","['intrapartum fetal electrocardiographic ST-segment analysis', 'oxygen, intravenous fluid bolus, amnioinfusion, or tocolytic administration']","['higher level neonatal care', 'improvement to category I within 60 minutes', 'operative vaginal delivery for nonreassuring fetal status', 'category II fetal heart rate (FHR) tracings', 'incidence of composite neonatal adverse outcome for category II tracings', 'FHR tracing improvement to category I 30-60 minutes after the intervention and composite neonatal outcome']","[{'cui': 'C4523998', 'cui_str': 'Category II fetal heart rate'}, {'cui': 'C0694756', 'cui_str': 'Intrauterine'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C0456337', 'cui_str': 'Intrapartum'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0429029', 'cui_str': 'ST segment'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1289919', 'cui_str': 'Intravenous fluid'}, {'cui': 'C0262671', 'cui_str': 'Amnioinfusion'}, {'cui': 'C0040349', 'cui_str': 'Tocolytic agent'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C4523998', 'cui_str': 'Category II fetal heart rate'}, {'cui': 'C0018811', 'cui_str': 'Fetal heart rate'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0442822', 'cui_str': 'Trace'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",11108.0,0.182191,"However, the group with improvement had 29% lower odds for higher level neonatal care (11.8% vs 15.9%, OR 0.71, 95% CI 0.55-0.91). ","[{'ForeName': 'Uma M', 'Initials': 'UM', 'LastName': 'Reddy', 'Affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD; the Departments of Obstetrics and Gynecology, the University of Texas Medical Branch at Galveston, Galveston, Texas, the University of Utah Health Sciences Center, Salt Lake City, Utah, the University of Texas McGovern Medical School at UT Health, Houston, Texas, the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, the University of Alabama at Birmingham, Birmingham, Alabama, Columbia University, New York, New York, Northwestern University, Chicago, Illinois, The Ohio State University, Columbus, Ohio, MetroHealth Medical Center-Case Western Reserve University, Cleveland, Ohio, Brown University, Providence, Rhode Island, Stanford University, Stanford, California, Wayne State University, Detroit, Michigan, and the University of Pittsburgh, Pittsburgh, Pennsylvania; and the George Washington University Biostatistics Center, Washington, DC.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Weiner', 'Affiliation': ''}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Saade', 'Affiliation': ''}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Varner', 'Affiliation': ''}, {'ForeName': 'Sean C', 'Initials': 'SC', 'LastName': 'Blackwell', 'Affiliation': ''}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Thorp', 'Affiliation': ''}, {'ForeName': 'Alan T N', 'Initials': 'ATN', 'LastName': 'Tita', 'Affiliation': ''}, {'ForeName': 'Russell S', 'Initials': 'RS', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Peaceman', 'Affiliation': ''}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'McKenna', 'Affiliation': ''}, {'ForeName': 'Edward K S', 'Initials': 'EKS', 'LastName': 'Chien', 'Affiliation': ''}, {'ForeName': 'Dwight J', 'Initials': 'DJ', 'LastName': 'Rouse', 'Affiliation': ''}, {'ForeName': 'Yasser Y', 'Initials': 'YY', 'LastName': 'El-Sayed', 'Affiliation': ''}, {'ForeName': 'Yoram', 'Initials': 'Y', 'LastName': 'Sorokin', 'Affiliation': ''}, {'ForeName': 'Steve N', 'Initials': 'SN', 'LastName': 'Caritis', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000004508'] 2051,34352497,"Effect of a parenting intervention on decreasing adolescents' behavioral problems via reduction in attachment insecurity: A longitudinal, multicenter, randomized controlled trial.","INTRODUCTION Secure attachment in adolescence, related to caregiving quality, is a robust predictor of positive behavioral adjustment in early adulthood and beyond. Nevertheless, few attempts have been made to develop treatments to promote parent-adolescent attachment security. METHODS Using a longitudinal, multicenter, randomized controlled trial design, two questionnaire-based studies were run in Italy (Study 1: n = 100 mothers of adolescents, 60% boys, M age  = 14.89, SD = 1.58; Study 2: n = 40 mothers and 40 adolescents, 60% boys, M age  = 14.90, SD = 1.91) to test the effectiveness of an attachment-based parenting intervention (i.e., Connect) in reducing adolescents' behavioral problems and attachment insecurity 2 weeks post-intervention (t2) and at a 4-month follow-up (t3). It was further investigated whether a decrease in avoidant and anxious attachment at t2 would account for changes in externalizing and internalizing problems, respectively, at t3. All adolescents belonged to two-parent intact families. RESULTS Mothers who completed Connect reported significantly fewer adolescent behavioral problems and lower adolescent attachment insecurity, compared to mothers in the waitlist group, at both t2 and t3 (Study 1). These findings were confirmed in a second subsample (Study 2), considering both mothers' and adolescents' reports. Controlling for pre-intervention behavioral problems, reductions in internalizing and externalizing problems were observed in both studies at t3 via a decrease in anxious and avoidant attachment, respectively, at t2. CONCLUSIONS The findings point to the malleability of attachment security in adolescence and highlight the importance of targeting parenting quality to promote adolescent behavioral adjustment.",2021,"Controlling for pre-intervention behavioral problems, reductions in internalizing and externalizing problems were observed in both studies at t3 via a decrease in anxious and avoidant attachment, respectively, at t2. ","[""adolescents' behavioral problems via reduction in attachment insecurity"", 'two questionnaire-based studies were run in Italy (Study 1: n\xa0=\xa0100 mothers of adolescents, 60% boys, M age \xa0=\xa014.89, SD\xa0=\xa01.58; Study 2: n\xa0=\xa040 mothers and 40 adolescents, 60% boys, M age \xa0=\xa014.90, SD\xa0']","['parenting intervention', 'attachment-based parenting intervention (i.e., Connect']","['avoidant and anxious attachment', 'adolescent behavioral problems and lower adolescent attachment insecurity', 'internalizing and externalizing problems']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0233497', 'cui_str': 'Insecurity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0233497', 'cui_str': 'Insecurity'}, {'cui': 'C0033213', 'cui_str': 'Problem'}]",,0.0546283,"Controlling for pre-intervention behavioral problems, reductions in internalizing and externalizing problems were observed in both studies at t3 via a decrease in anxious and avoidant attachment, respectively, at t2. ","[{'ForeName': 'Lavinia', 'Initials': 'L', 'LastName': 'Barone', 'Affiliation': 'Department of Brain and Behavioural Sciences, Lab on Attachment and Parenting - LAG, University of Pavia, Pavia, Italy. Electronic address: lavinia.barone@unipv.it.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Carone', 'Affiliation': 'Department of Brain and Behavioural Sciences, Lab on Attachment and Parenting - LAG, University of Pavia, Pavia, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Costantino', 'Affiliation': 'Child and Adolescent Neuropsychiatric Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Genschow', 'Affiliation': 'Child and Adolescent Neuropsychiatric Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Merelli', 'Affiliation': 'Child and Adolescent Neuropsychiatric Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'ForeName': 'Annarita', 'Initials': 'A', 'LastName': 'Milone', 'Affiliation': 'IRCCS Fondazione Stella Maris, Pisa, Italy.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Polidori', 'Affiliation': 'IRCCS Fondazione Stella Maris, Pisa, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ruglioni', 'Affiliation': 'IRCCS Fondazione Stella Maris, Pisa, Italy.'}, {'ForeName': 'Marlene M', 'Initials': 'MM', 'LastName': 'Moretti', 'Affiliation': 'Department of Psychology, Simon Fraser University, Burnaby, B.C, Canada.'}]",Journal of adolescence,['10.1016/j.adolescence.2021.07.008'] 2052,34352392,The interplay between domain-general and domain-specific mechanisms during the time-course of verbal associative learning: An event-related potential study.,"Humans continuously learn new information. Here, we examined the temporal brain dynamics of explicit verbal associative learning between unfamiliar items. In the first experiment, 25 adults learned object-pseudoword associations during a 5-day training program allowing us to track the N400 dynamics across learning blocks within and across days. Successful learning was accompanied by an initial frontal N400 that decreased in amplitude across blocks during the first day and shifted to parietal sites during the last training day. In Experiment 2, we replicated our findings with 38 new participants randomly assigned to a consistent learning or an inconsistent learning group. The N400 amplitude modulations that we found, both within and between learning sessions, are taken to reflect the emergence of novel lexical traces even when learning concerns items for which no semantic information is provided. The shift in N400 topography suggests that different N400 neural generators may contribute to specific word learning steps through a balance between domain-general and language-specific mechanisms.",2021,Successful learning was accompanied by an initial frontal N400 that decreased in amplitude across blocks during the first day and shifted to parietal sites during the last training day.,[],['consistent learning or an inconsistent learning group'],['Successful learning'],[],"[{'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0442809', 'cui_str': 'Inconsistent'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",38.0,0.0459673,Successful learning was accompanied by an initial frontal N400 that decreased in amplitude across blocks during the first day and shifted to parietal sites during the last training day.,"[{'ForeName': 'Neus', 'Initials': 'N', 'LastName': 'Ramos-Escobar', 'Affiliation': ""Dept. of Cognition, Development and Educational Science, Institute of Neuroscience, University of Barcelona, L'Hospitalet de Llobregat, Barcelona 08097, Spain; Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08097, Spain.""}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Laine', 'Affiliation': 'Department of Psychology, Abo Akademi University, 20500 Turku, Finland.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Sanseverino-Dillenburg', 'Affiliation': ""Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08097, Spain.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cucurell', 'Affiliation': ""Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08097, Spain.""}, {'ForeName': 'Clément', 'Initials': 'C', 'LastName': 'François', 'Affiliation': 'Aix Marseille Univ, CNRS, LPL, 13100 Aix-en-Provence, France. Electronic address: clement.francois@univ-amu.fr.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Rodriguez-Fornells', 'Affiliation': ""Dept. of Cognition, Development and Educational Science, Institute of Neuroscience, University of Barcelona, L'Hospitalet de Llobregat, Barcelona 08097, Spain; Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08097, Spain; Catalan Institution for Research and Advanced Studies, ICREA, Barcelona, Spain. Electronic address: antoni.rodriguez@icrea.es.""}]",NeuroImage,['10.1016/j.neuroimage.2021.118443'] 2053,34352387,Challenges of conducting a remote behavioral weight loss study: Lessons learned and a practical guide.,"OBJECTIVES To describe challenges and lessons learned in conducting a remote behavioral weight loss trial. METHODS The Personal Diet Study is an ongoing randomized clinical trial which aims to compare two mobile health (mHealth) weight loss approaches, standardized diet vs. personalized feedback, on glycemic response. Over a six-month period, participants attended dietitian-led group meetings via remote videoconferencing and were encouraged to self-monitor dietary intake using a smartphone app. Descriptive statistics were used to report adherence to counseling sessions and self-monitoring. Challenges were tracked during weekly project meetings. RESULTS Challenges in connecting to and engaging in the videoconferencing sessions were noted. To address these issues, we provided a step-by-step user manual and video tutorials regarding use of WebEx, encouraged alternative means to join sessions, and sent reminder emails/texts about the WebEx sessions and asking participants to join sessions early. Self-monitoring app-related issue included inability to find specific foods in the app database. To overcome this, the study team incorporated commonly consumed foods as ""favorites"" in the app database, provided a manual and video tutorials regarding use of the app and checked the self-monitoring app dashboard weekly to identify nonadherent participants and intervened as appropriate. Among 135 participants included in the analysis, the median attendance rate for the 14 remote sessions was 85.7% (IQR: 64.3%-92.9%). CONCLUSIONS Experience and lessons shared in this report may provide critical and timely guidance to other behavioral researchers and interventionists seeking to adapt behavioral counseling programs for remote delivery in the age of COVID-19.",2021,"Among 135 participants included in the analysis, the median attendance rate for the 14 remote sessions was 85.7% (IQR: 64.3%-92.9%). ",['135 participants'],['dietitian-led group meetings via remote videoconferencing and were encouraged to self-monitor dietary intake using a smartphone app'],['median attendance rate'],"[{'cui': 'C4517566', 'cui_str': '135'}]","[{'cui': 'C0334932', 'cui_str': 'Dietitian (general)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0018261', 'cui_str': 'Group Meetings'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C1450048', 'cui_str': 'Videoconferencing'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}]",135.0,0.0343956,"Among 135 participants included in the analysis, the median attendance rate for the 14 remote sessions was 85.7% (IQR: 64.3%-92.9%). ","[{'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Hu', 'Affiliation': 'Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: lu.hu@nyulangone.org.'}, {'ForeName': 'Paige', 'Initials': 'P', 'LastName': 'Illiano', 'Affiliation': 'Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Mary Lou', 'Initials': 'ML', 'LastName': 'Pompeii', 'Affiliation': 'Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Collin J', 'Initials': 'CJ', 'LastName': 'Popp', 'Affiliation': 'Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Anna Y', 'Initials': 'AY', 'LastName': 'Kharmats', 'Affiliation': 'Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Curran', 'Affiliation': 'Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Perdomo', 'Affiliation': 'Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bergman', 'Affiliation': 'Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Eran', 'Initials': 'E', 'LastName': 'Segal', 'Affiliation': 'Department of Computer Science and Applied Math, Weizmann Institute of Science, Rehovot, Israel.'}, {'ForeName': 'Mary Ann', 'Initials': 'MA', 'LastName': 'Sevick', 'Affiliation': 'Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA; Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, New York University Grossman School of Medicine, New York, NY, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106522'] 2054,34352386,"Optimizing scalable, technology-supported behavioral interventions to prevent opioid misuse among adolescents and young adults in the emergency department: A randomized controlled trial protocol.","Preventing opioid misuse and opioid use disorder is critical among at-risk adolescents and young adults (AYAs). An Emergency Department (ED) visit provides an opportunity for delivering interventions during a rapidly changing opioid landscape. This paper describes pilot data and the protocol for a 2 × 2 factorial randomized controlled trial testing efficacy of early interventions to reduce escalation of opioid (prescription or illicit) misuse among at-risk AYAs. Interventions are delivered using technology by health coaches. AYAs ages 16-30 in the ED screening positive for prescription opioid use (+ ≥ 1 risk factor) or opioid misuse will be stratified by risk severity, sex, and age group. Participants will be randomly assigned to a condition at intake, either a live video health coach-delivered single session or a control condition of an enhanced usual care (EUC) community resource brochure. They are also randomly assigned to one of two post-intake conditions: health coach-delivered portal-like messaging via web portal over 30 days or EUC delivered at 30 days post-intake. Thus, the trial has four groups: health coach-delivered session+portal, health coach-delivered session+EUC, EUC + portal, and EUC + EUC. Outcomes will be measured at 3-, 6-, and 12-months. The primary outcome is opioid misuse based on a modified Alcohol Smoking and Substance Involvement Screening Test. Secondary outcomes include other opioid outcomes (e.g., days of opioid misuse, overdose risk behaviors), other substance misuse and consequences, and impaired driving. This study is innovative by testing the efficacy of feasible and scalable technology-enabled interventions to reduce and prevent opioid misuse and opioid use disorder. Trial Registration:ClinicalTrials.gov University of Michigan HUM00177625 NCT Registration: NCT04550715.",2021,They are also randomly assigned to one of two post-intake conditions: health coach-delivered portal-like messaging via web portal over 30 days or EUC delivered at 30 days post-intake.,"['adolescents and young adults in the emergency department', 'AYAs ages 16-30 in the ED screening positive for prescription opioid use (+\u202f≥\u202f1 risk factor) or opioid misuse will be stratified by risk severity, sex, and age group', 'risk adolescents and young adults (AYAs']","['opioid (prescription or illicit', 'health coach-delivered session+portal, health coach-delivered session+EUC, EUC\u202f+\u202fportal, and EUC\u202f+\u202fEUC', 'health coach-delivered portal-like messaging via web portal over 30\u202fdays or EUC', 'technology-supported behavioral interventions', 'live video health coach-delivered single session or a control condition of an enhanced usual care (EUC) community resource brochure']","['opioid misuse based on a modified Alcohol Smoking and Substance Involvement Screening Test', 'opioid outcomes (e.g., days of opioid misuse, overdose risk behaviors), other substance misuse and consequences, and impaired driving']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0332266', 'cui_str': 'Illicit'}, {'cui': 'C2317129', 'cui_str': 'Health coach'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0029944', 'cui_str': 'Drug overdose'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]",,0.12002,They are also randomly assigned to one of two post-intake conditions: health coach-delivered portal-like messaging via web portal over 30 days or EUC delivered at 30 days post-intake.,"[{'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Bonar', 'Affiliation': 'Department of Psychiatry, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA; Addiction Center, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA; Injury Prevention Center, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 10, Ann Arbor, MI 48109, USA. Electronic address: erinbona@med.umich.edu.'}, {'ForeName': 'Kelley M', 'Initials': 'KM', 'LastName': 'Kidwell', 'Affiliation': 'Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Amy S B', 'Initials': 'ASB', 'LastName': 'Bohnert', 'Affiliation': 'Veterans Health Administration, Center for Clinical Management Research, North Campus Research Complex, 2800 Plymouth Rd Bldg 16, Ann Arbor, MI 48109, USA; Department of Anesthesiology, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Carrie A', 'Initials': 'CA', 'LastName': 'Bourque', 'Affiliation': 'Department of Psychiatry, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA; Addiction Center, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Carter', 'Affiliation': 'Injury Prevention Center, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 10, Ann Arbor, MI 48109, USA; Department of Emergency Medicine, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd Bldg 10-G080, Ann Arbor, MI 48109, USA; Department of Health Behavior and Health Education, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Sarah J', 'Initials': 'SJ', 'LastName': 'Clark', 'Affiliation': 'Susan B Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, 300 N. Ingalls Street, Room 6D04, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Meyer D', 'Initials': 'MD', 'LastName': 'Glantz', 'Affiliation': 'Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, 3WFN BG 11601 RM 08C79 MSC 6020, 301 North Stonestreet Ave., Bethesda, MD 20892, USA.'}, {'ForeName': 'Cheryl A', 'Initials': 'CA', 'LastName': 'King', 'Affiliation': 'Department of Psychiatry, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA; Injury Prevention Center, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 10, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Eve D', 'Initials': 'ED', 'LastName': 'Losman', 'Affiliation': 'Department of Emergency Medicine, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd Bldg 10-G080, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Sean Esteban', 'Initials': 'SE', 'LastName': 'McCabe', 'Affiliation': 'Department of Health Behavior and Biological Sciences and Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan, Ann Arbor 48109, USA.'}, {'ForeName': 'Meredith L', 'Initials': 'ML', 'LastName': 'Philyaw-Kotov', 'Affiliation': 'Department of Psychiatry, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA; Addiction Center, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Prosser', 'Affiliation': 'Susan B Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, 300 N. Ingalls Street, Room 6D04, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Terri', 'Initials': 'T', 'LastName': 'Voepel-Lewis', 'Affiliation': 'Department of Anesthesiology, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA; Department of Health Behavior and Biological Sciences and Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan, Ann Arbor 48109, USA.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Zheng', 'Affiliation': 'Department of Psychiatry, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA; Department of Informatics, Donald Bren School of Information and Computer Sciences, University of California, Irvine, CA 92697, USA; Department of Emergency Medicine, School of Medicine, University of California, Irvine, CA 92697, USA.'}, {'ForeName': 'Maureen A', 'Initials': 'MA', 'LastName': 'Walton', 'Affiliation': 'Department of Psychiatry, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA; Addiction Center, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 16, Ann Arbor, MI 48109, USA; Injury Prevention Center, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd. Building 10, Ann Arbor, MI 48109, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106523'] 2055,34362202,Effect of Progressive Head Extension Swallowing Exercise on Lingual Strength in the Elderly: A Randomized Controlled Trial.,"Lingual strengthening training can improve the swallowing function in older adults, but the optimal method is unclear. We investigated the effects of a new progressive resistance exercise in the elderly by comparing with a conventional isometric tongue strengthening exercise. Twenty-nine participants were divided into two groups randomly. One group performed forceful swallow of 2 mL of water every 10 s for 20 min, and a total of 120 swallowing tasks per session at 80% angle of maximum head extension. The other group performed five repetitions in 24 sets with a 30 s rest, and the target level was settled at 80% of one repetition maximum using the Iowa Oral Performance Instrument (IOPI). A total of 12 sessions were carried out by both groups over a 4-week period. Blinded measurements (for maximum lingual isometric pressure and peak pressure during swallowing) were obtained using IOPI before exercise and at four weeks in both groups. After four weeks, both groups showed a significant improvement in lingual strength involving both isometric and swallowing tasks. However, there was no significant difference between the groups in strength increase involving both tasks. Regardless of the manner, tongue-strengthening exercises substantially improved lingual pressure in the elderly with equal effect.",2021,"However, there was no significant difference between the groups in strength increase involving both tasks.","['Twenty-nine participants', 'older adults', 'Lingual Strength in the Elderly']","['conventional isometric tongue strengthening exercise', 'new progressive resistance exercise', 'Lingual strengthening training', 'Progressive Head Extension Swallowing Exercise']","['strength increase involving both tasks', 'swallowing function', 'lingual strength involving both isometric and swallowing tasks', 'lingual pressure', 'maximum lingual isometric pressure and peak pressure during swallowing']","[{'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0589276', 'cui_str': 'Swallowing exercises'}]","[{'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0445174', 'cui_str': 'Peak pressure'}]",29.0,0.0220155,"However, there was no significant difference between the groups in strength increase involving both tasks.","[{'ForeName': 'Jin-Woo', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dongguk University Ilsan Hospital, Goyang-si 10326, Gyeonggi-do, Korea.'}, {'ForeName': 'Chi-Hoon', 'Initials': 'CH', 'LastName': 'Oh', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dongguk University Ilsan Hospital, Goyang-si 10326, Gyeonggi-do, Korea.'}, {'ForeName': 'Bo-Un', 'Initials': 'BU', 'LastName': 'Choi', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dongguk University Ilsan Hospital, Goyang-si 10326, Gyeonggi-do, Korea.'}, {'ForeName': 'Ho-Jin', 'Initials': 'HJ', 'LastName': 'Hong', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dongguk University Ilsan Hospital, Goyang-si 10326, Gyeonggi-do, Korea.'}, {'ForeName': 'Joong-Hee', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dongguk University Ilsan Hospital, Goyang-si 10326, Gyeonggi-do, Korea.'}, {'ForeName': 'Tae-Yeon', 'Initials': 'TY', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dongguk University Ilsan Hospital, Goyang-si 10326, Gyeonggi-do, Korea.'}, {'ForeName': 'Yong-Jin', 'Initials': 'YJ', 'LastName': 'Cho', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dongguk University Ilsan Hospital, Goyang-si 10326, Gyeonggi-do, Korea.'}]",Journal of clinical medicine,['10.3390/jcm10153419'] 2056,34362196,Association of TNF-α (-308G/A) Gene Polymorphism with Circulating TNF-α Levels and Excessive Daytime Sleepiness in Adults with Coronary Artery Disease and Concomitant Obstructive Sleep Apnea.,"Obstructive sleep apnea (OSA) is common in patients with coronary artery disease (CAD), in which inflammatory activity has a crucial role. The manifestation of OSA varies significantly between individuals in clinical cohorts; not all adults with OSA demonstrate the same set of symptoms; i.e., excessive daytime sleepiness (EDS) and/or increased levels of inflammatory biomarkers. The further exploration of the molecular basis of these differences is therefore essential for a better understanding of the OSA phenotypes in cardiac patients. In this current secondary analysis of the Randomized Intervention with Continuous Positive Airway Pressure in CAD and OSA (RICCADSA) trial (Trial Registry: ClinicalTrials.gov; No: NCT00519597), we aimed to address the association of tumor necrosis factor alpha ( TNF-α )-308G/A gene polymorphism with circulating TNF-α levels and EDS among 326 participants. CAD patients with OSA (apnea-hypopnea-index (AHI) ≥ 15 events/h; n = 256) were categorized as having EDS ( n = 100) or no-EDS ( n = 156) based on the Epworth Sleepiness Scale score with a cut-off of 10. CAD patients with no-OSA (AHI < 5 events/h; n = 70) were included as a control group. The results demonstrated no significant differences regarding the distribution of the TNF-α alleles and genotypes between CAD patients with vs. without OSA. In a multivariate analysis, the oxygen desaturation index and TNF-α genotypes from GG to GA and GA to AA as well as the TNF-α-308A allele carriage were significantly associated with the circulating TNF-α levels. Moreover, the TNF-α-308A allele was associated with a decreased risk for EDS (odds ratio 0.64, 95% confidence interval 0.41-0.99; p = 0.043) independent of age, sex, obesity, OSA severity and the circulating TNF-α levels. We conclude that the TNF-α-308A allele appears to modulate circulatory TNF-α levels and mitigate EDS in adults with CAD and concomitant OSA.",2021,"Moreover, the TNF-α-308A allele was associated with a decreased risk for EDS (odds ratio 0.64, 95% confidence interval 0.41-0.99; p = 0.043) independent of age, sex, obesity, OSA severity and the circulating TNF-α levels.","['cardiac patients', 'patients with coronary artery disease (CAD', 'Adults with Coronary Artery Disease and Concomitant Obstructive Sleep Apnea', 'adults with CAD and concomitant OSA', 'CAD patients with no-OSA (AHI < 5 events/h; n = 70) were included as a control group', '326 participants', 'CAD patients with OSA (apnea-hypopnea-index (AHI) ≥ 15 events/h; n = 256) were categorized as having EDS ( n = 100) or no-EDS ( n = 156) based on the Epworth Sleepiness Scale score with a cut-off of 10']",['TNF-α (-308G/A'],"['Gene Polymorphism with Circulating TNF-α Levels and Excessive Daytime Sleepiness', 'Obstructive sleep apnea (OSA', 'excessive daytime sleepiness (EDS) and/or increased levels of inflammatory biomarkers', 'risk for EDS', 'oxygen desaturation index and TNF-α genotypes', 'circulatory TNF-α levels']","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C5191353', 'cui_str': '326'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C4551761', 'cui_str': 'Excessive daytime sleepiness'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4706348', 'cui_str': 'ESS (Epworth Sleepiness Scale) score'}, {'cui': 'C0000925', 'cui_str': 'Incised wound'}]","[{'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}]","[{'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4551761', 'cui_str': 'Excessive daytime sleepiness'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}]",326.0,0.0985583,"Moreover, the TNF-α-308A allele was associated with a decreased risk for EDS (odds ratio 0.64, 95% confidence interval 0.41-0.99; p = 0.043) independent of age, sex, obesity, OSA severity and the circulating TNF-α levels.","[{'ForeName': 'Afrouz', 'Initials': 'A', 'LastName': 'Behboudi', 'Affiliation': 'Division of Biomedicine, School of Heath Sciences, University of Skövde, SE 54128 Skövde, Sweden.'}, {'ForeName': 'Tilia', 'Initials': 'T', 'LastName': 'Thelander', 'Affiliation': 'Division of Biomedicine, School of Heath Sciences, University of Skövde, SE 54128 Skövde, Sweden.'}, {'ForeName': 'Duygu', 'Initials': 'D', 'LastName': 'Yazici', 'Affiliation': 'Koc University Research Center for Translational Medicine (KUTTAM), Koc University Hospital, TR 34010 Istanbul, Turkey.'}, {'ForeName': 'Yeliz', 'Initials': 'Y', 'LastName': 'Celik', 'Affiliation': 'Koc University Research Center for Translational Medicine (KUTTAM), Koc University Hospital, TR 34010 Istanbul, Turkey.'}, {'ForeName': 'Tülay', 'Initials': 'T', 'LastName': 'Yucel-Lindberg', 'Affiliation': 'Department of Dental Medicine, Karolinska Institute, SE 17177 Stockholm, Sweden.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Thunström', 'Affiliation': 'Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, SE 40530 Gothenburg, Sweden.'}, {'ForeName': 'Yüksel', 'Initials': 'Y', 'LastName': 'Peker', 'Affiliation': 'Koc University Research Center for Translational Medicine (KUTTAM), Koc University Hospital, TR 34010 Istanbul, Turkey.'}]",Journal of clinical medicine,['10.3390/jcm10153413'] 2057,34362106,Influence of an Implant Fixture including a Freely Removable Micro-Locking Implant Prosthesis on Peri-Implant Tissues and Implant Prostheses: A Prospective Clinical Study.,"This prospective study was undertaken to evaluate the clinical usefulness of a newly developed one-piece, screw-free, and micro-locking implant system, which was designed to overcome the shortcomings of the existing implant systems. Thirty-eight patients were recruited and randomly and equally assigned to an experimental group (micro-locking one-piece fixture, MLF; n = 19) or a control group (micro-locking abutment, MLA). Cumulative implant survival rates, marginal bone resorptions, probing depths, plaque indices, bleeding indices, and complications were obtained by using clinical and radiographic findings at 6 months and 12 months after prosthesis placement. Complications that occurred multiple times for single implants were counted. During the 12 month observation period, survival rates were 100% in both groups. No significant intergroup differences were observed for marginal bone resorption, probe depth, or bleeding index. However, mean plaque index was significantly lower in the MLF group at 12 months ( p < 0.05). During the 12-month observation period, food impaction (26.3%) was the main complication in the MLF group and screw loosening (5.3%), prosthesis detachment (5.3%), and food impaction (5.3%) were observed in the MLA group. The results of this study suggest that the one-piece micro-locking implant system offers a predictable treatment method.",2021,"However, mean plaque index was significantly lower in the MLF group at 12 months ( p < 0.05).",['Thirty-eight patients'],"['experimental group (micro-locking one-piece fixture, MLF; n = 19) or a control group (micro-locking abutment, MLA', 'MLF', 'Implant Fixture including a Freely Removable Micro-Locking Implant Prosthesis']","['screw loosening', 'prosthesis detachment', 'food impaction', 'Cumulative implant survival rates, marginal bone resorptions, probing depths, plaque indices, bleeding indices, and complications', 'marginal bone resorption, probe depth, or bleeding index', 'survival rates', 'mean plaque index']","[{'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0066495', 'cui_str': 'MFL protocol'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0599973', 'cui_str': 'Ophthalmo-acromelic syndrome'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0410830', 'cui_str': 'Loosening of screw'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}, {'cui': 'C0541879', 'cui_str': 'Detachment psychological'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",38.0,0.0148528,"However, mean plaque index was significantly lower in the MLF group at 12 months ( p < 0.05).","[{'ForeName': 'Young-Gun', 'Initials': 'YG', 'LastName': 'Shin', 'Affiliation': 'Department of Prosthodontics, Dental Research Institute, Dental and Life Sciences Institute, Education and Research Team for Life Science on Dentistry, School of Dentistry, Pusan National University, Yangsan 50612, Korea.'}, {'ForeName': 'Won-Tak', 'Initials': 'WT', 'LastName': 'Cho', 'Affiliation': 'Department of Prosthodontics, Dental Research Institute, Dental and Life Sciences Institute, Education and Research Team for Life Science on Dentistry, School of Dentistry, Pusan National University, Yangsan 50612, Korea.'}, {'ForeName': 'Ho-Kyung', 'Initials': 'HK', 'LastName': 'Lim', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Korea University Guro Hospital, Seoul 08308, Korea.'}, {'ForeName': 'Su-Hyun', 'Initials': 'SH', 'LastName': 'Hwang', 'Affiliation': 'Department of Prosthodontics, Dental Research Institute, Dental and Life Sciences Institute, Education and Research Team for Life Science on Dentistry, School of Dentistry, Pusan National University, Yangsan 50612, Korea.'}, {'ForeName': 'Ji-Hyeon', 'Initials': 'JH', 'LastName': 'Bae', 'Affiliation': 'Department of Prosthodontics, Dental Research Institute, Dental and Life Sciences Institute, Education and Research Team for Life Science on Dentistry, School of Dentistry, Pusan National University, Yangsan 50612, Korea.'}, {'ForeName': 'Gang-Ho', 'Initials': 'GH', 'LastName': 'Bae', 'Affiliation': 'Department of Prosthodontics, Dental Research Institute, Dental and Life Sciences Institute, Education and Research Team for Life Science on Dentistry, School of Dentistry, Pusan National University, Yangsan 50612, Korea.'}, {'ForeName': 'Jeong-Yol', 'Initials': 'JY', 'LastName': 'Lee', 'Affiliation': 'Department of Prosthodontics, Korea University Guro Hospital, Seoul 08308, Korea.'}, {'ForeName': 'Jung-Bo', 'Initials': 'JB', 'LastName': 'Huh', 'Affiliation': 'Department of Prosthodontics, Dental Research Institute, Dental and Life Sciences Institute, Education and Research Team for Life Science on Dentistry, School of Dentistry, Pusan National University, Yangsan 50612, Korea.'}]",Journal of clinical medicine,['10.3390/jcm10153321'] 2058,34362096,Liposomal Inhalation after Tracheostomy-A Randomized Controlled Trial.,"BACKGROUND Tracheostomy is a common procedure in critical care. The aim of this study was to evaluate the application of a liposomal inhalation compared to standard physiologic saline (SPS) inhalation on basis of objective and subjective parameters of airway inflammation. METHODS We evaluated in this two-armed, double-blinded and randomized control group study the effect of liposomal compared with SPS inhalation in newly tracheotomized patients. The primary endpoint was defined as trend of tracheobronchial IL-6 secretion at day 1 compared to day 10. Further objective and subjective parameter were evaluated. RESULTS Fifty patients were randomized in each arm. Tracheal IL-6 levels decreased significantly only after liposomal inhalation. Both inhalative agents seem to have an effect on the respiratory impairment after tracheostomy. Subjective patient impairment was reduced significantly from day 1 to day 10 after tracheostomy with liposomal inhalation. CONCLUSIONS Liposomal inhalation demonstrated an advantage over SPS inhalation in newly tracheotomized patients.",2021,Tracheal IL-6 levels decreased significantly only after liposomal inhalation.,"['newly tracheotomized patients', 'Fifty patients']","['Liposomal Inhalation after Tracheostomy', 'SPS inhalation', 'liposomal inhalation', 'Liposomal inhalation', 'standard physiologic saline (SPS) inhalation', 'liposomal']","['tracheobronchial IL-6 secretion', 'Subjective patient impairment', 'Tracheal IL-6 levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0040590', 'cui_str': 'Tracheostomy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0450123', 'cui_str': 'Tracheobronchial'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C2945595', 'cui_str': 'Tracheal'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",50.0,0.0714235,Tracheal IL-6 levels decreased significantly only after liposomal inhalation.,"[{'ForeName': 'Benedikt', 'Initials': 'B', 'LastName': 'Hofauer', 'Affiliation': 'Otorhinolaryngology/Head and Neck Surgery, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Straßen', 'Affiliation': 'Otorhinolaryngology/Head and Neck Surgery, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Chaker', 'Affiliation': 'Otorhinolaryngology/Head and Neck Surgery, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.'}, {'ForeName': 'Beate', 'Initials': 'B', 'LastName': 'Schossow', 'Affiliation': 'Study Center Munich, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Wirth', 'Affiliation': 'Otorhinolaryngology/Head and Neck Surgery, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Wirth', 'Affiliation': 'Otorhinolaryngology/Head and Neck Surgery, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.'}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Bas', 'Affiliation': 'Otorhinolaryngology/Head and Neck Surgery, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Knopf', 'Affiliation': 'Otorhinolaryngology/Head and Neck Surgery, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.'}]",Journal of clinical medicine,['10.3390/jcm10153312'] 2059,34362029,Efficacy of Manual Therapy and Transcutaneous Electrical Nerve Stimulation in Cervical Mobility and Endurance in Subacute and Chronic Neck Pain: A Randomized Clinical Trial.,"Neck pain is a frequent health problem. Manual therapy (MT) and transcutaneous electrical nerve stimulation (TENS) are recommended techniques for treatment of mechanical neck disorders (MND) in Spanish Public Primary Care Physiotherapy Services. The aim of this study was to compare the efficacy of MT versus TENS in active mobility and endurance in cervical subacute or chronic neck pain. Ninety patients with MND were randomly allocated to receive ten 30-min sessions of either MT or TENS, in a multi-centered study through 12 Primary Care Physiotherapy Units in the Madrid community. Active cervical range of motion (CD-ROM) and endurance (Palmer and Epler test) were evaluated pre- and post-intervention and at 6-month follow-up. A generalized linear model of repeated measures was constructed for the analysis of differences. Post-intervention MT yielded a significant improvement in active mobility and endurance in patients with subacute or chronic MND, and at 6-month follow-up the differences were only significant in endurance and in sagittal plane active mobility. In the TENS group, no significant improvement was detected. With regard to other variables, MT improved mobility and endurance more effectively than TENS at post-intervention and at 6-month follow-up in the sagittal plane. Only MT generated significant improvements in cervical mobility and endurance in the three movement planes.",2021,"Post-intervention MT yielded a significant improvement in active mobility and endurance in patients with subacute or chronic MND, and at 6-month follow-up the differences were only significant in endurance and in sagittal plane active mobility.","['cervical subacute or chronic neck pain', 'Cervical Mobility and Endurance in Subacute and Chronic Neck Pain', 'Ninety patients with MND', 'mechanical neck disorders (MND) in Spanish Public Primary Care Physiotherapy Services', 'patients with subacute or chronic MND']","['MT or TENS', 'Manual Therapy and Transcutaneous Electrical Nerve Stimulation', 'TENS', 'MT versus TENS', 'Manual therapy (MT) and transcutaneous electrical nerve stimulation (TENS']","['endurance and in sagittal plane active mobility', 'cervical mobility and endurance', 'active mobility and endurance', 'Active cervical range of motion (CD-ROM) and endurance (Palmer and Epler test', 'Neck pain']","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0205365', 'cui_str': 'Subacute'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0558385', 'cui_str': 'Disorder of neck'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0587629', 'cui_str': 'Physiotherapy service'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}]","[{'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C0040654', 'cui_str': 'Percutaneous electrical nerve stimulation'}]","[{'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0935598', 'cui_str': 'Sagittal plane'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0079090', 'cui_str': 'Compact Disk Read-Only Memory'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}]",90.0,0.0204354,"Post-intervention MT yielded a significant improvement in active mobility and endurance in patients with subacute or chronic MND, and at 6-month follow-up the differences were only significant in endurance and in sagittal plane active mobility.","[{'ForeName': 'Belén', 'Initials': 'B', 'LastName': 'Díaz-Pulido', 'Affiliation': 'Physiotherapy Department, University of Alcalá, 28871 Madrid, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Pérez-Martín', 'Affiliation': 'Physiotherapy Department, University of Alcalá, 28871 Madrid, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pecos-Martín', 'Affiliation': 'Physiotherapy Department, University of Alcalá, 28871 Madrid, Spain.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Rodríguez-Costa', 'Affiliation': 'Physiotherapy Department, University of Alcalá, 28871 Madrid, Spain.'}, {'ForeName': 'Milagros', 'Initials': 'M', 'LastName': 'Pérez-Muñoz', 'Affiliation': 'Physiotherapy Department, University of Alcalá, 28871 Madrid, Spain.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Calvo-Fuente', 'Affiliation': 'Physiotherapy Department, University of Alcalá, 28871 Madrid, Spain.'}, {'ForeName': 'María Félix', 'Initials': 'MF', 'LastName': 'Ortiz-Jiménez', 'Affiliation': 'Puerta de Madrid Health Center, Public Health System of the Community of Madrid, 28802 Madrid, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Asúnsolo-Del Barco', 'Affiliation': 'Surgery, Medical and Social Sciences Department, University of Alcalá, 28871 Madrid, Spain.'}]",Journal of clinical medicine,['10.3390/jcm10153245'] 2060,34362024,Whether a Gluten-Free Diet Should Be Recommended in Chronic Autoimmune Thyroiditis or Not?-A 12-Month Follow-Up.,"Elimination diets have recently become extremely popular among people with autoimmune diseases. A gluten-free diet is indicated in celiac disease (CD), but some studies show its effectiveness in cases of autoimmunity. The aim of this study was to assess whether the use of a gluten-free diet is also effective in patients with chronic autoimmune thyroid disease (cAITD), which is the most common thyroid autoimmune pathology associated with chronic inflammation, over-reactivity of the immune system, auto-destruction of thyrocytes and hypothyroidism. The final analysis of the study included 62 Caucasian women randomized into a control group (CG: n = 31) and an experimental group on a gluten-free diet (GFDG: n = 31), were subject to a 12-month follow-up, during which the concentrations of thyrotropin (TSH), free triiodothyronine (fT3), free thyroxine (fT4), anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies were assessed at baseline and after 3, 6 and 12 months. During the 12-month follow-up between the CG and the GFDG, no differences were found in anti-TPO and anti-TG antibodies, fT3 or fT4 levels, except a significant reduction in TSH levels in the GFDG. Additionally, performed analysis between individual appointments presented no significant differences in changes in the median concentrations of anti-TPO, anti-TG or fT3, but confirmed a significant decrease in TSH and showed accessory an increase in fT4 after 12 months in GFDG. Statistical analyses performed separately for both groups indicated a constant reduction of anti-TG concentrations in the GFDG. In conclusion, a GFD may be administered in cAITD after ruling out celiac disease, but it is necessary to perform more studies to assess if cAITD patients achieve the benefits of following a GFD. Patients with cAITD should be offered proper nutrition education combined with a healthy lifestyle promotion.",2021,"Additionally, performed analysis between individual appointments presented no significant differences in changes in the median concentrations of anti-TPO, anti-TG or fT3, but confirmed a significant decrease in TSH and showed accessory an increase in fT4 after 12 months in GFDG.","['62 Caucasian women randomized into a', 'patients with chronic autoimmune thyroid disease (cAITD', 'people with autoimmune diseases']","['control group (CG: n = 31) and an experimental group on a gluten-free diet (GFDG', 'Gluten-Free Diet', 'Elimination diets', 'gluten-free diet']","['TSH levels', 'constant reduction of anti-TG concentrations', 'TSH', 'concentrations of thyrotropin (TSH), free triiodothyronine (fT3), free thyroxine (fT4), anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies', 'median concentrations of anti-TPO, anti-TG or fT3', 'anti-TPO and anti-TG antibodies, fT3 or fT4 levels']","[{'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0443146', 'cui_str': 'Autoimmune reaction'}, {'cui': 'C0040128', 'cui_str': 'Disorder of thyroid gland'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004364', 'cui_str': 'Autoimmune disease'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0344351', 'cui_str': 'Gluten free diet'}, {'cui': 'C0452376', 'cui_str': 'Elimination diet'}]","[{'cui': 'C0202230', 'cui_str': 'Thyroid stimulating hormone measurement'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040160', 'cui_str': 'Thyrotropin'}, {'cui': 'C0370097', 'cui_str': 'Free triiodothyronine'}, {'cui': 'C0202225', 'cui_str': 'T4 free measurement'}, {'cui': 'C0021965', 'cui_str': 'Iodide peroxidase'}, {'cui': 'C0443883', 'cui_str': 'Anti-thyroglobulin antibody'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0560014', 'cui_str': 'ft3'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",62.0,0.0529994,"Additionally, performed analysis between individual appointments presented no significant differences in changes in the median concentrations of anti-TPO, anti-TG or fT3, but confirmed a significant decrease in TSH and showed accessory an increase in fT4 after 12 months in GFDG.","[{'ForeName': 'Jakub', 'Initials': 'J', 'LastName': 'Pobłocki', 'Affiliation': 'Department of Endocrinology, Metabolic Diseases and Internal Diseases, Pomeranian Medical University, 70-252 Szczecin, Poland.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Pańka', 'Affiliation': 'Department of Endocrinology, Metabolic Diseases and Internal Diseases, Pomeranian Medical University, 70-252 Szczecin, Poland.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Szczuko', 'Affiliation': 'Department of Human Nutrition and Metabolomic, Pomeranian Medical University, 71-460 Szczecin, Poland.'}, {'ForeName': 'Arkadiusz', 'Initials': 'A', 'LastName': 'Telesiński', 'Affiliation': 'Department of Bioengineering, Faculty of Environmental Management and Agriculture, West Pomeranian University of Technology, 71-434 Szczecin, Poland.'}, {'ForeName': 'Anhelli', 'Initials': 'A', 'LastName': 'Syrenicz', 'Affiliation': 'Department of Endocrinology, Metabolic Diseases and Internal Diseases, Pomeranian Medical University, 70-252 Szczecin, Poland.'}]",Journal of clinical medicine,['10.3390/jcm10153240'] 2061,34362011,Effect of Deep versus Moderate Neuromuscular Blockade on Quantitatively Assessed Postoperative Atelectasis Using Computed Tomography in Thoracic Surgery; a Randomized Double-Blind Controlled Trial.,"BACKGROUND postoperative atelectasis is a significant clinical problem during thoracic surgery with one-lung ventilation. Intraoperative deep neuromuscular blockade can improve surgical conditions, but an increased risk of residual paralysis may aggravate postoperative atelectasis. Every patient was verified to have full reversal before extubation. We compared the effect of deep versus moderate neuromuscular blockade on postoperative atelectasis quantitatively using chest computed tomography. METHODS patients undergoing thoracic surgery were randomly allocated to two groups: moderate neuromuscular blockade during surgery (group M) and deep neuromuscular blockade during surgery (group D). The primary outcome was the proportion and the volume of postoperative atelectasis measured by chest computed tomography on postoperative day 2. The mean values of the repeatedly measured intraoperative dynamic lung compliance during surgery were also compared. RESULT the proportion of postoperative atelectasis did not differ between the groups (1.32 [0.47-3.20]% in group M and 1.41 [0.24-3.07]% in group D, p = 0.690). The actual atelectasis volume was 38.2 (12.8-61.4) mL in group M and 31.9 (7.84-75.0) mL in group D ( p = 0.954). Some factors described in the lung protective ventilation were not taken into account and might explain the atelectasis in both groups. The mean lung compliance during one-lung ventilation was higher in group D (26.6% in group D vs. 24.1% in group M, p = 0.026). CONCLUSIONS intraoperative deep neuromuscular blockade did not affect postoperative atelectasis when compared with moderate neuromuscular blockade if full reversal was verified.",2021,the proportion of postoperative atelectasis did not differ between the groups (1.32 [0.47-3.20]% in group M and 1.41,"['patients undergoing thoracic surgery', 'Thoracic Surgery']","['Computed Tomography', 'Deep versus Moderate Neuromuscular Blockade', 'deep versus moderate neuromuscular blockade', 'moderate neuromuscular blockade during surgery (group M) and deep neuromuscular blockade during surgery']","['mean values of the repeatedly measured intraoperative dynamic lung compliance', 'proportion of postoperative atelectasis', 'mean lung compliance during one-lung ventilation', 'proportion and the volume of postoperative atelectasis', 'actual atelectasis volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039986', 'cui_str': 'Thoracic surgery'}]","[{'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0234119', 'cui_str': 'Neuromuscular blockade'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0024112', 'cui_str': 'Lung compliance'}, {'cui': 'C0340074', 'cui_str': 'Postoperative atelectasis'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0004144', 'cui_str': 'Atelectasis'}]",,0.193391,the proportion of postoperative atelectasis did not differ between the groups (1.32 [0.47-3.20]% in group M and 1.41,"[{'ForeName': 'Bong-Jae', 'Initials': 'BJ', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea.'}, {'ForeName': 'Han Na', 'Initials': 'HN', 'LastName': 'Lee', 'Affiliation': 'Department of Radiology, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea.'}, {'ForeName': 'Jun-Young', 'Initials': 'JY', 'LastName': 'Chung', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea.'}, {'ForeName': 'Daehyun', 'Initials': 'D', 'LastName': 'Kim', 'Affiliation': 'Department of Thoracic Surgery, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea.'}, {'ForeName': 'Jung Im', 'Initials': 'JI', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea.'}, {'ForeName': 'Hyungseok', 'Initials': 'H', 'LastName': 'Seo', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea.'}]",Journal of clinical medicine,['10.3390/jcm10153228'] 2062,34361902,"Lactobacillus plantarum TWK10 Improves Muscle Mass and Functional Performance in Frail Older Adults: A Randomized, Double-Blind Clinical Trial.","Sarcopenia is a condition in which there is a loss of muscle caused by aging and it is one of the most significant factors that affects physical fragility. In recent years, the role of the gut-muscle axis has garnered attention as, along with the gut microbiota, it potentially plays a significant role in muscle regeneration, in addition to nutritional supplements and exercise training. Past studies have found that supplementation with Lactobacillus plantarum TWK10 could effectively increase the muscle mass of animals or adult humans. Therefore, in this study, we investigated whether the supplementation of L. plantarum TWK10 produces increased muscle mass and improves the functional performance of elderly persons with mild fragility. A total of 68 elderly subjects were recruited, of which 13 subjects were excluded or withdrew from the study. We adopted a double-blind design, and the 55 subjects were randomly divided into three groups: the placebo group, the TWK10 low-dose group (2 × 10 10 CFU/day) (TWK10-L), and the TWK10 high-dose group (6 × 10 10 colony-forming unit (CFU)/day) (TWK10-H). For 18 weeks, all subjects were required to regularly take experimental samples, perform functional activity testing, and have their body composition analyzed before the study and every six weeks after the intervention. Finally, 17 subjects in the placebo group, 12 subjects in the TWK10-L group, and 13 subjects in the TWK10-H group finished the study. It was found that supplementation with TWK10 had a tendency to increase and improve muscle mass, left hand grip strength, lower limb muscle strength, and gait speed and balance after the sixth week, especially in the TWK10-H group, and, as the supplement time was longer up to the 18th week, it had an even greater effect ( p < 0.05). In conclusion, consecutive supplementation of L. plantarum TWK10 for more than six weeks could effectively improve the muscle strength and endurance of the elderly, reducing sarcopenia and physical fragility. This trial was registered as NCT04893746.",2021,"It was found that supplementation with TWK10 had a tendency to increase and improve muscle mass, left hand grip strength, lower limb muscle strength, and gait speed and balance after the sixth week, especially in the TWK10-H group, and, as the supplement time was longer up to the 18th week, it had an even greater effect ( p < 0.05).","['elderly persons with mild fragility', '17 subjects in the placebo group, 12 subjects in the TWK10-L group, and 13 subjects in the TWK10-H group finished the study', '55 subjects', 'Frail Older Adults', '68 elderly subjects were recruited, of which 13 subjects were excluded or withdrew from the study']","['Lactobacillus plantarum TWK10', 'TWK10 low-dose group (2 × 10 10 CFU/day) (TWK10-L), and the TWK10 high-dose group (6 × 10 10 colony-forming unit (CFU)/day) (TWK10-H', 'consecutive supplementation of L. plantarum', 'supplementation with Lactobacillus plantarum', 'supplementation of L. plantarum', 'placebo', 'TWK10']","['Muscle Mass and Functional Performance', 'muscle strength and endurance of the elderly, reducing sarcopenia and physical fragility', 'functional performance', 'muscle mass, left hand grip strength, lower limb muscle strength, and gait speed and balance']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0302113', 'cui_str': 'Fragility'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1706059', 'cui_str': 'Finish'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}]","[{'cui': 'C0317608', 'cui_str': 'Lactobacillus plantarum'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0553561', 'cui_str': 'colony-forming unit'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0439158', 'cui_str': 'colonies'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1231534', 'cui_str': 'Curtobacterium plantarum'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0302113', 'cui_str': 'Fragility'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",68.0,0.128533,"It was found that supplementation with TWK10 had a tendency to increase and improve muscle mass, left hand grip strength, lower limb muscle strength, and gait speed and balance after the sixth week, especially in the TWK10-H group, and, as the supplement time was longer up to the 18th week, it had an even greater effect ( p < 0.05).","[{'ForeName': 'Mon-Chien', 'Initials': 'MC', 'LastName': 'Lee', 'Affiliation': 'Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan City 333325, Taiwan.'}, {'ForeName': 'Yu-Tsai', 'Initials': 'YT', 'LastName': 'Tu', 'Affiliation': 'Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan City 333325, Taiwan.'}, {'ForeName': 'Chia-Chia', 'Initials': 'CC', 'LastName': 'Lee', 'Affiliation': 'Culture Collection & Research Institute, SYNBIO TECH INC., Kaohsiung City 82151, Taiwan.'}, {'ForeName': 'Shiow-Chwen', 'Initials': 'SC', 'LastName': 'Tsai', 'Affiliation': 'Institute of Sports Sciences, University of Taipei, Taipei City 112, Taiwan.'}, {'ForeName': 'Han-Yin', 'Initials': 'HY', 'LastName': 'Hsu', 'Affiliation': 'Culture Collection & Research Institute, SYNBIO TECH INC., Kaohsiung City 82151, Taiwan.'}, {'ForeName': 'Tsung-Yu', 'Initials': 'TY', 'LastName': 'Tsai', 'Affiliation': 'Department of Food Science, Fu Jen Catholic University, New Taipei City 24205, Taiwan.'}, {'ForeName': 'Te-Hua', 'Initials': 'TH', 'LastName': 'Liu', 'Affiliation': 'Department of Food Science, Fu Jen Catholic University, New Taipei City 24205, Taiwan.'}, {'ForeName': 'San-Land', 'Initials': 'SL', 'LastName': 'Young', 'Affiliation': 'Culture Collection & Research Institute, SYNBIO TECH INC., Kaohsiung City 82151, Taiwan.'}, {'ForeName': 'Jin-Seng', 'Initials': 'JS', 'LastName': 'Lin', 'Affiliation': 'Culture Collection & Research Institute, SYNBIO TECH INC., Kaohsiung City 82151, Taiwan.'}, {'ForeName': 'Chi-Chang', 'Initials': 'CC', 'LastName': 'Huang', 'Affiliation': 'Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan City 333325, Taiwan.'}]",Microorganisms,['10.3390/microorganisms9071466'] 2063,34364011,"Home-Based Interventions may Increase Recruitment, Adherence, and Measurement of outcomes in Clinical Trials of Stroke Rehabilitation.","OBJECTIVE This study aimed to investigate the completion rates of a home-based randomized trial, which examined home-based high-intensity respiratory muscle training after stroke compared with sham intervention. MATERIALS AND METHODS Completion was examined in terms of recruitment (enrolment and retention), intervention (adherence and delivery of home-visits) and measurement (collection of outcomes). RESULTS Enrolment was 32% and retention was 97% at post-intervention and 84% at follow-up. Adherence to the intervention was high at 87%. Furthermore, 83% of planned home-visits were conducted and 100% of outcomes were collected from those attending measurement sessions. CONCLUSION This home-based randomized trial demonstrated high rates of enrolment, retention, adherence, delivery of home-visits, and collection of outcomes. Home-based interventions may help to improve completion rates of randomized trials.",2021,"This home-based randomized trial demonstrated high rates of enrolment, retention, adherence, delivery of home-visits, and collection of outcomes.",[],['home-based high-intensity respiratory muscle training'],"['recruitment (enrolment and retention), intervention (adherence and delivery of home-visits) and measurement (collection of outcomes']",[],"[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0006155', 'cui_str': 'Physiotherapeutic breathing exercise'}]","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0614367,"This home-based randomized trial demonstrated high rates of enrolment, retention, adherence, delivery of home-visits, and collection of outcomes.","[{'ForeName': 'Kênia Kiefer Parreiras', 'Initials': 'KKP', 'LastName': 'de Menezes', 'Affiliation': 'NeuroGroup, Department of Physiotherapy, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Ada', 'Affiliation': 'Discipline of Physiotherapy, Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Luci Fuscaldi', 'Initials': 'LF', 'LastName': 'Teixeira-Salmela', 'Affiliation': 'NeuroGroup, Department of Physiotherapy, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'ForeName': 'Aline Alvim', 'Initials': 'AA', 'LastName': 'Scianni', 'Affiliation': 'NeuroGroup, Department of Physiotherapy, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'ForeName': 'Patrick Roberto', 'Initials': 'PR', 'LastName': 'Avelino', 'Affiliation': 'NeuroGroup, Department of Physiotherapy, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'ForeName': 'Christina Danielli Coelho de Morais', 'Initials': 'CDCM', 'LastName': 'Faria', 'Affiliation': 'NeuroGroup, Department of Physiotherapy, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'ForeName': 'Lucas Rodrigues', 'Initials': 'LR', 'LastName': 'Nascimento', 'Affiliation': 'NeuroGroup, Department of Physiotherapy, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Center of Health Sciences, Discipline of Physiotherapy, Universidade Federal do Espírito Santo, Vitória, ES 9043-900, Brazil. Electronic address: lucasanatomia@hotmail.com.'}]",Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,['10.1016/j.jstrokecerebrovasdis.2021.106022'] 2064,34293523,The Impact of Incorporating Evidence-Based Guidelines for Lumbar Fusion Surgery in Neurosurgical Resident Education.,"BACKGROUND Instrumented fusion procedures are essential in the treatment of degenerative lumbar spine disease to alleviate pain and improve neurological function, but they are being performed with increasing incidence and variability. We implemented a training module for neurosurgery residents that is based on evidence-based criteria for lumbar fusion surgery and measured its effectiveness in residents' decision making regarding whether patients should or should not undergo instrumented fusion. METHODS The study design was a pretest versus posttest experiment conducted from September 2019 until July 2020 to measure improvement after formalized instruction on evidence-based guidelines. Neurosurgery residents of all training levels at our institution participated. A test was administered at the beginning of each academic year. The highest possible score was 18 points in each pretest and posttest. RESULTS There was a general trend of test score improvement across all levels of training with a greater degree of change for participants with lower compared with higher pretest scores, indicating a possible ceiling effect. Paired t test demonstrated an overall mean score increase of 2 points (P < 0.0001), equivalent to an 11.11% increase (P < 0.0001). Stratified by training group, mean absolute change in test score was 2 (P = 0.0217), 1.67 (P = 0.0108), and 2.25 (P = 0.0173) points for junior, midlevel, and senior training groups, respectively. CONCLUSIONS Incorporating a targeted evidence-based learning module for lumbar spine fusion surgery can improve neurosurgery residents' clinical decision making toward a more uniform practice supported by published data.",2021,"Stratified by training group, mean absolute change in test score was 2 (P = 0.0217), 1.67 (P = 0.0108), and 2.25 (P ","['Neurosurgery residents of all training levels at our institution participated', 'Lumbar Fusion Surgery in Neurosurgical Resident Education']",[],[],"[{'cui': 'C0027926', 'cui_str': 'Neurosurgery'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0013658', 'cui_str': 'Educational achievement'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",[],[],,0.0503303,"Stratified by training group, mean absolute change in test score was 2 (P = 0.0217), 1.67 (P = 0.0108), and 2.25 (P ","[{'ForeName': 'Fadi', 'Initials': 'F', 'LastName': 'Al Saiegh', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA. Electronic address: fadi.al-saiegh@jefferson.edu.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Philipp', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Liam P', 'Initials': 'LP', 'LastName': 'Hughes', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Thiago Scharth', 'Initials': 'TS', 'LastName': 'Montenegro', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Hines', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Glenn A', 'Initials': 'GA', 'LastName': 'Gonzalez', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Aria', 'Initials': 'A', 'LastName': 'Mahtabfar', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Carrie', 'Initials': 'C', 'LastName': 'Andrews', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Kavantissa', 'Initials': 'K', 'LastName': 'Keppetipola', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Franco', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Hafazalla', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Omaditya', 'Initials': 'O', 'LastName': 'Khanna', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Mouchtouris', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Dwight Mitchell', 'Initials': 'DM', 'LastName': 'Self', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Heller', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Srinivas', 'Initials': 'S', 'LastName': 'Prasad', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Jallo', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Ashwini D', 'Initials': 'AD', 'LastName': 'Sharan', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Harrop', 'Affiliation': 'Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA.'}]",World neurosurgery,['10.1016/j.wneu.2021.07.045'] 2065,34369172,Cost-effectiveness of a telemonitoring program (telEPOC program) in frequently admitted chronic obstructive pulmonary disease patients.,"Chronic obstructive pulmonary disease is a typical disease among chronic and respiratory diseases. The costs associated with chronic disease care are rising dramatically, and this makes it necessary to redesign care processes, including new tools which allow the health system to be more sustainable without compromising on the quality of the care, compared to that currently provided. One approach may be to use information and communication technologies. In this context, we explored the cost-effectiveness of applying a telemonitoring system to a cohort of chronic obstructive pulmonary disease patients with frequent readmissions (the telEPOC programme).We conducted an intervention study with a control group. The inclusion criteria used were having chronic obstructive pulmonary disease (forced expiratory volume in the first second/forced vital capacity  < 70%) and having been hospitalised for exacerbation at least twice in the last year or three times in the last 2 years. We estimated the costs incurred by patients in each group and calculated the quality-adjusted life years and incremental cost-effectiveness ratio.Overall, 77 patients were included in the control group and 86 in the intervention group. The raw cost-effectiveness analysis showed that the cost of the telEPOC intervention was significantly lower than that of usual care, while there were no significant differences between the groups in effectiveness.The incremental cost-effectiveness ratio for the intervention was €175,719.71 per quality-adjusted life-year gained.There were no differences between the intervention group (telemonitoring) and the control group (standard care) from the cost-effectiveness point of view. On the other hand, the intervention programme (telEPOC) was less expensive than routine clinical practice.",2021,There were no differences between the intervention group (telemonitoring) and the control group (standard care) from the cost-effectiveness point of view.,"['chronic obstructive pulmonary disease patients with frequent readmissions (the telEPOC programme).We conducted an intervention study with a control group', 'The inclusion criteria used were having chronic obstructive pulmonary disease (forced expiratory volume in the first second/forced vital capacity \u2009<\u200970%) and having been hospitalised for exacerbation at least twice in the last year or three times in the last 2 years', '77 patients were included in the control group and 86 in the intervention group', 'frequently admitted chronic obstructive pulmonary disease patients']",['telemonitoring program (telEPOC program'],"['quality-adjusted life years and incremental cost-effectiveness ratio', 'incremental cost-effectiveness ratio', 'Cost-effectiveness', 'cost of the telEPOC intervention']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",77.0,0.0321782,There were no differences between the intervention group (telemonitoring) and the control group (standard care) from the cost-effectiveness point of view.,"[{'ForeName': 'Cristóbal', 'Initials': 'C', 'LastName': 'Esteban', 'Affiliation': 'Servicio de Neumología, 16250Hospital Galdakao, Spain.'}, {'ForeName': 'Ane', 'Initials': 'A', 'LastName': 'Antón', 'Affiliation': 'Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas (REDISSEC), Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Moraza', 'Affiliation': 'Servicio de Neumología, 16250Hospital Galdakao, Spain.'}, {'ForeName': 'Milagros', 'Initials': 'M', 'LastName': 'Iriberri', 'Affiliation': 'BioCrues-Bizkaia Health Research Institute, Spain.'}, {'ForeName': 'Mateo', 'Initials': 'M', 'LastName': 'Larrauri', 'Affiliation': 'BioCrues-Bizkaia Health Research Institute, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Mar', 'Affiliation': 'Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas (REDISSEC), Spain.'}, {'ForeName': 'Amaia', 'Initials': 'A', 'LastName': 'Aramburu', 'Affiliation': 'Servicio de Neumología, 16250Hospital Galdakao, Spain.'}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'Quintana', 'Affiliation': 'Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas (REDISSEC), Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of telemedicine and telecare,['10.1177/1357633X211037207'] 2066,34369109,Long Term Extension Study of Tofacitinib in Refractory Dermatomyositis.,"We previously demonstrated that tofacitinib was effective in treating skin-predominant refractory dermatomyositis (DM) at 12 weeks in a prospective open label clinical trial, Study of Tofacitinib In Refractory dermatomyositis (STIR) (1). Here, we report the long-term extension results of up to 96 weeks to investigate the treatment durability of tofacitinib in refractory DM. Inclusion criteria and outcome measures were the same as the parent study (1). Assessments were conducted at weeks 20, 72, and 96. The baseline demographic features of all 10 trial patients were reported previously (1).",2021,"We previously demonstrated that tofacitinib was effective in treating skin-predominant refractory dermatomyositis (DM) at 12 weeks in a prospective open label clinical trial, Study of Tofacitinib",['Refractory Dermatomyositis'],"['tofacitinib', 'Tofacitinib']",[],"[{'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0011633', 'cui_str': 'Dermatomyositis'}]","[{'cui': 'C2930696', 'cui_str': 'tofacitinib'}]",[],,0.144959,"We previously demonstrated that tofacitinib was effective in treating skin-predominant refractory dermatomyositis (DM) at 12 weeks in a prospective open label clinical trial, Study of Tofacitinib","[{'ForeName': 'Julie J', 'Initials': 'JJ', 'LastName': 'Paik', 'Affiliation': 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Shneyderman', 'Affiliation': 'Johns Hopkins University, Baltimore, Maryland, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Gutierrez-Alamillo', 'Affiliation': 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Jemima', 'Initials': 'J', 'LastName': 'Albayda', 'Affiliation': 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Tiniakou', 'Affiliation': 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Perin', 'Affiliation': 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Grazyna', 'Initials': 'G', 'LastName': 'Purwin', 'Affiliation': 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Sherry', 'Initials': 'S', 'LastName': 'Leung', 'Affiliation': 'Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Doris', 'Initials': 'D', 'LastName': 'Leung', 'Affiliation': 'Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Livia', 'Initials': 'L', 'LastName': 'Casciola-Rosen', 'Affiliation': 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'Koenig', 'Affiliation': 'Formerly of Pfizer Inflammation and Immunology US Medical Affairs, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Christopher-Stine', 'Affiliation': 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41944'] 2067,34369105,Changes in body weight and knee pain in adults with knee osteoarthritis 3.5 years after completing diet and exercise interventions.,"OBJECTIVE To determine whether long-term diet (D) and exercise (E) interventions, alone or in combination (D+E), have beneficial effects for older adults with knee osteoarthritis 3.5-years after the interventions end. METHODS This is a secondary analysis of a subset (N = 94) of the first 184 participants who had successfully completed the Intensive Diet and Exercise in Arthritis (IDEA) trial (N = 399) and who consented to follow-up testing. Participants were older (age ≥ 55 years), overweight and obese adults with radiographic and symptomatic knee osteoarthritis in at least one knee who completed 1.5-year D+E (N=27), D (N=35), or E (N=32) interventions and returned for 5-year follow-up testing an average of 3.5-years later. RESULTS During the 3.5-years following the interventions, weight regain in D+E and D was 5.9 kg (7%) and 3.1 kg (4%), respectively, with a 1 kg (1%) weight loss in E. Compared to baseline, weight (D+E, -3.7 kg, P=.0007; D, -5.8 kg, P<.0001; E, -2.9 kg, P=.003) and WOMAC pain (D+E, -1.2, P=.03; D, -1.5, P=.001; E -1.6, P=.0008) were lower in each group at 5-year follow-up. The effect of group assignment at 5-year follow-up was significant for body weight, with D less than E (-3.5 kg, P=.04). DISCUSSION Older adults with knee osteoarthritis who completed 1.5-year diet or diet plus exercise interventions experienced partial weight regain 3.5 years later, yet relative to baseline, they preserved statistically significant changes in weight loss and reductions in knee pain.",2021,"The effect of group assignment at 5-year follow-up was significant for body weight, with D less than E (-3.5 kg, P=.04). ","['older adults with knee osteoarthritis 3.5-years after the interventions end', 'Older adults with knee osteoarthritis', 'subset (N = 94) of the first 184 participants who had successfully completed the Intensive Diet and Exercise in Arthritis', 'adults with knee osteoarthritis 3.5 years after completing', 'Participants were older (age ≥ 55 years), overweight and obese adults with radiographic and symptomatic knee osteoarthritis in at least one knee who completed 1.5-year D+E (N=27), D (N=35), or E (N=32) interventions and returned for 5-year follow-up testing an average of 3.5-years later']","['long-term diet (D) and exercise (E) interventions, alone or in combination (D+E', 'diet and exercise interventions']","['weight loss', 'partial weight regain', 'WOMAC pain', 'body weight and knee pain', 'knee pain', 'weight regain in D+E and D']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0003864', 'cui_str': 'Arthritis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205087', 'cui_str': 'Late'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}]",399.0,0.0520786,"The effect of group assignment at 5-year follow-up was significant for body weight, with D less than E (-3.5 kg, P=.04). ","[{'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Messier', 'Affiliation': 'J.B. Snow Biomechanics Laboratory, Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, USA.'}, {'ForeName': 'Jovita J', 'Initials': 'JJ', 'LastName': 'Newman', 'Affiliation': 'Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Scarlett', 'Affiliation': 'J.B. Snow Biomechanics Laboratory, Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, USA.'}, {'ForeName': 'Shannon L', 'Initials': 'SL', 'LastName': 'Mihalko', 'Affiliation': 'Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, USA.'}, {'ForeName': 'Gary D', 'Initials': 'GD', 'LastName': 'Miller', 'Affiliation': 'Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, USA.'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Nicklas', 'Affiliation': 'Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'DeVita', 'Affiliation': 'Department of Kinesiology, East Carolina University, Greenville, NC, USA.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Hunter', 'Affiliation': 'Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Mary F', 'Initials': 'MF', 'LastName': 'Lyles', 'Affiliation': 'Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, USA.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Eckstein', 'Affiliation': 'Department of Imaging & Functional Musculoskeletal Research, Institute of Anatomy & Cell Biology, Paracelsus Medical University, Salzburg & Nuremberg, Salzburg, Austria, & Chondrometrics GmbH, Ainring, Germany & Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Guermazi', 'Affiliation': 'Quantitative Imaging Center, Department of Radiology, Boston University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Richard F', 'Initials': 'RF', 'LastName': 'Loeser', 'Affiliation': 'Thurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': 'Beavers', 'Affiliation': 'Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}]",Arthritis care & research,['10.1002/acr.24765'] 2068,34368999,Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.,"OBJECTIVE Two large randomized trials of patients with differentiated thyroid cancer (DTC) reported recently (HiLo and ESTIMABL1) found that the recurrence rate among patients who underwent 1.1 GBq radioactive iodine (RAI) ablation was not higher than that of patients who underwent 3.7 GBq radioactive iodine (RAI) ablation. However, no similar studies have been conducted in China. We aimed to report clinical outcomes in Chinese patients with low/intermediate risk of recurrence DTC after long-term follow-up, and evaluate the risk factors that influence the presence or absence of incomplete response at the final follow-up. DESIGN A long-term follow-up of a Chinese randomized clinical trial (October 2014 and February 2021) was conducted. PATIENTS A total of 506 DTC patients at low/intermediate risk of recurrence who were randomized into two groups to receive 1.1 (n = 251) or 3.7 GBq (n = 255) RAI ablation following thyroid hormone withdrawal were followed on levothyroxine treatment for a median of 4.5 years (range: 1.6-6.3). MEASUREMENTS Suppressed serum thyroglobulin (Tg) and anti-thyroglobulin antibody (TgAb) levels were determined, and neck ultrasonography was performed. RESULTS At the final follow-up, 499 (98.6%) patients showed an excellent response. The other seven patients (two patients underwent 1.1 GBq and five patients underwent 3.7 GBq RAI ablation, respectively) showed either structural incomplete response (lymph node metastasis, n = 1), biochemical incomplete response (increased serum Tg ≥ 1 ng/ml, or increased positive TgAb levels, n = 5), or indeterminate response (stable positive TgAb levels, n = 1). The risk of incomplete response at the final follow-up was significantly increased in patients with stimulated serum Tg ≥ 10 ng/ml at ablation (p = .003) and in patients with unsuccessful ablation (p = .008). CONCLUSION Our findings indicated that there was no difference in the long-term outcomes with RAI ablation using either 1.1 or 3.7 GBq in patients with low/intermediate risk of recurrence DTC, and 1.1 GBq RAI might be suitable for patients who are recommended for ablation.",2021,"MEASUREMENTS Suppressed serum thyroglobulin (Tg) and anti-thyroglobulin antibody (TgAb) levels were determined, and neck ultrasonography was performed. ","['patients with stimulated serum Tg\u2009≥', '10', 'patients with thyroid cancer', 'Chinese patients with low/intermediate risk of recurrence DTC after long-term follow-up', 'patients with differentiated thyroid cancer (DTC', '506 DTC patients at low/intermediate risk of recurrence']","['levothyroxine', 'GBq radioactive iodine (RAI) ablation', 'radioiodine ablation', '3.7\u2009GBq radioactive iodine (RAI) ablation']","['serum thyroglobulin (Tg) and anti-thyroglobulin antibody (TgAb) levels', 'recurrence rate', 'risk of incomplete response', 'structural incomplete response (lymph node metastasis, n\u2009=\u20091), biochemical incomplete response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0040123', 'cui_str': 'Thyroglobulin'}, {'cui': 'C0007115', 'cui_str': 'Malignant tumor of thyroid gland'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205615', 'cui_str': 'Well differentiated'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4722172', 'cui_str': 'Primary differentiated carcinoma of thyroid gland'}]","[{'cui': 'C0040165', 'cui_str': 'levothyroxine'}, {'cui': 'C1688582', 'cui_str': 'GBq'}, {'cui': 'C0034553', 'cui_str': 'Radioactivity'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C2828294', 'cui_str': 'iodide ion I-131'}, {'cui': 'C4517696', 'cui_str': '3.7'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0040123', 'cui_str': 'Thyroglobulin'}, {'cui': 'C0443883', 'cui_str': 'Anti-thyroglobulin antibody'}, {'cui': 'C0201512', 'cui_str': 'Thyroglobulin antibody measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0686619', 'cui_str': 'Secondary malignant neoplasm of lymph node'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}]",506.0,0.0235588,"MEASUREMENTS Suppressed serum thyroglobulin (Tg) and anti-thyroglobulin antibody (TgAb) levels were determined, and neck ultrasonography was performed. ","[{'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Dong', 'Affiliation': 'Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, P. R. China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Qu', 'Affiliation': 'Department of Medical Imaging, East Hospital, Tongji University, Shanghai, P. R. China.'}, {'ForeName': 'Liu', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, P. R. China.'}, {'ForeName': 'Liu', 'Initials': 'L', 'LastName': 'Xiao', 'Affiliation': 'Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, P. R. China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Huang', 'Affiliation': 'Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, P. R. China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, P. R. China.'}]",Clinical endocrinology,['10.1111/cen.14563'] 2069,34368971,Three-step irradiance schedule versus two-step irradiance schedule for pain control during topical 5-aminolevulinic acid-photodynamic therapy of facial acne in Chinese patients: A prospective randomized comparative study.,"BACKGROUND A two-step irradiance schedule has been found to be useful for pain control during photodynamic therapy (PDT) on nonmelanotic skin cancer and condyloma acuminatum. OBJECTIVES To evaluate the efficacy of a new three-step irradiance schedule derived from the psychological ""peak-end rule"" and two-step irradiance schedule in relieving pain during 5-aminolevulinic acid PDT (ALA-PDT) on acne. METHODS A total of 90 moderate to severe acne patients were enrolled in our study and randomly divided into two groups with a ratio of 1:1. They were treated by a light-emitting diode light source of 633 ± 10 nm after being incubated with 5% ALA for an hour using a two-step or three-step irradiance schedule, respectively. The total irradiance intensity was 84 J/cm 2 of each session and the treatment interval was 2 weeks. Pain was recorded 30 min after each PDT using a visual analog scale (VAS). Follow-up was done at baseline and 2 weeks after each treatment. The numbers of lesions were counted after the third treatment through the pictures taken before and all the side effects were recorded at each follow-up visit. RESULTS Eighty-seven subjects completed the total three treatments (44 cases in Group A and 43 cases in Group B). The average VAS of Group B (1.61 ± 0.67) was significantly lower than that of Group A (3.14 ± 0.67), with a difference of 1.52 ± 0.08 (p < 0.0001) between them. Both groups received a similar effective rate after the total three sessions (88.64% vs. 88.37%, p > 0.05). CONCLUSIONS The new three-step irradiance method could relieve pain during ALA-PDT more significantly than the two-step schedule with a similar effective rate.",2021,"The average VAS of Group B (1.61 ± 0.67) was significantly lower than that of Group A (3.14 ± 0.67), with a difference of 1.52 ± 0.08 (p < 0.0001) between them.","['Chinese patients', 'Eighty-seven subjects', '90 moderate to severe acne patients']","['5-aminolevulinic acid-photodynamic therapy', 'light-emitting diode light source of 633\u2009±\u200910\u2009nm after being incubated with 5% ALA', '5-aminolevulinic acid PDT (ALA-PDT', 'photodynamic therapy (PDT']","['visual analog scale (VAS', 'total irradiance intensity', 'Pain', 'effective rate', 'numbers of lesions']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517895', 'cui_str': '87'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}]","[{'cui': 'C0002563', 'cui_str': 'Aminolevulinic Acid'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0162676', 'cui_str': 'Enzyme-multiplied immunoassay technique'}, {'cui': 'C0181633', 'cui_str': 'Light source'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449791', 'cui_str': 'Number of lesions'}]",,0.0308995,"The average VAS of Group B (1.61 ± 0.67) was significantly lower than that of Group A (3.14 ± 0.67), with a difference of 1.52 ± 0.08 (p < 0.0001) between them.","[{'ForeName': 'Hai-En', 'Initials': 'HE', 'LastName': 'Wu', 'Affiliation': ""Department of Dermatology, The Seventh People's Hospital of Shenyang, Shenyang, China.""}, {'ForeName': 'Yong-Bin', 'Initials': 'YB', 'LastName': 'Liu', 'Affiliation': ""Department of Dermatology, The Seventh People's Hospital of Shenyang, Shenyang, China.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Cui', 'Affiliation': ""Department of Dermatology, The Seventh People's Hospital of Shenyang, Shenyang, China.""}, {'ForeName': 'Gui-Juan', 'Initials': 'GJ', 'LastName': 'Xu', 'Affiliation': ""Department of Cardiology, The Seventh People's Hospital of Shenyang, Shenyang, China.""}, {'ForeName': 'Xiao-Dong', 'Initials': 'XD', 'LastName': 'Sun', 'Affiliation': ""Department of Dermatology, The Seventh People's Hospital of Shenyang, Shenyang, China.""}]",Lasers in surgery and medicine,['10.1002/lsm.23464'] 2070,34368947,Multifaceted intervention including Facebook-groups to improve guideline-adherence in ICU: a quasi-experimental interrupted time series study.,"BACKGROUND The impact of social media, with its speed, reach and accessibility, in interventions aimed to improve adherence to guidelines such as assessment of Pain, Agitation/Sedation and Delirium (PAD) in intensive care is not described. Therefore, the primary objective of this quality improvement study was to evaluate the impact of a multifaceted intervention including audit and feedback of quality indicators (QI) via Facebook-groups, educational events, and engagement of opinion leaders on adherence to PAD-guidelines in four ICUs. METHODS A quasi-experimental interrupted time series study with eight monthly data points in the two phases Before and Intervention was designed. Proportion of nursing shifts with documented PAD-assessment (PAD-QIs) were retrieved from the electronical medical chart from included adult ICU patient-stays in four participating ICUs. Difference between the two time-periods was assessed using generalized mixed model for repeated measures with unstructured covariance matrix, and presented as Beta (B) with 95% confidence interval (CI). RESULTS Finally, 1049 ICU patient-stays were analysed; 534 in Before and 515 in Intervention. All three PAD-QIs significantly increased in Intervention by 31% (B=30.7, 95%CI [25.7 to 35.8]), 26% (B=25.8, 95%CI [19.4 to 32.2]), and 34% (B=33.9, 95%CI [28.4 to 39.4]) in pain, agitation/sedation and delirium, respectively. CONCLUSION A multifaceted intervention including use of Facebook-groups was associated with improved guideline-adherence in four ICUs, as measured with process PAD-QIs of PAD assessment. Further research on use of social media to improve guideline adherence is warranted, particularly as social distancing impacts clinical education and training and new approaches are needed.",2021,"A multifaceted intervention including use of Facebook-groups was associated with improved guideline-adherence in four ICUs, as measured with process PAD-QIs of PAD assessment.",['Proportion of nursing shifts with documented PAD-assessment (PAD-QIs) were retrieved from the electronical medical chart from included adult ICU patient-stays in four participating ICUs'],[],"['PAD-QIs', 'pain, agitation/sedation and delirium']","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}]",,0.0612266,"A multifaceted intervention including use of Facebook-groups was associated with improved guideline-adherence in four ICUs, as measured with process PAD-QIs of PAD assessment.","[{'ForeName': 'Antonija', 'Initials': 'A', 'LastName': 'Petosic', 'Affiliation': 'Oslo University Hospital, Division of Emergencies and critical care, Department of Postoperative and Intensive care, Oslo, Norway.'}, {'ForeName': 'Milada C', 'Initials': 'MC', 'LastName': 'Småstuen', 'Affiliation': 'Oslo Metropolitan University, Department of Public Health.'}, {'ForeName': 'Dimitri', 'Initials': 'D', 'LastName': 'Beeckman', 'Affiliation': 'Ghent University, Skin Integrity Research Group (SKINT), University Centre for Nursing and Midwifery, Department of Public Health and Primary Care, Ghent, Belgium.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Flaatten', 'Affiliation': 'University of Bergen, Bergen, Norway.'}, {'ForeName': 'Kjetil', 'Initials': 'K', 'LastName': 'Sunde', 'Affiliation': 'Oslo University Hospital, Division of Emergencies and critical care, Department of Anaesthesiology, Oslo, Norway.'}, {'ForeName': 'Hilde', 'Initials': 'H', 'LastName': 'Wøien', 'Affiliation': 'Oslo University Hospital, Division of Emergencies and critical care, Department of Postoperative and Intensive care, Oslo, Norway.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13969'] 2071,34368943,Efficacy and Tolerability of Oral Compared with Sublingual Ketamine Lozenges as Rescue Analgesics in Adults for Acute Pain: The OSKet Trial.,"BACKGROUND AND OBJECTIVE Ketamine is an N-methyl-D-aspartate receptor (NMDA) antagonist used widely as an intravenous analgesic for treatment of acute pain. Its use as oral and sublingual analgesics is not well studied. This study aims to compare the clinical efficacy and tolerability of oral (PO) versus sublingual (SL) ketamine lozenges in adult patients with moderate-to-severe breakthrough pain. METHODS The study had a randomized, double-blind crossover design in 23 inpatients requiring ketamine as rescue analgesics when pain scores exceeded 4/10 on the Numerical Rating Scales. Each participant received either SL 50 mg ketamine lozenge and PO placebo lozenge or SL placebo lozenge and PO 50 mg ketamine lozenge in two treatment periods with a minimum 24-h washout. Pain scores and adverse effects were documented half hourly for the first 2 h, then one hourly for the next 2 h after treatment. The time to first effect and time to meaningful pain relief were recorded. Patients reported their satisfaction and a global impression of change (GIC) at the end of each treatment period. Data were analysed using random effects regression models. RESULTS Sixteen subjects completed both days, 7 completed 1 day. Time to first effect was 13.1 min PO versus 6.6 min SL (p = 0.069), time to meaningful pain relief was 29.4 min PO versus 10.8 min SL (p = 0.02). Pain scores were not significantly different at all time points post-treatment. Satisfaction and GIC scores were similar for both groups. Overall, adverse events occurred more often with SL administration (p = 0.02). CONCLUSIONS Sublingual administration of ketamine led to a faster onset of pain relief (but also a higher adverse event rate), but in all other aspects treatment with ketamine given sublingually and orally produced similar analgesic effects. ACTRN ACTRN12621000240842, 08/03/2021, retrospectively registered.",2021,"Time to first effect was 13.1 min PO versus 6.6 min SL (p = 0.069), time to meaningful pain relief was 29.4 min PO versus 10.8 min SL (p = 0.02).","['Adults for Acute Pain', '23 inpatients requiring', 'adult patients with moderate-to-severe breakthrough pain']","['Ketamine', 'Sublingual Ketamine Lozenges', 'SL 50 mg ketamine lozenge and PO placebo lozenge or SL placebo lozenge and PO 50 mg ketamine lozenge', 'ketamine', 'sublingual (SL) ketamine lozenges', 'oral (PO']","['satisfaction and a global impression of change (GIC', 'Efficacy and Tolerability', 'time to meaningful pain relief', 'time to first effect and time to meaningful pain relief', 'Satisfaction and GIC scores', 'Pain scores', 'clinical efficacy and tolerability', 'adverse events', 'pain relief', 'Pain scores and adverse effects', 'pain scores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0184567', 'cui_str': 'Acute pain'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C1135120', 'cui_str': 'Breakthrough pain'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C0991564', 'cui_str': 'Lozenge'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",23.0,0.333511,"Time to first effect was 13.1 min PO versus 6.6 min SL (p = 0.069), time to meaningful pain relief was 29.4 min PO versus 10.8 min SL (p = 0.02).","[{'ForeName': 'Chui C', 'Initials': 'CC', 'LastName': 'Chong', 'Affiliation': 'Department of Anaesthesia and Pain, Royal Perth Hospital, GPO Box X2213, Perth, WA, 6847, Australia. chui.chong@health.wa.gov.au.'}, {'ForeName': 'Stephan A', 'Initials': 'SA', 'LastName': 'Schug', 'Affiliation': 'Emeritus Professor and Honorary Senior Research Fellow, Anaesthesiology and Pain Medicine, Medical School, University of Western Australia, Royal Perth Hospital, Level 4 MRF Building, GPO Box X2213, Perth, WA, 6847, Australia.'}]",Clinical drug investigation,['10.1007/s40261-021-01066-x'] 2072,34368944,A comparison of the in vitro effects of three fibrinogen concentrates on clot strength in blood samples from cardiac surgery patients.,"BACKGROUND Fibrinogen concentrate is used clinically to improve hemostasis in bleeding patients. We investigated and compared the efficacy of three commercially available fibrinogen concentrates to improve clot strength in blood samples from cardiac surgery patients. OBJECTIVES Postoperative blood samples were collected from 23 cardiac surgery patients. Samples were each divided into four vials, each supplemented with 1.125 mg of fibrinogen of one of three fibrinogen concentrates (RiaSTAP®, Fibryga®, FibCLOT®), or placebo. The fibrinogen dose corresponded to 2.5 g per 70 kg of body weight. Clot strength after supplementation was assessed in duplicate with rotational thromboelastometry (ROTEM®) using FIBTEM maximum clot firmness, EXTEM clot formation time, and maximum clot firmness assays. RESULTS In vitro fibrinogen concentrate supplementation of the samples resulted in higher plasma fibrinogen concentrations and improved clot strength with all three concentrates. Supplementation with FibCLOT increased FIBTEM maximum clot firmness (+46% [25th-75th percentile 35-55] compared to placebo) significantly more than did supplementation with Fibryga (+26% [21-35]) and RiaSTAP (+29% [22-47]), p<0.001). FibCLOT supplementation also shortened EXTEM clot formation time and increased EXTEM maximum clot firmness to a greater extent than did the other concentrates (both p<0.001). CONCLUSIONS At the selected dose, FibCLOT was more effective than Fibryga and RiaSTAP in restoring clot strength in postoperative blood samples from cardiac surgery patients. These results may have implications for the choice of fibrinogen concentrate and dosing.",2021,"FibCLOT supplementation also shortened EXTEM clot formation time and increased EXTEM maximum clot firmness to a greater extent than did the other concentrates (both p<0.001). ","['cardiac surgery patients', '23 cardiac surgery patients', 'bleeding patients']","['RiaSTAP', 'FibCLOT supplementation', 'Fibryga and RiaSTAP', 'fibrinogen concentrates', 'fibrinogen concentrates (RiaSTAP®, Fibryga®, FibCLOT®), or placebo', 'FibCLOT']","['FIBTEM maximum clot firmness', 'Clot strength', 'clot strength', 'plasma fibrinogen concentrations']","[{'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]","[{'cui': 'C2587183', 'cui_str': 'RiaSTAP'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C4529781', 'cui_str': 'Fibryga'}, {'cui': 'C2587184', 'cui_str': 'fibrinogen concentrate (human)'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0009074', 'cui_str': 'Clotrimazole'}, {'cui': 'C0856510', 'cui_str': 'Plasma fibrinogen'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.102486,"FibCLOT supplementation also shortened EXTEM clot formation time and increased EXTEM maximum clot firmness to a greater extent than did the other concentrates (both p<0.001). ","[{'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Stolt', 'Affiliation': 'Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Shams Hakimi', 'Affiliation': 'Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Sukhi', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Jeppsson', 'Affiliation': 'Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Karlsson', 'Affiliation': 'Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13967'] 2073,34368934,Economic Evaluation of an Intervention Designed to Reduce Bullying in Australian Schools.,"BACKGROUND There is a shortage of information on the costs and benefits of anti-bullying programs implemented in Australia. Information on the costs and benefits of anti-bullying programs is vital to assist policy making regarding the adoption of these programs. The aim of this study was to estimate the changes to costs and health benefits of implementing the ""Friendly Schools Friendly Families"" (FSFF) anti-bullying intervention in Australia. METHODS A societal perspective cost-effectiveness analysis was undertaken based on randomised controlled trial data for an anti-bullying intervention implemented in primary schools in Western Australia. The modelling strategy addressed changes to costs comprising intervention costs, less cost-savings, and then changes to health benefits measured by avoidable disability-adjusted life years (DALYs). Costs and health benefits were identified, measured, and valued in 2016 Australian dollars. Intermediate events modelled included anxiety disorders, depressive disorders, intentional self-harm, cost-savings accrued by educator time, and reduced productivity losses for carers associated with absenteeism. Uncertainty analysis and scenario analyses were also conducted. RESULTS The prevalence of bullying victimisation was reduced by 18% by the Friendly Schools Friendly Families anti-bullying intervention. At a national level, this is expected to result in the avoidance of 9114 DALYs (95% CI 8770-9459) and cost-savings of A$120 million per year. The majority of cost-savings were associated with the reduction in mental healthcare. The model results demonstrated that the FSFF anti-bullying intervention is likely to be a cost-effective approach to reduce bullying in Australia, relative to a threshold of A$50,000 per DALY averted, with an ICER of A$1646. CONCLUSIONS The Friendly Schools Friendly Families anti-bullying intervention represents a good investment compared to usual activities for the management of child and adolescent bullying in Australia. The investment and implementation of evidence-based interventions that reduce bullying victimisation and bullying perpetration in schools could reduce the economic burden associated with common mental health disorders and thereby improve the health of many Australians.",2021,The prevalence of bullying victimisation was reduced by 18% by the Friendly Schools Friendly Families anti-bullying intervention.,"['primary schools in Western Australia', 'Friendly Schools Friendly Families"" (FSFF) anti-bullying intervention in Australia', 'child and adolescent bullying in Australia', 'Australian Schools']",[],"['cost-savings', 'Costs and health benefits', 'prevalence of bullying victimisation', 'anxiety disorders, depressive disorders, intentional self-harm, cost-savings accrued by educator time, and reduced productivity losses']","[{'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0043128', 'cui_str': 'Western Australia'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0424318', 'cui_str': 'Bullying'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]",[],"[{'cui': 'C0085550', 'cui_str': 'Cost Savings'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0086387', 'cui_str': 'Health Benefits'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0424318', 'cui_str': 'Bullying'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0011581', 'cui_str': 'Depressive disorder'}, {'cui': 'C0480203', 'cui_str': 'Self inflicted injury'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}]",,0.0692247,The prevalence of bullying victimisation was reduced by 18% by the Friendly Schools Friendly Families anti-bullying intervention.,"[{'ForeName': 'Amarzaya', 'Initials': 'A', 'LastName': 'Jadambaa', 'Affiliation': 'School of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Kelvin Grove, QLD, Australia. jadambaa@qut.edu.au.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Graves', 'Affiliation': 'Duke-NUS Medical School, Health Services and Systems Research, 8 College Road, Singapore, Singapore.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Cross', 'Affiliation': 'Child Health Promotion Research Centre, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, 2 Bradford Street, Mount Lawley, WA, Australia.'}, {'ForeName': 'Rosana', 'Initials': 'R', 'LastName': 'Pacella', 'Affiliation': 'School of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Kelvin Grove, QLD, Australia.'}, {'ForeName': 'Hannah J', 'Initials': 'HJ', 'LastName': 'Thomas', 'Affiliation': 'Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, QLD, Australia.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Scott', 'Affiliation': 'Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, QLD, Australia.'}, {'ForeName': 'Qinglu', 'Initials': 'Q', 'LastName': 'Cheng', 'Affiliation': 'Kirby Institute, The University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Brain', 'Affiliation': 'School of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Kelvin Grove, QLD, Australia.'}]",Applied health economics and health policy,['10.1007/s40258-021-00676-y'] 2074,34368923,Three-dimensional assessment of two different canine retraction techniques: a randomized split-mouth clinical trial.,"INTRODUCTION The aim of this split-mouth trial was to compare power-arm sliding (PAS) and direct sliding (DS) canine retraction mechanics in terms of speed, rotation, angulation, and anchorage loss. METHODS Thirty-six class II division 1 patients (20 females, 16 males; mean age, 16.94 ± 3.23) requiring upper first premolar extraction were included in the study. Miniscrews were used as anchorage units, and a retraction force of 150 gr was applied from the power arm on one side and from the bracket on the opposite side by using elastomeric chains. Randomization was achieved by block randomization with a 1:1 allocation ratio either to the right or the left with allocations concealed in opaque, sealed envelopes. Digital models were acquired using an intraoral scanner at the beginning of the retraction (T0), the first month (T1), the second month (T2), and the third month (T3). Before the scans, the archwire was removed, and custom metal jigs were inserted into the vertical slot of the canine brackets to evaluate the canine angulation. The digital models of each patient were separately superimposed with the local best-fit algorithm, and the retraction rate, angulation, rotation, and anchorage loss were measured. The digital measurements were performed using the Geomagic Control X software. RESULTS The DS technique's total retraction rate was higher than that of the PAS technique (2.09 and 1.57, respectively, p = .002). There was, however, no significant difference between the two techniques in terms of angulation, rotation, and anchorage loss. A negative correlation was observed between the retraction rate and age, but it was not statistically significant. No significant difference was observed between the retraction rates of female and male participants in either retraction technique. CONCLUSIONS For both orthodontists and patients, the DS technique is simpler and more convenient; thus, it is the preferred method for canine retraction. TRIAL REGISTRATION The trial was not registered. PROTOCOL The protocol was not published before the trial commencement.",2021,"There was, however, no significant difference between the two techniques in terms of angulation, rotation, and anchorage loss.","['Thirty-six class II division 1 patients (20 females, 16 males; mean age, 16.94 ± 3.23) requiring upper first premolar extraction were included in the study']",['power-arm sliding (PAS) and direct sliding (DS) canine retraction mechanics'],"['retraction rate, angulation, rotation, and anchorage loss', 'speed, rotation, angulation, and anchorage loss', 'retraction rate', 'retraction rates', 'angulation, rotation, and anchorage loss', ""DS technique's total retraction rate""]","[{'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0441886', 'cui_str': 'Class 2'}, {'cui': 'C1293097', 'cui_str': 'Division'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332246', 'cui_str': 'Sliding'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}, {'cui': 'C0332523', 'cui_str': 'Retraction'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}]","[{'cui': 'C0332523', 'cui_str': 'Retraction'}, {'cui': 'C0333179', 'cui_str': 'Angulated'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0332246', 'cui_str': 'Sliding'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.0654288,"There was, however, no significant difference between the two techniques in terms of angulation, rotation, and anchorage loss.","[{'ForeName': 'Şuayip', 'Initials': 'Ş', 'LastName': 'Akın', 'Affiliation': 'Department of Orthodontics, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Camcı', 'Affiliation': 'Department of Orthodontics, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey. dt.hasan@hotmail.com.'}]",Progress in orthodontics,['10.1186/s40510-021-00374-4'] 2075,34368921,A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.,"BACKGROUND Although FOLFIRINOX is currently one of the standard therapies for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC), the high rate of febrile neutropenia (FN) presents a clinical problem. This study aimed to evaluate the safety and efficacy of primary prophylactic pegfilgrastim with FOLFIRINOX in Japanese MPC patients. METHODS FOLFIRINOX (intravenous oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , levofolinate 200 mg/m 2 , 5-fluorouracil (5-FU) bolus 400 mg/m 2 and 5-FU 46 h infusion 2400 mg/m 2 ) and pegfilgrastim 3.6 mg on day 4 or 5, every 2 weeks was administered to previously untreated MPC patients. The primary endpoint was the incidence of FN during the first 3 cycles. The planned sample size was 35 patients, but the trial was predefined to discontinue enrollment for safety if 4 patients developed FN. RESULTS At the enrollment of 22 patients, 4 patients developed FN in the first cycle, resulting in an incidence of FN of 18% {95% confidence interval [CI], 0.5-40.3%}, and enrollment was discontinued early. The incidence of grade 3 or higher neutropenia was 36.4%. Median relative dose intensities during the initial 3 cycles of oxaliplatin, irinotecan, bolus 5-FU, infusional 5-FU, and levofolinate maintained high (100%, 89.0%, 100%, 66.0%, and 100%, respectively). Response rate and median overall survival were 54.5% (95% CI 32.7-74.9) and 15.7 months (95% CI 7.9-18.8), respectively. CONCLUSIONS This phase II study could not demonstrate any reduction in the incidence of FN, nevertheless some patients experience benefits for efficacy by maintaining dose intensity using prophylactic pegfilgrastim. TRIAL REGISTRATION http://www.umin.ac.jp/ctr/index-j.htm , UMIN000017538. Date of registration: May/13/2015.",2021,"Response rate and median overall survival were 54.5% (95% CI 32.7-74.9) and 15.7 months (95% CI 7.9-18.8), respectively. ","['naïve Japanese patients with metastatic pancreatic cancer', 'Japanese MPC patients', 'chemotherapy-naïve patients with metastatic pancreatic cancer (MPC']","['oxaliplatin, irinotecan, bolus 5-FU, infusional 5-FU, and levofolinate', 'oxaliplatin 85', 'pegfilgrastim', '5-FU 46', 'irinotecan 180\xa0mg/m 2 , levofolinate 200\xa0mg/m 2 , 5-fluorouracil (5-FU) bolus', 'chemotherapy', 'primary prophylactic pegfilgrastim']","['incidence of FN', 'Response rate and median overall survival', 'safety and efficacy', 'incidence of grade 3 or higher neutropenia', 'Median relative dose intensities']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0346976', 'cui_str': 'Secondary malignant neoplasm of pancreas'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C2721771', 'cui_str': 'levoleucovorin'}, {'cui': 'C1136535', 'cui_str': 'pegfilgrastim'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0009653', 'cui_str': 'Condom'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",,0.169733,"Response rate and median overall survival were 54.5% (95% CI 32.7-74.9) and 15.7 months (95% CI 7.9-18.8), respectively. ","[{'ForeName': 'Mitsuhito', 'Initials': 'M', 'LastName': 'Sasaki', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. mitsasak@east.ncc.go.jp.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Ueno', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Shuichi', 'Initials': 'S', 'LastName': 'Mitsunaga', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Ohba', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Hosoi', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Kobayashi', 'Affiliation': 'Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Ueno', 'Affiliation': 'Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.'}, {'ForeName': 'Tetsuji', 'Initials': 'T', 'LastName': 'Terazawa', 'Affiliation': 'Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Osaka, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Goto', 'Affiliation': 'Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Osaka, Japan.'}, {'ForeName': 'Dai', 'Initials': 'D', 'LastName': 'Inoue', 'Affiliation': 'Department of Gastroenterology and Hepatology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Namiki', 'Affiliation': 'Department of Gastroenterology and Hepatology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo, Japan.'}, {'ForeName': 'Yasunari', 'Initials': 'Y', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Shunsuke', 'Initials': 'S', 'LastName': 'Kondo', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Chigusa', 'Initials': 'C', 'LastName': 'Morizane', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Ikeda', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.'}, {'ForeName': 'Takuji', 'Initials': 'T', 'LastName': 'Okusaka', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}]",International journal of clinical oncology,['10.1007/s10147-021-02001-y'] 2076,34368905,Minimal graft site morbidity using autogenous semitendinosus graft from the uninjured leg: a randomised controlled trial.,"PURPOSE To quantify the effect on strength of semitendinosus (ST) graft harvest by comparing isokinetic and isometric muscle strength. METHODS A cohort of 140 patients underwent anterior cruciate ligament (ACL) reconstruction (ACLR) and were randomized to ipsilateral or contralateral ST graft harvest. Isokinetic and isometric muscle strength testing using a dynamometer were collected for the operated and non-operated leg. Patients were assessed pre-surgery and at 6, 12 and 24 months after reconstruction. RESULTS ST graft harvest reduced isokinetic flexion muscle strength for 6 months. At 12 months follow up there was no significant difference between the two groups and they were all stronger than pre-injury. No other significant differences were found in any primary or secondary outcome measurements. CONCLUSION Solitary ST graft harvest does not appear to result in a permanent reduced isometric or isokinetic quadriceps muscle strength on the side where the graft is harvested. A reduction in hamstring muscle strength of less than 10% can be seen at short-term follow-up with full recovery by 12 months. Most patients report little or no donor site pain. Given these findings, ST autograft is an alternative graft choice that could be used for various reconstructions in terms of donor site morbidity. LEVEL OF EVIDENCE Level II.",2021,At 12 months follow up there was no significant difference between the two groups and they were all stronger than pre-injury.,['140 patients underwent'],"['anterior cruciate ligament (ACL) reconstruction (ACLR', 'ipsilateral or contralateral ST graft harvest', 'autogenous semitendinosus graft', 'ST autograft']","['strength of semitendinosus (ST) graft harvest', 'isokinetic flexion muscle strength', 'Minimal graft site morbidity', 'isometric or isokinetic quadriceps muscle strength', 'hamstring muscle strength']","[{'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0224453', 'cui_str': 'Semitendinosus muscle structure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0443145', 'cui_str': 'Autogenous'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}]","[{'cui': 'C0224453', 'cui_str': 'Semitendinosus muscle structure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}]",140.0,0.0443818,At 12 months follow up there was no significant difference between the two groups and they were all stronger than pre-injury.,"[{'ForeName': 'Christoffer', 'Initials': 'C', 'LastName': 'von Essen', 'Affiliation': 'Department of Orthopaedics, Stockholm South Hospital, Karolinska Institutet, Stockholm, Sweden. Christoffer.vonessen@gmail.com.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'McCallum', 'Affiliation': 'Department of Orthopaedics, Stockholm South Hospital, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Eriksson', 'Affiliation': 'Department of Orthopaedics, Stockholm South Hospital, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Barenius', 'Affiliation': 'Department of Orthopaedics, Stockholm South Hospital, Karolinska Institutet, Stockholm, Sweden.'}]","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA",['10.1007/s00167-021-06686-6'] 2077,34360494,Association of Self-Reported Physical Fitness during Late Pregnancy with Birth Outcomes and Oxytocin Administration during Labour-The GESTAFIT Project.,"We explored (a) the associations between self-reported maternal physical fitness and birth outcomes; (b) whether self-reported maternal physical fitness (PF) is related to the administration of oxytocin to induce or stimulate labour. Pregnant women from the GESTAFIT project randomized controlled trial (n = 117) participated in this prospective longitudinal study. Maternal physical fitness was assessed through the International Fitness Scale at the 34th gestational week. Maternal and neonatal birth outcomes and oxytocin administration were collected from the obstetric medical records. Umbilical arterial and venous cord blood gas were analysed immediately after birth. Self-reported overall fitness, cardiorespiratory fitness, muscular strength and flexibility were not related to any maternal and neonatal birth outcomes (all p > 0.05). Greater speed-agility was associated with a more alkaline arterial ( p = 0.04) and venous ( p = 0.02) pH in the umbilical cord blood. Women who were administered oxytocin to induce or stimulate labour reported lower cardiorespiratory fitness ( p = 0.013, Cohen's d = 0.55; 95% confidence interval (CI): 0.14, 0.93) and flexibility ( p = 0.040, Cohen´s d = 0.51; 95% CI: 0.09, 0.89) compared to women who were not administered oxytocin. Greater maternal physical fitness during pregnancy could be associated with better neonatal birth outcomes and lower risk of needing oxytocin administration.",2021,"Self-reported overall fitness, cardiorespiratory fitness, muscular strength and flexibility were not related to any maternal and neonatal birth outcomes (all p > 0.05).",['Pregnant women from the GESTAFIT project randomized controlled trial (n = 117) participated in this prospective longitudinal study'],"['oxytocin', 'Oxytocin']","['maternal physical fitness', 'maternal physical fitness (PF', 'cardiorespiratory fitness', 'flexibility', 'Greater speed-agility', 'overall fitness, cardiorespiratory fitness, muscular strength and flexibility', 'Maternal physical fitness', 'Umbilical arterial and venous cord blood gas', 'maternal and neonatal birth outcomes']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0041638', 'cui_str': 'Umbilical structure'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0162371', 'cui_str': 'Cord blood'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1286282', 'cui_str': 'Birth outcome'}]",117.0,0.250247,"Self-reported overall fitness, cardiorespiratory fitness, muscular strength and flexibility were not related to any maternal and neonatal birth outcomes (all p > 0.05).","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Baena-García', 'Affiliation': 'Department of Nursing, Faculty of Health Sciences, University of Granada, 51001 Ceuta, Spain.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Marín-Jiménez', 'Affiliation': 'Sport and Health University Research Institute (iMUDS), 18007 Granada, Spain.'}, {'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Romero-Gallardo', 'Affiliation': 'Sport and Health University Research Institute (iMUDS), 18007 Granada, Spain.'}, {'ForeName': 'Milkana', 'Initials': 'M', 'LastName': 'Borges-Cosic', 'Affiliation': 'Sport and Health University Research Institute (iMUDS), 18007 Granada, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Ocón-Hernández', 'Affiliation': ""Gynaecology and Obstetrics Unit, 'San Cecilio' University Hospital, 18016 Granada, Spain.""}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Flor-Alemany', 'Affiliation': 'Sport and Health University Research Institute (iMUDS), 18007 Granada, Spain.'}, {'ForeName': 'Virginia A', 'Initials': 'VA', 'LastName': 'Aparicio', 'Affiliation': 'Institute of Nutrition and Food Technology (INYTA), Biomedical Research Centre (CIBM), University of Granada, 18016 Granada, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18158201'] 2078,34360490,The Humanoid Robot Sil-Bot in a Cognitive Training Program for Community-Dwelling Elderly People with Mild Cognitive Impairment during the COVID-19 Pandemic: A Randomized Controlled Trial.,"BACKGROUND Mild cognitive impairment (MCI) is a stage preceding dementia, and early intervention is critical. This study investigated whether multi-domain cognitive training programs, especially robot-assisted training, conducted 12 times, twice a week for 6 weeks can improve cognitive function and depression decline in community-dwelling older adults with mild cognitive impairment (MCI). METHODS A randomized controlled trial was conducted with 135 volunteers without cognitive impairment aged 60 years old or older. Participants were first randomized into two groups. One group consisted of 90 participants who would receive cognitive training and 45 who would not receive any training (NI). The cognitive training group was randomly divided into two groups, 45 who received traditional cognitive training (TCT) and 45 who received robot-assisted cognitive training (RACT). The training for both groups consisted of a daily 60 min session, twice a week for six weeks. RESULTS RACT participants had significantly greater post-intervention improvement in cognitive function ( t = 4.707, p < 0.001), memory ( t = -2.282, p = 0.007), executive function (t = 4.610, p < 0.001), and depression ( t = -3.307, p = 0.004). TCT participants had greater post-intervention improvement in memory ( t = -6.671, p < 0.001) and executive function ( t = 5.393, p < 0.001). CONCLUSIONS A 6-week robot-assisted, multi-domain cognitive training program can improve the efficiency of global cognitive function and depression during cognitive tasks in older adults with MCI, which is associated with improvements in memory and executive function.",2021,"TCT participants had greater post-intervention improvement in memory ( t = -6.671, p < 0.001) and executive function ( t = 5.393, p < 0.001). ","['Community-Dwelling Elderly People with Mild Cognitive Impairment during the COVID-19 Pandemic', '135 volunteers without cognitive impairment aged 60 years old or older', 'older adults with MCI', 'community-dwelling older adults with mild cognitive impairment (MCI']","['Humanoid Robot Sil-Bot in a Cognitive Training Program', 'cognitive training', 'traditional cognitive training (TCT) and 45 who received robot-assisted cognitive training (RACT', '90 participants who would receive cognitive training and 45 who would not receive any training (NI', 'TCT', 'multi-domain cognitive training programs, especially robot-assisted training']","['cognitive function', 'depression', 'memory and executive function', 'cognitive function and depression decline', 'executive function']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0257766', 'cui_str': 'SILV protein, human'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",135.0,0.0366057,"TCT participants had greater post-intervention improvement in memory ( t = -6.671, p < 0.001) and executive function ( t = 5.393, p < 0.001). ","[{'ForeName': 'Eun-A', 'Initials': 'EA', 'LastName': 'Park', 'Affiliation': 'College of Nursing, Bucheon University, Bucheon 14774, Korea.'}, {'ForeName': 'Ae-Ri', 'Initials': 'AR', 'LastName': 'Jung', 'Affiliation': 'College of Nursing, Bucheon University, Bucheon 14774, Korea.'}, {'ForeName': 'Kyoung-A', 'Initials': 'KA', 'LastName': 'Lee', 'Affiliation': 'Research Institute of Nursing Science, Seoul National University, Seoul 03080, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph18158198'] 2079,34360464,Affective and Enjoyment Responses to Sprint Interval Exercise at Different Hypoxia Levels.,"Benefits of performing sprint interval training (SIT) under hypoxic conditions on improving cardiorespiratory fitness and body composition have been well-documented, yet data is still lacking regarding affective responses to SIT under hypoxia. This study aimed to compare affective responses to SIT exercise under different oxygen conditions. Nineteen active males participated in three sessions of acute SIT exercise (20 repetitions of 6 s of all-out cycling bouts interspersed with 15 s of passive recovery) under conditions of normobaric normoxia (SL: PIO 2 150 mmHg, FIO 2 0.209), moderate hypoxia (MH: PIO 2 117 mmHg, FIO 2 0.154, simulating an altitude corresponding to 2500 m), and severe hypoxia (SH: PIO 2 87 mmHg, FIO 2 0.112, simulating an altitude of 5000 m) in a randomized order. Perceived exertions (RPE), affect, activation, and enjoyment responses were recorded before and immediately after each SIT session. There were no significant differences across the three conditions in RPE or the measurements of affective responses, despite a statistically lower SpO 2 (%) in severe hypoxia. Participants maintained a positive affect valence and reported increased activation in all the three SIT conditions. Additionally, participants experienced a medium level of enjoyment after exercise as indicated by the exercise enjoyment scale (EES) and physical activity enjoyment scale (PACES). These results indicated that performing short duration SIT exercise under severe hypoxia could be perceived as pleasurable and enjoyable as performing it under normoxia in active male population.",2021,"There were no significant differences across the three conditions in RPE or the measurements of affective responses, despite a statistically lower SpO 2 (%) in severe hypoxia.",['Nineteen active males'],"['SIT exercise', 'performing sprint interval training (SIT', 'acute SIT exercise (20 repetitions of 6 s of all-out cycling bouts interspersed with 15 s of passive recovery) under conditions of normobaric normoxia (SL: PIO 2 150 mmHg, FIO 2 0.209), moderate hypoxia']","['severe hypoxia', 'activation', 'Perceived exertions (RPE), affect, activation, and enjoyment responses', 'exercise enjoyment scale (EES) and physical activity enjoyment scale (PACES']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C4279979', 'cui_str': 'Sprint Interval Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0030800', 'cui_str': 'Pemoline'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0287990', 'cui_str': 'Furin'}]",19.0,0.0255776,"There were no significant differences across the three conditions in RPE or the measurements of affective responses, despite a statistically lower SpO 2 (%) in severe hypoxia.","[{'ForeName': 'Zhaowei', 'Initials': 'Z', 'LastName': 'Kong', 'Affiliation': 'Faculty of Education, University of Macau, Macao 999078, China.'}, {'ForeName': 'Mingzhu', 'Initials': 'M', 'LastName': 'Hu', 'Affiliation': 'Faculty of Education, University of Macau, Macao 999078, China.'}, {'ForeName': 'Shengyan', 'Initials': 'S', 'LastName': 'Sun', 'Affiliation': 'Institute of Physical Education, Huzhou University, Huzhou 313000, China.'}, {'ForeName': 'Liye', 'Initials': 'L', 'LastName': 'Zou', 'Affiliation': 'Exercise Psychophysiology Laboratory, Institute of KEEP Collaborative Innovation, School of Psychology, Shenzhen University, Shenzhen 518060, China.'}, {'ForeName': 'Qingde', 'Initials': 'Q', 'LastName': 'Shi', 'Affiliation': 'School of Health Sciences and Sports, Macao Polytechnic Institute, Macao 999078, China.'}, {'ForeName': 'Yubo', 'Initials': 'Y', 'LastName': 'Jiao', 'Affiliation': 'Faculty of Education, University of Macau, Macao 999078, China.'}, {'ForeName': 'Jinlei', 'Initials': 'J', 'LastName': 'Nie', 'Affiliation': 'School of Health Sciences and Sports, Macao Polytechnic Institute, Macao 999078, China.'}]",International journal of environmental research and public health,['10.3390/ijerph18158171'] 2080,34360312,Effects of Exercise and Diet on Body Composition and Physical Function in Older Hispanics with Type 2 Diabetes.,"Type 2 Diabetes mellitus (DM2) affects 9.3% of the U.S. population. Health disparities are evident in DM2; twice as many Hispanics as non-Hispanic Whites have DM2. The objective of this study was to pilot test the feasibility of implementing and evaluating trends of nutrition and exercise interventions to improve diabetes management and physical function in 29 disadvantaged older Hispanics with DM2. We delivered combined diet and exercise ( n = 8) and diet-only ( n = 6) interventions and compared the results to a control/no intervention group ( n = 15). We cluster-randomized the participants into the three arms based on the senior center they attended. The interventions were delivered twice a week for 3 months (24 sessions) and assessments were conducted pre and post intervention. The results indicate the feasibility of implementing the interventions and slight improvements in both intervention groups compared to the control group. The diet-only group tended to have larger improvements on body composition measures (especially in muscle mass), while the diet + exercise group tended to have larger improvements on physical function (especially in chair stands). There was a high rate of attrition, especially in the diet + exercise group, but those who completed the intervention tended to have improvements in body composition and physical function.",2021,"The diet-only group tended to have larger improvements on body composition measures (especially in muscle mass), while the diet + exercise group tended to have larger improvements on physical function (especially in chair stands).","['Older Hispanics with Type 2 Diabetes', '29 disadvantaged older Hispanics with DM2']","['nutrition and exercise interventions', 'combined diet and exercise ( n = 8) and diet-only ( n = 6) interventions and compared the results to a control/no intervention group', 'Exercise and Diet']","['Body Composition and Physical Function', 'body composition measures', 'physical function', 'body composition and physical function']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1300562', 'cui_str': 'dm2'}]","[{'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1285593', 'cui_str': 'Body composition measure'}]",29.0,0.00380537,"The diet-only group tended to have larger improvements on body composition measures (especially in muscle mass), while the diet + exercise group tended to have larger improvements on physical function (especially in chair stands).","[{'ForeName': 'Edgar Ramos', 'Initials': 'ER', 'LastName': 'Vieira', 'Affiliation': 'Department of Physical Therapy, Florida International University, Miami, FL 33179, USA.'}, {'ForeName': 'Fabricia Azevedo da Costa', 'Initials': 'FADC', 'LastName': 'Cavalcanti', 'Affiliation': 'Department of Physical Therapy, Federal University of Rio Grande do Norte, Natal 59075-000, RN, Brazil.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Civitella', 'Affiliation': 'Department of Physical Therapy, Florida International University, Miami, FL 33179, USA.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Hollifield', 'Affiliation': 'Department of Dietetics and Nutrition, Florida International University, Miami, FL 33179, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Caceres', 'Affiliation': 'Department of Physical Therapy, Florida International University, Miami, FL 33179, USA.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Carreno', 'Affiliation': 'Department of Physical Therapy, Florida International University, Miami, FL 33179, USA.'}, {'ForeName': 'Trudy', 'Initials': 'T', 'LastName': 'Gaillard', 'Affiliation': 'Department of Undergraduate Nursing, Florida International University, Miami, FL 33179, USA.'}, {'ForeName': 'Fatma G', 'Initials': 'FG', 'LastName': 'Huffman', 'Affiliation': 'Department of Dietetics and Nutrition, Florida International University, Miami, FL 33179, USA.'}, {'ForeName': 'Jorge Camilo', 'Initials': 'JC', 'LastName': 'Mora', 'Affiliation': 'Department of Humanities, Health and Society, Florida International University, Miami, FL 33179, USA.'}, {'ForeName': 'Marcos Roberto', 'Initials': 'MR', 'LastName': 'Queiroga', 'Affiliation': 'Department of Physical Education, Midwestern Parana State University, Guarapuava 85040-167, PR, Brazil.'}]",International journal of environmental research and public health,['10.3390/ijerph18158019'] 2081,34360299,Effectiveness of the Functional and Cognitive Occupational Therapy (FaC o T) Intervention for Improving Daily Functioning and Participation of Individuals with Mild Stroke: A Randomized Controlled Trial.,"BACKGROUND Mild stroke can cause subtle cognitive-behavioral symptoms, which although might be hidden, can restrict community reintegration and participation. Cognitive rehabilitation programs exist for stroke but not specifically for mild stroke and the research evidence varies. The Functional and Cognitive Occupational Therapy (FaC o T) intervention was developed specifically for this population. OBJECTIVE To examine the effectiveness of FaC o T intervention for improving daily functioning and participation compared with standard care. METHOD A single blind randomized controlled trial with assessments pre (T1), post (T2) and 3-month follow-up (T3). Individuals in the FaC o T group received 10 weekly sessions practicing cognitive and behavioral strategies. The Canadian Occupational Performance Measure (COPM) was the primary outcome measure, IADL-questionnaire, Reintegration to Normal Living questionnaire (RNL) were secondary measures. RESULTS In total, 66 community-dwelling individuals with mild stroke were randomly allocated to FaC o T ( n = 33, mean (SD) age 64.6 (8.2), 33% women), or control group ( n = 33, mean (SD) age 64.4 (10.8), 45% women). Time X Group interaction effects were found for the COPM performance ( F (1.4,90.3) = 11.75, p < 0.000) and satisfaction ( F (1.5,96.8) = 15.70, p < 0.000), with large effect size values. Significant between-group effects were found for RNL ( F = 10.02, p < 0.002, ɳ P 2 = 0.13). Most participants in FaC o T achieved a clinically important difference in COPM between T1-T2, T1-T3, and in RNL between T1 to T3 compared with the control group. CONCLUSIONS FaC o T intervention is effective to improve daily functioning, participation and satisfaction of individuals with mild stroke compared with standard care, therefore FaC o T should be implemented in community rehabilitation settings.",2021,"Significant between-group effects were found for RNL ( F = 10.02, p < 0.002, ɳ P 2 = 0.13).","[' n = 33, mean (SD) age 64.6 (8.2), 33% women), or control group ( n = 33, mean (SD) age 64.4 (10.8), 45% women', 'Individuals with Mild Stroke', '66 community-dwelling individuals with mild stroke']","['Functional and Cognitive Occupational Therapy (FaC o T) Intervention', 'FaC o T', 'FaC o T intervention', 'Cognitive rehabilitation programs', 'Functional and Cognitive Occupational Therapy (FaC o T) intervention']","['RNL', 'daily functioning, participation and satisfaction', 'COPM', 'IADL-questionnaire, Reintegration to Normal Living questionnaire (RNL', 'Canadian Occupational Performance Measure (COPM', 'COPM performance']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517523', 'cui_str': '10.8'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0054427', 'cui_str': 'CAF protocol'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C2585956', 'cui_str': 'Canadian occupational performance measure'}, {'cui': 'C0150641', 'cui_str': 'Instrumental activities of daily living'}]",66.0,0.0910431,"Significant between-group effects were found for RNL ( F = 10.02, p < 0.002, ɳ P 2 = 0.13).","[{'ForeName': 'Tal', 'Initials': 'T', 'LastName': 'Adamit', 'Affiliation': 'Department of Occupational Therapy, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Shames', 'Affiliation': 'Maccabi Health-Care Services, Tel-Aviv 6812509, Israel.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Rand', 'Affiliation': 'Department of Occupational Therapy, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel.'}]",International journal of environmental research and public health,['10.3390/ijerph18157988'] 2082,34360294,Effect of Virtual Reality Exercises on the Cognitive Status and Dual Motor Task Performance of the Aging Population.,"Aging is a global phenomenon affecting numerous developed and developing countries. During this process, the functional state of the body, especially the cognitive state, declines. This research investigated the impact of virtual reality exercises on the cognitive status and dual-task performance in the elderly of Tabriz city, Iran. Forty men with a mean age of 71.5 were selected and assigned to either the experimental ( n = 20) or control groups ( n = 20). Both groups completed the Mini-Mental State Examination for cognitive status. The pre-test was performed through the Timed Up and Go test (TUG) along with a countdown of numbers. Then, the experimental group practiced virtual driving for six weeks, while the control group received no treatment. After the treatment, both groups completed the post-test. At each stage, the test was performed as a dual motor task as well. Data were analyzed using the paired t -test and the independent sample t -test to show the intra-group and inter-group differences, respectively. The results showed a significant improvement in the cognitive status and dual-task performance of the elderly men after the six-week training period, which was also significant compared to the control group. Virtual reality driving can be used to improve the cognitive status and dual task performance of elderly men.",2021,"The results showed a significant improvement in the cognitive status and dual-task performance of the elderly men after the six-week training period, which was also significant compared to the control group.","['elderly men', 'elderly of Tabriz city, Iran', 'Forty men with a mean age of 71.5 were selected and assigned to either the experimental ( n = 20) or control groups ( n = 20']","['virtual reality exercises', 'Virtual Reality Exercises']","['cognitive status and dual-task performance', 'Cognitive Status and Dual Motor Task Performance']","[{'cui': 'C0524337', 'cui_str': 'Elderly man'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}]",40.0,0.0733633,"The results showed a significant improvement in the cognitive status and dual-task performance of the elderly men after the six-week training period, which was also significant compared to the control group.","[{'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Nobari', 'Affiliation': 'Department of Physical Education and Sports, University of Granada, 18010 Granada, Spain.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Rezaei', 'Affiliation': 'Departments of Physical Education and Sport Sciences, University of Tehran, Tehran 6619-14155, Iran.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Sheikh', 'Affiliation': 'Departments of Physical Education and Sport Sciences, University of Tehran, Tehran 6619-14155, Iran.'}, {'ForeName': 'Juan Pedro', 'Initials': 'JP', 'LastName': 'Fuentes-García', 'Affiliation': 'Didactic and Behavioral Analysis of Sports (ADICODE) Research Group, Faculty of Sport Sciences, University of Extremadura, 10003 Cáceres, Spain.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Pérez-Gómez', 'Affiliation': 'HEME Research Group, Faculty of Sport Sciences, University of Extremadura, 10003 Cáceres, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18158005'] 2083,34360293,Unsupervised Exercise Training Was Not Found to Improve the Metabolic Health or Phenotype over a 6-Month Dietary Intervention: A Randomised Controlled Trial with an Embedded Economic Analysis.,"Ectopic fat leads to metabolic health problems. This research aimed to assess the effectiveness of a hypocaloric diet intervention together with an unsupervised exercise training program in comparison with a hypocaloric diet alone to reduce ectopic fat deposition. Sixty-one premenopausal women with overweight or obesity participated in this controlled trial and were each randomised into either a usual care group (hypocaloric diet) or intervention group (hypocaloric diet + unsupervised exercise training). Ectopic fat deposition, metabolic parameters, incremental costs from a societal perspective and incremental quality-adjusted life years (QALYs) were assessed before, during and after the six-month intervention period. In the total sample, there was a significant decrease in visceral adipose tissue (VAT: -18.88 cm 2 , 95% CI -11.82 to -25.95), subcutaneous abdominal adipose tissue (SAT: -46.74 cm 2 , 95% CI -29.76 to -63.18), epicardial fat (ECF: -14.50 cm 3 , 95% CI -10.9 to -18.98) and intrahepatic lipid content (IHL: -3.53%, 95% CI -1.72 to -5.32). Consequently, an ""adapted"" economic analysis revealed a non-significant decrease in costs and an increase in QALYs after the intervention. No significant differences were found between groups. A multidisciplinary lifestyle approach seems successful in reducing ectopic fat deposition and improving the metabolic risk profile in women with overweight and obesity. The addition of unsupervised exercise training did not further improve the metabolic health or phenotype over the six months.",2021,"In the total sample, there was a significant decrease in visceral adipose tissue (VAT: -18.88 cm 2 , 95% CI -11.82 to -25.95), subcutaneous abdominal adipose tissue (SAT: -46.74 cm 2 , 95% CI -29.76 to -63.18), epicardial fat (ECF:","['women with overweight and obesity', 'Sixty-one premenopausal women with overweight or obesity']","['unsupervised exercise training', 'hypocaloric diet intervention', 'Unsupervised Exercise Training', 'usual care group (hypocaloric diet) or intervention group (hypocaloric diet + unsupervised exercise training']","['metabolic health or phenotype', 'metabolic risk profile', 'Ectopic fat deposition, metabolic parameters, incremental costs from a societal perspective and incremental quality-adjusted life years (QALYs', 'ectopic fat deposition', 'visceral adipose tissue', 'epicardial fat (ECF', 'intrahepatic lipid content', 'Metabolic Health or Phenotype', 'subcutaneous abdominal adipose tissue']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0340464', 'cui_str': 'Ectopic beats'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0333562', 'cui_str': 'Deposition'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C0442016', 'cui_str': 'Epicardial'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C1563742', 'cui_str': 'Fat, Abdominal'}]",61.0,0.0205822,"In the total sample, there was a significant decrease in visceral adipose tissue (VAT: -18.88 cm 2 , 95% CI -11.82 to -25.95), subcutaneous abdominal adipose tissue (SAT: -46.74 cm 2 , 95% CI -29.76 to -63.18), epicardial fat (ECF:","[{'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Hens', 'Affiliation': 'Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Vissers', 'Affiliation': 'Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Verhaeghe', 'Affiliation': 'Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Gielen', 'Affiliation': 'Department of Radiology, Antwerp University Hospital, 2650 Edegem, Belgium.'}, {'ForeName': 'Luc', 'Initials': 'L', 'LastName': 'Van Gaal', 'Affiliation': 'Department of Endocrinology, Antwerp University Hospital, 2650 Edegem, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Taeymans', 'Affiliation': 'Health Department, Bern University of Applied Sciences, 3008 Bern, Switzerland.'}]",International journal of environmental research and public health,['10.3390/ijerph18158004'] 2084,34360267,Evaluating the Implementation of a Multicomponent Intervention Consisting of Education and Feedback on Reducing Benzodiazepine Prescriptions by General Practitioners: BENZORED Hybrid Type I Cluster Randomized Controlled Trial.,"BACKGROUND General practitioners (GPs) in developed countries widely prescribe benzodiazepines (BZDs) for their anxiolytic, hypnotic, and muscle-relaxant effects. Treatment duration, however, is rarely limited, and this results in a significant number of chronic users. Long-term BZD use is associated with cognitive impairment, falls with hip fractures, traffic accidents, and increased mortality. The BENZORED IV trial was a hybrid type-1 trial conducted to evaluate the effectiveness and implementation of an intervention to reduce BZD prescription in primary care. The purpose of this qualitative study was to analyze the facilitators and barriers regarding the implementation of the intervention in primary care settings. METHODS A qualitative interview study with 40 GPs from three Spanish health districts. Focus group meetings with GPs from the intervention arm of the BENZORED IV trial were held at primary healthcare centers in the three districts. For sampling purposes, the GPs were classified as high or low implementers according to the success of the intervention measured at 12 months. The Consolidated Framework for Implementation Research (CFIR) was used to conduct the meetings and to code, rate, and analyze the data. RESULTS Three of the 41 CFIR constructs strongly distinguished between high and low implementers: the complexity of the intervention, the individual Stage of Change, and the key stakeholder's engagement. Seven constructs weakly discriminated between the two groups: adaptability in the intervention, external policy and incentives, implementation climate, relative priority, self-efficacy, compatibility, and engaging a formally appointed implementation leader. Fourteen constructs did not discriminate between the two groups, six had insufficient data for evaluation, and eleven had no data for evaluation. CONCLUSIONS We identified constructs that could explain differences in the efficacy in implementation of the intervention. This information is relevant for the design of successful strategies for implementation of the intervention.",2021,"Long-term BZD use is associated with cognitive impairment, falls with hip fractures, traffic accidents, and increased mortality.","['40 GPs from three Spanish health districts', 'primary care', 'by General Practitioners']","['Hybrid Type', 'Benzodiazepine Prescriptions']","['external policy and incentives, implementation climate, relative priority, self-efficacy, compatibility, and engaging a formally appointed implementation leader']","[{'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]","[{'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0242456', 'cui_str': 'Policy'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0008946', 'cui_str': 'Climate'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0439607', 'cui_str': 'Priorities'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]",,0.0556593,"Long-term BZD use is associated with cognitive impairment, falls with hip fractures, traffic accidents, and increased mortality.","[{'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Socias', 'Affiliation': 'Healthcare Centre Manacor, Balearic Health Service IbSalut, 07500 Manacor, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Leiva', 'Affiliation': 'Balearic Islands Health Research Institute (IdISBa), 07120 Palma, Spain.'}, {'ForeName': 'Haizea', 'Initials': 'H', 'LastName': 'Pombo-Ramos', 'Affiliation': 'Primary Care Research Unit of Biscaia, Basque HealthCare Service Osakidetza, BioCruces Health Research Institute, 48903 Bizkaia, Spain.'}, {'ForeName': 'Ferran', 'Initials': 'F', 'LastName': 'Bejarano', 'Affiliation': 'Catalunya Health Services-CatSalut, DAP Camp de Tarragona, 43002 Tarragona, Spain.'}, {'ForeName': 'Ermengol', 'Initials': 'E', 'LastName': 'Sempere-Verdú', 'Affiliation': 'Paterna Healthcare Centre, Conselleria de Sanitat Universal i Salut Pública, 46980 Valencia, Spain.'}, {'ForeName': 'Raquel María', 'Initials': 'RM', 'LastName': 'Rodríguez-Rincón', 'Affiliation': 'Pharmacy Department, Hospital Universitari Son Espases, Balearic Health Service IbSalut, 07120 Palma, Spain.'}, {'ForeName': 'Francisca', 'Initials': 'F', 'LastName': 'Fiol', 'Affiliation': 'Balearic Islands Health Research Institute (IdISBa), 07120 Palma, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Mengual', 'Affiliation': 'Catalunya Health Services-CatSalut, DAP Camp de Tarragona, 43002 Tarragona, Spain.'}, {'ForeName': 'Asunción', 'Initials': 'A', 'LastName': 'Ajenjo-Navarro', 'Affiliation': 'Paterna Healthcare Centre, Conselleria de Sanitat Universal i Salut Pública, 46980 Valencia, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Do Pazo', 'Affiliation': 'Pharmacy Department, Hospital Universitari Son Espases, Balearic Health Service IbSalut, 07120 Palma, Spain.'}, {'ForeName': 'Catalina', 'Initials': 'C', 'LastName': 'Mateu', 'Affiliation': 'Son Serra-La Vileta Healthcare Centre, Balearic Health Service IbSalut, 07013 Palma, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Folch', 'Affiliation': 'Catalunya Health Services-CatSalut, DAP Camp de Tarragona, 43002 Tarragona, Spain.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Alegret', 'Affiliation': 'Son Serra-La Vileta Healthcare Centre, Balearic Health Service IbSalut, 07013 Palma, Spain.'}, {'ForeName': 'Jose Maria', 'Initials': 'JM', 'LastName': 'Coll', 'Affiliation': 'Menorca Primary Care Management, Balearic Health Service IbSalut, 07701 Maó, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Martín-Rabadán', 'Affiliation': 'Can Misses Healthcare Centre Ibiza, Balearic Health Service IbSalut, 07800 Ibiza, Spain.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Vicens', 'Affiliation': 'Balearic Islands Health Research Institute (IdISBa), 07120 Palma, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18157964'] 2085,34360249,Effects of an Information and Communication Technology-Based Fitness Program on Strength and Balance in Female Home Care Service Users.,"There is evidence that training for strength and balance prevents decline in physical function in old age when the training is personally instructed. It is an open question whether interventions that deliver training via up-to-date technologies can achieve long-term effects. This study examined the effects of an 8-month fitness training program delivered via information and communication technology (ICT) on lower-body strength and balance in female home care users ( n = 72) aged 75 years on average. For statistical analysis, the test group was divided into two subgroups, one who used the program at least 8 times per month ( n = 26) and another one who used the program less often ( n = 17) compared with a control group that received no exercise program ( n = 29). It was found that regular ICT-exercisers exhibited positive effects over time on lower-body strength and balance compared to a decrease in both indicators in irregular exercisers and the control group. The authors see potential in offering exercise programs to people of advanced age via ICT to counteract physical decline in old age.",2021,It was found that regular ICT-exercisers exhibited positive effects over time on lower-body strength and balance compared to a decrease in both indicators in irregular exercisers and the control group.,"['people of advanced age via ICT to counteract physical decline in old age', 'Female Home Care Service Users', 'female home care users ( n = 72) aged 75 years on average']","['Information and Communication Technology-Based Fitness Program', 'control group that received no exercise program', '8-month fitness training program delivered via information and communication technology (ICT']",['Strength and Balance'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0683867', 'cui_str': 'Information Technology'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0231337', 'cui_str': 'Senility'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019855', 'cui_str': 'Services, Home Care'}, {'cui': 'C0204977', 'cui_str': 'Home care of patient'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0683867', 'cui_str': 'Information Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",,0.00131228,It was found that regular ICT-exercisers exhibited positive effects over time on lower-body strength and balance compared to a decrease in both indicators in irregular exercisers and the control group.,"[{'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Jungreitmayr', 'Affiliation': 'Department of Sport and Exercise Science, Paris Lodron University of Salzburg, 5400 Hallein-Rif, Austria.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Ring-Dimitriou', 'Affiliation': 'Department of Sport and Exercise Science, Paris Lodron University of Salzburg, 5400 Hallein-Rif, Austria.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Trukeschitz', 'Affiliation': 'Research Institute for Economics of Aging, Vienna University of Economics and Business, 1020 Vienna, Austria.'}, {'ForeName': 'Siegfried', 'Initials': 'S', 'LastName': 'Eisenberg', 'Affiliation': 'Research Institute for Economics of Aging, Vienna University of Economics and Business, 1020 Vienna, Austria.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Schneider', 'Affiliation': 'Institute of Computer Science, University of Applied Sciences Wiener Neustadt, 2700 Wiener Neustadt, Austria.'}]",International journal of environmental research and public health,['10.3390/ijerph18157955'] 2086,34360216,"Afghan Women's Use of Violence against Their Children and Associations with IPV, Adverse Childhood Experiences and Poverty: A Cross-Sectional and Structural Equation Modelling Analysis.","Children who experience violence from a parent are more likely to experience and perpetrate intimate partner violence (IPV) later in life. Drawing on cross-sectional data among married women enrolled in the baseline of a randomized control trial in Afghanistan, we assess risk factors for women's use of violence against their children, focused on women's own adverse childhood experiences and experiences of IPV, poverty, poor mental health and gender attitudes. Analysis uses logistic regression and structural equation modelling (SEM). In total 744 married women reported on their use of violence against a child, with 71.8% ( n = 534) reporting this in the past month. In regression models, their own experiences of witnessing their mother being physically abused, poverty during childhood, current food insecurity, their husband using corporal punishment on their child, current IPV experience, and other violence in the home were all associated with increased likelihood of women reporting corporal punishment. In the SEM, three pathways emerged linking women's childhood trauma and poverty to use of corporal punishment. One pathway was mediated by poor mental health, a second was mediated by wider use of violence in the home and a third from food insecurity mediated by having more gender inequitable attitudes. Addressing the culture of violence in the home is critical to reducing violence against children, as well as enabling treatment of parental mental health problems and generally addressing gender equity.",2021,"In total 744 married women reported on their use of violence against a child, with 71.8% ( n = 534) reporting this in the past month.","['married women enrolled', 'In total 744 married women reported on their use of violence against a child, with 71.8% ( n = 534) reporting this in the past month', ""women's use of violence against their children, focused on women's own adverse childhood experiences and experiences of IPV, poverty, poor mental health and gender attitudes"", ""Afghan Women's Use of Violence against Their Children and Associations with IPV, Adverse Childhood Experiences and Poverty""]",[],[],"[{'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0521124', 'cui_str': 'Against'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C4296616', 'cui_str': 'Adverse Childhood Experiences'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}]",[],[],744.0,0.0451884,"In total 744 married women reported on their use of violence against a child, with 71.8% ( n = 534) reporting this in the past month.","[{'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Ndungu', 'Affiliation': 'Office of Engagement and Transformation, Nelson Mandela University, Port Elizabeth 6001, South Africa.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Jewkes', 'Affiliation': 'Office of the Executive Scientist, South African Medical Research Council, Pretoria 0001, South Africa.'}, {'ForeName': 'Magnolia', 'Initials': 'M', 'LastName': 'Ngcobo-Sithole', 'Affiliation': 'Department of Psychology, Nelson Mandela University, Port Elizabeth 6001, South Africa.'}, {'ForeName': 'Esnat', 'Initials': 'E', 'LastName': 'Chirwa', 'Affiliation': 'Gender and Health Research Unit, South African Medical Research Council, Pretoria 0001, South Africa.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Gibbs', 'Affiliation': 'Gender and Health Research Unit, South African Medical Research Council, Pretoria 0001, South Africa.'}]",International journal of environmental research and public health,['10.3390/ijerph18157923'] 2087,34360190,Self-Learning Methodology in Simulated Environments (MAES©) as a Learning Tool in Perioperative Nursing. An Evidence-Based Practice Model for Acquiring Clinical Safety Competencies.,"BACKGROUND The self-learning Methodology in Simulated Environments (Spanish acronym: MAES©, (Murcia, Spain) is a type of self-directed and collaborative training in health sciences. The objective of the present study was to compare the level of competence of postgraduate surgical nursing students in the clinical safety of surgical patients, after training with the MAES© methodology versus traditional theoretical-practical workshops, at different points in time (post-intervention, after three months, six months post-intervention, and at the end of the clinical training period, specifically nine months post-intervention). METHODS We conducted a prospective study with an experimental group of surgical nursing postgraduate students who participated in MAES© high-fidelity simulation sessions, and a control group of postgraduate nursing students who attended traditional theoretical-practical sessions at two universities in Catalonia (Spain). The levels of competence were compared between the two groups and at different time points of the study. RESULTS The score was higher and statistically significantly different in the experimental group for all the competencies, with a large effect size at every measurement point previously mentioned. CONCLUSIONS The postgraduate nurses were the most competent in the clinical safety of surgical patients when they trained with the MAES© methodology than when they learned through traditional theoretical-practical workshops. The learning of surgical safety competencies was more stable and superior in the experimental group who trained with MAES©, as compared to the control group.",2021,The postgraduate nurses were the most competent in the clinical safety of surgical patients when they trained with the MAES© methodology than when they learned through traditional theoretical-practical workshops.,"['Simulated Environments (Spanish acronym', 'postgraduate surgical nursing students', 'experimental group of surgical nursing postgraduate students who participated in MAES© high-fidelity simulation sessions, and a control group of postgraduate nursing students who attended traditional theoretical-practical sessions at two universities in Catalonia (Spain']",[],"['learning of surgical safety competencies', 'levels of competence']","[{'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C1956259', 'cui_str': 'Acronyms'}, {'cui': 'C0038931', 'cui_str': 'Nursing, Perioperative'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]",[],"[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0143142,The postgraduate nurses were the most competent in the clinical safety of surgical patients when they trained with the MAES© methodology than when they learned through traditional theoretical-practical workshops.,"[{'ForeName': 'Ester', 'Initials': 'E', 'LastName': 'Peñataro-Pintado', 'Affiliation': 'Nursing Department, University School of Nursing and Occupational Therapy of Terrassa (EUIT), 08221 Terrassa, Spain.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Díaz-Agea', 'Affiliation': 'Nursing Department, Catholic University of Murcia (UCAM), 30107 Guadalupe de Maciascoque, Spain.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Castillo', 'Affiliation': 'Nursing Department, International University of Catalonia (UIC), Campus Sant Cugat, 08195 Sant Cugat del Vallès, Spain.'}, {'ForeName': 'César', 'Initials': 'C', 'LastName': 'Leal-Costa', 'Affiliation': 'Nursing Department, University of Murcia, 30003 Murcia, Spain.'}, {'ForeName': 'Antonio Jesús', 'Initials': 'AJ', 'LastName': 'Ramos-Morcillo', 'Affiliation': 'Nursing Department, University of Murcia, 30003 Murcia, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Ruzafa-Martínez', 'Affiliation': 'Nursing Department, University of Murcia, 30003 Murcia, Spain.'}, {'ForeName': 'Encarna', 'Initials': 'E', 'LastName': 'Rodríguez-Higueras', 'Affiliation': 'Nursing Department, International University of Catalonia (UIC), Campus Sant Cugat, 08195 Sant Cugat del Vallès, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18157893'] 2088,34360151,Music Tempo: A Tool for Regulating Walking Cadence and Physical Activity Intensity in Overweight Adults?,"This study investigated if music tempo can prompt a desired walking cadence, and if music can provide a stimulus to regulate physical activity intensity in a longitudinal physical activity intervention with free-living adults. Overweight adults ( n = 37; 94.26 ± 17.11 kg; 49.63 ± 12.37 years) were randomly assigned to an intervention (IG, n = 17) or usual care group (UC, n = 20) as part of a novel nine-month walking intervention. IG participants walked to self-selected music with a predetermined tempo and received a behavioural change support programme. At baseline, four-, six- and nine-months participants were asked to walk around an elliptical track at their habitual pace (0-2 min) and then in time to a predetermined tempo (2-8 min) designed to elicit moderate intensity. Cadence response (steps/min) was assessed and intensity (heart rate (bpm) recorded using wireless telemetry. A repeated measures general linear model (GLM) examined differences between groups over time ( p < 0.05). All data is presented as means ± SD. At each assessment point both groups displayed an immediate cadence adjustment in response to music tempo ( p < 0.01) i.e., habitual cadence vs. 3 METs target cadence ( p < 0.05) and 3 METs target cadence vs. 5 METs target cadence ( p < 0.05). Additionally, IG participants displayed an increased habitual cadence (0-2 min) at each assessment point ( p < 0.05; 110 ± 9, 121.80 ± 7.5, 121.46 ± 10, 121.93 ± 7 steps/min respectively). UC participant's habitual cadence was unchanged from 0-9 months ( p > 0.05; 120 ± 10, 116 ± 13, 119 ± 12 and 119 ± 9 steps/min respectively). Music tempo may be a useful regulatory tool to prompt the free-living individual to reach an appropriate stride rate to achieve a walking pace that is at least moderate intensity. It also appears that results may be trainable as throughout the study an increased habitual walking cadence was observed, in the absence of music.",2021,"At each assessment point both groups displayed an immediate cadence adjustment in response to music tempo ( p < 0.01) i.e., habitual cadence vs. 3 METs target cadence ( p < 0.05) and 3 METs target cadence vs. 5 METs target cadence ( p < 0.05).","['free-living adults', 'Overweight adults ( n = 37; 94.26 ± 17.11 kg; 49.63 ± 12.37 years', 'Overweight Adults']","['Music Tempo', 'IG participants walked to self-selected music with a predetermined tempo and received a behavioural change support programme', 'intervention (IG, n = 17) or usual care group (UC, n = 20) as part of a novel nine-month walking intervention']","[""UC participant's habitual cadence"", 'Walking Cadence and Physical Activity Intensity', 'immediate cadence adjustment in response to music tempo', 'habitual cadence', 'habitual cadence vs. 3 METs target cadence', 'habitual walking cadence', 'Cadence response (steps/min) was assessed and intensity (heart rate (bpm']","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0076084', 'cui_str': '2,2,6,6-tetramethyl-4-piperidine-N-oxide'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0076084', 'cui_str': '2,2,6,6-tetramethyl-4-piperidine-N-oxide'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0439385', 'cui_str': 'beats/min'}]",,0.032312,"At each assessment point both groups displayed an immediate cadence adjustment in response to music tempo ( p < 0.01) i.e., habitual cadence vs. 3 METs target cadence ( p < 0.05) and 3 METs target cadence vs. 5 METs target cadence ( p < 0.05).","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Faulkner', 'Affiliation': 'Sports Lab North West, Letterkenny Institute of Technology, F92 FC93 Donegal, Ireland.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'McNeilly', 'Affiliation': 'Sport and Exercise Sciences Research Institute, Ulster University, Newtownabbey BT37 0QB, UK.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Davison', 'Affiliation': 'Sport and Exercise Sciences Research Institute, Ulster University, Newtownabbey BT37 0QB, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rowe', 'Affiliation': 'School of Psychological Sciences and Health, University of Strathclyde, Glasgow G1 1XQ, UK.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Hewitt', 'Affiliation': 'School of Psychological Sciences and Health, University of Strathclyde, Glasgow G1 1XQ, UK.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Nevill', 'Affiliation': 'Faculty of Education Health & Wellbeing, University of Wolverhampton, Walsall WS1 3BD, UK.'}, {'ForeName': 'Ellie', 'Initials': 'E', 'LastName': 'Duly', 'Affiliation': 'Clinical Biochemistry Department, Ulster Hospital, South Eastern Health Trust, Belfast BT16 1RH, UK.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Trinick', 'Affiliation': 'Clinical Biochemistry Department, Ulster Hospital, South Eastern Health Trust, Belfast BT16 1RH, UK.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Murphy', 'Affiliation': 'Sport and Exercise Sciences Research Institute, Ulster University, Newtownabbey BT37 0QB, UK.'}]",International journal of environmental research and public health,['10.3390/ijerph18157855'] 2089,34360146,Effect of Resonant Frequency Vibration on Delayed Onset Muscle Soreness and Resulting Stiffness as Measured by Shear-Wave Elastography.,"This study utilized resonant frequency vibration to the upper body to determine changes in pain, stiffness and isometric strength of the biceps brachii after eccentric damage. Thirty-one participants without recent resistance training were randomized into three groups: a Control (C) group and two eccentric exercise groups (No vibration (NV) and Vibration (V)). After muscle damage, participants in the V group received upper body vibration (UBV) therapy for 5 min on days 1-4. All participants completed a visual analog scale (VAS), maximum voluntary isometric contraction (MVIC), and shear wave elastography (SWE) of the bicep at baseline (pre-exercise), 24 h, 48 h, and 1-week post exercise. There was a significant difference between V and NV at 24 h for VAS ( p = 0.0051), at 24 h and 1-week for MVIC ( p = 0.0017 and p = 0.0016, respectively). There was a significant decrease in SWE for the V group from 24-48 h ( p = 0.0003), while there was no significant change in the NV group ( p = 0.9341). The use of UBV resonant vibration decreased MVIC decrement and reduced VAS pain ratings at 24 h post eccentric damage. SWE was strongly negatively correlated with MVIC and may function as a predictor of intrinsic muscle state in the time course of recovery of the biceps brachii.",2021,The use of UBV resonant vibration decreased MVIC decrement and reduced VAS pain ratings at 24 h post eccentric damage.,['Thirty-one participants without recent resistance training'],"['upper body vibration (UBV) therapy', 'Resonant Frequency Vibration', 'Control (C) group and two eccentric exercise groups (No vibration (NV) and Vibration (V', 'UBV resonant vibration']","['SWE', 'visual analog scale (VAS), maximum voluntary isometric contraction (MVIC), and shear wave elastography (SWE) of the bicep', 'VAS pain ratings', 'Delayed Onset Muscle Soreness and Resulting Stiffness', 'pain, stiffness and isometric strength']","[{'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C1268087', 'cui_str': 'Upper body structure'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0577554', 'cui_str': 'Resonant'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}]","[{'cui': 'C2748260', 'cui_str': 'Transient elastography'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}]",31.0,0.0236546,The use of UBV resonant vibration decreased MVIC decrement and reduced VAS pain ratings at 24 h post eccentric damage.,"[{'ForeName': 'Garrett C', 'Initials': 'GC', 'LastName': 'Jones', 'Affiliation': 'Department of Mechanical Engineering, College of Engineering, Campus of Brigham Young University, Provo, UT 4019, USA.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Blotter', 'Affiliation': 'Department of Mechanical Engineering, College of Engineering, Campus of Brigham Young University, Provo, UT 4019, USA.'}, {'ForeName': 'Cameron D', 'Initials': 'CD', 'LastName': 'Smallwood', 'Affiliation': 'Department of Mechanical Engineering, College of Engineering, Campus of Brigham Young University, Provo, UT 4019, USA.'}, {'ForeName': 'Dennis L', 'Initials': 'DL', 'LastName': 'Eggett', 'Affiliation': 'Department of Statistics, College of Physical and Mathematical Sciences, Brigham Young University, Provo, UT 4019, USA.'}, {'ForeName': 'Darryl J', 'Initials': 'DJ', 'LastName': 'Cochrane', 'Affiliation': 'School of Sport, Exercise & Nutrition, College of Health, Massey University, Palmerston North 4442, New Zealand.'}, {'ForeName': 'J Brent', 'Initials': 'JB', 'LastName': 'Feland', 'Affiliation': 'Department of Exercise Sciences, College of Life Sciences, Campus of Brigham Young University, Provo, UT 4019, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph18157853'] 2090,34360143,"Effects of Cognitive/Exercise Dual-Task Program on the Cognitive Function, Health Status, Depression, and Life Satisfaction of the Elderly Living in the Community.","The elderly population in Korea is rapidly increasing. It is necessary to develop multi-faceted and complex interventions for prevention and delay of dementia, balance improvement, and physical activity, among the elderly living in the community. This study aimed to examine the effects of the cognitive/exercise dual-task program on cognitive function, health status, depression, and life satisfaction of the elderly living in the community. A quasi-experimental study design using a pretest-posttest control group was employed. The study included a total of 65 elderly participants (intervention: n = 32, control: n = 33) in Seoul, South Korea. The cognitive/exercise dual-task program as an intervention was composed of 20 sessions for a total of 10 weeks, held twice a week for about 50 min each session. Measures were general characteristics of study participants, the Korean version of Mini-Mental State Examination (MMSE-K), Korean elderly health status assessment tool, Korean version of Geriatric Depression Scale, and the elderly life satisfaction scale. Data were collected from October 2020 to March 2021. There were statistically significant differences on cognitive function, health status, depression, and life satisfaction between two groups. The cognitive/exercise dual-task program was an effective intervention for improving cognitive function, health status, and life satisfaction, and for decreasing depression of the elderly living in the community. Health care providers need to pay attention to cognitive/exercise dual-task programs for elderly living in the community.",2021,"The cognitive/exercise dual-task program was an effective intervention for improving cognitive function, health status, and life satisfaction, and for decreasing depression of the elderly living in the community.","['65 elderly participants (intervention: n = 32, control: n = 33) in Seoul, South Korea', 'elderly living in the community', 'Elderly Living in the Community']","['Cognitive/Exercise Dual-Task Program', 'cognitive/exercise dual-task program', 'pay attention to cognitive/exercise dual-task programs']","['Korean version of Mini-Mental State Examination (MMSE-K), Korean elderly health status assessment tool, Korean version of Geriatric Depression Scale, and the elderly life satisfaction scale', 'cognitive function, health status, and life satisfaction', 'cognitive function, health status, depression, and life satisfaction', 'Cognitive Function, Health Status, Depression, and Life Satisfaction']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3850150', 'cui_str': 'Seoul'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]","[{'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0451184', 'cui_str': 'Geriatric depression scale'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",65.0,0.0276114,"The cognitive/exercise dual-task program was an effective intervention for improving cognitive function, health status, and life satisfaction, and for decreasing depression of the elderly living in the community.","[{'ForeName': 'Sohyune', 'Initials': 'S', 'LastName': 'Sok', 'Affiliation': 'College of Nursing Science, Kyung Hee University, Seoul 02447, Korea.'}, {'ForeName': 'Eunyoung', 'Initials': 'E', 'LastName': 'Shin', 'Affiliation': 'Department of Nursing, Graduate School, Kyung Hee University, Seoul 02447, Korea.'}, {'ForeName': 'Seyoon', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Nursing, Graduate School, Kyung Hee University, Seoul 02447, Korea.'}, {'ForeName': 'Myeongshin', 'Initials': 'M', 'LastName': 'Kim', 'Affiliation': 'Department of Nursing, Graduate School, Kyung Hee University, Seoul 02447, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph18157848'] 2091,34360118,"Feasibility and Efficacy of the ""FUNPALs Playgroup"" Intervention to Improve Toddler Dietary and Activity Behaviors: A Pilot Randomized Controlled Trial.","This study evaluated the feasibility and effects of the Families Understanding Nutrition and Physically Active Lifestyles (FUNPALs) Playgroup on toddler (12-36-month-old) diet and activity behaviors. Parent-toddler dyads were recruited from disadvantaged communities and randomly assigned to receive 10-weekly sessions of the FUNPALs Playgroup ( n = 24) or dose-matched health education control group ( n = 26). FUNPALs Playgroups involved physical and snack activities, delivery of health information, and positive parenting coaching. The control group involved group health education for parents only. Process outcomes (e.g., retention rate, fidelity) and focus groups determined feasibility and perceived effects. To evaluate preliminary effects, validated measures of toddler diet (food frequency questionnaire and a carotenoid biomarker), physical activity (PA; accelerometers), general and feeding parenting (self-report surveys), and home environment (phone interview) were collected pre and post. The sample comprised parents (84% female) who self-identified as Hispanic/Latino (38%) and/or African American (32%). Retention was high (78%). Parents from both groups enjoyed the program and perceived improvements in their children's health behaviors. Objective measures demonstrated improvement with large effects (η 2 = 0.29) in toddler diet ( p < 0.001) but not PA ( p = 0.099). In conclusion, the FUNPALs Playgroup is feasible and may improve toddler eating behaviors.",2021,Objective measures demonstrated improvement with large effects (η 2 = 0.29) in toddler diet ( p < 0.001) but not PA ( p = 0.099).,"['sample comprised parents (84% female) who self-identified as Hispanic/Latino (38%) and/or African American (32', 'Parent-toddler dyads were recruited from disadvantaged communities']","['Families Understanding Nutrition and Physically Active Lifestyles (FUNPALs) Playgroup', 'FUNPALs Playgroup"" Intervention', 'FUNPALs Playgroup ( n = 24) or dose-matched health education control group']","['toddler diet (food frequency questionnaire and a carotenoid biomarker), physical activity (PA; accelerometers), general and feeding parenting (self-report surveys), and home environment (phone interview', 'retention rate, fidelity) and', 'Toddler Dietary and Activity Behaviors', 'toddler eating behaviors', 'physical and snack activities, delivery of health information, and positive parenting coaching']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0012613', 'cui_str': 'Disadvantaged'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0543438', 'cui_str': 'Playgroup'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",,0.0092932,Objective measures demonstrated improvement with large effects (η 2 = 0.29) in toddler diet ( p < 0.001) but not PA ( p = 0.099).,"[{'ForeName': 'Aliye B', 'Initials': 'AB', 'LastName': 'Cepni', 'Affiliation': 'Department of Health and Human Performance, University of Houston, Houston, TX 77204, USA.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Taylor', 'Affiliation': 'Department of Psychological, Health and Learning Sciences, University of Houston, Houston, TX 77204, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Crumbley', 'Affiliation': 'Department of Health and Human Performance, University of Houston, Houston, TX 77204, USA.'}, {'ForeName': 'Debbe', 'Initials': 'D', 'LastName': 'Thompson', 'Affiliation': ""USDA/ARS Children's Nutrition Research Center and Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.""}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Moran', 'Affiliation': ""USDA/ARS Children's Nutrition Research Center and Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.""}, {'ForeName': 'Norma', 'Initials': 'N', 'LastName': 'Olvera', 'Affiliation': 'Department of Psychological, Latino Health Disparities Lab, University of Houston, Houston, TX 77204, USA.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Health and Human Performance, University of Houston, Houston, TX 77204, USA.'}, {'ForeName': 'Katherine R', 'Initials': 'KR', 'LastName': 'Arlinghaus', 'Affiliation': 'Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Johnston', 'Affiliation': 'Department of Health and Human Performance, University of Houston, Houston, TX 77204, USA.'}, {'ForeName': 'Tracey A', 'Initials': 'TA', 'LastName': 'Ledoux', 'Affiliation': 'Department of Health and Human Performance, University of Houston, Houston, TX 77204, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph18157828'] 2092,34360105,Is a Handful an Effective Way to Guide Nut Recommendations?,"Dietary guidelines recommend consuming 30 g of nuts per day to reduce the risk of chronic disease. A 'handful' is commonly used to guide consumers. Research is lacking on how this translates into actual gram amounts. This study quantified the grams of nuts represented by different portion size measures, including a 'handful' and '30 g serving' among 120 participants. Each participant was randomised to a sequence where they received three of six different nut types (from almonds, cashews, hazelnuts, macadamias, peanuts, and walnuts) and were instructed to take a: 'usual serving', 'handful', 'small handful', 'large handful', and '30 g serving' of each. Combining all nut types, the median 'handful' was 36.3 g, compared to 28.7 g for the estimated '30 g serving' and 24.8 for the 'usual serving'. The 'large handful' was approximately double the 'handful' (61.3 g), whereas the 'small handful' was about half (16.7 g). Eighty-three percent of portions chosen were at least 80% of the recommended 30 g intake when participants were asked to take a 'handful', compared to 63% for the '30 g serving'. It appears a 'handful' can be used as a practical tool to guide recommended nut intakes, and increases the amount selected compared to instructions to take a '30 g serving'.",2021,"Combining all nut types, the median 'handful' was 36.3 g, compared to 28.7 g for the estimated '30 g serving' and 24.8 for the 'usual serving'.",['120 participants'],[],['risk of chronic disease'],"[{'cui': 'C4319550', 'cui_str': '120'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}]",120.0,0.127867,"Combining all nut types, the median 'handful' was 36.3 g, compared to 28.7 g for the estimated '30 g serving' and 24.8 for the 'usual serving'.","[{'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Brown', 'Affiliation': 'Department of Human Nutrition, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.'}, {'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Gray', 'Affiliation': 'Biostatistics Centre, Division of Health Sciences, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.'}, {'ForeName': 'Mei Gee', 'Initials': 'MG', 'LastName': 'Chua', 'Affiliation': 'Department of Human Nutrition, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Ware', 'Affiliation': 'Department of Human Nutrition, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Chisholm', 'Affiliation': 'Department of Human Nutrition, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.'}, {'ForeName': 'Siew Ling', 'Initials': 'SL', 'LastName': 'Tey', 'Affiliation': 'Department of Human Nutrition, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.'}]",International journal of environmental research and public health,['10.3390/ijerph18157812'] 2093,34368808,The First Study Evaluating the Safety of Pre-Surgery Administration of Metformin in Patients with Colorectal and other Gastrointestinal Cancers and Effect on Cancer Stem Cells.,"BACKGROUND The cancer stem cell (CSC) hypothesis of tumor genesis suggests that unlike most cancer cells within tumor CSC resist chemotherapy and can regenerate various cell types in tumor thereby causing relapse. Hence drugs that selectively target CSC may offer great promise for cancer therapy especially when combined with chemotherapy. Current treatment options for colorectal cancer (CRC) and other gastrointestinal (GI) tumors rely on combination of surgical resection, cytotoxic and targeted drugs. Recent findings showed that metformin, an ant diabetic drug was associated with a significantly lower risk of CRC (0.63 [0.47 - 0.84]; P = 0.002) in patients with type 2 diabetes. We therefore hypothesize that administration of metformin will reduce CSC. METHODS Patients with CRC and other GI cancers undergoing resection were enrolled. Metformin was administered at 500 mg orally twice daily for up to 14 days and terminated 24 hours, prior to planned surgery. Both tumor and normal tissue was procured. Adverse events (AEs) were graded according to NCI CTCAE Version 3.0. Primary objective was to establish the safety of administering metformin prior to resection. Secondary objective was to evaluate the effects of metformin on the expression of CSC markers by measuring relative mRNA levels of CD133, OCT4 and NANOG by RT-PCR and immunohistochemistry. RESULTS A total of 10 patients (4 Male; 6 Female) received metformin. Grade 3 AEs included anemia, hypoalbuminemia, alanine aminotransferase elevation, abdominal pain and nausea but none of these were related to metformin. No hypoglycemia and lactic acidosis were observed. No unexpected post-operative complications were witnessed. Comparison of markers of CCSC results showed that expression of CD133, OCT4 and NANOG expression were decreased following metformin. CONCLUSIONS Our pilot study showed feasibility of metformin before surgery in GI cancers and indicated impact on CSC. This preliminary data warrants further investigation in a larger randomized placebo-control study to assess these markers and their correlation with survival.",2021,"Grade 3 AEs included anemia, hypoalbuminemia, alanine aminotransferase elevation, abdominal pain and nausea but none of these were related to metformin.","['patients with type 2 diabetes', 'Patients with CRC and other GI cancers undergoing resection were enrolled', 'Patients with Colorectal and other Gastrointestinal Cancers and Effect on Cancer Stem Cells', '10 patients (4 Male; 6 Female) received']","['placebo', 'metformin', 'Metformin']","['expression of CSC markers by measuring relative mRNA levels of CD133, OCT4 and NANOG by RT-PCR and immunohistochemistry', 'anemia, hypoalbuminemia, alanine aminotransferase elevation, abdominal pain and nausea', 'risk of CRC', 'expression of CD133, OCT4 and NANOG expression', 'Adverse events (AEs', 'hypoglycemia and lactic acidosis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0685938', 'cui_str': 'Malignant neoplasm of gastrointestinal tract'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C1956422', 'cui_str': 'Cancer Stem Cells'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C1956422', 'cui_str': 'Cancer Stem Cells'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0239981', 'cui_str': 'Hypoalbuminemia'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0001125', 'cui_str': 'Lactic acidosis'}]",10.0,0.229156,"Grade 3 AEs included anemia, hypoalbuminemia, alanine aminotransferase elevation, abdominal pain and nausea but none of these were related to metformin.","[{'ForeName': 'Muhammad Wasif', 'Initials': 'MW', 'LastName': 'Saif', 'Affiliation': 'Northwell Health Cancer Institute, Lake Success, NY 11042, USA.'}, {'ForeName': 'Shrikar', 'Initials': 'S', 'LastName': 'Rajagopal', 'Affiliation': 'Northwell Health Cancer Institute, Lake Success, NY 11042, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Caplain', 'Affiliation': 'Northwell Health Cancer Institute, Lake Success, NY 11042, USA.'}, {'ForeName': 'Martin D', 'Initials': 'MD', 'LastName': 'Goodman', 'Affiliation': 'Northwell Health Cancer Institute, Lake Success, NY 11042, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Popowich', 'Affiliation': 'Northwell Health Cancer Institute, Lake Success, NY 11042, USA.'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Orkin', 'Affiliation': 'Northwell Health Cancer Institute, Lake Success, NY 11042, USA.'}, {'ForeName': 'Philip N', 'Initials': 'PN', 'LastName': 'Tsichlis', 'Affiliation': 'Northwell Health Cancer Institute, Lake Success, NY 11042, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Martell', 'Affiliation': 'Northwell Health Cancer Institute, Lake Success, NY 11042, USA.'}]",Cancer medicine journal,[] 2094,34368629,Caregiver Response to an Online Dementia and Caregiver Wellness Education Platform.,"Background Web-based educational interventions are emerging as a potential solution to improve caregiver dementia knowledge and overall well-being. Objective To assess the feasibility of delivering a web-based intervention for dementia caregivers by examining: 1) engagement with the online platform, 2) skill implementation, and 3) changes on outcome metrics over the 30-day study period. Methods Enrolled participants were onboarded by a trained research coordinator and provided 24/7 access to the platform over 30 days. At study onset and completion, caregivers completed assessments of care recipient dementia severity and neuropsychiatric symptoms along with instruments which measured dementia knowledge, caregiver burden, and carer experience. Results Of 84 referrals, 60 caregivers met study inclusion criteria and 55 completed pre and post study measures. Caregivers completed an average of 8 hours of learning over the 30-day web-based intervention, with 84.4%of participants reporting using at least one skill they learned from the online platform. Eighty-nine percent of participants reported high satisfaction with the web-based educational intervention. There were small effect sizes for decreases in NPIQ neuropsychiatric symptom severity and caregiver distress scores from pre- to post-intervention. Small effect sizes were observed for changes in caregiver burden from pre- to post-intervention among caregivers who perceived their care recipient as having high global deterioration. Conclusion Findings show online educational programs are feasible for informal family caregivers of dementia and have perceived value. Future studies should address caregiver response to online education in less severe versus more severe care recipients, and explore the value of caregiver online platforms in diverse caregiver samples.",2021,"Small effect sizes were observed for changes in caregiver burden from pre- to post-intervention among caregivers who perceived their care recipient as having high global deterioration. ",[],[],"['dementia knowledge, caregiver burden, and carer experience', 'NPIQ neuropsychiatric symptom severity and caregiver distress scores']",[],[],"[{'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.118386,"Small effect sizes were observed for changes in caregiver burden from pre- to post-intervention among caregivers who perceived their care recipient as having high global deterioration. ","[{'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Rodriguez', 'Affiliation': 'Clinical and Health Psychology, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Madison', 'Initials': 'M', 'LastName': 'Fugard', 'Affiliation': 'Trualta Incorporated, Ottawa, Ontario, Canada.'}, {'ForeName': 'Shawna', 'Initials': 'S', 'LastName': 'Amini', 'Affiliation': ""Perioperative Cognitive Anesthesia Network for Alzheimer's Disease and Related Dementias, University of Florida, Gainesville, FL, USA.""}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Smith', 'Affiliation': 'Clinical and Health Psychology, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Deann', 'Initials': 'D', 'LastName': 'Marasco', 'Affiliation': ""Alzheimer's Association, FL, USA.""}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Shatzer', 'Affiliation': ""Alzheimer's Association, FL, USA.""}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Guerrero', 'Affiliation': 'Trualta Incorporated, Ottawa, Ontario, Canada.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Garvan', 'Affiliation': ""Perioperative Cognitive Anesthesia Network for Alzheimer's Disease and Related Dementias, University of Florida, Gainesville, FL, USA.""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Davis', 'Affiliation': 'Trualta Incorporated, Ottawa, Ontario, Canada.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Price', 'Affiliation': 'Clinical and Health Psychology, University of Florida, Gainesville, FL, USA.'}]",Journal of Alzheimer's disease reports,['10.3233/ADR-200292'] 2095,34368309,"Effects of perioperative rosuvastatin on postoperative delirium in elderly patients: A randomized, double-blind, and placebo-controlled trial.","BACKGROUND Experimental evidence has indicated the benefits of statins for the treatment of postoperative delirium. Previously, clinical trials did not reach definite conclusions on the effects of statins on delirium. Some clinical trials have indicated that statins reduce postoperative delirium and improve outcomes, while some studies have reported negative results. AIM To evaluate whether perioperative rosuvastatin treatment reduces the incidence of delirium and improves clinical outcomes. METHODS This randomized, double-blind, and placebo-controlled trial was conducted in a single center in Jiangsu, China. This study enrolled patients aged greater than 60 years who received general anesthesia during elective operations and provided informed consent. A computer-generated randomization sequence (in a 1:1 ratio) was used to randomly assign patients to receive either rosuvastatin (40 mg/d) or placebo. Participants, care providers, and investigators were all masked to group assignments. The primary endpoint was the incidence of delirium, which was assessed twice daily with the Confusion Assessment Method during the first 7 postoperative days. Analyses were performed on intention-to-treat and safety populations. RESULTS Between January 1, 2017 and January 1, 2020, 3512 patients were assessed. A total of 821 patients were randomly assigned to receive either placebo ( n = 411) or rosuvastatin ( n = 410). The incidence of postoperative delirium was significantly lower in the rosuvastatin group [23 (5.6%) of 410 patients] than in the placebo group {42 (13.5%) of 411 patients [odds ratios (OR) = 0.522, 95% confidence interval (CI): 0.308-0.885; P < 0.05]}. No significant difference in 30-d all-cause mortality (6.1% vs 8.7%, OR = 0.67, 95%CI: 0.39-1.2, P = 0.147) was observed between the two groups. Rosuvastatin decreased the hospitalization time (13.8 ± 2.5 vs 14.2 ± 2.8, P = 0.03) and hospitalization expenses (9.3 ± 2.5 vs 9.8 ± 2.9, P = 0.007). No significant differences in abnormal liver enzymes (9.0% vs 7.1%, OR = 1.307, 95%CI: 0.787-2.169, P = 0.30) or rhabdomyolysis (0.73% vs 0.24%, OR = 3.020, 95%CI: 0.31-29.2, P = 0.37) were observed between the two groups. CONCLUSION The current study suggests that perioperative rosuvastatin treatment reduces the incidence of delirium after an elective operation under general anesthesia. However, the evidence does not reveal that rosuvastatin improves clinical outcomes. The therapy is safe. Further investigation is necessary to fully understand the potential usefulness of rosuvastatin in elderly patients.",2021,"No significant differences in abnormal liver enzymes (9.0% vs 7.1%, OR = 1.307, 95%CI: 0.787-2.169, P = 0.30) or rhabdomyolysis (0.73% vs 0.24%, OR = 3.020, 95%CI: 0.31-29.2, P = 0.37) were observed between the two groups. ","['enrolled patients aged greater than 60 years who received general anesthesia during elective operations and provided informed consent', 'single center in Jiangsu, China', 'elderly patients', 'Between January 1, 2017 and January 1, 2020, 3512 patients were assessed', 'after an elective operation under general anesthesia', 'A total of 821 patients']","['placebo', 'rosuvastatin', 'Rosuvastatin', 'perioperative rosuvastatin']","['postoperative delirium', 'hospitalization time', 'incidence of delirium', 'incidence of delirium and improves clinical outcomes', 'hospitalization expenses', 'incidence of postoperative delirium', 'rhabdomyolysis', 'cause mortality', 'abnormal liver enzymes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}]","[{'cui': 'C4721772', 'cui_str': 'Postoperative delirium'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0035410', 'cui_str': 'Rhabdomyolysis'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0438237', 'cui_str': 'Liver enzymes abnormal'}]",3512.0,0.889268,"No significant differences in abnormal liver enzymes (9.0% vs 7.1%, OR = 1.307, 95%CI: 0.787-2.169, P = 0.30) or rhabdomyolysis (0.73% vs 0.24%, OR = 3.020, 95%CI: 0.31-29.2, P = 0.37) were observed between the two groups. ","[{'ForeName': 'Xiao-Qin', 'Initials': 'XQ', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesiology, Wuxi Clinical College of Anhui Medical University, 904 Hospital of Joint Logistic Support Force of PLA, Wuxi Clinical College of Anhui Medical University, Wuxi 214044, Jiangsu Province, China.'}, {'ForeName': 'Jing-Zhi', 'Initials': 'JZ', 'LastName': 'Luo', 'Affiliation': 'Department of Anesthesiology, Wuxi Clinical College of Anhui Medical University, 904 Hospital of Joint Logistic Support Force of PLA, Wuxi Clinical College of Anhui Medical University, Wuxi 214044, Jiangsu Province, China.'}, {'ForeName': 'Xiao-Yu', 'Initials': 'XY', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Wuxi Clinical College of Anhui Medical University, 904 Hospital of Joint Logistic Support Force of PLA, Wuxi Clinical College of Anhui Medical University, Wuxi 214044, Jiangsu Province, China. 742888988@qq.com.'}, {'ForeName': 'Hai-Qin', 'Initials': 'HQ', 'LastName': 'Tang', 'Affiliation': 'Department of Anesthesiology, Wuxi Clinical College of Anhui Medical University, 904 Hospital of Joint Logistic Support Force of PLA, Wuxi Clinical College of Anhui Medical University, Wuxi 214044, Jiangsu Province, China.'}, {'ForeName': 'Wei-Hong', 'Initials': 'WH', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, Wuxi Clinical College of Anhui Medical University, 904 Hospital of Joint Logistic Support Force of PLA, Wuxi Clinical College of Anhui Medical University, Wuxi 214044, Jiangsu Province, China.'}]",World journal of clinical cases,['10.12998/wjcc.v9.i21.5909'] 2096,34368308,Preprocedure ultrasound imaging combined with palpation technique in epidural labor analgesia.,"BACKGROUND For parturients with paroxysmal uterine contraction pain, rapid analgesia is needed. We used preprocedure ultrasound imaging combined with the palpation technique in epidural analgesia for labor, and evaluated the usefulness of this technique in epidural labor analgesia. AIM To evaluate the usefulness of preprocedure ultrasound imaging in epidural analgesia for labor. METHODS In this prospective randomized observational study, 72 parturients were assigned to two groups (combined or palpation group). The target interspace of all parturients was first identified by the palpation technique. Then in the combined group, preprocedure ultrasound imaging was used before epidural puncture. In the palpation group, only the traditional anatomical landmarks technique (palpation technique) was performed. The primary outcome was total duration of the epidural procedure (for the ultrasound group, the duration of the preprocedure ultrasound imaging was included). The secondary outcomes were the number of skin punctures, the success rate at first needle pass, the number of needle passes, the depth from the skin to epidural space, and the complications of the procedure. RESULTS Total duration of the epidural procedure was similar between the two groups (406.5 ± 92.15 s in the combined group and 380.03 ± 128.2 s in the palpation group; P = 0.318). A significant improvement was demonstrated for epidural puncture and catheterization in the combined group. The number of needle passes was 1.14 in the combined group and 1.72 in the palpation group ( P = 0.001). The number of skin puncture sites was 1.20 in the combined group and 1.25 in the palpation group ( P = 0.398). The success rate at first needle pass was 88.89% in the combined group and 66.67% in the palpation group ( P = 0.045). CONCLUSION This study demonstrated that the total duration of epidural procedures with preprocedure ultrasound imaging combined with the palpation technique was not longer than the traditional anatomical landmarks technique, which were performed by six experienced anesthesiologists in parturients with normal weights undergoing labor analgesia.",2021,The number of skin puncture sites was 1.20 in the combined group and 1.25 in the palpation group ( P = 0.398).,"['72 parturients', 'epidural labor analgesia', 'parturients with normal weights undergoing labor analgesia', 'parturients with paroxysmal uterine contraction pain']","['preprocedure ultrasound imaging combined with the palpation technique', 'preprocedure ultrasound imaging', 'Preprocedure ultrasound imaging combined with palpation technique']","['number of needle passes', 'total duration of the epidural procedure', 'number of skin puncture sites', 'number of skin punctures, the success rate at first needle pass, the number of needle passes, the depth from the skin to epidural space, and the complications of the procedure', 'Total duration of the epidural procedure', 'success rate at first needle pass', 'epidural puncture and catheterization']","[{'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C1301740', 'cui_str': 'Analgesia in labor'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0205311', 'cui_str': 'Paroxysmal'}, {'cui': 'C0042130', 'cui_str': 'Uterine contraction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0030247', 'cui_str': 'Palpation'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0014537', 'cui_str': 'Structure of epidural space'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}]",72.0,0.0284239,The number of skin puncture sites was 1.20 in the combined group and 1.25 in the palpation group ( P = 0.398).,"[{'ForeName': 'Jian-Ping', 'Initials': 'JP', 'LastName': 'Wu', 'Affiliation': 'Department of Pain Management, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.'}, {'ForeName': 'Yuan-Zhang', 'Initials': 'YZ', 'LastName': 'Tang', 'Affiliation': 'Department of Pain Management, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.'}, {'ForeName': 'Liang-Liang', 'Initials': 'LL', 'LastName': 'He', 'Affiliation': 'Department of Pain Management, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.'}, {'ForeName': 'Wen-Xing', 'Initials': 'WX', 'LastName': 'Zhao', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Aviation General Hospital of China Medical University, Beijing Institute of Translational Medicine, Chinese Academy of Sciences, Beijing 100012, China.'}, {'ForeName': 'Jian-Xiong', 'Initials': 'JX', 'LastName': 'An', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Aviation General Hospital of China Medical University, Beijing Institute of Translational Medicine, Chinese Academy of Sciences, Beijing 100012, China.'}, {'ForeName': 'Jia-Xiang', 'Initials': 'JX', 'LastName': 'Ni', 'Affiliation': 'Department of Pain Management, Xuanwu Hospital of Capital Medical University, Beijing 100053, China. nijiaxiang@263.net.'}]",World journal of clinical cases,['10.12998/wjcc.v9.i21.5900'] 2097,34367847,Smart Scar Care-Industry 4.0 in Individualized Compression Garments: A Randomized Controlled Crossover Feasibility Study.,"Background We tested the workflow and comparability of compression garments (CG) automatically knitted from 3D-body-scan data (3DBSD) versus manually measured data for scar treatment. Industry 4.0 has found its way into surgery, enhancing the trend toward personalized medicine, which plays an increasingly important role in CG scar therapy. Therefore, we conducted a study to evaluate the workflow from 3DBSD to fast and precisely knitted CG and compared it with standard of care. Methods A randomized controlled crossover feasibility study was conducted as part of the individual medical technology research project ""Smart Scar Care."" Objective and patient-reported outcome measures were documented for 10 patients with hypertrophic burn scars at baseline and after wearing CG automatically knitted from 3DBSD versus CG from manually measured data for one month. Results The ""scan-to-knit"" workflow and the study design were feasible in 10 of 10 patients. No adverse effects were found. 3DBSD showed a bias of half a centimeter compared with manually measured data and wider limits of agreement. With respect to fit, comfort, suitability, Vancouver Scar Scale, Patient and Observer Scar Assessment Scale, stiffness and microcirculation, this was a promising pilot study. Stiffness and blood flow were increased in scars compared with normal skin. The highest rank correlations were found between pain and itch, stiffness and Patient and Observer Scar Assessment Scale, Vancouver Scar Scale, and pain. Conclusions These results indicate that automatically knitted CG using 3DBSD could become an alternative to the standard of care, especially with regard to economical and faster patient care. The produced scan data opens the door for objective scar science.",2021,"The highest rank correlations were found between pain and itch, stiffness and Patient and Observer Scar Assessment Scale, Vancouver Scar Scale, and pain. ","['10 patients with hypertrophic burn scars', '10 of 10 patients']","['3DBSD', 'Individualized Compression Garments', 'compression garments (CG) automatically knitted from 3D-body-scan data (3DBSD']","['pain and itch, stiffness and Patient and Observer Scar Assessment Scale, Vancouver Scar Scale, and pain', 'adverse effects', 'fit, comfort, suitability, Vancouver Scar Scale, Patient and Observer Scar Assessment Scale, stiffness and microcirculation', 'Stiffness and blood flow']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020564', 'cui_str': 'Hypertrophy'}, {'cui': 'C0036280', 'cui_str': 'Burn scar'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C2985539', 'cui_str': 'Compression garment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0036572', 'cui_str': 'Seizure'}, {'cui': 'C0025962', 'cui_str': 'Microcirculation'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}]",10.0,0.0522606,"The highest rank correlations were found between pain and itch, stiffness and Patient and Observer Scar Assessment Scale, Vancouver Scar Scale, and pain. ","[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Kisch', 'Affiliation': 'Klinik für Plastische Chirurgie, Handchirurgie und Intensivstation für Schwerbrandverletzte, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Felix H', 'Initials': 'FH', 'LastName': 'Stang', 'Affiliation': 'Klinik für Plastische Chirurgie, Handchirurgie und Intensivstation für Schwerbrandverletzte, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Mailaender', 'Affiliation': 'Klinik für Plastische Chirurgie, Handchirurgie und Intensivstation für Schwerbrandverletzte, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Schleusser', 'Affiliation': 'Klinik für Plastische Chirurgie, Handchirurgie und Intensivstation für Schwerbrandverletzte, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Michel', 'Affiliation': 'Avalution, Kaiserslautern, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Trieb', 'Affiliation': 'Avalution, Kaiserslautern, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Bannwarth', 'Affiliation': 'Essity, Hamburg, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Maly', 'Affiliation': 'Essity, Hamburg, Germany.'}, {'ForeName': 'Anika', 'Initials': 'A', 'LastName': 'Dallmann', 'Affiliation': 'Essity, Hamburg, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Klasen', 'Affiliation': 'Essity, Hamburg, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Kaiser', 'Affiliation': 'Hochschule Albstadt-Sigmaringen, Albstadt-Ebingen, Germany.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Schmeltzpfenning', 'Affiliation': 'Stoll AG & Co. KG, Reutlingen, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Rempp', 'Affiliation': 'Assyst GmbH, Aschhein-Dornach, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Lades', 'Affiliation': 'Deutsche Institute für Textil- und Faserforschung, Denkendorf, Germany.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Šurc', 'Affiliation': 'Deutsche Institute für Textil- und Faserforschung, Denkendorf, Germany.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Bauer', 'Affiliation': 'Deutsche Institute für Textil- und Faserforschung, Denkendorf, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Artschwager', 'Affiliation': 'Deutsche Institute für Textil- und Faserforschung, Denkendorf, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Vonthein', 'Affiliation': 'Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}]",Plastic and reconstructive surgery. Global open,['10.1097/GOX.0000000000003683'] 2098,34367785,An Evaluation of the Effects of a Non-caffeinated Energy Dietary Supplement on Cognitive and Physical Performance: A Randomized Double-Blind Placebo-Controlled Study.,"A large and growing body of research shows that non-caffeinated plant-based nutritional supplements can increase cognitive and physical performance. This study aimed to build on this work by investigating the possibility that a specific botanical blend (consisting of Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins) could improve cognitive and physical performance. To this end, we carried out a randomized, double-blind, placebo-controlled 21-day parallel study on 36 healthy adults. We compared the effects of the botanical blend at baseline to a caffeine and a placebo condition on 1) self-reported alertness, anxiety, and headaches; 2) multiple measures of attention and cognition; 3) physical performance; and 4) stress biomarkers. We found that relative to baseline and compared to the Caffeine and Placebo groups, the botanical blend increased alertness and improved cognitive performance. The cognitive effects were most robust for attention measures. The botanical blend did not improve physical performance on a time to exhaustion (TTE) test. Of note, there was not the expected increase in catecholamine response after the TTE on Day 21, suggesting that long-term botanical blend use decreases the catecholamine stress response of a physical endurance task. In conclusion, we show that, within the confines of this study, a combination of the botanical blend could serve as a safe and effective nutritional supplement to improve cognitive performance.",2021,The botanical blend did not improve physical performance on a time to exhaustion (TTE) test.,['36 healthy adults'],"['Non-caffeinated Energy Dietary Supplement', 'Placebo', 'Caffeine and Placebo', 'placebo', 'caffeine and a placebo']","['alertness and improved cognitive performance', 'catecholamine stress response', 'catecholamine response', 'cognitive and physical performance', 'cognitive performance', 'Cognitive and Physical Performance', 'physical performance on a time to exhaustion (TTE) test']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}]","[{'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0007412', 'cui_str': 'Catecholamine'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",36.0,0.169927,The botanical blend did not improve physical performance on a time to exhaustion (TTE) test.,"[{'ForeName': 'Jaime L', 'Initials': 'JL', 'LastName': 'Tartar', 'Affiliation': 'Psychology and Neuroscience, Nova Southeastern University, Davie, USA.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Antonio', 'Affiliation': 'College of Health Care Sciences, Nova Southeastern University, Davie, USA.'}, {'ForeName': 'Douglas S', 'Initials': 'DS', 'LastName': 'Kalman', 'Affiliation': 'College of Health Care Sciences, Nova Southeastern University, Davie, USA.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Hewlings', 'Affiliation': 'The Herbert H & Grace A. Dow College of Health Professions, Central Michigan University, Mt. Pleasant, USA.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Baisley', 'Affiliation': 'Clinical Design and Delivery, Nutrasource Pharmaceutical and Nutraceutical Services, Guelph, CAN.'}, {'ForeName': 'Mykola', 'Initials': 'M', 'LastName': 'Marang', 'Affiliation': 'Psychology and Neuroscience, Nova Southeastern University, Davie, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Flynn', 'Affiliation': 'Glanbia Research and Development Center, Glanbia Nutritionals, Twin Falls, USA.'}, {'ForeName': 'Corey A', 'Initials': 'CA', 'LastName': 'Peacock', 'Affiliation': 'College of Health Care Sciences, Nova Southeastern University, Davie, USA.'}]",Cureus,['10.7759/cureus.16178'] 2099,34360051,Adjustment for Baseline Covariates to Increase Efficiency in RCTs with Binary Endpoint: A Comparison of Bayesian and Frequentist Approaches.,"BACKGROUND In a randomized controlled trial (RCT) with binary outcome the estimate of the marginal treatment effect can be biased by prognostic baseline covariates adjustment. Methods that target the marginal odds ratio, allowing for improved precision and power, have been developed. METHODS The performance of different estimators for the treatment effect in the frequentist (targeted maximum likelihood estimator, inverse-probability-of-treatment weighting, parametric G-computation, and the semiparametric locally efficient estimator) and Bayesian (model averaging), adjustment for confounding, and generalized Bayesian causal effect estimation frameworks are assessed and compared in a simulation study under different scenarios. The use of these estimators is illustrated on an RCT in type II diabetes. RESULTS Model mis-specification does not increase the bias. The approaches that are not doubly robust have increased standard error (SE) under the scenario of mis-specification of the treatment model. The Bayesian estimators showed a higher type II error than frequentist estimators if noisy covariates are included in the treatment model. CONCLUSIONS Adjusting for prognostic baseline covariates in the analysis of RCTs can have more power than intention-to-treat based tests. However, for some classes of model, when the regression model is mis-specified, inflated type I error and potential bias on treatment effect estimate may arise.",2021,"RESULTS Model mis-specification does not increase the bias.",[],[],[],[],[],[],,0.0664801,"RESULTS Model mis-specification does not increase the bias.","[{'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Berchialla', 'Affiliation': 'Department of Clinical and Biological Sciences, University of Torino, 10100 Torino, Italy.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Sciannameo', 'Affiliation': 'Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Urru', 'Affiliation': 'Department of Clinical and Biological Sciences, University of Torino, 10100 Torino, Italy.'}, {'ForeName': 'Corrado', 'Initials': 'C', 'LastName': 'Lanera', 'Affiliation': 'Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.'}, {'ForeName': 'Danila', 'Initials': 'D', 'LastName': 'Azzolina', 'Affiliation': 'Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Gregori', 'Affiliation': 'Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.'}, {'ForeName': 'Ileana', 'Initials': 'I', 'LastName': 'Baldi', 'Affiliation': 'Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.'}]",International journal of environmental research and public health,['10.3390/ijerph18157758'] 2100,34360036,Effects of Diet Control and Telemedicine-Based Resistance Exercise Intervention on Patients with Obesity and Knee Osteoarthritis: A Randomized Control Trial.,"This study investigated the effects of home-based nutritional and telemedicine-based resistance exercise interventions on improving body composition, blood biochemistry, and lower-limb functional performance. In total, 66 obese patients with mild-to-moderate knee osteoarthritis were randomly divided into a diet control group (D), elastic band resistance exercise group (E), and diet control plus elastic band exercise group (D + E). Each group was supervised by a clinical dietitian and follow-up was conducted via telephone calls or a communication application to track the participants' progress. After 12 weeks of intervention, the D ( p < 0.001) and D + E ( p < 0.001) groups achieved significant weight loss. The D + E group exhibited a significant reduction in body fat relative to the D ( p = 0.019) and E ( p = 0.012) groups. Compared with the D ( p = 0.002) and E ( p = 0.019) groups, the D + E group achieved significant improvements in the timed up-and-go test and Western Ontario and McMaster Universities Osteoarthritis total scale. The D + E group experienced significant improvements in total cholesterol ( p = 0.001), low-density lipoprotein cholesterol ( p = 0.01), and triglyceride levels ( p = 0.007) relative to other groups. In conclusion, individual diet control intervention combined with telemedicine-based resistance exercise intervention significantly improved the body composition, blood biochemistry, and lower-limb functional performance of the investigated population with comorbid conditions.",2021,The D + E group exhibited a significant reduction in body fat relative to the D ( p = 0.019) and E ( p = 0.012) groups.,"['Patients with Obesity and Knee Osteoarthritis', '66 obese patients with mild-to-moderate knee osteoarthritis']","['telemedicine-based resistance exercise intervention', 'diet control group (D), elastic band resistance exercise group (E), and diet control plus elastic band exercise group (D + E', 'home-based nutritional and telemedicine-based resistance exercise interventions', 'clinical dietitian and follow-up was conducted via telephone calls or a communication application', 'Diet Control and Telemedicine-Based Resistance Exercise Intervention']","['weight loss', 'timed up-and-go test and Western Ontario and McMaster Universities Osteoarthritis total scale', 'low-density lipoprotein cholesterol', 'body fat relative', 'triglyceride levels', 'total cholesterol', 'body composition, blood biochemistry, and lower-limb functional performance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0743195', 'cui_str': 'Dietary control'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0221839', 'cui_str': 'Orthodontic band, elastic'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",66.0,0.00652741,The D + E group exhibited a significant reduction in body fat relative to the D ( p = 0.019) and E ( p = 0.012) groups.,"[{'ForeName': 'Yen-I', 'Initials': 'YI', 'LastName': 'Hsu', 'Affiliation': 'Department of Sports Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.'}, {'ForeName': 'Ying-Chou', 'Initials': 'YC', 'LastName': 'Chen', 'Affiliation': 'Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, Kaohsiung 833, Taiwan.'}, {'ForeName': 'Chia-Lun', 'Initials': 'CL', 'LastName': 'Lee', 'Affiliation': 'Center for Physical and Health Education, National Sun Yat-Sen University, Kaohsiung 804, Taiwan.'}, {'ForeName': 'Nai-Jen', 'Initials': 'NJ', 'LastName': 'Chang', 'Affiliation': 'Department of Sports Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.'}]",International journal of environmental research and public health,['10.3390/ijerph18157744'] 2101,34360032,Acute Effects of a Percussive Massage Treatment on Movement Velocity during Resistance Training.,The aim of this research was to verify whether the application of percussion therapy during inter-set rest periods increases the number of repetitions performed before reaching a 30% velocity loss threshold during a bench press exercise. Methods: Twenty-four male university students participated in this study (24.3 ± 1.3 years; 77.5 ± 8.3 kg; 177.0 ± 5.6 cm; 24.7 ± 2.6 kg∙m -2 ). Participants were randomized into two groups: a percussion therapy group (PTG) and a control group (CG). They performed 4 sets at 70% of a one-repetition maximum before reaching a 30% velocity loss threshold with an inter-set recovery of 3 min. Results : The PTG performed a greater total number of repetitions compared to the CG (44.6 ± 4.8 vs. 39.5 ± 6.8; p = 0.047; ES = 0.867). No differences were observed for the different movement velocity variables and fatigue control ( p > 0.05). Conclusions : Percussion therapy is an effective method to delay the loss of movement velocity in the bench press exercise.,2021,No differences were observed for the different movement velocity variables and fatigue control ( p > 0.05). ,['Methods: Twenty-four male university students participated in this study (24.3 ± 1.3 years; 77.5 ± 8.3 kg; 177.0 ± 5.6 cm; 24.7 ± 2.6 kg∙m -2 '],"['percussion therapy group (PTG) and a control group (CG', 'Percussive Massage Treatment', 'Percussion therapy']","['movement velocity variables and fatigue control', 'total number of repetitions', 'Movement Velocity']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C4517633', 'cui_str': '2.6'}]","[{'cui': 'C0556838', 'cui_str': 'Percussion therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}]",,0.0290385,No differences were observed for the different movement velocity variables and fatigue control ( p > 0.05). ,"[{'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'García-Sillero', 'Affiliation': 'Faculty of Sport Sciences, EADE-University of Wales Trinity Saint David, 29018 Málaga, Spain.'}, {'ForeName': 'Jose Manuel', 'Initials': 'JM', 'LastName': 'Jurado-Castro', 'Affiliation': 'Metabolism and Investigation Unit, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Córdoba, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Benítez-Porres', 'Affiliation': 'Faculty of Medicine, University of Málaga, 29071 Málaga, Spain.'}, {'ForeName': 'Salvador', 'Initials': 'S', 'LastName': 'Vargas-Molina', 'Affiliation': 'Faculty of Sport Sciences, EADE-University of Wales Trinity Saint David, 29018 Málaga, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18157726'] 2102,34360028,Effects of Power and Ballistic Training on Table Tennis Players' Electromyography Changes.,"The aim of the present study was to analyze the effects of ballistic and power training on table tennis players' electromyography (EMG) changes. Thirty male table tennis players, who were able to perform top spin strikes properly, were randomly assigned to three groups: power training (PT; n = 10); ballistic training (BT; n = 10); and no training (CON = control group; n = 10). PT and BT were performed 3 times weekly for 8 weeks. Before and after training programs, a one-repetition maximum test (1RM) and the EMG activity of all the subjects' upper/lower body muscles while performing top spin strokes were analyzed. After training, significant interactions (group × time) were observed in increasing 1RM strength in upper/lower muscles ( p < 0.05). However, neither training type had any significant effect on muscle EMG activity. These findings suggest that there should not necessarily be any significant change in the EMG signal after BT and PT despite the increase in muscle strength.",2021,"After training, significant interactions (group × time) were observed in increasing 1RM strength in upper/lower muscles ( p < 0.05).","['Thirty male table tennis players, who were able to perform top spin strikes properly']","['power training (PT; n = 10); ballistic training (BT; n = 10); and no training (CON = control', 'ballistic and power training', 'Power and Ballistic Training']","['1RM strength', 'muscle EMG activity', 'EMG signal', ""Table Tennis Players' Electromyography Changes"", ""table tennis players' electromyography (EMG) changes"", 'muscle strength']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0039224', 'cui_str': 'Table'}, {'cui': 'C0039515', 'cui_str': 'Tennis'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0038452', 'cui_str': 'Employee Strikes'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0443149', 'cui_str': 'Ballistic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0039224', 'cui_str': 'Table'}, {'cui': 'C0039515', 'cui_str': 'Tennis'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}]",30.0,0.00465117,"After training, significant interactions (group × time) were observed in increasing 1RM strength in upper/lower muscles ( p < 0.05).","[{'ForeName': 'Amir Hossein', 'Initials': 'AH', 'LastName': 'Haghighi', 'Affiliation': 'Faculty of Sport Sciences, Hakim Sabzevari University, Sabzevar 9617976487, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Zaferanieh', 'Affiliation': 'Faculty of Sport Sciences, Hakim Sabzevari University, Sabzevar 9617976487, Iran.'}, {'ForeName': 'Seyed Alireza', 'Initials': 'SA', 'LastName': 'Hosseini-Kakhak', 'Affiliation': 'Faculty of Sport Sciences, Hakim Sabzevari University, Sabzevar 9617976487, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Maleki', 'Affiliation': 'Faculty of Electrical and Computer Engineering, Semnan University, Semnan 3513119111, Iran.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Esposito', 'Affiliation': 'Department of Biomedical Science for Health, Università degli Studi di Milano, 20122 Milan, Italy.'}, {'ForeName': 'Emiliano', 'Initials': 'E', 'LastName': 'Cè', 'Affiliation': 'Department of Biomedical Science for Health, Università degli Studi di Milano, 20122 Milan, Italy.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Castellar', 'Affiliation': 'ENFYRED Research Group, Faculty of Health and Sports Sciences, University of Zaragoza, 22001 Huesca, Spain.'}, {'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Toro-Román', 'Affiliation': 'School of Sport Sciences, University of Extremadura, Avenida de la Universidad s/n, 10003 Cáceres, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Pradas', 'Affiliation': 'ENFYRED Research Group, Faculty of Health and Sports Sciences, University of Zaragoza, 22001 Huesca, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph18157735'] 2103,34359996,"Association between Markers of Synovial Inflammation, Matrix Turnover and Symptoms in Knee Osteoarthritis: A Cross-Sectional Study.","To investigate the association between markers of synovial inflammation and matrix turnover (MRI-based and serum biomarkers) and knee symptoms in established knee osteoarthritis (KOA). This cross-sectional study utilised data from a randomised, multicentre placebo-controlled trial (UK-VIDEO) of vitamin D therapy in symptomatic KOA. Data on serum biomarkers, type III collagen degradation (C3M), metabolite of C-reactive protein (CRPM) and cartilage oligomeric matrix protein (COMP), were available at baseline whilst contrast-enhanced (CE) MRI data were acquired in a subsample at baseline and annually. Knee symptoms were assessed using WOMAC at all visits. We examined the cross-sectional association between knee symptoms and three MRI-based and three serum markers of synovitis and matrix turnover, respectively. A total of 447 participants were included in the serum and 136 participants in the MRI analyses. MRI-defined medial perimeniscal synovitis was positively associated with knee pain and, suprapatellar and medial perimeniscal synovitis with knee function in multivariate analysis. We observed a statistically significant, negative association between a higher concentration of serum C3M and CRPM and knee pain, respectively. Furthermore, the highest CRPM quartile was negatively associated with knee function. Our findings suggest that, in established painful radiographic KOA, MRI-defined medial perimeniscal and suprapatellar synovitis were positively associated with knee symptoms. Serum-based C3M and CRPM markers were negatively associated with knee symptoms. Pain fluctuations are common in KOA and a better understanding of the relationship between markers of synovitis and matrix turnover and knee symptoms would facilitate a more accurate assessment of temporal changes in disease progression.",2021,"We observed a statistically significant, negative association between a higher concentration of serum C3M and CRPM and knee pain, respectively.","['Knee Osteoarthritis', 'symptomatic KOA', 'established knee osteoarthritis (KOA', 'A total of 447 participants were included in the serum and 136 participants in the MRI analyses']","['placebo', 'vitamin D therapy']","['serum C3M and CRPM and knee pain', 'Pain fluctuations', 'Synovial Inflammation, Matrix Turnover and Symptoms', 'Knee symptoms', 'synovial inflammation and matrix turnover (MRI-based and serum biomarkers', 'serum biomarkers, type III collagen degradation (C3M), metabolite of C-reactive protein (CRPM) and cartilage oligomeric matrix protein (COMP', 'Serum-based C3M and CRPM markers']","[{'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0054856', 'cui_str': 'catch-relaxing peptide (Mytilus)'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0031227', 'cui_str': 'Employee Turnover'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0009332', 'cui_str': 'Collagen type III'}, {'cui': 'C0243125', 'cui_str': 'degradation'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0601900', 'cui_str': 'COMP (Cartilage Oligomeric Matrix Protein)'}]",447.0,0.0428116,"We observed a statistically significant, negative association between a higher concentration of serum C3M and CRPM and knee pain, respectively.","[{'ForeName': 'Xiaotian', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Rehabilitation Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.'}, {'ForeName': 'Christian S', 'Initials': 'CS', 'LastName': 'Thudium', 'Affiliation': 'Immunoscience, Nordic Bioscience, DK-2730 Herlev, Denmark.'}, {'ForeName': 'Anne-Christine', 'Initials': 'AC', 'LastName': 'Bay-Jensen', 'Affiliation': 'Immunoscience, Nordic Bioscience, DK-2730 Herlev, Denmark.'}, {'ForeName': 'Morten A', 'Initials': 'MA', 'LastName': 'Karsdal', 'Affiliation': 'Immunoscience, Nordic Bioscience, DK-2730 Herlev, Denmark.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'van Santen', 'Affiliation': 'Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.'}, {'ForeName': 'Nigel K', 'Initials': 'NK', 'LastName': 'Arden', 'Affiliation': 'Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Perry', 'Affiliation': 'Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kluzek', 'Affiliation': 'Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.'}]",Cells,['10.3390/cells10071826'] 2104,34359801,"Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol.","Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique with the ability to generate a window for the establishment of systemic antitumor immunity. IRE transiently alters the tumor's immunosuppressive microenvironment while simultaneously generating antigen release, thereby instigating an adaptive immune response. Combining IRE with immunotherapeutic drugs, i.e., electroimmunotherapy, has synergistic potential and might induce a durable antitumor response. The primary objective of this study is to assess the safety of the combination of IRE with IMO-2125 (a toll-like receptor 9 ligand) and/or nivolumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In this randomized controlled phase I clinical trial, 18 patients with mPDAC pretreated with chemotherapy will be enrolled in one of three study arms: A (control): nivolumab monotherapy; B: percutaneous IRE of the primary tumor followed by nivolumab; or C: intratumoral injection of IMO-2125 followed by percutaneous IRE of the primary tumor and nivolumab. Assessments include contrast enhanced computed tomography (ceCT), 18 F-FDG and 1 8 F-BMS-986192 (PD-L1) positron emission tomography (PET)-CT, biopsies of the primary tumor and metastases, peripheral blood samples, and quality of life and pain questionnaires. There is no curative treatment option for patients with mPDAC, and palliative chemotherapy regimens only moderately improve survival. Consequently, there is an urgent need for innovative and radically different treatment approaches. Should electroimmunotherapy establish an effective and durable anti-tumor response, it may ultimately improve PDAC's dismal prognosis.",2021,Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique with the ability to generate a window for the establishment of systemic antitumor immunity.,"['18 patients with mPDAC pretreated with', 'patients with metastatic pancreatic ductal adenocarcinoma (mPDAC']","['Irreversible electroporation (IRE', 'nivolumab monotherapy; B: percutaneous IRE of the primary tumor followed by nivolumab; or C: intratumoral injection of IMO-2125 followed by percutaneous IRE of the primary tumor and nivolumab', 'chemotherapy', 'electroimmunotherapy', 'IRE with IMO-2125']","['Assessments include contrast enhanced computed tomography (ceCT), 18 F-FDG and 1 8 F-BMS-986192 (PD-L1) positron emission tomography (PET)-CT, biopsies of the primary tumor and metastases, peripheral blood samples, and quality of life and pain questionnaires', 'survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C1335302', 'cui_str': 'Ductal adenocarcinoma of pancreas'}]","[{'cui': 'C4319935', 'cui_str': 'Irreversible electroporation'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0046056', 'cui_str': 'Fluorodeoxyglucose F18'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",18.0,0.0761939,Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique with the ability to generate a window for the establishment of systemic antitumor immunity.,"[{'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Geboers', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Florentine E F', 'Initials': 'FEF', 'LastName': 'Timmer', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Alette H', 'Initials': 'AH', 'LastName': 'Ruarus', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Johanna E E', 'Initials': 'JEE', 'LastName': 'Pouw', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Evelien A C', 'Initials': 'EAC', 'LastName': 'Schouten', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Bakker', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Robbert S', 'Initials': 'RS', 'LastName': 'Puijk', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Sanne', 'Initials': 'S', 'LastName': 'Nieuwenhuizen', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Madelon', 'Initials': 'M', 'LastName': 'Dijkstra', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'M Petrousjka', 'Initials': 'MP', 'LastName': 'van den Tol', 'Affiliation': 'Department of Surgery, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Jan J J', 'Initials': 'JJJ', 'LastName': 'de Vries', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Daniela E', 'Initials': 'DE', 'LastName': 'Oprea-Lager', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'C Willemien', 'Initials': 'CW', 'LastName': 'Menke-van der Houven van Oordt', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Hans J', 'Initials': 'HJ', 'LastName': 'van der Vliet', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Johanna W', 'Initials': 'JW', 'LastName': 'Wilmink', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Hester J', 'Initials': 'HJ', 'LastName': 'Scheffer', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Tanja D', 'Initials': 'TD', 'LastName': 'de Gruijl', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': 'Martijn R', 'Initials': 'MR', 'LastName': 'Meijerink', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': 'On Behalf Of The Dutch Pancreatic Cancer Group', 'Affiliation': ''}]",Cancers,['10.3390/cancers13153902'] 2105,34359796,"Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer.","In colorectal cancer (CRC), 20-50% of patients relapse after curative-intent surgery with or without adjuvant therapy. We investigated the lead times and prognostic value of post-adjuvant (8 months from randomisation to adjuvant treatment) serum CEA, CA19-9, IL-6, CRP, and YKL-40. We included 147 radically resected stage II-IV CRC treated with 24 weeks of adjuvant 5-fluorouracil-based chemotherapy in the phase III LIPSYT-study (ISRCTN98405441). All 147 were included in lead time analysis, but 12 relapsing during adjuvant therapy were excluded from post-adjuvant analysis. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired disease-free survival (DFS) with hazard ratio (HR) 5.21 (95% confidence interval 2.32-11.69); 3.72 (1.99-6.95); 2.58 (1.18-5.61), respectively, and elevated IL-6 and CRP with impaired overall survival (OS) HR 3.06 (1.64-5.73); 3.41 (1.55-7.49), respectively. Elevated post-adjuvant IL-6 in CEA-normal patients identified a subgroup with impaired DFS. HR 3.12 (1.38-7.04) and OS, HR 3.20 (1.39-7.37). The lead times between the elevated biomarker and radiological relapse were 7.8 months for CEA and 10.0-53.1 months for CA19-9, IL-6, CRP, and YKL-40, and the lead time for the five combined was 27.3 months. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired DFS. The lead time was shortest for CEA.",2021,"Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired disease-free survival (DFS) with hazard ratio (HR) 5.21","['147 radically resected stage II-IV CRC treated with 24 weeks of', 'All 147 were included in lead time analysis, but 12 relapsing during adjuvant therapy were excluded from post-adjuvant analysis', 'Colorectal Cancer']",['adjuvant 5-fluorouracil-based chemotherapy'],"['Elevated post-adjuvant CEA, IL-6, and CRP', 'elevated IL-6 and CRP with impaired overall survival', 'serum CEA, CA19-9, IL-6, CRP, and YKL-40', 'elevated biomarker and radiological relapse', 'impaired disease-free survival (DFS) with hazard ratio (HR) 5.21', 'Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40']","[{'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}]","[{'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0007082', 'cui_str': 'Carcinoembryonic antigen'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006613', 'cui_str': 'Cancer antigen 19-9'}, {'cui': 'C0528649', 'cui_str': 'CHI3L1 protein, human'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035820', 'cui_str': 'Role'}]",147.0,0.248041,"Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired disease-free survival (DFS) with hazard ratio (HR) 5.21","[{'ForeName': 'Kaisa', 'Initials': 'K', 'LastName': 'Lehtomäki', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland.'}, {'ForeName': 'Harri', 'Initials': 'H', 'LastName': 'Mustonen', 'Affiliation': 'Department of Gastrointestinal Surgery, Helsinki University Hospital and University of Helsinki, P.O. Box 440, 00029 HUS Helsinki, Finland.'}, {'ForeName': 'Pirkko-Liisa', 'Initials': 'PL', 'LastName': 'Kellokumpu-Lehtinen', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Joensuu', 'Affiliation': 'Department of Oncology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00290 Helsinki, Finland.'}, {'ForeName': 'Kethe', 'Initials': 'K', 'LastName': 'Hermunen', 'Affiliation': 'Department of Gastrointestinal Surgery, Helsinki University Hospital and University of Helsinki, P.O. Box 440, 00029 HUS Helsinki, Finland.'}, {'ForeName': 'Leena-Maija', 'Initials': 'LM', 'LastName': 'Soveri', 'Affiliation': 'Hyvinkää Hospital and Hyvinkää Homecare, Sairaalankatu 1, 05850 Hyvinkää, Finland.'}, {'ForeName': 'Mogens Karsbøl', 'Initials': 'MK', 'LastName': 'Boisen', 'Affiliation': 'Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Borgmester Ib Juuls vej 1, DK-2730 Herlev, Denmark.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Dehlendorff', 'Affiliation': 'Statistics and Data Analysis Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.'}, {'ForeName': 'Julia Sidenius', 'Initials': 'JS', 'LastName': 'Johansen', 'Affiliation': 'Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Borgmester Ib Juuls vej 1, DK-2730 Herlev, Denmark.'}, {'ForeName': 'Caj', 'Initials': 'C', 'LastName': 'Haglund', 'Affiliation': 'Department of Gastrointestinal Surgery, Helsinki University Hospital and University of Helsinki, P.O. Box 440, 00029 HUS Helsinki, Finland.'}, {'ForeName': 'Pia', 'Initials': 'P', 'LastName': 'Osterlund', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland.'}]",Cancers,['10.3390/cancers13153892'] 2106,34359450,Synbiotic Supplementation Improves Obesity Index and Metabolic Biomarkers in Thai Obese Adults: A Randomized Clinical Trial.,"The cluster of metabolic disorders includes obesity, dyslipidemia, hypertension, and glucose intolerance, increasing the risk of developing cardiovascular diseases and type 2 diabetes. Evolving proofs suggest an essential role of microbiota in human health and disease, including digestion, energy and glucose metabolism, immunomodulation, and brain function. The frequency of overweight is increasing, and the main causes for this are highly processed foods and less active lifestyles. Research is underway to unravel the probable relationship between obesity and intestinal microbiota. Here, we propose a method to understand and elucidate the synergistic function of prebiotics and probiotics in treating obesity. The biomarkers of obesity, such as cholesterol, gut permeability, oxidative stress, bacterial toxins, cytokines, and short-chain fatty acids, were analyzed in Thai obese individuals after being supplemented with a synbiotic preparation containing Lactobacillus paracasei , Bifidobacterium longum , Bifidobacterium breve , inulin, and fructooligosaccharide. The results reveal that the supplementation of synbiotics significantly altered the obesity-associated biomarkers in an appositive way. Further studies are warranted to use synbiotics as an adjuvant therapy for the management of obesity-related health issues.",2021,The results reveal that the supplementation of synbiotics significantly altered the obesity-associated biomarkers in an appositive way.,"['Thai Obese Adults', 'Thai obese individuals after being supplemented with a']","['synbiotic preparation containing Lactobacillus paracasei , Bifidobacterium longum , Bifidobacterium breve , inulin, and fructooligosaccharide', 'Synbiotic Supplementation']",['Obesity Index and Metabolic Biomarkers'],"[{'cui': 'C0039724', 'cui_str': 'Thai language'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C1080735', 'cui_str': 'Lactobacillus paracasei'}, {'cui': 'C0314977', 'cui_str': 'Bifidobacterium longum'}, {'cui': 'C0314975', 'cui_str': 'Bifidobacterium breve'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C0873033', 'cui_str': 'fructooligosaccharide'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",,0.0722867,The results reveal that the supplementation of synbiotics significantly altered the obesity-associated biomarkers in an appositive way.,"[{'ForeName': 'Chaiyavat', 'Initials': 'C', 'LastName': 'Chaiyasut', 'Affiliation': 'Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Bhagavathi Sundaram', 'Initials': 'BS', 'LastName': 'Sivamaruthi', 'Affiliation': 'Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Periyanaina', 'Initials': 'P', 'LastName': 'Kesika', 'Affiliation': 'Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Suchanat', 'Initials': 'S', 'LastName': 'Khongtan', 'Affiliation': 'Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Nanticha', 'Initials': 'N', 'LastName': 'Khampithum', 'Affiliation': 'Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Subramanian', 'Initials': 'S', 'LastName': 'Thangaleela', 'Affiliation': 'Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Sartjin', 'Initials': 'S', 'LastName': 'Peerajan', 'Affiliation': 'Health Innovation Institute, Chiangmai 50200, Thailand.'}, {'ForeName': 'Akkarach', 'Initials': 'A', 'LastName': 'Bumrungpert', 'Affiliation': 'Mahidol Nutrition Society, Faculty of Public Health, Mahidol University, Bangkok 10400, Thailand.'}, {'ForeName': 'Khontaros', 'Initials': 'K', 'LastName': 'Chaiyasut', 'Affiliation': 'Institute of Research and Development, Chiang Mai Rajabhat University, Chiangmai 50300, Thailand.'}, {'ForeName': 'Sasithorn', 'Initials': 'S', 'LastName': 'Sirilun', 'Affiliation': 'Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Phakkharawat', 'Initials': 'P', 'LastName': 'Sittiprapaporn', 'Affiliation': 'Neuropsychological Research Laboratory, Department of Anti-Aging and Regenerative Science, School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Bangkok 11120, Thailand.'}]","Foods (Basel, Switzerland)",['10.3390/foods10071580'] 2107,34359426,"Efficacy and Safety of Aronia, Red Ginseng, Shiitake Mushroom, and Nattokinase Mixture on Insulin Resistance in Prediabetic Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial.","We determined whether oral consumption of Aronia, red ginseng, shiitake mushroom, and nattokinase mixture (3.4: 4.1: 2.4: 0.1 w / w ; AGM) improved glucose metabolism and insulin resistance in prediabetic adults in a 12-week randomized, double-blinded clinical trial. Participants with fasting serum glucose concentrations of 100-140 mg/dL were recruited and randomly assigned to an AGM or placebo group. Participants of the AGM group ( n = 40) were given an AGM granule containing 4 g of freeze-dried Aronia, red ginseng, shiitake mushroom, and nattokinase (3.4: 4.1: 2.4: 0.1 w / w ) twice daily for 12 weeks, and the placebo group participants ( n = 40) were provided with corn starch granules identical in appearance, weight, and flavor for 12 weeks. Serum glucose and insulin concentrations were measured during oral-glucose tolerance tests (OGTT) after administering 75 g of glucose in a fasted state. HOMA-IR, liver damage, and inflammation indices were determined, and safety parameters and adverse reactions were assessed. As determined by OGTT, serum glucose concentrations were not significantly different between the AGM and placebo groups after the intervention. However, changes in serum insulin concentrations in the fasted state and Homeostatic model assessment-insulin resistance (HOMA-IR) index after the intervention were significantly lower in the AGM group than in the placebo group (-3.07 ± 7.06 vs. 0.05 ± 6.12, p = 0.043 for serum insulin; -0.85 ± 2.14 vs. 0.07 ± 1.92, p = 0.049 for HOMA-IR). Serum adiponectin concentrations were reduced by intervention in the placebo group but not in the AGM group. Changes in liver damage indexes, including serum activities of the γ-glutamyl transferase, alanine aminotransferase, and aspartate aminotransferase, were lower in the AGM group and significantly reduced in the AGM group more than in the placebo group ( p < 0.05). Changes in serum high sensitive-C-reactive protein concentrations in AGM and placebo groups were significantly different (-0.12 ± 0.81 vs. 0.51 ± 1.95, p = 0.06). In conclusion, AGM possibly improves insulin sensitivity and β-cell function and reduces liver damage and inflammation in prediabetic adults.",2021,"As determined by OGTT, serum glucose concentrations were not significantly different between the AGM and placebo groups after the intervention.","['Prediabetic Adults', 'Participants with fasting serum glucose concentrations of 100-140 mg/dL', 'prediabetic adults']","['oral consumption of Aronia, red ginseng, shiitake mushroom, and nattokinase mixture (3.4: 4.1: 2.4: 0.1 w / w ; AGM', 'Aronia, Red Ginseng, Shiitake Mushroom, and Nattokinase Mixture', 'AGM granule containing 4 g of freeze-dried Aronia, red ginseng, shiitake mushroom, and nattokinase', 'AGM or placebo', 'Placebo', 'AGM', 'placebo', 'corn starch granules identical in appearance, weight, and flavor for 12 weeks']","['insulin sensitivity and β-cell function', 'serum insulin concentrations', 'Serum adiponectin concentrations', 'safety parameters and adverse reactions', 'serum glucose concentrations', 'glucose metabolism and insulin resistance', 'HOMA-IR, liver damage, and inflammation indices', 'liver damage and inflammation', 'Serum glucose and insulin concentrations', 'serum high sensitive-C-reactive protein concentrations', 'Homeostatic model assessment-insulin resistance (HOMA-IR) index', 'liver damage indexes, including serum activities of the γ-glutamyl transferase, alanine aminotransferase, and aspartate aminotransferase']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0202041', 'cui_str': 'Glucose measurement, serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1215581', 'cui_str': 'Aronia'}, {'cui': 'C0873137', 'cui_str': 'Korean ginseng preparation'}, {'cui': 'C0752328', 'cui_str': 'Lentinula edodes'}, {'cui': 'C0131956', 'cui_str': 'nattokinase'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C4517692', 'cui_str': '3.4'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C4517631', 'cui_str': '2.4'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C2919747', 'cui_str': 'w/w'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0016698', 'cui_str': 'Lyophilization'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1384515', 'cui_str': 'corn starch'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0682897', 'cui_str': 'Flavor Enhancers'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0007613', 'cui_str': 'Physiology, Cell'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0202041', 'cui_str': 'Glucose measurement, serum'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0151763', 'cui_str': 'Liver damage'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0678107', 'cui_str': 'Glutamyl transferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}]",40.0,0.317925,"As determined by OGTT, serum glucose concentrations were not significantly different between the AGM and placebo groups after the intervention.","[{'ForeName': 'Sunmin', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'Department of Food & Nutrition, Obesity/Diabetes Center, Hoseo University, Asan 31499, Korea.'}, {'ForeName': 'Chan-Joong', 'Initials': 'CJ', 'LastName': 'Kim', 'Affiliation': 'Urban Agriculture Research Division, National Institute of Horticultural and Herbal Science, Wanju 55365, Korea.'}, {'ForeName': 'Ki-Chan', 'Initials': 'KC', 'LastName': 'Ha', 'Affiliation': 'Healthcare Claims & Management Incorporation, Jeonju 54858, Korea.'}, {'ForeName': 'Hyang-Im', 'Initials': 'HI', 'LastName': 'Baek', 'Affiliation': 'Healthcare Claims & Management Incorporation, Jeonju 54858, Korea.'}, {'ForeName': 'Hye-Jeong', 'Initials': 'HJ', 'LastName': 'Yang', 'Affiliation': 'Food Functional Research Division, Korean Food Research Institutes, Wanju 55365, Korea.'}, {'ForeName': 'Min-Jung', 'Initials': 'MJ', 'LastName': 'Kim', 'Affiliation': 'Food Functional Research Division, Korean Food Research Institutes, Wanju 55365, Korea.'}, {'ForeName': 'Soo-Jung', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Department of Sasang Constitutional Medicine, Woosuk University Korean Medicine Hospital, Jeonju 55338, Korea.'}]","Foods (Basel, Switzerland)",['10.3390/foods10071558'] 2108,34359384,Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer.,"Objective : To identify dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters predictive of early disease progression in patients with metastatic renal cell cancer (mRCC) treated with anti-angiogenic tyrosine kinase inhibitors (TKI). Methods : The study was linked to a phase II/III randomised control trial. Patients underwent DCE-MRI before, at 4- and 10-weeks after initiation of TKI. DCE-MRI parameters at each time-point were derived from a single-compartment tracer kinetic model, following semi-automated tumour segmentation by two independent readers. Primary endpoint was correlation of DCE-MRI parameters with disease progression at 6-months. Receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) values were calculated for parameters associated with disease progression at 6 months. Inter-observer agreement was assessed using the intraclass correlation coefficient (ICC). Results : 23 tumours in 14 patients were measurable. Three patients had disease progression at 6 months. The percentage (%) change in perfused tumour volume between baseline and 4-week DCE-MRI ( p = 0.016), mean transfer constant K trans change ( p = 0.038), and % change in extracellular volume ( p = 0.009) between 4- and 10-week MRI, correlated with early disease progression (AUC 0.879 for each parameter). Inter-observer agreement was excellent for perfused tumour volume, K trans and extracellular volume (ICC: 0.928, 0.949, 0.910 respectively). Conclusions : Early measurement of DCE-MRI biomarkers of tumour perfusion at 4- and 10-weeks predicts disease progression at 6-months following TKI therapy in mRCC.",2021,"Inter-observer agreement was excellent for perfused tumour volume, K trans and extracellular volume (ICC: 0.928, 0.949, 0.910 respectively). ","['Metastatic Renal Cell Cancer', 'patients with metastatic renal cell cancer (mRCC) treated with anti-angiogenic tyrosine kinase inhibitors (TKI', '23 tumours in 14 patients were measurable']","['TKI therapy', 'Tyrosine Kinase Inhibitor Therapy', 'dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI', 'DCE-MRI']","['disease progression', 'DCE-MRI parameters', 'DCE-MRI parameters with disease progression', 'Receiver operating characteristic (ROC) curve analysis and area under the curve', 'intraclass correlation coefficient (ICC', 'percentage (%) change in perfused tumour volume', 'mean transfer constant K trans change', 'extracellular volume', 'AUC) values']","[{'cui': 'C4721698', 'cui_str': 'Metastatic renal cell carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C1268567', 'cui_str': 'Protein-tyrosine kinase inhibitor'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]","[{'cui': 'C1268567', 'cui_str': 'Protein-tyrosine kinase inhibitor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0010101', 'cui_str': 'Correlation Studies'}, {'cui': 'C0242349', 'cui_str': 'Immunocytochemical procedure'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0475276', 'cui_str': 'Tumor volume'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0521119', 'cui_str': 'Extracellular'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",14.0,0.141886,"Inter-observer agreement was excellent for perfused tumour volume, K trans and extracellular volume (ICC: 0.928, 0.949, 0.910 respectively). ","[{'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Zhong', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Palkhi', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Buckley', 'Affiliation': 'Biomedical Imaging, School of Medicine, University of Leeds, Leeds LS2 9JT, UK.'}, {'ForeName': 'Fiona J', 'Initials': 'FJ', 'LastName': 'Collinson', 'Affiliation': ""Department of Medical Oncology, St James's Institute of Oncology, Leeds LS9 7TF, UK.""}, {'ForeName': 'Christy', 'Initials': 'C', 'LastName': 'Ralph', 'Affiliation': ""Department of Medical Oncology, St James's Institute of Oncology, Leeds LS9 7TF, UK.""}, {'ForeName': 'Satinder', 'Initials': 'S', 'LastName': 'Jagdev', 'Affiliation': ""Department of Medical Oncology, St James's Institute of Oncology, Leeds LS9 7TF, UK.""}, {'ForeName': 'Naveen S', 'Initials': 'NS', 'LastName': 'Vasudev', 'Affiliation': ""Department of Medical Oncology, St James's Institute of Oncology, Leeds LS9 7TF, UK.""}, {'ForeName': 'Jayne', 'Initials': 'J', 'LastName': 'Swain', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds LS9 7TF, UK.'}, {'ForeName': 'Janet E', 'Initials': 'JE', 'LastName': 'Brown', 'Affiliation': 'Department of Medical Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, UK.'}, {'ForeName': 'Tze Min', 'Initials': 'TM', 'LastName': 'Wah', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.'}]","Diagnostics (Basel, Switzerland)",['10.3390/diagnostics11071302'] 2109,34359349,Randomized Trial to Improve Primary Care Patient Management and Patient Outcomes Using a Drug-Drug Interaction Test: Confirmation of the DECART Simulated Patient Clinical Utility Trial Results.,"Drug-drug interactions (DDIs) are a serious problem in the healthcare system, leading to excess healthcare utilization and costs. We conducted a second prospective randomized, controlled trial to further establish the real-world clinical utility of a novel assay that objectively identifies potentially serious DDIs in real-world patients. Re-recruiting primary care physicians (PCPs) from our first randomized, controlled, simulated-patients study on DDIs, we experimentally introduced a definitive, urine-based mass spectrometry test intervention that the physicians could use when caring for their eligible patients. Patients were eligible if taking four or more prescription medications or suspected of taking other non-prescribed substances with potential medication interactions. The primary outcome was whether DDI testing changed clinical care. We explored a secondary outcome to see if the change in practice improved symptoms in patients with potential DDIs. A total of 169 control and 162 intervention patients were enrolled in the study, and their medical records were abstracted. In real-world patients, intervention physicians identified and/or treated a DDI at 3.0x the rate in their patient population compared to controls (21.6% vs. 7.1%, p < 0.001). Intervention physicians were more likely to discontinue or adjust the interacting agent compared to controls (62.9% vs. 8.3%, p = 0.001), and patient-reported symptoms also significantly declined (29.6% vs. 20.1%, p = 0.045). These results were nearly identical to concurrent measurements that used simulated patients, wherein intervention was more likely to both make a DDI diagnosis (56.3% vs. 21.6%, p < 0.001) and stop the interacting medications (58.3% versus 26.6%, p < 0.001). Bringing a new diagnostic test to market, particularly for an under-recognized clinical problem, requires robust data on both clinical validity and clinical utility. The results of this follow-up study showed that the use of DDI testing in real-world patients significantly improved (1) primary care patient management of drug interactions and (2) patient outcomes.",2021,"p < 0.001) and stop the interacting medications (58.3% versus 26.6%, ","['real-world patients', 'patients with potential DDIs', 'Patients were eligible if taking four or more prescription medications or suspected of taking other non-prescribed substances with potential medication interactions', 'A total of 169 control and 162 intervention patients were enrolled in the study, and their medical records were abstracted']","['Drug-Drug Interaction Test', 'Re-recruiting primary care physicians (PCPs']","['DDI diagnosis', 'DDI testing changed clinical care']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687133', 'cui_str': 'Drug interaction with drug'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C5191360', 'cui_str': '162'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}, {'cui': 'C0000857', 'cui_str': 'Abstracting as Topic'}]","[{'cui': 'C0687133', 'cui_str': 'Drug interaction with drug'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0033131', 'cui_str': 'Primary care physician'}]","[{'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",,0.0718541,"p < 0.001) and stop the interacting medications (58.3% versus 26.6%, ","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Peabody', 'Affiliation': 'College of Medicine, University of California, San Francisco, CA 94143, USA.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Schrecker', 'Affiliation': 'Aegis Sciences Corporation, Nashville, TN 37228, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Heltsley', 'Affiliation': 'Aegis Sciences Corporation, Nashville, TN 37228, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Paculdo', 'Affiliation': 'QURE Healthcare, San Francisco, CA 94133, USA.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'de Belen', 'Affiliation': 'QURE Healthcare, San Francisco, CA 94133, USA.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Tamondong-Lachica', 'Affiliation': 'QURE Healthcare, San Francisco, CA 94133, USA.'}, {'ForeName': 'M Czarina', 'Initials': 'MC', 'LastName': 'Acelajado', 'Affiliation': 'QURE Healthcare, San Francisco, CA 94133, USA.'}, {'ForeName': 'Othman', 'Initials': 'O', 'LastName': 'Ouenes', 'Affiliation': 'QURE Healthcare, San Francisco, CA 94133, USA.'}, {'ForeName': 'Trina', 'Initials': 'T', 'LastName': 'Kennedy', 'Affiliation': 'TJK Consulting, Sandpoint, ID 83864, USA.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Jeter', 'Affiliation': 'Aegis Sciences Corporation, Nashville, TN 37228, USA.'}]","Diagnostics (Basel, Switzerland)",['10.3390/diagnostics11071266'] 2110,34358832,Impact of β-hydroxy-β-methylbutyrate (HMB) on muscle loss and protein metabolism in critically ill patients: A RCT.,"PURPOSE Muscle wasting deteriorates life quality after critical illness and increases mortality. Wasting starts upon admission to intensive care unit (ICU). We aimed to determine whether β-hydroxy-β-methylbutyrate (HMB), a metabolite of leucine, can attenuate this process. METHODS Prospective randomized, placebo-controlled double blind trial. INCLUSION CRITERIA ICU patients depending on mechanical ventilation on day 3 having a functional gastrointestinal tract. They were randomized to HMB (3 g/day) or placebo (maltodextrin) from day 4 on for 30 days. PRIMARY OUTCOME magnitude of loss of skeletal muscle area (SMA) of the quadriceps femoris measured by ultrasound at days 4 and 15. SECONDARY OUTCOMES body composition, change in protein metabolism assessed by amino acids tracer pulse, and global health at 60 days. Data are mean [95% CI]. Statistics by ANCOVA with correction for confounders sex, age and/or BMI. RESULTS Thirty patients completed the trial, aged 65 [59, 71] years, SAPS2 score 48 [43, 52] and SOFA 8.5 [7.4, 9.7]. The loss of total SMA was 11% between days 4 and 15 (p < 0.001), but not different between the groups (p = 0.86). In the HMB group, net protein breakdown (Δ Estimate HMB-Placebo: -153 [-242, -63]; p = 0.0021) and production of several amino acid was significantly reduced, while phase angle increased more (0.66 [0.09, 1.24]; p = 0.0247), and SF-12 global health improved more (Δ Estimate HMB-Placebo: 27.39 [1.594, 53.19], p = 0.04). CONCLUSION HMB treatment did not significantly reduce muscle wasting over 10 days of observation (primary endpoint), but resulted in significantly improved amino acid metabolism, reduced net protein breakdown, a higher phase angle and better global health. CLINICALTRIALS. GOV IDENTIFIER NCT03628365.",2021,"0.0021) and production of several amino acid was significantly reduced, while phase angle increased more (0.66 [0.09, 1.24]; p = 0.0247), and SF-12 global health improved more (Δ Estimate HMB-Placebo: 27.39 [1.594, 53.19], p = 0.04). ","['Thirty patients completed the trial, aged 65 [59, 71] years, SAPS2 score 48 [43, 52] and SOFA 8.5 [7.4, 9.7', 'ICU patients depending on mechanical ventilation on day 3 having a functional gastrointestinal tract', 'critically ill patients']","['placebo (maltodextrin', 'Placebo', 'HMB', 'β-hydroxy-β-methylbutyrate (HMB', 'placebo']","['production of several amino acid', 'SF-12 global health', 'loss of skeletal muscle area (SMA) of the quadriceps femoris measured by ultrasound at days 4 and 15', 'loss of total SMA', 'body composition, change in protein metabolism assessed by amino acids tracer pulse, and global health', 'muscle loss and protein metabolism', 'mortality', 'net protein breakdown', 'amino acid metabolism, reduced net protein breakdown, a higher phase angle and better global health', 'muscle wasting']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C4517858', 'cui_str': '7.4'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}]","[{'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0699900', 'cui_str': 'Catabolism'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0026846', 'cui_str': 'Muscle atrophy'}]",,0.24333,"0.0021) and production of several amino acid was significantly reduced, while phase angle increased more (0.66 [0.09, 1.24]; p = 0.0247), and SF-12 global health improved more (Δ Estimate HMB-Placebo: 27.39 [1.594, 53.19], p = 0.04). ","[{'ForeName': 'Marina V', 'Initials': 'MV', 'LastName': 'Viana', 'Affiliation': 'Service of Adult Intensive Care, Lausanne University Hospital (CHUV), Lausanne, Switzerland. Electronic address: marivv1981@gmail.com.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Becce', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Pantet', 'Affiliation': 'Service of Adult Intensive Care, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Schmidt', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Géraldine', 'Initials': 'G', 'LastName': 'Bagnoud', 'Affiliation': 'Service of Adult Intensive Care, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Thaden', 'Affiliation': 'Center for Translational Research in Aging and Longevity, Department of Health & Kinesiology, Texas A&M University, College Station, United States.'}, {'ForeName': 'Gabriella A M', 'Initials': 'GAM', 'LastName': 'Ten Have', 'Affiliation': 'Center for Translational Research in Aging and Longevity, Department of Health & Kinesiology, Texas A&M University, College Station, United States.'}, {'ForeName': 'Mariëlle P K J', 'Initials': 'MPKJ', 'LastName': 'Engelen', 'Affiliation': 'Center for Translational Research in Aging and Longevity, Department of Health & Kinesiology, Texas A&M University, College Station, United States.'}, {'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Voidey', 'Affiliation': 'Department of Pharmacy, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'Nicolaas E P', 'Initials': 'NEP', 'LastName': 'Deutz', 'Affiliation': 'Center for Translational Research in Aging and Longevity, Department of Health & Kinesiology, Texas A&M University, College Station, United States.'}, {'ForeName': 'Mette M', 'Initials': 'MM', 'LastName': 'Berger', 'Affiliation': 'Service of Adult Intensive Care, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2021.07.018'] 2111,34358827,"Supplement-based nutritional strategies to tackle frailty: A multifactorial, double-blind, randomized placebo-controlled trial.","BACKGROUND Sarcopenia plays a central role in the development of frailty syndrome. Nutrition and exercise are cornerstone strategies to mitigate the transition to frailty; however, there is a paucity of evidence for which dietary and exercise strategies are effective. OBJECTIVE This large, multifactorial trial investigated the efficacy of different dietary strategies to enhance the adaptations to resistance training in pre-frail and frail elderly. METHODS This was a single-site 16-week, double-blind, randomized, placebo-controlled trial conducted at the Clinical Hospital, School of Medicine - University of São Paulo, Sao Paulo, Brazil. Four integrated, sub-investigations were conducted to compare: 1) leucine vs. placebo; 2) whey vs. soy vs. placebo; 3) creatine vs. whey vs. creatine plus whey vs. placebo; 4) women vs. men in response to whey. Sub-investigations 1 to 3 were conducted in women, only. Two-hundred participants (154 women/46 men, mean age 72 ± 6 years) underwent a twice-a-week, resistance training program. The main outcomes were muscle function (assessed by dynamic and isometric strength and functional tests) and lean mass (assessed by DXA). Muscle cross-sectional area, health-related quality of life, bone and fat mass, and biochemical markers were also assessed. RESULTS We observed that leucine supplementation was ineffective to improve muscle mass and function. Supplementation with whey and soy failed to enhance resistance-training effects. Similarly, supplementation with neither whey nor creatine potentiated the adaptations to resistance training. Finally, no sex-based differences were found in response to whey supplementation. Resistance exercise per se increased muscle mass and function in all sub-investigations. There were no adverse effects. CONCLUSION Neither protein (whey and soy), leucine, nor creatine supplementation enhanced resistance training-induced adaptations in pre-frail and frail elderly, regardless of sex. These findings do not support the notion that some widely used supplement-based interventions can add to the already potent effects of resistance exercise to counteract frailty-related muscle wasting and dynapenia. CLINICAL TRIAL REGISTRY NCT01890382; https://clinicaltrials.gov/ct2/show/NCT01890382. DATA SHARING Data described in the manuscript will be made available upon request pending application.",2021,"There were no adverse effects. ","['Two-hundred participants (154 women/46 men, mean age 72\xa0±\xa06 years', 'Clinical Hospital, School of Medicine - University of São Paulo, Sao Paulo, Brazil', 'pre-frail and frail elderly', '4) women vs. men in response to whey']","['Supplementation with whey and soy', 'protein (whey and soy), leucine, nor creatine supplementation', 'Supplement-based nutritional strategies', 'leucine supplementation', 'leucine vs. placebo; 2) whey vs. soy vs. placebo; 3) creatine vs. whey vs. creatine plus whey vs. placebo', 'Resistance exercise', 'resistance training program', 'resistance training', 'placebo']","['adverse effects', 'Muscle cross-sectional area, health-related quality of life, bone and fat mass, and biochemical markers', 'muscle function (assessed by dynamic and isometric strength and functional tests) and lean mass (assessed by DXA']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C1862322', 'cui_str': 'Southeast Asian ovalocytosis'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}]","[{'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0037733', 'cui_str': 'Soya bean'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}]",200.0,0.239724,"There were no adverse effects. ","[{'ForeName': 'Hamilton', 'Initials': 'H', 'LastName': 'Roschel', 'Affiliation': 'Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil; Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil. Electronic address: hars@usp.br.'}, {'ForeName': 'Ana Paula', 'Initials': 'AP', 'LastName': 'Hayashi', 'Affiliation': 'Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil; Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Fernandes', 'Affiliation': 'Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil.'}, {'ForeName': 'José Claudio', 'Initials': 'JC', 'LastName': 'Jambassi-Filho', 'Affiliation': 'Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Hevia-Larraín', 'Affiliation': 'Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'de Capitani', 'Affiliation': 'Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil.'}, {'ForeName': 'Davi A', 'Initials': 'DA', 'LastName': 'Santana', 'Affiliation': 'Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil.'}, {'ForeName': 'Lívia S', 'Initials': 'LS', 'LastName': 'Gonçalves', 'Affiliation': 'Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil.'}, {'ForeName': 'Ana Lúcia', 'Initials': 'AL', 'LastName': 'de Sá-Pinto', 'Affiliation': 'Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Fernanda R', 'Initials': 'FR', 'LastName': 'Lima', 'Affiliation': 'Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Marcelo T', 'Initials': 'MT', 'LastName': 'Sapienza', 'Affiliation': 'Faculdade de Medicina FMUSP, Disciplina de Radiologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Alberto J S', 'Initials': 'AJS', 'LastName': 'Duarte', 'Affiliation': 'Divisão de Laboratório Central do Hospital das Clínicas, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Rosa M R', 'Initials': 'RMR', 'LastName': 'Pereira', 'Affiliation': 'Laboratory of Bone Metabolism, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Stuart M', 'Initials': 'SM', 'LastName': 'Phillips', 'Affiliation': 'McMaster University, Department of Kinesiology, Hamilton, Ontario, Canada.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Gualano', 'Affiliation': 'Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil; Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2021.06.024'] 2112,34358819,The effect of intranasally administered oxytocin on observed social behavior in social anxiety disorder.,"Research has shown that patients with a social anxiety disorder (SAD) show social performance deficits. These deficits are a maintaining factor in SAD, as mending social behavior improves interpersonal judgments and reduces social anxiety. Thus finding ways to enhance social behavior is evidently of importance in the treatment of SAD. This double-blind, placebo-controlled study investigated the effect of an intranasal administration of the hormone oxytocin (24 IU) on social behavior and anxious appearance in SAD patients (N = 40) and healthy controls (N = 39). Forty minutes after oxytocin administration participants were submitted to two live social situations (i.e., a waiting room situation and a getting acquainted task). The participants ('self-rated') and observers ('observer-rated') scored participants' social behavior and anxious appearance. Participants also rated their positive and negative affect. Confirming the social performance deficits in SAD, observers regarded SAD patients as more anxious and less socially skilled than healthy controls. Results indicated oxytocin-induced improvement of observer-rated social behavior in SAD patients compared to placebo but only in the getting acquainted task. This effect was not perceived as such by patients themselves and did not improve their affect ratings. In conclusion, this study found support for the idea that oxytocin helps SAD patients to perform better in social interactions, although this improvement seemed context-dependent (i.e., only present in the getting-acquainted task) and 'not perceived by the patient.",2021,Results indicated oxytocin-induced improvement of observer-rated social behavior in SAD patients compared to placebo but only in the getting acquainted task.,"['social anxiety disorder', 'patients with a social anxiety disorder (SAD', 'SAD patients (N\xa0=\xa040) and healthy controls (N\xa0=\xa039']","['oxytocin', 'placebo', 'hormone oxytocin']","['social behavior and anxious appearance', 'social anxiety', 'observer-rated social behavior']","[{'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}]","[{'cui': 'C0037397', 'cui_str': 'Social behavior'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}]",40.0,0.0309259,Results indicated oxytocin-induced improvement of observer-rated social behavior in SAD patients compared to placebo but only in the getting acquainted task.,"[{'ForeName': 'Marisol J', 'Initials': 'MJ', 'LastName': 'Voncken', 'Affiliation': 'Department of Clinical Psychology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands. Electronic address: m.voncken@maastrichtuniversity.nl.'}, {'ForeName': 'Corine', 'Initials': 'C', 'LastName': 'Dijk', 'Affiliation': 'Programme group Clinical Psychology, Faculty of Social and Behavioural Sciences, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Stöhr', 'Affiliation': 'Department of Clinical Psychology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Isabella J M', 'Initials': 'IJM', 'LastName': 'Niesten', 'Affiliation': 'Department of Clinical Psychology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Schruers', 'Affiliation': 'Research Institute Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; Faculty of Psychology, Center for Experimental and Learning Psychology, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Kim P C', 'Initials': 'KPC', 'LastName': 'Kuypers', 'Affiliation': 'Department of Neuropsychology & Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2021.07.005'] 2113,34358777,"Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.","BACKGROUND Pre-clinical data suggest that docetaxel and enzalutamide interfere with androgen receptor translocation and signalling. The aim of this study is to assess the efficacy of their concurrent administration in the first-line treatment for metastatic castration-resistant prostate cancer (mCRPC). METHODS In this open-label, randomised, phase II trial, previously untreated mCRPC patients were randomised 1:1 to receive eight 21-d courses of docetaxel 75 mg/m 2 , oral prednisone 5 mg twice daily and oral enzalutamide 160 mg/d (arm DE), or the same treatment without enzalutamide (arm D). The primary end-point was the percentage of patients without investigator-assessed disease progression 6 months after the first docetaxel administration. RESULTS The 246 eligible patients were randomly assigned to receive docetaxel, prednisone and enzalutamide (n = 120) or docetaxel and prednisone (n = 126). The 6-month progression rate was 12.5% (95% confidence interval [CI] 8.1-20.6) in arm DE and 27.8% (95% CI 22.8-39.4) in arm D (chi-squared test 10.01; P = 0.002). The most frequent grade III-IV adverse events were fatigue (12.5% in arm DE versus 5.6% in arm D), febrile neutropenia (9.3% versus 4.0%) and neutropenia (7.6% versus 5.6%). CONCLUSIONS The combination of enzalutamide and docetaxel appears to be more clinically beneficial than docetaxel alone in previously untreated mCRPC patients, although serious adverse events were more frequent. Our findings suggest that first-line treatment with this combination could lead to an additional clinical benefit when prompt and prolonged disease control is simultaneously required. Clearly, these results should be considered cautiously because of the study's phase II design and the absence of an overall survival benefit. TRIAL REGISTRATION NUMBERS EudraCT 2014-000175-43 - NCT02453009.",2021,"The most frequent grade III-IV adverse events were fatigue (12.5% in arm DE versus 5.6% in arm D), febrile neutropenia (9.3% versus 4.0%) and neutropenia (7.6% versus 5.6%). ","['patients with metastatic castration-resistant prostate cancer', 'metastatic castration-resistant prostate cancer (mCRPC', '246 eligible patients', 'previously untreated mCRPC patients']","['docetaxel 75\xa0mg/m 2 , oral prednisone 5\xa0mg twice daily and oral enzalutamide 160\xa0mg', 'Docetaxel and prednisone with or without enzalutamide', 'docetaxel and enzalutamide', 'enzalutamide and docetaxel', 'docetaxel, prednisone and enzalutamide (n\xa0=\xa0120) or docetaxel and prednisone']","['percentage of patients without investigator-assessed disease progression', 'febrile neutropenia', 'neutropenia', '6-month progression rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1533720', 'cui_str': 'Prednisone 5 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",,0.133146,"The most frequent grade III-IV adverse events were fatigue (12.5% in arm DE versus 5.6% in arm D), febrile neutropenia (9.3% versus 4.0%) and neutropenia (7.6% versus 5.6%). ","[{'ForeName': 'Orazio', 'Initials': 'O', 'LastName': 'Caffo', 'Affiliation': 'Medical Oncology Department, Santa Chiara Hospital, Trento, Italy. Electronic address: orazio.caffo@apss.tn.it.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Ortega', 'Affiliation': 'Department of Oncology, University of Turin Candiolo Cancer Institute - FPO-IRCCS, Candiolo, Italy.'}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Nolè', 'Affiliation': 'Division of Urogenital and Head and Neck Tumours Medical Treatment, European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'Donatello', 'Initials': 'D', 'LastName': 'Gasparro', 'Affiliation': 'Medical Oncology Unit, Department of General & Specialistic Medicine, University Hospital of Parma, Parma, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Mucciarini', 'Affiliation': 'Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Aieta', 'Affiliation': 'Department of Onco-Hematology, Division of Medical Oncology, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.'}, {'ForeName': 'Vittorina', 'Initials': 'V', 'LastName': 'Zagonel', 'Affiliation': 'Department of Oncology, Oncology 1, Veneto Institute of Oncology - IRCCS, Padua, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Iacovelli', 'Affiliation': 'Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy.'}, {'ForeName': 'Ugo', 'Initials': 'U', 'LastName': 'De Giorgi', 'Affiliation': 'Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura de Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Facchini', 'Affiliation': 'Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy.'}, {'ForeName': 'Antonello', 'Initials': 'A', 'LastName': 'Veccia', 'Affiliation': 'Medical Oncology Department, Santa Chiara Hospital, Trento, Italy.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Palesandro', 'Affiliation': 'Department of Oncology, University of Turin Candiolo Cancer Institute - FPO-IRCCS, Candiolo, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Verri', 'Affiliation': 'Division of Urogenital and Head and Neck Tumours Medical Treatment, European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'Sebastiano', 'Initials': 'S', 'LastName': 'Buti', 'Affiliation': 'Medical Oncology Unit, Department of General & Specialistic Medicine, University Hospital of Parma, Parma, Italy.'}, {'ForeName': 'Giorgia', 'Initials': 'G', 'LastName': 'Razzini', 'Affiliation': 'Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Bozza', 'Affiliation': 'Department of Onco-Hematology, Division of Medical Oncology, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Maruzzo', 'Affiliation': 'Department of Oncology, Oncology 1, Veneto Institute of Oncology - IRCCS, Padua, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Ciccarese', 'Affiliation': 'Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Schepisi', 'Affiliation': 'Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura de Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Rossetti', 'Affiliation': 'Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Maines', 'Affiliation': 'Medical Oncology Department, Santa Chiara Hospital, Trento, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Fratino', 'Affiliation': 'Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Ermacora', 'Affiliation': 'Department of Oncology, Presidio Ospedaliero Universitario Santa Maria della Misericordia, Azienda Sanitaria Universitaria Integrata Friuli Centrale, Udine, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Nicodemo', 'Affiliation': 'Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Giordano', 'Affiliation': ""Department of Medical Oncology, ASST Lariana, Ospedale Sant'Anna, San Fermo della Battaglia (CO), Italy.""}, {'ForeName': 'Donata', 'Initials': 'D', 'LastName': 'Sartori', 'Affiliation': 'Oncology Unit, AULSS 3, Mirano, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Scapoli', 'Affiliation': 'Division of Clinical Oncology, S. Anna University Hospital, Ferrara, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Sabbatini', 'Affiliation': 'Department of Oncology, Hematology & Respiratory Diseases, Division of Oncology, University of Modena & Reggio Emilia, Modena, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Lo Re', 'Affiliation': 'Medical Oncology Department, Santa Maria degli Angeli Hospital, Pordenone, Italy.'}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Morelli', 'Affiliation': 'Medical Oncology Department, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': ""D'Angelo"", 'Affiliation': 'Department of Medical Oncology, San Vincenzo Hospital, Taormina, Italy.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Vittimberga', 'Affiliation': 'Dipartimento Oncologico, Ospedale Alessandro Manzoni, ASST Lecco, Lecco, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Lippe', 'Affiliation': 'Operative Oncology Unit, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Carrozza', 'Affiliation': 'Oncology Unit, Ospedale ""degli Infermi"", AUSL Romagna, Faenza, Italy.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Messina', 'Affiliation': 'Department\u2009of Medical Oncology, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Galli', 'Affiliation': 'Department of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Valcamonico', 'Affiliation': 'Unit of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Camillo', 'Initials': 'C', 'LastName': 'Porta', 'Affiliation': 'Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Pappagallo', 'Affiliation': 'Clinical Epidemiologist, Silea, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Aglietta', 'Affiliation': 'Department of Oncology, University of Turin Candiolo Cancer Institute - FPO-IRCCS, Candiolo, Italy.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.06.016'] 2114,34367533,Study on the Application and Efficacy of Responsibility Nursing in Dialysis Care.,"Providing high-quality care to patients undergoing hemodialysis (HD) is a priority for nurses. The present study was conducted to explore the experiences of the quality of nursing care among patients, nurses, and caregivers in Yanghu Branch of Changzhou Second People's Hospital, China. A total of 120 hemodialysis patients consecutively admitted to Yanghu Branch of Changzhou Second People's Hospital were enrolled and divided into two groups according to the nursing method they received: control group (routine nursing) and experimental group (responsibility nursing). The two cohorts were observed and compared for alterations of adverse emotions and inflammatory factors, the incidence of complications, pre-and post-nursing sleep quality, life quality, and patients' satisfaction with nursing. After nursing, the Self-Rating Anxiety/Depression Scale (SAS/DS) scores were lower in the experimental group (EG) than in the control group (CG) (both P < 0.05). Serum IL-6, hs-CRP, and TNF- α were decreased in both groups after nursing and were even lower in EG (both P < 0.05). EG had significantly improved sleep quality and life quality than CG, with a higher nursing satisfaction (all P < 0.05). This validates that the responsibility nursing for dialysis patients can validly mitigate patients' negative emotions, improve their quality of life, and ensure high-quality dialysis effect, which is feasible for wide popularization and application in clinics.",2021,"After nursing, the Self-Rating Anxiety/Depression Scale (SAS/DS) scores were lower in the experimental group (EG) than in the control group (CG) (both P < 0.05).","['Responsibility Nursing in Dialysis Care', ""Second People's Hospital"", 'patients undergoing hemodialysis (HD', '120 hemodialysis patients consecutively admitted to Yanghu Branch of Changzhou', 'patients, nurses, and caregivers in Yanghu Branch of Changzhou']",['control group (routine nursing) and experimental group (responsibility nursing'],"['sleep quality and life quality', ""adverse emotions and inflammatory factors, the incidence of complications, pre-and post-nursing sleep quality, life quality, and patients' satisfaction with nursing"", 'Serum IL-6, hs-CRP, and TNF- α', 'Self-Rating Anxiety/Depression Scale (SAS/DS) scores', 'nursing satisfaction']","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C1161201', 'cui_str': 'Dialysis care'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1253959', 'cui_str': 'Branch of'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",120.0,0.010942,"After nursing, the Self-Rating Anxiety/Depression Scale (SAS/DS) scores were lower in the experimental group (EG) than in the control group (CG) (both P < 0.05).","[{'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Wu', 'Affiliation': ""Blood Purification Center, Yanghu Branch of Changzhou Second People's Hospital, Changzhou 213000, Jiangsu, China.""}, {'ForeName': 'Meiling', 'Initials': 'M', 'LastName': 'Gao', 'Affiliation': ""Blood Purification Center, Yanghu Branch of Changzhou Second People's Hospital, Changzhou 213000, Jiangsu, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': ""Blood Purification Center, Yanghu Branch of Changzhou Second People's Hospital, Changzhou 213000, Jiangsu, China.""}, {'ForeName': 'Linfang', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': ""Blood Purification Center, Yanghu Branch of Changzhou Second People's Hospital, Changzhou 213000, Jiangsu, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Blood Purification Center, Yanghu Branch of Changzhou Second People's Hospital, Changzhou 213000, Jiangsu, China.""}, {'ForeName': 'Kaili', 'Initials': 'K', 'LastName': 'Zhang', 'Affiliation': ""Blood Purification Center, Yanghu Branch of Changzhou Second People's Hospital, Changzhou 213000, Jiangsu, China.""}]",Journal of healthcare engineering,['10.1155/2021/2210191'] 2115,34367355,Increasing Mindfulness Skills of Veterans With PTSD Through Daily Mindfulness Training Incorporated Into an Intensive Treatment Program.,"Objectives Mindfulness training is frequently included as part of an integrative care approach to treating PTSD in veterans. However, the utility and acceptability of daily group mindfulness training in an intensive treatment program (ITP) for PTSD have not been explored. The study objectives were to determine: (a) whether mindfulness skills significantly increased from pre- to post-treatment and (b) if daily group mindfulness training was acceptable to veterans. Methods Veterans ( N = 170 outpatients, age M = 40.7 ( SD 9.3), 67.6% male) in this prospective study were consecutively enrolled in a 3-week ITP that included daily mindfulness group sessions. Mindfulness skills were assessed using the Five Facet of Mindfulness Questionnaire (FFMQ) at intake and post-treatment. Acceptability was assessed using an anonymous post-treatment program satisfaction survey. Results Paired t tests demonstrated significant increases in overall mindfulness skills from pre- to post-treatment ( t (169) = - 6.33, p < 0.001, d = 0.49). Small to medium effect sizes were observed across subscales: describing, ( t (169) = - 5.91, p < 0.001, d = 0.38); acting with awareness, ( t (169) = - 3.70, p < 0.001, d = 0.29); nonjudging, ( t (169) = - 7.54, p < 0.001, d = 0.58); and nonreactivity, ( t (169) = - 4.84, p < 0.001, d = 0.41). Most veterans ( n = 125, 74.4%) found daily mindfulness training moderately to very helpful. Conclusions Veterans' mindfulness skills significantly increased over the course of a 3-week ITP, and mindfulness training was found acceptable. Mindfulness training can be delivered daily as part of an ITP for veterans with PTSD, and mindfulness skills can meaningfully increase over the course of 3 weeks. A significant limitation is the lack of control condition.",2021,"Results Paired t tests demonstrated significant increases in overall mindfulness skills from pre- to post-treatment ( t (169) = - 6.33, p < 0.001, d = 0.49).","['veterans', 'Veterans With PTSD', 'Methods\n\n\nVeterans ( N = 170 outpatients, age M = 40.7 ( SD 9.3), 67.6% male) in this prospective study were consecutively enrolled in a 3-week ITP that included daily mindfulness group sessions']",['Mindfulness training'],"['Five Facet of Mindfulness Questionnaire (FFMQ', 'Mindfulness skills', 'overall mindfulness skills', 'Acceptability']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0221134', 'cui_str': 'Blood group antigen M'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0021540', 'cui_str': 'Inosine triphosphate'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",170.0,0.0067324,"Results Paired t tests demonstrated significant increases in overall mindfulness skills from pre- to post-treatment ( t (169) = - 6.33, p < 0.001, d = 0.49).","[{'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': 'Miller', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Rush University Medical Center, 1645 W. Jackson Blvd, Suite 400, Chicago, IL 60612, USA.'}, {'ForeName': 'Jenna M', 'Initials': 'JM', 'LastName': 'Bagley', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Rush University Medical Center, 1645 W. Jackson Blvd, Suite 400, Chicago, IL 60612, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Normand', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Rush University Medical Center, 1645 W. Jackson Blvd, Suite 400, Chicago, IL 60612, USA.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Brennan', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Rush University Medical Center, 1645 W. Jackson Blvd, Suite 400, Chicago, IL 60612, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Van Horn', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Rush University Medical Center, 1645 W. Jackson Blvd, Suite 400, Chicago, IL 60612, USA.'}, {'ForeName': 'Mark H', 'Initials': 'MH', 'LastName': 'Pollack', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Rush University Medical Center, 1645 W. Jackson Blvd, Suite 400, Chicago, IL 60612, USA.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Held', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Rush University Medical Center, 1645 W. Jackson Blvd, Suite 400, Chicago, IL 60612, USA.'}]",Mindfulness,['10.1007/s12671-020-01326-5'] 2116,34367303,Auricular Point Acupressure Combined with Compound Lidocaine Cream to Manage Arteriovenous Fistula Puncture Pain: A Multicenter Randomized Controlled Trial.,"Background Arteriovenous fistula (AVF) puncture pain is an inevitable problem for maintenance hemodialysis (MHD) patients and may seriously endanger the physical and mental health of patients with MHD. Studies have shown that drug or nondrug measures can reduce AVF puncture pain, but much improvement is needed. When combined with compound lidocaine cream (CLC) in the treatment of AVF puncture pain, auricular point acupressure (APA)-a therapeutic method in which specific points on the auricle of the outer ear are stimulated to treat various disorders of the body-and the therapeutic value and synergistic effects of auriculotherapy merit further investigation. Methods 120 MHD patients were recruited at blood purification centers in three hospitals between January 2016 and April 2019. After completion of the baseline survey, all patients were randomly divided by the envelope method into a control group, APA group, CLC group, and APA combined with CLC, with 30 subjects per group. The numerical rating scale (NRS) of pain was used to measure the pain before intervention and 1, 4, and 8 weeks after intervention. The State-Trait Anxiety Inventory (STAI), General Comfort Questionnaire (GCQ), blood pressure, and heart rates were obtained before and after the intervention. Results Pain, anxiety, comfort, blood pressure (BP), and heart rates (HR) of the three groups were better than those of the control group; the difference was statistically significant ( P < 0.05). In addition, the APA combined with CLC group was better than the APA group and CLC group, respectively, in those outcomes ( P < 0.05). Conclusion Both APA and CLC can effectively relieve AVF puncture pain, and the combined application has more outstanding effects.",2021,"When combined with compound lidocaine cream (CLC) in the treatment of AVF puncture pain, auricular point acupressure (APA)-a therapeutic method in which specific points on the auricle of the outer ear are stimulated to treat various disorders of the body-and the therapeutic value and synergistic effects of auriculotherapy merit further investigation. ","['120 MHD patients were recruited at blood purification centers in three hospitals between January 2016 and April 2019', 'maintenance hemodialysis (MHD) patients and may seriously endanger the physical and mental health of patients with MHD', 'Arteriovenous Fistula Puncture Pain']","['APA group, CLC group, and APA combined with CLC', 'APA and CLC', 'APA combined with CLC', 'APA', 'lidocaine cream (CLC', '\n\n\nArteriovenous fistula (AVF) puncture pain', 'Auricular Point Acupressure Combined with Compound Lidocaine Cream']","['State-Trait Anxiety Inventory (STAI), General Comfort Questionnaire (GCQ), blood pressure, and heart rates', 'AVF puncture pain', 'numerical rating scale (NRS) of pain', 'Pain, anxiety, comfort, blood pressure (BP), and heart rates (HR']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0243114', 'cui_str': 'purification'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C1522191', 'cui_str': 'Otic route'}, {'cui': 'C0282614', 'cui_str': 'Acupressure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",3.0,0.0654447,"When combined with compound lidocaine cream (CLC) in the treatment of AVF puncture pain, auricular point acupressure (APA)-a therapeutic method in which specific points on the auricle of the outer ear are stimulated to treat various disorders of the body-and the therapeutic value and synergistic effects of auriculotherapy merit further investigation. ","[{'ForeName': 'Xiaohui', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Nursing, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wei', 'Affiliation': 'College of Nursing, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 473005, China.'}, {'ForeName': 'Yaqi', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'College of Nursing, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 473005, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'College of Nursing, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 473005, China.'}, {'ForeName': 'Xueqin', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'College of Nursing, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 473005, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'College of Nursing, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 473005, China.'}, {'ForeName': 'Chao Hsing', 'Initials': 'CH', 'LastName': 'Yeh', 'Affiliation': 'Johns Hopkins University School of Nursing, 525 N. Wolfe Street, Room 421, Baltimore, MD 21205, USA.'}, {'ForeName': 'Yuejuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Nursing, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China.'}]",Evidence-based complementary and alternative medicine : eCAM,['10.1155/2021/5573567'] 2117,34367298,Functional Outcome and Inflammatory Response of Patients with Extra-Articular Distal Humeral Fractures following Implantation of Anatomically Precontoured Locking Compression Plates through a Posterior Approach.,"Distal humeral fractures are challenging injuries to surgically correct and account for up to 2% of all adult fractures. Surgical management of extra-articular distal humeral fractures is challenging considering surgical approach, implant selection, and position of the implant owing to the availability of different precontoured implants and plate configurations. Anatomically precontoured locking compression plates (APLCPs) allow the placement of angular stable screws right underneath the reduced joint surface fragments. To date, there is a lack of evidence supporting its superiority to conventional locking plate osteosynthesis (LPO) in treating extra-articular distal humeral fractures. The objective of the study is to evaluate the efficacy and safety of APLCPs in the treatment of extra-articular distal humeral fractures. A total of 100 patients diagnosed with humeral fractures and receiving treatments in our hospital between May 2018 and May 2020 fulfilled inclusion and exclusion criteria and were randomly assigned to LPO and APLCP groups according to the odd-even of the order of hospital admission, 50 cases per groups. Clinical endpoints were assessed including operation time; in-bed time; length of hospital stay; volume of intraoperative blood loss; VSA scores before and 24, 48, and 72 h after surgery; MEPS scores before and 3, 6, and 12 months after surgery; range of motion, flexion, and extension of the elbow; serum levels of CK, CRP, and IL-6; and incidence of complications after surgery. It was found that the APLCP group exhibited shortened operation time and in-bed time, decreased length of hospital stay, and reduced volume of intraoperative blood loss compared to the LPO group (all P < 0.001). The two groups had declined VSA scores concomitant with increased MEPS scores after surgery in a time-dependent manner ( P < 0.001). Notably, the VSA scores in the APLCP group were all lower than those in the LPO group at indicated time points (24, 48, and 72 h) after surgery ( P < 0.001). Besides, the MEPS scores in the APLCP group were all higher than those in the LPO group at indicated time points (3, 6, and 12 months) after surgery ( P < 0.001). It was revealed that the patients receiving extra-articular distal humeral APLCP through posterior approaches exhibited greater ranges of motion, flexion, and extension of the elbow than those receiving LPO after surgery ( P < 0.001). The patients receiving extra-articular distal humeral APLCP through posterior approaches exhibited lower serum levels of IL-6, CRP, and CK than those receiving LPO after surgery (IL-6: P =0.007, CRP: P =0.001, CK: P =0.001). The APLCP had a lower total incidence rate of complication than the LPO group (48.00% vs. 18.00%, P =0.003). In conclusion, these data support the notion that the implantation of anatomically precontoured APLCP through a posterior approach allows for improved functional outcomes and attenuated inflammatory response and prevents the incidence of postoperative complications compared to conventional LPO for internal fixation of extra-articular distal humeral fractures.",2021,"It was found that the APLCP group exhibited shortened operation time and in-bed time, decreased length of hospital stay, and reduced volume of intraoperative blood loss compared to the LPO group (all P < 0.001).","['extra-articular distal humeral fractures', 'Patients with Extra-Articular Distal Humeral Fractures following', '100 patients diagnosed with humeral fractures and receiving treatments in our hospital between May 2018 and May 2020 fulfilled inclusion and exclusion criteria']","['APLCP', 'APLCPs', 'conventional locking plate osteosynthesis (LPO', 'Anatomically precontoured locking compression plates (APLCPs', 'Implantation of Anatomically Precontoured Locking Compression Plates', 'conventional LPO', 'LPO', 'LPO and APLCP']","['motion, flexion, and extension of the elbow; serum levels of CK, CRP, and IL-6; and incidence of complications', 'efficacy and safety', 'shortened operation time and in-bed time, decreased length of hospital stay, and reduced volume of intraoperative blood loss', 'ranges of motion, flexion, and extension of the elbow', 'operation time; in-bed time; length of hospital stay; volume of intraoperative blood loss; VSA scores', 'VSA scores', 'MEPS scores', 'total incidence rate of complication', 'Functional Outcome and Inflammatory Response', 'serum levels of IL-6, CRP, and CK', 'VSA scores concomitant with increased MEPS scores']","[{'cui': 'C0205135', 'cui_str': 'Extra-articular'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0020162', 'cui_str': 'Fracture of humerus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C4727954', 'cui_str': 'Plate osteosynthesis'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0054871', 'cui_str': 'Cathepsin L'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",100.0,0.0576184,"It was found that the APLCP group exhibited shortened operation time and in-bed time, decreased length of hospital stay, and reduced volume of intraoperative blood loss compared to the LPO group (all P < 0.001).","[{'ForeName': 'Jingwei', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Orthopedics Department, Xuanwu Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Limin', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Orthopedics Department, Xuanwu Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Huaijian', 'Initials': 'H', 'LastName': 'Hu', 'Affiliation': 'Orthopedics Department, Xuanwu Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Zhihua', 'Initials': 'Z', 'LastName': 'Gao', 'Affiliation': 'Orthopedics Department, Xuanwu Hospital, Capital Medical University, Beijing, China.'}]",Evidence-based complementary and alternative medicine : eCAM,['10.1155/2021/2426298'] 2118,34367045,"Effects of an Enhanced Training on Primary Care Providers Knowledge, Attitudes, Service and Skills of Dementia Detection: A Cluster Randomized Trial.","Background: Effective training programs for primary care providers (PCPs) to support dementia detection are needed, especially in developing countries. This study aimed to investigate the effect of an enhanced training on the competency and service of PCPs for dementia detection. Methods: We conducted a cluster randomized trial in Beijing, China. Community healthcare centers (CHCs) located in Fengtai or Fangshan District were eligible. The enrolled CHCs in each district were randomly assigned to the standard or the enhanced training group at a 1:1 ratio. PCPs serving older adults in enrolled CHCs were eligible to participate. The standard training group received three-hour didactic lectures, three monthly supervisions, 3 months of online support and dementia screening packages. The enhanced training group additionally received three monthly face-to-face supervisions and 3 months of online support. The participants became aware of their group membership at the end of the standard training. The knowledge, attitudes, service, and skills regarding dementia detection were assessed using questionnaires and submitted dementia detection records, respectively. Results: A total of 23 and 21 CHCs were randomly assigned to the standard and the enhanced training group, respectively, and 58 participants from 20 CHCs assigned to the standard training group and 48 from 16 CHCs assigned to the enhanced training group were included in the final analysis (mean age 37.5 years, and 67.0% women). A significant increase in the knowledge score was found in both groups, but the increase was similar in the two groups ( P = 0.262). The attitude score remained stable in both groups, and no between-group difference was found. Compared with the baseline, both groups reported an increase in dementia detection service, especially the enhanced training group (24.1% to 31.0% in the standard training group and 14.6% to 45.8% in the enhanced training group). The completion rate and accuracy of submitted dementia detection records in the enhanced training group were both significantly higher than those in the standard training group (both P < 0.001). Conclusion: The enhanced training had similar effect on the knowledge of PCPs comparing with the standard training, but was better on continuous service and skills of PCPs related to dementia detection. Trial registration: www.ClinicalTrials.gov, identifier: NCT02782000. Registration date: May 2016. The trial was completed in July 2017.",2021,The completion rate and accuracy of submitted dementia detection records in the enhanced training group were both significantly higher than those in the standard training group (both P < 0.001). ,"['primary care providers (PCPs', 'A total of 23 and 21 CHCs', 'PCPs serving older adults in enrolled CHCs were eligible to participate', '58 participants from 20 CHCs assigned to the standard training group and 48 from 16 CHCs assigned to the enhanced training group were included in the final analysis (mean age 37.5 years, and 67.0% women', 'Community healthcare centers (CHCs) located in Fengtai or Fangshan District were eligible']","['enhanced training', 'Enhanced Training', 'standard training group received three-hour didactic lectures, three monthly supervisions, 3 months of online support and dementia screening packages']","['attitude score', 'completion rate and accuracy of submitted dementia detection', 'knowledge of PCPs', 'Attitudes, Service and Skills of Dementia Detection', 'dementia detection service', 'knowledge score', 'knowledge, attitudes, service, and skills regarding dementia detection']","[{'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517742', 'cui_str': '37.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086034', 'cui_str': 'Community Healthcare'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332285', 'cui_str': 'In'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0376683', 'cui_str': 'Lectures'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0557854', 'cui_str': 'Services'}]",,0.0218118,The completion rate and accuracy of submitted dementia detection records in the enhanced training group were both significantly higher than those in the standard training group (both P < 0.001). ,"[{'ForeName': 'Xiaozhen', 'Initials': 'X', 'LastName': 'Lv', 'Affiliation': 'Beijing Dementia Key Lab, Dementia Care & Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Beijing Dementia Key Lab, Dementia Care & Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.'}, {'ForeName': 'Changzheng', 'Initials': 'C', 'LastName': 'Yuan', 'Affiliation': 'Department of Big Data in Health Science, School of Public Health, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Haifeng', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Beijing Dementia Key Lab, Dementia Care & Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.'}, {'ForeName': 'Chengcheng', 'Initials': 'C', 'LastName': 'Pu', 'Affiliation': 'Beijing Dementia Key Lab, Dementia Care & Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.'}, {'ForeName': 'Zhiying', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Beijing Dementia Key Lab, Dementia Care & Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': 'Psychological Department, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': 'Beijing Dementia Key Lab, Dementia Care & Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.'}, {'ForeName': 'Huali', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Beijing Dementia Key Lab, Dementia Care & Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.'}]",Frontiers in neurology,['10.3389/fneur.2021.651826'] 2119,34367021,Familiarity and Novelty in Aesthetic Preference: The Effects of the Properties of the Artwork and the Beholder.,"Familiarity and novelty are fundamental yet competing factors influencing aesthetic preference. However, whether people prefer familiar paintings or novel paintings has not been clear. Using both behavioral and eye-tracking measures, the present study aimed to investigate whether the effect of familiarity-novelty on aesthetic preference is independent or dependent on artwork properties (painting content, visual complexity) and viewer characteristics (experience in art). Participants were presented with two images of paintings, one of which was repeatedly presented but was always paired with a new painting in a randomized lateral arrangement. They were asked to indicate which of the two images they preferred with the degree of their preference. Behavioral results demonstrated an interactive influence of painting content and complexity on familiarity-novelty preference, especially alongside the distinction between representational and abstract paintings. Also, the familiarity-novelty preference was modulated by the degree of art experience, for abstract paintings in particular. Gaze results showed the differential effects of painting content, complexity, and art experience echoing the behavioral results. Taken together, the convergent results derived from behavioral and eye-tracking measures imply that novelty is an important feature of aesthetic appreciation, but its influence is modulated by properties of both the artwork and the beholder.",2021,"Behavioral results demonstrated an interactive influence of painting content and complexity on familiarity-novelty preference, especially alongside the distinction between representational and abstract paintings.","['Participants were presented with two images of paintings, one of which was repeatedly presented but was always paired with a new painting in a randomized lateral arrangement', 'Aesthetic Preference']",[],['familiarity-novelty preference'],"[{'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0030208', 'cui_str': 'Paintings'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0449830', 'cui_str': 'With configuration'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}]",[],"[{'cui': 'C0600269', 'cui_str': 'Familiarity'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}]",,0.0305843,"Behavioral results demonstrated an interactive influence of painting content and complexity on familiarity-novelty preference, especially alongside the distinction between representational and abstract paintings.","[{'ForeName': 'Jiwon', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': 'School of Psychology, Korea University, Seoul, South Korea.'}, {'ForeName': 'Yuna', 'Initials': 'Y', 'LastName': 'Kwak', 'Affiliation': 'School of Psychology, Korea University, Seoul, South Korea.'}, {'ForeName': 'Chai-Youn', 'Initials': 'CY', 'LastName': 'Kim', 'Affiliation': 'School of Psychology, Korea University, Seoul, South Korea.'}]",Frontiers in psychology,['10.3389/fpsyg.2021.694927'] 2120,34367014,Can Psychosocial Intervention Suppress Testosterone and Triglycerides Among Women With Polycystic Ovary Syndrome? A Feasibility Trial.,"Women with polycystic ovary syndrome (PCOS) suffer significant psychological distress, which may activate the hypothalamus-pituitary-ovary axis and further affect their physiological state. They often experience elevated levels of testosterone and triglycerides. Considering reports of psychological distress among women with PCOS, this study aimed to develop a psychosocial intervention to improve their emotional and physical health, particularly in Chinese society. This pilot study employed the Integrative Body-Mind-Spirit (I-BMS) intervention model for women with PCOS in China. After a 2 h health information session, 18 participants were randomly assigned to the I-BMS group (9) or the control group (9). The intervention group received 6 weekly, 3 h I-BMS sessions. Pre- and post-blood tests and psychosocial questionnaires were collected from all participants. Retention to treatment was high with 79.6% treatment adherence gained and an overall average of five sessions completed. Compared with the control group, depression and anxiety symptoms reduced significantly for those in the intervention group ( d = -1.24, p < 0.05 and d = -1.33, p < 0.01), their health-related quality of life improved significantly ( d = 1.02, p < 0.01) both at post-intervention and 3 month follow-up, and their testosterone and triglycerides levels reduced significantly ( d = -0.97, p < 0.001 and d = -0.41, p < 0.05) after joining the intervention. The I-BMS model is feasible and appears promising in improving psychological health, and reducing testosterone and triglyceride levels, in women with PCOS in China. Clinical Trial Registration: www.chictr.org.cn, identifier ChiCTR1900027606.",2021,"Compared with the control group, depression and anxiety symptoms reduced significantly for those in the intervention group ( d = -1.24, p < 0.05 and d = -1.33, p < 0.01),","['Women With Polycystic Ovary Syndrome', 'Women with polycystic ovary syndrome (PCOS', 'women with PCOS', '18 participants', 'women with PCOS in China']",['Integrative Body-Mind-Spirit (I-BMS) intervention model'],"['Pre- and post-blood tests and psychosocial questionnaires', 'testosterone and triglyceride levels', 'testosterone and triglycerides', 'testosterone and triglycerides levels', 'Testosterone and Triglycerides', 'depression and anxiety symptoms', 'quality of life']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0301611', 'cui_str': 'Distilled spirits'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",18.0,0.0185958,"Compared with the control group, depression and anxiety symptoms reduced significantly for those in the intervention group ( d = -1.24, p < 0.05 and d = -1.33, p < 0.01),","[{'ForeName': 'Margaret X C', 'Initials': 'MXC', 'LastName': 'Yin', 'Affiliation': 'Department of Social Work and Social Administration, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'L B', 'Initials': 'LB', 'LastName': 'Du', 'Affiliation': 'Reproductive Medicine Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'X N', 'Initials': 'XN', 'LastName': 'Zou', 'Affiliation': 'Kids Caring Corner, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'Y L', 'Initials': 'YL', 'LastName': 'Fung', 'Affiliation': 'Department of Social Work and Social Administration, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Y Y', 'Initials': 'YY', 'LastName': 'Sun', 'Affiliation': 'Kids Caring Corner, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'Celia H Y', 'Initials': 'CHY', 'LastName': 'Chan', 'Affiliation': 'Department of Social Work and Social Administration, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Cecilia L W', 'Initials': 'CLW', 'LastName': 'Chan', 'Affiliation': 'Department of Social Work and Social Administration, The University of Hong Kong, Hong Kong, China.'}]",Frontiers in psychology,['10.3389/fpsyg.2021.690539'] 2121,34367007,Acceptance and Commitment Training for Ice Hockey Players: A Randomized Controlled Trial.,"Recent systematic reviews on the topic of mindfulness- and acceptance-based approaches in sport psychology conclude that there is a need for further trials using a more robust research methodology with direct performance as outcome. Acceptance and Commitment Training (ACT) is a contextual behavioral change method that focuses on facilitating psychological processes such as values, committed action, acceptance and mindfulness. In the present study designed as a randomized controlled trial, 34 junior elite ice hockey players were allocated into either an ACT group intervention or a wait list control group. Results showed significant effects on both objective performance outcomes (goals, assists, and taken shots) and blinded coach ratings of players' performance, focus and commitment to their development in favor of the ACT group. Effects lasted at 3-month follow-up for the coach ratings, but not for the objective performance measures. All ACT trained players recommended ACT to other players and considered the training as important for their development as ice hockey players. The results add to the growing body of evidence on ACT interventions for athletes and its effect on performance. Future studies should investigate the maintenance of effects from the psychological training over time, using robust research methodology and investigate theoretical coherent potential mediating variables.",2021,All ACT trained players recommended ACT to other players and considered the training as important for their development as ice hockey players.,"['34 junior elite ice hockey players', 'Ice Hockey Players']","['ACT group intervention or a wait list control group', 'Acceptance and Commitment Training (ACT']","[""objective performance outcomes (goals, assists, and taken shots) and blinded coach ratings of players' performance, focus and commitment to their development""]","[{'cui': 'C0020748', 'cui_str': 'Ice hockey'}]","[{'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}]",34.0,0.0450617,All ACT trained players recommended ACT to other players and considered the training as important for their development as ice hockey players.,"[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Lundgren', 'Affiliation': 'Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.'}, {'ForeName': 'Gustaf', 'Initials': 'G', 'LastName': 'Reinebo', 'Affiliation': 'Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.'}, {'ForeName': 'Markus Jansson', 'Initials': 'MJ', 'LastName': 'Fröjmark', 'Affiliation': 'Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.'}, {'ForeName': 'Emil', 'Initials': 'E', 'LastName': 'Jäder', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Näslund', 'Affiliation': 'MoDo Hockey, Örnsköldsvik, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Svartvadet', 'Affiliation': 'MoDo Hockey, Örnsköldsvik, Sweden.'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Samuelsson', 'Affiliation': 'MoDo Hockey, Örnsköldsvik, Sweden.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Parling', 'Affiliation': 'Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.'}]",Frontiers in psychology,['10.3389/fpsyg.2021.685260'] 2122,34366925,Effects of Mindfulness-Based Cognitive Therapy on Stigma in Female Patients With Schizophrenia.,"Mindfulness-based cognitive therapy (MBCT) has been increasingly recognized as effective in different mental illnesses, but these effects are limited in schizophrenia. For patients with schizophrenia, stigma is one of the most negative factors that affects treatment, rehabilitation and social function. This research aimed to determine the effects of MBCT on stigma in patients with schizophrenia. In total, 62 inpatients with schizophrenia were recruited and randomly assigned to the experimental group or control group. The experimental group received an 8-week MBCT intervention, and the control group were treated as usual. Link's Stigma Scales (with three subscales, including perceived devaluation-discrimination (PDD), stigma-coping orientation, and stigma-related feeling), Five Facet Mindfulness Questionnaire (FFMQ), and Insight and Treatment Attitudes Questionnaire (ITAQ) were used to collect data before and after intervention. After intervention, the post-test score of PDD, stigma-coping orientation, FFMQ, and ITAQ were significantly different between the experimental group and the control group. In the experimental group, the PDD and stigma-coping orientation scores significantly decreased, and FFMQ and ITAQ scores increased remarkably ( P < 0.05). In addition, correlation analysis revealed a significant negative correlation between mindfulness and stigma. MBCT was effective in reducing stigma in patients with schizophrenia, which mainly manifested as changes in the patients' perception of stigma as well as the withdrawal and avoidance caused by schizophrenia. Enhancing mindfulness will help reduce the stigma level. MBCT is worthy of promotion and application in patients with schizophrenia.",2021,"In the experimental group, the PDD and stigma-coping orientation scores significantly decreased, and FFMQ and ITAQ scores increased remarkably ( P < 0.05).","['patients with schizophrenia', '62 inpatients with schizophrenia', 'Female Patients With Schizophrenia']","['Mindfulness-Based Cognitive Therapy', 'MBCT', '8-week MBCT intervention', 'Mindfulness-based cognitive therapy (MBCT']","[""Link's Stigma Scales"", 'PDD and stigma-coping orientation scores', 'FFMQ and ITAQ scores', 'perceived devaluation-discrimination (PDD), stigma-coping orientation, and stigma-related feeling), Five Facet Mindfulness Questionnaire (FFMQ), and Insight and Treatment Attitudes Questionnaire (ITAQ', 'post-test score of PDD, stigma-coping orientation, FFMQ, and ITAQ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0233820', 'cui_str': 'Insight'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",62.0,0.00491544,"In the experimental group, the PDD and stigma-coping orientation scores significantly decreased, and FFMQ and ITAQ scores increased remarkably ( P < 0.05).","[{'ForeName': 'Qiubi', 'Initials': 'Q', 'LastName': 'Tang', 'Affiliation': 'The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Shuixian', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Cuixia', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Liyan', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Fengchun', 'Initials': 'F', 'LastName': 'Wu', 'Affiliation': 'The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Xingbing', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2021.694575'] 2123,34366898,Heart Rate and Muscle Oxygenation Kinetics During Dynamic Constant Load Intermittent Breath-Holds.,"Introduction: Acute apnea evokes bradycardia and peripheral vasoconstriction in order to conserve oxygen, which is more pronounced with face immersion. This response is contrary to the tachycardia and increased blood flow to muscle tissue related to the higher oxygen consumption during exercise. The aim of this study was to investigate cardiovascular and metabolic responses of dynamic dry apnea (DRA) and face immersed apnea (FIA). Methods: Ten female volunteers (17.1 ± 0.6 years old) naive to breath-hold-related sports, performed a series of seven dynamic 30 s breath-holds while cycling at 25% of their peak power output. This was performed in two separate conditions in a randomized order: FIA (15°C) and DRA. Heart rate and muscle tissue oxygenation through near-infrared spectroscopy were continuously measured to determine oxygenated (m[O 2 Hb]) and deoxygenated hemoglobin concentration (m[HHb]) and tissue oxygenation index (mTOI). Capillary blood lactate was measured 1 min after the first, third, fifth, and seventh breath-hold. Results: Average duration of the seven breath-holds did not differ between conditions (25.3 s ± 1.4 s, p = 0.231). The apnea-induced bradycardia was stronger with FIA (from 134 ± 4 to 85 ± 3 bpm) than DRA (from 134 ± 4 to 100 ± 5 bpm, p < 0.001). mTOI decreased significantly from 69.9 ± 0.9% to 63.0 ± 1.3% ( p < 0.001) which is reflected in a steady decrease in m[O 2 Hb] ( p < 0.001) and concomitant increase in m[HHb] ( p = 0.001). However, this was similar in both conditions (0.121 < p < 0.542). Lactate was lower after the first apnea with FIA compared to DRA ( p = 0.038), while no differences were observed in the other breath-holds. Conclusion: Our data show strong decreases in heart rate and muscle tissue oxygenation during dynamic apneas. A stronger bradycardia was observed in FIA, while muscle oxygenation was not different, suggesting that FIA did not influence muscle oxygenation. An order of mechanisms was observed in which, after an initial tachycardia, heart rate starts to decrease after muscle tissue deoxygenation occurs, suggesting a role of peripheral vasoconstriction in the apnea-induced bradycardia. The apnea-induced increase in lactate was lower in FIA during the first apnea, probably caused by the stronger bradycardia.",2021,"Lactate was lower after the first apnea with FIA compared to DRA ( p = 0.038), while no differences were observed in the other breath-holds. ",['Ten female volunteers (17.1 ± 0.6 years old) naive to breath-hold-related sports'],[],"['Lactate', 'Capillary blood lactate', 'Heart Rate and Muscle Oxygenation Kinetics', 'm[HHb', 'bradycardia', 'apnea-induced bradycardia', 'cardiovascular and metabolic responses of dynamic dry apnea (DRA) and face immersed apnea (FIA', 'Heart rate and muscle tissue oxygenation', 'mTOI', 'Average duration of the seven breath-holds', 'heart rate and muscle tissue oxygenation', 'lactate', 'deoxygenated hemoglobin concentration (m[HHb]) and tissue oxygenation index (mTOI']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0235744', 'cui_str': 'Interrupted breathing'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0038039', 'cui_str': 'Sport'}]",[],"[{'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0229666', 'cui_str': 'Capillary blood'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0180917', 'cui_str': 'Fluorescence immunoassay analyzer'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0235744', 'cui_str': 'Interrupted breathing'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index measurement'}]",10.0,0.0159993,"Lactate was lower after the first apnea with FIA compared to DRA ( p = 0.038), while no differences were observed in the other breath-holds. ","[{'ForeName': 'Janne', 'Initials': 'J', 'LastName': 'Bouten', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Sander', 'Initials': 'S', 'LastName': 'De Bock', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Gil', 'Initials': 'G', 'LastName': 'Bourgois', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'de Jager', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Jasmien', 'Initials': 'J', 'LastName': 'Dumortier', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Boone', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Jan G', 'Initials': 'JG', 'LastName': 'Bourgois', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}]",Frontiers in physiology,['10.3389/fphys.2021.712629'] 2124,34366890,Once Weekly Whole-Body Electromyostimulation Enhances Muscle Quality in Men: Data of the Randomized Controlled Franconian Electromyostimulation and Golf Study.,"Whole-body electromyostimulation (WB-EMS) is commercially advertised as a time-efficient resistance-type exercise technology. Indeed, the commercial, non-medical setting applies 20 min of WB-EMS only once a week. However, this setting conflicts with the approved scientific approach of higher training frequencies. Using data from an ongoing study on WB-EMS and golf performance as a vehicle, we evaluate the effect of once weekly WB-EMS on changes of fatty muscle infiltration, as a crucial parameter of muscle quality. Fifty-four moderately physically active male amateur golfers 18-70 years old were randomly allocated to a WB-EMS ( n = 27) with a standard setting of once weekly 20 min and a non-WB-EMS control group (CG, n = 27). Intermuscular adipose tissue (IMAT) volume and intrafascial muscle tissue (MT) volume per unit of intrafascial volume as determined by magnetic resonance imaging were used to characterize muscle quality. Intention to treat analysis with multiple imputation was applied. WB-EMS was conducted at the participants' homes; thus, the attendance rate was close to 100%. After 16 weeks of intervention, we observed increases in volume-adjusted IMAT ( p = 0.040) and decreases in MT ( p = 0.206) in the CG. IMAT decreased in the WB-EMS group ( p = 0.215), while MT increased significantly ( p = 0.032). Of importance, group difference (i.e., ""effects"") for intra-group changes in volume-adjusted IMAT (effect size: d ´ = 0.66; p = 0.028) and MT ( d ´ = 0.70; p = 0.020) was significant for both parameters. Once weekly WB-EMS application significantly affects muscle quality of the mid-thigh in moderately active, healthy men 18-70 years old.",2021,"After 16 weeks of intervention, we observed increases in volume-adjusted IMAT ( p = 0.040) and decreases in MT ( p = 0.206) in the CG.","['healthy men 18-70 years old', 'Fifty-four moderately physically active male amateur golfers 18-70 years old', 'Men']","['standard setting of once weekly 20 min and a non-WB-EMS control', 'WB-EMS']","['muscle quality', 'Intermuscular adipose tissue (IMAT) volume and intrafascial muscle tissue (MT) volume per unit of intrafascial volume', 'volume-adjusted IMAT', 'IMAT', 'attendance rate']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}]",,0.0141904,"After 16 weeks of intervention, we observed increases in volume-adjusted IMAT ( p = 0.040) and decreases in MT ( p = 0.206) in the CG.","[{'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Zink-Rückel', 'Affiliation': 'Institute of Medical Physics, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Chaudry', 'Affiliation': 'Institute of Medical Physics, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Engelke', 'Affiliation': 'Institute of Medical Physics, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.'}, {'ForeName': 'Mansour', 'Initials': 'M', 'LastName': 'Ghasemikaram', 'Affiliation': 'Institute of Medical Physics, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Kohl', 'Affiliation': 'Faculty Medical and Life Sciences, University of Furtwangen, Villingen-Schwenningen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Uder', 'Affiliation': 'Institute of Radiology, FAU Erlangen-Nürnberg and University Hospital, Erlangen, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Kemmler', 'Affiliation': 'Institute of Medical Physics, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.'}]",Frontiers in physiology,['10.3389/fphys.2021.700423'] 2125,34366847,"First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults.","Background: As a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, TQ-F3083 represents a promising new drug for type 2 diabetes mellitus (T2DM). This phase I, first-in-human study evaluated the tolerability, pharmacokinetics, and pharmacodynamics of TQ-F3083 in healthy Chinese adults. Methods: Sixty healthy participants total were enrolled in the single-ascending dose, multiple-dose, and food-effect studies. Safety endpoints included adverse events (AEs), vital signs, 12-lead electrocardiogram, abdominal ultrasound, chest X-ray, physical examination, and clinical laboratory tests. Blood, urine, and feces samples were collected for pharmacokinetic analyses. Pharmacodynamic parameters were evaluated based on DPP-4 activity and the active glucagon-like peptide-1 concentration. Results: In total, 22 treatment-related AEs, mostly grade 1 or 2, were reported in 14 individuals. No deaths, serious AEs, or grade ≥4 AEs occurred, and no dose-dependent AEs were demonstrated. For pharmacokinetic characteristics, dose linearity was analyzed using power model. The slopes (90% CIs) were 1.08 (1.02-1.13) and 1.05 (0.99-1.11) for AUC 0-t and AUC 0-∞ , suggesting liner pharmacokinetic characteristic after oral dose TQ-F3083 from 2 to 160 mg. The accumulation factor was 1.39 after multiple dose for 7 days. Decreased plasma exposure (84.87% decrease in C max , 49.23% in AUC 0-t , and 47.77% in AUC 0-∞ ) was observed with administration after a high-fat and high-calorie standardized breakfast. The 0-72 h TQ-F3083 excretion recovery percentages were 7.84% in urine and 5.76% in feces. Over 80% DPP-4 inhibition for 24 h was observed in the 20-160 mg cohorts, and the model-estimated 50% effective concentration was 1.10 ng/ml. The concentration of active glucagon-like peptide-1 increased after TQ-F3083 administration, but no obvious dose dependency was observed. Conclusion: TQ-F3083 was well tolerated in healthy Chinese adults, and the pharmacokinetic and pharmacodynamic characteristics support further evaluation of TQ-F3083 in a trial in T2DM patients.",2021,"The concentration of active glucagon-like peptide-1 increased after TQ-F3083 administration, but no obvious dose dependency was observed. ","['healthy Chinese adults', 'Healthy Chinese Adults', 'Sixty healthy participants total were enrolled in the single-ascending dose, multiple-dose, and food-effect studies']","['novel dipeptidyl peptidase-4', 'Placebo']","['tolerability, pharmacokinetics, and pharmacodynamics', 'DPP-4 activity and the active glucagon-like peptide-1 concentration', 'Decreased plasma exposure', 'TQ-F3083 excretion recovery percentages', 'adverse events (AEs), vital signs, 12-lead electrocardiogram, abdominal ultrasound, chest X-ray, physical examination, and clinical laboratory tests', 'accumulation factor', 'No deaths, serious AEs, or grade ≥4 AEs', 'concentration of active glucagon-like peptide-1', 'DPP-4 inhibition', 'Blood, urine, and feces samples']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0081937', 'cui_str': 'Dipeptidyl peptidase IV'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0430456', 'cui_str': '12 lead ECG'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4505474', 'cui_str': 'Clinical Laboratory Tests'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0060133', 'cui_str': 'FEC protocol'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]",60.0,0.0692365,"The concentration of active glucagon-like peptide-1 increased after TQ-F3083 administration, but no obvious dose dependency was observed. ","[{'ForeName': 'Jingrui', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Xiaoxue', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Haijing', 'Initials': 'H', 'LastName': 'Wei', 'Affiliation': 'Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Deming', 'Initials': 'D', 'LastName': 'Yang', 'Affiliation': 'Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Zhongnan', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.'}, {'ForeName': 'Dandan', 'Initials': 'D', 'LastName': 'Huo', 'Affiliation': 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.'}, {'ForeName': 'Xiaojiao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Yanhua', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.'}]",Frontiers in pharmacology,['10.3389/fphar.2021.689523'] 2126,34366819,Robot-Assisted Therapy and Constraint-Induced Movement Therapy for Motor Recovery in Stroke: Results From a Randomized Clinical Trial.,"Background: Stroke is one of the leading causes of adult disability, and up to 80% of stroke survivors undergo upper extremity motor dysfunction. Constraint-Induced Movement Therapy (CIMT) and Robot-Assisted Therapy (RT) are used for upper limb stroke rehabilitation. Although CIMT and RT are different techniques, both are beneficial; however, their results must be compared. The objective is to establish the difference between RT and CIMT after a rehabilitation program for chronic stroke patients. Method: This is a randomized clinical trial, registered at ClinicalTrials.gov (ID number NCT02700061), in which patients with stroke received sessions of RT or CIMT protocol, combined with a conventional rehabilitation program for 12 weeks. The primary outcome was measured by Wolf Motor Function Test (WMFT) and Fugl-Meyer Assessment-Upper Limb (FMA-UL). Activities of daily living were also assessed. Results: Fifty one patients with mild to moderate upper limb impairment were enrolled in this trial, 25 women and 26 men, mean age of 60,02 years old (SD 14,48), with 6 to 36 months after stroke onset. Function significantly improved regardless of the treatment group. However, no statistical difference was found between both groups as p -values of the median change of function measured by WMFT and FMA were 0.293 and 0.187, respectively. Conclusion: This study showed that Robotic Therapy (RT) was not different from Constraint-Induced Movement Therapy (CIMT) regardless of the analyzed variables. There was an overall upper limb function, motor recovery, functionality, and activities of daily living improvement regardless of the interventions. At last, the combination of both techniques should be considered in future studies.",2021,"There was an overall upper limb function, motor recovery, functionality, and activities of daily living improvement regardless of the interventions.","['chronic stroke patients', 'one patients with mild to moderate upper limb impairment', 'Stroke', '25 women and 26 men, mean age of 60,02 years old (SD 14,48), with 6 to 36 months after stroke onset']","['Robot-Assisted Therapy and Constraint-Induced Movement Therapy', 'Robotic Therapy (RT', 'Constraint-Induced Movement Therapy (CIMT) and Robot-Assisted Therapy (RT', 'RT and CIMT', 'RT or CIMT protocol, combined with a conventional rehabilitation program']","['Wolf Motor Function Test (WMFT) and Fugl-Meyer Assessment-Upper Limb (FMA-UL', 'Activities of daily living', 'overall upper limb function, motor recovery, functionality, and activities of daily living improvement regardless']","[{'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0557035', 'cui_str': 'Assisting with therapy'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0454279', 'cui_str': 'Movement therapy'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}]","[{'cui': 'C0325001', 'cui_str': 'Wolf'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",25.0,0.0575777,"There was an overall upper limb function, motor recovery, functionality, and activities of daily living improvement regardless of the interventions.","[{'ForeName': 'Thais Tavares', 'Initials': 'TT', 'LastName': 'Terranova', 'Affiliation': 'Instituto de Medicina Fisica e Reabilitacao, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Simis', 'Affiliation': 'Instituto de Medicina Fisica e Reabilitacao, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Artur César Aquino', 'Initials': 'ACA', 'LastName': 'Santos', 'Affiliation': 'Instituto de Medicina Fisica e Reabilitacao, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Fábio Marcon', 'Initials': 'FM', 'LastName': 'Alfieri', 'Affiliation': 'Instituto de Medicina Fisica e Reabilitacao, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Imamura', 'Affiliation': 'Instituto de Medicina Fisica e Reabilitacao, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Fregni', 'Affiliation': 'Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Linamara Rizzo', 'Initials': 'LR', 'LastName': 'Battistella', 'Affiliation': 'Physiatry, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.'}]",Frontiers in neurorobotics,['10.3389/fnbot.2021.684019'] 2127,34366804,Punishment on Pause: Preliminary Evidence That Mindfulness Training Modifies Neural Responses in a Reactive Aggression Task.,"Reactive aggression, a hostile retaliatory response to perceived threat, has been attributed to failures in emotion regulation. Interventions for reactive aggression have largely focused on cognitive control training, which target top-down emotion regulation mechanisms to inhibit aggressive impulses. Recent theory suggests that mindfulness training (MT) improves emotion regulation via both top-down and bottom-up neural mechanisms and has thus been proposed as an alternative treatment for aggression. Using this framework, the current pilot study examined how MT impacts functional brain physiology in the regulation of reactive aggression. Participants were randomly assigned to 2 weeks of MT ( n = 11) or structurally equivalent active coping training (CT) that emphasizes cognitive control ( n = 12). Following training, participants underwent functional magnetic resonance imaging (fMRI) during a retaliatory aggression task, a 16-trial game in which participants could respond to provocation by choosing whether or not to retaliate in the next round. Training groups did not differ in levels of aggression displayed. However, participants assigned to MT exhibited enhanced ventromedial prefrontal cortex (vmPFC) recruitment during punishment events (i.e., the aversive consequence of losing) relative to those receiving active CT. Conversely, the active coping group demonstrated greater dorsomedial prefrontal cortex (dmPFC) activation when deciding how much to retaliate, in line with a bolstered top-down behavior monitoring function. The findings suggest that mindfulness and cognitive control training may regulate aggression via different neural circuits and at different temporal stages of the provocation-aggression cycle. Trial Registration: identification no. NCT03485807.",2021,Training groups did not differ in levels of aggression displayed.,[],"['MT', 'mindfulness training (MT', 'cognitive control training', 'MT ( n = 11) or structurally equivalent active coping training (CT) that emphasizes cognitive control', 'functional magnetic resonance imaging (fMRI']","['ventromedial prefrontal cortex (vmPFC) recruitment', 'dorsomedial prefrontal cortex (dmPFC) activation', 'Reactive aggression', 'levels of aggression displayed']",[],"[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C3850122', 'cui_str': 'Ventral Medial Prefrontal Cortex'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0246461,Training groups did not differ in levels of aggression displayed.,"[{'ForeName': 'Hadley', 'Initials': 'H', 'LastName': 'Rahrig', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA, United States.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Bjork', 'Affiliation': 'Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, United States.'}, {'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'Tirado', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA, United States.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Chester', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA, United States.'}, {'ForeName': 'J David', 'Initials': 'JD', 'LastName': 'Creswell', 'Affiliation': 'Department of Psychology, Carnegie Mellon University, Pittsburgh, PA, United States.'}, {'ForeName': 'Emily K', 'Initials': 'EK', 'LastName': 'Lindsay', 'Affiliation': 'Department of Psychology, University of Pittsburgh, Pittsburgh, PA, United States.'}, {'ForeName': 'Jennifer Kim', 'Initials': 'JK', 'LastName': 'Penberthy', 'Affiliation': 'Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States.'}, {'ForeName': 'Kirk Warren', 'Initials': 'KW', 'LastName': 'Brown', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA, United States.'}]",Frontiers in behavioral neuroscience,['10.3389/fnbeh.2021.689373'] 2128,34366768,Effectiveness of Melodic Intonation Therapy in Chinese Mandarin on Non-fluent Aphasia in Patients After Stroke: A Randomized Control Trial.,"Melodic intonation therapy (MIT) positively impacts the speech function of patients suffering from aphasia and strokes. Fixed-pitch melodies and phrases formulated in MIT provide the key to the target language to open the language pathway. This randomized controlled trial compared the effects of music therapy-based MIT and speech therapy on patients with non-fluent aphasia. The former is more effective in the recovery of language function in patients with aphasia. Forty-two participants were enrolled in the study, and 40 patients were registered. The participants were randomly assigned to two groups: the intervention group ( n = 20; 16 males, 4 females; 52.90 ± 9.08 years), which received MIT, and the control group ( n = 20; 15 males, 5 females; 54.05 ± 10.81 years), which received speech therapy. The intervention group received MIT treatment for 30 min/day, five times a week for 8 weeks, and the control group received identical sessions of speech therapy for 30 min/day, five times a week for 8 weeks. Each participant of the group was assessed by a Boston Diagnostic Aphasia Examination (BDAE) at the baseline (t1, before the start of the experiment), and after 8 weeks (t2, the experiment was finished). The Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) were also measured on the time points. The best medical care of the two groups is the same. Two-way ANOVA analysis of variance was used only for data detection. In the spontaneous speech (information), the listening comprehension (right or wrong, word recognition, and sequential order) and repetitions of the intervention group were significantly higher than the control group in terms of the cumulative effect of time and the difference between groups after 8 weeks. The intervention group has a significant time effect in fluency, but the results after 8 weeks were not significantly different from those in the control group. In terms of naming, the intervention group was much better than the control group in spontaneous naming. Regarding object naming, reaction naming, and sentence completing, the intervention group showed a strong time accumulation effect. Still, the results after 8 weeks were not significantly different from those in the control group. These results indicate that, compared with speech therapy, MIT based on music therapy is a more effective musical activity and is effective and valuable for the recovery of speech function in patients with non-fluent aphasia. As a more professional non-traumatic treatment method, MIT conducted by qualified music therapists requires deeper cooperation between doctors and music therapists to improve rehabilitating patients with aphasia. The Ethics Committee of the China Rehabilitation Research Center approved this study (Approval No. 2020-013-1 on April 1, 2020) and was registered with the Chinese Clinical Trial Registry (Registration number: Clinical Trials ChiCTR2000037871) on September 3, 2020.",2021,"The intervention group has a significant time effect in fluency, but the results after 8 weeks were not significantly different from those in the control group.","['patients with aphasia', ' n = 20; 16 males, 4 females; 52.90 ± 9.08 years), which received MIT, and the control group ( n = 20; 15 males, 5 females; 54.05 ± 10.81 years), which received', 'rehabilitating patients with aphasia', ' 2020-013-1 on April 1, 2020) and was registered with the Chinese Clinical Trial Registry (Registration number: Clinical Trials ChiCTR2000037871) on September 3, 2020', 'Chinese Mandarin on Non-fluent Aphasia in Patients', 'Forty-two participants were enrolled in the study, and 40 patients were registered', 'patients with non-fluent aphasia', 'patients suffering from aphasia and strokes']","['MIT treatment', 'control group received identical sessions of speech therapy', 'Fixed-pitch melodies and phrases formulated in MIT', 'music therapy-based MIT and speech therapy', 'speech therapy', 'Melodic Intonation Therapy', 'Melodic intonation therapy (MIT', 'intervention group']","['Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD', 'effective musical activity', 'listening comprehension (right or wrong, word recognition, and sequential order) and repetitions', 'time effect in fluency', 'Boston Diagnostic Aphasia Examination (BDAE']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003537', 'cui_str': 'Aphasia'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589195', 'cui_str': 'Melodic intonation therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0349390', 'cui_str': 'Non-fluent aphasia'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0589195', 'cui_str': 'Melodic intonation therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0009460', 'cui_str': 'Communication disorder'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0175681', 'cui_str': 'Pitch'}, {'cui': 'C0600665', 'cui_str': 'Phrase'}, {'cui': 'C0026868', 'cui_str': 'Music therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0451036', 'cui_str': 'Boston diagnostic aphasia examination'}]",42.0,0.0194604,"The intervention group has a significant time effect in fluency, but the results after 8 weeks were not significantly different from those in the control group.","[{'ForeName': 'Xiao-Ying', 'Initials': 'XY', 'LastName': 'Zhang', 'Affiliation': 'School of Rehabilitation Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Wei-Yong', 'Initials': 'WY', 'LastName': 'Yu', 'Affiliation': 'School of Rehabilitation Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Wen-Jia', 'Initials': 'WJ', 'LastName': 'Teng', 'Affiliation': 'School of Rehabilitation Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Meng-Yang', 'Initials': 'MY', 'LastName': 'Lu', 'Affiliation': 'School of Rehabilitation Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiao-Li', 'Initials': 'XL', 'LastName': 'Wu', 'Affiliation': 'School of Rehabilitation Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yu-Qi', 'Initials': 'YQ', 'LastName': 'Yang', 'Affiliation': 'School of Rehabilitation Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Music Education, Xinghai Conservatory of Music, Guangzhou, China.'}, {'ForeName': 'Li-Xu', 'Initials': 'LX', 'LastName': 'Liu', 'Affiliation': 'School of Rehabilitation Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Song-Huai', 'Initials': 'SH', 'LastName': 'Liu', 'Affiliation': 'School of Rehabilitation Medicine, Capital Medical University, Beijing, China.'}, {'ForeName': 'Jian-Jun', 'Initials': 'JJ', 'LastName': 'Li', 'Affiliation': 'School of Rehabilitation Medicine, Capital Medical University, Beijing, China.'}]",Frontiers in neuroscience,['10.3389/fnins.2021.648724'] 2129,34366747,"Demand for Information on Environmental Health Risk, Mode of Delivery, and Behavioral Change: Evidence from Sonargaon, Bangladesh.","Millions of villagers in Bangladesh are exposed to arsenic by drinking contaminated water from private wells. Testing for arsenic can encourage switching from unsafe wells to safer sources. This study describes results from a cluster randomized controlled trial conducted in 112 villages in Bangladesh to evaluate the effectiveness of different test selling schemes at inducing switching from unsafe wells. At a price of about US0.60, only one in four households purchased a test. Sales were not increased by informal inter-household agreements to share water from wells found to be safe, or by visual reminders of well status in the form of metal placards mounted on the well pump. However, switching away from unsafe wells almost doubled in response to agreements or placards relative to the one in three proportion of households that switched away from an unsafe well with simple individual sales.",2021,"Sales were not increased by informal inter-household agreements to share water from wells found to be safe, or by visual reminders of well status in the form of metal placards mounted on the well pump.",['112 villages in Bangladesh'],[],[],"[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}]",[],[],,0.0564009,"Sales were not increased by informal inter-household agreements to share water from wells found to be safe, or by visual reminders of well status in the form of metal placards mounted on the well pump.","[{'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Tarozzi', 'Affiliation': 'Universitat Pompeu Fabra and the Barcelona Graduate School of Economics, Barcelona.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Maertens', 'Affiliation': 'Harvard University.'}, {'ForeName': 'Kazi Matin', 'Initials': 'KM', 'LastName': 'Ahmed', 'Affiliation': 'University of Dhaka.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'van Geen', 'Affiliation': 'Columbia University, New York.'}]",The World Bank economic review,['10.1093/wber/lhaa009'] 2130,34366734,The VITamin D and OmegA-3 TriaL (VITAL): Do Results Differ by Sex or Race/Ethnicity?,"Whether vitamin D or marine omega-3 (n-3) fatty acid supplementation reduces risk of cancer or cardiovascular disease (CVD) in general populations at usual risk for these outcomes is relatively unexplored in randomized trials. The primary goal of the VIT amin D and Omeg A -3 Tria L (VITAL), a nationwide, randomized, placebo-controlled, 2 × 2 factorial trial of vitamin D 3 (2000 IU/day) and marine n-3 fatty acids (1 g/day) in the primary prevention of cancer and CVD among 25 871 US men aged ≥50 years and women aged ≥55 years, was to fill these knowledge gaps. Studying the influence of sex and race/ethnicity on treatment-related outcomes was a prespecified goal; such analyses help ensure that important effects are not missed and contribute to the foundation for developing targeted recommendations for supplement use. To enable investigation of potential sex- and race-specific treatment effects, trial investigators enrolled an even balance of men (n = 12 786) and women (n = 13 085) and oversampled African Americans (n = 5106). Significant or suggestive variation in intervention effects according to sex, race/ethnicity, and other participant characteristics was observed for some, though not all, outcomes. Additional research is needed to determine which individuals may be most likely to derive a net benefit from vitamin D or n-3 fatty acid supplementation. (VITAL clinicaltrials.gov identifier: NCT01169259).",2021,"Significant or suggestive variation in intervention effects according to sex, race/ethnicity, and other participant characteristics was observed for some, though not all, outcomes.","['men (n = 12\u2009786) and women (n = 13\u2009085) and oversampled African Americans (n = 5106', 'cancer and CVD among 25\u2009871 US men aged ≥50 years and women aged ≥55 years']","['VITamin D and OmegA-3 TriaL (VITAL', 'vitamin D or marine omega-3 (n-3) fatty acid supplementation', 'VIT amin D and Omeg A', 'placebo', 'vitamin D 3 (2000 IU/day) and marine n-3 fatty acids']",['risk of cancer or cardiovascular disease (CVD'],"[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0524645', 'cui_str': 'Marines'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]",25871.0,0.513649,"Significant or suggestive variation in intervention effects according to sex, race/ethnicity, and other participant characteristics was observed for some, though not all, outcomes.","[{'ForeName': 'Shari S', 'Initials': 'SS', 'LastName': 'Bassuk', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (SSB, PDC, JEB, JEM).""}, {'ForeName': 'Paulette D', 'Initials': 'PD', 'LastName': 'Chandler', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (SSB, PDC, JEB, JEM).""}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Buring', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (SSB, PDC, JEB, JEM).""}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (SSB, PDC, JEB, JEM).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of lifestyle medicine,['10.1177/1559827620972035'] 2131,34366631,Modified Xiaochaihu Decoction for gastroesophageal reflux disease: A randomized double-simulation controlled trial.,"BACKGROUND Gastroesophageal reflux disease (GERD) has a high prevalence worldwide, and its incidence is increasing annually. Modified Xiaochaihu Decoction (MXD) could relieve the symptoms of GERD, but the effects of MXD on GERD manifestations and relapse prevention need to be further explained. Therefore, we performed a prospective, double-blind, and double-simulation study. AIM To verify the efficacy of MXD for GERD and its effect on esophageal motility. METHODS Using randomization, double-blinding, and a simulation design, 288 participants with GERD were randomized to the treatment group and control group and received herbs (MXD) plus omeprazole simulation and omeprazole plus herbs simulation, respectively, for 4 wk. The GERD-Q scale score and esophageal manometry were measured at baseline, after treatment, and at 1 mo and 3 mo follow-up visits when medication was complete to evaluate recurrence indicators. RESULTS The GERD-Q scale score in both groups decreased significantly compared to those before treatment ( P < 0.01). However, no significant difference was observed between the two groups ( P > 0.05). Esophageal manometry showed that participants with lower esophageal sphincter pressure reduction and the proportion of ineffective swallowing (more than 50%) improved in both groups from baseline ( P < 0.01), especially in the treatment group ( P < 0.05). The percentage of small intermittent contractions, large intermittent contractions, and increased pre-phase contractions in the treatment group significantly improved compared with baseline ( P < 0.05) but did not improve in the control group ( P > 0.05). There was no significant difference between the groups after treatment ( P > 0.05). The percentage of weak esophageal contractility (distal contractile integral < 450 mmHg·s·cm), improved in both groups ( P < 0.01), but no significant difference was observed between the groups after treatment ( P > 0.05). The relapse rate in the treatment group was lower than that in the control group at the 1 mo ( P < 0.01) and 3 mo follow-up ( P < 0.05). CONCLUSION MXD has a similar therapeutic effect to omeprazole in mild-to-moderate GERD. The therapeutic effect may be related to increased pressure in the lower esophageal sphincter and reduced ineffective swallowing.",2021,"The percentage of weak esophageal contractility (distal contractile integral < 450 mmHg·s·cm), improved in both groups ( P < 0.01), but no significant difference was observed between the groups after treatment ( P > 0.05).","['288 participants with GERD', 'gastroesophageal reflux disease', 'Gastroesophageal reflux disease (GERD']","['control group and received herbs (MXD) plus omeprazole simulation and omeprazole plus herbs simulation', 'omeprazole', 'Modified Xiaochaihu Decoction', 'MXD', 'Modified Xiaochaihu Decoction (MXD']","['GERD-Q scale score and esophageal manometry', 'percentage of weak esophageal contractility', 'proportion of ineffective swallowing', 'GERD-Q scale score', 'percentage of small intermittent contractions, large intermittent contractions, and increased pre-phase contractions', 'esophageal sphincter pressure reduction', 'relapse rate']","[{'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0019240', 'cui_str': 'Herb'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2934737', 'cui_str': 'xiaochaihu'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0028978', 'cui_str': 'Omeprazole'}]","[{'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0199873', 'cui_str': 'Esophageal manometry'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1762617', 'cui_str': 'Weak'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0014865', 'cui_str': 'Esophageal sphincter'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]",288.0,0.189966,"The percentage of weak esophageal contractility (distal contractile integral < 450 mmHg·s·cm), improved in both groups ( P < 0.01), but no significant difference was observed between the groups after treatment ( P > 0.05).","[{'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'The Digestive Center, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Tao', 'Affiliation': 'The Digestive Center, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.'}, {'ForeName': 'Sheng-Sheng', 'Initials': 'SS', 'LastName': 'Zhang', 'Affiliation': 'The Digestive Center, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China. zhangshengsheng@bjzhongyi.com.'}, {'ForeName': 'Xiao-Hong', 'Initials': 'XH', 'LastName': 'Sun', 'Affiliation': 'Department of Digestive, Peking Union Medical College Hospital, Beijing 100730, China.'}, {'ForeName': 'Su-Ning', 'Initials': 'SN', 'LastName': 'Chen', 'Affiliation': 'Department of Digestive, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Digestive, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.'}]",World journal of gastroenterology,['10.3748/wjg.v27.i28.4710'] 2132,34366432,"Randomized controlled trial of the ""WISER"" intervention to reduce healthcare worker burnout.","OBJECTIVE Test web-based implementation for the science of enhancing resilience (WISER) intervention efficacy in reducing healthcare worker (HCW) burnout. DESIGN RCT using two cohorts of HCWs of four NICUs each, to improve HCW well-being (primary outcome: burnout). Cohort 1 received WISER while Cohort 2 acted as a waitlist control. RESULTS Cohorts were similar, mostly female (83%) and nurses (62%). In Cohorts 1 and 2 respectively, 182 and 299 initiated WISER, 100 and 176 completed 1-month follow-up, and 78 and 146 completed 6-month follow-up. Relative to control, WISER decreased burnout (-5.27 (95% CI: -10.44, -0.10), p = 0.046). Combined adjusted cohort results at 1-month showed that the percentage of HCWs reporting concerning outcomes was significantly decreased for burnout (-6.3% (95%CI: -11.6%, -1.0%); p = 0.008), and secondary outcomes depression (-5.2% (95%CI: -10.8, -0.4); p = 0.022) and work-life integration (-11.8% (95%CI: -17.9, -6.1); p < 0.001). Improvements endured at 6 months. CONCLUSION WISER appears to durably improve HCW well-being. CLINICAL TRIALS NUMBER NCT02603133; https://clinicaltrials.gov/ct2/show/NCT02603133.",2021,"Relative to control, WISER decreased burnout (-5.27 (95% CI: -10.44, -0.10), p = 0.046).",[],"['WISER"" intervention', 'WISER']","['work-life integration', 'percentage of HCWs reporting concerning outcomes']",[],"[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.395241,"Relative to control, WISER decreased burnout (-5.27 (95% CI: -10.44, -0.10), p = 0.046).","[{'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Profit', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'Kathryn C', 'Initials': 'KC', 'LastName': 'Adair', 'Affiliation': 'Department of Psychiatry, Duke University School of Medicine, Duke University Health System, Durham, NC, USA.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Cui', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'Briana', 'Initials': 'B', 'LastName': 'Mitchell', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Brandon', 'Affiliation': 'Duke University School of Nursing, Durham, USA.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Tawfik', 'Affiliation': ""Division of Pediatric Critical Care Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Rigdon', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Jeffrey B', 'Initials': 'JB', 'LastName': 'Gould', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'Henry C', 'Initials': 'HC', 'LastName': 'Lee', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'Wendy L', 'Initials': 'WL', 'LastName': 'Timpson', 'Affiliation': 'Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'McCaffrey', 'Affiliation': ""Division of Neonatal-Perinatal Medicine, University of North Carolina Chapel Hill School of Medicine and University of North Carolina Children's Hospital, Chapel Hill, NC, USA.""}, {'ForeName': 'Alexis S', 'Initials': 'AS', 'LastName': 'Davis', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.""}, {'ForeName': 'Mohan', 'Initials': 'M', 'LastName': 'Pammi', 'Affiliation': ""Section of Neonatology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.""}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Matthews', 'Affiliation': ""Department of Pediatrics-Neonatology, The University of Texas Health Science Center and Children's Memorial Hermann Hospital, Houston, TX, USA.""}, {'ForeName': 'Ann R', 'Initials': 'AR', 'LastName': 'Stark', 'Affiliation': 'Department of Pediatrics, Division of Newborn Medicine, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Lu-Ann', 'Initials': 'LA', 'LastName': 'Papile', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, The University of New Mexico School of Medicine, Albuquerque, NM, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Thomas', 'Affiliation': 'Department of Internal Medicine, The University of Texas Health Science Center and Memorial Hermann Medical Center, Houston, TX, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Cotten', 'Affiliation': 'Division of Pediatrics-Neonatology, Duke University School of Medicine and Duke University Hospital, Durham, NC, USA.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, The University of New Mexico School of Medicine, Albuquerque, NM, USA.'}, {'ForeName': 'J Bryan', 'Initials': 'JB', 'LastName': 'Sexton', 'Affiliation': 'Department of Psychiatry, Duke University School of Medicine, Duke University Health System, Durham, NC, USA. Bryan.Sexton@Duke.edu.'}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-021-01100-y'] 2133,34366425,Intra-operative open-lung ventilatory strategy reduces postoperative complications after laparoscopic colorectal cancer resection: A randomised controlled trial.,"BACKGROUND The role of the positive end-expiratory pressure (PEEP) and lung recruitment manoeuvre (LRM) combination (termed open-lung strategy, OLS) during intra-operative mechanical ventilation is not clear. OBJECTIVE To determine whether an open-lung strategy constituting medium PEEP (6-8 cmH2O) and repeated LRMs protects against postoperative complications in at-risk patients undergoing laparoscopic colorectal cancer resection under low-tidal-volume ventilation. DESIGN A prospective, assessor-blinded, randomised controlled trial. SETTING Single university-affiliated hospital, conducted from January 2017 to October 2018. PATIENTS A total of 280 patients at risk of pulmonary complications, scheduled for laparoscopic colorectal cancer resection under general anaesthesia and low-tidal-volume (6-8 ml kg-1 predicted body weight) ventilation. INTERVENTION The patients were randomly assigned (1 : 1) to a PEEP of 6-8 cmH2O with LRMs repeated every 30 min (OLS group) or a zero PEEP without LRMs (non-OLS group). MAIN OUTCOME MEASURES The primary outcome was a composite of major pulmonary and extrapulmonary complications occurring within 7 days after surgery. The secondary outcomes included intra-operative potentially harmful hypotension and the need for vasopressors. RESULTS A total of 130 patients from each group were included in the primary outcome analysis. Primary outcome events occurred in 24 patients (18.5%) in the OLS group and 43 patients (33.1%) in the non-OLS group [relative risk, 0.46; 95% confidence interval (CI), 0.26 to 0.82; P = 0.009). More patients in the OLS group developed potentially harmful hypotension (OLS vs. non-OLS, 15% vs. 4.3%; P = 0.004) and needed vasopressors (25% vs. 8.6%; P < 0.001). CONCLUSION Among at-risk patients undergoing laparoscopic colorectal cancer resection under low-tidal-volume ventilation, an open-lung strategy with a PEEP of 6-8 cmH2O and repeated LRMs reduced postoperative complications compared with a strategy using zero PEEP without LRMs. Of note, LRMs should be used with caution in patients with haemodynamic instability. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT03160144.",2021,"More patients in the OLS group developed potentially harmful hypotension (OLS vs. non-OLS, 15% vs. 4.3%; P = 0.004) and needed vasopressors (25% vs. 8.6%; P < 0.001). ","['patients with haemodynamic instability', '130 patients from each group', 'at-risk patients undergoing laparoscopic colorectal cancer resection under low-tidal-volume ventilation', 'Single university-affiliated hospital, conducted from January 2017 to October 2018', '280 patients at risk of pulmonary complications, scheduled for laparoscopic colorectal cancer resection under general anaesthesia and low-tidal-volume (6-8\u200aml\u200akg-1 predicted body weight) ventilation', 'laparoscopic colorectal cancer resection']","['PEEP of 6-8\u200acmH2O with LRMs repeated every 30\u200amin (OLS group) or a zero PEEP without LRMs (non-OLS group', 'open-lung strategy constituting medium PEEP (6-8\u200acmH2O) and repeated LRMs', 'positive end-expiratory pressure (PEEP) and lung recruitment manoeuvre (LRM) combination (termed open-lung strategy, OLS', 'laparoscopic colorectal cancer resection under low-tidal-volume ventilation', 'Intra-operative open-lung ventilatory strategy', 'OLS']","['potentially harmful hypotension', 'intra-operative potentially harmful hypotension and the need for vasopressors', 'postoperative complications', 'composite of major pulmonary and extrapulmonary complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948268', 'cui_str': 'Hemodynamic instability'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0439476', 'cui_str': 'cmH2O'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}]","[{'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",130.0,0.29355,"More patients in the OLS group developed potentially harmful hypotension (OLS vs. non-OLS, 15% vs. 4.3%; P = 0.004) and needed vasopressors (25% vs. 8.6%; P < 0.001). ","[{'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'From the Department of Anaesthesia, the Sixth Affiliated Hospital, Sun Yat-sen University, No. 26 Yuancun Erheng Road, Tianhe District, Guangzhou, China (HL, Z-NZ, N-RZ, JG, KW, WW, L-GL, JJ, JT, Y-JL, S-QJ).'}, {'ForeName': 'Zhi-Nan', 'Initials': 'ZN', 'LastName': 'Zheng', 'Affiliation': ''}, {'ForeName': 'Nan-Rong', 'Initials': 'NR', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': ''}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Lin-Gui', 'Initials': 'LG', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Jin', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': ''}, {'ForeName': 'Yao-Jun', 'Initials': 'YJ', 'LastName': 'Liao', 'Affiliation': ''}, {'ForeName': 'San-Qing', 'Initials': 'SQ', 'LastName': 'Jin', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001580'] 2134,34366419,"Caffeine Consumption Habits, Sleep Quality, Sleep Quantity, and Perceived Stress of Undergraduate Nursing Students.","BACKGROUND Consumption of energy drinks is prevalent among college students and has increased over the last decade. There is inadequate research about the energy drink consumption habits of prelicensure nursing students. PURPOSE This study determined if there were differences in sleep quality, sleep quantity, and perceived stress levels in nursing students who consume energy drinks compared with those who consume other sources of caffeine and those who abstain. METHODS A comparative study design was used. Participants (n = 272) from universities in 2 regions of the United States answered questions about sleep, perceived stress, caffeine, and energy drink consumption. RESULTS Nursing students at both universities who consumed energy drinks reported poorer sleep quality, fewer sleep hours, and higher levels of perceived stress than caffeine-only consumers and non-caffeine consumers. CONCLUSIONS Prelicensure nursing students may be unaware of the relationships among energy drink consumption, sleep quality, sleep quantity, and perceived stress levels.",2021,"Participants (n = 272) from universities in 2 regions of the United States answered questions about sleep, perceived stress, caffeine, and energy drink consumption. ","['Participants (n = 272) from universities in 2 regions of the United States answered questions about sleep, perceived stress, caffeine, and energy drink consumption', 'college students', 'Undergraduate Nursing Students', 'nursing students who consume energy drinks compared with those who consume other sources of caffeine and those who abstain']",[],"['Caffeine Consumption Habits, Sleep Quality, Sleep Quantity, and Perceived Stress', 'energy drink consumption, sleep quality, sleep quantity, and perceived stress levels', 'sleep quality, sleep quantity, and perceived stress levels', 'sleep quality']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C3179078', 'cui_str': 'Energy drink'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0449416', 'cui_str': 'Source'}]",[],"[{'cui': 'C0948365', 'cui_str': 'Caffeine consumption'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C3179078', 'cui_str': 'Energy drink'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}]",272.0,0.0675474,"Participants (n = 272) from universities in 2 regions of the United States answered questions about sleep, perceived stress, caffeine, and energy drink consumption. ","[{'ForeName': 'Mykin R', 'Initials': 'MR', 'LastName': 'Higbee', 'Affiliation': 'Author Affiliations: Assistant Professor, School of Nursing (Dr Higbee), and Professor, Department of Strategic Management and Operations (Dr El-Saidi), Utah Valley University, Orem; and Assistant Professor (Dr Gipson), School of Nursing, The University of Texas at Tyler.'}, {'ForeName': 'Christine S', 'Initials': 'CS', 'LastName': 'Gipson', 'Affiliation': ''}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'El-Saidi', 'Affiliation': ''}]",Nurse educator,['10.1097/NNE.0000000000001062'] 2135,34366380,Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.,"BACKGROUND Foslevodopa/foscarbidopa, formerly known as ABBV-951, is a formulation of levodopa/carbidopa prodrugs with solubility that allows for subcutaneous (SC) infusion and is in development for the treatment of motor complications for patients with advanced Parkinson's disease (aPD). OBJECTIVE The current work characterizes the levodopa (LD) and carbidopa (CD) pharmacokinetics (PK) following SC infusions of foslevodopa/foscarbidopa delivered at four different infusion rates in PD patients. METHODS This was a Phase 1, single ascending dose, single-blind study conducted in 28 adult male and female subjects at seven sites in the United States. Foslevodopa/foscarbidopa was administered via abdominal SC infusion in PD patients over 72 hours. Patients were stratified in 4 groups and received a fixed dose of foslevodopa/foscarbidopa based on their oral daily LD intake. Serial plasma PK samples were collected to assay for LD and CD concentrations. Safety and tolerability were assessed throughout the study. RESULTS LD exposure quickly reached steady state and remained stable with minimal fluctuations. Foslevodopa/foscarbidopa infusion provides stable LD and CD exposures compared to oral LD/CD dosing with the average steady-state exposure ranging from 747-4660 ng/mL for the different groups. CONCLUSION Foslevodopa/foscarbidopa was able to provide stable LD and CD exposures in PD patients over 72 hours via SC route of delivery with very low fluctuation in LD concentration level across a wide range of clinically relevant exposures. Foslevodopa/foscarbidopa had a favorable safety profile. The low PK fluctuation following foslevodopa/foscarbidopa infusion is expected to maintain LD exposure to treat aPD patients within a narrow therapeutic window.",2021,"Foslevodopa/foscarbidopa infusion provides stable LD and CD exposures compared to oral LD/CD dosing with the average steady-state exposure ranging from 747-4660 ng/mL for the different groups. ","['PD patients', '28 adult male and female subjects at seven sites in the United States', ""patients with advanced Parkinson's disease (aPD""]","['Foslevodopa/foscarbidopa was administered via abdominal SC infusion', 'levodopa/carbidopa', 'levodopa (LD) and carbidopa (CD) pharmacokinetics (PK', 'Foslevodopa/foscarbidopa infusion', 'foslevodopa/foscarbidopa based on their oral daily LD intake', 'oral LD/CD', 'Levodopa and Carbidopa Exposure']","['Safety and tolerability', 'Serial plasma PK samples', 'low PK fluctuation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0576773', 'cui_str': 'Subcutaneous infusion'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0006982', 'cui_str': 'Carbidopa'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}]",28.0,0.0891054,"Foslevodopa/foscarbidopa infusion provides stable LD and CD exposures compared to oral LD/CD dosing with the average steady-state exposure ranging from 747-4660 ng/mL for the different groups. ","[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Rosebraugh', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Melina', 'Initials': 'M', 'LastName': 'Neenan', 'Affiliation': 'Drug Metabolism and Pharmacokinetics - Bioanalysis, AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Maurizio F', 'Initials': 'MF', 'LastName': 'Facheris', 'Affiliation': 'Neuroscience Development, AbbVie, North Chicago, IL, USA.'}]",Journal of Parkinson's disease,['10.3233/JPD-212813'] 2136,34358756,Disentangling the mediating role of modifying interpretation bias on emotional distress using a novel cognitive bias modification program.,"BACKGROUND Negative interpretation bias is a potential risk factor for emotional disorders. In this study, we tested a clinically inspired 4-session online Cognitive Bias Modification-Interpretation (CBM-I Clin ) program to modify negative interpretation biases. METHODS We randomized one hundred and twenty-one volunteer young adults (Mean age = 21.6 years, SD = 3.5; 85 % women) with varying levels of emotional distress to either an experimental or waitlist control group. Mediation analyses were used to disentangle the associations between the intervention, changes in interpretation biases (assessed by both a self-report and an experimental task), and changes in measures of cognitive vulnerability and symptoms of depression and anxiety. RESULTS The results showed that the CBM-I Clin could change negative interpretation biases. Also, it had a direct effect on the change in negative memory bias, an indirect effect on the change in depression symptoms via the change in interpretation bias, and both direct and indirect effects on the change in self-reported dysfunctional attitudes. LIMITATIONS The study included a non-clinical sample of participants and it did not control for some potential confounding factors (e.g., attentional disorders). Furthermore, participants' engagement during the sessions at home was not supervised. CONCLUSIONS The CBM-I Clin is a potential tool to prevent and intervene in emotional disorders in young adults and could complement other traditional CBM procedures or clinical interventions.",2021,The CBM-I Clin is a potential tool to prevent and intervene in emotional disorders in young adults and could complement other traditional CBM procedures or clinical interventions.,"['hundred and twenty-one volunteer young adults (Mean age = 21.6 years, SD = 3.5; 85 % women) with varying levels of emotional distress to either an experimental or waitlist control group', 'young adults', 'non-clinical sample of participants and it did not control for some potential confounding factors (e.g., attentional disorders']",['clinically inspired 4-session online Cognitive Bias Modification-Interpretation (CBM-I Clin ) program'],['cognitive vulnerability and symptoms of depression and anxiety'],"[{'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0459471', 'cui_str': 'Interpretation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",121.0,0.0752458,The CBM-I Clin is a potential tool to prevent and intervene in emotional disorders in young adults and could complement other traditional CBM procedures or clinical interventions.,"[{'ForeName': 'Inés', 'Initials': 'I', 'LastName': 'Nieto', 'Affiliation': 'Department of Clinical Psychology, School of Psychology, Complutense University of Madrid, Spain. Electronic address: inenieto@ucm.es.'}, {'ForeName': 'Carmelo', 'Initials': 'C', 'LastName': 'Vazquez', 'Affiliation': 'Department of Clinical Psychology, School of Psychology, Complutense University of Madrid, Spain.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2021.102459'] 2137,34358497,Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.,"BACKGROUND Simplified antiretroviral therapy (ART) regimens are desirable for people with HIV. We investigated the efficacy and safety of switching from triple ART to dual dolutegravir plus lamivudine therapy. METHODS DOLAM is a phase 4, randomised, open-label, non-inferiority trial, done at six HIV clinics in Catalonia, Spain. Adults with HIV-1 receiving a triple ART regimen, aged 18 years or older, with virological suppression, a CD4 nadir of at least 200 cells per μL, who were HBsAg-negative, and without previous viral failure or resistance mutations to study drugs were eligible. Participants underwent computer-generated randomisation, stratified by the class of the third drug, and were assigned (1:1) to switch to oral dolutegravir 50 mg and lamivudine 300 mg once daily or to continue triple ART for 48 weeks. The primary endpoint was the proportion of people with an HIV RNA value of at least 50 copies per mL at week 48 (US Food and Drug Administration snapshot algorithm, 8% non-inferiority margin). Both the primary and safety outcomes were evaluated in the intention-to-treat exposed population. The study is completed and was registered with EudraCT 201500027435. FINDINGS Between July 7, 2015, and Oct 31, 2018, 265 participants were randomly assigned to switch to dolutegravir plus lamivudine (n=131) or to maintain triple ART (n=134) and all received at least one dose. Nine (7%) participants in the dual therapy group and ten (7%) in the triple therapy group were excluded before 48 weeks, mostly due to treatment discontinuations or virological failure. Participants were predominantly male (116 [87%] of 134 in the triple ART group and 111 [85%] of 131 in the dolutegravir plus lamivudine group). The difference in the proportion of participants with HIV RNA values of at least 50 copies per mL at 48 weeks between the dual therapy group (three [2%] of 131) and triple therapy group (two [1%] of 134) was 0·8 percentage points (95% CI -3·3 to 5·2), showing non-inferiority of dolutegravir plus lamivudine dual therapy compared with triple ART. 73 (56%) of 131 participants allocated to dual therapy had 150 adverse effects, compared with 78 (58%) of 134 participants allocated to triple therapy who also had 150 adverse events (p=0·68). Drug discontinuation due to adverse effects occurred in four people in the triple therapy group and three people in the dual therapy group. INTERPRETATION Our findings show the efficacy and safety of dolutegravir plus lamivudine as a simplified therapy switch option for selected people with HIV with virological suppression on triple ART. FUNDING Instituto de Salud Carlos III, Red de Investigación en Sida, and ViiV Healthcare.",2021,"Drug discontinuation due to adverse effects occurred in four people in the triple therapy group and three people in the dual therapy group. ","['six HIV clinics in Catalonia, Spain', 'selected people with HIV with virological suppression on triple ART', 'people with HIV', 'Adults with HIV-1 receiving a triple ART regimen, aged 18 years or older, with virological suppression, a CD4 nadir of at least 200 cells per μL, who were HBsAg-negative, and without previous viral failure or resistance mutations to study drugs were eligible', 'Participants were predominantly male (116 [87%] of 134 in the triple ART group and 111 [85%] of 131 in the dolutegravir plus lamivudine group', '73 (56%) of 131 participants allocated to', 'Between July 7, 2015, and Oct 31, 2018, 265 participants', 'virologically suppressed adults with HIV at 48 weeks']","['dual therapy', 'dolutegravir plus lamivudine', 'oral dolutegravir 50 mg and lamivudine 300 mg once daily or to continue triple ART', 'dolutegravir plus lamivudine (n=131) or to maintain triple ART']","['efficacy and safety', 'Efficacy and safety', 'proportion of participants with HIV RNA values', 'proportion of people with an HIV RNA value', 'adverse effects']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0919711', 'cui_str': 'Hepatitis B surface antigen negative'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C3253985', 'cui_str': 'dolutegravir'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0209738', 'cui_str': 'Lamivudine'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3253985', 'cui_str': 'dolutegravir'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0209738', 'cui_str': 'Lamivudine'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3663830', 'cui_str': 'dolutegravir 50 MG'}, {'cui': 'C1166421', 'cui_str': 'Lamivudine 300 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",265.0,0.246874,"Drug discontinuation due to adverse effects occurred in four people in the triple therapy group and three people in the dual therapy group. ","[{'ForeName': 'Jhon', 'Initials': 'J', 'LastName': 'Rojas', 'Affiliation': ""Hospital d'Igualada, Barcelona, Spain.""}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'de Lazzari', 'Affiliation': 'Hospital Clínic-IDIBAPS, Barcelona, Spain.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Negredo', 'Affiliation': 'Hospital Germans Trias i Pujol, Badalona, Spain; Lluita Contra La Sida Foundation, Badalona, Spain; Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain.'}, {'ForeName': 'Pere', 'Initials': 'P', 'LastName': 'Domingo', 'Affiliation': 'Hospital de Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Tiraboschi', 'Affiliation': ""Hospital de Bellvitge, l'Hospitalet de Llobregat, Spain.""}, {'ForeName': 'Esteve', 'Initials': 'E', 'LastName': 'Ribera', 'Affiliation': ""Hospital Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Abdulghani', 'Affiliation': 'Hospital Arnau de Vilanova, Lleida, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Puig', 'Affiliation': 'Hospital Germans Trias i Pujol, Badalona, Spain; Lluita Contra La Sida Foundation, Badalona, Spain.'}, {'ForeName': 'Maria G', 'Initials': 'MG', 'LastName': 'Mateo', 'Affiliation': 'Hospital de Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Podzamczer', 'Affiliation': ""Hospital de Bellvitge, l'Hospitalet de Llobregat, Spain.""}, {'ForeName': 'Maria M', 'Initials': 'MM', 'LastName': 'Gutierrez', 'Affiliation': 'Hospital de Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Paredes', 'Affiliation': 'Hospital Germans Trias i Pujol, Badalona, Spain; Lluita Contra La Sida Foundation, Badalona, Spain; Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain; IrsiCaixa AIDS Research Institute, Badalona, Spain.'}, {'ForeName': 'Bonaventura', 'Initials': 'B', 'LastName': 'Clotet', 'Affiliation': 'Hospital Germans Trias i Pujol, Badalona, Spain; Lluita Contra La Sida Foundation, Badalona, Spain; Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain; IrsiCaixa AIDS Research Institute, Badalona, Spain.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Gatell', 'Affiliation': 'University of Barcelona, Barcelona, Spain; ViiV Healthcare, Brentford, UK.'}, {'ForeName': 'Jose L', 'Initials': 'JL', 'LastName': 'Blanco', 'Affiliation': 'Hospital Clínic-IDIBAPS, Barcelona, Spain; University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Martínez', 'Affiliation': 'Hospital Clínic-IDIBAPS, Barcelona, Spain; University of Barcelona, Barcelona, Spain. Electronic address: estebanm@clinic.cat.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The lancet. HIV,['10.1016/S2352-3018(21)00100-4'] 2138,34358272,Complementary treatment comparison for chronic pain management: A randomized longitudinal study.,"BACKGROUND In chronic pain, it seems that the effect of cognitive-behavioral therapy (CBT) is boosted when it is combined with hypnosis. The aim of this study was to assess the efficacy of self-hypnosis combined with self-care (i.e., a type of CBT) compared to music/self-care, self-care and psychoeducation/CBT and to evaluate their long-term effects. METHODS An open label randomized clinical trial enrolled patients with chronic pain and was carried out at the University Hospital of Liège (Belgium). Patients were randomized into four groups: self-hypnosis/self-care, music/self-care, self-care, psychoeducation/CBT (7 monthly sessions of 2 hours). Two follow-up sessions were delivered at 6- and 12-month. Levels of pain, fatigue intensity, anxiety, depression, insomnia severity, disability, health locus of control, mental and physical quality of life and attitudes (control, disability, harm, emotion, medical cure, medication, solicitude) towards pain were assessed before and after the treatments, and at follow-up. RESULTS 203 patients were randomized: 52 in self-hypnosis/self-care, 59 in music/self-care, 47 in self-care, and 45 in psychoeducation/CBT. No group effect was found. A significant time effect was showed. Directly after the treatment, all groups decreased in pain attitudes and physical quality of life. Perceived control increased. At 6-month, all patients kept their levels of physical quality of life and perceived control, and showed decrease in pain intensity, harm, emotion and medical cure. At 12-month, scores that had change previously remained ameliorated, a decrease in insomnia severity and an increase in internal locus of control were observed. CONCLUSIONS The present findings are encouraging as they display long-term beneficial effects of complementary biopsychosocial-based treatments in chronic pain. It seems that patients continued to apply the learnt strategies as improvements were observed one year after the treatments had ended.",2021,"At 6-month, all patients kept their levels of physical quality of life and perceived control, and showed decrease in pain intensity, harm, emotion and medical cure.","['chronic pain management', '203 patients were randomized: 52 in', 'patients with chronic pain and was carried out at the University Hospital of Liège (Belgium']","['self-hypnosis combined with self-care (i.e., a type of CBT', 'cognitive-behavioral therapy (CBT', 'self-hypnosis/self-care, 59 in music/self-care, 47 in self-care, and 45 in psychoeducation/CBT', 'self-hypnosis/self-care, music/self-care, self-care, psychoeducation/CBT', 'music/self-care, self-care and psychoeducation/CBT']","['pain attitudes and physical quality of life', 'internal locus of control', 'insomnia severity', 'physical quality of life and perceived control', 'Levels of pain, fatigue intensity, anxiety, depression, insomnia severity, disability, health locus of control, mental and physical quality of life and attitudes (control, disability, harm, emotion, medical cure, medication, solicitude) towards pain', 'pain intensity, harm, emotion and medical cure']","[{'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0023953', 'cui_str': 'Locus of Control'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",203.0,0.0143026,"At 6-month, all patients kept their levels of physical quality of life and perceived control, and showed decrease in pain intensity, harm, emotion and medical cure.","[{'ForeName': 'Aminata', 'Initials': 'A', 'LastName': 'Bicego', 'Affiliation': 'Sensation and Perception Research Group, GIGA Consciousness, University of Liège, Liège, Belgium.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Monseur', 'Affiliation': 'Public Health Department, Biostatistics, University of Liège, Liège, Belgium.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Collinet', 'Affiliation': 'Musicothérapie & Counselling, Boncelles, Belgium.'}, {'ForeName': 'Anne-Françoise', 'Initials': 'AF', 'LastName': 'Donneau', 'Affiliation': 'Public Health Department, Biostatistics, University of Liège, Liège, Belgium.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Fontaine', 'Affiliation': 'Interdisciplinary Algology Department, Hospital University of Liège, Liège, Belgium.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Libbrecht', 'Affiliation': 'Interdisciplinary Algology Department, Hospital University of Liège, Liège, Belgium.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Malaise', 'Affiliation': 'Interdisciplinary Algology Department, Hospital University of Liège, Liège, Belgium.'}, {'ForeName': 'Anne-Sophie', 'Initials': 'AS', 'LastName': 'Nyssen', 'Affiliation': 'Sensation and Perception Research Group, GIGA Consciousness, University of Liège, Liège, Belgium.'}, {'ForeName': 'Mélissa', 'Initials': 'M', 'LastName': 'Raaf', 'Affiliation': 'Interdisciplinary Algology Department, Hospital University of Liège, Liège, Belgium.'}, {'ForeName': 'Floriane', 'Initials': 'F', 'LastName': 'Rousseaux', 'Affiliation': 'Sensation and Perception Research Group, GIGA Consciousness, University of Liège, Liège, Belgium.'}, {'ForeName': 'Irène', 'Initials': 'I', 'LastName': 'Salamun', 'Affiliation': 'Interdisciplinary Algology Department, Hospital University of Liège, Liège, Belgium.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Staquet', 'Affiliation': 'Interdisciplinary Algology Department, Hospital University of Liège, Liège, Belgium.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Teuwis', 'Affiliation': 'Interdisciplinary Algology Department, Hospital University of Liège, Liège, Belgium.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Tomasella', 'Affiliation': 'Interdisciplinary Algology Department, Hospital University of Liège, Liège, Belgium.'}, {'ForeName': 'Marie-Elisabeth', 'Initials': 'ME', 'LastName': 'Faymonville', 'Affiliation': 'Sensation and Perception Research Group, GIGA Consciousness, University of Liège, Liège, Belgium.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Vanhaudenhuyse', 'Affiliation': 'Sensation and Perception Research Group, GIGA Consciousness, University of Liège, Liège, Belgium.'}]",PloS one,['10.1371/journal.pone.0256001'] 2139,34358109,Efficacy of an Anti-Cellulite Herbal Emgel: A Randomized Clinical Trial.,"Cellulite describes unsightly skin overlying subcutaneous fat around thighs and buttocks of post-pubescent females. A herbal 'emgel' containing volatile oils and extracts of A traditional Thai herbal compress was tested in a double-blind, placebo-controlled trial with 18 women aged 20-50 year with severe cellulite. Appearance of cellulite (primary outcome), thigh circumferences, skin firmness, and cutaneous blood flow (secondary outcomes) were assessed at baseline, 2, 4, 8 and 12 weeks with a 2-week follow-up. Herbal emgel applied onto the thigh skin twice daily reduced cellulite severity scores in every time point. The score was reduced from 13.4 ± 0.3 (baseline) to 12.1 ± 0.3 (week 2) and 9.9 ± 0.6 (week 12). All secondary outcomes improved with both placebo and herbal emgels suggesting that ingredients in the base-formulation might be responsible. Querying of participants, analysis of their diaries, and physical monthly inspections found no adverse events. The herbal emgel safely improved the appearance of cellulite, while the base emgel may play a role for other endpoints. Further studies on the active constituents and their mechanism of action are needed to further explore these factors.",2021,The score was reduced from 13.4 ± 0.3 (baseline) to 12.1 ± 0.3 (week 2) and 9.9 ± 0.6 (week 12).,"['post-pubescent females', '18 women aged 20-50 year with severe cellulite']","['Anti-Cellulite Herbal Emgel', 'placebo']","['adverse events', 'Appearance of cellulite (primary outcome), thigh circumferences, skin firmness, and cutaneous blood flow (secondary outcomes', 'cellulite severity scores']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0424624', 'cui_str': 'Fatty dimpling of skin'}]","[{'cui': 'C0424624', 'cui_str': 'Fatty dimpling of skin'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0720190', 'cui_str': 'Emgel'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0424624', 'cui_str': 'Fatty dimpling of skin'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}]",18.0,0.406274,The score was reduced from 13.4 ± 0.3 (baseline) to 12.1 ± 0.3 (week 2) and 9.9 ± 0.6 (week 12).,"[{'ForeName': 'Ngamrayu', 'Initials': 'N', 'LastName': 'Ngamdokmai', 'Affiliation': 'Centre of Excellence in Cannabis Research, Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmaceutical Sciences and Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok 65000, Thailand.'}, {'ForeName': 'Neti', 'Initials': 'N', 'LastName': 'Waranuch', 'Affiliation': 'Cosmetics and Natural Products Research Center and Center of Excellence for Innovation in Chemistry, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok 65000, Thailand.'}, {'ForeName': 'Krongkarn', 'Initials': 'K', 'LastName': 'Chootip', 'Affiliation': 'Department of Physiology, Faculty of Medical Sciences, Naresuan University, Phitsanulok 65000, Thailand.'}, {'ForeName': 'Katechan', 'Initials': 'K', 'LastName': 'Jampachaisri', 'Affiliation': 'Department of Mathematics, Faculty of Sciences, Naresuan University, Phitsanulok 65000, Thailand.'}, {'ForeName': 'C Norman', 'Initials': 'CN', 'LastName': 'Scholfield', 'Affiliation': 'Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok 65000, Thailand.'}, {'ForeName': 'Kornkanok', 'Initials': 'K', 'LastName': 'Ingkaninan', 'Affiliation': 'Centre of Excellence in Cannabis Research, Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmaceutical Sciences and Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok 65000, Thailand.'}]","Pharmaceuticals (Basel, Switzerland)",['10.3390/ph14070683'] 2140,34357912,"Prenatal Household Air Pollution Exposure, Cord Blood Mononuclear Cell Telomere Length and Age Four Blood Pressure: Evidence from a Ghanaian Pregnancy Cohort.","Associations between prenatal household air pollution exposure (HAP), newborn telomere length and early childhood blood pressure are unknown. Methods: Pregnant women were randomized to liquefied petroleum gas (LPG) stove, improved biomass stove or control (traditional, open fire cook stove). HAP was measured by personal carbon monoxide (CO) ( n = 97) and fine particulate matter (PM 2.5 ) ( n = 60). At birth, cord blood mononuclear cells (CBMCs) were collected for telomere length (TL) analyses. At child age four years, we measured resting blood pressure (BP) ( n = 97). We employed multivariable linear regression to determine associations between prenatal HAP and cookstove arm and assessed CBMC relative to TL separately. We then examined associations between CBMC TL and resting BP. Results: Higher prenatal PM 2.5 exposure was associated with reduced TL (β = -4.9% (95% CI -8.6, -0.4), p = 0.03, per 10 ug/m 3 increase in PM 2.5 ). Infants born to mothers randomized to the LPG cookstove had longer TL (β = 55.3% (95% CI 16.2, 109.6), p < 0.01)) compared with control. In all children, shorter TL was associated with higher systolic BP (SBP) (β = 0.35 mmHg (95% CI 0.001, 0.71), p = 0.05, per 10% decrease in TL). Increased prenatal HAP exposure is associated with shorter TL at birth. Shorter TL at birth is associated with higher age four BP, suggesting that TL at birth may be a biomarker of HAP-associated disease risk.",2021,"In all children, shorter TL was associated with higher systolic BP (SBP) (β = 0.35 mmHg (95% CI 0.001, 0.71), p = 0.05, per 10% decrease in TL).",['Pregnant women'],"['personal carbon monoxide (CO', 'liquefied petroleum gas (LPG) stove, improved biomass stove or control (traditional, open fire cook stove']","['prenatal household air pollution exposure (HAP), newborn telomere length and early childhood blood pressure', 'resting blood pressure (BP', 'HAP', 'Higher prenatal PM', 'reduced TL', 'CBMC TL and resting BP', 'At birth, cord blood mononuclear cells (CBMCs', 'Prenatal Household Air Pollution Exposure, Cord Blood Mononuclear Cell Telomere Length and Age Four Blood Pressure', 'TL', 'higher systolic BP (SBP']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]","[{'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0303763', 'cui_str': 'Liquefied petroleum gas'}, {'cui': 'C0336754', 'cui_str': 'Stove'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0005535', 'cui_str': 'Biomass'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0014007', 'cui_str': 'Dismissed from job'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}]","[{'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0001873', 'cui_str': 'Air pollution'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0599196', 'cui_str': 'Early childhood'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C1744681', 'cui_str': 'Congenital'}, {'cui': 'C0162371', 'cui_str': 'Cord blood'}, {'cui': 'C1294062', 'cui_str': 'Mononuclear cell count'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}]",,0.124107,"In all children, shorter TL was associated with higher systolic BP (SBP) (β = 0.35 mmHg (95% CI 0.001, 0.71), p = 0.05, per 10% decrease in TL).","[{'ForeName': 'Seyram', 'Initials': 'S', 'LastName': 'Kaali', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Darby', 'Initials': 'D', 'LastName': 'Jack', 'Affiliation': 'Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.'}, {'ForeName': 'Jones', 'Initials': 'J', 'LastName': 'Opoku-Mensah', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Bloomquist', 'Affiliation': 'Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Aanaro', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Ashlinn', 'Initials': 'A', 'LastName': 'Quinn', 'Affiliation': 'Fogarty International Centre, National Institute of Health, Bethesda, MD 20892, USA.'}, {'ForeName': 'Ellen Abrafi', 'Initials': 'EA', 'LastName': 'Boamah-Kaali', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Kinney', 'Affiliation': 'Department of Environmental Health, Boston University School of Public Health, Boston, MA 02118, USA.'}, {'ForeName': 'Mohammed Nuhu', 'Initials': 'MN', 'LastName': 'Mujtaba', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Oscar', 'Initials': 'O', 'LastName': 'Agyei', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Abena Konadu', 'Initials': 'AK', 'LastName': 'Yawson', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Osei-Owusu', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Delimini', 'Affiliation': 'Department of Biomedical Sciences, University of Health and Allied Sciences, Ho PMB 31, Volta Region, Ghana.'}, {'ForeName': 'Blair', 'Initials': 'B', 'LastName': 'Wylie', 'Affiliation': 'Beth Israel Deaconess Medical Centre, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Boston, MA 02215, USA.'}, {'ForeName': 'Kenneth Ayuurebobi', 'Initials': 'KA', 'LastName': 'Ae-Ngibise', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Baccarelli', 'Affiliation': 'Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.'}, {'ForeName': 'Seth', 'Initials': 'S', 'LastName': 'Owusu-Agyei', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Steven N', 'Initials': 'SN', 'LastName': 'Chillrud', 'Affiliation': 'Department, Lamont Doherty Earth Observatory at Columbia University, Palisades, NY 10964, USA.'}, {'ForeName': 'Kwaku Poku', 'Initials': 'KP', 'LastName': 'Asante', 'Affiliation': 'Kintampo Health Research Centre, Ghana Health Service, Kintampo P.O. Box 200, Bono East Region, Ghana.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.'}]",Toxics,['10.3390/toxics9070169'] 2141,34357880,Platelet-Rich Plasma: Optimal Use in Surgical Wounds.,"Activated platelets release a rich broth of growth factors involved in wound healing. One way to deliver activated platelets to wounds is in the form of platelet-rich plasma (PRP) harvested by centrifuging the patient's venous blood after activating the platelets with collagen or calcium chloride and/or autologous thrombin, then delicately removing the supernatant, called platelet-poor plasma (PPP). Platelet-rich plasma is usually injected into the lesion and/or applied topically, then sealed in or over the wound using a moisture-retentive dressing. Platelet-rich plasma (often with PPP) has been applied at different times, depths, and frequencies to chronic and acute wounds using various PRP doses and vehicles to achieve widely differing results. Meta-analyses have reported that PRP improved healing rates of open diabetic foot ulcers and venous ulcers and may reduce pain and surgical site infection (SSI) incidence in open and closed acute surgical wounds. However, inconsistency in study methods and outcome measures limited consistency of pain and SSI results. No consistent effect on healing or deep SSI rates was reported as a result of adding 1 intraoperative dose of PRP in the surgical site before closing elective foot and ankle surgery incisions of 250 patients as compared with 250 similar patients receiving the same procedure without PRP. After decades of research, ideal parameters of PRP delivery and use on each type of wound remain unclear for improving SSI, acute wound pain, and healing outcomes. This installment of the Evidence Corner reviews 2 surgical studies that may provide clues about optimal PRP use. One triple-blind randomized clinical trial (RCT) focused on irrigation of freshly closed carpal ligament surgical incisions with PRP as compared with PPP. Another non-blind RCT explored the effect of injecting PRP into open pilonidal sinus excisions 4 days and 12 days after surgery.",2021,No consistent effect on healing or deep SSI rates was reported as a result of adding 1 intraoperative dose of PRP in the surgical site before closing elective foot and ankle surgery incisions of 250 patients as compared with 250 similar patients receiving the same procedure without PRP.,[],"['Platelet-Rich Plasma', 'Platelet-rich plasma (often with PPP', 'PPP', 'PRP']","['healing or deep SSI rates', 'pain and surgical site infection (SSI) incidence', 'healing rates']",[],"[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0370219', 'cui_str': 'Platelet poor plasma'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",250.0,0.0127238,No consistent effect on healing or deep SSI rates was reported as a result of adding 1 intraoperative dose of PRP in the surgical site before closing elective foot and ankle surgery incisions of 250 patients as compared with 250 similar patients receiving the same procedure without PRP.,"[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Bolton', 'Affiliation': 'Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.'}]",Wounds : a compendium of clinical research and practice,[] 2142,34363386,Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial.,"AIMS The aim of this study is to compare the Hestia rule vs. the simplified Pulmonary Embolism Severity Index (sPESI) for triaging patients with acute pulmonary embolism (PE) for home treatment. METHODS AND RESULTS Normotensive patients with PE of 26 hospitals from France, Belgium, the Netherlands, and Switzerland were randomized to either triaging with Hestia or sPESI. They were designated for home treatment if the triaging tool was negative and if the physician-in-charge, taking into account the patient's opinion, did not consider that hospitalization was required. The main outcomes were the 30-day composite of recurrent venous thrombo-embolism, major bleeding or all-cause death (non-inferiority analysis with 2.5% absolute risk difference as margin), and the rate of patients discharged home within 24 h after randomization (NCT02811237). From January 2017 through July 2019, 1975 patients were included. In the per-protocol population, the primary outcome occurred in 3.82% (34/891) in the Hestia arm and 3.57% (32/896) in the sPESI arm (P = 0.004 for non-inferiority). In the intention-to-treat population, 38.4% of the Hestia patients (378/984) were treated at home vs. 36.6% (361/986) of the sPESI patients (P = 0.41 for superiority), with a 30-day composite outcome rate of 1.33% (5/375) and 1.11% (4/359), respectively. No recurrent or fatal PE occurred in either home treatment arm. CONCLUSIONS For triaging PE patients, the strategy based on the Hestia rule and the strategy based on sPESI had similar safety and effectiveness. With either tool complemented by the overruling of the physician-in-charge, more than a third of patients were treated at home with a low incidence of complications.",2021,"The main outcomes were the 30-day composite of recurrent venous thrombo-embolism, major bleeding or all-cause death (non-inferiority analysis with 2.5% absolute risk difference as margin), and the rate of patients discharged home within 24 h after randomization (NCT02811237).","['Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria', 'triaging patients with acute pulmonary embolism (PE) for home treatment', 'Normotensive patients with PE of 26 hospitals from France, Belgium, the Netherlands, and Switzerland', 'From January 2017 through July 2019, 1975 patients were included', 'triaging PE patients']","['simplified Pulmonary Embolism Severity Index (sPESI', 'triaging with Hestia or sPESI']","['rate of patients discharged home', '30-day composite outcome rate', '30-day composite of recurrent venous thrombo-embolism, major bleeding or all-cause death', 'recurrent or fatal PE']","[{'cui': 'C2882221', 'cui_str': 'Acute pulmonary embolism'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]","[{'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0013922', 'cui_str': 'Embolism'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}]",,0.10598,"The main outcomes were the 30-day composite of recurrent venous thrombo-embolism, major bleeding or all-cause death (non-inferiority analysis with 2.5% absolute risk difference as margin), and the rate of patients discharged home within 24 h after randomization (NCT02811237).","[{'ForeName': 'Pierre-Marie', 'Initials': 'PM', 'LastName': 'Roy', 'Affiliation': 'Emergency Department, CHU Angers, 4 rue Larrey, Angers, France, F-49000.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Penaloza', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Hugli', 'Affiliation': 'Emergency Department, University Hospital of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Frederikus A', 'Initials': 'FA', 'LastName': 'Klok', 'Affiliation': 'Department of Medicine - Thrombosis and Hemostasis, DTN, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Armelle', 'Initials': 'A', 'LastName': 'Arnoux', 'Affiliation': 'Computing, Statistics and Public Health & CIC1418, Hôpital Européen Georges Pompidou, APHP, Paris, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Elias', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Couturaud', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Luc-Marie', 'Initials': 'LM', 'LastName': 'Joly', 'Affiliation': 'Emergency Department, CHU Rouen, Normandy Univ, UNIROUEN, Rouen, France.'}, {'ForeName': 'Raphaëlle', 'Initials': 'R', 'LastName': 'Lopez', 'Affiliation': 'Emergency Department, Sart Tilman University Hospital, Liège, Belgium.'}, {'ForeName': 'Laura M', 'Initials': 'LM', 'LastName': 'Faber', 'Affiliation': 'Department of Internal Medicine, Rode Kruis Hospital, Beverwijk, DTN, the Netherlands.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Daoud-Elias', 'Affiliation': 'Department of Cardiology and Vascular Medicine, CH Sainte Musse - Toulon, Toulon, France.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Planquette', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Bokobza', 'Affiliation': 'Emergency Department, Hôpital Cochin, APHP, Paris, France.'}, {'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'Viglino', 'Affiliation': 'Emergency Department, CHU Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Jeannot', 'Initials': 'J', 'LastName': 'Schmidt', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Juchet', 'Affiliation': 'Emergency Department, CHU Toulouse, Toulouse, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Mahe', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Frits', 'Initials': 'F', 'LastName': 'Mulder', 'Affiliation': 'Department of Internal Medicine, Tergooi Hospital, Hilversum, the Netherlands.'}, {'ForeName': 'Magali', 'Initials': 'M', 'LastName': 'Bartiaux', 'Affiliation': 'Emergency Department, Saint-Pierre Hospital, Brussels, Belgium.'}, {'ForeName': 'Rosen', 'Initials': 'R', 'LastName': 'Cren', 'Affiliation': 'Emergency Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Moumneh', 'Affiliation': 'Emergency Department, CHU Angers, 4 rue Larrey, Angers, France, F-49000.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Quere', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Falvo', 'Affiliation': 'Vascular Medicine Department, CHU Dijon, Dijon, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Montaclair', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Delphine', 'Initials': 'D', 'LastName': 'Douillet', 'Affiliation': 'Emergency Department, CHU Angers, 4 rue Larrey, Angers, France, F-49000.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Steinier', 'Affiliation': 'Emergency Department, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.'}, {'ForeName': 'Stephan V', 'Initials': 'SV', 'LastName': 'Hendriks', 'Affiliation': 'Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Ygal', 'Initials': 'Y', 'LastName': 'Benhamou', 'Affiliation': 'Department of Internal Medicine, CHU Charles Nicolle, Rouen, France.'}, {'ForeName': 'Tali-Anne', 'Initials': 'TA', 'LastName': 'Szwebel', 'Affiliation': 'Department of Internal Medicine, Cochin Hospital, APHP, Paris, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Pernod', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Dublanchet', 'Affiliation': 'Emergency Department, CHU Clermont-Ferrand, University of Clermont Auvergne, Clermont-Ferrand, France.'}, {'ForeName': 'François-Xavier', 'Initials': 'FX', 'LastName': 'Lapebie', 'Affiliation': 'Vascular Medicine Department, CHU Toulouse, Toulouse, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Javaud', 'Affiliation': 'Emergency Department, CréAk, Louis Mourier Hospital, APHP, University of Paris, Colombes, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Ghuysen', 'Affiliation': 'Emergency Department, Sart Tilman University Hospital, Liège, Belgium.'}, {'ForeName': 'Mustapha', 'Initials': 'M', 'LastName': 'Sebbane', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Chatellier', 'Affiliation': 'Computing, Statistics and Public Health & CIC1418, Hôpital Européen Georges Pompidou, APHP, Paris, France.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Meyer', 'Affiliation': 'Department of Pneumology and Intensive Care, Hôpital Europeen Georges Pompidou, APHP, Paris, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Jimenez', 'Affiliation': 'Respiratory Department and Medicine Department, Ramon y Cajal Hospital IRYCIS Alcal de Henares University, Madrid, Spain.'}, {'ForeName': 'Menno V', 'Initials': 'MV', 'LastName': 'Huisman', 'Affiliation': 'Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Sanchez', 'Affiliation': 'F-CRIN, INNOVTE, Saint-Etienne, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European heart journal,['10.1093/eurheartj/ehab373'] 2143,34363198,Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation.,"The Pre-IVF Treatment with a GnRH Antagonist in Women with Endometriosis (PREGnant) Trial (clinicaltrials.gov no. NCT04173169) was designed to test the hypothesis that 60-day pre-treatment with an oral GnRH antagonist in women with documented endometriosis and planning an IVF cycle will result in a superior live birth rate to placebo. Eight hundred fourteen women are required from 4 national sites. To determine the feasibility of using an electronic medical record (EMR)-based strategy to recruit 204 participants at the Colorado site, we conducted a survey of women within the UCHealth system. Eligible women, identified using relevant ICD-10 codes, were invited to complete a 6-question survey to assess planned utilization of IVF, potential interest in participation, and whether delays in treatment due to COVID-19 would influence their decision to participate. Of 6354 age-eligible women with an endometriosis diagnosis, 421 had a concurrent infertility diagnosis. After eliminating duplicates, 212 were emailed a survey; 76 (36%) responded, 6 of whom reported no endometriosis diagnosis. Of the remaining 70, 29 (41%) were planning fertility treatment; only 19 planned IVF. All 19 expressed interest in participation. COVID-19 delays in treatment were not considered as a factor affecting participation by 8/19; the remaining 11 felt that it would ""somewhat"" affect their decision. None reported that they would not consider participation because of COVID-19. EMR-based recruitment for an endometriosis clinical trial is feasible although the overall yield of participants is low. Delays in treatment due to COVID-19 did not appear to overly influence potential recruitment.",2021,Delays in treatment due to COVID-19 did not appear to overly influence potential recruitment.,"['6354 age-eligible women with an endometriosis diagnosis, 421 had a concurrent infertility diagnosis', '204 participants at the Colorado site, we conducted a survey of women within the UCHealth system', 'Eligible women, identified using relevant ICD-10 codes', 'Eight hundred fourteen women are required from 4 national sites', 'Women with Endometriosis (PREGnant']","['electronic medical record (EMR)-based strategy', 'placebo', 'GnRH Antagonist', 'oral GnRH antagonist']",[],"[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}, {'cui': 'C0009399', 'cui_str': 'Colorado'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1137110', 'cui_str': 'ICD-10'}, {'cui': 'C0009219', 'cui_str': 'Coding'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1268855', 'cui_str': 'Gonadotropin releasing hormone receptor antagonist-containing product'}]","[{'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1268855', 'cui_str': 'Gonadotropin releasing hormone receptor antagonist-containing product'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]",[],,0.256733,Delays in treatment due to COVID-19 did not appear to overly influence potential recruitment.,"[{'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Pretzel', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Kuhn', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'Lubna', 'Initials': 'L', 'LastName': 'Pal', 'Affiliation': 'Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Polotsky', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'Hugh S', 'Initials': 'HS', 'LastName': 'Taylor', 'Affiliation': 'Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Heping', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Collaborative Center for Statistics in Science, Yale School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Robins', 'Affiliation': 'Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Steven L', 'Initials': 'SL', 'LastName': 'Young', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'Nanette', 'Initials': 'N', 'LastName': 'Santoro', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO, USA. Nanette.Santoro@cuanschutz.edu.'}]","Reproductive sciences (Thousand Oaks, Calif.)",['10.1007/s43032-021-00705-0'] 2144,34362787,Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial.,"BACKGROUND AND OBJECTIVES Low serum 25-hydroxyvitamin D (25[OH]D) concentration has been associated with higher levels of proteinuria and lower levels of eGFR in observational studies. In the Vitamin D and Type 2 Diabetes (D2d) study, we investigated the effect of vitamin D supplementation on kidney outcomes in a population with prediabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Overweight/obese adults with high risk for type 2 diabetes (defined by meeting two of three glycemic criteria for prediabetes) were randomized to vitamin D 3 4000 IU per day versus placebo. Median duration of treatment was 2.9 years (interquartile range 2.0-3.5 years). Kidney outcomes included ( 1 ) worsening in Kidney Disease: Improving Global Outcomes (KDIGO ) risk score (low, moderate, high, very high) on two consecutive follow-up visits after the baseline visit and ( 2 ) mean changes in eGFR and urine albumin-to-creatinine ratio (UACR). RESULTS Among 2166 participants (mean age 60 years, body mass index 32 kg/m 2 , serum 25(OH)D 28 ng/ml, eGFR 87 ml/min per 1.73 m 2 , UACR 11 mg/g, 79% with hypertension), 10% had moderate, high, or very high KDIGO risk score. Over a median follow-up of 2.9 years, there were 28 cases of KDIGO worsening in the vitamin D group and 30 in the placebo group (hazard ratio, 0.89; 95% confidence interval [95% CI], 0.52 to 1.52]). Mean difference in eGFR from baseline was -1.0 ml/min per 1.73 m 2 (95% CI, -1.3 to -0.7) in the vitamin D group and -0.1 ml/min per 1.73 m 2 (95% CI, -0.4 to 0.2) in the placebo group; between-group difference was -1.0 ml/min per 1.73 m 2 (95% CI, -1.4 to -0.6). Mean difference in UACR was 2.7 mg/g (95% CI, 1.2 to 4.3) in the vitamin D group and 2.0 (95% CI, 0.5 to 3.6) in the placebo group; between-group difference was 0.7 mg/g (95% CI, -1.5 to 2.9). CONCLUSIONS Among persons with prediabetes, who were not preselected on the basis of serum 25(OH)D concentration, vitamin D supplementation did not affect progression of KDIGO risk scores and did not have a meaningful effect on change in UACR or eGFR.",2021,"ml/min per 1.73 m 2 (95% CI, -1.3 to -0.7) in the vitamin D group and -0.1 ml/min per 1.73 m 2 (95% CI, -0.4 to 0.2) in the placebo group;","['a population with prediabetes', 'persons with prediabetes', 'Adults with Prediabetes', 'Overweight/obese adults with high risk for type 2 diabetes (defined by meeting two of three glycemic criteria for prediabetes', '2166 participants (mean age 60 years, body mass index 32 kg/m 2 , serum 25(OH)D 28 ng/ml, eGFR 87 ml/min per 1.73 m 2 ']","['vitamin D supplementation', 'vitamin D', 'vitamin D 3 4000 IU per day versus placebo', 'Vitamin D Supplementation', 'placebo']","['Kidney Function', 'Mean difference in UACR', 'Kidney outcomes included ( 1 ) worsening in Kidney Disease: Improving Global Outcomes (KDIGO ) risk score (low, moderate, high, very high', 'eGFR and urine albumin-to-creatinine ratio (UACR', 'kidney outcomes', 'progression of KDIGO risk scores', 'Median duration of treatment']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C3842327', 'cui_str': '4000'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0442804', 'cui_str': 'Very high'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0042038', 'cui_str': 'Albumin urine'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}]",,0.728146,"ml/min per 1.73 m 2 (95% CI, -1.3 to -0.7) in the vitamin D group and -0.1 ml/min per 1.73 m 2 (95% CI, -0.4 to 0.2) in the placebo group;","[{'ForeName': 'Sun H', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, California sunhkim@stanford.edu.'}, {'ForeName': 'Irwin G', 'Initials': 'IG', 'LastName': 'Brodsky', 'Affiliation': 'Endocrinology and Diabetes Center, Maine Medical Center, and Maine Medical Center Research Institute, Scarborough, Maine.'}, {'ForeName': 'Ranee', 'Initials': 'R', 'LastName': 'Chatterjee', 'Affiliation': 'Department of Medicine, Duke University, Durham, North Carolina.'}, {'ForeName': 'Sangeeta R', 'Initials': 'SR', 'LastName': 'Kashyap', 'Affiliation': 'Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Knowler', 'Affiliation': 'Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Liao', 'Affiliation': 'Division of Endocrinology and Metabolism, Northwell Health Lenox Hill Hospital, New York, New York.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Nelson', 'Affiliation': 'Tufts Clinical and Translational Science Institute, Biostatistics, Epidemiology, and Research Design Center, Tufts Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pratley', 'Affiliation': 'AdventHealth Translational Research Institute, Orlando, Florida.'}, {'ForeName': 'Neda', 'Initials': 'N', 'LastName': 'Rasouli', 'Affiliation': 'Division of Endocrinology, Metabolism and Diabetes, University of Colorado, School of Medicine and Veterans Affairs Eastern Colorado Health Care System, Aurora, Colorado.'}, {'ForeName': 'Ellen M', 'Initials': 'EM', 'LastName': 'Vickery', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Sarnak', 'Affiliation': 'Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Anastassios G', 'Initials': 'AG', 'LastName': 'Pittas', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, Massachusetts.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.00420121'] 2145,34362786,Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.,"BACKGROUND AND OBJECTIVES We evaluated the efficacy and cardiovascular safety of roxadustat versus placebo by analyzing data pooled from three phase 3 studies of roxadustat in patients with non-dialysis-dependent CKD and CKD-related anemia. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS In the three phase 3, double-blind studies of roxadustat versus placebo evaluating the treatment of CKD-related anemia in patients not requiring dialysis, the primary efficacy end point was mean change from baseline in hemoglobin averaged over weeks 28-52, regardless of rescue therapy. The primary cardiovascular safety end point was a composite measure of major adverse cardiovascular events (MACE; all-cause mortality, myocardial infarction, stroke). MACE plus (MACE+; MACE plus unstable angina and heart failure requiring hospitalization) and all-cause mortality were key secondary safety end points. These safety end points were adjudicated. RESULTS A total of 4277 patients with non-dialysis-dependent CKD were randomized (roxadustat, n =2391; placebo, n =1886). Baseline characteristics were comparable between groups; the mean (SD) hemoglobin was 9.1 (0.7) g/dl and mean eGFR was 20 (12) ml/min per 1.73 m 2 . Patients treated with roxadustat versus those treated with placebo showed a mean change from baseline in hemoglobin averaged over weeks 28-52, regardless of rescue therapy, of 1.9 versus 0.2 g/dl, a treatment difference of 1.7 (95% confidence interval [95% CI], 1.7 to 1.8). Roxadustat reduced the need for red blood cell transfusion in the first 52 weeks versus placebo (6.1 versus 20.4 per 100 patient-exposure years, respectively; hazard ratio [HR], 0.26; 95% CI, 0.21 to 0.32). There were no increased risks of MACE (HR, 1.10; 95% CI, 0.96 to 1.27), MACE+ (HR, 1.07; 95% CI, 0.94 to 1.21), all-cause mortality (HR, 1.08; 95% CI, 0.93 to 1.26), or individual MACE+ components in patients treated with roxadustat versus those treated with placebo. CONCLUSIONS Roxadustat was more effective than placebo at increasing hemoglobin in patients with non-dialysis-dependent CKD and anemia, while decreasing transfusion rate and being noninferior to placebo with respect to risk of MACE. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis, NCT01750190; Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS), NCT01887600; Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis, NCT02174627.",2021,"Roxadustat reduced the need for red blood cell transfusion in the first 52 weeks versus placebo (6.1 versus 20.4 per 100 patient-exposure years, respectively; hazard ratio [HR], 0.26; 95% CI, 0.21 to 0.32).","['Chronic Kidney Disease Patients', 'Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS', '4277 patients with non-dialysis-dependent CKD', 'Patients with Non-Dialysis-Dependent CKD', 'Patients With Chronic Kidney Disease (CKD', 'patients with non-dialysis-dependent CKD and CKD-related anemia']","['placebo', 'roxadustat versus placebo', 'MACE plus', 'FG-4592']","['efficacy and cardiovascular safety', 'mean (SD) hemoglobin', 'composite measure of major adverse cardiovascular events (MACE; all-cause mortality, myocardial infarction, stroke', 'risks of MACE', 'transfusion rate', 'hemoglobin', 'individual MACE+ components', 'Efficacy and Cardiovascular Safety', 'red blood cell transfusion']","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3713379', 'cui_str': 'FG-4592'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0086252', 'cui_str': 'Transfusion of red blood cells'}]",4277.0,0.455725,"Roxadustat reduced the need for red blood cell transfusion in the first 52 weeks versus placebo (6.1 versus 20.4 per 100 patient-exposure years, respectively; hazard ratio [HR], 0.26; 95% CI, 0.21 to 0.32).","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Provenzano', 'Affiliation': 'Department of Internal Medicine, Wayne State University, Detroit, Michigan provenzanorobert5@gmail.com.'}, {'ForeName': 'Lynda', 'Initials': 'L', 'LastName': 'Szczech', 'Affiliation': 'FibroGen, Inc., San Francisco, California.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Leong', 'Affiliation': 'FibroGen, Inc., San Francisco, California.'}, {'ForeName': 'Khalil G', 'Initials': 'KG', 'LastName': 'Saikali', 'Affiliation': 'FibroGen, Inc., San Francisco, California.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Zhong', 'Affiliation': 'FibroGen, Inc., San Francisco, California.'}, {'ForeName': 'Tyson T', 'Initials': 'TT', 'LastName': 'Lee', 'Affiliation': 'FibroGen, Inc., San Francisco, California.'}, {'ForeName': 'Dustin J', 'Initials': 'DJ', 'LastName': 'Little', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Houser', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Frison', 'Affiliation': 'AstraZeneca, Mölndal, Sweden.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Houghton', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Neff', 'Affiliation': 'FibroGen, Inc., San Francisco, California.'}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.16191020'] 2146,34362490,[The Auxiliary Diagnostic Value of Serum Adenosine Deaminase in Acute Leukemia at Clinical Test].,"OBJECTIVE To investigate the auxiliary diagnostic value of serum adenosine deaminase (ADA) in acute leukemia (AL) at clinical test. METHODS 123 AL patients hospitalized in Zhejiang hospital from November 2018 to March 2020 were enrolled as the observation group, and 98 healthy people in the same period were randomly enrolled as the control group. AL patients were divided into two groups: 77 acute myeloid leukemia (AML) patients for AML group and 46 acute lymphoblastic leukemia (ALL) patients for ALL group. The levels of adenosine deaminase (ADA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH) and homocysteine (Hcy) in serum of the patients were detected, and the correlation of ADA with these items was analyzed. Receiver operating characteristic curve (ROC) was used to analyze the clinical diagnostic value of ADA, Yoden index was used to confirm the best cut-off point. RESULTS The serum ADA level in AL patients was significant higher than that in control group (P < 0.05). The results of Pearson correlation analysis showed that there was a significant positive correlation of ADA with Hcy, ALT, AST, GGT, LDH in AML group (r = 0.47, r = 0.28, r = 0.37, r = 0.22, r = 0.55); and also there was a significant positive correlation of ADA with GGT in ALL group (r = 0.54). In AML group, the maximum area under ROC curve was 0.761 (P = 0.00), 95% confidence interval was 0.682-0.841, sensitivity was 54.50%, specificity was 98.90%, and the best cut-off point was 17.1 U/L. In ALL group, the maximum area under ROC curve was 0.785, 95% confidence interval was 0.694-0.877, sensitivity was 65.90%, specificity was 84.00%, and the best cut-off point was 13.45 U/L. CONCLUSION The detection of ADA in serum can be used as an auxiliary examination in patients with AL, which can provide a certain value for the diagnosis of the disease.",2021,The serum ADA level in AL patients was significant higher than that in control group (P < 0.05).,"['AL patients were divided into two groups: 77 acute myeloid leukemia (AML) patients for AML group and 46 acute lymphoblastic leukemia (ALL) patients for ALL group', 'acute leukemia (AL', '123 AL patients hospitalized in Zhejiang hospital from November 2018 to March 2020 were enrolled as the observation group, and 98 healthy people in the same period were randomly enrolled as the control group']","['serum adenosine deaminase (ADA', 'Serum Adenosine Deaminase']","['levels of adenosine deaminase (ADA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH) and homocysteine (Hcy', 'maximum area under ROC curve', 'serum ADA level']","[{'cui': 'C0085669', 'cui_str': 'Acute leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0001457', 'cui_str': 'Adenosine deaminase'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0001457', 'cui_str': 'Adenosine deaminase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0019878', 'cui_str': 'Homocysteine'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0427556', 'cui_str': 'Adenosine deaminase measurement'}]",123.0,0.0522978,The serum ADA level in AL patients was significant higher than that in control group (P < 0.05).,"[{'ForeName': 'Pei', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of Clinical Laboratory Examination, Zhejiang Hospital, Hangzhou 310000, Zhejiang Province, China.'}, {'ForeName': 'Chun-Mei', 'Initials': 'CM', 'LastName': 'Yang', 'Affiliation': 'Department of Clinical Laboratory Examination, Zhejiang Hospital, Hangzhou 310000, Zhejiang Province, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Ye', 'Affiliation': 'Department of Clinical Laboratory Examination, Zhejiang Hospital, Hangzhou 310000, Zhejiang Province, China.'}, {'ForeName': 'Shi-Lei', 'Initials': 'SL', 'LastName': 'Dong', 'Affiliation': 'Department of Clinical Laboratory Examination, Zhejiang Hospital, Hangzhou 310000, Zhejiang Province, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Laboratory Examination, Zhejiang Hospital, Hangzhou 310000, Zhejiang Province, China E-mail:850355968@qq.com.'}]",Zhongguo shi yan xue ye xue za zhi,['10.19746/j.cnki.issn.1009-2137.2021.04.015'] 2147,34362453,Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial.,"BACKGROUND This study assessed the safety and efficacy of intrathecal injection of umbilical cord tissue mesenchymal stem cells (UCT-MSC) in individuals with cerebral palsy (CP). The diffusion tensor imaging (DTI) was performed to evaluate the alterations in white-matter integrity. METHODS Participants (4-14 years old) with spastic CP were assigned in 1:1 ratio to receive either UCT-MSC or sham procedure. Single-dose (2 × 10 7 ) cells were administered in the experimental group. Small needle pricks to the lower back were performed in the sham-control arm. All individuals were sedated to prevent awareness. The primary endpoints were the mean changes in gross motor function measure (GMFM)-66 from baseline to 12 months after procedures. The mean changes in the modified Ashworth scale (MAS), pediatric evaluation of disability inventory (PEDI), and CP quality of life (CP-QoL) were also assessed. Secondary endpoints were the mean changes in fractional anisotropy (FA) and mean diffusivity (MD) of corticospinal tract (CST) and posterior thalamic radiation (PTR). RESULTS There were 36 participants in each group. The mean GMFM-66 scores after 12 months of intervention were significantly higher in the UCT-MSC group compared to baseline (10.65; 95%CI 5.39, 15.91) and control (β 8.07; 95%CI 1.62, 14.52; Cohen's d 0.92). The increase was also seen in total PEDI scores (vs baseline 8.53; 95%CI 4.98, 12.08; vs control: β 6.87; 95%CI 1.52, 12.21; Cohen's d 0.70). The mean change in MAS scores after 12 months of cell injection reduced compared to baseline (-1.0; 95%CI -1.31, -0.69) and control (β -0.72; 95%CI -1.18, -0.26; Cohen's d 0.76). Regarding CP-QoL, mean changes in domains including friends and family, participation in activities, and communication were higher than the control group with a large effect size. The DTI analysis in the experimental group showed that mean FA increased (CST 0.032; 95%CI 0.02, 0.03. PTR 0.024; 95%CI 0.020, 0.028) and MD decreased (CST -0.035 × 10 -3 ; 95%CI -0.04 × 10 -3 , -0.02 × 10 -3 . PTR -0.045 × 10 -3 ; 95%CI -0.05 × 10 -3 , -0.03 × 10 -3 ); compared to baseline. The mean changes were significantly higher than the control group. CONCLUSIONS The UCT-MSC transplantation was safe and may improve the clinical and imaging outcomes. TRIAL REGISTRATION The study was registered with ClinicalTrials.gov ( NCT03795974 ).",2021,"The mean GMFM-66 scores after 12 months of intervention were significantly higher in the UCT-MSC group compared to baseline (10.65; 95%CI 5.39, 15.91) and control (β 8.07; 95%CI 1.62, 14.52; Cohen's d 0.92).","['individuals with cerebral palsy (CP', 'Participants (4-14 years old) with spastic CP', '36 participants in each group', 'cerebral palsy']","['intrathecal injection of umbilical cord tissue mesenchymal stem cells', 'UCT-MSC', 'UCT-MSC or sham procedure', 'intrathecal injection of umbilical cord tissue mesenchymal stem cells (UCT-MSC', 'diffusion tensor imaging (DTI']","['friends and family, participation in activities, and communication', 'safety and efficacy', 'mean FA', 'mean GMFM-66 scores', 'MD', 'total PEDI scores', 'mean changes in fractional anisotropy (FA) and mean diffusivity (MD) of corticospinal tract (CST) and posterior thalamic radiation (PTR', 'modified Ashworth scale (MAS), pediatric evaluation of disability inventory (PEDI), and CP quality of life (CP-QoL', 'mean changes', 'mean change in MAS scores', 'mean changes in gross motor function measure (GMFM)-66']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0021896', 'cui_str': 'Intrathecal injection'}, {'cui': 'C0444089', 'cui_str': 'Umbilical cord tissue sample'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1537007', 'cui_str': 'Diffusion Tensor MRI'}]","[{'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}, {'cui': 'C0677549', 'cui_str': 'Gross motor functions'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0936236', 'cui_str': 'Corticospinal Tracts'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",36.0,0.784013,"The mean GMFM-66 scores after 12 months of intervention were significantly higher in the UCT-MSC group compared to baseline (10.65; 95%CI 5.39, 15.91) and control (β 8.07; 95%CI 1.62, 14.52; Cohen's d 0.92).","[{'ForeName': 'Man', 'Initials': 'M', 'LastName': 'Amanat', 'Affiliation': 'Department of Science and Research Branch, AJA University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Anahita', 'Initials': 'A', 'LastName': 'Majmaa', 'Affiliation': ""Pediatrics Center of Excellence, Department of Pediatric Neurology, Children's Medical Center, Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Morteza', 'Initials': 'M', 'LastName': 'Zarrabi', 'Affiliation': 'Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.'}, {'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Nouri', 'Affiliation': 'Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.'}, {'ForeName': 'Masood Ghahvechi', 'Initials': 'MG', 'LastName': 'Akbari', 'Affiliation': ""Pediatrics Center of Excellence, Department of Pediatric Neurology, Children's Medical Center, Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Ali Reza', 'Initials': 'AR', 'LastName': 'Moaiedi', 'Affiliation': 'Department of Pediatric Neurology, Clinical Research Development Center of Children Hospital, Hormozgan University of Medical Sciences, Bandar Abass, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Ghaemi', 'Affiliation': ""Pediatrics Center of Excellence, Department of Radiology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Zamani', 'Affiliation': ""Pediatrics Center of Excellence, Department of Radiology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Sharif', 'Initials': 'S', 'LastName': 'Najafi', 'Affiliation': 'Clinical Biomechanics and Ergonomics Research Center, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Reza Shervin', 'Initials': 'RS', 'LastName': 'Badv', 'Affiliation': ""Pediatrics Center of Excellence, Department of Pediatric Neurology, Children's Medical Center, Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Massoud', 'Initials': 'M', 'LastName': 'Vosough', 'Affiliation': 'Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.'}, {'ForeName': 'Amir Ali', 'Initials': 'AA', 'LastName': 'Hamidieh', 'Affiliation': ""Pediatrics Center of Excellence Pediatric Hematology, Oncology and Stem Cell Transplantation Department, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Salehi', 'Affiliation': 'Psychiatry and Psychology Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Montazerlotfelahi', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Ali Reza', 'Initials': 'AR', 'LastName': 'Tavasoli', 'Affiliation': ""Pediatrics Center of Excellence, Department of Pediatric Neurology, Children's Medical Center, Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Morteza', 'Initials': 'M', 'LastName': 'Heidari', 'Affiliation': ""Pediatrics Center of Excellence, Department of Pediatric Neurology, Children's Medical Center, Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Mohebi', 'Affiliation': 'Department of Pediatric Neurology, AJA University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Fatemi', 'Affiliation': 'Moser Center for Leukodystrophies, Kennedy Krieger Institute, Baltimore, MD, 21205, USA.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Garakani', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Mahmoud Reza', 'Initials': 'MR', 'LastName': 'Ashrafi', 'Affiliation': ""Pediatrics Center of Excellence, Department of Pediatric Neurology, Children's Medical Center, Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran. ashrafim@tums.ac.ir.""}]",Stem cell research & therapy,['10.1186/s13287-021-02513-4'] 2148,34362410,"Impact of a medico-pharmaceutical follow-up and an optimized communication between hospital and community on the readmission to the emergency department for an adverse drug event: URGEIM, study protocol for a randomized controlled trial.","BACKGROUND Adverse drug events (ADE) represent one of the main causes of admission to emergency department (ED). Their detection, documentation, and reporting are essential to avoid readmission. We hypothesize that a pharmacist-initiated multidisciplinary transition of care program combining ED pharmacist contribution and medications' data transfer between inpatient and outpatient caregivers will reduce emergency visits related to ADE METHOD/DESIGN: This is a prospective, open-label, randomized controlled trial. The primary aim of the study is 6-month ED readmission related to the same ADE. Three hundred forty-six adult patients with an ADE detected by a binomial pharmacist-physician will be recruited from the ED of an University Hospital and will be randomized in two groups: [1] experimental group (multidisciplinary transition of care program and medications' data transfer between inpatient and outpatient caregivers) and [2] control group (usual care). Patients will be followed up over a period of 6 months. Endpoints will be carried out blindly of the randomization arm. The primary endpoint is the rate of patients who had at least one readmission in the ED for the same reason at 6 months (data collected during a phone call with the patient and the general practitioner). Trials registered NCT03725046. DISCUSSION The trial results will have implications for the role of the clinical pharmacist in an emergency department. If successful, the intervention could be considered for implementation across other hospitals. TRIAL REGISTRATION ClinicalTrials.gov NCT03725046 . Registered on 30 October 2018.",2021,The primary endpoint is the rate of patients who had at least one readmission in the ED for the same reason at 6 months (data collected during a phone call with the patient and the general practitioner).,['Three hundred forty-six adult patients with an ADE detected by a binomial pharmacist-physician will be recruited from the ED of an University Hospital'],"[""experimental group (multidisciplinary transition of care program and medications' data transfer between inpatient and outpatient caregivers) and [2] control group (usual care""]",['rate of patients who had at least one readmission'],"[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C3266241', 'cui_str': 'Transition of care'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}]",346.0,0.192231,The primary endpoint is the rate of patients who had at least one readmission in the ED for the same reason at 6 months (data collected during a phone call with the patient and the general practitioner).,"[{'ForeName': 'Cyril', 'Initials': 'C', 'LastName': 'Breuker', 'Affiliation': 'CHU Montpellier, Clinical Pharmacy Departement, Univ. Montpellier, 34 295, Montpellier Cedex 5, France. c-breuker@chu-montpellier.fr.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Faucanié', 'Affiliation': 'CHU Montpellier, Clinical Reasearch and Epidemiology Unit (Departement Information Médicale), Univ. Montpellier, 34 295, Montpellier Cedex 5, France.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Laureau', 'Affiliation': 'CHU Montpellier, Clinical Pharmacy Departement, Univ. Montpellier, 34 295, Montpellier Cedex 5, France.'}, {'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'Perier', 'Affiliation': 'CHU Montpellier, Emergency Medicine Department, Univ. Montpellier, 34 295, Montpellier Cedex 5, France.'}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Pinzani', 'Affiliation': 'CHU Montpellier, Medical Pharmacology and Toxicology Department, Univ. Montpellier, 34 295, Montpellier Cedex 5, France.'}, {'ForeName': 'Grégory', 'Initials': 'G', 'LastName': 'Marin', 'Affiliation': 'CHU Montpellier, Clinical Reasearch and Epidemiology Unit (Departement Information Médicale), Univ. Montpellier, 34 295, Montpellier Cedex 5, France.'}, {'ForeName': 'Mustapha', 'Initials': 'M', 'LastName': 'Sebbane', 'Affiliation': 'CHU Montpellier, Emergency Medicine Department, Univ. Montpellier, 34 295, Montpellier Cedex 5, France.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Villiet', 'Affiliation': 'CHU Montpellier, Clinical Pharmacy Departement, Univ. Montpellier, 34 295, Montpellier Cedex 5, France.'}]",Trials,['10.1186/s13063-021-05501-4'] 2149,34366208,Do oropharyngeal throat packs prevent fluid ingestion during orthognathic surgery?,"The oropharyngeal throat pack is commonly used in oral and maxillofacial surgery despite debated evidence regarding its barrier function. The study objectives were to investigate whether the oropharyngeal pack reduces blood ingestion and to evaluate its relationship with postoperative nausea and vomiting (PONV) and throat pain. This was a single-center, parallel group, single-blind randomized controlled trial. Participants undergoing orthognathic surgery, age ≥16 years, were included in the study. After intubation and prior to surgery start, the treatment group received oropharyngeal packing; the control group received no packing. Outcome variables were the quality of gastric contents aspirated by nasogastric tube (bloody or not bloody), PONV, and throat pain (visual analog scale). Thirty patients (treatment n = 15; control n = 15) were randomized and analyzed. There was no difference between the groups in quality of gastric contents (P = 1.00) or incidence of PONV at 2 hours and 24 hours (P = 1.00). Throat pain incidence and severity at 2 hours were both higher in the treatment group, but this was not statistically significant (P = 0.128, P = 0.223). The results indicate that the oropharyngeal pack is not an effective barrier against blood ingestion. Oropharyngeal packs do not improve or worsen PONV, but may increase throat pain.",2021,There was no difference between the groups in quality of gastric contents (P = 1.00) or incidence of PONV at 2 hours and 24 hours (P = 1.00).,"['Thirty patients (treatment n = 15; control n = 15', 'Participants undergoing orthognathic surgery, age ≥16 years']",['oropharyngeal packing; the control group received no packing'],"['quality of gastric contents', 'quality of gastric contents aspirated by nasogastric tube (bloody or not bloody), PONV, and throat pain (visual analog scale', 'incidence of PONV', 'postoperative nausea and vomiting (PONV) and throat pain', 'throat pain', 'Throat pain incidence and severity', 'effective barrier against blood ingestion']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0185624', 'cui_str': 'Orthognathic Surgery'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0038352', 'cui_str': 'Gastric contents'}, {'cui': 'C0370199', 'cui_str': 'Specimen obtained by aspiration'}, {'cui': 'C0085678', 'cui_str': 'Nasogastric tube'}, {'cui': 'C0333275', 'cui_str': 'Hemorrhagic'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0242429', 'cui_str': 'Pain in throat'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]",15.0,0.194978,There was no difference between the groups in quality of gastric contents (P = 1.00) or incidence of PONV at 2 hours and 24 hours (P = 1.00).,"[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Powell', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Alabama at Birmingham, Birmingham, Alabama, USA. Electronic address: krugelk@uab.edu.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Amin', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Oral and Maxillofacial Surgery, School of Medicine, Emory University, Atlanta, Georgia, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Sesanto', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bryant', 'Affiliation': 'Department of Anesthesiology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Kukreja', 'Affiliation': 'Department of Anesthesiology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Waite', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}]",International journal of oral and maxillofacial surgery,['10.1016/j.ijom.2021.07.011'] 2150,34366204,Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support.,"INTRODUCTION Peer recovery specialist (PRS) support has been used to varying degrees in community substance use and mental health treatment for a number of years. Although there has been some evidence of positive PRS impacts on client outcomes, previous research has shown inconsistent findings and methodological shortcomings. Given the high prevalence of substance use disorders among people involved in the criminal justice system, and limited available treatment opportunities, PRS support could provide a cost-effective opportunity to promote positive client outcomes. Drug courts, with their focus on treatment and rehabilitation rather than punishment, are an ideal laboratory to test the impacts of PRS on substance use recurrence and recidivism. METHODS The present study is, to our knowledge, the first experimental test of the PRS model in a justice system setting. We implemented a pilot experiment in the Philadelphia Treatment Court, randomizing 76 drug court participants to be linked to a PRS or to services as usual, and analyzed client outcomes over a nine-month follow-up period. Most participants' drug of choice was marijuana. RESULTS The results showed a reduction in rearrests and improvement in drug court engagement, but no impact on substance use recurrence or treatment engagement. CONCLUSIONS The mixed findings suggest some promise for the PRS model in the drug court setting, but the need for further research with more diverse and higher-risk drug court populations.",2021,"The results showed a reduction in rearrests and improvement in drug court engagement, but no impact on substance use recurrence or treatment engagement. ",[],['Peer recovery specialist (PRS'],['rearrests and improvement in drug court engagement'],[],"[{'cui': 'C0087009', 'cui_str': 'Hospital specialist'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]",,0.0537999,"The results showed a reduction in rearrests and improvement in drug court engagement, but no impact on substance use recurrence or treatment engagement. ","[{'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Belenko', 'Affiliation': 'Temple University, United States of America. Electronic address: sbelenko@temple.edu.'}, {'ForeName': 'Archana Bodas', 'Initials': 'AB', 'LastName': 'LaPollo', 'Affiliation': 'Public Health Management Corporation, United States of America.'}, {'ForeName': 'Nili', 'Initials': 'N', 'LastName': 'Gesser', 'Affiliation': 'Temple University, United States of America.'}, {'ForeName': 'Doris', 'Initials': 'D', 'LastName': 'Weiland', 'Affiliation': 'Temple University, United States of America.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Perron', 'Affiliation': 'Temple University, United States of America.'}, {'ForeName': 'Ingrid Diane', 'Initials': 'ID', 'LastName': 'Johnson', 'Affiliation': 'University of Alaska Anchorage, United States of America.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2021.108581'] 2151,34366201,Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes.,"INTRODUCTION Patient engagement may play a key role in the success or failure of treatments for substance use disorder (SUD). This exploratory analysis of data from a large, multisite effectiveness trial (NCT01104805) sought to determine how patient engagement with a digital therapeutic for SUD delivered at clinics was associated with abstinence outcomes. METHODS The study evaluated engagement for 206 participants enrolled in a treatment program for SUDs related to cocaine, alcohol, cannabis, or other stimulants who were randomized to receive treatment as usual (TAU) or reduced TAU plus the digital Therapeutic Education System (TES) for 12 weeks. Participants were eligible for contingency management incentives for module completion (modules cover Community Reinforcement Approach topic areas) and negative urine drug screens. Analyses examined the association of module completion with end-of-treatment abstinence. RESULTS Participants completed a mean of 38.8 (range 0-72) TES modules over 12 weeks of treatment. Study completers (n = 157) completed a mean of 45.5 (range 9-72) TES modules, whereas study noncompleters (n = 49) completed a mean of 17.4 (range 0-45) TES modules. The study observed a strong positive correlation between TES engagement (i.e., total number of modules completed) and the probability of abstinence during weeks 9-12 of treatment among 157 study completers (OR = 1.11; 95% CI 1.08-1.14). Each module completed increased the odds of abstinence during weeks 9-12 by approximately 11% for study completers and 9% for the full sample. The study observed a similar, but weaker, association between engagement and abstinence among 49 patients who did not complete the study (OR = 1.02; 95% CI 0.98-1.07). CONCLUSIONS Greater engagement with a digital therapeutic for patients with SUD (i.e., number of modules completed over time) was strongly associated with the probability of abstinence in the last four weeks of treatment among those who completed the recommended 12-week treatment. TRIALS REGISTRATION ClinicalTrials.gov Identifier: NCT01104805.",2021,Each module completed increased the odds of abstinence during weeks 9-12 by approximately 11% for study completers and 9% for the full sample.,"['Study completers (n\u202f=\u202f157) completed a mean of 45.5 (range 9-72', 'Participants completed a mean of 38.8 (range 0-72', 'patients with SUD', 'Participants were eligible for contingency management incentives for module completion (modules cover Community Reinforcement Approach topic areas) and negative urine drug screens', '49 patients who did not complete the study (OR', '206 participants enrolled in a treatment program for SUDs related to cocaine, alcohol, cannabis, or other stimulants who were randomized to']",['receive treatment as usual (TAU) or reduced TAU plus the digital Therapeutic Education System (TES'],"['probability of abstinence', 'odds of abstinence']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0035007', 'cui_str': 'Psychological Reinforcement'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0202274', 'cui_str': 'Urine drug screening'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0002763', 'cui_str': 'Central stimulant'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}]",206.0,0.0818219,Each module completed increased the odds of abstinence during weeks 9-12 by approximately 11% for study completers and 9% for the full sample.,"[{'ForeName': 'Hilary F', 'Initials': 'HF', 'LastName': 'Luderer', 'Affiliation': 'Pear Therapeutics, Boston, MA, United States of America. Electronic address: hilary.luderer@peartherapeutics.com.'}, {'ForeName': 'Aimee N C', 'Initials': 'ANC', 'LastName': 'Campbell', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States of America; New York State Psychiatric Institute, New York, NY, United States of America.'}, {'ForeName': 'Edward V', 'Initials': 'EV', 'LastName': 'Nunes', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States of America; New York State Psychiatric Institute, New York, NY, United States of America.'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Enman', 'Affiliation': 'Pear Therapeutics, Boston, MA, United States of America.'}, {'ForeName': 'Xiaorui', 'Initials': 'X', 'LastName': 'Xiong', 'Affiliation': 'Pear Therapeutics, Boston, MA, United States of America.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Gerwien', 'Affiliation': 'Pear Therapeutics, Boston, MA, United States of America.'}, {'ForeName': 'Yuri A', 'Initials': 'YA', 'LastName': 'Maricich', 'Affiliation': 'Pear Therapeutics, Boston, MA, United States of America.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2021.108585'] 2152,34366180,Traditional Versus Digital Media-Based Hand Therapy After Distal Radius Fracture.,"PURPOSE Distal radius fractures (DRFs) are common injuries with a rising incidence. A substantial portion of the cost of care is attributable to therapy services. Our purpose was to evaluate the effectiveness of a self-directed hand therapy program guided by digital media compared with that of traditional therapy. METHODS We conducted a randomized controlled trial in patients aged 18 years or older who underwent open reduction and internal fixation of a DRF with volar plating. Subjects were randomized to traditional hand therapy using a 12-week protocol or an identical protocol presented in digital videos and performed at home. Disabilities of the Arm, Shoulder, and Hand (QuickDASH) scores were collected as the primary outcome at 2 weeks (baseline), 6 weeks, and 12 weeks or greater. Pain visual analog scale (VAS) scores, Veterans RAND 12-Item Health Survey (VR-12) scores, wrist and forearm range of motion, wrist circumference, and grip strength were recorded as secondary outcomes. RESULTS Fifty-one patients were enrolled. Forty-nine patients were included in the analysis-21 in the digital media group and 28 in the traditional group. Both groups demonstrated significant improvements in QuickDASH scores between baseline and 12-week or greater time points. The QuickDASH scores in the digital media group were slightly more improved than those in the traditional group at the 6-week and 12-week or greater time points; however, these differences were not statistically significant. Pain VAS and VR-12 scores were comparable between group differences at each time point. CONCLUSIONS Our digital media program was at least as effective as traditional therapy for patients undergoing volar plating of DRF. These results may help inform the design of future trials investigating the effectiveness of digital media-based hand therapy programs. TYPE OF STUDY/LEVEL OF EVIDENCE Therapeutic II.",2021,"The QuickDASH scores in the digital media group were slightly more improved than those in the traditional group at the 6-week and 12-week or greater time points; however, these differences were not statistically significant.","['Forty-nine patients were included in the analysis-21 in the digital media group and 28 in the traditional group', 'Fifty-one patients were enrolled', 'patients undergoing volar plating of DRF', 'patients aged 18 years or older who underwent open reduction and internal fixation of a DRF with volar plating']","['traditional hand therapy using a 12-week protocol or an identical protocol presented in digital videos and performed at home', 'Traditional Versus Digital Media-Based Hand Therapy']","['Pain visual analog scale (VAS) scores, Veterans RAND 12-Item Health Survey (VR-12) scores, wrist and forearm range of motion, wrist circumference, and grip strength', 'Pain VAS and VR-12 scores', 'QuickDASH scores', 'Disabilities of the Arm, Shoulder, and Hand (QuickDASH) scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0443349', 'cui_str': 'Volar'}, {'cui': 'C0407295', 'cui_str': 'Fixation of fracture using plate'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0185373', 'cui_str': 'Open reduction of fracture'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0729315', 'cui_str': 'Hand therapy'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}]",51.0,0.0242891,"The QuickDASH scores in the digital media group were slightly more improved than those in the traditional group at the 6-week and 12-week or greater time points; however, these differences were not statistically significant.","[{'ForeName': 'Taylor R', 'Initials': 'TR', 'LastName': 'Lara', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Ryland P', 'Initials': 'RP', 'LastName': 'Kagan', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Shannon L', 'Initials': 'SL', 'LastName': 'Hiratzka', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Austin R', 'Initials': 'AR', 'LastName': 'Thompson', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Omar F', 'Initials': 'OF', 'LastName': 'Nazir', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Adam J', 'Initials': 'AJ', 'LastName': 'Mirarchi', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, OR. Electronic address: mirarchi@ohsu.edu.'}]",The Journal of hand surgery,['10.1016/j.jhsa.2021.06.018'] 2153,34365978,"Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study.","BACKGROUND Berberine and Bifidobacterium have been reported to improve glucose tolerance in people with hyperglycemia or other metabolic disorders. This study aimed to assess the hypoglycemic effect and the regulation of the gut microbiota caused by berberine and Bifidobacterium and the possible additive benefits of their combination. METHODS This was an 18-week, multi-center, randomized, double-blind, parallel-controlled study of patients newly diagnosed with hyperglycemia. After a 2-week run-in period, 300 participants were randomly assigned to the following four groups for 16 weeks of treatment: berberine (Be), Bifidobacterium (Bi), berberine and Bifidobacterium (BB), and placebo group. The primary efficacy endpoint was the absolute value of fasting plasma glucose (FPG) compared with baseline after 16 weeks of treatment. RESULTS Between October 2015 and April 2018, a total of 297 participants were included in the primary analysis. Significant reductions of FPG were observed in the Be and BB groups compared with the placebo group, with a least square (LS) mean difference of - 0.50, 95% CI [- 0.85, - 0.15] mmol/L, and - 0.55, 95% CI [- 0.91, - 0.20] mmol/L, respectively. The Be and BB groups also showed significant reductions in 2-h postprandial plasma glucose. A pronounced decrease in HbA1c occurred in the BB group compared to the placebo group. Moreover, compared with the Bi and placebo groups, the Be and BB groups had more changes in the gut microbiota from the baseline. CONCLUSIONS Berberine could regulate the structure and function of the human gut microbiota, and Bifidobacterium has the potential to enhance the hypoglycemic effect of berberine. These findings provide new insights into the hypoglycemic potential of berberine and Bifidobacterium. TRIAL REGISTRATION ClinicalTrials.gov , NCT03330184. Retrospectively registered on 18 October 2017.",2021,"Significant reductions of FPG were observed in the Be and BB groups compared with the placebo group, with a least square (LS) mean difference of - 0.50, 95% CI [- 0.85, - 0.15] mmol/L, and - 0.55, 95% CI [- 0.91, - 0.20] mmol/L, respectively.","['patients newly diagnosed with hyperglycemia', 'people with hyperglycemia or other metabolic disorders', '300 participants', 'Between October 2015 and April 2018, a total of 297 participants were included in the primary analysis']","['placebo', 'berberine (Be), Bifidobacterium (Bi), berberine and Bifidobacterium (BB), and placebo', 'Bifidobacterium and berberine']","['gut microbiota', 'hypoglycemic effect', '2-h postprandial plasma glucose', 'glucose tolerance', 'FPG', 'absolute value of fasting plasma glucose (FPG', 'HbA1c']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0268329', 'cui_str': 'Other disorders of metabolism'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0005117', 'cui_str': 'Berberine'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}]","[{'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C2936720', 'cui_str': 'Hypoglycemic Effects'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",300.0,0.738204,"Significant reductions of FPG were observed in the Be and BB groups compared with the placebo group, with a least square (LS) mean difference of - 0.50, 95% CI [- 0.85, - 0.15] mmol/L, and - 0.55, 95% CI [- 0.91, - 0.20] mmol/L, respectively.","[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Ming', 'Affiliation': ""Endocrinology Research Center, Department of Endocrinology and Metabolism, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.""}, {'ForeName': 'Xinwen', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ""Endocrinology Research Center, Department of Endocrinology and Metabolism, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.""}, {'ForeName': 'Xiaoqiang', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Aimigene Institute, Shenzhen, 518063, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Endocrinology Research Center, Department of Endocrinology and Metabolism, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.""}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Ding', 'Affiliation': 'Department of General Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.'}, {'ForeName': 'Zhifeng', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Aimigene Institute, Shenzhen, 518063, China.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Xie', 'Affiliation': ""Department of Endocrinology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Sheli', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': ""Department of Endocrinology, Affiliated Hospital of Yan'an University, Yan'an, China.""}, {'ForeName': 'Wenjuan', 'Initials': 'W', 'LastName': 'Yang', 'Affiliation': ""The Fifth Department of Internal Medicine, Shaanxi Aerospace Hospital, Xi'an, China.""}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Luo', 'Affiliation': ""Genertec Universal Xi'an Aero-Engine Hospital, Xi'an, China.""}, {'ForeName': 'Qingzhen', 'Initials': 'Q', 'LastName': 'He', 'Affiliation': ""Department of Endocrinology, Xi'an High-Tech Hospital, Xi'an, China.""}, {'ForeName': 'Yafang', 'Initials': 'Y', 'LastName': 'Du', 'Affiliation': ""Department of Endocrinology, Chang'an Hospital, Xi'an, China.""}, {'ForeName': 'Zhufang', 'Initials': 'Z', 'LastName': 'Tian', 'Affiliation': ""Department of Endocrinology, Xi'an Central Hospital, Xi'an, China.""}, {'ForeName': 'Xiling', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': ""Department of Endocrinology, Yan'an People's Hospital, Yan'an, China.""}, {'ForeName': 'Kaiyan', 'Initials': 'K', 'LastName': 'Ma', 'Affiliation': 'Department of Endocrinology, Shangluo Central Hospital, Shangluo, China.'}, {'ForeName': 'Yujie', 'Initials': 'Y', 'LastName': 'Fang', 'Affiliation': ""Endocrinology Research Center, Department of Endocrinology and Metabolism, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.""}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': ""Department of Health Statistics, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Jiajun', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Endocrinology and Metabolism, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China. jjzhao@sdu.edu.cn.'}, {'ForeName': 'Xiaokai', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Aimigene Institute, Shenzhen, 518063, China. wangxiaokai@aimigene.com.'}, {'ForeName': 'Qiuhe', 'Initials': 'Q', 'LastName': 'Ji', 'Affiliation': ""Endocrinology Research Center, Department of Endocrinology and Metabolism, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. qiuheji@hotmail.com.""}]",Genome medicine,['10.1186/s13073-021-00942-7'] 2154,34365971,Factors influencing the detection of treatable epileptogenic lesions on MRI. A randomized prospective study.,"BACKGROUND To prospectively analyze factors associated with detecting epileptogenic lesions on MRI within the work-sharing process of neurologists, epileptologists, radiologists and neuroradiologists. METHODS We assembled four sets of six MRI scans, each set representing five typical epileptogenic lesions (hippocampal sclerosis or limbic encephalitis; focal cortical dysplasias; periventricular nodular or other heterotopias; long-term epilepsy associated tumors; gliotic scar, hemosiderin or cavernoma), and non - lesional epilepsy. At professional conferences, we invited neurologists, epileptologists, radiologists, and neuroradiologists to read two out of four MRI sets, one of which was presented with a clinical focus hypothesis. Participants were randomly assigned to MRI sets. Effects of examiners' specialty, duration of training and professional experience on detection rate of epileptogenic lesions were investigated. RESULTS Fourty-eight neurologists, 22 epileptologists, 20 radiologists and 21 neuroradiologists read 1323 MRI scans. Overall, 613 of 1101 (55.7%) epileptogenic lesions were detected. Long-term epilepsy associated tumors (182/221, 82.4%) were found more frequently than gliotic scar, hemosiderin or cavernoma (157/220, 71.4%), hippocampal sclerosis or limbic encephalitis (141/220, 64.1%), nodular heterotopia (68/220, 30.9%) and focal cortical dysplasias (65/220, 29.5%, p < 0.001). Provision of a focus hypothesis improved the detection of hippocampal sclerosis or limbic encephalitis (86/110, 78.2% vs 55/110, 50%, p < 0.001) and focal cortical dysplasias (40/110, 36.4% vs 25/110, 22.7%, p = 0.037). Neuroradiologists and epileptologists were more likely than radiologists and neurologists to be amongst the most successful readers. In multivariable analysis, type of epileptogenic lesion, specialty of MRI reader, and provision of focus hypothesis predicted correct identification of epileptogenic lesions. CONCLUSIONS Epileptogenic lesions are often not recognized on MRI even by expert readers. Their detection can be improved by providing a focus hypothesis. These results stress the need for training in the MRI characteristics of epilepsy - specific pathology, and, most importantly, interdisciplinary communication between neurologists/epileptologists and (neuro)radiologists to improve detection of epileptogenic lesions.",2021,Neuroradiologists and epileptologists were more likely than radiologists and neurologists to be amongst the most successful readers.,"['typical epileptogenic lesions (hippocampal sclerosis or limbic encephalitis; focal cortical dysplasias; periventricular nodular or other heterotopias; long-term epilepsy associated tumors; gliotic scar, hemosiderin or cavernoma), and non - lesional epilepsy']",[],"['hippocampal sclerosis or limbic encephalitis', 'focal cortical dysplasias', 'epileptogenic lesions', 'detection of hippocampal sclerosis or limbic encephalitis', 'gliotic scar, hemosiderin or cavernoma', 'nodular heterotopia']","[{'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C1504404', 'cui_str': 'Hippocampal sclerosis'}, {'cui': 'C0338430', 'cui_str': 'Limbic encephalitis'}, {'cui': 'C2938983', 'cui_str': 'Focal cortical dysplasia'}, {'cui': 'C0205297', 'cui_str': 'Nodular'}, {'cui': 'C0008519', 'cui_str': 'Ectopic tissue'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0019113', 'cui_str': 'Hemosiderin'}, {'cui': 'C0018920', 'cui_str': 'Cavernous hemangioma'}]",[],"[{'cui': 'C1504404', 'cui_str': 'Hippocampal sclerosis'}, {'cui': 'C0338430', 'cui_str': 'Limbic encephalitis'}, {'cui': 'C2938983', 'cui_str': 'Focal cortical dysplasia'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0019113', 'cui_str': 'Hemosiderin'}, {'cui': 'C0018920', 'cui_str': 'Cavernous hemangioma'}, {'cui': 'C0431378', 'cui_str': 'Nodular heterotopia'}]",,0.0868612,Neuroradiologists and epileptologists were more likely than radiologists and neurologists to be amongst the most successful readers.,"[{'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Wehner', 'Affiliation': 'Ruhr - Epileptology, Department of Neurology, University Hospital Knappschafts-krankenhaus, Ruhr - University Bochum, In der Schornau 23 - 25, 44892, Bochum, Germany.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Weckesser', 'Affiliation': 'Ruhr - Epileptology, Department of Neurology, University Hospital Knappschafts-krankenhaus, Ruhr - University Bochum, In der Schornau 23 - 25, 44892, Bochum, Germany.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Schulz', 'Affiliation': 'Ruhr - Epileptology, Department of Neurology, University Hospital Knappschafts-krankenhaus, Ruhr - University Bochum, In der Schornau 23 - 25, 44892, Bochum, Germany.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Kowoll', 'Affiliation': 'Department of Neuroradiology, University Hospital Knappschaftskrankenhaus, Ruhr - University Bochum, In der Schornau 23 - 25, 44892, Bochum, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Fischer', 'Affiliation': 'Department of Neuroradiology, University Hospital Knappschaftskrankenhaus, Ruhr - University Bochum, In der Schornau 23 - 25, 44892, Bochum, Germany.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Bosch', 'Affiliation': 'Ruhr - Epileptology, Department of Neurology, University Hospital Knappschafts-krankenhaus, Ruhr - University Bochum, In der Schornau 23 - 25, 44892, Bochum, Germany.'}, {'ForeName': 'Leonie', 'Initials': 'L', 'LastName': 'Weinhold', 'Affiliation': 'Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg Campus 1, Gebäude 11, 53127, Bonn, Germany.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Fimmers', 'Affiliation': 'Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg Campus 1, Gebäude 11, 53127, Bonn, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Schmid', 'Affiliation': 'Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg Campus 1, Gebäude 11, 53127, Bonn, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Wellmer', 'Affiliation': 'Ruhr - Epileptology, Department of Neurology, University Hospital Knappschafts-krankenhaus, Ruhr - University Bochum, In der Schornau 23 - 25, 44892, Bochum, Germany. joerg.wellmer@kk-bochum.de.'}]",Neurological research and practice,['10.1186/s42466-021-00142-z'] 2155,34365959,Prefrontal Cortex Transcranial Direct Current Stimulation Treatment in Alcohol Dependence Syndrome (PreCoTTA): Study Protocol for a Double-Blind Randomized Sham-Controlled Trial.,"BACKGROUND Alcohol dependence is a significant public health problem, contributing to the global health burden. Due to its immense socio-economic burden, various psychosocial, psychological, and pharmacological approaches have attempted to alter the behaviour of the patient misusing or abusing alcohol, but their efficacy is modest at best. Therefore, there is a search for newer treatment approaches, including noninvasive brain stimulation in the management of alcohol dependence. We plan to study the efficacy of Prefrontal Cortex Transcranial direct current stimulation Treatment in Alcohol dependence syndrome (PreCoTTA). METHODS Two hundred twenty-five male patients with alcohol dependence syndrome will be randomized into the three study arms (2 active, left dorsolateral prefrontal cortex and left orbitofrontal cortex, and 1 sham) to receive a total of 14 tDCS sessions (10 continuous and 4 booster sessions). Data will be collected from them at five different time points on clinical, neuropsychological and biochemical parameters. In addition, 225 healthy age and education matched controls will be administered the neuropsychological test battery at baseline for comparison with the patient group. DISCUSSION The proposed study aims to explore the use of non-invasive brain stimulation; tDCS as a treatment alternative. We also aim to overcome the methodological gaps of limited sample sizes, fewer tDCS intervention sessions, lack of long term follow ups to measure the sustainability of gains and lack comprehensive measures to track changes in functioning and abstinence after tDCS intervention. The main outcomes include clinical (reduction in cue-induced craving, time to first drink and QFI); neuropsychological (risk-taking, impulsivity, and other neuropsychological domains) and biochemical markers (BDNF, leptin and adiponectin). The findings of the study will have translational value as it may help to improve the clinician's ability to effectively manage craving in patients with alcohol dependence syndrome. Furthermore, we will have a better understanding of the neuropsychological and biochemical effects of non-invasive brain stimulation techniques which are of interest in the comprehensive treatment of addiction disorders. TRIAL REGISTRATION The study has been registered with the Clinical Trials Registry-India (CTRI/2020/09/027582) on September 03rd 2020.",2021,"The main outcomes include clinical (reduction in cue-induced craving, time to first drink and QFI); neuropsychological (risk-taking, impulsivity, and other neuropsychological domains) and biochemical markers (BDNF, leptin and adiponectin).","['Alcohol Dependence Syndrome (PreCoTTA', 'patients with alcohol dependence syndrome', '225 healthy age and education matched controls', 'Two hundred twenty-five male patients with alcohol dependence syndrome', 'Alcohol dependence syndrome (PreCoTTA']","['Prefrontal Cortex Transcranial Direct Current Stimulation Treatment', 'Prefrontal Cortex Transcranial direct current stimulation Treatment']","['clinical (reduction in cue-induced craving, time to first drink and QFI); neuropsychological (risk-taking, impulsivity, and other neuropsychological domains) and biochemical markers (BDNF, leptin and adiponectin']","[{'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517652', 'cui_str': '225'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}]",225.0,0.088335,"The main outcomes include clinical (reduction in cue-induced craving, time to first drink and QFI); neuropsychological (risk-taking, impulsivity, and other neuropsychological domains) and biochemical markers (BDNF, leptin and adiponectin).","[{'ForeName': 'Anagha S', 'Initials': 'AS', 'LastName': 'Deshmukh', 'Affiliation': 'Department of Clinical Psychology, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, Karnataka - 576104. India.'}, {'ForeName': 'Samir Kumar', 'Initials': 'SK', 'LastName': 'Praharaj', 'Affiliation': 'Department of Psychiatry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka - 576104. India.'}, {'ForeName': 'Shweta', 'Initials': 'S', 'LastName': 'Rai', 'Affiliation': 'Department of Clinical Psychology, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, Karnataka - 576104. India.'}, {'ForeName': 'Asha', 'Initials': 'A', 'LastName': 'Kamath', 'Affiliation': 'Department of Data Science, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka - 576104. India.'}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Upadhya', 'Affiliation': 'Department of Anatomy, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka - 576104. India.'}]",Reviews on recent clinical trials,['10.2174/1574887116666210806091448'] 2156,34365843,In vivo performance of decellularized tracheal grafts in the reconstruction of long length tracheal defects: Experimental study.,"BACKGROUND The repair of long-segment tracheal lesions remains an important challenge. Nowdays no predictable and dependable substitute has been found. Decellularized tracheal scaffolds have shown to be a promising graft for tracheal transplantation, since it is non-immunogenic. OBJECTIVE Evaluate in vivo decellularized tracheal allografts performance to replace long tracheal segment. METHODS Forty-five swines underwent surgery as follows: Fifteen trachea donors and 30 receptors of decellularized trachea allografts. The receptors were randomly divided in five groups ( n  = 6). In groups I and II, donor trachea segment was decellularized by 15 cycles with sodium deoxycholate and deoxyribonuclease, in group II, the allograft was reinforced with external surgical steel wire. Groups, III, IV, and V decellularization was reduced to seven cycles, supplemented with cryopreservation in group IV and with glutaraldehyde in group V. A 10 rings segment was excised from the receptor swine and the decellularized trachea graft was implanted to re-establish trachea continuity. RESULTS Both decellularization cycles caused decreased stiffness. All trachea receptors underwent euthanasia before the third post-implant week due to severe dyspnea and trachea graft stenosis, necrosis, edema, inflammation, hemorrhage, and granulation tissue formation in anastomotic sites. Histologically all showed total loss of epithelium, separation of collagen fibers, and alterations in staining. CONCLUSIONS Both decellularization techniques severely damaged the structure of the trachea and the extracellular matrix of the cartilage, resulting in a no functional graft, in spite of the use of surgical wire, cryopreservation or glutaraldehyde treatment. An important drawback was the formation of fibrotic stenosis in both anastomosis.",2021,Both decellularization cycles caused decreased stiffness.,"['Forty-five swines underwent surgery as follows', 'Fifteen trachea donors and 30 receptors of decellularized trachea allografts']","['glutaraldehyde', 'sodium deoxycholate and deoxyribonuclease', 'decellularized tracheal grafts']","['total loss of epithelium, separation of collagen fibers, and alterations in staining', 'severe dyspnea and trachea graft stenosis, necrosis, edema, inflammation, hemorrhage, and granulation tissue formation']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0039005', 'cui_str': 'Suidae'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0040578', 'cui_str': 'Tracheal structure'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}]","[{'cui': 'C0017814', 'cui_str': 'Glutaral'}, {'cui': 'C0037500', 'cui_str': 'Sodium Deoxycholate'}, {'cui': 'C0011522', 'cui_str': 'Deoxyribonucleases'}, {'cui': 'C2945595', 'cui_str': 'Tracheal'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0014609', 'cui_str': 'Epithelium'}, {'cui': 'C0036679', 'cui_str': 'Separation'}, {'cui': 'C0225325', 'cui_str': 'Collagen fiber'}, {'cui': 'C0038128', 'cui_str': 'Stain'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0040578', 'cui_str': 'Tracheal structure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0018180', 'cui_str': 'Granulation tissue'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}]",45.0,0.0108879,Both decellularization cycles caused decreased stiffness.,"[{'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Villalba-Caloca', 'Affiliation': 'Unidad de Trasplante Pulmonar Experimental, Instituto Nacional de Enfermedades Respiratorias ""Ismael Cosío Villegas"", Ciudad de México, México.'}, {'ForeName': 'Avelina', 'Initials': 'A', 'LastName': 'Sotres-Vega', 'Affiliation': 'Unidad de Trasplante Pulmonar Experimental, Instituto Nacional de Enfermedades Respiratorias ""Ismael Cosío Villegas"", Ciudad de México, México.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Giraldo-Gómez', 'Affiliation': 'Instituto de Investigaciones en Materiales, Universidad Nacional Autónoma de México, Ciudad de México, México.'}, {'ForeName': 'Miguel O', 'Initials': 'MO', 'LastName': 'Gaxiola-Gaxiola', 'Affiliation': 'Unidad de Trasplante Pulmonar Experimental, Instituto Nacional de Enfermedades Respiratorias ""Ismael Cosío Villegas"", Ciudad de México, México.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Piña-Barba', 'Affiliation': 'Instituto de Investigaciones en Materiales, Universidad Nacional Autónoma de México, Ciudad de México, México.'}, {'ForeName': 'Jazmín A', 'Initials': 'JA', 'LastName': 'García-Montes', 'Affiliation': 'Unidad de Trasplante Pulmonar Experimental, Instituto Nacional de Enfermedades Respiratorias ""Ismael Cosío Villegas"", Ciudad de México, México.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Martínez-Fonseca', 'Affiliation': 'Unidad de Trasplante Pulmonar Experimental, Instituto Nacional de Enfermedades Respiratorias ""Ismael Cosío Villegas"", Ciudad de México, México.'}, {'ForeName': 'Marcelino', 'Initials': 'M', 'LastName': 'Alonso-Gómez', 'Affiliation': 'Unidad de Trasplante Pulmonar Experimental, Instituto Nacional de Enfermedades Respiratorias ""Ismael Cosío Villegas"", Ciudad de México, México.'}, {'ForeName': 'J Alfredo', 'Initials': 'JA', 'LastName': 'Santibáñez-Salgado', 'Affiliation': 'Unidad de Trasplante Pulmonar Experimental, Instituto Nacional de Enfermedades Respiratorias ""Ismael Cosío Villegas"", Ciudad de México, México.'}]",The International journal of artificial organs,['10.1177/03913988211025991'] 2157,34365776,Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus.,"Background Prospective comparative studies on the effects of various antidiabetic agents on bone metabolism are limited. This study aimed to assess changes in bone mass and biochemical bone markers in postmenopausal patients with type 2 diabetes mellitus (T2DM). Methods This prospective, multicenter, open-label, comparative trial included 264 patients with T2DM. Patients who had received a metformin, or sulfonylurea/metformin combination (Group 1); a thiazolidinedione combination (Group 2); a dipeptidyl peptidase-4 inhibitor (gemigliptin) combination (Group 3); or an sodium-glucose cotransporter 2 inhibitor (empagliflozin) combination (Group 4) were prospectively treated for 12 months; bone mineral density (BMD) and bone turnover marker (BTM) changes were evaluated. Results The femoral neck BMD percentage changes were -0.79%±2.86% (Group 1), -2.50%±3.08% (Group 2), -1.05%±2.74% (Group 3), and -1.24%±2.91% (Group 4) (P<0.05). The total hip BMD percentage changes were -0.57%±1.79% (Group 1), -1.74%±1.48% (Group 2), -0.75%±1.87% (Group 3), and -1.27%±1.72% (Group 4) (P<0.05). Mean serum BTM (C-terminal type 1 collagen telopeptide and procollagen type 1 amino-terminal propeptide) levels measured during the study period did not change over time or differ between groups. Conclusion Significant bone loss in the femoral neck and total hip was associated with thiazolidinedione combination regimens. However, bone loss was not significantly associated with combination regimens including gemigliptin or empagliflozin. Caution should be exercised during treatment with antidiabetic medications that adversely affect the bone in patients with diabetes at a high risk of bone loss.",2021,"The femoral neck BMD percentage changes were -0.79%±2.86% (Group 1), -2.50%±3.08% (Group 2), -1.05%±2.74% (Group 3), and -1.24%±2.91% (Group 4) (P<0.05).","['patients with diabetes at a high risk of bone loss', 'Patients with Type 2 Diabetes Mellitus', '264 patients with T2DM', 'postmenopausal patients with type 2 diabetes mellitus (T2DM']","['empagliflozin', 'Various Antidiabetic Medication', 'metformin, or sulfonylurea/metformin combination', 'thiazolidinedione combination', 'various antidiabetic agents', 'dipeptidyl peptidase-4 inhibitor (gemigliptin) combination (Group 3); or an sodium-glucose cotransporter 2 inhibitor (empagliflozin) combination']","['Mean serum BTM (C-terminal type 1 collagen telopeptide and procollagen type 1 amino-terminal propeptide) levels', 'bone mineral density (BMD) and bone turnover marker (BTM) changes', 'bone loss', 'femoral neck BMD percentage changes', 'Bone Mineral Density', 'total hip BMD percentage changes', 'bone mass and biochemical bone markers']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0935929', 'cui_str': 'Antidiabetic agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0038766', 'cui_str': 'Sulfonylurea'}, {'cui': 'C0289779', 'cui_str': '2,4-thiazolidinedione'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl peptidase IV inhibitor'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}, {'cui': 'C0033235', 'cui_str': 'Procollagen'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030786', 'cui_str': 'Hip Bone'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0181734', 'cui_str': 'Bone marker'}]",264.0,0.00494974,"The femoral neck BMD percentage changes were -0.79%±2.86% (Group 1), -2.50%±3.08% (Group 2), -1.05%±2.74% (Group 3), and -1.24%±2.91% (Group 4) (P<0.05).","[{'ForeName': 'Jeonghoon', 'Initials': 'J', 'LastName': 'Ha', 'Affiliation': ""Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Yejee', 'Initials': 'Y', 'LastName': 'Lim', 'Affiliation': 'Division of General Internal Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.'}, {'ForeName': 'Mee Kyoung', 'Initials': 'MK', 'LastName': 'Kim', 'Affiliation': ""Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Hyuk-Sang', 'Initials': 'HS', 'LastName': 'Kwon', 'Affiliation': ""Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Ki-Ho', 'Initials': 'KH', 'LastName': 'Song', 'Affiliation': ""Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Seung Hyun', 'Initials': 'SH', 'LastName': 'Ko', 'Affiliation': ""Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.""}, {'ForeName': 'Moo Il', 'Initials': 'MI', 'LastName': 'Kang', 'Affiliation': ""Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Sung Dae', 'Initials': 'SD', 'LastName': 'Moon', 'Affiliation': ""Division of Endocrinology and Metabolism, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.""}, {'ForeName': 'Ki-Hyun', 'Initials': 'KH', 'LastName': 'Baek', 'Affiliation': ""Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}]","Endocrinology and metabolism (Seoul, Korea)",['10.3803/EnM.2021.1026'] 2158,34365645,The effect of autonomous and controlled motivation on self-control performance and the acute cortisol response.,"Autonomously regulated self-control typically does not reduce over time as much, compared with self-control underpinned by controlled motivation. The proposed study tested whether an acute stress response is implicated in this process. Utilizing a framework grounded in self-determination theory, this study examined whether participants' motivational regulation would influence repeated self-control performance and acute stress levels, measured by the stress hormone cortisol. A single-blind randomized experimental design incorporating two motivational conditions (autonomous regulation and controlled regulation) tested these hypotheses. Participants (female = 28; male = 11; M age  = 22.33) performed three sequential self-control tasks; a modified Stroop task followed by two ""wall sit"" postural persistence tasks. Salivary cortisol was measured at baseline and after each of the wall sits. A repeated measures ANCOVA unexpectedly revealed that participants in the controlled regulation condition recorded greater wall sit performance in the first and second wall sits, compared with the autonomous condition. A repeated measures ANCOVA also revealed a significant quadratic interaction for cortisol. Controlled regulation was associated with an increase, and autonomous regulation condition a decrease, in cortisol that subsided at timepoint two. Results imply autonomous motivation facilitates an adaptive stress response. Performance on the self-control tasks was contrary to expectations, but may reflect short-term performance benefits of controlled motivation.",2021,"A repeated measures ANCOVA unexpectedly revealed that participants in the controlled regulation condition recorded greater wall sit performance in the first and second wall sits, compared with the autonomous condition.",['Participants (female\xa0=\xa028; male\xa0=\xa011; M age \xa0=\xa022.33) performed three'],"['sequential self-control tasks; a modified Stroop task followed by two ""wall sit"" postural persistence tasks']","['adaptive stress response', 'wall sit performance', 'Salivary cortisol', 'acute cortisol response']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0546816', 'cui_str': 'Persistence'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]",28.0,0.0487492,"A repeated measures ANCOVA unexpectedly revealed that participants in the controlled regulation condition recorded greater wall sit performance in the first and second wall sits, compared with the autonomous condition.","[{'ForeName': 'Richard P', 'Initials': 'RP', 'LastName': 'Steel', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.'}, {'ForeName': 'Nicolette C', 'Initials': 'NC', 'LastName': 'Bishop', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Taylor', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.'}]",Psychophysiology,['10.1111/psyp.13915'] 2159,34362344,"Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.","BACKGROUND Residual breast cancer after neo-adjuvant chemotherapy (NACT) predicts disease outcome and is a surrogate for survival in aggressive breast cancer (BC) subtypes. Pathological complete response (pCR) rate, however, is lower for luminal B BC in comparison to the triple negative (TNBC) and HER2+ subtypes. The addition of immune checkpoint blockade (ICB) to NACT has the potential to increase pCR rate but is hampered by the lower immunogenicity of luminal B BC. Novel strategies are needed to stimulate the immune response and increase the response rate to ICB in luminal B BC. METHODS The Neo-CheckRay trial is a randomized phase II trial investigating the impact of stereotactic body radiation therapy (SBRT) to the primary breast tumor in combination with an anti-CD73 (oleclumab) to increase response to anti PD-L1 (durvalumab) and NACT. The trial is designed as a three-arm study: NACT + SBRT +/- durvalumab +/- oleclumab. The result at surgery will be evaluated using the residual cancer burden (RCB) index as the primary endpoint. Six patients will be included in a safety run-in, followed by a randomized phase II trial that will include 136 evaluable patients in 3 arms. Inclusion is limited to luminal B breast cancers that are MammaPrint genomic high risk. DISCUSSION combination of ICB with chemotherapy in luminal B BC might benefit from immune priming agents to increase the response rate. As none have been identified so far, this phase II trial will evaluate SBRT and oleclumab as potential immune priming candidates. TRIAL REGISTRATION trial registered on ClinicalTrials.gov ( NCT03875573 ) on March 14th, 2019.",2021,"Pathological complete response (pCR) rate, however, is lower for luminal B BC in comparison to the triple negative (TNBC) and HER2+ subtypes.","['aggressive breast cancer (BC) subtypes', 'early stage luminal B breast cancer', '136 evaluable patients in 3 arms']","['stereotactic body radiation therapy (SBRT', 'neo-adjuvant chemotherapy (NACT', 'anti-CD73 (oleclumab', 'adenosine pathway blockade', 'NACT', 'durvalumab ', 'NACT + SBRT ']","['Pathological complete response (pCR) rate', 'residual cancer burden (RCB) index', 'pCR rate', 'response rate']","[{'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0729296', 'cui_str': 'Stereotactic'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0000530', 'cui_str': ""5'-nucleotidase""}, {'cui': 'C0001443', 'cui_str': 'Adenosine'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C4055109', 'cui_str': 'durvalumab'}]","[{'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C2919215', 'cui_str': 'Residual cancer burden index'}]",136.0,0.102252,"Pathological complete response (pCR) rate, however, is lower for luminal B BC in comparison to the triple negative (TNBC) and HER2+ subtypes.","[{'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'De Caluwé', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium. alex.decaluwe@bordet.be.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Buisseret', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Poortmans', 'Affiliation': 'Iridium Kankernetwerk & University Antwerpen, Antwerp, Belgium.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Van Gestel', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Salgado', 'Affiliation': 'GZA, Antwerp, Belgium.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Sotiriou', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Larsimont', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Paesmans', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Ligia', 'Initials': 'L', 'LastName': 'Craciun', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Drisis', 'Initials': 'D', 'LastName': 'Stylianos', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Vandekerckhove', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Fabien', 'Initials': 'F', 'LastName': 'Reyal', 'Affiliation': 'Institut Curie, Paris, France.'}, {'ForeName': 'Veys', 'Initials': 'V', 'LastName': 'Isabelle', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Eiger', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Piccart', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Romano', 'Affiliation': 'Institut Curie, Paris, France.'}, {'ForeName': 'Michail', 'Initials': 'M', 'LastName': 'Ignatiadis', 'Affiliation': 'Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger Bordet 1, 1000, Brussels, Belgium.'}]",BMC cancer,['10.1186/s12885-021-08601-1'] 2160,34362323,Increasing the HIV testing among MSM through HIV test result exchange mechanism: study protocol for a cluster randomized controlled trial.,"BACKGROUND HIV testing is an essential gateway to HIV prevention and treatment thus controlling the HIV epidemic. More innovative interventions are needed to increase HIV testing among men who have sex with men (MSM) since their testing rate is still low. We proposed an online HIV test results exchange mechanism whereby the one without a certified online HIV report will be asked to test HIV for exchanging HIV report with others. The exchange mechanism is developed as an extension to the existing online HIV testing service system. Through the extended system, MSM can obtain certified online HIV reports and exchange their reports with friends via WeChat. This study aims to assess effectiveness of the exchange mechanism to increase the HIV testing rate among MSM. METHODS This study will use a cluster randomized controlled trial (RCT) design. Participants are recruited based on the unit of individual social network, the sender and the receivers of the HIV report. An individual social network is composed of one sender (ego) and one or more receivers (alters). In this study, MSM in an HIV testing clinic are recruited as potential egos and forwarded online reports to their WeChat friends voluntarily. Friends are invited to participate by report links and become alters. Ego and alters serve as a cluster and are randomized to the group using the certified online HIV report with exchange mechanism (intervention group) or without exchange mechanism (control group). Alters are the intervention targeting participants. The primary outcome is HIV testing rate. Other outcomes are sexual transmitted infections, sexual behaviors, HIV testing norms, stigma, risk perception and HIV report delivery. The outcomes will be assessed at baseline and follow-up questionnaires. Analysis will be according to intention to treat approach and using mixed-effect models with networks and individuals as random effects. DISCUSSION This is the first study to evaluate the effectiveness of an HIV test result exchange mechanism to increase the HIV testing among MSM. This assessment of the intervention will also provide scientific evidence on other potential effects. Findings from this study will yield insights for sustainability driven by communities' intrinsic motivation. Trail registration: ClinicalTrials.gov NCT03984136. Registered 12 June 2019.",2021,More innovative interventions are needed to increase HIV testing among men who have sex with men (MSM) since their testing rate is still low.,"['men who have sex with men (MSM', 'Participants are recruited based on the unit of individual social network,\xa0the sender and the receivers of the HIV report']","['exchange mechanism (intervention group) or without exchange mechanism (control group', 'MSM']","['sexual transmitted infections, sexual behaviors, HIV testing norms, stigma, risk perception and HIV report delivery', 'HIV testing rate']","[{'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}]","[{'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]",,0.288217,More innovative interventions are needed to increase HIV testing among men who have sex with men (MSM) since their testing rate is still low.,"[{'ForeName': 'Yuning', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, P. R. China.'}, {'ForeName': 'Jialing', 'Initials': 'J', 'LastName': 'Qiu', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, P. R. China.'}, {'ForeName': 'Qingling', 'Initials': 'Q', 'LastName': 'Yang', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, P. R. China.'}, {'ForeName': 'Tailin', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, P. R. China.'}, {'ForeName': 'Yongheng', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Kangyuan Community Support Center of Yuexiu District, Guangzhou, 510000, Guangdong, P. R. China.'}, {'ForeName': 'Sha', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, P. R. China.'}, {'ForeName': 'Xiaoru', 'Initials': 'X', 'LastName': 'Fan', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, P. R. China.'}, {'ForeName': 'Zhiye', 'Initials': 'Z', 'LastName': 'Lin', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, P. R. China.'}, {'ForeName': 'Zhigang', 'Initials': 'Z', 'LastName': 'Han', 'Affiliation': 'Guangzhou Center for Disease Control and Prevention, Guangzhou, 510440, Guangdong, P. R. China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Kangyuan Community Support Center of Yuexiu District, Guangzhou, 510000, Guangdong, P. R. China.'}, {'ForeName': 'Haobing', 'Initials': 'H', 'LastName': 'Qian', 'Affiliation': 'Department of Health Management and Policy, College of Public Health, The University of Iowa, Iowa, IA, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Gu', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, P. R. China.'}, {'ForeName': 'Dong Roman', 'Initials': 'DR', 'LastName': 'Xu', 'Affiliation': 'Department of Health Management, School of Health Management of Southern Medical University, Guangzhou, 510000, Guangdong, P. R. China.'}, {'ForeName': 'Yuzhou', 'Initials': 'Y', 'LastName': 'Gu', 'Affiliation': 'Guangzhou Center for Disease Control and Prevention, Guangzhou, 510440, Guangdong, P. R. China. yuchoukoo@foxmail.com.'}, {'ForeName': 'Chun', 'Initials': 'C', 'LastName': 'Hao', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, P. R. China. haochun@mail.sysu.edu.cn.'}]",BMC infectious diseases,['10.1186/s12879-021-06484-y'] 2161,34362310,Community-based model for the delivery of antiretroviral therapy in Cambodia: a quasi-experimental study protocol.,"BACKGROUND Multi-month dispensing (MMD) is the mainstay mechanism for clinically stable people living with HIV in Cambodia to refill antiretroviral therapy (ART) every 3-6 months. However, less frequent ART dispensing through the community-based ART delivery (CAD) model could further reduce the clients' and health facilities' burden. While community-based services have been recognized as an integral component of HIV response in Cambodia, their role and effectiveness in ART delivery have yet to be systematically assessed. This study aims to evaluate the CAD model's effectiveness on the continuum of care and treatment outcomes for stable people living with HIV in Cambodia. METHODS We will conduct this quasi-experimental study in 20 ART clinics across the capital city and nine provinces between May 2021 and April 2023. Study sites were purposively selected based on the availability of implementing partners, the number of people living with HIV each clinic serves, and the accessibility of the clinics. In the intervention arm, approximately 2000 stable people living with HIV will receive ART and services from the CAD model. Another 2000 stable people living with HIV in the control arm will receive MMD-a standard care model for stable people living with HIV. The primary outcomes will be retention in care, viral load suppression, and adherence to ART. The secondary endpoints will include health providers' work burden, the model's cost-effectiveness, quality of life, mental health, social support, stigma, and discrimination. We will compare the outcome indicators within each arm at baseline, midline, and endline using descriptive and inferential statistics. We will evaluate the differences between the intervention and control arms using the difference-in-differences method. We will perform economic evaluations to determine if the intervention is cost-effective. DISCUSSION This study will build the evidence base for future implementation and scale-up of CAD model in Cambodia and other similar settings. Furthermore, it will strengthen engagements with community stakeholders and further improve community mobilization, a vital pillar of the Cambodian HIV response. TRIAL REGISTRATION ClinicalTrials.gov, NCT04766710 . Registered 23 February 2021, Version 1.",2021,Another 2000 stable people living with HIV in the control arm will receive MMD-a standard care model for stable people living with HIV.,"['Another 2000 stable people living with HIV in the control arm will receive', 'stable people living with HIV in Cambodia', 'Study sites were purposively selected based on the availability of implementing partners, the number of people living with HIV each clinic serves, and the accessibility of the clinics', '2000 stable people living with HIV will receive ART and services from the CAD model', 'clinically stable people living with HIV in Cambodia to refill antiretroviral therapy (ART) every 3-6 months', 'Cambodia', '20 ART clinics across the capital city and nine provinces between May 2021 and April 2023']",['MMD-a standard care model'],"['retention in care, viral load suppression, and adherence to ART', ""health providers' work burden, the model's cost-effectiveness, quality of life, mental health, social support, stigma, and discrimination""]","[{'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0006797', 'cui_str': 'Cambodia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0442759', 'cui_str': '3/6'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0006909', 'cui_str': 'Capital'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C4704685', 'cui_str': 'Care Retention'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}]",20.0,0.0796285,Another 2000 stable people living with HIV in the control arm will receive MMD-a standard care model for stable people living with HIV.,"[{'ForeName': 'Sovannary', 'Initials': 'S', 'LastName': 'Tuot', 'Affiliation': 'KHANA Center for Population Health Research, Phnom Penh, Cambodia.'}, {'ForeName': 'Alvin Kuo Jing', 'Initials': 'AKJ', 'LastName': 'Teo', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, 12 Science Drive 2, #10-01, Singapore, 117549, Singapore.'}, {'ForeName': 'Kiesha', 'Initials': 'K', 'LastName': 'Prem', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, 12 Science Drive 2, #10-01, Singapore, 117549, Singapore.'}, {'ForeName': 'Pheak', 'Initials': 'P', 'LastName': 'Chhoun', 'Affiliation': 'KHANA Center for Population Health Research, Phnom Penh, Cambodia.'}, {'ForeName': 'Chamroen', 'Initials': 'C', 'LastName': 'Pall', 'Affiliation': 'KHANA Center for Population Health Research, Phnom Penh, Cambodia.'}, {'ForeName': 'Mengieng', 'Initials': 'M', 'LastName': 'Ung', 'Affiliation': 'KHANA Center for Population Health Research, Phnom Penh, Cambodia.'}, {'ForeName': 'Penh Sun', 'Initials': 'PS', 'LastName': 'Ly', 'Affiliation': 'National Center for HIV/AIDS, Dermatology and STD, Phnom Penh, Cambodia.'}, {'ForeName': 'Masamine', 'Initials': 'M', 'LastName': 'Jimba', 'Affiliation': 'Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Siyan', 'Initials': 'S', 'LastName': 'Yi', 'Affiliation': 'KHANA Center for Population Health Research, Phnom Penh, Cambodia. siyan@doctor.com.'}]",BMC infectious diseases,['10.1186/s12879-021-06414-y'] 2162,34362303,Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease.,"BACKGROUND The purpose of this study was to assess the five-year treatment effects of a short course of intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) due to Alzheimer disease (AD). METHODS Fifty subjects 50 to 84 years of age with MCI due to AD were administered 0.4 g/kg 10% IVIG or 0.9% saline every two weeks x five doses in a randomized double-blinded design as part of a two-year study. Twenty-seven subjects completed an additional three-year extension study. MRI brain imaging, cognitive testing, and conversion to dementia were assessed annually. Participants were stratified into early MCI (E-MCI) and late MCI (L-MCI). The primary endpoint was brain atrophy measured as annualized percent change in ventricular volume (APCV) annually for five years. ANOVA was used to compare annualized percent change in ventricular volume from baseline between the groups adjusting for MCI status (E-MCI, L-MCI). RESULTS Differences in brain atrophy between the groups, which were statistically significant after one year, were no longer significant after five years. IVIG-treated L-MCI subjects did demonstrate a delay in conversion to dementia of 21.4 weeks. CONCLUSION An eight-week course of IVIG totaling 2 g/kg in MCI is safe but is not sufficient to sustain an initial reduction in brain atrophy or a temporary delay in conversion to dementia at five years. Other dosing strategies of IVIG in the early stages of AD should be investigated to assess more sustainable disease-modifying effects. Trial registration ClinicalTrials.gov NCT01300728. Registered 23 February 2011.",2021,"RESULTS Differences in brain atrophy between the groups, which were statistically significant after one year, were no longer significant after five years.","['subjects with mild cognitive impairment (MCI) due to Alzheimer disease (AD', 'Fifty subjects 50 to 84\xa0years of age with MCI due to AD', 'Twenty-seven subjects completed an additional three-year extension study']","['intravenous immunoglobulin (IVIG', 'IVIG-treated L-MCI']","['brain atrophy', 'brain atrophy measured as annualized percent change in ventricular volume (APCV', 'MRI brain imaging, cognitive testing, and conversion to dementia']","[{'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}]","[{'cui': 'C0235946', 'cui_str': 'Cerebral atrophy'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C4028269', 'cui_str': 'Nuclear magnetic resonance imaging brain'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]",27.0,0.505947,"RESULTS Differences in brain atrophy between the groups, which were statistically significant after one year, were no longer significant after five years.","[{'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Kile', 'Affiliation': 'Sutter Neuroscience Institute, 2800 L Street, Suite 500, Sacramento, CA, 95816, USA. kiles@sutterhealth.org.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Au', 'Affiliation': 'Sutter Neuroscience Institute, 2800 L Street, Suite 500, Sacramento, CA, 95816, USA.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Parise', 'Affiliation': 'Sutter Institute for Medical Research (SIMR), Sacramento, CA, USA.'}, {'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Rose', 'Affiliation': 'Sutter Neuroscience Institute, 2800 L Street, Suite 500, Sacramento, CA, 95816, USA.'}, {'ForeName': 'Tammy', 'Initials': 'T', 'LastName': 'Donnel', 'Affiliation': 'Sutter Institute for Medical Research (SIMR), Sacramento, CA, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Hankins', 'Affiliation': 'Sutter Institute for Medical Research (SIMR), Sacramento, CA, USA.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Au', 'Affiliation': 'Sutter Neuroscience Institute, 2800 L Street, Suite 500, Sacramento, CA, 95816, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Chan', 'Affiliation': 'Sutter Imaging, Neuroradiology, Sacramento, USA.'}, {'ForeName': 'Azad', 'Initials': 'A', 'LastName': 'Ghassemi', 'Affiliation': 'Sutter Imaging, Neuroradiology, Sacramento, USA.'}]",BMC neuroscience,['10.1186/s12868-021-00651-2'] 2163,34362221,"Comparison of Distal Radial, Proximal Radial, and Femoral Access in Patients with ST-Elevation Myocardial Infarction.","Recent studies have indicated that distal radial access (DRA) is feasible in patients undergoing percutaneous coronary intervention (PCI). The present study aimed to compare DRA, proximal radial access (PRA), and femoral access (FA) in patients with ST-elevation myocardial infarction (STEMI) undergoing PCI. Data were analyzed for 109 patients with STEMI treated via primary PCI from March 2020 to May 2021. The success rate of DRA was 83.3% (35/42), including seven cases of failed puncture (puncture failure = 5, severe radial artery spasm = 2). Primary PCI via the DRA was successful in all 35 patients. After classifying the patients requiring crossover into a separate group, the percentage of the puncture time in the door-to-wiring time was 2.7% [2.2-4.3], 3.3% [2.3-4.0], 2.6% [1.2-4.9], and 27.0% [13.5-29.3] in the DRA ( n = 35), PRA ( n = 24), FA ( n = 26), and crossover ( n = 9) groups, respectively ( p < 0.01). Only two local hematomas (≤5 cm) occurred in the DRA group, while one patient in the FA group required surgical treatment and a transfusion for an access-site vascular injury. When performed by an experienced operator, DRA may represent a feasible alternative to other access routes in select patients with STEMI undergoing PCI, such as those with a high risk of bleeding.",2021,"The success rate of DRA was 83.3% (35/42), including seven cases of failed puncture (puncture failure = 5, severe radial artery spasm = 2).","['patients with ST-elevation myocardial infarction (STEMI) undergoing PCI', '109 patients with STEMI treated via primary PCI from March 2020 to May 2021', 'patients undergoing percutaneous coronary intervention (PCI', 'Patients with ST-Elevation Myocardial Infarction']","['Distal Radial, Proximal Radial, and Femoral Access', 'DRA', 'distal radial access (DRA']","['success rate of DRA', 'percentage of the puncture time in the door-to-wiring time', 'DRA, proximal radial access (PRA), and femoral access (FA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1303258', 'cui_str': 'Acute ST segment elevation myocardial infarction'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0557698', 'cui_str': 'Door'}, {'cui': 'C0441650', 'cui_str': 'Closure by wire'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}]",109.0,0.0576331,"The success rate of DRA was 83.3% (35/42), including seven cases of failed puncture (puncture failure = 5, severe radial artery spasm = 2).","[{'ForeName': 'Oh-Hyun', 'Initials': 'OH', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin 16995, Korea.'}, {'ForeName': 'Yongcheol', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin 16995, Korea.'}, {'ForeName': 'Nak-Hoon', 'Initials': 'NH', 'LastName': 'Son', 'Affiliation': 'Data Science Team (Biostatistician), Center for Digital Health, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin 16995, Korea.'}, {'ForeName': 'Ji Woong', 'Initials': 'JW', 'LastName': 'Roh', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin 16995, Korea.'}, {'ForeName': 'Eui', 'Initials': 'E', 'LastName': 'Im', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin 16995, Korea.'}, {'ForeName': 'Deok-Kyu', 'Initials': 'DK', 'LastName': 'Cho', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin 16995, Korea.'}, {'ForeName': 'Donghoon', 'Initials': 'D', 'LastName': 'Choi', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin 16995, Korea.'}]",Journal of clinical medicine,['10.3390/jcm10153438'] 2164,34362054,Intravenous Tranexamic Acid Has Benefit for Reducing Blood Loss after Open-Wedge High Tibial Osteotomy: A Randomized Controlled Trial.,"(1) Background: the purpose of this study was to investigate the efficacy and safety of intravenous (IV) administration of tranexamic acid (TXA) in patients undergoing medial opening wedge high tibial osteotomy (MOWHTO). (2) Methods: a total of 73 patients were randomly allocated into two groups (TXA group and control group). The primary outcome was total perioperative calculated blood loss after MOWHTO. Secondary outcomes included self-reported pain severity using a 10-point visual analog scale (VAS) and the EuroQol-5 Dimension (EQ-5D) questionnaire. The postoperative allogeneic transfusion rate and wound complications were compared. Deep vein thrombosis (DVT) incidence was compared by conducting DVT computed tomography imaging. (3) Results: the total blood loss after surgery was 470.9 mL in the TXA group and 739.3 mL in the control group, showing a significant difference ( p < 0.001). There were no differences in pain VAS scores between the two groups (all p > 0.05). No difference in preoperative EQ-5D scores for any items existed between the two groups. No transfusion was performed in either group. There was no difference in DVT incidence or the rate of wound complications between the two groups. (4) Conclusion: in patients undergoing MOWHTO, IV TXA reduces total blood loss and drainage amount. However, no additional benefits in clinical outcomes, transfusion rate, or wound complications were apparent, with similar DVT incidence rates.",2021,"However, no additional benefits in clinical outcomes, transfusion rate, or wound complications were apparent, with similar DVT incidence rates.","['73 patients', 'after Open-Wedge High Tibial Osteotomy', 'patients undergoing medial opening wedge high tibial osteotomy (MOWHTO']","['Intravenous Tranexamic Acid', 'tranexamic acid (TXA', 'TXA']","['Blood Loss', 'efficacy and safety', 'self-reported pain severity using a 10-point visual analog scale (VAS) and the EuroQol-5 Dimension (EQ-5D) questionnaire', 'total blood loss', 'Deep vein thrombosis (DVT) incidence', 'preoperative EQ-5D scores', 'clinical outcomes, transfusion rate, or wound complications', 'total perioperative calculated blood loss', 'pain VAS scores', 'postoperative allogeneic transfusion rate and wound complications', 'total blood loss and drainage amount', 'DVT incidence or the rate of wound complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0445153', 'cui_str': 'Opening wedge'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0187826', 'cui_str': 'Osteotomy of tibia'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0439639', 'cui_str': 'Wedge'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0232100', 'cui_str': 'Exsanguination'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]",73.0,0.209788,"However, no additional benefits in clinical outcomes, transfusion rate, or wound complications were apparent, with similar DVT incidence rates.","[{'ForeName': 'Man-Soo', 'Initials': 'MS', 'LastName': 'Kim', 'Affiliation': ""Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea.""}, {'ForeName': 'In-Jun', 'Initials': 'IJ', 'LastName': 'Koh', 'Affiliation': ""Department of Orthopaedic Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 1021, Tongil Ro, Eunpyeong-gu, Seoul 03312, Korea.""}, {'ForeName': 'Yong-Gyu', 'Initials': 'YG', 'LastName': 'Sung', 'Affiliation': ""Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea.""}, {'ForeName': 'Dong-Chul', 'Initials': 'DC', 'LastName': 'Park', 'Affiliation': ""Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea.""}, {'ForeName': 'Won-Jun', 'Initials': 'WJ', 'LastName': 'Ha', 'Affiliation': ""Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'In', 'Affiliation': ""Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea.""}]",Journal of clinical medicine,['10.3390/jcm10153272'] 2165,34362051,Efficacy of Transcutaneous Spinal Stimulation versus Whole Body Vibration for Spasticity Reduction in Persons with Spinal Cord Injury.,"Transcutaneous spinal stimulation (TSS) and whole-body vibration (WBV) each have a robust ability to activate spinal afferents. Both forms of stimulation have been shown to influence spasticity in persons with spinal cord injury (SCI), and may be viable non-pharmacological approaches to spasticity management. In thirty-two individuals with motor-incomplete SCI, we used a randomized crossover design to compare single-session effects of TSS versus WBV on quadriceps spasticity, as measured by the pendulum test. TSS (50 Hz, 400 μs, 15 min) was delivered in supine through a cathode placed over the thoracic spine (T11-T12) and an anode over the abdomen. WBV (50 Hz; eight 45-s bouts) was delivered with the participants standing on a vibration platform. Pendulum test first swing excursion (FSE) was measured at baseline, immediately post-intervention, and 15 and 45 min post-intervention. In the whole-group analysis, there were no between- or within-group differences of TSS and WBV in the change from baseline FSE to any post-intervention timepoints. Significant correlations between baseline FSE and change in FSE were associated with TSS at all timepoints. In the subgroup analysis, participants with more pronounced spasticity showed significant decreases in spasticity immediately post-TSS and 45 min post-TSS. TSS and WBV are feasible physical therapeutic interventions for the reduction of spasticity, with persistent effects.",2021,"In the subgroup analysis, participants with more pronounced spasticity showed significant decreases in spasticity immediately post-TSS and 45 min post-TSS.","['persons with spinal cord injury (SCI', 'Persons with Spinal Cord Injury', 'In thirty-two individuals with motor-incomplete SCI']","['TSS versus WBV', 'Transcutaneous Spinal Stimulation versus Whole Body Vibration', 'Transcutaneous spinal stimulation (TSS) and whole-body vibration (WBV', 'TSS']","['spasticity', 'Pendulum test first swing excursion (FSE', 'baseline FSE and change in FSE', 'TSS and WBV']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C4545488', 'cui_str': 'Incomplete spinal cord injury'}]","[{'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}]","[{'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}]",32.0,0.0196507,"In the subgroup analysis, participants with more pronounced spasticity showed significant decreases in spasticity immediately post-TSS and 45 min post-TSS.","[{'ForeName': 'Evan B', 'Initials': 'EB', 'LastName': 'Sandler', 'Affiliation': 'Shepherd Center, Crawford Research Institute, Atlanta, GA 30309, USA.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Condon', 'Affiliation': 'Shepherd Center, Crawford Research Institute, Atlanta, GA 30309, USA.'}, {'ForeName': 'Edelle C', 'Initials': 'EC', 'LastName': 'Field-Fote', 'Affiliation': 'Shepherd Center, Crawford Research Institute, Atlanta, GA 30309, USA.'}]",Journal of clinical medicine,['10.3390/jcm10153267'] 2166,34362048,Resting Heart Rate and Cardiovascular Outcomes during Intensive and Standard Blood Pressure Reduction: An Analysis from SPRINT Trial.,"The association between elevated resting heart rate (RHR) as a cardiovascular risk factor and lowering of systolic blood pressure (SBP) to currently recommended values remain unknown. Systolic Blood Pressure Intervention Trial (SPRINT) data obtained from the NHLBI were used to describe the relationship between RHR and SBP reduction to <120 mmHg compared to SBP reduction to <140 mmHg. The composite clinical endpoint (CE) was defined as myocardial infarction, acute coronary syndrome, decompensation of heart failure, stroke, or cardiovascular death. Increased RHR was associated with a higher CE risk compared with low RHR in both treatment arms. A more potent increase of risk for CE was observed in subjects who were allocated to the SBP < 120 mmHg treatment goal. A similar effect of intensive and standard blood pressure (BP) reduction ( p for interaction, 0.826) was observed in subjects with RHR in the 5th quintile (hazard ratio, 0.78, with 95% confidence interval (CI), 0.55-1.11) and in other quintiles of baseline RHR (hazard ratio, 0.75, with 95% CI, 0.62-0.90). Lower in-trial than baseline RHR was associated with reduced CE risk (hazard ratio, 0.80, with 95% CI, 0.66-0.98). We concluded that elevated RHR remains an essential risk factor independent of SBP reduction.",2021,"A similar effect of intensive and standard blood pressure (BP) reduction ( p for interaction, 0.826) was observed in subjects with RHR in the 5th quintile (hazard ratio, 0.78, with 95% confidence interval (CI), 0.55-1.11) and in other quintiles of baseline RHR (hazard ratio, 0.75, with 95% CI, 0.62-0.90).",[],[],"['Resting Heart Rate and Cardiovascular Outcomes during Intensive and Standard Blood Pressure Reduction', 'Increased RHR', 'intensive and standard blood pressure (BP) reduction', 'reduced CE risk', 'systolic blood pressure (SBP', 'myocardial infarction, acute coronary syndrome, decompensation of heart failure, stroke, or cardiovascular death', 'risk for CE']",[],[],"[{'cui': 'C1821417', 'cui_str': 'Resting heart rate'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0231187', 'cui_str': 'Decompensation'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.180995,"A similar effect of intensive and standard blood pressure (BP) reduction ( p for interaction, 0.826) was observed in subjects with RHR in the 5th quintile (hazard ratio, 0.78, with 95% confidence interval (CI), 0.55-1.11) and in other quintiles of baseline RHR (hazard ratio, 0.75, with 95% CI, 0.62-0.90).","[{'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Sobieraj', 'Affiliation': 'Department of Internal Medicine, Hypertension and Vascular Diseases, Faculty of Medicine, Medical University of Warsaw, Banacha Str 1a, 02-097 Warsaw, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Siński', 'Affiliation': 'Department of Internal Medicine, Hypertension and Vascular Diseases, Faculty of Medicine, Medical University of Warsaw, Banacha Str 1a, 02-097 Warsaw, Poland.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Lewandowski', 'Affiliation': 'Department of Internal Medicine, Hypertension and Vascular Diseases, Faculty of Medicine, Medical University of Warsaw, Banacha Str 1a, 02-097 Warsaw, Poland.'}]",Journal of clinical medicine,['10.3390/jcm10153264'] 2167,34362043,"Effect of Vibrotherapy on Body Fatness, Blood Parameters and Fibrinogen Concentration in Elderly Men.","Elderly people need activities that will positively contribute to a satisfactory process of getting older. Vibration training uses mechanical stimulus of a vibrational character that, similarly to other forms of physical activity, affects metabolic processes and conditions of health. The aim of this work was to assess the influence of thirty vibration treatments on body fatness, hematologic and rheologic indexes of blood, and proteinogram and fibrinogen concentration in elderly men's blood. The study included twenty-one males, aged 60-70 years (mean age 65.3 ± 2.7), who were randomly assigned into a vibrotherapy group (VG) and took part in interventions on mattresses generating oscillatory-cycloid vibrations, and a control group (CG), without interventions. In all patients the following assessments were performed twice: an assessment of body fatness using the bioimpedance method, a complete blood count with a hematology analyzer, and erythrocyte aggregation by a laser-optical rotational cell analyzer; whereas, total plasma protein and fibrinogen values were established, respectively, by biuret and spectrophotometric methods. In order to compare the impact of vibrotherapy on changes in the analyzed variables, analysis of variance (ANOVA) or the Wilcoxon test were used. After applying thirty vibration treatments in the VG, a significant decrease in body fatness parameters was confirmed: BM (∆BM: -2.7 ± 2.0; p = 0.002), BMI (∆BMI: -0.9 ± 0.7; p = 0.002), BF (∆BF: -2.5 ± 2.5; p = 0.013), and %BF (∆%BF: -2.0 ± 2.7; p = 0.041), as well as in RBC (∆RBC: -0.1 ± 0.1; p = 0.035). However, changes in erythrocyte aggregation and proteinogram were not confirmed. It was found that after thirty treatments with VG, a significant decrease of fibrinogen level took place (∆ = -0.3 ± 0.3, p = 0.005). Application of thirty vibrotherapy treatments positively affected body fatness parameters and fibrinogen concentrations in the examined. However, further research should include a greater number of participants.",2021,"BM (∆BM: -2.7 ± 2.0; p = 0.002), BMI (∆BMI: -0.9 ± 0.7; p = 0.002), BF (∆BF: -2.5 ± 2.5; p = 0.013), and %BF (∆%BF: -2.0 ± 2.7; p = 0.041), as well as in RBC (","['Elderly Men', 'twenty-one males, aged 60-70 years (mean age 65.3 ± 2.7', ""elderly men's blood""]","['vibrotherapy', 'thirty vibration treatments', 'Vibrotherapy', 'Vibration training', 'vibrotherapy group (VG) and took part in interventions on mattresses generating oscillatory-cycloid vibrations, and a control group (CG), without interventions']","['body fatness, hematologic and rheologic indexes of blood, and proteinogram and fibrinogen concentration', 'total plasma protein and fibrinogen values', 'Body Fatness, Blood Parameters and Fibrinogen Concentration', 'erythrocyte aggregation and proteinogram', 'body fatness parameters and fibrinogen concentrations', 'body fatness parameters', 'fibrinogen level took place']","[{'cui': 'C0524337', 'cui_str': 'Elderly man'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517635', 'cui_str': '2.7'}, {'cui': 'C0005767', 'cui_str': 'Blood'}]","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0024940', 'cui_str': 'Mattress'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0016006', 'cui_str': 'Fibrinogen'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032120', 'cui_str': 'Plasma protein'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0014766', 'cui_str': 'Erythrocyte Aggregation'}, {'cui': 'C0337428', 'cui_str': 'Fibrinogen assay'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0442504', 'cui_str': 'Place'}]",21.0,0.012151,"BM (∆BM: -2.7 ± 2.0; p = 0.002), BMI (∆BMI: -0.9 ± 0.7; p = 0.002), BF (∆BF: -2.5 ± 2.5; p = 0.013), and %BF (∆%BF: -2.0 ± 2.7; p = 0.041), as well as in RBC (","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Kabata-Piżuch', 'Affiliation': 'Department of Anatomy, Faculty of Physical Rehabilitation, University of Physical Education, 31-571 Krakow, Poland.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Suder', 'Affiliation': 'Department of Anatomy, Faculty of Physical Rehabilitation, University of Physical Education, 31-571 Krakow, Poland.'}, {'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Jagielski', 'Affiliation': 'Department of Nutrition and Drug Research, Faculty of Health Science, Jagiellonian University Medical College, 31-066 Krakow, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Kubasiak', 'Affiliation': 'Department of Anatomy, Faculty of Physical Rehabilitation, University of Physical Education, 31-571 Krakow, Poland.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Handzlik', 'Affiliation': 'Department of Anatomy, Faculty of Physical Rehabilitation, University of Physical Education, 31-571 Krakow, Poland.'}, {'ForeName': 'Aneta', 'Initials': 'A', 'LastName': 'Teległów', 'Affiliation': 'Department of Clinical Rehabilitation, Faculty of Physical Rehabilitation, University of Physical Education, 31-571 Krakow, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Marchewka', 'Affiliation': 'Department of Clinical Rehabilitation, Faculty of Physical Rehabilitation, University of Physical Education, 31-571 Krakow, Poland.'}]",Journal of clinical medicine,['10.3390/jcm10153259'] 2168,34361532,A Proteomic Analysis of Discolored Tooth Surfaces after the Use of 0.12% Chlorhexidine (CHX) Mouthwash and CHX Provided with an Anti-Discoloration System (ADS).,"Chlorhexidine (CHX) is considered the gold standard for the chemical control of bacterial plaque and is often used after surgical treatment. However, CHX employment over an extended time is responsible for side effects such as the appearance of pigmentations on the teeth and tongue; the discoloration effects are less pronounced when using a CHX-based mouthwash with added an anti-discoloration system (ADS). The aim of this study was to evaluate, using one- and two-dimensional gel electrophoresis combined with mass spectrometry, the possible proteomic changes induced by CHX and CHX+ADS in the supragingival dental sites susceptible to a discoloration effect. The tooth surface collected material (TSCM) was obtained by curettage after resective bone surgery from three groups of patients following a supportive therapy protocol in which a mechanical control was combined with placebo rinses or CHX or a CHX+ADS mouthwash. The proteomic analysis was performed before surgery (basal conditions) and four weeks after surgery when CHX was used (or not) as chemical plaque control. Changes in the TSCM proteome were only revealed following CHX treatment: glycolytic enzymes, molecular chaperones and elongation factors were identified as more expressed. These changes were not detected after CHX+ADS treatment. An ADS could directly limit TSCM forming and also the CHX antiseptic effect reduces its ability to alter bacterial cell permeability. However, Maillard's reaction produces high molecular weight molecules that change the surface properties and could facilitate bacterial adhesion.",2021,"Changes in the TSCM proteome were only revealed following CHX treatment: glycolytic enzymes, molecular chaperones and elongation factors were identified as more expressed.",[],"['Chlorhexidine (CHX', 'placebo rinses or CHX or a CHX+ADS mouthwash', 'CHX and CHX+ADS', 'Chlorhexidine (CHX) Mouthwash and CHX']",[],[],"[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1701810', 'cui_str': 'Rinse'}, {'cui': 'C0332572', 'cui_str': 'Abnormal color'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0026647', 'cui_str': 'Oromucosal solution for gargle'}, {'cui': 'C0352155', 'cui_str': 'Chlorhexidine Mouthwash'}]",[],,0.0505824,"Changes in the TSCM proteome were only revealed following CHX treatment: glycolytic enzymes, molecular chaperones and elongation factors were identified as more expressed.","[{'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Bergamini', 'Affiliation': 'Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University-Hospital of Modena and Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Bellei', 'Affiliation': 'Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University-Hospital of Modena and Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Generali', 'Affiliation': 'Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University-Hospital of Modena and Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy.'}, {'ForeName': 'Aldo', 'Initials': 'A', 'LastName': 'Tomasi', 'Affiliation': 'Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University-Hospital of Modena and Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Bertoldi', 'Affiliation': 'Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University-Hospital of Modena and Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy.'}]","Materials (Basel, Switzerland)",['10.3390/ma14154338'] 2169,34361477,Clinical Evaluation of Flowable Composite Materials in Permanent Molars Small Class I Restorations: 3-Year Double Blind Clinical Study.,"This study evaluated the 3-year clinical performance of four different flowable composite materials used in Small Class I restorations in permanent molars. This double-blinded, clinical study analyzed 229 Small Class I restorations/103 children at baseline, 12, 24, and 36 months with modified United States Public Health Services (USPHS) criteria. The tested flowable materials were Voco Grandio Flow + Voco Solobond M, Vivadent Tetric EvoFlow + Vivadent Excite, Dentsply X-Flow + Dentsply Prime&Bond NT, and 3M ESPE Filtek Supreme XT Flow + 3M ESPE Scotchbond Universal. The retention and marginal adaptation rates were highest for Grandio Flow and X Flow materials after 36 months, resulting in the highest score of clinical acceptability at 95.3% and 97.6%, respectively. The Tetric EvoFlow and Filtek Supreme XT Flow had the same retention rate after 36 months at 88.1%. Statistical significance was found in Grandio flow material in postoperative sensitivity criteria ( p = 0.021). Tetric EvoFlow showed statistical differences in retention ( p = 0.01), color match ( p = 0.004), and marginal adaptation ( p = 0.042). Filtek Supreme showed statistical differences in retention ( p = 0.01) and marginal adaptation ( p < 0.001). The flowable composite materials showed excellent clinical efficacy after 36 months of their clinical usage. There was no difference among the tested flowable composite materials quality in Small Class I restorations over time.",2021,Filtek Supreme showed statistical differences in retention ( p = 0.01) and marginal adaptation ( p < 0.001).,"['229 Small Class I restorations/103 children at baseline, 12, 24, and 36 months with modified United States Public Health Services (USPHS) criteria', 'Permanent Molars Small Class I Restorations', 'Small Class I restorations in permanent molars']",['Flowable Composite Materials'],"['clinical efficacy', 'retention and marginal adaptation rates', 'Voco Grandio Flow + Voco Solobond M, Vivadent Tetric EvoFlow + Vivadent Excite, Dentsply X-Flow ', 'marginal adaptation', 'retention rate', 'clinical acceptability']","[{'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0441885', 'cui_str': 'Class 1'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0041734', 'cui_str': 'United States. Public Health Service'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}]","[{'cui': 'C0673997', 'cui_str': 'flowable hybrid composite'}, {'cui': 'C0520510', 'cui_str': 'Material'}]","[{'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C1721468', 'cui_str': 'Grandio'}, {'cui': 'C0966119', 'cui_str': 'Solobond M'}, {'cui': 'C0148539', 'cui_str': 'Vivadent'}, {'cui': 'C0292041', 'cui_str': 'Tetric'}, {'cui': 'C0112984', 'cui_str': 'Dentsply'}, {'cui': 'C4308551', 'cui_str': 'X-Flow'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",229.0,0.136407,Filtek Supreme showed statistical differences in retention ( p = 0.01) and marginal adaptation ( p < 0.001).,"[{'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Dukić', 'Affiliation': 'School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia.'}, {'ForeName': 'Mia', 'Initials': 'M', 'LastName': 'Majić', 'Affiliation': 'Public Health Clinic Daruvar, 43500 Daruvar, Croatia.'}, {'ForeName': 'Natalija', 'Initials': 'N', 'LastName': 'Prica', 'Affiliation': 'Dental Polyclinic Zagreb, 10000 Zagreb, Croatia.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Oreški', 'Affiliation': 'Clinical Hospital Dubrava, 10000 Zagreb, Croatia.'}]","Materials (Basel, Switzerland)",['10.3390/ma14154283'] 2170,34364301,Low-volume walking HIIT: Efficient strategy to improve physical capacity and reduce the risk of cardiovascular disease in older women with type 2 diabetes.,"BACKGROUND AND AIMS To compare the effect of a low-volume walking high-intensity interval training (HIIT) to moderate-intensity continuous training (MICT) on risk of cardiovascular diseases and physical capacity in older women with type 2 diabetes (T2D). METHODS Thirty inactive older women with T2D were randomized into either HIIT (75 min/week) or MICT (150 min/week). Cardiovascular risk profile (lipid profile; waist circumference and fat mass; resting, post-exercise and ambulatory blood pressure [BP]; VO 2 peak; UKPDS score; ABC's) and physical capacity were assessed before and after a 12-week intervention. RESULTS While resting systolic and diastolic BP (all p ≤ 0.01) were reduced, ambulatory BP (p ≥ 0.49) and lipid profile (p ≥ 0.40) remained unchanged after the intervention. Although VO 2 peak increased to a similar extent in both groups (p = 0.015), the distance covered during the 6MWT (p = 0.01) and grip strength (p = 0.02) increased to a greater extend in HIIT. The UKPDS risk score decreased in both groups after the intervention (p = 0.03) and 31% of the participants reached the ABC's compared to 24% at baseline. CONCLUSION Low-volume walking HIIT is an efficient exercise intervention for older women with T2D as it improved some CVD risk factors and physical capacity. Nevertheless, neither low-volume HIIT nor MICT is sufficient to affect ambulatory blood pressure in T2D patients.",2021,"The UKPDS risk score decreased in both groups after the intervention (p = 0.03) and 31% of the participants reached the ABC's compared to 24% at baseline. ","['older women with type 2 diabetes (T2D', 'T2D patients', 'older women with T2D', 'Thirty inactive older women with T2D', 'older women with type 2 diabetes']","['low-volume walking high-intensity interval training (HIIT) to moderate-intensity continuous training (MICT', 'Low-volume walking HIIT', 'MICT']","['lipid profile', 'UKPDS risk score', ""Cardiovascular risk profile (lipid profile; waist circumference and fat mass; resting, post-exercise and ambulatory blood pressure [BP]; VO 2 peak; UKPDS score; ABC's) and physical capacity"", 'ambulatory blood pressure', 'ambulatory BP', 'resting systolic and diastolic BP', 'grip strength']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0152244', 'cui_str': 'Aneurysmal bone cyst'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}]",,0.0111654,"The UKPDS risk score decreased in both groups after the intervention (p = 0.03) and 31% of the participants reached the ABC's compared to 24% at baseline. ","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Marcotte-Chénard', 'Affiliation': ""Faculty of Physical Activity Sciences, University of Sherbrooke, Sherbrooke, QC, J1K 2R1, Canada; Research Centre on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, J1H 4C4, Canada.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Tremblay', 'Affiliation': ""Research Centre on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, J1H 4C4, Canada; Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, J1H 5N4, Canada.""}, {'ForeName': 'M-M', 'Initials': 'MM', 'LastName': 'Mony', 'Affiliation': ""Faculty of Physical Activity Sciences, University of Sherbrooke, Sherbrooke, QC, J1K 2R1, Canada; Research Centre on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, J1H 4C4, Canada.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Brochu', 'Affiliation': ""Faculty of Physical Activity Sciences, University of Sherbrooke, Sherbrooke, QC, J1K 2R1, Canada; Research Centre on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, J1H 4C4, Canada.""}, {'ForeName': 'I J', 'Initials': 'IJ', 'LastName': 'Dionne', 'Affiliation': ""Faculty of Physical Activity Sciences, University of Sherbrooke, Sherbrooke, QC, J1K 2R1, Canada; Research Centre on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, J1H 4C4, Canada.""}, {'ForeName': 'M F', 'Initials': 'MF', 'LastName': 'Langlois', 'Affiliation': 'Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, J1H 5N4, Canada; Research Centre of the CHUS, Sherbrooke, QC, J1H 5N4, Canada.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Mampuya', 'Affiliation': 'Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, J1H 5N4, Canada.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Morais', 'Affiliation': 'Research Centre of McGill University Health Centre (MUHC) and Division of Geriatric Medicine of MUHC, Montréal, QC, H4A 3J1, Canada.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Tessier', 'Affiliation': ""Research Centre on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, J1H 4C4, Canada; Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, J1H 5N4, Canada.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Riesco', 'Affiliation': ""Faculty of Physical Activity Sciences, University of Sherbrooke, Sherbrooke, QC, J1K 2R1, Canada; Research Centre on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, J1H 4C4, Canada. Electronic address: E.Riesco@USherbrooke.ca.""}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2021.102233'] 2171,34364265,"Effect of the consumption of yacon flour and energy-restricted diet on glycation markers, and association between these markers and factors linked to obesity in adults with excess body weight: A randomized, double-blind, placebo-controlled clinical trial.","OBJECTIVES Regardless of the positive effect of yacon on metabolic markers, this food contains fructose molecules, which can originate advanced glycation end products (AGEs). High AGEs serum concentrations can contribute to excess body weight. We evaluated the effect of consuming an energy-restricted diet and yacon flour on glycation markers concentrations, and the associations between these markers and factors linked to obesity in adults with excess body weight. METHODS Twenty-six adults with excess body weight were included in this randomized, parallel, double-blind, placebo-controlled, 6-week clinical trial. Subjects were randomly allocated to the control group (n = 13) or the yacon-flour group (n = 13), and daily consumed a breakfast drink either not containing or containing 25 g of yacon flour (8.7 g of fructooligosaccharides). Energy-restricted diets were prescribed for both groups. Biochemical markers, anthropometric variables, and body composition were evaluated at baseline and the end of the study. RESULTS AGEs and early glycation products did not increase in the yacon flour group. Soluble receptor for AGEs (sRAGE) decreased regardless of group. Besides, changes in AGEs were positively associated with changes in body fat (β = 0.04, P = 0.038) and in sRAGE, with insulin (β = 0.02, P = 0.035) and homeostasis model assessment index of insulin resistance (β = 0.01, P = 0.049). CONCLUSIONS The consumption of 25 g of yacon flour associated with an energy-restricted diet did not increase concentrations of glycation markers. Changes in glycation markers were positively associated with changes in consolidated anthropometric and biochemical markers related to being overweight. Assessing glycation markers may be a useful strategy for monitoring responses to dietary interventions in subjects with excess body weight.",2021,The consumption of 25 g of yacon flour associated with an energy-restricted diet did not increase concentrations of glycation markers.,"['subjects with excess body weight', 'Twenty-six adults with excess body weight', 'adults with excess body weight']","['placebo', 'consumption of yacon flour and energy-restricted diet', 'control group (n\xa0=\xa013) or the yacon-flour group (n\xa0=\xa013), and daily consumed a breakfast drink either not containing or containing 25 g of yacon flour', 'energy-restricted diet and yacon flour']","['glycation markers', 'body fat', 'homeostasis model assessment index of insulin resistance', 'concentrations of glycation markers', 'Biochemical markers, anthropometric variables, and body composition']","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0016260', 'cui_str': 'Flour'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0456638', 'cui_str': '25G'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}]",26.0,0.0831927,The consumption of 25 g of yacon flour associated with an energy-restricted diet did not increase concentrations of glycation markers.,"[{'ForeName': 'Priscila Vaz de Melo', 'Initials': 'PVM', 'LastName': 'Ribeiro', 'Affiliation': 'Departamento de Nutrição e Saúde, Universidade Federal de Viçosa, Viçosa, Brazil. Electronic address: priscilavazdemelo@yahoo.com.br.'}, {'ForeName': 'Adriane Moreira', 'Initials': 'AM', 'LastName': 'Machado', 'Affiliation': 'Departamento de Nutrição e Saúde, Universidade Federal de Viçosa, Viçosa, Brazil.'}, {'ForeName': 'Nayara Benedito Martins', 'Initials': 'NBM', 'LastName': 'da Silva', 'Affiliation': 'Departamento de Ciência e Tecnologia de Alimentos, Universidade Federal de Viçosa, Viçosa, Brazil.'}, {'ForeName': 'Leandro Licursi', 'Initials': 'LL', 'LastName': 'de Oliveira', 'Affiliation': 'Departamento de Biologia Geral, Universidade Federal de Viçosa, Viçosa, Brazil.'}, {'ForeName': 'Rita de Cássia Gonçalves', 'Initials': 'RCG', 'LastName': 'Alfenas', 'Affiliation': 'Departamento de Nutrição e Saúde, Universidade Federal de Viçosa, Viçosa, Brazil.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2021.111395'] 2172,34364192,Smoking reduction is associated with lower alcohol consumption and depressive symptoms among young adults over one year.,"BACKGROUND This secondary analysis examined whether smoking reduction among young adults participating in a Facebook-based smoking cessation intervention study was associated with corresponding reductions in alcohol consumption and depressive symptoms. METHODS Participants were young adults who smoked and engaged in heavy episodic drinking (HED). Alcohol consumption (AUDIT-C, days of HED), depressive symptoms (PHQ-2), and past-month cigarettes per day (CPD) were self-reported at baseline and 12 months (N = 150). Linear regression estimated the relationship between the mean change in CPD and mean changes in alcohol consumption and depressive symptoms. RESULTS CPD, alcohol consumption, and depressive symptoms decreased significantly between baseline and 12 months. The adjusted mean reduction in CPD was significantly associated with mean reductions in AUDIT-C (Beta [β] = 0.09, 95 % confidence interval [CI] = 0.04-0.14), days of HED (β = 0.17, 95 % CI = 0.04-0.29) and PHQ-2 (β = 0.05, 95 % CI = 0.01-0.08). Smoking abstinence (n = 48) was associated with a significantly larger mean reduction in AUDIT-C compared to a ≥50 % reduction (n = 45) (-2.9 vs -1.7 points, p = 0.03) or <50 % reduction in CPD (n = 57) (-2.9 vs -1.1 points, p < 0.01). The mean reduction in AUDIT-C did not differ between a ≥50 % reduction and <50 % reduction in CPD (-1.7 vs.-1.1 points, p = 0.18). Mean reductions in days of HED and the PHQ-2 did not differ according to the level of reduction in CPD. CONCLUSION Smoking reduction was associated with reductions in alcohol consumption and depressive symptoms. Reductions appeared to be greater for those who achieved abstinence compared to a reduction in smoking.",2021,"The mean reduction in AUDIT-C did not differ between a ≥50 % reduction and <50 % reduction in CPD (-1.7 vs.-1.1 points, p = 0.18).","['young adults participating in a Facebook-based smoking cessation intervention study', 'Participants were young adults who smoked and engaged in heavy episodic drinking (HED']",[],"['Alcohol consumption (AUDIT-C, days of HED), depressive symptoms (PHQ-2), and past-month cigarettes per day (CPD', 'CPD, alcohol consumption, and depressive symptoms', 'CPD', 'Smoking abstinence', 'alcohol consumption and depressive symptoms']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}]",[],"[{'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C2706101', 'cui_str': 'PHQ-2'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}]",150.0,0.119735,"The mean reduction in AUDIT-C did not differ between a ≥50 % reduction and <50 % reduction in CPD (-1.7 vs.-1.1 points, p = 0.18).","[{'ForeName': 'Juliet C', 'Initials': 'JC', 'LastName': 'Yonek', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California at San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA; Zuckerberg San Francisco General Hospital and Trauma Center, 1001 Potrero Avenue, San Francisco, CA 94110, USA. Electronic address: juliet.yonek@ucsf.edu.'}, {'ForeName': 'Meredith C', 'Initials': 'MC', 'LastName': 'Meacham', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California at San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA. Electronic address: meredith.meacham@ucsf.edu.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Shumway', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California at San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA; Zuckerberg San Francisco General Hospital and Trauma Center, 1001 Potrero Avenue, San Francisco, CA 94110, USA. Electronic address: martha.shumway@ucsf.edu.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Tolou-Shams', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California at San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA; Zuckerberg San Francisco General Hospital and Trauma Center, 1001 Potrero Avenue, San Francisco, CA 94110, USA. Electronic address: marina.tolou-shams@ucsf.edu.'}, {'ForeName': 'Derek D', 'Initials': 'DD', 'LastName': 'Satre', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California at San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA; Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, Oakland, CA 94612, USA. Electronic address: derek.satre@ucsf.edu.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2021.108922'] 2173,34364099,Superficial vs. deep serratus anterior plane block for analgesia in patients undergoing mastectomy: A randomized prospective trial.,"STUDY OBJECTIVE In the initial description of the serratus anterior plane block (SAPB), both superficial and deep SAPB provided effective blockade. The purpose of this study was to investigate the difference in opioid consumption and postoperative analgesia between superficial and deep SAPB for patients undergoing mastectomy. DESIGN Randomized prospective trial. SETTING Academic hospital. PATIENTS 64 women, >18 years of age, ASA I-III, undergoing single or bilateral mastectomy, with and without lymph node biopsy, with and without tissue expander reconstruction. INTERVENTION Either superficial or deep SAPB by an ultrasound-guided technique in addition to multimodal analgesia. MEASUREMENTS The primary outcome was opioid consumption in the first 24 h. Secondary outcomes were pain scores, satisfaction scores, incidence of PONV, length of stay and block performance time. RESULTS Subjects who received a deep SAPB required 30% less oral morphine equivalents (OME) (113.5 mg vs. 147 mg, p = 0.009) and reported lower pain scores. There were no significant differences in satisfaction scores, incidence of PONV, LOS, or block performance time between the two groups. CONCLUSION There was a significant difference in opioid consumption between the deep and superficial SAPB groups. Subjects in the deep SAPB group had lower pain scores at 12 h; however, the difference was not statistically significant at other time points. While both the superficial and the deep SAPB can be used for post-operative analgesia in patients undergoing mastectomy, our study suggests that the deep SAPB may improve analgesia to a greater degree than the superficial SAPB as shown through decreased opioid consumption of 30% over a 24-h period post-block. CLINICAL TRIAL NUMBER AND REGISTRY URL: clinicaltrials.gov: NCT03154658.",2021,"Subjects in the deep SAPB group had lower pain scores at 12 h; however, the difference was not statistically significant at other time points.","['patients undergoing mastectomy', '18\xa0years of age, ASA I-III, undergoing single or bilateral mastectomy, with and without lymph node biopsy, with and without tissue expander reconstruction', '64 women', 'Academic hospital']",['Superficial vs. deep serratus anterior plane block'],"['lower pain scores', 'oral morphine equivalents (OME', 'pain scores, satisfaction scores, incidence of PONV, length of stay and block performance time', 'satisfaction scores, incidence of PONV, LOS, or block performance time', 'opioid consumption and postoperative analgesia', 'opioid consumption', 'pain scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0191877', 'cui_str': 'Bilateral mastectomy'}, {'cui': 'C0193842', 'cui_str': 'Biopsy of lymph node'}, {'cui': 'C0040289', 'cui_str': 'Tissue expander'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0224349', 'cui_str': 'Structure of serratus anterior muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0360457', 'cui_str': 'Morphine-containing product in oral dose form'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}]",,0.165569,"Subjects in the deep SAPB group had lower pain scores at 12 h; however, the difference was not statistically significant at other time points.","[{'ForeName': 'Jason T', 'Initials': 'JT', 'LastName': 'Edwards', 'Affiliation': 'Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical Center, Dallas, TX, United States of America.'}, {'ForeName': 'Xuan T', 'Initials': 'XT', 'LastName': 'Langridge', 'Affiliation': 'Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical Center, Dallas, TX, United States of America.'}, {'ForeName': 'Gloria S', 'Initials': 'GS', 'LastName': 'Cheng', 'Affiliation': 'Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical Center, Dallas, TX, United States of America.'}, {'ForeName': 'Mandy M', 'Initials': 'MM', 'LastName': 'McBroom', 'Affiliation': 'Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical Center, Dallas, TX, United States of America.'}, {'ForeName': 'Abu', 'Initials': 'A', 'LastName': 'Minhajuddin', 'Affiliation': 'Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical Center, Dallas, TX, United States of America.'}, {'ForeName': 'Anthony T', 'Initials': 'AT', 'LastName': 'Machi', 'Affiliation': 'Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical Center, Dallas, TX, United States of America. Electronic address: anthony.machi@utsouthwestern.edu.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2021.110470'] 2174,34365136,The prognostic significance of grade of ischemia in the ECG in patients with ST-elevation myocardial infarction: A substudy of the randomized trial of primary PCI with or without routine manual thrombectomy (TOTAL trial).,"BACKGROUND The importance of the grade of ischemia (GI) ECG classification in the risk assessment of patients with STEMI has been shown previously. Grade 3 ischemia (G3I) is defined as ST-elevation with distortion of the terminal portion of the QRS complex in two or more adjacent leads, while Grade 2 ischemia (G2I) is defined as ST-elevation without QRS distortion. Our aim was to evaluate the prognostic impact of the GI classification on the outcome in patients with STEMI. METHODS 7,211 patients from the TOTAL trial were included in our study. The primary outcome was a composite of cardiovascular death, recurrent myocardial infarction (MI), cardiogenic shock, or New York Heart Association (NYHA) class IV heart failure within one year. RESULTS The primary outcome occurred in 153 of 1,563 patients (9.8%) in the G3I group vs. 364 of 5,648 patients (6.4%) in the G2I group (adjusted HR 1.27; 95% CI, 1.04 - 1.55; p=0.022). The rate of cardiovascular death (4.8% vs. 2.5%; adjusted HR 1.48; 95% CI 1.09 - 2.00; p=0.013) was also higher in patients with G3I. CONCLUSIONS G3I in the presenting ECG was associated with an increased rate of the composite of cardiovascular death, recurrent MI, cardiogenic shock, or NYHA class IV heart failure within one year compared to patients with G2I. Patients with G3I also had a higher cardiovascular death compared to patients with G2I.",2021,"The rate of cardiovascular death (4.8% vs. 2.5%; adjusted HR 1.48; 95% CI 1.09 - 2.00; p=0.013) was also higher in patients with G3I. ","['patients with STEMI', 'patients with G3I', '7,211 patients from the TOTAL trial were included in our study', 'patients with ST-elevation myocardial infarction']",[],"['rate of the composite of cardiovascular death, recurrent MI, cardiogenic shock, or NYHA class IV heart failure', 'composite of cardiovascular death, recurrent myocardial infarction (MI), cardiogenic shock, or New York Heart Association (NYHA) class IV heart failure within one year', 'Grade 3 ischemia (G3I', 'cardiovascular death', 'rate of cardiovascular death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1303258', 'cui_str': 'Acute ST segment elevation myocardial infarction'}]",[],"[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0036980', 'cui_str': 'Cardiogenic shock'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441888', 'cui_str': 'Class 4'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}]",7211.0,0.329499,"The rate of cardiovascular death (4.8% vs. 2.5%; adjusted HR 1.48; 95% CI 1.09 - 2.00; p=0.013) was also higher in patients with G3I. ","[{'ForeName': 'Joonas', 'Initials': 'J', 'LastName': 'Leivo', 'Affiliation': 'Internal medicine, Kanta-Häme Central Hospital, Hämeenlinna, Ahvenistontie 20, 13530 Hämeenlinna, Finland; Faculty of Medicine and Health Technology, Tampere University and Finnish Cardiovascular Research Center, Tampere, Arvo Ylpön katu 34, 33520 Tampere, Finland. Electronic address: joonas.leivo@fimnet.fi.'}, {'ForeName': 'Eero', 'Initials': 'E', 'LastName': 'Anttonen', 'Affiliation': 'Päijät-sote, Primary health care, Lahti, Keskussairaalankatu 7, 15850 Lahti, Finland.'}, {'ForeName': 'Sanjit S', 'Initials': 'SS', 'LastName': 'Jolly', 'Affiliation': 'Population Health Research Institute, Hamilton, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada; Department of Medicine, McMaster University, Hamilton, 1280 Main Street West, Hamilton, Ontario L8S4L8, Canada; Hamilton Health Sciences, Hamilton, P.O. Box 2000, Hamilton, ON L8N 3Z5, Canada.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Dzavik', 'Affiliation': 'Peter Munk Cardiac Centre, University Health Network, Toronto, R. Fraser Elliott Building, 1st Floor 190 Elizabeth St., Toronto, ON M5G 2C4, Canada.'}, {'ForeName': 'Jyri', 'Initials': 'J', 'LastName': 'Koivumäki', 'Affiliation': 'Heart Center, Department of Cardiology, Tampere University Hospital, Tays Sydänkeskus Oy, PL 2000, 33521 Tampere, Finland.'}, {'ForeName': 'Minna', 'Initials': 'M', 'LastName': 'Tahvanainen', 'Affiliation': 'Heart Center, Department of Cardiology, Tampere University Hospital, Tays Sydänkeskus Oy, PL 2000, 33521 Tampere, Finland.'}, {'ForeName': 'Kimmo', 'Initials': 'K', 'LastName': 'Koivula', 'Affiliation': 'Internal medicine, South Karelia Central Hospital, Valto Käkelän katu 1, Lappeenranta 53130, Finland.'}, {'ForeName': 'Kjell', 'Initials': 'K', 'LastName': 'Nikus', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University and Finnish Cardiovascular Research Center, Tampere, Arvo Ylpön katu 34, 33520 Tampere, Finland; Heart Center, Department of Cardiology, Tampere University Hospital, Tays Sydänkeskus Oy, PL 2000, 33521 Tampere, Finland.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Population Health Research Institute, Hamilton, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada; Department of Medicine, McMaster University, Hamilton, 1280 Main Street West, Hamilton, Ontario L8S4L8, Canada; David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Faculty of Health Sciences, 1280 Main St. W., Hamilton, Ontario L8S4K1, Canada.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Cairns', 'Affiliation': 'The University of British Columbia, 2329 West Mall, Vancouver, British Columbia V6T1Z4, Canada.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Niemelä', 'Affiliation': 'Heart Center, Department of Cardiology, Tampere University Hospital, Tays Sydänkeskus Oy, PL 2000, 33521 Tampere, Finland.'}, {'ForeName': 'Markku', 'Initials': 'M', 'LastName': 'Eskola', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University and Finnish Cardiovascular Research Center, Tampere, Arvo Ylpön katu 34, 33520 Tampere, Finland; Heart Center, Department of Cardiology, Tampere University Hospital, Tays Sydänkeskus Oy, PL 2000, 33521 Tampere, Finland.'}]",Journal of electrocardiology,['10.1016/j.jelectrocard.2021.07.015'] 2175,34365104,Can machine learning improve randomized clinical trial analysis?,"PURPOSE Recently a realistic simulator of patient seizure diaries was developed that can reproduce effects seen in randomized clinical trials (RCTs). RCTs suffer from high costs and statistical inefficiencies. Using realistic simulation and machine learning this study aimed to identify a more statistically efficient outcome metric. METHODS Five candidate deep learning architectures with 54 permutations of hyperparameters were compared to the traditional standard, median percent change (MPC). Each were also tested for type 1 error. All models had similar outcomes, with appropriate low levels of type 1 error. RESULTS The simplest model was equivalent to a logistic regression of a histogram of individual percentage changes in seizure rate, requiring 21-22% less patients to discriminate drug from placebo at 90% power. This model was referred to as LPC. CONCLUSION Future studies to validate LPC may enable faster, cheaper and more efficient clinical trials.",2021,"All models had similar outcomes, with appropriate low levels of type 1 error. ",['Five candidate deep learning architectures with 54 permutations of hyperparameters'],['placebo'],[],"[{'cui': 'C4704761', 'cui_str': 'Hierarchical Learning'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.2711,"All models had similar outcomes, with appropriate low levels of type 1 error. ","[{'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Romero', 'Affiliation': 'Harvard Beth Israel Deaconess Medical Center, Boston MA, United States. Electronic address: jromero5@bidmc.harvard.edu.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Chiang', 'Affiliation': 'University of California San Francisco, San Francisco, CA, United States. Electronic address: Sharon.Chiang@ucsf.edu.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Goldenholz', 'Affiliation': 'Harvard Beth Israel Deaconess Medical Center, Boston MA, United States. Electronic address: daniel.goldenholz@bidmc.harvard.edu.'}]",Seizure,['10.1016/j.seizure.2021.07.033'] 2176,34365067,Respiratory-gated auricular vagal afferent nerve stimulation (RAVANS) modulates brain response to stress in major depression.,"BACKGROUND Negative stress significantly impacts major depressive disorder (MDD), given the shared brain circuitry between the stress response and mood. Thus, interventions that target this circuitry will have an important impact on MDD. The aim of this study was to evaluate the acute effects of a novel respiratory-gated auricular vagal afferent nerve stimulation (RAVANS) technique in the modulation of brain activity and connectivity in women with MDD in response to negative stressful stimuli. METHODS Twenty premenopausal women with recurrent MDD in an active episode were included in a cross-over experimental study that included two functional MRI visits within one week, randomized to receive exhalatory- (e-RAVANS) or inhalatory-gated (i-RAVANS) at each visit. Subjects were exposed to a visual stress challenge that preceded and followed RAVANS. A Factorial analysis was used to evaluate the effects of RAVANS on brain activity and connectivity and changes in depressive and anxiety symptomatology post-stress. RESULTS Compared with i-RAVANS, e-RAVANS was significantly associated with increased activation of subgenual anterior cingulate, orbitofrontal and ventromedial prefrontal cortices and increased connectivity between hypothalamus and dorsolateral prefrontal cortex, and from nucleus tractus solitarii to locus coeruleus and ventromedial prefrontal cortex. Changes in brain activity and connectivity after e-RAVANS were significantly associated with a reduction in depressive and anxiety symptoms. CONCLUSIONS Our study suggests exhalatory-gated RAVANS effectively modulates brain circuitries regulating response to negative stress and is associated with significant acute reduction of depressive and anxiety symptomatology in women with recurrent MDD. Findings suggest a potential non-pharmacologic intervention for acute relief of depressive symptomatology in MDD.",2021,"Compared with i-RAVANS, e-RAVANS was significantly associated with increased activation of subgenual anterior cingulate, orbitofrontal and ventromedial prefrontal cortices and increased connectivity between hypothalamus and dorsolateral prefrontal cortex, and from nucleus tractus solitarii to locus coeruleus and ventromedial prefrontal cortex.","['women with MDD in response to negative stressful stimuli', 'Twenty premenopausal women with recurrent MDD in an active episode were included in a cross-over experimental study that included two functional MRI visits within one week, randomized to receive', 'women with recurrent MDD']","['exhalatory', 'novel respiratory-gated auricular vagal afferent nerve stimulation (RAVANS) technique', 'RAVANS', 'Respiratory-gated auricular vagal afferent nerve stimulation (RAVANS', 'pharmacologic intervention', 'inhalatory-gated']","['activation of subgenual anterior cingulate, orbitofrontal and ventromedial prefrontal cortices and increased connectivity between hypothalamus and dorsolateral prefrontal cortex, and from nucleus tractus solitarii to locus coeruleus and ventromedial prefrontal cortex', 'depressive and anxiety symptoms', 'brain activity and connectivity', 'brain activity and connectivity and changes in depressive and anxiety symptomatology post-stress']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0154409', 'cui_str': 'Recurrent major depressive episodes'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C1442452', 'cui_str': 'One week'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0237633', 'cui_str': 'Sensory Filtering'}, {'cui': 'C1522191', 'cui_str': 'Otic route'}, {'cui': 'C0205115', 'cui_str': 'Afferent'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C3850122', 'cui_str': 'Ventral Medial Prefrontal Cortex'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0020663', 'cui_str': 'Hypothalamic structure'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0175518', 'cui_str': 'Structure of nucleus of tractus solitarius'}, {'cui': 'C0023951', 'cui_str': 'Structure of locus ceruleus'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",20.0,0.0237174,"Compared with i-RAVANS, e-RAVANS was significantly associated with increased activation of subgenual anterior cingulate, orbitofrontal and ventromedial prefrontal cortices and increased connectivity between hypothalamus and dorsolateral prefrontal cortex, and from nucleus tractus solitarii to locus coeruleus and ventromedial prefrontal cortex.","[{'ForeName': 'Ronald G', 'Initials': 'RG', 'LastName': 'Garcia', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Innovation Center on Sex Differences in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Justine E', 'Initials': 'JE', 'LastName': 'Cohen', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Innovation Center on Sex Differences in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Arielle D', 'Initials': 'AD', 'LastName': 'Stanford', 'Affiliation': 'Translational Medicine, Alkermes Inc, Waltham, MA, USA.'}, {'ForeName': 'Aileen', 'Initials': 'A', 'LastName': 'Gabriel', 'Affiliation': 'Innovation Center on Sex Differences in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Stowell', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Harlyn', 'Initials': 'H', 'LastName': 'Aizley', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Innovation Center on Sex Differences in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Barbieri', 'Affiliation': 'Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milano, Italy; Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gitlin', 'Affiliation': ""Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Vitaly', 'Initials': 'V', 'LastName': 'Napadow', 'Affiliation': 'Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Innovation Center on Sex Differences in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Logan University, Chesterfield, MO, USA.'}, {'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Goldstein', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Innovation Center on Sex Differences in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: jill_goldstein@hms.harvard.edu.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2021.07.048'] 2177,34365066,Pharmacist driven antibiotic redosing in the emergency department.,"STUDY OBJECTIVE Determine whether an expanded emergency medicine (EM) pharmacist scope of practice reduces the frequency of major delays in subsequent antibiotic administration in patients boarded in the emergency department (ED). METHODS A pre-post, quasi-experimental study conducted from November 2019-March 2020 at a single-center tertiary academic medical center following the implementation of an expanded EM pharmacist scope of practice. Adult patients were included if they received an initial antibiotic dose in the ED and deemed to be high-risk. Subsequent antibiotic doses were reordered by EM pharmacists for up to 24-h after the initial order pending ED length of stay (LOS). The historical control group consisted of retrospective chart review of cases from the previous year. RESULTS The study identified that of the 181 participants enrolled, major delays in subsequent antibiotic administration occurred in 13% of the intervention group and 48% of the control group (p < 0.01). When compared to the control group, the intervention group had a significant decrease in the number of delays among antibiotics dosed at 6-h (39% vs 13%) and 8-h (60% vs 8%) intervals. For antibiotics dosed at 12-h intervals, no statistically significant difference was observed between the control and intervention groups respectively (19% vs 5%). A statistically significant lower incidence of in-hospital mortality was observed in the intervention group (3% vs 11%, p = 0.02). In the intervention group, 97% of patients received subsequent antibiotic doses while boarded in the ED, compared to 65% in the control group (<0.01). CONCLUSION Expanding EM pharmacist scope of practice was associated with a significant reduction in the frequency of major delays in subsequent antibiotic administration as well as a decreased incidence of hospital mortality.",2021,"When compared to the control group, the intervention group had a significant decrease in the number of delays among antibiotics dosed at 6-h (39% vs 13%) and 8-h (60% vs 8%) intervals.","['A pre-post, quasi-experimental study conducted from November 2019-March 2020 at a single-center tertiary academic medical center following the implementation of an expanded EM pharmacist scope of practice', 'patients boarded in the emergency department (ED', 'Adult patients', '181 participants enrolled']",[],"['hospital mortality', 'major delays in subsequent antibiotic administration', 'number of delays among antibiotics']","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C2985410', 'cui_str': 'Controlled Clinical Trials, Non-Randomized'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C0013964', 'cui_str': 'Emergency medicine'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C5197872', 'cui_str': 'Scope of Practice'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0199779', 'cui_str': 'Administration of antibiotic'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}]",181.0,0.0236916,"When compared to the control group, the intervention group had a significant decrease in the number of delays among antibiotics dosed at 6-h (39% vs 13%) and 8-h (60% vs 8%) intervals.","[{'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Payne-Cardona', 'Affiliation': 'Department of Pharmacy Services, Amita Health Resurrection Medical Center Chicago, 7435 W Talcott Ave, Chicago, IL 60631, USA. Electronic address: monique.paynecardona@gmail.com.'}, {'ForeName': 'Valerie A', 'Initials': 'VA', 'LastName': 'San Luis', 'Affiliation': 'Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: Valerie.Sanluis@cshs.org.'}, {'ForeName': 'Roshanak', 'Initials': 'R', 'LastName': 'Aazami', 'Affiliation': 'Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: Roshanak.Aazami@cshs.org.'}, {'ForeName': 'Mira', 'Initials': 'M', 'LastName': 'Dermendjieva', 'Affiliation': 'Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: Lubomira.Dermendjieva@cshs.org.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Erin', 'Affiliation': 'Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: Melissa.Erin@cshs.org.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Kirkwood', 'Affiliation': 'Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: Jason.Kirkwood@cshs.org.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Tong', 'Affiliation': 'Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: Christopher.Tong@cshs.org.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Marks', 'Affiliation': 'Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: Gregory.Marks@cshs.org.'}, {'ForeName': 'Ethan A', 'Initials': 'EA', 'LastName': 'Smith', 'Affiliation': 'Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: Ethan.Smith@cshs.org.'}, {'ForeName': 'Sam S', 'Initials': 'SS', 'LastName': 'Torbati', 'Affiliation': 'Department of Emergency Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA. Electronic address: Sam.Torbati@cshs.org.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Gilmore', 'Affiliation': 'Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: James.Gilmore@cshs.org.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2021.07.039'] 2178,34365063,Comparing two doses of intramuscular ketorolac for treatment of acute musculoskeletal pain in a military emergency department.,"STUDY OBJECTIVE The goal of the study was to assess a low-dose versus a high-dose of intramuscular (IM) ketorolac for non-inferiority in adults with acute MSK pain in an emergency department (ED). METHODS This was a single-blinded, randomized controlled, non-inferiority trial of adults presenting to an ED with a chief complaint of acute MSK pain. Patients were randomized to either a 15 mg or a 60 mg IM ketorolac dose. The primary outcome was the mean difference of change in pain from baseline to 60-min between the two groups as reported on a 100-mm (mm) visual analog scale (VAS). Secondary outcomes included the mean difference of change in VAS scores at 30-min and the incidence of reported adverse effects associated with the administration of ketorolac. RESULTS One hundred ten patients were randomized with 55 in each group. The mean difference in pain between groups at 60-min (0.2 mm [95% CI -8.5-8.7]; p = .98) and 30 min (-1.7 mm [95% CI -8.5-5.1; p = .63) was less than the predetermined non-inferiority margin of 13 mm. There were no major adverse effects reported. Minor adverse effects were more frequent in the 60 mg group (n = 9; 16.4% vs. n = 1; 1.8%; p = .016) with burning at the injection site being the most commonly reported. CONCLUSIONS A 15 mg dose of IM ketorolac was found to be non-inferior to a 60 mg dose for acute MSK pain in adults presenting to the ED. Discontinuing the practice of ordering 60 mg doses of IM ketorolac in place of a lower dose for acute MSK pain should be considered.",2021,"Minor adverse effects were more frequent in the 60 mg group (n = 9; 16.4% vs. n = 1; 1.8%; p = .016) with burning at the injection site being the most commonly reported. ","['acute musculoskeletal pain in a military emergency department', 'adults presenting to an ED with a chief complaint of acute MSK pain', 'One hundred ten patients were randomized with 55 in each group', 'adults with acute MSK pain in an emergency department (ED']","['60 mg IM ketorolac', 'intramuscular (IM) ketorolac', 'intramuscular ketorolac', 'IM ketorolac']","['mean difference of change in pain', 'mean difference of change in VAS scores', 'Minor adverse effects', '100-mm (mm) visual analog scale (VAS', 'mean difference in pain']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal pain'}, {'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",110.0,0.512567,"Minor adverse effects were more frequent in the 60 mg group (n = 9; 16.4% vs. n = 1; 1.8%; p = .016) with burning at the injection site being the most commonly reported. ","[{'ForeName': 'Nathaniel J', 'Initials': 'NJ', 'LastName': 'Turner', 'Affiliation': '5005 N Piedras St, El Paso, TX 79920, USA; Department of Emergency Medicine, WBAMC, Fort Bliss, USA. Electronic address: nateturnerpac@gmail.com.'}, {'ForeName': 'Drew A', 'Initials': 'DA', 'LastName': 'Long', 'Affiliation': '5005 N Piedras St, El Paso, TX 79920, USA; Department of Emergency Medicine, WBAMC, Fort Bliss, USA.'}, {'ForeName': 'Joseph R', 'Initials': 'JR', 'LastName': 'Bongiorno', 'Affiliation': '5005 N Piedras St, El Paso, TX 79920, USA; Department of Emergency Medicine, WBAMC, Fort Bliss, USA. Electronic address: joseph.r.bongiorno.mil@mail.mil.'}, {'ForeName': 'Timothy P', 'Initials': 'TP', 'LastName': 'Katoski', 'Affiliation': '5005 N Piedras St, El Paso, TX 79920, USA; Department of Emergency Medicine, WBAMC, Fort Bliss, USA; Department of Emergency Medicine, MACH, Fort Benning, GA, USA. Electronic address: timothy.p.katoski.mil@mail.mil.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Jin', 'Affiliation': '5005 N Piedras St, El Paso, TX 79920, USA; Department of Emergency Medicine, WBAMC, Fort Bliss, USA. Electronic address: lisa.m.jin.mil@mail.mil.'}, {'ForeName': 'John Paul', 'Initials': 'JP', 'LastName': 'Horsch', 'Affiliation': '5005 N Piedras St, El Paso, TX 79920, USA; Department of Emergency Medicine, WBAMC, Fort Bliss, USA; Yuma Proving Ground Health Clinic, Yuma, AZ, USA.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Ahern', 'Affiliation': '5005 N Piedras St, El Paso, TX 79920, USA; Department of Emergency Medicine, WBAMC, Fort Bliss, USA.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2021.07.054'] 2179,34365016,"¡Mi Vida Saludable! A randomized, controlled, 2 × 2 factorial trial of a diet and physical activity intervention among Latina breast cancer survivors: Study design and methods.","BACKGROUND Most Latina breast cancer survivors do not meet diet and physical activity (PA) guidelines for cancer survivors and effective lifestyle interventions to adopt and maintain these recommendations are limited, especially among underserved populations. Here we describe the design, methods and enrollment of a 2 × 2 factorial-designed trial testing the separate effects of the ¡Mi Vida Saludable! (My Healthy Life!) intervention program on changes in diet and PA behaviors among Latina breast cancer survivors. METHODS Latinas with a history of stage 0-III breast cancer, no evidence of recurrent/metastatic disease, and > 90 days post-treatment were primarily identified via cancer registries and physician referral. Participants were randomized to four arms: 1) 4 weeks of in-person group sessions plus 11 months of eHealth communication, 2) in-person group sessions alone, 3) eHealth alone, or 4) control. All participants received a Fitbit to self-monitor PA. Assessments at baseline, 6 and 12 months include diet, PA, anthropometrics, predictors and mediators of behavior change, psychosocial and quality of life outcomes, and blood draw. RESULTS Of 884 women screened between January 2016 and September 2018, 27% were eligible. Primary reasons for ineligibility included not being willing/able to participate due to work/life responsibilities, health reasons, or transportation. Of 241 eligible women, 167 completed baseline assessment and enrolled. CONCLUSIONS We successfully enrolled a diverse group of breast cancer survivors representing more than 15 Latin American nationalities to a diet and physical activity trial. If effective, the ¡Mi Vida Saludable! program can be implemented by community groups and medical centers. TRIAL REGISTRATION ClinicalTrials.gov, NCT02780271, registered May 2016.",2021,"Participants were randomized to four arms: 1) 4 weeks of in-person group sessions plus 11 months of eHealth communication, 2) in-person","['Latina breast cancer survivors', 'breast cancer survivors representing more than 15 Latin American nationalities to a diet and physical activity trial', '241 eligible women, 167 completed baseline assessment and enrolled', '884 women screened between January 2016 and September 2018, 27% were eligible']","['Fitbit to self-monitor PA', 'diet and physical activity intervention', 'person group sessions plus 11\u202fmonths of eHealth communication, 2) in-person', '3) eHealth alone, or 4) control', 'Mi Vida Saludable', 'intervention program']","['diet, PA, anthropometrics, predictors and mediators of behavior change, psychosocial and quality of life outcomes, and blood draw', 'diet and PA behaviors', 'ineligibility included not being willing/able to participate due to work/life responsibilities, health reasons, or transportation']","[{'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0027473', 'cui_str': 'Nationality'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0600109', 'cui_str': 'Willing'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0040756', 'cui_str': 'Transportation'}]",241.0,0.0782037,"Participants were randomized to four arms: 1) 4 weeks of in-person group sessions plus 11 months of eHealth communication, 2) in-person","[{'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Santiago-Torres', 'Affiliation': 'Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Isobel', 'Initials': 'I', 'LastName': 'Contento', 'Affiliation': 'Teachers College, Columbia University, New York, NY, USA.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Koch', 'Affiliation': 'Teachers College, Columbia University, New York, NY, USA.'}, {'ForeName': 'Wei-Yann', 'Initials': 'WY', 'LastName': 'Tsai', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA.'}, {'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Brickman', 'Affiliation': ""Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.""}, {'ForeName': 'Ann Ogden', 'Initials': 'AO', 'LastName': 'Gaffney', 'Affiliation': 'Cook for Your Life, New York, NY, USA.'}, {'ForeName': 'Cynthia A', 'Initials': 'CA', 'LastName': 'Thomson', 'Affiliation': 'Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA.'}, {'ForeName': 'Tracy E', 'Initials': 'TE', 'LastName': 'Crane', 'Affiliation': 'College of Nursing, University of Arizona, Tucson, AZ, USA.'}, {'ForeName': 'Naxielly', 'Initials': 'N', 'LastName': 'Dominguez', 'Affiliation': 'Cook for Your Life, New York, NY, USA.'}, {'ForeName': 'Jhack', 'Initials': 'J', 'LastName': 'Sepulveda', 'Affiliation': 'Eat Good Consulting Inc., New York, NY, USA.'}, {'ForeName': 'Amanda M', 'Initials': 'AM', 'LastName': 'Marín-Chollom', 'Affiliation': 'Department of Psychological Science, Central Connecticut State University, Connecticut, CT, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Paul', 'Affiliation': 'Rachel Paul Nutrition LLC, New York, NY, USA.'}, {'ForeName': 'Zaixing', 'Initials': 'Z', 'LastName': 'Shi', 'Affiliation': 'State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China.'}, {'ForeName': 'Kathleene T', 'Initials': 'KT', 'LastName': 'Ulanday', 'Affiliation': 'Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.'}, {'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Hale', 'Affiliation': 'Columbia University Irving Medical Center, New York, NY, USA.'}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Hershman', 'Affiliation': 'College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Greenlee', 'Affiliation': 'Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: hgreenlee@fredhutch.org.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106524'] 2180,34364967,No effect of monosodium glutamate on subjective appetite and subsequent energy intake in children of different ethnicities.,"Studies have shown that monosodium glutamate (MSG) can enhance satiety and reduce appetite among infants and adults. In a multi-ethnic country such as Malaysia, it is also important to consider whether ethnic variations will influence the effects of MSG on appetite regulation. Thus, this crossover study aimed to investigate the effects of MSG on the subjective appetite and subsequent energy intake among Malaysian children from the three major ethnic groups, namely the Malays, Chinese and Indians. A total of 92 participants aged 9-11 years from the three ethnic groups were recruited for this study. A cup of low-energy vegetable preload soup (100g, with MSG or without MSG) was served to each of the participants on the day of the study, followed by an ad libitum meal 45 min later. Appetite ratings of hunger, fullness, desire to eat and desire to snack were recorded using visual analogue scale (VAS) before the preload, after the preload, before the ad libitum meal and after the ad libitum meal. Results showed that the subjective appetite of the children did not differ between preload conditions (MSG+ or MSG-) throughout the study. Malay, Chinese and Indian children had similar total energy intake during the subsequent meal after the consumption of preload soups. In conclusion, the addition of MSG to low energy preload neither influenced the perception of appetite nor total energy intake in a subsequent ad libitum meal among children. No difference attributable to the participants' ethnicity was observed. Future studies should be conducted to examine whether repeated ingestion of MSG-containing protein-rich preload has potential longer-term effects on appetite and subsequent meal intakes among children from different ethnicities.",2021,No difference attributable to the participants' ethnicity was observed.,"['children of different ethnicities', '92 participants aged 9-11 years from the three ethnic groups were recruited for this study', 'children from different ethnicities', 'Malaysian children from the three major ethnic groups, namely the Malays, Chinese and Indians', 'infants and adults', 'Malay, Chinese and Indian children']","['monosodium glutamate', 'MSG', 'monosodium glutamate (MSG', 'low-energy vegetable preload soup (100g, with MSG or without MSG']","['perception of appetite nor total energy intake', 'subjective appetite and subsequent energy intake', 'total energy intake', 'visual analogue scale (VAS', 'Appetite ratings of hunger, fullness, desire to eat and desire to snack', 'subjective appetite']","[{'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0024549', 'cui_str': 'Malay language'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0037511', 'cui_str': 'Monosodium glutamate'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0453399', 'cui_str': 'Soup'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0439650', 'cui_str': 'Fullness'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}]",92.0,0.0467059,No difference attributable to the participants' ethnicity was observed.,"[{'ForeName': 'Sim Yee', 'Initials': 'SY', 'LastName': 'Lim', 'Affiliation': 'Nutritional Sciences Programme & Centre for Community Health Studies (ReaCH), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala, Lumpur, Malaysia. Electronic address: p90234@siswa.ukm.edu.my.'}, {'ForeName': 'Rosmawati', 'Initials': 'R', 'LastName': 'Dora', 'Affiliation': 'Nutritional Sciences Programme & Centre for Community Health Studies (ReaCH), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala, Lumpur, Malaysia. Electronic address: rosmawati.dora@gmail.com.'}, {'ForeName': 'Noor Hafizah', 'Initials': 'NH', 'LastName': 'Yatiman', 'Affiliation': 'Nutritional Sciences Programme & Centre for Community Health Studies (ReaCH), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala, Lumpur, Malaysia. Electronic address: hafizahyatiman@ukm.edu.my.'}, {'ForeName': 'Jyh Eiin', 'Initials': 'JE', 'LastName': 'Wong', 'Affiliation': 'Nutritional Sciences Programme & Centre for Community Health Studies (ReaCH), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala, Lumpur, Malaysia. Electronic address: wjeiin@ukm.edu.my.'}, {'ForeName': 'Hasnah', 'Initials': 'H', 'LastName': 'Haron', 'Affiliation': 'Nutritional Sciences Programme & Centre for Community Health Studies (ReaCH), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala, Lumpur, Malaysia. Electronic address: hasnaharon@ukm.edu.my.'}, {'ForeName': 'Bee Koon', 'Initials': 'BK', 'LastName': 'Poh', 'Affiliation': 'Nutritional Sciences Programme & Centre for Community Health Studies (ReaCH), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala, Lumpur, Malaysia. Electronic address: pbkoon@ukm.edu.my.'}]",Appetite,['10.1016/j.appet.2021.105629'] 2181,34364917,"Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study).","BACKGROUND & AIMS Acute-on-chronic liver failure (ACLF) is a syndrome that develops in patients with decompensated liver cirrhosis and which is characterized by organ failure and poor short-term prognosis. Based on positive results from small single center studies, Granulocyte-Colony Stimulating Factor (G-CSF) is being widely used in the treatment of ACLF patients. The aim of that study was to evaluate the safety and efficacy of G-CSF in patients with ACLF. METHODS In this multicenter, prospective, controlled, open-label phase 2 study, 176 patients with ACLF defined by the EASL-CLIF criteria were randomized to receive G-CSF (at a dose 5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus standard medical therapy (SMT) (n=88) or SMT alone. The primary efficacy endpoint was the 90-day transplant free survival analysed by Cox regression modeling. The key secondary endpoints were the overall and transplant-free survival after 360 days, the development of ACLF-related complications, and the course of liver function scores (model of end-stage liver disease score (MELD) and CLIF-C OF score) during the entire observation period. RESULTS Patients treated with G-CSF had a 90-day transplant free survival of 34.1% compared to 37.5% in the SMT group with a hazard ratio (HR) of 1.05 (95%CI 0.711; 1.551) (p=0.805). The 360-day transplant free survival with a HR of 0.998 [95%CI 0.697; 1.430 (p=0.992)] and overall survival with a HR of 1.058 [95%CI 0.727; 1.548 (p=0.768)] also did not differ between groups. G-CSF did not improve the CLIF-C OF score (p=0.757), MELD score (p=0.884) or the occurrence of infections (p=0.251). In subgroups of patients without infections [p=0.883], with alcohol related ACLF [p=0.875], or with ACLF defined by the APASL criteria [p=0.405] G-CSF also failed to improve survival. Sixty-one serious adverse events (SAE) were reported in the G-CSF+SMT group and 57 SAEs in the SMT group. In total, seven drug-related serious adverse reactions occurred in the G-CSF group. The study was prematurely terminated due to futility after conditional power calculation. CONCLUSIONS In contrast to previous findings, this first multicenter, controlled trial failed to show a significant beneficial effect of G-CSF in treating patients with ACLF, and therefore, suggests G-CSF should not be used as a standard treatment for ACLF. LAY SUMMARY G-CSF was considered as a novel treatment for acute-on-chronic liver failure (ACLF). We performed the first randomized, multicenter, controlled trial phase 2 trial which showed that G-CSF in not improving survival or other clinical endpoints in patients with ACLF. Therefore, G-CSF should not be used to treat liver disease outside clinical studies. CLINICALTRAILS. GOV NUMBER NCT02669680.",2021,"G-CSF did not improve the CLIF-C OF score (p=0.757), MELD score (p=0.884) or the occurrence of infections (p=0.251).","['patients with decompensated liver cirrhosis', 'ACLF patients', 'patients with ACLF', '176 patients with ACLF defined by the EASL-CLIF criteria']","['standard medical therapy (SMT', 'SMT', 'G-CSF', 'Granulocyte-Colony Stimulating Factor (G-CSF', 'SMT alone']","['360-day transplant free survival', 'overall survival', 'safety and efficacy', 'MELD score', 'serious adverse events (SAE', 'serious adverse reactions', '90-day transplant free survival', 'CLIF-C OF score', 'survival', 'overall and transplant-free survival', 'development of ACLF-related complications, and the course of liver function scores (model of end-stage liver disease score (MELD) and CLIF-C OF score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C3850141', 'cui_str': 'Acute on chronic liver failure'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1309562', 'cui_str': 'ARNTL2 protein, human'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0079459', 'cui_str': 'Colony-stimulating factor, granulocytic'}]","[{'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C4048785', 'cui_str': 'Model for end stage liver disease score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C1309562', 'cui_str': 'ARNTL2 protein, human'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C3850141', 'cui_str': 'Acute on chronic liver failure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0745744', 'cui_str': 'End stage liver disease'}]",176.0,0.0861249,"G-CSF did not improve the CLIF-C OF score (p=0.757), MELD score (p=0.884) or the occurrence of infections (p=0.251).","[{'ForeName': 'Cornelius', 'Initials': 'C', 'LastName': 'Engelmann', 'Affiliation': 'Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany; Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Herber', 'Affiliation': 'Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.'}, {'ForeName': 'Annegret', 'Initials': 'A', 'LastName': 'Franke', 'Affiliation': 'Clinical Trial Centre (ZKS) Leipzig, Faculty of Medicine, University Leipzig, Leipzig, Germany.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Bruns', 'Affiliation': 'Department of Medicine III, Aachen University Hospital, Aachen, Germany; Clinic for Internal Medicine IV, University Hospital Jena, Jena, Germany.'}, {'ForeName': 'Ingolf', 'Initials': 'I', 'LastName': 'Schiefke', 'Affiliation': 'Clinic for Gastroenterology, Hepatology and Endocrinology, St. Georg Hospital, Leipzig, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Zipprich', 'Affiliation': 'University Hospital for Internal Medicine 1, Martin-Luther-University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Zeuzem', 'Affiliation': 'Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Goeser', 'Affiliation': 'Clinic for Gastroenterology and Hepatology, University Hospital Cologne, Cologne, Germany.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Canbay', 'Affiliation': 'Medical Department, University Hospital Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Berg', 'Affiliation': 'Department of Internal Medicine I, University Hospital Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Jonel', 'Initials': 'J', 'LastName': 'Trebicka', 'Affiliation': 'Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt, Germany; European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain; Department of Internal Medicine I, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Frank E', 'Initials': 'FE', 'LastName': 'Uschner', 'Affiliation': 'Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt, Germany; Department of Internal Medicine I, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Chang', 'Affiliation': 'Department of Internal Medicine I, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Mueller', 'Affiliation': 'Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Niklas', 'Initials': 'N', 'LastName': 'Aehling', 'Affiliation': 'Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Schmelzle', 'Affiliation': 'Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinik, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Splith', 'Affiliation': 'Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinik, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Lammert', 'Affiliation': 'Department of Medicine II, Saarland University Medical Center, Homburg, Germany.'}, {'ForeName': 'Christian M', 'Initials': 'CM', 'LastName': 'Lange', 'Affiliation': 'Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt, Germany; Clinic for Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Sarrazin', 'Affiliation': 'Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt, Germany; Medical Clinic 2, St. Josefs Hospital Wiesbaden, Wiesbaden, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Trautwein', 'Affiliation': 'Department of Medicine III, Aachen University Hospital, Aachen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Manns', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Dieter', 'Initials': 'D', 'LastName': 'Häussinger', 'Affiliation': 'Clinic and Policlinic of Gastroenterology, Hepatology and Infectious Disease, Heinrich Heine University Duesseldorf, Düsseldorf, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Pfeiffenberger', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Peter R', 'Initials': 'PR', 'LastName': 'Galle', 'Affiliation': '1. Medical Department, Johannes Gutenberg University Mainz, Mainz, Germany.'}, {'ForeName': 'Anett', 'Initials': 'A', 'LastName': 'Schmiedeknecht', 'Affiliation': 'Clinical Trial Centre (ZKS) Leipzig, Faculty of Medicine, University Leipzig, Leipzig, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Berg', 'Affiliation': 'Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany. Electronic address: thomas.berg@medizin.uni-leipzig.de.'}]",Journal of hepatology,['10.1016/j.jhep.2021.07.033'] 2182,34364814,Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.,"BACKGROUND A recent phase II randomized Japanese study reported better survival with regorafenib followed at progression by cetuximab ± irinotecan compared with the reverse standard sequence in chemo-refractory and anti-EGFR-naïve, RAS wild-type (wt) mCRC patients. Nowadays the use of anti-EGFR antibodies is more frequently anticipated to the first-line of therapy especially in patients with left-sided RAS/BRAF wt tumours. However, retrospective analyses and phase II single-arm trials showed promising activity of re-using anti-EGFRs in metastatic colorectal cancer (mCRC) patients who previously achieved benefit from a first-line anti-EGFR-based treatment. Post-hoc analyses of these trials revealed that the detection of RAS mutations in circulating tumour DNA (ct-DNA) at the time of re-treatment may be useful to identify resistant patients. PATIENTS AND METHODS PARERE (NCT04787341) is a prospective, open label, multicentre phase II study in which 214 RAS/BRAF wt chemo-refractory mCRC patients with previous benefit from first-line anti-EGFR-based treatment and RAS/BRAF wt ct-DNA in the liquid biopsy collected at the time of inclusion will be randomized in a 1:1 ratio to receive panitumumab followed after progression by regorafenib versus the reverse sequence. Primary endpoint is overall survival. Secondary endpoints are 1st-progression free-survival (PFS), 2nd-PFS, time to failure strategy, objective response rate, and safety. AIM OF THE STUDY The aim of this study is to validate the role of anti-EGFR retreatment and its proper placement in the therapeutic route of mCRC patients selected according to the analysis of ct-DNA in liquid biopsy. Results are expected at the end of 2023.",2021,"Post-hoc analyses of these trials revealed that the detection of RAS mutations in circulating tumour DNA (ct-DNA) at the time of re-treatment may be useful to identify resistant patients. ","['Metastatic Colorectal Cancer Patients', 'metastatic colorectal cancer (mCRC) patients who previously achieved benefit from a first-line anti-EGFR-based treatment', '214 RAS/BRAF wt chemo-refractory mCRC patients with previous benefit from first-line anti-EGFR-based treatment and RAS/BRAF wt ct-DNA in the liquid biopsy collected at the time of inclusion', 'mCRC patients']","['panitumumab', 'cetuximab ± irinotecan', 'Panitumumab Re-Treatment Followed by Regorafenib']","['overall survival', '1st-progression free-survival (PFS), 2nd-PFS, time to failure strategy, objective response rate, and safety']","[{'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1259929', 'cui_str': 'BRAF protein, human'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C4505151', 'cui_str': 'Liquid Biopsies'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C0879427', 'cui_str': 'panitumumab'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C2980094', 'cui_str': 'regorafenib'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205435', 'cui_str': 'First'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0365994,"Post-hoc analyses of these trials revealed that the detection of RAS mutations in circulating tumour DNA (ct-DNA) at the time of re-treatment may be useful to identify resistant patients. ","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Moretto', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Rossini', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Iolanda', 'Initials': 'I', 'LastName': 'Capone', 'Affiliation': 'Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Boccaccino', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Perrone', 'Affiliation': 'Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Tamborini', 'Affiliation': 'Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Masi', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Carlotta', 'Initials': 'C', 'LastName': 'Antoniotti', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Marmorino', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Conca', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Borelli', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Martignetti', 'Affiliation': 'UOC Medical Oncology, Azienda Toscana Sud Est, Poggibonsi, Italy.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Pecora', 'Affiliation': 'Division of Medical Oncology, Misericordia General Hospital, Grosseto, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Simionato', 'Affiliation': 'Department of Oncology, San Bortolo General Hospital, ULSS 8 Berica, Vicenza, Italy.'}, {'ForeName': 'Samanta', 'Initials': 'S', 'LastName': 'Cupini', 'Affiliation': 'Department of Oncology, Division of Medical Oncology, Azienda Toscana Nord Ovest, Livorno, Italy.'}, {'ForeName': 'Margherita', 'Initials': 'M', 'LastName': 'Ambrosini', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Manca', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Pietrantonio', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Oncology and Hemato-Oncology Department, University of Milan, Milan, Italy.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Falcone', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cremolini', 'Affiliation': 'Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy. Electronic address: chiaracremolini@gmail.com.'}]",Clinical colorectal cancer,['10.1016/j.clcc.2021.07.001'] 2183,34364698,"Response to Letter Regarding Article, ""Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial"".",,2021,,['Patients With COVID-19'],['Ivermectin'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}]","[{'cui': 'C0022322', 'cui_str': 'Ivermectin'}]",[],,0.744735,,"[{'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Shahbaznejad', 'Affiliation': 'Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Davoudi', 'Affiliation': 'Antimicrobial Resistance Research Center, Department of Infectious Diseases, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Gohar', 'Initials': 'G', 'LastName': 'Eslami', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Markowitz', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Navaeifar', 'Affiliation': 'Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Hosseinzadeh', 'Affiliation': 'Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Faeze Sadat', 'Initials': 'FS', 'LastName': 'Movahedi', 'Affiliation': 'Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Mohammad Sadegh', 'Initials': 'MS', 'LastName': 'Rezai', 'Affiliation': 'Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: drmsrezaii@yahoo.com.'}]",Clinical therapeutics,['10.1016/j.clinthera.2021.07.006'] 2184,34364684,[Components of geriatric assessment and therapeutic adherence in elderly patients with acute myocardial infarction].,"BACKGROUND AND OBJECTIVE Poor therapeutic adherence after acute myocardial infarction (AMI) can lead to early serious complications. Information on the impact of geriatric assessment on adherence is scarce. The objective of this study was to analyze, in older patients with AMI, the impact of geriatric assessment on therapeutic adherence 12 months after admission. MATERIALS AND METHODS A previous study randomized patients aged >75 years who had presented an AMI to a nursing health education program versus conventional management, evaluating the impact of this intervention on therapeutic adherence after 12 months. In-hospital geriatric assessment was performed. For this substudy, the adherence predictors were analyzed using binary logistic regression. Those patients who obtained adherence in the 4 tools were considered adherent: the Morisky-Green, Haynes-Sackett test, attendance at visits and correct withdrawal of drugs from the pharmacy. RESULTS A total of 119 patients with a mean age of 82.2 years were included. At one year, a total of 42 patients (35.3%) were adherent. The predictors of poor adherence in the final model were male sex, worse glomerular filtration rate, cognitive impairment, nutritional risk, not living alone and not belonging to the intervention group. CONCLUSIONS The data of this series show a low therapeutic adherence in the elderly after an AMI. Cognitive impairment or nutritional risk was significantly associated with poorer adherence, contrary to a nursing intervention, which highlights the importance of health education and supervision in high-risk patients.",2021,"The predictors of poor adherence in the final model were male sex, worse glomerular filtration rate, cognitive impairment, nutritional risk, not living alone and not belonging to the intervention group. ","['119 patients with a mean age of 82.2 years were included', 'patients who obtained adherence in the 4 tools were considered adherent: the Morisky-Green, Haynes-Sackett test, attendance at visits and correct withdrawal of drugs from the pharmacy', 'elderly patients with acute myocardial infarction', 'older patients with AMI', 'patients aged >75 years who had presented an AMI to a nursing health education program versus conventional management, evaluating the impact of this intervention on therapeutic adherence after 12 months']",[],"['glomerular filtration rate, cognitive impairment, nutritional risk', 'Cognitive impairment or nutritional risk']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4505265', 'cui_str': 'Therapeutic Adherence'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",[],"[{'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}]",119.0,0.0127513,"The predictors of poor adherence in the final model were male sex, worse glomerular filtration rate, cognitive impairment, nutritional risk, not living alone and not belonging to the intervention group. ","[{'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Calvo', 'Affiliation': 'Departamento de Cardiología, Hospital Universitario de Bellvitge; Universidad de Barcelona; Grupo de Investigación de Enfermería (GRIN-IDIBELL), Barcelona, España. Electronic address: ebarriuso@bellvitgehospital.cat.'}, {'ForeName': 'Francesc', 'Initials': 'F', 'LastName': 'Formiga', 'Affiliation': 'Programa de Geriatría, Servicio Medicina Interna, Hospital Universitario de Bellvitge; Universitat de Barcelona; Grupo de Investigación IDIBELL, Barcelona, España.'}, {'ForeName': 'Lola', 'Initials': 'L', 'LastName': 'Andreu-Periz', 'Affiliation': 'Departamento de Enfermería Fundamental y Médico-Quirúrgica. Escuela Universitaria de Enfermería. Universitat de Barcelona, Barcelona, España.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Ariza-Solé', 'Affiliation': 'Departamento de cardiología. Hospital Universitario de Bellvitge; Universitat de Barcelona; Grupo de Investigación IDIBELL, Barcelona, España.'}, {'ForeName': 'Joan Antoni', 'Initials': 'JA', 'LastName': 'Gómez-Hospital', 'Affiliation': 'Departamento de cardiología. Hospital Universitario de Bellvitge; Universitat de Barcelona; Grupo de Investigación IDIBELL, Barcelona, España.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Comín-Colet', 'Affiliation': 'Departamento de cardiología. Hospital Universitario de Bellvitge; Universitat de Barcelona; Grupo de Investigación IDIBELL, Barcelona, España.'}]",Revista espanola de geriatria y gerontologia,['10.1016/j.regg.2021.06.002'] 2185,34364670,Rate Versus Rhythm Control in Heart Failure Patients with Post-Operative Atrial Fibrillation After Cardiac Surgery.,"BACKGROUND Whether rhythm control for post-operative atrial fibrillation after cardiac surgery (POAF) is superior to rate control in patients with heart failure or systolic dysfunction (HF) is not known. METHODS We performed a post-hoc analysis of a trial by the Cardiothoracic Surgical Trials Network, which randomized patients with POAF after cardiac surgery to rate control or rhythm control with amiodarone/cardioversion. We assessed subgroups of trial participants defined by heart failure/cardiomyopathy history or left ventricular ejection fraction (LVEF) < 50%. We conducted a stratified analysis in patients with and without HF to explore outcomes of rhythm versus rate control strategy. RESULTS Of 523 subjects with POAF after cardiac surgery, 131 (25%) had HF. 49% of HF patients were randomized to rhythm control. In HF patients, rhythm control was associated with less atrial fibrillation within the first 7 days. There were no differences in rhythm at 30- and 60-day follow-up. In the HF group, there were significantly more subjects with AF < 48 hours in the rhythm control group compared to rate control group- 68.8% compared to 46.3%, P=0.009. By comparison, in the non-HF stratum, 54.4% of the rate control group had AF < 48 hours compared to 63.5% of the rhythm control group (P=0.067).), though there was no significant interaction of heart failure with cardiac rhythm at 7 days (Pinteraction 0.16). CONCLUSION Rhythm control for HF patients with POAF after cardiac surgery increases early restoration of sinus rhythm. Rate and rhythm control are both reasonable for HF patients with AF after cardiac surgery.",2021,There were no differences in rhythm at 30- and 60-day follow-up.,"['subgroups of trial participants defined by heart failure/cardiomyopathy history or left ventricular ejection fraction (LVEF) < 50', 'patients with and without HF to explore outcomes of rhythm versus rate control strategy', 'patients with heart failure or systolic dysfunction (HF', 'Heart Failure Patients with Post-Operative Atrial Fibrillation', 'HF patients with AF after cardiac surgery', 'HF patients with POAF after cardiac surgery increases early restoration of sinus rhythm', '523 subjects with POAF after cardiac surgery, 131 (25%) had HF', 'patients with POAF after cardiac surgery to rate control or rhythm control with']","['amiodarone/cardioversion', 'cardiac surgery (POAF']","['Rate and rhythm control', 'heart failure with cardiac rhythm', 'atrial fibrillation']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathy'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0749225', 'cui_str': 'Systolic dysfunction'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0232201', 'cui_str': 'Sinus rhythm'}]","[{'cui': 'C0002598', 'cui_str': 'Amiodarone'}, {'cui': 'C0013778', 'cui_str': 'Cardioversion'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0232187', 'cui_str': 'Cardiac rhythm type'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]",523.0,0.17815,There were no differences in rhythm at 30- and 60-day follow-up.,"[{'ForeName': 'Eunice', 'Initials': 'E', 'LastName': 'Yang', 'Affiliation': 'Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine, Baltimore MD.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Spragg', 'Affiliation': 'Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine, Baltimore MD.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Schulman', 'Affiliation': 'Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine, Baltimore MD.'}, {'ForeName': 'Nisha A', 'Initials': 'NA', 'LastName': 'Gilotra', 'Affiliation': 'Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine, Baltimore MD.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Kilic', 'Affiliation': 'Division of Cardiovascular Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore MD.'}, {'ForeName': 'Rawn', 'Initials': 'R', 'LastName': 'Salenger', 'Affiliation': 'Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Whitman', 'Affiliation': 'Division of Cardiovascular Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore MD.'}, {'ForeName': 'Thomas S', 'Initials': 'TS', 'LastName': 'Metkus', 'Affiliation': 'Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine, Baltimore MD; Division of Cardiovascular Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore MD. Electronic address: tmetkus1@jhmi.edu.'}]",Journal of cardiac failure,['10.1016/j.cardfail.2021.02.016'] 2186,34368894,"Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial.","AIM/HYPOTHESIS In two large RCTs, fenofibrate reduced the progression of diabetic retinopathy. We investigated whether fenofibrate increases circulating haematopoietic stem/progenitor cells (HSPCs), which have vascular properties and have been shown to protect from retinopathy. METHODS We conducted a 12 week parallel-group RCT comparing fenofibrate vs placebo. Patients with diabetic retinopathy and without other conditions that would affect HSPCs were enrolled at a tertiary diabetes outpatient clinic and randomised to receive fenofibrate or placebo based on a computer-generated sequence. Patients and study staff assessing the outcomes were blinded to group assignment. The primary endpoint was the change in the levels of circulating HSPCs, defined by expression of the stem cell markers CD34 and/or CD133. Secondary endpoints were the changes in endothelial progenitor cells, lipids, soluble mediators and gene expression. We used historical data on the association between HSPCs and retinopathy outcomes to estimate the effect of fenofibrate on retinopathy progression. RESULTS Forty-two participants with diabetic retinopathy were randomised and 41 completed treatment and were analysed (20 in the placebo group and 21 in the fenofibrate group). Mean age was 57.4 years, diabetes duration was 18.2 years and baseline HbA 1c was 60 mmol/mol (7.6%). When compared with placebo, fenofibrate significantly increased levels of HSPCs expressing CD34 and/or CD133. CD34 + HSPCs non-significantly declined in the placebo group (mean ± SD -44.2 ± 31.6 cells/10 6 ) and significantly increased in the fenofibrate group (53.8 ± 31.1 cells/10 6 ). The placebo-subtracted increase in CD34 + HSPCs from baseline was 30% (99.3 ± 43.3 cells/10 6 ; p = 0.027) which, projected onto the relationship between HSPC levels and retinopathy outcomes, yielded an OR of retinopathy progression of 0.67 for fenofibrate vs placebo. Endothelial differentiation of CD34 + cells, estimated by the %KDR (kinase insert domain receptor) expression, was significantly reduced by fenofibrate. Fenofibrate decreased serum triacylglycerols, but the change in triacylglycerols was unrelated to the change in HSPCs. No effect was observed for endothelial progenitor cells, cytokines/chemokines (stromal-cell derived factor-1, vascular endothelial growth factor, monocyte chemoattractant protein-1) and gene expression in peripheral blood mononuclear cells. CONCLUSIONS/INTERPRETATION Fenofibrate increased HSPC levels in participants with diabetic retinopathy and this mechanism may explain why fenofibrate reduced retinopathy progression in previous studies. TRIAL REGISTRATION ClinicalTrials.gov NCT01927315.",2021,"Fenofibrate decreased serum triacylglycerols, but the change in triacylglycerols was unrelated to the change in HSPCs.","['Forty-two participants with diabetic retinopathy', 'Patients with diabetic retinopathy and without other conditions that would affect HSPCs were enrolled at a tertiary diabetes outpatient clinic', 'people with diabetic retinopathy', 'Mean age was 57.4\xa0years, diabetes duration was 18.2\xa0years and baseline HbA 1c was 60\xa0mmol/mol (7.6', 'participants with diabetic retinopathy']","['Fenofibrate', 'fenofibrate or placebo', 'placebo, fenofibrate', 'fenofibrate', 'placebo', 'fenofibrate vs placebo']","['change in triacylglycerols', 'endothelial progenitor cells, cytokines/chemokines (stromal-cell derived factor-1, vascular endothelial growth factor, monocyte chemoattractant protein-1) and gene expression in peripheral blood mononuclear cells', 'HSPC levels and retinopathy outcomes, yielded an OR of retinopathy progression', 'changes in endothelial progenitor cells, lipids, soluble mediators and gene expression', 'CD34 + HSPCs', 'Endothelial differentiation of CD34 + cells, estimated by the %KDR (kinase insert domain receptor) expression', 'serum triacylglycerols', 'HSPC levels', 'progression of diabetic retinopathy', 'circulating haematopoietic stem cells', 'change in the levels of circulating HSPCs, defined by expression of the stem cell markers CD34 and/or CD133', 'levels of HSPCs expressing CD34 and/or CD133']","[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0018957', 'cui_str': 'Hematopoietic system structure'}, {'cui': 'C0162731', 'cui_str': 'STEM'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C4517610', 'cui_str': '18.2'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}]","[{'cui': 'C0033228', 'cui_str': 'Fenofibrate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C3850017', 'cui_str': 'Circulating Endothelial Progenitor Cells'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0218504', 'cui_str': 'CXCL12 Chemokine'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035309', 'cui_str': 'Retinal disorder'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0054953', 'cui_str': 'Lymphocyte antigen CD34'}, {'cui': 'C0018957', 'cui_str': 'Hematopoietic system structure'}, {'cui': 'C0162731', 'cui_str': 'STEM'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0007589', 'cui_str': 'Differentiation, Cell'}, {'cui': 'C0882849', 'cui_str': 'Cell positive for CD34 antigen'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C3849882', 'cui_str': 'vascular endothelial growth factor receptor-2, human'}, {'cui': 'C0378796', 'cui_str': 'KDR Tyrosine Kinase'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0018956', 'cui_str': 'Hematopoietic stem cell'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",42.0,0.440981,"Fenofibrate decreased serum triacylglycerols, but the change in triacylglycerols was unrelated to the change in HSPCs.","[{'ForeName': 'Benedetta Maria', 'Initials': 'BM', 'LastName': 'Bonora', 'Affiliation': 'Department of Medicine, University of Padova, Padua, Italy.'}, {'ForeName': 'Mattia', 'Initials': 'M', 'LastName': 'Albiero', 'Affiliation': 'Department of Medicine, University of Padova, Padua, Italy.'}, {'ForeName': 'Mario Luca', 'Initials': 'ML', 'LastName': 'Morieri', 'Affiliation': 'Department of Medicine, University of Padova, Padua, Italy.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Cappellari', 'Affiliation': 'Department of Medicine, University of Padova, Padua, Italy.'}, {'ForeName': 'Francesco Ivan', 'Initials': 'FI', 'LastName': 'Amendolagine', 'Affiliation': 'Veneto Institute of Molecular Medicine, Padua, Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Mazzucato', 'Affiliation': 'Department of Medicine, University of Padova, Padua, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Zambon', 'Affiliation': 'Department of Medicine, University of Padova, Padua, Italy.'}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Iori', 'Affiliation': 'Department of Medicine, University of Padova, Padua, Italy.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Avogaro', 'Affiliation': 'Department of Medicine, University of Padova, Padua, Italy.'}, {'ForeName': 'Gian Paolo', 'Initials': 'GP', 'LastName': 'Fadini', 'Affiliation': 'Department of Medicine, University of Padova, Padua, Italy. gianpaolo.fadini@unipd.it.'}]",Diabetologia,['10.1007/s00125-021-05532-1'] 2187,34368892,Pro-vegetarian food patterns and cardiometabolic risk in the PREDIMED-Plus study: a cross-sectional baseline analysis.,"PURPOSE We explored the cross-sectional association between the adherence to three different provegetarian (PVG) food patterns defined as general (gPVG), healthful (hPVG) and unhealthful (uPVG), and the cardiometabolic risk in adults with metabolic syndrome (MetS) of the PREDIMED-Plus randomized intervention study. METHODS We performed a cross-sectional analysis of baseline data from 6439 participants of the PREDIMED-Plus randomized intervention study. The gPVG food pattern was built by positively scoring plant foods (vegetables/fruits/legumes/grains/potatoes/nuts/olive oil) and negatively scoring, animal foods (meat and meat products/animal fats/eggs/fish and seafood/dairy products). The hPVG and uPVG were generated from the gPVG by adding four new food groups (tea and coffee/fruit juices/sugar-sweetened beverages/sweets and desserts), splitting grains and potatoes and scoring them differently. Multivariable-adjusted robust linear regression using MM-type estimator was used to assess the association between PVG food patterns and the standardized Metabolic Syndrome score (MetS z-score), a composed index that has been previously used to ascertain the cardiometabolic risk, adjusting for potential confounders. RESULTS A higher adherence to the gPVG and hPVG was associated with lower cardiometabolic risk in multivariable models. The regression coefficients for 5th vs. 1st quintile were - 0.16 (95% CI: - 0.33 to 0.01) for gPVG (p trend: 0.015), and - 0.23 (95% CI: - 0.41 to - 0.05) for hPVG (p trend: 0.016). In contrast, a higher adherence to the uPVG was associated with higher cardiometabolic risk, 0.21 (95% CI: 0.04 to 0.38) (p trend: 0.019). CONCLUSION Higher adherence to gPVG and hPVG food patterns was generally associated with lower cardiovascular risk, whereas higher adherence to uPVG was associated to higher cardiovascular risk.",2021,"Higher adherence to gPVG and hPVG food patterns was generally associated with lower cardiovascular risk, whereas higher adherence to uPVG was associated to higher cardiovascular risk.","['6439 participants', 'adults with metabolic syndrome (MetS']","['provegetarian (PVG) food patterns defined as general (gPVG), healthful (hPVG) and unhealthful (uPVG']",['lower cardiovascular risk'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}]","[{'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",6439.0,0.0818083,"Higher adherence to gPVG and hPVG food patterns was generally associated with lower cardiovascular risk, whereas higher adherence to uPVG was associated to higher cardiovascular risk.","[{'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Oncina-Cánovas', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Vioque', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. vioque@umh.es.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'González-Palacios', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Miguel Ángel', 'Initials': 'MÁ', 'LastName': 'Martínez-González', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Salas-Salvadó', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Corella', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Zomeño', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'J Alfredo', 'Initials': 'JA', 'LastName': 'Martínez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Ángel M', 'Initials': 'ÁM', 'LastName': 'Alonso-Gómez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Wärnberg', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Dora', 'Initials': 'D', 'LastName': 'Romaguera', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'López-Miranda', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'Estruch', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Rosa M', 'Initials': 'RM', 'LastName': 'Bernal-Lopez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Lapetra', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'J Luís', 'Initials': 'JL', 'LastName': 'Serra-Majem', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Aurora', 'Initials': 'A', 'LastName': 'Bueno-Cavanillas', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Josep A', 'Initials': 'JA', 'LastName': 'Tur', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Martín-Sánchez', 'Affiliation': 'Department of Preventive Medicine, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pintó', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Delgado-Rodríguez', 'Affiliation': 'Department of Preventive Medicine, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Matía-Martín', 'Affiliation': 'Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Vidal', 'Affiliation': 'CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Clotilde', 'Initials': 'C', 'LastName': 'Vázquez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Daimiel', 'Affiliation': 'Nutritional Control of the Epigenome Group, IMDEA Food, CEI UAM + CSIC, Madrid, Spain.'}, {'ForeName': 'Emili', 'Initials': 'E', 'LastName': 'Ros', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Estefanía', 'Initials': 'E', 'LastName': 'Toledo', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Babio', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Jose V', 'Initials': 'JV', 'LastName': 'Sorli', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Helmut', 'Initials': 'H', 'LastName': 'Schröder', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'María Angeles', 'Initials': 'MA', 'LastName': 'Zulet', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Sorto-Sánchez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Francisco Javier', 'Initials': 'FJ', 'LastName': 'Barón-López', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Compañ-Gabucio', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Marga', 'Initials': 'M', 'LastName': 'Morey', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'García-Ríos', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Casas', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Ana María', 'Initials': 'AM', 'LastName': 'Gómez-Pérez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'José Manuel', 'Initials': 'JM', 'LastName': 'Santos-Lozano', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Zenaida', 'Initials': 'Z', 'LastName': 'Vázquez-Ruiz', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Stephanie K', 'Initials': 'SK', 'LastName': 'Nishi', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Eva M', 'Initials': 'EM', 'LastName': 'Asensio', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Núria', 'Initials': 'N', 'LastName': 'Soldevila', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Abete', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Leire', 'Initials': 'L', 'LastName': 'Goicolea-Güemez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Buil-Cosiales', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Jesús F', 'Initials': 'JF', 'LastName': 'García-Gavilán', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Canals', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Torres-Collado', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'García-de-la-Hera', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.'}]",European journal of nutrition,['10.1007/s00394-021-02647-4'] 2188,34368890,Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial).,"PURPOSE The aim of this phase II study was to evaluate the efficacy and safety of combination therapy with five-cycle CAPOX (capecitabine plus oxaliplatin) plus bevacizumab, followed by five-cycle maintenance therapy with capecitabine plus bevacizumab and reintroduction of CAPOX plus bevacizumab for five cycles, with a preplanned intermittent oxaliplatin strategy in metastatic colorectal cancer (mCRC). METHODS Patients with untreated mCRC were administered CAPOX (130 mg/m 2 oxaliplatin on day 1, 2000 mg/m 2 /day capecitabine on days 1-14, every 21 days) + bevacizumab (7.5 mg/kg) every 3 weeks for five cycles, maintenance treatment without oxaliplatin for five cycles, and CAPOX + bevacizumab reintroduction for five cycles or upon tumor progression. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were the time to treatment failure (TTF), overall survival, response rate (RR), and safety. RESULTS Forty-seven patients who fulfilled the inclusion criteria were enrolled in the evaluation of efficacy and safety. Median PFS was 14.1 months (95% confidence interval [CI], 8.6-19.5), and median TTF was 12.3 months (95% CI, 10.3-14.3). The objective RRs were 51.1% (24/47) during induction therapy, 58.3% (21/36) during maintenance therapy, and 63.6% (14/22) during reintroduction therapy. The frequency of patients with neutropenia, diarrhea, peripheral sensory neuropathy, venous thromboembolism, or grade ≥ 3 allergic reactions was 2.1%. CONCLUSION CAPOX plus bevacizumab therapy with a preplanned intermittent oxaliplatin strategy consisting of brief five-cycle induction therapy, five-cycle maintenance therapy with capecitabine plus bevacizumab, and five-cycle reintroduction therapy consisting of CAPOX plus bevacizumab is safe and effective for mCRC patients. TRIAL REGISTRATION UMIN ID: 000,005,732, date of registration: June 7, 2011.  https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000006695.",2021,"Median PFS was 14.1 months (95% confidence interval [CI], 8.6-19.5), and median TTF was 12.3 months (95% CI, 10.3-14.3).","['Patients with untreated mCRC', 'patients with metastatic colorectal cancer (VOICE trial', 'metastatic colorectal cancer (mCRC', 'Forty-seven patients who fulfilled the inclusion criteria']","['CAPOX plus bevacizumab', 'oxaliplatin', 'CAPOX\u2009+\u2009bevacizumab reintroduction', 'bevacizumab', 'capecitabine plus bevacizumab', 'CAPOX (130\xa0mg/m 2 oxaliplatin on day 1, 2000\xa0mg/m 2 /day capecitabine', 'capecitabine plus bevacizumab and reintroduction of CAPOX plus bevacizumab', 'capecitabine plus intermittent oxaliplatin with bevacizumab', 'combination therapy with five-cycle CAPOX (capecitabine plus oxaliplatin) plus bevacizumab']","['efficacy and safety', 'Median PFS', 'objective RRs', 'frequency of patients with neutropenia, diarrhea, peripheral sensory neuropathy, venous thromboembolism, or grade\u2009≥\u20093 allergic reactions', 'median TTF', 'progression-free survival (PFS', 'time to treatment failure (TTF), overall survival, response rate (RR), and safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C4087167', 'cui_str': 'Tumour treating fields therapy'}, {'cui': 'C3494202', 'cui_str': 'Time to Treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",47.0,0.0653659,"Median PFS was 14.1 months (95% confidence interval [CI], 8.6-19.5), and median TTF was 12.3 months (95% CI, 10.3-14.3).","[{'ForeName': 'Chihiro', 'Initials': 'C', 'LastName': 'Kosugi', 'Affiliation': 'Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan. ckosugi0126@yahoo.co.jp.'}, {'ForeName': 'Keiji', 'Initials': 'K', 'LastName': 'Koda', 'Affiliation': 'Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan.'}, {'ForeName': 'Tadamichi', 'Initials': 'T', 'LastName': 'Denda', 'Affiliation': 'Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan.'}, {'ForeName': 'Keiichiro', 'Initials': 'K', 'LastName': 'Ishibashi', 'Affiliation': 'Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Ishida', 'Affiliation': 'Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Seike', 'Affiliation': 'Department of Surgery, Odawara Municipal Hospital, Odawara, Kanagawa, Japan.'}, {'ForeName': 'Haruhito', 'Initials': 'H', 'LastName': 'Sakata', 'Affiliation': 'Department of Surgery, Saisei Hospital, Hanamigawa, Chiba, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Yanagisawa', 'Affiliation': 'Department of Surgery, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.'}, {'ForeName': 'Akinari', 'Initials': 'A', 'LastName': 'Miyazaki', 'Affiliation': 'Department of Surgery, Funabashi Municipal Medical Center, Funabashi, Chiba, Japan.'}, {'ForeName': 'Wataru', 'Initials': 'W', 'LastName': 'Takayama', 'Affiliation': 'Department of Surgery, Chiba Prefectural Sawara Hospital, Sakura, Chiba, Japan.'}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Koike', 'Affiliation': 'Department of Surgery, Seirei Sakura Citizen Hospital, Sakura, Chiba, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Shimizu', 'Affiliation': 'Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan.'}, {'ForeName': 'Hisahiro', 'Initials': 'H', 'LastName': 'Matsubara', 'Affiliation': 'Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.'}]",International journal of colorectal disease,['10.1007/s00384-021-03995-7'] 2189,34368888,"Cognitive skill training improves memory, function, and use of cognitive strategies in cancer survivors.","BACKGROUND Cancer survivors commonly report symptoms of impaired cognition. This project examined effectiveness of a behavioral skills training intervention to improve cognition and reduce cognitive dysfunction symptoms in cancer survivors. METHODS Participants were randomly assigned to group-based workshops focused on learning new cognitive skills (skills treatment-TX) or an active control of education workshops (education control-EC) or a passive control of wait list (WL). Participants were evaluated pre- and post intervention with subjective mood and symptom questionnaires and objective neurocognitive tests. RESULTS One hundred twenty-eight participants (mean age 59 years), average 4.6 years (+ / - 5.5 years) post cancer treatment with various cancer types (breast, bladder, prostate, colon, uterine), were enrolled. Analysis of all participants who attended workshop(s) revealed improvement in the TX workshop completers on all objective cognitive measures (attention, concentration, declarative, and working memory) save one test of selective attention, and improvement on a single measure (verbal memory) and decline (selective attention) in the EC group. TX workshop completers also improved on all symptom and mood measures, in contrast to EC group which improved on a single subscale of a symptom measure, but increased on an anxiety measure. TX group alone improved on a quantified measure of each participants' unique, ""top three,"" self-described cognitive symptoms. CONCLUSION Improvement from behavioral skills training was evident from objective cognitive tests, subjective symptom measures, and quantified, individual patient-specific symptoms. Behavioral skill training is an effective treatment for cognitive dysfunction in cancer survivors, and should be considered as a treatment option by health care providers.",2021,"Analysis of all participants who attended workshop(s) revealed improvement in the TX workshop completers on all objective cognitive measures (attention, concentration, declarative, and working memory) save one test of selective attention, and improvement on a single measure (verbal memory) and decline (selective attention) in the EC group.","['One hundred twenty-eight participants (mean age 59\xa0years), average 4.6\xa0years (+\u2009/\u2009-\u20095.5\xa0years) post cancer treatment with various cancer types (breast, bladder, prostate, colon, uterine), were enrolled', 'cognitive dysfunction in cancer survivors', 'Participants', 'cancer survivors']","['behavioral skills training intervention', 'TX', 'Cognitive skill training', 'group-based workshops focused on learning new cognitive skills (skills treatment-TX) or an active control of education workshops (education control-EC) or a passive control of wait list (WL', 'Behavioral skill training']","['subjective mood and symptom questionnaires and objective neurocognitive tests', 'objective cognitive measures (attention, concentration, declarative, and working memory) save one test of selective attention, and improvement on a single measure (verbal memory) and decline (selective attention', 'symptom and mood measures', 'objective cognitive tests, subjective symptom measures, and quantified, individual patient-specific symptoms', 'memory, function, and use of cognitive strategies', 'anxiety measure']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517764', 'cui_str': '4.6'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0579088', 'cui_str': 'Cognitive skills training'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0872227', 'cui_str': 'Neurocognitive Tests'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",128.0,0.0303336,"Analysis of all participants who attended workshop(s) revealed improvement in the TX workshop completers on all objective cognitive measures (attention, concentration, declarative, and working memory) save one test of selective attention, and improvement on a single measure (verbal memory) and decline (selective attention) in the EC group.","[{'ForeName': 'Monique M', 'Initials': 'MM', 'LastName': 'Cherrier', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, School of Medicine University of Washington, Box 356560, Seattle, WA, 98195, USA. cherrier@uw.edu.'}, {'ForeName': 'Celestia S', 'Initials': 'CS', 'LastName': 'Higano', 'Affiliation': 'Department of Medicine, Division of Oncology, School of Medicine University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Heidi J', 'Initials': 'HJ', 'LastName': 'Gray', 'Affiliation': 'Fred Hutchinson Cancer Consortium, Seattle, WA, USA.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-021-06453-w'] 2190,34368886,Effect of mind and body education on quality of life among young breast cancer patients: a randomized controlled trial.,"PURPOSE This study aim was to evaluate efficacy of the combination with cosmetic and psychosocial education program on body image, sexual function, and emotional function among young-onset breast cancer (YBC). METHODS An unblended, randomized, controlled trial design was conducted in patients newly diagnosed with stage I-III breast cancer from 2014 to 2015. The intervention group received a structured education program including appearance management and mind control for 4 weeks. The outcome of this study shows effect on body image and sexual functioning and a distress due to altered appearance and anxiety after the intervention and 6 months after intervention. RESULTS Among 228 eligible patients, 109 (47.8%) agreed to participate in the present study and were randomized to intervention (n = 54) or control (n = 55) groups. After intervention, the intervention group reported significantly better body image compared to the control group (mean score of 75.0 vs. 59.3, respectively; P < 0.01). The intervention group also reported significantly lower levels of distress due to altered appearance and higher levels of sexual functioning compared to the control group after the intervention. The effects were maintained even 6 months after intervention. CONCLUSION(S) Body image intervention for YBC had effect on improving body image and sexual functioning and a reduction in distress due to altered appearance and anxiety. Trial registration number and date of registration: The study was registered at the Clinical Research Information Service (no. KCT0001191, https://cris.nih.go.kr/cris ) on 23 July 2014.",2021,The intervention group also reported significantly lower levels of distress due to altered appearance and higher levels of sexual functioning compared to the control group after the intervention.,"['young breast cancer patients', 'patients newly diagnosed with stage I-III breast cancer from 2014 to 2015', '228 eligible patients, 109 (47.8%) agreed to participate in the present study and were randomized to intervention (n\u2009=\u200954) or control (n\u2009=\u200955) groups', 'young-onset breast cancer (YBC', '23 July 2014']","['structured education program including appearance management and mind control for 4\xa0weeks', 'mind and body education', 'cosmetic and psychosocial education program']","['body image and sexual functioning', 'sexual functioning', 'levels of distress', 'body image, sexual function, and emotional function', 'better body image', 'quality of life']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}]","[{'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}]","[{'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",228.0,0.014137,The intervention group also reported significantly lower levels of distress due to altered appearance and higher levels of sexual functioning compared to the control group after the intervention.,"[{'ForeName': 'Danbee', 'Initials': 'D', 'LastName': 'Kang', 'Affiliation': 'Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.'}, {'ForeName': 'Jae Kyung', 'Initials': 'JK', 'LastName': 'Lee', 'Affiliation': 'Patient-Centered Outcomes Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Nayeon', 'Initials': 'N', 'LastName': 'Kim', 'Affiliation': 'Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.'}, {'ForeName': 'Sooyeon', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.'}, {'ForeName': 'Se Kyung', 'Initials': 'SK', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jeong Eon', 'Initials': 'JE', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Seok Jin', 'Initials': 'SJ', 'LastName': 'Nam', 'Affiliation': 'Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Juhee', 'Initials': 'J', 'LastName': 'Cho', 'Affiliation': 'Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea. jcho@skku.edu.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-021-06459-4'] 2191,34368303,Value of refined care in patients with acute exacerbation of chronic obstructive pulmonary disease.,"BACKGROUND Under physiological conditions, sputum produced during acute exacerbation of chronic obstructive pulmonary disease (AECOPD) can move passively with the cilia in the airway; the sputum is gradually excreted from the depth of the airways through the stimulation of the coughing reflex on the sensory nerve on the surface of the airway. However, when the sputum is thick, the cough is weak, or the tracheal cilia are abnormal, sputum accumulation may occur and affect the exchange of oxygen and carbon dioxide in the lung. Furthermore, the presence of pathogenic microorganisms in sputum may cause or aggravate the symptoms of pulmonary infection in patients, which is the main factor leading to AECOPD. Therefore, promoting effective drainage of sputum and maintaining airway opening are key points requiring clinical attention. AIM To explore the effect of refined nursing strategies in patients with AECOPD and dysphagia. METHODS We selected 126 patients with AECOPD and difficulty of expectoration at our hospital, and divided them into a refined care group and a routine care group, with 63 cases each, using a random number table. The two groups of patients were treated with expectorant, anti-infection, oxygen inhalation, and other basic treatment measures; patients in the refined care group were given refined nursing intervention during hospitalization, and the routine care group received conventional nursing intervention. The differences in sputum expectoration, negative pressure suction rate, blood gas parameters, dyspnea score measured through the tool developed by the Medical Research Council (MRC), and quality of life were compared between the two groups. RESULTS After 7 d of intervention, the sputum expectoration effect of the refined care group was 62.30%, the effective rate was 31.15%, and the inefficiency rate was 6.56%. The sputum expectoration effect of the routine care group was 44.07%, the effective rate was 42.37%, and the inefficiency rate was 13.56%. The refined care group had better sputum expectoration than the routine care group ( P < 0.05). The negative pressure suction rate in the refined care group was significantly lower than that of the routine care group during the treatment (22.95% vs 44.07%, P < 0.05). Before the intervention, the arterial oxygen saturation (PaO 2 ) and arterial carbon dioxide saturation (PaCO 2 ) values were not significantly different between the two groups ( P > 0.05); the PaO 2 and PaCO 2 values in the refined care group were comparable to those in the routine care group after 7 d of intervention ( P > 0.05). Before the intervention, there was no significant difference in the MRC score between the two groups ( P > 0.05); the MRC score of the refined care group was lower than that of the routine care group after 7 d of intervention, but the difference was not statistically significant ( P > 0.05). Before intervention, there was no significant difference in the symptoms, activities, disease impact, or St. George's Respiratory questionnaire (SGRQ) total scores between the two groups ( P > 0.05). After 7 days of intervention, the symptoms, activities, and total score of SGRQ of the refined care group were higher than those of the routine care group, but the difference was not statistically significant ( P > 0.05). CONCLUSION AECOPD with thick sputum, weak coughing reflex, and abnormal tracheal cilia function will lead to sputum accumulation and affect the exchange of oxygen and carbon dioxide in the lung. Patients with AECOPD who have difficulty expectorating sputum may undergo refined nursing strategies that will promote expectoration, alleviate clinical symptoms, and improve the quality of life.",2021,"The negative pressure suction rate in the refined care group was significantly lower than that of the routine care group during the treatment (22.95% vs 44.07%, P < 0.05).","['Patients with AECOPD who have difficulty expectorating sputum', 'patients with acute exacerbation of chronic obstructive pulmonary disease', 'patients with AECOPD and dysphagia', '126 patients with AECOPD and difficulty of expectoration at our hospital, and divided them into a refined care group and a routine care group, with 63 cases each, using a random number table']","['expectorant, anti-infection, oxygen inhalation, and other basic treatment measures; patients in the refined care group were given refined nursing intervention during hospitalization, and the routine care group received conventional nursing intervention']","['symptoms, activities, and total score of SGRQ', 'effective rate', 'arterial oxygen saturation (PaO 2 ) and arterial carbon dioxide saturation (PaCO 2 ) values', 'sputum expectoration, negative pressure suction rate, blood gas parameters, dyspnea score measured through the tool developed by the Medical Research Council (MRC), and quality of life', 'sputum expectoration effect', ""symptoms, activities, disease impact, or St. George's Respiratory questionnaire (SGRQ) total scores"", 'negative pressure suction rate', 'inefficiency rate', 'MRC score', 'sputum expectoration']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0340044', 'cui_str': 'Acute exacerbation of chronic obstructive airways disease'}, {'cui': 'C0566530', 'cui_str': 'Difficulty expectorating'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1457900', 'cui_str': 'Each'}, {'cui': 'C0039224', 'cui_str': 'Table'}]","[{'cui': 'C0015314', 'cui_str': 'Expectorant agent'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0428175', 'cui_str': 'Oxygen saturation measurement, arterial'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0231184', 'cui_str': 'Inefficiency'}]",126.0,0.0120686,"The negative pressure suction rate in the refined care group was significantly lower than that of the routine care group during the treatment (22.95% vs 44.07%, P < 0.05).","[{'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Na', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.'}, {'ForeName': 'Su-Ling', 'Initials': 'SL', 'LastName': 'Guo', 'Affiliation': 'Department of Hematology, The Eighth Medical Center, General Hospital of Chinese PLA, Beijing 100091, China.'}, {'ForeName': 'Ying-Ying', 'Initials': 'YY', 'LastName': 'Zhang', 'Affiliation': ""Operation Room, The Fourth People's Hospital of Jinan, Jinan 250031, Shandong Province, China.""}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Ye', 'Affiliation': 'Department of Gynecology and Pediatrics, PLA Rocket Force Characteristic Medical Center, Beijing 100088, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiovascular Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, Shandong Province, China.'}, {'ForeName': 'Gui-Xia', 'Initials': 'GX', 'LastName': 'Wu', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.'}, {'ForeName': 'Le-Wei', 'Initials': 'LW', 'LastName': 'Ma', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Jinan Central Hospital, Jinan 250013, Shandong Province, China. mlwjn0828@163.com.'}]",World journal of clinical cases,['10.12998/wjcc.v9.i21.5840'] 2192,34368243,Effect of High-Frequency Oscillatory Ventilation Combined With Pulmonary Surfactant in the Treatment of Acute Respiratory Distress Syndrome After Cardiac Surgery: A Prospective Randomised Controlled Trial.,"Background: This study aimed to evaluate the effects of pulmonary surfactant (PS) combined with high-frequency oscillatory ventilation (HFOV) or conventional mechanical ventilation (CMV) in infants with acute respiratory distress syndrome (ARDS) after congenital cardiac surgery. Methods: A total of 61 infants with ARDS were eligible and were randomised to the CMV + PS group ( n = 30) or the HFOV + PS group ( n = 31) between January 2020 and December 2020. The primary outcomes were the changes in arterial blood gas parameters. The duration of mechanical ventilation, length of hospitalisation and the incidence of complications were considered secondary outcomes. Results: A total of 61 infants completed the study. In the HFOV + PS group, the blood gas analysis results were significantly improved ( P < 0.05), while the duration of mechanical ventilation and length of hospitalisation were shorter than the CMV + PS group ( P < 0.05). However, the incidence of complications was not different between the two groups ( P > 0.05). Conclusions: Compared with the CMV + PS group, the HFOV + PS group showed significantly improved ABG variables and had a shortened length of hospitalisation and mechanical ventilation in infants with ARDS after cardiac surgery. Clinical Trial Registration: Chinese Clinical Trial Registry; Number: ChiCTR2000039457.",2021,"In the HFOV + PS group, the blood gas analysis results were significantly improved ( P < 0.05), while the duration of mechanical ventilation and length of hospitalisation were shorter than the CMV + PS group ( P < 0.05).","['61 infants with ARDS', 'infants with acute respiratory distress syndrome (ARDS) after congenital cardiac surgery', 'Acute Respiratory Distress Syndrome', 'infants with ARDS after cardiac surgery', 'group ( n = 31) between January 2020 and December 2020', '61 infants completed the study']","['HFOV + PS', 'pulmonary surfactant (PS) combined with high-frequency oscillatory ventilation (HFOV) or conventional mechanical ventilation (CMV', 'CMV + PS', 'High-Frequency Oscillatory Ventilation Combined With Pulmonary Surfactant']","['blood gas analysis results', 'incidence of complications', 'ABG variables', 'duration of mechanical ventilation, length of hospitalisation and the incidence of complications', 'changes in arterial blood gas parameters', 'duration of mechanical ventilation and length of hospitalisation', 'shortened length of hospitalisation and mechanical ventilation']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C0009678', 'cui_str': 'congenital'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0419017', 'cui_str': 'High frequency oscillatory ventilation'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}]","[{'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}]",61.0,0.0721347,"In the HFOV + PS group, the blood gas analysis results were significantly improved ( P < 0.05), while the duration of mechanical ventilation and length of hospitalisation were shorter than the CMV + PS group ( P < 0.05).","[{'ForeName': 'Yi-Rong', 'Initials': 'YR', 'LastName': 'Zheng', 'Affiliation': ""Department of Cardiac Surgery, Fujian Branch of Shanghai Children's Medical Center, Fuzhou, China.""}, {'ForeName': 'Yu-Qing', 'Initials': 'YQ', 'LastName': 'Lei', 'Affiliation': ""Department of Cardiac Surgery, Fujian Branch of Shanghai Children's Medical Center, Fuzhou, China.""}, {'ForeName': 'Jian-Feng', 'Initials': 'JF', 'LastName': 'Liu', 'Affiliation': ""Department of Cardiac Surgery, Fujian Branch of Shanghai Children's Medical Center, Fuzhou, China.""}, {'ForeName': 'Hong-Lin', 'Initials': 'HL', 'LastName': 'Wu', 'Affiliation': ""Department of Cardiac Surgery, Fujian Branch of Shanghai Children's Medical Center, Fuzhou, China.""}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Xu', 'Affiliation': ""Department of Cardiac Surgery, Fujian Branch of Shanghai Children's Medical Center, Fuzhou, China.""}, {'ForeName': 'Shu-Ting', 'Initials': 'ST', 'LastName': 'Huang', 'Affiliation': ""Department of Cardiac Surgery, Fujian Branch of Shanghai Children's Medical Center, Fuzhou, China.""}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Cao', 'Affiliation': ""Department of Cardiac Surgery, Fujian Branch of Shanghai Children's Medical Center, Fuzhou, China.""}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': ""Department of Cardiac Surgery, Fujian Branch of Shanghai Children's Medical Center, Fuzhou, China.""}]",Frontiers in cardiovascular medicine,['10.3389/fcvm.2021.675213'] 2193,34368242,Cardiac Shock Wave Therapy Ameliorates Myocardial Ischemia in Patients With Chronic Refractory Angina Pectoris: A Randomized Trial.,"Background: Cardiac shock wave therapy (CSWT) is a non-invasive new option for the treatment of chronic refractory angina pectoris (CRAP). This study aimed to evaluate the safety and efficiency of CSWT in the treatment of CRAP. Methods: Eighty-seven patients with CRAP were randomly allocated into CWST group ( n = 46) and Control group ( n = 41). Canadian Cardiovascular Society (CCS) grade of angina pectoris, Seattle Angina Questionnaire (SAQ) score, 6-min walk test (6MWT), weekly dosage of nitroglycerin, and myocardial perfusion on D-SPECT were determined at baseline and during the follow-up period. Adverse events were also evaluated. Results: CSWT was well-tolerated in the CSWT patients. CSWT significantly improved the CCS grade, SAQ score, and 6MWT ( p < 0.05). Imaging examinations showed that the ischemic area was reduced after CSWT. However, no significant changes were observed in the Control group. Conclusions: CSWT may improve the myocardial perfusion and reduce clinical symptoms without increasing adverse effects in CRAP patients. It provides a non-invasive and safe clinical therapy for CRAP patients. Clinical Trial registration: www.ClinicalTrials.gov, identifier: NCT03398096.",2021,"CSWT significantly improved the CCS grade, SAQ score, and 6MWT ( p < 0.05).","['Patients With Chronic Refractory Angina Pectoris', 'CRAP patients', 'chronic refractory angina pectoris (CRAP', 'Methods: Eighty-seven patients with CRAP']","['CWST', 'Cardiac Shock Wave Therapy', 'Cardiac shock wave therapy (CSWT', 'CSWT']","['CCS grade, SAQ score, and 6MWT', 'Myocardial Ischemia', 'Adverse events', 'Canadian Cardiovascular Society (CCS) grade of angina pectoris, Seattle Angina Questionnaire (SAQ) score, 6-min walk test (6MWT), weekly dosage of nitroglycerin, and myocardial perfusion on D-SPECT', 'safety and efficiency', 'ischemic area']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C1536180', 'cui_str': 'Refractory angina pectoris'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517895', 'cui_str': '87'}]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1737238', 'cui_str': 'Extracorporeal shock wave therapy'}]","[{'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0050133', 'cui_str': '9,10-anthraquinone'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0017887', 'cui_str': 'Nitroglycerin'}, {'cui': 'C0428857', 'cui_str': 'Myocardial perfusion'}, {'cui': 'C0040399', 'cui_str': 'Single photon emission computerized tomography'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]",87.0,0.0816683,"CSWT significantly improved the CCS grade, SAQ score, and 6MWT ( p < 0.05).","[{'ForeName': 'Liu', 'Initials': 'L', 'LastName': 'Weijing', 'Affiliation': ""Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.""}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Ximin', 'Affiliation': ""Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.""}, {'ForeName': 'Shen', 'Initials': 'S', 'LastName': 'Jianying', 'Affiliation': ""Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.""}, {'ForeName': 'Zhu', 'Initials': 'Z', 'LastName': 'Mengyun', 'Affiliation': ""Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.""}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Xuehua', 'Affiliation': ""Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.""}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Yawei', 'Affiliation': ""Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Liqiong', 'Affiliation': ""Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.""}]",Frontiers in cardiovascular medicine,['10.3389/fcvm.2021.664433'] 2194,34368215,"Corrigendum: A High-Protein, Low Glycemic Index Diet Suppresses Hunger but Not Weight Regain After Weight Loss: Results From a Large, 3-Years Randomized Trial (PREVIEW).",[This corrects the article DOI: 10.3389/fnut.2021.685648.].,2021,[This corrects the article DOI: 10.3389/fnut.2021.685648.].,[],"['Regain', 'High-Protein, Low Glycemic Index Diet']",[],[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]",[],,0.0499901,[This corrects the article DOI: 10.3389/fnut.2021.685648.].,"[{'ForeName': 'Ruixin', 'Initials': 'R', 'LastName': 'Zhu', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Fogelholm', 'Affiliation': 'Department of Food and Nutrition, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Larsen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Sally D', 'Initials': 'SD', 'LastName': 'Poppitt', 'Affiliation': 'Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Marta P', 'Initials': 'MP', 'LastName': 'Silvestre', 'Affiliation': 'Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Pia S', 'Initials': 'PS', 'LastName': 'Vestentoft', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Elli', 'Initials': 'E', 'LastName': 'Jalo', 'Affiliation': 'Department of Food and Nutrition, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Navas-Carretero', 'Affiliation': 'Centre for Nutrition Research, University of Navarra, Pamplona, Spain.'}, {'ForeName': 'Maija', 'Initials': 'M', 'LastName': 'Huttunen-Lenz', 'Affiliation': 'Institute for Nursing Science, University of Education Schwäbisch Gmünd, Schwäbisch Gmünd, Germany.'}, {'ForeName': 'Moira A', 'Initials': 'MA', 'LastName': 'Taylor', 'Affiliation': ""Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, Nottingham, United Kingdom.""}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Stratton', 'Affiliation': 'Applied Sports, Technology, Exercise and Medicine (A-STEM) Research Centre, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Swindell', 'Affiliation': 'Applied Sports, Technology, Exercise and Medicine (A-STEM) Research Centre, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Niina E', 'Initials': 'NE', 'LastName': 'Kaartinen', 'Affiliation': 'Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Lam', 'Affiliation': 'NetUnion sarl, Lausanne, Switzerland.'}, {'ForeName': 'Teodora', 'Initials': 'T', 'LastName': 'Handjieva-Darlenska', 'Affiliation': 'Department of Pharmacology and Toxicology, Medical University of Sofia, Sofia, Bulgaria.'}, {'ForeName': 'Svetoslav', 'Initials': 'S', 'LastName': 'Handjiev', 'Affiliation': 'Department of Pharmacology and Toxicology, Medical University of Sofia, Sofia, Bulgaria.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Schlicht', 'Affiliation': 'Exercise and Health Sciences, University of Stuttgart, Stuttgart, Germany.'}, {'ForeName': 'J Alfredo', 'Initials': 'JA', 'LastName': 'Martinez', 'Affiliation': 'Centro de Investigacion Biomedica en Red Area de Fisiologia de la Obesidad y la Nutricion (CIBEROBN), Madrid, Spain.'}, {'ForeName': 'Radhika V', 'Initials': 'RV', 'LastName': 'Seimon', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Sainsbury', 'Affiliation': 'School of Human Sciences (Exercise and Sports Science), Faculty of Science, The University of Western Australia, Crawley, WA, Australia.'}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Macdonald', 'Affiliation': ""Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, MRC/ARUK Centre for Musculoskeletal Ageing Research, ARUK Centre for Sport, Exercise and Osteoarthritis, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham, United Kingdom.""}, {'ForeName': 'Margriet S', 'Initials': 'MS', 'LastName': 'Westerterp-Plantenga', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'Brand-Miller', 'Affiliation': 'School of Life and Environmental Sciences and Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Raben', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}]",Frontiers in nutrition,['10.3389/fnut.2021.736531'] 2195,34368187,Acute Hemodynamic Effect of Acetazolamide in Patients With Pulmonary Hypertension Whilst Breathing Normoxic and Hypoxic Gas: A Randomized Cross-Over Trial.,"Aims: To test the acute hemodynamic effect of acetazolamide in patients with pulmonary hypertension (PH) under ambient air and hypoxia. Methods: Patients with pulmonary arterial or chronic thromboembolic PH (PAH/CTEPH) undergoing right heart catheterization were included in this randomized, placebo-controlled, double-blinded, crossover trial. The main outcome, pulmonary vascular resistance (PVR), further hemodynamics, blood- and cerebral oxygenation were measured 1 h after intravenous administration of 500 mg acetazolamide or placebo-saline on ambient air (normoxia) and at the end of breathing hypoxic gas (F I O 2 0.15, hypoxia) for 15 min. Results: 24 PH-patients, 71% men, mean ± SD age 59 ± 14 years, BMI 28 ± 5 kg/m 2 , PVR 4.7 ± 2.1 WU participated. Mean PVR after acetazolamide vs. placebo was 5.5 ± 3.0 vs. 5.3 ± 3.0 WU; mean difference (95% CI) 0.2 (-0.2-0.6, p = 0.341). Heart rate was higher after acetazolamide (79 ± 12 vs. 77 ± 11 bpm, p = 0.026), pH was lower (7.40 ± 0.02 vs. 7.42 ± 0.03, p = 0.002) but PaCO 2 and PaO 2 remained unchanged while cerebral tissue oxygenation increased (71 ± 6 vs. 69 ± 6%, p = 0.017). In acute hypoxia, acetazolamide decreased PVR by 0.4 WU (0.0-0.9, p = 0.046) while PaO 2 and PaCO 2 were not changed. No adverse effects occurred. Conclusions: In patients with PAH/CTEPH, i.v. acetazolamide did not change pulmonary hemodynamics compared to placebo after 1 hour in normoxia but it reduced PVR after subsequent acute exposure to hypoxia. Our findings in normoxia do not suggest a direct acute pulmonary vasodilator effect of acetazolamide. The reduction of PVR during hypoxia requires further corroboration. Whether acetazolamide improves PH when given over a prolonged period by stimulating ventilation, increasing oxygenation, and/or altering vascular inflammation and remodeling remains to be investigated.",2021,acetazolamide did not change pulmonary hemodynamics compared to placebo after 1 hour in normoxia,"['Patients with pulmonary arterial or chronic thromboembolic PH (PAH/CTEPH) undergoing right heart catheterization', '24 PH-patients, 71% men, mean ± SD age 59 ± 14 years, BMI 28 ± 5 kg/m 2 ', 'Patients With Pulmonary Hypertension Whilst Breathing Normoxic and Hypoxic Gas', 'patients with pulmonary hypertension (PH) under ambient air and hypoxia']","['acetazolamide vs. placebo', 'acetazolamide or placebo-saline', 'Acetazolamide', 'acetazolamide', 'placebo']","['change pulmonary hemodynamics', 'Mean PVR', 'PVR', 'pulmonary vascular resistance (PVR), further hemodynamics, blood- and cerebral oxygenation', 'ambient air (normoxia', 'Heart rate', 'cerebral tissue oxygenation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030123', 'cui_str': '4-Aminohippuric Acid'}, {'cui': 'C2363973', 'cui_str': 'Chronic thromboembolic pulmonary hypertension'}, {'cui': 'C0189896', 'cui_str': 'Catheterization of right heart'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0020542', 'cui_str': 'Pulmonary hypertension'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0001861', 'cui_str': 'Air'}]","[{'cui': 'C0000981', 'cui_str': 'Acetazolamide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0242852', 'cui_str': 'Proliferative vitreoretinopathy'}, {'cui': 'C0456261', 'cui_str': 'Pulmonary vascular resistance'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}]",,0.0882905,acetazolamide did not change pulmonary hemodynamics compared to placebo after 1 hour in normoxia,"[{'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Lichtblau', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Berlier', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Saxer', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Arcangelo F', 'Initials': 'AF', 'LastName': 'Carta', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Mayer', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Groth', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Patrick R', 'Initials': 'PR', 'LastName': 'Bader', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Simon R', 'Initials': 'SR', 'LastName': 'Schneider', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Furian', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Esther I', 'Initials': 'EI', 'LastName': 'Schwarz', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Erik R', 'Initials': 'ER', 'LastName': 'Swenson', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, VA Puget Sound Health Care System, University of Washington, Seattle, WA, United States.'}, {'ForeName': 'Konrad E', 'Initials': 'KE', 'LastName': 'Bloch', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Ulrich', 'Affiliation': 'Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.'}]",Frontiers in medicine,['10.3389/fmed.2021.681473'] 2196,34368045,Pilot of a Community Health Worker Video Intervention for Immigrant Day Laborers at Occupational Health Risk.,"Significance: Immigrant day laborers suffer from disproportionate occupational health risks from hazardous reconstruction jobs after natural disasters. Methods: We conducted a randomized controlled trial of a short-video educational intervention to improve safety knowledge and intent to engage in safety preventive behaviors among 98 Hispanic day laborers (49 randomized to video and 49 control). The short video featured a male promotor and a female promotora who narrated 3 stories of day laborers who were injured while doing construction work in post-Katrina New Orleans. The main outcome measures were changes in scores for day laborer-reported safety knowledge and safety behaviors derived from interviewer-delivered baseline and post-intervention surveys. Results: Video participants reported improvement in overall average safety knowledge score (mean score of 11.3 out of a max score of 12 or 94% when standardized to 0-100% scale), as compared to the control group (mean score of 8.6 or 72%) who were not offered the video ( p < 0.00001). The intervention was highly successful in workers stating that they learned and were willing to change their safety preventive behaviors to reduce their occupational risk. The average safety behavior score was higher among those watching the video (17.2 out of a max of 22 or 78.1% when standardized on a scale 0-100%) as compared to control (14.5 or 65.9%) ( p = 0.0024). Conclusion: A short video intervention can improve knowledge and intent to engage in preventive behaviors among Hispanic workers for which there is a dearth of construction safety preventive research.",2021,The average safety behavior score was higher among those watching the video (17.2 out of a max of 22 or 78.1% when standardized on a scale 0-100%) as compared to control (14.5 or 65.9%) ( p = 0.0024). ,"['Hispanic workers', '98 Hispanic day laborers (49 randomized to video and 49 control', 'male promotor and a female promotora who narrated 3 stories of day laborers who were injured while doing construction work in post-Katrina New Orleans', 'Immigrant Day Laborers at Occupational Health Risk', 'Immigrant day laborers suffer from disproportionate occupational health risks from hazardous reconstruction jobs after natural disasters']","['Community Health Worker Video Intervention', 'video intervention', 'short-video educational intervention']","['safety knowledge and intent to engage in safety preventive behaviors', 'average safety behavior score', 'changes in scores for day laborer-reported safety knowledge and safety behaviors', 'overall average safety knowledge score']","[{'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0240146', 'cui_str': 'Laborer'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0403066', 'cui_str': 'Construction worker'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0282163', 'cui_str': 'Immigrant'}, {'cui': 'C0079920', 'cui_str': 'Occupational Health'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205350', 'cui_str': 'Disproportionate'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0027485', 'cui_str': 'Natural Disaster'}]","[{'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1321226', 'cui_str': 'Safety behavior'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0240146', 'cui_str': 'Laborer'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0738377,The average safety behavior score was higher among those watching the video (17.2 out of a max of 22 or 78.1% when standardized on a scale 0-100%) as compared to control (14.5 or 65.9%) ( p = 0.0024). ,"[{'ForeName': 'Marielena', 'Initials': 'M', 'LastName': 'Lara', 'Affiliation': 'RAND Corporation, Santa Monica, CA, United States.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Díaz Fuentes', 'Affiliation': 'Department of Economics, University of New Mexico, Albuquerque, NM, United States.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Calderón', 'Affiliation': 'Common Ground Health Clinic, New Orleans, LA, United States.'}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Geschwind', 'Affiliation': 'RAND Corporation, Santa Monica, CA, United States.'}, {'ForeName': 'Meshawn', 'Initials': 'M', 'LastName': 'Tarver', 'Affiliation': 'Common Ground Health Clinic, New Orleans, LA, United States.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'RAND Corporation, Santa Monica, CA, United States.'}]",Frontiers in public health,['10.3389/fpubh.2021.662439'] 2197,34367855,The Effectiveness of Immediate Triamcinolone Acetonide Injection after Auricular Keloid Surgery: A Prospective Randomized Controlled Trial.,"The earlobe and helix are common sites for keloids following ear piercing. First-line therapy involves intra-keloidal excision followed by triamcinolone acetonide (TA) injection. Yet, the optimal timing for TA injection after keloid excision remains debated. The objective of this study was to compare outcomes between immediate and delayed TA injection after auricular keloid excision. Methods This was a prospective, controlled trial with patients randomized into immediate or delayed groups. The Vancouver Scar Scale (VSS) and Patient and Observer Scar Assessment Scale (POSAS) were used to evaluate scar quality. The number of recurrent keloid cases was recorded, defined as a VSS height of 3, POSAS thickness greater than 5, or an increase in VSS height or POSAS thickness after keloid excision. Overall complications were recorded. A P value less than 0.05 was considered statistically significant. Results The immediate group contained 18 patients, and the delayed group had 16 patients. The mean age of patients was 25.52 years, and the mean maximum keloid diameter was 14.49 mm (7-32.5 mm). The immediate group reported a statistically significant lower recurrence rate than did the delayed group at 5 months ( P = 0.042). No significant differences were noted between VSS and POSAS scores at 3 months, and no complications were recorded during the study. Conclusions Immediate TA injection is an acceptable option for auricular keloid treatment. Here, it was associated with a lower recurrence rate than with delayed injection and resulted in no complications. The immediate and delayed groups had similar outcomes for VSS and POSAS.",2021,"No significant differences were noted between VSS and POSAS scores at 3 months, and no complications were recorded during the study. ","['after Auricular Keloid Surgery', 'patients randomized into immediate or delayed groups']","['immediate and delayed TA injection', 'triamcinolone acetonide (TA) injection', 'Triamcinolone Acetonide Injection']","['VSS and POSAS', 'VSS and POSAS scores', 'scar quality', 'VSS height or POSAS thickness', 'recurrence rate', 'Vancouver Scar Scale (VSS) and Patient and Observer Scar Assessment Scale (POSAS', 'Overall complications', 'number of recurrent keloid cases']","[{'cui': 'C1522191', 'cui_str': 'Otic route'}, {'cui': 'C0022548', 'cui_str': 'Keloid'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0022548', 'cui_str': 'Keloid'}, {'cui': 'C0868928', 'cui_str': 'Case'}]",,0.0400398,"No significant differences were noted between VSS and POSAS scores at 3 months, and no complications were recorded during the study. ","[{'ForeName': 'Chairat', 'Initials': 'C', 'LastName': 'Burusapat', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Department of Surgery Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand.'}, {'ForeName': 'Nutthapong', 'Initials': 'N', 'LastName': 'Wanichjaroen', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Department of Surgery Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand.'}, {'ForeName': 'Nuttadon', 'Initials': 'N', 'LastName': 'Wongprakob', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Department of Surgery Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand.'}, {'ForeName': 'Rapeepat', 'Initials': 'R', 'LastName': 'Sapruangthong', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Department of Surgery Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand.'}]",Plastic and reconstructive surgery. Global open,['10.1097/GOX.0000000000003729'] 2198,34370331,"Effects of global postural reeducation on postural control, dynamic balance, and ankle range of motion in patients with hallux abducto valgus. A randomized controlled trial.","Hallux abducto valgus (HAV) is a common musculoskeletal disorder that has been addressed surgically. Nevertheless, the manual therapy approach may play an important role in the management of this condition. The present study aimed to determine the effectiveness of Global Postural Reeducation (GPR) in subjects with symptomatic mild to moderate HAV in static postural control, dynamic stability, and ankle dorsiflexion range of motion (DFROM). A total of 80 patients with mild to moderate symptomatic hallux abducto valgus (HAV) were allocated to the intervention group (GPR) or control group (no treatment) for 8 weeks. Outcome measures were assessed at baseline at 4 weeks and 8 weeks including static postural control (Romberg test), dynamic balance (Star Excursion Balance Test, SEBT), and ankle dorsiflexion range of motion (Weight-Bearing Lunge Test, WBLT). No improvements were observed at 4 weeks, but there were improvements at 8 weeks in: static postural control mediolateral displacement (X) of Center of Pressure (CoP) in both Eyes Open (EO) and Eyes Closed (EC): XEO (t(36)=2.892, p=0.006, d=0.67); XEC (t(68)=2.280, p=0.026, d=054); and Velocity (V) of CoP displacement: VEO (t(68)=2.380, p=0.020, d=0.57); VEC (t(36)=2.057, p=0.047, d=0.37). It were also improvements in: WBLT (t(36)=-2.869, p=0.007, d=0.54) and SEBT at three directions (Anterior, ANT; Posteromedial, PM; and Posterolateral, PL): SEBT.ANT (t(36)=-2.292, p=0.028, d=0.23); SEBT.PM (t(36)=-4.075, p<0.001, d=0.43); SEBT.PL (t(62)=-3.506, p=0.001, d=0.34).The present study showed that GPR compared to the control group might be effective in enhancing ankle function including postural control, dynamic balance, and dorsiflexion range of motion. This article is protected by copyright. All rights reserved.",2021,"No improvements were observed at 4 weeks, but there were improvements at 8 weeks in: static postural control mediolateral displacement (X) of Center of Pressure (CoP) in both Eyes Open (EO) and Eyes Closed (EC): XEO (t(36)=2.892, p=0.006, d=0.67); XEC (t(68)=2.280, p=0.026, d=054); and Velocity (V) of CoP displacement: VEO (t(68)=2.380, p=0.020, d=0.57); VEC (t(36)=2.057, p=0.047, d=0.37).","['patients with hallux abducto valgus', '80 patients with mild to moderate symptomatic hallux abducto valgus (HAV', 'subjects with symptomatic mild to moderate HAV in static postural control, dynamic stability, and ankle dorsiflexion range of motion (DFROM']","['Hallux abducto valgus (HAV', 'GPR', 'Global Postural Reeducation (GPR', 'global postural reeducation', 'intervention group (GPR) or control group (no treatment']","['postural control, dynamic balance, and dorsiflexion range of motion', 'static postural control (Romberg test), dynamic balance (Star Excursion Balance Test, SEBT), and ankle dorsiflexion range of motion (Weight-Bearing Lunge Test, WBLT', 'static postural control mediolateral displacement (X) of Center of Pressure (CoP) in both Eyes Open (EO) and Eyes Closed (EC): XEO', 'Velocity (V) of CoP displacement: VEO', 'postural control, dynamic balance, and ankle range of motion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018534', 'cui_str': 'Hallux structure'}, {'cui': 'C0042282', 'cui_str': 'Valgus deformity'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0231770', 'cui_str': 'Dorsiflexion of foot'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}]","[{'cui': 'C0018534', 'cui_str': 'Hallux structure'}, {'cui': 'C0042282', 'cui_str': 'Valgus deformity'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0278127', 'cui_str': 'Romberg sign'}, {'cui': 'C0282064', 'cui_str': 'Stars, Celestial'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0231770', 'cui_str': 'Dorsiflexion of foot'}, {'cui': 'C0085086', 'cui_str': 'Weight-bearing'}, {'cui': 'C0441992', 'cui_str': 'Mediolateral'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0229118', 'cui_str': 'Structure of both eyes'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0266574', 'cui_str': 'Ablepharon'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0576183', 'cui_str': 'Ankle joint - range of movement'}]",80.0,0.0640165,"No improvements were observed at 4 weeks, but there were improvements at 8 weeks in: static postural control mediolateral displacement (X) of Center of Pressure (CoP) in both Eyes Open (EO) and Eyes Closed (EC): XEO (t(36)=2.892, p=0.006, d=0.67); XEC (t(68)=2.280, p=0.026, d=054); and Velocity (V) of CoP displacement: VEO (t(68)=2.380, p=0.020, d=0.57); VEC (t(36)=2.057, p=0.047, d=0.37).","[{'ForeName': 'Alejandro Estepa-Gallego', 'Initials': 'AE', 'LastName': 'Msc', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, E-23071, Jaén, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Ibañez-Vera', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, E-23071, Jaén, Spain.'}, {'ForeName': 'María Dolores', 'Initials': 'MD', 'LastName': 'Estudillo-Martínez', 'Affiliation': 'Department of Statistics, Faculty of Experimental Sciences, University of Jaén, E-23071, Jaén, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Castellote-Caballero', 'Affiliation': 'Department of Statistics, Faculty of Experimental Sciences, University of Jaén, E-23071, Jaén, Spain.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Bergamin', 'Affiliation': 'Department of Medicine University of Padova Palazzina ex SemeioticaMedica-Via Ospedale Civile, 105 - 35128, Padova, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Gobbo', 'Affiliation': 'Department of Medicine University of Padova Palazzina ex SemeioticaMedica-Via Ospedale Civile, 105 - 35128, Padova, Italy.'}, {'ForeName': 'Miguel Ángel', 'Initials': 'MÁ', 'LastName': 'Lérida-Ortega', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, E-23071, Jaén, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cruz-Díaz', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, E-23071, Jaén, Spain.'}]",Journal of orthopaedic research : official publication of the Orthopaedic Research Society,['10.1002/jor.25156'] 2199,34370330,"Comparison between Movement Pattern Training and Strengthening on Muscle Volume, Muscle Fat and Strength in Patients with Hip-related Groin Pain: An Exploratory Analysis.","The purpose of this exploratory analysis was to compare the impact of movement pattern training (MoveTrain) and standard strength and flexibility training (Standard) on muscle volume, strength and fatty infiltration in patients with hip-related groin pain (HRGP). We completed a secondary analysis of data collected during an assessor-blinded randomized control trial. Data was used from 27 patients with HRGP, 15 to 40 years, who were randomized into MoveTrain or Standard groups. Both groups participated in their training protocol (MoveTrain, n = 14 or Standard, n = 13) which included 10 supervised sessions over 12 weeks and a daily home exercise program. Outcome measures were collected at baseline and immediately after treatment. Magnetic resonance images (MRI) data was used to determine muscle fat index (MFI) and muscle volume. A hand-held dynamometer was used to assess isometric hip abductor and extensor strength. The Standard group demonstrated a significant post-treatment increase in gluteus medius muscle volume compared to the MoveTrain group. Both groups demonstrated an increase in hip abductor strength and reduction in gluteus minimus and gluteus maximus MFI. The magnitude of change for all outcomes were modest. Statement of Clinical Significance: Movement pattern training or a program of strength/flexibility training may be effective at improving hip abductor strength and reducing fatty infiltration in the gluteal musculature among those with HRGP. Further research is needed to better understand etiology of strength changes and impact of muscle volume and MFI in HRGP and the effect of exercise on muscle structure and function. This article is protected by copyright. All rights reserved.",2021,Both groups demonstrated an increase in hip abductor strength and reduction in gluteus minimus and gluteus maximus MFI.,"['Patients with Hip-related Groin Pain', 'patients with hip-related groin pain (HRGP', '27 patients with HRGP, 15 to 40 years']","['daily home exercise program', 'MoveTrain', 'Movement pattern training or a program of strength/flexibility training', 'Movement Pattern Training and Strengthening', 'movement pattern training (MoveTrain) and standard strength and flexibility training (Standard']","['muscle volume, strength and fatty infiltration', 'hip abductor strength', 'hip abductor strength and reduction in gluteus minimus and gluteus maximus MFI', 'isometric hip abductor and extensor strength', 'Muscle Volume, Muscle Fat and Strength', 'gluteus medius muscle volume', 'muscle fat index (MFI) and muscle volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0239783', 'cui_str': 'Inguinal pain'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program'}, {'cui': 'C0427096', 'cui_str': 'Patterning of movement'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0333575', 'cui_str': 'Fatty infiltration'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0224427', 'cui_str': 'Structure of gluteus minimus muscle'}, {'cui': 'C0224424', 'cui_str': 'Structure of gluteus maximus muscle'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0224425', 'cui_str': 'Structure of gluteus medius muscle'}]",27.0,0.00671306,Both groups demonstrated an increase in hip abductor strength and reduction in gluteus minimus and gluteus maximus MFI.,"[{'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Koch', 'Affiliation': 'Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO, United States.'}, {'ForeName': 'Adam I', 'Initials': 'AI', 'LastName': 'Semciw', 'Affiliation': 'Department of Physiotherapy, Podiatry and Prosthetics and Orthotics, La Trobe University, Bundoora, Vic, Australia.'}, {'ForeName': 'Paul K', 'Initials': 'PK', 'LastName': 'Commean', 'Affiliation': 'Electronic Radiology Lab in Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, United States.'}, {'ForeName': 'Travis J', 'Initials': 'TJ', 'LastName': 'Hillen', 'Affiliation': 'Department of Radiology, Washington University School of Medicine, St. Louis, MO, United States.'}, {'ForeName': 'G Kelley', 'Initials': 'GK', 'LastName': 'Fitzgerald Pt', 'Affiliation': 'Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, United States.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Clohisy', 'Affiliation': 'Department of Orthopaedic Surgery, Washington University School of Medicine, St Louis, MO, United States.'}, {'ForeName': 'Marcie', 'Initials': 'M', 'LastName': 'Harris-Hayes', 'Affiliation': 'Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO, United States.'}]",Journal of orthopaedic research : official publication of the Orthopaedic Research Society,['10.1002/jor.25158'] 2200,34370327,"Effects of therapeutic exercise and aerobic exercise programs on pain, anxiety and oral health-related quality of life in patients with temporomandibular disorders.","BACKGROUND Pain and anxiety contribute to decreasing quality of life related to oral health in patients with temporomandibular disorders (TMD). Evidence-based practice has shown that therapeutic and aerobic exercise programs are adequate strategies for modifying these factors. OBJECTIVE Assess the effects of aerobic exercise on pain, anxiety and quality of life related to oral health in patients with TMD. METHODS Forty-five patients diagnosed with TMD were divided into three groups of 15 participants: a therapeutic exercise program (G1, mean 26.9±5.5 years), a therapeutic and aerobic exercise program (G2, mean 26±4.4 years) and an aerobic exercise program (G3, mean 24.9±3.4 years). Pain intensity was assessed using a numerical rating scale (NRS), anxiety level and quality of life related to oral health through GAD-7 and OHIP-14, respectively. These parameters were evaluated twice at baseline (T0a/T0b), ending 8-week intervention period (T1), and 8-12 weeks after ending intervention (T2). RESULTS NRS significantly decreased in G1 (mean difference T0a/T1=5.2, p˂0.001), G2 (mean difference T0a/T1=6.0, p˂0.001) and G3 (mean difference T0a/T1=2.2, p=0.001). OHIP-14 significantly decreased in G1 (mean difference T0a/T1=13.5, p˂0.001) and G2 (mean difference T0a/T1=15.8, p ˂ 0.001) but not in G3 (mean difference T0a/T1=1.2, p=0.55). There were no significant differences between groups regarding GAD-7. Between T1 and T2 there were no significant differences in variables. CONCLUSION Therapeutic exercises and therapeutic excercises combined with aerobic exercise groups had a significant decrease in pain and oral health related quality of life at 8 and 12 weeks. These decreases were not seen for the aerobic exercise group.",2021,Therapeutic exercises and therapeutic excercises combined with aerobic exercise groups had a significant decrease in pain and oral health related quality of life at 8 and 12 weeks.,"['patients with temporomandibular disorders', 'patients with temporomandibular disorders (TMD', 'Forty-five patients diagnosed with TMD were divided into three groups of 15 participants: a', 'patients with TMD']","['therapeutic and aerobic exercise program (G2, mean 26±4.4 years) and an aerobic exercise program', 'aerobic exercise', 'therapeutic exercise and aerobic exercise programs', 'therapeutic exercise program']","['pain, anxiety and quality of life related to oral health', 'numerical rating scale (NRS), anxiety level and quality of life related to oral health through GAD-7 and OHIP-14, respectively', 'pain, anxiety and oral health-related quality of life', 'Pain intensity', 'pain and oral health related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039494', 'cui_str': 'Temporomandibular joint disorder'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C3641330', 'cui_str': 'GAD-7'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",45.0,0.0250973,Therapeutic exercises and therapeutic excercises combined with aerobic exercise groups had a significant decrease in pain and oral health related quality of life at 8 and 12 weeks.,"[{'ForeName': 'Paula Manuela Mendes', 'Initials': 'PMM', 'LastName': 'Moleirinho-Alves', 'Affiliation': 'CIPER Neuromuscular Research Lab, Faculty of Human Kinetics, University of Lisbon, Lisbon, Portugal.'}, {'ForeName': 'André Mariz Coelho Santos', 'Initials': 'AMCS', 'LastName': 'de Almeida', 'Affiliation': 'Center of Interdisciplinary Research Egas Moniz (CiiEM), Egas Moniz Higher Institute of Health Science, Monte de Caparica, Portugal.'}, {'ForeName': 'Fernado Gustavo', 'Initials': 'FG', 'LastName': 'Exposto', 'Affiliation': 'Section of Orofacial Pain and Jaw Function, Department of Dentistry and Oral Health, Aarhus University, Scandinavian Center for Orofacial Neurosciences (SCON), Denmark.'}, {'ForeName': 'Raul Alexandre Nunes da Silva', 'Initials': 'RANDS', 'LastName': 'Oliveira', 'Affiliation': 'CIPER Neuromuscular Research Lab, Faculty of Human Kinetics, University of Lisbon, Lisbon, Portugal.'}, {'ForeName': 'Pedro Luís Camecelha', 'Initials': 'PLC', 'LastName': 'de Pezarat-Correia', 'Affiliation': 'CIPER Neuromuscular Research Lab, Faculty of Human Kinetics, University of Lisbon, Lisbon, Portugal.'}]",Journal of oral rehabilitation,['10.1111/joor.13239'] 2201,34370319,Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: a phase III randomized controlled study.,"The aim of our study was to evaluate the most optimal donor for young acute leukemia (AL) patients with multiple donors available for allogeneic hematopoietic stem cell transplantation (allo-HSCT), including HLA-matched sibling donors (MSDs), HLA-matched unrelated donors (URDs), haploidentical parental donors (HPDs), and haploidentical sibling donors (HSDs). From March 2008 to December 2016, 430 AL patients ≤ 35 years of age were included in the discovery, retrospective study. Patients who received transplantation from a MSD or a HSD had better 5-year OS rates compared with patients who received transplantation from a URD or a HPD. A superior graft-versus-leukemia effect was observed for high-risk patients undergoing HSD-HSCT with a lower relapse rate (P = .014) and a higher disease-free survival (DFS) rate (P = .029) compared with those undergoing MSD-HSCT. Outcomes of high-risk patients receiving an URD or HPD were equivalent. For intermediate/standard-risk patients, either a MSD or HSD may be the front-line donor selection with comparable outcomes. URDs were preferred over HPDs with reduced non-relapse mortality and higher overall survival (OS) and DFS rates. We further conducted an independent prospective randomized study to evaluate the survival advantage with the new donor hierarchy. Two hundred and fifty patients were randomly assigned to follow our new donor hierarchy or the traditional donor hierarchy at a 2:1 ratio. The new donor hierarchy contributed to significantly superior 2-year OS and DFS rates (OS: 76.2% vs. 67.8%, P = .046; DFS: 71.8% vs. 64.5%, P = .039). This article is protected by copyright. All rights reserved.",2021,URDs were preferred over HPDs with reduced non-relapse mortality and higher overall survival (OS) and DFS rates.,"['young acute leukemia (AL) patients with multiple donors available for allogeneic hematopoietic stem cell transplantation (allo-HSCT), including HLA-matched sibling donors (MSDs), HLA-matched unrelated donors (URDs), haploidentical parental donors (HPDs), and haploidentical sibling donors (HSDs', 'From March 2008 to December 2016, 430 AL patients ≤ 35\u2009years of age were included in the discovery, retrospective study', 'young acute leukemia patients', 'Patients who received transplantation from a MSD or a', 'high-risk patients receiving an URD or HPD', 'Two hundred and fifty patients']","['HSD', 'allogeneic hematopoietic stem cell transplantation']","['5-year OS rates', 'superior 2-year OS and DFS rates', 'higher disease-free survival (DFS) rate', 'Improved survival', 'overall survival (OS) and DFS rates', 'survival advantage', 'relapse rate']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0085669', 'cui_str': 'Acute leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0019630', 'cui_str': 'Class II Histocompatibility Antigens'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C3179133', 'cui_str': 'Donors, Unrelated'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0035363', 'cui_str': 'Retrospective Study'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0268263', 'cui_str': 'Multiple sulfatase deficiency'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0041941', 'cui_str': 'Urdu language'}, {'cui': 'C0121300', 'cui_str': 'Hematoporphyrin D'}, {'cui': 'C2348831', 'cui_str': '250'}]","[{'cui': 'C1837657', 'cui_str': 'CHST3-related skeletal dysplasia'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]",250.0,0.168482,URDs were preferred over HPDs with reduced non-relapse mortality and higher overall survival (OS) and DFS rates.,"[{'ForeName': 'Mingming', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}, {'ForeName': 'Haowen', 'Initials': 'H', 'LastName': 'Xiao', 'Affiliation': 'Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang province, P R China.'}, {'ForeName': 'Jimin', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}, {'ForeName': 'Yamin', 'Initials': 'Y', 'LastName': 'Tan', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}, {'ForeName': 'Yanmin', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}, {'ForeName': 'Xiaoyu', 'Initials': 'X', 'LastName': 'Lai', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}, {'ForeName': 'Yongxian', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}, {'ForeName': 'Weiyan', 'Initials': 'W', 'LastName': 'Zheng', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': 'Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang province, P R China.'}]",American journal of hematology,['10.1002/ajh.26317'] 2202,34370166,The effect of mobile health educational intervention on body image and fatigue in breast cancer survivors: a randomized controlled trial.,"BACKGROUND Cancer-related fatigue, physical changes, and pain are among the most troublesome symptoms caused by breast cancer treatment and influence the patients' quality of life. The aim of the present study was to examine the effect of mobile health educational intervention on body image and fatigue in breast cancer survivors. METHODS The present clinical trial study conducted on 38 women with breast cancer referred to Golestan and Shahid Baghaei 2 hospitals, Ahvaz, south west Iran in 2018-2019. Patients were randomly assigned into two intervention group, and control groups on 1:1 basis. Data collection tool included three parts: cancer fatigue scale, body image concern inventory, and demographic information. Text messages sent to intervention group via WhatsApp messenger for 7 weeks on a daily schedule. The control group did not receive any messages. Data were analyzed using SPSS Version 23.0. RESULTS The mean age of participants was 46.34 ± 9.96. The mean score of cancer fatigue scale after the intervention in the intervention group was decreased significantly (p = 0.005), but no statistically significant difference was observed in the control group. There was a significant difference in the mean score of body image concern inventory in the intervention group (p = 0.002) after the intervention compared with the control group. CONCLUSION Mobile health educational intervention improved cancer-related fatigue and body image among women breast cancer survivors. The integration of education for the management of fatigue and body image disturbance as part of routine care among breast cancer survivors is recommended.",2021,"The mean score of cancer fatigue scale after the intervention in the intervention group was decreased significantly (p = 0.005), but no statistically significant difference was observed in the control group.","['38 women with breast cancer referred to Golestan and Shahid Baghaei 2 hospitals, Ahvaz, south west Iran in 2018-2019', 'women breast cancer survivors', 'breast cancer survivors']","['mobile health educational intervention', 'Mobile health educational intervention']","['cancer-related fatigue and body image', 'mean score of cancer fatigue scale', 'mean score of body image concern inventory']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C4274302', 'cui_str': 'Cancer-related fatigue'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1332836', 'cui_str': 'Cancer fatigue'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",38.0,0.0602741,"The mean score of cancer fatigue scale after the intervention in the intervention group was decreased significantly (p = 0.005), but no statistically significant difference was observed in the control group.","[{'ForeName': 'Bahar', 'Initials': 'B', 'LastName': 'Bandani-Susan', 'Affiliation': 'Department of Health Education and Promotion, Public Health School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Montazeri', 'Affiliation': 'Health Metrics Research Center, Iranian Institute for Health Sciences Research, ACECR, Tehran, Iran.'}, {'ForeName': 'Mohammad Hossein', 'Initials': 'MH', 'LastName': 'Haghighizadeh', 'Affiliation': 'Department of Epidemiology and Biostatistics, Public Health School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Araban', 'Affiliation': 'Department of Health Education and Promotion, and Social Determinants of Health Research Center, Public Health School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. arabanm@ajums.ac.ir.'}]",Irish journal of medical science,['10.1007/s11845-021-02738-5'] 2203,34370153,Assertive skills: a comparison of two group interventions with Brazilian university students.,"The improvement or acquisition of socioemotional skills contributes to the academic and personal adaptation of university students. The way students think about themselves and others influence their social skills and well-being. Considering the importance of social competence for professional practice in the face of new social realities, the university must invest in programs that promote the socio-emotional development of students. This study compared the effects of interventions based on Rational Emotive Behavior Therapy and Psychoeducation on assertive skills and subjective well-being. This study involved 25 undergraduate students of a public university. The students were randomly allocated to three groups, including the Control group, and they were evaluated by means of questionnaires, inventories, scales, and written evaluation of the group process. The program consisted of 10 meetings and a 6-week follow-up. Irrational beliefs were reduced and their assertive skills' scores increased in the post-intervention and follow-up evaluations, regardless of the group. Only verbal reports from participants indicated an increase in well-being. The students' written reports after the end of the meetings indicate that the two forms of intervention were evaluated as promoting change by the students. One of the limitations of the study is the size of the groups. Despite the very small sample size, the study highlights that developing a set of flexible beliefs is fundamental to the exercise of assertiveness.",2021,"Irrational beliefs were reduced and their assertive skills' scores increased in the post-intervention and follow-up evaluations, regardless of the group.","['Brazilian university students', '25 undergraduate students of a public university']",['Rational Emotive Behavior Therapy and Psychoeducation'],"['improvement or acquisition of socioemotional skills', 'Irrational beliefs', ""assertive skills' scores""]","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}]","[{'cui': 'C0542058', 'cui_str': 'Irrational'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",25.0,0.0080759,"Irrational beliefs were reduced and their assertive skills' scores increased in the post-intervention and follow-up evaluations, regardless of the group.","[{'ForeName': 'Conceição Reis', 'Initials': 'CR', 'LastName': 'de Sousa', 'Affiliation': 'Curso Psicologia, Instituto Saúde e Sociedade, Universidade Federal de São Paulo (UNIFESP), Santos, Brazil. ceicaorsousa@gmail.com.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'da Costa Padovani', 'Affiliation': 'Departamento de Saúde, Educação e Sociedade, Instituto Saúde e Sociedade, Universidade Federal de São Paulo (UNIFESP), Santos, Brazil.'}]","Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS",['10.1186/s41155-021-00188-7'] 2204,34370125,Quantitative evaluation of colon perfusion after high versus low ligation in rectal surgery by indocyanine green: a pilot study.,"BACKGROUND In the field of rectal cancer surgery, there remains ongoing debate on the merits of high ligation (HL) and low ligation (LL) of the inferior mesenteric artery (IMA) in terms of perfusion and anastomosis leakage. Recently, infrared fluorescence of indocyanine green (ICG) imaging has been used to evaluate perfusion status during colorectal surgery. OBJECTIVE The purpose of this study is to compare the changes in perfusion status between HL and LL through quantitative evaluation of ICG. METHODS Patients with rectosigmoid or rectal cancer were randomized into a high or LL group. ICG was injected before and after IMA ligation, and region of interest (ROI) values were measured by an image analysis program (HSL video©). RESULTS From February to July 2020, 22 patients were enrolled, and 11 patients were assigned to each group. Basic demographics were similar between the two groups, except for albumin level and cardiac ejection fraction. There were no significant differences in F_max between the two groups, but T_max was significantly higher and Slope_max was significantly lower in the HL group than in the LL group. Anastomosis leakage was significantly associated with neoadjuvant chemoradiation and F_max. CONCLUSION After IMA ligation, T_max increased and Slope_max decreased significantly in the HL group. However, the intensity of perfusion status (F_max) did not change according to the level of IMA ligation.",2021,"There were no significant differences in F_max between the two groups, but T_max was significantly higher and Slope_max was significantly lower in the HL group than in the LL group.","['Patients with rectosigmoid or rectal cancer', 'From February to July 2020, 22 patients were enrolled, and 11 patients']","['indocyanine green (ICG) imaging', 'LL', 'indocyanine green', 'colon perfusion after high versus low ligation', 'HL']","['F_max', 'Anastomosis leakage', 'intensity of perfusion status (F_max', 'T_max increased and Slope_max', 'region of interest (ROI) values', 'Slope_max', 'albumin level and cardiac ejection fraction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521377', 'cui_str': 'Rectosigmoid structure'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}]","[{'cui': 'C0021234', 'cui_str': 'Indocyanine Green'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0332853', 'cui_str': 'Anastomosis'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0201838', 'cui_str': 'Albumin measurement'}, {'cui': 'C0232174', 'cui_str': 'Cardiac ejection fraction'}]",22.0,0.0521022,"There were no significant differences in F_max between the two groups, but T_max was significantly higher and Slope_max was significantly lower in the HL group than in the LL group.","[{'ForeName': 'Seung-Rim', 'Initials': 'SR', 'LastName': 'Han', 'Affiliation': ""Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Chul Seung', 'Initials': 'CS', 'LastName': 'Lee', 'Affiliation': ""Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Jung Hoon', 'Initials': 'JH', 'LastName': 'Bae', 'Affiliation': ""Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Hyo Jin', 'Initials': 'HJ', 'LastName': 'Lee', 'Affiliation': ""Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Mi Ran', 'Initials': 'MR', 'LastName': 'Yoon', 'Affiliation': ""Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Abdullah', 'Initials': 'A', 'LastName': 'Al-Sawat', 'Affiliation': ""Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Do Sang', 'Initials': 'DS', 'LastName': 'Lee', 'Affiliation': ""Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'In Kyu', 'Initials': 'IK', 'LastName': 'Lee', 'Affiliation': ""Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.""}, {'ForeName': 'Yoon Suk', 'Initials': 'YS', 'LastName': 'Lee', 'Affiliation': ""Division of Colorectal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea. yslee@catholic.ac.kr.""}]",Surgical endoscopy,['10.1007/s00464-021-08673-x'] 2205,34370076,"A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.","PURPOSE This study aimed at evaluating the effect of rucaparib on the pharmacokinetics of rosuvastatin and oral contraceptives in patients with advanced solid tumors and the safety of rucaparib with and without coadministration of rosuvastatin or oral contraceptives. METHODS Patients received single doses of oral rosuvastatin 20 mg (Arm A) or oral contraceptives ethinylestradiol 30 µg + levonorgestrel 150 µg (Arm B) on days 1 and 19 and continuous doses of rucaparib 600 mg BID from day 5 to 23. Serial blood samples were collected with and without rucaparib for pharmacokinetic analysis. RESULTS Thirty-six patients (n = 18 each arm) were enrolled and received at least 1 dose of study drug. In the drug-drug interaction analysis (n = 15 each arm), the geometric mean ratio (GMR) of maximum concentration (C max ) with and without rucaparib was 1.29 for rosuvastatin, 1.09 for ethinylestradiol, and 1.19 for levonorgestrel. GMR of area under the concentration-time curve from time zero to last quantifiable measurement (AUC 0-last ) was 1.34 for rosuvastatin, 1.43 for ethinylestradiol, and 1.56 for levonorgestrel. There was no increase in frequency of treatment-emergent adverse events (TEAEs) when rucaparib was given with either of the probe drugs. In both arms, most TEAEs were mild in severity and considered unrelated to study treatment. CONCLUSION Rucaparib 600 mg BID weakly increased the plasma exposure to rosuvastatin or oral contraceptives. Rucaparib safety profile when coadministered with rosuvastatin or oral contraceptives was consistent with that of rucaparib monotherapy. Dose adjustments of rosuvastatin and oral contraceptives are not necessary when coadministered with rucaparib. ClinicalTrials.gov NCT03954366; Date of registration May 17, 2019.",2021,There was no increase in frequency of treatment-emergent adverse events (TEAEs) when rucaparib was given with either of the probe drugs.,"['patients with advanced solid tumors', 'Thirty-six patients (n\u2009=\u200918 each arm) were enrolled and received at least 1 dose of study drug', 'patients with advanced solid tumors and the safety of rucaparib with and without coadministration of rosuvastatin or oral contraceptives']","['rucaparib with rosuvastatin and oral contraceptives', 'oral rosuvastatin 20\xa0mg (Arm A) or oral contraceptives ethinylestradiol 30\xa0µg\u2009+\u2009levonorgestrel', 'rucaparib 600\xa0mg BID', 'rosuvastatin and oral contraceptives', 'rosuvastatin', 'rucaparib']","['geometric mean ratio (GMR) of maximum concentration (C max ) with and without rucaparib', 'plasma exposure to rosuvastatin or oral contraceptives', 'frequency of treatment-emergent adverse events (TEAEs', 'GMR of area under the concentration-time curve']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3661315', 'cui_str': 'rucaparib'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}]","[{'cui': 'C3661315', 'cui_str': 'rucaparib'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C5136931', 'cui_str': 'rosuvastatin 20 MG [Ezallor]'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0015011', 'cui_str': 'Ethinyl Estradiol'}, {'cui': 'C0023566', 'cui_str': 'Levonorgestrel'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C3661315', 'cui_str': 'rucaparib'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",,0.10287,There was no increase in frequency of treatment-emergent adverse events (TEAEs) when rucaparib was given with either of the probe drugs.,"[{'ForeName': 'Mingxiang', 'Initials': 'M', 'LastName': 'Liao', 'Affiliation': 'Clinical Pharmacology, Clovis Oncology, Inc 5500 Flatrion Pkwy, Boulder, CO, 80301, USA.'}, {'ForeName': 'Krzysztof G', 'Initials': 'KG', 'LastName': 'Jeziorski', 'Affiliation': 'Department of Gerontology, Public Health and Didactics, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Tomaszewska-Kiecana', 'Affiliation': 'BioVirtus Research Site Sp. Z.O.O., BioVirtus Medical Centre, Józefów, Poland.'}, {'ForeName': 'István', 'Initials': 'I', 'LastName': 'Láng', 'Affiliation': 'Oncology Unit, Istenhegy Private Health Center, Budapest, Hungary.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Jasiówka', 'Affiliation': 'Gynecological Oncology Clinic, Centre of Oncology, Maria Skłodowska-Curie Memorial Institute, Krakow, Poland.'}, {'ForeName': 'Viera', 'Initials': 'V', 'LastName': 'Skarbová', 'Affiliation': 'Department of Internal Medicine and Clinical Pharmacology, Summit Clinical Research, Bratislava, Slovakia.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Centkowski', 'Affiliation': 'Department of Oncology and Hematology, Provincial Specialist Hospital, Biala Podlaska, Poland.'}, {'ForeName': 'Rodryg', 'Initials': 'R', 'LastName': 'Ramlau', 'Affiliation': 'Department of Oncology, Poznan University of Medical Sciences, Poznań, Poland.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Górnaś', 'Affiliation': 'Department of Chemotherapy, ATTIS Centre, Warsaw, Poland.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Regulatory Affairs, Clovis Oncology UK, Ltd., Cambridge, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Edwards', 'Affiliation': 'Medical Affairs, Clovis Oncology UK, Ltd., Cambridge, UK.'}, {'ForeName': 'Jenn', 'Initials': 'J', 'LastName': 'Habeck', 'Affiliation': 'Biostatistics, Clovis Oncology, Inc., Boulder, CO, USA.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Nash', 'Affiliation': 'Clinical Operations, Clovis Oncology, Inc., Boulder, CO, USA.'}, {'ForeName': 'Nikolay', 'Initials': 'N', 'LastName': 'Grechko', 'Affiliation': 'Clinical Science, Clovis Oncology UK, Ltd., Cambridge, UK.'}, {'ForeName': 'Jim J', 'Initials': 'JJ', 'LastName': 'Xiao', 'Affiliation': 'Clinical Pharmacology, Clovis Oncology, Inc 5500 Flatrion Pkwy, Boulder, CO, 80301, USA. jxiao@clovisoncology.com.'}]",Cancer chemotherapy and pharmacology,['10.1007/s00280-021-04338-7'] 2206,34370064,Functional connectivity and cognitive changes after donepezil treatment in healthy participants.,"RATIONALE Donepezil is a potent, noncompetitive, reversible, clinically effective acetylcholinesterase inhibitor. The effects of this drug on healthy brains have seldom been investigated. OBJECTIVES The primary objective of the present study was to identify possible functional connectivity markers of the effect of donepezil in healthy young adult volunteers. METHODS The study had a double-blind, randomized, crossover design. 30 healthy adult volunteers underwent resting-state MRI scans during 15 days of donepezil or placebo treatment, in accordance with the design. RESULTS Results showed significant differences in intrinsic functional connectivity between donepezil and placebo, mainly in the right executive control network (RECN). More specifically, we found a decrease in the connectivity of the right inferior parietal node with other RECN nodes. Analysis using the cingulate cortex and parahippocampal regions as seeds also revealed complex modulation of functional connectivity in the donepezil condition. CONCLUSIONS In conclusion, donepezil treatment for 15 days may result in reorganization of resting-state networks, compared with placebo.",2021,"RESULTS Results showed significant differences in intrinsic functional connectivity between donepezil and placebo, mainly in the right executive control network (RECN).","['30 healthy adult volunteers underwent', 'healthy young adult volunteers', 'healthy brains', 'healthy participants']","['donepezil', 'donepezil and placebo', 'resting-state MRI scans', 'donepezil or placebo', 'placebo', 'Donepezil']","['reorganization of resting-state networks', 'intrinsic functional connectivity', 'Functional connectivity and cognitive changes', 'right executive control network (RECN']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0527316', 'cui_str': 'donepezil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",30.0,0.156617,"RESULTS Results showed significant differences in intrinsic functional connectivity between donepezil and placebo, mainly in the right executive control network (RECN).","[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Péran', 'Affiliation': 'Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France. patrice.peran@inserm.fr.'}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Salabert', 'Affiliation': 'Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Dondaine', 'Affiliation': 'Degenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Leclerc', 'Affiliation': 'Degenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Gros-Dagnac', 'Affiliation': 'Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France.'}, {'ForeName': 'J-P', 'Initials': 'JP', 'LastName': 'Ranjeva', 'Affiliation': 'Centre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Lopes', 'Affiliation': 'Degenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Lanteaume', 'Affiliation': 'Centre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Blin', 'Affiliation': 'Centre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Thalamas', 'Affiliation': 'Clinical Investigation Center (CIC1436), Toulouse, France.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Bordet', 'Affiliation': 'Degenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Payoux', 'Affiliation': 'Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Psychopharmacology,['10.1007/s00213-021-05923-7'] 2207,34369914,Mobile Health Self-management Interventions for Patients With Heart Failure: A Pilot Study.,"BACKGROUND Heart failure (HF) is a multifaceted syndrome that requires self-management for adherence to treatment to control symptoms. Symptoms need to be monitored to prevent impending HF exacerbations. Few HF study authors have assessed efficacy of mobile health (mHealth) interventions particularly with virtual visits to evaluate outcomes such as symptoms and healthcare utilization. OBJECTIVE The aim of this pilot study was to evaluate the potential effect of mHealth self-management interventions on symptom status and health-related quality of life and describe health care utilization in patients with HF. METHODS This 3-month pilot study included 74 patients with HF and used a randomized 3-group repeated-measures design (enhanced usual care, mHealth, and mHealth plus [+] virtual visits). Surveys included the Heart Failure Symptom Survey, EuroQol, and a specialized phone application for patients to report weights and medications. RESULTS The mHealth groups had an overall decrease in most symptom severity and frequency, particularly shortness of breath. Compared to enhanced usual care, both the mHealth+ and mHealth groups showed promise with medium effect sizes (range .55-.60) in relation to shortness of breath and a medium effect (.51) for lower extremity edema for the mHealth+ group. There was a trend toward improvement in health-related quality of life in both intervention groups at month 3. The mHealth+ group had fewer rehospitalizations. CONCLUSIONS In general, both mHealth groups fared better on symptoms and health care utilization. Small to medium effect sizes on selected symptom outcomes warrant this study to be conducted in a fully powered study. Virtual visits may assist in symptom recognition and self-management.",2021,"Compared to enhanced usual care, both the mHealth+ and mHealth groups showed promise with medium effect sizes (range .55-.60) in relation to shortness of breath and a medium effect (.51) for lower extremity edema for the mHealth+ group.","['patients with HF.\nMETHODS', '74 patients with HF and used a', 'Patients With Heart Failure']","['Mobile Health Self-management Interventions', 'mobile health (mHealth) interventions', 'mHealth self-management interventions', 'randomized 3-group repeated-measures design (enhanced usual care, mHealth, and mHealth plus [+] virtual visits']","['symptom status and health-related quality of life and describe health care utilization', 'extremity edema', 'health-related quality of life', 'symptom severity and frequency, particularly shortness of breath', 'symptoms and health care utilization']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030672', 'cui_str': 'Health Care Utilization'}, {'cui': 'C0085649', 'cui_str': 'Peripheral edema'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}]",74.0,0.0175846,"Compared to enhanced usual care, both the mHealth+ and mHealth groups showed promise with medium effect sizes (range .55-.60) in relation to shortness of breath and a medium effect (.51) for lower extremity edema for the mHealth+ group.","[{'ForeName': 'Myra S', 'Initials': 'MS', 'LastName': 'Schmaderer', 'Affiliation': 'Myra S. Schmaderer, PhD, MSN, RN Assistant Professor, University of Nebraska Medical Center College of Nursing, Lincoln. Leeza Struwe, PhD, MSN, RN Assistant Professor, University of Nebraska Medical Center College of Nursing, Lincoln. Courtney Loecker, APRN-NP, AGACNP-BC, MSN Instructor, University of Nebraska Medical Center College of Nursing, Omaha. Lauren Lier, DNP, AGACNP-BC, RN Assistant Professor, University of Nebraska Medical Center College of Nursing, Omaha. Scott W. Lundgren, DO Assistant Professor, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha. Chris Wichman, PhD Assistant Professor, Department of Biostatistics, UNMC College of Public Health, Nebraska Medical Center, Omaha. Bunny Pozehl, PhD, APRN-NP, FHFSA, FAHA, FAAN Professor, University of Nebraska Medical Center College of Nursing, Omaha. Lani Zimmerman, PhD, RN, FAHA, FAAN Professor, University of Nebraska Medical Center College of Nursing, Lincoln.'}, {'ForeName': 'Leeza', 'Initials': 'L', 'LastName': 'Struwe', 'Affiliation': ''}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Loecker', 'Affiliation': ''}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Lier', 'Affiliation': ''}, {'ForeName': 'Scott W', 'Initials': 'SW', 'LastName': 'Lundgren', 'Affiliation': ''}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Wichman', 'Affiliation': ''}, {'ForeName': 'Bunny', 'Initials': 'B', 'LastName': 'Pozehl', 'Affiliation': ''}, {'ForeName': 'Lani', 'Initials': 'L', 'LastName': 'Zimmerman', 'Affiliation': ''}]",The Journal of cardiovascular nursing,['10.1097/JCN.0000000000000846'] 2208,34369908,Vaginal Viral Shedding with Undetectable Plasma HIV Viral Load in Pregnant Women Receiving Two Different Antiretroviral Regimens: A Randomized Clinical Trial.,"BACKGROUND Pregnant women using antiretrovirals (ART) may have persistent vaginal virus shedding, which could be associated with sexual and perinatal HIV transmission.However, there is scant data on on vaginal viral load (VVL) in pregant women with undetectable plasma viral load (PVL). METHODS This study was a post-hoc analysis of an open-label randomized trial to evaluate the virologic response of two ART regimens. The participants were ART-naïve women living with HIV initiating ART regimens between 20 and 36 weeks of pregnancy recruited at 19 clinical sites in six countries. Participants were randomized to receive raltegravir 400 mg BID or efavirenz 600 mg QD in addition to lamivudine 150 mg and zidovudine 300 mg BID. VVL and PVL tests were performed at every study visit. The primary outcomes measures were HIV-1 PVL and VVL at maternal study week 4 and rates of perinatal HIV transmission. RESULTS A total of 408 were enrolled, of whom 323 had VVL samples 4 weeks after enrollment and were included in this analysis. Among women with undetectable/non-quantifiable PVL during ART, the overall rate of quantifiable VVL at Week 4 was 2.54% (7/275). Of the 275 with non-quantifiable PVL, 99.1% (115/116) and 96.2% (153/159) had non-quantifiable VVL in the EFV and RAL arms, respectively. None of the seven women with quantifiable VVL at the week 4 study visit transmitted HIV to their infants. CONCLUSIONS Detectable VVL in pregnant women with undetectable/non-quantifiable PVL while receiving ART was rare and not associated with perinatal HIV transmission.",2021,Detectable VVL in pregnant women with undetectable/non-quantifiable PVL while receiving ART was rare and not associated with perinatal HIV transmission.,"['Pregnant women using antiretrovirals (ART', 'pregnant women', 'pregant women with undetectable plasma viral load (PVL', 'A total of 408 were enrolled, of whom 323 had VVL samples 4 weeks after enrollment and were included in this analysis', 'participants were ART-naïve women living with HIV initiating ART regimens between 20 and 36 weeks of pregnancy recruited at 19 clinical sites in six countries', 'Pregnant Women Receiving Two Different Antiretroviral Regimens', 'seven women with quantifiable VVL at the week 4 study visit transmitted HIV to their infants']","['lamivudine 150 mg and zidovudine', 'raltegravir 400 mg BID or efavirenz 600 mg QD']","['overall rate of quantifiable VVL', 'HIV-1 PVL and VVL at maternal study week 4 and rates of perinatal HIV transmission', 'virologic response', 'vaginal viral load (VVL']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0599685', 'cui_str': 'Antiretroviral-containing product'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517769', 'cui_str': '408'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0242781', 'cui_str': 'Communicable Disease Transmission'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0987069', 'cui_str': 'Lamivudine 150 MG'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C1967561', 'cui_str': 'raltegravir 400 MG'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}, {'cui': 'C1166418', 'cui_str': 'efavirenz 600 MG'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}]",408.0,0.454151,Detectable VVL in pregnant women with undetectable/non-quantifiable PVL while receiving ART was rare and not associated with perinatal HIV transmission.,"[{'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Frenkel', 'Affiliation': ""Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, Department of Laboratory Medicine and Pathology, Department of Global Health and Medicine, University of Washington, Seattle, WA, USA Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA, USA Infectious Diseases Department, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil Fundação Oswaldo Cruz, Rio de Janeiro, Brazil Boston University School of Medicine, Boston, MA, USA Westat, Rockville, MD, USA Frontier Science, Amherst, New York, USA Maternal and Pediatric Infectious Diseases Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.""}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Leavitt Morrison', 'Affiliation': ''}, {'ForeName': 'Trevon L', 'Initials': 'TL', 'LastName': 'Fuller', 'Affiliation': ''}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Isabel Gouvêa', 'Affiliation': ''}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'de Lourdes Benamor Teixeira', 'Affiliation': ''}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Coombs', 'Affiliation': ''}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Shapiro', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Mirochnick', 'Affiliation': ''}, {'ForeName': 'Roslyn', 'Initials': 'R', 'LastName': 'Hennessey', 'Affiliation': ''}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Whitson', 'Affiliation': ''}, {'ForeName': 'Nahida', 'Initials': 'N', 'LastName': 'Chakhtoura', 'Affiliation': ''}, {'ForeName': 'Esaú C', 'Initials': 'EC', 'LastName': 'João', 'Affiliation': ''}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002771'] 2209,34369902,"Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study.","PURPOSE Antipsychotic medications, including olanzapine, are associated with substantial weight gain and metabolic disturbances. We sought to determine whether coadministration of miricorilant, a selective glucocorticoid receptor modulator, with olanzapine can ameliorate these effects. METHODS Sixty-six healthy men were enrolled in a 2-week, randomized, double-blind, placebo-controlled trial. The primary objective was to evaluate changes in body weight after 14 days coadministration of olanzapine (10 mg) + miricorilant (600 mg) compared with olanzapine (10 mg) + placebo. Secondary objectives included evaluating (a) the safety and tolerability of the combination; (b) the effects of the combination on glucose, insulin, insulin resistance, and triglycerides; and (c) the impact of the combination on hepatic enzymes. RESULTS Subjects administered olanzapine + miricorilant gained less weight than subjects administered olanzapine + placebo (mean weight gain on day 15, 3.91 kg vs 4.98 kg; difference between groups, -1.07 kg; 95% confidence interval, -1.94 to -0.19; P = 0.017]). Compared with the placebo group, coadministration of miricorilant with olanzapine was associated with smaller increases in insulin (difference, -3.74 mIU/L; P = 0.007), homeostatic model assessment of insulin resistance (difference, -0.47; P = 0.007), triglycerides (difference, -0.29 mmol/L; P = 0.057), aspartate aminotransferase (difference, -32.24 IU/L; P = 0.009), and alanine aminotransferase (difference, -49.99 IU/L; P = 0.030). CONCLUSIONS Miricorilant may provide a promising option for ameliorating the detrimental effects of olanzapine, and investigation of this medication in patients affected by antipsychotic-induced weight gain is warranted. Two phase 2 studies of miricorilant in patients with recent and long-standing antipsychotic-induced weight gain are currently in progress.",2021,"Compared with the placebo group, coadministration of miricorilant with olanzapine was associated with smaller increases in insulin (difference, -3.74 mIU/L; P = 0.007), homeostatic model assessment of insulin resistance (difference, -0.47; P = 0.007), triglycerides (difference, -0.29 mmol/L; P = 0.057), aspartate aminotransferase (difference, -32.24 IU/L; P = 0.009), and alanine aminotransferase (difference, -49.99 IU/L; P = 0.030). ","['Healthy Subjects', 'Sixty-six healthy men', 'patients with recent and long-standing antipsychotic-induced weight gain']","['Olanzapine', 'olanzapine (10 mg) + miricorilant', 'olanzapine', 'olanzapine + placebo', 'placebo', 'Miricorilant, a Selective Glucocorticoid Receptor Modulator', 'olanzapine (10 mg) + placebo']","['aspartate aminotransferase', 'body weight', 'triglycerides', 'alanine aminotransferase', 'substantial weight gain and metabolic disturbances', 'homeostatic model assessment of insulin resistance', 'weight', 'safety and tolerability of the combination; (b) the effects of the combination on glucose, insulin, insulin resistance, and triglycerides; and (c) the impact of the combination on hepatic enzymes', 'insulin']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4517841', 'cui_str': '66'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0034809', 'cui_str': 'Glucocorticoid receptor'}]","[{'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0428321', 'cui_str': 'Measurement of liver enzyme'}]",66.0,0.340982,"Compared with the placebo group, coadministration of miricorilant with olanzapine was associated with smaller increases in insulin (difference, -3.74 mIU/L; P = 0.007), homeostatic model assessment of insulin resistance (difference, -0.47; P = 0.007), triglycerides (difference, -0.29 mmol/L; P = 0.057), aspartate aminotransferase (difference, -32.24 IU/L; P = 0.009), and alanine aminotransferase (difference, -49.99 IU/L; P = 0.030). ","[{'ForeName': 'Hazel J', 'Initials': 'HJ', 'LastName': 'Hunt', 'Affiliation': 'From Corcept Therapeutics, Menlo Park, CA Jade Consultants (Cambridge) Ltd, Cambridge, United Kingdom Quotient Sciences, Nottingham, United Kingdom.'}, {'ForeName': 'Kirsteen', 'Initials': 'K', 'LastName': 'Donaldson', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Strem', 'Affiliation': ''}, {'ForeName': 'Iulia Cristina', 'Initials': 'IC', 'LastName': 'Tudor', 'Affiliation': ''}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Sweet-Smith', 'Affiliation': ''}, {'ForeName': 'Sharan', 'Initials': 'S', 'LastName': 'Sidhu', 'Affiliation': ''}]",Journal of clinical psychopharmacology,['10.1097/JCP.0000000000001470'] 2210,34369853,Uterine massage to reduce blood loss after vaginal delivery.,"Postpartum hemorrhage (PPH) is a major cause of maternal mortality and disability. A need for simple, inexpensive techniques to prevent PPH and provide treatment exists, particularly in cases where uterotonics cannot be accessed. Uterine massage is recommended as part of the routine active management of the third stage of labor. This study was conducted to determine the effectiveness of uterine massage after delivery of the placenta in reducing postpartum blood loss. Thus, a randomized controlled trial was conducted in Turkey between March 2018 and September 2018. A total of 176 pregnant women (88 in the control and 88 in the uterine massage groups) were randomly allocated to the two groups: one group receiving sustained uterine massage, while the other comprising the control group. The uterine massage group was administered transabdominal uterine massage, starting immediately after delivery of the placenta and continuing every 15 min for a duration of 2 h until the uterus hardened. The blood loss within 2 h of delivery was recorded. Level of significance was taken as p  < 0.05, and the chi-square, t, and Mann-Whitney U tests as well as Spearman's correlation and linear regression were employed in the analysis of the data. The average amount blood loss within 2 h of the delivery was significantly higher in the control group than in the massage group ( X  = 170.49 ± 61.46 and X  = 186.20 ± 47.59, p  < 0.05). A statistically significant difference was present between the uterine massage and control groups in terms of hemoglobin, hematocrit, WBC, and RCB pre-delivery and pre-discharge (first 24 h) values and in the use of additional uterotonics and the amount of blood loss ( p  < 0.05). The results of the analysis show that postpartum uterine massage has a reducing effect on the amount of PPH.",2021,"A statistically significant difference was present between the uterine massage and control groups in terms of hemoglobin, hematocrit, WBC, and RCB pre-delivery and pre-discharge (first 24 h) values and in the use of additional uterotonics and the amount of blood loss ( p  < 0.05).","['Turkey between March 2018 and September 2018', '176 pregnant women (88 in the control and 88 in the uterine massage groups']","['Uterine massage', 'uterine massage group was administered transabdominal uterine massage', 'uterine massage', 'sustained uterine massage']","['postpartum blood loss', 'Postpartum hemorrhage (PPH', 'blood loss', 'average amount blood loss', 'hemoglobin, hematocrit, WBC, and RCB pre-delivery and pre-discharge (first 24\u2009h) values and in the use of additional uterotonics and the amount of blood loss']","[{'cui': 'C0041400', 'cui_str': 'Turkey - country'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0404386', 'cui_str': 'Uterine massage'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0404386', 'cui_str': 'Uterine massage'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0205496', 'cui_str': 'Abdominal approach'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}]","[{'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C3653843', 'cui_str': 'UTEROTONICS'}]",176.0,0.0291581,"A statistically significant difference was present between the uterine massage and control groups in terms of hemoglobin, hematocrit, WBC, and RCB pre-delivery and pre-discharge (first 24 h) values and in the use of additional uterotonics and the amount of blood loss ( p  < 0.05).","[{'ForeName': 'Reyhan', 'Initials': 'R', 'LastName': 'Erkaya', 'Affiliation': 'Faculty of Health Science, Obstetrics and Gynaecology Nursing Department, Karadeniz Technical University, Trabzon, Turkey.'}, {'ForeName': 'Özlem', 'Initials': 'Ö', 'LastName': 'Karabulutlu', 'Affiliation': 'Faculty of Health Sciences, Department of Midwifery, Kafkas University, Kars, Turkey.'}, {'ForeName': 'Kıymet Yeşilçiçek', 'Initials': 'KY', 'LastName': 'Çalik', 'Affiliation': 'Faculty of HealthScience, Obstetrics and Gynaecology Nursing Department, Karadeniz Technical University, Trabzon, Turkey.'}]",Health care for women international,['10.1080/07399332.2021.1940184'] 2211,34369837,Alpha-lipoic acid supplementation effects on serum values of some oxidative stress biomarkers in women with gestational diabetes.,"AIMS Alpha-lipoic acid (ALA) is a unique antioxidant that can eradicate different kinds of free radicals. The current trial was designed to investigate the effects of ALA supplementation on some oxidative stress biomarkers in women with GDM. MATERIALS AND METHODS Sixty women with GDM at 24-28 weeks of pregnancy were selected and then they were divided into the drug ( n  = 30) received ALA 300 mg/day for 8 weeks and the placebo ( n  = 30) groups. Serum values of fasting blood sugar (FBS), thiol groups, glutathione, catalase, total antioxidant capacity (TAC), total oxidant status (TOS) and malondialdehyde (MDA) were measured. Values of the oxidative stress index (OSI), the MDA/TAC ratio and total antioxidant gap (TAG) were calculated. RESULTS After the intervention values of FBS ( p  = .001), TAC ( p  < .001), OSI ( p  = .003), TAG ( p  = .001) and catalase ( p  < .001) were improved significantly in the drug group. Values of TOS ( p  = .070) and glutathione ( p  = .088) were improved marginally in the drug group. CONCLUSIONS The current study showed that ALA supplementation at a dosage of 300 mg/day in women with GDM had improving effects on maternal circulating values of FBS, TAC, OSI, TAG, TOS, glutathione and catalase.",2021,"Values of the oxidative stress index (OSI), the MDA/TAC ratio and total antioxidant gap (TAG) were calculated. ","['Sixty women with GDM at 24-28\u2009weeks of pregnancy', 'women with GDM', 'women with gestational diabetes']","['Alpha-lipoic acid (ALA', 'ALA supplementation', 'Alpha-lipoic acid supplementation', 'ALA 300\u2009mg/day for 8\u2009weeks and the placebo']","['FBS', 'Values of TOS', 'OSI', 'oxidative stress index (OSI), the MDA/TAC ratio and total antioxidant gap (TAG', 'oxidative stress biomarkers', 'Serum values of fasting blood sugar (FBS), thiol groups, glutathione, catalase, total antioxidant capacity (TAC), total oxidant status (TOS) and malondialdehyde (MDA', 'maternal circulating values of FBS, TAC, OSI, TAG, TOS, glutathione and catalase', 'TAC']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}]","[{'cui': 'C0023791', 'cui_str': 'thioctic acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C3495427', 'cui_str': 'Fanconi-Bickel Syndrome'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0039984', 'cui_str': 'Thoracic outlet syndrome'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C3489891', 'cui_str': 'TAC Alternate'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0037293', 'cui_str': 'Skin tag'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0038734', 'cui_str': 'Sulfhydryls'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0007367', 'cui_str': 'CATALASE'}, {'cui': 'C0085403', 'cui_str': 'Oxidizing Agents'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}]",60.0,0.253927,"Values of the oxidative stress index (OSI), the MDA/TAC ratio and total antioxidant gap (TAG) were calculated. ","[{'ForeName': 'Masoome', 'Initials': 'M', 'LastName': 'Mandani', 'Affiliation': 'Students Research Committee, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Bita', 'Initials': 'B', 'LastName': 'Badehnoosh', 'Affiliation': 'Department of Obstetrics and Gyncology, Dietary Supplements and Probiotic Research center, Alborz University of Medical Siences, Karaj, Iran.'}, {'ForeName': 'Farideh', 'Initials': 'F', 'LastName': 'Jalali-Mashayekhi', 'Affiliation': 'Traditional and Complementary Medicine Research Center (TCMRC), Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Bahareh', 'Initials': 'B', 'LastName': 'Tavakoli-Far', 'Affiliation': 'Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Khosrowbeygi', 'Affiliation': 'Traditional and Complementary Medicine Research Center (TCMRC), Arak University of Medical Sciences, Arak, Iran.'}]",Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,['10.1080/09513590.2021.1963955'] 2212,34369719,Effectiveness of Concentrated Growth Factor on Surgical Wound Healing: A Pilot Study.,"AIM The aim of the current study is to assess and evaluate the effectiveness of concentrated growth factors on wound healing after implant placement procedures. METHODOLOGY Twenty-four patients who underwent implant placement were included in the study and were divided into two groups (group 1 = non-CGF group; group 2 = CGF group). Conventional implant placement was done in both the groups followed by placement of CGF membrane and closure using 3-0 silk in the CGF group and only closure using 3-0 silk sutures in the control group. The patients were asked to report on the 3rd and 7th day respectively and the wound healing was assessed using an early wound healing index given by Lorenzo Marini. STATISTICAL ANALYSIS Shapiro-Wilk test was used to test the normality of the test, which was found to deviate from normal distribution and hence Mann-Whitney U test was employed to evaluate the statistical significance of the two independent samples. RESULTS The mean ± SD was found to be 6.17 ± 2.04 for the control (group 1) and 5.67 ± 0.51 for CGF group (group 2) on the 3rd day. The mean and SD of control group and test group on the 7th day was 7 ± 1.55 and 9.33 ± 1.63, respectively. The difference between the groups on the 7th day was found to be statistically significant (P value < 0.05). CONCLUSION Concentrated growth factor application had positive effects on surgical wound healing after implant placement.",2021,"The difference between the groups on the 7th day was found to be statistically significant (P value < 0.05). ",['Twenty-four patients who underwent'],"['Concentrated Growth Factor', 'Conventional implant placement', 'concentrated growth factors', 'implant placement', 'Concentrated growth factor application']","['surgical wound healing', 'wound healing', 'mean ± SD', 'Surgical Wound Healing']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0018284', 'cui_str': 'Growth factor'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0332803', 'cui_str': 'Surgical wound'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",24.0,0.0132113,"The difference between the groups on the 7th day was found to be statistically significant (P value < 0.05). ","[{'ForeName': 'R S', 'Initials': 'RS', 'LastName': 'Kabilamurthi', 'Affiliation': 'Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Science Saveetha University, Chennai 77, India.'}, {'ForeName': 'Rajendra Prabhu', 'Initials': 'RP', 'LastName': 'Abhinav', 'Affiliation': 'Oral and Maxillofacial Surgeon and Implantologist, Senior Lecturer, Department of Implantology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Science, Saveetha University, Chennai 77, India.'}, {'ForeName': 'Nesappan', 'Initials': 'N', 'LastName': 'Thiyaneswaran', 'Affiliation': 'Head of Department, Department of Implantology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Science, Saveetha University, Chennai 77, India.'}, {'ForeName': 'Rohinikumar', 'Initials': 'R', 'LastName': 'Subhashree', 'Affiliation': 'Department of Prosthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Science, Saveetha University, Chennai 77, India.'}, {'ForeName': 'Priya Lochana', 'Initials': 'PL', 'LastName': 'Gajendran', 'Affiliation': 'Lecturer, Department of Implantology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 77, India.'}]",Journal of long-term effects of medical implants,['10.1615/JLongTermEffMedImplants.2021036412'] 2213,34369699,[Effect of moxibustion on postpartum urodynamics and pelvic floor function in puerperal women].,"OBJECTIVE To observe the effect of moxibustion on postpartum urodynamics and recovery of pelvic floor function based on the pelvic floor muscle function training. METHODS A total of 150 puerperal women were randomly divided into an observation group (75 cases, 15 cases dropped off) and a control group (75 cases, 15 cases dropped off). The control group was treated with pelvic floor muscle function training, twice a day. Based on the treatment in the control group, the observation group was treated with Baixiao moxibustion at Qihai (CV 6), Guanyuan (CV 4), Sanyinjiao (SP 6) and Zusanli (ST 36), twice a week. The treatment started on the 42nd day after delivery, totaling for 12 weeks. The urodynamic indexes (functional urethral length [FUL], stress leak point pressure [SLPP], maximum urethral closure pressure [MUCP], bladder compliance [BC], maximum urethral pressure [MUP], detrusor pressure at maximum urinary flow rate [Pdet Qmax]), the international consultation on incontinence questionnaire-urinary incontinence-short form (ICIQ-UI-SF) score and vaginal muscle voltage were observed before and after treatment. The prolapse rate of pelvic floor organ and normal rate of pelvic floor muscle strength of the two groups were recorded after treatment. RESULTS Compared before treatment, the levels of FUL, MUCP, BC, Pdet Qmax and SLPP in the observation group after treatment were increased ( P <0.05), while the FUL and SLPP in the control group after treatment were increased ( P <0.05). After treatment, the levels of FUL, SLPP, MUCP and BC in the observation group were higher than those in the control group ( P <0.05). Compared before treatment, the ICIQ-UI-SF scores in the two groups after treatment were decreased ( P <0.01), and the vaginal muscle voltage was increased ( P <0.01). After treatment, the ICIQ-UI-SF score in the observation group was lower than that in the control group ( P <0.01), and the vaginal muscle voltage in the observation group was higher than that in the control group ( P <0.01). The prolapse rate of pelvic floor organ was 6.7% (4/60) in the observation group, which was lower than 20.0% (12/60) in the control group ( P <0.05). The normal rate of pelvic floor muscle strength in the observation group was 88.3% (53/60), which was higher than 65.0% (39/60) in the control group ( P <0.05). CONCLUSION The moxibustion combined with pelvic floor muscle function training could improve postpartum urodynamics and pelvic floor muscle strength.",2021,"After treatment, the ICIQ-UI-SF score in the observation group was lower than that in the control group ( P <0.01), and the vaginal muscle voltage in the observation group was higher than that in the control group ( P <0.01).","['A total of 150 puerperal women', 'puerperal women']","['Baixiao moxibustion at Qihai (CV 6), Guanyuan (CV 4), Sanyinjiao (SP 6) and Zusanli', 'moxibustion', 'pelvic floor muscle function training', 'moxibustion combined with pelvic floor muscle function training']","['postpartum urodynamics and recovery of pelvic floor function', 'prolapse rate of pelvic floor organ and normal rate of pelvic floor muscle strength', 'levels of FUL, SLPP, MUCP and BC', 'levels of FUL, MUCP, BC, Pdet Qmax and SLPP', 'urodynamic indexes (functional urethral length [FUL], stress leak point pressure [SLPP], maximum urethral closure pressure [MUCP], bladder compliance [BC], maximum urethral pressure [MUP], detrusor pressure at maximum urinary flow rate [Pdet Qmax]), the international consultation on incontinence questionnaire-urinary incontinence-short form (ICIQ-UI-SF) score and vaginal muscle voltage', 'prolapse rate of pelvic floor organ', 'FUL and SLPP', 'postpartum urodynamics and pelvic floor muscle strength', 'normal rate of pelvic floor muscle strength', 'postpartum urodynamics and pelvic floor function', 'vaginal muscle voltage', 'ICIQ-UI-SF score', 'ICIQ-UI-SF scores']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0626533', 'cui_str': 'SP 6'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0041967', 'cui_str': 'Urethral'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0332234', 'cui_str': 'Leaking'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0429760', 'cui_str': 'Maximum urethral closure pressure'}, {'cui': 'C0429810', 'cui_str': 'Bladder compliance'}, {'cui': 'C0429759', 'cui_str': 'Maximum urethral pressure'}, {'cui': 'C0429766', 'cui_str': 'Detrusor pressure'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0429783', 'cui_str': 'Urinary flow rate'}, {'cui': 'C4544471', 'cui_str': 'International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}]",150.0,0.021455,"After treatment, the ICIQ-UI-SF score in the observation group was lower than that in the control group ( P <0.01), and the vaginal muscle voltage in the observation group was higher than that in the control group ( P <0.01).","[{'ForeName': 'Qiu-Ye', 'Initials': 'QY', 'LastName': 'Yang', 'Affiliation': 'Department of Medical Technology, First Affiliated Hospital of Guangzhou University of CM, Guangzhou 510405, Guangdong Province, China.'}, {'ForeName': 'Yu-Kun', 'Initials': 'YK', 'LastName': 'Sun', 'Affiliation': 'Department of Medical Technology, First Affiliated Hospital of Guangzhou University of CM, Guangzhou 510405, Guangdong Province, China.'}, {'ForeName': 'Zhuang-Teng', 'Initials': 'ZT', 'LastName': 'Lin', 'Affiliation': 'Department of Medical Technology, First Affiliated Hospital of Guangzhou University of CM, Guangzhou 510405, Guangdong Province, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20200821-k0001'] 2214,34369697,[Effect of electroacupuncture at Baliao points on intrauterine residue and uterine volume restoration after uterine curettage of incomplete abortion].,"OBJECTIVE To observe the clinical therapeutic effect of the combination of electroacupuncture (EA) at Baliao points (bilateral Shangliao [BL 31], Ciliao [BL 32], Zhongliao [BL 33] and Xialiao [BL 34]) and oral administration of mifepristone tablets and its influence on uterine volume restoration after uterine curettage of incomplete abortion as compared with simple oral administration of mifeprstone tablets. METHODS A total of 58 patients after uterine curettage of incomplete abortion were randomized into an EA group and a western medication group, 29 cases in each one. In the western medication group, mifepristone tablets were administered orally, 2 tablets each time, once daily. In the EA group, on the base of the treatment as the western medication group, EA was applied to Baliao points, with disperse-dense wave, once daily, 50 min each time. The treatment for 3 days was as one course and 2 courses of treatment were required, at the interval of 1 day in the two courses. Before and after treatment, the area of intrauterine residue and blood flow signal positive rate of color Doppler flow imaging (CDFI) were recorded in patients of the two groups respectively. The days of vaginal bleeding and the rate of second operation were recorded after treatment in patients of the two groups. Using the three-dimensional ultrasound B reconstruction, the uterine endometrial volume after menstruation resumption was measured in patients of the two groups, and the clinical therapeutic effect was evaluated. RESULTS After treatment, the intrauterine residue area and CDFI blood flow signal positive rate were all reduced as compared with the values before treatment in patients of the two groups ( P <0.05). After treatment, the intrauterine residue area and CDFI blood flow signal positive rate in the EA group were less than those in the western medication group ( P <0.05). After treatment, the days of vaginal bleeding in patients of the EA group were less than that in the western medication group and the rate of second operation was lower than the western medication group ( P <0.05). The uterine endomentrial volume after menstruation resumption in the EA group was larger than that in the western medication group after treatment ( P <0.05). The total effective rate was 55.2% (16/29) in the EA group, higher than 37.9% (11/29) in the western medication group ( P <0.05). CONCLUSION The combined treatment of electroacupuncture at Baliao points and oral administration of mifepristone tablets effectively promotes uterine contraction, softens and discharges intrauterine residue and contributes to uterine volume restoration in the patients after uterine curettage of incomplete abortion. The therapeutic effect of this combined therapy is better than simple oral administration of mifepristone tablets.",2021,"After treatment, the days of vaginal bleeding in patients of the EA group were less than that in the western medication group and the rate of second operation was lower than the western medication group ( P <0.05).","['58 patients after uterine curettage of incomplete abortion', 'uterine curettage of incomplete abortion', 'patients after uterine curettage of incomplete abortion']","['electroacupuncture (EA) at Baliao points (bilateral Shangliao', 'mifepristone tablets', 'EA', 'electroacupuncture']","['intrauterine residue and uterine volume restoration', 'uterine contraction, softens and discharges intrauterine residue and contributes to uterine volume restoration', 'uterine volume restoration', 'intrauterine residue area and CDFI blood flow signal positive rate', 'uterine endomentrial volume after menstruation resumption', 'vaginal bleeding', 'Zhongliao [BL 33] and Xialiao ', 'vaginal bleeding and the rate of second operation', 'rate of second operation', 'total effective rate', 'Ciliao ', 'uterine endometrial volume after menstruation resumption', 'area of intrauterine residue and blood flow signal positive rate of color Doppler flow imaging (CDFI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0010468', 'cui_str': 'Curettage'}, {'cui': 'C0000810', 'cui_str': 'Incomplete miscarriage'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0026088', 'cui_str': 'Mifepristone'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0694756', 'cui_str': 'Intrauterine'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0042130', 'cui_str': 'Uterine contraction'}, {'cui': 'C0024524', 'cui_str': 'Malacia'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0025344', 'cui_str': 'Menstruation'}, {'cui': 'C2979982', 'cui_str': 'Vaginal bleeding'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0474781', 'cui_str': 'Color doppler ultrasound'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}]",58.0,0.0418076,"After treatment, the days of vaginal bleeding in patients of the EA group were less than that in the western medication group and the rate of second operation was lower than the western medication group ( P <0.05).","[{'ForeName': 'Wen-Wu', 'Initials': 'WW', 'LastName': 'Su', 'Affiliation': 'Department of TCM, Foshan Women and Children Hospital, Foshan 528000, Guangdong Province, China.'}, {'ForeName': 'Min-Hong', 'Initials': 'MH', 'LastName': 'Zhao', 'Affiliation': 'Department of TCM, Foshan Women and Children Hospital, Foshan 528000, Guangdong Province, China.'}, {'ForeName': 'Qing-Jie', 'Initials': 'QJ', 'LastName': 'Pan', 'Affiliation': 'Department of TCM, Foshan Women and Children Hospital, Foshan 528000, Guangdong Province, China.'}, {'ForeName': 'Zhi-Hao', 'Initials': 'ZH', 'LastName': 'Huo', 'Affiliation': 'Department of TCM, Foshan Women and Children Hospital, Foshan 528000, Guangdong Province, China.'}, {'ForeName': 'Xiu-An', 'Initials': 'XA', 'LastName': 'Gao', 'Affiliation': 'Department of TCM, Foshan Women and Children Hospital, Foshan 528000, Guangdong Province, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20200716-k0003'] 2215,34369696,"[Acupuncture at xing- spring point, shu- stream point and lower he -sea point for type-2 diabetic peripheral neuropathy].","OBJECTIVE To observe the effect of acupuncture at xing -spring point, shu -stream point and lower he -sea point on neurological function and clinical symptoms in patients with type-2 diabetic peripheral neuropathy. METHODS Sixty patients with type-2 diabetic peripheral neuropathy were randomly divided into an observation group and a control group, 30 cases in each one. Both groups were treated with basic treatment, and the observation group was additionally treated with acupuncture at Neiting (ST 44), Xiangu (ST 43), Dadu (SP 2), Taibai (SP 3), Zusanli (ST 36), etc. once every other day, 3 times a week for 4 weeks. The changes of TCM symptom score, Toronto clinical assessment (TCSS) score, visual analogue scale (VAS) score of pain and serum tumor necrosis factor α(TNF-α) level were observed before and after treatment in the two groups, and the clinical effects of the two groups were evaluated. RESULTS Compared before treatment, the TCM syndrome score and the TCSS score in the two groups were reduced after treatment ( P <0.05), and the TCM syndrome score after treatment in the observation group was lower than that in the control group ( P <0.05). After treatment, the VAS in the observation group was reduced ( P <0.05), and the VAS score of pain in the observation group was lower than that in the control group ( P <0.05). There was no significant difference in the level of serum TNF-α within and between the two groups ( P >0.05). The total effective rate was 76.7% (23/30) in the observation group, which was superior to 33.3% (10/30) in the control group ( P <0.05). CONCLUSION Acupuncture at xing -spring point, shu -stream point and lower he -sea point could effectively improve the neurological function and clinical symptoms in patients with type-2 diabetic peripheral neuropathy.",2021,"After treatment, the VAS in the observation group was reduced ( P <0.05), and the VAS score of pain in the observation group was lower than that in the control group ( P <0.05).","['patients with type-2 diabetic peripheral neuropathy', 'Sixty patients with type-2 diabetic peripheral neuropathy']","['acupuncture', 'Acupuncture at xing', 'Acupuncture', 'acupuncture at xing']","['VAS', 'neurological function and clinical symptoms', 'TCM symptom score, Toronto clinical assessment (TCSS) score, visual analogue scale (VAS) score of pain and serum tumor necrosis factor α(TNF-α) level', 'VAS score of pain', 'total effective rate', 'TCM syndrome score and the TCSS score', 'TCM syndrome score', 'level of serum TNF-α']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0740447', 'cui_str': 'Diabetic peripheral neuropathy'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}]",60.0,0.0155942,"After treatment, the VAS in the observation group was reduced ( P <0.05), and the VAS score of pain in the observation group was lower than that in the control group ( P <0.05).","[{'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Shu', 'Affiliation': 'Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.'}, {'ForeName': 'Jin-Chuan', 'Initials': 'JC', 'LastName': 'Ran', 'Affiliation': 'Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.'}, {'ForeName': 'Bing-Li', 'Initials': 'BL', 'LastName': 'Chen', 'Affiliation': 'Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.'}, {'ForeName': 'Chao-Nan', 'Initials': 'CN', 'LastName': 'Li', 'Affiliation': 'Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.'}, {'ForeName': 'Shuo-Quan', 'Initials': 'SQ', 'LastName': 'Ruan', 'Affiliation': 'Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.'}, {'ForeName': 'Wen-Guang', 'Initials': 'WG', 'LastName': 'Hou', 'Affiliation': 'Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20200720-0007'] 2216,34369695,[Effect of electroacupuncture on small airway function in patients with stable chronic obstructive pulmonary disease].,"OBJECTIVE To observe the regulatory effect of electroacupuncture (EA) on small airway function and exercise tolerance in patients with stable chronic obstructive pulmonary disease (COPD). METHODS A total of 62 patients with stable COPD were randomized into an observation group (31 cases, 1 case dropped off) and a control group (31 cases, 5 cases dropped off). On the base of routine medication and aerobic exercise, the patients of the two groups all received EA at Danzhong (CV 17), Rugen (ST 18), Guanyuan (CV 4), Zhongwan (CV 12), Tianshu (ST 25) and Yingchuang (ST 16). In the observation group, filiform needles were used and inserted perpendicularly, 3 mm in depth. In the control group, the placebo needling method was performed, in which the needle was not inserted through skin at each point. In both groups, electric stimulation with low-frequency electronic pulse instrument was exerted, with continuous wave, 2 Hz in frequency, lasting 30 min each time in the two groups. The treatment was given once every other day, 3 times a week, for 14 treatments totally. Before and after treatment, the following indexes were compared in patients between the two groups, i.e. the lung function indexes (forced expiratory volume in first second [FEV1], forced vital capacity [FVC], the ratio of FEV1 to FVC [FEV1/FVC], maximal voluntary ventilation [MVV], the percentage of maximal expiratory flow [MEF] at 25% of FVC exhaled [MEF25], MEF50 and MEF75 in predicted value), cardiopulmonary exercise test indexs (metabolic equivalent [METS], oxygen uptake per kg body weight [VO 2 /kg], minute ventilation [V E ], the percentage of oxygen pulse [VO 2 /HR] in predictd value, maximal minute ventilation [V Emax ], ventilatory equivalent for oxygen [V E /VO 2 ], ventilatory equivalent for carbon dioxide [V E /VCO 2 ]), 6-minute walk distance (6MWD), the total score of COPD assessment test (CAT), the modified British Medical Research Council (mMRC) score and COPD comprehensive grade. RESULTS After treatment, FVC%, MVV%, MEF75%, MEF50%, VO 2 /kg%, METs%, V Emax , VO 2 /HR%, 6MW and the total CAT score were all improved as compared with those before treatment in the observation group ( P <0.05, P <0.01). After treatment, MEF75% and the total CAT score were reduced as compared with those before treatment in the control group ( P <0.05). After treatment, MVV%, MEF50%, VO 2 /kg%, METs%, V Emax and 6MWD in the observation group were all better than those in the control group ( P <0.05, P <0.01). CONCLUSION Electroacupuncture can improve the respiratory function and exercise tolerance in COPD patients through removing small airway obstruction and increasing ventilation.",2021,"After treatment, MEF75% and the total CAT score were reduced as compared with those before treatment in the control group ( P <0.05).","['patients with stable chronic obstructive pulmonary disease (COPD', 'COPD patients', 'patients with stable chronic obstructive pulmonary disease', '62 patients with stable COPD']","['Electroacupuncture', 'electroacupuncture', 'EA at Danzhong (CV 17), Rugen (ST 18), Guanyuan (CV 4), Zhongwan (CV 12), Tianshu (ST 25) and Yingchuang (ST 16', 'placebo', 'electroacupuncture (EA']","['total CAT score', 'lung function indexes (forced expiratory volume in first second [FEV1], forced vital capacity [FVC], the ratio of FEV1 to FVC [FEV1/FVC], maximal voluntary ventilation [MVV], the percentage of maximal expiratory flow [MEF] at 25% of FVC exhaled [MEF25], MEF50 and MEF75 in predicted value), cardiopulmonary exercise test indexs (metabolic equivalent [METS], oxygen uptake per kg body weight [VO 2 /kg], minute ventilation [V E ], the percentage of oxygen pulse [VO 2 /HR] in predictd value, maximal minute ventilation [V Emax ], ventilatory equivalent for oxygen [V E /VO 2 ], ventilatory equivalent for carbon dioxide [V E /VCO 2 ]), 6-minute walk distance (6MWD), the total score of COPD assessment test (CAT), the modified British Medical Research Council (mMRC) score and COPD comprehensive grade', 'small airway function and exercise tolerance', 'small airway function', 'MVV%, MEF50%, VO 2 /kg%, METs%, V Emax and 6MWD', 'FVC%, MVV%, MEF75%, MEF50%, VO 2 /kg%, METs%, V Emax , VO 2 /HR%, 6MW and the total CAT score', 'respiratory function and exercise tolerance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4284282', 'cui_str': 'COPD assessment test'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0024967', 'cui_str': 'Maximum voluntary ventilation'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}, {'cui': 'C2355577', 'cui_str': 'Metabolic Equivalent'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439463', 'cui_str': 'IU/kg'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C0231963', 'cui_str': 'Volume of expired gas'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}]",62.0,0.0345941,"After treatment, MEF75% and the total CAT score were reduced as compared with those before treatment in the control group ( P <0.05).","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Respirtatory Specialty of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China.'}, {'ForeName': 'Gui-Yuan', 'Initials': 'GY', 'LastName': 'Li', 'Affiliation': 'Respirtatory Specialty of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China.'}, {'ForeName': 'Ze-Guang', 'Initials': 'ZG', 'LastName': 'Zheng', 'Affiliation': 'National Clinical Medical Research Center for Respiratory Diseases, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'National Clinical Medical Research Center for Respiratory Diseases, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China.'}, {'ForeName': 'Jun-Hui', 'Initials': 'JH', 'LastName': 'Pan', 'Affiliation': 'Respirtatory Specialty of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Respirtatory Specialty of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China.'}, {'ForeName': 'Wan-Yi', 'Initials': 'WY', 'LastName': 'Huang', 'Affiliation': 'Respirtatory Specialty of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Ge', 'Affiliation': 'Department of Emergency, Zhongshan Municipal Hospital of TCM.'}, {'ForeName': 'Guang-En', 'Initials': 'GE', 'LastName': 'Zhong', 'Affiliation': 'Department of Acupuncture, Tuina and Rehabilitation, Integrated Hospital of Traditional Chinese and Western Medicine, Affiliated to Southern Medical University.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Tong', 'Affiliation': 'Respirtatory Specialty of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20200813-0001'] 2217,34369693,[Acupuncture and moxibustion for vascular dementia and its effect on serum VEGF and AChE].,"OBJECTIVE To observe the efficacy of Huayu Tongluo moxibustion combined with acupuncture at Jing -well points on the differentiated meridians and routine acupuncture for vascular dementia (VD) and its effect on serum levels of vascular endothelial growth factor (VEGF) and acetylcholinesterase (AChE). METHODS A total of 60 patients with VD were randomized into an observation group (30 cases, 1 case dropped off) and a control group (30 cases, 2 cases dropped off). In the observation group, Huayu Tongluo moxibustion combined with acupuncture at Jing -well points on the differentiated meridians and routine acupuncture were adopted, Huayu Tongluo moxibustion was applied at Baihui (GV 20), Dazhui (GV 14) and Shenting (GV 24); acupuncture at Jing -well points on the differentiated meridians was applied at corresponding Jing -well points according to pattern of syndrome; routine acupuncture was applied at Baihui (GV 20), Sishencong (EX-HN 1), etc. Acupuncture and moxibustion were given once a day, 6 times a week for 4 weeks. In the control group, donepezil was prescribed for oral administration, 5 mg each time, once a day for 4 weeks. Before and after treatment, the scores of mini mental state examination (MMSE) and activities of daily living (ADL) were observed, and the serum levels of AChE and VEGF were detected in the two groups. RESULTS Compared before treatment, the MMSE and ADL scores and serum level of VEGF were increased ( P <0.05), the serum level of AChE was decreased ( P <0.05) after treatment in the two groups. The MMSE and ADL scores after treatment in the observation group were higher than the control group ( P <0.05). CONCLUSION Huayu Tongluo moxibustion combined with acupuncture at Jing -well points on the differentiated meridians and routine acupuncture could improve cognitive function and activities of daily living, which may be related to the regulation of serum levels of VEGF and AChE.",2021,"Compared before treatment, the MMSE and ADL scores and serum level of VEGF were increased ( P <0.05), the serum level of AChE was decreased ( P <0.05) after treatment in the two groups.",['60 patients with VD'],"['acupuncture', 'Huayu Tongluo moxibustion combined with acupuncture', 'donepezil', 'acupuncture at Jing', 'Acupuncture and moxibustion']","['MMSE and ADL scores and serum level of VEGF', 'scores of mini mental state examination (MMSE) and activities of daily living (ADL', 'serum levels of vascular endothelial growth factor (VEGF) and acetylcholinesterase (AChE', 'serum level of AChE', 'cognitive function and activities of daily living', 'serum levels of AChE and VEGF', 'MMSE and ADL scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C2352019', 'cui_str': 'tongluo'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0527316', 'cui_str': 'donepezil'}]","[{'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0001044', 'cui_str': 'Acetylcholinesterase'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",60.0,0.0419825,"Compared before treatment, the MMSE and ADL scores and serum level of VEGF were increased ( P <0.05), the serum level of AChE was decreased ( P <0.05) after treatment in the two groups.","[{'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Second Department of Rehabilitation, Second Affiliated Hospital of Anhui University of CM, Hefei 230061, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Graduate School, Anhui University of CM.'}, {'ForeName': 'Tian-Xin', 'Initials': 'TX', 'LastName': 'Jiang', 'Affiliation': 'Second Department of Rehabilitation, Second Affiliated Hospital of Anhui University of CM, Hefei 230061, China.'}, {'ForeName': 'Min-Jie', 'Initials': 'MJ', 'LastName': 'Zhu', 'Affiliation': 'Graduate School, Anhui University of CM.'}, {'ForeName': 'Jia-Jia', 'Initials': 'JJ', 'LastName': 'Ji', 'Affiliation': 'Graduate School, Anhui University of CM.'}, {'ForeName': 'Wei-Wei', 'Initials': 'WW', 'LastName': 'Wu', 'Affiliation': 'Second Department of Rehabilitation, Second Affiliated Hospital of Anhui University of CM, Hefei 230061, China.'}, {'ForeName': 'Sheng-Chao', 'Initials': 'SC', 'LastName': 'Cai', 'Affiliation': 'Second Department of Rehabilitation, Second Affiliated Hospital of Anhui University of CM, Hefei 230061, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Second Department of Acupuncture-Moxibustion and Rehabilitation, First Affiliated Hospital of Anhui University of CM.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20200816-0001'] 2218,34367747,Does Simulation Training Improve the Accuracy of Vaginal Assessment of Labour Progress?,"Aim To measure the utility of the Simulation training model for training purposes over and above conventional methods of training for vaginal assessment during labour. Methods The study group included undergraduate trainees, and the control group included postgraduate trainees and qualified personnel, i.e. senior registrars and consultants. Participants from the study group were trained for vaginal assessment on the simulation training model. Then both the groups were tested on the model for accuracy in estimating each value of cervical dilatation and fetal station. Mean cervical dilatation and station accuracy scores were noted, and comparative analysis was done between the study and control groups. Results A total of 150 participants were included. The overall mean dilatation and station accuracy scores of a model trained study group participants were better than subjectively trained control group participants. Study group participants showed greater accuracy for smaller dilatations, i.e. 1, 2, 3, 4cm and middle dilatation, i.e. 5cm and 6cm (p value=<0.05). In contrast, comparing the two groups for higher dilatations from 6 to 10 cm did not show any statistical significance. Study group participants also showed greater accuracy for all the fetal stations except stations 0 and +1. Conclusions The simulation training model can be considered an in vitro training device to improve the trainees' understanding of cervical dilatation and fetal station and can be made a part of a routine obstetric teaching program.",2021,The overall mean dilatation and station accuracy scores of a model trained study group participants were better than subjectively trained control group participants.,"['vaginal assessment during labour', 'A total of 150 participants were included']","['control group included postgraduate trainees and qualified personnel, i.e. senior registrars and consultants', 'Simulation Training']","['Accuracy of Vaginal Assessment of Labour Progress', 'Mean cervical dilatation and station accuracy scores', 'overall mean dilatation and station accuracy scores']","[{'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0557513', 'cui_str': 'Senior registrar'}, {'cui': 'C0009817', 'cui_str': 'Consultant'}, {'cui': 'C4042947', 'cui_str': 'Simulation Training'}]","[{'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0079103', 'cui_str': 'Cervical dilatation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}]",150.0,0.0400127,The overall mean dilatation and station accuracy scores of a model trained study group participants were better than subjectively trained control group participants.,"[{'ForeName': 'Girija', 'Initials': 'G', 'LastName': 'Swaminathan', 'Affiliation': 'Obstetrics and Gynaecology, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai, IND.'}, {'ForeName': 'Shashank V', 'Initials': 'SV', 'LastName': 'Parulekar', 'Affiliation': 'Obstetrics and Gynaecology, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai, IND.'}]",Cureus,['10.7759/cureus.16089'] 2219,34367682,A REDCap-based model for online interventional research: Parent sleep education in autism.,"Introduction The use of online platforms for pediatric healthcare research is timely, given the current pandemic. These platforms facilitate trial efficiency integration including electronic consent, randomization, collection of patient/family survey data, delivery of an intervention, and basic data analysis. Methods We created an online digital platform for a multicenter study that delivered an intervention for sleep disorders to parents of children with autism spectrum disorder (ASD). An advisory parent group provided input. Participants were randomized to receive either a sleep education pamphlet only or the sleep education pamphlet plus three quick-tips sheets and two videos that reinforced the material in the pamphlet (multimedia materials). Three measures - Family Inventory of Sleep Habits (FISH), Children's Sleep Habits Questionnaire modified for ASD (CSHQ-ASD), and Parenting Sense of Competence (PSOC) - were completed before and after 12 weeks of sleep education. Results Enrollment exceeded recruitment goals. Trial efficiency was improved, especially in data entry and automatic notification of participants related to survey completion. Most families commented favorably on the study. While study measures did not improve with treatment in either group (pamphlet or multimedia materials), parents reporting an improvement of ≥3 points in the FISH score showed a significantly improved change in the total CSHQ ( P = 0.038). Conclusion Our study demonstrates the feasibility of using online research delivery platforms to support studies in ASD, and more broadly, pediatric clinical and translational research. Online platforms may increase participant inclusion in enrollment and increase convenience and safety for participants and study personnel.",2021,"While study measures did not improve with treatment in either group (pamphlet or multimedia materials), parents reporting an improvement of ≥3 points in the FISH score showed a significantly improved change in the total CSHQ ( P = 0.038). ","['sleep disorders to parents of children with autism spectrum disorder (ASD', 'autism']",['sleep education pamphlet only or the sleep education pamphlet plus three quick-tips sheets and two videos that reinforced the material in the pamphlet (multimedia materials'],"['total CSHQ', ""measures - Family Inventory of Sleep Habits (FISH), Children's Sleep Habits Questionnaire modified for ASD (CSHQ-ASD), and Parenting Sense of Competence (PSOC) ""]","[{'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C0439643', 'cui_str': 'Sheets'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C2133558', 'cui_str': 'Sleep Habits'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0086035', 'cui_str': 'Competence'}]",,0.0852305,"While study measures did not improve with treatment in either group (pamphlet or multimedia materials), parents reporting an improvement of ≥3 points in the FISH score showed a significantly improved change in the total CSHQ ( P = 0.038). ","[{'ForeName': 'Beth A', 'Initials': 'BA', 'LastName': 'Malow', 'Affiliation': 'Sleep Disorders Division, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Anjalee', 'Initials': 'A', 'LastName': 'Galion', 'Affiliation': ""Division of Pediatric Neurology, Department of Pediatrics, University of California Irvine - Children's Hospital of Orange County, Orange, CA, USA.""}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Lu', 'Affiliation': 'Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Kennedy', 'Affiliation': 'Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Colleen E', 'Initials': 'CE', 'LastName': 'Lawrence', 'Affiliation': 'Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Tassone', 'Affiliation': 'Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Lexington, MA, USA.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': ""O'Neal"", 'Affiliation': 'Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Travis M', 'Initials': 'TM', 'LastName': 'Wilson', 'Affiliation': 'Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Parker', 'Affiliation': 'Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Harris', 'Affiliation': 'Department of Biomedical Informatics, Department of Biostatistics, and Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.'}, {'ForeName': 'Ann M', 'Initials': 'AM', 'LastName': 'Neumeyer', 'Affiliation': 'Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Lexington, MA, USA.'}]",Journal of clinical and translational science,['10.1017/cts.2021.798'] 2220,34367654,Effectiveness of high-intensity interval training for weight loss in adults with obesity: a randomised controlled non-inferiority trial.,"Introduction Obesity treatment guidelines suggest moderate-intensity continuous training (MICT), but the patient's compliance to this indication remains low. High-intensity interval training (HIIT) is a time sparing training mode whose metabolic effects are not clear. This study aimed to determine whether a 12-week HIIT was more effective than MICT for weight loss in obese adults. Methods 44 obese subjects were randomised and trained with isoenergetic treadmill exercises for 12 weeks: MICT (60% of maximal oxygen peak, VO 2 peak) or HIIT (3-7 repetition of 3 min 100% of VO 2 peak interspersed by 1.5 min 50% of VO 2 peak). The primary outcome was a change in body weight; the secondary outcomes were changes in body composition, blood pressure, lipid profile, glycaemia, insulin and VO 2 peak. Results 32 subjects (53% male, mean age: 38.5 years, mean body mass index: 35.5 kg/m 2 ) completed the trial. MICT and HIIT showed comparable effect within groups in weight loss (-6.0 kg (-9.0 kg to -3.0 kg) vs -5.7 kg (-8.3 kg to -3.1 kg)), changes in fat mass (-2.9% (-4.4% to -1.4%) vs -3.6% (-5.9% to -1.2%)), fat free mass (-5.3% (-7.8% to -2.8%) vs -5.5% (-8.3% to -2.6%)), diastolic blood pressure (-5.5 mm Hg (-10.6 mm Hg to -0.3 mm Hg) vs -5.8 mm Hg (-11.3 mm Hg to -0.3 mm Hg)) and low-density lipoprotein cholesterol (-16.4 mg/dL (-30.8 mg/dL to -2.0 mg/dL) vs -14.7 mg/dL (-25.6 mg/dL to -3.8 mg/dL)). There was a significant change between groups in VO 2 peak (HIIT: +461.6 mL (329.3‒593.8 mL); MICT: +170.5 mL (86.7-254.4 mL); p<0001) and duration of sessions (HIIT: 35.0 min (31.7 ‒35.6 min); MICT: 46.5 min (40.2‒48.3 min); p<0.001). No significant changes in systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, glycaemia or plasma insulin were observed. Conclusions In healthy adults with obesity, HIIT compared with MICT induced similar weight loss and cardiovascular risk factors improvement but resulted in a larger increase in cardiorespiratory fitness over a shorter period.",2021,"No significant changes in systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, glycaemia or plasma insulin were observed. ","['Hg', 'adults with obesity', 'healthy adults with obesity', '32 subjects (53% male, mean age: 38.5 years, mean body mass index: 35.5 kg/m 2 ) completed the trial', 'obese adults', '44 obese subjects']","['MICT', 'dL', 'isoenergetic treadmill exercises', 'High-intensity interval training (HIIT', 'high-intensity interval training']","['weight loss', 'body composition, blood pressure, lipid profile, glycaemia, insulin and VO 2 peak', 'cardiorespiratory fitness', 'low-density lipoprotein cholesterol', 'diastolic blood pressure', 'changes in fat mass', 'weight loss and cardiovascular risk factors improvement', 'fat free mass', 'systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, glycaemia or plasma insulin', 'change in body weight']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]",44.0,0.0426704,"No significant changes in systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, glycaemia or plasma insulin were observed. ","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': ""D'Amuri"", 'Affiliation': 'Department of Translational Medicine, University of Ferrara, Ferrara, Emilia Romagna, Italy.'}, {'ForeName': 'Juana Maria', 'Initials': 'JM', 'LastName': 'Sanz', 'Affiliation': 'Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Emilia Romagna, Italy.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Capatti', 'Affiliation': ""Medical Department, University Hospital of Ferrara Arcispedale Sant'Anna, Ferrara, Emilia Romagna, Italy.""}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Di Vece', 'Affiliation': ""Medical Department, University Hospital of Ferrara Arcispedale Sant'Anna, Ferrara, Emilia Romagna, Italy.""}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Vaccari', 'Affiliation': 'Department of Medical Sciences, University of Udine, Udine, Friuli Venezia Giulia, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Lazzer', 'Affiliation': 'Department of Medical Sciences, University of Udine, Udine, Friuli Venezia Giulia, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Zuliani', 'Affiliation': 'Department of Translational Medicine, University of Ferrara, Ferrara, Emilia Romagna, Italy.'}, {'ForeName': 'Edoardo', 'Initials': 'E', 'LastName': 'Dalla Nora', 'Affiliation': ""Medical Department, University Hospital of Ferrara Arcispedale Sant'Anna, Ferrara, Emilia Romagna, Italy.""}, {'ForeName': 'Angelina', 'Initials': 'A', 'LastName': 'Passaro', 'Affiliation': 'Department of Translational Medicine, University of Ferrara, Ferrara, Emilia Romagna, Italy.'}]",BMJ open sport & exercise medicine,['10.1136/bmjsem-2020-001021'] 2221,34367647,Patient Partner Perspectives Regarding Ethically and Clinically Important Aspects of Trial Design in Pragmatic Cluster Randomized Trials for Hemodialysis.,"Background Cluster randomized trials (CRTs) are trials in which intact groups such as hemodialysis centers or shifts are randomized to treatment or control arms. Pragmatic CRTs have been promoted as a promising trial design for nephrology research yet may also pose ethical challenges. While randomization occurs at the cluster level, the intervention and data collection may vary in a CRT, challenging the identification of research participants. Moreover, when a waiver of patient consent is granted by a research ethics committee, there is an open question as to whether and to what degree patients should be notified about ongoing research or be provided with a debrief regarding the nature and results of the trial upon completion. While empirical and conceptual research exploring ethical issues in pragmatic CRTs has begun to emerge, there has been limited discussion with patients, families, or caregivers of patients undergoing hemodialysis. Objective To explore with patients and families with experience of hemodialysis research the challenges raised by different approaches to designing pragmatic CRTs in hemodialysis. Specifically, their perceptions of (1) the use of a waiver of consent, (2) notification processes and information provided to participants, and (3) any other concerns about cluster randomized designs in hemodialysis. Design Focus group and interview discussions of hypothetical clinical trial designs. Setting Focus groups and interviews were conducted in-person or via videoconference or telephone. Participants Patient partners in hemodialysis research, defined as patients with personal experience of dialysis or a family member who had experience supporting a patient receiving hemodialysis, who have been actively involved in discussions to advise a research team on the design, conduct, or implementation of a hemodialysis trial. Methods Participants were invited to participate in focus groups or individual discussions that were audio recorded with consent. Recorded interviews were transcribed verbatim prior to analysis. Transcripts were analyzed using a thematic analysis approach. Results Two focus groups, three individual interviews, and one interview involving a patient and family member were conducted with 17 individuals between February 2019 and May 2020. Participants expressed support for approaches that emphasized patient choice. Disclosure of patient-relevant risks and information were key themes. Both consent and notification processes served to generate trust, but bypassing patient choice was perceived as undermining this trust. Participants did not dismiss the option of a waiver of consent. They were, however, more restrictive in their views about when a waiver of consent may be acceptable. Patient partners were skeptical of claims to impracticability based on costs or the time commitments for staff. Limitations All participants were from Canada and had been involved in the design or conduct of a trial, limiting the degree to which results may be extrapolated. Conclusions Given the preferences of participants to be afforded the opportunity to decide about trial participation, we argue that investigators should thoroughly investigate approaches that allow participants to make an informed choice regarding trial participation. In keeping with the preference for autonomous choice, there remains a need to further explore how consent approaches can be designed to facilitate clinical trial conduct while meeting their ethical requirements. Finally, further work is needed to define the limited circumstances in which waivers of consent are appropriate.",2021,"Both consent and notification processes served to generate trust, but bypassing patient choice was perceived as undermining this trust.","['patients undergoing hemodialysis', 'patients and families with experience of hemodialysis research', 'Participants\n\n\nPatient partners in hemodialysis research, defined as patients with personal experience of dialysis or a family member who had experience supporting a patient receiving hemodialysis, who have been actively involved in discussions to advise a research team on the design, conduct, or implementation of a hemodialysis trial', 'Two focus groups, three individual interviews, and one interview involving a patient and family member were conducted with 17 individuals between February 2019 and May 2020']",['videoconference or telephone'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C1828381', 'cui_str': 'Recommendation - action'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]","[{'cui': 'C1450049', 'cui_str': 'Videoconference'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}]",[],17.0,0.163297,"Both consent and notification processes served to generate trust, but bypassing patient choice was perceived as undermining this trust.","[{'ForeName': 'Stuart G', 'Initials': 'SG', 'LastName': 'Nicholls', 'Affiliation': 'Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Carroll', 'Affiliation': 'Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada.'}, {'ForeName': 'Cory E', 'Initials': 'CE', 'LastName': 'Goldstein', 'Affiliation': 'Department of Philosophy, Western University, London, ON, Canada.'}, {'ForeName': 'Jamie C', 'Initials': 'JC', 'LastName': 'Brehaut', 'Affiliation': 'Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Weijer', 'Affiliation': 'Department of Philosophy, Western University, London, ON, Canada.'}, {'ForeName': 'Merrick', 'Initials': 'M', 'LastName': 'Zwarenstein', 'Affiliation': 'Centre for Studies in Family Medicine, Western University, London, ON, Canada.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Dixon', 'Affiliation': 'Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.'}, {'ForeName': 'Jeremy M', 'Initials': 'JM', 'LastName': 'Grimshaw', 'Affiliation': 'Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada.'}, {'ForeName': 'Amit X', 'Initials': 'AX', 'LastName': 'Garg', 'Affiliation': 'Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Taljaard', 'Affiliation': 'Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada.'}]",Canadian journal of kidney health and disease,['10.1177/20543581211032818'] 2222,34367634,Randomised clinical trial: Effect of administering platelet-rich fibrin to autologous fat tissue in injection laryngoplasty for vocal cord paralysis.,"The vocal cord in humans is essential in producing voice used in communication and interaction between us. Vocal cord paralysis causes dysphonia, which interferes with communication, causing disruptions towards social activity and daily activities. One of the managements for vocal cord paralysis is medialization and augmentation of the vocal cord through injection laryngoplasty. Autologous fat is one of the best fillers used in this procedure, but it is highly absorbable and can be reabsorbed very quickly when injected into body tissues. Platelet Rich Fibrin (PRF) is a biomaterial consisting of growth factors that are thought to improve fat tissue viability by increasing adipogenesis and angiogenesis. Improvement in fat viability will improve clinical outcomes after the laryngoplasty procedure, potentially reducing the number of repeated injections needed to achieve a satisfactory resolution to vocal cord paralysis. The study evaluates a combination of PRF and autologous microlobular fat compared with autologous microlobular fat alone on laryngoplasty. This single-blinded randomised control trial recruit a total of 18 patients, which are then randomised into the treatment and control groups. The evaluation was done via computerized acoustic analysis/Multidimensional Voice Program (MDVP) parameters and maximum phonation time. The MDVP results and maximum phonation time in both groups showed clinical improvement after the operation with no statistically significant differences.",2021,The MDVP results and maximum phonation time in both groups showed clinical improvement after the operation with no statistically significant differences.,"['18 patients', 'vocal cord paralysis']","['platelet-rich fibrin to autologous fat tissue', 'PRF and autologous microlobular fat compared with autologous microlobular fat alone', 'Platelet Rich Fibrin (PRF']",['MDVP results and maximum phonation time'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042928', 'cui_str': 'Vocal cord paralysis'}]","[{'cui': 'C4505052', 'cui_str': 'Leukocyte- and Platelet-Rich Fibrin'}, {'cui': 'C4076692', 'cui_str': 'Autologous fat'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]","[{'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0234778', 'cui_str': 'Maximum phonation time'}]",18.0,0.0612038,The MDVP results and maximum phonation time in both groups showed clinical improvement after the operation with no statistically significant differences.,"[{'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Reksodiputro', 'Affiliation': 'Facial Plastic Reconstructive Division, Department of Otorhinolaryngology - Head and Neck Surgery, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital Jakarta, Indonesia.'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Hutauruk', 'Affiliation': 'Larynx Pharynx Division, Department of Otorhinolaryngology - Head and Neck Surgery, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital Jakarta, Indonesia.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Koento', 'Affiliation': 'Facial Plastic Reconstructive Division, Department of Otorhinolaryngology - Head and Neck Surgery, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital Jakarta, Indonesia.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Fardizza', 'Affiliation': 'Larynx Pharynx Division, Department of Otorhinolaryngology - Head and Neck Surgery, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital Jakarta, Indonesia.'}, {'ForeName': 'R Y R', 'Initials': 'RYR', 'LastName': 'Hakim', 'Affiliation': 'Department of Otorhinolaryngology - Head and Neck Surgery, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital Jakarta, Indonesia.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Audindra', 'Affiliation': 'Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital Jakarta, Indonesia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Yosia', 'Affiliation': 'Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital Jakarta, Indonesia.'}]",Annals of medicine and surgery (2012),['10.1016/j.amsu.2021.102564'] 2223,34367541,Artificial Intelligence Algorithm-Based Ultrasound Image Segmentation Technology in the Diagnosis of Breast Cancer Axillary Lymph Node Metastasis.,"This paper aimed to investigate the application of ultrasound image segmentation technology based on the back propagation neural network (BPNN) artificial intelligence algorithm in the diagnosis of breast cancer axillary lymph node metastasis, thereby providing a theoretical basis for clinical diagnosis. In this study, 90 breast cancer patients with axillary lymph node metastasis were selected as the research objects and rolled randomly into an experimental group and a control group. Besides, all of them were examined by ultrasound. The BPNN algorithm for the ultrasound image segmentation diagnosis method was applied to the patiens from the experimental group, while the control group was given routine ultrasound diagnosis. Thus, the value of this algorithm in ultrasonic diagnosis was compared and explored. The results showed that when the number of hidden layer nodes based on the BPNN artificial intelligence algorithm was 2, 3, 4, 5, 6, 7, and 8, the corresponding segmentation accuracy was 97.3%, 96.5%, 94.8%, 94.8%, and 94.1% in turn. Among them, the segmentation accuracy was the highest when the number of hidden layer nodes was 2. The correlation of independent variable bubble plot analysis showed that the presence or absence of capsules, the presence of crab feet or burrs in breast cancer lesions was critical influencing factors for the occurrence of axillary lymph node metastasis, and the standardized importance was 99.7% and 70.8%, respectively. Besides, the area under the two-dimensional receiver operating characteristic (ROC) curve of the BPNN artificial intelligence algorithm model classification was always greater than the area under the curve of manual segmentation, and the segmentation accuracy was 90.31%, 94.88%, 95.48%, 95.44%, and 97.65% in sequence. In addition, the segmentation specificity of different running times was higher than that of manual segmentation. In conclusion, the BPNN artificial intelligence algorithm had high accuracy, sensitivity, and specificity for ultrasound image segmentation, with a better segmentation effect. Therefore, it had a better diagnostic effect for breast cancer axillary lymph node metastasis.",2021,"In conclusion, the BPNN artificial intelligence algorithm had high accuracy, sensitivity, and specificity for ultrasound image segmentation, with a better segmentation effect.",['90 breast cancer patients with axillary lymph node metastasis'],"['Artificial Intelligence Algorithm-Based Ultrasound Image Segmentation Technology', 'back propagation neural network (BPNN) artificial intelligence algorithm']","['segmentation accuracy', 'number of hidden layer nodes']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0729594', 'cui_str': 'Axillary lymph node group'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]","[{'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0242406', 'cui_str': 'Neural Networks (Anatomic)'}]","[{'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",90.0,0.0442902,"In conclusion, the BPNN artificial intelligence algorithm had high accuracy, sensitivity, and specificity for ultrasound image segmentation, with a better segmentation effect.","[{'ForeName': 'Lianhua', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Ultrasound, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, Xinjiang, China.'}, {'ForeName': 'Zhiying', 'Initials': 'Z', 'LastName': 'Jia', 'Affiliation': 'Department of Ultrasound, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, Xinjiang, China.'}, {'ForeName': 'Xiaoling', 'Initials': 'X', 'LastName': 'Leng', 'Affiliation': 'Department of Ultrasound, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, Xinjiang, China.'}, {'ForeName': 'Fucheng', 'Initials': 'F', 'LastName': 'Ma', 'Affiliation': 'Department of Ultrasound, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, Xinjiang, China.'}]",Journal of healthcare engineering,['10.1155/2021/8830260'] 2224,34367535,Deep-Learning-Based Color Doppler Ultrasound Image Feature in the Diagnosis of Elderly Patients with Chronic Heart Failure Complicated with Sarcopenia.,"The neural network algorithm of deep learning was applied to optimize and improve color Doppler ultrasound images, which was used for the research on elderly patients with chronic heart failure (CHF) complicated with sarcopenia, so as to analyze the effect of the deep-learning-based color Doppler ultrasound image on the diagnosis of CHF. 259 patients were selected randomly in this study, who were admitted to hospital from October 2017 to March 2020 and were diagnosed with sarcopenia. Then, all of them underwent cardiac ultrasound examination and were divided into two groups according to whether deep learning technology was used for image processing or not. A group of routine unprocessed images was set as the control group, and the images processed by deep learning were set as the experimental group. The results of color Doppler images before and after processing were analyzed and compared; that is, the processed images of the experimental group were clearer and had higher resolution than the unprocessed images of the control group, with the peak signal-to-noise ratio (PSNR) = 20 and structural similarity index measure (SSIM) = 0.09; the similarity between the final diagnosis results and the examination results of the experimental group (93.5%) was higher than that of the control group (87.0%), and the comparison was statistically significant ( P < 0.05); among all the patients diagnosed with sarcopenia, 88.9% were also eventually diagnosed with CHF and only a small part of them were diagnosed with other diseases, with statistical significance ( P < 0.05). In conclusion, deep learning technology had certain application value in processing color Doppler ultrasound images. Although there was no obvious difference between the color Doppler ultrasound images before and after processing, they could all make a better diagnosis. Moreover, the research results showed the correlation between CHF and sarcopenia.",2021,"Although there was no obvious difference between the color Doppler ultrasound images before and after processing, they could all make a better diagnosis.","['259 patients were selected randomly in this study, who were admitted to hospital from October 2017 to March 2020 and were diagnosed with sarcopenia', 'Elderly Patients with Chronic Heart Failure Complicated with Sarcopenia', 'elderly patients with chronic heart failure (CHF']","['Deep-Learning-Based Color Doppler Ultrasound Image Feature', 'deep learning technology']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}]","[{'cui': 'C4704761', 'cui_str': 'Hierarchical Learning'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0474781', 'cui_str': 'Color doppler ultrasound'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]",[],259.0,0.021319,"Although there was no obvious difference between the color Doppler ultrasound images before and after processing, they could all make a better diagnosis.","[{'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Bian', 'Affiliation': 'Department of Statistics and Medical Record Management, Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China.'}, {'ForeName': 'Xiyu', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Statistics and Medical Record Management, Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China.'}, {'ForeName': 'Ruihong', 'Initials': 'R', 'LastName': 'Liu', 'Affiliation': 'Department of Statistics and Medical Record Management, Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China.'}, {'ForeName': 'Huijie', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Statistics and Medical Record Management, Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China.'}, {'ForeName': 'Qingqing', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Statistics and Medical Record Management, Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China.'}, {'ForeName': 'Baoling', 'Initials': 'B', 'LastName': 'Dai', 'Affiliation': 'Medical Office, Liaocheng Hospital of Traditional Chinese Medicine of Shandong Province, Liaocheng 252000, Shandong, China.'}]",Journal of healthcare engineering,['10.1155/2021/2603842'] 2225,34367288,Effect of Cold Atmospheric Pressure Plasma Coupled with Resin-Containing and Xylitol-Containing Fluoride Varnishes on Enamel Erosion.,"Purpose Considering the suggested advantages of cold atmospheric plasma (CAP) in increasing the fluoride uptake by the enamel, this study aimed to assess enamel erosion following the application of helium CAP and two types of fluoride varnishes. Methods The microhardness of 70 bovine enamel specimens was measured using a Vickers hardness tester. The specimens were randomly divided into 7 groups ( n  = 10): control, CAP (P), resin-containing fluoride varnish (RF), CAP + resin-containing fluoride varnish (PRF), fluoride varnish (F), CAP + fluoride varnish (PF), and erosion (E). The specimens in the control and erosion groups did not receive CAP or fluoride varnish. All specimens underwent erosive challenge 4 times/day using hydrochloric acid and artificial saliva except for the control specimens that remained in distilled water during the course of the study. After 5 days of erosive challenge, microhardness was measured again, and the percentage of microhardness change was calculated. Surface roughness of two specimens in each group was assessed by atomic force microscopy (AFM). Data were analyzed using one-way ANOVA followed by Tamhane's post-hoc test. Results The percentage of microhardness change in all groups was significantly higher than that of the control group. All groups showed significantly lower percentage of microhardness change compared with the E group except for the P group; no significant difference was noted in microhardness change of P and E groups. Other experimental groups had no significant difference with each other. Surface roughness was the highest in PRF and the lowest in the F group. Conclusion CAP application had no significant effect on increasing the enamel resistance to erosion. However, enamel resistance to erosion increased significantly after fluoride varnish application alone or fluoride varnish application combined with CAP. No significant difference was noted between the two types of varnishes in this regard. CAP increased the surface roughness while fluoride varnish application alone decreased the roughness.",2021,All groups showed significantly lower percentage of microhardness change compared with the E group except for the P group; no significant difference was noted in microhardness change of P and E groups.,[],"['cold atmospheric plasma (CAP', 'Cold Atmospheric Pressure Plasma Coupled with Resin-Containing and Xylitol-Containing Fluoride Varnishes', 'fluoride varnishes', 'CAP or fluoride varnish', 'control, CAP (P), resin-containing fluoride varnish (RF), CAP\u2009+\u2009resin-containing fluoride varnish (PRF), fluoride varnish (F), CAP\u2009+\u2009fluoride varnish (PF), and erosion (E']","['Enamel Erosion', 'roughness', 'enamel erosion', 'microhardness change', 'Surface roughness', 'enamel resistance to erosion', 'percentage of microhardness change']",[],"[{'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004180', 'cui_str': 'Atmospheric Pressure'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0035191', 'cui_str': 'Resins, Plant'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0043369', 'cui_str': 'Xylitol'}, {'cui': 'C0016326', 'cui_str': 'Fluoride Varnishes'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer'}]","[{'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0439165', 'cui_str': 'Percent'}]",70.0,0.0213692,All groups showed significantly lower percentage of microhardness change compared with the E group except for the P group; no significant difference was noted in microhardness change of P and E groups.,"[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Khoubrouypak', 'Affiliation': 'Department of Operative Dentistry, School of Dentistry, Guilan University of Medical Sciences, Rasht, Guilan, Iran.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Abbasi', 'Affiliation': 'Department of Operative Dentistry, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Operative Dentistry, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Niyousha', 'Initials': 'N', 'LastName': 'Rafeie', 'Affiliation': 'Dental Research Center, Dentistry Research Institute, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Marjan', 'Initials': 'M', 'LastName': 'Behroozibakhsh', 'Affiliation': 'Department of Dental Biomaterials, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.'}]",International journal of dentistry,['10.1155/2021/3298515'] 2226,34367287,Autogenous Bone and Bioactive Glass around Implants Placed Simultaneously with Ridge Splitting for the Treatment of Horizontal Bony Defects: A Randomised Clinical Trial.,"Objective To compare using autogenous bone with or without bioactive glass in ridge splitting of horizontal bone defects combined with simultaneous implant placement. Materials and Methods In control group, bone expansion was performed and autogenous bone was used to augment the intercortical bone defect. In study group, autogenous bone was mixed with bioactive glass (1 : 1 in volume). In both groups, the implants were inserted simultaneously with ridge splitting. Six months following implant insertion, bone width and height were evaluated. Statistical analysis utilizing paired Student's t -test was used for comparing results within the same group, whereas independent samples t -test was used for intergroup variables comparison. Results The mean bone width and labial and mesiodistal crestal bone height values were increased significantly in both groups from baseline to 6 months postoperatively. Comparing the two groups showed nonstatistical significant difference regarding the labial crestal bone loss, while the ridge width gain values were significantly higher in the study group than in the control group. The mesiodistal bone loss was significantly higher in control group than in study group. Conclusion Autogenous bone was mixed with bioactive glass (1 : 1 in volume) to fill intercortical defect created after ridge splitting to decrease peri-implant bone resorption associated with autogenous bone alone. This trial is registered with clinical trial registration: NCT04814160.",2021,The mean bone width and labial and mesiodistal crestal bone height values were increased significantly in both groups from baseline to 6 months postoperatively.,['Horizontal Bony Defects'],"['simultaneous implant placement', 'Autogenous Bone and Bioactive Glass', 'autogenous bone was mixed with bioactive glass', 'autogenous bone with or without bioactive glass']","['mean bone width and labial and mesiodistal crestal bone height values', 'bone width and height', 'mesiodistal bone loss', 'ridge width gain values', 'labial crestal bone loss']","[{'cui': 'C0205126', 'cui_str': 'Horizontal'}, {'cui': 'C0443157', 'cui_str': 'Bony'}, {'cui': 'C0243067', 'cui_str': 'defects'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0443145', 'cui_str': 'Autogenous'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0015421', 'cui_str': 'Eyeglasses'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C0023759', 'cui_str': 'Lip structure'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0332243', 'cui_str': 'Ridging'}]",,0.0370526,The mean bone width and labial and mesiodistal crestal bone height values were increased significantly in both groups from baseline to 6 months postoperatively.,"[{'ForeName': 'Walid', 'Initials': 'W', 'LastName': 'Elamrousy', 'Affiliation': 'Periodontology Department, Faculty of Dentistry, Kafrelsheikh University, Kafr El-Sheikh 21614, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Osama', 'Affiliation': 'Clinical Implantology Department, Faculty of Dentistry, Alexandria University, Alexandria 17862, Egypt.'}, {'ForeName': 'Dalia Rasheed', 'Initials': 'DR', 'LastName': 'Issa', 'Affiliation': 'Periodontology Department, Faculty of Dentistry, Kafrelsheikh University, Kafr El-Sheikh 21614, Egypt.'}]",International journal of dentistry,['10.1155/2021/2457328'] 2227,34367285,Clinical Effect of Iodine-125 Seed Implantation in Patients with Primary Liver Cancer and Its Effect on Th1/Th2 Cells in Peripheral Blood.,"Objective To investigate the clinical effect of iodine-125 seed implantation combined with chemotherapy in patients with primary liver cancer and the effect on peripheral blood Th1/Th2 cells. Methods A total of 136 patients with primary liver cancer from April 2017 to June 2018 were selected as subjects and randomly divided into the control group and observation group with 68 cases in each group. The control group was treated with chemotherapy, and the observation group was treated with iodine-125 seed implantation on the basis of the control group. After 3 months of treatment, the curative effect was investigated. Serum tumor markers, peripheral blood Th1/Th2 cells, and side effects and recurrence rate were compared between the two groups. Results The levels of serum tumor markers in both groups at 3 months after treatment were lower than before treatment ( P < 0.05). Three months after treatment, the levels of tumor markers AFP, AFP-L3, and GP73 in the observation group were 14.61 ± 3.49  μ g/L, 3.29 ± 0.41 ng/mL, and 51.24 ± 4.51  μ g/L, respectively, which were lower than those in the control group, 32.53 ± 4.59  μ g/L, 5.63 ± 0.63 ng/mL, and 71.52 ± 6.05  μ g/L ( P < 0.05). At 3 months after treatment, the level of including interleukin-2 (IL-2) and tumor necrosis factor- α (TNF- α ) in Th1 cells of the observation group was higher than that of the control group ( P < 0.05), whereas the levels of IL-4, IL-6, and IL-10 in Th2 cells were lower than those in the control group ( P < 0.05). There was no statistical significance in the incidence of leukopenia, thrombocytopenia, and gastrointestinal reactions between the two groups ( P > 0.05). The recurrence rate of the observation group at 12, 24, and 36 months after treatment was lower than that of the control group ( P < 0.05). Conclusion Iodine-125 seed implantation combined with chemotherapy in patients with primary liver cancer can reduce the level of serum tumor markers, improve the level of peripheral blood Th1/Th2 cells, and reduce the recurrence rate of patients without increasing the incidence of side effects, which is worthy of promoting the application of iodine-125 seed implantation.",2021,"There was no statistical significance in the incidence of leukopenia, thrombocytopenia, and gastrointestinal reactions between the two groups ( P > 0.05).","['Patients with Primary Liver Cancer and Its Effect on Th1/Th2 Cells in Peripheral Blood', 'patients with primary liver cancer and the effect on peripheral blood Th1/Th2 cells', '136 patients with primary liver cancer from April 2017 to June 2018 were selected as subjects and randomly divided into the control group and observation group with 68 cases in each group', 'patients with primary liver cancer']","['Iodine-125 Seed Implantation', 'iodine-125 seed implantation', 'iodine-125 seed implantation combined with chemotherapy', 'chemotherapy', 'Iodine-125 seed implantation combined with chemotherapy']","['levels of tumor markers AFP, AFP-L3, and GP73', 'levels of serum tumor markers', 'levels of IL-4, IL-6, and IL-10 in Th2 cells', 'incidence of leukopenia, thrombocytopenia, and gastrointestinal reactions', 'curative effect', 'Serum tumor markers, peripheral blood Th1/Th2 cells, and side effects and recurrence rate', 'recurrence rate', 'level of serum tumor markers', 'level of including interleukin-2 (IL-2) and tumor necrosis factor- α (TNF- α ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024620', 'cui_str': 'Primary malignant neoplasm of liver'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0868928', 'cui_str': 'Case'}]","[{'cui': 'C0796396', 'cui_str': 'Iodine-125'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0041365', 'cui_str': 'Biomarkers, Cancer'}, {'cui': 'C0201539', 'cui_str': 'Alpha-1-Fetoprotein measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0242633', 'cui_str': 'T helper subset 2 cell'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0021756', 'cui_str': 'Interleukin-2'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}]",136.0,0.054738,"There was no statistical significance in the incidence of leukopenia, thrombocytopenia, and gastrointestinal reactions between the two groups ( P > 0.05).","[{'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Zhu', 'Affiliation': 'Department of Hepatobiliary Surgery, Ezhou Central Hospital, Ezhou 436099, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Xiong', 'Affiliation': 'Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Fan', 'Affiliation': 'Department of Outpatient, Chengdu Wuhou District Enxi Medical Cosmetology Hospital, Chengdu 610047, China.'}, {'ForeName': 'Wenjie', 'Initials': 'W', 'LastName': 'Ke', 'Affiliation': 'Department of Henia and Abdominal Wall Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong Univerity of Science and Technology, Wuhan 430030, China.'}]",Journal of oncology,['10.1155/2021/6199732'] 2228,34367274,The Effect of Virtual Reality Training on Anticipatory Postural Adjustments in Patients with Chronic Nonspecific Low Back Pain: A Preliminary Study.,"Objectives This study is aimed at exploring the effects of virtual reality (VR) training on postural control, measured by anticipatory and compensatory postural adjustments (APAs and CPAs, respectively), in patients with chronic nonspecific low back pain (CNLBP) and the potential neuromuscular mechanism of VR training. Methods Thirty-four patients were recruited and randomly assigned to the VR group ( n = 11), the motor control exercise group (MCE, n = 12) and the control group (CG, n = 11). The VR group received VR training using Kinect Xbox 360 systems and magnetic therapy. Besides magnetic therapy, the participants in the MCE group performed real-time ultrasound-guided abdominal drawing-in maneuver (ADIM) and four-point kneeling exercise. The CG only received magnetic therapy. Surface muscle electromyography (sEMG) was used to record the muscle activities of transverse abdominis (TrA), multifidus (MF), lateral gastrocnemius (LG), and tibialis anterior (TA) during ball-hitting tasks. The muscle activation time and integrals of the electromyography activities (IEMGs) during the APA and CPA stages were calculated and used in the data analysis. The visual analogue scale (VAS) and Oswestry dysfunction index (ODI) scores were also recorded. Results A significant interaction effect of time × group was observed on the activation time of TrA ( p = 0.018) and MF ( p = 0.037). The post-intervention activation time of the TrA was earlier in the VR group ( p = 0.029). In contrast, the post-intervention activation time of the MF was significantly delayed in the VR group ( p = 0.001). The IEMGs of TrA ( p = 0.002) and TA ( p = 0.007) during CPA1 significantly decreased only in the VR group after the intervention. The VAS scores of three group participants showed significant decreases after intervention ( p < 0.001). Conclusions Patients with CNLBP showed reciprocal muscle activation patterns of the TrA and MF muscles after VR training. VR training may be a potential intervention for enhancing the APAs of the patients with CNLBP.",2021,The post-intervention activation time of the TrA was earlier in the VR group ( p = 0.029).,"['Methods\n\n\nThirty-four patients', 'patients with chronic nonspecific low back pain (CNLBP) and the potential neuromuscular mechanism of VR training', 'Patients with Chronic Nonspecific Low Back Pain']","['VR training using Kinect Xbox 360 systems and magnetic therapy', 'real-time ultrasound-guided abdominal drawing-in maneuver (ADIM) and four-point kneeling exercise', 'Virtual Reality Training', 'motor control exercise group (MCE, n = 12) and the control group (CG', 'VR training', 'Surface muscle electromyography (sEMG', 'virtual reality (VR) training', 'magnetic therapy']","['activation time of TrA', 'CPA1', 'muscle activities of transverse abdominis (TrA), multifidus (MF), lateral gastrocnemius (LG), and tibialis anterior (TA) during ball-hitting tasks', 'Anticipatory Postural Adjustments', 'visual analogue scale (VAS) and Oswestry dysfunction index (ODI) scores', 'reciprocal muscle activation patterns', 'MF', 'post-intervention activation time of the MF', 'muscle activation time and integrals of the electromyography activities (IEMGs', 'VAS scores']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0872210', 'cui_str': 'Magnetic therapy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C1260920', 'cui_str': 'Kneeling'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0025641', 'cui_str': 'Metergoline'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0040845', 'cui_str': 'Tretinoin'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205106', 'cui_str': 'Transverse plane'}, {'cui': 'C0224319', 'cui_str': 'Structure of multifidus muscle'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0242691', 'cui_str': 'Gastrocnemius muscle structure'}, {'cui': 'C0242690', 'cui_str': 'Tibialis anterior muscle structure'}, {'cui': 'C0039597', 'cui_str': 'Testis structure'}, {'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0443238', 'cui_str': 'Integral'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}]",34.0,0.00641707,The post-intervention activation time of the TrA was earlier in the VR group ( p = 0.029).,"[{'ForeName': 'Zhicheng', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Qiuhua', 'Initials': 'Q', 'LastName': 'Yu', 'Affiliation': 'Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Haizhen', 'Initials': 'H', 'LastName': 'Luo', 'Affiliation': 'Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.'}, {'ForeName': 'Wenzhao', 'Initials': 'W', 'LastName': 'Liang', 'Affiliation': 'Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Le', 'Initials': 'L', 'LastName': 'Ge', 'Affiliation': 'Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Siyun', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Le', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': ""Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China.""}, {'ForeName': 'Chuhuai', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}]",Neural plasticity,['10.1155/2021/9975862'] 2229,34367250,Identification and Validation of a Ferroptosis-Related Long Non-coding RNA Signature for Predicting the Outcome of Lung Adenocarcinoma.,"Background Ferroptosis is a recently recognized type of programmed cell death that is involved in the biological processes of various cancers. However, the mechanism of ferroptosis in lung adenocarcinoma (LUAD) remains unclear. This study aimed to determine the role of ferroptosis-associated long non-coding RNAs (lncRNAs) in LUAD and to establish a prognostic model. Methods We downloaded ferroptosis-related genes from the FerrDb database and RNA sequencing data and clinicopathological characteristics from The Cancer Genome Atlas. We randomly divided the data into training and validation sets. Ferroptosis-associated lncRNA signatures with the lowest Akaike information criteria were determined using COX regression analysis and the least absolute shrinkage and selection operator. The risk scores of ferroptosis-related lncRNAs were calculated, and patients with LUAD were assigned to high- and low-risk groups based on the median risk score. The prognostic value of the risk scores was evaluated using Kaplan-Meier curves, Cox regression analyses, and nomograms. We then explored relationships between ferroptosis-related lncRNAs and the immune response using gene set enrichment analysis (GSEA). Results Ten ferroptosis-related lncRNA signatures were identified in the training group, and Kaplan-Meier and Cox regression analyses confirmed that the risk scores were independent predictors of LUAD outcome in the training and validation sets (all P < 0.05). The area under the curve confirmed that the signatures could determine the prognosis of LUAD. The predictive accuracy of the established nomogram model was verified using the concordance index and calibration curve. The GSEA showed that the 10 ferroptosis-related lncRNAs might be associated with tumor immune response. Conclusion We established a novel signature involving 10 ferroptosis-related lncRNAs (LINC01843, MIR193BHG, AC091185.1, AC027031.2, AL021707.2, AL031667.3, AL606834.1, AC026355.1, AC124045.1, and AC025048.4) that can accurately predict the outcome of LUAD and are associated with the immune response. This will provide new insights into the development of new therapies for LUAD.",2021,"The prognostic value of the risk scores was evaluated using Kaplan-Meier curves, Cox regression analyses, and nomograms.",[],[],[],[],[],[],10.0,0.0409502,"The prognostic value of the risk scores was evaluated using Kaplan-Meier curves, Cox regression analyses, and nomograms.","[{'ForeName': 'Zhiyuan', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': 'Medical Technology and Engineering College of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Medical Technology and Engineering College of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': 'Medical Technology and Engineering College of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xue', 'Affiliation': 'Medical Technology and Engineering College of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Shuhan', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Medical Technology and Engineering College of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Qiaoqian', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Medical Technology and Engineering College of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Donghong', 'Initials': 'D', 'LastName': 'Lin', 'Affiliation': 'Medical Technology and Engineering College of Fujian Medical University, Fuzhou, China.'}]",Frontiers in genetics,['10.3389/fgene.2021.690509'] 2230,34366983,Effects of Attentional Control on Gait and Inter-Joint Coordination During Dual-Task Walking.,"In the process of walking, attentional resources are flexibly allocated to deal with varying environmental constraints correlated with attentional control (AC). A dual-task paradigm was used to investigate the effects of AC on gait and inter-joint coordination. Fifty students volunteered to participate in this study. Based on the reaction time (RT) in the Stroop task, the top 15 participants were assigned to the High Attentional Control (HAC) group, while the last 15 participants were assigned to the Low Attentional Control (LAC) group. The participants in the two groups were randomly asked to perform three tasks: (i) single 2-back working memory task (ST 2-back); (ii) single walking task (ST walking); and (iii) dual task (DT). Cognitive outcomes and gait spatiotemporal parameters were measured. Continuous relative phase (CRP), derived from phase angles of two adjacent joints, was used to assess inter-joint coordination. The LAC group exhibited significant task effects regarding RT, correct rate (CR), step width, gait cycle, step time, forefoot contact times, heel-forefoot times, hip-knee mean absolute relative phase (MARP), and deviation phase (DP) in the stance and swing phases ( p < 0.05). In the HAC group, significant task effects were only detected in RT and foot progression angle of the left foot ( p < 0.05). Under the three task conditions, the LAC group exhibited a higher CR in ST, longer heel contact times, and longer heel-forefoot times when compared with the LAC group ( p < 0.05). Compared with the LAC group, the HAC group exhibited significantly smaller (closer to zero) MARP and weaker hip-knee DP values in the swing phase across all gait conditions ( p < 0.05). In the stance phase, the HAC group had smaller MARP (closer to zero) values when compared with the LAC group ( p < 0.05). In conclusion, the ability to maintain gait control and modulate inter-joint coordination patterns in young adults is affected by the level of attentional control in accommodating gait disturbances. AC is correlated with the performance of motor control, which theoretically supports the competitive selection of athletes and fall prevention strategies for a specific population.",2021,MARP and weaker hip-knee DP values in the swing phase across all gait conditions ( p < 0.05).,"['Fifty students volunteered to participate in this study', 'young adults']","['HAC', 'High Attentional Control (HAC', 'perform three tasks: (i) single 2-back working memory task (ST 2-back); (ii) single walking task (ST walking); and (iii) dual task (DT', 'Low Attentional Control (LAC', 'LAC', 'Attentional Control']","['Gait and Inter-Joint Coordination', 'reaction time (RT', 'heel contact times, and longer heel-forefoot times', 'MARP and weaker hip-knee DP values', 'task effects regarding RT, correct rate (CR), step width, gait cycle, step time, forefoot contact times, heel-forefoot times, hip-knee mean absolute relative phase (MARP), and deviation phase (DP) in the stance and swing phases', 'smaller MARP', 'Cognitive outcomes and gait spatiotemporal parameters', 'RT and foot progression angle of the left foot']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0205251', 'cui_str': 'Low'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0018870', 'cui_str': 'Heel structure'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1510667', 'cui_str': 'Forefoot region of foot'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1762617', 'cui_str': 'Weak'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0230461', 'cui_str': 'Structure of left foot'}]",50.0,0.0188085,MARP and weaker hip-knee DP values in the swing phase across all gait conditions ( p < 0.05).,"[{'ForeName': 'Cenyi', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'School of Physical Education and Sports Science, Soochow University, Suzhou, China.'}, {'ForeName': 'Guodong', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'School of Physical Education and Sports Science, Soochow University, Suzhou, China.'}, {'ForeName': 'Aming', 'Initials': 'A', 'LastName': 'Lu', 'Affiliation': 'School of Physical Education and Sports Science, Soochow University, Suzhou, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'School of Physical Education and Sports Science, Soochow University, Suzhou, China.'}]",Frontiers in psychology,['10.3389/fpsyg.2021.665175'] 2231,34366977,Assessing the Individual Interviewer Rapport-Building and Supportive Techniques of the R-NICHD Protocol.,"The use of the rapport-building and supportive techniques formulated by the R-NICHD protocol is intended to support children and increase the quality of their statements as well as disclosures without possessing suggestive potential. While the effectiveness of the entire R-NICHD protocol for children who have actually experienced child sexual abuse (CSA) has been supported by research, to date no study assessed the effect of each individual socio-emotional interview technique in both interviewees with and without CSA experiences. The current study aimed to address this gap in research by means of an online vignette-study, asking participants to rate the identified rapport-building and supportive techniques on the scales well-being, willingness to talk, and perceived pressure. A total of 187 participants were randomly assigned to either a hypothetical ""abused"" or a hypothetical ""not abused"" group by means of a vignette-manipulation. The results suggest that many socio-emotional interview techniques were perceived as supportive and non-suggestive, while a number of techniques were perceived as not supportive but suggestive. Few differences emerged between the hypothetical ""abused"" group and the hypothetical ""not abused"" control group. To conclude, most but not all rapport-building and supportive techniques proposed by the R-NICHD protocol had a positive effect on interviewees.",2021,"Few differences emerged between the hypothetical ""abused"" group and the hypothetical ""not abused"" control group.","['A total of 187 participants', 'children who have actually experienced child sexual abuse (CSA']","['hypothetical ""abused"" or a hypothetical ""not abused"" group by means of a vignette-manipulation']",[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517618', 'cui_str': '187'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0008062', 'cui_str': 'Sexual Abuse of Child'}]","[{'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}]",[],187.0,0.0683934,"Few differences emerged between the hypothetical ""abused"" group and the hypothetical ""not abused"" control group.","[{'ForeName': 'Anett', 'Initials': 'A', 'LastName': 'Tamm', 'Affiliation': 'Psychologische Hochschule Berlin, Berlin, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Otzipka', 'Affiliation': 'Psychologische Hochschule Berlin, Berlin, Germany.'}, {'ForeName': 'Renate', 'Initials': 'R', 'LastName': 'Volbert', 'Affiliation': 'Psychologische Hochschule Berlin, Berlin, Germany.'}]",Frontiers in psychology,['10.3389/fpsyg.2021.659438'] 2232,34366968,Effects of Mindfulness Meditation on Musical Aesthetic Emotion Processing.,"Mindfulness meditation is a form of self-regulatory training for the mind and the body. The relationship between mindfulness meditation and musical aesthetic emotion processing (MAEP) remains unclear. This study aimed to explore the effect of temporary mindfulness meditation on MAEP while listening to Chinese classical folk instrumental musical works. A 2 [(groups: mindfulness meditation group (MMG); control group (CG)] × 3 (music emotions: calm music, happy music, and sad music) mixed experimental design and a convenience sample of university students were used to verify our hypotheses, which were based on the premise that temporary mindfulness meditation may affect MAEP (MMG vs. CG). Sixty-seven non-musically trained participants (65.7% female, age range: 18-22 years) were randomly assigned to two groups (MMG or CG). Participants in MMG were given a single 10-min recorded mindfulness meditation training before and when listening to music. The instruments for psychological measurement comprised of the Five Facet Mindfulness Questionnaire (FFMQ) and the Positive and Negative Affect Schedule (PANAS). Self-report results showed no significant between-group differences for PANAS and for the scores of four subscales of the FFMQ ( p > 0.05 throughout), except for the non-judging of inner experience subscale. Results showed that temporary mindfulness meditation training decreased the negative emotional experiences of happy and sad music and the positive emotional experiences of calm music during recognition and experience and promoted beautiful musical experiences in individuals with no musical training. Maintaining a state of mindfulness while listening to music enhanced body awareness and led to experiencing a faster passage of musical time. In addition, it was found that Chinese classical folk instrumental musical works effectively induced aesthetic emotion and produced multidimensional aesthetic experiences among non-musically trained adults. This study provides new insights into the relationship between mindfulness and music emotion.",2021,"Self-report results showed no significant between-group differences for PANAS and for the scores of four subscales of the FFMQ ( p > 0.05 throughout), except for the non-judging of inner experience subscale.","['Sixty-seven non-musically trained participants (65.7% female, age range: 18-22 years', 'individuals with no musical training', 'and a convenience sample of university students']","['temporary mindfulness meditation training', 'mindfulness meditation and musical aesthetic emotion processing (MAEP', 'Mindfulness meditation', 'temporary mindfulness meditation', 'single 10-min recorded mindfulness meditation training', 'mindfulness meditation group (MMG); control group (CG', 'Mindfulness Meditation', '× 3 (music emotions: calm music, happy music, and sad music) mixed experimental design']","['negative emotional experiences of happy and sad music and the positive emotional experiences of calm music during recognition and experience and promoted beautiful musical experiences', 'aesthetic emotion', 'Musical Aesthetic Emotion Processing', 'multidimensional aesthetic experiences', 'Five Facet Mindfulness Questionnaire (FFMQ) and the Positive and Negative Affect Schedule (PANAS']","[{'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0256697', 'cui_str': 'Myxococcus acidic endoprotease'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0582655', 'cui_str': 'Positive and negative affect schedule'}]",67.0,0.0281113,"Self-report results showed no significant between-group differences for PANAS and for the scores of four subscales of the FFMQ ( p > 0.05 throughout), except for the non-judging of inner experience subscale.","[{'ForeName': 'Xiaolin', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Key Laboratory of Cognition and Personality (Ministry of Education), Southwest University, Chongqing, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Key Laboratory of Cognition and Personality (Ministry of Education), Southwest University, Chongqing, China.'}, {'ForeName': 'Huijuan', 'Initials': 'H', 'LastName': 'Shi', 'Affiliation': 'Research Institute of Aesthetics Psychology of Chinese Classical Music and Basic Theory of Music Performance, Chongqing Institute of Foreign Studies, Chongqing, China.'}, {'ForeName': 'Maoping', 'Initials': 'M', 'LastName': 'Zheng', 'Affiliation': 'Key Laboratory of Cognition and Personality (Ministry of Education), Southwest University, Chongqing, China.'}]",Frontiers in psychology,['10.3389/fpsyg.2021.648062'] 2233,34366941,"Impact of Warning Pop-Up Messages on the Gambling Behavior, Craving, and Cognitions of Online Gamblers: A Randomized Controlled Trial.","Background: Many features of Internet gambling may impact problem severity, particularly for vulnerable populations (availability, anonymity, a convenience and ease of play, digital forms of payment, and a higher level of immersion). To prevent the risks associated with excessive gambling and to inform gamblers, we need responsible gambling strategies. Gambling-related warning messages are one possible strategy that can help minimizing gambling-related harm. Methods: Our experimental study aimed to evaluate the effectiveness of self-appraisal and informative pop-up messages compared to a control condition (blank pop-up messages), for both at-risk (ARG) and low risk/non-problem Internet gamblers (LR/NPG) according to their favorite type of game, in a semi naturalistic setting and with a 15-day follow-up. During the experimental session, participants were invited to gamble on their favorite website with their own money in the laboratory. Effectiveness was investigated through the impact of pop-ups on gambling behavior (money wagered and time spent), craving, cognitive distortions, and gambling experience, taking into account message recall. We analyzed data from 58 participants, playing preferentially either to skill and chance bank games (sports betting, horse race betting) and skill and chance social games (poker). Results: We observed a significant decrease in the illusion of control for ARG in the informative pop-up condition at the 15-day follow-up. A significant effect of self-appraisal pop-ups compared to blank pop-up messages was also demonstrated only for sport and horse bettors, with a decrease on time spent gambling and an increase of gambling-related expectancies at the follow-up. Finally, we also observed that a majority of the participants were disturbed and irritated by pop-ups during their gambling session. Conclusions: The results of our study demonstrated the limited impact of pop-up warning messages on gambling behavior and cognition in Internet gamblers according to the type of game and the status of gamblers. The limited impact of warning messages on gambling behavior and the inconvenience of the pop-ups for Internet gamblers lead us to only consider warning messages as one piece of a larger responsible gambling strategy. Trial Registration Number: NCT01789580 on February 12, 2013.",2021,"A significant effect of self-appraisal pop-ups compared to blank pop-up messages was also demonstrated only for sport and horse bettors, with a decrease on time spent gambling and an increase of gambling-related expectancies at the follow-up.","['58 participants, playing preferentially either to skill and chance bank games (sports betting, horse race betting) and skill and chance social games (poker', 'February 12, 2013']","['Warning Pop-Up Messages', 'self-appraisal and informative pop-up messages compared to a control condition (blank pop-up messages), for both at-risk (ARG) and low risk/non-problem Internet gamblers (LR/NPG']","['time spent gambling', 'illusion of control for ARG', 'Gambling Behavior, Craving, and Cognitions of Online Gamblers', 'gambling-related expectancies', 'gambling behavior (money wagered and time spent), craving, cognitive distortions, and gambling experience, taking into account message recall', 'gambling behavior and cognition']","[{'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0442598', 'cui_str': 'Bank'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0019944', 'cui_str': 'Equus caballus'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}]","[{'cui': 'C0439820', 'cui_str': 'Popping sensation quality'}, {'cui': 'C2936632', 'cui_str': 'Self-Appraisal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0858352', 'cui_str': 'Gambler'}, {'cui': 'C0068260', 'cui_str': 'N-palmitoylgalactosylsphingosine'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C0020903', 'cui_str': 'Illusions'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003761', 'cui_str': 'Argentina'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0858352', 'cui_str': 'Gambler'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0030976', 'cui_str': 'Distortions, Perceptual'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}]",,0.044374,"A significant effect of self-appraisal pop-ups compared to blank pop-up messages was also demonstrated only for sport and horse bettors, with a decrease on time spent gambling and an increase of gambling-related expectancies at the follow-up.","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Caillon', 'Affiliation': 'Addictology and Psychiatry Department, CHU Nantes, Nantes, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Grall-Bronnec', 'Affiliation': 'Addictology and Psychiatry Department, CHU Nantes, Nantes, France.'}, {'ForeName': 'Anaïs', 'Initials': 'A', 'LastName': 'Saillard', 'Affiliation': 'Addictology and Psychiatry Department, CHU Nantes, Nantes, France.'}, {'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Leboucher', 'Affiliation': 'Addictology and Psychiatry Department, CHU Nantes, Nantes, France.'}, {'ForeName': 'Morgane', 'Initials': 'M', 'LastName': 'Péré', 'Affiliation': 'Biostatistics and Methodology Unit, Department of Clinical Research and Innovation, CHU Nantes, Nantes, France.'}, {'ForeName': 'Gaelle', 'Initials': 'G', 'LastName': 'Challet-Bouju', 'Affiliation': 'Addictology and Psychiatry Department, CHU Nantes, Nantes, France.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2021.711431'] 2234,34366933,Mood and Activity Measured Using Smartphones in Unipolar Depressive Disorder.,"Background: Smartphones comprise a promising tool for symptom monitoring in patients with unipolar depressive disorder (UD) collected as either patient-reportings or possibly as automatically generated smartphone data. However, only limited research has been conducted in clinical populations. We investigated the association between smartphone-collected monitoring data and validated psychiatric ratings and questionnaires in a well-characterized clinical sample of patients diagnosed with UD. Methods: Smartphone data, clinical ratings, and questionnaires from patients with UD were collected 6 months following discharge from psychiatric hospitalization as part of a randomized controlled study. Smartphone data were collected daily, and clinical ratings (i.e., Hamilton Depression Rating Scale 17-item ) were conducted three times during the study. We investigated associations between (1) smartphone-based patient-reported mood and activity and clinical ratings and questionnaires; (2) automatically generated smartphone data resembling physical activity, social activity, and phone usage and clinical ratings; and (3) automatically generated smartphone data and same-day smartphone-based patient-reported mood and activity. Results: A total of 74 patients provided 11,368 days of smartphone data, 196 ratings, and 147 questionnaires. We found that: (1) patient-reported mood and activity were associated with clinical ratings and questionnaires ( p < 0.001), so that higher symptom scores were associated with lower patient-reported mood and activity, (2) Out of 30 investigated associations on automatically generated data and clinical ratings of depression, only four showed statistical significance. Further, lower psychosocial functioning was associated with fewer daily steps ( p = 0.036) and increased number of incoming ( p = 0.032), outgoing ( p = 0.015) and missed calls ( p = 0.007), and longer phone calls ( p = 0.012); (3) Out of 20 investigated associations between automatically generated data and daily patient-reported mood and activity, 12 showed statistical significance. For example, lower patient-reported activity was associated with fewer daily steps, shorter distance traveled, increased incoming and missed calls, and increased screen-time. Conclusion: Smartphone-based self-monitoring is feasible and associated with clinical ratings in UD. Some automatically generated data on behavior may reflect clinical features and psychosocial functioning, but these should be more clearly identified in future studies, potentially combining patient-reported and smartphone-generated data.",2021,"Further, lower psychosocial functioning was associated with fewer daily steps ( p = 0.036) and increased number of incoming ( p = 0.032), outgoing ( p = 0.015) and missed calls ( p = 0.007), and longer phone calls ( p = 0.012); (3) Out of 20 investigated associations between automatically generated data and daily patient-reported mood and activity, 12 showed statistical significance.","['patients diagnosed with UD', 'patients with unipolar depressive disorder (UD) collected as either patient-reportings or possibly as automatically generated smartphone data', '74 patients provided 11,368 days of smartphone data, 196 ratings, and 147 questionnaires', 'Unipolar Depressive Disorder', 'patients with UD']",['Smartphone-based self-monitoring'],"['lower psychosocial functioning', 'clinical ratings (i.e., Hamilton Depression Rating Scale 17-item ', 'screen-time', 'Mood and Activity', 'longer phone calls', 'mood and activity and clinical ratings and questionnaires; (2) automatically generated smartphone data resembling physical activity, social activity, and phone usage and clinical ratings']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0443340', 'cui_str': 'Unipolar'}, {'cui': 'C0011581', 'cui_str': 'Depressive disorder'}, {'cui': 'C2362652', 'cui_str': 'Possible diagnosis'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C4704787', 'cui_str': 'Screen Time'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0457083', 'cui_str': 'Usage'}]",74.0,0.265442,"Further, lower psychosocial functioning was associated with fewer daily steps ( p = 0.036) and increased number of incoming ( p = 0.032), outgoing ( p = 0.015) and missed calls ( p = 0.007), and longer phone calls ( p = 0.012); (3) Out of 20 investigated associations between automatically generated data and daily patient-reported mood and activity, 12 showed statistical significance.","[{'ForeName': 'Morten Lindbjerg', 'Initials': 'ML', 'LastName': 'Tønning', 'Affiliation': 'Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Faurholt-Jepsen', 'Affiliation': 'Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mads', 'Initials': 'M', 'LastName': 'Frost', 'Affiliation': 'Monsenso A/S, Copenhagen, Denmark.'}, {'ForeName': 'Jakob Eyvind', 'Initials': 'JE', 'LastName': 'Bardram', 'Affiliation': 'Monsenso A/S, Copenhagen, Denmark.'}, {'ForeName': 'Lars Vedel', 'Initials': 'LV', 'LastName': 'Kessing', 'Affiliation': 'Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen, Denmark.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2021.701360'] 2235,34369618,The impact of a tailored mindfulness-based program for resident physicians on distress and the quality of care: A randomised controlled trial.,"BACKGROUND Many resident physicians suffer from distress, which endangers their individual health and the quality of care. OBJECTIVE To examine the impact of a tailored mindfulness-based program (MBP) for resident physicians on distress and the quality of care. METHODS A single-centre, two-armed, longitudinal randomised controlled trial. The intervention group took part in an eight-week, tailored MBP that included a course book. The MBP was followed by a four-month maintenance phase. The active control group received the course book for self-study. Assessments were at baseline (t0, 0 months), after the intervention (t1, 2 months), after the maintenance phase (t2, 6 months), and at follow-up (t3, 12 months). The primary outcome was change in burnout at t2. Secondary outcomes included perceived stress, mental distress, perceived job strain, depression, anxiety, hair cortisol secretion, self-reported medical errors, and third-party ratings by patients, supervisors, and colleagues. RESULTS Seventy-six participants were randomised to the intervention- and seventy-one to the control group. The intervention group showed greater improvements in the primary outcome (burnout at t2, d = 0.32, p = .046), in perceived stress (d = 0.31, p = .046) and perceived job strain (d = 0.33, p = .026) at t1, and in supervisor rated empathy (d = 0.71, p = .037) and colleague rated attentiveness (d = 0.85, p = .006) at t2. There was no difference between groups in the other outcomes. CONCLUSION A tailored MBP for resident physicians improved burnout and might have improved other aspects of distress and the quality of care. This article is protected by copyright. All rights reserved.",2021,"The intervention group showed greater improvements in the primary outcome (burnout at t2, d = 0.32, p = .046), in perceived stress (d = 0.31, p = .046) and perceived job strain (d = 0.33, p = .026) at t1, and in supervisor rated empathy (d = 0.71, p = .037) and colleague rated attentiveness (d = 0.85, p = .006) at t2.","['resident physicians on distress and the quality of care', 'Seventy-six participants']","['tailored mindfulness-based program', 'tailored mindfulness-based program (MBP']","['colleague rated attentiveness', 'perceived stress, mental distress, perceived job strain, depression, anxiety, hair cortisol secretion, self-reported medical errors, and third-party ratings by patients, supervisors, and colleagues', 'perceived job strain', 'perceived stress']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C4319622', 'cui_str': '76'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0233413', 'cui_str': 'Attentiveness'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0235109', 'cui_str': 'Mental distress'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0376531', 'cui_str': 'Errors, Medical'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0403172', 'cui_str': 'Supervisor'}]",76.0,0.176501,"The intervention group showed greater improvements in the primary outcome (burnout at t2, d = 0.32, p = .046), in perceived stress (d = 0.31, p = .046) and perceived job strain (d = 0.33, p = .026) at t1, and in supervisor rated empathy (d = 0.71, p = .037) and colleague rated attentiveness (d = 0.85, p = .006) at t2.","[{'ForeName': 'Johannes C', 'Initials': 'JC', 'LastName': 'Fendel', 'Affiliation': 'Department of Occupational and Consumer Psychology, Institute of Psychology, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Vanessa M', 'Initials': 'VM', 'LastName': 'Aeschbach', 'Affiliation': 'Department of Occupational and Consumer Psychology, Institute of Psychology, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schmidt', 'Affiliation': 'Department for Psychosomatic Medicine and Psychotherapy, Medical Faculty, Medical Centre, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Anja S', 'Initials': 'AS', 'LastName': 'Göritz', 'Affiliation': 'Department of Occupational and Consumer Psychology, Institute of Psychology, University of Freiburg, Freiburg, Germany.'}]",Journal of internal medicine,['10.1111/joim.13374'] 2236,34369452,Comparison of Incremental Vestibulo-ocular Reflex Adaptation Training Versus x1 Training in Patients With Chronic Peripheral Vestibular Hypofunction: A Two-Year Randomized Controlled Trial.,"BACKGROUND AND PURPOSE A crossover, double-blinded randomized controlled trial to investigate once-daily incremental vestibulo-ocular reflex (VOR) adaptation (IVA) training over 2 years in people with stable and chronic peripheral vestibular hypofunction. METHODS Twenty-one patients with peripheral vestibular hypofunction were randomly assigned to intervention-then-control (n = 12) or control-then-intervention (n = 9) groups. The task consisted of either x1 (control) or IVA training, once daily every day for 15 minutes over 6-months, followed by a 6-month washout, then repeated for arm 2 of the crossover. Primary outcome: vestibulo-ocular reflex gain. Secondary outcomes: compensatory saccades, dynamic visual acuity, static balance, gait, and subjective symptoms. Multiple imputation was used for missing data. Between-group differences were analyzed using a linear mixed model with repeated measures. RESULTS On average patients trained once daily 4 days per week. IVA training resulted in significantly larger VOR gain increase (active: 20.6% ± 12.08%, P = 0.006; passive: 30.6% ± 25.45%, P = 0.016) compared with x1 training (active: -2.4% ± 12.88%, P = 0.99; passive: -0.6% ± 15.31%, P = 0.68) (P < 0.001). The increased IVA gain did not significantly reduce with approximately 27% persisting over the washout period. x1 training resulted in greater reduction of compensatory saccade latency (P = 0.04) and increase in amplitude (P = 0.02) compared with IVA training. There was no difference between groups in gait and balance measures; however, only the IVA group had improved total Dizziness Handicap Inventory (P = 0.006). DISCUSSION AND CONCLUSIONS Our results suggest IVA improves VOR gain and reduces perception of disability more than conventional x1 training. We suggest at least 4 weeks of once-daily 4 days-per-week IVA training should be part of a comprehensive vestibular rehabilitation program.Video Abstract available for more insights from the authors (see the Video, Supplemental Digital Content 1, available at: http://links.lww.com/JNPT/A356).",2021,x1 training resulted in greater reduction of compensatory saccade latency (P = 0.04) and increase in amplitude (P = 0.02) compared with IVA training.,"['Patients', 'Twenty-one patients with peripheral vestibular hypofunction', 'people with stable and chronic peripheral vestibular hypofunction']","['daily incremental vestibulo-ocular reflex (VOR) adaptation', 'x1 (control) or IVA training', 'IVA training', 'IVA) training', 'control-then-intervention', 'Incremental Vestibulo-ocular Reflex Adaptation Training Versus x1 Training']","['total Dizziness Handicap Inventory', 'larger VOR gain increase', 'IVA gain', 'compensatory saccade latency', 'amplitude', 'gait and balance measures', 'VOR gain and reduces perception of disability', 'compensatory saccades, dynamic visual acuity, static balance, gait, and subjective symptoms', 'vestibulo-ocular reflex gain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0034944', 'cui_str': 'Vestibulo-ocular reflex'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0034944', 'cui_str': 'Vestibulo-ocular reflex'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0036019', 'cui_str': 'Saccadic eye movement'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",21.0,0.0310528,x1 training resulted in greater reduction of compensatory saccade latency (P = 0.04) and increase in amplitude (P = 0.02) compared with IVA training.,"[{'ForeName': 'Carlo N', 'Initials': 'CN', 'LastName': 'Rinaudo', 'Affiliation': 'Balance and Vision Laboratory, Neuroscience Research Australia, Sydney, Australia (C.N.R., M.C.S., P.D.C., W.V.C.F., C.J.T., A.A.M.); Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia (C.N.R., A.A.M.); Laboratory of Vestibular NeuroAdaptation, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland (M.C.S.); Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland (M.C.S., A.A.M.); Royal North Shore Hospital, Sydney, Australia (P.D.C.); and School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, Australia (A.A.M.).'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Schubert', 'Affiliation': ''}, {'ForeName': 'Phillip D', 'Initials': 'PD', 'LastName': 'Cremer', 'Affiliation': ''}, {'ForeName': 'William V C', 'Initials': 'WVC', 'LastName': 'Figtree', 'Affiliation': ''}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Todd', 'Affiliation': ''}, {'ForeName': 'Americo A', 'Initials': 'AA', 'LastName': 'Migliaccio', 'Affiliation': ''}]",Journal of neurologic physical therapy : JNPT,['10.1097/NPT.0000000000000369'] 2237,34369441,Outcomes in Patients Resuming Intravitreal Anti-VEGF Therapy Following Treatment Delay during the COVID-19 Pandemic.,"PURPOSE To evaluate the outcomes of delay in care secondary to the coronavirus (COVID-19) pandemic in patients requiring intravitreal anti-vascular endothelial growth factor (VEGF) therapy. METHODS A retrospective review was performed, and subjects were divided into 1) a Study Group of patients who experienced a treatment delay ≥ 6 weeks from intended follow up during the COVID-19 pandemic and resumed treatment with ≥ 2 anti-VEGF injections over 6 months following treatment delay, and 2) a Control Group of patients who received regular care throughout the COVID-19 pandemic. RESULTS There were 234 subjects analyzed. The mean treatment delay from intended follow up in the Study Group was 11.8 (+/- 4.0) weeks. Visual acuity and central macular thickness (CMT) worsened from baseline to 6 months after resuming anti-VEGF therapy in the Study Group (p<0.0001 and p=0.001, respectively). Visual acuity and CMT were better in the Control Group compared to the Study Group at the end of the 6-month study period (p<0.0001 for both). CONCLUSIONS Treatment delay in subjects undergoing anti-VEGF therapy for retina disease during the COVID-19 pandemic had worse visual and anatomic outcomes despite reinitiating treatment over 6 months compared to a control group, suggesting irreversibility and permanence of outcomes.",2021,"Visual acuity and central macular thickness (CMT) worsened from baseline to 6 months after resuming anti-VEGF therapy in the Study Group (p<0.0001 and p=0.001, respectively).","['subjects undergoing', 'patients requiring intravitreal anti-vascular endothelial growth factor (VEGF) therapy', 'subjects were divided into 1) a Study Group of patients who experienced a treatment delay ≥ 6 weeks from intended follow up during the COVID-19 pandemic and resumed treatment with', '234 subjects analyzed']","['≥ 2 anti-VEGF injections', 'Intravitreal Anti-VEGF Therapy', 'anti-VEGF therapy', 'Control Group of patients who received regular care throughout the COVID-19 pandemic']","['Visual acuity and CMT', 'Visual acuity and central macular thickness (CMT', 'mean treatment delay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C3693346', 'cui_str': 'Treatment Delay'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C4727875', 'cui_str': 'Anti-vascular endothelial growth factor therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}]","[{'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3693346', 'cui_str': 'Treatment Delay'}]",,0.145616,"Visual acuity and central macular thickness (CMT) worsened from baseline to 6 months after resuming anti-VEGF therapy in the Study Group (p<0.0001 and p=0.001, respectively).","[{'ForeName': 'Ryan B', 'Initials': 'RB', 'LastName': 'Rush', 'Affiliation': 'Panhandle Eye Group - 7400 Fleming Ave., Amarillo, Texas 79106, USA Texas Tech University Health Science Center - 1400 S. Coulter, Amarillo, Texas 79106, USA Southwest Retina Specialists - 7411 Wallace Blvd., Amarillo, TX, 79106, USA.'}, {'ForeName': 'Sloan W', 'Initials': 'SW', 'LastName': 'Rush', 'Affiliation': ''}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000003276'] 2238,34369402,Randomized Cross-over Trial of Endobronchial Ultrasound Transbronchial Needle Aspiration With or Without Suction in Suspected Malignant Lymphadenopathy.,"RATIONALE The benefit from applying suction during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is unclear. BACKGROUND The purpose of this study was to evaluate the impact of applying suction during EBUS-TBNA of lymph nodes (LN) on the diagnostic yield and specimen quality of EBUS-TBNA smears and cellblocks. METHODS We conducted a randomized blinded cross-over trial comparing the diagnostic yield and quality of EBUS-TBNA samples obtained with suction (S+) and without suction (S-) from suspected malignant mediastinal LN. Each LN was aspirated 4 times in a randomly assigned alternating order: S+/S-/S+/S- or S-/S+/S-/S+, resulting in 2 matched S+/S- smears pairs and 1 matched S+/S- cellblocks pairs. Specimen were assessed by a blinded cytopathologist. The primary outcome was the diagnostic yield of EBUS-TBNA smears and cellblocks. Secondary analyses accounted for LN size (≤2 vs. >2 cm) and station (mediastinal vs. hilar). RESULTS Of 234 EBUS-TBNA smears and 114 cellblocks were obtained from 59 LN. The concordance of S+ and S- cellblocks diagnostic yield was low (43.8%; 95% confidence interval: 30.7-57.6) with a significantly higher diagnostic yield among S+ compared with S- cellblocks (56.1% vs. 10.5%, respectively, P<0.001), regardless of LN station and size. However, S+ and S- smears were moderately concordant (66.7%; 95% confidence interval: 57.4-75.1) with no overall difference in their respective diagnostic yield. Numerically higher diagnostic yield among S+ smears in LN≤2 cm or hilar LN was not statistically significant. Results were similar for specimen adequacy, sensitivity and diagnosis of malignancy. CONCLUSION Applying suction during EBUS-TBNA of suspected malignant LN enhanced the diagnostic yield of cellblocks regardless of mediastinal LN station or size, but not of smears.",2021,Numerically higher diagnostic yield among S+ smears in LN≤2 cm or hilar LN was not statistically significant.,"['Suspected Malignant Lymphadenopathy', 'suspected malignant mediastinal LN']","['endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA', 'Endobronchial Ultrasound Transbronchial Needle Aspiration With or Without Suction', 'S+/S-/S+/S- or S-/S+/S-/S', 'EBUS-TBNA samples obtained with suction (S+) and without suction (S']","['LN size', 'specimen adequacy, sensitivity and diagnosis of malignancy', 'concordance of S+ and S- cellblocks diagnostic yield', 'diagnostic yield of EBUS-TBNA smears and cellblocks', 'S+ and S- smears']","[{'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0205282', 'cui_str': 'Malignant'}, {'cui': 'C0497156', 'cui_str': 'Lymphadenopathy'}, {'cui': 'C0588055', 'cui_str': 'Mediastinal lymph node group'}]","[{'cui': 'C3160856', 'cui_str': 'Endobronchial ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0442342', 'cui_str': 'Transbronchial approach'}, {'cui': 'C0181959', 'cui_str': 'Aspiration needle'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C1277697', 'cui_str': 'Sample obtained'}]","[{'cui': 'C1285847', 'cui_str': 'Size of lymph node'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C3160856', 'cui_str': 'Endobronchial ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0442342', 'cui_str': 'Transbronchial approach'}, {'cui': 'C0181959', 'cui_str': 'Aspiration needle'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}]",,0.182086,Numerically higher diagnostic yield among S+ smears in LN≤2 cm or hilar LN was not statistically significant.,"[{'ForeName': 'Hassan A', 'Initials': 'HA', 'LastName': 'Chami', 'Affiliation': 'Faculty of Medicine Clinical Research Institute Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon.'}, {'ForeName': 'Rani', 'Initials': 'R', 'LastName': 'Abu Khouzam', 'Affiliation': ''}, {'ForeName': 'Maha', 'Initials': 'M', 'LastName': 'Makki', 'Affiliation': ''}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Kahwaji', 'Affiliation': ''}, {'ForeName': 'Nour', 'Initials': 'N', 'LastName': 'Hochaimi', 'Affiliation': ''}, {'ForeName': 'Hani', 'Initials': 'H', 'LastName': 'Tamim', 'Affiliation': ''}, {'ForeName': 'Nina S', 'Initials': 'NS', 'LastName': 'Shabb', 'Affiliation': ''}]",Journal of bronchology & interventional pulmonology,['10.1097/LBR.0000000000000801'] 2239,34369227,Does Daylength Affect Sleep and Mental Health Symptoms during Behavioral Interventions for Insomnia?,"BACKGROUND Approximately 11-33% of Australian adults experience Insomnia Disorder, which is associated with higher rates of psychiatric comorbidities, and lower quality of life. Non-pharmacological interventions are the front-line treatments for insomnia. Despite the known impact of light on the sleep/wake cycle via the circadian system, it is not yet known whether seasonal variations in environmental light levels (i.e., daylength) influence treatment outcome. We aimed to determine whether seasonal differences in daylength influenced baseline symptoms of Insomnia Disorder or treatment outcome. PARTICIPANTS One hundred treatment-seeking individuals with Insomnia Disorder (age: 49.3 ± 14.4y, range: 18-82 years; 58 F) enrolled in a Randomized Control Trial in Australia over a 29-month period. METHODS Clients completed a seven-session behavioral intervention for insomnia over a maximum of 12 weeks. Individuals completed questionnaires assessing insomnia symptoms, diurnal preference, depression and anxiety symptoms, and daily sleep diaries. Objective rest/activity patterns were monitored using wrist actigraphy for the duration of the treatment period. RESULTS Baseline daylength, sunset and sunrise times, and change in daylength over treatment, were not related to baseline insomnia severity or mental health symptoms. However, longer daylength at baseline predicted greater improvements in insomnia symptoms and anxiety, but not depression, symptoms. These improvements were also associated with later sunset and/or earlier sunrise at baseline. CONCLUSIONS Our results show, greater treatment-related improvements in subjective sleep and mental health symptoms during spring and summer months. This suggests that daylength could have a role to play in the outcomes of a behavioral insomnia treatment. Future research is needed to provide recommendations.",2021,"RESULTS Baseline daylength, sunset and sunrise times, and change in daylength over treatment, were not related to baseline insomnia severity or mental health symptoms.","['Australian adults experience Insomnia Disorder', 'Clients completed a seven-session behavioral intervention for insomnia over a maximum of 12 weeks', 'One hundred treatment-seeking individuals with Insomnia Disorder (age: 49.3\xa0±\xa014.4y, range: 18-82\xa0years; 58\xa0F']",[],"['questionnaires assessing insomnia symptoms, diurnal preference, depression and anxiety symptoms, and daily sleep diaries', 'Objective rest/activity patterns', 'baseline insomnia severity or mental health symptoms', 'insomnia symptoms and anxiety', 'subjective sleep and mental health symptoms', 'sunset and sunrise times, and change in daylength over treatment']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],"[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",100.0,0.083024,"RESULTS Baseline daylength, sunset and sunrise times, and change in daylength over treatment, were not related to baseline insomnia severity or mental health symptoms.","[{'ForeName': 'Kellie', 'Initials': 'K', 'LastName': 'Hamill', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Porcheret', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.'}, {'ForeName': 'Elise R', 'Initials': 'ER', 'LastName': 'Facer-Childs', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.'}, {'ForeName': 'Alix', 'Initials': 'A', 'LastName': 'Mellor', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.'}, {'ForeName': 'Sean P A', 'Initials': 'SPA', 'LastName': 'Drummond', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.'}]",Behavioral sleep medicine,['10.1080/15402002.2021.1960350'] 2240,34369199,Development and Validation of a Risk Score Model for Predicting the Cardiovascular Outcomes After Breast Cancer Therapy: The CHEMO-RADIAT Score.,"Background Cardiovascular disease is an important cause of mortality among survivors of breast cancer (BC). We developed a prediction model for major adverse cardiovascular events after BC therapy, which is based on conventional and BC treatment-related cardiovascular risk factors. Methods and Results The cohort of the study consisted of 1256 Asian female patients with BC from 4 medical centers in Korea and was randomized in a 1:1 ratio into the derivation and validation cohorts. The outcome measures comprised cardiovascular mortality, myocardial infarction, congestive heart failure, and transient ischemic attack/stroke. To correct overfitting, a penalized Cox proportional hazards regression was performed with a cross-validation approach. Number of cardiovascular diseases (myocardial infarction, peripheral artery disease, heart failure, and transient ischemic attack/stroke), number of baseline cardiovascular risk factors (hypertension, age ≥60, body mass index ≥30 kg/m 2 , estimated glomerular filtration rate <60 mL/min per 1.73 m 2 , dyslipidemia, and diabetes mellitus), radiation to the left breast, and anthracycline dose per 100 mg/m 2 were included in the risk prediction model. The time-dependent C-indices at 3 and 7 years after BC diagnosis were 0.876 and 0.842, respectively, in the validation cohort. Conclusions A prediction score model, including BC treatment-related risk factors and conventional risk factors, was developed and validated to predict major adverse cardiovascular events in patients with BC. The CHEMO-RADIAT (congestive heart failure, hypertension, elderly, myocardial infarction/peripheral artery occlusive disease, obesity, renal failure, abnormal lipid profile, diabetes mellitus, irradiation of the left breast, anthracycline dose, and transient ischemic attack/stroke) score may provide overall cardiovascular risk stratification in survivors of BC and can assist physicians in multidisciplinary decision-making regarding the BC treatment.",2021,estimated glomerular filtration rate,"['patients with BC', 'After Breast Cancer Therapy', '1256 Asian female patients with BC from 4 medical centers in Korea', 'survivors of breast cancer (BC']",[],"['Cardiovascular Outcomes', 'Number of cardiovascular diseases (myocardial infarction, peripheral artery disease, heart failure, and transient ischemic attack/stroke), number of baseline cardiovascular risk factors (hypertension, age ≥60, body mass index ≥30', 'time-dependent C-indices', 'm 2 , dyslipidemia, and diabetes mellitus', 'cardiovascular mortality, myocardial infarction, congestive heart failure, and transient ischemic attack/stroke', 'estimated glomerular filtration rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0022771', 'cui_str': 'Korea'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]",[],"[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}]",1256.0,0.0671543,estimated glomerular filtration rate,"[{'ForeName': 'Do Young', 'Initials': 'DY', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea.'}, {'ForeName': 'Myung-Soo', 'Initials': 'MS', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea.'}, {'ForeName': 'Jong-Chan', 'Initials': 'JC', 'LastName': 'Youn', 'Affiliation': 'Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea.'}, {'ForeName': 'Sunki', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea.'}, {'ForeName': 'Jae Hyuk', 'Initials': 'JH', 'LastName': 'Choi', 'Affiliation': 'Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea.'}, {'ForeName': 'Mi-Hyang', 'Initials': 'MH', 'LastName': 'Jung', 'Affiliation': 'Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea.'}, {'ForeName': 'Lee Su', 'Initials': 'LS', 'LastName': 'Kim', 'Affiliation': 'Division of Breast and Endocrine Surgery Hallym University Sacred Heart HospitalHallym University College of Medicine Anyang Republic of Korea.'}, {'ForeName': 'Sung Hea', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology Department of Internal Medicine Konkuk University HospitalSchool of MedicineKonkuk University Seoul Republic of Korea.'}, {'ForeName': 'Seongwoo', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': 'Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea.'}, {'ForeName': 'Kyu-Hyung', 'Initials': 'KH', 'LastName': 'Ryu', 'Affiliation': 'Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea.'}]",Journal of the American Heart Association,['10.1161/JAHA.121.021931'] 2241,33452871,Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis.,"OBJECTIVE Canakinumab is a human anti-interleukin-1β (anti-IL-1β) blocking agent that effectively neutralizes IL-1β-mediated signaling for treatment of systemic juvenile idiopathic arthritis (JIA). While many patients have dramatic clinical response to IL-1 blockade, approximately one-third fail to respond, but there are currently no validated clinical or immunologic predictors of response. We undertook this study to characterize distinct gene signatures for treatment response and nonresponse to canakinumab in systemic JIA patients. METHODS We performed a secondary analysis of whole-blood gene expression microarrays using blood samples obtained from healthy controls and systemic JIA patients at baseline and on day 3 after canakinumab treatment (GEO accession no. GSE80060). Patients were considered strong clinical responders if they met the ACR90 response (exhibited ≥90% improvement in the American College of Rheumatology [ACR] JIA response criteria; nonresponders were those who met ACR30 [exhibiting ≤30% improvement in the ACR JIA response criteria]). A random-effects model with patient identity as the random variable was used for differential expression analysis. RESULTS We identified a distinct gene expression signature in patients with a strong clinical response to canakinumab treatment as compared to nonresponders, mediated by up-regulation of neutrophil- and IL-1-associated genes and characterized by increasing divergence from control transcriptomes with increasing clinical response. We also identified a signature including up-regulated CD163 expression that was associated with canakinumab nonresponse. Intriguingly, canakinumab treatment induced either up- or down-regulation of type I interferon (IFN) genes, independent of clinical response. CONCLUSION Here, we identify a gene signature in systemic JIA patients prior to receiving treatment that distinguishes strong responders to canakinumab from nonresponders. Further prospective studies are needed to assess the utility of these insights for treatment decisions in systemic JIA and to track the association of up-regulated type I IFN signatures with systemic JIA complications.",2021,"We identified a distinct gene expression signature in patients with a strong clinical response to canakinumab treatment as compared to nonresponders, mediated by up-regulation of neutrophil- and IL-1-associated genes and characterized by increasing divergence from control transcriptomes with increasing clinical response.","['systemic JIA patients', 'systemic JIA patients prior to receiving treatment that distinguishes strong responders to canakinumab from nonresponders', 'Children']",[],['ACR90 response'],"[{'cui': 'C1384600', 'cui_str': 'Systemic onset juvenile chronic arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C2718773', 'cui_str': 'canakinumab'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",[],[],,0.0585274,"We identified a distinct gene expression signature in patients with a strong clinical response to canakinumab treatment as compared to nonresponders, mediated by up-regulation of neutrophil- and IL-1-associated genes and characterized by increasing divergence from control transcriptomes with increasing clinical response.","[{'ForeName': 'Emely L', 'Initials': 'EL', 'LastName': 'Verweyen', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Pickering', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Alexei A', 'Initials': 'AA', 'LastName': 'Grom', 'Affiliation': ""Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio.""}, {'ForeName': 'Grant S', 'Initials': 'GS', 'LastName': 'Schulert', 'Affiliation': ""Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio.""}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41640'] 2242,33446872,Role of prenatal imaging in the diagnosis and management of fetal facio-cervical masses.,"Congenital facio-cervical masses can be a developmental anomaly of cystic, solid, or vascular origin, and have an inseparable relationship with adverse prognosis. This retrospective cross-sectional study aimed at determining on the prenatal diagnosis of congenital facio-cervical masses, its management and outcome in a large tertiary referral center. We collected information on prenatal clinical data, pregnancy outcomes, survival information, and final diagnosis. Out of 130 cases of facio-cervical masses, a total of 119 cases of lymphatic malformations (LMs), 2 cases of teratoma, 2 cases of thyroglossal duct cyst, 4 cases of hemangioma, 1 case of congenital epulis, and 2 cases of dermoid cyst were reviewed. The accuracy of prenatal ultrasound was 93.85% (122/130). Observations of diameters using prenatal ultrasound revealed that the bigger the initial diameter is, the bigger the relative change during pregnancy. Magnetic resonance imaging (MRI) revealed that 2 cases of masses were associated with airway compression. In conclusion, ultrasound has a high overall diagnostic accuracy of fetal face and neck deformities. Prenatal US can enhance the management of ambulatory monitoring and classification. Furthermore, MRI provided a detailed assessment of fetal congenital malformations, as well as visualization of the trachea, presenting a multi-dimensional anatomical relationship.",2021,The accuracy of prenatal ultrasound was 93.85% (122/130).,"['fetal facio-cervical masses', '130 cases of facio-cervical masses, a total of 119 cases of lymphatic malformations (LMs), 2 cases of teratoma, 2 cases of thyroglossal duct cyst, 4 cases of hemangioma, 1 case of congenital epulis, and 2 cases of dermoid cyst were reviewed']",['Magnetic resonance imaging (MRI'],"['prenatal clinical data, pregnancy outcomes, survival information, and final diagnosis', 'accuracy of prenatal ultrasound']","[{'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0398368', 'cui_str': 'Lymphatic malformation'}, {'cui': 'C0039538', 'cui_str': 'Teratoma'}, {'cui': 'C0040124', 'cui_str': 'Thyroglossal duct cyst'}, {'cui': 'C0018916', 'cui_str': 'Hemangioma'}, {'cui': 'C0009678', 'cui_str': 'congenital'}, {'cui': 'C0011649', 'cui_str': 'Dermoid cyst'}, {'cui': 'C0282443', 'cui_str': 'Review'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0332144', 'cui_str': 'Final diagnosis (discharge)'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]",130.0,0.0365351,The accuracy of prenatal ultrasound was 93.85% (122/130).,"[{'ForeName': 'Weizeng', 'Initials': 'W', 'LastName': 'Zheng', 'Affiliation': ""Department of Radiology, Women's Hospital, Zhejiang University School of Medicine, Xueshi Rd No. 1, Hangzhou, Zhejiang, People's Republic of China.""}, {'ForeName': 'Shuangshuang', 'Initials': 'S', 'LastName': 'Gai', 'Affiliation': ""Department of Ultrasound, Women's Hospital, Zhejiang University School of Medicine, Xueshi Rd No. 1, Hangzhou, Zhejiang, People's Republic of China.""}, {'ForeName': 'Jiale', 'Initials': 'J', 'LastName': 'Qin', 'Affiliation': ""Department of Ultrasound, Women's Hospital, Zhejiang University School of Medicine, Xueshi Rd No. 1, Hangzhou, Zhejiang, People's Republic of China.""}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Qiu', 'Affiliation': ""Department of Otolaryngology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Binsheng Rd No. 3333, Hangzhou, Zhejiang, People's Republic of China.""}, {'ForeName': 'Baohua', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': ""Department of Obstetrics, Women's Hospital, Zhejiang University School of Medicine, Xueshi Rd No. 1, Hangzhou, Zhejiang, People's Republic of China.""}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zou', 'Affiliation': ""Department of Radiology, Women's Hospital, Zhejiang University School of Medicine, Xueshi Rd No. 1, Hangzhou, Zhejiang, People's Republic of China. zouyuzju@zju.edu.cn.""}]",Scientific reports,['10.1038/s41598-021-80976-4'] 2243,34286894,An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.,"AIM To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes. MATERIALS AND METHODS A Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg using published results from the SUSTAIN 7 and AWARD-11 trials. Sensitivity analyses using individual patient data from SUSTAIN 7 and aggregate data from AWARD-11 were conducted to explore the impact of adjustment for cross-trial imbalances in baseline characteristics. RESULTS Semaglutide 1.0 mg significantly reduced HbA1c versus dulaglutide 3.0 mg, with an estimated treatment difference (ETD) of -0.24%-points (95% confidence interval [CI] -0.43, -0.05), with comparable reductions in HbA1c versus dulaglutide 4.5 mg with an ETD of -0.07%-points (95% CI -0.26, 0.12). Semaglutide 1.0 mg significantly reduced body weight versus dulaglutide 3.0 and 4.5 mg with an ETD of -2.65 kg (95% CI -3.57, -1.73) and -1.95 kg (95% CI -2.87, -1.03), respectively. Sensitivity analyses supported the primary analysis findings. CONCLUSIONS This indirect comparison showed significantly greater reductions in HbA1c with semaglutide 1.0 mg versus dulaglutide 3.0 mg and comparable HbA1c reductions versus dulaglutide 4.5 mg. Semaglutide 1.0 mg significantly reduced body weight versus both dulaglutide 3.0 and 4.5 mg. With several glucagon-like peptide-1 receptor agonists available, information regarding their comparative efficacy can be valuable to clinicians.",2021,"mg significantly reduced HbA1c versus dulaglutide 3.0 mg, with an estimated treatment difference (ETD) of -0.24%-points",['patients with type 2 diabetes'],"['semaglutide 1.0\xa0mg versus dulaglutide 3.0 and 4.5', 'semaglutide 1.0\xa0mg versus dulaglutide 3.0 and 4.5\xa0mg on HbA1c and body weight', 'semaglutide 1.0\xa0mg versus dulaglutide']","['body weight', 'efficacy outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C3179549', 'cui_str': 'dulaglutide'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0713371,"mg significantly reduced HbA1c versus dulaglutide 3.0 mg, with an estimated treatment difference (ETD) of -0.24%-points","[{'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Pratley', 'Affiliation': 'AdventHealth Translational Research Institute, Orlando, Florida, USA.'}, {'ForeName': 'Andrei-Mircea', 'Initials': 'AM', 'LastName': 'Catarig', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Ildiko', 'Initials': 'I', 'LastName': 'Lingvay', 'Affiliation': 'Department of Internal Medicine/Endocrinology, Department of Clinical Sciences, UT Southwestern Medical Center, University of Texas, Dallas, Texas, USA.'}, {'ForeName': 'Adie', 'Initials': 'A', 'LastName': 'Viljoen', 'Affiliation': 'Borthwick Diabetes Research Centre, Stevenage, UK.'}, {'ForeName': 'Abby', 'Initials': 'A', 'LastName': 'Paine', 'Affiliation': 'Zedediah Consulting on behalf of DRG Abacus (part of Clarivate), Wokingham, UK.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Lawson', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Barrie', 'Initials': 'B', 'LastName': 'Chubb', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Gorst-Rasmussen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Nino', 'Initials': 'N', 'LastName': 'Miresashvili', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14497'] 2244,34366347,High-Definition Transcranial Direct Current Stimulation Improves Delayed Memory in Alzheimer's Disease Patients: A Pilot Study Using Computational Modeling to Optimize Electrode Position.,"BACKGROUND The optimal stimulation parameters when using transcranial direct current stimulation (tDCS) to improve memory performance in patients with Alzheimer's disease (AD) are lacking. In healthy individuals, inter-individual differences in brain anatomy significantly influence current distribution during tDCS, an effect that might be aggravated by variations in cortical atrophy in AD patients. OBJECTIVE To measure the effect of individualized HD-tDCS in AD patients. METHODS Nineteen AD patients were randomly assigned to receive active or sham high-definition tDCS (HD-tDCS). Computational modeling of the HD-tDCS-induced electric field in each patient's brain was analyzed based on magnetic resonance imaging (MRI) scans. The chosen montage provided the highest net anodal electric field in the left dorsolateral prefrontal cortex (DLPFC). An accelerated HD-tDCS design was conducted (2 mA for 3×20 min) on two separate days. Pre- and post-intervention cognitive tests and T1 and T2-weighted MRI and diffusion tensor imaging data at baseline were analyzed. RESULTS Different montages were optimal for individual patients. The active HD-tDCS group improved significantly in delayed memory and MMSE performance compared to the sham group. Five participants in the active group had higher scores on delayed memory post HD-tDCS, four remained stable and one declined. The active HD-tDCS group had a significant positive correlation between fractional anisotropy in the anterior thalamic radiation and delayed memory score. CONCLUSION HD-tDCS significantly improved delayed memory in AD. Our study can be regarded as a proof-of-concept attempt to increase tDCS efficacy. The present findings should be confirmed in larger samples.",2021,"The active HD-tDCS group had a significant positive correlation between fractional anisotropy in the anterior thalamic radiation and delayed memory score. ","[""Alzheimer's Disease Patients"", ""patients with Alzheimer's disease (AD"", 'Nineteen AD patients', 'AD patients']","['HD-tDCS', 'active or sham high-definition tDCS (HD-tDCS', 'transcranial direct current stimulation (tDCS', 'individualized HD-tDCS', 'Pre- and post-intervention cognitive tests and T1 and T2-weighted', 'High-Definition Transcranial Direct Current Stimulation']","['anterior thalamic radiation and delayed memory score', 'tDCS efficacy', 'delayed memory and MMSE performance', 'delayed memory post HD-tDCS', 'delayed memory']","[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450337', 'cui_str': '19'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0376364', 'cui_str': 'Delayed Memory'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0687676', 'cui_str': 'After values'}]",19.0,0.059462,"The active HD-tDCS group had a significant positive correlation between fractional anisotropy in the anterior thalamic radiation and delayed memory score. ","[{'ForeName': 'Ingrid Daae', 'Initials': 'ID', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Psychology, Research Group for Cognitive Neuroscience, Faculty of Health Sciences, UiT The Artic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Nya Mehnwolo', 'Initials': 'NM', 'LastName': 'Boayue', 'Affiliation': 'Department of Psychology, Research Group for Cognitive Neuroscience, Faculty of Health Sciences, UiT The Artic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Mittner', 'Affiliation': 'Department of Psychology, Research Group for Cognitive Neuroscience, Faculty of Health Sciences, UiT The Artic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Bystad', 'Affiliation': 'Department of Psychology, Research Group for Cognitive Neuroscience, Faculty of Health Sciences, UiT The Artic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Ole K', 'Initials': 'OK', 'LastName': 'Grnli', 'Affiliation': 'Department of Geropsychiatry, University Hospital of North Norway, Norway.'}, {'ForeName': 'Torgil Riise', 'Initials': 'TR', 'LastName': 'Vangberg', 'Affiliation': 'Department of Clinical Medicine, University hospital of North Norway, Norway.'}, {'ForeName': 'Gábor', 'Initials': 'G', 'LastName': 'Csifcsák', 'Affiliation': 'Department of Psychology, Research Group for Cognitive Neuroscience, Faculty of Health Sciences, UiT The Artic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Per M', 'Initials': 'PM', 'LastName': 'Aslaksen', 'Affiliation': 'Department of Psychology, Research Group for Cognitive Neuroscience, Faculty of Health Sciences, UiT The Artic University of Norway, Tromsø, Norway.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-210378'] 2245,34366319,Efficacy and safety of ultrasound-guided caudal epidural steroid injection in patients with low back pain and sciatica.,"BACKGROUND Fluoroscopy-guided caudal epidural steroid injection (EDSI) is an option for conservative treatment of low back pain and sciatica; however, repeated exposure to radiation is a concern. With the blind technique, the needle misplacement rate is 30%; hence, ultrasound-guided caudal EDSI is a favored option. OBJECTIVE To determine the efficacy of ultrasound-guided EDSI for low back pain and sciatica. METHODS One hundred and ten patients with low back pain and sciatica who were unresponsive to conservative treatment, were prospectively recruited. Ultrasound-guided caudal EDSI was administered at 0, 3, and 6 weeks. Visual Analog Scale (VAS) score was recorded at 0, 2, 4, 12, and 24 weeks. Patients completed the Roland-Morris Disability Questionnaire (RMDQ) at pre-injection and 24 weeks post-injection. RESULTS VAS was significantly reduced at 2, 4, 12, and 24 weeks (p< 0.01). At 2, 4, 12, and 24 weeks after injection, 20%, 26%, 74%, and 83% of patients displayed > 50% VAS reduction, respectively. The mean pre-injection RMDQ score was 15 and that post-injection at 24 weeks was 7 (p< 0.01). The majority of patients had > 50% reduction in the RMDQ score. CONCLUSIONS Ultrasound-guided EDSI was safe and efficacious for low back pain and sciatica treatment at the intermediate follow-up.",2021,"Patients completed the Roland-Morris Disability Questionnaire (RMDQ) at pre-injection and 24 weeks post-injection. ","['patients with low back pain and sciatica', 'One hundred and ten patients with low back pain and sciatica who were unresponsive to conservative treatment, were prospectively recruited']","['ultrasound-guided EDSI', 'Ultrasound-guided caudal EDSI', 'ultrasound-guided caudal epidural steroid injection', 'Ultrasound-guided EDSI', 'Fluoroscopy-guided caudal epidural steroid injection (EDSI']","['VAS', 'Roland-Morris Disability Questionnaire (RMDQ', 'Efficacy and safety', 'Visual Analog Scale (VAS) score', 'RMDQ score', 'mean pre-injection RMDQ score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0036396', 'cui_str': 'Sciatica'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0196394', 'cui_str': 'Epidural steroid injection'}, {'cui': 'C0394837', 'cui_str': 'Local anesthetic sacral epidural block'}, {'cui': 'C1261311', 'cui_str': 'Injection of steroid'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]",110.0,0.0495134,"Patients completed the Roland-Morris Disability Questionnaire (RMDQ) at pre-injection and 24 weeks post-injection. ","[{'ForeName': 'Kasisin', 'Initials': 'K', 'LastName': 'Klunklin', 'Affiliation': ''}, {'ForeName': 'Apiruk', 'Initials': 'A', 'LastName': 'Sangsin', 'Affiliation': ''}, {'ForeName': 'Taninnit', 'Initials': 'T', 'LastName': 'Leerapun', 'Affiliation': ''}]",Journal of back and musculoskeletal rehabilitation,['10.3233/BMR-200224'] 2246,34366317,Analysis of the quadratus lumborum muscle activity on leg length discrepancy: A randomized controlled trial.,"BACKGROUND Quadratus lumborum (QL) discrete region extensions might change depending on whether leg length discrepancy (LLD) individually has any extra erector spinae action in the lumbar spine, which can result in serious injury to the lower extremities and lumbar vertebrae. OBJECTIVE This study aims to investigate the effect of QL muscle activity on LLD by using electromyography (EMG) signals. METHODS The study employed a randomized controlled design. A total of 100 right-handed volunteers were included in this study. All participants were assessed manually by tape measurement for LLD. EMG signals were recorded during the resting and maximal isometric contraction positions to determine QL muscle activity. The power spectral density (PSD) methods were applied to compute EMG signals. RESULTS In maximal isometric contraction position, comparing the short right LLD (Right side = 0.00064 ± 0.00001, Left side = 0.00033 ± 0.0006) and short left LLD (Right side = 0.00001 ± 0.00008, Left side = 0.00017 ± 0.0001), it was found that the short right LLD group had significantly increased PSD of EMG values. In resting position, the short right LLD (Right side = 0.0002 ± 0.0073, Left side = 0.00016 ± 0.0065) had significantly increased PSD of EMG compared to the short left LLD (Right side = 0.00004 ± 0.0003, Left side = 0.0001 ± 0.0008) values of the QL muscle activity. The results of both groups were also statistically significant (p< 0.05). CONCLUSIONS The present study showed that it is possible to determine effective experimental interventions for functional LLD using EMG signal analysis of QL muscle activity on an asymptomatic normal population.",2021,"In resting position, the short right LLD (Right side = 0.0002 ± 0.0073, Left side = 0.00016 ± 0.0065) had significantly increased PSD of EMG compared to the short left LLD (Right side = 0.00004 ± 0.0003, Left side = 0.0001 ± 0.0008) values of the QL muscle activity.",['A total of 100 right-handed volunteers'],[],"['leg length discrepancy', 'PSD of EMG', 'PSD of EMG values', 'QL muscle activity', 'EMG signals']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0230370', 'cui_str': 'Structure of right hand'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]",[],"[{'cui': 'C0023221', 'cui_str': 'Leg length inequality'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0224380', 'cui_str': 'Structure of quadratus lumborum muscle'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}]",100.0,0.0703402,"In resting position, the short right LLD (Right side = 0.0002 ± 0.0073, Left side = 0.00016 ± 0.0065) had significantly increased PSD of EMG compared to the short left LLD (Right side = 0.00004 ± 0.0003, Left side = 0.0001 ± 0.0008) values of the QL muscle activity.","[{'ForeName': 'Sevim', 'Initials': 'S', 'LastName': 'Eryiğit', 'Affiliation': 'Department of Biomedical Engineering, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Abdullah', 'Initials': 'A', 'LastName': 'Al Kafee', 'Affiliation': 'Department of Biomedical Engineering, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Aydin', 'Initials': 'A', 'LastName': 'Akan', 'Affiliation': 'Department of Electrical and Electronics Engineering, Izmir University of Economics, Izmir, Turkey.'}]",Journal of back and musculoskeletal rehabilitation,['10.3233/BMR-181177'] 2247,34366306,SMART STEP - SMARTphone-driven exercise and pedometer-based STEP intervention to promote physical activity among desk-based employees: Study protocol for a three-arm cluster randomized controlled trial.,"BACKGROUND Prolonged sitting in desk-based office workers is found to be associated with increased cardiometabolic risk and poor cognitive performance. Technology-based physical activity (PA) interventions using smartphone applications (SmPh app) to promote PA levels might be effective in reducing cardiometabolic risk among sedentary population but the evidence remains inconclusive. OBJECTIVE The objective is to investigate the effects of a technology-based PA intervention compared to PA education with a worksite manual or no intervention on PA levels, cardiometabolic risk, cognitive performance, and work productivity among desk-based employees. METHOD A three-arm clustered randomized trial will be conducted. The study will be conducted among various administrative offices of a multifaceted university in India. Desk-based employees aged between 30 and 50 years (n = 159; 53 in each arm) will be recruited. Employees from various constituent institutions (clusters) of the university will be randomized into one of the three following groups - SMART: SmPh app-driven break reminders (visual exercise prompts) plus pedometer-based step intervention, TRADE: worksite PA education with a manual plus American College of Sports Medicine guided PA prescription, or CONTROL: usual work group. At baseline and after the 1st, 3rd and 6th month of the trial period, accelerometer-measured sitting time and PA levels, cardiometabolic risk (fasting blood glucose, triglycerides, insulin, blood pressure, heart rate variability, functional capacity, and subcutaneous fat), cognitive performance (executive function), sickness absenteeism and work limitations will be assessed by a blinded assessor. Therapist delivering interventions will not be blinded. CONCLUSION This trial will determine whether a combined SmPh-app and pedometer-based intervention is more effective than education or no intervention in altering PA levels, cardiometabolic risk and cognitive performance among desk-based employees in India. This study has the potential to foster institutional recommendations for using SmPh-based technology and pedometers to promote PA at work.",2021,"Technology-based physical activity (PA) interventions using smartphone applications (SmPh app) to promote PA levels might be effective in reducing cardiometabolic risk among sedentary population but the evidence remains inconclusive. ","['Employees from various constituent institutions (clusters) of the university', 'desk-based employees in India', 'various administrative offices of a multifaceted university in India', 'desk-based employees', 'Desk-based employees aged between 30 and 50 years (n\u200a=\u200a159; 53 in each arm) will be recruited']","['SMART STEP - SMARTphone-driven exercise and pedometer-based STEP intervention', 'technology-based PA intervention', 'combined SmPh-app and pedometer-based intervention', 'Technology-based physical activity (PA) interventions using smartphone applications (SmPh app', 'SMART: SmPh app-driven break reminders (visual exercise prompts) plus pedometer-based step intervention, TRADE: worksite PA education with a manual plus American College of Sports Medicine guided PA prescription, or CONTROL: usual work group', 'PA education with a worksite manual or no intervention']","['PA levels, cardiometabolic risk, cognitive performance, and work productivity', 'PA levels, cardiometabolic risk and cognitive performance', 'accelerometer-measured sitting time and PA levels, cardiometabolic risk (fasting blood glucose, triglycerides, insulin, blood pressure, heart rate variability, functional capacity, and subcutaneous fat), cognitive performance (executive function), sickness absenteeism and work limitations', 'cardiometabolic risk and poor cognitive performance']","[{'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0729650', 'cui_str': 'Constituents'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C1292785', 'cui_str': 'Administrative action'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038040', 'cui_str': 'Medicine, Sport'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous fatty tissue'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}]",,0.0453327,"Technology-based physical activity (PA) interventions using smartphone applications (SmPh app) to promote PA levels might be effective in reducing cardiometabolic risk among sedentary population but the evidence remains inconclusive. ","[{'ForeName': 'Baskaran', 'Initials': 'B', 'LastName': 'Chandrasekaran', 'Affiliation': 'Department of Exercise and Sports Sciences, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Chythra R', 'Initials': 'CR', 'LastName': 'Rao', 'Affiliation': 'Department of Community Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Fiddy', 'Initials': 'F', 'LastName': 'Davis', 'Affiliation': 'Department of Exercise and Sports Sciences, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Ashokan', 'Initials': 'A', 'LastName': 'Arumugam', 'Affiliation': 'Department of Physiotherapy, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.'}]","Work (Reading, Mass.)",['10.3233/WOR-213544'] 2248,34366293,Effect of six months pranayama training on stress-induced salivary cortisol response among adolescents-Randomized controlled study.,"BACKGROUND A combination of yoga practices has been documented to reduce stress and stress-induced cortisol levels. The objective of the current study is to examine the effects of six months of a single pranayama practice (Bhramari [Bhr. P]) on reducing salivary cortisol response to the cold pressor test (CPT) among adolescents. METHODS Twenty-six healthy adolescents between the ages of 11 and 19 were randomly assigned to either yoga group (n-13) or control group (n-13). Yoga group participants were trained to do Bhr. P for 45 min, thrice a week for six months. All participants underwent CPT at baseline and at end of six months. Saliva samples were collected at baseline (t0), at 20 min (t1), 40 min (t2), and 60 min after the CPT (t3). RESULTS Contradictory to our hypothesis, participants in the yoga group exhibited a higher salivary cortisol response to the CPT at t1 (p = 0.04) when compared to the control group. However, the t3 salivary cortisol levels showed a statistically significant reduction (p = 0.03) in yoga group when compared to the control group. A significant interaction with time (F (1, 88) = 316.5, p = .001, ηp 2 :0.91) and between the group × time (F (3, 88) = 2.83, p = 0.04, ηp 2 :0.8) was found after the intervention. CONCLUSIONS An increase in the cortisol responsiveness observed in the study is an indication of the adaptive capability achieved through regular yoga training, evidenced by an initial rise in cortisol followed by a rapid fall below baseline after 60 min. Further research is required to conclusively determine the changes in cortisol levels over time in response to stress in long-term yoga practitioners.",2021,"However, the t3 salivary cortisol levels showed a statistically significant reduction (p = 0.03) in yoga group when compared to the control group.","['Twenty-six healthy adolescents between the ages of 11 and 19', 'adolescents']","['yoga group (n-13) or control group (n-13', 'pranayama training', 'single pranayama practice (Bhramari [Bhr. P', 'cold pressor test (CPT']","['salivary cortisol response', 'stress-induced salivary cortisol response', 'cortisol responsiveness', 'Saliva samples', 't3 salivary cortisol levels']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0686747', 'cui_str': 'Well adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0004684', 'cui_str': 'Bahrain'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}]",26.0,0.0562824,"However, the t3 salivary cortisol levels showed a statistically significant reduction (p = 0.03) in yoga group when compared to the control group.","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Maheshkumar', 'Affiliation': 'Department of Physiology, Government Yoga and Naturopathy Medical college and Hospital, Chennai 600106, India. Electronic address: doctor.mahesh1985@gmail.com.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Dilara', 'Affiliation': 'Department of Physiology, Sri Ramachandra Medical College and Research Institute, SRIHER, Chennai, India.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ravishankar', 'Affiliation': 'Department of Community Medicine, Ramachandra Medical College and Research Institute, SRIHER, Chennai, India.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Julius', 'Affiliation': 'Department of Biochemistry, Sri Balaji Dental College and Hospital, Bharath University, Chennai, India.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Padmavathi', 'Affiliation': 'Department of Physiology, Sri Ramachandra Medical College and Research Institute, SRIHER, Chennai, India.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Poonguzhali', 'Affiliation': 'Department of Community Medicine, Government Yoga and Naturopathy Medical college and Hospital, Chennai, India.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Venugopal', 'Affiliation': 'Department of Yoga, Government Yoga and Naturopathy Medical college and Hospital, Chennai, India.'}]","Explore (New York, N.Y.)",['10.1016/j.explore.2021.07.005'] 2249,34366282,Pilot RCT of a telehealth intervention to reduce symptoms of depression and anxiety in adults with cystic fibrosis.,"BACKGROUND Adults with cystic fibrosis (awCF) have higher levels of depression and anxiety than community samples. The Coping and Learning to Manage Stress with CF (CALM) intervention was developed for awCF reporting elevated symptoms of depression or anxiety. METHODS In this pilot study, awCF were randomly assigned to either six telehealth sessions (CALM; n = 15) or treatment-as-usual (TAU; n = 16). Primary outcomes were depression and anxiety. Secondary outcomes were coping self-efficacy and health-related quality of life (HrQOL). Tertiary outcomes were feasibility, acceptability, and satisfaction. Assessments were completed at baseline, post-intervention, and 3-month follow-up. Group differences were examined via independent samples t-tests. Effect size (ES) was calculated via Cohen's d to provide a measure of the magnitude of the treatment effect. RESULTS At post-intervention, the CALM group had a lower mean score than the TAU group for depression (medium ES) and anxiety (large ES). The CALM group had higher (i.e., better) mean scores than the TAU group for coping (large ES) and HrQOL domains of Social Functioning (large ES) and Vitality (large ES). Most treatment gains were not sustained at 3-month follow-up. CALM was feasible, requiring <12 min. for setup and scheduling, and allowed seamless participation when hospitalized. Mean scores for acceptability and satisfaction indicated that most participants either agreed or strongly agreed that CALM was acceptable and satisfactory. CONCLUSIONS CALM shows promise as an intervention to reduce symptoms of depression and anxiety and improve coping and HrQOL. Next steps are to add a booster session and examine CALM via a multi-site RCT.",2021,"At post-intervention, the CALM group had a lower mean score than the TAU group for depression (medium ES) and anxiety (large ES).","['adults with cystic fibrosis', 'Adults with cystic fibrosis (awCF']","['TAU', 'CALM', 'CF (CALM) intervention', 'six telehealth sessions (CALM; n\xa0=\xa015) or treatment-as-usual (TAU', 'telehealth intervention']","['depression and anxiety', 'Mean scores for acceptability and satisfaction', 'feasibility, acceptability, and satisfaction', 'symptoms of depression and anxiety', 'HrQOL domains of Social Functioning (large ES) and Vitality (large ES', 'coping self-efficacy and health-related quality of life (HrQOL', 'Effect size (ES', 'symptoms of depression and anxiety and improve coping and HrQOL']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0010674', 'cui_str': 'Cystic fibrosis'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0554224,"At post-intervention, the CALM group had a lower mean score than the TAU group for depression (medium ES) and anxiety (large ES).","[{'ForeName': 'Christina J', 'Initials': 'CJ', 'LastName': 'Bathgate', 'Affiliation': 'Department of Medicine, National Jewish Health, 1400 Jackson St., M107D, Denver, CO 80206, USA. Electronic address: bathgatec@njhealth.org.'}, {'ForeName': 'Kristin M', 'Initials': 'KM', 'LastName': 'Kilbourn', 'Affiliation': 'Department of Psychology, University of Colorado Denver, 1200 Larimer St, Denver, CO 80204, USA.'}, {'ForeName': 'Nora H', 'Initials': 'NH', 'LastName': 'Murphy', 'Affiliation': 'Department of Medicine, National Jewish Health, 1400 Jackson St., M107D, Denver, CO 80206, USA.'}, {'ForeName': 'Frederick S', 'Initials': 'FS', 'LastName': 'Wamboldt', 'Affiliation': 'Department of Medicine, National Jewish Health, 1400 Jackson St., M107D, Denver, CO 80206, USA.'}, {'ForeName': 'Kristen E', 'Initials': 'KE', 'LastName': 'Holm', 'Affiliation': 'Department of Medicine, National Jewish Health, 1400 Jackson St., M107D, Denver, CO 80206, USA.'}]",Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,['10.1016/j.jcf.2021.07.012'] 2250,34366227,The right pick: Does a self-assessment measurement tool correctly identify health care consumers with inadequate health literacy?,"OBJECTIVES The aim of this study was to investigate whether a self-report measurement instrument (the Brief Health Literacy Screen, BHLS) correctly identifies healthcare consumers with inadequate health literacy. The yardstick for assessing the tool was the Newest Vital Sign (NVS). METHODS The study used baseline data from the Västerbotten Intervention Programme - VIsualiZation of Asymptomatic Atherosclerotic disease for Optimum Cardiovascular Prevention (VIPVIZA), a randomized controlled trial that is nested within the Västerbotten Intervention Program (VIP) in Sweden. Our analyses were computed on a subsample of 460 persons who underwent the measure of both health literacy scales. ROC analysis was used for the crucial computations. RESULTS The potential of the BHLS to identify healthcare consumers with inadequate health literacy remained unsatisfying for the complete sample, but reached an acceptable level for women and persons with only basic education. CONCLUSIONS The relationship is somewhat weaker than in comparable research in various other European countries. The differences might partly have been caused by the use of self-perception questions. Self-delusions, invariably a part of self-perception, may have affected the respective measure. PRACTICE IMPLICATIONS Caution is advised when patients' health literacy is assessed by only a few questions for self-report.",2021,"The potential of the BHLS to identify healthcare consumers with inadequate health literacy remained unsatisfying for the complete sample, but reached an acceptable level for women and persons with only basic education. ","['VIP) in Sweden', 'healthcare consumers with inadequate health literacy', '460 persons who underwent the measure of both health literacy scales']","['Västerbotten Intervention Program', 'Optimum Cardiovascular Prevention (VIPVIZA', 'self-report measurement instrument (the Brief Health Literacy Screen, BHLS']",[],"[{'cui': 'C0042395', 'cui_str': 'vasoactive intestinal peptide'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]",[],,0.0473957,"The potential of the BHLS to identify healthcare consumers with inadequate health literacy remained unsatisfying for the complete sample, but reached an acceptable level for women and persons with only basic education. ","[{'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Schulz', 'Affiliation': 'Institute of Communication and Health, University of Italian Switzerland, Lugano, Switzerland. Electronic address: peter.schulz@usi.ch.'}, {'ForeName': 'Bernt', 'Initials': 'B', 'LastName': 'Lindahl', 'Affiliation': 'Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. Electronic address: bernt.lindahl@umu.se.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Hartung', 'Affiliation': 'Institute of Communication and Health, University of Italian Switzerland, Lugano, Switzerland. Electronic address: uwe.hartung@usi.ch.'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Naslund', 'Affiliation': 'Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. Electronic address: ulf.naslund@umu.se.'}, {'ForeName': 'Margareta', 'Initials': 'M', 'LastName': 'Norberg', 'Affiliation': 'Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden. Electronic address: margareta.norberg@umu.se.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Nordin', 'Affiliation': 'Department of Psychology, Umeå University, Umeå, Sweden. Electronic address: steven.nordin@umu.se.'}]",Patient education and counseling,['10.1016/j.pec.2021.07.045'] 2251,34366223,"Corrigendum to ""Efficacy of Anise (Pimpinella anisum L.) oil for migraine headache: A pilot randomized placebo-controlled clinical trial"" [J. Ethnopharmacol. 236 (2019) 155-160].",,2021,,"['migraine headache', '236 (2019']","['Anise (Pimpinella anisum L.) oil', 'placebo']",[],"[{'cui': 'C0149931', 'cui_str': 'Migraine'}]","[{'cui': 'C1138839', 'cui_str': 'Anise Seed Extract'}, {'cui': 'C1135879', 'cui_str': 'Pimpinella anisum'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.348567,,"[{'ForeName': 'Seyed Hamdollah', 'Initials': 'SH', 'LastName': 'Mosavat', 'Affiliation': 'Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Abbas Rahimi', 'Initials': 'AR', 'LastName': 'Jaberi', 'Affiliation': 'Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: rahimeia@sums.ac.ir.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Sobhani', 'Affiliation': 'Quality Control Department, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Mosaffa-Jahromi', 'Affiliation': 'Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Iraji', 'Affiliation': 'Central Research Laboratory, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Moayedfard', 'Affiliation': 'Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: mosavath@sums.ac.ir.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.113111'] 2252,34366153,Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers.,"PURPOSE Henagliflozin is a highly selective and effective sodium glucose co-transporter (SGLT)-2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the effects of meal intake on the pharmacokinetic properties of henagliflozin, and to understand the excretion pathways of henagliflozin in humans. METHODS In this Phase I, randomized, open-label, single-dose, two-period crossover study, 12 healthy male Chinese volunteers were randomized to receive either henagliflozin 10 mg in the fasted condition followed by henagliflozin 10 mg in the fed condition, or the reverse schedule, with the two administrations separated by a washout period of at least 7 days. Samples of blood, urine, and feces were collected and analyzed for the investigation of the pharmacokinetic profile and excretion pathways in the fasted and fed conditions. Any adverse events that occurred throughout the study were recorded for tolerability assessment. FINDINGS After the administration of a single oral dose of henagliflozin, mean (SD) plasma AUC 0-∞ and C max were 1200 (274) h · ng/mL and 179 (48.8) ng/mL, respectively, in the fasted state and were decreased to 971 (245) h · ng/mL and 115 (34.2) ng/mL in the fed state. The fed/fasted ratios (90% CIs) of the geometric mean values of C max , AUC 0-t , and AUC 0-∞ were 64% (54%-76%), 80% (76%-85%), and 80% (76%-85%), respectively. The median (range) T max was prolonged from 1.5 (1-3) hours in the fasted condition to 2 (1.5-6) hours in the fed condition. Mass-balance testing revealed that henagliflozin was eliminated primarily as the parent drug in feces and as glucuronide metabolites in urine. In the fasted state, the cumulative excretion percentages of the parent drug and its metabolites to dose in feces and urine were 40.6% and 33.9%, respectively. The values in the fed condition were changed to 50.4% and 25.5%, respectively. These findings suggest that postprandial administration decreases the absorption rate and the extent of henagliflozin exposure in humans, but has no effect on the metabolism or elimination of the drug. IMPLICATIONS In the present study, the consumption of a high-fat meal prior to henagliflozin administration was associated with reductions in AUC 0-∞ and C max of 19.4% and 36.4%, respectively. However, based on the analysis of the pharmacokinetic/pharmacodynamic findings on henagliflozin, this slight change may not have clinical significance. Mass balance of henagliflozin in humans was achieved with ∼75% of the administered dose recovered in excretions within 4 days after administration whether in the fasted or fed state. These findings suggest that henagliflozin tablets can be administered with or without food.",2021,The median (range) T max was prolonged from 1.5 (1-3) hours in the fasted condition to 2 (1.5-6) hours in the fed condition.,"['patients with type 2 diabetes mellitus (T2DM', 'humans', 'Healthy Male Volunteers', '12 healthy male Chinese volunteers']","['henagliflozin', 'henagliflozin 10 mg in the fasted condition followed by henagliflozin', 'henagliflozin tablets', 'Henagliflozin']","['absorption rate', 'cumulative excretion percentages', 'tolerability assessment', 'median (range) T max', 'Mass balance of henagliflozin', 'geometric mean values of C max , AUC 0-t , and AUC 0-∞', 'Pharmacokinetic Properties and Mass Balance of Henagliflozin']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C4309480', 'cui_str': 'henagliflozin'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C4309480', 'cui_str': 'henagliflozin'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0871161', 'cui_str': 'Property'}]",12.0,0.0605815,The median (range) T max was prolonged from 1.5 (1-3) hours in the fasted condition to 2 (1.5-6) hours in the fed condition.,"[{'ForeName': 'Zhen-Dong', 'Initials': 'ZD', 'LastName': 'Chen', 'Affiliation': 'State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Shanghai Xuhui Central Hospital, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.'}, {'ForeName': 'Yun-Ting', 'Initials': 'YT', 'LastName': 'Zhu', 'Affiliation': 'State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.'}, {'ForeName': 'Yi-Fan', 'Initials': 'YF', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhan', 'Affiliation': 'State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.'}, {'ForeName': 'Xiao-Fei', 'Initials': 'XF', 'LastName': 'Chen', 'Affiliation': 'Shanghai Xuhui Central Hospital, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Liang', 'Affiliation': 'Shanghai Xuhui Central Hospital, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.'}, {'ForeName': 'Jing-Ying', 'Initials': 'JY', 'LastName': 'Jia', 'Affiliation': 'Shanghai Xuhui Central Hospital, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Shanghai Xuhui Central Hospital, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.'}, {'ForeName': 'Hai-Yan', 'Initials': 'HY', 'LastName': 'Liu', 'Affiliation': 'Jiangsu Hengrui Pharmaceuticals Company Ltd, Lianyungang, China.'}, {'ForeName': 'Jian-Jun', 'Initials': 'JJ', 'LastName': 'Zou', 'Affiliation': 'Jiangsu Hengrui Pharmaceuticals Company Ltd, Lianyungang, China.'}, {'ForeName': 'Yan-Mei', 'Initials': 'YM', 'LastName': 'Liu', 'Affiliation': 'Shanghai Xuhui Central Hospital, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China. Electronic address: ymliu@shxh-centerlab.com.'}, {'ForeName': 'Da-Fang', 'Initials': 'DF', 'LastName': 'Zhong', 'Affiliation': 'State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. Electronic address: dfzhong@simm.ac.cn.'}]",Clinical therapeutics,['10.1016/j.clinthera.2021.07.008'] 2253,34366152,Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.,"PURPOSE Limited information is available on acute treatments for migraine in elderly patients. Our objective was to evaluate the tolerability and safety of lasmiditan, a serotonin 1F agonist, for the acute treatment of migraine in elderly compared with nonelderly patients, with special emphasis on cardiovascular-related issues because cardiovascular comorbidities are more common in the elderly population. METHODS These post hoc analyses evaluated the incidence of treatment-emergent adverse events (TEAEs) in elderly (≥65 years of age) versus nonelderly (<65 years of age) lasmiditan-treated patients. Two clinical trials entitled A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne (SAMURAI) and A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe (SPARTAN) were randomized, double-blind, placebo-controlled, Phase III studies in adults (no upper age limit) who took placebo or lasmiditan 50 (SPARTAN only), 100, or 200 mg for a single migraine attack within 4 hours of the onset of moderate or severe pain. Patients who completed SAMURAI or SPARTAN were eligible to enroll in An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR), a Phase III, randomized, open-label, multiattack study of lasmiditan 100 or 200 mg. For pooled SAMURAI+SPARTAN data, treatment × age subgroup interactions were examined using logistic regression analyses. In addition, common cardiovascular event rates were assessed from GLADIATOR during 3 periods: treatment-emergent (<48 hours after dosing), intermediate (48 hours to 1 week after dosing), and remote (>1 week after dosing). FINDINGS Of 3177 lasmiditan-treated patients in SAMURAI or SPARTAN, 132 (4.2%) were elderly, and of 1262 placebo-treated patients, 54 (4.3%) were elderly. Of 2030 lasmiditan-treated patients in GLADIATOR, 85 (4.2%) were elderly. The incidences of at least 1 TEAE with lasmiditan in nonelderly and elderly patients with migraine were 36% and 35% in pooled SAMURAI+SPARTAN, respectively, and 49% and 38% in GLADIATOR, respectively. No significant treatment × age subgroup interactions were observed in patients with ≥1 TEAE overall or for any individual TEAE in pooled SPARTAN+SAMURAI; however, numerical differences in the incidence of some specific TEAEs were seen. No treatment × age subgroup interactions and no tolerability concerns for individual TEAEs were detected. Cardiovascular TEAEs were much more frequent in the nonelderly population than the elderly population. Cardiovascular events were not reported in the elderly population during the treatment-emergent period or intermediate period. There were 2 cases of increased blood pressure in elderly patients during the remote period. IMPLICATIONS The incidence of TEAEs was similar for elderly and nonelderly patients, and cardiovascular safety of lasmiditan was generally consistent with that in single-attack studies. No safety signals were observed with the limited number of patients in the elderly population. ClinicalTrials.gov identifiers: NCT02565186 (GLADIATOR), NCT02439320 (SAMURAI), and NCT02605174 (SPARTAN).",2021,"No significant treatment × age subgroup interactions were observed in patients with ≥1 TEAE overall or for any individual TEAE in pooled SPARTAN+SAMURAI; however, numerical differences in the incidence of some specific TEAEs were seen.","['Of 3177 lasmiditan-treated patients in SAMURAI or SPARTAN, 132 (4.2%) were elderly, and of 1262 placebo-treated patients, 54 (4.3%) were elderly', 'elderly patients', 'Of 2030 lasmiditan-treated patients in GLADIATOR, 85 (4.2%) were elderly', 'migraine in elderly compared with nonelderly patients', 'elderly (≥65 years of age) versus nonelderly (<65 years of age) lasmiditan-treated patients', 'Elderly Patients With Migraine']","['Lasmiditan', 'LAsmiDItan', 'Placebo', 'Lasmiditan Treatment', 'placebo', 'LAsMiditan', 'placebo or lasmiditan']","['Cardiovascular events', 'tolerability and safety', 'cardiovascular safety of lasmiditan', 'incidence of TEAEs', 'Tolerability and Safety', 'blood pressure']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4517759', 'cui_str': '4.3'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",,0.159353,"No significant treatment × age subgroup interactions were observed in patients with ≥1 TEAE overall or for any individual TEAE in pooled SPARTAN+SAMURAI; however, numerical differences in the incidence of some specific TEAEs were seen.","[{'ForeName': 'Vincent T', 'Initials': 'VT', 'LastName': 'Martin', 'Affiliation': 'Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.'}, {'ForeName': 'Zubair', 'Initials': 'Z', 'LastName': 'Ahmed', 'Affiliation': 'Department of Neurology, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Helen M', 'Initials': 'HM', 'LastName': 'Hochstetler', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana. Electronic address: hochstetler_helen_m@lilly.com.'}, {'ForeName': 'Simin K', 'Initials': 'SK', 'LastName': 'Baygani', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Dong', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Paula M', 'Initials': 'PM', 'LastName': 'Hauck', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Rashna', 'Initials': 'R', 'LastName': 'Khanna', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}]",Clinical therapeutics,['10.1016/j.clinthera.2021.04.004'] 2254,34366134,Colleagues Meeting to Promote and Sustain Satisfaction (COMPASS) Groups for Physician Well-Being: A Randomized Clinical Trial.,"OBJECTIVE To evaluate physician small groups to promote physician well-being in a scenario with provided discussion topics but without trained facilitators, and for which protected time was not provided but meal expenses were compensated. PARTICIPANTS AND METHODS We conducted a randomized controlled trial of 125 practicing physicians in the Department of Medicine, Mayo Clinic, Rochester, Minnesota, between October 2013 and October 2014 with subsequent assessment of organizational program implementation. Twelve biweekly self-facilitated discussion groups involving reflection, shared experience, and small-group learning took place over 6 months. Main outcome measures included meaning in work, burnout, symptoms of depression, quality of life, social support, and job satisfaction assessed using validated metrics. RESULTS At 6 months after completion of the intervention (12 months from baseline), the rate of overall burnout had decreased by 12.7% (31/62 to 19/51) in the intervention arm versus a 1.9% increase (25/61 to 24/56) in the control arm (P<.001). The rate of depressive symptoms had decreased by 12.8% (29/62 to 17/50) in the intervention arm versus a 1.1% increase (20/61 to 19/56) in the control arm (P<.001). The proportion of physicians endorsing at least moderate self-reported likelihood of leaving their current practice in the subsequent 2 years had decreased by 1.9% (17/62 to 13/51) in the intervention arm and increased by 6.1% (14/61 to 16/55) in the control arm (P<.001). No statistically significant differences were seen in mean changes in burnout scale scores, meaning, or social support, although numeric differences generally favored the intervention. CONCLUSION Self-facilitated physician small-group meetings improved burnout, depressive symptoms, and job satisfaction. This intervention represents a low-cost strategy to promote important dimensions of physician well-being. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT04466423.",2021,"No statistically significant differences were seen in mean changes in burnout scale scores, meaning, or social support, although numeric differences generally favored the intervention. ","['125 practicing physicians in the Department of Medicine, Mayo Clinic, Rochester, Minnesota, between October 2013 and October\xa02014 with subsequent assessment of organizational program implementation']",[],"['mean changes in burnout scale scores, meaning, or social support', 'rate of overall burnout', 'rate of depressive symptoms', 'burnout, depressive symptoms, and job satisfaction', 'Sustain Satisfaction (COMPASS', 'meaning in work, burnout, symptoms of depression, quality of life, social support, and job satisfaction assessed using validated metrics']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0026183', 'cui_str': 'Minnesota'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0029246', 'cui_str': 'Organizations'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0022397', 'cui_str': 'Work Satisfaction'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0699680', 'cui_str': 'Metric'}]",,0.066725,"No statistically significant differences were seen in mean changes in burnout scale scores, meaning, or social support, although numeric differences generally favored the intervention. ","[{'ForeName': 'Colin P', 'Initials': 'CP', 'LastName': 'West', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN. Electronic address: west.colin@mayo.edu.'}, {'ForeName': 'Liselotte N', 'Initials': 'LN', 'LastName': 'Dyrbye', 'Affiliation': 'Division of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Daniel V', 'Initials': 'DV', 'LastName': 'Satele', 'Affiliation': 'Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Tait D', 'Initials': 'TD', 'LastName': 'Shanafelt', 'Affiliation': 'Division of Hematology, Department of Medicine, Stanford University, Palo Alto, CA.'}]",Mayo Clinic proceedings,['10.1016/j.mayocp.2021.02.028'] 2255,34366004,"Drug Safety for Nursing-Home Residents - Findings of a Pragmatic, Cluster-Randomized, Controlled Intervention Trial in 44 Nursing Homes.","BACKGROUND The safety of drug use by nursing-home residents can be impaired by polypharmacy, potentially inappropriate medications (PIM), and neuroleptics, as well as by a lack of adequate interprofessional coordination in the nursing home. The goal of the HIOPP-3- iTBX Trial was to improve drug safety in nursing-home residents, including a reduction of PIM and/or neuroleptic use, by means of a complex interprofessional intervention. METHODS This cluster-randomized, controlled trial was performed in nursing homes in Germany. Residents over age 65 were included in the trial. The intervention was carried out over six months and consisted of four elements: a drug review by trained pharmacists, educational sessions for general practitioners and nurses, a drug safety toolbox, and change management seminars for members of the three participating professions. The nursing homes in the control group continued to provide usual care. The primary endpoint was the prescription of at least one PIM and/or at least two neuroleptic drugs simultaneously. The secondary endpoints were the incidence of falls and hospitalizations, quality of life, and health-care costs. This trial is registered in the German Clinical Trials Registry (DRKS00013588). RESULTS 44 nursing homes with 862 residents were randomized, 23 of them (with 452 residents) to the intervention group and 21 (with 410 residents) to the control group. 41% of all nursinghome residents initially took at least one PIM and/or at least two neuroleptic drugs simultaneously. Follow-up data (including, among other things, the current drug regimen) were obtained for 773 residents. The intention-to-treat analysis continued to show no difference between the intervention group and the control group with respect to the primary endpoint. CONCLUSION This trial of an intervention to improve drug safety in nursing homes led neither to reduced prescribing of PIM and/or neuroleptic drugs, nor to any improvement in the overall health status of the nursing-home residents.",2021,"This trial of an intervention to improve drug safety in nursing homes led neither to reduced prescribing of PIM and/or neuroleptic drugs, nor to any improvement in the overall health status of the nursing-home residents.","['nursing homes in Germany', '773 residents', 'nursing-home residents', '44 Nursing Homes', '44 nursing homes with 862 residents were randomized, 23 of them (with 452 residents) to the intervention group and 21 (with 410 residents) to the control group', 'nursing homes', 'Residents over age 65 were included in the trial']",[],"['prescription of at least one PIM', 'incidence of falls and hospitalizations, quality of life, and health-care costs']","[{'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C4042848', 'cui_str': 'PIM List'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0085552', 'cui_str': 'Health Costs'}]",862.0,0.0593783,"This trial of an intervention to improve drug safety in nursing homes led neither to reduced prescribing of PIM and/or neuroleptic drugs, nor to any improvement in the overall health status of the nursing-home residents.","[{'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Junius-Walker', 'Affiliation': ''}, {'ForeName': 'Olaf', 'Initials': 'O', 'LastName': 'Krause', 'Affiliation': ''}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Thürmann', 'Affiliation': ''}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Bernhard', 'Affiliation': ''}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Fuchs', 'Affiliation': ''}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Sparenberg', 'Affiliation': ''}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Wollny', 'Affiliation': ''}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Stolz', 'Affiliation': ''}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Haumann', 'Affiliation': ''}, {'ForeName': 'Antje', 'Initials': 'A', 'LastName': 'Freytag', 'Affiliation': ''}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Kirsch', 'Affiliation': ''}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Usacheva', 'Affiliation': ''}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Wilm', 'Affiliation': ''}, {'ForeName': 'Birgitt', 'Initials': 'B', 'LastName': 'Wiese', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Deutsches Arzteblatt international,['10.3238/arztebl.m2021.0297'] 2256,34365905,"A double-blind, 377-subject randomized study identifies Ruminococcus, Coprococcus, Christensenella , and Collinsella as long-term potential key players in the modulation of the gut microbiome of lactose intolerant individuals by galacto-oligosaccharides.","Background . Our recent publication (Chey et al., Nutrients 2020) showed that a 30-day administration of pure galacto-oligosaccharides (GOS) significantly reduced symptoms and altered the fecal microbiome in patients with lactose intolerance (LI). Results . In this addendum, we performed an in-depth analysis of the fecal microbiome of the 377 LI patients randomized to one of two GOS doses (Low, 10-15 grams/day or High, 15-20 grams/day), or placebo in a multi-center, double-blinded, placebo-controlled trial. Sequencing of 16S rRNA amplicons was done on GOS or placebo groups at weeks zero (baseline), four (end of treatment), nine, 16 and 22. Taxa impacted by treatment and subsequent dairy consumption included lactose-fermenting species of Bifidobacterium, Lactobacillus, Lactococcus , and Streptococcus . Increased secondary fermentation microorganisms included Coprococcus and Ruminococcus species, Blautia producta , and Methanobrevibacterium . Finally, tertiary fermenters that use acetate to generate butyrate were also increased, including Faecalibacterium prausnitzii, Roseburia faecis , and C. eutactus . Conclusions . Results confirmed and expanded data on GOS microbiome modulation in LI individuals. Microbiome analysis at 16 and 22 weeks after treatment further suggested relatively long-term benefits when individuals continued consumption of dairy products.",2021,Microbiome analysis at 16 and 22 weeks after treatment further suggested relatively long-term benefits when individuals continued consumption of dairy products.,"['lactose intolerant individuals by galacto-oligosaccharides', 'patients with lactose intolerance (LI', 'LI individuals', '377 LI patients']","['placebo', 'pure galacto-oligosaccharides (GOS']","['GOS microbiome modulation', 'lactose-fermenting species of Bifidobacterium, Lactobacillus, Lactococcus , and Streptococcus ', 'Increased secondary fermentation microorganisms included Coprococcus and Ruminococcus species, Blautia producta , and Methanobrevibacterium ', 'fecal microbiome', 'Faecalibacterium prausnitzii, Roseburia faecis , and C. eutactus ']","[{'cui': 'C0860475', 'cui_str': 'Lactose intolerant'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0028959', 'cui_str': 'Oligosaccharide'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022951', 'cui_str': 'Intolerance to lactose'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0028959', 'cui_str': 'Oligosaccharide'}]","[{'cui': 'C0028959', 'cui_str': 'Oligosaccharide'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0022949', 'cui_str': 'Lactose'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0085549', 'cui_str': 'Lactococcus'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0015852', 'cui_str': 'Fermentation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1004293', 'cui_str': 'Coprococcus'}, {'cui': 'C0318074', 'cui_str': 'Ruminococcus'}, {'cui': 'C0317943', 'cui_str': 'Blautia producta'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0317558', 'cui_str': 'Faecalibacterium prausnitzii'}, {'cui': 'C0995401', 'cui_str': 'Roseburia'}]",,0.472337,Microbiome analysis at 16 and 22 weeks after treatment further suggested relatively long-term benefits when individuals continued consumption of dairy products.,"[{'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Azcarate-Peril', 'Affiliation': 'Department of Medicine, Division of Gastroenterology and Hepatology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Roach', 'Affiliation': 'UNC Microbiome Core, Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Marsh', 'Affiliation': 'Department of Medicine, Division of Gastroenterology and Hepatology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Chey', 'Affiliation': 'Departments of Internal Medicine and Nutritional Sciences, University of Michigan Health System, Ann Arbor, MI, USA.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Sandborn', 'Affiliation': 'Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Ritter', 'Affiliation': 'Ritter Pharmaceuticals, Inc, Los Angeles, CA, USA.'}, {'ForeName': 'Dennis A', 'Initials': 'DA', 'LastName': 'Savaiano', 'Affiliation': 'Department of Nutrition Science, Purdue University, West Lafayette, IN, USA.'}, {'ForeName': 'T R', 'Initials': 'TR', 'LastName': 'Klaenhammer', 'Affiliation': 'Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, NC, USA.'}]",Gut microbes,['10.1080/19490976.2021.1957536'] 2257,34365900,Effects of FFP2/N95 face mask on low- and high-load resistance exercise performance in recreational weight lifters.,"COVID-19 pandemic, has led to several countries adopting the use of masks in public spaces. Mask used during physical exercise it may induce early fatigue. However, despite the results with aerobic exercise, as far as we know, no studies have been carried out on wearing a mask during resistance exercise.This randomized, crossover study verified the acute effect of an FFP2/N95 face mask on moderate- and high-load upper body resistance exercise performance in recreational weight lifters.The FFP2/N95 face mask impacted performance, evaluated with bar velocity, in the high-intensity resistance bench press exercise until movement failure but decreased oxygen saturation and increased rate of perceived effort only in the moderate-intensity exercise.",2021,"The FFP2/N95 face mask impacted performance, evaluated with bar velocity, in the high-intensity resistance bench press exercise until movement failure but decreased oxygen saturation and increased rate of perceived effort only in the moderate-intensity exercise.",['recreational weight lifters'],"['aerobic exercise', 'FFP2/N95 face mask']",['low- and high-load resistance exercise performance'],"[{'cui': 'C0436543', 'cui_str': 'Weight lifter'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0024861', 'cui_str': 'Mask'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0112497,"The FFP2/N95 face mask impacted performance, evaluated with bar velocity, in the high-intensity resistance bench press exercise until movement failure but decreased oxygen saturation and increased rate of perceived effort only in the moderate-intensity exercise.","[{'ForeName': 'Bruno Viana', 'Initials': 'BV', 'LastName': 'Rosa', 'Affiliation': ""Master's student in Science and Health, Immunometabolism of Skeletal Muscle and Exercise Research Group and Nucleus of Study in Physiology Applied to Performance and Health (NEFADS), Department of Physical Education, Federal University of Piaui (UFPI), Teresina-PI, Brazil.""}, {'ForeName': 'Fabrício Eduardo', 'Initials': 'FE', 'LastName': 'Rossi', 'Affiliation': 'Immunometabolism of Skeletal Muscle and Exercise Research Group, Department of Physical Education and Associate Professor at Graduation Program in Science and Health, Federal University of Piaui (UFPI), Teresina-PI, Brazil.'}, {'ForeName': 'Helton Pereira Dos Santos Nunes de', 'Initials': 'HPDSN', 'LastName': 'Moura', 'Affiliation': ""Master's student in Science and Health and Immunometabolism of Skeletal Muscle and Exercise Research Group, Department of Physical Education, Federal University of Piaui (UFPI), Teresina-PI, Brazil.""}, {'ForeName': 'Arilene Maria da Silva', 'Initials': 'AMDS', 'LastName': 'Santos', 'Affiliation': ""Master's student in Science and Health and Immunometabolism of Skeletal Muscle and Exercise Research Group, Department of Physical Education, Federal University of Piaui (UFPI), Teresina-PI, Brazil.""}, {'ForeName': 'Acácio Salvador', 'Initials': 'AS', 'LastName': 'Véras-Silva', 'Affiliation': 'Department of Biophysics and Physiology, Federal University of Piaui, Teresina-PI, Brazil.'}, {'ForeName': 'Sérgio Luís Galan', 'Initials': 'SLG', 'LastName': 'Ribeiro', 'Affiliation': 'Department of Biophysics and Physiology, Federal University of Piaui, Teresina-PI, Brazil.'}, {'ForeName': 'Fabio Yuzo', 'Initials': 'FY', 'LastName': 'Nakamura', 'Affiliation': 'Research Center in Sports Sciences, Health Sciences, and Human Development, University Institute of Maia, Maia, Portugal. . Associate Graduate Program in Physical Education Universidade de Pernambuco/Universidade Federal da Paraíba, João Pessoa, Brazil.'}, {'ForeName': 'Marcos Antonio', 'Initials': 'MA', 'LastName': 'Pereira Dos Santos', 'Affiliation': 'Nucleus of Study in Physiology Applied to Performance and Health (NEFADS), Department of Biophysics and Physiology, Federal University of Piaui, Teresina-PI, Brazil.'}]",European journal of sport science,['10.1080/17461391.2021.1953613'] 2258,34365883,Exergaming improves balance in children with spastic cerebral palsy with low balance performance: results from a multicenter controlled trial.,"PURPOSE Previous studies investigating the effectiveness of exergame balance-training (using video-games) in children with cerebral palsy (CP) yielded inconsistent results that could be related to underpowered studies. Therefore, in this multicenter intervention study, we investigated whether exergaming improves balance clinically in spastic CP. MATERIALS AND METHODS In total, 35 children with unilateral or bilateral spastic CP (GMFCS-level I-II) were included (age-range: 7-16 years); 16 at VUMC (trial: NTR6034), 19 at UHG (trial: NCT03219112). All participants received care as usual. The intervention group ( n  = 24) additionally performed exergame-training; 6-8 weeks home-based X-box One Kinect training focused on balance. Balance performance was assessed with the pediatric balance scale (PBS) and two subscales of the Bruininks-Oseretsky Test of Motor Proficiency-2nd edition (""balance"" [BOTbal] and ""running speed and agility"" [BOTrsa]). Mixed model ANOVAs with between and within factors were used to test differences between and within groups. RESULTS On group level, no post-intervention differences were found between the intervention and control group (PBS: p  = 0.248, η p 2 = 0.040; BOTbal: p  = 0.374, η p 2 = 0.024; BOTrsa: p  = 0.841, η p 2 = 0.001). Distribution of CP-symptoms (unilateral versus bilateral) did not affect training (PBS: p  = 0.373, η p 2 = 0.036; BOTbal: p  = 0.127, η p 2 = 0.103; BOTrsa: p  = 0.474, η p 2 = 0.024). Children with low baseline balance performance (based on PBS) in the intervention group showed improvements in balance performance after training (PBS: p  = 0.003, η p 2 = 0.304; BOTbal: p  = 0.008, η p 2 = 0.258), whereas children with high baseline balance performance did not. CONCLUSIONS This exergame-training resulted in balance improvements for the current population of CP that had a low baseline function.IMPLICATIONS FOR REHABILITATIONExergame-training (training using video-games) shows mixed results in children with cerebral palsy (CP).Children with spastic CP (GMFCS level I-II) with a high baseline balance-level did not show functional balance improvements after this home-based exergame-training, suggesting that these children should not be enrolled in this type of exergame-training protocol.Children with spastic CP (GMFCS level I-II) with a low baseline balance-level showed clinically relevant functional balance improvements after this home-based exergame-training, suggesting that these children can benefit from enrolment in this type of exergame-training protocol to improve their balance.The distribution of CP-symptoms did not affect the effectiveness of this balance exergame-training in children with spastic CP with GMFCS-level I and II.",2021,"Distribution of CP-symptoms (unilateral versus bilateral) did not affect training (PBS: p  = 0.373, η p 2 = 0.036; BOTbal: p  = 0.127, η p 2 = 0.103; BOTrsa: p  = 0.474, η p 2 = 0.024).","['Children with spastic CP (GMFCS level I-II', 'children with spastic CP with GMFCS-level I and II', 'children with cerebral palsy (CP).Children with spastic CP (GMFCS level I-II', 'spastic CP', '35 children with unilateral or bilateral spastic CP (GMFCS-level I-II) were included (age-range: 7-16\u2009years', 'children with spastic cerebral palsy with low balance performance', 'children with cerebral palsy (CP']","['exergame-training; 6-8\u2009weeks home-based X-box One Kinect training', 'exergame balance-training (using video-games']","['pediatric balance scale (PBS) and two subscales of the Bruininks-Oseretsky Test of Motor Proficiency-2nd edition (""balance"" [BOTbal] and ""running speed and agility"" [BOTrsa', 'Distribution of CP-symptoms', 'balance performance', 'Balance performance']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy'}, {'cui': 'C0441925', 'cui_str': 'Level I'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C3838784', 'cui_str': 'Bilateral cerebral palsy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0441792', 'cui_str': 'Editions'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",35.0,0.0176216,"Distribution of CP-symptoms (unilateral versus bilateral) did not affect training (PBS: p  = 0.373, η p 2 = 0.036; BOTbal: p  = 0.127, η p 2 = 0.103; BOTrsa: p  = 0.474, η p 2 = 0.024).","[{'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Meyns', 'Affiliation': 'Rehabilitation Research (REVAL), Rehabilitation Sciences, Hasselt University, Hasselt, Belgium.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Blanckaert', 'Affiliation': 'Pediatric Rehabilitation, Rehabilitation Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Chloé', 'Initials': 'C', 'LastName': 'Bras', 'Affiliation': 'Amsterdam Movement Sciences, Rehabilitation Medicine, Amsterdam UMC locatie VUmc, Amsterdam, The Netherlands.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Jacobs', 'Affiliation': 'Rehabilitation Research (REVAL), Rehabilitation Sciences, Hasselt University, Hasselt, Belgium.'}, {'ForeName': 'Jaap', 'Initials': 'J', 'LastName': 'Harlaar', 'Affiliation': 'Amsterdam Movement Sciences, Rehabilitation Medicine, Amsterdam UMC locatie VUmc, Amsterdam, The Netherlands.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'van de Pol', 'Affiliation': 'Child Neurology, Amsterdam UMC locatie VUmc, Amsterdam, The Netherlands.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Plasschaert', 'Affiliation': 'Cerebral Palsy Reference Center, University Hospital Ghent, Ghent, Belgium.'}, {'ForeName': 'Hilde', 'Initials': 'H', 'LastName': 'Van Waelvelde', 'Affiliation': 'Pediatric Rehabilitation, Rehabilitation Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Annemieke I', 'Initials': 'AI', 'LastName': 'Buizer', 'Affiliation': 'Amsterdam Movement Sciences, Rehabilitation Medicine, Amsterdam UMC locatie VUmc, Amsterdam, The Netherlands.'}]",Disability and rehabilitation,['10.1080/09638288.2021.1954704'] 2259,34365872,Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.,"OBJECTIVE In PSO-LONG, long-term proactive management (PAM) of psoriasis with fixed-dose combination calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) aerosol foam was superior to conventional reactive management. This post-hoc analysis investigated long-term PAM with Cal/BD foam in PSO-LONG patients who could be more susceptible to corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression. METHODS Efficacy and safety of PAM with Cal/BD foam (twice-weekly) versus reactive management (twice-weekly vehicle foam), with once-daily rescue Cal/BD foam for four weeks following relapse, was assessed in the HPA subgroup ( n  = 66); patients had moderate-to-severe psoriasis (physician global assessment score ≥3; 10-30% body surface area affected). Primary endpoint was time to first relapse. RESULTS PAM with Cal/BD foam was associated with longer median time to first relapse (111 versus 31 days), reduced risk of first relapse (hazard ratio: 0.49; p  = .029), greater proportion of days in remission (17%; p  = .001) and reduced rate of relapse (60% reduction; p  < .001) than reactive management. Adverse events occurred in 37.5% (PAM) and 47.1% (reactive management) of patients, with no new safety signals. No clinically significant HPA-axis suppression was observed. CONCLUSION Efficacy of PAM with Cal/BD foam is maintained in patients with moderate-to-severe psoriasis, with no new safety signals.",2021,"RESULTS PAM with Cal/BD foam was associated with longer median time to first relapse (111 versus 31 days), reduced risk of first relapse (hazard ratio: 0.49; p  = .029), greater proportion of days in remission (17%; p  = .001) and reduced rate of relapse (60% reduction; p  < .001) than reactive management.","['patients with moderate-to-severe psoriasis', 'patients with plaque psoriasis undergoing HPA-axis testing', 'HPA subgroup ( n \u2009=\u200966); patients had moderate-to-severe psoriasis (physician global assessment score ≥3; 10-30% body surface area affected']","['proactive treatment with twice-weekly topical Cal/BD foam', 'PAM with Cal/BD', 'betamethasone dipropionate', 'PAM with Cal/BD foam (twice-weekly) versus reactive management']","['longer median time to first relapse', 'Efficacy and safety', 'Adverse events', 'HPA-axis suppression', 'proportion of days in remission', 'rate of relapse', 'reduced risk of first relapse', 'time to first relapse']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0020663', 'cui_str': 'Hypothalamic structure'}, {'cui': 'C0032022', 'cui_str': 'Pituitary-Adrenal System'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0001625', 'cui_str': 'Adrenal structure'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}, {'cui': 'C0001721', 'cui_str': 'Affect'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0065767', 'cui_str': 'calcipotriene'}, {'cui': 'C0053523', 'cui_str': 'Betamethasone dipropionate'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C1300563', 'cui_str': 'g/kg'}, {'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3665848', 'cui_str': 'Hypothalamic pituitary adrenal axis suppression'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.0796448,"RESULTS PAM with Cal/BD foam was associated with longer median time to first relapse (111 versus 31 days), reduced risk of first relapse (hazard ratio: 0.49; p  = .029), greater proportion of days in remission (17%; p  = .001) and reduced rate of relapse (60% reduction; p  < .001) than reactive management.","[{'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Papp', 'Affiliation': 'K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada.'}, {'ForeName': 'Zygmunt', 'Initials': 'Z', 'LastName': 'Adamski', 'Affiliation': 'Department of Dermatology, University of Medical Sciences, Poznań, Poland.'}, {'ForeName': 'Lyn', 'Initials': 'L', 'LastName': 'Guenther', 'Affiliation': 'Western University, London, ON, Canada.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Liljedahl', 'Affiliation': 'LEO Pharma, Ballerup, Denmark.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Miasik-Pogodzinska', 'Affiliation': 'Medical Centre DrDerm, Nowy Targ, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Szponar-Bojda', 'Affiliation': 'Non-Public Health Care Centre Med-Laser, Lublin, Poland.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Lynde', 'Affiliation': 'Lynde Dermatology and Probity Medical Research, Markham, ON, Canada.'}, {'ForeName': 'Terri', 'Initials': 'T', 'LastName': 'Nutt', 'Affiliation': 'San Antonio Skin Care and Dermatology Clinic, Shavano Park, TX, USA.'}, {'ForeName': 'Marie Holst', 'Initials': 'MH', 'LastName': 'Mørch', 'Affiliation': 'LEO Pharma, Ballerup, Denmark.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Tyring', 'Affiliation': 'Department of Dermatology, Center for Clinical Studies, University of Texas Health Science Center, Houston, TX, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Werschler', 'Affiliation': 'Premier Clinical Research, Spokane, WA, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Reich', 'Affiliation': 'Department of Dermatology, University of Rzeszów, Rzeszów, Poland.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Sadick', 'Affiliation': 'Department of Dermatology, Weill Medical College of Cornell University, New York, NY, USA.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Turchin', 'Affiliation': 'Brunswick Dermatology Centre, Fredericton, NB, Canada.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Lacour', 'Affiliation': 'Department of Dermatology, University Hospital of Nice, Nice, France.'}]",The Journal of dermatological treatment,['10.1080/09546634.2021.1959501'] 2260,34370573,"Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor.","Taniborbactam (formerly VNRX-5133), an investigational β-lactamase inhibitor active against both serine- and metallo-β-lactamases, is being developed in combination with cefepime to treat serious infections caused by multidrug-resistant gram-negative bacteria. This first-in-human study evaluated the safety and pharmacokinetics of single and multiple doses of taniborbactam in healthy adult subjects. Single doses of 62.5 to 1500 mg taniborbactam and multiple doses of 250 to 750 mg taniborbactam every 8 hours (q8h) for 10 days were examined; all taniborbactam doses were administered as a 2-hour intravenous infusion. No subjects experienced serious adverse events or discontinued treatment due to adverse events. The most common adverse event in both placebo and taniborbactam treated subjects was headache. The pharmacokinetics of taniborbactam were similar to the pharmacokinetics reported for cefepime. Taniborbactam demonstrated dose-proportional pharmacokinetics with low intersubject variability. Following single doses and with extended sampling, the mean terminal elimination half-life ranged from 3.4 to 5.8 hours, however the majority of exposure was characterized by an earlier phase with a half-life of about 2 hours. Following multiple dosing there was minimal accumulation of taniborbactam in plasma. At steady-state, approximately 90% of the administered dose of taniborbactam was recovered in urine as intact drug. There was no appreciable metabolism observed in either plasma or urine samples. (This study is registered at clinicaltrials.gov as NCT02955459.).",2021,No subjects experienced serious adverse events or discontinued treatment due to adverse events.,"['Human Volunteers of Taniborbactam (VNRX-5133', 'healthy adult subjects']","['taniborbactam', 'placebo', 'Taniborbactam', 'Taniborbactam (formerly VNRX-5133']","['Safety and Pharmacokinetics', 'headache', 'serious adverse events']","[{'cui': 'C0020155', 'cui_str': 'Human Volunteers'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0713467,No subjects experienced serious adverse events or discontinued treatment due to adverse events.,"[{'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Dowell', 'Affiliation': 'Pharmacology Development Services, LLC, Collegeville, PA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Dickerson', 'Affiliation': 'PRA Health Sciences, Lenexa, KS.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Henkel', 'Affiliation': 'Venatorx Pharmaceuticals, Inc., Malvern, PA.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.01053-21'] 2261,34375023,Radiation dose for 320-row dose-modulated dynamic coronary CT angiography.,"OBJECTIVES The area detector 320-row CT scanner, which can cover the whole heart in one rotation, can aid in reducing radiation exposure during electrocardiography (ECG)-gated coronary CT angiography (CCTA). Recently, researchers have proposed dose-modulated dynamic CCTA with a 320-row scanner for the detection of functional myocardial ischemia. In the present study, we compared and validated the radiation dose of this method with that of the standard CCTA method and the latest diagnostic reference levels (DRLs). MATERIALS AND METHODS The study included a total of 164 consecutive patients with suspected or known coronary artery disease (CAD) who underwent CCTA with a 320-row scanner. The patients were randomly divided into dynamic and standard CCTA groups, and the CT dose index (CTDIvol) and dose length product (DLP) calculated by the CT system were compared between the two protocols and with the latest DRL. RESULTS Standard and dynamic CCTA scans were performed in 77 and 87 patients, respectively. CTDIvol was significantly higher for standard CCTA than for dynamic CCTA (41 ± 35 mGy vs. 22 ± 7 mGy, p = 0.0014). DLP was also significantly higher for standard CCTA than for dynamic CCTA (864 ± 702 mGy × cm vs. 434 ± 106 mGy × cm, p < .0001). For standard scans, CTDIvol and DLP exceeded the 2020 DRL in Japan in 16% (12/77) and 17% (13/77) of cases, respectively. In contrast, rates for the dynamic scan were only 1% (1/87) for CTDIvol and 0% (0/87) for DLP. CONCLUSION The dose of radiation exposure during dynamic CCTA with a 320-row scanner does not exceed that of standard CCTA and is sufficient to meet the latest DRL. Thus, our results suggest that the method is safe from the perspective of radiation exposure.",2021,DLP was also significantly higher for standard CCTA than for dynamic CCTA (864 ± 702 mGy ,"['106\xa0mGy', '164 consecutive patients with suspected or known coronary artery disease (CAD) who underwent CCTA with a 320-row scanner']","['Radiation dose for 320-row dose-modulated dynamic coronary CT angiography', 'standard CCTA', 'electrocardiography (ECG)-gated coronary CT angiography (CCTA', 'dynamic CCTA']","['DLP', 'CTDIvol']","[{'cui': 'C3873195', 'cui_str': 'mGy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1536105', 'cui_str': 'CT angiography'}, {'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C0183115', 'cui_str': 'Scanner'}]","[{'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1536105', 'cui_str': 'CT angiography'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0237633', 'cui_str': 'Sensory Filtering'}]","[{'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1444754', 'cui_str': 'Length'}]",164.0,0.0263447,DLP was also significantly higher for standard CCTA than for dynamic CCTA (864 ± 702 mGy ,"[{'ForeName': 'Yukako', 'Initials': 'Y', 'LastName': 'Izoe', 'Affiliation': 'Graduate School of Medicine, Health Sciences, Division of Radiological Examination and Technology, Tohoku University, Sendai City, Japan.'}, {'ForeName': 'Michinobu', 'Initials': 'M', 'LastName': 'Nagao', 'Affiliation': ""Department of Diagnostic imaging & Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.""}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Tokai', 'Affiliation': ""Department of Radiological Service, Tokyo Women's Medical University, Tokyo, Japan.""}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Hashimoto', 'Affiliation': ""Department of Radiological Service, Tokyo Women's Medical University, Tokyo, Japan.""}, {'ForeName': 'Isao', 'Initials': 'I', 'LastName': 'Tanaka', 'Affiliation': ""Department of Radiological Service, Tokyo Women's Medical University, Tokyo, Japan.""}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Chida', 'Affiliation': 'Graduate School of Medicine, Health Sciences, Division of Radiological Examination and Technology, Tohoku University, Sendai City, Japan.'}]",Journal of applied clinical medical physics,['10.1002/acm2.13390'] 2262,34374961,Sex-Specific Pharmacotherapy for Back Pain: A Proof-of-Concept Randomized Trial.,"BACKGROUND Preventing transition to chronic back pain (CBP) is a long-sought strategy that could rescue patients from prolonged suffering. Recent rodent and human brain imaging studies suggest involvement of sexually dimorphic, dopaminergic-motivational, mesolimbic circuits in the transition to chronic pain (tCBP), and hint that the combination of carbidopa/levodopa and naproxen (LDP + NPX) may block tCBP. Here we evaluated, in people with recent-onset back pain, whether a 3-month treatment with LDP + NPX is safe, blocks tCBP, and whether its efficacy is sex-dependent. METHODS A total of 72 participants were enrolled and stratified by risk for tCBP using brain-imaging biomarkers. Low-risk participants entered a no-treatment arm. Others were randomized to placebo + naproxen or LDP + NPX for 3 months. RESULTS Both treatments resulted in more than 50% pain relief for approximately 75% of participants. A strong sex by treatment interaction was observed for daily pain intensity (phone NRS, P = 0.007), replicated on 4-week average pain (Pain/4w, P = 0.00001), and in intent-to-treat analysis (Pain/4w, P = 0.000004). Nucleus accumbens functional connectivity with medial prefrontal cortex, a predefined objective biomarker, showed sex dependence at baseline (P = 0.03) and sex-by-treatment interaction effect 3 months after treatment cessation (P = 0.031). Treatment modified the psychological profile of participants, and disrupted brain modeling-based predicted back pain intensity trajectories. Forty participants were queried 3.3 years from trial start; back pain ratings were similar between end of treatment and at 3.3 years (P = 0.62), indicating persistence of relief for this duration. CONCLUSIONS These results provide the first evidence for preventing transition to chronic back pain using sex-specific pharmacotherapy. These provocative observations require confirmation in a larger study. ClinicalTrials.gov identifier: NCT01951105.",2021,"A strong sex by treatment interaction was observed for daily pain intensity (phone NRS, P = 0.007), replicated on 4-week average pain (Pain/4w, P = 0.00001), and in intent-to-treat analysis (Pain/4w, P = 0.000004).","['people with recent-onset back pain', '72 participants were enrolled and stratified by risk for tCBP using brain-imaging biomarkers', 'Back Pain']","['placebo\u2009+\u2009naproxen or LDP\u2009+\u2009NPX', 'carbidopa/levodopa and naproxen (LDP\u2009+\u2009NPX', 'LDP\u2009+\u2009NPX']","['pain relief', 'daily pain intensity', 'pain ratings', '4-week average pain']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0203860', 'cui_str': 'Imaging of brain'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0027396', 'cui_str': 'Naproxen'}, {'cui': 'C0353697', 'cui_str': 'Carbidopa- and levodopa-containing product'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439230', 'cui_str': 'week'}]",72.0,0.370715,"A strong sex by treatment interaction was observed for daily pain intensity (phone NRS, P = 0.007), replicated on 4-week average pain (Pain/4w, P = 0.00001), and in intent-to-treat analysis (Pain/4w, P = 0.000004).","[{'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Reckziegel', 'Affiliation': 'Center for Chronic Pain and Drug Abuse, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Tétreault', 'Affiliation': 'Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Mariam', 'Initials': 'M', 'LastName': 'Ghantous', 'Affiliation': 'Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Kenta', 'Initials': 'K', 'LastName': 'Wakaizumi', 'Affiliation': 'Center for Chronic Pain and Drug Abuse, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Bogdan', 'Initials': 'B', 'LastName': 'Petre', 'Affiliation': 'Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Lejian', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Center for Chronic Pain and Drug Abuse, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Rami', 'Initials': 'R', 'LastName': 'Jabakhanji', 'Affiliation': 'Center for Chronic Pain and Drug Abuse, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Taha', 'Initials': 'T', 'LastName': 'Abdullah', 'Affiliation': 'Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Vachon-Presseau', 'Affiliation': 'Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Berger', 'Affiliation': 'Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Baria', 'Affiliation': 'Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Griffith', 'Affiliation': 'Center for Chronic Pain and Drug Abuse, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Marwan N', 'Initials': 'MN', 'LastName': 'Baliki', 'Affiliation': 'Center for Chronic Pain and Drug Abuse, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Schnitzer', 'Affiliation': 'Center for Chronic Pain and Drug Abuse, Northwestern University Feinberg School of Medicine, Chicago, USA.'}, {'ForeName': 'A Vania', 'Initials': 'AV', 'LastName': 'Apkarian', 'Affiliation': 'Center for Chronic Pain and Drug Abuse, Northwestern University Feinberg School of Medicine, Chicago, USA. a-apkarian@northwestern.edu.'}]",Pain and therapy,['10.1007/s40122-021-00297-2'] 2263,34374960,Comparison of Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) and Laparoendoscopic Single-Site (LESS) Hysterectomy on Postoperative Pain Reduction: A Randomized Pilot Study.,"INTRODUCTION Vaginal natural orifice transluminal endoscopic surgery (vNOTES) hysterectomy has shown benefit in postoperative pain and operation time compared to laparoscopic hysterectomy in recent studies. However, no prospective studies comparing laparoendoscopic single-site (LESS) and vNOTES hysterectomy have been performed. This study aims to evaluate postoperative pain and safety of vNOTES hysterectomy compared to LESS hysterectomy for benign uterine disease. METHODS This study is a prospective, investigator-initiated randomized controlled pilot trial. A total of 26 patients were randomized and allocated to vNOTES group (n = 13) and LESS group (n = 13). The primary outcome was postoperative abdominal and vaginal pain evaluated 24 h after surgery. Secondary outcomes included the number of additional analgesics administered and the maintenance rate of patient-controlled analgesia (PCA). RESULTS No differences were shown in baseline characteristics between the two groups. Operation time was longer in the LESS group (median, 55 vs. 75 min; P = 0.027), and there were no differences in estimated blood loss, postoperative hemoglobin level, surgical indications, and hospitalization days. Postoperative abdominal pain intensity did not differ between the two groups, while the vNOTES group showed higher postoperative vaginal pain than the LESS group at 16 and 24 h after surgery (median, 3 vs. 1 and 2 vs. 0, P = 0.007 and P = 0.010, at 16 and 24 h respectively). No differences were shown in the number of additional analgesics and PCA use between the two groups. CONCLUSIONS vNOTES hysterectomy can be safely performed for benign uterine disease requiring hysterectomy. However, vNOTES hysterectomy might be associated with higher postoperative vaginal pain intensity compared to LESS hysterectomy. TRIAL REGISTRATION CRIS identifier KCT0004605.",2021,"Operation time was longer in the LESS group (median, 55 vs. 75 min; P = 0.027), and there were no differences in estimated blood loss, postoperative hemoglobin level, surgical indications, and hospitalization days.","['26 patients', 'benign uterine disease requiring hysterectomy']","['LESS hysterectomy', 'Hysterectomy', 'LESS', 'vNOTES hysterectomy', 'Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) and Laparoendoscopic Single-Site (LESS', 'laparoendoscopic single-site (LESS) and vNOTES hysterectomy', 'Vaginal natural orifice transluminal endoscopic surgery (vNOTES) hysterectomy', 'laparoscopic hysterectomy']","['Pain Reduction', 'number of additional analgesics administered and the maintenance rate of patient-controlled analgesia (PCA', 'Operation time', 'Postoperative', 'postoperative pain and safety', 'estimated blood loss, postoperative hemoglobin level, surgical indications, and hospitalization days', 'postoperative abdominal and vaginal pain evaluated 24\xa0h after surgery', 'postoperative vaginal pain', 'number of additional analgesics and PCA', 'Postoperative abdominal pain intensity', 'postoperative vaginal pain intensity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0042131', 'cui_str': 'Disorder of uterus'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C2936208', 'cui_str': 'Natural Orifice Transluminal Endoscopic Surgery'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0236082', 'cui_str': 'Vaginal pain'}, {'cui': 'C4047372', 'cui_str': 'Postoperative abdominal pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",26.0,0.137058,"Operation time was longer in the LESS group (median, 55 vs. 75 min; P = 0.027), and there were no differences in estimated blood loss, postoperative hemoglobin level, surgical indications, and hospitalization days.","[{'ForeName': 'Soo Jin', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101 Daehak-Ro Jongno-Gu, 110-744, Seoul, 03080, Republic of Korea.'}, {'ForeName': 'Hee Seung', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101 Daehak-Ro Jongno-Gu, 110-744, Seoul, 03080, Republic of Korea. bboddi0311@gmail.com.'}, {'ForeName': 'Ga Won', 'Initials': 'GW', 'LastName': 'Yim', 'Affiliation': 'Department of Obstetrics and Gynecology, Dongguk University College of Medicine, 27 Dongguk-ro, Ilsandong-gu, Goyang, Gyeonggi, 10326, Republic of Korea. gawonyim@gmail.com.'}]",Pain and therapy,['10.1007/s40122-021-00300-w'] 2264,34374952,Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.,"INTRODUCTION This exploratory analysis assessed efficacy and safety outcomes in patients with Gram-negative bacteremia treated with ceftazidime-avibactam or comparator across five phase 3, randomized, controlled, multi-center trials in adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI)/pyelonephritis, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). METHODS In each trial, RECLAIM and RECLAIM 3 (cIAI; NCT01499290/NCT01726023), REPRISE (cIAI/cUTI; NCT01644643), RECAPTURE (cUTI; NCT01595438/NCT01599806), and REPROVE (HAP/VAP; NCT01808092), patients were randomized 1:1 to intravenous ceftazidime-avibactam (plus metronidazole for those with cIAI) or comparators (carbapenems in > 97% patients) for 5-21 days. Efficacy assessments included clinical and microbiological responses at the test-of-cure visit in the pooled Gram-negative extended microbiologically evaluable (GNeME) population (bacteremia subset). Safety outcomes were summarized for patients with positive bacterial blood culture(s) at baseline who received ≥ 1 dose of study treatment. RESULTS The overall safety population included 4050 patients (ceftazidime-avibactam, n = 2024; comparator, n = 2026). The GNeME population (bacteremia subset) comprised 101 patients (ceftazidime-avibactam, n = 54; comparator, n = 47). Clinical cure rates (all indications combined) were 47/54 (87.0%) for ceftazidime-avibactam and 39/47 (83.0%) for comparators; favorable microbiological response rates were 43/54 (79.6%) and 32/47 (68.1%), respectively. Clinical and microbiological responses in the bacteremia subset were generally similar to those in the overall set. The pattern of adverse events in patients with bacteremia was similar between treatment groups and was consistent with the known safety profile of ceftazidime-avibactam. CONCLUSION This analysis provides supportive evidence of the efficacy and safety of ceftazidime-avibactam in patients with Gram-negative bacteremia associated with cIAI, cUTI/pyelonephritis, or HAP/VAP.",2021,"Clinical cure rates (all indications combined) were 47/54 (87.0%) for ceftazidime-avibactam and 39/47 (83.0%) for comparators; favorable microbiological response rates were 43/54 (79.6%) and 32/47 (68.1%), respectively.","['patients with Gram-negative bacteremia associated with cIAI, cUTI/pyelonephritis, or HAP/VAP', 'Adults with Gram-Negative Bacteremia', 'patients with positive bacterial blood culture(s) at baseline who received\u2009≥\u20091 dose of study treatment', 'adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI)/pyelonephritis, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP', '101 patients (ceftazidime-avibactam, n\u2009=\u200954; comparator, n\u2009=\u200947', '4050\xa0patients (ceftazidime-avibactam, n\u2009=\u20092024; comparator, n\u2009=\u20092026', 'patients with Gram-negative bacteremia treated with']","['Ceftazidime-Avibactam Treatment', 'ceftazidime-avibactam', 'ceftazidime-avibactam or comparator', 'ceftazidime-avibactam (plus metronidazole']","['Clinical and microbiological responses', 'microbiological response rates', 'efficacy and safety outcomes', 'Clinical cure rates', 'clinical and microbiological responses']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0744471', 'cui_str': 'Gram-negative bacteremia'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C4524048', 'cui_str': 'Complicated intra-abdominal infection'}, {'cui': 'C4552431', 'cui_str': 'Complicated urinary tract infection'}, {'cui': 'C0034186', 'cui_str': 'Pyelonephritis'}, {'cui': 'C0949083', 'cui_str': 'Hospital acquired pneumonia'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0200949', 'cui_str': 'Blood culture'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C1508753', 'cui_str': 'Urinary system structure'}, {'cui': 'C3656596', 'cui_str': 'Avibactam and ceftazidime'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C3656596', 'cui_str': 'Avibactam and ceftazidime'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.153307,"Clinical cure rates (all indications combined) were 47/54 (87.0%) for ceftazidime-avibactam and 39/47 (83.0%) for comparators; favorable microbiological response rates were 43/54 (79.6%) and 32/47 (68.1%), respectively.","[{'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Mazuski', 'Affiliation': 'Department of Surgery, Washington University School of Medicine, St Louis, MO, USA.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Wagenlehner', 'Affiliation': 'Department of Urology, Pediatric Urology and Andrology, Justus-Liebig-University, Giessen, Germany.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Torres', 'Affiliation': 'Department of Pulmonology, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, ICREA, Barcelona, Spain.'}, {'ForeName': 'Yehuda', 'Initials': 'Y', 'LastName': 'Carmeli', 'Affiliation': 'Division of Epidemiology, National Institute for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Joseph W', 'Initials': 'JW', 'LastName': 'Chow', 'Affiliation': 'Global Product Development, Pfizer, Collegeville, PA, USA.'}, {'ForeName': 'Dalia', 'Initials': 'D', 'LastName': 'Wajsbrot', 'Affiliation': 'Biostatistics, Pfizer, New York, NY, USA.'}, {'ForeName': 'Gregory G', 'Initials': 'GG', 'LastName': 'Stone', 'Affiliation': 'Microbiology, Internal Medicine, Pfizer, Groton, CT, USA.'}, {'ForeName': 'Paurus', 'Initials': 'P', 'LastName': 'Irani', 'Affiliation': 'Global Medical Affairs, Pfizer, Tadworth, Surrey, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Bharucha', 'Affiliation': 'Clinical Development, AbbVie, Madison, NJ, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Cheng', 'Affiliation': 'Safety Surveillance and Risk Management, Pfizer, Sandwich, Kent, UK.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Tawadrous', 'Affiliation': 'Global Product Development, Pfizer, Inc, 445 Eastern Point Road, Groton, CT, 06340, USA. Margaret.Tawadrous@pfizer.com.'}]",Infectious diseases and therapy,['10.1007/s40121-021-00506-7'] 2265,34374687,The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer.,"OBJECTIVE To compare the effect of tibolone to conjugated estrogens with medroxyprogesterone-acetate (CEE + MPA) on breast density, as a predictor for breast cancer risk, in women with a high risk of breast and ovarian cancer. METHODS Women aged 30-50 (N = 114) who had undergone risk-reducing salpingo-oophorectomy (RRSO) were randomized to tibolone or CEE + MPA. RESULTS Breast density decreased 46% after RRSO in untreated women, 39% after treatment with tibolone, and 17% after treatment with CEE + MPA; the decrease in breast density after CEE + MPA was significantly different compared with that of untreated women (P = 0.017). CONCLUSIONS A decline in breast density is seen after premenopausal RRSO despite the use of both CEE + MPA or tibolone, although lower breast density is seen after tibolone use.",2021,"A decline in breast density is seen after premenopausal RRSO despite the use of both CEE + MPA or tibolone, although lower breast density is seen after tibolone use.","['women with an increased risk for breast and ovarian cancer', 'Women aged 30-50 (N\u200a=\u200a114) who had undergone risk-reducing salpingo-oophorectomy (RRSO', 'women with a high risk of breast and ovarian cancer']","['tibolone', 'medroxyprogesterone-acetate (CEE\u200a+\u200aMPA', 'hormone therapy', 'tibolone or CEE\u200a+\u200aMPA']","['Breast density', 'breast density']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0036132', 'cui_str': 'Salpingo-oophorectomy'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0076660', 'cui_str': 'tibolone'}, {'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}, {'cui': 'C0046018', 'cui_str': '2-chloroethyl ethyl sulfide'}, {'cui': 'C0025147', 'cui_str': 'Medroxyprogesterone'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}]","[{'cui': 'C1659543', 'cui_str': 'Breast Density'}]",,0.0604775,"A decline in breast density is seen after premenopausal RRSO despite the use of both CEE + MPA or tibolone, although lower breast density is seen after tibolone use.","[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'van Barele', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands Department of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands Present address: Department of Gynecology, Nij Smellinghe Hospital, Drachten, The Netherlands Department of Gynecology, Amsterdam University Medical Centre and Antoni van Leeuwenhoek, Amsterdam, The Netherlands Department of Gynecology and Obstetrics, Leiden University Medical Centre, Leiden, The Netherlands Department of Gynecologic Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Chistien C M', 'Initials': 'CCM', 'LastName': 'Buis', 'Affiliation': ''}, {'ForeName': 'Monique M A', 'Initials': 'MMA', 'LastName': 'Brood-van Zanten', 'Affiliation': ''}, {'ForeName': 'H Lena C', 'Initials': 'HLC', 'LastName': 'van Doorn', 'Affiliation': ''}, {'ForeName': 'Katja N', 'Initials': 'KN', 'LastName': 'Gaarenstroom', 'Affiliation': ''}, {'ForeName': 'Bernadette A M', 'Initials': 'BAM', 'LastName': 'Heemskerk-Gerritsen', 'Affiliation': ''}, {'ForeName': 'Maartje J', 'Initials': 'MJ', 'LastName': 'Hooning', 'Affiliation': ''}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'de Hullu', 'Affiliation': ''}, {'ForeName': 'Marian J', 'Initials': 'MJ', 'LastName': 'Mourits', 'Affiliation': ''}, {'ForeName': 'Curt W', 'Initials': 'CW', 'LastName': 'Burger', 'Affiliation': ''}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001844'] 2266,34374633,Pilot randomized clinical trial targeting anxiety sensitivity: effects on physical activity.,"Anxiety sensitivity (AS)-the tendency to interpret anxiety as an aversive state-is associated with low rates of physical activity. Previous interventions targeting AS via exercise-based interoceptive exposure have not assessed physical activity as an outcome and are limited by brief follow-up periods. This study replicated and extended previous work by including a 6-week follow-up and assessing physical activity. Participants were 44 sedentary young adults with elevated AS randomized to intervention (six 20-minute sessions of moderate-intensity walking) or assessment-only control. Assessments of AS and physical activity were conducted at baseline and weeks 2 (post-treatment), 4, and 8. Between-group change in AS and physical activity over time was assessed using hierarchical linear modeling. The intervention condition demonstrated a marginally significant reduction in AS compared to control at week 4, which eroded by week 8. There were no significant between-group differences for change in physical activity. Findings indicate that a brief intervention might not be sufficient to produce lasting changes in AS or related exercise avoidance without additional treatment. Intervention effects were weaker than previous reports, which may be due to the greater racial/ethnic diversity of the current sample. Future research should objectively measure physical activity and explore individual variability in response.ClinicalTrials.gov identifier: NCT03128437.",2021,"The intervention condition demonstrated a marginally significant reduction in AS compared to control at week 4, which eroded by week 8.",['Participants were 44 sedentary young adults with elevated AS randomized to'],['intervention (six 20-minute sessions of moderate-intensity walking) or assessment-only control'],"['Anxiety sensitivity', 'physical activity', 'AS and physical activity', 'Assessments of AS and physical activity']","[{'cui': 'C0911524', 'cui_str': 'AM 44'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4039089', 'cui_str': 'Assessment of anxiety'}]",44.0,0.016712,"The intervention condition demonstrated a marginally significant reduction in AS compared to control at week 4, which eroded by week 8.","[{'ForeName': 'Autumn', 'Initials': 'A', 'LastName': 'Lanoye', 'Affiliation': 'Department of Health Behavior and Policy, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Rybarczyk', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Evans', 'Affiliation': 'Department of Kinesiology & Health Sciences, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Tricia', 'Initials': 'T', 'LastName': 'Leahey', 'Affiliation': 'Department of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'LaRose', 'Affiliation': 'Department of Health Behavior and Policy, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.'}]",Cognitive behaviour therapy,['10.1080/16506073.2021.1954082'] 2267,34374434,The effect of adjunctive systemic antibiotics on microbial populations compared to scaling and root planing alone for the treatment of periodontitis: A pilot randomized clinical trial.,"AIM To investigate the microbial shift after periodontitis being treated by scaling and root planing (SRP) with or without adjunctive antibiotics, and to assess the relationship between oral microbiota and systemic factors. METHODS A 6-month pilot randomized controlled trial recruited 14 subjects with severe periodontitis, divided into test group and control group to receive full-mouth SRP with or without amoxicillin (500mg) and metronidazole (200mg) (t.i.d. 7d). Clinical examination, collection of subgingival plaque and saliva, and blood tests were performed at baseline pre-treatment, three months, and six months post-treatment. The V3V4 region of 16S DNA was sequenced; taxonomic assignment was based on the Human Oral Microbiome Database. RESULTS The periodontal condition significantly improved in both groups; the test group showed a greater improvement in plaque index, probing depth, and bleeding index than the control group. The test group demonstrated significantly lower microbial richness and diversity, and less abundant Porphyromonas than the control group in at three months for both subgingival microbiome and salivary microbiome. However, the microbial differences narrowed within six months. The subgingival and salivary microbiota shifted synergistically. Glucose was positively related to subgingival Porphyromonas; mean platelet volume was positively related to subgingival Leptotrichia. CONCLUSIONS Systemic administration of amoxicillin and metronidazole along with SRP had an advantage over SRP alone in clinical improvement and infection control in both the subgingival region and saliva three months post-treatment. Microbial advantage nearly disappeared at six months; however, the clinical advantage lasted longer. The use of antibiotics also has potential benefits for systemic inflammation and glucose. This article is protected by copyright. All rights reserved.",2021,"The periodontal condition significantly improved in both groups; the test group showed a greater improvement in plaque index, probing depth, and bleeding index than the control group.","['periodontitis', '14 subjects with severe periodontitis']","['amoxicillin and metronidazole', 'metronidazole', 'adjunctive systemic antibiotics', 'scaling and root planing (SRP) with or without adjunctive antibiotics', 'control group to receive full-mouth SRP with or without amoxicillin']","['Glucose', 'Microbial advantage', 'subgingival Porphyromonas; mean platelet volume', 'microbial richness and diversity, and less abundant Porphyromonas', 'periodontal condition', 'plaque index, probing depth, and bleeding index', 'Clinical examination, collection of subgingival plaque and saliva, and blood tests']","[{'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]","[{'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0085287', 'cui_str': 'Root planing of tooth'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0595817', 'cui_str': 'Subgingival route'}, {'cui': 'C0200665', 'cui_str': 'Platelet mean volume determination'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0399451', 'cui_str': 'Subgingival plaque'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}]",14.0,0.0693121,"The periodontal condition significantly improved in both groups; the test group showed a greater improvement in plaque index, probing depth, and bleeding index than the control group.","[{'ForeName': 'Hongye', 'Initials': 'H', 'LastName': 'Lu', 'Affiliation': 'Department of Periodontology, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'He', 'Affiliation': 'Department of Periodontology, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Dongsiqi', 'Initials': 'D', 'LastName': 'Jin', 'Affiliation': 'The Third Clinical Division, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Yunxuan', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'The Second Clinical Division, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Huanxin', 'Initials': 'H', 'LastName': 'Meng', 'Affiliation': 'Department of Periodontology, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}]",Journal of periodontology,['10.1002/JPER.20-0764'] 2268,34374430,Effects by educational attainment of a mammography screening patient decision aid for women aged 75 years and older.,"BACKGROUND To help inform screening decisions, a mammography screening decision aid (DA) for women aged 75 years and older was tested in a cluster randomized clinical trial of 546 women. DA use increased women's knowledge of the benefits and harms of mammography and lowered screening rates. In the current study, the objective was to examine whether participants' views of the DA and/or its effects differed by educational attainment. METHODS A secondary analysis was conducted of 283 women who received the DA before a personal care provider (PCP) visit during the trial to examine the acceptability of the DA and its effects on knowledge of the benefits and harms of mammography, screening intentions, and receipt of screening by educational attainment. Adjusted analyses accounted for clustering by PCP. RESULTS Of the 283 participants, 43% had a college education or less. Regardless of educational attainment, 87.2% found the DA helpful. Women with lower educational attainment were less likely to understand all of the DA's content (46.3% vs 67.5%; P < .001), had less knowledge of the benefits and harms of mammography (adjusted mean ± standard error knowledge score, 7.1 ± 0.3 vs 8.1 ± 0.3; P < .001), and were less likely to lower screening intentions (adjusted percentage, 11.4% vs 19.4%; P = .01). Receipt of screening did not differ by educational attainment. CONCLUSIONS A mammography DA for women aged 75 years and older was helpful to women regardless of their educational attainment; however, those with a college degree or greater understood the DA and, possibly as a result, lowered their screening intentions. Future studies need to examine how to better support informed decision making around mammography screening in older women with lower educational attainment. LAY SUMMARY The authors examined data from a previous study to learn the effects of a mammography decision aid (DA) for women aged 75 years and older according to their level of education. Overall, women found the DA helpful, but women with lower educational attainment found it harder to understand the benefits and harms of mammography screening and were less likely to lower their screening intentions than women with a college degree. The findings suggest that women aged 75 years and older who have lower educational attainment may need an even lower literacy DA and/or more support from health care professionals.",2021,"Overall, women found the DA helpful, but women with lower educational attainment found it harder to understand the benefits and harms of mammography screening and were less likely to lower their screening intentions than women with a college degree.","['283 participants', '283 women who received the DA before a personal care provider (PCP) visit during the trial', 'older women with lower educational attainment', 'women aged 75\xa0years and older according to their level of education', 'women aged 75\xa0years and older who have lower educational attainment', 'women aged 75 years and older', '546 women', 'women aged 75\xa0years and older']","['mammography decision aid (DA', 'mammography DA', 'DA', 'mammography screening patient decision']","['benefits and harms of mammography screening', 'knowledge of the benefits and harms of mammography', ""women's knowledge of the benefits and harms of mammography and lowered screening rates"", 'screening intentions']","[{'cui': 'C4708786', 'cui_str': '283'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0013658', 'cui_str': 'Educational achievement'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0203028', 'cui_str': 'Screening mammography'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",546.0,0.129495,"Overall, women found the DA helpful, but women with lower educational attainment found it harder to understand the benefits and harms of mammography screening and were less likely to lower their screening intentions than women with a college degree.","[{'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Cadet', 'Affiliation': 'School of Social Policy and Practice, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Adlin', 'Initials': 'A', 'LastName': 'Pinheiro', 'Affiliation': 'Division of General Medicine, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Karamourtopoulos', 'Affiliation': 'Division of General Medicine, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Alicia R', 'Initials': 'AR', 'LastName': 'Jacobson', 'Affiliation': 'Division of General Medicine, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Gianna M', 'Initials': 'GM', 'LastName': 'Aliberti', 'Affiliation': 'Division of General Medicine, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Christine E', 'Initials': 'CE', 'LastName': 'Kistler', 'Affiliation': 'Division of Geriatric Medicine and Department of Family Medicine, University of North Carolina, Chapel Hill, North Carolina.'}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Davis', 'Affiliation': 'Division of General Medicine, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Mara A', 'Initials': 'MA', 'LastName': 'Schonberg', 'Affiliation': 'Division of General Medicine, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}]",Cancer,['10.1002/cncr.33857'] 2269,34374162,Counselling and education for prenatal screening and diagnostic tests for pregnant women: Randomized controlled trial.,"AIM The aim of this study is to evaluate the effect of education and counselling on prenatal screening and diagnostic tests on pregnant women's decisional conflict, anxiety levels and attitudes towards the tests. BACKGROUND Clinical practice guidelines recommend prenatal genetic counselling for pregnant women before participation in the tests. METHODS A total of 210 pregnant women participated in the study by completing the State-Trait Anxiety Inventory-I, Decisional Conflict Scale, SURE Scale, Knowledge Assessment Forms, Decision Satisfaction Form and Attitudes Scale between June 2017 and March 2018. In the first stage, pregnant women were evaluated who had only prenatal genetic screening tests and in the second stage, pregnant women who had been recommended to receive diagnostic tests. The intervention group received face-to-face individual education and counselling about prenatal genetic tests. Independent samples t test, t tests and Pearson correlation tests were used. RESULTS Education and counselling for prenatal screening tests and diagnostic tests from the first weeks of pregnancy were effective in decreasing anxiety, decisional conflict, increasing attitudes towards tests and had positive effects on pregnant women's knowledge level and decision satisfaction (P < 0.005). CONCLUSION Prenatal genetic counselling and education are more effective if provided from the first weeks of pregnancy. Decreasing anxiety, decisional conflict and increasing knowledge levels of pregnant women are important to make informed decisions.",2021,"RESULTS Education and counselling for prenatal screening tests and diagnostic tests from the first weeks of pregnancy were effective in decreasing anxiety, decisional conflict, increasing attitudes towards tests and had positive effects on pregnant women's knowledge level and decision satisfaction (P < 0.005). ","['pregnant women', ""pregnant women's"", 'pregnant women before participation in the tests', '210 pregnant women participated in the study by completing the', 'pregnant women were evaluated who had only prenatal genetic screening tests and in the second stage, pregnant women who had been recommended to receive diagnostic tests']","['face-to-face individual education and counselling about prenatal genetic tests', 'Counselling and education for prenatal screening and diagnostic tests', 'education and counselling']","['State-Trait Anxiety Inventory-I, Decisional Conflict Scale, SURE Scale, Knowledge Assessment Forms, Decision Satisfaction Form and Attitudes Scale', 'decisional conflict, anxiety levels and attitudes towards the tests', 'Decreasing anxiety, decisional conflict', ""anxiety, decisional conflict, increasing attitudes towards tests and had positive effects on pregnant women's knowledge level and decision satisfaction""]","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0679560', 'cui_str': 'Genetic test'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0430022', 'cui_str': 'Diagnostic procedure'}]","[{'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0679560', 'cui_str': 'Genetic test'}, {'cui': 'C0740178', 'cui_str': 'Antenatal screening'}, {'cui': 'C0430022', 'cui_str': 'Diagnostic procedure'}]","[{'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205423', 'cui_str': 'Certain'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0871796', 'cui_str': 'Knowledge level'}]",210.0,0.0196121,"RESULTS Education and counselling for prenatal screening tests and diagnostic tests from the first weeks of pregnancy were effective in decreasing anxiety, decisional conflict, increasing attitudes towards tests and had positive effects on pregnant women's knowledge level and decision satisfaction (P < 0.005). ","[{'ForeName': 'İlknur', 'Initials': 'İ', 'LastName': 'Yeşilçinar', 'Affiliation': 'Health Sciences Faculty, Nursing Department, Izmir Katip Celebi University, Izmir, Turkey.'}, {'ForeName': 'Gülten', 'Initials': 'G', 'LastName': 'Güvenç', 'Affiliation': 'Gülhane Faculty of Nursing, University of Health Sciences Turkey, Ankara, Turkey.'}]",International journal of nursing practice,['10.1111/ijn.13000'] 2270,34374114,"A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.","AIMS The pharmacokinetic (PK) similarity between MB02, a proposed bevacizumab biosimilar, and reference bevacizumab approved from United States (US-bevacizumab) and European Union (EU-bevacizumab) or was evaluated. Safety and immunogenicity were also assessed. METHODS In this phase 1, randomized, double blind, single dose, parallel group study, 114 healthy male volunteers were randomized 1:1:1 to receive a 3mg/kg intravenous dose of MB02, US-bevacizumab, or EU-bevacizumab, and evaluated for 100 days. PK similarity between MB02 and reference bevacizumab was determined using the standard bioequivalence criteria (0.80 to 1.25) for the area under the serum concentration-time curve from time 0 extrapolated to infinity [AUC (0-∞) ] and the maximum observed serum concentration (C max ). RESULTS Baseline demographics were similar across treatment groups. All study drugs exhibited similar PK profile. The 90% CI for the geometric lead square means ratios for the primary parameters AUC (0-∞) and C max for MB02, US-bevacizumab and EU-bevacizumab were fully contained within the pre-defined bioequivalence limits for the three pairwise comparisons: AUC (0-∞) (MB02:US-bevacizumab 0.998 [0.944 to 1.05]; MB02:EU-bevacizumab 1.07 [1.00 to 1.14] and; US-bevacizumab: EU-bevacizumab 0.934 [0.884 to 0.988]) and C max (MB02:US-bevacizumab 0.983 [0.897 to 1.08]; MB02:EU-bevacizumab 1.06 [0.976 to 1.16] and; US-bevacizumab: EU-bevacizumab 0.926 [0.851 to 1.01]). Treatment emergent adverse events (TEAEs) were reported in 87 subjects (76.3%), most being mild and with comparable incidence among treatment groups. Thirty-three subjects (28.9%) reported 56 possibly related TEAEs with comparable incidence across treatments, being the most frequent headache (10.5%) and fatigue (3.5%). Anti-drug antibodies incidence was low and similar between treatment groups. CONCLUSIONS This study demonstrates the PK similarity and bioequivalence of MB02 to the reference bevacizumab, whether approved from US or EU. The safety and immunogenicity profile of MB02 was shown also to be similar to the bevacizumab reference product (NCT04238663).",2021,"Treatment emergent adverse events (TEAEs) were reported in 87 subjects (76.3%), most being mild and with comparable incidence among treatment groups.","['healthy male volunteers', '114 healthy male volunteers']","['bevacizumab and EU-bevacizumab', 'bevacizumab) and European Union (EU-bevacizumab', 'MB02 (bevacizumab biosimilar) and reference bevacizumab', 'bevacizumab', 'MB02, US-bevacizumab, or EU-bevacizumab', 'bevacizumab: EU-bevacizumab']","['AUC (0-∞) and C max for MB02', 'Safety and immunogenicity', 'Anti-drug antibodies incidence', 'Treatment emergent adverse events (TEAEs', 'headache', 'safety and immunogenicity profile of MB02']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C4708785', 'cui_str': '114'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0015179', 'cui_str': 'European Community'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}]","[{'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018681', 'cui_str': 'Headache'}]",114.0,0.110822,"Treatment emergent adverse events (TEAEs) were reported in 87 subjects (76.3%), most being mild and with comparable incidence among treatment groups.","[{'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Sinn', 'Affiliation': 'Early Phase Clinical Unit Berlin, Parexel International GmbH, Berlin, Germany.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Garcia-Alvarado', 'Affiliation': 'Medical Department, mAbxience Research S.L. Madrid, Spain.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Gonzalez', 'Affiliation': 'Medical Department, mAbxience Research S.L. Madrid, Spain.'}, {'ForeName': 'Camino', 'Initials': 'C', 'LastName': 'Huerga', 'Affiliation': 'Medical Department, mAbxience Research S.L. Madrid, Spain.'}, {'ForeName': 'Felicitas', 'Initials': 'F', 'LastName': 'Bullo', 'Affiliation': 'Medical Department, mAbxience Research S.L. Madrid, Spain.'}]",British journal of clinical pharmacology,['10.1111/bcp.15032'] 2271,34374108,Impact of duloxetine on male fertility: A randomised controlled clinical trial.,"This study assessed the impact of duloxetine (serotonin and norepinephrine reuptake inhibitor) on semen parameters, sperm DNA fragmentation and serum hormones. We performed a double-blind, placebo-controlled, randomised clinical trial of duloxetine 60mg or placebo daily for 6 weeks (5 weeks full dose and 1 week taper). The primary outcome was the proportion of men with abnormal DNA fragmentation during and after duloxetine administration. Secondary outcomes were changes in semen parameters and hormones on treatment (2 and 6 weeks) and after discontinuation (8 and 10 weeks). Sixty-eight healthy males aged 18-65 were included. Duloxetine was not associated with an increase in the proportion of participants with abnormal sperm DNA fragmentation terminal deoxynucleotidyl transferase dUTP nick-end labelling scores (>25%) on treatment (p = 0.09) or after treatment (p = 0.56), nor did median sperm DNA fragmentation increase on treatment. Compared with placebo, there were no changes in bulk semen parameters during treatment. Limited changes in hormonal values were detected. This first published human study of a serotonin and norepinephrine reuptake inhibitor on male fertility revealed no clinically meaningful effects on sperm DNA fragmentation, semen parameters or serum hormones. Duloxetine, and possibly other serotonin and norepinephrine reuptake inhibitors, may be considered for men desiring fertility who require antidepressant treatment.",2021,"Duloxetine was not associated with an increase in the proportion of participants with abnormal sperm DNA fragmentation terminal deoxynucleotidyl transferase dUTP nick-end labelling scores (>25%) on treatment (p = 0.09) or after treatment (p = 0.56), nor did median sperm DNA fragmentation increase on treatment.","['Sixty-eight healthy males aged 18-65 were included', 'male fertility', 'men desiring fertility who require antidepressant treatment']","['Duloxetine', 'duloxetine 60mg or placebo', 'duloxetine (serotonin and norepinephrine reuptake inhibitor', 'duloxetine', 'serotonin and norepinephrine reuptake inhibitor', 'placebo']","['proportion of participants with abnormal sperm DNA fragmentation terminal deoxynucleotidyl transferase dUTP nick-end labelling scores', 'proportion of men with abnormal DNA fragmentation', 'semen parameters, sperm DNA fragmentation and serum hormones', 'hormonal values']","[{'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0245561', 'cui_str': 'duloxetine'}, {'cui': 'C1667738', 'cui_str': 'duloxetine 60 MG'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1579361', 'cui_str': 'SSRIs and NRIs'}]","[{'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0037868', 'cui_str': 'Spermatozoa'}, {'cui': 'C0376669', 'cui_str': 'DNA Fragmentation'}, {'cui': 'C0012881', 'cui_str': 'DNA nucleotidylexotransferase'}, {'cui': 'C0057470', 'cui_str': 'deoxyuridine triphosphate'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",68.0,0.332559,"Duloxetine was not associated with an increase in the proportion of participants with abnormal sperm DNA fragmentation terminal deoxynucleotidyl transferase dUTP nick-end labelling scores (>25%) on treatment (p = 0.09) or after treatment (p = 0.56), nor did median sperm DNA fragmentation increase on treatment.","[{'ForeName': 'Nahid', 'Initials': 'N', 'LastName': 'Punjani', 'Affiliation': 'Department of Urology, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Kang', 'Affiliation': 'Department of Urology, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Flannigan', 'Affiliation': 'Department of Urology, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Phil', 'Initials': 'P', 'LastName': 'Bach', 'Affiliation': 'Department of Urology, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Altemus', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'James H', 'Initials': 'JH', 'LastName': 'Kocsis', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Wu', 'Affiliation': 'Division of Biostatistics and Epidemiology, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Hudson', 'Initials': 'H', 'LastName': 'Pierce', 'Affiliation': 'Department of Urology, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Peter N', 'Initials': 'PN', 'LastName': 'Schlegel', 'Affiliation': 'Department of Urology, Weill Cornell Medicine, New York, NY, USA.'}]",Andrologia,['10.1111/and.14207'] 2272,34365635,Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.,"BACKGROUND Delayed recovery of urinary continence is a major adverse effect of robotic-assisted laparoscopic prostatectomy (RALP) in men undergoing prostate cancer treatment. To address this issue, a number of surgical techniques have been designed to reconstruct the posterior aspect of the rhabdosphincter, which is responsible for urinary continence after removal of the prostate; however, it is unclear how well they work.  OBJECTIVES: To assess the effects of posterior musculofascial reconstruction RALP compared to no posterior reconstruction during RALP for the treatment of clinically localized prostate cancer. SEARCH METHODS We performed a comprehensive search of the Cochrane Library, MEDLINE, Embase, three other databases, trials registries, other sources of the grey literature, and conference proceedings, up to 12 March 2021. We applied no restrictions on publication language or status. SELECTION CRITERIA We included randomized controlled trials (RCTs) in which participants were randomized to undergo variations of posterior musculofascial reconstruction RALP versus no posterior reconstruction during RALP for clinically localized prostate cancer. DATA COLLECTION AND ANALYSIS Two review authors independently classified studies and abstracted data from the included studies. Primary outcomes were: urinary continence recovery within one week after catheter removal, at three months after surgery, and serious adverse events. Secondary outcomes were: urinary continence recovery at six and twelve months after surgery, potency recovery twelve months after surgery, positive surgical margins (PSM), and biochemical recurrence-free survival (BCRFS). We performed statistical analyses using a random-effects model. We rated the certainty of evidence (CoE) according to the GRADE approach. MAIN RESULTS Our search identified 13 records of eight unique RCTs, of which six were published studies and two were abstract proceedings. We included 1085 randomized participants, of whom 963 completed the trials (88.8%). All participants had either cT1c or cT2 or cT3a disease, with a mean prostate-specific antigen level of 8.15 ng/mL. Primary outcomes Posterior reconstruction RALP (PR-RALP) may improve urinary continence one week after catheter removal compared to no posterior reconstruction during RALP (risk ratio (RR) 1.25, 95% confidence interval (CI) 0.90 to 1.73; I 2 = 42%; studies = 5, participants = 498; low CoE) although the CI also includes the possibility of no effect. Assuming 335 per 1000 men undergoing standard RALP are continent at this time point, this corresponds to 84 more men per 1000 (33 fewer to 244 more) reporting urinary continence recovery.  Posterior reconstruction may have little to no effect on urinary continence three months after surgery compared to no posterior reconstruction during RALP (RR 0.98, 95% CI 0.84 to 1.14; I 2 = 67%; studies = 6, participants = 842; low CoE). Assuming 701 per 1000 men undergoing standard RALP are continent at this time point, this corresponds to 14 fewer men per 1000 (112 fewer to 98 more) reporting urinary continence after three months. PR-RALP probably results in little to no difference in serious adverse events compared to no posterior reconstruction during RALP (RR 0.75, 95% CI 0.29 to 1.92; I 2 = 0%; studies = 6, participants = 835; moderate CoE). Assuming 25 per 1000 men undergoing standard RALP experience a serious adverse event at this time point, this corresponds to six fewer men per 1000 (17 fewer to 23 more) reporting serious adverse events.  Secondary outcomes PR-RALP may result in little to no difference in recovery of continence 12 months after surgery compared to no posterior reconstruction during RALP (RR 1.02, 95% CI 0.98 to 1.07; I 2 = 25%; studies = 3, participants = 602; low CoE). Assuming 918 per 1000 men undergoing standard RALP are continent at this time point, this corresponds to 18 more men per 1000 (18 fewer to 64 more) reporting urinary continence recovery.  We are very uncertain about the effects of PR-RALP on recovery of potency 12 months after surgery compared to no posterior reconstruction during RALP (RR 1.02, 95% CI 0.82 to 1.26; I 2 = 3%; studies = 2, participants = 308; very low CoE). Assuming 433 per 1000 men undergoing standard RALP are potent at this time point, this corresponds to nine more men per 1000 (78 fewer to 113 more) reporting potency recovery.  PR-RALP may result in little to no difference in positive surgical margins compared to no posterior reconstruction during RALP (RR 1.24, 95% CI 0.65 to 2.33; I 2 = 50%; studies = 3, participants = 517; low CoE). Assuming 130 per 1000 men undergoing standard RALP have a positive surgical margin, this corresponds to 31 more men per 1000 (46 fewer to 173 more) reporting positive surgical margins.  PR-RALP may result in little to no difference in biochemical recurrence compared to no posterior reconstruction during RALP (RR 1.36, 95% CI 0.74 to 2.52; I 2 = 0%; studies = 2, participants = 468; low CoE). Assuming 70 per 1000 men undergoing standard RALP have experienced biochemical recurrence at this time point, this corresponds to 25 more men per 1000 (18 fewer to 107 more) reporting biochemical recurrence.  AUTHORS' CONCLUSIONS: This review found evidence that PR-RALP may improve early continence one week after catheter removal but not thereafter. Meanwhile, adverse event rates are probably not impacted and surgical margins rates are likely similar. This review was unable to determine if or how these findings may be impacted by the person's age, nerve-sparing status, or clinical stage. Study limitations, imprecision, and inconsistency lowered the certainty of evidence for the outcomes assessed.",2021,"PR-RALP probably results in little to no difference in serious adverse events compared to no posterior reconstruction during RALP (RR 0.75, 95% CI 0.29 to 1.92;","['1085 randomized participants, of whom 963 completed the trials (88.8', 'Assuming 433 per 1000 men undergoing', 'clinically localized prostate cancer', 'Assuming 701\xa0per 1000 men undergoing', 'men undergoing prostate cancer treatment', 'Assuming 130 per 1000 men undergoing standard RALP have a positive surgical margin, this corresponds to 31 more men per 1000 (46 fewer to 173 more) reporting positive surgical margins', 'Assuming 335\xa0per 1000 men undergoing', '1000 men undergoing', 'Assuming 918\xa0per 1000 men undergoing']","['robotic-assisted laparoscopic prostatectomy', 'RALP', 'robotic-assisted laparoscopic prostatectomy (RALP', 'posterior musculofascial reconstruction RALP', 'Posterior musculofascial reconstruction', 'standard RALP', 'PR-RALP', 'posterior musculofascial reconstruction RALP versus no posterior reconstruction during RALP']","['biochemical recurrence', 'urinary continence recovery', 'urinary continence', 'recovery of continence', 'serious adverse events', 'cT1c or cT2 or cT3a disease', 'urinary continence recovery at six and twelve months after surgery, potency recovery twelve months after surgery, positive surgical margins (PSM), and biochemical recurrence-free survival (BCRFS']","[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0033573', 'cui_str': 'Prostatectomy'}, {'cui': 'C1709603', 'cui_str': 'Positive Surgical Margins'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C4709307', 'cui_str': '335'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0033573', 'cui_str': 'Prostatectomy'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0542565', 'cui_str': 'Bladder control'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1709603', 'cui_str': 'Positive Surgical Margins'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}]",1085.0,0.561723,"PR-RALP probably results in little to no difference in serious adverse events compared to no posterior reconstruction during RALP (RR 0.75, 95% CI 0.29 to 1.92;","[{'ForeName': 'Joel E', 'Initials': 'JE', 'LastName': 'Rosenberg', 'Affiliation': 'University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Jae Hung', 'Initials': 'JH', 'LastName': 'Jung', 'Affiliation': 'Department of Urology, Yonsei University Wonju College of Medicine, Wonju, Korea, South.'}, {'ForeName': 'Hunju', 'Initials': 'H', 'LastName': 'Lee', 'Affiliation': 'Department of Preventive Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea, South.'}, {'ForeName': 'Solam', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Preventive Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea, South.'}, {'ForeName': 'Caitlin J', 'Initials': 'CJ', 'LastName': 'Bakker', 'Affiliation': 'Health Sciences Libraries, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Dahm', 'Affiliation': 'Urology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013677.pub2'] 2273,34365636,Hypothalamic-pituitary-adrenal activity in adverse events reporting after placebo administration.,"Participants of clinical trials who receive a placebo treatment often report a variety of adverse events, sometimes called nocebo effects. The reason why these adverse events occur is not clear, and understanding the underlying mechanisms represents a challenge that is likely to improve the interpretation of clinical trials as well as medical practice. Here we studied 192 healthy subjects who received placebo oxygen through a mask after reading (READ) or not reading (NO-READ) a list of possible adverse events of oxygen breathing: headache, chest pain, abdominal pain, and cough. The whole hypothalamus-pituitary-adrenal axis was assessed just before and right after placebo breathing by measuring the hypothalamic corticotropin-releasing hormone (CRH), pituitary adrenocorticotropic hormone (ACTH) and adrenal cortisol (COR). In addition, both state and trait anxiety were assessed. We found that 64.5% of the NO-READ group reported no adverse events, 30.2% one, and only 5.2% two adverse events. In contrast, only 20.8% of the READ group reported no adverse events, whereas one, two, three, and four adverse events were reported with a frequency of 21.8%, 19.8%, 19.8%, and 17.7%, respectively. In addition, when the READ group reported three and four adverse events, CRH, ACTH and COR were significantly increased compared to the NO-READ group, along with an increase in state anxiety scores. These data indicate that hypothalamic-pituitary-adrenal activity and state anxiety are increased in those subjects who report many adverse events after reading a list of adverse events, thus highlighting a possible neuroendocrine mechanism after placebo administration.",2021,"In addition, when the READ group reported three and four adverse events, CRH, ACTH and COR were significantly increased compared to the NO-READ group, along with an increase in state anxiety scores.",['192 healthy subjects who received'],"['placebo', 'placebo oxygen through a mask after reading (READ) or not reading (NO-READ']","['hypothalamic corticotropin-releasing hormone (CRH), pituitary adrenocorticotropic hormone (ACTH) and adrenal cortisol (COR', 'adverse events, CRH, ACTH and COR', 'adverse events, sometimes called nocebo effects', 'hypothalamic-pituitary-adrenal activity and state anxiety', 'state anxiety scores', 'adverse events', 'state and trait anxiety']","[{'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0034754', 'cui_str': 'Reading'}]","[{'cui': 'C0020663', 'cui_str': 'Hypothalamic structure'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0001625', 'cui_str': 'Adrenal structure'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C3658218', 'cui_str': 'Nocebo'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",192.0,0.247471,"In addition, when the READ group reported three and four adverse events, CRH, ACTH and COR were significantly increased compared to the NO-READ group, along with an increase in state anxiety scores.","[{'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Benedetti', 'Affiliation': 'University of Turin Medical School, Neuroscience Dept, Turin, Italy.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Amanzio', 'Affiliation': 'Department of Psychology, University of Turin, Turin, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Giovannelli', 'Affiliation': ""Department of Neuroscience, Drug Research and Child's Health, University of Florence, Florence, Italy.""}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Craigs-Brackhahn', 'Affiliation': 'Medicine & Physiology of Hypoxia, Plateau Rosà, Italy, Switzerland.'}, {'ForeName': 'Aziz', 'Initials': 'A', 'LastName': 'Shaibani', 'Affiliation': 'Nerve & Muscle Center of Texas, Houston, Texas, USA.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.2388'] 2274,34365592,Home-Based Exercise Training During COVID-19 Pandemic in Post-Bariatric Patients: a Randomized Controlled Trial.,This data is mandatory Please provide.,2021,This data is mandatory Please provide.,['Post-Bariatric Patients'],['Home-Based Exercise Training'],[],"[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1450026', 'cui_str': 'Bariatrics'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]",[],,0.128851,This data is mandatory Please provide.,"[{'ForeName': 'Gersiel Nascimento', 'Initials': 'GN', 'LastName': 'de Oliveira Júnior', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Karla Fabiana', 'Initials': 'KF', 'LastName': 'Goessler', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Jhonnatan Vasconcelos Pereira', 'Initials': 'JVP', 'LastName': 'Santos', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Alisson Padilha', 'Initials': 'AP', 'LastName': 'de Lima', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Genário', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Carlos Alberto Abujabra', 'Initials': 'CAA', 'LastName': 'Merege-Filho', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Diego Augusto Nunes', 'Initials': 'DAN', 'LastName': 'Rezende', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Damiot', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'de Cleva', 'Affiliation': 'Department of Digestive Surgery, School of Medicine, University of Sao Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Marco Aurélio', 'Initials': 'MA', 'LastName': 'Santo', 'Affiliation': 'Department of Digestive Surgery, School of Medicine, University of Sao Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Hamilton', 'Initials': 'H', 'LastName': 'Roschel', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Gualano', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil. gualano@usp.br.'}]",Obesity surgery,['10.1007/s11695-021-05621-5'] 2275,34365570,"Using self-etch adhesive agents with pit and fissure sealants. In vitro analysis of shear bond strength, adhesive remnant index and enamel etching patterns.","PURPOSE The aim of this study was to evaluate in vitro, the shear bond strength (SBS) and adhesive remnant index (ARI) of pit and fissure sealants (PFS) after enamel conditioning with different new-generation self-etching (SE) agents; additionally, enamel etching patterns were assessed. METHODS Healthy unerupted third molars surgically removed for therapeutic reasons (n = 25p/g), were randomly assigned to six groups. Conventional etching (CE) or SE was applied prior to pit and fissure sealants bonding. Enamel conditioned surfaces were evaluated by SEM at × 500, × 1000, and × 2000 magnification to determine etching patterns. Subsequently, 25 PFS blocks (3 × 2 × 1.5 mm) p/g were bonded to enamel surface. Samples were stored in water at 37 °C for 24 h, previous to SBS and ARI test. One-way ANOVA and Tamhane statistic tests were used for SBS; while Mann-Whitney U and Kruskal-Wallis were employed for ARI (p ≤ 0.05). RESULTS For SBS test, CE_PFS_3M and SE1_PFS_Shofu groups showed the lowest values (8.74 ± 4.02 and 8.75 ± 3.90, respectively). The highest scores were observed in SE_PFS_Kuraray group (13.46 ± 5.83). Significant differences in SBS and ARI assessments were found. All experimental groups showed type 1 etching pattern. CONCLUSION The etching pattern was less pronounced in self-etching groups, which showed an equal or superior in vitro performance compared to conventional etching agents. The clinical use of self-etching agents could be recommended before pit and fissure sealants application in new dental protocols. The best in vitro performance was observed when both applied materials, self-etching agent and pit and fissure sealant have 10-methacryloyloxydecyl dihydrogen phosphate in their chemical composition.",2021,"The best in vitro performance was observed when both applied materials, self-etching agent and pit and fissure sealant have 10-methacryloyloxydecyl dihydrogen phosphate in their chemical composition.",['Healthy unerupted third molars surgically removed for therapeutic reasons (n\u2009=\u200925p/g'],['Conventional etching (CE) or SE'],"['shear bond strength (SBS) and adhesive remnant index (ARI) of pit and fissure sealants (PFS', 'SBS and ARI assessments', 'shear bond strength, adhesive remnant index and enamel etching patterns']","[{'cui': 'C0399551', 'cui_str': 'Impacted third molar tooth'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0175735', 'cui_str': 'Scissors'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0001516', 'cui_str': 'Adhesive'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0031992', 'cui_str': 'Pit Fissure Sealants'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]",,0.0360905,"The best in vitro performance was observed when both applied materials, self-etching agent and pit and fissure sealant have 10-methacryloyloxydecyl dihydrogen phosphate in their chemical composition.","[{'ForeName': 'I', 'Initials': 'I', 'LastName': 'Mézquita-Rodrigo', 'Affiliation': 'Facultad de Odontología, Centro de Investigación y Estudios Avanzados en Odontología (CIEAO), Universidad Autónoma del Estado de México, Jesús Carranza Esq. Paseo Tollocan, Col. Universidad Estado de México, 50130, Toluca, CP, México.'}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Scougall-Vilchis', 'Affiliation': 'Facultad de Odontología, Centro de Investigación y Estudios Avanzados en Odontología (CIEAO), Universidad Autónoma del Estado de México, Jesús Carranza Esq. Paseo Tollocan, Col. Universidad Estado de México, 50130, Toluca, CP, México.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Moyaho-Bernal', 'Affiliation': 'Facultad de Estomatología, Benemérita Universidad Autónoma de Puebla, Av. Manuel Espinosa Yglesias 31 Pte. 1304, Col. Los Volcanes, 72570, Puebla, CP, México.'}, {'ForeName': 'L E', 'Initials': 'LE', 'LastName': 'Rodríguez-Vilchis', 'Affiliation': 'Facultad de Odontología, Centro de Investigación y Estudios Avanzados en Odontología (CIEAO), Universidad Autónoma del Estado de México, Jesús Carranza Esq. Paseo Tollocan, Col. Universidad Estado de México, 50130, Toluca, CP, México.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Rubio-Rosas', 'Affiliation': 'Dirección de Innovación y Transferencia de Conocimiento, Benemérita Universidad Autónoma de Puebla, Prolongación de la 24 Sur y Av. San Claudio, Ciudad Universitaria, Col. San Manuel, 72570, Puebla, CP, México.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Contreras-Bulnes', 'Affiliation': 'Facultad de Odontología, Centro de Investigación y Estudios Avanzados en Odontología (CIEAO), Universidad Autónoma del Estado de México, Jesús Carranza Esq. Paseo Tollocan, Col. Universidad Estado de México, 50130, Toluca, CP, México. rcontrerasb@uaemex.mx.'}]",European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry,['10.1007/s40368-021-00655-w'] 2276,34365541,Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials.,"BACKGROUND Adjuvant therapy for gastric cancer is a standard among the world with no regimen selection criteria. Also, prognostic factors except for tumor staging have not been established. We aimed to identify prognostic and predictive markers for gastric cancer adjuvant therapy from large randomized controlled trials with standard lymph node dissection. METHODS Three studies: ACTS-GC, CLASSIC, and SAMIT were found and selected for a pooled analysis, following PRISMA guideline. The integrity of individual participant data (IPD) was verified in the eligible 3527 patients registered, and fixed-effect model was used. The primary endpoint was relapse-free survival (RFS) and the secondary endpoint was overall survival (OS). RESULTS Age was a significant prognostic factor in addition to tumor stages both in ""surgery alone"" and ""adjuvant"" groups. Adjuvant therapy was effective for every TN stage; however, it tended to be more effective in T1-2 than in T3-4. Also, it was more effective in low- or middle-BMI than in high-BMI group with Hazard ratio [HR]s: 0.58, 0.58, and 1.05, respectively. Capecitabine plus oxaliplatin (CAPOX) was more effective than S-1 for T1-2, N2-3, and differentiated type with HRs between 0.59 and 0.70, but with no difference among TNM stages. Combining histology to TN; the HRs in differentiated T1-2 N1-3 groups were between 0.29 and 0.45. For T3-4 N0-1 group, S-1 was likely to be effective, not significant. CONCLUSIONS Age is a significant prognostic factor both in surgery alone and adjuvant group. CAPOX is more effective for differentiated T1-2 tumors with lymph node metastasis.",2021,"Capecitabine plus oxaliplatin (CAPOX) was more effective than S-1 for T1-2, N2-3, and differentiated type with HRs between 0.59 and 0.70, but with no difference among TNM stages.",[],"['gastric cancer adjuvant therapy', 'CAPOX', 'adjuvant chemotherapy', 'Capecitabine plus oxaliplatin (CAPOX']","['relapse-free survival (RFS', 'integrity of individual participant data (IPD', 'overall survival (OS']",[],"[{'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",3527.0,0.105387,"Capecitabine plus oxaliplatin (CAPOX) was more effective than S-1 for T1-2, N2-3, and differentiated type with HRs between 0.59 and 0.70, but with no difference among TNM stages.","[{'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Tsuburaya', 'Affiliation': 'Department of Surgery, Tsuboi Cancer Center Hospital, Koriyama, Japan. tuburayaa@gmail.com.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Guan', 'Affiliation': 'Department of Clinical Biostatistics, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Yoshida', 'Affiliation': 'Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.'}, {'ForeName': 'Michiya', 'Initials': 'M', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Clinical Oncology and Minimally Invasive Surgery, Kochi University, Nangoku, Japan.'}, {'ForeName': 'Shigefumi', 'Initials': 'S', 'LastName': 'Yoshino', 'Affiliation': 'Department of Surgery, National Hospital Organization Kanmon Medical Center, Shimonoseki, Japan.'}, {'ForeName': 'Kazuaki', 'Initials': 'K', 'LastName': 'Tanabe', 'Affiliation': 'Department of Health Care for Adults, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Takaki', 'Initials': 'T', 'LastName': 'Yoshikawa', 'Affiliation': 'Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Oshima', 'Affiliation': 'Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.'}, {'ForeName': 'Yumi', 'Initials': 'Y', 'LastName': 'Miyashita', 'Affiliation': 'Nonprofit Organization Epidemiological and Clinical Research Information Network, Kyoto, Japan.'}, {'ForeName': 'Junichi', 'Initials': 'J', 'LastName': 'Sakamoto', 'Affiliation': 'Tokai Central Hospital, Kakamigahara, Japan.'}, {'ForeName': 'Shiro', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Department of Clinical Biostatistics, Kyoto University, Kyoto, Japan.'}]",Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,['10.1007/s10120-021-01228-y'] 2277,34365456,The Response and Tolerability of a Novel Cold Atmospheric Plasma Wound Dressing for the Healing of Split Skin Graft Donor Sites: A Controlled Pilot Study.,"INTRODUCTION Cold atmospheric plasma (CAP) has positive effects on wound healing and antimicrobial properties. However, an ongoing challenge is the development of specific modes of application for different clinical indications. OBJECTIVES We investigated in a prospective pilot study the response and tolerability of a newly developed CAP wound dressing for the acute healing of split skin graft donor sites compared to conventional therapy. METHODS We applied both treatments to each patient (n = 10) for 7 days and measured 4 parameters of wound healing every other day (i.e., 1,440 measurements) using a hyperspectral imaging camera. Additionally, we evaluated the clinical appearance and pain levels reported by the patients. RESULTS The CAP wound dressing was superior to the control (p < 0.001) in the improvement of 3 wound parameters, that is, deep tissue oxygen saturation, hemoglobin distribution, and tissue water distribution. CAP was well tolerated, and pain levels were lower in CAP-treated wound areas. CONCLUSION CAP wound dressing is a promising new tool for acute wound healing.",2021,"The CAP wound dressing was superior to the control (p < 0.001) in the improvement of 3 wound parameters, that is, deep tissue oxygen saturation, hemoglobin distribution, and tissue water distribution.",['Graft Donor Sites'],"['conventional therapy', 'CAP wound dressing', 'hyperspectral imaging camera', 'Cold atmospheric plasma (CAP', 'Novel Cold Atmospheric Plasma Wound Dressing', 'CAP']","['tolerated, and pain levels', 'clinical appearance and pain levels', 'deep tissue oxygen saturation, hemoglobin distribution, and tissue water distribution', 'Healing of Split Skin']","[{'cui': 'C0730393', 'cui_str': 'Donor graft'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0460765', 'cui_str': 'Wound management dressing'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0179533', 'cui_str': 'Camera'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]",,0.00441442,"The CAP wound dressing was superior to the control (p < 0.001) in the improvement of 3 wound parameters, that is, deep tissue oxygen saturation, hemoglobin distribution, and tissue water distribution.","[{'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'van Welzen', 'Affiliation': 'Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.'}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Hoch', 'Affiliation': 'Department of Systems Biology and Bioinformatics, University of Rostock, Rostock, Germany.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Wahl', 'Affiliation': 'Diaspective Vision GmbH, Pepelow, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Weber', 'Affiliation': 'Department for Biostatistics and Informatics in Medicine, University Medical Center, Rostock, Germany.'}, {'ForeName': 'Susen', 'Initials': 'S', 'LastName': 'Rode', 'Affiliation': 'Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.'}, {'ForeName': 'Julia Katharina', 'Initials': 'JK', 'LastName': 'Tietze', 'Affiliation': 'Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Boeckmann', 'Affiliation': 'Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Emmert', 'Affiliation': 'Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Thiem', 'Affiliation': 'Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.'}]",Skin pharmacology and physiology,['10.1159/000517524'] 2278,34365358,Lorlatinib Is Active in ROS1 -Positive Non-Small Cell Lung Cancer.,"In a phase I/II trial, lorlatinib was safe and effective in ROS1 -positive non-small cell lung cancer.",2020,"In a phase I/II trial, lorlatinib was safe and effective in ROS1 -positive non-small cell lung cancer.",[],[],[],[],[],[],,0.380193,"In a phase I/II trial, lorlatinib was safe and effective in ROS1 -positive non-small cell lung cancer.",[],Cancer discovery,['10.1158/2159-8290.CD-RW2019-169'] 2279,34365061,"Propolis increases Foxp3 expression and lymphocyte proliferation in HIV-infected people: A randomized, double blind, parallel-group and placebo-controlled study.","HIV infection and the prolonged use of antiretroviral therapy (ART) contribute to persistent inflammation and immune deregulation in people living with HIV/AIDS (PLWHA). Propolis is a bee product with plenty of biological properties, including immunomodulatory and anti-inflammatory action. This work aimed to evaluate possible changes in the immune/inflammatory response in PLWHA under ART after propolis intake. Asymptomatic PLWHA were double-blindly randomized into parallel groups receiving propolis (500 mg/day, n = 20) for 3 months or placebo (n = 20). Plasma cytokines (TNF-α, IL-2, IL-4, IL-6, IL-10 and IL17) were evaluated by cytometric bead array; cytokine production by PBMC (IFN-γ, IL-5, IL-17, IL-10, IL-1β, IL-18, and IL-33) was assessed by ELISA; gene expression (T-bet, GATA-3, RORγt and Foxp3) was determined by RT-qPCR, and cell proliferation was analysed by flow cytometry using CFSE staining. The average of gender, age, CD4 + /CD8 + T cell count, time of diagnosis and treatment were similar in both groups. No differences were observed in cytokine levels nor in inflammasome activation. However, Pearson's correlation showed that IL-10 was directly correlated to CD4 + T cell count and inversely to IFN-γ after treatment with propolis. Foxp3 expression and lymphocyte proliferation increased in the propolis group. Data suggested that daily propolis consumption may improve the immune response and decrease the inflammatory status in asymptomatic PLWHA under ART.",2021,"Plasma cytokines (TNF-α, IL-2, IL-4, IL-6, IL-10 and IL17) were evaluated by cytometric bead array; cytokine production by PBMC (IFN-γ, IL-5, IL-17, IL-10, IL-1β, IL-18, and IL-33) was assessed by ELISA; gene expression (T-bet, GATA-3, RORγt and Foxp3) was determined by RT-qPCR, and cell proliferation was analysed by flow cytometry using CFSE staining.","['people living with HIV/AIDS (PLWHA', 'HIV-infected people']","['antiretroviral therapy (ART', 'placebo']","['Foxp3 expression and lymphocyte proliferation', 'Plasma cytokines (TNF-α, IL-2, IL-4, IL-6, IL-10 and IL17', 'average of gender, age, CD4 + /CD8 + T cell count, time of diagnosis and treatment', 'ELISA; gene expression (T-bet, GATA-3, RORγt and Foxp3', 'RT-qPCR, and cell proliferation', 'cytokine levels', 'CD4 + T cell count', 'cytometric bead array; cytokine production by PBMC (IFN-γ, IL-5, IL-17, IL-10, IL-1β, IL-18, and IL-33']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0334094', 'cui_str': 'Proliferation'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021756', 'cui_str': 'Interleukin-2'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C1701790', 'cui_str': 'IL17A protein, human'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C1307598', 'cui_str': 'GATA3 protein, human'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C0596290', 'cui_str': 'Cellular Proliferation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0021759', 'cui_str': 'Interleukin-5'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0383327', 'cui_str': 'Interleukin 18'}, {'cui': 'C1667752', 'cui_str': 'IL33 protein, human'}]",,0.400836,"Plasma cytokines (TNF-α, IL-2, IL-4, IL-6, IL-10 and IL17) were evaluated by cytometric bead array; cytokine production by PBMC (IFN-γ, IL-5, IL-17, IL-10, IL-1β, IL-18, and IL-33) was assessed by ELISA; gene expression (T-bet, GATA-3, RORγt and Foxp3) was determined by RT-qPCR, and cell proliferation was analysed by flow cytometry using CFSE staining.","[{'ForeName': 'Fernanda Lopes', 'Initials': 'FL', 'LastName': 'Conte', 'Affiliation': 'São Paulo State University (UNESP), Institute of Biosciences, Campus Botucatu, São Paulo, Brazil; São Paulo State University (UNESP), Botucatu Medical School, Campus Botucatu, São Paulo, Brazil.'}, {'ForeName': 'Karen Ingrid', 'Initials': 'KI', 'LastName': 'Tasca', 'Affiliation': 'São Paulo State University (UNESP), Institute of Biosciences, Campus Botucatu, São Paulo, Brazil.'}, {'ForeName': 'Karina Basso', 'Initials': 'KB', 'LastName': 'Santiago', 'Affiliation': 'São Paulo State University (UNESP), Institute of Biosciences, Campus Botucatu, São Paulo, Brazil.'}, {'ForeName': 'Eliza', 'Initials': 'E', 'LastName': 'de Oliveira Cardoso', 'Affiliation': 'São Paulo State University (UNESP), Institute of Biosciences, Campus Botucatu, São Paulo, Brazil.'}, {'ForeName': 'Graziela Gorete', 'Initials': 'GG', 'LastName': 'Romagnoli', 'Affiliation': 'São Paulo State University (UNESP), Institute of Biosciences, Campus Botucatu, São Paulo, Brazil.'}, {'ForeName': 'Marjorie', 'Initials': 'M', 'LastName': 'de Assis Golim', 'Affiliation': 'São Paulo State University (UNESP), Botucatu Medical School, Campus Botucatu, São Paulo, Brazil.'}, {'ForeName': 'Aline Márcia Marques', 'Initials': 'AMM', 'LastName': 'Braz', 'Affiliation': 'São Paulo State University (UNESP), Botucatu Medical School, Campus Botucatu, São Paulo, Brazil.'}, {'ForeName': 'Andresa Aparecida', 'Initials': 'AA', 'LastName': 'Berretta', 'Affiliation': 'Research, Development & Innovation Laboratory, Apis Flora Indl. Coml. Ltda., Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Lenice', 'Initials': 'L', 'LastName': 'do Rosário de Souza', 'Affiliation': 'São Paulo State University (UNESP), Botucatu Medical School, Campus Botucatu, São Paulo, Brazil.'}, {'ForeName': 'José Maurício', 'Initials': 'JM', 'LastName': 'Sforcin', 'Affiliation': 'São Paulo State University (UNESP), Institute of Biosciences, Campus Botucatu, São Paulo, Brazil. Electronic address: jose.m.sforcin@unesp.br.'}]",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,['10.1016/j.biopha.2021.111984'] 2280,34365060,Advantages of using toothpaste containing propolis and plant oils for gingivitis prevention and oral cavity hygiene in cleft lip/palate patients.,"BACKGROUND The anti-inflammatory and antibacterial action of preparations used during oral hygiene procedures is particularly important in patients with oral cleft. Few reports have been published assessing the influence of natural products on the state of the oral cavity in patients with oral cleft. The aim of this study was to assess the effect of toothpaste containing Polish propolis and plant oils on oral cavity health in patients with oral cleft treated orthodontically. MATERIALS AND METHODS A total of 50 patients aged 9-16 years old (20 females, 23 males) were selected and randomly assigned into two groups. Group (A) received toothpaste with Polish propolis, tea tree oil, menthol, and rosemary oil. Group (B) received toothpaste without active ingredients (placebo). A baseline assessment was followed by an oral hygiene index (OHI, debris OHI-D, and calculus OHI-C component) and gingival bleeding index (GBI) after 35 days. The methodology of the oral condition assessment included the presence of cleft malformation as a dysmorphic of the anterior maxilla segment. RESULTS In group A, improvement in oral cavity hygiene assessed for incisors and molars was found (OHI-T p = 0.011). For the gingival condition, a decrease in the gingival bleeding index - total (GBI-T p = 0.002), as well as for the incisors (GBI-I p = 0.007) and molars (GBI-M p = 0.017) was found. CONCLUSIONS This research confirms the biological effectiveness of toothpaste with Polish propolis and plant oils. These results may be clinically useful for improving preventative oral care and for control of oral infectious diseases during orthodontic treatment in patients with oral cleft.",2021,"For the gingival condition, a decrease in the gingival bleeding index - total (GBI-T p = 0.002), as well as for the incisors (GBI-I p = 0.007) and molars (GBI-M p = 0.017) was found. ","['50 patients aged 9-16 years old (20 females, 23 males', 'cleft lip/palate patients', 'patients with oral cleft', 'patients with oral cleft treated orthodontically']","['toothpaste containing Polish propolis and plant oils', 'toothpaste containing propolis and plant oils', 'toothpaste without active ingredients (placebo', 'toothpaste with Polish propolis, tea tree oil, menthol, and rosemary oil', 'toothpaste with Polish propolis and plant oils']","['oral hygiene index (OHI, debris OHI-D, and calculus OHI-C component) and gingival bleeding index (GBI', 'oral cavity health', 'gingivitis prevention and oral cavity hygiene', 'gingival bleeding index - total', 'oral cavity hygiene']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0158646', 'cui_str': 'Cleft palate with cleft lip'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0205242', 'cui_str': 'Cleaved'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0040462', 'cui_str': 'Toothpaste'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0032376', 'cui_str': 'Polish language'}, {'cui': 'C0033488', 'cui_str': 'Propolis'}, {'cui': 'C0032085', 'cui_str': 'Plant oil'}, {'cui': 'C1292749', 'cui_str': 'Has active ingredient'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0216194', 'cui_str': 'Tea Tree Oil'}, {'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0304114', 'cui_str': 'rosemary oil'}]","[{'cui': 'C0029165', 'cui_str': 'Oral Hygiene Indexes'}, {'cui': 'C0440266', 'cui_str': 'Debris'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0580084', 'cui_str': 'Gingival bleeding index'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",50.0,0.0347767,"For the gingival condition, a decrease in the gingival bleeding index - total (GBI-T p = 0.002), as well as for the incisors (GBI-I p = 0.007) and molars (GBI-M p = 0.017) was found. ","[{'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Machorowska-Pieniążek', 'Affiliation': 'Department of Orthodontics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. Electronic address: apieniazek@sum.edu.pl.'}, {'ForeName': 'Tadeusz', 'Initials': 'T', 'LastName': 'Morawiec', 'Affiliation': 'Division of Dental Surgery, Department of Craniomaxillofacial Surgery and Oral Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Olek', 'Affiliation': 'Department of Orthodontics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Mertas', 'Affiliation': 'Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Aebisher', 'Affiliation': 'Medical College of The University of Rzeszow, Rzeszów, Poland.'}, {'ForeName': 'Dorota', 'Initials': 'D', 'LastName': 'Bartusik-Aebisher', 'Affiliation': 'Medical College of The University of Rzeszow, Rzeszów, Poland.'}, {'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Cieślar', 'Affiliation': 'Department of Internal Medicine, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Kawczyk-Krupka', 'Affiliation': 'Department of Internal Medicine, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland. Electronic address: akawczyk@gmail.com.'}]",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,['10.1016/j.biopha.2021.111992'] 2281,34365030,"The impact of nurse home visiting on the use, dose and quality of formal childcare: 3-year follow-up of a randomized trial.","OBJECTIVES We investigated whether nurse home visiting (NHV) affects the uptake and quality of formal early childhood education and care (ECEC) at child ages 2 and 3 years, and reasons for using ECEC at 3 years. METHODS Design: Secondary analysis of the ""right@home"" randomized trial of NHV. PARTICIPANTS 722 pregnant Australian, English-speaking women experiencing adversity recruited from antenatal clinics across two States. INTERVENTION 25 nurse home visits to 2-years; Control: universal well-child nursing service. MEASURES Parents reported formal ECEC use (government approved and subsidized), comprising long or family day care (LDC/FDC), and reasons for use. ECEC quality was classified using the Australian government's national ratings. 83% of parents provided data at 2-years (306 intervention/290 control); and 69% at 3-years (255 intervention/240 control). ANALYSIS Intention-to-treat analyses were conducted using adjusted regression models, addressing missing data using multiple imputation and inverse probability weighting. RESULTS There was no evidence of group differences in ECEC uptake or quality, although control families may have used more LDC at 3 years (mean difference 2.8 hours, 95% CI: -0.2 to 5.8 hours). Intervention parents reported using ECEC to support their children's social development more frequently than controls (48% versus 33%) but less for work/study (39% versus 46%). CONCLUSIONS The right@home NHV program did not impact ECEC uptake or quality, although it may influence parents' reasons for using ECEC. If supported by policy and provision, there is an opportunity for NHV programs to promote the transition to high-quality ECEC and evaluate the synergistic benefit on children's development.",2021,"The right@home NHV program did not impact ECEC uptake or quality, although it may influence parents' reasons for using ECEC.","['722 pregnant Australian, English-speaking women experiencing adversity recruited from antenatal clinics across two States']","['25 nurse home visits to 2-years; Control: universal well-child nursing service', 'ECEC', 'NHV', 'nurse home visiting (NHV']","['ECEC uptake or quality', 'ECEC quality']","[{'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1274027', 'cui_str': 'Antenatal clinic'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0028697', 'cui_str': 'Nursing service'}, {'cui': 'C0599196', 'cui_str': 'Early childhood'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C0599196', 'cui_str': 'Early childhood'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}]",722.0,0.0529918,"The right@home NHV program did not impact ECEC uptake or quality, although it may influence parents' reasons for using ECEC.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Price', 'Affiliation': ""Centre for Community Child Health, The Royal Children's Hospital, Parkville, Vic 3052, Australia; Population Health, Murdoch Children's Research Institute, Parkville, Vic 3052, Australia; Department of Paediatrics, University of Melbourne, Parkville, Vic 3052, Australia. Electronic address: anna.price@mcri.edu.au.""}, {'ForeName': 'Shalika Bohingamu', 'Initials': 'SB', 'LastName': 'Mudiyanselage', 'Affiliation': 'Deakin Health Economics, Centre for Population Health Research, Deakin University, Geelong, Vic, 3220, Australia.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Schembri', 'Affiliation': ""Population Health, Murdoch Children's Research Institute, Parkville, Vic 3052, Australia; Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Vic 3052, Australia.""}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Mensah', 'Affiliation': ""Population Health, Murdoch Children's Research Institute, Parkville, Vic 3052, Australia; Department of Paediatrics, University of Melbourne, Parkville, Vic 3052, Australia.""}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Kemp', 'Affiliation': 'Ingham Institute, Western Sydney University, NSW 2751, Australia.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Harris', 'Affiliation': 'Australian Research Alliance for Children and Youth, ACT 2601, Australia.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Goldfeld', 'Affiliation': ""Centre for Community Child Health, The Royal Children's Hospital, Parkville, Vic 3052, Australia; Population Health, Murdoch Children's Research Institute, Parkville, Vic 3052, Australia; Department of Paediatrics, University of Melbourne, Parkville, Vic 3052, Australia.""}]",Academic pediatrics,['10.1016/j.acap.2021.07.022'] 2282,34365019,A patient-oriented analysis of pain side effect: A step to improve the patient's experience during rTMS?,"BACKGROUND Repetitive transcranial magnetic stimulation (rTMS) is an efficacious and well-tolerated intervention for treatment-resistant depression (TRD). A novel rTMS protocol, intermittent theta burst stimulation (iTBS) has been recently implemented in clinical practice, and it is essential to characterize the factors associated to pain and the trajectory of pain of iTBS compared to standard rTMS protocols. OBJECTIVE We aimed to characterize the side effect profile and the pain trajectories of High-Frequency Left (HFL) and iTBS in TRD patients in the THREE-D trial. We also investigated factors associated to pain and the relationship between pain and clinical outcomes. METHODS 414 patients were randomized to either HFL or iTBS. Severity of pain was measured after every treatment. General Estimating Equation was used to investigate factors associated with pain. Latent class linear mixed model was used to investigate latent classes of pain trajectories over the course of rTMS. RESULTS Higher level of pain was associated with older age, higher stimulation intensity, higher anxiety, female, and non-response. The severity of pain significantly declined over the course of treatments with a steeper decrease early on in the course of the treatment in both protocols, and four latent pain trajectories were identified. The less favorable pain trajectories were associated with non-response and higher stimulation intensity. CONCLUSIONS HFL and iTBS were associated with similar factors and pain trajectories, although iTBS was more uncomfortable. Response to rTMS was associated with less pain and more favorable pain trajectories furthering the evince base of overlapping neurobiological underpinnings of mood and pain. We translated these results into patient-oriented information to aid in the decision-making process when considering rTMS.",2021,"Higher level of pain was associated with older age, higher stimulation intensity, higher anxiety, female, and non-response.","['414 patients', 'TRD patients in the THREE-D trial']","['Repetitive transcranial magnetic stimulation (rTMS', 'HFL or iTBS', 'rTMS', 'intermittent theta burst stimulation (iTBS']","['favorable pain trajectories', 'Severity of pain', 'pain', 'severity of pain', 'Higher level of pain']","[{'cui': 'C4517771', 'cui_str': '414'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",414.0,0.0318428,"Higher level of pain was associated with older age, higher stimulation intensity, higher anxiety, female, and non-response.","[{'ForeName': 'Afifa', 'Initials': 'A', 'LastName': 'Humaira', 'Affiliation': 'Non-Invasive Neurostimulation Therapies (NINET) Laboratory, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada, V6T 2A1.'}, {'ForeName': 'Sihaoyu', 'Initials': 'S', 'LastName': 'Gao', 'Affiliation': 'Non-Invasive Neurostimulation Therapies (NINET) Laboratory, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada, V6T 2A1.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Gregory', 'Affiliation': 'Non-Invasive Neurostimulation Therapies (NINET) Laboratory, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada, V6T 2A1.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Ridgway', 'Affiliation': 'Non-Invasive Neurostimulation Therapies (NINET) Laboratory, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada, V6T 2A1.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Blumberger', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, 250 College Street, Floor 8, Toronto, ON, Canada, M5T 1R8.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Downar', 'Affiliation': 'University Health Network, Toronto Western Hospital, 399 Bathurst St, TM432, Toronto, ON, Canada, M5T 2S8.'}, {'ForeName': 'Zafiris J', 'Initials': 'ZJ', 'LastName': 'Daskalakis', 'Affiliation': 'Department of Psychiatry, School of Medicine, UC San Diego Health, 9500 Gilman Drive, La Jolla, CA, 92093-0603, USA.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Ainsworth', 'Affiliation': 'Non-Invasive Neurostimulation Therapies (NINET) Laboratory, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada, V6T 2A1.'}, {'ForeName': 'Lang', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Department of Statistics, Faculty of Science, University of British Columbia, 3182 Earth Sciences Building, 2207 Main Mall, Vancouver, BC, Canada, V6T 1Z4.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Butterfield', 'Affiliation': 'Non-Invasive Neurostimulation Therapies (NINET) Laboratory, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada, V6T 2A1.'}, {'ForeName': 'Fidel', 'Initials': 'F', 'LastName': 'Vila-Rodriguez', 'Affiliation': 'Non-Invasive Neurostimulation Therapies (NINET) Laboratory, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada, V6T 2A1. Electronic address: fidel.vilarodriguez@ubc.ca.'}]",Brain stimulation,['10.1016/j.brs.2021.07.015'] 2283,34364775,Different frequencies of active interruptions to sitting have distinct effects on 22 h glycemic control in type 2 diabetes.,"BACKGROUND & AIMS Whether the frequency of interruptions to sitting time involving simple resistance activities (SRAs), compared to uninterrupted sitting, differentially affected 22 h glycemic control in adults with medication-controlled type 2 diabetes (T2D). METHODS & RESULTS Twenty-four participants (13 men; mean ± SD age 62 ± 8 years) completed three 8 h laboratory conditions: SIT: uninterrupted sitting; SRA3: sitting interrupted with 3 min of SRAs every 30 min; and, SRA6: sitting interrupted with 6 min of SRAs every 60 min. Flash glucose monitors assessed glycemic control over a 22 h period. No differences were observed between conditions for overall 22 h glycemic control as measured by AUC total , mean glucose and time in hyperglycemia. During the 3.5 h post-lunch period, mean glucose was significantly lower during SRA6 (10.1 mmol·L -1 , 95%CI 9.2, 11.0) compared to SIT (11.1 mmol·L -1 , 95%CI 10.2, 12.0; P = 0.006). Post-lunch iAUC net was significantly lower during SRA6 (6.2 mmol·h·L -1 , 95%CI 3.3, 9.1) compared to SIT (9.9 mmol·h·L -1 , 95%CI 7.0, 12.9; P = 0.003). During the post-lunch period, compared to SIT (2.2 h, 95%CI 1.7, 2.6), time in hyperglycemia was significantly lower during SRA6 (1.5 h, 95%CI 1.0, 1.9, P = 0.001). Nocturnal mean glucose was significantly lower following the SRA3 condition (7.6 mmol·L -1 , 95%CI 7.1, 8.1) compared to SIT (8.1 mmol·L -1 , 95%CI 7.6, 8.7, P = 0.024). CONCLUSIONS With standardized total activity time, less-frequent active interruptions to sitting may acutely improve glycemic control; while more-frequent interruptions may be beneficial for nocturnal glucose in those with medication-controlled T2D.",2021,"No differences were observed between conditions for overall 22 h glycemic control as measured by AUC total , mean glucose and time in hyperglycemia.","['type 2 diabetes', 'Twenty-four participants (13 men; mean\xa0±\xa0SD age 62\xa0±\xa08 years) completed three 8\xa0h laboratory conditions', 'adults with medication-controlled type 2 diabetes (T2D']","['Flash glucose monitors', 'SIT: uninterrupted sitting', 'Post-lunch']","['mean glucose', 'iAUC net', 'time in hyperglycemia', 'overall 22\xa0h glycemic control as measured by AUC total , mean glucose and time in hyperglycemia', 'Nocturnal mean glucose']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0085635', 'cui_str': 'Photopsia'}, {'cui': 'C0202048', 'cui_str': 'Glucose measurement by monitoring device'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C2697949', 'cui_str': 'Lunch'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0240526', 'cui_str': 'Night time'}]",,0.0731786,"No differences were observed between conditions for overall 22 h glycemic control as measured by AUC total , mean glucose and time in hyperglycemia.","[{'ForeName': 'Ashleigh R', 'Initials': 'AR', 'LastName': 'Homer', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia; Mary MacKillop Institute for Health Research, Australian Catholic University, Australia. Electronic address: Ashleigh.Homer@baker.edu.au.'}, {'ForeName': 'Frances C', 'Initials': 'FC', 'LastName': 'Taylor', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia; Mary MacKillop Institute for Health Research, Australian Catholic University, Australia.'}, {'ForeName': 'Paddy C', 'Initials': 'PC', 'LastName': 'Dempsey', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Wheeler', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia; Mary MacKillop Institute for Health Research, Australian Catholic University, Australia; School of Sport Science, Exercise and Health, University of Western Australia, Perth, Australia.'}, {'ForeName': 'Parneet', 'Initials': 'P', 'LastName': 'Sethi', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia.'}, {'ForeName': 'Megan S', 'Initials': 'MS', 'LastName': 'Grace', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia; School of Clinical Medicine, University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Green', 'Affiliation': 'School of Sport Science, Exercise and Health, University of Western Australia, Perth, Australia.'}, {'ForeName': 'Neale D', 'Initials': 'ND', 'LastName': 'Cohen', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia.'}, {'ForeName': 'Robyn N', 'Initials': 'RN', 'LastName': 'Larsen', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia; School of Agriculture and Food, University of Melbourne, Melbourne, VIC, Australia.'}, {'ForeName': 'Bronwyn A', 'Initials': 'BA', 'LastName': 'Kingwell', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia; CSL Ltd, Bio21, Parkville, Australia; Department of Physiology, School of Biomedical Science, University of Melbourne, Melbourne, VIC, Australia; Department of Physiology, School of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Neville', 'Initials': 'N', 'LastName': 'Owen', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia; Centre for Urban Transitions, Swinburne University of Technology, Melbourne, Victoria, Australia.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Dunstan', 'Affiliation': 'Baker Heart & Diabetes Institute, Melbourne, VIC, Australia; Mary MacKillop Institute for Health Research, Australian Catholic University, Australia.'}]","Nutrition, metabolism, and cardiovascular diseases : NMCD",['10.1016/j.numecd.2021.07.001'] 2284,34364765,Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II-III elderly colon cancer patients.,"PURPOSE 45% of colon cancer patients are elderly, yet they are often deviated from standard cancer management. The MOSAIC trial favored FOLFOX over FL with superior oncologic outcomes; however, which regimen is most beneficial in elderly population remains unclear. This study aimed to compare the efficacy of oxaliplatin-added chemotherapy and capecitabine monotherapy in high-risk stage II/stage III elderly colon cancer patients. METHODS Colon cancer patients ≥70 years of age who received adjuvant chemotherapy at Inje University Busan Paik Hospital between February 2009 to April 2016 were included. Patients were separated into the oxaliplatin-added group and capecitabine monotherapy group. The primary outcomes were CSS and OS. RESULTS Of 74 patients, 45 received oxaliplatin-added chemotherapy and 29 received capecitabine monotherapy. There was no difference between the two groups in CSS or OS (p = 0.9670 and p = 0.6801, respectively). The N stage was significantly associated with CSS in both uni/multivariate analysis (p = 0.0565 and p = 0.0347, respectively). The oxaliplatin-added group had more stage III patients, so we performed a subgroup analysis of CSS and OS based on stage, which also showed no significant difference. CONCLUSIONS Capecitabine monotherapy is an oncologically safe regimen compared to oxaliplatin-added regimens in elderly patients with high-risk stage II/stage III colon cancer.",2021,"There was no difference between the two groups in CSS or OS (p = 0.9670 and p = 0.6801, respectively).","['Colon cancer patients ≥70 years of age who received adjuvant chemotherapy at Inje University Busan Paik Hospital between February 2009 to April 2016 were included', 'elderly patients with high-risk stage II/stage III colon cancer', 'high-risk stage II-III elderly colon cancer patients', 'colon cancer patients', '74 patients', 'high-risk stage II/stage III elderly colon cancer patients']","['Capecitabine monotherapy', 'oxaliplatin', 'oxaliplatin-added chemotherapy', 'capecitabine monotherapy', 'oxaliplatin therapy and capecitabine monotherapy', 'oxaliplatin-added group and capecitabine monotherapy', 'FOLFOX', 'oxaliplatin-added chemotherapy and capecitabine monotherapy']","['CSS or OS', 'CSS and OS']","[{'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0278480', 'cui_str': 'Carcinoma of colon, stage III'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}]","[{'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0265338', 'cui_str': 'Coffin-Siris syndrome'}]",,0.15534,"There was no difference between the two groups in CSS or OS (p = 0.9670 and p = 0.6801, respectively).","[{'ForeName': 'Jueun', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Department of Surgery, College of Medicine, Busan Paik Hospital, South Korea. Electronic address: gsrcz@naver.com.'}, {'ForeName': 'HyungJoo', 'Initials': 'H', 'LastName': 'Baik', 'Affiliation': 'Department of Surgery, College of Medicine, Busan Paik Hospital, South Korea. Electronic address: laurenbaik@gmail.com.'}, {'ForeName': 'Sang Hyun', 'Initials': 'SH', 'LastName': 'Kang', 'Affiliation': 'Department of Surgery, College of Medicine, Busan Paik Hospital, South Korea.'}, {'ForeName': 'Sang Hyuk', 'Initials': 'SH', 'LastName': 'Seo', 'Affiliation': 'Department of Surgery, College of Medicine, Busan Paik Hospital, South Korea.'}, {'ForeName': 'Kwang Hee', 'Initials': 'KH', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, College of Medicine, Busan Paik Hospital, South Korea.'}, {'ForeName': 'Min Kyung', 'Initials': 'MK', 'LastName': 'Oh', 'Affiliation': 'Clinical Trial Center in Pharmacology, College of Medicine, Busan Paik Hospital, South Korea.'}, {'ForeName': 'Hong Sub', 'Initials': 'HS', 'LastName': 'Lee', 'Affiliation': 'Internal Medicine, Inje University, College of Medicine, Busan Paik Hospital, South Korea.'}, {'ForeName': 'Sang Heon', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Internal Medicine, Inje University, College of Medicine, Busan Paik Hospital, South Korea.'}, {'ForeName': 'Ki Hyang', 'Initials': 'KH', 'LastName': 'Kim', 'Affiliation': 'Internal Medicine, Inje University, College of Medicine, Busan Paik Hospital, South Korea.'}, {'ForeName': 'Min Sung', 'Initials': 'MS', 'LastName': 'An', 'Affiliation': 'Department of Surgery, College of Medicine, Busan Paik Hospital, South Korea. Electronic address: gsams@paik.ac.kr.'}]",Asian journal of surgery,['10.1016/j.asjsur.2021.07.067'] 2285,34364737,"Assessment of the effect of Mulabandha yoga therapy in healthy women, stigmatized for pelvic floor dysfunctions: A randomized controlled trial.","BACKGROUND In developing countries, women do not reveal their perineum related health issues because most of the time they are stigmatized by the society. Multiparity, mostly found in women of rural areas is one of the major causes of pelvic floor dysfunctions (PFDs) like pelvic organ prolapse, urinary incontinence, rectal incontinence, etc. Usually, they visit health centres in the advanced stage of diseases, and then medical treatment is not the only choice left. Many research studies show that yoga practices promote health conditions, contribute to enhancing endurance, flexibility, and muscular strength, and improving quality of life. OBJECTIVE(S) The study was conducted to assess the impact of Mulabandha yoga therapy (MYT) in healthy woman participants as a preventive measure. MATERIAL & METHODS The study was a prospective and randomized controlled trial. Fifty healthy woman participants were allocated in two groups viz., MYT group and No MYT group. Mulabandha yoga was conducted for the MYT group for 12 weeks. No MYT group was advised not to do yoga. Pelvic floor muscle strength was internally evaluated by employing the PERFECT scheme score (P = power, E = endurance, R = repetitions, F = fast contractions, ECT = every contraction timed). For eligible samples, MYT sessions were held for 12 weeks. Data interpretation was done with SPSS software 20.0 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY, USA). RESULTS Fifty healthy woman participants were allocated for analysis. There was no statistically significant difference in between the groups comparison in terms of age, socio-economic status, occupation, education, parity and mode of delivery. PERFECT scheme score significantly improved in participants after 12 weeks of regular MYT. No statistically significant differences were observed between the groups comparison in terms of PERFECT scheme score. CONCLUSION The current study shows that regular practice of MYT for 12 weeks is a better means to reinforce the strength of pelvic floor muscles in women. This MYT procedure will establish evidence for women who are reluctant towards their pelvic organ-related issues. Women must incorporate the MYT practice in their routine life as a preventive measure to refrain from pelvic floor dysfunctions.",2021,"There was no statistically significant difference in between the groups comparison in terms of age, socio-economic status, occupation, education, parity and mode of delivery.","['healthy woman participants as a preventive measure', 'women who are reluctant towards their pelvic organ-related issues', 'healthy women, stigmatized for pelvic floor dysfunctions', 'women', 'Fifty healthy woman participants']","['Mulabandha yoga therapy (MYT', 'Mulabandha yoga therapy', 'SPSS software 20.0 (IBM Corp', 'Mulabandha yoga']","['IBM SPSS Statistics', 'endurance, flexibility, and muscular strength, and improving quality of life', 'Pelvic floor muscle strength', 'age, socio-economic status, occupation, education, parity and mode of delivery']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0230273', 'cui_str': 'Structure of pelvic viscus'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C4041537', 'cui_str': 'Pelvic floor dysfunction'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0037585', 'cui_str': 'Software'}, {'cui': 'C0238190', 'cui_str': 'Inclusion body myositis'}]","[{'cui': 'C0238190', 'cui_str': 'Inclusion body myositis'}, {'cui': 'C0600673', 'cui_str': 'Statistics'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0030563', 'cui_str': 'Parity'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]",50.0,0.0485848,"There was no statistically significant difference in between the groups comparison in terms of age, socio-economic status, occupation, education, parity and mode of delivery.","[{'ForeName': 'Km', 'Initials': 'K', 'LastName': 'Sweta', 'Affiliation': 'Uttar Pradesh Public Service Commission, India. Electronic address: shweta51289@gmail.com.'}, {'ForeName': 'Amrit', 'Initials': 'A', 'LastName': 'Godbole', 'Affiliation': 'Department of Kayachikitsa, Faculty of Ayurveda, Institute of Medical Sciences, BHU, Varanasi, 221005, India.'}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Prajapati', 'Affiliation': 'Uttar Pradesh Public Service Commission, India.'}, {'ForeName': 'H H', 'Initials': 'HH', 'LastName': 'Awasthi', 'Affiliation': 'Department of Rachana sharira, Faculty of Ayurveda, IMS BHU, Varanasi, U.P., 221005, India.'}]",Journal of Ayurveda and integrative medicine,['10.1016/j.jaim.2021.04.001'] 2286,34364735,"Erratum to 'Effect of Different Tourniquet Pressure on Postoperative Pain and Complications After Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial [The Journal of Arthroplasty 36 (2021) 1638-1644].",,2021,,['After Total Knee Arthroplasty'],[],['Postoperative Pain and Complications'],"[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]",[],"[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.0929723,,"[{'ForeName': 'Piya', 'Initials': 'P', 'LastName': 'Pinsornsak', 'Affiliation': 'Department of Orthopaedic Surgery, Thammasat University, Pathum Thani, Bangkok, Thailand.'}, {'ForeName': 'Punnawit', 'Initials': 'P', 'LastName': 'Pinitchanon', 'Affiliation': 'Department of Orthopaedic Surgery, Thammasat University, Pathum Thani, Bangkok, Thailand.'}, {'ForeName': 'Krit', 'Initials': 'K', 'LastName': 'Boontanapibul', 'Affiliation': 'Department of Orthopaedic Surgery, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Bangkok, Thailand.'}]",The Journal of arthroplasty,['10.1016/j.arth.2021.07.016'] 2287,34364702,Battlefield Acupuncture Versus Standard Pharmacologic Treatment of Low Back Pain in the Emergency Department: A Randomized Controlled Trial.,"BACKGROUND Battlefield acupuncture (BFA) offers a novel analgesic option that avoids the need for pharmacologic interventions with problematic side effect profiles. OBJECTIVE To compare BFA with standard pharmacologic interventions to treat patients in the emergency department (ED) with low back pain. METHODS We conducted a nonblinded randomized controlled trial of a convenience sample of adults presenting to an urban tertiary care ED with a chief complaint of low back pain. We randomized subjects to undergo either BFA or the control arm in which they received standard pharmacologic therapies at the discretion of their treating clinician. The primary outcome was mean pain reduction measured on a 100-mm visual analogue scale (VAS) from enrollment to 30-40 min postintervention. Secondary outcomes included the Back Pain Functional Scale (BPFS; scores range from 0-60) measured at 30-40 min postintervention and again at 48-72 h postintervention. RESULTS We enrolled 52 subjects with 26 randomized to each arm. The mean decrease in pain VAS was 33.4 mm among patients undergoing BFA vs. 21.5 mm in the control arm (effect size difference 12.0 mm [95% confidence interval {CI} 0.1-23.8 mm]). The median improvement in the BPFS score at 48-72 h postintervention was 12.0 among patients undergoing BFA vs. 8.0 in the control arm (effect size difference 4 [95% CI -9.0 to 16.0]). There were no adverse events. CONCLUSIONS BFA shows promise for further study as an alternative to standard pharmacologic interventions among adults presenting to the ED with low back pain. © 2021 Elsevier Inc.",2021,The mean decrease in pain VAS was 33.4 mm among patients undergoing BFA vs. 21.5 mm in the control arm (effect size difference 12.0 mm [95% confidence interval {CI} 0.1-23.8 mm]).,"['treat patients in the emergency department (ED) with low back pain', 'adults presenting to the ED with low back pain', 'Low Back Pain in the Emergency Department', 'convenience sample of adults presenting to an urban tertiary care ED with a chief complaint of low back pain', '52 subjects with 26 randomized to each arm']","['Battlefield Acupuncture Versus Standard Pharmacologic Treatment', 'standard pharmacologic therapies', 'BFA with standard pharmacologic interventions', 'acupuncture (BFA', 'BFA']","['Back Pain Functional Scale (BPFS; scores range from 0-60', '100-mm visual analogue scale (VAS', 'pain VAS', 'mean pain reduction', 'BPFS score']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013217', 'cui_str': 'chemotherapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",52.0,0.384862,The mean decrease in pain VAS was 33.4 mm among patients undergoing BFA vs. 21.5 mm in the control arm (effect size difference 12.0 mm [95% confidence interval {CI} 0.1-23.8 mm]).,"[{'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Johnston', 'Affiliation': 'Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Bonjour', 'Affiliation': 'Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Powell', 'Affiliation': 'Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'April', 'Affiliation': '40th Forward Resuscitative Surgical Detachment, 627th Hospital Center, Fort Carson, Colorado; Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland.'}]",The Journal of emergency medicine,['10.1016/j.jemermed.2021.07.017'] 2288,34373374,A Prospective Multicenter Randomized Feasibility Trial of Double-guidewire Techniques for Difficult Biliary Cannulation Comparing a New Double-guidewire-supported Sphincterotome (MagicTome) to a Conventional Device.,"Purpose To evaluate the effectiveness and safety of the double-guidewire technique (DGT) using a new double-guidewire-supported sphincterotome (MagicTome) for patients who required endoscopic retrograde cholangiopancreatography (ERCP) for biliary cannulation. Methods This prospective multicenter randomized feasibility trial involved patients with difficult biliary cannulation at any of the three study sites from June 2017 to October 2018. Patients were assigned to the DGT with MagicTome (MDGT) initially performed group and the conventional DGT (CDGT) initially performed group. The success rates of biliary cannulation by MDGT and CDGT and the ERCP-related complications were evaluated. Results Twenty-eight patients were included in this study. No significant difference was observed in the success rates of first attempts and crossover attempts between the groups (p=0.69 and p=1.00). Furthermore, no significant difference was observed in the success rate of biliary cannulation between MDGT and CDGT (62.5% and 75.0%, respectively; p=0.48). CDGT was successful in two of four patients with malignant biliary obstruction. MDGT was successful in all four patients with malignant biliary obstruction, including the two for whom CDGT was unsuccessful. Post-ERCP pancreatitis occurred in only one MDGT case. Conclusion MDGT is safe for biliary cannulation and can be used in cases where biliary cannulation by CDGT is difficult.",2021,No significant difference was observed in the success rates of first attempts and crossover attempts between the groups (p=0.69 and p=1.00).,"['patients with malignant biliary obstruction', 'Results Twenty-eight patients were included in this study', 'patients who required endoscopic retrograde cholangiopancreatography (ERCP) for biliary cannulation', 'patients with difficult biliary cannulation at any of the three study sites from June 2017 to October 2018']","['new double-guidewire-supported sphincterotome (MagicTome', 'MDGT', 'New Double-guidewire-supported Sphincterotome (MagicTome', 'CDGT', 'Double-guidewire Techniques', 'double-guidewire technique (DGT', 'DGT with MagicTome (MDGT) initially performed group and the conventional DGT (CDGT']","['success rates of biliary cannulation by MDGT and CDGT and the ERCP-related complications', 'Post-ERCP pancreatitis', 'effectiveness and safety', 'success rates', 'success rate of biliary cannulation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3898473', 'cui_str': 'Malignant biliary obstruction'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0332218', 'cui_str': 'Difficult'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0181089', 'cui_str': 'Guide wire'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0183424', 'cui_str': 'Sphincterotome'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0030305', 'cui_str': 'Pancreatitis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",28.0,0.0410755,No significant difference was observed in the success rates of first attempts and crossover attempts between the groups (p=0.69 and p=1.00).,"[{'ForeName': 'Tomoya', 'Initials': 'T', 'LastName': 'Ogawa', 'Affiliation': 'Department of Gastroenterology, Saitama Medical University International Medical Center, Japan.'}, {'ForeName': 'Shomei', 'Initials': 'S', 'LastName': 'Ryozawa', 'Affiliation': 'Department of Gastroenterology, Saitama Medical University International Medical Center, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Irisawa', 'Affiliation': 'Department of Gastroenterology, Dokkyo Medical University School of Medicine, Japan.'}, {'ForeName': 'Atsuhiro', 'Initials': 'A', 'LastName': 'Masuda', 'Affiliation': 'Division of Gastroenterology Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Tanisaka', 'Affiliation': 'Department of Gastroenterology, Saitama Medical University International Medical Center, Japan.'}, {'ForeName': 'Akashi', 'Initials': 'A', 'LastName': 'Fujita', 'Affiliation': 'Department of Gastroenterology, Saitama Medical University International Medical Center, Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Mizuide', 'Affiliation': 'Department of Gastroenterology, Saitama Medical University International Medical Center, Japan.'}, {'ForeName': 'Akane', 'Initials': 'A', 'LastName': 'Yamabe', 'Affiliation': 'Department of Gastroenterology, Dokkyo Medical University School of Medicine, Japan.'}, {'ForeName': 'Goro', 'Initials': 'G', 'LastName': 'Shibukawa', 'Affiliation': 'Department of Gastroenterology, Aizu Medical Center, Fukushima Medical University, Japan.'}, {'ForeName': 'Arata', 'Initials': 'A', 'LastName': 'Sakai', 'Affiliation': 'Division of Gastroenterology Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Shiomi', 'Affiliation': 'Division of Gastroenterology Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.'}, {'ForeName': 'Hayato', 'Initials': 'H', 'LastName': 'Yoshinaka', 'Affiliation': 'Center for Clinical Research and Advanced Medicine Establishment, Shiga University of Medical Science, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Okabe', 'Affiliation': 'Department of Gastroenterology, Kakogawa Central City Hospital, Japan.'}, {'ForeName': 'Yoshifumi', 'Initials': 'Y', 'LastName': 'Arisaka', 'Affiliation': 'Department of Gastroenterology, Nippon Life Hospital, Japan.'}, {'ForeName': 'Hiromu', 'Initials': 'H', 'LastName': 'Kutsumi', 'Affiliation': 'Center for Clinical Research and Advanced Medicine Establishment, Shiga University of Medical Science, Japan.'}]","Internal medicine (Tokyo, Japan)",['10.2169/internalmedicine.7367-21'] 2289,34373362,Effect of Sodium Alginate on Gastrointestinal Symptoms after Esophagogastroduodenoscopy with Biopsy: Randomized Controlled Trial.,"Background/Aims After esophagogastroduodenoscopy (EGD) with biopsy, some patients experience gastrointestinal symptoms. This study investigated the effect of sodium alginate on biopsy-related gastrointestinal symptoms. Methods In this open-label, randomized, controlled trial, patients undergoing EGD with biopsy were randomly assigned to a treatment or control group. In the treatment group, sodium alginate was orally administered for 3 days after EGD. Patients completed questionnaires about their gastrointestinal symptoms at baseline (past week), the day after returning home, and after another 3 days. Gastrointestinal symptoms, including abdominal pain, epigastric pain/soreness, heartburn, acid reflux, nausea/vomiting, borborygmus, abdominal distension, and belching, were rated using an upper gastrointestinal symptom rating scale (GSRS). Results A total of 210 persons (138 men) who underwent EGD with biopsy were enrolled and allocated to the treatment (n=104) or control (n=106) group. At baseline, the demographic factors and GSRS scores were not different between the control and treatment groups. The epigastric pain/soreness score increased in the control group after endoscopic biopsy (+0.056), whereas the score was decreased in the treatment group (-0.067) (p=0.042). In the treatment group, the scores for acid regurgitation and epigastric soreness decreased during follow-up from those at baseline (p<0.05), whereas there were no significant reductions in the control group. The scores for belching and borborygmus decreased during follow-up only in the treatment group. Abdominal bloating decreased in both the control and treatment groups. Conclusions Sodium alginate reduced epigastric pain/soreness after EGD with biopsy. Therefore, the prescription of sodium alginate should be considered after endoscopic biopsy.",2021,"The epigastric pain/soreness score increased in the control group after endoscopic biopsy (+0.056), whereas the score was decreased in the treatment group (-0.067) (p=0.042).","['after Esophagogastroduodenoscopy with Biopsy', '210 persons (138 men) who underwent EGD with biopsy were enrolled and allocated to the treatment (n=104) or control (n=106) group', 'patients undergoing EGD with biopsy']","['Sodium Alginate', 'sodium alginate', 'Sodium alginate']","['epigastric pain/soreness score', 'demographic factors and GSRS scores', 'Abdominal bloating', 'Gastrointestinal Symptoms', 'scores for belching and borborygmus', 'scores for acid regurgitation and epigastric soreness', 'Gastrointestinal symptoms, including abdominal pain, epigastric pain/soreness, heartburn, acid reflux, nausea/vomiting, borborygmus, abdominal distension, and belching, were rated using an upper gastrointestinal symptom rating scale (GSRS', 'epigastric pain/soreness']","[{'cui': 'C0079304', 'cui_str': 'Esophagogastroduodenoscopy'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0142791', 'cui_str': 'Sodium alginate'}]","[{'cui': 'C0232493', 'cui_str': 'Epigastric pain'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011292', 'cui_str': 'Demographic Factors'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0000731', 'cui_str': 'Swollen abdomen'}, {'cui': 'C0014724', 'cui_str': 'Eructation'}, {'cui': 'C0232693', 'cui_str': 'Bowel sounds'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0232605', 'cui_str': 'Regurgitates after swallowing'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0018834', 'cui_str': 'Heartburn'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0857493', 'cui_str': 'Upper gastrointestinal symptoms'}]",210.0,0.0641019,"The epigastric pain/soreness score increased in the control group after endoscopic biopsy (+0.056), whereas the score was decreased in the treatment group (-0.067) (p=0.042).","[{'ForeName': 'Su Youn', 'Initials': 'SY', 'LastName': 'Nam', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Kyungpook National University and Kyungpook National University Hospital, Daegu, Korea.'}, {'ForeName': 'Sang Won', 'Initials': 'SW', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Kyungpook National University and Kyungpook National University Hospital, Daegu, Korea.'}, {'ForeName': 'Seong Woo', 'Initials': 'SW', 'LastName': 'Jeon', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Kyungpook National University and Kyungpook National University Hospital, Daegu, Korea.'}, {'ForeName': 'Yong Hwan', 'Initials': 'YH', 'LastName': 'Kwon', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Kyungpook National University and Kyungpook National University Hospital, Daegu, Korea.'}]",Gut and liver,['10.5009/gnl20298'] 2290,34373322,Serum Sodium Concentration and Mental Status in Children With Diabetic Ketoacidosis.,"OBJECTIVES Diabetic ketoacidosis (DKA) is typically characterized by low or low-normal serum sodium concentrations, which rise as hyperglycemia resolves. In retrospective studies, researchers found associations between declines in sodium concentrations during DKA and cerebral injury. We prospectively investigated determinants of sodium concentration changes and associations with mental status alterations during DKA. METHODS Using data from the Pediatric Emergency Care Applied Research Network Fluid Therapies Under Investigation in Diabetic Ketoacidosis Trial, we compared children who had declines in glucose-corrected sodium concentrations with those who had rising or stable concentrations. Children were randomly assigned to 1 of 4 intravenous fluid protocols that differed in infusion rate and sodium content. Data from the first 4, 8, and 12 hours of treatment were analyzed for 1251, 1086, and 877 episodes, respectively. RESULTS In multivariable analyses, declines in glucose-corrected sodium concentrations were associated with higher sodium and chloride concentrations at presentation and with previously diagnosed diabetes. Treatment with 0.45% (vs 0.9%) sodium chloride fluids was also associated with declines in sodium concentration; however, higher rates of fluid infusion were associated with declines in sodium concentration only at 12 hours. Frequencies of abnormal Glasgow Coma Scale scores and clinical diagnoses of cerebral injury were similar in patients with and without declines in glucose-corrected sodium concentrations. CONCLUSIONS Changes in glucose-corrected sodium concentrations during DKA treatment are influenced by the balance of free-water loss versus sodium loss at presentation and the sodium content of intravenous fluids. Declines in glucose-corrected sodium concentrations are not associated with mental status changes during treatment.",2021,"Frequencies of abnormal Glasgow Coma Scale scores and clinical diagnoses of cerebral injury were similar in patients with and without declines in glucose-corrected sodium concentrations. ","['Children With Diabetic Ketoacidosis', 'Diabetic ketoacidosis (DKA', 'children who had declines in glucose-corrected sodium concentrations with those who had rising or stable concentrations']",[],"['Serum Sodium Concentration and Mental Status', 'Frequencies of abnormal Glasgow Coma Scale scores and clinical diagnoses of cerebral injury', 'sodium concentration']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011880', 'cui_str': 'Diabetic ketoacidosis'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",[],"[{'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}]",,0.0856547,"Frequencies of abnormal Glasgow Coma Scale scores and clinical diagnoses of cerebral injury were similar in patients with and without declines in glucose-corrected sodium concentrations. ","[{'ForeName': 'Nicole S', 'Initials': 'NS', 'LastName': 'Glaser', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Stoner', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Nationwide Children's Hospital and School of Medicine, The Ohio State University, Columbus, Ohio.""}, {'ForeName': 'Aris', 'Initials': 'A', 'LastName': 'Garro', 'Affiliation': 'Departments of Emergency Medicine and Pediatrics, Rhode Island Hospital and The Warren Alpert Medical School, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Baird', 'Affiliation': ""Division of Critical Care Medicine, Department of Pediatrics, NewYork-Presbyterian Morgan Stanley Children's Hospital and College of Physicians and Surgeons, Columbia University, New York City, New York.""}, {'ForeName': 'Sage R', 'Initials': 'SR', 'LastName': 'Myers', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.""}, {'ForeName': 'Arleta', 'Initials': 'A', 'LastName': 'Rewers', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Children's Hospital Colorado and School of Medicine, University of Colorado, Aurora, Colorado.""}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Brown', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Children's National Medical Center and School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia.""}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Trainor', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago and Feinberg School of Medicine, Northwestern University, Chicago, Illinois.""}, {'ForeName': 'Kimberly S', 'Initials': 'KS', 'LastName': 'Quayle', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, St Louis Children's Hospital and School of Medicine, Washington University in St Louis, St Louis, Missouri.""}, {'ForeName': 'Julie K', 'Initials': 'JK', 'LastName': 'McManemy', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas.""}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'DePiero', 'Affiliation': 'Division of Emergency Medicine, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware.'}, {'ForeName': 'Lise E', 'Initials': 'LE', 'LastName': 'Nigrovic', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts.""}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Tzimenatos', 'Affiliation': 'Emergency Medicine, School of Medicine, University of California, Davis Health, University of California, Davis, Sacramento, California.'}, {'ForeName': 'Jeff E', 'Initials': 'JE', 'LastName': 'Schunk', 'Affiliation': 'Department of Pediatrics, School of Medicine, The University of Utah, Salt Lake City, Utah.'}, {'ForeName': 'Cody S', 'Initials': 'CS', 'LastName': 'Olsen', 'Affiliation': 'Department of Pediatrics, School of Medicine, The University of Utah, Salt Lake City, Utah.'}, {'ForeName': 'T Charles', 'Initials': 'TC', 'LastName': 'Casper', 'Affiliation': 'Department of Pediatrics, School of Medicine, The University of Utah, Salt Lake City, Utah.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Ghetti', 'Affiliation': 'Department of Psychology, University of California, Davis, Davis, California.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Kuppermann', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pediatrics,['10.1542/peds.2021-050243'] 2291,34373315,"Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol.","INTRODUCTION Stroke is a serious public health problem, given it is a major cause of disability worldwide despite the spread of recanalisation therapies. Enhancement of brain plasticity with stem cell administration is a promising innovative therapy to reduce sequelae in these patients. METHODS AND ANALYSIS We have developed a phase IIb, multicentre, randomised, double-blind, placebo-controlled clinical trial protocol to evaluate the safety and efficacy of intravenous administration of allogeneic adipose tissue-derived mesenchymal stem cells (AD-MSCs) in patients with acute ischaemic stroke, concurrently with conventional stroke treatment. Thirty patients will be randomised on a 1:1 basis to receive either intravenous placebo or allogeneic AD-MSCs as soon as possible within the first 4 days from stroke symptom onset. Patients will be followed up to 24 months after randomisation. The primary objective is the safety assessment of early intravenous administration of allogeneic AD-MSCs by reporting all adverse events and neurological or systemic complications in both treatment groups. Secondary objectives assess efficacy of early intravenous AD-MSC treatment in acute ischaemic stroke by evaluating changes in the modified Rankin Scale and the National Institutes of Health Stroke Scale throughout the follow-up period. In addition, brain repair biomarkers will be measured at various visits. ETHICS AND DISSEMINATION This clinical trial has been approved by the Clinical Research Ethics Committee of La Paz University Hospital (Madrid, Spain) and by the Spanish Agency of Medication and Health Products and has been registered in Eudra CT (2019-001724-35) and ClinicalTrials.gov (NCT04280003). Study results will be disseminated through peer-reviewed publications in Open Access format and at conference presentations.",2021,Secondary objectives assess efficacy of early intravenous AD-MSC treatment in acute ischaemic stroke by evaluating changes in the modified Rankin Scale and the National Institutes of Health Stroke Scale throughout the follow-up period.,"['Thirty patients', 'patients with acute ischaemic stroke, concurrently with conventional stroke treatment']","['Allogeneic adipose tissue-derived mesenchymal stem cells', 'early intravenous AD-MSC treatment', 'intravenous placebo or allogeneic AD-MSCs', 'allogeneic AD-MSCs', 'placebo', 'allogeneic adipose tissue-derived mesenchymal stem cells (AD-MSCs']","['safety and efficacy', 'acute ischaemic stroke', 'adverse events and neurological or systemic complications', 'modified Rankin Scale and the National Institutes of Health Stroke Scale']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C4704950', 'cui_str': 'Mesenchymal Stem Cells, Adipose-Derived'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0074299', 'cui_str': 'selenomethylselenocysteine'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C3472496', 'cui_str': 'National Institutes of Health stroke scale'}]",30.0,0.671766,Secondary objectives assess efficacy of early intravenous AD-MSC treatment in acute ischaemic stroke by evaluating changes in the modified Rankin Scale and the National Institutes of Health Stroke Scale throughout the follow-up period.,"[{'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'de Celis-Ruiz', 'Affiliation': 'Department of Neurology and Stroke Centre; Neurosciences Area, Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.'}, {'ForeName': 'Blanca', 'Initials': 'B', 'LastName': 'Fuentes', 'Affiliation': 'Department of Neurology and Stroke Centre; Neurosciences Area, Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain blanca.fuentes@salud.madrid.org.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Moniche', 'Affiliation': 'Department of Neurology and Stroke Research Program, Hospital Universitario Virgen del Rocío.Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville, Seville, Spain.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Montaner', 'Affiliation': 'Department of Neurology and Stroke Research Program, Hospital Universitario Virgen Macarena,Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville, Seville, Spain.'}, {'ForeName': 'Alberto M', 'Initials': 'AM', 'LastName': 'Borobia', 'Affiliation': 'Department of Clinical Pharmacology, Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Gutiérrez-Fernández', 'Affiliation': 'Department of Neurology and Stroke Centre; Neurosciences Area, Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.'}, {'ForeName': 'Exuperio', 'Initials': 'E', 'LastName': 'Díez-Tejedor', 'Affiliation': 'Department of Neurology and Stroke Centre; Neurosciences Area, Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.'}]",BMJ open,['10.1136/bmjopen-2021-051790'] 2292,34373303,Behavioural insights (BI) for childhood development and effective public policies in Latin America: a survey and a randomised controlled trial.,"OBJECTIVES We developed (a) a survey to investigate the knowledge of childhood health experts on public policies and behavioural insights (BI), as well as its use in Latin American and the Caribbean countries (LACs), and (b) an intervention (randomised controlled trial) to test the influence of nudges on the effect of a simulated public health programme communication. PARTICIPANTS AND SETTINGS A total of 2003 LACs childhood health professionals participated in the study through a Hispanic online platform. PRIMARY AND SECONDARY OUTCOMES We used regression models analysing expertise-related information, individual differences and location. We extracted several outcome variables related to (a) 'Public Policy Knowledge Index' based on the participants' degree of knowledge on childhood health public policies and (b) BI knowledge, perceived effectiveness and usefulness of a simulated public programme communication. We also analysed a 'Behavioural Insights Knowledge Index' (BIKI) based on participants' performance in BI questions. RESULTS In general, health professionals showed low BI knowledge (knowledge of the term BI: χ 2 =210.29, df=1 and p<0.001; BIKI: χ 2 =160.5, df=1 and p<0.001), and results were modulated by different factors (age, academic formation, public policy knowledge and location). The use of BI principles for the communication of the public programme revealed higher impact and clarity ratings from professionals than control messages. CONCLUSIONS Our findings provide relevant knowledge about BI in health professionals to inform governmental and non-governmental organisations' decision-making processes related with childhood public policies and BI designs.",2021,"The use of BI principles for the communication of the public programme revealed higher impact and clarity ratings from professionals than control messages. ","['A total of 2003 LACs childhood health professionals participated in the study through a Hispanic online platform', 'Latin America']",['Behavioural insights (BI'],[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0454721', 'cui_str': 'Caribbean country'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0023122', 'cui_str': 'Latin America'}]","[{'cui': 'C0233820', 'cui_str': 'Insight'}]",[],,0.0544319,"The use of BI principles for the communication of the public programme revealed higher impact and clarity ratings from professionals than control messages. ","[{'ForeName': 'Andrea A', 'Initials': 'AA', 'LastName': 'Tomio', 'Affiliation': 'Cognitive Neuroscience Center (CNC), Universidad de San Andres, Buenos Aires, Argentina.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Dottori', 'Affiliation': 'Cognitive Neuroscience Center (CNC), Universidad de San Andres, Buenos Aires, Argentina.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Hesse', 'Affiliation': 'Cognitive Neuroscience Center (CNC), Universidad de San Andres, Buenos Aires, Argentina.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Torrente', 'Affiliation': 'Institute of Cognitive and Translational Neurosciences, CONICET-Favaloro University-INECO Foundation, Buenos Aires, Argentina.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Flichtentrei', 'Affiliation': 'IntraMed, Buenos Aires, Argentina.'}, {'ForeName': 'Agustin M', 'Initials': 'AM', 'LastName': 'Ibanez', 'Affiliation': 'Cognitive Neuroscience Center (CNC), Universidad de San Andres, Buenos Aires, Argentina agustin.ibanez@gbhi.org.'}]",BMJ open,['10.1136/bmjopen-2020-047925'] 2293,34373138,"Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.","BACKGROUND Most available prognostic nomograms in metastatic castration-resistant prostate cancer (mCRPC) are derived from datasets not representative of the current treatment landscape. A prognostic nomogram for first-line mCRPC treatment was developed from patients treated in the PREVAIL study. OBJECTIVE To validate the Armstrong model in the COU-AA-302 trial. DESIGN, SETTING, AND PARTICIPANTS A post hoc analysis of mCRPC patients treated in the COU-AA-302 trial was carried out (NCT00887198). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The Armstrong prognostic model was applied to patients treated in COU-AA-302. A continuous risk score was derived from coefficients from the original model. Time-dependent area under the curve (tAUC) was used to evaluate the overall predictive ability of the model. Patients were categorized according to the number of risk factors present into those at a low (three or fewer risk factors), intermediate (four to six risk factors), and high (seven to ten risk factors) risk. The association with survival was assessed with Cox regression models. Interaction tests were used to assess the impact of treatment arm in each of the prognostic groups. RESULTS AND LIMITATIONS A total of 1088 patients were analyzed. The risk score was associated with overall survival (OS; tAUC 0.733). Most patients were at a low (49%) or intermediate (41%) risk. Risk category was significantly associated with OS (hazard ratio [HR]: 2.3; 95% confidence interval [CI]: 1.9-2.4; p < 0.001), radiographic progression-free survival (rPFS; HR: 1.7; 95% CI: 1.5-1.8; p < 0.001), and prostate-specific antigen progression-free survival (HR: 1.7; 95% CI: 1.5-1.9; p < 0.001). A significant interaction between risk group and OS (p = 0.007) and rPFS (p = 0.009) was observed. Survival was superior in low-risk patients (HR: 0.73; 95% CI: 0.59-0.89; p = 0.009), but similar in intermediate-risk (HR: 0.97; 95% CI: 0.79-1.21; p = 0.9) and high-risk (HR: 1.35; 95% CI: 0.80-2.28; p = 0.5) patients. Two-year OS rates in abiraterone versus placebo were 82% versus 74% in low-risk, 55% versus 52% in intermediate-risk, and 28% versus 31% in high-risk patients. CONCLUSIONS We validate the prognostic value of the Armstrong risk model in patients treated with first-line androgen receptor signaling inhibitors. Abiraterone provided a greater benefit in low-risk patients with less aggressive disease. Further research is needed to establish the role of Armstrong risk groups for treatment selection in mCRPC patients. PATIENT SUMMARY In this report, we validated the Armstrong nomogram in the COU-AA-302 trial population. We found a similar prognostic performance to that of the original model. Good-risk patients received the greatest benefit from abiraterone.",2021,A significant interaction between risk group and OS (p = 0.007) and rPFS (p = 0.009) was observed.,"['A total of 1088 patients were analyzed', 'mCRPC patients', 'Patients were categorized according to the number of risk factors present into those at a low (three or fewer risk factors), intermediate (four to six risk factors), and high (seven to ten risk factors) risk', 'metastatic castration-resistant prostate cancer (mCRPC', 'low-risk patients with less aggressive disease', 'patients treated with first-line androgen receptor signaling inhibitors']","['Abiraterone', 'placebo', 'abiraterone']","['overall survival', 'rPFS', 'Time-dependent area under the curve (tAUC', 'Survival', 'radiographic progression-free survival', 'prostate-specific antigen progression-free survival']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0034786', 'cui_str': 'Androgen receptor'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0754011', 'cui_str': 'abiraterone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0178415', 'cui_str': 'Raised prostate specific antigen'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",1088.0,0.124888,A significant interaction between risk group and OS (p = 0.007) and rPFS (p = 0.009) was observed.,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Lorente', 'Affiliation': 'Medical Oncology Department, Hospital Provincial de Castellón, Castellón de la Plana, Spain; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Electronic address: dlorenteestelles@seom.org.'}, {'ForeName': 'Casilda', 'Initials': 'C', 'LastName': 'Llacer', 'Affiliation': 'Genitourinary Cancer Traslational Research Group, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain; Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain.'}, {'ForeName': 'Rebeca', 'Initials': 'R', 'LastName': 'Lozano', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'de Velasco', 'Affiliation': 'Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Romero-Laorden', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Medical Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Rodrigo', 'Affiliation': 'Urology Department, Hospital General Universitario de Castellón, Castellón de la Plana, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Sánchez-Iglesias', 'Affiliation': 'Radiotherapy Department, Hospital Provincial de Castellón, Castellón de la Plana, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'di Capua', 'Affiliation': 'Urology Department, Hospital de La Plana, Villareal, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Castro', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Traslational Research Group, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Ferrer', 'Affiliation': 'Radiotherapy Department, Hospital Provincial de Castellón, Castellón de la Plana, Spain.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Sánchez-Hernández', 'Affiliation': 'Medical Oncology Department, Hospital Provincial de Castellón, Castellón de la Plana, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Olmos', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Traslational Research Group, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.'}]",European urology,['10.1016/j.eururo.2021.07.014'] 2294,34373072,Effect of a repeated educational intervention versus an initial intervention on blood pressure control in hypertensive patients.,"INTRODUCTION AND OBJECTIVES Hypertension is one of the main cardiovascular risk factors. An educational intervention, aimed at increasing or reinforcing the patient's knowledge, can contribute to better control of their blood pressure. Our goal was to evaluate the efficacy of a continuing therapeutic education versus an initial intervention in hypertensive patients. METHODS Experimental study of multicenter community intervention, through the application of a therapeutic education program in hypertension. RESULTS 980 patients on antihypertensive treatment were included, 490 in each group, with a mean age of 65 years, and 50% women, baseline mean SBP in both groups was136 mmHg. Regarding knowledge about hypertension, although a similar initial improvement was observed in both groups, at the end of the study, in the continuous intervention group (CIG) an average of 23.06 correct answers was observed, while in the Initial intervention group (IIG) the mean was 20.91, being the difference statistically significant (p < 0.001). At the end of the study, the mean SBP was 127.5 mmHg in the CIG and 136.57 mmHg in the IIG group. Likewise, a lower percentage of patients with a BMI ≥25 was observed in the CIG (78.2%) than in the IIG 82.6%, this difference being statistically significant (p < 0.001). This same effect was observed on the abdominal perimeter, observing an increased abdominal perimeter in 46.3% of the CIG compared to 68.8% in the IIG (p < 0.001). CONCLUSIóN: A continuous educational intervention increases the degree of knowledge about hypertension compared to an initial intervention. Likewise, this intervention is associated with an improvement in blood pressure, weight, body mass index and abdominal girth figures.",2021,"Regarding knowledge about hypertension, although a similar initial improvement was observed in both groups, at the end of the study, in the continuous intervention group (CIG) an average of 23.06 correct answers was observed, while in the Initial intervention group (IIG)","['980 patients on antihypertensive treatment were included, 490 in each group, with a mean age of 65 years, and 50% women, baseline mean SBP in both groups was136 mmHg', 'hypertensive patients']","['repeated educational intervention', 'therapeutic education program', 'continuous educational intervention']","['abdominal perimeter, observing an increased abdominal perimeter', 'blood pressure, weight, body mass index and abdominal girth figures', 'blood pressure control', 'mean SBP', 'degree of knowledge about hypertension']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]","[{'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0182215', 'cui_str': 'Perimeter'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",980.0,0.00788878,"Regarding knowledge about hypertension, although a similar initial improvement was observed in both groups, at the end of the study, in the continuous intervention group (CIG) an average of 23.06 correct answers was observed, while in the Initial intervention group (IIG)","[{'ForeName': 'Dolors', 'Initials': 'D', 'LastName': 'Estrada', 'Affiliation': 'Unidad de Hipertensión y Riesgo Cardiovascular, Medicina Interna, Hospital Clínico, Barcelona, España; Grupo de Riesgo Cardiovascular, Nutrición y Envejecimiento del Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, España.'}, {'ForeName': 'Rosa Mª', 'Initials': 'RM', 'LastName': 'Soriano', 'Affiliation': 'Unidad de Hipertensión y Riesgo Cardiovascular, Medicina Interna, Hospital Clínico, Barcelona, España; Grupo de Riesgo Cardiovascular, Nutrición y Envejecimiento del Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, España.'}, {'ForeName': 'Ana Isabel', 'Initials': 'AI', 'LastName': 'Jordán', 'Affiliation': 'Unidad de Hipertensión y Riesgo Cardiovascular, Medicina Interna, Hospital Clínico, Barcelona, España; Grupo de Riesgo Cardiovascular, Nutrición y Envejecimiento del Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, España.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Fernández', 'Affiliation': 'Unidad de Hipertensión y Riesgo Cardiovascular, Medicina Interna, Hospital Clínico, Barcelona, España; Grupo de Riesgo Cardiovascular, Nutrición y Envejecimiento del Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, España.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Camafort', 'Affiliation': 'Unidad de Hipertensión y Riesgo Cardiovascular, Medicina Interna, Hospital Clínico, Barcelona, España; Grupo de Riesgo Cardiovascular, Nutrición y Envejecimiento del Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, España. Electronic address: camafort@clinic.cat.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Sierra', 'Affiliation': 'Unidad de Hipertensión y Riesgo Cardiovascular, Medicina Interna, Hospital Clínico, Barcelona, España; Grupo de Riesgo Cardiovascular, Nutrición y Envejecimiento del Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, España.'}]",Medicina clinica,['10.1016/j.medcli.2021.04.032'] 2295,34373066,A preliminary study on the anxiety and depression situation and psychological intervention of the first-line medical staff in our hospital during the COVID-19 epidemic.,"To assess the anxiety and depression situation and psychological intervention effect of the first-line medical staff in our hospital during the COVID-19 epidemic. A total of 384 front-line medical staff in our hospital from January 25 to March 8, 2020 were selected as subjects, which were divided into group A and group B respectively. PHQ-9 depression scale and GAD-7 self-rating anxiety scale questionnaire were used to investigate their anxiety and depression. After 1 month, all subjects were re-self-assessed for anxiety and depression, which were named as A1 and B1 group respectively. The GAD-7 anxiety scale had mild, moderate, and severe anxiety scores before group A, which were significantly higher than those in group B (P < 0.05); after psychological intervention, group A1 had significantly reduced anxiety scores (P < 0.05). And there were no markedly difference of PHQ-9 scale scores before and after psychological intervention between groups A and B, A and A1, and B and B1 (P > 0.05). The first-line medical staff in our hospital have different degree of anxiety and depression during COVID-19. Early positive psychological intervention has an effect on ameliorating the anxiety.",2021,"And there were no markedly difference of PHQ-9 scale scores before and after psychological intervention between groups A and B, A and A1, and B and B1 (P > 0.05).","['A total of 384 front-line medical staff in our hospital from January 25 to March 8, 2020 were selected as subjects']",[],"['GAD-7 anxiety scale had mild, moderate, and severe anxiety scores', 'PHQ-9 depression scale and GAD-7 self-rating anxiety scale questionnaire', 'anxiety scores', 're-self-assessed for anxiety and depression', 'PHQ-9 scale scores']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0025106', 'cui_str': 'Medical Staffs'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]",[],"[{'cui': 'C3641330', 'cui_str': 'GAD-7'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0231403', 'cui_str': 'Severe anxiety (panic)'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.014076,"And there were no markedly difference of PHQ-9 scale scores before and after psychological intervention between groups A and B, A and A1, and B and B1 (P > 0.05).","[{'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': 'Department of General Medicine, Chongqing University Three Gorges Hospital, Chongqing 404000, China.'}, {'ForeName': 'Wenxin', 'Initials': 'W', 'LastName': 'Shi', 'Affiliation': 'Department of Mental and Mental Health, Chongqing University Three Gorges Hospital, Chongqing 404000, China.'}, {'ForeName': 'Danjun', 'Initials': 'D', 'LastName': 'Feng', 'Affiliation': 'Department of Mental and Mental Health, Chongqing University Three Gorges Hospital, Chongqing 404000, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Fang', 'Affiliation': 'Pharmaceutical Department, Chongqing University Three Gorges Hospital, Chongqing 404000, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Zeng', 'Affiliation': 'Department of General Medicine, Chongqing University Three Gorges Hospital, Chongqing 404000, China.'}, {'ForeName': 'Yunfei', 'Initials': 'Y', 'LastName': 'Qu', 'Affiliation': 'Department of Cardiovascular Surgery, Chongqing University Three Gorges Hospital, Chongqing 404000, China. Electronic address: yunfei4040@126.com.'}]",Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,['10.1016/j.jocn.2021.06.037'] 2296,34373044,"Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal, cross-over pilot study.","BACKGROUND Rapid Eye Movement sleep behavior disorder (RBD) is characterized by dream enactment and loss of muscle atonia during REM-sleep. RBD as a premotor feature occurred souvent in patients who develop Parkinson's disease. The glutamatergic, glycinergic, and GABA-ergic systems appear to play a crucial role in the pathogenesis of RBD. METHODS The present exploratory longitudinal cross-over study aimed to observe the effect of safinamide on RBD symptoms. Thirty patients with PD and RBD were randomized into two groups (15 subjects each), those that received for a period of 3-months safinamide (50 mg/die) in addition (Group A + ) or in absence (Group B - ) to the usual antiparkinsonian therapy. Patients exploring the clinical and video-polysomnographic changes occurred during this pharmacological therapy. RESULTS Twenty-two of 30 patients reported clear improvement in symptoms during safinamide treatment, and 16 were absolutely free from clinical RBD-symptoms at the end of the treatment. Eight patients reported slight improvement in RBD-symptoms. In 6/30 patients no substantial improvement was recorded about clinical RBD-symptoms had frightening dreams or from the bed after 1-week of treatment. In addition, after safinamide, the mean UPDRS-II and III scores decreased, while PDSS-2 score indicating an improvement in both motor symptoms and nocturnal sleep features. A significant reduction of sleep behavior disorder by questionnaire-Hong Kong-score (RBDQ-HS), mainly for two individual RBDQ-HK-items (dream related movements and failing out of bed) was registered. CONCLUSIONS This pilot study indicated that safinamide is well tolerated and improves RBD-symptom in parkinsonian.",2021,"A significant reduction of sleep behavior disorder by questionnaire-Hong Kong-score (RBDQ-HS), mainly for two individual RBDQ-HK-items (dream related movements and failing out of bed) was registered. ","['Thirty patients with PD and RBD', ""patients who develop Parkinson's disease"", 'Parkinson disease']","['safinamide (50\xa0mg/die) in addition (Group A\xa0+\xa0) or in absence (Group B\xa0-\xa0) to the usual antiparkinsonian therapy', 'safinamide']","['RBD-symptoms', 'mean UPDRS-II and III scores decreased, while PDSS-2 score', 'sleep behavior disorder by questionnaire-Hong Kong-score (RBDQ-HS', 'clinical and video-polysomnographic changes', 'clinical RBD-symptoms had frightening dreams', 'motor symptoms and nocturnal sleep features', 'clinical RBD-symptoms', 'RBD symptoms', 'tolerated and improves RBD-symptom']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751772', 'cui_str': 'REM sleep behavior disorder'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C1098261', 'cui_str': 'safinamide'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0003405', 'cui_str': 'Antiparkinson agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0751772', 'cui_str': 'REM sleep behavior disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0474396', 'cui_str': 'Sleep behavior finding'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0028084', 'cui_str': 'Nightmares'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",30.0,0.0159184,"A significant reduction of sleep behavior disorder by questionnaire-Hong Kong-score (RBDQ-HS), mainly for two individual RBDQ-HK-items (dream related movements and failing out of bed) was registered. ","[{'ForeName': 'Massimiliano', 'Initials': 'M', 'LastName': 'Plastino', 'Affiliation': 'Department of Neuroscience, ""Pugliese-Ciaccio"" Hospital Organization, 88100 Catanzaro, Italy.'}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Gorgone', 'Affiliation': 'Department of Neuroscience, ""Jazzolino"" Hospital, 89900 Vibo Valentia, Italy.'}, {'ForeName': 'Antonietta', 'Initials': 'A', 'LastName': 'Fava', 'Affiliation': 'Endocrinology Unit, Villa Elisa, Soverato (Catanzaro) 88068, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Ettore', 'Affiliation': 'Department of Neuroscience, ""Pugliese-Ciaccio"" Hospital Organization, 88100 Catanzaro, Italy.'}, {'ForeName': 'Rosario', 'Initials': 'R', 'LastName': 'Iannacchero', 'Affiliation': 'Department of Neuroscience, ""Pugliese - Ciaccio"" Hospital Organization, 88100 Catanzaro, Italy.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Scarfone', 'Affiliation': 'Department of Neuroscience, ""Pugliese-Ciaccio"" Hospital Organization, 88100 Catanzaro, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Vaccaro', 'Affiliation': 'Department of Neuroscience, ""Pugliese-Ciaccio"" Hospital Organization, 88100 Catanzaro, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'De Bartolo', 'Affiliation': 'Neurophysiology Unit, General Hospital, 87067 Rossano, Cosenza, Italy.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Bosco', 'Affiliation': 'Department of Neuroscience, ""Pugliese - Ciaccio"" Hospital Organization, 88100 Catanzaro, Italy. Electronic address: nico_bosco@libero.it.'}]",Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,['10.1016/j.jocn.2021.07.011'] 2297,34364665,Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.,"BACKGROUND In the EMPA-REG OUTCOME trial, ejection fraction (EF) data were not collected. In the subpopulation with heart failure (HF), we applied a new predictive model for EF to determine the effects of empagliflozin in HF with predicted reduced (HFrEF) vs preserved (HFpEF) EF vs no HF. METHODS AND RESULTS We applied a validated EF predictive model based on patient baseline characteristics and treatments to categorize patients with HF as being likely to have HF with mid-range EF (HFmrEF)/HFrEF (EF <50%) or HFpEF (EF ≥50%). Cox regression was used to assess the effect of empagliflozin vs placebo on cardiovascular death/HF hospitalization (HHF), cardiovascular and all-cause mortality, and HHF in patients with predicted HFpEF, HFmrEF/HFrEF and no HF. Of 7001 EMPA-REG OUTCOME patients with data available for this analysis, 6314 (90%) had no history of HF. Of the 687 with history of HF, 479 (69.7%) were predicted to have HFmrEF/HFrEF and 208 (30.3%) to have HFpEF. Empagliflozin's treatment effect was consistent in predicted HFpEF, HFmrEF/HFrEF and no-HF for each outcome (HR [95% CI] for the primary outcome 0.60 [0.31-1.17], 0.79 [0.51-1.23], and 0.63 [0.50-0.78], respectively; P interaction = 0.62). CONCLUSIONS In EMPA-REG OUTCOME, one-third of the patients with HF had predicted HFpEF. The benefits of empagliflozin on HF and mortality outcomes were consistent in nonHF, predicted HFpEF and HFmrEF/HFrEF.",2021,"The benefits of empagliflozin on HF and mortality outcomes were consistent in nonHF, predicted HFpEF and HFmrEF/HFrEF.","['Heart Failure', '687 with history of HF, 479 (69.7%) were predicted to have HFmrEF/HFrEF and 208 (30.3%) to have HFpEF', 'categorize patients with HF as being likely to have HF with mid-range EF (HFmrEF)/HFrEF (EF <50%) or HFpEF (EF ≥50', 'patients with data available for this analysis, 6314 (90%) had no history of HF', 'patients with predicted HFpEF, HFmrEF/HFrEF and no HF']","['empagliflozin vs placebo', 'Empagliflozin', 'empagliflozin']","['cardiovascular death/HF hospitalization (HHF), cardiovascular and all-cause mortality, and HHF', 'HF and mortality outcomes', 'HFpEF', 'predicted HFpEF, HFmrEF/HFrEF and no-HF']","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0455531', 'cui_str': 'H/O: heart failure'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0332122', 'cui_str': 'No history of'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]",,0.392637,"The benefits of empagliflozin on HF and mortality outcomes were consistent in nonHF, predicted HFpEF and HFmrEF/HFrEF.","[{'ForeName': 'Gianluigi', 'Initials': 'G', 'LastName': 'Savarese', 'Affiliation': 'Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden. Electronic address: gianluigi.savarese@ki.se.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Uijl', 'Affiliation': 'Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden; Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Institute of Cardiovascular Science, Faculty of Population Health Sciences, Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom.'}, {'ForeName': 'Lars H', 'Initials': 'LH', 'LastName': 'Lund', 'Affiliation': 'Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Germany.'}, {'ForeName': 'Folkert', 'Initials': 'F', 'LastName': 'Asselbergs', 'Affiliation': 'Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Institute of Cardiovascular Science, Faculty of Population Health Sciences, Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fitchett', 'Affiliation': ""St Michael's Hospital, Division of Cardiology, University of Toronto, ON, Canada.""}, {'ForeName': 'Silvio E', 'Initials': 'SE', 'LastName': 'Inzucchi', 'Affiliation': 'Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Koudstaal', 'Affiliation': 'Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Institute of Cardiovascular Science, Faculty of Population Health Sciences, Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom.'}, {'ForeName': 'Anne Pernille', 'Initials': 'AP', 'LastName': 'Ofstad', 'Affiliation': 'Boehringer Ingelheim Norway Ks, Asker, Norway.'}, {'ForeName': 'Benedikt', 'Initials': 'B', 'LastName': 'Schrage', 'Affiliation': 'Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'Ola', 'Initials': 'O', 'LastName': 'Vedin', 'Affiliation': 'Boehringer Ingelheim AB, Stockholm, Sweden.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Wanner', 'Affiliation': 'Würzburg University Clinic, Würzburg, Germany.'}, {'ForeName': 'Faiez', 'Initials': 'F', 'LastName': 'Zannad', 'Affiliation': 'Institut Lorrain du Coeur et des Vaisseaux, Nancy, France.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Zwiener', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.'}, {'ForeName': 'Javed', 'Initials': 'J', 'LastName': 'Butler', 'Affiliation': 'Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.'}]",Journal of cardiac failure,['10.1016/j.cardfail.2021.05.012'] 2298,34364386,Improving patient self-reporting of antihypertensive adverse drug events in primary care: a stepped wedge cluster randomised trial.,"BACKGROUND About 25% of patients experience adverse drug events (ADE) in primary care, but few events are reported by the patients themselves. One solution to improve the detection and management of ADEs in primary care is for patients to report them to their general practitioner. The study aimed to assess the effect of a booklet designed to improve communication and interaction between patients treated with anti-hypertensive drugs and general practitioners on the reporting of ADEs. METHODS A cluster randomized controlled cross-sectional stepped wedge open trial (five periods of 3 months) was conducted. A cluster was a group of general practitioners working in ambulatory offices in France. Adults consulting their general practitioner to initiate, modify, or renew an antihypertensive prescription were included. A booklet including information on cardiovascular risks, antihypertensive treatments, and ADE report forms was delivered by the general practitioner to the patient in the intervention group. The primary outcome was the reporting of at least one ADE by the patient to his general practitioner during the three-month period after enrolment. Two clusters were randomised by sequence for a total of 8 to receive the intervention. An intention-to-treat analysis was conducted. A logistic mixed model with random intercept was used. RESULTS Sixty general practitioners included 1095 patients (median: 14 per general practitioner; range: 1-103). More patients reported at least one ADE to their general practitioner in the intervention condition compared to the control condition (aOR = 3.5, IC 95 [1.2-10.1], p = 0.02). The modification and initiation of an antihypertensive treatment were also significantly associated with the reporting of ADEs (aOR = 4.4, CI 95 [1.9-10.0], p <  0.001 and aOR = 11.0, CI 95 [4.6-26.4], p <  0.001, respectively). The booklet delivery also improved patient satisfaction on general practitioner communication and high blood pressure management. CONCLUSION A booklet can improve patient self-reporting of ADEs to their general practitioners. Future research should assess whether it can improve general practitioner management of ADEs and patient's health status. TRIAL REGISTRATION Trial registry identifier NCT01610817 (2012/05/30).",2021,"More patients reported at least one ADE to their general practitioner in the intervention condition compared to the control condition (aOR = 3.5, IC 95 [1.2-10.1], p = 0.02).","['primary care', 'patients treated with anti-hypertensive drugs and general practitioners on the reporting of ADEs', 'Adults consulting their general practitioner to initiate, modify, or renew an antihypertensive prescription were included', 'general practitioners working in ambulatory offices in France', 'Sixty general practitioners included 1095 patients (median: 14 per general practitioner; range: 1-103']",[],"['reporting of ADEs', 'reporting of at least one ADE by the patient to his general practitioner', 'patient satisfaction on general practitioner communication and high blood pressure management', 'patient self-reporting of ADEs']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0057163', 'cui_str': 'DAV regimen'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4517526', 'cui_str': '103'}]",[],"[{'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0057163', 'cui_str': 'DAV regimen'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0036588', 'cui_str': 'Self'}]",2.0,0.0664907,"More patients reported at least one ADE to their general practitioner in the intervention condition compared to the control condition (aOR = 3.5, IC 95 [1.2-10.1], p = 0.02).","[{'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Buchet-Poyau', 'Affiliation': 'Hospices Civils de Lyon, Pôle de santé publique, Service Recherche et Epidémiologie Clinique, F-69003, Lyon, France. karine.poyau@chu-lyon.fr.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Occelli', 'Affiliation': 'Hospices Civils de Lyon, Pôle de santé publique, Service Recherche et Epidémiologie Clinique, F-69003, Lyon, France.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Touzet', 'Affiliation': 'Hospices Civils de Lyon, Pôle de santé publique, Service Recherche et Epidémiologie Clinique, F-69003, Lyon, France.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Langlois-Jacques', 'Affiliation': 'Hospices Civils de Lyon, Pôle de santé publique, Service de Biostatistique, F-69002, Lyon, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Figon', 'Affiliation': 'Collège universitaire de Médecine Générale, Université Lyon 1, F-69622, Villeurbanne, France.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Dubois', 'Affiliation': 'Collège universitaire de Médecine Générale, Université Lyon 1, F-69622, Villeurbanne, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Duclos', 'Affiliation': 'Laboratoire Research on Healthcare Performance RESHAPE, INSERM U1290, Université Lyon 1, F-69622, Villeurbanne, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Chanelière', 'Affiliation': 'Hospices Civils de Lyon, Pôle de santé publique, Service Recherche et Epidémiologie Clinique, F-69003, Lyon, France.'}, {'ForeName': 'Cyrille', 'Initials': 'C', 'LastName': 'Colin', 'Affiliation': 'Laboratoire Research on Healthcare Performance RESHAPE, INSERM U1290, Université Lyon 1, F-69622, Villeurbanne, France.'}, {'ForeName': 'Muriel', 'Initials': 'M', 'LastName': 'Rabilloud', 'Affiliation': 'Hospices Civils de Lyon, Pôle de santé publique, Service de Biostatistique, F-69002, Lyon, France.'}, {'ForeName': 'Maud', 'Initials': 'M', 'LastName': 'Keriel-Gascou', 'Affiliation': 'Hospices Civils de Lyon, Pôle de santé publique, Service Recherche et Epidémiologie Clinique, F-69003, Lyon, France.'}]",BMC family practice,['10.1186/s12875-021-01478-w'] 2299,34364385,"Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.","BACKGROUND In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. METHODS In this exploratory analysis, plasma biomarkers from baseline and week 4 from 621 of 658 randomized patients were analyzed for CA9, HGF, MET, GAS6, AXL, VEGF, VEGFR2, and IL-8. PFS and OS were analyzed by baseline biomarker levels as both dichotomized and continuous variables using univariate and multivariable methods. For on-treatment changes, PFS and OS were analyzed using fold change in biomarker levels at week 4. Biomarkers were considered prognostic if p < 0.05 and predictive if p interaction  < 0.05 for the interaction between treatment and biomarker. RESULTS Hazard ratios for PFS and OS favored cabozantinib versus everolimus for both low and high baseline levels of all biomarkers (hazard ratios ≤0.78). In univariate analyses, low baseline HGF, AXL, and VEGF were prognostic for improvements in both PFS and OS with cabozantinib, and low HGF was prognostic for improvements in both PFS and OS with everolimus. Low AXL was predictive of relative improvement in PFS for cabozantinib versus everolimus. Results were generally consistent when baseline biomarkers were expressed as continuous variables, although none were predictive of benefit with treatment. In multivariable analysis, low baseline HGF was independently prognostic for improved PFS for both cabozantinib and everolimus; low HGF, GAS6, and VEGF were independently prognostic for improved OS with cabozantinib. No biomarkers were independently prognostic for OS with everolimus. On-treatment increases in some biomarkers appeared prognostic for PFS or OS with cabozantinib in univariate analyses; however, none were independently prognostic in multivariable analysis. CONCLUSIONS PFS and OS were improved with cabozantinib versus everolimus at high and low baseline levels of all biomarkers. Low baseline HGF was consistently identified as a prognostic biomarker for improved PFS or OS with cabozantinib or everolimus, supporting further prospective evaluation of the prognostic significance of HGF in advanced RCC. TRIAL REGISTRATION ClinicalTrials.gov NCT01865747 (registered on 05/31/2013).",2021,"Low baseline HGF was consistently identified as a prognostic biomarker for improved PFS or OS with cabozantinib or everolimus, supporting further prospective evaluation of the prognostic significance of HGF in advanced RCC. ","['advanced renal cell carcinoma', 'patients with advanced RCC after prior antiangiogenic therapy']","['cabozantinib versus everolimus', 'cabozantinib vs everolimus', 'everolimus']","['PFS and OS', 'progression-free survival (PFS) and overall survival (OS']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007134', 'cui_str': 'Renal cell carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C2363719', 'cui_str': 'Antiangiogenic therapy'}]","[{'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",658.0,0.198725,"Low baseline HGF was consistently identified as a prognostic biomarker for improved PFS or OS with cabozantinib or everolimus, supporting further prospective evaluation of the prognostic significance of HGF in advanced RCC. ","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Powles', 'Affiliation': 'Barts Cancer Institute, Queen Mary University of London, London, UK. thomas.powles1@nhs.net.'}, {'ForeName': 'Toni K', 'Initials': 'TK', 'LastName': 'Choueiri', 'Affiliation': 'Dana-Farber Cancer Center, Boston, MA, USA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Motzer', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Jonasch', 'Affiliation': 'University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Sumanta', 'Initials': 'S', 'LastName': 'Pal', 'Affiliation': 'City of Hope National Medical Center, Duarte, CA, USA.'}, {'ForeName': 'Nizar M', 'Initials': 'NM', 'LastName': 'Tannir', 'Affiliation': 'University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Sabina', 'Initials': 'S', 'LastName': 'Signoretti', 'Affiliation': ""Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Kaldate', 'Affiliation': 'Exelixis, Inc, Alameda, CA, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Scheffold', 'Affiliation': 'Exelixis, Inc, Alameda, CA, USA.'}, {'ForeName': 'Evelyn', 'Initials': 'E', 'LastName': 'Wang', 'Affiliation': 'Exelixis, Inc, Alameda, CA, USA.'}, {'ForeName': 'Dana T', 'Initials': 'DT', 'LastName': 'Aftab', 'Affiliation': 'Exelixis, Inc, Alameda, CA, USA.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Escudier', 'Affiliation': 'Gustave-Roussy, Villejuif, France.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'George', 'Affiliation': 'Duke Cancer Institute, Durham, NC, USA.'}]",BMC cancer,['10.1186/s12885-021-08630-w'] 2300,34364382,Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms.,"BACKGROUND Colon neuroendocrine neoplasms (NENs) have one of the poorest median overall survival (OS) rates among all NENs. The American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system-currently the most commonly used prediction model-has limited prediction accuracy because it does not include parameters such as age, sex, and treatment. The aim of this study was to construct nomograms containing various clinically important parameters to predict the prognosis of patients with colon NENs more accurately. METHODS Using the Surveillance, Epidemiology, and End Results (SEER) database, we performed a retrospective analysis of colon NENs diagnosed from 1975 to 2016. Data were collected from 1196 patients; almost half were female (617/1196, 51.6%), and the average age was 61.94 ± 13.05 years. Based on the age triple cut-off values, there were 396 (33.1%), 408 (34.1%), and 392 (32.8%) patients in age groups 0-55 years, 55-67 years, and ≥ 68 years, respectively. Patients were randomized into training and validation cohorts (3:1). Independent prognostic factors were used for construction of nomograms to precisely predict OS and cancer-specific survival (CSS) in patients with colon NENs. RESULTS Multivariate analysis showed that age ≥ 68 years, sex, tumor size, grade, chemotherapy, N stage, and M stage were independent predictors of OS. In the validation cohort, the Concordance index (C-index) values of the OS and CSS nomograms were 0.8345 (95% confidence interval [CI], 0.8044-0.8646) and 0.8209 (95% CI, 0.7808-0.861), respectively. C-index also indicated superior performance of both nomograms (C-index 0.8347 for OS and 0.8668 for CSS) compared with the AJCC TNM classification (C-index 0.7159 for OS and 0.7366 for CSS). CONCLUSIONS We established and validated new nomograms for more precise prediction of OS and CSS in patients with colon NENs to facilitate individualized clinical decisions.",2021,"C-index also indicated superior performance of both nomograms (C-index 0.8347 for OS and 0.8668 for CSS) compared with the AJCC TNM classification (C-index 0.7159 for OS and 0.7366 for CSS). ","['Data were collected from 1196 patients; almost half were female (617/1196, 51.6%), and the average age was 61.94\u2009±\u200913.05\xa0years', 'patients with colon NENs', '0-55\xa0years, 55-67\xa0years, and\u2009≥', 'patients with colon neuroendocrine neoplasms']",[],"['median overall survival (OS) rates', 'Concordance index (C-index) values of the OS and CSS nomograms', 'OS and cancer-specific survival (CSS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0206754', 'cui_str': 'Neuroendocrine tumor'}]",[],"[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1450294', 'cui_str': 'Nomogram chart'}]",,0.0953175,"C-index also indicated superior performance of both nomograms (C-index 0.8347 for OS and 0.8668 for CSS) compared with the AJCC TNM classification (C-index 0.7159 for OS and 0.7366 for CSS). ","[{'ForeName': 'Ruitong', 'Initials': 'R', 'LastName': 'Xu', 'Affiliation': 'Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Gulou District, No. 300, Guangzhou Road, Nanjing, 210029, China.'}, {'ForeName': 'Bingrong', 'Initials': 'B', 'LastName': 'Zhou', 'Affiliation': 'Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University, Gulou District, No. 300, Guangzhou Road, Nanjing, 210029, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Hu', 'Affiliation': 'Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Gulou District, No. 300, Guangzhou Road, Nanjing, 210029, China.'}, {'ForeName': 'Bingyan', 'Initials': 'B', 'LastName': 'Xue', 'Affiliation': 'Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Gulou District, No. 300, Guangzhou Road, Nanjing, 210029, China.'}, {'ForeName': 'Danyang', 'Initials': 'D', 'LastName': 'Gu', 'Affiliation': 'Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Gulou District, No. 300, Guangzhou Road, Nanjing, 210029, China.'}, {'ForeName': 'Xiaolin', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Gulou District, No. 300, Guangzhou Road, Nanjing, 210029, China.'}, {'ForeName': 'Qiyun', 'Initials': 'Q', 'LastName': 'Tang', 'Affiliation': 'Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Gulou District, No. 300, Guangzhou Road, Nanjing, 210029, China. tqy831@163.com.'}]",World journal of surgical oncology,['10.1186/s12957-021-02338-8'] 2301,34370401,Five-year follow-up of a family-based multidisciplinary program for children with obesity.,"OBJECTIVE This study aimed to determine 5-year outcomes from a 12-month, family-based, multidisciplinary lifestyle intervention program for children. METHODS This study was the 5-year follow-up of a randomized clinical trial comparing a low-intensity control group (home-based assessments) with a high-intensity intervention group (assessments plus weekly sessions) in New Zealand. Participants were aged 5 to 16 years with BMI ≥ 98th centile or > 91st centile with weight-related comorbidities. The primary outcome was BMI standard deviation score (BMISDS). Secondary outcomes included various health markers. RESULTS Of the 199 children included in the study at baseline (47% who identified as Māori, 53% who identified as female, 28% in the most deprived quintile, mean age = 10.7 years, mean BMISDS = 3.12), 86 completed a 5-year assessment (43%). BMISDS reduction at 12 months was not retained (control = 0.00 [95% CI: -0.22 to 0.21] and intervention = 0.17 [95% CI: -0.01 to 0.34]; p = 0.221) but was greater in participants aged <10 years versus >10 years at baseline (-0.15 [95% CI: -0.33 to 0.03] vs. 0.21 [95% CI: 0.03 to 0.40]; p = 0.008). BMISDS trajectory favored participants with high attendance (p = 0.013). There were persistent improvements in water intake and health-related quality of life in both groups as well as reduced sweet drink intake in the intervention group. CONCLUSIONS This intervention, with high engagement from those most affected by obesity, did not achieve long-term efficacy of the primary outcome. Attendance and age remain important considerations for future interventions to achieve long-term BMISDS reduction.",2021,"There were persistent improvements in water intake and health-related quality of life in both groups as well as reduced sweet drink intake in the intervention group. ","['children with obesity', 'children', 'Participants were aged 5 to 16 years with BMI ≥ 98th centile or > 91st centile with weight-related comorbidities', '199 children included in the study at baseline (47% who identified as Māori, 53% who identified as female, 28% in the most deprived quintile, mean age = 10.7 years, mean BMISDS = 3.12), 86 completed a 5-year assessment (43']","['low-intensity control group (home-based assessments) with a high-intensity intervention', 'multidisciplinary lifestyle intervention program']","['various health markers', 'sweet drink intake', 'BMI standard deviation score (BMISDS', 'water intake and health-related quality of life', 'BMISDS reduction']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C5191365', 'cui_str': '10.7'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C0556158', 'cui_str': 'Drink intake'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013123', 'cui_str': 'Water intake'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",199.0,0.135667,"There were persistent improvements in water intake and health-related quality of life in both groups as well as reduced sweet drink intake in the intervention group. ","[{'ForeName': 'Cervantée E K', 'Initials': 'CEK', 'LastName': 'Wild', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Lisa E', 'Initials': 'LE', 'LastName': 'Wynter', 'Affiliation': 'Department of Pediatrics, Taranaki District Health Board, New Plymouth, New Zealand.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Triggs', 'Affiliation': 'Department of Statistics, Faculty of Science, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'José G B', 'Initials': 'JGB', 'LastName': 'Derraik', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Paul L', 'Initials': 'PL', 'LastName': 'Hofman', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Yvonne C', 'Initials': 'YC', 'LastName': 'Anderson', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.23225'] 2302,34370364,"A Randomized, Sham-Controlled Trial of Repetitive Transcranial Magnetic Stimulation Targeting M1 and S2 in Central Poststroke Pain: A Pilot Trial.","OBJECTIVES Central poststroke pain (CPSP), a neuropathic pain condition, is difficult to treat. Repetitive transcranial magnetic stimulation (rTMS) targeted to the primary motor cortex (M1) can alleviate the condition, but not all patients respond. We aimed to assess a promising alternative rTMS target, the secondary somatosensory cortex (S2), for CPSP treatment. MATERIALS AND METHODS This prospective, randomized, double-blind, Sham-controlled three-arm crossover trial assessed navigated rTMS (nrTMS) targeted to M1 and S2 (10 sessions, 5050 pulses per session at 10 Hz). Participants were evaluated for pain, depression, anxiety, health-related quality of life, upper limb function, and three plasticity-related gene polymorphisms including Dopamine D2 Receptor (DRD2). We monitored pain intensity and interference before and during stimulations, and at one month. A conditioned pain modulation test was performed using the cold pressor test. This assessed the efficacy of the descending inhibitory system, which may transmit TMS effects in pain control. RESULTS We prescreened 73 patients, screened 29, and included 21, of whom 17 completed the trial. NrTMS targeted to S2 resulted in long-term (from baseline to one-month follow-up) pain intensity reduction of ≥30% in 18% (3/17) of participants. All stimulations showed a short-term effect on pain (17-20% pain relief), with no difference between M1, S2, or Sham stimulations, indicating a strong placebo effect. Only nrTMS targeted to S2 resulted in a significant long-term pain intensity reduction (15% pain relief). The cold pressor test reduced CPSP pain intensity significantly (p = 0.001), indicating functioning descending inhibitory controls. The homozygous DRD2 T/T genotype is associated with the M1 stimulation response. CONCLUSIONS S2 is a promising nrTMS target in the treatment of CPSP. The DRD2 T/T genotype might be a biomarker for M1 nrTMS response, but this needs confirmation from a larger study.",2021,Only nrTMS targeted to S2 resulted in a significant long-term pain intensity reduction (15% pain relief).,"['73 patients, screened 29, and included 21, of whom 17 completed the trial', 'Central Poststroke Pain']","['Repetitive transcranial magnetic stimulation (rTMS', 'navigated rTMS (nrTMS', 'Repetitive Transcranial Magnetic Stimulation Targeting M1 and S2']","['pain, depression, anxiety, health-related quality of life, upper limb function, and three plasticity-related gene polymorphisms including Dopamine D2 Receptor (DRD2', 'CPSP pain intensity', 'significant long-term pain intensity reduction', 'pain', 'pain intensity reduction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0678558', 'cui_str': 'Plasticity'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0058698', 'cui_str': 'Dopamine-D2 Receptor'}, {'cui': 'C3659270', 'cui_str': 'DRD2 protein, human'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.116074,Only nrTMS targeted to S2 resulted in a significant long-term pain intensity reduction (15% pain relief).,"[{'ForeName': 'Juhani', 'Initials': 'J', 'LastName': 'Ojala', 'Affiliation': 'Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Jukka', 'Initials': 'J', 'LastName': 'Vanhanen', 'Affiliation': 'HUS Diagnostic Center, Clinical Neurophysiology, Clinical Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Harno', 'Affiliation': 'Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Pantelis', 'Initials': 'P', 'LastName': 'Lioumis', 'Affiliation': 'BioMag Laboratory, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Selja', 'Initials': 'S', 'LastName': 'Vaalto', 'Affiliation': 'HUS Diagnostic Center, Clinical Neurophysiology, Clinical Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Mari A', 'Initials': 'MA', 'LastName': 'Kaunisto', 'Affiliation': 'Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Jukka', 'Initials': 'J', 'LastName': 'Putaala', 'Affiliation': 'Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Marko', 'Initials': 'M', 'LastName': 'Kangasniemi', 'Affiliation': 'HUS Diagnostic Center, Department of Radiology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Kirveskari', 'Affiliation': 'HUS Diagnostic Center, Clinical Neurophysiology, Clinical Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Jyrki P', 'Initials': 'JP', 'LastName': 'Mäkelä', 'Affiliation': 'BioMag Laboratory, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Eija', 'Initials': 'E', 'LastName': 'Kalso', 'Affiliation': 'Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.'}]",Neuromodulation : journal of the International Neuromodulation Society,['10.1111/ner.13496'] 2303,34370275,Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.,"INTRODUCTION In the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study, cladribine tablets significantly reduced relapse rates and improved findings on magnetic resonance imaging versus placebo in patients with relapsing multiple sclerosis. In the CLARITY Extension study, treatment with cladribine tablets for 2 years followed by placebo for 2 years produced similar clinical benefits to 4 years of cladribine tablets. The objective of this exploratory post hoc analysis was to evaluate long-term disease stability (assessed by the Expanded Disability Status Scale [EDSS] score) after treatment with cladribine tablets. METHODS Patients enrolled into CLARITY Extension who were previously randomized to cladribine tablets 3.5 mg/kg in the CLARITY study were included in this post hoc analysis. Two treatment groups were investigated-patients randomized to cladribine tablets 3.5 mg/kg in CLARITY and thereafter randomized to placebo in CLARITY Extension (the CP3.5 group) or to cladribine tablets 3.5 mg/kg in CLARITY Extension (the CC7 group). In each treatment group, EDSS scores at 6-month intervals, EDSS score improvement/worsening each year, and time to 3- and 6-month confirmed EDSS progression were assessed from CLARITY baseline over 5 years of follow-up (including a variable bridging interval between studies). All analyses are descriptive, and no statistical comparisons were performed for between-treatment group differences. RESULTS The median (95% confidence interval [CI]) EDSS score for patients in the CP3.5 group at 5 years was 2.5 (2.0-3.5) compared with 3.0 (2.5-3.5) at baseline. In the CC7 group, median EDSS score (95% CI) at 5 years was 2.0 (2.0-3.0) compared with 2.5 (2.5-3.0) at baseline. During year 5 for the CP3.5 group, and based on changes in minimum score each year, EDSS score stability was observed in 53.9% of patients, improvement in 21.3%, and worsening in 24.7%. In the CC7 group, EDSS score remained stable in 66.1%, improved in 18.1%, and worsened in 15.8% of patients. Over 70% of patients in both treatment groups did not show 3- or 6-month confirmed EDSS progression at 5 years from CLARITY baseline. CONCLUSIONS These findings confirm long-term beneficial effects on disability afforded by either the recommended dose of cladribine tablets over 4 years (cumulative dose, 3.5 mg/kg) or a higher cumulative dose. TRIAL REGISTRATION ClinicalTrials.gov NCT00213135 (CLARITY); NCT00641537 (CLARITY Extension).",2021,"In the CC7 group, EDSS score remained stable in 66.1%, improved in 18.1%, and worsened in 15.8% of patients.","['patients with relapsing multiple sclerosis', 'Patients enrolled into CLARITY Extension who were previously randomized to']","['Cladribine Tablets', 'cladribine tablets 3.5\xa0mg/kg in CLARITY', 'cladribine tablets 3.5\xa0mg/kg in CLARITY Extension', 'CC7', 'cladribine tablets', 'cladribine', 'placebo']","['EDSS score', 'relapse rates', 'Expanded Disability Status Scale [EDSS] score', 'EDSS progression', 'median EDSS score', 'EDSS scores at 6-month intervals, EDSS score improvement/worsening each year, and time to 3- and 6-month confirmed EDSS progression', 'EDSS score stability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0856120', 'cui_str': 'Multiple sclerosis relapse'}, {'cui': 'C0092801', 'cui_str': 'Cladribine'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C0092801', 'cui_str': 'Cladribine'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",,0.170146,"In the CC7 group, EDSS score remained stable in 66.1%, improved in 18.1%, and worsened in 15.8% of patients.","[{'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Giovannoni', 'Affiliation': 'Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, Whitechapel, London, E1 2AT, UK. g.giovannoni@qmul.ac.uk.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Comi', 'Affiliation': 'Casa di Cura Privata del Policlinico, Università Vita-Salute San Raffaele, Milan, Italy.'}, {'ForeName': 'Kottil', 'Initials': 'K', 'LastName': 'Rammohan', 'Affiliation': 'MS Research Center, University of Miami School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rieckmann', 'Affiliation': 'Department of Neurology, Medical Park Loipl and University of Erlangen, Erlangen, Germany.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Dangond', 'Affiliation': 'EMD Serono Research and Development Institute, Inc., Billerica, MA, USA.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Keller', 'Affiliation': 'The healthcare business of Merck KGaA, Darmstadt, Germany.'}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Jack', 'Affiliation': 'Merck Serono Ltd (an affiliate of Merck KGaA, Darmstadt, Germany), Feltham, UK.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Vermersch', 'Affiliation': 'Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France.'}]",Advances in therapy,['10.1007/s12325-021-01865-w'] 2304,34370217,Clinical features of definite vestibular migraine through the lens of central sensitization: a cross-sectional study.,"BACKGROUND Vestibular migraine (VM) commonly causes episodic vertigo/dizziness; however, its clinical features are unknown. Based on the evidence that central sensitization is related to VM pathogenesis, we hypothesized that cutaneous allodynia is frequently associated with patients with VM compared with patients without VM. This study aims to (1) elucidate the clinical features of patients with VM and (2) evaluate whether patients with VM were more frequently associated with cutaneous allodynia than patients without VM. METHODS This cross-sectional study enrolled consecutive patients with migraine aged 18-65 years. The comprehensive interview form included diagnostic questions regarding migraine and VM, demographic characteristics, migraine-specific variables, migraine-associated symptoms, and cutaneous allodynia. RESULTS A total of 245 consecutive patients with migraine (mean age = 39.5 years, 81.2% women) were enrolled; 65 (26.5%) patients with VM were assigned to the VM group, 74 (30.2%) with migraine with vestibular symptoms not meeting the VM criteria (MwVS) were assigned to the MwVS group, and 106 (43.3%) patients with episodic migraine without vestibular symptoms (EM) were assigned to the EM group, respectively. Pairwise comparisons demonstrated no significant differences between the VM and MwVS groups, except for severe disability in the VM group. Compared with EM group, VM group had significant aura, severe disability, depression, tinnitus, sleep disorders, and widespread multimodal cutaneous allodynia. CONCLUSIONS VM and MwVS may be on the same spectrum of disorders. The VM group had significantly associated widespread multimodal cutaneous allodynia compared with the EM group, indicating that thalamic sensitization plays a key role in VM pathogenesis. Widespread allodynia may be a useful diagnostic aid for VM.",2021,"Pairwise comparisons demonstrated no significant differences between the VM and MwVS groups, except for severe disability in the VM group.","['245 consecutive patients with migraine (mean age\u2009=\u200939.5\xa0years, 81.2% women) were enrolled; 65 (26.5%) patients with VM were assigned to the VM group, 74 (30.2%) with migraine with vestibular symptoms not meeting the VM criteria (MwVS) were assigned to the MwVS group, and 106 (43.3%) patients with episodic migraine without vestibular symptoms (EM', 'enrolled consecutive patients with migraine aged 18-65\xa0years', 'patients with VM and (2) evaluate whether patients with VM']",[],"['aura, severe disability, depression, tinnitus, sleep disorders, and widespread multimodal cutaneous allodynia', 'multimodal cutaneous allodynia', 'cutaneous allodynia', 'severe disability']","[{'cui': 'C4517661', 'cui_str': '245'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0395920', 'cui_str': 'Migrainous vertigo'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}]",[],"[{'cui': 'C0236018', 'cui_str': 'Aura'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0205219', 'cui_str': 'Diffuse'}, {'cui': 'C1274924', 'cui_str': 'Cutaneous allodynia'}]",245.0,0.0895485,"Pairwise comparisons demonstrated no significant differences between the VM and MwVS groups, except for severe disability in the VM group.","[{'ForeName': 'Toshihide', 'Initials': 'T', 'LastName': 'Toriyama', 'Affiliation': 'Toriyama Clinic, Komoro, Nagano, Japan.'}, {'ForeName': 'Yoshiki', 'Initials': 'Y', 'LastName': 'Hanaoka', 'Affiliation': 'Department of Neurosurgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. hanaoka@shinshu-u.ac.jp.'}, {'ForeName': 'Tetsuyoshi', 'Initials': 'T', 'LastName': 'Horiuchi', 'Affiliation': 'Department of Neurosurgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.'}]",Acta neurologica Belgica,['10.1007/s13760-021-01772-5'] 2305,34370185,Effects of vibratory feedback stimuli through an oral appliance on sleep bruxism: a 6-week intervention trial.,"PURPOSE Various biofeedback stimulation techniques of managing sleep bruxism (SB) have recently emerged; however, the effect of successive application of vibratory feedback stimulation has not been clarified. This study elucidated the effect of vibration feedback stimulation via an oral appliance (OA) on SB when vibration feedback was applied for 4 weeks. METHODS This was a prospective, single-arm, open-label, intervention study. Ten participants diagnosed with ""definite"" SB wore a specially designed OA for 45 nights in a home-setting. A force-based SB detection system, including a pressure-sensitive piezoelectric film placed internally in the OA, triggered a vibrator attached to the OA. Vibratory stimulation was withheld during the first 2-week adaptation period (1st-15th nights), applied during the 4-week stimulation period (16th-43rd nights), and again withheld during the post-stimulation period (44th and 45th nights). The number and duration of SB episodes/hour of sleep were calculated based on masseter electromyographic activity recorded with in-home portable polysomnography and compared between the 15th and 45th nights (without stimulation) and the 17th and 43rd nights (with stimulation). RESULTS The number and duration of SB episodes significantly decreased after vibratory stimulation (15th vs. 17th nights: p = 0.012 and p = 0.012, respectively), then significantly increased upon cessation of vibratory stimulation after the stimulation period (43rd vs. 45th nights: p = 0.023 and p = 0.023, respectively). CONCLUSION Contingent vibratory stimulation through an OA may suppress SB-related masticatory muscle activity continuously for 4 weeks and may be an effective alternative for the management of SB. TRIAL REGISTRATION https://jrct.niph.go.jp/ ; trial registration number: jRCTs032190225.",2021,"The number and duration of SB episodes significantly decreased after vibratory stimulation (15th vs. 17th nights: p = 0.012 and p = 0.012, respectively), then significantly increased upon cessation of vibratory stimulation after the stimulation period (43rd vs. 45th nights: p = 0.023 and p = 0.023, respectively). ","['managing sleep bruxism (SB', 'Ten participants diagnosed with ""definite"" SB']","['vibratory feedback stimuli', 'vibration feedback stimulation via an oral appliance (OA']","['number and duration of SB episodes/hour of sleep', 'number and duration of SB episodes', 'sleep bruxism', 'cessation of vibratory stimulation', 'Vibratory stimulation']","[{'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0751771', 'cui_str': 'Nocturnal Teeth Grinding Disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0439544', 'cui_str': 'Definite'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1542418', 'cui_str': 'Appliance'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0006325', 'cui_str': 'Grinding teeth'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0751771', 'cui_str': 'Nocturnal Teeth Grinding Disorder'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]",10.0,0.025277,"The number and duration of SB episodes significantly decreased after vibratory stimulation (15th vs. 17th nights: p = 0.012 and p = 0.012, respectively), then significantly increased upon cessation of vibratory stimulation after the stimulation period (43rd vs. 45th nights: p = 0.023 and p = 0.023, respectively). ","[{'ForeName': 'Hironobu', 'Initials': 'H', 'LastName': 'Ohara', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo, 145-8515, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Takaba', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo, 145-8515, Japan.'}, {'ForeName': 'Yuka', 'Initials': 'Y', 'LastName': 'Abe', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo, 145-8515, Japan.'}, {'ForeName': 'Yukari', 'Initials': 'Y', 'LastName': 'Nakazato', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo, 145-8515, Japan.'}, {'ForeName': 'Risa', 'Initials': 'R', 'LastName': 'Aoki', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo, 145-8515, Japan.'}, {'ForeName': 'Yuya', 'Initials': 'Y', 'LastName': 'Yoshida', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo, 145-8515, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Suganuma', 'Affiliation': 'Department of Special Needs Dentistry, Division of Temporomandibular Disorders, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo, 145-8515, Japan.'}, {'ForeName': 'Kazuyoshi', 'Initials': 'K', 'LastName': 'Baba', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo, 145-8515, Japan. kazuyoshi@dent.showa-u.ac.jp.'}]",Sleep & breathing = Schlaf & Atmung,['10.1007/s11325-021-02460-7'] 2306,34370172,Phacoemulsification versus Phacotrabeculectomy in Medically Controlled Primary Angle Closure Glaucoma with Cataract in an Indian Cohort: A randomized controlled trial.,"PURPOSE To compare the outcomes of phacoemulsification with phacotrabeculectomy in primary angle closure glaucoma (PACG) eyes with medically controlled intraocular pressure (IOP). METHODS Prospective, randomized control trial including 33 eyes of 33 patients who underwent phacoemulsification (Phaco) and 37 eyes (37 patients) who underwent phacotrabeculectomy (PT). The primary outcome measure was survival defined as IOP control (IOP ≥ 6 and ≤ 21 mmHg without antiglaucoma medications (AGM) at different time points. Secondary outcome measures were the rate of visual recovery and complications. RESULTS The mean age in years (PT: 58.5 ± 9.8, Phaco:61.6 ± 8.9; p = 0.16), preoperative mean deviation in decibel (PT: -18.7 ± 9.3; Phaco: -16.6 ± 7.9; p = 0.32) and the mean follow up in years (PT: 2.5 ± 1.8; Phaco: 2.8 ± 2.0; p = 0.63) were similar in the two groups. The mean preoperative AGMs were more in the PT group (PT: 2.13 ± 0.97, Phaco: 1.60 ± 0.78; p = 0.01). In both the groups the survival was similar at all-time points (PT: 78% at 1-year and 52% at 5-years, Phaco: 80% at 1 year and 59% at 5 years (P = 0.82). The postoperative visual acuity in LogMAR was significantly better in the Phaco group at 1 month (PT: 0.22 ± 0.38, Phaco:0.06 ± 0.07; p = 0.02). Postoperative AGM (p = 0.68) and rate of visual field progression PT: -0.46 ± 0.41 dB/year; Phaco: -0.38 ± 0.73 dB/year; p = 0.67) were similar in both groups. One eye in PT group developed malignant glaucoma which resolved with laser hyaloidotomy and cycloplegic therapy. CONCLUSIONS More rapid visual recovery with similar IOP control and similar visual field stability favor phacoemulsification to phacotrabeculectomy in medically controlled PACG eyes with cataract.",2021,"In both the groups the survival was similar at all-time points (PT: 78% at 1-year and 52% at 5-years, Phaco: 80% at 1 year and 59% at 5 years (P = 0.82).","['33 eyes of 33 patients who underwent phacoemulsification (Phaco) and 37 eyes (37 patients) who underwent phacotrabeculectomy (PT', 'medically controlled PACG eyes with cataract', 'primary angle closure glaucoma (PACG) eyes with medically controlled intraocular pressure (IOP', 'mean age in years (PT: 58.5\u2009±\u20099.8, Phaco:61.6\u2009±\u20098.9; p\u2009=\u20090.16), preoperative mean deviation in decibel (PT: -18.7\u2009±\u20099.3; Phaco: -16.6\u2009±\u20097.9; p\u2009=\u20090.32) and the mean follow up in years (PT: 2.5\u2009±\u20091.8; Phaco: 2.8\u2009±\u20092.0; p\u2009=\u20090.63) were similar in the two groups', 'Medically Controlled Primary Angle Closure Glaucoma with Cataract in an Indian Cohort']","['phacoemulsification with phacotrabeculectomy', 'Phacoemulsification versus Phacotrabeculectomy']","['survival defined as IOP control (IOP\u2009≥\u20096 and\u2009≤\u200921\xa0mmHg without antiglaucoma medications (AGM', 'postoperative visual acuity in LogMAR', 'malignant glaucoma', 'survival', 'rate of visual recovery and complications', 'rate of visual field progression PT', 'Postoperative AGM', 'mean preoperative AGMs']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C1167708', 'cui_str': 'Phacotrabeculectomy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0017605', 'cui_str': 'Angle-closure glaucoma'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517431', 'cui_str': '0.16'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C1828170', 'cui_str': 'Mean deviation'}, {'cui': 'C0439497', 'cui_str': 'dB'}, {'cui': 'C4517448', 'cui_str': '0.32'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C4517468', 'cui_str': '0.63'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C1167708', 'cui_str': 'Phacotrabeculectomy'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0271152', 'cui_str': 'Malignant glaucoma'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]",,0.102584,"In both the groups the survival was similar at all-time points (PT: 78% at 1-year and 52% at 5-years, Phaco: 80% at 1 year and 59% at 5 years (P = 0.82).","[{'ForeName': 'Sirisha', 'Initials': 'S', 'LastName': 'Senthil', 'Affiliation': 'VST Glaucoma Center, L V Prasad Eye Institute, Banjara Hills, Hyderabad, India. sirishasenthil@lvpei.org.'}, {'ForeName': 'Harsha L', 'Initials': 'HL', 'LastName': 'Rao', 'Affiliation': 'Narayana Nethralaya, Bangalore, India.'}, {'ForeName': 'Nikhil', 'Initials': 'N', 'LastName': 'Choudhari', 'Affiliation': 'VST Glaucoma Center, L V Prasad Eye Institute, Banjara Hills, Hyderabad, India.'}, {'ForeName': 'Chandrasekhar', 'Initials': 'C', 'LastName': 'Garudadri', 'Affiliation': 'VST Glaucoma Center, L V Prasad Eye Institute, Banjara Hills, Hyderabad, India.'}]",International ophthalmology,['10.1007/s10792-021-01997-6'] 2307,34370025,Evaluation of At-home Bleaching Times on Effectiveness and Sensitivity with 10% Hydrogen Peroxide: A Randomized Controlled Double-blind Clinical Trial.,"OBJECTIVES The aim of this randomized double-blind controlled clinical trial was to evaluate different protocols for at-home use of 10% hydrogen peroxide in whitening effectiveness and tooth sensitivity. METHODS Seventy-two patients were selected according to the inclusion and exclusion criteria, with the upper central incisors having color A2 or darker according to the Vita Classical scale (VITA Zahnfabrik, Bad Säckingen, Germany) and randomized into two groups: 10% hydrogen peroxide applied once daily for 15 minutes (HP 15) or applied once daily for 30 minutes (HP 30). Bleaching was performed for 14 days in both groups. The color was evaluated before bleaching, during bleaching (1st and 2nd weeks), and 1 month after the bleaching treatment using the Vita Classical, Vita Bleachedguide 3D-MASTER, and Vita Easyshade spectrophotometer (VITA Zahnfabrik). Dental sensitivity was recorded by the patients using the numerical rating scale (0-4) and visual analogue scale (0-10 cm). Color data were evaluated by two-way analysis of variance (ANOVA) of repeated measures (group vs. treatment time). The Mann-Whitney test was performed to contrast the means (α=0.05). Tooth sensitivity was assessed by Fisher's exact test (p=1.00) and intensity of tooth sensitivity was evaluated by the Mann-Whitney test (α=0.05) for both scales. RESULTS A significant whitening effect was observed after 2 weeks of bleaching for all color measurements (p=0.01), with no difference between HP 15 and HP 30 (p>0.05). Also, the absolute risk and intensity of tooth sensitivity were similar (47%; p>0.05). CONCLUSIONS The effectiveness and tooth sensitivity of at-home bleaching carried out with 10% hydrogen peroxide applied for 15 minutes or 30 minutes are similar.",2021,"A significant whitening effect was observed after 2 weeks of bleaching for all color measurements (p=0.01), with no difference between HP 15 and HP 30 (p>0.05).","['Seventy-two patients were selected according to the inclusion and exclusion criteria, with the upper central incisors having color A2 or darker according to the Vita Classical scale (VITA Zahnfabrik, Bad Säckingen, Germany']","['hydrogen peroxide', '10% hydrogen peroxide', 'Bleaching', 'Hydrogen Peroxide']","['Effectiveness and Sensitivity', 'whitening effect', 'absolute risk and intensity of tooth sensitivity', 'effectiveness and tooth sensitivity', 'Dental sensitivity', 'Tooth sensitivity', 'intensity of tooth sensitivity', 'visual analogue scale']","[{'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}, {'cui': 'C0522507', 'cui_str': 'With color'}, {'cui': 'C0332582', 'cui_str': 'Dark color'}, {'cui': 'C0373745', 'cui_str': 'Vitamin A measurement'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0017480', 'cui_str': 'Germany'}]","[{'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0303749', 'cui_str': 'Bleach'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0011432', 'cui_str': 'Sensitive dentin'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",72.0,0.12334,"A significant whitening effect was observed after 2 weeks of bleaching for all color measurements (p=0.01), with no difference between HP 15 and HP 30 (p>0.05).","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Chemin', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rezende', 'Affiliation': ''}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Costa', 'Affiliation': ''}, {'ForeName': 'Ady', 'Initials': 'A', 'LastName': 'Salgado', 'Affiliation': ''}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'de Geus', 'Affiliation': ''}, {'ForeName': 'A D', 'Initials': 'AD', 'LastName': 'Loguercio', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Reis', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kossatz', 'Affiliation': ''}]",Operative dentistry,['10.2341/20-104-C'] 2308,34369981,Association of 1 Vaping Session With Cellular Oxidative Stress in Otherwise Healthy Young People With No History of Smoking or Vaping: A Randomized Clinical Crossover Trial.,,2021,,['Otherwise Healthy Young People'],"['Smoking or Vaping', 'Vaping Session With Cellular Oxidative Stress']",[],"[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C4083280', 'cui_str': 'Vape'}, {'cui': 'C0052148', 'cui_str': 'APEL protocol'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}]",[],,0.0863728,,"[{'ForeName': 'Theodoros', 'Initials': 'T', 'LastName': 'Kelesidis', 'Affiliation': 'Division of Infectious Disease, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Tran', 'Affiliation': 'Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Randy', 'Initials': 'R', 'LastName': 'Nguyen', 'Affiliation': 'Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Yuyan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Division of Infectious Disease, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Sosa', 'Affiliation': 'Division of Infectious Disease, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Holly R', 'Initials': 'HR', 'LastName': 'Middlekauff', 'Affiliation': 'Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.'}]",JAMA pediatrics,['10.1001/jamapediatrics.2021.2351'] 2309,34369975,Effects on Growth of Smell and Taste of Milk During Tube Feeding of Preterm Infants: A Randomized Clinical Trial.,"Importance Smell and taste of food increase food anticipation, activate gut motility, and stimulate digestion and metabolism. Despite poor growth of many preterm infants in neonatal intensive care units, the smell and taste of milk with tube feeding are not generally considered a regular component of care. Objective To determine the effect of smell and taste of milk with tube feeding on weight z scores at discharge from the hospital. Design, Setting, and Participants A randomized, controlled, nonblinded, superiority trial was conducted at 2 perinatal centers between May 9, 2017, and February 1, 2020. Eligible infants (n = 659) were born at less than 29 weeks' postmenstrual age (PMA) and/or with a birth weight of less than 1250 g. Interventions Infants were randomly assigned to receive either the smell and taste of milk with each tube feeding or routine care without the provision of smell and taste of milk. Main Outcomes and Measures The primary outcome was weight z score at discharge from any hospital. Secondary outcomes included anthropometric measures at predefined time points, time to full enteral feeds, and other health outcomes associated with prematurity. Results Of the 658 infants, a total of 396 infants were randomized; some parents had not been approached for consent (n = 144) or declined participation (n = 117), and 1 infant with consent was not randomized. Of the 396 infants, 196 were assigned to the treatment group (51% male; mean [SD] PMA at birth, 27.5 [2.2] weeks) and 200 were assigned to the control group (52% male; mean [SD] PMA at birth, 27.6 (2.3) weeks). Mean weight z scores at discharge were -0.87 (95% CI, -1.02 to -0.72) for the treatment group and -0.97 (95% CI, -1.11 to -0.83) for the control group (P = .40). The mean difference in z scores between the treatment and control groups at 36 weeks' PMA was 0.21 (95% CI, 0.01 to 0.4; P = .04) for head circumference and 0.26 (95% CI, 0.05 to 0.51; P = .04) for length. There were no clinically notable differences between the study groups for any other anthropometric, feeding, or health outcomes. Conclusions and Relevance In this randomized clinical trial, regular smell and taste of milk included with tube feeding did not improve weight at discharge in preterm infants. Secondary outcomes suggest exposure to smell and taste may improve head circumference and length at 36 weeks' PMA, but not at discharge. Regular exposure to the smell and taste of milk is a simple and inexpensive intervention with potential benefits and no apparent adverse effects. Trial Registration anzctr.org.au Identifier: ACTRN12617000583347.",2021,"Mean weight z scores at discharge were -0.87 (95% CI, -1.02 to -0.72) for the treatment group and -0.97","['preterm infants', 'Preterm Infants', ""Eligible infants (n\u2009=\u2009659) were born at less than 29 weeks' postmenstrual age (PMA) and/or with a birth weight of less than 1250 g.\nInterventions\n\n\nInfants"", '2 perinatal centers between May 9, 2017, and February 1, 2020', '396 infants, 196 were assigned to the treatment group (51% male; mean [SD] PMA at birth, 27.5 [2.2] weeks) and 200', '658 infants, a total of 396 infants were randomized; some parents had not been approached for consent (n\u2009=\u2009144) or declined participation (n\u2009=\u2009117), and 1 infant with consent was not randomized']","['smell and taste of milk with each tube feeding or routine care without the provision of smell and taste of milk', 'smell and taste of milk with tube feeding']","['anthropometric, feeding, or health outcomes', 'weight z scores', 'z scores', 'weight at discharge', 'anthropometric measures at predefined time points, time to full enteral feeds, and other health outcomes associated with prematurity', 'weight z score at discharge from any hospital', 'Growth of Smell and Taste of Milk', 'Mean weight z scores at discharge', ""exposure to smell and taste may improve head circumference and length at 36 weeks' PMA""]","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C4517554', 'cui_str': '1250'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C5191354', 'cui_str': '396'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1744681', 'cui_str': 'Congenital'}, {'cui': 'C4517674', 'cui_str': '27.5'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C4760627', 'cui_str': '144'}]","[{'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0039336', 'cui_str': 'Finding of sense of taste'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0086225', 'cui_str': 'Enteral feeding'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0039336', 'cui_str': 'Finding of sense of taste'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0262499', 'cui_str': 'Head circumference'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0001779', 'cui_str': 'Age'}]",396.0,0.28412,"Mean weight z scores at discharge were -0.87 (95% CI, -1.02 to -0.72) for the treatment group and -0.97","[{'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Beker', 'Affiliation': 'Mater Research Institute, Faculty of Medicine, The University of Queensland, South Brisbane, Queensland, Australia.'}, {'ForeName': 'Helen G', 'Initials': 'HG', 'LastName': 'Liley', 'Affiliation': 'Mater Research Institute, Faculty of Medicine, The University of Queensland, South Brisbane, Queensland, Australia.'}, {'ForeName': 'Ian P', 'Initials': 'IP', 'LastName': 'Hughes', 'Affiliation': 'Mater Research Institute, Faculty of Medicine, The University of Queensland, South Brisbane, Queensland, Australia.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Jacobs', 'Affiliation': ""Neonatal Services and Newborn Research, the Royal Women's Hospital, Melbourne, Victoria, Australia.""}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Macey', 'Affiliation': 'Mater Research Institute, Faculty of Medicine, The University of Queensland, South Brisbane, Queensland, Australia.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Twitchell', 'Affiliation': ""Neonatal Services and Newborn Research, the Royal Women's Hospital, Melbourne, Victoria, Australia.""}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Davis', 'Affiliation': ""Neonatal Services and Newborn Research, the Royal Women's Hospital, Melbourne, Victoria, Australia.""}]",JAMA pediatrics,['10.1001/jamapediatrics.2021.2336'] 2310,34369941,Comparative evaluation of anesthetic efficacy of inferior alveolar nerve block and inferior alveolar nerve block plus buccal or lingual infiltration using articaine in mandibular molars with irreversible pulpitis: a preliminary prospective randomized single-blind clinical trial.,"OBJECTIVES This study was designed as a prospective randomized single-blind clinical trial to compare the anesthetic efficacy of inferior alveolar nerve block (IANB), IANB plus buccal infiltration, and IANB plus lingual infiltration of 4% articaine with 1:100,000 epinephrine in mandibular molars with irreversible pulpitis. METHOD AND MATERIALS Sixty healthy volunteers who had a first or second mandibular molar diagnosed with irreversible pulpitis participated in the present study. This study was composed of three arms for the first molar and three arms for the second molar. Subjects in test arm A received two IANB injections (3.6 mL). Subjects in test arm B received 1.8 mL IANB injection plus 1.8 mL buccal infiltration. Subjects in test arm C received 1.8 mL IANB injection plus 1.8 mL lingual infiltration. Articaine (4%) with 1:100,000 epinephrine was used for all injections. The subject's pain during access preparation and pulp extirpation was recorded on the Heft-Parker visual analog scale. Success was defined as ""none"" or ""mild"" pain during treatment. Kruskal-Wallis test was used to compare pain categories in three groups of interventions for each mandibular molar. RESULTS IANB with a supplemented buccal infiltration provided more success than IANB alone or IANB plus lingual infiltration, in first molars (P = .019). There were no significant differences between the three injection techniques in second molars (P = .795). CONCLUSIONS Adding a supplemental buccal infiltration to a standard IANB was more successful in providing pain-free treatment for patients experiencing irreversible pulpitis in mandibular first molars.",2021,"provided more success than IANB alone or IANB plus lingual infiltration, in first molars (P = .019).","['patients experiencing irreversible pulpitis in mandibular first molars', 'mandibular molars with irreversible pulpitis', 'Sixty healthy volunteers who had a first or second mandibular molar diagnosed with irreversible pulpitis participated in the present study']","['IANB injections', 'mL IANB injection plus 1.8 mL buccal infiltration', 'inferior alveolar nerve block and inferior alveolar nerve block plus buccal or lingual infiltration \ufeffusing articaine', 'IANB injection plus 1.8 mL lingual infiltration', 'epinephrine', 'inferior alveolar nerve block (IANB), IANB plus buccal infiltration, and IANB plus lingual infiltration of 4% articaine with 1:100,000 epinephrine', 'Articaine']",['pain categories'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0227056', 'cui_str': 'Structure of mandibular left first molar tooth'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0394801', 'cui_str': 'Local anesthetic inferior alveolar nerve block'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C1608295', 'cui_str': 'Articaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}]",60.0,0.0332605,"provided more success than IANB alone or IANB plus lingual infiltration, in first molars (P = .019).","[{'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Afkhami', 'Affiliation': ''}, {'ForeName': 'Salma', 'Initials': 'S', 'LastName': 'Pirmoazen', 'Affiliation': ''}, {'ForeName': 'Adel', 'Initials': 'A', 'LastName': 'Ardestani', 'Affiliation': ''}, {'ForeName': 'Mohammad Javad Kharrazi', 'Initials': 'MJK', 'LastName': 'Fard', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.b1864321'] 2311,34369940,Clinical effects of the exposure to red wine during at-home bleaching.,"OBJECTIVES This clinical trial evaluated the effects of red wine exposure on the effectiveness of at-home bleaching with 10% carbamide peroxide, degree of tooth sensitivity, and levels of periodontal inflammatory markers. METHOD AND MATERIALS Eighty participants were assigned to two groups, namely, those who drank red wine (experimental group), and those who did not drink red wine (control group). The experimental group participants rinsed their mouths with 25 mL of red wine four times a day during the bleaching period. Shade evaluation was assessed visually by using the Vita Classical and Vita Easyshade techniques. Tooth sensitivity was evaluated by the numeric and visual analog scales, and the salivary and gingival crevicular fluids were collected for assessment of nitric oxide (NO) levels, a marker of inflammation. Differences in color change were analyzed by one-way analysis of variance (ANOVA). The absolute risks of tooth sensitivity were compared by the Fisher exact test. Tooth sensitivity intensity data sets for both the visual analog scale and the numeric rating scale were compared using the Wilcoxon signed rank test (α = .05). Repeated measures and two-way ANOVA followed by the Bonferroni test were used to assess time-course and differences between groups in NO production. RESULTS The bleaching technique was effective regardless of wine consumption (P > .05). Tooth sensitivity was classified as mild, with no differences between groups (P > .05). Red wine reduced both the gingival crevicular fluid and salivary levels of NO (P < .05). CONCLUSION Red wine does not interfere with the effectiveness and sensitivity of at-home teeth bleaching with 10% carbamide peroxide and protects against bleaching-induced inflammation.",2021,"Red wine reduced both the gingival crevicular fluid and salivary levels of NO (P < .05). ",['Eighty participants'],"['red wine exposure', 'Red wine', 'drank red wine (experimental group), and those who did not drink red wine (control group']","['nitric oxide (NO) levels, a marker of inflammation', 'tooth sensitivity, and levels of periodontal inflammatory markers', 'gingival crevicular fluid and salivary levels of NO', 'Tooth sensitivity', 'numeric and visual analog scales, and the salivary and gingival crevicular fluids', 'visual analog scale and the numeric rating scale', 'absolute risks of tooth sensitivity']","[{'cui': 'C3816958', 'cui_str': '80'}]","[{'cui': 'C0349371', 'cui_str': 'Red wine'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0566278', 'cui_str': 'Does not drink'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0011432', 'cui_str': 'Sensitive dentin'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0017564', 'cui_str': 'Gingival Exudate'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",80.0,0.033332,"Red wine reduced both the gingival crevicular fluid and salivary levels of NO (P < .05). ","[{'ForeName': 'Lucas Lage', 'Initials': 'LL', 'LastName': 'Menezes', 'Affiliation': ''}, {'ForeName': 'Suellen Nogueira Linares', 'Initials': 'SNL', 'LastName': 'Lima', 'Affiliation': ''}, {'ForeName': 'Etevaldo Matos', 'Initials': 'EM', 'LastName': 'Maia-Filho', 'Affiliation': ''}, {'ForeName': 'Elizabeth Soares', 'Initials': 'ES', 'LastName': 'Fernandes', 'Affiliation': ''}, {'ForeName': 'Saulo Jose Figueredo', 'Initials': 'SJF', 'LastName': 'Mendes', 'Affiliation': ''}, {'ForeName': 'Leticia Machado', 'Initials': 'LM', 'LastName': 'Gonçalves', 'Affiliation': ''}, {'ForeName': 'Matheus Coelho', 'Initials': 'MC', 'LastName': 'Bandeca', 'Affiliation': ''}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Reis', 'Affiliation': ''}, {'ForeName': 'Alessandro D', 'Initials': 'AD', 'LastName': 'Loguercio', 'Affiliation': ''}, {'ForeName': 'Rudys Rodolfo De Jesus', 'Initials': 'RRJ', 'LastName': 'Tavarez', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.b1864313'] 2312,34372888,A prospective randomised control trial comparing functional with mechanical axis alignment in total knee arthroplasty: study protocol for an investigator initiated trial.,"BACKGROUND A drive to improve functional outcomes for patients undergoing total knee arthroplasty (TKA) has led to alternative alignment being used. Functional alignment (FA) uses intraoperative soft tissue tension to determine the optimal position of the prosthesis within the patient's soft tissue envelope. Angular limits for bone resections are followed to prevent long-term prosthesis failure. This study will use the aid of robotic assistance to plan and implement the final prosthesis position. This method has yet to be compared to the traditional mechanically aligned (MA) knee in a randomised trial. METHODS A blinded randomised control trial with 100 patients will be undertaken via Perth Hip and Knee Clinic. Fifty patients will undergo a MA TKA and fifty will undergo a FA TKA. Both alignment techniques will be balanced via computer-assisted navigation to assess prosthetic gaps, being achieved via the initial bony resection and further soft tissue releases as required to achieve satisfactory balance. The primary outcome will be the Forgotten Joint Score (FJS) 2 years after surgery, with secondary outcomes being other patient-reported outcome measures, clinical functional assessment, radiographic position and complications. Other data that will be collected will be patient demography (sex, age, level of activity) and medical information (grade of knee injury, any other relevant medical information). The linear statistical model will be fitted to the response (FJS), including all the other variables as covariates. DISCUSSION Many surgeons are utilising alternative alignment techniques with a goal of achieving better functional outcomes for their patients. Currently, MA TKA remains the gold standard with good outcomes and excellent longevity. There is no published RCTs comparing FA to MA yet and only two registered studies are planned or currently in progress. This study utilises a FA technique which differs from the two studies. This study will help determine if FA TKA has superior functional results for patients. TRIAL REGISTRATION This trial has been registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au : U1111-1257-2291, registered 25th Jan 2021. It is also listed on www.clinicaltrials.gov : NCT04748510.",2021,"The primary outcome will be the Forgotten Joint Score (FJS) 2 years after surgery, with secondary outcomes being other patient-reported outcome measures, clinical functional assessment, radiographic position and complications.","['100 patients will be undertaken via Perth Hip and Knee Clinic', 'patients undergoing total knee arthroplasty (TKA', 'total knee arthroplasty', 'patients', 'Fifty patients will undergo a MA TKA and fifty will undergo a FA TKA']","['mechanical axis alignment', 'Functional alignment (FA']","['Forgotten Joint Score (FJS) 2\u2009years after surgery, with secondary outcomes being other patient-reported outcome measures, clinical functional assessment, radiographic position and complications']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C2369992', 'cui_str': 'Align'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]","[{'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]","[{'cui': 'C4759288', 'cui_str': 'Forgotten Joint Score'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",100.0,0.160946,"The primary outcome will be the Forgotten Joint Score (FJS) 2 years after surgery, with secondary outcomes being other patient-reported outcome measures, clinical functional assessment, radiographic position and complications.","[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Steer', 'Affiliation': 'Gold Coast University Hospital, 1 Hospital Boulevard, Southport, Queensland, Australia.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Tippett', 'Affiliation': 'Perth Hip and Knee Clinic, 1 Wexford St, Subiaco, Western Australia, Australia.'}, {'ForeName': 'R Nazim', 'Initials': 'RN', 'LastName': 'Khan', 'Affiliation': 'University of Western Australia, 35 Stirling Hwy, Crawley, Western Australia, Australia.'}, {'ForeName': 'Dermot', 'Initials': 'D', 'LastName': 'Collopy', 'Affiliation': 'Perth Hip and Knee Clinic, 1 Wexford St, Subiaco, Western Australia, Australia.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Clark', 'Affiliation': 'Perth Hip and Knee Clinic, 1 Wexford St, Subiaco, Western Australia, Australia. gavin@hipnknee.com.au.'}]",Trials,['10.1186/s13063-021-05433-z'] 2313,34372851,Experiences of frail older cardiac patients with a nurse-coordinated transitional care intervention - a qualitative study.,"BACKGROUND Older cardiac patients are at high risk of readmission and mortality. Transitional care interventions (TCIs) might contribute to the prevention of adverse outcomes. The Cardiac Care Bridge program was a randomized nurse-coordinated TCI combining case management, disease management and home-based rehabilitation for hospitalized frail older cardiac patients. This qualitative study explored the experiences of patients' participating in this study, as part of a larger process evaluation as this might support interpretation of the neutral study outcomes. In addition, understanding these experiences could contribute to the design and application of future transitional care interventions for frail older cardiac patients. METHODS A generic qualitative approach was used. Semi-structured interviews were performed with 16 patients ≥70 years who participated in the intervention group. Participants were selected by gender, diagnosis, living arrangement and hospital of inclusion. Data were analysed using thematic analysis. In addition, quantitative data about intervention delivery were analysed. RESULTS Three themes emerged from the data: 1) appreciation of care continuity; 2) varying experiences with recovery and, 3) the influence of an existing care network. Participants felt supported by the transitional care intervention as they experienced post-discharge support and continuity of care. The perceived contribution of the program in participants' recovery varied. Some participants reported physical improvements while others felt impeded by comorbidities or frailty. The home visits by the community nurse were appreciated, although some participants did not recognize the added value. Participants with an existing healthcare provider network preferred to consult these providers instead of the providers who were involved in the transitional care intervention. CONCLUSION Our results contribute to an explanation of the neutral study of a nurse-coordinated transitional care intervention. For future purpose, it is important to identify which patients might benefit most from TCIs. Furthermore, the intensity and content of TCIs could be more personalized by tailoring interventions to older cardiac patients' needs, considering their frailty, self-management skills and existing formal and informal caregiver networks.",2021,"Participants with an existing healthcare provider network preferred to consult these providers instead of the providers who were involved in the transitional care intervention. ","['frail older cardiac patients with a nurse-coordinated transitional care intervention - a qualitative study', '16 patients ≥70\u2009years who participated in the intervention group', 'hospitalized frail older cardiac patients', 'Participants were selected by gender, diagnosis, living arrangement and hospital of inclusion', 'Older cardiac patients', 'Participants with an existing healthcare provider network preferred to consult these providers instead of the providers who were involved in the transitional care intervention', 'frail older cardiac patients']","['TCI combining case management, disease management and home-based rehabilitation', 'Transitional care interventions (TCIs']",[],"[{'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0949415', 'cui_str': 'Qualitative Research'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0449830', 'cui_str': 'With configuration'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0085971', 'cui_str': 'Case management'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],16.0,0.0321368,"Participants with an existing healthcare provider network preferred to consult these providers instead of the providers who were involved in the transitional care intervention. ","[{'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Jepma', 'Affiliation': 'Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. p.jepma@amsterdamumc.nl.'}, {'ForeName': 'Corine H M', 'Initials': 'CHM', 'LastName': 'Latour', 'Affiliation': 'Center of Expertise Urban Vitality, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands.'}, {'ForeName': 'Iris H J', 'Initials': 'IHJ', 'LastName': 'Ten Barge', 'Affiliation': 'Nursing Sciences, Program of Clinical Health Sciences, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Lotte', 'Initials': 'L', 'LastName': 'Verweij', 'Affiliation': 'Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Ron J G', 'Initials': 'RJG', 'LastName': 'Peters', 'Affiliation': 'Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Wilma J M', 'Initials': 'WJM', 'LastName': 'Scholte Op Reimer', 'Affiliation': 'Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Bianca M', 'Initials': 'BM', 'LastName': 'Buurman', 'Affiliation': 'Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}]",BMC health services research,['10.1186/s12913-021-06719-3'] 2314,34372849,Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.,"BACKGROUND Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The ""Heart OMics in AGEing"" (HOMAGE) trial suggested that spironolactone had beneficial effect on fibrosis and cardiac remodelling in an at risk population, potentially slowing the progression towards HF. We compared the proteomic profile of patients with and without diabetes among patients at risk for HF in the HOMAGE trial. METHODS Protein biomarkers (n = 276) from the Olink®Proseek-Multiplex cardiovascular and inflammation panels were measured in plasma collected at baseline and 9 months (or last visit) from HOMAGE trial participants including 217 patients with, and 310 without, diabetes. RESULTS Twenty-one biomarkers were increased and five decreased in patients with diabetes compared to non-diabetics at baseline. The markers clustered mainly within inflammatory and proteolytic pathways, with granulin as the key-hub, as revealed by knowledge-induced network and subsequent gene enrichment analysis. Treatment with spironolactone in diabetic patients did not lead to large changes in biomarkers. The effects of spironolactone on NTproBNP, fibrosis biomarkers and echocardiographic measures of diastolic function were similar in patients with and without diabetes (all interaction analyses p > 0.05). CONCLUSIONS Amongst patients at risk for HF, those with diabetes have higher plasma concentrations of proteins involved in inflammation and proteolysis. Diabetes does not influence the effects of spironolactone on the proteomic profile, and spironolactone produced anti-fibrotic, anti-remodelling, blood pressure and natriuretic peptide lowering effects regardless of diabetes status.  Trial registration NCT02556450.",2021,"The effects of spironolactone on NTproBNP, fibrosis biomarkers and echocardiographic measures of diastolic function were similar in patients with and without diabetes (all interaction analyses p > 0.05). ","['patients with diabetes at risk of developing heart failure', 'diabetic patients', 'patients with and without diabetes (all interaction analyses p\u2009>\u20090.05', 'patients with and without diabetes among patients at risk for HF in the HOMAGE trial', 'Protein biomarkers (n\u2009=\u2009276) from the Olink®Proseek-Multiplex cardiovascular and inflammation panels were measured in plasma collected at baseline and 9 months (or last visit) from HOMAGE trial participants including 217 patients with, and 310 without, diabetes', 'Patients with diabetes mellitus (DM']",['spironolactone'],"['NTproBNP, fibrosis biomarkers and echocardiographic measures of diastolic function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C3662281', 'cui_str': 'At risk for heart failure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517646', 'cui_str': '217'}, {'cui': 'C5191352', 'cui_str': '310'}]","[{'cui': 'C0037982', 'cui_str': 'Spironolactone'}]","[{'cui': 'C0669479', 'cui_str': 'pro-brain natriuretic peptide (1-76)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",21.0,0.179876,"The effects of spironolactone on NTproBNP, fibrosis biomarkers and echocardiographic measures of diastolic function were similar in patients with and without diabetes (all interaction analyses p > 0.05). ","[{'ForeName': 'Job A J', 'Initials': 'JAJ', 'LastName': 'Verdonschot', 'Affiliation': 'Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'João Pedro', 'Initials': 'JP', 'LastName': 'Ferreira', 'Affiliation': ""Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, Institut National de la Santé et de la Recherche Médicale 1116, Centre Hospitalier Régional Universitaire de Nancy, French Clinical Research Infrastructure Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.""}, {'ForeName': 'Pierpaolo', 'Initials': 'P', 'LastName': 'Pellicori', 'Affiliation': 'Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, G12 8QQ, UK.'}, {'ForeName': 'Hans-Peter', 'Initials': 'HP', 'LastName': 'Brunner-La Rocca', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Center (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands.'}, {'ForeName': 'Andrew L', 'Initials': 'AL', 'LastName': 'Clark', 'Affiliation': 'Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, East Riding of Yorkshire, UK.'}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Cosmi', 'Affiliation': 'Department of Cardiology, Cortona Hospital, Arezzo, Italy.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Cuthbert', 'Affiliation': 'Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, East Riding of Yorkshire, UK.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Girerd', 'Affiliation': ""Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, Institut National de la Santé et de la Recherche Médicale 1116, Centre Hospitalier Régional Universitaire de Nancy, French Clinical Research Infrastructure Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.""}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Mariottoni', 'Affiliation': 'Department of Cardiology, Cortona Hospital, Arezzo, Italy.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Petutschnigg', 'Affiliation': 'Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charite´ University Medicine Berlin, Berlin Institute of Health (BIH), and German Centre for Cardiovascular research (DZHK), Partner Site Berlin, Berlin, Germany.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Rossignol', 'Affiliation': ""Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, Institut National de la Santé et de la Recherche Médicale 1116, Centre Hospitalier Régional Universitaire de Nancy, French Clinical Research Infrastructure Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.""}, {'ForeName': 'John G F', 'Initials': 'JGF', 'LastName': 'Cleland', 'Affiliation': 'Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, G12 8QQ, UK.'}, {'ForeName': 'Faiez', 'Initials': 'F', 'LastName': 'Zannad', 'Affiliation': ""Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, Institut National de la Santé et de la Recherche Médicale 1116, Centre Hospitalier Régional Universitaire de Nancy, French Clinical Research Infrastructure Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.""}, {'ForeName': 'Stephane R B', 'Initials': 'SRB', 'LastName': 'Heymans', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Center (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands. s.heymans@maastrichtuniversity.nl.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Cardiovascular diabetology,['10.1186/s12933-021-01357-9'] 2315,34372834,Corrections to: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.,,2021,,"['patients with airway reversibility and high eosinophil counts', 'patients with COPD']",['budesonide/glycopyrronium/formoterol'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0449261', 'cui_str': 'Reversibility'}, {'cui': 'C0014457', 'cui_str': 'Eosinophilia'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]","[{'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C3814772', 'cui_str': 'glycopyrronium'}, {'cui': 'C0060657', 'cui_str': 'formoterol'}]",[],,0.0340086,,"[{'ForeName': 'Shigeo', 'Initials': 'S', 'LastName': 'Muro', 'Affiliation': 'Department of Respiratory Medicine, Nara Medical University Graduate School of Medicine, 840 Shijo-cho, Kashihara-shi, 634-8521, Nara, Japan. smuro@naramed-u.ac.jp.'}, {'ForeName': 'Hisatoshi', 'Initials': 'H', 'LastName': 'Sugiura', 'Affiliation': 'Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Darken', 'Affiliation': 'AstraZeneca, Wilmington, DE, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dorinsky', 'Affiliation': 'AstraZeneca, Durham, NC, USA.'}]",Respiratory research,['10.1186/s12931-021-01803-y'] 2316,34372827,Correction to: Simulation in physiotherapy students for clinical decisions during interaction with people with low back pain: randomized controlled trial.,,2021,,['physiotherapy students for clinical decisions during interaction with people with low back pain'],[],[],"[{'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}]",[],[],,0.365439,,"[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Sandoval-Cuellar', 'Affiliation': 'Universidad de Boyacá, Tunja, Colombia. carolinasandoval@uniboyaca.edu.co.'}, {'ForeName': 'Margareth Lorena', 'Initials': 'ML', 'LastName': 'Alfonso-Mora', 'Affiliation': 'Universidad de La Sabana, Chía, Colombia.'}, {'ForeName': 'Adriana Lucia', 'Initials': 'AL', 'LastName': 'Castellanos-Garrido', 'Affiliation': 'Universidad de La Sabana, Chía, Colombia.'}, {'ForeName': 'Angélica', 'Initials': 'A', 'LastName': 'Del Pilar Villarraga-Nieto', 'Affiliation': 'Center of Clinical Simulation, Universidad de La Sabana, Chía, Colombia.'}, {'ForeName': 'Ruth Liliana', 'Initials': 'RL', 'LastName': 'Goyeneche-Ortegón', 'Affiliation': 'Universidad de Boyacá, Tunja, Colombia.'}, {'ForeName': 'Martha Lucia', 'Initials': 'ML', 'LastName': 'Acosta-Otalora', 'Affiliation': 'Universidad de La Sabana, Chía, Colombia.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Del Pilar Castellanos-Vega', 'Affiliation': 'Universidad de Boyacá, Tunja, Colombia.'}, {'ForeName': 'Elisa Andrea', 'Initials': 'EA', 'LastName': 'Cobo-Mejía', 'Affiliation': 'Universidad de Boyacá, Tunja, Colombia.'}]",BMC medical education,['10.1186/s12909-021-02859-6'] 2317,34372746,Pharmacokinetic and pharmacodynamic evaluation of the new prolonged-release leuprorelin acetate microspheres for injection compared with Enantone® in healthy Chinese male volunteers.,"PURPOSE To compare the pharmacokinetics, pharmacodynamics and safety of the new prolonged-release leuprorelin acetate microspheres for injection (3.75 mg) with the reference product Enantone® (3.75 mg). METHOD 48 healthy male volunteers were enrolled and randomly received a single 3.75 mg dose of the test drug or Enantone®. RESULTS There were no significant differences in C max , AUC 0-t and AUC 0-48 between the test group and reference group (P > 0.05). The 90% confidence intervals of the two groups were 87.49%~112.74%, 97.15%~154.25%, and 80.85%~109.01%, respectively. Twenty-eight days after administration, both groups reached 100.0% castration level; there was no difference in the time from administration to reaching castration level between the two groups (P > 0.05); However, the difference between the two groups in the duration of castration level was statistically significant (P < 0.05). There were no major or serious adverse events, and the severity was mild to moderate. CONCLUSION The pharmacokinetic characteristics of leuprorelin in two groups were consistent. The two groups exhibited similar inhibitory effects on testosterone and more subjects in the test group maintained a longer castration time than those in the reference group.",2021,The two groups exhibited similar inhibitory effects on testosterone and more subjects in the test group maintained a longer castration time than those in the reference group.,"['48', 'healthy male volunteers', 'healthy Chinese male volunteers']","['Enantone®', 'new prolonged-release leuprorelin acetate microspheres', 'single 3.75 mg dose of the test drug or Enantone®']","['C max , AUC 0-t and AUC 0-48', 'time from administration to reaching castration level', 'pharmacokinetics, pharmacodynamics and safety', 'inhibitory effects', 'longer castration time', 'serious adverse events', 'duration of castration level']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0524775', 'cui_str': 'Enantone'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C4544856', 'cui_str': 'Prolonged-release'}, {'cui': 'C0700596', 'cui_str': 'Leuprolide acetate'}, {'cui': 'C0026032', 'cui_str': 'Microbeads'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C4517697', 'cui_str': '3.75'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0038577', 'cui_str': 'Drug of abuse screen'}]","[{'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0007344', 'cui_str': 'Gonadectomy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",,0.0250113,The two groups exhibited similar inhibitory effects on testosterone and more subjects in the test group maintained a longer castration time than those in the reference group.,"[{'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Xie', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Xingyu', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Xiaoyi', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, China.'}, {'ForeName': 'Xiaohui', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': 'Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Su', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Cuixia', 'Initials': 'C', 'LastName': 'He', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Minhui', 'Initials': 'M', 'LastName': 'Zhu', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Xiao Li', 'Initials': 'XL', 'LastName': 'Li', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Dongmei', 'Initials': 'D', 'LastName': 'Cheng', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Mengmeng', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Ge', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Fan', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'ZhongHuan', 'Initials': 'Z', 'LastName': 'Shao', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Bingyan', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Rongfang', 'Initials': 'R', 'LastName': 'Shan', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Xiangrong', 'Initials': 'X', 'LastName': 'Dai', 'Affiliation': 'Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, China.'}, {'ForeName': 'Hongju', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}, {'ForeName': 'Huaxue', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.'}]",Expert opinion on drug metabolism & toxicology,['10.1080/17425255.2021.1948534'] 2318,34372719,Appropriate analyses of bimodal substance use frequency outcomes: a mixture model approach.,"Background: In addiction research, outcome measures are often characterized by bimodal distributions. One mode can be for individuals with low substance use and the other mode for individuals with high substance use. Applying standard statistical procedures to bimodal data may result in invalid inference. Mixture models are appropriate for bimodal data because they assume that the sampled population is composed of several underlying subpopulations. Objectives: To introduce a novel mixture modeling approach to analyze bimodal substance use frequency data. Methods: We reviewed existing models used to analyze substance use frequency outcomes and developed multiple alternative variants of a finite mixture model. We applied all methods to data from a randomized controlled study in which 30-day alcohol abstinence was the primary outcome. Study data included 73 individuals (38 men and 35 women). Models were implemented in the software packages SAS, Stata, and Stan. Results: Shortcomings of existing approaches include: 1) inability to model outcomes with multiple modes, 2) invalid statistical inferences, including anti-conservative p-values, 3) sensitivity of results to the arbitrary choice to model days of substance use versus days of substance abstention, and 4) generation of predictions outside the range of common substance use frequency outcomes. Our mixture model variants avoided all of these shortcomings. Conclusions: Standard models of substance use frequency outcomes can be problematic, sometimes overstating treatment effectiveness. The mixture models developed improve the analysis of bimodal substance use frequency.",2021,The mixture models developed improve the analysis of bimodal substance use frequency.,"['individuals with low substance use and the other mode for individuals with high substance use', '73 individuals (38 men and 35 women']",[],"['anti-conservative p-values, 3) sensitivity of results to the arbitrary choice to model days of substance use versus days of substance abstention, and 4) generation of predictions outside the range of common substance use frequency outcomes']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1264693', 'cui_str': 'Arbitrary'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",73.0,0.0430355,The mixture models developed improve the analysis of bimodal substance use frequency.,"[{'ForeName': 'Lane F', 'Initials': 'LF', 'LastName': 'Burgette', 'Affiliation': 'RAND Corporation, Pittsburgh, PA, USA.'}, {'ForeName': 'Irineo', 'Initials': 'I', 'LastName': 'Cabreros', 'Affiliation': 'Department for Burgette, RAND Corporation, Boston, MA, USA.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'Economics, Sociology, and Statistics Department, RAND Corporation, Santa Monica, CA, USA.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Paddock', 'Affiliation': 'NORC, University of Chicago, Chicago, IL, USA.'}]",The American journal of drug and alcohol abuse,['10.1080/00952990.2021.1946070'] 2319,34369692,[Bidirectional regulation of acupuncture: a subgroup analysis of multicenter randomized controlled trial of acupuncture with Tiaoshen Jianpi for irritable bowel syndrome].,"OBJECTIVE To explore the bidirectional regulation of acupuncture based on a subgroup analysis of multicenter randomized controlled trial of acupuncture with Tiaoshen Jianpi for irritable bowel syndrome (IBS). METHODS A total of 519 patients were included in the analysis, including 137 patients with constipation type irritable bowel syndrome (IBS-C) (92 cases in the acupuncture group and 45 cases in the polyethylene glycol [PEG] group), and 382 patients with diarrhea type irritable bowel syndrome (IBS-D) (252 cases in the acupuncture group and 130 cases in the pinaverium group). The patients in the acupuncture group were given acupuncture at Baihui (GV 20), Yintang (GV 29), Tianshu (ST 25), Shangjuxu (ST 37), Zusanli (ST 36), Sanyinjiao (SP 6) and Taichong (LR 3) once every other day, 3 times a week. The patients in the PEG group received polyethylene glycol 4000 powder orally, and the pinaverium group received pinaverium bromide tablets orally. All were treated for 6 weeks. The IBS symptom severity score (IBS-SSS) was assessed at baseline, treatment period (2, 4, 6 weeks of treatment) and 12 weeks of follow-up, and the IBS quality of life (IBS-QOL) score was evaluated at the baseline period, 6 weeks of treatment and 12 weeks of follow-up. RESULTS The total IBS-SSS scores of the two groups of IBS-C patients at 2, 4, 6 weeks of treatment and follow-up of 12 weeks were lower than those in the baseline period ( P <0.01). The total IBS-SSS score in the IBS-C acupuncture group was lower than that in the PEG group at 12 weeks of follow-up ( P <0.05). The total IBS-SSS scores of the two groups of IBS-D patients at 2, 4, 6 weeks of treatment and 12 weeks of follow-up were lower than those in the baseline period ( P <0.01). The total IBS-SSS scores in the IBS-D acupuncture group were lower than those in the pinaverium group at 2, 4, 6 weeks of treatment and 12 weeks of follow-up ( P <0.05). The total IBS-QOL scores at 6 weeks of treatment and 12 weeks of follow-up were higher than those in the baseline period in both groups of patients with IBS-C ( P <0.01). The total IBS-QOL scores at 6 weeks of treatment and 12 weeks of follow-up were higher than those in the baseline period in both groups in patients with IBS-D ( P <0.01). The total IBS-QOL score in the IBS-D acupuncture group was higher than that in the pinaverium group at 18 weeks of follow-up ( P <0.05). CONCLUSION Acupuncture with Tiaoshen Jianpi can improve the clinical symptoms and quality of life of patients with IBS-C and IBS-D, which can regulate different functional states (constipation and diarrhea) of the same disease (irritable bowel syndrome), reflecting the bidirectional regulation of acupuncture.",2021,"The total IBS-QOL score in the IBS-D acupuncture group was higher than that in the pinaverium group at 18 weeks of follow-up ( P <0.05). ","['519 patients were included in the analysis, including 137 patients with constipation type irritable bowel syndrome (IBS-C) (92 cases in the acupuncture group and 45 cases in the', 'group), and 382 patients with diarrhea type irritable bowel syndrome (IBS-D) (252 cases in the acupuncture group and 130 cases in the pinaverium group', 'irritable bowel syndrome (IBS', 'irritable bowel syndrome']","['acupuncture', 'acupuncture at Baihui (GV 20), Yintang (GV 29), Tianshu (ST 25), Shangjuxu (ST 37), Zusanli (ST 36), Sanyinjiao (SP 6) and Taichong', 'polyethylene glycol 4000 powder orally, and the pinaverium group received pinaverium bromide tablets orally', 'acupuncture with Tiaoshen Jianpi', 'polyethylene glycol [PEG', 'acupuncture with Tiaoshen Jianpi']","['total IBS-SSS score', 'clinical symptoms and quality of life', 'IBS symptom severity score (IBS-SSS', 'total IBS-SSS scores', 'total IBS-QOL score', 'IBS quality of life (IBS-QOL) score', 'total IBS-QOL scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517750', 'cui_str': '382'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0071081', 'cui_str': 'pinaverium'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0450834', 'cui_str': 'Yintang'}, {'cui': 'C1813433', 'cui_str': 'ST-37'}, {'cui': 'C0626533', 'cui_str': 'SP 6'}, {'cui': 'C0032479', 'cui_str': 'polyethylene glycol 4000'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0071081', 'cui_str': 'pinaverium'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0137073', 'cui_str': 'Pinaverium bromide'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0032483', 'cui_str': 'Polyethylene Glycols'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",519.0,0.0834849,"The total IBS-QOL score in the IBS-D acupuncture group was higher than that in the pinaverium group at 18 weeks of follow-up ( P <0.05). ","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.'}, {'ForeName': 'Jian-Hua', 'Initials': 'JH', 'LastName': 'Sun', 'Affiliation': 'Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Geng', 'Affiliation': 'Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.'}, {'ForeName': 'Guo-Hui', 'Initials': 'GH', 'LastName': 'Yang', 'Affiliation': 'Shuyang Hospital of TCM.'}, {'ForeName': 'Rong-Rong', 'Initials': 'RR', 'LastName': 'Shen', 'Affiliation': 'Nantong Hospital of TCM.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Ding', 'Affiliation': 'Wuxi Hospital of TCM.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Nanjing Hospital of Chinese Medicine.'}, {'ForeName': 'Lian', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Jiangbin Hospital of Zhenjiang City.'}, {'ForeName': 'Xiang-Dong', 'Initials': 'XD', 'LastName': 'Fang', 'Affiliation': 'Kunshan Hospital of TCM.'}, {'ForeName': 'Li-Xia', 'Initials': 'LX', 'LastName': 'Pei', 'Affiliation': 'Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20201111-k0001'] 2320,34369687,[Discussion of optimization of sham acupuncture setting based on a clinical trial about acupuncture treatment of migraine published in British Medical Journal ].,"In the randomized controlled clinical trials of acupuncture, the setting of the control group (sham acupuncture) directly affected the interpretations about their outcomes (beyond placebo), and has been being the hot spot and difficult problem. In the present paper, we discussed various types of sham acupuncture (invade and non-invade needling) commonly used nowadays and made an in-depth analysis on the factors contributing to the successful blinding to patients with episodic migraine without aura in a clinical study published in British Medical Journal (2020, 368:m697). Moreover, we put forward some thoughts on how to optimize the setting of sham acupuncture in the treatment of pain diseases. These thoughts are 1) setting different placebo control group for different types of pain, 2) selecting conventional acupoints not associated with the disease, 3) selecting the most sui-table type of placebo acupuncture through pre-tests, 4) choosing the distal non-meridian and non-acupoint not in the same neuronal segment with the pain locus when using non-invade consolation needling, 5) trying best to reduce the patients' doubts about placebo acupuncture operation, 6) selecting subjects with little or without acupuncture experience for multicenter studies, and 7) trying best to select objective indicators and to avoid the subjects' report bias when evaluating the effects of acupuncture and consolation acupuncture.",2021,"In the randomized controlled clinical trials of acupuncture, the setting of the control group (sham acupuncture) directly affected the interpretations about their outcomes (beyond placebo), and has been being the hot spot and difficult problem.","['patients with episodic migraine without aura in a clinical study published in British Medical Journal (2020, 368:m697']","['acupuncture', 'sham acupuncture (invade and non-invade needling', 'sham acupuncture', 'control group (sham acupuncture', 'placebo acupuncture', 'acupuncture and consolation acupuncture', 'placebo acupuncture operation, 6) selecting subjects with little or without acupuncture experience', 'placebo']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C0236018', 'cui_str': 'Aura'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0034037', 'cui_str': 'Publishing'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0162443', 'cui_str': 'Journals as Topic'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0023882', 'cui_str': 'Spastic diplegia'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",[],,0.424622,"In the randomized controlled clinical trials of acupuncture, the setting of the control group (sham acupuncture) directly affected the interpretations about their outcomes (beyond placebo), and has been being the hot spot and difficult problem.","[{'ForeName': 'Han-Tong', 'Initials': 'HT', 'LastName': 'Hu', 'Affiliation': 'The Third Affiliated Hospital of Zhejiang University of Chinese Medicine, Hangzhou 310000, China; Zhejiang University of Chinese Medicine, Hangzhou 310000.'}, {'ForeName': 'Tian-Ye', 'Initials': 'TY', 'LastName': 'Hu', 'Affiliation': 'The First Hospital of Jiaxing City, Jiaxing 314000, Zhejiang Province.'}, {'ForeName': 'Bang-Wei', 'Initials': 'BW', 'LastName': 'Li', 'Affiliation': 'The Third Affiliated Hospital of Zhejiang University of Chinese Medicine, Hangzhou 310000, China.'}, {'ForeName': 'De-Xiong', 'Initials': 'DX', 'LastName': 'Han', 'Affiliation': 'The Third Affiliated Hospital of Zhejiang University of Chinese Medicine, Hangzhou 310000, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Gao', 'Affiliation': 'The Third Affiliated Hospital of Zhejiang University of Chinese Medicine, Hangzhou 310000, China.'}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.200526'] 2321,34369682,[Effect of electroacupuncture combined with caudal epidural injection on functional rehabilitation of patients with lumbar hernia].,"OBJECTIVE To observe the effect of electroacupuncture (EA) combined with caudal epidural injection on subjective pain, walking capability, lumbar flexibility and muscle strength in patients with lumbar disc hernia (LDH). METHODS Sixty LDH patients were randomly allocated to the control group and the research group. The patients of the control group received ultrasound guided caudal epidural injection, and those of the research group received EA combined with ultrasound guided caudal epidural injection. Bilateral Jiaji (EX-B2) and adjunct points Guanyuanshu (BL26), Shenshu (BL23), Chengfu (BL36), Huantiao (GB30), Zhibian (BL54), etc. on the affected side were stimulated with EA (2 Hz/16 Hz, 5-8 mA) for 30 min each time, once every other day for 4 weeks, with 2 days' rest between every two weeks. The patients' pain was evaluated by using visual analogue scale (VAS), walking capability assessed by timed-up and go (TUG) test (time of walking back and forth in 3 m distance), lumbar flexibility (range of motion, ROM) detected by using an inclinometer and the strength of the lumbar flexor and extensor determined by using a push-pull dynamometer. RESULTS After the treatment, self-comparison showed that the VAS score and TUG-measured time in both groups were significantly decreased ( P <0.01, P <0.05), and the post-bucking ROM and extension ROM in the research group, and the lumbar flexor and extensor muscle strength in both groups were obviously increased compared with their own pre-treatment ( P <0.05). Comparison between two groups showed that the VAS score and TUG-measured time of the research group were significantly lower than those of the control group ( P <0.01), while the lumbar flexor's ROM as well as the extensor's strength were significantly higher in the research group than in the control group ( P <0.05). CONCLUSION For patients with LDH, EA combined with caudal epidural injection can alleviate pain, improve the walking capability, lumbar flexibility and strength of the lumbar extensor, and the therapeutic effect of the combined treatment is significantly better than that of simple caudal epidural injection.",2021,"After the treatment, self-comparison showed that the VAS score and TUG-measured time in both groups were significantly decreased ( P <0.01, P <0.05), and the post-bucking ROM and extension ROM in the research group, and the lumbar flexor and extensor muscle strength in both groups were obviously increased compared with their own pre-treatment ( P <0.05).","['patients with lumbar disc hernia (LDH', 'Sixty LDH patients', 'patients with lumbar hernia', 'patients with LDH']","['EA combined with caudal epidural injection', 'ultrasound guided caudal epidural injection', 'electroacupuncture combined with caudal epidural injection', 'EA combined with ultrasound guided caudal epidural injection', 'electroacupuncture (EA) combined with caudal epidural injection']","['lumbar flexor and extensor muscle strength', 'post-bucking ROM and extension ROM', ""lumbar flexor's ROM"", 'subjective pain, walking capability, lumbar flexibility and muscle strength', 'Bilateral Jiaji (EX-B2) and adjunct points Guanyuanshu (BL26), Shenshu (BL23), Chengfu (BL36), Huantiao (GB30), Zhibian (BL54), etc', ""extensor's strength"", 'walking capability, lumbar flexibility and strength of the lumbar extensor', 'VAS score and TUG-measured time', 'functional rehabilitation', 'visual analogue scale (VAS), walking capability assessed by timed-up and go (TUG) test (time of walking back and forth in 3 m distance), lumbar flexibility (range of motion, ROM']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0401119', 'cui_str': 'Lumbar hernia'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0394837', 'cui_str': 'Local anesthetic sacral epidural block'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]","[{'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0852885', 'cui_str': 'Bucking'}, {'cui': 'C0948106', 'cui_str': 'Amniorrhexis'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0454532', 'cui_str': 'Functional rehabilitation'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}]",60.0,0.00619628,"After the treatment, self-comparison showed that the VAS score and TUG-measured time in both groups were significantly decreased ( P <0.01, P <0.05), and the post-bucking ROM and extension ROM in the research group, and the lumbar flexor and extensor muscle strength in both groups were obviously increased compared with their own pre-treatment ( P <0.05).","[{'ForeName': 'Xiao-Jie', 'Initials': 'XJ', 'LastName': 'Yu', 'Affiliation': 'College of Rehabilitation Sciences, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China; Department of Rehabilitation, Central Hospital of Jiading District, Shanghai University of Medicine & Health Sciences, Shanghai 201800.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation, Central Hospital of Jiading District, Shanghai University of Medicine & Health Sciences, Shanghai 201800.'}, {'ForeName': 'Wen-Yu', 'Initials': 'WY', 'LastName': 'Lu', 'Affiliation': 'Department of Rehabilitation, Central Hospital of Jiading District, Shanghai University of Medicine & Health Sciences, Shanghai 201800.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Gao', 'Affiliation': 'Department of Rehabilitation, Central Hospital of Jiading District, Shanghai University of Medicine & Health Sciences, Shanghai 201800.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Department of Rehabilitation, Central Hospital of Jiading District, Shanghai University of Medicine & Health Sciences, Shanghai 201800.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Rehabilitation, Central Hospital of Jiading District, Shanghai University of Medicine & Health Sciences, Shanghai 201800.'}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.200383'] 2322,34369681,[Effect of transcutaneous electrical acupoint stimulation on lung function and risks of exacerbation for patients with chronic obstructive pulmonary disease].,"OBJECTIVE To evaluate the effect of transcutaneous electrical acupoint stimulation (TEAS) on lung function, clinical symptoms, exercise tolerance and risk of acute exacerbation in patients with chronic obstructive pulmonary disease (COPD). METHODS A total of 49 outpatients with COPD were randomly divided into TEAS group and control group by using a digital table. The clinical trials were conducted by using randomized, single-blinded and placebo-controlled method. Patients in the TEAS group were treated by TEAS of Feishu (BL13), Dingchuan (EX-B1), Zusanli (ST36) and Pishu (BL20) for 40 min, once every other day for 4 weeks, while patients in the control group were treated with placebo TEAS which the electrode plates were adhered to the same acupoints but without electrical current outputs. The treatment was conducted every 3 months in one year. In addition, patients of the two groups had no restriction on their original treatment with conventional western medicines and Chinese Materia medica. The lung function (forced expiratory volume in 1 second predicted，FEV1%, forced vital capacity predicted，FVC%) was detected using a spirometer), clinical symptom scores （CAT） for coughing, phlegm, chest tightness, climbing, family activities, out-door activities, sleeping and energy status were given. The patient's exercise tolerance was assessed using walking distance in 6 min, and the risks of acute exacerbation (times of exacerbation and hospitalization in 1 year) were recorded. RESULTS Correlative analysis showed a negative correlation between the risks of acute exacerbation and the levels of FEV1% and FVC% ( P <0.01) and a positive correlation between the risks of acute exacerbation and CAT score ( P <0.01). Self-comparison showed that 1 month after the treatment, the FEV1% and FVC% levels, 6MWD in the control group were significantly decreased ( P <0.001, P <0.01), while the CAT score in the control group, and FEV1% and 6MWD in the TEAS group were obviously increased in comparison with their own pretreatment ( P <0.05, P <0.001), but FVC% in the TEAS group and the times of exacerbation and hospitalization in the control group had no obvious changes in comparison with their own pre-treatment ( P >0.05). One year (1 year) after the treatment, FEV1% and FVC% levels, 6MWD in the control group, and CAT score and times of exacerbations and hospitalization in the TEAS group were significantly decreased ( P <0.001, P <0.01, P <0.05), while CAT score in the control group and 6MWD in the TEAS group were markedly increased ( P <0.05, P <0.01), but FEV1% in the TEAS group and the times of exacerbation and hospitalization in the control group had no significant change compared with their own pretreatment ( P >0.05). Comparison between two groups showed that after the treatment, the FEV1% (1 month) and FVC% (1 month and 1 year), 6MWD (1 month and 1 year) were significantly higher in the TEAS group than in the control group ( P <0.05), while the CAT (1 month and 1 year) and times of exacerbation and hospitalization (1 year) were significantly lower in the TEAS group than in the control group ( P <0.05, P <0.01, P <0.001), without significant difference in the FEV1% (1 year) level ( P >0.05). CONCLUSION TEAS can improve the lung function, clinical symptoms, exercise tolerance, and reduce the risks of acute exacerbation in patients with COPD.",2021,"One year (1 year) after the treatment, FEV1% and FVC% levels, 6MWD in the control group, and CAT score and times of exacerbations and hospitalization in the TEAS group were significantly decreased ( P <0.001, P <0.01, P <0.05), while CAT score in the control group and 6MWD in the TEAS group were markedly increased ( P <0.05, P <0.01), but FEV1% in the TEAS group and the times of exacerbation and hospitalization in the control group had no significant change compared with their own pretreatment ( P >0.05).","['patients with COPD', 'patients with chronic obstructive pulmonary disease', 'patients of the two groups had no restriction on their original treatment with conventional western medicines and Chinese Materia medica', '49 outpatients with COPD', 'patients with chronic obstructive pulmonary disease (COPD']","['TEAS of Feishu (BL13), Dingchuan (EX-B1), Zusanli (ST36) and Pishu (BL20', 'transcutaneous electrical acupoint stimulation', 'placebo TEAS', 'transcutaneous electrical acupoint stimulation (TEAS', 'placebo', 'TEAS']","['CAT score', 'lung function (forced expiratory volume in 1 second predicted，FEV1%, forced vital capacity predicted，FVC', 'risks of acute exacerbation and the levels of FEV1% and FVC', 'risks of acute exacerbation and CAT score', 'lung function, clinical symptoms, exercise tolerance and risk of acute exacerbation', 'FVC', 'lung function and risks of exacerbation', 'times of exacerbation and hospitalization', '6MWD', 'CAT score and times of exacerbations and hospitalization', 'clinical symptom scores （CAT） for coughing, phlegm, chest tightness, climbing, family activities, out-door activities, sleeping and energy status', 'FEV1% and 6MWD', 'lung function, clinical symptoms, exercise tolerance', 'FEV1% and FVC% levels, 6MWD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0024911', 'cui_str': 'Materia Medica'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}]","[{'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0450836', 'cui_str': 'Dingchuan'}, {'cui': 'C0450614', 'cui_str': 'BL20'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0007366', 'cui_str': 'Catalan language'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0225378', 'cui_str': 'Upper respiratory tract mucus'}, {'cui': 'C0232292', 'cui_str': 'Tight chest'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0557698', 'cui_str': 'Door'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",49.0,0.0337739,"One year (1 year) after the treatment, FEV1% and FVC% levels, 6MWD in the control group, and CAT score and times of exacerbations and hospitalization in the TEAS group were significantly decreased ( P <0.001, P <0.01, P <0.05), while CAT score in the control group and 6MWD in the TEAS group were markedly increased ( P <0.05, P <0.01), but FEV1% in the TEAS group and the times of exacerbation and hospitalization in the control group had no significant change compared with their own pretreatment ( P >0.05).","[{'ForeName': 'Xiong', 'Initials': 'X', 'LastName': 'Xiao', 'Affiliation': ""Department of Traditional Chinese Medicine, Chengdu Fifth People's Hospital, Chengdu 611130, China.""}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': ""Department of Traditional Chinese Medicine, Chengdu Wenjiang People's Hospital, Chengdu 611130.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Traditional Chinese Medicine, Chengdu Fifth People's Hospital, Chengdu 611130, China.""}, {'ForeName': 'Dong-Mei', 'Initials': 'DM', 'LastName': 'Lei', 'Affiliation': ""Department of Traditional Chinese Medicine, Chengdu Fifth People's Hospital, Chengdu 611130, China.""}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Traditional Chinese Medicine, Chengdu Wenjiang People's Hospital, Chengdu 611130.""}, {'ForeName': 'Feng-Ru', 'Initials': 'FR', 'LastName': 'Zhao', 'Affiliation': ""Department of Traditional Chinese Medicine, Chengdu Fifth People's Hospital, Chengdu 611130, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': ""Department of Traditional Chinese Medicine, Chengdu Fifth People's Hospital, Chengdu 611130, China.""}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.200646'] 2323,34369680,[Effect of warm-needle moxibustion intervention on immune function and intestinal flora in patients after colorectal cancer radical operation].,"OBJECTIVE To explore the effect of warm-needle moxibustion (WNM) on the levels of T cell subgroups and serum inflammatory factors, intestinal microecological balance and postoperative adverse reactions in patients with colorectal cancer. METHODS Eighty-four patients who underwent elective radical resection of colorectal cancer were randomly and equally divided into control (medication) group (23 men and 19 women) and WNM group (24 men and 18 women). Patients of the control group received conventional medication treatment (such as postoperative anti-infection and fluid supplementation), and those of the WNM group received conventional medication plus WNM stimulation (the acupuncture needle handle warmed by ignited moxa stick) of bilateral Zusanli(ST36), Sanyinjiao(SP6), Yinlingquan(SP9), Shangjuxu(ST37), and Zhaohai(KI6). The acupuncture needles were retained for 45 minutes every time, starting on the first day after surgery, once a day for 15 days. The number of T cell subsets (CD3 + , CD4 + , CD8 + ) positive cells was counted under fluorescence microscope, and the contents of serum tumor necrosis factor α(TNF-α) and interleukin-6 (IL-6) were detected by using ELISA, and the level of C-reactive protein (CRP) was detected by using immunoturbidimetry. The levels (logarithm of colony-forming units per gram of wet fecal weight) of Bifidobacterium, Lactobacillus, Escherichia coli and Enterococcus were determined. The adverse reactions (leukocyte decline, nausea and vomiting, peripheral phlebitis, cold stimulation sensitivity) were recorded after surgery. RESULTS Before treatment, there were no significant differences between the two groups in the number of T cell subgroups, TNF-α and IL-6 contents, and intestinal flora numbers ( P >0.05). After the treatment, self-comparison showed that the numbers of CD3 + and CD4 + positive cells, the ratio of CD4 + /CD8 + and the intestinal Bifidobacterium and Lactobacillus levels in the WNM group were significantly increased ( P <0.05), whereas the number of CD8+positive cells, intestinal Escherichia coli and Enterococcus levels in the WNM group, and the levels of TNF-α, IL-6 and CRP in both groups were obviously decreased in comparison with their own pretreatment ( P <0.05), but no significant changes were found in the levels of CD3 + and CD4 + positive cells, CD4 + /CD8 + and intestinal Bifidobacterium, Lactobacillus, Escherichia coli and Enterococcus in the control group ( P >0.05). Comparison between two groups displayed that after the treatment, the numbers of CD3 + and CD4 + positive cells, the ratio of CD4 + /CD8 + , as well as the levels of Bifidobacterium and Lactobacillus were significantly higher in the WNM group than in the control group ( P <0.05), whereas the number of CD8 + positive cells， TNF-a, IL-6 and CRP, and the levels of Escherichia coli and Enterococcus were obviously lower in the WNM group than in the control group ( P <0.05). The incidence of adverse reactions including leukopenia, nausea and vomiting, peripheral phlebitis, and sensitivity to cold stimulation in the WNM group were markedly lower than those of the control group ( P <0.05). CONCLUSION WNM intervention can significantly improve the immune function, reduce the level of inflammatory factors, regulate the level of beneficial intestinal flora, and also reduce the incidence of postoperative adverse reactions in patients experiencing radical resection of colorectal cancer.",2021,"Before treatment, there were no significant differences between the two groups in the number of T cell subgroups, TNF-α and IL-6 contents, and intestinal flora numbers ( P >0.05).","['patients with colorectal cancer', 'patients experiencing radical resection of colorectal cancer', 'patients after colorectal cancer radical operation', 'Eighty-four patients who underwent elective radical resection of colorectal cancer were randomly and equally divided into control (medication) group (23 men and 19 women) and WNM group (24 men and 18 women']","['warm-needle moxibustion (WNM', 'WNM intervention', 'warm-needle moxibustion intervention', 'conventional medication treatment (such as postoperative anti-infection and fluid supplementation), and those of the WNM group received conventional medication plus WNM stimulation (the acupuncture needle handle warmed by ignited moxa stick) of bilateral Zusanli(ST36), Sanyinjiao(SP6), Yinlingquan(SP9), Shangjuxu(ST37), and Zhaohai(KI6']","['number of CD8+positive cells, intestinal Escherichia coli and Enterococcus levels', 'numbers of CD3 + and CD4 + positive cells, the ratio of CD4 + /CD8 + , as well as the levels of Bifidobacterium and Lactobacillus', 'numbers of CD3 + and CD4 + positive cells, the ratio of CD4 + /CD8 + and the intestinal Bifidobacterium and Lactobacillus levels', 'levels of CD3 + and CD4 + positive cells, CD4 + /CD8 + and intestinal Bifidobacterium, Lactobacillus, Escherichia coli and Enterococcus', 'number of CD8 + positive cells， TNF-a, IL-6 and CRP, and the levels of Escherichia coli and Enterococcus', 'immune function and intestinal flora', 'incidence of adverse reactions including leukopenia, nausea and vomiting, peripheral phlebitis, and sensitivity to cold stimulation', 'number of T cell subgroups, TNF-α and IL-6 contents, and intestinal flora numbers', 'level of C-reactive protein (CRP', 'contents of serum tumor necrosis factor α(TNF-α) and interleukin-6 (IL-6', 'levels of TNF-α, IL-6 and CRP', 'levels (logarithm of colony-forming units per gram of wet fecal weight) of Bifidobacterium, Lactobacillus, Escherichia coli and Enterococcus', 'number of T cell subsets (CD3 + , CD4 + , CD8 + ) positive cells', 'adverse reactions (leukocyte decline, nausea and vomiting, peripheral phlebitis, cold stimulation sensitivity', 'levels of T cell subgroups and serum inflammatory factors, intestinal microecological balance and postoperative adverse reactions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C3469597', 'cui_str': 'Administration of medication'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0181956', 'cui_str': 'Acupuncture needle'}, {'cui': 'C0018578', 'cui_str': 'Handling (Psychology)'}, {'cui': 'C0260027', 'cui_str': 'Moxa'}, {'cui': 'C1706582', 'cui_str': 'Stick'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C0085494', 'cui_str': 'Genus Enterococcus'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0108779', 'cui_str': 'Lymphocyte antigen CD3'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0439178', 'cui_str': '% positive cells'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C1448177', 'cui_str': 'TNF protein, human'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C1817756', 'cui_str': 'Immunologic function'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0031542', 'cui_str': 'Phlebitis'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439362', 'cui_str': 'cfu/g'}, {'cui': 'C0205381', 'cui_str': 'Wet'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0080202', 'cui_str': 'T-Cell Subsets'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",84.0,0.0943149,"Before treatment, there were no significant differences between the two groups in the number of T cell subgroups, TNF-α and IL-6 contents, and intestinal flora numbers ( P >0.05).","[{'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Sun', 'Affiliation': 'Anorectum Department of Zhongda Hospital Affiliated to Southeast University, Nanjing 210000, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Anorectum Department of Zhongda Hospital Affiliated to Southeast University, Nanjing 210000, China.'}, {'ForeName': 'Hai-Hua', 'Initials': 'HH', 'LastName': 'Qian', 'Affiliation': 'Anorectum Department of The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210000.'}, {'ForeName': 'Zhi-Cheng', 'Initials': 'ZC', 'LastName': 'Chen', 'Affiliation': 'Anorectum Department of Zhongda Hospital Affiliated to Southeast University, Nanjing 210000, China.'}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.200647'] 2324,34369679,[Effect of transcutaneous electrical acupoint stimulation on epidural-related maternal fever in parturients undergoing epidural labor analgesia].,"OBJECTIVE To evaluate the therapeutic effect and safety of transcutaneous electrical acupoint stimulation (TEAS) on epidural-related maternal fever in parturients undergoing epidural labor analgesia. METHODS A total of 198 primiparas with single birth, full-term pregnancy and head position were recruited and randomized into a TEAS group (98 cases) and a control group (100 cases). In the TEAS group, after epidural labor analgesia, TEAS was applied to bilateral Hegu (LI4) and Quchi (LI11), once an hour, for 30 min each time, till the end of childbirth. In the control group, after epidural labor analgesia, TEAS electrodes were attached to the same acupoints, but without electric stimulation. Maternal tympanic temperature and the score of Visual Analogue Score (VAS) were measured before analgesia, at 1, 2, 3, 4 and 5 h after analgesia and during labor respectively and maternal fever rate was evaluated in the parturients of two groups. Separately, before analgesia, 2 h after analgesia and during labor, the levels of serum interleukin (IL-6) and IL-1β were determined in the parturients of two groups. The duration of labor, the mode of labor, oxytocin dosage, postpartum hemorrhage, neonatal Apgar scores, time of labor analgesia, labor analgesic consumption and adverse effects were recorded in the parturients of two groups. RESULTS Maternal tympanic temperature increased progressively in two groups as analgesic time prolonged. Tympanic temperature at 3, 4 and 5 h after analgesia and du-ring labor, and maternal fever rate during labor in the TEAS group were all lower than those in the control group respectively ( P <0.05). The levels of serum IL-6 and IL-1β increased after analgesia in the parturients of two groups. The serum IL-6 level during labor and the level of IL-1β at 2 h after analgesia and during labor in the parturients of the TEAS group were lower than those in the control group ( P <0.05). The analgesic consumption in the TEAS group was less than that in the control group ( P <0.05). The incidence of chills in the TEAS group was lower than that in the control group ( P <0.05). The differences were not statistical in VAS score, duration of labor, mode of labor, oxytocin dosage, postpartum hemorrhage, time of labor analgesia and neonatal Apgar score, as well as the incidence of urine retention, nausea and vomiting and urinary retention between two groups ( P >0.05). CONCLUSION Transcutaneous electrical acupoint stimulation at LI11 and LI4 is conductive to relieving epidural-rela-ted maternal fever and reducing serum levels of IL-6 and IL-1β in the parturients undergoing epidural labor analgesia. It is safe and effective in clinical application.",2021,The analgesic consumption in the TEAS group was less than that in the control group ( P <0.05).,"['parturients undergoing epidural labor analgesia', '198 primiparas with single birth, full-term pregnancy and head position']","['transcutaneous electrical acupoint stimulation (TEAS', 'TEAS', 'transcutaneous electrical acupoint stimulation']","['incidence of chills', 'levels of serum interleukin (IL-6) and IL-1β', 'maternal fever rate', 'levels of serum IL-6', 'Maternal tympanic temperature', 'analgesic consumption', 'Tympanic temperature', 'duration of labor, the mode of labor, oxytocin dosage, postpartum hemorrhage, neonatal Apgar scores, time of labor analgesia, labor analgesic consumption and adverse effects', 'Maternal tympanic temperature and the score of Visual Analogue Score (VAS', 'serum IL-6 level during labor and the level of IL-1β', 'VAS score, duration of labor, mode of labor, oxytocin dosage, postpartum hemorrhage, time of labor analgesia and neonatal Apgar score, as well as the incidence of urine retention, nausea and vomiting and urinary retention']","[{'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C1301740', 'cui_str': 'Analgesia in labor'}, {'cui': 'C0033150', 'cui_str': 'Para 1'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0232991', 'cui_str': 'Term pregnancy'}, {'cui': 'C0582540', 'cui_str': 'Head position finding'}]","[{'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0085593', 'cui_str': 'Chill'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C1532039', 'cui_str': 'Tympanic temperature'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0566679', 'cui_str': 'Duration of labor'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0003533', 'cui_str': 'Finding of Apgar score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1301740', 'cui_str': 'Analgesia in labor'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}]",198.0,0.0550785,The analgesic consumption in the TEAS group was less than that in the control group ( P <0.05).,"[{'ForeName': 'Wei-Ye', 'Initials': 'WY', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Guangzhou Tianhe District Maternal and Child Health Care Hospital, Guangzhou 510620, China.'}, {'ForeName': 'Zong-Cun', 'Initials': 'ZC', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Guangzhou Tianhe District Maternal and Child Health Care Hospital, Guangzhou 510620, China.'}, {'ForeName': 'Si-Ping', 'Initials': 'SP', 'LastName': 'Xi', 'Affiliation': 'Department of Anesthesiology, Guangzhou Tianhe District Maternal and Child Health Care Hospital, Guangzhou 510620, China.'}, {'ForeName': 'Li-Xian', 'Initials': 'LX', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Fourth Affiliated Hospital, Guangzhou Red Cross Hospital, Jinan University, Guangzhou 510220.'}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.200616'] 2325,34369667,"A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.","Proteinuria associated with podocyte effacement is a hallmark of focal segmental glomerulosclerosis (FSGS). Preclinical studies implicated ROBO2/SLIT2 signaling in the regulation of podocyte adhesion, and inhibition of this pathway is a novel target to slow FSGS disease progression. This first-in-human dose-escalation study evaluated the safety, tolerability, pharmacokinetics, and immunogenicity of PF-06730512, an Fc fusion protein that targets the ROBO2/SLIT2 pathway, in healthy adults. In this Phase 1, double-blind, sponsor-open study, single ascending dose (SAD) cohorts were randomized to receive up to 1000 mg or placebo intravenously (IV); multiple ascending dose (MAD) cohorts were randomized to receive up to 400 mg subcutaneous (SC) doses, 1000 mg IV dose, or matching placebo. Safety evaluations were performed up to 71 (SAD) and 113 (MAD) days after dosing; blood samples were collected to measure serum PF-06730512 concentrations and antidrug antibodies (ADA) to PF-06730512. Seventy-nine participants (SAD, 47; MAD, 32) were enrolled. There were 108 mild (SAD, 46; MAD, 62) and 21 moderate (SAD, 13; MAD, 8) treatment-emergent adverse events (TEAEs); no deaths, treatment-related serious AEs, severe TEAEs, or infusion reactions were reported. PF-06730512 exposure generally increased in an approximately dose-proportional manner; mean t 1/2 ranged from 12-15 days across 50-1000 mg doses. Immunogenicity incidence was low (SAD, 0 ADA+; MAD, 2 ADA+). In conclusion, single IV doses of PF-06730512 up to 1000 mg and multiple IV and SC dosing up to 1000 and 400 mg, respectively, were safe and well tolerated in healthy participants. Further trials in patients with FSGS are warranted. Clinical trial registration: Clinicaltrials.gov: NCT03146065.",2021,PF-06730512 exposure generally increased in an approximately dose-proportional manner; mean t 1/2 ranged from 12-15 days across 50-1000 mg doses.,"['patients with FSGS', 'Seventy-nine participants (SAD, 47; MAD, 32) were enrolled', 'healthy adults', 'healthy participants']","['placebo', 'PF-06730512']","['safety, tolerability, and pharmacokinetics', 'safe and well tolerated', 'safety, tolerability, pharmacokinetics, and immunogenicity of PF-06730512', 'Immunogenicity incidence', '21 moderate (SAD, 13; MAD, 8) treatment-emergent adverse events (TEAEs); no deaths, treatment-related serious AEs, severe TEAEs, or infusion reactions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017668', 'cui_str': 'Focal glomerular sclerosis'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C2368034', 'cui_str': 'Adverse reaction to drug or medicament administered by infusion'}]",32.0,0.244634,PF-06730512 exposure generally increased in an approximately dose-proportional manner; mean t 1/2 ranged from 12-15 days across 50-1000 mg doses.,"[{'ForeName': 'Chay Ngee', 'Initials': 'CN', 'LastName': 'Lim', 'Affiliation': 'Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'Constantino', 'Initials': 'C', 'LastName': 'Kantaridis', 'Affiliation': 'Pfizer N.V. - S.A, Brussels, Belgium.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Huyghe', 'Affiliation': 'Pfizer N.V. - S.A, Brussels, Belgium.'}, {'ForeName': 'Donal', 'Initials': 'D', 'LastName': 'Gorman', 'Affiliation': 'Pfizer Inc, Cambridge, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Berasi', 'Affiliation': 'Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'Gabriele E', 'Initials': 'GE', 'LastName': 'Sonnenberg', 'Affiliation': 'Pfizer Inc, Cambridge, MA, USA.'}]",Pharmacology research & perspectives,['10.1002/prp2.813'] 2326,34369339,The effect of 12 weeks of euenergetic high-protein diet in regulating appetite and body composition of women with normal-weight obesity: a randomised controlled trial - Corrigendum.,,2021,,['women with normal-weight obesity'],['euenergetic high-protein diet'],['appetite and body composition'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0425403', 'cui_str': 'Increased protein diet'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}]",,0.0738513,,"[{'ForeName': 'Neda', 'Initials': 'N', 'LastName': 'Haghighat', 'Affiliation': ''}, {'ForeName': 'Damoon', 'Initials': 'D', 'LastName': 'Ashtary-Larky', 'Affiliation': ''}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Bagheri', 'Affiliation': ''}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Mahmoodi', 'Affiliation': ''}, {'ForeName': 'Majdadin', 'Initials': 'M', 'LastName': 'Rajaei', 'Affiliation': ''}, {'ForeName': 'Meysam', 'Initials': 'M', 'LastName': 'Alipour', 'Affiliation': ''}, {'ForeName': 'Wesam', 'Initials': 'W', 'LastName': 'Kooti', 'Affiliation': ''}, {'ForeName': 'Vahideh', 'Initials': 'V', 'LastName': 'Aghamohammdi', 'Affiliation': ''}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': ''}]",The British journal of nutrition,['10.1017/S0007114521001896'] 2327,34369333,Plasma glucagon-like peptide-1 responses to ingestion of protein with increasing doses of milk minerals rich in calcium.,"A high dose of whey protein hydrolysate fed with milk minerals rich in calcium (Capolac®) results in enhanced glucagon-like peptide-1 (GLP-1) concentrations in lean individuals, however the effect of different calcium doses ingested alongside protein is unknown. The present study assessed the dose response of calcium fed alongside 25 g whey protein hydrolysate on GLP-1 concentrations in individuals with overweight/obesity. Eighteen adults (mean ± SD: 8M/10F, 34 ± 18 years, 28.2 ± 2.9 kg∙m-2) completed 4 trials in a randomised, double-blind, crossover design. Participants consumed test solutions consisting of 25 g whey protein hydrolysate (CON), supplemented with 3179 mg (LOW), 6363 mg (MED), or 9547 mg (HIGH) Capolac® on different occasions, separated by at least 48 hours. The calcium content of test solutions equated to 65, 892, 1719 and 2547 mg, respectively. Arterialised-venous blood was sampled over 180 min to determine plasma concentrations of GLP-1TOTAL, GLP-17-36amide, insulin, glucose, non-esterified fatty acids (NEFA), and serum concentrations of calcium and albumin. Ad libitum energy intake was measured at 180 min. Time-averaged incremental area under the curve (iAUC) for GLP-1TOTAL (pmol·L-1·min-1) did not differ between CON (23 ± 4), LOW (25 ± 6), MED (24 ± 5), and HIGH (24 ± 6). Energy intake (kcal) did not differ between CON (940 ± 387), LOW (884 ± 345), MED (920 ± 334), and HIGH (973 ± 390). Co-ingestion of whey protein hydrolysate with Capolac® does not potentiate GLP-1 release in comparison to whey protein hydrolysate alone. The study was registered at clinical trials (NCT03819972).",2021,Co-ingestion of whey protein hydrolysate with Capolac® does not potentiate GLP-1 release in comparison to whey protein hydrolysate alone.,"['individuals with overweight/obesity', 'Eighteen adults (mean ± SD: 8M/10F, 34 ± 18 years, 28.2 ± 2.9 kg∙m-2', 'lean individuals']","['25 g whey protein hydrolysate (CON), supplemented with 3179 mg (LOW', 'calcium fed alongside 25 g whey protein hydrolysate', 'Co-ingestion of whey protein hydrolysate with Capolac®']","['Arterialised-venous blood', 'Ad libitum energy intake', 'plasma concentrations of GLP-1TOTAL, GLP-17-36amide, insulin, glucose, non-esterified fatty acids (NEFA), and serum concentrations of calcium and albumin', 'glucagon-like peptide-1', 'Time-averaged incremental area under the curve (iAUC) for GLP-1TOTAL (pmol·L-1·min-1', 'GLP-1 concentrations']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517641', 'cui_str': '2.9'}]","[{'cui': 'C0456638', 'cui_str': '25G'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C0229667', 'cui_str': 'Venous blood'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0018301', 'cui_str': 'Guadeloupe island'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0369212', 'cui_str': 'Esterified fatty acid'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",18.0,0.132097,Co-ingestion of whey protein hydrolysate with Capolac® does not potentiate GLP-1 release in comparison to whey protein hydrolysate alone.,"[{'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Watkins', 'Affiliation': 'Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, UK.'}, {'ForeName': 'Harry A', 'Initials': 'HA', 'LastName': 'Smith', 'Affiliation': 'Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, UK.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Hengist', 'Affiliation': 'Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, UK.'}, {'ForeName': 'Lise Høj', 'Initials': 'LH', 'LastName': 'Brunsgaard', 'Affiliation': 'Arla Foods Ingredients Group P/S, Viby J, Denmark.'}, {'ForeName': 'Ulla Ramer', 'Initials': 'UR', 'LastName': 'Mikkelsen', 'Affiliation': 'Arla Foods Ingredients Group P/S, Viby J, Denmark.'}, {'ForeName': 'Francoise', 'Initials': 'F', 'LastName': 'Koumanov', 'Affiliation': 'Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, UK.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Betts', 'Affiliation': 'Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, UK.'}, {'ForeName': 'Javier T', 'Initials': 'JT', 'LastName': 'Gonzalez', 'Affiliation': 'Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, UK.'}]",The British journal of nutrition,['10.1017/S000711452100297X'] 2328,34369262,Evaluating the benefit of hearing aids with motion-based beamformer adaptation in a real-world setup.,"OBJECTIVE Conventional directional hearing aid microphone technology may obstruct listening intentions when the talker and listener walk side by side. The purpose of the current study was to evaluate hearing aids that use a motion sensor to address listening needs during walking. DESIGN Each participant completed two walks in randomised order, one walk with each of two hearing aid programs: (1) conventional beamformer adaptation that activated an adaptive, multiband beamformer in loud environments and (2) motion-based beamformer adaptation that activated a pinna-mimicking microphone setting when walking was detected. Participants walked along a pre-defined track and completed tasks assessing speech understanding and environmental awareness. STUDY SAMPLE Participants were 22 older adults with moderate-to-severe hearing loss and experience using hearing aids. RESULTS More participants preferred the motion-based than conventional beamformer adaptation for speech understanding, environmental awareness, overall listening, and sound quality ( p <  0.05). Measures of speech understanding ( p  < 0.01) and localisation of sound stimuli ( p  < 0.05) were significantly better with motion-based than conventional beamformer adaptation. CONCLUSIONS The results suggest that hearing aid users can benefit from beamforming that uses motion sensor input to adapt the signal processing according to the user's activity. The real-world setup of this study had limitations.",2021,"Measures of speech understanding ( p  < 0.01) and localisation of sound stimuli ( p  < 0.05) were significantly better with motion-based than conventional beamformer adaptation. ",['Participants were 22 older adults with moderate-to-severe hearing loss and experience using hearing aids'],"['hearing aid programs: (1) conventional beamformer adaptation that activated an adaptive, multiband beamformer in loud environments and (2) motion-based beamformer adaptation that activated a pinna-mimicking microphone setting', 'hearing aids with motion-based beamformer adaptation']","['speech understanding, environmental awareness, overall listening, and sound quality', 'localisation of sound stimuli', 'speech understanding']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C0018768', 'cui_str': 'Hearing aid'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0178733', 'cui_str': 'Loudness'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013453', 'cui_str': 'External ear structure'}, {'cui': 'C1709026', 'cui_str': 'Microphone'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0475264', 'cui_str': 'Localization - action'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}]",22.0,0.0545026,"Measures of speech understanding ( p  < 0.01) and localisation of sound stimuli ( p  < 0.05) were significantly better with motion-based than conventional beamformer adaptation. ","[{'ForeName': 'Solveig C', 'Initials': 'SC', 'LastName': 'Voss', 'Affiliation': 'Innovation Centre Toronto, Sonova Canada Inc, Mississauga, Canada.'}, {'ForeName': 'M Kathleen', 'Initials': 'MK', 'LastName': 'Pichora-Fuller', 'Affiliation': 'Department of Psychology, University of Toronto, Mississauga, Canada.'}, {'ForeName': 'Ieda', 'Initials': 'I', 'LastName': 'Ishida', 'Affiliation': 'Innovation Centre Toronto, Sonova Canada Inc, Mississauga, Canada.'}, {'ForeName': 'April', 'Initials': 'A', 'LastName': 'Pereira', 'Affiliation': 'Department of Psychology, University of Toronto, Mississauga, Canada.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Seiter', 'Affiliation': 'Sonova AG, Staefa, Switzerland.'}, {'ForeName': 'Nadim', 'Initials': 'N', 'LastName': 'El Guindi', 'Affiliation': 'Sonova AG, Staefa, Switzerland.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Kuehnel', 'Affiliation': 'Sonova AG, Staefa, Switzerland.'}, {'ForeName': 'Jinyu', 'Initials': 'J', 'LastName': 'Qian', 'Affiliation': 'Innovation Centre Toronto, Sonova Canada Inc, Mississauga, Canada.'}]",International journal of audiology,['10.1080/14992027.2021.1948120'] 2329,34369255,Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area.,"BACKGROUND Increasing clarithromycin resistance has led to the need for an alternative first-line therapy for the eradication of Helicobacter pylori ( H. pylori ) in Korea, and bismuth containing quadruple therapy (BQT) and tailored therapy (TT) have been proposed as alternative regimens. The aim of this study was to compare the eradication rates of BQT and TT as first-line H. pylori eradication therapies. METHODS H. pylori infection was diagnosed using the rapid urease test or dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR) during endoscopy. Patients positive for H. pylori were divided into two groups; those tested using the rapid urease test received empirical BQT (the BQT group) whereas those tested by DPO-PCR received TT (the TT group). Eradication rates, adverse events, and overall medical costs, which included diagnostic test and eradication regimen costs, were compared. RESULTS Three hundred and sixty patients were included in the study (TT group 178, BQT group 182). The modified intention-to-treat eradication rates of BQT and TT were 88.2% (142/161) and 80.3% (118/147), respectively ( p  = .055), and corresponding eradication rates in the per-protocol population were 88.8% (142/160) and 81.4% (118/145) ( p  = .07). Compliance and adverse event rates were similar in the two groups. Average medical costs were $90.3 per patient in the TT group and $75.5 in the BQT group ( p  = .000). CONCLUSIONS Empirical BQT and tailored therapy were similar in terms of H. pylori eradication rate, safety, and tolerability, but BQT was more cost-effective.",2021,"Average medical costs were $90.3 per patient in the TT group and $75.5 in the BQT group ( p  = .000). ","['Three hundred and sixty patients were included in the study (TT group 178, BQT group 182', 'Patients positive for H. pylori']","['Bismuth containing quadruple therapy', 'BQT', 'rapid urease test or dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR', 'bismuth containing quadruple therapy (BQT) and tailored therapy (TT']","['eradication rate, safety, and tolerability', 'Eradication rates, adverse events, and overall medical costs, which included diagnostic test and eradication regimen costs', 'eradication rates', 'Average medical costs', 'Compliance and adverse event rates']","[{'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}]","[{'cui': 'C0005642', 'cui_str': 'Bismuth'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0205175', 'cui_str': 'Quadruple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0585237', 'cui_str': 'CLO test for helicobacter pylori'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0331021', 'cui_str': 'Ligustrum vulgare'}, {'cui': 'C0028953', 'cui_str': 'Oligonucleotide'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3179032', 'cui_str': 'Multiplex PCR'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0430022', 'cui_str': 'Diagnostic procedure'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",360.0,0.0544909,"Average medical costs were $90.3 per patient in the TT group and $75.5 in the BQT group ( p  = .000). ","[{'ForeName': 'Boram', 'Initials': 'B', 'LastName': 'Cha', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Inha University College Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Byoung Wook', 'Initials': 'BW', 'LastName': 'Bang', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Inha University College Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Jong Beom', 'Initials': 'JB', 'LastName': 'Shin', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Inha University College Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Eun Jung', 'Initials': 'EJ', 'LastName': 'Ko', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Inha University College Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Weonjin', 'Initials': 'W', 'LastName': 'Ko', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Inha University College Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Kye Sook', 'Initials': 'KS', 'LastName': 'Kwon', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Inha University College Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Yong Woon', 'Initials': 'YW', 'LastName': 'Shin', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Inha University College Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Young Ju', 'Initials': 'YJ', 'LastName': 'Suh', 'Affiliation': 'Department of Biostatistics, Inha University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Hyungkil', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Inha University College Medicine, Incheon, Republic of Korea.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2021.1948606'] 2330,34369239,Increased maximum power output may improve speech recognition with bone conduction hearing devices.,"OBJECTIVE To investigate the influence of maximum power output of bone conduction hearing devices on speech recognition in quiet and in noise in experienced users of bone conduction hearing devices. DESIGN Prospective, randomised cross-over investigation comparing speech recognition performance, subjective sound quality, and device preference between two bone conduction hearing devices with different maximum power outputs. STUDY SAMPLE Sixteen adult subjects with conductive or mixed hearing loss. RESULTS Both speech recognition in quiet and speech recognition in noise improved significantly when using the device with high vs. lower maximum power output. Mean improvement in word recognition score in quiet was 10.5% and the mean speech reception threshold in noise improved by 0.9 dB SNR. Compared to the device with lower maximum power output, the sound quality was rated significantly higher with the device with high maximum power output, which was also the device of preference for 81% of the subjects. CONCLUSION Bone conduction hearing devices with higher maximum power output have the potential to improve speech recognition in both quiet and noisy listening environments.",2021,Both speech recognition in quiet and speech recognition in noise improved significantly when using the device with high vs. lower maximum power output.,['Sixteen adult subjects with conductive or mixed hearing loss'],['bone conduction hearing devices'],"['quiet and speech recognition in noise', 'sound quality', 'Mean improvement in word recognition score in quiet', 'speech recognition performance, subjective sound quality, and device preference']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0155552', 'cui_str': 'Mixed conductive AND sensorineural hearing loss'}]","[{'cui': 'C0005935', 'cui_str': 'Bone conduction'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0439654', 'cui_str': 'Quiet'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}]",16.0,0.0445467,Both speech recognition in quiet and speech recognition in noise improved significantly when using the device with high vs. lower maximum power output.,"[{'ForeName': 'Håkan', 'Initials': 'H', 'LastName': 'Hua', 'Affiliation': 'Cochlear Bone Anchored Solutions AB, Mölnlycke, Sweden.'}, {'ForeName': 'Tine', 'Initials': 'T', 'LastName': 'Goossens', 'Affiliation': 'Cochlear Bone Anchored Solutions AB, Mölnlycke, Sweden.'}, {'ForeName': 'Aaran T', 'Initials': 'AT', 'LastName': 'Lewis', 'Affiliation': 'Cochlear Bone Anchored Solutions AB, Mölnlycke, Sweden.'}]",International journal of audiology,['10.1080/14992027.2021.1959953'] 2331,31981279,Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B.,"Noninvasive tests (NITs) for liver fibrosis are highly needed for chronic hepatitis B (CHB) patients. We aimed to investigate whether plateletcrit (PCT) could be used as a NIT in predicting liver fibrosis for CHB patients. Five hundred and sixty-seven treatment-naïve CHB patients with available liver biopsies were included. Patients were randomly divided into a derivation cohort (n = 378) and a validation cohort (n = 189). The diagnostic accuracy of PCT was evaluated using receiver operating characteristic (ROC) curves. In the derivation cohort, PCT in CHB patients with S2-S4 (0.14%), S3-S4 (0.13%) and S4 (0.12%) was lower than patients with S0-S1 (0.17%, P < .001), S0-S2 (0.17%, P < .001) and S0-S3 (0.16%, P < .001), respectively. PCT was an independent predictor of significant fibrosis (≥S2), advanced fibrosis (≥S3) and cirrhosis (S4). The area under the ROC curve (AUROC) of PCT in predicting significant fibrosis, advanced fibrosis and cirrhosis was 0.645, 0.709 and 0.714, respectively. The AUROC of PCT was higher than the aspartate transaminase to platelet ratio index (APRI) in identifying advanced fibrosis and cirrhosis, while this was comparable with APRI in identifying significant fibrosis. The diagnostic value of PCT was comparable with fibrosis-4 score (FIB-4) in predicting significant fibrosis, advanced fibrosis and cirrhosis. In the validation cohort, PCT could also identify significant fibrosis, advanced fibrosis and cirrhosis with similar diagnostic accuracy as in the derivation cohort. PCT represents a simple and inexpensive indictor for liver fibrosis in CHB patients. PCT is just as good or better than other more complex tools for staging liver fibrosis in CHB patients.",2020,"The diagnostic value of PCT was comparable with fibrosis-4 score (FIB-4) in predicting significant fibrosis, advanced fibrosis and cirrhosis.","['Five hundred and sixty-seven treatment-naïve CHB patients with available liver biopsies were included', 'chronic hepatitis B', 'CHB patients']","['plateletcrit (PCT', 'PCT', 'S0-S1']","['S0-S3', 'area under the ROC curve (AUROC) of PCT', 'platelet ratio index (APRI', 'S0-S2', 'significant fibrosis (≥S2), advanced fibrosis (≥S3) and cirrhosis (S4']","[{'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0193388', 'cui_str': 'Biopsy of liver'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0474566', 'cui_str': 'Platelet hematocrit measurement'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0035787', 'cui_str': 'ROC Analysis'}, {'cui': 'C0474566', 'cui_str': 'Platelet hematocrit measurement'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}]",,0.0360161,"The diagnostic value of PCT was comparable with fibrosis-4 score (FIB-4) in predicting significant fibrosis, advanced fibrosis and cirrhosis.","[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Xia', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Xiaomin', 'Initials': 'X', 'LastName': 'Yan', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Wei', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Yali', 'Initials': 'Y', 'LastName': 'Xiong', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Weihua', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Yuxin', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Jia', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Zhong', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Zhaoping', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Weimao', 'Initials': 'W', 'LastName': 'Ding', 'Affiliation': ""Department of Hepatology, Huai'an No. 4 People's Hospital, Huai'an, China.""}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Huang', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': 'Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.'}]",Journal of viral hepatitis,['10.1111/jvh.13264'] 2332,31779001,Prevention of Potential Adverse Metabolic Effects of a Supplementation with Omega-3 Fatty Acids Using a Genetic Score Approach.,"INTRODUCTION The consumption of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFA) has been reported to have beneficial health effects, notably, by reducing plasma triglyceride levels. Nonetheless, a concomitant decrease in insulin sensitivity has also been observed, but is highly variable among subjects. Herein, we aimed to determine the importance of the genetic background in the interindividual variability of the insulin sensitivity response following an n-3 PUFA supplementation. METHODS A total of 210 participants completed a 6-week n-3 PUFA supplementation with 5 g/day of fish oil (providing 1.9-2.2 g of eicosapentaenoic acid + 1.1 g of docosahexaenoic acid). Insulin resistance was estimated by the homeostatic model assessment (HOMA-IR), and participants were further classified as high-risk or low-risk depending on their HOMA-IR change following the n-3 PUFA supplementation, as compared to pre-supplementation values. Genome-wide genotyping data were obtained for 138 participants using HumanOmni-5-Quad BeadChips containing 4,301,331 single nucleotide polymorphisms. A genome-wide association analysis (GWAS) was carried out between high-risk and low-risk participants. The population study was split into training (60%) and testing (40%) datasets to assess the predictive accuracy of a genetic risk score (GRS) constructed by summing the number of risk alleles. RESULTS Following the n-3 PUFA supplementation, 32 participants had increased HOMA-IR as compared to initial values and were classified as high risk (23.2%), whereas remaining subjects were classified as low risk (n = 106, 76.8%). A total of 8 loci had frequency differences between high-risk and low-risk participants at a suggestive GWAS association threshold (p value <1 × 10-5). After applying 10-fold cross validation, the GRS showed a significant association with the risk of increased HOMA-IR in the testing dataset (OR = 3.16 [95% CI, 1.85-7.14]), with a predictive accuracy of 0.85, and explained 40% of variation in HOMA-IR change. CONCLUSIONS These results suggest that the genetic background has a relevant role in the interindividual variability observed in the insulin sensitivity response following an n-3 PUFA supplementation. Subjects being at risk of insulin sensitivity lowering following an n-3 PUFA supplementation may be identified using genetic-based precision nutrition approaches.",2020,"After applying 10-fold cross validation, the GRS showed a significant association with the risk of increased HOMA-IR in the testing dataset (OR = 3.16 [95% CI, 1.85-7.14]), with a predictive accuracy of 0.85, and explained 40% of variation in HOMA-IR change. ","['138 participants using', '210 participants completed a 6-week']","['HumanOmni-5-Quad', 'Omega-3 Fatty Acids', 'n-3 PUFA supplementation with 5 g/day of fish oil (providing 1.9-2.2 g of eicosapentaenoic acid + 1.1 g of docosahexaenoic acid', 'n-3 PUFA supplementation', 'omega-3 polyunsaturated fatty acids (n-3 PUFA']","['plasma triglyceride levels', 'predictive accuracy of a genetic risk score (GRS', 'Insulin resistance', 'HOMA-IR', 'insulin sensitivity']","[{'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C4042790', 'cui_str': 'Quad'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C4517517', 'cui_str': '1.9'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C4517491', 'cui_str': '1.1'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}]","[{'cui': 'C0583329', 'cui_str': 'Plasma triglyceride measurement'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}]",210.0,0.342612,"After applying 10-fold cross validation, the GRS showed a significant association with the risk of increased HOMA-IR in the testing dataset (OR = 3.16 [95% CI, 1.85-7.14]), with a predictive accuracy of 0.85, and explained 40% of variation in HOMA-IR change. ","[{'ForeName': 'Maximilien', 'Initials': 'M', 'LastName': 'Franck', 'Affiliation': 'Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec City, Québec, Canada.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'de Toro-Martín', 'Affiliation': 'Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec City, Québec, Canada.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Guénard', 'Affiliation': 'Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec City, Québec, Canada.'}, {'ForeName': 'Iwona', 'Initials': 'I', 'LastName': 'Rudkowska', 'Affiliation': 'Department of Kinesiology, Laval University, Quebec City, Québec, Canada.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Lemieux', 'Affiliation': 'Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec City, Québec, Canada.'}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Lamarche', 'Affiliation': 'Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec City, Québec, Canada.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Couture', 'Affiliation': 'Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec City, Québec, Canada.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Vohl', 'Affiliation': 'Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec City, Québec, Canada, marie-claude.vohl@fsaa.ulaval.ca.'}]",Lifestyle genomics,['10.1159/000504022'] 2333,32466776,Effect of baseline cognitive impairment on association between predicted propofol effect site concentration and Bispectral index or sedation score.,"BACKGROUND This study determined whether the relationship between predicted propofol effect site concentration (Ce) and observer's assessment of alertness/sedation scale (OAA/S) or Bispectral Index (BIS) was similar comparing cognitively intact vs impaired patients undergoing hip fracture repair with spinal anesthesia and sedation. METHODS Following informed consent baseline mini-mental status exam (MMSE), Clinical Dementia Rating (CDR) and geriatric depression scale (GDS) were obtained. Intraoperatively OAA/S, BIS, and propofol (timing and exact amounts) administered were recorded. Cerebrospinal fluid was collected for Alzheimer's (AD) biomarkers. Mean Ce level (AvgCe) during surgery was calculated using the area under the Ce measurement series from incision to closure, divided by surgical time. Average OAA/S (AvgOAA/S), and BIS (AvgBIS) were similarly calculated. Pearson correlations of AvgCe with AvgOAA/S and AvgBIS were calculated overall and by CDR. Nonparametric locally weighted scatterplot smoothing (LOWESS) fits of AvgOAA/S and AvgBIS on AvgCe were produced, stratified by CDR. Multivariable regression incorporating baseline cognitive measurements or AD biomarkers assessed AvgOAA/S or AvgBIS associations with AvgCe. RESULTS In 186 participants AvgBIS and AvgOAA/S correlated with AvgCe (Pearson ρ = - 0.72; p < 0.0001 and Pearson ρ = - 0.81; p < 0.0001, respectively), and remained unchanged across CDR levels. Association patterns of AvgOAA/S or AvgBIS on AvgCe guided by LOWESS fits and modeled through regression, were similar when stratified by CDR (p = 0.16). Multivariable modeling found no independent effect on AvgBIS or AvgOAA/S by MMSE, CDR, GDS, or AD biomarkers after accounting for AvgCe. CONCLUSIONS When administering sedation in conjunction with spinal anesthesia, cognitive impairment does not affect the relationship between predicted propofol AvgCe and AvgOAA/S or AvgBIS.",2020,In 186 participants AvgBIS and AvgOAA/S correlated with AvgCe (Pearson ρ = - 0.72;,['patients undergoing hip fracture repair with spinal anesthesia and sedation'],"['Intraoperatively OAA/S, BIS, and propofol']","['Average OAA/S (AvgOAA/S), and BIS (AvgBIS', 'alertness/sedation scale (OAA/S) or Bispectral Index (BIS', 'Mean Ce level (AvgCe', 'AvgBIS or AvgOAA/S by MMSE, CDR, GDS, or AD biomarkers', 'mental status exam (MMSE), Clinical Dementia Rating (CDR) and geriatric depression scale (GDS', 'Bispectral index or sedation score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}]","[{'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0451074', 'cui_str': 'Clinical dementia rating scale'}, {'cui': 'C0451184', 'cui_str': 'Geriatric depression scale'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",186.0,0.112119,In 186 participants AvgBIS and AvgOAA/S correlated with AvgCe (Pearson ρ = - 0.72;,"[{'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Sieber', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD, 21224, USA. fsieber1@jhmi.edu.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Neufeld', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, A4Center Suite 457, 4940 Eastern Ave, Baltimore, USA.'}, {'ForeName': 'Esther S', 'Initials': 'ES', 'LastName': 'Oh', 'Affiliation': 'Division of Geriatric Medicine and Gerontology, Psychiatry and Behavioral Sciences & Neuropathology, Johns Hopkins University School of Medicine, Mason F. Lord Building, Center Tower, 5200 Eastern Avenue, 7th Floor, Baltimore, MD, 21224, USA.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Gottschalk', 'Affiliation': 'Departments of Anesthesiology and Critical Care Medicine and Neurosurgery, Johns Hopkins Hospital, 1800 Orleans St, Baltimore, MD, 21287, USA.'}, {'ForeName': 'Nae-Yuh', 'Initials': 'NY', 'LastName': 'Wang', 'Affiliation': 'Medicine, Biostatistics and Epidemiology, The Johns Hopkins University, 2024 E. Monument Street, Suite 2-500, Baltimore, MD, 21287, USA.'}]",BMC anesthesiology,['10.1186/s12871-020-01043-5'] 2334,33578001,Timing of Adjuvant Fractionated Stereotactic Radiosurgery Affects Local Control of Resected Brain Metastases.,"PURPOSE For resected brain metastases (BMs), stereotactic radiosurgery (SRS) is often offered to minimize local recurrence (LR). Although the aim is to deliver SRS within a few weeks of surgery, a variety of socioeconomic, medical, and procedural issues can cause delays. We evaluated the relationship between timing of postoperative SRS and LR. METHODS AND MATERIALS We retrospectively identified a consecutive series of patients with BM managed with resection and SRS or fractionated SRS at our institution from 2012 to 2018. We assessed the correlation of time to SRS and other demographic, disease, and treatment variables with LR, local recurrence-free survival, distant recurrence, distant recurrence-free survival, and overall survival. RESULTS A total of 133 patients met inclusion criteria. The median age was 64.5 years. Approximately half of patients had a single BM, and median BM size was 2.9 cm. Gross total resection was achieved in 111 patients (83.5%), and more than 90% of patients received fractionated SRS. The median time to SRS was 37.0 days, and the LR rate was 16.4%. Time to SRS was predictive of LR. The median time from surgery to SRS was 34.0 days for patients without LR versus 61.0 days for those with LR (P < .01). The LR rate was 2.3% with SRS administered ≤4 weeks postoperatively, compared with 23.6% if SRS was administered >4 weeks postoperatively (P < .01). Local recurrence-free survival was also improved for patients who underwent SRS at ≤4 weeks (P = .02). Delayed SRS was also predictive of distant recurrence (P = .02) but not overall survival. CONCLUSIONS In this retrospective study, the strongest predictor of LR after postoperative SRS for BM was time to SRS, and a cutoff of 4 weeks was a reliable predictor of recurrence. These findings merit investigation in a prospective, randomized trial.",2021,Local recurrence-free survival was also improved for patients who underwent SRS at ≤4 weeks (P = .02).,"['patients with BM managed with resection and SRS or fractionated SRS at our institution from 2012 to 2018', '133 patients met inclusion criteria']","['Adjuvant Fractionated Stereotactic Radiosurgery', 'fractionated SRS', 'stereotactic radiosurgery (SRS']","['distant recurrence', 'LR rate', 'Local recurrence-free survival', 'median BM size', 'correlation of time to SRS and other demographic, disease, and treatment variables with LR, local recurrence-free survival, distant recurrence, distant recurrence-free survival, and overall survival', 'Gross total resection', 'median time from surgery to SRS', 'median time to SRS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0175693', 'cui_str': 'Russell-Silver syndrome'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0085203', 'cui_str': 'Radiosurgery'}, {'cui': 'C0175693', 'cui_str': 'Russell-Silver syndrome'}]","[{'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0010101', 'cui_str': 'Correlation Studies'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0175693', 'cui_str': 'Russell-Silver syndrome'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0015250', 'cui_str': 'Complete excision'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",,0.243655,Local recurrence-free survival was also improved for patients who underwent SRS at ≤4 weeks (P = .02).,"[{'ForeName': 'Diana A', 'Initials': 'DA', 'LastName': ""Roth O'Brien"", 'Affiliation': 'Stich Radiation Oncology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Poppas', 'Affiliation': 'Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Sydney M', 'Initials': 'SM', 'LastName': 'Kaye', 'Affiliation': 'Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Sean S', 'Initials': 'SS', 'LastName': 'Mahase', 'Affiliation': 'Stich Radiation Oncology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Anjile', 'Initials': 'A', 'LastName': 'An', 'Affiliation': 'Division of Biostatistics and Epidemiology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Christos', 'Affiliation': 'Division of Biostatistics and Epidemiology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Liechty', 'Affiliation': 'Department of Neuropathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Pisapia', 'Affiliation': 'Department of Neuropathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Rohan', 'Initials': 'R', 'LastName': 'Ramakrishna', 'Affiliation': 'Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'A Gabriella', 'Initials': 'AG', 'LastName': 'Wernicke', 'Affiliation': 'Savera Liberty Medical, New York, New York.'}, {'ForeName': 'Jonathan P S', 'Initials': 'JPS', 'LastName': 'Knisely', 'Affiliation': 'Stich Radiation Oncology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Pannullo', 'Affiliation': 'Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Theodore H', 'Initials': 'TH', 'LastName': 'Schwartz', 'Affiliation': 'Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York; Department of Otolaryngology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York; Department of Neuroscience, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York. Electronic address: schwarh@med.cornell.edu.'}]",Practical radiation oncology,['10.1016/j.prro.2021.01.011'] 2335,34371893,Mental Health in New Mothers: A Randomised Controlled Study into the Effects of Dietary Flavonoids on Mood and Perceived Quality of Life.,"The postnatal period is a significant period of physical, physiological and psychological change for mothers, rendering them particularly vulnerable to changes in mood or disorders such as postnatal depression (PND). Previous interventions with foods high in flavonoids have demonstrated beneficial acute and chronic mood effects in healthy child, adolescent and adult populations. It is unclear whether mood effects persist in populations who are potentially at-risk of developing mood disorders, such as postnatal mothers. This exploratory study investigated the effects of a 2-week daily dietary flavonoid intervention on mood (PANAS-NOW), anxiety (STAI), depressive symptoms (PHQ-8) and perceived quality of life (WHOQOL-BREF) in forty-one new mothers in the 0-12-month postnatal period, before and after flavonoid intervention. Mothers either added high flavonoid foods to their daily diet, or did not include additions following a randomised, between-groups, controlled design. Significant effects were observed in the flavonoid group with mothers reporting lower state anxiety and higher perceived quality of physical health at the 2-week timepoint. These findings suggest that regular dietary consumption of flavonoids may benefit mothers' anxiety and perceived quality of life in the postnatal period. Replication of these results may indicate the potential for dietary flavonoids to promote healthy mood regulation in mothers or prevent the onset or severity of symptoms in postnatal psychological disorders, both of which would be beneficial for women's health services and public mental health.",2021,Significant effects were observed in the flavonoid group with mothers reporting lower state anxiety and higher perceived quality of physical health at the 2-week timepoint.,"['healthy child, adolescent and adult populations', 'New Mothers', 'forty-one new mothers in the 0-12-month postnatal period, before and after flavonoid intervention']","['daily dietary flavonoid intervention', 'flavonoid', 'foods high in flavonoids', 'Dietary Flavonoids']","['Mood and Perceived Quality of Life', 'state anxiety and higher perceived quality of physical health', 'quality of life', 'mood (PANAS-NOW), anxiety (STAI), depressive symptoms (PHQ-8) and perceived quality of life (WHOQOL-BREF']","[{'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0596577', 'cui_str': 'Flavonoid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0596577', 'cui_str': 'Flavonoid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}]",,0.00896158,Significant effects were observed in the flavonoid group with mothers reporting lower state anxiety and higher perceived quality of physical health at the 2-week timepoint.,"[{'ForeName': 'Katie Louise', 'Initials': 'KL', 'LastName': 'Barfoot', 'Affiliation': 'School of Psychology & Clinical Language Sciences, University of Reading, Earley Gate, Reading RG6 7BE, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Forster', 'Affiliation': 'School of Psychology & Clinical Language Sciences, University of Reading, Earley Gate, Reading RG6 7BE, UK.'}, {'ForeName': 'Daniel Joseph', 'Initials': 'DJ', 'LastName': 'Lamport', 'Affiliation': 'School of Psychology & Clinical Language Sciences, University of Reading, Earley Gate, Reading RG6 7BE, UK.'}]",Nutrients,['10.3390/nu13072383'] 2336,34371884,"Reversal of Insulin Resistance in Overweight and Obese Subjects by trans -Resveratrol and Hesperetin Combination-Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation.","The dietary supplement, trans -resveratrol and hesperetin combination (tRES-HESP), induces expression of glyoxalase 1, countering the accumulation of reactive dicarbonyl glycating agent, methylglyoxal (MG), in overweight and obese subjects. tRES-HESP produced reversal of insulin resistance, improving dysglycemia and low-grade inflammation in a randomized, double-blind, placebo-controlled crossover study. Herein, we report further analysis of study variables. MG metabolism-related variables correlated with BMI, dysglycemia, vascular inflammation, blood pressure, and dyslipidemia. With tRES-HESP treatment, plasma MG correlated negatively with endothelial independent arterial dilatation (r = -0.48, p < 0.05) and negatively with peripheral blood mononuclear cell (PBMC) quinone reductase activity (r = -0.68, p < 0.05)-a marker of the activation status of transcription factor Nrf2. For change from baseline of PBMC gene expression with tRES-HESP treatment, Glo1 expression correlated negatively with change in the oral glucose tolerance test area-under-the-curve plasma glucose (ΔAUGg) (r = -0.56, p < 0.05) and thioredoxin interacting protein (TXNIP) correlated positively with ΔAUGg (r = 0.59, p < 0.05). Tumor necrosis factor-α (TNFα) correlated positively with change in fasting plasma glucose (r = 0.70, p < 0.001) and negatively with change in insulin sensitivity (r = -0.68, p < 0.01). These correlations were not present with placebo. tRES-HESP decreased low-grade inflammation, characterized by decreased expression of CCL2, COX-2, IL-8, and RAGE. Changes in CCL2, IL-8, and RAGE were intercorrelated and all correlated positively with changes in MLXIP, MAFF, MAFG, NCF1, and FTH1, and negatively with changes in HMOX1 and TKT; changes in IL-8 also correlated positively with change in COX-2. Total urinary excretion of tRES and HESP metabolites were strongly correlated. These findings suggest tRES-HESP counters MG accumulation and protein glycation, decreasing activation of the unfolded protein response and expression of TXNIP and TNFα, producing reversal of insulin resistance. tRES-HESP is suitable for further evaluation for treatment of insulin resistance and related disorders.",2021,"tRES-HESP decreased low-grade inflammation, characterized by decreased expression of CCL2, COX-2, IL-8, and RAGE.","['Overweight and Obese Subjects', 'overweight and obese subjects']","['placebo', 'dietary supplement, trans -resveratrol and hesperetin combination (tRES-HESP', 'tRES-HESP']","['BMI, dysglycemia, vascular inflammation, blood pressure, and dyslipidemia', 'thioredoxin interacting protein (TXNIP', 'insulin resistance, improving dysglycemia and low-grade inflammation', 'insulin sensitivity', 'tRES-HESP decreased low-grade inflammation', 'expression of CCL2, COX-2, IL-8, and RAGE', 'endothelial independent arterial dilatation', 'MLXIP, MAFF, MAFG, NCF1, and FTH1, and negatively with changes in HMOX1 and TKT; changes in IL-8', 'Tumor necrosis factor-α (TNFα', 'oral glucose tolerance test area-under-the-curve plasma glucose (ΔAUGg', 'CCL2, IL-8, and RAGE', 'Total urinary excretion of tRES and HESP metabolites', 'peripheral blood mononuclear cell (PBMC) quinone reductase activity', 'fasting plasma glucose']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0073096', 'cui_str': 'resveratrol'}, {'cui': 'C0062585', 'cui_str': 'hesperetin'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1960636', 'cui_str': 'Dysglycemia'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C1450344', 'cui_str': 'thioredoxin-binding protein-2'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C1962916', 'cui_str': 'Low grade (lymphoma)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C1449159', 'cui_str': 'CCL2 protein, human'}, {'cui': 'C1565860', 'cui_str': 'PTGS2 protein, human'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0034634', 'cui_str': 'Rage'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0534921', 'cui_str': 'MAFG protein, human'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0538674', 'cui_str': 'Hemeoxygenase 1'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0027280', 'cui_str': 'NAD(P)H dehydrogenase (quinone)'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}]",,0.0693798,"tRES-HESP decreased low-grade inflammation, characterized by decreased expression of CCL2, COX-2, IL-8, and RAGE.","[{'ForeName': 'Naila', 'Initials': 'N', 'LastName': 'Rabbani', 'Affiliation': 'Department of Basic Medical Science, College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.'}, {'ForeName': 'Mingzhan', 'Initials': 'M', 'LastName': 'Xue', 'Affiliation': 'Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar.'}, {'ForeName': 'Martin O', 'Initials': 'MO', 'LastName': 'Weickert', 'Affiliation': 'Endocrinology & Metabolism, Warwickshire Institute for the Study of Diabetes, University Hospitals of Coventry & Warwickshire NHS Trust, Coventry CV2 2DX, UK.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Thornalley', 'Affiliation': 'Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar.'}]",Nutrients,['10.3390/nu13072374'] 2337,34371883,Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial.,"The aim of the study was to evaluate the overall biohumoral and metabolic effects of a 12-week add-on therapy consisting of a new nutraceutical formulation (BHC) based on berberine, hesperidin, and chromium picolinate in type 2 diabetes mellitus (T2D) patients with suboptimal glycemic compensation receiving metformin. After 12 weeks, participants in the group receiving metformin plus BHC, compared to the group receiving metformin only, saw a significant improvement in their glucose profile, in terms of both glycated hemoglobin (HbA1c) and fasting blood glucose (FBG). Their FBG dropped from 145 ± 20 mg/dL to 128 ± 23 mg/dL ( p < 0.01), a decrease of 11.7% compared with the baseline. This decrease differed significantly from the situation in the control arm ( p < 0.05). HbA1c decreased by 7.5% from the baseline, from 53.5 ± 4.3 mmol/mol to 49.5 ± 5.1 mmol/mol ( p < 0.01), in the group given BHC, while no difference was seen in the control group. Advanced glycation end products (AGEs) and malondialdehyde (MDA) were found to be significantly reduced ( p < 0.01) only in the BHC group, from 9.34 ± 7.61 μg/mL to 6.75 ± 6.13 μg/mL, and from 1.7 ± 0.15 μmol/L to 1.4 ± 0.25 μmol/L, respectively. In patients with T2D taking metformin with suboptimal glycemic compensation, adding BHC for 3 months significantly improved glucose control in terms of FBG and HbA1c, and had a positive effect on the lipid peroxidation profile, as indicated by a decrease in AGEs and MDA.",2021,"Their FBG dropped from 145 ± 20 mg/dL to 128 ± 23 mg/dL ( p < 0.01), a decrease of 11.7% compared with the baseline.","['type 2 diabetes mellitus (T2D) patients with suboptimal glycemic compensation receiving', 'Patients with Type 2 Diabetes and Suboptimal Glycemic Control']","['Metformin Monotherapy', 'metformin', 'new nutraceutical formulation (BHC) based on berberine, hesperidin, and chromium picolinate', 'metformin plus BHC']","['glycated hemoglobin (HbA1c) and fasting blood glucose (FBG', 'overall biohumoral and metabolic effects', 'lipid peroxidation profile', 'glucose profile', 'glucose control', 'AGEs and MDA', 'Advanced glycation end products (AGEs) and malondialdehyde (MDA', 'HbA1c']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1518478', 'cui_str': 'Nutriceuticals'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0005117', 'cui_str': 'Berberine'}, {'cui': 'C0019392', 'cui_str': 'Hesperidin'}, {'cui': 'C0163657', 'cui_str': 'CHROMIUM PICOLINATE'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0393584', 'cui_str': 'Benign hereditary chorea'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0023775', 'cui_str': 'Lipid peroxidation'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C0162574', 'cui_str': 'Advanced Glycation End Products'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",,0.0281792,"Their FBG dropped from 145 ± 20 mg/dL to 128 ± 23 mg/dL ( p < 0.01), a decrease of 11.7% compared with the baseline.","[{'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Sartore', 'Affiliation': 'Department of Medicine-DIMED, University of Padova, I-35128 Padova, Italy.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Ragazzi', 'Affiliation': 'Department of Pharmaceutical and Pharmacological Sciences, University of Padova, I-35131 Padova, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Antonello', 'Affiliation': 'Department of Medicine-DIMED, University of Padova, I-35128 Padova, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cosma', 'Affiliation': 'Department of Laboratory Medicine, University of Padova, I-35128 Padova, Italy.'}, {'ForeName': 'Annunziata', 'Initials': 'A', 'LastName': 'Lapolla', 'Affiliation': 'Department of Medicine-DIMED, University of Padova, I-35128 Padova, Italy.'}]",Nutrients,['10.3390/nu13072373'] 2338,34371880,Impact of Maternal Daily Oral Low-Dose Vitamin A Supplementation on the Mother-Infant Pair: A Randomised Placebo-Controlled Trial in China.,"BACKGROUND The nutritional status of vitamin A in lactating mothers and infants is still not optimistic. Due to the dietary habits and dietary restrictions of postpartum customs in China, vitamin A supplementation has been advocated as a potential strategy to improve vitamin A status of lactating mothers with inadequate dietary vitamin A intake. Existing clinical trials are limited to single or double high-dose maternal administrations. However, in China, vitamin A supplements are readily available in the form of daily oral low-dose supplements, and the effect of these is unknown. This study aimed to evaluate the effects of daily oral low-dose vitamin A supplementation on the retinol levels in the serum and breast milk of lactating mothers and the health status of infants in China. METHODS Lactating mothers who met the inclusion criteria and planned to continue exclusive breastfeeding were randomly assigned to receive either daily oral vitamin A and D drops (one soft capsule of 1800 IU vitamin A and 600 IU vitamin D 2 ), or a matching placebo for 2 months. Before and after the intervention, dietary intake was investigated by instant photography, and the retinol concentration in maternal serum and breast milk was determined by ultra-high performance liquid chromatography-tandem mass spectrometry. During the trial, the health status of infants was diagnosed by a paediatrician or reported by lactating mothers. A total of 245 participants completed the study, with 117 in the supplementation group and 128 in the control group. RESULTS After the 2-month intervention, maternal serum retinol concentrations increased in the supplementation group with no change in the control group. Although breast milk retinol concentrations decreased significantly in both groups, the decrease in the supplementation group was significantly lower than that in the control group. However, maternal vitamin A supplementation was not associated with a lower risk of infant febrile illness, respiratory tract infection, diarrhoea, and eczema. CONCLUSIONS Daily oral low-dose vitamin A supplementation is helpful in improving maternal vitamin A status, despite having no effect on infant health status through breast milk.",2021,"However, maternal vitamin A supplementation was not associated with a lower risk of infant febrile illness, respiratory tract infection, diarrhoea, and eczema. ","['lactating mothers with inadequate dietary vitamin A intake', 'infants was diagnosed by a paediatrician or reported by lactating mothers', 'lactating mothers and the health status of infants in China', 'Lactating mothers who met the inclusion criteria and planned to continue exclusive breastfeeding', 'lactating mothers and infants', 'Mother-Infant Pair', '245 participants completed the study, with 117 in the supplementation group and 128 in the control group']","['Maternal Daily Oral Low-Dose Vitamin A Supplementation', 'daily oral vitamin A and D drops (one soft capsule of 1800 IU vitamin A and 600 IU vitamin D 2 ), or a matching placebo', 'Placebo', 'daily oral low-dose vitamin A supplementation']","['retinol concentration in maternal serum and breast milk', 'maternal serum retinol concentrations', 'retinol levels', 'lower risk of infant febrile illness, respiratory tract infection, diarrhoea, and eczema', 'breast milk retinol concentrations']","[{'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0564436', 'cui_str': 'Vitamin A intake'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0237433', 'cui_str': 'Pediatrician'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0242205', 'cui_str': 'Breastfeeding, Exclusive'}, {'cui': 'C4517661', 'cui_str': '245'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0303409', 'cui_str': 'Indium-117'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C4524019', 'cui_str': 'Vitamin A supplementation'}, {'cui': 'C0310589', 'cui_str': 'Vitamin A- and vitamin D-containing product'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C1273639', 'cui_str': 'Soft capsule'}, {'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0014695', 'cui_str': 'Ergocalciferol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0743841', 'cui_str': 'Disorder characterized by fever'}, {'cui': 'C0035243', 'cui_str': 'Respiratory tract infection'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}]",245.0,0.262275,"However, maternal vitamin A supplementation was not associated with a lower risk of infant febrile illness, respiratory tract infection, diarrhoea, and eczema. ","[{'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Hu', 'Affiliation': 'Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.'}, {'ForeName': 'Fangping', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.'}, {'ForeName': 'Xiaolong', 'Initials': 'X', 'LastName': 'Lu', 'Affiliation': 'Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.'}, {'ForeName': 'Zhencheng', 'Initials': 'Z', 'LastName': 'Xie', 'Affiliation': 'Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.'}, {'ForeName': 'Zhixu', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.'}]",Nutrients,['10.3390/nu13072370'] 2339,34371872,Gastrointestinal Tolerance and Protein Absorption Markers with a New Peptide Enteral Formula Compared to a Standard Intact Protein Enteral Formula in Critically Ill Patients.,"The aim of this exploratory study was to investigate gastrointestinal tolerance and protein absorption markers with a new enteral peptide formula (PF) compared to an isocaloric enteral intact protein standard formula (SF) containing the same amount of protein in ICU patients. Patients admitted to a cardio-thoracic intensive care unit expected to receive tube feeding for ≥5 days were randomized to receive either PF (1.5 kcal/mL) or SF in a double-blind manner for ≤14 days. Twenty-six patients were randomized (13 SF and 13 PF) and 23 (12 SF and 11 PF) completed at least 5 days of product administration. There were no statistically significant differences between the feeds during the first 5 days of intervention for diarrhea (SF:3 (23%); PF:5 (39%), p = 0.388), vomiting (SF:1 (8%); PF:2 (15%), p = 0.549), constipation (SF:7 (54%), PF:3 (23%), p = 0.115), and high gastric residual volume (>500 mL: SF:1 (8%); PF: 2 (15%), p = 0.535). There were no differences in plasma amino acids or urinary markers of protein absorption and metabolism. In conclusion, no major differences were found in tolerability and protein absorption markers between the standard intact protein formula and the peptide formula.",2021,"There were no statistically significant differences between the feeds during the first 5 days of intervention for diarrhea (SF:3 (23%); PF:5 (39%), p = 0.388), vomiting (SF:1 (8%); PF:2 (15%), p = 0.549), constipation (SF:7 (54%), PF:3 (23%), p = 0.115), and high gastric residual volume (>500 mL: SF:1 (8%); PF: 2 (15%), p = 0.535).","['Critically Ill Patients', 'Patients admitted to a cardio-thoracic intensive care unit expected to receive tube feeding for ≥5 days', 'ICU patients', 'Twenty-six patients']","['new enteral peptide formula (PF', 'SF', 'PF', 'Standard Intact Protein Enteral Formula', 'New Peptide Enteral Formula', 'isocaloric enteral intact protein standard formula (SF']","['constipation (SF:7', 'vomiting (SF:1', 'tolerability and protein absorption markers', 'high gastric residual volume', 'plasma amino acids or urinary markers of protein absorption and metabolism', 'diarrhea (SF:3']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0450349', 'cui_str': '26'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1304890', 'cui_str': 'Enteral'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C3853255', 'cui_str': 'Standard formula'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0311187', 'cui_str': 'Enteral formula'}]","[{'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3665864', 'cui_str': 'Gastric residual assessment'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",26.0,0.0542934,"There were no statistically significant differences between the feeds during the first 5 days of intervention for diarrhea (SF:3 (23%); PF:5 (39%), p = 0.388), vomiting (SF:1 (8%); PF:2 (15%), p = 0.549), constipation (SF:7 (54%), PF:3 (23%), p = 0.115), and high gastric residual volume (>500 mL: SF:1 (8%); PF: 2 (15%), p = 0.535).","[{'ForeName': 'Ione', 'Initials': 'I', 'LastName': 'de Brito-Ashurst', 'Affiliation': 'Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Klebach', 'Affiliation': 'Danone Nutricia Research, Utrecht University, 3584 CT Utrecht, The Netherlands.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Tsompanaki', 'Affiliation': 'Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.'}, {'ForeName': 'Sundeep', 'Initials': 'S', 'LastName': 'Kaul', 'Affiliation': 'Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'van Horssen', 'Affiliation': 'Danone Nutricia Research, Utrecht University, 3584 CT Utrecht, The Netherlands.'}, {'ForeName': 'Zandrie', 'Initials': 'Z', 'LastName': 'Hofman', 'Affiliation': 'Danone Nutricia Research, Utrecht University, 3584 CT Utrecht, The Netherlands.'}]",Nutrients,['10.3390/nu13072362'] 2340,34371870,"Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial.","Kidney transplant recipients are at high risk of progressive bone loss and low-energy fractures in the years following transplantation. Marine n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation may have beneficial effects on bone strength. The Omega-3 fatty acids in Renal Transplantation (ORENTRA) trial was an investigator initiated, randomized, placebo-controlled trial investigating the effects of marine n-3 PUFA supplementation after kidney transplantation. Effects of supplementation on bone mineral density (BMD) and calcium metabolism were pre-defined secondary endpoints. Adult kidney transplant recipients ( n = 132) were randomized to 2.6 g marine n-3 PUFA supplement or olive oil (control) from 8 to 52 weeks post-transplant. Dual energy X-ray absorptiometry was performed to assess changes in bone mineral density of hip, spine, and forearm, as well as trabecular bone score (TBS) of the lumbar spine. Student's t test was used to assess between-group differences. There were no differences in ΔBMD between the two groups (intervention vs. control) at lumbar spine (-0.020 ± 0.08 vs. -0.007 ± 0.07 g/cm², p = 0.34), total hip (0.001 ± 0.03 vs. -0.005 ± 0.04, p = 0.38), or other skeletal sites in the intention-to-treat analyses. There was no difference in the change in TBS score (0.001 ± 0.096 vs. 0.009 ± 0.102, p = 0.62). Finally, no effect on biochemical parameters of mineral metabolism was seen. Results were similar when analyzed per protocol. In conclusion, we found no significant effect of 44 weeks of supplementation with 2.6 g of marine n-3 PUFA on BMD in kidney transplant recipients.",2021,"There were no differences in ΔBMD between the two groups (intervention vs. control) at lumbar spine (-0.020 ± 0.08 vs. -0.007 ± 0.07 g/cm², p = 0.34), total hip (0.001 ± 0.03 vs. -0.005 ± 0.04, p = 0.38), or other skeletal sites in the intention-to-treat analyses.","['kidney transplant recipients', 'after kidney transplantation', 'Kidney Transplant Recipients', 'Adult kidney transplant recipients ( n = 132', 'Kidney transplant recipients']","['marine n-3 PUFA', 'Marine n-3 Polyunsaturated Fatty Acids', 'Marine n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation', 'Omega-3 fatty acids', 'marine n-3 PUFA supplementation', 'Placebo', 'marine n-3 PUFA supplement or olive oil (control', 'Dual energy X-ray absorptiometry', 'placebo']","['bone mineral density (BMD) and calcium metabolism', 'ΔBMD', 'biochemical parameters of mineral metabolism', 'bone mineral density of hip, spine, and forearm, as well as trabecular bone score (TBS', 'TBS score']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0524645', 'cui_str': 'Marines'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0222660', 'cui_str': 'Trabecular substance of bone'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",132.0,0.0902083,"There were no differences in ΔBMD between the two groups (intervention vs. control) at lumbar spine (-0.020 ± 0.08 vs. -0.007 ± 0.07 g/cm², p = 0.34), total hip (0.001 ± 0.03 vs. -0.005 ± 0.04, p = 0.38), or other skeletal sites in the intention-to-treat analyses.","[{'ForeName': 'Hanne Skou', 'Initials': 'HS', 'LastName': 'Jørgensen', 'Affiliation': 'Department of Kidney Diseases, Aarhus University Hospital, 8200 Aarhus, Denmark.'}, {'ForeName': 'Ivar Anders', 'Initials': 'IA', 'LastName': 'Eide', 'Affiliation': 'Department of Nephrology, Division of Internal Medicine, Akershus University Hospital, 1478 Lørenskog, Norway.'}, {'ForeName': 'Trond', 'Initials': 'T', 'LastName': 'Jenssen', 'Affiliation': 'Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Åsberg', 'Affiliation': 'Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Bollerslev', 'Affiliation': 'Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Godang', 'Affiliation': 'Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Hartmann', 'Affiliation': 'Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.'}, {'ForeName': 'Erik Berg', 'Initials': 'EB', 'LastName': 'Schmidt', 'Affiliation': 'Department of Cardiology, Aalborg University Hospital, 9100 Aalborg, Denmark.'}, {'ForeName': 'My', 'Initials': 'M', 'LastName': 'Svensson', 'Affiliation': 'Department of Nephrology, Division of Internal Medicine, Akershus University Hospital, 1478 Lørenskog, Norway.'}]",Nutrients,['10.3390/nu13072361'] 2341,34371859,Impact of a Geriatric Intervention to Improve Screening and Management of Undernutrition in Older Patients Undergoing Surgery for Colorectal Cancer: Results of the ANC Stepped-Wedge Trial.,"Almost two in three patients who are aged 75 years and older and scheduled for surgery for colorectal cancer (CRC) are undernourished. Despite evidence that perioperative nutritional management can improve patients outcomes, international guidelines are still insufficiently applied in current practice. In this stepped-wedge cluster-randomized study of five surgical hospitals, we included 147 patients aged 70 years or older with scheduled abdominal surgery for CRC between October 2013 and December 2016. In the intervention condition, an outreach team comprising a geriatrician and a dietician visited patients and staff in surgical wards to assist with the correct application of guidelines. Evaluation, diagnosis, and prescription (according to nutritional status) were considered appropriate and strictly consistent with guidelines in 39.2% of patients in the intervention group compared to only 1.4% in the control group ( p = 0.0002). Prescription of oral nutritional supplements during the perioperative period was significantly improved (41.9% vs. 4.1%; p < 0.0001). However, there were no benefits of the intervention on surgical complications or adverse events. A possible benefit of hospital stay reduction will need to be confirmed in further studies. This study highlights the importance of the implementation of quality improvement interventions into current practice for the perioperative nutritional management of older patients with CRC.",2021,Prescription of oral nutritional supplements during the perioperative period was significantly improved (41.9% vs. 4.1%; p < 0.0001).,"['147 patients aged 70 years or older with scheduled abdominal surgery for CRC between October 2013 and December 2016', 'older patients with CRC', 'three patients who are aged 75 years and older and scheduled for surgery for colorectal cancer (CRC) are undernourished', 'Older Patients Undergoing Surgery for Colorectal Cancer']",['Geriatric Intervention'],['surgical complications or adverse events'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}]","[{'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",147.0,0.0273263,Prescription of oral nutritional supplements during the perioperative period was significantly improved (41.9% vs. 4.1%; p < 0.0001).,"[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Gilbert', 'Affiliation': 'Geriatric Medicine Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, CEDEX, 69495 Pierre-Bénite, France.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Bernard', 'Affiliation': 'Public Health Department, Epidemiology and Clinical Research Unit, Hospices Civils de Lyon, 69002 Lyon, France.'}, {'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Alexandre', 'Affiliation': 'Public Health Department, Epidemiology and Clinical Research Unit, Hospices Civils de Lyon, 69002 Lyon, France.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Bin-Dorel', 'Affiliation': 'Public Health Department, Epidemiology and Clinical Research Unit, Hospices Civils de Lyon, 69002 Lyon, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Villeneuve', 'Affiliation': 'Public Health Department, Epidemiology and Clinical Research Unit, Hospices Civils de Lyon, 69002 Lyon, France.'}, {'ForeName': 'Evelyne', 'Initials': 'E', 'LastName': 'Decullier', 'Affiliation': 'Public Health Department, Epidemiology and Clinical Research Unit, Hospices Civils de Lyon, 69002 Lyon, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Bonnefoy', 'Affiliation': 'Geriatric Medicine Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, CEDEX, 69495 Pierre-Bénite, France.'}, {'ForeName': '', 'Initials': '', 'LastName': 'Anc Working Group', 'Affiliation': ''}]",Nutrients,['10.3390/nu13072347'] 2342,34371847,"Lactobacillus plantarum HAC01 Supplementation Improves Glycemic Control in Prediabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial.","A recent animal study demonstrated that administration of Lactobacillus plantarum HAC01 isolated from Korean kimchi improved glycemic control in type 2 diabetic mice. In the present study, we evaluated Lactobacillus plantarum HAC01's effects on metabolic parameters of prediabetic human subjects. Forty subjects with isolated impaired glucose tolerance were randomly assigned to receive a daily placebo ( n = 20) or a dose of Lactobacillus plantarum HAC01 ( n = 20) over eight weeks. The primary endpoint was a change in 2 h postprandial glucose (2h-PPG) levels and the secondary endpoints were assessment of other glucose metabolism parameters, including HbA1c, gut microbiota composition, and fecal short-chain fatty acids (SCFAs). The group with a diet supplemented with Lactobacillus plantarum HAC01 saw a significant reduction in 2h-PPG and HbA1c levels compared to the placebo group. Fasting plasma glucose, insulin, HOMA-IR, QUICKI, microbiota composition, and fecal SCFAs, however, were not significantly altered. No serious adverse effects were reported. This is the first clinical trial to show a beneficial effect of single-strain probiotic supplementation administered over eight weeks on HbA1c levels in prediabetic subjects.",2021,The group with a diet supplemented with Lactobacillus plantarum HAC01 saw a significant reduction in 2h-PPG and HbA1c levels compared to the placebo group.,"['prediabetic human subjects', 'prediabetic subjects', 'Prediabetic Subjects', 'type 2 diabetic mice', 'Forty subjects with isolated impaired glucose tolerance']","['daily placebo', 'Lactobacillus plantarum HAC01 Supplementation', 'Placebo', 'placebo', 'Lactobacillus plantarum HAC01', 'single-strain probiotic supplementation']","['glucose metabolism parameters, including HbA1c, gut microbiota composition, and fecal short-chain fatty acids (SCFAs', 'PPG and HbA1c levels', 'Fasting plasma glucose, insulin, HOMA-IR, QUICKI, microbiota composition, and fecal SCFAs', 'change in 2 h postprandial glucose (2h-PPG) levels', 'glycemic control', 'serious adverse effects']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0025914', 'cui_str': 'Mouse'}, {'cui': 'C0151671', 'cui_str': 'Glucose tolerance decreased'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0317608', 'cui_str': 'Lactobacillus plantarum'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0049716', 'cui_str': ""6-thioguanosine 5'-diphosphate""}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",40.0,0.251639,The group with a diet supplemented with Lactobacillus plantarum HAC01 saw a significant reduction in 2h-PPG and HbA1c levels compared to the placebo group.,"[{'ForeName': 'Mi-Ra', 'Initials': 'MR', 'LastName': 'Oh', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}, {'ForeName': 'Hui-Yeon', 'Initials': 'HY', 'LastName': 'Jang', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}, {'ForeName': 'Si-Yeon', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}, {'ForeName': 'Su-Jin', 'Initials': 'SJ', 'LastName': 'Jung', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}, {'ForeName': 'Soo-Wan', 'Initials': 'SW', 'LastName': 'Chae', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}, {'ForeName': 'Seung-Ok', 'Initials': 'SO', 'LastName': 'Lee', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chonbuk National University Medical School, Jeonju 54896, Korea.'}, {'ForeName': 'Byung-Hyun', 'Initials': 'BH', 'LastName': 'Park', 'Affiliation': 'Department of Biochemistry and Molecular Biology, Chonbuk National University Medical School, Jeonju 54896, Korea.'}]",Nutrients,['10.3390/nu13072337'] 2343,34371810,Acute Administration of Bioavailable Curcumin Alongside Ferrous Sulphate Supplements Does Not Impair Iron Absorption in Healthy Adults in a Randomised Trial.,"Ferrous sulphate (FS) is a cost effective, readily available iron supplement for iron deficiency (ID). The pro-oxidant effect of oral ferrous iron is known to induce inflammation, causing gastric side-effects and resulting in poor compliance. Curcumin is a potent antioxidant and has also been shown to exhibit iron chelation in-vitro, although it is not established whether these effects are retained in-vivo. The aim of this study was therefore to assess the influence of a formulated bioavailable form of curcumin (HydroCurc TM ; 500 mg) on acute iron absorption and status in a double blind, placebo-controlled randomized trial recruiting 155 healthy participants (79 males; 26.42 years ± 0.55 and 76 females; 25.82 years ± 0.54). Participants were randomly allocated to five different treatment groups: iron and curcumin placebo (FS0_Plac), low dose (18 mg) iron and curcumin placebo (FS18_Plac), low dose iron and curcumin (FS18_Curc), high dose (65 mg) iron and curcumin placebo (FS65_Plac), and high dose iron and curcumin (FS65_Curc). Participants were provided with the supplements according to their relevant treatment groups at baseline (0 min), and blood collection was carried out at 0 min and at 180 min following supplementation. In the treatment groups, significant difference was observed in mean serum iron between baseline (0 min) and at end-point (180 min) (F (1, 144) = 331.9, p < 0.0001) with statistically significant intra-group increases after 180 min ( p < 0.0001) in the FS18_Plac (8.79 µmol/L), FS18_Curc (11.41 µmol/L), FS65_Plac (19.09 µmol/L), and FS65_Curc (16.39 µmol/L) groups. A significant difference was also observed between the two time points in serum TIBC levels and in whole blood haemoglobin (HGB) in the treatment groups, with a significant increase (1.55%/2.04 g/L) in HGB levels from baseline to end-point observed in the FS65_Curc group ( p < 0.05). All groups receiving iron demonstrated an increase in transferrin saturation (TS%) in a dose-related manner, demonstrating that increases in serum iron are translated into increases in physiological iron transportation. This study demonstrates, for the first time, that regardless of ferrous dose, formulated curcumin in the form of HydroCurc™ does not negatively influence acute iron absorption in healthy humans.",2021,"All groups receiving iron demonstrated an increase in transferrin saturation (TS%) in a dose-related manner, demonstrating that increases in serum iron are translated into increases in physiological iron transportation.","['healthy humans', 'Healthy Adults', '155 healthy participants (79 males; 26.42 years ± 0.55 and 76 females; 25.82 years ± 0.54']","['Alongside Ferrous Sulphate Supplements', 'Bioavailable Curcumin', 'iron and curcumin placebo (FS0_Plac), low dose (18 mg) iron and curcumin placebo (FS18_Plac), low dose iron and curcumin (FS18_Curc), high dose (65 mg) iron and curcumin placebo (FS65_Plac), and high dose iron and curcumin (FS65_Curc', 'Ferrous sulphate (FS', 'placebo', 'curcumin (HydroCurc TM ']","['blood haemoglobin (HGB', 'mean serum iron', 'HGB levels', 'physiological iron transportation', 'serum TIBC levels', 'transferrin saturation (TS']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517462', 'cui_str': '0.55'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0935763', 'cui_str': 'Bioavailable'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0444956', 'cui_str': 'High dose'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0040756', 'cui_str': 'Transportation'}, {'cui': 'C0427433', 'cui_str': 'Serum TIBC measurement'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}]",155.0,0.103136,"All groups receiving iron demonstrated an increase in transferrin saturation (TS%) in a dose-related manner, demonstrating that increases in serum iron are translated into increases in physiological iron transportation.","[{'ForeName': 'Helena Tiekou', 'Initials': 'HT', 'LastName': 'Lorinczova', 'Affiliation': 'Centre for Nutraceuticals, School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Gulshanara', 'Initials': 'G', 'LastName': 'Begum', 'Affiliation': 'Centre for Nutraceuticals, School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Renshaw', 'Affiliation': 'Centre for Sport, Exercise and Life Sciences, Institute for Health and Wellbeing, Coventry University, Priory St, Coventry CV1 5FB, UK.'}, {'ForeName': 'Mohammed Gulrez', 'Initials': 'MG', 'LastName': 'Zariwala', 'Affiliation': 'Centre for Nutraceuticals, School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}]",Nutrients,['10.3390/nu13072300'] 2344,34371806,The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study.,"BACKGROUND AND AIM Sarcopenia is considered an important risk factor for morbidity and mortality in liver cirrhosis. Beta-hydroxy-beta-methylbutyrate (HMB) has the potential to increase muscle mass and performance by stimulating protein synthesis and reducing muscle catabolism. The present study aimed at evaluating the effect of HMB supplementation on muscle mass and function in patients with liver cirrhosis. Changes in frailty during the study were also estimated, and the safety of HMB supplementation was verified. METHODS This is a randomized, single-blind, placebo-controlled pilot trial. Twenty-four patients (14 HMB and 10 placebo) affected by liver cirrhosis were enrolled in the study. Each patient received dedicated counseling, which included nutrition and physical activity recommendations for chronic liver disease patients. Patients were randomized to receive 3 g/day of HMB or placebo (sorbitol powder) for 12 consecutive weeks. A diet interview, anthropometry, electrical bioimpedance analysis (BIA), quadriceps ultrasound, physical performance battery, Liver Frailty Index (LFI), and cognitive tests were completed at enrolment (T0), at 12 weeks (T1), and 24 weeks after enrolment (T2). RESULTS At baseline, the two groups were similar in demography, severity of liver disease, muscle mass, muscle function, and cognitive tests. LFI at baseline was higher in patients in the HMB group vs. those in the placebo group (4.1 ± 0.4 vs. 3.4 ± 0.6, p < 0.01). After treatment, a statistically significant increase in muscle function was seen in the HMB group (chair stand test: 14.2 ± 5 s vs. 11.7 ± 2.6 s, p < 0.05; six-minute walk test: 361.8 ± 68 m vs. 409.4 ± 58 m, p < 0.05). Quadriceps muscle mass measured by ultrasound also increased (4.9 ± 1.8 vs. 5.4 ± 1.8 mm, p < 0.05) after HMB, while LFI decreased (4.1 ± 0.4 vs. 3.7 ± 0.4, p < 0.05). HMB was well tolerated by patients, and no adverse events were documented. CONCLUSIONS Our study suggests the efficacy of 12-week beta-hydroxy-beta-methylbutyrate supplementation in promoting improvements in muscle performance in compensated cirrhotic patients. LFI was also ameliorated. Further studies with a greater number of patients are required to reinforce this hypothesis.",2021,"p < 0.05; six-minute walk test: 361.8 ± 68 m vs. 409.4 ± 58 m, p < 0.05).","['patients with liver cirrhosis', 'Twenty-four patients (14 HMB and 10 placebo) affected by liver cirrhosis were enrolled in the study', 'compensated cirrhotic patients', 'chronic liver disease patients', 'liver cirrhosis', 'Patients with Liver Cirrhosis']","['12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation', 'HMB supplementation', 'dedicated counseling, which included nutrition and physical activity recommendations', 'HMB or placebo (sorbitol powder', 'Beta-hydroxy-beta-methylbutyrate (HMB', 'HMB', 'beta-hydroxy-beta-methylbutyrate supplementation', 'placebo']","['A diet interview, anthropometry, electrical bioimpedance analysis (BIA), quadriceps ultrasound, physical performance battery, Liver Frailty Index (LFI), and cognitive tests', 'demography, severity of liver disease, muscle mass, muscle function, and cognitive tests', 'muscle performance', 'Quadriceps muscle mass', 'LFI', 'muscle function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439686', 'cui_str': 'Cirrhotic'}, {'cui': 'C0341439', 'cui_str': 'Chronic liver disease'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0053454', 'cui_str': '3-hydroxyisovaleric acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0037688', 'cui_str': 'Sorbitol'}, {'cui': 'C0032861', 'cui_str': 'Powder'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C4075886', 'cui_str': 'Frailty Index'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0023895', 'cui_str': 'Disease of liver'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}]",24.0,0.0725513,"p < 0.05; six-minute walk test: 361.8 ± 68 m vs. 409.4 ± 58 m, p < 0.05).","[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Lattanzi', 'Affiliation': 'Gastroenterology, Department of Translational and Precision Medicine, ""Sapienza"" University, 00185 Rome, Italy.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Bruni', 'Affiliation': 'Gastroenterology, Department of Translational and Precision Medicine, ""Sapienza"" University, 00185 Rome, Italy.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Di Cola', 'Affiliation': 'Gastroenterology, Department of Translational and Precision Medicine, ""Sapienza"" University, 00185 Rome, Italy.'}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Molfino', 'Affiliation': 'Internal Medicine, Department of Translational and Precision Medicine, ""Sapienza"" University, 00185 Rome, Italy.'}, {'ForeName': 'Adriano', 'Initials': 'A', 'LastName': 'De Santis', 'Affiliation': 'Gastroenterology, Department of Translational and Precision Medicine, ""Sapienza"" University, 00185 Rome, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Muscaritoli', 'Affiliation': 'Internal Medicine, Department of Translational and Precision Medicine, ""Sapienza"" University, 00185 Rome, Italy.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Merli', 'Affiliation': 'Gastroenterology, Department of Translational and Precision Medicine, ""Sapienza"" University, 00185 Rome, Italy.'}]",Nutrients,['10.3390/nu13072296'] 2345,34371803,Pharmacodynamics of Oral Cholecalciferol in Healthy Individuals with Vitamin D Deficiency: A Randomized Open-Label Study.,"Comparative pharmacodynamic (PD) analyses on different dosing schedules for cholecalciferol supplementation are limited. This was an open-label, randomized, parallel-group study involving 75 healthy individuals deficient in vitamin D (baseline 25OHD < 20 ng/mL) receiving oral cholecalciferol with three different dosing regimens: Group A: 10,000 IU/day for 8 weeks followed by 1000 IU/day for 4 weeks; Group B: 50,000 IU/week for 12 weeks and Group C: 100,000 IU every other week for 12 weeks. Regulators of calcium and phosphate homeostasis, bone turnover markers and Wnt inhibitors were measured at baseline, Day 28, 53, 84, and 112. The 1,25OH2D increased at each time point. The increase was greater ( p < 0.05) for group A vs. B and C at Day 28, and vs. group B at Day 56. No significant difference among groups was observed for the other biomarkers. The 24,25OH2D remained stable over time. PTH decreased at Day 84 and FGF-23 increased at all time points. CTX-I and PINP increased slightly at Day 28. BALP decreased from Day 56 onward. Dkk-1 increased from Day 56 onward, while sclerostin did not show significant changes. In healthy individuals deficient in vitamin D, vitamin D supplementation exerted effects on multiple regulators of calcium, phosphate and bone metabolism, without marked differences using the three regimens.",2021,"The increase was greater ( p < 0.05) for group A vs. B and C at Day 28, and vs. group B at Day 56.","['healthy individuals deficient in', '75 healthy individuals deficient in vitamin D (baseline 25OHD', 'Healthy Individuals with Vitamin D Deficiency']","['vitamin D, vitamin D supplementation', 'oral cholecalciferol', 'Oral Cholecalciferol']","['CTX-I and PINP', 'multiple regulators of calcium, phosphate and bone metabolism', 'PTH', 'BALP']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0042870', 'cui_str': 'Vitamin D deficiency'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0631180', 'cui_str': 'C-telopeptide'}, {'cui': 'C0072053', 'cui_str': 'Procollagen peptide, type 1 N-terminal'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0020063', 'cui_str': 'PTH protein, human'}, {'cui': 'C0312399', 'cui_str': 'Alkaline phosphatase isoenzyme, bone fraction'}]",75.0,0.153084,"The increase was greater ( p < 0.05) for group A vs. B and C at Day 28, and vs. group B at Day 56.","[{'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Fassio', 'Affiliation': 'Rheumatology Unit, University of Verona, 37134 Verona, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Gatti', 'Affiliation': 'Rheumatology Unit, University of Verona, 37134 Verona, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Rossini', 'Affiliation': 'Rheumatology Unit, University of Verona, 37134 Verona, Italy.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Benini', 'Affiliation': 'Rheumatology Unit, University of Verona, 37134 Verona, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Fracassi', 'Affiliation': 'Rheumatology Unit, University of Verona, 37134 Verona, Italy.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Bertoldo', 'Affiliation': 'Rheumatology Unit, University of Verona, 37134 Verona, Italy.'}, {'ForeName': 'Ombretta', 'Initials': 'O', 'LastName': 'Viapiana', 'Affiliation': 'Rheumatology Unit, University of Verona, 37134 Verona, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Milleri', 'Affiliation': 'Centro Ricerche Cliniche di Verona, 37134 Verona, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Gatti', 'Affiliation': 'Rheumatology Unit, University of Verona, 37134 Verona, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Adami', 'Affiliation': 'Rheumatology Unit, University of Verona, 37134 Verona, Italy.'}]",Nutrients,['10.3390/nu13072293'] 2346,34371537,[Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].,"Objective: To observe the dynamic changes of serum RANTES during the treatment with nucleos(t)ide analogues combined with pegylated interferon alpha (peginterferon-α), and further analyze the predictive effect of RANTES on HBsAg clearance in patients with chronic hepatitis B. Methods: 98 cases of chronic hepatitis B with quantitative HBsAg < 3 000 IU/ml and HBV DNA < 20 IU/ml after≥1 year NAs treatment were enrolled. Among them, 26 cases continued to receive NAs monotherapy, 72 cases received NAs combined with pegylated interferon alpha therapy. The changes in RANTES during treatment were observed. The receiver operating characteristic curve was used to analyze the early changes of RANTES to predict the HBsAg clearance during 48 weeks. Results: During 48 weeks, 15 cases (20.83%) had achieved HBsAg clearance in combination group, while no patient had achieved HBsAg clearance in NAs group. The overall serum RANTES level had decreased from baseline in NAs and combination group. At week 48, in the combination group, the serum RANTES level was decreased more significantly in patients with HBsAg clearance than patients without. Further analysis showed that, in combination group, HBsAg clearance rate of patients with serum RANTES decreased at week 12 and 24 was higher than patients with elevated (29.17% vs. 4.17%, P = 0.014; 28.00% vs. 4.55%, P = 0.052), and quantitative HBsAg reduction was larger significantly [(1.49 ± 1.26) log(10)IU/ml vs. (0.73 ± 0.81) log(10)IU/ml, P = 0.017; (1.54 ± 1.27) log(10)IU/ml vs. (0.57 ± 0.56) log(10)IU/ml, P = 0.004]. Receiver operating characteristic curve analysis showed that the baseline quantitative HBsAg and the reduction in quantitative HBsAg and serum RANTES during the early period were predictors of HBsAg clearance after 48-week combination therapy. Furthermore, the combination of baseline quantitative HBsAg and 12 - or 24-week reduction of serum RANTES were better predictors of HBsAg clearance than that of baseline quantitative HBsAg combined with HBsAg decrease at week 12 or 24. The area under the receiver operating characteristic curve of the former was 0.925 and 0.939, while that of the latter was 0.909 and 0.929, respectively. Conclusion: Early reduction of serum RANTES at week 12 and 24 can predict HBsAg loss in CHB patients receiving addition of peginterferon-α to ongoing NAs Therapy, so serum RANTES could be one of the key immunological markers for predicting HBsAg clearance.",2021,"At week 48, in the combination group, the serum RANTES level was decreased more significantly in patients with HBsAg clearance than patients without.","['patients with chronic hepatitis B', 'patients with chronic hepatitis B treated with', 'CHB patients receiving addition of']","['nucleos(t)ide analogues combined with pegylated interferon alpha (peginterferon-α', 'peginterferon-α', 'NAs combined with pegylated interferon alpha therapy', 'nucleos(t)ide analogues combined with peginterferon alpha', 'quantitative HBsAg < 3 000 IU/ml and HBV DNA']","['HBsAg clearance', 'HBsAg clearance rate', 'quantitative HBsAg reduction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0151517', 'cui_str': 'Complete atrioventricular block'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C1579410', 'cui_str': 'Nucleoside analog'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002199', 'cui_str': 'interferon alfa natural'}, {'cui': 'C0027446', 'cui_str': 'National Academy of Sciences (U.S.)'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0019168', 'cui_str': 'Hepatitis B surface antigen'}, {'cui': 'C0439458', 'cui_str': 'IU/mL'}, {'cui': 'C0019163', 'cui_str': 'Type B viral hepatitis'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}]","[{'cui': 'C0019168', 'cui_str': 'Hepatitis B surface antigen'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0025515', 'cui_str': 'Metabolic clearance rate'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.0336375,"At week 48, in the combination group, the serum RANTES level was decreased more significantly in patients with HBsAg clearance than patients without.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Jia', 'Affiliation': 'Medical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.'}, {'ForeName': 'W X', 'Initials': 'WX', 'LastName': 'Wang', 'Affiliation': 'Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.'}, {'ForeName': 'Y Y', 'Initials': 'YY', 'LastName': 'Gao', 'Affiliation': 'Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.'}, {'ForeName': 'J Q', 'Initials': 'JQ', 'LastName': 'Luan', 'Affiliation': 'Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Qiao', 'Affiliation': 'Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.'}, {'ForeName': 'J Y', 'Initials': 'JY', 'LastName': 'Liu', 'Affiliation': 'Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.'}, {'ForeName': 'J H', 'Initials': 'JH', 'LastName': 'Yuan', 'Affiliation': 'Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.'}, {'ForeName': 'Y Q', 'Initials': 'YQ', 'LastName': 'Cheng', 'Affiliation': 'Department of Geriatric Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.'}, {'ForeName': 'F S', 'Initials': 'FS', 'LastName': 'Wang', 'Affiliation': 'Medical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Fu', 'Affiliation': 'Medical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.'}]",Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,['10.3760/cma.j.cn501113-20210706-00322'] 2347,34371382,"ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.","BACKGROUND The purpose of this study was to assess the concordance of real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) detection of ESR1, PGR, ERBB2, and MKi67 messenger RNA (mRNA) in breast cancer tissues with central immunohistochemistry (IHC) in women treated within the prospective, randomized Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6. PATIENTS AND METHODS We evaluated ESR1, PGR, ERBB2, and MKi67 mRNA expression by Xpert® Breast Cancer STRAT4 (enables cartridge-based RT-qPCR detection of mRNA in formalin-fixed paraffin-embedded tissues) and estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 protein expression by IHC [in situ hybridization (ISH) for HER2 IHC 2+] in 1115 surgical formalin-fixed paraffin-embedded specimens from patients of ABCSG Trial 6. Overall percent agreement (concordance), positive percent agreement (sensitivity), and negative percent agreement (specificity) between STRAT4 and IHC were determined for each marker. The primary objective of the study was concordance between STRAT4 mRNA measurements of ESR1, PGR, ERBB2, and MKi67 with central reference laboratory IHC (and ISH for HER2 IHC 2+ cases). Time to distant recurrence was analyzed by Cox models. RESULTS All performance targets for ER, PR, and Ki67 were met. For HER2, the negative percent agreement target but not the positive percent agreement target was met. Concordance between STRAT4 and IHC was 98.9% for ER, 89.9% for PR, 98.2% for HER2, and 84.8% for Ki67 (excluding intermediate IHC 10%-20% staining). In univariable and multivariable Cox regression analyses, all four biomarkers tested by either STRAT4 RT-qPCR or by central IHC (ISH) had a comparable time to distant recurrence indicating similar prognostic value. CONCLUSIONS With the exception of HER2, we demonstrate high concordance between centrally assessed IHC and mRNA measurements of ER, PR, and Ki67 as well as a high correlation of the two methods with clinical outcome. Thus, mRNA-based assessment by STRAT4 is a promising new tool for diagnostic and therapeutic decisions in breast cancer.",2021,"Concordance between STRAT4 and IHC was 98.9% for ER, 89.9% for PR, 98.2% for HER2, and 84.8% for Ki67 (excluding intermediate IHC 10%-20% staining).","['1115 surgical formalin-fixed paraffin-embedded specimens from patients of ABCSG Trial 6', 'postmenopausal women with hormone receptor-positive early breast cancer', 'breast cancer tissues with central immunohistochemistry (IHC) in women treated within the prospective, randomized Austrian Breast and Colorectal Cancer Study Group (ABCSG']",[],"['ESR1, PGR, ERBB2, and MKi67 messenger RNA (mRNA', 'ESR1, PGR, ERBB2, and MKi67 mRNA expression', 'Time to distant recurrence', 'ESR1, PGR, ERBB2, and MKi67 with central reference laboratory IHC (and ISH for HER2 IHC 2+ cases']","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0949307', 'cui_str': 'Formalin'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0030415', 'cui_str': 'Paraffin'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0337795', 'cui_str': 'Austrians'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],"[{'cui': 'C1521863', 'cui_str': 'estrogen receptor alpha, human'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0208804', 'cui_str': 'Antigen Ki-67'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1532342', 'cui_str': 'Reference laboratory'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C0162788', 'cui_str': 'Hybridization in Situ'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0868928', 'cui_str': 'Case'}]",6.0,0.106811,"Concordance between STRAT4 and IHC was 98.9% for ER, 89.9% for PR, 98.2% for HER2, and 84.8% for Ki67 (excluding intermediate IHC 10%-20% staining).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Filipits', 'Affiliation': 'Institute of Cancer Research, Department of Medicine I, Breast Health Center and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: martin.filipits@meduniwien.ac.at.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rudas', 'Affiliation': 'Institute of Cancer Research, Department of Medicine I, Breast Health Center and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'C F', 'Initials': 'CF', 'LastName': 'Singer', 'Affiliation': 'Department of Gynecology, Breast Health Center and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Fitzal', 'Affiliation': 'Department of General Surgery, Breast Health Center and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Bago-Horvath', 'Affiliation': 'Department of Pathology, Breast Health Center and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Greil', 'Affiliation': '3(rd) Medical Department, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Balic', 'Affiliation': 'Department of Internal Medicine, Division of Oncology, Medical University Graz, Graz, Austria.'}, {'ForeName': 'S F', 'Initials': 'SF', 'LastName': 'Lax', 'Affiliation': 'Department of Pathology, Hospital Graz II, Graz, Austria; Johannes Kepler University Linz, Linz, Austria.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Halper', 'Affiliation': 'Department of Surgery, Breast Health Center, Hospital Wiener Neustadt, Wiener Neustadt, Austria.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Hulla', 'Affiliation': 'Department of Clinical Pathology and Molecular Pathology, Breast Health Center, Hospital Wiener Neustadt, Wiener Neustadt, Austria.'}, {'ForeName': 'N C', 'Initials': 'NC', 'LastName': 'Wu', 'Affiliation': 'Oncology Research and Development, Cepheid, Sunnyvale, USA.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Clinical Data Management and Analytics, Cepheid, Sunnyvale, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Weidler', 'Affiliation': 'Medical and Scientific Affairs and Strategy, Oncology, Cepheid, Sunnyvale, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bates', 'Affiliation': 'Medical and Scientific Affairs and Strategy, Oncology, Cepheid, Sunnyvale, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Hlauschek', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gnant', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Dubsky', 'Affiliation': 'St. Anna Breast Center, Hirslanden Klinik St. Anna, Lucerne, Switzerland; Department of General Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.'}]",ESMO open,['10.1016/j.esmoop.2021.100228'] 2348,34371381,Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.,"BACKGROUND In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (GEJ) cancer. We present findings of prespecified health-related quality-of-life (HRQOL) analyses for pembrolizumab versus chemotherapy in this population. MATERIALS AND METHODS HRQOL, a secondary endpoint, was measured in patients who received ≥1 dose of study treatment and completed ≥1 HRQOL questionnaire [European Organisation for the Research and Treatment of Cancer (EORTC) 30-question quality-of-life (QLQ-C30), EORTC 22-question quality-of-life gastric-cancer-specific module (QLQ-STO22)]. Least squares mean (LSM) change (baseline to week 18) in global health status/quality of life (GHS/QOL; EORTC QLQ-C30) and time to deterioration (TTD) in GHS/QOL, nausea/vomiting and appetite loss scores (EORTC QLQ-C30) and abdominal pain/discomfort scores (EORTC QLQ-STO22) were evaluated. RESULTS The HRQOL population comprised 495 patients with CPS ≥1 (pembrolizumab, 252; chemotherapy, 243). Compliance rates at week 18 were similar for pembrolizumab and chemotherapy (EORTC QLQ-C30, 87.9% and 81.9%; EORTC QLQ-STO22, 87.9% and 81.3%, respectively). There was no between-arm difference in LSM score change in GHS/QOL [-0.16; 95% confidence interval (CI) -5.01 to 4.69; P = 0.948]. The LSM score change for most subscales showed comparable worsening in both arms. TTD for GHS/QOL [hazard ratio (HR), 0.96; 95% CI, 0.67-1.38; P = 0.826], appetite loss (HR, 0.83; 95% CI, 0.58-1.20; P = 0.314) and pain (HR, 1.22; 95% CI, 0.78-1.91; P = 0.381) were similar between arms. Longer TTD was observed for pembrolizumab versus chemotherapy for nausea/vomiting (HR, 0.61; 95% CI, 0.44-0.85; P = 0.003). CONCLUSIONS HRQOL was maintained with first-line treatment with pembrolizumab in patients with PD-L1-positive advanced gastric/GEJ cancer and was similar between pembrolizumab and chemotherapy in this population.",2021,"TTD for GHS/QOL [hazard ratio (HR), 0.96; 95% CI, 0.67-1.38; P = 0.826], appetite loss (HR, 0.83; 95% CI, 0.58-1.20; P = 0.314) and pain (HR, 1.22; 95% CI, 0.78-1.91; P = 0.381) were similar between arms.","['495 patients with CPS ≥1 (pembrolizumab, 252; chemotherapy, 243', 'patients with PD-L1-positive advanced gastric/GEJ cancer', '≥1] advanced gastric/gastroesophageal junction (GEJ) cancer', 'PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma', 'patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS']","['first-line pembrolizumab', 'pembrolizumab versus chemotherapy', 'pembrolizumab', 'pembrolizumab and chemotherapy']","['overall survival', 'global health status/quality of life (GHS/QOL; EORTC QLQ-C30) and time to deterioration (TTD) in GHS/QOL, nausea/vomiting and appetite loss scores (EORTC QLQ-C30) and abdominal pain/discomfort scores (EORTC QLQ-STO22', 'Quality of life', 'nausea/vomiting', 'Compliance rates', 'LSM score change', 'appetite loss', 'pain', 'LSM score change in GHS/QOL', 'HRQOL questionnaire [European Organisation for the Research and Treatment of Cancer (EORTC) 30-question quality-of-life (QLQ-C30), EORTC 22-question quality-of-life gastric-cancer-specific module (QLQ-STO22']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1332166', 'cui_str': 'Adenocarcinoma of the gastroesophageal junction'}]","[{'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C3542953', 'cui_str': 'Module'}]",495.0,0.235473,"TTD for GHS/QOL [hazard ratio (HR), 0.96; 95% CI, 0.67-1.38; P = 0.826], appetite loss (HR, 0.83; 95% CI, 0.58-1.20; P = 0.314) and pain (HR, 1.22; 95% CI, 0.78-1.91; P = 0.381) were similar between arms.","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Van Cutsem', 'Affiliation': 'Department of Digestive Oncology, University Hospital Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. Electronic address: eric.vancutsem@uzleuven.be.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Valderrama', 'Affiliation': 'Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'Y-J', 'Initials': 'YJ', 'LastName': 'Bang', 'Affiliation': 'Department of Biomedical Research, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'C S', 'Initials': 'CS', 'LastName': 'Fuchs', 'Affiliation': 'Department of Internal Medicine: Hematology, Medical Oncology, Gastro-oncology, Yale University Cancer Center, Smilow Cancer Hospital, New Haven, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Shitara', 'Affiliation': 'Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Y Y', 'Initials': 'YY', 'LastName': 'Janjigian', 'Affiliation': 'Department of Gastrointestinal Oncology, Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Qin', 'Affiliation': 'Cancer Center, PLA Cancer Centre of Nanjing Bayi Hospital, Nanjing, China.'}, {'ForeName': 'T G', 'Initials': 'TG', 'LastName': 'Larson', 'Affiliation': 'Department of Hematology/Oncology, Minnesota Oncology Hematology, Minneapolis.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Shankaran', 'Affiliation': 'Department of Medical Oncology, Seattle Cancer Care Alliance, Seattle.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Stein', 'Affiliation': 'Department of Internal Medicine: Hematology, Medical Oncology, Gastro-oncology, Yale University Cancer Center, Smilow Cancer Hospital, New Haven, USA.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Norquist', 'Affiliation': 'Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Kher', 'Affiliation': 'Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Shah', 'Affiliation': 'Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Alsina', 'Affiliation': ""Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona; University Autònoma de Barcelona, Barcelona, Spain.""}]",ESMO open,['10.1016/j.esmoop.2021.100189'] 2349,34371324,A comparative study of dexmedetomidine and propofol to prevent recovery agitation in adults undergoing procedural sedation with ketamine: A randomized double-blind clinical trial.,"BACKGROUND The present study was designed to evaluate the effect of dexmedetomidine and propofol on ketamine-induced recovery agitation in adults when used as co-administration with ketamine. METHODS In this prospective, randomized, and double-blind clinical trial, 93 patients aged 18 years or older who were candidates for painful procedures in the emergency department (ED) were enrolled and assigned into three equal groups to receive either ketadex (dexmedetomidine 0.7 μg/kg and ketamine 1 mg/kg), ketofol (propofol 0.5 mg/kg and ketamine 0.5 mg/kg) or ketamine alone (1 mg/kg) intravenously. Incidence and severity of recovery agitation were evaluated using the Richmond Agitation-Sedation Scale and compared between groups. RESULTS There were no significant differences in demographic characteristics, procedures, pain scores, pre-sedation agitation, and duration of procedure between the three groups. The incidence of recovery agitation was 26% in the Ketadex group, 29% in the Ketofol group, and 58% in the Ketamine group. The difference in incidence of recovery agitation between Ketadex group and Ketamine group was 32% (95% confidence interval (CI), 9 to 56]) and between Ketofol group and Ketamine group was 29% (95% CI, 6 to 53). The severe agitation was significantly higher in Ketamine group, with a difference between Ketamine and Ketadex group of 19% (95% CI, 6 to 33), and a difference between Ketamine and Ketofol group of 16% (95% CI, 1 to 31). CONCLUSIONS In this study, a combination of ketamine-dexmedetomidine and ketamine-propofol reduced the incidence and severity of ketamine-induced recovery agitation in adults undergoing procedural sedation in the ED.",2021,"There were no significant differences in demographic characteristics, procedures, pain scores, pre-sedation agitation, and duration of procedure between the three groups.","['adults when used as co-administration with ketamine', 'adults undergoing procedural sedation with', '93 patients aged 18 years or older who were candidates for painful procedures in the emergency department (ED', 'adults undergoing procedural sedation in the ED']","['Ketamine', 'ketamine-dexmedetomidine and ketamine-propofol', 'ketadex (dexmedetomidine 0.7 μg/kg and ketamine 1 mg/kg), ketofol (propofol 0.5 mg/kg and ketamine 0.5 mg/kg) or ketamine alone', 'dexmedetomidine and propofol', 'ketamine']","['incidence of recovery agitation', 'demographic characteristics, procedures, pain scores, pre-sedation agitation, and duration of procedure', 'recovery agitation', 'Incidence and severity of recovery agitation', 'severe agitation', 'Richmond Agitation-Sedation Scale']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C4517474', 'cui_str': '0.7'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0444500', 'cui_str': '0.5'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C4720839', 'cui_str': 'Richmond agitation-sedation scale'}]",93.0,0.256148,"There were no significant differences in demographic characteristics, procedures, pain scores, pre-sedation agitation, and duration of procedure between the three groups.","[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Azizkhani', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: r_azizkhani@med.mui.ac.ir.'}, {'ForeName': 'Soheila', 'Initials': 'S', 'LastName': 'Kouhestani', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: dr.kouhestani@gmail.com.'}, {'ForeName': 'Farhad', 'Initials': 'F', 'LastName': 'Heydari', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: farhad_heidari@med.mui.ac.ir.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Majidinejad', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2021.07.059'] 2350,34371299,"Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT).","OBJECTIVES Immune checkpoint inhibition after radiochemotherapy (RTCT) has become a new standard of care for locally advanced non-small cell lung cancer with programmed death-ligand 1 (PD-L1) expression. However, little is known about the prognostic role of immune response markers in this setting. We analysed PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in tumour biopsies from the multicenter German Intergroup Lung Trial (GILT), which previously randomised patients with stage III NSCLC to RTCT with or without consolidation chemotherapy. MATERIALS AND METHODS We retrospectively analyzed tumour biopsies from patients treated in the GILT trial. PD-L1 expression was analysed using the Ventana SP263 assay and TiL score (low, intermediate, high) and pattern (excluded, inflamed, desert) were assessed. The primary endpoint of the biomarker analysis was PFS in patients with PD-L1 ≥ 1% vs. PD-L1 < 1% NSCLC. Secondary endpoints explored the prognostic relevance of additional PD-L1 expression levels and TiL score and pattern. RESULTS Biopsies were available from 92 patients treated with RTCT. Patients with available tumor tissue did not differ significantly from the whole study population. PD-L1 scores from 78 samples were available for analysis. There was no difference in PFS in the PD-L1 < 1% vs. PD-L1 ≥ 1% subgroups. TiL score was available in 66 patients. Patients with high TiL score showed favourable overall survival compared to the low TiL subgroup. This trend was most pronounced in those patients treated with consolidative chemotherapy. CONCLUSION In this analysis, PD-L1 expression did not correlate with PFS following RTCT. However, patients with TiLs > 10% were found to have longer overall survival, especially for those patients treated with consolidation chemotherapy after the end of RTCT. Further analyses to explore the prognostic and predictive relevance of TiLs in the context of consolidative checkpoint inhibition with durvalumab are required.",2021,There was no difference in PFS in the PD-L1 ,"['We retrospectively analyzed tumour biopsies from patients treated in the GILT trial', '66 patients', 'patients with stage III NSCLC to RTCT with or without consolidation chemotherapy']","['simultaneous radiochemotherapy', 'radiochemotherapy (RTCT', 'RTCT']","['overall survival', 'TiL score', 'prognostic relevance of additional PD-L1 expression levels and TiL score and pattern', 'PFS', 'Ventana SP263 assay and TiL score', 'PD-L1 scores', 'PD-L1 expression']","[{'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278506', 'cui_str': 'Non-small cell lung cancer stage III'}, {'cui': 'C3179017', 'cui_str': 'Consolidation Chemotherapy'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0079722', 'cui_str': 'Tumor-Infiltrating Lymphocytes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}]",,0.127373,There was no difference in PFS in the PD-L1 ,"[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Tufman', 'Affiliation': 'Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz 31, 81377 Munich, Germany. Electronic address: Amanda.Tufman@med.uni-muenchen.de.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Neumann', 'Affiliation': 'Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany. Electronic address: Jens.Neumann@med.uni-muenchen.de.'}, {'ForeName': 'Farkhad', 'Initials': 'F', 'LastName': 'Manapov', 'Affiliation': 'Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany. Electronic address: Farkhad.Manapov@med.uni-muenchen.de.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Sellmer', 'Affiliation': 'Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz 31, 81377 Munich, Germany. Electronic address: Laura.Sellmer@med.uni-muenchen.de.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Jung', 'Affiliation': 'Institute of Pathology, Faculty of Medicine, LMU Munich, Thalkirchner Str. 36, 80337 Munich, Germany. Electronic address: Andreas.Jung@med.uni-muenchen.de.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Kauffmann-Guerrero', 'Affiliation': 'Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz 31, 81377 Munich, Germany. Electronic address: Diego.KauffmannGuerrero@med.uni-muenchen.de.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Kahnert', 'Affiliation': 'Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz 31, 81377 Munich, Germany. Electronic address: Kathrin.Kahnert@med.uni-muenchen.de.'}, {'ForeName': 'Pontus', 'Initials': 'P', 'LastName': 'Mertsch', 'Affiliation': 'Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz 31, 81377 Munich, Germany. Electronic address: Pontus.Mertsch@med.uni-muenchen.de.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Borgmeier', 'Affiliation': 'Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz 31, 81377 Munich, Germany. Electronic address: Astrid.Borgmeier@med.uni-muenchen.de.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Semrau', 'Affiliation': 'Department of Radiation Oncology, University Hospital Erlangen, Universitätsstr. 27, 91054 Erlangen, Germany. Electronic address: Sabine.Semrau@uk-erlangen.de.'}, {'ForeName': 'Achim', 'Initials': 'A', 'LastName': 'Rittmeyer', 'Affiliation': 'Department of Pneumology, Lung Clinic Immenhausen, Robert-Koch-Str. 3, 34376 Immenhausen, Germany. Electronic address: arittmeyer@lungenfachklinik-immenhausen.de.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Ulm', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, School of Medicine, Technical University of Munich, Munich, Germany. Electronic address: Bernhard.ulm@tum.de.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Ulm', 'Affiliation': 'Institute of Medical Informatics, Statistics and Epidemiology, Technical University of Munich, Ismaninger Str 22, 81675 Munich, Germany. Electronic address: kurt.ulm@tum.de.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Flentje', 'Affiliation': 'Department of Radiation Oncology, University Hospital Würzburg, Josef-Schneider Str. 2, 97080 Würzburg, Germany. Electronic address: flentje_m@ukw.de.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Fietkau', 'Affiliation': 'Department of Radiation Oncology, University Hospital Erlangen, Universitätsstr. 27, 91054 Erlangen, Germany. Electronic address: Rainer.Fietkau@uk-erlangen.de.'}, {'ForeName': 'Rudolf Maria', 'Initials': 'RM', 'LastName': 'Huber', 'Affiliation': 'Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz 31, 81377 Munich, Germany. Electronic address: Huber@med.uni-meunchen.de.'}]","Lung cancer (Amsterdam, Netherlands)",['10.1016/j.lungcan.2021.07.008'] 2351,34371253,Self-reported exercise capacity among current smokers eligible for lung cancer screening: Distribution and association with key comorbidities.,"ONE CONCERN: as lung cancer screening (LCS) is implemented is that patients will be screened who are too ill to benefit. Poor exercise capacity (EC) predicts adverse outcomes following lung resection. OBJECTIVE Describe the distribution of EC among smokers eligible for LCS and examine associations with comorbidities. METHODS Cross-sectional analysis of baseline data from a randomized controlled trial of tobacco treatment in the context of LCS. Participants responded regarding limitations in moderate activities, ability to climb stairs, and frequency of dyspnea on a scale from never/almost never to all or most of the time. Responses were assigned a numeric score and summed to categorize exercise limitation. Associations between poor EC and key comorbidities were examined using adjusted logistic regression. RESULTS 660 participants completed a survey with the following characteristics: 64.4% male, 89.5% white, mean age 64.5. Overall EC categories were: good 39.0%, intermediate 41.6%, and poor 19.4%.  Prevalence of poor EC was higher among patients with COPD (OR 4.62 95%CI 3.05-7.02), heart failure (OR 3.07 95%CI 1.62-5.82) and cardiovascular disease (OR 2.24, 95%CI 1.45-3.47), and was highest among patients with multimorbidity. Among patients with COPD and heart failure, 57% had poor and 0% had good EC. In adjusted logistic regression, only COPD and Charlson comorbidity index remained significantly associated with poor EC. CONCLUSIONS Many patients eligible for LCS reported poor EC, with increased odds of poor EC among patients with comorbidities. More research is needed to determine how to best integrate EC and comorbidity into eligibility and shared decision-making conversations.",2021,"Prevalence of poor EC was higher among patients with COPD (OR 4.62 95%CI 3.05-7.02), heart failure (OR 3.07 95%CI 1.62-5.82) and cardiovascular disease (OR 2.24, 95%CI 1.45-3.47), and was highest among patients with multimorbidity.","['patients with COPD and heart failure, 57% had poor and 0% had good EC', 'current smokers eligible for lung cancer screening', 'lung resection', '660 participants completed a survey with the following characteristics: 64.4% male, 89.5% white, mean age 64.5']","['tobacco', 'Poor exercise capacity (EC']","['moderate activities, ability to climb stairs, and frequency of dyspnea', 'heart failure', 'Prevalence of poor EC', 'COPD and Charlson comorbidity index', 'cardiovascular disease', 'Overall EC categories']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0281477', 'cui_str': 'Screening for malignant neoplasm of lung'}, {'cui': 'C0396565', 'cui_str': 'Lung excision'}, {'cui': 'C4517845', 'cui_str': '660'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0560076', 'cui_str': 'Ability to walk up stairs'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C4546361', 'cui_str': 'Charlson Comorbidity Index'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",660.0,0.232999,"Prevalence of poor EC was higher among patients with COPD (OR 4.62 95%CI 3.05-7.02), heart failure (OR 3.07 95%CI 1.62-5.82) and cardiovascular disease (OR 2.24, 95%CI 1.45-3.47), and was highest among patients with multimorbidity.","[{'ForeName': 'Anne C', 'Initials': 'AC', 'LastName': 'Melzer', 'Affiliation': 'Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, United States; Division of Pulmonary, Allergy, Critical Care and Sleep, University of Minnesota Medical School, United States. Electronic address: acmelzer@umn.edu.'}, {'ForeName': 'Abbie', 'Initials': 'A', 'LastName': 'Begnaud', 'Affiliation': 'Division of Pulmonary, Allergy, Critical Care and Sleep, University of Minnesota Medical School, United States.'}, {'ForeName': 'Bruce R', 'Initials': 'BR', 'LastName': 'Lindgren', 'Affiliation': 'Masonic Cancer Center, University of Minnesota, United States.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Schertz', 'Affiliation': 'Department of Medicine, University of Minnesota Medical School, United States.'}, {'ForeName': 'Steven S', 'Initials': 'SS', 'LastName': 'Fu', 'Affiliation': 'Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, United States; Department of Medicine, University of Minnesota Medical School, United States.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Vock', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, United States.'}, {'ForeName': 'Alexander J', 'Initials': 'AJ', 'LastName': 'Rothman', 'Affiliation': 'Department of Psychology, University of Minnesota, United States.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Joseph', 'Affiliation': 'Masonic Cancer Center, University of Minnesota, United States; Department of Medicine, University of Minnesota Medical School, United States.'}]",Cancer treatment and research communications,['10.1016/j.ctarc.2021.100443'] 2352,34371209,Analgesia induced by anodal tDCS and high-frequency tRNS over the motor cortex: Immediate and sustained effects on pain perception.,"BACKGROUND Many studies have shown effects of anodal transcranial direct current stimulation (a-tDCS) and high-frequency transcranial random noise stimulation (tRNS) on elevating cortical excitability. Moreover, tRNS with a direct current (DC)-offset is more likely to lead to increases in cortical excitability than solely tRNS. While a-tDCS over primary motor cortex (M1) has been shown to attenuate pain perception, tRNS + DC-offset may prove as an effective means for pain relief. OBJECTIVE This study aimed to examine effects of a-tDCS and high-frequency tRNS + DC-offset over M1 on pain expectation and perception, and assess whether these effects could be influenced by the certainty of pain expectation. METHODS Using a double-blinded and sham-controlled design, 150 healthy participants were recruited to receive a single-session a-tDCS, high-frequency tRNS + DC-offset, or sham stimulation over M1. The expectation and perception of electrical stimulation in certain and uncertain contexts were assessed at baseline, immediately after, and 30 min after stimulation. RESULTS Compared with sham stimulation, a-tDCS induced immediate analgesic effects that were greater when the stimulation outcome was expected with uncertainty; tRNS induced immediate and sustained analgesic effects that were mediated by decreasing pain expectation. Nevertheless, we found no strong evidence for tRNS being more effective for attenuating pain than a-tDCS. CONCLUSIONS The analgesic effects of a-tDCS and tRNS showed different temporal courses, which could be related to the more sustained effectiveness of high-frequency tRNS + DC-offset in elevating cortical excitability. Moreover, expectations of pain intensity should be taken into consideration to maximize the benefits of neuromodulation.",2021,"Compared with sham stimulation, a-tDCS induced immediate analgesic effects that were greater when the stimulation outcome was expected with uncertainty; tRNS induced immediate and sustained analgesic effects that were mediated by decreasing pain expectation.",['150 healthy participants'],"['anodal transcranial direct current stimulation (a-tDCS) and high-frequency transcranial random noise stimulation (tRNS', 'single-session a-tDCS, high-frequency tRNS\xa0+\xa0DC-offset, or sham stimulation over M1', 'anodal tDCS and high-frequency tRNS', 'tDCS and high-frequency tRNS\xa0+\xa0DC-offset over M1']","['cortical excitability', 'immediate and sustained analgesic effects', 'pain expectation', 'immediate analgesic effects', 'pain perception']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C3852967', 'cui_str': 'Transcranial Random Noise Stimulation'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0442831', 'cui_str': 'Direct current'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C4277734', 'cui_str': 'Cortical Excitability'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",150.0,0.073486,"Compared with sham stimulation, a-tDCS induced immediate analgesic effects that were greater when the stimulation outcome was expected with uncertainty; tRNS induced immediate and sustained analgesic effects that were mediated by decreasing pain expectation.","[{'ForeName': 'Junjie', 'Initials': 'J', 'LastName': 'Yao', 'Affiliation': 'School of Psychology, Shenzhen University, Shenzhen, Guangdong, China.'}, {'ForeName': 'Xiaoyun', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'School of Psychology, Shenzhen University, Shenzhen, Guangdong, China.'}, {'ForeName': 'Wenyun', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'School of Psychology, Shenzhen University, Shenzhen, Guangdong, China.'}, {'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Lin', 'Affiliation': 'School of Psychology, Shenzhen University, Shenzhen, Guangdong, China.'}, {'ForeName': 'Xiaohan', 'Initials': 'X', 'LastName': 'Lyu', 'Affiliation': 'School of Psychology, Shenzhen University, Shenzhen, Guangdong, China.'}, {'ForeName': 'Wutao', 'Initials': 'W', 'LastName': 'Lou', 'Affiliation': 'Department of Biomedical Engineering, The Chinese University of Hong Kong, Hong Kong SAR, China.'}, {'ForeName': 'Weiwei', 'Initials': 'W', 'LastName': 'Peng', 'Affiliation': 'School of Psychology, Shenzhen University, Shenzhen, Guangdong, China. Electronic address: ww.peng0923@gmail.com.'}]",Brain stimulation,['10.1016/j.brs.2021.07.011'] 2353,34371176,Endoscopic versus percutaneous biliary drainage for resectable pancreatic head cancer with hyperbilirubinemia and impact on pancreaticoduodenectomy: A randomized controlled study.,"BACKGROUND We hypothesized that percutaneous biliary drainage provides more short-term advantages over endoscopic stenting before pancreaticoduodenectomy. METHODS Between January 2019 and December 2010, a prospective cohort study was conducted. Sixty patients with potentially resectable pancreatic head cancers and high bilirubin levels were stratified into two equal groups according to the method of biliary drainage: endoscopic stenting or percutaneous drainage. The primary outcome measures were operative difficulties and early postoperative morbidity, the secondary outcome was post-drainage complications. RESULTS Both groups were comparable in age; gender; presenting symptoms, type of malignancy, post-drainage complications, and time intervals between drainage and surgery. Key preoperative significant differences were technically higher but clinical success rates was better in the PTD cohort. ERCP patients had significantly more difficult dissections, more blood loss, longer resection time, more postoperative bile leak, and longer hospital stay. CONCLUSION From the operative perspective, patients who underwent PTD in the preoperative setting had fewer morbidities and shorter hospital stay. Large scale studies are required to support the validity of these findings in surgical practice.",2021,"ERCP patients had significantly more difficult dissections, more blood loss, longer resection time, more postoperative bile leak, and longer hospital stay. ","['Between January 2019 and December 2010', 'resectable pancreatic head cancer with hyperbilirubinemia and impact on pancreaticoduodenectomy', 'Sixty patients with potentially resectable pancreatic head cancers and high bilirubin levels']","['ERCP', 'Endoscopic versus percutaneous biliary drainage', 'biliary drainage: endoscopic stenting or percutaneous drainage', 'percutaneous biliary drainage']","['morbidities and shorter hospital stay', 'clinical success rates', 'blood loss, longer resection time, more postoperative bile leak, and longer hospital stay', 'operative difficulties and early postoperative morbidity, the secondary outcome was post-drainage complications']","[{'cui': 'C0227579', 'cui_str': 'Structure of head of pancreas'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0020433', 'cui_str': 'Hyperbilirubinemia'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0085162', 'cui_str': 'Pancreaticoduodenectomy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}]","[{'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0400745', 'cui_str': 'Biliary drainage'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0400997', 'cui_str': 'Leakage of bile'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",60.0,0.0118594,"ERCP patients had significantly more difficult dissections, more blood loss, longer resection time, more postoperative bile leak, and longer hospital stay. ","[{'ForeName': 'Hany M', 'Initials': 'HM', 'LastName': 'El-Haddad', 'Affiliation': 'Department of Gastrointestinal Surgery, Faculty of Medicine, Alexandria University, Egypt. Electronic address: Hani.alhadad@alexmed.edu.eg.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Sabry', 'Affiliation': 'Department of Gastrointestinal Surgery, Faculty of Medicine, Alexandria University, Egypt.'}, {'ForeName': 'Gihan M', 'Initials': 'GM', 'LastName': 'Shehata', 'Affiliation': 'Biomedical Informatics and Medical Statistics Department, Medical Research Institute, Alexandria University, Egypt.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2021.106043'] 2354,34371175,Effect of a perioperative immune-enhancing diet in clean-contaminated head and neck cancer surgery: A randomized controlled trial.,"BACKGROUND Malnutrition is a common problem in head and neck cancer patients and is associated with an increased risk of postoperative complications and prolonged length of hospital stay (LOS). The purpose of this study was to evaluate the effect of an immune-enhancing diet with supplementary arginine, glutamine, and fish oil in clean-contaminated head and neck cancer surgery. MATERIALS AND METHODS A randomized controlled trial study in clean-contaminated head and neck cancer surgery patients was conducted. Patients undergoing surgery received either an immune-enhancing diet or hospital-prepared blenderized diet 7 days preoperatively and 14 days postoperatively. Clinical outcomes (mucocutaneous fistula, wound infection, general infection, LOS, and hospital costs) and nutritional parameters (body weight, prealbumin, transferrin, and albumin) were compared between the two groups. RESULTS 116 patients were included in the analysis, 60 in the immune-enhancing diet group and 56 in the blenderized diet group. There was a significant association between the immune-enhancing diet and the decrease in fistula rate (8.3 % vs. 23.2 %, p = 0.039), LOS (24 days vs. 29 days, p = 0.043), hospital costs (6312 US dollars vs. 7461 US dollars, p = 0.048), and higher prealbumin level on postoperative day 7 and 14 (p = 0.015 and 0.001, respectively) and transferrin level on postoperative day 14 (p = 0.047). In addition, the immune-enhancing diet also had a positive effect on body weight on postoperative day 14 (p = 0.028). However, there was no difference in nutrition-related adverse events between the two groups. CONCLUSION The administration of a perioperative diet containing arginine, glutamine, and fish oil in clean-contaminated head and neck cancer surgery patients led to a significant reduction in mucocutaneous fistula, LOS, and hospital costs. Results also indicated improved nutritional status, including body weight, prealbumin, and transferrin levels.",2021,"There was a significant association between the immune-enhancing diet and the decrease in fistula rate (8.3 % vs. 23.2 %, p = 0.039), LOS (24 days vs. 29 days, p = 0.043), hospital costs (6312 US dollars vs. 7461 US dollars, p = 0.048), and higher prealbumin level on postoperative day 7 and 14 (p = 0.015 and 0.001, respectively) and transferrin level on postoperative day 14 (p = 0.047).","['clean-contaminated head and neck cancer surgery patients', 'clean-contaminated head and neck cancer surgery', 'head and neck cancer patients', '116 patients were included in the analysis, 60 in the immune-enhancing diet group and 56 in the blenderized diet group', 'Patients undergoing surgery received either an']","['perioperative diet containing arginine, glutamine, and fish oil', 'perioperative immune-enhancing diet', 'immune-enhancing diet with supplementary arginine, glutamine, and fish oil', 'immune-enhancing diet or hospital-prepared blenderized diet']","['transferrin level', 'postoperative complications and prolonged length of hospital stay (LOS', 'hospital costs', 'LOS', 'body weight', 'mucocutaneous fistula, LOS, and hospital costs', 'nutritional status, including body weight, prealbumin, and transferrin levels', 'fistula rate', 'Clinical outcomes (mucocutaneous fistula, wound infection, general infection, LOS, and hospital costs) and nutritional parameters (body weight, prealbumin, transferrin, and albumin', 'higher prealbumin level', 'nutrition-related adverse events']","[{'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0205279', 'cui_str': 'Contaminated'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0202105', 'cui_str': 'Transferrin measurement'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0206174', 'cui_str': 'Cost, Hospital'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0032923', 'cui_str': 'Prealbumin'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0040679', 'cui_str': 'Transferrin'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0337441', 'cui_str': 'Transthyretin measurement'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",116.0,0.0693005,"There was a significant association between the immune-enhancing diet and the decrease in fistula rate (8.3 % vs. 23.2 %, p = 0.039), LOS (24 days vs. 29 days, p = 0.043), hospital costs (6312 US dollars vs. 7461 US dollars, p = 0.048), and higher prealbumin level on postoperative day 7 and 14 (p = 0.015 and 0.001, respectively) and transferrin level on postoperative day 14 (p = 0.047).","[{'ForeName': 'Pichit', 'Initials': 'P', 'LastName': 'Sittitrai', 'Affiliation': 'Department of Otolaryngology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Donyarat', 'Initials': 'D', 'LastName': 'Ruenmarkkaew', 'Affiliation': 'Department of Otolaryngology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Electronic address: rdonyarat@gmail.com.'}, {'ForeName': 'Somkamol', 'Initials': 'S', 'LastName': 'Booyaprapa', 'Affiliation': 'Department of Otolaryngology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Boosita', 'Initials': 'B', 'LastName': 'Kasempitakpong', 'Affiliation': 'Department of Otolaryngology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2021.106051'] 2355,34371163,Design of the healthcare worker exposure response and outcomes (HERO) research platform.,"BACKGROUND The SARS CoV-2 virus has caused one of the deadliest pandemics in recent history, resulting in over 170 million deaths and global economic disruption. There remains an urgent need for clinical trials to test therapies for treatment and prevention. DESIGN An online research platform was created to support a registry community of healthcare workers (HCWs) to understand their experiences and conduct clinical studies to address their concerns. The first study, HERO-HCQ, was a double-blind, multicenter, randomized, pragmatic trial to evaluate the superiority of hydroxychloroquine (HCQ) vs placebo for pre-exposure prophylaxis (PrEP) of COVID-19 clinical infection in HCWs. Secondary objectives were to assess the efficacy of HCQ in preventing viral shedding of COVID-19 among HCWs and to assess the safety and tolerability of HCQ. METHODS HCWs joined the Registry and were pre-screened for trial interest and eligibility. Trial participants were randomized 1:1 to receive HCQ or placebo. On-site baseline assessment included a COVID-19 nasopharyngeal PCR and blood serology test. Weekly follow-up was done via an online portal and included screening for symptoms of COVID-19, self-reported testing, adverse events, and quality of life assessments. The on-site visit was repeated at Day 30. DISCUSSION The HERO research platform offers an approach to rapidly engage, screen, invite and enroll into clinical studies using a novel participant-facing online portal interface and remote data collection, enabling limited onsite procedures for conduct of a pragmatic clinical trial. This platform may be an example for future clinical trials of common conditions to enable more rapid evidence generation.",2021,"DESIGN An online research platform was created to support a registry community of healthcare workers (HCWs) to understand their experiences and conduct clinical studies to address their concerns.","['HCWs joined the Registry and were pre-screened for trial interest and eligibility', 'HCWs']","['hydroxychloroquine (HCQ) vs placebo', 'HCQ', 'HCQ or placebo']","['COVID-19 nasopharyngeal PCR and blood serology test', 'safety and tolerability of HCQ', 'viral shedding of COVID-19 among HCWs', 'adverse events, and quality of life assessments']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0027442', 'cui_str': 'Nasopharyngeal'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0036743', 'cui_str': 'Serologic test'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0162633', 'cui_str': 'Viral Shedding'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}]",,0.573543,"DESIGN An online research platform was created to support a registry community of healthcare workers (HCWs) to understand their experiences and conduct clinical studies to address their concerns.","[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Friedland', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Adrian F', 'Initials': 'AF', 'LastName': 'Hernandez', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Anstrom', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Mei Lin', 'Initials': 'ML', 'LastName': 'Chen-Lim', 'Affiliation': ""Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Lauren W', 'Initials': 'LW', 'LastName': 'Cohen', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Currier', 'Affiliation': 'University of California Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'Forrest', 'Affiliation': ""Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Fraser', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Fraulo', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Anoop', 'Initials': 'A', 'LastName': 'George', 'Affiliation': 'Temple University Hospital, Philadelphia, PA, United States of America.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Handberg', 'Affiliation': 'University of Florida, Gainesville, FL, United States of America.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Jackman', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Jayne', 'Initials': 'J', 'LastName': 'Koellhoffer', 'Affiliation': 'Doylestown Health, Doylestown, PA, United States of America.'}, {'ForeName': 'Daryl', 'Initials': 'D', 'LastName': 'Lawrence', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN, United States of America.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Leverty', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Patty', 'Initials': 'P', 'LastName': 'McAdams', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'McCourt', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Mickley', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Syed Hasan', 'Initials': 'SH', 'LastName': 'Naqvi', 'Affiliation': 'University of Missouri, Columbia, MO, United States of America.'}, {'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': ""O'Brien"", 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Olson', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Clyde', 'Initials': 'C', 'LastName': 'Prater', 'Affiliation': 'Williamson Medical Center, Franklin, TN, United States of America.'}, {'ForeName': 'Russell L', 'Initials': 'RL', 'LastName': 'Rothman', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN, United States of America.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Shenkman', 'Affiliation': 'Doylestown Health, Doylestown, PA, United States of America.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Shostak', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Kisha Batey', 'Initials': 'KB', 'LastName': 'Turner', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN, United States of America.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Webb', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Woods', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Naggie', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, NC, United States of America. Electronic address: Susanna.naggie@duke.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2021.106525'] 2356,34371162,"Testing the effectiveness of community-engaged citizen science to promote physical activity, foster healthier neighborhood environments, and advance health equity in vulnerable communities: The steps for change randomized controlled trial design and methods.","While low-income midlife and older adults are disproportionately affected by non-communicable diseases that can be alleviated by regular physical activity, few physical activity programs have been developed specifically with their needs in mind. Those programs that are available typically do not address the recognized local environmental factors that can impact physical activity. The specific aim of the Steps for Change cluster-randomized controlled trial is to compare systematically the initial (one-year) and sustained (two-year) multi-level impacts of an evidence-based person-level physical activity intervention (Active Living Every Day [ALED] and age-relevant health education information), versus the ALED program in combination with a novel neighborhood-level citizen science intervention called Our Voice. The study sample (N = 300) consists of insufficiently active adults ages 40 years and over living in or around affordable senior public housing settings. Major study assessments occur at baseline, 12, and 24 months. The primary outcome is 12-month change in walking, and secondary outcomes include other forms of physical activity, assessed via validated self-report measures supported by accelerometry, and physical function and well-being variables. Additional intervention impacts are assessed at 24 months. Potential mediators and moderators of intervention success will be explored to better determine which subgroups do best with which type of intervention. Here we present the study design and methods, including recruitment strategies and yields. TRIAL REGISTRATION: clinicaltrial.gov Identifier = NCT03041415.",2021,Potential mediators and moderators of intervention success will be explored to better determine which subgroups do best with which type of intervention.,"['vulnerable communities', 'The study sample (N\u202f=\u202f300) consists of insufficiently active adults ages 40\u202fyears and over living in or around affordable senior public housing settings']","['evidence-based person-level physical activity intervention (Active Living', 'community-engaged citizen science']","['12-month change in walking, and secondary outcomes include other forms of physical activity, assessed via validated self-report measures supported by accelerometry, and physical function and well-being variables']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0034028', 'cui_str': 'Public Housing'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C5197881', 'cui_str': 'Citizen Science'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0441677', 'cui_str': 'Accelerometry'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439828', 'cui_str': 'Variable'}]",,0.0835823,Potential mediators and moderators of intervention success will be explored to better determine which subgroups do best with which type of intervention.,"[{'ForeName': 'Abby C', 'Initials': 'AC', 'LastName': 'King', 'Affiliation': 'Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA 94305, United States of America; Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: king@stanford.edu.'}, {'ForeName': 'Maria I', 'Initials': 'MI', 'LastName': 'Campero', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: icampero@stanford.edu.'}, {'ForeName': 'Dulce', 'Initials': 'D', 'LastName': 'Garcia', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: dgarcia3@stanford.edu.'}, {'ForeName': 'Isela', 'Initials': 'I', 'LastName': 'Blanco-Velazquez', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: iblanco6@stanford.edu.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Banchoff', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: banchoff@stanford.edu.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Fierros', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: ffierros@stanford.edu.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Escobar', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: mescob12@stanford.edu.'}, {'ForeName': 'Ana L', 'Initials': 'AL', 'LastName': 'Cortes', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: acortes@stanford.edu.'}, {'ForeName': 'Jylana L', 'Initials': 'JL', 'LastName': 'Sheats', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: jsheats@tulane.edu.'}, {'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Hua', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: jenna@millionmarker.com.'}, {'ForeName': 'Aldo', 'Initials': 'A', 'LastName': 'Chazaro', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: achazaro@stanfordchildrens.org.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Done', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America.'}, {'ForeName': 'Patricia Rodriguez', 'Initials': 'PR', 'LastName': 'Espinosa', 'Affiliation': 'Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA 94305, United States of America; Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: prespinosa@stanford.edu.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Vuong', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: vuongd@stanford.edu.'}, {'ForeName': 'David K', 'Initials': 'DK', 'LastName': 'Ahn', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: dahn@stanford.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106526'] 2357,34371142,Effects of the chelating agent DTPA on naturally accumulating metals in the body.,"Diethylenetriaminepentaacetate (DTPA) is the most widely used chelating agent for Pu and Am. Volunteers were assigned to receive intravenous injections or aerosol inhalations of 1 g of DTPA on days 1-4; volunteers received once daily injections of CaDTPA or ZnDTPA, CaDTPA inhalation as an aerosol, or CaDTPA injection on day 1 and ZnDTPA on days 2-4. CaDTPA injection or inhalation increased the excretion rates of Zn in urine with concomitantly reduced levels of serum Zn. Injection of CaDTPA reduced activities of serum alkaline phosphatase (AP) in parallel with the kinetics of Zn, whereas CaDTPA and ZnDTPA injection reduced activities of lactate dehydrogenase (LDH), and reduced activities of creatinine kinase (CK) were observed upon CaDTPA injection and its inhalation. Intravenous administration of CaDTPA and ZnDTPA enhanced excretion rates of Mn in urine, whereas transient reduction of Mn levels in serum was detected only via CaDTPA injection. Both CaDTPA and ZnDTPA transiently reduced levels of Mg in serum without affecting the excretion rates. On the other hand, both DTPAs increased excretion rates of toxic metals such as Pb and Cd, and CaDTPA also increased the rates of Hg. These results suggest that DTPA, and especially CaDTPA, removes essential metals and that the activities of these metalloenzymes are good indicators for the imbalance of essential metals during the DTPA administration. Our results also show that CaDTPA injection is more potent for removing these metals than ZnDTPA and inhalation of CaDTPA, and DTPA may be useful for the treatment of acute heavy metal poisoning with Pb, Cd, or Hg.",2021,"Injection of CaDTPA reduced activities of serum alkaline phosphatase (AP) in parallel with the kinetics of Zn, whereas CaDTPA and ZnDTPA injection reduced activities of lactate dehydrogenase (LDH), and reduced activities of creatinine kinase (CK) were observed upon CaDTPA injection and its inhalation.",[],"['chelating agent DTPA', 'CaDTPA and ZnDTPA', 'CaDTPA injection', 'CaDTPA or ZnDTPA, CaDTPA inhalation as an aerosol, or CaDTPA injection on day 1 and ZnDTPA', 'Diethylenetriaminepentaacetate (DTPA', 'intravenous injections or aerosol inhalations of 1\u2009g of DTPA']","['excretion rates of Mn in urine', 'activities of serum alkaline phosphatase (AP', 'excretion rates', 'activities of lactate dehydrogenase (LDH), and reduced activities of creatinine kinase (CK', 'excretion rates of toxic metals such as Pb and Cd, and CaDTPA']",[],"[{'cui': 'C0007974', 'cui_str': 'Chelating agent'}, {'cui': 'C0520458', 'cui_str': 'Pentetate calcium trisodium'}, {'cui': 'C0043501', 'cui_str': 'Zinc-DTPA'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0001712', 'cui_str': 'Aerosol'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021494', 'cui_str': 'Intravenous injection'}]","[{'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0036776', 'cui_str': 'Serum alkaline phosphatase measurement'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0025552', 'cui_str': 'Metal'}, {'cui': 'C0520458', 'cui_str': 'Pentetate calcium trisodium'}]",4.0,0.0502135,"Injection of CaDTPA reduced activities of serum alkaline phosphatase (AP) in parallel with the kinetics of Zn, whereas CaDTPA and ZnDTPA injection reduced activities of lactate dehydrogenase (LDH), and reduced activities of creatinine kinase (CK) were observed upon CaDTPA injection and its inhalation.","[{'ForeName': 'Takako', 'Initials': 'T', 'LastName': 'Tominaga', 'Affiliation': 'National Institute of Quantum and Radiological Science and Technology, Chiba, 265-8555, Japan. Electronic address: tominaga.takako@qst.go.jp.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Shimomura', 'Affiliation': 'Kusabana Clinic, Akiruno, Tokyo, 197-0802, Japan. Electronic address: satoshi@kusabanaclinic.jp.'}, {'ForeName': 'Sakae', 'Initials': 'S', 'LastName': 'Tanosaki', 'Affiliation': 'Fraternity Memorial Hospital, Sumida, Tokyo, 130-8587, Japan. Electronic address: stanosaki@douai.jp.'}, {'ForeName': 'Nobuyoshi', 'Initials': 'N', 'LastName': 'Kobayashi', 'Affiliation': 'Kobayashi Clinic, Yotsukaido, Chiba, 284-0001, Japan. Electronic address: koban@mve.biglobe.ne.jp.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Ikeda', 'Affiliation': 'Shizuoka Cancer Center, Nagaizumi, Shizuoka, 411-8777, Japan. Electronic address: t.ikeda@scchr.jp.'}, {'ForeName': 'Tetsuo', 'Initials': 'T', 'LastName': 'Yamamoto', 'Affiliation': 'Japan Ground Self-Defense Force (JGSDF), Setagaya, Tokyo, 154-8532, Japan. Electronic address: tetsuo-y@sol.dti.ne.jp.'}, {'ForeName': 'Taiji', 'Initials': 'T', 'LastName': 'Tamura', 'Affiliation': 'Kubokawa Hospital, Shimanto, Kochi, 786-0002, Japan. Electronic address: earlyhcc@gmail.com.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Umemura', 'Affiliation': 'Self Defense Forces Central Hospital, Setagaya, Tokyo, 154-8532, Japan. Electronic address: 2071nhn0529nnj@gmail.com.'}, {'ForeName': 'Shiori', 'Initials': 'S', 'LastName': 'Horibuchi-Matsusaki', 'Affiliation': 'Kyorin University, Mitaka, Tokyo, 181-8612, Japan. Electronic address: mshiori@ks.kyorin-u.ac.jp.'}, {'ForeName': 'Misao', 'Initials': 'M', 'LastName': 'Hachiya', 'Affiliation': 'Nuclear Safety Technology Center, Bunkyo, Tokyo, 112-8604, Japan. Electronic address: misao-hachiya@nustec.or.jp.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Akashi', 'Affiliation': 'Tokyo Healthcare University, Meguro, Tokyo, 152-8558, Japan. Electronic address: m-akashi@thcu.ac.jp.'}]",Toxicology letters,['10.1016/j.toxlet.2021.08.001'] 2358,34371137,Completion of Patient-Reported Outcome Questionnaires among Older Adults with Advanced Cancer.,"CONTEXT Systematic collection of patient-reported outcomes (PROs) reduces symptom burden and improves quality of life. The ability of older adults to complete PROs, however, has not been thoroughly studied. OBJECTIVES To determine whether older adults with advanced cancer received assistance completing PROs, the nature of the assistance, the factors associated with receiving assistance, and how the prevalence of assistance changed over time. METHODS Data were obtained from a multisite cluster randomized controlled study of geriatric assessment (Clinicaltrials.gov: NCT02107443). Adults ≥70 years with advanced cancer completed multiple PROs at 4 time points (enrollment, 6 weeks, 3 months, 6 months). Factors associated with receipt of assistance were assessed with bivariate and multivariate analyses. RESULTS The study included 541 adults (range 70-96 years, 49% female, mixed incurable cancer diagnoses). Twenty-eight percent (153/541) received assistance completing PROs. Of these, 42% received assistance from caregivers, 37% from research staff, and 15% from both. Factors associated with receiving assistance included older age [Adjusted Odds Ratio (AOR) 3.71, 95% Confidence Interval (CI) 1.03-13.38], lower education level (3.92, 2.11-7.29), impaired cognition (1.90, 1.23-2.93), impaired functional status (2.16, 1.33-3.52), and impaired hearing (1.38, 1.05-1.80). Eighty percent of individuals who received assistance were identified at study initiation. Receiving assistance decreased over time from 28% to 18%, partially due to drop-outs. CONCLUSION Over a quarter of older adults with advanced cancer in this study received assistance completing PROs. Completing PROs is a key aspect of many clinical programs and cancer trials; assistance in completing PROs should be offered and provided.",2021,"Factors associated with receiving assistance included older age [Adjusted Odds Ratio (AOR) 3.71, 95% Confidence Interval (CI) 1.03-13.38], lower education level (3.92, 2.11-7.29), impaired cognition (1.90, 1.23-2.93), impaired functional status (2.16, 1.33-3.52), and impaired hearing (1.38, 1.05-1.80).","['Older Adults with Advanced Cancer', 'Adults ≥70 years with advanced cancer', '541 adults (range 70-96 years, 49% female, mixed incurable cancer diagnoses', 'older adults with advanced cancer', 'older adults']",['assistance completing PROs'],"['impaired hearing', 'lower education level', 'impaired functional status', 'impaired cognition', 'quality of life']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}]","[{'cui': 'C0260662', 'cui_str': 'Hearing problem'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",541.0,0.256423,"Factors associated with receiving assistance included older age [Adjusted Odds Ratio (AOR) 3.71, 95% Confidence Interval (CI) 1.03-13.38], lower education level (3.92, 2.11-7.29), impaired cognition (1.90, 1.23-2.93), impaired functional status (2.16, 1.33-3.52), and impaired hearing (1.38, 1.05-1.80).","[{'ForeName': 'Marie A', 'Initials': 'MA', 'LastName': 'Flannery', 'Affiliation': 'School of Nursing, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: marie_flannery@urmc.rochester.edu.'}, {'ForeName': 'Supriya', 'Initials': 'S', 'LastName': 'Mohile', 'Affiliation': 'University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: supriya_mohile@urmc.rochester.edu.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Culakova', 'Affiliation': 'University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: eva_culakova@urmc.rochester.edu.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Norton', 'Affiliation': 'School of Nursing, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: sally_norton@urmc.rochester.edu.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Kamen', 'Affiliation': 'University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: Charles_Kamen@URMC.Rochester.edu.'}, {'ForeName': 'J Nicholas', 'Initials': 'JN', 'LastName': 'Dionne-Odom', 'Affiliation': 'University of Alabama, Birmingham, School of Nursing, Alabama, USA. Electronic address: dionneod@uab.edu.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'DiGiovanni', 'Affiliation': 'University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: Grace_DiGiovanni@URMC.Rochester.edu.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Griggs', 'Affiliation': 'University of Rochester Medical Center, SCOREBOARD, Patient Advisory Board, New York, USA. Electronic address: lmgriggs@rochester.rr.com.'}, {'ForeName': 'ThomasMD', 'Initials': 'T', 'LastName': 'Bradley', 'Affiliation': 'Northwell Health NCORP, USA. Electronic address: TBradley@northwell.edu.'}, {'ForeName': 'Judith O', 'Initials': 'JO', 'LastName': 'Hopkins', 'Affiliation': 'Southeast Clinical Oncology Research Consortium NCORP, USA. Electronic address: johopkins@novanthealth.org.'}, {'ForeName': 'Jane Jijun', 'Initials': 'JJ', 'LastName': 'Liu', 'Affiliation': 'Illinois Cancer Care and Heartland NCORP. Electronic address: JLiu@illinoiscancercare.com.'}, {'ForeName': 'Kah Poh', 'Initials': 'KP', 'LastName': 'Loh', 'Affiliation': 'University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: kahpoh_loh@urmc.rochester.edu.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2021.07.032'] 2359,34371121,"Taste education - A food-based intervention in a school setting, focusing on children with and without neurodevelopmental disorders and their families. A randomized controlled trial.","Children with neurodevelopmental disorders (ND) such as Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactive Disorder (ADHD) have high levels of fussy eating. However, no school-based food interventions exist for children with ASD and ADHD. To investigate the effect of Taste Education, 81 children with ND (n = 33), and without (n = 48), aged 8-12 years, and their parents, participated in a 7-week food intervention. Children were matched on age, ND, and sex, and randomized into Immediate-intervention and Delayed-intervention groups. Parents completed the Children's Eating Behaviour Questionnaire (CEBQ), and a food-variety questionnaire. After adjusting for baseline measures, repeated-measures analysis-of-variance with time-points, and condition as factors (Immediate intervention and Delayed intervention) were used to examine changes in CEBQ-scores, with a robust linear mixed-model fitted. Changes in percentage of accepted foods were tested using a logistic-regression model adjusting for baseline acceptance. Results showed superior results for Intervention compared to waiting, on Food fussiness, but not Enjoyment of food, with stable effects through six-months follow-up. There were non-significant differences between children with and without ND. Results also showed increased odds of accepting vegetables by a factor of 1.6 (95% Confidence Interval [CI]: 1.33-1.93, p < .001); nuts and seeds by a factor of 1.4 (95% CI: 1.27-1.6, p < .001), but no significant association for fruit (OR 1.12, 95% CI: 0.92-1.34, p = .244). Trends were similar for children regardless of ND-status. The Taste Education program, shows promise, as a simple, non-invasive way to decrease fussy eating and increase food variety in the long-term.",2021,"Results showed superior results for Intervention compared to waiting, on Food fussiness, but not Enjoyment of food, with stable effects through six-months follow-up.","['children with ASD and ADHD', '81 children with ND (n\u202f=\u202f33), and without (n\u202f=\u202f48), aged 8-12 years, and their parents, participated in a 7-week food intervention', 'children with and without neurodevelopmental disorders and their families', 'Children with neurodevelopmental disorders (ND']","['Taste education - A food-based intervention', 'Taste Education']","['CEBQ-scores', 'odds of accepting vegetables', ""Children's Eating Behaviour Questionnaire (CEBQ""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0041671', 'cui_str': 'Attention Deficit Disorder'}, {'cui': 'C0424295', 'cui_str': 'Hyperactive behavior'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1535926', 'cui_str': 'Neurodevelopmental disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0163299', 'cui_str': 'A 7'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015576', 'cui_str': 'Family'}]","[{'cui': 'C0039336', 'cui_str': 'Finding of sense of taste'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}]",81.0,0.0280374,"Results showed superior results for Intervention compared to waiting, on Food fussiness, but not Enjoyment of food, with stable effects through six-months follow-up.","[{'ForeName': 'Sigrun', 'Initials': 'S', 'LastName': 'Thorsteinsdottir', 'Affiliation': 'School of Education, University of Iceland, Iceland. Electronic address: sth265@hi.is.'}, {'ForeName': 'Urdur', 'Initials': 'U', 'LastName': 'Njardvik', 'Affiliation': 'School of Health Sciences, University of Iceland, Iceland. Electronic address: urdurn@hi.is.'}, {'ForeName': 'Ragnar', 'Initials': 'R', 'LastName': 'Bjarnason', 'Affiliation': 'School of Health Sciences, University of Iceland, Iceland; Department of Paediatrics, National University Hospital, Iceland. Electronic address: ragnarb@landspitali.is.'}, {'ForeName': 'Anna S', 'Initials': 'AS', 'LastName': 'Olafsdottir', 'Affiliation': 'School of Education, University of Iceland, Iceland. Electronic address: annaso@hi.is.'}]",Appetite,['10.1016/j.appet.2021.105623'] 2360,34371102,Adaptive Treatment for Youth With Substance Use and Depression: Early Depression Response and Short-Term Outcomes.,"OBJECTIVE To investigate prevalence and predictors of early depression response (EDR) in adolescents with substance use and depression receiving cognitive-behavioral therapy (CBT) for substance use; and to test the efficacy of supplemental CBT targeting depression (CBT-D) for non-EDR adolescents in an adaptive treatment approach. METHOD Ninety-five youths at two sites (ages 14-21, mean = 17.4, SD=1.8) with alcohol or cannabis use and depressive symptoms received up to 12 sessions of CBT for substance use over 14 weeks. Assessments were at baseline, weeks four, nine, and 14. The Childrens' Depression Rating Scale-Revised was the primary depression measure, with a reduction of 50% or more on this scale at week 4 defining EDR. The primary substance use outcomes of alcohol use, heavy alcohol use, and cannabis use frequency were assessed via interview report on the Alcohol Consumption Questionnaire and the Drug Checklist. Urinalysis provided a secondary measure of cannabis use. Non-EDR adolescents were randomized to supplemental CBT-D or enhanced depression treatment as usual (ETAU). RESULTS Thirty-five adolescents (37%, 95% CI = 27%-47%) demonstrated EDR. Fewer days of cannabis use (OR = 0.977; 95% CI = 0.961-0.992) and absence of conduct disorder (OR = 0.149; 95% CI = 0.031-0.716) predicted EDR. Frequency of drinking (F(1,82) = 11.09, η 2 = 0.119, p = 0.001), heavy drinking (F(1, 82) = 19.91, η 2 = 0.195, p < 0.0001) and cannabis use (F(1, 220) = 35.01, η 2 = 0.137, p < 0.001) decreased over time for EDR, CBT-D and ETAU youths, with EDR adolescents evidencing earlier lower cannabis use (F(2, 220) = 4.16, η 2 = 0.036, p = 0.0169). Negative (clean) urine screens increased over time (F(1, 219) = 5.10, η 2 = 0.023, p = 0.0249). Comparison of CBT-D and ETAU indicated depression significantly decreased over time in both groups (F(1,48) = 64.20, η 2 = 0.572, p < 0.001), with no advantage for CBT-D. CONCLUSION Approximately one-third of adolescents with substance use and depression attain EDR during substance use treatment. Less frequent cannabis use facilitates depression response. The relatively small sample may have precluded identification of additional EDR predictors.",2021,Fewer days of cannabis use (OR = 0.977; 95% CI = 0.961-0.992) and absence of conduct disorder (OR = 0.149; 95% CI = 0.031-0.716) predicted EDR.,"['adolescents with substance use and depression receiving', 'Youth With Substance Use and Depression', 'EDR adolescents', 'Ninety-five youths at two sites (ages 14-21, mean = 17.4, SD=1.8) with alcohol or cannabis use and depressive symptoms received up to 12 sessions of CBT for substance use over 14 weeks']","['supplemental CBT-D or enhanced depression treatment as usual (ETAU', 'cognitive-behavioral therapy (CBT', 'supplemental CBT targeting depression (CBT-D']","['heavy drinking', 'Negative (clean) urine screens', 'depression', 'absence of conduct disorder', 'alcohol use, heavy alcohol use, and cannabis use frequency were assessed via interview report on the Alcohol Consumption Questionnaire and the Drug Checklist', 'early depression response (EDR', 'EDR', ""Childrens' Depression Rating Scale""]","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C4517906', 'cui_str': '95'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0149654', 'cui_str': 'Conduct disorder'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0282221,Fewer days of cannabis use (OR = 0.977; 95% CI = 0.961-0.992) and absence of conduct disorder (OR = 0.149; 95% CI = 0.031-0.716) predicted EDR.,"[{'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Curry', 'Affiliation': 'Duke University School of Medicine, Durham, North Carolina. Electronic address: john.curry@duke.edu.'}, {'ForeName': 'Yifrah', 'Initials': 'Y', 'LastName': 'Kaminer', 'Affiliation': 'Alcohol Research Center, University of Connecticut, Farmington.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Goldston', 'Affiliation': 'Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Chan', 'Affiliation': 'Alcohol Research Center, University of Connecticut, Farmington.'}, {'ForeName': 'Karen C', 'Initials': 'KC', 'LastName': 'Wells', 'Affiliation': 'Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Rebecca H', 'Initials': 'RH', 'LastName': 'Burke', 'Affiliation': 'UConn School of Medicine, Farmington, Connecticut. At the time of the study.'}, {'ForeName': 'Adrienne Banny', 'Initials': 'AB', 'LastName': 'Inscoe', 'Affiliation': 'Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Allison E', 'Initials': 'AE', 'LastName': 'Meyer', 'Affiliation': 'Duke University, Durham, North Carolina, and is currently with the University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Shayna M', 'Initials': 'SM', 'LastName': 'Cheek', 'Affiliation': 'Duke University, Durham, North Carolina.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2021.07.807'] 2361,34371058,"Is Jedi Grip efficient and effective in ultrasound-guided peripheral nerve blocking? A prospective, randomized, observer-blinded study.","BACKGROUND In this prospective, randomized, controlled observer-blinded study, we aimed to compare the efficacy of a single-operator technique called the Jedi Grip and a conventional technique requiring a double operator in ultrasound-guided-axillary brachial plexus blocking. METHODS Ninety-two patients (ASA I-II; aged 18-65 years old) who underwent elective hand, wrist and forearm surgery were randomly assigned to Group Conventional (C) or Group Jedi (J). In both groups, axillary plexus blockade was performed by applying 5 cc of a mixture of 10 cc of 0.5% bupivacaine and 10 cc of 2% prilocaine to the ulnar, radial, median, and musculocutaneous nerves. Parameters such as the performance time and number of needle passes were recorded during the procedure. Subsequently, a blinded observer evaluated and recorded parameters related to the blockade success. The main outcome variables were the performance time and success rate (surgical anesthesia). RESULTS The block performance time of the Jedi technique was slightly longer than that of the conventional technique (220 (50), 202 (78) s, respectively) (median (IQR); p =  0.05). No significant difference was found between groups in terms of blocking success; 9 (20%) from the conventional group and 3 (6.4%) from the Jedi group were unsuccessful (p =  0.053). No differences were found in terms of arterial puncture, and no other complications occurred in either group. The motor-sensory block onset and termination times and initial analgesia requirements were similar. CONCLUSION The Jedi technique may be applied safely with similar block success and performance results as the conventional technique.",2021,No significant difference was found between groups in terms of blocking success; 9 (20%) from the conventional group and 3 (6.4%) from the Jedi group were unsuccessful (p =  0.053).,"['Ninety-two patients (ASA I-II; aged 18-65 years old) who underwent elective hand, wrist and forearm surgery']","['Group Conventional (C) or Group Jedi (J', 'bupivacaine', 'single-operator technique called the Jedi Grip and a conventional technique requiring a double operator', 'prilocaine']","['performance time and success rate (surgical anesthesia', 'block performance time of the Jedi technique', 'complications', 'performance time and number of needle passes', 'motor-sensory block onset and termination times and initial analgesia requirements', 'blocking success', 'arterial puncture']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0033124', 'cui_str': 'Prilocaine'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0189586', 'cui_str': 'Puncture of artery'}]",,0.0316874,No significant difference was found between groups in terms of blocking success; 9 (20%) from the conventional group and 3 (6.4%) from the Jedi group were unsuccessful (p =  0.053).,"[{'ForeName': 'Neslihan', 'Initials': 'N', 'LastName': 'Keklik', 'Affiliation': 'Afyonkarahisar Dinar State Hospital, Anesthesia Department, Afyonkarahisar, Turkey.'}, {'ForeName': 'İsmail', 'Initials': 'İ', 'LastName': 'Aytaç', 'Affiliation': 'Ankara City Hospital, Anesthesiology Department, Ankara, Turkey. Electronic address: aytacismail1972@gmail.com.'}, {'ForeName': 'Semih', 'Initials': 'S', 'LastName': 'Başkan', 'Affiliation': 'Ankara City Hospital, Ankara Yıldırım Beyazıt University, Anesthesiology Department, Ankara, Turkey.'}, {'ForeName': 'Betül', 'Initials': 'B', 'LastName': 'Güven Aytaç', 'Affiliation': 'Ankara Etlik Zübeyde Hanım Obstetric and Gynecology State Hospital, Anesthesia Department, Ankara, Turkey.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2021.07.016'] 2362,34371005,Home modifications to prevent home fall injuries in houses with Māori occupants (MHIPI): a randomised controlled trial.,"BACKGROUND As with many Indigenous populations internationally, Māori in New Zealand suffer health inequity. We aimed to assess the rate of fall injuries at home with and without home modifications in houses with Māori occupants. METHODS We did a single-blind randomised controlled trial in the Wellington and Taranaki regions of New Zealand and enrolled owner-occupied households with at least one Māori occupant. Only households who stated they intended to live at that address for the subsequent 3 years were eligible for participation. We randomly assigned (1:1) households to either the intervention group, who received home modifications (handrails for outside steps and internal stairs, grab rails for bathrooms, outside lighting, repairs to window catches, high-visibility and slip-resistant edging for outside steps, fixing of lifted edges of carpets and mats, non-slip bath mats, and slip-resistant surfacing for outside areas such as decks) immediately, or the control group, who received the modifications 3 years later. Data on home injuries were obtained from the Accident Compensation Corporation and coded by study team members, who were masked to study group allocation. The primary outcome was the rate of medically treated fall injuries at home per household per year, analysed according to intention to treat. This Māori Home Injury Prevention Intervention (MHIPI) trial is now completed, and is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12613000148774. FINDINGS Between Sept 3, 2013, and Oct 1, 2014, 824 households were assessed for eligibility and 254 were enrolled, of which 126 (50%) were assigned to the intervention group and 128 (50%) were assigned to the control group. After adjustment for previous falls and geographical region, there was an estimated 31% reduction in the rate of fall injuries at home per year exposed to the intervention compared with households in the control group (adjusted relative rate 0·69 [95% CI 0·47-1·00]). INTERPRETATION Low-cost home modifications and repairs can be an effective means to reduce injury disparities. The high prevalence of modifiable safety issues in Māori homes merits considerable policy and community effort. FUNDING Health Research Council of New Zealand.",2021,"After adjustment for previous falls and geographical region, there was an estimated 31% reduction in the rate of fall injuries at home per year exposed to the intervention compared with households in the control group (adjusted relative rate 0·69 [95% CI 0·47-1·00]). ","['houses with Māori occupants (MHIPI', 'Wellington and Taranaki regions of New Zealand and enrolled owner-occupied households with at least one Māori occupant', 'Only households who stated they intended to live at that address for the subsequent 3 years were eligible for participation', 'Between Sept 3, 2013, and Oct 1, 2014, 824 households were assessed for eligibility and 254 were enrolled, of which 126 (50%) were assigned to the intervention group and 128 (50%) were assigned to the control group', 'houses with Māori occupants']","['home modifications (handrails for outside steps and internal stairs, grab rails for bathrooms, outside lighting, repairs to window catches, high-visibility and slip-resistant edging for outside steps, fixing of lifted edges of carpets and mats, non-slip bath mats, and slip-resistant surfacing for outside areas such as decks']","['rate of medically treated fall injuries at home per household per year, analysed according to intention to treat', 'rate of fall injuries']","[{'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0856240', 'cui_str': 'Injury in the home'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0453965', 'cui_str': 'Gum boots'}, {'cui': 'C0454766', 'cui_str': 'Regions of New Zealand'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1442824', 'cui_str': 'POU2F1 protein, human'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0325736', 'cui_str': 'Family Rallidae'}, {'cui': 'C0040364', 'cui_str': 'Lavatory'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0557702', 'cui_str': 'Window'}, {'cui': 'C0231617', 'cui_str': 'Catch'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0337209', 'cui_str': 'Slipping'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0181620', 'cui_str': 'Hoist'}, {'cui': 'C0205154', 'cui_str': 'Along edge'}, {'cui': 'C0007287', 'cui_str': 'Carpet'}, {'cui': 'C0066317', 'cui_str': 'methylallyl trisulfide'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0085639', 'cui_str': 'Falls'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0439508', 'cui_str': '/year'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}]",824.0,0.0937309,"After adjustment for previous falls and geographical region, there was an estimated 31% reduction in the rate of fall injuries at home per year exposed to the intervention compared with households in the control group (adjusted relative rate 0·69 [95% CI 0·47-1·00]). ","[{'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Keall', 'Affiliation': 'Department of Public Health, University of Otago, Wellington, New Zealand. Electronic address: michael.keall@otago.ac.nz.'}, {'ForeName': 'Hope', 'Initials': 'H', 'LastName': 'Tupara', 'Affiliation': 'Research Centre for Hauora and Health, Massey University, Wellington, New Zealand.'}, {'ForeName': 'Nevil', 'Initials': 'N', 'LastName': 'Pierse', 'Affiliation': 'Department of Public Health, University of Otago, Wellington, New Zealand.'}, {'ForeName': 'Marg', 'Initials': 'M', 'LastName': 'Wilkie', 'Affiliation': 'Research Centre for Hauora and Health, Massey University, Wellington, New Zealand.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health, University of Otago, Wellington, New Zealand.'}, {'ForeName': 'Philippa', 'Initials': 'P', 'LastName': 'Howden-Chapman', 'Affiliation': 'Department of Public Health, University of Otago, Wellington, New Zealand.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Cunningham', 'Affiliation': 'Research Centre for Hauora and Health, Massey University, Wellington, New Zealand.'}]",The Lancet. Public health,['10.1016/S2468-2667(21)00135-3'] 2363,34371004,"Comparing N-acetylcysteine to sodium thiosulfate for relieving symptoms caused by Lugol's iodine chromoendoscopy: a randomized, double-blind trial.","BACKGROUND AND AIMS Lugol's iodine chromoendoscopy is an important method to detect esophageal squamous cell carcinoma. Sodium thiosulfate solution (STS) was used to neutralize iodine after Lugol's chromoendoscopy; nonetheless, it is not available in many medical centers. The aim of the current study was to assess the efficacy of N-acetylcysteine solution (NAC) for relieving symptoms caused by Lugol's iodine chromoendoscopy. METHODS Patients were randomized to receive either STS or NAC after spraying Lugol's iodine solution on the esophagus. The neutralizing effects for residual iodine in esophagus and gastric mucus pool were observed. The primary endpoint was the intensity of retrosternal pain and/or heartburn measured by a visual analogue scale (VAS) score 30 minutes after chromoendoscopy. The secondary endpoints were the rate of patients with any adverse symptom, the rate of moderate to severe retrosternal discomfort occurred, and the heart rate variability between timepoints before and after chromoendoscopy. RESULTS The neutralization rates for residual iodine between the NAC and STS groups were not significantly different (P > .999). The difference of median VAS scores between the NAC and STS groups 30 minutes after chromoendoscopy was 0.0 (P = .719; 95% CI, 0.0 - 0.0), and the 95% CI higher limit was 0.0, which was less than our prespecified margin of 0.5, concluding to noninferiority of NAC with regard to STS. There was no significant difference between the 2 groups regarding the rate of patients with any adverse symptom, the rate of moderate to severe retrosternal discomfort, or heart rate variability at 5 minutes or 30 minutes after chromoendoscopy. CONCLUSION As a very easily accessible reagent in clinical circumstances, NAC can also alleviate mucosal irritation symptoms induced by Lugol's chromoendoscopy at similar efficacy as STS and can be routinely recommended.",2021,The neutralization rates for residual iodine between the NAC and STS groups were not significantly different (P > .999).,"['Patients', 'esophageal squamous cell carcinoma']","['N-acetylcysteine solution (NAC', 'Sodium thiosulfate solution (STS', 'sodium thiosulfate', ""STS or NAC after spraying Lugol's iodine solution""]","['rate of patients with any adverse symptom, the rate of moderate to severe retrosternal discomfort', 'median VAS scores', 'heart rate variability', 'neutralization rates', 'rate of patients with any adverse symptom, the rate of moderate to severe retrosternal discomfort, or heart rate variability', 'intensity of retrosternal pain and/or heartburn measured by a visual analogue scale (VAS) score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0279626', 'cui_str': 'Squamous cell carcinoma of esophagus'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0074774', 'cui_str': 'sodium thiosulfate'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0065234', 'cui_str': ""Lugol's solution""}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0857400', 'cui_str': 'Retrosternal discomfort'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0151826', 'cui_str': 'Retrosternal pain'}, {'cui': 'C0018834', 'cui_str': 'Heartburn'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.183816,The neutralization rates for residual iodine between the NAC and STS groups were not significantly different (P > .999).,"[{'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Guo', 'Affiliation': 'Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University), Xian, China.'}, {'ForeName': 'Xiaotong', 'Initials': 'X', 'LastName': 'Fan', 'Affiliation': 'Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University), Xian, China.'}, {'ForeName': 'Shaohua', 'Initials': 'S', 'LastName': 'Zhu', 'Affiliation': 'Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University), Xian, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University), Xian, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Fang', 'Affiliation': 'Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University), Xian, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Guo', 'Affiliation': 'Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University), Xian, China.'}, {'ForeName': 'Zhiguo', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University), Xian, China. Electronic address: liuzhiguo@fmmu.edu.cn.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Han', 'Affiliation': 'Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University), Xian, China. Electronic address: hanying@fmmu.edu.cn.'}]",Gastrointestinal endoscopy,['10.1016/j.gie.2021.07.025'] 2364,34370677,Diabetic Foot Wounds Treated With Human Amniotic Membrane and Low-level Laser Therapy: A Pilot Clinical Study.,"BACKGROUND Low-level laser therapy (LLLT) and human amniotic membrane (HAM) application have been shown to be viable options for use in wound healing. PURPOSE This study sought to compare LLLT and HAM to a control treatment (hydrogel, saline, and gauze) in persons with diabetes mellitus (DM) and foot ulcers. METHODS Using a prospective pilot clinical study design, patients receiving care at a health center that specializes in the treatment of diabetic foot wounds between November 2016 and August 2017 were recruited. Eligible patients had to be 30 to 59 years of age; diagnosed with type 2 DM (postprandial capillary glucose levels between 140 and 350 mg/dL); and have uninfected, granulating stage 2 or 3 foot ulcers measuring less than 7 cm by 3 cm. Immunosuppressed and malnourished patients or those with neoplasms or in critical condition were not eligible to participate. Patients received the control treatment (2 mg hydrogel, saline, and gauze), HAM (patches of thawed HAM, applied with overlapping edges), or LLLT (phototherapy session, 2 mg hydrogel, saline, and gauze) for 28 days. Variables, wound area measurements, Pressure Ulcer Scale for Healing (PUSH) scores, and Visual Analog Scale (VAS) scores were used to assess wound improvement progress and pain on days 7, 14, 21, and 28. Descriptive statistics were used to analyze the participant anthropometric and clinical profiles. The Kolmogorov-Smirnov test was used to analyze the sample distribution. The Kruskal-Wallis test with Dunn's post-test was used to evaluate differences in PUSH and VAS scores and wound size for intergroup analysis, and the Mann-Whitney U test was used for the same outcomes in intragroup analysis. The level of significance was 5% (P < .05). RESULTS Twenty-seven (27) patients participated (mean age, 51.4 years; mean body mass index, 26.5 kg/m2), with 9 patients in each treatment group. No statistically significant differences were noted in clinical or anthropometric variables among the groups, but mean baseline wound areas were different (2.6 cm² for the control, 1.9 cm² for the LLLT, and 5.5 cm² for the HAM groups). Intragroup comparisons showed a significant reduction in PUSH score in the LLT group between days 0 and 21 (8.2 vs 4.9; P < .01) and days 21 to 28 (4.9 vs 3.2; P < .001). In all treatment groups the percent reduction was significantly different between days 7 and 28. No outcomes were significantly different between groups. CONCLUSION Diabetic foot ulcer wound area as well as PUSH and VAS scores showed more improvement for patients with DM receiving LLLT or HAM than for the control group, but the differences were not significant. Larger studies are needed to compare these treatment modalities.",2021,"CONCLUSION Diabetic foot ulcer wound area as well as PUSH and VAS scores showed more improvement for patients with DM receiving LLLT or HAM than for the control group, but the differences were not significant.","['Immunosuppressed and malnourished patients or those with neoplasms or in critical condition', 'Twenty-seven (27) patients participated (mean age, 51.4 years; mean body mass index, 26.5 kg/m2), with 9 patients in each treatment group', 'persons with diabetes mellitus (DM) and foot ulcers', 'Eligible patients had to be 30 to 59 years of age; diagnosed with type 2 DM (postprandial capillary glucose levels between 140 and 350 mg/dL); and have uninfected, granulating stage 2 or 3 foot ulcers measuring less than 7 cm by 3 cm', 'patients receiving care at a health center that specializes in the treatment of diabetic foot wounds between November 2016 and August 2017 were recruited']","['control treatment (2 mg hydrogel, saline, and gauze), HAM (patches of thawed HAM, applied with overlapping edges), or LLLT (phototherapy session, 2 mg hydrogel, saline, and gauze', 'LLT', 'Human Amniotic Membrane and Low-level Laser Therapy', 'Low-level laser therapy (LLLT) and human amniotic membrane (HAM) application', 'control treatment (hydrogel, saline, and gauze', 'LLLT and HAM']","['Variables, wound area measurements, Pressure Ulcer Scale for Healing (PUSH) scores, and Visual Analog Scale (VAS) scores', 'PUSH and VAS scores and wound size', 'clinical or anthropometric variables', 'PUSH and VAS scores', 'PUSH score']","[{'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0085119', 'cui_str': 'Ulcer of foot'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C4517735', 'cui_str': '350'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0206172', 'cui_str': 'Diabetic foot'}, {'cui': 'C0021501', 'cui_str': 'wounds'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0063083', 'cui_str': 'Hydrogel'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0590323', 'cui_str': 'Gauzes'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0002630', 'cui_str': 'Structure of amnion'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0185027', 'cui_str': 'Imbrication'}, {'cui': 'C0205154', 'cui_str': 'Along edge'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0011127', 'cui_str': 'Pressure ulcer'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",,0.0149901,"CONCLUSION Diabetic foot ulcer wound area as well as PUSH and VAS scores showed more improvement for patients with DM receiving LLLT or HAM than for the control group, but the differences were not significant.","[{'ForeName': 'Joelita', 'Initials': 'J', 'LastName': 'de Alencar F Santos', 'Affiliation': 'Department of Nursing, Federal University of Piaui, Teresina, Piaui, Brazil.'}, {'ForeName': 'Renata A', 'Initials': 'RA', 'LastName': 'Nicolau', 'Affiliation': 'Universidade do Vale do Paraíba (UNIVAP), São José dos Campos, São Paulo, Brazil.'}, {'ForeName': 'Luciana B', 'Initials': 'LB', 'LastName': ""Sant'Anna"", 'Affiliation': 'Universidade Estadual de Campinas, São José dos Campos, São Paulo, Brazil.'}, {'ForeName': 'Josne C', 'Initials': 'JC', 'LastName': 'Paterno', 'Affiliation': 'Department of Medicine, Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Priscila C', 'Initials': 'PC', 'LastName': 'Cristovam', 'Affiliation': 'Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Jose Álvaro P', 'Initials': 'JÁP', 'LastName': 'Gomes', 'Affiliation': 'Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'José Diego Marques', 'Initials': 'JDM', 'LastName': 'Santos', 'Affiliation': 'College of Medicine, University of Saskatchewan, Regina, Canada.'}, {'ForeName': 'Emilia A', 'Initials': 'EA', 'LastName': 'Lo Schiavo Arisawa', 'Affiliation': 'São José dos Campos, São Paulo, Brazil.'}]",Wound management & prevention,[] 2365,34370612,Nonimmersive Virtual Reality as Complementary Rehabilitation on Functional Mobility and Gait in Cerebral Palsy: A Randomized Controlled Clinical Trial.,"Objective: This study aimed to investigate the effects of nonimmersive virtual reality (VR) as complementary rehabilitation on functional mobility and gait in children with mild unilateral cerebral palsy (CP). Methods: Prospective, randomized, controlled, clinical trial. Twenty-two children with unilateral CP were randomized into two groups: intervention group (IG) ( n  = 11) and control group ( n  = 11). After baseline assessments, the participants either started the VR intervention (IG) associated with conventional therapy, or continued conventional physical therapy (control group). Participants in the IG attended 45-minute training sessions twice a week for 8 weeks (total: 16 sessions and 12 hours of training). Participants in the control group underwent standard therapy for 50 minutes, twice a week. Timed Up and Go test (TUG), gait spatiotemporal variables, and pelvic angles were measured at baseline and after treatment sessions. Results: When compared with the control group, the IG performed the following activities in decreased time: TUG, and stride time. Also, the IG increased the velocity of walking and the pelvis retroversion, and decreased the pelvis interval/external rotations and amplitude of pelvis rotation while walking. Conclusions: A rehabilitative approach based on a nonimmersive VR as complementary rehabilitation may improve functional mobility and change joint mobility functions during gait of children with mild unilateral CP. The results of the study demonstrate that the insertion of a therapy based on VR may help in better strategies in the gait of children with CP. Thus, rehabilitation professionals can use this tool combined with conventional therapy.",2021,"Results: When compared with the control group, the IG performed the following activities in decreased time: TUG, and stride time.","['children with mild unilateral cerebral palsy (CP', 'Twenty-two children with unilateral CP', 'children with mild unilateral CP', 'Cerebral Palsy', 'children with CP']","['nonimmersive virtual reality (VR', 'standard therapy', 'conventional therapy, or continued conventional physical therapy (control group']","['Functional Mobility and Gait', 'functional mobility and change joint mobility functions', 'pelvis interval/external rotations and amplitude of pelvis rotation while walking', 'time: TUG, and stride time', 'velocity of walking and the pelvis retroversion', 'functional mobility and gait', 'Timed Up and Go test (TUG), gait spatiotemporal variables, and pelvic angles']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C4284772', 'cui_str': '22'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0231462', 'cui_str': 'External rotation'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0333055', 'cui_str': 'Retroversion'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0205143', 'cui_str': 'Angular'}]",22.0,0.0156616,"Results: When compared with the control group, the IG performed the following activities in decreased time: TUG, and stride time.","[{'ForeName': 'Joice Luiza Bruno', 'Initials': 'JLB', 'LastName': 'Arnoni', 'Affiliation': 'Department of Physiotherapy, Neuropediatrics Section, Federal University of Sao Carlos, Sao Carlos, Brazil.'}, {'ForeName': 'Ana Francisca Rozin', 'Initials': 'AFR', 'LastName': 'Kleiner', 'Affiliation': 'Department of Physiotherapy, Neuropediatrics Section, Federal University of Sao Carlos, Sao Carlos, Brazil.'}, {'ForeName': 'Camila Resende Gâmbaro', 'Initials': 'CRG', 'LastName': 'Lima', 'Affiliation': 'Department of Physiotherapy, Neuropediatrics Section, Federal University of Sao Carlos, Sao Carlos, Brazil.'}, {'ForeName': 'Ana Carolina', 'Initials': 'AC', 'LastName': 'de Campos', 'Affiliation': 'Department of Physiotherapy, Neuropediatrics Section, Federal University of Sao Carlos, Sao Carlos, Brazil.'}, {'ForeName': 'Nelci Adriana Cicuto Ferreira', 'Initials': 'NACF', 'LastName': 'Rocha', 'Affiliation': 'Department of Physiotherapy, Neuropediatrics Section, Federal University of Sao Carlos, Sao Carlos, Brazil.'}]",Games for health journal,['10.1089/g4h.2021.0009'] 2366,34370610,A Virtual Reality Serious Videogame Versus Online Chess Augmentation in Patients with Attention Deficit Hyperactivity Disorder: A Randomized Clinical Trial.,"Objective: Serious videogames and virtual reality (VR) have gained increasing interest for treating attention deficit hyperactivity disorder (ADHD). ""The Secret Trail of Moon"" (TSTM) study is a clinical trial devoted to testing the efficacy of TSTM, a VR serious videogame developed to train in five major cognitive skills usually compromised in patients with ADHD. This study is a three-arm nonequality trial comparing TSTM to online chess training and a control group (CG). This study aims to demonstrate that augmentation with either TSTM or online chess is efficacious in clinically drug-stable patients with ADHD. Materials and Methods: This study is prospective, unicentric, and randomized with a CG. One hundred five patients with ADHD, ages 12-22 years old, and pharmacologically stable were enrolled. Patients were randomized into three groups: TSTM group, online chess group (therapeutic chess [TC]), and CG. Objective and subjective measures of the patient and parents are included. Patient visits differ for each group. TSTM group patients have 15 face-to-face visits: preinclusion visit, inclusion visit, 12 training visits, and final visit. TC and CG patients have 3 face-to-face visits (preinclusion, initial visit, and final visit) and 12 e-mail or phone communications during training (TC) or follow-up (CG group). This study was approved by the local Institutional Review Board (IRB). Results: Not applicable. This is a study protocol. Conclusion: This is the first study testing an augmentation strategy using either a serious videogame or chess in clinically drug-treated patients with ADHD. Using VR serious videogames present with several advantages over traditional videogames. Trial Registration: NCT04355065.",2021,This study aims to demonstrate that augmentation with either TSTM or online chess is efficacious in clinically drug-stable patients with ADHD. ,"['group patients have 15 face-to-face visits: preinclusion visit, inclusion visit, 12 training visits, and final visit', 'One hundred five patients with ADHD, ages 12-22 years old, and pharmacologically stable were enrolled', 'clinically drug-treated patients with ADHD', 'clinically drug-stable patients with ADHD', 'Patients with Attention Deficit Hyperactivity Disorder', 'patients with ADHD']","['TSTM', 'Virtual Reality Serious Videogame Versus Online Chess Augmentation', 'TSTM group, online chess group (therapeutic chess [TC]), and CG', 'Serious videogames and virtual reality (VR']",[],"[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]",[],105.0,0.014761,This study aims to demonstrate that augmentation with either TSTM or online chess is efficacious in clinically drug-stable patients with ADHD. ,"[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Rodrigo-Yanguas', 'Affiliation': 'Department of Psychiatry, Puerta de Hierro University Hospital-Health Research Institute Puerta de Hierro-Segovia de Arana (IDIPHISA), Madrid, Spain.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Martin-Moratinos', 'Affiliation': 'Department of Psychiatry, Puerta de Hierro University Hospital-Health Research Institute Puerta de Hierro-Segovia de Arana (IDIPHISA), Madrid, Spain.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Menendez-Garcia', 'Affiliation': 'Department of Psychiatry, Puerta de Hierro University Hospital-Health Research Institute Puerta de Hierro-Segovia de Arana (IDIPHISA), Madrid, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Gonzalez-Tardon', 'Affiliation': 'Tecnocampus Universitat Pompeu Fabra, Barcelona, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Sanchez-Sanchez', 'Affiliation': 'R&D Department, TEA Ediciones, Madrid, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Royuela', 'Affiliation': 'Clinical Biostatistics Unit, Health Research Institute Puerta de Hierro-Segovia de Arana, CIBERESP, Madrid, Spain.'}, {'ForeName': 'Hilario', 'Initials': 'H', 'LastName': 'Blasco-Fontecilla', 'Affiliation': 'Department of Psychiatry, Puerta de Hierro University Hospital-Health Research Institute Puerta de Hierro-Segovia de Arana (IDIPHISA), Madrid, Spain.'}]",Games for health journal,['10.1089/g4h.2021.0073'] 2367,34370609,"The Benefits of Custom Exergames for Fitness, Balance, and Health-Related Quality of Life: A Randomized Controlled Trial with Community-Dwelling Older Adults.","Objective: This research aimed to measure the benefits in older adults' motor performance and quality of life during a 12-week-long multidimensional training combining custom-made exergames and traditional exercise in a complementary manner, compared with traditional training alone. Materials and Methods: Community-dwelling older adults participated in a randomized controlled trial ( N  = 31) consisting of two weekly exercise sessions of 60 minutes for 12 weeks. Participants allocated to the exergames group ( n  = 15) had one individual session of exergames and one traditional exercise group session per week. Control group participants ( n  = 16) had two weekly traditional exercise group sessions. Outcome measures on fitness, balance, and health-related quality of life were measured at the start of the intervention, 6th, 12th, and 16th week (1-month follow-up). Results: The exergames group showed a significant increase in lower-body and upper-body strength from pre- to postintervention. When compared with control, participants had significantly higher developments of upper-body strength from pre- to postassessments. There was a significant decrease in shoulder range of motion between the end of the intervention and follow-up for participants in both conditions. Balance increased significantly during the intervention but decreased at follow-up in both conditions. The mental component of health-related quality of life was significantly higher at the end compared with the start of the intervention in the exergames group, and this difference was significantly higher when compared with control. Conclusion: Integrating personalized exergames designed for multidimensional fitness training in traditional settings can be an effective strategy to enhance older adults' motor performance and mental well-being.",2021,"The mental component of health-related quality of life was significantly higher at the end compared with the start of the intervention in the exergames group, and this difference was significantly higher when compared with control. ","['Community-dwelling older adults', 'older adults', 'Community-Dwelling Older Adults']","['multidimensional fitness training', 'exergames group ( n \u2009=\u200915) had one individual session of exergames and one traditional exercise group session per week', 'traditional exercise group sessions', 'multidimensional training combining custom-made exergames and traditional exercise', 'traditional training alone']","['lower-body and upper-body strength', 'motor performance and quality of life', 'upper-body strength', 'Fitness, Balance, and Health-Related Quality of Life', 'Balance', 'fitness, balance, and health-related quality of life', 'shoulder range of motion', 'mental component of health-related quality of life']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0162343', 'cui_str': 'Customs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C1268088', 'cui_str': 'Lower body structure'}, {'cui': 'C1268087', 'cui_str': 'Upper body structure'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0575545', 'cui_str': 'Shoulder joint - range of movement'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",,0.0146459,"The mental component of health-related quality of life was significantly higher at the end compared with the start of the intervention in the exergames group, and this difference was significantly higher when compared with control. ","[{'ForeName': 'Afonso', 'Initials': 'A', 'LastName': 'Gonçalves', 'Affiliation': 'Faculty of Exact Sciences and Engineering, Universidade da Madeira, Funchal, Portugal.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Muñoz', 'Affiliation': 'Department of System Design and Engineering, University of Waterloo, Waterloo, Canada.'}, {'ForeName': 'Mónica S', 'Initials': 'MS', 'LastName': 'Cameirão', 'Affiliation': 'Faculty of Exact Sciences and Engineering, Universidade da Madeira, Funchal, Portugal.'}, {'ForeName': 'Élvio Rúbio', 'Initials': 'ÉR', 'LastName': 'Gouveia', 'Affiliation': 'Department of Physical Education and Sport, Universidade da Madeira, Funchal, Portugal.'}, {'ForeName': 'Honorato', 'Initials': 'H', 'LastName': 'Sousa', 'Affiliation': 'Interactive Technologies Institute-LARSyS/ITI, Funchal, Portugal.'}, {'ForeName': 'Sergi', 'Initials': 'S', 'LastName': 'Bermúdez I Badia', 'Affiliation': 'Faculty of Exact Sciences and Engineering, Universidade da Madeira, Funchal, Portugal.'}]",Games for health journal,['10.1089/g4h.2020.0092'] 2368,34370587,Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei .,"First-line treatment of talaromycosis with amphotericin B deoxycholate (DAmB) is labour intensive and toxic. Itraconazole is an appealing alternative antifungal agent. Pharmacokinetic data were obtained from 76 patients who were randomized to itraconazole in the Itraconazole versus Amphotericin B for Talaromycosis (IVAP) trial. Plasma levels of itraconazole and its active metabolite, hydroxyitraconazole, were analysed alongside longitudinal fungal colony forming unit counts in a population model. Itraconazole and hydroxyitraconazole pharmacokinetic variability was considerable, with area under the concentration-time curve over 24 hours (AUC 24 ) mean ± standard deviation 3.34 ± 4.31 mg*h/litre and 3.57 ± 4.46 mg*h/litre, respectively. Levels of both analytes were low; itraconazole minimum concentration (Cmin) 0.11 ± 0.16 mg/liter; hydroxyitraconazole Cmin 0.13 ± 0.17 mg/litre. The mean maximal rates of drug-induced killing were 0.206 and 0.208 log 10 CFU/mL/h, respectively. There were no associations between itraconazole Cmin:MIC and time to sterilisation of the bloodstream (HR 1.01, 95% CI 0.99 to 1.03, p=0.43), time to death (HR 0.99, 95% CI 0.96 to 1.02, p=0.77) or early fungicidal activity EFA (coefficient -0.004, 95% CI -0.010 to 0.002, p=0.18). Similarly, there was no relationship between AUC:MIC and time to sterilisation of the bloodstream (HR 1.00, 95% CI 0.99 to 1.00, p=0.50), time to death (HR 1.00, 95% CI 0.99 to 1.00, p=0.91) or EFA (coefficient -0.0001, 95% CI -0.0003 to 0.0001, p = 0.19). This study raises the possibility that the failure of itraconazole to satisfy non-inferiority criteria against DAmB for talaromycosis in the IVAP trial was a pharmacokinetic and pharmacodynamic failure.",2021,Levels of both analytes were low; itraconazole minimum concentration (Cmin) 0.11 ± 0.16 mg/liter; hydroxyitraconazole Cmin 0.13 ± 0.17 mg/litre.,['76 patients who were randomized to'],"['Itraconazole', 'amphotericin B deoxycholate (DAmB', 'Itraconazole versus Amphotericin', 'itraconazole']","['early fungicidal activity EFA', 'time to death', 'mean maximal rates of drug-induced killing', 'AUC:MIC and time to sterilisation of the bloodstream', 'Plasma levels', 'time to sterilisation of the bloodstream']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0064113', 'cui_str': 'Itraconazole'}, {'cui': 'C0051761', 'cui_str': 'amphotericin B, deoxycholate drug combination'}, {'cui': 'C0085795', 'cui_str': 'Amphotericin'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1321381', 'cui_str': 'Fungicidal activity'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0458082', 'cui_str': 'Drug-induced'}, {'cui': 'C0162388', 'cui_str': 'Killing'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0066256', 'cui_str': 'Methyl isocyanate'}, {'cui': 'C0038288', 'cui_str': 'Sterilisation'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.10222,Levels of both analytes were low; itraconazole minimum concentration (Cmin) 0.11 ± 0.16 mg/liter; hydroxyitraconazole Cmin 0.13 ± 0.17 mg/litre.,"[{'ForeName': 'Katharine E', 'Initials': 'KE', 'LastName': 'Stott', 'Affiliation': 'Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.'}, {'ForeName': 'Thuy', 'Initials': 'T', 'LastName': 'Le', 'Affiliation': 'Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Thu', 'Initials': 'T', 'LastName': 'Nguyen', 'Affiliation': 'Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Whalley', 'Affiliation': 'Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Unsworth', 'Affiliation': 'Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.'}, {'ForeName': 'Vo Trieu', 'Initials': 'VT', 'LastName': 'Ly', 'Affiliation': 'University of Medicine and Pharmacy at Ho Chi Minh city, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Ruwanthi', 'Initials': 'R', 'LastName': 'Kolamunnage-Dona', 'Affiliation': 'Department of Health Data Science, Institute of Population Health, University of Liverpool.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Hope', 'Affiliation': 'Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00636-21'] 2369,34370575,"A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers.","V-7404, a direct-acting enterovirus (EV) 3C protease inhibitor, is being developed as a treatment option for serious EV infections, including infections in immunodeficient people excreting vaccine-derived polioviruses. V-7404 may be combined with pocapavir (V-073), a capsid inhibitor, to treat these infections. A Phase 1 single ascending dose (SAD; N=36) and multiple ascending doses (MAD; N=40) study was conducted to assess the safety, tolerability, and pharmacokinetics (PK) of V-7404 in healthy adult volunteers following oral doses starting at 200 mg and escalating to 2000 mg once daily (QD) and 2000 mg twice daily (BID). Adverse events (AEs), vital signs, electrocardiographic findings, physical examinations, clinical laboratory values, and PK of blood samples were assessed. No notable differences in demographic and baseline characteristics were observed across the dose cohorts. A total of 35/36 participants (97.2%) completed the SAD study (1 withdrew in placebo group), and 37/41 participants (90.2%) completed the MAD study (1 withdrew from the 2000 mg QD and 3 withdrew from the 2000 mg BID cohorts). No serious AEs or deaths were reported. Treatment-emergent AEs were mild or moderate in severity. Oral doses of V-7404 in all cohorts were readily absorbed and showed no significant accumulation. PK exposure increased in an approximately dose proportional manner and appeared to be independent of time. Overall, V-7404 was well-tolerated and exhibited an acceptable safety and PK profile, supporting further clinical investigation of V-7404 for the treatment of serious EV infections.",2021,No serious AEs or deaths were reported.,"['A total of 35/36 participants (97.2%) completed the SAD study (1 withdrew in placebo group), and 37/41 participants (90.2%) completed the MAD study', 'Healthy Adult Volunteers', 'healthy adult volunteers following']",['oral doses starting at 200 mg and escalating to 2000 mg once daily (QD'],"['safety, tolerability, and pharmacokinetics (PK', 'Adverse events (AEs), vital signs, electrocardiographic findings, physical examinations, clinical laboratory values, and PK of blood samples', 'Safety, Tolerability, and Pharmacokinetics', 'direct-acting enterovirus (EV', 'PK exposure']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517910', 'cui_str': '97.2'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0438154', 'cui_str': 'ECG finding'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0014378', 'cui_str': 'Disease due to Enterovirus'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]",,0.210828,No serious AEs or deaths were reported.,"[{'ForeName': 'Martin K', 'Initials': 'MK', 'LastName': 'Kankam', 'Affiliation': 'Altasciences, Overland Park, Kansas, USA.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Burns', 'Affiliation': 'ViroDefense, Chevy Chase, Maryland, USA.'}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Collett', 'Affiliation': 'ViroDefense, Chevy Chase, Maryland, USA.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Corrado', 'Affiliation': 'Independent Consultant/Advisor, Perkasie, PA, USA.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Hincks', 'Affiliation': 'ViroDefense, Chevy Chase, Maryland, USA.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.01029-21'] 2370,34374894,"Comparative effects of high-intensity interval training and moderate-intensity continuous training on soleus muscle fibronectin type III domain-containing protein 5, myonectin and glucose transporter type 4 gene expressions: a study on the diabetic rat model.","BACKGROUND The increase in fibronectin type-III domain-containing protein 5 (FNDC5), myonectin, and glucose transporter 4 (GLUT4) leads to a decrease in diabetes; meanwhile, exercise training can affect these factors. The result regarding the comparison between the effect of high-intensity interval training (HIIT) and that of moderate-intensity continuous training (MICT) is confusing. Thus, the present study investigated the comparative effects of HIIT and MICT on soleus muscle FNDC5, myonectin, and GLUT4 gene expressions in the diabetic rat model. METHODS AND RESULTS Seventy-two male Wistar rats (weight 200 g ± 20) were randomly and equally assigned to six groups: control-healthy, MICT-healthy, HIIT-healthy, control-diabetes, MICT-diabetes, and HIIT-diabetes. At the first level, Streptozotocin (STZ) was utilized to induce diabetes in rats (at a dose of 55 mg/kg). After that, the training groups performed HIIT and MICT programs on the rodent treadmill for 6 weeks (five-session/week). Twenty-four hours after the last intervention, soleus muscle was removed, and sent to a research facility for future examinations. HIIT and MICT increased the muscle FNDC5, myonectin, and GLUT4 gene expression compared to the control group (P < 0.05). The type of training had no significant effect on the FNDC5 (P > 0.05), while the MICT program induced a greater increase in the myonec ztin and GLUT4 compared to the HIIT program (P < 0.05). Meanwhile, a positive relationship between all variables was observed. CONCLUSIONS Exercise training has a beneficial effect on diabetes conditions via the effect of FNDC5, myonectin, and GLUT4. Due to the correlation between myonectin and GLUT4 shown in the present study, physical activity may alter myonectin through its effect on GLUT requiring further investigation by subsequent studies.",2021,"HIIT and MICT increased the muscle FNDC5, myonectin, and GLUT4 gene expression compared to the control group (P < 0.05).",['Seventy-two male Wistar rats (weight 200\xa0g\u2009±\u200920'],"['high-intensity interval training and moderate-intensity continuous training', 'high-intensity interval training (HIIT) and that of moderate-intensity continuous training (MICT', 'HIIT and MICT', 'control-healthy, MICT-healthy, HIIT-healthy, control-diabetes, MICT-diabetes, and HIIT-diabetes', 'Exercise training', 'Streptozotocin (STZ']","['FNDC5', 'muscle FNDC5, myonectin, and GLUT4 gene expression', 'myonec ztin and GLUT4']","[{'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0034716', 'cui_str': 'Wistar rat'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0038432', 'cui_str': 'Streptozocin'}]","[{'cui': 'C4277623', 'cui_str': 'Fibronectin Type III Domains'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0017742', 'cui_str': 'Glucose Transporter'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}]",72.0,0.00292522,"HIIT and MICT increased the muscle FNDC5, myonectin, and GLUT4 gene expression compared to the control group (P < 0.05).","[{'ForeName': 'Saleh', 'Initials': 'S', 'LastName': 'Rahmati-Ahmadabad', 'Affiliation': 'Department of\xa0Physical Education, Pardis Branch, Islamic Azad University, Pardis, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Rostamkhani', 'Affiliation': 'Department of Biology, Yadegar-e-Imam Khomeini (RAH) Shahre Rey Branch, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Gholam Hossein', 'Initials': 'GH', 'LastName': 'Meftahi', 'Affiliation': 'Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Shirvani', 'Affiliation': 'Exercise Physiology Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. shirvani@bmsu.ac.ir.'}]",Molecular biology reports,['10.1007/s11033-021-06633-1'] 2371,34374847,Feasibility and acceptability of hypnosis-derived communication administered by trained nurses to improve patient well-being during outpatient chemotherapy: a pilot-controlled trial.,"PURPOSE This pilot-controlled trial aimed to examine the feasibility and acceptability of hypnosis-derived communication (HC) administered by trained nurses during outpatient chemotherapy to optimize symptom management and emotional support - two important aspects of patient well-being in oncology. METHODS The trial was conducted in two outpatient oncology units: (1) intervention site (usual care with HC), and (2) control site (usual care). Nurses at the intervention site were invited to take part in an 8-h training in HC. Participants' self-ratings of symptoms and emotional support were gathered at predetermined time points during three consecutive outpatient visits using the Edmonton Symptom Assessment Scale and the Emotional Support Scale. RESULTS Forty-nine patients (24 in the intervention group, 25 in the control group) with different cancer types/stages were recruited over a period of 3 weeks and completed the study. All nurses (N = 10) at the intervention site volunteered to complete the training and were able to include HC into their chemotherapy protocols (about ± 5 min/intervention). Compared to usual care, patients exposed to HC showed a significant reduction in physical symptoms during chemotherapy. In contrast, perception of emotional support did not show any significant effect of the intervention. Participants exposed to HC report that the intervention helped them relax and connect on a more personal level with the nurse during chemotherapy infusion. CONCLUSIONS Our results suggest that HC is feasible, acceptable, and beneficial for symptom management during outpatient chemotherapy. While future studies are needed, hypnosis techniques could facilitate meaningful contacts between cancer patients and clinicians in oncology. TRIAL REGISTRATION Clinical Trial Identifier: NCT04173195, first posted on November 19, 2019.",2021,"Compared to usual care, patients exposed to HC showed a significant reduction in physical symptoms during chemotherapy.","['Forty-nine patients (24 in the intervention group, 25 in the control group) with different cancer types/stages were recruited over a period of 3\xa0weeks and completed the study', 'patient well-being in oncology', 'cancer patients and clinicians in oncology']","['intervention site (usual care with HC), and (2) control site (usual care', 'hypnosis-derived communication administered by trained nurses', 'hypnosis-derived communication (HC']","['physical symptoms', ""Participants' self-ratings of symptoms and emotional support"", 'Edmonton Symptom Assessment Scale and the Emotional Support Scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0730490', 'cui_str': 'Stage 1S'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0600015', 'cui_str': 'Emotional support'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0300042,"Compared to usual care, patients exposed to HC showed a significant reduction in physical symptoms during chemotherapy.","[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Arbour', 'Affiliation': ""Hôpital du Sacré-Cœur de Montréal, CIUSSS du Nord-de-L'Île-de-Montréal, 5400 Boul. Gouin Ouest, Room: E-1381, Montreal, QC, H4J 1C5, Canada. caroline.arbour@umontreal.ca.""}, {'ForeName': 'Marjorie', 'Initials': 'M', 'LastName': 'Tremblay', 'Affiliation': 'Hôpital de La Cité-de-La-Santé, CISSS de Laval, Laval, QC, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ogez', 'Affiliation': 'Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Chloé', 'Initials': 'C', 'LastName': 'Martineau-Lessard', 'Affiliation': ""Hôpital du Sacré-Cœur de Montréal, CIUSSS du Nord-de-L'Île-de-Montréal, 5400 Boul. Gouin Ouest, Room: E-1381, Montreal, QC, H4J 1C5, Canada.""}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Lavigne', 'Affiliation': ""Hôpital du Sacré-Cœur de Montréal, CIUSSS du Nord-de-L'Île-de-Montréal, 5400 Boul. Gouin Ouest, Room: E-1381, Montreal, QC, H4J 1C5, Canada.""}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Rainville', 'Affiliation': 'Faculty of Dental Medicine, Université de Montréal, Montreal, QC, Canada.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-021-06481-6'] 2372,34374766,Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter.,"AIMS Age and sex may impact the efficacy of antiarrhythmic drugs on cardiovascular outcomes and arrhythmia recurrences in patients with atrial fibrillation (AF). We report on a post hoc analysis of the ATHENA study (NCT00174785), which examined cardiovascular outcomes in patients with non-permanent AF treated with dronedarone vs. placebo. METHODS AND RESULTS Efficacy and safety of dronedarone were assessed in patients according to age and sex. Baseline characteristics were comparable across subgroups, except for cardiovascular comorbidities, which were more frequent with increasing age. Dronedarone significantly reduced the risk of cardiovascular hospitalization or death due to any cause among patients 65-74 [n = 1830; hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.60-0.83; P < 0.0001] and ≥75 (n = 1925; HR 0.75, 95% CI 0.65-0.88; P = 0.0002) years old and among males (n = 2459; HR 0.74, 95% CI 0.64-0.84; P < 0.00001) and females (n = 2169; HR 0.77, 95% CI 0.67-0.89; P = 0.0002); outcomes were similar for time to AF/AFL recurrence. Among patients aged <65 years (n = 873), cardiovascular hospitalization or death due to any cause with dronedarone vs. placebo was associated with an HR of 0.89 (95% CI 0.71-1.11; P = 0.3). The incidence of all treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation was comparable among males and females, and increased with increasing age. CONCLUSIONS These results support the use of dronedarone for the improvement of clinical outcomes among patients aged ≥65 years and regardless of sex.",2021,"The incidence of all treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation was comparable among males and females, and increased with increasing age. ","['patients aged ≥65\u2009years and regardless of sex', 'patients with non-permanent atrial fibrillation/flutter', 'patients with non-permanent AF treated with', 'patients according to age and sex', 'patients with atrial fibrillation (AF']","['Dronedarone', 'antiarrhythmic drugs', 'dronedarone vs. placebo', 'dronedarone']","['risk of cardiovascular hospitalization or death', 'Efficacy and safety', 'cardiovascular outcomes and arrhythmia recurrences', 'incidence of all treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation', 'cardiovascular hospitalization or death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C2586056', 'cui_str': 'Permanent atrial fibrillation'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]","[{'cui': 'C0766326', 'cui_str': 'dronedarone'}, {'cui': 'C0003195', 'cui_str': 'Antiarrhythmic agent'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]",,0.209091,"The incidence of all treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation was comparable among males and females, and increased with increasing age. ","[{'ForeName': 'Anne B', 'Initials': 'AB', 'LastName': 'Curtis', 'Affiliation': 'Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo General Medical Center, 100 High Street, D2-76, Buffalo, NY 14203, USA.'}, {'ForeName': 'Emily P', 'Initials': 'EP', 'LastName': 'Zeitler', 'Affiliation': 'Department of Cardiology, Dartmouth-Hitchcock Medical Center, The Dartmouth Institute, Lebanon, NH, USA.'}, {'ForeName': 'Aysha', 'Initials': 'A', 'LastName': 'Malik', 'Affiliation': 'Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo General Medical Center, 100 High Street, D2-76, Buffalo, NY 14203, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Bogard', 'Affiliation': 'US General Medicines Medical, Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Nidhi', 'Initials': 'N', 'LastName': 'Bhattacharyya', 'Affiliation': 'US General Medicines Medical, Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Stewart', 'Affiliation': 'Biostatistics, Sanofi, Laval, QC, Canada.'}, {'ForeName': 'Stefan H', 'Initials': 'SH', 'LastName': 'Hohnloser', 'Affiliation': 'Department of Cardiology, J.W. Goethe University, Frankfurt, Germany.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euab208'] 2373,34374751,The effect of different bonded retainer wires on tooth mobility immediately after orthodontic treatment.,"OBJECTIVES This study aimed to compare the immediate influence of four commonly used retainer wires on tooth mobility following orthodontic treatment with fixed appliances. MATERIALS AND METHODS Eighty patients after orthodontic treatment were assigned to four study groups (n = 20 in each group). Groups were provided with directly bonded fixed retainers-0.0150″ (group A), 0.0175″ (group B), 0.016 × 0.022″ (group C), and 0.0215″ (group D). Tooth mobility was measured using the Periotest device at two times-after removal of fixed appliance (T1) and after bonding of the retainer (T2). Values of tooth mobility, 'Periotest values', were analysed between groups and compared with the physiologic tooth mobility in a control group of untreated patients (n = 65). Kruskal-Wallis H, Mann-Whitney U, Dunn's test, Fisher's exact test, and binary logistic regression tests were used to analyze the data. RESULTS Tooth mobility after orthodontic treatment was significantly increased. While canines remained within normal range of tooth mobility, values for incisors increased on average to the first degree of tooth mobility (slight mobility). Logistic regression analysis identified age as a significant predictor for increased tooth mobility (P = 0.032) with odds ratio 1.065 (95% CI 1.005-1.128), with mobility increasing with age. After bonding of the retainer in all four groups, the tooth mobility was reduced to values which were not significantly different form normal physiological values found in the control group (P > 0.05). There were no differences in the amount of change or in tooth mobility values at T2 between the different types of bonded retainers. LIMITATIONS Age of subjects in the control group was significantly higher than that in the study groups. An alternation method was used instead of randomization to distribute the four different types of retainers. CONCLUSIONS All of the retainer wires were able to successfully reduce the increased tooth mobility caused by orthodontic treatment to normal levels. The values of tooth mobility after placement of retainers were within the range of physiologic tooth mobility.",2021,"There were no differences in the amount of change or in tooth mobility values at T2 between the different types of bonded retainers. ",['Eighty patients after orthodontic treatment'],['bonded retainer wires'],"['normal physiological values', 'Tooth mobility', 'amount of change or in tooth mobility values', 'physiologic tooth mobility', 'tooth mobility', ""Values of tooth mobility, 'Periotest values"", 'values of tooth mobility']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0204193', 'cui_str': 'Orthodontic procedure'}]","[{'cui': 'C0441421', 'cui_str': 'Fixed orthodontic appliance'}, {'cui': 'C0005978', 'cui_str': 'Bone wire'}]","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0031845', 'cui_str': 'Physiological process'}, {'cui': 'C0040445', 'cui_str': 'Tooth mobility'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}]",,0.0442992,"There were no differences in the amount of change or in tooth mobility values at T2 between the different types of bonded retainers. ","[{'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Kučera', 'Affiliation': 'Department of Orthodontics, Clinic of Dental Medicine, First Medical Faculty, Charles University, Prague, Czech Republic.'}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Marek', 'Affiliation': 'Department of Orthodontics, Clinic of Dental Medicine, Palacky University, Olomouc, Czech Republic.'}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Littlewood', 'Affiliation': ""Department of Orthodontics, St Luke's Hospital, Bradford, UK.""}]",European journal of orthodontics,['10.1093/ejo/cjab038'] 2374,34374425,"Functional antibodies and innate immune responses to WRSS1, a live oral Shigella sonnei vaccine candidate in Bangladeshi adults and children.","BACKGROUND We have reported earlier in a randomized placebo-controlled trial that WRSS1, a live oral Shigella sonnei vaccine candidate is safe in Bangladeshi adults and children, and elicits antigen-specific antibody responses. Here, we describe the functional antibodies and innate immune responses induced by WRSS1. METHODS Adults (18-39 years) and children (5-9 years), received three doses of 3x10 5 or 3x10 6 colony forming unit (CFU) of WRSS1 or placebo, 4 weeks apart; children additionally received 3x10 4 CFU. Blood and stool were collected at baseline and 7 days after each dose. Functional antibodies were measured using serum bactericidal antibody (SBA) assay. Cyto/Chemokine concentrations were measured in lymphocyte cultures. Host defense peptides LL-37, human beta defensin-1 (HBD-1) and human defensin-5 (HD-5) were analyzed in plasma and stool. RESULTS Children showed increased SBA titers over baseline after the 3 rd dose of 3x10 6 CFU (p=0.048). Significant increases of Th-17 and pro-inflammatory cytokines (TNF-α, G-CFS, MIP-1β), and reduction of anti-inflammatory and Th2 cytokines (IL-10, IL-13, GM-CSF) were observed in children. Plasma levels of HBD-1 and LL-37 decreased in children after vaccination but were increased/unchanged in adults. CONCLUSION Functional antibodies and Th1/Th17 cytokine responses in children may serve as important indicators of immunogenicity and protective potential of WRSS1.",2021,"Significant increases of Th-17 and pro-inflammatory cytokines (TNF-α, G-CFS, MIP-1β), and reduction of anti-inflammatory and Th2 cytokines (IL-10, IL-13, GM-CSF) were observed in children.","['Bangladeshi adults and children', 'Adults (18-39 years) and children (5-9 years']","['placebo', '3x10 5 or 3x10 6 colony forming unit (CFU) of WRSS1 or placebo, 4 weeks apart; children additionally received 3x10 4 CFU', 'WRSS1']","['Cyto/Chemokine concentrations', 'Plasma levels of HBD-1 and LL-37', 'serum bactericidal antibody (SBA) assay', 'Th-17 and pro-inflammatory cytokines (TNF-α, G-CFS, MIP-1β), and reduction of anti-inflammatory and Th2 cytokines (IL-10, IL-13, GM-CSF', 'Blood and stool', 'Functional antibodies', 'SBA titers']","[{'cui': 'C0422784', 'cui_str': 'Bangladeshi'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439158', 'cui_str': 'colonies'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C1305671', 'cui_str': 'Cytology'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0625647', 'cui_str': 'DEFB1 protein, human'}, {'cui': 'C0042950', 'cui_str': 'Volition'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0015674', 'cui_str': 'Chronic fatigue syndrome'}, {'cui': 'C0376579', 'cui_str': 'Macrophage Inflammatory Proteins'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0214743', 'cui_str': 'Interleukin 13'}, {'cui': 'C0079460', 'cui_str': 'Colony-stimulating factor, granulocyte-macrophage'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0474643', 'cui_str': 'Antibody titer measurement'}]",,0.196875,"Significant increases of Th-17 and pro-inflammatory cytokines (TNF-α, G-CFS, MIP-1β), and reduction of anti-inflammatory and Th2 cytokines (IL-10, IL-13, GM-CSF) were observed in children.","[{'ForeName': 'Protim', 'Initials': 'P', 'LastName': 'Sarker', 'Affiliation': 'Infectious Diseases Division, icddr,b, Dhaka, Bangladesh.'}, {'ForeName': 'Akhirunnesa', 'Initials': 'A', 'LastName': 'Mily', 'Affiliation': 'Infectious Diseases Division, icddr,b, Dhaka, Bangladesh.'}, {'ForeName': 'Anjuman', 'Initials': 'A', 'LastName': 'Ara', 'Affiliation': 'Infectious Diseases Division, icddr,b, Dhaka, Bangladesh.'}, {'ForeName': 'Farjana', 'Initials': 'F', 'LastName': 'Haque', 'Affiliation': 'Infectious Diseases Division, icddr,b, Dhaka, Bangladesh.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Maier', 'Affiliation': 'Center for Vaccine Innovation and Access, PATH, Washington DC, USA.'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Wierzba', 'Affiliation': 'Center for Vaccine Innovation and Access, PATH, Washington DC, USA.'}, {'ForeName': 'Richard I', 'Initials': 'RI', 'LastName': 'Walker', 'Affiliation': 'Center for Vaccine Innovation and Access, PATH, Washington DC, USA.'}, {'ForeName': 'Malabi M', 'Initials': 'MM', 'LastName': 'Venkatesan', 'Affiliation': 'Bacterial Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Maryland, USA.'}, {'ForeName': 'Rubhana', 'Initials': 'R', 'LastName': 'Raqib', 'Affiliation': 'Infectious Diseases Division, icddr,b, Dhaka, Bangladesh.'}]",The Journal of infectious diseases,['10.1093/infdis/jiab395'] 2375,34374343,Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score.,"BACKGROUND The radial artery is recommended by international guidelines as the default vascular access in patients with acute coronary syndromes (ACS) managed invasively. However, crossover from radial to femoral access is required in 4-10% of cases and has been associated with worse outcomes. No standardised algorithm exists to predict the risk of radial crossover. AIMS We sought to derive and externally validate a risk score to predict radial crossover in patients with ACS managed invasively. METHODS The derivation cohort consisted of 4,197 patients with ACS undergoing invasive management via the randomly allocated radial access from the MATRIX trial. Using logistic regression, we selected predictors of radial crossover and developed a numerical risk score. External validation was accomplished among 3,451 and 491 ACS patients managed invasively and randomised to radial access from the RIVAL and RIFLE-STEACS trials, respectively. RESULTS The MATRIX score (age, height, smoking, renal failure, prior coronary artery bypass grafting, ST-segment elevation myocardial infarction, Killip class, radial expertise) showed a c-index for radial crossover of 0.71 (95% CI: 0.67-0.75) in the derivation cohort. Discrimination ability was modest in the RIVAL (c-index: 0.64; 95% CI: 0.59-0.67) and RIFLE-STEACS (c-index: 0.66; 95% CI: 0.57-0.75) cohorts. A cut-off of ≥41 points was selected to identify patients at high risk of radial crossover. CONCLUSIONS The MATRIX score is a simple eight-item risk score which provides a standardised tool for the prediction of radial crossover among patients with ACS managed invasively. This tool can assist operators in anticipating and better addressing difficulties related to transradial procedures, potentially improving outcomes.",2021,Discrimination ability was modest in the RIVAL (c-index: 0.64; 95% CI: 0.59-0.67) and RIFLE-STEACS (c-index: 0.66; 95% CI: 0.57-0.75) cohorts.,"['patients with ACS managed invasively', 'acute coronary syndromes', '4,197 patients with ACS undergoing invasive management via the randomly allocated radial access from the MATRIX trial', 'patients with acute coronary syndromes (ACS) managed invasively']",[],['Discrimination ability'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",4197.0,0.110519,Discrimination ability was modest in the RIVAL (c-index: 0.64; 95% CI: 0.59-0.67) and RIFLE-STEACS (c-index: 0.66; 95% CI: 0.57-0.75) cohorts.,"[{'ForeName': 'Felice', 'Initials': 'F', 'LastName': 'Gragnano', 'Affiliation': 'Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Sanjit S', 'Initials': 'SS', 'LastName': 'Jolly', 'Affiliation': ''}, {'ForeName': 'Shamir R', 'Initials': 'SR', 'LastName': 'Mehta', 'Affiliation': ''}, {'ForeName': 'Mattia', 'Initials': 'M', 'LastName': 'Branca', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'van Klaveren', 'Affiliation': ''}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Frigoli', 'Affiliation': ''}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Gargiulo', 'Affiliation': ''}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Leonardi', 'Affiliation': ''}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Vranckx', 'Affiliation': ''}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Di Maio', 'Affiliation': ''}, {'ForeName': 'Emanuele', 'Initials': 'E', 'LastName': 'Monda', 'Affiliation': ''}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Fimiani', 'Affiliation': ''}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Fioretti', 'Affiliation': ''}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Chianese', 'Affiliation': ''}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Andò', 'Affiliation': ''}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Esposito', 'Affiliation': ''}, {'ForeName': 'Giuseppe Massimo', 'Initials': 'GM', 'LastName': 'Sangiorgi', 'Affiliation': ''}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Biondi-Zoccai', 'Affiliation': ''}, {'ForeName': 'Dik', 'Initials': 'D', 'LastName': 'Heg', 'Affiliation': ''}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Calabrò', 'Affiliation': ''}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Windecker', 'Affiliation': ''}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Romagnoli', 'Affiliation': ''}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Valgimigli', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-21-00441'] 2376,34374330,Effectiveness of different physiotherapy interventions in the management of cervicogenic headache: a pilot randomized controlled trial.,"BACKGROUND Cervicogenic headache is a secondary headache which leads to decreased functional activity, quality of life and functional disability. OBJECTIVE To determine the feasibility and acceptability of different physiotherapy interventions in the management of cervicogenic headache and to determine sample size for a full trial. TRIAL DESIGN A pilot randomized controlled trial. SETTINGS Various physiotherapy outpatient department. METHODS Participants suffering from cervicogenic headache with age 20- 60 years were randomly allocated into four groups. Sessions were given over 4 weeks 4 times a week (16 sessions). The primary outcomes were feasibility of participant recruitment, assessment procedure, retention, adherence, and acceptability. The secondary outcomes were headache impact test-6 for a headache disability, headache diary for headache intensity, frequency, duration, and neck disability index for neck pain, disability measured at baseline, 4th week, and follow up after 1 month. RESULT 178 subjects were screened based on selection criteria. Out of them, 93 (52%) were eligible and 80 (86%) participated in the study. 96.25% of participants completed the final 8-week assessment. Overall 93.75% of participants completed the entire assessment item across all time points. 95% completed all treatment sessions. 97.5-100% of participants were satisfied with the treatment protocol. No adverse effects were reported by participants. Based on the data obtained from the pilot trial, sample size was determined as 35 participants in each group. CONCLUSION The results indicate that the trial methodology and intervention are feasible for implementing a full-powered randomized controlled trial to determine the effectiveness of physiotherapy intervention in the management of cervicogenic headache.",2021,No adverse effects were reported by participants.,"['Out of them, 93 (52%) were eligible and 80 (86%) participated in the study', 'Various physiotherapy outpatient department', 'Participants suffering from cervicogenic headache with age', '20- 60\xa0years', '35 participants in each group', 'cervicogenic headache', '178 subjects were screened based on selection criteria']","['physiotherapy intervention', 'physiotherapy interventions']","['feasibility of participant recruitment, assessment procedure, retention, adherence, and acceptability', 'functional activity, quality of life and functional disability', 'adverse effects', 'headache impact test-6 for a headache disability, headache diary for headache intensity, frequency, duration, and neck disability index for neck pain, disability', 'cervicogenic headache']","[{'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0458101', 'cui_str': 'Cervicogenic headache'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0242801', 'cui_str': 'Selection Criteria'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0458101', 'cui_str': 'Cervicogenic headache'}]",178.0,0.16672,No adverse effects were reported by participants.,"[{'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Rani', 'Affiliation': 'Department of Physiotherapy, Guru Jambheshwar University of Science & Technology, Hisar, Haryana, India.'}, {'ForeName': 'Jaspreet', 'Initials': 'J', 'LastName': 'Kaur', 'Affiliation': 'Department of Physiotherapy, Guru Jambheshwar University of Science & Technology, Hisar, Haryana, India.'}]",The Journal of manual & manipulative therapy,['10.1080/10669817.2021.1962687'] 2377,34374180,Observing physicians acting with different levels of empathy modulates later assessed pain tolerance.,"OBJECTIVES The patient-physician relationship is essential for treatment success. Previous studies demonstrated that physicians who behave empathic in their interaction with patients have a positive effect on health outcomes. In this study, we investigated if the mere perception of physicians as empathic/not empathic modulates pain despite an emotionally neutral interaction with the patients. METHODS N = 60 women took part in an experimental study that simulated a clinical interaction. In the paradigm, each participant watched two immersive 360° videos via a head-mounted display from a patient's perspective. The physicians in the videos behaved either empathic or not empathic towards a third person. Importantly, these physicians remained emotionally neutral in the subsequent virtual interaction with the participants. Finally, participants received a controlled, painful pressure stimulus within the narratives of the videos. RESULTS The physicians in the high compared with the low empathy videos were rated as more empathic and more likable, indicating successful experimental manipulation. In spite of later neutral behaviour of physicians, this short observation of physicians' behaviour towards a third person was sufficient to modulate pain tolerance of the participants. CONCLUSIONS The finding of this study that the mere observation of physicians' behaviour towards a third person modulates pain, despite a neutral direct interaction with the participants, has important clinical implications. Further, the proposed paradigm enables investigating aspects of patient-physician communication that are difficult to examine in a clinical setting.",2021,"The physicians in the high compared with the low empathy videos were rated as more empathic and more likable, indicating successful experimental manipulation.","['60 women took part in an experimental study that simulated a clinical interaction', 'N\xa0']",[],['pain tolerance'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}]",[],"[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}]",60.0,0.0739362,"The physicians in the high compared with the low empathy videos were rated as more empathic and more likable, indicating successful experimental manipulation.","[{'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Käthner', 'Affiliation': 'Department of Psychology I, Biological Psychology, Clinical Psychology and Psychotherapy, University of Würzburg, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Eidel', 'Affiliation': 'Department of Psychology I, Psychological Intervention, Behaviour Analysis and Regulation of Behaviour, University of Würzburg, Germany.'}, {'ForeName': 'Anne-Sophie', 'Initials': 'AS', 'LastName': 'Häge', 'Affiliation': 'Department of Psychology I, Biological Psychology, Clinical Psychology and Psychotherapy, University of Würzburg, Germany.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Gram', 'Affiliation': 'Department of Psychology I, Biological Psychology, Clinical Psychology and Psychotherapy, University of Würzburg, Germany.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Pauli', 'Affiliation': 'Department of Psychology I, Biological Psychology, Clinical Psychology and Psychotherapy, University of Würzburg, Germany.'}]",British journal of health psychology,['10.1111/bjhp.12553'] 2378,34373901,Motor cortex stimulation for chronic neuropathic pain: results of a double-blind randomized study.,"Motor cortex stimulation (MCS) via surgically implanted electrodes has been used as an off-label treatment for chronic neuropathic pain (cNeP) but its efficacy has not been fully established. We aimed to objectively study the efficacy of MCS and characterize potential predictors of response. In this randomised, double-blind, sham-controlled, single centre trial, we recruited 18 cNeP patients who did not adequately respond to conventional treatment and had a numerical rating pain scale (NRS) score ≥ 6. Patients were initially assigned to receive three months of active (""on"") or sham (""off"") stimulation in a double-blind cross-over phase. This was followed by a 3-month single-blind phase, and 6 months of open-label follow-up. A meaningful response in our trial was defined as a ≥ 30% or 2-point reduction in NRS scores during active stimulation. Using Bayesian statistics, we found a 41.4% probability of response towards ""on"" vs. ""off"" MCS. The probability of improvement during active stimulation (double-blind, single-blind and open label phases) compared to baseline was of 47.2-68.5%. 39% of patients were long-term responders, 71.4% of whom had facial pain, phantom limb pain, or complex regional pain syndrome. In contrast, 72.7% of non-responders had either post-stroke pain or pain associated with brachial plexus avulsion. 39% of patients had a substantial post-operative analgesic effect after electrode insertion in the absence of stimulation. Individuals with diagnoses associated with a good postoperative outcome or those who developed an insertional effect had a near 100% probability of response to MCS. In summary, we found that approximately 40% of patients responded to MCS, particularly those who developed an insertional effect or had specific clinical conditions that seemed to predict an appropriate postoperative response.",2021,"39% of patients were long-term responders, 71.4% of whom had facial pain, phantom limb pain, or complex regional pain syndrome.","['chronic neuropathic pain', '18 cNeP patients who did not adequately respond to conventional treatment and had a numerical rating pain scale (NRS) score ≥ 6']","['Motor cortex stimulation (MCS) via surgically implanted electrodes', 'active (""on"") or sham (""off"") stimulation in a double-blind cross-over phase', 'Motor cortex stimulation', 'MCS']","['post-stroke pain or pain', 'facial pain, phantom limb pain, or complex regional pain syndrome', 'NRS scores', 'probability of improvement during active stimulation']","[{'cui': 'C4544057', 'cui_str': 'Chronic neuropathic pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0026607', 'cui_str': 'Motor cortex'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0013814', 'cui_str': 'Implanted Electrodes'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]","[{'cui': 'C4076169', 'cui_str': 'Pain following cerebrovascular accident'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015468', 'cui_str': 'Pain in face'}, {'cui': 'C0031315', 'cui_str': 'Phantom limb'}, {'cui': 'C0458219', 'cui_str': 'Complex regional pain syndrome'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]",18.0,0.212996,"39% of patients were long-term responders, 71.4% of whom had facial pain, phantom limb pain, or complex regional pain syndrome.","[{'ForeName': 'Clement', 'Initials': 'C', 'LastName': 'Hamani', 'Affiliation': 'Division of Functional Neurosurgery, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Erich T', 'Initials': 'ET', 'LastName': 'Fonoff', 'Affiliation': 'Division of Functional Neurosurgery, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Daniella C', 'Initials': 'DC', 'LastName': 'Parravano', 'Affiliation': 'Division of Functional Neurosurgery, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Valquiria A', 'Initials': 'VA', 'LastName': 'Silva', 'Affiliation': 'Pain Center, LIM-62, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Galhardoni', 'Affiliation': 'Pain Center, LIM-62, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Bernardo', 'Initials': 'B', 'LastName': 'Monaco', 'Affiliation': 'Division of Functional Neurosurgery, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Jessie', 'Initials': 'J', 'LastName': 'Navarro', 'Affiliation': 'Division of Functional Neurosurgery, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Lin T', 'Initials': 'LT', 'LastName': 'Yeng', 'Affiliation': 'Pain Center, LIM-62, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Manoel J', 'Initials': 'MJ', 'LastName': 'Teixeira', 'Affiliation': 'Division of Functional Neurosurgery, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Ciampi de Andrade', 'Affiliation': 'Division of Functional Neurosurgery, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}]",Brain : a journal of neurology,['10.1093/brain/awab189'] 2379,34373778,Predicting Independence 6 and 18 Months after Ischemic Stroke Considering Differences in 12 Countries: A Secondary Analysis of the IST-3 Trial.,"Objectives This study is aimed at identifying the best clinical model to predict poststroke independence at 6 and 18 months, considering sociodemographic and clinical characteristics, and then identifying differences between countries. Methods Data was retrieved from the International Stroke Trial 3 study. Nine clinical variables (age, gender, severity, rt-PA, living alone, atrial fibrillation, history of transient ischemic attack/stroke, and abilities to lift arms and walk) were measured immediately after the stroke and considered to predict independence at 6 and 18 months poststroke. Independence was measured using the Oxford Handicap Scale. The adequacy, predictive capacity, and discriminative capacity of the models were checked. Countries were added to the final models. Results At 6 months poststroke, 35.8% ( n = 1088) of participants were independent, and at 18 months, this proportion decreased to 29.9% ( n = 747). Both 6 and 18 months poststroke predictive models obtained fair discriminatory capacities. Gender, living alone, and rt-PA only reached predictive significance at 18 months. Poststroke patients from Poland and Sweden showed greater chances to achieve independence at 6 months compared to the UK. Poland also achieved greater chances at 18 months. Italy had worse chances than the UK at both follow-ups. Discussion . Six and eight variables predicted poststroke independence at 6 and 18 months, respectively. Some variables only reached significance at 18 months, suggesting a late influence in stroke patients' rehabilitation. Differences found between countries in achieving independence may be related to healthcare system organization or cultural characteristics, a hypothesis that must be addressed in future studies. These results can allow the development of tailored interventions to improve the outcomes.",2021,Italy had worse chances than the UK at both follow-ups. ,['12 Countries'],[],"['Oxford Handicap Scale', 'poststroke independence']","[{'cui': 'C0454664', 'cui_str': 'Country'}]",[],"[{'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.17713,Italy had worse chances than the UK at both follow-ups. ,"[{'ForeName': 'André', 'Initials': 'A', 'LastName': 'Vieira', 'Affiliation': 'NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Portugal.'}, {'ForeName': 'Patrícia', 'Initials': 'P', 'LastName': 'Soares', 'Affiliation': 'NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Portugal.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Nunes', 'Affiliation': 'NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Portugal.'}]",Stroke research and treatment,['10.1155/2021/5627868'] 2380,34373773,Back Propagation Neural Network-Based Ultrasound Image for Diagnosis of Cartilage Lesions in Knee Osteoarthritis.,"Objective To explore the application value of ultrasound image based on back propagation (BP) neural network algorithm in knee osteoarthritis (KOA) and evaluate the application effect and value of ultrasound image technology based on the BP neural network in the diagnosis of knee osteoarthritis cartilage lesions, 98 patients who were admitted to our hospital were diagnosed with KOA and had undergone arthroscopic soft tissue examinations were randomly selected. According to whether image processing was performed, the ultrasound images of all patients were divided into two groups. The control group was image before processing, and the experimental group was image after processing optimization. The consistency of the inspection results of the ultrasound images before and after the processing with the arthroscopy results was compared. The results showed that the staging accuracy of the control group was 68.3% and that of the experimental group was 76.9%. The accuracy of staging cartilage degeneration of the experimental group was higher than that of the control group, and the difference was not remarkable ( P > 0.05). The kappa coefficient of the experimental group was 0.61, and that of the control group was 0.40. The kappa coefficient of the experimental group was higher than that of the control group, and the difference was significant ( P < 0.05). Conclusion The inspection effect of the ultrasound image processed by the BP neural network was superior to that of the conventional ultrasound image. It reflected the good adoption prospect of neural networks in image processing.",2021,The results showed that the staging accuracy of the control group was 68.3% and that of the experimental group was 76.9%.,"['98 patients who were admitted to our hospital were diagnosed with KOA and had undergone arthroscopic soft tissue examinations', 'Knee Osteoarthritis', 'knee osteoarthritis (KOA']","['ultrasound image based on back propagation (BP) neural network algorithm', 'Back Propagation Neural Network-Based Ultrasound Image']","['staging accuracy', 'accuracy of staging cartilage degeneration', 'kappa coefficient']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0242406', 'cui_str': 'Neural Networks (Anatomic)'}]","[{'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C1285228', 'cui_str': 'Degenerative disorder of cartilage'}, {'cui': 'C0439099', 'cui_str': 'Kappa'}]",98.0,0.019956,The results showed that the staging accuracy of the control group was 68.3% and that of the experimental group was 76.9%.,"[{'ForeName': 'Xiaoming', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Orthopaedics, Baoji Central Hospital of Shaanxi Province, Baoji 721008, Shaanxi, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Gong', 'Affiliation': 'Department of Orthopaedics, Baoji Central Hospital of Shaanxi Province, Baoji 721008, Shaanxi, China.'}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Orthopaedics, Baoji Central Hospital of Shaanxi Province, Baoji 721008, Shaanxi, China.'}, {'ForeName': 'Weibing', 'Initials': 'W', 'LastName': 'Yang', 'Affiliation': 'Department of Bone and Joint Trauma, Hanzhong City Center Hospital, Hanzhong 713000, Shaanxi, China.'}, {'ForeName': 'Dengfeng', 'Initials': 'D', 'LastName': 'Yang', 'Affiliation': 'Department of Bone and Joint Trauma, Hanzhong City Center Hospital, Hanzhong 713000, Shaanxi, China.'}, {'ForeName': 'Zhiguo', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Bone and Joint Trauma, Hanzhong City Center Hospital, Hanzhong 713000, Shaanxi, China.'}]",Journal of healthcare engineering,['10.1155/2021/2584291'] 2381,34373696,Cyclic Fatigue Resistance of Blue Heat-Treated Instruments at Different Temperatures.,"The main aim is to evaluate the cyclic fatigue resistance of blue heat-treated instruments with different kinematics. Twenty-four endodontic instruments of the same brand were used for each of three experimental groups: VB (Vortex Blue 40/0.04), RB (RECIPROC Blue 40/0.06), and XB (X1 Blue 40/0.06). The instruments were randomly distributed and subjected to temperatures of 20°C and 37°C. The fatigue test was performed using a stainless steel device. Data were analysed using the Shapiro-Wilk test, Student's t- test, the F test, and Tukey's and Tamhane tests at significance level P =0.05. The instruments' cyclic fatigue resistance at both temperatures differed significantly for each instrument type ( P < 0.001). The RB instruments displayed greater cyclic fatigue resistance at the tested temperatures compared with the VB and XB instruments ( P < 0.001). Reciprocating kinematics positively influenced cyclic fatigue resistance. Blue heat-treated instruments showed decreased cyclic fatigue resistance as the temperature increased ( P < 0.001).",2021,The instruments' cyclic fatigue resistance at both temperatures differed significantly for each instrument type ( P < 0.001).,[],[],['cyclic fatigue resistance'],[],[],"[{'cui': 'C0439596', 'cui_str': 'Cyclic'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]",,0.0754539,The instruments' cyclic fatigue resistance at both temperatures differed significantly for each instrument type ( P < 0.001).,"[{'ForeName': 'Thalita Miranda', 'Initials': 'TM', 'LastName': 'Vieira', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Dental College of Pernambuco, University of Pernambuco (UPE), Camaragibe, PE, Zip Code 54756-220, Brazil.'}, {'ForeName': 'Ryhan Menezes', 'Initials': 'RM', 'LastName': 'Cardoso', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Dental College of Pernambuco, University of Pernambuco (UPE), Camaragibe, PE, Zip Code 54756-220, Brazil.'}, {'ForeName': 'Nayane Chagas Carvalho', 'Initials': 'NCC', 'LastName': 'Alves', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Dental College of Pernambuco, University of Pernambuco (UPE), Camaragibe, PE, Zip Code 54756-220, Brazil.'}, {'ForeName': 'Silvio', 'Initials': 'S', 'LastName': 'Emanuel Acioly Conrado de Menezes', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Dental College of Pernambuco, University of Pernambuco (UPE), Camaragibe, PE, Zip Code 54756-220, Brazil.'}, {'ForeName': 'Shirley Machado', 'Initials': 'SM', 'LastName': 'Batista', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Dental College of Pernambuco, University of Pernambuco (UPE), Camaragibe, PE, Zip Code 54756-220, Brazil.'}, {'ForeName': 'Silmara de Andrade', 'Initials': 'SA', 'LastName': 'Silva', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Dental College of Pernambuco, University of Pernambuco (UPE), Camaragibe, PE, Zip Code 54756-220, Brazil.'}, {'ForeName': 'Christianne', 'Initials': 'C', 'LastName': 'Velozo', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Dental College of Pernambuco, University of Pernambuco (UPE), Camaragibe, PE, Zip Code 54756-220, Brazil.'}, {'ForeName': 'Diana Santana', 'Initials': 'DS', 'LastName': 'de Albuquerque', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Dental College of Pernambuco, University of Pernambuco (UPE), Camaragibe, PE, Zip Code 54756-220, Brazil.'}, {'ForeName': 'Gabriela Queiroz de Melo', 'Initials': 'GQM', 'LastName': 'Monteiro', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Dental College of Pernambuco, University of Pernambuco (UPE), Camaragibe, PE, Zip Code 54756-220, Brazil.'}]",International journal of biomaterials,['10.1155/2021/5584766'] 2382,34373566,Association of Troponin T levels and functional outcome 3 months after subarachnoid hemorrhage.,"TroponinT levels are frequently elevated after subarachnoid hemorrhage (SAH). However, their clinical impact on long term outcomes still remains unclear. This study evaluates the association of TroponinT and functional outcomes 3 months after SAH. Data were obtained in the frame of a randomized controlled trial exploring the association of Goal-directed hemodynamic therapy and outcomes after SAH (NCT01832389). TroponinT was measured daily for the first 14 days after admission or until discharge from the ICU. Outcome was assessed using Glasgow Outcome Scale (GOS) 3 months after discharge. Logistic regression was used to explore the association between initial TroponinT values stratified by tertiles and admission as well as outcome parameters. TroponinT measurements were analyzed in 105 patients. TroponinT values at admission were associated with outcome assessed by GOS in a univariate analysis. TroponinT was not predictive of vasospasm or delayed cerebral ischemia, but an association with pulmonary and cardiac complications was observed. After adjustment for age, history of arterial hypertension and World Federation of Neurosurgical Societies (WFNS) grade, TroponinT levels at admission were not independently associated with worse outcome (GOS 1-3) or death at 3 months. In summary, TroponinT levels at admission are associated with 3 months-GOS but have limited ability to independently predict outcome after SAH.",2021,"TroponinT was not predictive of vasospasm or delayed cerebral ischemia, but an association with pulmonary and cardiac complications was observed.","['subarachnoid hemorrhage', '105 patients']",['TroponinT'],"['Glasgow Outcome Scale (GOS', 'arterial hypertension and World Federation of Neurosurgical Societies (WFNS) grade, TroponinT levels at admission', 'vasospasm or delayed cerebral ischemia', 'TroponinT levels', 'TroponinT values at admission', 'TroponinT measurements']","[{'cui': 'C0038525', 'cui_str': 'Subarachnoid hemorrhage'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0701887', 'cui_str': 'Glasgow outcome scale'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0042396', 'cui_str': 'Vascular constriction'}, {'cui': 'C4761225', 'cui_str': 'Delayed cerebral ischaemia'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",105.0,0.146682,"TroponinT was not predictive of vasospasm or delayed cerebral ischemia, but an association with pulmonary and cardiac complications was observed.","[{'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Anetsberger', 'Affiliation': 'Department of Anesthesiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Jungwirth', 'Affiliation': 'Department of Anesthesiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Manfred', 'Initials': 'M', 'LastName': 'Blobner', 'Affiliation': 'Department of Anesthesiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Ringel', 'Affiliation': 'Department of Neurosurgery, Universitätsmedizin Mainz, Langenbeckstr.1, 55131, Mainz, Germany.'}, {'ForeName': 'Isabell', 'Initials': 'I', 'LastName': 'Bernlochner', 'Affiliation': 'I. Medizinische Klinik und Poliklinik, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Heim', 'Affiliation': 'Department of Anesthesiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Bogdanski', 'Affiliation': 'Department of Anesthesiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Wostrack', 'Affiliation': 'Department of Neurosurgery, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Str.22, 81675, Munich, Germany.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Schneider', 'Affiliation': 'Department of Anesthesiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Meyer', 'Affiliation': 'Department of Neurosurgery, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Str.22, 81675, Munich, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Graeßner', 'Affiliation': 'Department of Anesthesiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Lea', 'Initials': 'L', 'LastName': 'Baumgart', 'Affiliation': 'Department of Neurosurgery, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Str.22, 81675, Munich, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Gempt', 'Affiliation': 'Department of Neurosurgery, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Str.22, 81675, Munich, Germany. jens.gempt@tum.de.'}]",Scientific reports,['10.1038/s41598-021-95717-w'] 2383,34373384,"A Pilot Study Evaluating the Effectiveness and Safety of Daikenchuto (TJ-100) for the Treatment of Postoperative Abdominal Pain or Bloating in Patients Undergoing Hepatectomy: Study Protocol for a Randomized, Open, Controlled Trial.","This study is being performed to evaluate the effectiveness and safety of TJ-100 TSUMURA Daikenchuto (DKT) Extract Granules in preventing post-hepatectomy digestive symptoms, and to examine the effects of DKT on small intestinal mucosal atrophy using diamine oxidase (DAO) and glucagon-like peptide-2 (GLP-2) activities. This is a randomized, open, controlled trial using patients treated with usual care as the control group. Patients who meet the inclusion criteria are randomized to the study groups. Eligible patients are randomized to the DKT therapy group (DKT administration for 14 days postoperatively or until the day of discharge if a patient leaves the hospital less than 14 days after the surgery) or the usual care group (no administration of DKT (ratio 1:1). Using the NRS (numeric rating scale) as an indicator, we will attempt to show whether DKT is effective for abdominal pain and bloating after surgery by comparing both groups. We will also attempt to evaluate postoperative small intestinal mucosal atrophy using DAO and GLP-2 activities in the serum, and postoperative nutrient absorption using nutrient assessment indicators. This study is being conducted according to the CONSORT statement. A consent form was signed by all participants, and the study protocol has been approved by the Central Review Board and Local Ethics Committee (CRB7180001).",2021,"Using the NRS (numeric rating scale) as an indicator, we will attempt to show whether DKT is effective for abdominal pain and bloating after surgery by comparing both groups.","['Patients Undergoing Hepatectomy', 'patients treated with usual care as the control group', 'Eligible patients']","['DKT therapy group (DKT administration', 'DKT', 'usual care group (no administration of DKT', 'TJ-100 TSUMURA Daikenchuto (DKT) Extract Granules', 'Daikenchuto (TJ-100']","['abdominal pain and bloating', 'Postoperative Abdominal Pain or Bloating']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019144', 'cui_str': 'Liver excision'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0909027', 'cui_str': 'dai-kenchu-to'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}]","[{'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C4047372', 'cui_str': 'Postoperative abdominal pain'}]",,0.029029,"Using the NRS (numeric rating scale) as an indicator, we will attempt to show whether DKT is effective for abdominal pain and bloating after surgery by comparing both groups.","[{'ForeName': 'Susumu', 'Initials': 'S', 'LastName': 'Eguchi', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Hidaka', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Akihiko', 'Initials': 'A', 'LastName': 'Soyama', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Takanobu', 'Initials': 'T', 'LastName': 'Hara', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Tota', 'Initials': 'T', 'LastName': 'Kugiyama', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Hamada', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Tanaka', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Matsushima', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Tomohiko', 'Initials': 'T', 'LastName': 'Adachi', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Ito', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}, {'ForeName': 'Kengo', 'Initials': 'K', 'LastName': 'Kanetaka', 'Affiliation': 'Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.'}]",The Kurume medical journal,['10.2739/kurumemedj.MS663005'] 2384,34370833,A randomized controlled trial comparing the effect of three-dimensional simulation of aesthetic outcome from breast-conserving surgery with viewing photographs or standard care.,"INTRODUCTION Over half of women with surgically managed breast cancer in the UK undergo breast-conserving treatment (BCT). While photographs are shown prior to reconstructive surgery or complex oncoplastic procedures, standard practice prior to breast conservation is to simply describe the likely aesthetic changes. Patients have expressed the desire for more personalized information about likely appearance after surgery. The hypothesis was that viewing a three-dimensional (3D) simulation improves patients' confidence in knowing their likely aesthetic outcome after surgery. METHODS A randomized, controlled trial of 117 women planning unilateral BCT was undertaken. The randomization was three-way: standard of care (verbal description alone, control group), viewing two-dimensional (2D) photographs, or viewing a 3D simulation before surgery. The primary endpoint was the comparison between groups' median answer on a visual analogue scale (VAS) for the question administered before surgery: 'How confident are you that you know how your breasts are likely to look after treatment?' RESULTS The median VAS in the control group was 5.2 (i.q.r. 2.6-7.8); 8.0 (i.q.r. 5.7-8.7) for 2D photography, and 8.9 (i.q.r. 8.2-9.5) for 3D simulation. There was a significant difference between groups (P < 0.010) with post-hoc pairwise comparisons demonstrating a statistically significant difference between 3D simulation and both standard care and viewing 2D photographs (P < 0.010 and P = 0.012, respectively). CONCLUSIONS This RCT has demonstrated that women who viewed an individualized 3D simulation of likely aesthetic outcome for BCT were more confident going into surgery than those who received standard care or who were shown 2D photographs of other women. The impact on longer-term satisfaction with outcome remains to be determined.Registration number: NCT03250260 (http://www.clinicaltrials.gov).",2021,"There was a significant difference between groups (P < 0.010) with post-hoc pairwise comparisons demonstrating a statistically significant difference between 3D simulation and both standard care and viewing 2D photographs (P < 0.010 and P = 0.012, respectively). ","['women with surgically managed breast cancer in the UK undergo breast-conserving treatment (BCT', '117 women planning unilateral BCT was undertaken']","['standard of care (verbal description alone, control group), viewing two-dimensional (2D) photographs, or viewing a 3D simulation before surgery', 'breast-conserving surgery with viewing photographs or standard care']","['3D simulation and both standard care and viewing 2D photographs', 'visual analogue scale (VAS', 'median VAS']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",117.0,0.204069,"There was a significant difference between groups (P < 0.010) with post-hoc pairwise comparisons demonstrating a statistically significant difference between 3D simulation and both standard care and viewing 2D photographs (P < 0.010 and P = 0.012, respectively). ","[{'ForeName': 'A R', 'Initials': 'AR', 'LastName': 'Godden', 'Affiliation': 'Department of Breast Surgery, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Micha', 'Affiliation': 'Department of Breast Surgery, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.'}, {'ForeName': 'L M', 'Initials': 'LM', 'LastName': 'Wolf', 'Affiliation': 'Department of Breast Surgery, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Pitches', 'Affiliation': 'Independent patient co-designer, Institute of Cancer Research, Sutton, Surrey, UK.'}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'Barry', 'Affiliation': 'Department of Breast Surgery, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Khan', 'Affiliation': 'Department of Plastic Surgery, The Royal Marsden NHS Foundation Trust, London, UK.'}, {'ForeName': 'K D C', 'Initials': 'KDC', 'LastName': 'Krupa', 'Affiliation': 'Department of Breast Surgery, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Kirby', 'Affiliation': 'Department of Breast Surgery, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.'}, {'ForeName': 'J E', 'Initials': 'JE', 'LastName': 'Rusby', 'Affiliation': 'Department of Breast Surgery, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.'}]",The British journal of surgery,['10.1093/bjs/znab217'] 2385,34370829,Comment on 'low pressure versus standard pressure laparoscopic colorectal surgery (PAROS trial): a phase III randomized controlled trial'.,,2021,,[],['standard pressure laparoscopic colorectal surgery'],[],[],"[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}]",[],,0.321952,,"[{'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Khan', 'Affiliation': 'General Surgery, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, England.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Perin', 'Affiliation': 'General Surgery, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, England.'}, {'ForeName': 'S P', 'Initials': 'SP', 'LastName': 'Balasubramanian', 'Affiliation': 'Department of Oncology and Metabolism, University of Sheffield, Sheffield, England.'}]",The British journal of surgery,['10.1093/bjs/znab206'] 2386,34374086,Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.,"BACKGROUND Migraine is associated with depression as well as negative impact on quality of life and work productivity. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa), selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. OBJECTIVE In this open-label extension (OLE) of the phase 3b FOCUS study, we assessed patient-reported outcomes (PROs) over time. METHODS Patients with episodic migraine (EM) and chronic migraine (CM) completing the 12-week, double-blind (DB) period of the FOCUS trial entered the 12-week OLE and received three monthly doses of fremanezumab (225 mg). PROs included the Migraine-Specific Quality of Life (MSQoL) questionnaire (role function-restrictive [RFR], role function-preventive [RFP], and emotional function [EF] domains), EuroQol-5-Dimension-5-Level (EQ-5D-5L) questionnaire, Patient Global Impression of Change (PGIC) assessment, Work Productivity and Activity Impairment (WPAI) questionnaire, and 9-Item Patient Health Questionnaire (PHQ-9). RESULTS A total of 838 patients were randomized in the DB period, 807 entered the OLE at 3 months, and 772 were still enrolled at 6 months. At 6 months, patients in the quarterly fremanezumab, monthly fremanezumab, and placebo DB randomization groups, respectively, reported improvements in RFR (mean [standard deviation] change from baseline: 24.6 [21.9]; 22.9 [21.3]; 20.8 [26.5]), RFP (19.6 [20.0]; 18.3 [19.7]; 16.0 [19.9]), and EF (22.5 [24.2]; 19.1 [23.6]; 17.2 [24.7]) domains of the MSQoL questionnaire, the EQ-5D-5L questionnaire (8.0 [19.6]; 7.3 [21.1]; 6.6 [21.0]), all four domains of the WPAI questionnaire, and the PHQ-9 (-2.4 [5.3]; -1.6 [5.5]; -2.0 [4.9]); 77.1% (209/271), 75.4% (205/272), and 68.8% (181/263) of patients were identified as PGIC responders. CONCLUSION Among patients with EM or CM and prior inadequate response to multiple migraine-preventive medication classes, progressive improvements in MSQoL, depression, and work productivity were achieved during 6 months of fremanezumab treatment.",2021,"Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa), selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. ","['Patients with episodic migraine (EM) and chronic migraine (CM) completing the 12-week, double-blind (DB) period of the FOCUS trial entered the 12-week', 'patients with episodic and chronic migraine', '838 patients were randomized in the DB period, 807 entered the OLE at 3\xa0months, and 772 were still enrolled at 6\xa0months']","['fremanezumab', 'Fremanezumab', 'OLE']","['MSQoL, depression, and work productivity', 'quality of life and work productivity', 'MSQoL questionnaire, the EQ-5D-5L questionnaire', 'RFP', 'RFR', 'Migraine-Specific Quality of Life (MSQoL) questionnaire (role function-restrictive [RFR], role function-preventive [RFP], and emotional function [EF] domains), EuroQol-5-Dimension-5-Level (EQ-5D-5L) questionnaire, Patient Global Impression of Change (PGIC) assessment, Work Productivity and Activity Impairment (WPAI) questionnaire, and 9-Item Patient Health Questionnaire (PHQ-9']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C1960870', 'cui_str': 'Transformed migraine'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C4549503', 'cui_str': 'fremanezumab'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0035164', 'cui_str': 'Request for Proposals'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}]",838.0,0.112859,"Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa), selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. ","[{'ForeName': 'Egilius L H', 'Initials': 'ELH', 'LastName': 'Spierings', 'Affiliation': 'Boston Headache Institute & MedVadis Research Corporation, Waltham, MA, USA.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Ning', 'Affiliation': 'Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Ramirez Campos', 'Affiliation': 'Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Cohen', 'Affiliation': 'Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Barash', 'Affiliation': 'Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Dawn C', 'Initials': 'DC', 'LastName': 'Buse', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, New York, NY, USA.'}]",Headache,['10.1111/head.14196'] 2387,34374082,Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931).,"BACKGROUND The objective of this study was to evaluate the association between self-identified race and overall survival (OS), progression-free survival (PFS), and response to therapy among patients enrolled in the randomized Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial. METHODS Patients with advanced or metastatic colorectal cancer who were enrolled in the CALGB/SWOG 80405 trial were identified by race. On the basis of covariates (treatment arm, KRAS status, sex, age, and body mass index), each Black patient was exact matched with a White patient. The association between race and OS and PFS was examined using a marginal Cox proportional hazard model for matched pairs. The interaction between KRAS status and race was tested in the model. The association between race and response to therapy and adverse events were examined using a marginal logistic regression model. RESULTS In total, 392 patients were matched and included in the final data set. No difference in OS (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.73-1.16), PFS (HR, 0.97; 95% CI, 0.78-1.20), or response to therapy (odds ratio [OR], 1.00; 95% CI, 0.65-1.52) was observed between Black and White patients. Patients with KRAS mutant status (HR, 1.31; 95% CI, 1.02-1.67), a performance statusscore of 1 (reference, a performance status of 0; HR, 1.49; 95% CI, 1.18-1.88), or ≥3 metastatic sites (reference, 1 metastatic site; HR, 1.67; 95% CI, 1.22-2.28) experienced worse OS. Black patients experienced lower rates and risk of grade ≥3 fatigue (6.6% vs 13.3%; OR, 0.46; 95% CI, 0.24-0.91) but were equally likely to be treated with a dose reduction (OR, 1.09; 95% CI, 0.72-1.65). CONCLUSIONS No difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial. LAY SUMMARY Despite improvements in screening and treatment, studies have demonstrated worse outcomes in Black patients with colorectal cancer. The purpose of this study was to determine whether there was a difference in cancer-specific outcomes among Black and White patients receiving equivalent treatment on the CALGB/SWOG 80405 randomized clinical trial. In this study, there was no difference in overall survival, progression-free survival, or response to therapy between Black and White patients treated on a clinical trial. These findings suggest that access to care and differences in treatment may be responsible for racial disparities in colorectal cancer.",2021,"No difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial. ","['Black patients with colorectal cancer', 'patients with metastatic colorectal cancer', '392 patients were matched and included in the final data set', 'Black and White patients receiving equivalent treatment on the CALGB/SWOG 80405 randomized clinical trial', 'patients enrolled in the randomized Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial', 'Patients with advanced or metastatic colorectal cancer who were enrolled in the CALGB/SWOG 80405 trial were identified by race']",[],"['cancer-specific outcomes', 'OS', 'overall survival, progression-free survival', 'PFS', 'rates and risk of grade ≥3 fatigue', 'OS, PFS, or response to therapy', 'worse OS', 'overall survival (OS), progression-free survival (PFS']","[{'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0023418', 'cui_str': 'Leukemia'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}]",[],"[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}]",392.0,0.415933,"No difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial. ","[{'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Snyder', 'Affiliation': 'Department of Surgery and Public Health, Brody School of Medicine at East Carolina University, Greenville, North Carolina.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Le-Rademacher', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Fang-Shu', 'Initials': 'FS', 'LastName': 'Ou', 'Affiliation': 'Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Andrew B', 'Initials': 'AB', 'LastName': 'Dodge', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Tyler J', 'Initials': 'TJ', 'LastName': 'Zemla', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Electra D', 'Initials': 'ED', 'LastName': 'Paskett', 'Affiliation': 'College of Public Health, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'George J', 'Initials': 'GJ', 'LastName': 'Chang', 'Affiliation': 'Departments of Surgical Oncology and Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Innocenti', 'Affiliation': 'Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Blanke', 'Affiliation': ""Southwest Oncology Group Chair's Office and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.""}, {'ForeName': 'Heinz-Josef', 'Initials': 'HJ', 'LastName': 'Lenz', 'Affiliation': 'Department of Preventative Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California.'}, {'ForeName': 'Blasé N', 'Initials': 'BN', 'LastName': 'Polite', 'Affiliation': 'University of Chicago Comprehensive Cancer Center, Chicago, Illinois.'}, {'ForeName': 'Alan P', 'Initials': 'AP', 'LastName': 'Venook', 'Affiliation': 'Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.'}]",Cancer,['10.1002/cncr.33649'] 2388,34374027,"Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.","BACKGROUND Atopic dermatitis is a chronic, inflammatory condition causing a substantial burden to patients and caregivers. SHR0302 is an oral, highly selective, Janus kinase 1 inhibitor under investigation for inflammatory skin diseases. OBJECTIVE The aim of this study was to investigate the efficacy and safety of SHR0302 in Chinese patients with moderate to severe atopic dermatitis. DESIGN AND SETTING A randomized, double-blind, placebo-controlled, multicenter, phase II trial was conducted in China between October 2019 and August 2020. PARTICIPANTS Patients (n = 105) aged 18-75 years with moderate to severe dermatitis and nonresponsive or intolerant to topical or conventional systemic treatments were included. INTERVENTIONS Patients were randomly assigned in a ratio of 1:1:1 to receive SHR0302 4 mg once daily, SHR0302 8 mg once daily, or placebo for 12 weeks. MAIN OUTCOME MEASURES The primary efficacy endpoint was the proportion of patients achieving Investigator's Global Assessment (IGA) response (IGA of 0 [clear] or 1 [almost clear] with improvement of ≥2 grades) at week 12. Secondary efficacy assessments included Eczema Area and Severity Index (EASI) and pruritus Numerical Rating Scale (NRS) scores. RESULTS At week 12, IGA response was achieved in nine patients (25.7%; 90% confidence interval [CI] 13.6-37.9%; p = 0.022) in the SHR0302 4 mg group, 19 patients (54.3%; 90% CI 40.4-68.1%; p < 0.001) in the SHR0302 8 mg group, and two patients (5.7%; 90% CI 0.0-12.2%) in the placebo group. EASI75 was achieved in 51.4% (p = 0.013), 74.3% (p < 0.001), and 22.9% of patients in the SHR0302 4 mg, SHR0302 8 mg, and placebo groups, respectively, while an NRS ≥3-point improvement occurred in 65.7% (p < 0.001), 74.3% (p < 0.001), and 22.9% of patients, respectively. Treatment-emergent adverse events were reported in 60.0%, 68.6%, and 51.4% of patients in the SHR0302 4 mg, SHR0302 8 mg, and placebo groups, respectively. The adverse events were mild in most cases. Three serious adverse events were reported, all being worsening of atopic dermatitis. No serious infection was reported. CONCLUSIONS AND RELEVANCE Oral SHR0302 was effective and well tolerated in Chinese adult patients with moderate to severe atopic dermatitis. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT04162899; URL: https://clinicaltrials.gov/ . Date first registered: 14 November 2019.",2021,"Secondary efficacy assessments included Eczema Area and Severity Index (EASI) and pruritus Numerical Rating Scale (NRS) scores. ","['Patients (n\xa0=\xa0105) aged 18-75\xa0years with moderate to severe dermatitis and nonresponsive or intolerant to topical or conventional systemic treatments were included', 'China between October 2019 and August 2020', 'Chinese adult patients with moderate to severe atopic dermatitis', 'Patients with Moderate to Severe Atopic Dermatitis', 'Chinese patients with moderate to severe atopic dermatitis']","['placebo', 'SHR0302 4\xa0mg once daily, SHR0302 8\xa0mg once daily, or placebo', 'SHR0302']","['Eczema Area and Severity Index (EASI) and pruritus Numerical Rating Scale (NRS) scores', 'EASI75', 'efficacy and safety', 'serious adverse events', 'adverse events', ""proportion of patients achieving Investigator's Global Assessment (IGA) response (IGA of 0 [clear] or 1 [almost clear] with improvement of ≥2 grades"", 'NRS ≥3-point improvement', 'Treatment-emergent adverse events', 'IGA response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0011603', 'cui_str': 'Dermatitis'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4505983', 'cui_str': 'SHR0302'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.50221,"Secondary efficacy assessments included Eczema Area and Severity Index (EASI) and pruritus Numerical Rating Scale (NRS) scores. ","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': ""Department of Dermatology, Peking University People's Hospital, Beijing, 100044, China.""}, {'ForeName': 'Litao', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.'}, {'ForeName': 'Yangfeng', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Tao', 'Affiliation': ""Department of Dermatology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.""}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Ji', 'Affiliation': 'Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Xiuqin', 'Initials': 'X', 'LastName': 'Dong', 'Affiliation': ""Department of Dermatology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.""}, {'ForeName': 'Jianyun', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Liming', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': ""Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.""}, {'ForeName': 'Rupeng', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'Department of Dermatology and Rheumatology Immunology, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.'}, {'ForeName': 'Qianjin', 'Initials': 'Q', 'LastName': 'Lu', 'Affiliation': 'Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Aik Han', 'Initials': 'AH', 'LastName': 'Goh', 'Affiliation': 'Reistone Biopharma Co., Ltd., Shanghai, China.'}, {'ForeName': 'Rongjun', 'Initials': 'R', 'LastName': 'Liu', 'Affiliation': 'Reistone Biopharma Co., Ltd., Shanghai, China.'}, {'ForeName': 'Zhiguo', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Reistone Biopharma Co., Ltd., Shanghai, China.'}, {'ForeName': 'Jianzhong', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Dermatology, Peking University People's Hospital, Beijing, 100044, China. rmzjz@126.com.""}]",American journal of clinical dermatology,['10.1007/s40257-021-00627-2'] 2389,34373988,Effects of a 12-Week Transtheoretical Model-Based Exercise Training Program in Chinese Postoperative Bariatric Patients: a Randomized Controlled Trial.,"PURPOSE This study aims to investigate the effectiveness of the transtheoretical model (TTM)-based exercise training on TTM variables, exercise adherence, and physical function in patients in the early stages after bariatric surgery (BS). MATERIALS AND METHODS We conducted a single-blinded, prospective, randomized controlled trial (RCT) to evaluate the effects of TTM-based exercise training on BS patients immediately after surgery. Participants (n = 120) were randomized into a TTM-based exercise training group (n = 60) and a control group (n = 60). Main outcomes included TTM variables (measured by exercise stages of change (ESCs), exercise self-efficacy (ESE), and decisional balance), exercise adherence, and physical function (determined by the 6-min walk distance (6MWD)). Secondary outcomes were physical activity, anthropometrics, and body composition. We performed all analyses in accordance with the intention-to-treat principle. RESULTS Retention rates for the interventions were 91.7% for the intervention group and 90.0% for the control group. Compared with the control group, the 12-week TTM-based intervention significantly helped participants advance through ESCs, demonstrate higher ESE, perceive more benefits and fewer barriers to exercise, and show higher exercise adherence and better physical function afterward (all P < 0.05). However, we observed no statistically significant difference between the two groups in anthropometric parameters or body composition after intervention. CONCLUSION The TTM-based exercise intervention had significant positive effects on the TTM variables, which could further help increase patients' exercise adherence and physical function immediately after BS. TRIAL REGISTRATION This study was retrospectively registered at the Chinese Clinical Trial Registry (website: www.chictr.org.cn , registry number: ChiCTR2000039319).",2021,"Compared with the control group, the 12-week TTM-based intervention significantly helped participants advance through ESCs, demonstrate higher ESE, perceive more benefits and fewer barriers to exercise, and show higher exercise adherence and better physical function afterward (all P < 0.05).","['Participants (n = 120', 'Chinese Postoperative Bariatric Patients', 'patients in the early stages after bariatric surgery (BS', 'BS patients immediately after surgery']","['TTM-based exercise intervention', '12-Week Transtheoretical Model-Based Exercise Training Program', 'transtheoretical model (TTM)-based exercise training', 'TTM-based exercise training']","['anthropometric parameters or body composition', 'Retention rates', 'TTM variables, exercise adherence, and physical function', 'exercise adherence and better physical function', 'physical activity, anthropometrics, and body composition', 'TTM variables (measured by exercise stages of change (ESCs), exercise self-efficacy (ESE), and decisional balance), exercise adherence, and physical function (determined by the 6-min walk distance (6MWD', ""patients' exercise adherence and physical function""]","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1450026', 'cui_str': 'Bariatrics'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0205548', 'cui_str': 'Stat'}]","[{'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",120.0,0.0128556,"Compared with the control group, the 12-week TTM-based intervention significantly helped participants advance through ESCs, demonstrate higher ESE, perceive more benefits and fewer barriers to exercise, and show higher exercise adherence and better physical function afterward (all P < 0.05).","[{'ForeName': 'Ziqi', 'Initials': 'Z', 'LastName': 'Ren', 'Affiliation': 'School of Nursing, Nanjing Medical University, 818 Tianyuan East Road, Jiangning District, Nanjing, 210029, Jiangsu, China.'}, {'ForeName': 'Hanfei', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'School of Nursing, Nanjing Medical University, 818 Tianyuan East Road, Jiangning District, Nanjing, 210029, Jiangsu, China.'}, {'ForeName': 'Tianzi', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': ""Department of Nursing, Jiangsu College of Nursing, Huai'an, 223000, Jiangsu, China.""}, {'ForeName': 'Hongxia', 'Initials': 'H', 'LastName': 'Hua', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.'}, {'ForeName': 'Kang', 'Initials': 'K', 'LastName': 'Zhao', 'Affiliation': 'School of Nursing, Nanjing Medical University, 818 Tianyuan East Road, Jiangning District, Nanjing, 210029, Jiangsu, China.'}, {'ForeName': 'Ningli', 'Initials': 'N', 'LastName': 'Yang', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Liang', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Xu', 'Affiliation': 'School of Nursing, Nanjing Medical University, 818 Tianyuan East Road, Jiangning District, Nanjing, 210029, Jiangsu, China. qinxu@njmu.edu.cn.'}]",Obesity surgery,['10.1007/s11695-021-05607-3'] 2390,34373903,Erratum to: Efficacy of an m-health physical activity and sleep intervention to improve sleep quality in middle-aged adults: The Refresh Study randomized controlled trial.,,2021,,['middle-aged adults'],['m-health physical activity and sleep intervention'],['sleep quality'],"[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",,0.145862,,"[{'ForeName': 'Anna T', 'Initials': 'AT', 'LastName': 'Rayward', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, School of Medicine & Public Health, University of Newcastle, Callaghan, New South Wales, Australia.'}, {'ForeName': 'Ronald C', 'Initials': 'RC', 'LastName': 'Plotnikoff', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, School of Education, University of Newcastle, Callaghan, New South Wales, Australia.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Murawski', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, School of Medicine & Public Health, University of Newcastle, Callaghan, New South Wales, Australia.'}, {'ForeName': 'Corneel', 'Initials': 'C', 'LastName': 'Vandelanotte', 'Affiliation': 'Physical Activity Research Group, School for Health, Medical and Applied Sciences, Central Queensland, University, Rockhampton, Queensland, Australia.'}, {'ForeName': 'Wendy J', 'Initials': 'WJ', 'LastName': 'Brown', 'Affiliation': 'School of Human Movement and Nutrition Sciences, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Elizabeth G', 'Initials': 'EG', 'LastName': 'Holliday', 'Affiliation': 'School of Medicine & Public Health, University of Newcastle, Callaghan, New South Wales, Australia.'}, {'ForeName': 'Mitch J', 'Initials': 'MJ', 'LastName': 'Duncan', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, School of Medicine & Public Health, University of Newcastle, Callaghan, New South Wales, Australia.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaab067'] 2391,34373301,"Rationale and design of the IRON-AF study: a double-blind, randomised, placebo-controlled study to assess the effect of intravenous ferric carboxymaltose in patients with atrial fibrillation and iron deficiency.","INTRODUCTION Atrial fibrillation (AF) is associated with significantly impaired quality-of-life. Iron deficiency (ID) is prevalent in patients with AF. Correction of ID in other patient populations with intravenous iron supplementation has been shown to be a safe, convenient and effective way of improving exercise tolerance, fatigue and quality-of-life. The IRON-AF (Effect of Iron Repletion in Atrial Fibrillation) study is designed to assess the effect of iron repletion with intravenous ferric carboxymaltose in patients with AF and ID. METHODS AND ANALYSIS The IRON-AF study is a double-blind, randomised controlled trial that will recruit at least 84 patients with AF and ID. Patients will be randomised to receive infusions of either ferric carboxymaltose or placebo, given in repletion and then maintenance doses. The study will have follow-up visits at weeks 4, 8 and 12. The primary endpoint is change in peak oxygen uptake from baseline to week 12, as measured by cardiopulmonary exercise testing (CPET) on a cycle ergometer. Secondary endpoints include changes in quality-of-life and AF disease burden scores, blood parameters, other CPET parameters, transthoracic echocardiogram parameters, 6-minute walk test distance, 7-day Holter/Event monitor burden of AF, health resource utilisation and mortality. ETHICS AND DISSEMINATION The study protocol has been approved by the Central Adelaide Local Health Network Human Research Ethics Committee, Australia. The results of this study will be disseminated through publications in peer-reviewed journals and conference presentations. TRIAL REGISTRATION NUMBER Australian New Zealand Clinical Trials Registry (ACTRN12620000285954).",2021,"Correction of ID in other patient populations with intravenous iron supplementation has been shown to be a safe, convenient and effective way of improving exercise tolerance, fatigue and quality-of-life.","['patients with AF and ID', '84 patients with AF and ID', 'patients with atrial fibrillation and iron deficiency', 'patients with AF']","['placebo', 'intravenous iron supplementation', 'intravenous ferric carboxymaltose', 'ferric carboxymaltose or placebo']","['cardiopulmonary exercise testing (CPET) on a cycle ergometer', 'changes in quality-of-life and AF disease burden scores, blood parameters, other CPET parameters, transthoracic echocardiogram parameters, 6-minute walk test distance, 7-day Holter/Event monitor burden of AF, health resource utilisation and mortality', 'peak oxygen uptake']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}, {'cui': 'C2001867', 'cui_str': 'ferric carboxymaltose'}]","[{'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0430462', 'cui_str': 'Transthoracic echocardiography'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0018741', 'cui_str': 'Health Resources'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",84.0,0.338214,"Correction of ID in other patient populations with intravenous iron supplementation has been shown to be a safe, convenient and effective way of improving exercise tolerance, fatigue and quality-of-life.","[{'ForeName': 'Samuel J', 'Initials': 'SJ', 'LastName': 'Tu', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Adrian D', 'Initials': 'AD', 'LastName': 'Elliott', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Hanna-Rivero', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Celine', 'Initials': 'C', 'LastName': 'Gallagher', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Ricardo S', 'Initials': 'RS', 'LastName': 'Mishima', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Lyrtzis', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Wlochowicz', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Nicholas Ar', 'Initials': 'NA', 'LastName': 'Clarke', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Kurt C', 'Initials': 'KC', 'LastName': 'Roberts-Thomson', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Stokes', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Mehrdad', 'Initials': 'M', 'LastName': 'Emami', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Dennis H', 'Initials': 'DH', 'LastName': 'Lau', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Prashanthan', 'Initials': 'P', 'LastName': 'Sanders', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Christopher X', 'Initials': 'CX', 'LastName': 'Wong', 'Affiliation': 'Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia c.wong@adelaide.edu.au.'}]",BMJ open,['10.1136/bmjopen-2020-047642'] 2392,34373299,Effect of a smartphone application (Perx) on medication adherence and clinical outcomes: a 12-month randomised controlled trial.,"OBJECTIVE To determine whether the Perx app improves medication adherence and clinical outcomes over 12 months compared with standard care in patients requiring polypharmacy. DESIGN Randomised controlled trial with 12-month follow-up. SETTING Outpatient clinics in three tertiary hospitals in Sydney, Australia. PARTICIPANTS Eligible participants were aged 18-75 years, with at least one chronic condition, taking ≥3 different medications (oral medications or injections), with smartphone accessibility. Participants were randomised in a 1:1 ratio. INTERVENTIONS The intervention group used the Perx app that contained customised reminders and gamified interactions to reward verified medication adherence. MAIN OUTCOME MEASURES The primary outcome was medication adherence over 12 months measured using pill counts. Secondary outcomes included clinical outcomes (haemoglobin A1c (HbA1c), cholesterol, blood glucose, triglycerides, creatinine, thyroid function, blood pressure and weight). RESULTS Of 1412 participants screened for eligibility, 124 participants were randomised; 45 in the Perx arm and 40 in the control arm completed the study. The average age was 59.5, 58.9% were women, chronic conditions were cardiovascular disease (78%), type 2 diabetes (75%), obesity (65%) or other endocrine disorders (18%). On average, participants were taking six medications daily. The Perx group had greater improvements in adherence at month 2 (Coef. 8%; 95% CI 0.01 to 0.15), month 3 (Coef. 7%; 95% CI 0.00 to 0.14) and month 12 (Coef. 7%; 95% CI 0.00 to 0.13). The probability of HbA1c ≤6.5% was greater in the Perx group at months 9 and 12 and cholesterol (total and low-density lipoprotein cholesterol) was lower in the Perx group at month 3. The intervention was particularly effective for those with obesity, taking medications for diabetes and taking ≤4 medications. CONCLUSIONS This study provides evidence that app-based behavioural change interventions can increase medication adherence and produce longer-term improvements in some clinical outcomes in adults managing multimorbidity. More trials are needed to build the evidence base. TRIAL REGISTRATION NUMBER ACTRN12617001285347.",2021,The probability of HbA1c ≤6.5% was greater in the Perx group at months 9 and 12 and cholesterol (total and low-density lipoprotein cholesterol) was lower in the Perx group at month 3.,"['average age was 59.5, 58.9% were women, chronic conditions were cardiovascular disease (78%), type 2 diabetes (75%), obesity (65%) or other endocrine disorders (18', '1412 participants screened for eligibility', 'Outpatient clinics in three tertiary hospitals in Sydney, Australia', '124 participants were randomised; 45 in the Perx arm and 40 in the control arm completed the study', 'patients requiring polypharmacy', 'adults managing multimorbidity', 'Eligible participants were aged 18-75 years, with at least one chronic condition, taking ≥3 different medications (oral medications or injections), with smartphone accessibility']","['smartphone application (Perx', 'Perx app that contained customised reminders and gamified interactions to reward verified medication adherence']","['cholesterol (total and low-density lipoprotein cholesterol', 'clinical outcomes (haemoglobin A1c (HbA1c), cholesterol, blood glucose, triglycerides, creatinine, thyroid function, blood pressure and weight', 'medication adherence and clinical outcomes', 'adherence', 'medication adherence']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0014130', 'cui_str': 'Disorder of endocrine system'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2922974', 'cui_str': 'Polypharmacy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C1535889', 'cui_str': 'Multimorbidity'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}]","[{'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0040132', 'cui_str': 'Thyroid structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",124.0,0.387871,The probability of HbA1c ≤6.5% was greater in the Perx group at months 9 and 12 and cholesterol (total and low-density lipoprotein cholesterol) was lower in the Perx group at month 3.,"[{'ForeName': 'Ang', 'Initials': 'A', 'LastName': 'Li', 'Affiliation': 'Boden Collaboration, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia ang.li5@unimelb.edu.au.'}, {'ForeName': 'M Gail', 'Initials': 'MG', 'LastName': 'Del Olmo', 'Affiliation': 'Boden Collaboration, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Mackenzie', 'Initials': 'M', 'LastName': 'Fong', 'Affiliation': 'Boden Collaboration, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Kyra', 'Initials': 'K', 'LastName': 'Sim', 'Affiliation': 'Boden Collaboration, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Sharyn J', 'Initials': 'SJ', 'LastName': 'Lymer', 'Affiliation': 'Boden Collaboration, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Cunich', 'Affiliation': 'Boden Collaboration, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Caterson', 'Affiliation': 'Boden Collaboration, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.'}]",BMJ open,['10.1136/bmjopen-2020-047041'] 2393,34373298,"Yoga, cognitive-behavioural therapy versus education to improve quality of life and reduce healthcare costs in people with endometriosis: a randomised controlled trial.","INTRODUCTION Endometriosis is a debilitating chronic inflammatory condition highly burdensome to the healthcare system. The present trial will establish the efficacy of (1) yoga and (2) cognitive-behavioural therapy (CBT), above (3) education, on quality of life, biopsychosocial outcomes and cost-effectiveness. METHODS AND ANALYSIS This study is a parallel randomised controlled trial. Participants will be randomly allocated to yoga, CBT or education. Participants will be English-speaking adults, have a diagnosis of endometriosis by a qualified physician, with pain for at least 6 months, and access to internet. Participants will attend 8 weekly group CBT sessions of 120 min; or 8 weekly group yoga sessions of 60 min; or receive weekly educational handouts on endometriosis. The primary outcome measure is quality of life. The analysis will include mixed-effects analysis of variance and linear models, cost-utility analysis from a societal and health system perspective and qualitative thematic analysis. ETHICS AND DISSEMINATION Enrolment in the study is voluntary and participants can withdraw at any time. Participants will be given the option to discuss the study with their next of kin/treating physician. Findings will be disseminated via publications, conferences and briefs to professional organisations. The University's media team will also be used to further disseminate via lay person articles and media releases. TRIAL REGISTRATION NUMBER ACTRN12620000756921p; Pre-results.",2021,"The present trial will establish the efficacy of (1) yoga and (2) cognitive-behavioural therapy (CBT), above (3) education, on quality of life, biopsychosocial outcomes and cost-effectiveness. ","['people with endometriosis', 'Participants will be English-speaking adults, have a diagnosis of endometriosis by a qualified physician, with pain for at least 6 months, and access to internet']","['1) yoga and (2) cognitive-behavioural therapy (CBT), above (3) education', 'CBT sessions of 120\u2009min; or 8 weekly group yoga sessions of 60\u2009min; or receive weekly educational handouts on endometriosis', 'Yoga, cognitive-behavioural therapy versus education']","['quality of life, biopsychosocial outcomes and cost-effectiveness', 'quality of life and reduce healthcare costs', 'quality of life']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0085552', 'cui_str': 'Health Costs'}]",,0.141292,"The present trial will establish the efficacy of (1) yoga and (2) cognitive-behavioural therapy (CBT), above (3) education, on quality of life, biopsychosocial outcomes and cost-effectiveness. ","[{'ForeName': 'Antonina', 'Initials': 'A', 'LastName': 'Mikocka-Walus', 'Affiliation': 'School of Psychology, Deakin University Geelong, Geelong and Burwood, Victoria, Australia antonina.mikockawalus@deakin.edu.au.'}, {'ForeName': 'Marilla', 'Initials': 'M', 'LastName': 'Druitt', 'Affiliation': 'Department of Obstetrics and Gynaecology, University Hospital Geelong, Geelong, Victoria, Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': ""O'Shea"", 'Affiliation': 'School of Psychology, Deakin University Geelong, Geelong and Burwood, Victoria, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Skvarc', 'Affiliation': 'School of Psychology, Deakin University Geelong, Geelong and Burwood, Victoria, Australia.'}, {'ForeName': 'Jennifer J', 'Initials': 'JJ', 'LastName': 'Watts', 'Affiliation': 'School of Health & Social Development, Faculty of Health, Deakin University, Burwood, Victoria, Australia.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Esterman', 'Affiliation': 'School of Nursing and Midwifery, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Tsaltas', 'Affiliation': 'Department of Gynaecology, Epworth Freemasons Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Knowles', 'Affiliation': 'Department of Psychological Sciences, Swinburne University of Technology, Hawthorn, Victoria, Australia.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Harris', 'Affiliation': 'Kyo Yoga & Healing, Ocean Grove, Victoria, Australia.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Dowding', 'Affiliation': 'School of Psychology, Deakin University Geelong, Geelong and Burwood, Victoria, Australia.'}, {'ForeName': 'Elesha', 'Initials': 'E', 'LastName': 'Parigi', 'Affiliation': 'School of Psychology, Deakin University Geelong, Geelong and Burwood, Victoria, Australia.'}, {'ForeName': 'Subhadra', 'Initials': 'S', 'LastName': 'Evans', 'Affiliation': 'School of Psychology, Deakin University Geelong, Geelong and Burwood, Victoria, Australia.'}]",BMJ open,['10.1136/bmjopen-2020-046603'] 2394,34373282,Advanced prostate cancer experimental radioactive treatment-clinical trial decision making: patient experiences.,"OBJECTIVES Nested qualitative studies within clinical trials provide the opportunity to better understand participant experiences of participation and identify areas where improved support is required. The purpose of this qualitative study is to describe the lived experiences of men with advanced prostate cancer participating in the TheraP trial; a randomised trial of 177 Lu-PSMA-617 compared with cabazitaxel chemotherapy. METHODS Fifteen men with advanced prostate cancer were recruited from the TheraP clinical trial and interviewed at three time points during the trial. Interviews were inductively analysed using thematic analysis. This research paper reports the results from the baseline interview at commencement of the trial, focusing specifically on participants' enrolment experiences. RESULTS Four themes were identified representing the lived experiences of men with advanced prostate cancer deciding to participate in the TheraP trial: (1) hoping to survive; (2) needing to feel informed; (3) choosing to participate and (4) being randomised. The process of deciding to enrol in a clinical trial is filled with indecision, emotional difficulties and focused on a desire to live. CONCLUSIONS For men with advanced prostate cancer, the experience of deciding to enrol in a clinical trial is principally driven by a desire to survive but interlinked with the need to make an informed decision as participants in this study expressed a preference for allocation to the experimental arm. Men seeking to enrol in clinical trials of new prostate cancer treatments would benefit from improved informational and decision support. TRIAL REGISTRATION NUMBER NCT03392428, ANZUP1603.",2021,"RESULTS Four themes were identified representing the lived experiences of men with advanced prostate cancer deciding to participate in the TheraP trial: (1) hoping to survive; (2) needing to feel informed; (3) choosing to participate and (4) being randomised.","['men with advanced prostate cancer deciding to participate in the TheraP trial: (1) hoping to survive; (2) needing to feel informed; (3) choosing to participate and (4) being randomised', 'Fifteen men with advanced prostate cancer were recruited from the TheraP clinical trial and interviewed at three time points during the trial', 'men with advanced prostate cancer', 'lived experiences of men with advanced prostate cancer participating in the TheraP trial']",['cabazitaxel chemotherapy'],[],"[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0078040', 'cui_str': 'VAP protocol'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C2830183', 'cui_str': 'cabazitaxel'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],15.0,0.615956,"RESULTS Four themes were identified representing the lived experiences of men with advanced prostate cancer deciding to participate in the TheraP trial: (1) hoping to survive; (2) needing to feel informed; (3) choosing to participate and (4) being randomised.","[{'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Viljoen', 'Affiliation': 'School of Nursing and Midwifery, University of Southern Queensland, Toowoomba, Queensland, Australia.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Hofman', 'Affiliation': 'Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.'}, {'ForeName': 'Suzanne K', 'Initials': 'SK', 'LastName': 'Chambers', 'Affiliation': 'Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Dunn', 'Affiliation': 'Centre for Health Research, University of Southern Queensland, Toowoomba, Queensland, Australia.'}, {'ForeName': 'Haryana', 'Initials': 'H', 'LastName': 'Dhillon', 'Affiliation': 'CeMPED, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Ian D', 'Initials': 'ID', 'LastName': 'Davis', 'Affiliation': 'Department of Medical Oncology, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Ralph', 'Affiliation': 'School of Nursing and Midwifery, University of Southern Queensland, Toowoomba, Queensland, Australia nicholas.ralph@usq.edu.au.'}]",BMJ supportive & palliative care,['10.1136/bmjspcare-2021-002994'] 2395,34373214,Arthrocentesis versus nonsurgical methods in the management of temporomandibular joint closed lock and pain: a double-blind randomized controlled trial.,"OBJECTIVE The present double-blind randomized clinical trial aimed to compare the efficacy of conservative treatment and articular lavage, either alone or combined, to reduce joint pain and improve mandibular opening. STUDY DESIGN The sample consisted of patients presenting with limited mouth opening and joint pain. The diagnosis was made according to the diagnostic criteria for temporomandibular disorders guideline and confirmed by magnetic resonance imaging. Sixty patients were selected and randomly allocated to 4 groups of 15 patients each with different treatments: group A (conservative), group B (conservative + medication), group C (arthrocentesis), and group D (arthrocentesis + medication). The groups were compared in terms of maximal interincisal opening and pain. RESULTS The average age of the patients was 34.17 ± 13.1 years, 88.1% were women, 72.9% had internal derangement, 54% had joint sounds, and 55.9% presented with locking. Clinical improvement was noted in all parameters compared with baseline in all groups (P < .005), but no significant differences were observed when the groups were compared (P > .05). CONCLUSIONS Both arthrocentesis and conservative modalities were efficient treatments to reduce joint pain and increase mandibular opening.",2021,"Clinical improvement was noted in all parameters compared with baseline in all groups (P < .005), but no significant differences were observed when the groups were compared (P > .05). ","['patients presenting with limited mouth opening and joint pain', 'Sixty patients', 'temporomandibular joint closed lock and pain', 'average age of the patients was 34.17 ± 13.1 years, 88.1% were women, 72.9% had internal derangement, 54% had joint sounds, and 55.9% presented with locking']","['conservative treatment and articular lavage', 'Arthrocentesis versus nonsurgical methods', 'group B (conservative\xa0+\xa0medication), group C (arthrocentesis), and group D (arthrocentesis\xa0+\xa0medication']","['maximal interincisal opening and pain', 'joint pain and improve mandibular opening', 'joint pain and increase mandibular opening']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0039493', 'cui_str': 'Temporomandibular joint structure'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}]","[{'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0204854', 'cui_str': 'Arthrocentesis'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0441838', 'cui_str': 'Group D'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",60.0,0.271954,"Clinical improvement was noted in all parameters compared with baseline in all groups (P < .005), but no significant differences were observed when the groups were compared (P > .05). ","[{'ForeName': 'Fabio G', 'Initials': 'FG', 'LastName': 'Ritto', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Rio de Janeiro State University, Rio de Janeiro, Brazil. Electronic address: fabioritto@cirurgiamaxilofacial.com.'}, {'ForeName': 'Alexander Pomares', 'Initials': 'AP', 'LastName': 'Cueto', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Rio de Janeiro State University, Rio de Janeiro, Brazil.'}, {'ForeName': 'João Vitor', 'Initials': 'JV', 'LastName': 'Dos Santos Canellas', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Rio de Janeiro State University, Rio de Janeiro, Brazil.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Zuniga', 'Affiliation': 'Division of Oral and Maxillofacial Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Tiwana', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Health Sciences Center, University of Oklahoma, Oklahoma City, OK, USA.'}, {'ForeName': 'Thais', 'Initials': 'T', 'LastName': 'Pimentel', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Rio de Janeiro State University, Rio de Janeiro, Brazil.'}, {'ForeName': 'Paulo Jose', 'Initials': 'PJ', 'LastName': 'Medeiros', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Rio de Janeiro State University, Rio de Janeiro, Brazil.'}]","Oral surgery, oral medicine, oral pathology and oral radiology",['10.1016/j.oooo.2021.06.020'] 2396,34373201,Stabilization of comfort and visual quality after the insertion of soft contact lenses.,"PURPOSE To evaluate comfort, visual function, and in vivo wettability after the insertion of hydrogel and silicone hydrogel contact lenses for a better understanding of how long practitioners should wait for the initial evaluation of soft contact lenses. METHODS A short-term prospective, contralateral, randomized, and participant-masked study was carried out. Twenty healthy participants (25.4 ± 2.6 years) were evaluated after the insertion of two different soft contact lenses at different times (1, 5, 10, 20, 30 min). Ocufilcon D (hydrogel) and Somofilcon A (silicone hydrogel) contact lenses were randomly assigned to both eyes of the same participant. Comfort, visual function under photopic conditions in terms of high-contrast visual acuity, low-contrast visual acuity, contrast sensitivity, and in vivo wettability were measured. RESULTS There was an increase in comfort (p < 0.001), high-contrast visual acuity (p < 0.05), and contrast sensitivity (p < 0.001, only with silicone hydrogel) directly related to time after contact lens insertion. Besides, in vivo wettability suffered a statistically significant deterioration directly related to time with both contact lenses (p < 0.05). Except for comfort and contrast sensitivity, all the parameters stabilized their values 10 min after the insertion of both soft contact lenses. Additionally, in vivo wettability and visual acuity differences were found between hydrogel and silicone hydrogel contact lenses (p < 0.05). CONCLUSIONS It would be possible to properly evaluate high-contrast visual acuity, low-contrast visual acuity, and in vivo wettability 10 min after the insertion of both soft contact lenses.",2021,"Except for comfort and contrast sensitivity, all the parameters stabilized their values 10 min after the insertion of both soft contact lenses.","['contact lenses', 'Twenty healthy participants (25.4\xa0±\xa02.6\xa0years']","['hydrogel and silicone hydrogel contact lenses', 'Ocufilcon D (hydrogel) and Somofilcon A (silicone hydrogel']","['high-contrast visual acuity', 'high-contrast visual acuity, low-contrast visual acuity, contrast sensitivity, and in vivo wettability', 'vivo wettability and visual acuity differences', 'contrast sensitivity', 'Stabilization of comfort and visual quality', 'comfort']","[{'cui': 'C0009836', 'cui_str': 'Contact lenses'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4517633', 'cui_str': '2.6'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0063083', 'cui_str': 'Hydrogel'}, {'cui': 'C0037114', 'cui_str': 'Silicones'}, {'cui': 'C0009836', 'cui_str': 'Contact lenses'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009928', 'cui_str': 'Contrast sensitivity'}, {'cui': 'C0162598', 'cui_str': 'Wetability'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0332306', 'cui_str': 'Quality'}]",20.0,0.0412206,"Except for comfort and contrast sensitivity, all the parameters stabilized their values 10 min after the insertion of both soft contact lenses.","[{'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Carpena-Torres', 'Affiliation': 'Ocupharm Research Group, Department of Optometry and Vision, Faculty of Optics and Optometry, Complutense University of Madrid, Madrid, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Pastrana', 'Affiliation': 'Ocupharm Research Group, Department of Optometry and Vision, Faculty of Optics and Optometry, Complutense University of Madrid, Madrid, Spain.'}, {'ForeName': 'Candela', 'Initials': 'C', 'LastName': 'Rodríguez-Pomar', 'Affiliation': 'Ocupharm Research Group, Department of Optometry and Vision, Faculty of Optics and Optometry, Complutense University of Madrid, Madrid, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Serramito', 'Affiliation': 'Ocupharm Research Group, Department of Optometry and Vision, Faculty of Optics and Optometry, Complutense University of Madrid, Madrid, Spain.'}, {'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Carracedo', 'Affiliation': 'Ocupharm Research Group, Department of Optometry and Vision, Faculty of Optics and Optometry, Complutense University of Madrid, Madrid, Spain. Electronic address: jgcarrac@ucm.es.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2021.101498'] 2397,34373175,Effect of peer support on adults with diabetes-related peripheral neuropathy.,"OBJECTIVE To explore the effect of peer support on exercise self-efficacy, physical activity level, and neuropathic symptoms in patients with diabetes-related peripheral neuropathy (DPN). METHODS A total of 60 adults with DPN were assigned to groups. Patients in the control group received routine education (RE), while patients in the intervention group received peer support (PS) combined with routine diabetes education. Data were collected at baseline and after intervention (12 weeks). RESULTS At 12 weeks, better outcomes were found in the PS group compared to the RE group for the following aspects: exercise self-efficacy, steps, total physical activity, fasting blood glucose and 2-hour postprandial blood glucose. Decreases in scores on Toronto Clinical Scoring System occurred between baseline and post-intervention in both groups. CONCLUSION Peer support is an effective way to improve exercise self-efficacy, number of steps, and general physical activity and to reduce blood glucose for patients with DPN. But the effects of peer support on neuropathic symptoms is are obvious. Further research is needed. PRACTICE IMPLICATIONS As a low-cost, effective education approach, peer support strategies should be integrated into our healthcare system to meet the minimum needs of patients with DPN.",2021,"At 12 weeks, better outcomes were found in the PS group compared to the RE group for the following aspects: exercise self-efficacy, steps, total physical activity, fasting blood glucose and 2-hour postprandial blood glucose.","['patients with DPN', 'adults with diabetes-related peripheral neuropathy', '60 adults with DPN', 'patients with diabetes-related peripheral neuropathy (DPN']","['peer support', 'routine education (RE', 'peer support (PS) combined with routine diabetes education']","['exercise self-efficacy, physical activity level, and neuropathic symptoms', 'blood glucose', 'exercise self-efficacy, steps, total physical activity, fasting blood glucose and 2-hour postprandial blood glucose', 'neuropathic symptoms', 'exercise self-efficacy, number of steps, and general physical activity', 'Toronto Clinical Scoring System']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",60.0,0.00878601,"At 12 weeks, better outcomes were found in the PS group compared to the RE group for the following aspects: exercise self-efficacy, steps, total physical activity, fasting blood glucose and 2-hour postprandial blood glucose.","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Nursing Department, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Pei', 'Affiliation': 'School of Nursing, Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'ForeName': 'Meifeng', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Nursing Department, YanTai Stomatological Hospital, Shandong Province, China.'}, {'ForeName': 'Shiquan', 'Initials': 'S', 'LastName': 'Sun', 'Affiliation': 'Acupuncture and Tuina Department, Tianjin Beichen North Gate Hospital, Tianjin, China.'}, {'ForeName': 'Shuling', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Nursing Department, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Tianjin Medical University, School of Nursing, Tianjin, China. Electronic address: snzhangqing@tmu.edu.cn.'}]",Patient education and counseling,['10.1016/j.pec.2021.07.047'] 2398,34373167,Intraoperative multimodal analgesic bundle containing dexmedetomidine and ketorolac may improve analgesia after robot-assisted prostatectomy in patients receiving rectus sheath blocks.,"BACKGROUND Minimally invasive robot-assisted laparoscopic radical prostatectomy (RALP) has replaced open prostatectomy. However, RALP does not reduce postoperative pain compared to the open approach. We explored whether bundled intraoperative intravenous infusion of dexmedetomidine and ketorolac reduced opioid requirements during the 24 h after RALP. METHODS Eighty patients (two parallel groups) were enrolled in this prospective non-randomized study from September 2020 to November 2020. All received preoperative rectus sheath blocks for analgesia after RALP. A multimodal analgesic bundle (dexmedetomidine and ketorolac) was administered intraoperatively in the study group (n = 39) but not in the control group (n = 40). The total postoperative opioid requirements (expressed in milligrams of intravenous morphine) and pain scores (derived using a visual analog scale) were compared between the two groups up to 24 h after surgery. RESULTS The two groups were demographically similar. During surgery, patients in the study group received less remifentanil and more ephedrine than controls. The study group required significantly less opioids during the 24 h after surgery (28.3 vs. 40.0 mg, p = 0.006). The between-group pain scores differed significantly at 1 and 6 h after surgery. All other postoperative characteristics were comparable between the two groups. CONCLUSIONS The intraoperative multimodal analgesic bundle (intravenous dexmedetomidine and ketorolac) improved postoperative analgesia after RALP in patients with rectus sheath blocks, as evidenced by the opioid-sparing effect after surgery.",2021,"The intraoperative multimodal analgesic bundle (intravenous dexmedetomidine and ketorolac) improved postoperative analgesia after RALP in patients with rectus sheath blocks, as evidenced by the opioid-sparing effect after surgery.","['Eighty patients (two parallel groups) were enrolled in this prospective non-randomized study from September 2020 to November 2020', 'patients receiving rectus sheath blocks', 'patients with rectus sheath blocks']","['RALP', 'multimodal analgesic bundle (dexmedetomidine and ketorolac', 'invasive robot-assisted laparoscopic radical prostatectomy (RALP', 'ephedrine', 'preoperative rectus sheath blocks', 'dexmedetomidine and ketorolac', 'remifentanil']","['opioid requirements', 'postoperative pain', 'opioids', 'postoperative analgesia', 'analgesia', 'total postoperative opioid requirements', 'pain scores']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]","[{'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C4039115', 'cui_str': 'Robot assisted laparoscopic radical prostatectomy'}, {'cui': 'C0014479', 'cui_str': 'Ephedrine'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",,0.151102,"The intraoperative multimodal analgesic bundle (intravenous dexmedetomidine and ketorolac) improved postoperative analgesia after RALP in patients with rectus sheath blocks, as evidenced by the opioid-sparing effect after surgery.","[{'ForeName': 'Jung-Woo', 'Initials': 'JW', 'LastName': 'Shim', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Eun Hwa', 'Initials': 'EH', 'LastName': 'Jun', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Jinhoon', 'Initials': 'J', 'LastName': 'Bae', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Hyong Woo', 'Initials': 'HW', 'LastName': 'Moon', 'Affiliation': ""Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Sung Hoo', 'Initials': 'SH', 'LastName': 'Hong', 'Affiliation': ""Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Jaesik', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Hyung Mook', 'Initials': 'HM', 'LastName': 'Lee', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Sang Hyun', 'Initials': 'SH', 'LastName': 'Hong', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Min Suk', 'Initials': 'MS', 'LastName': 'Chae', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address: shscms@gmail.com.""}]",Asian journal of surgery,['10.1016/j.asjsur.2021.07.043'] 2399,34376358,Oral mucosal mouthwash with chlorhexidine does not reduce the incidence of ventilator-associated pneumonia in critically ill children: A randomised controlled trial.,"BACKGROUND Ventilator-associated pneumonia (VAP) is one of the most frequently encountered causes of hospital-acquired infection and results in high morbidity among intubated patients. Few trials have investigated the efficacy of oral care with chlorhexidine (CHX) mouthwash for the prevention of VAP in the paediatric population. OBJECTIVES The objective of this study was to assess the efficacy of CHX mouthwash in the prevention of VAP and to determine risk factors for VAP in children aged 1 month to 18 years admitted to the paediatric intensive care unit (PICU). METHODS This was a prospective, randomised, controlled, double-blind trial performed in the PICU. Patients were randomised into two groups receiving CHX (0.12%) (n = 88) or placebo (0.9% NaCl) (n = 86) and were followed up for VAP development. The main outcome measures were incidence of VAP, duration of hospital stay, duration of PICU stay, duration of ventilation, mortality, and the characteristics of organisms isolated in cases with VAP. RESULTS No difference was observed in the incidence of VAP and the type and distribution of organisms in the two groups (p > 0.05). In the CHX and placebo groups, we identified 21 and 22 patients with VAP, respectively. Incidence per 1000 ventilation days was 29.5 events in the CHX group and 35.1 events in the placebo group. Gram-negative bacteria were most common (71.4% in CHX vs. 54.5% in placebo). The use of 0.12% CHX did not influence hospital stay, PICU stay, ventilation, and mortality (p > 0.05). Multivariate analysis identified duration of ventilation as the only independent risk factor for VAP (p = 0.001). CONCLUSION The use of 0.12% CHX did not reduce VAP frequency among critically ill children. The only factor that increased VAP frequency was longer duration on ventilation. It appears that low concentration of CHX is not effective for VAP prevention, especially in the presence of multiresistant bacteria. CLINICALTRIALS. GOV IDENTIFIER NCT04527276.",2021,Gram-negative bacteria were most common (71.4% in CHX vs. 54.5% in placebo).,"['children aged 1 month to 18 years admitted to the paediatric intensive care unit (PICU', 'intubated patients', 'critically ill children']","['chlorhexidine (CHX) mouthwash', 'chlorhexidine', 'CHX', 'placebo (0.9% NaCl', 'placebo']","['VAP frequency', 'Gram-negative bacteria', 'incidence of ventilator-associated pneumonia', 'incidence of VAP, duration of hospital stay, duration of PICU stay, duration of ventilation, mortality, and the characteristics of organisms isolated in cases with VAP', 'hospital stay, PICU stay, ventilation, and mortality', 'incidence of VAP and the type and distribution of organisms']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021710', 'cui_str': 'Pediatric intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}]","[{'cui': 'C0352155', 'cui_str': 'Chlorhexidine Mouthwash'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0018150', 'cui_str': 'Gram-negative bacterium'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0021710', 'cui_str': 'Pediatric intensive care unit'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0029235', 'cui_str': 'Organism'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}]",,0.164635,Gram-negative bacteria were most common (71.4% in CHX vs. 54.5% in placebo).,"[{'ForeName': 'Zeynep', 'Initials': 'Z', 'LastName': 'Karakaya', 'Affiliation': 'Istanbul Medeniyet University Goztepe Training and Research Hospital, Department of Paediatrics, Turkey. Electronic address: sirac.26@hotmail.com.'}, {'ForeName': 'Muhterem', 'Initials': 'M', 'LastName': 'Duyu', 'Affiliation': 'Istanbul Medeniyet University Goztepe Training and Research Hospital, Department of Paediatrics, Pediatric Intensive Care Unit, Istanbul, Turkey. Electronic address: drmuhteremduyu@gmail.com.'}, {'ForeName': 'Meryem Nihal', 'Initials': 'MN', 'LastName': 'Yersel', 'Affiliation': 'Istanbul Medeniyet University Goztepe Training and Research Hospital, Department of Paediatrics, Pediatric Intensive Care Unit, Istanbul, Turkey. Electronic address: nihalyersel@hotmail.com.'}]",Australian critical care : official journal of the Confederation of Australian Critical Care Nurses,['10.1016/j.aucc.2021.06.011'] 2400,34376322,Response to letter to the editor re: Economic outcomes of depression screening after acute coronary syndromes: The CODIACS-QoL randomized clinical trial.,,2021,,['after acute coronary syndromes'],['depression screening'],[],"[{'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}]","[{'cui': 'C0740218', 'cui_str': 'Depression screening'}]",[],,0.24153,,"[{'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Ladapo', 'Affiliation': 'David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America. Electronic address: jladapo@mednet.ucla.edu.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Kronish', 'Affiliation': 'Center for Behavioral Cardiovascular Health, Columbia University Irving Medical Center, New York, NY, United States of America.'}]",General hospital psychiatry,['10.1016/j.genhosppsych.2021.08.001'] 2401,34376321,Thoracic Spinal Manipulation Effect on Neuroendocrine Response in People With Achilles Tendinopathy: A Randomized Crossover Trial.,"OBJECTIVE The purpose of the present study was to determine the neuroendocrine response after a thoracic spinal manipulation in people with Achilles tendinopathy. METHODS This was a randomized 2-sequence, 2-period crossover trial. A total of 24 participants, mean (standard deviation) age of 48 (7) years, with a diagnosis of Achilles tendinopathy (>3 mo) were randomly assigned into sequence 1 (sham intervention and then thoracic spinal manipulation) or sequence 2 (thoracic spinal manipulation and then sham intervention). The trial was conducted at a university laboratory with a washout period of 1 week. The primary outcome measure was the testosterone/cortisol (T/C) ratio (salivary samples). The secondary outcome measures included heart rate variability (measured with electrocardiography) and total oxygenation index (nmol/L) of calf muscle and Achilles tendon (measured with near-infrared spectroscopy). A 2-way mixed-model analysis of variance was performed. The statistic of interest was the condition by time interaction. RESULTS A statistically significant condition by time interaction was found for the T/C ratio (mean difference: -0.16; confidence interval: -0.33 to 0.006; interaction: P < .05) and the total oxygenation index (mean difference: 1.35; confidence interval: -1.3 to 4.1; interaction: P < .05) of calf muscle but not for Achilles tendon (P = .6); however, no difference was found for heart rate variability (P = .5). CONCLUSION In people with Achilles tendinopathy, thoracic spinal manipulation resulted in immediate increase in the total oxygenation index in the calf muscle followed by an increase in the T/C ratio 6 hours post-intervention.",2021,"A statistically significant condition by time interaction was found for the T/C ratio (mean difference: -0.16; confidence interval: -0.33 to 0.006; interaction: P < .05) and the total oxygenation index (mean difference: 1.35; confidence interval: -1.3 to 4.1; interaction: P < .05) of calf muscle but not for Achilles tendon (P = .6); however, no difference was found for heart rate variability (P = .5). ","['People With Achilles Tendinopathy', 'people with Achilles tendinopathy', '24 participants, mean (standard deviation) age of 48 (7) years, with a diagnosis of Achilles tendinopathy (>3 mo']","['sequence 1 (sham intervention and then thoracic spinal manipulation) or sequence 2 (thoracic spinal manipulation and then sham intervention', 'Thoracic Spinal Manipulation', 'thoracic spinal manipulation']","['Neuroendocrine Response', 'heart rate variability', 'total oxygenation index', 'testosterone/cortisol (T/C) ratio (salivary samples', 'neuroendocrine response', 'heart rate variability (measured with electrocardiography) and total oxygenation index (nmol/L) of calf muscle and Achilles tendon (measured with near-infrared spectroscopy']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001074', 'cui_str': 'Structure of Achilles tendon'}, {'cui': 'C0151936', 'cui_str': 'Disorder of tendon'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0086586', 'cui_str': 'Manipulation of spine'}]","[{'cui': 'C0027912', 'cui_str': 'Neuroendocrine System'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index measurement'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0439282', 'cui_str': 'nmol/L'}, {'cui': 'C0448482', 'cui_str': 'Posterior crural muscle structure'}, {'cui': 'C0001074', 'cui_str': 'Structure of Achilles tendon'}, {'cui': 'C0376519', 'cui_str': 'Near-infrared spectroscopy'}]",24.0,0.323082,"A statistically significant condition by time interaction was found for the T/C ratio (mean difference: -0.16; confidence interval: -0.33 to 0.006; interaction: P < .05) and the total oxygenation index (mean difference: 1.35; confidence interval: -1.3 to 4.1; interaction: P < .05) of calf muscle but not for Achilles tendon (P = .6); however, no difference was found for heart rate variability (P = .5). ","[{'ForeName': 'Kesava', 'Initials': 'K', 'LastName': 'Kovanur Sampath', 'Affiliation': 'Centre for Health, Activity, and Rehabilitation Research, School of Physiotherapy, University of Otago, Dunedin, New Zealand. Electronic address: Kesava.KovanurSampath@ara.ac.nz.'}, {'ForeName': 'Ramakrishnan', 'Initials': 'R', 'LastName': 'Mani', 'Affiliation': 'Centre for Health, Activity, and Rehabilitation Research, School of Physiotherapy, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Katare', 'Affiliation': 'Department of Physiology-Heart Otago, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Neale', 'Affiliation': 'Department of Physiology-Heart Otago, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Cotter', 'Affiliation': 'School of Physical Education, Sport and Exercise Science, Dunedin, New Zealand.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Tumilty', 'Affiliation': 'Centre for Health, Activity, and Rehabilitation Research, School of Physiotherapy, University of Otago, Dunedin, New Zealand.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2021.06.001'] 2402,34376320,The Influence of Sacroiliac Joint Manipulation on Changes in the Values of the Center of Pressure in the Process of Maintaining Static Body Balance.,"OBJECTIVE The aim of the study was to determine the influence of manipulative treatment of sacroiliac joint (SIJ) hypomobility on the ability to maintain static balance of the body. METHODS We compared displacements of the center of pressure (COP) in 2 groups of students of the University of Physical Education: the experimental group (30 people exhibiting SIJ hypomobility) and the control group (29 people without SIJ hypomobility). A manipulation was performed in the experimental group and a placebo procedure in the control group. Sacroiliac joint hypomobility was diagnosed by the following SIJ mobility tests: forward flexion test, Gillet test, long sitting test, lower limb adduction test. These and podometric tests were performed on all participants twice-before and after the procedure. The influence of experimental manipulation was examined by applying repeated-measures analysis of variance, and comparisons were made with Student's t test for dependent and independent samples and nonparametric tests. RESULTS A statistically significant difference between before and after treatment was found in the experimental group (P < .05) in terms of COP pathway, COP pathway area, and average COP speed. Furthermore, the groups differed in before-treatment values of these parameters in favor of the control group, but after-treatment measurement revealed normalization of the levels of these characteristics in the experimental group to the level of the control group. CONCLUSION As a result of SIJ manipulation, parameters related to the ability to maintain balance improved in the experimental group.",2021,"RESULTS A statistically significant difference between before and after treatment was found in the experimental group (P < .05) in terms of COP pathway, COP pathway area, and average COP speed.",['2 groups of students of the University of Physical Education: the experimental group (30 people exhibiting SIJ hypomobility) and the control group (29 people without SIJ hypomobility'],"['Sacroiliac Joint Manipulation', 'manipulative treatment of sacroiliac joint (SIJ) hypomobility', 'placebo']","['flexion test, Gillet test, long sitting test, lower limb adduction test', 'COP pathway, COP pathway area, and average COP speed', 'Sacroiliac joint hypomobility']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0036036', 'cui_str': 'Sacroiliac joint structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0036036', 'cui_str': 'Sacroiliac joint structure'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1627359', 'cui_str': 'Flexion test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0444357', 'cui_str': 'Long-sitting'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231457', 'cui_str': 'Adduction'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0036036', 'cui_str': 'Sacroiliac joint structure'}]",30.0,0.0300989,"RESULTS A statistically significant difference between before and after treatment was found in the experimental group (P < .05) in terms of COP pathway, COP pathway area, and average COP speed.","[{'ForeName': 'Michał O', 'Initials': 'MO', 'LastName': 'Posłuszny', 'Affiliation': 'Department of Anatomy, Poznan University of Physical Education, Poznań, Poland. Electronic address: posluszny.michal@gmail.com.'}, {'ForeName': 'Małgorzata M', 'Initials': 'MM', 'LastName': 'Waszak', 'Affiliation': 'Department of Anatomy, Poznan University of Physical Education, Poznań, Poland.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2021.05.003'] 2403,34376319,Effects of Dry Needling on Biomechanical Properties of the Myofascial Trigger Points Measured by Myotonometry: A Randomized Controlled Trial.,"OBJECTIVE The purpose of the present study was to examine the effect of dry needling (DN) on the biomechanical properties of a latent medial myofascial trigger point (MTrP) of the soleus muscle compared with an adjacent point within the taut band (TB) measured by myotonometry. METHODS Fifty asymptomatic volunteers were randomly assigned to an intervention group (n = 26) or control group (n = 24). One session of DN was performed in every group as follows: 10 needle insertions into the MTrP area (intervention group) or TB area (control group). Myotonometric measurements (frequency, decrement, and stiffness) were performed at baseline (pre-intervention) and after the intervention (post-intervention) in both locations (MTrP and TB areas). RESULTS The results showed that stiffness outcome significantly decreased with a large effect size after DN in the MTrP when measured in the MTrP location (P = .002; d = 0.928) but not when measured in the TB location. In contrast, no significant changes were observed in any location when the TB was needled (P > .05). CONCLUSIONS The findings suggest that only DN into the MTrP area was effective in decreasing stiffness outcome, therefore a specific puncture was needed to modify myofascial muscle stiffness.",2021,"In contrast, no significant changes were observed in any location when the TB was needled (P > .05). ","['Myotonometry', 'Fifty asymptomatic volunteers']","['MTrP area (intervention group) or TB area (control group', 'dry needling (DN', 'Dry Needling']","['Myotonometric measurements (frequency, decrement, and stiffness', 'Biomechanical Properties of the Myofascial Trigger Points']","[{'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4019022', 'cui_str': 'Taut'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}]","[{'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}]",50.0,0.0586368,"In contrast, no significant changes were observed in any location when the TB was needled (P > .05). ","[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Jiménez-Sánchez', 'Affiliation': 'iPhysio Research Group, Universidad San Jorge, Zaragoza, Spain.'}, {'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Gómez-Soriano', 'Affiliation': 'Toledo Physiotherapy Research Group, Facultad de Fisioterapia de Toledo, Universidad Castilla La Mancha, Toledo, Castilla La Mancha, Spain; Sensorimotor Function Group, Hospital Nacional de Parapléjicos, Toledo, Castilla La Mancha, Spain. Electronic address: Julio.Soriano@uclm.es.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Bravo-Esteban', 'Affiliation': 'Toledo Physiotherapy Research Group, Facultad de Fisioterapia de Toledo, Universidad Castilla La Mancha, Toledo, Castilla La Mancha, Spain.'}, {'ForeName': 'Orlando', 'Initials': 'O', 'LastName': 'Mayoral-Del Moral', 'Affiliation': 'Physical Therapy Unit, Hospital Provincial, Toledo, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Herrero-Gállego', 'Affiliation': 'iPhysio Research Group, Universidad San Jorge, Zaragoza, Spain.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Serrano-Muñoz', 'Affiliation': 'Toledo Physiotherapy Research Group, Facultad de Fisioterapia de Toledo, Universidad Castilla La Mancha, Toledo, Castilla La Mancha, Spain; Sensorimotor Function Group, Hospital Nacional de Parapléjicos, Toledo, Castilla La Mancha, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Ortiz-Lucas', 'Affiliation': 'iPhysio Research Group, Universidad San Jorge, Zaragoza, Spain.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2021.06.002'] 2404,34376218,Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial.,"BACKGROUND Cardiogenic shock (CS) is associated with significant morbidity and mortality. The impact of beta-blocker (BB) use on patients who develop CS remains unknown. We sought to evaluate the clinical outcomes and hemodynamic response profiles in patients treated with BB in the 24 h prior to the development of CS. METHODS Patients with CS enrolled in the DObutamine compaREd to MIlrinone trial were analyzed. The primary outcome was a composite of all-cause mortality, resuscitated cardiac arrest, need for cardiac transplant or mechanical circulatory support, non-fatal myocardial infarction, transient ischemic attack or stroke, or initiation of renal replacement therapy. Secondary outcomes included the individual components of the primary composite and hemodynamic response profiles derived from pulmonary artery catheters. RESULTS Among 192 participants, 93 patients (48%) had received BB therapy. The primary outcome occurred in 47 patients (51%) in the BB group and in 52 (53%) in the no BB group (RR 0.96; 95% CI 0.73-1.27; P = 0.78) throughout the in-hospital period. There were fewer early deaths in the BB group (RR 0.41; 95% CI 0.18-0.95; P = 0.03). There were no differences in other individual components of the primary outcome or in hemodynamic response between the two groups throughout the remainder of the hospitalization. CONCLUSIONS BB therapy in the 24 h preceding the development of CS did not negatively influence clinical outcomes or hemodynamic parameters. On the contrary, BB use was associated with fewer deaths in the early resuscitation period, suggesting a paradoxically protective effect in patients with CS. Trial registration ClinicalTrials.gov Identifier: NCT03207165.",2021,"There were no differences in other individual components of the primary outcome or in hemodynamic response between the two groups throughout the remainder of the hospitalization. ","['192 participants, 93 patients (48%) had received BB therapy', 'patients treated with BB in the 24\xa0h prior to the development of CS', 'patients who develop CS remains unknown', 'Patients with CS enrolled in the', 'cardiogenic shock', 'patients with CS']","['DObutamine', 'MIlrinone', 'beta-blocker (BB', 'baseline beta-blocker']","['inotrope response and clinical outcomes', 'composite of all-cause mortality, resuscitated cardiac arrest, need for cardiac transplant or mechanical circulatory support, non-fatal myocardial infarction, transient ischemic attack or stroke, or initiation of renal replacement therapy', 'hemodynamic response', 'early deaths', 'individual components of the primary composite and hemodynamic response profiles derived from pulmonary artery catheters']","[{'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001645', 'cui_str': 'Beta adrenergic receptor antagonist'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0036980', 'cui_str': 'Cardiogenic shock'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}]","[{'cui': 'C0012963', 'cui_str': 'Dobutamine'}, {'cui': 'C0128513', 'cui_str': 'Milrinone'}, {'cui': 'C0001645', 'cui_str': 'Beta adrenergic receptor antagonist'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C2587207', 'cui_str': 'For resuscitation'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0179790', 'cui_str': 'Pulmonary artery flotation catheter'}]",192.0,0.375876,"There were no differences in other individual components of the primary outcome or in hemodynamic response between the two groups throughout the remainder of the hospitalization. ","[{'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Di Santo', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Mathew', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Jung', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Trevor', 'Initials': 'T', 'LastName': 'Simard', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Skanes', 'Affiliation': 'Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Brennan', 'Initials': 'B', 'LastName': 'Mao', 'Affiliation': 'Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'F Daniel', 'Initials': 'FD', 'LastName': 'Ramirez', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Marbach', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Abdel-Razek', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Pouya', 'Initials': 'P', 'LastName': 'Motazedian', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Parlow', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Kevin E', 'Initials': 'KE', 'LastName': 'Boczar', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Gianni', 'Initials': 'G', 'LastName': ""D'Egidio"", 'Affiliation': 'Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Hawken', 'Affiliation': 'Ottawa Hospital Research Institute, Ottawa, ON, Canada.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Bernick', 'Affiliation': 'Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Wells', 'Affiliation': 'Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Dick', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Derek Y', 'Initials': 'DY', 'LastName': 'So', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Glover', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Juan J', 'Initials': 'JJ', 'LastName': 'Russo', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'McGuinty', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Hibbert', 'Affiliation': 'CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada. bhibbert@ottawaheart.ca.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Critical care (London, England)",['10.1186/s13054-021-03706-2'] 2405,34376190,Low-frequency STN-DBS provides acute gait improvements in Parkinson's disease: a double-blinded randomised cross-over feasibility trial.,"BACKGROUND Some people with Parkinson's disease (PD) report poorer dynamic postural stability following high-frequency deep brain stimulation of the subthalamic nucleus (STN-DBS), which may contribute to an increased falls risk. However, some studies have shown low-frequency (60 Hz) STN-DBS improves clinical measures of postural stability, potentially providing support for this treatment. This double-blind randomised crossover study aimed to investigate the effects of low-frequency STN-DBS compared to high-frequency stimulation on objective measures of gait rhythmicity in people with PD. METHODS During high- and low-frequency STN-DBS and while off-medication, participants completed assessments of symptom severity and walking (e.g., Timed Up-and-Go). During comfortable walking, the harmonic ratio, an objective measures of gait rhythmicity, was derived from head- and trunk-mounted accelerometers to provide insight in dynamic postural stability. Lower harmonic ratios represent less rhythmic walking and have discriminated people with PD who experience falls. Linear mixed model analyses were performed on fourteen participants. RESULTS Low-frequency STN-DBS significantly improved medial-lateral and vertical trunk rhythmicity compared to high-frequency. Improvements were independent of electrode location and total electrical energy delivered. No differences were noted between stimulation conditions for temporal gait measures, clinical mobility measures, motor symptom severity or the presence of gait retropulsion. CONCLUSIONS This study provides evidence for the acute benefits of low-frequency stimulation for gait outcomes in STN-DBS PD patients, independent of electrode location. However, the perceived benefits of this therapy may be diminished for people who experienced significant tremor pre-operatively, as lower frequencies may cause these symptoms to re-emerge. TRIAL REGISTRATION This study was prospectively registered with the Australian and New Zealand Clinical Trials Registry on 5 June 2018 (ACTRN12618000944235).",2021,"No differences were noted between stimulation conditions for temporal gait measures, clinical mobility measures, motor symptom severity or the presence of gait retropulsion. ","[""people with Parkinson's disease (PD"", 'STN-DBS PD patients', 'people with PD', ""Parkinson's disease""]","['Low-frequency STN-DBS', 'low-frequency STN-DBS']","['temporal gait measures, clinical mobility measures, motor symptom severity or the presence of gait retropulsion', 'medial-lateral and vertical trunk rhythmicity']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0038427', 'cui_str': 'Bruneomycin'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0038427', 'cui_str': 'Bruneomycin'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}]","[{'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0277845', 'cui_str': 'Retropulsion'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0031084', 'cui_str': 'Periodicities'}]",14.0,0.20044,"No differences were noted between stimulation conditions for temporal gait measures, clinical mobility measures, motor symptom severity or the presence of gait retropulsion. ","[{'ForeName': 'Zachary J', 'Initials': 'ZJ', 'LastName': 'Conway', 'Affiliation': 'School of Behavioural and Health Sciences, Australian Catholic University, P.O. Box 456, Brisbane, QLD, 4014, Australia. zachary.conway@acu.edu.au.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Silburn', 'Affiliation': 'Asia-Pacific Centre for Neuromodulation, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Thushara', 'Initials': 'T', 'LastName': 'Perera', 'Affiliation': 'The Bionics Institute, East Melbourne, VIC, Australia.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': ""O'Maley"", 'Affiliation': 'Neurosciences Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Cole', 'Affiliation': 'School of Behavioural and Health Sciences, Australian Catholic University, P.O. Box 456, Brisbane, QLD, 4014, Australia. michael.cole@acu.edu.au.'}]",Journal of neuroengineering and rehabilitation,['10.1186/s12984-021-00921-4'] 2406,34376188,Nurses' and occupational therapists' experiences of conducting a home-based psychosocial intervention following stroke: a qualitative process evaluation.,"BACKGROUND Persons with stroke are susceptible to psychosocial problems, and express disappointment at how health care professionals fail to meet their psychosocial needs following discharge to home. The responsibility of nurses and occupational therapists in stroke rehabilitation is to assist the persons and their families during the recovery and adjustment process. A home-based dialogical intervention aiming to enhance psychosocial support was therefore developed and tested in a randomized controlled trial. This study is a part of the process evaluation conducted alongside the trial. The aim was to explore the nurses' and occupational therapists' experiences of conducting the intervention. METHODS Eighteen nurses and four occupational therapists participated in six focus groups to explore their experiences when providing the intervention. The themes discussed in the focus groups were the aspects that facilitated the delivering of the intervention and the challenges they encountered during the study period. The interviews were analysed using qualitative content analysis. RESULTS The analysis generated two themes. The theme Developing a supportive relationship to facilitate the adjustment process following stroke had two subthemes: Getting personally involved and Handling challenges. This theme reveals how the nurses and occupational therapists experienced their relationship with the persons with stroke and potential threats which challenged them while conducting the intervention. The theme Developing professional skills in providing psychosocial support had two subthemes: Becoming confident in conducting dialogues and Integrating psychosocial topics. This theme reveals the aspects that the nurses and occupational therapists perceived as facilitating the development of their professional skills in conducting the dialogues. CONCLUSION Delivering the psychosocial intervention was perceived as deeply meaningful and increased the nurses' and occupational therapists' understanding of how to support stroke survivors to live with the consequences of stroke. However, balancing the professional and the personal relationship was challenging. A basic educational programme, training, supervision and having dedicated time were crucial elements to instil confidence in professionals conducting theme-based dialogues to promote post-stroke psychosocial well-being. Individual clinical experience and knowledge of stroke care were considering important to enable professionals to integrate psychosocial rehabilitation into community health care. TRIAL REGISTRATION ClinicalTrials.gov, NCT02338869 , registered 10/04/2014.",2021,Delivering the psychosocial intervention was perceived as deeply meaningful and increased the nurses' and occupational therapists' understanding of how to support stroke survivors to live with the consequences of stroke.,"['Eighteen nurses and four occupational therapists participated in six focus groups', 'Persons with stroke']",['home-based psychosocial intervention'],[],"[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0028807', 'cui_str': 'Occupational therapist'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],18.0,0.0441833,Delivering the psychosocial intervention was perceived as deeply meaningful and increased the nurses' and occupational therapists' understanding of how to support stroke survivors to live with the consequences of stroke.,"[{'ForeName': 'Randi', 'Initials': 'R', 'LastName': 'Martinsen', 'Affiliation': 'Department of Health and Nursing Sciences, Faculty of Social and Health Sciences, Inland Norway University of Applied Sciences, P.B. 400, 2418, Elverum, Norway. randi.martinsen@inn.no.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Kitzmüller', 'Affiliation': 'Department of Health and Care Sciences, Faculty of Health Sciences, UIT The Arctic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Margrete', 'Initials': 'M', 'LastName': 'Mangset', 'Affiliation': 'Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Kvigne', 'Affiliation': 'Department of Health and Nursing Sciences, Faculty of Social and Health Sciences, Inland Norway University of Applied Sciences, P.B. 400, 2418, Elverum, Norway.'}, {'ForeName': 'Anne Svelstad', 'Initials': 'AS', 'LastName': 'Evju', 'Affiliation': 'Department of Health and Care Sciences, Faculty of Health Sciences, UIT The Arctic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Berit Arnesveen', 'Initials': 'BA', 'LastName': 'Bronken', 'Affiliation': 'Department of Health and Nursing Sciences, Faculty of Social and Health Sciences, Inland Norway University of Applied Sciences, P.B. 400, 2418, Elverum, Norway.'}, {'ForeName': 'Line Kildal', 'Initials': 'LK', 'LastName': 'Bragstad', 'Affiliation': 'Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Ellen Gabrielsen', 'Initials': 'EG', 'LastName': 'Hjelle', 'Affiliation': 'Department of Nursing Science and Research Center for habilitation and rehabilitation services and models (CHARM), Faculty of Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Unni', 'Initials': 'U', 'LastName': 'Sveen', 'Affiliation': 'Department of Geriatric Medicine and Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Kirkevold', 'Affiliation': 'Department of Nursing Science and Research Center for habilitation and rehabilitation services and models (CHARM), Faculty of Medicine, University of Oslo, Oslo, Norway.'}]",BMC health services research,['10.1186/s12913-021-06857-8'] 2407,34376181,Study protocol: behaviour change intervention to promote healthy diet and physical activity in overweight/obese adults with diabetes attending health care facilities in Muscat: a cluster rendomised control trial.,"BACKGROUND Healthy behavior is an essential component in type 2 diabetes (T2D) management. Promoting healthy lifestyle is one of the priorities of primary health care in Oman. This study aims to evaluate the effectiveness of a multi-component intervention in promoting physical activity (PA) and healthy diet and its implications on body mass index and glycemic control in adults with diabetes attending primary care. METHODS A one year 1:1 cluster randomized controlled trial will be utilized to compare the use of phone consultations, a multi component interactive phone application and pedometers with the usual diabetes care on promoting PA and healthy diet. Participants will be screened for inactivity and should be T2D, aged18-65 years, and overweight or obese. Eight primary centers will be randomly selected in each arm (n = 375). The primary outcome is the between arms differences in PA and diet scores, BMI and HbA1c over 12 months from baseline. Additionally, secondary outcomes will include cardiovascular outcomes (BP, and lipids). The trial has received ethical approval from the Omani Research and Ethical Review and Approval Committee. All eligible participants will be invited to their respected health centers to provide informed consent. DISCUSSION This study will contribute to the integration of healthy lifestyle approach using artificial intelligence to primary diabetes care. Results from this study will be disseminated through workshops, policy briefs, and peer-reviewed publications, local and international conferences. TRIAL REGISTRATION Trial registration number ISRCTN71889430 . Date applied: 28/11/2020. Date assigned: 01/12/2020.",2021,"The primary outcome is the between arms differences in PA and diet scores, BMI and HbA1c over 12 months from baseline.","['All eligible participants will be invited to their respected health centers to provide informed consent', 'overweight/obese adults with diabetes attending health care facilities in Muscat', 'Participants will be screened for inactivity and should be T2D, aged18-65\u2009years, and overweight or obese', 'adults with diabetes attending primary care']","['multi-component intervention', 'phone consultations, a multi component interactive phone application and pedometers with the usual diabetes care on promoting PA and healthy diet', 'behaviour change intervention to promote healthy diet and physical activity']","['PA and diet scores, BMI and HbA1c', 'cardiovascular outcomes (BP, and lipids']","[{'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0205871', 'cui_str': 'Muscat'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C3890554', 'cui_str': 'Physical Inactivity'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}]",,0.032239,"The primary outcome is the between arms differences in PA and diet scores, BMI and HbA1c over 12 months from baseline.","[{'ForeName': 'Thamra', 'Initials': 'T', 'LastName': 'Al Ghafri', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman. thamra74@yahoo.com.'}, {'ForeName': 'Huda', 'Initials': 'H', 'LastName': 'Anwar', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman.'}, {'ForeName': 'Eiman', 'Initials': 'E', 'LastName': 'Al Hinai', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman.'}, {'ForeName': 'Thuraya', 'Initials': 'T', 'LastName': 'Al Harthi', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman.'}, {'ForeName': 'Fathiya', 'Initials': 'F', 'LastName': 'Al Jufaili', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman.'}, {'ForeName': 'Reyadh', 'Initials': 'R', 'LastName': 'Al Siyabi', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman.'}, {'ForeName': 'Shamsa', 'Initials': 'S', 'LastName': 'Al Harthi', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman.'}, {'ForeName': 'Said', 'Initials': 'S', 'LastName': 'Al Hasani', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Al Harthi', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman.'}, {'ForeName': 'Saud', 'Initials': 'S', 'LastName': 'Al Harthi', 'Affiliation': 'Directorate of health services, Muscat governorate, Oman Ministry of Health, PO Box 2723, Postal Code 112, Muscat, Oman.'}]",BMC public health,['10.1186/s12889-021-11549-3'] 2408,34375990,Loaded Inter-set Stretching for Muscular Adaptations in Trained Males: Is the Hype Real?,"The study examined the effects of adding a loaded stretch in the inter-set rest period (ISS) compared to traditional resistance training (TR) on muscular adaptations in resistance-trained males. Twenty-six subjects were randomly assigned into two groups (ISS: n=12; TR: n=14) and underwent an 8-week training regimen. Subjects in ISS underwent an additional loaded stretch for 30 s at 15% of their working load from the prior set during the inter-set rest periods. Muscle thickness of the pectoralis major at the belly (BMT) and lateral (LMT) portions, One-repetition maximum (1RM) and repetitions-to-failure (RTF) on the bench press exercise were measured at baseline and post 8 weeks of training. Additionally, volume load and perceptual parameters for exertion and recovery were measured. Both groups had similar total volume load and average perceptual parameters (p>0.05). There was a main time effect (p<0.01) for all but one dependent variable indicating that both groups responded similarly across time [(∆BMT: ISS=2.7±1.7 mm; TR = 3.0±2.2 mm), (∆LMT: ISS=3.2±1.6 mm; TR=2.8±1.7 mm, (∆1RM: ISS=6.6±3.8 kg; TR=7.5±5.7 kg). Repetitions-to-failure did not change in either group (∆RTF: ISS=0.0±2.1 repetitions; TR=0.0±2.3 repetitions, p>0.05). Our results suggest that addition of a loaded ISS does not affect muscular adaptations either positively or negatively in resistance-trained males.",2021,"There was a main time effect (p<0.01) for all but one dependent variable indicating that both groups responded similarly across time [(∆BMT: ISS=2.7±1.7 mm; TR = 3.0±2.2 mm), (∆LMT: ISS=3.2±1.6 mm; TR=2.8±1.7 mm, (∆1RM: ISS=6.6±3.8 kg; TR=7.5±5.7 kg).","['Twenty-six subjects', 'Trained Males', 'resistance-trained males']","['loaded ISS', 'traditional resistance training (TR']","['Repetitions-to-failure', 'Muscle thickness of the pectoralis major at the belly (BMT) and lateral (LMT) portions, One-repetition maximum (1RM) and repetitions-to-failure (RTF) on the bench press exercise', 'volume load and perceptual parameters for exertion and recovery', 'total volume load and average perceptual parameters']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]","[{'cui': 'C1740819', 'cui_str': 'Idiopathic short stature'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0224086', 'cui_str': 'Belly of skeletal muscle'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0454326', 'cui_str': 'Bench press'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}]",26.0,0.0234865,"There was a main time effect (p<0.01) for all but one dependent variable indicating that both groups responded similarly across time [(∆BMT: ISS=2.7±1.7 mm; TR = 3.0±2.2 mm), (∆LMT: ISS=3.2±1.6 mm; TR=2.8±1.7 mm, (∆1RM: ISS=6.6±3.8 kg; TR=7.5±5.7 kg).","[{'ForeName': 'Tanuj', 'Initials': 'T', 'LastName': 'Wadhi', 'Affiliation': 'Department of Health Sciences & Human Performance, The University of Tampa, Tampa, United States.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Barakat', 'Affiliation': 'Department of Health Sciences & Human Performance, The University of Tampa, Tampa, United States.'}, {'ForeName': 'Alexandre L', 'Initials': 'AL', 'LastName': 'Evangelista', 'Affiliation': 'Department of Physical Education, Nove de Julho University, SP, Brazil.'}, {'ForeName': 'Jeremy R', 'Initials': 'JR', 'LastName': 'Pearson', 'Affiliation': 'Department of Health Sciences & Human Performance, The University of Tampa, Tampa, United States.'}, {'ForeName': 'Ashmeet S', 'Initials': 'AS', 'LastName': 'Anand', 'Affiliation': 'Medical and Performance Department, Seattle Sounders FC, Seattle, United States.'}, {'ForeName': 'Taylor E A', 'Initials': 'TEA', 'LastName': 'Morrison', 'Affiliation': 'Department of Health Sciences & Human Performance, The University of Tampa, Tampa, United States.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': ""O'Sullivan"", 'Affiliation': 'Department of Health Sciences & Human Performance, The University of Tampa, Tampa, United States.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Walters', 'Affiliation': 'Department of Health Sciences & Human Performance, The University of Tampa, Tampa, United States.'}, {'ForeName': 'Eduardo Oliveira De', 'Initials': 'EO', 'LastName': 'Souza', 'Affiliation': 'Department of Health Sciences & Human Performance, The University of Tampa, Tampa, United States.'}]",International journal of sports medicine,['10.1055/a-1529-6281'] 2409,34375982,Feasibility of a Wearable-Based Physical Activity Goal-Setting Intervention Among Individuals With Anterior Cruciate Ligament Reconstruction.,"CONTEXT Individuals with a history of anterior cruciate ligament reconstruction (ACLR) demonstrate persistent reductions in physical activity (PA) volume that are not being addressed during rehabilitation. Currently, it is challenging for clinicians to prescribe exercise interventions that extend beyond in-person rehabilitative care in a manner that is responsive and acceptable to patients. OBJECTIVE To investigate the feasibility of using a novel, technology-driven, personalized goal-setting intervention over a 2-month period among young individuals with a history of primary unilateral ACLR. DESIGN Single-blinded feasibility study. SETTING University community. PATIENTS OR OTHER PARTICIPANTS Ten women and 2 men (age = 22.0 ± 3.0 years, time since surgery = 56.0 ± 36.3 months) with a history of primary unilateral ACLR. INTERVENTION(S) All participants completed a 28-day PA observation period immediately followed by a 28-day individualized PA goal-setting intervention period delivered via a commercially available PA monitor. MAIN OUTCOME MEASURE(S) Primary feasibility outcomes were days of PA monitor wear compliance and days of goal achievement during the intervention period. Participants also completed the Knee Osteoarthritis Outcome Score (KOOS) at study enrollment and after the intervention period, and the individual change in the KOOS Quality of Life subscale was compared with the minimal detectable change (7.2 points). RESULTS Average PA monitor wear compliance was 95.5% ± 7.3% during the observation period and 97.7% ± 2.9% during the intervention period. Median goal achievement was 31.5% ± 6.8% during the intervention period. Five participants demonstrated meaningful improvements in the KOOS Quality of Life subscale during the study period. CONCLUSIONS Individualized goal setting via mobile technology appears to be a feasible approach to PA promotion. However, based on the low rate of daily goal attainment during the intervention period, continued refinement of this intervention aproach would be beneficial before broad clinical implementation.",2021,"Five participants demonstrated meaningful improvements in the KOOS Quality of Life subscale during the study period. ","['Ten women and 2 men (age = 22.0 ± 3.0 years, time since surgery = 56.0 ± 36.3 months) with a history of primary unilateral ACLR', 'Individuals With Anterior Cruciate Ligament Reconstruction', 'young individuals with a history of primary unilateral ACLR', 'University community', 'Individuals with a history of anterior cruciate ligament reconstruction (ACLR']","['Wearable-Based Physical Activity Goal-Setting Intervention', 'novel, technology-driven, personalized goal-setting intervention']","['days of PA monitor wear compliance and days of goal achievement', 'KOOS Quality of Life subscale', 'Knee Osteoarthritis Outcome Score (KOOS', 'physical activity (PA) volume', 'Median goal achievement']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0150598', 'cui_str': 'Goal setting'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",10.0,0.0322453,"Five participants demonstrated meaningful improvements in the KOOS Quality of Life subscale during the study period. ","[{'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Kuenze', 'Affiliation': 'Department of Kinesiology, Michigan State University, East Lansing.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Pfeiffer', 'Affiliation': 'Department of Kinesiology, Michigan State University, East Lansing.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Pfeiffer', 'Affiliation': 'Department of Orthopedics, Michigan State University, East Lansing.'}, {'ForeName': 'Jeffrey B', 'Initials': 'JB', 'LastName': 'Driban', 'Affiliation': 'Division of Rheumatology, Allergy, & Immunology, Tufts Medical Center, Boston, MA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Pietrosimone', 'Affiliation': 'Department of Exercise and Sport Science, University of North Carolina at Chapel Hill.'}]",Journal of athletic training,['10.4085/1062-6050-203-20'] 2410,34375937,Effect of interdisciplinary teaching on collaborative interactions among nursing student teams in Taiwan: A quasi-experimental study.,"BACKGROUND Empirical research has demonstrated the academic, collaborative, and organizational benefits of Interdisciplinary Teaching. However, few studies have examined the effectiveness of Interdisciplinary Teaching in higher education, particular in healthcare education in Taiwan. In addition, there is no consensus on how the effectiveness of this form of teaching should be evaluated. OBJECTIVE To evaluate the effect of Interdisciplinary Teaching on collaborative interactions for teams of nursing students. DESIGN A quasi-experimental study design employed pretest-posttest scores on measures of team collaboration to compare an Interdisciplinary Teaching intervention with a control group. SETTING Capstone courses at two universities of science and technology in Taiwan, which focused on creating patentable healthcare-related products. PARTICIPANTS Nursing students (N = 145) enrolled in capstone courses between September 2019 and January 2020 participated in this study. The intervention group (n = 61) received creativity training from interdisciplinary faculty from departments of nursing and design. The control group (n = 84) received traditional teaching from nursing faculty. METHODS Data were collected using self-report instruments for team interaction behaviors, swift trust, and conflict at the beginning and end of the 18-week course. Differences between groups were examined with analysis of covariance. RESULTS Compared with controls, nursing students in teams that received the teaching intervention had significantly better mean post-test scores for team interaction behaviors and the subscale for communication (both p < .05); team swift trust and affective-based trust (p < .001); and lower scores for the team conflict subscale of relationships (p = .01). CONCLUSIONS These findings suggest creativity training using Interdisciplinary Teaching benefited collaborative interactions for interactive behaviors and swift trust, and decreased relationship conflict for teams of nursing students. Interdisciplinary Teaching should be integrated into nursing students' curriculum, which could enhance collaborative interactions and improve the ability of student teams to create novel, patentable healthcare products.",2021,"Compared with controls, nursing students in teams that received the teaching intervention had significantly better mean post-test scores for team interaction behaviors and the subscale for communication (both p < .05); team swift trust and affective-based trust (p < .001); and lower scores for the team conflict subscale of relationships (p = .01). ","['teams of nursing students', 'Nursing students (N\xa0=\xa0145) enrolled in capstone courses between September 2019 and January 2020 participated in this study', 'Capstone courses at two universities of science and technology in Taiwan, which focused on creating patentable healthcare-related products', 'nursing student teams in Taiwan']","['traditional teaching from nursing faculty', 'interdisciplinary teaching', 'creativity training from interdisciplinary faculty from departments of nursing and design', 'Interdisciplinary Teaching']","['mean post-test scores for team interaction behaviors and the subscale for communication', 'team swift trust and affective-based trust']","[{'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0015538', 'cui_str': 'Nurse teacher'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0010297', 'cui_str': 'Creative thought'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0001198', 'cui_str': 'Acrodynia due to mercury'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]",145.0,0.0362152,"Compared with controls, nursing students in teams that received the teaching intervention had significantly better mean post-test scores for team interaction behaviors and the subscale for communication (both p < .05); team swift trust and affective-based trust (p < .001); and lower scores for the team conflict subscale of relationships (p = .01). ","[{'ForeName': 'Hsing-Yuan', 'Initials': 'HY', 'LastName': 'Liu', 'Affiliation': 'Department of Nursing, Chang Gung University of Science and Technology, No. 261, Wunhua 1st Rd., Gueishan Township, Taoyuan 33303, Taiwan, ROC; Chang Gung Memorial Hospital, No.5, Fuxing St., Guishan Dist., Taoyuan City 333, Taiwan, ROC. Electronic address: hyliu@mail.cgust.edu.tw.'}]",Nurse education today,['10.1016/j.nedt.2021.105083'] 2411,34373019,Comparison of subcutaneous pocket with cryopreservation method for storing autologous bone flaps in developing surgical wound infection after Cranioplasty: A randomized clinical trial.,"BACKGROUND Following a decompressive craniectomy (DC), the harvested bone flap is stored for future cranioplasty. There are two different methods proposed for bone banking, namely subcutaneous pocketing (SP) in the abdominal wall and cryopreservation (CP) in a refrigerator. This study was designed to evaluate the risk of developing infection in each study group. METHODS In this randomized clinical trial design, a total of 143 patients underwent a primary decompressive craniectomy. Thereafter, they were randomly allocated into two groups, as SP and CP, and they were then scheduled for a future cranioplasty. Next, 108 patients underwent cranioplasty using an autologous bone flap and then followed-up for 18 months. Some variables, including demographic data, indications for primary DC, rate of post-operative clinical infection, bacterial culture results, the interval between craniectomy and cranioplasty, post-operative hospitalization duration, new morbidities, mortality rate, bone flap resorption rate, and several possible associated risk factors, were also recorded. The obtained data were analyzed by an expert bio-statistician using proper bio-statistical methods. A P value < 0.05 was considered as statistically significant. RESULTS Four patients in the cryopreservation group (n = 50) indicated post-operative bone flap infection (8%), which was statistically significant (P = 0.041). Accordingly, all of them were resulted as positive for Methicillin-Resistant-Staphylococcus aureus (MRSA). Using the subcutaneous pocket method, no post-operative infection was observed after cranioplasty. The overall postoperative infection rate was estimated as 4%. The mean of age in the post-operative infection group's participants was 50.25 years old, and in the non-infected, it was 34.93 years old, which was also significant (P = 0.048). Bone flap resorption (BFR) rate was found to be higher by the use of CP method in comparison to SP technique (p = 0.0001). Of note, no other risk factor was found attributable to a higher BFR rate (p-values > 0.05). CONCLUSIONS Older age and cryopreservation method at higher storage temperature (-18C˚) may be associated with infection's development after performing cranioplasty. BFR is more prevalent in the use of CP method rather than SP preservation technique.",2021,Bone flap resorption (BFR) rate was found to be higher by the use of CP method in comparison to SP technique (p = 0.0001).,"['143 patients underwent a primary decompressive craniectomy', '108 patients underwent']","['subcutaneous pocket with cryopreservation method for storing autologous bone flaps', 'cranioplasty using an autologous bone flap', 'decompressive craniectomy (DC']","['overall postoperative infection rate', 'BFR', 'BFR rate', 'demographic data, indications for primary DC, rate of post-operative clinical infection, bacterial culture results, the interval between craniectomy and cranioplasty, post-operative hospitalization duration, new morbidities, mortality rate, bone flap resorption rate, and several possible associated risk factors', 'Bone flap resorption (BFR) rate', 'post-operative bone flap infection']","[{'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C2717817', 'cui_str': 'Decompressive craniectomy'}, {'cui': 'C4517530', 'cui_str': '108'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0010405', 'cui_str': 'Cryopreservation'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C1562423', 'cui_str': 'Flap with osseous tissue only'}, {'cui': 'C0196112', 'cui_str': 'Cranioplasty'}, {'cui': 'C2717817', 'cui_str': 'Decompressive craniectomy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0392618', 'cui_str': 'Postoperative infection'}, {'cui': 'C1562423', 'cui_str': 'Flap with osseous tissue only'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C2717817', 'cui_str': 'Decompressive craniectomy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0430402', 'cui_str': 'Bacterial culture'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0195897', 'cui_str': 'Craniectomy'}, {'cui': 'C0196112', 'cui_str': 'Cranioplasty'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332149', 'cui_str': 'Possible'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}]",143.0,0.112836,Bone flap resorption (BFR) rate was found to be higher by the use of CP method in comparison to SP technique (p = 0.0001).,"[{'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Shafiei', 'Affiliation': 'Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Sourani', 'Affiliation': 'Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: armansourani@resident.mui.ac.ir.'}, {'ForeName': 'Masih', 'Initials': 'M', 'LastName': 'Saboori', 'Affiliation': 'Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: sabouri@med.mui.ac.ir.'}, {'ForeName': 'Bahram', 'Initials': 'B', 'LastName': 'Aminmansour', 'Affiliation': 'Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: aminmansour@med.mui.ac.ir.'}, {'ForeName': 'Saeid', 'Initials': 'S', 'LastName': 'Mahram', 'Affiliation': 'Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,['10.1016/j.jocn.2021.06.042'] 2412,34372973,Mapping World Health Organization Quality of Life-BREF Onto 5-Level EQ-5D in Thai Patients With Chronic Diseases.,"OBJECTIVES This study aimed to map the World Health Organization Quality of Life-BREF (WHOQOL-BREF) onto the 5-level EQ-5D (EQ-5D-5L) using a real Thai valuation set of the EQ-5D-5L. The second objective was to explore the impacts of the differences between observed and predicted EQ-5D-5L index scores on the incremental cost-utility ratio (ICUR) using 5 hypothetical scenarios. METHODS This is a secondary data analysis. A total of 800 outpatients with chronic diseases were recruited from 2 university hospitals in Bangkok, Thailand, between July 2014 and March 2015. The 800 patients were randomly divided into 2 samples: estimation and validation samples. The estimation sample was used to assess the relationships between the EQ-5D-5L index score and 4 WHOQOL-BREF dimension scores and to find the best-fit model and its equation. For the validation sample, the equation of the best-fit model from the estimation sample was used to calculate predicted EQ-5D-5L index scores. RESULTS A multiple linear regression showed that only the physical domain of the WHOQOL-BREF was significantly associated with the EQ-5D-5L. Among 11 regression models, the curve estimation found that the inverse model was the best-fit model. The prediction equation of EQ-5D-5L was equal to 1.385 minus 7.572/physical domain of the WHOQOL-BREF. The impacts of the differences between the observed and predicted EQ-5D-5L index scores on ICUR were only 0.4% to 1.8% from the base case. CONCLUSIONS A nonlinear relationship between the physical domain of the WHOQOL-BREF and EQ-5D-5L utility was shown. The impacts of the differences between the observed and predicted EQ-5D-5L index scores on ICUR were minimal.",2021,The prediction equation of EQ-5D-5L was equal to 1.385 minus 7.572/physical domain of the WHOQOL-BREF.,"['Thai Patients With Chronic Diseases', '800 outpatients with chronic diseases were recruited from 2 university hospitals in Bangkok, Thailand, between July 2014 and March 2015', '800 patients']","['5-Level EQ-5D', 'EQ-5D-5L']","['WHOQOL-BREF', 'EQ-5D-5L index scores on ICUR', 'EQ-5D-5L index score and 4 WHOQOL-BREF dimension scores', 'EQ-5D-5L index scores', 'incremental cost-utility ratio (ICUR']","[{'cui': 'C0039724', 'cui_str': 'Thai language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0456951', 'cui_str': 'Level 5'}]","[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}]",800.0,0.0613908,The prediction equation of EQ-5D-5L was equal to 1.385 minus 7.572/physical domain of the WHOQOL-BREF.,"[{'ForeName': 'Phantipa', 'Initials': 'P', 'LastName': 'Sakthong', 'Affiliation': 'Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Electronic address: phantipa.s@pharm.chula.ac.th.'}]",Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,['10.1016/j.jval.2021.03.001'] 2413,34372971,Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.,"OBJECTIVE Due to previously reported trastuzumab safety concerns and the scant data available in endometrial cancer patients, we sought to assess the safety, tolerability and toxicity profile of trastuzumab in patients with advanced/recurrent uterine serous carcinoma (USC) that overexpress HER2/neu in our multicenter randomized phase II trial. METHODS Patients were randomized 1:1 to receive carboplatin/paclitaxel (C/P) for 6 cycles ± trastuzumab (T) with the experimental arm continuing to receive single agent trastuzumab maintenance treatment until disease progression/toxicity. Progression-free-survival was the primary endpoint; overall-survival and toxicity were secondary endpoints. Adverse events (AEs) were compared between treatment arms. RESULTS There were 28 patients in the C/P arm and 32 patients in the experimental (C/P + T) arm. Fifty-eight patients (97%) experienced 977 treatment-related AEs of which 875 (89.6%) were low-grade (grade 1-2) and 102 (10.4%) were high-grade (grade 3-5). The mean ± standard deviation of AEs per patient was 15.5 ± 16.3 in the C/P arm and 17.0 ± 16.0 in the C/P + T arm. Gastrointestinal AEs were the most common in both arms (n = 155, 15.7%) of which 94.2% were low-grade (n = 146). Importantly, no significant difference between treatment arms was detected in any system-organ class of AE including cardiac AE. Five (17%) of 29 patients who received prolonged trastuzumab maintenance therapy had no sign of cumulative toxicity after an average (range) of 5.1 (4.2-6.3) years. CONCLUSIONS Trastuzumab appears to be safe and has a manageable toxicity profile both when used in combination with chemotherapy and when used for single agent maintenance in patients with HER2/neu positive USC. This safety profile is reassuring given the proven efficacy of trastuzumab in advanced/recurrent HER2/neu positive USC.",2021,"Gastrointestinal AEs were the most common in both arms (n = 155, 15.7%) of which 94.2% were low-grade (n = 146).","['Patients', 'advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu', 'patients with HER2/neu positive USC', 'patients with advanced/recurrent uterine serous carcinoma (USC', 'endometrial cancer patients', 'Fifty-eight patients (97%) experienced 977 treatment-related AEs of which 875 (89.6%) were low-grade (grade 1-2) and 102 (10.4%) were high-grade (grade 3-5']","['Trastuzumab', 'prolonged trastuzumab maintenance therapy', 'carboplatin/paclitaxel (C/P) for 6 cycles ± trastuzumab (T) with the experimental arm continuing to receive single agent trastuzumab maintenance treatment until disease progression/toxicity', 'trastuzumab']","['Progression-free-survival', 'Gastrointestinal AEs', 'overall-survival and toxicity', 'system-organ class of AE including cardiac AE', 'safety, tolerability and toxicity profile', 'cumulative toxicity', 'Adverse events (AEs', 'Trastuzumab tolerability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0854924', 'cui_str': 'Papillary serous endometrial carcinoma'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0007103', 'cui_str': 'Endometrial neoplasms malignant'}, {'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4517897', 'cui_str': '875'}, {'cui': 'C1962916', 'cui_str': 'Low grade (lymphoma)'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C5191376', 'cui_str': '10.4'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}]","[{'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0040539', 'cui_str': 'TO'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0460002', 'cui_str': 'Body system structure'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}]",,0.232682,"Gastrointestinal AEs were the most common in both arms (n = 155, 15.7%) of which 94.2% were low-grade (n = 146).","[{'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Tymon-Rosario', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Eric R', 'Initials': 'ER', 'LastName': 'Siegel', 'Affiliation': 'Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Bellone', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Harold', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Adjei', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Burak', 'Initials': 'B', 'LastName': 'Zeybek', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Mauricio', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Altwerger', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Gulden', 'Initials': 'G', 'LastName': 'Menderes', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Ratner', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Mitchell', 'Initials': 'M', 'LastName': 'Clark', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Vaagn', 'Initials': 'V', 'LastName': 'Andikyan', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Gloria S', 'Initials': 'GS', 'LastName': 'Huang', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Azodi', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Peter E', 'Initials': 'PE', 'LastName': 'Schwartz', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA.'}, {'ForeName': 'Amanda N', 'Initials': 'AN', 'LastName': 'Fader', 'Affiliation': 'John Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Alessandro D', 'Initials': 'AD', 'LastName': 'Santin', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA. Electronic address: alessandro.santin@yale.edu.'}]",Gynecologic oncology,['10.1016/j.ygyno.2021.07.033'] 2414,34372928,The influence of fasting and carbohydrate-enriched drink administration on body water amount and distribution: a volunteer randomized study.,"BACKGROUND Fasting prior to anesthesia is considered aspiration prophylaxis. However, prolonged food and drink restrictions may increase the risk of other complications. The aim of this study was to assess whether a carbohydrate-enriched drink (Nutricia™ preOp®), recommended by the enhanced recovery after surgery (ERAS) protocol, can improve body hydration in fasting healthy individuals. METHODS Measurements were done with the bioelectric impedance analysis with a Fresenius body composition monitor. Body composition, total body water, water distribution, and hemodynamic parameters were measured at the beginning of the study and after 10 h and 12 h of fasting. Patients fasted for 10 h and then were divided into two groups: the control (n = 40) and the pre-op group (n = 41). The pre-op group received 400 mL of Nutricia™ preOp®, as suggested in the ERAS guidance. The two-tailed Student's t test was used to compare two groups with normally distributed data and homogenous variances; if variances were heterogeneous, Welch's test was used. The Mann-Whitney U test was used to compare two groups with non-normal data distribution. p < 0.05 was considered statistically significant. RESULTS We found no significant differences between the control and pre-op groups regarding body water distribution and body composition. We did not observe significant losses in the total body water after fasting. Also, blood pressure was not affected by fasting. CONCLUSION We have proven that pre-op did not impact either body composition or body water. TRIAL REGISTRATION ClinicalTrials.gov , NCT04665349 . Registered on 11 December 2020-retrospectively registered.",2021,We found no significant differences between the control and pre-op groups regarding body water distribution and body composition.,['fasting healthy individuals'],"['400\u2009mL of Nutricia™ preOp®', 'carbohydrate-enriched drink (Nutricia™ preOp®', 'fasting and carbohydrate-enriched drink administration']","['body water distribution and body composition', 'body hydration', 'Body composition, total body water, water distribution, and hemodynamic parameters', 'blood pressure', 'total body water']","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0005909', 'cui_str': 'Body water'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0412472', 'cui_str': 'Total body water measurement'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",,0.0119452,We found no significant differences between the control and pre-op groups regarding body water distribution and body composition.,"[{'ForeName': 'Jakub', 'Initials': 'J', 'LastName': 'Kukliński', 'Affiliation': 'Student Scientific Society, Department of Anesthesiology and Intensive Care, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.'}, {'ForeName': 'Karol P', 'Initials': 'KP', 'LastName': 'Steckiewicz', 'Affiliation': 'Student Scientific Society, Department of Anesthesiology and Intensive Care, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. karol.steckiewicz@gumed.edu.pl.'}, {'ForeName': 'Bartosz', 'Initials': 'B', 'LastName': 'Sekuła', 'Affiliation': 'Student Scientific Society, Department of Anesthesiology and Intensive Care, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.'}, {'ForeName': 'Aleksander', 'Initials': 'A', 'LastName': 'Aszkiełowicz', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.'}, {'ForeName': 'Radosław', 'Initials': 'R', 'LastName': 'Owczuk', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.'}]","Perioperative medicine (London, England)",['10.1186/s13741-021-00198-0'] 2415,34372930,Coronary risk reduction intervention for siblings and offspring of patients with premature coronary heart disease: the CRISO study protocol for a randomised controlled pilot study.,"BACKGROUND Research has consistently demonstrated that preventive cardiology programs have limited success, and healthy practices among high-risk individuals remain suboptimal. Furthermore, there are no current programmes in Malta that offer support to first-degree relatives of patients with premature coronary heart disease. This internal pilot study will determine the feasibility, acceptability, and potential effectiveness of a preventative intervention. METHODS/DESIGN We are conducting a 12-month single-centre, two-armed group randomised controlled trial (RCT), recruiting a sample of 100 asymptomatic first-degree relatives of patients with premature coronary heart disease (CHD). The study seeks to test an evidence-based intervention to reduce modifiable risk and determine its feasibility and acceptability. The Intervention will be delivered at an outpatient office based in a large acute academic hospital. It will comprise risk communication using an online risk calculator, a counselling style adapted from motivational interviewing, and 12 weekly telephone goal reinforcement calls (3 months). Control subjects will receive verbal lifestyle advice only. Feasibility will be assessed through recruitment and retention. Qualitative evaluation interviews will be conducted with a subsample of 24 purposefully selected participants at 12 months. Assessment for risk factor changes will be measured at pre-intervention and 6 and 12 months. Associations between variables will also be assessed descriptively. DISCUSSION Preventive cardiology guidelines highlighted the importance of lifestyle interventions, and lifestyle intervention adherence was proven to reduce atherosclerotic cardiovascular disease (ASCVD) risk, regardless of the individual's genetic risk. Preventive cardiology programmes may fail to adequately support persons in modifying risky behaviours, and research demonstrates that healthy practices among high-risk individuals can remain suboptimal. Siblings and offspring of patients with premature CHD are at increased risk of ASCVD. Despite this, there is no process in place for routine screening and support to modify risk. It is hypothesised that participants assigned to the intervention arm will show more cardio-protective lifestyle-related improvement from the baseline than those in the control group. To date, this is the first trial being conducted amongst Maltese first-degree relatives. This study addresses the needed research, and the results will inform a definitive trial. The funding institution is the University of Malta. TRIAL REGISTRATION ISRCTN, ISRCTN21559170 ; Registered 06/08/2020.",2021,It is hypothesised that participants assigned to the intervention arm will show more cardio-protective lifestyle-related improvement from the baseline than those in the control group.,"['subsample of 24 purposefully selected participants at 12 months', 'siblings and offspring of patients with premature coronary heart disease', '100 asymptomatic first-degree relatives of patients with premature coronary heart disease (CHD', 'patients with premature coronary heart disease']",['Coronary risk reduction intervention'],"['risk of ASCVD', 'risk factor changes', 'atherosclerotic cardiovascular disease (ASCVD) risk']","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0444502', 'cui_str': 'First degree'}, {'cui': 'C0080103', 'cui_str': 'Relative'}]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",100.0,0.0389571,It is hypothesised that participants assigned to the intervention arm will show more cardio-protective lifestyle-related improvement from the baseline than those in the control group.,"[{'ForeName': 'Justin Lee', 'Initials': 'JL', 'LastName': 'Mifsud', 'Affiliation': 'Faculty of Health Sciences, University of Malta, Msida, Malta. justin-lee.mifsud@um.edu.mt.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Stephenson', 'Affiliation': 'School of Human of Health Sciences, University of Huddersfield, Huddersfield, UK.'}, {'ForeName': 'Felicity', 'Initials': 'F', 'LastName': 'Astin', 'Affiliation': 'School of Human of Health Sciences, University of Huddersfield, Huddersfield, UK.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Galea', 'Affiliation': 'Faculty of Medicine and Surgery, University of Malta, Msida, Malta.'}]",Pilot and feasibility studies,['10.1186/s40814-021-00874-4'] 2416,34372913,Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial.,"BACKGROUND The PD COMM pilot randomised controlled trial compared Lee Silverman Voice Treatment (LSVT® LOUD) with standard NHS speech and language therapy (SLT) and a control arm in people with Parkinson's disease (PwPD) with self-reported problems with voice or speech. This analysis compares costs and quality of life outcomes between the trial arms, and considers the validity of the alternative outcome measures for economic evaluations. METHODS A comparison of costs and outcomes was undertaken alongside the PD COMM pilot trial involving three arms: LSVT® LOUD treatment (n = 30); standard NHS SLT (n = 30); and a control arm (n = 29) excluded from receiving therapy for at least 6 months after randomisation unless deemed medically necessary. For all trial arms, resource use and NHS, social care and patient costs and quality of life were collected prospectively at baseline, 3, 6, and 12 months. Total economic costs and outcomes (EQ-5D-3L, ICECAP-O) were considered over the 12-month follow-up period from an NHS payer perspective. Quality of life measures for economic evaluation of SLT for people with Parkinson's disease were compared. RESULTS Whilst there was no difference between arms in voice or quality of life outcomes at 12 months, there were indications of differences at 3 months in favour of SLT, which need to be confirmed in the main trial. The estimated mean cost of NHS care was £3288 per patient per year for the LSVT® LOUD arm, £2033 for NHS SLT, and £1788 for the control arm. EQ-5D-3L was more strongly correlated to voice impairment than ICECAP-O, and was sensitive to differences in voice impairment between arms. CONCLUSIONS The pilot did not identify an effect of SLT on disease-specific or economic outcomes for PwPD at 12 months; however, there appeared to be improvements at 3 months. In addition to the sample size not powered to detect difference in cost-consequence analysis, many patients in the control arm started SLT during the 12-month period used for economic analysis, in line with the study protocol. The LSVT® LOUD intervention was more intense and therefore more costly. Early indications suggest that the preferred economic outcome measure for the full trial is EQ-5D-3L; however, the ICECAP-O should still be included to capture a broader measure of wellbeing. TRIAL REGISTRATION International Standard Randomised Controlled Trial Number Register: ISRCTN75223808. Registered 22 March 2012.",2021,"The pilot did not identify an effect of SLT on disease-specific or economic outcomes for PwPD at 12 months; however, there appeared to be improvements at 3 months.","[""people with Parkinson's disease (PwPD) with self-reported problems with voice or speech"", ""people with Parkinson's disease"", ""Parkinson's disease""]","['SLT', 'Lee Silverman Voice Treatment versus standard speech and language therapy', 'LSVT® LOUD treatment (n\u2009=\u200930); standard NHS SLT', 'EQ-5D-3L', 'Lee Silverman Voice Treatment (LSVT® LOUD) with standard NHS speech and language therapy (SLT']","['mean cost of NHS care', 'resource use and NHS, social care and patient costs and quality of life', 'costs and quality of life outcomes', 'voice or quality of life outcomes', 'Total economic costs and outcomes (EQ-5D-3L, ICECAP-O', 'voice impairment']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0042940', 'cui_str': 'Voice Disorders'}, {'cui': 'C0037817', 'cui_str': 'Speech'}]","[{'cui': 'C0037831', 'cui_str': 'Speech therapy'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178733', 'cui_str': 'Loudness'}, {'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0419189', 'cui_str': 'Social care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0013556', 'cui_str': 'Economics'}, {'cui': 'C1527340', 'cui_str': 'Abnormal voice'}]",,0.156331,"The pilot did not identify an effect of SLT on disease-specific or economic outcomes for PwPD at 12 months; however, there appeared to be improvements at 3 months.","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Scobie', 'Affiliation': 'Nuffield, Trust, London, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Jowett', 'Affiliation': 'Health Economics Unit, Institute for Applied Health Research, University of Birmingham, Birmingham, UK. s.jowett@bham.ac.uk.'}, {'ForeName': 'Tosin', 'Initials': 'T', 'LastName': 'Lambe', 'Affiliation': 'Institute of Population Health Sciences, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Smitaa', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Birmingham Clinical Trials Unit, Institute for Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Woolley', 'Affiliation': 'Birmingham Clinical Trials Unit, Institute for Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Ives', 'Affiliation': 'Birmingham Clinical Trials Unit, Institute for Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Rick', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Smith', 'Affiliation': 'Psychology and Language Science, University College London, London, UK.'}, {'ForeName': 'Marion C', 'Initials': 'MC', 'LastName': 'Brady', 'Affiliation': 'Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, Glasgow, UK.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Clarke', 'Affiliation': 'Health Economics Unit, Institute for Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Cath', 'Initials': 'C', 'LastName': 'Sackley', 'Affiliation': ""Faculty of Life Sciences and Medicine, King's College London, London, UK.""}]",Pilot and feasibility studies,['10.1186/s40814-021-00888-y'] 2417,34372906,Caudal epidural steroid injections versus selective nerve root blocks for single-level lumbar spinal stenosis: a study protocol for a randomized controlled trial.,"BACKGROUND Lumbar spinal stenosis (LSS) is a common degenerative condition associated with old age. Its incidence continues to increase with the rapidly aging population in China. Treatment for LSS usually begins with conservative treatments, as some patients refuse surgical procedures or have surgery contraindications. Caudal epidural steroid injections (CESIs) and selective nerve root blocks (SNRBs) are two commonly used conservative treatments for LSS, which have proven to be effective at relieving LSS symptoms in many studies. However, there are no randomized controlled trials comparing these two procedures. We planned the first study to assess which one of these two procedures is more effective in treating LSS. We will compare the efficacy of these two treatment methods in terms of duration of symptom relief and recurrence rate. We hope our findings will help clinicians choose an optimal treatment for LSS patients. METHODS/DESIGN We plan to conduct a 1-year randomized controlled trial that will include a total of 76 subjects. They will be randomly divided into two groups: group A (patients will receive CESIs) and group B (patients will receive SNRBs). Two days before the procedure, we will assess these patients using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale, Oswestry Disability Index (ODI), and numeric rating scale (NRS) for pain. One day, 2 weeks, 3 months, 6 months, and 1 year after the procedure, we will assess the condition of these patients again with the NRS and ODI. DISCUSSION We hope our findings will lay the foundation for the design of further comprehensive studies and help clinicians make a choice between CESIs and SNRBs for LSS patients. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR1900028038 . Registered on 8 December 2019.",2021,"Caudal epidural steroid injections (CESIs) and selective nerve root blocks (SNRBs) are two commonly used conservative treatments for LSS, which have proven to be effective at relieving LSS symptoms in many studies.","['76 subjects', 'Lumbar spinal stenosis (LSS', 'single-level lumbar spinal stenosis']","['Caudal epidural steroid injections versus selective nerve root blocks', 'CESIs', 'Caudal epidural steroid injections (CESIs) and selective nerve root blocks (SNRBs']","['Neuropathic Symptoms and Signs (LANSS) pain scale, Oswestry Disability Index (ODI), and numeric rating scale (NRS) for pain', 'duration of symptom relief and recurrence rate']","[{'cui': 'C0158288', 'cui_str': 'Spinal stenosis of lumbar region'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0394837', 'cui_str': 'Local anesthetic sacral epidural block'}, {'cui': 'C1261311', 'cui_str': 'Injection of steroid'}, {'cui': 'C0228084', 'cui_str': 'Nerve root structure'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]","[{'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",76.0,0.113467,"Caudal epidural steroid injections (CESIs) and selective nerve root blocks (SNRBs) are two commonly used conservative treatments for LSS, which have proven to be effective at relieving LSS symptoms in many studies.","[{'ForeName': 'Akram', 'Initials': 'A', 'LastName': 'Osman', 'Affiliation': 'The Second Spine Department of the Fourth School of Clinical Medicine of Xinjiang Medical University, Spine Department of the First Affiliated Hospital of Shihezi University, Shihezi, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hu', 'Affiliation': 'The Second Spine Department of the Fourth School of Clinical Medicine of Xinjiang Medical University, Spine Department of the First Affiliated Hospital of Shihezi University, Shihezi, China. realhuwei@163.com.'}, {'ForeName': '', 'Initials': '', 'LastName': 'Jianhua-Sun', 'Affiliation': 'The Second Spine Department of the Fourth School of Clinical Medicine of Xinjiang Medical University, Spine Department of the First Affiliated Hospital of Shihezi University, Shihezi, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'The Second Spine Department of the Fourth School of Clinical Medicine of Xinjiang Medical University, Spine Department of the First Affiliated Hospital of Shihezi University, Shihezi, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Luo', 'Affiliation': 'The Second Spine Department of the Fourth School of Clinical Medicine of Xinjiang Medical University, Spine Department of the First Affiliated Hospital of Shihezi University, Shihezi, China.'}, {'ForeName': 'Nianrong', 'Initials': 'N', 'LastName': 'Han', 'Affiliation': 'The Second Spine Department of the Fourth School of Clinical Medicine of Xinjiang Medical University, Spine Department of the First Affiliated Hospital of Shihezi University, Shihezi, China.'}, {'ForeName': 'Ehsan', 'Initials': 'E', 'LastName': 'Abduhani', 'Affiliation': 'The Second Spine Department of the Fourth School of Clinical Medicine of Xinjiang Medical University, Spine Department of the First Affiliated Hospital of Shihezi University, Shihezi, China.'}, {'ForeName': 'Zhenqiang', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'The Second Spine Department of the Fourth School of Clinical Medicine of Xinjiang Medical University, Spine Department of the First Affiliated Hospital of Shihezi University, Shihezi, China.'}]",Trials,['10.1186/s13063-021-05485-1'] 2418,34372905,The effect of a case-finding app on the detection rate of atrial fibrillation compared with opportunistic screening in primary care patients: protocol for a cluster randomized trial.,"BACKGROUND Atrial fibrillation is a cardiac arrhythmia commonly encountered in a primary care setting. Current screening is limited to pulse palpation and ECG confirmation when an irregular pulse is found. Paroxysmal atrial fibrillation will, however, still be difficult to pick up. With the advent of smartphones, screening could be more cost-efficient by making use of simple applications, lowering the need for intensive screening to discover (paroxysmal) atrial fibrillation. METHODS/DESIGN This cluster randomized trial will examine the effect of using a smartphone-based application such as FibriCheck® on the detection rate of atrial fibrillation in a Flemish general practice population. This study will be conducted in 22 primary care practices across the Flanders region of Belgium and will last 12 months. Patients above 65 years of age will be divided in control and intervention groups on the practice level. The control group will be subjected to standard opportunistic screening only, while the intervention group will be prescribed the FibriCheck® app on top of this opportunistic screening. The difference in detection rate between control and intervention groups will be calculated at the end of the study. We will use the online platform INTEGO for pseudonymized data collection and analysis, and risk calculation. DISCUSSION Smartphone applications might offer a way to cost-effectively screen for (paroxysmal) atrial fibrillation in a primary care setting. This could open the door for the update of future screening guidelines. TRIAL REGISTRATION ClinicalTrials.gov NCT04545723 . Registered on September 10, 2020.",2021,"With the advent of smartphones, screening could be more cost-efficient by making use of simple applications, lowering the need for intensive screening to discover (paroxysmal) atrial fibrillation. ","['primary care patients', '22 primary care practices across the Flanders region of Belgium and will last 12\u2009months', 'Patients above 65\u2009years of age']","['smartphone-based application such as FibriCheck®', 'opportunistic screening']","['detection rate of atrial fibrillation', 'detection rate']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1875156', 'cui_str': 'Flanders'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0422389', 'cui_str': 'Opportunistic screening'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]",,0.108605,"With the advent of smartphones, screening could be more cost-efficient by making use of simple applications, lowering the need for intensive screening to discover (paroxysmal) atrial fibrillation. ","[{'ForeName': 'Simon Gabriël', 'Initials': 'SG', 'LastName': 'Beerten', 'Affiliation': 'Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium. simon.beerten@kuleuven.be.'}, {'ForeName': 'Tine', 'Initials': 'T', 'LastName': 'Proesmans', 'Affiliation': 'Qompium, Hasselt, Belgium.'}, {'ForeName': 'Bert', 'Initials': 'B', 'LastName': 'Vaes', 'Affiliation': 'Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.'}]",Trials,['10.1186/s13063-021-05497-x'] 2419,34372818,Combined topical and intravenous administration of tranexamic acid further reduces postoperative blood loss in adolescent idiopathic scoliosis patients undergoing spinal fusion surgery: a randomized controlled trial.,"BACKGROUND To indicate whether combined topical and intravenous (IV) administration of tranexamic acid (TXA) could further reduce the blood loss after surgery for adolescent idiopathic scoliosis (AIS) compared with IV-TXA alone. METHODS Ninety AIS patients who underwent posterior spinal fusion were prospectively randomized to combined group (IV + topical- TXA group) and IV-TXA alone group. TXA was infused at a loading dose of 1 g from the beginning of the surgery with a maintenance dose of 10 mg/kg/h until the wound was closed. In the combined group, 2 g TXA was injected retrogradely through a drain, while an equivalent amount of normal saline was injected in the IV-TXA alone group. The drain tube was clamped for 2 h in both groups. The amount of wound drainage and transfusion rates were analyzed. RESULTS The drainage volume and duration of drain were significantly lower in the combined group compared with that in the IV-TXA alone group (372.0 ± 129.7 mL vs. 545.2 ± 207.7 mL, P < 0.001;64.7 ± 13.9 h vs. 82.0 ± 12.5 h, P < 0.001). Postoperative length of hospital stay was also significantly shorter in the combined group (6.5 ± 1.51 days vs. 7.95 ± 1.44 days, P < 0.05). Transfusion and complication rates were comparable between the two groups . CONCLUSIONS IV injection of TXA combined with retrograde injection of TXA into a drain and clamping it for 2 h could further reduce the total volume of drainage in AIS patients who underwent spinal fusion surgery. TRIAL REGISTRATION Chinese Clinical Trial Registry: ChiCTR1900024177 , Registered 29 June 2019, http://www.chictr.org.cn/showproj.aspx?proj=40214.",2021,"The drainage volume and duration of drain were significantly lower in the combined group compared with that in the IV-TXA alone group (372.0 ± 129.7 mL vs. 545.2 ± 207.7 mL, P < 0.001;64.7 ± 13.9 h vs. 82.0 ± 12.5 h, P < 0.001).","['adolescent idiopathic scoliosis patients undergoing spinal fusion surgery', 'Ninety AIS patients who underwent posterior spinal fusion']","['TXA', 'tranexamic acid (TXA', 'tranexamic acid', 'combined group (IV\u2009+\u2009topical- TXA group) and IV-TXA alone group']","['postoperative blood loss', 'total volume of drainage', 'amount of wound drainage and transfusion rates', 'Transfusion and complication rates', 'blood loss', 'Postoperative length of hospital stay', 'drainage volume and duration of drain']","[{'cui': 'C0410702', 'cui_str': 'Adolescent idiopathic scoliosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0919636', 'cui_str': 'Spinal fusion surgery'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0037935', 'cui_str': 'Spinal arthrodesis'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0332237', 'cui_str': 'Topical'}]","[{'cui': 'C0032788', 'cui_str': 'Postoperative hemorrhage'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0406834', 'cui_str': 'Wound discharge finding'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}]",90.0,0.248711,"The drainage volume and duration of drain were significantly lower in the combined group compared with that in the IV-TXA alone group (372.0 ± 129.7 mL vs. 545.2 ± 207.7 mL, P < 0.001;64.7 ± 13.9 h vs. 82.0 ± 12.5 h, P < 0.001).","[{'ForeName': 'Yulei', 'Initials': 'Y', 'LastName': 'Dong', 'Affiliation': 'Department of Orthopedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.'}, {'ForeName': 'Jinqian', 'Initials': 'J', 'LastName': 'Liang', 'Affiliation': 'Department of Orthopedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.'}, {'ForeName': 'Bingdu', 'Initials': 'B', 'LastName': 'Tong', 'Affiliation': 'Department of Orthopedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.'}, {'ForeName': 'Jianxiong', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': 'Department of Orthopedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'Department of Orthopedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.'}, {'ForeName': 'Qiyi', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China. liqiyi@medmail.com.cn.'}]",BMC musculoskeletal disorders,['10.1186/s12891-021-04562-5'] 2420,34372803,Protocol for the Weight-bearing in Ankle Fractures (WAX) trial: a multicentre prospective non-inferiority trial of early versus delayed weight-bearing after operatively managed ankle fracture.,"BACKGROUND Unstable ankle fractures represent a substantial burden of disease, accounting for a mean hospital stay of nine days, a mean cost of £4,491 per patient and 20,000 operations per year. There is variation in UK practice around weight-bearing instructions after operatively managed ankle fracture. Early weight-bearing may reduce reliance on health services, time off work, and improve functional outcomes. However, concerns remain about the potential for complications such as implant failure. This is the protocol of a multicentre randomised non-inferiority clinical trial of weight-bearing following operatively treated ankle fracture. METHODS Adults aged 18 years and over who have been managed operatively for ankle fracture will be assessed for eligibility. Baseline function (Olerud and Molander Ankle Score [OMAS]), health-related quality of life (EQ-5D-5L), and complications will be collected after informed consent has been obtained. A randomisation sequence has been prepared by a trial statistician to allow for 1:1 allocation to receive either instruction to weight-bear as pain allows from the point of randomisation, two weeks after the time of surgery ('early weight-bearing' group) or to not weight-bear for a further four weeks ('delayed weight -bearing' group). All other treatment will be as per the guidance of the treating clinician. Participants will be asked about their weight-bearing status weekly until four weeks post-randomisation. At four weeks post-randomisation complications will be collected. At six weeks, four months, and 12 months post-randomisation, the OMAS, EQ-5D-5L, complications, physiotherapy input, and resource use will be collected. The primary outcome measure is ankle function (OMAS) at four months post-randomisation. A minimum of 436 participants will be recruited to obtain 80% power to detect a non-inferiority margin of -6 points on the OMAS 4 months post-randomisation. A within-trial health economic evaluation will be conducted to estimate the cost-effectiveness of the treatment options. DISCUSSION The results of this study will inform national guidance with regards to the most clinically and cost-effective strategy for weight-bearing after surgery for unstable ankle fractures. TRIAL REGISTRATION ISRCTN12883981 , Registered 02 December 2019.",2021,"At six weeks, four months, and 12 months post-randomisation, the OMAS, EQ-5D-5L, complications, physiotherapy input, and resource use will be collected.","['Adults aged 18 years and over who have been managed operatively for ankle fracture will be assessed for eligibility', '436 participants will be recruited to obtain 80% power to detect a non-inferiority margin of -6 points on the OMAS 4 months post-randomisation']",[],"['OMAS, EQ-5D-5L, complications, physiotherapy input, and resource use will be collected', 'Baseline function (Olerud and Molander Ankle Score [OMAS]), health-related quality of life (EQ-5D-5L), and complications', 'ankle function (OMAS']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0159877', 'cui_str': 'Fracture of ankle'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}]",[],"[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",,0.187241,"At six weeks, four months, and 12 months post-randomisation, the OMAS, EQ-5D-5L, complications, physiotherapy input, and resource use will be collected.","[{'ForeName': 'C P', 'Initials': 'CP', 'LastName': 'Bretherton', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Christopher.Bretherton@ndorms.ox.ac.uk.'}, {'ForeName': 'H A', 'Initials': 'HA', 'LastName': 'Claireaux', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Achten', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Athwal', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Dutton', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Peckham', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Petrou', 'Affiliation': 'Nuffield Department of Primary Care, University of Oxford, Oxford, UK.'}, {'ForeName': 'R S', 'Initials': 'RS', 'LastName': 'Kearney', 'Affiliation': 'Department of Musculoskeletal Rehabilitation, University of Warwick, Coventry, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Appelbe', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'X L', 'Initials': 'XL', 'LastName': 'Griffin', 'Affiliation': 'Trauma and Orthopaedic Surgery, Division of Orthopaedics, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}]",BMC musculoskeletal disorders,['10.1186/s12891-021-04560-7'] 2421,34372769,"Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.","BACKGROUND Children with influenza virus infections are prone to complications and are common sources of influenza transmission. Baloxavir marboxil inhibits cap-dependent endonuclease and was approved for influenza treatment in adolescent, adult, and pediatric patients in Japan. The miniSTONE-2 study included pediatric patients with influenza (1 to < 12 years) and demonstrated similar median times to alleviation of signs and symptoms of influenza with a single dose of baloxavir granules (weight < 20 kg: 2 mg/kg, ≥ 20 kg: 40 mg) and oseltamivir. Although the baloxavir dose in miniSTONE-2 was higher than the Japanese-approved dose, baloxavir exposure in miniSTONE-2 was similar to Japanese pediatric patients who receive the Japanese-approved dose. This study will be the first randomized active-controlled study in pediatric patients with influenza using the Japanese-approved dose of baloxavir. METHODS This is a multicenter, open-label, randomized, active-controlled trial in which 200 Japanese subjects aged 6 to < 12 years with influenza virus infection are randomly allocated (2:1) to a single dose of baloxavir at the approved dose in Japan (weight ≥ 10 to < 20 kg: 10 mg, ≥ 20 to  < 40 kg: 20 mg, ≥ 40 kg: 40 mg) or oseltamivir twice daily for 5 days. The primary clinical endpoint is the time to illness alleviation of influenza, from administration of baloxavir or oseltamivir until the following criteria were met and sustained for at least 21.5 h (24 h-10%): cough and nasal discharge/nasal congestion rated as absent or mild axillary body temperature < 37.5 °C. The primary analysis population is the intention-to-treat infected population, which includes all pediatric subjects who receive at least one dose of study drug and have confirmed influenza virus infection by reverse transcription-polymerase chain reaction. The safety population includes all subjects who receive at least one dose of study drug. DISCUSSION No comparative studies have been conducted to confirm the efficacy and safety of baloxavir versus a comparator in pediatric patients with influenza infection in Japan. The outcomes from this trial will provide evidence on the efficacy and safety of baloxavir as an antiviral treatment option for Japanese pediatric patients with influenza infection. Trial registration Japan Registry of Clinical Trials: jRCTs011200011. Registered November 2020. ( https://rctportal.niph.go.jp/en/ ).",2021,"Baloxavir marboxil inhibits cap-dependent endonuclease and was approved for influenza treatment in adolescent, adult, and pediatric patients in Japan.","['pediatric patients with influenza infection in Japan', 'pediatric patients with influenza using the Japanese-approved dose of baloxavir', 'pediatric patients with influenza (1 to <\u200912\xa0years) and demonstrated similar median times to alleviation of signs and symptoms of influenza with a single dose of baloxavir granules (weight\u2009<\u200920\xa0kg: 2\xa0mg/kg,\u2009≥', 'Children with influenza virus infections', 'subjects who receive at least one dose of study drug', '200 Japanese subjects aged 6 to\u2009<\u200912\xa0years with influenza virus infection', 'adolescent, adult, and pediatric patients in Japan', 'Japanese pediatric patients with influenza infection', 'pediatric subjects who receive at least one dose of study drug and have confirmed influenza virus infection by reverse transcription-polymerase chain reaction', 'pediatric patients aged 6 to <\u200912\xa0years with influenza']","['baloxavir at the approved dose in Japan (weight\u2009≥\u200910 to <\u200920\xa0kg', 'baloxavir', 'Baloxavir marboxil', 'oseltamivir']","['time to illness\xa0alleviation of influenza, from administration of baloxavir or oseltamivir', 'efficacy and safety', 'cough and nasal discharge/nasal congestion rated as absent or mild axillary body temperature']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C4734224', 'cui_str': 'baloxavir'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0029341', 'cui_str': 'Family Orthomyxoviridae'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}]","[{'cui': 'C4734224', 'cui_str': 'baloxavir'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C4688747', 'cui_str': 'Baloxavir marboxil'}, {'cui': 'C0874161', 'cui_str': 'Oseltamivir'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C4734224', 'cui_str': 'baloxavir'}, {'cui': 'C0874161', 'cui_str': 'Oseltamivir'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C1260880', 'cui_str': 'Nasal discharge'}, {'cui': 'C0027424', 'cui_str': 'Nasal congestion'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0004454', 'cui_str': 'Axillary'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}]",200.0,0.182154,"Baloxavir marboxil inhibits cap-dependent endonuclease and was approved for influenza treatment in adolescent, adult, and pediatric patients in Japan.","[{'ForeName': 'Nobuhisa', 'Initials': 'N', 'LastName': 'Ishiguro', 'Affiliation': 'Division of Infection Control, Hokkaido University Hospital, Nishi 5, Kita 14, Kita-ku, Sapporo, 060-8648, Japan. nisgr@mrj.biglobe.ne.jp.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Morioka', 'Affiliation': 'Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Nakano', 'Affiliation': 'Department of Pediatrics, Kawasaki Medical School, Okayama, Japan.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Furukawa', 'Affiliation': 'Biostatistics Center, Shionogi & Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Shintaro', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Medical Affairs, Shionogi & Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Kinoshita', 'Affiliation': 'Medical Affairs, Shionogi & Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Manabe', 'Affiliation': 'Department of Pediatrics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.'}]",BMC infectious diseases,['10.1186/s12879-021-06494-w'] 2422,34372752,Stroke survivors' perceptions of participating in a high repetition arm training trial early after stroke.,"PURPOSE The study explored the acceptability of high repetition arm training as part of a randomised controlled trial, early after stroke, when fatigue levels and emotional strain are often high. MATERIALS AND METHODS 36 sub-acute stroke survivors (61 years+/-15) attended for assessment sessions at 3, 6, and 12 weeks after stroke. Individuals were randomised to receive 6 high repetition arm training sessions between 3 and 6 weeks (intervention) or the control group. Semi-structured interviews were conducted at trial completion. Interview transcripts were analysed through framework analysis conducted independently by 2 researchers. RESULTS Stroke survivors participated despite high levels of fatigue because they hoped for personal benefit or to potentially benefit future patients. Benefits reported from participation included physical improvements, psychological benefit, improved understanding of their condition as well as a feeling of hope and distraction. The arm training at three weeks after stroke, aiming for 420 movement repetitions was not considered to be too intensive or too early, and most individuals felt lucky to have been, or would have preferred to be in the early training group. CONCLUSION High repetition arm training early after stroke was acceptable to participants. Study participation was generally viewed as a positive experience, suggesting that early intervention may not only be physically beneficial but also psychologically.Implications for rehabilitationStroke survivors report that high repetition arm training early after stroke is acceptable.Participation in rehabilitation research early after stroke provides stroke survivors with hope and meaning despite the high prevalence of fatigue.Complex information needs to be repeated and provided in a number of formats early after stroke.",2021,Individuals were randomised to receive 6 high repetition arm training sessions between 3 and 6 weeks (intervention) or the control group.,"['36 sub-acute stroke survivors (61\u2009years+/-15) attended for assessment sessions at 3, 6, and 12\u2009weeks after stroke', ""Stroke survivors' perceptions of participating in a high repetition arm training trial early after stroke"", 'rehabilitationStroke survivors']",[],"['physical improvements, psychological benefit, improved understanding of their condition as well as a feeling of hope and distraction']","[{'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1279919', 'cui_str': 'Early'}]",[],"[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0150189', 'cui_str': 'Distraction training'}]",,0.0347129,Individuals were randomised to receive 6 high repetition arm training sessions between 3 and 6 weeks (intervention) or the control group.,"[{'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Hammerbeck', 'Affiliation': 'School of Health, Psychology and Social Care, Manchester Metropolitan University, Manchester, UK.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Hargreaves', 'Affiliation': 'Division of Cardiovascular Sciences, University of Manchester, Manchester, UK.'}, {'ForeName': 'Kristen L', 'Initials': 'KL', 'LastName': 'Hollands', 'Affiliation': 'Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance & Greater Manchester Universities, Manchester, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Tyson', 'Affiliation': 'Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance & Greater Manchester Universities, Manchester, UK.'}]",Disability and rehabilitation,['10.1080/09638288.2021.1955984'] 2423,34371975,"Efficacy of a Multi-Component m-Health Diet, Physical Activity, and Sleep Intervention on Dietary Intake in Adults with Overweight and Obesity: A Randomised Controlled Trial.","This three-arm randomised controlled trial evaluated whether (1) a multi-component weight loss intervention targeting diet, physical activity (PA), and sleep was effective at improving dietary intake over six months and 12 months, compared with a control, and (2) the enhanced diet, PA, and sleep intervention was more effective at improving dietary intake than the traditional diet and PA intervention. A total of 116 adults (70% female, 44.5 years, BMI 31.7 kg/m 2 ) were randomised to either traditional diet and PA intervention; enhanced diet, PA, and sleep intervention; or wait-list control. To examine between-group differences, intervention groups were pooled and compared with the control. Then, the two intervention groups were compared. At six months, the pooled intervention group consumed 1011 fewer kilojoules/day (95% CI -1922, -101), less sodium (-313.2 mg/day; 95% CI -591.3, -35.0), and higher %EI from fruit (+2.1%EI; 95% CI 0.1, 4.1) than the controls. There were no differences in intake between the enhanced and traditional groups at six months. At 12 months, the pooled intervention and control groups reported no significant differences. However, compared to the traditional group, the enhanced reported higher %EI from nutrient-dense foods (+7.4%EI; 95% CI 1.3, 13.5) and protein (+2.4%EI; 95% CI 0.1, 4.6), and reduced %EI from fried/takeaway foods (-3.6%EI; 95% CI -6.5, -0.7), baked sweet products (-2.0%EI; 95% CI -3.6, -0.4), and packaged snacks (-1.1%EI; 95% CI -2.2, -0.3). This weight loss intervention reduced total energy and sodium intakes as well as increased fruit intake in adults at six months. The enhanced intervention group reported improved dietary intake relative to the traditional group at 12 months.",2021,"At 12 months, the pooled intervention and control groups reported no significant differences.","['Adults with Overweight and Obesity', '116 adults (70% female, 44.5 years, BMI 31.7 kg/m 2 ']","['Multi-Component m-Health Diet, Physical Activity, and Sleep Intervention', 'traditional diet and PA intervention; enhanced diet, PA, and sleep intervention; or wait-list control', 'multi-component weight loss intervention targeting diet, physical activity (PA), and sleep was effective at improving dietary intake over six months and 12 months, compared with a control, and (2) the enhanced diet, PA, and sleep intervention']","['packaged snacks', 'dietary intake relative', 'fruit intake', 'total energy and sodium intakes']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4708784', 'cui_str': '31.7'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0556227', 'cui_str': 'Fruit intake'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}]",116.0,0.0298311,"At 12 months, the pooled intervention and control groups reported no significant differences.","[{'ForeName': 'Sasha', 'Initials': 'S', 'LastName': 'Fenton', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'Burrows', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Clare E', 'Initials': 'CE', 'LastName': 'Collins', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Anna T', 'Initials': 'AT', 'LastName': 'Rayward', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Murawski', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Mitch J', 'Initials': 'MJ', 'LastName': 'Duncan', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.'}]",Nutrients,['10.3390/nu13072468'] 2424,34371972,Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women.,"Resistance training (RT) and n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation have emerged as strategies to improve muscle function in older adults. Overweight/obese postmenopausal women (55-70 years) were randomly allocated to one of four experimental groups, receiving placebo (olive oil) or docosahexaenoic acid (DHA)-rich n-3 PUFA supplementation alone or in combination with a supervised RT-program for 16 weeks. At baseline and at end of the trial, body composition, anthropometrical measures, blood pressure and serum glucose and lipid biomarkers were analyzed. Oral glucose tolerance tests (OGTT) and strength tests were also performed. All groups exhibit a similar moderate reduction in body weight and fat mass, but the RT-groups maintained bone mineral content, increased upper limbs lean mass, decreased lower limbs fat mass, and increased muscle strength and quality compared to untrained-groups. The RT-program also improved glucose tolerance (lowering the OGTT incremental area under the curve). The DHA-rich supplementation lowered diastolic blood pressure and circulating triglycerides and increased muscle quality in lower limbs. In conclusion, 16-week RT-program improved segmented body composition, bone mineral content, and glucose tolerance, while the DHA-rich supplement had beneficial effects on cardiovascular health markers in overweight/obese postmenopausal women. No synergistic effects were observed for DHA supplementation and RT-program combination.",2021,"All groups exhibit a similar moderate reduction in body weight and fat mass, but the RT-groups maintained bone mineral content, increased upper limbs lean mass, decreased lower limbs fat mass, and increased muscle strength and quality compared to untrained-groups.","['overweight/obese postmenopausal women', 'Overweight/obese postmenopausal women (55-70 years', 'older adults', 'Overweight and Obese Post-Menopausal Women']","['placebo (olive oil) or docosahexaenoic acid (DHA)-rich n-3 PUFA supplementation alone or in combination with a supervised RT-program', 'Resistance training (RT) and n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation', 'DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training']","['Body Composition and Cardiometabolic Biomarkers', 'segmented body composition, bone mineral content, and glucose tolerance', 'cardiovascular health markers', 'synergistic effects', 'Oral glucose tolerance tests (OGTT) and strength tests', 'glucose tolerance', 'muscle strength and quality', 'diastolic blood pressure and circulating triglycerides and increased muscle quality', 'body weight and fat mass', 'body composition, anthropometrical measures, blood pressure and serum glucose and lipid biomarkers']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0561929', 'cui_str': 'N-3 fatty acid supplementation'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0005963', 'cui_str': 'Bone Mineral Content'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0202041', 'cui_str': 'Glucose measurement, serum'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}]",,0.023692,"All groups exhibit a similar moderate reduction in body weight and fat mass, but the RT-groups maintained bone mineral content, increased upper limbs lean mass, decreased lower limbs fat mass, and increased muscle strength and quality compared to untrained-groups.","[{'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Félix-Soriano', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Martínez-Gayo', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Cobo', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Pérez-Chávez', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Ibáñez-Santos', 'Affiliation': 'Studies, Research and Sports Medicine Centre (CEIMD), Government of Navarre, 31005 Pamplona, Spain.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Palacios Samper', 'Affiliation': 'Studies, Research and Sports Medicine Centre (CEIMD), Government of Navarre, 31005 Pamplona, Spain.'}, {'ForeName': 'Iñaki', 'Initials': 'I', 'LastName': 'Goikoetxea Galarza', 'Affiliation': 'Studies, Research and Sports Medicine Centre (CEIMD), Government of Navarre, 31005 Pamplona, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Cuervo', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.'}, {'ForeName': 'Marisol', 'Initials': 'M', 'LastName': 'García-Unciti', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'González-Muniesa', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Lorente-Cebrián', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.'}, {'ForeName': 'María J', 'Initials': 'MJ', 'LastName': 'Moreno-Aliaga', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.'}]",Nutrients,['10.3390/nu13072465'] 2425,34371963,"A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort.","Joint pain and disease affects more than one in four adults in the United States. We conducted a double-blind, randomized, placebo-controlled trial to investigate the efficacy of a hydrolyzed chicken collagen type II (HCII) supplement in reducing joint-related discomfort such as pain and stiffness, and in improving mobility. We enrolled adults aged 40-65 (65.5% were women) who had joint discomfort, but had no co-morbidities, and who were not taking pain medications. The participants were randomized to receive either the HCII supplement ( n = 47) or a placebo ( n = 43) for eight weeks. At the baseline, and at week 4 and week 8, we administered the Western Ontario and McMaster Universities Arthritis Index (WOMAC) survey with three additional wrist-related questions and the Visual Analog Scale for assessments of joint-related symptoms. In the WOMAC stiffness and physical activity domains and in the overall WOMAC score, the HCII group had a significant reduction in joint-related discomforts compared with the placebo group. For example, at week 4, the HCII group had a 36.9% reduction in the overall WOMAC score, compared with a 14.3% reduction in the placebo group ( p = 0.027). This HCII product is effective in reducing joint pain and stiffness and in improving joint function among otherwise healthy adults.",2021,"In the WOMAC stiffness and physical activity domains and in the overall WOMAC score, the HCII group had a significant reduction in joint-related discomforts compared with the placebo group.","['otherwise healthy adults', 'enrolled adults aged 40-65 (65.5% were women) who had joint discomfort, but had no co-morbidities, and who were not taking pain medications']","['Hydrolyzed Chicken Collagen Type II Supplement', 'HCII supplement', 'Placebo', 'placebo', 'hydrolyzed chicken collagen type II (HCII) supplement']","['Alleviating Joint Discomfort', 'overall WOMAC score', 'joint function', 'WOMAC stiffness and physical activity domains']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}]","[{'cui': 'C0008051', 'cui_str': 'Gallus gallus'}, {'cui': 'C0009331', 'cui_str': 'Collagen type II'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0542330', 'cui_str': 'Joint mobilization'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",,0.71638,"In the WOMAC stiffness and physical activity domains and in the overall WOMAC score, the HCII group had a significant reduction in joint-related discomforts compared with the placebo group.","[{'ForeName': 'Anaam', 'Initials': 'A', 'LastName': 'Mohammed', 'Affiliation': 'Pro Case Management Trials, Denver, CO 80218, USA.'}, {'ForeName': 'Siran', 'Initials': 'S', 'LastName': 'He', 'Affiliation': 'Milken Institute School of Public Health, The George Washington University, Washington, DC 20052, USA.'}]",Nutrients,['10.3390/nu13072454'] 2426,34371945,Effect of Extra Virgin Olive Oil and Butter on Endothelial Function in Type 1 Diabetes.,"Post-prandial hyperglycemia can be relevant in developing early manifestations of atherosclerosis. EVOO (Extra Virgin Olive Oil), rich in saturated fatty acids and commonly used in the Mediterranean diet, seems to control post-prandial hyperglycemia better than butter. Subjects with type 1 diabetes are at higher risk of developing cardiovascular disease and show endothelial dysfunction, an early manifestation of atherosclerosis in the first years of the disease. Our study aims to evaluate whether EVOO and butter influence endothelial function in subjects with type 1 diabetes when added to a single high glycemic index (HGI) meal. In this exploratory cross-over study, 10 subjects with type 1 diabetes and 6 healthy subjects were scheduled to receive two types of HGI meals: one enriched with EVOO and one with butter. Before and after each test meal at different time points, all subjects underwent the evaluation of endothelial function by flow-mediated dilation technique, glucose and lipids measurements, and gastric emptying assessment by ultrasound. Flow-mediated dilation significantly increased after EVOO-enriched meal compared with butter in subjects with type 1 diabetes (two-way-repeated measurements ANOVA, p = 0.007). In patients with type 1 diabetes, the add-on of EVOO to HGI meal improves vascular function compared to butter, which has detrimental effects.",2021,"Flow-mediated dilation significantly increased after EVOO-enriched meal compared with butter in subjects with type 1 diabetes (two-way-repeated measurements ANOVA, p = 0.007).","['Subjects with type 1 diabetes', '10 subjects with type 1 diabetes and 6 healthy subjects', 'Type 1 Diabetes', 'patients with type 1 diabetes', 'subjects with type 1 diabetes when added to a single high glycemic index (HGI) meal']","['Extra Virgin Olive Oil and Butter', 'HGI meals: one enriched with EVOO and one with butter', 'Extra Virgin Olive Oil', 'EVOO and butter']","['Flow-mediated dilation', 'vascular function', 'Endothelial Function', 'EVOO ']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0555061', 'cui_str': 'Virgin'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C0006494', 'cui_str': 'Butter'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",10.0,0.0294976,"Flow-mediated dilation significantly increased after EVOO-enriched meal compared with butter in subjects with type 1 diabetes (two-way-repeated measurements ANOVA, p = 0.007).","[{'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Cutruzzolà', 'Affiliation': 'Dipartimento di Medicina Sperimentale e Clinica, University Magna Græcia, 88100 Catanzaro, Italy.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Parise', 'Affiliation': 'Dipartimento di Scienze della Salute, University Magna Græcia, 88100 Catanzaro, Italy.'}, {'ForeName': 'Rosarina', 'Initials': 'R', 'LastName': 'Vallelunga', 'Affiliation': 'Dipartimento di Medicina Sperimentale e Clinica, University Magna Græcia, 88100 Catanzaro, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Lamanna', 'Affiliation': 'Dipartimento di Medicina Sperimentale e Clinica, University Magna Græcia, 88100 Catanzaro, Italy.'}, {'ForeName': 'Agostino', 'Initials': 'A', 'LastName': 'Gnasso', 'Affiliation': 'Dipartimento di Medicina Sperimentale e Clinica, University Magna Græcia, 88100 Catanzaro, Italy.'}, {'ForeName': 'Concetta', 'Initials': 'C', 'LastName': 'Irace', 'Affiliation': 'Dipartimento di Scienze della Salute, University Magna Græcia, 88100 Catanzaro, Italy.'}]",Nutrients,['10.3390/nu13072436'] 2427,34375501,The Effect of Combining Plyometrics Exercises and Balance Exercises in Improving Dynamic Balance among Female College Athletes: A Randomized Controlled Trial.,"INTRODUCTION Plyometrics and balance exercises have been shown to reduce lower limb injury incidence. The effects of combining these exercises on dynamic balance have not been investigated. OBJECTIVE This study aimed to evaluate the effect of plyometrics and balance exercises and a combination of both exercises on postural stability among female athletes compared to those who did not perform any specific exercise (control). DESIGN Randomized controlled trial. SETTING Sports Medicine Laboratory. PARTICIPANTS Two hundred female athletes aged 21.9±2.4 years were randomly assigned to a plyometrics exercises group (n = 50), a balance exercises group (n = 50), a combination of both exercises group (n = 50), or a control group (n = 50). One hundred seventy-nine female college athletes completed the study. INTERVENTIONS Plyometrics exercises, balance exercises and a combination of both exercises. OUTCOME MEASURES Limits of stability, which was assessed using the Biodex Stability System to assess the performance of the dynamic balance. It was measured pre and post-intervention after six weeks. RESULTS There were no differences in baseline data between groups (p = .557). All groups showed significant improvements in limits of stability (p < .001). The most marked improvement in the limits of stability was shown in the combination group compared to the control group (MD = 4.1 %, 95% CI [2.8, 5.3], p < .001). CONCLUSIONS Combining plyometrics and balance exercises significantly increases the dynamic balance performance post-intervention among female athletes compared to the control group. This article is protected by copyright. All rights reserved.",2021,All groups showed significant improvements in limits of stability (p < .001).,"['Female College Athletes', 'Two hundred female athletes aged 21.9±2.4\u2009years', 'One hundred seventy-nine female college athletes completed the study', 'female athletes', 'female athletes compared to those who did not perform any specific exercise (control']","['Plyometrics Exercises and Balance Exercises', 'Plyometrics exercises, balance exercises and a combination of both exercises', 'plyometrics exercises', 'balance exercises group (n\xa0=\xa050), a combination of both exercises group', 'Combining plyometrics and balance exercises', 'plyometrics and balance exercises and a combination of both exercises']","['performance of the dynamic balance', 'limits of stability', 'postural stability', 'dynamic balance performance', 'Dynamic Balance']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C3178799', 'cui_str': 'Plyometric Drill'}, {'cui': 'C0150219', 'cui_str': 'Balance exercises'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205278', 'cui_str': 'Postural'}]",200.0,0.0789784,All groups showed significant improvements in limits of stability (p < .001).,"[{'ForeName': 'Wesam Saleh A', 'Initials': 'WSA', 'LastName': 'Al Attar', 'Affiliation': 'Department of Physical Therapy, Faculty of Applied Medical Sciences, Umm Al Qura University, Makkah, Saudi Arabia.'}, {'ForeName': 'Mohamed A', 'Initials': 'MA', 'LastName': 'Husain', 'Affiliation': 'Department of Physiotherapy, College of Health and Sport Sciences, University of Bahrain, Manama, Bahrain.'}]","PM & R : the journal of injury, function, and rehabilitation",['10.1002/pmrj.12690'] 2428,34375489,Efficacy of ice slurry and carbohydrate-electrolyte solutions for firefighters.,"OBJECTIVES To examine the thermoregulatory and fluid-electrolyte responses of firefighters ingesting ice slurry and carbohydrate-electrolyte solutions before and after firefighting operations. METHODS Twelve volunteer firefighters put on fireproof clothing and ingested 5 g/kg of beverage in an anteroom at 25°C and 50% relative humidity (RH; pre-ingestion), and then performed 30 minutes of exercise on a cycle ergometer (at 125 W for 10 minutes and then 75 W for 20 minutes) in a room at 35℃ and 50% RH. The participants then returned to the anteroom, removed their fireproof clothing, ingested 20 g/kg of beverage (post-ingestion), and rested for 90 minutes. Three combinations of pre-ingestion and post-ingestion beverages were provided: a 25℃ carbohydrate-electrolyte solution for both (CH condition); 25℃ water for both (W condition); and a -1.7℃ ice slurry pre-exercise and 25℃ carbohydrate-electrolyte solution post-exercise (ICE condition). RESULTS The elevation of body temperature during exercise was lower in the ICE condition than in the other conditions. The sweat volume during exercise was lower in the ICE condition than in the other conditions. The serum sodium concentration and serum osmolality were lower in the W condition than in the CH condition. CONCLUSIONS The ingestion of ice slurry while firefighters were wearing fireproof clothing before exercise suppressed the elevation of body temperature during exercise. Moreover, the ingestion of carbohydrate-electrolyte solution by firefighters after exercise was useful for recovery from dehydration.",2021,The elevation of body temperature during exercise was lower in the ICE condition than in the other conditions.,['Twelve volunteer firefighters put on'],"['firefighters ingesting ice slurry and carbohydrate-electrolyte solutions', 'ice slurry and carbohydrate-electrolyte solutions', 'fireproof clothing and ingested 5\xa0g/kg of beverage in an anteroom at 25°C and 50% relative humidity (RH; pre-ingestion), and then performed 30\xa0minutes of exercise on a cycle ergometer', '25℃ carbohydrate-electrolyte solution for both (CH condition); 25℃ water for both (W condition); and a -1.7℃ ice slurry pre-exercise and 25℃ carbohydrate-electrolyte solution post-exercise (ICE condition']","['serum sodium concentration and serum osmolality', 'sweat volume during exercise', 'elevation of body temperature during exercise']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0221459', 'cui_str': 'Fire fighter'}]","[{'cui': 'C0221459', 'cui_str': 'Fire fighter'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0020746', 'cui_str': 'Ice'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C3541941', 'cui_str': 'Electrolyte solutions'}, {'cui': 'C0009072', 'cui_str': 'Garments'}, {'cui': 'C1300563', 'cui_str': 'g/kg'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0428696', 'cui_str': 'Relative humidity'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}]","[{'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0202151', 'cui_str': 'Osmolality measurement, serum'}, {'cui': 'C1278296', 'cui_str': 'Sweat volume'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}]",,0.0356133,The elevation of body temperature during exercise was lower in the ICE condition than in the other conditions.,"[{'ForeName': 'Shota', 'Initials': 'S', 'LastName': 'Tabuchi', 'Affiliation': 'Department of Health Policy and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan (UOEH), Kitakyushu, Japan.'}, {'ForeName': 'Seichi', 'Initials': 'S', 'LastName': 'Horie', 'Affiliation': 'Department of Health Policy and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan (UOEH), Kitakyushu, Japan.'}, {'ForeName': 'Shoko', 'Initials': 'S', 'LastName': 'Kawanami', 'Affiliation': 'Occupational Health Training Center, UOEH, Kitakyushu, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Inoue', 'Affiliation': 'Department of Health Policy and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan (UOEH), Kitakyushu, Japan.'}, {'ForeName': 'Shuhei', 'Initials': 'S', 'LastName': 'Morizane', 'Affiliation': 'Department of Health Policy and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan (UOEH), Kitakyushu, Japan.'}, {'ForeName': 'Jinro', 'Initials': 'J', 'LastName': 'Inoue', 'Affiliation': 'Department of Health Policy and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan (UOEH), Kitakyushu, Japan.'}, {'ForeName': 'Chikage', 'Initials': 'C', 'LastName': 'Nagano', 'Affiliation': 'Department of Health Policy and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan (UOEH), Kitakyushu, Japan.'}, {'ForeName': 'Masao', 'Initials': 'M', 'LastName': 'Sakurai', 'Affiliation': 'Saga Nutraceuticals Research Institute, Otsuka Pharmaceutical Co., Ltd., Kanzaki, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Serizawa', 'Affiliation': 'Saga Nutraceuticals Research Institute, Otsuka Pharmaceutical Co., Ltd., Kanzaki, Japan.'}, {'ForeName': 'Koichiro', 'Initials': 'K', 'LastName': 'Hamada', 'Affiliation': 'Saga Nutraceuticals Research Institute, Otsuka Pharmaceutical Co., Ltd., Kanzaki, Japan.'}]",Journal of occupational health,['10.1002/1348-9585.12263'] 2429,34375444,Mechanisms of Change in Acceptance and Commitment Therapy for Primary Headaches.,"BACKGROUND Despite the demonstrated effectiveness of behavioural headache interventions, it is not yet known which intervention processes account for treatment responses. Acceptance and commitment therapy (ACT), an emerging behavioural intervention for headaches, proposes psychological flexibility (PF) processes as the mechanisms via which intervention change occurs. This is the first study examining these process of change variables on headache-related disability and quality of life (treatment outcome). METHODS Data originated from a Randomized Clinical Trial evaluating the efficacy of ACT for primary headaches. Ninety-four individuals with primary headaches (M=43 yrs; 84% females; M headache frequency/month=9.30) were randomized to either an ACT-based or a Wait-list control group (N=47 in each). Participants completed questionnaires related to their headache experiences and PF processes at pre- (T1), post-treatment (T2), and 3-month follow-up (T3). RESULTS Following a bootstrapped cross product of coefficients approach, results demonstrated mediating effects of headache acceptance, cognitive defusion, avoidance of headache, and mindfulness in the ACT group compared to control on parameters of headache-related disability and quality of life at post and 3-month follow-ups. CONCLUSIONS These findings demonstrate that changes in certain PF processes lower disability and improve quality of life in headache sufferers, supporting that ACT works via its proposed mechanisms of change. Interventions for headache management may be optimized if they target increases in headache acceptance, defusion from thoughts, and mindfulness.",2021,"Interventions for headache management may be optimized if they target increases in headache acceptance, defusion from thoughts, and mindfulness.","['headache sufferers', 'Ninety-four individuals with primary headaches (M=43 yrs; 84% females; M headache frequency/month=9.30', 'primary headaches', 'Primary Headaches']","['Acceptance and commitment therapy (ACT', 'ACT-based or a Wait-list control group', 'ACT']","['headache-related disability and quality of life', 'headache experiences and PF processes', 'quality of life', 'headache acceptance, cognitive defusion, avoidance of headache, and mindfulness']","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",94.0,0.0358457,"Interventions for headache management may be optimized if they target increases in headache acceptance, defusion from thoughts, and mindfulness.","[{'ForeName': 'Vasilis S', 'Initials': 'VS', 'LastName': 'Vasiliou', 'Affiliation': 'University College Cork, Department of Applied Psychology, Ireland.'}, {'ForeName': 'Evangelos C', 'Initials': 'EC', 'LastName': 'Karademas', 'Affiliation': 'University of Crete, Department of Psychology, Greece.'}, {'ForeName': 'Yiolanda', 'Initials': 'Y', 'LastName': 'Christou', 'Affiliation': ""Neurology Clinic B', Institute of Neurology and Genetics, Cyprus.""}, {'ForeName': 'Savvas', 'Initials': 'S', 'LastName': 'Papacostas', 'Affiliation': ""Neurology Clinic B', Institute of Neurology and Genetics, Cyprus.""}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Karekla', 'Affiliation': 'University of Cyprus, Department of Psychology, ACTHealthy laboratory, Cyprus.'}]","European journal of pain (London, England)",['10.1002/ejp.1851'] 2430,34375409,Substance Use and Mental Health Outcomes from a Text Messaging-Based Intervention for Smoking Cessation Among Young People Experiencing Homelessness.,"INTRODUCTION Cigarette smoking and associated high-risk behaviors are prevalent among youth experiencing homelessness (YEH), making appropriately tailored interventions targeting smoking behavior important for this group. We pilot tested a brief text-messaging intervention (TMI) as an adjunct to standard care for YEH who smoke and found promising preliminary effects of the intervention on smoking cessation. The purpose of the present study was to test the TMI's effect on the secondary outcomes of other substance use (including use of other tobacco/nicotine devices) and mental health symptoms. METHODS A total of 77 participants completed the pilot randomized controlled trial, with 40 receiving the TMI (174 automated text messages plus a group smoking counseling session and provision of nicotine patches). They completed an assessment at baseline and another three months later that evaluated use of other tobacco/nicotine devices, alcohol, marijuana, and anxiety and depression symptoms. RESULTS We found that the TMI helped to reduce secondary substance use behaviors and mental health symptoms among the participants; mainly there were medium effects of the intervention on changes in other tobacco/nicotine use, drinking, and anxiety and depression symptoms. The intervention did not have an effect on number of marijuana use days in the past month; however, past 30-day marijuana users who received the intervention benefited by reducing the number of times they used marijuana per day. CONCLUSIONS In addition to helping reduce cigarette smoking, we found that a TMI for YEH was helpful in improving secondary outcomes, suggesting the promise of the TMI on benefiting YEH even beyond targeted smoking behavior. IMPLICATIONS This pilot study demonstrates that by targeting cigarette smoking using a text message-based intervention among youth experiencing homelessness, effects may be seen in other areas of functioning such as other substance use and mental health.",2021,"We found that the TMI helped to reduce secondary substance use behaviors and mental health symptoms among the participants; mainly there were medium effects of the intervention on changes in other tobacco/nicotine use, drinking, and anxiety and depression symptoms.","['77 participants', 'Young People Experiencing Homelessness']","['TMI (174 automated text messages plus a group smoking counseling session and provision of nicotine patches', 'Text Messaging-Based Intervention for Smoking Cessation', 'TMI', 'text message-based intervention', 'text-messaging intervention (TMI']","['Substance Use and Mental Health Outcomes', 'number of times they used marijuana per day', 'secondary substance use behaviors and mental health symptoms']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0237154', 'cui_str': 'Homeless'}]","[{'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C1273715', 'cui_str': 'Advice on smoking'}, {'cui': 'C0358855', 'cui_str': 'Nicotine Transdermal Patch'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}]","[{'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449809', 'cui_str': 'Number of times'}, {'cui': 'C0024810', 'cui_str': 'Marihuana Smoking'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",77.0,0.0149528,"We found that the TMI helped to reduce secondary substance use behaviors and mental health symptoms among the participants; mainly there were medium effects of the intervention on changes in other tobacco/nicotine use, drinking, and anxiety and depression symptoms.","[{'ForeName': 'Eric R', 'Initials': 'ER', 'LastName': 'Pedersen', 'Affiliation': 'University of Southern California, Keck School of Medicine, Department of Psychiatry and Behavioral Sciences, Los Angeles, CA.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Linnemayr', 'Affiliation': 'RAND Corporation; Santa Monica, CA.'}, {'ForeName': 'William G', 'Initials': 'WG', 'LastName': 'Shadel', 'Affiliation': 'RAND Corporation, Suite, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Rushil', 'Initials': 'R', 'LastName': 'Zutshi', 'Affiliation': 'RAND Corporation; Santa Monica, CA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'DeYoreo', 'Affiliation': 'RAND Corporation; Santa Monica, CA.'}, {'ForeName': 'Irineo', 'Initials': 'I', 'LastName': 'Cabreros', 'Affiliation': 'RAND Corporation; Santa Monica, CA.'}, {'ForeName': 'Joan S', 'Initials': 'JS', 'LastName': 'Tucker', 'Affiliation': 'RAND Corporation; Santa Monica, CA.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntab160'] 2431,34372716,"When early and late risers were left to their own devices: six distinct chronotypes under ""lockdown"" remained dissimilar on their sleep and health problems.","Under national ""lockdown,"" the habitual late risers need not wake up early, and, similarly to the early risers, they don't lose much sleep on weekdays. We tested whether, despite a decrease in weekday sleep loss, the difference between distinct chronotypes in health and sleep problems persisted during ""lockdown."" Two online surveys were conducted from 10th to 20th of May, 2020 and 2021, one of them after 6 non-working weeks and another after 14 working weeks (during and after ""lockdown,"" respectively). Participants were students of the same grade at the same university department (572 and 773, respectively). The self-assessments included the Single-Item Chronotyping (SIC) designed for self-choosing chronotype among several their short descriptions and several questions about general health, mood state, outdoors and physical activity, and sleep concerns. The results suggested that the responses to each of the questions were not randomly distributed over 6 distinct chronotypes. Such a nonrandomness was identified within each of three pairs of these chronotypes, evening vs. morning types (with a rising throughout the day vs. a falling level of alertness, respectively), afternoon vs. napping types (with a peak vs. a dip of alertness in the afternoon, respectively), and vigilant vs. lethargic types (with the levels of alertness being permanently high vs. low, respectively). Morning, afternoon, and vigilant types reported healthier sleep/mood/behavior/habits than three other types. The most and the least healthy sleep/mood/behavior/habits were reported by morning and evening types, respectively. These relationships with health and sleep problems and the frequencies of 6 chronotypes remained unchanged after ""lockdown."" Such results, in particular, suggested that the association of evening types with poorer health and sleep might not be attributed to a big amount of weekday sleep loss. The accounting for this association might help in designing interventions purposed on reduction of sleep and health problems.",2021,"These relationships with health and sleep problems and the frequencies of 6 chronotypes remained unchanged after ""lockdown.""","['Participants were students of the same grade at the same university department (572 and 773, respectively']",[],"['weekday sleep loss', 'healthier sleep/mood/behavior/habits']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0041740', 'cui_str': 'University'}]",[],"[{'cui': 'C0235161', 'cui_str': 'Sleep loss'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018464', 'cui_str': 'Habits'}]",,0.0274458,"These relationships with health and sleep problems and the frequencies of 6 chronotypes remained unchanged after ""lockdown.""","[{'ForeName': 'Arcady A', 'Initials': 'AA', 'LastName': 'Putilov', 'Affiliation': 'Research Group for Math-Modeling of Biomedical Systems, Research Institute for Molecular Biology and Biophysics of the Federal Research Centre for Fundamental and Translational Medicine, Novosibirsk, Russia.'}, {'ForeName': 'Dmitry S', 'Initials': 'DS', 'LastName': 'Sveshnikov', 'Affiliation': ""Department of Normal Physiology, Medical Institute of the Peoples' Friendship University of Russia, Moscow, Russia.""}, {'ForeName': 'Zarina V', 'Initials': 'ZV', 'LastName': 'Bakaeva', 'Affiliation': ""Department of Normal Physiology, Medical Institute of the Peoples' Friendship University of Russia, Moscow, Russia.""}, {'ForeName': 'Elena B', 'Initials': 'EB', 'LastName': 'Yakunina', 'Affiliation': ""Department of Normal Physiology, Medical Institute of the Peoples' Friendship University of Russia, Moscow, Russia.""}, {'ForeName': 'Yuri P', 'Initials': 'YP', 'LastName': 'Starshinov', 'Affiliation': ""Department of Normal Physiology, Medical Institute of the Peoples' Friendship University of Russia, Moscow, Russia.""}, {'ForeName': 'Vladimir I', 'Initials': 'VI', 'LastName': 'Torshin', 'Affiliation': ""Department of Normal Physiology, Medical Institute of the Peoples' Friendship University of Russia, Moscow, Russia.""}, {'ForeName': 'Ravoori Priyamsha', 'Initials': 'RP', 'LastName': 'Lahana', 'Affiliation': ""Department of Normal Physiology, Medical Institute of the Peoples' Friendship University of Russia, Moscow, Russia.""}, {'ForeName': 'Roman O', 'Initials': 'RO', 'LastName': 'Budkevich', 'Affiliation': 'Laboratory of Nanobiotechnology and Biophysics, The North-Caucasus Federal University, Stavropol, Russia.'}, {'ForeName': 'Elena V', 'Initials': 'EV', 'LastName': 'Budkevich', 'Affiliation': 'Laboratory of Nanobiotechnology and Biophysics, The North-Caucasus Federal University, Stavropol, Russia.'}, {'ForeName': 'Alexandra N', 'Initials': 'AN', 'LastName': 'Puchkova', 'Affiliation': 'Laboratory of Sleep/Wake Neurobiology, Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences, Moscow, Russia.'}, {'ForeName': 'Vladimir B', 'Initials': 'VB', 'LastName': 'Dorokhov', 'Affiliation': 'Laboratory of Sleep/Wake Neurobiology, Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences, Moscow, Russia.'}]",Chronobiology international,['10.1080/07420528.2021.1964518'] 2432,34372670,Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease: An Analysis of the CORDIOPREV Randomized Controlled Trial.,"BACKGROUND AND PURPOSE Lifestyle and diet affect cardiovascular risk, although there is currently no consensus about the best dietary model for the secondary prevention of cardiovascular disease. The CORDIOPREV study (Coronary Diet Intervention With Olive Oil and Cardiovascular Prevention) is an ongoing prospective, randomized, single-blind, controlled trial in 1002 coronary heart disease patients, whose primary objective is to compare the effect of 2 healthy dietary patterns (low-fat rich in complex carbohydrates versus Mediterranean diet rich in extra virgin olive oil) on the incidence of cardiovascular events. Here, we report the results of one secondary outcome of the CORDIOPREV study. Thus, to evaluate the efficacy of these diets in reducing cardiovascular disease risk. Intima-media thickness of both common carotid arteries (IMT-CC) was ultrasonically assessed bilaterally. IMT-CC is a validated surrogate for the status and future cardiovascular disease risk. METHODS From the total participants, 939 completed IMT-CC evaluation at baseline and were randomized to follow a Mediterranean diet (35% fat, 22% monounsaturated fatty acids, <50% carbohydrates) or a low-fat diet (28% fat, 12% monounsaturated fatty acids, >55% carbohydrates) with IMT-CC measurements at 5 and 7 years. We also analyzed the carotid plaque number and height. RESULTS The Mediterranean diet decreased IMT-CC at 5 years (-0.027±0.008 mm; P <0.001), maintained at 7 years (-0.031±0.008 mm; P <0.001), compared to baseline. The low-fat diet did not modify IMT-CC. IMT-CC and carotid plaque max height were higher decreased after the Mediterranean diet, compared to the low-fat diet, throughout follow-up. Baseline IMT-CC had the strongest association with the changes in IMT-CC after the dietary intervention. CONCLUSIONS Long-term consumption of a Mediterranean diet rich in extravirgin olive oil, if compared to a low-fat diet, was associated with decreased atherosclerosis progression, as shown by reduced IMT-CC and carotid plaque height. These findings reinforce the clinical benefits of the Mediterranean diet in the context of secondary cardiovascular prevention. REGISTRATION URL: https://www.clinicaltrials.gov; Unique identifier: NCT00924937.",2021,"IMT-CC and carotid plaque max height were higher decreased after the Mediterranean diet, compared to the low-fat diet, throughout follow-up.","['Coronary Heart Disease', '1002 coronary heart disease patients', 'From the total participants']","['IMT-CC', 'Mediterranean diet (35% fat, 22% monounsaturated fatty acids, <50% carbohydrates) or a low-fat diet (28% fat, 12% monounsaturated fatty acids, >55% carbohydrates) with IMT-CC measurements', 'healthy dietary patterns (low-fat rich in complex carbohydrates versus Mediterranean diet rich in extra virgin olive oil', 'Mediterranean Diet', 'Olive Oil and Cardiovascular Prevention']","['IMT-CC', 'cardiovascular disease risk', 'carotid plaque number and height', 'Atherosclerosis Progression', 'IMT-CC and carotid plaque max height', 'atherosclerosis progression']","[{'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0007272', 'cui_str': 'Carotid artery structure'}, {'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0556154', 'cui_str': 'Complex carbohydrate'}, {'cui': 'C0555061', 'cui_str': 'Virgin'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0007272', 'cui_str': 'Carotid artery structure'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",1002.0,0.0601479,"IMT-CC and carotid plaque max height were higher decreased after the Mediterranean diet, compared to the low-fat diet, throughout follow-up.","[{'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Jimenez-Torres', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Alcalá-Diaz', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Jose D', 'Initials': 'JD', 'LastName': 'Torres-Peña', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Francisco M', 'Initials': 'FM', 'LastName': 'Gutierrez-Mariscal', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Leon-Acuña', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Purificación', 'Initials': 'P', 'LastName': 'Gómez-Luna', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Fernández-Gandara', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Gracia M', 'Initials': 'GM', 'LastName': 'Quintana-Navarro', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Jose C', 'Initials': 'JC', 'LastName': 'Fernandez-Garcia', 'Affiliation': 'Department of Endocrinology and Nutrition, Regional University Hospital of Málaga, Instituto de Investigación Biomédica de Malaga (IBIMA), Spain (J.C.F.-G.).'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Perez-Martinez', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Ordovas', 'Affiliation': 'Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University School of Medicine, Boston, MA (J.M.O.).'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Delgado-Lista', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Elena M', 'Initials': 'EM', 'LastName': 'Yubero-Serrano', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lopez-Miranda', 'Affiliation': 'Unidad de Gestión Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Córdoba, Reina Sofia University Hospital, University of Córdoba, Spain (J.J.-T., J.F.A.-D., J.D.T.-P., F.M.G.-M., A.L.-A., P.G.-L., C.F.-G., G.M.Q.-N., P.P.-M., J.D.-L., E.M.Y.-S., J.L.-M.).'}]",Stroke,['10.1161/STROKEAHA.120.033214'] 2433,34371933,Eating Dinner Early Improves 24-h Blood Glucose Levels and Boosts Lipid Metabolism after Breakfast the Next Day: A Randomized Cross-Over Trial.,"Aim: To examine whether mild early time-restricted eating (eating dinner at 18:00 vs. at 21:00) improves 24-h blood glucose levels and postprandial lipid metabolism in healthy adults. Methods: Twelve participants (2 males and 10 females) were included in the study. In this 3-day (until the morning of day 3) randomized crossover study, two different conditions were tested: eating a late dinner (at 21:00) or an early dinner (at 18:00). During the experimental period, blood glucose levels were evaluated by each participant wearing a continuous blood glucose measuring device. Metabolic measurements were performed using the indirect calorimetry method on the morning of day 3. The study was conducted over three days; day 1 was excluded from the analysis to adjust for the effects of the previous day's meal, and only data from the mornings of days 2 and 3 were used for the analysis. Results: Significant differences were observed in mean 24-h blood glucose levels on day 2 between the two groups ( p = 0.034). There was a significant decrease in the postprandial respiratory quotient 30 min and 60 min after breakfast on day 3 in the early dinner group compared with the late dinner group ( p < 0.05). Conclusion: Despite a difference of only 3 h, eating dinner early (at 18:00) has a positive effect on blood glucose level fluctuation and substrate oxidation compared with eating dinner late (at 21:00).",2021,There was a significant decrease in the postprandial respiratory quotient 30 min and 60 min after breakfast on day 3 in the early dinner group compared with the late dinner group ( p < 0.05). ,"['Twelve participants (2 males and 10 females', 'healthy adults']",[],"['24-h blood glucose levels and postprandial lipid metabolism', 'postprandial respiratory quotient', 'blood glucose levels', 'mean 24-h blood glucose levels', 'blood glucose level fluctuation and substrate oxidation', 'Eating Dinner Early Improves 24-h Blood Glucose Levels and Boosts Lipid Metabolism']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]",[],"[{'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C4048877', 'cui_str': 'Supper'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0455916,There was a significant decrease in the postprandial respiratory quotient 30 min and 60 min after breakfast on day 3 in the early dinner group compared with the late dinner group ( p < 0.05). ,"[{'ForeName': 'Kaho', 'Initials': 'K', 'LastName': 'Nakamura', 'Affiliation': 'Graduate School of Environmental & Symbiotic Sciences, Prefectural University of Kumamoto, 3-1-100 Tsukide, Higashi-ku, Kumamoto 862-8502, Japan.'}, {'ForeName': 'Eri', 'Initials': 'E', 'LastName': 'Tajiri', 'Affiliation': 'Graduate School of Environmental & Symbiotic Sciences, Prefectural University of Kumamoto, 3-1-100 Tsukide, Higashi-ku, Kumamoto 862-8502, Japan.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Hatamoto', 'Affiliation': 'Department of Nutrition and Metabolism, National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8636, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Ando', 'Affiliation': 'Human-Centered Mobility Research Center, Information Technology and Human Factors, National Institute of Advanced Industrial Science and Technology, AIST Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan.'}, {'ForeName': 'Seiya', 'Initials': 'S', 'LastName': 'Shimoda', 'Affiliation': 'Graduate School of Environmental & Symbiotic Sciences, Prefectural University of Kumamoto, 3-1-100 Tsukide, Higashi-ku, Kumamoto 862-8502, Japan.'}, {'ForeName': 'Eiichi', 'Initials': 'E', 'LastName': 'Yoshimura', 'Affiliation': 'Graduate School of Environmental & Symbiotic Sciences, Prefectural University of Kumamoto, 3-1-100 Tsukide, Higashi-ku, Kumamoto 862-8502, Japan.'}]",Nutrients,['10.3390/nu13072424'] 2434,34371914,A Cluster Randomized Controlled Trial Evaluating the Impact of Tailored Feedback on the Purchase of Healthier Foods from Primary School Online Canteens.,"Few online food ordering systems provide tailored dietary feedback to consumers, despite suggested benefits. The study aim was to determine the effect of providing tailored feedback on the healthiness of students' lunch orders from a school canteen online ordering system. A cluster randomized controlled trial with ten government primary schools in New South Wales, Australia was conducted. Consenting schools that used an online canteen provider ('Flexischools') were randomized to either: a graph and prompt showing the proportion of 'everyday' foods selected or a standard online ordering system. Students with an online lunch order during baseline data collection were included ( n = 2200 students; n = 7604 orders). Primary outcomes were the proportion of foods classified as 'everyday' or 'caution'. Secondary outcomes included: mean energy, saturated fat, sugar, and sodium content. There was no difference over time between groups on the proportion of 'everyday' (OR 0.99; p = 0.88) or 'caution' items purchased (OR 1.17; p = 0.45). There was a significant difference between groups for average energy content (mean difference 51 kJ; p -0.02), with both groups decreasing. There was no difference in the saturated fat, sugar, or sodium content. Tailored feedback did not impact the proportion of 'everyday' or 'caution' foods or the nutritional quality of online canteen orders. Future research should explore whether additional strategies and specific feedback formats can promote healthy purchasing decisions.",2021,"There was a significant difference between groups for average energy content (mean difference 51 kJ; p -0.02), with both groups decreasing.","[""Consenting schools that used an online canteen provider ('Flexischools"", 'ten government primary schools in New South Wales, Australia was conducted', 'Purchase of Healthier Foods from Primary School Online Canteens', 'Students with an online lunch order during baseline data collection were included ( n = 2200 students; n = 7604 orders', ""students' lunch orders from a school canteen online ordering system""]",[],"[""proportion of 'everyday"", 'saturated fat, sugar, or sodium content', 'average energy content', ""proportion of foods classified as 'everyday' or 'caution"", 'mean energy, saturated fat, sugar, and sodium content']","[{'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C2697949', 'cui_str': 'Lunch'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517651', 'cui_str': '2200'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",[],"[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0597423', 'cui_str': 'Saturated fat'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.140539,"There was a significant difference between groups for average energy content (mean difference 51 kJ; p -0.02), with both groups decreasing.","[{'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Stacey', 'Affiliation': 'Hunter New England Population Health, Locked Bag 10, Wallsend, NSW 2287, Australia.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Delaney', 'Affiliation': 'Hunter New England Population Health, Locked Bag 10, Wallsend, NSW 2287, Australia.'}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Ball', 'Affiliation': 'Institute for Physical Activity and Nutrition, Deakin University, Burwood, VIC 3125, Australia.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Zoetemeyer', 'Affiliation': 'Hunter New England Population Health, Locked Bag 10, Wallsend, NSW 2287, Australia.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Lecathelinais', 'Affiliation': 'Hunter New England Population Health, Locked Bag 10, Wallsend, NSW 2287, Australia.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Wolfenden', 'Affiliation': 'Hunter New England Population Health, Locked Bag 10, Wallsend, NSW 2287, Australia.'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'Seward', 'Affiliation': 'Hunter New England Population Health, Locked Bag 10, Wallsend, NSW 2287, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Wyse', 'Affiliation': 'Hunter New England Population Health, Locked Bag 10, Wallsend, NSW 2287, Australia.'}]",Nutrients,['10.3390/nu13072405'] 2435,34371907,Effect of Coffee and Cocoa-Based Confectionery Containing Coffee on Markers of DNA Damage and Lipid Peroxidation Products: Results from a Human Intervention Study.,"The effect of coffee and cocoa on oxidative damage to macromolecules has been investigated in several studies, often with controversial results. This study aimed to investigate the effect of one-month consumption of different doses of coffee or cocoa-based products containing coffee on markers of DNA damage and lipid peroxidation in young healthy volunteers. Twenty-one volunteers were randomly assigned into a three-arm, crossover, randomized trial. Subjects were assigned to consume one of the three following treatments: one cup of espresso coffee/day (1C), three cups of espresso coffee/day (3C), and one cup of espresso coffee plus two cocoa-based products containing coffee (PC) twice per day for 1 month. At the end of each treatment, blood samples were collected for the analysis of endogenous and H 2 O 2 -induced DNA damage and DNA oxidation catabolites, while urines were used for the analysis of oxylipins. On the whole, four DNA catabolites (cyclic guanosine monophosphate (cGMP), 8-OH-2'-deoxy-guanosine, 8-OH-guanine, and 8-NO2-cGMP) were detected in plasma samples following the one-month intervention. No significant modulation of DNA and lipid damage markers was documented among groups, apart from an effect of time for DNA strand breaks and some markers of lipid peroxidation. In conclusion, the consumption of coffee and cocoa-based confectionery containing coffee was apparently not able to affect oxidative stress markers. More studies are encouraged to better explain the findings obtained and to understand the impact of different dosages of these products on specific target groups.",2021,"No significant modulation of DNA and lipid damage markers was documented among groups, apart from an effect of time for DNA strand breaks and some markers of lipid peroxidation.","['Twenty-one volunteers', 'young healthy volunteers']","['coffee or cocoa-based products containing coffee', 'cup of espresso coffee/day (1C), three cups of espresso coffee/day (3C), and one cup of espresso coffee plus two cocoa-based products containing coffee (PC', 'Coffee and Cocoa-Based Confectionery', 'coffee and cocoa']","['DNA and lipid damage markers', 'DNA damage and lipid peroxidation', 'oxidative stress markers', 'lipid peroxidation', ""DNA catabolites (cyclic guanosine monophosphate (cGMP), 8-OH-2'-deoxy-guanosine, 8-OH-guanine, and 8-NO2-cGMP"", 'Markers of DNA Damage and Lipid Peroxidation Products']","[{'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0009237', 'cui_str': 'Coffee'}, {'cui': 'C0006622', 'cui_str': 'Theobroma cacao'}, {'cui': 'C0360301', 'cui_str': 'Product base'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0006855', 'cui_str': 'Candy'}]","[{'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0012860', 'cui_str': 'DNA damage'}, {'cui': 'C0023775', 'cui_str': 'Lipid peroxidation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0018338', 'cui_str': 'Cyclic guanosine monophosphate'}, {'cui': 'C0011503', 'cui_str': 'Deoxyguanosine'}, {'cui': 'C0018321', 'cui_str': 'Guanine'}]",21.0,0.112699,"No significant modulation of DNA and lipid damage markers was documented among groups, apart from an effect of time for DNA strand breaks and some markers of lipid peroxidation.","[{'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Martini', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133 Milan, Italy.'}, {'ForeName': 'Raúl', 'Initials': 'R', 'LastName': 'Domínguez-Perles', 'Affiliation': 'Research Group on Quality, Safety, and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS-CSIC, Espinardo, 30100 Murcia, Spain.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Rosi', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125 Parma, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Tassotti', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125 Parma, Italy.'}, {'ForeName': 'Donato', 'Initials': 'D', 'LastName': 'Angelino', 'Affiliation': 'Faculty of Bioscience and Technology for Food, Agriculture, and Environment, University of Teramo, 64100 Teramo, Italy.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Medina', 'Affiliation': 'Research Group on Quality, Safety, and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS-CSIC, Espinardo, 30100 Murcia, Spain.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Ricci', 'Affiliation': 'Pediatric Epidemiology, Department of Pediatrics, University Medicine Leipzig, 04103 Leipzig, Germany.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Guy', 'Affiliation': 'Institut des Biomolécules Max Mousseron, IBMM, University of Montpellier, CNRS, ENSCM, 34093 Montpellier, France.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Oger', 'Affiliation': 'Institut des Biomolécules Max Mousseron, IBMM, University of Montpellier, CNRS, ENSCM, 34093 Montpellier, France.'}, {'ForeName': 'Letizia', 'Initials': 'L', 'LastName': 'Gigliotti', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133 Milan, Italy.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Durand', 'Affiliation': 'Institut des Biomolécules Max Mousseron, IBMM, University of Montpellier, CNRS, ENSCM, 34093 Montpellier, France.'}, {'ForeName': 'Mirko', 'Initials': 'M', 'LastName': 'Marino', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133 Milan, Italy.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Gottfried-Genieser', 'Affiliation': 'BIOLOG Life Science Institute, 28199 Bremen, Germany.'}, {'ForeName': 'Marisa', 'Initials': 'M', 'LastName': 'Porrini', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133 Milan, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Antonini', 'Affiliation': 'Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Dei Cas', 'Affiliation': 'Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.'}, {'ForeName': 'Riccardo C', 'Initials': 'RC', 'LastName': 'Bonadonna', 'Affiliation': 'Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Ferreres', 'Affiliation': 'Department of Food Technology and Nutrition, Molecular Recognition and Encapsulation (REM) Group, Universidad Católica de Murcia, UCAM, 30107 Murcia, Spain.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Scazzina', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125 Parma, Italy.'}, {'ForeName': 'Furio', 'Initials': 'F', 'LastName': 'Brighenti', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125 Parma, Italy.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Riso', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133 Milan, Italy.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': ""Del Bo'"", 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133 Milan, Italy.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Mena', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125 Parma, Italy.'}, {'ForeName': 'Angel', 'Initials': 'A', 'LastName': 'Gil-Izquierdo', 'Affiliation': 'Research Group on Quality, Safety, and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS-CSIC, Espinardo, 30100 Murcia, Spain.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Del Rio', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125 Parma, Italy.'}]",Nutrients,['10.3390/nu13072399'] 2436,34371898,Effects of Mediterranean Diet or Low-Fat Diet on Blood Fatty Acids in Patients with Coronary Heart Disease. A Randomized Intervention Study.,"The Mediterranean diet (MD) prevents cardiovascular disease by different putative mechanisms, including modifications in the blood fatty acid (FA) profile. Polytherapy for secondary cardiovascular prevention might mask the effect of MD on the FA profile. This study was aimed to assess whether MD, in comparison with a low-fat diet (LFD), favorably modifies the blood FA profile in patients with coronary heart disease (CHD) on polytherapy. One hundred and twenty patients with a recent history of coronary stenting, randomized to MD or to LFD, completed 3 months of this open-label dietary intervention study. Diet Mediterranean-ness was evaluated using the Mediterranean Diet Adherence Screener (MeDAS) score. Both diets significantly reduced saturated FA ( p < 0.01). Putative favorable changes in total n -3 FA ( p = 0.03) and eicosapentaenoic acid plus docosahexaenoic acid (EPA + DHA; p = 0.04) were significantly larger with MD than with LFD. At 3 months, in the whole cohort, the MeDAS score correlated inversely with palmitic acid (R = -0.21, p = 0.02), and with palmitoleic acid (R = -0.32, p = 0.007), and positively with total n -3 FA (R = 0.19, p = 0.03), EPA (R = 0.28, p = 0.002), and EPA + DHA (R = 0.21, p = 0.02). In CHD patients on polytherapy, both MD and LFD shift FA blood composition towards a healthier profile, with a more favorable effect of MD on omega-3 levels.",2021,Putative favorable changes in total n -3 FA ( p = 0.03) and eicosapentaenoic acid plus docosahexaenoic acid (EPA + DHA; p = 0.04) were significantly larger with MD than with LFD.,"['One hundred and twenty patients with a recent history of coronary stenting, randomized to MD or to', 'Patients with Coronary Heart Disease', 'patients with coronary heart disease (CHD) on polytherapy']","['low-fat diet (LFD', 'Polytherapy', 'Mediterranean diet (MD', 'Mediterranean Diet or Low-Fat Diet', 'LFD']","['EPA + DHA', 'blood FA profile', 'Blood Fatty Acids', 'Mediterranean Diet Adherence Screener (MeDAS) score', 'palmitoleic acid', 'palmitic acid', 'eicosapentaenoic acid plus docosahexaenoic acid', 'saturated FA']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}]","[{'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0142831', 'cui_str': 'sodium dehydroacetate'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0069966', 'cui_str': 'Palmitoleic acid'}, {'cui': 'C0030234', 'cui_str': 'Palmitic acid'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0597423', 'cui_str': 'Saturated fat'}]",120.0,0.0233991,Putative favorable changes in total n -3 FA ( p = 0.03) and eicosapentaenoic acid plus docosahexaenoic acid (EPA + DHA; p = 0.04) were significantly larger with MD than with LFD.,"[{'ForeName': 'Monica Gianna', 'Initials': 'MG', 'LastName': 'Giroli', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Via Parea, 4, 20138 Milan, Italy.'}, {'ForeName': 'José Pablo', 'Initials': 'JP', 'LastName': 'Werba', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Via Parea, 4, 20138 Milan, Italy.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Risé', 'Affiliation': 'Department of Pharmaceutical Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy.'}, {'ForeName': 'Benedetta', 'Initials': 'B', 'LastName': 'Porro', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Via Parea, 4, 20138 Milan, Italy.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Sala', 'Affiliation': 'Department of Pharmaceutical Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Amato', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Via Parea, 4, 20138 Milan, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Tremoli', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Via Parea, 4, 20138 Milan, Italy.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Bonomi', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Via Parea, 4, 20138 Milan, Italy.'}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Veglia', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Via Parea, 4, 20138 Milan, Italy.'}]",Nutrients,['10.3390/nu13072389'] 2437,34371826,Peripheral Blood T Cell Gene Expression Responses to Exercise and HMB in Sarcopenia.,"BACKGROUND Sarcopenia is a major health problem in older adults. Exercise and nutrient supplementation have been shown to be effective interventions but there are limited studies to investigate their effects on the management of sarcopenia and its possible underlying mechanisms. Here, we studied T cell gene expression responses to interventions in sarcopenia. METHODS The results of this study were part of a completed trial examining the effectiveness of a 12-week intervention with exercise and nutrition supplementation in community-dwelling Chinese older adults with sarcopenia, based on the available blood samples at baseline and 12 weeks from 46 randomized participants from three study groups, namely: exercise program alone ( n = 11), combined-exercise program and nutrition supplement ( n = 23), and waitlist control group ( n = 12). T cell gene expression was evaluated, with emphasis on inflammation-related genes. Real-time PCR (RT-PCR) was performed on CD3 T cells in 38 selected genes. Correlation analysis was performed to relate the results of gene expression analysis with lower limb muscle strength performance, measured using leg extension tests. RESULTS Our results showed a significant improvement in leg extension for both the exercise program alone and the combined groups ( p < 0.001). Nine genes showed significant pre- and post-difference in gene expression over 12 weeks of intervention in the combined group. Seven genes ( RASGRP1 , BIN1 , LEF1 , ANXA6 , IL-7R , LRRN3 , and PRKCQ ) showed an interaction effect between intervention and gene expression levels on leg extension in the confirmatory analysis, with confounder variables controlled and FDR correction. CONCLUSIONS Our findings showed that T cell-specific inflammatory gene expression was changed significantly after 12 weeks of intervention with combined exercise and HMB supplementation in sarcopenia, and that this was associated with lower limb muscle strength performance.",2021,Our results showed a significant improvement in leg extension for both the exercise program alone and the combined groups ( p < 0.001).,"['community-dwelling Chinese older adults with sarcopenia, based on the available blood samples at baseline and 12 weeks from 46 randomized participants from three study groups, namely', 'older adults']","['exercise and nutrition supplementation', 'exercise program alone ( n = 11), combined-exercise program and nutrition supplement', 'Exercise and nutrient supplementation']","['Seven genes ( RASGRP1 , BIN1 , LEF1 , ANXA6 , IL-7R , LRRN3 , and PRKCQ ', 'gene expression', 'limb muscle strength performance', 'leg extension', 'Peripheral Blood T Cell Gene Expression Responses', 'T cell-specific inflammatory gene expression', 'T cell gene expression']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C4319709', 'cui_str': 'Protein Kinase C theta'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0205369', 'cui_str': 'Specific'}]",46.0,0.0214162,Our results showed a significant improvement in leg extension for both the exercise program alone and the combined groups ( p < 0.001).,"[{'ForeName': 'Suk-Ling', 'Initials': 'SL', 'LastName': 'Ma', 'Affiliation': 'Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Junyi', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Liuying', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Ruth Suk-Mei', 'Initials': 'RS', 'LastName': 'Chan', 'Affiliation': 'Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.'}, {'ForeName': 'Xingyan', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Huang', 'Affiliation': 'Cytomics Limited, Building 19W, Hong Kong Science Park, Hong Kong, China.'}, {'ForeName': 'Nelson Leung-Sang', 'Initials': 'NL', 'LastName': 'Tang', 'Affiliation': 'Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Woo', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.'}]",Nutrients,['10.3390/nu13072313'] 2438,34371825,The Impact of a Culinary Coaching Telemedicine Program on Home Cooking and Emotional Well-Being during the COVID-19 Pandemic.,"The coronavirus pandemic enforced social restrictions with abrupt impacts on mental health and changes to health behaviors. From a randomized clinical trial, we assessed the impact of culinary education on home cooking practices, coping strategies and resiliency during the first wave of the COVID-19 pandemic (March/April 2020). Participants ( n = 28) were aged 25-70 years with a BMI of 27.5-35 kg/m 2 . The intervention consisted of 12 weekly 30-min one-on-one telemedicine culinary coaching sessions. Coping strategies were assessed through the Brief Coping with Problems Experienced Inventory, and resiliency using the Brief Resilient Coping Scale. Home cooking practices were assessed through qualitative analysis. The average use of self-care as a coping strategy by the intervention group was 6.14 (1.66), compared to the control with 4.64 (1.69); p = 0.03. While more intervention participants had high ( n = 5) and medium ( n = 8) resiliency compared to controls ( n = 4, n = 6, respectively), this difference was not significant ( p = 0.33). Intervention participants reported using home cooking skills such as meal planning and time saving techniques during the pandemic. The key findings were that culinary coaching via telemedicine may be an effective intervention for teaching home cooking skills and promoting the use of self-care as a coping strategy during times of stress, including the COVID-19 pandemic.",2021,"The average use of self-care as a coping strategy by the intervention group was 6.14 (1.66), compared to the control with 4.64 (1.69); ",['Participants ( n = 28) were aged 25-70 years with a BMI of 27.5-35 kg/m 2 '],"['telemedicine culinary coaching sessions', 'Culinary Coaching Telemedicine Program', 'home cooking skills such as meal planning and time saving techniques']",[],"[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517674', 'cui_str': '27.5'}]","[{'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C0596014', 'cui_str': 'Does plan meals'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0036245', 'cui_str': 'Savings'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",[],28.0,0.0249283,"The average use of self-care as a coping strategy by the intervention group was 6.14 (1.66), compared to the control with 4.64 (1.69); ","[{'ForeName': 'Julie K', 'Initials': 'JK', 'LastName': 'Silver', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Finkelstein', 'Affiliation': 'Department of Nursing, Faculty of Life and Health Sciences, Jerusalem College of Technology, Jerusalem 95483, Israel.'}, {'ForeName': 'Kaya', 'Initials': 'K', 'LastName': 'Minezaki', 'Affiliation': 'Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Parks', 'Affiliation': 'Department of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02462, USA.'}, {'ForeName': 'Maggi A', 'Initials': 'MA', 'LastName': 'Budd', 'Affiliation': 'Department of Spinal Cord Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA 02130, USA.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Tello', 'Affiliation': 'Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Paganoni', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Tirosh', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Tel-Aviv University, Tel Aviv 5262000, Israel.'}, {'ForeName': 'Rani', 'Initials': 'R', 'LastName': 'Polak', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02129, USA.'}]",Nutrients,['10.3390/nu13072311'] 2439,34371824,The Effects of Crocodile Blood Supplementation on Delayed-Onset Muscle Soreness.,"Delayed-onset muscle soreness (DOMS) is associated with increases in acute inflammatory and biochemical markers, muscle swelling, pain, and reduced functional performance. This study aimed to investigate the preventative effects of crocodile blood supplementation on DOMS induced by eccentric exercise. Sixteen healthy males were randomly allocated to either a crocodile blood (CB, n = 8) or a placebo (PL, n = 8) treatment. Participants receiving the CB treatment consumed four capsules of freeze-dried CB powder (1 g day -1 ) over 18 days. Participants receiving the other treatment were administered a placebo over the same period. An eccentric exercise protocol was performed, and functional performance, visual analogue scale (VAS)-measured pain, knee range of movement (ROM), thigh circumference (swelling), and cytokines, enzymes, and biochemical parameters were assessed immediately after exercise as well as after 24 h, 48 h, and 72 h. CB supplementation could significantly maintain maximum voluntary isometric contraction (MVIC) at 24 h ( p = 0.001) and 48 h after exercise ( p = 0.001) when comparing values at different times for the CB group. In the CB group, thigh circumference decreased only immediately after eccentric exercise ( p = 0.031) in comparison with pre-eccentric exercise values. An 18-day supplementation (1 g day -1 ) of crocodile blood does aid in the maintenance of functional performance and muscle swelling after eccentric exercise. Our data indicate that 1 g day -1 of crocodile blood supplementation should be safe for human consumption.",2021,CB supplementation could significantly maintain maximum voluntary isometric contraction (MVIC) at 24 h ( p = 0.001) and 48 h after exercise ( p = 0.001) when comparing values at different times for the CB group.,['Sixteen healthy males'],"['CB supplementation', 'crocodile blood supplementation', 'crocodile blood (CB, n = 8) or a placebo (PL, n = 8) treatment', 'Crocodile Blood Supplementation', 'placebo', 'CB treatment consumed four capsules of freeze-dried CB powder']","['thigh circumference', 'maximum voluntary isometric contraction (MVIC', 'acute inflammatory and biochemical markers, muscle swelling, pain, and reduced functional performance', 'Delayed-onset muscle soreness (DOMS', 'Delayed-Onset Muscle Soreness', 'functional performance, visual analogue scale (VAS)-measured pain, knee range of movement (ROM), thigh circumference (swelling), and cytokines, enzymes, and biochemical parameters']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0010345', 'cui_str': 'True crocodile'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0016698', 'cui_str': 'Lyophilization'}, {'cui': 'C0032861', 'cui_str': 'Powder'}]","[{'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0281913', 'cui_str': 'Swelling of skeletal muscle'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0014442', 'cui_str': 'Enzyme'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",16.0,0.0934513,CB supplementation could significantly maintain maximum voluntary isometric contraction (MVIC) at 24 h ( p = 0.001) and 48 h after exercise ( p = 0.001) when comparing values at different times for the CB group.,"[{'ForeName': 'Chirawat', 'Initials': 'C', 'LastName': 'Paratthakonkun', 'Affiliation': 'College of Sports Science and Technology, Mahidol University, Nakhon Pathom 73170, Thailand.'}, {'ForeName': 'Vipu', 'Initials': 'V', 'LastName': 'Vimuttipong', 'Affiliation': 'College of Sports Science and Technology, Mahidol University, Nakhon Pathom 73170, Thailand.'}, {'ForeName': 'Alisa', 'Initials': 'A', 'LastName': 'Nana', 'Affiliation': 'College of Sports Science and Technology, Mahidol University, Nakhon Pathom 73170, Thailand.'}, {'ForeName': 'Kornkit', 'Initials': 'K', 'LastName': 'Chaijenkij', 'Affiliation': 'College of Sports Science and Technology, Mahidol University, Nakhon Pathom 73170, Thailand.'}, {'ForeName': 'Ngamphol', 'Initials': 'N', 'LastName': 'Soonthornworasiri', 'Affiliation': 'Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.'}, {'ForeName': 'Dumrongkiet', 'Initials': 'D', 'LastName': 'Arthan', 'Affiliation': 'Department of Tropical Nutrition and Food Science, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.'}]",Nutrients,['10.3390/nu13072312'] 2440,34371813,Creatine Enhances the Effects of Cluster-Set Resistance Training on Lower-Limb Body Composition and Strength in Resistance-Trained Men: A Pilot Study.,"Creatine monohydrate (CrM) supplementation has been shown to improve body composition and muscle strength when combined with resistance training (RT); however, no study has evaluated the combination of this nutritional strategy with cluster-set resistance training (CS-RT). The purpose of this pilot study was to evaluate the effects of CrM supplementation during a high-protein diet and a CS-RT program on lower-limb fat-free mass (LL-FFM) and muscular strength. Twenty-three resistance-trained men (>2 years of training experience, 26.6 ± 8.1 years, 176.3 ± 6.8 cm, 75.6 ± 8.9 kg) participated in this study. Subjects were randomly allocated to a CS-RT+CrM ( n = 8), a CS-RT ( n = 8), or a control group ( n = 7). The CS-RT+CrM group followed a CrM supplementation protocol with 0.1 g·kg -1 ·day -1 over eight weeks. Two sessions per week of lower-limb CS-RT were performed. LL-FFM corrected for fat-free adipose tissue (dual-energy X-ray absorptiometry) and muscle strength (back squat 1 repetition maximum (SQ-1RM) and countermovement jump (CMJ)) were measured pre- and post-intervention. Significant improvements were found in whole-body fat mass, fat percentage, LL-fat mass, LL-FFM, and SQ-1RM in the CS-RT+CrM and CS-RT groups; however, larger effect sizes were obtained in the CS-RT+CrM group regarding whole body FFM (0.64 versus 0.16), lower-limb FFM (0.62 versus 0.18), and SQ-1RM (1.23 versus 0.75) when compared to the CS-RT group. CMJ showed a significant improvement in the CS-RT+CrM group with no significant changes in CS-RT or control groups. No significant differences were found between groups. Eight weeks of CrM supplementation plus a high-protein diet during a CS-RT program has a higher clinical meaningfulness on lower-limb body composition and strength-related variables in trained males than CS-RT alone. Further research might study the potential health and therapeutic effects of this nutrition and exercise strategy.",2021,"Significant improvements were found in whole-body fat mass, fat percentage, LL-fat mass, LL-FFM, and SQ-1RM in the CS-RT+CrM and CS-RT groups; however, larger effect sizes were obtained in the CS-RT+CrM group regarding whole body FFM (0.64 versus 0.16), lower-limb FFM (0.62 versus 0.18), and SQ-1RM (1.23 versus 0.75) when compared to the CS-RT group.","['Twenty-three resistance-trained men (>2 years of training experience, 26.6 ± 8.1 years, 176.3 ± 6.8 cm, 75.6 ± 8.9 kg) participated in this study', 'Resistance-Trained Men']","['CS-RT program', 'CrM supplementation', 'CMJ', 'CrM supplementation plus a high-protein diet', 'Creatine monohydrate (CrM) supplementation', 'CS-RT+CrM', 'CS-RT', 'Cluster-Set Resistance Training']","['body composition and muscle strength', 'whole-body fat mass, fat percentage, LL-fat mass, LL-FFM, and SQ-1RM', 'SQ-1RM', 'lower-limb fat-free mass (LL-FFM) and muscular strength', 'lower-limb FFM', 'muscle strength (back squat 1 repetition maximum (SQ-1RM) and countermovement jump (CMJ']","[{'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4517875', 'cui_str': '8.1'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0873188', 'cui_str': 'Creatine monohydrate'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0425403', 'cui_str': 'Increased protein diet'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0042950', 'cui_str': 'Volition'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0271093', 'cui_str': ""Stargardt's disease""}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}]",,0.00718688,"Significant improvements were found in whole-body fat mass, fat percentage, LL-fat mass, LL-FFM, and SQ-1RM in the CS-RT+CrM and CS-RT groups; however, larger effect sizes were obtained in the CS-RT+CrM group regarding whole body FFM (0.64 versus 0.16), lower-limb FFM (0.62 versus 0.18), and SQ-1RM (1.23 versus 0.75) when compared to the CS-RT group.","[{'ForeName': 'Diego A', 'Initials': 'DA', 'LastName': 'Bonilla', 'Affiliation': 'Research Division, Dynamical Business & Science Society-DBSS International SAS, Bogotá 110861, Colombia.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Kreider', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Texas A&M University, College Station, TX 77843, USA.'}, {'ForeName': 'Jorge L', 'Initials': 'JL', 'LastName': 'Petro', 'Affiliation': 'Research Division, Dynamical Business & Science Society-DBSS International SAS, Bogotá 110861, Colombia.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Romance', 'Affiliation': 'Body Composition and Biodynamic Laboratory, Faculty of Education Sciences, University of Málaga, 29071 Málaga, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'García-Sillero', 'Affiliation': 'Faculty of Sport Sciences, EADE-University of Wales Trinity Saint David, 29018 Málaga, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Benítez-Porres', 'Affiliation': 'Physical Education and Sports, Faculty of Medicine, University of Málaga, 29071 Málaga, Spain.'}, {'ForeName': 'Salvador', 'Initials': 'S', 'LastName': 'Vargas-Molina', 'Affiliation': 'Faculty of Sport Sciences, EADE-University of Wales Trinity Saint David, 29018 Málaga, Spain.'}]",Nutrients,['10.3390/nu13072303'] 2441,34371524,"Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist.","AIM Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia. The solubility of daridorexant is pH dependent and daridorexant has been shown to be a sensitive CYP3A4 substrate when co-administered with moderate CYP3A4 inhibitors. The purpose of this study was to assess the effect of an increased gastric pH on daridorexant pharmacokinetics (PK) and the extent of interaction when daridorexant is co-administered with a moderate CYP3A4 inducer. METHODS In this prospective, single-centre, randomized, open-label study, 24 male subjects consecutively received four treatments, i.e., daridorexant 50 mg single dose; famotidine 40 mg single dose + daridorexant 50 mg single dose; efavirenz 600 mg once a day (o.d.) during 10 days; and daridorexant 50 mg single dose + efavirenz 600 mg o.d. for 2 days. Plasma PK parameters of daridorexant were derived by noncompartmental analysis. Standard safety and tolerability evaluations were analysed descriptively. RESULTS When daridorexant administration was preceded by administration of famotidine, daridorexant C max decreased by 39%, geometric means ratio (GMR) (90% confidence interval (90% CI)): 0.61 (0.50, 0.73). AUC 0-∞ remained unchanged. In the presence of steady-state efavirenz, daridorexant C max , AUC 0-∞ , and t ½ decreased by approximately 35% (GMR (90% CI)): 0.65 (0.54, 0.78), 61% (0.39 (0.348, 0.44), and 35% (0.65 (0.58, 0.73), respectively. T max remained unaffected. All treatments containing daridorexant were well tolerated. CONCLUSION Daridorexant 50 mg can be administered concomitantly with gastric pH modifiers or with moderate CYP3A4 inducers without dose adaptation based on efficacy observed at lower doses in Phase 3 studies.",2021,"When daridorexant administration was preceded by administration of famotidine, daridorexant C max decreased by 39%, geometric means ratio (GMR)",['24 male subjects'],"['gastric pH', 'daridorexant 50 mg single dose; famotidine 40 mg single dose + daridorexant 50 mg single dose; efavirenz', 'daridorexant', 'daridorexant 50 mg single dose + efavirenz', 'Daridorexant']","['Plasma PK parameters of daridorexant', 'Standard safety and tolerability evaluations', 'tolerated', 'geometric means ratio (GMR', 'famotidine, daridorexant C max']","[{'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C1168023', 'cui_str': 'Gastric pH'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0992319', 'cui_str': 'Famotidine 40 MG'}, {'cui': 'C0674428', 'cui_str': 'efavirenz'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1522544', 'cui_str': 'CSF2RA protein, human'}, {'cui': 'C0015620', 'cui_str': 'Famotidine'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",24.0,0.0544507,"When daridorexant administration was preceded by administration of famotidine, daridorexant C max decreased by 39%, geometric means ratio (GMR)","[{'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Gehin', 'Affiliation': 'Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.'}, {'ForeName': 'Jolanta', 'Initials': 'J', 'LastName': 'Wierdak', 'Affiliation': 'Clinical Research Services Mannheim GmbH, Mannheim, Germany.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Sabattini', 'Affiliation': 'Preclinical Drug Metabolism and Pharmacokinetics, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.'}, {'ForeName': 'Patricia N', 'Initials': 'PN', 'LastName': 'Sidharta', 'Affiliation': 'Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.'}, {'ForeName': 'Jasper', 'Initials': 'J', 'LastName': 'Dingemanse', 'Affiliation': 'Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.'}]",British journal of clinical pharmacology,['10.1111/bcp.15029'] 2442,34371511,Active sentry versus ozil hand piece - A prospective randomized comparative study.,"PURPOSE To compare the safety and efficacy of active sentry hand piece with ozil hand piece for centurion phacoemulsification system. SETTING Tertiary eye centre, South India. DESIGN Prospective observational study. METHODS A total of 204 eyes of 204 patients with uncomplicated cataract who underwent phacoemulsification cataract surgery with centurion vision system were randomized into two groups: Ozil hand piece (n=101) and active sentry hand piece (n =103). Intra-operative factors like patient's pain perception, surgeon's comfort level, amount of phacoemulsification energy and aspiration fluid used, frequency of activation of active surge mitigation (ASM) were analyzed and post-operatively corrected distance visual acuity (CDVA) and corneal edema on day one were compared. RESULTS Patient's pain perception was comparable between the groups with no significant differences in proportion of patients who had pain free surgery (66% vs 61.3%) or those experienced moderate pain (24.3% vs 28.7%). Surgeons were more comfortable using ozil hand piece during entry into anterior chamber and emulsification of hard nuclei (48.5% vs 28.6%). The mean CDE for soft cataracts was 5.6 and 4.8 and for hard cataracts it was 9.3 and 9.4 for ozil and active sentry group respectively. ASM was activated for 53 (51.5%) eyes, of which 42 (79.2%) eyes had soft cataract and 11 (20.7%) had hard cataract. Post-operative CDVA and incidence of corneal edema was comparable between the groups. CONCLUSION For centurion vision system, active sentry hand piece is safe and efficacious as the ozil hand piece with added benefit of operating at lower IOP levels.",2021,"RESULTS Patient's pain perception was comparable between the groups with no significant differences in proportion of patients who had pain free surgery (66% vs 61.3%) or those experienced moderate pain (24.3% vs 28.7%).","['204 eyes of 204 patients with uncomplicated cataract who underwent phacoemulsification cataract surgery with centurion vision system', 'Tertiary eye centre, South India']","['active sentry hand piece with ozil hand piece', 'Ozil hand piece (n=101) and active sentry hand piece']","['pain free surgery', 'distance visual acuity (CDVA) and corneal edema', 'safety and efficacy', 'mean CDE for soft cataracts', 'soft cataract', 'pain perception', ""Intra-operative factors like patient's pain perception, surgeon's comfort level, amount of phacoemulsification energy and aspiration fluid used, frequency of activation of active surge mitigation (ASM"", 'moderate pain', 'corneal edema', 'ASM']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021201', 'cui_str': 'India'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0018563', 'cui_str': 'Hand'}]","[{'cui': 'C0908489', 'cui_str': 'Pain-Free'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0010037', 'cui_str': 'Corneal edema'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0108844', 'cui_str': 'CDE protocol'}, {'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0517225', 'cui_str': 'Comfort level'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C0449896', 'cui_str': 'Fluid used'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0278139', 'cui_str': 'Moderate pain'}]",204.0,0.0490406,"RESULTS Patient's pain perception was comparable between the groups with no significant differences in proportion of patients who had pain free surgery (66% vs 61.3%) or those experienced moderate pain (24.3% vs 28.7%).","[{'ForeName': 'Dhanya', 'Initials': 'D', 'LastName': 'Cyril', 'Affiliation': 'Department of intraocular lens and cataract services, Aravind eye hospital and post graduate institute of ophthalmology, Madurai, India Department of biostatistics, Aravind eye care system, Madurai, India.'}, {'ForeName': 'Pathakamuri', 'Initials': 'P', 'LastName': 'Brahmani', 'Affiliation': ''}, {'ForeName': 'Senthil', 'Initials': 'S', 'LastName': 'Prasad', 'Affiliation': ''}, {'ForeName': 'Vinitha L', 'Initials': 'VL', 'LastName': 'Rashme', 'Affiliation': ''}, {'ForeName': 'Sankarananthan', 'Initials': 'S', 'LastName': 'R', 'Affiliation': ''}, {'ForeName': 'Nikhil Rajendra', 'Initials': 'NR', 'LastName': 'Kamble', 'Affiliation': ''}, {'ForeName': 'Logesh', 'Initials': 'L', 'LastName': 'Balakrishnan', 'Affiliation': ''}, {'ForeName': 'Kamachi', 'Initials': 'K', 'LastName': 'Nagu', 'Affiliation': ''}, {'ForeName': 'Madhu', 'Initials': 'M', 'LastName': 'Shekhar', 'Affiliation': ''}]",Journal of cataract and refractive surgery,['10.1097/j.jcrs.0000000000000769'] 2443,34371478,"Oxytocin, PTSD, and sexual abuse are associated with attention network intrinsic functional connectivity.","Childhood maltreatment is linked to Posttraumatic Stress Disorder (PTSD) in adulthood. Neural attention network function contributes to resilience against PTSD following maltreatment; oxytocin administration alters functional connectivity differentially among resilient to PTSD groups. The present study examined intrinsic connectivity between ventral and dorsal neural attention networks (VAN and DAN) to clarify the nature of dysfunction versus resilience in the context of maltreatment-related PTSD, and to explore differential dysfunction related to varied aspects of maltreatment. Oxytocin administration was examined as a factor in these relationships. Resting-state functional connectivity data were collected from 39 adults with maltreatment histories, with and without PTSD, who were randomly assigned to receive oxytocin or placebo. We found that PTSD and sexual abuse (SA) were associated with reduced VAN-DAN connectivity. There were no significant effects with regard to physical abuse. Oxytocin was associated with greater VAN-DAN connectivity strength. These preliminary findings suggest dysfunction within attentional systems in PTSD, as well as following SA. Further, oxytocin may help ameliorate attentional neurocircuitry dysfunction in individuals with PTSD and those with maltreatment histories.",2021,Neural attention network function contributes to resilience against PTSD following maltreatment; oxytocin administration alters functional connectivity differentially among resilient to PTSD groups.,"['individuals with PTSD and those with maltreatment histories', '39 adults with maltreatment histories, with and without PTSD']","['oxytocin', 'ventral and dorsal neural attention networks (VAN and DAN', 'oxytocin or placebo', 'Oxytocin']","['Oxytocin, PTSD, and sexual abuse', 'PTSD and sexual abuse (SA', 'attentional neurocircuitry dysfunction', 'reduced VAN-DAN connectivity', 'greater VAN-DAN connectivity strength']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C1704448', 'cui_str': 'Ventral'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0557775', 'cui_str': 'Van'}, {'cui': 'C0010961', 'cui_str': 'Danazol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0282350', 'cui_str': 'Sexual abuse'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0557775', 'cui_str': 'Van'}, {'cui': 'C0010961', 'cui_str': 'Danazol'}, {'cui': 'C0205393', 'cui_str': 'Most'}]",39.0,0.0478848,Neural attention network function contributes to resilience against PTSD following maltreatment; oxytocin administration alters functional connectivity differentially among resilient to PTSD groups.,"[{'ForeName': 'Kathleen I', 'Initials': 'KI', 'LastName': 'Crum', 'Affiliation': 'Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA; Department of Psychiatry, Indiana University School of Medicine, 1002 Wishard Blvd, Suite 4110, Indianapolis, 46202, IN, USA. Electronic address: kicrum@iu.edu.'}, {'ForeName': 'Julianne C', 'Initials': 'JC', 'LastName': 'Flanagan', 'Affiliation': ""Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Veteran's Affairs Medical Center, Charleston, SC, USA.""}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Vaughan', 'Affiliation': 'Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Aloi', 'Affiliation': 'Department of Psychiatry, Indiana University School of Medicine, 1002 Wishard Blvd, Suite 4110, Indianapolis, 46202, IN, USA; Center for Neurobehavioral Research, Boys Town National Research Hospital, Omaha, NE, USA; MD/PhD Scholars Program, University of Nebraska Medical Center, Omaha, NE, USA.'}, {'ForeName': 'Megan M', 'Initials': 'MM', 'LastName': 'Moran-Santa Maria', 'Affiliation': 'Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Sudie E', 'Initials': 'SE', 'LastName': 'Back', 'Affiliation': ""Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Veteran's Affairs Medical Center, Charleston, SC, USA.""}, {'ForeName': 'Kathleen T', 'Initials': 'KT', 'LastName': 'Brady', 'Affiliation': 'Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Jane E', 'Initials': 'JE', 'LastName': 'Joseph', 'Affiliation': 'Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA.'}]",Psychiatry research. Neuroimaging,['10.1016/j.pscychresns.2021.111345'] 2444,34371442,"Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.","BACKGROUND This study was designed to demonstrate the non-inferiority (NI) in overall survival (OS) of suspension of androgen deprivation therapy (ADT) versus maintenance and intermittent versus continuous docetaxel administration in metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS AND METHODS mCRPC patients were randomised to first-line docetaxel with maintenance or suspension of ADT. Patients attaining a prostate-specific antigen (PSA) response after four chemotherapy cycles underwent second randomisation to receive continuous or intermittent docetaxel therapy. Six hundred patients were to be randomised to achieve 80% statistical power to demonstrate an NI hazard ratio (HR) of 1.25 of interruption versus maintenance of ADT. RESULTS The trial was prematurely closed when 198 participants were randomised. OS was similar in patients who continued (N = 96) versus those who interrupted (n = 102) ADT during docetaxel therapy (HR 0.98, 95% confidence interval [CI] 0.72-1.33] and those on a continuous (N = 35) versus an intermittent (N = 42) docetaxel schedule (HR 0.86, 95% CI 0.55-1.43). No difference in radiological progression-free survival, PSA response, or toxicity was observed between the study arms. The actual NI hazard margins of OS in Arms A and B patients were 1.33 and 1.43, respectively. CONCLUSIONS This trial enrolled one-third of the planned patients; this main weakness dramatically limits the interpretation of the results. ADT discontinuation and switching to an intermittent schedule did not seem to affect docetaxel efficacy. The absence of testosterone recovery in the majority of patients could have been a contributory factor. In men with mCRPC, ADT discontinuation should only be done with regular biochemical and clinical monitoring, with the option of quickly restarting ADT at disease progression.",2021,"OS was similar in patients who continued (N = 96) versus those who interrupted (n = 102) ADT during docetaxel therapy (HR 0.98, 95% confidence interval [CI] 0.72-1.33] and those on a continuous (N = 35) versus an intermittent (N = 42) docetaxel schedule (HR 0.86, 95% CI 0.55-1.43).","['Six hundred patients', 'Patients attaining a prostate-specific antigen (PSA) response after four chemotherapy cycles underwent second randomisation to receive', '198 participants were randomised', 'metastatic castration-resistant prostate cancer (mCRPC) patients', 'mCRPC patients', 'castration-resistant prostate cancer patients']","['androgen deprivation therapy (ADT) versus maintenance and intermittent versus continuous docetaxel', 'docetaxel with maintenance or suspension of ADT', 'continuous or intermittent docetaxel therapy', 'androgen deprivation therapy', 'docetaxel administration']","['radiological progression-free survival, PSA response, or toxicity', 'docetaxel efficacy', 'OS']","[{'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C1302181', 'cui_str': 'Chemotherapy cycle'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C1328504', 'cui_str': 'Hormone refractory prostate cancer'}]","[{'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",600.0,0.169857,"OS was similar in patients who continued (N = 96) versus those who interrupted (n = 102) ADT during docetaxel therapy (HR 0.98, 95% confidence interval [CI] 0.72-1.33] and those on a continuous (N = 35) versus an intermittent (N = 42) docetaxel schedule (HR 0.86, 95% CI 0.55-1.43).","[{'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Bianchi', 'Affiliation': 'Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST-Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Mosca', 'Affiliation': 'Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Dalla Volta', 'Affiliation': 'Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST-Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Prati', 'Affiliation': 'Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; Department of Medical Oncology, Ospedale S. Lazzaro Azienda Sanitaria Locale CN2, Alba-Bra, Cuneo, Italy.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Ortega', 'Affiliation': 'Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; Department of Medical Oncology, Ospedale S. Lazzaro Azienda Sanitaria Locale CN2, Alba-Bra, Cuneo, Italy.'}, {'ForeName': 'Consuelo', 'Initials': 'C', 'LastName': 'Buttigliero', 'Affiliation': 'Department of Medical Oncology, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Fea', 'Affiliation': 'Department of Medical Oncology, S Croce and Carle Teaching Hospital, Cuneo, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Vanella', 'Affiliation': 'Department of Medical Oncology, S Croce and Carle Teaching Hospital, Cuneo, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Valcamonico', 'Affiliation': 'Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST-Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Zamparini', 'Affiliation': 'Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST-Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.'}, {'ForeName': 'Zuzana', 'Initials': 'Z', 'LastName': 'Sirotova', 'Affiliation': 'Unit of Medical Oncology, Aosta Regional Hospital, Aosta, Italy.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Chiappino', 'Affiliation': 'Medical Oncology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.'}, {'ForeName': 'Orietta', 'Initials': 'O', 'LastName': 'Dal Canton', 'Affiliation': 'Medical Oncology Unit, Humanitas Gradenigo Hospital, Turin, Italy; Department of Medical Oncology, Azienda Sanitaria Locale Città di Torino, Turin, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Masini', 'Affiliation': 'Medical Oncology Unit, Clinical Cancer Center, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Cosimo', 'Initials': 'C', 'LastName': 'Sacco', 'Affiliation': 'Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Amoroso', 'Affiliation': 'Medical Oncology Unit, Azienda USL Toscana Nord-Ovest, Ospedale Versilia, Lido di Camaiore, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Montagnani', 'Affiliation': 'Medical Oncology Unit, Azienda Sanitaria Locale Biella, Biella, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Comandone', 'Affiliation': 'Medical Oncology Unit, Humanitas Gradenigo Hospital, Turin, Italy; Department of Medical Oncology, Azienda Sanitaria Locale Città di Torino, Turin, Italy.'}, {'ForeName': 'Andrea R', 'Initials': 'AR', 'LastName': 'Bellissimo', 'Affiliation': 'Unit of Clinical Epidemiology, Azienda Ospedaliero Universitaria Città Della Salute e Della Scienza di Torino and Centro di Prevenzione Oncologica Piemonte, Torino, Italy.'}, {'ForeName': 'Giovannino', 'Initials': 'G', 'LastName': 'Ciccone', 'Affiliation': 'Unit of Clinical Epidemiology, Azienda Ospedaliero Universitaria Città Della Salute e Della Scienza di Torino and Centro di Prevenzione Oncologica Piemonte, Torino, Italy.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Baier', 'Affiliation': 'Medical Oncology Unit, Ospedale Centrale di Bolzano, 39100 Bolzano, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Gennari', 'Affiliation': 'Division of Oncology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Tucci', 'Affiliation': 'Department of Medical Oncology, Cardinal Massaia Hospital, Asti, Italy.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Berruti', 'Affiliation': 'Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST-Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy. Electronic address: alfredo.berruti@unibs.it.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.06.034'] 2445,34371386,Six-month-olds' ability to use linguistic cues when interpreting others' pointing actions.,"The present research investigated whether six-month-olds who rarely produce pointing actions can detect the object-directedness and communicative function of others' pointing actions when linguistic information is provided. In Experiment 1, infants were randomly assigned to either a novel-word or emotional-vocalization condition. They were first familiarized with an event in which an actor uttered either a novel label (novel-word condition) or exclamatory expression (emotional-vocalization condition) and then pointed to one of two objects. Next, the positions of the objects were switched. During test trials, each infant watched the new-referent event where the actor pointed to the object to which the actor had not pointed before or the old-referent event where the actor pointed to the old object in its new location. Infants in the novel-word condition looked reliably longer at the new-referent event than at the old-referent event, suggesting that they encoded the object-directedness of the actor's point. In contrast, infants in the emotional-vocalization condition showed roughly equal looking times to the two events. To further examine infants' understanding of the communicative aspect of an actor's point using a different communicative context, Experiment 2 used an identical procedure to the novel-word condition in Experiment 1, except there was only one object present during the familiarization trials. When the familiarization trials did not include a contrasting object, we found that the communicative intention of the actor's point could be ambiguous. The infants showed roughly equal looking times during the two test events. The current research suggests that six-month-olds understand the object-directedness and communicative intention of others' pointing when presented with a label, but not when presented with an emotional non-speech vocalization.",2021,"Infants in the novel-word condition looked reliably longer at the new-referent event than at the old-referent event, suggesting that they encoded the object-directedness of the actor's point.",[],"['novel label (novel-word condition) or exclamatory expression (emotional-vocalization condition', 'novel-word or emotional-vocalization condition']",[],[],"[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0042932', 'cui_str': 'Singing, Animal'}]",[],,0.0482112,"Infants in the novel-word condition looked reliably longer at the new-referent event than at the old-referent event, suggesting that they encoded the object-directedness of the actor's point.","[{'ForeName': 'Isu', 'Initials': 'I', 'LastName': 'Cho', 'Affiliation': 'Department of Psychology, Brandeis University, Waltham, Massachusetts, USA.'}, {'ForeName': 'Yoonha', 'Initials': 'Y', 'LastName': 'Lee', 'Affiliation': 'Department of Psychology, Yonsei University, Seoul, South Korea.'}, {'ForeName': 'Hyun-Joo', 'Initials': 'HJ', 'LastName': 'Song', 'Affiliation': 'Department of Psychology, Yonsei University, Seoul, South Korea. Electronic address: hsong@yonsei.ac.kr.'}]",Infant behavior & development,['10.1016/j.infbeh.2021.101621'] 2446,34379277,Blood Pressure Visit Intensification in Treatment (BP-Visit) Findings: a Pragmatic Stepped Wedge Cluster Randomized Trial.,"BACKGROUND Shortening time between office visits for patients with uncontrolled hypertension represents a potential strategy for improving blood pressure (BP). OBJECTIVE We evaluated the impact of multimodal strategies on time between visits and on improvement in systolic BP (SBP) among patients with uncontrolled hypertension. DESIGN We used a stepped-wedge cluster randomized controlled trial with three wedges involving 12 federally qualified health centers with three study periods: pre-intervention, intervention, and post-intervention. PARTICIPANTS Adult patients with diagnosed hypertension and two BPs ≥ 140/90 pre-randomization and at least one visit during post-randomization control period (N = 4277). INTERVENTION The core intervention included three, clinician hypertension group-based trainings, monthly clinician feedback reports, and monthly meetings with practice champions to facilitate implementation. MAIN MEASURES The main measures were change in time between visits when BP was not controlled and change in SBP. A secondary planned outcome was changed in BP control among all hypertension patients in the practices. KEY RESULTS Median follow-up times were 34, 32, and 32 days and the mean SBPs were 142.0, 139.5, and 139.8 mmHg, respectively. In adjusted analyses, the intervention did not improve time to the next visit compared with control periods, HR = 1.01 (95% CI: 0.98, 1.04). SBP was reduced by 1.13 mmHg (95% CI: -2.10, -0.16), but was not maintained during follow-up. Hypertension control (< 140/90) in the practices improved by 5% during intervention (95% CI: 2.6%, 7.3%) and was sustained post-intervention 5.4% (95% CI: 2.6%, 8.2%). CONCLUSIONS The intervention failed to shorten follow-up time for patients with uncontrolled BP and showed very small, statistically significant improvements in SBP that were not sustained. However, the intervention showed statistically and clinically relevant improvement in hypertension control suggesting that the intervention affected clinician decision-making regarding BP control apart from visit frequency. Future practice initiatives should consider hypertension control as a primary outcome. CLINICAL TRIAL www.ClinicalTrials.gov Identifier: NCT02164331.",2021,"The intervention failed to shorten follow-up time for patients with uncontrolled BP and showed very small, statistically significant improvements in SBP that were not sustained.","['12 federally qualified health centers with three study periods', 'Adult patients with diagnosed hypertension and two BPs ≥ 140/90 pre-randomization and at least one visit during post-randomization control period (N = 4277', 'patients with uncontrolled hypertension']","['pre-intervention, intervention, and post-intervention', 'clinician hypertension group-based trainings, monthly clinician feedback reports, and monthly meetings with practice champions to facilitate implementation']","['mean SBPs', 'Hypertension control', 'time to the next visit', 'BP control', 'Blood Pressure Visit Intensification', 'blood pressure (BP', 'systolic BP (SBP', 'SBP']","[{'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C1849718', 'cui_str': 'Autosomal recessive popliteal pterygium syndrome'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1868885', 'cui_str': 'Uncontrolled hypertension'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",4277.0,0.0606313,"The intervention failed to shorten follow-up time for patients with uncontrolled BP and showed very small, statistically significant improvements in SBP that were not sustained.","[{'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Fiscella', 'Affiliation': 'University of Rochester, Rochester, NY, USA. Kevin_Fiscella@URMC.rochester.edu.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'He', 'Affiliation': 'Tulane University, New Orleans, LA, USA.'}, {'ForeName': 'Mechelle', 'Initials': 'M', 'LastName': 'Sanders', 'Affiliation': 'University of Rochester, Rochester, NY, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Cassells', 'Affiliation': 'Clinical Directors Network (CDN), New York, NY, USA.'}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Carroll', 'Affiliation': 'University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Stephen K', 'Initials': 'SK', 'LastName': 'Williams', 'Affiliation': 'NYU Langone Health, New York, NY, USA.'}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Cornell', 'Affiliation': 'Family Medicine Research, 1381 South Ave, Rochester, NY, 14620, USA.'}, {'ForeName': 'Tameir', 'Initials': 'T', 'LastName': 'Holder', 'Affiliation': 'Tulane University, New Orleans, LA, USA.'}, {'ForeName': 'Chamanara', 'Initials': 'C', 'LastName': 'Khalida', 'Affiliation': 'Tulane University, New Orleans, LA, USA.'}, {'ForeName': 'Jonathan N', 'Initials': 'JN', 'LastName': 'Tobin', 'Affiliation': 'Tulane University, New Orleans, LA, USA.'}]",Journal of general internal medicine,['10.1007/s11606-021-07016-9'] 2447,34379236,Physical activity outcomes from a randomized trial of a theory- and technology-enhanced intervention for Latinas: the Seamos Activas II study.,"Latina women report disproportionately high and increasing prevalence of chronic health conditions (obesity, diabetes) related to low physical activity levels. Efforts to date at addressing high rates of physical inactivity in this at-risk population have shown modest success. The original Seamos Saludables (sample size N = 266) was a culturally and linguistically adapted, print-based physical activity intervention that showed significant increases in moderate to vigorous physical activity (MVPA) from baseline to 6 months. However, only 11% of intervention participants reached the national PA guidelines of ≥ 150 min/week of aerobic MVPA. The current study tests the original Seamos Saludables intervention (Original Intervention) against an enhanced iteration Seamos Activas II (Enhanced Intervention). Study aims and intervention refinements focus on increasing the percentage of Latinas meeting national aerobic PA guidelines. For the current study (Seamos Activas II), a randomized controlled trial with (N = 199 participants) of two PA interventions (original intervention, N = 102; vs. enhanced intervention, N = 97) was conducted. Intervention refinements involved further targeting key constructs of the Social Cognitive Theory and incorporating text-message-based strategies for self-monitoring, in response to participant feedback for greater interactivity and accountability. PA assessments were conducted at baseline and 6 months. The sample was predominantly Mexican American (89%) with average age of 43.8 years (SD = 10.11) and mean BMI at baseline was 30.6 (SD = 7.56). There were significant within group increases in MVPA from baseline to 6 months (p < .05) in both Original and Enhanced Intervention arms. However, quantile regression models did not indicate significant differences in 6-month outcomes between conditions controlling for baseline, p = 0.73. There were significant differences between conditions with respect to meeting national guidelines for aerobic MVPA at 6 months, with 57% of Enhanced Intervention participants meeting guidelines compared to 44% of Original Intervention participants, OR = 1.66, 95% CI: 1.09 -2.89. Models suggest trends favoring the enhanced condition for improvements in biomarkers over 6 months. Findings indicate that the intervention enhancements likely helped more Latinas achieve nationally recommended, health enhancing PA levels than the original intervention and showed promise for improving physiological response to exercise.Trial Registration ClinicalTrials.Gov; NCT02630953. Registered 14 December 2015. https://clinicaltrials.gov/ct2/show/NCT02630953 .",2021,There were significant within group increases in MVPA from baseline to 6 months (p < .05) in both Original and Enhanced Intervention arms.,"['Latinas', 'The sample was predominantly Mexican American (89%) with average age of 43.8\xa0years (SD\u2009=\u200910.11) and mean BMI at baseline was 30.6 (SD\u2009=\u20097.56', 'N\u2009=\u2009199 participants) of two', 'Latina women report disproportionately high and increasing prevalence of chronic health conditions (obesity, diabetes']","['PA interventions (original intervention, N\u2009=\u2009102; vs. enhanced intervention, N\u2009=\u200997', 'theory- and technology-enhanced intervention']","['MVPA', 'moderate to vigorous physical activity (MVPA', 'national PA guidelines', 'Physical activity outcomes']","[{'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0025884', 'cui_str': 'Chicanos'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.071833,There were significant within group increases in MVPA from baseline to 6 months (p < .05) in both Original and Enhanced Intervention arms.,"[{'ForeName': 'Bess H', 'Initials': 'BH', 'LastName': 'Marcus', 'Affiliation': 'Department of Behavioral and Social Sciences, Center for Health Promotion and Health Equity, School of Public Health, Brown University, 121 South Main Street, Providence, RI, 02903, USA. bess_marcus@brown.edu.'}, {'ForeName': 'Shira', 'Initials': 'S', 'LastName': 'Dunsiger', 'Affiliation': 'Department of Behavioral and Social Sciences, Center for Health Promotion and Health Equity, School of Public Health, Brown University, 121 South Main Street, Providence, RI, 02903, USA.'}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Pekmezi', 'Affiliation': 'School of Public Health, University of Alabama Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Benitez', 'Affiliation': 'Department of Behavioral and Social Sciences, Center for Health Promotion and Health Equity, School of Public Health, Brown University, 121 South Main Street, Providence, RI, 02903, USA.'}, {'ForeName': 'Britta', 'Initials': 'B', 'LastName': 'Larsen', 'Affiliation': 'Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Meyer', 'Affiliation': 'School of Medicine, University of California San Diego, La Jolla, CA, USA.'}]",Journal of behavioral medicine,['10.1007/s10865-021-00246-6'] 2448,34379182,Physical fatigue and its effect on road crossing decisions: an examination of the embodied perception perspective.,"Road crossing is an everyday task that requires integration of information (e.g., speed and distance of an oncoming vehicle) to effectively guide behaviour. The embodied perception perspective suggests that individuals' perception of environmental stimuli is influenced by their psychophysiological state. Upon this premise, the current study examined whether acute physical fatigue influences visual perception and associated decision-making in road crossing. Using a between-subject design, 54 participants (healthy adults, aged 18-35) were divided into a fatigue and no-fatigue group. To manipulate fatigue, participants completed a vigorous cycling protocol (fatigue group) or a light cycling protocol (no-fatigue group) prior to completing a video-based examination of road crossing decisions (cross vs. not cross; action-based) and verbal judgments of speed and distance of an oncoming vehicle. Measures of heart rate, self-perceived recovery, and preferred walking speed indicated that fatigue was successfully induced (all p's < 0.03). Participants effectively distinguished between different speeds (30-50-70 km/h; p < 0.001), and distances (10-100 m in 10 m increments; p < 0.001). Moreover, both vehicle speed and distance (p's < 0.001) significantly influenced road crossing decisions. However, no significant effects of fatigue were observed for visual perception or road crossing decisions (all p's > 0.26). This study demonstrated that individuals are sensitive to changes in vehicle speed and distance and respond to these changes in making road crossing decisions. In contrast to the embodied perception perspective, however, physical fatigue did not alter perceptual judgments of vehicle speed and distance nor did it influence road crossing decisions in a video-simulated road crossing environment.",2021,"Participants effectively distinguished between different speeds (30-50-70 km/h; p < 0.001), and distances (10-100 m in 10 m increments; p < 0.001).","['54 participants (healthy adults, aged 18-35']",['vigorous cycling protocol (fatigue group) or a light cycling protocol (no-fatigue group) prior to completing a video-based examination of road crossing decisions (cross vs. not cross; action-based) and verbal judgments of speed and distance of an oncoming vehicle'],"['Physical fatigue', 'visual perception or road crossing decisions', 'fatigue', 'heart rate, self-perceived recovery, and preferred walking speed indicated that fatigue']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0442650', 'cui_str': 'Road'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0442650', 'cui_str': 'Road'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}]",54.0,0.0917324,"Participants effectively distinguished between different speeds (30-50-70 km/h; p < 0.001), and distances (10-100 m in 10 m increments; p < 0.001).","[{'ForeName': 'Robyn', 'Initials': 'R', 'LastName': 'Sullivan', 'Affiliation': 'Department of Exercise Sciences, University of Auckland, Auckland, New Zealand. robyn.sullivan@auckland.ac.nz.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Nieuwenhuys', 'Affiliation': 'Department of Exercise Sciences, University of Auckland, Auckland, New Zealand.'}]",Psychological research,['10.1007/s00426-021-01570-x'] 2449,34379136,[Radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : A multicentre phase III trial].,,2021,,['early-stage unfavourable Hodgkin lymphoma (GHSG HD17) '],['Radiotherapy'],[],"[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0019829', 'cui_str': 'Hodgkin lymphoma'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}]",[],,0.0788794,,"[{'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Süß', 'Affiliation': 'Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee\xa011, 93053, Regensburg, Deutschland. christoph.suess@ukr.de.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Kölbl', 'Affiliation': 'Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee\xa011, 93053, Regensburg, Deutschland.'}]",Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],['10.1007/s00066-021-01826-w'] 2450,34379122,The development of an intervention to support uptake and adherence to antiretroviral therapy in people living with HIV: the SUPA intervention. A brief report.,"The effectiveness of antiretroviral therapy (ART) depends on prompt uptake of treatment and a high level of adherence over the long-term, yet these behaviors are suboptimal. Previous interventions have significantly improved adherence but effect sizes are generally small. The aim of this article is to describe the design and content of an intervention to support uptake and adherence to treatment in HIV positive patients (SUPA intervention), utilizing cognitive behavioral and motivational interviewing (MI) techniques. The intervention was developed in line with Medical Research Council (MRC) guidance for the development of complex interventions and informed by the NICE (National Institute for Health and Care Excellence) Guidelines for adherence, empirical evidence and focus groups. Behavior change techniques were mapped to perceptual and practical barriers to uptake and adherence to ART, identified in previous research. Intervention materials were designed and later discussed within focus groups, where feedback enabled an iterative process of development. We conclude it is possible to transparently report the design and content of a theory-based intervention to increase uptake and adherence to ART. The intervention has been evaluated within a randomized controlled trial (RCT) at 10 HIV clinics in England, the results of which will be reported elsewhere.",2021,Previous interventions have significantly improved adherence but effect sizes are generally small.,"['HIV positive patients (SUPA intervention', 'people living with HIV']","['antiretroviral therapy (ART', 'cognitive behavioral and motivational interviewing (MI) techniques']",[],"[{'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]","[{'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",[],10.0,0.0467085,Previous interventions have significantly improved adherence but effect sizes are generally small.,"[{'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'King', 'Affiliation': 'Centre for Behavioural Medicine, UCL School of Pharmacy, London, United Kingdom.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Horne', 'Affiliation': 'Centre for Behavioural Medicine, UCL School of Pharmacy, London, United Kingdom.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Cooper', 'Affiliation': 'Centre for Behavioural Medicine, UCL School of Pharmacy, London, United Kingdom.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Glendinning', 'Affiliation': 'Centre for Behavioural Medicine, UCL School of Pharmacy, London, United Kingdom.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Michie', 'Affiliation': 'Centre for Behavioural Medicine, UCL School of Pharmacy, London, United Kingdom.'}, {'ForeName': 'Trudie', 'Initials': 'T', 'LastName': 'Chalder', 'Affiliation': ""Psychological Medicine, King's College London, London, United Kingdom.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Translational behavioral medicine,['10.1093/tbm/ibab104'] 2451,34371000,Underwater- versus conventional endoscopic mucosal resection of large sessile or flat colorectal polyps: a prospective randomized controlled trial.,"BACKGROUND AND AIMS Conventional endoscopic mucosal resection (CEMR) with submucosal injection is the current standard for the resection of large, non-malignant colorectal polyps. We investigated whether underwater endoscopic mucosal resection (UEMR) is superior to CEMR for large (20-40 mm) sessile or flat colorectal polyps. METHODS In this prospective randomized controlled study, patients with sessile or flat colorectal polyps between 20 and 40 mm in size were randomly assigned to UEMR or CEMR. The primary outcome was the recurrence rate after 6 months. Secondary outcomes included en bloc and R0 resection rates, number of resected pieces, procedure time, and adverse events. RESULTS En bloc resection rates were 33.3% in the UEMR group and 18.4% in the CEMR group (P = .045); R0 resection rates were 32.1% and 15.8% for UEMR vs CEMR, respectively (P = .025). UEMR was performed with significantly fewer pieces compared to CEMR (2 pieces: 45.5% UEMR vs. 17.7% CEMR; P = .001). The overall recurrence rate did not differ between both groups (P = .253); however, subgroup analysis showed a significant difference in favor of UEMR for lesions >30 mm to ≤40 mm in size (P = .031). The resection time was significantly shorter in the UEMR group (8 vs. 14 minutes; P = .000). Adverse events did not differ between both groups (P = .611). CONCLUSION UEMR is superior to CEMR regarding en bloc resection, R0 resection and procedure time for large colorectal lesions and shows significantly lower recurrence rates for lesions >30 mm to ≤40 mm in size. UEMR should be considered for the endoscopic resection of large colorectal polyps.",2021,"UEMR is superior to CEMR regarding en bloc resection, R0 resection and procedure time for large colorectal lesions and shows significantly lower recurrence rates for lesions","['large sessile or flat colorectal polyps', 'patients with sessile or flat colorectal polyps between 20 and 40 mm in size']","['Underwater- versus conventional endoscopic mucosal resection', 'CEMR', 'UEMR', 'UEMR or CEMR', 'underwater endoscopic mucosal resection (UEMR', 'Conventional endoscopic mucosal resection (CEMR) with submucosal injection']","['overall recurrence rate', 'en bloc and R0 resection rates, number of resected pieces, procedure time, and adverse events', 'Adverse events', 'UEMR', 'En bloc resection rates', 'recurrence rate', 'R0 resection rates', 'resection time', 'recurrence rates for lesions']","[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0205348', 'cui_str': 'Sessile'}, {'cui': 'C0205324', 'cui_str': 'Flat'}, {'cui': 'C0949059', 'cui_str': 'Polyp of large intestine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450402', 'cui_str': '40mm'}, {'cui': 'C0456389', 'cui_str': 'Size'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C1700928', 'cui_str': 'Strip Biopsy'}, {'cui': 'C1515025', 'cui_str': 'Submucosal route'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1700928', 'cui_str': 'Strip Biopsy'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",,0.124887,"UEMR is superior to CEMR regarding en bloc resection, R0 resection and procedure time for large colorectal lesions and shows significantly lower recurrence rates for lesions","[{'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Nagl', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany. Electronic address: sandra.nagl@uk-augsburg.de.'}, {'ForeName': 'Alanna', 'Initials': 'A', 'LastName': 'Ebigbo', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Stefan Karl', 'Initials': 'SK', 'LastName': 'Goelder', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Roemmele', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Neuhaus', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Weber', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Braun', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Probst', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Schnoy', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Agnieszka Jowita', 'Initials': 'AJ', 'LastName': 'Kafel', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Muzalyova', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}, {'ForeName': 'Helmut', 'Initials': 'H', 'LastName': 'Messmann', 'Affiliation': 'Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany.'}]",Gastroenterology,['10.1053/j.gastro.2021.07.044'] 2452,34370994,Comparative evaluation of dacryocystorhinostomy with retrograde intubation and conjunctivo-dacryocystorhinostomy.,"OBJECTIVE To compare the surgical outcomes of dacryocystorhinostomy with retrograde intubation and conjunctivo-dacryocystorhinostomy for the management of proximal mid-bicanalicular lacrimal obstruction. DESIGN Randomized, controlled trial. METHODS The study was conducted in 50 eyes of 50 adult patients with bicanalicular obstruction ≤ 6 mm from the punctum. The etiology, duration of symptoms, and Munk scores were recorded. Group A underwent dacryocystorhinostomy with retrograde intubation, and in group B, conjunctivo-dacryocystorhinostomy was performed. Success was defined as anatomic patency on syringing, a negative fluorescein dye disappearance test, and a Munk score < 2 twelve months postoperatively. RESULTS There were 23 males and 27 females, 18-66 years of age, with a 6-month to 20-year duration of epiphora. The etiologies were idiopathic, trauma, and allergic conjunctivitis and ocular surface inflammation. In group A, the pseudopunctum was located medial to the diagnosed level of canalicular block by 1.28 ± 0.54 mm and 1.04 ± 0.88 mm in upper and lower canaliculi, respectively. Four post-traumatic cases required intervention following closure of the pseudopunctum, all being located ≥ 7 mm from the true punctum (p = 0.001). The complication rate was higher in group B than in group A (p = 0.001). At 12 months, the success rate was 100% in group A and 88% in group B (22 of 25; p = 0.74), with reduction in Munk scores from preoperative levels in both groups (p = 0.001). CONCLUSION Dacryocystorhinostomy with retrograde intubation and conjunctivo-dacryocystorhinostomy have comparable success rates in the management of proximal mid-bicanalicular obstructions. Dacryocystorhinostomy with retrograde intubation has lower complication rates and does not require long-term maintenance of the bypass tube, unlike conjunctivo-dacryocystorhinostomy.",2021,"Dacryocystorhinostomy with retrograde intubation has lower complication rates and does not require long-term maintenance of the bypass tube, unlike conjunctivo-dacryocystorhinostomy.","['50 eyes of 50 adult patients with bicanalicular obstruction\u2009≤\u20096 mm from the punctum', '23 males and 27 females, 18-66 years of age, with a 6-month to 20-year duration of epiphora']","['Dacryocystorhinostomy with retrograde intubation', 'dacryocystorhinostomy with retrograde intubation and conjunctivo-dacryocystorhinostomy', 'Dacryocystorhinostomy with retrograde intubation and conjunctivo-dacryocystorhinostomy', 'dacryocystorhinostomy with retrograde intubation']","['etiology, duration of symptoms, and Munk scores', 'success rate', 'anatomic patency on syringing, a negative fluorescein dye disappearance test, and a Munk score', 'complication rates', 'complication rate']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0152227', 'cui_str': 'Epiphora'}]","[{'cui': 'C0010931', 'cui_str': 'Dacryocystorhinostomy'}, {'cui': 'C1301699', 'cui_str': 'Retrograde intubation'}]","[{'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1633730', 'cui_str': 'Fluorescein dye disappearance test'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",50.0,0.0624866,"Dacryocystorhinostomy with retrograde intubation has lower complication rates and does not require long-term maintenance of the bypass tube, unlike conjunctivo-dacryocystorhinostomy.","[{'ForeName': 'Ruchi', 'Initials': 'R', 'LastName': 'Goel', 'Affiliation': 'Department of Ophthalmology, Guru Nanak Eye Centre, Maulana Azad Medical College, New Delhi, India. Electronic address: gruchi1@rediffmail.com.'}, {'ForeName': 'Priyanka', 'Initials': 'P', 'LastName': 'Golhait', 'Affiliation': 'Department of Ophthalmology, Guru Nanak Eye Centre, Maulana Azad Medical College, New Delhi, India.'}, {'ForeName': 'Samreen', 'Initials': 'S', 'LastName': 'Khanam', 'Affiliation': 'Department of Ophthalmology, Guru Nanak Eye Centre, Maulana Azad Medical College, New Delhi, India.'}, {'ForeName': 'Shweta', 'Initials': 'S', 'LastName': 'Raghav', 'Affiliation': 'Department of Ophthalmology, Guru Nanak Eye Centre, Maulana Azad Medical College, New Delhi, India.'}, {'ForeName': 'Shalin', 'Initials': 'S', 'LastName': 'Shah', 'Affiliation': 'Department of Ophthalmology, Guru Nanak Eye Centre, Maulana Azad Medical College, New Delhi, India.'}, {'ForeName': 'Sonam', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'Department of Ophthalmology, Guru Nanak Eye Centre, Maulana Azad Medical College, New Delhi, India.'}]",Canadian journal of ophthalmology. Journal canadien d'ophtalmologie,['10.1016/j.jcjo.2021.07.002'] 2453,34370971,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.","BACKGROUND Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA vaccine (BNT162b2, Pfizer-BioNTech; hereafter referred to as BNT) at a 4-week interval are more reactogenic than homologous schedules. Here, we report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines. METHODS Com-COV is a participant-blinded, randomised, non-inferiority trial evaluating vaccine safety, reactogenicity, and immunogenicity. Adults aged 50 years and older with no or well controlled comorbidities and no previous SARS-CoV-2 infection by laboratory confirmation were eligible and were recruited at eight sites across the UK. The majority of eligible participants were enrolled into the general cohort (28-day or 84-day prime-boost intervals), who were randomly assigned (1:1:1:1:1:1:1:1) to receive ChAd/ChAd, ChAd/BNT, BNT/BNT, or BNT/ChAd, administered at either 28-day or 84-day prime-boost intervals. A small subset of eligible participants (n=100) were enrolled into an immunology cohort, who had additional blood tests to evaluate immune responses; these participants were randomly assigned (1:1:1:1) to the four schedules (28-day interval only). Participants were masked to the vaccine received but not to the prime-boost interval. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentration (measured by ELISA) at 28 days after boost, when comparing ChAd/BNT with ChAd/ChAd, and BNT/ChAd with BNT/BNT. The heterologous schedules were considered non-inferior to the approved homologous schedules if the lower limit of the one-sided 97·5% CI of the GMR of these comparisons was greater than 0·63. The primary analysis was done in the per-protocol population, who were seronegative at baseline. Safety analyses were done among participants receiving at least one dose of a study vaccine. The trial is registered with ISRCTN, 69254139. FINDINGS Between Feb 11 and Feb 26, 2021, 830 participants were enrolled and randomised, including 463 participants with a 28-day prime-boost interval, for whom results are reported here. The mean age of participants was 57·8 years (SD 4·7), with 212 (46%) female participants and 117 (25%) from ethnic minorities. At day 28 post boost, the geometric mean concentration of SARS-CoV-2 anti-spike IgG in ChAd/BNT recipients (12 906 ELU/mL) was non-inferior to that in ChAd/ChAd recipients (1392 ELU/mL), with a GMR of 9·2 (one-sided 97·5% CI 7·5 to ∞). In participants primed with BNT, we did not show non-inferiority of the heterologous schedule (BNT/ChAd, 7133 ELU/mL) against the homologous schedule (BNT/BNT, 14 080 ELU/mL), with a GMR of 0·51 (one-sided 97·5% CI 0·43 to ∞). Four serious adverse events occurred across all groups, none of which were considered to be related to immunisation. INTERPRETATION Despite the BNT/ChAd regimen not meeting non-inferiority criteria, the SARS-CoV-2 anti-spike IgG concentrations of both heterologous schedules were higher than that of a licensed vaccine schedule (ChAd/ChAd) with proven efficacy against COVID-19 disease and hospitalisation. Along with the higher immunogenicity of ChAd/BNT compared with ChAD/ChAd, these data support flexibility in the use of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines. FUNDING UK Vaccine Task Force and National Institute for Health Research.",2021,"In participants primed with BNT, we did not show non-inferiority of the heterologous schedule (BNT/ChAd, 7133 ELU/mL) against the homologous schedule (BNT/BNT, 14 080 ELU/mL), with a GMR of 0·51 (one-sided 97·5% CI 0·43 to ∞).","['The mean age of participants was 57·8 years (SD 4·7), with 212 (46%) female participants and 117 (25%) from ethnic minorities', 'Between Feb 11 and Feb 26, 2021, 830 participants were enrolled and randomised, including 463 participants with a 28-day prime-boost interval, for whom results are reported here', 'A small subset of eligible participants (n=100) were enrolled into an immunology cohort, who had additional blood tests to evaluate immune responses; these participants', 'eligible participants were enrolled into the general cohort (28-day or 84-day prime-boost intervals', 'Adults aged 50 years and older with no or well controlled comorbidities and no previous SARS-CoV-2 infection by laboratory confirmation were eligible and were recruited at eight sites across the UK']","['heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV', 'ChAd and BNT vaccines', 'ChAd/ChAd, ChAd/BNT, BNT/BNT, or BNT/ChAd, administered at either 28-day or 84-day prime-boost intervals']","['geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentration (measured by ELISA', 'vaccine safety, reactogenicity, and immunogenicity', 'adverse events', 'geometric mean concentration of SARS-CoV-2 anti-spike IgG']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C4517889', 'cui_str': '830'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0071973', 'cui_str': 'PRIME protocol'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0152036', 'cui_str': 'Immunology'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C3853142', 'cui_str': 'Well controlled'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0439860', 'cui_str': 'Heterologous'}, {'cui': 'C0071973', 'cui_str': 'PRIME protocol'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0001483', 'cui_str': 'Adenoviridae'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0009490', 'cui_str': 'Comoros islands'}, {'cui': 'C0007928', 'cui_str': 'Chad'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",830.0,0.650998,"In participants primed with BNT, we did not show non-inferiority of the heterologous schedule (BNT/ChAd, 7133 ELU/mL) against the homologous schedule (BNT/BNT, 14 080 ELU/mL), with a GMR of 0·51 (one-sided 97·5% CI 0·43 to ∞).","[{'ForeName': 'Xinxue', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Shaw', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.'}, {'ForeName': 'Arabella S V', 'Initials': 'ASV', 'LastName': 'Stuart', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Greenland', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Parvinder K', 'Initials': 'PK', 'LastName': 'Aley', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Nick J', 'Initials': 'NJ', 'LastName': 'Andrews', 'Affiliation': 'Statistics, Modelling and Economics Department, Public Health England, London, UK; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, UK.'}, {'ForeName': 'J Claire', 'Initials': 'JC', 'LastName': 'Cameron', 'Affiliation': 'Health Protection Scotland, Glasgow, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Charlton', 'Affiliation': 'Public Health England, Porton Down, Salisbury, UK.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Clutterbuck', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Collins', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Dinesh', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'England', 'Affiliation': 'Public Health England, Porton Down, Salisbury, UK.'}, {'ForeName': 'Saul N', 'Initials': 'SN', 'LastName': 'Faust', 'Affiliation': 'NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.'}, {'ForeName': 'Daniela M', 'Initials': 'DM', 'LastName': 'Ferreira', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Finn', 'Affiliation': 'School of Population Health Sciences and School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.'}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Green', 'Affiliation': 'NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Bassam', 'Initials': 'B', 'LastName': 'Hallis', 'Affiliation': 'Public Health England, Porton Down, Salisbury, UK.'}, {'ForeName': 'Paul T', 'Initials': 'PT', 'LastName': 'Heath', 'Affiliation': ""The Vaccine Institute, St George's University of London, London, UK.""}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Hill', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Lambe', 'Affiliation': 'Jenner Institute, University of Oxford, Oxford, UK.'}, {'ForeName': 'Rajeka', 'Initials': 'R', 'LastName': 'Lazarus', 'Affiliation': 'North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Libri', 'Affiliation': 'NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Long', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Yama F', 'Initials': 'YF', 'LastName': 'Mujadidi', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Plested', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Provstgaard-Morys', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Maheshi N', 'Initials': 'MN', 'LastName': 'Ramasamy', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Ramsay', 'Affiliation': 'Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, UK.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Read', 'Affiliation': 'NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Robinson', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Nisha', 'Initials': 'N', 'LastName': 'Singh', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'David P J', 'Initials': 'DPJ', 'LastName': 'Turner', 'Affiliation': 'University of Nottingham, Nottingham, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Turner', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Laura L', 'Initials': 'LL', 'LastName': 'Walker', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'White', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Nguyen-Van-Tam', 'Affiliation': 'Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Snape', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: matthew.snape@paediatrics.ox.ac.uk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(21)01694-9'] 2454,34370970,"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.","BACKGROUND Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of tirzepatide versus titrated insulin degludec in people with type 2 diabetes inadequately controlled by metformin with or without SGLT2 inhibitors. METHODS In this open-label, parallel-group, multicentre (122 sites), multinational (13 countries), phase 3 study, eligible participants (aged ≥18 years) had a baseline glycated haemoglobin (HbA 1c ) of 7·0-10·5%, body-mass index of at least 25 kg/m 2 , stable weight, and were insulin-naive and treated with metformin alone or in combination with an SGLT2 inhibitor for at least 3 months before screening. Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to once-weekly subcutaneous injection of tirzepatide (5, 10, or 15 mg) or once-daily subcutaneous injection of titrated insulin degludec, and were stratified by country, HbA 1c , and concomitant use of oral antihyperglycaemic medications. Tirzepatide was initially given at 2·5 mg and the dose was escalated by 2·5 mg every 4 weeks until the assigned dose was reached. Insulin degludec was initially given at 10 U per day and was titrated once weekly to a fasting self-monitored blood glucose of less than 5·0 mmol/L (<90 mg/dL), following a treat-to-target algorithm, for 52 weeks. The primary efficacy endpoint was non-inferiority of tirzepatide 10 mg or 15 mg, or both, versus insulin degludec in mean change from baseline in HbA 1c at week 52. Key secondary efficacy endpoints were non-inferiority of tirzepatide 5 mg versus insulin degludec in mean change from baseline in HbA 1c at week 52, superiority of all doses of tirzepatide versus insulin degludec in mean change from baseline in HbA 1c and bodyweight, and the proportion of participants achieving HbA 1c of less than 7·0% (<53 mmol/mol) at week 52. We used a boundary of 0·3% to establish non-inferiority in HbA 1c difference between treatments. Efficacy and safety analyses were assessed in the modified intention-to-treat population (all participants who received at least one dose of study drug). This trial is registered with ClinicalTrials.gov, number NCT03882970, and is complete. FINDINGS Between April 1 and Nov 15, 2019, we assessed 1947 participants for eligibility, 1444 of whom were randomly assigned to treatment. The modified intention-to-treat population was 1437 participants from the tirzepatide 5 mg (n=358), tirzepatide 10 mg (n=360), tirzepatide 15 mg (n=359), and insulin degludec (n=360) groups. From a mean baseline HbA 1c of 8·17% (SD 0·91), the reductions in HbA 1c at week 52 were 1·93% (SE 0·05) for tirzepatide 5 mg, 2·20% (0·05) for tirzepatide 10 mg, and 2·37% (0·05) for tirzepatide 15 mg, and 1·34% (0·05) for insulin degludec. The non-inferiority margin of 0·3% was met. The estimated treatment difference (ETD) versus insulin degludec ranged from -0·59% to -1·04% for tirzepatide (p<0·0001 for all tirzepatide doses). The proportion of participants achieving a HbA 1c of less than 7·0% (<53 mmol/mol) at week 52 was greater (p<0·0001) in all three tirzepatide groups (82%-93%) versus insulin degludec (61%). At week 52, from a baseline of 94·3 kg (SD 20·1), all three tirzepatide doses decreased bodyweight (-7·5 kg to -12·9 kg), whereas insulin degludec increased bodyweight by 2·3 kg. The ETD versus insulin degludec ranged from -9·8 kg to -15·2 kg for tirzepatide (p<0·0001 for all tirzepatide doses). The most common adverse events in tirzepatide-treated participants were mild to moderate gastrointestinal events that decreased over time. A higher incidence of nausea (12-24%), diarrhoea (15-17%), decreased appetite (6-12%), and vomiting (6-10%) was reported in participants treated with tirzepatide than in those treated with insulin degludec (2%, 4%, 1%, and 1%, respectively). Hypoglycaemia (<54 mg/dL or severe) was reported in five (1%), four (1%), and eight (2%) participants on tirzepatide 5, 10, and 15 mg, respectively, versus 26 (7%) on insulin degludec. Treatment discontinuation due to an adverse event was more common in the tirzepatide groups than in the insulin degludec group. Five participants died during the study; none of the deaths were considered by the investigators to be related to the study treatment. INTERPRETATION In patients with type 2 diabetes, tirzepatide (5, 10, and 15 mg) was superior to titrated insulin degludec, with greater reductions in HbA 1c and bodyweight at week 52 and a lower risk of hypoglycaemia. Tirzepatide showed a similar safety profile to that of GLP-1 receptor agonists. FUNDING Eli Lilly and Company.",2021,"The primary efficacy endpoint was non-inferiority of tirzepatide 10 mg or 15 mg, or both, versus insulin degludec in mean change from baseline in HbA 1c at week 52.","['people with type 2 diabetes inadequately controlled by metformin with or without SGLT2 inhibitors', '1437 participants from the', 'patients with type 2 diabetes (SURPASS-3', '1947 participants for eligibility, 1444 of whom were randomly assigned to treatment', 'eligible participants (aged ≥18 years) had a baseline glycated haemoglobin (HbA 1c ) of 7·0-10·5%, body-mass index of at least 25 kg/m 2 , stable weight, and were insulin-naive and treated with', 'for at least 3 months before screening', 'Between April 1 and Nov 15, 2019']","['Tirzepatide', 'tirzepatide 10 mg (n=360), tirzepatide 15 mg (n=359), and insulin degludec', 'metformin alone or in combination with an SGLT2 inhibitor', 'tirzepatide', 'metformin with or without SGLT2 inhibitors']","['efficacy and safety', 'Efficacy and safety analyses', 'Hypoglycaemia', 'diarrhoea', 'decreased appetite', 'inferiority of tirzepatide 5 mg versus insulin degludec', 'vomiting', 'inferiority of tirzepatide', 'nausea']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0332298', 'cui_str': 'Controlled by'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C3273807', 'cui_str': 'SGLT2 Inhibitors'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}]","[{'cui': 'C3491971', 'cui_str': 'insulin degludec'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C3273807', 'cui_str': 'SGLT2 Inhibitors'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C3491971', 'cui_str': 'insulin degludec'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",1947.0,0.201951,"The primary efficacy endpoint was non-inferiority of tirzepatide 10 mg or 15 mg, or both, versus insulin degludec in mean change from baseline in HbA 1c at week 52.","[{'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Ludvik', 'Affiliation': '1st Medical Department and Karl Landsteiner Institute for Obesity and Metabolic Disorders, Landstrasse Clinic, Vienna Health Association, Vienna, Austria.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Giorgino', 'Affiliation': 'University of Bari Aldo Moro, University Hospital Policlinico Consorziale, Bari, Italy.'}, {'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Jódar', 'Affiliation': 'Hospital Universitario Quirónsalud Madrid, Universidad Europea, Madrid, Spain.'}, {'ForeName': 'Juan P', 'Initials': 'JP', 'LastName': 'Frias', 'Affiliation': 'National Research Institute, Los Angeles, CA, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Fernández Landó', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Katelyn', 'Initials': 'K', 'LastName': 'Brown', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Bray', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Rodríguez', 'Affiliation': 'Lilly Spain, Madrid, Spain. Electronic address: rodriguez_angel@lilly.com.'}]","Lancet (London, England)",['10.1016/S0140-6736(21)01443-4'] 2455,34370964,"Hibiscus sabdariffa tea affects diet-induced thermogenesis and subjective satiety responses in healthy men, but not in women: a randomized crossover trial.","The aim of this study was to investigate the effect of Hibiscus sabdariffa tea on energy expenditure, satiety response and food intake. This is an open-label, crossover, randomized clinical trial (RBR-5HZ86T), including 21 subjects (11 women, 10 men). The individuals were evaluated at acute moments (fasting and after eating standardized breakfast accompanied by water or Hibiscus sabdariffa tea). Resting energy expenditure was measured by indirect calorimetry, subjective satiety responses were evaluated with a visual analogue scale and food intake was assessed by using food records. The volunteers who drank the Hibiscus sabdariffa tea had lower perception of hunger (p=0.002) and greater feeling of satiety (p=0.010) and fullness (p=0.009) compared to control. Men who ingested the Hibiscus sabdariffa tea had an increase in nitrogen energy expenditure (water: 1501±290.7kcal, Hibiscus sabdariffa tea: 1619±288.9kcal; p=0.029). In comparison to control, men presented less perception of hunger (p=0.003) and desire to eat (p=0.016), increased satiety (p=0.021) and fullness (p=0.010), and women oxidized more fat (p=0.034) when they drank Hibiscus sabdariffa tea. There was no difference between treatments regarding the energy and macronutrient intake from the first meal and throughout the day (p>0.050) for all participants. The Hibiscus sabdariffa tea only affected energy expenditure and satiety responses in men. Clinical trial registry: ReBEC Platform of the Brazilian Clinical Trials Registry - RBR-5HZ86T Novelty bullets • Hibiscus sabdariffa tea promoted an increase in energy expenditure and caused less perception of hunger/desire to eat in men. • Hibiscus sabdariffa tea intake increased postprandial fat oxidation in women.",2021,"In comparison to control, men presented less perception of hunger (p=0.003) and desire to eat (p=0.016), increased satiety (p=0.021) and fullness (p=0.010), and women oxidized more fat (p=0.034) when they drank Hibiscus sabdariffa tea.","['hunger/desire to eat in men', 'men', 'women', 'healthy men', '21 subjects (11 women, 10 men']","['Hibiscus sabdariffa tea', 'Hibiscus sabdariffa tea intake']","['thermogenesis and subjective satiety responses', 'energy and macronutrient intake', 'postprandial fat oxidation', 'Resting energy expenditure', 'desire to eat', 'lower perception of hunger', 'energy expenditure and satiety responses', 'energy expenditure', 'feeling of satiety', 'perception of hunger', 'energy expenditure, satiety response and food intake', 'visual analogue scale and food intake', 'nitrogen energy expenditure (water', 'fullness', 'increased satiety']","[{'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1207898', 'cui_str': 'Roselle'}, {'cui': 'C0039400', 'cui_str': 'Tea'}, {'cui': 'C0556161', 'cui_str': 'Tea intake'}]","[{'cui': 'C0018841', 'cui_str': 'Heat Production'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0036240', 'cui_str': 'Satiety Response'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0028158', 'cui_str': 'Nitrogen'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0439650', 'cui_str': 'Fullness'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",21.0,0.0586318,"In comparison to control, men presented less perception of hunger (p=0.003) and desire to eat (p=0.016), increased satiety (p=0.021) and fullness (p=0.010), and women oxidized more fat (p=0.034) when they drank Hibiscus sabdariffa tea.","[{'ForeName': 'Natália Cristina de', 'Initials': 'NC', 'LastName': 'Faria', 'Affiliation': 'Universidade Federal de Minas Gerais, 28114, Departamento de Alimentos, 6627 Antônio Carlos Avenue, Pampulha Campus, Belo Horizonte, Minas Gerais, Brazil, 31270-901; natfarianutri@yahoo.com.br.'}, {'ForeName': 'Ana Paula da Costa', 'Initials': 'APDC', 'LastName': 'Soares', 'Affiliation': 'Universidade Federal de Minas Gerais, 28114, Departamento de Alimentos, Belo Horizonte, MG, Brazil; anapaulacsoares@yahoo.com.br.'}, {'ForeName': 'Guilherme Fonseca', 'Initials': 'GF', 'LastName': 'Graciano', 'Affiliation': 'Universidade Federal de Minas Gerais, 28114, Departamento de Nutrição, Belo Horizonte, MG, Brazil; guilhermegracianonutri@gmail.com.'}, {'ForeName': 'Maria Isabel Toulson Davisson', 'Initials': 'MITD', 'LastName': 'Correia', 'Affiliation': 'Universidade Federal de Minas Gerais, 28114, Instituto Alfa de Gastroenterologia, Belo Horizonte, MG, Brazil; isabel_correia@uol.com.br.'}, {'ForeName': 'Magda Carvalho', 'Initials': 'MC', 'LastName': 'Pires', 'Affiliation': 'Universidade Federal de Minas Gerais, Department of Statistics; Institute of Exact Sciences, Belo Horizonte, Minas Gerais, Brazil; magdacpires@gmail.com.'}, {'ForeName': 'Virginia Del Carmen T', 'Initials': 'VDCT', 'LastName': 'Valenzuela', 'Affiliation': 'Fundação Ezequiel Dias, 282795, Belo Horizonte, MG, Brazil; virginia.delcarmen@funed.mg.gov.br.'}, {'ForeName': 'Lucilene Rezende', 'Initials': 'LR', 'LastName': 'Anastácio', 'Affiliation': 'Universidade Federal de Minas Gerais, 28114, Departamento de Alimentos, Belo Horizonte, MG, Brazil; lucilene.rezende@gmail.com.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2021-0051'] 2456,34370941,The Effect of an Empowerment Program on the Health-promoting Behaviors of Iranian Women Workers: A Randomized Controlled Trial.,"OBJECTIVES The workplace is an ideal place for encouraging health-promoting behaviors. Therefore, the aim of the present study was to determine the effect of an empowerment program on the health-promoting behaviors of women workers. METHODS This randomized clinical trial was conducted with 80 women workers employed at a food packaging facility in 2020. The subjects were selected using convenience sampling and were classified into intervention and control groups using block randomization. An empowerment program for women workers was conducted across 6 sessions based on an empowerment model. Data collection tools included a demographic questionnaire and the Health Promoting Lifestyle Profile-II, which participants completed both before the program and 8 weeks after the last session. Data analysis was performed in SPSS version 16 using descriptive analysis and inferential statistics. RESULTS There were no significant differences between the 2 groups in various health-promoting behaviors before the program. However, the intervention group's scores for nutrition (34.92±1.09 vs. 27.87±4.23), physical activity (24.40±2.94 vs. 17.40±5.03), stress management (26.35±2.60 vs. 23.05±4.27), spiritual growth (34.02±3.00 vs. 30.22±5.40), interpersonal relationships (30.82±2.38 vs. 27.60±4.61), and health responsibility (31.60±2.71 vs. 28.22±4.59) were significantly higher than the control group's 8 weeks after the program had ended. Moreover, there was a significant difference in the total score of health-promoting behaviors for the intervention group compared to the control group (179.00±9.22 vs. 151.42±20.25, p=0.001). CONCLUSIONS An empowerment program for women workers led to significant improvements in the health-promoting behaviors of the participants. Similar programs can ultimately improve women's health in the workplace.",2021,"However, the intervention group's scores for nutrition (34.92±1.09 vs. 27.87±4.23), physical activity (24.40±2.94 vs. 17.40±5.03), stress management (26.35±2.60 vs. 23.05±4.27), spiritual growth (34.02±3.00 vs. 30.22±5.40), interpersonal relationships (30.82±2.38 vs. 27.60±4.61), and health responsibility (31.60±2.71 vs. 28.22±4.59) were significantly higher than the control group's 8 weeks after the program had ended.","['Iranian Women Workers', '80 women workers employed at a food packaging facility in 2020', 'women workers']","['Empowerment Program', 'empowerment program']","['health responsibility', 'physical activity', 'stress management', 'various health-promoting behaviors', 'interpersonal relationships', 'total score of health-promoting behaviors', 'health-promoting behaviors', 'spiritual growth']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0282490', 'cui_str': 'Packaging, Food'}]","[{'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0517496', 'cui_str': 'Health promotion behavior'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0687002', 'cui_str': 'Spiritual growth'}]",80.0,0.0259156,"However, the intervention group's scores for nutrition (34.92±1.09 vs. 27.87±4.23), physical activity (24.40±2.94 vs. 17.40±5.03), stress management (26.35±2.60 vs. 23.05±4.27), spiritual growth (34.02±3.00 vs. 30.22±5.40), interpersonal relationships (30.82±2.38 vs. 27.60±4.61), and health responsibility (31.60±2.71 vs. 28.22±4.59) were significantly higher than the control group's 8 weeks after the program had ended.","[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Noori', 'Affiliation': 'Department of Community Health and Geriatric Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Behboodimoghadam', 'Affiliation': 'Department of Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shima', 'Initials': 'S', 'LastName': 'Haghani', 'Affiliation': 'Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shahzad', 'Initials': 'S', 'LastName': 'Pashaeypoor', 'Affiliation': 'Department of Community Health and Geriatric Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.'}]",Journal of preventive medicine and public health = Yebang Uihakhoe chi,['10.3961/jpmph.21.088'] 2457,34370930,Mixed versus predilution hemodiafiltration effects on convection volume and small and middle molecule clearance in hemodialysis patients: a prospective randomized controlled trial.,"Background The use of newly developed mixed-dilution hemodiafiltration (HDF) can supplement the weaknesses of pre- and postdilution HDF. However, it is unclear whether mixed-HDF performs well compared to predilution HDF. Methods We conducted a prospective, open-labeled, randomized controlled trial from two hemodialysis centers in Korea. Between January 2017 and September 2019, 60 patients who underwent chronic hemodialysis were randomly assigned at a 1:1 ratio to receive either predilution HDF (n = 30) or mixed-HDF (n = 30) for 6 months. We compared convection volume, changes in small- and medium-sized molecule clearance, high-sensitive C-reactive protein (hs-CRP) level, and dialysis-related parameters between the two dialysis modalities. Results A mean effective convection volume of 41.0 ± 10.3 L/session in the predilution HDF group and 51.5 ± 9.0 L/session in the mixed-HDF group was obtained by averaging values of three time-points. The difference in effective convection volume between the groups was 10.5 ± 1.3 L/session. This met the preset noninferiority criteria, suggesting that mixed-HDF was noninferior to predilution HDF. Moreover, the β2-microglobulin reduction rate was greater in the mixed-HDF group than in the predilution HDF group, while mixed-HDF provided greater transmembrane pressure. There were no significant between-group differences in Kt/V urea levels, changes in predialysis hs-CRP levels, proportions of overhydration, or blood pressure values. Symptomatic intradialytic hypotension episodes and other adverse events occurred similarly in the two groups. Conclusion Use of mixed-HDF was comparable to predilution HDF in terms of delivered convection volume and clinical parameters. Moreover, mixed-HDF provided better β2-microglobulin clearance than predilution HDF.",2021,"There were no significant between-group differences in Kt/V urea levels, changes in predialysis hs-CRP levels, proportions of overhydration, or blood pressure values.","['Between January 2017 and September 2019, 60 patients who underwent chronic hemodialysis', 'two hemodialysis centers in Korea', 'hemodialysis patients']","['newly developed mixed-dilution hemodiafiltration (HDF', 'mixed-HDF', 'Mixed versus predilution hemodiafiltration', 'predilution HDF (n = 30) or mixed-HDF']","['transmembrane pressure', 'Kt/V urea levels, changes in predialysis hs-CRP levels, proportions of overhydration, or blood pressure values', 'adverse events', 'β2-microglobulin reduction rate', 'Symptomatic intradialytic hypotension episodes', 'β2-microglobulin clearance', 'effective convection volume', 'convection volume and small and middle molecule clearance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1740835', 'cui_str': 'Chronic haemodialysis'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022771', 'cui_str': 'Korea'}]","[{'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0079240', 'cui_str': 'Dilution'}, {'cui': 'C0206075', 'cui_str': 'Hemodiafiltration'}]","[{'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0429662', 'cui_str': 'kt/V'}, {'cui': 'C0428275', 'cui_str': 'Urea level - finding'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0392689', 'cui_str': 'Overhydration'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0242689', 'cui_str': 'Convection'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0567416', 'cui_str': 'Molecule'}]",,0.0637733,"There were no significant between-group differences in Kt/V urea levels, changes in predialysis hs-CRP levels, proportions of overhydration, or blood pressure values.","[{'ForeName': 'Kyoung Sook', 'Initials': 'KS', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.'}, {'ForeName': 'Ea Wha', 'Initials': 'EW', 'LastName': 'Kang', 'Affiliation': 'Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.'}, {'ForeName': 'Tae Ik', 'Initials': 'TI', 'LastName': 'Chang', 'Affiliation': 'Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.'}, {'ForeName': 'Wonji', 'Initials': 'W', 'LastName': 'Jo', 'Affiliation': 'Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jung Tak', 'Initials': 'JT', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Tae-Hyun', 'Initials': 'TH', 'LastName': 'Yoo', 'Affiliation': 'Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Shin-Wook', 'Initials': 'SW', 'LastName': 'Kang', 'Affiliation': 'Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Seung Hyeok', 'Initials': 'SH', 'LastName': 'Han', 'Affiliation': 'Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea.'}]",Kidney research and clinical practice,['10.23876/j.krcp.21.044'] 2458,34370916,"A randomized, controlled comparison of a stannous-containing dentifrice for reducing gingival bleeding and balancing the oral microbiome relative to a positive control.","PURPOSE To evaluate the effect of a stannous-containing fluoride dentifrice on gingival health and on the composition of the oral microbiome versus a positive control dentifrice over 2 weeks, in a population of healthy adults with self-reported sub-optimal oral health at baseline. METHODS This was a randomized, controlled, double-blind clinical study. 87 subjects with self-reported sub-optimal oral health at enrollment were randomized to brush twice daily with either an experimental dentifrice (n= 43) or a marketed positive control dentifrice (n= 43), both containing stannous chloride and 0.321% sodium fluoride. All subjects used a soft, manual toothbrush that was provided. The Mazza modification of gingival papillary bleeding Index (Mazza GI) was used to assess gingivitis at baseline and at Week 2. Supragingival plaque was collected for microbiome composition analyses at baseline, Week 1, and Week 2. RESULTS 83 subjects completed the study. Baseline means were balanced between the treatment groups (P> 0.34). At Week 2, the positive control dentifrice demonstrated a 63.8% statistically significant (P< 0.0001) reduction relative to baseline for Mazza number of gingival bleeding sites. The experimental stannous containing dentifrice provided a comparable 63.5% gingival bleeding reduction versus baseline. There was no significant (P= 0.96) difference between the two dentifrices for either Mazza GI score or number of bleeding sites measured. The microbiome composition analysis at Week 1 found that 28 gingivitis-associated bacterial genera, including Porphyromonas, Tannerella, and Fusobacterium, were significantly inhibited in both dentifrice groups when compared to baseline, while the relative abundance of genera associated with oral health, such as Rothia, Streptococcus, Haemophilus, and Lautropia, was significantly elevated after treatment. These improvements in the oral ecosystem were sustained at Week 2. CLINICAL SIGNIFICANCE An experimental stannous-containing sodium fluoride dentifrice significantly reduced gingival bleeding comparable to a positive control, and both dentifrices promoted a shift in the oral microbiome towards those genera associated with oral health in a subject population with self-reported sub-optimal oral health at baseline.",2021,"At Week 2, the positive control dentifrice demonstrated a 63.8% statistically significant (P< 0.0001) reduction relative to baseline for Mazza number of gingival bleeding sites.","['healthy adults with self-reported sub-optimal oral health at baseline', '83 subjects completed the study', '87 subjects with self-reported sub-optimal oral health at enrollment']","['experimental dentifrice (n= 43) or a marketed positive control dentifrice (n= 43), both containing stannous chloride and 0.321% sodium fluoride', 'stannous-containing fluoride dentifrice', 'stannous containing dentifrice', 'positive control dentifrice', 'stannous-containing sodium fluoride dentifrice', 'stannous-containing dentifrice']","['bacterial genera, including Porphyromonas, Tannerella, and Fusobacterium', 'Mazza number of gingival bleeding sites', 'gingival bleeding', 'Mazza GI score or number of bleeding sites', 'Supragingival plaque', 'Mazza modification of gingival papillary bleeding Index (Mazza GI', 'gingival bleeding reduction']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}]","[{'cui': 'C0011427', 'cui_str': 'Dentifrice'}, {'cui': 'C1318228', 'cui_str': 'Market'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0075160', 'cui_str': 'stannous chloride'}, {'cui': 'C0037508', 'cui_str': 'Sodium Fluoride'}, {'cui': 'C0016327', 'cui_str': 'Fluoride'}]","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1217351', 'cui_str': 'Tannerella'}, {'cui': 'C0016878', 'cui_str': 'Fusobacterium'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0017565', 'cui_str': 'Bleeding gums'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0399452', 'cui_str': 'Supragingival dental plaque'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0205312', 'cui_str': 'Papillary'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",87.0,0.188539,"At Week 2, the positive control dentifrice demonstrated a 63.8% statistically significant (P< 0.0001) reduction relative to baseline for Mazza number of gingival bleeding sites.","[{'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'He', 'Affiliation': 'The Procter & Gamble Company, Mason, Ohio, USA, he.t@pg.com.'}, {'ForeName': 'Shi', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'Qingdao Institute of BioEnergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Yue', 'Affiliation': 'Procter & Gamble Technology Beijing Company Ltd., Beijing, China.'}, {'ForeName': 'Lijiang', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Procter & Gamble Technology Beijing Company Ltd., Beijing, China.'}, {'ForeName': 'Jiquan', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Procter & Gamble Singapore International Operations, Singapore.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Qingdao Institute of BioEnergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, China.'}]",American journal of dentistry,[] 2459,34370912,Influence of light irradiation for in-office tooth whitening: A randomized clinical study.,"PURPOSE To evaluate the influence of light irradiation on the clinical efficiency of an in-office whitening agent. METHODS The in-office whitening agent (Opalescence Boost 35%) was used in this study. Two whitening regimens were evaluated on maxillary anterior teeth: (1) with light irradiation; and (2) without light irradiation. The ΔE*, changes of L*, a*, b*, and the best shade match on the central incisor before, immediately after, and 6 months after whitening procedures were evaluated using a dental spectrophotometer. RESULTS The ΔE and shade had no significant differences with or without light irradiation. In addition, the ΔE, changes of L*, a*, b*, and shade did not change over 6 months after bleaching at a level detectable to the naked eye. The results suggested that the in-office whitening agent using 35% hydrogen peroxide without photocatalysts can improve tooth color with or without light irradiation for 6 months after whitening. CLINICAL SIGNIFICANCE In office whitening using 35% hydrogen peroxide without photocatalysts should be considered as a good treatment option for vital teeth whitening.",2021,The ΔE and shade had no significant differences with or without light irradiation.,['The in-office whitening agent'],"['light irradiation; and (2) without light irradiation', 'light irradiation']",[],"[{'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C2936259', 'cui_str': 'Whitening Agents'}]","[{'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}]",[],,0.0208067,The ΔE and shade had no significant differences with or without light irradiation.,"[{'ForeName': 'Akimasa', 'Initials': 'A', 'LastName': 'Tsujimoto', 'Affiliation': 'Department of Operative Dentistry, University of Iowa College of Dentistry, Iowa City, Iowa, USA, akimasa-tsujimoto@uiowa.edu.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Jurado', 'Affiliation': 'Texas Tech University Health Sciences Center El Paso Woody L. Hunt School of Dental Medicine, El Paso, Texas, USA.'}, {'ForeName': 'Mohammed E', 'Initials': 'ME', 'LastName': 'Sayed', 'Affiliation': 'Department of Prosthetic Dental Sciences, College of Dentistry, Jazan University, Jazan, Kingdom of Saudi Arabia.'}, {'ForeName': 'Nicholas G', 'Initials': 'NG', 'LastName': 'Fischer', 'Affiliation': 'University of Minnesota School of Dentistry, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Toshiki', 'Initials': 'T', 'LastName': 'Takamizawa', 'Affiliation': 'Department of Operative Dentistry, Nihon University School of Dentistry, Tokyo, Japan.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Latta', 'Affiliation': 'Department of General Dentistry, Creighton University School of Dentistry, Omaha, Nebraska, USA.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Miyazaki', 'Affiliation': 'Department of Operative Dentistry, Nihon University School of Dentistry, Tokyo, Japan.'}, {'ForeName': 'Franklin', 'Initials': 'F', 'LastName': 'Garcia-Godoy', 'Affiliation': 'Department of Bioscience Research, College of Dentistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA.'}]",American journal of dentistry,[] 2460,34370911,"A randomized, blinded, clinical investigation of breath odor reduction efficacy of a stabilized chlorine-dioxide containing flavored mouthwash.","PURPOSE To evaluate the efficacy of a flavored, non-fluoridated, alcohol-free mouthwash containing 0.1% chlorine dioxide in reducing oral malodor. METHODS This was a randomized, 8-week, single site, double blind, crossover design with a 2-week washout period between crossover phases. Fifty subjects with clinically diagnosed intrinsic oral malodor were enrolled according to inclusion/exclusion criteria and randomized to one of two groups. Washout period initiated at end of Phase I and crossover design implemented prior to Phase II. Calibration for organoleptic judges performed at baseline for both phases. RESULTS 48 subjects completed the study. No significant differences in intensity scores at baseline were found for both groups during both phases (P> 0.05). Within group comparisons for placebo revealed no significant differences with organoleptic intensity scores for all visits during both phases (P> 0.05). During Phase I, the mean changes in organoleptic scores for the test group were significantly different from the baseline at each visit: Weeks 1 to 3 (P< 0.05). After crossover, significant differences were found for the last two visits: Weeks 7 and 8 (P< 0.05). No adverse effects to oral tissues were observed or reported. This product is safe to use for up to 3 weeks and resulted in a decrease in oral malodor. CLINICAL SIGNIFICANCE Results suggested that twice-daily use of a 0.1% chlorine dioxide-containing flavored mouthwash, in conjunction with normal oral hygiene care, provided clinically relevant improvements in oral malodor for up to 3 weeks.",2021,No significant differences in intensity scores at baseline were found for both groups during both phases (P> 0.05).,"['Fifty subjects with clinically diagnosed intrinsic oral malodor', '48 subjects completed the study']","['flavored, non-fluoridated, alcohol-free mouthwash containing 0.1% chlorine dioxide', 'chlorine dioxide-containing flavored mouthwash', 'placebo', 'stabilized chlorine-dioxide containing flavored mouthwash']","['mean changes in organoleptic scores', 'organoleptic intensity scores', 'intensity scores']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0682897', 'cui_str': 'Flavor Enhancers'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0026647', 'cui_str': 'Oromucosal solution for gargle'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0055370', 'cui_str': 'chlorine dioxide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0184512', 'cui_str': 'Stabilized'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",50.0,0.188749,No significant differences in intensity scores at baseline were found for both groups during both phases (P> 0.05).,"[{'ForeName': 'Sean S', 'Initials': 'SS', 'LastName': 'Lee', 'Affiliation': 'Center for Dental Research, Loma Linda University School of Dentistry, Loma Linda, California, USA.'}, {'ForeName': 'Montry S', 'Initials': 'MS', 'LastName': 'Suprono', 'Affiliation': 'Center for Dental Research, Loma Linda University School of Dentistry, Loma Linda, California, USA, msuprono@llu.edu.'}, {'ForeName': 'Jonelle', 'Initials': 'J', 'LastName': 'Stephens', 'Affiliation': 'Center for Dental Research, Loma Linda University School of Dentistry, Loma Linda, California, USA.'}, {'ForeName': 'Shelly A', 'Initials': 'SA', 'LastName': 'Withers', 'Affiliation': 'Center for Dental Research, Loma Linda University School of Dentistry, Loma Linda, California, USA.'}, {'ForeName': 'Udochukwu', 'Initials': 'U', 'LastName': 'Oyoyo', 'Affiliation': 'Educational Support Services, Loma Linda University School of Dentistry, Loma Linda, California, USA.'}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Center for Dental Research, Loma Linda University School of Dentistry, Loma Linda, California, USA.'}]",American journal of dentistry,[] 2461,34370858,The ultra-long study: a randomized controlled trial evaluating long-term GnRH downregulation prior to ART in women with endometriosis.,"STUDY QUESTION Does ultra-long downregulation with a GnRH agonist (triptorelin depot) in previously operated patients with endometriosis improve the rate of clinical pregnancy with positive fetal heart beat (CPHB) in the subsequent initiated fresh ART cycle? SUMMARY ANSWER Ultra-long downregulation with a GnRH agonist prior to ART did not improve the rate of CPHB in the subsequent fresh ART cycle in previously completely operated patients but the trial was underpowered due to early termination. WHAT IS KNOWN ALREADY Administration of GnRH agonists for a period of 3-6 months prior to ART in women with endometriosis may increase the odds of clinical pregnancy. However, the quality of the studies on which this statement is based is questionable, so these findings need confirmation. STUDY DESIGN, SIZE, DURATION A controlled, randomized, open label trial was performed between 1 June 2013 and 31 December 2016 (start and end of recruitment, respectively). Patients with prior complete laparoscopic treatment of any type or stage of endometriosis and an indication for ART were randomized (by a computer-generated allocation sequence) into two groups: the control group underwent ART stimulation in a classical long agonist protocol using preparation with oral contraceptives, the ultra-long group first underwent at least 3 months downregulation followed by a long agonist protocol for ART stimulation. The sample size was calculated to detect a superiority of the ultra-long downregulation protocol, based on the hypothesis that baseline CPHB rate in the control group of 20% would increase to 40% in the ultra-long group. For a power of 20% at a significance level of 5%, based on two-sided testing, including 5% of patients lost to follow-up, the necessary sample size was 172 patients (86 per group). PARTICIPANTS/MATERIALS, SETTING, METHODS This trial was conducted at the Leuven University Fertility Center, a tertiary care center for endometriosis and infertility, and a total of 42 patients were randomized (21 in the control group and 21 in the ultra-long group). MAIN RESULTS AND THE ROLE OF CHANCE Baseline characteristics were similar in both groups. The primary outcome studied-CPHB after the initiated ART treatment-did not differ and was 25% (5/20) in the control group, and 20% (4/20) in the ultra-long group (P > 0.999; relative risk (RR) 1.25, 95% CI 0.41-3.88). Cumulative (fresh + associated frozen) CPHB rates were also similar in the control versus ultra-long group (8/20, 40% vs 6/20, 30%, P = 0.7411; RR = 1.33, 95% CI 0.57-3.19). When other secondary outcomes were compared with the ultra-long group, patients from the control group had a shorter duration of stimulation (mean 11.8 days (SD ± 2.4) versus 13.2 days (SD ± 1.5), P = 0.0373), a lower total dose of gonadotrophins used (mean 1793 IU/d (SD ± 787) vs 2329 (SD ± 680), P = 0.0154), and a higher serum estradiol concentration (ng/ml) at the end of ovarian stimulation on the day of ovulation triggering or cycle cancellation (mean1971 (SD ± 1495) vs 929 (± 548); P = 0.0326), suggesting a better ovarian response in the control group. LIMITATIONS, REASONS FOR CAUTION Due to a strong patient preference, nearly exclusively against ultra-long downregulation (even though patients were thoroughly informed of the potential benefits), the targeted sample size could not be achieved and the trial was stopped prematurely. WIDER IMPLICATIONS OF THE FINDINGS Conditional power analysis revealed that the probability of confirming the study hypothesis if the study were completed would be low. We hypothesize that in patients with prior complete surgical treatment of endometriosis, the ultra-long protocol does not enhance ART-CPHB rates. Patient's concerns and preferences regarding possible side-effects, and delay of ART treatment start with the ultra-long protocol should be taken into account when considering this type of treatment in women with endometriosis. STUDY FUNDING/COMPETING INTEREST(S) C.T. was during 2 years funded by a grant from the Clinical research Foundation of UZ Leuven (KOF) and during 2 years by the Research Foundation-Flanders (FWO grant number: 1700816N). C.T. reports grants from Clinical Research Foundation of the University Hospitals of Leuven (KOF), grants from Fund for Scientific Research Flanders (FWO), during the conduct of the study; grants, non-financial support and other from Merck SA, non-financial support and other from Gedeon Richter, non-financial support from Ferring Pharmaceuticals, outside the submitted work. T.D. is vice president and head of Global Medical Affairs Fertility, Research and Development, Merck KGaA, Darmstadt, Germany. He is also a professor in Reproductive Medicine and Biology at the Department of Development and Regeneration, Group Biomedical Sciences, KU Leuven (University of Leuven), Belgium and an adjunct professor at the Department of Obstetrics and Gynecology in the University of Yale, New Haven, USA. Neither his corporate role nor his academic roles represent a conflict of interest with respect to the work done by him for this study. A.C. reports personal fees from Merck S.p.A., outside the submitted work. The other co-authors have no conflict of interest. TRIAL REGISTRATION NUMBER UZ Leuven trial registry SS55300, EudraCT number 2013-000993-32, clinicaltrials.gov NCT02400801. TRIAL REGISTRATION DATE Registration for EudraCT on 1 March 2013. DATE OF FIRST PATIENT’S ENROLMENT 4 September 2013.",2021,"Cumulative (fresh + associated frozen) CPHB rates were also similar in the control versus ultra-long group (8/20, 40% vs 6/20, 30%, P = 0.7411; RR = 1.33, 95% CI 0.57-3.19).","['women with endometriosis', 'previously operated patients with endometriosis', '1 June 2013 and 31 December 2016 (start and end of recruitment, respectively', 'This trial was conducted at the Leuven University Fertility Center, a tertiary care center for endometriosis and infertility, and a total of 42 patients were randomized (21 in the control group and 21 in the ultra-long group', 'patients with prior complete surgical treatment of endometriosis', 'Patients with prior complete laparoscopic treatment of any type or stage of endometriosis and an indication for ART']","['GnRH downregulation prior to ART', 'GnRH agonist (triptorelin depot', 'GnRH agonists', 'control group underwent ART stimulation in a classical long agonist protocol using preparation with oral contraceptives, the ultra-long group first underwent at least 3\u2009months downregulation followed by a long agonist protocol for ART stimulation']","['CPHB', 'serum estradiol concentration', 'Cumulative (fresh + associated frozen) CPHB rates', 'baseline CPHB rate', 'rate of CPHB', 'ovarian response', 'shorter duration of stimulation']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0003826', 'cui_str': 'Arts'}]","[{'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C0013081', 'cui_str': 'Down-regulation'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0077275', 'cui_str': 'Triptorelin'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0015935', 'cui_str': 'Fetal Heart'}, {'cui': 'C0474672', 'cui_str': 'Serum estradiol measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439593', 'cui_str': 'Short duration'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]",42.0,0.272614,"Cumulative (fresh + associated frozen) CPHB rates were also similar in the control versus ultra-long group (8/20, 40% vs 6/20, 30%, P = 0.7411; RR = 1.33, 95% CI 0.57-3.19).","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Tomassetti', 'Affiliation': 'Department of Obstetrics and Gynaecology, Leuven University Fertility Center, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Beukeleirs', 'Affiliation': 'Department of Obstetrics and Gynaecology, Leuven University Fertility Center, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Conforti', 'Affiliation': ""Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples 'Federico II', Naples, Italy.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Debrock', 'Affiliation': 'Department of Obstetrics and Gynaecology, Leuven University Fertility Center, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Peeraer', 'Affiliation': 'Department of Obstetrics and Gynaecology, Leuven University Fertility Center, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Meuleman', 'Affiliation': 'Department of Obstetrics and Gynaecology, Leuven University Fertility Center, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': ""D'Hooghe"", 'Affiliation': 'Department of Development and Regeneration, KU Leuven, Leuven, Belgium.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/deab163'] 2462,32306083,Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA).,"BACKGROUND Single-session high-dose stereotactic radiotherapy (radiosurgery) is a new treatment option for otherwise untreatable patients suffering from refractory ventricular tachycardia (VT). In the initial single-center case studies and feasibility trials, cardiac radiosurgery has led to significant reductions of VT burden with limited toxicities. However, the full safety profile remains largely unknown. METHODS/DESIGN In this multi-center, multi-platform clinical feasibility trial which we plan is to assess the initial safety profile of radiosurgery for ventricular tachycardia (RAVENTA). High-precision image-guided single-session radiosurgery with 25 Gy will be delivered to the VT substrate determined by high-definition endocardial electrophysiological mapping. The primary endpoint is safety in terms of successful dose delivery without severe treatment-related side effects in the first 30 days after radiosurgery. Secondary endpoints are the assessment of VT burden, reduction of implantable cardioverter defibrillator (ICD) interventions [shock, anti-tachycardia pacing (ATP)], mid-term side effects and quality-of-life (QoL) in the first year after radiosurgery. The planned sample size is 20 patients with the goal of demonstrating safety and feasibility of cardiac radiosurgery in ≥ 70% of the patients. Quality assurance is provided by initial contouring and planning benchmark studies, joint multi-center treatment decisions, sequential patient safety evaluations, interim analyses, independent monitoring, and a dedicated data and safety monitoring board. DISCUSSION RAVENTA will be the first study to provide the initial robust multi-center multi-platform prospective data on the therapeutic value of cardiac radiosurgery for ventricular tachycardia. TRIAL REGISTRATION NUMBER NCT03867747 (clinicaltrials.gov). Registered March 8, 2019. The study was initiated on November 18th, 2019, and is currently recruiting patients.",2020,The primary endpoint is safety in terms of successful dose delivery without severe treatment-related side effects in the first 30 days after radiosurgery.,"['otherwise untreatable patients suffering from refractory ventricular tachycardia (VT', '20 patients with the goal of demonstrating safety and feasibility of cardiac radiosurgery in\u2009≥\u200970% of the patients']",['stereotactic radiotherapy (radiosurgery'],"['assessment of VT burden, reduction of implantable cardioverter defibrillator (ICD) interventions [shock, anti-tachycardia pacing (ATP)], mid-term side effects and quality-of-life (QoL', 'successful dose delivery without severe treatment-related side effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0042514', 'cui_str': 'Ventricular tachycardia'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0085203', 'cui_str': 'Radiosurgery'}]","[{'cui': 'C3846112', 'cui_str': 'Stereotactic radiosurgery'}, {'cui': 'C0085203', 'cui_str': 'Radiosurgery'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0042514', 'cui_str': 'Ventricular tachycardia'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0162589', 'cui_str': 'Implantable defibrillator'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.155679,The primary endpoint is safety in terms of successful dose delivery without severe treatment-related side effects in the first 30 days after radiosurgery.,"[{'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Blanck', 'Affiliation': 'Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 50, 24105, Kiel, Germany. oliver.blanck@uksh.de.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Buergy', 'Affiliation': 'Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Universität Heidelberg, Medizinische Fakultät Mannheim, Mannheim, Germany.'}, {'ForeName': 'Maren', 'Initials': 'M', 'LastName': 'Vens', 'Affiliation': 'Universität zu Lübeck, Zentrum für Klinische Studien, Lübeck, Germany.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Eidinger', 'Affiliation': 'Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 50, 24105, Kiel, Germany.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Zaman', 'Affiliation': 'Klinik für Innere Medizin III, Abteilung für Elektrophysiologie und Rhythmologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Krug', 'Affiliation': 'Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 50, 24105, Kiel, Germany.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Rudic', 'Affiliation': 'Medizinische Klinik I, Abteilung für Elektrophysiologie und Rhythmologie, Universitätsmedizin Mannheim, Universität Heidelberg, Medizinische Fakultät Mannheim, Mannheim, Germany.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Boda-Heggemann', 'Affiliation': 'Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Universität Heidelberg, Medizinische Fakultät Mannheim, Mannheim, Germany.'}, {'ForeName': 'Frank A', 'Initials': 'FA', 'LastName': 'Giordano', 'Affiliation': 'Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Universität Heidelberg, Medizinische Fakultät Mannheim, Mannheim, Germany.'}, {'ForeName': 'Leif-Hendrik', 'Initials': 'LH', 'LastName': 'Boldt', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie (CVK), Abteilung für Elektrophysiologie und Rhythmologie, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Mehrhof', 'Affiliation': 'Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Budach', 'Affiliation': 'Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Achim', 'Initials': 'A', 'LastName': 'Schweikard', 'Affiliation': 'Institut für Robotik und Kognitive Systeme, Universität zu Lübeck, Lübeck, Germany.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Olbrich', 'Affiliation': 'Universität zu Lübeck, Zentrum für Klinische Studien, Lübeck, Germany.'}, {'ForeName': 'Inke R', 'Initials': 'IR', 'LastName': 'König', 'Affiliation': 'Institut für Medizinische Biometrie und Statistik, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Frank-Andre', 'Initials': 'FA', 'LastName': 'Siebert', 'Affiliation': 'Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 50, 24105, Kiel, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Vonthein', 'Affiliation': 'Institut für Medizinische Biometrie und Statistik, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Dunst', 'Affiliation': 'Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 50, 24105, Kiel, Germany.'}, {'ForeName': 'Hendrik', 'Initials': 'H', 'LastName': 'Bonnemeier', 'Affiliation': 'Klinik für Innere Medizin III, Abteilung für Elektrophysiologie und Rhythmologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.'}]",Clinical research in cardiology : official journal of the German Cardiac Society,['10.1007/s00392-020-01650-9'] 2463,32421229,The effect of glaucoma treatment using high-intensity focused ultrasound on total and corneal astigmatism: a prospective multicentre study.,"PURPOSE Ultrasound cycloplasty (UCP) acts through the selective coagulation of the ciliary body using high-intensity focused ultrasound (HIFU) technology. The aim of this study was to investigate whether the application of ultrasound beams targeting the ciliary body using an external probe influences astigmatism. METHODS Multicentre, prospective, single-arm, open-label study in adult patients with primary open-angle glaucoma and moderately uncontrolled intraocular pressure (IOP) under glaucoma medication. The primary outcome was induced corneal astigmatism, calculated from topography, and assessed statistically through vector analysis. Secondary outcomes included induced total astigmatism and mean changes from baseline in best-corrected visual acuity (logMAR) and IOP. Subgroup analysis was performed to assess the impact of device centring on corneal and total induced astigmatism. RESULTS Fifty eyes were enrolled. Mean age was 69.6 ± 11.3 years. At 1, 3 and 6 months postprocedure, HIFU-induced corneal astigmatism was 0.88 D × 93°, 0.87 D × 106° and 1.16 D × 97°, respectively, while induced total astigmatism was 0.62 D × 103°, 0.42 × 106° and 0.39 × 107°. By the last follow-up, the percentage of patients with <0.50, <1.00, <1.50 and <2.00 D of induced corneal versus total astigmatism was 8.3% versus 46%, 29% versus 66%, 62.5% versus 88% and 79% versus 94%. Visual acuity was statistically significantly impaired at 1 month, but no difference remained by 3 and 6 months postprocedure. CONCLUSION Ultrasound cycloplasty procedure is associated with increased corneal astigmatism. However, its impact on total refractive astigmatism is less pronounced.",2020,"At 1, 3 and 6 months postprocedure, HIFU-induced corneal astigmatism was 0.88 D ","['Fifty eyes were enrolled', '93°, 0.87', '103°, 0.42', '106° and 0.39', '106° and 1.16\xa0D', 'adult patients with primary open-angle glaucoma and moderately uncontrolled intraocular pressure (IOP) under glaucoma medication', 'Mean age was 69.6\xa0±\xa011.3\xa0years']","['glaucoma treatment', 'Ultrasound cycloplasty (UCP']","['induced corneal astigmatism, calculated from topography, and assessed statistically through vector analysis', 'Visual acuity', 'corneal astigmatism', 'total refractive astigmatism', 'induced total astigmatism and mean changes from baseline in best-corrected visual acuity (logMAR) and IOP']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C4517458', 'cui_str': '0.42'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0339573', 'cui_str': 'Primary open angle glaucoma'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1515995', 'cui_str': 'Antiglaucoma agent'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0339682', 'cui_str': 'Regular astigmatism - corneal'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0004106', 'cui_str': 'Astigmatism'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}]",50.0,0.0469724,"At 1, 3 and 6 months postprocedure, HIFU-induced corneal astigmatism was 0.88 D ","[{'ForeName': 'Raquel Esteves', 'Initials': 'RE', 'LastName': 'Marques', 'Affiliation': 'Department of Ophthalmology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal.'}, {'ForeName': 'David Cordeiro', 'Initials': 'DC', 'LastName': 'Sousa', 'Affiliation': 'Department of Ophthalmology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal.'}, {'ForeName': 'Evelien', 'Initials': 'E', 'LastName': 'Vandewalle', 'Affiliation': 'Department of Neurosciences, Research Group of Ophthalmology, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Alix', 'Initials': 'A', 'LastName': 'Somers', 'Affiliation': 'Department of Neurosciences, Research Group of Ophthalmology, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Shlomo', 'Initials': 'S', 'LastName': 'Melamed', 'Affiliation': 'The Sam Rothberg Glaucoma Centre, Goldschleger Eye Institute, Sheba Medical Centre, Tel-Aviv University, Tel-Hashomer, Israel.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Nardi', 'Affiliation': 'Department of Surgical, Medical, Molecular Pathology and of Critical Area, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Figus', 'Affiliation': 'Department of Surgical, Medical, Molecular Pathology and of Critical Area, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Ingeborg', 'Initials': 'I', 'LastName': 'Stalmans', 'Affiliation': 'Department of Neurosciences, Research Group of Ophthalmology, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Abegao Pinto', 'Affiliation': 'Department of Ophthalmology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal.'}]",Acta ophthalmologica,['10.1111/aos.14467'] 2464,32439227,"Region-specific effects of acute haloperidol in the human midbrain, striatum and cortex.","D2 autoreceptors provide an important regulatory mechanism of dopaminergic neurotransmission. However, D2 receptors are also expressed as heteroreceptors at postsynaptic membranes. The expression and the functional characteristics of both, D2 auto- and heteroreceptors, differ between brain regions. Therefore, one would expect that also the net response to a D2 antagonist, i.e. whether and to what degree overall neural activity increases or decreases, varies across brain areas. In the current study we systematically tested this hypothesis by parametrically increasing haloperidol levels (placebo, 2 and 3 mg) in healthy volunteers and measuring brain activity in the three major dopaminergic pathways. In particular, activity was assessed using fMRI while participants performed a working memory and a reinforcement learning task. Consistent with the hypothesis, across brain regions activity parametrically in- and decreased. Moreover, even within the same area there were function-specific concurrent de- and increases of activity, likely caused by input from upstream dopaminergic regions. In the ventral striatum, for instance, activity during reinforcement learning decreased for outcome processing while prediction error related activity increased. In conclusion, the current study highlights the intricacy of D2 neurotransmission which makes it difficult to predict the function-specific net response of a given area to pharmacological manipulations.",2020,"Consistent with the hypothesis, across brain regions activity parametrically in- and decreased.",['healthy volunteers'],"['haloperidol levels (placebo', 'acute haloperidol']",['brain activity'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0919241', 'cui_str': 'Haloperidol measurement'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0018546', 'cui_str': 'Haloperidol'}]","[{'cui': 'C0443158', 'cui_str': 'Brain activity'}]",,0.0595107,"Consistent with the hypothesis, across brain regions activity parametrically in- and decreased.","[{'ForeName': 'Christian Ole', 'Initials': 'CO', 'LastName': 'Wächtler', 'Affiliation': 'Institute of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Karima', 'Initials': 'K', 'LastName': 'Chakroun', 'Affiliation': 'Institute of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Mareike', 'Initials': 'M', 'LastName': 'Clos', 'Affiliation': 'Institute of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Bayer', 'Affiliation': 'Institute of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Hennies', 'Affiliation': 'Institute of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Jean Martin', 'Initials': 'JM', 'LastName': 'Beaulieu', 'Affiliation': 'Department of Pharmacology and Toxicology, Faculty of medicine, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Sommer', 'Affiliation': 'Institute of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: tsommer@uke.de.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2020.04.008'] 2465,32583541,A blackberry-dill extract combination synergistically increases skin elasticity.,"BACKGROUND The loss of structural elastin due to intrinsic and extrinsic ageing results in the skin's inability to stretch and recoil (decrease in elasticity) and manifests as loss of skin firmness and sagging. While other extracellular matrix (ECM) components such as collagen and hyaluronic acid are continually synthesized and assembled through life, elastic fibres are not. Elastic fibre assembly and functionality require fibre cross-linking, induced by the lysyl oxidase-like (LOXL) enzymes, which sharply decrease during ageing. OBJECTIVE To evaluate the enhanced elastogenic effect of a blackberry-dill extract combination, which was hypothesized to induce elastin fibre component synthesis, fibre cross-linking and reduce elastin fibre degradation. METHODS The blackberry and the dill extracts were tested separately and in combination to confirm single ingredient bioactivity and synergistic benefits. Human skin explants, dermal fibroblasts, elastase assays, ELISAs, quantitative real-time PCRs and spectrofluorometer measurements were used. Moreover, a double-blinded, placebo-controlled clinical study was carried out to assess skin elasticity using Cutometer and histologically from biopsies. RESULTS The blackberry extract induced elastin gene expression, elastin promoter activity and inhibited elastic fibre degradation by matrix metalloproteinases (MMPs) 9 and 12. The dill extract induced elastin, collagen and LOXL1 gene expression, resulting in enhanced fibre cross-linking in human skin explants. Clinically, the blackberry and dill combination treatment displayed synergistic pro-elasticity activity as compared to each ingredient alone and placebo. CONCLUSION Taken together, these results demonstrated the two multimodal plant-based extracts complemented each other in terms of bioactivity and resulted in a synergistic elastogenesis induction.",2020,"The blackberry extract induced elastin gene expression, elastin promoter activity and inhibited elastic fibre degradation by matrix metalloproteinases (MMPs) 9 and 12.",[],"['blackberry-dill extract combination', 'placebo']","['Human skin explants, dermal fibroblasts, elastase assays, ELISAs, quantitative real-time PCRs and spectrofluorometer measurements', 'synergistic pro-elasticity activity', 'skin elasticity']",[],"[{'cui': 'C0453270', 'cui_str': 'Blackberries'}, {'cui': 'C4722241', 'cui_str': 'dill extract'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C3859811', 'cui_str': 'human skin preparation'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0016030', 'cui_str': 'Fibroblast'}, {'cui': 'C0030306', 'cui_str': 'Pancreatic elastase'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0423761', 'cui_str': 'Skin elasticity'}]",,0.0654485,"The blackberry extract induced elastin gene expression, elastin promoter activity and inhibited elastic fibre degradation by matrix metalloproteinases (MMPs) 9 and 12.","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Meza', 'Affiliation': 'Johnson & Johnson Consumer Inc., Skillman, NJ, USA.'}, {'ForeName': 'W-H', 'Initials': 'WH', 'LastName': 'Li', 'Affiliation': 'Johnson & Johnson Consumer Inc., Skillman, NJ, USA.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Seo', 'Affiliation': 'Johnson & Johnson Consumer Inc., Skillman, NJ, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Parsa', 'Affiliation': 'Johnson & Johnson Consumer Inc., Skillman, NJ, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kaur', 'Affiliation': 'Johnson & Johnson Consumer Inc., Skillman, NJ, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kizoulis', 'Affiliation': 'Johnson & Johnson Consumer Inc., Skillman, NJ, USA.'}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Southall', 'Affiliation': 'Johnson & Johnson Consumer Inc., Skillman, NJ, USA.'}]",International journal of cosmetic science,['10.1111/ics.12644'] 2466,34176657,The development and use of an anatomy-based retraining program (MusAARP) to assess and treat focal hand dystonia in musicians-A pilot study.,"BACKGROUND Movement dysfunctions are commonly reported in musicians, and in extreme cases may result in a persisting loss of motor control. This condition, whereby motor control of the hand during previously highly trained movements on the instrument is lost, is termed focal hand dystonia. It is widely considered to be a consequence of prolonged repetitive daily practice, often in combination with exposure to a range of other risk factors. Current literature recommends retraining as a promising treatment intervention, although only scant scientific evidence exists on which components should be included in a retraining program, and how these may be best administered. METHODS A progressive muscle activation and movement exercise program was devised by one of the authors applying a series of anatomy-based off-instrument movement tasks. This series of fine motor control exercises, was used to both assess and retrain focal hand dystonia in a population of musicians. The standardized approach aimed to provide a systematic method of retraining musically relevant muscular synergies that could later be applied to the instrument, while still allowing individual modifications. Retraining sessions were mostly run online as a consequence of the coronavirus pandemic, although some early sessions were also able to be undertaken face to face. Both qualitative and quantitative measures were used in this case series to evaluate program efficacy, due to the typical heterogeneity of the focal hand dystonia participants. This included: blinded external neurological evaluation of video footage using the Tubiana grading system, written subjective feedback, exercise progressions, and performance outcomes. RESULTS Pilot testing of 4 patients indicated the utility of the program over approximately a 12- month time period. All subjects improved, 2 of whom have returned to pre-dystonia performance levels. These patients reported the importance of patience and persistence with daily exercise sessions in their recovery. CONCLUSION Using off-instrument playing-relevant exercises to enhance fine motor control and muscle activation can be effective in retraining focal hand dystonia, regardless of additional treatments or level of performance. They should be regularly practiced and progressed in order for effects to be best progressed to instrumental applications. Further research may elucidate whether there are optimal outcomes with single or particular combinations of treatment approaches.",2021,"This series of fine motor control exercises, was used to both assess and retrain focal hand dystonia in a population of musicians.",[],"['fine motor control exercises', 'movement exercise program', 'anatomy-based retraining program (MusAARP']",[],[],"[{'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]",[],,0.0100652,"This series of fine motor control exercises, was used to both assess and retrain focal hand dystonia in a population of musicians.","[{'ForeName': 'Bronwen', 'Initials': 'B', 'LastName': 'Ackermann', 'Affiliation': 'Institut für Musikphysiologie und Musiker-Medizin, Hochschule für Musik, Theater und Medien, Hannover, Germany; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, NSW, Australia. Electronic address: Bronwen.Ackermann@sydney.edu.au.'}, {'ForeName': 'Eckart', 'Initials': 'E', 'LastName': 'Altenmüller', 'Affiliation': 'Institut für Musikphysiologie und Musiker-Medizin, Hochschule für Musik, Theater und Medien, Hannover, Germany.'}]",Journal of hand therapy : official journal of the American Society of Hand Therapists,['10.1016/j.jht.2021.05.007'] 2467,34260955,Safety and efficacy of a 5-minute infusion versus the standard 30-minute infusion for antibiotics in an outpatient setting.,,2021,,[],[],['Safety and efficacy'],[],[],"[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0448274,,"[{'ForeName': 'Jolene Ee Ling', 'Initials': 'JEL', 'LastName': 'Oon', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, National University Hospital, 5, Lower Kent Ridge Road, Singapore, 119074; Yong Loo Lin School of Medicine, National University of Singapore, 10, Medical Drive, Singapore, 117597. Electronic address: jolene_oon@nuhs.edu.sg.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Salada', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, National University Hospital, 5, Lower Kent Ridge Road, Singapore, 119074. Electronic address: brenda_mae_alferez@nuhs.edu.sg.'}, {'ForeName': 'Yin Shan', 'Initials': 'YS', 'LastName': 'Lim', 'Affiliation': 'Department of Pharmacy, National University Hospital, 5, Lower Kent Ridge Road, Singapore, 119074. Electronic address: Yin_Shan_LIM@nuhs.edu.sg.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Archuleta', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, National University Hospital, 5, Lower Kent Ridge Road, Singapore, 119074; Yong Loo Lin School of Medicine, National University of Singapore, 10, Medical Drive, Singapore, 117597. Electronic address: mdcsa@nus.edu.sg.'}, {'ForeName': 'Dale', 'Initials': 'D', 'LastName': 'Fisher', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, National University Hospital, 5, Lower Kent Ridge Road, Singapore, 119074; Yong Loo Lin School of Medicine, National University of Singapore, 10, Medical Drive, Singapore, 117597. Electronic address: mdcfda@nus.edu.sg.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2021.07.018'] 2468,34378669,"Early recovery after surgery protocol in orthognathic surgery: a randomized, blind clinical study.","A randomized, blind and prospective clinical trial was conducted to compare two clinical rehabilitation protocols in patients submitted to orthognathic surgery, during the first 60 days after surgery. Pain, edema, mandibular movement, masticatory efficiency and quality of life were evaluated. Nineteen (19) patients were separated into control and experimental groups. The control group consisted of 10 patients followed by oral and maxillofacial surgeons and submitted to a rehabilitation protocol that involved active and passive mouth opening exercises. The experimental group had 9 patients and followed the surgeons' protocol, in addition to an Early Recovery After Surgery (ERAS) protocol performed by speech therapists, and involving specific motricity exercises and lymphatic drainage. The Student's t-test was applied to compare the results, and the Fisher's exact test of independence, to analyze the quality of life and the masticatory efficiency variables. The statistical significance was set at 5% (p < 0.05) for all the tests. The results showed that the ERAS protocol made a positive difference in pain perception in the first 14 days. However, it did not improve the other variables. Although many variables showed no significant difference, it was concluded that the surgeons can delegate patient rehabilitation to qualified professionals, so that they can optimize their postoperative clinical time.",2021,"Although many variables showed no significant difference, it was concluded that the surgeons can delegate patient rehabilitation to qualified professionals, so that they can optimize their postoperative clinical time.","['patients submitted to orthognathic surgery, during the first 60 days after surgery', 'orthognathic surgery', 'Nineteen (19) patients']",['oral and maxillofacial surgeons and submitted to a rehabilitation protocol that involved active and passive mouth opening exercises'],"['Pain, edema, mandibular movement, masticatory efficiency and quality of life', 'quality of life and the masticatory efficiency variables', 'pain perception']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0185624', 'cui_str': 'Orthognathic Surgery'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0450337', 'cui_str': '19'}]","[{'cui': 'C0260272', 'cui_str': 'Oral surgeon'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",,0.0653799,"Although many variables showed no significant difference, it was concluded that the surgeons can delegate patient rehabilitation to qualified professionals, so that they can optimize their postoperative clinical time.","[{'ForeName': 'Zilane Silva Barbosa de', 'Initials': 'ZSB', 'LastName': 'Oliveira', 'Affiliation': 'Universidade Potiguar - UnP, Department of Speech Therapy, Natal, RN, Brazil.'}, {'ForeName': 'Marcelo Leite Machado da', 'Initials': 'MLMD', 'LastName': 'Silveira', 'Affiliation': 'Universidade Federal do Rio Grande do Norte - UFRN, Departtment of Oral and Maxillofacial Surgery, Natal, RN, Brazil.'}, {'ForeName': 'Petrus Pereira', 'Initials': 'PP', 'LastName': 'Gomes', 'Affiliation': 'Universidade Federal do Rio Grande do Norte - UFRN, Departtment of Oral and Maxillofacial Surgery, Natal, RN, Brazil.'}, {'ForeName': 'José Sandro Pereira da', 'Initials': 'JSPD', 'LastName': 'Silva', 'Affiliation': 'Universidade Federal do Rio Grande do Norte - UFRN, Departtment of Oral and Maxillofacial Surgery, Natal, RN, Brazil.'}, {'ForeName': 'Adriano Rocha', 'Initials': 'AR', 'LastName': 'Germano', 'Affiliation': 'Universidade Federal do Rio Grande do Norte - UFRN, Departtment of Oral and Maxillofacial Surgery, Natal, RN, Brazil.'}]",Brazilian oral research,['10.1590/1807-3107bor-2021.vol35.0087'] 2469,34370769,"Perceived food palatability, blood glucose level and future discounting: Lack of evidence for blood glucose level's impact on reward discounting.","Some previous studies have shown that an increase in blood glucose level makes people more future oriented, however, results are inconsistent, other studies failing to replicate this effect. Here, we tested whether psychological factors (in this instance, perception of food pleasantness after consumption of more palatable or less palatable meal) can play a moderating role. We hypothesized that consuming more palatable food (perceived as rewarding) should cause blood glucose levels to affect future discounting, but that this should not occur for the consumption of less palatable food. A high-powered, independent groups experiment (N = 149, power β = .90) showed that, subsequent to performing an initial discounting task, the two groups consuming a meal (a control group consumed no meal) displayed a significant increase in blood glucose levels 10 minutes after meal consumption and just before repeating the discounting task. However, the increased blood glucose levels did not cause changes in delay discounting in either experimental group.",2021,"However, the increased blood glucose levels did not cause changes in delay discounting in either experimental group.",[],[],"['blood glucose levels', 'blood glucose level', 'Perceived food palatability, blood glucose level']",[],[],"[{'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0016452', 'cui_str': 'Foods'}]",,0.0394997,"However, the increased blood glucose levels did not cause changes in delay discounting in either experimental group.","[{'ForeName': 'Rafał', 'Initials': 'R', 'LastName': 'Muda', 'Affiliation': 'Faculty of Economics, Maria Curie-Sklodowska University, Lublin, Poland.'}, {'ForeName': 'Przemysław', 'Initials': 'P', 'LastName': 'Sawicki', 'Affiliation': 'Centre for Economic Psychology and Decision Sciences, Kozminski University, Warsaw, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Ginszt', 'Affiliation': 'Department of Rehabilitation and Physiotherapy, Medical University of Lublin, Lublin, Poland.'}]",PloS one,['10.1371/journal.pone.0255484'] 2470,34370760,"PReventing Idiopathic SCOliosis PROgression (PRISCOPRO): A protocol for a quadruple-blinded, randomized controlled trial comparing 3D designed Boston brace to standard Boston brace.","INTRODUCTION Idiopathic scoliosis is the most common spinal deformity in children. Treatment strategies aim to halt progression of the curve. Patients are treated mainly with thoracolumbosacral orthosis (TLSO) if indicated. This form of brace treatment has been shown to be cumbersome and tough on growing individuals. However, computer aided design and manufactured (CAD/CAM) braces might increase comfortability and ultimately outcome if compliance is improved. In a multicenter, randomized controlled trial, we aim to compare CAD/CAM designed Boston 3D-brace to standard Boston brace. METHODS Subjects: 170 previously untreated and skeletally immature children diagnosed with idiopathic scoliosis, aged 9-17 years of age (curve magnitude Cobb 25-40 degrees) will be included. Interventions: Both groups will receive a physical activity prescription according to the World Health Organization recommendations. Randomization will be performed 1:1 to a 3D CAD/CAM designed Boston 3D-brace or a standard Boston brace, both with prescribed daily wear time of 20 hours. Outcome: The subjects will participate in the study until curve progression or until skeletal maturity. The primary outcome variable is failure of treatment, defined as progression of the Cobb angle more than 6 degrees compared to the baseline x-ray. The progression is confirmed if seen on two consecutive standing spinal x-rays. Radiographs will be taken at each six-month follow-up. Secondary outcome measures include patient and clinical reported outcomes, including number of individuals requiring surgical intervention. DISCUSSION This study will show if efficacy in brace treatment can be improved with new brace designs. TRIAL REGISTRATION The protocol has been registered on ClinicalTrials.gov, identifier: NCT04805437.",2021,"The primary outcome variable is failure of treatment, defined as progression of the Cobb angle more than 6 degrees compared to the baseline x-ray.","['Subjects: 170 previously untreated and skeletally immature children diagnosed with idiopathic scoliosis, aged 9-17 years of age (curve magnitude Cobb 25-40 degrees', 'Patients are treated mainly with thoracolumbosacral orthosis (TLSO) if indicated']","['physical activity prescription', 'Boston brace to standard Boston brace', 'CAD/CAM designed Boston 3D-brace to standard Boston brace']","['patient and clinical reported outcomes, including number of individuals requiring surgical intervention', 'failure of treatment, defined as progression of the Cobb angle more than 6 degrees', 'Idiopathic SCOliosis PROgression (PRISCOPRO']","[{'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0205252', 'cui_str': 'Immature'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0595995', 'cui_str': 'Idiopathic scoliosis'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0449286', 'cui_str': 'Degree'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0438891', 'cui_str': 'Boston brace'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0162517', 'cui_str': 'Computer-Assisted Design'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0006086', 'cui_str': 'Brace'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0563192', 'cui_str': 'Cobb angle'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0595995', 'cui_str': 'Idiopathic scoliosis'}]",170.0,0.297164,"The primary outcome variable is failure of treatment, defined as progression of the Cobb angle more than 6 degrees compared to the baseline x-ray.","[{'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Diarbakerli', 'Affiliation': 'Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Anastasios', 'Initials': 'A', 'LastName': 'Charalampidis', 'Affiliation': 'Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Abbott', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, Division of Prevention, Rehabilitation and Community Medicine, Unit of Physiotherapy, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Gerdhem', 'Affiliation': 'Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}]",PloS one,['10.1371/journal.pone.0255264'] 2471,33446795,The calming effect of roasted coffee aroma in patients undergoing dental procedures.,"Coffee beverage consumption is well-known to exert various health benefits; however, the effects of coffee aroma are rarely explored. This study aimed to investigate the calming effect of inhaling coffee aroma while the patients underwent dental procedures (probing and scaling). Salivary α-amylase (sAA) and cortisol (sCort) levels were measured as proxies of sympathetic nervous system and hypothalamic-pituitary-adrenal axis responses to stress respectively. Blood pressures and pulse rates were recorded. The results showed that undergoing dental procedures could increase sAA and sCort levels of the patients inhaling sham aroma while those inhaling coffee aroma had significantly decreased sAA and sCort levels (40% and 25% differences, respectively). The pulse rates of those inhaling coffee aroma were also lower. Subjective assessment using visual analog scale was in line with objective measures as well. The preference for coffee aroma or the frequency of coffee drinking had no effect on the sAA and sCort responses. This is the first study to provide evidence on the effect of coffee aroma on sAA and sCort levels in patients undergoing dental procedures.",2021,The preference for coffee aroma or the frequency of coffee drinking had no effect on the sAA and sCort responses.,"['patients underwent dental procedures (probing and scaling', 'patients undergoing dental procedures']",[],"['sAA and sCort levels', 'Blood pressures and pulse rates', 'Salivary α-amylase (sAA) and cortisol (sCort) levels', 'pulse rates', 'Subjective assessment using visual analog scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011331', 'cui_str': 'Dental care'}, {'cui': 'C0182400', 'cui_str': 'Probe'}]",[],"[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0002712', 'cui_str': 'Amylases'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C2959685', 'cui_str': 'Assessment using visual analog scale'}]",,0.0531377,The preference for coffee aroma or the frequency of coffee drinking had no effect on the sAA and sCort responses.,"[{'ForeName': 'Praewpat', 'Initials': 'P', 'LastName': 'Pachimsawat', 'Affiliation': 'Department of Advanced General Dentistry, Faculty of Dentistry, Mahidol University, Bangkok, 10400, Thailand.'}, {'ForeName': 'Kanlayanee', 'Initials': 'K', 'LastName': 'Tangprasert', 'Affiliation': 'Department of Advanced General Dentistry, Faculty of Dentistry, Mahidol University, Bangkok, 10400, Thailand.'}, {'ForeName': 'Nattinee', 'Initials': 'N', 'LastName': 'Jantaratnotai', 'Affiliation': 'Department of Pharmacology, Faculty of Science, Mahidol University, 272 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand. nattinee.jan@mahidol.ac.th.'}]",Scientific reports,['10.1038/s41598-020-80910-0'] 2472,34376257,Integrated malaria prevention in rural communities in Uganda: a qualitative feasibility study for a randomised controlled trial.,"BACKGROUND A randomised controlled trial (RCT) on integrated malaria prevention, which advocates the use of several malaria prevention methods holistically, has been proposed. However, before conducting an RCT, it is recommended that a feasibility study is carried out to provide information to support the main study, particularly for such a complex intervention. Therefore, a feasibility study for an RCT on integrated malaria prevention in Uganda was conducted. METHODS The qualitative study carried out in Wakiso District employed focus group discussions (FGDs) and key informant interviews (KIIs) to explore community willingness to participate in the RCT as well as assess stakeholder perspectives on the future study. The participants of the FGDs were community members, while the key informants were selected from malaria stakeholders including Ministry of Health officials, health practitioners, local leaders, district health team members, and community health workers (CHWs). Thematic analysis was employed with the support of NVivo. RESULTS A total of 12 FGDs and 19 KIIs were conducted. Five main themes emerged from the study: malaria prevention practices related to integrated malaria prevention; preferred malaria prevention methods in the integrated approach; potential challenges of integrated malaria prevention; perspectives on the proposed RCT; and sustainability of integrated malaria prevention. Despite a few methods being employed holistically in the community, insecticide-treated nets were the most widely used and preferred method for malaria prevention mainly because they were provided free by the government. The main challenges in the integrated approach were the high cost of some methods such as house screening, and concerns about the potential side effects of insecticide-based methods such as indoor residual spraying. Participants expressed high willingness to participate in the RCT to promote the use of multiple methods in their households and community. Involvement of CHWs during implementation was proposed as a sustainability strategy for the RCT interventions. CONCLUSION There was high willingness to participate in the proposed RCT on integrated malaria prevention. However, high cost and perceived negative health effects from some methods were identified as potential challenges. The type of methods to be included as well as sustainability mechanisms needs to be considered during the design of the RCT.",2021,The qualitative study carried out in Wakiso District employed focus group discussions (FGDs) and key informant interviews (KIIs) to explore community willingness to participate in the RCT as well as assess stakeholder perspectives on the future study.,"['participants of the FGDs were community members, while the key informants were selected from malaria stakeholders including Ministry of Health officials, health practitioners, local leaders, district health team members, and community health workers (CHWs', 'rural communities in Uganda', 'A total of 12 FGDs and 19 KIIs']",['RCT'],[],"[{'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0086944', 'cui_str': 'Rural Communities'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],,0.14204,The qualitative study carried out in Wakiso District employed focus group discussions (FGDs) and key informant interviews (KIIs) to explore community willingness to participate in the RCT as well as assess stakeholder perspectives on the future study.,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Musoke', 'Affiliation': 'Department of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda. dmusoke@musph.ac.ug.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Namata', 'Affiliation': 'Department of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Rawlance', 'Initials': 'R', 'LastName': 'Ndejjo', 'Affiliation': 'Department of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Ssempebwa', 'Affiliation': 'Department of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Miph B', 'Initials': 'MB', 'LastName': 'Musoke', 'Affiliation': 'Department of Applied Sciences, School of Sciences, Nkumba University, Entebbe, Uganda.'}]",Pilot and feasibility studies,['10.1186/s40814-021-00894-0'] 2473,34376241,Intervention with inulin prior to and during sanative therapy to further support periodontal health: study protocol for a randomized controlled trial.,"BACKGROUND Periodontal disease is a chronic state of inflammation that can destroy the supporting tissues around the teeth, leading to the resorption of alveolar bone. The initial strategy for treating periodontal disease is non-surgical sanative therapy (ST). Periodontal disease can also induce dysbiosis in the gut microbiota and contribute to low-grade systemic inflammation. Prebiotic fibers such as inulin can selectively alter the intestinal microbiota and support homeostasis by improving gut barrier functions and preventing inflammation. Providing an inulin supplement prior to and post-ST may influence periodontal health while providing insight into the complex relationship between periodontal disease and the gut microbiota. The primary objective is to determine if inulin is more effective than the placebo at improving clinical periodontal outcomes including probing depth (PD) and bleeding on probing (BOP). Secondary objectives include determining the effects of inulin supplementation pre- and post-ST on salivary markers of inflammation and periodontal-associated pathogens, as these outcomes reflect more rapid changes that can occur. METHODS We will employ a single-center, randomized, double-blind, placebo-controlled study design and recruit and randomize 170 participants who are receiving ST to manage the periodontal disease to the intervention (inulin) or placebo (maltodextrin) group. A pilot study will be embedded within the randomized controlled trial using the first 48 participants to test the feasibility for the larger, powered trial. The intervention period will begin 4 weeks before ST through to their follow-up appointment at 10 weeks post-ST. Clinical outcomes of periodontal disease including the number of sites with PD ≥ 4 mm and the presence of BOP will be measured at baseline and post-ST. Salivary markers of inflammation, periodontal-associated pathogens, body mass index, and diet will be measured at baseline, pre-ST (after 4 weeks of intervention), and post-ST (after 14 weeks of intervention). DISCUSSION We expect that inulin will enhance the positive effect of ST on the management of periodontal disease. The results of the study will provide guidance regarding the use of prebiotics prior to and as a supportive adjunct to ST for periodontal health. TRIAL REGISTRATION ClinicalTrials.gov NCT04670133 . Registered on 17 December 2020.",2021,The primary objective is to determine if inulin is more effective than the placebo at improving clinical periodontal outcomes including probing depth (PD) and bleeding on probing (BOP).,"['48 participants', '170 participants who are receiving ST to manage the periodontal disease to the intervention (inulin) or']","['placebo (maltodextrin', 'placebo']","['clinical periodontal outcomes including probing depth (PD) and bleeding on probing (BOP', 'inulin supplementation pre- and post-ST on salivary markers of inflammation and periodontal-associated pathogens', 'Salivary markers of inflammation, periodontal-associated pathogens, body mass index, and diet']","[{'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0031090', 'cui_str': 'Periodontal disease'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0450254', 'cui_str': 'Pathogenic organism'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]",,0.377874,The primary objective is to determine if inulin is more effective than the placebo at improving clinical periodontal outcomes including probing depth (PD) and bleeding on probing (BOP).,"[{'ForeName': 'Carly A R', 'Initials': 'CAR', 'LastName': 'Zanatta', 'Affiliation': 'Department of Kinesiology, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Fritz', 'Affiliation': 'Department of Kinesiology, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada.'}, {'ForeName': 'Elena M', 'Initials': 'EM', 'LastName': 'Comelli', 'Affiliation': 'Department of Kinesiology, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada.'}, {'ForeName': 'Wendy E', 'Initials': 'WE', 'LastName': 'Ward', 'Affiliation': 'Department of Kinesiology, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada. wward@brocku.ca.'}]",Trials,['10.1186/s13063-021-05504-1'] 2474,34376233,"Implementing nudges to promote utilization of low tidal volume ventilation (INPUT): a stepped-wedge, hybrid type III trial of strategies to improve evidence-based mechanical ventilation management.","BACKGROUND Behavioral economic insights have yielded strategies to overcome implementation barriers. For example, default strategies and accountable justification strategies have improved adherence to best practices in clinical settings. Embedding such strategies in the electronic health record (EHR) holds promise for simple and scalable approaches to facilitating implementation. A proven-effective but under-utilized treatment for patients who undergo mechanical ventilation involves prescribing low tidal volumes, which protects the lungs from injury. We will evaluate EHR-based implementation strategies grounded in behavioral economic theory to improve evidence-based management of mechanical ventilation. METHODS The Implementing Nudges to Promote Utilization of low Tidal volume ventilation (INPUT) study is a pragmatic, stepped-wedge, hybrid type III effectiveness implementation trial of three strategies to improve adherence to low tidal volume ventilation. The strategies target clinicians who enter electronic orders and respiratory therapists who manage the mechanical ventilator, two key stakeholder groups. INPUT has five study arms: usual care, a default strategy within the mechanical ventilation order, an accountable justification strategy within the mechanical ventilation order, and each of the order strategies combined with an accountable justification strategy within flowsheet documentation. We will create six matched pairs of twelve intensive care units (ICUs) in five hospitals in one large health system to balance patient volume and baseline adherence to low tidal volume ventilation. We will randomly assign ICUs within each matched pair to one of the order panels, and each pair to one of six wedges, which will determine date of adoption of the order panel strategy. All ICUs will adopt the flowsheet documentation strategy 6 months afterwards. The primary outcome will be fidelity to low tidal volume ventilation. The secondary effectiveness outcomes will include in-hospital mortality, duration of mechanical ventilation, ICU and hospital length of stay, and occurrence of potential adverse events. DISCUSSION This stepped-wedge, hybrid type III trial will provide evidence regarding the role of EHR-based behavioral economic strategies to improve adherence to evidence-based practices among patients who undergo mechanical ventilation in ICUs, thereby advancing the field of implementation science, as well as testing the effectiveness of low tidal volume ventilation among broad patient populations. TRIAL REGISTRATION ClinicalTrials.gov , NCT04663802 . Registered 11 December 2020.",2021,We will create six matched pairs of twelve intensive care units (ICUs) in five hospitals in one large health system to balance patient volume and baseline adherence to low tidal volume ventilation.,['six matched pairs of twelve intensive care units (ICUs) in five hospitals in one large health system to balance patient volume and baseline adherence to low tidal volume ventilation'],"['low tidal volume ventilation (INPUT', 'low Tidal volume ventilation (INPUT']","['hospital mortality, duration of mechanical ventilation, ICU and hospital length of stay, and occurrence of potential adverse events', 'fidelity to low tidal volume ventilation']","[{'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}]",6.0,0.0121736,We will create six matched pairs of twelve intensive care units (ICUs) in five hospitals in one large health system to balance patient volume and baseline adherence to low tidal volume ventilation.,"[{'ForeName': 'Meeta Prasad', 'Initials': 'MP', 'LastName': 'Kerlin', 'Affiliation': 'Pulmonary, Critical Care and Allergy Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. prasadm@pennmedicine.upenn.edu.'}, {'ForeName': 'Dylan', 'Initials': 'D', 'LastName': 'Small', 'Affiliation': 'Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Barry D', 'Initials': 'BD', 'LastName': 'Fuchs', 'Affiliation': 'Pulmonary, Critical Care and Allergy Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Mikkelsen', 'Affiliation': 'Pulmonary, Critical Care and Allergy Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Tran', 'Affiliation': 'Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Scott', 'Affiliation': 'Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Aerielle', 'Initials': 'A', 'LastName': 'Belk', 'Affiliation': 'Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Jasmine A', 'Initials': 'JA', 'LastName': 'Silvestri', 'Affiliation': 'Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Tamar', 'Initials': 'T', 'LastName': 'Klaiman', 'Affiliation': 'Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Halpern', 'Affiliation': 'Pulmonary, Critical Care and Allergy Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Rinad S', 'Initials': 'RS', 'LastName': 'Beidas', 'Affiliation': 'Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}]",Implementation science : IS,['10.1186/s13012-021-01147-7'] 2475,34376228,Effectiveness of an interactive web-based health program for adults: a study protocol for three concurrent controlled-randomized trials (EVA-TK-Coach).,"BACKGROUND A healthy lifestyle can help prevent diseases that impair quality of life and lead to premature death. The Techniker health insurance fund offers a comprehensive online health program to support users in achieving their health goals of Increasing Fitness, Losing and Maintaining Weight, or Smoking Cessation. METHODS The aim of this study is to test the long-term effectiveness of the web-based TK-HealthCoach with regard to the primary outcomes of increased physical activity, sustainable weight reduction, and smoking abstinence. We are conducting three interconnected, randomized controlled trials (RCT), one for each health goal, within which participants are allocated to an intervention group (interactive online health program) or a control group (non-interactive online health program). The effects of the intervention groups compared to the control groups will be analyzed by multi-level models for change. Participants' data are captured via online questionnaires before the program starts (baseline t0), again when it ends (t1), and later at two follow-up surveys (t2 and t3); the latter 12 months after t1. We are documenting socio-demographic, health-related, and psychological variables as well as usage behavior data of the programs. According to our sample size calculation, we have to enroll 1114 participants in each Losing and Maintaining Weight and Increasing Fitness RCT and 339 participants in the Smoking Cessation RCT. Additionally, 15-20 participants in the interactive smoking-cessation program will be invited to qualitative telephone interviews with the aim to obtain detailed information concerning utilization, compliance, and satisfaction. The online RCTs' inclusion criteria are: adults of each gender regardless of whether they are insured with Techniker health insurance fund. Persons with impairments or pre-existing conditions require a medical assessment as to whether the program is suitable for them. Specific exclusion criteria apply to each program/RCT. DISCUSSION We assume that study participants will improve their health behavior by using the offered online health programs and that each health goal's intervention group will reveal advantages regarding the outcome variables compared to the control groups. Study enrollment started on January 1, 2020. TRIAL REGISTRATION German Clinical Trials Register, Universal Trial Number (UTN): U1111-1245-0273 . Registered on 11 December 2019.",2021,"The aim of this study is to test the long-term effectiveness of the web-based TK-HealthCoach with regard to the primary outcomes of increased physical activity, sustainable weight reduction, and smoking abstinence.","['1114 participants in each Losing and Maintaining Weight and Increasing Fitness RCT and 339 participants in the Smoking Cessation RCT', '15-20 participants in the interactive smoking-cessation program', 'adults']","['intervention group (interactive online health program) or a control group (non-interactive online health program', 'interactive web-based health program']","['physical activity, sustainable weight reduction, and smoking abstinence']","[{'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}]",,0.0380191,"The aim of this study is to test the long-term effectiveness of the web-based TK-HealthCoach with regard to the primary outcomes of increased physical activity, sustainable weight reduction, and smoking abstinence.","[{'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Tinsel', 'Affiliation': 'Section of Health Care Research and Rehabilitation Research (SEVERA), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 49, 79106, Freiburg, Germany. iris.tinsel@uniklinik-freiburg.de.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Metzner', 'Affiliation': 'Section of Health Care Research and Rehabilitation Research (SEVERA), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 49, 79106, Freiburg, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schlett', 'Affiliation': 'Section of Health Care Research and Rehabilitation Research (SEVERA), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 49, 79106, Freiburg, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Sehlbrede', 'Affiliation': 'Section of Health Care Research and Rehabilitation Research (SEVERA), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 49, 79106, Freiburg, Germany.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Bischoff', 'Affiliation': 'Section of Health Care Research and Rehabilitation Research (SEVERA), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 49, 79106, Freiburg, Germany.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Anger', 'Affiliation': 'Section of Health Care Research and Rehabilitation Research (SEVERA), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 49, 79106, Freiburg, Germany.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Brame', 'Affiliation': 'Department of Sport and Sport Science (IfSS), University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'König', 'Affiliation': 'Department of Sport and Sport Science (IfSS), University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Ramona', 'Initials': 'R', 'LastName': 'Wurst', 'Affiliation': 'Department of Sport and Sport Science (IfSS), University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Fuchs', 'Affiliation': 'Department of Sport and Sport Science (IfSS), University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Lindinger', 'Affiliation': 'Scientific Working Group in Smoking Cessation (WAT), Tübingen, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Bredenkamp', 'Affiliation': 'Clinical Trials Unit UMG, University Medical Center Göttingen, Georg-August-University, Göttingen, Germany.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Farin-Glattacker', 'Affiliation': 'Section of Health Care Research and Rehabilitation Research (SEVERA), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 49, 79106, Freiburg, Germany.'}]",Trials,['10.1186/s13063-021-05470-8'] 2476,34376180,Tranexamic acid in a periarticular multimodal cocktail injection for blood management in total knee arthroplasty: a prospective randomized study.,"BACKGROUND This study aimed to assess the efficacy of tranexamic acid (TXA) mixed in a periarticular multimodal cocktail (PAMC) as a topical administration and to determine whether combined use of intravenous and topical administration is more effective than a single administration of TXA. METHODS A total of 240 patients who underwent primary total knee arthroplasty (TKA) was enrolled for this prospective randomized controlled study. Patients were divided into three groups of 80 patients each. Baseline data were comparable for all groups. Average follow-up was 18.7 months. Group 1 consisted of patients who received intravenous (IV) TXA, Group 2 patients were those who received TXA in a PAMC injection for topical administration, and Group 3 consisted of patients who received a combination of both intravenous and topical administration of TXA. Primary outcomes were postoperative hemoglobin drop and amount of suction drainage. Secondary outcomes were estimated blood loss (EBL), postoperative transfusion rate, and complications. RESULTS The mean postoperative hemoglobin drop was significantly lower in Group 3 (2.13 ± 0.77 g/dL, p=0.004), and there was no difference between Group 1 and Group 2 (2.56 ± 1.07 g/dL vs 2.55 ± 0.86 g/dL, p=0.999). The mean drainage amount was significantly lower in Group 3 (326.58 ± 57.55 ml, p<0.001), and there was no difference between Group 1 and Group 2 (367.93 ± 87.26 ml vs 397.66 ± 104.10 ml, p=0.072). Similarly, the mean EBL was significantly lower in Group 3 (p=0.003), and there was no significant difference between Group 1 and Group 2 (p=0.992). There were no significant differences in requirement for postoperative transfusion rate or incidence of complications among the three groups. CONCLUSION TXA mixed in a PAMC injection showed a similar effect to IV administration of TXA following TKA. Furthermore, combined use of both IV and PAMC injection provided better perioperative bleeding control with similar safety in patients without relevant comorbidities. TRIAL REGISTRATION WHO ICTRP identifier KCT0005703 . Retrospectively registered: 12/24/2020.",2021,"The mean drainage amount was significantly lower in Group 3 (326.58 ± 57.55 ml, p<0.001), and there was no difference between Group 1 and Group 2 (367.93 ± 87.26 ml vs 397.66 ± 104.10 ml, p=0.072).","['total knee arthroplasty', '240 patients who underwent primary total knee arthroplasty (TKA', 'patients without relevant comorbidities']","['Tranexamic acid', 'intravenous (IV) TXA', 'PAMC injection for topical administration, and Group 3 consisted of patients who received a combination of both intravenous and topical administration of TXA', 'TXA', 'tranexamic acid (TXA', 'PAMC injection']","['mean postoperative hemoglobin drop', 'blood loss (EBL), postoperative transfusion rate, and complications', 'postoperative hemoglobin drop and amount of suction drainage', 'mean EBL', 'mean drainage amount', 'postoperative transfusion rate or incidence of complications']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0595695', 'cui_str': 'Periarticular route'}, {'cui': 'C0678420', 'cui_str': 'Cocktail'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0001566', 'cui_str': 'Topical administration of treatment'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0162119', 'cui_str': 'Hemoglobin low'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",240.0,0.0938903,"The mean drainage amount was significantly lower in Group 3 (326.58 ± 57.55 ml, p<0.001), and there was no difference between Group 1 and Group 2 (367.93 ± 87.26 ml vs 397.66 ± 104.10 ml, p=0.072).","[{'ForeName': 'Kang-Il', 'Initials': 'KI', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopaedic Surgery, Kyung Hee University Hospital at Gangdong, 892 Dongnam-ro, Gangdong-gu, Seoul, 134-727, Republic of Korea.'}, {'ForeName': 'Jung-Kwon', 'Initials': 'JK', 'LastName': 'Bae', 'Affiliation': 'Department of Orthopaedic Surgery, Kyung Hee University Hospital at Gangdong, 892 Dongnam-ro, Gangdong-gu, Seoul, 134-727, Republic of Korea. roundnfirm@hanmail.net.'}, {'ForeName': 'Jun-Ho', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopaedic Surgery, Kyung Hee University Hospital at Gangdong, 892 Dongnam-ro, Gangdong-gu, Seoul, 134-727, Republic of Korea.'}, {'ForeName': 'Hyun-Gon', 'Initials': 'HG', 'LastName': 'Gwak', 'Affiliation': 'Department of Orthopaedic Surgery, Kyung Hee University Hospital at Gangdong, 892 Dongnam-ro, Gangdong-gu, Seoul, 134-727, Republic of Korea.'}, {'ForeName': 'Sang Hak', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopaedic Surgery, Kyung Hee University Hospital at Gangdong, 892 Dongnam-ro, Gangdong-gu, Seoul, 134-727, Republic of Korea.'}]",BMC musculoskeletal disorders,['10.1186/s12891-021-04551-8'] 2477,34376153,Adequacy of maternal anesthesia depth with two sodium thiopental doses in elective caesarean section: a randomized clinical trial.,"BACKGROUND Administration of an optimal dose of anesthetic agent to ensure adequate depth of hypnosis with the lowest risk of adverse effects to the fetus is highly important in cesarean section. Sodium thiopental (STP) is still the first choice for induction of anesthesia in some countries for this obstetric surgery. We aimed to compare two doses of STP with regarding the depth of anesthesia and the condition of newborn infants. METHODS In this clinical trial, parturient undergoing elective Caesarian section were randomized into two groups receiving either low-dose (5 mg/kg) or high-dose (7 mg/kg) STP. Muscle relaxation was provided with succinylcholine 2 mg/kg and anesthesia was maintained with O2/N2O and sevoflurane. The depth of anesthesia was evaluated using isolated forearm technique (IFT) and bispectral index (BIS) in various phases. Additionally, infants were assessed using Apgar score and neurobehavioral test. RESULTS Forty parturient were evaluated in each group. BIS was significantly lower in high-dose group at skin incision to delivery and subcutaneous and skin closure. Also, significant differences were noticed in IFT over induction to incision and incision to delivery. Apgar score was significantly lower in high-dose group at 1 min after delivery. Newborn infants in low-dose group had significantly better outcomes in all three domains of the neurobehavioral test. CONCLUSION 7 mg/kg STP is superior to 5 mg/kg in creating deeper hypnosis for mothers. However, it negatively impacts Apgar score and neurobehavioral test of neonates. STP seems to has dropped behind as an acceptable anesthetic in Cesarean section. TRIAL REGISTRATION IRCT No: 2016082819470 N45 , 13/03/2019.",2021,"Newborn infants in low-dose group had significantly better outcomes in all three domains of the neurobehavioral test. ","['elective caesarean section', 'parturient undergoing elective Caesarian section', 'newborn infants']","['STP', 'sodium thiopental', 'succinylcholine 2\u2009mg/kg and anesthesia was maintained with O2/N2O and sevoflurane', 'low-dose (5\u2009mg/kg) or high-dose (7\u2009mg/kg) STP', 'Sodium thiopental (STP', 'IRCT']","['BIS', 'isolated forearm technique (IFT) and bispectral index (BIS', 'Apgar score', 'IFT', 'neurobehavioral test', 'Apgar score and neurobehavioral test']","[{'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}]","[{'cui': 'C0936073', 'cui_str': 'Thiopental sodium'}, {'cui': 'C0038627', 'cui_str': 'Succinylcholine'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0444956', 'cui_str': 'High dose'}]","[{'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0003533', 'cui_str': 'Finding of Apgar score'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",40.0,0.0339191,"Newborn infants in low-dose group had significantly better outcomes in all three domains of the neurobehavioral test. ","[{'ForeName': 'Golnar', 'Initials': 'G', 'LastName': 'Sabetian', 'Affiliation': 'Trauma Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Farid', 'Initials': 'F', 'LastName': 'Zand', 'Affiliation': 'Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. zandf@sums.ac.ir.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Mirhadi', 'Affiliation': 'Trauma Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Hadavi', 'Affiliation': 'Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Asadpour', 'Affiliation': 'Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Laleh', 'Initials': 'L', 'LastName': 'Dehghanpisheh', 'Affiliation': 'Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Zeinabsadat', 'Initials': 'Z', 'LastName': 'Fattahi Saravi', 'Affiliation': 'Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Seyed Mostajab', 'Initials': 'SM', 'LastName': 'Razavi', 'Affiliation': 'Neonatal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",BMC anesthesiology,['10.1186/s12871-021-01421-7'] 2478,34376082,Are Survivors of Sexual Assault Blamed More Than Victims of Other Crimes?,"Although victim blaming in the context of sexual assault is often emphasized, little research has compared rates of victim blaming following sexual assault relative to other forms of victimization. This research investigated whether there is a crime-specific bias toward blaming victims of sexual assault. Victim blaming was assessed via different methods from the observer perspective in vignette-based studies, as well as survivors' accounts of social reactions they received. In Study 1, participants were asked to rate how much the survivor was to blame in three vignettes, each with a different randomized crime outcome: rape, physical assault, or theft. Study 2 assessed blame for a vignette that either ended in rape or theft, via a causal attribution statement. Study 3 asked interpersonal trauma survivors who had experienced at least two forms of victimization (i.e., sexual assault, physical assault, or theft) to report the social reactions they received following disclosure of each of these crimes. Across all three studies, victim blaming occurred following multiple forms of victimization and there was no evidence of a particular bias toward blaming survivors of sexual assault more so than other crimes. However, results of Study 3 highlight that, following sexual assault, survivors receive more silencing and stigmatizing reactions than they experienced after other crimes. Interpersonal traumas (i.e., sexual or physical assault) also resulted in more egocentric responses compared to theft. Altogether, there does not appear to be a crime-specific bias for victim blaming; however, crime-specific bias is apparent for some other, potentially understudied, social reactions. Implications of these findings highlight the value of victim blaming education and prevention efforts through trauma-informed services and outreach following victimization. Furthermore, service providers and advocates might especially seek to recognize and prevent silencing and stigmatizing reactions following sexual assault disclosures.",2021,"Across all three studies, victim blaming occurred following multiple forms of victimization and there was no evidence of a particular bias toward blaming survivors of sexual assault more so than other crimes.","['Study 3 asked interpersonal trauma survivors who had experienced at least two forms of victimization (i.e., sexual assault, physical assault, or theft) to report the social reactions they received following disclosure of each of these crimes']",[],"['egocentric responses', 'Interpersonal traumas']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0376695', 'cui_str': 'Victimization'}, {'cui': 'C0237236', 'cui_str': 'Sexual assault'}, {'cui': 'C0740319', 'cui_str': 'Physical assault'}, {'cui': 'C0039751', 'cui_str': 'Theft'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0010325', 'cui_str': 'Crime'}]",[],"[{'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]",1.0,0.0463704,"Across all three studies, victim blaming occurred following multiple forms of victimization and there was no evidence of a particular bias toward blaming survivors of sexual assault more so than other crimes.","[{'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Reich', 'Affiliation': 'University of Minnesota Duluth, MN, USA.'}, {'ForeName': 'Grace A', 'Initials': 'GA', 'LastName': 'Pegel', 'Affiliation': 'University of Minnesota Duluth, MN, USA.'}, {'ForeName': 'Alixandra B', 'Initials': 'AB', 'LastName': 'Johnson', 'Affiliation': 'University of Minnesota Duluth, MN, USA.'}]",Journal of interpersonal violence,['10.1177/08862605211037423'] 2479,34376072,Comparing Performance of Methods to Deal With Differential Attrition in Randomized Experimental Evaluations.,"Background: In randomized controlled trials, attrition rates often differ by treatment status, jeopardizing causal inference. Inverse probability weighting methods and estimation of treatment effect bounds have been used to adjust for this bias. Objectives: We compare the performance of various methods within two samples, both generated through lottery-based randomization: one with considerable differential attrition and an augmented dataset with less problematic attrition. Research Design: We assess the performance of various correction methods within the dataset with problematic attrition. In addition, we conduct simulation analyses. Results: Within the more problematic dataset, we find the correction methods often performed poorly. Simulation analyses indicate that deviations from the underlying assumptions for bounding approaches damage the performance of estimated bounds. Conclusions: We recommend the verification of the underlying assumptions in attrition correction methods whenever possible and, when verification is not possible, using these methods with caution.",2021,"Within the more problematic dataset, we find the correction methods often performed poorly.",[],[],['attrition rates'],[],[],"[{'cui': 'C0004277', 'cui_str': 'Dental Attrition'}]",,0.201137,"Within the more problematic dataset, we find the correction methods often performed poorly.","[{'ForeName': 'Kaitlin', 'Initials': 'K', 'LastName': 'Anderson', 'Affiliation': 'Department of Education and Human Services, 1687Lehigh University, Bethlehem, PA, USA.'}, {'ForeName': 'Gema', 'Initials': 'G', 'LastName': 'Zamarro', 'Affiliation': 'Department of Education Reform, 3341The University of Arkansas, Fayetteville, AR, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Steele', 'Affiliation': 'School of Education, 8363American University, Washington, DC, USA.'}, {'ForeName': 'Trey', 'Initials': 'T', 'LastName': 'Miller', 'Affiliation': '7341School of Economic, Political and Policy Sciences, University of Texas at Dallas, Richardson, TX, USA.'}]",Evaluation review,['10.1177/0193841X211034363'] 2480,34375992,Effect of online low-intensity exercise training on fitness and cardiovascular parameters.,"Online exercise is undoubtedly useful and important; however, chronic adaptations to online exercise, particularly strength gain, muscle hypertrophy, and cardiovascular parameters, remain unclear. We investigated the effect of online exercise training using Zoom on fitness parameters compared with the same exercises supervised directly. In the present study, 34 subjects (age: 42.9±14.4 years) were included. Twenty-three subjects performed eight weeks of body mass-based exercise training online using Zoom, and eleven subjects performed the same exercise supervised directly as the control group. The subjects performed low-load resistance exercises twice a week for 8 weeks for a total of 16 sessions. The sessions included 9 exercises: leg raises, squats, rear raises, shoulder presses, rowing, dips, lunges, Romanian dead lifts, and push-ups. Chair-stand, push-up, and sit-and-reach tests were performed on all subjects. Overall, the home exercise program effectively increased strength and muscle mass and decreased blood pressure and arterial stiffness, but there were no differences between the groups. Changes in chair-stand and sit-and-reach test results were higher in the control group than in the online group. Our results show that there is a similar training response to body mass-based training in both groups, even with virtual experiences using Zoom.",2021,Changes in chair-stand and sit-and-reach test results were higher in the control group than in the online group.,['34 subjects (age: 42.9±14.4 years) were included'],"['online exercise training', 'Online exercise', 'body mass-based exercise training online using Zoom, and eleven subjects performed the same exercise supervised directly as the control group', 'online low-intensity exercise training']","['9 exercises: leg raises, squats, rear raises, shoulder presses, rowing, dips, lunges, Romanian dead lifts, and push-ups', 'fitness and cardiovascular parameters', 'strength and muscle mass and decreased blood pressure and arterial stiffness', 'Changes in chair-stand and sit-and-reach test results']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0442818', 'cui_str': 'Raised'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0454325', 'cui_str': 'Shoulder press'}, {'cui': 'C4505111', 'cui_str': 'Rowing'}, {'cui': 'C0037390', 'cui_str': 'Snuff tobacco'}, {'cui': 'C0035827', 'cui_str': 'Rumanian language'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0181620', 'cui_str': 'Hoist'}, {'cui': 'C0580841', 'cui_str': 'Does push'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}]",34.0,0.00165915,Changes in chair-stand and sit-and-reach test results were higher in the control group than in the online group.,"[{'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Kikuchi', 'Affiliation': 'Graduate School of Physical education Sports Science, Nippon Sport Science University, Setagaya-ku, Japan.'}, {'ForeName': 'Yukina', 'Initials': 'Y', 'LastName': 'Mochizuki', 'Affiliation': 'my.ca0813@gmail.com, Nippon Sport Science University, Setagaya-ku, Japan.'}, {'ForeName': 'Ayumu', 'Initials': 'A', 'LastName': 'Kozuma', 'Affiliation': 'Graduate School of Physical education Sports Science, Nippon Sport Science University, Setagaya-ku, Japan.'}, {'ForeName': 'Takamichi', 'Initials': 'T', 'LastName': 'Inoguchi', 'Affiliation': 'Graduate School of Physical education Sports Science, Nippon Sport Science University, Setagaya-ku, Japan.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Saito', 'Affiliation': 'Graduate School of Health and Sport Science, Nippon Sport Science University, Tokyo, Japan.'}, {'ForeName': 'Minoru', 'Initials': 'M', 'LastName': 'Deguchi', 'Affiliation': 'Graduate School of Physical education Sports Science, Nippon Sport Science University, Setagaya-ku, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Homma', 'Affiliation': 'Graduate School of Physical education Sports Science, Nippon Sport Science University, Setagaya-ku, Japan.'}, {'ForeName': 'Madoka', 'Initials': 'M', 'LastName': 'Ogawa', 'Affiliation': 'Research Institute for Sport Science, Nippon Sport Science University, Setagaya-ku, Japan.'}, {'ForeName': 'Yuto', 'Initials': 'Y', 'LastName': 'Hashimoto', 'Affiliation': 'Graduate School of Physical education Sports Science, Nippon Sport Science University, Setagaya-ku, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Nakazato', 'Affiliation': 'Graduate School of Physical education Sports Science, Nippon Sport Science University, Tokyo, Japan.'}, {'ForeName': 'Takanobu', 'Initials': 'T', 'LastName': 'Okamoto', 'Affiliation': 'Graduate School of Physical education Sports Science, Nippon Sport Science University, Setagaya-ku, Japan.'}]",International journal of sports medicine,['10.1055/a-1582-2874'] 2481,34375789,No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.,"Given the role of low-grade inflammation in the pathophysiology of major depressive disorder (MDD), anti-inflammatory strategies may improve treatment outcomes in some patients. However, it is controversial whether they can be used as adjunctive treatments and whether pre-treatment levels of inflammation can predict treatment outcomes. This study was conducted to measure the efficacy of anti-inflammatory augmentation of antidepressant treatment in MDD patients; and to investigate whether treatment response was dependent on baseline inflammation levels. This parallel-group randomised, double-blind, placebo-controlled trial was conducted at the University of Adelaide (Australia). Participants with MDD were randomised to receive vortioxetine with celecoxib or vortioxetine with placebo for six weeks, and baseline blood high sensitivity C reactive protein levels were measured. Primary outcome was change in depressive symptoms (Montgomery-Åsberg Depression Rating Scale) and secondary outcomes included change in cognition (THINC-integrated tool - Codebreaker task) and functioning (Functioning Assessment Short Test) over 6 weeks. There was no evidence of superior efficacy of celecoxib augmentation over placebo on depressive symptom severity, response and remission rates, cognition and psychosocial functioning. There was also no evidence that pre-treatment inflammation levels modified the effect of celecoxib augmentation versus placebo. This observed lack of efficacy of celecoxib add-on does not support the use of celecoxib augmentation of antidepressants in the treatment of MDD in a cohort that mostly comprises treatment-resistant individuals. Additionally, C-reactive protein may not be suitable to predict treatment selection and response in MDD. The study was registered on the Australian New Zealand Clinical Trials Registry: ACTRN12617000527369 (www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000527369p).",2021,"There was no evidence of superior efficacy of celecoxib augmentation over placebo on depressive symptom severity, response and remission rates, cognition and psychosocial functioning.","['Australian New Zealand Clinical Trials Registry', 'Participants with MDD', 'MDD patients', 'depression', 'University of Adelaide (Australia']","['adjunctive celecoxib', 'vortioxetine', 'vortioxetine with celecoxib or vortioxetine with placebo', 'celecoxib', 'placebo']","['change in depressive symptoms (Montgomery-Åsberg Depression Rating Scale) and secondary outcomes included change in cognition (THINC-integrated tool - Codebreaker task) and functioning (Functioning Assessment Short Test', 'depressive symptom severity, response and remission rates, cognition and psychosocial functioning']","[{'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0538927', 'cui_str': 'celecoxib'}, {'cui': 'C3661282', 'cui_str': 'vortioxetine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}]",,0.560348,"There was no evidence of superior efficacy of celecoxib augmentation over placebo on depressive symptom severity, response and remission rates, cognition and psychosocial functioning.","[{'ForeName': 'Bernhard T', 'Initials': 'BT', 'LastName': 'Baune', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia; Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia; The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia; Department of Psychiatry and Psychotherapy, University Hospital Münster, University of Münster, Münster, Germany. Electronic address: bernhard.baune@ukmuenster.de.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Sampson', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'Louise', 'Affiliation': ""'Faculty of Health Sciences, University of Adelaide, Adelaide, Australia.""}, {'ForeName': 'Hikaru', 'Initials': 'H', 'LastName': 'Hori', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'K Oliver', 'Initials': 'KO', 'LastName': 'Schubert', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia; Northern Adelaide Mental Health Service, Salisbury, Australia.'}, {'ForeName': 'Scott R', 'Initials': 'SR', 'LastName': 'Clark', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Natalie T', 'Initials': 'NT', 'LastName': 'Mills', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Célia', 'Initials': 'C', 'LastName': 'Fourrier', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia; Lysosomal Health in Ageing, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2021.07.092'] 2482,34375749,Sense2Stop: A micro-randomized trial using wearable sensors to optimize a just-in-time-adaptive stress management intervention for smoking relapse prevention.,"BACKGROUND Relapse to smoking is commonly triggered by stress, but behavioral interventions have shown only modest efficacy in preventing stress-related relapse. Continuous digital sensing to detect states of smoking risk and intervention receptivity may make it feasible to increase treatment efficacy by adapting intervention timing. OBJECTIVE Aims are to investigate whether the delivery of a prompt to perform stress management behavior, as compared to no prompt, reduces the likelihood of (a) being stressed and (b) smoking in the subsequent two hours, and (c) whether current stress moderates these effects. STUDY DESIGN A micro-randomized trial will be implemented with 75 adult smokers who wear Autosense chest and wrist sensors and use the mCerebrum suite of smartphone apps to report and respond to ecological momentary assessment (EMA) questions about smoking and mood for 4 days before and 10 days after a quit attempt and to access a set of stress-management apps. Sensor data will be processed on the smartphone in real time using the cStress algorithm to classify minutes as probably stressed or probably not stressed. Stressed and non-stressed minutes will be micro-randomized to deliver either a prompt to perform a stress management exercise via one of the apps or no prompt (2.5-3 stress management prompts will be delivered daily). Sensor and self-report assessments of stress and smoking will be analyzed to optimize decision rules for a just-in-time adaptive intervention (JITAI) to prevent smoking relapse. SIGNIFICANCE Sense2Stop will be the first digital trial using wearable sensors and micro-randomization to optimize a just-in-time adaptive stress management intervention for smoking relapse prevention.",2021,Stressed and non-stressed minutes will be micro-randomized to deliver either a prompt to perform a stress management exercise via one of the apps or no prompt (2.5-3 stress management prompts will be delivered daily).,['75 adult smokers who wear Autosense chest and wrist sensors and use the mCerebrum suite of smartphone apps to report and respond to ecological momentary assessment (EMA) questions about smoking and mood for 4\u202fdays before and 10\u202fdays after a quit attempt and to access a set of stress-management apps'],"['wearable sensors to optimize a just-in-time-adaptive stress management intervention', 'Sense2Stop']",[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0183210', 'cui_str': 'Sensor device'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}]","[{'cui': 'C0183210', 'cui_str': 'Sensor device'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],75.0,0.0207162,Stressed and non-stressed minutes will be micro-randomized to deliver either a prompt to perform a stress management exercise via one of the apps or no prompt (2.5-3 stress management prompts will be delivered daily).,"[{'ForeName': 'Samuel L', 'Initials': 'SL', 'LastName': 'Battalio', 'Affiliation': 'Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, 680 N. Lakeshore Drive, Suite 1400, Chicago, IL 60611, United States of America.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Conroy', 'Affiliation': 'Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, 680 N. Lakeshore Drive, Suite 1400, Chicago, IL 60611, United States of America; Department of Kinesiology, Penn State University, 266 Recreation Building, University Park, PA 16802, United States of America.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Dempsey', 'Affiliation': 'Survey Research Center, University of Michigan, 426 Thompson Street, Room 2464, Ann Arbor, MI 48106, United States of America.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Liao', 'Affiliation': 'Department of Statistics, Harvard University, Science Center 400 Suite, One Oxford Street, Cambridge, MA 02138, United States of America.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Menictas', 'Affiliation': 'Department of Statistics, Harvard University, Science Center 400 Suite, One Oxford Street, Cambridge, MA 02138, United States of America.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Murphy', 'Affiliation': 'Department of Statistics, Harvard University, Science Center 400 Suite, One Oxford Street, Cambridge, MA 02138, United States of America.'}, {'ForeName': 'Inbal', 'Initials': 'I', 'LastName': 'Nahum-Shani', 'Affiliation': 'Survey Research Center, University of Michigan, 426 Thompson Street, Room 2464, Ann Arbor, MI 48106, United States of America.'}, {'ForeName': 'Tianchen', 'Initials': 'T', 'LastName': 'Qian', 'Affiliation': 'Department of Statistics, University of California, Irvine, Irvine, CA 92697, United States of America.'}, {'ForeName': 'Santosh', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Department of Computer Science, University of Memphis, 319 Dunn Hall, Memphis, TN 38152, United States of America.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Spring', 'Affiliation': 'Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, 680 N. Lakeshore Drive, Suite 1400, Chicago, IL 60611, United States of America. Electronic address: bspring@northwestern.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106534'] 2483,34375748,Multilevel follow-up of cancer screening (mFOCUS): Protocol for a multilevel intervention to improve the follow-up of abnormal cancer screening test results.,"INTRODUCTION While substantial attention is focused on the delivery of routine preventive cancer screening, less attention has been paid to systematically ensuring that there is timely follow-up of abnormal screening test results. Barriers to completion of timely follow-up occur at the patient, provider, care team and system levels. METHODS In this pragmatic cluster randomized controlled trial, primary care sites in three networks are randomized to one of four arms: (1) standard care, (2) ""visit-based"" reminders that appear in a patient's electronic health record (EHR) when it is accessed by either patient or providers (3) visit based reminders with population health outreach, and (4) visit based reminders, population health outreach, and patient navigation with systematic screening and referral to address social barriers to care. Eligible patients in participating practices are those overdue for follow-up of an abnormal results on breast, cervical, colorectal and lung cancer screening tests. RESULTS The primary outcome is whether an individual receives follow-up, specific to the organ type and screening abnormality, within 120 days of becoming eligible for the trial. Secondary outcomes assess the effect of intervention components on the patient and provider experience of obtaining follow-up care and the delivery of the intervention components. CONCLUSIONS This trial will provide evidence for the role of a multilevel intervention on improving the follow-up of abnormal cancer screening test results. We will also specifically assess the relative impact of the components of the intervention, compared to standard care. TRIAL REGISTRATION ClinicalTrials.gov NCT03979495.",2021,"The primary outcome is whether an individual receives follow-up, specific to the organ type and screening abnormality, within 120 days of becoming eligible for the trial.","['Eligible patients in participating practices are those overdue for follow-up of an abnormal results on breast, cervical, colorectal and lung cancer screening tests']","['standard care, (2) ""visit-based"" reminders that appear in a patient\'s electronic health record (EHR) when it is accessed by either patient or providers (3) visit based reminders with population health outreach, and (4) visit based reminders, population health outreach, and patient navigation with systematic screening and referral to address social barriers to care']","['effect of intervention components on the patient and provider experience of obtaining follow-up care and the delivery of the intervention components', 'individual receives follow-up, specific to the organ type and screening abnormality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0459424', 'cui_str': 'Abnormal result'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0281477', 'cui_str': 'Screening for malignant neoplasm of lung'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3242284', 'cui_str': 'Population Health'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C3494323', 'cui_str': 'Patient Navigation'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}]","[{'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C3899107', 'cui_str': 'Follow-Up Care'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}]",,0.299859,"The primary outcome is whether an individual receives follow-up, specific to the organ type and screening abnormality, within 120 days of becoming eligible for the trial.","[{'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Haas', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: Jennifer.Haas@mgh.harvard.edu.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Atlas', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Wright', 'Affiliation': 'Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'E John', 'Initials': 'EJ', 'LastName': 'Orav', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Aman', 'Affiliation': 'Information, Technology and Consulting (ITC), Dartmouth College, Lebanon, NH.'}, {'ForeName': 'Erica S', 'Initials': 'ES', 'LastName': 'Breslau', 'Affiliation': 'Division of Cancer Prevention and Control, National Cancer Institute, Rockville, MD, USA.'}, {'ForeName': 'Timothy E', 'Initials': 'TE', 'LastName': 'Burdick', 'Affiliation': 'Department of Community and Family Medicine, Dartmouth-Hitchcock Health, Lebanon, NH; The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, NH, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Carpenter', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Chang', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Tin', 'Initials': 'T', 'LastName': 'Dang', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Courtney J', 'Initials': 'CJ', 'LastName': 'Diamond', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Feldman', 'Affiliation': ""Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Harris', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Shoshana J', 'Initials': 'SJ', 'LastName': 'Hort', 'Affiliation': 'Department of Medicine, Dartmouth-Hitchcock Health, Lebanon, NH, USA.'}, {'ForeName': 'Molly L', 'Initials': 'ML', 'LastName': 'Housman', 'Affiliation': 'The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, NH, USA.'}, {'ForeName': 'Amrita', 'Initials': 'A', 'LastName': 'Mecker', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Constance D', 'Initials': 'CD', 'LastName': 'Lehman', 'Affiliation': 'Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Sanja', 'Initials': 'S', 'LastName': 'Percac-Lima', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Smith', 'Affiliation': 'The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, NH, USA.'}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Wint', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhou', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Anna N A', 'Initials': 'ANA', 'LastName': 'Tosteson', 'Affiliation': 'The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, NH, USA; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106533'] 2484,34375712,Effectiveness of Receptive Music Therapy with Imbedded 10 Hz Binaural Beats Compared with Standard Care for Patients with Major Depressive Disorder: A Randomized Controlled Trial.,"OBJECTIVES The purpose of this study was to determine the effectiveness of music therapy (MT) with imbedded 10 Hz binaural beats in combination with standard treatment in comparison to standard treatment alone in patients diagnosed with major depressive disorder (MDD). METHODS This study was a randomized controlled trial enrolling 18 MDD adult patients aged ≥20 years old with mild to moderate levels of acute phase depression. The intervention group received MT along with standard treatment, while the control group received only standard treatment. 10-Hz binaural beats were embedded into soothing music. The participants listened to the MT via stereo headphones for 20 minutes at the clinic and were instructed to continue listening to the track at home at least 3 times/week. The primary outcome was depression score using patient health questionnaire depression screening (PHQ-9). The secondary outcomes were quality of life, measured by the Euro Quality of Life Five-Dimension (EQ-5D) rating, and medications adherence, measured by the medication adherence rating scale (MARS). The outcomes were measured at week 0, week 4, and week 8. RESULTS At baseline, the primary outcome of PHQ-9 did not differ between the MT group and the control group (13.3 ± 4.4; 13.9 ± 3.37; p-value = 0.77). After a follow-up of 4 and 8 weeks, the PHQ-9 in the MT group was lower than the control group by 1.50 (95% confidence interval: -4.46 to 1.46). However, this difference was not significant, with p-value = 0.32. As for the secondary outcome, there were no significant differences in terms of EQ-5D and MARS. CONCLUSIONS This study concluded that MDD patients who received 10-Hz binaural beat imbedded MT combined with standard treatment had experienced no significant differences compared with control group in terms of depression score, quality of life, and medication adherence. Further studies are suggested to investigate the long-term effect of MT with binaural beats.",2021,"After a follow-up of 4 and 8 weeks, the PHQ-9 in the MT group was lower than the control group by 1.50 (95% confidence interval: -4.46 to 1.46).","['Patients with Major Depressive Disorder', '18 MDD adult patients aged ≥20 years old with mild to moderate levels of acute phase depression', 'patients diagnosed with major depressive disorder (MDD']","['MT via stereo headphones', 'MT along with standard treatment, while the control group received only standard treatment', 'Receptive Music Therapy with Imbedded 10\u2009Hz Binaural Beats Compared with Standard Care', 'music therapy (MT) with imbedded 10\u2009Hz binaural beats in combination with standard treatment']","['EQ-5D and MARS', 'PHQ-9', 'quality of life, measured by the Euro Quality of Life Five-Dimension (EQ-5D) rating, and medications adherence, measured by the medication adherence rating scale (MARS', 'depression score using patient health questionnaire depression screening (PHQ-9', 'depression score, quality of life, and medication adherence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439557', 'cui_str': 'Acute phase'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0026868', 'cui_str': 'Music therapy'}, {'cui': 'C0441067', 'cui_str': 'Earphones'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1533125', 'cui_str': 'Euro'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0740218', 'cui_str': 'Depression screening'}]",18.0,0.0999651,"After a follow-up of 4 and 8 weeks, the PHQ-9 in the MT group was lower than the control group by 1.50 (95% confidence interval: -4.46 to 1.46).","[{'ForeName': 'Panitan', 'Initials': 'P', 'LastName': 'Daengruan', 'Affiliation': 'Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Rattapong', 'Initials': 'R', 'LastName': 'Chairat', 'Affiliation': 'Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Rewadee', 'Initials': 'R', 'LastName': 'Jenruamjit', 'Affiliation': 'Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Dujrudee', 'Initials': 'D', 'LastName': 'Chinwong', 'Affiliation': 'Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Awirut', 'Initials': 'A', 'LastName': 'Oon-Arom', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine Chiangmai, Chiangmai University, Thailand.'}, {'ForeName': 'Jakkrit', 'Initials': 'J', 'LastName': 'Klaphajone', 'Affiliation': 'Department of Rehabilitation Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Electronic address: jakkrit.k@cmu.ac.th.'}, {'ForeName': 'Poukwan', 'Initials': 'P', 'LastName': 'Arunmanakul', 'Affiliation': 'Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. Electronic address: poukwan@gmail.com.'}]",Complementary therapies in medicine,['10.1016/j.ctim.2021.102765'] 2485,34378269,Endocrowns Clinical Performance and Patient Satisfaction: A Randomised Clinical Trial of Three Monolithic Ceramic Restorations.,"PURPOSE The purpose of this randomized, double-blind, clinical trial was to assess the survival of endocrowns made from three different monolithic ceramic materials, and to evaluate patient satisfaction. MATERIALS AND METHODS Fifty-three patients (sixty root canal treated molar teeth) were enrolled. Teeth were prepared to a flat butt-joint margin and randomly divided between three material groups: lithium disilicate-reinforced glass-ceramic, monolithic zirconia and polymer infiltrated hybrid ceramic. Predefined cementation protocols were used. Clinical assessment using modified United States Public Health Service (USPHS) criteria was carried out after two years by two independent clinicians blinded to the material used. Radiographic examination was conducted to check for the presence of caries, excess cement, and periapical infection. Statistical analysis was performed using the Kruskal Wallis and Wilcoxon signed-rank tests as well as the Kaplan-Meier survival estimate. RESULTS Forty-eight patients were available for assessment after 2 years (recall rate 90.6%). The overall Kaplan-Meier survival estimate among all groups was 90.9% with no statistically significant difference between the groups (p = 0.17). Three zirconia endocrowns debonded after 9, 10 and 13 months (82.4% survival rate), while 2 hybrid ceramic endocrowns chipped/fractured (89.5% survival rate). Lithium disilicate endocrowns had a 100% survival rate. The Kruskal Wallis test revealed no statistically significant difference between the groups in the USPHS criteria ratings and the radiographic assessment (P>0.05). Patient satisfaction ranged from 82.3% in the zirconia group to 100% in both the lithium disilicate and hybrid ceramic groups. CONCLUSIONS Endocrowns provide a predictable option for the restoration of endodontically treated molar teeth in the short term. Lithium disilicate-reinforced ceramic had fewer complications and required less intervention compared with zirconia and hybrid ceramics. Long-term follow-up is required to substantiate these study results. This article is protected by copyright. All rights reserved.",2021,The Kruskal Wallis test revealed no statistically significant difference between the groups in the USPHS criteria ratings and the radiographic assessment (P>0.05).,['Fifty-three patients (sixty root canal treated molar teeth) were enrolled'],"['lithium disilicate-reinforced glass-ceramic, monolithic zirconia and polymer infiltrated hybrid ceramic', 'Lithium disilicate-reinforced ceramic', 'Lithium disilicate endocrowns']","['survival rate', 'overall Kaplan-Meier survival estimate', 'USPHS criteria ratings and the radiographic assessment', 'Endocrowns Clinical Performance and Patient Satisfaction', 'Patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}]","[{'cui': 'C1528812', 'cui_str': 'lithia disilicate'}, {'cui': 'C0015421', 'cui_str': 'Eyeglasses'}, {'cui': 'C0007742', 'cui_str': 'Ceramic'}, {'cui': 'C0078814', 'cui_str': 'zirconium oxide'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0007597', 'cui_str': 'Cell hybridization'}]","[{'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0041734', 'cui_str': 'United States. Public Health Service'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",48.0,0.195634,The Kruskal Wallis test revealed no statistically significant difference between the groups in the USPHS criteria ratings and the radiographic assessment (P>0.05).,"[{'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': ""El-Ma'aita"", 'Affiliation': 'School of Dentistry, University of Jordan, Amman, Jordan.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': ""A Al-Rabab'ah"", 'Affiliation': 'School of Dentistry, University of Jordan, Amman, Jordan.'}, {'ForeName': 'Motasum', 'Initials': 'M', 'LastName': 'Abu-Awwad', 'Affiliation': 'School of Dentistry, University of Jordan, Amman, Jordan.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Hattar', 'Affiliation': 'School of Dentistry, University of Jordan, Amman, Jordan.'}, {'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Devlin', 'Affiliation': 'Division of Dentistry, The University of Manchester, Manchester, UK.'}]",Journal of prosthodontics : official journal of the American College of Prosthodontists,['10.1111/jopr.13414'] 2486,34378260,"Effectiveness of Pistacia atlantica on older adult knee osteoarthritis, a randomized triple blind clinical trial.","Osteoarthritis is the most common cause of disability and aging is the major risk factor. One of the low-risk herbal medicines for reducing pain and inflammation in persian medicine is Pistacia atlantica gum. A triple-blind placebo-controlled clinical trial was performed in order to evaluate the efficacy of P. atlantica gum ointment on knee osteoarthritis in elderly people. A total of 60 patients were randomly allocated to two groups. The intervention group used 4% P. atlantica ointment and the control group used placebo, topically applied three times a day, for 8 weeks. The patients were evaluated before and after the intervention using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale. There were significant differences (p < .001) between two the groups in terms of joint stiffness and pain as well as function. Within groups, regarding the effect size (EF) in joint stiffness was 2.82 and 0.74 in the Pistacia and placebo groups, respectively. Regarding pain, the effect size of the intervention and placebo groups were 3.90 and 0.99, respectively. In addition, regarding function, the effect size of the intervention and the placebo groups were 4.33 and 1.17, respectively. Therefore, it seems that topical P. atlantica is significantly better than the placebo in the old patients with knee osteoarthritis.",2021,There were significant differences (p < .001) between two the groups in terms of joint stiffness and pain as well as function.,"['older adult knee osteoarthritis', 'A total of 60 patients', 'knee osteoarthritis in elderly people', 'old patients with knee osteoarthritis']","['placebo', 'Pistacia atlantica']","['Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale', 'joint stiffness and pain', 'effect size (EF) in joint stiffness', 'pain and inflammation']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0949836', 'cui_str': 'Pistacia'}]","[{'cui': 'C3472647', 'cui_str': 'Western Ontario and McMaster Universities osteoarthritis index'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0162298', 'cui_str': 'Joint stiffness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0444497', 'cui_str': 'In joint'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",60.0,0.0980604,There were significant differences (p < .001) between two the groups in terms of joint stiffness and pain as well as function.,"[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Khamevar', 'Affiliation': 'Department of Traditional Persian Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Mohammad Ali', 'Initials': 'MA', 'LastName': 'Ebrahimzadeh', 'Affiliation': 'Department of Medicinal Chemistry, School of Pharmacy, Traditional and Complementary Medicine Research Center, Addiction Research Institutes, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Mahmood', 'Initials': 'M', 'LastName': 'Moosazadeh', 'Affiliation': 'Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Shayesteh Azar', 'Affiliation': 'Department of Orthopedics, School of Medicine, Orthopedic Research Center, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Saeedi', 'Affiliation': 'Department of Pharmaceutics, School of Pharmacy, Pharmaceutical Sciences Research Center, Hemoglobinopathy Research Institute, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Adel', 'Initials': 'A', 'LastName': 'Bakhtiary Far', 'Affiliation': 'Department of Pharmaceutics, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Seyde Sedighe', 'Initials': 'SS', 'LastName': 'Yousefi', 'Affiliation': 'Department of Traditional Persian Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.7178'] 2487,34378247,Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.,"OBJECTIVES To compare the effects of naftopidil and silodosin administration on the quality of life of patients with prostate cancer who underwent low-dose-rate brachytherapy. METHODS In total, 141 men diagnosed with localized prostate cancer who were treated with low-dose-rate brachytherapy were enrolled. Patients were randomized (1:1) to the naftopidil (75 mg/day, n = 63) or silodosin group (8 mg/day, n = 64). Naftopidil and silodosin were administered 1 day after low-dose-rate brachytherapy, and were continued for at least 3 months. Using the University of California at Los Angeles Prostate Cancer Index and Sexual Health Inventory for Men scores, the mean changes and rates of deterioration from baseline were compared. The deterioration rates in the quality of life of patients at 1 and 3 months after low-dose-rate brachytherapy were evaluated based on the minimal important difference. RESULTS The rates of deterioration from baseline to 1 and 3 months after low-dose-rate brachytherapy were not significantly different between the two groups in terms of urinary function, urinary bother, bowel bother, sexual function or Sexual Health Inventory for Men scores. In contrast, there were significant differences in bowel function (naftopidil 1 month, 52%; 3 months, 52%; silodosin 1 month, 28%; 3 months, 34%; 1 month, P < 0.01; 3 months, P = 0.048) and sexual bother (naftopidil 3 months, 11%; silodosin 3 months, 29%; P = 0.01). CONCLUSIONS Naftopidil and silodosin provide different disease-specific quality of life outcomes in patients undergoing, especially in terms of bowel function and sexual bother. These findings can help in the selection of α-1 adrenoceptor antagonists after low-dose-rate brachytherapy.",2021,"The rates of deterioration from baseline to 1 and 3 months after low-dose-rate brachytherapy were not significantly different between the two groups in terms of urinary function, urinary bother, bowel bother, sexual function or Sexual Health Inventory for Men scores.","['141 men diagnosed with localized prostate cancer who were treated with low-dose-rate brachytherapy were enrolled', 'prostate cancer patients treated with', 'patients with prostate cancer who underwent low-dose-rate brachytherapy', 'patients undergoing']","['naftopidil', 'naftopidil and silodosin', 'low-dose-rate brachytherapy', 'silodosin', 'silodosin versus naftopidil', 'Naftopidil and silodosin']","['rates of deterioration', 'sexual bother', 'urinary function, urinary bother, bowel bother, sexual function or Sexual Health Inventory for Men scores', 'bowel function', 'deterioration rates', 'quality of life']","[{'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0454271', 'cui_str': 'Low dose rate brachytherapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0083701', 'cui_str': 'naftopidil'}, {'cui': 'C1870115', 'cui_str': 'silodosin'}, {'cui': 'C0454271', 'cui_str': 'Low dose rate brachytherapy'}]","[{'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C3472504', 'cui_str': 'Sexual health inventory for men'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",141.0,0.0798121,"The rates of deterioration from baseline to 1 and 3 months after low-dose-rate brachytherapy were not significantly different between the two groups in terms of urinary function, urinary bother, bowel bother, sexual function or Sexual Health Inventory for Men scores.","[{'ForeName': 'Fumisato', 'Initials': 'F', 'LastName': 'Maesaka', 'Affiliation': 'Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Nobumichi', 'Initials': 'N', 'LastName': 'Tanaka', 'Affiliation': 'Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Nakai', 'Affiliation': 'Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Isao', 'Initials': 'I', 'LastName': 'Asakawa', 'Affiliation': 'Department ofRadiation Oncology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Mitsuru', 'Initials': 'M', 'LastName': 'Tomizawa', 'Affiliation': 'Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Owari', 'Affiliation': 'Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Makito', 'Initials': 'M', 'LastName': 'Miyake', 'Affiliation': 'Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Anai', 'Affiliation': 'Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Yamaki', 'Affiliation': 'Department ofRadiation Oncology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Tomomi', 'Initials': 'T', 'LastName': 'Fujii', 'Affiliation': 'Department ofDiagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Masatoshi', 'Initials': 'M', 'LastName': 'Hasegawa', 'Affiliation': 'Department ofRadiation Oncology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Kiyohide', 'Initials': 'K', 'LastName': 'Fujimoto', 'Affiliation': 'Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.'}]",International journal of urology : official journal of the Japanese Urological Association,['10.1111/iju.14667'] 2488,34378245,"A Randomized, Open-label, Two-period Crossover Bridging Study on Fuzuloparib Capsules of Different Specifications in Healthy Chinese Volunteers.","INTRODUCTION Fuzuloparib, also known as fluzoparib or SHR3162, is a poly ADP-ribose polymerase (PARP) inhibitor developed for the treatment of malignant tumor. Three specifications of fuzuloparib capsules (10mg, 40mg and 100mg) were originally developed for clinical trials. After the recommended dose was determined, a new specification of fuzuloparib capsule (50mg) was produced for clinical use. This bridging study was conducted to determine the bioequivalence of the new specification to 3 other specifications at the recommended dose. METHODS A single-center, randomized, open-label, two-period, crossover bridging study was conducted in 40 healthy Chinese subjects under fed conditions. Enrolled subjects received a single oral dose of test or reference preparations according to a randomization list in the first period and crossed over to receive the other preparations in the second period after a 6-day washout interval. Blood samples were collected pre-dose and post-dose at specified time intervals. Plasma fuzuloparib concentrations were analyzed by liquid chromatography-mass spectroscopy. A non-compartment model was adopted to calculate pharmacokinetic parameters of investigational preparations. Primary PK parameters including area under the concentration-time curve (AUC) from administration to the last sampling time (AUC 0-t ), AUC extrapolated to infinity (AUC 0-∞ ) and C max of test and reference preparations were compared to evaluate their bioequivalence. RESULTS The 90% CIs of geometric mean ratios of AUC 0-t , AUC 0-∞ and C max were 96.99%-104.95%, 97.03%-104.93% and 96.53%- 108.98%, respectively, all of which were within the bioequivalence range of 80%-125%. No serious adverse events were observed in this study and no subjects withdrew from the study due to adverse events. CONCLUSIONS The test preparations were bioequivalent to the reference preparations. All investigational products were well-tolerated.",2021,"No serious adverse events were observed in this study and no subjects withdrew from the study due to adverse events. ","['40 healthy Chinese subjects under fed conditions', 'Healthy Chinese Volunteers']","['Fuzuloparib Capsules', 'fuzuloparib capsules']","['geometric mean ratios of AUC 0-t , AUC 0-∞ and C max', 'serious adverse events', 'Plasma fuzuloparib concentrations', 'area under the concentration-time curve (AUC) from administration to the last sampling time (AUC 0-t ']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}]",40.0,0.0369677,"No serious adverse events were observed in this study and no subjects withdrew from the study due to adverse events. ","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Tao', 'Affiliation': 'Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Shi', 'Affiliation': 'Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Feifei', 'Initials': 'F', 'LastName': 'Sun', 'Affiliation': 'Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': 'Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Chenjing', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.'}]",British journal of clinical pharmacology,['10.1111/bcp.15035'] 2489,34378092,ASO Visual Abstract: Surgical Outcomes for Cancer Patients Undergoing Elective Surgery after Recovering from Mild to Moderate SARS-CoV-2 Infection.,,2021,,['Cancer Patients Undergoing Elective Surgery after Recovering from Mild to Moderate SARS-CoV-2 Infection'],[],[],"[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",[],[],,0.204272,,"[{'ForeName': 'Anai N', 'Initials': 'AN', 'LastName': 'Kothari', 'Affiliation': 'Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Sandra R', 'Initials': 'SR', 'LastName': 'DiBrito', 'Affiliation': 'Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'J Jack', 'Initials': 'JJ', 'LastName': 'Lee', 'Affiliation': 'Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Abigail S', 'Initials': 'AS', 'LastName': 'Caudle', 'Affiliation': 'Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Clemens', 'Affiliation': 'Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Vijaya N', 'Initials': 'VN', 'LastName': 'Gottumukkala', 'Affiliation': 'Department of Anesthesia and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Matthew H G', 'Initials': 'MHG', 'LastName': 'Katz', 'Affiliation': 'Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Anaeze C', 'Initials': 'AC', 'LastName': 'Offodile', 'Affiliation': 'Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Abhineet', 'Initials': 'A', 'LastName': 'Uppal', 'Affiliation': 'Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'George J', 'Initials': 'GJ', 'LastName': 'Chang', 'Affiliation': 'Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. gchang@mdanderson.org.'}]",Annals of surgical oncology,['10.1245/s10434-021-10351-0'] 2490,34378091,ASO Visual Abstract: Invasive Lobular Breast Cancer-Data to Support Surgical Decision-Making.,,2021,,[],[],[],[],[],[],,0.091369,,"[{'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Cocco', 'Affiliation': 'Division of Breast Surgery, Department of General Surgery Cleveland Clinic, Cleveland Clinic, 9500 Euclid Ave/A80, Cleveland, OH, USA.'}, {'ForeName': 'Ayat', 'Initials': 'A', 'LastName': 'ElSherif', 'Affiliation': 'Division of Breast Surgery, Department of General Surgery Cleveland Clinic, Cleveland Clinic, 9500 Euclid Ave/A80, Cleveland, OH, USA.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Wright', 'Affiliation': 'Division of Breast Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Marcus S', 'Initials': 'MS', 'LastName': 'Dempster', 'Affiliation': 'Division of Breast Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Megan L', 'Initials': 'ML', 'LastName': 'Kruse', 'Affiliation': 'Division of Breast Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Quantitative Health Science, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Valente', 'Affiliation': 'Division of Breast Surgery, Department of General Surgery Cleveland Clinic, Cleveland Clinic, 9500 Euclid Ave/A80, Cleveland, OH, USA. Valents3@ccf.org.'}]",Annals of surgical oncology,['10.1245/s10434-021-10599-6'] 2491,34378087,Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.,"BACKGROUND We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein encapsulated in lipid nanoparticles (LNP). METHODS This is an interim analysis of a dosage escalation phase 1 study in healthy 18-60-year-old volunteers in Hannover, Munich and Tübingen, Germany, and Ghent, Belgium. After giving 2 intramuscular doses of CVnCoV or placebo 28 days apart we assessed solicited local and systemic adverse events (AE) for 7 days and unsolicited AEs for 28 days after each vaccination. Immunogenicity was measured as enzyme-linked immunosorbent assay (ELISA) IgG antibodies to SARS-CoV‑2 S‑protein and receptor binding domain (RBD), and SARS-CoV‑2 neutralizing titers (MN 50 ). RESULTS In 245 volunteers who received 2 CVnCoV vaccinations (2 μg, n = 47, 4 μg, n = 48, 6 μg, n = 46, 8 μg, n = 44, 12 μg, n = 28) or placebo (n = 32) there were no vaccine-related serious AEs. Dosage-dependent increases in frequency and severity of solicited systemic AEs, and to a lesser extent local AEs, were mainly mild or moderate and transient in duration. Dosage-dependent increases in IgG antibodies to S‑protein and RBD and MN 50 were evident in all groups 2 weeks after the second dose when 100% (23/23) seroconverted to S‑protein or RBD, and 83% (19/23) seroconverted for MN 50 in the 12 μg group. Responses to 12 μg were comparable to those observed in convalescent sera from known COVID-19 patients. CONCLUSION In this study 2 CVnCoV doses were safe, with acceptable reactogenicity and 12 μg dosages elicited levels of immune responses that overlapped those observed in convalescent sera.",2021,"Dosage-dependent increases in IgG antibodies to S‑protein and RBD and MN 50 were evident in all groups 2 weeks after the second dose when 100% (23/23) seroconverted to S‑protein or RBD, and 83% (19/23) seroconverted for MN 50 in the 12 μg group.","['healthy 18-60-year-old volunteers in Hannover, Munich and Tübingen, Germany, and Ghent, Belgium', '245 volunteers who received']","['placebo', 'CVnCoV or placebo', 'vaccine-related serious AEs', 'mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 ', '2 CVnCoV vaccinations']","['Safety and immunogenicity', 'IgG antibodies to S‑protein and RBD and MN 50', 'immune responses', 'enzyme-linked immunosorbent assay (ELISA', 'frequency and severity of solicited systemic AEs', 'solicited local and systemic adverse events (AE', 'Immunogenicity']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C4517661', 'cui_str': '245'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1450054', 'cui_str': 'Nanoparticles'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",245.0,0.139727,"Dosage-dependent increases in IgG antibodies to S‑protein and RBD and MN 50 were evident in all groups 2 weeks after the second dose when 100% (23/23) seroconverted to S‑protein or RBD, and 83% (19/23) seroconverted for MN 50 in the 12 μg group.","[{'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Kremsner', 'Affiliation': 'Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Mann', 'Affiliation': 'CureVac AG, Schumannstraße\xa027, 60325, Frankfurt, Germany. Philipp.Mann@curevac.com.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Kroidl', 'Affiliation': 'Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Leroux-Roels', 'Affiliation': 'Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Schindler', 'Affiliation': 'Hannover Medical School (MHH), Hannover, Germany.'}, {'ForeName': 'Julian J', 'Initials': 'JJ', 'LastName': 'Gabor', 'Affiliation': 'Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Schunk', 'Affiliation': 'Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Geert', 'Initials': 'G', 'LastName': 'Leroux-Roels', 'Affiliation': 'Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Jacobus J', 'Initials': 'JJ', 'LastName': 'Bosch', 'Affiliation': 'Hannover Medical School (MHH), Hannover, Germany.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Fendel', 'Affiliation': 'Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Kreidenweiss', 'Affiliation': 'Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Thirumalaisamy P', 'Initials': 'TP', 'LastName': 'Velavan', 'Affiliation': 'Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Mariola', 'Initials': 'M', 'LastName': 'Fotin-Mleczek', 'Affiliation': 'CureVac AG, Tübingen, Germany.'}, {'ForeName': 'Stefan O', 'Initials': 'SO', 'LastName': 'Mueller', 'Affiliation': 'CureVac AG, Schumannstraße\xa027, 60325, Frankfurt, Germany.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Quintini', 'Affiliation': 'CureVac AG, Tübingen, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Schönborn-Kellenberger', 'Affiliation': 'Cogitars, Heidelberg, Germany.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Vahrenhorst', 'Affiliation': 'CureVac AG, Tübingen, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Verstraeten', 'Affiliation': 'P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.'}, {'ForeName': 'Margarida', 'Initials': 'M', 'LastName': 'Alves de Mesquita', 'Affiliation': 'CureVac AG, Schumannstraße\xa027, 60325, Frankfurt, Germany.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Walz', 'Affiliation': 'CureVac AG, Schumannstraße\xa027, 60325, Frankfurt, Germany.'}, {'ForeName': 'Olaf-Oliver', 'Initials': 'OO', 'LastName': 'Wolz', 'Affiliation': 'CureVac AG, Tübingen, Germany.'}, {'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Oostvogels', 'Affiliation': 'CureVac AG, Schumannstraße\xa027, 60325, Frankfurt, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Wiener klinische Wochenschrift,['10.1007/s00508-021-01922-y'] 2492,34375855,Are manual therapy or booster sessions worthwhile in addition to exercise therapy for knee osteoarthritis: Economic evaluation and 2-year follow-up of a randomized controlled trial.,"BACKGROUND Exercise therapy is known to be an effective intervention for patients with osteoarthritis, however the evidence is limited as to whether adding manual therapy or booster sessions are cost-effective strategies to extend the duration of benefits. OBJECTIVE To investigate the cost-effectiveness, at 2-year follow-up, of adding manual therapy and/or booster sessions to exercise therapy. DESIGN 2-by-2 factorial randomized controlled trial. METHODS Participants with knee osteoarthritis were randomly allocated (1:1:1:1) to: exercise therapy delivered in consecutive sessions within 9 weeks (control group), exercise therapy distributed over 1 year using booster sessions, exercise therapy plus manual therapy delivered within 9 weeks, and exercise therapy plus manual therapy with booster sessions. The primary outcome was incremental cost-effectiveness from health system and societal perspectives interpreted as incremental net monetary benefit (INMB). RESULTS Of 75 participants, 66 (88 %) were retained at 1-year and 40 (53 %) at 2-year follow-up. All three interventions were cost-effective from both the health system and societal perspectives (INMBs, at 0.5 × GDP/capita willingness to pay (WTP) threshold: $3278 (95%CI -3244 to 9800) and $3904 (95%CI -2823 to 10,632) respectively for booster sessions; $2941 (95%CI -3686 to 9568) and $2618 (95%CI -4005 to 9241) for manual therapy; $270 (95%CI -6139 to 6679) and $404 (95%CI -6097 to 6905) for manual therapy with booster sessions). CONCLUSION Manual therapy or booster sessions in addition to exercise therapy are cost-effective at 2-year follow-up. The evidence did not support combining both booster sessions and manual therapy in addition to exercise therapy.",2021,"All three interventions were cost-effective from both the health system and societal perspectives (INMBs, at 0.5 × GDP/capita willingness to pay (WTP) threshold: $3278 (95%CI -3244 to 9800) and $3904 (95%CI -2823 to 10,632) respectively for booster sessions; $2941 (95%CI -3686 to 9568) and $2618 (95%CI -4005 to 9241) for manual therapy; $270 (95%CI -6139 to 6679) and $404 (95%CI -6097 to 6905) for manual therapy with booster sessions). ","['patients with osteoarthritis', 'Participants with knee osteoarthritis']","['exercise therapy delivered in consecutive sessions within 9 weeks (control group), exercise therapy distributed over 1 year using booster sessions, exercise therapy plus manual therapy delivered within 9 weeks, and exercise therapy plus manual therapy with booster sessions', 'exercise therapy']","['cost-effectiveness', 'incremental cost-effectiveness from health system and societal perspectives interpreted as incremental net monetary benefit (INMB']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}]","[{'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0020975', 'cui_str': 'Booster vaccination'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0454525', 'cui_str': 'Manual therapy'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C1285553', 'cui_str': 'Interprets'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}]",,0.0714341,"All three interventions were cost-effective from both the health system and societal perspectives (INMBs, at 0.5 × GDP/capita willingness to pay (WTP) threshold: $3278 (95%CI -3244 to 9800) and $3904 (95%CI -2823 to 10,632) respectively for booster sessions; $2941 (95%CI -3686 to 9568) and $2618 (95%CI -4005 to 9241) for manual therapy; $270 (95%CI -6139 to 6679) and $404 (95%CI -6097 to 6905) for manual therapy with booster sessions). ","[{'ForeName': 'Yana', 'Initials': 'Y', 'LastName': 'Pryymachenko', 'Affiliation': 'Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, Otago Medical School, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. Electronic address: yana.pryymachenko@otago.ac.nz.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Wilson', 'Affiliation': 'Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, Otago Medical School, University of Otago, PO Box 56, Dunedin, 9054, New Zealand.'}, {'ForeName': 'Saurab', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, Otago Medical School, University of Otago, PO Box 56, Dunedin, 9054, New Zealand; Department of Physiotherapy, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.'}, {'ForeName': 'Anupa', 'Initials': 'A', 'LastName': 'Pathak', 'Affiliation': 'Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, Otago Medical School, University of Otago, PO Box 56, Dunedin, 9054, New Zealand.'}, {'ForeName': 'J Haxby', 'Initials': 'JH', 'LastName': 'Abbott', 'Affiliation': 'Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, Otago Medical School, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. Electronic address: haxby.abbott@otago.ac.nz.'}]",Musculoskeletal science & practice,['10.1016/j.msksp.2021.102439'] 2493,34375844,Using error-estimation to probe the psychological processes underlying contextual interference effects.,"Although the learning benefits of interleaved practice schedules relative to blocked schedules are well-reported, the mechanisms underlying these effects are not fully understood. Researchers have generally suggested that random schedules of practice increase task-related information processing which arises due to switching between variations of the same task (or switching between different tasks). Thus, one potentially useful way to both probe and manipulate contextual interference is to pair it with error estimation during practice. Forced error estimation increases task-related information processing and recording these estimates provides insight into learners' self-awareness of their errors. In the present study, 84 participants were randomly allocated to four groups. Participants practiced a timing task under blocked or random schedules, with and without error estimations prior to feedback. During the acquisition phase, three target times were trained (1500, 1700, 1900 ms), with feedback delivered after every trial. We used delayed post-tests (24 hrs later) to evaluate the retention of these target times and their transfer to two new target times (1600, 1800 ms). Participants who practiced with a random schedule performed worse (i.e., greater absolute error) than those with a blocked schedule during acquisition (p = .006); however, randomly scheduled participants also showed reduced error (p = .004) on the retention and transfer tests. Although prompting error estimations led to greater self-reported mental effort being invested on the task (p = .001), error estimation was not reliably associated with superior learning (p = .133). The accuracy of error estimations did not differ as a function of practice structure (p = .070), although the accuracy of error estimations improved during acquisition (p = .006). Findings highlight the robustness of the contextual interference effect, but we did not find evidence that error estimations moderated the effect on this task. It is in some ways surprising that we found an effect of contextual interference, as past-work suggests that interference effects are attenuated (or eliminated) when participants switch between different parameters of the same task. We speculate that this might be due to the difficulty of the task; even though participants switched between parametric variations of the same task, the distinction between parameters was subtle (i.e., tenths of a second).",2021,"Although prompting error estimations led to greater self-reported mental effort being invested on the task (p = .001), error estimation was not reliably associated with superior learning (p = .133).",['84 participants'],[],"['accuracy of error estimations', 'retention and transfer tests']",[],[],"[{'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",84.0,0.0384408,"Although prompting error estimations led to greater self-reported mental effort being invested on the task (p = .001), error estimation was not reliably associated with superior learning (p = .133).","[{'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Thomas', 'Affiliation': 'Department of Health and Kinesiology, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Fawver', 'Affiliation': 'Department of Health and Kinesiology, University of Utah, Salt Lake City, UT, USA; US Army Medical Research Directorate-West, Walter Reed Army Institute of Research, Joint Base Lewis McChord, WA, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Taylor', 'Affiliation': 'Department of Health and Kinesiology, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Matthew W', 'Initials': 'MW', 'LastName': 'Miller', 'Affiliation': 'School of Kinesiology and Center for Neuroscience, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'A Mark', 'Initials': 'AM', 'LastName': 'Williams', 'Affiliation': 'Department of Health and Kinesiology, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Keith R', 'Initials': 'KR', 'LastName': 'Lohse', 'Affiliation': 'Program in Physical Therapy, Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA. Electronic address: lohse@wustl.edu.'}]",Human movement science,['10.1016/j.humov.2021.102854'] 2494,34375706,Impact of major infections on 10-year mortality after revascularization in patients with complex coronary artery disease.,"BACKGROUND The significant interaction between major infection and 5-year mortality after percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) for complex coronary artery disease (CAD) was observed previously. However, the very long-term outcomes beyond 5 years remains unclear. METHODS AND RESULTS This is a subgroup analysis of the SYNTAX Extended Survival (SYNTAXES) trial, which is the extended follow-up of the randomized SYNTAX trial comparing PCI versus CABG in patients with three-vessel disease (3VD) or left-main CAD (LMCAD). Out of 1517 patients enrolled in the SYNTAX trial with available survival status from 5 to 10 years, 140 patients had experienced major infections and survived at 5 years (major infection group). From 5 to 10 years, the mortality of major infection group was 19.8% whereas the mortality of no major infection group was 15.1% (p = 0.157). After the adjustment of other clinical factors, the risk of mortality from 5 to 10 years did not significantly differ between major infection and no major infection groups (HR: 1.10; 95% CI: 0.62-1.96; p = 0.740). When stratified by the presence or absence of periprocedural major infections, defined as a major infection within 60 days after index procedure, there was also no significant difference in 10-year mortality between two groups (30.8% vs. 24.5%; p = 0.057). CONCLUSIONS Despite the initial association between major infections and 5 years mortality, postprocedural major infection was not evident in the 10 years follow-up, suggesting that the impact of major infection on mortality subsided over time beyond 5 years. TRIAL REGISTRATION SYNTAXES ClinicalTrials.gov reference: NCT03417050 SYNTAX ClinicalTrials.gov reference: NCT00114972.",2021,"After the adjustment of other clinical factors, the risk of mortality from 5 to 10 years did not significantly differ between major infection and no major infection groups (HR: 1.10; 95% CI: 0.62-1.96; p = 0.740).","['patients with three-vessel disease (3VD) or left-main CAD (LMCAD', '1517 patients enrolled in the SYNTAX trial with available survival status from 5 to 10\u202fyears, 140 patients had experienced major infections and survived at 5\u202fyears (major infection group', 'patients with complex coronary artery disease']","['PCI versus CABG', 'percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG']","['risk of mortality', '10-year mortality', 'mortality of major infection', '5-year mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1299433', 'cui_str': 'Left main coronary artery disease'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0011905', 'cui_str': 'Computer-Assisted Diagnosis'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",1517.0,0.105907,"After the adjustment of other clinical factors, the risk of mortality from 5 to 10 years did not significantly differ between major infection and no major infection groups (HR: 1.10; 95% CI: 0.62-1.96; p = 0.740).","[{'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Ono', 'Affiliation': 'Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Kawashima', 'Affiliation': 'Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.'}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Mancone', 'Affiliation': 'Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Mack', 'Affiliation': 'Department of Cardiothoracic Surgery, Baylor University Medical Center, Dallas, TX, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Holmes', 'Affiliation': 'Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Morice', 'Affiliation': 'Département of Cardiologie, Hôpital privé Jacques Cartier, Générale de Santé Massy, France.'}, {'ForeName': 'Arie Pieter', 'Initials': 'AP', 'LastName': 'Kappetein', 'Affiliation': 'Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands.'}, {'ForeName': 'Daniel J F M', 'Initials': 'DJFM', 'LastName': 'Thuijs', 'Affiliation': 'Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands.'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Noack', 'Affiliation': 'University Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany.'}, {'ForeName': 'Friedrick W', 'Initials': 'FW', 'LastName': 'Mohr', 'Affiliation': 'University Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany.'}, {'ForeName': 'Piroze M', 'Initials': 'PM', 'LastName': 'Davierwala', 'Affiliation': 'University Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany.'}, {'ForeName': 'Yoshinobu', 'Initials': 'Y', 'LastName': 'Onuma', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; NHLI, Imperial College London, London, United Kingdom. Electronic address: patrick.serruys@nuigalway.ie.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",International journal of cardiology,['10.1016/j.ijcard.2021.08.013'] 2495,34375677,Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.,"BACKGROUND AND PURPOSE Proprotein convertase subtilisin-kexin type 9(PCSK9) monoclonal antibody (Mab; Evolocumab) has been reported to inhibit low-density lipoprotein cholesterol (LDL-C) and Lipoprotein(a) [LP(a)] in coronary heart diseases (CHD) patients in America, Europe and Japan. However, little is known about the effect of Evolocumab in Chinese population. This retrospective study in Chinese CHD patients compared the efficacy without or with Evolocumab therapy added to the conventional treatment with a statin (Rosuvastatin) and a gut cholesterol absorption inhibitor (Ezetimibe). METHODS CHD patients from our hospital were divided into three therapeutic groups, A) the statin monotherapy group (10 mg Rosuvastatin every night); B) the statin/cholesterol absorption inhibitor group (10 mg Rosuvastatin and 10 mg Ezetimibe daily); and C) the triple therapy with PCSK9 Mab group (10 mg Rosuvastatin daily, 10 mg Ezetimibe daily, and 140 mg Evolocumab once 2 weeks). The plasma lipid data were collected at 0, 4, 12, and 24 Week(s). The Graphpad Prism 7 program was used to perform all the statistical analysis. RESULTS Out of 103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C. The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels. Neither the statin therapy alone (5.95%; P = 0.6), nor the double therapy (5.27%; P = 0.7) affected LP(a) levels. In contrast, addition of Evolocumab to the double therapy significantly decreased LP(a) level by 37.2% (P < 0.0001). CONCLUSION Addition of Evolocumab to the standard double therapy in Chinese CHD patients improved the efficacy in LDL-C reduction when compared to Rosuvastatin alone or in Rosuvastatin/Ezetimibe double therapy. Furthermore, the addition of Evolocumab lowered LP(a) level in Chinese CHD patients.",2021,"The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels.","['Chinese CHD patients', 'coronary heart diseases (CHD) patients in America, Europe and Japan', 'single center in China', 'CHD patients from our hospital', 'patients with coronary heart disease (CHD', '103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C']","['statin/cholesterol absorption inhibitor group (10\u202fmg Rosuvastatin and 10\u202fmg Ezetimibe', 'PCSK9 Mab group (10\u202fmg Rosuvastatin daily, 10\u202fmg Ezetimibe', 'monoclonal antibody (Mab; Evolocumab', 'Evolocumab/Rosuvastatin/Ezetimibe', 'Rosuvastatin and Ezetimibe', 'Evolocumab therapy added to the conventional treatment with a statin (Rosuvastatin) and a gut cholesterol absorption inhibitor (Ezetimibe', 'Rosuvastatin', 'Evolocumab', 'Rosuvastatin/Ezetimibe', 'PCSK9 monoclonal antibody (Evolocumab', 'statin monotherapy']","['plasma lipid data', 'LP(a) level', 'efficacy in LDL-C reduction', 'LP(a) levels', 'plasma LDL-C levels', 'cholesterol levels']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0002454', 'cui_str': 'America'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0441837', 'cui_str': 'Group C'}]","[{'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C1426592', 'cui_str': 'Proprotein convertase subtilisin/kexin type 9 gene'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3529352', 'cui_str': 'evolocumab'}, {'cui': 'C3700394', 'cui_str': 'rosuvastatin and ezetimibe'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}]","[{'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}]",,0.0607838,"The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels.","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'MM, Cardiac Diagnosis and Treatment Center, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'MM, Cardiac Diagnosis and Treatment Center, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China. Electronic address: dw566855@126.com.'}]",Transplant immunology,['10.1016/j.trim.2021.101444'] 2496,34375630,Response: Bilateral Arm Training vs Unilateral Arm Training for Severely Letter to the Editor.,,2021,,[],['Bilateral Arm Training vs Unilateral Arm Training for Severely Letter to the Editor'],['Response'],[],"[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}]",[],,0.0168259,,"[{'ForeName': 'Caroline Ie', 'Initials': 'CI', 'LastName': 'Renner', 'Affiliation': 'Department of Neurology/Early Rehabilitation, Mediclin Waldkrankenhaus Bad Düben. Electronic address: caroline.renner@mediclin.de.'}, {'ForeName': 'Horst', 'Initials': 'H', 'LastName': 'Hummelsheim', 'Affiliation': 'NRZ Neurological Rehabilitation Center, University of Leipzig, Germany.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2021.06.019'] 2497,34375514,"Effects of Shiitake Culinary-Medicinal Mushroom, Lentinus edodes (Agaricomycetes), Bars on Lipid and Antioxidant Profiles in Individuals with Borderline High Cholesterol: A Double-Blind Randomized Clinical Trial.","Shiitake (Lentinus edodes) is a culinary-medicinal mushroom that has low lipid content and is rich in protein, fiber, minerals, vitamins, antioxidant compounds, and β-glucans. We assessed the effects of L. edodes bars on cholesterolemia and oxidative stress levels in individuals with borderline high cholesterol through a randomized, double-blind, placebo-controlled study. Individuals with borderline high cholesterol, low-density lipoprotein, or triglycerides were recruited. Sixty-eight individuals were randomly allocated to group I (placebo; n = 32) or group II (intervention; n = 36). Blood samples were collected at 0, 33, and 66 days, and all individuals received an unidentified opaque envelope containing the bars. Biochemical (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein, and glucose) and oxidative stress biomarkers (reduced glutathione, catalase, and thiobarbituric acid reactive substances) in the blood were assessed. Participants in the intervention group showed a 10% reduction in triglycerides after 66 days of consuming the shiitake bars (P = 0.0352). In oxidative stress biomarkers, L. edodes increased the main endogenous antioxidant reduced glutathione and reduced lipid peroxidation. Exposure to L. edodes triggered dermatitis in 10% of individuals sensitive to the mushroom. In conclusion, L. edodes bars are a nutritious food and a functional health food alternative. This food improves redox status and can be considered as an adjuvant in the prevention of dyslipidemia.",2021,Participants in the intervention group showed a 10% reduction in triglycerides after 66 days of consuming the shiitake bars (P = 0.0352).,"['Sixty-eight individuals', 'Individuals with borderline high cholesterol, low-density lipoprotein, or triglycerides were recruited', 'Individuals with Borderline High Cholesterol', 'individuals with borderline high cholesterol']","['Shiitake Culinary-Medicinal Mushroom, Lentinus edodes (Agaricomycetes', 'placebo']","['Biochemical (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein, and glucose) and oxidative stress biomarkers (reduced glutathione, catalase, and thiobarbituric acid reactive substances', 'cholesterolemia and oxidative stress levels', 'triglycerides', 'lipid peroxidation', 'redox status']","[{'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C2711208', 'cui_str': 'Borderline high'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]","[{'cui': 'C0001774', 'cui_str': 'Order Agaricales'}, {'cui': 'C0752328', 'cui_str': 'Lentinula edodes'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0007367', 'cui_str': 'CATALASE'}, {'cui': 'C0162781', 'cui_str': 'TBARs'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023775', 'cui_str': 'Lipid peroxidation'}, {'cui': 'C0030012', 'cui_str': 'Oxidation-reduction'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",68.0,0.271855,Participants in the intervention group showed a 10% reduction in triglycerides after 66 days of consuming the shiitake bars (P = 0.0352).,"[{'ForeName': 'Sara Rosicler Vieira', 'Initials': 'SRV', 'LastName': 'Spim', 'Affiliation': 'Post Graduate Program in Pharmaceutical Sciences, Department of Development and Evaluation of Bioactive Substances, University of Sorocaba, SP, Brazil; Laboratory of Toxicological Research (Lapetox), University of Sorocaba, UNISO, Sorocaba, SP, Brazil.'}, {'ForeName': 'Ana Maria Holtz', 'Initials': 'AMH', 'LastName': 'Pistila', 'Affiliation': 'University of Sorocaba, Sorocaba, São Paulo, Brazil.'}, {'ForeName': 'Thaisa Borim', 'Initials': 'TB', 'LastName': 'Pickler', 'Affiliation': 'University of Sorocaba (UNISO), Rodovia Raposo Tavares Km 92.5, CEP. 18023-000, Sorocaba, Brazil SP, Brazil.'}, {'ForeName': 'Marcus Tolentino', 'Initials': 'MT', 'LastName': 'Silva', 'Affiliation': 'University of Sorocaba, Sorocaba, São Paulo, Brazil.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Grotto', 'Affiliation': 'University of Sorocaba (UNISO), Rodovia Raposo Tavares Km 92.5, CEP. 18023-000, Sorocaba, Brazil SP, Brazil.'}]",International journal of medicinal mushrooms,['10.1615/IntJMedMushrooms.2021038773'] 2498,34375394,Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial.,"Importance Intravenous fluids are used for almost all intensive care unit (ICU) patients. Clinical and laboratory studies have questioned whether specific fluid types result in improved outcomes, including mortality and acute kidney injury. Objective To determine the effect of a balanced solution vs saline solution (0.9% sodium chloride) on 90-day survival in critically ill patients. Design, Setting, and Participants Double-blind, factorial, randomized clinical trial conducted at 75 ICUs in Brazil. Patients who were admitted to the ICU with at least 1 risk factor for worse outcomes, who required at least 1 fluid expansion, and who were expected to remain in the ICU for more than 24 hours were randomized between May 29, 2017, and March 2, 2020; follow-up concluded on October 29, 2020. Patients were randomized to 2 different fluid types (a balanced solution vs saline solution reported in this article) and 2 different infusion rates (reported separately). Interventions Patients were randomly assigned 1:1 to receive either a balanced solution (n = 5522) or 0.9% saline solution (n = 5530) for all intravenous fluids. Main Outcomes and Measures The primary outcome was 90-day survival. Results Among 11 052 patients who were randomized, 10 520 (95.2%) were available for the analysis (mean age, 61.1 [SD, 17] years; 44.2% were women). There was no significant interaction between the 2 interventions (fluid type and infusion speed; P = .98). Planned surgical admissions represented 48.4% of all patients. Of all the patients, 60.6% had hypotension or vasopressor use and 44.3% required mechanical ventilation at enrollment. Patients in both groups received a median of 1.5 L of fluid during the first day after enrollment. By day 90, 1381 of 5230 patients (26.4%) assigned to a balanced solution died vs 1439 of 5290 patients (27.2%) assigned to saline solution (adjusted hazard ratio, 0.97 [95% CI, 0.90-1.05]; P = .47). There were no unexpected treatment-related severe adverse events in either group. Conclusion and Relevance Among critically ill patients requiring fluid challenges, use of a balanced solution compared with 0.9% saline solution did not significantly reduce 90-day mortality. The findings do not support the use of this balanced solution. Trial Registration ClinicalTrials.gov Identifier: NCT02875873.",2021,"Among critically ill patients requiring fluid challenges, use of a balanced solution compared with 0.9% saline solution did not significantly reduce 90-day mortality.","['Critically Ill Patients', 'critically ill patients', 'Among 11\u202f052 patients who were randomized, 10\u202f520 (95.2%) were available for the analysis (mean age, 61.1 [SD, 17] years; 44.2% were women', 'critically ill patients requiring fluid challenges', 'Patients who were admitted to the ICU with at least 1 risk factor for worse outcomes, who required at least 1 fluid expansion, and who were expected to remain in the ICU for more than 24 hours were randomized between May 29, 2017, and March 2, 2020; follow-up concluded on October 29, 2020']","['saline solution', 'Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution', 'balanced solution vs saline solution (0.9% sodium chloride', 'balanced solution vs saline solution', 'balanced solution (n\u2009=\u20095522) or 0.9% saline solution']","['Mortality', '90-day mortality', 'severe adverse events', 'mechanical ventilation', '90-day survival', 'hypotension or vasopressor']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517803', 'cui_str': '520'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0917903', 'cui_str': 'Conclude Composite Resin'}]","[{'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C1289919', 'cui_str': 'Intravenous fluid'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205415', 'cui_str': 'Balanced'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0990166', 'cui_str': 'Sodium Chloride 0.154 MEQ/ML'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}]",11052.0,0.736598,"Among critically ill patients requiring fluid challenges, use of a balanced solution compared with 0.9% saline solution did not significantly reduce 90-day mortality.","[{'ForeName': 'Fernando G', 'Initials': 'FG', 'LastName': 'Zampieri', 'Affiliation': 'HCor Research Institute, São Paulo, Brazil.'}, {'ForeName': 'Flávia R', 'Initials': 'FR', 'LastName': 'Machado', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'Rodrigo S', 'Initials': 'RS', 'LastName': 'Biondi', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'Flávio G R', 'Initials': 'FGR', 'LastName': 'Freitas', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'Viviane C', 'Initials': 'VC', 'LastName': 'Veiga', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'Rodrigo C', 'Initials': 'RC', 'LastName': 'Figueiredo', 'Affiliation': 'Hospital Maternidade São José, Centro Universitário do Espírito Santo, Colatina, Brazil.'}, {'ForeName': 'Wilson J', 'Initials': 'WJ', 'LastName': 'Lovato', 'Affiliation': 'Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.'}, {'ForeName': 'Cristina P', 'Initials': 'CP', 'LastName': 'Amêndola', 'Affiliation': 'Fundação Pio XII, Hospital de Câncer de Barretos, Barretos, Brazil.'}, {'ForeName': 'Ary', 'Initials': 'A', 'LastName': 'Serpa-Neto', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'Jorge L R', 'Initials': 'JLR', 'LastName': 'Paranhos', 'Affiliation': 'Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, Brazil.'}, {'ForeName': 'Marco A V', 'Initials': 'MAV', 'LastName': 'Guedes', 'Affiliation': 'Hospital Ana Nery, Salvador, Brazil.'}, {'ForeName': 'Eraldo A', 'Initials': 'EA', 'LastName': 'Lúcio', 'Affiliation': 'Hospital São Francisco, Santa Casa de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Lúcio C', 'Initials': 'LC', 'LastName': 'Oliveira-Júnior', 'Affiliation': 'Hospital Geral Clériston Andrade, Feira de Santana, Brazil.'}, {'ForeName': 'Thiago C', 'Initials': 'TC', 'LastName': 'Lisboa', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'Fábio H', 'Initials': 'FH', 'LastName': 'Lacerda', 'Affiliation': 'Hospital da Luz, São Paulo, Brazil.'}, {'ForeName': 'Israel S', 'Initials': 'IS', 'LastName': 'Maia', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'Cintia M C', 'Initials': 'CMC', 'LastName': 'Grion', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'Murillo S C', 'Initials': 'MSC', 'LastName': 'Assunção', 'Affiliation': 'Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Airton L O', 'Initials': 'ALO', 'LastName': 'Manoel', 'Affiliation': 'Hospital Paulistano, São Paulo, Brazil.'}, {'ForeName': 'João M', 'Initials': 'JM', 'LastName': 'Silva-Junior', 'Affiliation': 'Hospital do Servidor Público Estadual, São Paulo, Brazil.'}, {'ForeName': 'Péricles', 'Initials': 'P', 'LastName': 'Duarte', 'Affiliation': 'Hospital Universitário de Cascavel, Cascavel, Brazil.'}, {'ForeName': 'Rafael M', 'Initials': 'RM', 'LastName': 'Soares', 'Affiliation': 'HCor Research Institute, São Paulo, Brazil.'}, {'ForeName': 'Tamiris A', 'Initials': 'TA', 'LastName': 'Miranda', 'Affiliation': 'HCor Research Institute, São Paulo, Brazil.'}, {'ForeName': 'Lucas M', 'Initials': 'LM', 'LastName': 'de Lima', 'Affiliation': 'HCor Research Institute, São Paulo, Brazil.'}, {'ForeName': 'Rodrigo M', 'Initials': 'RM', 'LastName': 'Gurgel', 'Affiliation': 'HCor Research Institute, São Paulo, Brazil.'}, {'ForeName': 'Denise M', 'Initials': 'DM', 'LastName': 'Paisani', 'Affiliation': 'HCor Research Institute, São Paulo, Brazil.'}, {'ForeName': 'Thiago D', 'Initials': 'TD', 'LastName': 'Corrêa', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'Luciano C P', 'Initials': 'LCP', 'LastName': 'Azevedo', 'Affiliation': 'Brazilian Research in Intensive Care Network, São Paulo, Brazil.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Kellum', 'Affiliation': 'Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Lucas P', 'Initials': 'LP', 'LastName': 'Damiani', 'Affiliation': 'HCor Research Institute, São Paulo, Brazil.'}, {'ForeName': 'Nilton', 'Initials': 'N', 'LastName': 'Brandão da Silva', 'Affiliation': 'School of Medicine, Federal University of Health Sciences, Porto Alegre, Brazil.'}, {'ForeName': 'Alexandre B', 'Initials': 'AB', 'LastName': 'Cavalcanti', 'Affiliation': 'HCor Research Institute, São Paulo, Brazil.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2021.11684'] 2499,34375393,Cognitive response to testosterone replacement added to intensive lifestyle intervention in older men with obesity and hypogonadism: prespecified secondary analyses of a randomized clinical trial.,"BACKGROUND Both obesity and hypogonadism are common in older men which could additively exacerbate age-related declines in cognitive function. However, little is known about the effects of lifestyle intervention plus testosterone replacement therapy in this population. OBJECTIVES In this secondary analysis of the LITROS (Lifestyle Intervention and Testosterone Replacement in Obese Seniors) trial, we examined whether testosterone replacement therapy would improve cognitive function when added to intensive lifestyle intervention in older men with obesity and hypogonadism. METHODS Eighty-three older, obese hypogonadal men with frailty were randomly assigned to lifestyle therapy (weight management and exercise training) plus testosterone (LT + Test) or lifestyle therapy plus placebo (LT + Pbo) for 6 mo. For this report, the primary outcome was change in the global cognition composite z score. Secondary outcomes included changes in z score subcomponents: attention/information processing, memory, executive function, and language. Changes between groups were analyzed using mixed-model repeated-measures ANCOVAs following the intention-to-treat principle. RESULTS Global cognition z score increased more in the LT + Test than in the LT + Pbo group (mean change: 0.49 compared with 0.21; between-group difference: -0.28; 95% CI: -0.45, -0.11; Cohen's d = 0.74). Moreover, attention/information z score and memory z score increased more in the LT + Test than in the LT + Pbo group (mean change: 0.55 compared with 0.23; between-group difference: -0.32; 95% CI: -0.55, -0.09; Cohen's d = 0.49 and mean change: 0.90 compared with 0.37; between-group difference: -0.53; 95% CI: -0.93, -0.13; Cohen's d = 1.43, respectively). Multiple regression analyses showed that changes in peak oxygen consumption, strength, total testosterone, and luteinizing hormone were independent predictors of the improvement in global cognition (R2 = 0.38; P < 0.001). CONCLUSIONS These findings suggest that in the high-risk population of older men with obesity and hypogonadism, testosterone replacement may improve cognitive function with lifestyle behaviors controlled via lifestyle intervention therapy.This trial was registered at clinicaltrials.gov as NCT02367105.",2021,"Multiple regression analyses showed that changes in peak oxygen consumption, strength, total testosterone, and luteinizing hormone were independent predictors of the improvement in global cognition (R2 = 0.38; P < 0.001). ","['Obese Seniors', 'Eighty-three older, obese hypogonadal men with frailty', 'older men with obesity and hypogonadism', 'older men']","['testosterone replacement added to intensive lifestyle intervention', 'lifestyle therapy (weight management and exercise training) plus testosterone (LT\xa0+\xa0Test) or lifestyle therapy plus placebo (LT\xa0+\xa0Pbo', 'intensive lifestyle intervention', 'Lifestyle Intervention and Testosterone Replacement', 'testosterone replacement therapy', 'testosterone replacement']","['cognitive function', 'global cognition', 'attention/information z score and memory z score', 'Global cognition z score', 'global cognition composite z score', 'changes in z score subcomponents: attention/information processing, memory, executive function, and language', 'peak oxygen consumption, strength, total testosterone, and luteinizing hormone', 'Cognitive response']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0020619', 'cui_str': 'Hypogonadism'}]","[{'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0031962', 'cui_str': 'Piperonyl Butoxide'}, {'cui': 'C4510497', 'cui_str': 'Testosterone replacement therapy'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0202227', 'cui_str': 'Testosterone measurement, total'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}]",,0.192091,"Multiple regression analyses showed that changes in peak oxygen consumption, strength, total testosterone, and luteinizing hormone were independent predictors of the improvement in global cognition (R2 = 0.38; P < 0.001). ","[{'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Gregori', 'Affiliation': 'Center for Translational Research on Inflammatory Diseases, Michael E DeBakey VA Medical Center, Houston, TX, USA.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Celli', 'Affiliation': 'Center for Translational Research on Inflammatory Diseases, Michael E DeBakey VA Medical Center, Houston, TX, USA.'}, {'ForeName': 'Yoann', 'Initials': 'Y', 'LastName': 'Barnouin', 'Affiliation': 'Center for Translational Research on Inflammatory Diseases, Michael E DeBakey VA Medical Center, Houston, TX, USA.'}, {'ForeName': 'Arjun', 'Initials': 'A', 'LastName': 'Paudyal', 'Affiliation': 'Center for Translational Research on Inflammatory Diseases, Michael E DeBakey VA Medical Center, Houston, TX, USA.'}, {'ForeName': 'Reina', 'Initials': 'R', 'LastName': 'Armamento-Villareal', 'Affiliation': 'Center for Translational Research on Inflammatory Diseases, Michael E DeBakey VA Medical Center, Houston, TX, USA.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Napoli', 'Affiliation': 'Division of Endocrinology and Metabolism, Washington University School of Medicine, St Louis, MO, USA.'}, {'ForeName': 'Clifford', 'Initials': 'C', 'LastName': 'Qualls', 'Affiliation': 'Department of Mathematics and Statistics, University of New Mexico School of Medicine, Albuquerque, NM, USA.'}, {'ForeName': 'Dennis T', 'Initials': 'DT', 'LastName': 'Villareal', 'Affiliation': 'Center for Translational Research on Inflammatory Diseases, Michael E DeBakey VA Medical Center, Houston, TX, USA.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqab253'] 2500,34375388,"Temporal changes in soluble angiotensin-converting enzyme 2 associated with metabolic health, body composition, and proteome dynamics during a weight loss diet intervention: a randomized trial with implications for the COVID-19 pandemic.","BACKGROUND Angiotensin-converting enzyme 2 (ACE2) serves protective functions in metabolic, cardiovascular, renal, and pulmonary diseases and is linked to COVID-19 pathology. The correlates of temporal changes in soluble ACE2 (sACE2) remain understudied. OBJECTIVES We explored the associations of sACE2 with metabolic health and proteome dynamics during a weight loss diet intervention. METHODS We analyzed 457 healthy individuals (mean ± SD age: 39.8 ± 6.6 y) with BMI 28-40 kg/m2 in the DIETFITS (Diet Intervention Examining the Factors Interacting with Treatment Success) study. Biochemical markers of metabolic health and 236 proteins were measured by Olink CVDII, CVDIII, and Inflammation I arrays at baseline and at 6 mo during the dietary intervention. We determined clinical and routine biochemical correlates of the diet-induced change in sACE2 (ΔsACE2) using stepwise linear regression. We combined feature selection models and multivariable-adjusted linear regression to identify protein dynamics associated with ΔsACE2. RESULTS sACE2 decreased on average at 6 mo during the diet intervention. Stronger decline in sACE2 during the diet intervention was independently associated with female sex, lower HOMA-IR and LDL cholesterol at baseline, and a stronger decline in HOMA-IR, triglycerides, HDL cholesterol, and fat mass. Participants with decreasing HOMA-IR (OR: 1.97; 95% CI: 1.28, 3.03) and triglycerides (OR: 2.71; 95% CI: 1.72, 4.26) had significantly higher odds for a decrease in sACE2 during the diet intervention than those without (P ≤ 0.0073). Feature selection models linked ΔsACE2 to changes in α-1-microglobulin/bikunin precursor, E-selectin, hydroxyacid oxidase 1, kidney injury molecule 1, tyrosine-protein kinase Mer, placental growth factor, thrombomodulin, and TNF receptor superfamily member 10B. ΔsACE2 remained associated with these protein changes in multivariable-adjusted linear regression. CONCLUSIONS Decrease in sACE2 during a weight loss diet intervention was associated with improvements in metabolic health, fat mass, and markers of angiotensin peptide metabolism, hepatic and vascular injury, renal function, chronic inflammation, and oxidative stress. Our findings may improve the risk stratification, prevention, and management of cardiometabolic complications.This trial was registered at clinicaltrials.gov as NCT01826591.",2021,"Participants with decreasing HOMA-IR (OR: 1.97; 95% CI: 1.28, 3.03) and triglycerides (OR: 2.71; 95% CI: 1.72, 4.26) had significantly higher odds for a decrease in sACE2 during the diet intervention than those without (P ≤ 0.0073).",['457 healthy individuals (mean\xa0±\xa0SD age: 39.8\xa0±\xa06.6 y) with BMI 28-40\xa0kg/m2 in the DIETFITS'],['Angiotensin-converting enzyme 2 (ACE2'],"['HOMA-IR, triglycerides, HDL cholesterol, and fat mass', 'sACE2', 'female sex, lower HOMA-IR and LDL cholesterol', 'metabolic health, fat mass, and markers of angiotensin peptide metabolism, hepatic and vascular injury, renal function, chronic inflammation, and oxidative stress', 'Mer, placental growth factor, thrombomodulin, and TNF receptor superfamily member 10B. ΔsACE2', 'HOMA-IR', 'Olink CVDII, CVDIII, and Inflammation']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517823', 'cui_str': '6.6'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}]","[{'cui': 'C0960880', 'cui_str': 'angiotensin converting enzyme 2'}]","[{'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0086287', 'cui_str': 'Female'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0003018', 'cui_str': 'Angiotensin'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0178324', 'cui_str': 'Injury of blood vessel'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0021376', 'cui_str': 'Chronic inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0065973', 'cui_str': 'methanol extraction residue (MER) tubercle bacillus fraction'}, {'cui': 'C0138514', 'cui_str': 'Placenta Growth Factor'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C1527752', 'cui_str': 'TNFRSF10B protein, human'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",457.0,0.0445956,"Participants with decreasing HOMA-IR (OR: 1.97; 95% CI: 1.28, 3.03) and triglycerides (OR: 2.71; 95% CI: 1.72, 4.26) had significantly higher odds for a decrease in sACE2 during the diet intervention than those without (P ≤ 0.0073).","[{'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Cauwenberghs', 'Affiliation': 'Stanford Cardiovascular Institute, Department of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Prunicki', 'Affiliation': 'Sean N Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'František', 'Initials': 'F', 'LastName': 'Sabovčik', 'Affiliation': 'Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Dalia', 'Initials': 'D', 'LastName': 'Perelman', 'Affiliation': 'Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Kévin', 'Initials': 'K', 'LastName': 'Contrepois', 'Affiliation': 'Stanford Cardiovascular Institute, Department of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Biochemistry, The Center for RNA Science and Therapeutics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Snyder', 'Affiliation': 'Stanford Cardiovascular Institute, Department of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Kari C', 'Initials': 'KC', 'LastName': 'Nadeau', 'Affiliation': 'Sean N Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Kuznetsova', 'Affiliation': 'Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Haddad', 'Affiliation': 'Stanford Cardiovascular Institute, Department of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Gardner', 'Affiliation': 'Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqab243'] 2501,34375387,Randomized trial of a novel lifestyle intervention compared with the Diabetes Prevention Program for weight loss in adult dependents of military service members.,"BACKGROUND Lifestyle interventions are the first-line treatment for obesity, but participant weight loss is typically low. OBJECTIVES We evaluated the efficacy of an alternative lifestyle intervention [Healthy Weight for Living (HWL)] compared with a modified Diabetes Prevention Program (m-DPP). HWL was based on a revised health behavior change model emphasizing hunger management and the development of healthy food preferences. m-DPP was a standard Diabetes Prevention Program implemented with counselor time matched to HWL. Participants were adult dependents of military personnel and had overweight or obesity. METHODS Participants were randomly assigned to HWL (n = 121) or m-DPP (n = 117), delivered primarily by group videoconference with additional midweek emails. The primary outcome was 12-mo weight change. Secondary outcomes included 6-mo changes in cardiometabolic risk factors and diet. Intention-to-treat (ITT) and complete case (CC) analyses were performed using linear mixed models. RESULTS Retention did not differ between groups (72% and 66% for HWL and m-DPP at 12 mo, respectively; P = 0.30). Mean ± SE adjusted 12-mo weight loss in the ITT cohort was 7.46 ± 0.85 kg for HWL and 7.32 ± 0.87 kg for m-DPP (P = 0.91); in the CC cohort, it was 7.83 ± 0.82 kg for HWL and 6.86 ± 0.88 kg for m-DPP (P = 0.43). Thirty-eight percent of HWL and 30% of m-DPP completers achieved ≥10% weight loss (P = 0.32). Improvements in systolic blood pressure, LDL cholesterol, triglycerides, fasting glucose, general health, sleep, and mood were similar across groups; improvements in diastolic blood pressure were greater in m-DPP. Adjusted group mean reductions in energy intake were not significantly different between groups, but HWL participants were more adherent to their dietary prescription for lower glycemic index and high fiber and protein (P = 0.05 to <0.001 for ITT). CONCLUSIONS HWL and m-DPP showed equivalent and clinically impactful mean weight loss with cardiometabolic benefits. These results identify an alternative approach for behavioral treatment of overweight and obesity.This trial was registered at clinicaltrials.gov as NCT02348853.",2021,"RESULTS Retention did not differ between groups (72% and 66% for HWL and m-DPP at 12 mo, respectively; P = 0.30).","['Participants were adult dependents of military personnel and had overweight or obesity', 'adult dependents of military service members', 'Participants were randomly assigned to HWL (n\xa0=\xa0121) or']","['novel lifestyle intervention', 'm-DPP', 'modified Diabetes Prevention Program (m-DPP', 'Diabetes Prevention Program', 'alternative lifestyle intervention [Healthy Weight for Living (HWL', 'videoconference with additional midweek emails']","['weight loss', 'Mean\xa0±\xa0SE adjusted 12-mo weight loss', '6-mo changes in cardiometabolic risk factors and diet', 'diastolic blood pressure', 'energy intake', 'glycemic index and high fiber and protein', 'systolic blood pressure, LDL cholesterol, triglycerides, fasting glucose, general health, sleep, and mood', '12-mo weight change', 'Retention']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0336524', 'cui_str': 'Military services member'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1450049', 'cui_str': 'Videoconference'}, {'cui': 'C0013849', 'cui_str': 'Email'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}]",,0.0786152,"RESULTS Retention did not differ between groups (72% and 66% for HWL and m-DPP at 12 mo, respectively; P = 0.30).","[{'ForeName': 'Sai K', 'Initials': 'SK', 'LastName': 'Das', 'Affiliation': 'Energy Metabolism, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Asma S', 'Initials': 'AS', 'LastName': 'Bukhari', 'Affiliation': 'Military Nutrition Division, US Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Amy G', 'Initials': 'AG', 'LastName': 'Taetzsch', 'Affiliation': 'Energy Metabolism, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Amy K', 'Initials': 'AK', 'LastName': 'Ernst', 'Affiliation': 'Energy Metabolism, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Gail T', 'Initials': 'GT', 'LastName': 'Rogers', 'Affiliation': 'Biostatistics and Data Management Unit, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Cheryl H', 'Initials': 'CH', 'LastName': 'Gilhooly', 'Affiliation': 'Metabolic Research Unit, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Hatch-McChesney', 'Affiliation': 'Military Nutrition Division, US Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Caroline M', 'Initials': 'CM', 'LastName': 'Blanchard', 'Affiliation': 'Energy Metabolism, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Kara A', 'Initials': 'KA', 'LastName': 'Livingston', 'Affiliation': 'Nutritional Epidemiology, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Silver', 'Affiliation': 'Energy Metabolism, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Martin', 'Affiliation': 'Energy Metabolism, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'McGraw', 'Affiliation': 'Military Nutrition Division, US Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Meghan K', 'Initials': 'MK', 'LastName': 'Chin', 'Affiliation': 'Energy Metabolism, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Taylor A', 'Initials': 'TA', 'LastName': 'Vail', 'Affiliation': 'Energy Metabolism, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Lutz', 'Affiliation': 'Military Nutrition Division, US Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Scott J', 'Initials': 'SJ', 'LastName': 'Montain', 'Affiliation': 'Military Nutrition Division, US Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Anastassios G', 'Initials': 'AG', 'LastName': 'Pittas', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, MA, USA.'}, {'ForeName': 'Alice H', 'Initials': 'AH', 'LastName': 'Lichtenstein', 'Affiliation': 'Cardiovascular Nutrition, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Allison', 'Affiliation': 'Department of Epidemiology, School of Public Health, Indiana University, Bloomington, IN, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Dickinson', 'Affiliation': 'Department of Epidemiology, School of Public Health, Indiana University, Bloomington, IN, USA.'}, {'ForeName': 'Xiwei', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Epidemiology, School of Public Health, Indiana University, Bloomington, IN, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Saltzman', 'Affiliation': 'Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Young', 'Affiliation': 'Military Nutrition Division, US Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Susan B', 'Initials': 'SB', 'LastName': 'Roberts', 'Affiliation': 'Energy Metabolism, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqab259'] 2502,34375320,Comparative Analysis of Serial Union Patterns After Opening-Wedge High Tibial Osteotomy with and without Bone-Void Fillers.,"BACKGROUND Opening-wedge high tibial osteotomy produces opening gaps; however, there is little consensus on bone graft necessity and the material that would produce a superior union. The purposes of the present study were (1) to compare the serial union patterns associated with various bone-void fillers, (2) to determine whether bone-void filler is necessary to achieve bone union of the opening gap, and (3) to determine whether bone union is different according to the correction degree during opening-wedge high tibial osteotomy. METHODS In this retrospective study, 97 knees were randomly assigned to treatment with hydroxyapatite chip bone (Group A), allogenic chip bone (Group B), or no bone graft (Group C) and were analyzed after a minimum 1-year follow-up. To compare the bone union pattern, the area of callus filling located at the most medial side on an anteroposterior radiograph of the knee was recorded, and a modified van Hemert scoring system was used in the mediolaterally divided 5 zones. The correlations between the correction degree and bone union scores were evaluated. RESULTS There were no significant differences in the extent of mediolateral bone-healing at 6 weeks or 3 months postoperatively (p = 0.172 and p = 0.228). However, Group C showed more prominent progression of the gap filling to the medial side compared with Groups A and B at 6 months postoperatively (p = 0.002). Group C showed slow progression of bone union up to 6 weeks but surpassed the other groups at 6 months. The union pattern was not different between Groups A and B, and the correction degree was not correlated with bone union beyond 3 months postoperatively. CONCLUSIONS Despite the different gap-healing patterns, opening-wedge high tibial osteotomy without bone graft achieved bone union comparable with allogenic and synthetic graft materials. Group C (no bone graft) showed slower progression of bone union but surpassed the other groups at around 6 months. Based on the union pattern, there was no difference depending on the correction degree and the use of bone-void fillers. LEVEL OF EVIDENCE Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.",2021,"Based on the union pattern, there was no difference depending on the correction degree and the use of bone-void fillers. ",['97 knees'],"['hydroxyapatite chip bone (Group A), allogenic chip bone (Group B), or no bone graft', 'Serial Union Patterns', 'Opening-Wedge High Tibial Osteotomy with and without Bone-Void Fillers']","['correction degree and bone union scores', 'mediolateral bone-healing', 'prominent progression of the gap filling to the medial side', 'slower progression of bone union', 'slow progression of bone union']","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}]","[{'cui': 'C0020326', 'cui_str': 'Hydroxyapatite Derivatives'}, {'cui': 'C0057856', 'cui_str': 'iproplatin'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0005976', 'cui_str': 'Bone graft'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0445153', 'cui_str': 'Opening wedge'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0187826', 'cui_str': 'Osteotomy of tibia'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0729441', 'cui_str': 'Filler'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441992', 'cui_str': 'Mediolateral'}, {'cui': 'C1321023', 'cui_str': 'Bone healing status'}, {'cui': 'C0205402', 'cui_str': 'Prominent'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0439834', 'cui_str': 'Slow'}]",97.0,0.0147067,"Based on the union pattern, there was no difference depending on the correction degree and the use of bone-void fillers. ","[{'ForeName': 'Seong', 'Initials': 'S', 'LastName': 'Chan Kim', 'Affiliation': 'Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital Seongnam, Seongnam, South Korea.'}, {'ForeName': 'Dong Hyun', 'Initials': 'DH', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital Seongnam, Seongnam, South Korea.'}, {'ForeName': 'Jae Ik', 'Initials': 'JI', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital Seongnam, Seongnam, South Korea.'}, {'ForeName': 'Tae Woo', 'Initials': 'TW', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul National University Boramae Medical Center, Seoul, South Korea.'}, {'ForeName': 'Yong Seuk', 'Initials': 'YS', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital Seongnam, Seongnam, South Korea.'}]",The Journal of bone and joint surgery. American volume,['10.2106/JBJS.20.00778'] 2503,34375164,Uncovered versus covered metallic stents for the management of unresectable malignant distal biliary obstruction: a randomized multicenter trial.,"OBJECTIVE The treatment result of the uncovered metallic stent (uncovered MS) and covered metallic stent (covered MS) for unresectable malignant distal biliary obstruction is controversial. This time, we conducted this study to compare the efficacies and complication rates of uncovered MS and covered MS in unresectable malignant distal biliary obstructions at a prospective randomized multicenter trial. MATERIALS AND METHODS From April 2014 to September 2018, patients with unresectable malignant distal biliary obstruction were randomly assigned to 2 groups: the uncovered MS group and the covered MS group. RESULTS 92 treatment results patients were discussed. 48 patients were assigned to the uncovered MS group and 44 cases were assigned to the covered MS group. Both groups showed a drainage effect. No significant difference was found in the drainage effect between the 2 groups. The number of stent occlusion was significantly greater ( p  = .0467) in uncovered MS (43.8%) comparing with those in covered MS (22.7%). As the cause of stent occlusion, tumor ingrowth was significantly greater ( p  < .001) in the uncovered MS group (35.4%) than in the covered MS group (2.3%). The median stent patency period was significantly longer ( p  = .0112) in the covered MS group (455 days) than that of the uncovered MS group (301 days). A significant difference in the median survival period was not found between the 2 groups. CONCLUSIONS Covered MS showed the possibility of extending the stent patency period by suppressing tumor ingrowth more than uncovered MS does. The UMIN Clinical Trial Registry number is UMIN000015093.",2021,The median stent patency period was significantly longer ( p  = .0112) in the covered MS group (455 days) than that of the uncovered MS group (301 days).,"['48 patients were assigned to the uncovered MS group and 44 cases', 'unresectable malignant distal biliary obstructions', 'unresectable malignant distal biliary obstruction', 'From April 2014 to September 2018, patients with unresectable malignant distal biliary obstruction']","['metallic stent (uncovered MS) and covered metallic stent (covered MS', 'MS and covered MS', 'covered metallic stents', 'MS group and the covered MS group']","['number of stent occlusion', 'median stent patency period', 'cause of stent occlusion, tumor ingrowth', 'drainage effect', 'median survival period', 'efficacies and complication rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439845', 'cui_str': 'Uncovered'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0205282', 'cui_str': 'Malignant'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0400979', 'cui_str': 'Obstruction of biliary tree'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0441290', 'cui_str': 'Metal stent'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0449958', 'cui_str': 'Number of stent(s)'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449591', 'cui_str': 'Stent patency'}, {'cui': 'C0919560', 'cui_str': 'Stent occlusion'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",48.0,0.0235043,The median stent patency period was significantly longer ( p  = .0112) in the covered MS group (455 days) than that of the uncovered MS group (301 days).,"[{'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Sakai', 'Affiliation': 'Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Harutoshi', 'Initials': 'H', 'LastName': 'Sugiyama', 'Affiliation': 'Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Yoshiaki', 'Initials': 'Y', 'LastName': 'Kawaguchi', 'Affiliation': 'Department of Gastroenterology, Tokai University Hospital, Iseahara, Japan.'}, {'ForeName': 'Yohei', 'Initials': 'Y', 'LastName': 'Kawashima', 'Affiliation': 'Department of Gastroenterology, Tokai University Hospital, Iseahara, Japan.'}, {'ForeName': 'Nobuto', 'Initials': 'N', 'LastName': 'Hirata', 'Affiliation': 'Department of Gastroenterology, Kameda Medical Center, Kamogawa, Japan.'}, {'ForeName': 'So', 'Initials': 'S', 'LastName': 'Nakaji', 'Affiliation': 'Department of Gastroenterology, Kameda Medical Center, Kamogawa, Japan.'}, {'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Natsui', 'Affiliation': 'Department of Internal Medicine, Niigata Prefectural Shibata Hospital, Shibara, Japan.'}, {'ForeName': 'Kazuhiko', 'Initials': 'K', 'LastName': 'Shioji', 'Affiliation': 'Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.'}, {'ForeName': 'Kazunari', 'Initials': 'K', 'LastName': 'Nakahara', 'Affiliation': 'Department of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kawasaki, Japan.'}, {'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Tsuyuguchi', 'Affiliation': 'Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Naoya', 'Initials': 'N', 'LastName': 'Kato', 'Affiliation': 'Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2021.1938207'] 2504,34375135,MR-proANP and NT-proBNP During Targeted Temperature Management Following Out-of-Hospital Cardiac Arrest: A Post hoc Analysis of the TTH48 Trial.,"We aimed to evaluate the effect of prolonged targeted temperature management (TTM) in patients with out-of-hospital cardiac arrest (OHCA) on the levels of midregional pro-atrial natriuretic peptide (MR-proANP) and N-terminal pro b-type natriuretic peptide (NT-proBNP) and assess their potential as prognostic biomarkers. A preplanned post hoc analysis of ""Targeted temperature management for 48 h vs 24 h and neurologic outcome after out-of-hospital cardiac arrest: A randomized clinical trial (TTH48 trial),"" where patients were randomized to TTM at 33°C ± 1°C of standard duration (24 hours) versus prolonged (48 hours). Blood samples were drawn from patients with OHCA at two Scandinavian university hospitals at admission to the ICU and at 24, 48, and 72 hours after reaching the target temperature. Primary outcome was levels of MR-proANP and NT-proBNP. Secondary outcome was cerebral performance category (CPC 1-5) at 6 months. Samples from 114 patients were analyzed. Prolonged TTM significantly decreased the levels of MR-proANP and NT-proBNP at 48 hours compared with standard 24 hours-TTM ( p  < 0.01). However, there were no significant differences at other time points. Patients with poor outcome (CPC 3-5) had a statistically significantly increased MR-proANP level at 24 hours ( p  < 0.01) and 72 hours ( p  < 0.01) compared with the good outcome group (CPC 1-2). Prognostic performance was best at 24 hours for both MR-proANP and NT-proBNP; with an AUC of 0.73 (confidence interval [95% CI]: 0.63-0.83) and 0.72 (95 % CI: 0.59-0.85), respectively. Prolonged TTM lowered the levels of both MR-proANP and NT-proBNP at 48 hours. MR-proANP may add prognostic information in postcardiac arrest patients. ClinicalTrials.gov ID: NCT01689077.",2021,Prolonged TTM significantly decreased the levels of MR-proANP and NT-proBNP at 48 hours compared with standard 24 hours-TTM ( p  < 0.01).,"['patients with out-of-hospital cardiac arrest (OHCA) on the levels of midregional pro-atrial natriuretic peptide (MR-proANP) and N-terminal pro b-type', '114 patients were analyzed', 'postcardiac arrest patients']","['MR-proANP', 'TTM', 'prolonged targeted temperature management (TTM', 'natriuretic peptide (NT-proBNP', 'MR-proANP and NT-proBNP']","['cerebral performance category (CPC 1-5', 'levels of MR-proANP and NT-proBNP', 'neurologic outcome', 'Prognostic performance', 'MR-proANP level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2936490', 'cui_str': 'Out-of-Hospital Heart Arrest'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0027481', 'cui_str': 'A-type natriuretic peptide'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C1292769', 'cui_str': 'Precursor B-cell lymphoblastic leukemia'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4708785', 'cui_str': '114'}]","[{'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0027481', 'cui_str': 'A-type natriuretic peptide'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0020674', 'cui_str': 'Induction of hypothermia'}, {'cui': 'C1144709', 'cui_str': 'Natriuretic Peptide Hormones'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0056911', 'cui_str': ""cytidylyl-(3'-5')-cytidine""}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0027481', 'cui_str': 'A-type natriuretic peptide'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",114.0,0.15988,Prolonged TTM significantly decreased the levels of MR-proANP and NT-proBNP at 48 hours compared with standard 24 hours-TTM ( p  < 0.01).,"[{'ForeName': 'Henriette Michelsen', 'Initials': 'HM', 'LastName': 'Bach', 'Affiliation': 'Department of Intensive Care and Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Christophe Henri Valdemar', 'Initials': 'CHV', 'LastName': 'Duez', 'Affiliation': 'Department of Otorhinolaryngology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Anni Nørgaard', 'Initials': 'AN', 'LastName': 'Jeppesen', 'Affiliation': 'Department of Anesthesiology, Regional Hospital West Jutland, Herning, Denmark.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Strand', 'Affiliation': 'Department of Intensive Care, Stavanger University Hospital, Stavanger, Norway.'}, {'ForeName': 'Eldar', 'Initials': 'E', 'LastName': 'Søreide', 'Affiliation': 'Critical Care and Anesthesiology Research Group and Department of Clinical Medicine, Stavanager University Hospital, Stavanger, Norway.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Kirkegaard', 'Affiliation': 'Research Center for Emergency Medicine, Emergency Department and Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Anders Morten', 'Initials': 'AM', 'LastName': 'Grejs', 'Affiliation': 'Department of Intensive Care, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.'}]",Therapeutic hypothermia and temperature management,['10.1089/ther.2021.0012'] 2505,34375134,Placebo Benefits for Disruptive Aspects of Mood Dysregulation after Traumatic Brain Injury.,,2021,,['Mood Dysregulation after Traumatic Brain Injury'],['Placebo'],[],"[{'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.222,,"[{'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Brody', 'Affiliation': ''}]",Journal of neurotrauma,['10.1089/neu.2021.29114.editorial'] 2506,34375130,High School Sports-related Concussion and the Effect of a Jugular Vein Compression Collar: A Prospective Longitudinal Investigation of Neuroimaging and Neurofunctional Outcomes.,"Sports-related concussion (SRC) can exert serious acute and long-term consequences on brain microstructure, function, and behavioral outcomes. We aimed to quantify the alterations in white matter (WM) microstructure and global network organization, and the decrements in behavioral and cognitive outcomes from pre-season to post-concussion in youth athletes who experienced SRC. We also aimed to evaluate whether wearing a jugular compression neck collar, a device designed to mitigate brain ""slosh"" injury, would mitigate the pre-season to post-concussion alterations in neuroimaging, behavioral, and cognitive outcomes. A total of 488 high school football and soccer athletes (14-18 yrs) were prospectively enrolled and assigned to the non-collar group (n=237) or the collar group (n=251). The outcomes of the study were the pre-season to post-concussion neuroimaging, behavioral, and cognitive alterations. Forty-six participants (non-collar: n=24; collar: n=22) were diagnosed with a SRC during the season. Forty of these 46 athletes (non-collar: n=20; collar: n=20) completed neuroimaging assessment. Significant pre-season to post-concussion alterations in WM microstructural integrity and brain network organization were found in these athletes (corrected p<0.05). The alterations were significantly reduced in collar-wearing athletes compared to non-collar-wearing athletes (corrected p<0.05). Concussion and collar main effects were identified for some of the behavioral and cognitive outcomes, but no collar by SRC interaction effects were observed in any outcomes. In summary, young athletes exhibited significant WM microstructural and network organizational, and cognitive alterations following SRC. The use of the jugular vein compression collar showed promising evidence to reduce these alterations in high school contact sport athletes.",2021,Significant pre-season to post-concussion alterations in WM microstructural integrity and brain network organization were found in these athletes (corrected p<0.05).,"['youth athletes who experienced SRC', 'Forty-six participants (non-collar', '488 high school football and soccer athletes (14-18 yrs', 'high school contact sport athletes', 'n=20; collar: n=20) completed neuroimaging assessment', 'n=24; collar: n=22) were diagnosed with a SRC during the season', 'Forty of these 46 athletes (non-collar']","['Jugular Vein Compression Collar', 'jugular vein compression collar', 'Sports-related concussion (SRC']","['pre-season to post-concussion neuroimaging, behavioral, and cognitive alterations', 'SRC interaction effects', 'behavioral and cognitive outcomes', 'WM microstructural and network organizational, and cognitive alterations', 'WM microstructural integrity and brain network organization']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0175751', 'cui_str': 'Cervical collar'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0016517', 'cui_str': 'American or Canadian football - sport'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0336924', 'cui_str': 'Contact sport'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0679575', 'cui_str': 'Neuroimaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}]","[{'cui': 'C0022427', 'cui_str': 'Structure of jugular vein'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0175751', 'cui_str': 'Cervical collar'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0679575', 'cui_str': 'Neuroimaging'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0029246', 'cui_str': 'Organizations'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0029237', 'cui_str': 'Organization'}]",488.0,0.0366989,Significant pre-season to post-concussion alterations in WM microstructural integrity and brain network organization were found in these athletes (corrected p<0.05).,"[{'ForeName': 'Weihong', 'Initials': 'W', 'LastName': 'Yuan', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, 2518, Pediatric Neuroimaging Research Consortium, Cincinnati, Ohio, United States.""}, {'ForeName': 'Jed A', 'Initials': 'JA', 'LastName': 'Diekfuss', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, The SPORT Center, Division of Sports Medicine, Cincinnati, Ohio, United States; Jed.a.diekfuss@emory.edu.""}, {'ForeName': 'Kim D', 'Initials': 'KD', 'LastName': 'Barber Foss', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, The SPORT Center, Division of Sports Medicine, Cincinnati, Ohio, United States; Kim.barberfoss@emory.edu.""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Dudley', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, 2518, Pediatric Neuroimaging Research Consortium, Cincinnati, Ohio, United States; Jonathan.Dudley@cchmc.org.""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Leach', 'Affiliation': 'University of Cincinnati College of Medicine, Department of Radiology, Cincinnati, Ohio, United States.'}, {'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Narad', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Division of Behavioral Medicine & Clinical Psychology, Cincinnati, Ohio, United States.""}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'DiCesare', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, The SPORT Center, Division of Sports Medicine, Cincinnati, Ohio, United States; dicesaca@umich.edu.""}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Bonnette', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, 2518, The SPORT Center, Division of Sports Medicine, Cincinnati, Ohio, United States; Scott.bonnette@cchmc.org.""}, {'ForeName': 'Jeffery', 'Initials': 'J', 'LastName': 'Epstein', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Division of Behavioral Medicine and Clinical Psychology, Cincinnati, Ohio, United States.""}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Logan', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, The SPORT Center, Division of Sports Medicine, Cincinnati, Ohio, United States.""}, {'ForeName': 'Mekibib', 'Initials': 'M', 'LastName': 'Altaye', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Biostatistics & Epidemiology, Cincinnati, Ohio, United States.""}, {'ForeName': 'Greg D', 'Initials': 'GD', 'LastName': 'Myer', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, The SPORT Center, Division of Sports Medicine, , Cincinnati, Ohio, United States.""}]",Journal of neurotrauma,['10.1089/neu.2021.0141'] 2507,34377599,Effect of Shirts with 42% Celliant™ Fiber on tcPO 2 Levels and Grip Strength in Healthy Subjects: A Placebo-controlled Clinical Trial.,"Celliant™ fabric contains quartz, silicon oxide and titanium oxide particles embedded into polymer fibers. Garments woven with Celliant™ yarns can be activated by body heat (conduction, convection and radiation) and remit the energy as far infrared radiation (FIR) back into the body. Wearing Celliant garments has been shown to increase blood flow and oxygen levels in the skin. In the present study we recruited twenty-four healthy volunteers (18-60 years of age) to wear a placebo shirt for 90 minutes, and after a 15-minute break, to wear a real Celliant shirt for 90 minutes. The mean transcutaneous oxygen (tcPO 2 ) measured over two sites (biceps and abdomen) was significantly increased at 3 time points (30, 60, and 90 minutes) by between 5-8% (P<0.05) in Celliant vs. placebo. The mean grip strength in the dominant hand measured at 90 minutes was 12.44% higher after wearing Celliant vs. after placebo (p=0.0002). There was a small but significant increase in systolic blood pressure (113.71 vs. 109.38; p=0.02) but no statistically significant changes in diastolic or mean blood pressure, heart rate, or skin temperature. These data provide more evidence of the physiological effects of FIR emitting garments and suggest they could be used for athletic training and recovery.",2019,The mean grip strength in the dominant hand measured at 90 minutes was 12.44% higher after wearing Celliant vs. after placebo (p=0.0002).,"['Healthy Subjects', 'recruited twenty-four healthy volunteers (18-60 years of age) to wear a placebo shirt for 90 minutes, and after a 15-minute break, to wear a real Celliant shirt for 90 minutes']","['Placebo', 'placebo', 'Shirts with 42% Celliant™ Fiber']","['systolic blood pressure', 'mean transcutaneous oxygen (tcPO 2 ) measured over two sites (biceps and abdomen', 'diastolic or mean blood pressure, heart rate, or skin temperature', 'mean grip strength', 'blood flow and oxygen levels']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0453917', 'cui_str': 'Shirt'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1442447', 'cui_str': 'Fifteen minutes'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0453917', 'cui_str': 'Shirt'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0607422', 'cui_str': 'Abdoman (drug)'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",24.0,0.0490736,The mean grip strength in the dominant hand measured at 90 minutes was 12.44% higher after wearing Celliant vs. after placebo (p=0.0002).,"[{'ForeName': 'Ian L', 'Initials': 'IL', 'LastName': 'Gordon', 'Affiliation': 'Veterans Affairs Long Beach Healthcare System 5901 E, 7th Street, Long Beach, California, USA.'}, {'ForeName': 'Seth', 'Initials': 'S', 'LastName': 'Casden', 'Affiliation': 'Hologenix LLC, Santa Monica, CA 90403, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Vangel', 'Affiliation': 'Department of Biostatistics, Massachusetts General Hospital, Boston, MA 02114, USA.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Hamblin', 'Affiliation': 'Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA.'}]",Journal of textile science & engineering,[] 2508,34377527,Impact of the Swank and Wahls elimination dietary interventions on fatigue and quality of life in relapsing-remitting multiple sclerosis: The WAVES randomized parallel-arm clinical trial.,"Objective To compare the effect of the modified Paleolithic elimination (Wahls) and low-saturated fat (Swank) diets in relapsing-remitting MS (RRMS). Methods Individuals (n = 87) with RRMS were randomized to the Swank or Wahls diets in a parallel group clinical trial consisting of four timepoints: 1) run-in, 2) baseline, 3) 12-weeks, and 4) 24-weeks. Results 77 participants completed 12 weeks and 72 completed 24 weeks. The 12-week change from baseline in fatigue was -0.94 ± 0.18 (FSS) and -9.87 ± 1.93 (MFIS; both p < 0.0001) for Swank, and -0.71 ± 0.24 (FSS; p = 0.004) and -14.41 ± 2.22 (MFIS; p ≤ 0.0001) for Wahls. Physical MSQoL scores improved by 6.04 ± 2.18 (p = 0.006) for Swank and by 14.5 ± 2.63 (p < 0.0001) for Wahls. Mental MSQoL scores improved by 11.3 ± at 2.79 (p < 0.0001) for Wahls while the Swank did not change (3.85 ± 2.63; p = 0.14). Neither group showed significant changes in 6-minute walking distance at 12 weeks. All outcomes were maintained or further improved at 24 weeks. Conclusions Both diets were associated with clinically meaningful within-group reductions in fatigue and improvements in QoL. Trial Registration : Clinicaltrials.gov Identifier: NCT02914964.",2021,Mental MSQoL scores improved by 11.3 ± at 2.79 (p < 0.0001) for Wahls while the Swank did not change (3.85 ± 2.63; p = 0.14).,"['relapsing-remitting multiple sclerosis', 'relapsing-remitting MS (RRMS', 'Methods\n\n\nIndividuals (n\u2009=\u200987) with RRMS']","['modified Paleolithic elimination (Wahls) and low-saturated fat (Swank) diets', 'Swank or Wahls diets', 'Swank and Wahls elimination dietary interventions']","['Mental MSQoL scores', 'fatigue and quality of life', '6-minute walking distance', 'Physical MSQoL scores']","[{'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0439600', 'cui_str': 'Remitting'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0452298', 'cui_str': 'Low saturated fat diet'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",87.0,0.26214,Mental MSQoL scores improved by 11.3 ± at 2.79 (p < 0.0001) for Wahls while the Swank did not change (3.85 ± 2.63; p = 0.14).,"[{'ForeName': 'Terry L', 'Initials': 'TL', 'LastName': 'Wahls', 'Affiliation': 'Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Tyler J', 'Initials': 'TJ', 'LastName': 'Titcomb', 'Affiliation': 'Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Babita', 'Initials': 'B', 'LastName': 'Bisht', 'Affiliation': 'Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Patrick Ten', 'Initials': 'PT', 'LastName': 'Eyck', 'Affiliation': 'Institute for Clinical and Translational Science, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Rubenstein', 'Affiliation': 'Department of Epidemiology, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Lucas J', 'Initials': 'LJ', 'LastName': 'Carr', 'Affiliation': 'Department of Epidemiology, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Warren G', 'Initials': 'WG', 'LastName': 'Darling', 'Affiliation': 'Department of Health and Human Physiology, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Karin F', 'Initials': 'KF', 'LastName': 'Hoth', 'Affiliation': 'Department of Psychiatry, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kamholz', 'Affiliation': 'Department of Neurology, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Linda G', 'Initials': 'LG', 'LastName': 'Snetselaar', 'Affiliation': 'Department of Epidemiology, University of Iowa, Iowa City, IA, USA.'}]","Multiple sclerosis journal - experimental, translational and clinical",['10.1177/20552173211035399'] 2509,34377501,"Voicing Individual Concerns for Engagement in Hemodialysis (VOICE-HD): A Mixed Method, Randomized Pilot Trial of Digital Health in Dialysis Care Delivery.","Background People receiving in-center hemodialysis (HD) have prioritized the need for more individualized health information and better communication with nephrologists. The most common setting for patient-nephrologist interactions is during the HD treatment, which is a time pressured setting that lacks privacy. Objective To facilitate effective communication in the hemodialysis (HD) unit, we evaluated the usability of a web application (web app) from both the patient and physician perspective. The main aim of the web app was to support patients in prioritizing their dialysis concerns outside of the clinical HD encounter. Design Mixed method, parallel arm, multi-site, pilot randomized controlled trial. Setting Two outpatient Canadian HD centers. Participants Adult patients receiving in-center HD and their attending nephrologists. Methods Patients were randomized to either a web application or an active control (paper form) for logging concerns to be addressed at weekly encounters with the nephrologist over 8 weeks. Topics included: HD treatment, symptoms, modality, and medications. The primary outcome was usability, defined as effectiveness (engagement with the tool, frequency of submitted concerns, whether the concern was satisfactorily addressed) and satisfaction with the tool using a priori thresholds and explored in interviews with patients and nephrologists. Results 77 patients (30 women, median age 61, interquartile range [53,67], median 2 years [1,4] on dialysis) and 19 nephrologists (4 women, median age 46 [36,65]) were enrolled. Patient use of a digital device at baseline was low (20%). Engagement with the tool was 70% (web app) and 100% (paper) with a lower proportion of patients in the web app group submitting at least one concern over 8 weeks compared to the paper form group: 56.7% vs 87.9%. Weekly concerns were satisfactorily addressed in both groups and ≥70% of patients would continue to use the tools. For patients, both tools promoted preparation and participation in the encounter; however, only the web app facilitated greater privacy in relaying concerns. For most nephrologists, the tools were disruptive to their workflow and were perceived as unnecessary given existing processes and familiarity with patients. For future versions of the app, patients suggested more features to facilitate self-management and nephrologists suggested integration with health databases and multidisciplinary teams. Limitations Tertiary setting may limit generalizability. Conclusions Both tools promoted fundamental components of self-management; however, patients in the paper form group submitted concerns more often and this tool was easier to remember to use. Although modifications would likely enhance web app usability, successful future adoption is limited by physician acceptance. Trial registration ClinicalTrials.gov NCT03605875.",2021,Engagement with the tool was 70% (web app) and 100% (paper) with a lower proportion of patients in the web app group submitting at least one concern over 8 weeks compared to the paper form group: 56.7% vs 87.9%.,"['Participants\n\n\nAdult patients receiving in-center HD and their attending nephrologists', 'median 2 years [1,4] on dialysis) and 19 nephrologists (4 women, median age 46 [36,65]) were enrolled', '77 patients (30 women, median age 61, interquartile range [53,67', 'Hemodialysis (VOICE-HD', 'Dialysis Care Delivery', 'Setting\n\n\nTwo outpatient Canadian HD centers', '\n\n\nPeople receiving in-center hemodialysis (HD']",['web application or an active control (paper form) for logging concerns to be addressed at weekly encounters with the nephrologist over 8 weeks'],"['usability, defined as effectiveness (engagement with the tool, frequency of submitted concerns, whether the concern was satisfactorily addressed) and satisfaction with the tool using a priori thresholds and explored in interviews with patients and nephrologists']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0260039', 'cui_str': 'Nephrologist'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C1161201', 'cui_str': 'Dialysis care'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0260039', 'cui_str': 'Nephrologist'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0260039', 'cui_str': 'Nephrologist'}]",,0.0478154,Engagement with the tool was 70% (web app) and 100% (paper) with a lower proportion of patients in the web app group submitting at least one concern over 8 weeks compared to the paper form group: 56.7% vs 87.9%.,"[{'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Thompson', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Kara', 'Initials': 'K', 'LastName': 'Schick-Makaroff', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Aminu', 'Initials': 'A', 'LastName': 'Bello', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Tonelli', 'Affiliation': 'University of Calgary, AB, Canada.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Wiebe', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Buzinski', 'Affiliation': 'Patient Partner, Lethbridge, AB, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Courtney', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Szigety', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Nikhil', 'Initials': 'N', 'LastName': 'Shah', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Bohm', 'Affiliation': 'Department of Internal Medicine, Health Sciences, Health Sciences Centre, University of Manitoba, Winnipeg, Canada.'}]",Canadian journal of kidney health and disease,['10.1177/20543581211032857'] 2510,34377472,A single-dose nitrate-producing dietary supplement affects cardiorespiratory endurance and muscular fitness in healthy men: A randomized controlled pilot trial.,"Introduction The main aim of this pilot study was to examine the effects of a single-dose intervention with a novel nitrate-producing formulation (MagNOVOx™) on biomarkers of cardiorespiratory endurance and muscular fitness in 12 healthy men. Methods The study participants (age = 22.7 ± 2.8 years, height = 184.1 ± 5.7 cm, and weight = 82.5 ± 8.4 kg) were randomly allocated to receive either a single dose of MagNOVOx™ or a placebo (inulin) in a cross-over design. The primary outcome for this study was the change in running time to exhaustion evaluated at baseline (before supplementation) and post-intervention. Results Time to exhaustion was improved after the intervention in 8 out of 11 participants (72.7%) who received MagNOVOx™, and in 1 out of 11 participants (9.1%) who received placebo ( p  = 0.004), and MagNOVOx™ outcompeted placebo in terms of improving leg press performance ( p  < 0.01). No significant differences between MagNOVOx™ and placebo were found for blood pressure responses ( p  > 0.05). Conclusion These promising findings should be further corroborated in medium- and long-term trials, and different populations, while the exact mechanism of MagNOVOx™ requires additional physiological studies.",2021,"Results Time to exhaustion was improved after the intervention in 8 out of 11 participants (72.7%) who received MagNOVOx™, and in 1 out of 11 participants (9.1%) who received placebo ( p  = 0.004), and MagNOVOx™ outcompeted placebo in terms of improving leg press performance ( p  < 0.01).","['study participants (age\u2009=\u200922.7\u2009±\u20092.8\u2009years, height\u2009=\u2009184.1\u2009±\u20095.7\u2009cm, and weight\u2009=\u200982.5\u2009±\u20098.4\u2009kg', 'healthy men', '12 healthy men']","['nitrate-producing dietary supplement', 'placebo', 'MagNOVOx™ or a placebo (inulin', 'novel nitrate-producing formulation (MagNOVOx™']","['cardiorespiratory endurance and muscular fitness', 'leg press performance', 'change in running time to exhaustion evaluated at baseline (before supplementation) and post-intervention', 'blood pressure responses', 'Results\n\n\nTime to exhaustion']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C4517795', 'cui_str': '5.7'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C4517887', 'cui_str': '82.5'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1997183', 'cui_str': 'Speed of blood pressure response'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]",12.0,0.38393,"Results Time to exhaustion was improved after the intervention in 8 out of 11 participants (72.7%) who received MagNOVOx™, and in 1 out of 11 participants (9.1%) who received placebo ( p  = 0.004), and MagNOVOx™ outcompeted placebo in terms of improving leg press performance ( p  < 0.01).","[{'ForeName': 'Nikola', 'Initials': 'N', 'LastName': 'Todorovic', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Applied Bioenergetics Lab, Novi Sad, Serbia.'}, {'ForeName': 'Valdemar', 'Initials': 'V', 'LastName': 'Stajer', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Applied Bioenergetics Lab, Novi Sad, Serbia.'}, {'ForeName': 'Laszlo', 'Initials': 'L', 'LastName': 'Ratgeber', 'Affiliation': 'Faculty of Health Sciences, University of Pecs, Pecs, Hungary.'}, {'ForeName': 'Jozsef', 'Initials': 'J', 'LastName': 'Betlehem', 'Affiliation': 'Faculty of Health Sciences, University of Pecs, Pecs, Hungary.'}, {'ForeName': 'Pongrac', 'Initials': 'P', 'LastName': 'Acs', 'Affiliation': 'Faculty of Health Sciences, University of Pecs, Pecs, Hungary.'}, {'ForeName': 'Nebojsa', 'Initials': 'N', 'LastName': 'Maksimovic', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Applied Bioenergetics Lab, Novi Sad, Serbia.'}, {'ForeName': 'Sergej M', 'Initials': 'SM', 'LastName': 'Ostojic', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Applied Bioenergetics Lab, Novi Sad, Serbia.'}]",SAGE open medicine,['10.1177/20503121211036119'] 2511,34377456,Radiofrequency denervation of the lumbar facet joints: guidelines for the RADICAL randomised controlled trial.,"Background and aim The RADICAL trial has been funded by the National Institute for Health Research (NIHR) to evaluate the clinical and cost-effectiveness of radiofrequency denervation (RFD) for low back pain. Recommendations have been published which aim to standardise selection of patients and RFD technique. However, it is important to ensure these recommendations are acceptable to clinicians within the context of the trial. The aim of this work was to develop standardised criteria for the trial entry and RFD technique for implementation within the RADICAL trial. Methods Fourteen pain clinicians completed a survey, which involved reviewing the current recommendations and indicating whether they disagreed with any of the recommendations and if so why. Responses were collated and presented at a half-day workshop with 14 attendees. During the workshop, the National Low Back and Radicular Pain Pathway (NLBRPP) guidelines for patient selection and an article by Eldabe and colleagues presenting recommendations on the RFD technique were reviewed. Attendees discussed whether each component of the recommendations should be mandatory, mandatory with alteration or clarification or optional within the RADICAL trial. Results Attendees agreed during the workshop that 5 of the 10 criteria for patient selection described in the NLBRPP should be mandatory within the RADICAL trial. Three were agreed as mandatory criteria but required further clarification, one of which involved defining a positive response to a diagnostic medial branch block as ⩾60% pain relief. Two criteria had optional components. After reviewing the recommendations on the RFD technique from Eldabe and colleagues, seven components were agreed as mandatory, three were mandatory with alterations and three were optional. Conclusion When evaluating complex interventions, such as RFD, it is important to ensure agreement and clarity on the clinical protocol, so that the intervention can be reproduced, if found to be effective.",2021,"Results Attendees agreed during the workshop that 5 of the 10 criteria for patient selection described in the NLBRPP should be mandatory within the RADICAL trial.",['lumbar facet joints'],['radiofrequency denervation (RFD'],[],"[{'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0224521', 'cui_str': 'Zygapophyseal joint structure'}]","[{'cui': 'C1740811', 'cui_str': 'Radiofrequency denervation'}]",[],3.0,0.288166,"Results Attendees agreed during the workshop that 5 of the 10 criteria for patient selection described in the NLBRPP should be mandatory within the RADICAL trial.","[{'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Price', 'Affiliation': 'Solent NHS Trust, Southampton, UK.'}, {'ForeName': 'Barney', 'Initials': 'B', 'LastName': 'Reeves', 'Affiliation': 'Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Alia', 'Initials': 'A', 'LastName': 'Ahmad', 'Affiliation': 'Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Mohjir', 'Initials': 'M', 'LastName': 'Baloch', 'Affiliation': 'Frimley Health NHS Trust, Frimley, UK.'}, {'ForeName': 'Ganesan', 'Initials': 'G', 'LastName': 'Baranidharan', 'Affiliation': 'Leeds Teaching Hospitals NHS Trust, Leeds, UK.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Correa', 'Affiliation': 'University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'McCormick', 'Affiliation': 'Oxford University Hospitals NHS Trust, Oxford, UK.'}, {'ForeName': 'Manohar', 'Initials': 'M', 'LastName': 'Sharma', 'Affiliation': 'The Walton Centre NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Bala', 'Initials': 'B', 'LastName': 'Veemarajan', 'Affiliation': 'Sherwood Forest Hospital NHS Trust, Sutton-In-Ashfield, UK.'}, {'ForeName': 'Margot', 'Initials': 'M', 'LastName': 'Grimwood', 'Affiliation': 'Solent NHS Trust, Southampton, UK.'}, {'ForeName': 'Katrina Ishbel', 'Initials': 'KI', 'LastName': 'Pirie', 'Affiliation': 'Solent NHS Trust, Southampton, UK.'}, {'ForeName': 'Vikki', 'Initials': 'V', 'LastName': 'Wylde', 'Affiliation': 'Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK.'}]",British journal of pain,['10.1177/2049463720941053'] 2512,34377343,"Comprehensive nursing care on the psychological states, quality of life, and serum indexes of NSCLC patients with TCM combined with chemotherapy.","OBJECTIVE To study the effect of comprehensive nursing care on the psychological status, quality of life, and serum indicators of non-small cell lung cancer (NSCLC) patients undergoing traditional Chinese medicine (TCM) and chemotherapy. METHODS Ninety-two patients with NSCLC admitted to this hospital between January 2018 and June 2020 were recruited for this study. All the patients underwent combined Chinese medicine chemotherapy. The control group underwent conventional nursing care, and the observation group underwent comprehensive nursing. The clinical efficacy, lung function, serum indexes, quality of life, and psychological states of the two groups, their adverse reactions during the treatment period, and the patients' satisfaction with the nursing work were compared. RESULTS The overall efficacy of the observation group was better in comparison with the control group. After the treatment, the PEF, FVC, and FEV1 levels in the observation group were higher than they were in the control group. After the treatment, the physical functioning, role functioning, emotional functioning, social functioning, and overall health scores in the observation group were higher than they were in the control group. The serum IL-6, TNF-α, and MMP-9 levels in the observation group were lower than they were in the control group. Regarding the incidence of nausea, vomiting, and diarrhea, the observation group had a lower incidence. In terms of of the total satisfaction rate, the observation group was better than the control group (97.83% vs 82.61%), and the differences were all statistically significant (P<0.05). CONCLUSION Comprehensive nursing can help improve the clinical efficacy of TCM combined with chemotherapy, reduce the serum indicator expression levels, improve the patients' mental states and quality of life, improve patient satisfaction, and reduce the incidence of adverse reactions.",2021,"The serum IL-6, TNF-α, and MMP-9 levels in the observation group were lower than they were in the control group.","['non-small cell lung cancer (NSCLC) patients undergoing traditional Chinese medicine (TCM) and chemotherapy', 'Ninety-two patients with NSCLC admitted to this hospital between January 2018 and June 2020 were recruited for this study', 'NSCLC patients with']","['comprehensive nursing care', 'conventional nursing care, and the observation group underwent comprehensive nursing', 'TCM combined with chemotherapy', 'combined Chinese medicine chemotherapy']","['clinical efficacy, lung function, serum indexes, quality of life, and psychological states of the two groups, their adverse reactions', 'physical functioning, role functioning, emotional functioning, social functioning, and overall health scores', 'total satisfaction rate', 'serum indicator expression levels', 'nausea, vomiting, and diarrhea', 'psychological states, quality of life, and serum indexes', 'incidence of adverse reactions', 'serum IL-6, TNF-α, and MMP-9 levels', 'overall efficacy', ""patients' mental states and quality of life, improve patient satisfaction"", 'psychological status, quality of life, and serum indicators', 'PEF, FVC, and FEV1 levels']","[{'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0028678', 'cui_str': 'nursing'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0165519', 'cui_str': 'Gelatinase B'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0030771', 'cui_str': 'Pefloxacin'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}]",92.0,0.0396519,"The serum IL-6, TNF-α, and MMP-9 levels in the observation group were lower than they were in the control group.","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Sui', 'Affiliation': ""Xingtai People's Hospital Xingtai, China.""}]",American journal of translational research,[] 2513,34377342,Effect of nursing based on the hopeless self-esteem theory plus multi-dimensional intensive nursing for elderly patients with acute cerebral infarction complicated with depression.,"PURPOSE To explore the effect of nursing based on the hopeless self-esteem theory plus multi-dimensional intensive nursing on the self-esteem level and prognosis of elderly patients with acute cerebral infarction (ACI) complicated with depression. METHODS Eighty patients with ACI complicated with depression who were treated in our hospital from September 2018 to September 2020 were selected and randomized into the observation group and the control group (n = 40 each). The observation group received the model of hopeless self-esteem theory combined with multi-dimensional intensive nursing, while the control group received conventional nursing. The clinical efficacy, depression degree, self-esteem level, living ability, quality of life, and attribution mode were compared. RESULTS The overall effective rate was reported at a notably higher rate in the observation group (90.00%) compared to the control group (65.00%) (P < 0.05); After intervention, the observation group had a markedly lower Geriatric Depression Scale (GDS) score than the control group (P < 0.05); After intervention, the observation group showed appreciably higher Rosenberg Self Esteem Scale (RSES) score and Barthel index compared to the control group (P < 0.05); After intervention, the observation group had a remarkably higher level of the quality of life in all dimensions than the control group (P < 0.05); After intervention, there were more positive events in the observation group as compared to the control group (P < 0.05), whereas there were more negative events in the control group as compared to the observation group (P < 0.05). CONCLUSION The hopeless self-esteem theory combined with multi-dimensional intensive nursing can apparently increase the self-esteem level of patients, establish a positive attribution mode, beef up their self-confidence, reduce the degree of depression, upgrade their postoperative living ability and quality of life, and improve prognosis and clinical efficacy.",2021,"After intervention, the observation group showed appreciably higher Rosenberg Self Esteem Scale (RSES) score and Barthel index compared to the control group (P < 0.05); After intervention, the observation group had a remarkably higher level of the quality of life in all dimensions than the control group (P < 0.05); After intervention, there were more positive events in the observation group as compared to the control group (P < 0.05), whereas there were more negative events in the control group as compared to the observation group (P < 0.05). ","['Eighty patients with ACI complicated with depression who were treated in our hospital from September 2018 to September 2020', 'elderly patients with acute cerebral infarction complicated with depression', 'elderly patients with acute cerebral infarction (ACI) complicated with depression']","['nursing based on the hopeless self-esteem theory plus multi-dimensional intensive nursing', 'model of hopeless self-esteem theory combined with multi-dimensional intensive nursing, while the control group received conventional nursing']","['overall effective rate', 'Rosenberg Self Esteem Scale (RSES) score and Barthel index', 'negative events', 'clinical efficacy, depression degree, self-esteem level, living ability, quality of life, and attribution mode', 'Geriatric Depression Scale (GDS) score', 'quality of life', 'positive events']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150041', 'cui_str': 'Feeling hopeless'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0582666', 'cui_str': 'Rosenberg self-esteem scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0451184', 'cui_str': 'Geriatric depression scale'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",80.0,0.0521889,"After intervention, the observation group showed appreciably higher Rosenberg Self Esteem Scale (RSES) score and Barthel index compared to the control group (P < 0.05); After intervention, the observation group had a remarkably higher level of the quality of life in all dimensions than the control group (P < 0.05); After intervention, there were more positive events in the observation group as compared to the control group (P < 0.05), whereas there were more negative events in the control group as compared to the observation group (P < 0.05). ","[{'ForeName': 'Zhiru', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Neurology Department, The First Affiliated Hospital of Qiqihar Medical University Qiqihar, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Shang', 'Affiliation': 'Neurology Department, The First Affiliated Hospital of Qiqihar Medical University Qiqihar, China.'}, {'ForeName': 'Guihong', 'Initials': 'G', 'LastName': 'Fan', 'Affiliation': 'Nursing Department, The First Affiliated Hospital of Qiqihar Medical University Qiqihar, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Neurology Department, The First Affiliated Hospital of Qiqihar Medical University Qiqihar, China.'}, {'ForeName': 'Zhaoping', 'Initials': 'Z', 'LastName': 'Zang', 'Affiliation': 'Neurology Department, The First Affiliated Hospital of Qiqihar Medical University Qiqihar, China.'}]",American journal of translational research,[] 2514,34377339,Effect of minocycline hydrochloride combined with photodynamic therapy on skin barrier function of patients with acne.,"OBJECTIVE The aim of this study is to evaluate the effects of minocycline hydrochloride combined with photodynamic therapy on skin barrier function of patients with acne. METHODS Eighty-eight acne patients admitted to our hospital were randomized into research group (n=44, photodynamic therapy on the basis of minocycline hydrochloride) and control group (n=44, minocycline hydrochloride). The clinical efficacy, skin barrier function indexes (transdermal water loss (TEWL), stratum corneum water content, pH value), scores of GAGS and Acne-QOL, cosmetic satisfaction and adverse reaction rates of the two groups were compared. RESULTS The total effective rate of research group was higher than that of control group (P<0.05). After treatment, TEWL, cuticle water content and pH value were improved compared with those before treatment, and the research group was superior to the control group (all P<0.05). After treatment, the GAGS scores of both groups were lower than those before treatment, and the research group was lower than that of the control group (all P<0.05). The cosmetic satisfaction in the research group was higher than that in the control group (P<0.05). There was no marked difference in the incidence of adverse reactions between the two groups (P>0.05). After treatment, the quality of life scores of patients were higher than before treatment, and the research group was higher than that of the control group (all P<0.05). CONCLUSION Minocycline hydrochloride combined with photodynamic therapy can effectively improve the skin barrier function of patients, relieve clinical symptoms, and enhance the overall efficacy and quality of life. It is also safe and patients are highly satisfied with the cosmetic effect.",2021,There was no marked difference in the incidence of adverse reactions between the two groups (P>0.05).,"['Eighty-eight acne patients admitted to our hospital', 'patients with acne']","['minocycline hydrochloride combined with photodynamic therapy', 'minocycline hydrochloride) and control group (n=44, minocycline hydrochloride', 'photodynamic therapy', 'Minocycline hydrochloride combined with photodynamic therapy']","['skin barrier function', 'TEWL, cuticle water content and pH value', 'clinical efficacy, skin barrier function indexes (transdermal water loss (TEWL), stratum corneum water content, pH value), scores of GAGS and Acne-QOL, cosmetic satisfaction and adverse reaction rates', 'incidence of adverse reactions', 'GAGS scores', 'overall efficacy and quality of life', 'total effective rate', 'cosmetic satisfaction', 'quality of life scores']","[{'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0026186', 'cui_str': 'Minocycline hydrochloride'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0040652', 'cui_str': 'Transdermal route'}, {'cui': 'C0221921', 'cui_str': 'Stratum corneum structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0016927', 'cui_str': 'Gagging'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",88.0,0.0194929,There was no marked difference in the incidence of adverse reactions between the two groups (P>0.05).,"[{'ForeName': 'Keye', 'Initials': 'K', 'LastName': 'Guo', 'Affiliation': ""Department of Dermatology, Shengzhou People's Hospital Shaoxing, Zhejiang Province, China.""}, {'ForeName': 'Dingxian', 'Initials': 'D', 'LastName': 'Zhu', 'Affiliation': 'Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Zhongming', 'Initials': 'Z', 'LastName': 'Lu', 'Affiliation': ""Department of Dermatology, Shengzhou People's Hospital Shaoxing, Zhejiang Province, China.""}, {'ForeName': 'Yunlei', 'Initials': 'Y', 'LastName': 'Pan', 'Affiliation': 'Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Huazhou', 'Initials': 'H', 'LastName': 'Deng', 'Affiliation': ""Department of Dermatology, Shengzhou People's Hospital Shaoxing, Zhejiang Province, China.""}]",American journal of translational research,[] 2515,34377337,Influence of psychological nursing on negative emotion and sleep quality of glaucoma trabeculectomy patients.,"OBJECTIVE To investigate the influence of psychological nursing on negative emotion and sleep quality of glaucoma trabeculectomy patients. METHODS Ninety glaucoma patients treated in our hospital were obtained as research participants and were randomly divided into the control group (45 cases, adopted eyeball massage) and the observation group (45 cases adopted eyeball massage with psychological nursing). The negative emotions (Hamilton Anxiety and Depression Scale (HAMA, HAMD)), sleep quality (PSQI scale), quality of life (GQOLI-74 scale), vision (national standard visual acuity chart) and complications were compared between the two groups. RESULTS The scores of HAMA, HAMD and PSQI of patients in both groups decreased when they were discharged from hospital, especially in the observation group (all P<0.05). One month and 3 months after operation, BCVA of affected eyes in both groups was significantly higher than that before operation, and that of the control group was higher than that in the observation group (all P<0.05). The scores of GQOLI-74 in both groups were increased, and the scores of the control group were higher than those in the observation group (all P<0.05). The incidence of complications in the observation group was lower than that in the control group (P<0.05). CONCLUSION Psychological nursing on the basis of eyeball massage can effectively relieve the bad psychology of glaucoma patients after trabeculectomy, improve their sleep quality and life quality, and have less postoperative complications and good vision recovery.",2021,"The incidence of complications in the observation group was lower than that in the control group (P<0.05). ","['Ninety glaucoma patients treated in our hospital were obtained as research participants', 'glaucoma trabeculectomy patients', 'glaucoma patients after trabeculectomy']","['psychological nursing', 'control group (45 cases, adopted eyeball massage) and the observation group (45 cases adopted eyeball massage with psychological nursing']","['sleep quality and life quality', 'scores of HAMA, HAMD and PSQI', 'incidence of complications', 'negative emotion and sleep quality', 'scores of GQOLI-74', 'negative emotions (Hamilton Anxiety and Depression Scale (HAMA, HAMD)), sleep quality (PSQI scale), quality of life (GQOLI-74 scale), vision (national standard visual acuity chart) and complications']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0040574', 'cui_str': 'Trabeculoplasty'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0425382', 'cui_str': 'Adopted'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1291910', 'cui_str': 'Human anti-mouse antibody'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0183370', 'cui_str': 'Snellen chart'}]",90.0,0.0210381,"The incidence of complications in the observation group was lower than that in the control group (P<0.05). ","[{'ForeName': 'Meisong', 'Initials': 'M', 'LastName': 'Chang', 'Affiliation': ""Department of Ophthalmology, Shenyang Fourth People's Hospital Shenyang, Liaoning Province, China.""}, {'ForeName': 'Hailin', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ""Department of Ophthalmology, Shenyang Fourth People's Hospital Shenyang, Liaoning Province, China.""}, {'ForeName': 'Tongtong', 'Initials': 'T', 'LastName': 'Niu', 'Affiliation': ""Department of Ophthalmology, Shenyang Fourth People's Hospital Shenyang, Liaoning Province, China.""}]",American journal of translational research,[] 2516,34377330,Acupuncture around the greater tuberosity of the femur combined with acupuncture at Xuehai acupoint alleviates the postoperative pain of elderly patients with intertrochanteric fracture.,"OBJECTIVE To determine the efficacy of acupuncture around the greater tuberosity of the femur (AGTF) combined with acupuncture at Xuehai acupoint for postoperative pain in elderly patients with intertrochanteric fracture. METHODS A total of 97 elderly patients with intertrochanteric fracture treated by proximal femoral nail antirotation (PFNA) were enrolled and randomly assigned into an observation group (Obs group, n=48) and a control group (Con group, n=49). The Obs group was treated by aspirin and AGTF combined with acupuncture at Xuehai acupoint for analgesia, while the Con group was treated by aspirin alone for analgesia. Both groups were treated for 7 consecutive days. The two groups were compared in pain degree (visual analog scale (VAS) score) after operation and hip joint function (Harris score), daily living ability (modified Barthel index (MBI) score), bone metabolism-related indexes, and inflammatory factors before and after treatment. RESULTS At 1-7 d after operation, both groups had gradually lower VAS scores, and at 5 and 7 d after operation, the Obs group had a lower VAS score than the Con group (both P<0.05). Additionally, at 2 months after operation, both groups had higher Harris scores and MBI scores, and the scores of the Obs group were both higher than those of the Con group (both P<0.05). At 7 d after operation, both groups showed a decrease in serum beta collagen degradation products (β-CTx) and an increase in procollagen type I amino-terminal propeptide (PINP) (both P<0.05), but the differences between the two groups in β-CTx and PINP were insignificant (P>0.05). Moreover, at 7 d after operation, both groups showed a decrease in C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α), and the two levels in the Obs group were lower than those in the Con group (both P<0.05). CONCLUSION For elderly patients with intertrochanteric fracture, AGTF combined with acupuncture at the Xuehai acupoint can more effectively relieve their postoperative pain and postoperative inflammation and more strongly promote their postoperative recovery of hip joint function.",2021,"At 7 d after operation, both groups showed a decrease in serum beta collagen degradation products (β-CTx) and an increase in procollagen type I amino-terminal propeptide (PINP) (both P<0.05), but the differences between the two groups in β-CTx and PINP were insignificant (P>0.05).","['elderly patients with intertrochanteric fracture', '97 elderly patients with intertrochanteric fracture treated by proximal femoral nail antirotation (PFNA']","['acupuncture', 'acupuncture at Xuehai acupoint', 'control group (Con', 'aspirin and AGTF combined with acupuncture at Xuehai acupoint', 'aspirin alone for analgesia', 'Acupuncture']","['C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α', 'serum beta collagen degradation products (β-CTx', 'higher Harris scores and MBI scores', 'VAS score', 'postoperative pain', 'pain degree (visual analog scale (VAS) score) after operation and hip joint function (Harris score), daily living ability (modified Barthel index (MBI) score), bone metabolism-related indexes, and inflammatory factors', 'VAS scores', 'procollagen type I amino-terminal propeptide (PINP', 'postoperative pain and postoperative inflammation']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162385', 'cui_str': 'Intertrochanteric fracture'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0243125', 'cui_str': 'degradation'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2985547', 'cui_str': 'Scintimammography'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0041457', 'cui_str': 'Type I Procollagen'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",97.0,0.0358013,"At 7 d after operation, both groups showed a decrease in serum beta collagen degradation products (β-CTx) and an increase in procollagen type I amino-terminal propeptide (PINP) (both P<0.05), but the differences between the two groups in β-CTx and PINP were insignificant (P>0.05).","[{'ForeName': 'Hanjing', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Traditional Chinese Medicine, Fuzhou Second Hospital Affiliated to Xiamen University Fuzhou, Fujian Province, China.'}, {'ForeName': 'Biao', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Department of Orthopedics, Fuzhou Second Hospital Affiliated to Xiamen University Fuzhou, Fujian Province, China.'}, {'ForeName': 'Chuanyuan', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Orthopedics, Fuzhou Second Hospital Affiliated to Xiamen University Fuzhou, Fujian Province, China.'}]",American journal of translational research,[] 2517,34377329,Application of antagonist regimen in patients with failed pregnancy assisted by previous long-term regimen during early follicular phase.,"OBJECTIVE To investigate the clinical application of gonadotropin-releasing hormone antagonist (GnRH-ant) in patients with failed pregnancy assisted by the previous long-term regimen during early follicular phase (EFP). METHODS A total of 122 patients with good ovarian function and two previous failed EFP long-term assisted pregnancy were selected from the reproductive center of our hospital for study. All patients were assisted by in vitro fertilization-embryo transfer (IVF-ET) twice. According to the random number table method, the participants were divided into group A (n=61) for subcutaneous injection of gonadotropin-releasing hormone agonist (GnRH-a) and group B (n=61) for GnRH-ant, and the clinical efficacy of the two groups were observed. RESULTS Group B presented reduced dosage and duration of Gn, increased number and probability of eggs retrieved, and increased number of 2PN, cleavage and transplantable embryos than group A (all P<0.05). Serum estradiol (E2) and luteinizing hormone (LH) levels elevated and T level decreased in group B as compared to group A (all P<0.05). There was no significant difference in follicle-stimulating hormone (FSH) indexes between the two groups (P>0.05). Endometrial thickness and mean ovarian volume (MOV, the mean volume of bilateral ovaries) were not significantly different between group A and group B before treatment (both P>0.05), while were lower in group B than in group A after treatment (both P<0.05). Group B had higher high-quality egg rate (%), fertilization rate (should have numbers here %), cleavage rate (%), high-quality embryo rate (should have numbers here %) and cumulative pregnancy rate (%) than group A (all P<0.05). The incidences of moderate OHSS, early abortion and hydrosalpinx were lower in group B than in group A (all P<0.05), while there was no evident difference between the two groups in the occurrence of severe OHSS and ectopic pregnancy (both P>0.05). CONCLUSION GnRH-ant can improve the clinical high-quality embryo rate in patients with the previous failed EFP long-term assisted pregnancy, and reduce the occurrence of OHSS events. Compared with GnRH-a, GnRH-ant is more suitable for clinical application of controlled ovarian hyperstimulation.",2021,Serum estradiol (E2) and luteinizing hormone (LH) levels elevated and T level decreased in group B as compared to group A (all P<0.05).,"['patients with failed pregnancy assisted by the previous long-term regimen during early follicular phase (EFP', '122 patients with good ovarian function and two previous failed EFP long-term assisted pregnancy were selected from the reproductive center of our hospital for study', 'patients with failed pregnancy assisted by previous long-term regimen during early follicular phase']","['gonadotropin-releasing hormone antagonist (GnRH-ant', 'gonadotropin-releasing hormone agonist (GnRH-a) and group B']","['cumulative pregnancy rate', 'occurrence of severe OHSS and ectopic pregnancy', 'clinical high-quality embryo rate', 'Serum estradiol (E2) and luteinizing hormone (LH) levels elevated and T level', 'reduced dosage and duration of Gn, increased number and probability of eggs retrieved, and increased number of 2PN, cleavage and transplantable embryos', 'Endometrial thickness and mean ovarian volume (MOV, the mean volume of bilateral ovaries', 'follicle-stimulating hormone (FSH) indexes', 'incidences of moderate OHSS, early abortion and hydrosalpinx', 'cleavage rate (%), high-quality embryo rate', 'fertilization rate', 'high-quality egg rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0016434', 'cui_str': 'Menstrual Cycle, Proliferative Phase'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C1268855', 'cui_str': 'Gonadotropin releasing hormone receptor antagonist-containing product'}, {'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0085083', 'cui_str': 'Ovarian hyperstimulation syndrome'}, {'cui': 'C0032987', 'cui_str': 'Ectopic pregnancy'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0013935', 'cui_str': 'Embryos'}, {'cui': 'C0474672', 'cui_str': 'Serum estradiol measurement'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0010813', 'cui_str': 'Cytokinesis'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0227898', 'cui_str': 'Both ovaries'}, {'cui': 'C0202022', 'cui_str': 'Follicle stimulating hormone measurement'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0948915', 'cui_str': 'Abortion early'}, {'cui': 'C0221376', 'cui_str': 'Hydrosalpinx'}, {'cui': 'C0015914', 'cui_str': 'Fertilization'}]",122.0,0.0480758,Serum estradiol (E2) and luteinizing hormone (LH) levels elevated and T level decreased in group B as compared to group A (all P<0.05).,"[{'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Reproduction and Genetics, Ganzhou Maternal and Child Health Centre Ganzhou, Jiangxi Province, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Shuai', 'Affiliation': 'Department of Reproduction and Genetics, Ganzhou Maternal and Child Health Centre Ganzhou, Jiangxi Province, China.'}, {'ForeName': 'Linlin', 'Initials': 'L', 'LastName': 'Yue', 'Affiliation': 'Department of Reproduction and Genetics, Ganzhou Maternal and Child Health Centre Ganzhou, Jiangxi Province, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Liao', 'Affiliation': 'Department of Reproduction and Genetics, Ganzhou Maternal and Child Health Centre Ganzhou, Jiangxi Province, China.'}]",American journal of translational research,[] 2518,34377328,Effect and prognosis of emergency nursing path in patients with acute stroke.,"OBJECTIVE To evaluate the effect and prognosis of the emergency nursing path in patients with acute stroke. METHODS In this prospective study, 108 patients with acute stroke were randomly divided into an observation group (n=54, implementing the emergency nursing path) and a control group (n=54, implementing emergency routine care). We compared the rescue time-related indicators, neurological function, cognitive function and prognosis of the two groups. RESULTS The time from admission to diagnosis and the time from diagnosis to specialist treatment in the observation group were shorter than those in the control group (all P<0.05). After two weeks of intervention, the score of National Institute of Health Stroke Scale in the two groups of patients were lower than before the intervention, and the observation group was even lower (all P<0.05). After one month of discharge, the score of Activity of Daily Living Scale decreased while the scores of Montreal Cognitive Assessment, Mini-mental State Examination and Glasgow Outcome Scale increased in both groups, with more significant changes in the observation group (all P<0.05). The disability rate in the observation group was lower than that in the control group (P<0.05). CONCLUSION The implementation of emergency nursing could significantly shorten the time from admission to specialist treatment for patients with acute stroke. It could also promote the recovery of neurological and cognitive functions, which was conducive to the prognosis of patients.",2021,"After two weeks of intervention, the score of National Institute of Health Stroke Scale in the two groups of patients were lower than before the intervention, and the observation group was even lower (all P<0.05).","['patients with acute stroke', '108 patients with acute stroke']","['observation group (n=54, implementing the emergency nursing path) and a control group (n=54, implementing emergency routine care']","['score of Activity of Daily Living Scale', 'time from admission to diagnosis and the time from diagnosis to specialist treatment', 'score of National Institute of Health Stroke Scale', 'disability rate', 'recovery of neurological and cognitive functions', 'rescue time-related indicators, neurological function, cognitive function and prognosis', 'Montreal Cognitive Assessment, Mini-mental State Examination and Glasgow Outcome Scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C4517530', 'cui_str': '108'}]","[{'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0085125', 'cui_str': 'Nursing, Emergency'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0701887', 'cui_str': 'Glasgow outcome scale'}]",108.0,0.0256999,"After two weeks of intervention, the score of National Institute of Health Stroke Scale in the two groups of patients were lower than before the intervention, and the observation group was even lower (all P<0.05).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Emergency, The Second Affiliated Hospital, Nantong University Nantong, Jiangsu Province, China.'}, {'ForeName': 'Haiyang', 'Initials': 'H', 'LastName': 'Guan', 'Affiliation': 'Department of Emergency, The Second Affiliated Hospital, Nantong University Nantong, Jiangsu Province, China.'}, {'ForeName': 'Xintong', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Emergency, The Second Affiliated Hospital, Nantong University Nantong, Jiangsu Province, China.'}, {'ForeName': 'Danfeng', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Department of Emergency, The Second Affiliated Hospital, Nantong University Nantong, Jiangsu Province, China.'}, {'ForeName': 'Yuqin', 'Initials': 'Y', 'LastName': 'Ren', 'Affiliation': 'Department of Emergency, The Second Affiliated Hospital, Nantong University Nantong, Jiangsu Province, China.'}, {'ForeName': 'Jianhong', 'Initials': 'J', 'LastName': 'Ji', 'Affiliation': 'Department of Emergency, The Second Affiliated Hospital, Nantong University Nantong, Jiangsu Province, China.'}]",American journal of translational research,[] 2519,34377327,Efficacy of hysteroscopic cold knife separation on intrauterine adhesions.,"OBJECTIVE This research aimed to explore the efficacy of hysteroscopic cold knife separation in the treatment of intrauterine adhesions (IUA). METHODS Altogether 110 patients with IUA who were treated in our hospital were randomized into the observation group (n=55, hysteroscopic cold knife) and the control group (n=55, hysteroscopic electroacupuncture and collecting ring). This research compared the operation-related indexes (operation time, intraoperative blood loss, amount of distending media), IUA and menstrual flow, endometrial epithelization of the uterine wound, endometrial thickness one month after operation, recurrence and pregnancy rates one year after operation. RESULTS The operation time and intraoperative blood loss in the observation group were less than those in the control group (all P<0.05). After treatment, the total effective rate of IUA, menstrual flow and satisfaction rate of endometrial epithelization of the uterine wound in the observation group were higher than those in the control group, and the recurrence rate of the former one year after operation was lower (all P<0.05). One month after operation, the thickness of the endometrium in the observation group was clearly larger than that in the control group on the 11th and 13th day of menstruation (all P<0.05). CONCLUSION Hysteroscopic cold knife separation can improve the efficacy of IUA and protect the endometrium.",2021,The operation time and intraoperative blood loss in the observation group were less than those in the control group (all P<0.05).,['Altogether 110 patients with IUA who were treated in our hospital'],"['control group (n=55, hysteroscopic electroacupuncture and collecting ring', 'hysteroscopic cold knife', 'Hysteroscopic cold knife separation', 'hysteroscopic cold knife separation']","['operation-related indexes (operation time, intraoperative blood loss, amount of distending media), IUA and menstrual flow, endometrial epithelization of the uterine wound, endometrial thickness one month after operation, recurrence and pregnancy rates', 'total effective rate of IUA, menstrual flow and satisfaction rate of endometrial epithelization of the uterine wound', 'recurrence rate', 'thickness of the endometrium', 'operation time and intraoperative blood loss', 'intrauterine adhesions']","[{'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0241593', 'cui_str': 'Adhesions of uterus'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0181467', 'cui_str': 'Knife'}, {'cui': 'C0036679', 'cui_str': 'Separation'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0700124', 'cui_str': 'Ectatic'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0241593', 'cui_str': 'Adhesions of uterus'}, {'cui': 'C0025344', 'cui_str': 'Menstruation'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C4082115', 'cui_str': 'One month'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0014180', 'cui_str': 'Endometrial structure'}]",110.0,0.0795292,The operation time and intraoperative blood loss in the observation group were less than those in the control group (all P<0.05).,"[{'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Jin', 'Affiliation': 'Department of Obstetrics and Gynecology, Anhui Province Maternity and Child Health Hospital Hefei, Anhui Province, China.'}, {'ForeName': 'Junliang', 'Initials': 'J', 'LastName': 'Ye', 'Affiliation': 'Department of Obstetrics and Gynecology, Anhui Province Maternity and Child Health Hospital Hefei, Anhui Province, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Obstetrics and Gynecology, Anhui Province Maternity and Child Health Hospital Hefei, Anhui Province, China.'}, {'ForeName': 'Lichun', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Obstetrics and Gynecology, Anhui Province Maternity and Child Health Hospital Hefei, Anhui Province, China.'}]",American journal of translational research,[] 2520,34377322,Effect of early partial weight-bearing rehabilitative exercise on postoperative functional recovery of sanders IV calcaneal fractures.,"OBJECTIVES This research explored and analyzed the effects of early partial weight-bearing rehabilitative exercise on postoperative recovery after Sanders IV calcaneal fractures. METHODS 86 patients hospitalized with Sanders IV calcaneal fracture from April 2018 to January 2020 were selected as the research participants. The patients were randomly divided into the observation group (n=44) and the control group (n=42). The control group carried out the conventional rehabilitative exercise, and the observation group underwent early partial weight-bearing rehabilitative exercise. The foot function between the two groups was compared after 24 weeks of treatment. RESULTS The foot function of the observation group after 24 weeks of treatment was notably superior to that of the control group ( P<0.05 ). The Maryland foot function scores of the two groups 6 weeks, 12 weeks and 24 weeks post-operation were critically higher than those before treatment ( P<0.05 ), and the score of the observation group was substantially higher than that of the control group ( P<0.05 ). The AOFAS score of patients in the two groups 6 weeks, 12 weeks and 24 weeks post-operation increased apparently than that before treatment ( P<0.05 ), and the scores of observation group was evidently higher than that of control group ( P<0.05 ). In addition, the comparison of Angle B'hler and Angle Gissane between the two groups of patients 24 weeks postoperation showed statistically insignificant difference ( P>0.05 ). CONCLUSION The early partial weight-bearing rehabilitative exercise can effectively promote the postoperative functional recovery of patients with Sander IV calcaneal fractures, and at the same time it has no impact on internal fixation and calcaneus shape of patients, which is worthy popularizing in clinic.",2021,"The Maryland foot function scores of the two groups 6 weeks, 12 weeks and 24 weeks post-operation were critically higher than those before treatment ( P<0.05 ), and the score of the observation group was substantially higher than that of the control group ( P<0.05 ).","['86 patients hospitalized with Sanders IV calcaneal fracture from April 2018 to January 2020 were selected as the research participants', 'after Sanders IV calcaneal fractures', 'sanders IV calcaneal fractures', 'patients with Sander IV calcaneal fractures']","['conventional rehabilitative exercise, and the observation group underwent early partial weight-bearing rehabilitative exercise', 'early partial weight-bearing rehabilitative exercise']","['postoperative functional recovery', 'foot function', 'postoperative recovery', ""Angle B'hler and Angle Gissane"", 'Maryland foot function scores', 'AOFAS score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0006655', 'cui_str': 'Bone structure of calcaneum'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0085086', 'cui_str': 'Weight-bearing'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0599766', 'cui_str': 'Recovery of Function'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0024858', 'cui_str': 'Maryland'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",86.0,0.0284851,"The Maryland foot function scores of the two groups 6 weeks, 12 weeks and 24 weeks post-operation were critically higher than those before treatment ( P<0.05 ), and the score of the observation group was substantially higher than that of the control group ( P<0.05 ).","[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Traumatic Orthopedicss, Yantai Shan Hospital Yantai 264000, Shandong, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Department of Rehabilitation Medicine, Yantai Yuhuangding Hospital Yantai 264000, Shandong, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Rehabilitation Medicine, Yantai Yuhuangding Hospital Yantai 264000, Shandong, China.'}]",American journal of translational research,[] 2521,34375362,Effect of electroencephalography-guided anesthesia on neurocognitive disorders in elderly patients undergoing major non-cardiac surgery: A trial protocol The POEGEA trial (POncd Elderly GEneral Anesthesia).,"INTRODUCTION The number of elderly patients undergoing major surgery is rapidly increasing. They are particularly at risk of developing postoperative neurocognitive disorders (NCD). Earlier studies suggested that processed electroencephalographic (EEG) monitors may reduce the incidence of postoperative NCD. However, none of these studies controlled for intraoperative nociception levels or personalized blood pressure targets. Their results remain unclear if the reduction in the incidence of postoperative NCD relates to avoidance of any electroencephalographic pattern suggesting excessive anesthesia depth. OBJECTIVE The objective of this trial is to investigate-in patients ≥ 70 years old undergoing major non-cardiac surgery-the effect of EEG-guided anesthesia on postoperative NCD while controlling for intraoperative nociception, personalized blood pressure targets, and using detailed information provided by the EEG monitor (including burst suppression ratio, density spectral array, and raw EEG waveform). MATERIAL AND METHODS This prospective, randomized, controlled trial will be conducted in a single Canadian university hospital. Patients ≥ 70 years old undergoing elective major non-cardiac surgery will be included in the trial. The administration of sevoflurane will be adjusted to maintain a BIS index value between 40 and 60, to keep a Suppression Ratio (SR) at 0%, to keep a direct EEG display without any suppression time and a spectrogram with most of the EEG wave frequency within the alpha, theta, and delta frequencies in the EEG-guided group. In the control group, sevoflurane will be administered to achieve an age-adjusted minimum alveolar concentration of [0.8-1.2]. In both groups, a nociception monitor will guide intraoperative opioid administration, individual blood pressure targets will be used, and cerebral oximetry used to tailor intraoperative hemodynamic management. The primary endpoint will be the incidence of NCD at postoperative day 1, as evaluated by the Montreal Cognitive Assessment (MoCA). Secondary endpoints will include the incidence of postoperative NCD at different time points and the evaluation of cognitive trajectories up to 90 days after surgery among EEG-guided and control groups. STUDY REGISTRATION NCT04825847 on ClinicalTrials.gov.",2021,"Secondary endpoints will include the incidence of postoperative NCD at different time points and the evaluation of cognitive trajectories up to 90 days after surgery among EEG-guided and control groups. ","['elderly patients undergoing major non-cardiac surgery', 'Patients ≥ 70 years old undergoing elective major non-cardiac surgery', 'patients ≥ 70 years old undergoing major non-cardiac surgery-the effect of', 'single Canadian university hospital', 'elderly patients undergoing major surgery']","['EEG-guided anesthesia', 'sevoflurane', 'electroencephalography-guided anesthesia']","['Suppression Ratio (SR', 'incidence of NCD at postoperative day 1, as evaluated by the Montreal Cognitive Assessment (MoCA', 'incidence of postoperative NCD at different time points and the evaluation of cognitive trajectories', 'neurocognitive disorders']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}]","[{'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C4041080', 'cui_str': 'Neurocognitive disorder'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]",,0.182996,"Secondary endpoints will include the incidence of postoperative NCD at different time points and the evaluation of cognitive trajectories up to 90 days after surgery among EEG-guided and control groups. ","[{'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Morisson', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital - CIUSSS de L'Est de l'Ile de Montréal, Université de Montréal, Montréal, Québec, Canada.""}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Laferrière-Langlois', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital - CIUSSS de L'Est de l'Ile de Montréal, Université de Montréal, Montréal, Québec, Canada.""}, {'ForeName': 'François Martin', 'Initials': 'FM', 'LastName': 'Carrier', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Université de Montréal, Québec, Canada.'}, {'ForeName': 'Gabrielle', 'Initials': 'G', 'LastName': 'Pagé', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Université de Montréal, Québec, Canada.'}, {'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Godbout', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital - CIUSSS de L'Est de l'Ile de Montréal, Université de Montréal, Montréal, Québec, Canada.""}, {'ForeName': 'Louis-Philippe', 'Initials': 'LP', 'LastName': 'Fortier', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital - CIUSSS de L'Est de l'Ile de Montréal, Université de Montréal, Montréal, Québec, Canada.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ogez', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital - CIUSSS de L'Est de l'Ile de Montréal, Université de Montréal, Montréal, Québec, Canada.""}, {'ForeName': 'Geneviève', 'Initials': 'G', 'LastName': 'Létourneau', 'Affiliation': ""Research Center of the CIUSSS de L'Est de l'Ile de Montréal, Université de Montréal, Montréal, Québec, Canada.""}, {'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Jarry', 'Affiliation': 'Department of Anesthesiology, Montréal Heart Institute, Montréal, Québec, Canada.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Denault', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Université de Montréal, Québec, Canada.'}, {'ForeName': 'Annik', 'Initials': 'A', 'LastName': 'Fortier', 'Affiliation': 'Department of Statistics, Montreal Health Innovations Coordinating Center (MHICC), Montréal, Québec, Canada.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Guertin', 'Affiliation': 'Department of Statistics, Montreal Health Innovations Coordinating Center (MHICC), Montréal, Québec, Canada.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Verdonck', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital - CIUSSS de L'Est de l'Ile de Montréal, Université de Montréal, Montréal, Québec, Canada.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Richebé', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital - CIUSSS de L'Est de l'Ile de Montréal, Université de Montréal, Montréal, Québec, Canada.""}]",PloS one,['10.1371/journal.pone.0255852'] 2522,34375343,"To achieve 95-95-95 targets we must reach men and youth: High level of knowledge of HIV status, ART coverage, and viral suppression in the Botswana Combination Prevention Project through universal test and treat approach.","BACKGROUND Increasing HIV treatment coverage is crucial to reducing population-level HIV incidence. METHODS The Botswana Combination Prevention Project (BCPP) was a community randomized trial examining the impact of multiple prevention interventions on population-level HIV incidence and was conducted from October 2013 through June 2017. Home and mobile campaigns offered HIV testing to all individuals ≥ age 16. All identified HIV-positive persons who were not on antiretroviral therapy (ART) were referred to treatment and tracked to determine linkage to care, ART status, retention in treatment, and viral suppression. RESULTS Of an estimated total of 14,270 people living with HIV (PLHIV) residing in the 15 intervention communities, BCPP identified 13,328 HIV-positive persons (93%). At study start, 10,703 (80%) of estimated PLHIV knew their status; 2,625 (20%) learned their status during BCPP, a 25% increase with the greatest increases occurring among men (37%) and youth (77%). At study start, 9,258 (65%) of estimated PLHIV were on ART. An additional 3,001 persons started ART through the study. By study end, 12,259 had initiated and were retained on ART, increasing coverage to 93%. A greater increase in ART coverage was achieved among men (40%) compared to women (29%). Of the 11,954 persons who had viral load (VL) test results, 11,687 (98%) were virally suppressed (HIV-1 RNA ≤400 copies/mL). Overall, 82% had documented VL suppression by study end. CONCLUSIONS Knowledge of HIV-positive status and ART coverage increased towards 95-95 targets with universal testing, linkage interventions, and ART. The increases in HIV testing and ART use among men and youth were essential to reaching these targets. CLINICAL TRIAL NUMBER NCT01965470.",2021,A greater increase in ART coverage was achieved among men (40%) compared to women (29%).,"['14,270 people living with HIV (PLHIV) residing in the 15 intervention communities', '11,954 persons who had viral load (VL) test results, 11,687 (98%) were virally suppressed (HIV-1 RNA ≤400 copies/mL', 'population-level HIV incidence and was conducted from October 2013 through June 2017', 'All identified HIV-positive persons who were not on antiretroviral therapy (ART']",['multiple prevention interventions'],"['VL suppression', 'HIV testing and ART', 'ART coverage']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}, {'cui': 'C0369499', 'cui_str': 'Human immunodeficiency virus 1 RNA'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]",14270.0,0.380315,A greater increase in ART coverage was achieved among men (40%) compared to women (29%).,"[{'ForeName': 'Refeletswe', 'Initials': 'R', 'LastName': 'Lebelonyane', 'Affiliation': 'Ministry of Health and Wellness, Gaborone, Botswana.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Bachanas', 'Affiliation': 'U.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Block', 'Affiliation': 'Northrop Grumman, Atlanta, GA, United States of America.'}, {'ForeName': 'Faith', 'Initials': 'F', 'LastName': 'Ussery', 'Affiliation': 'U.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Mary Grace', 'Initials': 'MG', 'LastName': 'Alwano', 'Affiliation': 'U.S. Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Tafireyi', 'Initials': 'T', 'LastName': 'Marukutira', 'Affiliation': 'U.S. Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Shenaaz', 'Initials': 'S', 'LastName': 'El Halabi', 'Affiliation': 'Ministry of Health and Wellness, Gaborone, Botswana.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Roland', 'Affiliation': 'U.S. Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Abrams', 'Affiliation': 'U.S. Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Gene', 'Initials': 'G', 'LastName': 'Ussery', 'Affiliation': 'Northrop Grumman, Atlanta, GA, United States of America.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Miller', 'Affiliation': 'Northrop Grumman, Atlanta, GA, United States of America.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Lockman', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.'}, {'ForeName': 'Tendani', 'Initials': 'T', 'LastName': 'Gaolathe', 'Affiliation': 'Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.'}, {'ForeName': 'Molly Pretorius', 'Initials': 'MP', 'LastName': 'Holme', 'Affiliation': 'Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Hader', 'Affiliation': 'UNAIDS, Geneva, Switzerland.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Mills', 'Affiliation': 'U.S. Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Wirth', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Bock', 'Affiliation': 'U.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Moore', 'Affiliation': 'U.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.'}]",PloS one,['10.1371/journal.pone.0255227'] 2523,34375336,Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial.,"BACKGROUND Nutritional status may play a role in infant immune development. To identify potential boosters of immunogenicity in low-income countries where oral vaccine efficacy is low, we tested the effect of prenatal nutritional supplementation on immune response to 3 doses of a live oral rotavirus vaccine. METHODS AND FINDINGS We nested a cluster randomized trial within a double-blind, placebo-controlled randomized efficacy trial to assess the effect of 3 prenatal nutritional supplements (lipid-based nutrient supplement [LNS], multiple micronutrient supplement [MMS], or iron-folic acid [IFA]) on infant immune response (n = 53 villages and 1,525 infants with valid serology results: 794 in the vaccine group and 731 in the placebo group). From September 2015 to February 2017, participating women received prenatal nutrient supplement during pregnancy. Eligible infants were then randomized to receive 3 doses of an oral rotavirus vaccine or placebo at 6-8 weeks of age (mean age: 6.3 weeks, 50% female). Infant sera (pre-Dose 1 and 28 days post-Dose 3) were analyzed for anti-rotavirus immunoglobulin A (IgA) using enzyme-linked immunosorbent assay (ELISA). The primary immunogenicity end point, seroconversion defined as ≥3-fold increase in IgA, was compared in vaccinated infants among the 3 supplement groups and between vaccine/placebo groups using mixed model analysis of variance procedures. Seroconversion did not differ by supplementation group (41.1% (94/229) with LNS vs. 39.1% (102/261) with multiple micronutrients (MMN) vs. 38.8% (118/304) with IFA, p = 0.91). Overall, 39.6% (n = 314/794) of infants who received vaccine seroconverted, compared to 29.0% (n = 212/731) of infants who received placebo (relative risk [RR]: 1.36; 95% confidence interval [CI]: 1.18, 1.57, p < 0.001). This study was conducted in a high rotavirus transmission setting. Study limitations include the absence of an immune correlate of protection for rotavirus vaccines, with the implications of using serum anti-rotavirus IgA for the assessment of immunogenicity and efficacy in low-income countries unclear. CONCLUSIONS This study showed no effect of the type of prenatal nutrient supplementation on immune response in this setting. Immune response varied depending on previous exposure to rotavirus, suggesting that alternative delivery modalities and schedules may be considered to improve vaccine performance in high transmission settings. TRIAL REGISTRATION ClinicalTrials.gov NCT02145000.",2021,"Seroconversion did not differ by supplementation group (41.1% (94/229) with LNS vs. 39.1% (102/261) with multiple micronutrients (MMN) vs. 38.8% (118/304) with IFA, p = 0.91).","['infant immune response (n = 53 villages and 1,525 infants with valid serology results: 794 in the vaccine group and 731 in the placebo group', 'Niger', 'From September 2015 to February 2017, participating women received', 'Eligible infants']","['prenatal nutrient supplement', 'oral rotavirus vaccine or placebo', 'vaccine/placebo', 'prenatal nutritional supplementation', '3 prenatal nutritional supplements (lipid-based nutrient supplement [LNS], multiple micronutrient supplement [MMS], or iron-folic acid [IFA', 'placebo', 'oral rotavirus vaccine', 'prenatal nutrient supplementation']","['Seroconversion', 'vaccine performance', 'immunogenicity and efficacy', 'Immunogenicity', 'seroconversion defined as ≥3-fold increase in IgA']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0036743', 'cui_str': 'Serologic test'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0597418', 'cui_str': 'Rotavirus vaccine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0357067', 'cui_str': 'Folic acid- and iron-containing product'}, {'cui': 'C0281643', 'cui_str': ""incomplete Freund's adjuvant""}]","[{'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0185026', 'cui_str': 'Plication'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}]",,0.509104,"Seroconversion did not differ by supplementation group (41.1% (94/229) with LNS vs. 39.1% (102/261) with multiple micronutrients (MMN) vs. 38.8% (118/304) with IFA, p = 0.91).","[{'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Isanaka', 'Affiliation': 'Department of Research, Epicentre, Paris, France.'}, {'ForeName': 'Souna', 'Initials': 'S', 'LastName': 'Garba', 'Affiliation': 'Epicentre, Niamey, Niger.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Plikaytis', 'Affiliation': 'BioStat Consulting, LLC, Worthington, Ohio, United States of America.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Malone McNeal', 'Affiliation': ""Department of Pediatrics, University of Cincinnati, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.""}, {'ForeName': 'Ousmane', 'Initials': 'O', 'LastName': 'Guindo', 'Affiliation': 'Epicentre, Niamey, Niger.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Langendorf', 'Affiliation': 'Department of Research, Epicentre, Paris, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Adehossi', 'Affiliation': 'National Hospital, Niamey, Niger.'}, {'ForeName': 'Iza', 'Initials': 'I', 'LastName': 'Ciglenecki', 'Affiliation': 'Médecins Sans Frontières-Operational Center Geneva, Geneva, Switzerland.'}, {'ForeName': 'Rebecca F', 'Initials': 'RF', 'LastName': 'Grais', 'Affiliation': 'Department of Research, Epicentre, Paris, France.'}]",PLoS medicine,['10.1371/journal.pmed.1003720'] 2524,34375323,A Novel Substrate-Inspired Fluorescence-Based Albumin Detection Improves Assessment of Clinical Outcomes in Hemodialysis Patients Receiving a Nursing Nutrition Intervention.,"BACKGROUND Albumin level does not precisely reflect nutritional status. We aimed to investigate the impact of a nutrition intervention on hemodialysis patients by use of fluorescence-based plasma albumin (FPA) detection. MATERIAL AND METHODS Eighty patients underwent maintenance hemodialysis for more than half a year and had a mean albumin <3.5 g/dL for over 3 months. The subjects were randomly divided into either a Control Group (CG) or an Intervention Group (IG). The IG received nutritional supplementation, and the CG group received routine nutritional support for 12 months. FPA and plasma albumin (PA) concentrations were measured. The fluorescence probe 1,3-Dichloro-7-hydroxy-9,9-dimethyl-2(9H)-acridone methyl biphenyl benzoate was used in FPA detection. Quality of life was estimated using WHOQOL-BREF (Quality of Life Scale developed through the World Health Organization), the 36-Item Short-Form Survey (SF-36), and the 6-minute walking test (6MWT). RESULTS After a 6-month and a 12-month intervention, PA and FPA concentrations increased, and the increase in FPA concentration was higher than that of PA in the IG group (P<0.05). Comparatively, the parameters of quality of life and 6MWT were improved in the IG group (P<0.05) but there were only minor changes in the CG group (P>0.05). There is an obvious association between the changes in FPA concentration and the parameters of quality of life and 6MWT but not PA. CONCLUSIONS Use of the fluorescence probe improves the detection sensitivity of plasma albumin and provides a potential method to assess clinical outcomes in hemodialysis patients.",2021,There is an obvious association between the changes in FPA concentration and the parameters of quality of life and 6MWT but not PA.,"['Eighty patients underwent maintenance hemodialysis for more than half a year and had a mean albumin <3.5 g/dL for over 3 months', 'Hemodialysis Patients', 'hemodialysis patients']","['Novel Substrate-Inspired Fluorescence-Based Albumin Detection', 'Nursing Nutrition Intervention', 'nutrition intervention', 'CG group received routine nutritional support', 'Control Group (CG) or an Intervention Group (IG']","['quality of life and 6MWT', 'Quality of life', 'FPA and plasma albumin (PA) concentrations', 'FPA concentration', 'fluorescence-based plasma albumin (FPA) detection', 'PA and FPA concentrations', 'WHOQOL-BREF (Quality of Life Scale', '6-minute walking test (6MWT']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0439267', 'cui_str': 'g/dL'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0857876', 'cui_str': 'Plasma albumin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}]",80.0,0.0231498,There is an obvious association between the changes in FPA concentration and the parameters of quality of life and 6MWT but not PA.,"[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'You', 'Affiliation': 'Blood Purification Center, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China (mainland).'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Blood Purification Center, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China (mainland).'}, {'ForeName': 'Wenhong', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Blood Purification Center, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China (mainland).'}]",Medical science monitor : international medical journal of experimental and clinical research,['10.12659/MSM.930257'] 2525,34375127,Single-use digital flexible ureteroscopes as a safe and effective choice for the treatment of lower pole renal stones: secondary analysis of a randomized controlled trial.,"OBJECTIVE To compare the efficacy and safety of a single-use digital flexible ureteroscope (FURS) and a reusable FURS for the treatment of lower pole stones (LPS) smaller than 20 mm. PATIENTS AND METHODS We analyzed the data of 49 patients with LPS from our previous multicenter, randomized, open-label clinical trial in four hospitals in China. All patients underwent FURS for LPS with a single-use FURS ZebraScope™ (trial group) or a reusable FURS URF-V (control group). The efficacy endpoints assessed were the 1-month postsurgical stone-free rate (SFR), operative time, length of postoperative hospital stay, and mean reduction in hemoglobin level. The safety outcomes assessed were the presence of adverse events (AEs), severe AEs (SAEs), and postoperative complications. RESULTS The demographic and preoperative parameters were comparable between the 2 groups. The 1-month SFR was 84.00% for the ZebraScope™ group and 58.33% for the URF-V group (P<0.05). There was no difference between the two groups in the operative time (P=0.665), the length of hospital stay (P=0.308), the presence of postoperative complications (P=0.307), the presence of AEs (P=0.483), and the presence of SAEs (P = 0.141). CONCLUSIONS This study demonstrates that single-use digital FURS is a safe and effective option and can offer higher SFR than the reusable FURS in the treatment of LPS smaller than 20 mm. We recommend single-use digital FURS as an alternative to reusable FURS for the treatment of LPS.",2021,"There was no difference between the two groups in the operative time (P=0.665), the length of hospital stay (P=0.308), the presence of postoperative complications (P=0.307), the presence of AEs (P=0.483), and the presence of SAEs (P = 0.141). ","['49 patients with LPS from our previous multicenter, randomized, open-label clinical trial in four hospitals in China', 'lower pole renal stones', 'lower pole stones (LPS) smaller than 20 mm']","['reusable FURS URF-V (control group', 'Single-use digital flexible ureteroscopes', 'single-use digital flexible ureteroscope (FURS']","['efficacy and safety', 'presence of SAEs', '1-month postsurgical stone-free rate (SFR), operative time, length of postoperative hospital stay, and mean reduction in hemoglobin level', 'presence of postoperative complications', '1-month SFR', 'operative time', 'length of hospital stay', 'presence of adverse events (AEs), severe AEs (SAEs), and postoperative complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0337815', 'cui_str': 'Poles'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0022650', 'cui_str': 'Kidney stone'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}]","[{'cui': 'C0392306', 'cui_str': 'Flexible ureteroscope'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}]",49.0,0.0816458,"There was no difference between the two groups in the operative time (P=0.665), the length of hospital stay (P=0.308), the presence of postoperative complications (P=0.307), the presence of AEs (P=0.483), and the presence of SAEs (P = 0.141). ","[{'ForeName': 'Enguang', 'Initials': 'E', 'LastName': 'Yang', 'Affiliation': 'Lanzhou University Second Hospital, 74713, NO. 82 Linxia Road, Chengguan District Lanzhou, China, Lanzhou, China, 730030; 283286709@qq.com.'}, {'ForeName': 'Suoshi', 'Initials': 'S', 'LastName': 'Jing', 'Affiliation': 'Lanzhou University First Affiliated Hospital, 117741, Lanzhou, Gansu, China; jingsshi@qq.com.'}, {'ForeName': 'Yuanjie', 'Initials': 'Y', 'LastName': 'Niu', 'Affiliation': 'Tianjin Medical University Second Hospital, 74671, Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China; niuyj_uro@163.com.'}, {'ForeName': 'Shiyong', 'Initials': 'S', 'LastName': 'Qi', 'Affiliation': 'Tianjin Medical University Second Hospital, 74671, Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China; 1317628735@qq.com.'}, {'ForeName': 'Kumar Yadav', 'Initials': 'KY', 'LastName': 'Prabin', 'Affiliation': 'Lanzhou University Second Hospital, 74713, Lanzhou, Gansu, China; prabin_y@yahoo.com.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Lanzhou University Second Hospital, 74713, Lanzhou, Gansu, China; y199501@yeah.net.'}, {'ForeName': 'Junsheng', 'Initials': 'J', 'LastName': 'Bao', 'Affiliation': 'Lanzhou University Second Hospital, 74713, Lanzhou, Gansu, China; 1163521364@qq.com.'}, {'ForeName': 'Junqiang', 'Initials': 'J', 'LastName': 'Tian', 'Affiliation': 'Lanzhou University Second Hospital, 74713, Lanzhou, Gansu, China; y196701@yeah.net.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Lanzhou University Second Hospital, 74713, Lanzhou, Gansu, China; y176501@yeah.net.'}, {'ForeName': 'Ningchen', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Peking University Shougang Hospital, 74580, Department of Urology, Peking University Shougang Hospital, Beijing, China; 517496104@qq.com.'}, {'ForeName': 'Tongwen', 'Initials': 'T', 'LastName': 'Ou', 'Affiliation': 'Capital Medical University, 12517, Department of Urology, Beijing Xuanwu Hospital, Capital Medical University, Beijing, China; ou_tongw@163.com.'}, {'ForeName': 'Zhiping', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Lanzhou University Second Hospital, 74713, Institute of Urology, Lanzhou, Gansu, China; wangzplzu@163.com.'}]",Journal of endourology,['10.1089/end.2021.0170'] 2526,34379363,What men want: Results from a national survey on decision making for prostate cancer treatment and research participation.,"Data comparing outcomes in prostate cancer and factors affecting treatment choice are sparse. To inform the design of a comparative effectiveness clinical trial, we engaged patients in developing a 28-question survey about decision making on treatment and research participation and dispersed it among men greater than or equal to 50 years of age. The 1046 respondents ranked long-term clinical outcomes as most important in making treatment decisions, specific functional outcomes as slightly less important, and duration, location, and cost of treatment as least important. Treatment choice was strongly impacted by side effect profile. Responses to whether the subject would agree to participation in a randomized trial between two types of radiation with minimal differences in outcomes were ""yes"" in 15%, ""no"" in 39%, and ""undecided"" in 46%. Responses to whether the subject would agree to participation in a randomized trial between two treatment durations with similar outcomes were yes in 36%, no in 24%, and undecided in 40%. Findings suggest many potential patients have strong treatment preferences and are averse to randomization, particularly when outcomes of importance may be affected. Patient engagement in study design and novel nonrandomized trial designs may offer a path to increase clinical trial success.",2021,"The 1046 respondents ranked long-term clinical outcomes as most important in making treatment decisions, specific functional outcomes as slightly less important, and duration, location, and cost of treatment as least important.",['engaged patients in developing a 28-question survey about decision making on treatment and research participation and dispersed it among men greater than or equal to 50\xa0years of age'],[],"['specific functional outcomes as slightly less important, and duration, location, and cost of treatment as least important']","[{'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0332624', 'cui_str': 'Dispersion'}, {'cui': 'C0439091', 'cui_str': '>='}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]",[],"[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0750482', 'cui_str': 'Slightly'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.113977,"The 1046 respondents ranked long-term clinical outcomes as most important in making treatment decisions, specific functional outcomes as slightly less important, and duration, location, and cost of treatment as least important.","[{'ForeName': 'Nancy P', 'Initials': 'NP', 'LastName': 'Mendenhall', 'Affiliation': 'Department of Radiation Oncology, University of Florida College of Medicine, Gainesville and Jacksonville, Florida, USA.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Rausch Osian', 'Affiliation': 'Department of Health Psychology, SIMED Health, Ocala, Florida, USA.'}, {'ForeName': 'Curtis M', 'Initials': 'CM', 'LastName': 'Bryant', 'Affiliation': 'Department of Radiation Oncology, University of Florida College of Medicine, Gainesville and Jacksonville, Florida, USA.'}, {'ForeName': 'Bradford S', 'Initials': 'BS', 'LastName': 'Hoppe', 'Affiliation': 'Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Morris', 'Affiliation': 'Department of Radiation Oncology, University of Florida College of Medicine, Gainesville and Jacksonville, Florida, USA.'}]",Clinical and translational science,['10.1111/cts.13090'] 2527,34379337,"fficacy and safety of Sofosbuvir plus Daclatasvir or Ravidasvir in patients with COVID-19, A Randomized Controlled Trial.","BACKGROUND Only a few treatments are approved for COVID-19 infections, with continuous debate about their clinical impact. Repurposing antiviral treatments might prove the fastest way to identify effective therapy. OBJECTIVES This trial aimed to evaluate the efficacy and safety of sofosbuvir (SOF) plus daclatasvir (DCV) or ravidasvir (RDV) added to standard care (SOC) for patients with moderate and severe COVID-19 infection. METHOD Multicentre parallel randomized controlled open lapel trial. One-hundred-twenty eligible patients with moderate and severe COVID-19 infection were randomized to one of the study arms. INTERVENTION Ten days treatment with SOF plus DCV or RDV in addition to the standard of care compared to SOC. Follow up 7 days. MAIN OUTCOME MEASURES Sum of the counted symptoms at 7 & 10 days, mean change in oxygen saturation level, viral negativity and rate of ICU admission. RESULTS Compared to SOC, SOF-DCV group experienced a significantly lower sum of the counted symptoms (fever, headache, generalized aches, or respiratory distress) combined with no evidence of deterioration (ICU admission and mechanical ventilation) on days 7 and 10 of treatment. Oxygen saturation also significantly improved among SOF-DCV group compared to SOC starting from day 4. The study also showed positive trends regarding the efficacy of SOF-DCV with lower incidence of mortality. On the other hand, adding SOF-RDV to SOC did not show significant improvements in endpoints. CONCLUSION The results support the efficacy and safety of SOF-DCV as an add-on to SOC for treatment of moderate to severe COVID-19 infections. This article is protected by copyright. All rights reserved.",2021,"Compared to SOC, SOF-DCV group experienced a significantly lower sum of the counted symptoms (fever, headache, generalized aches, or respiratory distress) combined with no evidence of deterioration (ICU admission and mechanical ventilation) on days 7 and 10 of treatment.","['One-hundred-twenty eligible patients with moderate and severe COVID-19 infection', 'patients with COVID-19', 'patients with moderate and severe COVID-19 infection']","['SOC, SOF-DCV', 'SOF plus DCV or RDV', 'sofosbuvir (SOF) plus daclatasvir (DCV) or ravidasvir (RDV) added to standard care (SOC', 'Sofosbuvir plus Daclatasvir or Ravidasvir', 'SOF-DCV']","['counted symptoms (fever, headache, generalized aches, or respiratory distress', 'deterioration (ICU admission and mechanical ventilation', 'fficacy and safety', 'oxygen saturation level, viral negativity and rate of ICU admission', 'Oxygen saturation']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]","[{'cui': 'C2976303', 'cui_str': 'sofosbuvir'}, {'cui': 'C3252090', 'cui_str': 'daclatasvir'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4508633', 'cui_str': 'ravidasvir'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0281856', 'cui_str': 'Generalized aches and pains'}, {'cui': 'C0476273', 'cui_str': 'Respiratory distress'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0521026', 'cui_str': 'viruses'}]",120.0,0.120341,"Compared to SOC, SOF-DCV group experienced a significantly lower sum of the counted symptoms (fever, headache, generalized aches, or respiratory distress) combined with no evidence of deterioration (ICU admission and mechanical ventilation) on days 7 and 10 of treatment.","[{'ForeName': 'Sherif', 'Initials': 'S', 'LastName': 'Abbass', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Salama', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}, {'ForeName': 'Tary', 'Initials': 'T', 'LastName': 'Salman', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}, {'ForeName': 'Alyaa', 'Initials': 'A', 'LastName': 'Sabry', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}, {'ForeName': 'Wael', 'Initials': 'W', 'LastName': 'Abdel-Razek', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}, {'ForeName': 'Ehab', 'Initials': 'E', 'LastName': 'Kamal', 'Affiliation': 'Fever Hospitals Directorate, MOH, Egypt.'}, {'ForeName': 'Sherin', 'Initials': 'S', 'LastName': 'Helmy', 'Affiliation': 'Pharco Corporate, Alexandria, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Abdelgwad', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}, {'ForeName': 'Neamt', 'Initials': 'N', 'LastName': 'Sakr', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Elgazzar', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Einar', 'Affiliation': 'Mahalla Fever Hospital, Gharbia, Egypt.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Farouk', 'Affiliation': 'Shebin Fever Hospital, Menoufia, Egypt.'}, {'ForeName': 'Mounir', 'Initials': 'M', 'LastName': 'Saif', 'Affiliation': 'Menouf Fever Hospital, Menoufia, Egypt.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Shehab', 'Affiliation': 'Menouf Fever Hospital, Menoufia, Egypt.'}, {'ForeName': 'Eman', 'Initials': 'E', 'LastName': 'El-Hosieny', 'Affiliation': 'Mahalla Fever Hospital, Gharbia, Egypt.'}, {'ForeName': 'Mai', 'Initials': 'M', 'LastName': 'Mansour', 'Affiliation': 'Shebin Fever Hospital, Menoufia, Egypt.'}, {'ForeName': 'Doaa', 'Initials': 'D', 'LastName': 'Mahdi', 'Affiliation': 'Menouf Fever Hospital, Menoufia, Egypt.'}, {'ForeName': 'El-Sayed', 'Initials': 'ES', 'LastName': 'Tharwa', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Salah', 'Affiliation': 'TCD MENA, Cairo, Egypt.'}, {'ForeName': 'Ola', 'Initials': 'O', 'LastName': 'Elrouby', 'Affiliation': 'Pharco Corporate, Alexandria, Egypt.'}, {'ForeName': 'Imam', 'Initials': 'I', 'LastName': 'Waked', 'Affiliation': 'National Liver Institute, Menoufia, Egypt.'}]",Journal of medical virology,['10.1002/jmv.27264'] 2528,34379314,Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.,"BACKGROUND Tadalafil 40 mg once daily is approved for adult patients with pulmonary arterial hypertension (PAH). To investigate and potentially fulfill an unmet need in pediatric patients with PAH, pharmacokinetic (PK) data were explored in a pediatric phase Ib/II study and pooled with prior phase III (pulmonary arterial hypertension and response to tadalafil [PHIRST-1]) adult data to develop the first population PK model for tadalafil in pediatric patients with PAH. METHODS H6D-MC-LVIG (NCT01484431) was an open-label, multicenter, multiple ascending dose study in pediatric patients with PAH, while PHIRST-1 was a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel design study in adults with PAH who received one of five treatments (tadalafil 2.5, 10, 20, or 40 mg, or placebo orally, once daily). PK data from the studies were pooled to develop a pediatric population PK model for tadalafil that characterized relationships among dose, exposure, and the effects of covariates with an aim to develop a population PK model that could simulate concentration-time profiles and assess exposure-matched dosing strategies in a pediatric PAH population. RESULTS In line with the observed data, modeling and simulation demonstrated that the doses studied in the pediatric population produced area under the concentration-time curves (AUCs) within the range of those associated with improved exercise ability in adults with PAH. The analyses included 1430 observations from 305 adult patients (PHIRST-1: 69 males and 236 females, 1102 observations) and 19 pediatric patients (LVIG: 6 males and 13 females, 328 observations) who received tadalafil once daily at different dose levels. The best-fit base model retained an effect of weight on apparent volume of distribution (V/F), fixed to the allometric scaling value of 1, and did not include an effect of weight on apparent clearance (CL/F). Other covariate effects were that bosentan increased CL/F, V/F decreased with decreasing body weight, and bioavailability (F) decreased with increasing dose and decreasing age. The PK model reliably predicted the observed concentrations and overall variability evident from the overlap of the individual observed concentrations with the distributions of simulated concentrations. CONCLUSIONS A one-compartment model parameterized in terms of F, absorption rate constant, CL/F, and V/F described the data well. The model demonstrated that plasma tadalafil concentrations in pediatric patients aged 2 to < 18 years were similar to those in adults at similar doses, and confirmed that dosing of 40 mg once daily in pediatric patients with a bodyweight ≥ 40 kg, and a dose of 20 mg once daily in patients with a body weight < 40 kg and aged ≥ 2 years are suitable for phase III evaluation. TRIAL REGISTRATION NUMBER (DATE OF REGISTRATION) LVIG: ClinicalTrials.gov identifier: NCT01484431 (2 December 2011). PHIRST-1: ClinicalTrials.gov identifier: NCT00125918 (2 August 2005).",2021,"The PK model reliably predicted the observed concentrations and overall variability evident from the overlap of the individual observed concentrations with the distributions of simulated concentrations. ","['adults with PAH who received one of five treatments ', 'pediatric patients with PAH', '305 adult patients (PHIRST-1: 69 males and 236 females, 1102 observations) and 19 pediatric patients (LVIG: 6 males and 13 females, 328 observations) who received', 'adult patients with pulmonary arterial hypertension (PAH', 'pediatric patients with PAH, pharmacokinetic (PK) data were explored in a pediatric phase Ib/II study and pooled with prior phase III (pulmonary arterial hypertension and response to tadalafil [PHIRST-1', 'Pediatric Patients with Pulmonary Arterial Hypertension', 'adults with PAH', 'H6D-MC-LVIG', 'pediatric patients aged 2 to <\xa018 years']","['Tadalafil', 'placebo', 'tadalafil']","['concentration-time curves (AUCs', 'plasma tadalafil concentrations', 'body weight, and bioavailability (F']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2973725', 'cui_str': 'Pulmonary arterial hypertension'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517703', 'cui_str': '305'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1176316', 'cui_str': 'tadalafil'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1176316', 'cui_str': 'tadalafil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C1176316', 'cui_str': 'tadalafil'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}]",305.0,0.097738,"The PK model reliably predicted the observed concentrations and overall variability evident from the overlap of the individual observed concentrations with the distributions of simulated concentrations. ","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Ferguson-Sells', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, 46285, USA. lis@lilly.com.'}, {'ForeName': 'Nieves', 'Initials': 'N', 'LastName': 'Velez de Mendizabal', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, 46285, USA.'}, {'ForeName': 'Baohui', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, 46285, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Small', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, 46285, USA.'}]",Clinical pharmacokinetics,['10.1007/s40262-021-01052-8'] 2529,34379121,Evaluation of the preventive effect of two concentrations of xylitol varnish versus fluoride varnish on enamel demineralization around orthodontic brackets: a randomized controlled trial.,"BACKGROUND The highly prevalent white spot lesions around orthodontic brackets necessitate introducing preventive materials without relying on patient compliance. OBJECTIVE To evaluate the antidemineralizing effect of two concentrations of xylitol varnish. TRIAL DESIGN Triple-blind, four-arm, parallel-group, single-center, randomized controlled clinical trial. METHODS A total of 120 orthodontic patients were randomly assigned to four groups (n = 30), using a computer-generated randomized block list. The treatment groups were: 10% xylitol, 20% xylitol, 5% fluoride, and placebo. Tooth demineralization was measured with DIAGNOdent at T1 (before treatment), followed by varnish application. At T2 (third month), the varnish was re-applied, and at the third (T2) and sixth (T3) months, and after treatment (T4), the demineralization was measured. The white spot lesion frequency was assessed visually after treatment. The participants, the clinician, and data assessors were all blinded to group assignments. RESULTS A total of 115 patients underwent per-protocol analyses. At T2, the mean DIAGNOdent numbers in the fluoride and 10% xylitol groups were significantly lower than the placebo group (P = 0.00), with a mean difference of 0.63 (95% CI, 0.15-1.10) and 0.5 (95% CI, 0.04-0.95), respectively. At T3, the fluoride and 10% xylitol groups had significantly lower mineral loss than the placebo group (P=0.046) with a mean difference of 0.52 (95% CI, 0.14-0.89) in the fluoride and 0.45 (95% CI, 0.03-0.86) in the 10% xylitol groups, respectively. However, at T4, only the mean for the 10% xylitol group was significantly different (P=0.049) from the placebo group, with a mean difference of 1.18 (95% CI, 0.42-1.93). Visual assessment showed that after treatment, the prevalence of white spot lesions in the fluoride (P=0.03) and 10% xylitol (P=0.00) groups was less than the placebo group with the odds ratio of 0.67 (95% CI, 0.46-0.96) and 0.43 (95% CI, 0.28-0.64), respectively. CONCLUSION The 10% xylitol varnish short-term effects on caries control were significantly greater than 20% xylitol varnish and placebo but similar to fluoride varnish. However, the 10% xylitol long-term effect was almost better than fluoride varnish. TRIAL REGISTRATION The protocol was registered at IRCT.ir under the code IRCT20180913041032N1.",2021,"Visual assessment showed that after treatment, the prevalence of white spot lesions in the fluoride (P=0.03) and 10% xylitol (P=0.00) groups was less than the placebo group with the odds ratio of 0.67 (95% CI, 0.46-0.96) and 0.43 (95% CI, 0.28-0.64), respectively. ","['enamel demineralization around orthodontic brackets', '120 orthodontic patients', '115 patients underwent per-protocol analyses']","['xylitol varnish and placebo', 'xylitol varnish', 'placebo', 'xylitol varnish versus fluoride varnish', '10% xylitol, 20% xylitol, 5% fluoride, and placebo']","['white spot lesion frequency', 'Visual assessment', 'caries control', 'mineral loss', 'Tooth demineralization', 'prevalence of white spot lesions']","[{'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C0700185', 'cui_str': 'Decalcified structure'}, {'cui': 'C0085428', 'cui_str': 'Orthodontic bracket'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0043369', 'cui_str': 'Xylitol'}, {'cui': 'C0042359', 'cui_str': 'Varnish'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0016326', 'cui_str': 'Fluoride Varnishes'}, {'cui': 'C0016327', 'cui_str': 'Fluoride'}]","[{'cui': 'C0043154', 'cui_str': 'Dental White Spots'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0085511', 'cui_str': 'Demineralization of tooth'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}]",120.0,0.748886,"Visual assessment showed that after treatment, the prevalence of white spot lesions in the fluoride (P=0.03) and 10% xylitol (P=0.00) groups was less than the placebo group with the odds ratio of 0.67 (95% CI, 0.46-0.96) and 0.43 (95% CI, 0.28-0.64), respectively. ","[{'ForeName': 'Hooman', 'Initials': 'H', 'LastName': 'Zarif Najafi', 'Affiliation': 'Orthodontic Research Center, Department of Orthodontics, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Shavakhi', 'Affiliation': 'Department of Orthodontics, Dental Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Hamid Reza', 'Initials': 'HR', 'LastName': 'Pakshir', 'Affiliation': 'Orthodontic Research Center, Department of Orthodontics, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",European journal of orthodontics,['10.1093/ejo/cjab049'] 2530,34379101,Response to a Randomized Trial on Mannitol Use During Partial Nephrectomy.,,2021,,[],['Mannitol Use'],[],[],"[{'cui': 'C0024730', 'cui_str': 'Mannitol'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",[],,0.0600047,,"[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Lewicki', 'Affiliation': 'Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York.'}, {'ForeName': 'Spyridon P', 'Initials': 'SP', 'LastName': 'Basourakos', 'Affiliation': 'Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York.'}, {'ForeName': 'Yuqing', 'Initials': 'Y', 'LastName': 'Qiu', 'Affiliation': 'Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York.'}, {'ForeName': 'Camilo', 'Initials': 'C', 'LastName': 'Arenas-Gallo', 'Affiliation': 'Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.'}, {'ForeName': 'Douglas S', 'Initials': 'DS', 'LastName': 'Scherr', 'Affiliation': 'Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York.'}, {'ForeName': 'Lee E', 'Initials': 'LE', 'LastName': 'Ponsky', 'Affiliation': 'Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.'}, {'ForeName': 'Jonathan E', 'Initials': 'JE', 'LastName': 'Shoag', 'Affiliation': 'Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York.'}]",JAMA surgery,['10.1001/jamasurg.2021.3598'] 2531,34379025,"Safety and tolerability of a natural supplement containing glucosinolates, phytosterols and citrus flavonoids in adult women: a randomized phase I, placebo-controlled, multi-arm, double-blinded clinical trial.","OBJECTIVE To evaluate the safety and tolerability of an oral herbal supplement containing glucosinolates, phytosterols, and citrus flavonoids (Warmi®, Lima Perú;) in otherwise healthy adult women. METHODS This was a phase-I, randomized parallel three arms, double-blinded, and a placebo-controlled clinical trial. A total of 55 participants aged 18-40 were randomly assigned to one of three groups to receive for three months: (1) an oral herbal supplement of 1650 mg/day; (2) an oral herbal supplement of 3300 mg/day; or (3) an oral placebo 3300 mg/day. The primary endpoints were oral safety and tolerability of the supplement. The secondary endpoint was its effect on vital functions, anthropometrics, and laboratory tests. We used an exploratory approach by covariance analysis (ANCOVA) adjusted for the variables' baseline value for the secondary outcomes. RESULTS All women completed three months of follow-up, reporting no side effects. Our exploratory analysis revealed that treatment with the herbal supplement of 1650 mg/day was associated with increased glucose and uric acid levels. In comparison, the herbal supplement 3300 mg/day was associated with reduced breathing rate, increased basal temperature, and systolic blood pressure, both compared to the placebo group. However, despite significant differences, none of these was clinically significant. CONCLUSION The oral herbal supplement had a favorable safety and tolerability profile in studied women. There is a need to study its potential as an option to treat menopausal symptoms.",2021,"In comparison, the herbal supplement 3300 mg/day was associated with reduced breathing rate, increased basal temperature, and systolic blood pressure, both compared to the placebo group.","['studied women', 'otherwise healthy adult women', 'adult women', '55 participants aged 18-40']","['oral herbal supplement of 1650\u2009mg/day; (2) an oral herbal supplement of 3300\u2009mg/day; or (3) an oral placebo', 'natural supplement containing glucosinolates, phytosterols and citrus flavonoids', 'oral herbal supplement containing glucosinolates, phytosterols, and citrus flavonoids (Warmi®, Lima Perú', 'placebo']","['glucose and uric acid levels', 'vital functions, anthropometrics, and laboratory tests', 'Safety and tolerability', 'favorable safety and tolerability profile', 'oral safety and tolerability', 'reduced breathing rate, increased basal temperature, and systolic blood pressure', 'safety and tolerability']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1504473', 'cui_str': 'Herbal Supplements'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C4517720', 'cui_str': '3300'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0017767', 'cui_str': 'Glucosinolate'}, {'cui': 'C0031866', 'cui_str': 'Phytosterols'}, {'cui': 'C0008865', 'cui_str': 'Citrus'}, {'cui': 'C0596577', 'cui_str': 'Flavonoid'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0202239', 'cui_str': 'Uric acid measurement'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",55.0,0.672242,"In comparison, the herbal supplement 3300 mg/day was associated with reduced breathing rate, increased basal temperature, and systolic blood pressure, both compared to the placebo group.","[{'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Villar-López', 'Affiliation': 'Universidad Nacional Mayor de San Marcos, Facultad de Medicina ""San Fernando"", Departamento de Medicina Preventiva y Salud Pública, Lima, Perú.'}, {'ForeName': 'Percy', 'Initials': 'P', 'LastName': 'Soto-Becerra', 'Affiliation': 'Universidad San Ignacio de Loyola, Centro de Excelencia en Investigaciones Económicas y Sociales en Salud, Lima, Perú.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Curse Choque', 'Affiliation': 'Hospital Carlos Alcántara Butterfield, Servicio de Pediatría, Lima, Perú.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Al-Kassab-Córdova', 'Affiliation': 'Universidad Peruana de Ciencias Aplicadas, Facultad de Ciencias de la Salud, Lima, Perú.'}, {'ForeName': 'Félix', 'Initials': 'F', 'LastName': 'Bernuy-Barrera', 'Affiliation': 'Universidad Nacional Federico Villarreal, Facultad de Medicina Hipólito Unanue, Lima, Perú.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Palomino', 'Affiliation': 'Hospital Nacional Edgardo Rebagliati Martins, Departamento de Obstetricia y Ginecología, Lima, Perú.'}, {'ForeName': 'Percy A', 'Initials': 'PA', 'LastName': 'Rojas', 'Affiliation': 'Universidad Peruana Cayetano Heredia, Laboratorios de Investigación y Desarrollo, Unidad de Biotecnología Molecular, Lima, Perú.'}, {'ForeName': 'Carmela', 'Initials': 'C', 'LastName': 'Vera', 'Affiliation': 'Hospital Nacional Edgardo Rebagliati Martins Lima, Servicio de Psicología, Perú.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Lugo-Martínez', 'Affiliation': 'Instituto Politécnico Nacional, Escuela Superior de Medicina, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Mezones-Holguín', 'Affiliation': 'Universidad San Ignacio de Loyola, Centro de Excelencia en Investigaciones Económicas y Sociales en Salud, Lima, Perú.'}]",Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,['10.1080/09513590.2021.1960965'] 2532,34379024,"The Impact of Transitions, a Mental Health Literacy Intervention With Embedded Life Skills for Postsecondary Students: Preliminary Findings From a Naturalistic Cohort Study : L'effet des transitions, une intervention de littératie en santé mentale avec compétences essentielles intégrées pour des étudiants du post-secondaire : résultats préliminaires d'une étude de cohorte naturaliste.","OBJECTIVE Mental illness is a common medical condition to onset during adolescence. Young people who leave for postsecondary life are at an especially challenging period of lifetime when many will leave home and familiar environments for prolonged periods of time. These new circumstances may put young people at risk of developing mental health problems or disorders or exacerbate existing mental disorders. Alternatively, some young people may misinterpret the normal negative emotional states occurring as a result of these new challenges as a mental disorder requiring professional intervention. We conducted a quasiexperimental cohort study to investigate the effectiveness of a mental health literacy intervention Transitions with blended life skills to address these challenges for first-year postsecondary students. METHODS Students ( n  = 2,397) from five Canadian postsecondary institutions were assigned to the intervention or the control group and were administered a survey at baseline, postintervention, and at 2-month follow-up (September 2017 to February 2018). We applied generalized linear mixed effects (PROC Mixed procedure) to test the between-group difference in the post-pre/follow-up-pre and to determine the predicted least-square mean values. RESULTS The findings showed that students who were exposed to the Transitions intervention significantly improved their mental health knowledge, decreased stigma against mental illness, improved help-seeking attitudes and behaviours, and decreased perceived stress when compared to students who had not been exposed to the intervention. However, we did not identify significant changes in general health. This may be due to the relatively short follow-up time (2 months) to determine participants' general health status. CONCLUSIONS Transitions delivered to first-year postsecondary students may be a beneficial intervention to help young people adjust to their new postsecondary life and improve their mental health.",2021,"The findings showed that students who were exposed to the Transitions intervention significantly improved their mental health knowledge, decreased stigma against mental illness, improved help-seeking attitudes and behaviours, and decreased perceived stress when compared to students who had not been exposed to the intervention.","['Postsecondary Students', 'Young people who leave for postsecondary life', 'Students ( n \u2009=\u20092,397) from five Canadian postsecondary institutions', 'first-year postsecondary students', "" résultats préliminaires d'une étude de cohorte naturaliste""]","['mental health literacy intervention Transitions with blended life skills', 'littératie', 'Mental Health Literacy Intervention With Embedded Life Skills']","['mental health knowledge, decreased stigma against mental illness, improved help-seeking attitudes and behaviours, and decreased perceived stress', 'general health']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0376558', 'cui_str': 'Life'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}]",,0.0172069,"The findings showed that students who were exposed to the Transitions intervention significantly improved their mental health knowledge, decreased stigma against mental illness, improved help-seeking attitudes and behaviours, and decreased perceived stress when compared to students who had not been exposed to the intervention.","[{'ForeName': 'Yifeng', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': '3158 University of Alberta, Edmonton, Alberta.'}, {'ForeName': 'Stan', 'Initials': 'S', 'LastName': 'Kutcher', 'Affiliation': '12361 Dalhousie University, Halifax, Nova Scotia.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Austen', 'Affiliation': '1270 Saint Francis Xavier University, Antigonish, Nova Scotia.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Comfort', 'Affiliation': '7017 Mount Allison University, Sackville, New Brunswick.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Gilham', 'Affiliation': '1270 Saint Francis Xavier University, Antigonish, Nova Scotia.'}, {'ForeName': 'Christiana', 'Initials': 'C', 'LastName': 'MacDougall', 'Affiliation': '7017 Mount Allison University, Sackville, New Brunswick.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'McKenna', 'Affiliation': '113192 Holland College, Charlottetown, Prince Edward Island.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'McKinnon', 'Affiliation': '1270 Saint Francis Xavier University, Antigonish, Nova Scotia.'}, {'ForeName': 'Kara', 'Initials': 'K', 'LastName': 'Thompson', 'Affiliation': '1270 Saint Francis Xavier University, Antigonish, Nova Scotia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Yeo', 'Affiliation': '1270 Saint Francis Xavier University, Antigonish, Nova Scotia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': ""3690 Saint Mary's University, Halifax, Nova Scotia.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Baxter', 'Affiliation': '3146 Alberta Health Services, Calgary, Alberta.'}, {'ForeName': 'Kara', 'Initials': 'K', 'LastName': 'Matheson', 'Affiliation': 'Nova Scotia Health Authority, Halifax, Nova Scotia.'}]",Canadian journal of psychiatry. Revue canadienne de psychiatrie,['10.1177/07067437211037131'] 2533,34378834,"Effect of slow, deep breathing on visceral pain perception and its underlying psychophysiological mechanisms.","BACKGROUND Studies using somatic pain models have shown the hypoalgesic effects of slow, deep breathing. We evaluated the effect of slow, deep breathing on visceral pain and explored putative mediating mechanisms including autonomic and emotional responses. METHODS Fifty-seven healthy volunteers (36 females, mean age = 22.0 years) performed controlled, deep breathing at a slow frequency (6 breaths per minute), controlled breathing at a normal frequency (14 breaths per minute; active control), and uncontrolled breathing (no-treatment control) in randomized order. Moderate painful stimuli were given during each condition by delivering electrical stimulation in the distal esophagus. Participants rated pain intensity after each stimulation. Heart rate variability and self-reported arousal were measured during each condition. KEY RESULTS Compared to uncontrolled breathing, pain intensity was lower during slow, deep breathing (Cohen's d = 0.40) and normal controlled breathing (d = 0.47), but not different between slow, deep breathing and normal controlled breathing. Arousal was lower (d = 0.53, 0.55) and heart rate variability was higher (d = 0.70, 0.86) during slow, deep breathing compared to the two control conditions. The effect of slow, deep breathing on pain was not mediated by alterations in heart rate variability or arousal but was moderated by pain catastrophizing. CONCLUSIONS AND INFERENCES Slow, deep breathing can reduce visceral pain intensity. However, the effect is not specific to the slow breathing frequency and is not mediated by autonomic or emotional responses, suggesting other underlying mechanisms (notably distraction). Whether a long-term practice of slow, deep breathing can influence (clinical) visceral pain warrants to be investigated.",2021,"Compared to uncontrolled breathing, pain intensity was lower during slow, deep breathing (Cohen's d = 0.40) and normal controlled breathing (d = 0.47), but not different between slow, deep breathing and normal controlled breathing.","['Fifty-seven healthy volunteers (36 females, mean age\xa0=\xa022.0\xa0years']","['slow, deep breathing', 'deep breathing at a slow frequency (6 breaths per minute), controlled breathing at a normal frequency (14 breaths per minute; active control), and uncontrolled breathing (no-treatment control']","['heart rate variability', 'Heart rate variability and self-reported arousal', 'pain intensity', 'visceral pain intensity', 'normal controlled breathing', 'Moderate painful stimuli', 'visceral pain perception', 'Arousal']","[{'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C1321587', 'cui_str': 'Excessively deep breathing'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439386', 'cui_str': 'breaths/min'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0234245', 'cui_str': 'Visceral pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",57.0,0.0365752,"Compared to uncontrolled breathing, pain intensity was lower during slow, deep breathing (Cohen's d = 0.40) and normal controlled breathing (d = 0.47), but not different between slow, deep breathing and normal controlled breathing.","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Gholamrezaei', 'Affiliation': 'Laboratory for Brain-Gut Axis Studies (LaBGAS), Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Ilse', 'Initials': 'I', 'LastName': 'Van Diest', 'Affiliation': 'Health Psychology Research Group, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Qasim', 'Initials': 'Q', 'LastName': 'Aziz', 'Affiliation': 'Centre for Neuroscience and Trauma, Blizard Institute, Wingate Institute of Neurogastroeneterology, Queen Mary University of London, London, UK.'}, {'ForeName': 'Ans', 'Initials': 'A', 'LastName': 'Pauwels', 'Affiliation': 'Gastrointestinal Sensitivity and Motility Research Group, Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Tack', 'Affiliation': 'Gastrointestinal Sensitivity and Motility Research Group, Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Johan W S', 'Initials': 'JWS', 'LastName': 'Vlaeyen', 'Affiliation': 'Health Psychology Research Group, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Van Oudenhove', 'Affiliation': 'Laboratory for Brain-Gut Axis Studies (LaBGAS), Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.14242'] 2534,34378804,NICU music therapy effects on maternal mental health and preterm infant's emotional arousal.,"In recent decades, music therapy in the Neonatal Intensive Care Unit (NICU) has been shown to regulate preterm infant's physiological responses and improve maternal mental health. This study investigated the effects of the music therapy intervention for the mother-preterm infant dyad (MUSIP) for maternal anxiety, postnatal depression, and stress, and preterm infants' weight gain, length of hospitalization, heart rate (HR), and oxygen saturation (So 2 ). A pre-experimental design was used with 33 mother-preterm infant dyads in a Brazilian NICU: 16 dyads in the Music Therapy Group (MTG) and 17 dyads in the Control Group (CG). The MTG took part in the MUSIP, aimed at supporting maternal singing with the preterm baby. Infants' HR and So 2 were recorded at each minute from 10 min before to 10 min after sessions 1, 3, and 6. Before infants' discharge, maternal anxiety and depression scores were lower in the MTG compared to the CG. Anxiety, depression, and stress levels decreased significantly after the intervention in the MTG. With regard to infants, HR and So 2 ranges were higher during music therapy, compared to before and after sessions. MUSIP improved maternal mental health and affected preterm infants' emotional arousal, with positive trends in decreasing HR, stabilizing So 2 , and reducing length of hospitalization.",2021,"Before infants' discharge, maternal anxiety and depression scores were lower in the MTG compared to the CG.",['33 mother-preterm infant dyads in a Brazilian NICU: 16 dyads in the'],"['music therapy intervention', 'MUSIP', 'NICU music therapy', 'Music Therapy Group (MTG) and 17 dyads in the Control Group (CG']","['Anxiety, depression, and stress levels', ""maternal anxiety, postnatal depression, and stress, and preterm infants' weight gain, length of hospitalization, heart rate (HR), and oxygen saturation (So 2 "", 'maternal anxiety and depression scores', ""maternal mental health and preterm infant's emotional arousal"", ""maternal mental health and affected preterm infants' emotional arousal, with positive trends in decreasing HR, stabilizing So 2 , and reducing length of hospitalization""]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}]","[{'cui': 'C0026868', 'cui_str': 'Music therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0040833', 'cui_str': 'trends'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0184512', 'cui_str': 'Stabilized'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",,0.0210715,"Before infants' discharge, maternal anxiety and depression scores were lower in the MTG compared to the CG.","[{'ForeName': 'Ambra', 'Initials': 'A', 'LastName': 'Palazzi', 'Affiliation': 'Universidade Federal do Rio Grande do Sul (UFRGS), Psychology Institute, Porto Alegre, Brazil.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Meschini', 'Affiliation': 'S. Stefano Rehabilitation Institute, Porto Potenza Picena (MC), Italy.'}, {'ForeName': 'Cesar Augusto', 'Initials': 'CA', 'LastName': 'Piccinini', 'Affiliation': 'Universidade Federal do Rio Grande do Sul (UFRGS), Psychology Institute, Porto Alegre, Brazil.'}]",Infant mental health journal,['10.1002/imhj.21938'] 2535,34378800,Remodeling after myocardial infarction and effects of heart failure treatment investigated by hyperpolarized [1- 13 C]pyruvate magnetic resonance spectroscopy.,"PURPOSE Hyperpolarized [1- 13 C]pyruvate MRS can measure cardiac metabolism in vivo. We investigated whether [1- 13 C]pyruvate MRS could predict left ventricular remodeling following myocardial infarction (MI), long-term left ventricular effects of heart failure medication, and could identify responders to treatment. METHODS Thirty-five rats were scanned with hyperpolarized [1- 13 C]pyruvate MRS 3 days after MI or sham surgery. The animals were re-examined after 30 days of therapy with β-blockers and ACE-inhibitors (active group, n = 12), placebo treatment (placebo group, n = 13) or no treatment (sham group, n = 10). Furthermore, heart tissue mitochondrial respiratory capacity was assessed by high-resolution respirometry. Metabolic results were compared between groups, over time and correlated to functional MR data at each time point. RESULTS At 30 ± 0.5 days post MI, left ventricular ejection fraction (LVEF) differed between groups (sham, 77% ± 1%; placebo, 52% ± 3%; active, 63% ± 2%, P < .001). Cardiac metabolism, measured by both hyperpolarized [1- 13 C]pyruvate MRS and respirometry, neither differed between groups nor between baseline and follow-up. Three days post MI, low bicarbonate + CO 2 /pyruvate ratio was associated with low LVEF. At follow-up, in the active group, a poor recovery of LVEF was associated with high bicarbonate + CO 2 /pyruvate ratio, as measured by hyperpolarized MRS. CONCLUSION In a rat model of moderate heart failure, medical treatment improved function, but did not on average influence [1- 13 C]pyruvate flux as measured by MRS; however, responders to heart failure medication had reduced capacity for carbohydrate metabolism.",2021,"At 30 ± 0.5 days post MI, left ventricular ejection fraction (LVEF) differed between groups (sham, 77% ± 1%; placebo, 52% ± 3%; active, 63% ± 2%, P < .001).",['Thirty-five rats were scanned with'],"['MRS', 'hyperpolarized [1- 13 C]pyruvate MRS 3 days after MI or sham surgery', 'β-blockers and ACE-inhibitors (active group, n = 12), placebo treatment (placebo', '1- 13 C]pyruvate', 'hyperpolarized [1- 13 C]pyruvate magnetic resonance spectroscopy', 'placebo', 'Hyperpolarized']","['left ventricular ejection fraction (LVEF', 'carbohydrate metabolism', 'cardiac metabolism', 'Furthermore, heart tissue mitochondrial respiratory capacity', 'Cardiac metabolism', 'functional MR data']","[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}]","[{'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0302820', 'cui_str': 'Metabolism, Carbohydrate'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C1272575', 'cui_str': 'Heart tissue'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",35.0,0.126485,"At 30 ± 0.5 days post MI, left ventricular ejection fraction (LVEF) differed between groups (sham, 77% ± 1%; placebo, 52% ± 3%; active, 63% ± 2%, P < .001).","[{'ForeName': 'Rasmus Stilling', 'Initials': 'RS', 'LastName': 'Tougaard', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark.'}, {'ForeName': 'Christoffer', 'Initials': 'C', 'LastName': 'Laustsen', 'Affiliation': 'MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Thomas Ravn', 'Initials': 'TR', 'LastName': 'Lassen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark.'}, {'ForeName': 'Haiyun', 'Initials': 'H', 'LastName': 'Qi', 'Affiliation': 'MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Jakob Lykke', 'Initials': 'JL', 'LastName': 'Lindhardt', 'Affiliation': 'MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Schroeder', 'Affiliation': 'MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Nichlas Riise', 'Initials': 'NR', 'LastName': 'Jespersen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark.'}, {'ForeName': 'Esben Søvsø Szocska', 'Initials': 'ESS', 'LastName': 'Hansen', 'Affiliation': 'MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Ringgaard', 'Affiliation': 'MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Hans Erik', 'Initials': 'HE', 'LastName': 'Bøtker', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark.'}, {'ForeName': 'Won Yong', 'Initials': 'WY', 'LastName': 'Kim', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Stødkilde-Jørgensen', 'Affiliation': 'MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Wiggers', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark.'}]",Magnetic resonance in medicine,['10.1002/mrm.28964'] 2536,34378693,Reducing alcohol-related risks among adolescents: a feasibility study of the SHAHRP program in Brazilian schools.,"The SHAHRP program was effective reducing drinking and alcohol - harms in Australia, but cross-cultural adaptation is required before replication. This study aimed at assessing the feasibility of SHAHRP in Brazil focused on implementation and acceptability. A mixed-methodsdesign was used: quantitative for implementing the program and evaluation and qualitative for acceptability. The quantitative design was a pilot of a randomized controlled trial. Private schools were randomly divided into four intervention (n=160) and four control (n=188) schools. Student's mean age was 12.7 years. The fidelity of implementation and likely outcome measures were assessed. Qualitative data on acceptability were provided by students and teachers. The percentage of implementation varied from 62.5% to 87.5%. Behaviours such as alcohol-harms requires a larger cohort and longer follow-up to be adequately evaluated. The risk reduction approach and activities had good acceptability from students and teachers. Quantitative and qualitative outcomes on knowledge and decision-making indicated possible improvement in SHAHRP schools. The program is feasible and well accepted in a Brazilian setting, opening the way for a more comprehensive evaluation and dissemination.",2021,"The SHAHRP program was effective reducing drinking and alcohol - harms in Australia, but cross-cultural adaptation is required before replication.","['Brazilian schools', ""Student's mean age was 12.7 years"", 'Private schools', 'adolescents', 'SHAHRP schools']","['SHAHRP', 'SHAHRP program']",['percentage of implementation'],"[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517546', 'cui_str': '12.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}]",,0.00808919,"The SHAHRP program was effective reducing drinking and alcohol - harms in Australia, but cross-cultural adaptation is required before replication.","[{'ForeName': 'Tatiana de Castro', 'Initials': 'TC', 'LastName': 'Amato', 'Affiliation': 'Núcleo de Pesquisa em Saúde e Uso de Substâncias, Departamento de Psicobiologia, Universidade Federal de São Paulo. Rua Botucatu 862 1º andar, Vila Clementino. 04023-062 São Paulo SP Brasil. taticastroamato@gmail.com.'}, {'ForeName': 'Emérita Sátiro', 'Initials': 'ES', 'LastName': 'Opaleye', 'Affiliation': 'Núcleo de Pesquisa em Saúde e Uso de Substâncias, Departamento de Psicobiologia, Universidade Federal de São Paulo. Rua Botucatu 862 1º andar, Vila Clementino. 04023-062 São Paulo SP Brasil. taticastroamato@gmail.com.'}, {'ForeName': 'Nyanda', 'Initials': 'N', 'LastName': 'McBride', 'Affiliation': 'National Drug Research Institute, Curtin University. Perth WA Austrália.'}, {'ForeName': 'Ana Regina', 'Initials': 'AR', 'LastName': 'Noto', 'Affiliation': 'Núcleo de Pesquisa em Saúde e Uso de Substâncias, Departamento de Psicobiologia, Universidade Federal de São Paulo. Rua Botucatu 862 1º andar, Vila Clementino. 04023-062 São Paulo SP Brasil. taticastroamato@gmail.com.'}]",Ciencia & saude coletiva,['10.1590/1413-81232021268.13472020'] 2537,34377309,Effects of comprehensive nursing on negative emotion and prognosis of patients with sepsis.,"OBJECTIVE To explore the effect of comprehensive nursing on negative emotion and prognosis of patients with sepsis. METHODS As a prospective study, 104 patients with sepsis were randomized into the observation group (n=52) and the control group (n=52). The patients in the control group underwent routine nursing, whereas the patients in the observation group underwent comprehensive nursing care in addition to routine nursing. The level of negative emotions, patients' prognosis, quality of life (QOL), Acute Physiology and Chronic Health Evaluation (APACHE) ll score, clinical indicators, and patient satisfaction with nursing were compared between the two groups. RESULTS Compared with the control group, the observation group had lower Self-Rating Anxiety Scale score, Self-Rating Depression Scale score, and APACHE ll score (all P<0.001). The scores of physical functioning, general health perceptions, social role functioning, emotional role functioning, and mental health of the observation group were all higher than those of the control group (all P<0.01). The duration of mechanical ventilation, hospitalization expenses, and the length of stay in the Intensive Care Unit (ICU) in the observation group were lower than those in the control group (all P<0.01). Moreover, the observation group had a lower total incidence of shock, multiple organ dysfunction syndrome, and death and higher patient satisfaction with the nursing care than the control group (all P<0.05). CONCLUSION Comprehensive nursing care can alleviate anxiety and depression in patients with sepsis and can improve the prognosis and QOL of patients. Also, it can shorten the length of stay in the ICU, lower treatment costs, and improve patient satisfaction; all of which can be recommended for clinical application.",2021,"Compared with the control group, the observation group had lower Self-Rating Anxiety Scale score, Self-Rating Depression Scale score, and APACHE ll score (all P<0.001).","['104 patients with sepsis', 'patients with sepsis']","['comprehensive nursing', 'comprehensive nursing care', 'Comprehensive nursing care', 'routine nursing']","['scores of physical functioning, general health perceptions, social role functioning, emotional role functioning, and mental health', 'patient satisfaction', 'negative emotion and prognosis', 'duration of mechanical ventilation, hospitalization expenses, and the length of stay in the Intensive Care Unit (ICU', 'lower Self-Rating Anxiety Scale score, Self-Rating Depression Scale score, and APACHE ll score', 'total incidence of shock, multiple organ dysfunction syndrome, and death and higher patient satisfaction', ""level of negative emotions, patients' prognosis, quality of life (QOL), Acute Physiology and Chronic Health Evaluation (APACHE) ll score, clinical indicators, and patient satisfaction with nursing""]","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0028678', 'cui_str': 'nursing'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0243030', 'cui_str': 'Acute physiology and chronic health evaluation'}, {'cui': 'C0042950', 'cui_str': 'Volition'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0026766', 'cui_str': 'Multiple organ failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]",104.0,0.0197432,"Compared with the control group, the observation group had lower Self-Rating Anxiety Scale score, Self-Rating Depression Scale score, and APACHE ll score (all P<0.001).","[{'ForeName': 'Guofeng', 'Initials': 'G', 'LastName': 'Shen', 'Affiliation': 'Department of Critical Care Medicine, Minhang Hospital, Fudan University Shanghai, China.'}, {'ForeName': 'Yunfen', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Department of Nursing, Minhang District Maternal and Child Health Hospital of Shanghai Shanghai, China.'}, {'ForeName': 'Jindi', 'Initials': 'J', 'LastName': 'Ni', 'Affiliation': 'Department of Critical Care Medicine, Minhang Hospital, Fudan University Shanghai, China.'}, {'ForeName': 'Lijing', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Department of Critical Care Medicine, Minhang Hospital, Fudan University Shanghai, China.'}, {'ForeName': 'Zhuye', 'Initials': 'Z', 'LastName': 'Xia', 'Affiliation': 'Department of Critical Care Medicine, Minhang Hospital, Fudan University Shanghai, China.'}, {'ForeName': 'Hongjie', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Critical Care Medicine, Minhang Hospital, Fudan University Shanghai, China.'}, {'ForeName': 'Shengfu', 'Initials': 'S', 'LastName': 'Pan', 'Affiliation': 'Department of Critical Care Medicine, Minhang Hospital, Fudan University Shanghai, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Critical Care Medicine, Minhang Hospital, Fudan University Shanghai, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hu', 'Affiliation': 'Department of Cardiology, Minhang Hospital, Fudan University Shanghai, China.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Critical Care Medicine, Minhang Hospital, Fudan University Shanghai, China.'}]",American journal of translational research,[] 2538,34377308,The effects of Roy's adaptation model and the forgetting curve in the clinical instruction of operating room nursing interns.,"OBJECTIVE To investigate the effects of Roy's adaptation model combined with the forgetting curve in the clinical instruction of operating room nursing interns. METHODS 115 nursing students in our hospital were randomized and allocated into two groups: the observation group (n=60) and the control group (n=55). The control group underwent the traditional nursing instruction method, and the observation group underwent a new instruction mode guided by Roy's adaptation model combined with the forgetting curve method. The learning effects of the two groups of nursing students and their satisfaction with the nursing instruction were compared. RESULTS The observation group's theoretical examination score was (96.18±3.94) points, and the group's skill examination score was (83.78±5.19) points, which were higher than the corresponding scores in the control group (83.78±5.19) and (81.32±3.66), with statistical significance (all P<0.05). The operating doctors' scores on the operating room nursing students' psychological adaptability in the operating room, their proficiency in common operation cooperation, their aseptic concepts, their ability to prepare and dispose of instruments and articles, and their work and learning initiatives were significantly higher than they were in the control group, and the differences were statistically significant (P<0.05). The nursing students' professional level, interpersonal communication ability, and teaching ability scores and their total score in the observation group were significantly higher than they were in the control group (P<0.05). CONCLUSION The new instruction method which combines Roy's adaptation model with the forgetting curve can not only effectively improve the nursing students' learning abilities and adaptability, but it also has an important significance in improving the relationship between doctors and nurses, the instruction relationship, and in improving the quality of the nursing instruction and the comprehensive ability of the nursing staff in the operating room.",2021,"The operating doctors' scores on the operating room nursing students' psychological adaptability in the operating room, their proficiency in common operation cooperation, their aseptic concepts, their ability to prepare and dispose of instruments and articles, and their work and learning initiatives were significantly higher than they were in the control group, and the differences were statistically significant (P<0.05).","['operating room nursing interns', '115 nursing students in our hospital']","[""traditional nursing instruction method, and the observation group underwent a new instruction mode guided by Roy's adaptation model combined with the forgetting curve method""]","['skill examination score', 'professional level, interpersonal communication ability, and teaching ability scores and their total score', 'theoretical examination score']","[{'cui': 'C0029062', 'cui_str': 'Nursing, Operating Room'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0086792', 'cui_str': 'Personal Communication'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0039401', 'cui_str': 'Education'}]",115.0,0.0265826,"The operating doctors' scores on the operating room nursing students' psychological adaptability in the operating room, their proficiency in common operation cooperation, their aseptic concepts, their ability to prepare and dispose of instruments and articles, and their work and learning initiatives were significantly higher than they were in the control group, and the differences were statistically significant (P<0.05).","[{'ForeName': 'Weiming', 'Initials': 'W', 'LastName': 'Qian', 'Affiliation': 'Department of Nursing, The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou 310009, Zhejiang, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Qian', 'Affiliation': 'Department of Nursing, The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou 310009, Zhejiang, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Xu', 'Affiliation': 'Department of Nursing, The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou 310009, Zhejiang, China.'}, {'ForeName': 'Lijun', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Department of Nursing, The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou 310009, Zhejiang, China.'}]",American journal of translational research,[] 2539,34377306,The application of a structural nutritional care management model in severe acute pancreatitis patients undergoing early enteral nutrition via nasal jejunal nutrition tubes.,"OBJECTIVE To investigate the advantages of a structural nutritional care management model (hereafter referred to as structural management) in severe acute pancreatitis (SAP) patients undergoing early enteral nutrition via nasal jejunal nutrition tubes. METHODS A total of 88 patients with SAP diagnosed and treated in our hospital were recruited as the study cohort and underwent enteral nutrition treatment. A random number table was used for the random grouping. The control group was routinely managed, and the study group was also administered structural management. In the study, we observed and compared the differences and changes in the relevant nutritional indexes (albumin (ALB), prealbumin (PA), and transferrin (TRF)) and the gastrointestinal hormone indexes (gastrin (MTL), vasoactive peptide (VIP), and 5-hydroxytryptamine (5-HT)) before and after the treatment. Between the two groups, we also compared the times required for the recovery of the relevant gastrointestinal physiological function indexes, the mechanical ventilation times, the hospitalization durations in the ICU, the complications, the satisfaction indexes and the satisfaction rates. RESULTS After the treatment, the relevant nutritional indicators, including ALB (35.26±3.35 g/L), PA (25.19±5.64 g/L), and TRF (2.82±0.54 g/L) in the study group were higher than the ALB (28.19±2.74 g/L), PA (21.29±4.32 g/L), and TRF (2.26±0.32 g/L) in the control group (all P<0.05). After the treatment, the relevant gastrointestinal hormone indicators, including MTL (269.72±37.18 pg/mL) and 5-HT (2214.61±432.95 ng/mL) in the study group were higher than the MTL (231.25±32.63 pg/mL) and 5-HT (1914.26±391.53 ng/mL) in the control group (all P<0.05). Moreover, the VIP in the study group was 53.13±6.17 pg/mL, which was significantly lower than the VIP in the control group (65.29±9.35 pg/mL, P<0.05). The time required for the recovery of the gastrointestinal function indexes in the study group was less than it was in the control group (P<0.05). The duration of the mechanical ventilation (8.16±1.93 days) and the hospitalization durations in the ICU (9.24±0.77 days) in the study group were significantly shorter than the duration of the mechanical ventilation (12.24±1.65 days) and the hospitalization durations in the ICU (13.23±0.88 days) in the control group (all P<0.05). The overall complication rate in the study group was significantly lower than it was in the control group (P<0.05), and the satisfaction rate in the study group was significantly higher than it was in the control group (P<0.05). CONCLUSION The combined use of structural management in SAP patients undergoing enteral nutrition treatment significantly improved the relevant nutritional indicator and gastrointestinal hormone indicator levels. It also contributed to the recovery of the gastrointestinal function indicators in the SAP patients, reduced the durations of their mechanical ventilation, their hospitalization durations in the ICU, and their complications and contributed to a significant increase in their satisfaction with the nursing.",2021,"The overall complication rate in the study group was significantly lower than it was in the control group (P<0.05), and the satisfaction rate in the study group was significantly higher than it was in the control group (P<0.05). ","['severe acute pancreatitis patients undergoing early enteral nutrition via nasal jejunal nutrition tubes', 'SAP patients undergoing', 'severe acute pancreatitis (SAP) patients undergoing early enteral nutrition via nasal jejunal nutrition tubes', '88 patients with SAP diagnosed and treated in our hospital were recruited as the study cohort and underwent']","['structural nutritional care management model', 'enteral nutrition', '5-HT', 'enteral nutrition treatment', 'structural nutritional care management model (hereafter referred to as structural management']","['hospitalization durations', 'overall complication rate', 'relevant nutritional indicator and gastrointestinal hormone indicator levels', 'time required for the recovery of the gastrointestinal function indexes', 'TRF', 'durations of their mechanical ventilation, their hospitalization durations', 'relevant nutritional indexes (albumin (ALB), prealbumin (PA), and transferrin (TRF)) and the gastrointestinal hormone indexes (gastrin (MTL), vasoactive peptide (VIP), and 5-hydroxytryptamine (5-HT', 'satisfaction rate', 'duration of the mechanical ventilation', 'times required for the recovery of the relevant gastrointestinal physiological function indexes, the mechanical ventilation times, the hospitalization durations in the ICU, the complications, the satisfaction indexes and the satisfaction rates', 'relevant gastrointestinal hormone indicators, including MTL']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0022378', 'cui_str': 'Jejunal'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0017182', 'cui_str': 'Gastrointestinal hormone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0040162', 'cui_str': 'Thyrotropin-Releasing Hormone'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0028710', 'cui_str': 'Nutrition Index'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0032923', 'cui_str': 'Prealbumin'}, {'cui': 'C0040679', 'cui_str': 'Transferrin'}, {'cui': 'C0017151', 'cui_str': 'Gastrins'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",88.0,0.0285837,"The overall complication rate in the study group was significantly lower than it was in the control group (P<0.05), and the satisfaction rate in the study group was significantly higher than it was in the control group (P<0.05). ","[{'ForeName': 'Wenjie', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""Department of Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China Chengdu, Sichuan Province, China.""}, {'ForeName': 'Yanting', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': ""Department of Hepatobiliary and Pancreatic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China Chengdu, Sichuan Province, China.""}, {'ForeName': 'Yunping', 'Initials': 'Y', 'LastName': 'Lan', 'Affiliation': ""Department of Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China Chengdu, Sichuan Province, China.""}, {'ForeName': 'Le', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Department of Cardiac Surgery One, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China Chengdu, Sichuan Province, China.""}]",American journal of translational research,[] 2540,34377305,Narrow-band UVB combined with compound clobetasol propionate can improve the therapeutic effect in hand eczema patients.,"OBJECTIVE To explore the therapeutic effect of narrow-band UVB combined with compound clobetasol propionate on hand eczema patients. METHODS From June 2017 to June 2020, 102 patients with hand eczema in our hospital were recruited for this study and divided into group A (GA) and group B (GB). The 50 patients in GA were treated with narrow-band UVB irradiation only, and the 52 patients in GB were treated with compound clobetasol propionate in addition to the treatment administered to GA. The patients' general data and therapeutic effects were observed in both groups. The adverse reactions were also observed during the treatment. The severity index scores (EASI) of the pruritus and eczema areas of the skin lesions were observed before and after the therapy. The IFN-γ and IL-4 levels in the serum were tested using ELISA. After the therapy, the quality of life and any recurrences within 3 months were observed in both groups. RESULTS There were no differences in the baseline data between the two groups (P>0.05). The curative effect in GB was better than it was in GA (P<0.05). The incidence of adverse reactions in GB was significantly lower than the incidence in GA (P<0.05). After the therapy, the EASI scores of the pruritus and eczema areas of the skin lesions in GB were significantly lower than they were in GA (P<0.05). After the therapy, the patients' serum IFN-γ and IL-4 levels in GB were significantly better than they were in GA. After the therapy, the quality of life of the patients in GB was significantly higher than it was in in GA (P<0.05). After 3 months of therapy, the recurrence rate in GB was significantly lower than it was in GA (P<0.05). CONCLUSION Narrow-band UVB combined with compound clobetasol propionate is effective at treating patients with hand eczema, as it can effectively improve their clinical symptoms and is very safe.",2021,The severity index scores (EASI) of the pruritus and eczema areas of the skin lesions were observed before and after the therapy.,"['From June 2017 to June 2020, 102 patients with hand eczema in our hospital', 'hand eczema patients', 'patients with hand eczema', '50 patients in GA']","['Narrow-band UVB combined with compound clobetasol propionate', 'compound clobetasol propionate', 'narrow-band UVB irradiation', 'narrow-band UVB combined with compound clobetasol propionate']","['recurrence rate in GB', 'adverse reactions in GB', 'serum IFN-γ and IL-4 levels in GB', 'adverse reactions', 'EASI scores of the pruritus and eczema areas of the skin lesions in GB', 'quality of life of the patients in GB', 'IFN-γ and IL-4 levels', 'quality of life and any recurrences', 'severity index scores (EASI) of the pruritus and eczema areas of the skin lesions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0239816', 'cui_str': 'Hand eczema'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0454530', 'cui_str': 'Ultraviolet B therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C0055895', 'cui_str': 'Clobetasol propionate'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0037284', 'cui_str': 'Skin lesion'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",102.0,0.00943522,The severity index scores (EASI) of the pruritus and eczema areas of the skin lesions were observed before and after the therapy.,"[{'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Yuan', 'Affiliation': 'Department of Dermatology, Beijing Friendship Hospital Affiliated to Capital Medical University Beijing 100050, China.'}, {'ForeName': 'Zeyu', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Dermatology, Beijing Changping District Hospital Beijing 102200, China.'}, {'ForeName': 'Linfeng', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Dermatology, Beijing Friendship Hospital Affiliated to Capital Medical University Beijing 100050, China.'}]",American journal of translational research,[] 2541,34377296,"The clinical efficacy of compound Danshen injection on acute cerebral infarction and on the changes in the CRP, D-dimer, and IL-6 levels.","OBJECTIVE To study the clinical curative effect of compound Danshen injection on acute cerebral infarction (ACI) patients and its impact on the CRP, D-dimer, and IL-6 levels. METHODS 116 patients with ACI admitted to our hospital were randomly placed in an observation group (n=58) or a control group (n=58). The control group received rosuvastatin tablets (10 mg/time, qd) in addition to the standard treatment. The observation group received compound Danshen injection in addition to the standard treatment. The treatment continued for 21 days. The clinical treatment efficacy, the CRP, D-dimer, and IL-6 levels, the NIHSS scores (to evaluate the degree of neurological impairment), the Fugl-Meyer scores (to access patients' motor function), the ADL scores, the sleep quality (the PSQI and AIS scores), and the complication incidence rates were compared between the two groups. RESULTS After the treatment, the effective rate in the observation group (89.66%) was significantly higher than it was in the control group (74.14%) (P<0.05). After the treatment, the serum CRP, D-dimer, and IL-6 levels in the two groups were lower than they were before the treatment, and the levels were lower in the observation group than they were in the control group (all P<0.05). After the treatment, the NIHSS scores in the observation group were lower than they were in the control group, and the Fugl-Meyer and ADL scores were higher than they were in the control group (all P<0.05). Compared with the control group, the PSQI and AIS scores in the observation group were lower than they were in the control group after the treatment (P<0.05). The severe diarrhea, bedsore, urinary tract infection, liver and kidney function injury, skin allergic reactions and other total adverse reaction incidence rates in the observation group were lower than they were in the control group. CONCLUSION Rosuvastatin combined with compound Danshen injection is effective in ACI treatment. It is able to effectively improve the clinical symptoms, reduce the incidence of complications, improve the recovery of the IL-6, CRP, and D-dimer levels and enhance patients' sleep quality.",2021,"After the treatment, the serum CRP, D-dimer, and IL-6 levels in the two groups were lower than they were before the treatment, and the levels were lower in the observation group than they were in the control group (all P<0.05).","['116 patients with ACI admitted to our hospital were randomly placed in an observation group (n=58) or a control group (n=58', 'acute cerebral infarction (ACI) patients']","['Danshen injection', 'compound Danshen injection', 'rosuvastatin tablets', 'Rosuvastatin combined with compound Danshen injection']","['severe diarrhea, bedsore, urinary tract infection, liver and kidney function injury, skin allergic reactions and other total adverse reaction incidence rates', ""recovery of the IL-6, CRP, and D-dimer levels and enhance patients' sleep quality"", 'Fugl-Meyer scores', 'CRP, D-dimer, and IL-6 levels, the NIHSS scores', 'effective rate', 'NIHSS scores', 'Fugl-Meyer and ADL scores', 'serum CRP, D-dimer, and IL-6 levels', 'acute cerebral infarction', 'CRP, D-dimer, and IL-6 levels', 'complication incidence rates', 'ADL scores, the sleep quality (the PSQI and AIS scores', 'PSQI and AIS scores']","[{'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0377336', 'cui_str': 'dan-shen root extract'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C1321648', 'cui_str': 'rosuvastatin Oral Tablet'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C1443924', 'cui_str': 'Severe diarrhea'}, {'cui': 'C0011127', 'cui_str': 'Pressure ulcer'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0863090', 'cui_str': 'Allergic skin reaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0039585', 'cui_str': 'Androgen resistance syndrome'}]",116.0,0.0434175,"After the treatment, the serum CRP, D-dimer, and IL-6 levels in the two groups were lower than they were before the treatment, and the levels were lower in the observation group than they were in the control group (all P<0.05).","[{'ForeName': 'Fengming', 'Initials': 'F', 'LastName': 'Bian', 'Affiliation': 'Department of Neurology, The Fifth Hospital in Harbin Harbin, Heilongjiang Province, China.'}, {'ForeName': 'Shijin', 'Initials': 'S', 'LastName': 'Kang', 'Affiliation': ""Department of Neurology, Mishan People's Hospital Mishan, Heilongjiang Province, China.""}, {'ForeName': 'Honghai', 'Initials': 'H', 'LastName': 'Cui', 'Affiliation': ""The Second Ward, Department of General Internal Medicine, Daoli District People's Hospital Harbin, Heilongjiang Province, China.""}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, The Fifth Hospital in Harbin Harbin, Heilongjiang Province, China.'}, {'ForeName': 'Tianwei', 'Initials': 'T', 'LastName': 'Luan', 'Affiliation': 'Department of Neurology, The Fifth Hospital in Harbin Harbin, Heilongjiang Province, China.'}]",American journal of translational research,[] 2542,34377295,Effects of acupuncture on clinical outcome and helper T cell distribution and abundance in patients with convalescent ischemic stroke.,"OBJECTIVE To study the effects of acupuncture on clinical outcomes and helper T cell levels in patients with convalescent ischemic stroke. METHODS One hundred and thirty-six patients with cerebral ischemic stroke were selected for this prospective study. Patients in the control group were treated with routine therapy, and patients in the observation group were treated with acupuncture for 30 minutes once a day for 14 days plus the treatment of the control group. The clinical efficacy, cognitive function, T cell subsets distribution and inflammatory factors of patients in both groups were recorded before and after treatment. RESULTS Total effectiveness rate of the observation group was significantly higher than that of the control group (P<0.05). After treatment, CD3 + cell percentage, CD4 + cell percentage and CD4 + cell percentage/CD8 + cell percentage of patients in both groups were significantly increased (P<0.05), while CD8 + cell percentage in both groups was significantly decreased (P<0.05). Compared to those in the control group, the overall response rate as well as CD3 + cell percentage, CD4 + cell percentage and CD4 + /CD8 + of patients after treatment in the observation group were higher (P<0.001), while CD8 + cell percentage was lower (all P<0.001). Moreover, the improvement in inflammatory factors as well as scores of Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) in observation group were better than those of the control group (P<0.001) respectively. CONCLUSION Treatment of cerebral ischemic stroke by acupuncture can improve clinical outcome and cognitive function, which may be related to its regulation of immune response and reduction of inflammation in vivo.",2021,"RESULTS Total effectiveness rate of the observation group was significantly higher than that of the control group (P<0.05).","['One hundred and thirty-six patients with cerebral ischemic stroke', 'patients with convalescent ischemic stroke']","['acupuncture', 'routine therapy']","['overall response rate', 'clinical efficacy, cognitive function, T cell subsets distribution and inflammatory factors', 'CD3 + cell percentage, CD4 + cell percentage and CD4 + /CD8 ', 'Total effectiveness rate', 'CD3 + cell percentage, CD4 + cell percentage and CD4 + cell percentage/CD8 + cell percentage', 'inflammatory factors', 'scores of Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA', 'CD8 + cell percentage', 'clinical outcomes and helper T cell levels', 'clinical outcome and helper T cell distribution and abundance']","[{'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0740326', 'cui_str': 'Convalescent'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0080202', 'cui_str': 'T-Cell Subsets'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0882828', 'cui_str': 'Cell positive for CD3 antigen'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C3251824', 'cui_str': 'Cell positive for CD4 antigen'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C4316924', 'cui_str': 'CD8+ cell'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0025750', 'cui_str': ""3,3'-Dichloro-4,4'-Diaminodiphenylmethane""}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0018894', 'cui_str': 'Helper cell'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",136.0,0.0495934,"RESULTS Total effectiveness rate of the observation group was significantly higher than that of the control group (P<0.05).","[{'ForeName': 'Lingli', 'Initials': 'L', 'LastName': 'Jin', 'Affiliation': ""Department of Traditional Chinese Medicine, Wuhan University People's Hospital of Hanchuan Hospital (People Avenue Hospital District) Xiaogan, Hubei Province, China.""}, {'ForeName': 'Caiyan', 'Initials': 'C', 'LastName': 'Han', 'Affiliation': ""Department of Neurology, Wuhan University People's Hospital of Hanchuan Hospital (People Avenue Hospital District) Xiaogan, Hubei Province, China.""}]",American journal of translational research,[] 2543,34377294,The safety of high-dose rocuronium bromide in general anesthesia for spinal surgery and its effects on muscle relaxation.,"PURPOSE This study aimed to investigate the effects of high-dose rocuronium bromide in general anesthesia for spinal surgery and analyze its safety. METHODS A total of 90 patients with spine diseases who underwent elective spinal surgery in our hospital were enrolled as study subjects, and were divided into 2-fold group (intraoperative administration of 0.6 mg/kg rocuronium bromide, n=30), 3-fold group (0.9 mg/kg rocuronium bromide, n=30) and 4-fold group (1.2 mg/kg rocuronium bromide, n=30). The effects of rocuronium bromide on muscle relaxation, the operative time and the incidence of adverse reactions were compared among the three groups. RESULTS The onset time of muscle relaxation in the 4-fold group was significantly lower than that in 2-fold and 3-fold groups. The duration of muscle relaxation and duration of action in the 4-fold group were significantly higher than those in the 2-fold and 3-fold groups ( P <0.05). The satisfaction rate in the 4-fold group (100.00%) was significantly higher than that in the 2-fold group (66.67%) and the 3-fold group (86.67%) ( P <0.05). The 4-fold group exhibited significantly higher intubating condition score at 1 min and significantly lower operative time than the 2-fold and 3-fold groups ( P <0.05). The incidence of adverse reactions in the 4-fold group was 23.33%, slightly higher than those in the 2-fold (20.00%) and 3-fold groups (20.00%) ( P >0.05). CONCLUSION High-dose rocuronium bromide shortens the onset time of muscle relaxation in patients undergoing spinal surgery, creates better intubation conditions, has longer duration of action, and shortens the patient's operative time, without increasing adverse reactions such as skin flushing, rash, increased airway resistance and bronchospasm, laryngeal edema, etc. Meanwhile, high-dose rocuronium bromide can shorten intubation time, which is conducive to the smooth operation and reduces surgical stress injuries.",2021,The duration of muscle relaxation and duration of action in the 4-fold group were significantly higher than those in the 2-fold and 3-fold groups ( P <0.05).,"['patients undergoing spinal surgery', '90 patients with spine diseases who underwent elective spinal surgery in our hospital were enrolled as study subjects']","['rocuronium bromide', '2-fold group (intraoperative administration of 0.6 mg/kg rocuronium bromide, n=30), 3-fold group (0.9 mg/kg rocuronium bromide, n=30) and 4-fold group (1.2 mg/kg rocuronium bromide']","['onset time of muscle relaxation', 'duration of muscle relaxation and duration of action', 'incidence of adverse reactions', 'operative time', 'intubating condition score', 'muscle relaxation', 'satisfaction rate', 'muscle relaxation, the operative time and the incidence of adverse reactions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0037933', 'cui_str': 'Disorder of vertebral column'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0069632', 'cui_str': 'rocuronium bromide'}, {'cui': 'C0185026', 'cui_str': 'Plication'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C4068880', 'cui_str': '1.2'}]","[{'cui': 'C0449244', 'cui_str': 'Time of onset'}, {'cui': 'C0026836', 'cui_str': 'Muscle relaxation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",90.0,0.174737,The duration of muscle relaxation and duration of action in the 4-fold group were significantly higher than those in the 2-fold and 3-fold groups ( P <0.05).,"[{'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun, Jiangxi Province, China.""}, {'ForeName': 'Shaojin', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun, Jiangxi Province, China.""}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Yin', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun, Jiangxi Province, China.""}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Luo', 'Affiliation': ""Department of Physical Examination, Yichun People's Hospital Yichun, Jiangxi Province, China.""}, {'ForeName': 'Ronghong', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Third People's Hospital of Ganzhou Ganzhou, Jiangxi Province, China.""}, {'ForeName': 'Shengyang', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun, Jiangxi Province, China.""}]",American journal of translational research,[] 2544,34377293,Study on parental satisfaction and clinical treatment outcomes of 128 diarrheic children receiving comprehensive nursing.,"OBJECTIVE To explore the clinical treatment outcomes and parental satisfaction of children with diarrhea receiving comprehensive nursing intervention. METHODS A total of 128 diarrheic children treated in our hospital from June 2016 to June 2017 were recruited and divided into a control group (n=64) receiving conventional nursing and an observation group (n=64) receiving comprehensive nursing intervention, as per a random number table. The clinical outcomes, electrolyte disorders, recovery of gastrointestinal function, quality of life and parental satisfaction were compared between the two groups after nursing. RESULTS The overall response rate of the observation group was higher than that of the control group (81.25% vs. 51.56%) ( P < 0.05). Nursing satisfaction in the observation group was higher than that in the control group (100.00% vs. 75.00%) ( P < 0.05). However, the time to resolution of clinical symptoms and time to return of bowel sounds in the observation group were shorter than those in the control group ( P < 0.05). After nursing, the incidence of electrolyte disorders in the observation group was lower than that in the control group. The scores of physical symptoms, physical functioning, emotional functioning, cognitive functioning and social functioning in PedsQLTM Measurement Model were higher than those in the control group, and the electrolyte index monitoring results were better than those in the control group ( P < 0.05). CONCLUSION Comprehensive nursing intervention can effectively reduce the incidence of electrolyte disorders, improve parental satisfaction, accelerate the recovery of gastrointestinal function and improve the quality of life in the treatment of pediatric diarrhea.",2021,Nursing satisfaction in the observation group was higher than that in the control group (100.00% vs. 75.00%) ( P < 0.05).,"['128 diarrheic children treated in our hospital from June 2016 to June 2017 were recruited and divided into a control group (n=64) receiving', '128 diarrheic children receiving comprehensive nursing', 'children with diarrhea receiving comprehensive nursing intervention']","['conventional nursing and an observation group (n=64) receiving comprehensive nursing intervention', 'Comprehensive nursing intervention']","['overall response rate', 'clinical outcomes, electrolyte disorders, recovery of gastrointestinal function, quality of life and parental satisfaction', 'electrolyte index monitoring results', 'scores of physical symptoms, physical functioning, emotional functioning, cognitive functioning and social functioning in PedsQLTM Measurement Model', 'quality of life', 'time to resolution of clinical symptoms and time to return of bowel sounds', 'incidence of electrolyte disorders', 'Nursing satisfaction']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0342579', 'cui_str': 'Electrolyte imbalance'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0013832', 'cui_str': 'electrolytes'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0232693', 'cui_str': 'Bowel sounds'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]",128.0,0.0339636,Nursing satisfaction in the observation group was higher than that in the control group (100.00% vs. 75.00%) ( P < 0.05).,"[{'ForeName': 'Shumei', 'Initials': 'S', 'LastName': 'Ju', 'Affiliation': 'The Second Department of Pediatrics and Internal Medicine, Linyi Central Hospital Linyi 276400, Shandong Province, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': ""Department of Nursing, Dongying People's Hospital Dongying 257091, Shandong Province, China.""}, {'ForeName': 'Wenjing', 'Initials': 'W', 'LastName': 'Yang', 'Affiliation': 'Department of Nursing, Jinan Hospital Jinan 250013, Shandong Province, China.'}, {'ForeName': 'Guiying', 'Initials': 'G', 'LastName': 'Tian', 'Affiliation': ""Department of Pediatrics, Dongying People's Hospital Dongying 257091, Shandong Province, China.""}]",American journal of translational research,[] 2545,34377287,Five-in-one nursing management promotes rapid recovery of patients after thoracic surgery.,"OBJECTIVE To explore the application effect of five-in-one nursing management in the rapid recovery of patients undergoing thoracic surgery. METHODS This prospective study included 45 patients admitted to thoracic surgery before the implementation of five-in-one nursing as the control group and 40 patients admitted during the implementation as the test group. The patients in the control group were nursed by conventional nursing plan, whole those in the test group received the five-in-one nursing management. The perioperative indicators, mental state, postoperative rehabilitation, surgical complications, and nursing satisfaction were compared between the two groups. RESULTS Compared with the control group, the time of extubation, the time of getting out of bed for the first time, the recovery time of bowel sounds, the time of the first defecation, and the length of hospital stay in the experimental group were significantly shortened (P<0.05). At 24 h after surgery, MTL and GAS levels of patients in the test group were significantly higher than those of the control group (P<0.001). Moreover, the test group had lower visual analogue score (VAS) at different times after the operation, as well as lower the Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) scores after nursing than the control group (P<0.001). The total incidence of postoperative complications in the experimental group was significantly reduced, while nursing satisfaction was significantly increased (P<0.001) when compared with the control group. CONCLUSION The five-in-one nursing management effectively promoted the rapid recovery of patients after thoracic surgery, shortened the length of hospital stay, and improved nursing satisfaction.",2021,"The total incidence of postoperative complications in the experimental group was significantly reduced, while nursing satisfaction was significantly increased (P<0.001) when compared with the control group. ","['45 patients admitted to thoracic surgery before the implementation of five-in-one nursing as the control group and 40 patients admitted during the implementation as the test group', 'patients undergoing thoracic surgery', 'patients after thoracic surgery']",[],"['MTL and GAS levels', 'length of hospital stay, and improved nursing satisfaction', 'Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) scores', 'total incidence of postoperative complications', 'time of extubation, the time of getting out of bed for the first time, the recovery time of bowel sounds, the time of the first defecation, and the length of hospital stay', 'nursing satisfaction', 'lower visual analogue score (VAS', 'perioperative indicators, mental state, postoperative rehabilitation, surgical complications, and nursing satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0039986', 'cui_str': 'Thoracic surgery'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],"[{'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0232693', 'cui_str': 'Bowel sounds'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0877071', 'cui_str': 'Postoperative rehabilitation'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",45.0,0.028236,"The total incidence of postoperative complications in the experimental group was significantly reduced, while nursing satisfaction was significantly increased (P<0.001) when compared with the control group. ","[{'ForeName': 'Fen', 'Initials': 'F', 'LastName': 'Zhou', 'Affiliation': ""Department of Nursing, Hanchuan People's Hospital Hanchuan, Hubei Province, China.""}, {'ForeName': 'Minghong', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': ""Department of Dermatology and Venereology, Hanchuan People's Hospital Hanchuan, Hubei Province, China.""}]",American journal of translational research,[] 2546,34377284,"Analysis of the application of ""psycho-cardiology"" model in nursing care of acute stroke patients with depression.","OBJECTIVE To evaluate the effect of ""psycho-cardiology"" model in nursing care of acute stroke patients with depression. METHODS Seventy-eight acute stroke patients with depression were selected for this prospective study, and they were divided into two groups according to the random number table method. The control group (n=39) were given usual care, and the study group (n=39) were given nursing intervention of ""psycho-cardiology"" model in addition to usual care. The changes of mental state (Hamilton Depression Scale, HAMD; Hamilton Anxiety Scale, HAMA), the neurological function (National Institute of Health Stroke scale, NIHSS), and the cognitive function (Mini-Mental State Examination, MMSE), the prognostic indicator (Fugl-Meyer Assessment, FMA; Barthel Index, BI) were compared between the two groups before and after the intervention. The incidence of complications and nursing satisfaction were also compared between the two groups. RESULTS After nursing, the scores of HAMA and HAMD in the study group were significantly lower than those in the control group (P<0.05). The NIHSS score of the study group was significantly lower than that of the control group (P<0.05). The score of MMSE in the study group was significantly higher than that of the control group (P<0.05). The scores of FMA and BI in the study group were significantly higher than those of the control group (P<0.05). There was no significant difference in the incidence of complications between the two groups (P>0.05). The nursing satisfaction of the study group was significantly higher than that of the control group (P<0.05). CONCLUSION Nursing intervention of ""psycho-cardiology"" model for acute stroke patients with depression can effectively alleviate the mental stress of patients, improve neurological function and cognitive function, reduce the occurrence of complications, improve prognosis and nursing satisfaction.",2021,"The nursing satisfaction of the study group was significantly higher than that of the control group (P<0.05). ","['acute stroke patients with depression', 'Seventy-eight acute stroke patients with depression']","['Nursing intervention of ""psycho-cardiology"" model', 'psycho-cardiology"" model', 'nursing intervention of ""psycho-cardiology"" model in addition to usual care']","['changes of mental state (Hamilton Depression Scale, HAMD; Hamilton Anxiety Scale, HAMA), the neurological function (National Institute of Health Stroke scale, NIHSS), and the cognitive function (Mini-Mental State Examination, MMSE), the prognostic indicator (Fugl-Meyer Assessment, FMA; Barthel Index, BI', 'NIHSS score', 'incidence of complications', 'neurological function and cognitive function', 'incidence of complications and nursing satisfaction', 'score of MMSE', 'scores of FMA and BI', 'scores of HAMA and HAMD', 'nursing satisfaction']","[{'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C3816957', 'cui_str': '70'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1291910', 'cui_str': 'Human anti-mouse antibody'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",78.0,0.0172468,"The nursing satisfaction of the study group was significantly higher than that of the control group (P<0.05). ","[{'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Wei', 'Affiliation': 'Department of Neurology, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Xiangyuan', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Neurology, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Wen', 'Affiliation': 'Department of Neurology, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Jingjie', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Neurology, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Weijun', 'Initials': 'W', 'LastName': 'Fang', 'Affiliation': 'Department of Neurology, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Neurology, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Huijuan', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Neurology, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Chun', 'Initials': 'C', 'LastName': 'Liang', 'Affiliation': 'Department of Neurology, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Tang', 'Affiliation': 'Department of Neurology, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Lingxiao', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Nursing, Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong Province, China.'}]",American journal of translational research,[] 2547,34378869,Effects of sandplay therapy in reducing emotional and behavioural problems in school-age children with chronic diseases: A randomized controlled trial.,"PURPOSE Children with chronic diseases exhibit a higher incidence of emotional-behavioural problems. Though sandplay therapy is a universally recognized psychological treatment method, experimental evidence for this form of therapy is lacking. Our aims were to examine the effectiveness of sandplay therapy in reducing emotional and behavioural problems in school-age children with chronic diseases as well as anxiety and depression in their caregivers. DESIGN AND METHODS A total of 60 children and their caregivers were enrolled in the present study between January and October 2019. A randomized controlled trial was conducted at the Children's Hospital of Chongqing Medical University, China. Participants were divided into an intervention and a control group. Both groups received regular treatment, and the intervention group received additional sandplay therapy. Four behavioural rating scales were used to evaluate the differences between the two groups. The children's scores on the Child Behavior Checklist (CBCL), Eysenck Personality Questionnaire (EPQ), Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) before and after the intervention were compared using the Mann-Whitney test. The Wilcoxon signed rank test was also employed to compare the median results before and after treatment. RESULTS The total scores for CBCL, anxiety and depression, withdrawal, and social behavioural problems for children in the intervention group were all lower than the corresponding scores for those in the control group (p < .05). The EPQ scores for emotional stability and psychosis in the intervention group were both lower than those in the control group (p < .05). The SAS and SDS scores for the caregivers of children in the intervention group were also lower than the corresponding scores for those in the control group (p < .05). CONCLUSION Sandplay therapy can reduce anxiety, withdrawal, and social behavioural problems in school-age children with chronic diseases, as well as relieve anxiety and depression symptoms in their caregivers. Our study provided evidence for the clinical application of sandplay therapy and highlights the importance of offering and integrating psychological treatment in clinical nursing care.",2021,"The total scores for CBCL, anxiety and depression, withdrawal, and social behavioural problems for children in the intervention group were all lower than the corresponding scores for those in the control group (p < .05).","['Children with chronic diseases exhibit a higher incidence of emotional-behavioural problems', 'school-age children with chronic diseases', '60 children and their caregivers were enrolled in the present study between January and October 2019', ""Children's Hospital of Chongqing Medical University, China""]","['additional sandplay therapy', 'sandplay therapy', 'Sandplay therapy']","['Four behavioural rating scales', 'total scores for CBCL, anxiety and depression, withdrawal, and social behavioural problems', 'anxiety, withdrawal, and social behavioural problems', 'Child Behavior Checklist (CBCL), Eysenck Personality Questionnaire (EPQ), Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS', 'EPQ scores for emotional stability and psychosis', 'SAS and SDS scores', 'emotional and behavioural problems']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C2350829', 'cui_str': 'Sandplay'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0008065', 'cui_str': 'Behavior, Child'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0582625', 'cui_str': 'Eysenck personality questionnaire'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}]",60.0,0.0331241,"The total scores for CBCL, anxiety and depression, withdrawal, and social behavioural problems for children in the intervention group were all lower than the corresponding scores for those in the control group (p < .05).","[{'ForeName': 'Judan', 'Initials': 'J', 'LastName': 'Tan', 'Affiliation': ""Department of child health in Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Chongqing Key Laboratory of Child Health and Nutrition, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.""}, {'ForeName': 'Huaying', 'Initials': 'H', 'LastName': 'Yin', 'Affiliation': ""Department of child health in Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Chongqing Key Laboratory of Child Health and Nutrition, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.""}, {'ForeName': 'Tuo', 'Initials': 'T', 'LastName': 'Meng', 'Affiliation': ""Department of child health in Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Chongqing Key Laboratory of Child Health and Nutrition, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.""}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': ""Department of child health in Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Chongqing Key Laboratory of Child Health and Nutrition, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.""}]",Nursing open,['10.1002/nop2.1022'] 2548,34378862,A single application of chlorhexidine gel reduces gingival inflammation and interleukin 1-β following one-stage implant placement: A randomized controlled study.,"BACKGROUND Chlorhexidine (CHX) is a broad-spectrum antimicrobial agent commonly used in medicine. Application of (CHX) during abutment connection reduced the bacterial load at the implant-abutment interface. We hypothesize this treatment may consequently reduce peri-implant soft tissue inflammation and marginal bone loss. PURPOSE To evaluate the effect of a single application of CHX gel inside the dental implant internal hexagon on peri-implant tissue. METHODS Forty patients were recruited to this randomized, double-blinded, clinical trial. At the time of implant installation, a 4-mm healing abutment was connected to the implant. In the test group, chlorhexidine gel 1% was applied inside the implant hex, whereas control implants did not receive any gel. Clinical and radiographic measurements included soft tissue recession (REC), plaque index (PI), gingival index (GI), plaque index (PI), keratinized mucosa width (KM), probing depth (PD), and a peri-apical parallel x-ray. Peri-implant crevicular fluid (PICF) was collected for cytokine analysis. t-Test was used to compare changes from baseline to 3 months. Mann-Whitney U test and t test were used to compare test and control groups. RESULTS Twenty patients in the test group and 17 in the control group completed the study. One implant in the control group failed to osteointegrate. There were no significant differences between the control and test groups for REC changes, bone loss, and PD. GI was significantly lower in the test group after 1 week (1.79 ± 0.24 vs 0.75 ± 0.18, respectively) and 3 months (1.18 ± 0.21 vs 0.25 ± 0.12, respectively) although PI was equal. At 3 months, interleukin 1-β (IL1-β) was higher in the control group (p < 0.01) and a positive correlation was found between GI and IL1-β (r s  = 0.60424, p = 0.00032). CONCLUSIONS Application of chlorhexidine gel reduced inflammation and IL1-β levels in the peri-implant soft tissue.",2021,Application of (CHX) during abutment connection reduced the bacterial load at the implant-abutment interface.,"['one-stage implant placement', 'Twenty patients in the test group and 17 in the control group completed the study', 'Forty patients']","['CHX gel', 'Chlorhexidine (CHX', 'chlorhexidine gel']","['gingival inflammation and interleukin 1-β', 'interleukin 1-β (IL1-β', 'inflammation and IL1-β levels', 'GI', 'REC changes, bone loss, and PD', 'soft tissue recession (REC), plaque index (PI), gingival index (GI), plaque index (PI), keratinized mucosa width (KM), probing depth (PD), and a peri-apical parallel x-ray']","[{'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0017243', 'cui_str': 'Gel'}]","[{'cui': 'C0017574', 'cui_str': 'Gingivitis'}, {'cui': 'C0021755', 'cui_str': 'Interleukin-1'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0333047', 'cui_str': 'Recession'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0205111', 'cui_str': 'Apical'}, {'cui': 'C0034571', 'cui_str': 'radiography'}]",40.0,0.0482644,Application of (CHX) during abutment connection reduced the bacterial load at the implant-abutment interface.,"[{'ForeName': 'Thabet', 'Initials': 'T', 'LastName': 'Asbi', 'Affiliation': 'Department of Periodontology, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Hiba Abu', 'Initials': 'HA', 'LastName': 'Hussein', 'Affiliation': 'Department of Periodontology, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Horwitz', 'Affiliation': 'Department of Periodontology, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Eran', 'Initials': 'E', 'LastName': 'Gabay', 'Affiliation': 'Department of Periodontology, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Eli E', 'Initials': 'EE', 'LastName': 'Machtei', 'Affiliation': 'Department of Periodontology, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Hadar Zigdon', 'Initials': 'HZ', 'LastName': 'Giladi', 'Affiliation': 'Department of Periodontology, Rambam Health Care Campus, Haifa, Israel.'}]",Clinical implant dentistry and related research,['10.1111/cid.13041'] 2549,34378863,"Efficacy of High versus Conventional Dose of Ergocalciferol Supplementation on Serum 25-Hydroxyvitamin D and Interleukin-6 Levels among Hemodialysis Patients with Vitamin D Deficiency: a Multicenter, Randomized, Controlled Study.","Long term dialysis involves a chronic inflammatory state and produces a high prevalence of vitamin D deficiency. A clinical trial was conducted in hemodialysis with serum 25-hydroxyvitamin D (25[OH]D) level < 30 ng/mL. The conventional-group (N = 35) and the high-dose group (N = 35) were treated with ergocalciferol according to the K/DOQI guidelines and double dosage of ergocalciferol from the recommendation for 8 weeks, respectively. The main outcomes were measured by serum 25[OH]D and interleukin-6 (IL-6). At the end of 8 weeks, a statistically significantly greater increase was observed of mean serum 25[OH]D levels and decrease of mean PTH levels in the high-dose group compared with the conventional-dose group. The high dose group had higher achievement of vitamin D sufficiency than the conventional-dose group (97.4% vs. 76.4%, P = 0.012). No significance difference was found in mean changes of serum IL-6 level in the both groups, except subgroup patients with vitamin D deficiency or serum 25[OH]D < 20 ng/mL, high dose treatment suppressed serum IL-6 level (-2.67 pg/mL [IQR -6.56 to -0.17], P = 0.039). No differences were observed between the two groups in adverse events. Oral high-dose ergocalciferol supplementation has achieved higher vitamin D sufficiency than standard dose in ESRD patients on dialysis.",2021,"At the end of 8 weeks, a statistically significantly greater increase was observed of mean serum 25[OH]D levels and decrease of mean PTH levels in the high-dose group compared with the conventional-dose group.","['subgroup patients with vitamin D deficiency or serum', 'ESRD patients on dialysis', 'Hemodialysis Patients with Vitamin D Deficiency', 'hemodialysis with serum 25-hydroxyvitamin D (25[OH]D) level\u2009<\u200930']","['Oral high-dose ergocalciferol supplementation', 'Ergocalciferol Supplementation', 'ergocalciferol according to the K/DOQI guidelines and double dosage of ergocalciferol']","['adverse events', 'serum IL-6 level', 'mean serum 25[OH]D levels', 'serum 25[OH]D and interleukin-6 (IL-6', 'mean PTH levels', 'Serum 25-Hydroxyvitamin D and Interleukin-6 Levels', 'vitamin D sufficiency']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042870', 'cui_str': 'Vitamin D deficiency'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0014695', 'cui_str': 'Ergocalciferol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0020063', 'cui_str': 'PTH protein, human'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}]",35.0,0.199123,"At the end of 8 weeks, a statistically significantly greater increase was observed of mean serum 25[OH]D levels and decrease of mean PTH levels in the high-dose group compared with the conventional-dose group.","[{'ForeName': 'Naowanit', 'Initials': 'N', 'LastName': 'Nata', 'Affiliation': 'Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.'}, {'ForeName': 'Wittaya', 'Initials': 'W', 'LastName': 'Siricheepchaiyan', 'Affiliation': 'Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.'}, {'ForeName': 'Ouppatham', 'Initials': 'O', 'LastName': 'Supasyndh', 'Affiliation': 'Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.'}, {'ForeName': 'Bancha', 'Initials': 'B', 'LastName': 'Satirapoj', 'Affiliation': 'Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.'}]","Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy",['10.1111/1744-9987.13722'] 2550,34378861,"Pharmacokinetic and Pharmacodynamic Bioequivalence of Biosimilar MYL-1601D with US and European Insulin Aspart in Healthy Volunteers: A Randomized Double-Blind, Crossover, Euglycemic Glucose Clamp Study.","AIM To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence (BE) of MYL-1601D biosimilar with originator, NovoLog® (Ref-InsAsp-US) and NovoRapid® (Ref-InsAsp-EU). MATERIALS AND METHODS This was a double-blind, randomized, crossover study that enrolled 71 healthy subjects to receive a single subcutaneous dose (0.2 U/kg) of each formulation under automated euglycemic clamp conditions (ClampArt®, level 81 mg/dL, duration 12 h post-dose). Primary PK endpoints were area under the plasma insulin aspart concentration-time curve from 0 to 12 hours (AUC 0-12h ) and maximum plasma insulin aspart concentration (C max ). Primary PD endpoints were area under the glucose infusion rate (GIR) time curve from 0 to 12 hours (AUC GIR0-12h ) and maximum GIR (GIR max ). Insulin aspart in plasma was quantified using immunoaffinity purification followed by ultra-performance liquid chromatography and tandem mass spectrometric detection. The pairwise comparisons of geometric LS-mean ratio for 90% confidence interval (CI) of primary PK and 90% CIs (MYL-1601D vs. Ref-InsAsp-US) and 95% CIs (MYL-1601D vs. Ref-InsAsp-EU) of primary PD parameters were to be within 80% to 125% to demonstrate BE. RESULTS MYL-1601D showed PK bioequivalence to both Ref-InsAsp-US (AUC 0-12h geometric LS-mean ratio 102.17, 90% CI [100.26; 104.11]; C max 106.13 [100.71; 111.85]) and Ref-InsAsp-EU (AUC 0-12h 101.84 [100.04; 103.67]; C max 105.74 [101.09; 110.60]). Likewise, MYL-1601D showed PD bioequivalence to Ref-InsAsp-US (AUC GIR_0-last 99.93; 90% CI [95.74; 104.30]; GIR _max 100.12 [94.46; 106.12]) and Ref-InsAsp-EU (AUC GIR_0-last 96.42; 95% CI [91.17; 101.98]; GIR _max 95.10 [89.37; 101.19]). All three insulin aspart products were well tolerated. CONCLUSION MYL-1601D demonstrated bioequivalence to Ref-InsAsp-US and Ref-InsAsp-EU with a comparable safety profile. This article is protected by copyright. All rights reserved.",2021,"MYL-1601D showed PK bioequivalence to both Ref-InsAsp-US (AUC 0-12h geometric LS-mean ratio 102.17, 90% CI [100.26; 104.11]; C max 106.13","['enrolled 71 healthy subjects', 'Healthy Volunteers']","['Insulin aspart', 'Biosimilar MYL-1601D with US and European Insulin Aspart', 'MYL-1601D biosimilar with originator, NovoLog® (Ref-InsAsp-US) and NovoRapid® (Ref-InsAsp-EU', 'single subcutaneous dose (0.2\u2009U/kg) of each formulation under automated euglycemic clamp conditions (ClampArt®, level 81\u2009mg/dL']","['area under the glucose infusion rate (GIR) time curve from 0 to 12\u2009hours (AUC GIR0-12h ) and maximum GIR (GIR max ', 'PK bioequivalence', 'pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence', 'tolerated', 'area under the plasma insulin aspart concentration-time curve from 0 to 12\u2009hours (AUC 0-12h ) and maximum plasma insulin aspart concentration (C max ']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0123677', 'cui_str': 'Insulin, Aspart, Human'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}, {'cui': 'C0939412', 'cui_str': 'NovoRapid'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C1300561', 'cui_str': 'U/kg'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0079318', 'cui_str': 'Euglycaemic Clamp'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C1292430', 'cui_str': '12 hours'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0456695', 'cui_str': '/12h'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0039789', 'cui_str': 'Equivalencies, Therapeutic'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0123677', 'cui_str': 'Insulin, Aspart, Human'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",71.0,0.427086,"MYL-1601D showed PK bioequivalence to both Ref-InsAsp-US (AUC 0-12h geometric LS-mean ratio 102.17, 90% CI [100.26; 104.11]; C max 106.13","[{'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Hövelmann', 'Affiliation': 'Profil Institute Hellersbergstr, Germany, Europe.'}, {'ForeName': 'Yaron', 'Initials': 'Y', 'LastName': 'Raiter', 'Affiliation': 'Viatris Inc., Netherlands, Europe.'}, {'ForeName': 'Anoop', 'Initials': 'A', 'LastName': 'Chullikana', 'Affiliation': 'Biocon Biologics Limited, Bengaluru, India.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Viatris Inc. Morgantown, West Virginia, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Donnelly', 'Affiliation': 'Viatris Inc. Morgantown, West Virginia, USA.'}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Lawrence', 'Affiliation': 'Viatris Inc. Morgantown, West Virginia, USA.'}, {'ForeName': 'Nilanjan', 'Initials': 'N', 'LastName': 'Sengupta', 'Affiliation': 'Biocon Biologics Limited, Bengaluru, India.'}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Gopu', 'Affiliation': 'Biocon Biologics Limited, Bengaluru, India.'}, {'ForeName': 'Gopinath', 'Initials': 'G', 'LastName': 'Ranganna', 'Affiliation': 'Viatris, Bengaluru, India.'}, {'ForeName': 'Abhijit', 'Initials': 'A', 'LastName': 'Barve', 'Affiliation': 'Viatris Inc. Canonsburg, Pennsylvania, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14519'] 2551,34378860,Four-implant-supported overdenture treatment in the maxilla. Part I: A randomized controlled split mouth trial assessing the effect of microthreads and abutment connection type on 4 years peri-implant health.,"BACKGROUND According to literature, peri-implant bone loss is minimized on implants with microthreaded neck design and internal type of abutment connection. However, most clinical studies may be biased due to confounding factors. PURPOSE This nonblinded RCT assessed the effect of implant neck (microthreaded vs non-microthreaded) as well as the type of abutment connection (internal conical vs external flat-to-flat) on peri-implant bone stability and peri-implant health after at least 36 months. MATERIALS AND METHODS Twenty-five patients were treated with a maxillary implant-supported bar-retained overdenture on four different implant types: internal connection with microthreads (I-MT), internal connection without microthreads (I-NMT), external connection with microthreads (E-MT), and external connection without microthreads (E-NMT). To control confounding factors, all other design features were similar. A linear mixed-model analysis or mixed-model logistic regression analysis was used to determine the effect of implant type on bone level, probing pocket depth, bleeding on probing, and plaque. RESULTS Four out of 98 implants (4.1%) placed in 25 patients failed during provisionalization and were replaced. Mean overall bone loss after 6 months was 0.39 mm (SD 0.62, range 0.00-3.48) with limited additional bone loss of 0.04 mm (SD 0.54, range -1.80-1.63) after at least 3 years. Microthreads or connection type had no effect on the bone level, probing pocket depth, bleeding on probing, nor plaque. CONCLUSIONS With 96% of implant survival, the maxillary overdenture supported with a bar on four implants yield a predictable outcome and the implant-abutment connection type (internal vs external) and implant neck design (microthreaded vs non-microthreaded) have no influence on peri-implant bone remodeling after initial bone remodeling nor up to 4 years of function. Peri-implant bone levels are within international success standards and peri-implant health is indicative of absence of peri-implantitis.",2021,"Microthreads or connection type had no effect on the bone level, probing pocket depth, bleeding on probing, nor plaque. ","['Twenty-five', '4\u2009years peri-implant health']","['maxillary implant-supported bar-retained overdenture on four different implant types: internal connection with microthreads (I-MT), internal connection without microthreads (I-NMT), external connection with microthreads (E-MT), and external connection without microthreads (E-NMT', 'microthreads and abutment connection type', 'implant neck (microthreaded vs non-microthreaded']","['bone level, probing pocket depth, bleeding on probing, and plaque', 'bone level, probing pocket depth, bleeding on probing, nor plaque', 'Mean overall bone loss']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0001643', 'cui_str': 'Beta-2 adrenergic receptor'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0011459', 'cui_str': 'Overlay denture'}, {'cui': 'C0449497', 'cui_str': 'Type of device'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0449379', 'cui_str': 'Connection'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}]",25.0,0.0326471,"Microthreads or connection type had no effect on the bone level, probing pocket depth, bleeding on probing, nor plaque. ","[{'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Doornewaard', 'Affiliation': 'Department of Periodontology & Oral Implantology, Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Sakani', 'Affiliation': 'Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Carine', 'Initials': 'C', 'LastName': 'Matthys', 'Affiliation': 'Department of Periodontology & Oral Implantology, Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Maarten', 'Initials': 'M', 'LastName': 'Glibert', 'Affiliation': 'Department of Periodontology & Oral Implantology, Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Ewald', 'Initials': 'E', 'LastName': 'Bronkhorst', 'Affiliation': 'Department of Dentistry, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Vandeweghe', 'Affiliation': 'Department of Reconstructive Dentistry, Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Stijn', 'Initials': 'S', 'LastName': 'Vervaeke', 'Affiliation': 'Department of Periodontology & Oral Implantology, Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'De Bruyn', 'Affiliation': 'Department of Periodontology & Oral Implantology, Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.'}]",Clinical implant dentistry and related research,['10.1111/cid.13037'] 2552,34378853,Immediate loading of fixed partial prostheses reconstructed using either tapered or straight implants in the posterior area: A randomized clinical trial.,"BACKGROUND In immediately loaded implants within 72 h after the implant placement in the unilaterally and partially edentulous ridge, primary stability is considered critical, which can be influenced by the design of the implant fixture. PURPOSE To determine the outcomes at 1 year after the immediate loading of multiunit fixed partial prostheses over either tapered implants (TIs) or straight implants (SIs) in the posterior region. MATERIALS AND METHODS Forty-eight patients (24 patients, 52 implants in TI group; 24 patients, 50 implants in SI group) were included for the study. Except for the one SI group patient whose two implants showed the insertion torque less than 30 Ncm, provisional prostheses designed and fabricated from intraoral scan data obtained immediately after implant surgery were delivered to rest of the 47 subjects at 3-7 days. After a year, the survival rate was estimated by intention-to-treat (ITT) and per-protocol (PP) analyses, and marginal bone loss (MBL) and implant stability were also analyzed statistically (p < 0.05). RESULTS Survival rate at implant level in TI group was 96.2%, and that of SI group in the ITT analysis was 86.0%. Intergroup difference, however, was not statistically significant (p > 0.05). Insertion torque was significantly higher in TI group than SI group (47.12 ± 6.37 Ncm vs. 41.60 ± 9.77 Ncm; p < 0.05). MBLs of both groups were less than 0.1 mm at 1-year follow-up and was similar between two groups (p > 0.05). CONCLUSIONS Immediate loading of fixed partial prostheses after TI and SI placement showed reliable outcomes in the partially edentulous posterior ridge. In terms of the initial mechanical stability, the performance was superior for TIs than for SIs.",2021,"CONCLUSIONS Immediate loading of fixed partial prostheses after TI and SI placement showed reliable outcomes in the partially edentulous posterior ridge.","['Forty-eight patients (24 patients, 52 implants in TI group; 24 patients, 50 implants in SI group']","['fixed partial prostheses reconstructed using either tapered or straight implants', 'multiunit fixed partial prostheses over either tapered implants (TIs) or straight implants (SIs', 'TI and SI placement']","['Survival rate at implant level', 'Insertion torque', 'insertion torque less', 'survival rate', 'intention-to-treat (ITT) and per-protocol (PP) analyses, and marginal bone loss (MBL) and implant stability', 'MBLs']","[{'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}, {'cui': 'C0441640', 'cui_str': 'Tapering - action'}, {'cui': 'C0019421', 'cui_str': 'Heterosexuality'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",,0.133495,"CONCLUSIONS Immediate loading of fixed partial prostheses after TI and SI placement showed reliable outcomes in the partially edentulous posterior ridge.","[{'ForeName': 'Yoo-Yeon', 'Initials': 'YY', 'LastName': 'Kim', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul, South Korea.'}, {'ForeName': 'Young Woo', 'Initials': 'YW', 'LastName': 'Song', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul, South Korea.'}, {'ForeName': 'Myong Ji', 'Initials': 'MJ', 'LastName': 'Kim', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul, South Korea.'}, {'ForeName': 'Jae-Kook', 'Initials': 'JK', 'LastName': 'Cha', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul, South Korea.'}, {'ForeName': 'Ji-Man', 'Initials': 'JM', 'LastName': 'Park', 'Affiliation': 'Department of Prosthodontics, Yonsei University College of Dentistry, Seoul, South Korea.'}, {'ForeName': 'Jee-Hwan', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Prosthodontics, Yonsei University College of Dentistry, Seoul, South Korea.'}, {'ForeName': 'Ui-Won', 'Initials': 'UW', 'LastName': 'Jung', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul, South Korea.'}]",Clinical implant dentistry and related research,['10.1111/cid.13039'] 2553,34378852,"Effects of Empagliflozin on Erythropoiesis in Patients with Type 2 Diabetes - data from a randomized, placebo controlled study.","BACKGROUND Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to significantly reduce heart failure hospitalization (HHF) and cardiovascular (CV) mortality in various cardiovascular outcome trials in patients with and without type 2 diabetes mellitus (T2D). SGLT2 inhibition further increased haemoglobin concentration and hematocrit by a yet unknown mechanism and this increase proved as an independent predictor for the CV benefit of these agents e.g. in the EMPA-REG OUTCOME trial. AIM This analysis of the EMPA hemodynamic study examined early and delayed effects of empagliflozin treatment on haemoglobin concentrations and hematocrit in addition to parameters of erythropoiesis and iron metabolism to better understand the underlying mechanisms. METHODS In this prospective, placebo-controlled, double blind, randomized, 2-arm parallel, interventional and exploratory study 44 patients with T2D were randomized into 2 groups and received empagliflozin 10 mg or placebo for a period of 3 months in addition to their concomitant medication. Blood and urin was collected at baseline, day 1, day 3 and after 3 months of treatment to investigate effects on haematological parameters, erythropoietin concentrations and indices of iron stores. RESULTS Baseline characteristics were comparable in the empagliflozin (n = 20) and placebo (n = 22) group. Empagliflozin led to a significant increase in urinary glucose excretion (baseline: 7.3 ± 22.7 g/24 hrs; day 1: 48.4 ± 34.7 g/24 hrs, p < 0.001) as well as urinary volume (baseline: 1740 ± 601 mL/24 hrs; day 1: 2112 ± 837 mL/24 hrs, p = 0.011) already after one day and throughout the 3 months study period while hematocrit and hemoglobin were only increased after 3 months of treatment (hematocrit: baseline: 41.0 ± 4.5%; month 3: 43.3 ± 5.6%, p < 0.001; hemoglobin: baseline: 13.7 ± 1.8 g/dL; month 3: 14.2 ± 2.4 g/dL, p = 0.005). In addition, after 3 months, empagliflozin further increased red blood cell count (p < 0.001) and transferrin concentrations (p = 0.063) and a trend toward increased erythropoietin levels (p = 0.117) while ferritin (p = 0.017), total iron (p = 0.053) and transferrin saturation (p = 0.030) decreased. Interestingly, the increase in urinary glucose excretion significantly correlated with the induction of erythropoietin in empagliflozin treated patients at the 3 month timepoint (Spearman rho 0.64, p = 0.008). CONCLUSION Empagliflozin increased hemoglobin concentrations and hematocrit with a delayed time kinetic which was most likely attributable to increased erythropoiesis with augmented iron utilization and not hemoconcentration. This might be attributable to reduced tubular glucose reabsorption in response to SGLT2 inhibition possibly resulting in diminished cellular stress as a mechanism for increased renal erythropoietin secretion.",2021,"In addition, after 3 months, empagliflozin further increased red blood cell count (p < 0.001) and transferrin concentrations (p = 0.063) and a trend toward increased erythropoietin levels (p = 0.117) while ferritin (p = 0.017), total iron (p = 0.053) and transferrin saturation (p = 0.030) decreased.","['patients with and without type 2 diabetes mellitus (T2D', '44 patients with T2D', 'Patients with Type 2 Diabetes - data']","['Sodium-glucose cotransporter-2 (SGLT2) inhibitors', 'empagliflozin', 'empagliflozin 10\xa0mg or placebo', 'placebo', 'Empagliflozin']","['urinary glucose excretion', 'heart failure hospitalization (HHF) and cardiovascular (CV) mortality', 'haemoglobin concentration and hematocrit', 'transferrin concentrations', 'haemoglobin concentrations and hematocrit', 'urinary volume', 'haematological parameters, erythropoietin concentrations and indices of iron stores', 'transferrin saturation', 'erythropoietin levels', 'hematocrit and hemoglobin', 'red blood cell count', 'hemoglobin concentrations and hematocrit', 'total iron']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C3848773', 'cui_str': 'empagliflozin 10 MG [Jardiance]'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0040679', 'cui_str': 'Transferrin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0450235', 'cui_str': 'Evaluation of iron stores'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0202001', 'cui_str': 'Erythropoietin measurement'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}]",44.0,0.147169,"In addition, after 3 months, empagliflozin further increased red blood cell count (p < 0.001) and transferrin concentrations (p = 0.063) and a trend toward increased erythropoietin levels (p = 0.117) while ferritin (p = 0.017), total iron (p = 0.053) and transferrin saturation (p = 0.030) decreased.","[{'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Thiele', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Rau', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Niels-Ulrik Korbinian', 'Initials': 'NK', 'LastName': 'Hartmann', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Möllmann', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Jankowski', 'Affiliation': 'Institute for Molecular Cardiovascular Research, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Department of Internal Medicine III, University Hospital Saarland, Saarland University, Homburg/Saar, Germany.'}, {'ForeName': 'András P', 'Initials': 'AP', 'LastName': 'Keszei', 'Affiliation': 'Center for Translational & Clinical Research Aachen (CTC-A), RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Marx', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lehrke', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14517'] 2554,34378842,Application of evidence-based nursing in prevention of postoperative complications of breast augmentation.,"OBJECTIVE To study the application of evidence-based nursing in prosthesis postoperative complications. METHODS A total of 78 cases of patients who underwent prosthetic breast augmentation were selected from July 2017 to July 2019. All the patients were divided into control group and study group according to the random number table method. The patients in the control group received routine nursing interventions, and the patients in the study group performed evidence-based nursing interventions based on the control group's care. The mental health, external esthetic effects, and complications of the two groups were observed and compared. RESULTS Before the implementation of nursing intervention, there was no significant difference in mental health indicators (SAS, SDS) between the two groups (p > 0.05). After the intervention, the SAS and SDS scores of the two groups were lower than before the intervention, and the study group was lower than the control group, and the difference was statistically significant (p < 0.05); before the implementation of nursing intervention, there was no significant difference in the scores of HADS-A and HADS-D between the two groups (p > 0.05). After the intervention, the scores of HADS-A and HADS-D of the two groups were lower than those before the intervention, and the scores of the study group were lower than those of the control group, and the difference was statistically significant (p < 0.05); 94.9% (37 / 39) was better than 71. 8% (28 / 39) in the control group. The difference was statistically significant (p < 0.05), and the total incidence of postoperative complications in the study group was 5.1% (2 / 39), which was lower than 15.4% (6 / 39) in the control group (p < 0.05). CONCLUSION Evidence-based nursing intervention is effective in preventing postoperative complications of silicone breast augmentation prosthesis. It can effectively reduce postoperative complications, improve external esthetic effects, and improve the level of mental health of patients. It is worthy of clinical promotion and application.",2021,"The difference was statistically significant (p < 0.05), and the total incidence of postoperative complications in the study group was 5.1% (2 / 39), which was lower than 15.4% (6 / 39) in the control group (p < 0.05). ","['78 cases of patients who underwent prosthetic breast augmentation were selected from July 2017 to July 2019', 'silicone breast augmentation prosthesis']","['routine nursing interventions', 'Evidence-based nursing intervention', ""evidence-based nursing interventions based on the control group's care""]","['scores of HADS-A and HADS-D', 'external esthetic effects', 'SAS and SDS scores', 'mental health, external esthetic effects, and complications', 'mental health indicators (SAS, SDS', 'total incidence of postoperative complications']","[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0179412', 'cui_str': 'Breast prosthesis'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0037114', 'cui_str': 'Silicones'}, {'cui': 'C0191925', 'cui_str': 'Augmentation mammoplasty'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2350328', 'cui_str': 'Nursing, Evidence-Based'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}]",,0.021135,"The difference was statistically significant (p < 0.05), and the total incidence of postoperative complications in the study group was 5.1% (2 / 39), which was lower than 15.4% (6 / 39) in the control group (p < 0.05). ","[{'ForeName': 'XueM', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Yak', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'TingT', 'Initials': 'T', 'LastName': 'Xi', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'YuX', 'Initials': 'Y', 'LastName': 'Qian', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Hu', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.'}]",Journal of cosmetic dermatology,['10.1111/jocd.14375'] 2555,34378472,Framing Youth Vaping Prevention Messages: The Role of Uncertainty Tolerance.,"Vaping is the most prevalent form of tobacco use among youth in the United States. Motivated by the certainty effect in prospect theory, this study investigated the role of uncertainty tolerance as a potential moderator of the effects of gain- vs. loss-framed text messages for youth vaping prevention. Youth susceptible to future vaping (N = 536) were randomized to view a series of eight gain- or loss-framed text messages about the health consequences of vaping. Cognitive and affective responses to the messages as well as beliefs, attitude, and intentions about vaping were assessed post-exposure. Results showed an overall advantage of the loss frame on several outcomes. Additionally, an interaction between framing and uncertainty tolerance was observed for most outcomes such that the loss frame was more effective for those high in uncertainty tolerance, while the gain frame held a slight edge for those low in uncertainty tolerance. Findings from this study have implications for further engaging prospect theory in message framing research. They may also inform audience segmentation and targeted message design for youth vaping prevention efforts.",2021,"Cognitive and affective responses to the messages as well as beliefs, attitude, and intentions about vaping were assessed post-exposure.","['Framing Youth Vaping Prevention Messages', 'Youth susceptible to future vaping (N\xa0= 536']",['gain- or loss-framed text messages'],['Cognitive and affective responses'],"[{'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0052148', 'cui_str': 'APEL protocol'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0231204', 'cui_str': 'Susceptible'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C4083280', 'cui_str': 'Vape'}]","[{'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]",[],536.0,0.0278476,"Cognitive and affective responses to the messages as well as beliefs, attitude, and intentions about vaping were assessed post-exposure.","[{'ForeName': 'Xiaomei', 'Initials': 'X', 'LastName': 'Cai', 'Affiliation': 'Department of Communication, George Mason University.'}, {'ForeName': 'Xiaoquan', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Communication, George Mason University.'}]",Health communication,['10.1080/10410236.2021.1966181'] 2556,34378458,Testing for a Sweet Spot in Randomized Trials.,"INTRODUCTION Randomized trials recruit diverse patients, including some individuals who may be unresponsive to the treatment. Here we follow up on prior conceptual advances and introduce a specific method that does not rely on stratification analysis and that tests whether patients in the intermediate range of disease severity experience more relative benefit than patients at the extremes of disease severity (sweet spot). METHODS We contrast linear models to sigmoidal models when describing associations between disease severity and accumulating treatment benefit. The Gompertz curve is highlighted as a specific sigmoidal curve along with the Akaike information criterion (AIC) as a measure of goodness of fit. This approach is then applied to a matched analysis of a published landmark randomized trial evaluating whether implantable defibrillators reduce overall mortality in cardiac patients ( n = 2,521). RESULTS The linear model suggested a significant survival advantage across the spectrum of increasing disease severity (β = 0.0847, P < 0.001, AIC = 2,491). Similarly, the sigmoidal model suggested a significant survival advantage across the spectrum of disease severity (α = 93, β = 4.939, γ = 0.00316, P < 0.001 for all, AIC = 1,660). The discrepancy between the 2 models indicated worse goodness of fit with a linear model compared to a sigmoidal model (AIC: 2,491 v. 1,660, P < 0.001), thereby suggesting a sweet spot in the midrange of disease severity. Model cross-validation using computational statistics also confirmed the superior goodness of fit of the sigmoidal curve with a concentration of survival benefits for patients in the midrange of disease severity. CONCLUSION Systematic methods are available beyond simple stratification for identifying a sweet spot according to disease severity. The approach can assess whether some patients experience more relative benefit than other patients in a randomized trial.[Box: see text].",2021,"The discrepancy between the 2 models indicated worse goodness of fit with a linear model compared to a sigmoidal model (AIC: 2,491 v. 1,660, P < 0.001), thereby suggesting a sweet spot in the midrange of disease severity.","['cardiac patients ( n = 2,521']",['implantable defibrillators'],"['overall mortality', 'survival advantage across the spectrum of disease severity']","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0162589', 'cui_str': 'Implantable defibrillator'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",,0.0971437,"The discrepancy between the 2 models indicated worse goodness of fit with a linear model compared to a sigmoidal model (AIC: 2,491 v. 1,660, P < 0.001), thereby suggesting a sweet spot in the midrange of disease severity.","[{'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Redelmeier', 'Affiliation': 'Department of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Deva', 'Initials': 'D', 'LastName': 'Thiruchelvam', 'Affiliation': 'Evaluative Clinical Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Tibshirani', 'Affiliation': 'Department of Biomedical Data Sciences, Stanford University, Stanford, CA, USA.'}]",Medical decision making : an international journal of the Society for Medical Decision Making,['10.1177/0272989X211025525'] 2557,34378456,"CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.","BACKGROUND Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). OBJECTIVE Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS CONCERTO was a randomized, double-blind, placebo-controlled, phase-3 study. RRMS patients were randomized 1:1:1 to receive once-daily oral laquinimod 0.6 or 1.2 mg or placebo for ⩽24 months ( n  = 727, n  = 732, and n  = 740, respectively). Primary endpoint was time to 3-month confirmed disability progression (CDP). The laquinimod 1.2-mg dose arm was discontinued (1 January 2016) due to cardiovascular events at high doses. Safety was monitored throughout the study. RESULTS CONCERTO did not meet the primary endpoint of significant effect with laquinimod 0.6-mg versus placebo on 3-month CDP (hazard ratio: 0.94; 95% confidence interval: 0.67-1.31; p  = 0.706). Secondary endpoint p values were nominal and non-inferential. Laquinimod 0.6 mg demonstrated 40% reduction in percent brain volume change from baseline to Month 15 versus placebo ( p  < 0.0001). The other secondary endpoint, time to first relapse, and annualized relapse rate (an exploratory endpoint) were numerically lower (both, p  = 0.0001). No unexpected safety findings were reported with laquinimod 0.6 mg. CONCLUSION Laquinimod 0.6 mg demonstrated only nominally significant effects on clinical relapses and magnetic resonance imaging (MRI) outcomes and was generally well tolerated. CLINICAL TRIAL REGISTRATION NUMBER ClinicalTrials.gov (NCT01707992).",2021,Laquinimod 0.6 mg demonstrated 40% reduction in percent brain volume change from baseline to Month 15 versus placebo ( p  < 0.0001).,"['patients with relapsing-remitting multiple sclerosis (RRMS', 'RRMS patients', 'relapsing-remitting multiple sclerosis']","['placebo', 'laquinimod 0.6 or 1.2\u2009mg or placebo', 'oral laquinimod', 'Laquinimod']","['percent brain volume change', 'time to 3-month confirmed disability progression (CDP', 'time to first relapse, and annualized relapse rate', 'clinical relapses and magnetic resonance imaging (MRI) outcomes', 'tolerated', 'Safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1260208', 'cui_str': 'laquinimod'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0008188', 'cui_str': 'Chlordiazepoxide'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.563852,Laquinimod 0.6 mg demonstrated 40% reduction in percent brain volume change from baseline to Month 15 versus placebo ( p  < 0.0001).,"[{'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Comi', 'Affiliation': 'Vita-Salute San Raffaele University, Milan, Italy/Centro Sclerosi Multipla, Presidio Ospedaliero di Gallarate, Gallarate, Italy.'}, {'ForeName': 'Yuval', 'Initials': 'Y', 'LastName': 'Dadon', 'Affiliation': 'Teva Pharmaceutical Industries, Netanya, Israel.'}, {'ForeName': 'Nissim', 'Initials': 'N', 'LastName': 'Sasson', 'Affiliation': 'Teva Pharmaceutical Industries, Netanya, Israel.'}, {'ForeName': 'Joshua R', 'Initials': 'JR', 'LastName': 'Steinerman', 'Affiliation': 'Teva Pharmaceutical Industries, Great Valley, PA, USA.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Knappertz', 'Affiliation': 'Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany.'}, {'ForeName': 'Timothy L', 'Initials': 'TL', 'LastName': 'Vollmer', 'Affiliation': 'University of Colorado, Aurora, CO, USA.'}, {'ForeName': 'Alexey', 'Initials': 'A', 'LastName': 'Boyko', 'Affiliation': 'Pirogov Russian National Research University and Department of Neuroimmunology of the Federal Center of Cerebrovascular Pathology and Stroke, Moscow, Russia.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Vermersch', 'Affiliation': 'Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France.'}, {'ForeName': 'Tjalf', 'Initials': 'T', 'LastName': 'Ziemssen', 'Affiliation': 'Center of Clinical Neuroscience, University Hospital, Dresden, Germany.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Montalban', 'Affiliation': ""Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada/Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Fred D', 'Initials': 'FD', 'LastName': 'Lublin', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Rocca', 'Affiliation': 'Vita-Salute San Raffaele University, Milan, Italy/Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy/Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Volkinshtein', 'Affiliation': 'Teva Pharmaceutical Industries, Netanya, Israel.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Rubinchick', 'Affiliation': 'Teva Pharmaceutical Industries, Netanya, Israel.'}, {'ForeName': 'Nitsan', 'Initials': 'N', 'LastName': 'Halevy', 'Affiliation': 'Teva Pharmaceutical Industries, Netanya, Israel.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Filippi', 'Affiliation': 'Vita-Salute San Raffaele University, Milan, Italy/Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy/Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy/Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy/Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}]","Multiple sclerosis (Houndmills, Basingstoke, England)",['10.1177/13524585211032803'] 2558,34378446,Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.,"BACKGROUND Alemtuzumab efficacy and safety was demonstrated in CARE-MS I and extension studies (CAMMS03409; TOPAZ). OBJECTIVE Evaluate serum neurofilament light chain (sNfL) in CARE-MS I patients and highly active disease (HAD) subgroup, over 7 and 2 years for alemtuzumab and subcutaneous interferon beta-1a (SC IFNB-1a), respectively. METHODS Patients received SC IFNB-1a 44 µg 3×/week or alemtuzumab 12 mg/day at baseline and month 12, with further as-needed 3-day courses. sNfL was measured using single-molecule array (Simoa™). HAD definition was ⩾2 relapses in year before randomization and ⩾1 baseline gadolinium-enhancing lesion. RESULTS Baseline median sNfL levels were similar in alemtuzumab ( n = 354) and SC IFNB-1a-treated ( n = 159) patients (31.7 vs 31.4 pg/mL), but decreased with alemtuzumab versus SC IFNB-1a until year 2 (Y2; 13.2 vs 18.7 pg/mL; p < 0.0001); 12.7 pg/mL for alemtuzumab at Y7. Alemtuzumab-treated patients had sNfL at/below healthy control median at Y2 (72% vs 47%; p < 0.0001); 73% for alemtuzumab at Y7. HAD patients ( n = 102) had higher baseline sNfL (49.4 pg/mL) versus overall population; alemtuzumab HAD patients attained similar levels (Y2, 12.8 pg/mL; Y7, 12.7 pg/mL; 75% were at/below control median at Y7). CONCLUSION Alemtuzumab was superior to SC IFNB-1a in reducing sNfL, with levels in alemtuzumab patients remaining stable through Y7. CLINICALTRIALS.GOV IDENTIFIER NCT00530348, NCT00930553, NCT02255656.",2021,"Alemtuzumab was superior to SC IFNB-1a in reducing sNfL, with levels in alemtuzumab patients remaining stable through Y7. ","['CARE-MS I patients and highly active disease (HAD) subgroup, over 7 and 2\u2009years for alemtuzumab and subcutaneous interferon beta-1a (SC IFNB-1a), respectively', 'HAD patients ( n = 102) had higher baseline sNfL']","['alemtuzumab', 'SC IFNB-1a 44 µg 3×/week or alemtuzumab', 'Alemtuzumab', 'serum neurofilament light chain (sNfL']","['Baseline median sNfL levels', 'serum neurofilament light chain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0383429', 'cui_str': 'alemtuzumab'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0254119', 'cui_str': 'Interferon beta-1a'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0337112', 'cui_str': 'Chain'}]","[{'cui': 'C0383429', 'cui_str': 'alemtuzumab'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0254119', 'cui_str': 'Interferon beta-1a'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0337112', 'cui_str': 'Chain'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C1562562', 'cui_str': 'Light chain level'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0337112', 'cui_str': 'Chain'}]",,0.0884624,"Alemtuzumab was superior to SC IFNB-1a in reducing sNfL, with levels in alemtuzumab patients remaining stable through Y7. ","[{'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Kuhle', 'Affiliation': 'Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Daizadeh', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Benkert', 'Affiliation': 'Clinical Trial Unit Basel, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Maceski', 'Affiliation': 'Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Barro', 'Affiliation': ""Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland Current affiliation: Ann Romney Center for Neurologic Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Zuzanna', 'Initials': 'Z', 'LastName': 'Michalak', 'Affiliation': 'Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland Current affiliation: F. Hoffmann-La Roche Ltd., Basel, Switzerland.'}, {'ForeName': 'Maria Pia', 'Initials': 'MP', 'LastName': 'Sormani', 'Affiliation': 'Department of Health Sciences, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Godin', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Srinivas', 'Initials': 'S', 'LastName': 'Shankara', 'Affiliation': 'Sanofi, Framingham, MA, USA.'}, {'ForeName': 'Tarek A', 'Initials': 'TA', 'LastName': 'Samad', 'Affiliation': 'Sanofi, Framingham, MA, USA.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Jacobs', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Chung', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Rӧsch', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Kaiser', 'Affiliation': 'Sanofi, Baar, Switzerland.'}, {'ForeName': 'Colin P', 'Initials': 'CP', 'LastName': 'Mitchell', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Leppert', 'Affiliation': 'Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Evis', 'Initials': 'E', 'LastName': 'Havari', 'Affiliation': 'Sanofi, Framingham, MA, USA.'}, {'ForeName': 'Ludwig', 'Initials': 'L', 'LastName': 'Kappos', 'Affiliation': 'Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.'}]","Multiple sclerosis (Houndmills, Basingstoke, England)",['10.1177/13524585211032348'] 2559,34378406,Barriers to recruitment to an orthopaedic randomized controlled trial comparing two surgical procedures for ankle arthritis : a qualitative study.,"AIMS A multicentre, randomized, clinician-led, pragmatic, parallel-group orthopaedic trial of two surgical procedures was set up to obtain high-quality evidence of effectiveness. However, the trial faced recruitment challenges and struggled to maintain recruitment rates over 30%, although this is not unusual for surgical trials. We conducted a qualitative study with the aim of gathering information about recruitment practices to identify barriers to patient consent and participation to an orthopaedic trial. METHODS We collected 11 audio recordings of recruitment appointments and interviews of research team members (principal investigators and research nurses) from five hospitals involved in recruitment to an orthopaedic trial. We analyzed the qualitative data sets thematically with the aim of identifying aspects of informed consent and information provision that was either unclear, disrupted, or hindered trial recruitment. RESULTS Recruiters faced four common obstacles when recruiting to a surgical orthopaedic trial: patient preferences for an intervention; a complex recruitment pathway; various logistical issues; and conflicting views on equipoise. Clinicians expressed concerns that the trial may not show significant differences in the treatments, validating their equipoise. However, they experienced role conflicts due to their own preference and perceived patient preference for an intervention arm. CONCLUSION This study provided initial information about barriers to recruitment to an orthopaedic randomized controlled trial. We shared these findings in an all-site investigators' meeting and encouraged researchers to find solutions to identified barriers; this led to the successful completion of recruitment. Complex trials may benefit for using of a mixed-methods approach to mitigate against recruitment failure, and to improve patient participation and informed consent. Cite this article: Bone Jt Open  2021;2(8):631-637.",2021,Bone Jt Open  2021;2(8):631,['ankle arthritis '],[],[],"[{'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0003864', 'cui_str': 'Arthritis'}]",[],[],11.0,0.37484,Bone Jt Open  2021;2(8):631,"[{'ForeName': 'Alba X', 'Initials': 'AX', 'LastName': 'Realpe', 'Affiliation': 'Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Blackstone', 'Affiliation': 'Comprehensive Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'Damian R', 'Initials': 'DR', 'LastName': 'Griffin', 'Affiliation': 'University of Warwick Warwick Medical School, Coventry, UK.'}, {'ForeName': 'Andrew J F', 'Initials': 'AJF', 'LastName': 'Bing', 'Affiliation': 'Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust, Oswestry, Shropshire, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Karski', 'Affiliation': 'Foot and Ankle Surgery, Wrightington Hospital, Wigan, UK.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Milner', 'Affiliation': 'University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.'}, {'ForeName': 'Malik', 'Initials': 'M', 'LastName': 'Siddique', 'Affiliation': 'Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Newcastle upon Tyne, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Goldberg', 'Affiliation': 'The Wellington Hospital, London, UK.'}]",Bone & joint open,['10.1302/2633-1462.28.BJO-2021-0074.R1'] 2560,34378365,"Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.","OBJECTIVE The addition of maintenance olaparib to bevacizumab demonstrated a significant progression-free survival (PFS) benefit in patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1/ENGOT-ov25 trial (NCT02477644). We evaluated maintenance olaparib plus bevacizumab in the Japan subset of PAOLA-1. METHODS PAOLA-1 was a randomized, double-blind, phase III trial. Patients received maintenance olaparib tablets 300 mg twice daily or placebo twice daily for up to 24 months, plus bevacizumab 15 mg/kg every 3 weeks for up to 15 months in total. This prespecified subgroup analysis evaluated investigator-assessed PFS (primary endpoint). RESULTS Of 24 randomized Japanese patients, 15 were assigned to olaparib and 9 to placebo. After a median follow-up for PFS of 27.7 months for olaparib plus bevacizumab and 24.0 months for placebo plus bevacizumab, median PFS was 27.4 versus 19.4 months, respectively (hazard ratio [HR]=0.34; 95% confidence interval [CI]=0.11-1.00). In patients with tumors positive for homologous recombination deficiency, the HR for PFS was 0.57 (95% CI=0.16-2.09). Adverse events in the Japan subset were generally consistent with those of the PAOLA-1 overall population and with the established safety and tolerability profiles of olaparib and bevacizumab. CONCLUSION Results in the Japan subset of PAOLA-1 support the overall conclusion of the PAOLA-1 trial demonstrating that the addition of maintenance olaparib to bevacizumab provides a PFS benefit in patients with newly diagnosed, advanced ovarian cancer. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02477644.",2021,"In patients with tumors positive for homologous recombination deficiency, the HR for PFS was 0.57 (95% CI=0.16-2.09).","['patients with newly diagnosed, advanced ovarian cancer', '24 randomized Japanese patients', 'Japan subset of PAOLA-1']","['bevacizumab', 'Olaparib plus bevacizumab', 'maintenance olaparib tablets 300 mg twice daily or placebo', 'placebo', 'olaparib plus bevacizumab', 'placebo plus bevacizumab']","['HR for PFS', 'median PFS', 'progression-free survival (PFS) benefit', 'Adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C2316164', 'cui_str': 'olaparib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C4520027', 'cui_str': 'olaparib Oral Tablet'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.797867,"In patients with tumors positive for homologous recombination deficiency, the HR for PFS was 0.57 (95% CI=0.16-2.09).","[{'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Fujiwara', 'Affiliation': 'Saitama Medical University International Medical Center, Saitama, Japan. fujiwara@saitama-med.ac.jp.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Fujiwara', 'Affiliation': 'Jichi Medical University Hospital, Tochigi, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Yoshida', 'Affiliation': 'Saitama Medical University International Medical Center, Saitama, Japan.'}, {'ForeName': 'Toyomi', 'Initials': 'T', 'LastName': 'Satoh', 'Affiliation': 'University of Tsukuba Hospital, Ibaraki, Japan.'}, {'ForeName': 'Kan', 'Initials': 'K', 'LastName': 'Yonemori', 'Affiliation': 'National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Shoji', 'Initials': 'S', 'LastName': 'Nagao', 'Affiliation': 'Hyogo Cancer Center, Akashi, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Matsumoto', 'Affiliation': 'Ehime University Hospital, Ehime, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Kobayashi', 'Affiliation': 'Kagoshima University Hospital, Kagoshima, Japan.'}, {'ForeName': 'Hughes', 'Initials': 'H', 'LastName': 'Bourgeois', 'Affiliation': 'Centre Jean Bernard - Clinique Victor Hugo, GINECO, Le Mans, France.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Harter', 'Affiliation': 'Kliniken Essen Mitte, Essen, Germany.'}, {'ForeName': 'Anna Maria', 'Initials': 'AM', 'LastName': 'Mosconi', 'Affiliation': 'Ospedale Santa Maria della Misericordia, Perugia, Italy.'}, {'ForeName': 'Isabel Palacio', 'Initials': 'IP', 'LastName': 'Vazquez', 'Affiliation': 'Hospital Universitario Central de Asturias, Oviedo, Spain.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Reinthaller', 'Affiliation': 'Medical University Vienna, Vienna, Austria.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Fujita', 'Affiliation': 'Astrazeneca, Osaka, Japan.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Rowe', 'Affiliation': 'AstraZeneca, Cambridge, UK.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Pujade-Lauraine', 'Affiliation': 'Medical Oncology, Université Paris Descartes, Paris, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Ray-Coquard', 'Affiliation': 'Centre Léon BERARD and University Claude Bernard Lyon I, GINECO, Lyon, France.'}]",Journal of gynecologic oncology,['10.3802/jgo.2021.32.e82'] 2561,34377259,Evidence-based bundled care for patients with dysphagia after severe traumatic brain injury: a randomized controlled trial.,"OBJECTIVE To explore the effect of an evidence-based bundled care model in patients with dysphagia after severe traumatic brain injury (TBI). METHODS This is a prospective randomized controlled study. A total of 60 patients with dysphagia after severe TBI (traumatic brain injury) admitted to the Department of Rehabilitation Medicine were selected and randomly divided into the test group (n=30) and the control group (n=30). Patients in the control group received routine care in the Department of Rehabilitation Medicine, while patients in the test group received evidence-based bundled care on the basis of the treatment of the control group. The improvement of swallowing function (dye test in comatose patients), oral hygiene, and nutritional risk was assessed in both groups. The incidence of adverse events such as aspiration and aspiration pneumonia, as well as the length and costs of hospitalization were compared between the two groups. RESULTS Compared with patients in the control group, swallowing function of patients in the test group was significantly improved after the care (P<0.05), and for comatose patients, the positive rate of Evans blue dye test was markedly reduced (P<0.05). Compared with patients in the control group, the oral hygiene of patients in the test group was significantly improved after care, and the nutritional risk scores were also significantly decreased (P<0.05). During hospitalization, the total incidence of adverse events, length and costs of hospitalization of patients in the test group were significantly lower than those in the control group (P<0.05). CONCLUSION Evidence-based bundled care can effectively improve swallowing function and reduce the incidence of nutritional risks and adverse events in patients with dysphagia after severe TBI, which further promotes postoperative rehabilitation of patients.",2021,"Compared with patients in the control group, the oral hygiene of patients in the test group was significantly improved after care, and the nutritional risk scores were also significantly decreased (P<0.05).","['60 patients with dysphagia after severe TBI (traumatic brain injury) admitted to the Department of Rehabilitation Medicine', 'patients with dysphagia after severe traumatic brain injury', 'patients with dysphagia after severe traumatic brain injury (TBI', 'patients with dysphagia after severe TBI']","['Evidence-based bundled care', 'routine care', 'evidence-based bundled care model']","['nutritional risk scores', 'swallowing function', 'oral hygiene', 'incidence of adverse events such as aspiration and aspiration pneumonia, as well as the length and costs of hospitalization', 'positive rate of Evans blue dye test', 'total incidence of adverse events, length and costs of hospitalization', 'oral hygiene, and nutritional risk']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0031813', 'cui_str': 'Physical Medicine and Rehabilitation'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C0032290', 'cui_str': 'Aspiration pneumonia'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0015205', 'cui_str': 'Evans blue'}, {'cui': 'C0441697', 'cui_str': 'Dye test'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",60.0,0.0275464,"Compared with patients in the control group, the oral hygiene of patients in the test group was significantly improved after care, and the nutritional risk scores were also significantly decreased (P<0.05).","[{'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Yan', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}, {'ForeName': 'Jinyue', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}, {'ForeName': 'Huali', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Deng', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}, {'ForeName': 'Qiongfang', 'Initials': 'Q', 'LastName': 'Hu', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}, {'ForeName': 'Jiawei', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Department of Rehabilitation Medicine, The Second Affiliated Hospital of Kunming Medical University Kunming, Yunnan Province, China.'}, {'ForeName': 'Meifen', 'Initials': 'M', 'LastName': 'Lv', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}]",American journal of translational research,[] 2562,34377258,Effect of carboprost tromethamine injection combined with modified B-lynch suture and carboprost methylate suppositories in parturients with placenta previa.,"OBJECTIVE To investigate the clinical value of carboprost tromethamine injection combined with modified B-lynch suture and carboprost methylate suppositories in the treatment of placenta previa parturients with postpartum hemorrhage after cesarean section. METHODS A total of 102 parturients with placenta previa and postpartum hemorrhage after cesarean section in our hospital were selected as the study subjects, and they were divided into Group A (carboprost tromethamine injection combined with modified B-lynch suture, n=35), Group B (carboprost methylate suppositories, n=34), and Group C (carboprost tromethamine injection, n=33) in accordance with a random number table. The amounts of hemorrhaging and clinical indices in the three groups were recorded, and the rescue effects were compared among the three groups. RESULTS The amount of hemorrhaging in Group A was significantly lower than that in Groups B and C during surgery and 24 h after surgery ( P < 0.05). There were markedly improved clinical indices in Groups A, B and C, showing statistical significance ( P < 0.05). There were statistically significant differences in hemostatic failure rate, hysterectomy, postoperative abdominal pain and puerperal infection between Groups A and B ( P < 0.05). The intraoperative indices, postoperative infection, effective hemostasis rate and rate of advanced postpartum hemorrhage in Group A were remarkably higher than those in Groups B and C ( P < 0.05), showing statistical significance ( P < 0.05). There were statistically significant differences in blood oxygen saturation and pulse among the three groups before surgery and 2 h after surgery ( P < 0.05). CONCLUSION Carboprost tromethamine injection combined with modified B-lynch suture and carboprost methylate suppositories can reduce the amount of hemorrhaging and the risk of postoperative infection in placenta previa patients with postpartum hemorrhage after cesarean section.",2021,"There were statistically significant differences in hemostatic failure rate, hysterectomy, postoperative abdominal pain and puerperal infection between Groups A and B ( P < 0.05).","['parturients with placenta previa', 'placenta previa parturients with postpartum hemorrhage after cesarean section', '102 parturients with placenta previa and postpartum hemorrhage after cesarean section in our hospital were selected as the study subjects', 'placenta previa patients with postpartum hemorrhage after cesarean section']","['carboprost tromethamine injection combined with modified B-lynch suture and carboprost methylate suppositories', 'tromethamine injection combined with modified B-lynch suture, n=35), Group B (carboprost methylate suppositories, n=34), and Group C (carboprost tromethamine injection', 'Carboprost tromethamine injection combined with modified B-lynch suture and carboprost methylate suppositories']","['intraoperative indices, postoperative infection, effective hemostasis rate and rate of advanced postpartum hemorrhage', 'hemostatic failure rate, hysterectomy, postoperative abdominal pain and puerperal infection', 'blood oxygen saturation and pulse', 'clinical indices']","[{'cui': 'C0032046', 'cui_str': 'Placenta previa'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0054721', 'cui_str': 'Carboprost tromethamine'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0007047', 'cui_str': 'Carboprost'}, {'cui': 'C0031246', 'cui_str': 'Pessary'}, {'cui': 'C4307249', 'cui_str': 'Tromethamine Injection'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0441837', 'cui_str': 'Group C'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0392618', 'cui_str': 'Postoperative infection'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C4047372', 'cui_str': 'Postoperative abdominal pain'}, {'cui': 'C0034041', 'cui_str': 'Puerperal infection'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",102.0,0.0958647,"There were statistically significant differences in hemostatic failure rate, hysterectomy, postoperative abdominal pain and puerperal infection between Groups A and B ( P < 0.05).","[{'ForeName': 'Jianli', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Obstetrics, The First Hospital of Shanxi Medical University Taiyuan 030000, Shanxi, China.'}, {'ForeName': 'Hailan', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Obstetrics, The First Hospital of Shanxi Medical University Taiyuan 030000, Shanxi, China.'}]",American journal of translational research,[] 2563,34377257,Effects of heat-sensitive moxibustion combined with naprapathy and warming needle moxibustion combined with naprapathy in patients with periarthritis of shoulder.,"OBJECTIVE To evaluate the effects of heat-sensitive moxibustion (HSM) combined with naprapathy and warming needle moxibustion (WNM) combined with naprapathy on shoulder function and serum levels of calcitonin gene-related peptide (CGRP), substance P (SP), tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2) in patients with periarthritis of shoulder (POS). METHODS From July 2017 to July 2020, sixty patients with POS admitted to our hospital were selected as the study subjects, and divided into HSM group (n=29) receiving HSM combined with naprapathy and WNM group receiving WNM combined with naprapathy (n=31). The changes in shoulder function, degrees of pain and serum levels of CGRP, SP, TNF-α and IL-2 were compared between the two groups. RESULTS After treatment, the scores of myodynamia, pain, range of motion (ROM) of shoulder joint and activities of daily living (ADLs) were improved in both groups ( P <0.05), and the scores in HSM group were remarkably higher than those in WNM group ( P <0.05). Visual analogue scale (VAS) scores after 3 courses of treatment were lower than those after 1 and 2 courses of treatment respectively ( P <0.05), and the VAS scores in HSM group were markedly lower than those in WNM group after 1, 2, and 3 courses of treatment ( P <0.05). After treatment, the serum levels of CGRP, SP, TNF-α and IL-2 were decreased in both groups ( P <0.05), and the levels in HSM group were noticeably lower than those in WNM group ( P <0.05). CONCLUSION HSM combined with naprapathy is superior to WNM combined with naprapathy in inhibition of inflammatory factors of pain and serum inflammatory factors, alleviating the pain and promoting the restoration of shoulder function in patients with POS.",2021,"The changes in shoulder function, degrees of pain and serum levels of CGRP, SP, TNF-α and IL-2 were compared between the two groups. ","['patients with periarthritis of shoulder (POS', 'patients with periarthritis of shoulder', 'patients with POS', 'From July 2017 to July 2020, sixty patients with POS admitted to our hospital were selected as the study subjects, and divided into HSM group (n=29) receiving']","['heat-sensitive moxibustion combined with naprapathy and warming needle moxibustion combined with naprapathy', 'heat-sensitive moxibustion (HSM) combined with naprapathy and warming needle moxibustion (WNM) combined with naprapathy', 'HSM combined with naprapathy and WNM group receiving WNM combined with naprapathy']","['scores of myodynamia, pain, range of motion (ROM) of shoulder joint and activities of daily living (ADLs', 'Visual analogue scale (VAS) scores', 'shoulder function and serum levels of calcitonin gene-related peptide (CGRP), substance P (SP), tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2', 'shoulder function, degrees of pain and serum levels of CGRP, SP, TNF-α and IL-2', 'serum levels of CGRP, SP, TNF-α and IL-2', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1306835', 'cui_str': 'Periarthritis of shoulder'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0231274', 'cui_str': 'Intolerant of heat'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0231274', 'cui_str': 'Intolerant of heat'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1735870', 'cui_str': 'Naprapathy'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0037009', 'cui_str': 'Joint structure of shoulder region'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006669', 'cui_str': 'Calcitonin gene-related peptide'}, {'cui': 'C0038585', 'cui_str': 'Substance P'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021756', 'cui_str': 'Interleukin-2'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",60.0,0.0285187,"The changes in shoulder function, degrees of pain and serum levels of CGRP, SP, TNF-α and IL-2 were compared between the two groups. ","[{'ForeName': 'Minghua', 'Initials': 'M', 'LastName': 'Yuan', 'Affiliation': ""Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.""}, {'ForeName': 'Xiaoyuan', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.""}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Yan', 'Affiliation': ""Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': ""Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Yi', 'Affiliation': ""Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.""}, {'ForeName': 'Hongmei', 'Initials': 'H', 'LastName': 'Xia', 'Affiliation': ""Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.""}, {'ForeName': 'Xueqin', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ""Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.""}]",American journal of translational research,[] 2564,34377253,The effects of comprehensive nursing intervention on the negative emotions of patients with infertility.,"OBJECTIVE To investigate the effects of comprehensive nursing intervention (CNI) on the negative emotions of patients with infertility. METHODS A total of 132 patients were recruited as the study cohort and randomly divided into an observation group (n=62) and a control group (n=70). The patients in both groups underwent routine treatment and nursing. In addition, the patients in the observation group were administered CNI. The quality of life (QOL) scores and depression levels of all the patients were evaluated after the intervention. RESULTS Before the CNI, the QOL scores and the anxiety and depression levels showed no significant differences between two the groups (P>0.05). After the intervention, the observation group showed much higher mild-depression and non-depression levels, higher mild-anxiety and non-anxiety levels and higher QOL and physiological function scores than the control group (all P <0.05). CONCLUSION CNI has an effect on the negative emotions of patients with infertility.",2021,"Before the CNI, the QOL scores and the anxiety and depression levels showed no significant differences between two the groups (P>0.05).","['A total of 132 patients were recruited as the study cohort and randomly divided into an observation group (n=62) and a control group (n=70', 'patients with infertility']","['CNI', 'comprehensive nursing intervention (CNI', 'comprehensive nursing intervention']","['mild-anxiety and non-anxiety levels and higher QOL and physiological function scores', 'mild-depression and non-depression levels', 'QOL scores and the anxiety and depression levels', 'quality of life (QOL) scores and depression levels']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0231401', 'cui_str': 'Mild anxiety'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0588006', 'cui_str': 'Mild depression'}, {'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",132.0,0.0071127,"Before the CNI, the QOL scores and the anxiety and depression levels showed no significant differences between two the groups (P>0.05).","[{'ForeName': 'Hailing', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'Department of Reproductive Medicine, The First Affiliated Hospital of Hainan Medical University Haikou 570100, Hainan Province, China.'}, {'ForeName': 'Siyi', 'Initials': 'S', 'LastName': 'Xu', 'Affiliation': 'Department of Urology, The First Affiliated Hospital of Hainan Medical University Haikou 570100, Hainan Province, China.'}, {'ForeName': 'Meihong', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Reproductive Medicine, The First Affiliated Hospital of Hainan Medical University Haikou 570100, Hainan Province, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Shang', 'Affiliation': 'Department of Urology, The First Affiliated Hospital of Hainan Medical University Haikou 570100, Hainan Province, China.'}, {'ForeName': 'Chan', 'Initials': 'C', 'LastName': 'Wei', 'Affiliation': 'Department of Reproductive Medicine, The First Affiliated Hospital of Hainan Medical University Haikou 570100, Hainan Province, China.'}, {'ForeName': 'Jinshan', 'Initials': 'J', 'LastName': 'Fu', 'Affiliation': 'Department of Urology, The First Affiliated Hospital of Hainan Medical University Haikou 570100, Hainan Province, China.'}]",American journal of translational research,[] 2565,34377245,Effect of risk management combined with precision care in interventional embolization of cerebral aneurysm in elderly patients.,"OBJECTIVE To investigate the effect of risk management combined with intraoperative precision care on the efficacy and safety of interventional embolization therapy for elderly patients with cerebral aneurysms. METHODS In this prospective randomized controlled study, we included 60 elderly patients with cerebral aneurysm treated with interventional embolization. The patients were randomly divided into an experiment group (n=30) and a control group (n=30). The control group received conventional care during the interventional procedure, while the experiment group received risk management combined with precision care. The outcome of the procedure, time to disappearance of clinical symptoms, length of hospitalization, incidence of complications, neurological function and quality of life before and 3 months after the procedure in both groups were assessed and compared. RESULTS Compared with the control group, the experiment group had significantly less intraoperative bleeding, shorter operative time (all P<0.001), shorter time to disappearance of clinical symptoms and shorter hospitalization (all P<0.001), and a lower rate of surgical complications (P<0.05). Three months after the operation, the experiment group had better neurological function and quality of life, with significantly lower mRs scores (modified Rankin scale), NIHSS (National Institute of Health Stroke Scale) and higher SF-36 scores (MOS item short from health survey) than those of the control group (both P<0.001). CONCLUSION Risk management combined with precision care can effectively improve the surgical safety of interventional embolization in elderly patients with cerebral aneurysm, reduce the incidence of surgical complications, and thus improve the prognosis.",2021,"Compared with the control group, the experiment group had significantly less intraoperative bleeding, shorter operative time (all P<0.001), shorter time to disappearance of clinical symptoms and shorter hospitalization (all P<0.001), and a lower rate of surgical complications (P<0.05).","['elderly patients with cerebral aneurysms', 'elderly patients with cerebral aneurysm', '60 elderly patients with cerebral aneurysm treated with', 'elderly patients']","['risk management combined with intraoperative precision care', 'Risk management combined with precision care', 'risk management combined with precision care', 'interventional embolization therapy', 'conventional care during the interventional procedure, while the experiment group received risk management combined with precision care', 'interventional embolization']","['surgical safety', 'efficacy and safety', 'procedure, time to disappearance of clinical symptoms, length of hospitalization, incidence of complications, neurological function and quality of life', 'neurological function and quality of life', 'mRs scores (modified Rankin scale), NIHSS (National Institute of Health Stroke Scale) and higher SF-36 scores (MOS item short from health survey', 'shorter time to disappearance of clinical symptoms and shorter hospitalization', 'intraoperative bleeding, shorter operative time', 'rate of surgical complications']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155730', 'cui_str': 'Cerebral aneurysm, nonruptured'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0035649', 'cui_str': 'Risk management'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013931', 'cui_str': 'Embolization - action'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0026574', 'cui_str': 'mos Oncogenes'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}]",60.0,0.0164072,"Compared with the control group, the experiment group had significantly less intraoperative bleeding, shorter operative time (all P<0.001), shorter time to disappearance of clinical symptoms and shorter hospitalization (all P<0.001), and a lower rate of surgical complications (P<0.05).","[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Interventional Radiology, Xuanwu Hospital of Capital Medical University Beijing, China.'}, {'ForeName': 'Hongyan', 'Initials': 'H', 'LastName': 'Tang', 'Affiliation': 'Department of Interventional Radiology, Xuanwu Hospital of Capital Medical University Beijing, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Interventional Radiology, Xuanwu Hospital of Capital Medical University Beijing, China.'}, {'ForeName': 'Mengmeng', 'Initials': 'M', 'LastName': 'Sun', 'Affiliation': 'Department of Interventional Radiology, Xuanwu Hospital of Capital Medical University Beijing, China.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Interventional Radiology, Xuanwu Hospital of Capital Medical University Beijing, China.'}]",American journal of translational research,[] 2566,34377210,"Health schools as an organizational form of realization of the ""life course health development"" concept.","This study was conducted to evaluate the effectiveness of health education in the Tatarstan Republic by establishing educational programs - Health Schools - for groups of patients with a high risk of developing potentially fatal cardiac and respiratory conditions. The concept of ""Life Course Health Development"" implies the development of mechanisms for personalized health management. The goal of the study is to explore the effectiveness of the specialized Health Schools in Tatarstan. For the comparative study of health education effects on the overall state of personal health, 590 patients were surveyed in a randomized controlled trial. The groups of patients were compared in relation to their health education; their health status was observed prior to and afterward undergoing the educative preventative programs and estimated in comparison between the two groups. Extrapolation of the data on Tatarstan's patient population was obtained through this study, taking into account the state of health of the Health Schools students, obtaining the regression equations of population mortality and the effects of training on it. The effectiveness of Health Schools for patients with cardiovascular pathology has been proven. However, additional efforts are required to involve a wider range of patients and increase learning effectiveness to critical levels of awareness by introducing new forms of education in Health Schools since it statistically significantly increased the awareness level regarding disease nature and preventive measures.",2021,The groups of patients were compared in relation to their health education; their health status was observed prior to and afterward undergoing the educative preventative programs and estimated in comparison between the two groups.,"['patients with cardiovascular pathology', 'Tatarstan Republic by establishing educational programs - Health Schools - for groups of patients with a high risk of developing potentially fatal cardiac and respiratory conditions', '590 patients', 'specialized Health Schools in Tatarstan']",['Health Schools'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C3658204', 'cui_str': 'Republic of Tatarstan'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C5191356', 'cui_str': '590'}, {'cui': 'C0205555', 'cui_str': 'Special'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036375', 'cui_str': 'School'}]",[],590.0,0.0464718,The groups of patients were compared in relation to their health education; their health status was observed prior to and afterward undergoing the educative preventative programs and estimated in comparison between the two groups.,"[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Fomina', 'Affiliation': ""Department of Public Health, Healthcare and Hygene, Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation.""}, {'ForeName': 'Lyudmila', 'Initials': 'L', 'LastName': 'Maksimenko', 'Affiliation': ""Department of Public Health, Healthcare and Hygene, Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation.""}, {'ForeName': 'Evgeniya', 'Initials': 'E', 'LastName': 'Atsel', 'Affiliation': 'Kazan State Medical Academy, Branch of the Russian Ministry of Health of the Russian Federation, Kazan, Russian Federation.'}]",Journal of medicine and life,['10.25122/jml-2021-1127'] 2567,34377217,A Randomized Controlled Trial to Examine the Feasibility and Preliminary Efficacy of a Digital Mindfulness-Based Therapy for Improving Insomnia Symptoms.,"Objectives Insomnia has widespread negative implications for health and well-being. Online delivery of mindfulness-based therapy for insomnia (MBTI) has not previously been evaluated. This study investigated the feasibility and preliminary efficacy of a digital MBTI program for improving insomnia symptoms. It was hypothesized that a 6-week digital MBTI program would reduce insomnia symptoms and pre-sleep arousal and improve mood, compared to a waitlist control condition. Methods Twenty-seven participants (M = 29.44, SD = 11.97 years) experiencing insomnia symptoms (insomnia severity index [ISI] ≥ 8) were randomized to either a 6-week intervention or waitlist condition. Participants completed the ISI, pre-sleep arousal scale (PSAS), and the positive and negative affect schedule at baseline, mid-, and post-study. Feasibility was assessed across four domains (acceptability, implementation, practicality, and preliminary efficacy) using self-reports, attrition, program completions, and module completions. Results Feasibility data for the intervention indicated that there was 22% attrition, and 79% of the modules were completed. There were significantly greater reductions in the severity of insomnia symptoms ( p  < .001) and both cognitive ( p  = .03) and somatic ( p  = .02) subscales of the PSAS, at post-intervention compared to the waitlist group. There were no significant group differences in mood. Conclusions This study provides preliminary evidence of the feasibility and efficacy of a digital MBTI, which may assist in the broader dissemination of insomnia treatment.Trial RegistrationAustralian and New Zealand Clinical Trials Registry: ACTRN12620000398909.",2021,"There were significantly greater reductions in the severity of insomnia symptoms ( p  < .001) and both cognitive ( p  = .03) and somatic ( p  = .02) subscales of the PSAS, at post-intervention compared to the waitlist group.","['Methods\n\n\nTwenty-seven participants (M\u2009=\u200929.44, SD\u2009=\u200911.97\xa0years) experiencing insomnia symptoms (insomnia severity index [ISI]\u2009≥']","['6-week intervention or waitlist condition', 'digital MBTI program', 'digital MBTI', 'Digital Mindfulness-Based Therapy']","['insomnia symptoms', 'Insomnia Symptoms', 'domains (acceptability, implementation, practicality, and preliminary efficacy) using self-reports, attrition, program completions, and module completions', 'mood', 'severity of insomnia symptoms', 'ISI, pre-sleep arousal scale (PSAS', 'insomnia symptoms and pre-sleep arousal and improve mood']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0439611', 'cui_str': 'Preliminary'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",27.0,0.0397296,"There were significantly greater reductions in the severity of insomnia symptoms ( p  < .001) and both cognitive ( p  = .03) and somatic ( p  = .02) subscales of the PSAS, at post-intervention compared to the waitlist group.","[{'ForeName': 'Lucinda', 'Initials': 'L', 'LastName': 'Kennett', 'Affiliation': 'School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, 18 Innovation Walk, Clayton, Melbourne, VIC 3001 Australia.'}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Bei', 'Affiliation': 'School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, 18 Innovation Walk, Clayton, Melbourne, VIC 3001 Australia.'}, {'ForeName': 'Melinda L', 'Initials': 'ML', 'LastName': 'Jackson', 'Affiliation': 'School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, 18 Innovation Walk, Clayton, Melbourne, VIC 3001 Australia.'}]",Mindfulness,['10.1007/s12671-021-01714-5'] 2568,34377204,Efficacy of intravenous eptifibatide in primary percutaneous coronary intervention patients.,"Early and complete restoration of blood flow in closed coronary arteries is the main goal in treating patients with myocardial infarction. Primary angioplasty is not always successful in establishing myocardial blood flow. Although the strategy of adding eptifibatide leads to better blood flow, its value as part of a routine strategy is questionable. Therefore, this study was performed to evaluate the efficacy of intravenous eptifibatide in primary percutaneous coronary intervention (PCI) patients. This clinical, randomized, double-blind trial was performed on patients aged 20-80 years undergoing primary PCI. The patients were selected for study by convenience sampling and were randomly divided into two equal groups. The first group was treated with intravenous eptifibatide immediately before angioplasty with heparin. The second group received only coronary angioplasty with heparin. After data collection, statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software, version 16. A total of 104 patients were enrolled in the study, and there were no statistically significant differences in terms of age (P=0.188), gender (P=0.345), risk factor (P>0.05), or history of PCI (P=0.199). Mean thrombolysis in myocardial infarction (TIMI) score was not significant between the two groups after receiving the drug and performing angioplasty (P>0.05), and the rate of ejection fraction was 46.33±6.69 in patients receiving eptifibatide and 47.54±4.67 in the heparin group, which was not statistically significant (P=0.884). We found that eptifibatide improves clinical indexes in patients undergoing primary PCI, but these differences were not significant in the two groups.",2021,"Mean thrombolysis in myocardial infarction (TIMI) score was not significant between the two groups after receiving the drug and performing angioplasty (P>0.05), and the rate of ejection fraction was 46.33±6.69 in patients receiving eptifibatide and 47.54±4.67 in the heparin group, which was not statistically significant (P=0.884).","['patients with myocardial infarction', 'primary percutaneous coronary intervention (PCI) patients', 'patients aged 20-80 years undergoing primary PCI', 'patients undergoing primary PCI', 'primary percutaneous coronary intervention patients', '104 patients']","['intravenous eptifibatide', 'eptifibatide', 'heparin', 'Primary angioplasty', 'coronary angioplasty with heparin']","['Mean thrombolysis in myocardial infarction (TIMI) score', 'clinical indexes', 'blood flow', 'rate of ejection fraction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517527', 'cui_str': '104'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0253563', 'cui_str': 'eptifibatide'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty of blood vessel'}, {'cui': 'C0002997', 'cui_str': 'Angioplasty, Coronary Balloon'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]",104.0,0.0412559,"Mean thrombolysis in myocardial infarction (TIMI) score was not significant between the two groups after receiving the drug and performing angioplasty (P>0.05), and the rate of ejection fraction was 46.33±6.69 in patients receiving eptifibatide and 47.54±4.67 in the heparin group, which was not statistically significant (P=0.884).","[{'ForeName': 'Rozita', 'Initials': 'R', 'LastName': 'Jalalian', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Samad', 'Initials': 'S', 'LastName': 'Golshani', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Farsavian', 'Affiliation': 'Department of Vascular Surgery, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Vatani', 'Affiliation': 'Department of Cardiology, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Ali Asghar', 'Initials': 'AA', 'LastName': 'Farsavian', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}]",Journal of medicine and life,['10.25122/jml-2021-0035'] 2569,34378545,Use of Iris Scanning for Biometric Recognition of Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo: Mixed Methods Study.,"BACKGROUND A partnership between the University of Antwerp and the University of Kinshasa implemented the EBOVAC3 clinical trial with an Ebola vaccine regimen administered to health care provider participants in Tshuapa Province, Democratic Republic of the Congo. This randomized controlled trial was part of an Ebola outbreak preparedness initiative financed through Innovative Medicines Initiative-European Union. The EBOVAC3 clinical trial used iris scan technology to identify all health care provider participants enrolled in the vaccine trial, to ensure that the right participant received the right vaccine at the right visit. OBJECTIVE We aimed to assess the acceptability, accuracy, and feasibility of iris scan technology as an identification method within a population of health care provider participants in a vaccine trial in a remote setting. METHODS We used a mixed methods study. The acceptability was assessed prior to the trial through 12 focus group discussions (FGDs) and was assessed at enrollment. Feasibility and accuracy research was conducted using a longitudinal trial study design, where iris scanning was compared with the unique study ID card to identify health care provider participants at enrollment and at their follow-up visits. RESULTS During the FGDs, health care provider participants were mainly concerned about the iris scan technology causing physical problems to their eyes or exposing them to spiritual problems through sorcery. However, 99% (85/86; 95% CI 97.1-100.0) of health care provider participants in the FGDs agreed to be identified by the iris scan. Also, at enrollment, 99.0% (692/699; 95% CI 98.2-99.7) of health care provider participants accepted to be identified by iris scan. Iris scan technology correctly identified 93.1% (636/683; 95% CI 91.2-95.0) of the participants returning for scheduled follow-up visits. The iris scanning operation lasted 2 minutes or less for 96.0% (656/683; 95% CI 94.6-97.5), and 1 attempt was enough to identify the majority of study participants (475/683, 69.5%; 95% CI 66.1-73.0). CONCLUSIONS Iris scans are highly acceptable as an identification tool in a clinical trial for health care provider participants in a remote setting. Its operationalization during the trial demonstrated a high level of accuracy that can reliably identify individuals. Iris scanning is found to be feasible in clinical trials but requires a trained operator to reduce the duration and the number of attempts to identify a participant. TRIAL REGISTRATION ClinicalTrials.gov NCT04186000; https://clinicaltrials.gov/ct2/show/NCT04186000.",2021,"CONCLUSIONS Iris scans are highly acceptable as an identification tool in a clinical trial for health care provider participants in a remote setting.","['population of health care provider participants in a vaccine trial in a remote setting', 'A partnership between the University of Antwerp and the University of Kinshasa implemented the EBOVAC3 clinical trial with an Ebola vaccine regimen administered to health care provider participants in Tshuapa Province, Democratic Republic of the Congo', 'health care provider participants in a remote setting', 'health care provider participants enrolled in the vaccine trial', 'Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo', 'health care provider participants at enrollment and at their follow-up visits']","['iris scan technology', 'Iris Scanning']",[],"[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C1449556', 'cui_str': 'Ebolavirus Vaccines'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0043444', 'cui_str': 'Zaire'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0589121', 'cui_str': 'Follow-up visit'}]","[{'cui': 'C0022077', 'cui_str': 'Iris structure'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]",[],,0.453902,"CONCLUSIONS Iris scans are highly acceptable as an identification tool in a clinical trial for health care provider participants in a remote setting.","[{'ForeName': 'Trésor', 'Initials': 'T', 'LastName': 'Zola Matuvanga', 'Affiliation': 'Department of Tropical Medicine, University of Kinshasa, Kinshasa, the Democratic Republic of the Congo.'}, {'ForeName': 'Ginger', 'Initials': 'G', 'LastName': 'Johnson', 'Affiliation': 'Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.'}, {'ForeName': 'Ynke', 'Initials': 'Y', 'LastName': 'Larivière', 'Affiliation': 'Global Health Institute, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Esanga Longomo', 'Affiliation': 'Division Provinciale de la Santé de la Province de la Tshuapa, Boende, the Democratic Republic of the Congo.'}, {'ForeName': 'Junior', 'Initials': 'J', 'LastName': 'Matangila', 'Affiliation': 'Department of Tropical Medicine, University of Kinshasa, Kinshasa, the Democratic Republic of the Congo.'}, {'ForeName': 'Vivi', 'Initials': 'V', 'LastName': 'Maketa', 'Affiliation': 'Department of Tropical Medicine, University of Kinshasa, Kinshasa, the Democratic Republic of the Congo.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Lapika', 'Affiliation': 'Department of Anthropology, University of Kinshasa, Kinshasa, the Democratic Republic of the Congo.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Mitashi', 'Affiliation': 'Department of Tropical Medicine, University of Kinshasa, Kinshasa, the Democratic Republic of the Congo.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Mc Kenna', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Jessie', 'Initials': 'J', 'LastName': 'De Bie', 'Affiliation': 'Global Health Institute, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Van Geertruyden', 'Affiliation': 'Global Health Institute, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Van Damme', 'Affiliation': 'Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Hypolite', 'Initials': 'H', 'LastName': 'Muhindo Mavoko', 'Affiliation': 'Department of Tropical Medicine, University of Kinshasa, Kinshasa, the Democratic Republic of the Congo.'}]",Journal of medical Internet research,['10.2196/28573'] 2570,34378517,How I Do It: Temporarily Implanted Nitinol Device (iTind).,"Benign prostatic hyperplasia is a common and progressive disease affecting aging men which has a significant impact on quality of life. The second-generation Temporarily Implanted Nitinol Device (iTind) is an FDA approved temporary prostatic urethral device which can be deployed using standard flexible cystoscopy without sedation or general anesthesia. The device is left in-situ for 5 to 7 days and is then entirely removed in the office, using an open-ended silicone catheter. Prospective, randomized data indicate that iTind has favorable functional and sexual patient outcomes. Readers will familiarize themselves with iTind, significant historical studies and the technique for deploying iTind using a flexible cystoscope in the office setting.",2021,The second-generation Temporarily Implanted Nitinol Device (iTind) is an FDA approved temporary prostatic urethral device which can be deployed using standard flexible cystoscopy without sedation or general anesthesia.,[],['Temporarily Implanted Nitinol Device (iTind'],[],[],"[{'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0068790', 'cui_str': 'nitinol'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]",[],,0.0329302,The second-generation Temporarily Implanted Nitinol Device (iTind) is an FDA approved temporary prostatic urethral device which can be deployed using standard flexible cystoscopy without sedation or general anesthesia.,"[{'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Elterman', 'Affiliation': 'Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Zorn', 'Affiliation': ''}, {'ForeName': 'Naeem', 'Initials': 'N', 'LastName': 'Bhojani', 'Affiliation': ''}, {'ForeName': 'Bilal', 'Initials': 'B', 'LastName': 'Chughtai', 'Affiliation': ''}]",The Canadian journal of urology,[] 2571,34378511,The value of a comprehensive primary outcome - results of a negative randomized control trial in the non-muscle invasive bladder cancer population.,"INTRODUCTION American Urological Association (AUA) guidelines recommend intravesical chemotherapy to be given following transurethral resection of a bladder tumor. Prior studies have shown the benefit of mitomycin as well as gemcitabine. However, no study has compared the two agents. MATERIALS AND METHODS The study was designed as an open label 1:1:1 randomized controlled trial, comparing intravesical mitomycin, gemcitabine and saline as a single intraoperative instillation immediately following transurethral resection of suspected bladder tumor. Primary endpoint was any grade ≥ 3 events according to NCI CTCAE Version 4.03, this captures any return trip to the operating room for recurrence of cancer or other event (benign bladder/urethra). Secondary endpoints were progression free survival for urothelial cell carcinoma and adverse events. RESULTS A total of 82 patients were enrolled and randomized, unfortunately the trial was suspended early due to protocol deviations. In an intention to treat analysis, freedom from grade > 3 events at 2 years was 74.8% in the no treatment arm, 51.0% in the mitomycin arm, and 56.0% in the gemcitabine arm (p = 0.81). Freedom from cancer recurrence for all patients was 62.3%. In the no treatment arm, it was 78.8%, and 50.7% and 63.6% in the mitomycin arm and gemcitabine arm respectively. (p = 0.28). In a univariate analysis, the only patient variable significantly associated with the primary outcome was pathologic T stage (p < 0.002). CONCLUSION This study provides an example of a novel, patient centered primary outcome with the goal of determining which treatment paradigms provide the greatest oncologic and clinic benefit.",2021,"In an intention to treat analysis, freedom from grade > 3 events at 2 years was 74.8% in the no treatment arm, 51.0% in the mitomycin arm, and 56.0% in the gemcitabine arm (p = 0.81).","['non-muscle invasive bladder cancer population', 'A total of 82 patients', 'transurethral resection of suspected bladder tumor']","['intravesical mitomycin, gemcitabine and saline', 'mitomycin', 'gemcitabine']","['grade ≥ 3 events according to NCI CTCAE Version 4.03, this captures any return trip to the operating room for recurrence of cancer or other event (benign bladder/urethra', 'progression free survival for urothelial cell carcinoma and adverse events', 'cancer recurrence', 'pathologic T stage']","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0005695', 'cui_str': 'Neoplasm of bladder'}]","[{'cui': 'C0442124', 'cui_str': 'Intravesical approach'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0560007', 'cui_str': 'nCi'}, {'cui': 'C1516728', 'cui_str': 'National Cancer Institute common terminology criteria for adverse events'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0077275', 'cui_str': 'Triptorelin'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C0041967', 'cui_str': 'Urethral'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0227599', 'cui_str': 'Urinary tract transitional epithelial cell'}, {'cui': 'C0007097', 'cui_str': 'Carcinoma'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0475455', 'cui_str': 'T - Tumor stage'}]",82.0,0.351588,"In an intention to treat analysis, freedom from grade > 3 events at 2 years was 74.8% in the no treatment arm, 51.0% in the mitomycin arm, and 56.0% in the gemcitabine arm (p = 0.81).","[{'ForeName': 'Cory A', 'Initials': 'CA', 'LastName': 'Taylor', 'Affiliation': 'Michigan State University College of Human Medicine, East Lansing, Michigan, USA.'}, {'ForeName': 'Conrad M', 'Initials': 'CM', 'LastName': 'Tobert', 'Affiliation': ''}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Kahnoski', 'Affiliation': ''}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Humphrey', 'Affiliation': ''}, {'ForeName': 'Brian R', 'Initials': 'BR', 'LastName': 'Lane', 'Affiliation': ''}]",The Canadian journal of urology,[] 2572,34378330,Sing4Health: Randomised controlled trial of the effects of a singing group program on the subjective and social well-being of older adults.,"Group singing may be an optimal intervention strategy to promote active ageing and well-being; however, evidence with experimental validity is scarce. This study aims to fill this gap by analysing the effects of a 34-session singing group programme (SGP) on participants' subjective and social well-being and the mediating roles of social identification with the singing group and of self-esteem. An RCT with intervention (n = 89) and active waiting-list control (n = 60) conditions was conducted, and a mixed method quantitative and qualitative data collection and analysis were performed. Participants were mostly elderly day-care centre users (M = 76.66 years old; SD = 8.79) with low average levels of education and income. Structured measures of life satisfaction, positive and negative affect, self-esteem, loneliness, social identification and social well-being were collected, as well as interviews on the perceived benefits of participating in the SGP. Results showed significant effects of the SGP on the positive affect, social well-being and marginally on the self-esteem of the participants. The observed effects were sustained at the follow-up. Qualitative analysis corroborated the quantitative results. Mediation analysis showed indirect effects of social identification with the singing group on loneliness and social identification with the social care institution group; and of self-esteem on positive and negative affect.",2021,Mediation analysis showed indirect effects of social identification with the singing group on loneliness and social identification with the social care institution group; and of self-esteem on positive and negative affect.,"['Participants were mostly elderly day-care centre users (M\u2009=\u200976.66\u2009years old; SD\u2009=\u20098.79) with low average levels of education and income', 'Sing4Health', 'older adults']","['34-session singing group programme (SGP', 'singing group program', 'active waiting-list control (n\u2009']","['loneliness and social identification', 'life satisfaction, positive and negative affect, self-esteem, loneliness, social identification and social well-being']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0175952', 'cui_str': 'Day care center'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0021162', 'cui_str': 'Income'}]","[{'cui': 'C0234857', 'cui_str': 'Singing'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0023974', 'cui_str': 'Feeling lonely'}, {'cui': 'C0037417', 'cui_str': 'Identification, Social'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",,0.0176237,Mediation analysis showed indirect effects of social identification with the singing group on loneliness and social identification with the social care institution group; and of self-esteem on positive and negative affect.,"[{'ForeName': 'Iolanda Costa', 'Initials': 'IC', 'LastName': 'Galinha', 'Affiliation': 'Psychology Department, Universidade Autónoma de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Miguel Ángel', 'Initials': 'MÁ', 'LastName': 'García-Martín', 'Affiliation': 'Universidad de Málaga, Departamento de Psicología Social, Trabajo Social, Antropología Social y Estudios de Asia Oriental, Málaga, Spain.'}, {'ForeName': 'Maria Luísa', 'Initials': 'ML', 'LastName': 'Lima', 'Affiliation': 'ISCTE CIS IUL, Dept of Social and Organizational Psychology, Lisbon, Portugal.'}]",Applied psychology. Health and well-being,['10.1111/aphw.12297'] 2573,34378320,Effects of mobile mindfulness on emergency department work stress: A randomised controlled trial.,"OBJECTIVE High-occupational stress among ED staff has a detrimental impact on both staff wellness and patient care. The objective of the study is to determine whether 4 weeks of smartphone app-guided mindfulness practice reduces stress levels of ED staff. METHODS This two-arm randomised controlled trial was conducted in two Australian EDs in 2019-2020. Eligible participants were randomly assigned (1:1) to either an App group or a Wait to Treat group to practice daily 10 min app-guided mindfulness for 4 weeks. Online surveys were collected for both groups at three time periods: before (T1), immediately after (T2) and 3 months after cessation (T3). Then the Wait to Treat group received the same intervention, followed by surveys immediately after the intervention (T4) and 3 months later (T5). Primary outcome was measured using the Perceived Stress Scale. Secondary outcomes were measured using the Maslach Burnout Inventory (three subscales: emotional exhaustion, depersonalisation and personal accomplishment), Mindfulness Attention Awareness Scale and Warwick-Edinburgh Mental Well-being Scale. Both intention-to-treat and per-protocol analysis were performed. Repeated measurement data were analysed by the linear mixed model. RESULTS Of 148 enrolled participants 98 completed all the surveys, but only half (48%) reported continuous use of the app. Based on the results of the intention-to-treat analysis, there was a statistically significant improvement of perceived stress levels (F = 15.70, P < 0.001), all three components of burnout (emotional exhaustion [F = 14.22, P < 0.001], depersonalisation [F = 3.62, P = 0.030], personal accomplishment [F = 7.51, P < 0.001]), mindfulness (F = 8.83, P < 0.001) and wellbeing levels (F = 10.71, P < 0.001) from pre-intervention to 3 months later with small effect sizes. CONCLUSION Results of the present study demonstrate that brief mindfulness training via innovative digital technology had a small positive effect in improving emergency staff stress, burnout, mindfulness and wellbeing.",2021,"Based on the results of the intention-to-treat analysis, there was a statistically significant improvement of perceived stress levels (F = 15.70, P < 0.001), all three components of burnout (emotional exhaustion [F = 14.22, P < 0.001], depersonalisation [F = 3.62, P = 0.030], personal accomplishment [F = 7.51, P < 0.001]), mindfulness (F = 8.83, P < 0.001) and wellbeing levels (F = 10.71, P < 0.001) from pre-intervention to 3 months later with small effect sizes. ","['Eligible participants', 'emergency department work stress', 'Of 148 enrolled participants 98 completed all the surveys, but only half (48%) reported continuous use of the app', 'two Australian EDs in 2019-2020']","['smartphone app-guided mindfulness practice', 'mobile mindfulness', 'App group or a Wait to Treat group to practice daily 10\xa0min app-guided mindfulness for 4\u2009weeks']","['Perceived Stress Scale', 'Maslach Burnout Inventory (three subscales: emotional exhaustion, depersonalisation and personal accomplishment), Mindfulness Attention Awareness Scale and Warwick-Edinburgh Mental Well-being Scale', 'emergency staff stress, burnout, mindfulness and wellbeing', 'personal accomplishment', 'perceived stress levels', 'wellbeing levels']","[{'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0814090', 'cui_str': 'Job-related Stress'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0011551', 'cui_str': 'Depersonalization'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4273514', 'cui_str': 'Warwick Edinburgh Mental Well Being Scale'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",148.0,0.232836,"Based on the results of the intention-to-treat analysis, there was a statistically significant improvement of perceived stress levels (F = 15.70, P < 0.001), all three components of burnout (emotional exhaustion [F = 14.22, P < 0.001], depersonalisation [F = 3.62, P = 0.030], personal accomplishment [F = 7.51, P < 0.001]), mindfulness (F = 8.83, P < 0.001) and wellbeing levels (F = 10.71, P < 0.001) from pre-intervention to 3 months later with small effect sizes. ","[{'ForeName': 'Hui Grace', 'Initials': 'HG', 'LastName': 'Xu', 'Affiliation': 'School of Nursing, Midwifery and Social Work, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Eley', 'Affiliation': 'Emergency Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Kynoch', 'Affiliation': 'Clinical Governance Unit and the Queensland Centre for Evidence Based Nursing and Midwifery: a Joanna Briggs Institute Centre of Excellence, Mater Health, Brisbane, Queensland, Australia.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Tuckett', 'Affiliation': 'School of Nursing, Midwifery and Social Work, The University of Queensland, Brisbane, Queensland, Australia.'}]",Emergency medicine Australasia : EMA,['10.1111/1742-6723.13836'] 2574,34378307,Pharmacokinetic and Pharmacodynamic Bioequivalence between regular human insulin [rDNA origin] in 0.9% sodium chloride ready-to-use infusion 1U/mL and in 100U/mL concentrate diluted to 1U/mL in Healthy Males.,"AIMS To demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence between MYXREDLIN, a novel ready-to-use regular human insulin 1U/mL formulation (BAX-HI), and NOVOLIN R 100U/mL concentrate diluted to 1U/mL (NOVO-HI). MATERIALS AND METHODS This phase 1, double-blind, randomized, two-way crossover study compared the PK and PD properties of BAX-HI (ready-to-use regular human insulin, 1 U/mL) and NOVO-HI (NOVOLIN R 100U/mL concentrate diluted to 1 U/mL). A total of 58 healthy males received 0.36 U/kg of each study drug, administered intravenously over a 6-hour period, concurrent with an 8-hour euglycemic clamp at two treatment periods separated by a washout period of 7-10 days. The primary PK endpoint was the area under the insulin concentration-time curve at steady state (SS) measured from 300-360 minutes (AUC INS-SS 300-360 min ). The primary PD endpoint was the area under the glucose infusion rate-time curve at SS measured from 300-360 minutes (AUC GIR-SS 300-360 min ). RESULTS All subjects completed the first treatment period and 54 subjects completed both treatment periods. Bioequivalence between BAX-HI and NOVO-HI was demonstrated for the primary endpoints as the 90% confidence interval (CI) of the geometric least-squares (LS) mean ratio for AUC INS-SS 300-360 min and the 90% CI and 95% CI of the geometric LS mean ratio for AUC GIR-SS 300-360 min were entirely contained within the prespecified limits of 80-125%. Safety profiles were comparable for both study drugs and there were no serious adverse events. CONCLUSIONS The study demonstrated bioequivalence between BAX-HI and NOVO-HI in terms of PK and PD characteristics in healthy males. This article is protected by copyright. All rights reserved.",2021,Bioequivalence between BAX-HI and NOVO-HI was demonstrated for the primary endpoints as the 90% confidence interval (CI) of the geometric least-squares (LS) mean ratio for AUC INS-SS 300-360 min and the 90% CI and 95% CI of the geometric LS mean ratio for AUC GIR-SS 300-360 min were entirely contained within the prespecified limits of 80-125%.,"['Healthy Males', 'healthy males', '58 healthy males']",['regular human insulin [rDNA origin'],"['area under the insulin concentration-time curve at steady state (SS', 'pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence', 'Pharmacokinetic and Pharmacodynamic Bioequivalence', 'BAX-HI and NOVO-HI', 'Safety profiles', 'area under the glucose infusion rate-time curve at SS']","[{'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0795635', 'cui_str': 'Regular Insulin, Human'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C0439659', 'cui_str': 'Origins'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0039789', 'cui_str': 'Equivalencies, Therapeutic'}, {'cui': 'C0219474', 'cui_str': 'Bax Protein'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]",58.0,0.215275,Bioequivalence between BAX-HI and NOVO-HI was demonstrated for the primary endpoints as the 90% confidence interval (CI) of the geometric least-squares (LS) mean ratio for AUC INS-SS 300-360 min and the 90% CI and 95% CI of the geometric LS mean ratio for AUC GIR-SS 300-360 min were entirely contained within the prespecified limits of 80-125%.,"[{'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Hompesch', 'Affiliation': 'ProSciento, Inc. Chula Vista, California.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Hawryluk', 'Affiliation': 'Baxter Healthcare Corporation, Worldwide Medical, Warsaw, Poland.'}, {'ForeName': 'Moises', 'Initials': 'M', 'LastName': 'Hernandez', 'Affiliation': 'ProSciento, Inc. Chula Vista, California.'}, {'ForeName': 'Beena', 'Initials': 'B', 'LastName': 'Uchil', 'Affiliation': 'Celerity Pharmaceuticals, LLC, Rosemont, Illinois.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Wilmington', 'Affiliation': 'Baxter Healthcare Corporation, Worldwide Medical, Deerfield, Illinois.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Peterson', 'Affiliation': 'Baxter Healthcare Corporation, Worldwide Medical, Deerfield, Illinois.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14520'] 2575,34378304,"Reply to the comments on ""Effectiveness of a video-based advance care planning intervention in hospitalized elderly patients: A randomized controlled trial"".",,2021,,['hospitalized elderly patients'],['video-based advance care planning intervention'],[],"[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.100014,,"[{'ForeName': 'Li-Hwa', 'Initials': 'LH', 'LastName': 'Lin', 'Affiliation': 'Department of Nursing, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Hui-Chuan', 'Initials': 'HC', 'LastName': 'Cheng', 'Affiliation': 'Department of Nursing, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Yu-Chih', 'Initials': 'YC', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Li-Yin', 'Initials': 'LY', 'LastName': 'Chien', 'Affiliation': 'Institute of Community Health Care, College of Nursing, National Yang Ming Chiao Tung University, Taipei, Taiwan.'}]",Geriatrics & gerontology international,['10.1111/ggi.14257'] 2576,34378238,Effect and safety evaluation of tacrolimus and tripterygium glycosides combined therapy in treatment of Henoch-Schönlein purpura nephritis.,"OBJECTIVE Henoch-Schönlein purpura nephritis has become a significant threat to children's health. Traditional combined therapy of glucocorticoids and cyclophosphamide leads to severe toxicity and complications. Therefore, identifying a feasible and effective strategy with low side-effects for the treatment of Henoch-Schönlein purpura nephritis is of great significance. METHODS A randomized, controlled trial was carried out. A total of 279 children with Henoch-Schönlein purpura nephritis were recruited and randomly divided into three groups: control group (receiving the current standard therapy), TA group (receiving tacrolimus) and TA + tripterygium glycosides group (receiving tacrolimus + tripterygium treatment). The total duration of the trial was 6 months, and the duration of follow-up observation was 9 months. RESULTS Various therapies showed similar therapeutic effects in the third and sixth months. The relief of Henoch-Schönlein purpura nephritis symptoms caused by TA + tripterygium glycosides was slower than the TA and control groups. The incidence of adverse reactions in the TA + tripterygium glycosides group was lower in the control and TA groups. The final treatment effect of the experimental groups was better than the control group. The recurrence rate in the TA + tripterygium glycosides group was also significantly lower. CONCLUSION Tacrolimus and tripterygium glycosides combined therapy had better effects and safety for long-term treatment of Henoch-Schönlein purpura nephritis.",2021,The incidence of adverse reactions in the TA + tripterygium glycosides group was lower in the control and TA groups.,"['Henoch-Schönlein purpura nephritis', '279 children with Henoch-Schönlein purpura nephritis']","['tacrolimus and tripterygium glycosides combined therapy', 'glucocorticoids and cyclophosphamide', 'Tacrolimus', 'control group (receiving the current standard therapy), TA group (receiving tacrolimus) and TA\xa0+\xa0tripterygium glycosides group (receiving tacrolimus\xa0+\xa0tripterygium treatment']","['recurrence rate', 'severe toxicity and complications', 'incidence of adverse reactions']","[{'cui': 'C2721603', 'cui_str': 'Henoch-Schonlein purpura nephritis'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0969732', 'cui_str': 'Tripterygium'}, {'cui': 'C0007158', 'cui_str': 'Glycoside'}, {'cui': 'C0033972', 'cui_str': 'Combined therapy'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",279.0,0.0209094,The incidence of adverse reactions in the TA + tripterygium glycosides group was lower in the control and TA groups.,"[{'ForeName': 'Huiwu', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Pediatrics, Cangzhou Central Hospital, Cangzhou, Hebei, China.'}, {'ForeName': 'Xiuli', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Nephrology, Cangzhou Central Hospital, Cangzhou, Hebei, China.'}, {'ForeName': 'Haiping', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Department of Nephrology, Cangzhou Central Hospital, Cangzhou, Hebei, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Ran', 'Affiliation': 'Department of Nephrology, Baoding First Central Hospital, Cangzhou, Hebei, China.'}, {'ForeName': 'Guoxia', 'Initials': 'G', 'LastName': 'Zhao', 'Affiliation': 'Department of Neonatology, Cangzhou Central Hospital, Cangzhou, Hebei, China.'}]",International journal of urology : official journal of the Japanese Urological Association,['10.1111/iju.14665'] 2577,34378200,Transcranial direct current stimulation reduces ischemia-induced sensory disturbance in the hands of healthy subjects.,"INTRODUCTION/AIMS The treatment of entrapment neuropathies such as carpal tunnel syndrome or cubital tunnel syndrome has significant challenges that have yet to be solved. To a large extent, the success of the treatment of peripheral nerve damage is dependent on brain plasticity during the recovery process. Recently, non-invasive brain stimulation procedures such as transcranial direct current stimulation (tDCS) to modulate brain activity have been developed. This study aimed to investigate whether tDCS can improve artificially induced ischemic sensory disturbances in the finger. METHODS Ten right-handed healthy volunteers with an average age of 25.5 years participated in this study. A rubber bandage at the base of the right index finger was used to induce a regional sensory disturbance for 30 min. An anodal tDCS was applied over their left M1 area 15 minutes into the session. The current perception threshold (CPT) in the index and little finger pad was evaluated using the PainVision™ and used as a measure of the sensory threshold. RESULTS In the index finger, the CPT increased significantly with time, a finding that was absent after tDCS application. DISCUSSION It has been reported that anodal tDCS over M1 primarily modulates the functional connectivity of sensory networks, and this study demonstrated that it improved ischemia-induced sensory disturbances. Modulating the central nervous system using tDCS represents a potential avenue for treating entrapment neuropathies.",2021,"To a large extent, the success of the treatment of peripheral nerve damage is dependent on brain plasticity during the recovery process.","['Ten right-handed healthy volunteers with an average age of 25.5\u2009years participated in this study', 'hands of healthy subjects']","['anodal tDCS', 'transcranial direct current stimulation (tDCS', 'tDCS', 'Transcranial direct current stimulation']",['ischemic sensory disturbances'],"[{'cui': 'C0230370', 'cui_str': 'Structure of right hand'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517663', 'cui_str': '25.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0018563', 'cui_str': 'Hand'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0152027', 'cui_str': 'Sensory disorder'}]",,0.0194903,"To a large extent, the success of the treatment of peripheral nerve damage is dependent on brain plasticity during the recovery process.","[{'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Sunagawa', 'Affiliation': 'Laboratory of Analysis and Control of Upper Extremity Function, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Akio', 'Initials': 'A', 'LastName': 'Ueda', 'Affiliation': 'Laboratory of Analysis and Control of Upper Extremity Function, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Kurumadani', 'Affiliation': 'Laboratory of Analysis and Control of Upper Extremity Function, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Hanan Ibrahim', 'Initials': 'HI', 'LastName': 'Zehry', 'Affiliation': 'Laboratory of Analysis and Control of Upper Extremity Function, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Shota', 'Initials': 'S', 'LastName': 'Date', 'Affiliation': 'Laboratory of Analysis and Control of Upper Extremity Function, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Ishii', 'Affiliation': 'Laboratory of Analysis and Control of Upper Extremity Function, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}]",Muscle & nerve,['10.1002/mus.27394'] 2578,34378161,Evaluation of a Safe Sleep Training for Home Visitors and Their Clients.,"Sleep-related deaths are a common preventable cause of death, and such deaths occur disproportionately in families of color. Home visitors provide families with education about infant safe sleep guidelines; however, families face many barriers to engaging in safe sleep practices. This study evaluated the efficacy of a program to train home visitors to talk to clients about infant safe sleep using Motivational Interviewing and cultural sensitivity. We examined the effects of the intervention on home visitors' (n = 23) knowledge, MI skill use, and cultural sensitivity using a single group pre-post design. We also examined home visiting clients' (n = 78) knowledge, attitudes, and behaviors using a quasi-experimental design. Home visitors were primarily female (97%), had a college degree (86%), and were primarily white (50%) or African American (43%). The home visiting clients were all female and were primarily African American (43%) and Caucasian (36%). Most clients (59%) earned less than 30,000 dollars per year. Home visitors showed significant improvement in MI skill use and cultural sensitivity from pre- to post-test. Regarding client outcomes, our results indicate a significant group by time interaction when predicting changes in client knowledge such that the treatment group showed larger gains than the control group. There were no significant differences between groups when predicting changes in client attitudes or behavior. MI may be an effective technique for home visitors to help increase families' safe sleep knowledge. Additional research is needed to examine whether such training can translate to changes in families' safe sleep behavior.",2021,This study evaluated the efficacy of a program to train home visitors to talk to clients about infant safe sleep using Motivational Interviewing and cultural sensitivity.,"['home visiting clients were all female and were primarily African American (43%) and Caucasian (36', 'Home visitors were primarily female (97%), had a college degree (86%), and were primarily white (50%) or African American (43', 'Home Visitors and Their Clients', ""home visiting clients' (n\u2009=\u200978) knowledge, attitudes, and behaviors using a quasi-experimental design"", 'Home visitors provide families with education about infant safe sleep guidelines']",['Safe Sleep Training'],"[""home visitors' (n\u2009=\u200923) knowledge, MI skill use, and cultural sensitivity"", 'MI skill use and cultural sensitivity', 'client attitudes or behavior']","[{'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.00578912,This study evaluated the efficacy of a program to train home visitors to talk to clients about infant safe sleep using Motivational Interviewing and cultural sensitivity.,"[{'ForeName': 'Summer', 'Initials': 'S', 'LastName': 'Chahin', 'Affiliation': 'Western Michigan University, Kalamazoo, USA. summer.s.chahin@wmich.edu.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Damashek', 'Affiliation': 'Western Michigan University, Kalamazoo, USA.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Ospina', 'Affiliation': 'Western Michigan University, Kalamazoo, USA.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Dickson', 'Affiliation': 'Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, USA.'}]",Journal of clinical psychology in medical settings,['10.1007/s10880-021-09811-2'] 2579,34378159,Effects of remote ischemic postconditioning on HIF-1α and other markers in on-pump cardiac surgery.,"BACKGROUND There is a lack of data about the effects of remote ischemic postconditioning (RIPostC) on hypoxia-inducible factor-1α (HIF-1α) plasma levels after on-pump cardiac surgery (OPCS). This study aimed to measure the effects of RIPostC on postoperative HIF-1α plasma levels, cardiac markers and arterial oxygenation in patients undergoing OPCS. METHODS This single-centre randomized, double blind, controlled trial, enrolled 70 patients (35 control and 35 RIPostC). RIPostC was performed by 3 cycles (5 min of ischemia followed by 5 min of reperfusion) administered in upper arm immediately after the pump period. The primary outcome was to measure HIF-1α plasma levels: before surgery (T0), and 2 h (T1), 8 h (T2), 24 h (T3), 36 h (T4) and 48 h (T5) after RIPostC. As secondary endpoint, Troponin T, CK-MB, CPK plasma levels and PaO 2 /FiO 2 ratio were measured. RESULTS HIF-1α plasma levels were increased at T1-T3 compared to T0 in both groups (P < 0.001). In the RIPostC group HIF-1α increased compared to the control group: differences between means (95% CI) were 0.034 (0.006-0.06) P = 0.019 at T1; 0.041 (0.013-0.069) P = 0.005 at T2; and 0.021 (0.001-0.042) P = 0.045 at T3. PaO 2 /FiO 2 was higher in the RIPostC group than in the control group: at T3, T4 and T5. Moreover, Troponin T, CK-MB and CPK values decreased in the RIPostC group compared to the control group. CONCLUSIONS HIF-1α plasma levels increased in control patients during for at least 36 h after OPCS. RIPostC resulted in even higher HIF-1α levels during at least the first 24 h and improved arterial oxygenation and cardiac markers.",2021,"Moreover, Troponin T, CK-MB and CPK values decreased in the RIPostC group compared to the control group. ","['patients undergoing OPCS', 'enrolled 70 patients (35 control and 35 RIPostC']","['remote ischemic postconditioning', 'remote ischemic postconditioning (RIPostC', 'RIPostC']","['HIF-1α plasma levels', 'PaO 2 /FiO 2', 'HIF-1α levels', 'Troponin T, CK-MB, CPK plasma levels and PaO 2 /FiO 2 ratio', 'hypoxia-inducible factor-1α (HIF-1α) plasma levels', 'postoperative HIF-1α plasma levels, cardiac markers and arterial oxygenation', 'Troponin T, CK-MB and CPK values', 'arterial oxygenation and cardiac markers', 'HIF-1α plasma levels: before surgery (T0), and 2\xa0h (T1), 8\xa0h (T2), 24\xa0h (T3), 36\xa0h (T4) and 48\xa0h (T5) after RIPostC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C2936234', 'cui_str': 'Ischemic Post-Conditioning'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C2936234', 'cui_str': 'Ischemic Post-Conditioning'}]","[{'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C0077404', 'cui_str': 'Troponin T'}, {'cui': 'C0010290', 'cui_str': 'Creatine kinase isoenzyme, MB fraction'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1271630', 'cui_str': 'Cardiac markers'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C2936234', 'cui_str': 'Ischemic Post-Conditioning'}]",70.0,0.434038,"Moreover, Troponin T, CK-MB and CPK values decreased in the RIPostC group compared to the control group. ","[{'ForeName': 'José', 'Initials': 'J', 'LastName': 'García-de-la-Asunción', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Hospital Clínico Universitario, Instituto de Investigación Sanitaria-INCLIVA, Valencia, Spain. josegarciadelaasuncion@gmail.com.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Moreno', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Hospital Clínico Universitario, Instituto de Investigación Sanitaria-INCLIVA, Valencia, Spain.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Duca', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Hospital Clínico Universitario, Instituto de Investigación Sanitaria-INCLIVA, Valencia, Spain.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'García-Del-Olmo', 'Affiliation': 'Department of General Surgery, Hospital Lluís Alcanyís, Xàtiva, Spain.'}, {'ForeName': 'Jaume', 'Initials': 'J', 'LastName': 'Perez-Griera', 'Affiliation': 'Laboratory of Biochemistry, Hospital Clínico Universitario, Instituto de Investigación Sanitaria-INCLIVA, Valencia, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Belda', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Hospital Clínico Universitario, Instituto de Investigación Sanitaria-INCLIVA, Valencia, Spain.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Soro', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Hospital Clínico Universitario, Instituto de Investigación Sanitaria-INCLIVA, Valencia, Spain.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'García-Del-Olmo', 'Affiliation': 'Department of Thoracic Surgery, Consorcio Hospital General Universitario, Valencia, Spain.'}]",General thoracic and cardiovascular surgery,['10.1007/s11748-021-01690-6'] 2580,34377989,Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.,"Background Evidence from single and multicenter phase II trials have suggested diffusion MRI is a predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF therapy. The current study confirms these findings in a large, randomized phase III clinical trial. Methods Patients with rGBM were enrolled in a phase III randomized (1:1), controlled trial (NCT02511405) to compare the efficacy and safety of bevacizumab (BV) versus BV in combination with ofranergene obadenovec (BV+VB-111), an anti-cancer viral therapy. In 170 patients with diffusion MRI available, pretreatment enhancing tumor volume and ADC histogram analysis were used to phenotype patients as having high (>1.24 µm 2 /ms) or low (<1.24 µm 2 /ms) ADC L , the mean value of the lower peak of the ADC histogram, within the contrast enhancing tumor. Results Baseline tumor volume ( P = .3460) and ADC L ( P = .2143) did not differ between treatment arms. Univariate analysis showed patients with high ADC L had a significant survival advantage in all patients ( P = .0006), as well as BV ( P = .0159) and BV+VB-111 individually ( P = .0262). Multivariable Cox regression accounting for treatment arm, age, baseline tumor volume, and ADC L identified continuous measures of tumor volume ( P < .0001; HR = 1.0212) and ADC L phenotypes ( P = .0012; HR = 0.5574) as independent predictors of OS. Conclusion Baseline diffusion MRI and tumor volume are independent imaging biomarkers of OS in rGBM treated with BV or BV+VB-111.",2021,"Univariate analysis showed patients with high ADC L had a significant survival advantage in all patients ( P = .0006), as well as BV ( P = .0159) and BV+VB-111 individually ( P = .0262).","['Methods\n\n\nPatients with rGBM', '170 patients with diffusion MRI', 'recurrent glioblastoma']","['bevacizumab (BV) versus BV in combination with ofranergene obadenovec (BV+VB-111), an anti-cancer viral therapy', 'bevacizumab']",['survival advantage'],"[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0017636', 'cui_str': 'Glioblastoma'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C1136216', 'cui_str': 'Magnetic Resonance Imaging, Diffusion'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1563738', 'cui_str': 'Virotherapy, Oncolytic'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}]",170.0,0.0756024,"Univariate analysis showed patients with high ADC L had a significant survival advantage in all patients ( P = .0006), as well as BV ( P = .0159) and BV+VB-111 individually ( P = .0262).","[{'ForeName': 'Benjamin M', 'Initials': 'BM', 'LastName': 'Ellingson', 'Affiliation': 'UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Kunal', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': 'UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Chencai', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Catalina', 'Initials': 'C', 'LastName': 'Raymond', 'Affiliation': 'UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Brenner', 'Affiliation': 'University of Texas Health San Antonio Cancer Center, San Antonio, Texas, USA.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'de Groot', 'Affiliation': 'Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Butowski', 'Affiliation': 'Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Leor', 'Initials': 'L', 'LastName': 'Zach', 'Affiliation': 'Oncology Institute, Chaim Sheba Medical Center, Tel HaShomer, Israel.'}, {'ForeName': 'Jian L', 'Initials': 'JL', 'LastName': 'Campian', 'Affiliation': 'Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Schlossman', 'Affiliation': 'UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Rizvi', 'Affiliation': 'UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Yael C', 'Initials': 'YC', 'LastName': 'Cohen', 'Affiliation': ""VBL Therapeutics, Modi'in, Israel.""}, {'ForeName': 'Noa', 'Initials': 'N', 'LastName': 'Lowenton-Spier', 'Affiliation': ""VBL Therapeutics, Modi'in, Israel.""}, {'ForeName': 'Tamar Rachmilewitz', 'Initials': 'TR', 'LastName': 'Minei', 'Affiliation': ""VBL Therapeutics, Modi'in, Israel.""}, {'ForeName': 'Shifra Fain', 'Initials': 'SF', 'LastName': 'Shmueli', 'Affiliation': ""VBL Therapeutics, Modi'in, Israel.""}, {'ForeName': 'Patrick Y', 'Initials': 'PY', 'LastName': 'Wen', 'Affiliation': 'Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.'}, {'ForeName': 'Timothy F', 'Initials': 'TF', 'LastName': 'Cloughesy', 'Affiliation': 'UCLA Neuro Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.'}]",Neuro-oncology advances,['10.1093/noajnl/vdab082'] 2581,34377985,A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.,"Background The dismal prognosis of glioblastoma (GBM) may be related to the ability of GBM cells to develop mechanisms of treatment resistance. We designed a protocol called Coordinated Undermining of Survival Paths combining 9 repurposed non-oncological drugs with metronomic temozolomide-version 3-(CUSP9v3) to address this issue. The aim of this phase Ib/IIa trial was to assess the safety of CUSP9v3. Methods Ten adults with histologically confirmed GBM and recurrent or progressive disease were included. Treatment consisted of aprepitant, auranofin, celecoxib, captopril, disulfiram, itraconazole, minocycline, ritonavir, and sertraline added to metronomic low-dose temozolomide. Treatment was continued until toxicity or progression. Primary endpoint was dose-limiting toxicity defined as either any unmanageable grade 3-4 toxicity or inability to receive at least 7 of the 10 drugs at ≥ 50% of the per-protocol doses at the end of the second treatment cycle. Results One patient was not evaluable for the primary endpoint (safety). All 9 evaluable patients met the primary endpoint. Ritonavir, temozolomide, captopril, and itraconazole were the drugs most frequently requiring dose modification or pausing. The most common adverse events were nausea, headache, fatigue, diarrhea, and ataxia. Progression-free survival at 12 months was 50%. Conclusions CUSP9v3 can be safely administered in patients with recurrent GBM under careful monitoring. A randomized phase II trial is in preparation to assess the efficacy of the CUSP9v3 regimen in GBM.",2021,"Ritonavir, temozolomide, captopril, and itraconazole were the drugs most frequently requiring dose modification or pausing.","['Methods\n\n\nTen adults with histologically confirmed GBM and recurrent or progressive disease were included', 'patients with recurrent GBM under careful monitoring']","['temozolomide', 'CUSP9v3', 'aprepitant, auranofin, celecoxib, captopril, disulfiram, itraconazole, minocycline, ritonavir, and sertraline added to metronomic low-dose temozolomide', 'Ritonavir, temozolomide, captopril, and itraconazole', 'protocol called Coordinated Undermining of Survival Paths combining 9 repurposed non-oncological drugs with metronomic temozolomide-version 3-(CUSP9v3']","['dose-limiting toxicity defined as either any unmanageable grade 3-4 toxicity or inability to receive', 'nausea, headache, fatigue, diarrhea, and ataxia', 'Progression-free survival']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0017636', 'cui_str': 'Glioblastoma'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]","[{'cui': 'C0076080', 'cui_str': 'temozolomide'}, {'cui': 'C1176306', 'cui_str': 'aprepitant'}, {'cui': 'C0004320', 'cui_str': 'Auranofin'}, {'cui': 'C0538927', 'cui_str': 'celecoxib'}, {'cui': 'C0006938', 'cui_str': 'Captopril'}, {'cui': 'C0012772', 'cui_str': 'Disulfiram'}, {'cui': 'C0064113', 'cui_str': 'Itraconazole'}, {'cui': 'C0026187', 'cui_str': 'Minocycline'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C2607870', 'cui_str': 'Version'}]","[{'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0004134', 'cui_str': 'Ataxia'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",10.0,0.195199,"Ritonavir, temozolomide, captopril, and itraconazole were the drugs most frequently requiring dose modification or pausing.","[{'ForeName': 'Marc-Eric', 'Initials': 'ME', 'LastName': 'Halatsch', 'Affiliation': 'Department of Neurosurgery, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Kast', 'Affiliation': 'IIAIGC Study Center, Burlington, Vermont, USA.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Karpel-Massler', 'Affiliation': 'Department of Neurosurgery, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Mayer', 'Affiliation': 'Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Zolk', 'Affiliation': 'Department of Clinical Pharmacology, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Schmitz', 'Affiliation': 'Division of Neuroradiology, Department of Diagnostic and Interventional Radiology, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Angelika', 'Initials': 'A', 'LastName': 'Scheuerle', 'Affiliation': 'Division of Neuropathology, Department of Pathology, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Ludwig', 'Initials': 'L', 'LastName': 'Maier', 'Affiliation': 'Central Pharmacy, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Bullinger', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Regine', 'Initials': 'R', 'LastName': 'Mayer-Steinacker', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Schmidt', 'Affiliation': 'Department of Neurosurgery, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Zeiler', 'Affiliation': 'Department of Neurosurgery, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Ziad', 'Initials': 'Z', 'LastName': 'Elshaer', 'Affiliation': 'Department of Neurosurgery, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Panther', 'Affiliation': 'Department of Neurosurgery, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Schmelzle', 'Affiliation': 'Institute of Experimental Cancer Research, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Anke', 'Initials': 'A', 'LastName': 'Hallmen', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Dwucet', 'Affiliation': 'Department of Neurosurgery, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Markus D', 'Initials': 'MD', 'LastName': 'Siegelin', 'Affiliation': 'Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.'}, {'ForeName': 'Mike-Andrew', 'Initials': 'MA', 'LastName': 'Westhoff', 'Affiliation': 'Department of Pediatric and Adolescent Medicine, Basic Research Division, Ulm University Hospital, Ulm, Germany.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Beckers', 'Affiliation': 'Anticancer Fund, Brussels, Belgium.'}, {'ForeName': 'Gauthier', 'Initials': 'G', 'LastName': 'Bouche', 'Affiliation': 'Anticancer Fund, Brussels, Belgium.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Heiland', 'Affiliation': 'Department of Neurosurgery, Ulm University Hospital, Ulm, Germany.'}]",Neuro-oncology advances,['10.1093/noajnl/vdab075'] 2582,34377934,MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.,"Background The Adjuvant Zoledronic Acid (ZA) study in early breast cancer (AZURE) showed correlation between a nonamplified MAF gene in the primary tumor and benefit from adjuvant ZA. Adverse ZA outcomes occurred in MAF-amplified patients. NSABP B-34 is a validation study. Methods A retrospective analysis of MAF gene status in NSABP B-34 was performed. Eligible patients were randomly assigned to standard adjuvant systemic treatment plus 3 years oral clodronate (1600 mg/daily) or placebo. Tumors were tested for MAF gene amplification and analyzed for their relationship to clodronate for disease-free survival (DFS) and overall survival (OS) in MAF nonamplified patients. All statistical tests were 2-sided . Results MAF status was assessed in 2533 available primary tumor samples from 3311 patients. Of these, 37 withdrew consent; in 77 samples, no tumor was found; 536 assays did not meet quality standards, leaving 1883 (77.8%) evaluable for MAF assay by fluorescence in situ hybridization (947 from placebo and 936 from clodronate arms). At 5 years, in MAF nonamplified patients receiving clodronate, DFS improved by 30% (hazard ratio = 0.70, 95% confidence interval = 0.51 to 0.94; P  =   .02). OS improved at 5 years (hazard ratio = 0.59, 95% confidence interval = 0.37 to 0.93; P  =   .02) remaining statistically significant for clodronate throughout study follow-up. Conversely, adjuvant clodronate in women with MAF -amplified tumors was not associated with benefit but rather possible harm in some subgroups. Association between MAF status and menopausal status was not seen. Conclusions Nonamplified MAF showed statistically significant benefits (DFS and OS) with oral clodronate, supporting validation of the AZURE study.",2021,"OS improved at 5 years (hazard ratio = 0.59, 95% confidence interval = 0.37 to 0.93; P  =   .02) remaining statistically significant for clodronate throughout study follow-up.","['women with MAF', 'early breast cancer (AZURE', '2533 available primary tumor samples from 3311 patients', 'Eligible patients']","['oral clodronate', 'Zoledronic Acid (ZA', 'standard adjuvant systemic treatment plus 3 years oral clodronate', 'clodronate', 'placebo', 'adjuvant clodronate']","['Adverse ZA outcomes', 'disease-free survival (DFS) and overall survival (OS', 'OS', 'MAF status and menopausal status']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0079786', 'cui_str': 'Macrophage activating factor'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0475358', 'cui_str': 'Tumor tissue sample'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0162357', 'cui_str': 'Clodronate'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0257685', 'cui_str': 'zoledronic acid'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0079786', 'cui_str': 'Macrophage activating factor'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}]",3311.0,0.389442,"OS improved at 5 years (hazard ratio = 0.59, 95% confidence interval = 0.37 to 0.93; P  =   .02) remaining statistically significant for clodronate throughout study follow-up.","[{'ForeName': 'Alexander H G', 'Initials': 'AHG', 'LastName': 'Paterson', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Lucas', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Stewart J', 'Initials': 'SJ', 'LastName': 'Anderson', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Eleftherios P', 'Initials': 'EP', 'LastName': 'Mamounas', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Brufsky', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Baez-Diaz', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'King', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lad', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Robidoux', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Finnigan', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Sampayo', 'Affiliation': 'Syntax for Science SL, Palma de Mallorca, Spain.'}, {'ForeName': 'Juan Carlos', 'Initials': 'JC', 'LastName': 'Tercero', 'Affiliation': 'Inbiomotion SL, Barcelona, Spain.'}, {'ForeName': 'Joël Jean', 'Initials': 'JJ', 'LastName': 'Mairet', 'Affiliation': 'Inbiomotion SL, Barcelona, Spain.'}, {'ForeName': 'Antonio C', 'Initials': 'AC', 'LastName': 'Wolff', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Fehrenbacher', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Wolmark', 'Affiliation': 'NSABP Foundation and NRG Oncology, Pittsburgh, PA, USA.'}, {'ForeName': 'Roger R', 'Initials': 'RR', 'LastName': 'Gomis', 'Affiliation': 'Cancer Science, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.'}]",JNCI cancer spectrum,['10.1093/jncics/pkab054'] 2583,34377928,Impact of educational intervention on the best immunization practices among practicing health care professionals in a south Indian city.,"Background and Aims Maintaining the quality and safety of immunization is as important as the efficacy of vaccines in vaccine-preventable diseases (VPD) programs. The aim of this study was to determine the problems associated with different stages of vaccine use and to assess the outcome of an educational intervention on safety and quality use of vaccines among health care providers. Methods A pilot prospective interventional study was conducted over a period of 2 years at 271 sites in Mysuru, India. The study population was health care professionals (HCPs) involved in immunization and a sample of parents (one per site). A validated questionnaire was used as a study tool. An educational intervention on best immunization practice was conducted for the enrolled HCPs and the impact of the educational intervention was assessed using the study tool after 3 weeks. Results The total number of the study population was 594 (323 HCPs and 271 parents). Of these, 41.49% were working at community health care facility and 33.13% were enrolled from primary care centers. There were statistically significant improvements in post interventional assessment of all stages of the immunization process including storage ( p -0.001), transportation ( p -0.001), administration ( p 0.001), monitoring and reporting of adverse events following immunization (AEFIs) ( p -0.001), knowledge of AEFIs ( p 0.001), and HCP-parent communication ( p 0.001). AEFI reporting improved by 30% in the post education phase. Conclusion Continuous education and motivation can result in positive behavioral changes on best immunization practices amongst HCPs involved in immunization, which may help to improve and maintain the safety and quality use of vaccines in immunization centers irrespective of the type of facility.",2021,"There were statistically significant improvements in post interventional assessment of all stages of the immunization process including storage ( p -0.001), transportation ( p -0.001), administration ( p 0.001), monitoring and reporting of adverse events following immunization (AEFIs) ( p -0.001), knowledge of AEFIs ( p 0.001), and HCP-parent communication ( p 0.001).","['41.49% were working at community health care facility and 33.13% were enrolled from primary care centers', 'study population was health care professionals (HCPs) involved in immunization and a sample of parents (one per site', 'practicing health care professionals in a south Indian city', '2\u2009years at 271 sites in Mysuru, India']",['educational intervention'],"['HCP-parent communication', 'AEFI reporting', 'knowledge of AEFIs', 'monitoring and reporting of adverse events following immunization (AEFIs']","[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0086034', 'cui_str': 'Community Healthcare'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0020971', 'cui_str': 'Immunization'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021201', 'cui_str': 'India'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0162531', 'cui_str': 'Hereditary coproporphyria'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C2721654', 'cui_str': 'Adverse event following immunisation'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}]",,0.0473658,"There were statistically significant improvements in post interventional assessment of all stages of the immunization process including storage ( p -0.001), transportation ( p -0.001), administration ( p 0.001), monitoring and reporting of adverse events following immunization (AEFIs) ( p -0.001), knowledge of AEFIs ( p 0.001), and HCP-parent communication ( p 0.001).","[{'ForeName': 'Juny', 'Initials': 'J', 'LastName': 'Sebastian', 'Affiliation': 'Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.'}, {'ForeName': 'Gurumurthy', 'Initials': 'G', 'LastName': 'Parthasarathi', 'Affiliation': 'Director, Pharmacovigilance and Clinical Trials, Botswana Medicines Regulatory Authority, Gaborone, Botswana.'}, {'ForeName': 'Mandyam Dhati', 'Initials': 'MD', 'LastName': 'Ravi', 'Affiliation': 'Department of Pediatrics, JSS Medical College and Hospital, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.'}]",Therapeutic advances in vaccines and immunotherapy,['10.1177/25151355211032590'] 2584,34376967,Treatment Success Across Different Levels of Preoperative Disease Burden: Stratified Two-Year Outcomes from the Pivotal Trial of iStent inject ® Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract.,"Purpose To examine effectiveness outcomes stratified by preoperative disease burden in the pivotal trial of iStent inject ® with cataract surgery (INJ) vs cataract surgery alone (CS). Materials and Methods Prospective, 3:1 randomized, single-masked, concurrently-controlled, multicenter trial enrolling 505 subjects with cataract and mild-to-moderate primary open-angle glaucoma who underwent iStent inject implantation with phacoemulsification or phacoemulsification alone, and were followed for 2 years including annual medication washouts. Post hoc stratification was completed for baseline mean diurnal intraocular pressure (BL DIOP; Low-DIOP <25mmHg, Mid-DIOP ≥25 to <30 mmHg, High-DIOP ≥30mmHg) and preoperative medication burden (Low-Med 1 medication, Mid-Med 2 medications, High-Med ≥3 medications). Results The 24-month primary and secondary effectiveness endpoints were met, with significant treatment-over-control differences in percent of eyes achieving ≥20% unmedicated DIOP reduction and in unmedicated DIOP reduction, respectively. In subgroup analyses, the proportions of INJ eyes achieving the primary endpoint remained steady across all BL DIOP (75.4%, 77.1%, 74.4% in Low/Mid/High-DIOP strata, respectively) and preoperative medication levels (76.8%, 70.8%, 79.7% in Low/Mid/High-Med strata, respectively); meanwhile, the proportions of CS eyes diminished with higher BL DIOP (64.5%, 63.6%, 33.3%, respectively) and more medications (69.0%, 63.3%, 29.4%, respectively). Regarding secondary effectiveness, postoperative DIOP reduction increased with higher BL DIOP in INJ eyes (6.2mmHg, 7.8mmHg, 9.8mmHg, respectively) but plateaued in CS eyes (5.2mmHg, 5.8mmHg, 5.4mmHg, respectively). INJ eyes also had consistent DIOP reduction regardless of preoperative medication burden (6.8mmHg, 6.7mmHg, 7.8mmHg, respectively), while DIOP reduction diminished with more medications in CS eyes (6.1mmHg, 5.0mmHg, 3.3mmHg, respectively). Safety was favorable, comparable to phacoemulsification alone. Conclusion Significant IOP reductions occurred across all levels of BL DIOP and preoperative medication burden in iStent inject eyes. DIOP reductions increased with higher BL DIOP and remained stable across all levels of preoperative medication burden, suggesting the device's potential utility in more medically challenging cases.",2021,"Regarding secondary effectiveness, postoperative DIOP reduction increased with higher BL DIOP in INJ eyes (6.2mmHg, 7.8mmHg, 9.8mmHg, respectively) but plateaued in CS eyes (5.2mmHg, 5.8mmHg, 5.4mmHg, respectively).","['505 subjects with cataract and mild-to-moderate primary open-angle glaucoma who underwent iStent inject implantation with phacoemulsification or phacoemulsification alone, and were followed for 2 years including annual medication washouts']","['iStent inject ® Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract', 'iStent inject ® with cataract surgery (INJ) vs cataract surgery alone (CS']","['postoperative DIOP reduction', 'DIOP reductions', 'BL DIOP and preoperative medication burden', 'preoperative medication levels', 'higher BL DIOP', 'Preoperative Disease Burden', 'BL DIOP', 'preoperative medication burden', 'DIOP reduction', 'IOP reductions']","[{'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0339573', 'cui_str': 'Primary open angle glaucoma'}, {'cui': 'C1720154', 'cui_str': 'Inject'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C1720154', 'cui_str': 'Inject'}, {'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0741847', 'cui_str': 'Bypass'}, {'cui': 'C0339573', 'cui_str': 'Primary open angle glaucoma'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0578862', 'cui_str': 'Intraocular pressure finding'}]",505.0,0.146464,"Regarding secondary effectiveness, postoperative DIOP reduction increased with higher BL DIOP in INJ eyes (6.2mmHg, 7.8mmHg, 9.8mmHg, respectively) but plateaued in CS eyes (5.2mmHg, 5.8mmHg, 5.4mmHg, respectively).","[{'ForeName': 'Inder Paul', 'Initials': 'IP', 'LastName': 'Singh', 'Affiliation': 'The Eyes Centers of Racine & Kenosha, Racine, WI, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Sarkisian', 'Affiliation': 'Oklahoma Eye Surgeons, Oklahoma City, OK, USA.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Hornbeak', 'Affiliation': 'Glaukos Corporation, San Clemente, CA, USA.'}, {'ForeName': 'L Jay', 'Initials': 'LJ', 'LastName': 'Katz', 'Affiliation': 'Glaukos Corporation, San Clemente, CA, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Samuelson', 'Affiliation': 'Minnesota Eye Consultants, Minneapolis, MN, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Clinical ophthalmology (Auckland, N.Z.)",['10.2147/OPTH.S316270'] 2585,34376928,Erratum to: Double Rectangle Fascia Lata Frontalis Sling: A Rationale Approach for Ptosis.,[This corrects the article DOI: 10.1055/s-0041-1723909.].,2021,[This corrects the article DOI: 10.1055/s-0041-1723909.].,['Ptosis'],['Double Rectangle Fascia Lata Frontalis'],[],"[{'cui': 'C0005745', 'cui_str': 'Ptosis of eyelid'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0205142', 'cui_str': 'Rectangular'}, {'cui': 'C0015642', 'cui_str': 'Fascia lata structure'}]",[],,0.264429,[This corrects the article DOI: 10.1055/s-0041-1723909.].,"[{'ForeName': 'Pawan', 'Initials': 'P', 'LastName': 'Agarwal', 'Affiliation': 'Plastic Surgery Unit, Department of Surgery, NSCB Government Medical College, Jabalpur, Madhya Pradesh, India.'}, {'ForeName': 'Dhananjaya', 'Initials': 'D', 'LastName': 'Sharma', 'Affiliation': 'Department of Surgery NSCB Government Medical College, Jabalpur, Madhya Pradesh, India.'}, {'ForeName': 'Vikesh', 'Initials': 'V', 'LastName': 'Agrawal', 'Affiliation': 'Medical College, Jabalpur, Madhya Pradesh, India.'}, {'ForeName': 'Swati', 'Initials': 'S', 'LastName': 'Tiwari', 'Affiliation': 'Department of Surgery NSCB Government Medical College, Jabalpur, Madhya Pradesh, India.'}, {'ForeName': 'Rajeev', 'Initials': 'R', 'LastName': 'Kukrele', 'Affiliation': 'Plastic Surgery Unit, Department of Surgery, NSCB Government Medical College, Jabalpur, Madhya Pradesh, India.'}]",Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India,['10.1055/s-0041-1731098'] 2586,34376917,"Effects of anthocyanin, astaxanthin, and lutein on eye functions: a randomized, double-blind, placebo-controlled study.","We examined the effects of a test food containing anthocyanin, astaxanthin, and lutein on the eye function in healthy Japanese adults with eye fatigue after operating visual display terminals. Forty-four subjects were randomly but equally assigned to the active or placebo group. Two active or placebo capsules were taken once daily for 6 weeks. Accommodative function, tear film break-up time, visual acuity, the value of Schirmer's test, macular pigment optical density level, muscle hardness, and a questionnaire were evaluated before and after a 6-week intervention. Each group included 20 subjects in the efficacy analysis. The active group showed a significant improvement in the percentage of pupillary response of an average of both eyes and dominant eye pre- and post-visual display terminal operation at 6 weeks compared with the placebo group. Moreover, the active group showed a significant improvement in the scores of ""A sensation of trouble in focusing the eyes"" and ""Difficulty in seeing objects in one's hand and nearby, or fine print"" compared with the placebo group between before and after ingestion. Therefore, 6-weeks consumption of the test food inhibited a decrease in the accommodative function caused by visual display terminal operation (UMIN000036989).",2021,The active group showed a significant improvement in the percentage of pupillary response of an average of both eyes and dominant eye pre- and post-visual display terminal operation at 6 weeks compared with the placebo group.,"['healthy Japanese adults with eye fatigue after operating visual display terminals', 'Forty-four subjects']","['placebo', 'anthocyanin, astaxanthin, and lutein', 'test food containing anthocyanin, astaxanthin, and lutein']","[""Accommodative function, tear film break-up time, visual acuity, the value of Schirmer's test, macular pigment optical density level, muscle hardness, and a questionnaire"", 'percentage of pupillary response of an average of both eyes and dominant eye pre- and post-visual display terminal operation', 'scores of ""A sensation of trouble', 'eye functions', 'accommodative function']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004095', 'cui_str': 'Accommodative asthenopia'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C4319568', 'cui_str': '44'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C0052565', 'cui_str': 'astaxanthin'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0429495', 'cui_str': 'Tear film break-up time'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0200152', 'cui_str': ""Schirmer's test""}, {'cui': 'C3850163', 'cui_str': 'Macular Pigment'}, {'cui': 'C0439164', 'cui_str': 'OD units'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0229118', 'cui_str': 'Structure of both eyes'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0028853', 'cui_str': 'Ocular Physiological Phenomenon'}]",44.0,0.0784293,The active group showed a significant improvement in the percentage of pupillary response of an average of both eyes and dominant eye pre- and post-visual display terminal operation at 6 weeks compared with the placebo group.,"[{'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Kizawa', 'Affiliation': 'BGG Japan Co., Ltd., 8F Ginza Kobikicho Building, 8-18-1 Ginza, Chuo-ku, Tokyo 104-0061, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Sekikawa', 'Affiliation': 'BGG Japan Co., Ltd., 8F Ginza Kobikicho Building, 8-18-1 Ginza, Chuo-ku, Tokyo 104-0061, Japan.'}, {'ForeName': 'Masakatsu', 'Initials': 'M', 'LastName': 'Kageyama', 'Affiliation': 'DHC Corporation, Laboratories Division 2, 2-42 Hamada, Mihama-ku, Chiba-shi, Chiba, 261-0025, Japan.'}, {'ForeName': 'Haruna', 'Initials': 'H', 'LastName': 'Tomobe', 'Affiliation': 'DHC Corporation, Laboratories Division 2, 2-42 Hamada, Mihama-ku, Chiba-shi, Chiba, 261-0025, Japan.'}, {'ForeName': 'Riyo', 'Initials': 'R', 'LastName': 'Kobashi', 'Affiliation': 'DHC Corporation, Laboratories Division 2, 2-42 Hamada, Mihama-ku, Chiba-shi, Chiba, 261-0025, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Yamada', 'Affiliation': 'Ario Nishiarai Eye Clinic, 2F Ario Nishiarai, 1-20-1 Nishiarai Sakae-cho, Adachi-ku, Tokyo 123-0843, Japan.'}]",Journal of clinical biochemistry and nutrition,['10.3164/jcbn.20-149'] 2587,34376906,Cognitive Flexibility and Reaction Time Improvements After Cognitive Training Designed for Men Perpetrators of Intimate Partner Violence: Results of a Pilot Randomized Controlled Trial.,"Purpose Current interventions for intimate partner violence (IPV) perpetrators are designed to reduce IPV recidivism by treating risk factors and increasing protective factors. However, these interventions pay less attention to cognitive functioning in IPV perpetrators and how these variables interfere with the future risk of recidivism. Therefore, the main objective of this research was to compare the effectiveness of Standard Intervention Programs for men who perpetrate IPV [SIP] + cognitive training vs SIP + placebo training in promoting cognitive improvements and reducing recidivism. Furthermore, we also aimed to assess whether changes in the risk of recidivism would be related to cognitive changes after the intervention. Method IPV perpetrators who agreed to participate were randomly allocated to receive SIP + cognitive training or SIP + placebo training. Several cognitive variables were assessed before and after the interventions with a complete battery of neuropsychological tests assessing processing speed, memory, attention, executive functions, and emotion decoding abilities. Moreover, we also assessed the risk of recidivism. Results Our data pointed out that only the IPV perpetrators who received the SIP + cognitive training improved their processing speed and cognitive flexibility after this intervention. Furthermore, these participants presented the lowest risk of recidivism after the intervention. Nonetheless, cognitive improvements and reductions in the risk of recidivism after the intervention were unrelated. Conclusions Our study reinforces the importance of implementing cognitive training to reduce risk of recidivism after SIP. Hence, these results might encourage professionals to incorporate neuropsychological variables in IPV intervention programs.",2021,"Several cognitive variables were assessed before and after the interventions with a complete battery of neuropsychological tests assessing processing speed, memory, attention, executive functions, and emotion decoding abilities.","['Men Perpetrators of Intimate Partner Violence', 'intimate partner violence (IPV', 'Method IPV perpetrators who agreed to participate', 'men who perpetrate IPV [SIP']","['cognitive training vs SIP\u2009+\u2009placebo training', 'SIP\u2009+\u2009cognitive training or SIP\u2009+\u2009placebo training', 'implementing cognitive training', 'SIP\u2009+\u2009cognitive training']","['processing speed and cognitive flexibility', 'Cognitive Flexibility and Reaction Time Improvements', 'cognitive improvements and reducing recidivism', 'risk of recidivism', 'neuropsychological tests assessing processing speed, memory, attention, executive functions, and emotion decoding abilities']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0718003', 'cui_str': 'Inactivated Poliovirus vaccine'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}]","[{'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0680458', 'cui_str': 'Recidivism'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",,0.0229825,"Several cognitive variables were assessed before and after the interventions with a complete battery of neuropsychological tests assessing processing speed, memory, attention, executive functions, and emotion decoding abilities.","[{'ForeName': 'Á', 'Initials': 'Á', 'LastName': 'Romero-Martínez', 'Affiliation': 'Department of Psychobiology, University of Valencia, Avenida Blasco Ibañez, 21, 46010 Valencia, Spain.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Santirso', 'Affiliation': 'Department of Social Psychology, University of Valencia, Valencia, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lila', 'Affiliation': 'Department of Social Psychology, University of Valencia, Valencia, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Comes-Fayos', 'Affiliation': 'Department of Psychobiology, University of Valencia, Avenida Blasco Ibañez, 21, 46010 Valencia, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Moya-Albiol', 'Affiliation': 'Department of Psychobiology, University of Valencia, Avenida Blasco Ibañez, 21, 46010 Valencia, Spain.'}]",Journal of family violence,['10.1007/s10896-021-00304-2'] 2588,34376890,A Randomized Controlled Trial to Assess Feasibility and Acceptability of Telephone-Based Psychosocial Interventions in Individuals who Attempted Suicide.,"Background Brief contact interventions such as telephone-based contacts appear to be useful in individuals who attempted suicide. Most studies of telephone-based contacts in such individuals typically consisted of frequent phone reminders for adherence to treatment and seeking help for mental health issues. Telephone-based psychosocial interventions that incorporate elements of supportive and problem-solving strategies are of interest in Indian settings due to their potential application in mitigating the wide mental health gap. Feasibility studies of telephone-based psychosocial interventions could help ascertain the difficulties that arise in the implementation of such treatments. Methods A multicentric randomized controlled trial (RCT) is currently underway in general hospital settings in two Indian cities to study the efficacy of telephone-based psychosocial interventions in individuals with a recent suicide attempt, with routine telephone contacts (TCs) serving as the comparator. Prior to that RCT, this feasibility study was conducted to assess the acceptability of the telephone-based intervention and telephone contacts. Feasibility was assessed using dropout rates. Acceptability was assessed using participant-rated Likert-based visual analog scores from 0 to 10, with higher scores indicating greater acceptability. Results Dropout rates and mean acceptability scores for telephone-based psychosocial interventions were 38.5% and 8.63, while those for TCs were 41.7% and 7.57, respectively. Conclusions Telephone-based psychosocial interventions are feasible and acceptable in individuals with a recent suicide attempt.",2021,"Results Dropout rates and mean acceptability scores for telephone-based psychosocial interventions were 38.5% and 8.63, while those for TCs were 41.7% and 7.57, respectively. ","['Individuals who Attempted Suicide', 'individuals who attempted suicide', 'individuals with a recent suicide attempt, with routine telephone contacts (TCs) serving as the comparator']","['Telephone-Based Psychosocial Interventions', 'telephone-based psychosocial interventions', 'Telephone-based psychosocial interventions']","['Acceptability', 'Dropout rates and mean acceptability scores for telephone-based psychosocial interventions']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038663', 'cui_str': 'Suicide attempt'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",,0.107152,"Results Dropout rates and mean acceptability scores for telephone-based psychosocial interventions were 38.5% and 8.63, while those for TCs were 41.7% and 7.57, respectively. ","[{'ForeName': 'Priya', 'Initials': 'P', 'LastName': 'Sreedaran', 'Affiliation': ""Dept. of Psychiatry, St John's Medical College, Bengaluru, Karnataka, India.""}, {'ForeName': 'Ram Pratap', 'Initials': 'RP', 'LastName': 'Beniwal', 'Affiliation': 'Dept. of Psychiatry, Centre of Excellence in Mental Health, ABVIMS & Dr RML Hospital, New Delhi, India.'}, {'ForeName': 'Uttara', 'Initials': 'U', 'LastName': 'Chari', 'Affiliation': ""Dept. of Clinical Psychology, St John's MEDICAL college, Bengaluru, Karnataka, India.""}, {'ForeName': '', 'Initials': '', 'LastName': 'Smitha T S', 'Affiliation': ""Dept. of Psychiatry, St John's Medical College, Bengaluru, Karnataka, India.""}, {'ForeName': '', 'Initials': '', 'LastName': 'Vidhya Shree S V', 'Affiliation': ""Dept. of Psychiatry, St John's Medical College, Bengaluru, Karnataka, India.""}, {'ForeName': 'Varsha', 'Initials': 'V', 'LastName': 'Gupta', 'Affiliation': 'Dept. of Psychiatry, Centre of Excellence in Mental Health, ABVIMS & Dr RML Hospital, New Delhi, India.'}, {'ForeName': 'Triptish', 'Initials': 'T', 'LastName': 'Bhatia', 'Affiliation': 'Dept. of Psychiatry, Centre of Excellence in Mental Health, ABVIMS & Dr RML Hospital, New Delhi, India.'}, {'ForeName': 'Smita N', 'Initials': 'SN', 'LastName': 'Deshpande', 'Affiliation': 'Dept. of Psychiatry, Centre of Excellence in Mental Health, ABVIMS & Dr RML Hospital, New Delhi, India.'}]",Indian journal of psychological medicine,['10.1177/0253717620939272'] 2589,34377862,"Contrasting effects of three breathing techniques on pulmonary function, functional capacity and daily life functional tasks in patients following valve replacement surgery- A pilot randomized clinical trial.","Background Valve replacement surgeries affect the physiological mechanisms of patients leading to various postoperative pulmonary complications. Lung expansion therapy consisting of numerous techniques is routinely used for the prevention and treatment of these complications. Objectives Our study aimed to compare the effects of diaphragmatic breathing (DB), flow (FS) and volume-oriented incentive spirometer (VS) in patients following valve replacement surgery. Methods 29 patients posted valve replacement surgeries were randomly assigned to VS, FS and DB groups. Patients underwent preoperative training and seven-day rehabilitation post-surgery. Pulmonary function tests were performed before surgery and for seven days afterward. On the seventh postoperative day, patients performed a six-minute walk test and completed a functional difficulties questionnaire (FDQ). Results Pulmonary function test values reduced in all three groups postoperatively when compared to the preoperative values but improved by the seventh postoperative day (p < 0.05). On comparing the seventh postoperative day values to the preoperative values, the VS group had no significant difference (p = 1.00) (Forced Vital Capacity- % change: DB-37.76, VS-1.59, FS-27.98), indicating that the value had nearly returned to the baseline. As compared to the DB and FS groups, FVC showed a greater improvement in the VS group (p = 0.01 and p = 0.06 respectively). No significant differences were observed between groups for distance walked (p > 0.05), however, FDQ scores demonstrated positive changes in favor of VS when contrasted with FS or DB (p < 0.05). Conclusion Diaphragmatic breathing, flow or volume-oriented spirometer could improve pulmonary function in the postoperative period. The volume-oriented spirometer, however, was found to be the most beneficial among the three techniques in improving patients' pulmonary function and daily life functional tasks. Further research is warranted to confirm these findings.",2021,"No significant differences were observed between groups for distance walked (p > 0.05), however, FDQ scores demonstrated positive changes in favor of VS when contrasted with FS or DB (p < 0.05). ","['patients leading to various postoperative pulmonary complications', '29 patients posted valve replacement surgeries', 'patients following valve replacement surgery']","['preoperative training and seven-day rehabilitation post-surgery', 'diaphragmatic breathing (DB), flow (FS) and volume-oriented incentive spirometer (VS']","['functional difficulties questionnaire (FDQ', 'Pulmonary function test values', 'pulmonary function, functional capacity and daily life functional tasks', ""patients' pulmonary function and daily life functional tasks"", 'pulmonary function', 'FDQ scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0231898', 'cui_str': 'Diaphragmatic breathing'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0454512', 'cui_str': 'Incentive spirometry'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",29.0,0.0282181,"No significant differences were observed between groups for distance walked (p > 0.05), however, FDQ scores demonstrated positive changes in favor of VS when contrasted with FS or DB (p < 0.05). ","[{'ForeName': 'Gopala Krishna', 'Initials': 'GK', 'LastName': 'Alaparthi', 'Affiliation': 'Department of Physiotherapy, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.'}, {'ForeName': 'Revati', 'Initials': 'R', 'LastName': 'Amin', 'Affiliation': 'Department of Physiotherapy, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, India.'}, {'ForeName': 'Aishwarya', 'Initials': 'A', 'LastName': 'Gatty', 'Affiliation': 'College of Physiotherapy, Srinivas University, Mangaluru, India.'}, {'ForeName': 'Harish', 'Initials': 'H', 'LastName': 'Raghavan', 'Affiliation': 'Department of Cardiothoracic Surgery, Kasturba Medical College Hospital, Mangalore, Karnataka, India.'}, {'ForeName': 'Kalyana Chakravarthy', 'Initials': 'KC', 'LastName': 'Bairapareddy', 'Affiliation': 'Department of Physiotherapy, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Vaishali', 'Affiliation': 'Department of Physiotherapy, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, India.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Borghi-Silva', 'Affiliation': 'Laboratório de Fisioterapia Cardiopulmonar, Universidade Federal De São Carlos, São Carlos, SP, Brazil.'}, {'ForeName': 'Fatma A', 'Initials': 'FA', 'LastName': 'Hegazy', 'Affiliation': 'Department of Physiotherapy, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.'}]",Heliyon,['10.1016/j.heliyon.2021.e07643'] 2590,34377857,N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis.,"Background The purpose of this study was to explore if administration of N-acetyl-cysteine (NAC) in patients with multiple sclerosis (MS) resulted in altered cerebral blood flow (CBF) based on Arterial Spin Labeling (ASL) magnetic resonance imaging (MRI). Methods Twenty-three patients with mild to moderate MS, (17 relapsing remitting and 6 primary progressive) were randomized to either NAC plus standard of care (N = 11), or standard of care only (N = 12). The experimental group received NAC intravenously (50 mg/kg) once per week and orally (500mg 2x/day) the other six days. Patients in both groups were evaluated initially and after 2 months (of receiving the NAC or waitlist control) with ASL MRI to measure CBF. Clinical symptom questionnaires were also completed at both time points. Results The CBF data showed significant differences in several brain regions including the pons, midbrain, left temporal and frontal lobe, left thalamus, right middle frontal lobe and right temporal/hippocampus (p < 0.001) in the MS group after treatment with NAC, when compared to the control group. Self-reported scores related to cognition and attention were also significantly improved in the NAC group as compared to the control group. Conclusions The results of this study suggest that NAC administration alters resting CBF in MS patients, and this is associated with qualitative improvements in cognition and attention. Given these findings, large scale efficacy studies will be of value to determine the potential clinical impact of NAC over the course of illness in patients with MS, as well as the most effective dosages and differential effects across subpopulations.",2021,"Self-reported scores related to cognition and attention were also significantly improved in the NAC group as compared to the control group. ","['Methods\n\n\nTwenty-three patients with mild to moderate MS, (17 relapsing remitting and 6 primary progressive', 'patients with multiple sclerosis (MS', 'patients with multiple sclerosis']","['NAC plus standard of care', 'NAC', 'N-acetyl-cysteine (NAC', 'Arterial Spin Labeling (ASL) magnetic resonance imaging (MRI', 'N-acetyl cysteine']","['several brain regions including the pons, midbrain, left temporal and frontal lobe, left thalamus, right middle frontal lobe and right temporal/hippocampus', 'Clinical symptom questionnaires', 'cerebral blood flow', 'cerebral blood flow (CBF']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C1273723', 'cui_str': 'Brain region'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0032639', 'cui_str': 'Pontine structure'}, {'cui': 'C0025462', 'cui_str': 'Midbrain structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0016733', 'cui_str': 'Frontal lobe structure'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}]",23.0,0.0650745,"Self-reported scores related to cognition and attention were also significantly improved in the NAC group as compared to the control group. ","[{'ForeName': 'Shiva', 'Initials': 'S', 'LastName': 'Shahrampour', 'Affiliation': 'Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Heholt', 'Affiliation': 'Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wang', 'Affiliation': 'Charles E. Schmidt College of Medicine, Marcus Institute of Integrative Health at FAU Medicine, Florida Atlantic University, Boca Raton, FL USA.'}, {'ForeName': 'Faezeh', 'Initials': 'F', 'LastName': 'Vedaei', 'Affiliation': 'Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Feroze B', 'Initials': 'FB', 'LastName': 'Mohamed', 'Affiliation': 'Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Alizadeh', 'Affiliation': 'Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Ze', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Radiology, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Zabrecky', 'Affiliation': 'Department of Integrative Medicine and Nutritional Sciences, Marcus Institute of Integrative Health, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Wintering', 'Affiliation': 'Department of Integrative Medicine and Nutritional Sciences, Marcus Institute of Integrative Health, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Anthony J', 'Initials': 'AJ', 'LastName': 'Bazzan', 'Affiliation': 'Department of Integrative Medicine and Nutritional Sciences, Marcus Institute of Integrative Health, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Leist', 'Affiliation': 'Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Monti', 'Affiliation': 'Department of Integrative Medicine and Nutritional Sciences, Marcus Institute of Integrative Health, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Andrew B', 'Initials': 'AB', 'LastName': 'Newberg', 'Affiliation': 'Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.'}]",Heliyon,['10.1016/j.heliyon.2021.e07615'] 2591,34377726,"Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064).","Background Direct-acting antivirals can cure hepatitis C virus (HCV). Persons with HCV/HIV and living with substance use are disadvantaged in benefiting from advances in HCV treatment. Methods In this randomized controlled trial, participants with HCV/HIV were randomized between February 2016 and January 2017 to either care facilitation or control. Twelve-month follow-up assessments were completed in January 2018.Care facilitation group participants received motivation and strengths-based case management addressing retrieval of HCV viral load results, engagement in HCV/HIV care, and medication adherence. Control group participants received referral to HCV evaluation and an offer of assistance in making care appointments. Primary outcome was number of steps achieved along a series of 8 clinical steps (eg, receiving HCV results, initiating treatment, sustained virologic response [SVR]) of the HCV/HIV care continuum over 12 months postrandomization. Results Three hundred eighty-one individuals were screened and 113 randomized. Median age was 51 years; 58.4% of participants were male and 72.6% were Black/African American. Median HIV-1 viral load was 27 209 copies/mL, with 69% having a detectable viral load. Mean number of steps completed was statistically significantly higher in the intervention group vs controls (2.44 vs 1.68 steps; χ  2 [1] = 7.36, P  = .0067). Men in the intervention group completed a statistically significantly higher number of steps than controls. Eleven participants achieved SVR with no difference by treatment group. Conclusions The care facilitation intervention increased progress along the HCV/HIV care continuum, as observed for men and not women. Study findings also highlight continued challenges to achieve individual-patient SVR and population-level HCV elimination. Clinical Trials Registration NCT02641158.",2021,Mean number of steps completed was statistically significantly higher in the intervention group vs controls (2.44 vs 1.68 steps;,"['Persons with HCV/HIV and living with substance', 'Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use', 'Three hundred eighty-one individuals were screened and 113 randomized', 'Median age was 51 years; 58.4% of participants were male and 72.6% were Black/African American', 'participants with HCV/HIV were randomized between February 2016 and January 2017 to either']","['motivation and strengths-based case management addressing retrieval of HCV viral load results, engagement in HCV/HIV care, and medication adherence', 'care facilitation intervention', 'care facilitation or control', 'referral to HCV evaluation and an offer of assistance in making care appointments']","['number of steps', 'Median HIV-1 viral load', 'number of steps achieved along a series of 8 clinical steps (eg, receiving HCV results, initiating treatment, sustained virologic response [SVR]) of the HCV/HIV care continuum', 'SVR', 'Mean number of steps completed']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0019196', 'cui_str': 'Viral hepatitis C'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C4517884', 'cui_str': '81'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0085756', 'cui_str': 'African American'}]","[{'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085971', 'cui_str': 'Case management'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0205549', 'cui_str': 'Series'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0009853', 'cui_str': 'Continuity of Care'}, {'cui': 'C1258192', 'cui_str': 'Systemic vascular resistance'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",381.0,0.0887842,Mean number of steps completed was statistically significantly higher in the intervention group vs controls (2.44 vs 1.68 steps;,"[{'ForeName': 'Lisa R', 'Initials': 'LR', 'LastName': 'Metsch', 'Affiliation': 'Department of Sociomedical Sciences, Columbia University, New York, New York, USA.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Feaster', 'Affiliation': 'Department of Public Health Sciences, University of Miami, Miami, Florida, USA.'}, {'ForeName': 'Lauren K', 'Initials': 'LK', 'LastName': 'Gooden', 'Affiliation': 'Department of Sociomedical Sciences, Columbia University, New York, New York, USA.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Masson', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Perlman', 'Affiliation': 'Division of Infectious Diseases, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Mamta K', 'Initials': 'MK', 'LastName': 'Jain', 'Affiliation': 'Division of Infectious Diseases, University of Texas Southwestern Medical Center and Parkland Health & Hospital System, Dallas, Texas, USA.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Matheson', 'Affiliation': 'Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, California, USA.'}, {'ForeName': 'C Mindy', 'Initials': 'CM', 'LastName': 'Nelson', 'Affiliation': 'Department of Public Health Sciences, University of Miami, Miami, Florida, USA.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Jacobs', 'Affiliation': 'Center for Clinical Trials Network, National Institute on Drug Abuse, Rockville, Maryland, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Tross', 'Affiliation': 'Department of Psychiatry, Columbia University, New York, New York, USA.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Haynes', 'Affiliation': 'College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.'}, {'ForeName': 'Gregory M', 'Initials': 'GM', 'LastName': 'Lucas', 'Affiliation': 'Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Colasanti', 'Affiliation': 'Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Rodriguez', 'Affiliation': 'Infectious Disease, University of Miami, Miami, Florida, USA.'}, {'ForeName': 'Mari-Lynn', 'Initials': 'ML', 'LastName': 'Drainoni', 'Affiliation': 'Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Osorio', 'Affiliation': 'Division of Infectious Diseases, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Ank E', 'Initials': 'AE', 'LastName': 'Nijhawan', 'Affiliation': 'Division of Infectious Diseases, University of Texas Southwestern Medical Center and Parkland Health & Hospital System, Dallas, Texas, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Jacobson', 'Affiliation': 'Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, Ohio, USA.'}, {'ForeName': 'Meg', 'Initials': 'M', 'LastName': 'Sullivan', 'Affiliation': 'Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Metzger', 'Affiliation': 'HIV/AIDS Prevention Research Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Vergara-Rodriguez', 'Affiliation': 'Mental Health and Substance Abuse Division, John H. Stroger, Jr Hospital of Cook County, Chicago, Illinois, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Lubelchek', 'Affiliation': 'Infectious Diseases, John H. Stroger, Jr Hospital of Cook County, Chicago, Illinois, USA.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Duan', 'Affiliation': 'Department of Public Health Sciences, University of Miami, Miami, Florida, USA.'}, {'ForeName': 'Jacob N', 'Initials': 'JN', 'LastName': 'Batycki', 'Affiliation': 'Department of Public Health Sciences, University of Miami, Miami, Florida, USA.'}, {'ForeName': 'Abigail G', 'Initials': 'AG', 'LastName': 'Matthews', 'Affiliation': 'Data Statistical Center, The Emmes Company, LLC, Rockville, Maryland, USA.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Munoz', 'Affiliation': 'Data Statistical Center, The Emmes Company, LLC, Rockville, Maryland, USA.'}, {'ForeName': 'Eve', 'Initials': 'E', 'LastName': 'Jelstrom', 'Affiliation': 'Clinical Coordinating Center, The Emmes Company, LLC, Rockville, Maryland, USA.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Mandler', 'Affiliation': 'Clinical/Medical Branch, National Institute on Drug Abuse, Rockville, Maryland, USA.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Del Rio', 'Affiliation': 'Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA.'}]",Open forum infectious diseases,['10.1093/ofid/ofab334'] 2592,34377621,Evaluation of an Extended-duration Chemoprophylaxis Regimen for Venous Thromboembolism after Microsurgical Breast Reconstruction.,"Patients undergoing free flap breast reconstruction are at a high risk for venous thromboembolism based upon Caprini scores. Guidelines for venous thromboembolism prophylaxis recommend high-risk groups receive extended chemoprophylaxis for several weeks after gynecological, orthopedic, and surgical oncology cases. Extended prophylaxis has not been studied in free flap breast reconstruction. The purpose of this study was to compare outcomes of free flap breast reconstruction patients who received extended venous thromboembolism (VTE) prophylaxis with those who received standard inpatient-only prophylaxis. METHODS Patients undergoing microsurgical breast reconstruction were divided into two groups: standard VTE prophylaxis (Group I) and extended prophylaxis (Group II). Both groups received prophylactic subcutaneous heparin or enoxaparin preoperatively and enoxaparin 40 mg daily postoperatively while inpatient. Group II was discharged with a home regimen of enoxaparin 40 mg daily for an additional 14 days. RESULTS In total, 103 patients met inclusion criteria (36 patients in Group I, 67 patients in Group II). The incidence of VTE was 1.5% in Group II compared with 2.8% in Group I ( P = 0.6). There was no difference in reoperative hematoma between Group I (n = 0) and Group II (n = 1) ( P = 0.7). Total flap loss was 2.2%. Conclusions Although this retrospective pilot study did not show statistical significance in VTE between those receiving extended home chemoprophylaxis (1.5% incidence) compared with inpatient-only chemoprophylaxis (2.8%), the risk of bleeding complications was similar. These results indicate that a larger, higher powered study is justified to assess if an extended home chemoprophylaxis protocol should be standard of care post free flap breast reconstruction.",2021,"Although this retrospective pilot study did not show statistical significance in VTE between those receiving extended home chemoprophylaxis (1.5% incidence) compared with inpatient-only chemoprophylaxis (2.8%), the risk of bleeding complications was similar.","['Venous Thromboembolism after Microsurgical Breast Reconstruction', 'Patients undergoing microsurgical breast reconstruction', 'Patients undergoing', 'free flap breast reconstruction patients who received extended venous thromboembolism (VTE) prophylaxis with those who received standard inpatient-only prophylaxis']","['enoxaparin', 'Extended-duration Chemoprophylaxis Regimen', 'prophylactic subcutaneous heparin or enoxaparin preoperatively and enoxaparin', 'standard VTE prophylaxis (Group I) and extended prophylaxis', 'free flap breast reconstruction']","['incidence of VTE', 'Total flap loss', 'reoperative hematoma', 'risk of bleeding complications']","[{'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441031', 'cui_str': 'Free flap'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}]","[{'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0199242', 'cui_str': 'Anticoagulant prophylaxis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0630906', 'cui_str': 'vinyltriethoxysilane'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0441031', 'cui_str': 'Free flap'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0406864', 'cui_str': 'Flap loss'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",103.0,0.0738519,"Although this retrospective pilot study did not show statistical significance in VTE between those receiving extended home chemoprophylaxis (1.5% incidence) compared with inpatient-only chemoprophylaxis (2.8%), the risk of bleeding complications was similar.","[{'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Pittelkow', 'Affiliation': 'Division of Plastic Surgery, Indiana University School of Medicine, Indianapolis, Ia.'}, {'ForeName': 'Will C', 'Initials': 'WC', 'LastName': 'DeBrock', 'Affiliation': 'Division of Plastic Surgery, Indiana University School of Medicine, Indianapolis, Ia.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Mailey', 'Affiliation': 'Institute for Plastic Surgery, Southern Illinois University, Springfield, Ill.'}, {'ForeName': 'Tarah J', 'Initials': 'TJ', 'LastName': 'Ballinger', 'Affiliation': 'Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Ia.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Socas', 'Affiliation': 'Division of Plastic Surgery, Indiana University School of Medicine, Indianapolis, Ia.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Lester', 'Affiliation': 'Division of Plastic Surgery, Indiana University School of Medicine, Indianapolis, Ia.'}, {'ForeName': 'Aladdin H', 'Initials': 'AH', 'LastName': 'Hassanein', 'Affiliation': 'Division of Plastic Surgery, Indiana University School of Medicine, Indianapolis, Ia.'}]",Plastic and reconstructive surgery. Global open,['10.1097/GOX.0000000000003741'] 2593,34377358,Feasibility and acceptability of Problem Management Plus with Emotional Processing (PM+EP) for refugee youth living in the Netherlands: study protocol.,"Background Refugee youth experience hardships associated with exposure to trauma in their homelands and during and after displacement, which results in higher rates of common mental disorders. The World Health Organization (WHO) developed Problem Management Plus (PM+), a non-specialist-delivered brief psychological intervention, for individuals who have faced adversity. PM+ comprises problem-solving, stress management, behavioural activation and strengthening social support. However, it does not include an emotional processing component, which is indicated in trauma-exposed populations. Objective This pilot randomized controlled trial (RCT) aims to evaluate the feasibility and acceptability of PM+, adapted to Syrian, Eritrean and Iraqi refugee youth residing in the Netherlands, with and without a newly developed Emotional Processing (EP) Module. Methods Refugee youth ( N = 90) between 16 and 25 years of age will be randomized into PM+ with care-as-usual (CAU), ( n = 30), PM+ with Emotional Processing (PM+EP) with CAU ( n = 30) or CAU only ( n = 30). Inclusion criteria are self-reported psychological distress (Kessler Psychological Distress Scale; K10 > 15) and impaired daily functioning (WHO Disability Assessment Schedule; WHODAS 2.0 > 16). Participants will be assessed at baseline, one-week post-intervention and three-month follow-up. The main outcome is the feasibility and acceptability of the adapted PM+ and PM+EP. The secondary outcomes are self-reported psychological distress, functional impairment, post-traumatic stress disorder (PTSD) symptom severity and diagnosis, social support, and self-identified problems. The pilot RCT will be succeeded by a process evaluation including trial participants, participants' significant others, helpers, and mental health professionals ( n = 20) to evaluate their experiences with the PM+ and PM+EP programmes. Results and Conclusion This is the first study that evaluates the feasibility of PM+ for this age range with an emotional processing module integrated. The results may inform larger RCTs and implementation of PM+ interventions among refugee youth. Trial Registration Registered to Dutch Trial Registry, NL8750, on 3 July 2020. Medical Ethical Committee of the Amsterdam University Medical Centre, location Vrije Universiteit Medical Centre, Protocol ID: 2020.224, 1 July 2020.",2021,"This pilot randomized controlled trial (RCT) aims to evaluate the feasibility and acceptability of PM+, adapted to Syrian, Eritrean and Iraqi refugee youth residing in the Netherlands, with and without a newly developed Emotional Processing (EP) Module. ","['Methods\n\n\nRefugee youth ( N =\xa090) between 16 and 25\xa0years of age', ""trial participants, participants' significant others, helpers, and mental health professionals ( n =\xa020) to evaluate their experiences with the PM+ and PM+EP programmes"", 'refugee youth living in the Netherlands']","['PM+ with care-as-usual (CAU', 'PM', 'Problem Management Plus with Emotional Processing (PM+EP', 'Problem Management Plus (PM+), a non-specialist-delivered brief psychological intervention', 'PM+ with Emotional Processing (PM+EP) with CAU ( n =\xa030) or CAU']","['feasibility and acceptability of the adapted PM+ and PM+EP', 'self-reported psychological distress, functional impairment, post-traumatic stress disorder (PTSD) symptom severity and diagnosis, social support, and self-identified problems']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0034961', 'cui_str': 'Refugee'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]","[{'cui': 'C0444892', 'cui_str': 'CAU'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0683510', 'cui_str': 'Identifying problems'}]",90.0,0.121402,"This pilot randomized controlled trial (RCT) aims to evaluate the feasibility and acceptability of PM+, adapted to Syrian, Eritrean and Iraqi refugee youth residing in the Netherlands, with and without a newly developed Emotional Processing (EP) Module. ","[{'ForeName': 'Cansu', 'Initials': 'C', 'LastName': 'Alozkan Sever', 'Affiliation': 'Department of Clinical, Neuro-, and Developmental Psychology and WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Cuijpers', 'Affiliation': 'Department of Clinical, Neuro-, and Developmental Psychology and WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Ellenor', 'Initials': 'E', 'LastName': 'Mittendorfer-Rutz', 'Affiliation': 'Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Bryant', 'Affiliation': 'School of Psychology, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Katie S', 'Initials': 'KS', 'LastName': 'Dawson', 'Affiliation': 'School of Psychology, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Emily A', 'Initials': 'EA', 'LastName': 'Holmes', 'Affiliation': 'Department of Psychology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Trudy', 'Initials': 'T', 'LastName': 'Mooren', 'Affiliation': 'Department of Clinical Psychology, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Marie Louise', 'Initials': 'ML', 'LastName': 'Norredam', 'Affiliation': 'Danish Research Centre for Migration, Ethnicity and Health, Section for Health Services Research, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Sijbrandij', 'Affiliation': 'Department of Clinical, Neuro-, and Developmental Psychology and WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}]",European journal of psychotraumatology,['10.1080/20008198.2021.1947003'] 2594,34377356,The reconsolidation using rewind study (RETURN): trial protocol.,"Background: An increasing body of research highlights reconsolidation-based therapies as emerging treatments for post-traumatic stress disorder (PTSD). The Rewind Technique is a non-pharmacological reconsolidation-based therapy with promising early results, which now requires evaluation through an RCT. Objectives: This is a preliminary efficacy RCT to determine if the Rewind Technique is likely to be a good candidate to test against usual care in a future pragmatic efficacy RCT. Methods: 40 participants will be randomised to receive either the Rewind Technique immediately, or after an 8 week wait. The primary outcome will be PTSD symptom severity as measured by the Clinician-Administered PTSD Scale for DSM5 (CAPS-5) at 8 and 16 weeks post-randomisation. Secondary outcome measures include the PTSD Checklist (PCL-5), International Trauma Questionnaire (ITQ), Patient Health Questionnaire (PHQ-9), the General Anxiety Disorder-7 (GAD-7), Insomnia Severity Index, the Euro-Qol-5D (EQ5D-5 L), the prominence of re-experiencing specific symptoms (CAPS-5) and an intervention acceptability questionnaire to measure tolerability of the intervention. Conclusions: This study will be the first RCT to assess the Rewind Technique. Using a cross-over methodology we hope to rigorously assess the efficacy and tolerability of Rewind using pragmatic inclusion criteria. Potential challenges include participant recruitment and retention. Trial registration: ISRCTN91345822.",2021,"Secondary outcome measures include the PTSD Checklist (PCL-5), International Trauma Questionnaire (ITQ), Patient Health Questionnaire (PHQ-9), the General Anxiety Disorder-7 (GAD-7), Insomnia Severity Index, the Euro-Qol-5D (EQ5D-5 L), the prominence of re-experiencing specific symptoms (CAPS-5) and an intervention acceptability questionnaire to measure tolerability of the intervention. ","['40 participants', 'post-traumatic stress disorder (PTSD']",[],"['PTSD Checklist (PCL-5), International Trauma Questionnaire (ITQ), Patient Health Questionnaire (PHQ-9), the General Anxiety Disorder-7 (GAD-7), Insomnia Severity Index, the Euro-Qol-5D (EQ5D-5\xa0L), the prominence of re-experiencing specific symptoms (CAPS-5) and an intervention acceptability questionnaire to measure tolerability of the intervention', 'PTSD symptom severity as measured by the Clinician-Administered PTSD Scale for DSM5 (CAPS-5', 'efficacy and tolerability']","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}]",[],"[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C1704423', 'cui_str': 'Hereditary lymphedema'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C3641330', 'cui_str': 'GAD-7'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C1533125', 'cui_str': 'Euro'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",40.0,0.0563993,"Secondary outcome measures include the PTSD Checklist (PCL-5), International Trauma Questionnaire (ITQ), Patient Health Questionnaire (PHQ-9), the General Anxiety Disorder-7 (GAD-7), Insomnia Severity Index, the Euro-Qol-5D (EQ5D-5 L), the prominence of re-experiencing specific symptoms (CAPS-5) and an intervention acceptability questionnaire to measure tolerability of the intervention. ","[{'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Astill Wright', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK.'}, {'ForeName': 'Kali', 'Initials': 'K', 'LastName': 'Barawi', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Simon', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK.'}, {'ForeName': 'Catrin', 'Initials': 'C', 'LastName': 'Lewis', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Muss', 'Affiliation': 'International Association for Rewind Trauma Therapy, UK.'}, {'ForeName': 'Neil P', 'Initials': 'NP', 'LastName': 'Roberts', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK.'}, {'ForeName': 'Neil J', 'Initials': 'NJ', 'LastName': 'Kitchiner', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK.'}, {'ForeName': 'Jonathan I', 'Initials': 'JI', 'LastName': 'Bisson', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK.'}]",European journal of psychotraumatology,['10.1080/20008198.2020.1844439'] 2595,34377347,Impact of dietary management using teach-back method on glucose and lipid metabolism and quality of life in patients with hepatitis B complicated by diabetes.,"OBJECTIVE To investigate the impact of dietary management using teach-back method on glucose and lipid metabolism and quality of life in patients with hepatitis B complicated with diabetes. METHODS A total of 110 patients with hepatitis B complicated with diabetes admitted to our hospital were selected as the study subjects, and divided into Group A (n=60) and Group B (n=50) in accordance with different intervention measures. Group A was treated with dietary management using teach-back method, while Group B was treated with conventional dietary management. The two groups received follow-up observations. The changes in indices of glucose and lipid metabolism within 12 months after intervention were recorded and compared between the two groups, and the changes in treatment adherence, dietary adherence and quality of life scores were compared between the two groups before and after intervention. RESULTS The results showed that at month 1-12 after intervention, Group A had lower levels of fasting plasma glucose (FPG), 2-h post-load plasma glucose (2hPG), hemoglobin A1c (HbA1c), triglycerides (TG), and total cholesterol (TC) compared with Group B ( P < 0.05). The comparison of treatment adherence revealed that the good and excellent adherence rate in Group A was noticeably higher than that in Group B after intervention (93.33% VS. 70.00%) ( P < 0.05). The scores of dietary adherence attitude and behavior and quality of life in Group A were also remarkably higher than those in Group B after intervention ( P < 0.05). CONCLUSION The dietary management using teach-back method can effectively improve the indices of glucose and lipid metabolism, treatment adherence, dietary adherence, and quality of life in patients with hepatitis B complicated with diabetes.",2021,"The changes in indices of glucose and lipid metabolism within 12 months after intervention were recorded and compared between the two groups, and the changes in treatment adherence, dietary adherence and quality of life scores were compared between the two groups before and after intervention. ","['patients with hepatitis B complicated with diabetes', '110 patients with hepatitis B complicated with diabetes admitted to our hospital', 'patients with hepatitis B complicated by diabetes']","['dietary management using teach-back method', 'dietary management using teach-back method, while Group B was treated with conventional dietary management']","['adherence rate', 'scores of dietary adherence attitude and behavior and quality of life', 'indices of glucose and lipid metabolism, treatment adherence, dietary adherence, and quality of life', 'fasting plasma glucose (FPG), 2-h post-load plasma glucose (2hPG), hemoglobin A1c (HbA1c), triglycerides (TG), and total cholesterol (TC', 'treatment adherence, dietary adherence and quality of life scores', 'glucose and lipid metabolism and quality of life', 'indices of glucose and lipid metabolism']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019163', 'cui_str': 'Type B viral hepatitis'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0012160', 'cui_str': 'nutritional management'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C4505265', 'cui_str': 'Therapeutic Adherence'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}]",110.0,0.00392313,"The changes in indices of glucose and lipid metabolism within 12 months after intervention were recorded and compared between the two groups, and the changes in treatment adherence, dietary adherence and quality of life scores were compared between the two groups before and after intervention. ","[{'ForeName': 'Jiaying', 'Initials': 'J', 'LastName': 'Xia', 'Affiliation': ""Public Health Division, The First People's Hospital of Fuyang Hangzhou Hangzhou 311400, Zhejiang, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'He', 'Affiliation': ""Department of Otolaryngology, The First People's Hospital of Fuyang Hangzhou Hangzhou 311400, Zhejiang, China.""}]",American journal of translational research,[] 2596,34377345,Effect of different preoperative fasting time on safety and postoperative complications of painless gastrointestinal endoscopy for polyps in patients.,"OBJECTIVE To determine the effect of different preoperative fasting time on safety and postoperative complications of painless gastrointestinal endoscopy for polyps in patients. METHODS Enrolled patients were assigned to an observation group and a control group by the random number table method (each n=68). Before operation, each patient in the observation group was fasted from solids for 6 h and from liquids for 2 h, while each one in the control group was fasted from solids for 8-12 h and from liquids for 4 h according to the conventional method. The levels of blood glucose, insulin, potassium and sodium in patients before and after operation were determined, and their hunger and thirst were recorded before anesthesia. Additionally, the incidences and degrees of vomiting and nausea among the patients after anesthesia and operation were recorded. RESULTS Before operation, the observation group showed higher levels of blood glucose, insulin, serum potassium and serum sodium than the control group (all P<0.001), while after operation, the observation group showed lower levels of blood glucose and insulin and higher levels of serum potassium and serum sodium than the control group (all P<0.001). In addition, the degrees and incidences of hunger and thirst in patients of the observation group were significantly lower than those in the control group before operation (P<0.01), and the degrees and incidences of nausea and vomiting in the observation group were also notably lower than those in the control group before and after operation (both P<0.05). CONCLUSION For patients undergoing painless gastrointestinal endoscopy for polyps, shortening their fasting time from solids and liquids before operation can stabilize their blood glucose, insulin and electrolyte levels before and after operation, relieve their thirst and hunger before operation, and reduce the incidences of postoperative nausea and vomiting.",2021,"In addition, the degrees and incidences of hunger and thirst in patients of the observation group were significantly lower than those in the control group before operation (P<0.01), and the degrees and incidences of nausea and vomiting in the observation group were also notably lower than those in the control group before and after operation (both P<0.05). ","['Enrolled patients', 'painless gastrointestinal endoscopy for polyps in patients', 'patients undergoing painless gastrointestinal endoscopy for polyps']",[],"['levels of blood glucose, insulin, serum potassium and serum sodium', 'nausea and vomiting', 'levels of blood glucose and insulin and higher levels of serum potassium and serum sodium', 'incidences and degrees of vomiting and nausea', 'postoperative nausea and vomiting', 'levels of blood glucose, insulin, potassium and sodium']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0234226', 'cui_str': 'Painless'}, {'cui': 'C0079278', 'cui_str': 'Gastrointestinal tract endoscopy'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}]",[],"[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0302353', 'cui_str': 'Serum potassium measurement'}, {'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}]",,0.0162516,"In addition, the degrees and incidences of hunger and thirst in patients of the observation group were significantly lower than those in the control group before operation (P<0.01), and the degrees and incidences of nausea and vomiting in the observation group were also notably lower than those in the control group before and after operation (both P<0.05). ","[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Endoscopic Center, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Yanling', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Oncology, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': 'Department of Breast and Thoracic Tumors Surgery, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Bai', 'Affiliation': 'Department of Stomatology, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Hai', 'Initials': 'H', 'LastName': 'Xie', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Keng', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Endoscopic Center, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Xiangmei', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Endoscopic Center, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': ""Li'na"", 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of General Surgery, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': 'Department of Ophthalmology, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Ophthalmology, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Xiuyu', 'Initials': 'X', 'LastName': 'Cai', 'Affiliation': 'Disinfection and Supply Center, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Lu', 'Affiliation': 'Endoscopic Center, The First Affiliated Hospital of Hainan Medical University Haikou, Hainan Province, China.'}]",American journal of translational research,[] 2597,34377336,Application of sputum suction by fiberoptic bronchoscope in patients with severe pneumonia and its effect on inflammatory factors.,"OBJECTIVE To evaluate the application of sputum suction by fiberoptic bronchoscope to patients with severe pneumonia and its effect on inflammatory factors. METHODS One hundred and three patients with severe pneumonia were randomly divided into the control group (n=52) and the observation group (n=51). Both groups were given anti-infection, antitussive and expectoration treatment. The observation group was treated with sputum suction by fiberoptic bronchoscope. The control group was treated with a vibration sputum extractor. The clinical efficacy, clinically related indexes, inflammatory factors, blood gas indexes and the Acute Physiology and Chronic Health Evaluation (APACHE II) score of the two groups were compared. RESULTS After the treatment, the total effective rate of the observation group was higher than that of the control group; the length of stay in ICU, mechanical ventilation time and duration of antibiotics of the observation group were shorter than those of the control group (all P<0.05). After the treatment, the serum levels of CRP, TNF-α and PCT and APACHE II scores in the two groups were all decreased, while PaO 2 , SaO 2 and OI were increased; the changes in the observation group were more significant than the control group (all P<0.05). CONCLUSION Sputum suction and lavage by fiberoptic bronchoscope can significantly control the body's inflammatory reaction state in patients with severe pneumonia, improve their blood oxygen and promote the treatment effect.",2021,"After the treatment, the serum levels of CRP, TNF-α and PCT and APACHE II scores in the two groups were all decreased, while PaO 2 , SaO 2 and OI were increased; the changes in the observation group were more significant than the control group (all P<0.05). ","['patients with severe pneumonia', 'One hundred and three patients with severe pneumonia']","['sputum suction by fiberoptic bronchoscope', 'Sputum suction and lavage by fiberoptic bronchoscope', 'vibration sputum extractor']","['clinical efficacy, clinically related indexes, inflammatory factors, blood gas indexes and the Acute Physiology and Chronic Health Evaluation (APACHE II) score', 'length of stay in ICU, mechanical ventilation time and duration of antibiotics', 'serum levels of CRP, TNF-α and PCT and APACHE II scores', 'total effective rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C4517526', 'cui_str': '103'}]","[{'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0179433', 'cui_str': 'Flexible bronchoscope'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}]","[{'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0243030', 'cui_str': 'Acute physiology and chronic health evaluation'}, {'cui': 'C0243028', 'cui_str': 'Acute physiology and chronic health evaluation II'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0032452', 'cui_str': 'Polychlorotriphenyl Compounds'}, {'cui': 'C0489438', 'cui_str': 'APACHE II score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",103.0,0.00614871,"After the treatment, the serum levels of CRP, TNF-α and PCT and APACHE II scores in the two groups were all decreased, while PaO 2 , SaO 2 and OI were increased; the changes in the observation group were more significant than the control group (all P<0.05). ","[{'ForeName': 'Binbin', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': ""Department of Respiratory, Yongjia People's Hospital Wenzhou, Zhejiang Province, China.""}, {'ForeName': 'Zhihai', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ""Department of General Practice, Yongjia People's Hospital Wenzhou, Zhejiang Province, China.""}, {'ForeName': 'Wu', 'Initials': 'W', 'LastName': 'Cheng', 'Affiliation': ""Department of Respiratory, Yongjia People's Hospital Wenzhou, Zhejiang Province, China.""}, {'ForeName': 'Baoyi', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Department of Respiratory, Wenzhou Central Hospital Wenzhou, Zhejiang Province, China.'}, {'ForeName': 'Wengui', 'Initials': 'W', 'LastName': 'Zhu', 'Affiliation': ""Department of Respiratory, Yongjia People's Hospital Wenzhou, Zhejiang Province, China.""}, {'ForeName': 'Zhongtie', 'Initials': 'Z', 'LastName': 'Lin', 'Affiliation': ""Department of Infectious Diseases, Yongjia People's Hospital Wenzhou, Zhejiang Province, China.""}]",American journal of translational research,[] 2598,34377335,Application of etomidate and propofol mixture in hematoma removal in patients with intracranial epidural hematoma.,"OBJECTIVE To innvestigate the application of etomidate and propofol mixture in the evacuation of hematoma in patients with epidural hematoma. METHODS 98 patients with epidural hematoma were randomly divided into two groups: the joint group (n=49, anesthesia induction with etomidate and propofol) and the etomidate group (n=49, anesthesia induction with etomidate) using a random number table. Hemodynamics, stress response and cerebral oxygen metabolism were compared between the two groups at T0 (pre-anesthesia induction), T1 (after endotracheal intubation), T2 (10 min after the beginning of the operation) and T3 (the end of the operation). Adverse reactions were also analyzed. RESULTS Compared with T0, the mean arterial pressure (MAP) at T1, T2 and T3 in the joint group decreased first and then increased, and the MAP at T1 was significantly lower than that in the etomidate group (P<0.05). Compared with T0, blood oxygen saturation of internal jugular vein bulb (SjvO 2 ) increased in T1-T3 groups, and SjvO 2 in the joint group was higher than that in the etomidate group (all P<0.05). Compared with T0, cerebral oxygen uptake rate (CERO 2 ) in the T1-T3 groups decreased significantly, and CERO 2 at T3 in the joint group was higher than that in the etomidate group (all P<0.05). Compared with T0, the levels of cortisol and superoxide dismutase (SOD) at T3 in the two groups were significantly lower, but those in the etomidate group were higher than those in the combination group (all P<0.05). There was no significant difference in the incidence of postoperative anesthesia-related adverse reactions between the two groups (P>0.05). CONCLUSION Etomidate has less effect on hemodynamics and stress reaction during intravenous anesthesia, but its combination with propofol can improve cerebral oxygen metabolism to a certain extent with fewer adverse reactions.",2021,"Compared with T0, blood oxygen saturation of internal jugular vein bulb (SjvO 2 ) increased in T1-T3 groups, and SjvO 2 in the joint group was higher than that in the etomidate group (all P<0.05).","['98 patients with epidural hematoma', 'patients with intracranial epidural hematoma', 'patients with epidural hematoma']","['etomidate', 'propofol', 'etomidate group (n=49, anesthesia induction with etomidate', 'joint group (n=49, anesthesia induction with etomidate and propofol', 'etomidate and propofol mixture', 'Etomidate']","['hemodynamics and stress reaction', 'levels of cortisol and superoxide dismutase (SOD', 'cerebral oxygen metabolism', 'incidence of postoperative anesthesia-related adverse reactions', 'blood oxygen saturation of internal jugular vein bulb (SjvO 2 ', 'mean arterial pressure (MAP', 'Hemodynamics, stress response and cerebral oxygen metabolism', 'MAP at T1', 'Adverse reactions', 'cerebral oxygen uptake rate (CERO 2 ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238154', 'cui_str': 'Epidural hemorrhage'}]","[{'cui': 'C0015131', 'cui_str': 'Etomidate'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0473960', 'cui_str': 'Induction of general anesthesia'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0016664', 'cui_str': 'Stress fracture'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0226550', 'cui_str': 'Internal jugular vein structure'}, {'cui': 'C0025148', 'cui_str': 'Medulla oblongata structure'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0329599', 'cui_str': 'Scomberomorus regalis'}]",98.0,0.0290532,"Compared with T0, blood oxygen saturation of internal jugular vein bulb (SjvO 2 ) increased in T1-T3 groups, and SjvO 2 in the joint group was higher than that in the etomidate group (all P<0.05).","[{'ForeName': 'Jinju', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': ""Department of Anesthesiology, Central Theater Command General Hospital of The Chinese People's Liberation Army Wuhan, Hubei Province, China.""}, {'ForeName': 'Xiaomin', 'Initials': 'X', 'LastName': 'Bie', 'Affiliation': 'Department of Anesthesiology, Wuhan No. 1 Hospital Wuhan, Hubei Province, China.'}, {'ForeName': 'Degang', 'Initials': 'D', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, Wuhan No. 1 Hospital Wuhan, Hubei Province, China.'}]",American journal of translational research,[] 2599,34377334,Effects of platelet-rich fibrin combined with guided bone regeneration in the reconstruction of peri-implantitis bone defect.,"OBJECTIVE To investigate the clinical effect of platelet-rich fibrin (PRF) combined with guided bone regeneration (GBR) in the reconstruction of peri-implantitis bone defect. METHODS This prospective study included 80 patients with peri-implantitis who underwent implant restoration in the Department of Stomatology in our hospital. The eligible patients were randomly divided into control group and observation group, with 40 cases in each group. Patients in the control group were treated with flap curettage combined with GBR, while those in the observation group received a mixture of PRF and bone powder implanted with GBR and covered with PRF biofilm. The differences of pain 24 hours after surgery, bleeding at 7 days after surgery, and the degree of bone defect between the two groups at 60 days after surgery were compared. At 60 days and 120 days after surgery, separately, the regenerated bone density of patients in the two groups was measured, analyzed and compared. The degree of regenerated bone defect in transverse and longitudinal directions after 60 days was compared between the two reconstruction procedures. RESULTS The pain at 24 hours after surgery and the bleeding at 7 days after surgery in the observation group were milder than those in the control group (P<0.001). There was significant difference in the degrees of bone defect at 60 days after surgery (P<0.05). Compared with the control group, the regenerated bone density of the observation group was significantly higher both at 60 days and 120 days after surgery (P<0.001). CONCLUSION The combination of PRF and GBR technology has an obvious effect in repairing bone defects in patients with peri-implantitis, and can reduce the pain of patients during the repair process.",2021,"Compared with the control group, the regenerated bone density of the observation group was significantly higher both at 60 days and 120 days after surgery (P<0.001). ","['80 patients with peri-implantitis who underwent implant restoration in the Department of Stomatology in our hospital', 'patients with peri-implantitis']","['PRF and GBR technology', 'flap curettage combined with GBR', 'platelet-rich fibrin combined with guided bone regeneration', 'mixture of PRF and bone powder implanted with GBR and covered with PRF biofilm', 'platelet-rich fibrin (PRF) combined with guided bone regeneration (GBR']","['bleeding', 'degrees of bone defect', 'pain', 'degree of bone defect', 'regenerated bone density']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2936258', 'cui_str': 'Dental peri-implantitis'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0029167', 'cui_str': 'Medicine, Oral'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C4505052', 'cui_str': 'Leukocyte- and Platelet-Rich Fibrin'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0005972', 'cui_str': 'Bone Regeneration'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0010468', 'cui_str': 'Curettage'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0081786', 'cui_str': 'Biofilm'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}]",80.0,0.028299,"Compared with the control group, the regenerated bone density of the observation group was significantly higher both at 60 days and 120 days after surgery (P<0.001). ","[{'ForeName': 'Guoxi', 'Initials': 'G', 'LastName': 'Sun', 'Affiliation': 'Department of Stomatology, Jiaozhou Central Hospital of Qingdao Qingdao, Shandong Province, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Cao', 'Affiliation': 'Department of Stomatology, Qingdao Stomatology Hospital Qingdao, Shandong Province, China.'}, {'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Stomatology, Jiaozhou Central Hospital of Qingdao Qingdao, Shandong Province, China.'}]",American journal of translational research,[] 2600,34377332,Effect of Tripterygium wilfordii polyglycoside tablets on serum inflammatory factors and T cells in patients with chronic nephritis.,"OBJECTIVE Investigate the effect of Tripterygium wilfordii polyglycoside tablets on serum inflammatory factors and T cells in patients with chronic nephritis. METHODS A total of 89 patients with chronic nephritis were randomly divided into a control group (44 cases, treated with irbesartan hydrochlorothiazide combined with dipyridamole) and an observation group (45 cases, treated with Tripterygium wilfordii polyglycoside tablets based on irbesartan hydrochlorothiazide and dipyridamole like the control group). Patients in both groups were treated for two months. The renal function, inflammatory factors, the proportion of T lymphocyte subsets, and 24 h urinary protein quantification (24 h Upro) of patients with hemodialysis were compared between the two groups before and after treatment. The occurrence of adverse reactions was recorded. RESULTS SCR, BUN levels, 24 h Upro, serum hs-CRP, TNF-α, and IL-8 levels in the two groups after treatment were lower than those before treatment, and those of the observation group were lower than those of the control group (all P<0.05). After treatment, the CD4+ ratio and CD4+/CD8+ ratio of the two groups of patients increased, while the CD8+ ratio decreased. The changes in the observation group were greater than those in the control group (all P<0.05). There was no significant difference in the incidence of total adverse reactions between the two groups during treatment (P>0.05). CONCLUSION Treatment combined with Tripterygium wilfordii polyglycosides can significantly alleviate the inflammatory state of patients with chronic glomerulonephritis, reduce the level of proteinuria, and improve renal function. Tripterygium wilfordii polyglycosides can improve immune function of the body and has high safety.",2021,The changes in the observation group were greater than those in the control group (all P<0.05).,"['89 patients with chronic nephritis', 'patients with chronic nephritis', 'patients with chronic glomerulonephritis']","['Tripterygium wilfordii polyglycosides', 'irbesartan hydrochlorothiazide combined with dipyridamole', 'Tripterygium wilfordii polyglycoside tablets', 'Tripterygium wilfordii polyglycoside tablets based on irbesartan hydrochlorothiazide and dipyridamole like the control group']","['renal function, inflammatory factors, the proportion of T lymphocyte subsets, and 24 h urinary protein quantification', 'SCR, BUN levels, 24 h Upro, serum hs-CRP, TNF-α, and IL-8 levels', 'occurrence of adverse reactions', 'CD8+ ratio', 'serum inflammatory factors and T cells', 'inflammatory state', 'level of proteinuria, and improve renal function', 'incidence of total adverse reactions', 'CD4+ ratio and CD4+/CD8+ ratio']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2364010', 'cui_str': 'Nephritis - chronic'}, {'cui': 'C0152451', 'cui_str': 'Chronic glomerulonephritis'}]","[{'cui': 'C0077273', 'cui_str': 'Leigong Teng'}, {'cui': 'C0717823', 'cui_str': 'Hydrochlorothiazide- and irbesartan-containing product'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0012582', 'cui_str': 'Dipyridamole'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0080202', 'cui_str': 'T-Cell Subsets'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}]",89.0,0.0222745,The changes in the observation group were greater than those in the control group (all P<0.05).,"[{'ForeName': 'Qingzhen', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Nephrology, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine Nanchang, Jiangxi Province, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Nephrology, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine Nanchang, Jiangxi Province, China.'}, {'ForeName': 'Peipei', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of Nephrology, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine Nanchang, Jiangxi Province, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': 'Jiangxi University of Traditional Chinese Medicine Nanchang, Jiangxi Province, China.'}, {'ForeName': 'Jisheng', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Zhao Jisheng Famous Traditional Chinese Medicine Studio, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine Nanchang, Jiangxi Province, China.'}]",American journal of translational research,[] 2601,34377326,The effect of joint distraction osteogenesis combined with platelet-rich plasma injections on traumatic ankle arthritis.,"OBJECTIVE To study effect of joint distraction osteogenesis combined with platelet-rich plasma injections on traumatic ankle arthritis (TAA). METHODS 106 patients with TAA admitted to our hospital (from January 2018 to January 2020) were recruited as the study cohort and randomly divided into a surgical group and a combined group. The surgical group was treated with simple joint retraction surgery, and the combined group was treated with platelet-rich plasma injections in addition to the surgery administered to the operation group. After 6 months of treatment, the clinical efficacy of the two groups was evaluated, and the changes in the ankle joint function, the serum related factors, and the quality of life before and at six months after the treatment were observed. The incidences of adverse reactions (ARS) in the two groups were counted to evaluate the treatment safety. RESULTS The total effective rate was 98.11% in the combined group and 77.36% in the operation group. The overall curative effect of the combined group was better than it was in the operation group ( P <0.05). After the treatment, the ankle joint movement angles, the joint function, the serum factor levels, and the quality of life of the patients in combined group were better than they were in the operation group ( P <0.05). No significant difference was found in the incidence of ARs ( P >0.05). CONCLUSION Arthroplasty with platelet-rich plasma injections can improve joint function recovery, inhibit the inflammatory factor expression levels, and enhance TAA patients' quality of life.",2021,The overall curative effect of the combined group was better than it was in the operation group ( P <0.05).,"['traumatic ankle arthritis (TAA', 'traumatic ankle arthritis', '106 patients with TAA admitted to our hospital (from January 2018 to January 2020']","['simple joint retraction surgery', 'platelet-rich plasma injections in addition to the surgery administered to the operation group', 'joint distraction osteogenesis combined with platelet-rich plasma injections']","['clinical efficacy', 'overall curative effect', 'adverse reactions (ARS', 'incidence of ARs', 'ankle joint movement angles, the joint function, the serum factor levels, and the quality of life', 'total effective rate', 'ankle joint function, the serum related factors, and the quality of life']","[{'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0003864', 'cui_str': 'Arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0224499', 'cui_str': 'Simple joint structure'}, {'cui': 'C0332523', 'cui_str': 'Retraction'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0524975', 'cui_str': 'Distraction osteogenesis'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0003087', 'cui_str': 'Ankle joint structure'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0542330', 'cui_str': 'Joint mobilization'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",106.0,0.0169088,The overall curative effect of the combined group was better than it was in the operation group ( P <0.05).,"[{'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': ""Department of Orthopedics, The Second People's Hospital of Yibin Yibin, PR China.""}, {'ForeName': 'Pan', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': ""Department of Orthopedics, The Second People's Hospital of Yibin Yibin, PR China.""}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Nie', 'Affiliation': ""Department of Orthopedics, The Second People's Hospital of Yibin Yibin, PR China.""}, {'ForeName': 'Hongsheng', 'Initials': 'H', 'LastName': 'Luo', 'Affiliation': ""Department of Orthopedics, The Second People's Hospital of Yibin Yibin, PR China.""}, {'ForeName': 'Deshui', 'Initials': 'D', 'LastName': 'Yu', 'Affiliation': ""Department of Anesthesiology, The Second People's Hospital of Yibin Yibin, PR China.""}]",American journal of translational research,[] 2602,34377325,"The effect of self-management on the knowledge, beliefs, behavior and subjective well-being in stroke patients during the rehabilitation phase.","OBJECTIVE To investigate the effects of self-management on the knowledge, beliefs, behavior, and subjective well-being in stroke patients during the rehabilitation phase. METHODS the data from 60 first-episode stroke patients in the rehabilitation phase who were discharged from the Department of Neurology were analyzed in this retrospective study. The patients were assigned to an observational group or a control group, with 30 patients in each group. The routine intervention mode was used in the control group, and the self-management intervention mode was used in the observation group. Subsequently, the muscle strength of the upper and lower extremities, the self-care ability scores, the ADL, NIHSS, and FMA scores, the subjective well-being levels, and the patients' complication rates were compared between two groups. RESULTS After the intervention, the muscle strength of the upper and lower extremities, the self-care ability scores, and the ADL, NIHSS, and FMA scores of the patients in the observational group were all better than they were in the control group, with statistically significant differences (all P<0.05). The subjective well-being levels of the patients in the observation group were also significantly better than they were in the control group (P<0.05). The incidence of complications in the observation group was lower than it was in the control group (P<0.05). CONCLUSION Self-management intervention measures effectively improve the self-care abilities, enhance patient confidence in self-management, and help to improve the quality of life in stroke patients during the rehabilitation phase.",2021,"The incidence of complications in the observation group was lower than it was in the control group (P<0.05). ","['stroke patients during the rehabilitation phase', '60 first-episode stroke patients in the rehabilitation phase who were discharged from the Department of Neurology']",[],"['self-care abilities', 'incidence of complications', 'muscle strength of the upper and lower extremities, the self-care ability scores, and the ADL, NIHSS, and FMA scores', ""muscle strength of the upper and lower extremities, the self-care ability scores, the ADL, NIHSS, and FMA scores, the subjective well-being levels, and the patients' complication rates"", 'subjective well-being levels', 'quality of life', 'knowledge, beliefs, behavior and subjective well-being']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0027855', 'cui_str': 'Neurology'}]",[],"[{'cui': 'C0562734', 'cui_str': 'Ability to perform personal care activity'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.00368571,"The incidence of complications in the observation group was lower than it was in the control group (P<0.05). ","[{'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Xing', 'Affiliation': 'Medical School, Baoji Vocational Technology College Baoji, Shaanxi Province, China.'}, {'ForeName': 'Jianhui', 'Initials': 'J', 'LastName': 'Wei', 'Affiliation': 'Department of Neurology, Baoji Central Hospital Baoji, Shaanxi Province, China.'}]",American journal of translational research,[] 2603,34377324,Pulmonary rehabilitation training for improving pulmonary function and exercise tolerance in patients with stable chronic obstructive pulmonary disease.,"OBJECTIVE To investigate the effect of pulmonary rehabilitation training on pulmonary function and exercise tolerance in patients with stable chronic obstructive pulmonary disease (COPD). METHODS By a random number table method, 90 patients with COPD admitted to our hospital from January 2019 to January 2020 were divided into three groups: the control group (conventional treatment), the observation group A (conventional treatment + pulmonary rehabilitation training three times a week) and the observation group B (conventional treatment + pulmonary rehabilitation training five times a week), with 30 patients in each group. The pulmonary function, exercise tolerance (the 6-min walking distance (6MWD)), sleep quality (Pittsburgh Sleep Quality Index (PSQI)) and quality of life (generic quality of life inventory-74 (GQOLI-74)) before and after intervention were compared among the three groups. Also, the satisfaction rate was recorded in all groups. RESULTS After 6 months of intervention, the FEV 1 %, FVC% and FEV 1 /FVC as well as the GQOLI-74 scores increased significantly, while the PSQI scores decreased markedly in all groups as compared to those before intervention; the index levels and GQOLI-74 scores were significantly higher, and PSQI scores were markedly lower in the observation group B than in the other two groups (all P<0.05). After 3 and 6 months of intervention, the 6MWDs of the three groups were significantly increased compared with those before intervention, and the 6MWD was significantly longer in the observation group B than in the other two groups (P<0.05). Moreover, the satisfaction rate was significantly higher in observation group B than in the other two groups (P<0.05). CONCLUSION For patients with stable COPD, pulmonary rehabilitation training based on drug therapy can improve the pulmonary function, exercise tolerance, sleep quality and quality of life more effectively than drug treatment alone. What's more, the therapeutic effect of training five times a week is significantly better than that of training three times a week.",2021,"After 3 and 6 months of intervention, the 6MWDs of the three groups were significantly increased compared with those before intervention, and the 6MWD was significantly longer in the observation group B than in the other two groups (P<0.05).","['patients with stable chronic obstructive pulmonary disease (COPD', 'patients with stable chronic obstructive pulmonary disease', '90 patients with COPD admitted to our hospital from January 2019 to January 2020']","['Pulmonary rehabilitation training', 'control group (conventional treatment), the observation group A (conventional treatment + pulmonary rehabilitation training three times a week) and the observation group B (conventional treatment + pulmonary rehabilitation training', 'pulmonary rehabilitation training']","['GQOLI-74 scores', 'pulmonary function and exercise tolerance', 'pulmonary function, exercise tolerance, sleep quality and quality of life more effectively', '6MWDs', 'pulmonary function, exercise tolerance (the 6-min walking distance (6MWD)), sleep quality (Pittsburgh Sleep Quality Index (PSQI)) and quality of life (generic quality of life inventory-74 (GQOLI-74', '6MWD', 'PSQI scores', 'index levels and GQOLI-74 scores', 'satisfaction rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0556987', 'cui_str': 'Three times weekly'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",90.0,0.00307361,"After 3 and 6 months of intervention, the 6MWDs of the three groups were significantly increased compared with those before intervention, and the 6MWD was significantly longer in the observation group B than in the other two groups (P<0.05).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Jin', 'Affiliation': 'Department of Quality Control Section, Xintai Hospital of Traditional Chinese Medicine Xintai, Shandong Province, China.'}, {'ForeName': 'Wencan', 'Initials': 'W', 'LastName': 'An', 'Affiliation': 'Department of Geriatrics, Xintai Hospital of Traditional Chinese Medicine Xintai, Shandong Province, China.'}, {'ForeName': 'Zhenshuang', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Traditional Chinese Medicine Hall, Xintai Hospital of Traditional Chinese Medicine Xintai, Shandong Province, China.'}, {'ForeName': 'Liyong', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Department of Pharmacy, Xintai Hospital of Traditional Chinese Medicine Xintai, Shandong Province, China.'}, {'ForeName': 'Caili', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Quality Control Section, Xintai Hospital of Traditional Chinese Medicine Xintai, Shandong Province, China.'}]",American journal of translational research,[] 2604,34377323,The application of whole-course nursing in patients undergoing emergency PCI and its impact on cardiac function.,"OBJECTIVE To implement whole-course care in patients undergoing emergency percutaneous coronary intervention and investigate its impact on cardiac function. METHODS This study included 88 acute myocardial infarction patients undergoing percutaneous coronary intervention. These patients were randomly divided into the control group (n=44, which underwent routine care) and the experimental group (n=44, which underwent whole-course care). The cardiac function, physiological states, quality of life, complications, and the patient satisfaction with the care were compared between the two groups. RESULTS Compared with before the surgery, the left ventricular ejection fractions and the cardiac output in both groups at discharge were increased, while the left ventricular end-systolic diameters and left ventricular end-diastolic diameters were decreased (all P<0.05). In addition, the changes in the experimental group were greater than they were in the control group (all P<0.05). The HAMA and HAMD scores in the two groups at discharge were decreased compared with before the surgeries, but the GQOLI-74 scores in all aspects were increased (all P<0.05). Similarly, the changes in the experimental group were greater than those in the control group (all P<0.05). The incidence of postoperative complications in the experimental group was lower than it was in the control group, and the satisfaction with care was higher than it was in the control group (both P<0.05). CONCLUSIONS The whole-course care of AMI patients undergoing PCI can significantly relieve their negative emotions, improve their cardiac function, increase their quality of life, and reduce their incidences of complications.",2021,"Similarly, the changes in the experimental group were greater than those in the control group (all P<0.05).","['88 acute myocardial infarction patients undergoing', 'patients undergoing emergency percutaneous coronary intervention', 'patients undergoing emergency PCI and its impact on cardiac function']",['percutaneous coronary intervention'],"['left ventricular ejection fractions and the cardiac output', 'GQOLI-74 scores', 'quality of life, and reduce their incidences of complications', 'negative emotions, improve their cardiac function', 'cardiac function, physiological states, quality of life, complications, and the patient satisfaction with the care', 'incidence of postoperative complications', 'satisfaction with care', 'HAMA and HAMD scores', 'left ventricular end-systolic diameters and left ventricular end-diastolic diameters']","[{'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1532297', 'cui_str': 'Emergency percutaneous coronary intervention'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1291910', 'cui_str': 'Human anti-mouse antibody'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}]",88.0,0.042776,"Similarly, the changes in the experimental group were greater than those in the control group (all P<0.05).","[{'ForeName': 'Caixia', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'Department of Nursing, Quanzhou First Hospital Affiliated to Fujian Medical University Quanzhou, Fujian Province, China.'}, {'ForeName': 'Haijin', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Emergency, Quanzhou First Hospital Affiliated to Fujian Medical University Quanzhou, Fujian Province, China.'}, {'ForeName': 'Xiarong', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Emergency, Quanzhou First Hospital Affiliated to Fujian Medical University Quanzhou, Fujian Province, China.'}, {'ForeName': 'Yumei', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Quanzhou First Hospital Affiliated to Fujian Medical University Quanzhou, Fujian Province, China.'}, {'ForeName': 'Fenfen', 'Initials': 'F', 'LastName': 'Wu', 'Affiliation': 'Department of Nursing, Quanzhou First Hospital Affiliated to Fujian Medical University Quanzhou, Fujian Province, China.'}]",American journal of translational research,[] 2605,32633158,Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis.,"BACKGROUND Oral vancomycin (OV) in primary sclerosing cholangitis (PSC) has been evaluated as a potential therapeutic agent. We report the long-term biochemical course and outcomes of patients with PSC treated with OV. METHODS Patients were enrolled in 2 open-label clinical trials (ClinicalTrials.gov Identifier: NCT01802073 and NCT01322386) and offered OV at 50 mg/kg/day in 3 divided doses if weight <30kg, and 500 mg 3 times/day if weight ≥30kg. Patients with biliary strictures requiring stenting or awaiting liver transplant were excluded. Liver biochemistry, MRCP and histology were documented at baseline and while on OV. The primary outcome was a decrease in elevated gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), and/or alanine aminotransferase (ALT) from baseline. RESULTS 30 subjects were enrolled, and 29 additional subjects who learned of the clinical trial requested OV (total n  = 59; median age was 13.5 years [range, 1.5-44 years]; 64.4% were male; and 94.9% had inflammatory bowel disease [IBD]). The median treatment duration was 2.7 years (range, 0.2-14 years). Ninety-six percent (57/59), 81.3% (48/59), and 94.9% (56/59) experienced reduction of GGT, ALP, and ALT, respectively. Furthermore, 39% (23/59), 22% (13/59), and 55.9% (33/59) experienced normalization of GGT, ALP, and ALT, respectively, within the first 6 months of OV treatment. One patient underwent liver transplantation 8 years after beginning OV treatment, and one developed biliary strictures requiring endoscopic intervention. OV was well-tolerated by patients, and no patient developed treatment-related adverse events. CONCLUSION In PSC, OV was well-tolerated and was associated with improvement in liver chemistry. A randomized placebo-controlled clinical trial is warranted.",2020,"The primary outcome was a decrease in elevated gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), and/or alanine aminotransferase (ALT) from baseline. ","['patients with PSC treated with OV', 'children and adults with primary sclerosing cholangitis', 'Patients were enrolled in 2 open-label clinical trials', 'Patients with biliary strictures requiring stenting or awaiting liver transplant were excluded', 'primary sclerosing cholangitis (PSC', '30 subjects were enrolled, and 29 additional subjects who learned of the clinical trial requested OV (total n \u2009=\u200959; median age was 13.5\u2009years [range, 1.5-44\u2009years]; 64.4% were male; and 94.9% had inflammatory bowel disease [IBD']","['vancomycin (OV', 'placebo', 'vancomycin']","['Liver biochemistry, MRCP and histology', 'liver chemistry', 'median treatment duration', 'normalization of GGT, ALP, and ALT', 'elevated gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), and/or alanine aminotransferase (ALT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0566602', 'cui_str': 'Primary sclerosing cholangitis'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0360373', 'cui_str': 'Vancomycin-containing product in oral dose form'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0597984', 'cui_str': 'Biliary stricture'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C3697559', 'cui_str': 'Awaiting transplantation of liver'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517559', 'cui_str': '13.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}]","[{'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0360373', 'cui_str': 'Vancomycin-containing product in oral dose form'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0994163', 'cui_str': 'Magnetic resonance cholangiopancreatography'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0007996', 'cui_str': 'Chemistry'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0205250', 'cui_str': 'High'}]",30.0,0.106909,"The primary outcome was a decrease in elevated gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), and/or alanine aminotransferase (ALT) from baseline. ","[{'ForeName': 'Ahmad Hassan', 'Initials': 'AH', 'LastName': 'Ali', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Damman', 'Affiliation': ""Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA.""}, {'ForeName': 'Shamita B', 'Initials': 'SB', 'LastName': 'Shah', 'Affiliation': 'Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Yinka', 'Initials': 'Y', 'LastName': 'Davies', 'Affiliation': 'Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Hurwitz', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Mariam', 'Initials': 'M', 'LastName': 'Stephen', 'Affiliation': ""Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA.""}, {'ForeName': 'Leta M', 'Initials': 'LM', 'LastName': 'Lemos', 'Affiliation': 'Sacramento Pediatric Gastroenterology, Sacramento, CA, USA.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Carey', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA.'}, {'ForeName': 'Keith D', 'Initials': 'KD', 'LastName': 'Lindor', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA.'}, {'ForeName': 'Cynthia W', 'Initials': 'CW', 'LastName': 'Buness', 'Affiliation': 'National Patient Advocate Foundation, Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Leina', 'Initials': 'L', 'LastName': 'Alrabadi', 'Affiliation': 'Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'William E', 'Initials': 'WE', 'LastName': 'Berquist', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Kenneth L', 'Initials': 'KL', 'LastName': 'Cox', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2020.1787501'] 2606,33245028,An Investigation of Cognitive Processing of Fear Appeal Messages Promoting HPV Vaccination: Predictors and Outcomes of Magnitude and Valence of Cognitive Responses.,"An improvement in HPV vaccination rates is one of the primary goals of public health organizations. Toward this end, fear appeal communication is commonly used in health interventions, warning individuals of threats of HPV infection and promoting vaccination. However, little is known about how threat-related emotions, such as fear and anxiety, influence the cognitive processing of vaccination information and how this processing is associated with vaccination intention. To address this void, this study tests a model drawing upon functional emotion theories and dual-process models of persuasion. Results from an experimental study showed that fear and anxiety, which arose from exposure to threat information, triggered motivation to process HPV protection-related information, which in turn, was positively associated with depth of HPV vaccination information processing. Subsequently, greater depth of processing led to a greater number of positive cognitive responses when participants were presented with information with a high (vs. low), level of response efficacy. Finally, greater positivity of cognitive responses predicted greater intention to obtain HPV vaccination. Collectively, our findings provide a theory-based explanation about how the sequential provision and processing of threat and efficacy information in fear appeals contribute to the promotion of HPV vaccination. Implications for designing fear appeal messages are discussed.",2020,"Finally, greater positivity of cognitive responses predicted greater intention to obtain HPV vaccination.",[],[],"['positive cognitive responses', 'HPV vaccination rates', 'fear and anxiety']",[],[],"[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.0408756,"Finally, greater positivity of cognitive responses predicted greater intention to obtain HPV vaccination.","[{'ForeName': 'Hanyoung', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Advertising and Public Relations, Grady College of Journalism and Mass Communication, University of Georgia, Athens, Georgia.'}, {'ForeName': 'Jeong Yeob', 'Initials': 'JY', 'LastName': 'Han', 'Affiliation': 'Department of Advertising and Public Relations, Grady College of Journalism and Mass Communication, University of Georgia, Athens, Georgia.'}, {'ForeName': 'Jiyeon', 'Initials': 'J', 'LastName': 'So', 'Affiliation': 'College of Communication, Yonsei University, Seoul, Republic of Korea.'}, {'ForeName': 'Youngji', 'Initials': 'Y', 'LastName': 'Seo', 'Affiliation': 'Department of Advertising and Public Relations, Grady College of Journalism and Mass Communication, University of Georgia, Athens, Georgia.'}]",Journal of health communication,['10.1080/10810730.2020.1842566'] 2607,34342626,Simple Intervention Motivates Expectant Fathers to Quit Smoking.,,2021,,[],[],[],[],[],[],,0.0234285,,"[{'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Slomski', 'Affiliation': ''}]",JAMA,['10.1001/jama.2021.12117'] 2608,33280541,"Closer to the Heart, Closer to the Mind: Using Psychological Distance to Communicate a Measles Outbreak.","Psychological distance can influence a variety of risk-related perceptions and behaviors. This study ( N = 205) examines the effect of spatial distance manipulation on emotions, risk perception, and behavioral intention following a recent measles outbreak in the United States. Results indicate that experimentally induced spatial distance influences emotional intensity, which affects psychological distance perception. Perceived distance subsequently influences risk perception, while emotions influence information engagement and support for mandatory vaccination.",2020,"This study ( N = 205) examines the effect of spatial distance manipulation on emotions, risk perception, and behavioral intention following a recent measles outbreak in the United States.",[],['spatial distance manipulation'],"['spatial distance influences emotional intensity', 'emotions, risk perception, and behavioral intention', 'psychological distance perception']",[],"[{'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}]","[{'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0012752', 'cui_str': 'Distance Perception'}]",205.0,0.0348815,"This study ( N = 205) examines the effect of spatial distance manipulation on emotions, risk perception, and behavioral intention following a recent measles outbreak in the United States.","[{'ForeName': 'Janet Z', 'Initials': 'JZ', 'LastName': 'Yang', 'Affiliation': 'Department of Communication, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Cass', 'Initials': 'C', 'LastName': 'McAllister', 'Affiliation': 'Department of Communication, University at Buffalo, Buffalo, NY, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1851822'] 2609,33161336,Accelerated partial breast irradiation with 3-dimensional conformal and image-guided intensity-modulated radiotherapy following breast conserving surgery - 7-Year results of a phase II trial.,"PURPOSE To present the 7-year results of accelerated partial breast irradiation (APBI) using three-dimensional conformal (3D-CRT) and image-guided intensity-modulated radiotherapy (IG-IMRT) following breast-conserving surgery (BCS). PATIENTS AND METHODS Between 2006 and 2014, 104 patients were treated with APBI given by means of 3D-CRT using 3-5 non-coplanar, isocentric wedged fields, or IG-IMRT using kV-CBCT. The total dose of APBI was 36.9 Gy (9 × 4.1 Gy) using twice-a-day fractionation. Survival results, side effects and cosmetic results were assessed. RESULTS At a median follow-up of 90 months three (2.9%) local recurrences, one (0.9%) regional recurrence and two (1.9%) distant metastases were observed. The 7-year local (LRFS), recurrence free survival was 98.9%. The 7-year disease-free (DFS), metastases free (MFS) and overall survival (OS) was 94.8%, 97.9% and 94.8%, respectively. Late side effects included G1 skin toxicity in 15 (14.4%), G1, G2, and G3 fibrosis in 26 (25%), 3 (2.9%) and 1 (0.9%) patients respectively. Asymptomatic (G1) fat necrosis occurred in 10 (9.6%) patients. No ≥ G2 or higher late side effects occurred with IMRT. The rate of excellent/good and fair/poor cosmetic results was 93.2% and 6.8%, respectively. CONCLUSION 7-year results of APBI with 3D-CRT and IG-IMRT are encouraging. Toxicity profile and local tumor control are comparable to other series using multicatheter interstitial brachytherapy. Therefore, these external beam APBI techniques are valid alternatives to whole breast irradiation and brachytherapy based APBI.",2020,"The 7-year disease-free (DFS), metastases free (MFS) and overall survival (OS) was 94.8%, 97.9% and 94.8%, respectively.","['Between 2006 and 2014', '104 patients were treated with']","['breast-conserving surgery (BCS', 'IMRT', 'accelerated partial breast irradiation (APBI) using three-dimensional conformal (3D-CRT) and image-guided intensity-modulated radiotherapy (IG-IMRT', 'APBI', 'Accelerated partial breast irradiation with 3-dimensional conformal and image-guided intensity-modulated radiotherapy']","['regional recurrence', 'total dose of APBI', 'No\xa0≥', 'Toxicity profile and local tumor control', 'Asymptomatic (G1) fat necrosis', 'rate of excellent/good and fair/poor cosmetic results', '7-year local (LRFS), recurrence free survival', '7-year disease-free (DFS), metastases free (MFS) and overall survival (OS', 'Survival results, side effects and cosmetic results', 'G1 skin toxicity', 'local recurrences', 'G1, G2, and G3 fibrosis']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C1512814', 'cui_str': 'Intensity modulated radiation therapy'}, {'cui': 'C3896696', 'cui_str': 'Accelerated partial breast irradiation'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0026377', 'cui_str': 'Molecular conformation'}, {'cui': 'C0600521', 'cui_str': 'Conformal radiotherapy'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C3896696', 'cui_str': 'Accelerated partial breast irradiation'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0015668', 'cui_str': 'Fat necrosis'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C2911689', 'cui_str': 'Fair'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}]",104.0,0.0217641,"The 7-year disease-free (DFS), metastases free (MFS) and overall survival (OS) was 94.8%, 97.9% and 94.8%, respectively.","[{'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Mészáros', 'Affiliation': 'Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Faculty of Medicine, Budapest, Hungary. Electronic address: meszarosnorbert@oncol.hu.'}, {'ForeName': 'Tibor', 'Initials': 'T', 'LastName': 'Major', 'Affiliation': 'Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Faculty of Medicine, Budapest, Hungary.'}, {'ForeName': 'Gábor', 'Initials': 'G', 'LastName': 'Stelczer', 'Affiliation': 'Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary. Electronic address: gabor.stelczer@gmail.com.'}, {'ForeName': 'Levente', 'Initials': 'L', 'LastName': 'Jánváry', 'Affiliation': 'Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.'}, {'ForeName': 'Zoltán', 'Initials': 'Z', 'LastName': 'Zaka', 'Affiliation': 'Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.'}, {'ForeName': 'Dávid', 'Initials': 'D', 'LastName': 'Pukancsik', 'Affiliation': 'Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary.'}, {'ForeName': 'Zoltán', 'Initials': 'Z', 'LastName': 'Takácsi-Nagy', 'Affiliation': 'Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Faculty of Medicine, Budapest, Hungary.'}, {'ForeName': 'János Fodor', 'Initials': 'JF', 'LastName': 'Md', 'Affiliation': 'Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.'}, {'ForeName': 'Csaba', 'Initials': 'C', 'LastName': 'Polgár', 'Affiliation': 'Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Faculty of Medicine, Budapest, Hungary.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.10.010'] 2610,32673189,The Role of Temporal Distance Perception in Narrative vs. Non-Narrative Persuasion Related to E-Cigarettes.,"Research has long identified narrative persuasion as an effective health communication strategy. This study explores temporal distance perception, which is the perceived distance of a health threat, as a possible psychological mechanism through which narrative persuasion influences young adults' attitude and behavioral intention related to e-cigarette use. When reading the narrative message featuring negative consequences of nicotine addiction, participants demonstrate a higher level of transportation and subsequently perceive the health threat related to e-cigarette as temporally closer. The shortened temporal distance perception, along with transportation, mediates the relationship between exposure to the narrative message and participants' attitude and behavioral intention. Participants' past experience also plays an important role. In particular, participants who have not used e-cigarette before report more negative attitude after reading the narrative message. Findings of the current study indicate that narrative persuasion may be an effective strategy to deter young adults from using e-cigarettes.",2020,"The shortened temporal distance perception, along with transportation, mediates the relationship between exposure to the narrative message and participants' attitude and behavioral intention.",[],[],['shortened temporal distance perception'],[],[],"[{'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0012752', 'cui_str': 'Distance Perception'}]",,0.0296516,"The shortened temporal distance perception, along with transportation, mediates the relationship between exposure to the narrative message and participants' attitude and behavioral intention.","[{'ForeName': 'Sixiao', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Department of Communication, University at Buffalo, State University of New York , Buffalo, New York, USA.'}, {'ForeName': 'Janet Z', 'Initials': 'JZ', 'LastName': 'Yang', 'Affiliation': 'Department of Communication, University at Buffalo, State University of New York , Buffalo, New York, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1788678'] 2611,32543424,Influence of built environment on quality of life changes in African-American patients with non-metastatic breast cancer.,"Research links the built environment to health outcomes, but little is known about how this affects quality of life (QOL) of African American breast cancer patients, especially those residing in disadvantaged neighborhoods. Using latent trajectory models, we examined whether the built environment using Google Street View was associated with changes in QOL over a 2-year follow-up in 228 newly diagnosed African American breast cancer patients. We measured QOL using the RAND 36-Item Health Survey subscales. After adjusting for covariates, improvement in emotional well-being and pain over time was greater for women living on streets with low-quality (vs. high-quality) sidewalks.",2020,"After adjusting for covariates, improvement in emotional well-being and pain over time was greater for women living on streets with low-quality (vs. high-quality) sidewalks.","['African-American patients with non-metastatic breast cancer', 'African American breast cancer patients', '228 newly diagnosed African American breast cancer patients']",['built environment'],"['emotional well-being and pain over time', 'QOL using the RAND 36-Item Health Survey subscales', 'quality of life changes']","[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C4505382', 'cui_str': 'Built Environment'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",228.0,0.0625665,"After adjusting for covariates, improvement in emotional well-being and pain over time was greater for women living on streets with low-quality (vs. high-quality) sidewalks.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Schootman', 'Affiliation': 'SSM Health, Department of Clinical Analytics and Insights, Center for Clinical Excellence, 10101 Woodfield Lane, St. Louis, MO, 63132, USA. Electronic address: mario.schootman@ssmhealth.com.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Perez', 'Affiliation': 'Washington University in St Louis, School of Medicine, Department of Medicine, St. Louis, MO, 63110, USA.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Schootman', 'Affiliation': 'Saint Louis University, College for Public Health and Social Justice, Department of Epidemiology and Biostatistics, St. Louis, MO, 63103, USA.'}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Fu', 'Affiliation': 'Saint Louis University, College for Public Health and Social Justice, Department of Epidemiology and Biostatistics, St. Louis, MO, 63103, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'McVay', 'Affiliation': 'Saint Louis University, College for Public Health and Social Justice, Department of Epidemiology and Biostatistics, St. Louis, MO, 63103, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Margenthaler', 'Affiliation': 'Washington University in St. Louis, School of Medicine, Department of Surgery, St. Louis, MO, 63110, USA.'}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Colditz', 'Affiliation': 'Washington University in St. Louis, School of Medicine, Department of Surgery, St. Louis, MO, 63110, USA.'}, {'ForeName': 'M W', 'Initials': 'MW', 'LastName': 'Kreuter', 'Affiliation': 'Washington University in St. Louis, The Brown School, Health Communication Research Laboratory, St. Louis, MO, 63130, USA.'}, {'ForeName': 'D B', 'Initials': 'DB', 'LastName': 'Jeffe', 'Affiliation': 'Washington University in St Louis, School of Medicine, Department of Medicine, St. Louis, MO, 63110, USA.'}]",Health & place,['10.1016/j.healthplace.2020.102333'] 2612,32543422,Are low income children more physically active when they live in homes with bigger yards? A longitudinal analysis of the NET-Works Study.,"This study prospectively examined the relationship of home yard-size to objectively measured physical activity over three years among a cohort of 531 low-income pre-school-aged children. An adjusted total-effect association of 12.72 additional minutes per week of moderate/vigorous physical activity (MVPA) was observed for each additional hectare of yard-size. The direct-effect association, adjusting for previous year MVPA, was not statistically significant. This study provides evidence that the private or semi-private space around the house may impact children's' physical activity. Public health and urban planning practitioners should consider these results to identify built environment solutions for improving MVPA among low-income minority children.",2020,"The direct-effect association, adjusting for previous year MVPA, was not statistically significant.","['531 low-income pre-school-aged children', 'Public health and urban planning practitioners']",[],['moderate/vigorous physical activity (MVPA'],"[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0087138', 'cui_str': 'Urban Planning'}]",[],"[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",531.0,0.0414317,"The direct-effect association, adjusting for previous year MVPA, was not statistically significant.","[{'ForeName': 'Jonathan M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'Division of Family Medicine and Community Health, University of Minnesota, USA. Electronic address: mill5687@umn.edu.'}, {'ForeName': 'Yingling', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': 'Humphrey School of Public Affairs, University of Minnesota, USA. Electronic address: yingling@umn.edu.'}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Sherwood', 'Affiliation': 'Division of Epidemiology and Community Health, University of Minnesota, USA. Electronic address: sherw005@umn.edu.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Osypuk', 'Affiliation': 'Division of Epidemiology and Community Health, University of Minnesota, USA. Electronic address: tosypuk@umn.edu.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'French', 'Affiliation': 'Division of Epidemiology and Community Health, University of Minnesota, USA. Electronic address: frenc001@umn.edu.'}]",Health & place,['10.1016/j.healthplace.2020.102330'] 2613,34377321,The effect of evidence-based cluster nursing intervention on the incidences of delirium and the prognoses of ICU patients.,"OBJECTIVE This study explored the effect of evidence-based cluster nursing intervention on the incidences of delirium and the prognoses of ICU patients. METHODS 108 ICU patients admitted to our hospital from January 2020 to June 2020 were recruited as the study cohort and randomly divided into a control group and an observation group, with 54 cases in each group. The patients in the control group underwent routine nursing intervention, and the patients in the observation group underwent evidence-based cluster nursing intervention. The incidences of delirium, the durations of the mechanical ventilation, the ICU hospitalization durations, as well as the satisfaction levels in the two groups of patients were compared. RESULT The incidences of delirium in the observation group were conspicuously lower than they were in the control group (14.81%, 40.74%, X 2 = 9.0462, P = 0.0026). The duration of the delirium in the observation group was conspicuously lower than it was in the control group (2.87 ± 1.28), (5.21 ± 1.33), t = 9.3155, P = 0.0000. The durations of the mechanical ventilation and the ICU hospitalizations in the observation group were conspicuously shorter than they were in the control group. The differences were statistically significant (P < 0.05). The nursing satisfaction levels in the observation group were conspicuously higher than they were in the control group (94.44%, 72.22%, X 2 = 9.6000, P = 0.0019). There was no significant difference in the in-hospital mortality between the two groups (X 2 = 2.1862, 0.1393). CONCLUSION Evidence-based cluster nursing intervention can conspicuously reduce the incidences of delirium, shorten the durations of the mechanical ventilation and the ICU stays, and improve patient prognosis, so it is worthy of clinical application.",2021,"There was no significant difference in the in-hospital mortality between the two groups (X 2 = 2.1862, 0.1393). ","['ICU patients', '108 ICU patients admitted to our hospital from January 2020 to June 2020']","['observation group underwent evidence-based cluster nursing intervention', 'evidence-based cluster nursing intervention', 'routine nursing intervention']","['nursing satisfaction levels', 'incidences of delirium, the durations of the mechanical ventilation, the ICU hospitalization durations, as well as the satisfaction levels', 'duration of the delirium', 'incidences of delirium', 'durations of the mechanical ventilation and the ICU hospitalizations', 'hospital mortality']","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}]",108.0,0.0270158,"There was no significant difference in the in-hospital mortality between the two groups (X 2 = 2.1862, 0.1393). ","[{'ForeName': 'Suping', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'Department of Nursing, Shenzhen Longhua District Central Hospital Shenzhen 518110, China.'}, {'ForeName': 'Jiaqing', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Nursing, Piking University Shenzhen Hospital Shenzhen 518110, China.'}, {'ForeName': 'Yunbo', 'Initials': 'Y', 'LastName': 'Du', 'Affiliation': 'Department of Critical Care Medicine, Shenzhen Longhua District Central Hospital Shenzhen 518110, China.'}, {'ForeName': 'Yanmei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Nursing, Shenzhen Longhua District Central Hospital Shenzhen 518110, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Wei', 'Affiliation': 'Department of Nursing, Shenzhen Longhua District Central Hospital Shenzhen 518110, China.'}, {'ForeName': 'Guiju', 'Initials': 'G', 'LastName': 'Wei', 'Affiliation': 'Department of Nursing, Shenzhen Longhua District Central Hospital Shenzhen 518110, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Hu', 'Affiliation': 'Department of Nursing, Shenzhen Longhua District Central Hospital Shenzhen 518110, China.'}]",American journal of translational research,[] 2614,34377319,The effects of modified Buzhong Yiqi decoction combined with Gangtai ointment on the wound healing and anal function in circumferential mixed hemorrhoid patients.,"OBJECTIVE To investigate the effects of modified Buzhong Yiqi decoction combined with Gangtai ointment on the wound healing and anal function of circumferential mixed hemorrhoid patients. METHODS Patients (n=120) with circumferential mixed hemorrhoids were recruited as the research cohort. All the patients underwent surgical treatment and were randomly divided into a control group and a research group. The control group was administered chitosan hydrogels for wound healing, once a day. The research group was administered modified Buzhong Yiqi decoction (1 dose a day, orally) combined with Kangtai ointment for external application (twice a day, for two consecutive weeks). We compared the two groups' effective rates, their pain indexes, their perianal edema scores, their quality of life scores, their wound healing times, their pain resolution times, their anal functions, their wound exudate scores, and their adverse reactions. RESULTS Compared with the control group, the research group had a higher effective rate (P<0.01), a lower pain index, and a lower perianal edema score (both P<0.001), a higher quality of life score (P<0.001), a shorter wound healing time, a shorter pain resolution time, and fewer adverse reactions than the control group (both P<0.001). The lengths of the anal canals in the research group were shorter than they were in the control group (P<0.01), and the resting pressure, maximum diastolic blood pressure, and maximum systolic blood pressure were higher than they were in the control group (all P<0.001). The wound exudate scores at 7 and 14 days after the treatment in the research group were lower than they were in the control group (all P<0.001). There were fewer adverse reactions in the research group than there were in the control group (P<0.05). CONCLUSION Modified Buzhong Yiqi decoction combined with Gangtai ointment for patients with circumferential mixed hemorrhoids has good short-term efficacy. It helps to promote wound healing, improves anal function, and does not increase the incidence of adverse reactions. It is worthy of promotion and application.",2021,"There were fewer adverse reactions in the research group than there were in the control group (P<0.05). ","['Patients (n=120) with circumferential mixed hemorrhoids were recruited as the research cohort', 'circumferential mixed hemorrhoid patients', 'patients with circumferential mixed hemorrhoids']","['modified Buzhong Yiqi decoction', 'Modified Buzhong Yiqi decoction combined with Gangtai ointment', 'Kangtai ointment for external application', 'modified Buzhong Yiqi decoction combined with Gangtai ointment']","['lower pain index', 'effective rate', 'perianal edema score', 'effective rates, their pain indexes, their perianal edema scores, their quality of life scores, their wound healing times, their pain resolution times, their anal functions, their wound exudate scores, and their adverse reactions', 'higher quality of life score', 'resting pressure, maximum diastolic blood pressure, and maximum systolic blood pressure', 'adverse reactions', 'lengths of the anal canals', 'wound healing, improves anal function', 'shorter wound healing time, a shorter pain resolution time', 'wound exudate scores', 'wound healing and anal function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205113', 'cui_str': 'Circumferential'}, {'cui': 'C0341434', 'cui_str': 'Interno-external hemorrhoid'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0028912', 'cui_str': 'Ointment'}, {'cui': 'C3658671', 'cui_str': 'kangtai'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0442158', 'cui_str': 'Perianal'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0232722', 'cui_str': 'Anal function'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0015388', 'cui_str': 'Exudate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C1282162', 'cui_str': 'Maximum diastolic blood pressure'}, {'cui': 'C1282150', 'cui_str': 'Maximum systolic blood pressure'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0227411', 'cui_str': 'Anal canal structure'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}]",120.0,0.0193862,"There were fewer adverse reactions in the research group than there were in the control group (P<0.05). ","[{'ForeName': 'Benyin', 'Initials': 'B', 'LastName': 'Lu', 'Affiliation': ""Department of Traditional Chinese Medicine Anorectal, The First People's Hospital of Shuangliu District, Chengdu/West China (Airport) Hospital Sichuan University Chengdu, Sichuan Province, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': ""Department of Anorectal, The First People's Hospital of Shuangliu District, Chengdu/West China (Airport) Hospital Sichuan University Chengdu, Sichuan Province, China.""}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': ""Department of Anorectal, The First People's Hospital of Shuangliu District, Chengdu/West China (Airport) Hospital Sichuan University Chengdu, Sichuan Province, China.""}]",American journal of translational research,[] 2615,34377317,The effect of community nursing based on the Roy adaptation model on postpartum depression and sleep quality of parturients.,"OBJECTIVE The study aimed to explore the effect of community nursing based on the Roy adaptation model on postpartum depression and sleep quality of parturients. METHODS According to different nursing methods, 96 parturients with postpartum depression were selected and divided into 47 cases in the regular group (undergoing regular nursing) and 49 cases in the combined group (undergoing community nursing based on the Roy adaptation model). The improvement in depression and sleep quality was compared between the two groups. RESULTS Comparison of the Hamilton Depression Scale (HAMD), Self-Rating Depression Scale (SDS) and Edinburgh Postpartum Depression Scale (EPDS) scores between the two groups showed that the above mentioned scores at intervention for 3 months < those of intervention for 2 months < those of intervention for 1 month < those of before intervention; showing significant differences ( P <0.05). The scores of HAMA, SDS and EPDS in the combined group after intervention for 1, 2 and 3 months were significantly lower than those in the regular group ( P <0.05). After intervention, the total score and the scores of all dimensions of Pittsburgh Sleep Quality Index (PSQI) were decreased in the two groups ( P <0.05), and the combined group had scores that were significantly lower than the regular group ( P <0.05). CONCLUSION The use of community nursing intervention based on the Roy adaptation model for postpartum depressed parturients can effectively alleviate depression and improve sleep quality.",2021,"The scores of HAMA, SDS and EPDS in the combined group after intervention for 1, 2 and 3 months were significantly lower than those in the regular group ( P <0.05).","['parturients', '96 parturients with postpartum depression were selected and divided into 47 cases in the regular group (undergoing regular nursing) and 49 cases in the combined group (undergoing community nursing based on the Roy adaptation model']","['community nursing intervention', 'community nursing based on the Roy adaptation model']","['total score and the scores of all dimensions of Pittsburgh Sleep Quality Index (PSQI', 'postpartum depression and sleep quality', 'scores of HAMA, SDS and EPDS', 'depression and sleep quality', 'sleep quality', 'Hamilton Depression Scale (HAMD), Self-Rating Depression Scale (SDS) and Edinburgh Postpartum Depression Scale (EPDS) scores']","[{'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C1291910', 'cui_str': 'Human anti-mouse antibody'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",96.0,0.0369999,"The scores of HAMA, SDS and EPDS in the combined group after intervention for 1, 2 and 3 months were significantly lower than those in the regular group ( P <0.05).","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Wang', 'Affiliation': 'Department of Medicine, Ordos Insititute of Technology Ordos 017000, Inner Mongolia Autonomous Region, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Continuing Education Center of Ordos Insititute of Technology Ordos 017000, Inner Mongolia Autonomous Region, China.'}]",American journal of translational research,[] 2616,34377316,Effect of a WeChat-based perioperative nursing intervention on risk events and self-management efficacy in patients with thyroid cancer.,"OBJECTIVE This study aimed to explore the effect of perioperative nursing intervention based on WeChat app on the incidence of risk events and self-management efficacy after thyroid cancer surgery. METHODS A total of 96 patients with thyroid cancer were enrolled and divided into a conventional group (n=49) receiving conventional perioperative nursing intervention and the WeChat app group (n=47) receiving WeChat-based perioperative nursing intervention plus conventional nursing. The Chinese version of Strategies Used by People to Promote Health (C-SUPPH) was used to assess self-management efficacy, and the Self-Assessment Scale for Anxiety (SAS) and the Self-Assessment Scale for Depression (SDS) were used to assess psychological status. The occurrence of risk events, changes in self-management efficacy and psychological status, and the occurrence of adverse events were compared between the two groups. RESULTS The risk event rate in the WeChat app group (2.13%) was significantly lower than that of the conventional group (14.29%) ( P <0.05). Stress reduction, positive attitudes, and decision-making scores were elevated in both groups after intervention ( P <0.05), and were significantly higher in the WeChat app group than in the conventional group ( P <0.05). SAS and SDS scores were lower in both groups after intervention ( P <0.05), and were significantly lower in the WeChat app group than in the conventional group ( P <0.05). The rate of postoperative adverse reactions in the WeChat app group (31.91%) was significantly lower than that in the conventional group (73.47%) ( P <0.05). CONCLUSIONS WeChat app-based perioperative nursing interventions can effectively reduce risk events, improve self-management efficacy, and alleviate adverse emotions of thyroid cancer patients, leading to fewer adverse reactions.",2021,"SAS and SDS scores were lower in both groups after intervention ( P <0.05), and were significantly lower in the WeChat app group than in the conventional group ( P <0.05).","['thyroid cancer patients', 'patients with thyroid cancer', '96 patients with thyroid cancer']","['WeChat app-based perioperative nursing interventions', 'WeChat-based perioperative nursing intervention', 'conventional group (n=49) receiving conventional perioperative nursing intervention and the WeChat app group (n=47) receiving WeChat-based perioperative nursing intervention plus conventional nursing', 'perioperative nursing intervention']","['risk event rate', 'Stress reduction, positive attitudes, and decision-making scores', 'occurrence of risk events, changes in self-management efficacy and psychological status, and the occurrence of adverse events', 'Self-Assessment Scale for Anxiety (SAS) and the Self-Assessment Scale for Depression', 'risk events, improve self-management efficacy', 'risk events and self-management efficacy', 'SAS and SDS scores', 'rate of postoperative adverse reactions', 'incidence of risk events and self-management efficacy']","[{'cui': 'C0007115', 'cui_str': 'Malignant tumor of thyroid gland'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038931', 'cui_str': 'Nursing, Perioperative'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036591', 'cui_str': 'Self Assessment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",96.0,0.0233233,"SAS and SDS scores were lower in both groups after intervention ( P <0.05), and were significantly lower in the WeChat app group than in the conventional group ( P <0.05).","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'He', 'Affiliation': ""Department of Ophthalmology-ENT-Stmatology, The First People's Hospital of Fuyang Hangzhou Hangzhou 311400, Zhejiang, China.""}, {'ForeName': 'Jiaying', 'Initials': 'J', 'LastName': 'Xia', 'Affiliation': ""Department of Public Health Division, The First People's Hospital Fuyang District, Hangzhou 311400, Zhejiang, China.""}]",American journal of translational research,[] 2617,34377315,Analysis of rehabilitation in stroke patients in a High Dependency Unit.,"OBJECTIVE To analyze the rehabilitation effict of stroke patients in the High Dependency Unit (HDU). METHODS A retrospective study was conducted on 96 ischemic stroke patients who met the inclusion criteria and were hospitalized in the Department of Rehabilitation Medicine of Qujing No. 1 Hospital by convenience sampling. All patients were divided into two groups according to the inclusion and exclusion criteria: experimental group (n=49) and control group (n=47). The experimental group was admitted to the HDU and treated with the whole-process of full cycle rehabilitation management and treatment, and the control group was admitted to the general ward and treated with the conventional treatment model of the Department of Rehabilitation Medicine. RESULTS The improvement of muscle strength at discharge was compared between the two groups. The results showed that the muscle strength effective rate was 85.7% in the experimental group and 55.3% in the control group, and the difference had statistical significance (P<0.01). The Barthel index score at admission and at discharge were compared between the two groups, the results showed that there was no significant difference in the Barthel index score at admission between the two groups (t=0.668, P>0.05). The Barthel index score at discharge in the experimental group was higher than that in the control group, and the difference had statistical significance (t=7.969, P<0.05). The Montreal Cognitive Assessment (MoCA) score of the experimental group before treatment was (25.67±3.11) points, and the MoCA score after treatment was (29.01±2.21) points; the MoCA score of the control group before treatment was (24.11±4.65) points, and the MoCA score after treatment was (25.35±2.29) points. After implementation of the clinical nursing pathway, the improvement in cognitive function in the experimental group of patients was significantly higher than that in the control group, and the difference had statistical significance (P<0.01). Through the investigation of the satisfaction rate of nursing work in the two groups, it was found that the satisfaction rate in the experimental group was better than that in the control group, and the difference had statistical significance (P<0.05); there was 1 case of pressure sores that occurred in the experimental group, and 3 cases that occurred in the control group, χ 2 =1.133, P=0.287, and the difference had no statistical significance (P>0.05). The length of hospital stay was compared between the two groups, the results showed that the length of hospital stay was (11.76±2.06) days in the experimental group and (14.21±2.40) days in the control group, thus, the average length of hospital stay in the experimental group was less than that in the control group, and the difference had statistical significance (P<0.001). CONCLUSION The whole-process of full cycle rehabilitation management and treatment can improve the activities of daily living, limb muscle strength and cognitive function of patients, as well as shorten the length of hospital stay and improve the satisfaction of patients with treatment. Thus, it is worthy of being widely popularized in clinical application.",2021,"The Barthel index score at discharge in the experimental group was higher than that in the control group, and the difference had statistical significance (t=7.969, P<0.05).","['stroke patients in a High Dependency Unit', 'stroke patients in the High Dependency Unit (HDU', '96 ischemic stroke patients who met the inclusion criteria and were hospitalized in the Department of Rehabilitation Medicine of Qujing No. 1 Hospital by convenience sampling']","['HDU and treated with the whole-process of full cycle rehabilitation management and treatment, and the control group was admitted to the general ward and treated with the conventional treatment model of the Department of Rehabilitation Medicine']","['length of hospital stay', 'muscle strength effective rate', 'cognitive function', 'MoCA score', 'activities of daily living, limb muscle strength and cognitive function', 'satisfaction rate of nursing work', 'Barthel index score at discharge', 'Montreal Cognitive Assessment (MoCA) score', 'average length of hospital stay', 'muscle strength', 'satisfaction rate', 'Barthel index score at admission', 'pressure sores', 'Barthel index score at admission and at discharge']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1627345', 'cui_str': 'Stepdown unit'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0031813', 'cui_str': 'Physical Medicine and Rehabilitation'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}]","[{'cui': 'C1627345', 'cui_str': 'Stepdown unit'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0043030', 'cui_str': 'Wards, General'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031813', 'cui_str': 'Physical Medicine and Rehabilitation'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0011127', 'cui_str': 'Pressure ulcer'}]",,0.0136524,"The Barthel index score at discharge in the experimental group was higher than that in the control group, and the difference had statistical significance (t=7.969, P<0.05).","[{'ForeName': 'Huimin', 'Initials': 'H', 'LastName': 'Yu', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Department of Rehabilitation Medicine, The Second Affiliated Hospital of Kunming Medical University Kunming, Yunnan Province, China.'}, {'ForeName': 'Shuangmei', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}, {'ForeName': 'Yonghua', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}, {'ForeName': 'Wenxian', 'Initials': 'W', 'LastName': 'Yang', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}, {'ForeName': 'Liqing', 'Initials': 'L', 'LastName': 'Yao', 'Affiliation': 'Department of Rehabilitation Medicine, The Second Affiliated Hospital of Kunming Medical University Kunming, Yunnan Province, China.'}, {'ForeName': 'Shaokun', 'Initials': 'S', 'LastName': 'Lv', 'Affiliation': 'Department of Rehabilitation Medicine, Qujing No. 1 Hospital Qujing, Yunnan Province, China.'}]",American journal of translational research,[] 2618,34377312,Comparison of clinical effects of general anesthesia and intraspinal anesthesia on total hip arthroplasty.,"OBJECTIVE To evaluate the clinical effects of general anesthesia and intraspinal anesthesia on total hip arthroplasty. METHODS A total of 110 patients who underwent unilateral total hip arthroplasty in our hospital were randomly divided into the observation group and the control group, with 55 patients in each group. The observation group was given intraspinal anesthesia, while the control group was given general anesthesia. The excellent anesthesia rate, intraoperative blood pressure, intraoperative heart rate, observation time in the postoperative recovery room, the incidence of complications and hospitalization time were observed and compared between the two groups. RESULTS Compared with the control group, the excellent anesthesia rate of the observation group increased (P<0.05). The observation time in the postoperative recovery room, intraoperative blood pressure, intraoperative heart rate and incidence of complications in the observation group were lower than those in the control group (all P<0.05). The hospitalization time of the observation group was significantly shorter than that of the control group (P<0.05). CONCLUSION Intraspinal anesthesia in total hip arthroplasty can significantly improve the excellent anesthesia rate, help maintain the intraoperative blood pressure and heart rate and reduce the observation time in the postoperative recovery room, incidence of complications and hospitalization time of patients, which can be recommended in clinical application.",2021,"The hospitalization time of the observation group was significantly shorter than that of the control group (P<0.05). ","['110 patients who underwent unilateral total hip arthroplasty in our hospital', 'total hip arthroplasty']",['general anesthesia and intraspinal anesthesia'],"['hospitalization time', 'excellent anesthesia rate', 'excellent anesthesia rate, intraoperative blood pressure, intraoperative heart rate, observation time in the postoperative recovery room, the incidence of complications and hospitalization time', 'observation time in the postoperative recovery room, intraoperative blood pressure, intraoperative heart rate and incidence of complications', 'intraoperative blood pressure and heart rate']","[{'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C1283188', 'cui_str': 'Intraspinal'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0034871', 'cui_str': 'Postoperative anesthesia care unit'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",110.0,0.0845354,"The hospitalization time of the observation group was significantly shorter than that of the control group (P<0.05). ","[{'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Ji'nan Hospital of Integrated Traditional Chinese and Western Medicine Ji'nan, Shandong Province, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': ""Department of Anesthesiology, Gucheng County Hospital of Hebei Province (The Eighth People's Hospital of Hengshui) Hengshui, Hebei Province, China.""}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesiology, The Second People's Hospital of Dongying Dongying, Shandong Province, China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Wei County Hospital of Traditional Chinese Medicine Handan, Hebei Province, China.'}, {'ForeName': 'Xiankui', 'Initials': 'X', 'LastName': 'Jia', 'Affiliation': ""Department of Anesthesiology, Heze Dingtao People's Hospital Heze, Shandong Province, China.""}, {'ForeName': 'Yuguo', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Ji'nan Hospital of Integrated Traditional Chinese and Western Medicine Ji'nan, Shandong Province, China.""}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Dong', 'Affiliation': ""Department of Anesthesiology, The Second People's Hospital of Dongying Dongying, Shandong Province, China.""}]",American journal of translational research,[] 2619,34377311,Impact of pain care and hospice care on quality of life in patients with advanced gastric cancer.,"PURPOSE To assess the influence of pain care and hospice care on the quality of life of patients with advanced gastric cancer. METHODS 136 patients with advanced gastric cancer were randomly divided into a experimental group (n=68) and a control group (n=68). The experimental group received pain care combined with hospice care, and control group received routine nursing. We measured quality of life and pain relief to assess the effect of pain care and hospice care. RESULTS After nursing, the visual analogue scale (VAS) of the two groups decreased, the VAS score of the experimental group was lower than that of the control group (P < 0.05). Compared with the control group, the scores of SF-36 questionnaire (physiological function, psychological function, physical pain, emotional function, social function, and mental health) of the control group were lower than those of the experimental group (P < 0.05). CONCLUSIONS Pain care and hospice care can effectively reduce the pain degree of patients with advanced gastric cancer and improve the quality of nursing.",2021,"Compared with the control group, the scores of SF-36 questionnaire (physiological function, psychological function, physical pain, emotional function, social function, and mental health) of the control group were lower than those of the experimental group (P < 0.05). ","['136 patients with advanced gastric cancer', 'patients with advanced gastric cancer']","['pain care combined with hospice care, and control group received routine nursing', 'pain care and hospice care']","['scores of SF-36 questionnaire (physiological function, psychological function, physical pain, emotional function, social function, and mental health', 'quality of life and pain relief', 'pain degree', 'VAS score', 'visual analogue scale (VAS', 'quality of life']","[{'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0085555', 'cui_str': 'Hospice care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0233398', 'cui_str': 'Psychological function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",136.0,0.0377481,"Compared with the control group, the scores of SF-36 questionnaire (physiological function, psychological function, physical pain, emotional function, social function, and mental health) of the control group were lower than those of the experimental group (P < 0.05). ","[{'ForeName': 'Xiaoxia', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': 'Department of Medical Insurance, Traditional Chinese Medicine Hospital Beichen District, Tianjin 300400, China.'}, {'ForeName': 'Suying', 'Initials': 'S', 'LastName': 'Sun', 'Affiliation': 'Department of Internal Medicine, Yantai Affiliated Hospital of Binzhou Medical University Yantai 264000, Shandong, China.'}, {'ForeName': 'Yueling', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Science and Education, Traditional Chinese Medicine Hospital Beichen District, Tianjin 300400, China.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Nursing, Traditional Chinese Medicine Hospital Beichen District, Tianjin 300400, China.'}, {'ForeName': 'Weiying', 'Initials': 'W', 'LastName': 'Meng', 'Affiliation': 'Department of Nursing, Traditional Chinese Medicine Hospital Beichen District, Tianjin 300400, China.'}, {'ForeName': 'Zhixi', 'Initials': 'Z', 'LastName': 'Pang', 'Affiliation': 'Department of Encephalopathy, Traditional Chinese Medicine Hospital Beichen District, Tianjin 300400, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Gao', 'Affiliation': 'Department of Encephalopathy, Traditional Chinese Medicine Hospital Beichen District, Tianjin 300400, China.'}, {'ForeName': 'Botao', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Department of Orthopedics, Traditional Chinese Medicine Hospital Beichen District, Tianjin 300400, China.'}]",American journal of translational research,[] 2620,34377304,Application value of goal-directed fluid therapy with ERAS in patients undergoing radical lung cancer surgery.,"OBJECTIVE To explore the application value of goal-directed fluid therapy (GDFT) in the enhanced recovery after surgery (ERAS) of patients undergoing radical lung cancer surgery (RLCS). METHODS A total of 74 patients undergoing elective RLCS based on the enhance recovery after surgery (ERAS) concept in the HanDan Central Hospital between December 2016 and December 2019 were enrolled and assigned to a group treated by regular conventional liquids (regular group, n=34) and a group treated by goal-directed fluid (GDFT group, n=40) according to the fluid infusion scheme. The two groups were compared in intraoperative fluid inflow and outflow, hemodynamic indexes at 30 min (T0) before operation, 4 h (T1) and 24 h (T2) after operation, postoperative complications, postoperative recovery, inflammatory factors at 1 day (d 0) before operation, and at 1 day (d 1) and 7 days (d 3) after operation, as well as for postoperative life quality. RESULTS Crystalloid fluid input, fluid infusion, and urine output of the GDFT group were all significantly less than those of the regular group (all P <0.05), and the GDFT group showed significantly lower fluctuations of MAP, cardiac index, and stroke volume (SV) than the regular group (all P <0.05). Additionally, the GDFT group showed a significantly lower overall complication rate and experienced notably earlier time to flatus and getting out-of-bed time and notably shorter hospitalization time than the regular group (all P <0.05). Moreover, the GDFT group presented with less fluctuation of IL-10, IL-6, and TNF-α levels and experienced notably higher life quality scores than the regular group. CONCLUSION GDFT is beneficial to the rapid recovery of patients after RLCS, because it can exert a positive effect on maintaining the stability of hemodynamic indexes and reducing inflammation and postoperative complications.",2021,"Moreover, the GDFT group presented with less fluctuation of IL-10, IL-6, and TNF-α levels and experienced notably higher life quality scores than the regular group. ","['patients undergoing radical lung cancer surgery', '74 patients undergoing elective RLCS based on the enhance recovery after surgery (ERAS) concept in the HanDan Central Hospital between December 2016 and December 2019', 'patients undergoing radical lung cancer surgery (RLCS']","['GDFT', 'regular conventional liquids (regular group, n=34) and a group treated by goal-directed fluid (GDFT group, n=40) according to the fluid infusion scheme', 'goal-directed fluid therapy with ERAS', 'goal-directed fluid therapy (GDFT']","['urine output', 'overall complication rate', 'postoperative complications, postoperative recovery, inflammatory factors', 'fluctuation of IL-10, IL-6, and TNF-α levels', 'fluctuations of MAP, cardiac index, and stroke volume (SV', 'postoperative life quality', 'earlier time to flatus and getting out-of-bed time and notably shorter hospitalization time', 'life quality scores', 'intraoperative fluid inflow and outflow, hemodynamic indexes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0016286', 'cui_str': 'Therapy, Fluid'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]","[{'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",74.0,0.343351,"Moreover, the GDFT group presented with less fluctuation of IL-10, IL-6, and TNF-α levels and experienced notably higher life quality scores than the regular group. ","[{'ForeName': 'Xianghui', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesia Operation, The First People's Hospital of Shuangliu District, Chengdu (West China Airport Hospital of Sichuan University) Chengdu 610200, Sichuan Province, China.""}, {'ForeName': 'Xinbo', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}, {'ForeName': 'Xiaona', 'Initials': 'X', 'LastName': 'Wei', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}, {'ForeName': 'Manman', 'Initials': 'M', 'LastName': 'Ma', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}, {'ForeName': 'Danqi', 'Initials': 'D', 'LastName': 'Ren', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}, {'ForeName': 'Yanan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}, {'ForeName': 'Yaning', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}, {'ForeName': 'Yongxue', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Handan Central Hospital Handan 056001, Hebei Province, China.'}]",American journal of translational research,[] 2621,34377301,Effectiveness of supraglottic ventilation by transtracheal catheter for painless ERCP.,"PURPOSE This study aimed to investigate the effect of supraglottic ventilation via transtracheal catheter in painless endoscopic retrograde cholangiopancreatography (ERCP). METHODS Sixty patients with painless ERCP who were treated in our hospital were enrolled as the study subjects and divided into a study group (n=30) and a control group (n=30) according to the method of ventilation during the operation. The control group received ventilation via modified laryngeal mask, while the study group received supraglottic ventilation through a transtracheal tube. The mean arterial pressure (MAP), heart rate (HR), oxygen saturation (SpO 2 ), and End-tidal CO 2 (EtCO 2 ) at multiple time points after admission (T0), after induction of anesthesia (T1), immediately after catheter placement (T2), immediately after operation (T3), and at the time of resuscitation (T4) were compared between the two groups. The incidence of various adverse events in the perioperative period was also compared. RESULTS The two groups showed significant fluctuations in intraoperative hemodynamic parameters. However, the changes in MAP, SpO 2 and ETCO 2 of the study group were more stable, and better than those of the control group at the T2 and T3 ( P <0.05). The intubation time, operation time and recovery time of patients in the study group were significantly lower than those in the control group ( P <0.05). The total incidence of adverse events in the study group was significantly lower than that in the control group ( P <0.05). CONCLUSION It is highly feasible to apply supraglottic ventilation with transvalvular catheter in painless ERCP, which can significantly stabilize the perioperative hemodynamic parameters, accelerate recovery and also help decrease the rate of postoperative complications.",2021,"The intubation time, operation time and recovery time of patients in the study group were significantly lower than those in the control group ( P <0.05).","['painless endoscopic retrograde cholangiopancreatography (ERCP', 'Sixty patients with painless ERCP who were treated in our hospital were enrolled as the study subjects and divided into a study group (n=30) and a control group (n=30) according to the method of ventilation during the operation', 'painless ERCP']","['supraglottic ventilation by transtracheal catheter', 'supraglottic ventilation through a transtracheal tube', 'supraglottic ventilation via transtracheal catheter', 'ventilation via modified laryngeal mask']","['intubation time, operation time and recovery time', 'rate of postoperative complications', 'mean arterial pressure (MAP), heart rate (HR), oxygen saturation (SpO 2 ), and End-tidal CO 2 (EtCO 2 ) at multiple time points after admission (T0), after induction of anesthesia (T1), immediately after catheter placement (T2), immediately after operation (T3), and at the time of resuscitation (T4', 'intraoperative hemodynamic parameters', 'total incidence of adverse events']","[{'cui': 'C0234226', 'cui_str': 'Painless'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0442192', 'cui_str': 'Supraglottic'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0179796', 'cui_str': 'Transtracheal catheter'}, {'cui': 'C0442387', 'cui_str': 'Transtracheal approach'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}]","[{'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0853212', 'cui_str': 'Induction of anaesthesia'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0883301', 'cui_str': 'Catheter placement'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",60.0,0.0154682,"The intubation time, operation time and recovery time of patients in the study group were significantly lower than those in the control group ( P <0.05).","[{'ForeName': 'Shaojin', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Jiying', 'Initials': 'J', 'LastName': 'Nie', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Wencai', 'Initials': 'W', 'LastName': 'Tu', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Changgen', 'Initials': 'C', 'LastName': 'Zhong', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}]",American journal of translational research,[] 2622,34377298,Application research of chronic disease health management in an urban community based on the PRECEDE-PROCEED model in the long-term management of diabetes mellitus.,"OBJECTIVE To evaluate the application of chronic disease health management in an urban community in the long-term management of diabetes mellitus (DM) based on the PRECEDE-PROCEED model. METHODS The PRECEDE-PROCEED model combines PRECEDE (predisposing, enabling and reinforcing constructs in educational diagnosis and evaluation) with PROCEED (policy, management and organization constructs in educational and environmental intervention). A total of 96 diabetic patients treated in our hospital were selected and divided into two groups by random number table, with 48 cases in each group. The routine group was given routine health management, while the PP group was given the urban community chronic disease health management based on the PRECEDE-PROCEED model in addition to the routine health management. After six months of management, the patients' effect was evaluated by comparing the blood glucose, diabetes knowledge, self-efficacy, self-management level and quality of life between the two groups. RESULTS The FPG, 2hPG and HbAlc levels of the PP group were lower than those of the routine group after six months of management (all P<0.05). The 6-month awareness rate, self-efficacy, self-management level and quality of life scores of the PP group were higher than those of the routine group (all P<0.05). CONCLUSION The chronic disease health management in urban communities based on the PRECEDE-PROCEED model in long-term diabetes management can effectively improve patients' diabetes knowledge, lower blood glucose levels, improve self-efficacy and self-management, and improve the quality of life.",2021,"The FPG, 2hPG and HbAlc levels of the PP group were lower than those of the routine group after six months of management (all P<0.05).","['urban communities', 'urban community in the long-term management of diabetes mellitus (DM', '96 diabetic patients treated in our hospital']",[],"['blood glucose, diabetes knowledge, self-efficacy, self-management level and quality of life', 'quality of life', '6-month awareness rate, self-efficacy, self-management level and quality of life scores', 'FPG, 2hPG and HbAlc levels']","[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]",[],"[{'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",96.0,0.00233008,"The FPG, 2hPG and HbAlc levels of the PP group were lower than those of the routine group after six months of management (all P<0.05).","[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Kan', 'Affiliation': 'Hangzhou Road Community Health Service Center, The Fifth Affiliated Hospital of Xinjiang Medical University Urumqi, Xinjiang Uygur Autonomous Region, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Yang', 'Affiliation': 'Department of General Practice, The Fifth Affiliated Hospital of Xinjiang Medical University Urumqi, Xinjiang Uygur Autonomous Region, China.'}, {'ForeName': 'Meifang', 'Initials': 'M', 'LastName': 'Tang', 'Affiliation': 'Department of Nursing, The Fifth Affiliated Hospital of Xinjiang Medical University Urumqi, Xinjiang Uygur Autonomous Region, China.'}]",American journal of translational research,[] 2623,34377297,Application of painless nursing in cesarean delivery parturients due to the failure of natural childbirth via labor analgesia.,"OBJECTIVE To evaluate the application of painless nursing in cesarean delivery parturients due to the failure of natural childbirth via labor analgesia. METHODS A total of 124 parturients who were transferred to cesarean delivery due to the failure of natural childbirth via labor analgesia were selected and randomly divided into two groups. The control group received routine nursing, while the research group was given painless nursing in the operating room, which mainly included interventions in terms of the environment, labor process, and delivery procedure. The visual analog scale (VAS), gestation outcome, stress response, anxiety, sleep quality, and nursing satisfaction were compared between the two groups. RESULTS Compared with the control group, the sleep quality score was significantly lower in the research group (all P<0.001). Compared with before nursing, the anxiety and VAS scores of the two groups were significantly decreased after nursing (P<0.001). Additionally, the anxiety and VAS scores of the research group after nursing were significantly lower than those of the control group (P<0.001). There was no significant difference for the gestation outcome between the two groups (P>0.05). Compared with before nursing, the levels of malondialdehyde (MDA) and reactive oxygen species (ROS) after nursing were significantly downregulated, while the level of superoxide dismutase (SOD) was significantly upregulated in both groups (all P<0.001). Compared with the control group, the levels of MDA and ROS were significantly lower, while SOD level was significantly higher in the research group after nursing (all P<0.001). Compared with the control group, the nursing satisfaction was significantly higher in the research group (P<0.05). CONCLUSION The painless nursing for cesarean delivery parturients in the operating room due to the failure of natural childbirth via labor analgesia can effectively improve the sleep quality and negative moods of the parturients, reduce the degree of pain and stress response in the process of delivery, and result in better satisfaction and compliance.",2021,"Compared with the control group, the nursing satisfaction was significantly higher in the research group (P<0.05). ","['124 parturients who were transferred to cesarean delivery due to the failure of natural childbirth via labor analgesia', 'painless nursing in cesarean delivery parturients']","['routine nursing, while the research group was given painless nursing in the operating room, which mainly included interventions in terms of the environment, labor process, and delivery procedure']","['levels of malondialdehyde (MDA) and reactive oxygen species (ROS', 'levels of MDA and ROS', 'SOD level', 'level of superoxide dismutase (SOD', 'gestation outcome', 'anxiety and VAS scores', 'visual analog scale (VAS), gestation outcome, stress response, anxiety, sleep quality, and nursing satisfaction', 'sleep quality score', 'nursing satisfaction']","[{'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0027484', 'cui_str': 'Natural Childbirth'}, {'cui': 'C1301740', 'cui_str': 'Analgesia in labor'}, {'cui': 'C0234226', 'cui_str': 'Painless'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0234226', 'cui_str': 'Painless'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0162772', 'cui_str': 'Oxygen Species, Reactive'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",124.0,0.0225961,"Compared with the control group, the nursing satisfaction was significantly higher in the research group (P<0.05). ","[{'ForeName': 'Xuqin', 'Initials': 'X', 'LastName': 'Fang', 'Affiliation': ""Quality Control Office, Chun'an Hospital of Traditional Chinese Medicine Hangzhou, Zhejiang Province, China.""}, {'ForeName': 'Jinfeng', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Maternal and Child Health, The Second Hospital of Dongying Dongying, Shandong Province, China.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Duan', 'Affiliation': ""The First Department of Obstetrics, The Eighth People's Hospital of Hengshui Hengshui, Hebei Province, China.""}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Xue', 'Affiliation': 'Department of Respiratory Medicine, Zaozhuang Hospital of Zaozhuang Mining Group Zaozhuang, Shandong Province, China.'}, {'ForeName': 'Jinghua', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Operation Room, The Fourth Hospital of Shijiazhuang Shijiazhuang, Hebei Province, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Fetal Heart Care Unit, The Fourth Hospital of Shijiazhuang Shijiazhuang, Hebei Province, China.'}, {'ForeName': 'Yuanying', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': ""Operating Room, Chun'an Maternal and Child Health Hospital Hangzhou, Zhejiang Province, China.""}]",American journal of translational research,[] 2624,34377292,The curative effect of ultrasonic subgingival curettage combined with Xipayi gingival rinse on patients with chronic periodontitis.,"OBJECTIVES We explored and analyzed the effect and masticatory function of ultrasonic subgingival curettage combined with rinsing and gargling of Xipayi gingival rinse on patients with moderate to severe chronic periodontitis. METHODS We selected 98 patients with moderate to severe chronic periodontitis admitted to our hospital, and randomly divided them into observation group and control group (n=49 in each group). The control group was treated with ultrasonic subgingival curettage. The observation group received ultrasonic subgingival curettage with Xipayi gingival rinse, and continued to use-Xipayi gingival rinse for 4 weeks. The changes of periodontal index, inflammatory degree of gingival crevicular fluid, occlusal and masticatory efficiency before and after treatment were compared. RESULTS The periodontal indexes and the degree of inflammatory factors in gingival crevicular fluid of the two groups post-treatment decreased critically than those of pre-treatment ( P<0.05 ), and the periodontal index and the degree of inflammatory factors in gingival crevicular fluid of the observation group was remarkably lower than those of the control group ( P<0.05 ). The occlusal time and the balance of occlusal force of the two groups decreased significantly post-treatment compared with those of pre-treatment ( P<0.05 ), and the indexes in observation group were dramatically lower than those in control group ( P<0.05 ). The standard deviation of masticatory efficiency in the two groups decreased remarkably post-treatment than that of pre-treatment ( P<0.05 ), and the index in observation group was obviously lower than that in control group ( P<0.05 ). CONCLUSION The combined therapy of ultrasonic subgingival curettage and Xipayi gingival rinse can effectively cure moderate to severe chronic periodontitis. Through this treatment, patients can improve periodontal condition and inhibit periodontal inflammation. Meanwhile, patients can improve the stability of occlusion and increase the bite force, thus improving the chewing efficiency. Therefore, the application of this method is worthy of clinical application.",2021,"The standard deviation of masticatory efficiency in the two groups decreased remarkably post-treatment than that of pre-treatment ( P<0.05 ), and the index in observation group was obviously lower than that in control group ( P<0.05 ). ","['patients with moderate to severe chronic periodontitis', '98 patients with moderate to severe chronic periodontitis admitted to our hospital', 'patients with chronic periodontitis']","['ultrasonic subgingival curettage', 'ultrasonic subgingival curettage with Xipayi gingival rinse, and continued to use-Xipayi gingival rinse', 'ultrasonic subgingival curettage combined with rinsing and gargling of Xipayi gingival rinse', 'observation group and control group ', 'ultrasonic subgingival curettage and Xipayi gingival rinse', 'ultrasonic subgingival curettage combined with Xipayi gingival rinse']","['degree of inflammatory factors in gingival crevicular fluid', 'standard deviation of masticatory efficiency', 'periodontal index and the degree of inflammatory factors in gingival crevicular fluid', 'occlusal time and the balance of occlusal force', 'periodontal index, inflammatory degree of gingival crevicular fluid, occlusal and masticatory efficiency', 'stability of occlusion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0266929', 'cui_str': 'Chronic periodontitis'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0038544', 'cui_str': 'Subgingival curettage'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C1701810', 'cui_str': 'Rinse'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017564', 'cui_str': 'Gingival Exudate'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0031092', 'cui_str': 'Periodontal Indexes'}, {'cui': 'C0447303', 'cui_str': 'Structure of occlusal surface of tooth'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0005654', 'cui_str': 'Masticatory Force'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}]",98.0,0.0173302,"The standard deviation of masticatory efficiency in the two groups decreased remarkably post-treatment than that of pre-treatment ( P<0.05 ), and the index in observation group was obviously lower than that in control group ( P<0.05 ). ","[{'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Mai', 'Affiliation': 'Department of Stomatology, Haikou Longhua Mai Tingting Dental Clinic Haikou 570105, Hainan, China.'}, {'ForeName': 'Dongmei', 'Initials': 'D', 'LastName': 'Lv', 'Affiliation': 'Department of Stomatology, First Clinical Division, Peking University School and Hospital Beijing 100034, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Fu', 'Affiliation': 'Department of Stomatology, Haikou Longhua Mai Yamei Dental Clinic Haikou 570105, Hainan, China.'}]",American journal of translational research,[] 2625,34377291,Effect of Shujin Xiaotong capsules combined with ultrashort wave therapy on pain and inflammatory cytokines in patients with chronic knee osteoarthritis.,"OBJECTIVE To investigate the effect of Shujin Xiaotong capsules combined with ultrashort wave therapy on pain, high-sensitivity C-reactive protein (hs-CRP) level and inflammatory cytokines in patients with chronic knee osteoarthritis. METHODS One hundred and eighteen patients with chronic knee osteoarthritis included in this study were randomly divided into the control group (n=59) and the experimental group (n=59). The patients in the control group were treated with Shujin Xiaotong capsules, and the patients in the experimental group were treated with Shujin Xiaotong capsules combined with ultrashort wave therapy. The knee motion before and after treatment, pain and curative effect were evaluated by the Lysholm Scale, Mc-Gee Scale and Japanese Orthopaedic Association (JOA) Score, respectively. Color Doppler ultrasonography was performed to observe the blood flow in the synovium of knee joint. Serum inflammatory cytokines and oxidative stress indicators were measured using corresponding kits. The quality of life of the patients was measured using the World Health Organization Quality of Life-BREF Scale. RESULTS There was no significant difference in the scores of the Lysholm, Mc-Gee and JOA, synovial blood flow signal distribution, levels of hs-CRP, inflammatory cytokines, superoxide dismutase, malondialdehyde and nitric oxide as well as quality of life of patients between the two groups before treatment (all P>0.05). After treatment, the scores of Lysholm, JOA and World Health Organization Quality of Life-BREF as well as levels of superoxide dismutase in both groups were improved, while the scores of Mc-Gee as well as levels of hs-CRP, inflammatory cytokines, malondialdehyde and nitric oxide in both groups were decreased (all P<0.05). After treatment, compared with the control group, the proportion of synovial blood flow signal distribution and quality of life of patients in the experimental group were higher, while the levels of hs-CRP, inflammatory cytokines, superoxide dismutase, malondialdehyde and nitric oxide were lower (all P<0.05). CONCLUSION Shujin Xiaotong capsules combined with physical ultrashort wave therapy can significantly reduce serum inflammation cytokines and hs-CRP expression and pain, as well as improve serum oxidative stress levels, knee joint function and quality of life in patients with chronic knee osteoarthritis.",2021,"There was no significant difference in the scores of the Lysholm, Mc-Gee and JOA, synovial blood flow signal distribution, levels of hs-CRP, inflammatory cytokines, superoxide dismutase, malondialdehyde and nitric oxide as well as quality of life of patients between the two groups before treatment (all P>0.05).","['patients with chronic knee osteoarthritis', 'One hundred and eighteen patients with chronic knee osteoarthritis']","['physical ultrashort wave therapy', 'Color Doppler ultrasonography', 'Shujin Xiaotong capsules combined with ultrashort wave therapy', 'Shujin Xiaotong capsules']","['serum oxidative stress levels, knee joint function and quality of life', 'pain, high-sensitivity C-reactive protein (hs-CRP) level and inflammatory cytokines', 'pain and curative effect', 'proportion of synovial blood flow signal distribution and quality of life', 'scores of Mc-Gee as well as levels of hs-CRP, inflammatory cytokines, malondialdehyde and nitric oxide', 'Serum inflammatory cytokines and oxidative stress indicators', 'Lysholm Scale, Mc-Gee Scale and Japanese Orthopaedic Association (JOA) Score', 'pain and inflammatory cytokines', 'levels of hs-CRP, inflammatory cytokines, superoxide dismutase, malondialdehyde and nitric oxide', 'scores of the Lysholm, Mc-Gee and JOA, synovial blood flow signal distribution, levels of hs-CRP, inflammatory cytokines, superoxide dismutase, malondialdehyde and nitric oxide as well as quality of life', 'World Health Organization Quality of Life-BREF Scale', 'quality of life', 'scores of Lysholm, JOA and World Health Organization Quality of Life-BREF as well as levels of superoxide dismutase', 'serum inflammation cytokines and hs-CRP expression and pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C4517542', 'cui_str': '118'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0242844', 'cui_str': 'Ultrasonography, Doppler Color'}, {'cui': 'C5200213', 'cui_str': 'xiaotong'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0267642', 'cui_str': 'Celiac infantilism'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",118.0,0.0135748,"There was no significant difference in the scores of the Lysholm, Mc-Gee and JOA, synovial blood flow signal distribution, levels of hs-CRP, inflammatory cytokines, superoxide dismutase, malondialdehyde and nitric oxide as well as quality of life of patients between the two groups before treatment (all P>0.05).","[{'ForeName': 'Zhengbing', 'Initials': 'Z', 'LastName': 'Guo', 'Affiliation': 'Preparation Center, Nanchang Hongdu Hospital of Traditional Chinese Medicine Nanchang, Jiangxi Province, China.'}, {'ForeName': 'Xinwei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Drug Control Office, Nanchang Hongdu Hospital of Traditional Chinese Medicine Nanchang, Jiangxi Province, China.'}, {'ForeName': 'Yaping', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Preparation Center, Nanchang Hongdu Hospital of Traditional Chinese Medicine Nanchang, Jiangxi Province, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Xu', 'Affiliation': 'Preparation Center, Nanchang Hongdu Hospital of Traditional Chinese Medicine Nanchang, Jiangxi Province, China.'}]",American journal of translational research,[] 2626,34377289,Effect of continuous renal replacement therapy adjuvant to broad-spectrum enzyme inhibitors on the efficacy and inflammatory cytokines in patients with severe acute pancreatitis.,"OBJECTIVE To investigate the effect of continuous renal replacement therapy (CRRT) combined with ulinastatin, a broad-spectrum enzyme inhibitor, on the treatment effect and inflammatory mediator levels in patients with severe acute pancreatitis (SAP). METHODS A total of 80 patients with SAP admitted to our hospital were divided into two groups according to a random number table, with 40 cases in the control group and 40 cases in the experimental group. The control group was treated with the broad-spectrum enzyme inhibitor ulinastatin, and the experimental group was treated with continuous renal replacement therapy (CRRT) in addition to the control group's treatment method. The clinical efficacy was evaluated. Serum inflammation indicators, critical illness-related scores, pancreatic microcirculation and coagulation indicators were also detected before and after treatment. RESULTS After 14 days of continuous intervention, the total effective rate of the experimental group was 92.50%, and that of the control group was 75.00%, with statistical significance between the two groups (P<0.05). The expression of APN in the two groups' serum increased, and the other inflammatory indexes decreased. The experimental group's serum APN was higher than that of the control group, and the other inflammatory indexes were lower than those of the control group (all P<0.001). The two groups' critical illness-related scores were improved, and there was a difference between the two groups (P<0.05). The levels of BF and BV increased, while TTP levels decreased, and there was a difference between the experimental and control groups (all P<0.01). The coagulation indexes of the two groups of patients were all improved. Compared with the control group, the coagulation indexes of the experimental group were lower. There was a difference between the two groups (P<0.01). CONCLUSION CRRT adjuvant to broad-spectrum enzyme inhibitor ulinastatin can significantly improve the inflammatory response, microcirculation, hypercoagulability and clinical treatment efficacy in patients with severe acute pancreatitis.",2021,"The levels of BF and BV increased, while TTP levels decreased, and there was a difference between the experimental and control groups (all P<0.01).","['patients with severe acute pancreatitis (SAP', 'patients with severe acute pancreatitis', '80 patients with SAP admitted to our hospital']","['continuous renal replacement therapy adjuvant to broad-spectrum enzyme inhibitors', 'continuous renal replacement therapy (CRRT', 'broad-spectrum enzyme inhibitor ulinastatin', 'continuous renal replacement therapy (CRRT) combined with ulinastatin']","['critical illness-related scores', 'serum APN', 'expression of APN', 'Serum inflammation indicators, critical illness-related scores, pancreatic microcirculation and coagulation indicators', 'efficacy and inflammatory cytokines', 'levels of BF and BV increased, while TTP levels', 'inflammatory indexes', 'total effective rate', 'coagulation indexes', 'inflammatory response, microcirculation, hypercoagulability and clinical treatment efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C3649547', 'cui_str': 'Continuous renal replacement therapy'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0014432', 'cui_str': 'Enzyme inhibitor'}, {'cui': 'C0077906', 'cui_str': 'urinastatin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0030274', 'cui_str': 'Pancreatic structure'}, {'cui': 'C0025962', 'cui_str': 'Microcirculation'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0034155', 'cui_str': 'Thrombotic thrombocytopenic purpura'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0398623', 'cui_str': 'Thrombophilia'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}]",80.0,0.00456897,"The levels of BF and BV increased, while TTP levels decreased, and there was a difference between the experimental and control groups (all P<0.01).","[{'ForeName': 'Qiuping', 'Initials': 'Q', 'LastName': 'Zhu', 'Affiliation': 'Department of Intensive Care Unit, The First Affiliated Hospital of Gannan Medical College Ganzhou, Jiangxi Province, China.'}, {'ForeName': 'Fangqin', 'Initials': 'F', 'LastName': 'Zou', 'Affiliation': 'Department of Nephrology, The First Affiliated Hospital of Gannan Medical College Ganzhou, Jiangxi Province, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Lin', 'Affiliation': 'Department of Intensive Care Unit, The First Affiliated Hospital of Gannan Medical College Ganzhou, Jiangxi Province, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Intensive Care Unit, The First Affiliated Hospital of Gannan Medical College Ganzhou, Jiangxi Province, China.'}, {'ForeName': 'Yulong', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': 'Department of Gastroenterology, The First Affiliated Hospital of Gannan Medical College Ganzhou, Jiangxi Province, China.'}]",American journal of translational research,[] 2627,34377288,"Effect of multidimensional comprehensive intervention on medication compliance, social function and incidence of MACE in patients undergoing PCI.","OBJECTIVE To analyze the effect of multidimensional comprehensive intervention on medication compliance, social function and incidence of major adverse cardiovascular events (MACE) in patients undergoing percutaneous coronary intervention (PCI). METHODS Ninety-eight patients with coronary heart disease (CHD) who underwent PCI in our hospital were selected and divided into the regular group (n=46, receiving regular nursing intervention) and the comprehensive group (n=52, receiving multidimensional comprehensive nursing intervention) according to the different nursing intervention methods. The medication compliance, social function, quality of life, and incidence of MACE were compared between the two groups. RESULTS The comprehensive group showed significantly higher rates of taking medication on time, taking medication according to the proper amount, taking medication at the recomended times, no increase or decrease in the amount of medication, and taking medication without interruption than the regular group ( P < 0.05). The comprehensive group exhibited significantly higher scores of medication compliance than the regular group ( P < 0.05). The Social Disability Screening Schedule (SDSS) scores of both groups during intervention for 8 weeks were lower than those before intervention and after intervention for 2 and 4 weeks ( P < 0.05). The SDSS scores of intervention for 2, 4, and 8 weeks in the comprehensive group were significantly lower than that in the regular group ( P < 0.05). After intervention, the comprehensive group showed significantly higher scores of physiological function, psychological function, cognitive function, emotional function, role function, and total quality of life than the regular group ( P < 0.05). The incidence of MACE in the comprehensive group was significantly lower than that in the regular group ( P < 0.05). CONCLUSION The use of multidimensional comprehensive intervention for patients undergoing PCI can effectively improve patients' medication compliance, social function and quality of life, and reduce the incidence of MACE.",2021,The comprehensive group exhibited significantly higher scores of medication compliance than the regular group ( P < 0.05).,"['Ninety-eight patients with coronary heart disease (CHD) who underwent PCI in our hospital were selected and divided into the regular group (n=46, receiving', 'patients undergoing percutaneous coronary intervention (PCI', 'patients undergoing PCI']","['multidimensional comprehensive intervention', 'regular nursing intervention) and the comprehensive group (n=52, receiving multidimensional comprehensive nursing intervention']","['SDSS scores of intervention', 'medication compliance, social function and incidence of major adverse cardiovascular events (MACE', 'amount of medication, and taking medication without interruption', 'rates of taking medication on time, taking medication', 'medication compliance, social function, quality of life, and incidence of MACE', 'Social Disability Screening Schedule (SDSS) scores', 'scores of physiological function, psychological function, cognitive function, emotional function, role function, and total quality of life', ""patients' medication compliance, social function and quality of life"", 'scores of medication compliance', 'medication compliance, social function and incidence of MACE', 'incidence of MACE']","[{'cui': 'C4319627', 'cui_str': '98'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1290952', 'cui_str': 'Taking medication'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0233398', 'cui_str': 'Psychological function'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",98.0,0.0205318,The comprehensive group exhibited significantly higher scores of medication compliance than the regular group ( P < 0.05).,"[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Cardiovascular Medicine, Jinan People's Hospital Affiliated to Shandong First Medical University Jinan, Shandong, China.""}, {'ForeName': 'Yuhua', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Drug Dispensing, Zibo Central Hospital Zibo, Shandong, China.'}, {'ForeName': 'Jinggang', 'Initials': 'J', 'LastName': 'Xiao', 'Affiliation': ""The Second Department of Cardiovascular Medicine, Linqing People's Hospital Linqing, Shandong, China.""}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Department of General Practice, Zibo Central Hospital Zibo, Shandong, China.'}, {'ForeName': 'Suping', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Department of Geriatrics, Binzhou Hospital of Traditional Chinese Medicine Binzhou, Shandong, China.'}, {'ForeName': 'Xintao', 'Initials': 'X', 'LastName': 'Fu', 'Affiliation': 'Department of Cardiac Surgery, Zibo Municipal Hospital Zibo, Shandong, China.'}]",American journal of translational research,[] 2628,34377278,Effects of esketamine combined with ultrasound-guided nerve block on cognitive function in children with lower extremity fractures.,"OBJECTIVE To explore the effect and complications of esketamine combined with ultrasound-guided nerve block in children with lower extremity fractures. METHODS 120 children with fractures of lower extremities were included into the observation group (OG) and control group (CG) according to the specific anesthesia method. The OG was given esketamine combined with ultrasound-guided nerve block, and the CG was given ultrasound-guided nerve block combined with general anesthesia. Serum norepinephrine (NE), epinephrine (E), renin (R), mean arterial pressure (MAP), heart rate (HR), oxyhemoglobin saturation (SpO 2 ) and respiration rate (RR) were measured before, at 10, 20, and 30 min after anesthesia. The incidence of clinical complications and the anesthetic effects were compared between the two groups. The mini-mental state examination (MMES) scale was performed to evaluate the cognitive function of children in the two groups before and after surgery. RESULTS At 10 min and 20 min after anesthesia, the CG showed higher MAP and HR than the OG ( P <0.05); however, RR and SpO 2 showed no difference between the two groups ( P >0.05). At 30 min after anesthesia, HR and MAP were not significantly different between the two groups ( P >0.05); NE, E, and R showed no significant difference before surgery ( P >0.05), which were higher in CG than those in the OG after surgery ( P <0.05). The success rate of nerve block and anesthesia were 91.67% and 85.00%, respectively in the OG, which were higher than 88.33% and 83.33% in the CG ( P >0.05). The OG had a complication rate of 8.33%, significantly lower than that of 20.00% in the CG ( P <0.05). CONCLUSION Esketamine combined with ultrasound-guided nerve block anesthesia was superior to ultrasound-guided nerve block combined with general anesthesia in children with lower extremity fractures, with fewer compilations.",2021,"At 30 min after anesthesia, HR and MAP were not significantly different between the two groups ( P >0.05); NE, E, and R showed no significant difference before surgery ( P >0.05), which were higher in CG than those in the OG after surgery ( P <0.05).","['children with lower extremity fractures', '120 children with fractures of lower extremities were included into the observation group (OG) and control group (CG) according to the specific anesthesia method']","['Esketamine combined with ultrasound-guided nerve block anesthesia was superior to ultrasound-guided nerve block combined with general anesthesia', 'esketamine combined with ultrasound-guided nerve block', 'esketamine combined with ultrasound-guided nerve block, and the CG was given ultrasound-guided nerve block combined with general anesthesia']","['cognitive function', 'mini-mental state examination (MMES) scale', 'incidence of clinical complications', 'success rate of nerve block and anesthesia', 'complication rate', 'Serum norepinephrine (NE), epinephrine (E), renin (R), mean arterial pressure (MAP), heart rate (HR), oxyhemoglobin saturation (SpO 2 ) and respiration rate (RR', 'anesthetic effects']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1542178', 'cui_str': 'Fracture of lower leg'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C2825616', 'cui_str': 'esketamine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0198802', 'cui_str': 'Nerve block anesthesia'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1947971', 'cui_str': 'Give'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0030069', 'cui_str': 'Oxyhemoglobin'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C3179301', 'cui_str': 'Anesthetic Effects'}]",120.0,0.0516904,"At 30 min after anesthesia, HR and MAP were not significantly different between the two groups ( P >0.05); NE, E, and R showed no significant difference before surgery ( P >0.05), which were higher in CG than those in the OG after surgery ( P <0.05).","[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Hainan Medical College Haikou 570102, Hainan Province, China.'}, {'ForeName': 'Meiting', 'Initials': 'M', 'LastName': 'Pu', 'Affiliation': ""Department of Anesthesiology, Sanya People's Hospital Sanya 572000, Hainan Province, China.""}]",American journal of translational research,[] 2629,34377276,Clinical intervention effect of TACE combined with 3DCRT in patients with primary liver cancer.,"OBJECTIVE To investigate the clinical intervention effect of transcatheter arterial chemoembolization (TACE) combined with three-dimensional conformal radiotherapy (3DCRT) in patients with primary liver cancer (PLC). METHODS A total of 110 PLC patients admitted to our hospital were selected and divided into the study group (SG, n=60, treated with TACE combined with 3DCRT) and the control group (CG, n=50, treated with TACE alone) in accordance with the different clinical intervention measures. The clinical intervention effect and the changes of tumor factors and quality of life scores were compared between the two groups before and after intervention, and the three-year survival and the incidence of adverse reactions were evaluated. RESULTS The objective response rate (ORR) and disease control rate (DCR) in the SG (78.33% and 95.00%) were higher than those in the CG (38.00% and 80.00%), whereas the carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP) levels in the SG were lower than those in the CG ( P < 0.05). After intervention, the quality of life score in the SG was higher than that in the CG ( P < 0.05). The SG was superior to the CG in follow-up survival ( P < 0.05). CONCLUSION TACE combined with 3DCRT has a high safety and leads to remarkable clinical intervention effects, marked improvement of the serological indices, better quality of life, as well as satisfactory long-term survival.",2021,"After intervention, the quality of life score in the SG was higher than that in the CG ( P < 0.05).","['patients with primary liver cancer (PLC', 'patients with primary liver cancer', '110 PLC patients admitted to our hospital']","['transcatheter arterial chemoembolization (TACE) combined with three-dimensional conformal radiotherapy (3DCRT', 'TACE combined with 3DCRT']","['carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP) levels', 'quality of life score', 'adverse reactions', 'objective response rate (ORR) and disease control rate (DCR', 'tumor factors and quality of life scores', 'quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024620', 'cui_str': 'Primary malignant neoplasm of liver'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C2711393', 'cui_str': 'Transarterial chemoembolization of hepatic artery'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0600521', 'cui_str': 'Conformal radiotherapy'}]","[{'cui': 'C0007082', 'cui_str': 'Carcinoembryonic antigen'}, {'cui': 'C0002210', 'cui_str': 'Alpha fetoprotein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]",110.0,0.0299181,"After intervention, the quality of life score in the SG was higher than that in the CG ( P < 0.05).","[{'ForeName': 'Lifeng', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Affiliated Jiangnan Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou Xiaoshan District Hospital of Traditional Chinese Medicine, Hangzhou Xiaoshan District Hospital of Traditional Chinese Medicine General Hospital Hangzhou 311200, Zhejiang Province, China.'}, {'ForeName': 'Zhuliang', 'Initials': 'Z', 'LastName': 'Qian', 'Affiliation': 'Affiliated Jiangnan Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou Xiaoshan District Hospital of Traditional Chinese Medicine, Hangzhou Xiaoshan District Hospital of Traditional Chinese Medicine General Hospital Hangzhou 311200, Zhejiang Province, China.'}, {'ForeName': 'Jianchang', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Affiliated Jiangnan Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou Xiaoshan District Hospital of Traditional Chinese Medicine, Hangzhou Xiaoshan District Hospital of Traditional Chinese Medicine General Hospital Hangzhou 311200, Zhejiang Province, China.'}]",American journal of translational research,[] 2630,34377275,The effect of psychological nursing on the short- and long-term negative emotions and quality of life of cervical cancer patients undergoing postoperative chemotherapy.,"OBJECTIVE The purpose of this study was to analyze the effect of psychological nursing intervention on the short- and long-term negative emotions and changes in the quality of life in patients with cervical cancer who underwent postoperative chemotherapy. METHODS 141 patients with cervical cancer who received postoperative chemotherapy in our hospital were recruited as the study cohort. They were divided into the study group (80 cases) and the control group (61 cases) according to the different nursing methods each underwent. The patients in the control group underwent routine nursing, and the study group also underwent psychological nursing. The changes in the quality of life and the negative emotions of the patients in the two groups before and after the intervention were compared, and the correlation between the quality of life and the negative emotions were explored. RESULTS The patients' Quality of Life Questionnaire (EROTC-QLQ-C30) and Self-rating Anxiety Scale (SAS) scores in the two groups before the intervention were not significantly different (P > 0.05). A re-evaluation at the end of the 90 day-intervention showed that the EROTC-QLQ-C30 scores in the study group were significantly higher than they were in the control group (P < 0.05). A dynamic evaluation showed that the proportion of patients with mild anxiety in the study group was higher than it was in the control group at 30, 60, and 90 days of intervention (P < 0.05). A Spearman correlation analysis showed that the SAS scale and EROTC-QLQ-C30 scores were negatively correlated (r=-0.4438, P < 0.05). CONCLUSION The implementation of psychological intervention can help alleviate the short- and long-term negative emotions of cervical cancer patients who underwent postoperative chemotherapy, and it is feasible and conducive to the patients' quality of life. We recommend carrying out the clinical promotion and application of this psychological intervention.",2021,"A Spearman correlation analysis showed that the SAS scale and EROTC-QLQ-C30 scores were negatively correlated (r=-0.4438, P < 0.05). ","['cervical cancer patients who underwent', '141 patients with cervical cancer who received postoperative chemotherapy in our hospital were recruited as the study cohort', 'patients with cervical cancer who underwent postoperative chemotherapy', 'cervical cancer patients undergoing postoperative chemotherapy']","['postoperative chemotherapy', 'psychological intervention', 'routine nursing', 'psychological nursing intervention', 'psychological nursing']","['Quality of Life Questionnaire (EROTC-QLQ-C30) and Self-rating Anxiety Scale (SAS) scores', 'EROTC-QLQ-C30 scores', 'quality of life and the negative emotions', 'SAS scale and EROTC-QLQ-C30 scores', 'proportion of patients with mild anxiety', 'quality of life']","[{'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C1273551', 'cui_str': 'Postoperative chemotherapy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C1273551', 'cui_str': 'Postoperative chemotherapy'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231401', 'cui_str': 'Mild anxiety'}]",141.0,0.011381,"A Spearman correlation analysis showed that the SAS scale and EROTC-QLQ-C30 scores were negatively correlated (r=-0.4438, P < 0.05). ","[{'ForeName': 'Muzi', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Department of Oncology, Rheumatology and Immunology, The First Affiliated Hospital of Qiqihar Medical College Qiqihar 161041, Heilongjiang, China.'}, {'ForeName': 'Jianli', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Dialysis Room, The First Affiliated Hospital of Qiqihar Medical College Qiqihar 161041, Heilongjiang, China.'}, {'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Sun', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Qiqihar Medical College Qiqihar 161041, Heilongjiang, China.'}, {'ForeName': 'Guifeng', 'Initials': 'G', 'LastName': 'Liu', 'Affiliation': 'The Third Department of General Surgery, The First Affiliated Hospital of Qiqihar Medical College Qiqihar 161041, Heilongjiang, China.'}]",American journal of translational research,[] 2631,34377273,Effect of continuous nursing on negative emotion and quality of life in patients with leukemia under chemotherapy.,"OBJECTIVE To investigate the effect of continuous nursing on negative emotion and quality of life in patients with leukemia under chemotherapy. METHODS Ninety-two patients with leukemia who received chemotherapy in our department were divided into observation group (n=46) and control group (n=46) according to the random number table. The patients in the control group were treated with routine nursing. The patients in the observation group were treated with continuous nursing on the basis of routine nursing. The scores of Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA) and Quality of Life Index Scale (Spitzer) of patients on admission and one month after discharge in both groups were compared. RESULTS There was no significant difference in HAMD, HAMA and Spitzer scores of patients on admission between the two groups (P>0.05). After one month of discharge, the HAMD and HAMA scores of patients in both groups were decreased, while the Spitzer scores of patients in both groups were increased (all P<0.05). In addition, compared with the control group, the HAMD and HAMA scores in the observation group were lower, while the Spitzer scores and nursing satisfaction in the observation group were higher (all P<0.001). The incidence of chemotherapy-related adverse reactions in the observation group was lower than that in the control group (P<0.01). CONCLUSION Continuous nursing can improve the negative emotion, quality of life and nursing satisfaction in patients with leukemia under chemotherapy.",2021,"There was no significant difference in HAMD, HAMA and Spitzer scores of patients on admission between the two groups (P>0.05).","['patients with leukemia under chemotherapy', 'Ninety-two patients with leukemia who received chemotherapy in our department were divided into observation group (n=46) and control group (n=46) according to the random number table']","['continuous nursing', 'routine nursing']","['incidence of chemotherapy-related adverse reactions', 'negative emotion and quality of life', 'scores of Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA) and Quality of Life Index Scale (Spitzer) of patients on admission and one month after discharge', 'negative emotion, quality of life and nursing satisfaction', 'Spitzer scores and nursing satisfaction', 'HAMD and HAMA scores', 'HAMD, HAMA and Spitzer scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023418', 'cui_str': 'Leukemia'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0039224', 'cui_str': 'Table'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451498', 'cui_str': 'Spitzer quality of life index'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457453', 'cui_str': 'On admission'}, {'cui': 'C4082115', 'cui_str': 'One month'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",92.0,0.0144697,"There was no significant difference in HAMD, HAMA and Spitzer scores of patients on admission between the two groups (P>0.05).","[{'ForeName': 'Zhuanyi', 'Initials': 'Z', 'LastName': 'Sun', 'Affiliation': 'Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Yunhua', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang Province, China.'}, {'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Feng', 'Affiliation': 'Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang Province, China.'}]",American journal of translational research,[] 2632,34383324,The effect of two rotary and two reciprocating NiTi systems on postoperative pain after root canal retreatment on single-rooted incisor teeth: A randomized controlled trial.,"AIM This randomized clinical trial aimed to assess the effect of two rotary (ProTaper Retreatment + ProTaper Gold and Hyflex EDM) and two reciprocating (Reciproc Blue and WaveOne Gold) NiTi systems on postoperative pain after root canal retreatment on single-rooted incisor teeth. METHODOLOGY One hundred and eighty patients scheduled for root canal retreatment were randomly assigned to one of the four groups according to the NiTi system (ProTaper Retreatment + ProTaper Gold, Hyflex EDM, Reciproc Blue or WaveOne Gold) used for removal of root canal fillings and further canal preparation. The working length was determined to be 1 mm shorter than the ""0.0"" mark of the apex locator. Root canals were filled with gutta-percha and epoxy resin-based root canal sealer using a lateral condensation technique. The teeth were restored using a resin composite material. A single operator performed the retreatments in a single visit. The incidence and intensity of postoperative pain were rated on a numeric rating scale by patients at 24, 48, and 72 h after retreatment. The number of analgesic tablets (400 mg Ibuprofen) taken by patiens was also recorded. Data were analysed using Mann - Whitney U, Wilcoxon, and chi-square tests. RESULTS For the intensity of postoperative pain, the difference between the four groups was not significantly different (P > 0.05). No significant difference was found between the groups in terms of analgesic medication intake (P > 0.05). CONCLUSIONS The rotary and reciprocating NiTi systems tested in this study were associated with similar levels of postoperative pain and intake of analgesics following root canal retreatment on single-rooted incisor teeth completed in one visit.",2021,"For the intensity of postoperative pain, the difference between the four groups was not significantly different (P > 0.05).","['One hundred and eighty patients scheduled for root canal retreatment', 'after root canal retreatment on single-rooted incisor teeth']","['NiTi system (ProTaper Retreatment + ProTaper Gold, Hyflex EDM, Reciproc Blue or WaveOne Gold) used for removal of root canal fillings and further canal preparation', 'gutta-percha and epoxy resin-based root canal sealer using a lateral condensation technique', 'two rotary and two reciprocating NiTi systems', 'two rotary (ProTaper Retreatment + ProTaper Gold and Hyflex EDM) and two reciprocating (Reciproc Blue and WaveOne Gold', 'NiTi systems']","['numeric rating scale', 'intensity of postoperative pain', 'analgesic medication intake', 'postoperative pain and intake of analgesics', 'number of analgesic tablets', 'working length', 'postoperative pain', 'incidence and intensity of postoperative pain']","[{'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}]","[{'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0035848', 'cui_str': 'Root canal obturation'}, {'cui': 'C0086881', 'cui_str': 'Pulp canal'}, {'cui': 'C0018407', 'cui_str': 'Gutta percha'}, {'cui': 'C3489722', 'cui_str': 'epoxy resin-based root canal sealer'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0233656', 'cui_str': 'Mental condensation'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",180.0,0.104375,"For the intensity of postoperative pain, the difference between the four groups was not significantly different (P > 0.05).","[{'ForeName': 'Burhan Can', 'Initials': 'BC', 'LastName': 'Çanakçi', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Trakya University, Edirne.'}, {'ForeName': 'Özgür', 'Initials': 'Ö', 'LastName': 'Er', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Trakya University, Edirne.'}, {'ForeName': 'Özgür', 'Initials': 'Ö', 'LastName': 'Genç Şen', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Yüzüncü Yıl University, Van.'}, {'ForeName': 'Necdet', 'Initials': 'N', 'LastName': 'Süt', 'Affiliation': 'Department of Biostatistics, Medical Faculty, Trakya University, Edirne, Turkey.'}]",International endodontic journal,['10.1111/iej.13609'] 2633,34383312,Evaluating longitudinal therapy effects via the North Star Ambulatory Assessment.,"INTRODUCTION/AIMS In comparative studies, treatment effects are typically evaluated at a specific time point. When data are collected periodically, an alternative, clinically meaningful approach could be used to assess the totality of treatment effects. We applied a well-developed analytical procedure for evaluating longitudinal treatment effects using North Star Ambulatory Assessment (NSAA) data for illustration. METHODS The NSAA comprises 17 scorable items/outcomes which measure changes in motor function. Using NSAA data from the published ataluren phase 3, randomized, placebo-controlled trial (NCT01826487), cumulative counts of failures to perform each item (transition from 2/1 [able/impaired] to 0 [unable]) were collected at specified time points for each patient over 48 weeks. Treatment group-wise mean cumulative item failure count curves were constructed, comparing ataluren versus placebo and deflazacort versus prednisone/prednisolone among placebo-treated patients. The steeper the curve, the worse the outcome. A clinically meaningful summary of the between-group difference was provided for each comparison. RESULTS The curve was uniformly steeper for placebo than ataluren after 16 weeks and for prednisone/prednisolone than deflazacort after 8 weeks. The two curves in each comparison continued to diverge thereafter, indicating sustained treatment benefits over time. Calculated using a unique analytical approach, cumulative failure rates were reduced, on average, by 27% for ataluren versus placebo (rate ratio, 0.73; 95% confidence interval [CI] 0.55-0.97; p = 0.027) and 28% for deflazacort versus prednisone/prednisolone (rate ratio, 0.72; 95% CI 0.53-0.96; p = 0.028). DISCUSSION Unlike fixed-time analyses, this analytical approach enabled demonstration of cumulative, longitudinal treatment effects over time using repeatedly measured NSAA observations.",2021,The curve was uniformly steeper for placebo than ataluren after 16 weeks and for prednisone/prednisolone than deflazacort after 8 weeks.,[],"['prednisone/prednisolone', 'placebo']","['cumulative failure rates', 'motor function']",[],"[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}]",,0.233059,The curve was uniformly steeper for placebo than ataluren after 16 weeks and for prednisone/prednisolone than deflazacort after 8 weeks.,"[{'ForeName': 'Craig M', 'Initials': 'CM', 'LastName': 'McDonald', 'Affiliation': 'Physical Medicine & Rehabilitation, University of California Davis, Davis, California, USA.'}, {'ForeName': 'Lee-Jen', 'Initials': 'LJ', 'LastName': 'Wei', 'Affiliation': 'Harvard University, Boston, Massachusetts, USA.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Flanigan', 'Affiliation': ""Nationwide Children's Hospital, Columbus, Ohio, USA.""}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Elfring', 'Affiliation': 'PTC Therapeutics Inc, 100 Corporate Court, New Jersey, USA.'}, {'ForeName': 'Panayiota', 'Initials': 'P', 'LastName': 'Trifillis', 'Affiliation': 'PTC Therapeutics Inc, 100 Corporate Court, New Jersey, USA.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Muntoni', 'Affiliation': 'University College London Great Ormond Street Institute of Child Health and NIHR Biomedical Research Centre, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Muscle & nerve,['10.1002/mus.27396'] 2634,34383296,Teaching pediatric behavior management in student dentists with constructive video feedback from faculty.,"PURPOSE The range of child behaviors encountered in real-life situations far exceeds that of any classroom-based simulated scenarios. For such reasons, clinical training with real-time clinical supervisor's feedback is optimal for learner-centricity. This study aimed to objectively evaluate the effect of video feedback on the student dentist's ability to manage behaviors in children. METHODS Third-year dental student volunteers were randomly allocated to two groups: control and intervention. They were video recorded for three pediatric dental treatment sessions and received standard feedback for all sessions. Additionally, the intervention group received two constructive 1-on-1 feedback sessions after the first and second video sessions. Students' application of behavior management techniques for all recorded treatment sessions was scored with a study-specific objective scale (maximum score: 20; larger score indicating better performance) by two independent and blinded evaluators. A self-administered student questionnaire elicited subjective feedback on the intervention. RESULTS There was a significant difference (p = 0.008) between behavior management scores when comparing all pre-intervention sessions (10.74 ± 3.55) and all post-intervention sessions (13.57 ± 2.96). The intervention significantly improved these techniques: 1. Providing specific feedback - positive reinforcement and descriptive praise (p = 0.006) and 2. Distraction - Using imagination with stories and singing (p = 0.035). The feedback sessions (4.29 ± 0.54) were perceived to be significantly (p = 0.032) more effective than having the students view the videos on their own (3.76 ± 0.87). CONCLUSION Video feedback improved the behavior management scores of student dentists. The faculty feedback sessions were found by student dentists to improve confidence and the techniques for managing children.",2021,"The feedback sessions (4.29 ± 0.54) were perceived to be significantly (p = 0.032) more effective than having the students view the videos on their own (3.76 ± 0.87). ","['student dentists with constructive video feedback from faculty', 'children', 'student dentists', 'Third-year dental student volunteers']","['constructive 1-on-1 feedback sessions', 'Video feedback', 'video feedback']",['behavior management scores'],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0011441', 'cui_str': 'Dentist'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038493', 'cui_str': 'Dental Student'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0150143', 'cui_str': 'Behavior management'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.00349899,"The feedback sessions (4.29 ± 0.54) were perceived to be significantly (p = 0.032) more effective than having the students view the videos on their own (3.76 ± 0.87). ","[{'ForeName': 'Shijia', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'Faculty of Dentistry, National University of Singapore, Singapore, Singapore.'}, {'ForeName': 'Betty Yuen Yue', 'Initials': 'BYY', 'LastName': 'Mok', 'Affiliation': 'Faculty of Dentistry, National University of Singapore, Singapore, Singapore.'}, {'ForeName': 'Wee Wah', 'Initials': 'WW', 'LastName': 'Tok', 'Affiliation': 'Faculty of Dentistry, National University of Singapore, Singapore, Singapore.'}, {'ForeName': 'Mun Loke', 'Initials': 'ML', 'LastName': 'Wong', 'Affiliation': 'Faculty of Dentistry, National University of Singapore, Singapore, Singapore.'}, {'ForeName': 'Catherine Hsu Ling', 'Initials': 'CHL', 'LastName': 'Hong', 'Affiliation': 'Faculty of Dentistry, National University of Singapore, Singapore, Singapore.'}]",Journal of dental education,['10.1002/jdd.12756'] 2635,34383274,Impact of transdermal trigeminal electrical neuromodulation on subjective and objective sleep parameters in patients with insomnia: a pilot study.,"PURPOSE Transcutaneous trigeminal electrical neuromodulation (TTEN) is a new treatment modality that has a potential to improve sleep through the suppression of noradrenergic activity. This study aimed to explore the changes of subjective and objective sleep parameters after 4-weeks of daily session of transcutaneous trigeminal electrical neuromodulation in a group of patients with insomnia. METHODS In a group of patients with insomnia, TTEN targeting the ophthalmic division of the trigeminal nerve was utilized to test the effects of transcutaneous trigeminal electrical neuromodulation. Patients went through daily 20-min sessions of TTEN for 4 weeks. Polysomnography parameters, Pittsburgh sleep quality index, insomnia severity index, and Epworth sleepiness scale were obtained pre- and post-intervention. Changes in these parameters were compared and analyzed. RESULTS Among 13 patients with insomnia there was a statistically significant reduction in Pittsburgh sleep quality index, insomnia severity index, and Epworth sleepiness scale scores after 4-week daily sessions of TTEN. There were no differences in polysomnography parameters pre- and post-intervention. CONCLUSION This is the first study to demonstrate the effects of TTEN in a group of insomnia patients. TTEN may improve subjective parameters in patients with insomnia. Further replication studies are needed to support this finding. TRIAL REGISTRATION The data presented in the study are from a study exploring the effect of TTEN on insomnia ( www.clinicaltrials.gov , registration number: NCT04838067, date of registration: April 8, 2021, ""retrospectively registered"").",2021,"Among 13 patients with insomnia there was a statistically significant reduction in Pittsburgh sleep quality index, insomnia severity index, and Epworth sleepiness scale scores after 4-week daily sessions of TTEN.","['patients with insomnia', 'patients with\xa0insomnia', '13 patients with insomnia', 'group of insomnia patients']","['Transcutaneous trigeminal electrical neuromodulation (TTEN', 'transdermal trigeminal electrical neuromodulation', 'TTEN', 'transcutaneous trigeminal electrical neuromodulation']","['Polysomnography parameters, Pittsburgh sleep quality index, insomnia severity index, and Epworth sleepiness scale', 'subjective parameters', 'Pittsburgh sleep quality index, insomnia severity index, and Epworth sleepiness scale scores', 'subjective and objective sleep parameters']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0394674', 'cui_str': 'Neurostimulation/modulation'}, {'cui': 'C0040652', 'cui_str': 'Transdermal route'}]","[{'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C3541276', 'cui_str': 'Epworth Sleepiness Scale'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C4706348', 'cui_str': 'ESS (Epworth Sleepiness Scale) score'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",13.0,0.0209415,"Among 13 patients with insomnia there was a statistically significant reduction in Pittsburgh sleep quality index, insomnia severity index, and Epworth sleepiness scale scores after 4-week daily sessions of TTEN.","[{'ForeName': 'Yoo Hyun', 'Initials': 'YH', 'LastName': 'Um', 'Affiliation': ""Department of Psychiatry, St.Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Sheng-Min', 'Initials': 'SM', 'LastName': 'Wang', 'Affiliation': ""Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Dong Woo', 'Initials': 'DW', 'LastName': 'Kang', 'Affiliation': ""Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Nak-Young', 'Initials': 'NY', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation, Uiwang, Republic of Korea.'}, {'ForeName': 'Hyun Kook', 'Initials': 'HK', 'LastName': 'Lim', 'Affiliation': ""Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. drblues@catholic.ac.kr.""}]",Sleep & breathing = Schlaf & Atmung,['10.1007/s11325-021-02459-0'] 2636,34383261,"The Durability of an Intensive, Structured Education-Based Rehabilitation Protocol for Best Insulin Injection Practice: The ISTERP-2 Study.","INTRODUCTION Studies on the durability of an intensive, structured education protocol on best insulin injection practice are missing for people with type 2 diabetes mellitus (T2DM). The aim of this study was to assess the durability of an intensive, structured education-based rehabilitation protocol on best insulin injection practice in well-trained subjects from our previous intensive, multimedia intervention study registered as the ISTERP-1 study. A total of 158 subjects with T2DM from the well-trained group of the 6-month-long ISTERP-1 study, all of whom had successfully attained lower glucose levels compared to baseline levels with lower daily insulin doses and with less frequent and severe hypoglycemic episodes, participated in the present investigation involving an additional 6-month follow-up period, called the ISTERP-2 study. METHODS Participants were randomized into an intervention group and a control group, depending on whether they were provided or not provided with further education refresher courses for 6 months. At the end of the 6 months, the two groups were compared in terms of injection habits, daily insulin dose requirement, number of severe or symptomatic hypoglycemic events, and glycated hemoglobin (HbA1c) levels. RESULTS Despite being virtually superimposable at baseline, the two groups behaved quite differently during the follow-up. The within-group analysis of observed parameters showed that the subjects in the intervention group maintained and even improved the good behavioral results learned during the ISTERP-1 study by further reducing both the rate of injection technique errors (p < 0.001) and size of lipohypertrophic lesions at injection sites (p < 0.02). Conversely, those in the control group progressively abandoned best practice, except for the use of ice-cold insulin and, consequently, had significantly higher HbA1c levels and daily insulin dose requirements at the end of the follow-up than at baseline (p < 0.05). In addition, as expected from all the above, the rate of hypoglycemic episodes also decreased in the intervention group (p < 0.05), resulting in a significant difference between groups after 6 months (p < 0.02). CONCLUSION Our data provide evidence that intensive, structured education refresher courses have no outstanding durability, so that repeated refresher courses, at least at 6-month intervals, are needed to have positive effects on people with T2DM, contributing not only to prevention but also to long-term rehabilitation. TRIAL REGISTRATION Trial Registration no. 118 bis/15.04.2018.",2021,The within-group analysis of observed parameters showed that the subjects in the intervention group maintained and even improved the good behavioral results learned during the ISTERP-1 study by further reducing both the rate of injection technique errors (p < 0.001) and size of lipohypertrophic lesions at injection sites (p < 0.02).,"['well-trained subjects from our previous intensive, multimedia intervention study registered as the ISTERP-1 study', '158 subjects with T2DM from the well-trained group of the 6-month-long ISTERP-1 study, all of whom had successfully attained lower glucose levels compared to baseline levels with lower daily insulin doses and with less frequent and severe hypoglycemic episodes, participated in the present investigation involving an additional 6-month follow-up period, called the ISTERP-2 study', 'Participants', 'people with type 2 diabetes mellitus (T2DM']","['intensive, structured education-based rehabilitation protocol']","['injection habits, daily insulin dose requirement, number of severe or symptomatic hypoglycemic events, and glycated hemoglobin (HbA1c) levels', 'rate of hypoglycemic episodes', 'size of lipohypertrophic lesions', 'HbA1c levels and daily insulin dose requirements', 'rate of injection technique errors']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0860801', 'cui_str': 'Glucose low'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0745153', 'cui_str': 'Hypoglycaemic episode'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0745153', 'cui_str': 'Hypoglycaemic episode'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960425', 'cui_str': 'Injection technique'}]",158.0,0.0672994,The within-group analysis of observed parameters showed that the subjects in the intervention group maintained and even improved the good behavioral results learned during the ISTERP-1 study by further reducing both the rate of injection technique errors (p < 0.001) and size of lipohypertrophic lesions at injection sites (p < 0.02).,"[{'ForeName': 'Sandro', 'Initials': 'S', 'LastName': 'Gentile', 'Affiliation': 'Nefrocenter Research and Nyx Start-Up, Naples, Italy.'}, {'ForeName': 'Giuseppina', 'Initials': 'G', 'LastName': 'Guarino', 'Affiliation': 'Nefrocenter Research and Nyx Start-Up, Naples, Italy.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Della Corte', 'Affiliation': 'Nefrocenter Research and Nyx Start-Up, Naples, Italy.'}, {'ForeName': 'Giampiero', 'Initials': 'G', 'LastName': 'Marino', 'Affiliation': 'Department of Internal Medicine, Campania University ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Ersilia', 'Initials': 'E', 'LastName': 'Satta', 'Affiliation': 'Nefrocenter Research and Nyx Start-Up, Naples, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pasquarella', 'Affiliation': 'Nefrocenter Research and Nyx Start-Up, Naples, Italy.'}, {'ForeName': 'Carmine', 'Initials': 'C', 'LastName': 'Romano', 'Affiliation': 'Nefrocenter Research and Nyx Start-Up, Naples, Italy.'}, {'ForeName': 'Carmelo', 'Initials': 'C', 'LastName': 'Alfrone', 'Affiliation': 'Nefrocenter Research and Nyx Start-Up, Naples, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Giordano', 'Affiliation': 'Emodialysis Center Srl, Nefrocenter Network, Naples, Italy.'}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Loiacono', 'Affiliation': 'Nefrocenter Research, Naples, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Capace', 'Affiliation': 'Vomero Center Crisci Bersabea & C SNC, Nefrocenter Network, Naples, Italy.'}, {'ForeName': 'Rossella', 'Initials': 'R', 'LastName': 'Lamberti', 'Affiliation': 'Metelliano Medical Center, Nefrocenter Network, Naples, Italy.'}, {'ForeName': 'Felice', 'Initials': 'F', 'LastName': 'Strollo', 'Affiliation': 'Endocrinology and Diabetes, IRCCS San Raffaele Pisana, Rome, Italy. felix.strollo@gmail.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-021-01108-9'] 2637,34382998,Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.,"Importance Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment with cetuximab plus avelumab with overall survival (OS) may be worthy of investigation in this setting. Objective To assess the efficacy and safety of cetuximab rechallenge therapy plus avelumab. Design, Setting, and Participants This single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020. Eligible patients with RAS WT mCRC had a complete or partial response to first-line chemotherapy plus anti-EGFR drugs, developed acquired resistance, and failed second-line therapy. Baseline circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R mutation analysis was done. Interventions Patients received avelumab (10 mg/kg every 2 weeks) and cetuximab (400 mg/m2 and, subsequently, 250 mg/m2 weekly) until disease progression or unacceptable toxic effects. Main Outcomes and Measures The primary end point was OS. Secondary end points were progression-free survival (PFS), overall response rate (ORR), and safety. Results Seventy-seven patients were enrolled (42 men, 35 women; median age, 63 years); 71 had microsatellite stable tumors (MSS), 3 microsatellite instability-high tumors (MSI-H), 3 unknown. The study met the primary end point, with median OS (mOS) of 11.6 months (95% CI, 8.4-14.8 months). Median PFS (mPFS) was 3.6 months (95% CI, 3.2-4.1 months). Common grade-3 adverse events were cutaneous eruption, 11 (14%), and diarrhea, 3 (4%). For 67 of 77 (87%) patients, baseline analysis of plasma circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R variations was feasible. Forty-eight patients had WT disease, whereas 19 had mutations. Patients with RAS/BRAF WT ctDNA had mOS of 17.3 months (95% CI, 12.5-22.0 months) compared with 10.4 months (95% CI, 7.2-13.6 months) in patients with mutated ctDNA (hazard ratio [HR], 0.49; 95% CI, 0.27-0.90; P = .02). The mPFS was 4.1 months (95% CI, 2.9-5.2 months) in RAS/BRAF WT patients compared with 3.0 months (95% CI, 2.6-3.5 months) in patients with mutated ctDNA (HR, 0.42; 95% CI, 0.23-0.75; P = .004). Conclusions and Relevance The findings of this single-arm phase 2 trial suggest that cetuximab plus avelumab is an active, well tolerated rechallenge therapy in RAS WT mCRC. Plasma ctDNA analysis before treatment may allow selection of patients who could benefit. Trial Registration ClinicalTrials.gov Identifier: NCT04561336.",2021,"Median PFS (mPFS) was 3.6 months (95% CI, 3.2-4.1 months).","['patients who could benefit', 'Seventy-seven patients were enrolled (42 men, 35 women; median age, 63 years); 71 had microsatellite stable tumors (MSS), 3 microsatellite instability-high tumors (MSI-H), 3 unknown', 'Pretreated Patients', 'Forty-eight patients had WT disease, whereas 19 had mutations', 'patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC', 'Participants\n\n\nThis single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020', 'With RAS Wild-type Metastatic Colorectal Cancer', 'Eligible patients with RAS WT mCRC']","['cetuximab', 'avelumab', 'Cetuximab Rechallenge Plus Avelumab', 'anti-epidermal growth factor receptor (EGFR) drugs', 'cetuximab plus avelumab', 'cetuximab rechallenge therapy plus avelumab']","['Baseline circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R mutation analysis', 'complete or partial response', 'efficacy and safety', 'OS', 'overall survival (OS', 'progression-free survival (PFS), overall response rate (ORR), and safety', 'median OS (mOS', 'plasma circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R variations', 'Median PFS (mPFS', 'diarrhea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1519302', 'cui_str': 'Short Tandem Repeats'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0796369', 'cui_str': 'Microsatellite instability'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C4055417', 'cui_str': 'avelumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C3827014', 'cui_str': 'Cell-Free Tumor DNA'}, {'cui': 'C1259929', 'cui_str': 'BRAF protein, human'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",77.0,0.295568,"Median PFS (mPFS) was 3.6 months (95% CI, 3.2-4.1 months).","[{'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Martinelli', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Martini', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Famiglietti', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Troiani', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Napolitano', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Pietrantonio', 'Affiliation': 'Oncologia Medica, Istituto Nazionale dei Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Ciardiello', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Marinella', 'Initials': 'M', 'LastName': 'Terminiello', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Carola', 'Initials': 'C', 'LastName': 'Borrelli', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Pietro Paolo', 'Initials': 'PP', 'LastName': 'Vitiello', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'De Braud', 'Affiliation': 'Oncologia Medica, Istituto Nazionale dei Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Morano', 'Affiliation': 'Oncologia Medica, Istituto Nazionale dei Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Avallone', 'Affiliation': 'Biologia Cellulare e Bioterapie, Istituto Nazionale per lo Studio e la Cura dei Tumori ""Fondazione Giovanni Pascale"" - IRCCS, Napoli, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Normanno', 'Affiliation': 'Oncologia Medica, Istituto Nazionale per lo Studio e la Cura dei Tumori ""Fondazione Giovanni Pascale"" - IRCCS, Napoli, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Nappi', 'Affiliation': 'Biologia Cellulare e Bioterapie, Istituto Nazionale per lo Studio e la Cura dei Tumori ""Fondazione Giovanni Pascale"" - IRCCS, Napoli, Italy.'}, {'ForeName': 'Evaristo', 'Initials': 'E', 'LastName': 'Maiello', 'Affiliation': 'Oncologia Medica, Ospedale Casa Sollievo della Sofferenza - San Giovanni Rotondo (FG), Italy.'}, {'ForeName': 'Tiziana', 'Initials': 'T', 'LastName': 'Latiano', 'Affiliation': 'Oncologia Medica, Ospedale Casa Sollievo della Sofferenza - San Giovanni Rotondo (FG), Italy.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Falcone', 'Affiliation': 'Oncologia Medica, Azienda Ospedaliera Universitaria, Università di Pisa, Pisa, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cremolini', 'Affiliation': 'Oncologia Medica, Azienda Ospedaliera Universitaria, Università di Pisa, Pisa, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Rossini', 'Affiliation': 'Oncologia Medica, Azienda Ospedaliera Universitaria, Università di Pisa, Pisa, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Santabarbara', 'Affiliation': 'Oncologia Medica, Azienda Ospedaliera di Rilievo Nazionale ""S. G. Moscati"", Avellino, Italy.'}, {'ForeName': 'Carmine', 'Initials': 'C', 'LastName': 'Pinto', 'Affiliation': 'Oncologia Medica, IRCCS Santa Maria Nuova, Reggio Emilia, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Santini', 'Affiliation': 'Oncologia Medica, Campus Biomedico, Roma, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Cardone', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Nicoletta', 'Initials': 'N', 'LastName': 'Zanaletti', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Di Liello', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Renato', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Esposito', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Marrone', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}, {'ForeName': 'Fortunato', 'Initials': 'F', 'LastName': 'Ciardiello', 'Affiliation': 'Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania ""L. Vanvitelli,"" Napoli, Italy.'}]",JAMA oncology,['10.1001/jamaoncol.2021.2915'] 2638,34382947,"Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.","INTRODUCTION AXA1125 and AXA1957 are novel, orally administered endogenous metabolic modulator compositions, specifically designed to simultaneously support multiple metabolic and fibroinflammatory pathways associated with nonalcoholic fatty liver disease (NAFLD). This study assessed safety, tolerability, and biologic activity of AXA1125 and AXA1957 in NAFLD. METHODS In this multicenter, 16-week, placebo-controlled, single-blind, randomized clinical study in subjects with NAFLD stratified by type 2 diabetes, AXA1125 24 g, AXA1957 13.5 g or 20.3 g, or placebo was administered twice daily. Key metabolism (MRI-proton density fat fraction [MRI-PDFF] and homeostasis model assessment of insulin resistance [HOMA-IR]) and fibroinflammation markers (alanine aminotransferase [ALT], corrected T1 [cT1], keratin-18 [K-18] M65, and N-terminal type III collagen propeptide [Pro-C3]) were evaluated. Safety outcomes included adverse events and standard laboratory assessments. RESULTS Baseline characteristics of the 102 enrolled subjects, including 40 with type 2 diabetes, were consistent with presumed nonalcoholic steatohepatitis. AXA1125 showed consistently greater biologic activity than AXA1957 or placebo. Week 16 changes from baseline with AXA1125 vs placebo: MRI-PDFF -22.9% vs -5.7%, HOMA-IR -4.4 vs +0.7, ALT -21.9% vs -7.2%, K-18 M65 -13.6% vs +20.1%, cT1 -69.6 vs +18.3 ms (P < 0.05), and Pro-C3 -13.6% vs -3.6%. Week 16 changes from baseline with AXA1957 20.3 g: MRI-PDFF -8.1%, HOMA-IR +8.4, ALT -20.7%, K-18 M65 6.6%, cT1 -34.7 ms, and Pro-C3 -15.6%. A greater proportion of subjects treated with AXA1125 achieved clinically relevant thresholds: ≥30% MRI-PDFF, ≥17-IU/L ALT, and ≥80-ms cT1 reductions at week 16. Study products were safe and well tolerated with stable lipid and weight profiles. DISCUSSION Both compositions showed multitargeted activity on relevant NAFLD pathways. AXA1125 demonstrated the greatest activity over 16 weeks, warranting continued clinical investigation in nonalcoholic steatohepatitis subjects.",2021,"A greater proportion of subjects treated with AXA1125 achieved clinically relevant thresholds: ≥30% MRI-PDFF, ≥17-IU/L ALT, and ≥80-ms cT1 reductions at week 16.","['subjects with NAFLD stratified by type 2 diabetes', '102 enrolled subjects, including 40 with type 2 diabetes', 'Subjects With Nonalcoholic Fatty Liver Disease']","['AXA1125', 'AXA1957', 'AXA1125 and AXA1957', 'AXA1957 or placebo', 'placebo', 'AXA1125 24 g, AXA1957 13.5 g or 20.3 g, or placebo']","['fibroinflammation markers (alanine aminotransferase [ALT], corrected T1 [cT1], keratin-18 [K-18] M65, and N-terminal type III collagen propeptide [Pro-C3', 'HOMA-IR', 'safety, tolerability, and biologic activity', 'Key metabolism (MRI-proton density fat fraction', 'safe and well tolerated with stable lipid and weight profiles', 'biologic activity', 'adverse events and standard laboratory assessments', 'Safety, Tolerability, and Biologic Activity']","[{'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0450405', 'cui_str': '24G'}, {'cui': 'C4517559', 'cui_str': '13.5'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0010805', 'cui_str': 'Cytokeratin 18'}, {'cui': 'C0064197', 'cui_str': 'K-18 conjugate'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0009332', 'cui_str': 'Collagen type III'}, {'cui': 'C0071997', 'cui_str': 'Pro-Complement 3'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0033727', 'cui_str': 'Proton'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",102.0,0.222401,"A greater proportion of subjects treated with AXA1125 achieved clinically relevant thresholds: ≥30% MRI-PDFF, ≥17-IU/L ALT, and ≥80-ms cT1 reductions at week 16.","[{'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Harrison', 'Affiliation': 'Pinnacle Clinical Research, San Antonio, Texas, USA.'}, {'ForeName': 'Seth J', 'Initials': 'SJ', 'LastName': 'Baum', 'Affiliation': 'Excel Medical Clinical Trials, Boca Raton, Florida, USA.'}, {'ForeName': 'Nadege T', 'Initials': 'NT', 'LastName': 'Gunn', 'Affiliation': 'Pinnacle Clinical Research, Austin, Texas, USA.'}, {'ForeName': 'Ziad H', 'Initials': 'ZH', 'LastName': 'Younes', 'Affiliation': 'Gastro One, Germantown, Tennessee, USA.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Kohli', 'Affiliation': 'Arizona Liver Health, Chandler, Arizona, USA.'}, {'ForeName': 'Rashmee', 'Initials': 'R', 'LastName': 'Patil', 'Affiliation': 'South Texas Research Institute, Edinburg, Texas, USA.'}, {'ForeName': 'Margaret J', 'Initials': 'MJ', 'LastName': 'Koziel', 'Affiliation': 'Axcella Health, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Harinder', 'Initials': 'H', 'LastName': 'Chera', 'Affiliation': 'Axcella Health, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Axcella Health, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Manu V', 'Initials': 'MV', 'LastName': 'Chakravarthy', 'Affiliation': 'Axcella Health, Cambridge, Massachusetts, USA.'}]",The American journal of gastroenterology,['10.14309/ajg.0000000000001375'] 2639,34382932,Practice nurse-supported weight self-management delivered within the national child immunisation programme for postnatal women: a feasibility cluster RCT.,"BACKGROUND Pregnancy is a high-risk time for excessive weight gain. The rising prevalence of obesity in women, combined with excess weight gain during pregnancy, means that there are more women with obesity in the postnatal period. This can have adverse health consequences for women in later life and increases the health risks during subsequent pregnancies. OBJECTIVE The primary aim was to produce evidence of whether or not a Phase III trial of a brief weight management intervention, in which postnatal women are encouraged by practice nurses as part of the national child immunisation programme to self-monitor their weight and use an online weight management programme, is feasible and acceptable. DESIGN The research involved a cluster randomised controlled feasibility trial and two semistructured interview studies with intervention participants and practice nurses who delivered the intervention. Trial data were collected at baseline and 3 months later. The interview studies took place after trial follow-up. SETTING The trial took place in Birmingham, UK. PARTICIPANTS Twenty-eight postnatal women who were overweight/obese were recruited via Birmingham Women's Hospital or general practices. Nine intervention participants and seven nurses were interviewed. INTERVENTIONS The intervention was delivered in the context of the national child immunisation programme. The intervention group were offered brief support that encouraged self-management of weight when they attended their practice to have their child immunised at 2, 3 and 4 months of age. The intervention involved the provision of motivation and support by nurses to encourage participants to make healthier lifestyle choices through self-monitoring of weight and signposting to an online weight management programme. The role of the nurse was to provide regular external accountability for weight loss. Women were asked to weigh themselves weekly and record this on a record card in their child's health record ('red book') or using the online programme. The behavioural goal was for women to lose 0.5-1 kg per week. The usual-care group received a healthy lifestyle leaflet. MAIN OUTCOME MEASURES The primary outcome was the feasibility of a Phase III trial to test the effectiveness of the intervention, as assessed against three traffic-light stop-go criteria (recruitment, adherence to regular self-weighing and registration with an online weight management programme). RESULTS The traffic-light criteria results were red for recruitment (28/80, 35% of target), amber for registration with the online weight loss programme (9/16, 56%) and green for adherence to weekly self-weighing (10/16, 63%). Nurses delivered the intervention with high fidelity. In the qualitative studies, participants indicated that the intervention was acceptable to them and they welcomed receiving support to lose weight at their child immunisation appointments. Although nurses raised some caveats to implementation, they felt that the intervention was easy to deliver and that it would motivate postnatal women to lose weight. LIMITATIONS Fewer participants were recruited than planned. CONCLUSIONS Although women and practice nurses responded well to the intervention and adherence to self-weighing was high, recruitment was challenging and there is scope to improve engagement with the intervention. FUTURE WORK Future research should focus on investigating other methods of recruitment and, thereafter, testing the effectiveness of the intervention. TRIAL REGISTRATION Current Controlled Trials ISRCTN12209332. FUNDING This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 25, No. 49. See the NIHR Journals Library website for further project information.",2021,"The traffic-light criteria results were red for recruitment (28/80, 35% of target), amber for registration with the online weight loss programme (9/16, 56%) and green for adherence to weekly self-weighing (10/16, 63%).","[""Twenty-eight postnatal women who were overweight/obese were recruited via Birmingham Women's Hospital or general practices"", 'Nine intervention participants and seven nurses were interviewed', 'postnatal women', 'Fewer participants were recruited than planned', 'intervention participants and practice nurses who delivered the intervention']","['brief support that encouraged self-management of weight', 'provision of motivation and support by nurses to encourage participants to make healthier lifestyle choices through self-monitoring of weight and signposting to an online weight management programme', 'Practice nurse-supported weight self-management delivered within the national child immunisation programme', 'healthy lifestyle leaflet', 'weight management intervention']","['traffic-light stop-go criteria (recruitment, adherence to regular self-weighing and registration with an online weight management programme', 'health risks']","[{'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0401999', 'cui_str': 'Practice nurse'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C0401999', 'cui_str': 'Practice nurse'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0020971', 'cui_str': 'Immunization'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0442664', 'cui_str': 'Traffic light'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",28.0,0.0568924,"The traffic-light criteria results were red for recruitment (28/80, 35% of target), amber for registration with the online weight loss programme (9/16, 56%) and green for adherence to weekly self-weighing (10/16, 63%).","[{'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Daley', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Jolly', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Ives', 'Affiliation': 'Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Susan A', 'Initials': 'SA', 'LastName': 'Jebb', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Tearne', 'Affiliation': 'Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Sheila M', 'Initials': 'SM', 'LastName': 'Greenfield', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Yardley', 'Affiliation': 'School of Psychological Science, University of Bristol, Bristol, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Little', 'Affiliation': 'Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Tyldesley-Marshall', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Bensoussane', 'Affiliation': 'Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Ruth V', 'Initials': 'RV', 'LastName': 'Pritchett', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Frew', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Helen M', 'Initials': 'HM', 'LastName': 'Parretti', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}]","Health technology assessment (Winchester, England)",['10.3310/hta25490'] 2640,34382931,"Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT.","BACKGROUND Rotator cuff-related shoulder pain is very common, but there is uncertainty regarding which modes of exercise delivery are optimal and the long-term benefits of corticosteroid injections. OBJECTIVES To assess the clinical effectiveness and cost-effectiveness of progressive exercise compared with best-practice physiotherapy advice, with or without corticosteroid injection, in adults with a rotator cuff disorder. DESIGN This was a pragmatic multicentre superiority randomised controlled trial (with a 2 × 2 factorial design). SETTING Twenty NHS primary care-based musculoskeletal and related physiotherapy services. PARTICIPANTS Adults aged ≥ 18 years with a new episode of rotator cuff-related shoulder pain in the previous 6 months. INTERVENTIONS A total of 708 participants were randomised (March 2017-May 2019) by a centralised computer-generated 1 : 1 : 1 : 1 allocation ratio to one of four interventions: (1) progressive exercise ( n  = 174) (six or fewer physiotherapy sessions), (2) best-practice advice ( n  = 174) (one physiotherapy session), (3) corticosteroid injection then progressive exercise ( n  = 182) (six or fewer physiotherapy sessions) or (4) corticosteroid injection then best-practice advice ( n  = 178) (one physiotherapy session). MAIN OUTCOME MEASURES The primary outcome was Shoulder Pain and Disability Index (SPADI) score over 12 months. Secondary outcomes included SPADI subdomains, the EuroQol 5 Dimensions, five-level version, sleep disturbance, fear avoidance, pain self-efficacy, return to activity, Global Impression of Treatment and health resource use. Outcomes were collected by postal questionnaires at 8 weeks and at 6 and 12 months. A within-trial economic evaluation was also conducted. The primary analysis was intention to treat. RESULTS Participants had a mean age of 55.5 (standard deviation 13.1) years and 49.3% were female. The mean baseline SPADI score was 54.1 (standard deviation 18.5). Follow-up rates were 91% at 8 weeks and 87% at 6 and 12 months. There was an overall improvement in SPADI score from baseline in each group over time. Over 12 months, there was no evidence of a difference in the SPADI scores between the progressive exercise intervention and the best-practice advice intervention in shoulder pain and function (adjusted mean difference between groups over 12 months -0.66, 99% confidence interval -4.52 to 3.20). There was also no difference in SPADI scores between the progressive exercise intervention and best-practice advice intervention when analysed at the 8-week and 6- and 12-month time points. Injection resulted in improvement in shoulder pain and function at 8 weeks compared with no injection (adjusted mean difference -5.64, 99% confidence interval -9.93 to -1.35), but not when analysed over 12 months (adjusted mean difference -1.11, 99% confidence interval -4.47 to 2.26), or at 6 and 12 months. There were no serious adverse events. In the base-case analysis, adding injection to best-practice advice gained 0.021 quality-adjusted life-years ( p  = 0.184) and increased the cost by £10 per participant ( p  = 0.747). Progressive exercise alone was £52 ( p  = 0.247) more expensive per participant than best-practice advice, and gained 0.019 QALYs ( p  = 0.220). At a ceiling ratio of £20,000 per quality-adjusted life-year, injection plus best-practice advice had a 54.93% probability of being the most cost-effective treatment. LIMITATIONS Participants and physiotherapists were not blinded to group allocation. Twelve-month follow-up may be insufficient for identifying all safety concerns. CONCLUSIONS Progressive exercise was not superior to a best-practice advice session with a physiotherapist. Subacromial corticosteroid injection improved shoulder pain and function, but provided only modest short-term benefit. Best-practice advice in combination with corticosteroid injection was expected to be most cost-effective, although there was substantial uncertainty. FUTURE WORK Longer-term follow-up, including any serious adverse effects of corticosteroid injection. TRIAL REGISTRATION Current Controlled Trials ISRCTN16539266 and EudraCT 2016-002991-28. FUNDING This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 25, No. 48. See the NIHR Journals Library website for further project information.",2021,"Progressive exercise alone was £52 ( p  = 0.247) more expensive per participant than best-practice advice, and gained 0.019 QALYs ( p  = 0.220).","['adults with a rotator cuff disorder', 'Participants had a mean age of 55.5 (standard deviation 13.1) years and 49.3% were female', 'Twenty NHS primary care-based musculoskeletal and related physiotherapy services', '2016-002991-28', 'Adults aged ≥\u200918 years with a new episode of rotator cuff-related shoulder pain in the previous 6 months', '708 participants were randomised (March 2017-May 2019) by a']","['Subacromial corticosteroid injection', 'Progressive exercise', 'EudraCT', 'Progressive exercise alone', 'Progressive exercise compared with best-practice advice, with or without corticosteroid injection', 'progressive exercise compared with best-practice physiotherapy advice, with or without corticosteroid injection', 'centralised computer-generated 1\u2009:\u20091\u2009', 'corticosteroid injection', 'progressive exercise ( n \u2009=\u2009174) (six or fewer physiotherapy sessions), (2) best-practice advice ( n \u2009=\u2009174) (one physiotherapy session), (3) corticosteroid injection then progressive exercise ( n \u2009=\u2009182) (six or fewer physiotherapy sessions) or (4) corticosteroid injection then best-practice advice ( n \u2009=\u2009178) (one physiotherapy session']","['Shoulder Pain and Disability Index (SPADI) score', 'SPADI score', 'clinical effectiveness and cost-effectiveness', 'shoulder pain and function', 'serious adverse events', 'SPADI subdomains, the EuroQol 5 Dimensions, five-level version, sleep disturbance, fear avoidance, pain self-efficacy, return to activity, Global Impression of Treatment and health resource use', 'SPADI scores', 'mean baseline SPADI score']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0085515', 'cui_str': 'Structure of rotator cuff including muscles and tendons'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0587629', 'cui_str': 'Physiotherapy service'}, {'cui': 'C0565959', 'cui_str': 'New episode'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0205388', 'cui_str': 'Few'}]","[{'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018741', 'cui_str': 'Health Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",708.0,0.31256,"Progressive exercise alone was £52 ( p  = 0.247) more expensive per participant than best-practice advice, and gained 0.019 QALYs ( p  = 0.220).","[{'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Hopewell', 'Affiliation': 'Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Keene', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Heine', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Ioana R', 'Initials': 'IR', 'LastName': 'Marian', 'Affiliation': 'Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Melina', 'Initials': 'M', 'LastName': 'Dritsaki', 'Affiliation': 'Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Cureton', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Dutton', 'Affiliation': 'Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Dakin', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Carr', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Willie', 'Initials': 'W', 'LastName': 'Hamilton', 'Affiliation': 'College of Medicine and Health, University of Exeter, Exeter, UK.'}, {'ForeName': 'Zara', 'Initials': 'Z', 'LastName': 'Hansen', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Anju', 'Initials': 'A', 'LastName': 'Jaggi', 'Affiliation': 'Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Littlewood', 'Affiliation': 'Manchester Metropolitan University, Manchester, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Barker', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Alastair', 'Initials': 'A', 'LastName': 'Gray', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Lamb', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}]","Health technology assessment (Winchester, England)",['10.3310/hta25480'] 2641,34382886,Recruiting and Retaining Dyads of Hospitalized Persons with Dementia and Family Caregivers.,"Persons with dementia have high rates of hospitalization, and along with their caregivers commonly experience negative hospital outcomes. The recruitment and retention of acutely ill older adults with dementia and caregivers can pose a challenge to investigators and threaten the validity of findings. The challenges encountered in an ongoing cluster randomized clinical trial in dyads of hospitalized persons with dementia and family care partners are described. The trial tests the efficacy of a nurse-family partnership model that aims to improve the following: (a) the physical and cognitive recovery in hospitalized persons with dementia, and (b) caregiver preparedness and anxiety. Strategies that address challenges include careful preplanning and preparation with the hospital site, strong communication with dyads and between team members, and honoring preferences and needs related to communication.",2021,"The trial tests the efficacy of a nurse-family partnership model that aims to improve the following: (a) the physical and cognitive recovery in hospitalized persons with dementia, and (b) caregiver preparedness and anxiety.","['Persons with dementia', 'Hospitalized Persons with Dementia and Family Caregivers', 'acutely ill older adults with dementia and caregivers', 'hospitalized persons with dementia and family care partners', 'hospitalized persons with dementia, and (b) caregiver preparedness and anxiety']",['nurse-family partnership model'],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]",[],,0.0681798,"The trial tests the efficacy of a nurse-family partnership model that aims to improve the following: (a) the physical and cognitive recovery in hospitalized persons with dementia, and (b) caregiver preparedness and anxiety.","[{'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Boltz', 'Affiliation': 'The Pennsylvania State University, College of Nursing, University Park, PA, USA.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Kuzmik', 'Affiliation': 'The Pennsylvania State University, College of Nursing, University Park, PA, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Resnick', 'Affiliation': 'University of Maryland School of Nursing, Baltimore MD, USA.'}, {'ForeName': 'Rhonda', 'Initials': 'R', 'LastName': 'BeLue', 'Affiliation': 'St. Louis University, St. Louis, MO, USA.'}]",Western journal of nursing research,['10.1177/01939459211032282'] 2642,34382590,Oral opening training increases oral opening in patients with oral submucous fibrosis.,"OBJECTIVES The mouth restriction of patients with oral submucous fibrosis (OSF) seriously affects their eating food and the quality of life. There are few reports about improving the oral opening degree in patients with OSF. This study aims to explore the effect of oral opening training on the improvement of mouth opening limitation in patients with OSF treated with local injection. METHODS A total of 220 outpatients with limited mouth opening of OSF were collected from the Center of Stomatology, Xiangya Hospital, Central South University, and randomly divided into a control group and an experiment group ( n =110). The control group were treated with local injection of Salvia miltiorrhiza and triamcinolone acetonide, once a week, and 8 times a course. The experimental group were treated with local injection combined with mouth opening training for 2 years. The degree of mouth opening was compared between the 2 groups at the end of local injection treatment, 1 year and 2 years after the treatment. The curative effect was evaluated according to the size of the opening, the lamellar structure of the mucosa, and the condition of the cords. RESULTS A total of 197 patients completed the whole course of treatment, with 107 in the experimental group and 90 in the control group. At the end of treatment, 1 year and 2 years after the treatment, the degree of mouth opening in the experimental group was (36.14±2.62), (39.67±2.67), and (39.80±2.57) mm, respectively, which was significantly higher than that in the control group (24.71±1.97), (22.82±2.13), and (22.02±2.09) mm, respectively. The difference was significant ( P <0.05). The increase of mouth opening in the experimental group was significantly better than that in the control group. Two years after local injection treatment, the effective rate of the experimental group was 97.1%, which was significantly higher than that of the control group (47.8%, P <0.05). CONCLUSIONS Mouth opening training can significantly increase the degree of mouth opening in patients with OSF treated with local injection.",2021,The increase of mouth opening in the experimental group was significantly better than that in the control group.,"['patients with oral submucous fibrosis', '220 outpatients with limited mouth opening of OSF were collected from the Center of Stomatology, Xiangya Hospital, Central South University', 'patients with oral submucous fibrosis (OSF', 'patients with OSF treated with local injection', '197 patients completed the whole course of treatment, with 107 in the experimental group and 90 in the control group', 'patients with OSF']","['local injection combined with mouth opening training', 'oral opening training', 'local injection of Salvia miltiorrhiza and triamcinolone acetonide', 'Oral opening training']","['effective rate', 'degree of mouth opening', 'increase of mouth opening']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029172', 'cui_str': 'Oral submucosal fibrosis'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0029167', 'cui_str': 'Medicine, Oral'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0226895', 'cui_str': 'Structure of rima oris'}, {'cui': 'C0696940', 'cui_str': 'Salvia miltiorrhizae'}, {'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",220.0,0.0146614,The increase of mouth opening in the experimental group was significantly better than that in the control group.,"[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Teaching and Research Section of Clinical Nursing, Xiangya Hospital, Central South University, Changsha 410008.'}, {'ForeName': 'Yingfang', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Oral Mucosa, Center of Stomatology, Xiangya Hospital, Central South University, Changsha 410008.'}, {'ForeName': 'Jieying', 'Initials': 'J', 'LastName': 'Peng', 'Affiliation': 'Department of Oral Mucosa, Center of Stomatology, Xiangya Hospital, Central South University, Changsha 410008.'}, {'ForeName': 'Liwei', 'Initials': 'L', 'LastName': 'Ma', 'Affiliation': 'Department of Oral Mucosa, Center of Stomatology, Xiangya Hospital, Central South University, Changsha 410008.'}]",Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences,['10.11817/j.issn.1672-7347.2021.200786'] 2643,34382580,Hypogonadism in the Prader-Willi syndrome from birth to adulthood: a 28-year experience in a single centre.,"BACKGROUND Hypogonadism is a key feature of Prader-Willi syndrome (PWS) but clear strategies for hormone replacement are lacking. OBJECTIVE To evaluate gonadal status and outcome in patients attending a Scottish PWS clinic from 1991-2019. METHODS In 93 (35F:56M) patients, median follow-up 11.2 years, gonadal and pubertal status were assessed clinically. Pelvic ultrasound findings and basal/stimulated gonadotrophins were compared with age-matched controls. RESULTS Females: Of 22 patients aged >11, 9 had reached B4-5, while 5 were still at B2-3, and 6 remained prepubertal. Eight patients experienced menarche aged 9.8-21.4 years, none with a normal cycle. Uterine length and ovarian volumes were normal but uterine configuration remained immature, with low follicular counts. Gonadotrophins were unremarkable, serum estradiol 129 (70 - 520) pmol/L. Only 5 patients received oestrogen replacement. Males: Fifty-four (96%) patients were cryptorchid (9 unilateral). Weekly hCG injections resulted in unilateral/bilateral descent in 2/1 of 25 patients. Of 37 boys aged >11, 14 (9 with failed/untreated bilateral cryptorchidism) failed to progress beyond G1, 15 arrested at G2-3 (testes 3-10 ml), and 8 reached G4-5. Gonadotrophins were unremarkable except in boys at G2-5 in whom FSH was elevated: 12.3/27.3 vs 3.25/6.26 U/L in controls (p<0.001). In males aged >13, testosterone was 3.1 (0.5-8.4) nmol/L. Androgen therapy, given from 13.5-29.2 years, was stopped in 4/24 patients owing to behavioural problems. CONCLUSION Despite invariable hypogonadism, few females and only half the males with PWS in this study received hormone replacement. Double-blind placebo-controlled crossover trials of sex steroids are required to address unproven behavioural concerns.",2021,"In males aged >13, testosterone was 3.1 (0.5-8.4) nmol/L. Androgen therapy, given from 13.5-29.2 years, was stopped in 4/24 patients owing to behavioural problems. ","['Males: Fifty-four (96', 'males aged >13, testosterone was 3.1 (0.5-8.4) nmol/L. Androgen therapy, given from 13.5-29.2 years, was stopped in 4/24 patients owing to behavioural problems', 'Eight patients experienced menarche aged 9.8-21.4 years, none with a normal cycle', 'Females', '22 patients aged >11, 9 had reached B4-5, while 5 were still at B2-3, and 6 remained prepubertal', '37 boys aged >11, 14 (9 with failed/untreated bilateral cryptorchidism) failed to progress beyond G1, 15 arrested at G2-3 (testes 3-10 ml), and 8 reached G4-5', 'patients attending a Scottish PWS clinic from 1991-2019']","['Weekly hCG injections', 'placebo', 'oestrogen replacement', 'hormone replacement']","['unilateral/bilateral descent', 'Uterine length and ovarian volumes']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C4517683', 'cui_str': '3.1'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C0439282', 'cui_str': 'nmol/L'}, {'cui': 'C0279493', 'cui_str': 'Androgen therapy'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C4517559', 'cui_str': '13.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0025274', 'cui_str': 'Menarche'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0431663', 'cui_str': 'Undescended testes - bilateral'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0021358', 'cui_str': 'Structure of inferior colliculus of corpora quadrigemina'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0032897', 'cui_str': 'Prader-Willi syndrome'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C1141639', 'cui_str': 'Human chorionic gonadotropin'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy'}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205386', 'cui_str': 'Descending'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",22.0,0.163929,"In males aged >13, testosterone was 3.1 (0.5-8.4) nmol/L. Androgen therapy, given from 13.5-29.2 years, was stopped in 4/24 patients owing to behavioural problems. ","[{'ForeName': 'Sakina', 'Initials': 'S', 'LastName': 'Kherra', 'Affiliation': 'S Kherra, Pediatrics, CHU Parnet Hopital, Algiers, Algeria.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Forsyth Paterson', 'Affiliation': 'W Forsyth Paterson , Royal Hospital for Sick Children Yorkhill, Glasgow, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Filiz Mine', 'Initials': 'FM', 'LastName': 'Cizmecioğlu', 'Affiliation': 'F Cizmecioğlu, Pediatric Endocrinology and Diabetes Department, Kocaeli University School of Medicine,, Kocaeli, Turkey.'}, {'ForeName': 'Jeremy Huw', 'Initials': 'JH', 'LastName': 'Jones', 'Affiliation': 'J Jones, Child Health, Royal Hospital for Children Glasgow, Glasgow, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Mariam', 'Initials': 'M', 'LastName': 'Kourime', 'Affiliation': 'M Kourime, Pediatrics, 5Abderrahim Harouchi Hôpital, Casablanca, Morocco.'}, {'ForeName': 'Heba Hassan', 'Initials': 'HH', 'LastName': 'Elsedfy', 'Affiliation': 'H Elsedfy, Pediatrics, Ain Shams University, Cairo, 11511, Egypt.'}, {'ForeName': 'Sameh Tawfik', 'Initials': 'ST', 'LastName': 'Amer', 'Affiliation': 'S Amer, Department of Pediatrics, Maadi Military Hospital, Cairo, Egypt.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Kyriakou', 'Affiliation': 'A Kyriakou, Department of Pediatric Endocrinology, Royal Hospital for Children Glasgow, Glasgow, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Mohammed Guftar', 'Initials': 'MG', 'LastName': 'Shaikh', 'Affiliation': 'M Shaikh, Department of Pediatric Endocrinology, Royal Hospital for Children Glasgow, Glasgow, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Malcolm David Cairns', 'Initials': 'MDC', 'LastName': 'Donaldson', 'Affiliation': 'M Donaldson, Department of Child Health, Glasgow University, Glasgow, G61 2RE, United Kingdom of Great Britain and Northern Ireland.'}]",Endocrine connections,['10.1530/EC-21-0277'] 2644,34382579,The liver-alpha-cell axis after a mixed meal and during weight loss in type 2 diabetes.,"OBJECTIVE Glucagon and amino acids may be regulated in a feedback loop called the liver-alpha-cell axis with alanine or glutamine as suggested signal molecules. We assessed this concept in individuals with type 2 diabetes in the fasting state, after ingestion of a protein rich meal and during weight loss. Moreover, we investigated if postprandial glucagon secretion and hepatic insulin sensitivity were related. METHODS This is a secondary analysis of a 12-week weight loss trial (Paleolithic diet ± exercise) in 29 individuals with type 2 diabetes. Before and after the intervention, plasma glucagon and amino acids were measured in the fasting state and during 180 min after a protein-rich mixed meal. Hepatic insulin sensitivity was measured using the hyperinsulinemic euglycemic clamp with [6,6-2H2]glucose as tracer. RESULTS The postprandial increase of plasma glucagon was associated with the postprandial increase of alanine and several other amino acids but not glutamine. In the fasted state and after the meal, glucagon levels were negatively correlated with hepatic insulin sensitivity (rS = -0.51 / r = -0.58 respectively; both P<0.05). Improved hepatic insulin sensitivity with weight loss was correlated with decreased postprandial glucagon response (r = -0.78; P<0.001). CONCLUSIONS Several amino acids, notably alanine, but not glutamine could be key signals to the alpha cell to increase glucagon secretion. Amino acids may be part of a feedback mechanism as glucagon increases endogenous glucose production and ureagenesis in the liver. Moreover, postprandial glucagon secretion seems to be tightly related to hepatic insulin sensitivity.",2021,"Improved hepatic insulin sensitivity with weight loss was correlated with decreased postprandial glucagon response (r = -0.78; P<0.001). ","['individuals with type 2 diabetes in the fasting state, after ingestion of a protein rich meal and during weight loss', '29 individuals with type 2 diabetes']",['weight loss trial (Paleolithic diet ± exercise'],"['postprandial increase of plasma glucagon', 'plasma glucagon and amino acids', 'postprandial glucagon response', 'hepatic insulin sensitivity with weight loss', 'Hepatic insulin sensitivity', 'glucagon secretion', 'liver-alpha-cell axis', 'hepatic insulin sensitivity', 'postprandial glucagon secretion and hepatic insulin sensitivity']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0038164', 'cui_str': 'Protein A'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0452423', 'cui_str': 'Stone age diet'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1278023', 'cui_str': 'Plasma glucagon measurement'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0017687', 'cui_str': 'Glucagon'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0030280', 'cui_str': 'Structure of alpha Cell of islet'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}]",29.0,0.0800781,"Improved hepatic insulin sensitivity with weight loss was correlated with decreased postprandial glucagon response (r = -0.78; P<0.001). ","[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Otten', 'Affiliation': 'J Otten, Department of Public Health and Clinical Medicine, Umeå Universitet Medicinska fakulteten, Umea, Sweden.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Stomby', 'Affiliation': 'A Stomby, Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Waling', 'Affiliation': 'M Waling, Department of Food, Nutrition and Culinary Science, Umea University, Umea, Sweden.'}, {'ForeName': 'Elin', 'Initials': 'E', 'LastName': 'Chorell', 'Affiliation': 'E Chorell, Public Health and Clinical Medicine, Umea Universitet Medicinska fakulteten, Umea, Sweden.'}, {'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Ryberg', 'Affiliation': 'M Ryberg, Department of Public Health and Clinical Medicine, Medicine, Umeå Universitet Medicinska fakulteten, Umea, Sweden.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Svensson', 'Affiliation': 'M Svensson, Department of Community Medicine and Rehabilitation, Umea University, Umea, Sweden.'}, {'ForeName': 'Jens Juul', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'J Holst, NNF Center for Basic Metabolic Research, University of Copenhagen, Kobenhavn, Denmark.'}, {'ForeName': 'Tommy', 'Initials': 'T', 'LastName': 'Olsson', 'Affiliation': 'T Olsson, Department of Public Health and Clinical Medicine, Umeå Universitet Medicinska fakulteten, Umea, Sweden.'}]",Endocrine connections,['10.1530/EC-21-0171'] 2645,34377283,Effect of a nursing intervention strategy oriented by Orem's self-care theory on the recovery of gastrointestinal function in patients after colon cancer surgery.,"OBJECTIVE To investigate the effect of nursing intervention strategies based on the Orem self-care theory on the recovery of gastrointestinal function in patients after colon cancer surgery. METHODS In this prospective study, a total of 115 patients with colon cancer who had radical resection of the colon cancer tissue were selected as the research subjects and randomized into two groups: an Orem group (59 cases), which was given nursing based on the Orem self-care model and a control group (56 cases), which was given regular nursing. The postoperative recovery of the two groups was compared. RESULTS After the intervention, the time to first getting out of bed, gastric tube removal, first postoperative flatus, first fluid food intake and general food intake were significantly earlier than those of the control group. Time of intestinal peristalsis and the average length of hospital stay of the Orem group were much shorter than those of the control group (all P<0.001). The cost of nutrient supply of the Orem group was significantly lower than that of the control group (P<0.001), and the postoperative pain and incidence of complications of patients in the Orem group were significantly lower than those in the control group (P<0.05). After 3 months of follow-up, the scores of positive attitude, intimacy and total score of hope in the hope level of the patients in the Orem group were significantly higher than those in the control group (all P<0.01). There was no significant difference in the positive action scores (P>0.05). Besides, the scores of the Orem group in all dimensions of the quality of life were significantly higher than those of the control group (all P<0.01). CONCLUSION Nursing intervention based on the Orem self-care theory can promote the recovery of patients with colon cancer after surgery, speed up the recovery of their gastrointestinal function, and ultimately improve their level of hope and quality of life. Therefore, it is worthy of promotion in clinical practice.",2021,"The cost of nutrient supply of the Orem group was significantly lower than that of the control group (P<0.001), and the postoperative pain and incidence of complications of patients in the Orem group were significantly lower than those in the control group (P<0.05).","['patients after colon cancer surgery', '115 patients with colon cancer who had radical resection of the colon cancer tissue']","['Nursing intervention', ""nursing intervention strategy oriented by Orem's self-care theory"", 'nursing intervention strategies']","['Time of intestinal peristalsis and the average length of hospital stay', 'positive action scores', 'postoperative recovery', 'time to first getting out of bed, gastric tube removal, first postoperative flatus, first fluid food intake and general food intake', 'postoperative pain and incidence of complications', 'gastrointestinal function', 'quality of life', 'scores of positive attitude, intimacy and total score of hope in the hope level', 'cost of nutrient supply']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0031133', 'cui_str': 'Peristalsis'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C0699756', 'cui_str': 'Intimate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0392347', 'cui_str': 'Hope'}, {'cui': 'C0424133', 'cui_str': 'Level of hope'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}]",115.0,0.0199528,"The cost of nutrient supply of the Orem group was significantly lower than that of the control group (P<0.001), and the postoperative pain and incidence of complications of patients in the Orem group were significantly lower than those in the control group (P<0.05).","[{'ForeName': 'Lianhong', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Admission and Discharge Management Center, Huzhou Central Hospital, Affiliated Hospital of Huzhou Normal University Huzhou, Zhejiang Province, China.'}, {'ForeName': 'Wenyan', 'Initials': 'W', 'LastName': 'Pan', 'Affiliation': 'Department of General Surgery, Huzhou Central Hospital, Affiliated Hospital of Huzhou Normal University Huzhou, Zhejiang Province, China.'}]",American journal of translational research,[] 2646,34377281,Effects of mild hypothermia therapy combined with minimally invasive debridement in patients with hypertensive intracranial hemorrhage: a randomized controlled study.,"OBJECTIVE To investigate the clinical effect of mild hypothermia therapy (MHT) combined with minimally invasive debridement (MID) in patients with severe hypertensive intracranial hemorrhage (HICH). METHODS A total of 120 patients with severe HICH who received clinical intervention in our hospital were enrolled as study subjects. In this randomized, controlled, double-blind trial, they were divided into a study group (SG, n=70) and a control group (CNG, n=50). The CNG was treated with MID, and the SG was treated with MID combined with MHT. The general surgical indices, short-term postoperative outcomes, postoperative neurological and recovery in activities of daily living, and complications were compared between the two groups. Patients' Glasgow prognosis (Glasgow Outcome Scale, GOS) scores at 1 year after surgery were analyzed. RESULTS The operative time, intraoperative blood loss and intensive care unit (ICU) admission were shorter/lower in the SG than in the CNG ( P <0.05). The SG had higher hematoma clearance rate at 1 d and 3 d postoperatively, and lower residual hematoma volume at 3 d and 7 d postoperatively than the CNG ( P <0.05). Patients in the SG had higher Barthel scores and lower National Institutes of Health Stroke Scale (NIHSS) scores than the CNG at 1-12 months after intervention ( P <0.05). The incidence of complications in the SG was lower than that in the CNG ( P <0.05). The percentage of GOS grade IV and V was significantly higher in the SG than in the CNG 1 year after surgery ( P <0.05). CONCLUSION The combination of MID and MHT in patients with severe HICH has better clinical results in the short and long term, and improves the postoperative outcomes and quality of life. It can also reduce the incidence of perioperative complications.",2021,"The percentage of GOS grade IV and V was significantly higher in the SG than in the CNG 1 year after surgery ( P <0.05). ","['patients with severe hypertensive intracranial hemorrhage (HICH', 'patients with severe HICH', 'patients with hypertensive intracranial hemorrhage', '120 patients with severe HICH who received clinical intervention in our hospital were enrolled as study subjects']","['mild hypothermia therapy (MHT) combined with minimally invasive debridement (MID', 'MID combined with MHT', 'mild hypothermia therapy combined with minimally invasive debridement']","['general surgical indices, short-term postoperative outcomes, postoperative neurological and recovery in activities of daily living, and complications', 'higher Barthel scores and lower National Institutes of Health Stroke Scale (NIHSS) scores', 'percentage of GOS grade IV and V', 'residual hematoma volume', 'hematoma clearance rate', 'operative time, intraoperative blood loss and intensive care unit (ICU) admission', 'incidence of complications in the SG', 'postoperative outcomes and quality of life', 'Glasgow prognosis (Glasgow Outcome Scale, GOS) scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0751891', 'cui_str': 'Hypertensive Hemorrhage, Intracranial'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0445043', 'cui_str': 'Mild hypothermia'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0025515', 'cui_str': 'Metabolic clearance rate'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C0701887', 'cui_str': 'Glasgow outcome scale'}]",120.0,0.0754145,"The percentage of GOS grade IV and V was significantly higher in the SG than in the CNG 1 year after surgery ( P <0.05). ","[{'ForeName': 'Xuping', 'Initials': 'X', 'LastName': 'Qian', 'Affiliation': 'Department of Neurosurgery, Huzhou Central Hospital, Affiliated Hospital of Huzhou Normal University Huzhou 313000, Zhejiang Province, China.'}, {'ForeName': 'Shali', 'Initials': 'S', 'LastName': 'Lan', 'Affiliation': 'Department of Neurosurgery, Huzhou Central Hospital, Affiliated Hospital of Huzhou Normal University Huzhou 313000, Zhejiang Province, China.'}, {'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopedics, Huzhou Central Hospital, Affiliated Hospital of Huzhou Normal University Huzhou 313000, Zhejiang Province, China.'}]",American journal of translational research,[] 2647,34377271,Feasibility of epidural injection of ropivacaine and dexamethasone for labor analgesia in women with preeclampsia.,"OBJECTIVE This study aimed to investigate the feasibility of epidural injection of ropivacaine (Rop) and dexamethasone (Dex) for labor analgesia in women with preeclampsia. METHODS A total of 80 women with preeclampsia delivered in our hospital were enrolled, and were divided into a study group (n=41, Rop + Dex) and a control group (n=39, Rop alone). The changes in pain level, sedation, catecholamine hormone levels and vital signs were compared between the two groups after intervention. The motor blockade score and the incidence of adverse reactions after administration of anesthesia were compared in both groups. RESULTS Pain level [visual analogue scale (VAS) score], sedation (Ramsay score), adrenaline (AD), norepinephrine (NE), heart rate (HR), and mean arterial pressure (MAP) did not differ significantly between the two groups at pre-analgesia (T0) ( P >0.05), and Ramsay score in the study group was significantly higher than that in the control group at 30 min (T1), 60 min (T2), 120 min after analgesia (T3), and cessation of analgesia (T4), and VAS score, AD, NE, HR, MAP in the study group were significantly lower than those in the control group during all stages of labor. CONCLUSION The epidural injection of Rop + Dex in women with preeclampsia can play a better analgesic and sedative effect, stabilize maternal hemodynamic index and improve postpartum motor blockade.",2021,"The changes in pain level, sedation, catecholamine hormone levels and vital signs were compared between the two groups after intervention.","['80 women with preeclampsia delivered in our hospital', 'women with preeclampsia']","['epidural injection of Rop + Dex', 'ropivacaine (Rop) and dexamethasone (Dex', 'ropivacaine and dexamethasone', 'Rop + Dex']","['pain level, sedation, catecholamine hormone levels and vital signs', 'motor blockade score and the incidence of adverse reactions', 'Ramsay score', 'cessation of analgesia (T4), and VAS score, AD, NE, HR, MAP', 'analgesic and sedative effect, stabilize maternal hemodynamic index', 'Pain level [visual analogue scale (VAS) score], sedation (Ramsay score), adrenaline (AD), norepinephrine (NE), heart rate (HR), and mean arterial pressure (MAP']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0021486', 'cui_str': 'Injections, Peridural'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0007412', 'cui_str': 'Catecholamine'}, {'cui': 'C1287355', 'cui_str': 'Hormone level - finding'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C3179159', 'cui_str': 'Sedative Effects'}, {'cui': 'C0184512', 'cui_str': 'Stabilized'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",80.0,0.14145,"The changes in pain level, sedation, catecholamine hormone levels and vital signs were compared between the two groups after intervention.","[{'ForeName': 'Shengyang', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Changgen', 'Initials': 'C', 'LastName': 'Zhong', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Ailian', 'Initials': 'A', 'LastName': 'Huang', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Chuanfeng', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}, {'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': ""Department of Anesthesiology, Yichun People's Hospital Yichun 336000, Jiangxi Province, China.""}]",American journal of translational research,[] 2648,34377266,Effect of different routes of administration on early cognitive function following inguinal hernia repair.,"PURPOSE To analyze the effects of different routes of dexmedetomidine administration on early cognitive function following inguinal hernia repair. METHODS A total of 83 patients with pediatric inguinal hernias admitted to our hospital from January 2018 to October 2020 were divided into control group (CNG, n = 41) and observation group (OG, n = 42) by random number table. The OG was given 2 μg/kg of dexmedetomidine hydrochloride by intranasal administration, and the CNG was treated with 0.5 μg/kg of dexmedetomidine hydrochloride via intravenous (IV) infusion pump. The hemodynamics, condition of anesthesia, awakening, and safety were compared between the two groups. RESULTS Systolic blood pressure and oxygen saturation levels at T1 and T2 in the OG were not different from those in the CNG ( P > 0.05), and heart rates in the OG were all higher than those in the CNG ( P < 0.05). The incidence of emergence agitation during awakening was 4.76% in the OG, which was lower than 21.95% compared with the CNG ( P < 0.05). Ramsay sedation scores at 15 and 30 min after awakening in the OG were higher than those in the CNG, and PAED scores in the OG were lower than those in the CNG ( P < 0.05). Cognitive, language, and motor scores in the OG were higher than those in the CNG at 3 days after surgery ( P < 0.05), and the incidence of cognitive dysfunction was 4.76% in the OG at 3 days after surgery, which was lower compared with 21.95% in the CNG ( P < 0.05). CONCLUSION Application of dexmedetomidine hydrochloride by intranasal administration or intravenous infusion before induction can ensure rapid postoperative awakening of the children without causing significant fluctuations in blood pressure and oxygen saturation, and both methods have a high safety profile. However, intranasal administration results in more satisfactory sedation, less postoperative agitation upon awakening, and reduces postoperative cognitive dysfunction.",2021,"Ramsay sedation scores at 15 and 30 min after awakening in the OG were higher than those in the CNG, and PAED scores in the OG were lower than those in the CNG ( P < 0.05).","['inguinal hernia repair', '83 patients with pediatric inguinal hernias admitted to our hospital from January 2018 to October 2020']","['dexmedetomidine hydrochloride via intravenous (IV) infusion pump', 'dexmedetomidine', 'dexmedetomidine hydrochloride']","['satisfactory sedation', 'Systolic blood pressure and oxygen saturation levels', 'heart rates', 'postoperative cognitive dysfunction', 'Cognitive, language, and motor scores in the OG', 'incidence of cognitive dysfunction', 'early cognitive function', 'blood pressure and oxygen saturation', 'hemodynamics, condition of anesthesia, awakening, and safety', 'PAED scores', 'Ramsay sedation scores', 'incidence of emergence agitation']","[{'cui': 'C0021446', 'cui_str': 'Repair of inguinal hernia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0019294', 'cui_str': 'Inguinal hernia'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0752310', 'cui_str': 'Dexmedetomidine hydrochloride'}, {'cui': 'C0021440', 'cui_str': 'Intravenous infusion'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]","[{'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C4721773', 'cui_str': 'Postoperative cognitive dysfunction'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C1720052', 'cui_str': 'Awakening'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0920253', 'cui_str': 'Agitated Emergence'}]",83.0,0.0537717,"Ramsay sedation scores at 15 and 30 min after awakening in the OG were higher than those in the CNG, and PAED scores in the OG were lower than those in the CNG ( P < 0.05).","[{'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': ""Department of Anesthesiology, Ji'an Maternal and Child Health Care Hospital Ji'an 343000, Jiangxi Province, China.""}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Deng', 'Affiliation': ""Department of Gynaecology, Ji'an Maternal and Child Health Care Hospital Ji'an 343000, Jiangxi Province, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Shuai', 'Affiliation': ""Operating Room, Ji'an Maternal and Child Health Care Hospital Ji'an 343000, Jiangxi Province, China.""}, {'ForeName': 'Suli', 'Initials': 'S', 'LastName': 'Zhao', 'Affiliation': ""Operating Room, Ji'an Maternal and Child Health Care Hospital Ji'an 343000, Jiangxi Province, China.""}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Qiu', 'Affiliation': ""Department of Gynaecology, Ji'an Maternal and Child Health Care Hospital Ji'an 343000, Jiangxi Province, China.""}]",American journal of translational research,[] 2649,34377264,The effects of acute hypervolemic hemodilution and conventional infusion in laparoscopic radical prostatectomy patients.,"OBJECTIVE To compare the effect of acute hypervolemic hemodilution and conventional infusion in prostate cancer patients undergoing laparoscopic radical prostatectomies. METHODS A total of 87 patients with prostate cancer who underwent laparoscopic radical prostatectomies in our hospital were retrospectively analyzed. The patients were randomly divided into a control group (the CNG, n=43, conventional infusion) and an observation group (the OG, n=44, acute hypervolemic hemodilution). Blood gas analyses were performed at different time points, and the patients' cognitive dysfunction was evaluated. RESULTS The intraoperative blood transfusion rates of the OG and the CNG were 11.36% and 30.23%. The average intraoperative blood transfusions in the OG and the CNG were (315.46±24.49) ml and (486.95±42.17) ml ( P < 0.05). The CVP and JVP levels in the OG and the CNG at T2 and T3 were significantly higher than the levels at T0 ( P < 0.05). The Hb levels of the CNG at T3 and T4 were lower than they were at T0 ( P < 0.05), and the Hb level in the OG at T4 was lower than it was at T1 ( P < 0.05). The Hb levels in the CNG at T3 and T4 were lower than they were at T1 ( P < 0.05), and the Hb levels in the OG at T1 and T2 were lower than they were in the CNG ( P < 0.05). The MMSE cognitive function scores were lower than the scores recorded on the day before the operations ( P < 0.05). CONCLUSION Acute hypervolemic hemodilution in laparoscopic radical prostatectomy patients can maintain their hemodynamics in a stable state, help reduce blood transfusion, improve the oxygen supply to the brain tissue to maintain the supply and demand balance, and reduce the impact on the patients' cognitive function.",2021,The CVP and JVP levels in the OG and the CNG at T2 and T3 were significantly higher than the levels at T0 ( P < 0.05).,"['prostate cancer patients undergoing laparoscopic radical prostatectomies', '87 patients with prostate cancer who underwent', 'laparoscopic radical prostatectomy patients']","['laparoscopic radical prostatectomies', 'acute hypervolemic hemodilution and conventional infusion']","['average intraoperative blood transfusions', 'CVP and JVP levels', 'Hb levels', 'Hb level', 'MMSE cognitive function scores', 'intraoperative blood transfusion rates']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}]","[{'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0019009', 'cui_str': 'Hemodilution'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0056633', 'cui_str': 'COP protocol 2'}, {'cui': 'C0428897', 'cui_str': 'Jugular venous pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",87.0,0.12092,The CVP and JVP levels in the OG and the CNG at T2 and T3 were significantly higher than the levels at T0 ( P < 0.05).,"[{'ForeName': 'Jinguang', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Urologic Surgery, Shengli Hospital of Dongying Dongying 257000, Shandong Province, China.'}, {'ForeName': 'Zhilei', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Urologic Surgery, Shengli Hospital of Dongying Dongying 257000, Shandong Province, China.'}]",American journal of translational research,[] 2650,34377263,"Effect of pemetrexed on the efficacy, toxic reaction, and survival rate of patients with EGFR-TKI resistant moderate and advanced lung cancer.","OBJECTIVE To explore the effect of pemetrexed on the efficacy, toxic reaction, and survival rate of patients with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistant moderate to advanced lung cancer. METHODS A total of 86 patients with EGFR-TKI resistant moderate and advanced lung cancer in our hospital were divided by therapeutic drugs into a control group (39 patients) and pemetrexed group (47 patients). Differences in general data, clinical efficacy, immunoglobulin expression, tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) levels, tumor markers, toxic reaction, and survival rate between the two groups were analyzed. RESULTS Similar expression levels of carcinoembryonic antigen, IL-6, carbohydrate antigen 125, TNF-α, carbohydrate antigen 153 and immunoglobulin were found in the control group and pemetrexed group before treatment (all P>0.05). Expression levels of the above indicators in all patients decreased one month after the end of treatment, and levels of immunoglobulin, inflammatory factors, and tumor markers in the control group were higher than those in the pemetrexed group (all P<0.05). Similar incidence rates of toxic reactions were shown in the two groups (P>0.05). Twelve months after the end of treatment, one-year survival rate was significantly higher in the pemetrexed group than in the control group (χ 2 =3.332, P=0.042). CONCLUSION Pemetrexed can significantly improve the clinical efficacy in patients with EGFR-TKI resistant lung cancer, decrease the expression of inflammatory factors, tumor markers, and immunoglobulin in serum, has few side effects on the body, and prolongs the long-term survival rate.",2021,"Twelve months after the end of treatment, one-year survival rate was significantly higher in the pemetrexed group than in the control group (χ 2 =3.332, P=0.042). ","['patients with epidermal growth factor receptor tyrosine kinase inhibitor', '86 patients with EGFR-TKI resistant moderate and advanced lung cancer in our hospital were divided by therapeutic drugs into a control group (39 patients) and pemetrexed group (47 patients', 'patients with EGFR-TKI resistant moderate and advanced lung cancer', 'patients with EGFR-TKI resistant lung cancer']","['Pemetrexed', 'pemetrexed']","['Expression levels', 'clinical efficacy', 'general data, clinical efficacy, immunoglobulin expression, tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) levels, tumor markers, toxic reaction, and survival rate', 'year survival rate', 'efficacy, toxic reaction, and survival rate', 'toxic reactions', 'carcinoembryonic antigen, IL-6, carbohydrate antigen 125, TNF-α, carbohydrate antigen 153 and immunoglobulin', 'levels of immunoglobulin, inflammatory factors, and tumor markers']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1443775', 'cui_str': 'Epidermal growth factor receptor antagonist-containing product'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4524268', 'cui_str': 'Advanced lung cancer'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}]",[],"[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0021027', 'cui_str': 'Immunoglobulin'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041365', 'cui_str': 'Biomarkers, Cancer'}, {'cui': 'C0542243', 'cui_str': 'Toxic reaction (NOS)'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0007082', 'cui_str': 'Carcinoembryonic antigen'}, {'cui': 'C0006610', 'cui_str': 'Cancer antigen 125'}, {'cui': 'C0443758', 'cui_str': 'Carbohydrate antigen'}]",86.0,0.0404993,"Twelve months after the end of treatment, one-year survival rate was significantly higher in the pemetrexed group than in the control group (χ 2 =3.332, P=0.042). ","[{'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'Cao', 'Affiliation': ""The First Department of Respiratory Medicine, The First People's Hospital of Wenling Wenling, Zhejiang Province, China.""}, {'ForeName': 'Yaoji', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""The First Department of Respiratory Medicine, The First People's Hospital of Wenling Wenling, Zhejiang Province, China.""}]",American journal of translational research,[] 2651,34377251,Impact of improved prehospital emergency medical service system on the time management of chest pain patients in the emergency department.,"OBJECTIVES To investigate the impact of an improved prehospital emergency medical service system (EMSS) on the time management of chest pain (CP) patients in the Emergency Department in our hospital and define the role of the improved prehospital EMSS in the treatment of CP patients. METHODS All patients with ST-elevation myocardial infarction (STEMI) undergoing coronary artery stent placement (CASP) in our hospital from August 2011 to December 2012 were included in this study, and were randomly divided into a study group (SG) and control group (COG) by the random number table method. The critical time periods [e.g., time to dispatch ambulance upon the receipt of the call to 120, time from hospital entrance to the Emergency Department, time from arrival at hospital to: first treatment, to first electrocardiogram (ECG), to monitoring of vital signs, to establishment of venous access device (VAD), and to entrance to catheter room in the two groups were sorted out for statistical analysis. RESULTS Improved prehospital EMSS can markedly shorten the time to dispatch ambulance upon the receipt of the call to 120, time from hospital entrance to the Emergency Department, and time to first treatment, time to first ECG, to monitoring of vital signs, to establishment of VAD, and to entrance to the catheter room; it also prolonged the 5-year survival rate ( P < 0.05). CONCLUSION Improved prehospital EMSS can significantly improve the time management of CP patients in the Emergency Department.",2021,"To investigate the impact of an improved prehospital emergency medical service system (EMSS) on the time management of chest pain (CP) patients in the Emergency Department in our hospital and define the role of the improved prehospital EMSS in the treatment of CP patients. ","['All patients with ST-elevation myocardial infarction (STEMI) undergoing coronary artery stent placement (CASP) in our hospital from August 2011 to December 2012', 'CP patients', 'chest pain patients in the emergency department', 'chest pain (CP) patients in the Emergency Department in our hospital']","['prehospital emergency medical service system (EMSS', 'prehospital emergency medical service system', 'control group (COG']","['5-year survival rate', 'critical time periods [e.g., time to dispatch ambulance upon the receipt of the call to 120, time from hospital entrance to the Emergency Department, time from arrival at hospital to: first treatment, to first electrocardiogram (ECG), to monitoring of vital signs, to establishment of venous access device (VAD), and to entrance to catheter room']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1303258', 'cui_str': 'Acute ST segment elevation myocardial infarction'}, {'cui': 'C0687568', 'cui_str': 'Coronary artery stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008031', 'cui_str': 'Chest pain'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}]","[{'cui': 'C0013961', 'cui_str': 'Emergency medical services'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C1948053', 'cui_str': 'Time periods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002422', 'cui_str': 'Ambulance'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0337095', 'cui_str': 'Entrance'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}]",,0.0321749,"To investigate the impact of an improved prehospital emergency medical service system (EMSS) on the time management of chest pain (CP) patients in the Emergency Department in our hospital and define the role of the improved prehospital EMSS in the treatment of CP patients. ","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Jin', 'Affiliation': ""Nursing Department, The First People's Hospital of Fuyang Hangzhou Hangzhou 311400, Zhejiang, China.""}, {'ForeName': 'Jiajia', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': ""Emergency Department, The First People's Hospital of Fuyang Hangzhou Hangzhou 311400, Zhejiang, China.""}, {'ForeName': 'Junjun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Emergency Department, The First People's Hospital of Fuyang Hangzhou Hangzhou 311400, Zhejiang, China.""}]",American journal of translational research,[] 2652,34377250,Analysis of subjective and objective safety risks in nursing care of pediatric hematologic diseases.,"OBJECTIVE To explore safety risks in the common nursing care of pediatric hematologic diseases. METHODS A total of 100 children with hematologic diseases treated in our hospital were included and randomly divided into a control group (n = 49) and an observation group (n = 51). Children in the control group received routine nursing according to previous practice, while children in the observation group received special environmental nursing with a large number of nurses who had received professional nursing education. After a period of time, the related satisfaction of the two groups of patients was investigated and compared. RESULTS There were significant differences in nursing environment, the quantity of nursing staff, and the nursing level between the control group and the observation group. The proportion of patients with treatment compliance and accident incidence in the observation group was significantly different from that in the control group, indicating some safety risks in the nursing care of pediatric hematologic diseases. CONCLUSION Reducing the probability of various risks in the process of nursing care can create a high-quality and comfortable rehabilitation environment for patients, so as to improve the patients' satisfaction with the service of medical staffs.",2021,"The proportion of patients with treatment compliance and accident incidence in the observation group was significantly different from that in the control group, indicating some safety risks in the nursing care of pediatric hematologic diseases. ","['nursing care of pediatric hematologic diseases', '100 children with hematologic diseases treated in our hospital']","['special environmental nursing with a large number of nurses who had received professional nursing education', 'routine nursing']","['nursing environment, the quantity of nursing staff, and the nursing level', 'accident incidence']","[{'cui': 'C0028678', 'cui_str': 'nursing'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0018939', 'cui_str': 'Disorder of hematopoietic system'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0013636', 'cui_str': 'Nursing Education'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0028698', 'cui_str': 'Nursing Staffs'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0000924', 'cui_str': 'Accident'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",100.0,0.0186435,"The proportion of patients with treatment compliance and accident incidence in the observation group was significantly different from that in the control group, indicating some safety risks in the nursing care of pediatric hematologic diseases. ","[{'ForeName': 'Fuyu', 'Initials': 'F', 'LastName': 'He', 'Affiliation': 'Department of Pediatric Digestive and Hematology, Ganzhou Maternal and Child Health Care Hospital Ganzhou 341000, Jiangxi Province, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Huang', 'Affiliation': 'Department of Pediatric Digestive and Hematology, Ganzhou Maternal and Child Health Care Hospital Ganzhou 341000, Jiangxi Province, China.'}, {'ForeName': 'Binbin', 'Initials': 'B', 'LastName': 'Liao', 'Affiliation': 'Department of Pediatric Digestive and Hematology, Ganzhou Maternal and Child Health Care Hospital Ganzhou 341000, Jiangxi Province, China.'}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Huang', 'Affiliation': 'Department of Pediatric Digestive and Hematology, Ganzhou Maternal and Child Health Care Hospital Ganzhou 341000, Jiangxi Province, China.'}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Peng', 'Affiliation': 'Department of Pediatric Digestive and Hematology, Ganzhou Maternal and Child Health Care Hospital Ganzhou 341000, Jiangxi Province, China.'}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Zhong', 'Affiliation': 'Department of Pediatric Digestive and Hematology, Ganzhou Maternal and Child Health Care Hospital Ganzhou 341000, Jiangxi Province, China.'}]",American journal of translational research,[] 2653,34377247,Effect of microincisional cataract surgery on inflammatory indicators in tears and corneal endothelial cells in cataract patients.,"OBJECTIVE To analyze the effect of microincisional cataract surgery on inflammation in tears and corneal endothelial cells in cataract patients. METHODS A total of 103 patients with cataracts in our hospital were enrolled and randomly divided into group A (n=52) and group B (n=51) by a random double-blind lottery. Group A received 1.8 mm coaxial microincision cataract surgery (C-MICS) while group B received 3.0 mm C-MICS, and the efficacy was compared between the two groups. RESULTS Average ultrasound energy (AVG), accumulative phaco time (APT), and effective phaco time (EPT) did not differ between groups ( P > 0.05). Group A exhibited higher interleukin-2 (IL-2) levels at 5 days postoperatively and lower interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and tumor necrosis factor-β1 (TNF-β1) levels than group B ( P < 0.05). The density of corneal endothelial cells, coefficient of variation, and percentage of hexagonal cells showed no significant difference in both groups at 5 days postoperatively ( P > 0.05). Group A had higher visual acuity and lower visual acuity loss, visual fatigue, foreign body sensation, tingling, and photophobia scores than group B at 7, 14, and 28 days postoperatively ( P < 0.05). The tear film break-up time (TBUT) in group A was longer than that in group B at 7, 14, and 28 days postoperatively, and the tear secretion length (in mm) on the strip in group A was longer than that in group B at 14 and 28 days postoperatively ( P < 0.05). CONCLUSION Compared with other types of similar surgery, C-MICS can significantly control inflammation levels, with less effect on corneal endothelial cells, improve postoperative visual acuity, delay tear film break-up, increase tear secretion, and improve dry eye syndrome.",2021,"Group A exhibited higher interleukin-2 (IL-2) levels at 5 days postoperatively and lower interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and tumor necrosis factor-β1 (TNF-β1) levels than group B ( P < 0.05).","['cataract patients', '103 patients with cataracts in our hospital']","['microincisional cataract surgery', 'coaxial microincision cataract surgery (C-MICS']","['tear film break-up time (TBUT', 'density of corneal endothelial cells, coefficient of variation, and percentage of hexagonal cells', 'corneal endothelial cells, improve postoperative visual acuity, delay tear film break-up, increase tear secretion, and improve dry eye syndrome', 'Average ultrasound energy (AVG), accumulative phaco time (APT), and effective phaco time (EPT', 'tear secretion length', 'higher visual acuity and lower visual acuity loss, visual fatigue, foreign body sensation, tingling, and photophobia scores', 'interleukin-2 (IL-2) levels', 'inflammatory indicators in tears and corneal endothelial cells', 'interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and tumor necrosis factor-β1 (TNF-β1) levels']","[{'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C1690970', 'cui_str': 'Bimanual microincisional phacoemulsification of cataract with intraocular lens implantation'}]","[{'cui': 'C0429495', 'cui_str': 'Tear film break-up time'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0225336', 'cui_str': 'Endothelial cell'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0041620', 'cui_str': 'Therapeutic ultrasound'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0234632', 'cui_str': 'Reduced visual acuity'}, {'cui': 'C0004095', 'cui_str': 'Accommodative asthenopia'}, {'cui': 'C0423602', 'cui_str': 'Foreign body sensation'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0085636', 'cui_str': 'Photophobia'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021756', 'cui_str': 'Interleukin-2'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}]",103.0,0.051912,"Group A exhibited higher interleukin-2 (IL-2) levels at 5 days postoperatively and lower interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and tumor necrosis factor-β1 (TNF-β1) levels than group B ( P < 0.05).","[{'ForeName': 'Hangzhu', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': ""Department of Ophthalmology, The First People's Hospital of Fuyang Hangzhou Hangzhou 311400, Zhejiang, China.""}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Fang', 'Affiliation': ""Department of Ophthalmology, The First People's Hospital of Fuyang Hangzhou Hangzhou 311400, Zhejiang, China.""}]",American journal of translational research,[] 2654,34377197,Comparison of the prophylactic effect of dexamethasone and dexmedetomidine and their combination in reducing postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.,"Nausea and vomiting are some of the most common complaints of patients after any anesthesia, which is often associated with postoperative pain. The double-blind clinical trial study aimed to compare the prophylactic effect of dexamethasone and dexmedetomidine and their combination in reducing postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. One hundred sixty-two patients undergoing laparoscopic cholecystectomy were enrolled in the study. In the first group of patients, 25 mg of dexmedetomidine were administered slowly. In comparison, the patients in the second group received dexamethasone (4 ml/2 mg) with 0.1 mg/kg of normal saline solution. The third group received a combination of dexmedetomidine and dexamethasone. Hemodynamic changes were recorded during surgery and after surgery, and the patients were admitted to recovery. Nausea and vomiting scores were recorded 2 and 4 hours after surgery. Blood pressure and heart rate were lower in the dexmedetomidine group at all times (P<0.05). Two hours after surgery, the dexamethasone and dexmedetomidine combination group had less vomiting (P=0.012). The incidence of nausea 2 and 4 hours after surgery was lower in the dexamethasone and dexmedetomidine combination group (P<0.05). Blood pressure and heart rate were lower in the dexmedetomidine group at all times. The dexmedetomidine and dexamethasone combination decreased postoperative nausea and vomiting in patients. Therefore, we recommend using a dexmedetomidine and dexamethasone combination for reducing postoperative nausea and vomiting.",2021,The incidence of nausea 2 and 4 hours after surgery was lower in the dexamethasone and dexmedetomidine combination group (P<0.05).,"['One hundred sixty-two patients undergoing', 'patients', 'patients undergoing laparoscopic cholecystectomy']","['dexmedetomidine', 'dexamethasone and dexmedetomidine', 'dexmedetomidine and dexamethasone', 'laparoscopic cholecystectomy', 'dexamethasone', 'dexmedetomidine and dexamethasone combination', 'normal saline solution']","['incidence of nausea', 'Nausea and vomiting', 'Hemodynamic changes', 'Nausea and vomiting scores', 'vomiting', 'Blood pressure and heart rate', 'postoperative nausea and vomiting']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}]",162.0,0.264138,The incidence of nausea 2 and 4 hours after surgery was lower in the dexamethasone and dexmedetomidine combination group (P<0.05).,"[{'ForeName': 'Siamak', 'Initials': 'S', 'LastName': 'Rekei', 'Affiliation': 'Department of Surgery, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Amir Reza', 'Initials': 'AR', 'LastName': 'Naeimi', 'Affiliation': 'Department of Surgery, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Behnam', 'Initials': 'B', 'LastName': 'Mahmodiyeh', 'Affiliation': 'Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Roya', 'Initials': 'R', 'LastName': 'Golmoradi', 'Affiliation': 'Department of Surgery, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Kamali', 'Affiliation': 'Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran.'}]",Journal of medicine and life,['10.25122/jml-2020-0030'] 2655,34377184,Assessment of the Effectiveness of Transcranial Magnetic Stimulation in Subjective Tinnitus.,"Introduction  Increases in spontaneous activity in the neurons of the auditory cortex are presumed as the pathophysiology of tinnitus. Objective  To investigate the effectiveness of transcranial magnetic stimulation (TMS) in the treatment of tinnitus. Methods  A total of 62 patients between the ages of 22 and 74 with chronic subjective tinnitus were enrolled in the study. The inclusion criteria were normal findings on an otolaryngologic examination and normal ranges of complete blood count, routine biochemical parameter levels, thyroid function, air-bone gap on pure-tone audiometry, and middle-ear pressure and stapedial reflex on tympanometry. The patients were randomized into 2 groups: 40 patients were placed in the treatment for TMS (tTMS) group, and the rest (22 patients) were placed in the sham TMS group. The frequency and severity of the tinnitus, as well as the tinnitus handicap inventory (THI) score of each patient were measured before and one month after the treatment, and the values were statistically evaluated. Results  We observed a statistically significant improvement in the tTMS group ( p  < 0.05 and p  < 0.05 respectively) regarding the THI and tinnitus severity scores. The sham TMS group showed no significant improvement in terms of the THI ( p  > 0.05). However, the tinnitus severity showed a significant increase in this group ( p  < 0.05). The comparison of differences in the changes in the THI and the tinnitus severity scores showed a significant statistical improvement in the tTMS group compared with the sham TMS group ( p  < 0.05 and p  < 0.05 respectively). Conclusion  Transcranial magnetic stimulation was found to be effective in the treatment of tinnitus, and may be adopted as a treatment for tinnitus after further comprehensive studies.",2021,We observed a statistically significant improvement in the tTMS group ( p  < 0.05 and p  < 0.05 respectively) regarding the THI and tinnitus severity scores.,"['tinnitus', 'Subjective Tinnitus', '62 patients between the ages of 22 and 74 with chronic subjective tinnitus were enrolled in the study']","['sham TMS', 'TMS (tTMS', 'Transcranial Magnetic Stimulation', 'Transcranial magnetic stimulation', 'tTMS', 'transcranial magnetic stimulation (TMS']","['spontaneous activity', 'THI', 'tinnitus severity', 'THI and tinnitus severity scores', 'frequency and severity of the tinnitus, as well as the tinnitus handicap inventory (THI) score of each patient', 'otolaryngologic examination and normal ranges of complete blood count, routine biochemical parameter levels, thyroid function, air-bone gap on pure-tone audiometry, and middle-ear pressure and stapedial reflex on tympanometry']","[{'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0155533', 'cui_str': 'Subjective tinnitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0047118', 'cui_str': '3-(2-(2,4,6-trimethylphenyl)thioethyl)-4-methylsydnone'}]","[{'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0272238', 'cui_str': 'Transient hypogammaglobulinemia of infancy'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0086715', 'cui_str': 'Normal range'}, {'cui': 'C0009555', 'cui_str': 'Complete blood count'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040132', 'cui_str': 'Thyroid structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0004292', 'cui_str': 'Pure tone audiometry'}, {'cui': 'C0457587', 'cui_str': 'Middle ear pressure'}, {'cui': 'C0034934', 'cui_str': 'Stapedial reflex'}, {'cui': 'C0085853', 'cui_str': 'Tympanometry testing'}]",62.0,0.0115111,We observed a statistically significant improvement in the tTMS group ( p  < 0.05 and p  < 0.05 respectively) regarding the THI and tinnitus severity scores.,"[{'ForeName': 'Mesut', 'Initials': 'M', 'LastName': 'Aydın', 'Affiliation': 'Deparment of Otolaryngology, Kayseri City Hospital, Kayseri, Turkey.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Erkan', 'Affiliation': 'Deparment of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Erciyes University, Kayseri, Turkey.'}, {'ForeName': 'Ramazan', 'Initials': 'R', 'LastName': 'Gündoğdu', 'Affiliation': 'Deparment of Otolaryngology, Derince Training and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Alperen', 'Initials': 'A', 'LastName': 'Vural', 'Affiliation': 'Deparment of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Erciyes University, Kayseri, Turkey.'}, {'ForeName': 'Kerem', 'Initials': 'K', 'LastName': 'Kökoğlu', 'Affiliation': 'Deparment of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Erciyes University, Kayseri, Turkey.'}, {'ForeName': 'Mehmet İlhan', 'Initials': 'Mİ', 'LastName': 'Şahin', 'Affiliation': 'Deparment of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Erciyes University, Kayseri, Turkey.'}]",International archives of otorhinolaryngology,['10.1055/s-0040-1718530'] 2656,34377181,Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival.,"Introduction  Head and neck cancer of unknown primary (HNCUP) is a rare condition whose prognostic factors that are significant for survival vary between studies. No randomized treatment study has been performed thus far, and the optimal treatment is not established. Objective  The present study aimed to explore various prognostic factors and compare the two main treatments for HNCUP: neck dissection and (chemo) radiation vs primary (chemo) radiation. Methods  A national multicenter study was performed with data from the Swedish Head and Neck Cancer Register (SweHNCR) and from the patients' medical records from 2008 to 2012. Results  Two-hundred and sixty HNCUP patients were included. The tumors were HPV-positive in 80%. The overall 5-year survival rate of patients treated with curative intent was 71%. Age ( p  < 0.001), performance status ( p = 0.036), and N stage ( p = 0.046) were significant factors for overall survival according to the multivariable analysis. Treatment with neck dissection and (chemo) radiation (122 patients) gave an overall 5-year survival of 73%, and treatment with primary (chemo) radiation (87 patients) gave an overall 5-year survival of 71%, with no significant difference in overall or disease-free survival between the 2 groups. Conclusions  Age, performance status, and N stage were significant prognostic factors. Treatment with neck dissection and (chemo) radiation and primary (chemo) radiation gave similar survival outcomes. A randomized treatment study that includes quality of life is needed to establish the optimal treatment.",2021,"Treatment with neck dissection and (chemo) radiation (122 patients) gave an overall 5-year survival of 73%, and treatment with primary (chemo) radiation (87 patients) gave an overall 5-year survival of 71%, with no significant difference in overall or disease-free survival between the 2 groups. ","['Swedish Head and Neck Cancer Register', 'Two-hundred and sixty HNCUP patients were included', ""SweHNCR) and from the patients' medical records from 2008 to 2012""]","['HNCUP: neck dissection and (chemo) radiation vs primary (chemo) radiation', 'neck dissection and (chemo) radiation and primary (chemo) radiation', 'neck dissection and (chemo) radiation']","['overall 5-year survival rate', 'overall survival', 'overall or disease-free survival', 'overall 5-year survival', 'performance status', 'Survival']","[{'cui': 'C0038996', 'cui_str': 'Swedish language'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C4517669', 'cui_str': '260'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}]","[{'cui': 'C0398395', 'cui_str': 'Block dissection of cervical lymph nodes'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0205225', 'cui_str': 'Principal'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",260.0,0.133868,"Treatment with neck dissection and (chemo) radiation (122 patients) gave an overall 5-year survival of 73%, and treatment with primary (chemo) radiation (87 patients) gave an overall 5-year survival of 71%, with no significant difference in overall or disease-free survival between the 2 groups. ","[{'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Axelsson', 'Affiliation': 'Department of Otorhinolaryngology, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Holmberg', 'Affiliation': 'Regional Cancer Center in Western Sweden, Gothenburg, Sweden.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Nyman', 'Affiliation': 'Department of Oncology, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Högmo', 'Affiliation': 'Department of Otorhinolaryngology - Head and Neck Surgery, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Sjödin', 'Affiliation': 'Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Gebre-Medhin', 'Affiliation': 'Department of Oncology, Lund University Hospital, Lund, Skåne, Sweden.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'von Beckerath', 'Affiliation': 'Department of Otorhinolaryngology - Head and Neck Surgery, Örebro University Hospital, Örebro, Sweden.'}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Ekberg', 'Affiliation': 'Department of Otorhinolaryngology - Head and Neck Surgery, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Farnebo', 'Affiliation': 'Department of Otorhinolaryngology - Head and Neck Surgery, Linköping University Hospital, Linkoping, Sweden.'}, {'ForeName': 'Charbel', 'Initials': 'C', 'LastName': 'Talani', 'Affiliation': 'Department of Oncology, Linköping University Hospital, Linkoping, Sweden.'}, {'ForeName': 'Lena Norberg', 'Initials': 'LN', 'LastName': 'Spak', 'Affiliation': 'Department of Otorhinolaryngology - Head and Neck Surgery, Norrlands University Hospital, Umea, Sweden.'}, {'ForeName': 'Isak', 'Initials': 'I', 'LastName': 'Notstam', 'Affiliation': 'Department of Otorhinolaryngology, County Hospital Sundsvall-Harnosand, Sundsvall, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Hammerlid', 'Affiliation': 'Department of Otorhinolaryngology, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden.'}]",International archives of otorhinolaryngology,['10.1055/s-0040-1712106'] 2657,34377158,IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.,"Background Biliary tract cancers (BTCs) are heterogenous, highly aggressive tumors that harbor a dismal prognosis for which more effective treatments are needed. The role of cancer immunotherapy in BTC remains to be characterized. The tumor microenvironment (TME) of BTC is highly immunosuppressed and combination treatments are needed to promote effective anticancer immunity. Vascular endothelial growth factor (VEGF) drives immunosuppression in the TME by disrupting antigen presentation, limiting T-cell infiltration, or potentiating immune-suppressive cells. Many VEGF-regulated mechanisms are thought to be relevant to repressed antitumor immunity in BTC, making dual targeting of VEGF and programmed cell death protein 1 (PD-1)/PD-L1 pathways a rational approach. Gemcitabine and Cisplatin (Gem/Cis) can also modulate anticancer immunity through overlapping and complementary mechanisms to those regulated by VEGF. Anti-PD-L1/VEGF inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit. Methods IMbrave 151 is a randomized, double-blind, placebo-controlled, multicenter, international phase II study to evaluate atezolizumab (a PD-L1 inhibitor) in combination with chemotherapy (gemcitabine and cisplatin) and bevacizumab (an anti-VEGF monoclonal antibody) as a first-line treatment for advanced BTC. Approximately 150 patients with previously untreated, advanced BTC will be randomized to either Arm A (atezolizumab + bevacizumab + Gem/Cis) or Arm B (atezolizumab + placebo + Gem/Cis). Randomization is stratified by the presence of metastatic disease, primary tumor location, and geographic region. The primary efficacy endpoint is investigator-assessed progression-free survival (PFS) per RECIST 1.1. Secondary endpoints include objective response rate (ORR), duration of response (DoR), disease control rate (DCR), overall survival (OS), and safety and patient reported outcomes (PROs). Tissue, blood, and stool samples will be collected at baseline and on-treatment in order to perform correlative biomarker analyses. Discussion IMbrave 151 represents the first randomized study to evaluate combined PD-L1/VEGF blockade on a chemotherapy backbone in BTC. Trial registration NCT identifier: NCT04677504; EUDRACT number: 2020-003759-14.",2021,"Secondary endpoints include objective response rate (ORR), duration of response (DoR), disease control rate (DCR), overall survival (OS), and safety and patient reported outcomes (PROs).","['Approximately 150 patients with previously untreated, advanced BTC', 'patients with advanced biliary tract cancer']","['atezolizumab combined with bevacizumab and chemotherapy', 'combined PD-L1/VEGF blockade', 'chemotherapy (gemcitabine and cisplatin) and bevacizumab', 'Gemcitabine and Cisplatin (Gem/Cis', 'atezolizumab', 'placebo', 'Arm A (atezolizumab\u2009+\u2009bevacizumab\u2009+\u2009Gem/Cis) or Arm B (atezolizumab\u2009+\u2009placebo\u2009+\u2009Gem/Cis']","['Tissue, blood, and stool samples', 'objective response rate (ORR), duration of response (DoR), disease control rate (DCR), overall survival (OS), and safety and patient reported outcomes (PROs', 'investigator-assessed progression-free survival (PFS']","[{'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0053251', 'cui_str': 'Benzotrichloride'}, {'cui': 'C0750952', 'cui_str': 'Malignant tumor of biliary tract'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0079280', 'cui_str': 'Endothelial Growth Factor'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C1550661', 'cui_str': 'Stool specimen'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.170635,"Secondary endpoints include objective response rate (ORR), duration of response (DoR), disease control rate (DCR), overall survival (OS), and safety and patient reported outcomes (PROs).","[{'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Hack', 'Affiliation': 'Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Verret', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Sohail', 'Initials': 'S', 'LastName': 'Mulla', 'Affiliation': 'Hoffmann-La Roche Limited, Mississauga, ON, Canada.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Yulei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Macarulla', 'Affiliation': ""Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Zhenggang', 'Initials': 'Z', 'LastName': 'Ren', 'Affiliation': 'Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Anthony B', 'Initials': 'AB', 'LastName': 'El-Khoueiry', 'Affiliation': 'USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Andrew X', 'Initials': 'AX', 'LastName': 'Zhu', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, MA, USA.'}]",Therapeutic advances in medical oncology,['10.1177/17588359211036544'] 2658,34376809,Implementation of the spinal cord injury exercise guidelines in the hospital and community settings: Protocol for a type II hybrid trial.,"STUDY DESIGN Type II hybrid effectiveness-implementation trial protocol. OBJECTIVES To (1) evaluate the implementation of coordinated physical activity (PA) coaching delivered by physiotherapists and spinal cord injury (SCI) peers during the transition from in-hospital care to living in a community (implementation objective) and (2) assess the effect of coaching on PA behaviour and psychosocial predictors among people with SCI (effectiveness objective). SETTING Rehabilitation hospital and home/community settings in British Columbia, Canada. METHODS Implementation objective: PA coaches (physiotherapists and SCI peers) receive an implementation intervention including training, monitoring, feedback, and champion support. A Theoretical Domains Framework-based questionnaire is collected at baseline, post-training, 2, and 6 months follow-up and semi-structured interviews conducted at 6 months. Effectiveness objective: Using a quasi-experimental design, 55 adults with SCI are allocated to intervention (PA coaching, n = 30) or control (usual care, n = 25) groups. Participants in the intervention group are referred by physiotherapists to receive 11 SCI peer-delivered PA coaching sessions in the community. Control participants received usual care. Questionnaires assessing PA behaviour and psychosocial predictors are administered at baseline, 2-months, 6-months, and 1-year. Semi-structured interviews are conducted to assess intervention satisfaction at 6 months. Analyses include one-way (implementation objective) and two-way (effectiveness objective) repeated measures ANCOVAs for questionnaire-reported outcomes and thematic content analysis for interview data. Data are summarised using the reach effectiveness adoption implementation maintenance (RE-AIM) framework. ETHICS AND DISSEMINATION The University of British Columbia Clinical Research Ethics Board approved the protocol (#H19-02694), clinicaltrials.gov registration NCT04493606. Documentation of the adoption process will inform implementation in future sites.",2021,Analyses include one-way (implementation objective) and two-way (effectiveness objective) repeated measures ANCOVAs for questionnaire-reported outcomes and thematic content analysis for interview data.,"['55 adults with SCI', 'Implementation objective: PA coaches (physiotherapists and SCI peers', 'Rehabilitation hospital and home/community settings in British Columbia, Canada', 'people with SCI (effectiveness objective']","['spinal cord injury exercise guidelines', 'implementation intervention including training, monitoring, feedback, and champion support', 'physiotherapists to receive 11 SCI peer-delivered PA coaching sessions', 'usual care', 'intervention (PA coaching, n\u2009=\u200930) or control (usual care', 'coordinated physical activity (PA) coaching delivered by physiotherapists and spinal cord injury (SCI) peers']","['Effectiveness objective', 'Questionnaires assessing PA behaviour and psychosocial predictors']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0337962', 'cui_str': 'Rehabilitation hospital'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0006193', 'cui_str': 'British Columbia'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]","[{'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",55.0,0.0337661,Analyses include one-way (implementation objective) and two-way (effectiveness objective) repeated measures ANCOVAs for questionnaire-reported outcomes and thematic content analysis for interview data.,"[{'ForeName': 'Jasmin K', 'Initials': 'JK', 'LastName': 'Ma', 'Affiliation': 'University of British Columbia, Vancouver, BC, Canada. Jasmin.ma@ubc.ca.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Walden', 'Affiliation': 'Praxis Spinal Cord Institute, Vancouver, BC, Canada.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'McBride', 'Affiliation': 'Spinal Cord Injury BC, Vancouver, BC, Canada.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Le Cornu Levett', 'Affiliation': 'GF Strong Rehabilitation Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Colistro', 'Affiliation': 'GF Strong Rehabilitation Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Tova', 'Initials': 'T', 'LastName': 'Plashkes', 'Affiliation': 'GF Strong Rehabilitation Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Teri', 'Initials': 'T', 'LastName': 'Thorson', 'Affiliation': 'Spinal Cord Injury BC, Vancouver, BC, Canada.'}, {'ForeName': 'Hattie', 'Initials': 'H', 'LastName': 'Shu', 'Affiliation': 'University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Kathleen A', 'Initials': 'KA', 'LastName': 'Martin Ginis', 'Affiliation': 'Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.'}]",Spinal cord,['10.1038/s41393-021-00685-7'] 2659,34376779,Long transcripts minus touchdown qPCR (LTMT-qPCR): a simplified and convenient method for the screening and quantification of microRNA profiles.,"Due to the short length and differences in abundance of microRNAs, microRNA profile screening and quantification is challenging. In this study, we found that size selection magnetic beads could be employed to easily and efficiently remove long RNA transcripts. After removing the long transcripts, the remaining small RNAs could be concentrated and then reverse-transcribed using universal stem-loop primers (USLP), with six randomized nucleotides at the 3' end region. The efficiency of reverse transcription decreased when the number of randomized nucleotides was reduced. In addition, we found that touchdown qPCR improved microRNA profile detection, with lower C T values and better detection efficiency than the regular qPCR protocol, especially for those low-abundance microRNAs. Finally, we incorporated these observations to create a new protocol we named long transcripts minus touchdown qPCR (LTMT-qPCR). We performed a side-by-side comparison of LTMT with USLP and traditional stem-loop primer (TSLP) protocols. We found that LTMT has higher detection efficiency than USLP, especially for the detection of low-abundance microRNAs. Although LTMT was equivalent to TSLP in terms of microRNA profile detection, LTMT is more convenient, user-friendly, and cost-effective. Taken together, the present data indicate that LTMT is a simple, rapid, and user-friendly approach that has higher precision, accuracy, and sensitivity than the previously described methods, making it more suitable for microRNA profile screening and quantification.",2021,"In addition, we found that touchdown qPCR improved microRNA profile detection, with lower C T values and better detection efficiency than the regular qPCR protocol, especially for those low-abundance microRNAs.",[],"['TSLP', 'LTMT with USLP and traditional stem-loop primer (TSLP) protocols', 'touchdown qPCR', 'touchdown qPCR (LTMT-qPCR', 'LTMT']",['efficiency of reverse transcription'],[],"[{'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0162731', 'cui_str': 'STEM'}, {'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0206415', 'cui_str': 'Oligonucleotide Primers'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}]","[{'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0035380', 'cui_str': 'Transcription, Reverse'}]",,0.0635672,"In addition, we found that touchdown qPCR improved microRNA profile detection, with lower C T values and better detection efficiency than the regular qPCR protocol, especially for those low-abundance microRNAs.","[{'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Yixiao', 'Initials': 'Y', 'LastName': 'Feng', 'Affiliation': 'Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Shixian', 'Initials': 'S', 'LastName': 'Zhou', 'Affiliation': 'Department of Pathology, Central Hospital of Jiangjin District, Chongqing, China.'}, {'ForeName': 'Xiaorong', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Chongqing Institute for Food and Drug Control, Chongqing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Key Laboratory of Diagnostic Medicine Designated by the Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Peng', 'Affiliation': 'Key Laboratory of Diagnostic Medicine Designated by the Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Xuehua', 'Initials': 'X', 'LastName': 'Kong', 'Affiliation': 'Key Laboratory of Diagnostic Medicine Designated by the Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Zhou', 'Affiliation': 'Key Laboratory of Diagnostic Medicine Designated by the Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Zongyue', 'Initials': 'Z', 'LastName': 'Zeng', 'Affiliation': 'Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. zengzongyue@126.com.'}]",Laboratory investigation; a journal of technical methods and pathology,['10.1038/s41374-021-00648-9'] 2660,34376554,Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T.,"BACKGROUND Combining an immune checkpoint inhibitor with a tumor vaccine may modulate the immune system to leverage complementary mechanisms of action that lead to sustained T-cell activation and a potent prolonged immunotherapeutic response in metastatic castration resistant prostate cancer (mCRPC). METHODS Subjects with asymptomatic or minimally symptomatic mCRPC were randomly assigned in a 1:1 ratio to receive either atezolizumab followed by sipuleucel-T (Arm 1) or sipuleucel-T followed by atezolizumab (Arm 2). The primary endpoint was safety, while secondary endpoints included preliminary clinical activity such as objective tumor response and systemic immune responses that could identify key molecular and immunological changes associated with sequential administration of atezolizumab and sipuleucel-T. RESULTS A total of 37 subjects were enrolled. The median age was 75.0 years, median prostate specific antigen (PSA) was 21.9 ng/mL, and subjects had a median number of three prior treatments. Most subjects (83.8%) had at least one treatment-related adverse event. There were no grade 4 or 5 toxicities attributed to either study drug. Immune-related adverse events and infusion reactions occurred in 13.5% of subjects, and all of which were grade 1 or 2. Of 23 subjects with Response Evaluation Criteria in Solid Tumors measurable disease, only one subject in Arm 2 had a partial response (PR) and four subjects overall had stable disease (SD) at 6 months reflecting an objective response rate of 4.3% and a disease control rate of 21.7%. T-cell receptor diversity was higher in subjects with a response, including SD. Immune response to three novel putative antigens (SIK3, KDM1A/LSD1, and PIK3R6) appeared to increase with treatment. CONCLUSIONS Overall, regardless of the order in which they were administered, the combination of atezolizumab with sipuleucel-T appears to be safe and well tolerated with a comparable safety profile to each agent administered as monotherapy. Correlative immune studies may suggest the combination to be beneficial; however, further studies are needed. TRIAL REGISTRATION NUMBER NCT03024216.",2021,"Immune-related adverse events and infusion reactions occurred in 13.5% of subjects, and all of which were grade 1 or 2.","['37 subjects were enrolled', 'Subjects with asymptomatic or minimally symptomatic mCRPC', 'metastatic castration resistant prostate cancer (mCRPC', 'patients with metastatic castrate-resistant prostate cancer']","['atezolizumab and sipuleucel-T', 'atezolizumab', 'atezolizumab followed by sipuleucel-T (Arm 1) or sipuleucel-T followed by atezolizumab']","['clinical activity such as objective tumor response and systemic immune responses that could identify key molecular and immunological changes associated with sequential administration of atezolizumab and sipuleucel-T', 'median prostate specific antigen (PSA', 'T-cell receptor diversity', 'toxicities', 'Immune response', 'partial response (PR', 'Immune-related adverse events and infusion reactions', 'stable disease (SD', 'objective response rate']","[{'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C1328504', 'cui_str': 'Hormone refractory prostate cancer'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C1706668', 'cui_str': 'sipuleucel-T'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0205470', 'cui_str': 'Immunologic'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C1706668', 'cui_str': 'sipuleucel-T'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0034790', 'cui_str': 'T-cell antigen receptor'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2368034', 'cui_str': 'Adverse reaction to drug or medicament administered by infusion'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",37.0,0.047513,"Immune-related adverse events and infusion reactions occurred in 13.5% of subjects, and all of which were grade 1 or 2.","[{'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Dorff', 'Affiliation': 'Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Hirasawa', 'Affiliation': 'Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Acoba', 'Affiliation': 'University of Hawaii Cancer Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Pagano', 'Affiliation': 'University of Hawaii Cancer Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Tamura', 'Affiliation': 'University of Hawaii Cancer Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'Sumanta', 'Initials': 'S', 'LastName': 'Pal', 'Affiliation': 'Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.'}, {'ForeName': 'Minlu', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Serimmune, Goleta, California, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Waitz', 'Affiliation': 'Serimmune, Goleta, California, USA.'}, {'ForeName': 'Abhilash', 'Initials': 'A', 'LastName': 'Dhal', 'Affiliation': 'Serimmune, Goleta, California, USA.'}, {'ForeName': 'Winston', 'Initials': 'W', 'LastName': 'Haynes', 'Affiliation': 'Serimmune, Goleta, California, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Shon', 'Affiliation': 'Serimmune, Goleta, California, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Scholz', 'Affiliation': 'Prostate Oncology Specialists, Marina del Rey, California, USA.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Furuya', 'Affiliation': 'Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.'}, {'ForeName': 'Owen T M', 'Initials': 'OTM', 'LastName': 'Chan', 'Affiliation': 'University of Hawaii Cancer Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'University of Hawaii Cancer Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Rosser', 'Affiliation': 'Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA charles.rosser@cshs.org.'}]",Journal for immunotherapy of cancer,['10.1136/jitc-2021-002931'] 2661,34376546,Impact of a seated-standing protocol on postures and pain among undergraduate dental hygiene students: A pilot study.,"Purpose: Although repetitive movements may lead to musculoskeletal pain, static and sedentary postures may be primary contributors to musculoskeletal disorders. The purpose of this pilot study was to determine whether an alternating seated-standing protocol would improve postures, decrease ergonomic risks, and reduce perceived pain scores among dental hygiene students. Methods: Thirty undergraduate dental hygiene students enrolled during the summer term were recruited to participate in the randomized control design pilot study. Participants were randomly assigned to the training (n=15) and control (n=15) groups. The training group alternated between sitting and standing every 30 minutes while providing dental hygiene care. The Modified-Dental Operator Posture Assessment Instrument (M-DOPAI) was used to evaluate ergonomic scores, the Rapid Upper Limb Assessment (RULA) was used to evaluate ergonomic risk, and the Modified-Standardized Nordic Musculoskeletal Questionnaire (M-SNMQ) was used to assess self-reported pain. Photographs were captured and levels of perceived pain were assessed at baseline, week-4, and week-8. Three raters independently evaluated the photographs using the M-DOPAI and RULA. Participants completed a survey about their experiences in the study at the end of week-8. Descriptive statistics and repeated measures ANOVAs were used to analyze the quantitative data; thematic analysis was used to analyze the qualitative data. Results: Although all participants perceived a reduction of pain over the duration of the eight-week study ( p <.05), the training group demonstrated no significant differences in ergonomic scores, ergonomic risks, or pain scores at the three time points ( p >.05). Qualitatively, participants in the training group perceived that the seated-standing protocol clinically improved their postures and reduced their pain. Conclusion: The results suggest there were minimal impacts of the alternating seated standing protocol on ergonomic scores, ergonomic risks, or perceived pain. More research is needed to determine whether there are objective benefits to an alternating seated-standing protocol.",2021,"Although all participants perceived a reduction of pain over the duration of the eight-week study ( p <.05), the training group demonstrated no significant differences in ergonomic scores, ergonomic risks, or pain scores at the three time points ( p >.05).","['dental hygiene students', 'Thirty undergraduate dental hygiene students enrolled during the summer term', 'undergraduate dental hygiene students']","['training group alternated between sitting and standing every 30 minutes while providing dental hygiene care', 'alternating seated-standing protocol', 'seated-standing protocol']","['levels of perceived pain', 'ergonomic scores, ergonomic risks, or pain scores', 'postures and pain', 'reduction of pain', 'pain', 'ergonomic scores, ergonomic risks, or perceived pain', 'pain scores']","[{'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0585318', 'cui_str': 'Every thirty minutes'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0086246', 'cui_str': 'Human Engineering'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.0345015,"Although all participants perceived a reduction of pain over the duration of the eight-week study ( p <.05), the training group demonstrated no significant differences in ergonomic scores, ergonomic risks, or pain scores at the three time points ( p >.05).","[{'ForeName': 'Brian B', 'Initials': 'BB', 'LastName': 'Partido', 'Affiliation': 'Executive Director of Dental Programs, Seattle Central College, Seattle, WA, USA. brian.partido@seattlecolleges.edu.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Henderson', 'Affiliation': 'Assistant professor-clinical in the Division of Dental Hygiene t The Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Lally', 'Affiliation': 'Graduate from the Division of Dental Hygiene at The Ohio State University, Columbus, OH, USA.'}]",Journal of dental hygiene : JDH,[] 2662,34382304,"Evaluation of Inter-professional Education (IPE) with medical, nursing and pharmacy students through a simulated IPL Educational Intervention.","INTRODUCTION Inter-professional education (IPE) is becoming an integral part of many professional programmes throughout the UK, ensuring health professionals are competent to work as part of an inter-professional team upon entry into their profession. IPE has become a fundamental component of curriculum content in health and social care degrees. AIMS Research aim - to evaluate a simulated IPE intervention. METHODS A one day IPE intervention, 'Evening On-Call' was run involving nursing and medical students and pre-registration pharmacists (student pharmacists in year 5 of training) in an on-call setting. This IPE incorporated manikin and actor patients in a simulated ward. During the intervention, the 3 groups of students are assessed under observation on their clinical, prioritisation and communication skills. Participants perceptions of this intervention were evaluated by completion of a questionnaire to capture their perceptions regarding the experience, the pre-IPL briefing and post-IPL feedback and perceived relevance of this training. Free text sections collected additional comments and a follow-up questionnaire was sent six months later. RESULTS Initial questionnaire feedback was predominantly positive for each professional group. The majority perceived the simulated IPL had given them a greater understanding of other professionals' roles, had enhanced their professional confidence and would help them prioritise workload once qualified. The 6 months follow up questionnaire supported the initial questionnaire findings. Some responses highlighted participants believed the simulated IPL had helped them work more effectively with other healthcare professionals, communicate more effectively and better prioritise their workload. There may be some evidence of sustained self-reported effectiveness in teaching certain professional and clinical skills to participants using this type of simulated intervention.",2021,"Some responses highlighted participants believed the simulated IPL had helped them work more effectively with other healthcare professionals, communicate more effectively and better prioritise their workload.",[],"['Inter-professional Education (IPE', ""IPE intervention, 'Evening On-Call' was run involving nursing and medical students and pre-registration pharmacists (student pharmacists in year 5 of training) in an on-call setting"", 'IPE', 'Inter-professional education (IPE']",[],[],"[{'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0013647', 'cui_str': 'Professional Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],,0.0195072,"Some responses highlighted participants believed the simulated IPL had helped them work more effectively with other healthcare professionals, communicate more effectively and better prioritise their workload.","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hamilton', 'Affiliation': 'NHS Education for Scotland, 2 Central Quay, 89 Hydepark Street, Glasgow, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Coey-Niebel', 'Affiliation': 'NHS Education for Scotland, 2 Central Quay, 89 Hydepark Street, Glasgow, UK.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'McCaig', 'Affiliation': 'NHS Education for Scotland, 2 Central Quay, 89 Hydepark Street, Glasgow, UK.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Zlotos', 'Affiliation': 'NHS Education for Scotland, 2 Central Quay, 89 Hydepark Street, Glasgow, UK.'}, {'ForeName': 'Ailsa', 'Initials': 'A', 'LastName': 'Power', 'Affiliation': 'NHS Education for Scotland, 2 Central Quay, 89 Hydepark Street, Glasgow, UK.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Craig', 'Affiliation': 'NHS Education for Scotland, 2 Central Quay, 89 Hydepark Street, Glasgow, UK.'}, {'ForeName': 'Sheelagh', 'Initials': 'S', 'LastName': 'Peacock', 'Affiliation': 'Medical Education Lanarkshire, Kirklands Hospital, Bothwell, Lanarkshire, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Paton', 'Affiliation': 'Medical Education Lanarkshire, Kirklands Hospital, Bothwell, Lanarkshire, UK.'}]",International journal of clinical practice,['10.1111/ijcp.14725'] 2663,34382279,Patient handover education programme based on situated learning theory for nursing students in clinical practice.,"AIM If not conducted correctly, nursing handover can threaten patient safety, and so nursing students require good handover education. This study evaluated a handover education programme based on situated learning theory in a clinical practicum. METHODS A quasi-experimental design and convenience sampling technique were used. The participants (fourth-grade nursing students recruited from a college in the C province of South Korea) were assigned to an intervention group (n = 38) or a control group (n = 39). A handover education programme that included lectures, expert observations, role playing, peer learning and reflection was received by the intervention group. The control group attended lectures and observed handovers. The handover skills of all participants were tested 2 weeks before and on the last day of the clinical practicum. Handover performance ability, handover clinical judgement ability and handover self-efficacy were outcome variables. RESULTS Significant improvements in handover performance ability, handover clinical judgement ability and handover self-efficacy were observed in the intervention group compared with the control group. CONCLUSION The significance of this study lies in the development and application of a programme based on situated learning theory for handover education. Application of theory-based handover education in clinical practicums is recommended to improve the handover capabilities of nursing students.",2021,"RESULTS Significant improvements in handover performance ability, handover clinical judgement ability and handover self-efficacy were observed in the intervention group compared with the control group. ","['participants (fourth-grade nursing students recruited from a college in the C province of South Korea', 'nursing students in clinical practice', 'nursing students', 'handover education']",['handover education programme'],"['handover performance ability, handover clinical judgement ability and handover self-efficacy', 'Handover performance ability, handover clinical judgement ability and handover self-efficacy']","[{'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0729314', 'cui_str': 'Education provision'}]","[{'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",,0.0572878,"RESULTS Significant improvements in handover performance ability, handover clinical judgement ability and handover self-efficacy were observed in the intervention group compared with the control group. ","[{'ForeName': 'Jung Hee', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Nursing Science, Shinsung University, Dangjin-si, South Korea.'}, {'ForeName': 'Jong Mi', 'Initials': 'JM', 'LastName': 'Lim', 'Affiliation': 'Department of Nursing Science, Shinsung University, Dangjin-si, South Korea.'}, {'ForeName': 'Eun Man', 'Initials': 'EM', 'LastName': 'Kim', 'Affiliation': 'Department of Nursing Science, SunMoon University, Asan-si, South Korea.'}]",International journal of nursing practice,['10.1111/ijn.13005'] 2664,34382277,Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance.,"BACKGROUND Failure of second or third-line eradication treatment against Helicobacter pylori (H. pylori) is principally caused by antimicrobial resistance and reduced treatment adherence. AIMS To evaluate the efficacy and safety of culture-based rescue eradication treatments in patients who have previously experienced failed eradication treatment. METHODS Patients who had persistent H. pylori infection following at least one eradication treatment were recommended to undergo culture analysis to determine the minimal inhibitory concentrations of various antimicrobials via endoscopic resection. Consenting patients were assigned one of four therapeutic treatments based on an algorithm determined by antimicrobial resistance. These treatments consisted of 7 or 14-day administration of clarithromycin-containing proton pump inhibitor (PPI) triple therapy; esomeprazole, moxifloxacin, and amoxicillin (MEA) therapy; esomeprazole, bismuth, metronidazole, and tetracycline (quadruple) therapy; or lansoprazole, rifabutin, and amoxicillin (RLA) therapy. Eradication efficacy, adherence, and adverse events were assessed aside clinical outcomes. RESULTS A total of 132 patients were enrolled, with 84 patients completing the study. The overall resistance rates to amoxicillin, clarithromycin, metronidazole, and moxifloxacin were 13.1%, 83.3%, 47.6%, and 71.4%, respectively. The patients were allocated to the PPI triple (n = 11), MEA (n = 15), quadruple (n = 53), or RLA triple (n = 5) therapy group. The eradication rates in the intention-to-treat and per-protocol analyses were 90.5% (76 of 84 patients) and 93.8% (76 of 81 patients), respectively. Nausea was the most frequent adverse event (25.0%). CONCLUSIONS As a rescue therapy, culture-based susceptibility-guided eradication treatment was both effective and safe, even for patients exhibiting high antimicrobial resistance.",2021,"Nausea was the most frequent adverse event (25.0%). ","['132 patients were enrolled, with 84 patients completing the study', 'patients who have previously experienced failed eradication treatment', 'areas of high antimicrobial resistance', 'patients exhibiting high antimicrobial resistance', 'Patients who had persistent H.\xa0pylori infection following at least one eradication treatment', 'Consenting patients']","['PPI triple', 'clarithromycin-containing proton pump inhibitor (PPI) triple therapy; esomeprazole, moxifloxacin, and amoxicillin (MEA) therapy; esomeprazole, bismuth, metronidazole, and tetracycline (quadruple) therapy; or lansoprazole, rifabutin, and amoxicillin (RLA) therapy', 'amoxicillin, clarithromycin, metronidazole, and moxifloxacin', 'rescue second- or third-line culture-based Helicobacter pylori eradication', 'MEA', 'RLA triple']","['efficacy and safety', 'Nausea', 'eradication rates', 'Eradication efficacy, adherence, and adverse events', 'overall resistance rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0850666', 'cui_str': 'Infection caused by Helicobacter pylori'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]","[{'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0358591', 'cui_str': 'H+/K+-exchanging ATPase inhibitor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0937846', 'cui_str': 'Esomeprazole'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0005642', 'cui_str': 'Bismuth'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0039644', 'cui_str': 'Tetracycline'}, {'cui': 'C0050940', 'cui_str': 'lansoprazole'}, {'cui': 'C0140575', 'cui_str': 'Rifabutin'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0010648', 'cui_str': 'Cysteamine'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]",132.0,0.0882498,"Nausea was the most frequent adverse event (25.0%). ","[{'ForeName': 'Jung Won', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.'}, {'ForeName': 'Nayoung', 'Initials': 'N', 'LastName': 'Kim', 'Affiliation': 'Department of Internal medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Ryoung Hee', 'Initials': 'RH', 'LastName': 'Nam', 'Affiliation': 'Department of Internal medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Jae Young', 'Initials': 'JY', 'LastName': 'Jang', 'Affiliation': 'Department of Internal medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Yonghoon', 'Initials': 'Y', 'LastName': 'Choi', 'Affiliation': 'Department of Internal medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Dong Ho', 'Initials': 'DH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}]",Helicobacter,['10.1111/hel.12844'] 2665,34382217,He Tapu Te Whare Tangata (sacred house of humanity): Under-screened Māori women talk about HPV self-testing cervical screening clinical pathways.,"OBJECTIVE To develop an in-depth understanding of HPV self-testing cervical screening clinical pathways for never-/under-screened Māori women. METHODS Based on a community-based cluster randomized controlled trial in Aotearoa (New Zealand), a Kaupapa Māori (by Māori, for Māori) qualitative study enrolled Māori women who met the eligibility criteria of the HPV trial intervention (aged 25-69 years, no screen in >4 years). In total, 28 were recruited (22 had a negative test, six had a positive test and colposcopy). They were asked about their clinical pathway. RESULTS The HPV self-test was seen as empowering and promoting bodily autonomy, although some women expressed fears or misconceptions about this new technology. While those with a negative test were relieved, for the six women who had a positive test, there were many fears, compounded by seeking out information on the Internet. When attending colposcopy, the importance of support and responsive care was emphasized. CONCLUSION HPV self-testing has the potential to improve access to cervical screening and reduce inequities for Māori. Care must be taken in the delivery of screening and colposcopy results. Primary care and colposcopy services need to take special care with never-/under-screened Māori women to provide sensitive, responsive care, and mitigate trauma.",2021,"The HPV self-test was seen as empowering and promoting bodily autonomy, although some women expressed fears or misconceptions about this new technology.","['He Tapu Te Whare Tangata (sacred house of humanity', 'In total, 28 were recruited (22 had a negative test, six had a positive test and colposcopy', 'Aotearoa (New Zealand), a Kaupapa Māori (by Māori, for Māori) qualitative study enrolled Māori women who met the eligibility criteria of the HPV trial intervention (aged 25-69 years, no screen in >4 years', 'never-/under-screened Māori women']",[],[],"[{'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0020157', 'cui_str': 'Humanities'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0009417', 'cui_str': 'Colposcopy'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0949415', 'cui_str': 'Qualitative Research'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]",[],[],28.0,0.116422,"The HPV self-test was seen as empowering and promoting bodily autonomy, although some women expressed fears or misconceptions about this new technology.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Adcock', 'Affiliation': ""Te Tātai Hauora o Hine Centre for Women's Health Research, Te Herenga Waka Victoria University of Wellington, Aotearoa, New Zealand.""}, {'ForeName': 'Kendall', 'Initials': 'K', 'LastName': 'Stevenson', 'Affiliation': ""Te Tātai Hauora o Hine Centre for Women's Health Research, Te Herenga Waka Victoria University of Wellington, Aotearoa, New Zealand.""}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Cram', 'Affiliation': 'Katoa Ltd, Auckland, Aotearoa, New Zealand.'}, {'ForeName': 'E Jane', 'Initials': 'EJ', 'LastName': 'MacDonald', 'Affiliation': ""Te Tātai Hauora o Hine Centre for Women's Health Research, Te Herenga Waka Victoria University of Wellington, Aotearoa, New Zealand.""}, {'ForeName': 'Stacie', 'Initials': 'S', 'LastName': 'Geller', 'Affiliation': 'Division of Academic Internal Medicine, Department of Medicine, Center for Research on Women and Gender, College of Medicine, University of Illinois, Chicago, IL, USA.'}, {'ForeName': 'Jordanna', 'Initials': 'J', 'LastName': 'Hermens', 'Affiliation': ""Te Tātai Hauora o Hine Centre for Women's Health Research, Te Herenga Waka Victoria University of Wellington, Aotearoa, New Zealand.""}, {'ForeName': 'Beverley', 'Initials': 'B', 'LastName': 'Lawton', 'Affiliation': ""Te Tātai Hauora o Hine Centre for Women's Health Research, Te Herenga Waka Victoria University of Wellington, Aotearoa, New Zealand.""}]",International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,['10.1002/ijgo.13873'] 2666,34381919,Implementing Primary Palliative Care in Post-acute nursing home care: Protocol for an embedded pilot pragmatic trial.,"Introduction Older adults with serious illness frequently receive post-acute rehabilitative care in nursing homes (NH) under the Part A Medicare Skilled Nursing Facility (SNF) Benefit. Treatment is commonly focused on disease-modifying therapies with minimal consideration for goals of care, symptom relief, and other elements of palliative care. Intervention The evidence-based Primary Palliative Care in Post-Acute Care (PPC-PAC) intervention for older adults is delivered by nurse practitioners (NP). PPC-PAC NPs assess and manage symptoms, conduct goals of care discussions and assist with decision making; they communicate findings with NH staff and providers. Implementation of PPC-PAC includes online and face-to-face training of NPs, ongoing facilitation, and a template embedded in the NH electronic health record to document PPC-PAC. Objectives The objectives of this pilot pragmatic clinical trial are to assess the feasibility, acceptability, and preliminary effectiveness of the PPC-PAC intervention and its implementation for 80 seriously ill older adults newly admitted to a NH for post-acute care. Methods Design is a two-arm nonequivalent group multi-site pilot pragmatic clinical trial. The unit of assignment is at the NP and unit of analysis is NH patients. Recruitment occurs at NHs in Pennsylvania, New Jersey, Delaware, and Maryland. Effectiveness (patient quality of life) data are collected at two times points-baseline and 14-21 days. Conclusion This will be the first study to evaluate the implementation of an evidence-based primary palliative care intervention specifically designed for older adults with serious illness who are receiving post-acute NH care.",2021,The evidence-based Primary Palliative Care in Post-Acute Care (PPC-PAC) intervention for older adults is delivered by nurse practitioners (NP).,"['80 seriously ill older adults newly admitted to a NH for post-acute care', 'Older adults with serious illness', 'older adults', 'older adults with serious illness who are receiving post-acute NH care']","['PPC-PAC intervention', 'Post-Acute Care (PPC-PAC) intervention']",[],"[{'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0376635', 'cui_str': 'Postacute Care'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0376635', 'cui_str': 'Postacute Care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],80.0,0.0950926,The evidence-based Primary Palliative Care in Post-Acute Care (PPC-PAC) intervention for older adults is delivered by nurse practitioners (NP).,"[{'ForeName': 'Joan G', 'Initials': 'JG', 'LastName': 'Carpenter', 'Affiliation': 'University of Maryland School of Nursing, Baltimore, MD, USA.'}, {'ForeName': 'Laura C', 'Initials': 'LC', 'LastName': 'Hanson', 'Affiliation': 'Division of Geriatric Medicine & Palliative Care Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Hodgson', 'Affiliation': 'University of Pennsylvania School of Nursing, Philadelphia, PA, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Murray', 'Affiliation': 'Veteran Experience Center, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Hippe', 'Affiliation': 'The Mountain Whisper Light Statistics $ Data Science, Seattle, WA, USA.'}, {'ForeName': 'Nayak L', 'Initials': 'NL', 'LastName': 'Polissar', 'Affiliation': 'The Mountain Whisper Light Statistics $ Data Science, Seattle, WA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Ersek', 'Affiliation': 'Veteran Experience Center, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2021.100822'] 2667,34381916,"Effect of combined lipid-lowering and antioxidant nutraceutical on plasma lipids, endothelial function, and estimated cardiovascular disease risk in moderately hypercholesterolemic patients: a double-blind, placebo-controlled randomized clinical trial.","Introduction Nutraceuticals are a good means to lower cardiovascular risk. Having established a reasonable pharmacological background, a new nutraceutical combination should be tested in clinical trials. Material and methods This double-blind, placebo-controlled randomized clinical trial aims to evaluate the modulating effect, in a setting of controlled nutritional habits, of a combined food supplement with DIF1STAT (based on red yeast rice with a very low content of monacolins, linear aliphatic alcohols and niacin) and Olea europaea on plasma lipids and endothelial function, in a group of 40 healthy, moderately hypercholesterolemic patients in primary cardiovascular prevention. Results After 8 weeks of treatment, when compared to the placebo group, the active treated patients experienced significant improvements of different metabolic parameters and endothelial reactivity compared to placebo. The treated patients showed a statistically significant percentage change in total cholesterol (-12.25 delta% vs. -1.8%, p < 0.01), low-density lipoprotein (LDL) cholesterol (-28.7 delta% vs. -1.1%, p < 0.01), high-density lipoprotein (HDL) cholesterol (+4.99% vs. +0.9%, p < 0.05), non-HDL cholesterol (-16.02 delta% vs. -1.5%, p < 0.01), SUA (-12.96 delta%, p < 0.05) and endothelial reactivity (+6.73% vs. -1.4%, p < 0.01). In both groups, there was no case of intolerance and the safety parameters were unchanged. Conclusions The tested nutraceutical association is able to significantly improve different lipid parameters compared to placebo, and endothelial reactivity compared to baseline. Even if the study power appears to be adequate for the primary endpoints, the effect on endothelial function needs confirmation in a longer clinical trial.",2021,"After 8 weeks of treatment, when compared to the placebo group, the active treated patients experienced significant improvements of different metabolic parameters and endothelial reactivity compared to placebo.","['moderately hypercholesterolemic patients', '40 healthy, moderately hypercholesterolemic patients in primary cardiovascular prevention']","['placebo', 'SUA', 'DIF1STAT', 'combined lipid-lowering and antioxidant nutraceutical']","['plasma lipids, endothelial function, and estimated cardiovascular disease risk', 'non-HDL cholesterol', 'high-density lipoprotein (HDL) cholesterol', 'low-density lipoprotein (LDL) cholesterol', 'metabolic parameters and endothelial reactivity', 'endothelial reactivity', 'intolerance and the safety parameters', 'total cholesterol ']","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C1518478', 'cui_str': 'Nutriceuticals'}]","[{'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0231199', 'cui_str': 'Intolerance'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}]",40.0,0.314868,"After 8 weeks of treatment, when compared to the placebo group, the active treated patients experienced significant improvements of different metabolic parameters and endothelial reactivity compared to placebo.","[{'ForeName': 'Arrigo F G', 'Initials': 'AFG', 'LastName': 'Cicero', 'Affiliation': 'Center for the Study of Hypertension and Related Cardiovascular Risk Factors, Medical and Surgery Sciences Department (DIMEC), University of Bologna, Bologna, Italy.'}, {'ForeName': 'Marilisa', 'Initials': 'M', 'LastName': 'Bove', 'Affiliation': 'IRCCS Policlinico S. Orsola-Malpighi, Bologna, Italy.'}, {'ForeName': 'Raffaele I', 'Initials': 'RI', 'LastName': 'Cincione', 'Affiliation': 'Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Fogacci', 'Affiliation': 'Center for the Study of Hypertension and Related Cardiovascular Risk Factors, Medical and Surgery Sciences Department (DIMEC), University of Bologna, Bologna, Italy.'}, {'ForeName': 'Maddalena', 'Initials': 'M', 'LastName': 'Veronesi', 'Affiliation': 'Center for the Study of Hypertension and Related Cardiovascular Risk Factors, Medical and Surgery Sciences Department (DIMEC), University of Bologna, Bologna, Italy.'}]",Archives of medical sciences. Atherosclerotic diseases,['10.5114/amsad.2021.107843'] 2668,34381906,Effect of exercise on depression and fatigue in breast cancer women undergoing chemotherapy: A randomized controlled trial.,"Background Depression and fatigue are common consequences of breast cancer that lead to dysfunction and reduced quality of life of patients. The aim of the present study was to determine the effect of exercise program on depression and fatigue in breast cancer women undergoing chemotherapy. Methods This randomized controlled trial study was performed on 60 breast cancer women undergoing chemotherapy in Kermanshah hospitals from 2017-2018. Participants were selected using convenience sampling and were randomly divided into intervention and control groups. Data collection tools included demographic information form and standard Beck depression inventory (BDI-II) and fatigue severity scale (FSS). The intervention group performed the 20-30-minute indoor exercise program 3 sessions a week for 6 weeks. Questionnaires were completed before, immediately, and one month after the intervention by both groups and data analysis was carried out using SPSS ver.22. Results There was no statistically significant difference between the two groups in terms of the mean fatigue intensity and depression scores before the intervention; however, the mean fatigue intensity scores were significantly decreased in the intervention group as compared to the control group immediately and one month after the intervention (P = 0.001). There was no statistically significant difference between the two groups in terms of mean depression score immediately and one month after the intervention (p > 0.05). Conclusion Considering that indoor exercises reduced fatigue in breast cancer women undergoing chemotherapy, patients are recommended to perform exercise interventions as a non-pharmacological, safe, easy, and non-invasive solution to improve their physiological capacities and functional abilities as well as Quality of life. On the other hand, since exercise program had no effect on depression among breast cancer women in the present study, longer studies with larger sample size are recommended.",2021,"There was no statistically significant difference between the two groups in terms of mean depression score immediately and one month after the intervention (p > 0.05). ","['60 breast cancer women undergoing chemotherapy in Kermanshah hospitals from 2017-2018', 'breast cancer women undergoing chemotherapy', 'breast cancer women', 'breast cancer women undergoing']","['indoor exercises', 'chemotherapy', 'exercise program', 'exercise']","['depression', 'demographic information form and standard Beck depression inventory (BDI-II) and fatigue severity scale (FSS', 'mean fatigue intensity scores', 'mean depression score', 'depression and fatigue', 'mean fatigue intensity and depression scores']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0006448', 'cui_str': 'Burundi'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",60.0,0.0600278,"There was no statistically significant difference between the two groups in terms of mean depression score immediately and one month after the intervention (p > 0.05). ","[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Mostafaei', 'Affiliation': 'Department of Nursing, Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Azizi', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, Razi University, Kermanshah, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Jalali', 'Affiliation': 'Substance Abuse Prevention Research Center, Research Institute for Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Nader', 'Initials': 'N', 'LastName': 'Salari', 'Affiliation': 'Department of Biostatistics Department, School of Nursing & Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Parvin', 'Initials': 'P', 'LastName': 'Abbasi', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]",Heliyon,['10.1016/j.heliyon.2021.e07657'] 2669,34381802,"Effects of Low-Speed and High-Speed Resistance Training Programs on Frailty Status, Physical Performance, Cognitive Function, and Blood Pressure in Prefrail and Frail Older Adults.","Aim: The current study investigated the effects of low-speed resistance training (LSRT) and high-speed resistance training (HSRT) on frailty status, physical performance, cognitive function and blood pressure in pre-frail and frail older people. Material and Methods: Sixty older adults, 32 prefrail and 28 frail, were randomly allocated into LSRT, HSRT, and control group (CG). Before and after intervention periods frailty status, blood pressure, heart rate, and a set of physical performance capabilities and cognitive domains were assessed. Exercise interventions occurred over 16 weeks and included four resistance exercises with 4-8 sets of 4-10 repetitions at moderate intensity. Results: The prevalence of frailty criteria in prefrail and frail older adults were reduced after both LSRT and HSRT. In prefrail, LSRT significantly improved lower-limb muscle strength, while mobility was only improved after HSRT. Muscle power and dual-task performance were significantly increased in both LSRT and HSRT. In frail, LSRT and HSRT similarly improved lower-limb muscle strength and power. However, exclusive improvements in dual-task were observed after LSRT. Memory was significantly increased in prefrail and frail, regardless of the type of resistance training. No significant changes were observed in blood pressure and heart rate. Conclusion: Findings of the present study indicated that both LSRT and HSRT reversed frailty status and improved physical performance in prefrail and frail older adults. Notably, different patterns of improvement were observed among RT protocols. Regarding frailty status, LSRT seemed to be more effective in reverse prefrailty and frailty when compared to HSRT. Greater improvements in muscle strength and power were also observed after LSRT, while HSRT produced superior increases in mobility and dual-task performance. One-leg stand performance was significantly reduced in LSRT, but not HSRT and CG, after 16 weeks. In contrast, RT programs similarly improved verbal memory in prefrail. Finally, no changes in blood pressure and heart rate were observed, regardless of the type of RT. Trial Registration: The protocol was approved by the University of Campinas Human Research Ethics Committee (Protocol No. 20021919.7.0000.5404) and retrospectively registered at ClinicalTrials.gov Protocol Registration and Results System: NCT04868071.",2021,The prevalence of frailty criteria in prefrail and frail older adults were reduced after both LSRT and HSRT.,"['Sixty older adults, 32 prefrail and 28 frail', 'pre-frail and frail older people', 'prefrail and frail older adults', 'Prefrail and Frail Older Adults']","['LSRT and HSRT', 'LSRT, HSRT, and control group (CG', 'Low-Speed and High-Speed Resistance Training Programs', 'low-speed resistance training (LSRT) and high-speed resistance training (HSRT', 'Exercise interventions']","['dual-task', 'muscle strength and power', 'Muscle power and dual-task performance', 'frailty status, blood pressure, heart rate, and a set of physical performance capabilities and cognitive domains', 'blood pressure and heart rate', 'verbal memory', 'Frailty Status, Physical Performance, Cognitive Function, and Blood Pressure', 'Memory', 'frailty status, physical performance, cognitive function and blood pressure', 'lower-limb muscle strength, while mobility', 'physical performance', 'mobility and dual-task performance', 'lower-limb muscle strength and power']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}]",60.0,0.0276897,The prevalence of frailty criteria in prefrail and frail older adults were reduced after both LSRT and HSRT.,"[{'ForeName': 'Hélio José', 'Initials': 'HJ', 'LastName': 'Coelho-Júnior', 'Affiliation': 'Laboratory of Applied Kinesiology, School of Physical Education, University of Campinas, Campinas, Brazil.'}, {'ForeName': 'Marco Carlos', 'Initials': 'MC', 'LastName': 'Uchida', 'Affiliation': 'Laboratory of Applied Kinesiology, School of Physical Education, University of Campinas, Campinas, Brazil.'}]",Frontiers in medicine,['10.3389/fmed.2021.702436'] 2670,34381586,Computerized Tomography Image Feature under Convolutional Neural Network Algorithm Evaluated for Therapeutic Effect of Clarithromycin Combined with Salmeterol/Fluticasone on Chronic Obstructive Pulmonary Disease.,"This study was to explore the use of convolutional neural network (CNN) for the classification and recognition of computerized tomography (CT) images of chronic obstructive pulmonary disease (COPD) and the therapeutic effect of clarithromycin combined with salmeterol/fluticasone. First, the clinical data of COPD patients treated in hospital from September 2018 to December 2020 were collected, and CT and X-ray images were also collected. CT-CNN and X ray-CNN single modal models were constructed based on the LeNet-5 model. The randomized fusion algorithm was introduced to construct a fused CNN model for the diagnosis of COPD patients, and the recognition effect of the model was verified. Subsequently, the three-dimensional reconstruction of the patient's bronchus was performed using the classified CT images, and the changes of CT quantitative parameters in COPD patients were compared and analyzed. Finally, COPD patients were treated with salmeterol/fluticasone (COPD-C) and combined with clarithromycin (COPD-T). In addition, the differences between patients' lung function indexes, blood gas indexes, St. George respiratory questionnaire (SGRQ) scores, and the number of acute exacerbations (AECOPD) before and after treatment were evaluated. The results showed that the randomized fusion model under different iteration times and batch sizes always had the highest recognition rate, sensitivity, and specificity compared to the two single modal CNN models, but it also had longer training time. After CT images were used to quantitatively evaluate the changes of the patient's bronchus, it was found that the area of the upper and lower lung lobes of the affected side of COPD patients and the ratio of the area of the tube wall to the bronchus were significantly changed. The lung function, blood gas index, and SGRQ score of COPD-T patients were significantly improved compared with the COPD-C group ( P < 0.05), but there was no considerable difference in AECOPD ( P > 0.05). In summary, the randomized fusion-based CNN model can improve the recognition rate of COPD, and salmeterol/fluticasone combined with clarithromycin therapy can significantly improve the clinical treatment effect of COPD patients.",2021,"The lung function, blood gas index, and SGRQ score of COPD-T patients were significantly improved compared with the COPD-C group ( P < 0.05), but there was no considerable difference in AECOPD ( P > 0.05).","['Chronic Obstructive Pulmonary Disease', 'COPD patients', 'chronic obstructive pulmonary disease (COPD']","['clarithromycin therapy', 'Computerized Tomography Image Feature under Convolutional Neural Network', 'convolutional neural network (CNN', 'clarithromycin', 'salmeterol/fluticasone (COPD-C) and combined with clarithromycin (COPD-T', 'Clarithromycin Combined with Salmeterol/Fluticasone', 'salmeterol/fluticasone']","['lung function, blood gas index, and SGRQ score of COPD-T patients', 'recognition rate of COPD', 'AECOPD', 'highest recognition rate, sensitivity, and specificity', 'CT quantitative parameters', 'lung function indexes, blood gas indexes, St. George respiratory questionnaire (SGRQ) scores, and the number of acute exacerbations (AECOPD']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0242406', 'cui_str': 'Neural Networks (Anatomic)'}, {'cui': 'C0073992', 'cui_str': 'salmeterol'}, {'cui': 'C0082607', 'cui_str': 'fluticasone'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3472502', 'cui_str': ""Saint George's respiratory questionnaire score""}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]",,0.0140071,"The lung function, blood gas index, and SGRQ score of COPD-T patients were significantly improved compared with the COPD-C group ( P < 0.05), but there was no considerable difference in AECOPD ( P > 0.05).","[{'ForeName': 'Guoping', 'Initials': 'G', 'LastName': 'Luo', 'Affiliation': 'Department of Respiration, Shunde Hospital of Guangzhou University of Traditional Chinese Medicine, Shunde District, Foshan City 528300, Guangdong Province, China.'}, {'ForeName': 'Anqi', 'Initials': 'A', 'LastName': 'Lin', 'Affiliation': 'Department of Respiration, Shunde Hospital of Guangzhou University of Traditional Chinese Medicine, Shunde District, Foshan City 528300, Guangdong Province, China.'}, {'ForeName': 'Zhaoqiang', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Department of Respiration, Shunde Hospital of Guangzhou University of Traditional Chinese Medicine, Shunde District, Foshan City 528300, Guangdong Province, China.'}, {'ForeName': 'Yujian', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Respiration, Shunde Hospital of Guangzhou University of Traditional Chinese Medicine, Shunde District, Foshan City 528300, Guangdong Province, China.'}, {'ForeName': 'Cuiying', 'Initials': 'C', 'LastName': 'Mo', 'Affiliation': 'Department of Respiration, Shunde Hospital of Guangzhou University of Traditional Chinese Medicine, Shunde District, Foshan City 528300, Guangdong Province, China.'}]",Journal of healthcare engineering,['10.1155/2021/8563181'] 2671,34381574,"Sleep deprivation effects on basic cognitive processes: which components of attention, working memory, and executive functions are more susceptible to the lack of sleep?","Introduction Sleep deprived people have difficulties to perform daily activities. Their performance depends on three basic cognitive processes: attention, working memory, and executive functions. Objectives The aim of this study was to identify which specific components of these cognitive processes are more susceptible to a 24-h sleep deprivation period. Material and Methods Participants were 23 undergraduate students assigned to one of two groups: a control group (n=11, age=18.73±1.62 years) and a sleep deprivation group (n=12, age=18.08±1.16 years). After sleeping freely, control group participants performed a continuous performance task to evaluate the components of attention, a phonological and a visuospatial tasks to record these components of working memory, and a Stroop-like task to assess cognitive inhibition and flexibility, two components of executive functions, at noon for 3 days. Whereas, the sleep deprivation group participants performed the same tasks at noon: after sleeping freely for one night, after a 24-h sleep deprivation, and after one recovery night. Results After the sleep deprivation, participants had a significant reduction in tonic alertness, selective and sustained attention, components of attention; and in cognitive inhibition, component of executive functions. Conclusion A 24-h sleep deprivation period reduces several specific components of the basic cognitive processes, which are crucial for performing many everyday activities, thus increasing the risk of errors and accidents.",2021,"After the sleep deprivation, participants had a significant reduction in tonic alertness, selective and sustained attention, components of attention; and in cognitive inhibition, component of executive functions. ","['23 undergraduate students assigned to one of two groups: a control group (n=11, age=18.73±1.62 years) and a']","['sleep deprivation group', 'continuous performance task to evaluate the components of attention, a phonological and a visuospatial tasks to record these components of working memory, and a Stroop-like task']","['tonic alertness, selective and sustained attention, components of attention; and in cognitive inhibition, component of executive functions']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4329232', 'cui_str': 'AX-CPT'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}]","[{'cui': 'C3543842', 'cui_str': 'TONICS'}, {'cui': 'C0589099', 'cui_str': 'Sustained attention'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",23.0,0.101143,"After the sleep deprivation, participants had a significant reduction in tonic alertness, selective and sustained attention, components of attention; and in cognitive inhibition, component of executive functions. ","[{'ForeName': 'Aída', 'Initials': 'A', 'LastName': 'García', 'Affiliation': 'Universidad Autónoma de Nuevo León, Laboratory of Psychophysiology, School of Psychology - Monterrey - Nuevo León - Mexico.'}, {'ForeName': 'Jacqueline Del', 'Initials': 'JD', 'LastName': 'Angel', 'Affiliation': 'Universidad Autónoma de Nuevo León, Laboratory of Psychophysiology, School of Psychology - Monterrey - Nuevo León - Mexico.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Borrani', 'Affiliation': 'Universidad Autónoma de Nuevo León, Laboratory of Psychophysiology, School of Psychology - Monterrey - Nuevo León - Mexico.'}, {'ForeName': 'Candelaria', 'Initials': 'C', 'LastName': 'Ramirez', 'Affiliation': 'Universidad Autónoma de Nuevo León, Laboratory of Psychophysiology, School of Psychology - Monterrey - Nuevo León - Mexico.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Valdez', 'Affiliation': 'Universidad Autónoma de Nuevo León, Laboratory of Psychophysiology, School of Psychology - Monterrey - Nuevo León - Mexico.'}]","Sleep science (Sao Paulo, Brazil)",['10.5935/1984-0063.20200049'] 2672,34377150,Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives.,"Background Two studies demonstrated the efficacy and safety of naldemedine in adult patients with chronic non-cancer pain and opioid-induced constipation (OIC). However, no studies have compared the efficacy of peripherally acting µ-opioid receptor antagonists in patients with adequate and inadequate responses to prior OIC therapy with laxatives. This post hoc analysis of integrated data from the two previous studies compared the efficacy of naldemedine in patients who were unsuccessfully treated with laxatives [poor laxative responders (PLRs)] with those who either did not receive laxatives >30 days prior to screening or those who only received rescue laxative at or after screening (non-PLRs). Methods Patients with OIC were randomized to once-daily treatment with naldemedine 0.2 mg or placebo. The primary efficacy endpoint was the proportion of responders [⩾3 spontaneous bowel movements (SBMs)/week and an increase from baseline of ⩾1 SBM/week for ⩾9 weeks of the 12-week treatment period and ⩾3 weeks of the final 4 weeks of the 12-week treatment period]. Additional endpoints included change in SBM frequency, change in frequency of SBMs without straining, proportion of complete SBM (CSBM) responders, change in CSBM frequency, and time to first SBM. Treatment-emergent adverse events (TEAEs) were assessed. Results The analysis included 538 (317 PLRs, 221 non-PLRs) and 537 (311 PLRs, 226 non-PLRs) patients in the naldemedine and placebo arms, respectively. There were significantly more responders in the naldemedine PLR (46.4%; p  < 0.0001) and non-PLR (54.3%; p  = 0.0009) subgroups versus the placebo groups (30.2% and 38.9%, respectively). In both the PLR and non-PLR subgroups, naldemedine treatment was superior to placebo on all additional endpoints. Overall incidence of TEAEs in the PLR subgroups treated with naldemedine or placebo was similar. Conclusion This integrated analysis further supports the efficacy and tolerability of naldemedine in the treatment of OIC and demonstrates a consistent effect in both PLR and non-PLR subgroups.[ClinicalTrials.gov identifier: NCT01965158 and NCT01993940].",2021,"In both the PLR and non-PLR subgroups, naldemedine treatment was superior to placebo on all additional endpoints.","['patients who were unsuccessfully treated with laxatives [poor laxative responders (PLRs)] with those who either did not receive laxatives >30\u2009days prior to screening or those who only received rescue laxative at or after screening (non-PLRs', 'Methods\n\n\nPatients with OIC', 'patients with chronic non-cancer pain who had a poor response to laxatives', '538 (317 PLRs, 221 non-PLRs) and 537 (311 PLRs, 226 non-PLRs) patients in the', 'adult patients with chronic non-cancer pain and opioid-induced constipation (OIC']","['naldemedine 0.2\u2009mg or placebo', 'Naldemedine', 'naldemedine or placebo', 'naldemedine', 'placebo', 'naldemedine and placebo']","['proportion of responders [⩾3 spontaneous bowel movements (SBMs)/week and an increase from baseline of ⩾1 SBM', 'efficacy and safety', 'efficacy and tolerability', 'change in SBM frequency, change in frequency of SBMs without straining, proportion of complete SBM (CSBM) responders, change in CSBM frequency, and time to first SBM', 'naldemedine PLR', 'Overall incidence of TEAEs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0282090', 'cui_str': 'Laxative'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0596240', 'cui_str': 'Cancer pain'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C4325237', 'cui_str': 'naldemedine 0.2 MG'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4325235', 'cui_str': 'naldemedine'}]","[{'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C4325235', 'cui_str': 'naldemedine'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",538.0,0.125766,"In both the PLR and non-PLR subgroups, naldemedine treatment was superior to placebo on all additional endpoints.","[{'ForeName': 'Martin E', 'Initials': 'ME', 'LastName': 'Hale', 'Affiliation': 'Gold Coast Research LLC, 499 NW 70th Ave Ste 200, Plantation, FL 33317, USA.'}, {'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Wild', 'Affiliation': 'Upstate Clinical Research Associates, Williamsville, NY, USA.'}, {'ForeName': 'Tadaaki', 'Initials': 'T', 'LastName': 'Yamada', 'Affiliation': 'Shionogi Inc., Florham Park, NJ, USA.'}, {'ForeName': 'Takaaki', 'Initials': 'T', 'LastName': 'Yokota', 'Affiliation': 'Shionogi & Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Tack', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Viola', 'Initials': 'V', 'LastName': 'Andresen', 'Affiliation': 'Senior Physician Medical Clinic/Head of Palliative Team/Head of Nutrition Team, Israelitian Hospital Hamburg, Academic Teaching Hospital of University of Hamburg, Germany.'}, {'ForeName': 'Asbjørn Mohr', 'Initials': 'AM', 'LastName': 'Drewes', 'Affiliation': 'Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Denmark.'}]",Therapeutic advances in gastroenterology,['10.1177/17562848211032320'] 2673,34377137,Shirazi thyme ( Zataria multiflora ) extract can alleviate allergic rhinitis: a randomized clinical trial.,"Introduction Atopic diseases are global concerns in the today's industrialized world. Allergic rhinitis is the most common allergic condition affecting 20% of individuals. This disorder is associated with remarkable morbidity and rising healthcare expenditure. Aim Considering the anti-inflammatory properties of a plant Zataria multiflora (ZM) with the common name of Shirazi thyme, a randomized clinical trial was designed to evaluate the alleviation of the symptoms of allergic rhinitis. Material and methods A total of 30 allergic rhinitis patients were randomly and equally assigned to experimental and control groups. Afterwards, the case group was treated with an extract of ZM and the control group with placebo for 2 months. Finally, the clinical signs and symptoms before and after the treatment according to the SNOT22 questionnaire were analysed. Results Comparing the symptoms of allergic rhinitis and an average score of SNOT22 questionnaire between the two groups before the intervention provided some difference, which was significantly greater after the treatment. Based on this questionnaire, our patients in the ZM syrup group had lower grades than before the treatment and experienced amelioration. Conclusions Regarding the significant effect of the ZM syrup in reducing symptoms of allergic rhinitis, its use is highly recommended. Since allergic rhinitis is a multifactorial condition, the use of herbal antioxidants along with conventional treatment would result in a more effective improvement of the disease.",2021,"Comparing the symptoms of allergic rhinitis and an average score of SNOT22 questionnaire between the two groups before the intervention provided some difference, which was significantly greater after the treatment.",['30 allergic rhinitis patients'],"['extract of ZM', 'ZM syrup', 'placebo', 'plant Zataria multiflora (ZM', 'Shirazi thyme ( Zataria multiflora ) extract']","['average score of SNOT22 questionnaire', 'allergic rhinitis', 'symptoms of allergic rhinitis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0458173', 'cui_str': 'Syrup'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C0697238', 'cui_str': 'Thymus vulgaris'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",30.0,0.035821,"Comparing the symptoms of allergic rhinitis and an average score of SNOT22 questionnaire between the two groups before the intervention provided some difference, which was significantly greater after the treatment.","[{'ForeName': 'Nazila', 'Initials': 'N', 'LastName': 'Ariaee', 'Affiliation': 'Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Panahi', 'Affiliation': 'Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Bakhshaee', 'Affiliation': 'Ear, Nose, and Throat Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Jalal', 'Initials': 'J', 'LastName': 'Ghorbani', 'Affiliation': 'Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Yalda', 'Initials': 'Y', 'LastName': 'Ravanshad', 'Affiliation': 'Clinical Research Development Units, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Reza Farid', 'Initials': 'RF', 'LastName': 'Hosseini', 'Affiliation': 'Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Ranjbar', 'Affiliation': 'Research Institute of Interventional Allergology and Immunology, Bonn/Cologne, Germany.'}, {'ForeName': 'Farahzad', 'Initials': 'F', 'LastName': 'Jabbari', 'Affiliation': 'Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Postepy dermatologii i alergologii,['10.5114/ada.2020.102295'] 2674,34377047,Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies.,"Background Evidence suggests that efficacy and safety of disease-modifying treatments for multiple sclerosis may differ with age. We evaluate efficacy and safety of teriflunomide across age subgroups of patients from pooled clinical trials and real-world studies. Methods Post hoc analyses of patients who received teriflunomide 14 mg in the pooled phase II and III TEMSO, TOWER, TENERE, and TOPIC core and extension studies (n = 1978), and the real-world Teri-PRO (n = 928) and TAURUS-MS I (n = 1126) studies were conducted. Data were stratified by age at study entry: ⩽25, >25 to ⩽35, >35 to ⩽45, and >45 years. In Teri-PRO and TAURUS-MS I, an additional group, >55 years, was assessed. Results In the pooled core studies, teriflunomide reduced annualized relapse rate (ARR) versus placebo across all ages. Unadjusted ARRs remained low across age groups in pooled extensions (0.18-0.30), Teri-PRO (0.10-0.35), and TAURUS-MS I (0.14-0.35). Baseline Expanded Disability Status Scale scores were higher with age, but stable through core and extension studies (mean increases over 7 years: ⩽25 years, +0.59; >25 to ⩽35 years, +0.46; >35 to ⩽45 years, +0.35; >45 years, +0.81). Across age groups, adverse event (AE) incidences were 78.4% to 90.7% in pooled core and extension studies and Teri-PRO, and 29.2% to 37.7% in TAURUS-MS I; serious AE incidences were ⩽21.3% in all studies. In pooled phase III and Teri-PRO studies, lymphocyte count decreases over 1 year after initiating teriflunomide, and proportions of patients developing lymphopenia, were small across age groups. Conclusions Teriflunomide efficacy was demonstrated regardless of age. Safety was generally consistent across age groups.",2021,"Unadjusted ARRs remained low across age groups in pooled extensions (0.18-0.30), Teri-PRO (0.10-0.35), and TAURUS-MS I (0.14-0.35).","['across age subgroups of patients from pooled clinical trials and real-world studies', 'Data were stratified by age at study entry: ⩽25, >25 to ⩽35, >35 to ⩽45, and >45 years']","['placebo', 'Teriflunomide', 'teriflunomide']","['efficacy and safety', 'Efficacy and Safety', 'annualized relapse rate (ARR', 'Baseline Expanded Disability Status Scale scores', 'Safety', 'adverse event (AE) incidences', 'Unadjusted ARRs']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1718383', 'cui_str': 'teriflunomide'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.101651,"Unadjusted ARRs remained low across age groups in pooled extensions (0.18-0.30), Teri-PRO (0.10-0.35), and TAURUS-MS I (0.14-0.35).","[{'ForeName': 'Jiwon', 'Initials': 'J', 'LastName': 'Oh', 'Affiliation': ""St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.""}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Vukusic', 'Affiliation': 'Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation et Fondation Eugène Devic EDMUS Pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Tiel-Wilck', 'Affiliation': 'Neurologisches Facharztzentrum Berlin, Berlin, Germany.'}, {'ForeName': 'Jihad Said', 'Initials': 'JS', 'LastName': 'Inshasi', 'Affiliation': 'Dubai Medical College, Dubai, United Arab Emirates.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rog', 'Affiliation': 'Manchester Centre for Clinical Neurosciences, Salford, UK.'}, {'ForeName': 'Darren P', 'Initials': 'DP', 'LastName': 'Baker', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Yelena', 'Initials': 'Y', 'LastName': 'Pyatkevich', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Poole', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Vermersch', 'Affiliation': 'Universite de Lille, Inserm U1172, CHU Lille, FHU Precise, Lille, France.'}]",Journal of central nervous system disease,['10.1177/11795735211028781'] 2675,34377044,A Randomized Placebo-Controlled Trial of Efficacy and Safety: Drug-Free Gel Containing Ultra-Deformable Phospholipid Vesicles (TDT 064) in Osteoarthritic Knees.,"Background There are a number of topical agents that are used for treatment of knee osteoarthritis. Drug-free gels, containing ultra-deformable phospholipid vesicles (TDT 064) are one such topical therapy, which have been stated to act as a bio lubricant. However, the evidence of TDT 064 in treatment of knee osteoarthritis is limited. Hence, the aim of this study was to evaluate the efficacy of pain control as a primary outcome and safety of TDT 064 compared with a topical placebo. Methods Sixty-four patients with primary osteoarthritis, with radiographic showing Kellgren and Lawrence classification grade II to III, were randomized into 2 groups. In the first group of 32 patients TDT 064 was used as topical agent, whilst in the second group of 32 patients a placebo identical in appearance was used instead. The verbal numerical rating scale (VNRS) was used for recording pain levels, Self-reported Knee Injury and Osteoarthritis Outcome Scores (KOOS) as well as amounts of rescue medication were also recorded. The data were recorded at the start of the study, and then at follow-up appointments of 14 days, 6 weeks, and 3 months. Results The mean VNRS for pain in both groups were significantly improved, when compared to the start of treatment ( P  < .0001); however, there were no differences between groups at any follow up visit. KOOS in all subscales were not significantly different between both groups at baseline and at the end of treatment. However, the average amount of NSAIDs in the TDT 064 group was 26.39 ± 22.11 tabs, which was significantly lower than the control group; which used an average 37.03 ± 19.22 tabs in 3 months ( P  = .047). Conclusions There were no differences in the VNRS for pain and KOOS scores between the active and placebo groups. Although, TDT 064 could decrease usage of rescue medication the difference with use of a placebo was minimal. Further, larger trials would also be beneficial to demonstrate any differences between TDT 064 and a placebo. Trial Registration TCTR, TCTR 20190302001. Registered 1 March, 2019: http://www.clinicaltrials.in.th.",2021,"The mean VNRS for pain in both groups were significantly improved, when compared to the start of treatment ( P  < .0001); however, there were no differences between groups at any follow up visit.","['Methods\n\n\nSixty-four patients with primary osteoarthritis, with radiographic showing Kellgren and Lawrence classification grade II to III', 'Osteoarthritic Knees']","['Safety: Drug-Free Gel Containing Ultra-Deformable Phospholipid Vesicles (TDT 064', 'TDT', 'topical placebo', 'Placebo', 'placebo']","['Self-reported Knee Injury and Osteoarthritis Outcome Scores (KOOS', 'mean VNRS for pain', 'VNRS for pain and KOOS scores', 'average amount of NSAIDs', 'verbal numerical rating scale (VNRS']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409952', 'cui_str': 'Idiopathic osteoarthritis'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0031676', 'cui_str': 'Phospholipids'}, {'cui': 'C0333262', 'cui_str': 'Vesicle'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C3476088', 'cui_str': 'Knee Injury and Osteoarthritis Outcome Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}]",64.0,0.27426,"The mean VNRS for pain in both groups were significantly improved, when compared to the start of treatment ( P  < .0001); however, there were no differences between groups at any follow up visit.","[{'ForeName': 'Varah', 'Initials': 'V', 'LastName': 'Yuenyongviwat', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.'}, {'ForeName': 'Khanin', 'Initials': 'K', 'LastName': 'Iamthanaporn', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.'}, {'ForeName': 'Pakjai', 'Initials': 'P', 'LastName': 'Tuntarattanapong', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.'}, {'ForeName': 'Theerawit', 'Initials': 'T', 'LastName': 'Hongnaparak', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.'}, {'ForeName': 'Boonsin', 'Initials': 'B', 'LastName': 'Tangtrakulwanich', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.'}]",Clinical medicine insights. Arthritis and musculoskeletal disorders,['10.1177/11795441211031338'] 2676,34376972,"Effect of Intravenous Lidocaine on Serum Interleukin-17 After Video-Assisted Thoracic Surgery for Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial.","Purpose Surgical stress promotes tumor metastasis. Interleukin (IL)-17 plays a pivotal role in cancer progression, and high IL-17 expression predicts poor prognosis of non-small-cell lung cancer (NSCLC). Lidocaine may exert tumor-inhibiting effects. We hypothesize that intravenous lidocaine attenuates surgical stress and reduces serum IL-17 levels during video-assisted thoracic surgery (VATS) for NSCLC. Methods This randomized, double-blind, placebo-controlled trial included 60 early-stage NSCLC patients undergoing VATS, into a lidocaine group (n = 30; intravenous lidocaine bolus 1.0 mg/kg, and 1.0 mg/kg/h until the end of surgery) or a normal saline control group (n = 30). The primary outcome was serum IL-17 level at 24 hours postoperatively. The secondary outcomes included serum IL-17 level at the time of post-anesthesia care unit (PACU) discharge, serum cortisol level at PACU discharge and postoperative 24 hours, pain scores (0-10) from PACU discharge to 48 hours postoperatively, incidences of postoperative nausea and vomiting, dizziness, and arrhythmia during 0-48 hours postoperatively, and 30-day mortality. Long-term outcomes included chemotherapy, cancer recurrence, and mortality. Results The lidocaine group had lower serum IL-17 at 24 hours postoperatively compared with the control group (23.0 ± 5.8 pg/mL vs 27.3 ± 8.2 pg/mL, difference [95% CI] = -4.3 [-8.4 to -0.2] pg/mL; P = 0.038). The lidocaine group also had reduced serum IL-17 (difference [95% CI] = -4.6 [-8.7 to -0.5] pg/mL), serum cortisol (difference [95% CI] = -37 [-73 to -2] ng/mL), and pain scores (difference [95% CI] = -0.7 [-1.3 to -0.1] points) at PACU discharge. During a median follow-up of 10 (IQR, 9-13) months, 2 patients in the lidocaine group and 6 patients in the control group received chemotherapy, one patient in the control group had cancer recurrence, and no death event occurred. Conclusion Intravenous lidocaine was associated with reduced serum IL-17 and cortisol following VATS procedures in early-stage NSCLC patients. Trial Registration ChiCTR2000030629.",2021,"Conclusion Intravenous lidocaine was associated with reduced serum IL-17 and cortisol following VATS procedures in early-stage NSCLC patients. ","['group (n = 30', 'Non-Small-Cell Lung Cancer', '60 early-stage NSCLC patients undergoing VATS, into a', 'early-stage NSCLC patients']","['intravenous lidocaine', 'normal saline control group', 'Video-Assisted Thoracic Surgery', 'Lidocaine', 'lidocaine', 'Placebo', 'video-assisted thoracic surgery (VATS', 'chemotherapy', 'placebo', 'Interleukin']","['serum IL-17 levels', 'chemotherapy, cancer recurrence, and mortality', 'cancer recurrence, and no death event', 'serum IL-17 level', 'serum cortisol', 'pain scores', 'serum IL-17 and cortisol', 'lower serum IL-17', 'reduced serum IL-17', 'serum IL-17 level at the time of post-anesthesia care unit (PACU) discharge, serum cortisol level at PACU discharge and postoperative 24 hours, pain scores (0-10) from PACU discharge to 48 hours postoperatively, incidences of postoperative nausea and vomiting, dizziness, and arrhythmia during 0-48 hours postoperatively, and 30-day mortality', 'Serum Interleukin-17']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0236396', 'cui_str': 'Serum cortisol measurement'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0034871', 'cui_str': 'Postoperative anesthesia care unit'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",60.0,0.790134,"Conclusion Intravenous lidocaine was associated with reduced serum IL-17 and cortisol following VATS procedures in early-stage NSCLC patients. ","[{'ForeName': 'Yong-Heng', 'Initials': 'YH', 'LastName': 'Hou', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.""}, {'ForeName': 'Wen-Cheng', 'Initials': 'WC', 'LastName': 'Shi', 'Affiliation': ""Department of Anesthesiology, Taicang First People's Hospital, Taicang Affiliated Hospital of Soochow University, Taicang, Jiangsu, People's Republic of China.""}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Cai', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, University of California Davis Health, Sacramento, CA, USA.'}, {'ForeName': 'Zhong', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': ""Department of Anesthesiology, Taicang First People's Hospital, Taicang Affiliated Hospital of Soochow University, Taicang, Jiangsu, People's Republic of China.""}, {'ForeName': 'Fu-Wei', 'Initials': 'FW', 'LastName': 'Qi', 'Affiliation': ""Department of Anesthesiology, Taicang First People's Hospital, Taicang Affiliated Hospital of Soochow University, Taicang, Jiangsu, People's Republic of China.""}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': ""Department of Thoracic Surgery, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.""}, {'ForeName': 'Xiao-Mei', 'Initials': 'XM', 'LastName': 'Feng', 'Affiliation': 'Department of Anesthesiology, University of Utah health, Salt Lake City, UT, USA.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Peng', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.""}, {'ForeName': 'Fu-Hai', 'Initials': 'FH', 'LastName': 'Ji', 'Affiliation': ""Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.""}]","Drug design, development and therapy",['10.2147/DDDT.S316804'] 2677,34376533,"MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer.","PURPOSE In MONARCH 2, abemaciclib plus fulvestrant significantly prolonged progression-free survival (PFS) and overall survival (OS) versus placebo plus fulvestrant in patients with hormone receptor positive (HR+), HER2- advanced breast cancer. This exploratory analysis assessed the efficacy of abemaciclib plus fulvestrant across subgroups of patients receiving study therapy as first- or second-line treatment for metastatic disease. EXPERIMENTAL DESIGN Improvements were estimated using Cox models, and a test of interactions of subgroups with treatment was performed. RESULTS The benefit in PFS (first-line, HR=0.57 [95% CI: 0.45-0.73]; second-line, HR=0.48 [95% CI: 0.36-0.64]) and OS (first-line, HR=0.85 [95% CI: 0.64-1.14]; second-line, HR=0.66 [95% CI: 0.46-0.94]) was observed across both subgroups, consistent with the intent-to-treat (ITT) population. In first-line patients (abemaciclib arm, n=265; placebo arm, n=133), the numerically largest effect on PFS and OS was observed in patients with primary resistance to endocrine therapy (ET) (PFS, HR=0.40 [95% CI: 0.26-0.63]; OS, HR=0.58 [95% CI: 0.35-0.97]) and visceral disease (PFS, HR=0.54 [95% CI: 0.39-0.73]; OS, HR=0.82 [95% CI: 0.58-1.20]). In second-line patients (abemaciclib arm, n=170; placebo arm, n=86), a numerical benefit in PFS and OS was observed across primary and secondary ET resistance, with numerically more pronounced effects observed in patients with visceral disease (PFS, HR=0.39 [CI: 0.27-0.57]; OS, HR=0.51 [95% CI: 0.33-0.81]). Prolongation of time to second disease progression, time to chemotherapy, and chemotherapy‑free survival was observed in both subgroups. CONCLUSIONS Consistent with the ITT population, a benefit in PFS and OS was observed across the first- and second-line subgroups in MONARCH 2.",2021,"The benefit in PFS (first-line, HR=0.57 [95% CI: 0.45-0.73]; second-line, HR=0.48 [95% CI: 0.36-0.64]) and OS (first-line, HR=0.85","['subgroups of patients receiving study therapy as first- or second-line treatment for metastatic disease', 'patients with primary resistance to endocrine therapy (ET) (PFS, HR=0.40', 'patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer', 'patients with hormone receptor positive (HR+), HER2- advanced breast cancer']","['placebo plus fulvestrant', 'placebo', 'abemaciclib plus fulvestrant']","['PFS and OS', 'Prolongation of time to second disease progression, time to chemotherapy, and chemotherapy‑free survival', 'progression-free survival (PFS) and overall survival (OS', 'visceral disease']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1710038', 'cui_str': 'Second line treatment'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C3852841', 'cui_str': 'abemaciclib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C3852841', 'cui_str': 'abemaciclib'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",,0.257857,"The benefit in PFS (first-line, HR=0.57 [95% CI: 0.45-0.73]; second-line, HR=0.48 [95% CI: 0.36-0.64]) and OS (first-line, HR=0.85","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Neven', 'Affiliation': 'Department of Gynaecology and Obstetrics, UZ Leuven.'}, {'ForeName': 'Stephen R D', 'Initials': 'SRD', 'LastName': 'Johnston', 'Affiliation': 'Breast Unit, Royal Marsden Hospital.'}, {'ForeName': 'Masakazu', 'Initials': 'M', 'LastName': 'Toi', 'Affiliation': 'Department of Breast Surgery, Kyoto University.'}, {'ForeName': 'Joohyuk', 'Initials': 'J', 'LastName': 'Sohn', 'Affiliation': 'Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Inoue', 'Affiliation': 'Division of Breast Oncology, Saitama Cancer Center.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pivot', 'Affiliation': 'Centre Paul Strauss, Inserm U110.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Burdaeva', 'Affiliation': 'Arkhangelsk Regional Clinical Oncology Dispensary.'}, {'ForeName': 'Meena', 'Initials': 'M', 'LastName': 'Okera', 'Affiliation': 'Adelaide Cancer Centre.'}, {'ForeName': 'Norikazu', 'Initials': 'N', 'LastName': 'Masuda', 'Affiliation': 'Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Kaufman', 'Affiliation': 'Breast Oncology, Division of Hematology/Oncology, University of Vermont Cancer Center.'}, {'ForeName': 'Han', 'Initials': 'H', 'LastName': 'Koh', 'Affiliation': 'Division of Hematology/Oncology, Loma Linda University.'}, {'ForeName': 'Eva-Maria', 'Initials': 'EM', 'LastName': 'Grischke', 'Affiliation': 'gynecology, Universitӓts Frauenklinik Tubingen, Eberhard Karls University.'}, {'ForeName': 'PierFranco', 'Initials': 'P', 'LastName': 'Conte', 'Affiliation': 'Medical Oncology 2, University of Padova, Istituto Oncologico Veneto IRCCS.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Global Statistical Sciences, Eli Lilly and Company.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Haddad', 'Affiliation': 'Eli Lilly (United States).'}, {'ForeName': 'Karla C', 'Initials': 'KC', 'LastName': 'Hurt', 'Affiliation': 'Clinical PM CP&E- Oncology, Eli Lilly and Company.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Llombart-Cussac', 'Affiliation': 'Servicio de Oncología Médica, Hospital Arnau de Vilanova.'}, {'ForeName': 'George W', 'Initials': 'GW', 'LastName': 'Sledge', 'Affiliation': 'Medicine, Stanford University School of Medicine gsledge@stanford.edu.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-4685'] 2678,34376508,Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.,"OBJECTIVE To investigate the association of age and the presence of contrast enhancing lesions (CELs) on cranial MRI scans in different disease courses of multiple sclerosis (MS), we describe the frequency of CELs as a function of age in four large randomized controlled trial (RCT) datasets. METHODS Using original trial data from CombiRx (clinicaltrials.gov identifier NCT00211887), a trial in relapsing-remitting MS, ASCEND (NCT01416181) a trial in secondary progressive MS, and the two primary progressive MS trials PROMISE and INFORMS (NCT00731692), we describe the occurrence of CELs per age group at baseline for the entire trial cohort, and at one year follow-up in the treatment arms. RESULTS CombiRx included 1,008, ASCEND 889, PROMISE 943, and INFORMS 970 participants. At baseline, CEL frequency differed between datasets according to disease courses: 39.6% of CombiRx, 23.9% of ASCEND, 14.0% of PROMISE, and 12.3% of INFORMS participants had CELs. This distribution by disease course was largely preserved within each age group. In all datasets, there was an almost linear decrease of the percentage of participants with CELs with advancing age. After one year of experimental treatment, CEL occurrence was reduced in all trial datasets, and almost absent in ASCEND. The decrease of CEL occurrence with advancing age was preserved in CombiRx, PROMISE and INFORMS after one year of treatment. We investigated the association of the baseline factors age, disease duration, sex and EDSS with having CELs at baseline with multivariable binary logistic regression models. Age was the only characteristic associated with the risk of CELs at baseline in all datasets, with higher age associated with a lower risk of CELs (odds ratios (OR) for having CELs at baseline per year increase in age: CombiRx: 0.96, 95% confidence interval (CI) 0.95 to 0.98, ASCEND: 0.94, 95% CI 0.92 to 0.97, PROMISE: OR 0.94, 95% CI 0.91 to 0.96, INFORMS: 0.97 95% CI 0.94 to 0.99). CONCLUSIONS Our analysis of four large, well-characterized RCT datasets shows that the association of age and CEL occurrence is a general phenomenon across the spectrum of MS disease courses. Our findings should be replicated in real world MS datasets.",2021,"The decrease of CEL occurrence with advancing age was preserved in CombiRx, PROMISE and INFORMS after one year of treatment.",['different disease courses of multiple sclerosis (MS'],[],"['CEL occurrence', 'CEL frequency', 'cranial MRI scans', 'risk of CELs']","[{'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]",[],"[{'cui': 'C0208736', 'cui_str': 'N(6)-(1-carboxyethyl)lysine'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",,0.255937,"The decrease of CEL occurrence with advancing age was preserved in CombiRx, PROMISE and INFORMS after one year of treatment.","[{'ForeName': 'Marcus W', 'Initials': 'MW', 'LastName': 'Koch', 'Affiliation': 'Department of Clinical Neurosciences, University of Calgary, Canada.'}, {'ForeName': 'Jop', 'Initials': 'J', 'LastName': 'Mostert', 'Affiliation': 'Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.'}, {'ForeName': 'Yinan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurology, Icahn School of Medicine at Mount Sinai, USA.'}, {'ForeName': 'Jerry S', 'Initials': 'JS', 'LastName': 'Wolinsky', 'Affiliation': 'Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), USA.'}, {'ForeName': 'Fred D', 'Initials': 'FD', 'LastName': 'Lublin', 'Affiliation': 'Department of Neurology, Icahn School of Medicine at Mount Sinai, USA.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Strijbis', 'Affiliation': 'Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Cutter', 'Affiliation': 'Department of Biostatistics, University of Alabama at Birmingham, Birmingham, USA.'}]",Neurology,['10.1212/WNL.0000000000012603'] 2679,34376454,"Effectiveness of endolymphatic duct blockage versus endolymphatic sac decompression in patients with intractable Ménière's disease: study protocol for a double-blinded, randomised controlled trial.","INTRODUCTION Outcomes of surgery for Ménière's disease (MD) remain discordant. Recently, a new surgical procedure in which the endolymphatic duct is clipped was proposed. To date, only one prospective trial assessing this technique was published, yielding promising results. This protocol describes a prospective, double-blinded, randomised controlled trial that will be carried out to assess the effectiveness of this surgical intervention. METHODS Eighty-four patients with intractable MD will be recruited from 13 hospitals in the Netherlands. Intraoperatively, randomisation will determine whether endolymphatic duct blockage (EDB) or endolymphatic sac decompression (ESD) will be performed. Randomisation will be 1:1 stratified for gender and duration of MD (recent-onset versus mature MD). All participants receive vestibular rehabilitation after surgery. Patients are followed up during 1 year after surgery. Follow-up visits will take place at 1 week, 3 months, 6 months and 12 months after surgery. The main study endpoint is proportion of patients who are free of vertigo spells at 12 months postoperatively. Secondary parameters include cumulative number of vertigo bouts, co-intervention, tinnitus, hearing, quality of life, cost effectiveness and a budget impact analysis. Total duration of the study is 4 years. ANALYSIS The primary analysis will follow the intention-to-treat principle. For the primary outcome, a χ 2 test will be performed. Secondary outcomes will be analysed using a linear mixed model (EDB versus decompression group) at the different time measurement point. ETHICS AND DISSEMINATION This study was reviewed and approved by a board of specialists before funding was obtained, as well as by the Medical Research Ethics Committee Leiden-The Hague-Delft and the boards of all participating centres. Results of this study will be published in international peer-reviewed scientific journals and will be presented on (inter)national scientific conferences and meetings. TRIAL REGISTRATION NUMBERS NL9095 and ISRCTN12074571; Pre-Results.",2021,"Secondary parameters include cumulative number of vertigo bouts, co-intervention, tinnitus, hearing, quality of life, cost effectiveness and a budget impact analysis.","[""patients with intractable Ménière's disease"", 'Eighty-four patients with intractable MD will be recruited from 13 hospitals in the Netherlands']","['endolymphatic duct blockage (EDB) or endolymphatic sac decompression (ESD', 'endolymphatic duct blockage', 'vestibular rehabilitation', 'endolymphatic sac decompression']","['free of vertigo spells', 'cumulative number of vertigo bouts, co-intervention, tinnitus, hearing, quality of life, cost effectiveness and a budget impact analysis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0025281', 'cui_str': ""Ménière's disease""}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]","[{'cui': 'C0014167', 'cui_str': 'Endolymphatic duct structure'}, {'cui': 'C0198276', 'cui_str': 'Decompression of endolymphatic sac'}, {'cui': 'C0200324', 'cui_str': 'Vestibular rehabilitation'}]","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0042571', 'cui_str': 'Vertigo'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0006347', 'cui_str': 'Budgets'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",84.0,0.409621,"Secondary parameters include cumulative number of vertigo bouts, co-intervention, tinnitus, hearing, quality of life, cost effectiveness and a budget impact analysis.","[{'ForeName': 'Annejet A', 'Initials': 'AA', 'LastName': 'Schenck', 'Affiliation': 'Department of Otorhinolaryngology, Haga Hospital, The Hague, The Netherlands j.schenck@hagaziekenhuis.nl.'}, {'ForeName': 'Josephina M', 'Initials': 'JM', 'LastName': 'Kruyt', 'Affiliation': 'Department of Otorhinolaryngology, Medical Centre Haaglanden, The Hague, The Netherlands.'}, {'ForeName': 'Peter Paul', 'Initials': 'PP', 'LastName': 'van Benthem', 'Affiliation': 'Department of Otorhinolaryngology, Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Suzanne C', 'Initials': 'SC', 'LastName': 'Cannegieter', 'Affiliation': 'Department of Thrombosis and Hemostasis, Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Wilbert B', 'Initials': 'WB', 'LastName': 'van den Hout', 'Affiliation': 'Department of Medical Decision Making, Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Böhringer', 'Affiliation': 'Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Sebastiaan', 'Initials': 'S', 'LastName': 'Hammer', 'Affiliation': 'Department of Radiology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Susan P M', 'Initials': 'SPM', 'LastName': 'Hombergen', 'Affiliation': 'Department of Physiotherapy, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Henk M', 'Initials': 'HM', 'LastName': 'Blom', 'Affiliation': 'Department of Otorhinolaryngology, Haga Hospital, The Hague, The Netherlands.'}]",BMJ open,['10.1136/bmjopen-2021-054514'] 2680,34376447,Study protocol for a randomised controlled trial assessing the impact of pulmonary rehabilitation on maximal exercise capacity for adults living with post-TB lung disease: Global RECHARGE Uganda.,"INTRODUCTION The burden of post-tuberculosis (TB) lung disease (PTBLD) is steadily increasing in sub-Saharan Africa, causing disability among TB survivors. Without effective medicines, the mainstay of PTBLD treatment evolves around disease prevention and supportive treatment. Pulmonary rehabilitation (PR), a low-cost, non-pharmacological intervention has shown effectiveness in a group of PTBLD individuals but has not been tested in a clinical trial. This study aims to assess the impact of a 6-week PR programme on maximal exercise capacity and other outcomes among adults in Uganda living with PTBLD. METHODS AND ANALYSIS This is a randomised waiting-list controlled trial with blinded outcome measures, comparing PR versus usual care for patients with PTBLD. A total of 114 participants will be randomised (1:1) to receive either usual care (on the waiting list) or PR, with follow-up assessments at 6 weeks and 12 weeks postintervention. The primary outcome is change in walking distance measured by the Incremental Shuttle Walk Test from baseline to the end of 6 weeks of PR. All secondary outcomes will be compared between the PR and usual care arms from baseline to 6-week and 12-week follow-ups. Secondary outcomes include self-reported respiratory symptoms, physical activity, psychological well-being, health-related quality of life and cost-benefit analysis. All randomised participants will be included in the intention-to-treat analysis population. The primary efficacy analysis will be based on both per-protocol and modified intention-to-treat populations. ETHICS AND DISSEMINATION The trial has received ethical clearance from the Mulago Hospital Research and Ethics Committee (MHREC 1478), Kampala, Uganda as well as the Uganda National Council for Science and Technology (SS 5105). Ethical approval has been obtained from the University of Leicester, UK research ethics committee (Ref No. 22349). Study findings will be published in appropriate peer-reviewed journals and disseminated at appropriate local, regional and international scientific meetings and conferences. TRIAL REGISTRATION NUMBER ISRCTN18256843. PROTOCOL VERSION Version 1.0 July 2019.",2021,"Pulmonary rehabilitation (PR), a low-cost, non-pharmacological intervention has shown effectiveness in a group of PTBLD individuals but has not been tested in a clinical trial.","['adults in Uganda living with PTBLD', '114 participants', 'adults living with post-TB lung disease', 'patients with PTBLD']","['Pulmonary rehabilitation (PR', 'pulmonary rehabilitation', 'PR programme', 'usual care (on the waiting list) or PR']","['change in walking distance', 'maximal exercise capacity', 'self-reported respiratory symptoms, physical activity, psychological well-being, health-related quality of life and cost-benefit analysis', 'burden of post-tuberculosis (TB) lung disease (PTBLD']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0024115', 'cui_str': 'Disorder of lung'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0010174', 'cui_str': 'Cost Benefit Analysis'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0024115', 'cui_str': 'Disorder of lung'}]",114.0,0.540775,"Pulmonary rehabilitation (PR), a low-cost, non-pharmacological intervention has shown effectiveness in a group of PTBLD individuals but has not been tested in a clinical trial.","[{'ForeName': 'Winceslaus', 'Initials': 'W', 'LastName': 'Katagira', 'Affiliation': 'Makerere University Lung Institute, Kampala, Uganda wincegira@gmail.com.'}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Orme', 'Affiliation': 'Department of Respiratory Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Amy V', 'Initials': 'AV', 'LastName': 'Jones', 'Affiliation': 'Department of Respiratory Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kasiita', 'Affiliation': 'Department of Physiotherapy, Mulago National Referral Hospital, Kampala, Uganda.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'Faculty of Health, University of Plymouth, Plymouth, UK.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Barton', 'Affiliation': 'Faculty of Health, University of Plymouth, Plymouth, UK.'}, {'ForeName': 'Ruhme B', 'Initials': 'RB', 'LastName': 'Miah', 'Affiliation': 'Department of Respiratory Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Manise', 'Affiliation': 'NIHR Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, UK.'}, {'ForeName': 'Jesse A', 'Initials': 'JA', 'LastName': 'Matheson', 'Affiliation': 'Department of Economics, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Free', 'Affiliation': 'Centre for Exercise and Rehabilitation Science (CERS), NIHR Leicester Biomedical Research Centre - Respiratory, University Hospitals of Leicester NHS Trust, Leicester, UK.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Steiner', 'Affiliation': 'Department of Respiratory Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Bruce J', 'Initials': 'BJ', 'LastName': 'Kirenga', 'Affiliation': 'Makerere University Lung Institute, Kampala, Uganda.'}, {'ForeName': 'Sally J', 'Initials': 'SJ', 'LastName': 'Singh', 'Affiliation': 'Department of Respiratory Sciences, University of Leicester, Leicester, UK.'}]",BMJ open,['10.1136/bmjopen-2020-047641'] 2681,31747001,Work-relatedness of the presented health problem and sickness absence.,"BACKGROUND Perception by workers of their health problems as work-related is possibly associated with sickness absence (SA). The aim of this study was to to study the relationship between perceived work-relatedness of health problems and SA among workers who visit their GP, taking the influence of other potential determinants into account and to study the influence of these determinants on SA. Design and setting prospective cohort study in 32 Dutch GP practices. METHODS A secondary analysis of RCT data among workers, aged 18-63 years, who visited their GP. We measured self-reported SA days in 12 months and high SA (>20 days in 12 months) and compared workers who perceived work-relatedness (WR+) with workers who did not (WR-). With multivariable linear and logistic regression models, we analyzed the influence of age, gender, experienced health, chronic illness, prior SA, number of GP consultations and perceived work ability. RESULTS We analyzed data of 209 workers, 31% perceived work-relatedness. Geometric mean of SA days was 1.6 (95% CI: 0.9-3.0) for WR+- workers and 1.2 (95% CI: 0.8-1.8) for WR- workers (P = 0.42). Incidence of high SA was 21.5 and 13.3%, respectively (odds ratio 1.79; 95% CI: 0.84-3.84). SA was positively associated with chronic illness, prior SA, low perceived work ability and age over 50. CONCLUSIONS Perceived work-relatedness was not associated with SA. SA was associated with chronic illness, prior SA, low perceived work ability and age over 50.",2020,"Incidence of high SA was 21.5 and 13.3%, respectively (odds ratio 1.79; 95% CI: 0.84-3.84).","['workers, aged 18-63 years, who visited their GP', '32 Dutch GP practices', '209 workers, 31% perceived work-relatedness']",[],"['Geometric mean of SA days', 'Incidence of high SA']","[{'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0043227', 'cui_str': 'Working'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205250', 'cui_str': 'High'}]",32.0,0.0818803,"Incidence of high SA was 21.5 and 13.3%, respectively (odds ratio 1.79; 95% CI: 0.84-3.84).","[{'ForeName': 'Cornelis A', 'Initials': 'CA', 'LastName': 'de Kock', 'Affiliation': 'Department of Primary and Community Care.'}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Lucassen', 'Affiliation': 'Department of Primary and Community Care.'}, {'ForeName': 'Reinier P', 'Initials': 'RP', 'LastName': 'Akkermans', 'Affiliation': 'Department of Primary and Community Care.'}, {'ForeName': 'J André', 'Initials': 'JA', 'LastName': 'Knottnerus', 'Affiliation': 'Department of General Practice, Maastricht University, Maastricht.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Buijs', 'Affiliation': 'TNO Work, Health and Care, Leiden, (retired in 2014).'}, {'ForeName': 'Romy', 'Initials': 'R', 'LastName': 'Steenbeek', 'Affiliation': 'Health, Technology, TNO Work, Leiden.'}, {'ForeName': 'Antoine L', 'Initials': 'AL', 'LastName': 'Lagro-Janssen', 'Affiliation': 'Department of Primary and Community Care.'}]",Family practice,['10.1093/fampra/cmz072'] 2682,34030124,Dietary Intake and Gastrointestinal Integrity in Runners Undertaking High-Intensity Exercise in the Heat.,"Gastrointestinal disturbances are one of the most common issues for endurance athletes during training and competition in the heat. The relationship between typical dietary intake or nutritional interventions and perturbations in or maintenance of gut integrity is unclear. Twelve well-trained male endurance athletes (peak oxygen consumption = 61.4 ± 7.0 ml·kg-1·min-1) completed two trials in a randomized order in 35 °C (heat) and 21 °C (thermoneutral) conditions and kept a detailed nutritional diary for eight consecutive days between the two trials. The treadmill running trials consisted of 15 min at 60% peak oxygen consumption, 15 min at 75% peak oxygen consumption, followed by 8 × 1-min high-intensity efforts. Venous blood samples were taken at the baseline, at the end of each of the three exercise stages, and 1 hr postexercise to measure gut integrity and the permeability biomarker concentration for intestinal fatty-acid-binding protein, lipopolysaccharide, and lipopolysaccharide-binding protein. The runners self-reported gut symptoms 1 hr postexercise and 3 days postexercise. The heat condition induced large (45-370%) increases in intestinal fatty-acid-binding protein, lipopolysaccharide-binding protein, and lipopolysaccharide concentrations compared with the baseline, but induced mild gastrointestinal symptoms. Carbohydrate and polyunsaturated fat intake 24 hr preexercise were associated with less lipopolysaccharide translocation. Protein, carbohydrate, total fat, and polyunsaturated fat intake (8 days) were positively associated with the percentage increase of intestinal fatty-acid-binding protein in both conditions (range of correlations, 95% confidence interval = .62-.93 [.02, .98]). Typical nutrition intake partly explained increases in biomarkers and the attenuation of symptoms induced by moderate- and high-intensity exercise under both heat and thermoneutral conditions.",2021,"The heat condition induced large (45-370%) increases in intestinal fatty-acid-binding protein, lipopolysaccharide-binding protein, and lipopolysaccharide concentrations compared with the baseline, but induced mild gastrointestinal symptoms.","['Twelve well-trained male endurance athletes (peak oxygen consumption = 61.4 ± 7.0\xa0ml·kg-1·min-1', 'Runners Undertaking High-Intensity Exercise in the Heat']","['15\xa0min at 60% peak oxygen consumption, 15\xa0min at 75% peak oxygen consumption']","['intestinal fatty-acid-binding protein, lipopolysaccharide-binding protein, and lipopolysaccharide concentrations', 'Venous blood samples', 'Gastrointestinal disturbances', 'Protein, carbohydrate, total fat, and polyunsaturated fat intake', 'intestinal fatty-acid-binding protein']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018837', 'cui_str': 'Heat'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}]","[{'cui': 'C0163314', 'cui_str': 'Intestinal Fatty Acid-Binding Protein'}, {'cui': 'C0065054', 'cui_str': 'lipopolysaccharide-binding protein'}, {'cui': 'C0023810', 'cui_str': 'Lipopolysaccharide'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0444255', 'cui_str': 'Venous blood specimen'}, {'cui': 'C0232459', 'cui_str': 'Abnormal digestive tract function'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}]",,0.0466727,"The heat condition induced large (45-370%) increases in intestinal fatty-acid-binding protein, lipopolysaccharide-binding protein, and lipopolysaccharide concentrations compared with the baseline, but induced mild gastrointestinal symptoms.","[{'ForeName': 'Naroa', 'Initials': 'N', 'LastName': 'Etxebarria', 'Affiliation': 'University of Canberra.'}, {'ForeName': 'Nicole A', 'Initials': 'NA', 'LastName': 'Beard', 'Affiliation': 'University of Canberra.'}, {'ForeName': 'Maree', 'Initials': 'M', 'LastName': 'Gleeson', 'Affiliation': 'University of Newcastle Australia.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Wallett', 'Affiliation': 'University of Canberra.'}, {'ForeName': 'Warren A', 'Initials': 'WA', 'LastName': 'McDonald', 'Affiliation': 'University of Canberra.'}, {'ForeName': 'Kate L', 'Initials': 'KL', 'LastName': 'Pumpa', 'Affiliation': 'University of Canberra.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Pyne', 'Affiliation': 'University of Canberra.'}]",International journal of sport nutrition and exercise metabolism,['10.1123/ijsnem.2020-0367'] 2683,33656415,Effects of Egocentric Projection and Identification on Narrative Persuasion in Foodborne Illness Messages.,"This study conceptually and empirically distinguishes two mental processes in narrative processing of food safety health messages-identification with and egocentric projection onto story characters. Two studies examined the effects of narrative autobiographical accounts of contracting foodborne illness (salmonella) because of careless food preparation. Both studies consistently found that identification increased, but egocentric projection decreased audience members' behavioral intention to perform safe food handling practices, indicating that egocentric projection and identification represent unique mental processes and yield distinct persuasive outcomes. In addition, confirmatory factor analyses provided evidence that egocentric projection and identification are distinct constructs. Implications for the role of identification and egocentric projection for understanding narrative processing and for health persuasion are discussed.",2020,"Both studies consistently found that identification increased, but egocentric projection decreased audience members' behavioral intention to perform safe food handling practices, indicating that egocentric projection and identification represent unique mental processes and yield distinct persuasive outcomes.",[],"['narrative processing of food safety health messages-identification with and egocentric projection onto story characters', 'Egocentric Projection', 'narrative autobiographical']",[],[],"[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C1456535', 'cui_str': 'Food Safety'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0007952', 'cui_str': 'Character'}]",[],2.0,0.0480964,"Both studies consistently found that identification increased, but egocentric projection decreased audience members' behavioral intention to perform safe food handling practices, indicating that egocentric projection and identification represent unique mental processes and yield distinct persuasive outcomes.","[{'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Zhou', 'Affiliation': 'Department of Community & Behavioral Health, Colorado School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Shapiro', 'Affiliation': 'Department of Communication, Cornell University, Ithaca, NY, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1868627'] 2684,33595241,Quantifying the Degree of Bruise Visibility Observed Under White Light and an Alternate Light Source.,,2021,,[],[],[],[],[],[],,0.0578016,,[],Journal of forensic nursing,['10.1097/JFN.0000000000000317'] 2685,33544052,Tailoring Temporal Message Frames to Individuals' Time Orientation Strengthens the Relationship between Risk Perception and Behavioral Intention.,"While health behavior theories conceptualize risk perception as a major factor motivating protective action against risk, empirical support for this widely-assumed proposition has been inconclusive. Given the inherent issue concerning the delay of desired outcomes in most health behaviors, this research proposes the congruence between temporal frame and individuals' trait time orientation (i.e., consideration of future consequences; CFC) as an important moderator in the risk perception-behavioral intention relationship. Findings from two experiments concerning messages promoting adequate sleep ( N = 227; Study 1) and plastic bottle recycling ( N = 223; Study 2) showed that the relationship between risk perception and behavioral intention was significantly stronger when temporal frames and CFC were more congruent (i.e., tailored). Nuanced differences in the moderating effects of frame-CFC congruence were observed depending on how risk perception was operationalized (i.e., susceptibility only, severity only, or combination of the two). Implications for health communication message design are discussed.",2020,"Nuanced differences in the moderating effects of frame-CFC congruence were observed depending on how risk perception was operationalized (i.e., susceptibility only, severity only, or combination of the two).",[],[],['risk perception and behavioral intention'],[],[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",227.0,0.0338179,"Nuanced differences in the moderating effects of frame-CFC congruence were observed depending on how risk perception was operationalized (i.e., susceptibility only, severity only, or combination of the two).","[{'ForeName': 'Mengfei', 'Initials': 'M', 'LastName': 'Guan', 'Affiliation': 'Department of Communication, University of Arkansas, Fayetteville, USA.'}, {'ForeName': 'Jiyeon', 'Initials': 'J', 'LastName': 'So', 'Affiliation': 'Department of Communication, Yonsei University, Seoul, Republic of Korea.'}]",Journal of health communication,['10.1080/10810730.2021.1878310'] 2686,33103600,Feeling angry: the effects of vaccine misinformation and refutational messages on negative emotions and vaccination attitude.,"Vaccine misinformation circulated on social media has negatively impacted people's vaccine beliefs and behaviors. Communication strategies to address misinformation including fact-checking and warning labels have shown conflicting effects. This study examined how short-term exposure to vaccine misinformation impacted vaccination attitude through both cognitive and affective routes and tested whether and how two-sided refutational messages could negate the misinformation's impact. We conducted an online experiment involving a convenient sample of 609 U.S. adult participants with five message conditions: two misinformation messages (one using the conspiracy frame and one using the uncertainty frame), two corresponding two-sided refutational messages, and a control group. Results showed that both conspiracy and uncertainty framed misinformation messages decreased pro-vaccination attitude in comparison to the control. The two refutational messages increased pro-vaccination attitude in comparison to the corresponding misinformation messages. These effects were further mediated by the emotion of anger. Parental status and conspiracy beliefs did not moderate effects of the messages on vaccination attitude. Our findings indicate two-sided refutational messages can be a promising strategy to combat vaccine misinformation.",2020,Results showed that both conspiracy and uncertainty framed misinformation messages decreased pro-vaccination attitude in comparison to the control.,['609\xa0U.S. adult participants with five message conditions'],['vaccine misinformation and refutational messages'],"['pro-vaccination attitude', 'negative emotions and vaccination attitude', 'vaccination attitude']","[{'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0079843', 'cui_str': 'Misinformation'}]","[{'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",,0.0546928,Results showed that both conspiracy and uncertainty framed misinformation messages decreased pro-vaccination attitude in comparison to the control.,"[{'ForeName': 'Jieyu Ding', 'Initials': 'JD', 'LastName': 'Featherstone', 'Affiliation': 'Department of Communication, University of California , Davis, CA, USA.'}, {'ForeName': 'Jingwen', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Communication, University of California , Davis, CA, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1838671'] 2687,33256546,"Adapting Online Patient Decision Aids: Effects of Modality and Narration Style on Patients' Satisfaction, Information Recall and Informed Decision Making.","Audiovisual and narrative information are often used in online decision aids. However, few studies have tested whether these strategies are more effective compared to other types of information. We tested the effect of these strategies on satisfaction with the information, recall and informed decision-making in a 2 (Modality: audiovisual vs. textual) x 2 (Narration style: narrative vs. factual) experimental design. Data was collected in an online experiment among 262 analogue cancer patients. Since most cancer patients are older people, we also assessed if the effectiveness of these strategies differs depending on the patient's age. Data was analyzed using Structural Equation Modeling. Findings showed audiovisual modality had a positive effect on satisfaction. Moreover, audiovisual modality improved recall, both directly and indirectly via satisfaction, which subsequently resulted in better-informed decision-making. Narratives resulted in more satisfaction, but not better recall or informed decision-making. These effects were found in patients of all ages.",2020,"Moreover, audiovisual modality improved recall, both directly and indirectly via satisfaction, which subsequently resulted in better-informed decision-making.","['262 analogue cancer patients', 'cancer patients are older people']",['Modality and Narration Style'],['satisfaction'],"[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",262.0,0.0353425,"Moreover, audiovisual modality improved recall, both directly and indirectly via satisfaction, which subsequently resulted in better-informed decision-making.","[{'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'De Looper', 'Affiliation': 'Amsterdam School of Communication Research (ASCoR), University of Amsterdam , Amsterdam, The Netherlands.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Damman', 'Affiliation': 'Public and Occupational Health, VU University Medical Center/EMGO+ Institute dor Health and Care Research , Amsterdam, The Netherlands.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Smets', 'Affiliation': 'Medical Psychology, Amsterdam UMC , Amsterdam, The Netherlands.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Timmermans', 'Affiliation': 'Public and Occupational Health, VU University Medical Center/EMGO+ Institute dor Health and Care Research , Amsterdam, The Netherlands.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Van Weert', 'Affiliation': 'Amsterdam School of Communication Research (ASCoR), University of Amsterdam , Amsterdam, The Netherlands.'}]",Journal of health communication,['10.1080/10810730.2020.1840674'] 2688,34379777,Error-Manipulation Gait Training for Veterans with Non-Traumatic Lower Limb Amputation: A Randomized Controlled Trial Protocol.,"OBJECTIVE The purpose of this study will be to determine the efficacy of error-manipulation gait training (error-augmentation or error-correction) to improve step length symmetry and secondary health outcomes in veterans with unilateral nontraumatic transtibial amputation (TTA). METHODS This will be a 3-arm, parallel, assessor-blinded, randomized controlled trial, with baseline, postintervention, and 3-month follow-up assessments in a VA Geriatric Research Education and Clinical Center. Participants are 54 US military veterans ranging in age from 50 to 85 years with a unilateral transtibial nontraumatic amputation. Participants will be randomized into 1 of 3 groups: error-augmentation training (EAT), error-correction training (ECT), or supervised walking (CTL). Each group will complete 8 split-belt treadmill walking training sessions of 25 minutes each over 4 weeks. The EAT group will walk with belts moving at asymmetrical speeds. The ECT group will walk to the cadence of a metronome and the split belts moving at symmetrical speeds. The CTL group will walk with symmetrical belt speeds and without feedback. Step length symmetry is the primary outcome and will be assessed using an asymmetry index during overground walking. Secondary outcomes include lower extremity joint work during treadmill walking, 6-Minute Walk Test performance, daily step count, participant-perceived disability, and residual-limb integumentary health. Outcomes will be assessed at preintervention, 1-week postintervention (primary endpoint), and 13 weeks postintervention. IMPACT This study protocol focuses on an understudied area of rehabilitation for patients with nontraumatic unilateral TTA who have high levels of spatiotemporal gait asymmetry and mobility impairment. The results of this study will inform future implementation of clinical gait training interventions to improve spatiotemporal gait symmetry and long-term health and disability outcomes in patients with nontraumatic unilateral TTA.",2021,Participants are 54 US military veterans ranging in age from 50 to 85 years with a unilateral transtibial nontraumatic amputation.,"['patients with nontraumatic unilateral TTA', 'veterans with unilateral nontraumatic transtibial amputation (TTA', 'Veterans with Non-Traumatic Lower Limb Amputation', 'Participants are 54 US military veterans ranging in age from 50 to 85\xa0years with a unilateral transtibial nontraumatic amputation', 'patients with nontraumatic unilateral TTA who have high levels of spatiotemporal gait asymmetry and mobility impairment']","['CTL', 'Error-Manipulation Gait Training', 'error-augmentation training (EAT), error-correction training (ECT), or supervised walking (CTL', 'EAT', 'error-manipulation gait training (error-augmentation or error-correction', 'ECT']","['lower extremity joint work during treadmill walking, 6-Minute Walk Test performance, daily step count, participant-perceived disability, and residual-limb integumentary health']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0337308', 'cui_str': 'Amputation of lower limb'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}]","[{'cui': 'C0584731', 'cui_str': 'Joint structure of lower extremity'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",,0.119615,Participants are 54 US military veterans ranging in age from 50 to 85 years with a unilateral transtibial nontraumatic amputation.,"[{'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Kline', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Colorado, Aurora, CO, United States.'}, {'ForeName': 'Noel', 'Initials': 'N', 'LastName': 'So', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Rocky Mountain Regional VA Medical Center, Aurora, CO, United States.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Fields', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Rocky Mountain Regional VA Medical Center, Aurora, CO, United States.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Juarez-Colunga', 'Affiliation': 'VA Eastern Colorado Geriatric Research, Education, and Clinical Center, Rocky Mountain Regional VA Medical Center, Aurora, CO, United States.'}, {'ForeName': 'Cory L', 'Initials': 'CL', 'LastName': 'Christiansen', 'Affiliation': 'VA Eastern Colorado Geriatric Research, Education, and Clinical Center, Rocky Mountain Regional VA Medical Center, Aurora, CO, United States.'}]",Physical therapy,['10.1093/ptj/pzab192'] 2689,34379740,Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19 - A post-hoc analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data.,"This post-hoc analysis of The Adaptive COVID-19 Treatment Trial-1 shows a treatment effect of remdesivir on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.",2021,This post-hoc analysis of The Adaptive COVID-19 Treatment Trial-1 shows a treatment effect of remdesivir on progression to invasive mechanical ventilation (IMV) or death.,[],[],[],[],[],[],,0.208481,This post-hoc analysis of The Adaptive COVID-19 Treatment Trial-1 shows a treatment effect of remdesivir on progression to invasive mechanical ventilation (IMV) or death.,"[{'ForeName': 'Catharine I', 'Initials': 'CI', 'LastName': 'Paules', 'Affiliation': 'Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.'}, {'ForeName': 'Shannon K', 'Initials': 'SK', 'LastName': 'Gallagher', 'Affiliation': 'Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.'}, {'ForeName': 'Rekha R', 'Initials': 'RR', 'LastName': 'Rapaka', 'Affiliation': 'University of Maryland Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Richard T', 'Initials': 'RT', 'LastName': 'Davey', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Sarah B', 'Initials': 'SB', 'LastName': 'Doernberg', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Grossberg', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA.'}, {'ForeName': 'Noreen A', 'Initials': 'NA', 'LastName': 'Hynes', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Ponce', 'Affiliation': 'Division of Infectious Diseases, University of Texas Health San Antonio and University Health San Antonio, TX, USA.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Short', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Jocelyn', 'Initials': 'J', 'LastName': 'Voell', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.'}, {'ForeName': 'Otto O', 'Initials': 'OO', 'LastName': 'Yang', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Cameron R', 'Initials': 'CR', 'LastName': 'Wolfe', 'Affiliation': 'Department of Medicine, Infectious Disease, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Lye', 'Affiliation': 'National Centre for Infectious Diseases; Tan Tock Seng Hospital; Yong Loo Lin School of Medicine; Lee Kong Chian School of Medicine; Singapore.'}, {'ForeName': 'Lori E', 'Initials': 'LE', 'LastName': 'Dodd', 'Affiliation': 'Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.'}, {'ForeName': 'Constance A', 'Initials': 'CA', 'LastName': 'Benson', 'Affiliation': 'Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciab695'] 2690,34379701,Elevated plasma free thiols are associated with early and one-year graft function in renal transplant recipients.,"BACKGROUND Reduced free thiols in plasma are indicative of oxidative stress, which is an important contributor to ischaemia-reperfusion injury (IRI) in kidney transplantation leading to kidney damage and possibly delayed graft function (DGF). In a post-hoc, exploratory analysis of the randomised controlled CONTEXT trial, we investigated whether higher (i.e. less oxidised) plasma levels of free thiols as a biomarker of reduced oxidative stress are associated with a better initial graft function or a higher GFR. METHODS Free thiol levels were measured in plasma at baseline, 30 and 90 minutes after reperfusion of the kidney as well as at Day 1, Day 5 and twelve months after kidney transplantation in 217 patients from the CONTEXT study. Free thiol levels were compared to the kidney graft function measured as the estimated time to a 50% reduction in plasma creatinine (tCr50), the risk of DGF and measured GFR (mGFR) at Day 5 and twelve months after transplantation. RESULTS Higher levels of free thiols at Day 1 and Day 5 are associated with higher mGFR at Day 5 (p<0.001, r2adj. = 0.16; p<0.001, r2adj. = 0.25), as well as with mGFR at twelve months (p<0.001, r2adj. = 0.20; p<0.001, r2adj. = 0.16). However, plasma levels of free thiols at 30 minutes and 90 minutes, but not Day 1, were significantly higher among patients experiencing DGF. CONCLUSION Higher levels of plasma free thiols at Day 1 and Day 5, which are reflective of lower levels of oxidative stress, are associated with better early and late graft function in recipients of a kidney graft from deceased donors. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01395719.",2021,"However, plasma levels of free thiols at 30 minutes and 90 minutes, but not Day 1, were significantly higher among patients experiencing DGF. ",['renal transplant recipients'],[],"['plasma creatinine (tCr50), the risk of DGF and measured GFR (mGFR', 'plasma levels of free thiols', 'Free thiol levels', 'kidney graft function']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}]",[],"[{'cui': 'C1278055', 'cui_str': 'Plasma creatinine measurement'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1566590', 'cui_str': 'Delayed graft function'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038734', 'cui_str': 'Sulfhydryls'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",217.0,0.209331,"However, plasma levels of free thiols at 30 minutes and 90 minutes, but not Day 1, were significantly higher among patients experiencing DGF. ","[{'ForeName': 'Marie B', 'Initials': 'MB', 'LastName': 'Nielsen', 'Affiliation': 'Department of Renal Medicine, Aarhus University Hospital, Aarhus N, Denmark.'}, {'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Jespersen', 'Affiliation': 'Department of Renal Medicine, Aarhus University Hospital, Aarhus N, Denmark.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Birn', 'Affiliation': 'Department of Renal Medicine, Aarhus University Hospital, Aarhus N, Denmark.'}, {'ForeName': 'Nicoline V', 'Initials': 'NV', 'LastName': 'Krogstrup', 'Affiliation': 'Department of Renal Medicine, Aarhus University Hospital, Aarhus N, Denmark.'}, {'ForeName': 'Arno R', 'Initials': 'AR', 'LastName': 'Bourgonje', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Henri G D', 'Initials': 'HGD', 'LastName': 'Leuvenink', 'Affiliation': 'Department of Surgery, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'van Goor', 'Affiliation': 'Department of Pathology and Medical Biology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Rikke', 'Initials': 'R', 'LastName': 'Nørregaard', 'Affiliation': 'Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.'}]",PloS one,['10.1371/journal.pone.0255930'] 2691,34379633,Proximity can induce diverse friendships: A large randomized classroom experiment.,"Can outside interventions foster socio-culturally diverse friendships? We executed a large field experiment that randomized the seating charts of 182 3rd through 8th grade classrooms (N = 2,966 students) for the duration of one semester. We found that being seated next to each other increased the probability of a mutual friendship from 15% to 22% on average. Furthermore, induced proximity increased the latent propensity toward friendship equally for all students, regardless of students' dyadic similarity with respect to educational achievement, gender, and ethnicity. However, the probability of a manifest friendship increased more among similar than among dissimilar students-a pattern mainly driven by gender. Our findings demonstrate that a scalable light-touch intervention can affect face-to-face networks and foster diverse friendships in groups that already know each other, but they also highlight that transgressing boundaries, especially those defined by gender, remains an uphill battle.",2021,"Furthermore, induced proximity increased the latent propensity toward friendship equally for all students, regardless of students' dyadic similarity with respect to educational achievement, gender, and ethnicity.","['seating charts of 182 3rd through 8th grade classrooms (N = 2,966 students) for the duration of one semester']",[],"['probability of a manifest friendship', 'probability of a mutual friendship']","[{'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0205437', 'cui_str': 'Third'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",[],"[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0178647', 'cui_str': 'Friendship'}]",2966.0,0.0319442,"Furthermore, induced proximity increased the latent propensity toward friendship equally for all students, regardless of students' dyadic similarity with respect to educational achievement, gender, and ethnicity.","[{'ForeName': 'Julia M', 'Initials': 'JM', 'LastName': 'Rohrer', 'Affiliation': 'Department of Psychology, University of Leipzig, Leipzig, Germany.'}, {'ForeName': 'Tamás', 'Initials': 'T', 'LastName': 'Keller', 'Affiliation': 'Computational Social Science - Research Center for Educational and Network Studies, Center for Social Sciences, Budapest, Hungary.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Elwert', 'Affiliation': 'Department of Sociology & Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.'}]",PloS one,['10.1371/journal.pone.0255097'] 2692,34379607,"Protein Supplement and Enhanced Recovery After Posterior Spine Fusion Surgery: A Randomized, Double-blind, Placebo-controlled Trial.","STUDY DESIGN This was a randomized, double-blind clinical trial study. OBJECTIVE The objective of this study was to evaluate the effect of protein supplementation on vertebral fusion and enhanced recovery after posterior spine fusion (PSF) surgery. SUMMARY OF BACKGROUND DATA Nonfusion is one of the most common complications of lumbar spine surgery. It has been shown that protein plays an important role in bone repair; however, its correlation to vertebral fusion following PSF surgery is unknown. PATIENTS AND METHODS In this randomized, double-blind clinical trial study, the intervention group received a diet with 1.2 g of protein plus high-protein supplement (36 g whey protein), and the control group received a similar diet, except for starch as a placebo from 48 hours before to 1 month after surgery. RESULTS The intervention group showed a significantly higher rate of vertebral fusion compared with the control group (P=0.019). Surgical site infection and pain were significantly lower in the intervention group. A significant difference was found in the wound healing rate in favor of the intervention group. The rates of decrease in serum high-sensitivity C-reactive protein levels and increase in serum levels of insulin-like growth factor 1, albumin, total protein, and alkaline phosphatase were greater in the intervention group than in the control group (P<0.001). CONCLUSIONS Increased protein intake improves vertebral fusion and enhances recovery in patients undergoing PSF. This was the first study to investigate the effect of protein on fusion and healing factors; as a result, further clinical trials are needed to confirm the current results.",2021,The intervention group showed a significantly higher rate of vertebral fusion compared with the control group (P=0.019).,"['patients undergoing PSF', 'After Posterior Spine Fusion Surgery']","['diet with 1.2\u2009g of protein plus high-protein supplement', 'Protein Supplement and Enhanced Recovery', 'Increased protein intake', 'protein supplementation', 'similar diet, except for starch as a placebo', 'Placebo']","['serum high-sensitivity C-reactive protein levels', 'rate of vertebral fusion', 'wound healing rate', 'serum levels of insulin-like growth factor 1, albumin, total protein, and alkaline phosphatase', 'fusion and healing factors', 'Surgical site infection and pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0770246', 'cui_str': 'Protein supplementation'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0332300', 'cui_str': 'Except for'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}, {'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0555903', 'cui_str': 'Total protein measurement'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.236907,The intervention group showed a significantly higher rate of vertebral fusion compared with the control group (P=0.019).,"[{'ForeName': 'Razieh', 'Initials': 'R', 'LastName': 'Khalooeifard', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences Shohada Tajrish Neurosurgical Center of Excellence, Functional Neurosurgery Research Center, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Oraee-Yazdani', 'Affiliation': ''}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Keikhaee', 'Affiliation': ''}, {'ForeName': 'Zahra Vahdat', 'Initials': 'ZV', 'LastName': 'Shariatpanahi', 'Affiliation': ''}]",Clinical spine surgery,['10.1097/BSD.0000000000001222'] 2693,34381126,Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis.,"Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and preventing hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). However, patients often do not receive sacubitril/valsartan because of concerns about hypotension. We examined the feasibility of initiating sacubitril/valsartan at a very low dose (VLD) in potentially intolerant patients with HFrEF and subsequent dose up-titration, treatment persistence and outcomes. We analyzed 206 patients with HFrEF grouped according to starting sacubitril/valsartan dose. The VLD group (n = 106) commenced 25 mg twice daily, and the standard-dose (SD) group (n = 100) started on ≥ 50 mg twice daily. Baseline systolic blood pressure was 103 ± 12 mmHg vs. 119 ± 14 mmHg in the SD group (P < 0.001). The maximal target dose achievement rate was higher in the SD group (27.0% vs 9.4%, p = 0.001) and the VLD group experienced more dose up-titrations and fewer down-titrations than the SD group. The VLD group had a decrease in N-terminal prohormone of brain natriuretic peptide (NT-proBNP) similar to the SD group and a similar increase in left ventricular ejection fraction. There were no significant differences in symptomatic hypotension, worsening renal function, hyperkalemia, cardiovascular mortality, and rehospitalization due to HF between the two groups during follow-up period. In patients considered by the treating physician likely to be intolerant of sacubitril/valsartan, initiation with 25 mg twice daily was generally possible and patients remained in therapy, with similar decreases in NT-proBNP and increases in left ventricular ejection fraction to those observed in patients receiving SD sacubitril/valsartan.",2021,"There were no significant differences in symptomatic hypotension, worsening renal function, hyperkalemia, cardiovascular mortality, and rehospitalization due to HF between the two groups during follow-up period.","['patients with heart failure and reduced ejection fraction (HFrEF', 'potentially intolerant patients with HFrEF and subsequent dose up-titration, treatment persistence and outcomes', '206 patients with HFrEF grouped according to starting sacubitril/valsartan dose']","['enalapril', 'sacubitril/valsartan', 'Sacubitril/valsartan']","['risks of cardiovascular death', 'N-terminal prohormone of brain natriuretic peptide (NT-proBNP', 'maximal target dose achievement rate', 'symptomatic hypotension, worsening renal function, hyperkalemia, cardiovascular mortality, and rehospitalization due to HF', 'NT-proBNP', 'left ventricular ejection fraction', 'Baseline systolic blood pressure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0546816', 'cui_str': 'Persistence'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C4033631', 'cui_str': 'valsartan and sacubitril'}]","[{'cui': 'C0014025', 'cui_str': 'Enalapril'}, {'cui': 'C4033631', 'cui_str': 'valsartan and sacubitril'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0301817', 'cui_str': 'Prohormone'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0020461', 'cui_str': 'Hyperkalemia'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C4274438', 'cui_str': 'Baseline systolic blood pressure'}]",206.0,0.0402881,"There were no significant differences in symptomatic hypotension, worsening renal function, hyperkalemia, cardiovascular mortality, and rehospitalization due to HF between the two groups during follow-up period.","[{'ForeName': 'Hyoeun', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea.'}, {'ForeName': 'Jaewon', 'Initials': 'J', 'LastName': 'Oh', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea.'}, {'ForeName': 'Sanghyup', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea.'}, {'ForeName': 'Jaehyung', 'Initials': 'J', 'LastName': 'Ha', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea.'}, {'ForeName': 'Minjae', 'Initials': 'M', 'LastName': 'Yoon', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea.'}, {'ForeName': 'Kyeong-Hyeon', 'Initials': 'KH', 'LastName': 'Chun', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea.'}, {'ForeName': 'Chan Joo', 'Initials': 'CJ', 'LastName': 'Lee', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea.'}, {'ForeName': 'Sungha', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea.'}, {'ForeName': 'Sang-Hak', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea.'}, {'ForeName': 'Seok-Min', 'Initials': 'SM', 'LastName': 'Kang', 'Affiliation': 'Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Korea. smkang@yuhs.ac.'}]",Scientific reports,['10.1038/s41598-021-95787-w'] 2694,34381108,Differential and shared effects of eicosapentaenoic acid and docosahexaenoic acid on serum metabolome in subjects with chronic inflammation.,"The omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) affect cell function and metabolism, but the differential effects of EPA and DHA are not known. In a randomized, controlled, double-blind, crossover study, we assessed the effects of 10-week supplementation with EPA-only and DHA-only (3 g/d), relative to a 4-week lead-in phase of high oleic acid sunflower oil (3 g/day, defined as baseline), on fasting serum metabolites in 21 subjects (9 men and 12 post-menopausal women) with chronic inflammation and some characteristics of metabolic syndrome. Relative to baseline, EPA significantly lowered the tricarboxylic acid (TCA) cycle intermediates fumarate and α-ketoglutarate and increased glucuronate, UDP-glucuronate, and non-esterified DHA. DHA significantly lowered the TCA cycle intermediates pyruvate, citrate, isocitrate, fumarate, α-ketoglutarate, and malate, and increased succinate and glucuronate. Pathway analysis showed that both EPA and DHA significantly affected the TCA cycle, the interconversion of pentose and glucuronate, and alanine, and aspartate and glutamate pathways (FDR < 0.05) and that DHA had a significantly greater effect on the TCA cycle than EPA. Our results indicate that EPA and DHA exhibit both common and differential effects on cell metabolism in subjects with chronic inflammation and some key aspects of metabolic syndrome.",2021,"DHA significantly lowered the TCA cycle intermediates pyruvate, citrate, isocitrate, fumarate, α-ketoglutarate, and malate, and increased succinate and glucuronate.","['21 subjects (9 men and 12 post-menopausal women) with chronic inflammation and some characteristics of metabolic syndrome', 'subjects with chronic inflammation']","['eicosapentaenoic acid and docosahexaenoic acid', 'omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA', '10-week supplementation with EPA-only and DHA-only (3\xa0g/d), relative to a 4-week lead-in phase of high oleic acid sunflower oil']","['tricarboxylic acid (TCA) cycle intermediates fumarate and α-ketoglutarate and increased glucuronate, UDP-glucuronate, and non-esterified DHA', 'serum metabolome', 'TCA cycle intermediates pyruvate, citrate, isocitrate, fumarate, α-ketoglutarate, and malate, and increased succinate and glucuronate', 'TCA cycle, the interconversion of pentose and glucuronate, and alanine, and aspartate and glutamate pathways', 'cell metabolism']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0021376', 'cui_str': 'Chronic inflammation'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}]","[{'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028928', 'cui_str': '9 cis-octadecenoic acid'}, {'cui': 'C0947381', 'cui_str': 'Helianthus annuus'}, {'cui': 'C0028908', 'cui_str': 'Oil'}]","[{'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0016801', 'cui_str': 'Fumarates'}, {'cui': 'C0051395', 'cui_str': 'alpha-ketoglutaric acid'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0017774', 'cui_str': 'Glucosiduronates'}, {'cui': 'C0041986', 'cui_str': 'Uridine diphosphate'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C2350399', 'cui_str': 'Metabolome'}, {'cui': 'C0008858', 'cui_str': 'Krebs cycle pathway'}, {'cui': 'C0034354', 'cui_str': 'Pyruvates'}, {'cui': 'C0008857', 'cui_str': 'Citrates'}, {'cui': 'C0022160', 'cui_str': 'Isocitrates'}, {'cui': 'C0024546', 'cui_str': 'Malates'}, {'cui': 'C0038617', 'cui_str': 'Succinates'}, {'cui': 'C0030894', 'cui_str': 'Pentose'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}, {'cui': 'C0085845', 'cui_str': 'Aspartate'}, {'cui': 'C0017789', 'cui_str': 'Glutamates'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}]",21.0,0.15326,"DHA significantly lowered the TCA cycle intermediates pyruvate, citrate, isocitrate, fumarate, α-ketoglutarate, and malate, and increased succinate and glucuronate.","[{'ForeName': 'Wan-Chi', 'Initials': 'WC', 'LastName': 'Chang', 'Affiliation': 'Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center On Aging, Tufts University, 711 Washington Street, Boston, MA, 02111, USA.'}, {'ForeName': 'Jisun', 'Initials': 'J', 'LastName': 'So', 'Affiliation': 'Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center On Aging, Tufts University, 711 Washington Street, Boston, MA, 02111, USA.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Lamon-Fava', 'Affiliation': 'Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center On Aging, Tufts University, 711 Washington Street, Boston, MA, 02111, USA. stefania.lamon-fava@tufts.edu.'}]",Scientific reports,['10.1038/s41598-021-95590-7'] 2695,34380964,"Comment on ""A Randomised Clinical Trial Evaluating the Efficacy and Quality of Life of Antibiotic Only Treatment of Acute Uncomplicated Appendicitis"".",,2021,,['Acute Uncomplicated Appendicitis'],[],[],"[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}]",[],[],,0.188156,,"[{'ForeName': 'Max A', 'Initials': 'MA', 'LastName': 'Schumm', 'Affiliation': 'Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA Deputy Editor, JAMA.'}, {'ForeName': 'Edward H', 'Initials': 'EH', 'LastName': 'Livingston', 'Affiliation': ''}]",Annals of surgery,['10.1097/SLA.0000000000005144'] 2696,34380963,Effect of Solution-Focused Therapy on Cancer-Related Fatigue in Patients With Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial.,"BACKGROUND Cancer-related fatigue (CRF) has gained increased attention in the past decade but remains difficult to treat. It is a predictor of patients' overall health and quality of life (QoL). Therefore, controlling fatigue is important for patients with cancer. OBJECTIVE The aim of this study was to test the effect of solution-focused therapy (SFT) in reducing CRF and improving QoL in patients with colorectal cancer (CRC) undergoing chemotherapy. METHODS A total of 124 patients with CRC undergoing chemotherapy were recruited and randomized to the SFT group or control group. Cancer-related fatigue was measured with the Cancer Fatigue Scale-Chinese version (CFS-C) at baseline, 3 months, and 6 months. Quality of life was measured with the Quality of Life Instruments for Colorectal Cancer Patients at baseline and 6 months. RESULTS Of 124 patients, 119 (95.9%) were evaluable. The SFT group showed significantly lower Cancer Fatigue Scale-Chinese version scores than the control group in all subscales and the total scores at 3 months (P < .001). At 6 months, the SFT group had significantly lower scores in cognitive fatigue (P < .001) and total fatigue (P = .005). The CRF of the SFT group decreased in the first 3 months (P = .012) but increased at 6 months (P < .001). The SFT group had significantly higher scores in the physical and psychological domains and overall QoL (P = .002, P <.001, and P = .02) than the control group at 6 months. CONCLUSION Solution-focused therapy may decrease the CRF and improve QoL during chemotherapy for patients with CRC. IMPLICATION FOR PRACTICE Solution-focused therapy can be implemented to relieve fatigue and improve QoL in patients with CRC.",2021,"The SFT group had significantly higher scores in the physical and psychological domains and overall QoL (P = .002, P <.001, and P = .02) than the control group at 6 months. ","['Patients', 'patients with colorectal cancer (CRC) undergoing chemotherapy', 'Of 124 patients, 119 (95.9%) were evaluable', '124 patients with CRC undergoing chemotherapy', 'patients with CRC', 'Cancer-related fatigue (CRF', 'patients with cancer']","['Chemotherapy', 'SFT', 'solution-focused therapy (SFT', 'Solution-Focused Therapy']","['Cancer Fatigue Scale-Chinese version (CFS-C', 'physical and psychological domains and overall QoL', 'Quality of life', 'cognitive fatigue', 'Cancer-Related Fatigue', 'Cancer Fatigue Scale-Chinese version scores', 'Cancer-related fatigue', 'CRF and improve QoL', 'total fatigue', 'Quality of Life Instruments', 'overall health and quality of life (QoL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C4274302', 'cui_str': 'Cancer-related fatigue'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}]","[{'cui': 'C1332836', 'cui_str': 'Cancer fatigue'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C4274302', 'cui_str': 'Cancer-related fatigue'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",124.0,0.230027,"The SFT group had significantly higher scores in the physical and psychological domains and overall QoL (P = .002, P <.001, and P = .02) than the control group at 6 months. ","[{'ForeName': 'Xuemei', 'Initials': 'X', 'LastName': 'Xian', 'Affiliation': 'Author Affiliations: Department of Colorectal Surgery (Dr Xian, Dr Chen, and Ms Huang) and Department of Nursing (Ms Zhu and Ms Xiang), Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Chenping', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Yilin', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Binbin', 'Initials': 'B', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Weilan', 'Initials': 'W', 'LastName': 'Xiang', 'Affiliation': ''}]",Cancer nursing,['10.1097/NCC.0000000000000994'] 2697,34380945,The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus 2: Part 6.,,2021,,[],[],[],[],[],[],,0.216462,,"[{'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Frishman', 'Affiliation': 'Departments of Medicine and Cardiology, New York Medical College/Westchester Medical Center, Valhalla, NY.'}]",Cardiology in review,['10.1097/CRD.0000000000000411'] 2698,34380871,Characteristics of patients who underwent gastric electrical stimulation vs. surgical pyloric interventions for refractory gastroparesis.,"Background There has been recent debate comparing the efficacy of gastric electrical stimulation (GES) with pyloric intervention, but medical literature lacks clear indications for when to perform GES or pyloric intervention. This study aims to assess the effect of sociodemographic factors and hospital characteristics on the surgical technique chosen for the treatment of gastroparesis. Methods Data was extracted from the National Inpatient Sample between the years 2012 and 2014, using any discharge diagnosis of gastroparesis. For comparison of analysis between GES and pyloric surgical intervention, pyloroplasty, endoscopic pyloric dilation, and pyloromyotomy were considered to be pyloric interventions. The study population was divided into two groups, one which received GES and the other receiving pyloric intervention, to compare socioeconomic factors and hospital characteristics. Results In total, 737,930 hospitalizations had a discharge diagnosis of gastroparesis between 2012 and 2014. On weighted multivariant analysis of patients undergoing GES or pyloric intervention for gastroparesis, being female (odds ratio (OR) 1.49, 95% confidence interval (CI) 1.25-1.78; P < 0.001), being Hispanic (OR 1.75, 95%CI; P < 0.001), being in urban teaching (OR 1.41, 95%CI 1.15-1.72; P < 0.001), and nonteaching hospitals (OR 2.93, 95%CI 2.4-3.58; P < 0.001), early satiety (OR 6.70, 95%CI 1.54-31.25; P = 0.01), and diabetes mellitus (OR 2.14, 95%CI 1.78-2.56; P < 0.001) were each statistically significantly correlated with receiving GES intervention compared to pyloric intervention. Conclusion The racial difference, payer source, and hospital location affected the surgical intervention (GES or pyloric intervention) that patients with gastroparesis would receive.",2021,"The racial difference, payer source, and hospital location affected the surgical intervention (GES or pyloric intervention) that patients with gastroparesis would receive.","['National Inpatient Sample between the years 2012 and 2014, using any discharge diagnosis of gastroparesis', 'In total, 737,930 hospitalizations had a discharge diagnosis of gastroparesis between 2012 and 2014']","['GES intervention', 'gastric electrical stimulation (GES) with pyloric intervention', 'gastric electrical stimulation vs. surgical pyloric interventions', 'GES or pyloric intervention', 'GES and the other receiving pyloric intervention']","['diabetes mellitus', 'early satiety']","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]","[{'cui': 'C4761037', 'cui_str': 'Gastric electrical stimulation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0034196', 'cui_str': 'Pyloric structure of stomach'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0239233', 'cui_str': 'Early satiety'}]",737930.0,0.10884,"The racial difference, payer source, and hospital location affected the surgical intervention (GES or pyloric intervention) that patients with gastroparesis would receive.","[{'ForeName': 'Saad', 'Initials': 'S', 'LastName': 'Saleem', 'Affiliation': 'Department of Internal Medicine, Sunrise Hospital and Medical Center, Las Vegas, NV, United States.'}, {'ForeName': 'Azhar', 'Initials': 'A', 'LastName': 'Hussain', 'Affiliation': 'Department of Internal Medicine, SUNY Downstate Medical Center, Brooklyn, NY, United States.'}, {'ForeName': 'Mohd A', 'Initials': 'MA', 'LastName': 'Alsamman', 'Affiliation': 'Department of Gastroenterology, Georgetown University, Washington, D.C, United States.'}, {'ForeName': 'Faisal', 'Initials': 'F', 'LastName': 'Inayat', 'Affiliation': 'Department of Internal Medicine, Allama Iqbal Medical College, Lahore, Pakistan.'}, {'ForeName': 'Jasndeep', 'Initials': 'J', 'LastName': 'Kaler', 'Affiliation': 'Department of Internal Medicine, Xavier University School of Medicine, Oranjestad, Aruba.'}, {'ForeName': 'Aylin', 'Initials': 'A', 'LastName': 'Tansel', 'Affiliation': 'Department of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.'}, {'ForeName': 'Abell L', 'Initials': 'AL', 'LastName': 'Thomas', 'Affiliation': 'Department of Gastroenterology, University of Louisville, KY, United States.'}]",Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association,['10.4103/sjg.sjg_673_20'] 2699,34380796,Vaginal & gut microbiota diversity in pregnant women with bacterial vaginosis & effect of oral probiotics: An exploratory study.,"Background & objectives The vaginal microbiota undergoes subtle changes during pregnancy and may affect several aspects of pregnancy outcomes. There has been no comprehensive study characterizing the gestational vaginal and gut microbiota and the dynamics of the microbiota with oral probiotics among Indian women. Hence, the study was aimed to explore the microbiota of pregnant women with normal microbiota and bacterial vaginosis (BV) environments and the effect of oral probiotics on the microbiota and the BV status in these women. Methods Using high-throughput Illumina-MiSeq sequencing approach, the 16S rRNA gene amplicons were analyzed and the vaginal and gut microbiota of pregnant women with and without BV and pre- and post-probiotics (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) intervention for a month was characterized. Results The study revealed a compositional difference in the vaginal and gut microbiota between BV and healthy pregnant women. The vaginal microbiota of healthy women was characteristically predominated by Lactobacillus helveticus, followed by L. iners and L. gasseri; in contrast, women positive for BV harboured higher α-diversity and had lower abundance of L. helveticus. Similarly, Prevotella copri, a gut microbe, associated with normal environment was detected in the vaginal samples of all pregnant women without BV, it remained undetected in women with the infection, while all women with BV had Gardnerella vaginalis, which decreased significantly with probiotic treatment. Gut microbiota also revealed dominant abundance of P. copri in healthy women, whereas it was significantly lower in women with BV. The bacterial clade, P. copri abundance increased from 9.17 to 16.49 per cent in the probiotic group and reduced from 7.75 to 4.84 per cent in the placebo group. Interpretation & conclusions This study showed gestational vaginal and gut microbiota differences in normal and BV environments. With probiotic treatment, the dynamics of L. helveticus and P. copri hint towards a possible role of probiotics in modulating the vaginal microbiota.",2021,"The bacterial clade, P. copri abundance increased from 9.17 to 16.49 per cent in the probiotic group and reduced from 7.75 to 4.84 per cent in the placebo group. ","['healthy women', 'BV and healthy pregnant women', 'pregnant women with bacterial vaginosis', 'Indian women', 'pregnant women with normal microbiota and bacterial vaginosis (BV) environments']","['placebo', 'oral probiotics']","['gestational vaginal and gut microbiota differences', 'vaginal microbiota', 'bacterial clade, P. copri abundance']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085166', 'cui_str': 'Bacterial vaginosis'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}]","[{'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}]",,0.0416314,"The bacterial clade, P. copri abundance increased from 9.17 to 16.49 per cent in the probiotic group and reduced from 7.75 to 4.84 per cent in the placebo group. ","[{'ForeName': 'Donugama', 'Initials': 'D', 'LastName': 'Vasundhara', 'Affiliation': 'Department of Clinical Epidemiology, ICMR-National Institute of Nutrition, Hyderabad, Telangana, India.'}, {'ForeName': 'Vankudavath Naik', 'Initials': 'VN', 'LastName': 'Raju', 'Affiliation': 'Nutrition Information, Communication & Health Education (NICHE), ICMR-National Institute of Nutrition, Hyderabad, Telangana, India.'}, {'ForeName': 'Rajkumar', 'Initials': 'R', 'LastName': 'Hemalatha', 'Affiliation': 'ICMR-National Institute of Nutrition, Hyderabad, Telangana, India.'}, {'ForeName': 'Ravinder', 'Initials': 'R', 'LastName': 'Nagpal', 'Affiliation': 'Department of Internal Medicine-Molecular Medicine; Department of Microbiology & Immunology, Wake Forest, School of Medicine, Winston-Salem, NC, United States.'}, {'ForeName': 'Manoj', 'Initials': 'M', 'LastName': 'Kumar', 'Affiliation': 'Department of Microbiology, ICMR-National Institute for Research in Environmental Health, Bhopal, Madhya Pradesh, India.'}]",The Indian journal of medical research,['10.4103/ijmr.IJMR_350_19'] 2700,34380793,"Impact of long-term doxycycline on lung function & exacerbations: A real-world open, prospective pilot observation on chronic obstructive pulmonary disease.","Background & objectives Upregulation of matrix metalloproteinases (MMPs) is related to the pathogenesis of chronic obstructive pulmonary disease (COPD). We aimed at assessing the tolerability and impact of long-term use of MMP inhibitor doxycycline in COPD. Methods A cohort of COPD patients was randomized to continue a uniform COPD treatment with or without add-on long-term oral doxycycline. The lung exacerbations (spirometry), adverse events and health status (COPD Assessment Test score) were noted at 3, 6, 9 and 12 months of therapy. Measurement of the serum MMP-2, and 9 and high-sensitive C-reactive protein (hs-CRP) levels was done at the start of the study and at three months, whenever possible. Results There were 27, 19, 13 and 10 patients with add-on doxycycline group and 22, 19, 11 and 7 patients with COPD treatment alone at 3, 6, 9 and 12 months of treatment respectively. The improvement was obvious and mostly (at 6 and 12 months) significant (P >0.05) for lung function parameters [forced expiratory volume in one second (FEV 1 ), FEV 1 /forced vital capacity (FVC) and forced expiratory flow at 25-75% of FVC (FEF 25-75 )] and universal for health status at all measurements, with an overall 26.69 per cent reduction in exacerbations. The analysis with the lung function changes in the available population with protocol violation also supported the same trend. The concomitant reduction in serum MMP-9 (P =0.01), MMP-2 (P =0.01) and hs-CRP (P =0.0001) levels (n=21) at three months was also significant. The adverse reactions with add-on doxycycline appeared acceptable. Interpretation & conclusions Long-term doxycycline appears well tolerated and seems to improve lung function, health status and exacerbations in COPD. The claim needs further scientific validations.",2021,"The concomitant reduction in serum MMP-9 (P =0.01), MMP-2 (P =0.01) and hs-CRP (P","['chronic obstructive pulmonary disease', 'A cohort of COPD patients', 'chronic obstructive pulmonary disease (COPD', 'lung function & exacerbations']","['MMP inhibitor doxycycline', 'doxycycline', 'long-term doxycycline', 'COPD treatment with or without add-on long-term oral doxycycline', 'matrix metalloproteinases (MMPs']","['lung function, health status and exacerbations', 'lung exacerbations (spirometry), adverse events and health status (COPD Assessment Test score', 'lung function parameters [forced expiratory volume in one second (FEV 1 ), FEV 1 /forced vital capacity (FVC) and forced expiratory flow', 'serum MMP-9', 'MMP-2', 'universal for health status', 'adverse reactions', 'serum MMP-2, and 9 and high-sensitive C-reactive protein (hs-CRP) levels']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}]","[{'cui': 'C1513016', 'cui_str': 'MMP Inhibitors'}, {'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}]","[{'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2960692', 'cui_str': 'Chronic obstructive pulmonary disease assessment test score'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0042834', 'cui_str': 'Vital capacity'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C3804964', 'cui_str': 'Forced expiratory flow'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0165519', 'cui_str': 'Gelatinase B'}, {'cui': 'C0172537', 'cui_str': 'Gelatinase A'}, {'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.154437,"The concomitant reduction in serum MMP-9 (P =0.01), MMP-2 (P =0.01) and hs-CRP (P","[{'ForeName': 'Parthasarathi', 'Initials': 'P', 'LastName': 'Bhattacharyya', 'Affiliation': 'Department of Pulmonology, Institute of Pulmocare & Research, Kolkata, West Bengal, India.'}, {'ForeName': 'Brajesh', 'Initials': 'B', 'LastName': 'Singh', 'Affiliation': 'Department of Biochemistry, Command Hospital, Kolkata, West Bengal, India.'}, {'ForeName': 'Surita', 'Initials': 'S', 'LastName': 'Sarkar', 'Affiliation': 'Department of Applied Physics, University of Calcutta, Kolkata, West Bengal, India.'}, {'ForeName': 'Soumen Kumar', 'Initials': 'SK', 'LastName': 'Das', 'Affiliation': 'Department of Pulmonology, Institute of Pulmocare & Research, Kolkata, West Bengal, India.'}, {'ForeName': 'Bodhisattwa', 'Initials': 'B', 'LastName': 'Chakraborty', 'Affiliation': 'Department of Pulmonology, Institute of Pulmocare & Research, Kolkata, West Bengal, India.'}, {'ForeName': 'Dipanjan', 'Initials': 'D', 'LastName': 'Saha', 'Affiliation': 'Department of Pulmonology, Institute of Pulmocare & Research, Kolkata, West Bengal, India.'}, {'ForeName': 'Kumar', 'Initials': 'K', 'LastName': 'Chakraborty', 'Affiliation': 'Department of General Medicine, Fortis Medical Centre, Sarat Bose Road, Kolkata, West Bengal, India.'}, {'ForeName': 'Indranil', 'Initials': 'I', 'LastName': 'Saha', 'Affiliation': 'Department of Community Medicine, ESI PGIMSR & ESIC Medical College, Kolkata, West Bengal, India.'}, {'ForeName': 'Koel', 'Initials': 'K', 'LastName': 'Chaudhury', 'Affiliation': 'School of Medical Science & Technology, Indian Institute of Technology, Kharagpur, West Bengal, India.'}]",The Indian journal of medical research,['10.4103/ijmr.IJMR_1254_18'] 2701,34380790,"Comparison of efficacy, safety & satisfaction of intermittent versus continuous phototherapy in hyperbilirubinaemic newborns ≥35 week gestation: A randomized controlled trial.","Background & objectives Phototherapy (PT) has become the standard of care for treating neonatal jaundice. This study was aimed to find out if intermittent PT (IPT) results in comparable rate of fall of bilirubin level to continuous PT (CPT) and results in lesser side effects and better acceptance. Methods In this non-inferiority trial, 174 neonates ≥35 wk gestation and >2000 g with jaundice requiring PT were randomized to receive either IPT (one hour on and two hours off) or CPT (with minimum interruptions for feeding) after device stratification [light-emitting diode (LED) or compact fluorescent light (CFL)]. Bilirubin was checked 12 th hourly, and calcium, vitamin D and nitric oxide (NO) levels were analyzed along with the clinical side effects and nursing and maternal satisfaction scores (CTRI Registration No. CTRI/2018/01/011072). Results The rate of fall of bilirubin was similar in both the CPT and IPT groups [0.16 (0.10, 0.22) vs. 0.13 (0.09, 0.20) mg/dl/h, P=0.22]. The median difference with 95 per cent confidence interval of 0.03 (0.03, 0.03) mg/dl was also within the pre-defined inferiority limits. There was no significant change in the duration of PT and side effects such as fall in calcium levels, rise in vitamin D and NO levels or the clinical side effects. Maternal satisfaction favoured the IPT group, but the nurses opined that IPT was difficult to implement. Subgroup analysis for PT devices used showed that efficacy of both CFL and LED devices was equivalent. Interpretation & conclusions IPT was non-inferior to CPT in reducing bilirubin levels in ≥35 wk neonates, irrespective of device used, and also mothers reported better satisfaction with IPT. Although IPT appears promising, CPT does not increase clinical and biochemical side effects compared to IPT.",2021,"There was no significant change in the duration of PT and side effects such as fall in calcium levels, rise in vitamin D and NO levels or the clinical side effects.","['174 neonates ≥35 wk gestation and >2000', 'g with jaundice requiring PT', 'hyperbilirubinaemic newborns ≥35 week gestation']","['intermittent PT (IPT', 'Phototherapy (PT', 'continuous phototherapy', 'IPT', 'CPT (with minimum interruptions for feeding) after device stratification [light-emitting diode (LED) or compact fluorescent light (CFL']","['calcium, vitamin D and nitric oxide (NO) levels', 'rate of fall of bilirubin', 'rate of fall of bilirubin level to continuous PT (CPT', 'Maternal satisfaction', 'bilirubin levels', 'clinical side effects and nursing and maternal satisfaction scores (CTRI Registration No. CTRI/2018/01/011072', 'Bilirubin', 'efficacy, safety & satisfaction', 'duration of PT and side effects such as fall in calcium levels, rise in vitamin D and NO levels or the clinical side effects']","[{'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0022346', 'cui_str': 'Jaundice'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C2585564', 'cui_str': 'Intermittent phototherapy'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0162676', 'cui_str': 'Enzyme-multiplied immunoassay technique'}, {'cui': 'C0303920', 'cui_str': 'Fluorescent stain'}]","[{'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0201925', 'cui_str': 'Calcium measurement'}, {'cui': 'C0035853', 'cui_str': 'Rose'}]",174.0,0.145742,"There was no significant change in the duration of PT and side effects such as fall in calcium levels, rise in vitamin D and NO levels or the clinical side effects.","[{'ForeName': 'Sasi Bhushan', 'Initials': 'SB', 'LastName': 'Gottimukkala', 'Affiliation': 'Department of Neonatology, Chettinad Hospital & Research Institute, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Giridhar', 'Initials': 'G', 'LastName': 'Sethuraman', 'Affiliation': 'Department of Neonatology, Chettinad Hospital & Research Institute, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Srinivasan', 'Initials': 'S', 'LastName': 'Kitchanan', 'Affiliation': 'Department of Neonatology, Chettinad Hospital & Research Institute, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Surajit', 'Initials': 'S', 'LastName': 'Pathak', 'Affiliation': 'Department of Allied Health Sciences, Chettinad Hospital & Research Institute, Chennai, Tamil Nadu, India.'}]",The Indian journal of medical research,['10.4103/ijmr.IJMR_2156_18'] 2702,34380725,Efficacy of therapeutic fasting and plant-based diet in patients with rheumatoid arthritis (NutriFast): study protocol for a randomised controlled clinical trial.,"BACKGROUND Previous studies have shown beneficial effects of therapeutic fasting and plant-based dietary interventions on disease activity in patients with rheumatoid arthritis (RA) for a duration of up to 1 year. To date, the effects of such interventions on the gut microbiome and on modern diagnostic markers in patients with RA have not been studied. This trial aims to investigate the clinical effects of therapeutic fasting and a plant-based diet in patients with RA, additionally considering current immunological diagnostic tools and microbiome analyses. METHODS/DESIGN This trial is an open-label, single-centre, randomised, controlled, parallel-group clinical trial. We will randomly assign 84 patients with RA under a stable standard therapy to either (1) therapeutic fasting followed by a plant-based dietary intervention or (2) to a conventional nutritional counselling focusing on an anti-inflammatory dietary pattern according to the recommendations of the Deutsche Gesellschaft für Ernährung (German society for nutrition). Primary outcome parameter is the group difference from baseline to 12 weeks on the Health Assessment Questionnaire (HAQ). Other secondary outcomes include established clinical criteria for disease activity and treatment response in RA (Disease Activity Score 28, Simple Disease Activity Index, ACR-Response Criteria), changes in self-reported health and physical functional ability, mood, stress, quality of life, dietary behaviour via 3-day food records and a modified Food Frequency Questionnaire, body composition, changes in the gut microbiome, metabolomics and cytometric parameters. Outcomes will be assessed at baseline and day 7, after 6 weeks, 12 weeks and after 6 months. ETHICS AND DISSEMINATION Ethical approval to process and analyse data, and to publish the results was obtained through the institutional review board of Charité-Universitätsmedizin Berlin. Results of this trial will be disseminated through peer-reviewed publications and scientific presentations. TRIAL REGISTRATION NUMBER NCT03856190.",2021,"To date, the effects of such interventions on the gut microbiome and on modern diagnostic markers in patients with RA have not been studied.","['patients with rheumatoid arthritis (NutriFast', '84 patients with RA under a', 'patients with rheumatoid arthritis (RA', 'patients with RA']","['therapeutic fasting and plant-based dietary interventions', 'stable standard therapy to either (1) therapeutic fasting followed by a plant-based dietary intervention or (2) to a conventional nutritional counselling focusing on an anti-inflammatory dietary pattern according to the recommendations of the Deutsche Gesellschaft für Ernährung (German society for nutrition', 'therapeutic fasting and a plant-based diet', 'therapeutic fasting and plant-based diet']","['Health Assessment Questionnaire (HAQ', 'established clinical criteria for disease activity and treatment response in RA (Disease Activity Score 28, Simple Disease Activity Index, ACR-Response Criteria), changes in self-reported health and physical functional ability, mood, stress, quality of life, dietary behaviour via 3-day food records and a modified Food Frequency Questionnaire, body composition, changes in the gut microbiome, metabolomics and cytometric parameters']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C5197846', 'cui_str': 'Diet, Plant-Based'}]","[{'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",84.0,0.211424,"To date, the effects of such interventions on the gut microbiome and on modern diagnostic markers in patients with RA have not been studied.","[{'ForeName': 'Anika M', 'Initials': 'AM', 'LastName': 'Hartmann', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany anika.hartmann@charite.de.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': ""Dell'Oro"", 'Affiliation': 'Department of Internal and Integrative Medicine, Immanuel Hospital Berlin-Wannsee Branch, Berlin, Germany.'}, {'ForeName': 'Christian S', 'Initials': 'CS', 'LastName': 'Kessler', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Dania', 'Initials': 'D', 'LastName': 'Schumann', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Nico', 'Initials': 'N', 'LastName': 'Steckhan', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jeitler', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Jan Moritz', 'Initials': 'JM', 'LastName': 'Fischer', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Spoo', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Martin A', 'Initials': 'MA', 'LastName': 'Kriegel', 'Affiliation': 'Institute for Musculoskeletal Medicine, Department of Translational Rheumatology and Immunology, University of Münster, Münster, Germany.'}, {'ForeName': 'Jochen G', 'Initials': 'JG', 'LastName': 'Schneider', 'Affiliation': 'Department of Internal Medicine II, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Häupl', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Farid I', 'Initials': 'FI', 'LastName': 'Kandil', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Michalsen', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Daniela A', 'Initials': 'DA', 'LastName': 'Koppold-Liebscher', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.'}]",BMJ open,['10.1136/bmjopen-2020-047758'] 2703,34380637,Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine vs Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.,"PURPOSE Neratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C versus lapatinib + capecitabine (L+C) in 621 patients with HER2+ metastatic breast cancer (MBC) who had received {greater than or equal to}2 prior HER2-directed regimens in the metastatic setting. We evaluated correlations between exploratory biomarkers and PFS. EXPERIMENTAL DESIGN Somatic mutations were evaluated by next-generation sequencing on primary or metastatic samples. HER2 protein expression was evaluated by central immunohistochemistry (IHC), H-score, and VeraTag/HERmark. p95 expression (truncated HER2) was measured by VeraTag. Hazard ratios (HRs) were estimated using unstratified Cox proportional hazards models. RESULTS 420 samples had successful sequencing: 34.0% had PIK3CA mutations and 5.5% had HER2 (ERBB2) mutations. In the combined patient populations, PIK3CA mutations trended towards shorter PFS (wild-type vs. mutant, HR [95% CI]: 0.81 0.64-1.03]), whereas HER2 mutations trended towards longer PFS (HR=1.69 [0.97-3.29]). Higher HER2 protein expression was associated with longer PFS (IHC 3+ vs. 2+, HR=0.67 [0.54-0.82]; H-score {greater than or equal to}240 vs. <240, HR=0.77 [0.63-0.93]; HERmark - positive vs. - negative, HR=0.76 [0.59-0.98]). Patients whose tumors had higher HER2 protein expression (any method) derived an increased benefit from N+C versus L+C (IHC=3+, HR=0.64 [0.51-0.81]; H-score {greater than or equal to}240, HR=0.54 [0.41-0.72]; HERmark-positive, HR=0.65 [0.50-0.84]), as did patients with high p95 (HR [95% CI]: p95 {greater than or equal to}2.8 RF/mm 2 , HR=0.66 [0.50-0.86] vs. p95 <2.8, HR=0.91 [0.61-1.36]). CONCLUSION PIK3CA mutations were associated with shorter PFS whereas higher HER2 expression was associated with longer PFS. Higher HER2 protein expression was also associated with a greater benefit for N+C versus L+C.",2021,"Patients whose tumors had higher HER2 protein expression (any method) derived an increased benefit from N+C versus L+C (IHC=3+, HR=0.64 [0.51-0.81]; H-score {greater than or equal to}240, HR=0.54 [0.41-0.72]; HERmark-positive, HR=0.65 [0.50-0.84]), as did patients with high p95 (HR [95% CI]: p95 {greater than or equal to}2.8 RF/mm 2 , HR=0.66 [0.50-0.86] vs. p95","['Somatic mutations were evaluated by next-generation sequencing on primary or metastatic samples', 'Patients with Previously Treated Metastatic Breast Cancer', '621 patients with HER2+ metastatic breast cancer (MBC) who had received {greater than or equal to}2 prior HER2-directed regimens in the metastatic setting']","['capecitabine', 'Neratinib + Capecitabine vs Lapatinib + Capecitabine', 'N+C versus lapatinib + capecitabine (L+C', 'N+C versus L+C']","['central immunohistochemistry (IHC), H-score, and VeraTag/HERmark', 'HER2 protein expression', 'Hazard ratios (HRs', 'PFS', 'Higher HER2 protein expression', 'progression-free survival (PFS) benefit', 'p95 expression (truncated HER2']","[{'cui': 'C0544886', 'cui_str': 'Somatic mutation'}, {'cui': 'C2936621', 'cui_str': 'Next-Generation Sequencing'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0439091', 'cui_str': '>='}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C2713008', 'cui_str': 'neratinib'}, {'cui': 'C1506770', 'cui_str': 'lapatinib'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0205250', 'cui_str': 'High'}]",621.0,0.0454843,"Patients whose tumors had higher HER2 protein expression (any method) derived an increased benefit from N+C versus L+C (IHC=3+, HR=0.64 [0.51-0.81]; H-score {greater than or equal to}240, HR=0.54 [0.41-0.72]; HERmark-positive, HR=0.65 [0.50-0.84]), as did patients with high p95 (HR [95% CI]: p95 {greater than or equal to}2.8 RF/mm 2 , HR=0.66 [0.50-0.86] vs. p95","[{'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Saura', 'Affiliation': ""Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Medical Oncology Department; SOLTI Breast Cancer Research Group csaura@vhio.net.""}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Matito', 'Affiliation': ""Genomics Cancer Group, Vall d'Hebron Institut d'Oncologia (VHIO).""}, {'ForeName': 'Mafalda', 'Initials': 'M', 'LastName': 'Oliveira', 'Affiliation': ""Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO).""}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Wildiers', 'Affiliation': 'Multidisciplinary Breast Center, University Hospitals Leuven.'}, {'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Brufksy', 'Affiliation': 'UPMC Hillman Cancer Center.'}, {'ForeName': 'Simon H', 'Initials': 'SH', 'LastName': 'Waters', 'Affiliation': 'Medical Directorate, Velindre Cancer Centre.'}, {'ForeName': 'Sara A', 'Initials': 'SA', 'LastName': 'Hurvitz', 'Affiliation': 'David Geffen School of Medicine Division of Hematology-Oncology, University of California, Los Angeles.'}, {'ForeName': 'Beverly', 'Initials': 'B', 'LastName': 'Moy', 'Affiliation': 'Cancer Center, Massachusetts General Hospital.'}, {'ForeName': 'Sung-Bae', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'University of Ulsan College of Medicine, Seoul.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Gradishar', 'Affiliation': 'Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago.'}, {'ForeName': 'Geraldo Silva', 'Initials': 'GS', 'LastName': 'Queiroz', 'Affiliation': 'Hospital Araújo Jorge, Goiânia.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Cronemberger', 'Affiliation': 'Clinical Research Dpt., Centro Regional Integrado de Oncologia, Fortaleza.'}, {'ForeName': 'Gerald J', 'Initials': 'GJ', 'LastName': 'Wallweber', 'Affiliation': 'R&D, LabCorp (United States).'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Bebchuk', 'Affiliation': 'Puma Biotechnology Inc.'}, {'ForeName': 'Kiana', 'Initials': 'K', 'LastName': 'Keyvanjah', 'Affiliation': 'Medical Director Early Development, Amgen Inc.'}, {'ForeName': 'Alshad S', 'Initials': 'AS', 'LastName': 'Lalani', 'Affiliation': 'Translational Medicine, Puma Biotechnology, Inc.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Bryce', 'Affiliation': 'Clinical Development, Rain Therapeutics Inc.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Vivancos', 'Affiliation': ""Cancer Genomic Group, Vall d'Hebron Institute of Oncology (VHIO).""}, {'ForeName': 'Lisa D', 'Initials': 'LD', 'LastName': 'Eli', 'Affiliation': 'Translational Medicine and Diagnostics, Puma Biotechnology Inc.'}, {'ForeName': 'Suzette', 'Initials': 'S', 'LastName': 'Delaloge', 'Affiliation': 'Breast Cancer Group and High-Risk Clinic, Institut Gustave Roussy.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-21-1584'] 2704,34380636,Prognostic and predictive value of HER2 expression in ductal carcinoma in situ : Results from the UK/ANZ DCIS randomized trial.,"PURPOSE HER2 is overexpressed more frequently in ductal carcinoma in situ (DCIS) than in invasive breast cancer but its prognostic significance and predictive role for radiotherapy has not been clearly established. We investigated the prognostic and predictive value of HER2 overexpression in DCIS. EXPERIMENTAL DESIGN HER2 expression was evaluated by immunohistochemistry (IHC) using the HercepTest{trade mark, serif} in samples from UK/ANZ DCIS trial participants (n=755) with IHC3+ expression categorized as HER2-positive for primary analyses. Sensitivity analyses included HER2 categorisation as negative (IHC0,1+), equivocal (IHC2+) and positive (IHC3+) and analyses restricted to a nested case-control component where 181 cases (with recurrence) were matched to 362 controls by treatment arm and age. RESULTS Two-hundred and forty-five (34.4%) of evaluable 713 samples [181 ipsilateral breast events (IBE)] were HER2-positive. HER2 overexpression was associated with significantly increased risk of IBE [Hazard ratio (HR)=2.29; 95% Confidence Interval (95%CI) 1.64-3.14; P< 0.0001] and in situ IBE (DCIS-IBE) [HR=2.90; 95%CI, 1.91-4.40; p< 0.0001] but not of invasive IBE (I-IBE) [HR=1.40; 95%CI, 0.81-2.42; P= 0.23], P heterogeneity = 0.04. Inclusion of HER2 significantly improved [Δχ 2 (1d.f.) 12.25; P= 0.0005] a prognostic model of clinicopathological and treatment variables, HER2 being an independent predictor of IBE [multivariate HR=1.91; 95%CI, 1.33-2.76; P= 0.0004]. Radiotherapy benefit in preventing DCIS-IBE was significantly greater ( P heterogeneity = 0.04) in HER2-positive DCIS (HR=0.16; 95% CI, 0.07-0.41) compared with HER2-negative DCIS (HR=0.58; 95%CI, 0.28-1.19). CONCLUSIONS HER2 overexpression is associated with significantly increased risk of in situ recurrence and is also predictive of radiotherapy benefit, with greater reductions in in situ but not invasive recurrences in HER2-positive DCIS.",2021,Radiotherapy benefit in preventing DCIS-IBE was significantly greater ( P heterogeneity = 0.04) in HER2-positive DCIS,['ductal carcinoma in situ '],"['UK', 'Radiotherapy']","['risk of IBE [Hazard ratio', 'HER2 categorisation as negative (IHC0,1+), equivocal (IHC2+) and positive (IHC3', 'HER2-positive DCIS', 'invasive IBE', 'DCIS-IBE']","[{'cui': 'C0007124', 'cui_str': 'Intraductal carcinoma, noninfiltrating'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0332241', 'cui_str': 'Equivocal'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0007124', 'cui_str': 'Intraductal carcinoma, noninfiltrating'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}]",755.0,0.0983754,Radiotherapy benefit in preventing DCIS-IBE was significantly greater ( P heterogeneity = 0.04) in HER2-positive DCIS,"[{'ForeName': 'Mangesh A', 'Initials': 'MA', 'LastName': 'Thorat', 'Affiliation': 'Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London thoratmangesh@gmail.com.'}, {'ForeName': 'Pauline M', 'Initials': 'PM', 'LastName': 'Levey', 'Affiliation': 'Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London.'}, {'ForeName': 'J Louise', 'Initials': 'JL', 'LastName': 'Jones', 'Affiliation': 'Barts Cancer Institute, Queen Mary University of London.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Pinder', 'Affiliation': ""Department of Research Oncology, King's Health Partners AHSC, Life Sciences and Medicine, King's College London.""}, {'ForeName': 'Nigel J', 'Initials': 'NJ', 'LastName': 'Bundred', 'Affiliation': 'Department of Academic Surgery, Manchester University Foundation Trust.'}, {'ForeName': 'Ian S', 'Initials': 'IS', 'LastName': 'Fentiman', 'Affiliation': ""School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London.""}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Cuzick', 'Affiliation': 'Centre for Cancer Prevention, Queen Mary University of London.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-21-1239'] 2705,34376438,Transmuscular quadratus lumborum block versus oblique subcostal transversus abdominis plane block for analgesia in laparoscopic hysterectomy: a randomised single-blind trial.,"OBJECTIVE The transmuscular quadratus lumborum (TQL) block and the oblique subcostal transversus abdominis plane (OSTAP) block both contribute to multimodal analgesia after laparoscopic surgery. The objective of this study was to compare the analgesic effects of the TQL block versus OSTAP block after laparoscopic hysterectomy. DESIGN Prospective single-centre randomised single-blind trial. SETTING University-affiliated hospital. PARTICIPANTS Patients aged between 18 and 65 years scheduled for laparoscopic hysterectomy. INTERVENTIONS Patients were randomised into two groups (1:1 ratio) and received bilateral TQL block or bilateral OSTAP block with 0.375% ropivacaine 20 mL on each side before surgery. PRIMARY AND SECONDARY OUTCOME MEASURES The primary outcome measure was the cumulative morphine dose in the first 24 hours. The secondary outcome measures were the morphine consumption at each time interval after surgery, the time from the end of surgery to the first need for morphine, the Numerical Rating Scale (NRS) scores for visceral and incisional pain intensity, and the incidence of adverse events. RESULTS The cumulative morphine dose was significantly lower in the TQL group than in the OSTAP group (17.2 (12.5) vs 26.1 (13.3) mg, p=0.010). Compared with the OSTAP group, the morphine doses from 6 to 12, 12 to 18, and 18 to 24 hours were significantly lower, the time of first need for morphine was significantly longer and the NRS scores for visceral pain intensity were significantly lower in the TQL group. CONCLUSION Compared with the OSTAP block, the TQL block reduced morphine consumption and provided better visceral pain relief with a longer duration of effect after laparoscopic hysterectomy. TRIAL REGISTRATION NUMBER Chinese Clinical Trial Registry (ChiCTR1800017995); pre-results.",2021,"Compared with the OSTAP block, the TQL block reduced morphine consumption and provided better visceral pain relief with a longer duration of effect after laparoscopic hysterectomy. ","['University-affiliated hospital', 'Patients aged between 18 and 65 years scheduled for laparoscopic hysterectomy', 'laparoscopic hysterectomy']","['transmuscular quadratus lumborum (TQL) block and the oblique subcostal transversus abdominis plane (OSTAP) block', 'OSTAP', 'bilateral TQL block or bilateral OSTAP block with 0.375% ropivacaine 20\u2009mL on each side before surgery', 'morphine', 'TQL block versus OSTAP block', 'Transmuscular quadratus lumborum block versus oblique subcostal transversus abdominis plane block', 'TQL']","['time of first need for morphine', 'visceral pain relief', 'NRS scores for visceral pain intensity', 'analgesic effects', 'morphine consumption at each time interval after surgery, the time from the end of surgery to the first need for morphine, the Numerical Rating Scale (NRS) scores for visceral and incisional pain intensity, and the incidence of adverse events', 'cumulative morphine dose']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}]","[{'cui': 'C0224380', 'cui_str': 'Structure of quadratus lumborum muscle'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0442184', 'cui_str': 'Subcostal'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C4517455', 'cui_str': '0.375'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0234245', 'cui_str': 'Visceral pain'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]",,0.50051,"Compared with the OSTAP block, the TQL block reduced morphine consumption and provided better visceral pain relief with a longer duration of effect after laparoscopic hysterectomy. ","[{'ForeName': 'Lvdan', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Liangyu', 'Initials': 'L', 'LastName': 'Zheng', 'Affiliation': 'Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Jingxiong', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Xiaona', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Linmin', 'Initials': 'L', 'LastName': 'Pan', 'Affiliation': 'Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Yujian', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Quanguang', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Kejian', 'Initials': 'K', 'LastName': 'Shi', 'Affiliation': 'Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China wzshikejian@163.com.'}]",BMJ open,['10.1136/bmjopen-2020-043883'] 2706,34376401,Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.,"RATIONALE Convalescent plasma (CCP) has been studied as a potential therapy for COVID-19, but data on its efficacy in Africa are limited. OBJECTIVE In this trial we set out to determine the efficacy of CCP for treatment of COVID-19 in Uganda. MEASUREMENTS Patients with a positive SARS-CoV-2 reverse transcriptase (RT)-PCR test irrespective of disease severity were hospitalised and randomised to receive either COVID-19 CCP plus standard of care (SOC) or SOC alone. The primary outcome was time to viral clearance, defined as having two consecutive RT-PCR-negative tests by day 28. Secondary outcomes included time to symptom resolution, clinical status on the modified WHO Ordinal Clinical Scale (≥1-point increase), progression to severe/critical condition (defined as oxygen saturation <93% or needing oxygen), mortality and safety. MAIN RESULTS A total of 136 patients were randomised, 69 to CCP+SOC and 67 to SOC only. The median age was 50 years (IQR: 38.5-62.0), 71.3% were male and the median duration of symptom was 7 days (IQR=4-8). Time to viral clearance was not different between the CCP+SOC and SOC arms (median of 6 days (IQR=4-11) vs 4 (IQR=4-6), p=0.196). There were no statistically significant differences in secondary outcomes in CCP+SOC versus SOC: time to symptom resolution (median=7 (IQR=5-7) vs 7 (IQR=5-10) days, p=0.450), disease progression (9 (22.0%) vs 7 (24.0%) patients, p=0.830) and mortality (10 (14.5%) vs 8 (11.9%) deaths, p=0.476). CONCLUSION In this African trial, CCP therapy did not result in beneficial virological or clinical improvements. Further trials are needed to determine subgroups of patients who may benefit from CCP in Africa. Trial registration number NCT04542941.",2021,"There were no statistically significant differences in secondary outcomes in CCP+SOC versus SOC: time to symptom resolution (median=7 (IQR=5-7) vs 7 (IQR=5-10) days, p=0.450), disease progression (9 (22.0%) vs 7 (24.0%) patients, p=0.830) and mortality (10 (14.5%) vs 8 (11.9%) deaths, p=0.476). ","['COVID-19 in Uganda', 'The median age was 50 years (IQR: 38.5-62.0), 71.3% were male and the median duration of symptom was 7\u2009days (IQR=4-8', 'Patients with a positive SARS-CoV-2 reverse transcriptase (RT)-PCR test irrespective of disease severity were hospitalised', '136 patients were randomised, 69 to CCP+SOC\u2009and 67 to SOC only']","['COVID-19 CCP plus standard of care (SOC) or SOC alone', 'CCP therapy', 'convalescent plasma', 'CCP']","['disease progression', 'time to symptom resolution, clinical status on the modified WHO Ordinal Clinical Scale (≥1-point increase), progression to severe/critical condition (defined as oxygen saturation <93%\u2009or needing oxygen), mortality and safety', 'time to viral clearance, defined as having two consecutive RT-PCR-negative tests', 'mortality', 'secondary outcomes in CCP+SOC\u2009versus SOC: time to symptom resolution', 'Time to viral clearance']","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0035379', 'cui_str': 'RNA-directed DNA polymerase'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0740326', 'cui_str': 'Convalescent'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]","[{'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449440', 'cui_str': 'Clinical status'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]",136.0,0.332482,"There were no statistically significant differences in secondary outcomes in CCP+SOC versus SOC: time to symptom resolution (median=7 (IQR=5-7) vs 7 (IQR=5-10) days, p=0.450), disease progression (9 (22.0%) vs 7 (24.0%) patients, p=0.830) and mortality (10 (14.5%) vs 8 (11.9%) deaths, p=0.476). ","[{'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Kirenga', 'Affiliation': 'Makerere University Lung Institute, Makerere University College of Health Sciences, Kampala, Uganda, Uganda brucekirenga@yahoo.co.uk.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Byakika-Kibwika', 'Affiliation': 'Department of Internal Medicine, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Winters', 'Initials': 'W', 'LastName': 'Muttamba', 'Affiliation': 'Makerere University Lung Institute, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Kayongo', 'Affiliation': 'Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda, Uganda.'}, {'ForeName': 'Namakula Olive', 'Initials': 'NO', 'LastName': 'Loryndah', 'Affiliation': 'Makerere University Lung Institute, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Levicatus', 'Initials': 'L', 'LastName': 'Mugenyi', 'Affiliation': 'Biostatistics Department, The AIDS Support Organisation (TASO), Kampala, Uganda, Uganda.'}, {'ForeName': 'Noah', 'Initials': 'N', 'LastName': 'Kiwanuka', 'Affiliation': 'Department of research, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda, Uganda.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Lusiba', 'Affiliation': 'Clinical services, Uganda Peoples Defense Forces Medical Services, Kampala, Uganda, Uganda.'}, {'ForeName': 'Angella', 'Initials': 'A', 'LastName': 'Atukunda', 'Affiliation': 'Clinical services, Mulago National Referral Hospital, Kampala, Uganda, Kampala, Uganda, Uganda.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Mugume', 'Affiliation': 'Makerere University Lung Institute, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Ssali', 'Affiliation': 'Joint Clinical Research Centre, Kampala, Uganda.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Ddungu', 'Affiliation': 'Research Department, Uganda Cancer Institute, Kampala, Uganda, Uganda.'}, {'ForeName': 'Winceslaus', 'Initials': 'W', 'LastName': 'Katagira', 'Affiliation': 'Makerere University Lung Institute, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Rogers', 'Initials': 'R', 'LastName': 'Sekibira', 'Affiliation': 'Makerere University Lung Institute, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Cissy', 'Initials': 'C', 'LastName': 'Kityo', 'Affiliation': 'Joint Clinical Research Centre, Kampala, Uganda.'}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Kyeyune', 'Affiliation': 'Clinical services, Uganda Blood Transfusion Services, Kampala, Uganda, Uganda.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Acana', 'Affiliation': 'Clinical services, Uganda Blood Transfusion Services, Kampala, Uganda, Uganda.'}, {'ForeName': 'Hellen', 'Initials': 'H', 'LastName': 'Aanyu-Tukamuhebwa', 'Affiliation': 'Clinical services, Mulago National Referral Hospital, Kampala, Uganda, Kampala, Uganda, Uganda.'}, {'ForeName': 'Wilberforce', 'Initials': 'W', 'LastName': 'Kabweru', 'Affiliation': 'Clinical services, Ministry of Health, Kampala, Uganda, Uganda.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Nakwagala', 'Affiliation': 'Clinical services, Mulago National Referral Hospital, Kampala, Uganda, Kampala, Uganda, Uganda.'}, {'ForeName': 'Bernard Sentalo', 'Initials': 'BS', 'LastName': 'Bagaya', 'Affiliation': 'Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda, Uganda.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Kimuli', 'Affiliation': 'Makerere University Lung Institute, Makerere University College of Health Sciences, Kampala, Uganda, Uganda.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Nantanda', 'Affiliation': 'Makerere University Lung Institute, Makerere University College of Health Sciences, Kampala, Uganda, Uganda.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Buregyeya', 'Affiliation': 'Department of research, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda, Uganda.'}, {'ForeName': 'Baterana', 'Initials': 'B', 'LastName': 'Byarugaba', 'Affiliation': 'Clinical services, Mulago National Referral Hospital, Kampala, Uganda, Kampala, Uganda, Uganda.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Olaro', 'Affiliation': 'Clinical services, Ministry of Health, Kampala, Uganda, Uganda.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Mwebesa', 'Affiliation': 'Clinical services, Ministry of Health, Kampala, Uganda, Uganda.'}, {'ForeName': 'Moses Lutaakome', 'Initials': 'ML', 'LastName': 'Joloba', 'Affiliation': 'Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda, Uganda.'}, {'ForeName': 'Trishul', 'Initials': 'T', 'LastName': 'Siddharthan', 'Affiliation': 'Division of Respiratory and Critical Care Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Bazeyo', 'Affiliation': 'Department of research, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda, Uganda.'}]",BMJ open respiratory research,['10.1136/bmjresp-2021-001017'] 2707,33404379,Undermining Credibility: The Limited Influence of Online Comments to Vaccine-related News Stories.,"State-sponsored disinformation campaigns increasingly use anti-vaccine comments to not only undermine public health but to also reduce confidence and participation in a democratic society. Despite these dangers, research has not fully explored whether anti-vaccine comments can achieve these effects. To address this gap, an online survey experiment was conducted using a national sample of 1010 U.S. adults. Participants read a mainstream news article discussing the flu vaccine that included random variations of user comments adapted from a documented state-sponsored disinformation campaign. While exposure to anti-vaccine comments did not affect participants' views of vaccines or their willingness to discuss vaccines, participants holding pro-vaccine views reported lower confidence in news organizations and viewed the journalist who authored their article as less credible. These results suggest that anti-vaccine comments may produce effects that align with the goals of state-sponsored disinformation campaigns.",2020,"While exposure to anti-vaccine comments did not affect participants' views of vaccines or their willingness to discuss vaccines, participants holding pro-vaccine views reported lower confidence in news organizations and viewed the journalist who authored their article as less credible.","['Undermining Credibility', 'national sample of 1010\xa0U.S. adults']",[],[],"[{'cui': 'C1822301', 'cui_str': 'Wound tissue undermining'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],[],,0.133139,"While exposure to anti-vaccine comments did not affect participants' views of vaccines or their willingness to discuss vaccines, participants holding pro-vaccine views reported lower confidence in news organizations and viewed the journalist who authored their article as less credible.","[{'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Dixon', 'Affiliation': 'School of Communication, The Ohio State University, Columbus, Ohio, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1865485'] 2708,32485024,"Microneedle patch based on dissolving, detachable microneedle technology for improved skin quality of the periorbital region. Part 2: Clinical Evaluation.","OBJECTIVE Microneedle patches based on dissolving, detachable microneedle technology (Russian patent No. 2652567; US patent EFS No. 32735812; WO/2019/231360) are novel dermatological products that allow safe, painless and effective reduction of epidermal wrinkles after six procedures. The purpose of this study was two-fold (a) to assess the safety and efficacy of microneedle patches comprising 650 microneedles containing hyaluronic and ferulic acids after 6 procedures of applying the applicator to the skin for 25 min; and (b) to correlate our previously reported ex vivo findings. METHODS The microneedle applicator contains 650 microneedles, which dissolve in 25 min of exposure. The effectiveness of microneedle applicators was confirmed by a randomized split-phase study involving 82 subjects. Applications of microneedle patches were performed at intervals of two times per week, and the effectiveness was assessed at 6 weeks after the start of the study. RESULTS The results of the profilometric evaluation of skin smoothness demonstrated a significant reduction in the average roughness index by 65.32 ± 2.99% and in the mean skin waviness by 66.84 ± 1.6% compared with these indicators in the control group (P < 0.05). The therapeutic effect of the procedure was confirmed by an ultrasound examination that registered a 72.2 ± 5.4% and 25 ± 1.4% increase in echo-density of the epidermis and dermis, respectively. An independent blinded skin evaluation by dermatologists revealed steady decrease in puffiness of the application area in 89.9% of patients, increased elasticity in 78.3% of the patients, and reduced severity of epidermal wrinkles in 89.9% of the patients. CONCLUSIONS The applicator with 650 soluble microneedles on its surface containing hyaluronic and ferulic acids is considered a safe, effective and convenient way to improve the skin quality in the periorbital region after six procedures. Nevertheless, additional studies of soluble microneedles are required to fully assess the amount and distribution area of the injected hyaluronic acid and other active components, as well as to detail the mechanism of action of soluble microneedles to improve skin quality.",2020,The results of the profilometric evaluation of skin smoothness demonstrated a significant reduction in the average roughness index by 65.32 ± 2.99% and in the mean skin waviness by 66.84 ± 1.6% compared with these indicators in the control group (P < 0.05).,['82 subjects'],"['microneedle patches comprising 650 microneedles containing hyaluronic and ferulic acids', 'hyaluronic and ferulic acids']","['safety and efficacy', 'mean skin waviness', 'skin quality', 'average roughness index', 'elasticity', 'severity of epidermal wrinkles']",[],"[{'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C3844101', 'cui_str': '650'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0060291', 'cui_str': 'ferulic acid'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0014520', 'cui_str': 'Epidermis structure'}, {'cui': 'C0037301', 'cui_str': 'Wrinkled skin'}]",82.0,0.0271186,The results of the profilometric evaluation of skin smoothness demonstrated a significant reduction in the average roughness index by 65.32 ± 2.99% and in the mean skin waviness by 66.84 ± 1.6% compared with these indicators in the control group (P < 0.05).,"[{'ForeName': 'V', 'Initials': 'V', 'LastName': 'Zvezdin', 'Affiliation': 'Microneedles Inc., 919 North Market Street, Wilmington, DE, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Kasatkina', 'Affiliation': 'Microneedle Industrial LLC, 1130-42 Bolshoj bulvar, Moscow, Russia.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Kasatkin', 'Affiliation': 'Microneedle Industrial LLC, 1130-42 Bolshoj bulvar, Moscow, Russia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gavrilova', 'Affiliation': 'Medlife LLC, Perm, Russia.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Kazakova', 'Affiliation': 'Medlife LLC, Perm, Russia.'}]",International journal of cosmetic science,['10.1111/ics.12636'] 2709,32291210,Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning.,"Negative symptoms are associated with poor clinical and psychosocial outcome in schizophrenia. Their prevalence and identification in first-episode patients remains controversial. In a large cohort of patients in the early stage of schizophrenia, schizophreniform or schizoaffective disorder, we investigated, over the different phases of the OPTiMiSE trial (baseline, 4, 10 and 22 weeks of treatment), the prevalence of negative symptoms of moderate severity, unconfounded by depression and extrapyramidal symptoms at baseline. Moreover, we assessed symptomatic remission, attrition rate and psychosocial functioning in subjects with short-term (4 weeks) persistent unconfounded negative symptoms (PNS) and in those with negative symptoms that did not persist at follow-up and/or were confounded at baseline (N-PNS). Negative symptoms of moderate severity were observed in 59% of subjects at baseline. They were associated with worse psychosocial functioning and longer duration of psychosis at intake in the study. Eleven percent of subjects had PNS unconfounded at baseline and 7.9% had PNS unconfounded at both baseline and end of 4-week treatment. Psychosocial functioning was comparable in PNS and N-PNS subjects at baseline but it was significantly worse in the former group after 4-weeks. PNS subjects showed lower remission and higher attrition rates at the end of all treatment phases. Fifty-six percent of subjects completing phase 3 (clozapine treatment) had PNS, and 60% of them were non-remitters at the end of this phase. The presence of short-term PNS during the first phases of psychosis was associated with poor clinical outcome and resistance to antipsychotic treatment, including clozapine.",2020,Psychosocial functioning was comparable in PNS and N-PNS subjects at baseline but it was significantly worse in the former group after 4-weeks.,"['patients in the early stage of schizophrenia, schizophreniform or schizoaffective disorder']",['clozapine'],"['worse psychosocial functioning and longer duration of psychosis', 'lower remission and higher attrition rates', 'Negative symptoms of moderate severity', 'symptomatic remission, attrition rate and psychosocial functioning', 'Psychosocial functioning']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0036337', 'cui_str': 'Schizoaffective disorder'}]","[{'cui': 'C0009079', 'cui_str': 'Clozapine'}]","[{'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0439591', 'cui_str': 'Long duration'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}]",,0.153375,Psychosocial functioning was comparable in PNS and N-PNS subjects at baseline but it was significantly worse in the former group after 4-weeks.,"[{'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Bucci', 'Affiliation': 'Department of Psychiatry, University of Campania Luigi Vanvitelli, Largo Madonna delle Grazie, 80138 Naples, Italy. Electronic address: paolabucci456@gmail.com.'}, {'ForeName': 'Armida', 'Initials': 'A', 'LastName': 'Mucci', 'Affiliation': 'Department of Psychiatry, University of Campania Luigi Vanvitelli, Largo Madonna delle Grazie, 80138 Naples, Italy.'}, {'ForeName': 'Inge Winter', 'Initials': 'IW', 'LastName': 'van Rossum', 'Affiliation': 'Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Aiello', 'Affiliation': 'Department of Psychiatry, University of Campania Luigi Vanvitelli, Largo Madonna delle Grazie, 80138 Naples, Italy.'}, {'ForeName': 'Celso', 'Initials': 'C', 'LastName': 'Arango', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.'}, {'ForeName': 'Lone', 'Initials': 'L', 'LastName': 'Baandrup', 'Affiliation': 'Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Center Glostrup, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Buchanan', 'Affiliation': 'Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Dazzan', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, United Kingdom.""}, {'ForeName': 'Arsime', 'Initials': 'A', 'LastName': 'Demjaha', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, United Kingdom.""}, {'ForeName': 'Covadonga M', 'Initials': 'CM', 'LastName': 'Díaz-Caneja', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.'}, {'ForeName': 'Giulia Maria', 'Initials': 'GM', 'LastName': 'Giordano', 'Affiliation': 'Department of Psychiatry, University of Campania Luigi Vanvitelli, Largo Madonna delle Grazie, 80138 Naples, Italy.'}, {'ForeName': 'Birte Y', 'Initials': 'BY', 'LastName': 'Glenthøj', 'Affiliation': 'Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Center Glostrup, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Leucht', 'Affiliation': 'Department of Psychiatry and Psychotherapy, School of Medicine, Technical University Munich, Munich, Germany.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'McGuire', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, United Kingdom.""}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Rodriguez-Jimenez', 'Affiliation': 'Department of Psychiatry, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; CIBERSAM (Biomedical Research Networking Centre in Mental Health), Madrid, Spain.'}, {'ForeName': 'Annarita', 'Initials': 'A', 'LastName': 'Vignapiano', 'Affiliation': 'Department of Psychiatry, University of Campania Luigi Vanvitelli, Largo Madonna delle Grazie, 80138 Naples, Italy.'}, {'ForeName': 'René S', 'Initials': 'RS', 'LastName': 'Kahn', 'Affiliation': 'Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Silvana', 'Initials': 'S', 'LastName': 'Galderisi', 'Affiliation': 'Department of Psychiatry, University of Campania Luigi Vanvitelli, Largo Madonna delle Grazie, 80138 Naples, Italy.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2020.03.010'] 2710,32216168,Reversible obstruction of the olfactory cleft: impact on olfactory perception and nasal patency.,"BACKGROUND Temporary disruption of sensory input can be studied relatively easily for vision or hearing by covering the eyes or ears. In contrast, closing the nostrils affects not only the sense of smell, but also the ability to breathe through the nose and humidify and warm inhaled air. We hypothesized that filling the olfactory cleft (OC) with dissolvable nasal dressing (foam) would temporarily block olfaction while respecting nasal airflow. METHODS In 30 healthy volunteers, the OC was unilaterally obstructed in a back-to-front fashion. Orthonasal and retronasal olfactory function were tested before and after foam application. Ratings of odors and subjective nasal patency (SNP) were collected. Peak nasal inspiratory flow (PNIF) was used to measure nasal patency. RESULTS Foam was safely applied in every case using minimal instruments. No complications were reported. Orthonasal and retronasal test results decreased significantly in overall participants (all p < 0.0008). Indicating temporary anosmia, 3 subjects reached the lowest possible score for odor-threshold testing, with corresponding drops in retronasal test scores. PNIF values before and after foam application were not significantly different (p = 0.11). SNP ratings decreased slightly, but not significantly (p = 0.052). Odor-intensity ratings dropped significantly (all p < 0.05). CONCLUSION The OC can be safely obstructed with dissolvable nasal dressing, resulting in a decrease in odor-intensity and orthonasal and retronasal olfactory function test scores. This procedure may serve as a hyposmia model that maintains normal nasal airflow.",2020,Orthonasal and retronasal test results decreased significantly in overall participants (all p < 0.0008).,['30 healthy volunteers'],['dissolvable nasal dressing (foam'],"['Odor-intensity ratings', 'SNP ratings', 'Peak nasal inspiratory flow (PNIF', 'olfactory perception and nasal patency', 'Orthonasal and retronasal test results', 'PNIF values', 'odor-intensity and orthonasal and retronasal olfactory function test scores', 'Ratings of odors and subjective nasal patency (SNP', 'Orthonasal and retronasal olfactory function']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0991510', 'cui_str': 'Foam'}]","[{'cui': 'C0028884', 'cui_str': 'With odor'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0429205', 'cui_str': 'Nasal peak inspiratory flow'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",30.0,0.0171583,Orthonasal and retronasal test results decreased significantly in overall participants (all p < 0.0008).,"[{'ForeName': 'Gerold', 'Initials': 'G', 'LastName': 'Besser', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Liu', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Bertold', 'Initials': 'B', 'LastName': 'Renner', 'Affiliation': 'Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hummel', 'Affiliation': 'Smell and Taste Clinic, Department of Otorhinolaryngology, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Christian A', 'Initials': 'CA', 'LastName': 'Mueller', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.'}]",International forum of allergy & rhinology,['10.1002/alr.22549'] 2711,31954996,Approach and avoidance patterns in reward learning across domains: An initial examination of the Social Iowa Gambling Task.,"The current study examines learning patterns in response to both monetary and social incentives through both approach and avoidance behaviors using modified versions of the Iowa Gambling Task. Specifically, we investigated learning in response to both positive and negative feedback in a sample of 191 undergraduate students. The social task was a novel paradigm, and social feedback were images of faces displaying positive and negative emotions. We examined internal validity of the tasks through modeling changes in approach and avoidance. We also explored associations between approach and avoidance learning and individual differences in anxiety and social anxiety, depression and well-being, general anhedonia and social closeness, and fun-seeking, using multilevel models (MLMs). Results showed that both the monetary and social tasks demonstrated learning as shown by decreases in plays on disadvantageous decks across the task. Additionally, we found that overall task performance on the monetary task was associated with fun-seeking and overall task performance on the social task was associated with fun-seeking and depressive symptoms. Initial findings suggest promise for the novel task in the examination of social avoidance learning.",2020,Results showed that both the monetary and social tasks demonstrated learning as shown by decreases in plays on disadvantageous decks across the task.,['191 undergraduate students'],[],"['anxiety and social anxiety, depression and well-being, general anhedonia and social closeness, and fun-seeking', 'overall task performance', 'fun-seeking and overall task performance']","[{'cui': 'C0038492', 'cui_str': 'Student'}]",[],"[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}]",191.0,0.0324093,Results showed that both the monetary and social tasks demonstrated learning as shown by decreases in plays on disadvantageous decks across the task.,"[{'ForeName': 'Julia A C', 'Initials': 'JAC', 'LastName': 'Case', 'Affiliation': 'Temple University, Department of Psychology, 1701 North 13th Street, 6th Floor Weiss Hall, Philadelphia, PA, 191221, USA. Electronic address: Julia.case@temple.edu.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Olino', 'Affiliation': 'Temple University, Department of Psychology, 1701 North 13th Street, 6th Floor Weiss Hall, Philadelphia, PA, 191221, USA.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103547'] 2712,34379856,Clinical Effectiveness of Resin-modified Glass Ionomer Based Fluoride Varnish for Preventing Occlusal Caries Lesions in Partially Erupted Permanent Molars: A Randomized Active Controlled Trial.,"BACKGROUND Deep pits and fissures in partially erupted permanent molars are vulnerable to dental caries. AIM To assess the clinical effectiveness of resin-modified glass ionomer based fluoride varnish (RMGI-F varnish: Clinpro XT TM varnish) in preventing occlusal caries lesions in partially erupted permanent first molars DESIGN: In this randomized active controlled superiority trial with a single blind parallel design, 74 children with 182 partially erupted first permanent molars were allocated into two groups, Group 1: RMGI-F varnish; Group 2: GI sealant (active control), with application of 0.1% sodium fluoride varnish for all other teeth. The primary outcome was ICDAS score≥1 at 12-months follow-up. Data were analyzed using adjusted Chi-square test and GEE regression for binary outcomes. RESULTS Group 1 (15.7%) and Group 2 (13.8%) did not differ significantly in ICDAS≥1 scores at 12-months follow-up: (Adjusted χ 2 = 0.373, p=0.541). There was no significant difference in retention between Group 1 (48.3%) and Group 2 (20.7%) at 12-months follow-up (Adjusted χ 2 =0.1, p=0.752). Mean application time per tooth (16±5.9 Vs 20.2±5.4 minutes) was significantly different (t=5.26, p=0.014). CONCLUSIONS RMGI-F varnish was not superior to GI sealant in preventing occlusal caries lesions in partially erupted molars.",2021,"Mean application time per tooth (16±5.9 Vs 20.2±5.4 minutes) was significantly different (t=5.26, p=0.014). ","['Partially Erupted Permanent Molars', '74 children with 182 partially erupted first permanent molars']","['resin-modified glass ionomer based fluoride varnish (RMGI-F varnish: Clinpro XT TM varnish', 'RMGI-F varnish', 'Resin-modified Glass Ionomer Based Fluoride Varnish', 'RMGI-F varnish; Group 2: GI sealant (active control), with application of 0.1% sodium fluoride varnish', 'GI sealant']","['occlusal caries lesions', 'retention', 'Occlusal Caries Lesions', 'Mean application time per tooth', 'ICDAS≥1 scores', 'ICDAS score≥1']","[{'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0035191', 'cui_str': 'Resins, Plant'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0061297', 'cui_str': 'glass ionomer'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0016326', 'cui_str': 'Fluoride Varnishes'}, {'cui': 'C0042359', 'cui_str': 'Varnish'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0729415', 'cui_str': 'Sealant'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0037508', 'cui_str': 'Sodium Fluoride'}]","[{'cui': 'C0447303', 'cui_str': 'Structure of occlusal surface of tooth'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",74.0,0.0957913,"Mean application time per tooth (16±5.9 Vs 20.2±5.4 minutes) was significantly different (t=5.26, p=0.014). ","[{'ForeName': 'Savil Ramachandra', 'Initials': 'SR', 'LastName': 'Uchil', 'Affiliation': 'Department of Pediatric and Preventive Dentistry, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Mangalore, Manipal, India.'}, {'ForeName': 'Baranya Shrikrishna', 'Initials': 'BS', 'LastName': 'Suprabha', 'Affiliation': 'Department of Pediatric and Preventive Dentistry, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Mangalore, Manipal, India.'}, {'ForeName': 'Ramya', 'Initials': 'R', 'LastName': 'Shenoy', 'Affiliation': 'Department of Pediatric and Preventive Dentistry, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Mangalore, Manipal, India.'}, {'ForeName': 'Arathi', 'Initials': 'A', 'LastName': 'Rao', 'Affiliation': 'Department of Pediatric and Preventive Dentistry, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Mangalore, Manipal, India.'}]",International journal of paediatric dentistry,['10.1111/ipd.12887'] 2713,34379802,High dose pollen intralymphatic immunotherapy: two RDBPC trials question the benefit of dose increase.,"BACKGROUND The same dosing schedule, 1000 SQ-U times three, with one-month intervals, have been evaluated in most trials of intralymphatic immunotherapy (ILIT) for the treatment of allergic rhinitis (AR). The present studies evaluated if a dose escalation in ILIT can enhance the clinical and immunological effects, without compromising safety. METHODS Two randomized double-blind placebo-controlled trials of ILIT for grass pollen induced AR were performed. The first included 29 patients that had recently ended 3 years of SCIT and the second contained 39 not previously vaccinated patients. An up-dosage of 1000-3000-10 000 (5000 + 5000 with 30 minutes apart) SQ-U with one month in between was evaluated. RESULTS Doses up to 10 000 SQ-U was safe after recent SCIT. The combined symptom-medication scores (CSMS) were reduced by 31% and the grass specific IgG4 levels in blood were doubled. In ILIT de novo, the two first patients that received active treatment developed serious adverse reactions at 5000 SQ-U. A modified up-dosing schedule; 1000-3000-3000 SQ-U appeared to be safe but failed to improve the CSMS. Flow cytometry analyses showed increased activation of lymph node derived dendritic but not T-cells. Quality of life and nasal provocation response did not improve in any study. CONCLUSION ILIT in high doses after SCIT appears to further reduce grass pollen induced seasonal symptoms and may be considered as an add-on treatment for patients that do not reach full symptom control after SCIT. Up-dosing schedules de novo with three monthly injections that exceeds 3 000 SQ-U should be avoided.",2021,The combined symptom-medication scores (CSMS) were reduced by 31% and the grass specific IgG4 levels in blood were doubled.,['29 patients that had recently ended 3 years of SCIT and the second contained 39 not previously vaccinated patients'],"['placebo', 'ILIT', 'intralymphatic immunotherapy (ILIT']","['combined symptom-medication scores (CSMS', 'Quality of life and nasal provocation response', 'serious adverse reactions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1512956', 'cui_str': 'Intralymphatic route'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0449428', 'cui_str': 'Provocation'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",10000.0,0.112489,The combined symptom-medication scores (CSMS) were reduced by 31% and the grass specific IgG4 levels in blood were doubled.,"[{'ForeName': 'Laila', 'Initials': 'L', 'LastName': 'Hellkvist', 'Affiliation': 'Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Hjalmarsson', 'Affiliation': 'Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Weinfeld', 'Affiliation': 'Asthma and Allergy Clinic Outpatient Unit (adults), Department of Internal Medicine, South Alvsborgs Central Hospital, Boras, Sweden.'}, {'ForeName': 'Åslög', 'Initials': 'Å', 'LastName': 'Dahl', 'Affiliation': 'Departments of Biological and Environmental Sciences, Gothenburg University, Gothenburg, Sweden.'}, {'ForeName': 'Agneta', 'Initials': 'A', 'LastName': 'Karlsson', 'Affiliation': 'Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Westman', 'Affiliation': 'Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Lundkvist', 'Affiliation': 'Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Ola', 'Initials': 'O', 'LastName': 'Winqvist', 'Affiliation': 'ABC labs, Biomedicum.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Kumlien Georén', 'Affiliation': 'Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Ulla', 'Initials': 'U', 'LastName': 'Westin', 'Affiliation': 'Laboratory of Clinical and Experimental Allergy Research, Department of Otorhinolaryngology Malmö, Lund University, Skåne University Hospital, Malmö, Sweden.'}, {'ForeName': 'Lars Olaf', 'Initials': 'LO', 'LastName': 'Cardell', 'Affiliation': 'Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}]",Allergy,['10.1111/all.15042'] 2714,34379791,Interventions for tophi in gout.,"BACKGROUND Tophi develop in untreated or uncontrolled gout. This is an update of a Cochrane Review first published in 2014.  OBJECTIVES: To assess the benefits and harms of non-surgical and surgical treatments for the management of tophi in gout. SEARCH METHODS We updated the search of Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase databases to 28 August 2020. SELECTION CRITERIA We included all published randomised controlled trials (RCTs) or controlled clinical trials examining interventions for tophi in gout in adults. DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by Cochrane. MAIN RESULTS We included one trial in our original review. We added four more trials (1796 participants) in this update. One had three arms; pegloticase infusion every two weeks (biweekly), monthly pegloticase infusion (pegloticase infusion alternating with placebo infusion every two weeks) and placebo. Two studies looked at lesinurad 200 mg or 400 mg in combination with allopurinol. One trial studied lesinurad 200 mg or 400 mg in combination with febuxostat. One trial compared febuxostat 80 mg and 120 mg to allopurinol. Two trials were at unclear risk of performance and detection bias due to lack of information on blinding of participants and personnel. All other trials were at low risk of bias. Moderate-certainty evidence (downgraded for imprecision; one study; 79 participants) showed that biweekly pegloticase resolved tophi in 21/52 participants compared with 2/27 on placebo (risk ratio (RR) 5.45, 95% confidence interval (CI) 1.38 to 21.54; number needed to treat for a benefit (NNTB) 3, 95% CI 2 to 6). Similar proportions of participants receiving biweekly pegloticase (80/85) had an adverse event compared to placebo (41/43) (RR 0.99, 95% CI 0.91 to 1.07). However, more participants on biweekly pegloticase (15/85) withdrew due to an adverse event compared to placebo (1/43) (RR 7.59, 95% CI 1.04 to 55.55; number needed to treat for a harm (NNTH) 7, 95% CI 4 to 16). More participants on monthly pegloticase (11/52) showed complete resolution of tophi compared with placebo (2/27) (RR 2.86, 95% CI 0.68 to 11.97; NNTB 8, 95% CI 4 to 91). Similar numbers of participants on monthly pegloticase (84/84) had an adverse event compared to placebo (41/43) (RR 1.05, 95% CI 0.98 to 1.14). More participants on monthly pegloticase (16/84) withdrew due to adverse events compared to placebo (1/43) (RR 8.19, 95% CI 1.12 to 59.71; NNTH 6, 95% CI 4 to 14). Infusion reaction was the most common reason for withdrawal. Moderate-certainty evidence (2 studies; 103 participants; downgraded for imprecision) showed no clinically significant difference for complete resolution of target tophus in the lesinurad 200 mg plus allopurinol arm (11/53) compared to the placebo plus allopurinol arm (16/50) (RR 0.40, 95% CI 0.04 to 4.57), or in the lesinurad 400 mg plus allopurinol arm (12/48) compared to the placebo plus allopurinol arm (16/50) (RR 0.79, 95% CI 0.42 to 1.49). An extension study examined lesinurad 200 mg or 400 mg in combination with febuxostat, or placebo (low-certainty evidence, downgraded for indirectness and imprecision). Participants on lesinurad in the original study continued (CONT) on the same dose. Lesinurad 400 mg plus febuxostat may be beneficial for tophi resolution; 43/65 in the lesinurad 400 mg CONT arm compared to 38/64 in the lesinurad 200 mg CONT arm had tophi resolution (RR 1.11, 95% CI 0.85 to 1.46). Lesinurad 400 mg plus febuxostat may result in no difference in adverse events; 57/65 in the lesinurad 400 mg CONT arm had an adverse event compared to 50/64 in lesinurad 200 mg CONT arm (RR 1.12, 95% CI 0.96 to 1.32). Lesinurad 400 mg plus febuxostat may result in no difference in withdrawals due to adverse events; 10/65 participants in the lesinurad 400 mg CONT arm withdrew due to an adverse event compared to 10/64 participants in the lesinurad 200 mg CONT arm (RR 0.98, 95% CI 0.44 to 2.20). Lesinurad 400 mg plus febuxostat may result in no difference in mean serum uric acid (sUA), which was 3 mg/dl in the lesinurad 400 mg CONT group compared to 3.9 mg/dl in the lesinurad 200 mg CONT group (mean difference -0.90, 95% CI -1.51 to -0.29). Participants who were not on lesinurad in the original study were randomised (CROSS) to lesinurad 200 mg or 400 mg, both in combination with febuxostat. Low-certainty evidence downgraded for indirectness and imprecision showed that lesinurad 400 mg (CROSS) may result in tophi resolution (17/34) compared to lesinurad 200 mg (CROSS) (14/33) (RR 1.18, 95% CI 0.70 to 1.98). Lesinurad 400 mg in combination with febuxostat may result in no difference in adverse events (33/34 in the lesinurad 400 mg CROSS arm compared to 27/33 in the lesinurad 200 mg (CROSS); RR 1.19, 95% CI 1.00 to 1.41). Lesinurad 400 mg plus febuxostat may result in no difference in withdrawals due to adverse events, 5/34 in the lesinurad 400 mg CROSS arm withdrew compared to 2/33 in the lesinurad 200 mg CROSS arm (RR 2.43, 95% CI 0.51 to 11.64). Lesinurad 400 mg plus febuxostat results in no difference in sUA (4.2 mg/dl in lesinurad 400 mg CROSS) compared to lesinurad 200 mg (3.8 mg/dl in lesinurad 200 mg CROSS), mean difference 0.40 mg/dl, 95% CI -0.75 to 1.55. AUTHORS' CONCLUSIONS Moderate-certainty evidence showed that pegloticase is probably beneficial for resolution of tophi in gout. Although there was little difference in adverse events when compared to placebo, participants on pegloticase had more withdrawals due to adverse events. Lesinurad 400 mg plus febuxostat may be beneficial for tophi resolution compared with lesinurad 200 mg plus febuxostat; there was no difference in adverse events between these groups. We were unable to determine whether lesinurad plus febuxostat is more effective than placebo. Lesinurad (400 mg or 200 mg) plus allopurinol is probably not beneficial for tophi resolution, and there was no difference in adverse events between these groups. RCTs on interventions for managing tophi in gout are needed, and the lack of trial data is surprising given that allopurinol is a well-established treatment for gout.",2021,"Although there was little difference in adverse events when compared to placebo, participants on pegloticase had more withdrawals due to adverse events. ","['28 August 2020', 'tophi in gout in adults', 'Participants who were not on lesinurad in the original study']","['lesinurad 200 mg or 400 mg in combination with febuxostat, or placebo', 'pegloticase infusion (pegloticase infusion alternating with placebo', 'placebo plus allopurinol', 'Lesinurad 400 mg plus febuxostat', 'febuxostat', 'allopurinol', 'placebo', 'RCTs', 'lesinurad 200 mg or 400 mg in combination with febuxostat']","['complete resolution of target tophus', 'complete resolution of tophi', 'adverse events', 'tophi resolution', 'adverse event', 'mean serum uric acid (sUA', 'sUA']","[{'cui': 'C0221248', 'cui_str': 'Tophus'}, {'cui': 'C0018099', 'cui_str': 'Gout'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3886073', 'cui_str': 'lesinurad'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C4074452', 'cui_str': 'lesinurad 200 MG [Zurampic]'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0249529', 'cui_str': 'febuxostat'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2350656', 'cui_str': 'Pegloticase'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002144', 'cui_str': 'Allopurinol'}, {'cui': 'C3886073', 'cui_str': 'lesinurad'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0221248', 'cui_str': 'Tophus'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0455272', 'cui_str': 'Serum urate measurement'}]",79.0,0.56,"Although there was little difference in adverse events when compared to placebo, participants on pegloticase had more withdrawals due to adverse events. ","[{'ForeName': 'Melonie K', 'Initials': 'MK', 'LastName': 'Sriranganathan', 'Affiliation': 'Rheumatology Service, Department of General Medicine, Changi General Hospital, Singapore City, Singapore.'}, {'ForeName': 'Ophir', 'Initials': 'O', 'LastName': 'Vinik', 'Affiliation': ""Division of Rheumatology, St Michael's Hospital, Toronto, Canada.""}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Pardo Pardo', 'Affiliation': 'Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus, Ottawa, Canada.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Bombardier', 'Affiliation': 'Toronto General Research Institute, University Health Network, Toronto, Canada.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Edwards', 'Affiliation': 'Department of Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD010069.pub3'] 2715,34379548,Understanding Teach-Back and Teach-To-Goal Strategies Embedded in Support Calls for a Health Literacy-Sensitive Childhood Obesity Treatment Trial.,"BACKGROUND Low caregiver health literacy (HL) is related to increased obesity risk for their children. Teach-Back and Teach-to-Goal (TB/TTG) are strategies that may improve comprehension of key concepts for people who have low HL but have yet to be examined in the context of childhood obesity treatment. OBJECTIVE This study evaluated TB/TTG strategies integrated within support calls delivered to caregivers as part of a 3-month childhood obesity intervention. METHODS Ninety-four caregivers (60% Black, 42% high school education or less, 53% with income ≤$29,999, and 34% low HL) with overweight/obese children age 8 to 12 years enrolled in a childhood obesity intervention. Caregiver HL was assessed at baseline using the Newest Vital Sign and caregivers were dichotomized to low and adequate HL groups for analyses. Caregivers received 6 bi-weekly support calls that alternated with in-person, family sessions. Call completion rates, comprehension of key content (correct responses on TB/TTG questions), and satisfaction with support calls were evaluated. Qualitative information on call satisfaction was gathered at the 3-month time point. KEY RESULTS Average completion rate across all calls was 62% with a mean call time of 26 minutes (no significant difference between HL groups). Caregivers had an average score of 0.90 out of 1 when evaluating overall call comprehension by scoring TB/TTG performance. Content comprehension in calls 1, 3, and 4 was significantly higher among caregivers with adequate HL relative to low HL ( p < .1). Caregivers from both HL groups felt satisfied with calls [9.1 (2.0)/10-point scale] and agreed that calls helped them learn class material better [8.1 (2.7)]. Qualitatively, caregivers provided 81 (75%) positive responses (e.g., good content) and 27 (25%) negative responses (e.g., too lengthy) regarding the support calls. CONCLUSIONS Support calls using TB/TTG strategies were feasible, well received, and should be considered for incorporation into childhood obesity interventions. [ HLRP: Health Literacy Research and Practice . 2021;5(3):e208-e217.] Plain Language Summary: This study evaluated support calls that used Teach-Back and Teach-to-Goal health literacy strategies as part of a childhood obesity treatment trial. Support calls were well accepted and facilitated comprehension of the key learning objectives in caregivers, regardless of health literacy level. These strategies should be considered for incorporation into childhood obesity treatment interventions to increase uptake of main concepts.",2021,Caregivers had an average score of 0.90 out of 1 when evaluating overall call comprehension by scoring TB/TTG performance.,"['age 8 to 12 years enrolled in a childhood obesity intervention', 'Ninety-four caregivers (60% Black, 42% high school education or less, 53% with income ≤$29,999, and 34% low HL) with overweight/obese children', 'Plain Language Summary']",[],"['overall call comprehension by scoring TB/TTG performance', 'Call completion rates, comprehension of key content (correct responses on TB/TTG questions), and satisfaction with support calls', 'call satisfaction', 'Content comprehension', 'Caregiver HL']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2362324', 'cui_str': 'Childhood obesity'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0455002', 'cui_str': 'Education and schooling detail'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023008', 'cui_str': 'Language'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}]",94.0,0.0285529,Caregivers had an average score of 0.90 out of 1 when evaluating overall call comprehension by scoring TB/TTG performance.,"[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Yuhas', 'Affiliation': ''}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Zoellner', 'Affiliation': ''}, {'ForeName': 'Xiaolu', 'Initials': 'X', 'LastName': 'Hou', 'Affiliation': ''}, {'ForeName': 'Ramine', 'Initials': 'R', 'LastName': 'Alexander', 'Affiliation': ''}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'Hill', 'Affiliation': ''}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'You', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Estabrooks', 'Affiliation': ''}]",Health literacy research and practice,['10.3928/24748307-20210713-01'] 2716,34379539,The effect of chewing gum on bowel function postoperatively in patients with total laparoscopic hysterectomy: a randomised controlled trial.,"We aimed to investigate the efficacy of chewing gum on bowel movements after minimally invasive gynaecologic surgery, total laparoscopic hysterectomy (TLH). The study was designed as a prospective randomised controlled study. We divided the patients into two groups regarding postoperative chewing gum after elective TLH operation. The demographic status and characteristics of the patients as well as, anaesthesia and operation records were obtained. The study group was asked to chew gum for 15 min in an hour starting from post-operative 4th hour until the patient passed flatus. In each patient, first auscultation of bowel sounds, first flatus and first defaecation time, as well as first mobilisation time and discharge time, were recorded. We compared the difference in abdominal distension, nausea and vomiting and post-operative ileus (POI) rates. Eight patients were excluded from the study due to matching with exclusion criteria. The remaining 126 patients were divided into two groups. First bowel sounds, first bowel movements, the timing of first gas discharge and the timing of the first defaecation was found significantly earlier in the given-chewing gum group ( p  < .001). The timing of patient discharge and POI were found to be similar in each group ( p  > .05). Mild symptoms of ileus were observed in two patients (3.2%) in the not given-chewing gum group and three patients (5.5%) in the given-chewing gum group. The symptoms were better tolerated by the patients who chew gums and no side effects regarding the treatment were observed. In post-operative patient care after minimally invasive surgery, chewing gum has a beneficial effect on bowel movements. This inexpensive and well-tolerated procedure ameliorates gastrointestinal (GI) functions, whereas it has little benefit on early mobilisation and timing of the patient discharge after patients undergoing TLH.Impact Statement What is already known on this subject? There are many studies in the literature on the effect of gum on postoperative bowel movements, early mobilisation and short-term hospitalisation. However, there are still doubts about its use after minimally invasive surgery, especially in gynaecology practice. What do the results of this study add? Chewing gum after surgery is a well-tolerated, effective, safe, easy and convenient method and is easily accepted by patients. Its use by gynaecologists after TLH is still not clear. Our aim is to show the relationship between chewing gum and TLH with this study; We believe that early mobilisation after laparoscopic hysterectomy will not be of significant benefit after minimally invasive gynaecological surgeries as it is not significantly effective in early nutrition and early patient discharge. What are the implications of these findings for clinical practice and/or further research? Our statistically not significant results obtained in this study may change after conducting randomised prospective studies involving more patients. However, we believe that giving chewing-gum after laparoscopic hysterectomy will not have a significant benefit.",2021,"Chewing gum after surgery is a well-tolerated, effective, safe, easy and convenient method and is easily accepted by patients.","['126 patients', 'patients with total laparoscopic hysterectomy', 'Eight patients were excluded from the study due to matching with exclusion criteria']","['minimally invasive gynaecologic surgery, total laparoscopic hysterectomy (TLH', 'postoperative chewing gum after elective TLH operation', 'chewing gum']","['auscultation of bowel sounds, first flatus and first defaecation time, as well as first mobilisation time and discharge time', 'postoperative bowel movements, early mobilisation and short-term hospitalisation', 'Mild symptoms of ileus', 'abdominal distension, nausea and vomiting and post-operative ileus (POI) rates']","[{'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0008037', 'cui_str': 'Chewing Gum'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}]","[{'cui': 'C0004339', 'cui_str': 'Auscultation'}, {'cui': 'C0232693', 'cui_str': 'Bowel sounds'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0436343', 'cui_str': 'Symptom mild'}, {'cui': 'C1258215', 'cui_str': 'Ileus'}, {'cui': 'C0000731', 'cui_str': 'Swollen abdomen'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}]",126.0,0.00818821,"Chewing gum after surgery is a well-tolerated, effective, safe, easy and convenient method and is easily accepted by patients.","[{'ForeName': 'Pinar', 'Initials': 'P', 'LastName': 'Kadirogullari', 'Affiliation': 'Department of Obstetrics and Gynecology, Acıbadem University Atakent Hospital, Istanbul, Turkey.'}, {'ForeName': 'Kerem Doga', 'Initials': 'KD', 'LastName': 'Seckin', 'Affiliation': 'Department of Obstetrics and Gynecology, Health Sciences University, Istanbul Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey.'}, {'ForeName': 'Pinar', 'Initials': 'P', 'LastName': 'Yalcin Bahat', 'Affiliation': 'Department of Obstetrics and Gynecology, Health Sciences University, Istanbul Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey.'}, {'ForeName': 'Zubeyde', 'Initials': 'Z', 'LastName': 'Aytufan', 'Affiliation': 'Department of Obstetrics and Gynecology, Health Sciences University, Istanbul Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey.'}]",Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology,['10.1080/01443615.2021.1941821'] 2717,34379443,Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.,"PURPOSE GEM20110714 (ClinicalTrials.gov identifier: NCT01528618), the first randomized, phase III study of systemic chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC), reported significant progression-free survival improvement with gemcitabine plus cisplatin (GP) versus fluorouracil plus cisplatin (FP; hazard ratio, 0.55; 95% CI, 0.44 to 0.68; P < .001). Data from the final analysis of overall survival (OS) are presented here. METHODS From February 2012 to October 2015, 362 patients were randomly assigned to receive either GP (gemcitabine 1 g/m 2 once daily on days 1 and 8 and cisplatin 80 mg/m 2 once daily on day 1; n = 181) or FP (fluorouracil 4 g/m 2 in continuous intravenous infusion over 96 hours and cisplatin 80 mg/m 2 once daily on day 1; n = 181) once every 21 days. The primary end point was progression-free survival, which has been previously reported; OS was a secondary end point. RESULTS After a median follow-up time of 69.5 months with GP and 69.7 months with FP, 148 (81.8%) and 166 (91.7%) deaths occurred in the GP and FP arms, respectively. The estimated hazard ratio for OS was 0.72 (95% CI, 0.58 to 0.90; two-sided P = .004). The median OS was 22.1 months (95% CI, 19.2 to 25.0 months) with GP versus 18.6 months (95% CI, 15.4 to 21.7 months) with FP. The OS probabilities at 1, 3, and 5 years were 79.9% versus 71.8%, 31.0% versus 20.4%, and 19.2% versus 7.8%, respectively. Poststudy therapy was administered in 51.9% and 55.2% of patients in the GP and FP arms, respectively. CONCLUSION Among patients with previously untreated advanced nasopharyngeal carcinoma, those who receive GP have longer OS than those receive FP. Gemcitabine plus cisplatin should be considered a preferred front-line option for these patients.",2021,The estimated hazard ratio for OS was 0.72,"['From February 2012 to October 2015', 'Recurrent or Metastatic Nasopharyngeal Carcinoma', 'patients with previously untreated advanced nasopharyngeal carcinoma', '362 patients', 'recurrent or metastatic nasopharyngeal carcinoma (NPC']","['FP (fluorouracil 4 g/m 2 in continuous intravenous infusion over 96 hours and cisplatin 80 mg', 'Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin', 'gemcitabine plus cisplatin (GP) versus fluorouracil plus cisplatin', 'GP', 'systemic chemotherapy', 'FP', 'Gemcitabine plus cisplatin', 'GP (gemcitabine 1 g/m 2 once daily on days 1 and 8 and cisplatin 80 mg']","['progression-free survival', 'deaths', 'overall survival (OS', 'OS probabilities', 'estimated hazard ratio for OS', 'median OS']","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C2931822', 'cui_str': 'Nasopharyngeal carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}]","[{'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0021440', 'cui_str': 'Intravenous infusion'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",362.0,0.230119,The estimated hazard ratio for OS was 0.72,"[{'ForeName': 'Shaodong', 'Initials': 'S', 'LastName': 'Hong', 'Affiliation': 'Department of Medical Oncology of Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yaxiong', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Oncology of Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Gengsheng', 'Initials': 'G', 'LastName': 'Yu', 'Affiliation': 'Department of Medical Oncology, Jiangmen Central Hospital, Jiangmen, China.'}, {'ForeName': 'Peijian', 'Initials': 'P', 'LastName': 'Peng', 'Affiliation': 'Department of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.'}, {'ForeName': 'Jiewen', 'Initials': 'J', 'LastName': 'Peng', 'Affiliation': ""Department of Medical Oncology, Zhongshan People's Hospital, Zhongshan, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Jia', 'Affiliation': ""Department of Medical Oncology, Dongguan People's Hospital, Dongguan, China.""}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Medical Oncology of Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yunpeng', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Medical Oncology of Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Lin', 'Affiliation': 'Department of Oncology, Shunde Hospital Guangzhou University of Chinese Medicine, Foshan, China.'}, {'ForeName': 'Xuping', 'Initials': 'X', 'LastName': 'Xi', 'Affiliation': 'Department of Radiotherapy, Cancer Hospital of Hunan Province, Changsha, China.'}, {'ForeName': 'Mingjun', 'Initials': 'M', 'LastName': 'Xu', 'Affiliation': 'Department of Oncology, The First Affiliated Hospital of Gangnan Medical College, Gangnan, China.'}, {'ForeName': 'Dongping', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Department of Radiotherapy, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Xiaojun', 'Initials': 'X', 'LastName': 'Lu', 'Affiliation': ""Department of Radiotherapy, Zhongshan People's Hospital, Zhongshan, China.""}, {'ForeName': 'Rensheng', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.'}, {'ForeName': 'Xiaolong', 'Initials': 'X', 'LastName': 'Cao', 'Affiliation': 'Department of Oncology, Panyu Central Hospital, Guangzhou, China.'}, {'ForeName': 'Xiaozhong', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Radiotherapy, Cancer Hospital of Zhejiang Province, Hangzhou, China.'}, {'ForeName': 'Zhixiong', 'Initials': 'Z', 'LastName': 'Lin', 'Affiliation': 'Department of Medical Oncology, The Affiliated Cancer Hospital of Shantou University, Shantou, China.'}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Xiong', 'Affiliation': 'Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Lin', 'Affiliation': 'Department of Radiotherapy, The First Affiliated Hospital of Xiamen University, Xiamen, China.'}, {'ForeName': 'Conghua', 'Initials': 'C', 'LastName': 'Xie', 'Affiliation': 'Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Zhihua', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Oncology, Sun Yat-sen Memorial Hospital, Guangzhou, China.'}, {'ForeName': 'Jianji', 'Initials': 'J', 'LastName': 'Pan', 'Affiliation': 'Department of Radiotherapy, Fujian Provincial Cancer Hospital, Fuzhou, China.'}, {'ForeName': 'Jingao', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Radiotherapy, Jiangxi Provincial Cancer Hospital, Nanchang, China.'}, {'ForeName': 'Shixiu', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': 'Department of Radiotherapy, Cancer Hospital of Hangzhou City, Hangzhou, China.'}, {'ForeName': 'Yingni', 'Initials': 'Y', 'LastName': 'Lian', 'Affiliation': ""Department of Medical Oncology, The First People's Hospital of Zhaoqing City, Zhaoqing, China.""}, {'ForeName': 'Quanlie', 'Initials': 'Q', 'LastName': 'Yang', 'Affiliation': ""Department of Chemotherapy, People's Hospital of Meizhou, Meizhou, China.""}, {'ForeName': 'Chong', 'Initials': 'C', 'LastName': 'Zhao', 'Affiliation': 'Department of Nasopharyngeal Carcinoma of Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Wenfeng', 'Initials': 'W', 'LastName': 'Fang', 'Affiliation': 'Department of Medical Oncology of Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Oncology of Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University, Guangzhou, China.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.21.00396'] 2718,34379442,Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.,"PURPOSE Radiation dose received by the neural stem cells of the hippocampus during whole-brain radiotherapy has been associated with neurocognitive decline. The key concern using hippocampal avoidance-prophylactic cranial irradiation (HA-PCI) in patients with small-cell lung cancer (SCLC) is the incidence of brain metastasis within the hippocampal avoidance zone. METHODS This phase III trial enrolled 150 patients with SCLC (71.3% with limited disease) to standard prophylactic cranial irradiation (PCI; 25 Gy in 10 fractions) or HA-PCI. The primary objective was the delayed free recall (DFR) on the Free and Cued Selective Reminding Test (FCSRT) at 3 months; a decrease of 3 points or greater from baseline was considered a decline. Secondary end points included other FCSRT scores, quality of life (QoL), evaluation of the incidence and location of brain metastases, and overall survival (OS). Data were recorded at baseline, and 3, 6, 12, and 24 months after PCI. RESULTS Participants' baseline characteristics were well balanced between the two groups. The median follow-up time for living patients was 40.4 months. Decline on DFR from baseline to 3 months was lower in the HA-PCI arm (5.8%) compared with the PCI arm (23.5%; odds ratio, 5; 95% CI, 1.57 to 15.86; P = .003). Analysis of all FCSRT scores showed a decline on the total recall (TR; 8.7% v 20.6%) at 3 months; DFR (11.1% v 33.3%), TR (20.3% v 38.9%), and total free recall (14.8% v 31.5%) at 6 months, and TR (14.2% v 47.6%) at 24 months. The incidence of brain metastases, OS, and QoL were not significantly different. CONCLUSION Sparing the hippocampus during PCI better preserves cognitive function in patients with SCLC. No differences were observed with regard to brain failure, OS, and QoL compared with standard PCI.",2021,"Decline on DFR from baseline to 3 months was lower in the HA-PCI arm (5.8%) compared with the PCI arm (23.5%; odds ratio, 5; 95% CI, 1.57 to 15.86; P = .003).","['patients with small-cell lung cancer (SCLC', 'patients with SCLC', '150 patients with SCLC (71.3% with limited disease', 'Small-Cell Lung Cancer (PREMER']","['hippocampal avoidance-prophylactic cranial irradiation (HA-PCI', 'standard prophylactic cranial irradiation (PCI; 25 Gy in 10 fractions) or HA-PCI', 'Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance']","['FCSRT scores, quality of life (QoL), evaluation of the incidence and location of brain metastases, and overall survival (OS', 'incidence of brain metastases, OS, and QoL', 'total free recall', 'cognitive function', 'TR', 'median follow-up time', 'brain failure, OS, and QoL', 'total recall', 'DFR', 'delayed free recall (DFR) on the Free and Cued Selective Reminding Test (FCSRT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0149925', 'cui_str': 'Small cell carcinoma of lung'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0079172', 'cui_str': 'Cranial Irradiation'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}]","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0557033', 'cui_str': 'Reminding'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]",150.0,0.420433,"Decline on DFR from baseline to 3 months was lower in the HA-PCI arm (5.8%) compared with the PCI arm (23.5%; odds ratio, 5; 95% CI, 1.57 to 15.86; P = .003).","[{'ForeName': 'Núria', 'Initials': 'N', 'LastName': 'Rodríguez de Dios', 'Affiliation': 'Radiation Oncology, Hospital del Mar, Barcelona, Spain.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Couñago', 'Affiliation': 'Department of Radiation Oncology, Hospital Universitario Quirónsalud, Madrid, Spain.'}, {'ForeName': 'Mauricio', 'Initials': 'M', 'LastName': 'Murcia-Mejía', 'Affiliation': 'Department of Radiation Oncology, Hospital Universitario Sant Joan de Reus, Reus, Tarragona, Spain.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Rico-Oses', 'Affiliation': 'Department of Radiation Oncology, Complejo Hospitalario Navarra, Pamplona, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Calvo-Crespo', 'Affiliation': 'Department of Radiation Oncology, Hospital Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Samper', 'Affiliation': 'Department of Radiation Oncology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Vallejo', 'Affiliation': 'Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Luna', 'Affiliation': 'Department of Radiation Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.'}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Trueba', 'Affiliation': 'Department of Radiation Oncology, Hospital Universitario de Álava-sede Txagorritxu.Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Amalia', 'Initials': 'A', 'LastName': 'Sotoca', 'Affiliation': 'Department of Radiation Oncology, Hospital Ruber Internacional, Madrid, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Cigarral', 'Affiliation': 'Department of Radiation Oncology, Hospital Clínico de Salamanca, Salamanca, Spain.'}, {'ForeName': 'Núria', 'Initials': 'N', 'LastName': 'Farré', 'Affiliation': 'Department of Radiation Oncology, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Rosa M', 'Initials': 'RM', 'LastName': 'Manero', 'Affiliation': 'Department of Neurology, Hospital del Mar, Barcelona, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Durán', 'Affiliation': 'IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.'}, {'ForeName': 'Juan Domigo', 'Initials': 'JD', 'LastName': 'Gispert', 'Affiliation': 'IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.'}, {'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Sánchez-Benavides', 'Affiliation': 'IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Rognoni', 'Affiliation': 'Department of Neurology, Clínica Universidad de Navarrra, Madrid, Spain.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Torrente', 'Affiliation': 'Department of Psychology, School of Educational Sciences and Psychology, Rovira i Virgili University, Tarragona, Spain.'}, {'ForeName': 'Jaume', 'Initials': 'J', 'LastName': 'Capellades', 'Affiliation': 'Department of Radiology, Hospital del Mar, Barcelona, Spain.'}, {'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Jiménez', 'Affiliation': 'Department of Radiology, Hospital Universitario Quirónsalud, Madrid, Spain.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Cabada', 'Affiliation': 'Department of Radiology, Complejo Hospitalario Navarra, Pamplona, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Blanco', 'Affiliation': 'Department of Radiology, Hospital Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Alonso', 'Affiliation': 'Department of Radiology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Martínez-San Millán', 'Affiliation': 'Department of Radiology, Hospital Universitario Ramón y Cajal, Madrid, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Escribano', 'Affiliation': 'Department of Radiology, Hospital Ruber Internacional, Madrid, Spain.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'González', 'Affiliation': 'Department of Radiation Oncology, Hospital Clínico de Salamanca, Salamanca, Spain.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'López-Guerra', 'Affiliation': 'Department of Radiation Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.21.00639'] 2719,34380527,The NUDGE trial pragmatic trial to enhance cardiovascular medication adherence: study protocol for a randomized controlled trial.,"BACKGROUND Nearly half of patients do not take their cardiovascular medications as prescribed, resulting in increased morbidity, mortality, and healthcare costs. Mobile and digital technologies for health promotion and disease self-management offer an opportunity to adapt behavioral ""nudges"" using ubiquitous mobile phone technology to facilitate medication adherence. The Nudge pragmatic clinical trial uses population-level pharmacy data to deliver nudges via mobile phone text messaging and an artificial intelligent interactive chat bot with the goal of improving medication adherence and patient outcomes in three integrated healthcare delivery systems. METHODS The Theory of mHealth, the Expanded RE-AIM/PRISM, and the PRECIS-2 frameworks were used for program planning, implementation, and evaluation, along with a focus on dissemination and cost considerations. During the planning phase, the Nudge study team developed and piloted a technology-based nudge message and chat bot of optimized interactive content libraries for a range of diverse patients. Inclusion criteria are very broad and include patients in one of three diverse health systems who take medications to treat hypertension, atrial fibrillation, coronary artery disease, diabetes, or hyperlipidemia. A target of approximately 10,000 participants will be randomized to one of 4 study arms: usual care (no intervention), generic nudge (text reminder), optimized nudge, and optimized nudge plus interactive AI chat bot. The PRECIS-2 tool indicated that the study protocol is very pragmatic, although there is variability across PRECIS-2 dimensions. DISCUSSION The primary effectiveness outcome is medication adherence defined by the proportion of days covered (PDC) using pharmacy refill data. Implementation outcomes are assessed using the RE-AIM framework, with a particular focus on reach, consistency of implementation, adaptations, cost, and maintenance/sustainability. The project has limitations including limited power to detect some subgroup effects, medication complications (bleeding), and longer-term outcomes (myocardial infarction). Strengths of the study include the diverse healthcare systems, a feasible and generalizable intervention, transparent reporting using established pragmatic research and implementation science frameworks, strong stakeholder engagement, and planning for dissemination and sustainment. TRIAL REGISTRATION ClinicalTrials.gov NCT03973931 . Registered on 4 June 2019. The study was funded by the NIH; grant number is 4UH3HL144163-02 issued 4/5/19.",2021,The primary effectiveness outcome is medication adherence defined by the proportion of days covered (PDC) using pharmacy refill data.,"['Inclusion criteria are very broad and include patients in one of three diverse health systems who take medications to treat hypertension, atrial fibrillation, coronary artery disease, diabetes, or hyperlipidemia']","['usual care (no intervention), generic nudge (text reminder), optimized nudge, and optimized nudge plus interactive AI chat bot']","['reach, consistency of implementation, adaptations, cost, and maintenance/sustainability', 'medication adherence defined by the proportion of days covered (PDC) using pharmacy refill data']","[{'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C1290952', 'cui_str': 'Taking medication'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0020473', 'cui_str': 'Hyperlipidemia'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0124604', 'cui_str': 'Catha edulis'}]","[{'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}]",10000.0,0.128875,The primary effectiveness outcome is medication adherence defined by the proportion of days covered (PDC) using pharmacy refill data.,"[{'ForeName': 'Russell E', 'Initials': 'RE', 'LastName': 'Glasgow', 'Affiliation': 'Department of Family Medicine, University of Colorado Denver - Anschutz Medical Campus, Denver, USA. russell.glasgow@cuanschutz.edu.'}, {'ForeName': 'Christopher E', 'Initials': 'CE', 'LastName': 'Knoepke', 'Affiliation': 'Department of Medicine, Division of Cardiology, University of Colorado Denver - Anschutz Medical Campus, Denver, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Magid', 'Affiliation': 'University of Colorado Denver - Anschutz, Denver, USA.'}, {'ForeName': 'Gary K', 'Initials': 'GK', 'LastName': 'Grunwald', 'Affiliation': 'Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Denver, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Glorioso', 'Affiliation': 'U.S. Department of Veterans Affairs, Washington, DC, USA.'}, {'ForeName': 'Joy', 'Initials': 'J', 'LastName': 'Waughtal', 'Affiliation': 'mHealth Impact Laboratory Colorado School of Public Health, Aurora, USA.'}, {'ForeName': 'Joel C', 'Initials': 'JC', 'LastName': 'Marrs', 'Affiliation': 'Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, USA.'}, {'ForeName': 'Sheana', 'Initials': 'S', 'LastName': 'Bull', 'Affiliation': 'mHealth Impact Laboratory Colorado School of Public Health, Aurora, USA.'}, {'ForeName': 'P Michael', 'Initials': 'PM', 'LastName': 'Ho', 'Affiliation': 'Department of Medicine, University of Colorado School of Medicine, Aurora, USA.'}]",Trials,['10.1186/s13063-021-05453-9'] 2720,34380498,The effect of a training program on maternal role adaptation and self-esteem of mothers with preterm infants: a quasi-experimental study.,"BACKGROUND Admission of preterm infants in the neonatal intensive care unit limits the mother's interaction with their infants, delaying accepting and playing the motherhood role. Besides, mothers of preterm infants have low self-esteem due to their infants' condition. Accordingly, the present study explored the effect of implementing the training program on maternal role adaptation and self-esteem of mothers of preterm infants admitted to the neonatal intensive care unit. METHODS This study employed a quasi-experimental design with two groups. The participants were 80 mothers of preterm infants. The participants were selected using convenience sampling and simply randomly assigned to the intervention and control groups. The instruments included a demographic information questionnaire, the Rosenberg Self-Esteem Scale, and the Maternal Role Adaptation Scale. The participants in the intervention group attended the training program, while the control group did not receive any intervention. The questionnaires were completed by the two groups before and 2 weeks after the intervention. The collected data were analyzed using SPSS software version 21, a significance level of 0.05. RESULTS The maternal role adaptation scores before the intervention in the control and intervention groups were 134.222 ± 11.84 and 138.800 ± 12.42, respectively, showing no statistically significant difference (P = 0.096). The corresponding scores after the intervention for the control and intervention groups were 139.17 ± 12.46 and 154.05 ± 8.57, showing a significant intergroup difference (P < 0.001). Similarly, the pre-intervention self-esteem scores in the control and intervention groups were 30.30 ± 3.79 and 30.95 ± 8.61, showing no statistically significant difference between the two groups (P = 0.664). Besides, the post-intervention self-esteem scores in the control and intervention groups were 31.52 ± 3.42 and 36.001 ± 7.74, respectively, indicating a statistically significant difference between the two groups (P < 0.001). CONCLUSION Given the insight from this study, implementing training programs is a suitable solution for improving maternal role adaptation and increasing mothers' self-esteem. Furthermore, nurses' training packages can help the mother accept the maternal role more quickly and improve the mother's self-esteem for better care of the baby. Trial registration The registration number for this study was obtained from Kerman University of Medical Sciences, and the number of the grant was 98000150.",2021,"Besides, the post-intervention self-esteem scores in the control and intervention groups were 31.52 ± 3.42 and 36.001 ± 7.74, respectively, indicating a statistically significant difference between the two groups (P < 0.001). ","['mothers of preterm infants admitted to the neonatal intensive care unit', 'mothers with preterm infants', 'participants were 80 mothers of preterm infants']","['training program, while the control group did not receive any intervention', 'training program']","['maternal role adaptation scores', 'pre-intervention self-esteem scores', 'maternal role adaptation and self-esteem', 'demographic information questionnaire, the Rosenberg Self-Esteem Scale, and the Maternal Role Adaptation Scale']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0051533', 'cui_str': 'Am 80'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0582666', 'cui_str': 'Rosenberg self-esteem scale'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.00542037,"Besides, the post-intervention self-esteem scores in the control and intervention groups were 31.52 ± 3.42 and 36.001 ± 7.74, respectively, indicating a statistically significant difference between the two groups (P < 0.001). ","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Sohrabi', 'Affiliation': 'Department of Pediatrics and Neonatal Intensive Nursing, Razi Faculty of Nursing and Midwifery, Kerman University of Medical Science, Kerman, Iran.'}, {'ForeName': 'Mansooreh', 'Initials': 'M', 'LastName': 'Azizzadeh Forouzi', 'Affiliation': 'Nursing Research Center, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Roghayeh', 'Initials': 'R', 'LastName': 'Mehdipour-Rabori', 'Affiliation': 'Nursing Research Center, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Behnaz', 'Initials': 'B', 'LastName': 'Bagherian', 'Affiliation': 'Nursing Research Center, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Monirsadat', 'Initials': 'M', 'LastName': 'Nematollahi', 'Affiliation': 'Nursing Research Center, Kerman University of Medical Sciences, Kerman, Iran. m.nematolahi@kmu.ac.ir.'}]",BMC women's health,['10.1186/s12905-021-01440-z'] 2721,34380473,Piezo-surgery technique and intramuscular dexamethasone injection to reduce postoperative pain after impacted mandibular third molar surgery: a randomized clinical trial.,"BACKGROUND Surgical extraction of the impacted mandibular third molar is commonly associated with postoperative pain, swelling, and trismus. Usually, rotatory instruments like burs have been used for osteotomy, while Piezosurgery is an innovative technique introduced to overcome the weaknesses related to the conventional technique. In addition, Dexamethasone administration before the extraction of impacted third molars is an efficient way to reduce postoperative pain due to robust anti-inflammatory activity. The purpose of the study is to evaluate the effect of piezo-surgery and dexamethasone injection on postoperative sequelae after the surgical extraction of impacted mandibular third molars, and ultimately to compare their effect on reducing postoperative pain. METHODS A randomized controlled clinical trial was conducted with a sample of 80 patients. Participants were divided into four groups: Group 1 (Conventional rotatory), Group 2 (Conventional rotatory with 8 mg dose of dexamethasone 30 min before surgery), Group 3 (Piezo-surgery), and Group 4 (Piezo-surgery with 8 mg dose of dexamethasone 30 min before surgery). The outcome variables were surgical working time calculated in minutes, maximal mouth opening measured in millimeters using Vernier Caliper at baseline and day 3 and postoperative pain assessed using a Visual Analog Scale (VAS) on days 1, 3, and 7. RESULTS The surgical working time was longer in piezo-surgery groups compared with the conventional rotatory instruments groups (15.82 ± 3.47 vs 23.33 ± 2.54; p value < 0.0001). The lowest reduction in mouth opening between baseline and 3rd-day post-op was found in the Piezo-surgery with Dexamethasone group (mean difference = 5.0, SD = 3.9, p value < 0.0001) followed by the Piezosurgery without Dexamethasone group (mean difference = 5.8, SD = 4.5, p value < 0.0001) and the highest average was reported by the Conventional rotatory without Dexamethasone (mean difference = 9.7, SD = 4.5, p value < 0.0001. In the four groups, the mean pain score was highest on the 1st day and gradually decreased over the following days. Comparison of the 1st and 3rd postoperative pain between groups revealed a lowest mean pain score in the Piezo-surgery with Dexamethasone group, followed by Conventional rotatory with Dexamethasone group and a highest mean score in the Conventional rotatory without Dexamethasone group (p value < 0.0001). CONCLUSION The association of Piezosurgery osteotomy and Dexamethasone intramuscular injection could be an effective combination to reduce postoperative pain and trismus after impacted third molar surgery. TRIAL REGISTRATION NCT04889781 ( https://clinicaltrials.gov/ ), Date of Registration: 17/05/2021 (retrospectively registered), https://clinicaltrials.gov/ct2/show/NCT04889781?term=NCT04889781&draw=2&rank=1.",2021,"In the four groups, the mean pain score was highest on the 1st day and gradually decreased over the following days.","['after impacted mandibular third molar surgery', 'sample of 80 patients']","['piezo-surgery and dexamethasone injection', 'Group 1 (Conventional rotatory), Group 2 (Conventional rotatory with 8\xa0mg dose of dexamethasone 30\xa0min before surgery), Group 3 (Piezo-surgery), and Group 4 (Piezo-surgery with 8\xa0mg dose of dexamethasone', 'Piezo-surgery technique and intramuscular dexamethasone injection', 'Dexamethasone']","['mean pain score', 'surgical working time calculated in minutes, maximal mouth opening measured in millimeters using Vernier Caliper at baseline and day 3 and postoperative pain assessed using a Visual Analog Scale (VAS) on days 1, 3, and 7', 'lowest reduction in mouth opening', 'surgical working time', 'postoperative pain', 'postoperative pain and trismus']","[{'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4283889', 'cui_str': 'Dexamethasone Injection'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439200', 'cui_str': 'mm'}, {'cui': 'C0175720', 'cui_str': 'Caliper'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0041105', 'cui_str': 'Trismus'}]",80.0,0.390558,"In the four groups, the mean pain score was highest on the 1st day and gradually decreased over the following days.","[{'ForeName': 'Wissam', 'Initials': 'W', 'LastName': 'Nehme', 'Affiliation': 'Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.'}, {'ForeName': 'Youssef', 'Initials': 'Y', 'LastName': 'Fares', 'Affiliation': 'Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Abou-Abbas', 'Affiliation': 'Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. l.abouabbas@ul.edu.lb.'}]",BMC oral health,['10.1186/s12903-021-01759-x'] 2722,34380392,"Efficacy of Intra-Articular Injection of 10 mg and 20 mg Triamcinolone for Rheumatoid Arthritis of the Wrist: A Prospective, Randomized, Pilot Study.","Background: To compare the efficacy of intra-articular injection (IA) with 10 mg and 20 mg triamcinolone for treatment of rheumatoid arthritis (RA) of the wrist joint. Methods: We enrolled 20 patients with swelling and pain in wrist due to RA in the present prospective, randomized, pilot study. Patients were randomly assigned in a 1:1 ratio to either the 20 mg or 10 mg group, and received IA of the appropriate dose of triamcinolone. Efficacy was assessed by recording Numerical Rating Scale (NRS) for pain and improvement in power doppler (PD) scale score at weeks 1, 4, and 12 of treatment compared with baseline. The shortened Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH) was recorded at baseline and week 12. Results: The NRS was found to be significantly improved at weeks 4 ( p = 0.006) and 12 ( p = 0.036) among the total study population. Neither the change in NRS nor the improvement PD scale score from baseline were significantly different between the two groups at any week (NRS: week 1, p = 0.617; week 4, p = 0.727; and week 12, p = 0.878; PD scale score: week 1, p = 0.370; week 4, p = 1.000; and week 12, p = 0.179). Among the entire study population, the QuickDASH was not significantly improved at week 12 nor was the change from baseline significantly different between the two groups at week 12 ( p = 0.592). Conclusions: IA of triamcinolone was effective for pain relief in context of RA in the wrist joint. However, in terms of NRS, improvement of PD scale score, and QuickDASH score, the efficacies of 10 mg and 20 mg triamcinolone were not significantly different. Thus, IA of 10 mg triamcinolone may be sufficient for the treatment of RA in the wrist joint.",2021,"Neither the change in NRS nor the improvement PD scale score from baseline were significantly different between the two groups at any week (NRS: week 1, p = 0.617; week 4, p = 0.727; and week 12, p = 0.878; PD scale score: week 1, ","['Rheumatoid Arthritis of the Wrist', '20 patients with swelling and pain in wrist due to RA', 'rheumatoid arthritis (RA) of the wrist joint']","['triamcinolone', 'Intra-Articular Injection of 10 mg and 20 mg', 'intra-articular injection (IA) with 10 mg and 20 mg triamcinolone', 'Triamcinolone']","['shortened Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH', 'recording Numerical Rating Scale (NRS) for pain and improvement in power doppler (PD) scale score', 'PD scale score, and QuickDASH score', 'Efficacy', 'pain relief', 'improvement PD scale score', 'QuickDASH']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0221785', 'cui_str': 'Pain in wrist'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1322271', 'cui_str': 'Wrist joint structure'}]","[{'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0021488', 'cui_str': 'Intra-articular injection'}]","[{'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0554756', 'cui_str': 'Doppler studies'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}]",20.0,0.0522385,"Neither the change in NRS nor the improvement PD scale score from baseline were significantly different between the two groups at any week (NRS: week 1, p = 0.617; week 4, p = 0.727; and week 12, p = 0.878; PD scale score: week 1, ","[{'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Mochizuki', 'Affiliation': 'Department of Orthopedic Surgery, Kamagaya General Hospital, Chiba, Japan.'}, {'ForeName': 'Koichiro', 'Initials': 'K', 'LastName': 'Yano', 'Affiliation': ""Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.""}, {'ForeName': 'Katsunori', 'Initials': 'K', 'LastName': 'Ikari', 'Affiliation': ""Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.""}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Okazaki', 'Affiliation': ""Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.""}]",The journal of hand surgery Asian-Pacific volume,['10.1142/S2424835521200046'] 2723,34380322,Effect of Rivaroxaban and Aspirin in Patients with Peripheral Artery Disease Undergoing Surgical Revascularization: Insights from the VOYAGER PAD Trial.,"Background: Patients with peripheral artery disease (PAD) requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. VOYAGER PAD demonstrated that rivaroxaban significantly reduced this risk. The efficacy and safety of rivaroxaban has not been described in patients who underwent surgical LER. Methods: The VOYAGER PAD trial randomized patients with PAD after surgical and endovascular LER to rivaroxaban 2.5mg twice daily plus aspirin or matching placebo plus aspirin and followed for a median of 28 months. The primary endpoint was a composite of acute limb ischemia, major vascular amputation, myocardial infarction, ischemic stroke, or cardiovascular death. The principal safety outcome was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. International Society on Thrombosis and Haemostasis (ISTH) bleeding was a secondary safety outcome. All efficacy and safety outcomes were adjudicated by a blinded independent committee. Results: Of the 6564 randomized, 2185 (33%) underwent surgical LER and 4379 (67%) endovascular. Compared to placebo, rivaroxaban reduced the primary endpoint consistently regardless of LER method (p-interaction 0.43). Following surgical LER, the primary efficacy outcome occurred in 199 (18.4%) patients in the rivaroxaban group and 242 (22.0%) patients in the placebo group with a cumulative incidence at 3 years of 19.7% and 23.9%, respectively (HR 0.81, 95% CI 0.67 - 0.98; p=0.026). In the overall trial, TIMI major bleeding and ISTH major bleeding were increased with rivaroxaban. There was no heterogeneity for TIMI major bleeding (p-interaction 0.17) or ISTH major bleeding (p-interaction 0.73) based on LER approach. Following surgical LER, the principal safety outcome occurred in 11 (1.0%) patients in the rivaroxaban group and 13 (1.2%) patients in the placebo group; 3-year cumulative incidence 1.3% and 1.4% respectively (HR 0.88, 95% CI 0.39-1.95; p=0.75) Among surgical patients, the composite of fatal bleeding or intracranial hemorrhage (p=0.95) and postprocedural bleeding requiring intervention (p=0.93) were not significantly increased. Conclusions: The efficacy of rivaroxaban is associated with a benefit in surgical LER patients. While bleeding was increased with rivaroxaban plus aspirin, the incidence was low, with no significant increase in fatal bleeding, intracranial hemorrhage or postprocedural bleeds requiring intervention. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02504216.",2021,"Compared to placebo, rivaroxaban reduced the primary endpoint consistently regardless of LER method (p-interaction 0.43).","['Patients with Peripheral Artery Disease Undergoing Surgical Revascularization', 'surgical LER patients', 'patients who underwent surgical LER', 'Patients with peripheral artery disease (PAD) requiring lower extremity revascularization (LER', 'patients with PAD after surgical and', '6564 randomized, 2185 (33']","['placebo, rivaroxaban', 'endovascular LER to rivaroxaban 2.5mg twice daily plus aspirin or matching placebo plus aspirin', 'rivaroxaban', 'rivaroxaban plus aspirin', 'placebo', 'Rivaroxaban and Aspirin']","['composite of acute limb ischemia, major vascular amputation, myocardial infarction, ischemic stroke, or cardiovascular death', 'efficacy and safety', 'Myocardial Infarction (TIMI) major bleeding', 'ISTH major bleeding', 'fatal bleeding, intracranial hemorrhage or postprocedural bleeds', 'cumulative incidence', 'Thrombosis and Haemostasis (ISTH) bleeding', 'principal safety outcome', 'While bleeding', 'composite of fatal bleeding or intracranial hemorrhage', 'postprocedural bleeding requiring intervention', '3-year cumulative incidence', 'TIMI major bleeding and ISTH major bleeding', 'TIMI major bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0332568', 'cui_str': 'Pad'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C4731644', 'cui_str': 'rivaroxaban 2.5 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C4049535', 'cui_str': 'Acute limb ischaemia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0151699', 'cui_str': 'Intracranial hemorrhage'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439234', 'cui_str': 'year'}]",,0.368795,"Compared to placebo, rivaroxaban reduced the primary endpoint consistently regardless of LER method (p-interaction 0.43).","[{'ForeName': 'E Sebastian', 'Initials': 'ES', 'LastName': 'Debus', 'Affiliation': 'Department of Vascular Medicine, Vascular Surgery-Angiology-Endovascular Therapy, University of Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Nehler', 'Affiliation': 'CPC Clinical Research, Aurora, CO; Department of Surgery, Division of Vascular Surgery, University of Colorado School of Medicine, Aurora, CO.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Govsyeyev', 'Affiliation': 'CPC Clinical Research, Aurora, CO; Department of Surgery, Division of Vascular Surgery, University of Colorado School of Medicine, Aurora, CO.'}, {'ForeName': 'Rupert M', 'Initials': 'RM', 'LastName': 'Bauersachs', 'Affiliation': 'Department of Vascular Medicine, Klinikum Darmstadt, Darmstadt, and Center for Thrombosis and Hemostasis, University of Mainz, Mainz, Germany.'}, {'ForeName': 'Sonia S', 'Initials': 'SS', 'LastName': 'Anand', 'Affiliation': 'Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Manesh R', 'Initials': 'MR', 'LastName': 'Patel', 'Affiliation': 'Duke Clinical Research Institute, Division of Cardiology, Duke University, Durham, NC.'}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Fanelli', 'Affiliation': 'Vascular and Interventional Radiology Department, Careggi University Hospital, University of Florence, Florence, Italy.'}, {'ForeName': 'Warren H', 'Initials': 'WH', 'LastName': 'Capell', 'Affiliation': 'CPC Clinical Research, Aurora, CO; Department of Medicine, Division of Endocrinology, University of Colorado School of Medicine, Aurora, CO.'}, {'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Brackin', 'Affiliation': 'CPC Clinical Research, Aurora, CO.'}, {'ForeName': 'Franz', 'Initials': 'F', 'LastName': 'Hinterreiter', 'Affiliation': 'Department for Vascular Surgery KH BHB Linz, Seilerstätte 2, 4020, Austria.'}, {'ForeName': 'Dainis', 'Initials': 'D', 'LastName': 'Krievins', 'Affiliation': 'Pauls Stradins University Hospital, University of Latvia.'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Nault', 'Affiliation': 'Vascular and Endovascular Surgery, McGill University Montreal, Canada.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Piffaretti', 'Affiliation': 'Vascular Surgery, Department of Medicine and Surgery, University of Insubria School of Medicine, Varese, Italy.'}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Svetlikov', 'Affiliation': 'The I.I. Mechnikov North-Western State Medical University, Department of Cardio-Vascular surgery, St-Petersburg, Russia.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Jaeger', 'Affiliation': 'CPC Clinical Research, Aurora, CO.'}, {'ForeName': 'Connie N', 'Initials': 'CN', 'LastName': 'Hess', 'Affiliation': 'CPC Clinical Research, Aurora, CO; Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora, CO.'}, {'ForeName': 'Henrik H', 'Initials': 'HH', 'LastName': 'Sillesen', 'Affiliation': 'Department of Vascular Surgery, Rigshospitalet, Institute of Clinical Medicine, University of Copenhagen, Denmark.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Conte', 'Affiliation': 'Division of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Mills', 'Affiliation': 'Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Muehlhofer', 'Affiliation': 'Bayer, Wuppertal, Germany.'}, {'ForeName': 'Lloyd P', 'Initials': 'LP', 'LastName': 'Haskell', 'Affiliation': 'Janssen Research and Development, Raritan, NJ.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Berkowitz', 'Affiliation': 'Thrombosis Group Head, Clinical Development, Bayer U.S., Whippany, NJ.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Hiatt', 'Affiliation': 'CPC Clinical Research, Aurora, CO; Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora, CO.'}, {'ForeName': 'Marc P', 'Initials': 'MP', 'LastName': 'Bonaca', 'Affiliation': 'CPC Clinical Research, Aurora, CO; Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora, CO.'}]",Circulation,['10.1161/CIRCULATIONAHA.121.054835'] 2724,34380301,[Nutraceutical correction in the complex non-drug treatment of metabolic syndrome].,"The use of complex non-drug technologies at the stage of rehabilitation of metabolic syndrome (MS) includes multifactorial correction of its main manifestations: abdominal obesity, insulin resistance, arterial hypertension and dyslipidemia. A prospective randomized study on the use of low-calorie diet (LCD) and nutraceutical correction of the nutritional status of patients with MS was carried out. OBJECTIVE To study the effect of a non-drug complex including LCD, physical exercises, as well as correction of the gut microbiome and hepatic protection in relation to reduction of visceral fat volume in abdominal obesity and the dynamics of lipid and carbohydrate metabolism hormones in metabolic syndrome. MATERIAL AND METHODS 120 patients with MS were randomized into 2 groups: Group 1 received LCD, physical exercises in the gym, and physical activity like daily walking up to 3-5 km/day. Group 2 received LCD, physical exercises in the gym, physical activity like daily walking up to 3-5 km/day, as well as nutraceutical correction of increased appetite, gut probiotic composition, hepatic protection. The treatment duration was 4 weeks. Anthropometric methods in order to control the body weight, waist and hip circumferences and bioimpedansometry were used. RESULTS As a treatment result, patients in group 1 represented a reduction in body weight, lean and active cell mass, a decrease in musculoskeletal mass and a decrease in total fluid due to extracellular fluid. A decrease in total cholesterol and blood triglyceride fraction was noted. Leptin decreased by 13.96%. Patients of the 2 nd group represented a decrease in body weight, fat mass, lean mass, total fluid and extracellular fluid. There was a statistically significant increase in active cell mass, skeletal muscle mass. There was a decrease in total cholesterol, triglycerides and transaminases. Due to weight loss and fat mass reduction a decrease in leptin expression by 29.85% and decrease in blood insulin levels by 11.2% were noted. CONCLUSION Thus, LCD accompanied by nutraceutical correction of the gut microbiota and hepatic protection can be effectively used in combination with physical training in order to reduce the fat mass without pre-sarcopenia development that was confirmed by positive dynamics of volume indices, bioimpedance measurements and reduction in leptin and insulin expression.",2021,"Patients of the 2 nd group represented a decrease in body weight, fat mass, lean mass, total fluid and extracellular fluid.","['120 patients with MS', 'metabolic syndrome', 'patients with MS']","['low-calorie diet (LCD) and nutraceutical correction', 'LCD, physical exercises in the gym, and physical activity like daily walking up to 3-5 km/day', 'LCD, physical exercises in the gym, physical activity like daily walking']","['musculoskeletal mass', 'total cholesterol, triglycerides and transaminases', 'Leptin', 'total cholesterol and blood triglyceride fraction', 'leptin and insulin expression', 'blood insulin levels', 'leptin expression', 'body weight, lean and active cell mass', 'active cell mass, skeletal muscle mass', 'body weight, fat mass, lean mass, total fluid and extracellular fluid']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}]","[{'cui': 'C2930544', 'cui_str': 'Calorie restricted diet'}, {'cui': 'C1518478', 'cui_str': 'Nutriceuticals'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0442758', 'cui_str': '3/5'}]","[{'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferase'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0518018', 'cui_str': 'Blood triglycerides'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0853230', 'cui_str': 'Blood insulin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0015349', 'cui_str': 'Extracellular fluid'}]",120.0,0.00481509,"Patients of the 2 nd group represented a decrease in body weight, fat mass, lean mass, total fluid and extracellular fluid.","[{'ForeName': 'L G', 'Initials': 'LG', 'LastName': 'Agasarov', 'Affiliation': 'National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'T V', 'Initials': 'TV', 'LastName': 'Apkhanova', 'Affiliation': 'National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'V N', 'Initials': 'VN', 'LastName': 'Sergeev', 'Affiliation': 'National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'A D', 'Initials': 'AD', 'LastName': 'Fesun', 'Affiliation': 'Moscow State University of Food Production, Moscow, Russia.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Krukova', 'Affiliation': 'National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'V A', 'Initials': 'VA', 'LastName': 'Vasilyeva', 'Affiliation': 'National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'D B', 'Initials': 'DB', 'LastName': 'Kulchitskaya', 'Affiliation': 'National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'T V', 'Initials': 'TV', 'LastName': 'Konchugova', 'Affiliation': 'National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Puzyreva', 'Affiliation': 'National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'M Yu', 'Initials': 'MY', 'LastName': 'Yakovlev', 'Affiliation': 'Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russia.'}]","Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury",['10.17116/kurort20219804125'] 2725,34380300,[Vacuum interference therapy in the complex treatment of patients with chronic bacterial prostatitis].,"Taking into account the complex etiology and pathogenesis of chronic prostatitis, a large number of complications including the reproductive function impairment, the developing new effective methods of treating this pathology remains highly relevant. OBJECTIVE Scientific substantiation of combined electric vacuum exposure in patients with chronic bacterial prostatitis (CBP). MATERIAL AND METHODS The 90 patients with CBP aged 27-55 years were examined and were divided into 3 equal groups by the method of simple randomization. Patients of the main group received vacuum interference therapy procedures, the comparison group received interference therapy without vacuum exposure, and the control group received only standard drug therapy that was also prescribed in the first two groups. The effectiveness of therapy was assessed before, immediately after and 6 months after using the NIH-CPS, IPSS, QOL scales, trans-rectal ultrasound examination of the prostate gland, bacteriological examination and microscopy of a native preparation of prostate secretion and uroflowmetry. RESULTS An improvement in the clinical symptoms of CBP was found largely in the groups receiving physiotherapy. In the main group there was a more significant volume decrease in the inflammatory-altered prostate gland (by 31.5%), in the comparison group the volume of the prostate gland decreased by 14%, and in the control group - by 9.6% that indicates the most pronounced anti-inflammatory effect of electro-vacuum actions. In the main group, there was also a more pronounced positive dynamics of dysuric disorders' indicators and maximum urination rate compared to the comparison and control groups. CONCLUSION A higher clinical efficacy of vacuum interference therapy in patients with CBP (93.3%) has been proven compared with interference therapy (80.0%) and standard therapy (66.6%). The data obtained confirm the advantages and usage prospects of the combined physiotherapeutic effects.",2021,"In the main group there was a more significant volume decrease in the inflammatory-altered prostate gland (by 31.5%), in the comparison group the volume of the prostate gland decreased by 14%, and in the control group - by 9.6% that indicates the most pronounced anti-inflammatory effect of electro-vacuum actions.","['patients with chronic bacterial prostatitis (CBP', 'patients with chronic bacterial prostatitis', 'patients with CBP (93.3', '90 patients with CBP aged 27-55 years']","['vacuum interference therapy', 'interference therapy without vacuum exposure, and the control group received only standard drug therapy', 'Vacuum interference therapy', 'combined electric vacuum exposure', 'vacuum interference therapy procedures']","['inflammatory-altered prostate gland', 'volume of the prostate gland', ""positive dynamics of dysuric disorders' indicators and maximum urination rate"", 'clinical symptoms of CBP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1720797', 'cui_str': 'Chronic Bacterial Prostatitis'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0042221', 'cui_str': 'Vacuum'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1720797', 'cui_str': 'Chronic Bacterial Prostatitis'}]",90.0,0.0097657,"In the main group there was a more significant volume decrease in the inflammatory-altered prostate gland (by 31.5%), in the comparison group the volume of the prostate gland decreased by 14%, and in the control group - by 9.6% that indicates the most pronounced anti-inflammatory effect of electro-vacuum actions.","[{'ForeName': 'A I', 'Initials': 'AI', 'LastName': 'Bokov', 'Affiliation': 'National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'T V', 'Initials': 'TV', 'LastName': 'Konchugova', 'Affiliation': 'National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'V A', 'Initials': 'VA', 'LastName': 'Kiyatkin', 'Affiliation': 'National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'D B', 'Initials': 'DB', 'LastName': 'Kulchitskaya', 'Affiliation': 'National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia.'}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'Kyzlasov', 'Affiliation': 'A.I. Burnazyan State Scientific Center of the Russian Federation, Moscow, Russia.'}]","Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury",['10.17116/kurort20219804118'] 2726,34380299,[The effectiveness of local and general magnetotherapy in early rehabilitation of women after surgical treatment of breast cancer].,"OBJECTIVE Effectiveness comparison of local and general magneto-therapy for determining differentiated indications in order to prescribe the techniques for early rehabilitation of patients after surgical treatment of breast cancer (BC). MATERIAL AND METHODS It was examined 114 women after radical mastectomy for breast cancer. The patients were divided into 3 groups by the method of simple randomization: the control group (37 women) received therapeutic exercises without additional prescription of physiotherapeutic procedures; 1 st main group (38 women) - in addition to exercises a course of local magneto-therapy; 2 nd main group (39 women) - general magneto-therapy. The results were assessed using a visual analogue pain scale, goniometry results, remote infrared thermography, hospital anxiety and depression scale (HADS). RESULTS The inclusion of magneto-therapy in the rehabilitation complex reduced local hyperemia and edema in the area of the postoperative suture on the 7 th -8 th day in 73.7 and 76.9% of patients of the 1 st and 2 nd groups, respectively, while in the control group a similar result was observed by 10-14 days. Both methods of magneto-therapy eliminated temperature asymmetry and restored the normal thermographic pattern of the skin surface in the area of the surgical field, reduced the severity of pain, and increased the range of motion in the shoulder joint on the side of the operation. When studying the possibility of eliminating the manifestations of asthenic syndrome a comparison of the two studied methods showed the undoubted advantage of the general exposure to a magnetic field. In addition, it has also caused a statistically significant decrease in indicators of anxiety and depression on the HADS scale, while local exposure to a magnetic field did not have a similar effect. CONCLUSION The choice of exposure to a magnetic field at the stage of early rehabilitation of women after surgery for breast cancer is determined by the intensity of the pain syndrome, the degree of activity of aseptic inflammation in the area of the postoperative suture, the level of anxiety and depression, and the severity of asthenic syndrome.",2021,"In addition, it has also caused a statistically significant decrease in indicators of anxiety and depression on the HADS scale, while local exposure to a magnetic field did not have a similar effect. ","['It was examined 114 women after radical mastectomy for breast cancer', 'patients after surgical treatment of breast cancer (BC', 'women after surgical treatment of breast cancer']","['local and general magnetotherapy', 'therapeutic exercises without additional prescription of physiotherapeutic procedures; 1 st main group (38 women) - in addition to exercises a course of local magneto-therapy; 2 nd main group (39 women) - general magneto-therapy', 'local and general magneto-therapy']","['visual analogue pain scale, goniometry results, remote infrared thermography, hospital anxiety and depression scale (HADS', 'local hyperemia and edema', 'severity of pain']","[{'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0024884', 'cui_str': 'Radical mastectomy'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C1532326', 'cui_str': 'Infra-red'}, {'cui': 'C0039810', 'cui_str': 'Thermography'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0020452', 'cui_str': 'Hyperemia'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.0181761,"In addition, it has also caused a statistically significant decrease in indicators of anxiety and depression on the HADS scale, while local exposure to a magnetic field did not have a similar effect. ","[{'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Kochetkova', 'Affiliation': 'Russian Medical Academy of Continuing Professional Education, Moscow, Russia.'}, {'ForeName': 'A G', 'Initials': 'AG', 'LastName': 'Kulikov', 'Affiliation': 'Moscow Scientific and Practical Center for Medical Rehabilitation and Sports Medicine, Moscow, Russia.'}]","Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury",['10.17116/kurort20219804111'] 2727,34379375,"Effect of Static Stretching, Dynamic Stretching, and Myofascial Foam Rolling on Range of Motion During Hip Flexion: A Randomized Crossover Trial.","Siebert, T, Donath, L, Borsdorf, M, and Stutzig, N. Effect of static stretching, dynamic stretching, and myofascial foam rolling on range of motion during hip flexion: A randomized crossover trial. J Strength Cond Res XX(X): 000-000, 2020-Static and dynamic stretching (DS) are commonly used in sports and physical therapy to increase the range of motion (ROM). However, prolonged static stretching (SS) can deteriorate athletic performance. Alternative methods to increase ROM are thus needed. Foam rolling (FR) may initiate muscle relaxation, improve muscular function, physical performance, and ROM. Previous studies that examined effects of FR on ROM did not control for increased tissue compliance or shifted pain threshold. In this study, the isolated influence of altered tissue compliance on ROM after FR, SS, and DS was investigated using a randomized crossover design. Hip flexion ROM at given joint torques before and after SS, DS, and FR was randomly assessed in 14 young male adults (age: 23.7 +/- 1.3 years; height: 182 +/- 8 cm; body mass: 79.4 +/- 6.9 kg). Hip flexion ROM was measured in the sagittal plane with the subjects lying in a lateral position (no gravitational effects on ROM measurements). Surface electromyographic (EMG) analysis of 2 representative hip extensors (M. biceps femoris and M. semitendinosus) was applied to control for active muscle contribution during ROM measurements. Significant increases in ROM for SS (3.8 +/- 1.1[degrees]; p < 0.001) and DS (3.7 +/- 1.8[degrees]; p < 0.001) were observed, but not for FR (0.8 +/- 3.1[degrees]; p = 0.954). Because stretch forces on tendon and muscle tissue during SS and DS predominately act in longitudinal direction, FR induces mainly transversal forces in the muscle tissue. Thus, increased ROM after FR reported in the literature is more likely due to a shift in the pain threshold. These results provide a better understanding of differential loading conditions during SS, DS, and FR for coaches and practitioners.",2020,Surface electromyographic (EMG) analysis of 2 representative hip extensors (M. biceps femoris and M. semitendinosus) was applied to control for active muscle contribution during ROM measurements.,"['14 young male adults (age: 23.7 ', '1.8[degrees']","['Foam rolling (FR', '2020-Static and dynamic stretching (DS', 'prolonged static stretching (SS', 'Hip flexion ROM at given joint torques before and after SS, DS, and FR', 'Static Stretching, Dynamic Stretching, and Myofascial Foam Rolling on Range of Motion', 'J Strength Cond Res XX(X']","['muscular function, physical performance, and ROM', 'range of motion (ROM', 'Hip flexion ROM', 'ROM for SS', 'Siebert, T, Donath, L, Borsdorf, M, and Stutzig, N. Effect of static stretching, dynamic stretching, and myofascial foam rolling on range of motion during hip flexion', 'DS']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C1720875', 'cui_str': 'Static Stretching'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C1720875', 'cui_str': 'Static Stretching'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0991510', 'cui_str': 'Foam'}]",14.0,0.0197574,Surface electromyographic (EMG) analysis of 2 representative hip extensors (M. biceps femoris and M. semitendinosus) was applied to control for active muscle contribution during ROM measurements.,"[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Siebert', 'Affiliation': 'Department of Motion and Exercise Science, University of Stuttgart, Stuttgart, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Donath', 'Affiliation': 'Department of Intervention Research in Exercise Training, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Mischa', 'Initials': 'M', 'LastName': 'Borsdorf', 'Affiliation': 'Department of Motion and Exercise Science, University of Stuttgart, Stuttgart, Germany.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Stutzig', 'Affiliation': 'Department of Motion and Exercise Science, University of Stuttgart, Stuttgart, Germany.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003517'] 2728,32270527,Association of bacterial load in drinking water and allergic diseases in childhood.,"BACKGROUND Treatment of drinking water may decrease microbial exposure. OBJECTIVE To investigate whether bacterial load in drinking water is associated with altered risk of allergic diseases. METHODS We recruited 1,110 schoolchildren aged 6-16 years between 2011 and 2013 in Požega-Slavonia County in Croatia, where we capitalized on a natural experiment whereby individuals receive drinking water through public mains supply or individual wells. We obtained data on microbial content of drinking water for all participants; 585 children were randomly selected for more detailed assessments, including skin prick testing. Since water supply was highly correlated with rural residence, we compared clinical outcomes across four groups (Rural/Individual, Rural/Public, Urban/Individual and Urban/Public). For each child, we derived quantitative index of microbial exposure (bacterial load in the drinking water measured during the child's first year of life). RESULTS Cumulative bacterial load in drinking water was higher (median [IQR]: 6390 [4190-9550] vs 0 [0-0]; P < .0001), and lifetime prevalence of allergic diseases was significantly lower among children with individual supply (5.5% vs 2.3%, P = .01; 14.4% vs 6.7%, P < .001; 25.2% vs 15.1%, P < .001; asthma, atopic dermatitis [AD] and rhinitis, respectively). Compared with the reference group (Urban/Public), there was a significant reduction in the risk of ever asthma, AD and rhinitis amongst rural children with individual supply: OR [95% CI]: 0.14 [0.03,0.67], P = .013; 0.20 [0.09,0.43], P < .001; 0.17 [0.10,0.32], P < .001. Protection was also observed in the Rural/Public group, but the effect was consistently highest among Rural/Individual children. In the quantitative analysis, the risk of allergic diseases decreased significantly with increasing bacterial load in drinking water in the first year of life (0.79 [0.70,0.88], P < .001; 0.90 [0.83,0.99], P = .025; 0.80 [0.74,0.86], P < .001; current wheeze, AD and rhinitis). CONCLUSIONS AND CLINICAL RELEVANCE High commensal bacterial content in drinking water may protect against allergic diseases.",2020,"Compared with the reference group (Urban/Public), there was a significant reduction in the risk of ever asthma, AD and rhinitis amongst rural children with individual supply: OR [95% CI]: 0.14 [0.03,0.67], P = .013; 0.20 [0.09,0.43], P < .001; 0.17 [0.10,0.32], P < .001.","['all participants; 585 children', 'drinking water and allergic diseases in childhood', '1,110 schoolchildren aged 6-16\xa0years between 2011 and 2013 in Požega-Slavonia County in Croatia, where we capitalized on a natural experiment whereby individuals receive drinking water through public mains supply or individual wells']",[],"['risk of ever asthma, AD and rhinitis', 'Protection', 'lifetime prevalence of allergic diseases']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0010343', 'cui_str': 'Croatia'}, {'cui': 'C0599638', 'cui_str': 'Drinking Water'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205170', 'cui_str': 'Good'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0008711', 'cui_str': 'Chronic rhinitis'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",585.0,0.163701,"Compared with the reference group (Urban/Public), there was a significant reduction in the risk of ever asthma, AD and rhinitis amongst rural children with individual supply: OR [95% CI]: 0.14 [0.03,0.67], P = .013; 0.20 [0.09,0.43], P < .001; 0.17 [0.10,0.32], P < .001.","[{'ForeName': 'Mirjana', 'Initials': 'M', 'LastName': 'Turkalj', 'Affiliation': ""Children's Hospital Srebrnjak, Zagreb, Croatia.""}, {'ForeName': 'Vlado', 'Initials': 'V', 'LastName': 'Drkulec', 'Affiliation': 'County Hospital Požega, Požega, Croatia.'}, {'ForeName': 'Sadia', 'Initials': 'S', 'LastName': 'Haider', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Davor', 'Initials': 'D', 'LastName': 'Plavec', 'Affiliation': ""Children's Hospital Srebrnjak, Zagreb, Croatia.""}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Banić', 'Affiliation': ""Children's Hospital Srebrnjak, Zagreb, Croatia.""}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Malev', 'Affiliation': ""Children's Hospital Srebrnjak, Zagreb, Croatia.""}, {'ForeName': 'Damir', 'Initials': 'D', 'LastName': 'Erceg', 'Affiliation': ""Children's Hospital Srebrnjak, Zagreb, Croatia.""}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Woodcock', 'Affiliation': 'Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, University of Manchester and University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Boro', 'Initials': 'B', 'LastName': 'Nogalo', 'Affiliation': ""Children's Hospital Srebrnjak, Zagreb, Croatia.""}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Custovic', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, London, UK.'}]",Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,['10.1111/cea.13605'] 2729,34383381,Intravesical MMC and MMC+Ara-C for non-muscle invasive bladder cancer: A randomized clinical trial.,"OBJECTIVES To compare the urinary pH, recurrence-free survival, and safety of adjuvant intravesical therapy in non-muscle invasive bladder cancer (NMIBC) patients receiving mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara-C) therapy. PATIENTS AND METHODS One hundred and sixty-five NMIBC patients from six hospitals were randomly allocated to two groups: weekly instillation of MMC+Ara-C (30 mg/30 ml+200 mg/10 ml) for 6 weeks and the same instillation schedule of MMC (30 mg/40 ml). The primary outcome was recurrence-free survival, and secondary outcomes were urinary pH and toxicity in the two groups. RESULTS A total of 81 and 87 patients were randomised into the MMC and MMC+Ara-C groups, respectively. In all patients, recurrence-free survival in the MMC+Ara-C group was significantly longer (P=0.018) than that in the MMC group. A similar significant difference was detected in patients with intermediate-risk NMIBC, but not in those with high-risk NMIBC. Mean/SD urinary pH was significantly higher in the MMC+Ara-C group than in the MMC group (6.56/0.61 vs. 5.78/0.64; P<0.001), and the frequencies of urinary pH of >7.0 in the MMC and MMC+Ara-C groups were 6.3 and 26.7%, respectively (P<0.001). Multivariate analysis models including clinicopathological features and second transurethral resection demonstrated that increased urinary pH was associated with better outcomes (hazard ratio=0.18, 95% confidential interval=0.18-0.038, P<0.001). Fourteen and ten adverse events were observed in the MMC and MMC+Ara-C groups, respectively, without significant difference (P=0.113). CONCLUSIONS Our randomized clinical trial suggested that intravesical therapy with MMC and Ara-C is useful and safe for patients with intermediate-risk NMIBC. Increase in urinary pH with Ara-C is speculated as a mechanism for increased anticancer effects.",2021,Mean/SD urinary pH was significantly higher in the MMC+Ara-C group than in the MMC group (,"['One hundred and sixty-five NMIBC patients from six hospitals', 'patients with intermediate-risk NMIBC', 'A total of 81 and 87 patients', 'non-muscle invasive bladder cancer (NMIBC) patients receiving', 'non-muscle invasive bladder cancer']","['mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara-C) therapy', 'MMC', 'adjuvant intravesical therapy', 'Intravesical MMC and MMC+Ara-C', 'intravesical therapy with MMC and Ara-C', 'MMC+Ara-C']","['frequencies of urinary pH', 'adverse events', 'urinary pH', 'recurrence-free survival', 'urinary pH and toxicity', 'urinary pH, recurrence-free survival, and safety', 'Mean/SD urinary pH']","[{'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0002475', 'cui_str': 'Mitomycin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0733521', 'cui_str': 'Ara-C'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0442124', 'cui_str': 'Intravesical approach'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",165.0,0.309184,Mean/SD urinary pH was significantly higher in the MMC+Ara-C group than in the MMC group (,"[{'ForeName': 'Yasuyoshi', 'Initials': 'Y', 'LastName': 'Miyata', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Tsurusaki', 'Affiliation': 'Department of Urology, The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Hayashida', 'Affiliation': 'Department of Urology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Imasato', 'Affiliation': 'Department of Urology, The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.'}, {'ForeName': 'Kosuke', 'Initials': 'K', 'LastName': 'Takehara', 'Affiliation': 'Department of Urology, Nagasaki Harbor Medical Center, Nagasaki, Japan.'}, {'ForeName': 'Daiyu', 'Initials': 'D', 'LastName': 'Aoki', 'Affiliation': 'Department of Urology, Japan Community Health care Organization Isahaya General Hospital, Isahaya, Japan.'}, {'ForeName': 'Masaharu', 'Initials': 'M', 'LastName': 'Nishikido', 'Affiliation': 'Department of Urology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.'}, {'ForeName': 'Junichi', 'Initials': 'J', 'LastName': 'Watanabe', 'Affiliation': 'Department of Urology, Nagasaki Harbor Medical Center, Nagasaki, Japan.'}, {'ForeName': 'Kensuke', 'Initials': 'K', 'LastName': 'Mitsunari', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Matsuo', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.'}, {'ForeName': 'Kojiro', 'Initials': 'K', 'LastName': 'Ohb', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.'}, {'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Taniguchi', 'Affiliation': 'Department of Urology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Sakai', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BJU international,['10.1111/bju.15571'] 2730,34383325,Effect of low-level laser therapy on postoperative pain after single-visit root canal retreatment of mandibular molars: a randomized-controlled clinical trial.,"AIM To compare the effect of low level laser therapy (LLLT) on postoperative pain after single-visit root canal retreatment in mandibular molars. METHODOLOGY This randomized controlled clinical trial included 36 patients referred to the Department of Endodontics, Islamic Azad University, Tehran, Iran. Healthy patients who required root canal retreatment on symptomatic first or second mandibular molars, with PAI index scores of 2 or 3, preoperative tooth and percussion pain of <56 mm on a 170-mm visual analog scale (VAS) were included. After local anaesthesia using inferior alveolar nerve block followed by rubber dam isolation and access cavity preparation, the D RaCe retreatment system was used to remove the existing root filling material and after canal negotiation and gaining patency, working length was determined with an apex locator. Further canal enlargement was carried out with size 35, .04 taper, and size 40, .04 taper RaCe rotary instruments and then canals were filled using laterally compacted gutta-percha points and AH-Plus sealer. The patients were randomly assigned to treatment groups: In the LLLT group, a 980 nm diode laser set at 6.89 W/cm 2 energy density, 0.5 W power and a tip diameter of 10 mm was activated from the buccal side on the mesial and distal root apices for 15 seconds. In the sham group the laser handpiece was placed inside the patient's mouth at the same location but the laser was not activated. Then patients were instructed to record their postoperative pain levels on 4, 8, 12, 24 hours and 2, 3 and 7 days after treatment on separate VAS scales. For data analysis the independent sample t and the Mann-Whitney U tests were used. Nominal variables were analyzed by the Chi-square test. RESULTS In the LLLT group the most intense pain was reported 24 and 48 hours post treatment [mean (SD)=0.22 (0.54) for both] while in the sham group the most intense pain level was observed 4 hours post treatment [mean (SD)=0.78 (0.80)]. For the 4-hour interval pain intensity was significantly lower in the LLLT group (P=0.016). CONCLUSIONS LLLT reduced postoperative pain after single-visit root canal retreatment of mandibular molars only four hours following the procedure.",2021,"For the 4-hour interval pain intensity was significantly lower in the LLLT group (P=0.016). ","['after single-visit root canal retreatment in mandibular molars', 'after single-visit root canal retreatment of mandibular molars', 'Healthy patients who required root canal retreatment on symptomatic first or second mandibular molars, with PAI index scores of 2 or 3, preoperative tooth and percussion pain of <56 mm on a 170-mm visual analog scale (VAS) were included', '36 patients referred to the Department of Endodontics, Islamic Azad University, Tehran, Iran']","['980 nm diode laser set at 6.89 W/cm 2 energy density, 0.5 W power and a tip diameter of 10 mm was activated from the buccal side', 'low-level laser therapy', 'low level laser therapy (LLLT', 'laser handpiece', 'LLLT']","['intense pain level', 'intense pain', 'postoperative pain levels', '4-hour interval pain intensity', 'postoperative pain']","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0032145', 'cui_str': 'Plasminogen activator inhibitor'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0030987', 'cui_str': 'Percussion'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0332274', 'cui_str': 'Endodontic'}, {'cui': 'C0022126', 'cui_str': 'Islam'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0181115', 'cui_str': 'Handpiece'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1292426', 'cui_str': '4 hours'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",36.0,0.143067,"For the 4-hour interval pain intensity was significantly lower in the LLLT group (P=0.016). ","[{'ForeName': 'Sepideh Esmaeili', 'Initials': 'SE', 'LastName': 'Shahmirzadi', 'Affiliation': 'Faculty of Dentistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Mahta', 'Initials': 'M', 'LastName': 'Fazlyab', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Ehsan', 'Initials': 'E', 'LastName': 'Esnaashari', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Azizi', 'Affiliation': 'Oral Medicine Department, Faculty Of Dentistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Amir Abbas', 'Initials': 'AA', 'LastName': 'Moshari', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.'}]",International endodontic journal,['10.1111/iej.13608'] 2731,34383228,Patients' Reactions to Letters Communicating Collateral Findings of Pragmatic Clinical Trials: a National Web-Based Survey.,"BACKGROUND Collateral findings in pragmatic clinical trials are findings that may have implications for patients' health but were not generated to address a trial's primary research questions. It is uncertain how best to communicate these collateral findings to patients. OBJECTIVES To determine how reactions to a letter communicating collateral findings relate to who signed the letter, the type of finding, or whether the letter specified that the finding arose from a pragmatic clinical trial. RESEARCH DESIGN Web-based survey experiment using a between-subjects design in which respondents were randomly assigned within education strata to view and respond to 1 of 16 hypothetical scenarios. SUBJECTS Adults recruited from an online panel constructed from a probability sample of US-based postal addresses. MEASURES The primary outcomes were the action the respondent would take next (i.e., contact a doctor immediately or something else) and the respondent's emotional reactions (i.e., all positive, all negative, mixed, or none). RESULTS A total of 4080 respondents had analyzable data. Although some effects were statistically significant (P < .05), none exceeded a prespecified threshold for policy relevance (15 or more percentage points). Ratings of letter clarity and level of understanding were lower for letters that included a description of the clinical trial. CONCLUSIONS Signatory and level of detail about collateral findings did not substantially affect people's intentions to take the recommended action of contacting their doctor. Deciding whether to include a description of the pragmatic clinical trial requires a trade-off between transparency and more difficulty understanding the contents of the letter.",2021,"Although some effects were statistically significant (P < .05), none exceeded a prespecified threshold for policy relevance (15 or more percentage points).","['Web-based survey experiment using a between-subjects design in which respondents were randomly assigned within education strata to view and respond to 1 of 16 hypothetical scenarios', '4080 respondents had analyzable data', 'Adults recruited from an online panel constructed from a probability sample of US-based postal addresses']",[],"[""action the respondent would take next (i.e., contact a doctor immediately or something else) and the respondent's emotional reactions (i.e., all positive, all negative, mixed, or none"", 'Ratings of letter clarity and level of understanding']","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C0033206', 'cui_str': 'Probability Sample'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}]",[],"[{'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0221736', 'cui_str': 'Reaction emotional'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0486588', 'cui_str': 'Clarity (property)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}]",4080.0,0.222648,"Although some effects were statistically significant (P < .05), none exceeded a prespecified threshold for policy relevance (15 or more percentage points).","[{'ForeName': 'Kevin P', 'Initials': 'KP', 'LastName': 'Weinfurt', 'Affiliation': 'Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA. kevin.weinfurt@duke.edu.'}, {'ForeName': 'Juli M', 'Initials': 'JM', 'LastName': 'Bollinger', 'Affiliation': 'Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'May', 'Affiliation': 'Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Geller', 'Affiliation': 'Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Debra J H', 'Initials': 'DJH', 'LastName': 'Mathews', 'Affiliation': 'Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Stephanie R', 'Initials': 'SR', 'LastName': 'Morain', 'Affiliation': 'Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Lorrie', 'Initials': 'L', 'LastName': 'Schmid', 'Affiliation': 'Social Science Research Institute, Duke University, Durham, NC, USA.'}, {'ForeName': 'Diane L', 'Initials': 'DL', 'LastName': 'Bloom', 'Affiliation': 'Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Sugarman', 'Affiliation': 'Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.'}]",Journal of general internal medicine,['10.1007/s11606-021-07087-8'] 2732,34383222,Effectiveness of inhaled hypertonic saline application for sputum induction to improve Mycobacterium tuberculosis identification in patients with pulmonary tuberculosis.,"BACKGROUND This study assessed the effectiveness and diagnostic significance of hypertonic saline sputum induction for improving Mycobacterium tuberculosis (MTB) detection. METHODS A prospective, randomized, open, two-arm, comparative study on MTB identification effectiveness when using inhaled sodium chloride hypertonic solution was performed in patients diagnosed with pulmonary tuberculosis (TB). Patients were randomly assigned into two groups: group 1 (inhalation group) included patients who inhaled a 7% sodium chloride solution upon admission to the hospital, and group 2 (control group) coughed up their sputum as usual. For both groups, specimens were tested by bacterioscopic, bacteriological, and molecular genetic methods. Diagnostic chest radiography was performed for all participants. RESULTS In this study, 644 patients (mean age 42.2 years; 151 women, 23.4%) were randomly divided into two groups. Low-quality sputum samples were observed in 7.4% of patients from the inhalation group and 28.8% in the control group (p < 0.001). Acid-fast bacilli (AFB) smear was positive in 65.1% of patients from the inhalation group and 51.3% of controls (p = 0.002). A similar statistically significant situation was observed when culture methods (93.9% inhalation group and 81.9% control group, p < 0.001) and molecular genetic tests (92.2% inhalation group and 79.4% control group, p < 0.001) were used. Thus, active pulmonary TB was not verified microbiologically in 6.1% of patients from the inhalation group and in 18.1% of controls (p < 0.001). CONCLUSIONS Hypertonic saline sputum induction improves the quality of collected samples. This method may be appropriate to increase the rate of MTB detection in sputum using microscopic, bacteriological, and molecular genetic methods for diagnosing TB on the day of specimen collection. Hypertonic saline sputum induction is suitable for middle- and low-income countries with limited resources and causes no severe adverse effects in TB patients.",2021,Acid-fast bacilli (AFB) smear was positive in 65.1% of patients from the inhalation group and 51.3% of controls (p = 0.002).,"['644 patients (mean age 42.2\xa0years; 151 women, 23.4', 'patients with pulmonary tuberculosis', 'patients diagnosed with pulmonary tuberculosis (TB', 'TB patients']","['inhaled hypertonic saline application', 'hypertonic saline sputum induction', 'group\xa01 (inhalation group) included patients who inhaled a\xa07% sodium chloride solution upon admission to the hospital, and group\xa02 (control group) coughed up their sputum as usual', 'inhaled sodium chloride hypertonic solution', 'Diagnostic chest radiography', 'Hypertonic saline sputum induction']","['active pulmonary TB', 'quality of collected samples', 'Acid-fast bacilli (AFB) smear', 'Low-quality sputum samples', 'Mycobacterium tuberculosis identification', 'molecular genetic tests']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517655', 'cui_str': '23.4'}, {'cui': 'C0041327', 'cui_str': 'Pulmonary tuberculosis'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0036085', 'cui_str': 'sodium chloride, hypertonic'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0163299', 'cui_str': 'A 7'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0239134', 'cui_str': 'Productive cough'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0041327', 'cui_str': 'Pulmonary tuberculosis'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1318720', 'cui_str': 'Acid fast stain'}, {'cui': 'C0004587', 'cui_str': 'Bacillus'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0444159', 'cui_str': 'Sputum specimen'}, {'cui': 'C0026926', 'cui_str': 'Mycobacterium tuberculosis'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C1320549', 'cui_str': 'Molecular genetic test'}]",644.0,0.0434459,Acid-fast bacilli (AFB) smear was positive in 65.1% of patients from the inhalation group and 51.3% of controls (p = 0.002).,"[{'ForeName': 'Dmytro', 'Initials': 'D', 'LastName': 'Butov', 'Affiliation': 'Departments of Phthisiology and Pulmonology, Kharkiv National Medical University, 4 Nauky Avenue, 61022, Kharkiv, Ukraine. dddimad@gmail.com.'}, {'ForeName': 'Yurii', 'Initials': 'Y', 'LastName': 'Feshchenko', 'Affiliation': 'National Institute of Phthisiology and Pulmonology named after F. G. Yanovskyi NAMS of Ukraine, Kyiv, Ukraine.'}, {'ForeName': 'Valeriy', 'Initials': 'V', 'LastName': 'Myasoedov', 'Affiliation': 'Departments of Phthisiology and Pulmonology, Kharkiv National Medical University, 4 Nauky Avenue, 61022, Kharkiv, Ukraine.'}, {'ForeName': 'Mykhailo', 'Initials': 'M', 'LastName': 'Kuzhko', 'Affiliation': 'National Institute of Phthisiology and Pulmonology named after F. G. Yanovskyi NAMS of Ukraine, Kyiv, Ukraine.'}, {'ForeName': 'Mykola', 'Initials': 'M', 'LastName': 'Gumeniuk', 'Affiliation': 'National Institute of Phthisiology and Pulmonology named after F. G. Yanovskyi NAMS of Ukraine, Kyiv, Ukraine.'}, {'ForeName': 'Galyna', 'Initials': 'G', 'LastName': 'Gumeniuk', 'Affiliation': 'National Institute of Phthisiology and Pulmonology named after F. G. Yanovskyi NAMS of Ukraine, Kyiv, Ukraine.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Tkachenko', 'Affiliation': 'Departments of Phthisiology and Pulmonology, Kharkiv National Medical University, 4 Nauky Avenue, 61022, Kharkiv, Ukraine.'}, {'ForeName': 'Nekrasova', 'Initials': 'N', 'LastName': 'Nataliya', 'Affiliation': 'Departments of Phthisiology and Pulmonology, Kharkiv National Medical University, 4 Nauky Avenue, 61022, Kharkiv, Ukraine.'}, {'ForeName': 'Olena', 'Initials': 'O', 'LastName': 'Borysova', 'Affiliation': 'Departments of Phthisiology and Pulmonology, Kharkiv National Medical University, 4 Nauky Avenue, 61022, Kharkiv, Ukraine.'}, {'ForeName': 'Tetiana', 'Initials': 'T', 'LastName': 'Butova', 'Affiliation': 'Departments of Phthisiology and Pulmonology, Kharkiv National Medical University, 4 Nauky Avenue, 61022, Kharkiv, Ukraine.'}]",Wiener medizinische Wochenschrift (1946),['10.1007/s10354-021-00871-5'] 2733,34383179,A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density.,"PURPOSE Obesity is a known risk factor for post-menopausal breast cancer and may increase risk for triple negative breast cancer in premenopausal women. Intervention strategies are clearly needed to reduce obesity-associated breast cancer risk. METHODS We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention. Eligible participants were randomized to receive metformin (850 mg BID, n = 76) or placebo (n = 75) for 12 months. Outcomes included breast density, assessed by fat/water MRI with change in percent breast density as the primary endpoint, anthropometric measures, and intervention feasibility. RESULTS Seventy-six percent in the metformin arm and 83% in the placebo arm (p = 0.182) completed the 12-month intervention. Adherence to study agent was high with more than 80% of participants taking ≥ 80% assigned pills. The most common adverse events reported in the metformin arm were gastrointestinal in nature and subsided over time. Compared to placebo, metformin intervention led to a significant reduction in waist circumference (p < 0.001) and waist-to-hip ratio (p = 0.019). Compared to placebo, metformin did not change percent breast density and dense breast volume but led to a numerical but not significant decrease in non-dense breast volume (p = 0.070). CONCLUSION We conclude that metformin intervention resulted in favorable changes in anthropometric measures of adiposity and a borderline decrease in non-dense breast volume in women with metabolic dysregulation. More research is needed to understand the impact of metformin on breast cancer risk reduction. TRIAL REGISTRATION ClinicalTrials.gov NCT02028221. Registered January 7, 2014, https://clinicaltrials.gov/ct2/show/NCT02028221.",2021,"RESULTS Seventy-six percent in the metformin arm and 83% in the placebo arm (p = 0.182) completed the 12-month intervention.","['overweight/obese premenopausal women with components of metabolic syndrome', 'premenopausal women', 'Eligible participants', 'women with metabolic dysregulation', 'primary breast cancer prevention', 'women with components of metabolic syndrome']","['placebo, metformin', 'metformin', 'metformin intervention', 'placebo, metformin intervention', 'placebo']","['breast density and dense breast volume', 'adiposity and breast density', 'anthropometric measures of adiposity', 'waist circumference', 'breast density, assessed by fat/water MRI with change in percent breast density as the primary endpoint, anthropometric measures, and intervention feasibility', 'waist-to-hip ratio']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1659543', 'cui_str': 'Breast Density'}, {'cui': 'C0439794', 'cui_str': 'Dense'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}]",,0.364078,"RESULTS Seventy-six percent in the metformin arm and 83% in the placebo arm (p = 0.182) completed the 12-month intervention.","[{'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Tapia', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Diana Evelyn', 'Initials': 'DE', 'LastName': 'Villa-Guillen', 'Affiliation': 'Department of Biological-Chemistry Sciences, University of Sonora, Hermosillo, Sonora, Mexico.'}, {'ForeName': 'Pavani', 'Initials': 'P', 'LastName': 'Chalasani', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Centuori', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Denise J', 'Initials': 'DJ', 'LastName': 'Roe', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Guillen-Rodriguez', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Chuan', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': 'Department of Radiology, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Jean-Phillippe', 'Initials': 'JP', 'LastName': 'Galons', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Cynthia A', 'Initials': 'CA', 'LastName': 'Thomson', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Altbach', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Trujillo', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Liane', 'Initials': 'L', 'LastName': 'Pinto', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Martinez', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'Amit M', 'Initials': 'AM', 'LastName': 'Algotar', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA.'}, {'ForeName': 'H-H Sherry', 'Initials': 'HS', 'LastName': 'Chow', 'Affiliation': 'University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA. schow@azcc.arizona.edu.'}]",Breast cancer research and treatment,['10.1007/s10549-021-06355-9'] 2734,34383175,Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study.,"Whether cefazolin is as effective and safer than antistaphylococcal penicillins (ASPs) for the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) is still debated in the absence of a randomized controlled trial. In this quasi-experimental study, we aimed to assess the effectiveness and safety of these two treatments in MSSA-IE, using the ASPs nationwide shortage in April 2016 as a unique opportunity to overcome the indication bias associated with observational studies. In this single-centre study, we compared patients with Duke-Li definite MSSA-IE treated with ASPs from January 2015 to March 2016 versus those treated with cefazolin from April 2016 to December 2018, when ASPs were not available. Effectiveness outcome was 90-day all-cause mortality. Safety outcomes included significant decrease in GFR and significant increase in serum liver enzymes. Logrank test was used to compare survival rates. Of 73 patients with MSSA-IE, 35 and 38 were treated with ASPs and cefazolin, respectively. Baseline patients' characteristics (demography, native or prosthetic valve IE, clinical characteristics, cardiac and septic complications) were similar between groups. Ninety-day all-cause mortality was 28.6% and 21.1%, in patients treated with ASPs and cefazolin, respectively (logrank p = 0.5727). There was no difference between groups for incident renal or liver toxicity events: acute kidney injury 45.7% vs. 44.7% (p = 0.933), increased ALT 5.7% vs. 13.2% (p = 0.432), bilirubin increase 5.7% vs. 10.5% (p = 0.676), in ASPs vs. cefazolin groups, respectively. In this quasi-experimental, effectiveness and safety did not statistically differ between ASPs and cefazolin for MSSA-IE treatment.",2021,"In this quasi-experimental, effectiveness and safety did not statistically differ between ASPs and cefazolin for MSSA-IE treatment.","['methicillin-susceptible Staphylococcus aureus infective endocarditis', 'patients with Duke-Li definite MSSA-IE treated with ASPs from January 2015 to March 2016 versus those treated with', '73 patients with MSSA-IE, 35 and 38 were treated with']","['ASPs and cefazolin', 'Antistaphylococcal penicillins vs. cefazolin', 'cefazolin']","[""Baseline patients' characteristics (demography, native or prosthetic valve IE, clinical characteristics, cardiac and septic complications"", 'survival rates', 'effectiveness and safety', 'serum liver enzymes', 'cause mortality', 'incident renal or liver toxicity events: acute kidney injury', 'GFR', 'bilirubin']","[{'cui': 'C1635274', 'cui_str': 'Methicillin susceptible Staphylococcus aureus'}, {'cui': 'C0014121', 'cui_str': 'Bacterial endocarditis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1512090', 'cui_str': 'Dukes staging system'}, {'cui': 'C0439544', 'cui_str': 'Definite'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0030842', 'cui_str': 'Penicillin'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0030842', 'cui_str': 'Penicillin'}, {'cui': 'C0007546', 'cui_str': 'Cefazolin'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0336548', 'cui_str': 'Prosthetic valve'}, {'cui': 'C0014121', 'cui_str': 'Bacterial endocarditis'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}]",73.0,0.0560824,"In this quasi-experimental, effectiveness and safety did not statistically differ between ASPs and cefazolin for MSSA-IE treatment.","[{'ForeName': 'B', 'Initials': 'B', 'LastName': 'Lefèvre', 'Affiliation': 'Infectious and Tropical Diseases, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France. b.lefevre@chru-nancy.fr.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Hoen', 'Affiliation': 'Infectious and Tropical Diseases, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Goehringer', 'Affiliation': 'Infectious and Tropical Diseases, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.'}, {'ForeName': 'W Ngueyon', 'Initials': 'WN', 'LastName': 'Sime', 'Affiliation': 'INSERM, CIC-EC, Epidémiologie clinique, CHRU-Nancy, 54000, Nancy, France.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Aissa', 'Affiliation': 'Service de Microbiologie, CHRU-Nancy, 54000, Nancy, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Alauzet', 'Affiliation': 'Service de Microbiologie, CHRU-Nancy, 54000, Nancy, France.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Jeanmaire', 'Affiliation': 'Infectious and Tropical Diseases, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Hénard', 'Affiliation': 'Infectious and Tropical Diseases, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Filippetti', 'Affiliation': 'Cardiology, CHRU-Nancy, 54000, Nancy, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Selton-Suty', 'Affiliation': 'Cardiology, CHRU-Nancy, 54000, Nancy, France.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Agrinier', 'Affiliation': 'APEMAC, Université de Lorraine, 54000, Nancy, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,['10.1007/s10096-021-04313-3'] 2735,34383143,Efficacy and tooth sensitivity of at-home bleaching in patients with esthetic restorations: a randomized clinical trial.,"OBJECTIVES This study aims to evaluate the color change and tooth sensitivity (TS) caused by at-home bleaching in patients with sound and with restored teeth. METHODS Forty patients were selected according to the inclusion and exclusion criteria and divided into two groups: So (patients with six caries-free maxillary anterior teeth) and Re (patients with at least one restoration in the six maxillary anterior teeth). Both groups were bleached with 10% carbamide peroxide (CP) at-home bleaching. The color change (CIELab [ΔE* ab ], CIEDE00 [ΔE 00 ], and whiteness index [∆WI D ]) were assessed using a spectrophotometer at baseline, 2 weeks, and 1 and 3 months after bleaching. Patients recorded their TS using a numeric rating scale (0-4). Data of color change were submitted to Student's T-test. The absolute risk and intensity of TS were compared using Fisher's and the Mann-Whitney tests, respectively (α = 0.05). RESULTS Higher ΔE* ab , ΔE 00 , and ∆WI D values were observed for So in relation to Re after all recall rate (p < 0.0001). No significant differences were observed regarding of bleaching-induced TS (p > 0.9). CONCLUSIONS At-home dental bleaching with 10% CP generated the same pattern of TS in patients with or without restorations. However, in patients with restored teeth, it produced a lower color change after 2 weeks of bleaching. CLINICAL SIGNIFICANCE After 2 weeks of at-home bleaching, a lower whitening effect was observed in patients with anterior restorations when compared with patients with sound teeth. TRIAL REGISTRATION ClinicalTrials.gov identifier RBR-52j6gmg.",2021,"No significant differences were observed regarding of bleaching-induced TS (p > 0.9). ","['patients with sound and with restored teeth', 'So (patients with six caries-free maxillary anterior teeth) and Re (patients with at least one restoration in the six maxillary anterior teeth', 'Forty patients were selected according to the inclusion and exclusion criteria and divided into two groups', 'patients with or without restorations', 'patients with esthetic restorations']",['carbamide peroxide (CP'],"['numeric rating scale', 'absolute risk and intensity of TS', 'whitening effect', 'bleaching-induced TS', 'Efficacy and tooth sensitivity', 'color change and tooth sensitivity (TS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}]","[{'cui': 'C0108342', 'cui_str': 'carbamide peroxide'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0011432', 'cui_str': 'Sensitive dentin'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0303749', 'cui_str': 'Bleach'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0475330', 'cui_str': 'Color change'}]",40.0,0.0649954,"No significant differences were observed regarding of bleaching-induced TS (p > 0.9). ","[{'ForeName': 'Sônia Saeger', 'Initials': 'SS', 'LastName': 'Meireles', 'Affiliation': 'Departamento de Odontologia Restauradora, Universidade Federal da Paraíba, PB, João Pessoa, Brazil. soniasaeger@hotmail.com.'}, {'ForeName': 'Renata Dantas Barreto', 'Initials': 'RDB', 'LastName': 'de Oliveira', 'Affiliation': 'Programa de Pós-graduação em Odontologia, Universidade Federal da Paraíba, PB, João Pessoa, Brazil.'}, {'ForeName': 'Marcella Tuanny Guedes', 'Initials': 'MTG', 'LastName': 'Barbosa', 'Affiliation': 'Programa de Pós-graduação em Odontologia, Universidade Federal da Paraíba, PB, João Pessoa, Brazil.'}, {'ForeName': 'Karine Letícia', 'Initials': 'KL', 'LastName': 'da Silva', 'Affiliation': 'Departamento de Odontologia Restauradora, Universidade Estadual de Ponta Grossa, PR, Ponta Grossa, Brazil.'}, {'ForeName': 'Alessandro Dourado', 'Initials': 'AD', 'LastName': 'Loguercio', 'Affiliation': 'Departamento de Odontologia Restauradora, Universidade Estadual de Ponta Grossa, PR, Ponta Grossa, Brazil.'}]",Clinical oral investigations,['10.1007/s00784-021-04035-y'] 2736,34383100,Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.,"Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months. With TPTD, there was no evidence of improved healing by CT or pain reduction; however, physical performance improved with TPTD but not placebo (group difference p < 0.03). INTRODUCTION To determine if teriparatide (20 μg/day; TPTD) results in improved radiologic healing, reduced pain, and improved functional outcome vs placebo over 3 months in pelvic fracture patients. METHODS This randomized, placebo-controlled study enrolled 35 patients (women and men >50 years old) within 4 weeks of pelvic fracture and evaluated the effect of blinded TPTD vs placebo over 3 months on fracture healing. Fracture healing from CT images at 0 and 3 months was assessed as cortical bridging using a 5-point scale. The numeric rating scale (NRS) for pain was administered monthly. Physical performance was assessed monthly by Continuous Summary Physical Performance Score (based on 4 m walk speed, timed repeated chair stands, and balance) and the Timed Up and Go (TUG) test. RESULTS The mean age was 82, and >80% were female. The intention to treat analysis showed no group difference in cortical bridging score, and 50% of fractures in TPTD-treated and 53% of fractures in placebo-treated patients were healed at 3 months, unchanged after adjustment for age, sacral fracture, and fracture displacement. Median pain score dropped significantly in both groups with no group differences. Both CSPPS and TUG improved in the teriparatide group, whereas there was no improvement in the placebo group (group difference p < 0.03 for CSPPS at 2 and 3 months). CONCLUSION In this small randomized, blinded study, there was no improvement in radiographic healing (CT at 3 months) or pain with TPTD vs placebo; however, there was improved physical performance in TPTD-treated subjects that was not evident in the placebo group.",2021,"Both CSPPS and TUG improved in the teriparatide group, whereas there was no improvement in the placebo group (group difference p < 0.03 for CSPPS at 2 and 3 months). ","['pelvic fracture patients', 'Pelvic fracture patients', '35 patients (women and men >50 years old) within 4 weeks of pelvic fracture and evaluated the effect of', 'The mean age was 82, and >80% were female']","['Teriparatide', 'subcutaneous teriparatide (TPTD) or placebo', 'teriparatide (20 μg/day; TPTD', 'placebo', 'blinded TPTD vs placebo']","['Median pain score', 'radiographic healing', 'healing by CT or pain reduction', 'numeric rating scale (NRS) for pain', 'healing and functional outcomes', 'pelvic fracture healing', 'Physical performance', 'Continuous Summary Physical Performance Score (based on 4 m walk speed, timed repeated chair stands, and balance) and the Timed Up and Go (TUG) test', 'cortical bridging score', 'radiologic healing, reduced pain, and improved functional outcome', 'Fracture healing', 'physical performance']","[{'cui': 'C0149531', 'cui_str': 'Fracture of pelvis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0070093', 'cui_str': 'Teriparatide'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0149531', 'cui_str': 'Fracture of pelvis'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0034599', 'cui_str': 'Radiology - specialty'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0152231', 'cui_str': 'Fracture, healed'}]",35.0,0.311657,"Both CSPPS and TUG improved in the teriparatide group, whereas there was no improvement in the placebo group (group difference p < 0.03 for CSPPS at 2 and 3 months). ","[{'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Nieves', 'Affiliation': 'Hospital for Special Surgery, New York, NY, USA. nievesje@hss.edu.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Cosman', 'Affiliation': 'Department of Medicine, Columbia University, New York, NY, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'McMahon', 'Affiliation': 'Hospital for Special Surgery, New York, NY, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Redko', 'Affiliation': 'Hospital for Special Surgery, New York, NY, USA.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Hentschel', 'Affiliation': 'Hospital for Special Surgery, New York, NY, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Bartolotta', 'Affiliation': 'Department of Radiology, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Loftus', 'Affiliation': 'Department of Radiology, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Kazam', 'Affiliation': 'Department of Radiology, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Rotman', 'Affiliation': 'Department of Radiology, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Lane', 'Affiliation': 'Hospital for Special Surgery, New York, NY, USA.'}]",Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,['10.1007/s00198-021-06065-4'] 2737,34383010,Prednisolone and Ketorolac vs Ketorolac Monotherapy or Sub-Tenon Prophylaxis for Macular Thickening in Cataract Surgery: A Randomized Clinical Trial.,"Importance The choice of anti-inflammatory prophylaxis parallel to cataract surgery is important for patient safety and successful outcome of surgery, but which regimen to choose is contested. Objectives To determine whether a combination of prednisolone and nonsteroidal anti-inflammatory drug (NSAID) eye drops was superior in preventing increased central macular thickness (central subfield thickness [CST]) after uncomplicated cataract surgery compared with NSAID monotherapy and sub-Tenon capsule depot (dropless surgery), and to test whether preoperative initiation of eye drop treatment was superior to initiation on the day of surgery. Design, Setting, and Participants This investigator-driven, single-center, randomized clinical trial with masked statistical analyses enrolled patients at the Department of Ophthalmology, Rigshospitalet Glostrup, Glostrup, Denmark, from February 1, 2018, to August 15, 2019. Follow-up was completed December 18, 2019. Participants included low-risk patients undergoing phacoemulsification for age-related cataract by an experienced surgeon (1 eye per participant). Data were analyzed from February 17 to June 15, 2020. Interventions Participants scheduled for cataract removal were randomized to 1 of 5 anti-inflammatory prophylactic regimens: eye drops with a combination of prednisolone, 1%, and ketorolac tromethamine, 0.5%, with or without preoperative initiation (preoperative prednisolone plus NSAID [control] and postoperative prednisolone plus NSAID groups), ketorolac monotherapy with or without preoperative initiation (preoperative and postoperative NSAID groups), or sub-Tenon depot of dexamethasone phosphate (sub-Tenon group). Eye drops were administered 3 times per day until 3 weeks postoperatively. Main Outcomes and Measures CST 3 months postoperatively. Results A total of 470 participants (mean [SD] age, 72.2 [7.0] years; 290 women [61.7%]) with 94 participants in each group were included in the analysis. Three months after surgery, the mean CST was 250.7 (95% CI, 247.6-253.7) μm in the preoperative prednisolone plus NSAID group, 250.7 (95% CI, 247.8-253.7) μm in the postoperative prednisolone plus NSAID group, 251.3 (95% CI, 248.2-254.4) μm in the preoperative NSAID group, 249.2 (95% CI, 246.2-252.3) μm in the postoperative NSAID group, and 255.2 (95% CI, 252.0-258.3) μm in the sub-Tenon group. There were no significant differences in CST or visual acuity compared with control and no differences between preoperative and postoperative groups, but 47 of 83 participants (56.6%) in the sub-Tenon group needed additional anti-inflammatory treatment. Conclusions and Relevance No differences in CST or visual acuity were detected between the combination of prednisolone and NSAID eye drops vs NSAID monotherapy or sub-Tenon dexamethasone depot, although more than one-half of patients in the sub-Tenon arm received additional anti-inflammatory treatment. Initiating prophylaxis 3 days preoperatively was not superior to initiation on the day of surgery. Monotherapy with NSAIDs may be preferred in uncomplicated cataract surgery. Trial Registration ClinicalTrials.gov Identifier: NCT03383328.",2021,"Conclusions and Relevance No differences in CST or visual acuity were detected between the combination of prednisolone and NSAID eye drops vs NSAID monotherapy or sub-Tenon dexamethasone depot, although more than one-half of patients in the sub-Tenon arm received additional anti-inflammatory treatment.","['Interventions\n\n\nParticipants scheduled for cataract removal', 'Macular Thickening in Cataract Surgery', '470 participants (mean [SD] age, 72.2 [7.0] years', 'Participants included low-risk patients undergoing phacoemulsification for age-related cataract by an experienced surgeon (1 eye per participant', 'enrolled patients at the Department of Ophthalmology, Rigshospitalet Glostrup, Glostrup, Denmark, from February 1, 2018, to August 15, 2019', ' 290 women [61.7%]) with 94 participants in each group were included in the analysis', 'Data were analyzed from February 17 to June 15, 2020']","['Prednisolone and Ketorolac vs Ketorolac Monotherapy or Sub-Tenon Prophylaxis', 'prednisolone and nonsteroidal anti-inflammatory drug (NSAID) eye drops', 'NSAID monotherapy and sub-Tenon capsule depot (dropless surgery', 'prednisolone', '5 anti-inflammatory prophylactic regimens: eye drops with a combination of prednisolone, 1%, and ketorolac tromethamine, 0.5%, with or without preoperative initiation (preoperative prednisolone plus NSAID [control] and postoperative prednisolone plus NSAID groups), ketorolac monotherapy with or without preoperative initiation (preoperative and postoperative NSAID groups), or sub-Tenon depot of dexamethasone phosphate (sub-Tenon group', 'Monotherapy with NSAIDs']","['CST or visual acuity', 'central macular thickness (central subfield thickness [CST', 'mean CST']","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205400', 'cui_str': 'Thickened'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C5191218', 'cui_str': '290'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0015399', 'cui_str': 'Eye drops'}, {'cui': 'C2586323', 'cui_str': ""Tenon's capsule structure""}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0064326', 'cui_str': 'Ketorolac tromethamine'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0770565', 'cui_str': 'Dexamethasone phosphate'}]","[{'cui': 'C0560172', 'cui_str': 'cSt'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",470.0,0.606774,"Conclusions and Relevance No differences in CST or visual acuity were detected between the combination of prednisolone and NSAID eye drops vs NSAID monotherapy or sub-Tenon dexamethasone depot, although more than one-half of patients in the sub-Tenon arm received additional anti-inflammatory treatment.","[{'ForeName': 'Jesper Høiberg', 'Initials': 'JH', 'LastName': 'Erichsen', 'Affiliation': 'Department of Ophthalmology, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Lars M', 'Initials': 'LM', 'LastName': 'Holm', 'Affiliation': 'Department of Ophthalmology, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Mads', 'Initials': 'M', 'LastName': 'Forslund Jacobsen', 'Affiliation': 'Department of Ophthalmology, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Forman', 'Affiliation': 'Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Line', 'Initials': 'L', 'LastName': 'Kessel', 'Affiliation': 'Department of Ophthalmology, Rigshospitalet Glostrup, Glostrup, Denmark.'}]",JAMA ophthalmology,['10.1001/jamaophthalmol.2021.2976'] 2738,34383006,Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.,"Importance A significant subset of patients with stage II/III non-small cell lung cancer (NSCLC) cannot receive standard concurrent chemoradiotherapy owing to the risk of toxic effects outweighing potential benefits. Without concurrent chemotherapy, however, the efficacy of conventional radiotherapy is reduced. Objective To determine whether hypofractionated image-guided radiotherapy (IGRT) would improve overall survival in patients with stage II/III NSCLC who could not receive concurrent chemoradiotherapy and therefore were traditionally relegated to receiving only conventionally fractionated radiotherapy (CFRT). Design, Setting, and Participants This nonblinded, phase 3 randomized clinical study enrolled 103 patients and analyzed 96 patients with stage II/III NSCLC and Zubrod performance status of at least 2, with greater than 10% weight loss in the previous 6 months, and/or who were ineligible for concurrent chemoradiotherapy after oncology consultation. Enrollment occurred at multiple US institutions. Patients were enrolled from November 13, 2012, to August 28, 2018, with a median follow-up of 8.7 (3.6-19.9) months. Data were analyzed from September 14, 2018, to April 11, 2021. Interventions Eligible patients were randomized to hypofractionated IGRT (60 Gy in 15 fractions) vs CFRT (60 Gy in 30 fractions). Main Outcomes and Measures The primary end point was 1-year overall survival. Results A total of 103 patients (96 of whom were analyzed [63 men (65.6%); mean (SD) age, 71.0 (10.2) years (range, 50-90 years)]) were randomized to hypofractionated IGRT (n = 50) or CFRT (n = 46) when a planned interim analysis suggested futility in reaching the primary end point, and the study was closed to further accrual. There was no statistically significant difference between the treatment groups for 1-year overall survival (37.7% [95% CI, 24.2%-51.0%] for hypofractionated IGRT vs 44.6% [95% CI, 29.9%-58.3%] for CFRT; P = .29). There were also no significant differences in median overall survival, progression-free survival, time to local failure, time to distant metastasis, and toxic effects of grade 3 or greater between the 2 treatment groups. Conclusions and Relevance This phase 3 randomized clinical trial found that hypofractionated IGRT (60 Gy in 15 fractions) was not superior to CFRT (60 Gy in 30 fractions) for patients with stage II/III NSCLC ineligible for concurrent chemoradiotherapy. Further studies are needed to verify equivalence between these radiotherapy regimens. Regardless, for well-selected patients with NSCLC (ie, peripheral primary tumors and limited mediastinal/hilar adenopathy), the convenience of hypofractionated radiotherapy regimens may offer an appropriate treatment option. Trial Registration ClinicalTrials.gov Identifier: NCT01459497.",2021,"There was no statistically significant difference between the treatment groups for 1-year overall survival (37.7% [95% CI, 24.2%-51.0%] for hypofractionated IGRT vs 44.6% [95% CI, 29.9%-58.3%] for CFRT; P = .29).","['Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance', 'patients with stage II/III NSCLC who could not receive concurrent chemoradiotherapy and therefore were traditionally relegated to receiving only conventionally fractionated radiotherapy (CFRT', 'patients with stage II/III NSCLC ineligible for concurrent chemoradiotherapy', 'Patients were enrolled from November 13, 2012, to August 28, 2018, with a median follow-up of 8.7 (3.6-19.9) months', 'patients with stage II/III non-small cell lung cancer (NSCLC', 'Status', '103 patients and analyzed 96 patients with stage II/III', '103 patients (96 of whom were analyzed [63 men (65.6%); mean (SD) age, 71.0 (10.2) years (range, 50-90 years']","['hypofractionated IGRT', 'conventional radiotherapy', 'CFRT', 'Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy', 'standard concurrent chemoradiotherapy', 'hypofractionated image-guided radiotherapy (IGRT']","['1-year overall survival', 'overall survival', 'median overall survival, progression-free survival, time to local failure, time to distant metastasis, and toxic effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4517880', 'cui_str': '8.7'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]","[{'cui': 'C3179062', 'cui_str': 'Image-Guided Radiation Therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1269798', 'cui_str': 'pM category'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]",103.0,0.494242,"There was no statistically significant difference between the treatment groups for 1-year overall survival (37.7% [95% CI, 24.2%-51.0%] for hypofractionated IGRT vs 44.6% [95% CI, 29.9%-58.3%] for CFRT; P = .29).","[{'ForeName': 'Puneeth', 'Initials': 'P', 'LastName': 'Iyengar', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Zhang-Velten', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Court', 'Affiliation': 'Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Westover', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Yulong', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Mu-Han', 'Initials': 'MH', 'LastName': 'Lin', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Zhenyu', 'Initials': 'Z', 'LastName': 'Xiong', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Mehul', 'Initials': 'M', 'LastName': 'Patel', 'Affiliation': 'Department of Radiation Oncology, Baylor Scott & White Memorial Hospital, Temple, Texas.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Rivera', 'Affiliation': 'Department of Radiation Oncology, Austin Cancer Center, Austin, Texas.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Chang', 'Affiliation': 'Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Saunders', 'Affiliation': 'Department of Radiation Oncology, Texas Oncology Tyler, Tyler.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Shivnani', 'Affiliation': 'Department of Radiation Oncology, Texas Oncology Sherman, Sherman.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'Department of Radiation Oncology, Texas Center for Proton Therapy, Irving.'}, {'ForeName': 'Randall', 'Initials': 'R', 'LastName': 'Hughes', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gerber', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Dowell', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Ang', 'Initials': 'A', 'LastName': 'Gao', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Heinzerling', 'Affiliation': 'Department of Radiation Oncology, Levine Cancer Institute, Atrium Heath, Charlotte, North Carolina.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona.'}, {'ForeName': 'Chul', 'Initials': 'C', 'LastName': 'Ahn', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Hak', 'Initials': 'H', 'LastName': 'Choy', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Timmerman', 'Affiliation': 'Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.'}]",JAMA oncology,['10.1001/jamaoncol.2021.3186'] 2739,34383007,Errors in Reported Primary and Secondary Outcomes and Table Numbers in a Trial of Radiotherapy for Pain Relief in Patients With Bone Metastases.,,2021,,['Patients With Bone Metastases'],['Radiotherapy'],['Pain Relief'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0153690', 'cui_str': 'Secondary malignant neoplasm of bone'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}]",,0.278073,,"[{'ForeName': 'Quynh-Nhu', 'Initials': 'QN', 'LastName': 'Nguyen', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}]",JAMA oncology,['10.1001/jamaoncol.2021.3054'] 2740,34382846,Effect of interface pressure and skin surface temperature on pressure injury incidence: a turning schedule pilot study.,"OBJECTIVE This study aimed to evaluate the interface pressure and skin surface temperature in relation to the incidence of pressure injury (PI) using three different turning schedules. METHOD This was a pilot study with a three-armed randomised clinical trial design. Participants at risk of PI and treated in the high dependency care unit in a regional hospital in Makassar, Indonesia participated in this study. Patients were repositioned at three different turning schedules (two-, three- and four-hourly intervals). Interface pressure measurement and skin surface temperature were measured between 14:00 and 18:00 every three days. The incidence of PI was assessed during the two-week observation period. RESULTS A total of 44 participants took part in the study. A one-way ANOVA test revealed no difference in interface pressure among the three different turning schedule groups within two weeks of observations: day zero, p=0.56; day four, p=0.95; day seven, p=0.56; day 10, p=0.63; and day 14, p=0.92. Although the average periumbilical temperature and skin surface temperature were not significant (p>0.05), comparison between these observation sites was significant on all observation days (p<0.05). Regarding the incidence of PI, the proportional hazard test for the development of PI in the three groups was considered not different (hazard ratio: 1.46, 95% confidence interval: 0.43-4.87, p=0.54). CONCLUSION No difference in interface pressure and incidence of PI on the three turning schedules was observed; however, there was a potential increase in skin surface temperature in comparison with periumbilical temperature for all three turning schedules.",2021,"A one-way ANOVA test revealed no difference in interface pressure among the three different turning schedule groups within two weeks of observations: day zero, p=0.56; day four, p=0.95; day seven, p=0.56; day 10, p=0.63; and day 14, p=0.92.","['Participants at risk of PI and treated in the high dependency care unit in a regional hospital in Makassar, Indonesia participated in this study', '44 participants took part in the study']",['interface pressure and skin surface temperature'],"['interface pressure', 'pressure injury incidence', 'incidence of PI', 'Interface pressure measurement and skin surface temperature', 'average periumbilical temperature and skin surface temperature', 'interface pressure and incidence of PI', 'skin surface temperature']","[{'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0332679', 'cui_str': 'Crushing injury'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}]","[{'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0332679', 'cui_str': 'Crushing injury'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0457792', 'cui_str': 'Periumbilical'}]",44.0,0.0787481,"A one-way ANOVA test revealed no difference in interface pressure among the three different turning schedule groups within two weeks of observations: day zero, p=0.56; day four, p=0.95; day seven, p=0.56; day 10, p=0.63; and day 14, p=0.92.","[{'ForeName': 'Sumiati', 'Initials': 'S', 'LastName': 'Tarigan', 'Affiliation': 'Faculty of Nursing, Hasanuddin University, Makassar, Indonesia.'}, {'ForeName': 'Saldy', 'Initials': 'S', 'LastName': 'Yusuf', 'Affiliation': 'Faculty of Nursing, Hasanuddin University, Makassar, Indonesia.'}, {'ForeName': 'Yuliana', 'Initials': 'Y', 'LastName': 'Syam', 'Affiliation': 'Faculty of Nursing, Hasanuddin University, Makassar, Indonesia.'}]",Journal of wound care,['10.12968/jowc.2021.30.8.632'] 2741,34382725,Occurrence and characteristics of pain after ICU discharge: A longitudinal study.,"BACKGROUND Pain is a serious problem for intensive care unit (ICU) patients, but we are lacking data on pain at the hospital ward after ICU discharge. AIMS AND OBJECTIVES To describe pain intensity, -interference with function and -location in patients up to 1 year after ICU discharge. To identify demographic and clinical variables and their association with worst pain intensity and pain interference. DESIGN A longitudinal descriptive secondary analysis of a randomized controlled trial on nurse-led follow-up consultations on post-traumatic stress and sense of coherence after ICU discharge. METHODS Pain intensity, -interference, and -location were measured using Brief Pain Inventory at the hospital ward and 3, 6, and 12 months after ICU discharge. For associations, data were analysed using multivariate linear mixed models for repeated measures. RESULTS Of 523 included patients, 68% reported worst pain intensity score above 0 (no pain) at the ward. Estimated means for worst pain intensity and -interference (from 0 to 10) after ICU discharge were 5.5 [CI 4.6-6.5] and 4.5 [CI 3.7-5.3], and decreased to 3.8 [CI 2.8-4.8] (P ≤ .001) and 2.9 [CI 2.1-3.7] after 12 months (P ≤ .001). Most common pain locations were abdomen (43%), lower lumbar back (28%), and shoulder/forearm (22%). At 12 months, post-traumatic stress (PTS) symptoms ≥25 (scale 10-70), female gender, shorter ICU stay, and more traumatic ICU memories were significantly associated with higher worst pain intensity. PTS symptoms ≥25, female gender, more traumatic ICU memories, younger age, and not having an internal medical diagnosis were significantly associated with higher pain interference. CONCLUSIONS Early after ICU discharge pain was present in 68% of patients. Thereafter, pain intensity and -interference declined, but pain intensity was still at a moderate level at 12 months. Health professionals should be aware of patients' pain and identify potentially vulnerable patients. IMPLICATION FOR PRACTICE Longitudinal assessment of factors associated with pain early after ICU discharge and the following year is a first step that could improve follow-up focus and contribute to reduced development of chronic pain.",2021,"Most common pain locations were abdomen (43%), lower lumbar back (28%), and shoulder/forearm (22%).","['intensive care unit (ICU) patients', 'patients up to 1\xa0year after ICU discharge', 'Of 523 included patients', 'pain after ICU discharge']",[],"['worst pain intensity score above 0 (no pain', 'lower lumbar back', 'pain interference', 'pain intensity and -interference declined, but pain intensity', 'post-traumatic stress (PTS) symptoms ≥25 (scale 10-70), female gender, shorter ICU stay, and more traumatic ICU memories', 'pain intensity, -interference with function and -location', 'Pain intensity, -interference, and -location']","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",[],"[{'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0234225', 'cui_str': 'No pain'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0086287', 'cui_str': 'Female'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0450429', 'cui_str': 'Location'}]",523.0,0.0889039,"Most common pain locations were abdomen (43%), lower lumbar back (28%), and shoulder/forearm (22%).","[{'ForeName': 'Åse', 'Initials': 'Å', 'LastName': 'Valsø', 'Affiliation': 'Department of Postoperative and Intensive Care, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Tone', 'Initials': 'T', 'LastName': 'Rustøen', 'Affiliation': 'Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Milada Cvancarova', 'Initials': 'MC', 'LastName': 'Småstuen', 'Affiliation': 'Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Puntillo', 'Affiliation': 'Department of Physiological Nursing, University of California, San Francisco, California, USA.'}, {'ForeName': 'Laila', 'Initials': 'L', 'LastName': 'Skogstad', 'Affiliation': 'Department of Research, Sunnaas Rehabilitation Hospital, Bjørnemyr, Norway.'}, {'ForeName': 'Inger', 'Initials': 'I', 'LastName': 'Schou-Bredal', 'Affiliation': 'Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Kjetil', 'Initials': 'K', 'LastName': 'Sunde', 'Affiliation': 'Department of Anaesthesiology, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Kirsti', 'Initials': 'K', 'LastName': 'Tøien', 'Affiliation': 'Department of Postoperative and Intensive Care, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.'}]",Nursing in critical care,['10.1111/nicc.12701'] 2742,34382717,"The effect of French maritime pine bark extract supplementation on inflammation, nutritional and clinical status in critically ill patients with traumatic brain injury: A randomized controlled trial.","Inflammation plays an important role in the pathophysiology of traumatic brain injury (TBI). Based on the anti-inflammatory properties of French maritime pine bark extract and the neuroprotective effects, we aimed to evaluate the effects of its supplementation on TBI. Sixty-seven TBI patients admitted to the intensive care units (ICUs) were enrolled. After stabilizing the hemodynamic status, the intervention group received 150 mg of French maritime pine bark extract supplementation (Oligopin) with enteral nutrition for 10 days. The control group received a placebo. Inflammatory status and oxidative stress markers were measured three times. Also, clinical and nutritional statuses were assessed. Supplementation, significantly decreased IL-6 (β = -53.43 pg/ml, 95% confidence interval [CI] = -91.74, -15.13, p = .006), IL-1β (β = -111.66 pg/ml, 95% CI = -183.79, -39.5402, p = .002) and C-reactive protein (β = -19.99 mg/L, 95% CI = -27.23, -12.76, p ˃ .001) in the intervention group compared to control group after 10 days. Clinical scores including acute physiology and chronic health evaluation II and sequential organ failure assessment were reduced (β = -3.72, 95% CI = -5.96, -1.49, p = .001and β = -2.07, 95% CI = -3.23, -0.90, p < .001, respectively), and Nutric score was reduced compared to control group (β = -.60, 95% CI = -1.08, -0.12, p = .01). The survival rate was higher by 15% in the intervention group compared to control group. Oligopin supplementation in TBI patients in ICU reduced inflammation and improved the clinical status and malnutrition score and thereby reducing the mortality rate.",2021,Oligopin supplementation in TBI patients in ICU reduced inflammation and improved the clinical status and malnutrition score and thereby reducing the mortality rate.,"['Sixty-seven TBI patients admitted to the intensive care units (ICUs) were enrolled', 'critically ill patients with traumatic brain injury', 'TBI patients']","['150\u2009mg of French maritime pine bark extract supplementation (Oligopin) with enteral nutrition', 'placebo', 'French maritime pine bark extract supplementation', 'Oligopin supplementation']","['IL-6', 'acute physiology and chronic health evaluation II and sequential organ failure assessment', 'Nutric score', 'C-reactive protein', 'Inflammatory status and oxidative stress markers', 'survival rate', 'mortality rate', 'IL-1β', 'clinical status and malnutrition score', 'inflammation, nutritional and clinical status']","[{'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}]","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C4283948', 'cui_str': 'French maritime pine bark extract'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3850608', 'cui_str': 'Oligopin'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0243028', 'cui_str': 'Acute physiology and chronic health evaluation II'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0449440', 'cui_str': 'Clinical status'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",67.0,0.130859,Oligopin supplementation in TBI patients in ICU reduced inflammation and improved the clinical status and malnutrition score and thereby reducing the mortality rate.,"[{'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Malekahmadi', 'Affiliation': 'Department of Clinical Nutrition, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Shadnoush', 'Affiliation': 'National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Sheikh Mohammed Shariful', 'Initials': 'SMS', 'LastName': 'Islam', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Shirvani', 'Affiliation': 'Virtual School of Medical Education and Management, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Naseh', 'Initials': 'N', 'LastName': 'Pahlavani', 'Affiliation': 'Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}, {'ForeName': 'Jamshid', 'Initials': 'J', 'LastName': 'Gholizadeh Navashenaq', 'Affiliation': 'Student Research Committee, School of Medicine, Bam University of Medical Sciences, Bam, Iran.'}, {'ForeName': 'Safieh', 'Initials': 'S', 'LastName': 'Firouzi', 'Affiliation': 'Department of Clinical Nutrition, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'McVicar', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Nematy', 'Affiliation': 'Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Zali', 'Affiliation': 'Department of Clinical Nutrition, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Moradi Moghaddam', 'Affiliation': 'Trauma and Injury Research Center, Critical Care Department, Rasoul-e-Akram Complex Hospital, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Abdolreza', 'Initials': 'A', 'LastName': 'Norouzy', 'Affiliation': 'Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.7187'] 2743,34382648,The Retail Outlet Health Kiosk Hypertension Trial (ROKHYT): Pilot Results.,"BACKGROUND Blood pressure (BP) control was only 43.7% in the National Health and Nutrition Survey (NHANES) survey in 2017-2018. Scalable, non-clinic-based strategies to control BP are needed. We therefore conducted a pilot trial of a text-messaging intervention in a national network of retail outlet health kiosks with BP devices. All study procedures were conducted remotely. METHODS Eligible individuals (N=140), based on average BP >140/90 mmHg at kiosks during the prior year, were randomized to intervention vs. usual care. Intervention consisted of tailored text messages providing educational information with embedded links to educational videos on topics related to BP control. BP measurements were obtained at kiosks at 3, 6, and 12 months following randomization; control was defined as BP <140/90 mmHg. Follow-up at 12 months was curtailed due to SARS-CoV-2. We therefore combined 12-month (N=62) or carried forward 6-month (N=61) data as the primary endpoint. RESULTS Participants were 51.4% male, 70.7% white/Caucasian, had mean age of 52.1 years, and mean baseline BP 145.5/91.8 mmHg. At the endpoint, 37.7% intervention vs. 27.4% usual care subjects achieved BP control (difference, 10.3%, 95% CI -6.2%, 26.8%). In an intention-to-treat analysis with multiple imputation of missing data, 12-month BP control was 29.0% vs. 19.8% favoring intervention (difference, 9.2%. 95% CI -7.3%, 25.7%); intervention vs. control differences in adjusted mean BP levels were SBP: -5.4 mmHg (95% CI: -13.5, 2.7) and DBP: +0.6 mmHg (95% CI: -4.2, 5.4). CONCLUSIONS These pilot results support the potential for a highly scalable text-messaging intervention to improve BP.",2021,"At the endpoint, 37.7% intervention vs. 27.4% usual care subjects achieved BP control (difference, 10.3%, 95% CI -6.2%, 26.8%).","['Eligible individuals (N=140), based on average BP ', 'national network of retail outlet health kiosks with BP devices', 'Participants were 51.4% male, 70.7% white/Caucasian, had mean age of 52.1 years, and mean baseline BP 145.5/91.8 mmHg']","['text-messaging intervention', 'tailored text messages providing educational information with embedded links to educational videos']","['BP control', 'BP', 'mean BP levels', 'BP measurements']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4301973', 'cui_str': 'Average blood pressure'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0183427', 'cui_str': 'Sphygmomanometer'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043157', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}]","[{'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}]",,0.12712,"At the endpoint, 37.7% intervention vs. 27.4% usual care subjects achieved BP control (difference, 10.3%, 95% CI -6.2%, 26.8%).","[{'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Shea', 'Affiliation': 'Department of Medicine, Columbia University, New York, NY.'}, {'ForeName': 'John L P', 'Initials': 'JLP', 'LastName': 'Thompson', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Schwartz', 'Affiliation': '4Department of Psychiatry and Behavioral Science, Stony Brook University, Stony Brook, NY.'}, {'ForeName': 'Yineng', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY.'}, {'ForeName': 'Morgan', 'Initials': 'M', 'LastName': 'de Ferrante', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY.'}, {'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Vanderbeek', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Buchsbaum', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY.'}, {'ForeName': 'Vargas', 'Initials': 'V', 'LastName': 'Celibell', 'Affiliation': '7Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.'}, {'ForeName': 'Khan M', 'Initials': 'KM', 'LastName': 'Siddiqui', 'Affiliation': '8Hyperfine Research, Inc., Guilford, CT.'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Moran', 'Affiliation': 'Department of Medicine, Columbia University, New York, NY.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Stockwell', 'Affiliation': '7Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.'}]",American journal of hypertension,['10.1093/ajh/hpab129'] 2744,34379915,Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.,"BACKGROUND The incidence of coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents are unknown. METHODS In this ongoing phase 2-3, placebo-controlled trial, we randomly assigned healthy adolescents (12 to 17 years of age) in a 2:1 ratio to receive two injections of the mRNA-1273 vaccine (100 μg in each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of mRNA-1273 in adolescents and the noninferiority of the immune response in adolescents as compared with that in young adults (18 to 25 years of age) in a phase 3 trial. Secondary objectives included the efficacy of mRNA-1273 in preventing Covid-19 or asymptomatic severe acute respiratory syndrome coronavirus 2 infection. RESULTS A total of 3732 participants were randomly assigned to receive mRNA-1273 (2489 participants) or placebo (1243 participants). In the mRNA-1273 group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 93.1% and 92.4%, respectively), headache (in 44.6% and 70.2%, respectively), and fatigue (in 47.9% and 67.8%, respectively); in the placebo group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 34.8% or 30.3%, respectively), headache (in 38.5% and 30.2%, respectively), and fatigue (in 36.6% and 28.9%, respectively). No serious adverse events related to mRNA-1273 or placebo were noted. The geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents relative to young adults was 1.08 (95% confidence interval [CI], 0.94 to 1.24), and the absolute difference in serologic response was 0.2 percentage points (95% CI, -1.8 to 2.4), which met the noninferiority criterion. No cases of Covid-19 with an onset of 14 days after the second injection were reported in the mRNA-1273 group, and four cases occurred in the placebo group. CONCLUSIONS The mRNA-1273 vaccine had an acceptable safety profile in adolescents. The immune response was similar to that in young adults, and the vaccine was efficacious in preventing Covid-19. (Funded by Moderna and the Biomedical Advanced Research and Development Authority; Teen COVE ClinicalTrials.gov number, NCT04649151.).",2021,The geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents relative to young adults was 1.08,"['healthy adolescents (12 to 17 years of age', '1243 participants', 'young adults (18 to 25 years of age) in a phase 3 trial', 'Adolescents', 'A total of 3732 participants', 'coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021', 'adolescents']","['mRNA-1273 vaccine', 'placebo', 'mRNA-1273', 'mRNA-1273 SARS-CoV-2 Vaccine']","['solicited adverse reactions', 'injection-site pain', 'immune response', 'safety, immunogenicity, and efficacy', 'serologic response', 'Covid-19 or asymptomatic severe acute respiratory syndrome coronavirus 2 infection', 'safety of mRNA-1273 in adolescents and the noninferiority of the immune response', 'headache', 'fatigue']","[{'cui': 'C0686747', 'cui_str': 'Well adolescent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0151828', 'cui_str': 'Injection site pain'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205473', 'cui_str': 'Serologic'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",3732.0,0.713569,The geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents relative to young adults was 1.08,"[{'ForeName': 'Kashif', 'Initials': 'K', 'LastName': 'Ali', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Berman', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Honghong', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Weiping', 'Initials': 'W', 'LastName': 'Deng', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Faughnan', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Coronado-Voges', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Baoyu', 'Initials': 'B', 'LastName': 'Ding', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Dooley', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Girard', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Hillebrand', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Rolando', 'Initials': 'R', 'LastName': 'Pajon', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Jacqueline M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Brett', 'Initials': 'B', 'LastName': 'Leav', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}, {'ForeName': 'Roderick', 'Initials': 'R', 'LastName': 'McPhee', 'Affiliation': 'From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).'}]",The New England journal of medicine,['10.1056/NEJMoa2109522'] 2745,34379891,"Cardiorespiratory effects of NIV-NAVA, NIPPV, and NCPAP shortly after extubation in extremely preterm infants: A randomized crossover trial.","OBJECTIVE Investigate the cardiorespiratory effects of noninvasive neurally adjusted ventilatory assist (NIV-NAVA), nonsynchronized nasal intermittent positive pressure ventilation (NIPPV), and nasal continuous positive airway pressure (NCPAP) shortly after extubation. HYPOTHESIS Types of noninvasive pressure support and the presence of synchronization may affect cardiorespiratory parameters. STUDY DESIGN Randomized crossover trial. PATIENT-SUBJECT SELECTION Infants with birth weight (BW) 1250 g or under, undergoing their first planned extubation were randomly assigned to all three modes using a computer-generated sequence. METHODOLOGY Electrocardiogram and electrical activity of the diaphragm (Edi) were recorded for 30 min on each mode. Analysis of heart rate variability (HRV), diaphragmatic activity (Edi area, breath area, amplitude, inspiratory and expiratory times), and respiratory variability were compared between modes. RESULTS Twenty-three infants had full data recordings and analysis: Median (IQR) gestational age = 25.9 weeks (25.2-26.4), BW = 760 g (595-900), and postnatal age 7 (4-19) days. There were no differences in HRV between modes. A significantly reduced Edi area and breath amplitude, and increased coefficient of variation (CV) of breath amplitude were observed during NIV-NAVA and NIPPV compared to NCPAP. A higher proportion of assisted breaths (99% vs. 51%; p < .001) provided a higher mean airway pressure (MAP; 9.4 vs. 8.2 cmH 2 O; p = .002) with lower peak inflation pressures (PIPs; 14 vs. 16 cmH 2 O; p < .001) during NIV-NAVA compared to NIPPV. CONCLUSIONS NIV-NAVA and NIPPV applied shortly after extubation were associated with lower respiratory efforts and higher respiratory variability. These effects were more evident for NIV-NAVA where optimal patient-ventilator synchronization provided a higher MAP with lower PIPs.",2021,A higher proportion of assisted breaths (99% vs. 51%; p < .001) provided a higher mean airway pressure (MAP; 9.4 vs. 8.2 cmH 2 O; p = .002) with lower peak inflation pressures (PIPs; 14 vs. 16 cmH 2 ,"['Infants with birth weight (BW', 'Twenty-three infants had full data recordings and analysis: Median (IQR) gestational age\u2009=\u200925.9 weeks (25.2-26.4), BW\u2009=\u2009760\u2009g (595-900), and postnatal age 7 (4-19) days', '1250\u2009g or under, undergoing their first planned extubation', 'extremely preterm infants']","['NIV-NAVA, NIPPV, and NCPAP', 'noninvasive neurally adjusted ventilatory assist (NIV-NAVA), nonsynchronized nasal intermittent positive pressure ventilation (NIPPV), and nasal continuous positive airway pressure (NCPAP']","['heart rate variability (HRV), diaphragmatic activity (Edi area, breath area, amplitude, inspiratory and expiratory times), and respiratory variability', 'assisted breaths', 'peak inflation pressures', 'Edi area and breath amplitude, and increased coefficient of variation (CV) of breath amplitude', 'mean airway pressure', 'HRV']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C5191367', 'cui_str': '595'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4517554', 'cui_str': '1250'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C3494262', 'cui_str': 'Extremely Premature Infants'}]","[{'cui': 'C3178854', 'cui_str': 'Neurally Adjusted Ventilatory Assist'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0021778', 'cui_str': 'Intermittent positive pressure ventilation'}, {'cui': 'C1258045', 'cui_str': 'nCPAP Ventilation'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0234388', 'cui_str': 'Electrical activity of brain'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0428687', 'cui_str': 'Expiratory time'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0021398', 'cui_str': 'Economic Inflation'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}]",,0.108386,A higher proportion of assisted breaths (99% vs. 51%; p < .001) provided a higher mean airway pressure (MAP; 9.4 vs. 8.2 cmH 2 O; p = .002) with lower peak inflation pressures (PIPs; 14 vs. 16 cmH 2 ,"[{'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Latremouille', 'Affiliation': 'Division of Experimental Medicine, McGill University Health Center, Montreal, Quebec, Canada.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Bhuller', 'Affiliation': 'Division of Experimental Medicine, McGill University Health Center, Montreal, Quebec, Canada.'}, {'ForeName': 'Wissam', 'Initials': 'W', 'LastName': 'Shalish', 'Affiliation': 'Division of Neonatology, McGill University Health Center, Montreal, Quebec, Canada.'}, {'ForeName': 'Guilherme', 'Initials': 'G', 'LastName': ""Sant'Anna"", 'Affiliation': 'Division of Neonatology, McGill University Health Center, Montreal, Quebec, Canada.'}]",Pediatric pulmonology,['10.1002/ppul.25607'] 2746,33068876,Differential regulation of a placental SAM68 and sFLT1 gene pathway and the relevance to maternal vitamin D sufficiency.,"OBJECTIVE The goal of this study was to determine if an axis of placental gene expression associated with early onset and severe preeclampsia (EOSPE) was operative in term pregnancy and correlated with vitamin D sufficiency. METHODS qPCR analysis of NKX2-5, SAM68, sFLT1 and membrane bound VEGFR1/FLT1 mRNA expression was conducted in placentas from 43 subjects enrolled in a vitamin D3 pregnancy supplementation trial. Pair-wise rank order correlations between patient-specific gene expression levels were calculated, and their relationship to maternal 25(OH)D status was assessed by a two-sample Wilcoxon test. Additionally, we probed the mechanistic link between SAM68 and sFLT1 using siRNA depletion in a human trophoblast cell line model. RESULTS Positive and highly significant correlations were found between SAM68 vs. sFLT1 and SAM68 vs. FLT1 expression levels, as were significant and differential correlations between the expression of these genes and perinatal 25(OH)D status. The variability when stratified by race/ethnicity was qualitatively distinct from those previously observed in EOSPE. Mechanistic studies confirmed a functional role for SAM68 protein in the regulation of sFLT1 expression. NKX2-5 expression was not significantly correlated with sFLT1 or SAM68 expression in these samples, suggesting that its expression may be significant at earlier stages of pregnancy or be restricted to pathological settings. CONCLUSIONS These data further support our overarching hypothesis that SAM68 expression is a key determinant of VEGFR1 isoform expression in the placenta, and provide additional insights into how this gene pathway may be differentially deployed or modified in normal and pathological pregnancies.",2020,"NKX2-5 expression was not significantly correlated with sFLT1 or SAM68 expression in these samples, suggesting that its expression may be significant at earlier stages of pregnancy or be restricted to pathological settings. ",['43 subjects enrolled in a vitamin D3 pregnancy supplementation trial'],[],['SAM68 vs. sFLT1 and SAM68 vs. FLT1 expression levels'],"[{'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C1568520', 'cui_str': 'FLT1 protein, human'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",43.0,0.128941,"NKX2-5 expression was not significantly correlated with sFLT1 or SAM68 expression in these samples, suggesting that its expression may be significant at earlier stages of pregnancy or be restricted to pathological settings. ","[{'ForeName': 'Oyindamola', 'Initials': 'O', 'LastName': 'Awe', 'Affiliation': 'Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, United States.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Sinkway', 'Affiliation': 'Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, United States.'}, {'ForeName': 'Rebecca P', 'Initials': 'RP', 'LastName': 'Chow', 'Affiliation': 'Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States.'}, {'ForeName': 'Quentell', 'Initials': 'Q', 'LastName': 'Wagener', 'Affiliation': 'Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, United States.'}, {'ForeName': 'Elizabeth V', 'Initials': 'EV', 'LastName': 'Schulz', 'Affiliation': 'Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, United States.'}, {'ForeName': 'Jeremy Y', 'Initials': 'JY', 'LastName': 'Yu', 'Affiliation': 'Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Nietert', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC 29425, United States.'}, {'ForeName': 'Carol L', 'Initials': 'CL', 'LastName': 'Wagner', 'Affiliation': 'Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, United States.'}, {'ForeName': 'Kyu-Ho', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, United States; Regenerative Medicine and Cell Biology Department, Medical University of South Carolina, Charleston, SC 29425, United States; Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, United States. Electronic address: leekh@musc.edu.'}]",Pregnancy hypertension,['10.1016/j.preghy.2020.09.004'] 2747,33090946,Influence of Risk Severity and Intentionality on Perceptions of Food Contamination Risks among Pregnant Women: An Experimental Investigation.,"Given the potential for severe health consequences of consuming contaminated foods during pregnancy, effective communication of food contamination risks to pregnant women is especially important. This study examines pregnant women's risk perceptions and intentions to adopt risk-reduction behaviors following exposure to a simulated news story about a food contamination incident. The news story was experimentally manipulated to depict the severity of the incident as high or low and the cause of the incident as accidental or intentional. Results showed that both severity and intentionality of the incident elevated pregnant women's perceptions of getting sick as well as their intentions to temporarily reduce consumption of the contaminated food product and to seek more information. Implications of these findings for effectively communicating food contamination risks to pregnant women are discussed.",2020,This study examines pregnant women's risk perceptions and intentions to adopt risk-reduction behaviors following exposure to a simulated news story about a food contamination incident.,"[""pregnant women's risk perceptions and intentions"", 'pregnant women', 'Pregnant Women']",[],[],"[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",[],[],,0.0326315,This study examines pregnant women's risk perceptions and intentions to adopt risk-reduction behaviors following exposure to a simulated news story about a food contamination incident.,"[{'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Nan', 'Affiliation': 'Department of Communication, University of Maryland , College Park, Maryland, USA.'}, {'ForeName': 'Jarim', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Communication, Yonsei University , Seoul, South Korea.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Verrill', 'Affiliation': 'Food and Drug Administration , USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Daily', 'Affiliation': 'Department of Communication, La Salle University , Philadelphia, Pennsylvania, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1818149'] 2748,32543421,Do changes in neighborhood social context mediate the effects of the moving to opportunity experiment on adolescent mental health?,"This study investigated whether changes in neighborhood context induced by neighborhood relocation mediated the impact of the Moving to Opportunity (MTO) housing voucher experiment on adolescent mental health. Mediators included participant-reported neighborhood safety, social control, disorder, and externally-collected neighborhood collective efficacy. For treatment group members, improvement in neighborhood disorder and drug activity partially explained MTO's beneficial effects on girls' distress. Improvement in neighborhood disorder, violent victimization, and informal social control helped counteract MTO's adverse effects on boys' behavioral problems, but not distress. Housing mobility policy targeting neighborhood improvements may improve mental health for adolescent girls, and mitigate harmful effects for boys.",2020,"Improvement in neighborhood disorder, violent victimization, and informal social control helped counteract MTO's adverse effects on boys' behavioral problems, but not distress.","['adolescent girls', 'adolescent mental health']",[],"['neighborhood safety, social control, disorder, and externally-collected neighborhood collective efficacy', 'mental health']","[{'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",[],"[{'cui': 'C0027569', 'cui_str': 'Neighborhood'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0037405', 'cui_str': 'Social Control'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",,0.0293073,"Improvement in neighborhood disorder, violent victimization, and informal social control helped counteract MTO's adverse effects on boys' behavioral problems, but not distress.","[{'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Schmidt', 'Affiliation': 'Minnesota Population Center, University of Minnesota, Minneapolis, MN, USA. Electronic address: schmidtn@umn.edu.'}, {'ForeName': 'Quynh C', 'Initials': 'QC', 'LastName': 'Nguyen', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of Maryland School of Public Health, College Park, MD, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Kehm', 'Affiliation': 'Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.'}, {'ForeName': 'Theresa L', 'Initials': 'TL', 'LastName': 'Osypuk', 'Affiliation': 'Minnesota Population Center, University of Minnesota, Minneapolis, MN, USA; Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA.'}]",Health & place,['10.1016/j.healthplace.2020.102331'] 2749,34382504,Evaluation of the Child Safety Matters Curriculum for Improving Knowledge about Victimization among Elementary School Children: A Randomized Trial.,"This project employed a randomized-control design to evaluate the effectiveness of the MBF Child Safety Matters® (CSM) curriculum. Six Georgia schools across 3 counties agreed to participate, and 136 K - 5th grade classrooms were randomized to either receive the CSM curriculum or be a wait-list control and to receive the curriculum after the evaluation. In total, 2,414 students participated at pretest (1195 CSM and 1219 control) and 2,260 participated at posttest (1159 CSM and 1101 control). Pre/posttests were collected from all students prior to the delivery of the CSM curriculum and again approximately a month later to measure knowledge gains related to child safety. Intervention students displayed a greater increase in knowledge for the information taught in the CSM program as compared to students who did not receive the intervention (d = .29).",2021,Intervention students displayed a greater increase in knowledge for the information taught in the CSM program as compared to students who did not receive the intervention (d = .29).,"['Six Georgia schools across 3 counties agreed to participate, and 136\xa0K - 5th grade classrooms', 'Elementary School Children', '2,414 students participated at pretest (1195 CSM and 1219 control) and 2,260 participated at posttest (1159 CSM and 1101 control']","['MBF Child Safety Matters® (CSM) curriculum', 'Child Safety Matters Curriculum', 'CSM curriculum or be a wait-list control']",['knowledge for the information taught'],"[{'cui': 'C0017452', 'cui_str': 'Georgia state'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0260267', 'cui_str': 'School child'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0039401', 'cui_str': 'Education'}]",2414.0,0.0256782,Intervention students displayed a greater increase in knowledge for the information taught in the CSM program as compared to students who did not receive the intervention (d = .29).,"[{'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'Weeks', 'Affiliation': 'Georgia State University, School of Public Health, Atlanta, United States.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Whitaker', 'Affiliation': 'Georgia State University, School of Public Health, Atlanta, United States.'}, {'ForeName': 'Stacy', 'Initials': 'S', 'LastName': 'Pendarvis', 'Affiliation': 'Monique Burr Foundation, Jacksonville, United States.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Finkelhor', 'Affiliation': 'Univ New Hampshire, Durham, United States.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Neal-Rossi', 'Affiliation': 'Issues Consulting, LLC, Atlanta, United States.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Rivers', 'Affiliation': 'Georgia State University, School of Public Health, Atlanta, United States.'}]",Journal of child sexual abuse,['10.1080/10538712.2021.1960458'] 2750,34382454,Patient engagement with digital disease management and readmission rates: The case of congestive heart failure.,"Congestive heart failure (CHF) is one of the most common diagnoses in the elderly United States Medicare (⩾ age 65) population. This patient population has a particularly high readmission rate, with one estimate of the 6-month readmission rate topping 40%. The rapid rise of mobile health (mHealth) presents a promising new pathway for reducing hospital readmissions of CHF, and, more generally, the management of chronic conditions. Using a randomized research design and a multivariate regression model, we evaluated the effectiveness of a hybrid mHealth model-the integration of remote patient monitoring with an applied health technology and digital disease management platform-on 45-day hospital readmissions for patients diagnosed with CHF. We find a 78% decrease in the likelihood of CHF hospital readmission for patients who were assigned to the digital disease management platform as compared to patients assigned to control.",2021,We find a 78% decrease in the likelihood of CHF hospital readmission for patients who were assigned to the digital disease management platform as compared to patients assigned to control.,"['patients diagnosed with CHF', 'elderly United States Medicare (⩾ age 65) population']",['hybrid mHealth model-the integration of remote patient monitoring with an applied health technology and digital disease management platform'],"['readmission rates', '45-day hospital readmissions', 'Congestive heart failure (CHF', 'likelihood of CHF hospital readmission']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0018717', 'cui_str': 'Health Insurance for Aged and Disabled, Title 18'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0752189', 'cui_str': 'Health Care Technology'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0587438', 'cui_str': 'Day hospital'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",,0.0377222,We find a 78% decrease in the likelihood of CHF hospital readmission for patients who were assigned to the digital disease management platform as compared to patients assigned to control.,"[{'ForeName': 'Rudin', 'Initials': 'R', 'LastName': 'Gjeka', 'Affiliation': 'St. Joseph Mercy Hospital Oakland, USA.'}, {'ForeName': 'Kirit', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': 'St. Joseph Mercy Hospital Oakland, USA.'}, {'ForeName': 'Chandra', 'Initials': 'C', 'LastName': 'Reddy', 'Affiliation': 'St. Joseph Mercy Hospital Oakland, USA.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Zetsche', 'Affiliation': 'Veta Health, USA.'}]",Health informatics journal,['10.1177/14604582211030959'] 2751,34382434,Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis.,"BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease with variable underlying pathophysiologies. Numerous patient factors have been linked to differences in disease severity, control, and response to treatment, including asthma status, aspirin sensitivity, previous sinonasal surgery, and blood eosinophil levels. OBJECTIVE The present study examines the efficacy of the anti-immunoglobulin E therapy, omalizumab, versus placebo in patients with CRSwNP from the replicate POLYP 1 (NCT03280550) and POLYP 2 (NCT03280537) trials, grouped by inherent patient characteristics to determine the response to therapy. METHODS Patients in prespecified subgroups from POLYP 1 and POLYP 2 (studies pooled for analysis) were examined. Subgroups included blood eosinophil count at baseline (>300 or ≤300 cells/μL), previous sinonasal surgery (yes or no), asthma status (yes or no), and aspirin sensitivity status (yes or no). Subgroups were examined for subgroup-specific adjusted mean difference (95% confidence interval [CI]) (omalizumab-placebo) in change from baseline at week 24 in Nasal Congestion Score (NCS), Nasal Polyp Score (NPS), Sino-Nasal Outcome Test-22 (SNOT-22), Total Nasal Symptom Score (TNSS), and University of Pennsylvania Smell Identification Test (UPSIT). RESULTS Adjusted mean difference (95% CI) (omalizumab-placebo) in NCS, NPS, SNOT-22, TNSS, and UPSIT change from baseline at week 24 consistently favored omalizumab treatment over placebo in patients with blood eosinophil count >300 and ≤300 cells/μL, with or without previous sinonasal surgery, asthma, and aspirin sensitivity. CONCLUSION Together, these data suggest broad efficacy of omalizumab across clinical and patient-reported outcomes in patients with CRSwNP, independent of the underlying patient factors examined, including those with high eosinophil levels and those who have undergone previous surgery, which are associated with high recurrence. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov identifiers: POLYP 1: ClinicalTrials.gov identifier NCT03280550 (https://clinicaltrials.gov/ct2/show/NCT03280550); POLYP 2: ClinicalTrials.gov identifier NCT03280537 (https://clinicaltrials.gov/ct2/show/NCT03280537).",2021,"Adjusted mean difference (95% CI) (omalizumab-placebo) in NCS, NPS, SNOT-22, TNSS, and UPSIT change from baseline at week 24 consistently favored omalizumab treatment over placebo in patients with blood eosinophil count >300 and ≤300 cells/μL, with or without previous sinonasal surgery, asthma, and aspirin sensitivity. ","['Nasal Polyposis', 'at baseline (>300 or ≤300\xa0cells/μL), previous sinonasal surgery (yes or no), asthma status (yes or no), and aspirin sensitivity status (yes or no', 'patients with CRSwNP from the replicate', 'Chronic rhinosinusitis with nasal polyps (CRSwNP', 'Patients in prespecified subgroups from POLYP 1 and POLYP 2 (studies pooled for analysis) were examined']","['placebo', 'Omalizumab', 'anti-immunoglobulin E therapy, omalizumab, versus placebo', 'omalizumab']","['NCS, NPS, SNOT-22, TNSS, and UPSIT change', 'blood eosinophil count', 'Nasal Congestion Score (NCS), Nasal Polyp Score (NPS), Sino-Nasal Outcome Test-22 (SNOT-22), Total Nasal Symptom Score (TNSS), and University of Pennsylvania Smell Identification Test (UPSIT']","[{'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1298907', 'cui_str': 'Yes'}, {'cui': 'C1298908', 'cui_str': 'No'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0966225', 'cui_str': 'omalizumab'}, {'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0027424', 'cui_str': 'Nasal congestion'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}, {'cui': 'C5197690', 'cui_str': 'SNOT-22'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0231918', 'cui_str': 'Nose symptoms'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}]",,0.666251,"Adjusted mean difference (95% CI) (omalizumab-placebo) in NCS, NPS, SNOT-22, TNSS, and UPSIT change from baseline at week 24 consistently favored omalizumab treatment over placebo in patients with blood eosinophil count >300 and ≤300 cells/μL, with or without previous sinonasal surgery, asthma, and aspirin sensitivity. ","[{'ForeName': 'Cecelia', 'Initials': 'C', 'LastName': 'Damask', 'Affiliation': 'Lake Mary ENT and Allergy, Lake Mary, Florida.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': '7412Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Cecile T J', 'Initials': 'CTJ', 'LastName': 'Holweg', 'Affiliation': '7412Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Bongin', 'Initials': 'B', 'LastName': 'Yoo', 'Affiliation': '7412Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Lauren A', 'Initials': 'LA', 'LastName': 'Millette', 'Affiliation': '7412Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Franzese', 'Affiliation': 'Department of Otolaryngology, 14716University of Missouri, MU Health Care, Columbia, Missouri.'}]",American journal of rhinology & allergy,['10.1177/19458924211030486'] 2752,34382427,"The Effects of Mindfulness-Based Stress Reduction Training on Hope, Psychological Well-Being, and Functional Recovery in Patients with Schizophrenia.","This study tested the effects of mindfulness-based stress reduction (MBSR) training on multiple outcomes in patients with schizophrenia. We compared MBSR, psychoeducation, and control groups in a randomized controlled research design. Outcome measures assessed hope, psychological wellbeing, and functional recovery over three time points in 137 participants. The results of this study indicate that MBSR training was more effective in terms of increasing the level of hope, psychological well-being, and functional recovery of schizophrenia patients when compared with psychoeducation and control patients.",2021,"The results of this study indicate that MBSR training was more effective in terms of increasing the level of hope, psychological well-being, and functional recovery of schizophrenia patients when compared with psychoeducation and control patients.","['patients with schizophrenia', 'Patients with Schizophrenia']","['mindfulness-based stress reduction (MBSR) training', 'Mindfulness-Based Stress Reduction Training', 'MBSR training']","['level of hope, psychological well-being, and functional recovery', 'Hope, Psychological Well-Being, and Functional Recovery', 'hope, psychological wellbeing, and functional recovery']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0424133', 'cui_str': 'Level of hope'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0599766', 'cui_str': 'Recovery of Function'}, {'cui': 'C0392347', 'cui_str': 'Hope'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}]",137.0,0.0209442,"The results of this study indicate that MBSR training was more effective in terms of increasing the level of hope, psychological well-being, and functional recovery of schizophrenia patients when compared with psychoeducation and control patients.","[{'ForeName': 'Aysel A', 'Initials': 'AA', 'LastName': 'Özdemir', 'Affiliation': 'Malatya Turgut Özal University, Turkey.'}, {'ForeName': 'Funda', 'Initials': 'F', 'LastName': 'Kavak Budak', 'Affiliation': 'Inonu Unıversity, Malatya, Turkey.'}]",Clinical nursing research,['10.1177/10547738211039069'] 2753,34382420,Phacoemulsification and dexamethasone intravitreal implant in diabetic patients: A combined approach.,"PURPOSE To analyse the morpho-functional outcomes of dexamethasone intravitreal implant (Ozurdex) injected after lens surgery in diabetic patients with coexisting cataract and macular oedema. METHODS This is a non-randomized, perspective, single-group study on 17 eyes with a diagnosis of cataract and early and advanced diabetic macular oedema. All eyes underwent combined phacoemulsification and Ozurdex injection at the end of surgery and morpho-functional outcomes were analysed in 3 months follow-up. RESULTS Foveal thickness decreased significantly from 349.6 ± 19.8 (95% CI) at baseline to 310.7 ± 17.5 (95% CI) 90 days after surgery ( p  < 0.01).Mean BCVA (LogMAR) improved significantly from 0.38 ± 0.08 (95% CI) at baseline to 0.15 ± 0.06 (95% CI) after 90 days ( p  < 0.01). Any ocular or systemic complications were observed during follow-up. CONCLUSIONS Dexamethasone intravitreal implant combined with phacoemulsification may be safe and effective to improve morpho-functional outcomes in diabetic patients with coexisting cataract and macular oedema.",2021,"Any ocular or systemic complications were observed during follow-up. ","['diabetic patients', 'diabetic patients with coexisting cataract and macular oedema', '17 eyes with a diagnosis of cataract and early and advanced diabetic macular oedema']","['dexamethasone intravitreal implant (Ozurdex', 'combined phacoemulsification and Ozurdex injection', 'Dexamethasone intravitreal implant combined with phacoemulsification', 'Phacoemulsification and dexamethasone intravitreal implant']","['Foveal thickness', 'ocular or systemic complications']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0271051', 'cui_str': 'Macular retinal edema'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}]","[{'cui': 'C2702454', 'cui_str': 'Dexamethasone Drug Implant'}, {'cui': 'C2702456', 'cui_str': 'Ozurdex'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",17.0,0.109039,"Any ocular or systemic complications were observed during follow-up. ","[{'ForeName': 'Lucrezia', 'Initials': 'L', 'LastName': 'Montrone', 'Affiliation': 'Department of Ophthalmology, Terlizzi Hospital, Terlizzi, Italy.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Macinagrossa', 'Affiliation': 'Department of Ophthalmology, Terlizzi Hospital, Terlizzi, Italy.'}]",European journal of ophthalmology,['10.1177/11206721211039347'] 2754,34382412,"OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.","While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in a Phase II study in patients with relapsed/refractory osteosarcoma. This Phase II randomized controlled trial (OLIE) will assess whether the combination of lenvatinib + ifosfamide + etoposide is superior to ifosfamide + etoposide alone in children, adolescents and young adults with relapsed/refractory osteosarcoma. The primary end point is progression-free survival; secondary and exploratory end points include, but are not limited to, overall survival, objective response rate, safety and tolerability, pharmacokinetic characterization of lenvatinib in the combination treatment, quality of life and quantification of baseline unresectable lesions that are converted to resectable.",2021,"This Phase II randomized controlled trial (OLIE) will assess whether the combination of lenvatinib + ifosfamide + etoposide is superior to ifosfamide + etoposide alone in children, adolescents and young adults with relapsed/refractory osteosarcoma.","['relapsed/refractory osteosarcoma', 'patients with relapsed/refractory osteosarcoma', 'children, adolescents\xa0and young adults with relapsed/refractory osteosarcoma']","['ifosfamide\xa0+\xa0etoposide alone', 'lenvatinib\xa0+\xa0ifosfamide\xa0+\xa0etoposide', 'OLIE, ITCC-082', 'lenvatinib plus ifosfamide and etoposide', 'ifosfamide and etoposide']","['antitumor activity', 'overall survival, objective response rate, safety and tolerability, pharmacokinetic characterization of lenvatinib in the combination treatment, quality of life and quantification of baseline unresectable lesions that are converted to resectable', 'progression-free survival', 'survival rates']","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0029463', 'cui_str': 'Osteosarcoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0020823', 'cui_str': 'Ifosfamide'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C2986924', 'cui_str': 'lenvatinib'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C2986924', 'cui_str': 'lenvatinib'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",,0.146744,"This Phase II randomized controlled trial (OLIE) will assess whether the combination of lenvatinib + ifosfamide + etoposide is superior to ifosfamide + etoposide alone in children, adolescents and young adults with relapsed/refractory osteosarcoma.","[{'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Gaspar', 'Affiliation': 'Department of Childhood & Adolescent Oncology, Gustave Roussy Cancer Campus, Villejuif, France.'}, {'ForeName': 'Quentin', 'Initials': 'Q', 'LastName': 'Campbell-Hewson', 'Affiliation': ""The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Biostatistics, Eisai Inc., Woodcliff Lake, NJ\xa007677, USA.'}, {'ForeName': 'Chinyere E', 'Initials': 'CE', 'LastName': 'Okpara', 'Affiliation': 'Clinical Research, Eisai Ltd., Hatfield, UK.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Bautista', 'Affiliation': 'Pediatric Oncology Department, Hospital del Niño Jesús, Madrid, Spain.'}]","Future oncology (London, England)",['10.2217/fon-2021-0743'] 2755,34382385,Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.,"The effect of renal impairment (RI) on risk of bleeding and recurrent thrombosis in cancer patients treated with direct oral anticoagulants for venous thromboembolism (VTE) is undefined. We run a prespecified analysis of the randomized Caravaggio study to evaluate the role of RI as risk factor for bleeding or recurrence in patients treated with dalteparin or apixaban for cancer-associated VTE. RI was graded as moderate (creatinine clearance between 30-59 ml/minute; 275 patients) and mild (between 60-89 ml/minute; 444 patients). In 1142 patients included in this analysis, the incidence of major bleeding was similar in patients with moderate vs. no or mild RI (HR 1.06, 95% CI 0.53-2.11), with no difference in the relative safety of apixaban and dalteparin. Recurrent VTE was not different in moderate vs. no or mild RI (HR 0 .67, 95% CI 0.38-1.20); in moderate RI, apixaban reduced recurrent VTE compared to dalteparin (HR 0.27, 95% CI 0.08-0.96; P for interaction 0.1085). At multivariate analysis, no association was found between variation of renal function over time and major bleeding or recurrent VTE. Advanced or metastatic cancer was the only independent predictor of major bleeding (HR 2.84, 95% CI 1.20-6.71), with no effect of treatment with apixaban or dalteparin. In our study in cancer patients treated with apixaban or dalteparin, moderate RI was not associated with major bleeding or recurrent VTE. In patients with moderate renal failure, the safety profile of apixaban was confirmed with the potential for improved efficacy in comparison to dalteparin.",2021,"Recurrent VTE was not different in moderate vs. no or mild RI (HR 0 .67, 95% CI 0.38-1.20); in moderate RI, apixaban reduced recurrent VTE compared to dalteparin (HR 0.27, 95% CI 0.08-0.96; P for interaction 0.1085).","['for cancer-associated VTE', 'patients with cancer-associated venous thromboembolism randomized to receive', 'patients with moderate renal failure', 'cancer patients treated with direct oral anticoagulants for venous thromboembolism (VTE', 'patients treated with']","['dalteparin', 'apixaban or dalteparin', 'renal impairment (RI', 'dalteparin or apixaban']","['renal function over time and major bleeding or recurrent VTE', 'Advanced or metastatic cancer', 'moderate RI, apixaban reduced recurrent VTE', 'moderate (creatinine clearance', 'Recurrent VTE', 'incidence of major bleeding', 'major bleeding', 'major bleeding or recurrent VTE', 'risk of bleeding and recurrent thrombosis']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0035078', 'cui_str': 'Renal insufficiency'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}]","[{'cui': 'C0206461', 'cui_str': 'Dalteparin'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}]","[{'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}]",1142.0,0.0759414,"Recurrent VTE was not different in moderate vs. no or mild RI (HR 0 .67, 95% CI 0.38-1.20); in moderate RI, apixaban reduced recurrent VTE compared to dalteparin (HR 0.27, 95% CI 0.08-0.96; P for interaction 0.1085).","[{'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Becattini', 'Affiliation': 'Internal, Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia. cecilia.becattini@unipg.it.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Bauersachs', 'Affiliation': 'Klinikum Darmstadt GmbH, Darmstadt.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Maraziti', 'Affiliation': 'Internal, Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Bertoletti', 'Affiliation': 'Service de Medecine Vasculaire et Therapeutique, CHU de St-Etienne, Saint-Etienne.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Cohen', 'Affiliation': ""Department of Haematology, St. Thomas' Hospital, King's College London.""}, {'ForeName': 'Jean M', 'Initials': 'JM', 'LastName': 'Connors', 'Affiliation': ""Brigham and Women's Hospital/Hematology Division, Harvard Medical School, Boston.""}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Manfellotto', 'Affiliation': 'Clinical Research Department, FADOI Foundation, Milan, Italy 6 Internal Medicine Department, Fatebenefratelli Foundation, San Giovanni Calibita Fatebenefratelli Hospital,, Rome.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Sanchez', 'Affiliation': 'Hospital Puerta de Hierro, Madrid.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Brenner', 'Affiliation': 'Institute of Hematology and BMT Rambam Health Care Campus Technion, Israel Institute of Technology Haifa.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Agnelli', 'Affiliation': 'Internal, Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia.'}]",Haematologica,['10.3324/haematol.2021.279072'] 2756,34382353,Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial.,"AIMS This study aimed to explore the rapid effects of dapagliflozin in heart failure with reduced ejection fraction (HFrEF). METHODS AND RESULTS We studied the functional, echocardiographic, electrophysiological, lung ultrasound, ambulatory blood pressure (BP), microvascular and macrovascular function, and biochemical effects of 2 week treatment with dapagliflozin in 19 type 2 diabetic HFrEF patients in a double-blind, crossover, placebo-controlled trial. Dapagliflozin had no significant effect on clinical, functional, or quality of life parameters. Dapagliflozin reduced systolic BP [114 (105, 131) vs. 106 (98, 113) mmHg, P < 0.01] and diastolic BP [71 (61, 78) vs. 62 (55, 70) mmHg, P < 0.01]. There was no effect on cardiac chamber size, ventricular systolic function, lung ultrasound, or arterial wave reflection. Dapagliflozin increased creatinine [117 (92, 129) vs. 122 (107, 135) μmol/L, P < 0.05] and haemoglobin [135 (118, 138) vs. 136 (123, 144) g/L, P < 0.05]. There was a reduction in ventricular ectopy [1.4 (0.1, 2.9) vs. 0.2 (0.1, 1.4) %, P < 0.05] and an increase in standard deviation of normal heart beat intervals [70 (58, 90) vs. 74 (62, 103), P < 0.05]. Unexpectedly, dapagliflozin increased high-sensitivity troponin T [25 (19, 37) vs. 28 (20, 42) ng/L, P < 0.01] and reduced reactive hyperaemia index [1.29 (1.21, 1.56) vs. 1.40 (1.23, 1.84), P < 0.05]. CONCLUSIONS After 2 weeks, while multiple parameters supported BP reduction and haemoconcentration with dapagliflozin, reduction in cardiac filling pressure, lung water, and functional improvement was not shown. Reduced ventricular ectopic burden suggests an early antiarrhythmic benefit. The small increase in troponin T and the reduction in the reactive hyperaemia index warrant further mechanistic exploration in this treatment of proven mortality benefit in HFrEF.",2021,"Dapagliflozin reduced systolic BP [114 (105, 131) vs. 106 (98, 113)","['type 2 diabetic patients with heart failure with reduced ejection fraction', '19 type 2 diabetic HFrEF patients']","['dapagliflozin', 'placebo', 'Dapagliflozin']","['ventricular ectopy', 'standard deviation of normal heart beat intervals', 'systolic BP', 'functional, echocardiographic, electrophysiological, lung ultrasound, ambulatory blood pressure (BP), microvascular and macrovascular function, and biochemical effects', 'cardiac chamber size, ventricular systolic function, lung ultrasound, or arterial wave reflection', 'dapagliflozin increased high-sensitivity troponin T', 'haemoglobin', 'Dapagliflozin increased creatinine', 'diastolic BP', 'BP reduction and haemoconcentration with dapagliflozin, reduction in cardiac filling pressure, lung water, and functional improvement', 'clinical, functional, or quality of life parameters', 'reduced reactive hyperaemia index']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0151636', 'cui_str': 'Ventricular premature beats'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C2712143', 'cui_str': 'Normal heart rate'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0729936', 'cui_str': 'Cardiac chamber structure'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0077404', 'cui_str': 'Troponin T'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0151578', 'cui_str': 'Creatinine increased'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0854379', 'cui_str': 'Haemoconcentration'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0020452', 'cui_str': 'Hyperemia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.061597,"Dapagliflozin reduced systolic BP [114 (105, 131) vs. 106 (98, 113)","[{'ForeName': 'Fahmida', 'Initials': 'F', 'LastName': 'Ilyas', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Lynette', 'Initials': 'L', 'LastName': 'Jones', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Su Ling', 'Initials': 'SL', 'LastName': 'Tee', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Horsfall', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Swan', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Wollaston', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Hecker', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'De Pasquale', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Simeoni', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Chong', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Stranks', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Arduino A', 'Initials': 'AA', 'LastName': 'Mangoni', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Joseph B', 'Initials': 'JB', 'LastName': 'Selvanayagam', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Derek P', 'Initials': 'DP', 'LastName': 'Chew', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'Carmine G', 'Initials': 'CG', 'LastName': 'De Pasquale', 'Affiliation': 'Flinders Medical Centre, Bedford Park, South Australia, Australia.'}]",ESC heart failure,['10.1002/ehf2.13553'] 2757,34382318,"The impact of the Shanley Pressure Ulcer Prevention Programme on older persons' knowledge of, and attitudes and behaviours towards, pressure ulcer prevention.","Pressure ulcers (PUs) have a profound impact on individuals, with studies demonstrating that compared with similarly aged persons, those living with a PU have a significantly lower quality of life. The aim of this study was to explore the impact of the Shanley Pressure Ulcer Prevention Programme (SPUPP) on older persons' knowledge of, and attitudes and behaviours towards, PU prevention. This was a multi-centre, open-label, randomised controlled trial. The population of interest was older persons living in the community who attended either a day care centre or a retirement group and were deemed to be at risk of PUs due to reduced mobility. Stratified random sampling was used to randomise based on days of attendance at day care centre/retirement group. Pretest and post-test were applied to the intervention and control groups. The SPUPP is a multimedia programme delivered using electronic media, hard copy materials, activities, and patient diaries and addresses the key tenets of PU prevention as described by the SKIN bundle. The programme contains five separate sessions delivered over 5 weeks. The impact of the SPUPP was assessed using the patient knowledge of and attitude and behaviour towards PU prevention instrument (KPUP). A total of 64 persons, 32 in each group, took part in the study. Of these, 75% (n = 48) were female, with a mean age of 81.9 years (SD: 5.56 years). Further, 68.8% (n = 44) were either overweight or obese and 40.6% (n = 26) were usually incontinent of urine. There were no differences between the intervention and control groups in mean scores during the pretest stage. However, at post-test, the mean scores for the intervention group were higher than the control group, 16.87 (SD: 1.88) versus 12.41 (SD: 3.21), respectively. For the post-test stage, mean differences between the two groups in favour of the intervention group (∆ = 4.46) were statistically significant, as t = 6.76, P = .0001, and equal variances were not assumed. The SPUPP impacted positively on knowledge scores of the participants and positively influenced attitudes and behaviours towards PU prevention. Thus, this research provides information regarding the potential to enhance patient involvement in PU prevention.",2021,"However, at post-test, the mean scores for the intervention group were higher than the control group, 16.87","['64 persons, 32 in each group, took part in the study', 'older persons', 'older persons living in the community who attended either a day care centre or a retirement group and were deemed to be at risk of PUs due to reduced mobility', '75% (n\xa0=\xa048) were female, with a mean age of 81.9\u2009years (SD: 5.56\u2009years']","['Shanley Pressure Ulcer Prevention Programme', 'Shanley Pressure Ulcer Prevention Programme (SPUPP']","['patient knowledge of and attitude and behaviour towards PU prevention instrument (KPUP', 'attitudes and behaviours towards PU prevention', 'Pressure ulcers (PUs', 'quality of life', 'mean scores', 'knowledge scores']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0175952', 'cui_str': 'Day care center'}, {'cui': 'C0035345', 'cui_str': 'Retired'}, {'cui': 'C0563204', 'cui_str': 'At risk of pressure ulcer'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0476650', 'cui_str': 'Reduced mobility'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517793', 'cui_str': '5.56'}]","[{'cui': 'C0150315', 'cui_str': 'Pressure ulcer prevention'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0011127', 'cui_str': 'Pressure ulcer'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",48.0,0.0275402,"However, at post-test, the mean scores for the intervention group were higher than the control group, 16.87","[{'ForeName': 'Emer', 'Initials': 'E', 'LastName': 'Shanley', 'Affiliation': 'Skin Wounds and Trauma Research Centre. The Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, Dublin, Republic of Ireland.'}, {'ForeName': 'Declan', 'Initials': 'D', 'LastName': 'Patton', 'Affiliation': 'Director of Nursing and Midwifery Research and Deputy Director of the Skin, Wounds and Trauma Research Centre, School of Nursing and Midwifery, The Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, Dublin, Republic of Ireland.'}, {'ForeName': 'Pinar', 'Initials': 'P', 'LastName': 'Avsar', 'Affiliation': 'Skin Wounds and Trauma Research Centre. The Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, Dublin, Republic of Ireland.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': ""O'Connor"", 'Affiliation': 'Fakeeh College of Health Sciences, Jeddah, Saudi Arabia.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Nugent', 'Affiliation': 'Fakeeh College of Health Sciences, Jeddah, Saudi Arabia.'}, {'ForeName': 'Zena', 'Initials': 'Z', 'LastName': 'Moore', 'Affiliation': 'Fakeeh College of Health Sciences, Jeddah, Saudi Arabia.'}]",International wound journal,['10.1111/iwj.13671'] 2758,34382209,"Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity and Smoking in Japanese Patients.","Guselkumab is a human IgG1λ monoclonal antibody that has been approved for treatment of multiple immunological diseases including palmoplantar pustulosis (PPP) in Japan. The efficacy of guselkumab in reducing disease severity as compared with placebo has been demonstrated in phase 2 and 3 clinical studies. In some patients assigned to the placebo treatment, worsening of PPP Area and Severity Index (PPPASI) score was noted. Most of these patients were smokers, raising a possibility of an association of smoking with the disease progression. To understand the clinical implications of guselkumab dose, baseline disease severity and smoking on the treatment effect and describe the longitudinal relationship between guselkumab exposure and the PPPASI score, a PK/PD modeling analysis was conducted using the pooled data from one phase 2 and one phase 3 study. Data from 207 Japanese patients (77% women and 60% smokers) with a median PPPASI score of 24.6 were included in the analysis. The observed treatment efficacy (the PPPASI score reduction) appeared to be similar at the current approved dose (100) mg and the higher dose (200 mg). Greater extent of the PPPASI score reduction (in absolute points) is expected in patients with higher baseline PPPASI score (severe disease). However, the higher baseline did not translate to larger magnitude of the change from baseline (in percentage) in the PPPASI score. Incorporating a linear disease progression effect in the model significantly decreased the NONMEM objective function value (p<0.001). Smoking status appeared tobe related to disease worsening in some patients, but the covariate did not reach statistical significance in the model. This article is protected by copyright. All rights reserved.",2021,Greater extent of the PPPASI score reduction (in absolute points) is expected in patients with higher baseline PPPASI score (severe disease).,"['Japanese Patients', 'Palmoplantar Pustulosis', '207 Japanese patients (77% women and 60% smokers) with a median PPPASI score of 24.6 were included in the analysis', 'palmoplantar pustulosis (PPP) in Japan']","['Guselkumab', 'placebo', 'guselkumab']","['worsening of PPP Area and Severity Index (PPPASI) score', 'PPPASI score reduction']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030246', 'cui_str': 'Pustular psoriasis of palms and soles'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0031106', 'cui_str': 'Aggressive periodontitis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C3852217', 'cui_str': 'guselkumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0031106', 'cui_str': 'Aggressive periodontitis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",207.0,0.164318,Greater extent of the PPPASI score reduction (in absolute points) is expected in patients with higher baseline PPPASI score (severe disease).,"[{'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Iwaki', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Janssen Pharmaceutical K.K. Chiyoda-ku, Tokyo, Japan.'}, {'ForeName': 'Sayori', 'Initials': 'S', 'LastName': 'Shibata', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Janssen Pharmaceutical K.K. Chiyoda-ku, Tokyo, Japan.'}, {'ForeName': 'Chuanpu', 'Initials': 'C', 'LastName': 'Hu', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1953'] 2759,34382158,Efficacy of a New Protocol of Premixed 70/30 Human Insulin in Haitian Youth with Diabetes.,"INTRODUCTION Controlling insulin-treated diabetes is challenging in low-resource settings where only Neutral Protamine Hagedorn (NPH), regular (R) and premixed insulin formulations are available, self-monitoring of blood glucose (SMBG) supplies are scarce and food insecurity is common. We examined the impact of a treatment protocol that includes sliding scale-based 70/30 insulin adjustments in Haiti. METHODS Thirty young patients aged 11-28 years with diabetes treated with premixed 70/30 insulin twice daily were included in the study. The participants performed one or two daily self-monitoring of blood glucose (SMBG) tests and attended our diabetes clinic monthly. They were randomized to two treatment groups, with one group remaining on the 70/30 insulin formulation (group 70 [G70]) and the other group switching to self-mixed NPH + R (group NR [GNR]). Sliding scales for insulin correction doses and meal insulin doses were designed based on the total daily insulin dose (TDD), carbohydrate ratio and insulin sensitivity factor. SMBG tests and insulin were administered before the morning and evening meals. The frequency of visits to the diabetes clinic was increased to biweekly during a 14-week follow-up. RESULTS Fifteen patients of each group were included in the analysis. Baseline characteristics, increase in total daily dose and number of missed SMBG tests and skipped meals at 14 weeks did not differ between the two groups. Hemoglobin A1c (HbA1c) decreased from 9.5% (interquartile range [IQR] 8.8, 10.5) (80.3 mmol/mol) to 8.0% (IQR 7.1%, 9.0%) (63.9 mmol/mol) in G70 (p = 0.01), and from 10.6% (IQR 8.1,% 13.1)% (92.4 mmol/mol) to 9.0% (IQR 7.6%, 9.6%) (74.9 mmol/mol) in GNR (p = 0.10), with no significant between-group difference in reductions (p = 0.12). No serious acute complications were reported. Stopping the use of sliding scales and resuming monthly visits increased HbA1c to values not significantly different from baseline in both groups after 15 weeks. CONCLUSION The use of sliding scales adjusted for missed SMBG tests and skipped meals, and frequent clinic visits that focus on patient self-management education significantly improved glycemic control in the patients with youth-onset diabetes in our study treated with premixed 70/30 human insulin in a low-resource setting.",2021,"Stopping the use of sliding scales and resuming monthly visits increased HbA1c to values not significantly different from baseline in both groups after 15 weeks. ","['Haitian Youth with Diabetes', 'Thirty young patients aged 11-28\xa0years with diabetes treated with premixed 70/30 insulin twice daily were included in the study', 'Fifteen patients of each group were included in the analysis', 'patients with youth-onset diabetes']","['Premixed 70/30 Human Insulin', 'premixed 70/30 human insulin', '70/30 insulin formulation (group 70 [G70]) and the other group switching to self-mixed NPH\u2009+\u2009R (group NR [GNR', 'daily self-monitoring of blood glucose (SMBG) tests and attended our diabetes clinic monthly']","['glycemic control', 'serious acute complications', 'frequency of visits to the diabetes clinic', 'total daily insulin dose (TDD), carbohydrate ratio and insulin sensitivity factor', 'total daily dose and number of missed SMBG tests and skipped meals', 'Hemoglobin A1c (HbA1c']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}]","[{'cui': 'C0795635', 'cui_str': 'Regular Insulin, Human'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0033603', 'cui_str': 'Protamines'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005803', 'cui_str': 'Self-monitoring of blood glucose'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0730262', 'cui_str': 'Attending diabetes clinic'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C3839636', 'cui_str': 'Diabetes clinic'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0005803', 'cui_str': 'Self-monitoring of blood glucose'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0560435', 'cui_str': 'Does skip'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",30.0,0.0524543,"Stopping the use of sliding scales and resuming monthly visits increased HbA1c to values not significantly different from baseline in both groups after 15 weeks. ","[{'ForeName': 'Eddy', 'Initials': 'E', 'LastName': 'Jean-Baptiste', 'Affiliation': 'Haitian Foundation for Diabetes and Cardiovascular Diseases (FHADIMAC), 208, Lalue, HT 6114, Port-au-Prince, Haiti. eddyjeanba@yahoo.com.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Larco', 'Affiliation': 'Haitian Foundation for Diabetes and Cardiovascular Diseases (FHADIMAC), 208, Lalue, HT 6114, Port-au-Prince, Haiti.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'von Oettingen', 'Affiliation': 'Research Institute of the McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, H3G 1A3, Canada.'}, {'ForeName': 'Graham David', 'Initials': 'GD', 'LastName': 'Ogle', 'Affiliation': 'Life for a Child Program, Diabetes NSW, 26 Arundel St., Glebe, NSW, 2037, Australia.'}, {'ForeName': 'Keddy', 'Initials': 'K', 'LastName': 'Moïse', 'Affiliation': 'Haitian Foundation for Diabetes and Cardiovascular Diseases (FHADIMAC), 208, Lalue, HT 6114, Port-au-Prince, Haiti.'}, {'ForeName': 'Evelyne', 'Initials': 'E', 'LastName': 'Fleury-Milfort', 'Affiliation': 'Haitian Foundation for Diabetes and Cardiovascular Diseases (FHADIMAC), 208, Lalue, HT 6114, Port-au-Prince, Haiti.'}, {'ForeName': 'Rodolphe', 'Initials': 'R', 'LastName': 'Paul', 'Affiliation': 'Haitian Foundation for Diabetes and Cardiovascular Diseases (FHADIMAC), 208, Lalue, HT 6114, Port-au-Prince, Haiti.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Charles', 'Affiliation': 'Haitian Foundation for Diabetes and Cardiovascular Diseases (FHADIMAC), 208, Lalue, HT 6114, Port-au-Prince, Haiti.'}, {'ForeName': 'Nancy Charles', 'Initials': 'NC', 'LastName': 'Larco', 'Affiliation': 'Haitian Foundation for Diabetes and Cardiovascular Diseases (FHADIMAC), 208, Lalue, HT 6114, Port-au-Prince, Haiti.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-021-01130-x'] 2760,34382063,The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial.,"AIMS Cardiogenic shock (CS) is a state of low cardiac output resulting in end-organ hypoperfusion. Despite high in-hospital mortality rates, little evidence exists regarding the optimal mean arterial pressure (MAP) target in CS. We therefore evaluated the relationship between achieved MAP and clinical outcomes in patients with CS. METHODS AND RESULTS We performed a post hoc analysis of the CAPITAL DOREMI trial: a randomized, double-blind trial comparing dobutamine to milrinone in patients with CS. We divided patients into a high MAP group (average MAP ≥ 70 mmHg over the 36 h following randomization), and a low MAP group (average MAP < 70 mmHg). Our primary outcome included in-hospital all-cause mortality, resuscitated cardiac arrest, need for cardiac transplantation or mechanical circulatory support, non-fatal myocardial infarction, transient ischaemic attack or stroke, or initiation of renal replacement therapy. In total, 71 (37.0%) patients achieved an average MAP < 70 mmHg, and 121 (63.0%) achieved an average MAP ≥ 70 mmHg. The primary outcome occurred in 48 (67.6%) patients in the low MAP group and 51 (42.2%) patients in the high MAP group [adjusted relative risk (aRR) 0.70; 95% confidence interval (CI) 0.53-0.92; P = 0.01]. All-cause mortality occurred in 41 (57.8%) and 35 (28.9%) patients in the low and high MAP groups, respectively (aRR 0.56; 95% CI 0.40-0.79; P < 0.01). There were no significant differences in any secondary outcomes between each group. CONCLUSIONS In patients with CS treated with inotrope therapy, low MAP is associated with worse clinical outcomes. Randomized data evaluating optimal MAP targets in CS is needed to guide medical therapy.",2021,"There were no significant differences in any secondary outcomes between each group. ","['patients with cardiogenic shock', 'patients with CS']","['milrinone', 'dobutamine']","['hospital all-cause mortality, resuscitated cardiac arrest, need for cardiac transplantation or mechanical circulatory support, non-fatal myocardial infarction, transient ischaemic attack or stroke, or initiation of renal replacement therapy', 'mean arterial pressure and outcomes', 'All-cause mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036980', 'cui_str': 'Cardiogenic shock'}]","[{'cui': 'C0128513', 'cui_str': 'Milrinone'}, {'cui': 'C0012963', 'cui_str': 'Dobutamine'}]","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C2587207', 'cui_str': 'For resuscitation'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.221192,"There were no significant differences in any secondary outcomes between each group. ","[{'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Parlow', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Di Santo', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Mathew', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Jung', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Trevor', 'Initials': 'T', 'LastName': 'Simard', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Gillmore', 'Affiliation': 'Faculty of Medicine, University of Ottawa, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, Ontario, K1H 8M5, Canada.'}, {'ForeName': 'Brennan', 'Initials': 'B', 'LastName': 'Mao', 'Affiliation': 'Faculty of Medicine, University of Ottawa, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, Ontario, K1H 8M5, Canada.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Abdel-Razek', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'F Daniel', 'Initials': 'FD', 'LastName': 'Ramirez', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Marbach', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Dick', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Glover', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Juan J', 'Initials': 'JJ', 'LastName': 'Russo', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Froeschl', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Marino', 'Initials': 'M', 'LastName': 'Labinaz', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Fernando', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Hibbert', 'Affiliation': 'CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.'}]",European heart journal. Acute cardiovascular care,['10.1093/ehjacc/zuab052'] 2761,34381998,"Short-Term, Equipment-Free High Intensity Interval Training Elicits Significant Improvements in Cardiorespiratory Fitness Irrespective of Supervision in Early Adulthood.","Introduction: Serious health implications from having low levels of cardiorespiratory fitness (CRF) and being overweight in young adulthood are carried forward into later life. High-intensity interval training (HIIT) is a time-effective, potent stimulus for improving CRF and indices of cardiometabolic health. To date, few studies have investigated the use of equipment-free HIIT or the impact of supervision for improving CRF via HIIT. Methods: Thirty healthy young adults (18-30 y) were randomised to 4 weeks (12 sessions) equipment-free, bodyweight based supervised laboratory HIIT (L-HIIT), unsupervised home HIIT (H-HIIT) or no-intervention (CON). Utilised exercises were star jumps, squats and standing sprints. Measurements of CRF (anaerobic threshold (AT) and VO 2 peak), blood pressure (BP), body mass index (BMI), blood glucose and plasma insulin by oral glucose tolerance test (OGTT), and muscle architecture were performed at baseline and after the intervention. Results: When compared to the control group, both HIIT protocols improved CRF (AT: L-HIIT mean difference compared to the control group (MD) +2.1 (95% CI: 0.34-4.03) ml/kg/min; p = 0.02; H-HIIT MD +3.01 (1.17-4.85) ml/kg/min; p = 0.002), VO 2 peak: L-HIIT (MD +2.94 (0.64-5.25) ml/kg/min; p = 0.01; H-HIIT MD +2.55 (0.34-4.76) ml/kg/min; p = 0.03), BMI (L-HIIT MD -0.43 (-0.86 to 0.00) kg/m 2 ; p = 0.05; H-HIIT: MD -0.51 (-0.95 to -0.07) kg/m 2 ; p = 0.03) and m. vastus lateralis pennation angle (L-HIIT MD 0.2 (0.13-0.27)°; p < 0.001; H-HIIT MD 0.17 (0.09 to 0.24)°; p < 0.001). There was no significant change in BP, blood glucose or plasma insulin in any of the groups. Conclusions: Four weeks time-efficient, equipment-free, bodyweight-based HIIT is able to elicit improvements in CRF irrespective of supervision status. Unsupervised HIIT may be a useful tool for counteracting the rise of sedentary behaviours and consequent cardiometabolic disorders in young adults.",2021,"When compared to the control group, both HIIT protocols improved CRF (AT: L-HIIT mean difference compared to the control group (MD) +2.1 (95% CI: 0.34-4.03) ml/kg/min; p = 0.02; H-HIIT MD +3.01 (1.17-4.85) ml/kg/min; p = 0.002), VO 2 peak: L-HIIT (MD +2.94 (0.64-5.25)","['Thirty healthy young adults (18-30 y', 'young adults']","['High-intensity interval training (HIIT', 'equipment-free, bodyweight based supervised laboratory HIIT (L-HIIT), unsupervised home HIIT (H-HIIT) or no-intervention (CON']","['Measurements of CRF (anaerobic threshold (AT) and VO 2 peak), blood pressure (BP), body mass index (BMI), blood glucose and plasma insulin by oral glucose tolerance test (OGTT), and muscle architecture', 'BP, blood glucose or plasma insulin', 'Short-Term, Equipment-Free High Intensity Interval', 'CRF', 'BMI']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0002749', 'cui_str': 'Anaerobic Threshold'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]",30.0,0.0943587,"When compared to the control group, both HIIT protocols improved CRF (AT: L-HIIT mean difference compared to the control group (MD) +2.1 (95% CI: 0.34-4.03) ml/kg/min; p = 0.02; H-HIIT MD +3.01 (1.17-4.85) ml/kg/min; p = 0.002), VO 2 peak: L-HIIT (MD +2.94 (0.64-5.25)","[{'ForeName': 'Tanvir S', 'Initials': 'TS', 'LastName': 'Sian', 'Affiliation': 'MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research and NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Derby, United Kingdom.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Inns', 'Affiliation': 'MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research and NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Derby, United Kingdom.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Gates', 'Affiliation': 'MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research and NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Derby, United Kingdom.'}, {'ForeName': 'Brett', 'Initials': 'B', 'LastName': 'Doleman', 'Affiliation': 'Department of Surgery and Anaesthesia, Royal Derby Hospital, University Hospitals of Derby and Burton, Derby, United Kingdom.'}, {'ForeName': 'Nima', 'Initials': 'N', 'LastName': 'Gharahdaghi', 'Affiliation': 'MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research and NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Derby, United Kingdom.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Atherton', 'Affiliation': 'University of Nottingham, Derby, United Kingdom.'}, {'ForeName': 'Jon N', 'Initials': 'JN', 'LastName': 'Lund', 'Affiliation': 'MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research and NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Derby, United Kingdom.'}, {'ForeName': 'Bethan E', 'Initials': 'BE', 'LastName': 'Phillips', 'Affiliation': 'MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research and NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Derby, United Kingdom.'}]",Frontiers in sports and active living,['10.3389/fspor.2021.697518'] 2762,34381767,Mechanical Parameters and Trajectory of Two Chinese Cervical Manipulations Compared by a Motion Capture System.,"Objective: To compare the mechanical parameters and trajectory while operating the oblique pulling manipulation and the cervical rotation-traction manipulation. Methods: An experimental research measuring kinematics parameter and recording motion trajectories of two cervical manipulations were carried out. A total of 48 healthy volunteers participated in this study, who were randomly divided into two groups of 24 representing each of the two manipulations. A clinician performed two manipulations in two groups separately. A motion capture system was used to monitor and analyze kinematics parameters during the operation. Results: The two cervical manipulations have similar thrust time, displacement, mean velocity, max velocity, and max acceleration. There were no significant differences in active and passive amplitudes between the two cervical rotation manipulations. The thrust amplitudes of the oblique pulling manipulation and the cervical rotation-traction manipulation were 5.735 ± 3.041° and 2.142 ± 1.742°, respectively. The thrust amplitudes of the oblique pulling manipulation was significantly greater than that of the cervical rotation-traction manipulation ( P < 0.001). Conclusion: Compared with the oblique pulling manipulation, the cervical rotation-traction manipulation has a less thrust amplitudes.",2021,The thrust amplitudes of the oblique pulling manipulation was significantly greater than that of the cervical rotation-traction manipulation ( P < 0.001). ,['48 healthy volunteers'],['Chinese Cervical Manipulations'],"['oblique pulling manipulation', 'time, displacement, mean velocity, max velocity, and max acceleration', 'active and passive amplitudes']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0600576', 'cui_str': 'Neck manipulation'}]","[{'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0580846', 'cui_str': 'Does pull'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}, {'cui': 'C0205177', 'cui_str': 'Active'}]",48.0,0.0328729,The thrust amplitudes of the oblique pulling manipulation was significantly greater than that of the cervical rotation-traction manipulation ( P < 0.001). ,"[{'ForeName': 'Xuecheng', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Dongxin', 'Initials': 'D', 'LastName': 'Lin', 'Affiliation': 'National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Zeyu', 'Initials': 'Z', 'LastName': 'Liang', 'Affiliation': 'National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Yuping', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Zaopeng', 'Initials': 'Z', 'LastName': 'He', 'Affiliation': 'Hand and Foot Surgery and Plastic Surgery, Affiliated Shunde Hospital of Guangzhou Medical University, Foshan, China.'}, {'ForeName': 'Mian', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Jinchuan', 'Initials': 'J', 'LastName': 'Tan', 'Affiliation': 'National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Yikai', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'School of Chinese Medicine, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Wenhua', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': 'National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}]",Frontiers in bioengineering and biotechnology,['10.3389/fbioe.2021.714292'] 2763,34381699,Improving social functioning in people with schizophrenia-spectrum disorders via mobile experimental interventions: Results from the CLIMB pilot trial.,"Background Patients with Schizophrenia Spectrum Disorders (SSD) demonstrate poor social functioning. While group-based approaches show long-term improvements, access to treatments is limited. Digital platforms hold promise to overcome barriers to treatment delivery and improve outcomes. Objective In a parallel arm, double-blind RCT, we tested CLIMB, a clinician-assisted, adjunct to treatment that includes computerized social cognition training (SCT), ecological momentary assessments (EMAs), group tele-therapy, and moderated messaging. CLIMB was compared to an active control that includes computerized general cognitive training (GCT), unstructured support groups, and unmoderated messaging. Methods The primary outcome was social functioning. Secondary outcomes were negative symptoms and quality of life (QoL). Given the sample size, Propensity Score Models were used to ensure balanced baseline covariates. Mixed-effects models examined change over time. Results 24 participants completed the study (12 per arm). No significant between-group differences emerged in engagement. CLIMB participants engaged in a median of 8 sessions (IQR = 2), 2.8 h of SCT (IQR = 7.5), and 2710 EMAs; control participants engaged in a median of 9 sessions (IQR = 3) and 2.2 h of GCT (IQR = 7.9). As a group, participants showed significant improvements in social functioning ( p  = .046), with no between-group differences. Intent-to-treat analyses indicated greater improvements in QoL ( p  = .025) for the active control. Conclusions Delivering group-based mobile interventions to individuals with SSD is feasible. EMAs allow clinicians to maintain inter-session engagement, build participant self-awareness, and tailor treatment delivery. In this treatment model, whether SCT or GCT is more effective remains unclear. Further research will evaluate group-based mobile interventions to improve outcomes in SSD.",2021,"As a group, participants showed significant improvements in social functioning ( p  = .046), with no between-group differences.","['\n\n\nPatients with Schizophrenia Spectrum Disorders (SSD', 'people with schizophrenia-spectrum disorders via mobile experimental interventions', '24 participants completed the study (12 per arm']","['computerized general cognitive training (GCT), unstructured support groups, and unmoderated messaging', 'SCT or GCT', 'computerized social cognition training (SCT), ecological momentary assessments (EMAs), group tele-therapy, and moderated messaging']","['QoL', 'negative symptoms and quality of life (QoL', 'social functioning']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0036606', 'cui_str': 'Support Groups'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1515258', 'cui_str': 'Telephone number (property)'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}]",24.0,0.144165,"As a group, participants showed significant improvements in social functioning ( p  = .046), with no between-group differences.","[{'ForeName': 'Sawsan', 'Initials': 'S', 'LastName': 'Dabit', 'Affiliation': 'Department of R&D, Posit Science Corporation, San Francisco, CA, USA.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Quraishi', 'Affiliation': 'Smeltzer Digital Consultancy, Toronto, ON, Canada.'}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Jordan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of California San Francisco, CA, USA.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Biagianti', 'Affiliation': 'Department of R&D, Posit Science Corporation, San Francisco, CA, USA.'}]",Schizophrenia research. Cognition,['10.1016/j.scog.2021.100211'] 2764,34381635,Factors Associated with a Recommendation for Operative Treatment for Fracture of the Distal Radius.,"Background  Evidence suggests that there is substantial and unexplained surgeon-to-surgeon variation in recommendation of operative treatment for fractures of the distal radius. We studied (1) what factors are associated with recommendation for operative treatment of a fracture of the distal radius and (2) which factors are rated as the most influential on recommendation of operative treatment. Methods  One-hundred thirty-one upper extremity and fracture surgeons evaluated 20 fictitious patient scenarios with randomly assigned factors (e.g., personal, clinical, and radiologic factors) for patients with a fracture of the distal radius. They addressed the following questions: (1) Do you recommend operative treatment for this patient (yes/no)? We determined the influence of each factor on this recommendation using random forest algorithms. Also, participants rated the influence of each factor-excluding age and sex- on a scale from 0 (not at all important) to 10 (extremely important). Results  Random forest algorithms determined that age and angulation were having the most influence on recommendation for operative treatment of a fracture of the distal radius. Angulation on the lateral radiograph and presence or absence of lunate subluxation were rated as having the greatest influence and smoking status and stress levels the lowest influence on advice to patients. Conclusions  The observation that-other than age-personal factors have limited influence on surgeon recommendations for surgery may reflect how surgeon cognitive biases, personal preferences, different perspectives, and incentives may contribute to variations in care. Future research can determine whether decision aids-those that use patient-specific probabilities based on predictive analytics in particular-might help match patient treatment choices to what matters most to them, in part by helping to neutralize the influence of common misconceptions as well as surgeon bias and incentives. Level of Evidence  There is no level of evidence for the study.",2021,Angulation on the lateral radiograph and presence or absence of lunate subluxation were rated as having the greatest influence and smoking status and stress levels the lowest influence on advice to patients. ,"['Methods \u2003One-hundred thirty-one upper extremity and fracture', 'patients with a fracture of the distal radius']",[],['Level of Evidence'],"[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}]",[],"[{'cui': 'C0441889', 'cui_str': 'Levels'}]",131.0,0.0287353,Angulation on the lateral radiograph and presence or absence of lunate subluxation were rated as having the greatest influence and smoking status and stress levels the lowest influence on advice to patients. ,"[{'ForeName': 'David W G', 'Initials': 'DWG', 'LastName': 'Langerhuizen', 'Affiliation': 'Department of Orthopaedic & Trauma Surgery, Flinders University, Flinders Medical Centre, Adelaide, Australia.'}, {'ForeName': 'Stein J', 'Initials': 'SJ', 'LastName': 'Janssen', 'Affiliation': 'Department of Orthopaedic Surgery, Amsterdam Movement Sciences (AMS), Amsterdam University Medical Centre, Amsterdam, The Netherlands.'}, {'ForeName': 'Joost T P', 'Initials': 'JTP', 'LastName': 'Kortlever', 'Affiliation': 'Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, Texas.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ring', 'Affiliation': 'Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, Texas.'}, {'ForeName': 'Gino M M J', 'Initials': 'GMMJ', 'LastName': 'Kerkhoffs', 'Affiliation': 'Department of Orthopaedic Surgery, Amsterdam Movement Sciences (AMS), Amsterdam University Medical Centre, Amsterdam, The Netherlands.'}, {'ForeName': 'Ruurd L', 'Initials': 'RL', 'LastName': 'Jaarsma', 'Affiliation': 'Department of Orthopaedic & Trauma Surgery, Flinders University, Flinders Medical Centre, Adelaide, Australia.'}, {'ForeName': 'Job N', 'Initials': 'JN', 'LastName': 'Doornberg', 'Affiliation': 'Department of Orthopaedic & Trauma Surgery, Flinders University, Flinders Medical Centre, Adelaide, Australia.'}]",Journal of wrist surgery,['10.1055/s-0041-1725962'] 2765,34381630,Effectiveness and Safety of Triangular Fibrocartilage Complex Injection Regarding Anatomical Landmarks: A Cadaveric Study.,"Background  Triangular fibrocartilage complex (TFCC) injections can be applied using anatomical landmarks or under the guide of ultrasound (US). US is not always available, and the physician may rely on the anatomical landmarks. Objective  The study aims to evaluate the effectiveness and safety of TFCC injection with anatomic landmarks. Methods  Forty wrist specimens from cadavers were randomly assigned to four rapid blue stain injection groups as follows: Group A: perpendicular to skin with 5 mm depth; Group B: perpendicular to skin with 10 mm depth; Group C: 45-degree angulation to skin surface, oriented from proximal to distal with 10 mm depth; and Group D: 45-degree angulation to skin surface, oriented from distal to proximal with 10 mm depth. TFCC specimens were excised and evaluated with microscopy, and adjacent neurovascular structures were checked for any injury. Results  Injections in group A were more accurate than others, in which 8/10 injections were successful. Group C injections were least accurate in that only 4/10 were successful. The other remaining groups (groups B and D) revealed similar results (5/10 were successful). However, statistical analyses did not show any significant difference ( p -value = 0.35). No injury to neurovascular structures was seen. Conclusion  Needle placement perpendicular to skin with 5 mm depth and just medial to ulnar styloid can be used as an accurate method of palpation-guided technique for TFCC injections.",2021,No injury to neurovascular structures was seen. ,['Methods \u2003Forty wrist specimens from cadavers'],"['TFCC', ' \u2003Triangular fibrocartilage complex (TFCC) injections', 'perpendicular to skin with 5\u2009mm depth; Group B: perpendicular to skin with 10\u2009mm depth; Group C: 45-degree angulation to skin surface, oriented from proximal to distal with 10\u2009mm depth; and Group D: 45-degree angulation to skin surface, oriented from distal to proximal with 10\u2009mm depth', 'rapid blue stain injection', 'Triangular Fibrocartilage Complex Injection Regarding Anatomical Landmarks']",[],"[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0006629', 'cui_str': 'Cadaver'}]","[{'cui': 'C1565659', 'cui_str': 'Structure of triangular fibrocartilage complex of wrist'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C1295725', 'cui_str': 'Perpendicular axis'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0333179', 'cui_str': 'Angulated'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0441838', 'cui_str': 'Group D'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0038128', 'cui_str': 'Stain'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}]",[],,0.0358897,No injury to neurovascular structures was seen. ,"[{'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Namazi', 'Affiliation': 'Department of Orthopedic Surgery, Bone and Joint Diseases Research Center, Chamran Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Ghane', 'Affiliation': 'Department of Orthopedic Surgery, Bone and Joint Diseases Research Center, Chamran Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Amir Reza', 'Initials': 'AR', 'LastName': 'Dehghanian', 'Affiliation': 'Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mehran', 'Initials': 'M', 'LastName': 'Fereidooni', 'Affiliation': 'Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Akbarzadeh', 'Affiliation': 'Department of Orthopedic Surgery, Bone and Joint Diseases Research Center, Chamran Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Journal of wrist surgery,['10.1055/s-0041-1723795'] 2766,34381612,"Randomized controlled trials between dorsal root ganglion thermal radiofrequency, pulsed radiofrequency and steroids for the management of intractable metastatic back pain in thoracic vertebral body.","BACKGROUND Bone metastasis is a complication of various cancers causing severe pain. The current modalities for the treatment of metastatic axial pain include pharmacological, surgical and vertebral augmentation techniques, each of which has its own challenges. OBJECTIVES To evaluate the effectiveness of pulsed radiofrequency (PRF), thermal radiofrequency (RF) and steroids on dorsal root ganglion (DRG) in patients with thoracic axial pain due to vertebral metastasis. METHODS In this randomized controlled prospective study, 140 patients were assessed for eligibility, of which only 69 fulfilled the criteria. Patients were randomly divided into three equal groups, PRF, RF and steroid. RESULTS During the assessment of pain using Visual Analogue Scale (VAS), Oswestry Disability Index (ODI), Opioid consumption using oral Morphine Equivalence (OME) and Analgesic Quantification Algorithm (AQA) - at baseline, 1 week, 1 month and 3 months - 81 patients were assessed for final eligibility, of which 12 were excluded before intervention due to drop-out. The remaining 69 were randomized (mean age: 53.87 ± 10.55, 55.78 ± 7.34 and 59.39 ± 13.72) for PRF, RF and steroid, respectively with no statistical difference. VAS% and ODI% decreased significantly at 3 months in RF group ( p  <0.001, 0.014, respectively), as did the AQA ( p  <0.027). Steroid group was the worst. DISCUSSION RF on DRG is the main stay for controlling intractable metastatic pain. PRF is a good alternative.",2021,"VAS% and ODI% decreased significantly at 3 months in RF group ( p  <0.001, 0.014, respectively), as did the AQA ( p  <0.027).","['intractable metastatic back pain in thoracic vertebral body', 'patients with thoracic axial pain due to vertebral metastasis', '140 patients were assessed for eligibility, of which only 69 fulfilled the criteria']","['PRF', 'pulsed radiofrequency (PRF), thermal radiofrequency (RF) and steroids', 'dorsal root ganglion thermal radiofrequency, pulsed radiofrequency and steroids', 'PRF, RF and steroid']","['pain using Visual Analogue Scale (VAS), Oswestry Disability Index (ODI), Opioid consumption using oral Morphine Equivalence (OME) and Analgesic Quantification Algorithm (AQA', 'VAS% and ODI', 'dorsal root ganglion (DRG']","[{'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0223199', 'cui_str': 'Structure of body of thoracic vertebra'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0205131', 'cui_str': 'Axial'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0684550', 'cui_str': 'Secondary malignant neoplasm of vertebral column'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0017070', 'cui_str': 'Structure of spinal nerve ganglion'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0360457', 'cui_str': 'Morphine-containing product in oral dose form'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0017070', 'cui_str': 'Structure of spinal nerve ganglion'}]",140.0,0.028582,"VAS% and ODI% decreased significantly at 3 months in RF group ( p  <0.001, 0.014, respectively), as did the AQA ( p  <0.027).","[{'ForeName': 'Sherry Nabil', 'Initials': 'SN', 'LastName': 'Fanous', 'Affiliation': 'Department of Anaesthesia, ICU and Pain Management, National Cancer Institute, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Emad Gerges', 'Initials': 'EG', 'LastName': 'Saleh', 'Affiliation': 'Department of Anaesthesia, ICU and Pain Management, National Cancer Institute, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ekramy Mansour', 'Initials': 'EM', 'LastName': 'Abd Elghafar', 'Affiliation': 'Department of Anaesthesia, ICU and Pain Management, National Cancer Institute, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Hossam Zarif', 'Initials': 'HZ', 'LastName': 'Ghobrial', 'Affiliation': 'Department of Anaesthesia, ICU and Pain Management, National Cancer Institute, Cairo University, Cairo, Egypt.'}]",British journal of pain,['10.1177/2049463720942538'] 2767,34385760,The Modest Effects of Fact Boxes on Cancer Screening.,"As health care becomes increasingly personalized to the needs and values of individual patients, informational interventions that aim to inform and debias consumer decision-making are likely to become important tools. In a randomized controlled experiment, we explore the effects of providing participants with published fact boxes on the benefits and harms of common cancer screening procedures. Female participants were surveyed about breast cancer screening by mammography, while male participants were surveyed about prostate cancer screening by prostate-specific antigen (PSA) testing. For these screening procedures, we expect consumers to have overly optimistic prior beliefs about the benefits and harms. We find that participants update their beliefs about the net benefits of screening modestly, but we observe little change in their stated preferences to seek screening. Participants who scored higher on a numeracy test updated their beliefs about screening benefits more in response to the fact boxes than did participants who scored lower on the numeracy test.",2021,Participants who scored higher on a numeracy test updated their beliefs about screening benefits more in response to the fact boxes than did participants who scored lower on the numeracy test.,"['Female participants were surveyed about breast cancer screening by mammography, while male participants were surveyed about prostate cancer screening by prostate-specific antigen (PSA) testing']",[],['Cancer Screening'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0281182', 'cui_str': 'Screening for malignant neoplasm of breast'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]",[],"[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]",,0.204187,Participants who scored higher on a numeracy test updated their beliefs about screening benefits more in response to the fact boxes than did participants who scored lower on the numeracy test.,"[{'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Eber', 'Affiliation': 'Harvard University, Interfaculty Initiative in Health Policy, Cambridge, MA, USA.'}, {'ForeName': 'Cass R', 'Initials': 'CR', 'LastName': 'Sunstein', 'Affiliation': 'Harvard University, Robert Walmsley University Professor, Cambridge, MA, USA.'}, {'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Hammitt', 'Affiliation': 'Harvard University, Center for Risk Analysis, Boston, MA USA; Toulouse School of Economics, Université Toulouse Capitole, Toulouse, France.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Yeh', 'Affiliation': ""Harvard Medical School, Boston, MA, USA; Boston Children's Hospital, Boston, MA, USA.""}]",Journal of risk and uncertainty,['10.1007/s11166-021-09344-x'] 2768,34385732,"The Ceiling Effect, the Floor Effect, and the Importance of Active and Placebo Control Arms in Randomized Controlled Trials of an Investigational Drug.","Randomized controlled trials (RCTs) of a new investigational drug often include active as well as placebo control arms. The active arm, comprising an approved treatment for the indication under study, along with the placebo arm, are together required to establish assay sensitivity; if the active treatment outperforms placebo, as expected, the results of the RCT can be further interpreted, but if the active treatment is no better than placebo (such as because of ceiling or floor effects), the RCT is a failed trial. The concepts involved are explained from scientific and ethical perspectives.",2021,"The active arm, comprising an approved treatment for the indication under study, along with the placebo arm, are together required to establish assay sensitivity; if the active treatment outperforms placebo, as expected, the results of the RCT can be further interpreted, but if the active treatment is no better than placebo (such as because of ceiling or floor effects), the RCT is a failed trial.",[],['placebo'],[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.233665,"The active arm, comprising an approved treatment for the indication under study, along with the placebo arm, are together required to establish assay sensitivity; if the active treatment outperforms placebo, as expected, the results of the RCT can be further interpreted, but if the active treatment is no better than placebo (such as because of ceiling or floor effects), the RCT is a failed trial.","[{'ForeName': 'Chittaranjan', 'Initials': 'C', 'LastName': 'Andrade', 'Affiliation': 'Dept. of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.'}]",Indian journal of psychological medicine,['10.1177/02537176211021280'] 2769,34385729,Feasibility and Effectiveness of Telecounseling on the Psychological Problems of Frontline Healthcare Workers Amidst COVID-19: A Randomized Controlled Trial from Central India.,"Background Preliminary reports suggest that during the COVID-19 pandemic, telecounseling could be an effective model of psychological intervention for the frontline healthcare workers (fHCW) with psychological problems. Literature is sparse in this area, particularly from low- and middle-income countries, including India. We aimed to investigate the feasibility and the effectiveness of telecounseling (vs. general education) on the psychological problems of the fHCW over three time-points (baseline vs. end-of-session and at two and four weeks after the intervention). Methods The study followed a single-blind, active arm versus general education, parallel-group randomized control design, with participant allocation in 1:1. Active healthcare workers (HCWs) with mild- to-severe or clinically concerning scores on any of the sub-scales of Depression, Anxiety and Stress Scale (DASS-21) or Impact of Event Scale-Revised (IES-R; represented by higher scores) were included, while those with known psychiatric illness were excluded. Chi-square and Mann-Whitney U test and linear-mixed effect model (group-, time, and group by time-effect) were used for analysis. Results There were no baseline group differences (telecounseling group, active arm, n = 9; general education group, control arm, n = 10). A significant time-effect (P = 0.044 to <.001) was found on DASS-21 on intention-to-treat analysis. Per-protocol analysis, additionally, found a significant group effect on Impact of Event Scale-Revised (IES-R; P = 0.036). A significant random effect of the participants was also found (P <.001). Conclusion Telecounseling could be a feasible and scalable model of psychological interventions for the fHCW with psychological problems, albeit with some feasibility challenges.",2021,"Conclusion Telecounseling could be a feasible and scalable model of psychological interventions for the fHCW with psychological problems, albeit with some feasibility challenges.",['Frontline Healthcare Workers'],"['Amidst COVID-19', 'telecounseling (vs. general education', 'Telecounseling']","['time-effect', 'Depression, Anxiety and Stress Scale (DASS-21) or Impact of Event Scale-Revised (IES-R']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1832594', 'cui_str': 'Verloes Bourguignon syndrome'}, {'cui': 'C3472482', 'cui_str': 'Impact of event scale revised'}]",,0.0754197,"Conclusion Telecounseling could be a feasible and scalable model of psychological interventions for the fHCW with psychological problems, albeit with some feasibility challenges.","[{'ForeName': 'Snehil', 'Initials': 'S', 'LastName': 'Gupta', 'Affiliation': 'Dept. of Psychiatry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.'}, {'ForeName': 'Mohit', 'Initials': 'M', 'LastName': 'Kumar', 'Affiliation': 'Dept. of Psychiatry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.'}, {'ForeName': 'Abhijit R', 'Initials': 'AR', 'LastName': 'Rozatkar', 'Affiliation': 'Dept. of Psychiatry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.'}, {'ForeName': 'Devendra', 'Initials': 'D', 'LastName': 'Basera', 'Affiliation': 'Dept. of Psychiatry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.'}, {'ForeName': 'Shashank', 'Initials': 'S', 'LastName': 'Purwar', 'Affiliation': 'Dept. of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.'}, {'ForeName': 'Disha', 'Initials': 'D', 'LastName': 'Gautam', 'Affiliation': 'Dept. of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.'}, {'ForeName': 'Rahat', 'Initials': 'R', 'LastName': 'Jahan', 'Affiliation': 'Dept. of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.'}]",Indian journal of psychological medicine,['10.1177/02537176211024537'] 2770,34385722,Effects of Cognitive Versus Mind-Motor Training on Cognition and Functional Skills in the Community-Dwelling Older Adults.,"Background There is a decline in cognitive and functional skills in older adults. The objective of this study was to compare the effects of cognitive and mind-motor training (MMT) on cognition and functional skills in a community-dwelling sample of older adults. Methods In this observer-blinded randomized clinical trial, 40 older adults with medical stability, ability to comprehend and respond to simple verbal instructions, no diagnosed psychological disorders, absence of severe visual and hearing problems, the capacity to walk independently, and a score of more than 46 in Berg Balance Scale were included. They were randomly allocated into cognitive or MMT groups. Cognitive training (CT) was practiced with activities for memory and attention, using paper-pencil tasks. MMT was practiced using a simple, indoor based square-stepping exercise. They practiced one-hour of training per day, three days a week, for eight weeks. Results General linear model analysis showed that the time by groups was not statistically significant. The mean (standard deviation) scores in General Practitioner Assessment of Cognition Scale and Hindi Mental State Examination improved significantly (P < 0.001) following MMT [1.75 (1.29); 2.4 (1.34)] and CT [1.5 (1.36); 2.7 (0.99)]. The functional skills measured using Lawton Instrumental Activities of Daily Living Scale revealed beneficial changes for both the groups. None of the outcomes were statistically significant between the groups (P > 0.05). Conclusion Both cognitive and MMTs showed similar practice effects on cognition and functional skills in community-dwelling older adults.",2021,The functional skills measured using Lawton Instrumental Activities of Daily Living Scale revealed beneficial changes for both the groups.,"['40 older adults with medical stability, ability to comprehend and respond to simple verbal instructions, no diagnosed psychological disorders, absence of severe visual and hearing problems, the capacity to walk independently, and a score of more than 46 in Berg Balance Scale were included', 'Community-Dwelling Older Adults', 'a community-dwelling sample of older adults', 'community-dwelling older adults', 'older adults']","['cognitive and mind-motor training (MMT', 'Cognitive training (CT', 'MMT', 'Cognitive Versus Mind-Motor Training']","['cognitive and functional skills', 'cognition and functional skills', 'mean (standard deviation) scores in General Practitioner Assessment of Cognition Scale and Hindi Mental State Examination', 'Cognition and Functional Skills']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1273101', 'cui_str': 'Ability to comprehend'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4068262', 'cui_str': 'General Practitioner Assessment of Cognition'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0019547', 'cui_str': 'Hindi language'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",40.0,0.0274699,The functional skills measured using Lawton Instrumental Activities of Daily Living Scale revealed beneficial changes for both the groups.,"[{'ForeName': 'Shruti', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Chitkara School of Health Sciences, Chitkara University, Punjab, India.'}, {'ForeName': 'Gandhi Karunanithi', 'Initials': 'GK', 'LastName': 'Balaji', 'Affiliation': 'Chitkara School of Health Sciences, Chitkara University, Punjab, India.'}, {'ForeName': '', 'Initials': '', 'LastName': 'Sahana A', 'Affiliation': 'Chitkara School of Health Sciences, Chitkara University, Punjab, India.'}, {'ForeName': 'Suruliraj', 'Initials': 'S', 'LastName': 'Karthikbabu', 'Affiliation': 'Dept. of Physiotherapy, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal Hospital, Bangalore, Karnataka, India.'}]",Indian journal of psychological medicine,['10.1177/0253717620957517'] 2771,34385707,"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.","A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468) evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive supranuclear palsy (PSP). In total, 486 participants dosed were assigned to either gosuranemab (n = 321) or placebo (n = 165). Efficacy was not demonstrated on adjusted mean change of PSP Rating Scale score at week 52 between gosuranemab and placebo (10.4 versus 10.6, P = 0.85, primary endpoint), or at secondary endpoints, resulting in discontinuation of the open-label, long-term extension. Unbound N-terminal tau in cerebrospinal fluid decreased by 98% with gosuranemab and increased by 11% with placebo (P < 0.0001). Incidences of adverse events and deaths were similar between groups. This well-powered study suggests that N-terminal tau neutralization does not translate into clinical efficacy.",2021,"Efficacy was not demonstrated on adjusted mean change of PSP Rating Scale score at week 52 between gosuranemab and placebo (10.4 versus 10.6, P = 0.85, primary endpoint), or at secondary endpoints, resulting in discontinuation of the open-label, long-term extension.","['progressive supranuclear palsy (PSP', '486\u2009participants dosed were assigned to either', 'progressive supranuclear palsy']","['anti-tau monoclonal antibody gosuranemab', 'gosuranemab', 'placebo']","['PSP Rating Scale score', 'Unbound N-terminal tau in cerebrospinal fluid', 'Incidences of adverse events and deaths', 'Safety and efficacy', 'Efficacy']","[{'cui': 'C0038868', 'cui_str': 'Progressive supranuclear palsy'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0038868', 'cui_str': 'Progressive supranuclear palsy'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",486.0,0.580688,"Efficacy was not demonstrated on adjusted mean change of PSP Rating Scale score at week 52 between gosuranemab and placebo (10.4 versus 10.6, P = 0.85, primary endpoint), or at secondary endpoints, resulting in discontinuation of the open-label, long-term extension.","[{'ForeName': 'Tien', 'Initials': 'T', 'LastName': 'Dam', 'Affiliation': 'Biogen, Cambridge, MA, USA. tien.dam@biogen.com.'}, {'ForeName': 'Adam L', 'Initials': 'AL', 'LastName': 'Boxer', 'Affiliation': 'Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Lawrence I', 'Initials': 'LI', 'LastName': 'Golbe', 'Affiliation': 'Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Günter U', 'Initials': 'GU', 'LastName': 'Höglinger', 'Affiliation': 'Department of Neurology, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Huw R', 'Initials': 'HR', 'LastName': 'Morris', 'Affiliation': 'National Hospital for Neurology and Neurosurgery, London, UK.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Litvan', 'Affiliation': 'University of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA.'}, {'ForeName': 'Anthony E', 'Initials': 'AE', 'LastName': 'Lang', 'Affiliation': ""Edmond J. Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Jean-Christophe', 'Initials': 'JC', 'LastName': 'Corvol', 'Affiliation': 'Sorbonne Université, Assistance Publique Hôpitaux de Paris, INSERM, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, Hôpital Pitié-Salpêtrière, Paris, France.'}, {'ForeName': 'Ikuko', 'Initials': 'I', 'LastName': 'Aiba', 'Affiliation': 'Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Grundman', 'Affiliation': 'University of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Tidemann-Miller', 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Kupferman', 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Harper', 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': 'Kubra', 'Initials': 'K', 'LastName': 'Kamisoglu', 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Wald', 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': 'Danielle L', 'Initials': 'DL', 'LastName': 'Graham', 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': 'Liz', 'Initials': 'L', 'LastName': 'Gedney', 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': ""O'Gorman"", 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': 'Samantha Budd', 'Initials': 'SB', 'LastName': 'Haeberlein', 'Affiliation': 'Biogen, Cambridge, MA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Nature medicine,['10.1038/s41591-021-01455-x'] 2772,34385272,"Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF™ 1 - a randomised, Phase II study.","BACKGROUND Inhibition of the epithelial sodium channel (ENaC) in cystic fibrosis (CF) airways provides a mutation-agnostic approach that could improve mucociliary clearance in all CF patients. BI 1265162 is an ENaC inhibitor with demonstrated preclinical efficacy and safety already demonstrated in humans. OBJECTIVE We present results from BALANCE-CF™ 1, a Phase II, placebo-controlled, randomised, double-blind study of four dose levels of BI 1265162 versus placebo for 4 weeks on top of standard of care in adults and adolescents with CF. RESULTS Initially, 28 randomised subjects (n=14 each BI 1265162 200 µg BID, placebo BID) were assessed at an interim futility analysis. Compared with placebo, numerical changes of -0.8% (95%CI -6.6, 4.9) in ppFEV 1 and +2.1 units (95%CI -2.4, 6.5) in LCI were observed in the active group, meeting a predefined stopping rule; accordingly, the study was terminated. Recruitment had continued during the interim analysis and pending results; 24 patients were added across three dose levels and placebo. The final results including these patients (+1.5% ppFEV 1 , 200 µg BID dose versus placebo) were not supportive of relevant clinical effect. LCI change was also not supportive, although interpretation was limited due to insufficient traces meeting quality criteria. A 9.4-point improvement in CFQ-R Respiratory Domain was observed in the 200 µg BID dose group versus placebo. BI 1265162 up to 200 µg BID was safe and well-tolerated. Pharmacokinetics were similar to those in healthy volunteers. CONCLUSION BI 1265162 was safe, but did not demonstrate a potential for clinical benefit. Development has been terminated.",2021,A 9.4-point improvement in CFQ-R Respiratory Domain was observed in the 200 µg BID dose group versus placebo.,"['healthy volunteers', 'patients with cystic fibrosis', 'adults and adolescents with CF']","['inhaled ENaC inhibitor BI 1265162', 'BI 1265162 versus placebo', 'placebo BID', 'placebo', 'epithelial sodium channel (ENaC']","['safe and well-tolerated', 'mucociliary clearance', 'Efficacy and safety', 'CFQ-R Respiratory Domain']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010674', 'cui_str': 'Cystic fibrosis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}, {'cui': 'C0384156', 'cui_str': 'Epithelial Sodium Channel'}]","[{'cui': 'C0026687', 'cui_str': 'Mucociliary clearance'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",24.0,0.299208,A 9.4-point improvement in CFQ-R Respiratory Domain was observed in the 200 µg BID dose group versus placebo.,"[{'ForeName': 'Christopher H', 'Initials': 'CH', 'LastName': 'Goss', 'Affiliation': ""Department of Medicine, Department of Pediatrics, University of Washington; Seattle Children's Hospital & Research Institute, Seattle, WA, USA CGoss@medicine.washington.edu.""}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Fajac', 'Affiliation': 'AP-HP, Université de Paris, Paris, France.'}, {'ForeName': 'Raksha', 'Initials': 'R', 'LastName': 'Jain', 'Affiliation': 'Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Seibold', 'Affiliation': 'Boehringer Ingelheim, Germany, China.'}, {'ForeName': 'Abhya', 'Initials': 'A', 'LastName': 'Gupta', 'Affiliation': 'Boehringer Ingelheim, Germany, China.'}, {'ForeName': 'Ming-Chi', 'Initials': 'MC', 'LastName': 'Hsu', 'Affiliation': 'Boehringer Ingelheim, Germany, China.'}, {'ForeName': 'Sivagurunathan', 'Initials': 'S', 'LastName': 'Sutharsan', 'Affiliation': 'Division for Cystic Fibrosis, Department of Pulmonary Medicine, University Medicine Essen - Ruhrlandklinik, Essen, Germany.'}, {'ForeName': 'Jane C', 'Initials': 'JC', 'LastName': 'Davies', 'Affiliation': 'National Heart & Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Marcus A', 'Initials': 'MA', 'LastName': 'Mall', 'Affiliation': 'Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}]",The European respiratory journal,['10.1183/13993003.00746-2021'] 2773,34385269,Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism.,"BACKGROUND The length of hospital stay ( LOS ) for acute pulmonary embolism ( PE ) varies considerably. Whether the upfront use of a PE prognostic assessment and management pathway is effective in reducing the LOS remains unknown. METHODS We conducted a randomised, controlled trial of adults hospitalised for acute PE: patients were assigned to a prognostic assessment and management pathway involving risk stratification, followed by predefined criteria for mobilisation and discharge (intervention group), or usual care (control group). The primary end point was LOS. The secondary end points were the cost of prognostic tests and of hospitalisation, and 30-day clinical outcomes. RESULTS Of 500 patients who underwent randomisation, 498 were included in the modified intention-to-treat analysis. The median LOS was 4.0 days (interquartile range [ IQR ], 3.7 to 4.2 days) in the intervention group and 6.1 days (IQR, 5.7 to 6.5 days) in the control group (p<0.001). The mean total cost of prognostic tests was €174.76 in the intervention group, as compared with €233.12 in the control group (mean difference, €-58.37; 95% confidence interval [ CI ], €-84.34 to €-32.40). The mean total hospitalisation cost per patient was €2085.66 in the intervention group, compared with €3232.97 in the control group (mean difference, €-1147.31; 95% CI, €-1414.97 to €-879.65). No significant differences were observed in 30-day readmissions (4.0% versus 4.8%, respectively), or all-cause (2.4% versus 2.0%) and PE-related mortality rates (0.8% versus 1.2%). CONCLUSIONS The use of a prognostic assessment and management pathway was effective in reducing the LOS for acute PE.",2021,"The mean total hospitalisation cost per patient was €2085.66 in the intervention group, compared with €3232.97 in the control group (mean difference, €-1147.31; 95% CI, €-1414.97 to €-879.65).","['adults hospitalised for acute PE: patients', '500 patients who underwent randomisation', 'normotensive patients with acute pulmonary embolism']","['prognostic assessment and management pathway involving risk stratification, followed by predefined criteria for mobilisation and discharge (intervention group), or usual care (control group']","['median LOS', 'LOS', 'PE-related mortality rates', 'mean total cost of prognostic tests', 'cost of prognostic tests and of hospitalisation, and 30-day clinical outcomes', '30-day readmissions', 'mean total hospitalisation cost', 'length of hospital stay']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure'}, {'cui': 'C2882221', 'cui_str': 'Acute pulmonary embolism'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0030700', 'cui_str': 'Thirty Day Readmission'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",500.0,0.156298,"The mean total hospitalisation cost per patient was €2085.66 in the intervention group, compared with €3232.97 in the control group (mean difference, €-1147.31; 95% CI, €-1414.97 to €-879.65).","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Jiménez', 'Affiliation': 'Respiratory Department, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain djimenez.hrc@gmail.com.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Rodríguez', 'Affiliation': 'Respiratory Department, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'León', 'Affiliation': 'Respiratory Department, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Jara-Palomares', 'Affiliation': 'Respiratory Department, Virgen del Rocío Hospital and Instituto de Biomedicina, Sevilla.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'López-Reyes', 'Affiliation': 'Respiratory Department, Hospital La Fe, Valencia, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Ruiz-Artacho', 'Affiliation': 'CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Elías', 'Affiliation': 'Respiratory Department, Virgen del Rocío Hospital and Instituto de Biomedicina, Sevilla.'}, {'ForeName': 'Remedios', 'Initials': 'R', 'LastName': 'Otero', 'Affiliation': 'CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'García-Ortega', 'Affiliation': 'Respiratory Department, Hospital La Fe, Valencia, Spain.'}, {'ForeName': 'Agustina', 'Initials': 'A', 'LastName': 'Rivas-Guerrero', 'Affiliation': 'Respiratory Department, Hospital Araba, Vitoria, Spain.'}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Abelaira', 'Affiliation': 'Emergency Department, Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Jiménez', 'Affiliation': 'Emergency Department, Hospital Clinic, Grupo UPP, Área 1 IDIBAPS, Barcelona, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Muriel', 'Affiliation': 'Biostatistics Department, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, CIBERESP, Madrid, Spain.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Morillo', 'Affiliation': 'Respiratory Department, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain.'}, {'ForeName': 'Deisy', 'Initials': 'D', 'LastName': 'Barrios', 'Affiliation': 'Respiratory Department, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Le Mao', 'Affiliation': ""EA3878, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université Européenne de Bretagne, Brest, France.""}, {'ForeName': 'Roger D', 'Initials': 'RD', 'LastName': 'Yusen', 'Affiliation': 'Divisions of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'Behnood', 'Initials': 'B', 'LastName': 'Bikdeli', 'Affiliation': 'Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York-Presbyterian Hospital, New York, USA.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Monreal', 'Affiliation': 'CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Lobo', 'Affiliation': 'CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The European respiratory journal,['10.1183/13993003.00412-2021'] 2774,34385241,A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.,"INTRODUCTION Limited data from controlled clinical trials are available for men who experience biochemical recurrence after definitive therapy for prostate cancer. In the absence of overt metastases, patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) often receive androgen deprivation therapy (ADT). There is no standard-of-care consensus on optimal ADT timing, although most men are treated prior to metastases, especially those with high-risk features (Gleason score 8-10 or prostate-specific antigen doubling time (PSADT) <9-12 months). Given data that ADT plus novel hormonal agents improve survival in men with metastatic CSPC, there is a desire to evaluate these agents earlier in the disease course. The main objective of EMBARK is the comparative assessment of enzalutamide plus leuprolide (luteinising hormone-releasing hormone agonist (LHRHa)) or enzalutamide monotherapy versus monotherapy LHRHa to improve metastasis-free survival (MFS) in patients with high-risk nmCSPC PSA recurrence after definitive therapy. METHODS AND ANALYSIS EMBARK is a randomised, phase 3 study of high-risk patients with nmCSPC, a PSADT of ≤9 months and a screening PSA of ≥2 ng/mL above the nadir after radiotherapy (RT) or ≥1 ng/mL after radical prostatectomy (RP) with or without postoperative RT. Men (n=1050) are randomised 1:1:1 to enzalutamide 160 mg/day plus LHRHa or placebo plus LHRHa (double-blind arms) or enzalutamide monotherapy (open-label arm). Treatment is suspended at week 37 if PSA concentrations are <0.2 ng/mL and reinstated if levels rise to ≥2.0 ng/mL with RP or ≥5.0 ng/mL without RP. Patients with PSA ≥0.2 ng/mL at week 37 continue until treatment discontinuation criteria are met. The primary endpoint is MFS comparing enzalutamide plus LHRHa versus placebo plus LHRHa. ETHICS AND DISSEMINATION The study is conducted under the guiding principles of the World Medical Association Declaration of Helsinki. The results will be disseminated at research conferences and in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT02319837.",2021,PSA of ≥2 ng/mL above the nadir after radiotherapy (RT) or ≥1 ng/mL after radical prostatectomy (RP) with or without postoperative RT.,"['high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy', 'Men (n=1050', 'high-risk patients with nmCSPC, a PSADT of ≤9 months and a screening', 'patients with high-risk nmCSPC PSA recurrence after definitive therapy', 'men who experience biochemical recurrence after definitive therapy for prostate cancer', 'patients with non-metastatic castration-sensitive prostate cancer (nmCSPC', 'men with metastatic CSPC']","['enzalutamide plus leuprolide and enzalutamide monotherapy', 'enzalutamide plus leuprolide (luteinising hormone-releasing hormone agonist (LHRHa)) or enzalutamide monotherapy versus monotherapy LHRHa', 'radiotherapy (RT) or ≥1\u2009ng/mL after radical prostatectomy (RP) with or without postoperative RT', 'androgen deprivation therapy (ADT', 'ADT plus novel hormonal agents', 'enzalutamide 160\u2009mg/day plus LHRHa or placebo plus LHRHa (double-blind arms) or enzalutamide monotherapy']","['metastasis-free survival (MFS', 'survival']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C4302896', 'cui_str': 'Hormone sensitive prostate cancer'}, {'cui': 'C0178415', 'cui_str': 'Raised prostate specific antigen'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0443196', 'cui_str': 'Definitive'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0085272', 'cui_str': 'Leuprolide'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.364772,PSA of ≥2 ng/mL above the nadir after radiotherapy (RT) or ≥1 ng/mL after radical prostatectomy (RP) with or without postoperative RT.,"[{'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Freedland', 'Affiliation': 'Division of Urology, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA stephen.freedland@cshs.org.'}, {'ForeName': 'Ugo', 'Initials': 'U', 'LastName': 'De Giorgi', 'Affiliation': 'Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Gleave', 'Affiliation': 'Department of Urologic Sciences, Vancouver Prostate Centre, The University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Brad', 'Initials': 'B', 'LastName': 'Rosbrook', 'Affiliation': 'Department of Global Biometrics and Data Management, Pfizer, New York, New York, USA.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Shen', 'Affiliation': 'Department of Product Development, Pfizer, New York, New York, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Sugg', 'Affiliation': 'Department of Biostatistics, Astellas Pharma US, Northbrook, Illinois, USA.'}, {'ForeName': 'Gabriel P', 'Initials': 'GP', 'LastName': 'Haas', 'Affiliation': 'Astellas Pharma Global Development, Northbrook, Illinois, USA.'}, {'ForeName': 'Neal D', 'Initials': 'ND', 'LastName': 'Shore', 'Affiliation': 'Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA.'}]",BMJ open,['10.1136/bmjopen-2020-046588'] 2775,34385236,Point-of-care testing and treatment of sexually transmitted and genital infections during pregnancy in Papua New Guinea (WANTAIM trial): protocol for an economic evaluation alongside a cluster-randomised trial.,"INTRODUCTION Left untreated, sexually transmitted and genital infections (henceforth STIs) in pregnancy can lead to serious adverse outcomes for mother and child. Papua New Guinea (PNG) has among the highest prevalence of curable STIs including syphilis, chlamydia, gonorrhoea, trichomoniasis and bacterial vaginosis, and high neonatal mortality rates. Diagnosis and treatment of these STIs in PNG rely on syndromic management. Advances in STI diagnostics through point-of-care (PoC) testing using GeneXpert technology hold promise for resource-constrained countries such as PNG. This paper describes the planned economic evaluation of a cluster-randomised cross-over trial comparing antenatal PoC testing and immediate treatment of curable STIs with standard antenatal care in two provinces in PNG. METHODS AND ANALYSIS Cost-effectiveness of the PoC intervention compared with standard antenatal care will be assessed prospectively over the trial period (2017-2021) from societal and provider perspectives. Incremental cost-effectiveness ratios will be calculated for the primary health outcome, a composite measure of the proportion of either preterm birth and/or low birth weight; for life years saved; for disability-adjusted life years averted; and for non-health benefits (financial risk protection and improved health equity). Scenario analyses will be conducted to identify scale-up options, and budget impact analysis will be undertaken to understand short-term financial impacts of intervention adoption on the national budget. Deterministic and probabilistic sensitivity analysis will be conducted to account for uncertainty in key model inputs. ETHICS AND DISSEMINATION This study has ethical approval from the Institutional Review Board of the PNG Institute of Medical Research; the Medical Research Advisory Committee of the PNG National Department of Health; the Human Research Ethics Committee of the University of New South Wales; and the Research Ethics Committee of the London School of Hygiene and Tropical Medicine. Findings will be disseminated through national stakeholder meetings, conferences, peer-reviewed publications and policy briefs. TRIAL REGISTRATION NUMBER ISRCTN37134032.",2021,"Papua New Guinea (PNG) has among the highest prevalence of curable STIs including syphilis, chlamydia, gonorrhoea, trichomoniasis and bacterial vaginosis, and high neonatal mortality rates.","['curable STIs with standard antenatal care in two provinces in PNG', 'sexually transmitted and genital infections during pregnancy in Papua New Guinea']","['standard antenatal care', 'Papua New Guinea (PNG', 'PoC intervention']","['non-health benefits (financial risk protection and improved health equity', 'proportion of either preterm birth and/or low birth weight', 'Incremental cost-effectiveness ratios']","[{'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0030375', 'cui_str': 'Papua New Guinea'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0242781', 'cui_str': 'Communicable Disease Transmission'}, {'cui': 'C0729552', 'cui_str': 'Genital infection'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0030375', 'cui_str': 'Papua New Guinea'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0086387', 'cui_str': 'Health Benefits'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C4042901', 'cui_str': 'Health Equity'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0926952,"Papua New Guinea (PNG) has among the highest prevalence of curable STIs including syphilis, chlamydia, gonorrhoea, trichomoniasis and bacterial vaginosis, and high neonatal mortality rates.","[{'ForeName': 'Neha', 'Initials': 'N', 'LastName': 'Batura', 'Affiliation': 'Institute for Global Health, University College London, London, UK n.batura@ucl.ac.uk.'}, {'ForeName': 'Olga Pm', 'Initials': 'OP', 'LastName': 'Saweri', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Vallely', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Pomat', 'Affiliation': 'The Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Homer', 'Affiliation': 'The Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Guy', 'Affiliation': 'The Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.'}, {'ForeName': 'Stanley', 'Initials': 'S', 'LastName': 'Luchters', 'Affiliation': 'The Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Mola', 'Affiliation': 'School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Vallely', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Morgan', 'Affiliation': 'The Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Kariwiga', 'Affiliation': 'Milne Bay Provincial Health Authority, Alotau, Papua New Guinea.'}, {'ForeName': 'Handan', 'Initials': 'H', 'LastName': 'Wand', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Rogerson', 'Affiliation': 'Department of Medicine, The Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Sepehr N', 'Initials': 'SN', 'LastName': 'Tabrizi', 'Affiliation': ""The Royal Women's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Whiley', 'Affiliation': 'The University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Low', 'Affiliation': 'Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Rosanna W', 'Initials': 'RW', 'LastName': 'Peeling', 'Affiliation': 'Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Siba', 'Affiliation': 'The Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Riddell', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Moses', 'Initials': 'M', 'LastName': 'Laman', 'Affiliation': 'Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Bolnga', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Leanne J', 'Initials': 'LJ', 'LastName': 'Robinson', 'Affiliation': 'The Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Morewaya', 'Affiliation': 'Milne Bay Provincial Health Authority, Alotau, Papua New Guinea.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Badman', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Kelly-Hanku', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Pamela J', 'Initials': 'PJ', 'LastName': 'Toliman', 'Affiliation': 'The Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.'}, {'ForeName': 'Wilfred', 'Initials': 'W', 'LastName': 'Peter', 'Affiliation': 'Madang Provincial Health Authority, Madang, Papua New Guinea.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Peach', 'Affiliation': 'The Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Garland', 'Affiliation': ""Microbiology and Infectious Diseases Department, The Royal Women's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kaldor', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Wiseman', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}]",BMJ open,['10.1136/bmjopen-2020-046308'] 2776,34385232,Protocol for the evaluation of cost-effectiveness and health equity impact of a school-based tobacco prevention programme in a cluster randomised controlled trial (the TOPAS study).,"INTRODUCTION Despite a long-term downward trend in smoking prevalence, tobacco remains the number one risk factor for death and disability in Sweden. Globally, tobacco use generates a substantial economic burden for health systems and is also a major driver of socioeconomic inequalities in health. This article describes the planned cost-effectiveness and health equity impact evaluation of a multicomponent school-based programme to prevent the onset of tobacco use in adolescents. METHODS AND ANALYSIS Cost-effectiveness of the multicomponent Tobacco-Free Duo programme will be evaluated against the educational component of the same programme only. An incremental cost-effectiveness ratio (ICER) will be calculated in terms of the cost per case prevented using the trial primary outcome and within-trial payer costs. If the ICER is negative, an incremental net benefit ratio will be calculated. Robustness of the results will be assessed through one-way sensitivity analyses. The slope index of inequality will be computed to assess the potential impact of the Tobacco-free Duo programme on education-related inequalities in the onset of smoking and in adult smoking cessation, comparing the two trial arms. ETHICS AND DISSEMINATION Ethical approval was obtained from the Regional Ethics Review Board, Umeå (registration number 2017/255-31). The Public Health Agency of Sweden commissioned the study. The findings will be disseminated internationally within academia and to national and local policy-makers. TRIAL REGISTRATION NUMBER ISRCTN52858080; Pre-results.",2021,"Globally, tobacco use generates a substantial economic burden for health systems and is also a major driver of socioeconomic inequalities in health.",['adolescents'],"['school-based tobacco prevention programme', 'multicomponent school-based programme', 'multicomponent Tobacco-Free Duo programme']",['incremental cost-effectiveness ratio (ICER'],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.168739,"Globally, tobacco use generates a substantial economic burden for health systems and is also a major driver of socioeconomic inequalities in health.","[{'ForeName': 'Anni-Maria', 'Initials': 'AM', 'LastName': 'Pulkki-Brännström', 'Affiliation': 'Department of Epidemiology and Global Health, Umea University, Umea, Sweden anni-maria.pulkki-brannstrom@umu.se.'}, {'ForeName': 'Maria R', 'Initials': 'MR', 'LastName': 'Galanti', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Nilsson', 'Affiliation': 'Department of Epidemiology and Global Health, Umea University, Umea, Sweden.'}]",BMJ open,['10.1136/bmjopen-2020-045476'] 2777,34381382,Mindfulness-Based Cognitive Therapy in Major Depressive Disorder: A Study Protocol of a Randomized Control Trial and a Case-Control Study With Electroencephalogram.,"Background: In this report, a study protocol for a randomized control trial is presented in an attempt to explore the efficacy of mindfulness-based cognitive therapy (MBCT) for major depressive disorder (MMD), and a case-control study is conducted to find the difference in electroencephalograms (EEGs) between MMD and normal controls. Design: Seventy Chinese patients with MMD will be chosen for random division in the MBCT group or medication group, with half of the participants receiving common medication treatment [selective serotonin reuptake inhibitors (SSRIs)] and half receiving MBCT as a supplement to the common medication treatment. All participants, namely, 70 MMD cases and 35 matched normal controls, will be tested by a range of scales and EEG at baseline (week 0), mid-intervention (weeks 2, 4, and 6), post-intervention (week 8), and 6-months follow-up (weeks 12, 20, and 32). Discussion: The findings of this study will provide a positive reference for the treatment of depression and future research on MBCT treatment mechanism. Trial Registration: NCT03558256. Registered: June 13, 2018-retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03558256.",2021,"All participants, namely, 70 MMD cases and 35 matched normal controls, will be tested by a range of scales and EEG at baseline (week 0), mid-intervention (weeks 2, 4, and 6), post-intervention (week 8), and 6-months follow-up (weeks 12, 20, and 32). ","['Seventy Chinese patients with MMD will be chosen for random division in the MBCT group or medication group, with half of the participants receiving', 'Major Depressive Disorder', 'All participants, namely, 70 MMD cases and 35 matched normal controls', 'major depressive disorder (MMD']","['mindfulness-based cognitive therapy (MBCT', 'common medication treatment [selective serotonin reuptake inhibitors (SSRIs', 'MBCT', 'Electroencephalogram', 'Mindfulness-Based Cognitive Therapy']",[],"[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1293097', 'cui_str': 'Division'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C3469597', 'cui_str': 'Administration of medication'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}]",[],70.0,0.0673002,"All participants, namely, 70 MMD cases and 35 matched normal controls, will be tested by a range of scales and EEG at baseline (week 0), mid-intervention (weeks 2, 4, and 6), post-intervention (week 8), and 6-months follow-up (weeks 12, 20, and 32). ","[{'ForeName': 'Tianran', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Lanlan', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Yanle', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': 'Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Wenqing', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Yanru', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Wenhui', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': 'Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Fan', 'Affiliation': 'Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Jianyin', 'Initials': 'J', 'LastName': 'Qiu', 'Affiliation': 'Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2021.499633'] 2778,34381353,tDCS-Induced Memory Reconsolidation Effects and Its Associations With Structural and Functional MRI Substrates in Subjective Cognitive Decline.,"Previous evidence suggests that transcranial direct current stimulation (tDCS) to the left dorsolateral prefrontal cortex (l-DLPFC) can enhance episodic memory in subjects with subjective cognitive decline (SCD), known to be at risk of dementia. Our main goal was to replicate such findings in an independent sample and elucidate if baseline magnetic resonance imaging (MRI) characteristics predicted putative memory improvement. Thirty-eight participants with SCD (aged: 60-65 years) were randomly assigned to receive active ( N = 19) or sham ( N = 19) tDCS in a double-blind design. They underwent a verbal learning task with 15 words (DAY-1), and 24 h later (DAY-2) stimulation was applied for 15 min at 1.5 mA targeting the l-DLPFC after offering a contextual reminder. Delayed recall and recognition were measured 1 day after the stimulation session (DAY-3), and at 1-month follow-up (DAY-30). Before the experimental session, structural and functional MRI were acquired. We identified a group ∗ time interaction in recognition memory, being the active tDCS group able to maintain stable memory performance between DAY-3 and DAY-30. MRI results revealed that individuals with superior tDCS-induced effects on memory reconsolidation exhibited higher left temporal lobe thickness and greater intrinsic FC within the default-mode network. Present findings confirm that tDCS, through the modulation of memory reconsolidation, is capable of enhancing performance in people with self-perceived cognitive complaints. Results suggest that SCD subjects with more preserved structural and functional integrity might benefit from these interventions, promoting maintenance of cognitive function in a population at risk to develop dementia.",2021,"We identified a group ∗ time interaction in recognition memory, being the active tDCS group able to maintain stable memory performance between DAY-3 and DAY-30.","['subjects with subjective cognitive decline (SCD', 'Thirty-eight participants with SCD (aged: 60-65 years']","['active ( N = 19) or sham ( N = 19) tDCS', 'transcranial direct current stimulation (tDCS']","['Delayed recall and recognition', 'intrinsic FC', 'Subjective Cognitive Decline']","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0234985', 'cui_str': 'Mental Deterioration'}, {'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0234985', 'cui_str': 'Mental Deterioration'}]",38.0,0.101073,"We identified a group ∗ time interaction in recognition memory, being the active tDCS group able to maintain stable memory performance between DAY-3 and DAY-30.","[{'ForeName': 'Lídia', 'Initials': 'L', 'LastName': 'Vaqué-Alcázar', 'Affiliation': 'Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Lídia', 'Initials': 'L', 'LastName': 'Mulet-Pons', 'Affiliation': 'Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Kilian', 'Initials': 'K', 'LastName': 'Abellaneda-Pérez', 'Affiliation': 'Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Solé-Padullés', 'Affiliation': 'Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Cabello-Toscano', 'Affiliation': 'Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Dídac', 'Initials': 'D', 'LastName': 'Macià', 'Affiliation': 'Department of Biomedicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Roser', 'Initials': 'R', 'LastName': 'Sala-Llonch', 'Affiliation': 'Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Bargalló', 'Affiliation': 'Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Solana', 'Affiliation': 'Guttmann Institute, Badalona, Spain.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Cattaneo', 'Affiliation': 'Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.'}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'Tormos', 'Affiliation': 'Guttmann Institute, Badalona, Spain.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Pascual-Leone', 'Affiliation': 'Guttmann Institute, Badalona, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Bartrés-Faz', 'Affiliation': 'Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.'}]",Frontiers in aging neuroscience,['10.3389/fnagi.2021.695232'] 2779,34381326,A Sham-Controlled Study of Neurofeedback for Pain Management.,"Background Neurofeedback (NFB) attempts to alter the brain's electrophysiological activity and has shown potential as a pain management technique. Existing studies, however, often lack appropriate control groups or fail to assess whether electrophysiological activity has been successfully regulated. The current study is a randomized controlled trial comparing changes in brain activity and pain during NFB with those of a sham-control group. Methods An experimental pain paradigm in healthy participants was used to provide optimal control of pain sensation. Twenty four healthy participants were blind randomized to receive either 10 × NFB (with real EEG feedback) or 10 × sham (with false EEG feedback) sessions during noxious cold stimulation. Prior to actual NFB training, training protocols were individually determined for each participant based on a comparison of an initial 32-channel qEEG assessment administered at both baseline and during an experimental pain task. Each individual protocol was based on the electrode site and frequency band that showed the greatest change in amplitude during pain, with alpha or theta up-regulation at various electrode sites (especially Pz) the most common protocols chosen. During the NFB sessions themselves, pain was assessed at multiple times during each session on a 0-10 rating scale, and ANOVA was used to examine changes in pain ratings and EEG amplitude both across and during sessions for both NFB and sham groups. Results For pain, ANOVA trend analysis found a significant general linear decrease in pain across the 10 sessions ( p = 0.015). However, no significant main or interaction effects of group were observed suggesting decreases in pain occurred independently of NFB. For EEG, there was a significant During Session X Group interaction ( p = 0.004), which indicated that EEG amplitude at the training site was significantly closer to the target amplitude for the NFB compared to the sham group during painful stimulation, but this was only the case at the beginning of the cold task. Conclusion While these results must be interpreted within the context of an experimental pain model, they underline the importance of including an appropriate comparison group to avoid attributing naturally occurring changes to therapeutic effects.",2021,"Results For pain","['Twenty four healthy participants', 'healthy participants']","['\n\n\nNeurofeedback (NFB', '10 × NFB (with real EEG feedback) or 10 × sham (with false EEG feedback) sessions during noxious cold stimulation']","['brain activity and pain', 'pain', 'EEG amplitude', 'pain ratings and EEG amplitude']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C2713542', 'cui_str': 'Electromyography Feedback'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0205237', 'cui_str': 'False'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}]",24.0,0.0640642,"Results For pain","[{'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Ide-Walters', 'Affiliation': 'Centre for Chronic Illness and Ageing, University of Greenwich, London, United Kingdom.'}, {'ForeName': 'Trevor', 'Initials': 'T', 'LastName': 'Thompson', 'Affiliation': 'Centre for Chronic Illness and Ageing, University of Greenwich, London, United Kingdom.'}]",Frontiers in neuroscience,['10.3389/fnins.2021.591006'] 2780,34381303,Deepening the Group Training Experience: Group Cohesion and Supervision Impact in Alliance-Focused Training.,"Objective The aim of the current study is to explore experiences of trainees engaged in alliance-focused training (AFT), a group supervision modality with an explicit focus on awareness of ruptures and implementation of repair strategies. Using Cognitive Behavioral Therapy (CBT) group supervision as a point of comparison, the study examines supervisory alliance, ruptures, group cohesion and safety, and supervision impact. Method Eighty-three trainees (clinical psychology interns, advanced-level psychology externs and psychiatry residents) at a metropolitan medical center in New York City who received supervision in CBT (N = 38) or AFT (N = 45) reported on their group supervision experience. Participants had a mean age of 29.5 ( SD = 4.9); 77% were women; 84% of participants identified as White, 7% as Multiethnic, 6% as Hispanic/Latinx, 1% as Black, and 1% as Asian. Participants reported on occurrence of ruptures with their supervisor, supervisory alliance (Working Alliance Inventory-Short), group safety, supervision depth and smoothness (Session Evaluation Questionnaire), and group cohesion (Group Climate Questionnaire). Mixed and general linear models, and correlation analyses were used for analysis. Results All trainees reported equally low incidence of ruptures with their supervisor alongside high ratings of supervisory alliance. Trainees in AFT reported experiencing less safety, smoothness, and greater intergroup conflict than trainees in CBT supervision; however, they also reported stronger group engagement and a deeper supervision experience. Conclusions Results suggest that AFT may provide a rich environment to foster a certain level of discomfort and risk-taking that may facilitate an engaging and meaningful learning experience.",2021,"Trainees in AFT reported experiencing less safety, smoothness, and greater intergroup conflict than trainees in CBT supervision; however, they also reported stronger group engagement and a deeper supervision experience. ","['Method\n\n\nEighty-three trainees (clinical psychology interns, advanced-level psychology externs and psychiatry residents) at a metropolitan medical center in New York City who received supervision in CBT (N = 38) or AFT (N = 45', 'Participants had a mean age of 29.5 ( SD = 4.9); 77% were women; 84% of participants identified as White, 7% as Multiethnic, 6% as Hispanic/Latinx, 1% as Black, and 1% as Asian']","['trainees engaged in alliance-focused training (AFT', 'Cohesion and Supervision Impact in Alliance-Focused Training', 'AFT', 'Cognitive Behavioral Therapy (CBT']","['occurrence of ruptures with their supervisor, supervisory alliance (Working Alliance Inventory-Short), group safety, supervision depth and smoothness (Session Evaluation Questionnaire), and group cohesion (Group Climate Questionnaire']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C0033912', 'cui_str': 'Clinical Psychology'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0033909', 'cui_str': 'Psychology'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0027977', 'cui_str': 'New York City'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}]","[{'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0443294', 'cui_str': 'Ruptured'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0008946', 'cui_str': 'Climate'}]",,0.038987,"Trainees in AFT reported experiencing less safety, smoothness, and greater intergroup conflict than trainees in CBT supervision; however, they also reported stronger group engagement and a deeper supervision experience. ","[{'ForeName': 'Adelya A', 'Initials': 'AA', 'LastName': 'Urmanche', 'Affiliation': 'Derner School of Psychology, Adelphi University, Hy Weinberg Center, 158 Cambridge Avenue, Garden City, NY 11530, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Minges', 'Affiliation': 'Brief Psychotherapy Research Program, Mount Sinai Beth Israel, 10 Nathan D. Perlman Place, New York, NY 10003.'}, {'ForeName': 'Catherine F', 'Initials': 'CF', 'LastName': 'Eubanks', 'Affiliation': 'Ferkauf Graduate School in Psychology, Yeshiva University, 1165 Morris Park Avenue, Bronx, NY 10461, USA.'}, {'ForeName': 'Bernard S', 'Initials': 'BS', 'LastName': 'Gorman', 'Affiliation': 'Derner School of Psychology, Adelphi University, Hy Weinberg Center, 158 Cambridge Avenue, Garden City, NY 11530, USA.'}, {'ForeName': 'J Christopher', 'Initials': 'JC', 'LastName': 'Muran', 'Affiliation': 'Derner School of Psychology, Adelphi University, Hy Weinberg Center, 158 Cambridge Avenue, Garden City, NY 11530, USA.'}]","Group dynamics : theory, research, and practice : the official journal of Division 49, Group Psychology and Group Psychotherapy of the American Psychological Association",['10.1037/gdn0000134'] 2781,34381177,Providing sealants at the general anaesthetic assessment visit for children requiring caries-related dental extractions under general anaesthetic: a pilot randomised controlled trial.,"Introduction Children experiencing a caries-related dental general anaesthetic (GA) are at high risk of developing new caries. It is thus important to maximise opportunities for prevention.Aim To undertake a pilot randomised controlled clinical trial (RCT) to assess the feasibility of delivering and evaluating the effectiveness of sealing sound permanent molars at the pre-GA assessment appointment in children needing caries-related extractions under GA.Methods Children (5-15 years) scheduled for GA extractions at Birmingham Dental Hospital were randomised to control or sealant groups. At the pre-GA assessment appointment, sound permanent molars were sealed. Participants were followed up at two years.Results In total, 132 children were assessed for eligibility and 100 randomised (50 control, 50 sealant). Forty-nine children in the intervention group had sealants applied. At two years, 82 children returned for follow-up (43 control, 39 sealant). Sealants were retained on 93.5% (244/261) of surfaces sealed at baseline. Overall, 42% (n = 18) of control group participants had dentine caries in at least one permanent molar that was sound at baseline compared with none in the sealant group.Conclusion Following caries-related extractions under GA, children are at high risk of developing new caries in permanent molars that were sound at the time of the GA. Sealant placement during the pre-GA assessment visit is feasible and may reduce caries incidence in this vulnerable group. High-risk families were found to be reliable study participants.",2021,Sealants were retained on 93.5% (244/261) of surfaces sealed at baseline.,"['132 children', 'Introduction Children experiencing a caries-related dental general anaesthetic (GA', 'Forty-nine children in the intervention group had sealants applied', 'children needing caries-related extractions under GA.Methods Children (5-15 years) scheduled for GA extractions at Birmingham Dental Hospital', 'children requiring caries-related dental extractions under general anaesthetic']",['sealing sound permanent molars at the pre-GA assessment appointment'],"['caries incidence', 'dentine caries']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0729415', 'cui_str': 'Sealant'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C1277300', 'cui_str': 'Child in need'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C3164440', 'cui_str': 'Dental hospital'}, {'cui': 'C0040440', 'cui_str': 'Tooth extraction'}]","[{'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}]","[{'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0266846', 'cui_str': 'Dental caries extending into dentin'}]",132.0,0.180441,Sealants were retained on 93.5% (244/261) of surfaces sealed at baseline.,"[{'ForeName': 'Abida', 'Initials': 'A', 'LastName': 'Raja', 'Affiliation': 'Clinical Lecturer in Paediatric Dentistry, School of Dentistry, University of Birmingham, 5 Mill Pool Way, Edgbaston, Birmingham, B5 7EG, UK. a.raja@bham.ac.uk.'}, {'ForeName': 'Deborah Anne', 'Initials': 'DA', 'LastName': 'White', 'Affiliation': 'Emeritus Professor of Dental Public Health, School of Dentistry, University of Birmingham, 5 Mill Pool Way, Edgbaston, Birmingham, B5 7EG, UK.'}, {'ForeName': 'Sally Elizabeth', 'Initials': 'SE', 'LastName': 'Kerr', 'Affiliation': 'Associate Specialist in Oral Surgery, Birmingham Dental Hospital, Birmingham Community Healthcare NHS Foundation Trust, 5 Mill Pool Way, Birmingham, B5 7EG, UK.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Dietrich', 'Affiliation': 'Professor and Head of Oral Surgery, School of Dentistry, University of Birmingham, 5 Mill Pool Way, Edgbaston, Birmingham, B5 7EG, UK.'}]",British dental journal,['10.1038/s41415-021-3220-8'] 2782,34381173,Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.,"Polymorphisms in genes associated with opioid signaling and dopamine reuptake and inactivation may moderate naltrexone efficacy in Alcohol Use Disorder (AUD), but the effects of epigenetic modification of these genes on naltrexone response are largely unexplored. This study tested interactions between methylation in the μ-opioid receptor (OPRM1), dopamine transporter (SLC6A3), and catechol-O-methyltransferase (COMT) genes as predictors of naltrexone effects on heavy drinking in a 16-week randomized, placebo-controlled trial among 145 treatment-seeking AUD patients. OPRM1 methylation interacted with both SLC6A3 and COMT methylation to moderate naltrexone efficacy, such that naltrexone-treated individuals with lower methylation of the OPRM1 promoter and the SLC6A3 promoter (p = 0.006), COMT promoter (p = 0.005), or SLC6A3 3' untranslated region (p = 0.004), relative to placebo and to those with higher OPRM1 and SLC6A3 or COMT methylation, had significantly fewer heavy drinking days. Epigenetic modification of opioid- and dopamine-related genes may represent a novel pharmacoepigenetic predictor of naltrexone efficacy in AUD.",2021,OPRM1,"['heavy drinking in Alcohol Use Disorder', '145 treatment-seeking AUD patients']","['OPRM1', 'placebo', 'naltrexone']","['COMT promoter', 'heavy drinking days']","[{'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}]","[{'cui': 'C0007407', 'cui_str': 'Catechol methyltransferase'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0556347', 'cui_str': 'Drinking day'}]",145.0,0.0977473,OPRM1,"[{'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Schacht', 'Affiliation': 'Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. joseph.schacht@cuanschutz.edu.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Hoffman', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Brian H', 'Initials': 'BH', 'LastName': 'Chen', 'Affiliation': 'FOXO Technologies Inc., Minneapolis, MN, USA.'}, {'ForeName': 'Raymond F', 'Initials': 'RF', 'LastName': 'Anton', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.'}]",The pharmacogenomics journal,['10.1038/s41397-021-00250-8'] 2783,34381155,Therapeutic efficacy of macrolides in management of patients with mild COVID-19.,"Evidence on the efficacy of adding macrolides (azithromycin or clarithromycin) to the treatment regimen for COVID-19 is limited. We testify whether adding azithromycin or clarithromycin to a standard of care regimen was superior to standard of supportive care alone in patients with mild COVID-19.This randomized trial included three groups of patients with COVID-19. The azithromycin group included, 107 patients who received azithromycin 500 mg/24 h for 7 days, the clarithromycin group included 99 patients who received clarithromycin 500 /12 h for 7 days, and the control group included 99 patients who received standard care only. All three groups received only symptomatic treatment for control of fever and cough .Clinical and biochemical evaluations of the study participants including assessment of the symptoms duration, real-time reverse transcription-polymerase chain reaction (rRT-PCR), C-reactive protein (CRP), serum ferritin, D-dimer, complete blood count (CBC), in addition to non-contrast chest computed tomography (CT), were performed. The overall results revealed significant early improvement of symptoms (fever, dyspnea and cough) in patients treated with either azithromycin or clarithromycin compared to control group, also there was significant early conversion of SARS-CoV-2 PCR to negative in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).There was no significant difference in time to improvement of fever, cough, dyspnea, anosmia, gastrointestinal tract ""GIT"" symptoms and time to PCR negative conversion between patients treated with azithromycin compared to patients treated with clarithromycin (p > 0.05 for all). Follow up chest CT done after 2 weeks of start of treatment showed significant improvement in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).Adding Clarithromycin or azithromycin to the therapeutic protocols for COVID-19 could be beneficial for early control of fever and early PCR negative conversion in Mild COVID-19.Trial registration: (NCT04622891) www.ClinicalTrials.gov retrospectively registered (November 10, 2020).",2021,Follow up chest CT done after 2 weeks of start of treatment showed significant improvement in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).Adding Clarithromycin or azithromycin to the therapeutic protocols for COVID-19 could be beneficial for early control of fever and early PCR negative conversion in Mild COVID-19.Trial registration: (NCT04622891) www.,"['99 patients who received standard care only', 'patients with mild COVID-19', 'patients with mild COVID-19.This randomized trial included three groups of patients with COVID-19', '107 patients who received']","['clarithromycin 500', 'azithromycin', 'macrolides (azithromycin or clarithromycin', 'azithromycin or clarithromycin', 'Clarithromycin', 'clarithromycin']","['symptoms (fever, dyspnea and cough', 'symptoms duration, real-time reverse transcription-polymerase chain reaction (rRT-PCR), C-reactive protein (CRP), serum ferritin, D-dimer, complete blood count (CBC), in addition to non-contrast chest computed tomography (CT', 'early conversion of SARS-CoV-2 PCR to negative', 'fever, cough, dyspnea, anosmia, gastrointestinal tract ""GIT"" symptoms and time to PCR negative conversion', 'Therapeutic efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517529', 'cui_str': '107'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0003240', 'cui_str': 'Macrolide antibiotic product'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0696113', 'cui_str': 'Serum ferritin measurement'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0009555', 'cui_str': 'Complete blood count'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0003126', 'cui_str': 'Loss of sense of smell'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0073146,Follow up chest CT done after 2 weeks of start of treatment showed significant improvement in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).Adding Clarithromycin or azithromycin to the therapeutic protocols for COVID-19 could be beneficial for early control of fever and early PCR negative conversion in Mild COVID-19.Trial registration: (NCT04622891) www.,"[{'ForeName': 'Alaa', 'Initials': 'A', 'LastName': 'Rashad', 'Affiliation': 'Department of Chest Diseases and Tuberculosis, Faculty of Medicine, South Valley-University, Qena, Egypt.'}, {'ForeName': 'Asmaa', 'Initials': 'A', 'LastName': 'Nafady', 'Affiliation': 'Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Mohammed H', 'Initials': 'MH', 'LastName': 'Hassan', 'Affiliation': 'Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, 83523, Egypt. Mohammedhosnyhassaan@yahoo.com.'}, {'ForeName': 'Haggagy', 'Initials': 'H', 'LastName': 'Mansour', 'Affiliation': 'Department of Chest Diseases and Tuberculosis, Faculty of Medicine, South Valley-University, Qena, Egypt.'}, {'ForeName': 'Usama', 'Initials': 'U', 'LastName': 'Taya', 'Affiliation': 'ENT Department, Faculty of Medicine, South Valley University, Qena, Egypt.'}, {'ForeName': 'Shamardan Ezzeldin S', 'Initials': 'SES', 'LastName': 'Bazeed', 'Affiliation': 'Tropical Medicine and Gastroenterology Department, Faculty of Medicine, South Valley University, Qena, Egypt.'}, {'ForeName': 'Zaki F', 'Initials': 'ZF', 'LastName': 'Aref', 'Affiliation': 'ENT Department, Faculty of Medicine, South Valley University, Qena, Egypt.'}, {'ForeName': 'Mennatallah Ali Abdelrhman', 'Initials': 'MAA', 'LastName': 'Sayed', 'Affiliation': 'King Salman International University, Sharm El-Sheikh, Egypt.'}, {'ForeName': 'Hanaa', 'Initials': 'H', 'LastName': 'Nafady-Hego', 'Affiliation': 'Department of Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Aida A', 'Initials': 'AA', 'LastName': 'Abdelmaksoud', 'Affiliation': 'ENT Department, Faculty of Medicine, South Valley University, Qena, Egypt.'}]",Scientific reports,['10.1038/s41598-021-95900-z'] 2784,34380867,Split dose bowel preparation before colonoscopy of PEG (Nulytely) in comparison to routine single dose bowel preparation.,"Background The aim of this study was to compare the efficacy and tolerability of polyethylene glycol (PEG) in single- or split-dose regimens for colonoscopy bowel preparation. Methods This is a prospective, randomized, endoscopist blinded, single-center study, that included adult patients who underwent colonoscopy during the period from December 2017 to October 2018. Two groups were enrolled in the same period: One group used 4 L of PEG (Nulytely) in a single-dose preparation, administered a day before the procedure, and the other group received a split-dose regimen of 2 L PEG (Nulytely), given a day before the procedure and 2 L on the day of the procedure in the early morning. The Boston Bowel Preparation Scale (BBPS) was used for bowel preparation adequacy; scales 0 and 1 were considered inadequate, and scales 2 and 3 were considered adequate preparation. Results Two hundred and forty patients were enrolled, 120 (50%) using the split-dose regimen and 120 (50%) using the single-dose regimen, for bowel preparation. Males constituted 51.6% of the study cohort. In the single-dose group, 62.5% achieved adequate bowel preparation compared to 89.2% in the split-dose group (p< 0.001). In addition, polyp detection in the split-dose group was 23.3% in comparison to 10.8% in the single-dose group (P = 0.016). We also found hypertension and diabetes as significant predictors of bowel preparation inadequacy, while sex and age were not related to bowel preparation adequacy. Conclusions Split-dose bowel preparation for colonoscopy with PEG (Nulytely) is better than routine single-dose, in terms of adequate bowel preparation and polyp detection.",2021,"In addition, polyp detection in the split-dose group was 23.3% in comparison to 10.8% in the single-dose group (P = 0.016).","['Two hundred and forty patients were enrolled, 120 (50%) using the split-dose regimen and 120 (50%) using the single-dose regimen, for bowel preparation', 'adult patients who underwent colonoscopy during the period from December 2017 to October 2018']","['polyethylene glycol (PEG', 'Split dose bowel preparation before colonoscopy of PEG (Nulytely', 'split-dose regimen of 2 L PEG (Nulytely']","['polyp detection', 'efficacy and tolerability', 'adequate bowel preparation', 'Boston Bowel Preparation Scale (BBPS']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}]","[{'cui': 'C0032483', 'cui_str': 'Polyethylene Glycols'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0083807', 'cui_str': 'NuLytely'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure'}, {'cui': 'C4302285', 'cui_str': 'BBPS - Boston bowel preparation scale'}]",240.0,0.0156771,"In addition, polyp detection in the split-dose group was 23.3% in comparison to 10.8% in the single-dose group (P = 0.016).","[{'ForeName': 'Said', 'Initials': 'S', 'LastName': 'Al Alawi', 'Affiliation': 'Internal Medicine Department, Oman Medical Specialty Board; Department of Gastroenterology, The Royal Hospital, Muscat, Oman.'}, {'ForeName': 'Hisham', 'Initials': 'H', 'LastName': 'Al Dhahab', 'Affiliation': 'Department of Gastroenterology, The Royal Hospital, Muscat, Oman.'}, {'ForeName': 'Issa', 'Initials': 'I', 'LastName': 'Al Salmi', 'Affiliation': 'Internal Medicine Department, Oman Medical Specialty Board; Department of Medicine, The Royal Hospital, Muscat, Oman.'}]",Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association,['10.4103/sjg.sjg_563_20'] 2785,34380854,Does educational-supportive program affect anxiety in women with endometrial cancer? Result from a randomized clinical trials.,"Background Following a diagnosis of cancer, distress is a common reaction. For Iranian women with endometrial cancer, treatment and survivorship can result in disabling symptoms of depression, anxiety, social, and spiritual crises. The aim of this study was to determine whether a combination of education and support intervention as a comprehensive program focusing on education, coping, and support had better short- and long-term effects on anxiety of these patients. Methods The current randomized clinical trial was performed on a sample of 140 women with endometrial cancer. A two-part instrument was used - a demographic information form and ""Beck's Anxiety"" questionnaire. The intervention was an educational-supportive program in 3 weekly sessions in experimental group (N = 70), whereas control group (N = 70) received routine care. Descriptive statistics, Chi-square test, t-tests, and repeated measure analysis of variance were used to analyze data. P value less than 0.05 was considered as statistically significant. Results The total scores of anxiety (mean± standard deviation) was significantly lower in the experimental group immediately after intervention (8.46 ± 5.17, P < 0.001), 1 month (7.78 ± 4.59, P < 0.001) and 2 months (7.55 ± 4.55, P < 0.001) after intervention to compare with before intervention (16.82 ± 10.19). Conclusion In this study, this program could decrease the anxiety in women with endometrial cancer.",2021,"The total scores of anxiety (mean± standard deviation) was significantly lower in the experimental group immediately after intervention (8.46 ± 5.17, P < 0.001), 1 month (7.78 ± 4.59, P < 0.001) and 2 months (7.55 ± 4.55, P < 0.001) after intervention to compare with before intervention (16.82 ± 10.19). ","['women with endometrial cancer', 'Iranian women with endometrial cancer', '140 women with endometrial cancer']","['education and support intervention', 'routine care']","['total scores of anxiety (mean± standard deviation', 'anxiety']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007103', 'cui_str': 'Endometrial neoplasms malignant'}, {'cui': 'C4319553', 'cui_str': '140'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]",140.0,0.0345628,"The total scores of anxiety (mean± standard deviation) was significantly lower in the experimental group immediately after intervention (8.46 ± 5.17, P < 0.001), 1 month (7.78 ± 4.59, P < 0.001) and 2 months (7.55 ± 4.55, P < 0.001) after intervention to compare with before intervention (16.82 ± 10.19). ","[{'ForeName': 'Soudabeh', 'Initials': 'S', 'LastName': 'Niroomand', 'Affiliation': 'Department of Midwifery, Zanjan University of Medical Science, Zanjan, Iran.'}, {'ForeName': 'Samaneh', 'Initials': 'S', 'LastName': 'Youseflu', 'Affiliation': 'Department of Midwifery, Zanjan University of Medical Science, Zanjan, Iran.'}, {'ForeName': 'Mitra Modares', 'Initials': 'MM', 'LastName': 'Gilani', 'Affiliation': 'Department of Obstetrics and Gynecology, School of Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Anoshirvan', 'Initials': 'A', 'LastName': 'Kazemnejad', 'Affiliation': 'Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Leila Neisani', 'Initials': 'LN', 'LastName': 'Samani', 'Affiliation': 'Department of Nursing and Midwifery, School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.'}]",Indian journal of cancer,['10.4103/ijc.IJC_741_18'] 2786,34380842,Effect of multimodal analgesia on perioperative insulin resistance in patients with colon cancer.,"Background High risk of post-surgery complications have always been related with uncontrolled blood glucose, while the relationship between blood glucose and analgesia has not been compared on radical resection of colon cancer. The aim of this study is to investigate the effects of multimodal analgesia on perioperative insulin resistance in patients undergoing radical resection of colon cancer. Methods Sixty patients with colon cancer scheduled for radical resection surgery were equally divided into two groups randomly, the control group (TAP group) received general anesthesia and the transversus abdominis plane block analgesia, and the experimental group (GEA group) received extra epidural anesthesia. The analgesic efficacy was evaluated with visual analog scale (VAS). Insulin resistance indicators like fasting plasma glucose (FPG), resistin (RESIS), fasting insulin (FINS), homeostasis model assessment (HOMA) levels, and inflammation indicator interleukin-6 (IL-6) were evaluated during the surgery. Results IL-6 increase was significant in the TAP group than that in GEA group (P < 0.01). The insulin resistance increased significantly in TAP group than that in GEA group including HOMA (P < 0.05) and FPG (P < 0.05). There was no significant difference in RESIS levels and VAS scores in the two groups. Conclusion Epidural anesthesia leads to less inflammation in radical resection of colon cancer and the insulin level and insulin resistance increased after the surgeries based on FINS and HOMA..",2021,"Results IL-6 increase was significant in the TAP group than that in GEA group (P < 0.01).","['patients undergoing radical resection of colon cancer', 'patients with colon cancer', 'Sixty patients with colon cancer scheduled for radical resection surgery']","['TAP', 'GEA', 'control group (TAP group) received general anesthesia and the transversus abdominis plane block analgesia, and the experimental group (GEA group) received extra epidural anesthesia', 'multimodal analgesia']","['visual analog scale (VAS', 'perioperative insulin resistance', 'analgesic efficacy', 'HOMA', 'insulin resistance', 'RESIS levels and VAS scores', 'insulin level and insulin resistance', 'IL-6 increase', 'FPG', 'Insulin resistance indicators like fasting plasma glucose (FPG), resistin (RESIS), fasting insulin (FINS), homeostasis model assessment (HOMA) levels, and inflammation indicator interleukin-6 (IL-6']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0963992', 'cui_str': 'Resistin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0877589', 'cui_str': 'Interleukin-6 increased'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}]",60.0,0.0648128,"Results IL-6 increase was significant in the TAP group than that in GEA group (P < 0.01).","[{'ForeName': 'Yuxuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Su', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Ruixuan', 'Initials': 'R', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Yan', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Guiping', 'Initials': 'G', 'LastName': 'Xu', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}]",Indian journal of cancer,['10.4103/ijc.IJC_197_19'] 2787,34380811,"Speech intelligibility, nasal resonance, and swallowing ability of maxillectomy patients with customized obturator: A non randomized controlled study.","Aim To compare speech intelligibility (SI), nasal resonance, and swallowing ability in maxillectomy patients with a customized obturator to the conventional obturator. Settings and Design Non-randomized controlled study. Materials and Methods Forty-eight maxillectomy patients were recruited and assessment of SI, nasal resonance, and swallowing ability was done at three situations: without obturator, with conventional obturator, and with customized obturator. Recordings of unrehearsed conversation, counting from number 1-20 and four sets of Chapel Hill Multilingual Intelligibility Test in the Hindi language were used to assess SI and nasal resonance. SI was evaluated by untrained listeners and graded according to a 6-point scale. Nasal resonance was evaluated by speech pathologists on a 7-point scale of severity. Swallowing ability was evaluated by water drinking test. Statistical Analysis Used One-way ANOVA, Post hoc Bonferroni and Chi square test. Results SI and nasal resonance showed a statistically significant difference between any two groups (P < 0.001). Water drinking time was significantly different between without obturator and with customized obturator (P < 0.001), but the difference was not statistically significant between without obturator and with obturator (P < 0.004). Conclusion SI, nasal resonance, and swallowing ability improved with customized obturator in comparison to the conventional obturator.",2021,"Water drinking time was significantly different between without obturator and with customized obturator (P < 0.001), but the difference was not statistically significant between without obturator and with obturator (P < 0.004). ","['maxillectomy patients with customized obturator', 'Materials and Methods\n\n\nForty-eight maxillectomy patients', 'maxillectomy patients with a customized obturator to the conventional obturator']",[],"['Speech intelligibility, nasal resonance, and swallowing ability', 'Water drinking time', 'speech intelligibility (SI), nasal resonance, and swallowing ability', 'Results\n\n\nSI and nasal resonance', 'Conclusion\n\n\nSI, nasal resonance, and swallowing ability', 'SI, nasal resonance, and swallowing ability', 'Swallowing ability', 'SI', 'Nasal resonance']","[{'cui': 'C0407722', 'cui_str': 'Maxillectomy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0182021', 'cui_str': 'Obturator'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]",[],"[{'cui': 'C0037824', 'cui_str': 'Speech Intelligibility'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0231881', 'cui_str': 'Resonance'}, {'cui': 'C0566355', 'cui_str': 'Ability to swallow'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]",48.0,0.0719629,"Water drinking time was significantly different between without obturator and with customized obturator (P < 0.001), but the difference was not statistically significant between without obturator and with obturator (P < 0.004). ","[{'ForeName': 'Rohan', 'Initials': 'R', 'LastName': 'Grover', 'Affiliation': ""Department of Prosthodontics, Crown and Bridge, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Sunit Kumar', 'Initials': 'SK', 'LastName': 'Jurel', 'Affiliation': ""Department of Prosthodontics, Crown and Bridge, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Bhaskar', 'Initials': 'B', 'LastName': 'Agarwal', 'Affiliation': ""Department of Prosthodontics, Crown and Bridge, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Jitendra', 'Initials': 'J', 'LastName': 'Rao', 'Affiliation': ""Department of Prosthodontics, Crown and Bridge, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Saumya', 'Initials': 'S', 'LastName': 'Kapoor', 'Affiliation': ""Department of Prosthodontics, Crown and Bridge, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Niraj', 'Initials': 'N', 'LastName': 'Mishra', 'Affiliation': ""Department of Prosthodontics, Crown and Bridge, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Balendra Pratap', 'Initials': 'BP', 'LastName': 'Singh', 'Affiliation': ""Department of Prosthodontics, Crown and Bridge, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India.""}]",Journal of Indian Prosthodontic Society,['10.4103/jips.jips_98_21'] 2788,34380724,"Single-centre, open-label, randomised, trial to compare rapid molecular point-of-care streptococcal testing to standard laboratory-based testing for the management of streptococcal pharyngitis in children: study protocol.","INTRODUCTION Streptococcal pharyngitis, which commonly occurs in children, should be treated with antibiotics. Clinical prediction rules to differentiate streptococcal pharyngitis from viral infection are not recommended in children. Rapid point-of-care (POC) antigen tests have limited sensitivity and so are not often used in Canadian paediatric emergency departments (EDs). Standard paediatric practice is to rely on laboratory-based testing, which often results in a delay before the results can be communicated to the patient; this may impede appropriate prescribing, decrease caregiver satisfaction and delay recovery. The objective of this study is to determine whether a novel rapid molecular POC assay for streptococcal pharyngitis leads to more appropriate antibiotic use in children seeking care in a paediatric ED than standard laboratory-based testing. METHODS AND ANALYSIS A randomised, superiority, open-label, trial with two parallel groups. Children presenting to a tertiary paediatric ED at least 3 years of age who have a throat swab ordered for diagnosis of streptococcal pharyngitis will be eligible; those who have taken antibiotics within 72 hours prior to presentation and those with additional active infections will be excluded. The primary study outcome will be appropriate antibiotic treatment at 3-5 days postenrolment. Secondary outcomes include time to symptom resolution, caregiver satisfaction, caregiver/child absenteeism, number of subsequent healthcare visits, clinician satisfaction and incremental cost-effectiveness of POC testing. A total of 352 participants will be needed. ETHICS AND DISSEMINATION All study documentation has been approved by the Hamilton Integrated Research Ethics board and informed consent will be obtained from all participants. Data from this trial will be presented at major conferences and published in peer-reviewed publications to facilitate collaborations with networks of clinicians experienced in the dissemination of clinical guidelines. TRIAL REGISTRATION NUMBER NCT04247243.",2021,"Secondary outcomes include time to symptom resolution, caregiver satisfaction, caregiver/child absenteeism, number of subsequent healthcare visits, clinician satisfaction and incremental cost-effectiveness of POC testing.","['Children presenting to a tertiary paediatric ED at least 3 years of age who have a throat swab ordered for diagnosis of streptococcal pharyngitis will be eligible; those who have taken antibiotics within 72\u2009hours prior to presentation and those with additional active infections', 'children', 'Canadian paediatric emergency departments (EDs', '352 participants will be needed', 'children seeking care in a paediatric ED than standard laboratory-based testing']",['rapid molecular point-of-care streptococcal testing to standard laboratory-based testing'],"['time to symptom resolution, caregiver satisfaction, caregiver/child absenteeism, number of subsequent healthcare visits, clinician satisfaction and incremental cost-effectiveness of POC testing']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439056', 'cui_str': 'Throat swab'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0036689', 'cui_str': 'Streptococcal sore throat'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1319173', 'cui_str': 'Caregiver wellbeing status'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C1319069', 'cui_str': 'Point of care testing'}]",352.0,0.101454,"Secondary outcomes include time to symptom resolution, caregiver satisfaction, caregiver/child absenteeism, number of subsequent healthcare visits, clinician satisfaction and incremental cost-effectiveness of POC testing.","[{'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Pernica', 'Affiliation': 'Paediatrics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada pernica@mcmaster.ca.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Smaill', 'Affiliation': 'Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'April J', 'Initials': 'AJ', 'LastName': 'Kam', 'Affiliation': 'Paediatrics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Bartholomew', 'Affiliation': 'Paediatrics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Quynh', 'Initials': 'Q', 'LastName': 'Doan', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Smieja', 'Affiliation': 'Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Khan', 'Affiliation': 'Paediatrics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Melani', 'Initials': 'M', 'LastName': 'Sung', 'Affiliation': 'Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': 'Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Goldfarb', 'Affiliation': 'Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}]",BMJ open,['10.1136/bmjopen-2020-047271'] 2789,34380719,"Effects of local handwashing agents on microbial contamination of hands in the rural settings of northwest Ethiopia: protocol for a two-arm, clustered-randomised controlled trial.","INTRODUCTION Hands play a part in the transmission of infections. Handwashing with soap sufficiently reduces the level of hand contamination and the spread of infections. As soap is not usually available due to cost, ash is often used as a zero-cost alternative to soap in the rural settings of developing countries. However, there is limited evidence on the effectiveness of ash to reduce microbial contamination of hands. This study is, therefore, designed to assess the effect of ash on microbial contamination of hands in the rural settings of northwest Ethiopia. METHODS AND ANALYSIS A two-arm clustered-randomised controlled trial will be employed. A total of 11 clusters per arm will be selected using simple random sampling technique. A total of 220 mothers or caregivers of under-5 children will be included in each arm. After providing health education on effective handwashing process, we will ask study subjects to do the usual activities. We will then take swab samples from the dominant hand before washing. After swabbing, participants will be asked to wash their hands with water only and with ash by following effective handwashing procedures. We will again take swab samples from the dominant hand after washing and drying. Finally, we will compare each intervention arm against the control. A generalised estimating equation (GEE) with robust SE estimation will be used to account the cluster nature of data. ETHICS AND DISSEMINATION Results will be published in peer-reviewed journal and presented at international conferences. The protocol is approved by the Institutional Review Board of the University of Gondar, Ethiopia. TRIAL REGISTRATION NUMBER Pan African Clinical Trial Registry; PACTR202011855730652.",2021,Handwashing with soap sufficiently reduces the level of hand contamination and the spread of infections.,"['microbial contamination of hands in the rural settings of northwest Ethiopia', 'hands in the rural settings of northwest Ethiopia', '220 mothers or caregivers of under-5 children']",['local handwashing agents'],['level of hand contamination and the spread of infections'],"[{'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0015024', 'cui_str': 'Ethiopia'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0450442', 'cui_str': 'Agent'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0332261', 'cui_str': 'Spreading'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",220.0,0.0634678,Handwashing with soap sufficiently reduces the level of hand contamination and the spread of infections.,"[{'ForeName': 'Zemichael', 'Initials': 'Z', 'LastName': 'Gizaw', 'Affiliation': 'Department of Environmental and Occupational Health and Safety, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia zemichael12@gmail.com.'}, {'ForeName': 'Alemayehu Worku', 'Initials': 'AW', 'LastName': 'Yalew', 'Affiliation': 'School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.'}, {'ForeName': 'Bikes Destaw', 'Initials': 'BD', 'LastName': 'Bitew', 'Affiliation': 'Department of Environmental and Occupational Health and Safety, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.'}, {'ForeName': 'Jiyoung', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Division of Environmental Health Sciences, College of Public Health, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bisesi', 'Affiliation': 'Division of Environmental Health Sciences, College of Public Health, The Ohio State University, Columbus, Ohio, USA.'}]",BMJ open,['10.1136/bmjopen-2020-046828'] 2790,34380643,Single-Agent Ibrutinib for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Substudy of the Phase III iNNOVATE TM Trial.,"PURPOSE The first report from the open-label substudy of the phase III iNNOVATE study (PCYC-1127; NCT02165397) demonstrated that single-agent ibrutinib was efficacious and well tolerated in patients with heavily pretreated, rituximab-refractory Waldenström's macroglobulinemia (WM). Results from the final analysis are now reported. EXPERIMENTAL DESIGN Ibrutinib 420 mg was administered once daily to patients (N=31) who failed to achieve at least a minor response (MR) or who relapsed <12 months after their last rituximab-containing therapy. Endpoints included progression-free survival (PFS) and overall response rate (ORR; MR or better) per independent review committee, hemoglobin improvement, overall survival (OS), and safety; serum immunoglobulin M (IgM) was also assessed. RESULTS After a median follow-up of 58 months (range: 9-61), median PFS was 39 months (95% CI: 25-not evaluable); 60-month PFS rate was 40%. In MYD88 L265P /CXCR4 WHIM and MYD88 L265P /CXCR4 WT subtypes, median PFS was 18 months and not reached, respectively. In all patients, ORR was 87%; responses deepened over time with major response ({greater than or equal to} partial response) rates increasing from 61% at 6 months to 77% at 60 months. Median OS was not reached. 17/21 patients (81%) with baseline hemoglobin {less than or equal to}11.0 g/dL had sustained hemoglobin improvement. Improvements in serum IgM levels were sustained, reaching a maximum median change of -37 g/L at 54 months. Ibrutinib maintained a manageable safety profile, with no new safety signals identified. There were no events of major hemorrhage or atrial fibrillation. CONCLUSIONS In the final analysis from iNNOVATE, single-agent ibrutinib continued to show sustained efficacy in patients with heavily pretreated, rituximab-refractory WM.",2021,"There were no events of major hemorrhage or atrial fibrillation. ","['17/21 patients (81%) with baseline hemoglobin ', ""patients with heavily pretreated, rituximab-refractory Waldenström's macroglobulinemia (WM""]","['rituximab-containing therapy', 'PCYC-1127', 'MYD88 L265P /CXCR4']","['progression-free survival (PFS) and overall response rate (ORR; MR or better) per independent review committee, hemoglobin improvement, overall survival (OS), and safety; serum immunoglobulin M (IgM', 'Median OS', 'efficacious and well tolerated', 'major hemorrhage or atrial fibrillation', '60-month PFS rate', 'median PFS', 'serum IgM levels', 'WHIM and MYD88 L265P /CXCR4 WT subtypes, median PFS', 'sustained hemoglobin improvement', 'ORR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0024419', 'cui_str': ""Waldenstrom's macroglobulinemia""}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0949759', 'cui_str': 'Review Committees'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0858458', 'cui_str': 'Serum immunoglobulin M'}, {'cui': 'C0020861', 'cui_str': 'Immunoglobulin M'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0472817', 'cui_str': 'Warts, hypogammaglobulinemia, infections, and myelokathexis'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}]",,0.0591476,"There were no events of major hemorrhage or atrial fibrillation. ","[{'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Trotman', 'Affiliation': 'Haematology, Concord Hospital judith.trotman@health.nsw.gov.au.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Buske', 'Affiliation': 'University Hospital Ulm, Institute of Experimental Cancer Research.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Tedeschi', 'Affiliation': 'Department of Hematology, Niguarda Hospital.'}, {'ForeName': 'Jeffrey V', 'Initials': 'JV', 'LastName': 'Matous', 'Affiliation': 'Hematology, Colorado Blood Cancer Institute.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'MacDonald', 'Affiliation': 'The Ottawa Hospital, University of Ottawa.'}, {'ForeName': 'Constantine S', 'Initials': 'CS', 'LastName': 'Tam', 'Affiliation': ""Peter MacCallum Cancer Centre, Royal Melbourne Hospital, St Vincent's Hospital and University of Melbourne.""}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Tournilhac', 'Affiliation': ""Hématologie Clinique, H�'pital Estaing, CHU, Clermont-Ferrand.""}, {'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Ma', 'Affiliation': 'Medicine, Northwestern University.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Treon', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Oriol', 'Affiliation': 'Servicio de Hematologia, Hospital Universitari Germans Trias i Pujol.'}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Ping', 'Affiliation': 'Pharmacyclics LLC, an AbbVie Company.'}, {'ForeName': 'Eva M', 'Initials': 'EM', 'LastName': 'Briso de Montiano', 'Affiliation': 'Medical Affairs, Seagen International GmbH.'}, {'ForeName': 'Israel', 'Initials': 'I', 'LastName': 'Arango-Hisijara', 'Affiliation': 'Medical Affairs, Pharmacyclics LLC, an AbbVie Company.'}, {'ForeName': 'Meletios A', 'Initials': 'MA', 'LastName': 'Dimopoulos', 'Affiliation': 'Clinical Therapeutics, National and Kapodistrian University of Athens Alexandra Hospital.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-21-1497'] 2791,34380638,"The OncoMasTR test predicts distant recurrence in estrogen receptor-positive, HER2-negative early-stage breast cancer: A validation study in ABCSG Trial 8.","PURPOSE To validate the clinical performance of the OncoMasTR Risk Score in the biomarker cohort of ABCSG Trial 8. EXPERIMENTAL DESIGN We evaluated the OncoMasTR test in 1200 formalin-fixed, paraffin-embedded surgical specimens from postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer with 0-3 involved lymph nodes in the prospective, randomized ABCSG Trial 8. Time to distant recurrence (DR) was analyzed by Cox models. RESULTS The OncoMasTR Risk Score categorized 850 of 1087 (78.2%) evaluable patients as ""low risk"". At 10 years, the DR rate for patients in the low-risk group was 5.8% versus 21.1% for patients in the high-risk group (P<0.0001, absolute risk reduction 15.3%). The OncoMasTR Risk Score was highly prognostic for prediction of DR in years 0-10 in all patients (hazard ratio (HR) 1.91, 95% confidence interval (CI) 1.62 to 2.26, P<0.0001; C-index 0.73), in node-negative patients (HR 1.79, 95% CI 1.43 to 2.24, P<0.0001; C-index 0.72), and in patients with 1-3 involved lymph nodes (HR 1.93, 95% CI 1.44 to 2.58, P<0.0001; C-index 0.71). The OncoMasTR Risk Score provided significant additional prognostic information beyond clinical parameters, Ki67, Nottingham Prognostic Index, and Clinical Treatment Score. CONCLUSIONS OncoMasTR Risk Score is highly prognostic for DR in postmenopausal women with ER-positive, HER2-negative primary breast cancer with 0-3 involved lymph nodes. In combination with prior validation studies, this fully independent validation in ABCSG Trial 8 provides level 1B evidence for the prognostic capability of the OncoMasTR Risk Score.",2021,"The OncoMasTR Risk Score provided significant additional prognostic information beyond clinical parameters, Ki67, Nottingham Prognostic Index, and Clinical Treatment Score. ","['postmenopausal women with ER-positive, HER2-negative primary breast cancer with 0-3 involved lymph nodes', 'HER2-negative early-stage breast cancer', '1200 formalin-fixed, paraffin-embedded surgical specimens from postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer with 0-3 involved lymph nodes']",[],"['Time to distant recurrence (DR', 'DR rate', 'OncoMasTR Risk Score', 'OncoMasTR Risk Score provided significant additional prognostic information beyond clinical parameters, Ki67, Nottingham Prognostic Index, and Clinical Treatment Score']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0279754', 'cui_str': 'ESR1 positive'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C4517548', 'cui_str': '1200'}, {'cui': 'C0949307', 'cui_str': 'Formalin'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0030415', 'cui_str': 'Paraffin'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0034804', 'cui_str': 'Estrogen receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",[],"[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1532391', 'cui_str': 'Nottingham prognostic index'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.166525,"The OncoMasTR Risk Score provided significant additional prognostic information beyond clinical parameters, Ki67, Nottingham Prognostic Index, and Clinical Treatment Score. ","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Filipits', 'Affiliation': 'Department of Medicine I, Institute of Cancer Research, Medical University of Vienna martin.filipits@meduniwien.ac.at.'}, {'ForeName': 'Margaretha', 'Initials': 'M', 'LastName': 'Rudas', 'Affiliation': 'Department of Pathology, Medical University of Vienna.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Kainz', 'Affiliation': 'Department of Medicine I, Institute of Cancer Research, Medical University of Vienna.'}, {'ForeName': 'Christian F', 'Initials': 'CF', 'LastName': 'Singer', 'Affiliation': 'Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Fitzal', 'Affiliation': 'Department of Surgery, Medical University of Vienna.'}, {'ForeName': 'Zsuzsanna', 'Initials': 'Z', 'LastName': 'Bago-Horvath', 'Affiliation': 'Department of Clinical Pathology, Medical University of Vienna.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Greil', 'Affiliation': 'Department of Internal Medicine III, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg.'}, {'ForeName': 'Marija', 'Initials': 'M', 'LastName': 'Balic', 'Affiliation': 'Departement, Medical University of Graz.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Regitnig', 'Affiliation': 'Diagnostic- and Researchinstitute of Pathology, Medical University of Graz.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Halper', 'Affiliation': 'Department of Surgery, Breast Health Center, Hospital Wiener Neustadt.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Hulla', 'Affiliation': 'Department of Clinical Pathology and Molecular Pathology, Hospital Wiener Neustadt.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Egle', 'Affiliation': 'Department of Obstetrics and Gynecology, Medical University of Innsbruck.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Barron', 'Affiliation': 'Breast Cancer, OncoMark (Ireland).'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Loughman', 'Affiliation': 'Breast Cancer, OncoMark (Ireland).'}, {'ForeName': 'Des', 'Initials': 'D', 'LastName': ""O'Leary"", 'Affiliation': 'Management, OncoMark Ltd.'}, {'ForeName': 'William M', 'Initials': 'WM', 'LastName': 'Gallagher', 'Affiliation': 'UCD Conway Institute, University.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Hlauschek', 'Affiliation': 'Statistic, Austrian Breast and Colorectal Study Group.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gnant', 'Affiliation': 'Comprehensive Cancer Center, Medical University of Vienna.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Dubsky', 'Affiliation': 'Breast Centre, Hirslanden Klinik St. Anna.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-21-1023'] 2792,34384882,Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.,"BACKGROUND Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy. In animal models, resistance was reversed with restoration of circulating estrogen level during interruption of letrozole treatment. This phase 3 randomized, open-label Study of Letrozole Extension (SOLE) studied the effect of extended intermittent letrozole treatment in comparison with continuous letrozole. In parallel, the SOLE estrogen sub-study (SOLE-EST) analyzed the level of estrogen during the interruption of treatment. PATIENTS AND METHODS SOLE enrolled 4884 postmenopausal women with hormone receptor-positive, lymph node-positive, operable breast cancer between December 2007 and October 2012 and among them, 104 patients were enrolled in SOLE-EST. They must have undergone local treatment and have completed 4-6 years of adjuvant endocrine therapy. Patients were randomized between continuous letrozole (2.5 mg/day orally for 5 years) and intermittent letrozole treatment (2.5 mg/day during 9 months followed by a 3-month interruption in years 1-4 and then 2.5 mg/day during all year 5). RESULTS Intention-to-treat population included 4851 women in SOLE (n=2425 in intermittent and n=2426 in continuous letrozole groups) and 103 women in SOLE-EST (n=78 in intermittent and n=25 in continuous letrozole groups). After a median follow-up of 84 months, 7-year disease-free survival was 81.4% in intermittent group and 81.5% in continuous group (hazard ratio: 1.03, 95%CI: 0.91-1.17). Reported adverse events were similar in both groups. Circulating estrogen recovery was demonstrated within 6 weeks after the stop of letrozole treatment. CONCLUSIONS Extended adjuvant endocrine therapy by intermittent administration of letrozole did not improve disease-free survival compared to continuous use despite the recovery of circulating estrogen level. The similar disease-free survival coupled with previously reported quality-of-life advantages suggest intermittent extended treatment is a valid option for patients who require or prefer a treatment interruption.",2021,"After a median follow-up of 84 months, 7-year disease-free survival was 81.4% in intermittent group and 81.5% in continuous group (hazard ratio: 1.03, 95%CI: 0.91-1.17).","['breast cancer', 'SOLE enrolled 4884 postmenopausal women with hormone receptor-positive, lymph node-positive, operable breast cancer between December 2007 and October 2012 and among them, 104 patients were enrolled in SOLE-EST', 'patients who require or prefer a treatment interruption', '4851 women in SOLE (n=2425 in intermittent and n=2426 in continuous letrozole groups) and 103 women in SOLE-EST (n=78 in intermittent and n=25 in continuous letrozole groups', 'postmenopausal women with hormone receptor-positive breast cancers']","['letrozole', 'continuous letrozole', 'intermittent letrozole treatment', 'Letrozole Extension (SOLE', 'Continuous vs intermittent extended adjuvant letrozole']","['Circulating estrogen recovery', '7-year disease-free survival', 'adverse events', 'disease-free survival']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0205188', 'cui_str': 'Operable'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517526', 'cui_str': '103'}]","[{'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",4884.0,0.132755,"After a median follow-up of 84 months, 7-year disease-free survival was 81.4% in intermittent group and 81.5% in continuous group (hazard ratio: 1.03, 95%CI: 0.91-1.17).","[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Jerusalem', 'Affiliation': 'International Breast Cancer Study Group and CHU Liège, Liège University, Liège, Belgium. Electronic address: g.jerusalem@chuliege.be.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Farah', 'Affiliation': 'International Breast Cancer Study Group Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Courtois', 'Affiliation': 'Medical Oncology Department, CHU Liège, Liège University, Liège, Belgium.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Chirgwin', 'Affiliation': 'Breast Cancer Trials-Australia and New Zealand, University of Newcastle, Callaghan, NSW, Australia and Box Hill and Maroondah Hospitals, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Aebi', 'Affiliation': 'Division of Medical Oncology, Cancer Center, Lucerne Cantonal Hospital, Lucerne, Switzerland and University of Bern, Bern, Switzerland.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Karlsson', 'Affiliation': 'Department of Oncology, Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Neven', 'Affiliation': 'Gynecologic Oncology and Multidisciplinary Breast Center, University Hospitals UZ-Leuven, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Hitre', 'Affiliation': 'Department of Medical Oncology and Clinical Pharmacology ""B"", National Institute of Oncology, Budapest, Hungary.'}, {'ForeName': 'M P', 'Initials': 'MP', 'LastName': 'Graas', 'Affiliation': 'Montlégia hospital, Liège, Belgium.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Simoncini', 'Affiliation': 'ASST Spedali Civili di Brescia, Brescia, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Abdi', 'Affiliation': 'The Tweed Hospital, Griffith University Gold Coast, Tweed Heads, NSW, Australia.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Kamby', 'Affiliation': 'Danish Breast Cancer Group and Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Thompson', 'Affiliation': 'Scottish Cancer Trials Breast Group and Division of Surgical Oncology, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loibl', 'Affiliation': 'German Breast Group Forschungs GmbH, Neu-Isenburg, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Gavilá', 'Affiliation': 'SOLTI Group and Fundación Instituto Valenciano de Oncologia, Valencia, Spain.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kuroi', 'Affiliation': 'Japan Breast Cancer Research Group and Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan Japan Breast Cancer Research Group and Tokyo Metropolitan Health and Hospitals Corporation Ebara Hospital, Tokyo, Japan (Present address).'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Marth', 'Affiliation': 'Austrian Breast & Colorectal Cancer Study Group and Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Müller', 'Affiliation': 'Chilean Cooperative Group for Oncologic Research (GOCCHI), Providencia, Santiago, Chile.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': ""O'Reilly"", 'Affiliation': 'Cancer Trials Ireland; University College Cork, Cork University Hospital, Cork Ireland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Gombos', 'Affiliation': 'Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet, Brussels, Belgium.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Ruhstaller', 'Affiliation': 'Swiss Group for Clinical Cancer Research SAKK, International Breast Cancer Study Group, Bern; Breast Center St. Gallen, St. Gallen; University of Basel, Basel Switzerland.'}, {'ForeName': 'H J', 'Initials': 'HJ', 'LastName': 'Burstein', 'Affiliation': 'Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rabaglio', 'Affiliation': 'International Breast Cancer Study Group; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern; Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Ruepp', 'Affiliation': 'International Breast Cancer Study Group, Bern, Switzerland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Ribi', 'Affiliation': 'International Breast Cancer Study Group, Bern, Switzerland.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Viale', 'Affiliation': 'Department of Pathology, University of Milan, and IEO European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'R D', 'Initials': 'RD', 'LastName': 'Gelber', 'Affiliation': 'International Breast Cancer Study Group Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, and Frontier Science Foundation, Boston, MA, USA.'}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Coates', 'Affiliation': 'International Breast Cancer Study Group; University of Sydney, Sydney, Australia.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loi', 'Affiliation': 'International Breast Cancer Study Group; Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Goldhirsch', 'Affiliation': 'International Breast Cancer Study Group; IEO European Institute of Oncology, IRCCS, Milan, Italy (deceased).'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Regan', 'Affiliation': 'International Breast Cancer Study Group Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. Electronic address: mregan@jimmy.harvard.edu.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Colleoni', 'Affiliation': 'International Breast Cancer Study Group; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.07.017'] 2793,34384821,A Pragmatic Parallel Group Implementation Study of a Prehospital-Activated ECPR Protocol for Refractory Out-of-Hospital Cardiac Arrest.,"OBJECTIVES Extracorporeal membrane oxygenation within CPR (ECPR) may improve survival among patients with refractory out-of-hospital cardiac arrest (OHCA). We evaluated outcomes after incorporating ECPR into a conventional resuscitation system. METHODS We introduced a prehospital-activated ECPR protocol for select refractory OHCAs into one of four metropolitan regions in British Columbia. We prospectively identified ECPR-eligible patients in both the ECPR region and the three other regions to serve as the control group. We compared the proportion with favorable neurological outcomes at hospital discharge (cerebral performance category ≤2) and used logistic regression to estimate the association with treatment region. RESULTS The study was terminated prematurely due to changes in hospital protocols and COVID-19. In the ECPR region, 15/58 (25.9%) patients had favourable neurological outcomes owing to conventional resuscitation and 2/58 (3.4%) owing to ECPR, for a total of 17/58 (29.3%). In the control regions, 67/250 (26.8%) patients had a favourable outcome owing to conventional resuscitation, for a between-group difference of 2.5% (95% CI -10 to 15%). We did not detect a statistically significant association between treatment region and outcomes. CONCLUSION In this prematurely-terminated study of ECPR for refractory OHCA, we did not detect an association between a regional ECPR protocol and neurologically favorable outcomes. However, our data suggests that outcomes owing to conventional resuscitation were similar, with the potential for additional survivors due to ECPR therapies.",2021,"In the control regions, 67/250 (26.8%) patients had a favourable outcome owing to conventional resuscitation, for a between-group difference of 2.5% (95% CI -10 to 15%).","['ECPR-eligible patients in both the ECPR region and the three other regions to serve as the control group', 'patients with refractory out-of-hospital cardiac arrest (OHCA', 'four metropolitan regions in British Columbia']","['Extracorporeal membrane oxygenation within CPR (ECPR', 'ECPR', 'Prehospital-Activated ECPR Protocol']",['favourable neurological outcomes'],"[{'cui': 'C0015357', 'cui_str': 'Extracorporeal membrane oxygenation'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C2936490', 'cui_str': 'Out-of-Hospital Heart Arrest'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0006193', 'cui_str': 'British Columbia'}]","[{'cui': 'C0015357', 'cui_str': 'Extracorporeal membrane oxygenation'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.134999,"In the control regions, 67/250 (26.8%) patients had a favourable outcome owing to conventional resuscitation, for a between-group difference of 2.5% (95% CI -10 to 15%).","[{'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Grunau', 'Affiliation': ""St. Paul's Hospital, Vancouver, B.C; Department of Emergency Medicine, University of British Columbia; Centre for Health Evaluation and Outcomes Sciences, Vancouver, B.C; British Columbia Emergency Health Services, British Columbia; BC Resuscitation Research Collaborative, British Columbia. Electronic address: Brian.Grunau@ubc.ca.""}, {'ForeName': 'Jamil', 'Initials': 'J', 'LastName': 'Bashir', 'Affiliation': ""St. Paul's Hospital, Vancouver, B.C; Division of Cardiovascular Surgery, University of British Columbia.""}, {'ForeName': 'Anson', 'Initials': 'A', 'LastName': 'Cheung', 'Affiliation': ""St. Paul's Hospital, Vancouver, B.C; Division of Cardiovascular Surgery, University of British Columbia.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Boone', 'Affiliation': ""St. Paul's Hospital, Vancouver, B.C; Division of Cardiology, University of British Columbia.""}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'McDonald', 'Affiliation': ""St. Paul's Hospital, Vancouver, B.C; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia.""}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Scheuermeyer', 'Affiliation': ""St. Paul's Hospital, Vancouver, B.C; Department of Emergency Medicine, University of British Columbia; Centre for Health Evaluation and Outcomes Sciences, Vancouver, B.C; BC Resuscitation Research Collaborative, British Columbia.""}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Singer', 'Affiliation': 'Centre for Health Evaluation and Outcomes Sciences, Vancouver, B.C.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Jenneson', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia; British Columbia Emergency Health Services, British Columbia; BC Resuscitation Research Collaborative, British Columbia; Royal Columbian Hospital, New Westminster, B.C.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Straight', 'Affiliation': 'British Columbia Emergency Health Services, British Columbia; BC Resuscitation Research Collaborative, British Columbia.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Twaites', 'Affiliation': 'British Columbia Emergency Health Services, British Columbia; BC Resuscitation Research Collaborative, British Columbia.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Harris', 'Affiliation': ""St. Paul's Hospital, Vancouver, B.C; Division of Cardiovascular Surgery, University of British Columbia.""}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Haig Pcp', 'Affiliation': 'British Columbia Emergency Health Services, British Columbia; BC Resuscitation Research Collaborative, British Columbia.'}, {'ForeName': 'Devin', 'Initials': 'D', 'LastName': 'Harris', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia; Kelowna General Hospital, Kelowna, B.C.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Vandegriend', 'Affiliation': 'Royal Columbian Hospital, New Westminster, B.C; Division of Critical Care, University of British Columbia.'}, {'ForeName': 'Hussein', 'Initials': 'H', 'LastName': 'Kanji', 'Affiliation': 'Royal Columbian Hospital, New Westminster, B.C; Division of Critical Care, University of British Columbia; Vancouver General Hospital, Vancouver, B.C.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Christenson', 'Affiliation': ""St. Paul's Hospital, Vancouver, B.C; Department of Emergency Medicine, University of British Columbia; Centre for Health Evaluation and Outcomes Sciences, Vancouver, B.C; BC Resuscitation Research Collaborative, British Columbia.""}]",Resuscitation,['10.1016/j.resuscitation.2021.08.004'] 2794,34384793,Comparison of haemodynamic response to tracheal intubation with two different videolaryngoscopes: A randomized clinical trial.,"BACKGROUND Endotracheal intubation (ETI), which is the gold standard in coronary artery bypass grafting (CABG), may cause myocardial ischaemia by disturbing the balance between haemodynamic changes and oxygen supply and consumption of the myocardium as a result of sympathetic stimulation. In this study, we aimed to compare two different videolaryngoscopes (C-MAC and Airtraq) in the hemodynamic response to ETI. METHODS Fifty ASA II-III CABG surgery patients were randomly assigned to C-MAC or Airtraq. The hemodynamic data included arterial blood pressure [systolic (SAP), diastolic (DAP) and mean (MAP)] and heart rate (HR) and were recorded at six different points in time: before laryngoscopy-T1, during laryngoscopy-T2, immediately after intubation-T3, and 3 (T4), 5 (T5) and 10 (T6) minutes after intubation. Intraoperative complications were recorded. Patients were questioned about postoperative complications 2 and 24 hours following extubation. RESULTS The hemodynamic response to ETI was significantly greater with C-MAC. The increase in HR started with the laryngoscopy procedure, whereas increases in SAP, DAP, and MAP started immediately after ETI (p = 0.024; p = 0.012; p = 0.030; p = 0.009, respectively). In group analyses, T1-T2, T2-T3 and T1-T3 comparisons did not show any significant differences in HR with Airtraq. However, with C-MAC, HR after intubation increased significantly compared to the pre-laryngoscopy values (T1-T3) (p = 0.004). The duration of laryngoscopy was significantly reduced with C-MAC (p < 0.001), but the duration of intubation and total intubation were similar (p = 0.36; p = 0.79). CONCLUSIONS Compared to C-MAC, the hemodynamic response to ETI was less with Airtraq. Thus, Airtraq may be preferred in CABG patients for ETI.",2021,"The duration of laryngoscopy was significantly reduced with C-MAC (p < 0.001), but the duration of intubation and total intubation were similar (p = 0.36; p = 0.79). ","['Fifty ASA II-III', 'CABG surgery patients']","['coronary artery bypass grafting (CABG', 'tracheal intubation with two different videolaryngoscopes', 'Endotracheal intubation (ETI']","['hemodynamic response to ETI', 'arterial blood pressure [systolic (SAP), diastolic (DAP) and mean (MAP)] and heart rate (HR', 'Intraoperative complications', 'duration of intubation and total intubation', 'haemodynamic response', 'duration of laryngoscopy', 'SAP, DAP, and MAP started immediately after ETI']","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C3164607', 'cui_str': 'Videolaryngoscope'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C1272641', 'cui_str': 'Systemic arterial pressure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0021890', 'cui_str': 'Intraoperative complication'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023072', 'cui_str': 'Laryngoscopy'}, {'cui': 'C1740186', 'cui_str': 'SKAP2 protein, human'}, {'cui': 'C0045587', 'cui_str': '2,6-diaminopurine'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205548', 'cui_str': 'Stat'}]",50.0,0.0469553,"The duration of laryngoscopy was significantly reduced with C-MAC (p < 0.001), but the duration of intubation and total intubation were similar (p = 0.36; p = 0.79). ","[{'ForeName': 'Tülay', 'Initials': 'T', 'LastName': 'Çardaközü', 'Affiliation': 'Kocaeli University of Medical Faculty, Department of Anesthesiology and Reanimation, İzmit, Turkey. Electronic address: tulayhosten@hotmail.com.'}, {'ForeName': 'Z İpek', 'Initials': 'Zİ', 'LastName': 'Arslan', 'Affiliation': 'Kocaeli University of Medical Faculty, Department of Anesthesiology and Reanimation, İzmit, Turkey.'}, {'ForeName': 'Sevim', 'Initials': 'S', 'LastName': 'Cesur', 'Affiliation': 'Kocaeli University of Medical Faculty, Department of Anesthesiology and Reanimation, İzmit, Turkey.'}, {'ForeName': 'Barış', 'Initials': 'B', 'LastName': 'Aksu', 'Affiliation': 'Kocaeli University of Kandıra Vocational School, İzmit, Turkey.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2021.07.017'] 2795,34384777,Evaluation of the usefulness of ultrasound measurement of the lower uterine segment before delivery of women with a prior cesarean: a randomized trial.,"BACKGROUND The main reason to avoid trial of labor after cesarean delivery is the possibility of uterine rupture. Identifying women at risk is thus an important aim, for it would enable women at low risk to proceed with a secure planned vaginal birth. OBJECTIVE To evaluate the impact of proposing mode of delivery based on the ultrasound measurement of the lower uterine segment thickness on a composite outcome of maternal-fetal mortality and morbidity, compared with usual management, among pregnant women with a previous cesarean delivery. STUDY DESIGN This multicenter, randomized, controlled, parallel-group, unmasked trial was conducted at 8 referral university hospitals with a neonatal intensive care unit and enrolled 2948 women at 36 +0 to 38 +6 weeks of gestation with 1 prior low transverse cesarean delivery and no contraindication to trial of labor were enrolled. Women in the study group had their lower uterine segment thickness measured by ultrasound. Those with measurements >3.5 mm were encouraged to choose a planned vaginal delivery and those with measurements ≤3.5 mm were encouraged to choose a planned repeat cesarean delivery. This measurement was not taken in the control group: their mode of delivery was decided according to standard management. The primary outcome was a composite criterion comprising maternal mortality, uterine rupture, uterine dehiscence, hysterectomy, thromboembolic disease, transfusion, endometritis, perinatal death, or neonatal encephalopathy. Prespecified secondary outcomes were repeat cesarean deliveries, elective or after trial of labor. RESULTS The study group included 1472 women, and the control group 1476. These groups were similar at baseline. The primary outcome occurred in 3.4% of the study group and 4.3% of the control group (relative risk, 0.78; 95% confidence interval, 0.54-1.13: risk difference, -1.0%; 95% confidence interval -2.4 to 0.5). The uterine rupture rate in the study group was 0.4% and in the control group 0.9% (relative risk, 0.43; 95% confidence interval, 0.15-1.19). The planned cesarean rate was 16.4% in the study group and 13.7% in the control group (relative risk, 1.21; 95% confidence interval, 1.00-1.47) and the rates of cesarean during labor respectively 25.1% and 25.0% (relative risk, 1.01; 95% confidence interval, 0.89-1.14). CONCLUSIONS Ultrasound measurements of lower uterine segment thickness did not result in a statistically significant lower frequency of maternal and perinatal adverse outcomes than standard management. However, because this study was underpowered, further research should be encouraged.",2021,"CONCLUSIONS Ultrasound measurements of lower uterine segment thickness did not result in a statistically significant lower frequency of maternal and perinatal adverse outcomes than standard management.","['8 referral university hospitals with a neonatal intensive care unit and enrolled 2948 women at 36 +0 to 38 +6 weeks of gestation with 1 prior low transverse cesarean delivery and no contraindication to trial of labor were enrolled', 'women with a prior cesarean', '1472 women, and the control group 1476', 'pregnant women with a previous cesarean delivery']",['ultrasound measurement'],"['planned cesarean rate', 'uterine rupture rate', 'uterine segment thickness', 'maternal-fetal mortality and morbidity', 'composite criterion comprising maternal mortality, uterine rupture, uterine dehiscence, hysterectomy, thromboembolic disease, transfusion, endometritis, perinatal death, or neonatal encephalopathy', 'repeat cesarean deliveries, elective or after trial of labor', 'rates of cesarean', 'frequency of maternal and perinatal adverse outcomes']","[{'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205106', 'cui_str': 'Transverse plane'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C0040862', 'cui_str': 'Trial labor'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0205156', 'cui_str': 'Previous'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]","[{'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0042143', 'cui_str': 'Rupture of uterus'}, {'cui': 'C0447618', 'cui_str': 'Uterine segment'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C1449632', 'cui_str': 'Mortality, Fetal'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0024923', 'cui_str': 'Maternal death'}, {'cui': 'C3665608', 'cui_str': 'Cesarean wound disruption'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0014179', 'cui_str': 'Endometritis'}, {'cui': 'C0701826', 'cui_str': 'Perinatal death'}, {'cui': 'C0235820', 'cui_str': 'Neonatal encephalopathy'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0040862', 'cui_str': 'Trial labor'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",2948.0,0.487569,"CONCLUSIONS Ultrasound measurements of lower uterine segment thickness did not result in a statistically significant lower frequency of maternal and perinatal adverse outcomes than standard management.","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Rozenberg', 'Affiliation': 'Department of Obstetrics and Gynecology, Hôpital Poissy-Saint Germain, Versailles-Saint Quentin University, research unit EA 7285. Electronic address: patrick.rozenberg@ght-yvelinesnord.fr.'}, {'ForeName': 'Marie-Victoire', 'Initials': 'MV', 'LastName': 'Sénat', 'Affiliation': 'Department of Obstetrics and Gynecology, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Deruelle', 'Affiliation': 'Department of Obstetrics and Gynecology, Hôpital Jeanne de Flandre, Lille.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Winer', 'Affiliation': 'Department of Obstetrics and Gynecology, Hôpital Mère-Enfant, Nantes.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Simon', 'Affiliation': 'Department of Obstetrics and Gynecology, Hôpital Bretonneau, Tours.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Ville', 'Affiliation': 'Department of Obstetrics and Gynecology, Hôpital Necker, AP-HP, Paris.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Kayem', 'Affiliation': 'Department of Obstetrics and Gynecology, Hôpital Armand-Trousseau, AP-HP, Paris.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Porcher', 'Affiliation': 'Centre of Research Epidemiology and Statistics, INSERM U1153, Université de Paris, Paris; Centre of Clinical Epidemiology, Hôpital Hôtel-Dieu, AP-HP, Paris.'}, {'ForeName': 'Élodie', 'Initials': 'É', 'LastName': 'Perrodeau', 'Affiliation': 'Centre of Research Epidemiology and Statistics, INSERM U1153, Université de Paris, Paris; Centre of Clinical Epidemiology, Hôpital Hôtel-Dieu, AP-HP, Paris.'}, {'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Desbrière', 'Affiliation': 'Department of Obstetrics and Gynecology, Hôpital Saint Joseph, Marseille.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Boutron', 'Affiliation': 'Centre of Research Epidemiology and Statistics, INSERM U1153, Université de Paris, Paris; Centre of Clinical Epidemiology, Hôpital Hôtel-Dieu, AP-HP, Paris.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2021.08.005'] 2796,34384772,Further Implications from a Pragmatic Randomized Clinical Trial of Gestational Diabetes Screening: Per-Protocol and As-Treated Estimates.,,2021,,[],[],[],[],[],[],,0.2415,,"[{'ForeName': 'Teresa A', 'Initials': 'TA', 'LastName': 'Hillier', 'Affiliation': 'Center for Health Research, Kaiser Permanente Northwest, 3800 N Interstate Ave, Portland, OR 97227; Center for Integrated Health Care Research, Kaiser Permanente Hawaii, 501 Alakawa St, Suite 201, Honolulu, HI 96817. Electronic address: Teresa.Hillier@kpchr.org.'}, {'ForeName': 'Kathryn L', 'Initials': 'KL', 'LastName': 'Pedula', 'Affiliation': 'Center for Health Research, Kaiser Permanente Northwest, 3800 N Interstate Ave, Portland, OR 97227; Hawaii Permanente Medical Group, Kaiser Permanente, 501 Alakawa St, Suite 201, Honolulu, HI 96817.'}, {'ForeName': 'Keith K', 'Initials': 'KK', 'LastName': 'Ogasawara', 'Affiliation': 'Chief of Perinatology, Department of Obstetrics & Gynecology, Hawaii Permanente Medical Group, Kaiser Permanente, 3288 Moanalua Road, Honolulu, HI 96819.'}, {'ForeName': 'Kimberly K', 'Initials': 'KK', 'LastName': 'Vesco', 'Affiliation': 'Center for Health Research, Kaiser Permanente Northwest, 3800 N Interstate Ave, Portland, OR 97227.'}, {'ForeName': 'Caryn E S', 'Initials': 'CES', 'LastName': 'Oshiro', 'Affiliation': 'Center for Integrated Health Care Research, Kaiser Permanente Hawaii, 501 Alakawa St, Suite 201, Honolulu, HI 96817.'}, {'ForeName': 'Suzanne L', 'Initials': 'SL', 'LastName': 'Lubarsky', 'Affiliation': 'Division of Perinatology, Department of Obstetrics & Gynecology, Northwest Permanente, Kaiser Permanente, 10180 SE Sunnyside Rd, Clackamas, OR 97015.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Van Marter', 'Affiliation': 'Center for Health Research, Kaiser Permanente Northwest, 3800 N Interstate Ave, Portland, OR 97227.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2021.08.006'] 2797,34384499,"Safety, tolerability of ES16001, a novel varicella zoster virus reactivation inhibitor, in healthy adults.","PURPOSE Herpes zoster (HZ), or shingles, is a clinical syndrome resulting from the reactivation of latent varicella zoster virus (VZV) within the sensory ganglia. We evaluated the safety and tolerability of ES16001 (ethanol extract of Elaeocarpus sylvestris var. ellipticus), a novel inhibitor of varicella zoster virus reactivation in healthy adults. METHOD Single-center, randomized, double-blind, placebo-controlled, single and multiple ascending dose (SAD and MAD, respectively) studies were conducted in 20- to 45-year-old healthy adults without chronic disease. In the SAD study (n = 32), subjects randomly received a single oral dose of 240, 480, 960, or 1440 mg ES16001 or a placebo. In the MAD study (n = 16), subjects randomly received once daily doses of 480 or 960 mg ES16001 or a placebo for 5 days. The safety and tolerability of the drug were evaluated by monitoring participants' treatment emergent adverse events (TEAEs) and vital signs, electrocardiograms (ECGs), physical examinations, and clinical laboratory tests. RESULTS In the SAD study, 11 adverse reactions were seen in 5 subjects, and in the MAD study, 8 adverse reactions were seen in 6 subjects. All adverse reactions were mild, and no serious adverse reactions occurred. The most common adverse reaction was an increase in alanine aminotransferase (ALT), but all test values were in the clinically non-significant range, and their clinical significance was judged to be small considering the fact that most of the test values returned to normal immediately after the end of drug administration. CONCLUSION ES16001 has good safety and tolerability when administered both once and repeatedly to healthy subjects. Further research is needed to identify any possible drug-induced hepatotoxicity, which appears infrequently. Our findings provide a rationale for further clinical investigations of ES16001 for the prevention of HZ. TRIAL REGISTRATION CRIS, KCT0006066. Registered 7 April 2021-Retrospectively registered, https://cris.nih.go.kr/cris/search/detailSearch.do/19071 ).",2021,"The most common adverse reaction was an increase in alanine aminotransferase (ALT), but all test values were in the clinically non-significant range, and their clinical significance was judged to be small considering the fact that most of the test values returned to normal immediately after the end of drug administration. ","['20- to 45-year-old healthy adults without chronic disease', 'healthy subjects', 'healthy adults']","['placebo', 'ES16001', 'ES16001 (ethanol extract of Elaeocarpus sylvestris var']","['Safety, tolerability', 'adverse reactions', 'good safety and tolerability', 'alanine aminotransferase (ALT', 'safety and tolerability', 'adverse events (TEAEs) and vital signs, electrocardiograms (ECGs), physical examinations, and clinical laboratory tests']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C1001353', 'cui_str': 'Elaeocarpus'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4505474', 'cui_str': 'Clinical Laboratory Tests'}]",,0.131371,"The most common adverse reaction was an increase in alanine aminotransferase (ALT), but all test values were in the clinically non-significant range, and their clinical significance was judged to be small considering the fact that most of the test values returned to normal immediately after the end of drug administration. ","[{'ForeName': 'Jeon', 'Initials': 'J', 'LastName': 'Hwang-Bo', 'Affiliation': 'Graduate School of Biotechnology and Department of Oriental Medicine Biotechnology, Kyung Hee University, Yongin, 17104, Republic of Korea.'}, {'ForeName': 'Byungwook', 'Initials': 'B', 'LastName': 'Kim', 'Affiliation': 'Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Dae Won', 'Initials': 'DW', 'LastName': 'Park', 'Affiliation': 'Graduate School of Biotechnology and Department of Oriental Medicine Biotechnology, Kyung Hee University, Yongin, 17104, Republic of Korea.'}, {'ForeName': 'Yeong-Geun', 'Initials': 'YG', 'LastName': 'Lee', 'Affiliation': 'Graduate School of Biotechnology and Department of Oriental Medicine Biotechnology, Kyung Hee University, Yongin, 17104, Republic of Korea.'}, {'ForeName': 'Jeong Eun', 'Initials': 'JE', 'LastName': 'Kwon', 'Affiliation': 'Graduate School of Biotechnology and Department of Oriental Medicine Biotechnology, Kyung Hee University, Yongin, 17104, Republic of Korea.'}, {'ForeName': 'Jae-Yong', 'Initials': 'JY', 'LastName': 'Chung', 'Affiliation': 'Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea. jychung@snubh.org.'}, {'ForeName': 'Se Chan', 'Initials': 'SC', 'LastName': 'Kang', 'Affiliation': 'Graduate School of Biotechnology and Department of Oriental Medicine Biotechnology, Kyung Hee University, Yongin, 17104, Republic of Korea. sckang@khu.ac.kr.'}]",European journal of medical research,['10.1186/s40001-021-00565-z'] 2798,34384461,Effects of moderate-intensity intermittent hypoxic training on health outcomes of patients recovered from COVID-19: the AEROBICOVID study protocol for a randomized controlled trial.,"BACKGROUND Recent studies point to a lower number and reduced severity of cases in higher altitude cities with decreased oxygen concentration. Specific literature has shown several benefits of physical training, so, in this sense, physical training with hypoxic stimulus appears as an alternative that supports the conventional treatments of the COVID-19 patient's recovery. Thus, this study's primary aim is to analyze the effects of moderate-intensity intermittent hypoxic training on health outcomes in COVID-19 recovered patients. METHODS A clinical trial controlled double-blind study was designed. Participants (30-69 years old) will be recruited among those with moderate to severe COVID-19 symptoms, approximately 30 days after recovery. They will be included in groups according to the training (T) and recovery (R) association with hypoxia (H) or normoxia (N): (a) T H :R H , (b) T N :R H , (c) T N :R N , and last (d) the control group. The 8-week exercise bike intervention will be carried out with a gradual load increase according to the established periods, three times a week in sets of 5 min, 90 to 100% of the anaerobic threshold (AT), and a 2.5-min break. Blood will be collected for genotyping. First, after 4 weeks (partial), after 8 weeks, and later, 4 weeks after the end of the physical training intervention, participants will perform assessments. The primary outcome is the maximum oxygen consumption (VO 2 peak). The secondary outcomes include lung function, inflammatory mediators, hematological, autonomic parameters, AT, body composition analysis, quality of life, mental health, anthropometric measurements, and physical fitness. The statistical analysis will be executed using the linear regression model with mixed effects at a 5% significance level. DISCUSSION This study is designed to provide evidence to support the clinical benefits of moderate-intensity intermittent hypoxic training as a part of the treatment of patients recovered from COVID-19. It may also provide evidence on the efficacy and safety of intermittent hypoxic training in different health conditions. Lastly, this study presents an innovative strategy enabling up to 16 participants in the same training session. TRIAL REGISTRATION ClinicalTrials.gov RBR-5d7hkv. Registered after the start of inclusion on 3 November 2020 with the Brazilian Clinical Trials Registry.",2021,"They will be included in groups according to the training (T) and recovery (R) association with hypoxia (H) or normoxia (N): (a) T H :R H , (b)","['16 participants in the same training session', 'Participants (30-69 years old', 'COVID-19 recovered patients', 'patients recovered from COVID-19']","['moderate-intensity intermittent hypoxic training', 'physical training intervention']","['health outcomes', 'efficacy and safety', 'training (T) and recovery (R) association with hypoxia (H) or normoxia (N): (a) T H :R H , (b', 'lung function, inflammatory mediators, hematological, autonomic parameters, AT, body composition analysis, quality of life, mental health, anthropometric measurements, and physical fitness', 'maximum oxygen consumption (VO 2 peak']","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0002749', 'cui_str': 'Anaerobic Threshold'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0444505', 'cui_str': 'Peak'}]",,0.113528,"They will be included in groups according to the training (T) and recovery (R) association with hypoxia (H) or normoxia (N): (a) T H :R H , (b)","[{'ForeName': 'Átila Alexandre', 'Initials': 'ÁA', 'LastName': 'Trapé', 'Affiliation': 'School of Physical Education and Sport of Ribeirão Preto, University of Sao Paulo (USP), Ribeirão Preto, SP, Brazil. atrape@usp.br.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Camacho-Cardenosa', 'Affiliation': 'Faculty of Languages and Education, University of Nebrija, Madrid, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Camacho-Cardenosa', 'Affiliation': 'Faculty of Sport Science, University of Extremadura, Cáceres, Spain.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Merellano-Navarro', 'Affiliation': 'Grupo de Investigación EFISAL, Universidad Autónoma de Chile, Talca, Chile.'}, {'ForeName': 'Jhennyfer Aline Lima', 'Initials': 'JAL', 'LastName': 'Rodrigues', 'Affiliation': 'Ribeirão Preto Medical School, USP, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Elisangela Aparecida', 'Initials': 'EA', 'LastName': 'da Silva Lizzi', 'Affiliation': 'Academic Department of Mathematics, Federal University of Technology, Paraná, Cornélio Procópio, PR, Brazil.'}, {'ForeName': 'Carlos Arterio', 'Initials': 'CA', 'LastName': 'Sorgi', 'Affiliation': 'Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, USP, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Papoti', 'Affiliation': 'School of Physical Education and Sport of Ribeirão Preto, University of Sao Paulo (USP), Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Brazo-Sayavera', 'Affiliation': 'Department of Sports and Computer Science, Universidad Pablo de Olavide (UPO), Seville, Spain.'}]",Trials,['10.1186/s13063-021-05414-2'] 2799,34380586,Impact of educational programs on nurses' knowledge and attitude toward pediatric palliative care.,"OBJECTIVE This study aims to assess the knowledge and attitude of nurses toward pediatric palliative care (PPC) and examine the impact of an educational program on pediatric nurses' knowledge and attitude regarding PPC for children facing life-threatening illnesses or chronic diseases in Jordan. METHOD A quasi-experimental design was used. Exactly 120 pediatric nurses participated in the study, of which 60 were in the intervention group and 60 in the control group. RESULTS The results of the study showed that nurses had a low score in knowledge and attitude toward PPC. The mean knowledge score of PPC for the control group is 6.88 (SD = 2.26), while that of the intervention group was 7.92 (SD = 1.99; p = 0.052). The mean attitude for PPC score for the control group was 95.88 (SD = 7.90), while that of the intervention group was 100 (SD = 10.95; p = 0.009). Also, the educational intervention had a significant positive effect on the knowledge and attitude toward PPC among nurses. SIGNIFICANCE OF THE RESULTS Based on the result of this study, the authors found strong evidence of the effectiveness of the PPC educational program when it came to improving the nurses' knowledge and attitude toward PPC services and offer us an effective educational program.",2021,"The mean attitude for PPC score for the control group was 95.88 (SD = 7.90), while that of the intervention group was 100 (SD = 10.95; p = 0.009).","['children facing life-threatening illnesses or chronic diseases in Jordan', '120 pediatric nurses participated in the study, of which 60 were in the intervention group and 60 in the control group', ""nurses' knowledge and attitude toward pediatric palliative care""]","['educational program', 'educational programs', 'PPC educational program', 'nurses toward pediatric palliative care (PPC']","['knowledge and attitude toward PPC', 'mean attitude for PPC score', 'mean knowledge score of PPC']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0022418', 'cui_str': 'Jordan'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030753', 'cui_str': 'Nursing, Pediatric'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",120.0,0.0124733,"The mean attitude for PPC score for the control group was 95.88 (SD = 7.90), while that of the intervention group was 100 (SD = 10.95; p = 0.009).","[{'ForeName': 'Sawsan', 'Initials': 'S', 'LastName': 'Abuhammad', 'Affiliation': 'Department of Maternal and Child Health, Jordan University of Science and Technology/Faculty of Nursing, Irbid, Jordan.'}, {'ForeName': 'Ruaa', 'Initials': 'R', 'LastName': 'Almasri', 'Affiliation': 'Department of Maternal and Child Health, Jordan University of Science and Technology/Faculty of Nursing, Irbid, Jordan.'}]",Palliative & supportive care,['10.1017/S1478951521001139'] 2800,34380573,A feasibility study using mid-upper arm circumference as the sole anthropometric criterion for admission and discharge in the outpatient treatment for severe acute malnutrition.,"BACKGROUND The World Health Organization recommends the use of a weight-for-height Z-score (WHZ) and/or mid-upper arm circumference (MUAC) as anthropometric criteria for the admission and discharge of young children for the community-based management of severe acute malnutrition. However, using MUAC as a single anthropometric criterion for admission and discharge in therapeutic nutritional programs may offer operational advantages to simplify admission processes at therapeutic nutritional centers and improve program coverage. METHODS This pragmatic, non-randomized, intervention study compared a standard outpatient nutritional program (n = 824) for the treatment of uncomplicated severe acute malnutrition using WHZ < - 3 and/or MUAC< 115 mm and/or bipedal edema for admission and discharge to a program (n = 1019) using MUAC as the sole anthropometric criterion for admission (MUAC< 120 mm) and discharge (MUAC ≥125 mm at two consecutive visits) in the Tahoua Region of Niger. RESULTS Compared to the standard program, the MUAC-only program discharged more children as recovered (70.1% vs. 51.6%; aOR 2.31, 95%CI 1.79-2.98) and fewer children as non-respondent or defaulters, based on respective program definitions. The risk of non-response was high in both programs. Three months post-discharge, children who were discharged after recovery in the MUAC-only program had lower WHZ and MUAC measures. Sixty-three children ineligible for the MUAC-only program but eligible for a standard program (MUAC ≥120 mm and WHZ < -3) were followed for twelve weeks and the anthropometric status of 69.8% of these children did not deteriorate (i.e. MUAC ≥120 mm) despite not immediately receiving treatment in the MUAC-only program. CONCLUSIONS The results from this study share the first operational experience of using MUAC as sole anthropometric criterion for admission and discharge in Niger and overall support the consideration for MUAC-only programming: the MUAC-only model of care was associated with a higher recovery and a lower defaulter rate than the standard program with very few children found to be excluded from treatment with an admission criterion of MUAC < 120 mm. Further consideration of the appropriate MUAC-based discharge criterion as it relates to an increased risk of non-response and adverse post-discharge outcomes would be prudent.",2021,"Three months post-discharge, children who were discharged after recovery in the MUAC-only program had lower WHZ and MUAC measures.","['severe acute malnutrition', 'uncomplicated severe acute malnutrition using WHZ\u2009<\u2009-\u20093 and/or MUAC<\u2009115\u2009mm and/or bipedal edema for admission and discharge to a program (n\u2009=\u20091019) using MUAC as the sole anthropometric criterion for admission (MUAC<\u2009120\u2009mm) and discharge (MUAC ≥125\u2009mm at two consecutive visits) in the Tahoua Region of Niger', 'Sixty-three children ineligible for the MUAC-only program but eligible for a standard program (MUAC ≥120\u2009mm and WHZ\u2009<\u2009-3']","['standard outpatient nutritional program', 'MUAC']",['risk of non-response'],"[{'cui': 'C4042945', 'cui_str': 'Severe Acute Malnutrition'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0424670', 'cui_str': 'Weight for height'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0239340', 'cui_str': 'Edema of lower extremity'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0450318', 'cui_str': '1019'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0028074', 'cui_str': 'Niger'}, {'cui': 'C4319614', 'cui_str': '63'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}]",63.0,0.0325465,"Three months post-discharge, children who were discharged after recovery in the MUAC-only program had lower WHZ and MUAC measures.","[{'ForeName': 'Souna', 'Initials': 'S', 'LastName': 'Garba', 'Affiliation': 'Epicentre Niger, Maradi, Niger.'}, {'ForeName': 'Halidou', 'Initials': 'H', 'LastName': 'Salou', 'Affiliation': 'Epicentre Niger, Maradi, Niger.'}, {'ForeName': 'Fabienne', 'Initials': 'F', 'LastName': 'Nackers', 'Affiliation': 'Médecins Sans Frontières Operational Center Brussels, Brussels, Belgium.'}, {'ForeName': 'Amadou', 'Initials': 'A', 'LastName': 'Ayouba', 'Affiliation': 'District Sanitaire de Madaoua, Madaoua, Niger.'}, {'ForeName': 'Montse', 'Initials': 'M', 'LastName': 'Escruela', 'Affiliation': 'Médecins Sans Frontières Operational Center Barcelona, Barcelona, Spain.'}, {'ForeName': 'Ousmane', 'Initials': 'O', 'LastName': 'Guindo', 'Affiliation': 'Epicentre Niger, Maradi, Niger.'}, {'ForeName': 'Mercé', 'Initials': 'M', 'LastName': 'Rocaspana', 'Affiliation': 'Médecins Sans Frontières Operational Center Barcelona, Barcelona, Spain.'}, {'ForeName': 'Rebecca F', 'Initials': 'RF', 'LastName': 'Grais', 'Affiliation': 'Epicentre, 14-34 avenue Jean Juarès, 75019, Paris, France.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Isanaka', 'Affiliation': 'Epicentre, 14-34 avenue Jean Juarès, 75019, Paris, France. sheila.isanaka@epicentre.msf.org.'}]",BMC nutrition,['10.1186/s40795-021-00448-w'] 2801,34380542,Lessons learned from Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): a pragmatic clinical trial of computerized decision support in primary care.,"BACKGROUND Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) was a pragmatic, cluster randomized trial assessing the effectiveness of a clinical decision support (CDS) tool in primary care, Nova Scotia, Canada. We evaluated if CDS software versus Usual Care could help primary care providers (PCPs) deliver individualized guideline-based AF patient care. METHODS Key study challenges including CDS development and implementation, recruitment, and data integration documented over the trial duration are presented as lessons learned. RESULTS Adequate resources must be allocated for software development, updates and feasibility testing. Development took longer than projected. End-user feedback suggested network access and broadband speeds impeded uptake; they felt further that the CDS was not sufficiently user-friendly or efficient in supporting AF care (i.e., repetitive alerts). Integration across e-platforms is crucial. Intellectual property and other issues prohibited CDS integration within electronic medical records and provincial e-health platforms. Double login and data entry were impediments to participation or reasons for provider withdrawal. Data integration challenges prevented easy and timely data access, analysis, and reporting. Primary care study recruitment is resource intensive. Altogether, 203 PCPs and 1145 of their patients participated, representing 25% of eligible providers and 12% of AF patients in Nova Scotia, respectively. The most effective provider recruitment strategy was in-office, small group lunch-and-learns. PCPs with past research experience or who led patient consent were top recruiters. The study office played a pivotal role in achieving patient recruitment targets. CONCLUSIONS A rapid growth in healthcare data is leading to widespread development of CDS. Our experience found practical issues to address for such applications to succeed. Feasibility testing to assess the utility of any healthcare CDS prior to implementation is recommended. Adequate resources are necessary to support successful recruitment for future pragmatic trials. CDS tools that integrate multiple co-morbid guidelines across eHealth platforms should be pursued. TRIAL REGISTRATION ClinicalTrials.gov NCT01927367. Registered on August 22, 2013.",2021,"We evaluated if CDS software versus Usual Care could help primary care providers (PCPs) deliver individualized guideline-based AF patient care. ",[],"['CDS software versus Usual Care', 'clinical decision support (CDS']",[],[],"[{'cui': 'C4042765', 'cui_str': 'Decision Support, Clinical'}, {'cui': 'C0037585', 'cui_str': 'Software'}]",[],,0.104884,"We evaluated if CDS software versus Usual Care could help primary care providers (PCPs) deliver individualized guideline-based AF patient care. ","[{'ForeName': 'Joanna M', 'Initials': 'JM', 'LastName': 'Nemis-White', 'Affiliation': 'Principal, Strive Health Management Consulting Ltd., Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Laura M', 'Initials': 'LM', 'LastName': 'Hamilton', 'Affiliation': 'Research Manager, QEII Health Sciences Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Shaw', 'Affiliation': 'Healthy Communities Program Officer, Public Health, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'James H', 'Initials': 'JH', 'LastName': 'MacKillop', 'Affiliation': 'Family Physician, Sydney Primary Care Medical Clinic, Sydney, Nova Scotia, Canada.'}, {'ForeName': 'Ratika', 'Initials': 'R', 'LastName': 'Parkash', 'Affiliation': 'Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Shurjeel H', 'Initials': 'SH', 'LastName': 'Choudhri', 'Affiliation': 'Senior Vice President and Head, Medical & Scientific Affairs, Bayer Inc, Mississauga, Ontario, Canada.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Ciaccia', 'Affiliation': 'Director & Head, Medical Affairs - Cardiovascular Medicine, Bayer Inc, Mississauga, Ontario, Canada.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Xie', 'Affiliation': 'Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': 'Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Jafna L', 'Initials': 'JL', 'LastName': 'Cox', 'Affiliation': 'Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. jafna.cox@dal.ca.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Trials,['10.1186/s13063-021-05488-y'] 2802,34380540,A three-dimensional printed model in preoperative consent for ventricular septal defect repair.,"BACKGROUND The 3D printing technology in congenital cardiac surgery has been widely utilized to improve patients' understanding of their disease. However, there has been no randomized controlled study on its usefulness in surgical consent for congenital heart disease repair. METHODS A randomized controlled study was performed during consent process in which guardians of candidates for ventricular septal defect repair were given detailed explanation of the anatomy, indication for surgery and potential complication and risks using 3D print ventricular septal defect model (n = 20) versus a conventional 2D diagram (n = 20). A questionnaire was finished by each guardian of the patients. Data collected from questionnaires as well as medical records were statistically analyzed. RESULTS Statistically significant improvements in ratings of understanding of ventricular septal defect anatomy (p = 0.02), and of the surgical procedure and potential complications (p = 0.02) were noted in the group that used the 3D model, though there was no difference in overall ratings of the consent process (p = 0.09). There was no difference in questionnaire score between subjects with different education levels. The clinical outcomes, as represented by the duration of intensive care unit stay, intubation duration was comparable between the two groups. CONCLUSIONS The results indicated that it was an effective tool which may be used to consent for congenital heart surgery. Different education levels do not affect guardians' understanding in consent. The impact of 3D printing used in this scenario on long term outcomes remains to be defined.",2021,"The clinical outcomes, as represented by the duration of intensive care unit stay, intubation duration was comparable between the two groups. ",[],"['ventricular septal defect repair were given detailed explanation of the anatomy, indication for surgery and potential complication and risks using 3D print ventricular septal defect model (n\u2009=\u200920) versus a conventional 2D diagram']","['overall ratings', 'duration of intensive care unit stay, intubation duration', 'ratings of understanding of ventricular septal defect anatomy', 'surgical procedure and potential complications', 'questionnaire score']",[],"[{'cui': 'C0189969', 'cui_str': 'Correction of ventricular septal defect'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0018818', 'cui_str': 'Ventricular septal defect'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0018818', 'cui_str': 'Ventricular septal defect'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0535965,"The clinical outcomes, as represented by the duration of intensive care unit stay, intubation duration was comparable between the two groups. ","[{'ForeName': 'Xicheng', 'Initials': 'X', 'LastName': 'Deng', 'Affiliation': ""Heart Center, Hunan Children's Hospital, No. 86 Ziyuan Road, Changsha, 410007, China. justindxc@gmail.com.""}, {'ForeName': 'Siping', 'Initials': 'S', 'LastName': 'He', 'Affiliation': ""Department of Radiology, Hunan Children's Hospital, Changsha, 410007, China.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Huang', 'Affiliation': ""Heart Center, Hunan Children's Hospital, No. 86 Ziyuan Road, Changsha, 410007, China.""}, {'ForeName': 'Jinwen', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': ""Heart Center, Hunan Children's Hospital, No. 86 Ziyuan Road, Changsha, 410007, China.""}, {'ForeName': 'Guangxian', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': ""Heart Center, Hunan Children's Hospital, No. 86 Ziyuan Road, Changsha, 410007, China.""}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Zhou', 'Affiliation': 'Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, 410007, Hunan, China.'}, {'ForeName': 'Yunbin', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': ""Heart Center, Hunan Children's Hospital, No. 86 Ziyuan Road, Changsha, 410007, China.""}]",Journal of cardiothoracic surgery,['10.1186/s13019-021-01604-w'] 2803,34380538,"Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.","BACKGROUND Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites. Among nosocomial pneumonia subtypes, ventilated HABP (vHABP) is associated with the lowest survival. In the ASPECT-NP randomized, controlled trial, participants with vHABP treated with ceftolozane/tazobactam had lower 28-day all-cause mortality (ACM) than those receiving meropenem. We conducted a series of post hoc analyses to explore the clinical significance of this finding. METHODS ASPECT-NP was a multinational, phase 3, noninferiority trial comparing ceftolozane/tazobactam with meropenem for treating vHABP and VABP; study design, efficacy, and safety results have been reported previously. The primary endpoint was 28-day ACM. The key secondary endpoint was clinical response at test-of-cure. Participants with vHABP were a prospectively defined subgroup, but subgroup analyses were not powered for noninferiority testing. We compared baseline and treatment factors, efficacy, and safety between ceftolozane/tazobactam and meropenem in participants with vHABP. We also conducted a retrospective multivariable logistic regression analysis in this subgroup to determine the impact of treatment arm on mortality when adjusted for significant prognostic factors. RESULTS Overall, 99 participants in the ceftolozane/tazobactam and 108 in the meropenem arm had vHABP. 28-day ACM was 24.2% and 37.0%, respectively, in the intention-to-treat population (95% confidence interval [CI] for difference: 0.2, 24.8) and 18.2% and 36.6%, respectively, in the microbiologic intention-to-treat population (95% CI 2.5, 32.5). Clinical cure rates in the intention-to-treat population were 50.5% and 44.4%, respectively (95% CI - 7.4, 19.3). Baseline clinical, baseline microbiologic, and treatment factors were comparable between treatment arms. Multivariable regression identified concomitant vasopressor use and baseline bacteremia as significantly impacting ACM in ASPECT-NP; adjusting for these two factors, the odds of dying by day 28 were 2.3-fold greater when participants received meropenem instead of ceftolozane/tazobactam. CONCLUSIONS There were no underlying differences between treatment arms expected to have biased the observed survival advantage with ceftolozane/tazobactam in the vHABP subgroup. After adjusting for clinically relevant factors found to impact ACM significantly in this trial, the mortality risk in participants with vHABP was over twice as high when treated with meropenem compared with ceftolozane/tazobactam. TRIAL REGISTRATION clinicaltrials.gov, NCT02070757. Registered 25 February, 2014, clinicaltrials.gov/ct2/show/NCT02070757.",2021,"Clinical cure rates in the intention-to-treat population were 50.5% and 44.4%, respectively (95% CI - 7.4, 19.3).","['patients with ventilated hospital-acquired bacterial pneumonia', 'participants with vHABP treated with', 'Participants with vHABP', 'participants with vHABP', '99 participants in the']","['Ceftolozane/tazobactam', 'ventilated HABP (vHABP', 'ceftolozane/tazobactam and meropenem', 'meropenem', 'ceftolozane/tazobactam with meropenem', 'ceftolozane/tazobactam', 'Ceftolozane/tazobactam versus meropenem']","['mortality risk', '28-day all-cause mortality (ACM', 'clinical response at test-of-cure', '28-day ACM', 'vHABP', 'Clinical cure rates', 'survival advantage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4727976', 'cui_str': 'Ventilated HABP'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C3656593', 'cui_str': 'Ceftolozane and tazobactam'}, {'cui': 'C4727976', 'cui_str': 'Ventilated HABP'}, {'cui': 'C0066005', 'cui_str': 'meropenem'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C4727976', 'cui_str': 'Ventilated HABP'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.790638,"Clinical cure rates in the intention-to-treat population were 50.5% and 44.4%, respectively (95% CI - 7.4, 19.3).","[{'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Timsit', 'Affiliation': 'Intensive Care Medicine Department, Université Paris Diderot, Paris, France.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Huntington', 'Affiliation': 'MRL, Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Wunderink', 'Affiliation': 'Pulmonary and Critical Care Division, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Nobuaki', 'Initials': 'N', 'LastName': 'Shime', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Marin H', 'Initials': 'MH', 'LastName': 'Kollef', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Ülo', 'Initials': 'Ü', 'LastName': 'Kivistik', 'Affiliation': 'Pulmonology Centre, North Estonia Medical Centre, Tallinn, Estonia.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Nováček', 'Affiliation': 'Department of Anaesthesia and Intensive Care, General Hospital of Kolin, Kolin, Czech Republic.'}, {'ForeName': 'Álvaro', 'Initials': 'Á', 'LastName': 'Réa-Neto', 'Affiliation': 'Departamento de Clínica Médica, Universidade Federal do Paraná, Curitiba, Brazil.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Martin-Loeches', 'Affiliation': ""Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St James' Hospital, Dublin, Ireland.""}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Yu', 'Affiliation': 'MRL, Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Erin H', 'Initials': 'EH', 'LastName': 'Jensen', 'Affiliation': 'MRL, Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Joan R', 'Initials': 'JR', 'LastName': 'Butterton', 'Affiliation': 'MRL, Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Dominik J', 'Initials': 'DJ', 'LastName': 'Wolf', 'Affiliation': 'MRL, Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Elizabeth G', 'Initials': 'EG', 'LastName': 'Rhee', 'Affiliation': 'MRL, Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Bruno', 'Affiliation': 'MRL, Merck & Co., Inc., Kenilworth, NJ, USA. christopher.bruno@merck.com.'}]","Critical care (London, England)",['10.1186/s13054-021-03694-3'] 2804,34380536,"Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study).","BACKGROUND Systemic lupus erythematosus (SLE) is an autoimmune disease that can involve multiple organs or systems. Lupus nephritis (LN) is associated with high mortality and morbidity. However, plenty of patients do not respond to present treatment or relapse. Iguratimod (IGU) is a new small molecular, anti-rheumatic drug and has shown the potential for drug repurposing from rheumatoid arthritis (RA) to LN treatment. It has been approved for treating RA in northeast Asia. Beyond expectation in a recent observational study, over 90% of thirteen refractory LN patients responded to iguratimod monotherapy in 24 weeks, with no steroids dose increasing or any other medication add-on during the entire follow-up. METHODS/DESIGN This study is a multi-center, randomized, 52-week parallel positive drug-controlled study. The study was designed as a head-to-head comparison between the iguratimod and present first-line therapy on LN patients. A total of 120 patients (60 patients each group) is in the enrolling plan. All enrolled patients are assigned randomly into trial and control groups. The patients will be selected from six study sites in China and will all have biopsy-proven active lupus nephritis. In the first 24 weeks of the trial, IGU is compared with cyclophosphamide as an induction therapy, and in the second 24 weeks, IGU is compared with azathioprine as a maintenance therapy. The primary outcome is renal remission rate including both complete remission and partial remission at week 52, which will be analyzed using a non-inferiority hypothesis test. DISCUSSION Most patients diagnosed with SLE will develop LN within 5 years and LN remains a major cause of morbidity and death for SLE patients. Although some medications are proven effective for the treatment of this condition, at least 20-35% LN patients have to suffer from relapse or ineffective treatment and medication intolerance is also frequent. This trial is designed to demonstrate whether iguratimod can be used as an alternative induction or maintenance therapy in subjects who have lupus nephritis. Data from this study will provide an evidence on whether or not iguratimod should be recommended to active LN patients. TRIAL REGISTRATION ClinicalTrials.gov NCT02936375 . Registered on October 18, 2016.",2021,The study was designed as a head-to-head comparison between the iguratimod and present first-line therapy on LN patients.,"['subjects who have lupus nephritis', 'active lupus nephritis', 'LN patients', '120 patients (60 patients each group']","['azathioprine', 'iguratimod and conventional cyclophosphamide with sequential azathioprine', 'cyclophosphamide']",['renal remission rate including both complete remission and partial remission'],"[{'cui': 'C0024143', 'cui_str': 'SLE glomerulonephritis syndrome'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C1872427', 'cui_str': 'iguratimod'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}]",120.0,0.0860327,The study was designed as a head-to-head comparison between the iguratimod and present first-line therapy on LN patients.,"[{'ForeName': 'Qingran', 'Initials': 'Q', 'LastName': 'Yan', 'Affiliation': 'Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China. yanqingran@163.com.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Du', 'Affiliation': 'Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.'}, {'ForeName': 'Yuening', 'Initials': 'Y', 'LastName': 'Kang', 'Affiliation': 'Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Ye', 'Affiliation': 'Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Rheumatology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.'}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Department of Rheumatology and Immunology, Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, China.'}, {'ForeName': 'Niansong', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': ""Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Gengru', 'Initials': 'G', 'LastName': 'Jiang', 'Affiliation': 'Renal Division, Department of Internal Medicine, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.'}, {'ForeName': 'Zhijun', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, Anhui, China.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Rheumatology and Immunology, Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Xue', 'Affiliation': ""Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Xinfang', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Department of Rheumatology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.'}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Renal Division, Department of Internal Medicine, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, Anhui, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Dai', 'Affiliation': 'Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China. maverickdai@sina.com.'}, {'ForeName': 'Chunde', 'Initials': 'C', 'LastName': 'Bao', 'Affiliation': 'Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China. baochunde_1678@126.com.'}]",Trials,['10.1186/s13063-021-05475-3'] 2805,34380528,C-STICH2: emergency cervical cerclage to prevent miscarriage and preterm birth-study protocol for a randomised controlled trial.,"BACKGROUND Cervical cerclage is a recognised treatment to prevent late miscarriage and pre-term birth (PTB). Emergency cervical cerclage (ECC) for cervical dilatation with exposed unruptured membranes is less common and the potential benefits of cerclage are less certain. A randomised control trial is needed to accurately assess the effectiveness of ECC in preventing pregnancy loss compared to an expectant approach. METHODS C-STICH2 is a multicentre randomised controlled trial in which women presenting with cervical dilatation and unruptured exposed membranes at 16 + 0 to 27 + 6 weeks gestation are randomised to ECC or expectant management. Trial design includes 18 month internal pilot with embedded qualitative process evaluation, minimal data set and a within-trial health economic analysis. Inclusion criteria are ≥16 years, singleton pregnancy, exposed membranes at the external os, gestation 16 + 0-27 + 6 weeks, and informed consent. Exclusion criteria are contraindication to cerclage, cerclage in situ or previous cerclage in this pregnancy. Randomisation occurs via an online service in a 1:1 ratio, using a minimisation algorithm to reduce chance imbalances in key prognostic variables (site, gestation and dilatation). Primary outcome is pregnancy loss; a composite including miscarriage, termination of pregnancy and perinatal mortality defined as stillbirth and neonatal death in the first week of life. Secondary outcomes include all core outcomes for PTB. Two-year development outcomes will be assessed using general health and Parent Report of Children's Abilities-Revised (PARCA-R) questionnaires. Intended sample size is 260 participants (130 each arm) based on 60% rate of pregnancy loss in the expectant management arm and 40% in the ECC arm, with 90% power and alpha 0.05. Analysis will be by intention-to-treat. DISCUSSION To date there has been one small trial of ECC in 23 participants which included twin and singleton pregnancies. This small trial along with the largest observational study (n = 161) found ECC to prolong pregnancy duration and reduce deliveries before 34 weeks gestation. It is important to generate high quality evidence on the effectiveness of ECC in preventing pregnancy loss, and improve understanding of the prevalence of the condition and frequency of complications associated with ECC. An adequately powered RCT will provide the highest quality evidence regarding optimum care for these women and their babies. TRIAL REGISTRATION ISRCTN Registry ISRCTN12981869 . Registered on 13th June 2018.",2021,"A randomised control trial is needed to accurately assess the effectiveness of ECC in preventing pregnancy loss compared to an expectant approach. ","['women presenting with cervical dilatation and unruptured exposed membranes at 16 +\u20090 to 27 +\u20096\u2009weeks gestation', '23 participants which included twin and singleton pregnancies']","['ECC', 'Emergency cervical cerclage (ECC', 'emergency cervical cerclage', 'C-STICH2', 'ECC or expectant management']","['pregnancy duration and reduce deliveries', 'pregnancy loss', 'core outcomes for PTB', 'pregnancy loss; a composite including miscarriage, termination of pregnancy and perinatal mortality defined as stillbirth and neonatal death in the first week of life', ""general health and Parent Report of Children's Abilities-Revised (PARCA-R) questionnaires""]","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0079103', 'cui_str': 'Cervical dilatation'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0041427', 'cui_str': 'Twin sibling'}]","[{'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0195681', 'cui_str': 'Cerclage of uterine cervix'}, {'cui': 'C0700325', 'cui_str': 'Patient status observation'}]","[{'cui': 'C0460089', 'cui_str': 'Finding of length of gestation'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0156543', 'cui_str': 'Pregnancy with abortive outcome'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0392535', 'cui_str': 'Termination of pregnancy'}, {'cui': 'C0031062', 'cui_str': 'Perinatal Mortality'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0410916', 'cui_str': 'Newborn death'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.35497,"A randomised control trial is needed to accurately assess the effectiveness of ECC in preventing pregnancy loss compared to an expectant approach. ","[{'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Hodgetts-Morton', 'Affiliation': 'University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Hewitt', 'Affiliation': 'Birmingham Clinical Trials Unit, Birmingham, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Jones', 'Affiliation': 'University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Leighton', 'Affiliation': 'Birmingham Clinical Trials Unit, Birmingham, UK.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Pilarski', 'Affiliation': ""Birmingham Women's and Children's Hospital, Birmingham, UK.""}, {'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Molloy', 'Affiliation': 'University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Hinshaw', 'Affiliation': 'City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Norman', 'Affiliation': 'University of Bristol, Bristol, UK.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Waugh', 'Affiliation': 'University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Stock', 'Affiliation': 'University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Thornton', 'Affiliation': 'University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Toozs-Hobson', 'Affiliation': ""Birmingham Women's and Children's Hospital, Birmingham, UK.""}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Johnston', 'Affiliation': ""Birmingham Women's and Children's Hospital, Birmingham, UK.""}, {'ForeName': 'Arri', 'Initials': 'A', 'LastName': 'Coomarasamy', 'Affiliation': 'University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Shakila', 'Initials': 'S', 'LastName': 'Thangaratinam', 'Affiliation': 'University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Mol', 'Affiliation': 'University of Adelaide, Adelaide, UK.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Pajkrt', 'Affiliation': 'University of Amsterdam, Amsterdamm, UK.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Marlow', 'Affiliation': 'University College London, London, UK.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Roberts', 'Affiliation': 'University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Middleton', 'Affiliation': 'Birmingham Clinical Trials Unit, Birmingham, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Brocklehurst', 'Affiliation': 'Birmingham Clinical Trials Unit, Birmingham, UK.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Morris', 'Affiliation': 'Birmingham Clinical Trials Unit, Birmingham, UK. R.K.Morris@bham.ac.uk.'}]",Trials,['10.1186/s13063-021-05464-6'] 2806,34380382,"Acute cognitive performance and mood effects of coffee berry and apple extracts: A randomised, double blind, placebo controlled crossover study in healthy humans.","Background: Polyphenols from coffee berry (chlorogenic acid) and apple (flavanol) have been shown to improve mood and increase cerebral blood flow in healthy humans. These effects may underpin the cognitive effects of polyphenols seen previously. Objective: The aim of the present paper was to extend previous research by investigating the effects of coffee berry at high and low doses when combined with apple extract on cognitive performance and mood. Design: This randomised, double-blind, placebo controlled, crossover trial included 46 healthy males and females,18-49 years of age (mean age 23 years),consuming: 1100 mg coffee berry extract, 1100 mg coffee berry extract plus 275 mg apple extract, 100 mg coffee berry extract plus 275 mg apple extract or placebo on 4 separate occasions, completing cognitive and mood assessments pre-dose and then again at 1-, 3- and 6 hrs post-dose. Results: Analysis revealed a consistent pattern of alerting effects following 1100 mg coffee berry extract. Limited effects on cognitive function were observed. Specifically, faster peg and ball performance (executive function) was observed following 1100 mg coffee berry plus apple extract and accuracy on the Rapid Visual Information Processing (RVIP) task increased on the third of four repetitions following 1100 mg coffee berry alone. Interestingly, more false alarms on RVIP were observed following the same intervention. Conclusions: In line with previous findings, 1100 mg coffee berry engendered increased arousal. The absence of effects on mood when an apple extract was added, and the potential for the low dose of caffeine within the coffee berry to act synergistically with polyphenols, raise interesting future avenues of research. Abbreviations: Cognitive demand battery (CDB), Profile Of Mood States (POMS), Visual Analogue Scale (VAS), Rapid Visual Information Processing (RVIP).",2021,"Specifically, faster peg and ball performance (executive function) was observed following 1100 mg coffee berry plus apple extract and accuracy on the Rapid Visual Information Processing (RVIP) task increased on the third of four repetitions following 1100 mg coffee berry alone.","['healthy humans', '46 healthy males and females,18-49 years of age (mean age 23 years),consuming: 1100']","['apple extract', 'Polyphenols from coffee berry (chlorogenic acid) and apple (flavanol', 'coffee berry and apple extracts', 'placebo', 'apple extract or placebo']","['cognitive function', 'RVIP', 'Cognitive demand battery (CDB', 'faster peg and ball performance (executive function', 'Rapid Visual Information Processing (RVIP) task', 'Acute cognitive performance and mood effects', 'Profile Of Mood States (POMS), Visual Analogue Scale (VAS), Rapid Visual Information Processing (RVIP', 'arousal', 'cerebral blood flow', 'cognitive performance and mood']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517537', 'cui_str': '1100'}]","[{'cui': 'C3257517', 'cui_str': 'Apple extract'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0009237', 'cui_str': 'Coffee'}, {'cui': 'C0005135', 'cui_str': 'Berry'}, {'cui': 'C0008240', 'cui_str': 'Chlorogenic acid'}, {'cui': 'C0003625', 'cui_str': 'Malus'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0039597', 'cui_str': 'Testis structure'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}]",46.0,0.0900437,"Specifically, faster peg and ball performance (executive function) was observed following 1100 mg coffee berry plus apple extract and accuracy on the Rapid Visual Information Processing (RVIP) task increased on the third of four repetitions following 1100 mg coffee berry alone.","[{'ForeName': 'Philippa A', 'Initials': 'PA', 'LastName': 'Jackson', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne, United Kingdom.'}, {'ForeName': 'Crystal', 'Initials': 'C', 'LastName': 'Haskell-Ramsay', 'Affiliation': 'Psychology department, Faculty of Health and Life Sciences, Northumbria University, Newcastle Upon Tyne, United Kingdom.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Forster', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne, United Kingdom.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Khan', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne, United Kingdom.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Veasey', 'Affiliation': 'PHMR Ltd, Berkeley Works, Berkley Grove, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'David O', 'Initials': 'DO', 'LastName': 'Kennedy', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne, United Kingdom.'}, {'ForeName': 'Alissa R', 'Initials': 'AR', 'LastName': 'Wilson', 'Affiliation': 'Health & Nutrition Sciences, PepsiCo R&D, Purchase, NY, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Saunders', 'Affiliation': 'Suntory Beverage & Food Europe, Hillingdon.'}, {'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Wightman', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne, United Kingdom.'}]",Nutritional neuroscience,['10.1080/1028415X.2021.1963068'] 2807,34380364,Daily Training efficiency during computerized cognitive rehabilitation training (CCRT): an analysis from a randomized trial in Ugandan children with and without severe malaria.,"Children in Uganda are at risk for significant cognitive sequelae from severe malaria. Computerized cognitive rehabilitation training (CCRT) represents a potential method to improve working memory, behavior, and executive functioning, cognitive domains most at risk following severe malaria. The primary aim of this study was to complete a secondary analysis of data from a concluded CCRT randomized control trial in order to compare the training efficiency of a commonly used CCRT program under conditions of titrated (adaptive) or non-titrated (non-adaptive) training and with children with increasing malaria severity to determine how various factors may affect potential CCRT improvement. A total of 201 school-aged children (66.2% boys) who were either healthy (n = 102) or previously diagnosed with severe or cerebral malaria (n = 99) were randomized into two active treatment arms (titrated and non-titrated learning). Each child received 24 one-hour sessions of training over 8 weeks using Captain's Log® CCRT by BrainTrain, which includes a comprehensive set of CCRT tasks. Children generally benefited from CCRT over the 24 training sessions, but titrated CCRT showed a clear advantage over non-titrated. Severity of illness or factors such as BMI, did not moderate CCRT performance indicators. These findings support our hypothesis that titrated CCRT would result in steeper improvement in learning, but do not support our hypothesis that history of recent significant illness would affect learning proficiency. Findings were evident across all CCRT performance scores, even given that children were from generally rural, low-resource settings and were generally unfamiliar with computers. ABBREVIATIONS: Computerized Cognitive Rehabilitation Training (CCRT); Mental Processing Index (MPI); Home Observation for the Measurement of the Environment (HOME); Socioeconomic Status (SES); least square means (LSM).",2021,"Children generally benefited from CCRT over the 24 training sessions, but titrated CCRT showed a clear advantage over non-titrated.","['201 school-aged children (66.2% boys) who were either healthy (n\xa0=\xa0102) or previously diagnosed with severe or cerebral malaria (n\xa0=\xa099', 'Ugandan children with and without severe malaria']","['CCRT program under conditions of titrated (adaptive) or non-titrated (non-adaptive) training', 'CCRT', 'computerized cognitive rehabilitation training (CCRT', 'Computerized Cognitive Rehabilitation Training (CCRT); Mental Processing Index (MPI', 'Computerized cognitive rehabilitation training (CCRT']",['CCRT performance scores'],"[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0024534', 'cui_str': 'Cerebral malaria'}, {'cui': 'C2747816', 'cui_str': 'Complicated malaria'}]","[{'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]","[{'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",99.0,0.0141164,"Children generally benefited from CCRT over the 24 training sessions, but titrated CCRT showed a clear advantage over non-titrated.","[{'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Larrivey', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Neva', 'Affiliation': 'Medical School, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Finn', 'Affiliation': 'School of Nursing, Calvin University, Seoul, South Korea.'}, {'ForeName': 'Alla', 'Initials': 'A', 'LastName': 'Sikorskii', 'Affiliation': 'Global Neuropsychiatry Program, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Familiar-Lopez', 'Affiliation': 'Global Neuropsychiatry Program, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Valentine', 'Initials': 'V', 'LastName': 'Ucheagwu', 'Affiliation': 'Departments of Psychiatry, Neurology, Psychology and School of Nursing, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Amara', 'Initials': 'A', 'LastName': 'Ezeamama', 'Affiliation': 'Global Neuropsychiatry Program, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Horacio', 'Initials': 'H', 'LastName': 'Ruisenor-Escudero', 'Affiliation': 'Global Neuropsychiatry Program, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Noeline', 'Initials': 'N', 'LastName': 'Nakasujja', 'Affiliation': 'Makerere School of Medicine, Madonna University, Okija, Nigeria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Boivin', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Giordani', 'Affiliation': 'Departments of Psychiatry, Neurology, Psychology and School of Nursing, University of Michigan, Ann Arbor, MI, USA.'}]",Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence,['10.1080/09297049.2021.1962266'] 2808,34380355,Towards an embedded symptom validity indicator for the rivermead postconcussion symptom questionnaire.,"This simulation study aimed to develop and test an embedded symptom validity indicator for use with the Rivermead Post Concussion Symptoms Questionnaire (RPQ). Seven mild traumatic brain injury (mTBI) experts assisted in generating a shortlist of 15 atypical postconcussion symptoms. A modified RPQ (mRPQ) was constructed by embedding these items with the 16 standard RPQ items. Eighty-four mTBI simulators completed the mRPQ after random allocation to a symptom-exaggeration condition (ES group; n  = 46) or simulation-only condition (S group; n  = 38). They also completed the Test of Memory Malingering (TOMM) and the Recognition Memory Test (RMT), and the groups were re-formed and compared using modified criteria for Malingered Neurocognitive Dysfunction (mMND). There was no significant group by item-type interaction for either grouping methods (i.e. as allocated or as reclassified). Exploratory analyses of the main effects showed that ES group had higher mRPQ scores than the S group, and standard symptoms were endorsed more than atypical symptoms. If further developed, the mRPQ could eventually aid the screening of PCS over-reporting.",2021,"Exploratory analyses of the main effects showed that ES group had higher mRPQ scores than the S group, and standard symptoms were endorsed more than atypical symptoms.",[],"['ES', 'modified RPQ (mRPQ']","['mRPQ scores', 'Test of Memory Malingering (TOMM) and the Recognition Memory Test (RMT']",[],"[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0546983', 'cui_str': 'Postconcussion syndrome'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0024630', 'cui_str': 'Malingering'}, {'cui': 'C0451414', 'cui_str': 'Recognition memory test'}]",,0.0397535,"Exploratory analyses of the main effects showed that ES group had higher mRPQ scores than the S group, and standard symptoms were endorsed more than atypical symptoms.","[{'ForeName': 'Kristy', 'Initials': 'K', 'LastName': 'Windle', 'Affiliation': 'School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia.'}, {'ForeName': 'Karen A', 'Initials': 'KA', 'LastName': 'Sullivan', 'Affiliation': 'School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia.'}]",Applied neuropsychology. Adult,['10.1080/23279095.2019.1660880'] 2809,34380344,Comparison of the effects of Wii and conventional training on functional abilities and neurocognitive function in basketball-players with functional ankle instability: Matched randomized clinical trial.,"OBJECTIVE To compare the effects of Wii and conventional training on functional abilities and neurocognitive function in basketball-players with Functional Ankle Instability (FAI). DESIGN Single-blind matched randomized clinical trial study. SETTING Outpatients setting. PARTICIPANTS Fifty-four basketball-players were randomly assigned to the Wii and control group. INTERVENTIONS All athletes in the Wii group ( n  = 27) performed Wii Fit Plus games; and in the control group ( n  = 27), they performed conventional training three days a week for 12 sessions. MAIN OUTCOME MEASURES To assess functional performance and neurocognitive function, we used hop tests (8-hop, side hop, and single hop) and Deary-Liewald Reaction Time Task (DLRT), respectively. DLRT measured simple and choice reaction time and error rate. Measures were taken at baseline, four weeks, and eight weeks after baseline. RESULTS In all 54 athletes completed the study. The results showed no significant differences for all hop tests in between-group comparison but the neurocognitive function showed significant improvements in the Wii group compared to the control group ( P  < 0.05). Mean (SD) for 8-hop and side hop tests for the involved limb, and simple and choice reaction time four weeks after baseline in the control group were 10.15 (1.02), 12.36 (1.31), and 339.10 (41.57), 530.52 (53.36), respectively and in the Wii group, were 10.46 (1.23), 12.40 (1.31), and 295.25 (13.16), 431.19 (33.46), respectively. CONCLUSION Based on our results, both training protocols were equal to positively affect functional abilities. Besides, Wii training improved neurocognitive function and can be applied in FAI rehabilitation protocols.",2021,The results showed no significant differences for all hop tests in between-group comparison but the neurocognitive function showed significant improvements in the Wii group compared to the control group ( P  < 0.05).,"['54 athletes completed the study', 'Outpatients setting', 'Fifty-four basketball-players', 'basketball-players with functional ankle instability', 'basketball-players with Functional Ankle Instability (FAI']",['Wii and conventional training'],"['Mean (SD', 'neurocognitive function', 'functional abilities and neurocognitive function', 'functional performance and neurocognitive function', 'DLRT measured simple and choice reaction time and error rate']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0004818', 'cui_str': 'Basketball'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0277851', 'cui_str': 'Ankle instability'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}]",54.0,0.0842836,The results showed no significant differences for all hop tests in between-group comparison but the neurocognitive function showed significant improvements in the Wii group compared to the control group ( P  < 0.05).,"[{'ForeName': 'Niloofar', 'Initials': 'N', 'LastName': 'Mohammadi', 'Affiliation': 'School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad-Reza', 'Initials': 'MR', 'LastName': 'Hadian', 'Affiliation': 'School of Rehabilitation; Institute of Neurosciences, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Gholam-Reza', 'Initials': 'GR', 'LastName': 'Olyaei', 'Affiliation': 'School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.'}]",Clinical rehabilitation,['10.1177/02692155211010249'] 2810,34380150,Effects of 7-week Resistance Training on Handcycle Performance in Able-bodied Males.,"The effect of an upper body resistance training program on maximal and submaximal handcycling performance in able-bodied males was explored. Eighteen able-bodied men were randomly assigned to a training group (TG: n=10) and a control group (CG: n=8). TG received 7 weeks of upper body resistance training (60% of 1 repetition maximum (1RM), 3×10 repetitions, 6 exercise stations, 2 times per week). CG received no training. Peak values for oxygen uptake (V˙O 2peak ), power output (PO peak ), heart rate (HR peak ), minute ventilation (V˙O Epeak ) and respiratory exchange ratio (RER peak ), submaximal values (HR, V˙O 2 , RER, PO, and gross mechanical efficiency (GE)), and time to exhaustion (TTE) were determined in an incremental test pre- and post-training. Maximal isokinetic arm strength and 1RM tests were conducted. Ratings of perceived exertion (RPE) were assessed. A two-way repeated measures ANOVA and post-hoc comparisons were performed to examine the effect of time, group and its interaction (p<0.05). TG improved on PO peak (8.55%), TTE (10.73%), and 1RM (12.28-38.98%). RPE at the same stage during pre- and post-test was lower during the post-test (8.17%). Despite no improvements in V˙O 2peak , training improved PO peak , muscular strength, and TTE. Upper body resistance training has the potential to improve handcycling performance.",2021,"TG improved on PO peak (8.55%), TTE (10.73%), and 1RM (12.28-38.98%).","['Eighteen able-bodied men', 'able-bodied males', 'Able-bodied Males']","['upper body resistance training', '7-week Resistance Training', 'upper body resistance training program']","['Ratings of perceived exertion (RPE', 'Maximal isokinetic arm strength and 1RM tests', 'Peak values for oxygen uptake (V˙O 2peak ), power output (PO peak ), heart rate (HR peak ), minute ventilation (V˙O Epeak ) and respiratory exchange ratio (RER peak ), submaximal values (HR, V˙O 2 , RER, PO, and gross mechanical efficiency (GE)), and time to exhaustion (TTE', '1RM', 'Handcycle Performance', 'TG improved on PO peak', 'maximal and submaximal handcycling performance', 'V˙O 2peak , training improved PO peak , muscular strength, and TTE']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C1268087', 'cui_str': 'Upper body structure'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient'}, {'cui': 'C0230779', 'cui_str': 'Granular endoplasmic reticulum'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}]",,0.00708284,"TG improved on PO peak (8.55%), TTE (10.73%), and 1RM (12.28-38.98%).","[{'ForeName': 'Ulric Sena', 'Initials': 'US', 'LastName': 'Abonie', 'Affiliation': 'Department of Physiotherapy and Rehabilitation Sciences, University of Health and Allied Sciences, Ho, Ghana.'}, {'ForeName': 'Tryntje', 'Initials': 'T', 'LastName': 'Albada', 'Affiliation': 'Center for Human Movement Sciences, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Floor', 'Initials': 'F', 'LastName': 'Morrien', 'Affiliation': 'Center for Human Movement Sciences, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'van der Woude', 'Affiliation': 'Center for Human Movement Sciences, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Florentina', 'Initials': 'F', 'LastName': 'Hettinga', 'Affiliation': 'Department of Sport, Exercise & Rehabilitation, Northumbria University, Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland.'}]",International journal of sports medicine,['10.1055/a-1373-6033'] 2811,34380099,Effects of transcranial direct current stimulation associated with an aerobic exercise bout on blood pressure and autonomic modulation of hypertensive patients: A pilot randomized clinical trial.,"The objective of this article was to evaluate the effects of an aerobic exercise bout associated with a single session of anodal transcranial direct current stimulation (tDCS) over the left temporal lobe on blood pressure (BP) and heart rate variability (HRV) in hypertensive people. After met the inclusion criteria, twenty hypertensive people were randomized to active-tDCS or sham-tDCS group. Initially, they provided their sociodemographic data, a blood sample, and went through an evaluation of the cardiorespiratory performance. Then, a single session of tDCS with an intensity of 2 mA over the left lobe during 20 min was carried out. After tDCS, it was performed a session of moderate-intensity aerobic exercise during 40 min. BP during 24 h and HRV measurements were performed before (baseline) and after the intervention. Systolic BP during sleep time decreased in the active-tDCS group (p = 0.008). Diastolic BP showed a significant decrease 3 h after the intervention in the active-tDCS group (p = 0.01). An intragroup comparison showed a significant decrease in systolic BP 3 h after intervention only for the active-tDCS group (p = 0.04). Besides, there was a trend toward a difference in wake for diastolic BP for active-tDCS (p = 0.07). Lastly, there were no changes in the HRV for both groups. It is suggested that anodal tDCS associated with moderate-intensity aerobic exercise can decrease systolic and diastolic BP of hypertensive people during sleep time and 3 h after the intervention.",2021,An intragroup comparison showed a significant decrease in systolic BP 3 h after intervention only for the active-tDCS group (p = 0.04).,"['twenty hypertensive people', 'hypertensive people', 'hypertensive patients']","['anodal transcranial direct current stimulation (tDCS', 'active-tDCS or sham-tDCS', 'transcranial direct current stimulation', 'aerobic exercise bout']","['systolic BP', 'BP', 'Systolic BP during sleep time', 'Diastolic BP', 'wake for diastolic BP for active-tDCS', 'blood pressure and autonomic modulation', 'blood pressure (BP) and heart rate variability (HRV', 'systolic and diastolic BP']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0587116', 'cui_str': 'During sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0039155', 'cui_str': 'Systole'}]",,0.0463815,An intragroup comparison showed a significant decrease in systolic BP 3 h after intervention only for the active-tDCS group (p = 0.04).,"[{'ForeName': 'Edson', 'Initials': 'E', 'LastName': 'Silva-Filho', 'Affiliation': 'Associated Postgraduate Program in Physical Education, Federal University of Paraíba, João Pessoa, Paraíba, Brazil. Electronic address: edson.fisio.meneses@gmail.com.'}, {'ForeName': 'Jéssica', 'Initials': 'J', 'LastName': 'Albuquerque', 'Affiliation': 'Department of Social Psychology, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.'}, {'ForeName': 'Marom', 'Initials': 'M', 'LastName': 'Bikson', 'Affiliation': 'Department of Biomedical Engineering, The City College of The City University of New York, New York, USA.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Pegado', 'Affiliation': 'Postgraduate Program in Rehabilitation Sciences, Federal University of Rio Grande do Norte, Santa Cruz, Brazil.'}, {'ForeName': 'Amilton', 'Initials': 'A', 'LastName': 'da Cruz Santos', 'Affiliation': 'Associated graduate Program in Physical Education, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'do Socorro Brasileiro-Santos', 'Affiliation': 'Associated graduate Program in Physical Education, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.'}]",Autonomic neuroscience : basic & clinical,['10.1016/j.autneu.2021.102866'] 2812,34380024,Bilateral versus unilateral arm training for patients with stroke.,,2021,,['patients with stroke'],['Bilateral versus unilateral arm training'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],,0.0220793,,"[{'ForeName': 'Yi-Hsiang', 'Initials': 'YH', 'LastName': 'Chiu', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Kuan-Cheng', 'Initials': 'KC', 'LastName': 'Chen', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: ckc1232001@hotmail.com.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2021.05.020'] 2813,34380000,High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: A three-arm feasibility randomized controlled trial.,"BACKGROUND This study assessed the feasibility of a phase II randomized controlled trial of high-intensity interval training (HIIT), resistance training (RT), and usual care (UC) in men with prostate cancer (PCa) on active surveillance (AS) and evaluated changes in clinically relevant outcomes. METHODS Eighteen men undergoing AS for PCa were randomized to HIIT (n=5), RT (n=7), or UC (n=6). Exercise participants attended two supervised sessions weekly and were instructed to complete one home-based session weekly for 8 weeks. UC participants were provided with physical activity guidelines. RESULTS Feasibility was met for attendance, compliance, and retention, but not recruitment. HIIT increased leg press (mean: +8.2kg, 95%CI 1.1, 15.3) from baseline to 8 weeks. RT increased seated row (mean: +11.7kg, 95%CI 6.1, 17.3) and chest press (mean: +10.4kg, 95%CI 5.3, 15.5), leg press (mean: +13.1kg, 95%CI 5.9, 20.3), serum insulin-like binding protein-3 (IGFBP-3) (mean: +400.0ng/ml, 95%CI 94.5, 705.5), and decreased interferon-γ (mean: -3.1pg/ml, 95%CI -5.7, -0.4). No changes were observed in the UC group. CONCLUSION HIIT and RT may be effective strategies for improving muscle strength; however, only RT may increase serum IGFBP-3. Strategies that can enhance recruitment in men on AS are important prior to conducting a phase II trial. TRIAL REGISTRATION NUMBER ClinicalTrials.gov number NCT04266262 Novelty bullets • High-intensity interval training or resistance training are feasible during active surveillance for prostate cancer. • Resistance training may suppress the tumor-promoting effects of insulin-like growth factor-I (IGF-I) via increased expression of IGFBP-3.",2021,"HIIT increased leg press (mean: +8.2kg, 95%CI 1.1, 15.3) from baseline to 8 weeks.","['Eighteen men undergoing AS for PCa were randomized to HIIT (n=5), RT (n=7), or UC (n=6', 'men with prostate cancer on active surveillance', 'men with prostate cancer (PCa']","['high-intensity interval training (HIIT), resistance training (RT), and usual care (UC', 'Resistance training', 'High-intensity interval training or resistance training versus usual care', 'High-intensity interval training or resistance training']","['HIIT increased leg press', 'serum insulin-like binding protein-3 (IGFBP-3', 'leg press']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0700325', 'cui_str': 'Patient status observation'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0443625', 'cui_str': 'Binding protein 3'}, {'cui': 'C0123707', 'cui_str': 'Insulin-like growth factor binding protein 3'}]",18.0,0.0898601,"HIIT increased leg press (mean: +8.2kg, 95%CI 1.1, 15.3) from baseline to 8 weeks.","[{'ForeName': 'Efthymios', 'Initials': 'E', 'LastName': 'Papadopoulos', 'Affiliation': 'University Health Network, 7989, Medicine, Toronto, Canada, M5G 2C4; efthymios.papadopoulos@uhnresearch.ca.'}, {'ForeName': 'Jenna B', 'Initials': 'JB', 'LastName': 'Gillen', 'Affiliation': 'University of Toronto, 100 Devonshire Pl, Toronto, Ontario, Canada, m5s 2c9; jenna.gillen@utoronto.ca.'}, {'ForeName': 'Daniel R', 'Initials': 'DR', 'LastName': 'Moore', 'Affiliation': 'University of Toronto, Faculty of Kinesiology and Physical Education, 55 Harbord St., Toronto, Ontario, Canada, M5S 2W6; dr.moore@utoronto.ca.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Au', 'Affiliation': 'University Health Network, 7989, Toronto, Ontario, Canada; darren.au@uhnresearch.ca.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Kurgan', 'Affiliation': 'Brock University, Health Sciences, St. Catharines, Ontario, Canada; nk10gw@brocku.ca.'}, {'ForeName': 'Panagiota', 'Initials': 'P', 'LastName': 'Klentrou', 'Affiliation': 'Brock University, Kinesiology, 1812 Sir Isaak Brock Way, L2S 3A1, St. Catharines, Ontario, Canada, L2S 3A1; nklentrou@brocku.ca.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Finelli', 'Affiliation': 'University Health Network, 7989, Toronto, Ontario, Canada; antonio.finelli@uhn.ca.'}, {'ForeName': 'Shabbir Mh', 'Initials': 'SM', 'LastName': 'Alibhai', 'Affiliation': 'University of Toronto, Medicine, 200 Elizabeth St, Room EN14-214, Toronto, Ontario, Canada, M5G 2C4; shabbir.alibhai@uhn.ca.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Santa Mina', 'Affiliation': 'University of Toronto, Kinesiology & Physical Education, 55 Harbord St., Toronto, Ontario, Canada, M5S 2W6; daniel.santamina@utoronto.ca.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2021-0365'] 2814,34379997,DHA-Rich Fish Oil Increases the Omega-3 Index in Healthy Adults and Slows Resting Heart Rate without Altering Cardiac Autonomic Reflex Modulation.,"Regular fish consumption, a rich source of long-chain omega-3 (ω-3) docosahexaenoic acid (DHA), modifies cardiac electrophysiology. However, human studies investigating fish oil and cardiac electrophysiology have predominantly supplemented therapeutic (high) doses of fish oil (often ω-3 eicosapentaenoic acid (EPA) rich sources). This study examined whether non-therapeutic doses of DHA-rich fish oil modulate cardiac electrophysiology at rest and during cardiovascular reflex challenges to the same extent, if at all, in young healthy adults. Participants (N = 20) were supplemented (double-blinded) with (2x1g.day -1 ) soy oil (Control n = 9) or DHA-rich tuna fish oil (FO n = 11) providing DHA: 560 mg and EPA: 140 mg. The Omega-3 Index (O3I; erythrocyte membrane % EPA + DHA), heart rate (HR) and HR variability (HRV) were analyzed during rest, maximal isometric handgrip and cold diving reflex challenges at baseline and following 8 weeks. The baseline O3I (Control: 5.1 ± 1.0; FO: 5.4 ± 0.9; P  > 0.05), resting HR (Control: 65 ± 12bpm; FO: 66 ± 8bpm; P  > 0.05) and HRV metrics did not significantly differ between the groups prior to supplementation. Relative to the control group, the O3I was increased (Control: 5.0 ± 1.1; FO: 7.8 ± 1.2; P  < 0.001), and resting HR was slowed in the FO group following supplementation (Control: 66 ± 9bpm; FO: 61 ± 6bpm; P =  0.046). However, no significant ( P  > 0.05) between-group differences were observed in HR responsiveness or any indices of HRV during reflex challenges. In young healthy adults, dietary achievable doses of ω-3 DHA-rich fish oil exerted a direct slowing effect on resting HR, without compromising the HR response to either dominant sympathetic or parasympathetic modulation.",2021,"Relative to the control group, the O3I was increased","['Healthy Adults', 'young healthy adults', 'Participants (N\u2009=\u200920']","['DHA-Rich Fish Oil', 'Regular fish consumption, a rich source of long-chain omega-3 (ω-3) docosahexaenoic acid (DHA', 'DHA-rich fish oil', 'soy oil (Control n\u2009=\u20099) or DHA-rich tuna fish oil (FO n\u2009=\u200911) providing DHA: 560\u2009mg and EPA']","['resting HR (Control', 'maximal isometric handgrip and cold diving reflex challenges', 'resting HR', 'HRV metrics', 'Omega-3 Index (O3I; erythrocyte membrane % EPA\u2009+\u2009DHA), heart rate (HR) and HR variability (HRV', 'HR responsiveness']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0016163', 'cui_str': 'Fish'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0037732', 'cui_str': 'Soybean Oil'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0041382', 'cui_str': 'Tuna'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0599289', 'cui_str': 'Reflex, Diving'}, {'cui': 'C0010343', 'cui_str': 'Croatia'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0014780', 'cui_str': 'Erythrocyte Cytoskeleton'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",,0.164389,"Relative to the control group, the O3I was increased","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Macartney', 'Affiliation': 'Graduate Medicine, School of Medicine, University of Wollongong, Wollongong, Australia.'}, {'ForeName': 'Mathew M', 'Initials': 'MM', 'LastName': 'Ghodsian', 'Affiliation': 'Graduate Medicine, School of Medicine, University of Wollongong, Wollongong, Australia.'}, {'ForeName': 'Bransen', 'Initials': 'B', 'LastName': 'Noel-Gough', 'Affiliation': 'Graduate Medicine, School of Medicine, University of Wollongong, Wollongong, Australia.'}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'McLennan', 'Affiliation': 'Graduate Medicine, School of Medicine, University of Wollongong, Wollongong, Australia.'}, {'ForeName': 'Gregory E', 'Initials': 'GE', 'LastName': 'Peoples', 'Affiliation': 'Graduate Medicine, School of Medicine, University of Wollongong, Wollongong, Australia.'}]",Journal of the American College of Nutrition,['10.1080/07315724.2021.1953417'] 2815,34384042,Comparing Smoking Cessation Interventions among Underserved Patients Referred for Lung Cancer Screening: A Pragmatic Trial Protocol.,"Smoking burdens are greatest among underserved patients. Lung cancer screening (LCS) reduces mortality among individuals at risk for smoking-associated lung cancer. Although LCS programs must offer smoking cessation support, the interventions that best promote cessation among underserved patients in this setting are unknown. This stakeholder-engaged, pragmatic randomized clinical trial (RCT) will compare the effectiveness of four interventions promoting smoking cessation among underserved patients referred for LCS. Using an additive study design, all four arms provide standard ""Ask-Advise-Refer"" care. Arm 2 adds free or subsidized pharmacologic cessation aids; Arm 3 adds financial incentives up to $600 for cessation; and Arm 4 adds a mobile device-delivered episodic future thinking tool to promote attention to long-term health goals. We hypothesize that smoking abstinence rates will be higher with the addition of each intervention when compared to Arm 1. We will enroll 3,200 adults with LCS orders at four United States health systems. Eligible patients include those who smoke at least one cigarette daily and self-identify as a member of an underserved group (i.e., Black or Latinx, a rural resident, completed a high school education or less, and/or with a household income <200% of the federal poverty line). The primary outcome is biochemically confirmed smoking abstinence sustained through 6 months. Secondary outcomes include abstinence sustained through 12 months, other smoking-related clinical outcomes, and patient-reported outcomes. This pragmatic RCT will identify the most effective smoking cessation strategies that LCS programs can implement to reduce smoking burdens affecting underserved populations. Clinical trial registered with ClinicalTrials.gov (NCT04798664). Date of registration: March 12, 2021. Date of trial launch: May 17, 2021.",2021,"This stakeholder-engaged, pragmatic randomized clinical trial (RCT) will compare the effectiveness of four interventions promoting smoking cessation among underserved patients referred for LCS.","['Eligible patients include those who smoke at least one cigarette daily and self-identify as a member of an underserved group (i.e., Black or Latinx, a rural resident, completed a high school education or less, and/or with a household income <200% of the federal poverty line', 'Underserved Patients Referred for Lung Cancer Screening', 'individuals at risk for smoking-associated lung cancer', 'underserved patients referred for LCS', 'underserved patients', '3,200 adults with LCS orders at four United States health systems']","['Smoking Cessation Interventions', 'Lung cancer screening (LCS']","['Smoking burdens', 'smoking abstinence rates', 'abstinence sustained through 12 months, other smoking-related clinical outcomes, and patient-reported outcomes', 'smoking abstinence sustained through 6 months']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0455002', 'cui_str': 'Education and schooling detail'}, {'cui': 'C0557163', 'cui_str': 'Household income'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0872319', 'cui_str': 'Patients, Underserved'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0281477', 'cui_str': 'Screening for malignant neoplasm of lung'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0281477', 'cui_str': 'Screening for malignant neoplasm of lung'}]","[{'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}]",3200.0,0.0912829,"This stakeholder-engaged, pragmatic randomized clinical trial (RCT) will compare the effectiveness of four interventions promoting smoking cessation among underserved patients referred for LCS.","[{'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kohn', 'Affiliation': 'University of Pennsylvania, Palliative and Advanced Illness Research (PAIR) Center, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Anil', 'Initials': 'A', 'LastName': 'Vachani', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Dylan', 'Initials': 'D', 'LastName': 'Small', 'Affiliation': 'The Wharton School, Department of Statistics, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Alisa J', 'Initials': 'AJ', 'LastName': 'Stephens-Shields', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Department of Biostatistics, Epidemiology and Informatics, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Sheu', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Palliative and Advanced Illness Research (PAIR) Center, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Vanessa L', 'Initials': 'VL', 'LastName': 'Madden', 'Affiliation': 'University of Pennsylvania, 6572, Palliative and Advanced Illness Research (PAIR) Center, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Brian A', 'Initials': 'BA', 'LastName': 'Bayes', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Palliative and Advanced Illness Research (PAIR) Center, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Marzana', 'Initials': 'M', 'LastName': 'Chowdhury', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Palliative and Advanced Illness Research (PAIR) Center, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Sadie', 'Initials': 'S', 'LastName': 'Friday', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Palliative and Advanced Illness Research (PAIR) Center, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Jannie', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Palliative and Advanced Illness Research (PAIR) Center, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Gould', 'Affiliation': 'Kaiser Permanente Bernard J Tyson School of Medicine, 547934, Department of Health Systems Science, Pasadena, California, United States.'}, {'ForeName': 'Mohamed H', 'Initials': 'MH', 'LastName': 'Ismail', 'Affiliation': 'Kaiser Permanente Southern California, 82579, Department of Preventive Medicine, Riverside, California, United States.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Creekmur', 'Affiliation': 'Kaiser Permanente Southern California, Department of Research and Evaluation, Pasadena, California, United States.'}, {'ForeName': 'Matthew A', 'Initials': 'MA', 'LastName': 'Facktor', 'Affiliation': 'Geisinger Heart Institute, Department of Thoracic Surgery, Danville, Pennsylvania, United States.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Collins', 'Affiliation': 'Geisinger Health System, 2780, Department of Psychiatry, Danville, Pennsylvania, United States.'}, {'ForeName': 'Kristina K', 'Initials': 'KK', 'LastName': 'Blessing', 'Affiliation': 'Geisinger Health System, 2780, Investigator Initiated Research Operations, Danville, Pennsylvania, United States.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Neslund-Dudas', 'Affiliation': 'Henry Ford Health System, 2971, Department of Public Health Sciences and Henry Ford Cancer Institute, Detroit, Michigan, United States.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Simoff', 'Affiliation': 'Henry Ford Health System, 2971, Department of Pulmonary and Critical Care Medicine and the Henry Ford Cancer Institute, Detroit, Michigan, United States.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Alleman', 'Affiliation': 'Henry Ford Health System, 2971, Department of Public Health Sciences and Henry Ford Cancer Institute, Detroit, Michigan, United States.'}, {'ForeName': 'Leonard H', 'Initials': 'LH', 'LastName': 'Epstein', 'Affiliation': 'University at Buffalo Jacobs School of Medicine and Biomedical Sciences, 12291, Department of Pediatrics, Buffalo, New York, United States.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Horst', 'Affiliation': 'Penn Medicine/Lancaster General Health Research Institute, Lancaster, Pennsylvania, United States.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Scott', 'Affiliation': 'The Center for Black Health & Equity, Durham, North Carolina, United States.'}, {'ForeName': 'Kevin G', 'Initials': 'KG', 'LastName': 'Volpp', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Departments of Medicine and Medical Ethics and Health Policy, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Halpern', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Palliative and Advanced Illness Research (PAIR) Center, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Joanna L', 'Initials': 'JL', 'LastName': 'Hart', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, 14640, Palliative and Advanced Illness Research (PAIR) Center, Philadelphia, Pennsylvania, United States.'}]",Annals of the American Thoracic Society,['10.1513/AnnalsATS.202104-499SD'] 2816,34384001,Central blood pressure lowering effect of telmisartan-rosuvastatin single-pill combination in hypertensive patients combined with dyslipidemia: A pilot study.,"This multicenter, phase 4, Prospective Randomized Open, Blinded End-point (PROBE) study aimed to evaluate safety and efficacy of telmisartan/rosuvastatin single-pill combination (SPC) therapy on lowering central blood pressure (BP) compared with telmisartan monotherapy in hypertensive patients with dyslipidemia in Korea. Study was terminated earlier than planned due to COVID-19 pandemic, thus should be considered as a pilot study. Among 125 patients who met the inclusion criteria of hypertension and dyslipidemia (defined as 10-year Atherosclerotic Cardiovascular Disease risk score over 5%), 80 patients went through 4-week single-group run-in period with telmisartan 40-80 mg, then randomized to telmisartan 80 mg + rosuvastatin (10 or 20 mg) SPC group or telmisartan 80 mg monotherapy group. The central/brachial BP, brachial-ankle pulse wave velocity (baPWV), and augmentation index (AIx) were assessed at baseline and 16 weeks later. Mean brachial SBP changed from 135.80 ± 14.22 mmHg to 130.69 ± 13.23 mmHg in telmisartan/rosuvastatin group and from 134.37 ± 12.50 mmHg to 133.75 ± 12.30 mmHg in telmisartan monotherapy group without significant difference (between-group difference p = .149). Mean central SBP were reduced significantly in the telmisartan/rosuvastatin group with change from 126.72 ± 14.44 mmHg to 121.56 ± 14.56 mmHg while telmisartan monotherapy group showed no significant change (between-group difference p = .028). BaPWV changed from 1672.57 ± 371.72 m/s to 1591.75 ± 272.16 m/s in telmisartan/rosuvastatin group and from 1542.85 ± 263.70 m/s to 1586.12 ± 297.45 m/s in telmisartan group with no significance (between-group difference p = .078). Change of AIx had no significant difference (between-group difference p = .314). Both groups showed excellent compliance rate of 96.9 ± 4.5% with no significant difference in adverse rate. Telmisartan/rosuvastatin SPC therapy was more effective in lowering central BP compared with the telmisartan monotherapy. The results of this study showed benefit of additive statin therapy in hypertensive patients combined with dyslipidemia.",2021,Telmisartan/rosuvastatin SPC therapy was more effective in lowering central BP compared with the telmisartan monotherapy.,"['125 patients who met the inclusion criteria of hypertension and dyslipidemia (defined as 10-year Atherosclerotic Cardiovascular Disease risk score over 5%), 80 patients went through 4-week single-group run-in period with', 'hypertensive patients with dyslipidemia in Korea', 'hypertensive patients combined with dyslipidemia']","['telmisartan/rosuvastatin', 'Telmisartan/rosuvastatin SPC therapy', 'additive statin therapy', 'telmisartan', 'telmisartan/rosuvastatin single-pill combination (SPC) therapy', 'telmisartan monotherapy', 'telmisartan-rosuvastatin single-pill combination', 'telmisartan 80\xa0mg + rosuvastatin']","['Mean brachial SBP', 'central/brachial BP, brachial-ankle pulse wave velocity (baPWV), and augmentation index (AIx', 'lowering central BP', 'excellent compliance rate', 'lowering central blood pressure (BP', 'adverse rate', 'Mean central SBP']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0022771', 'cui_str': 'Korea'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0248719', 'cui_str': 'telmisartan'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0442796', 'cui_str': 'Additive'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0990503', 'cui_str': 'telmisartan 80 MG'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232154', 'cui_str': 'Ankle pulse'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",125.0,0.032329,Telmisartan/rosuvastatin SPC therapy was more effective in lowering central BP compared with the telmisartan monotherapy.,"[{'ForeName': 'JungMin', 'Initials': 'J', 'LastName': 'Choi', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Ki-Chul', 'Initials': 'KC', 'LastName': 'Sung', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, School of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Republic of Korea.'}, {'ForeName': 'Sang-Hyun', 'Initials': 'SH', 'LastName': 'Ihm', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.'}, {'ForeName': 'Chang-Hwan', 'Initials': 'CH', 'LastName': 'Yoon', 'Affiliation': 'Cardiovascular Center & Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.'}, {'ForeName': 'Seung Woo', 'Initials': 'SW', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Department of Medicine, Samsung Medical Center, Heart Vascular Stroke Institute, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sung-Ha', 'Initials': 'SH', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jang-Young', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Department of Cardiology, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea.'}, {'ForeName': 'Sung-Uk', 'Initials': 'SU', 'LastName': 'Kwon', 'Affiliation': 'Department of Medicine, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea.'}, {'ForeName': 'Hae-Young', 'Initials': 'HY', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.'}]","Journal of clinical hypertension (Greenwich, Conn.)",['10.1111/jch.14345'] 2817,34384000,"Bioequivalence Assessment of an Oral Fixed-Dose Formulation of Dutasteride-Tamsulosin 0.5 mg/0.4 mg: A Randomized, Single-Blind, Single-Dose, 2-Period Crossover Study in Mexican Population Under Fasted Conditions.","The aim of the present study was to compare the bioavailability and to demonstrate the bioequivalence between a dutasteride-tamsulosin 0.5 mg/0.4 mg capsule formulation and the regulatory reference drug (Combodart®, GlaxoSmithKline). A randomized, single-blind, single-dose, 2-way crossover study under fasting conditions, with at least a 28-day washout period was carried out in healthy volunteers. Plasma concentrations of drugs were determined by high-performance liquid chromatography-tandem mass spectrometry. The pharmacokinetic analysis included maximum plasma concentration (C max ), area under the plasma concentration-time curve (AUC) from time 0 to 72 hours, and AUC from baseline to infinity. The test formulation was considered bioequivalent if the geometric mean ratios (test/reference) were within the predetermined range of 80% to 125%. Safety and tolerability were evaluated by clinical assessment. The confidence intervals for the log-transformed test/reference ratios for dutasteride, C max (95.4-109.2) and AUC from baseline to 72 hours (93.2-109.1), and for tamsulosin, C max (101.9-119.8), AUC from baseline to the last quantifiable concentration (91.4-106.3) and AUC from baseline to infinity (90.9-103.3), were within the allowed limit specified by the regulatory authorities (80%-125%). In addition, both test and reference drugs were safe and tolerated. These results demonstrated the bioequivalence of test product (Dakart®) compared with Combodart®.",2021,These results demonstrated the bioequivalence of test product (Dakart®) compared with Combodart®.,"['healthy volunteers', 'Mexican Population Under Fasted Conditions']","['Dutasteride-Tamsulosin', 'dutasteride-tamsulosin']","['safe and tolerated', 'bioavailability', 'Safety and tolerability', 'maximum plasma concentration (C max ), area under the plasma concentration-time curve (AUC) from time 0 to 72 hours, and AUC']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C2926870', 'cui_str': 'tamsulosin and dutasteride'}]","[{'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",,0.095281,These results demonstrated the bioequivalence of test product (Dakart®) compared with Combodart®.,"[{'ForeName': 'Everardo', 'Initials': 'E', 'LastName': 'Piñeyro-Garza', 'Affiliation': 'Ipharma, S.A. de C.V., Colonia Mitras Centro, Monterrey, Nuevo León, México.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Gómez-Silva', 'Affiliation': 'Ipharma, S.A. de C.V., Colonia Mitras Centro, Monterrey, Nuevo León, México.'}, {'ForeName': 'María E', 'Initials': 'ME', 'LastName': 'Gamino', 'Affiliation': 'Ipharma, S.A. de C.V., Colonia Mitras Centro, Monterrey, Nuevo León, México.'}, {'ForeName': 'Livan', 'Initials': 'L', 'LastName': 'Delgado-Roche', 'Affiliation': 'Laboratorios Liomont, S.A. de C.V., Colonia Cuajimalpa, Cuajimalpa de Morelos, Ciudad de México, México.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.1011'] 2818,34383972,Validation of the scored Patient-Generated Subjective Global Assessment short form (PG-SGA SF) as a prognostic tool for incurable cancer patients.,"BACKGROUND & AIM The Patient-Generated Subjective Global Assessment short form (PG-SGA SF) is a standardized tool for assessing nutritional risk in patients with cancer. The aim of this study was to propose and validate a cutoff point for the PG-SGA SF score related to the prognosis of patients with incurable cancer in exclusive palliative care. METHODS This data analysis is from a prospective cohort study carried out patients with incurable cancer at the National Cancer Institute in Brazil. A total sample (n = 2,144) was randomly divided into groups: (A) training (n = 1,072), to determine the most accurate PG-SGA SF cutoff; and (B) validation (n = 1,072), to test the predictive accuracy of this cutoff point. The receiver operating characteristic (ROC) curve was plotted to determine the best cutoff point of the PG-SGA SF related to death. Concordance statistics (c-statistic) were used to test the predictive accuracy of the models. Kaplan Meier's curve and the Cox hazard model were used to verify a prognostic value of the cutoff point. RESULTS PG-SGA SF score ≥15 was found to be the best cutoff based on 90-day mortality with good accuracy discrimination (C-statistic ≥0.74). Patients whose PG-SGA SF score ≥15 had a shorter survival of 32 days (interquartile range, IQR: 12-75) vs. 83 days (IQR: 31-90), p-value <0.001, and higher risk of death (hazard ratio: 2.20; 95% CI: 1.64-2.95). CONCLUSIONS The proposed PG-SGA SF cutoff score is valid and alongside its usefulness in nutritional triage, it could provide prognostic value for patients with incurable cancer. CLINICAL RELEVANCY STATEMENT Patients with incurable cancer in palliative care are often undernourished, and have shortened overall survival. As nutritional status in constantly evaluated in these patients, tools commonly used could also have prognostic value, broadening their applicability. PG-SGA is a validated tool for patients with cancer, and alongside its usefulness in screening for nutritional risk, it could provide prognostic value, guiding interventions better suited to each patient. This article is protected by copyright. All rights reserved.",2021,"PG-SGA is a validated tool for patients with cancer, and alongside its usefulness in screening for nutritional risk, it could provide prognostic value, guiding interventions better suited to each patient.","['Patients with incurable cancer in palliative care', 'A total sample (n = 2,144) was randomly divided into groups', 'patients with incurable cancer', 'patients with incurable cancer in exclusive palliative care', 'patients with incurable cancer at the National Cancer Institute in Brazil', 'incurable cancer patients', 'patients with cancer']","['Subjective Global Assessment short form (PG-SGA SF', 'scored Patient-Generated Subjective Global Assessment short form (PG-SGA SF', 'PG-SGA']","['shorter survival', 'risk of death', 'receiver operating characteristic (ROC) curve']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0451514', 'cui_str': 'Subjective global assessment'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",2144.0,0.158981,"PG-SGA is a validated tool for patients with cancer, and alongside its usefulness in screening for nutritional risk, it could provide prognostic value, guiding interventions better suited to each patient.","[{'ForeName': 'Marcela Souza', 'Initials': 'MS', 'LastName': 'Cunha', 'Affiliation': 'Nutritionist, Postgraduate Program in Oncology, José Alencar Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Emanuelly Varea Maria', 'Initials': 'EVM', 'LastName': 'Wiegert', 'Affiliation': 'Nutritionist, Palliative Care Unit, José Alencar Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazi.'}, {'ForeName': 'Larissa Calixto', 'Initials': 'LC', 'LastName': 'Lima', 'Affiliation': 'Nutritionist, Palliative Care Unit, José Alencar Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazi.'}, {'ForeName': 'Livia Costa', 'Initials': 'LC', 'LastName': 'de Oliveira', 'Affiliation': 'Nutritionist, Palliative Care Unit, José Alencar Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazi.'}]",JPEN. Journal of parenteral and enteral nutrition,['10.1002/jpen.2251'] 2819,34383958,Exoskeleton gait training to improve lower urinary tract function in people with motor-complete spinal cord injury: A randomized pilot trial.,"OBJECTIVE The primary aim of this study was to determine the feasibility of delivering an exoskeleton-assisted walking intervention targeting lower urinary tract function in people with motor-complete spinal cord injury. Secondary aims were to determine if exoskeleton walking activates the pelvic floor muscles, and compare 2 exoskeleton programmes regarding lower urinary tract function. DESIGN Randomized pilot trial. SUBJECTS Adults with motor-complete spinal cord injury at or above T10. METHODS Participants were randomized to receive Ekso or Lokomat training. Feasibility outcomes included recruitment rate, adherence, and adverse events. Pelvic floor muscle electromyography was recorded during walking. Urodynamic studies, 3-day bladder diary, and Qualiveen-30 were administered pre- and post-training. RESULTS Twelve people were screened and 6 people enrolled in the study. Two subjects withdrew from unrelated reasons. There was one adverse event. Pelvic floor muscle activity was greater in the Ekso group. Lower urinary tract function did not clearly change in either group. CONCLUSION This pilot study demonstrates the feasibility of delivering an exoskeleton training programme targeting lower urinary tract function. Ekso-walking elicits pelvic floor muscle activity, but it remains unclear how locomotor training impacts lower urinary tract function.",2021,Pelvic floor muscle activity was greater in the Ekso group.,"['people with motor-complete spinal cord injury', 'Twelve people were screened and 6 people enrolled in the study', 'Adults with motor-complete spinal cord injury at or above T10', 'Participants']","['exoskeleton-assisted walking intervention', 'Ekso or Lokomat training', 'Exoskeleton gait training', 'exoskeleton training programme']","['Urodynamic studies, 3-day bladder diary, and Qualiveen-30', 'recruitment rate, adherence, and adverse events', 'urinary tract function', 'Pelvic floor muscle electromyography', 'Lower urinary tract function', 'Pelvic floor muscle activity']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3544168', 'cui_str': 'Complete spinal cord injury'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}]","[{'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0430970', 'cui_str': 'Urinary frequency volume chart'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042031', 'cui_str': 'Urinary tract function'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0729866', 'cui_str': 'Lower urinary tract structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",12.0,0.0569221,Pelvic floor muscle activity was greater in the Ekso group.,"[{'ForeName': 'Alison M M', 'Initials': 'AMM', 'LastName': 'Williams', 'Affiliation': 'Kinesiology, University of British Columbia, Vancouver, Canada. E-mail: awilliams@icord.org.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Deegan', 'Affiliation': ''}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Walter', 'Affiliation': ''}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Stothers', 'Affiliation': ''}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Lam', 'Affiliation': ''}]",Journal of rehabilitation medicine,['10.2340/16501977-2864'] 2820,34383954,"Rationale, design, demographics, and baseline characteristics of the randomised, controlled, phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia.","BACKGROUND Verinurad is a human uric acid transporter (URAT1) inhibitor known to decrease serum uric acid (sUA) levels and may reduce albuminuria. In a Phase 2a study (NCT03118739), treatment with verinurad + febuxostat lowered urine albumin-to-creatinine ratio (UACR) at 12 weeks by 39% (90% confidence interval: 4%, 62%) among patients with type 2 diabetes mellitus, hyperuricaemia and albuminuria. The Phase 2 b, randomised, placebo-controlled Study of verinurAd and alloPurinol in Patients with cHronic kIdney disease and hyperuRicaEmia (SAPPHIRE; NCT03990363) will examine the effect of verinurad + allopurinol on albuminuria and estimated glomerular filtration rate (eGFR) slope among patients with chronic kidney disease (CKD) and hyperuricaemia. METHODS Adults (≥18 years of age) with CKD, eGFR ≥25 mL/min/1.73 m2, UACR 30-5000 mg/g and sUA ≥6.0 mg/dL will be enrolled. Approximately 725 patients will be randomised 1:1:1:1:1 to 12, 7.5 or 3 mg verinurad + allopurinol, allopurinol or placebo. An 8-week dose-titration period will precede a 12-month treatment period; verinurad dose will be increased to 24 mg at month 9 in a subset of patients in the 3 mg verinurad + allopurinol arm. The primary efficacy endpoint is change from baseline in UACR at 6 months. Secondary efficacy endpoints include changes in UACR, eGFR and sUA from baseline at 6 and 12 months. CONCLUSIONS This study will assess the combined clinical effect of verinurad + allopurinol on kidney function in patients with CKD, hyperuricaemia and albuminuria, and whether this combination confers renoprotection beyond standard-of-care.",2021,"BACKGROUND Verinurad is a human uric acid transporter (URAT1) inhibitor known to decrease serum uric acid (sUA) levels and may reduce albuminuria.","['Adults (≥18\u2009years of age) with CKD, eGFR ≥25', 'patients with CKD, hyperuricaemia and albuminuria', 'patients with chronic kidney disease and hyperuricaemia', 'patients with chronic kidney disease (CKD', 'Patients with cHronic kIdney disease and hyperuRicaEmia', 'Approximately 725 patients']","['verinurAd and alloPurinol', 'allopurinol, allopurinol or placebo', 'verinurad + allopurinol', 'placebo', 'allopurinol']","['serum uric acid (sUA) levels', 'albuminuria and estimated glomerular filtration rate (eGFR) slope', 'changes in UACR, eGFR and sUA', 'kidney function', 'urine albumin-to-creatinine ratio (UACR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0740394', 'cui_str': 'Hyperuricemia'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}]","[{'cui': 'C4519235', 'cui_str': 'verinurad'}, {'cui': 'C0002144', 'cui_str': 'Allopurinol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0455272', 'cui_str': 'Serum urate measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0042038', 'cui_str': 'Albumin urine'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}]",,0.113636,"BACKGROUND Verinurad is a human uric acid transporter (URAT1) inhibitor known to decrease serum uric acid (sUA) levels and may reduce albuminuria.","[{'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Austin G', 'Initials': 'AG', 'LastName': 'Stack', 'Affiliation': 'School of Medicine & Health Research Institute, University of Limerick, Limerick, Ireland.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Terkeltaub', 'Affiliation': 'San Francisco VA Health Care System, University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Tom A', 'Initials': 'TA', 'LastName': 'Greene', 'Affiliation': 'University of Utah School of Medicine, Salt Lake City, UT, USA.'}, {'ForeName': 'Lesley A', 'Initials': 'LA', 'LastName': 'Inker', 'Affiliation': 'Tufts Medical Center, Boston, MA, USA.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Bjursell', 'Affiliation': 'AstraZeneca R&D Gothenburg, Mölndal, Sweden.'}, {'ForeName': 'Shira', 'Initials': 'S', 'LastName': 'Perl', 'Affiliation': 'AstraZeneca R&D, Gaithersburg, MD, USA.'}, {'ForeName': 'Tord', 'Initials': 'T', 'LastName': 'Rikte', 'Affiliation': 'AstraZeneca R&D Gothenburg, Mölndal, Sweden.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Erlandsson', 'Affiliation': 'AstraZeneca R&D Gothenburg, Mölndal, Sweden.'}, {'ForeName': 'Vlado', 'Initials': 'V', 'LastName': 'Perkovic', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association",['10.1093/ndt/gfab237'] 2821,34383903,"Pecan-Enriched Diets Alter Cholesterol Profiles and Triglycerides in Adults at Risk for Cardiovascular Disease in a Randomized, Controlled Trial.","BACKGROUND Research indicates that tree nuts are cardioprotective, but studies on pecans are limited. OBJECTIVES We examined the impact of daily pecan consumption on blood lipids and glycemia in adults at-risk for cardiovascular disease (CVD). METHODS This was a randomized, controlled trial where 56 adults (BMI ≥28 kg/m2 or hypercholesterolemia) were randomly allocated into a control group (n = 18) or 1 of 2 pecan groups. The ADD group (n = 16) consumed pecans (68 g) as part of a free-living diet. The SUB group (n = 18) substituted the pecans (68 g) for isocaloric foods from their diet. At baseline and 8 wk, a high-fat meal was consumed with 4-h postprandial blood draws to determine changes in blood lipids and glycemia. RESULTS There was a significant reduction from baseline to 8 wk in fasting total cholesterol (TC) (204 ± 8.76 to 195 ± 8.12; 205 ± 8.06 to 195 ± 6.94 mg/dL), LDL cholesterol (143 ± 8.09 to 129 ± 7.71; 144 ± 6.60 to 135 ± 6.16 mg/dL), triglycerides (TGs) (139 ± 12.1 to 125 ± 14.6; 133 ± 10.7 to 120 ± 10.3 mg/dL), TC/HDL cholesterol ratio (3.92 ± 0.206 to 3.58 ± 0.175; 4.08 ± 0.167 to 3.79 ± 0.151), non-HDL cholesterol (151 ± 8.24 to 140 ± 7.95; 155 ± 6.87 to 143 ± 6.00 mg/dL), and apolipoprotein B (99.1 ± 5.96 to 93.0 ± 5.35; 104 ± 3.43 to 97.1 ± 3.11 mg/dL) in the ADD and SUB groups, respectively (P ≤ 0.05 for all), with no changes in control. There was a reduction in postprandial TGs (P ≤ 0.01) in ADD, and a reduction in postprandial glucose (P < 0.05) in SUB. CONCLUSIONS Pecan consumption improves fasting and postprandial blood lipids in CVD at-risk adults. This trial was registered at clinicaltrials.gov as NCT04376632.",2021,"There was a reduction in postprandial TGs (P ≤ 0.01) in ADD, and a reduction in postprandial glucose (P < 0.05) in SUB. ","['Adults at Risk for Cardiovascular Disease', 'adults at-risk for cardiovascular disease (CVD', '56 adults (BMI ≥28\xa0kg/m2 or hypercholesterolemia', 'CVD at-risk adults']","['Pecan-Enriched Diets', 'daily pecan consumption', 'Pecan consumption']","['TC/HDL cholesterol ratio', 'blood lipids and glycemia', 'non-HDL cholesterol', 'LDL cholesterol', 'fasting and postprandial blood lipids', 'postprandial TGs', 'apolipoprotein B', 'postprandial glucose', 'fasting total cholesterol (TC']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0020443', 'cui_str': 'Hypercholesterolemia'}]","[{'cui': 'C0946601', 'cui_str': 'Carya illinoinensis'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0003593', 'cui_str': 'Apolipoprotein B'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}]",56.0,0.407432,"There was a reduction in postprandial TGs (P ≤ 0.01) in ADD, and a reduction in postprandial glucose (P < 0.05) in SUB. ","[{'ForeName': 'Liana L', 'Initials': 'LL', 'LastName': 'Guarneiri', 'Affiliation': 'Department of Nutritional Sciences, University of Georgia, Athens, GA, USA.'}, {'ForeName': 'Chad M', 'Initials': 'CM', 'LastName': 'Paton', 'Affiliation': 'Department of Nutritional Sciences, University of Georgia, Athens, GA, USA.'}, {'ForeName': 'Jamie A', 'Initials': 'JA', 'LastName': 'Cooper', 'Affiliation': 'Department of Nutritional Sciences, University of Georgia, Athens, GA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxab248'] 2822,34383762,Prevalence and factors associated with experience of corporal punishment in public schools in South Africa.,"BACKGROUND Corporal punishment (CP) is still a common practice in schools globally. Although illegal, studies in South Africa report its continued use, but only a few have explored factors associated with school CP. Moreover, extant studies have not shown the interrelationships between explanatory factors. This study aimed to determine the prevalence and factors associated with learners' experiences, and to examine pathways to the learners' experiences of CP at school. METHOD 3743 grade 8 learners (2118 girls and 1625 boys) from 24 selected public schools in Tshwane, South Africa, enrolled in a cluster randomised controlled trial evaluating a multi-component school-based intervention to prevent intimate partner violence, and completed self-administered questionnaires. We carried out descriptive analysis, simple linear and structural equation modelling to examine factors and pathways to the learners' experience of CP at school. RESULTS About 52% of learners had experienced CP at school in the last 6 months. It was higher among boys compared to girls. Experience of CP at school amongst learners was associated with learner behavior, home environment, and school environment. Learners from households with low-socio economic status (SES) had an increased risk of CP experience at school. Amongst boys, low family SES status was associated with a negative home environment and had a direct negative impact on a learner's mental health, directly associated with misbehavior. CONCLUSION CP in public schools in South Africa continues despite legislation prohibiting its use. While addressing learner behaviour is critical, evidence-based interventions addressing home and school environment are needed to change the culture among teachers of using corporal punishment to discipline adolescents and inculcate one that promotes positive discipline.",2021,"Amongst boys, low family SES status was associated with a negative home environment and had a direct negative impact on a learner's mental health, directly associated with misbehavior. ","['public schools in South Africa', '3743 grade 8 learners (2118 girls and 1625 boys) from 24 selected public schools in Tshwane, South Africa', 'Learners from households with low-socio economic status (SES']","['multi-component school-based intervention to prevent intimate partner violence, and completed self-administered questionnaires', 'Corporal punishment (CP']",['risk of CP experience'],"[{'cui': 'C0557800', 'cui_str': 'Public school'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C4521398', 'cui_str': 'US Military enlisted E4'}, {'cui': 'C0006912', 'cui_str': 'Death Penalty'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C4521398', 'cui_str': 'US Military enlisted E4'}, {'cui': 'C0006912', 'cui_str': 'Death Penalty'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",,0.0426883,"Amongst boys, low family SES status was associated with a negative home environment and had a direct negative impact on a learner's mental health, directly associated with misbehavior. ","[{'ForeName': 'Pinky', 'Initials': 'P', 'LastName': 'Mahlangu', 'Affiliation': 'Gender & Health Research Unit, South African Medical Research Council, Pretoria, South Africa.'}, {'ForeName': 'Esnat', 'Initials': 'E', 'LastName': 'Chirwa', 'Affiliation': 'Gender & Health Research Unit, South African Medical Research Council, Pretoria, South Africa.'}, {'ForeName': 'Mercilene', 'Initials': 'M', 'LastName': 'Machisa', 'Affiliation': 'Gender & Health Research Unit, South African Medical Research Council, Pretoria, South Africa.'}, {'ForeName': 'Yandisa', 'Initials': 'Y', 'LastName': 'Sikweyiya', 'Affiliation': 'Gender & Health Research Unit, South African Medical Research Council, Pretoria, South Africa.'}, {'ForeName': 'Nwabisa', 'Initials': 'N', 'LastName': 'Shai', 'Affiliation': 'Gender & Health Research Unit, South African Medical Research Council, Pretoria, South Africa.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Jewkes', 'Affiliation': 'Gender & Health Research Unit, South African Medical Research Council, Pretoria, South Africa.'}]",PloS one,['10.1371/journal.pone.0254503'] 2823,34383632,Aerobic Versus Resistance Training: Leptin and Metabolic Parameters Improvement in Type 2 Diabetes Obese Men.,"Purpose : The purpose of the research was to determine the changes in metabolic parameters, leptin, and irisin levels after aerobic and resistance training in type-2 diabetes obese men. Methods : Forty-five participants in the age range of 17-25 years were randomized into three groups: aerobic training (AT), resistance training (RT), and control (CO). All training sessions were fulfilled 4 days per week for two months. The aerobic training began with intensity of 65% of the maximum aerobic power and finished with 90%. The resistance program started with 50% of one-repetition maximum and reached 70% in the 8th week. Results : Factorial analysis of variance and Bonferroni post-hoc test revealed significant decreases in leptin ( p = .043), fasting blood sugar (FBS) ( p = .023), insulin ( p = .001), homeostasis model assessment for insulin resistance (HOMA-IR) ( p = .022) in AT compared with CO and insulin ( p = .006) in AT compared with RT. The change of percent body fat (PBF) was positively correlated only with change of HOMA-IR in AT group ( p = .032) at p < .05. Conclusion : The result suggests that, compared to resistance training, aerobic training can control metabolic situations such as insulin resistance through the leptin hormone function, and not irisin in type-2 diabetes obese men.",2021,"Factorial analysis of variance and Bonferroni post-hoc test revealed significant decreases in leptin ( p = .043), fasting blood sugar (FBS) ( p = .023), insulin ( p = .001), homeostasis model assessment for insulin resistance (HOMA-IR) ( p = .022) in AT compared with CO and insulin ( p = .006) in AT compared with RT.","['type-2 diabetes obese men', 'Type 2 Diabetes Obese Men', 'Methods : Forty-five participants in the age range of 17-25\xa0years']","['aerobic training', 'aerobic training (AT), resistance training (RT), and control (CO', 'aerobic and resistance training', 'Aerobic Versus Resistance Training: Leptin']","['homeostasis model assessment for insulin resistance (HOMA-IR', 'change of percent body fat (PBF', 'metabolic parameters, leptin, and irisin levels', 'fasting blood sugar (FBS', 'HOMA-IR', 'leptin']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0299583', 'cui_str': 'leptin'}]","[{'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C3495427', 'cui_str': 'Fanconi-Bickel Syndrome'}]",,0.0141243,"Factorial analysis of variance and Bonferroni post-hoc test revealed significant decreases in leptin ( p = .043), fasting blood sugar (FBS) ( p = .023), insulin ( p = .001), homeostasis model assessment for insulin resistance (HOMA-IR) ( p = .022) in AT compared with CO and insulin ( p = .006) in AT compared with RT.","[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Rezaeeshirazi', 'Affiliation': 'Islamic Azad University.'}]",Research quarterly for exercise and sport,['10.1080/02701367.2021.1875111'] 2824,34383607,Acute Caffeine Intake Reduces Perceived Exertion But Not Muscle Pain during Moderate Intensity Cycling Exercise in Women with Fibromyalgia.,"OBJECTIVE Exacerbated perceived exertion and muscle pain responses during exercise might limit physical activity practice in fibromyalgia patients. Thus, nutritional strategies that can reduce perceived exertion and muscle pain during exercise in fibromyalgia patients would be useful. The purpose of this study was to investigate the effects of acute caffeine intake on the perceptions of exertion and muscle pain during a moderate intensity exercise in women with fibromyalgia. Method: Using a randomized, double-blinded, placebo-controlled and crossover experimental design, eleven sedentary women diagnosed with fibromyalgia (age: 44.6 ± 10.5 years; body mass index: 28.5 ± 4.5 kg.m -2 ) ingested a capsule containing either caffeine (5 mg per kg of body mass) or cellulose (placebo), 60 minutes before performing a 30-minute constant-load cycling exercise, with work rate fixed at 50% of their individual peak workload attained in an incremental exercise test. Ratings of perceived leg muscle pain and perceived exertion were assessed every 5 minutes of exercise. Results: The perceived leg muscle pain was similar (F (1,10) = 1.18, p = 0.30, ŋ 2 = 0.11) between caffeine (2.1 ± 1.2 arbitrary units) and placebo conditions (2.2 ± 0.9 arbitrary units). The perceived exertion, however, was on average 8 ± 6% lower (F (1,10) = 12.13; p = 0.006; ŋ 2 = 0.55) during exercise in the caffeine condition (12.4 ± 1.3 arbitrary units) than in the placebo condition (13.1 ± 1.1 arbitrary units). Conclusions: These findings indicate that acute caffeine intake could be an attractive strategy to attenuate the exacerbated perceived exertion of fibromyalgia patients during moderate intensity exercise.",2021,"The perceived leg muscle pain was similar (F (1,10) = 1.18, p = 0.30, ŋ 2 = 0.11) between caffeine (2.1 ± 1.2 arbitrary units) and placebo conditions (2.2 ± 0.9 arbitrary units).","['women with fibromyalgia', 'Women with Fibromyalgia', 'eleven sedentary women diagnosed with fibromyalgia (age: 44.6\u2009±\u200910.5\u2009years; body mass index: 28.5\u2009±\u20094.5\u2009kg.m -2 ) ingested a', 'fibromyalgia patients']","['capsule containing either caffeine (5\u2009mg per kg of body mass) or cellulose (placebo), 60\u2009minutes before performing a 30-minute constant-load cycling exercise, with work rate fixed at 50% of their individual peak workload attained in an incremental exercise test', 'acute caffeine intake', 'Moderate Intensity Cycling Exercise', 'Acute Caffeine Intake', 'caffeine', 'placebo']","['Exertion', 'leg muscle pain', 'Ratings of perceived leg muscle pain and perceived exertion']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517521', 'cui_str': '10.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517678', 'cui_str': '28.5'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0007648', 'cui_str': 'Cellulose'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0224456', 'cui_str': 'Skeletal muscle structure of lower leg'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",11.0,0.102752,"The perceived leg muscle pain was similar (F (1,10) = 1.18, p = 0.30, ŋ 2 = 0.11) between caffeine (2.1 ± 1.2 arbitrary units) and placebo conditions (2.2 ± 0.9 arbitrary units).","[{'ForeName': 'Julio Cezar', 'Initials': 'JC', 'LastName': 'Schamne', 'Affiliation': 'Human Performance Research Group, Academic Department of Physical Education, Federal University of Technology - Parana (UTFPR), Curitiba, Brazil.'}, {'ForeName': 'Juliana Campos', 'Initials': 'JC', 'LastName': 'Ressetti', 'Affiliation': 'Department of Physical Education, State University of Ponta Grossa (UEPG), Ponta Grossa, Brazil.'}, {'ForeName': 'Romulo', 'Initials': 'R', 'LastName': 'Bertuzzi', 'Affiliation': 'Endurance Performance Research Group (GEDAE-USP), University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Nilo Massaru', 'Initials': 'NM', 'LastName': 'Okuno', 'Affiliation': 'Department of Physical Education, State University of Ponta Grossa (UEPG), Ponta Grossa, Brazil.'}, {'ForeName': 'Adriano Eduardo', 'Initials': 'AE', 'LastName': 'Lima-Silva', 'Affiliation': 'Human Performance Research Group, Academic Department of Physical Education, Federal University of Technology - Parana (UTFPR), Curitiba, Brazil.'}]",Journal of the American College of Nutrition,['10.1080/07315724.2021.1958102'] 2825,34383578,Reasonable Attempt at a Randomized Trial in Relapsed Rhabdomyosarcoma.,,2021,,[],[],[],[],[],[],,0.11121,,"[{'ForeName': 'Abha A', 'Initials': 'AA', 'LastName': 'Gupta', 'Affiliation': 'Division of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.21.01631'] 2826,34383540,Metacognitive interpersonal therapy in group versus TAU + waiting list for young adults with personality disorders: Randomized clinical trial.,"Young adults presenting with personality disorders (PDs) featuring overcontrol and social inhibition urgently require effective psychological interventions to help them navigate important life transitions. metacognitive interpersonal therapy-group (MIT-G) is a time-limited group program designed to enable individuals to find adaptive solutions to their social difficulties. A small randomized clinical trial (RCT) of MIT-G versus treatment as usual (TAU) was conducted with the primary outcomes of improvements in social and interpersonal functioning and global psychological symptoms. Secondary outcomes were specific symptoms of anxiety and depression and changes in alexithymia and emotion dysregulation. From 40 participants, 20 were randomized to 16 weekly sessions of MIT-G, plus 3 individual sessions and 20 to TAU + waiting list. All 20 patients allocated to MIT-G completed treatments, while 2 dropped-out in the TAU arm. Patients in the MIT-G arm reported significant improvements on primary outcomes of functioning, interpersonal problems and global symptoms of medium magnitude, medium effect sizes for changes in depression and anxiety, and large magnitude changes for alexithymia. However, other than alexithymia no significant differences were observed between groups at treatment end. A Time × Condition interaction, indicated that MIT-G was associated with more rapid and larger magnitude improvements in functioning and alexithymia. MIT-G is a well-tolerated treatment option for young adults with overcontrolled PD. Further effectiveness studies in larger samples are underway. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Patients in the MIT-G arm reported significant improvements on primary outcomes of functioning, interpersonal problems and global symptoms of medium magnitude, medium effect sizes for changes in depression and anxiety, and large magnitude changes for alexithymia.","['Young adults presenting with personality disorders (PDs', 'young adults with personality disorders', 'young adults with overcontrolled PD']","['MIT-G, plus 3 individual sessions and 20 to TAU + waiting list', 'TAU + waiting list', 'Metacognitive interpersonal therapy', 'MIT-G', 'metacognitive interpersonal therapy-group (MIT-G']","['social and interpersonal functioning and global psychological symptoms', 'specific symptoms of anxiety and depression and changes in alexithymia and emotion dysregulation', 'functioning and alexithymia', 'functioning, interpersonal problems and global symptoms of medium magnitude, medium effect sizes for changes in depression and anxiety, and large magnitude changes for alexithymia']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0031212', 'cui_str': 'Personality disorder'}]","[{'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0002020', 'cui_str': 'Alexithymia'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0449286', 'cui_str': 'Degree'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",20.0,0.059797,"Patients in the MIT-G arm reported significant improvements on primary outcomes of functioning, interpersonal problems and global symptoms of medium magnitude, medium effect sizes for changes in depression and anxiety, and large magnitude changes for alexithymia.","[{'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'Popolo', 'Affiliation': 'Centro di Terapia Metacognitiva Interpersonale.'}, {'ForeName': 'Angus', 'Initials': 'A', 'LastName': 'MacBeth', 'Affiliation': 'School of Health in Social Science.'}, {'ForeName': 'Luana', 'Initials': 'L', 'LastName': 'Lazzerini', 'Affiliation': 'Studi Cognitivi.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Brunello', 'Affiliation': 'Unity for Clinical Psychology.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Venturelli', 'Affiliation': 'Unity for Clinical Psychology.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Rebecchi', 'Affiliation': 'Studi Cognitivi.'}, {'ForeName': 'Maria Francisca', 'Initials': 'MF', 'LastName': 'Morales', 'Affiliation': 'School of Health in Social Science.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Dimaggio', 'Affiliation': 'Centro di Terapia Metacognitiva Interpersonale.'}]",Personality disorders,['10.1037/per0000497'] 2827,34379996,Does Physical Dance Training with Virtual Games Change Muscle Quality of Community-Dwelling Older Women?,"Objective: The aim of the study is to analyze the effects of physical dance training with a virtual game on muscle quality (MQ) of community-dwelling older women. Materials and Methods: In total, 46 older women participated in the study and were assigned to either a control group (CG, n  = 25, 71 ± 5 years) or training group (TG, n  = 21, 69 ± 4 years). The following assessments were performed at baseline and after 12 weeks: quadriceps, ankle plantar flexor, and dorsiflexor isokinetic peak torque (PT) (Biodex System 4 Dynamometer); quadriceps cross-sectional area (CSA) measured using magnetic resonance imaging; intramuscular noncontractile tissue (IMNCT) ( Image-Pro Plus 4.5.0.29 for Windows); and MQ (ratio of quadriceps PT to CSA). Each week for 12 weeks, the TG undertook three 40-minute sessions of physical training with the ""Dance Central"" game for Xbox 360 ® with Kinect, while the CG was instructed to maintain usual activities of daily living. Results: The TG increased quadriceps eccentric PT at 60°/s ( P  = 0.04) and ankle plantar flexor concentric PT at 60°/s ( P  = 0.02) when compared with the CG. No significant difference in quadriceps CSA, IMNCT, and MQ was observed. Conclusion: Physical dance training with virtual games can increase quadriceps and ankle plantar flexor strength without changing IMNCT and MQ of community-dwelling older women. Trial number: RBR-8xkwyp (ensaiosclinicos.gov.br-Brazilian Clinical Trials Registry).",2021,Physical dance training with virtual games can increase quadriceps and ankle plantar flexor strength without changing IMNCT and MQ of community-dwelling older women.,"['community-dwelling older women', 'Community-Dwelling Older Women', '46 older women participated in the study']","['physical training with the ""Dance Central"" game for Xbox 360 ® with Kinect, while the CG was instructed to maintain usual activities of daily living', 'physical dance training', 'control group (CG, n \u2009=\u200925, 71\u2009±\u20095 years) or training group (TG', 'Physical dance training with virtual games']","['quadriceps and ankle plantar flexor strength', 'quadriceps CSA, IMNCT, and MQ', 'muscle quality (MQ', 'TG increased quadriceps eccentric PT', 'quadriceps, ankle plantar flexor, and dorsiflexor isokinetic peak torque (PT) (Biodex System 4 Dynamometer); quadriceps cross-sectional area (CSA) measured using magnetic resonance imaging; intramuscular noncontractile tissue (IMNCT) ( Image-Pro Plus 4.5.0.29 for Windows); and MQ (ratio of quadriceps PT to CSA', 'ankle plantar flexor concentric PT']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0010963', 'cui_str': 'Dance'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0180572', 'cui_str': 'Dynamometer'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0557702', 'cui_str': 'Window'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}]",46.0,0.030086,Physical dance training with virtual games can increase quadriceps and ankle plantar flexor strength without changing IMNCT and MQ of community-dwelling older women.,"[{'ForeName': 'Audrin Said', 'Initials': 'AS', 'LastName': 'Vojciechowski', 'Affiliation': 'Master and PhD Programs in Physical Education, Federal University of Paraná, Curitiba, Brazil.'}, {'ForeName': 'Carla Tissiane De Souza', 'Initials': 'CTS', 'LastName': 'Silva', 'Affiliation': 'Master and PhD Programs in Physical Education, Federal University of Paraná, Curitiba, Brazil.'}, {'ForeName': 'Elisângela Valevein', 'Initials': 'EV', 'LastName': 'Rodrigues', 'Affiliation': 'Massage Therapy Course, Federal Institute of Paraná, Curitiba, Brazil.'}, {'ForeName': 'Luiza Hermínia', 'Initials': 'LH', 'LastName': 'Gallo', 'Affiliation': 'Physical Education Course, State University of Ponta Grossa, Ponta Grossa, Brazil.'}, {'ForeName': 'Jarbas', 'Initials': 'J', 'LastName': 'Melo Filho', 'Affiliation': 'Massage Therapy Course, Federal Institute of Paraná, Curitiba, Brazil.'}, {'ForeName': 'Anna Raquel Silveira', 'Initials': 'ARS', 'LastName': 'Gomes', 'Affiliation': 'Master and PhD Programs in Physical Education, Federal University of Paraná, Curitiba, Brazil.'}]",Games for health journal,['10.1089/g4h.2020.0223'] 2828,34379946,A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.,"BACKGROUND Melasma is the commonest cause of facial hypermelanosis in skin type IV-VI. First-line treatment includes a triple combination containing topical corticosteroid and hydroquinone which have side effects on prolonged use. Chemical peels are a second-line management option with the laser being used in refractory cases, but the worsening of hyperpigmentation in darker skin types can occur following laser therapy. Sunscreen is a must to prevent relapses. AIMS AND OBJECTIVES (i) To compare the effects of treatment with a proprietary combination (phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen) versus sunscreen alone in limiting or reducing, melasma and preventing recurrence as a maintenance regimen after the initial use of triple combination,(ii) to evaluate the safety of the formulation studied, and (iii) to study the improvement of the quality of life of the patients after using the study formulation versus placebo. METHODS It was a prospective double-blinded parallel-group randomized controlled pilot study. A total of 46 subjects were recruited by consecutive sampling methods and randomized to 23 each in case and control groups. The study period was eight months with three phases. Phase 1 constituted the application of triple combination for eight weeks by both groups followed by phase 2 with the case group applying proprietary medicine and the control group applying sunscreen. Phase 3 was a follow-up period to see the sustenance of results in both groups as well as any evidence of relapses. Sunscreen was applied in all three phases. RESULTS Case group in the study showed improvement in the melasma severity score and mean melanin index as measured by mexameter but it did not attain statistical significance as compared to the control group. The melasma area and severity index score showed a consistent reduction in the case group, whereas it increased in the control group from baseline. LIMITATIONS Small sample size and a short follow-up period of our study were major limitations. CONCLUSION The proprietary combination, which has sunscreen as one of its constituents, is more effective in maintaining remission after triple combination without any added inconvenience of application of two separate preparations as compared to sunscreen alone.",2021,"The melasma area and severity index score showed a consistent reduction in the case group, whereas it increased in the control group from baseline. ","['i', 'melasma maintenance', 'A total of 46 subjects']","['proprietary combination (phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen) versus sunscreen alone', 'control group applying sunscreen', 'proprietary combination versus sunscreen', 'hydroquinone', 'placebo']","['melasma severity score and mean melanin index', 'quality of life', 'melasma area and severity index score']","[{'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0035197', 'cui_str': 'meta-Dihydroxybenzenes'}, {'cui': 'C0031626', 'cui_str': 'Hypophosphorous Acids'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0038818', 'cui_str': 'Sunscreen agent'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0020306', 'cui_str': 'hydroquinone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0025196', 'cui_str': 'Melanin'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",46.0,0.0417056,"The melasma area and severity index score showed a consistent reduction in the case group, whereas it increased in the control group from baseline. ","[{'ForeName': 'Manas', 'Initials': 'M', 'LastName': 'Chatterjee', 'Affiliation': 'Department of Dermatology, Venereology and Leprology, Institute of Naval Medicine, INHS Asvini, Mumbai, Maharashtra, India.'}, {'ForeName': 'Shekhar', 'Initials': 'S', 'LastName': 'Neema', 'Affiliation': 'Department of Dermatology, Venereology and Leprology, Armed Forces Medical College, Pune, Maharashtra, India.'}, {'ForeName': 'Gopalsing Rameshsing', 'Initials': 'GR', 'LastName': 'Rajput', 'Affiliation': 'Department of Dermatology, Venereology and Leprology, Institute of Naval Medicine, INHS Asvini, Mumbai, Maharashtra, India.'}]","Indian journal of dermatology, venereology and leprology",['10.25259/IJDVL_976_18'] 2829,31926442,Increases of correct memories and spontaneous false memories due to eye movements when memories are retrieved after a time delay.,"Eye Movement Desensitization and Reprocessing (EMDR) is an effective treatment for post-traumatic stress disorder. However, literature on possible adverse memory effects of EMDR is scarce. Using the Deese/Roediger-McDermott (DRM) false memory paradigm, we examined the susceptibility to spontaneous false memories after performing eye movements, as used in EMDR. In Experiment 1, 72 undergraduates received word lists containing negative and neutral associated words and immediately after this they were given a free recall and recognition test. In Experiment 2, 68 undergraduates underwent the free recall and recognition test 48 h later. During the free recall phase in both experiments, participants either performed eye movements or not (control condition). In Experiment 1, the two conditions did not differ statistically with regard to correct and false recall/recognition. In Experiment 2, correct memory rates were higher in the eye movement than in the control condition and this was accompanied by an increase in spontaneous false memories on both free recall and recognition. Although our experimental approach is far removed from clinical practice, our findings suggest that eye movements as used in EMDR might amplify both correct and false memory rates.",2020,"In Experiment 2, correct memory rates were higher in the eye movement than in the control condition and this was accompanied by an increase in spontaneous false memories on both free recall and recognition.","['72 undergraduates received', '68 undergraduates underwent the free recall and recognition test 48\xa0h later']","['EMDR', 'word lists containing negative and neutral associated words', 'Eye Movement Desensitization and Reprocessing (EMDR']","['correct memories and spontaneous false memories', 'correct memory rates', 'spontaneous false memories', 'correct and false recall/recognition']","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205087', 'cui_str': 'Late'}]","[{'cui': 'C0870535', 'cui_str': 'EMDR'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]","[{'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0561845', 'cui_str': 'False memories'}, {'cui': 'C0205237', 'cui_str': 'False'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}]",,0.0256306,"In Experiment 2, correct memory rates were higher in the eye movement than in the control condition and this was accompanied by an increase in spontaneous false memories on both free recall and recognition.","[{'ForeName': 'Sanne T L', 'Initials': 'STL', 'LastName': 'Houben', 'Affiliation': 'Clinical Psychological Science, Maastricht University, the Netherlands; Leuven Institute of Criminology, Catholic University of Leuven, Belgium. Electronic address: sanne.houben@maastrichtuniversity.nl.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Otgaar', 'Affiliation': 'Clinical Psychological Science, Maastricht University, the Netherlands; Leuven Institute of Criminology, Catholic University of Leuven, Belgium.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Roelofs', 'Affiliation': 'Clinical Psychological Science, Maastricht University, the Netherlands.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Smeets', 'Affiliation': 'CoRPS - Center of Research on Psychological and Somatic Disorders, Department of Medical and Clinical Psychology, Tilburg University, the Netherlands.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Merckelbach', 'Affiliation': 'Clinical Psychological Science, Maastricht University, the Netherlands.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103546'] 2830,32198794,Real-word experience with mepolizumab: Does it deliver what it has promised?,"BACKGROUND Randomized control trials performed in selected populations of severe eosinophilic asthmatics have shown that mepolizumab, an anti-IL5 therapy, was able to reduce exacerbations and OCS maintenance dose and in some studies, to improve asthma control and lung function. OBJECTIVE The aim of this study was to confirm the results of the RCTs in real-life in a population of 116 severe eosinophilic asthmatics treated with mepolizumab and who were followed up at the asthma clinic every month for at least 18 months. Severe asthmatics underwent FENO, lung function, asthma control and quality of life questionnaires, sputum induction and gave a blood sample at baseline, after 6 months and then every year. RESULTS We found a significant reduction in exacerbations by 85% after 6 months (P < .0001), which was maintained over time. We also found a significant and maintained reduction by 50% in the dose of oral corticosteroids (P < .001). Patients improved their ACT (+5.31pts, p<0.0001) ACQ (-1.13pts, P < .0001) and their AQLQ score (+1.24, P < .0001) at 6 months and this was maintained during follow-up. Only 37% reached asthma control (ACQ <1.5, ACT> 20). We observed a progressive increase in post-BD FEV1 that reached significance after 18 months (190ml or 11%, P < .01). Patients improving their FEV1had higher baseline sputum eosinophils than those not improving airway caliber. We found a significant reduction in sputum eosinophil counts by 60% after 6 months (P < .01) and a maintained reduction in blood eosinophil counts by 98% (P < .0001). CONCLUSION In our real-life study, we confirm the results published in the RCTs showing a sharp reduction in exacerbation and oral corticosteroids dose and an improvement in asthma control and quality of life. CLINICAL RELEVANCE Mepolizumab is efficient in severe eosinophilic asthma in real life.",2020,"Patients improved their ACT (+5.31pts, p<0.0001) ACQ (-1.13pts, P < .0001) and their AQLQ score (+1.24, P < .0001) at 6 months and this was maintained during follow-up.","['116 severe eosinophilic asthmatics treated with mepolizumab and who were followed up at the asthma clinic every month for at least 18 months', 'selected populations of severe eosinophilic asthmatics']","['RCTs', 'mepolizumab', 'oral corticosteroids']","['sputum eosinophil counts', 'asthma control and quality of life', 'exacerbations', 'blood eosinophil counts', 'Severe asthmatics underwent FENO, lung function, asthma control and quality of life questionnaires, sputum induction and gave a blood sample', 'AQLQ score']","[{'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0969324', 'cui_str': 'mepolizumab'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C3838770', 'cui_str': 'Asthma clinic'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0969324', 'cui_str': 'mepolizumab'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]","[{'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",116.0,0.0711326,"Patients improved their ACT (+5.31pts, p<0.0001) ACQ (-1.13pts, P < .0001) and their AQLQ score (+1.24, P < .0001) at 6 months and this was maintained during follow-up.","[{'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Schleich', 'Affiliation': 'Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Graff', 'Affiliation': 'Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium.'}, {'ForeName': 'Haleh', 'Initials': 'H', 'LastName': 'Nekoee', 'Affiliation': 'Medical Informatics and Biostatistics, University of Liege, Liege, Belgium.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Moermans', 'Affiliation': 'Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Henket', 'Affiliation': 'Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Sanchez', 'Affiliation': 'Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Paulus', 'Affiliation': 'Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium.'}, {'ForeName': 'Françoise', 'Initials': 'F', 'LastName': 'Guissard', 'Affiliation': 'Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium.'}, {'ForeName': 'Anne-Françoise', 'Initials': 'AF', 'LastName': 'Donneau', 'Affiliation': 'Medical Informatics and Biostatistics, University of Liege, Liege, Belgium.'}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Louis', 'Affiliation': 'Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium.'}]",Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,['10.1111/cea.13601'] 2831,33441798,A pilot study on essential oil aroma stimulation for enhancing slow-wave EEG in sleeping brain.,"Sleep quality is important to health and life quality. Lack of sleep can lead to a variety of health issues and reduce in daytime function. Recent study by Fultz et al. also indicated that sleep is crucial to brain metabolism. Delta power in sleep EEG often indicates good sleep quality while alpha power usually indicates sleep interruptions and poor sleep quality. Essential oil has been speculated to improve sleep quality. Previous studies also suggest essential oil aroma may affect human brain activity when applied awake. However, those studies were often not blinded, which makes the effectiveness and mechanism of aroma a heavily debated topic. In this study, we aim to explore the effect of essential oil aroma on human sleep quality and sleep EEG in a single-blinded setup. The aroma was released when the participants are asleep, which kept the influence of psychological expectation to the minimum. We recruited nine young, healthy participants with regular lifestyle and no sleep problem. All participants reported better sleep quality and more daytime vigorous after exposing to lavender aroma in sleep. We also observed that upon lavender aroma releases, alpha wave in wake stage was reduced while delta wave in slow-wave sleep (SWS) was increased. Lastly, we found that lavender oil promote occurrence of SWS. Overall, our study results show that essential oil aroma can be used to promote both subjective and objective sleep quality in healthy human subjects. This makes aroma intervention a potential solution for poor sleep quality and insomnia.",2021,"The aroma was released when the participants are asleep, which kept the influence of psychological expectation to the minimum.","['sleeping brain', 'healthy human subjects', 'nine young, healthy participants with regular lifestyle and no sleep problem']","['essential oil aroma', 'essential oil aroma stimulation', 'lavender oil']","['human sleep quality and sleep EEG', 'Sleep quality', 'human brain activity', 'sleep quality and more daytime vigorous', 'subjective and objective sleep quality', 'sleep quality', 'delta wave in slow-wave sleep (SWS']","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}]","[{'cui': 'C0028910', 'cui_str': 'Volatile oil'}, {'cui': 'C2987717', 'cui_str': 'Scents'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0064694', 'cui_str': 'lavender oil'}]","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0200101', 'cui_str': 'Sleep electroencephalogram'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}]",9.0,0.0384099,"The aroma was released when the participants are asleep, which kept the influence of psychological expectation to the minimum.","[{'ForeName': 'Li-Wei', 'Initials': 'LW', 'LastName': 'Ko', 'Affiliation': 'Center for Intelligent Drug Systems and Smart Bio-Devices (IDS2B), National Chiao Tung University, Hsinchu City, Taiwan. lwko@nctu.edu.tw.'}, {'ForeName': 'Cheng-Hua', 'Initials': 'CH', 'LastName': 'Su', 'Affiliation': 'Center for Intelligent Drug Systems and Smart Bio-Devices (IDS2B), National Chiao Tung University, Hsinchu City, Taiwan.'}, {'ForeName': 'Meng-Hsun', 'Initials': 'MH', 'LastName': 'Yang', 'Affiliation': 'Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu City, Taiwan.'}, {'ForeName': 'Shen-Yi', 'Initials': 'SY', 'LastName': 'Liu', 'Affiliation': 'Sleep Center, Taipei Veterans General Hospital, Taipei City, Taiwan.'}, {'ForeName': 'Tung-Ping', 'Initials': 'TP', 'LastName': 'Su', 'Affiliation': 'Department of Psychiatry, Cheng Hsin General Hospital, Taipei City, Taiwan.'}]",Scientific reports,['10.1038/s41598-020-80171-x'] 2832,33441772,High cut-off dialysis mitigates pro-calcific effects of plasma on vascular progenitor cells.,"Mortality of patients with end-stage renal disease tremendously exceeds that of the general population due to excess cardiovascular morbidity. Large middle-sized molecules (LMM) including pro-inflammatory cytokines are major drivers of uremic cardiovascular toxicity and cannot be removed sufficiently by conventional high-flux (HFL) hemodialysis. We tested the ability of plasma from 19 hemodialysis patients participating in a trial comparing HFL with high cut-off (HCO) membranes facilitating removal of LMM to induce calcification in mesenchymal stromal cells (MSC) functioning as vascular progenitors. HCO dialysis favorably changed plasma composition resulting in reduced pro-calcific activity. LMM were removed more effectively by HCO dialysis including FGF23, a typical LMM we found to promote osteoblastic differentiation of MSC. Protein-bound uremic retention solutes with known cardiovascular toxicity but not LMM inhibited proliferation of MSC without direct toxicity in screening experiments. We could not attribute the effect of HCO dialysis on MSC calcification to distinct mediators. However, we found evidence of sustained reduced inflammation that might parallel other anti-calcifying mechanisms such as altered generation of extracellular vesicles. Our findings imply protection of MSC from dysfunctional differentiation by novel dialysis techniques targeted at removal of LMM. HCO dialysis might preserve their physiologic role in vascular regeneration and improve outcomes in dialysis patients.",2021,Protein-bound uremic retention solutes with known cardiovascular toxicity but not LMM inhibited proliferation of MSC without direct toxicity in screening experiments.,"['patients with end-stage renal disease', '19 hemodialysis patients participating in a trial comparing HFL with high cut-off (HCO) membranes facilitating removal of LMM to induce calcification in mesenchymal stromal cells (MSC) functioning as vascular progenitors', 'dialysis patients']","['LMM', 'HCO dialysis']","['Mortality', 'vascular progenitor cells', 'cardiovascular morbidity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0000925', 'cui_str': 'Incised wound'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0567416', 'cui_str': 'Molecule'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C3178844', 'cui_str': 'Mesenchymal Stromal Cells'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}]","[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0567416', 'cui_str': 'Molecule'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0000925', 'cui_str': 'Incised wound'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}, {'cui': 'C1301700', 'cui_str': 'Cardiovascular morbidity'}]",19.0,0.0420473,Protein-bound uremic retention solutes with known cardiovascular toxicity but not LMM inhibited proliferation of MSC without direct toxicity in screening experiments.,"[{'ForeName': 'Theres', 'Initials': 'T', 'LastName': 'Schaub', 'Affiliation': 'Clinic for Nephrology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Campus Virchow-Clinic, Augustenburger Platz 1, 13353, Berlin, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Janke', 'Affiliation': 'Clinic for Nephrology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Campus Virchow-Clinic, Augustenburger Platz 1, 13353, Berlin, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Zickler', 'Affiliation': 'Clinic for Nephrology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Campus Virchow-Clinic, Augustenburger Platz 1, 13353, Berlin, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Lange', 'Affiliation': 'Clinic for Stem Cell Transplantation, Department of Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Girndt', 'Affiliation': 'Department of Internal Medicine II, Martin-Luther-University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Schindler', 'Affiliation': 'Clinic for Nephrology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Campus Virchow-Clinic, Augustenburger Platz 1, 13353, Berlin, Germany.'}, {'ForeName': 'Duska', 'Initials': 'D', 'LastName': 'Dragun', 'Affiliation': 'Clinic for Nephrology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Campus Virchow-Clinic, Augustenburger Platz 1, 13353, Berlin, Germany. duska.dragun@charite.de.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Hegner', 'Affiliation': 'Clinic for Nephrology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Campus Virchow-Clinic, Augustenburger Platz 1, 13353, Berlin, Germany. bjoern.hegner@gmx.de.'}]",Scientific reports,['10.1038/s41598-020-80016-7'] 2833,32755236,Retrospective collection of 90-day modified Rankin Scale is accurate.,"BACKGROUND The 90-day modified Rankin Scale is a widely used outcome after stroke but is sometimes hard to ascertain due to loss to follow-up. Missing outcomes can result in biased and/or inefficient estimates in clinical trials. The aim of this study is to assess the validity of acquiring the 90-day modified Rankin Scale at a later point of time when the patient has been lost at 90 days to impute the missing value. METHODS Participants who had prospectively completed a 90-day modified Rankin Scale questionnaire on their own in the Benefits of Stroke Treatment Using a Mobile Stroke Unit study were randomly interviewed to recall the 90-day modified Rankin Scale at 6, 9, or 12 months after hospital discharge over the phone. Concordance between the two scores was assessed using kappa and weighted kappa statistics. Logistic regression was used to identify factors associated with inconsistent reporting of the 90-day modified Rankin Scale. RESULTS Substantial agreement was observed between in-the-moment and retrospective 90-day modified Rankin Scale recalled at 6, 9, or 12 months (weighted kappa = 0.93, 95% confidence interval: 0.89-0.98; weighted kappa = 0.93, 95% confidence interval: 0.85-1.00 and weighted kappa = 0.89, 95% confidence interval: 0.82-0.95, respectively). CONCLUSION Retrospective recall of 90-day modified Rankin Scale at a later time point is a valid means to impute missing data in stroke clinical trials.",2020,"RESULTS Substantial agreement was observed between in-the-moment and retrospective 90-day modified Rankin Scale recalled at 6, 9, or 12 months (weighted kappa = 0.93,",['Participants who had prospectively completed a 90-day modified Rankin Scale questionnaire on their own in the Benefits of Stroke Treatment Using a Mobile Stroke Unit study'],[],['90-day modified Rankin Scale'],"[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0587502', 'cui_str': 'Stroke unit'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}]",,0.137251,"RESULTS Substantial agreement was observed between in-the-moment and retrospective 90-day modified Rankin Scale recalled at 6, 9, or 12 months (weighted kappa = 0.93,","[{'ForeName': 'Mengxi', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Biostatistics and Data Science, School of Public Health at The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Suja S', 'Initials': 'SS', 'LastName': 'Rajan', 'Affiliation': 'Department of Management, Policy and Community Health, School of Public Health at the University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Asha P', 'Initials': 'AP', 'LastName': 'Jacob', 'Affiliation': 'Department of Biostatistics and Data Science, School of Public Health at The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Noopur', 'Initials': 'N', 'LastName': 'Singh', 'Affiliation': 'Department of Biostatistics and Data Science, School of Public Health at The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Parker', 'Affiliation': 'Mobile Stroke Unit and Stroke Research, Clinical Innovation and Research Institute at the Memorial Hermann Hospital, Houston, TX, USA.'}, {'ForeName': 'Ritvij', 'Initials': 'R', 'LastName': 'Bowry', 'Affiliation': 'Department of Neurology, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Grotta', 'Affiliation': 'Mobile Stroke Unit and Stroke Research, Clinical Innovation and Research Institute at the Memorial Hermann Hospital, Houston, TX, USA.'}, {'ForeName': 'Jose-Miguel', 'Initials': 'JM', 'LastName': 'Yamal', 'Affiliation': 'Department of Biostatistics and Data Science, School of Public Health at The University of Texas Health Science Center at Houston, Houston, TX, USA.'}]","Clinical trials (London, England)",['10.1177/1740774520942466'] 2834,32515118,Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma.,,2020,,['patients with severe eosinophilic asthma'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0034068', 'cui_str': 'Eosinophilic asthma'}]",[],[],,0.0303155,,"[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wardlaw', 'Affiliation': 'Institute for Lung Health, University of Leicester, Leicester, UK.'}, {'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': 'Howarth', 'Affiliation': 'Global Medical Franchise, GSK House, Brentford, UK.'}, {'ForeName': 'Elliot', 'Initials': 'E', 'LastName': 'Israel', 'Affiliation': ""Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Taillé', 'Affiliation': 'AP-HP, Hôpital Bichat, Service de Pneumologie et Centre de Référence des Maladies Pulmonaires Rares, Dépt Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR, Paris, France.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Quirce', 'Affiliation': 'Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), and CIBER of Respiratory Diseases (CIBERES), Madrid, Spain.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Mallett', 'Affiliation': 'Clinical Statistics, GSK, Uxbridge, UK.'}, {'ForeName': 'Stewart', 'Initials': 'S', 'LastName': 'Bates', 'Affiliation': 'Respiratory Discovery Medicine, GSK, Stevenage, UK.'}, {'ForeName': 'Frank C', 'Initials': 'FC', 'LastName': 'Albers', 'Affiliation': 'Respiratory Medical Franchise, GSK, Research Triangle Park, NC, USA.'}, {'ForeName': 'Namhee', 'Initials': 'N', 'LastName': 'Kwon', 'Affiliation': 'Respiratory Medical Franchise, GSK, Brentford, UK.'}]",Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,['10.1111/cea.13680'] 2835,32068354,"Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-γ-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic Dosing.","BMS-986184 is a human, second-generation, anti-interferon-γ-induced protein 10 (IP-10) monoclonal antibody. In this study the pharmacokinetics and target engagement (TE) of BMS-986184 in healthy participants were characterized using population-based target-mediated drug disposition (TMDD) modeling and data from a first-in-human study (NCT02864264). The results of the first-in-human study and the model generated were used to conduct stochastic simulations of a virtual population of healthy participants to predict pharmacokinetic exposures and TE responses for different dosage regimens. A 2-compartment, 2-target, TMDD structural model, assuming quasi-steady-state and stimulated production on treatment, was developed by simultaneous fitting of the total drug, serum-free IP-10, and serum total IP-10 concentration data, with the second unobservable target contribution to drug elimination described by the Michaelis-Menten elimination term. Model evaluation confirmed agreement between model predictions and observed data. Simulation of a virtual population of healthy individuals demonstrated that steady state was reached at the eighth dosing interval, and that around 150 mg subcutaneously every other week could be a suitable target dosage regimen for future clinical trials. Integrated modeling strategies such as this can be used to help guide rational clinical trial development of drugs with TMDD, leading to improved dose selection and greater patient benefits.",2020,"Simulation of a virtual population of healthy individuals demonstrated that steady state was reached at the eighth dosing interval, and that around 150 mg subcutaneously every other week could be a suitable target dosage regimen for future clinical trials.","['healthy participants were characterized using population-based target-mediated drug disposition (TMDD) modeling and data from a first-in-human study (NCT02864264', 'healthy individuals', 'Healthy Participants to Guide Therapeutic Dosing']",[],[],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0184758', 'cui_str': 'Patient disposition'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]",[],[],,0.0255764,"Simulation of a virtual population of healthy individuals demonstrated that steady state was reached at the eighth dosing interval, and that around 150 mg subcutaneously every other week could be a suitable target dosage regimen for future clinical trials.","[{'ForeName': 'Weiguo', 'Initials': 'W', 'LastName': 'Cai', 'Affiliation': 'Bristol-Myers Squibb, Princeton, New Jersey, USA.'}, {'ForeName': 'Tarek A', 'Initials': 'TA', 'LastName': 'Leil', 'Affiliation': 'Bristol-Myers Squibb, Princeton, New Jersey, USA.'}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Gibiansky', 'Affiliation': 'QuantPharm LLC, North Potomac, Maryland, USA.'}, {'ForeName': 'Murli', 'Initials': 'M', 'LastName': 'Krishna', 'Affiliation': 'Bristol-Myers Squibb, Princeton, New Jersey, USA.'}, {'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Bristol-Myers Squibb, Princeton, New Jersey, USA.'}, {'ForeName': 'Huidong', 'Initials': 'H', 'LastName': 'Gu', 'Affiliation': 'Bristol-Myers Squibb, Princeton, New Jersey, USA.'}, {'ForeName': 'Huadong', 'Initials': 'H', 'LastName': 'Sun', 'Affiliation': 'Bristol-Myers Squibb, Princeton, New Jersey, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Throup', 'Affiliation': 'Bristol-Myers Squibb, Princeton, New Jersey, USA.'}, {'ForeName': 'Subhashis', 'Initials': 'S', 'LastName': 'Banerjee', 'Affiliation': 'Bristol-Myers Squibb, Princeton, New Jersey, USA.'}, {'ForeName': 'Ihab', 'Initials': 'I', 'LastName': 'Girgis', 'Affiliation': 'Bristol-Myers Squibb, Princeton, New Jersey, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.784'] 2836,33686137,Socioeconomic and physical health status changes after visual impairment in Korea using difference-in-difference estimations.,"This study analyzed the impact of visual impairment on socioeconomic and physical health status and its heterogeneity by severity of visual impairment. We used nationally representative cohort data based on Korean national health insurance claims (2002-2013), which were extracted for 11,030 persons (2206 visually impaired, 8824 control). This was restructured as monthly data for each person (person-month). Multivariate and ordered logistic regressions were conducted, and the pre-impairment status between the visually impaired and non-visually impaired people was adjusted by difference-in-difference (DiD) estimation. Focusing on medical aid (a public healthcare service assistance program for people who cannot afford health insurance premiums), the DiD estimate showed that the likelihood of receiving aid was higher among visually impaired compared with non-impaired people. Mildly and severely visually impaired people were more likely to be medical aid recipients than their counterparts. The severely visually impaired group was more likely to be unemployed. The visually impaired group were less likely to have no comorbidity. Our findings show that the socioeconomic and physical health status of visually impaired people is more likely to deteriorate than that of their non-visually impaired counterparts following onset of impairment.",2021,Mildly and severely visually impaired people were more likely to be medical aid recipients than their counterparts.,"['nationally representative cohort data based on Korean national health insurance claims (2002-2013), which were extracted for 11,030 persons (2206 visually impaired, 8824 control', 'people who cannot afford health insurance premiums']",[],[],"[{'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0027452', 'cui_str': 'National Health Insurance'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}]",[],[],,0.0682175,Mildly and severely visually impaired people were more likely to be medical aid recipients than their counterparts.,"[{'ForeName': 'Hyero', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 162-1 Songdo-Dong, Yeonsu-Gu, Incheon, South Korea.'}, {'ForeName': 'Heejo', 'Initials': 'H', 'LastName': 'Koo', 'Affiliation': 'College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 162-1 Songdo-Dong, Yeonsu-Gu, Incheon, South Korea.'}, {'ForeName': 'Euna', 'Initials': 'E', 'LastName': 'Han', 'Affiliation': 'College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 162-1 Songdo-Dong, Yeonsu-Gu, Incheon, South Korea. eunahan@yonsei.ac.kr.'}]",Scientific reports,['10.1038/s41598-020-79760-7'] 2837,34385704,Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial.,"In heart failure with preserved ejection fraction (HFpEF), the occurrence of myocardial fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent without hemodynamic effect, is efficacious and safe for the treatment of HFpEF is unknown. In this double-blind, phase 2 trial ( NCT02932566 ), we enrolled patients with heart failure, an ejection fraction of 45% or higher and elevated levels of natriuretic peptides. Eligible patients underwent cardiovascular magnetic resonance and those with evidence of myocardial fibrosis, defined as a myocardial extracellular volume of 27% or greater, were randomly assigned to receive pirfenidone or placebo for 52 weeks. Forty-seven patients were randomized to each of the pirfenidone and placebo groups. The primary outcome was change in myocardial extracellular volume, from baseline to 52 weeks. In comparison to placebo, pirfenidone reduced myocardial extracellular volume (between-group difference, -1.21%; 95% confidence interval, -2.12 to -0.31; P = 0.009), meeting the predefined primary outcome. Twelve patients (26%) in the pirfenidone group and 14 patients (30%) in the placebo group experienced one or more serious adverse events. The most common adverse events in the pirfenidone group were nausea, insomnia and rash. In conclusion, among patients with HFpEF and myocardial fibrosis, administration of pirfenidone for 52 weeks reduced myocardial fibrosis. The favorable effects of pirfenidone in patients with HFpEF will need to be confirmed in future trials.",2021,"In comparison to placebo, pirfenidone reduced myocardial extracellular volume (between-group difference, -1.21%; 95% confidence interval, -2.12 to -0.31; P = 0.009), meeting the predefined primary outcome.","['patients with HFpEF', 'Eligible patients underwent cardiovascular magnetic resonance and those with evidence of myocardial fibrosis, defined as a myocardial extracellular volume of 27% or greater', 'Forty-seven patients', 'enrolled patients with heart failure, an ejection fraction of 45% or higher and elevated levels of natriuretic peptides', 'patients with HFpEF and myocardial fibrosis', 'heart failure with preserved ejection fraction']","['placebo, pirfenidone', 'placebo', 'pirfenidone', 'pirfenidone or placebo', 'pirfenidone and placebo', 'Pirfenidone']","['myocardial extracellular volume', 'nausea, insomnia and rash', 'serious adverse events', 'myocardial fibrosis', 'change in myocardial extracellular volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2960127', 'cui_str': 'Heart failure with normal ejection fraction'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0151654', 'cui_str': 'Myocardial fibrosis'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0521119', 'cui_str': 'Extracellular'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1144709', 'cui_str': 'Natriuretic Peptide Hormones'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0298067', 'cui_str': 'pirfenidone'}]","[{'cui': 'C0521119', 'cui_str': 'Extracellular'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0151654', 'cui_str': 'Myocardial fibrosis'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",47.0,0.398586,"In comparison to placebo, pirfenidone reduced myocardial extracellular volume (between-group difference, -1.21%; 95% confidence interval, -2.12 to -0.31; P = 0.009), meeting the predefined primary outcome.","[{'ForeName': 'Gavin A', 'Initials': 'GA', 'LastName': 'Lewis', 'Affiliation': 'Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Dodd', 'Affiliation': 'Department of Health Data Science, University of Liverpool, a Member of Liverpool Health Partners, Liverpool, UK.'}, {'ForeName': 'Dannii', 'Initials': 'D', 'LastName': 'Clayton', 'Affiliation': ""Liverpool Clinical Trials Centre, University of Liverpool, Institute of Child Health, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.""}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Bedson', 'Affiliation': ""Liverpool Clinical Trials Centre, University of Liverpool, Institute of Child Health, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.""}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Eccleson', 'Affiliation': ""Liverpool Clinical Trials Centre, University of Liverpool, Institute of Child Health, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.""}, {'ForeName': 'Erik B', 'Initials': 'EB', 'LastName': 'Schelbert', 'Affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Josephine H', 'Initials': 'JH', 'LastName': 'Naish', 'Affiliation': 'Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Beatriz Duran', 'Initials': 'BD', 'LastName': 'Jimenez', 'Affiliation': 'Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Simon G', 'Initials': 'SG', 'LastName': 'Williams', 'Affiliation': 'Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Cunnington', 'Affiliation': 'Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Fozia Zahir', 'Initials': 'FZ', 'LastName': 'Ahmed', 'Affiliation': 'Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Cooper', 'Affiliation': 'Salford Royal NHS Foundation Trust, Salford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': 'Rajavarma Viswesvaraiah', 'Affiliation': 'Stockport NHS Foundation Trust, Stepping Hill Hospital, Stockport, UK.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Russell', 'Affiliation': 'East Cheshire NHS Trust, Macclesfield, UK.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'McDonagh', 'Affiliation': ""King's College Hospital, London, UK.""}, {'ForeName': 'Paula R', 'Initials': 'PR', 'LastName': 'Williamson', 'Affiliation': 'Department of Health Data Science, University of Liverpool, a Member of Liverpool Health Partners, Liverpool, UK.'}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Miller', 'Affiliation': 'Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. Christopher.Miller@manchester.ac.uk.'}]",Nature medicine,['10.1038/s41591-021-01452-0'] 2838,34385669,Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial.,"PURPOSE We evaluated the impact of personal melanoma genomic risk information on sun-related behaviors and psychological outcomes. METHODS In this parallel group, open, randomized controlled trial, 1,025 Australians of European ancestry without melanoma and aged 18-69 years were recruited via the Medicare database (3% consent). Participants were randomized to the intervention (n = 513; saliva sample for genetic testing, personalized melanoma risk booklet based on a 40-variant polygenic risk score, telephone-based genetic counseling, educational booklet) or control (n = 512; educational booklet). Wrist-worn ultraviolet (UV) radiation dosimeters (10-day wear) and questionnaires were administered at baseline, 1 month postintervention, and 12 months postbaseline. RESULTS At 12 months, 948 (92%) participants completed dosimetry and 973 (95%) the questionnaire. For the primary outcome, there was no effect of the genomic risk intervention on objectively measured UV exposure at 12 months, irrespective of traditional risk factors. For secondary outcomes at 12 months, the intervention reduced sunburns (risk ratio: 0.72, 95% confidence interval: 0.54-0.96), and increased skin examinations among women. Melanoma-related worry was reduced. There was no overall impact on general psychological distress. CONCLUSION Personalized genomic risk information did not influence sun exposure patterns but did improve some skin cancer prevention and early detection behaviors, suggesting it may be useful for precision prevention. There was no evidence of psychological harm.",2021,"For the primary outcome, there was no effect of the genomic risk intervention on objectively measured UV exposure at 12 months, irrespective of traditional risk factors.","['1,025 Australians of European ancestry without melanoma and aged 18-69 years were recruited via the Medicare database (3% consent']","['Wrist-worn ultraviolet (UV) radiation dosimeters (10-day wear) and questionnaires', 'personal genomic risk information', 'intervention (n\u2009=\u2009513; saliva sample for genetic testing, personalized melanoma risk booklet based on a 40-variant polygenic risk score, telephone-based genetic counseling, educational booklet) or control (n\u2009=\u2009512; educational booklet']","['skin cancer prevention and early detection behaviors', 'general psychological distress', 'skin examinations', 'melanoma prevention behaviors and psychological outcomes', 'sunburns (risk ratio']","[{'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018717', 'cui_str': 'Health Insurance for Aged and Disabled, Title 18'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]","[{'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0041625', 'cui_str': 'Ultraviolet radiation'}, {'cui': 'C0180488', 'cui_str': 'Dosimeter'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0679560', 'cui_str': 'Genetic test'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205419', 'cui_str': 'Variant'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0017382', 'cui_str': 'Genetic counseling'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0007114', 'cui_str': 'Malignant neoplasm of skin'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0596473', 'cui_str': 'Early Diagnosis'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0436149', 'cui_str': 'Examination of skin'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038814', 'cui_str': 'Sunburn'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",1025.0,0.485784,"For the primary outcome, there was no effect of the genomic risk intervention on objectively measured UV exposure at 12 months, irrespective of traditional risk factors.","[{'ForeName': 'Amelia K', 'Initials': 'AK', 'LastName': 'Smit', 'Affiliation': 'The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, NSW, Sydney, Australia.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Allen', 'Affiliation': 'Electrical and Computer Engineering, University of Canterbury, Christchurch, New Zealand.'}, {'ForeName': 'Brooke', 'Initials': 'B', 'LastName': 'Beswick', 'Affiliation': 'The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, NSW, Sydney, Australia.'}, {'ForeName': 'Phyllis', 'Initials': 'P', 'LastName': 'Butow', 'Affiliation': 'Centre for Medical Psychology and Evidence-based Decision-making, School of Psychology, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Dawkins', 'Affiliation': 'Division of Genetics, School of Biomedical Sciences, University of Western Australia, Crawley, WA, Australia.'}, {'ForeName': 'Suzanne J', 'Initials': 'SJ', 'LastName': 'Dobbinson', 'Affiliation': 'Cancer Council Victoria, Melbourne, VIC, Australia.'}, {'ForeName': 'Kate L', 'Initials': 'KL', 'LastName': 'Dunlop', 'Affiliation': 'The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, NSW, Sydney, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Espinoza', 'Affiliation': 'NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Fenton', 'Affiliation': 'The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, NSW, Sydney, Australia.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Kanetsky', 'Affiliation': 'H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Keogh', 'Affiliation': 'Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Kimlin', 'Affiliation': 'Queensland University of Technology, School of Biomedical Sciences, Brisbane, QLD, Australia.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Kirk', 'Affiliation': 'Westmead Clinical School and Westmead Institute for Medical Research, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Matthew H', 'Initials': 'MH', 'LastName': 'Law', 'Affiliation': 'Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.'}, {'ForeName': 'Serigne', 'Initials': 'S', 'LastName': 'Lo', 'Affiliation': 'Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Low', 'Affiliation': 'Consumer representative, Brisbane, QLD, Australia.'}, {'ForeName': 'Graham J', 'Initials': 'GJ', 'LastName': 'Mann', 'Affiliation': 'Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Reyes-Marcelino', 'Affiliation': 'The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, NSW, Sydney, Australia.'}, {'ForeName': 'Rachael L', 'Initials': 'RL', 'LastName': 'Morton', 'Affiliation': 'Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Ainsley J', 'Initials': 'AJ', 'LastName': 'Newson', 'Affiliation': 'Sydney Health Ethics, Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Savard', 'Affiliation': 'School of Medicine, Faculty of Health, Deakin University, Geelong, VIC, Australia.'}, {'ForeName': 'Lyndal', 'Initials': 'L', 'LastName': 'Trevena', 'Affiliation': 'Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Wordsworth', 'Affiliation': 'Health Economics Research Centre, The University of Oxford, Oxford, UK.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Cust', 'Affiliation': 'The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, NSW, Sydney, Australia. anne.cust@sydney.edu.au.'}]",Genetics in medicine : official journal of the American College of Medical Genetics,['10.1038/s41436-021-01292-w'] 2839,34385507,Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid.,"Evaluate the biological action of valproic acid in the acetylation of histones and in the methylation of tumor suppressor genes via oral rinse in patients with a previous history of head and neck squamous cell carcinoma (HNSCC). Forty-two active or former smokers were included in this randomized, double-blind, placebo-controlled trial. Oral rinse samples were collected prior to treatment with valproic acid or placebo and after 90 days of treatment. The methylation status of five tumor suppressor genes and histone acetylation were evaluated by pyrosequencing and ELISA techniques, respectively. Differences between the 90-day and baseline oral rinse acetylation and methylation results were analyzed by comparing groups. Thirty-four patients were considered for analysis. The mean percentage adherence in the valproic and placebo groups was 93.4 and 93.0, respectively (p = 0.718). There was no statistically significant difference between groups when comparing the medians of the histone acetylation ratio and the methylation ratio for most of the studied genes. A significant reduction in the DCC methylation pattern was observed in the valproic group (p = 0.023). The use of valproic acid was safe and accompanied by good therapeutic adherence. DCC methylation was lower in the valproic acid group than in the placebo group.",2021,A significant reduction in the DCC methylation pattern was observed in the valproic group (p = 0.023).,"['patients with head and neck cancer history exposed to valproic acid', 'Forty-two active or former smokers', 'patients with a previous history of head and neck squamous cell carcinoma (HNSCC']","['valproic acid', 'placebo', 'valproic acid or placebo']","['histone acetylation ratio and the methylation ratio', 'mean percentage adherence', 'DCC methylation', 'DCC methylation pattern', 'methylation status of five tumor suppressor genes and histone acetylation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0042291', 'cui_str': 'valproic acid'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0337671', 'cui_str': 'Ex-smoker'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C1168401', 'cui_str': 'Squamous cell carcinoma of head and neck'}]","[{'cui': 'C0042291', 'cui_str': 'valproic acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0019652', 'cui_str': 'Histone'}, {'cui': 'C0001038', 'cui_str': 'Acetylation'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0025723', 'cui_str': 'Methylation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1259909', 'cui_str': 'DCC protein, human'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0079427', 'cui_str': 'Antioncogene'}]",34.0,0.188521,A significant reduction in the DCC methylation pattern was observed in the valproic group (p = 0.023).,"[{'ForeName': 'Ricardo Ribeiro', 'Initials': 'RR', 'LastName': 'Gama', 'Affiliation': 'Head and Neck Surgery Department, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Bairro Dr. Paulo Prata, Barretos, SP, 14784-400, Brazil. ricardorgama@yahoo.com.br.'}, {'ForeName': 'Lidia Maria Rebolho Batista', 'Initials': 'LMRB', 'LastName': 'Arantes', 'Affiliation': 'Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.'}, {'ForeName': 'Bruna Pereira', 'Initials': 'BP', 'LastName': 'Sorroche', 'Affiliation': 'Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'De Marchi', 'Affiliation': 'Clinical Oncology Department, Barretos Cancer Hospital, Barretos, SP, Brazil.'}, {'ForeName': 'Matias Eliseo', 'Initials': 'ME', 'LastName': 'Melendez', 'Affiliation': 'Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.'}, {'ForeName': 'Raiany Santos', 'Initials': 'RS', 'LastName': 'Carvalho', 'Affiliation': 'Researcher Support Center, Teaching and Research Institute, Barretos Cancer Hospital, Barretos, SP, Brazil.'}, {'ForeName': 'Marcos Alves', 'Initials': 'MA', 'LastName': 'de Lima', 'Affiliation': 'Biostatistics Center, Teaching and Research Institute, Barretos Cancer Hospital, Barretos, SP, Brazil.'}, {'ForeName': 'André Luiz', 'Initials': 'AL', 'LastName': 'Vettore', 'Affiliation': 'Cancer Molecular Biology Laboratory, São Paulo Federal University, Diadema, SP, Brazil.'}, {'ForeName': 'André Lopes', 'Initials': 'AL', 'LastName': 'Carvalho', 'Affiliation': 'Head and Neck Surgery Department, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Bairro Dr. Paulo Prata, Barretos, SP, 14784-400, Brazil.'}]",Scientific reports,['10.1038/s41598-021-95845-3'] 2840,34385364,Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.,"OBJECTIVE This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with multiple poor prognostic factors (PPFs). METHODS This was a post hoc analysis of the phase III, randomised, double-blind, active-controlled, FINCH 3 study (clinicaltrials.gov NCT02886728). Patients received once-daily oral filgotinib 200 or 100 mg plus once-weekly oral MTX ≤20 mg (FIL200 + MTX and FIL100 + MTX), filgotinib 200 mg monotherapy (FIL200), or oral MTX monotherapy (MTX-mono) for up to 52 weeks. PPFs investigated were seropositivity for rheumatoid factor or anticyclic citrullinated peptide antibodies, high-sensitivity C reactive protein (CRP) ≥4 mg/L, Disease Activity Score in 28 joints with CRP (DAS28(CRP)) >5.1, and presence of erosions. Filgotinib efficacy and safety in patients with all four PPFs at baseline were explored versus MTX-mono within this subgroup and compared informally with the overall population. RESULTS Of 1249 patients in FINCH 3, 510 (40.8%) had all PPFs. Efficacy of FIL200 + MTX among these patients was comparable to the overall population, with higher rates of 20%/50%/70% improvement from baseline by American College of Rheumatology criteria, DAS28(CRP) <2.6, and remission; greater improvement in physical function and pain; and better inhibition of structural damage relative to MTX-mono. FIL100 + MTX and FIL200 were not consistently more efficacious versus MTX-mono. Safety of filgotinib in patients with PPFs was comparable to the overall population; no new safety signals were observed. CONCLUSION FIL200 + MTX efficacy and safety in patients with multiple PPFs were similar to the overall population.",2021,"Safety of filgotinib in patients with PPFs was comparable to the overall population; no new safety signals were observed. ","['MTX)-naive patients with rheumatoid arthritis (RA) with multiple poor prognostic factors (PPFs', 'patients with multiple PPFs', 'patients with all four PPFs at baseline were explored versus MTX-mono within this subgroup and compared informally with the overall population', 'naive patients with rheumatoid arthritis with poor prognostic factors', 'Of 1249 patients in FINCH 3, 510 (40.8%) had all PPFs', 'patients with PPFs', '28 joints with CRP (DAS28(CRP)) >5.1, and presence of erosions']","['FIL100 + MTX', 'methotrexate', 'filgotinib', 'FIL200 + MTX', 'once-daily oral filgotinib 200 or 100\u2009mg plus once-weekly oral MTX ≤20\u2009mg (FIL200 + MTX\u2009and FIL100 + MTX), filgotinib 200\u2009mg monotherapy (FIL200), or oral MTX monotherapy (MTX-mono']","['Filgotinib efficacy and safety', 'efficacy and safety', 'Efficacy and safety', 'physical function and pain', 'Disease Activity Score']","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C1514474', 'cui_str': 'Prognostic Factors'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0021345', 'cui_str': 'Infectious mononucleosis'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0326914', 'cui_str': 'Family Fringillidae'}, {'cui': 'C4517800', 'cui_str': '510'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}, {'cui': 'C0021345', 'cui_str': 'Infectious mononucleosis'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}]",,0.27564,"Safety of filgotinib in patients with PPFs was comparable to the overall population; no new safety signals were observed. ","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Aletaha', 'Affiliation': 'Division of Rheumatology, Medical University of Vienna, Wien, Austria daniel.aletaha@meduniwien.ac.at.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Westhovens', 'Affiliation': 'Department of Development and Regeneration, KU Leuven University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Cecile', 'Initials': 'C', 'LastName': 'Gaujoux-Viala', 'Affiliation': 'Department of Rheumatologie, Centre Hospitalier Universitaire de Nîmes, Nimes, France.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Adami', 'Affiliation': 'Division of Rheumatology, University of Verona, Verona, Italy.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Matsumoto', 'Affiliation': 'Arthritis and Rheumatism Associates PC, Wheaton, Maryland, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Bird', 'Affiliation': 'St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Osvaldo Daniel', 'Initials': 'OD', 'LastName': 'Messina', 'Affiliation': 'Department of Rheumatology and Metabolic Bone Diseases, Investigaciones Reumatológicas y Osteológicas srl, Buenos Aires, Argentina.'}, {'ForeName': 'Maya H', 'Initials': 'MH', 'LastName': 'Buch', 'Affiliation': 'Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Manchester, UK.'}, {'ForeName': 'Beatrix', 'Initials': 'B', 'LastName': 'Bartok', 'Affiliation': 'Gilead Sciences Inc, Foster City, California, USA.'}, {'ForeName': 'Zhaoyu', 'Initials': 'Z', 'LastName': 'Yin', 'Affiliation': 'Gilead Sciences Inc, Foster City, California, USA.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Gilead Sciences Inc, Foster City, California, USA.'}, {'ForeName': 'Thijs', 'Initials': 'T', 'LastName': 'Hendrikx', 'Affiliation': 'Galapagos BV, Leiden, The Netherlands.'}, {'ForeName': 'Gerd R', 'Initials': 'GR', 'LastName': 'Burmester', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.'}]",RMD open,['10.1136/rmdopen-2021-001621'] 2841,34385318,Measuring the scientific effectiveness of contact tracing: Evidence from a natural experiment.,"Contact tracing has for decades been a cornerstone of the public health approach to epidemics, including Ebola, severe acute respiratory syndrome, and now COVID-19. It has not yet been possible, however, to causally assess the method's effectiveness using a randomized controlled trial of the sort familiar throughout other areas of science. This study provides evidence that comes close to that ideal. It exploits a large-scale natural experiment that occurred by accident in England in late September 2020. Because of a coding error involving spreadsheet data used by the health authorities, a total of 15,841 COVID-19 cases (around 20% of all cases) failed to have timely contact tracing. By chance, some areas of England were much more severely affected than others. This study finds that the random breakdown of contact tracing led to more illness and death. Conservative causal estimates imply that, relative to cases that were initially missed by the contact tracing system, cases subject to proper contact tracing were associated with a reduction in subsequent new infections of 63% and a reduction insubsequent COVID-19-related deaths of 66% across the 6 wk following the data glitch.",2021,"It has not yet been possible, however, to causally assess the method's effectiveness using a randomized controlled trial of the sort familiar throughout other areas of science.",[],[],['COVID-19-related deaths'],[],[],"[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",15841.0,0.0518102,"It has not yet been possible, however, to causally assess the method's effectiveness using a randomized controlled trial of the sort familiar throughout other areas of science.","[{'ForeName': 'Thiemo', 'Initials': 'T', 'LastName': 'Fetzer', 'Affiliation': 'Competitive Advantage in the Global Economy Research Centre, Department of Economics, University of Warwick, Coventry CV4 7AL, United Kingdom.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Graeber', 'Affiliation': 'Harvard Business School, Harvard University, Boston, MA 02163 tgraeber@hbs.edu.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.2100814118'] 2842,34385274,Effect of surgical mask on exercise capacity in COPD: a randomised crossover trial.,,2021,,['COPD'],['surgical mask'],['exercise capacity'],"[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]","[{'cui': 'C0181758', 'cui_str': 'Surgical face mask'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.107722,,"[{'ForeName': 'Kuniaki', 'Initials': 'K', 'LastName': 'Hirai', 'Affiliation': 'Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan hiraik@med.showa-u.ac.jp.'}, {'ForeName': 'Akihiko', 'Initials': 'A', 'LastName': 'Tanaka', 'Affiliation': 'Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Sato', 'Affiliation': 'Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Sato', 'Affiliation': 'Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yoshitaka', 'Initials': 'Y', 'LastName': 'Uchida', 'Affiliation': 'Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Eisuke', 'Initials': 'E', 'LastName': 'Inoue', 'Affiliation': 'Showa University Research Administration Center, Showa University, Shinagawa-ku, Tokyo, Japan.'}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Sagara', 'Affiliation': 'Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.'}]",The European respiratory journal,['10.1183/13993003.02041-2021'] 2843,34385169,Novel Use of LMS Data to Predict Online Learning Success in A Pharmacy Capstone Course.,"Objective. Learning management system (LMS) data from online classes may provide opportunities to identify students at risk of failure. Previous LMS studies have not addressed the possibility of change in student engagement over time. The purpose of this study was to apply a novel statistical technique, group-based trajectory modeling (GBTM), to LMS data for an online course to identify predictors of successful course completion. Methods. Exploratory GBTM assessed the association of LMS activity (total activity time, dates of activity, and pages viewed) and attendance at virtual synchronous learning sessions with examination performance in a capstone disease-management course delivered in the final didactic quarter of a three-year Doctor of Pharmacy program. Groups were assigned based on trajectories of weekly page-view counts using structural-equation modeling. Results. GBTM identified three page-view engagement groups (median total page views, n): Group 1, high (1,818, n=24): Group 2, moderate (1,029, n=74), and Group 3, low (441 views, n=35). Group assignment alone was somewhat associated with final grade. Stratification based on consistent virtual synchronous learning session attendance improved predictive accuracy; for example, a top (A or A-) grade was earned by 49.0% and 24.0%, respectively, of Group 2 students with and without consistent synchronous engagement. Conclusion. Application of GBTM to LMS data, including information about synchronous engagement, could provide early warning signs of potential for course failure, helping instructors to target interventions to at-risk students. The technique should be further tested with alternative LMS data and early in didactics, before patterns of engagement are established.",2021,"Application of GBTM to LMS data, including information about synchronous engagement, could provide early warning signs of potential for course failure, helping instructors to target interventions to at-risk students.",[],"['LMS', 'Learning management system (LMS']","['LMS activity (total activity time, dates of activity, and pages viewed) and attendance']",[],"[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0013862', 'cui_str': 'Polyacrylamide gel electrophoresis'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}]",,0.0649148,"Application of GBTM to LMS data, including information about synchronous engagement, could provide early warning signs of potential for course failure, helping instructors to target interventions to at-risk students.","[{'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Buckley', 'Affiliation': 'Midwestern University, College of Pharmacy, Glendale, Arizona kbuckley@midwestern.edu.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Fairman', 'Affiliation': 'Midwestern University, College of Pharmacy, Glendale, Arizona.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Pogge', 'Affiliation': 'Midwestern University, College of Pharmacy, Glendale, Arizona.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Raney', 'Affiliation': 'Midwestern University, College of Pharmacy, Glendale, Arizona.'}]",American journal of pharmaceutical education,['10.5688/ajpe8594'] 2844,34385148,Mentored implementation to initiate a diabetes program in an underserved community: a pilot study.,"INTRODUCTION Community clinics often face pragmatic barriers, hindering program initiation and replication of controlled research trial results. Mentoring is a potential strategy to overcome these barriers. We piloted an in-person and telehealth mentoring strategy to implement the T elehealth-supported, I ntegrated Community Health Workers (CHWs), M edication-access, group visit E ducation (TIME) program in a community clinic. RESEARCH DESIGN AND METHODS Participants (n=55) were low-income Latino(a)s with type 2 diabetes. The study occurred in two, 6-month phases. Phase I provided proof-of-concept and an observational experience for the clinic team; participants (n=37) were randomized to the intervention (TIME) or control (usual care), and the research team conducted TIME while the clinic team observed. Phase II provided mentorship to implement TIME, and the research team mentored the clinic team as they conducted TIME for a new single-arm cohort of participants (n=18) with no previous exposure to the program. Analyses included baseline to 6-month comparisons of diabetes outcomes (primary outcome: hemoglobin A1c (HbA1c)): phase I intervention versus control, phase II (within group), and research-run (phase I intervention) versus clinic-run (phase II) arms. We also evaluated baseline to 6-month CHW knowledge changes. RESULTS Phase I: compared with the control, intervention participants had superior baseline to 6-month improvements for HbA1c (mean change: intervention: -0.73% vs control: 0.08%, p=0.016), weight (p=0.044), target HbA1c (p=0.035), hypoglycemia (p=0.021), medication non-adherence (p=0.0003), and five of six American Diabetes Association (ADA) measures (p<0.001-0.002). Phase II: participants had significant reductions in HbA1c (mean change: -0.78%, p=0.006), diastolic blood pressure (p=0.004), body mass index (0.012), weight (p=0.010), medication non-adherence (p<0.001), and six ADA measures (p=0.007-0.005). Phase I intervention versus phase II outcomes were comparable. CHWs improved knowledge from pre-test to post-tests (p<0.001). CONCLUSIONS A novel, mentored approach to implement TIME into a community clinic resulted in improved diabetes outcomes. Larger studies of longer duration are needed to fully evaluate the potential of mentoring community clinics.",2021,"participants had significant reductions in HbA1c (mean change: -0.78%, p=0.006), diastolic blood pressure (p=0.004), body mass index (0.012), weight (p=0.010), medication non-adherence (p<0.001), and six ADA measures (p=0.007-0.005).","['Participants (n=55) were low-income Latino(a)s with type 2 diabetes', 'clinic team; participants (n=37']",['intervention (TIME) or control (usual care'],"['hypoglycemia (p=0.021), medication non-adherence (p=0.0003), and five of six American Diabetes Association (ADA) measures', 'diabetes outcomes', 'medication non-adherence (p<0.001), and six ADA measures', 'body mass index', 'diastolic blood pressure', 'diabetes outcomes (primary outcome: hemoglobin A1c (HbA1c', 'weight']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0746935', 'cui_str': 'Noncompliance with medication regimen'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001457', 'cui_str': 'Adenosine deaminase'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]",55.0,0.0377339,"participants had significant reductions in HbA1c (mean change: -0.78%, p=0.006), diastolic blood pressure (p=0.004), body mass index (0.012), weight (p=0.010), medication non-adherence (p<0.001), and six ADA measures (p=0.007-0.005).","[{'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Vaughan', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, Texas, USA elizabeth.vaughan@bcm.edu.'}, {'ForeName': 'Aanand D', 'Initials': 'AD', 'LastName': 'Naik', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Amber B', 'Initials': 'AB', 'LastName': 'Amspoker', 'Affiliation': 'Health Policy, Quality & Informatics Program, Michael E. DeBakey VA Medical Center, Houston, Texas, USA.'}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Johnston', 'Affiliation': 'Department of Health and Human Performance, University of Houston, Houston, Texas, USA.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Landrum', 'Affiliation': 'School of Health Professions, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Ashok', 'Initials': 'A', 'LastName': 'Balasubramanyam', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Salim S', 'Initials': 'SS', 'LastName': 'Virani', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Christie M', 'Initials': 'CM', 'LastName': 'Ballantyne', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Foreyt', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.'}]",BMJ open diabetes research & care,['10.1136/bmjdrc-2021-002320'] 2845,34385097,Examining the Information Systems Success (ISS) of a mobile sexual health app (MyPEEPS Mobile) from the perspective of very young men who have sex with men (YMSM).,"OBJECTIVE The widespread and frequent use of mobile technology among adolescents, including sexual minority adolescents, presents an opportunity for the development of mobile health (mHealth) technology to combat the continuing HIV epidemic among young men who have sex with men (YMSM). We analyzed perceptions of the quality and impact of an HIV prevention mobile app on sexual risk reduction among YMSM. METHODS Participants were recruited from a larger randomized controlled trial of the MyPEEPS Mobile app among YMSM aged 13-18 years. Data were collected via semi-structured interviews to assess quality and user satisfaction with MyPEEPS Mobile app using analysis informed by the Information Systems Success framework. Interview data were transcribed verbatim and analyzed using six themes: information quality, net benefit, user satisfaction, product quality, service quality, and health care barriers. RESULTS Interviews were conducted with 40 YMSM (45% Hispanic; 80% non-White; 88% non-rural resident; 28% aged 17 years). Participants' responses indicated that information quality was high, reporting that the app information was concise, easy to understand, useful, and relevant to their life. The net benefits were stated as improvements in their decision-making skills, health behaviors, communication skills with partner(s), and increased knowledge of HIV risk. There was general user satisfaction and enjoyment when using the app, although most of the participants did not intend to reuse the app unless new activities were added. Participants expressed that the product quality of the app was good due to its personalization, representation of the LGBTQIA + community, and user-friendly interface. Although no major technical issues were reported, participants suggested that adaption to a native app, rather than a web app, would improve service quality through faster loading speed. Participants also identified some health care barriers that were minimized by app use. CONCLUSIONS The MyPEEPS Mobile app is a well received, functional, and entertaining mHealth HIV prevention tool that may improve HIV prevention skills and reduce HIV risk among YMSM.",2021,"The net benefits were stated as improvements in their decision-making skills, health behaviors, communication skills with partner(s), and increased knowledge of HIV risk.","['Participants were recruited from a larger randomized controlled trial of the MyPEEPS Mobile app among YMSM aged 13-18 years', 'young men who have sex with men (YMSM', 'Interviews were conducted with 40 YMSM (45% Hispanic; 80% non-White; 88% non-rural resident; 28% aged 17\xa0years', 'adolescents, including sexual minority adolescents']",['mobile sexual health app (MyPEEPS Mobile'],"['service quality', 'information quality, net benefit, user satisfaction, product quality, service quality, and health care barriers', 'decision-making skills, health behaviors, communication skills with partner(s), and increased knowledge of HIV risk', 'sexual risk reduction']","[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4277573', 'cui_str': 'Lesbigay Persons'}]","[{'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]","[{'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}]",,0.170465,"The net benefits were stated as improvements in their decision-making skills, health behaviors, communication skills with partner(s), and increased knowledge of HIV risk.","[{'ForeName': 'Evette', 'Initials': 'E', 'LastName': 'Cordoba', 'Affiliation': 'School of Nursing, Columbia University, New York, NY 10032, USA. Electronic address: ec2678@cumc.columbia.edu.'}, {'ForeName': 'Betina', 'Initials': 'B', 'LastName': 'Idnay', 'Affiliation': 'School of Nursing, Columbia University, New York, NY 10032, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Garofalo', 'Affiliation': ""Division of Adolescent Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Chicago, IL 60611, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, USA.""}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Kuhns', 'Affiliation': ""Division of Adolescent Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Chicago, IL 60611, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, USA.""}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Pearson', 'Affiliation': 'Indigenous Wellness Research Institute, School of Social Work, University of Washington, 4101 15th Avenue Northeast, Seattle, WA 98105, USA.'}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Bruce', 'Affiliation': 'Birmingham AIDS Outreach, 205 32nd Street, Birmingham, AL 35233, USA.'}, {'ForeName': 'D Scott', 'Initials': 'DS', 'LastName': 'Batey', 'Affiliation': 'Department of Social Work, University of Alabama at Birmingham, 1720 2nd Avenue, South, Birmingham, AL 35294, USA.'}, {'ForeName': 'Asa', 'Initials': 'A', 'LastName': 'Radix', 'Affiliation': 'Callen-Lorde Community Health Center, 356 West 18th Street, New York, NY 10011, USA.'}, {'ForeName': 'Uri', 'Initials': 'U', 'LastName': 'Belkind', 'Affiliation': 'Callen-Lorde Community Health Center, 356 West 18th Street, New York, NY 10011, USA.'}, {'ForeName': 'Marco A', 'Initials': 'MA', 'LastName': 'Hidalgo', 'Affiliation': ""Children's Hospital Los Angeles, The Saban Research Institute, 4661 Sunset Blvd, Los Angeles, CA 90027, USA; Keck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA.""}, {'ForeName': 'Sabina', 'Initials': 'S', 'LastName': 'Hirshfield', 'Affiliation': 'Department of Medicine, SUNY Downstate Health Sciences University, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.'}, {'ForeName': 'Rafael Garibay', 'Initials': 'RG', 'LastName': 'Rodriguez', 'Affiliation': 'School of Nursing, Columbia University, New York, NY 10032, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Schnall', 'Affiliation': 'School of Nursing, Columbia University, New York, NY 10032, USA.'}]",International journal of medical informatics,['10.1016/j.ijmedinf.2021.104529'] 2846,34385093,Effect of processed aloe vera gel on immunogenicity in inactivated quadrivalent influenza vaccine and upper respiratory tract infection in healthy adults: A randomized double-blind placebo-controlled trial.,"BACKGROUND Aloe vera is a functional food with various pharmacological functions, including an immune-modulating effect. Until now, A. vera has never been studied as an adjuvant in influenza vaccine, and its effects on upper respiratory tract infection (URI) are unknown. PURPOSE The objective of our study was to investigate the effect of processed A. vera gel (PAG) on immunogenicity of quadrivalent inactivated influenza vaccine and URI in healthy adults. STUDY DESIGN A randomized, double-blind, placebo-controlled clinical trial was performed. METHODS This study was conducted in 100 healthy adults at a single center from September 2017 to May 2018. Subjects were randomly divided into a PAG group (n = 50) and a placebo group (n = 50). The enrolled subjects were instructed to ingest the study drug for 8 weeks. The participants received a single dose of quadrivalent inactivated influenza vaccine after taking the study drug for the first 4 weeks of the study. The primary endpoint was seroprotection rate against at least one viral strain at 4 weeks post-vaccination. Other outcomes were seroprotection rate at 24 weeks post-vaccination, seroconversion rate, geometric mean fold increase (GMFI) at 4 and 24 weeks post-vaccination, seroprotection rate ratio and geometric mean titer ratio (GMTR) at 4 weeks post-vaccination between PAG and placebo groups, and incidence, severity, and duration of URI. RESULTS The European Committee for proprietary medicinal products (CPMP) evaluation criteria were met at least one in the PAG and placebo groups for all strains. However, there was no significant difference in the seroprotection rate at 4 weeks post-vaccination against all strains in both PAG and placebo groups. Among secondary endpoints, the GMFI at 4 weeks post-vaccination for the A/H3N2 was significantly higher in the PAG than in placebo group. The GMTR as adjuvant effect was 1.382 (95% CI, 1.014-1.1883). Kaplan-Meier curve analysis showed a reduction in incidence of URI (p = 0.035), and a generalized estimating equation model identified a decrease in repeated URI events (odds ratio 0.57; 95% CI, 0.39-0.83; p = 0.003) in the PAG group. CONCLUSIONS Oral intake of PAG did not show a significant increase in seroprotection rate from an immunogenicity perspective. However, it reduced the number of URI episodes. A well-designed further study is needed on the effect of PAG's antibody response against A/H3N2 in the future.",2021,"However, there was no significant difference in the seroprotection rate at 4 weeks post-vaccination against all strains in both PAG and placebo groups.","['100 healthy adults at a single center from September 2017 to May 2018', 'healthy adults']","['processed aloe vera gel', 'quadrivalent inactivated influenza vaccine', 'PAG', 'placebo', 'processed A. vera gel (PAG']","['seroprotection rate ratio and geometric mean titer ratio (GMTR', 'seroprotection rate', 'incidence of URI', 'number of URI episodes', 'immunogenicity', 'seroprotection rate against at least one viral strain', 'incidence, severity, and duration of URI', 'seroconversion rate, geometric mean fold increase (GMFI', 'repeated URI events', 'GMFI at 4 weeks post-vaccination']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0974143', 'cui_str': 'Aloe vera gel'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0185026', 'cui_str': 'Plication'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",100.0,0.709017,"However, there was no significant difference in the seroprotection rate at 4 weeks post-vaccination against all strains in both PAG and placebo groups.","[{'ForeName': 'Jeong-Hwan', 'Initials': 'JH', 'LastName': 'Hwang', 'Affiliation': 'Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Jeonbuk 54896, Republic of Korea; Research Institute of Clinical Medicine of Jeonbuk National University, Jeonju, Jeonbuk, 54896, Republic of Korea; Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Jeonbuk, 54907, Republic of Korea.'}, {'ForeName': 'Mi-Ra', 'Initials': 'MR', 'LastName': 'Oh', 'Affiliation': 'Clinical Trial Center for Functional Foods, Jeonbuk National University Hospital, Jeonju, Jeonbuk 54907, Republic of Korea.'}, {'ForeName': 'Ji-Hyun', 'Initials': 'JH', 'LastName': 'Hwang', 'Affiliation': 'Clinical Trial Center for Functional Foods, Jeonbuk National University Hospital, Jeonju, Jeonbuk 54907, Republic of Korea.'}, {'ForeName': 'Eun-Kyung', 'Initials': 'EK', 'LastName': 'Choi', 'Affiliation': 'Clinical Trial Center for Functional Foods, Jeonbuk National University Hospital, Jeonju, Jeonbuk 54907, Republic of Korea.'}, {'ForeName': 'Su-Jin', 'Initials': 'SJ', 'LastName': 'Jung', 'Affiliation': 'Clinical Trial Center for Functional Foods, Jeonbuk National University Hospital, Jeonju, Jeonbuk 54907, Republic of Korea.'}, {'ForeName': 'Eun-Jung', 'Initials': 'EJ', 'LastName': 'Song', 'Affiliation': 'Department of Pharmacy, Korea University College of Pharmacy, Sejong 30019, Republic of Korea.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Españo', 'Affiliation': 'Department of Pharmacy, Korea University College of Pharmacy, Sejong 30019, Republic of Korea.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Webby', 'Affiliation': ""Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.""}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Webster', 'Affiliation': ""Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.""}, {'ForeName': 'Jeong-Ki', 'Initials': 'JK', 'LastName': 'Kim', 'Affiliation': 'Department of Pharmacy, Korea University College of Pharmacy, Sejong 30019, Republic of Korea. Electronic address: jkfrancis@korea.ac.kr.'}, {'ForeName': 'Soo-Wan', 'Initials': 'SW', 'LastName': 'Chae', 'Affiliation': 'Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Jeonbuk, 54907, Republic of Korea; Clinical Trial Center for Functional Foods, Jeonbuk National University Hospital, Jeonju, Jeonbuk 54907, Republic of Korea. Electronic address: swchae@jbctc.org.'}]",Phytomedicine : international journal of phytotherapy and phytopharmacology,['10.1016/j.phymed.2021.153668'] 2847,34387826,Prophylactic Postoperative High Flow Nasal Oxygen Versus Conventional Oxygen Therapy in Obese Patients Undergoing Bariatric Surgery (OXYBAR Study): a Pilot Randomised Controlled Trial.,"BACKGROUND Patients with obesity are predisposed to a reduction in end-expiratory lung volume (EELV) and atelectasis after anaesthesia. High flow nasal oxygen (HFNO) may increase EELV, reducing the likelihood of postoperative pulmonary complications (PPC). We conducted a pilot randomised controlled trial (RCT) of conventional oxygen therapy versus HFNO after bariatric surgery. The aim was to investigate the feasibility of using electrical impedance tomography (EIT) as a means of assessing respiratory mechanics and to inform the design of a definitive RCT. METHODS We performed a single-centre, parallel-group, pilot RCT. Adult patients with obesity undergoing elective bariatric surgery were eligible for inclusion. We excluded patients with a known contraindication to HFNO or with chronic lung disease. RESULTS Fifty patients were randomised in equal proportions. One patient crossed over from conventional O 2 to HFNO. Delta EELI was higher at 1 hour in patients receiving HFNO (mean difference = 831 Au (95% CI - 1636-3298), p = 0.5). Continuous EIT beyond 1 hour was poorly tolerated. At 6 hours, there were no differences in PaO 2 /FiO 2 ratio or PaCO 2 . Only one patient developed a PPC (in the HFNO group) by 6 weeks. CONCLUSIONS These data suggest that a large-scale RCT of HFNO after bariatric surgery in an 'all-comers' population is likely infeasible. While EIT was an effective means of assessing respiratory mechanics, it was impractical over time. Similarly, the infrequency of PPC precludes its use as a primary outcome. Future studies should focus on identifying patients at the greatest risk of PPC.",2021,Delta EELI was higher at 1 hour in patients receiving HFNO (mean difference = 831,"['Adult patients with obesity undergoing elective bariatric surgery were eligible for inclusion', 'Obese Patients Undergoing Bariatric Surgery (OXYBAR Study', 'Patients with obesity', 'patients with a known contraindication to HFNO or with chronic lung disease', 'Fifty patients']","['Prophylactic Postoperative High Flow Nasal Oxygen Versus Conventional Oxygen Therapy', 'electrical impedance tomography (EIT', 'High flow nasal oxygen (HFNO', 'conventional oxygen therapy']",['Delta EELI'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0746102', 'cui_str': 'Chronic lung disease'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0162537', 'cui_str': 'Impedance'}, {'cui': 'C0040395', 'cui_str': 'Diagnostic tomography'}]","[{'cui': 'C0439097', 'cui_str': 'Delta'}]",50.0,0.385831,Delta EELI was higher at 1 hour in patients receiving HFNO (mean difference = 831,"[{'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Fulton', 'Affiliation': 'Department of Anaesthesia and Critical Care, Queen Elizabeth II University Hospital, Glasgow, UK.'}, {'ForeName': 'Jonathan E', 'Initials': 'JE', 'LastName': 'Millar', 'Affiliation': 'Critical Care Research Group, The Prince Charles Hospital, Rode Road, Brisbane, Queensland, 4032, Australia.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Merza', 'Affiliation': ""St. Andrew's War Memorial Hospital, Brisbane, Australia.""}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Johnston', 'Affiliation': ""St. Andrew's War Memorial Hospital, Brisbane, Australia.""}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Corley', 'Affiliation': 'Critical Care Research Group, The Prince Charles Hospital, Rode Road, Brisbane, Queensland, 4032, Australia.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Faulke', 'Affiliation': ""St. Andrew's War Memorial Hospital, Brisbane, Australia.""}, {'ForeName': 'Ivan L', 'Initials': 'IL', 'LastName': 'Rapchuk', 'Affiliation': 'Faculty of Medicine, University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Tarpey', 'Affiliation': ""St. Andrew's War Memorial Hospital, Brisbane, Australia.""}, {'ForeName': 'Jonathon P', 'Initials': 'JP', 'LastName': 'Fanning', 'Affiliation': 'Critical Care Research Group, The Prince Charles Hospital, Rode Road, Brisbane, Queensland, 4032, Australia.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Lockie', 'Affiliation': ""St. Andrew's War Memorial Hospital, Brisbane, Australia.""}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Lockie', 'Affiliation': ""St. Andrew's War Memorial Hospital, Brisbane, Australia.""}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Fraser', 'Affiliation': 'Critical Care Research Group, The Prince Charles Hospital, Rode Road, Brisbane, Queensland, 4032, Australia. fraserjohn001@gmail.com.'}]",Obesity surgery,['10.1007/s11695-021-05644-y'] 2848,34387823,Effects of Moderate-Intensity Aerobic Exercise on Blood Glucose Levels and Pregnancy Outcomes in Patients With Gestational Diabetes Mellitus: A Randomized Controlled Trial.,"INTRODUCTION To investigate the effects of structured moderate-intensity aerobic exercise on blood glucose, insulin, and pregnancy outcomes in patients with gestational diabetes mellitus (GDM). METHODS One hundred one patients with GDM were randomly divided into a control group (50 cases) and an experimental group (51 cases) in a class 3 first-level general hospital. GDM patients in the control group received a personalized diabetes diet intervention, online education, and routine prenatal care. The experimental group added 6 weeks of moderate-intensity aerobic exercise in addition to the identical conditions given to the control group. The differences of fasting and 2-h postprandial blood glucose, insulin use, and adverse pregnancy outcomes were evaluated between the experimental and control group after intervention. RESULTS Outcomes were available from 89 participants. Compared with before intervention, there were statistically significant differences in fasting blood glucose and 2-h blood glucose after three meals in both groups (P < 0.05). There were statistically significant differences in the average fasting blood glucose, the average 2-h postprandial blood glucose, the insulin dosage, and the utilization rate between the experimental and control group after the intervention (P < 0.05). Parameters in the experimental group were all lower than in the control group. Compared with the control group, the incidence of adverse pregnancy outcomes in the experimental group after intervention was not statistically significant (P > 0.05). CONCLUSION Moderate-intensity aerobic exercise can help improve blood glucose control and insulin use in patients with GDM. In the future, long-term follow-up can be conducted for maternal and neonatal infants to evaluate the impact of exercise intervention on the risk of type 2 diabetes. CLINICAL TRIAL REGISTRATION The trial was approved by the registration of the Chinese Clinical Trial Registry. Registration number: ChiCTR1900027929.",2021,"There were statistically significant differences in the average fasting blood glucose, the average 2-h postprandial blood glucose, the insulin dosage, and the utilization rate between the experimental and control group after the intervention (P < 0.05).","['Patients With Gestational Diabetes Mellitus', 'One hundred one patients with GDM', 'patients with GDM', 'patients with gestational diabetes mellitus (GDM']","['GDM', 'personalized diabetes diet intervention, online education, and routine prenatal care', 'Moderate-intensity aerobic exercise', 'exercise intervention', 'structured moderate-intensity aerobic exercise', 'moderate-intensity aerobic exercise', 'Moderate-Intensity Aerobic Exercise']","['incidence of adverse pregnancy outcomes', 'fasting and 2-h postprandial blood glucose, insulin use, and adverse pregnancy outcomes', 'blood glucose, insulin, and pregnancy outcomes', 'average fasting blood glucose, the average 2-h postprandial blood glucose, the insulin dosage, and the utilization rate', 'blood glucose control and insulin use', 'Blood Glucose Levels and Pregnancy Outcomes', 'fasting blood glucose and 2-h blood glucose']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4505477', 'cui_str': 'Online Education'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0240016', 'cui_str': 'Insulin used'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}]",101.0,0.0157435,"There were statistically significant differences in the average fasting blood glucose, the average 2-h postprandial blood glucose, the insulin dosage, and the utilization rate between the experimental and control group after the intervention (P < 0.05).","[{'ForeName': 'Xie', 'Initials': 'X', 'LastName': 'Yaping', 'Affiliation': 'Nursing Department, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China.'}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Huifen', 'Affiliation': 'Clinical Nursing Teaching and Research Department, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China. 624633497@qq.com.'}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Meijing', 'Affiliation': 'Gynaecology and Obstetrics Department, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian province, China.'}, {'ForeName': 'Huang', 'Initials': 'H', 'LastName': 'Huibin', 'Affiliation': 'Endocrinology Department, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian province, China.'}, {'ForeName': 'Liu', 'Initials': 'L', 'LastName': 'Chunhong', 'Affiliation': 'Outpatient Department, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China.'}, {'ForeName': 'Huang', 'Initials': 'H', 'LastName': 'Fengfeng', 'Affiliation': 'Clinical Nursing Teaching and Research Department, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China.'}, {'ForeName': 'Wu', 'Initials': 'W', 'LastName': 'Jingjing', 'Affiliation': 'Gynaecology and Obstetrics Department, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian province, China.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-021-01135-6'] 2849,34387797,The Effect of Spiritual Care on Anxiety and Depression Level in Patients Receiving Hemodialysis Treatment: a Randomized Controlled Trial.,"The present study was conducted to determine the effect of spiritual care on the anxiety and depression levels of patients receiving hemodialysis treatment. The research was carried out between January and May 2019 in a training and research hospital hemodialysis unit in the Eastern Anatolian Region of Turkey. The research was completed with a total of 71 patients (33 experiments, 38 controls) who received hemodialysis treatment. Regarding in-group comparison, the difference between the mean scores of pre-test and post-test of the patients concerning the anxiety and depression in the experimental group was found to be statistically significant (p ˂ 0.05). It was determined that training for strengthening spirituality was effective in reducing the anxiety and depression levels of patients receiving hemodialysis treatment. It can be suggested that spiritual care should be used as a complementary method in health care practices to increase the effectiveness of the treatment.",2021,It was determined that training for strengthening spirituality was effective in reducing the anxiety and depression levels of patients receiving hemodialysis treatment.,"['patients receiving hemodialysis treatment', 'January and May 2019 in a training and research hospital hemodialysis unit in the Eastern Anatolian Region of Turkey', '71 patients (33 experiments, 38 controls) who received hemodialysis treatment', 'Patients Receiving Hemodialysis Treatment']","['spiritual care', 'Spiritual Care']","['anxiety and depression levels', 'anxiety and depression', 'Anxiety and Depression Level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0019007', 'cui_str': 'Hospital Hemodialysis Units'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0041400', 'cui_str': 'Turkey - country'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0150355', 'cui_str': 'Spiritual support'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",71.0,0.0082431,It was determined that training for strengthening spirituality was effective in reducing the anxiety and depression levels of patients receiving hemodialysis treatment.,"[{'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Durmuş', 'Affiliation': 'Department of Gerontology, Faculty of Health Sciences, Mus Alparslan University, 49100, Muş, Turkey. saremeryem01@gmail.com.'}, {'ForeName': 'Mine', 'Initials': 'M', 'LastName': 'Ekinci', 'Affiliation': 'Psychiatry Nursing Department, Faculty of Nursing, Atatürk University, 25100, Erzurum, Turkey.'}]",Journal of religion and health,['10.1007/s10943-021-01386-4'] 2850,34387765,PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.,"BACKGROUND Peritoneal metastases (PM) from ovarian, gastric, appendiceal, or colorectal origin can be treated via cytoreductive surgery with or without the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) for selected patients. Unfortunately, not all patients are candidates for aggressive surgical debulking. For these patients, pressurized intraperitoneal aerosolized chemotherapy (PIPAC) has emerged as an alternative method for intraperitoneal (IP) chemotherapy administration. This report presents the design and implementation of the first phase 1 trial to evaluate the safety and efficacy of PIPAC in the United States. METHODS This is an ongoing prospective phase 1 clinical trial of PIPAC for patients who have histologically confirmed ovarian, uterine, gastric, appendiceal, or colorectal cancer with PM and have progressed to at least one evidence-based chemotherapeutic regimen. The trial has two clinical arms. The patients in arm 1 have gynecologic and gastric malignancies treated with IP cisplatin and doxorubicin, and the arm 2 patients have colorectal and appendiceal malignancies treated with intravenous fluorouracil and leucovorin followed by IP oxaliplatin. All the patients are monitored for dose-limiting toxicities and adverse events. RESULTS Practical and technical considerations for the phase 1 PIPAC trial are presented. These considerations include patient selection, operating room setup, and technical details for successful aerosolized chemotherapy delivery. The phase 1 study results will be reported separately at completion of the trial. CONCLUSIONS The PIPAC treatment is a feasible, minimally invasive approach that permits IP delivery of chemotherapy. Once completed, the ongoing phase 1 trial will help to provide safety and initial efficacy data.",2021,"This is an ongoing prospective phase 1 clinical trial of PIPAC for patients who have histologically confirmed ovarian, uterine, gastric, appendiceal, or colorectal cancer with PM and have progressed to at least one evidence-based chemotherapeutic regimen.","['Gynecologic and Gastrointestinal Peritoneal Metastases', 'patients who have histologically confirmed ovarian, uterine, gastric, appendiceal, or colorectal cancer with PM and have progressed to at least one evidence-based chemotherapeutic regimen', 'patients in arm 1 have gynecologic and gastric malignancies treated with']","['pressurized intraperitoneal aerosolized chemotherapy (PIPAC', 'intravenous fluorouracil and leucovorin followed by IP oxaliplatin', 'hyperthermic intraperitoneal chemotherapy (HIPEC', 'PIPAC', 'IP cisplatin and doxorubicin']",[],"[{'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0346989', 'cui_str': 'Secondary malignant neoplasm of peritoneum'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0003392', 'cui_str': 'Antineoplastic agent'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0442120', 'cui_str': 'Intraperitoneal'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}]",[],,0.0521359,"This is an ongoing prospective phase 1 clinical trial of PIPAC for patients who have histologically confirmed ovarian, uterine, gastric, appendiceal, or colorectal cancer with PM and have progressed to at least one evidence-based chemotherapeutic regimen.","[{'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Raoof', 'Affiliation': 'Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center (COH), Duarte, CA, USA. Mraoof@coh.org.'}, {'ForeName': 'Gautam', 'Initials': 'G', 'LastName': 'Malhotra', 'Affiliation': 'Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center (COH), Duarte, CA, USA.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Kohut', 'Affiliation': 'Division of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': ""O'Leary"", 'Affiliation': 'Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center (COH), Duarte, CA, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Frankel', 'Affiliation': 'Biostatistics Core, City of Hope Beckman Research Institute, Duarte, CA, USA.'}, {'ForeName': 'Thuy', 'Initials': 'T', 'LastName': 'Tran', 'Affiliation': 'Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center (COH), Duarte, CA, USA.'}, {'ForeName': 'Marwan', 'Initials': 'M', 'LastName': 'Fakih', 'Affiliation': 'Department of Medical Oncology, COH, Duarte, CA, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Chao', 'Affiliation': 'Department of Medical Oncology, COH, Duarte, CA, USA.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Lim', 'Affiliation': 'Department of Medical Oncology, COH, Duarte, CA, USA.'}, {'ForeName': 'Yanghee', 'Initials': 'Y', 'LastName': 'Woo', 'Affiliation': 'Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center (COH), Duarte, CA, USA.'}, {'ForeName': 'Isaac B', 'Initials': 'IB', 'LastName': 'Paz', 'Affiliation': 'Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center (COH), Duarte, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lew', 'Affiliation': 'Department of Anesthesiology, COH, Duarte, CA, USA.'}, {'ForeName': 'Mihaela C', 'Initials': 'MC', 'LastName': 'Cristea', 'Affiliation': 'Department of Medical Oncology, COH, Duarte, CA, USA.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Rodriguez-Rodriguez', 'Affiliation': 'Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center (COH), Duarte, CA, USA.'}, {'ForeName': 'Yuman', 'Initials': 'Y', 'LastName': 'Fong', 'Affiliation': 'Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center (COH), Duarte, CA, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Blakely', 'Affiliation': 'National Institute of Health, Bethesda, MD, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Whelan', 'Affiliation': 'Northwell Cancer Center, New York, NY, USA.'}, {'ForeName': 'Marc A', 'Initials': 'MA', 'LastName': 'Reymond', 'Affiliation': 'Tuebingen Universitaet, Tübingen, Germany.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Merchea', 'Affiliation': 'Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Thanh H', 'Initials': 'TH', 'LastName': 'Dellinger', 'Affiliation': 'Division of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA. tdellinger@coh.org.'}]",Annals of surgical oncology,['10.1245/s10434-021-10505-0'] 2851,34385047,Effectiveness of Yoga Nidra in reducing stress in school going adolescents: An experimental study.,"BACKGROUND AND OBJECTIVES Academic stress can exert severe stress in adolescents answering their career deciding board exams. The present study attempted to understand the efficacy of Yoga Nidra (YN) in mitigating psychosocial stress. DESIGN and Methods: This study was carried on 10th-grade students (ages 14 to 16) and had two arms, one performing YN (experimental) and the other without YN (control) for 21 consecutive days. Modified Adolescent Stress Questionnaire (ASQ-I) was used to assess the stress in the students before and after the intervention. RESULTS The results indicate that performing YN was effective and significantly decreased the total stress (P < 0.001) and vital domains like the stress of home life (P < 0.005), school performance (P < 0.026), teacher interaction (P < 0.024), future uncertainty (P < 0.001), school and leisure conflict (P < 0.001). Also, at the end of the study in control, low and moderate stress was observed in 58.06% and 41.93%, while in the YN group, it was 96.15% and 3.85% and was statistically significant (p < 0.001). CONCLUSIONS This study shows that YN effectively reduced psychosocial stress in adolescents and could be useful in school curriculum.",2021,"The results indicate that performing YN was effective and significantly decreased the total stress (P < 0.001) and vital domains like the stress of home life (P < 0.005), school performance (P < 0.026), teacher interaction (P < 0.024), future uncertainty (P < 0.001), school and leisure conflict (P < 0.001).","['adolescents answering their career deciding board exams', 'school going adolescents', '10th-grade students (ages 14 to 16) and had two arms, one performing YN (experimental) and the other without YN (control) for 21 consecutive days']","['Yoga Nidra (YN', 'Yoga Nidra']","['vital domains like the stress of home life', 'psychosocial stress', 'school performance', 'Modified Adolescent Stress Questionnaire (ASQ-I', 'low and moderate stress', 'school and leisure conflict', 'teacher interaction', 'total stress']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}]","[{'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0086542', 'cui_str': 'Leisure'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.0354304,"The results indicate that performing YN was effective and significantly decreased the total stress (P < 0.001) and vital domains like the stress of home life (P < 0.005), school performance (P < 0.026), teacher interaction (P < 0.024), future uncertainty (P < 0.001), school and leisure conflict (P < 0.001).","[{'ForeName': 'Ovine Loyster', 'Initials': 'OL', 'LastName': ""D'souza"", 'Affiliation': 'Department of Psychiatric Nursing, Father Muller College of Nursing, Mangalore, Karnataka, 575002, India. Electronic address: ovine.dsouza@gmail.com.'}, {'ForeName': 'Agnes Elizabeth', 'Initials': 'AE', 'LastName': 'Jose', 'Affiliation': 'Department of Psychiatric Nursing, Father Muller College of Nursing, Mangalore, Karnataka, 575002, India.'}, {'ForeName': 'Sucharitha', 'Initials': 'S', 'LastName': 'Suresh', 'Affiliation': 'Department of Community Medicine, Father Muller Medical College Hospital, Mangalore, Karnataka, 575002, India.'}, {'ForeName': 'Manjeshwar Shrinath', 'Initials': 'MS', 'LastName': 'Baliga', 'Affiliation': 'Father Muller Medical Research Centre, Mangalore, Karnataka, 575002, India. Electronic address: msbaliga@gmail.com.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2021.101462'] 2852,34385027,Sinus-like versus random vibration: Acute effects on elderly people with a high risk of falling.,"BACKGROUND Whole-body vibration (WBV) could be an alternative training method for elderly with a high risk of falling. RESEARCH QUESTION What acute effects of sinus-like and random WBV intervention occur in this risk group and how do they differ? METHODS This prospective pilot study was performed on two days separated by a one-week wash-out phase. Twelve subjects (10 women and 2 men, age 77.7 ± 5.3; 162.3 ± 7.4 cm; 82.4 ± 15.2 kg; BMI 31.2 ± 5.1 kg/m²) undertook sinus-like WBV intervention. One week later random WBV were performed. This consisted of six intervals each lasting 60 s, with heart and respiratory rates monitored. Feasibility outcomes involved safety and compliance. The primary endpoint was postural control, measured by a static posturography before and after the first interval and complete intervention. Secondary outcomes measured before and after the intervention were a Timed-Up-and-Go-Test (TUGT) and an instrumental gait analysis. RESULTS Random WBV intervention showed positive acute effect on postural control (Standard deviation (SD) Ellipse area p = 0.007; SD of the Center of force (CoF) independent from direction p = 0.017; SD of the CoF in the antero-posterior direction p = 0.011). There were no significant acute effects on TUGT or gait analysis (comparison between sinus-like and random WBV: Single Task: ΔVelocity p = 0.373, ΔStep time p = 0.077, ΔStep length p = 0.369, ΔStride length p = 0.408, ΔDouble-support-time p = 0.492; Dual task: ΔVelocity p = 0.580, ΔStep-time p = 0.559, ΔStep length p = 0.626, ΔStride length p = 0.584, ΔDouble-support-time p = 0.550). During sinus-like WBV, heart rate increased significantly from rest 69.7 ± 20.9bpm to max.146.0 ± 24.9bpm (p = 0.025). Respiratory rate increased significantly from 10.0 ± 1.0 to max.32.0 ± 6.0 (p = 0.011) during random WBV. No undesirable side effects were observed. SIGNIFICANCE Findings demonstrate that random WBV improves acute functional ability of postural control, but not gait for elderly people with a high risk of falling. Intervention with WBV seems safe and well accepted by participants. Monitoring of heart and respiratory rate offers protection for subjects with heart disease.",2021,"There were no significant acute effects on TUGT or gait analysis (comparison between sinus-like and random WBV: Single Task: ΔVelocity p = 0.373, ΔStep time p = 0.077, ΔStep length p = 0.369, ΔStride length p = 0.408, ΔDouble-support-time p = 0.492; Dual task: ΔVelocity p = 0.580, ΔStep-time p = 0.559, ΔStep length p = 0.626, ΔStride length p = 0.584, ΔDouble-support-time p = 0.550).","['elderly with a high risk of falling', 'subjects with heart disease', 'Twelve subjects (10 women and 2 men, age 77.7 ± 5.3; 162.3 ± 7.4 cm; 82.4 ± 15.2 kg; BMI 31.2 ± 5.1 kg/m²) undertook sinus-like WBV intervention', 'elderly people with a high risk of falling']","['Sinus-like versus random vibration', 'Whole-body vibration (WBV', 'random WBV']","['acute functional ability of postural control', 'Respiratory rate', 'postural control, measured by a static posturography', 'positive acute effect on postural control', 'heart rate', 'undesirable side effects', 'acute effects on TUGT or gait analysis', 'safety and compliance', 'Timed-Up-and-Go-Test (TUGT) and an instrumental gait analysis']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C4517858', 'cui_str': '7.4'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C5191319', 'cui_str': '31.2'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0919611', 'cui_str': 'Posturography'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0558820', 'cui_str': 'Examination of gait'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",10.0,0.0392162,"There were no significant acute effects on TUGT or gait analysis (comparison between sinus-like and random WBV: Single Task: ΔVelocity p = 0.373, ΔStep time p = 0.077, ΔStep length p = 0.369, ΔStride length p = 0.408, ΔDouble-support-time p = 0.492; Dual task: ΔVelocity p = 0.580, ΔStep-time p = 0.559, ΔStep length p = 0.626, ΔStride length p = 0.584, ΔDouble-support-time p = 0.550).","[{'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Kiehl', 'Affiliation': 'Hannover Medical School (MHH), Institute of Sports Medicine, Hannover, Germany.'}, {'ForeName': 'Lothar', 'Initials': 'L', 'LastName': 'Stein', 'Affiliation': 'Hannover Medical School (MHH), Institute of Sports Medicine, Hannover, Germany. Electronic address: Stein.Lothar@mh-hannover.de.'}, {'ForeName': 'Arno', 'Initials': 'A', 'LastName': 'Kerling', 'Affiliation': 'Hannover Medical School (MHH), Institute of Sports Medicine, Hannover, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Tegtbur', 'Affiliation': 'Hannover Medical School (MHH), Institute of Sports Medicine, Hannover, Germany.'}, {'ForeName': 'Tobias S', 'Initials': 'TS', 'LastName': 'Kaeding', 'Affiliation': 'Hannover Medical School (MHH), Institute of Sports Medicine, Hannover, Germany; Leibniz University Hannover, Institute of Sport Science, Department of Sport and Health, Hannover, Germany.'}]",Gait & posture,['10.1016/j.gaitpost.2021.07.018'] 2853,34384991,The role of anxiety sensitivity in anger symptomatology: Results from a randomized controlled trial.,"Anger is often overlooked in the assessment and treatment of pathological anxiety, despite there being evidence that anger is elevated across all anxiety disorders. Anxiety sensitivity (AS), a major risk factor of anxiety disorders, has been shown to modulate anger in response to threat induced hyperarousal. The current study therefore examined if reductions in anxiety sensitivity (AS) mediate reductions in anger symptoms. Outcomes from a randomized control trial evaluating the efficacy of a brief AS mitigation intervention were analyzed. Patients with anxiety and comorbid conditions were randomly assigned to AS reduction (n  = 58) or a repeated contact control condition (n  = 60) and followed up with for three months. Analyses evaluated whether treatment related change in AS mediated later reductions in anger, hostility, verbal aggression, and physical aggression. Results revealed that reductions in AS temporally mediated the effects of treatment on later reductions in anger, hostility, verbal aggression, and physical aggression. Specificity analyses provided further support for the direction and specific variables examined in these models. Results suggest that AS may be a promising treatment target for anger symptoms among those with elevated anxiety symptoms.",2021,"Results revealed that reductions in AS temporally mediated the effects of treatment on later reductions in anger, hostility, verbal aggression, and physical aggression.","['Patients with anxiety and comorbid conditions', 'anger symptomatology']",['repeated contact control condition'],"['Anxiety sensitivity (AS', 'anger, hostility, verbal aggression, and physical aggression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1275743', 'cui_str': 'Co-morbid conditions'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0020039', 'cui_str': 'Hostile behavior'}, {'cui': 'C0424322', 'cui_str': 'Verbal aggression'}, {'cui': 'C0424323', 'cui_str': 'Physical aggression'}]",,0.043501,"Results revealed that reductions in AS temporally mediated the effects of treatment on later reductions in anger, hostility, verbal aggression, and physical aggression.","[{'ForeName': 'Justine S', 'Initials': 'JS', 'LastName': 'Thompson', 'Affiliation': 'Department of Psychology, Florida State University, United States. Electronic address: justinethompson@psy.fsu.edu.'}, {'ForeName': 'Norman B', 'Initials': 'NB', 'LastName': 'Schmidt', 'Affiliation': 'Department of Psychology, Florida State University, United States.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2021.102462'] 2854,34384941,Inertial flywheel vs heavy slow resistance training among athletes with patellar tendinopathy: A randomised trial.,"OBJECTIVES To compare the efficacy of inertial flywheel and heavy slow resistance training in reducing pain and improving function in patellar tendinopathy. DESIGN Randomised clinical trial. METHODS Fourty two participants (1 woman, 41 men) with longstanding (>3 months) patellar tendinopathy were randomised into inertial flywheel resistance (N = 21) or heavy slow resistance (N = 21) group. Both programmes consisted of three supervised inertial flywheel or heavy slow resistance exercise sessions per week in a fitness center during 12 weeks. Primary outcome was pain and function, assessed by the Spanish Victorian Institute of Sport Assessment for Patella (VISA-P) score at 6 and 12 weeks. Secondary outcomes were activity limitation using Patient Specific Functional Scale (PSFS), health status (EuroQol-5D), patient impression of change on pain and function, adherence, adverse events, pain provocation test for the patellar tendon (numerical rating score of pain between 0 and 10), physical test, patellar tendon thickness and doppler signal on ultrasound. Secondary outcomes were taken at 0 and 12 weeks. RESULTS Both groups showed significant improvements in VISA-P scores from 0 to 12 weeks but there was not statistically significant between-group difference (P = 0.506). No adverse events or side effects occurred in any of the groups during the intervention period. CONCLUSIONS Inertial flywheel resistance three times a week during 12 weeks resulted in similar pain and function benefit at 12 weeks compared with the heavy slow resistance training among people with patellar tendinopathy. Flywheel training is another exercise option for managing people with patellar tendinopathy. CLINICALTRIALS. GOV REGISTRY NCT03917849.",2021,Both groups showed significant improvements in VISA-P scores from 0 to 12 weeks but there was not statistically significant between-group difference (P = 0.506).,"['managing people with patellar tendinopathy', 'athletes with patellar tendinopathy', 'Fourty two participants (1 woman, 41 men) with longstanding (>3 months) patellar tendinopathy', 'people with patellar tendinopathy']","['Flywheel training', 'supervised inertial flywheel or heavy slow resistance exercise sessions', 'Inertial flywheel vs heavy slow resistance training', 'heavy slow resistance training', 'inertial flywheel resistance (N\xa0=\xa021) or heavy slow resistance', 'inertial flywheel and heavy slow resistance training']","['VISA-P scores', 'activity limitation using Patient Specific Functional Scale (PSFS), health status (EuroQol-5D), patient impression of change on pain and function, adherence, adverse events, pain provocation test for the patellar tendon (numerical rating score of pain between 0 and 10), physical test, patellar tendon thickness and doppler signal on ultrasound', 'pain and function, assessed by the Spanish Victorian Institute of Sport Assessment for Patella (VISA-P) score', 'adverse events or side effects', 'similar pain and function benefit']","[{'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}, {'cui': 'C0151936', 'cui_str': 'Disorder of tendon'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C4304943', 'cui_str': 'Patient-Specific Functional Scale'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449428', 'cui_str': 'Provocation'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0206332', 'cui_str': 'Structure of patellar ligament'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0554756', 'cui_str': 'Doppler studies'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",41.0,0.128523,Both groups showed significant improvements in VISA-P scores from 0 to 12 weeks but there was not statistically significant between-group difference (P = 0.506).,"[{'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Ruffino', 'Affiliation': 'Escuela de Kinesiología y Fisioterapia, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enrique Barros, Ciudad Universitaria, 5000, Córdoba, Argentina. Electronic address: diegoruffino@unc.edu.ar.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Malliaras', 'Affiliation': 'Physiotherapy Department, School of Primary and Allied Health Care, Faculty of Medicine Nursing and Health Sciences, Monash University, Frankston, Victoria, 3199, Australia. Electronic address: peter.malliaras@monash.edu.'}, {'ForeName': 'Silvio', 'Initials': 'S', 'LastName': 'Marchegiani', 'Affiliation': 'Centro de Diagnóstico por Imágenes Marchegiani, Córdoba, Argentina. Electronic address: silviomarchegiani@hotmail.com.'}, {'ForeName': 'Vilma', 'Initials': 'V', 'LastName': 'Campana', 'Affiliation': 'Cátedra Física Biomédica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Santa Rosa 1085, 5000, Cordoba, Argentina. Electronic address: campanav@hotmail.com.'}]",Physical therapy in sport : official journal of the Association of Chartered Physiotherapists in Sports Medicine,['10.1016/j.ptsp.2021.08.002'] 2855,34384742,Cardiovascular Risk and Outcomes in Symptomatic Patients with Suspected CAD and Non Coronary Vascular Disease: A Report from the PROMISE Trial.,"BACKGROUND Non-coronary vascular disease (NCVD) is associated with adverse cardiovascular events. Little is known about physician risk assessment, prevalence of CAD, cardiac catheterization, and the performance of the ASCVD risk score in patients with NCVD. METHODS Retrospective analysis of outpatients with angina and no known CAD from the PROMISE trial. NCVD included carotid artery stenosis ≥ 50%, or history of stroke or peripheral artery disease. Multivariable models of physician estimates of the probability of obstructive CAD, prevalence of non-obstructive and obstructive CAD, referral to cardiac catheterization, and all-cause death/myocardial infarction/unstable angina were performed. RESULTS Among 10,001 patients in the PROMISE trial, 379 (3.8%) patients had NCVD. Only 8.5% of participants with NCVD were categorized as high-risk for obstructive CAD by physicians, though 15.5% (25/161) had obstructive CAD in those randomized to coronary CTA. NCVD was independently associated with non-obstructive (aOR = 1.58; 95% CI 1.18 - 2.61; p=0.006) but not obstructive CAD by CTA. Adjusted referral to cardiac catheterization was similar with and without NCVD (aOR 1.04; 95% CI 0.88 - 1.94, p = 0.19). NCVD was associated with an increased risk of all-cause death/MI/UA (aOR 2.03; 95% CI 1.37 - 3.01, p < 0.001). There was no interaction between NCVD status and ASCVD risk score. CONCLUSIONS Among patients with NCVD and angina, NCVD had increased adjusted risks of CAD and adverse outcomes which were not well described by ASCVD risk score and were underrecognized by physicians. Increased awareness and better risk stratification tools for patients with NCVD may be necessary to recognize the associated CV risk and optimize diagnostic testing and therapies.",2021,NCVD was independently associated with non-obstructive (aOR = 1.58; 95% CI 1.18 - 2.61; p=0.006) but not obstructive CAD by CTA.,"['10,001 patients in the PROMISE trial, 379 (3.8%) patients had NCVD', 'outpatients with angina and no known CAD from the PROMISE trial', 'patients with NCVD', 'Symptomatic Patients with Suspected CAD and Non Coronary Vascular Disease']",['NCVD'],"['Cardiovascular Risk and Outcomes', 'ASCVD risk score', 'probability of obstructive CAD, prevalence of non-obstructive and obstructive CAD, referral to cardiac catheterization, and all-cause death/myocardial infarction/unstable angina', 'NCVD', 'carotid artery stenosis ≥ 50%, or history of stroke or peripheral artery disease', 'Adjusted referral to cardiac catheterization', 'NCVD status and ASCVD risk score', 'risk of all-cause death/MI/UA', 'adjusted risks of CAD and adverse outcomes', 'obstructive CAD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0042373', 'cui_str': 'Vascular disorder'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0011905', 'cui_str': 'Computer-Assisted Diagnosis'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0042373', 'cui_str': 'Vascular disorder'}]","[{'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0011905', 'cui_str': 'Computer-Assisted Diagnosis'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0205304', 'cui_str': 'Non-obstructive'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0018795', 'cui_str': 'Cardiac catheterization'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0002965', 'cui_str': 'Impending infarction'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0042373', 'cui_str': 'Vascular disorder'}, {'cui': 'C0007282', 'cui_str': 'Carotid artery stenosis'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",10001.0,0.29888,NCVD was independently associated with non-obstructive (aOR = 1.58; 95% CI 1.18 - 2.61; p=0.006) but not obstructive CAD by CTA.,"[{'ForeName': 'Sreekanth', 'Initials': 'S', 'LastName': 'Vemulapalli', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC 27705; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, 27710. Electronic address: sreekanth.vemulapalli@duke.edu.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Stebbins', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC 27705.'}, {'ForeName': 'W Schuyler', 'Initials': 'WS', 'LastName': 'Jones', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC 27705; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, 27710.'}, {'ForeName': 'J Antonio', 'Initials': 'JA', 'LastName': 'Gutierrez', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC 27705; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, 27710.'}, {'ForeName': 'Manesh R', 'Initials': 'MR', 'LastName': 'Patel', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC 27705; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, 27710.'}, {'ForeName': 'Rowena J', 'Initials': 'RJ', 'LastName': 'Dolor', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC 27705; Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC, 27701.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Pellikka', 'Affiliation': 'Department of Cardiovascular Medicine, Mayo Clinic School of Medicine, Rochester, MN.'}, {'ForeName': 'Brooke', 'Initials': 'B', 'LastName': 'Alhanti', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC 27705.'}, {'ForeName': 'Udo', 'Initials': 'U', 'LastName': 'Hoffmann', 'Affiliation': 'Massachusetts General Hospital, Boston, MA.'}, {'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Douglas', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC 27705; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, 27710.'}]",American heart journal,['10.1016/j.ahj.2021.07.010'] 2856,34384737,Tackling risk factors for type 2 diabetes in adolescents: PRE-STARt study in Euskadi.,"INTRODUCTION Obesity in the child population and its effect in the development of metabolic diseases are a public health issue. One of the aims of the European Project in a health system, is the evaluation of the effectiveness of a multidisciplinary health promotion program directed at adolescents with risk factors associated with the development of type 2 Diabetes Mellitus (T2DM). PATIENTS AND METHODS Randomised clinical trial with two groups of 12-14 year-old overweight adolescents. The intervention group took part in a multidisciplinary program for 24 months. This program was based on 11 group sessions (8 main sessions and 3 additional support ones) for adolescents and their guardians. The control group received usual care at primary care level. Longitudinal regression models were adjusted to assess the evolution of anthropometric measures and living habits at baseline, 3, 6, 12, and 24 months in both groups. RESULTS There were 92 participants, equally distributed by group. Statistically significant differences were observed between intervention and control groups in several results: evolution of the body mass index; increase in the consumption of fruits and vegetables; decrease in the consumption of snacks and sweetened drinks; and increase in the number of days per week with more than one hour of physical activity. CONCLUSIONS The results confirm the effectiveness of this multidisciplinary program, both in the evolution of the body mass index, and in the improvement of the eating and physical activity habits, all of them risk factors for the future development of metabolic diseases, such as T2DM.",2021,"Statistically significant differences were observed between intervention and control groups in several results: evolution of the body mass index; increase in the consumption of fruits and vegetables; decrease in the consumption of snacks and sweetened drinks; and increase in the number of days per week with more than one hour of physical activity. ","['type 2 diabetes in adolescents', 'two groups of 12-14 year-old overweight adolescents']",['usual care at primary care level'],['consumption of snacks and sweetened drinks'],"[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}]","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C0452428', 'cui_str': 'Drink'}]",92.0,0.0108618,"Statistically significant differences were observed between intervention and control groups in several results: evolution of the body mass index; increase in the consumption of fruits and vegetables; decrease in the consumption of snacks and sweetened drinks; and increase in the number of days per week with more than one hour of physical activity. ","[{'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Alustiza', 'Affiliation': 'Osakidetza, Centro de Salud de Egia, Donostia-San Sebastián, Gipuzkoa, Spain.'}, {'ForeName': 'Amaia', 'Initials': 'A', 'LastName': 'Perales', 'Affiliation': 'Consulta de Asesoramiento en Alimentación y Salud, Beasain, Gipuzkoa, Spain.'}, {'ForeName': 'Maider', 'Initials': 'M', 'LastName': 'Mateo-Abad', 'Affiliation': 'Instituto de Investigación en Servicios de Salud Kronikgune, Barakaldo, Bizkaia, Spain; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Barakaldo, Bizkaia, Spain. Electronic address: maider.mateoabad@osakidetza.eus.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Ozcoidi', 'Affiliation': 'Osakidetza, Centro de Salud de Amara Berri, Donostia-San Sebastián, Gipuzkoa, Spain.'}, {'ForeName': 'Garbiñe', 'Initials': 'G', 'LastName': 'Aizpuru', 'Affiliation': 'Consulta de Dietética y Asesoramiento Nutricional, Donostia-San Sebastián, Gipuzkoa, Spain.'}, {'ForeName': 'Olatz', 'Initials': 'O', 'LastName': 'Albaina', 'Affiliation': 'Instituto de Investigación en Servicios de Salud Kronikgune, Barakaldo, Bizkaia, Spain.'}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Vergara', 'Affiliation': 'Instituto de Investigación en Servicios de Salud Kronikgune, Barakaldo, Bizkaia, Spain; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Barakaldo, Bizkaia, Spain; Instituto de Investigación Sanitaria Biodonostia, Grupo de Atención Primaria, Donostia-San Sebastián, Gipuzkoa, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Anales de pediatria,['10.1016/j.anpede.2020.11.005'] 2857,34384655,Transanal Transection and Single-Stapled Anastomosis (TTSS): A comparison of anastomotic leak rates with the double-stapled technique and with transanal total mesorectal excision (TaTME) for rectal cancer.,"BACKGROUND in the literature on rectal cancer (RC) surgery many studies have focused on the quality of total mesorectal excision (TME) dissection, while there is a scarcity of comparative data on transection and anastomosis. No anastomosis has so far proved to be superior to any other. The aim of this study was to compare anastomotic leak (AL) rates between conventional laparoscopic double-stapled (DS), transanal total mesorectal excision (TaTME) and Transanal Transection and Single-Stapled anastomosis (TTSS) techniques. METHODS consecutive mid-low RC patients undergoing elective laparoscopic TME with stapled anastomosis and protective stoma, by either DS, TaTME or TTSS techniques were retrieved from a prospectively collected database. RESULTS 127 DS; 100 TaTME and 50 TTSS were included. Demographics, distance of the tumor from anal verge and neoadjuvant therapy were comparable. Operative time was longer in TaTME over DS and TTSS (p < 0.0001). More 90-days complications occurred in DS group vs TTSS (p = 0.029). The AL rate was 17.5% in DS, 6% in TaTME and 2% in TTSS group (p = 0.005). AL grade was: one B (2%) in TTSS; 2 grade B (2%) and 4 grade C (4%) in TaTME; 6 grade A (4.7%), 7 grade B (5.5%) and 9 grade C (7.1%) in DS group. Reintervention rate after AL was higher in DS group over TTSS (12.6% vs 2%; p = 0.003). The rate of stoma closure, pathology data and margin positivity did not differ. CONCLUSIONS TTSS strategy is feasible, safe and leads to very low AL rates after TME for RC.",2021,Operative time was longer in TaTME over DS and TTSS (p < 0.0001).,"['127 DS', 'rectal cancer', 'consecutive mid-low RC patients undergoing elective laparoscopic TME with stapled anastomosis and protective stoma, by either DS, TaTME or TTSS techniques were retrieved from a prospectively collected database']","['conventional laparoscopic double-stapled (DS), transanal total mesorectal excision (TaTME) and Transanal Transection and Single-Stapled anastomosis (TTSS) techniques', 'TTSS', 'Transanal Transection and Single-Stapled Anastomosis (TTSS', 'double-stapled technique and with transanal total mesorectal excision (TaTME']","['90-days complications', 'Operative time', 'Reintervention rate after AL', 'anastomotic leak rates', 'AL rate', 'rate of stoma closure, pathology data and margin positivity', 'Demographics, distance of the tumor from anal verge and neoadjuvant therapy', 'anastomotic leak (AL) rates']","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0524724', 'cui_str': 'Surgical staple'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0332853', 'cui_str': 'Anastomosis'}, {'cui': 'C1955856', 'cui_str': 'Stoma site'}, {'cui': 'C0185012', 'cui_str': 'Closure by staple'}, {'cui': 'C0589371', 'cui_str': 'Transanal approach'}, {'cui': 'C0152060', 'cui_str': 'Transection'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0185012', 'cui_str': 'Closure by staple'}, {'cui': 'C0589371', 'cui_str': 'Transanal approach'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0152060', 'cui_str': 'Transection'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0524724', 'cui_str': 'Surgical staple'}, {'cui': 'C0332853', 'cui_str': 'Anastomosis'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0919691', 'cui_str': 'Anastomotic leak'}, {'cui': 'C3665863', 'cui_str': 'Stoma closure'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0227423', 'cui_str': 'Structure of transition zone of anal mucous membrane'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}]",,0.19352,Operative time was longer in TaTME over DS and TTSS (p < 0.0001).,"[{'ForeName': 'Antonino', 'Initials': 'A', 'LastName': 'Spinelli', 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, via Manzoni 56, 20089, Rozzano, Milan, Italy. Electronic address: antonino.spinelli@humanitas.it.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Foppa', 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, via Manzoni 56, 20089, Rozzano, Milan, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Carvello', 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, via Manzoni 56, 20089, Rozzano, Milan, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Sacchi', 'Affiliation': 'IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, via Manzoni 56, 20089, Rozzano, Milan, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'De Lucia', 'Affiliation': 'IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, via Manzoni 56, 20089, Rozzano, Milan, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Clerico', 'Affiliation': 'IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, via Manzoni 56, 20089, Rozzano, Milan, Italy.'}, {'ForeName': 'Francesco Maria', 'Initials': 'FM', 'LastName': 'Carrano', 'Affiliation': 'IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, via Manzoni 56, 20089, Rozzano, Milan, Italy.'}, {'ForeName': 'Annalisa', 'Initials': 'A', 'LastName': 'Maroli', 'Affiliation': 'IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, via Manzoni 56, 20089, Rozzano, Milan, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Montorsi', 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, via Manzoni 56, 20089, Rozzano, Milan, Italy.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Heald', 'Affiliation': 'Champalimaud Institute for the Unknown, Lisboa, Portugal.'}]",European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,['10.1016/j.ejso.2021.08.002'] 2858,34384638,"A comparative assessment of failures and periodontal health between 2 mandibular lingual retainers in orthodontic patients. A 2-year follow-up, single practice-based randomized trial.","INTRODUCTION The objective of this study was to compare the survival rates and periodontal health in patients with 3-strand round twisted (RT) vs 8-strand rectangular braided (RB) fixed retainers bonded to all 6 anterior teeth in the mandible. METHODS A total of 133 patients completing orthodontic treatment (median age, 24.6 years; 25th percentile, 17.2 years; 75th percentile, 32.4 years; minimum, 15.1 years; maximum, 49.8 years) were randomly allocated in a 1:1 ratio to receive either an RT or RB wire retainer. Inclusion criteria were all mandibular permanent incisors and canines present, no active caries, no restorations, no fractures on the mandibular incisors and canines, no periodontal disease. Patients with poor oral hygiene before debonding were excluded from the trial. The primary outcome was any first-time retainer failure. Secondary outcomes were periodontal index, bleeding on probing, plaque index, gingival index, and probing depth. Randomization was accomplished with random permuted blocks of size 4, 6, or 8 with allocation concealed in sequentially numbered, opaque, sealed envelopes. Blinding was not possible in this trial. Patients were evaluated at baseline, 3, 6, 12, 18, and 24 months after placement of the retainer. Retainer survival was assessed using Cox regression. Periodontal parameters were reported at each time point and generalised estimating equations were used to assess the effect of treatment, time, tooth and treatment X time interaction on the indices. RESULTS Baseline characteristics were similar between groups; in 1 patient, the intervention was discontinued. During 2-year follow-up 37 of 66 (56.1%, RT group) and 32 of 66 (48.5%, RB group) retainers failed at least once (log-rank test, P = 0.55). The adjusted hazard ratio was 0.69 (95% confidence interval, 0.42-1.12; P = 0.13). Neither age nor gender was a predictor of failure. All periodontal parameters (periodontal index, bleeding on probing, plaque index, gingival index, and pocket depth) were comparable between groups and remained relatively stable during follow-up. CONCLUSIONS The overall risk for first-time failure was high and amounted to 52.3% (56.1% in the RT group and 48.5% in the RB group). There was no difference in terms of survival or periodontal health between the examined retainers.",2021,"All periodontal parameters (periodontal index, bleeding on probing, plaque index, gingival index, and pocket depth) were comparable between groups and remained relatively stable during follow-up. ","['Inclusion criteria were all mandibular permanent incisors and canines present, no active caries, no restorations, no fractures on the mandibular incisors and canines, no periodontal disease', 'Patients with poor oral hygiene before debonding were excluded from the trial', '2 mandibular lingual retainers in orthodontic patients', 'patients with 3-strand round twisted (RT) vs 8-strand rectangular braided (RB) fixed retainers bonded to all 6 anterior teeth in the mandible', '133 patients completing orthodontic treatment (median age, 24.6\xa0years; 25th percentile, 17.2\xa0years; 75th percentile, 32.4\xa0years; minimum, 15.1\xa0years; maximum, 49.8\xa0years']",['RT or RB wire retainer'],"['periodontal index, bleeding on probing, plaque index, gingival index, and probing depth', 'survival or periodontal health', 'overall risk for first-time failure', 'survival rates and periodontal health', 'first-time retainer failure', 'Retainer survival', 'All periodontal parameters (periodontal index, bleeding on probing, plaque index, gingival index, and pocket depth', 'failures and periodontal health']","[{'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}, {'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0429170', 'cui_str': 'Caries active'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0031090', 'cui_str': 'Periodontal disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457640', 'cui_str': 'Poor oral hygiene'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0242919', 'cui_str': 'Orthodontic retainer'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0332490', 'cui_str': 'Round shape'}, {'cui': 'C0205142', 'cui_str': 'Rectangular'}, {'cui': 'C0441421', 'cui_str': 'Fixed orthodontic appliance'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0204193', 'cui_str': 'Orthodontic procedure'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C4517709', 'cui_str': '32.4'}, {'cui': 'C0806909', 'cui_str': 'Max'}]","[{'cui': 'C0332490', 'cui_str': 'Round shape'}, {'cui': 'C0205142', 'cui_str': 'Rectangular'}, {'cui': 'C0005978', 'cui_str': 'Bone wire'}, {'cui': 'C0242919', 'cui_str': 'Orthodontic retainer'}]","[{'cui': 'C0031092', 'cui_str': 'Periodontal Indexes'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0242919', 'cui_str': 'Orthodontic retainer'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",133.0,0.112732,"All periodontal parameters (periodontal index, bleeding on probing, plaque index, gingival index, and pocket depth) were comparable between groups and remained relatively stable during follow-up. ","[{'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Węgrodzka', 'Affiliation': 'Private practice, Warsaw, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Kornatowska', 'Affiliation': 'Private practice, Warsaw, Poland.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Pandis', 'Affiliation': 'Department of Orthodontics and Dentofacial Orthopedics, School of Dental Medicine, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Piotr S', 'Initials': 'PS', 'LastName': 'Fudalej', 'Affiliation': 'Department of Orthodontics and Dentofacial Orthopedics, School of Dental Medicine, University of Bern, Bern, Switzerland Institute of Dentistry and Oral Sciences, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic Department of Orthodontics, Institute of Dentistry, Jagiellonian University, Kraków, Poland. Electronic address: piotr.fudalej@uj.edu.pl.'}]","American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics",['10.1016/j.ajodo.2021.02.015'] 2859,34384597,Blood loss and transfusion rate compared among different dosing regimens of tranexamic acid administration in patients undergoing hip hemiarthroplasty for femoral neck fracture: A randomized controlled trial.,"BACKGROUND Intravenous tranexamic acid (TXA) administration is a proven safe and effective method for reducing both blood loss and transfusion in total joint arthroplasty. However, data specific to its efficacy in hip hemiarthroplasty (HHA) for femoral neck fracture are scarce. Furthermore, no study has investigated the efficacy of an additional dose of TXA administration. Accordingly, this study aimed to assess blood loss and the transfusion rate compared among different regimens of TXA administration in patients undergoing HHA for femoral neck fracture. METHODS Between January 2019 to December 2020, 90 HHA patients were randomized into one of three groups (30 patients/group). Control group patients received intravenous normal saline solution (NSS) 20 mL before skin incision, and NSS 20 mL at 3 hours after surgery. one-dose (1D) group patients received 750 mg of intravenous TXA before skin incision, and NSS 20 mL at 3 hours after surgery. Two-dose (2D) group patients received 750 mg of intravenous TXA before skin incision, and 750 mg of TXA at 3 hours after surgery. The primary outcome was blood transfusion rate. Intraoperative blood loss, hemoglobin levels at 24- and 48-hours postoperation, and calculated total blood loss were compared among the three groups. RESULTS The mean age of the study population was 79.7 years, and 76.7% of participants were women. The transfusion rate in the control, 1D and 2D groups was 43.3%, 16.7%, and 3.3%, respectively. Total hemoglobin loss; total red blood cell loss; intraoperative blood loss; hemoglobin level at 24- and 48-hours postoperation; change in hemoglobin level between 0 and 24 hours, and between 0 and 48 hours; blood transfusion rate; and, the number of patients who did not require blood transfusion were all significantly improved in the 2D group compared to baseline. No parameters were significantly improved in the 1D group compared to controls. CONCLUSIONS The results of this study demonstrate both the efficacy of TXA administration in HHA, and the superiority of two-dose TXA administration over one-dose TXA administration in HHA for femoral neck fracture.",2021,"The transfusion rate in the control, 1D and 2D groups was 43.3%, 16.7%, and 3.3%, respectively.","['patients undergoing HHA for femoral neck fracture', 'The mean age of the study population was 79.7 years, and 76.7% of participants were women', 'patients undergoing hip hemiarthroplasty for femoral neck fracture', 'Between January 2019 to December 2020, 90 HHA patients']","['intravenous TXA', 'intravenous TXA before skin incision, and 750 mg of TXA', 'TXA', 'tranexamic acid (TXA', 'hip hemiarthroplasty (HHA', 'intravenous normal saline solution (NSS) 20 mL before skin incision, and NSS 20 mL', 'tranexamic acid']","['Intraoperative blood loss, hemoglobin levels at 24- and 48-hours postoperation, and calculated total blood loss', 'Blood loss and transfusion rate', 'blood loss and the transfusion rate', 'Total hemoglobin loss; total red blood cell loss; intraoperative blood loss; hemoglobin level', 'hemoglobin level', 'transfusion rate', 'blood transfusion', 'blood transfusion rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0744743', 'cui_str': 'Hemi-Arthroplasty'}, {'cui': 'C0015806', 'cui_str': 'Fracture of neck of femur'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1112760', 'cui_str': 'Hip hemiarthroplasty'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0191279', 'cui_str': 'Incision of skin'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C1112760', 'cui_str': 'Hip hemiarthroplasty'}, {'cui': 'C0744743', 'cui_str': 'Hemi-Arthroplasty'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0232100', 'cui_str': 'Exsanguination'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0475206', 'cui_str': '% total hemoglobin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}]",,0.198544,"The transfusion rate in the control, 1D and 2D groups was 43.3%, 16.7%, and 3.3%, respectively.","[{'ForeName': 'Rapeepat', 'Initials': 'R', 'LastName': 'Narkbunnam', 'Affiliation': 'Division of Adult Reconstructive Surgery, Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.'}, {'ForeName': 'Apivuth', 'Initials': 'A', 'LastName': 'Chompoonutprapa', 'Affiliation': 'Division of Adult Reconstructive Surgery, Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.'}, {'ForeName': 'Pakpoom', 'Initials': 'P', 'LastName': 'Ruangsomboon', 'Affiliation': 'Division of Adult Reconstructive Surgery, Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.'}, {'ForeName': 'Pacharapol', 'Initials': 'P', 'LastName': 'Udomkiat', 'Affiliation': 'Division of Adult Reconstructive Surgery, Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.'}, {'ForeName': 'Keerati', 'Initials': 'K', 'LastName': 'Chareancholvanich', 'Affiliation': 'Division of Adult Reconstructive Surgery, Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.'}, {'ForeName': 'Chaturong', 'Initials': 'C', 'LastName': 'Pornrattanamaneewong', 'Affiliation': 'Division of Adult Reconstructive Surgery, Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand. Electronic address: toonchaturong@gmail.com.'}]",Injury,['10.1016/j.injury.2021.08.001'] 2860,34384540,Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.,"BACKGROUND Typhoid fever remains a major cause of morbidity and mortality in low-income and middle-income countries. Vi-tetanus toxoid conjugate vaccine (Vi-TT) is recommended by WHO for implementation in high-burden countries, but there is little evidence about its ability to protect against clinical typhoid in such settings. METHODS We did a participant-masked and observer-masked cluster-randomised trial preceded by a safety pilot phase in an urban endemic setting in Dhaka, Bangladesh. 150 clusters, each with approximately 1350 residents, were randomly assigned (1:1) to either Vi-TT or SA 14-14-2 Japanese encephalitis (JE) vaccine. Children aged 9 months to less than 16 years were invited via parent or guardian to receive a single, parenteral dose of vaccine according to their cluster of residence. The study population was followed for an average of 17·1 months. Total and overall protection by Vi-TT against blood culture-confirmed typhoid were the primary endpoints assessed in the intention-to-treat population of vaccinees or all residents in the clusters. A subset of approximately 4800 participants was assessed with active surveillance for adverse events. The trial is registered at www.isrctn.com, ISRCTN11643110. FINDINGS 41 344 children were vaccinated in April-May, 2018, with another 20 412 children vaccinated at catch-up vaccination campaigns between September and December, 2018, and April and May, 2019. The incidence of typhoid fever (cases per 100 000 person-years) was 635 in JE vaccinees and 96 in Vi-TT vaccinees (total Vi-TT protection 85%; 97·5% CI 76 to 91, p<0·0001). Total vaccine protection was consistent in different age groups, including children vaccinated at ages under 2 years (81%; 95% CI 39 to 94, p=0·0052). The incidence was 213 among all residents in the JE clusters and 93 in the Vi-TT clusters (overall Vi-TT protection 57%; 97·5% CI 43 to 68, p<0·0001). We did not observe significant indirect vaccine protection by Vi-TT (19%; 95% CI -12 to 41, p=0·20). The vaccines were well tolerated, and no serious adverse events judged to be vaccine-related were observed. INTERPRETATION Vi-TT provided protection against typhoid fever to children vaccinated between 9 months and less than 16 years. Longer-term follow-up will be needed to assess the duration of protection and the need for booster doses. FUNDING The study was funded by the Bill & Melinda Gates Foundation.",2021,"We did not observe significant indirect vaccine protection by Vi-TT (19%; 95% CI -12 to 41, p=0·20).","['150 clusters, each with approximately 1350 residents', 'children against typhoid fever with a', '41\u2009344 children were vaccinated in April-May, 2018, with another 20\u2009412 children vaccinated at catch-up vaccination campaigns between September and December, 2018, and April and May, 2019', 'Children aged 9 months to less than 16 years', 'urban Bangladesh', 'urban endemic setting in Dhaka, Bangladesh']","['Vi-tetanus toxoid conjugate vaccine', 'Vi-TT or SA 14-14-2 Japanese encephalitis (JE) vaccine', 'Vi-tetanus toxoid conjugate vaccine (Vi-TT']","['active surveillance for adverse events', 'Total vaccine protection', 'indirect vaccine protection', 'incidence of typhoid fever', 'Total and overall protection']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C4517567', 'cui_str': '1350'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0041466', 'cui_str': 'Typhoid fever'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0231617', 'cui_str': 'Catch'}, {'cui': 'C4279933', 'cui_str': 'Vaccination Campaign'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0243130', 'cui_str': 'endemics'}]","[{'cui': 'C0039620', 'cui_str': 'Tetanus vaccine'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0014057', 'cui_str': 'Japanese encephalitis virus disease'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0700325', 'cui_str': 'Patient status observation'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0041466', 'cui_str': 'Typhoid fever'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",41344.0,0.388241,"We did not observe significant indirect vaccine protection by Vi-TT (19%; 95% CI -12 to 41, p=0·20).","[{'ForeName': 'Firdausi', 'Initials': 'F', 'LastName': 'Qadri', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh. Electronic address: fqadri@icddrb.org.'}, {'ForeName': 'Farhana', 'Initials': 'F', 'LastName': 'Khanam', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Xinxue', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Theiss-Nyland', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Prasanta Kumar', 'Initials': 'PK', 'LastName': 'Biswas', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Amirul Islam', 'Initials': 'AI', 'LastName': 'Bhuiyan', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Faisal', 'Initials': 'F', 'LastName': 'Ahmmed', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Colin-Jones', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Smith', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Tonks', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Merryn', 'Initials': 'M', 'LastName': 'Voysey', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Yama F', 'Initials': 'YF', 'LastName': 'Mujadidi', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Mazur', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Nazmul Hasan', 'Initials': 'NH', 'LastName': 'Rajib', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Md Ismail', 'Initials': 'MI', 'LastName': 'Hossen', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Shams Uddin', 'Initials': 'SU', 'LastName': 'Ahmed', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Arifuzzaman', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Nazia', 'Initials': 'N', 'LastName': 'Rahman', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Golap', 'Initials': 'G', 'LastName': 'Babu', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Greenland', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Kelly', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Mahzabeen', 'Initials': 'M', 'LastName': 'Ireen', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Kamrul', 'Initials': 'K', 'LastName': 'Islam', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': ""O'Reilly"", 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Karin Sofia', 'Initials': 'KS', 'LastName': 'Scherrer', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Virginia E', 'Initials': 'VE', 'LastName': 'Pitzer', 'Affiliation': 'Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT USA.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Neuzil', 'Affiliation': 'University of Maryland School of Medicine, Baltimore MD, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Zaman', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Pollard', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Clemens', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; University of California Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA.'}]","Lancet (London, England)",['10.1016/S0140-6736(21)01124-7'] 2861,34384513,Evaluation of the 'H2NOE Water Schools' programme to promote water consumption in elementary school children - a non-randomised controlled cluster trial.,"OBJECTIVE This study evaluated a simple environmental intervention called 'Water Schools' in Lower Austria providing free refillable water bottles and educational material. DESIGN Non-randomised controlled cluster trial with three measurements: at baseline (T0), after the intervention at 9 months (T1), after one-year follow-up (T2). SETTING Half-day elementary schools in Lower Austria (Austria). PARTICIPANTS Third-grade pupils from 22 schools in the intervention group (IG) and 32 schools in the control group (CG) participated in the study. Data were analysed for 569 to 598 pupils in the IG and for 545 to 613 in the CG, depending on the time of measurement. RESULTS The consumption of tap water increased in the IG from baseline to T1 and then decreased again at T2, but this was similar in the CG (no statistically significant difference in the time trend between the IG and CG). Similar results were seen for tap water consumption in the mornings. The proportion of children who only drank tap water on school mornings increased significantly from baseline to T1 in the IG compared to the CG (p=0.020). No difference in the changes over time occurred between the groups for the proportion of pupils drinking approximately one bottle of tap water during school mornings. CONCLUSIONS Not only the children in the IG but also those in the CG drank more tap water after 1 school year than at the beginning. The measurement of drinking habits in the CG may have been intervention enough to bring about changes or to initiate projects.",2021,"No difference in the changes over time occurred between the groups for the proportion of pupils drinking approximately one bottle of tap water during school mornings. ","[""simple environmental intervention called 'Water Schools' in Lower Austria providing free refillable water bottles and educational material"", 'Half-day elementary schools in Lower Austria (Austria', 'Third-grade pupils from 22 schools in the intervention group (IG) and 32 schools in the control group (CG) participated in the study', 'elementary school children', '569 to 598 pupils in the IG and for 545 to 613 in the CG, depending on the time of measurement']",[],"['consumption of tap water', 'proportion of children who only drank tap water on school mornings']","[{'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0026118', 'cui_str': 'Environmental intervention'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0004348', 'cui_str': 'Austria'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0179376', 'cui_str': 'Bottle'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0034121', 'cui_str': 'Pupil structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0260267', 'cui_str': 'School child'}, {'cui': 'C4517809', 'cui_str': '545'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",[],"[{'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C2919405', 'cui_str': 'Tap water'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0332170', 'cui_str': 'Morning'}]",,0.118608,"No difference in the changes over time occurred between the groups for the proportion of pupils drinking approximately one bottle of tap water during school mornings. ","[{'ForeName': 'Ursula', 'Initials': 'U', 'LastName': 'Griebler', 'Affiliation': 'Department for Evidence-based Medicine and Evaluation, Danube University Krems, Dr.-Karl-Dorrek-Straße 30, 3500 Krems, Austria.'}, {'ForeName': 'Viktoria', 'Initials': 'V', 'LastName': 'Titscher', 'Affiliation': 'Department for Evidence-based Medicine and Evaluation, Danube University Krems, Dr.-Karl-Dorrek-Straße 30, 3500 Krems, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Weber', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Affengruber', 'Affiliation': 'Department for Evidence-based Medicine and Evaluation, Danube University Krems, Dr.-Karl-Dorrek-Straße 30, 3500 Krems, Austria.'}]",Public health nutrition,['10.1017/S1368980021003438'] 2862,34384509,"COVID-19. Effect of Moral Messages to Persuade the Population to Stay at Home in Spain, Chile, and Colombia.","Analyze whether the content of three moral messages (deontological, ethical utilitarianism, ethical virtue) and a control message differentially affect the probability of engaging in four behaviors: Washing their hands, participating in public gatherings, staying at home/avoiding social contact, and forwarding the message to inform more people. In our study, the sender of the message is a university professor. These variables are measured in terms of their behavioral intentions and others' behavioral intentions (beliefs about others' behavior). Randomized Controlled Trial. Our study includes the analysis of the possible moderating effect of the country of residence (Spain n = 1,122, Chile n = 1,107, and Colombia n = 1,433). The message with content referring to ethical virtue and staying at home obtains statistically significant lower scores on the probability of carrying out public health behaviors and sharing the message received. Regarding beliefs about the behavior of others, the message of ethical virtue has the same negative effect, but only on the likelihood of other people washing their hands, staying at home, and sharing the public health message. Institutional messages aimed at promoting public health behaviors are necessary in a pandemic situation. Our recommendation is to use deontological and utilitarian, or non-moral, content.",2021,The message with content referring to ethical virtue and staying at home obtains statistically significant lower scores on the probability of carrying out public health behaviors and sharing the message received.,"['country of residence (Spain n = 1,122, Chile n = 1,107, and Colombia n = 1,433']",['Moral Messages'],['probability of engaging in four behaviors'],"[{'cui': 'C1562954', 'cui_str': 'Country of residence'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0008107', 'cui_str': 'Chile'}, {'cui': 'C3245499', 'cui_str': 'Colombia'}]","[{'cui': 'C0026531', 'cui_str': 'Morality'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",1433.0,0.0287927,The message with content referring to ethical virtue and staying at home obtains statistically significant lower scores on the probability of carrying out public health behaviors and sharing the message received.,"[{'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Frias-Navarro', 'Affiliation': 'Universitat de Vàlencia (Spain).'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Pascual-Soler', 'Affiliation': 'ESIC Business & Marketing School (Spain).'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Berrios-Riquelme', 'Affiliation': 'Universidad de Tarapacá (Chile).'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Gomez-Frias', 'Affiliation': 'Universitat de Vàlencia (Spain).'}, {'ForeName': 'Leynin', 'Initials': 'L', 'LastName': 'Caamaño-Rocha', 'Affiliation': 'Universidad del Magdalena (Colombia).'}]",The Spanish journal of psychology,['10.1017/SJP.2021.39'] 2863,34384420,Self-managed occupational therapy and physiotherapy for adults receiving inpatient rehabilitation ('My Therapy'): protocol for a mixed-methods process evaluation.,"BACKGROUND Process evaluations have been recommended alongside clinical and economic evaluations to enable an in-depth understanding of factors impacting results. My Therapy is a self-management program designed to augment usual care inpatient rehabilitation through the provision of additional occupational therapy and physiotherapy exercises and activities, for the patient to complete outside of supervised therapy. The aims of the process evaluation are to assess the implementation process by investigating fidelity, quality of implementation, acceptability, adoption, appropriateness, feasibility and adaptation of the My Therapy intervention; and identify contextual factors associated with variations in outcomes, including the perspectives and experiences of patients and therapists. METHODS The process evaluation will be conducted alongside the clinical and economic evaluation of My Therapy, within eight rehabilitation wards across two public and two private Australian health networks. All participants of the stepped wedge cluster randomised trial (2,160 rehabilitation patients) will be included in the process evaluation (e.g., ward audit); with a subset of 120 participants undergoing more intensive evaluation (e.g., surveys and activity logs). In addition, 24 staff (occupational therapists and physiotherapists) from participating wards will participate in the process evaluation. The mixed-methods study design will adopt a range of quantitative and qualitative research approaches. Data will be collected via a service profile survey and audits of clinical practice across the participating wards (considering areas such as staffing profiles and prescription of self-management programs). The intensive patient participant data collection will involve structured therapy participation and self-management program audits, Exercise Self Efficacy Scale, patient activity logs, patient surveys, and patient-worn activity monitors. Staff data collection will include surveys and focus groups. DISCUSSION The process evaluation will provide context to the clinical and economic outcomes associated with the My Therapy clinical trial. It considers how clinical and economic outcomes were achieved, and how to sustain the outcomes within the participating health networks. It will also provide context to inform future scaling of My Therapy to other health networks, and influence future models of rehabilitation and related policy. TRIAL REGISTRATION This study was prospectively registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12621000313831; registered 22/03/2021, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380828&isReview=true ).",2021,"All participants of the stepped wedge cluster randomised trial (2,160 rehabilitation patients) will be included in the process evaluation (e.g., ward audit); with a subset of 120 participants undergoing more intensive evaluation (e.g., surveys and activity logs).","[""adults receiving inpatient rehabilitation ('My Therapy"", 'eight rehabilitation wards across two public and two private Australian health networks', 'All participants of the stepped wedge cluster randomised trial (2,160 rehabilitation patients) will be included in the process evaluation (e.g., ward audit); with a subset of 120 participants undergoing more intensive evaluation (e.g., surveys and activity logs']",['Self-managed occupational therapy and physiotherapy'],"['fidelity, quality of implementation, acceptability, adoption, appropriateness, feasibility and adaptation', 'Exercise Self Efficacy Scale, patient activity logs, patient surveys, and patient-worn activity monitors']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439639', 'cui_str': 'Wedge'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C4264352', 'cui_str': 'Activity Trackers'}]",2160.0,0.0325665,"All participants of the stepped wedge cluster randomised trial (2,160 rehabilitation patients) will be included in the process evaluation (e.g., ward audit); with a subset of 120 participants undergoing more intensive evaluation (e.g., surveys and activity logs).","[{'ForeName': 'Sara L', 'Initials': 'SL', 'LastName': 'Whittaker', 'Affiliation': 'Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Monash University, 47-49 Moorooduc Hwy, VIC, 3199, Frankston, Australia. sara.whittaker1@monash.edu.'}, {'ForeName': 'Nicholas F', 'Initials': 'NF', 'LastName': 'Taylor', 'Affiliation': 'La Trobe University Centre for Sport and Exercise Medicine Research, Plenty Road & Kingsbury Drive, 3086, Bundoora, Australia.'}, {'ForeName': 'Keith D', 'Initials': 'KD', 'LastName': 'Hill', 'Affiliation': 'Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Monash University, 47-49 Moorooduc Hwy, VIC, 3199, Frankston, Australia.'}, {'ForeName': 'Christina L', 'Initials': 'CL', 'LastName': 'Ekegren', 'Affiliation': 'Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Monash University, 47-49 Moorooduc Hwy, VIC, 3199, Frankston, Australia.'}, {'ForeName': 'Natasha K', 'Initials': 'NK', 'LastName': 'Brusco', 'Affiliation': 'Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Monash University, 47-49 Moorooduc Hwy, VIC, 3199, Frankston, Australia.'}]",BMC health services research,['10.1186/s12913-021-06463-8'] 2864,34384419,Effectiveness and cost-effectiveness of primary arthrodesis versus open reduction and internal fixation in patients with Lisfranc fracture instability (The BFF Study) study protocol for a multicenter randomized controlled trial.,"BACKGROUND The Lisfranc injury is a complex injury of the midfoot. It can result in persistent pain and functional impairment if treated inappropriately. In Lisfranc fracture dislocation, treatment options are primary arthrodesis of the midfoot joints or open reduction and internal fixation. The purpose of the proposed study is to define the optimal treatment for the Lisfranc fracture dislocation, either primary arthrodesis or open reduction and internal fixation, in regard to quality of life, complications, functional outcomes, and cost effectiveness. METHODS Study design: A prospective multicenter RCT. STUDY POPULATION All patients of 18 years and older with an acute (< 6 weeks) traumatic fracture dislocation in the Lisfranc midfoot joints, displaced on static radiographic evaluation or unstable with dynamic evaluation, weight bearing radiographs or fluoroscopic stress testing under anesthesia, and eligible for either one of the surgical procedures. In total, this study will include n = 112 patients with Lisfranc fracture dislocation. INTERVENTIONS Patients with Lisfranc fracture dislocation will be randomly allocated to treatment in ""The Better to Fix or Fuse Study"" (The BFF Study) with either PA or ORIF. Main study parameters/endpoints: Primary outcome parameter: the quality of life. SECONDARY OUTCOMES complications, functional outcomes, secondary surgical interventions and cost effectiveness. Nature and extent of the burden: PA is expected to have a better outcome, however both treatments are accepted for this injury with a similar low risk of complications. Follow up is standardized and therefore this study will not add extra burden to the patient. DISCUSSION This study protocol provides a comprehensive overview of the aims and methods of the attached clinical study. Limitations of this study are the absence of patient blinding since it is impossible in surgical intervention, and the outcome measure (AOFAS) that has limited validity not for these injuries. This study will be the first with enough power to define optimal treatment for Lisfranc fracture dislocations. This is necessary since current literature is unclear on this topic. Trial registration Current controlled Trial: NCT04519242 with registration date: 08/13/2020. Retrospectively registered; Protocol date and version: Version 4 05/06/2020.",2021,"All patients of 18 years and older with an acute (< 6 weeks) traumatic fracture dislocation in the Lisfranc midfoot joints, displaced on static radiographic evaluation or unstable with dynamic evaluation, weight bearing radiographs or fluoroscopic stress testing under anesthesia, and eligible for either one of the surgical procedures.","['patients with Lisfranc fracture instability', 'Patients with Lisfranc fracture dislocation', 'All patients of 18\xa0years and older with an acute (<\u20096\xa0weeks) traumatic fracture dislocation in the Lisfranc midfoot joints, displaced on static radiographic evaluation or unstable with dynamic evaluation, weight bearing radiographs or fluoroscopic stress testing under anesthesia, and eligible for either one of the surgical procedures', 'n\u2009=\u2009112 patients with Lisfranc fracture dislocation']","['primary arthrodesis versus open reduction and internal fixation', 'primary arthrodesis or open reduction and internal fixation', 'PA or ORIF']","['quality of life, complications, functional outcomes, and cost effectiveness', 'quality of life', 'Effectiveness and cost-effectiveness', 'complications, functional outcomes, secondary surgical interventions and cost effectiveness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4324279', 'cui_str': 'Lisfranc fracture'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0877237', 'cui_str': 'Traumatic fracture'}, {'cui': 'C0932074', 'cui_str': 'Midfoot region of foot'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0443343', 'cui_str': 'Unstable status'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0085086', 'cui_str': 'Weight-bearing'}, {'cui': 'C1306645', 'cui_str': 'Plain radiography'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C1720436', 'cui_str': 'Under anesthesia'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C4319548', 'cui_str': '112'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0003881', 'cui_str': 'Arthrodesis'}, {'cui': 'C0185373', 'cui_str': 'Open reduction of fracture'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]",112.0,0.0988663,"All patients of 18 years and older with an acute (< 6 weeks) traumatic fracture dislocation in the Lisfranc midfoot joints, displaced on static radiographic evaluation or unstable with dynamic evaluation, weight bearing radiographs or fluoroscopic stress testing under anesthesia, and eligible for either one of the surgical procedures.","[{'ForeName': 'N A C', 'Initials': 'NAC', 'LastName': 'van den Boom', 'Affiliation': 'Dept. of Trauma Surgery, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands. n.vandenboom@maastrichtuniversity.nl.'}, {'ForeName': 'G A N L', 'Initials': 'GANL', 'LastName': 'Stollenwerck', 'Affiliation': 'Dept. of Surgery-Trauma Surgery, Alrijne Hospital, Simon Smitweg 1, 2353 GA, Leiderdorp, The Netherlands.'}, {'ForeName': 'S M A A', 'Initials': 'SMAA', 'LastName': 'Evers', 'Affiliation': 'Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Da Costakade 45, 3521 VS, Utrecht, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Poeze', 'Affiliation': 'Dept. of Trauma Surgery, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.'}]",BMC surgery,['10.1186/s12893-021-01320-1'] 2865,34384345,THE EFFECTS OF ASSISTED AND RESISTED PLYOMETRIC TRAINING ON JUMP HEIGHT AND SPRINT PERFORMANCE AMONG PHYSICALLY ACTIVE FEMALES.,"The aim of the present study was to compare the effects of assisted and resisted plyometric jump training on jump height, sprint performance (acceleration (0-20m), maximum speed (30-40m) and 40m sprint time) among physically active females. Fifty-six participants (age: 21.1 ± 1.7 years; body mass: 64.2 ± 7.0 kg; height: 168.0 ± 5.6 cm) were randomly allocated to either an assisted (n=16) or resisted training group (n=17), or a control group (n=14). Nine participants dropped out during the intervention. The training sessions consisted of three different plyometric jump exercises over an eight-week period, while the control group continued their normal training routine. The results revealed a significant between-group difference in jump height and maximal speed. The resisted training group achieved a significantly greater improvement in jump height compared to the active control group (p=0.04, ES=1.06), and a significant greater improvement in maximal speed (p=0.02, ES=0.93) when compared to the assisted training group. No other group differences were observed for jump height, acceleration or in the maximal speed (p=0.31-0.53). The resisted training group improved jump height (p=0.01, ES=0.62) and maximum speed (p=0.03, ES=0.48) from pre- to post test, while the control group improved maximal speed (p=0.04, ES=0.37) and acceleration (p=0.01, ES=0.68). All three groups improved their 40m sprint time from pre- to post test (p=0.01-0.04, ES=0.38-0.45). In conclusion, resisted plyometric training was more effective than assisted plyometric training for improving the maximal speed and more effective than the active control condition for increasing jump height.",2021,"The resisted training group improved jump height (p=0.01, ES=0.62) and maximum speed (p=0.03, ES=0.48) from pre- to post test, while the control group improved maximal speed (p=0.04, ES=0.37) and acceleration (p=0.01, ES=0.68).","['physically active females', 'Fifty-six participants (age: 21.1 ± 1.7 years; body mass: 64.2 ± 7.0 kg; height: 168.0 ± 5.6 cm']","['plyometric training', 'assisted plyometric training', 'control group continued their normal training routine', 'resisted training group', 'assisted and resisted plyometric jump training', 'plyometric jump exercises']","['maximal speed', 'maximum speed', 'jump height, acceleration or in the maximal speed', 'jump height and maximal speed', '40m sprint time', 'jump height', 'jump height, sprint performance (acceleration (0-20m), maximum speed (30-40m) and 40m sprint time']","[{'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C4517794', 'cui_str': '5.6'}]","[{'cui': 'C3178799', 'cui_str': 'Plyometric Drill'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",56.0,0.00527504,"The resisted training group improved jump height (p=0.01, ES=0.62) and maximum speed (p=0.03, ES=0.48) from pre- to post test, while the control group improved maximal speed (p=0.04, ES=0.37) and acceleration (p=0.01, ES=0.68).","[{'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Strate', 'Affiliation': 'Faculty of Sport Science and Physical Education, University of Agder, Norway.'}, {'ForeName': 'Nicolay', 'Initials': 'N', 'LastName': 'Stien', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Norway.'}, {'ForeName': 'Atle Hole', 'Initials': 'AH', 'LastName': 'Saeterbakken', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Norway.'}, {'ForeName': 'Vidar', 'Initials': 'V', 'LastName': 'Andersen', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Norway.'}]",European journal of sport science,['10.1080/17461391.2021.1968503'] 2866,34384301,Duration and onset of effect of incobotulinumtoxina for the treatment of blepharospasm in botulinum toxin-naïve subjects.,"Objective: Blepharospasm is a focal dystonia whereby excessive eyelid muscle contractions cause involuntary eye closure. Botulinum neurotoxin type A (BoNT-A) injections are an approved treatment. This randomized placebo-controlled trial (NCT01896895; EudraCT number 2012-004821-26) assessed the efficacy, safety, and treatment effect duration of incobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals GmbH), a BoNT-A formulation without complexing proteins, in BoNT-A-naïve adults with blepharospasm. Methods: Subjects received incobotulinumtoxinA 50 U, 25 U (total dose) or placebo during a main study period (MP; 6-20 weeks). Patients needing a second injection received incobotulinumtoxinA ≤70 U in an open-label extension period (EP; 6-20 weeks). Treatment effect durations were time from first injection to EP injection or final MP visit and from EP injection to end-of-study visit. Times to effect onset and to waning of effect (MP) were time from injection to first subject-assessed onset effect and time from injection to subject-reported waning of effect, respectively. Results: Of 61 subjects, 39 entered the EP. During the MP, median duration of treatment effect was longer with incobotulinumtoxinA 50 U (20 weeks) versus incobotulinumtoxinA 25 U (11 weeks) or placebo (6 weeks). Median duration of treatment effect was 20 weeks during the EP. Median time to effect onset was 5, 7 and 14 days with 50 U, 25 U and placebo, respectively (p = 0.022 for 50 U versus placebo). Median time to waning of treatment effect was comparable between groups. Conclusion: Subjects reported an effect onset from 5 days after injection lasting up to 20 weeks (maximum observation period). Data indicate that incobotulinumtoxinA re-treatment of blepharospasm may not be required at fixed 12-week intervals and provide evidence for a patient-tailored approach.",2021,Median time to waning of treatment effect was comparable between groups.,"['61 subjects, 39 entered the EP', 'botulinum toxin-naïve subjects']","['incobotulinumtoxina', 'Blepharospasm', 'Botulinum neurotoxin type A (BoNT-A) injections', 'incobotulinumtoxinA', 'incobotulinumtoxinA 50\u2009U, 25\u2009U (total dose) or placebo', 'incobotulinumtoxinA ≤70\u2009U in an open-label extension', 'placebo']","['Median time to waning of treatment effect', 'Median duration of treatment effect', 'Median time to effect onset', 'efficacy, safety']","[{'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0006055', 'cui_str': 'botulinum toxin'}]","[{'cui': 'C2930113', 'cui_str': 'IncobotulinumtoxinA'}, {'cui': 'C0005747', 'cui_str': 'Blepharospasm'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0913027,Median time to waning of treatment effect was comparable between groups.,"[{'ForeName': 'Dimos D', 'Initials': 'DD', 'LastName': 'Mitsikostas', 'Affiliation': '1st Neurology Department, Aeginition Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Dekundy', 'Affiliation': 'Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.'}, {'ForeName': 'Angelika', 'Initials': 'A', 'LastName': 'Hanschmann', 'Affiliation': 'Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Althaus', 'Affiliation': 'Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Scheschonka', 'Affiliation': 'Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Pagan', 'Affiliation': 'Department of Neurology, Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Jankovic', 'Affiliation': ""Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.""}]",Current medical research and opinion,['10.1080/03007995.2021.1965975'] 2867,34387408,Liraglutide Reduces Cardiac Adipose Tissue in Type 2 Diabetes: A secondary analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.,"BACKGROUND Increased cardiac adipose tissue is associated with cardiovascular morbidity in type 2 diabetes. We hypothesized that treatment with liraglutide can reduce cardiac adipose tissue. MATERIALS AND METHODS LIRAFLAME is a randomized placebo-controlled, double-blind, parallel clinical study. Participants with type 2 diabetes were randomized to treatment with liraglutide 1.8 mg/day or placebo for 26 weeks. Computed tomography was performed at baseline and end-of-treatment to evaluate the cardiac adipose tissue volume, quantified automatically. We report the results of a secondary endpoint evaluating changes in cardiac adipose tissue. RESULTS A total of 102 participants were randomly assigned to liraglutide (n = 51) or placebo (n = 51). At baseline, the mean (SD) cardiac adipose tissue volume was comparable between the liraglutide and the placebo group [232.6 (112.8) vs 227.0 (103.2) ml, p = 0.80]. Mean change in body weight was -3.7 (-4.8, -2.6) kg in the liraglutide and - 0.18 (-0.76, 0.40) kg in the placebo group. From baseline to end-of-treatment the mean cardiac adipose tissue change was -11.5 (95% CI: -17.6, -5.4) ml in the liraglutide (p < 0.001) and - 0.01 (-5.3, 5.3) ml in the placebo (p = 1.00) groups. The reduction in cardiac adipose tissue was significantly larger in the liraglutide compared to the placebo group (mean difference: -11.4 [-19.4, -3.3] ml, p = 0.006), but significance was lost after adjustment for changes in body mass index (P = 0.46). CONCLUSION Treatment with liraglutide for 26 weeks was associated with a reduction in cardiac adipose tissue compared to placebo. The reduction was not independent of weight-loss, suggesting that this is not a drug-specific effect. This article is protected by copyright. All rights reserved.",2021,"At baseline, the mean (SD) cardiac adipose tissue volume was comparable between the liraglutide and the placebo group [232.6 (112.8) vs 227.0 (103.2) ml, p = 0.80].","['type 2 diabetes', 'Type 2', 'A total of 102 participants', 'Participants with type 2 diabetes', 'Diabetes']","['liraglutide', 'Placebo', 'Liraglutide', 'placebo', 'liraglutide 1.8\xa0mg/day or placebo']","['cardiac adipose tissue', 'Mean change in body weight', 'mean (SD) cardiac adipose tissue volume', 'mean cardiac adipose tissue change', 'weight-loss']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",102.0,0.659525,"At baseline, the mean (SD) cardiac adipose tissue volume was comparable between the liraglutide and the placebo group [232.6 (112.8) vs 227.0 (103.2) ml, p = 0.80].","[{'ForeName': 'Ida K B', 'Initials': 'IKB', 'LastName': 'Rasmussen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Emilie H', 'Initials': 'EH', 'LastName': 'Zobel', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Rasmus S', 'Initials': 'RS', 'LastName': 'Ripa', 'Affiliation': 'Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet, Denmark.'}, {'ForeName': 'Bernt J', 'Initials': 'BJ', 'LastName': 'von Scholten', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Viktor R', 'Initials': 'VR', 'LastName': 'Curovic', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Jacob K', 'Initials': 'JK', 'LastName': 'Jensen', 'Affiliation': 'Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet, Denmark.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Kjaer', 'Affiliation': 'Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet, Denmark.'}, {'ForeName': 'Tine W', 'Initials': 'TW', 'LastName': 'Hansen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rossing', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14516'] 2868,34387353,Community Perspectives on Patient Credibility and Provider Burden in the Treatment of Chronic Pain.,"OBJECTIVE This study examined factors influencing lay perceptions of a provider's clinical burden in providing care to a person with chronic pain. DESIGN In a between-subjects design that varied three levels of pain severity (4-6-8/10) with two levels of medical evidence (low/high), participants rated the credibility of pain reported by a hypothetical patient and psychosocial factors expected to mediate the effects of evidence and severity on a provider's burden of care. SETTING A randomized vignette study in which community participants were recruited via Amazon Mechanical Turk. SUBJECTS 337 community participants. METHODS Using a Qualtrics platform, participants read one of six vignettes describing a hypothetical patient with varying levels of medical evidence and pain severity, and then rated perceived pain severity, pain credibility, psychosocial variables, and burden. RESULTS Serial mediation models accounted for all effects of medical evidence and pain severity on burden. Low medical evidence was associated with increased burden, as mediated through lower pain credibility and greater concerns about patient depression, opioid abuse, and learning pain management. Higher levels of reported pain severity were associated with increased burden, as mediated through greater pain discounting and concerns about opioid abuse. CONCLUSIONS The lay public is skeptical of chronic pain that is not supported by medical evidence or is reported at high levels of severity, raising concerns about psychosocial complications and drug seeking and expectations of higher burden of care. Such negative stereotypes can pose obstacles to people seeking necessary care if they or others develop a chronic pain condition.",2021,"Higher levels of reported pain severity were associated with increased burden, as mediated through greater pain discounting and concerns about opioid abuse. ","['337 community participants', 'community participants were recruited via Amazon Mechanical Turk']",[],"['pain discounting and concerns about opioid abuse', 'pain severity', 'pain severity, pain credibility, psychosocial variables, and burden']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0337911', 'cui_str': 'Turks'}]",[],"[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0029095', 'cui_str': 'Opioid abuse'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0033963', 'cui_str': 'Psychosocial Factors'}]",337.0,0.160654,"Higher levels of reported pain severity were associated with increased burden, as mediated through greater pain discounting and concerns about opioid abuse. ","[{'ForeName': 'Raymond C', 'Initials': 'RC', 'LastName': 'Tait', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine.'}, {'ForeName': 'John T', 'Initials': 'JT', 'LastName': 'Chibnall', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnab256'] 2869,34387269,Modified Burr-Hole Craniostomy for the Treatment of Chronic Subdural Hematoma in Adults.,"BACKGROUND Burr-hole craniostomy (BHC) is considered to be the most effective method for the treatment of chronic subdural hematoma (CSDH), and middle meningeal artery embolization is a new therapy used in clinical practice in recent years to treat CSDH. However, the optimal therapeutic effect of these 2 procedures is still controversial. This study prospectively designed a modified burr-hole craniostomy (mBHC) with drainage to treat CSDH. METHODS A total of 101 patients diagnosed with CSDH from January 2019 to April 2020 were prospectively included in this study. They were divided into BHC and mBHC groups. Among them, 40 selected CSDH patients received mBHC treatment. For comparison, 61 CSDH patients who received BHC treatment were used as the control group. Primary outcomes were hematoma recurrence and postoperative complications. Secondary outcomes included midline recovery, hematoma clearance, operation time, and hospital stay. The Chi-square test was used to compare the 6-month follow-up results between the 2 groups. RESULTS Among patients treated with mBHC, 39 patients had a good prognosis, and one 87-year-old patient with bilateral hematoma died of postoperative heart failure. Of the patients treated with BHC, 52 patients had good prognoses, and one 53-year-old patient with unilateral hematoma died of postoperative acute intracranial bleeding. During the 6-month follow-up period, no relapse occurred in the patients treated with mBHC, whereas 8 (13%) of the patients treated with BHC relapsed. There was a significant difference in the recurrence rate between the 2 groups (P < 0.05). In addition, midline recovery, hematoma clearance rate, operation time, and complications were found to be significantly different statistically (P < 0.05), and other characteristics of operation and outcome were not significantly different (P > 0.05) between the 2 groups. CONCLUSIONS Modified burr-hole craniostomy has a positive therapeutic effect on patients with CSDH and is more effective than conventional BHC therapy.",2021,"In addition, midline recovery, hematoma clearance rate, operation time, and complications were found to be significantly different statistically","['40 selected CSDH patients received mBHC treatment', '101 patients diagnosed with CSDH from January 2019 to April 2020', 'patients treated with mBHC, 39 patients had a good prognosis, and one 87-year-old patient with bilateral hematoma died of postoperative heart failure', 'Chronic Subdural Hematoma in Adults', 'patients with CSDH', '61 CSDH patients who received']","['Burr-hole craniostomy (BHC', 'modified burr-hole craniostomy (mBHC', 'Modified Burr-Hole Craniostomy', 'BHC']","['midline recovery, hematoma clearance, operation time, and hospital stay', 'hematoma recurrence and postoperative complications', 'midline recovery, hematoma clearance rate, operation time, and complications', 'relapse', 'recurrence rate', 'unilateral hematoma died of postoperative acute intracranial bleeding']","[{'cui': 'C0749095', 'cui_str': 'Subdural Hematoma, Chronic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0040836', 'cui_str': 'Trephination of cranium'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0278250', 'cui_str': 'Prognosis good'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0040836', 'cui_str': 'Trephination of cranium'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0025515', 'cui_str': 'Metabolic clearance rate'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0151699', 'cui_str': 'Intracranial hemorrhage'}]",101.0,0.0149377,"In addition, midline recovery, hematoma clearance rate, operation time, and complications were found to be significantly different statistically","[{'ForeName': 'Zhiyong', 'Initials': 'Z', 'LastName': 'Zhao', 'Affiliation': 'Second Clinical School, Lanzhou University Department of Neurosurgery Department of Radiology, Lanzhou University Second Hospital Key Laboratory of Medical Imaging of Gansu Province Institute of Neurology, Lanzhou University, Lanzhou, China.'}, {'ForeName': 'Jinglong', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Guojin', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Yuntai', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': ''}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Yin', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Miaojuan', 'Initials': 'M', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Yawen', 'Initials': 'Y', 'LastName': 'Pan', 'Affiliation': ''}, {'ForeName': 'Junlin', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': ''}]",The Journal of craniofacial surgery,['10.1097/SCS.0000000000008073'] 2870,34387261,Community-based Versus Traditional Research Among Older Minority Women With Urinary Incontinence.,"OBJECTIVE The aim of this study was to evaluate research retention of older minority women with urinary incontinence (UI) using a community-based participatory research (CBPR) versus a traditional research approach. METHODS An ancillary prospective study was conducted within an ongoing pilot randomized clinical trial to treat UI. Participants were recruited using CBPR in collaboration with a local community versus a traditional research approach at an academic center. Inclusion criteria were women 65 years and older and symptomatic UI. The primary outcome was the randomization rate defined as the proportion of women randomized into the randomized clinical trial out of screened participants. Screening and consent rates were also evaluated. Pearson χ2, Fisher exact, and t tests were used. The effect of CBPR on research retention rates was expressed as odds ratio (OR) with 95% confidence intervals (CI). RESULTS There were 10 and 88 women screened in the CBPR and traditional research groups, respectively. The CBPR participants were Hispanic (n = 10, 100%) and older (78.4 ± 8.3 years; P < 0.01). Most of the traditional research participants were non-Hispanic Black (n = 55, 62.5%) and younger (71.0 ± 4.9 years). The CBPR group had higher rates of screening (76.9% vs 40.6%; P = 0.01), consent (80% vs 44.3%; P = 0.045), and randomization (50.0% vs 14.8%; P < 0.01) compared with the traditional research group. Community-based participatory research increased the odds of research retention during screening (OR, 4.9; 95% CI, 1.3-18.2), consent (OR, 5.0; 95% CI, 1.0-25.0), and randomization (OR, 5.8; 95% CI, 1.5-22.7). CONCLUSION Compared with traditional research, CBPR yielded higher research retention among older minority women with UI in a clinical study.",2021,"Community-based participatory research increased the odds of research retention during screening (OR, 4.9; 95% CI, 1.3-18.2), consent (OR, 5.0; 95% CI, 1.0-25.0), and randomization (OR, 5.8; 95% CI, 1.5-22.7). ","['Participants were recruited using CBPR in collaboration with a local community versus a traditional research approach at an academic center', 'older minority women with urinary incontinence (UI', 'traditional research participants were non-Hispanic Black (n = 55, 62.5%) and younger (71.0 ± 4.9 years', '88 women screened in the CBPR and traditional research groups, respectively', 'older minority women with UI in a clinical study', 'Inclusion criteria were women 65 years and older and symptomatic UI', 'Older Minority Women With Urinary Incontinence']","['CBPR', 'community-based participatory research (CBPR']","['Screening and consent rates', 'randomization rate', 'rates of screening', 'research retention rates']","[{'cui': 'C2350575', 'cui_str': 'Community-Based Participatory Research'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C4517836', 'cui_str': '62.5'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}]","[{'cui': 'C2350575', 'cui_str': 'Community-Based Participatory Research'}]","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}]",,0.147614,"Community-based participatory research increased the odds of research retention during screening (OR, 4.9; 95% CI, 1.3-18.2), consent (OR, 5.0; 95% CI, 1.0-25.0), and randomization (OR, 5.8; 95% CI, 1.5-22.7). ","[{'ForeName': 'Sharee', 'Initials': 'S', 'LastName': 'Pearson', 'Affiliation': 'From the Department of Obstetrics and Gynecology, Howard University College of Medicine, Washington, DC Medstar Health, Hyattsville, MD Clinical Research Unit, Howard University Hospital Howard University, Washington, DC.'}, {'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Temple', 'Affiliation': ''}, {'ForeName': 'Tonya', 'Initials': 'T', 'LastName': 'Bishop', 'Affiliation': ''}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Ukaegbu', 'Affiliation': ''}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Alden', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kwagyan', 'Affiliation': ''}, {'ForeName': 'Tatiana V D', 'Initials': 'TVD', 'LastName': 'Sanses', 'Affiliation': ''}]",Female pelvic medicine & reconstructive surgery,['10.1097/SPV.0000000000001089'] 2871,34387258,The Impact of Tape Sealing Face Masks on Visual Field Scores in the Era of COVID-19 -A Randomized Cross-Over Study.,"PRCIS Tape sealing of the face mask can prevent fogging artifacts of visual field testing. Here we demonstrate that tape sealing can improve visual field scores even when fogging artifacts are not obvious. PURPOSE To demonstrate that visual field scores improve when the face masks are taped in order to prevent fogging artifacts. METHODS Single-center, randomized 2×2 cross-over study. Twenty-six visual fields of 13 patients of the glaucoma outpatient clinic were included. Patients were randomized in either sequence 1 (Octopus visual field examination without tape sealing, followed by examination with tape sealing) or sequence 2 (examination with, followed by without tape sealing). RESULTS The results for mean defect and square root of Loss Variance (sLV) differ significantly in the examination with and without tape sealing (mean difference (without-with) 0.39▒dB; 95% CI: 0.07 to 0.70▒dB; P=0.018 and 0.49▒dB; 95% CI: 0.19 to 0.79▒dB; P=0.003, respectively). There was no sequence effect (P=0.967) for mean defect nor sLV (P=0.779). A significant effect for period (P=0.023) for mean defect was yielded. CONCLUSION Tape sealing of face masks during visual field testing prevented fogging artifacts and improved visual field scores even when fogging artifacts were not obvious, and should be considered in clinical practice.",2021,There was no sequence effect (P=0.967) for mean defect nor sLV (P=0.779).,['Twenty-six visual fields of 13 patients of the glaucoma outpatient clinic were included'],"['Tape Sealing Face Masks', 'sequence 1 (Octopus visual field examination without tape sealing, followed by examination with tape sealing) or sequence 2 (examination with, followed by without tape sealing', 'tape sealing']","['mean defect and square root of Loss Variance (sLV', 'visual field scores', 'Visual Field Scores']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0028831', 'cui_str': 'Octopus'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C1719837', 'cui_str': 'Loss variance'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",26.0,0.0890133,There was no sequence effect (P=0.967) for mean defect nor sLV (P=0.779).,"[{'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Heidinger', 'Affiliation': 'Department of Ophthalmology, Medical University of Graz, Graz, Austria Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria Department of Ophthalmology, Sanatorium Hera, Vienna, Austria.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Falb', 'Affiliation': ''}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Werkl', 'Affiliation': ''}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'List', 'Affiliation': ''}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Hoeflechner', 'Affiliation': ''}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Riedl', 'Affiliation': ''}, {'ForeName': 'Domagoj', 'Initials': 'D', 'LastName': 'Ivastinovic', 'Affiliation': ''}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Hommer', 'Affiliation': ''}, {'ForeName': 'Ewald', 'Initials': 'E', 'LastName': 'Lindner', 'Affiliation': ''}]",Journal of glaucoma,['10.1097/IJG.0000000000001922'] 2872,34387101,Effect of Heart Rate Variabilities on Outcome After Acute Intracerebral Hemorrhage: A Post Hoc Analysis of ATACH-2.,"Background To explore how the clinical impact of heart rate (HR) and heart rate variabilities (HRV) during the initial 24 hours after acute intracerebral hemorrhage (ICH) contribute to worse clinical outcomes. Methods and Results In the ATACH-2 (Antihypertensive Treatment in Intracerebral Hemorrhage 2) trial, the HR was recorded for every 15 minutes from baseline to 1 hour and hourly during the initial 24 hours post-randomization. We calculated the following: mean, standard deviation, coefficient of variation, successive variation, and average real variability (ARV). Outcomes were hematoma expansion at 24 hours and unfavorable functional outcome, defined as modified Rankin Scale score 4 to 6 at 90 days. Of the 1000 subjects in ATACH-2, 994 with available HR data were included in the analyses. Overall, 262 experienced hematoma expansion, and 362 had unfavorable outcomes. Increased mean HR was linearly associated with unfavorable outcome (per 10 bpm increase adjusted odds ratio [aOR], 1.31, 95% CI, 1.14-1.50) but not with hematoma expansion, while HR-ARV was associated with hematoma expansion (aOR, 1.06, 95% CI, 1.01-1.12) and unfavorable outcome (aOR, 1.07, 95% CI, 1.01-1.3). Every 10-bpm increase in mean HR increased the probability of unfavorable outcome by 4.3%, while every 1 increase in HR-ARV increased the probability of hematoma expansion by 1.1% and unfavorable outcome by 1.3%. Conclusions Increased mean HR and HR-ARV within the initial 24 hours were independently associated with unfavorable outcome in acute ICH. Moreover, HR-ARV was associated with hematoma expansion at 24 hours. This may have future therapeutic implications to accommodate HR and HRV in acute ICH. Registration URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01176565.",2021,"Increased mean HR was linearly associated with unfavorable outcome (per 10 bpm increase adjusted odds ratio [aOR], 1.31, 95% CI, 1.14-1.50) but not with hematoma expansion, while HR-ARV was associated with hematoma expansion (aOR, 1.06, 95% CI, 1.01-1.12) and unfavorable outcome (aOR, 1.07, 95% CI, 1.01-1.3).","['After Acute Intracerebral Hemorrhage', '1000 subjects in ATACH-2, 994 with available HR data were included in the analyses']",['ATACH-2 (Antihypertensive Treatment'],"['HR-ARV', 'hematoma expansion, while HR-ARV', 'mean HR', 'probability of hematoma expansion', 'mean, standard deviation, coefficient of variation, successive variation, and average real variability (ARV', 'mean HR and HR-ARV', 'heart rate (HR) and heart rate variabilities (HRV', 'modified Rankin Scale score', 'hematoma expansion']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",1000.0,0.165363,"Increased mean HR was linearly associated with unfavorable outcome (per 10 bpm increase adjusted odds ratio [aOR], 1.31, 95% CI, 1.14-1.50) but not with hematoma expansion, while HR-ARV was associated with hematoma expansion (aOR, 1.06, 95% CI, 1.01-1.12) and unfavorable outcome (aOR, 1.07, 95% CI, 1.01-1.3).","[{'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Miwa', 'Affiliation': 'Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita Japan.'}, {'ForeName': 'Masatoshi', 'Initials': 'M', 'LastName': 'Koga', 'Affiliation': 'Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita Japan.'}, {'ForeName': 'Mayumi', 'Initials': 'M', 'LastName': 'Fukuda-Doi', 'Affiliation': 'Center for Advancing Clinical and Translational Sciences National Cerebral and Cardiovascular Center Suita Japan.'}, {'ForeName': 'Haruko', 'Initials': 'H', 'LastName': 'Yamamoto', 'Affiliation': 'Center for Advancing Clinical and Translational Sciences National Cerebral and Cardiovascular Center Suita Japan.'}, {'ForeName': 'Kanata', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': 'Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita Japan.'}, {'ForeName': 'Sohei', 'Initials': 'S', 'LastName': 'Yoshimura', 'Affiliation': 'Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Ihara', 'Affiliation': 'Department of Neurology National Cerebral and Cardiovascular Center Suita Japan.'}, {'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': 'Zeenat Qureshi Stroke Institute and Department of Neurology University of Missouri Columbia MO.'}, {'ForeName': 'Kazunori', 'Initials': 'K', 'LastName': 'Toyoda', 'Affiliation': 'Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita Japan.'}]",Journal of the American Heart Association,['10.1161/JAHA.120.020364'] 2873,34387047,Chemical cleansing as an adjunct to subgingival instrumentation with ultrasonic and hand devices in deep periodontal pockets: a randomized controlled study.,"PURPOSE The aim of this randomized clinical trial was to assess whether chemical cleansing using a sulfonic/sulfuric acid gel solution (HBX) as an adjunct to scaling and root planing (SRP) resulted in a decrease in residual plaque and calculus in deep periodontal pockets compared to SRP alone. METHODS Fifty-six patients with 56 hopeless posterior teeth, scheduled for extraction due to severe periodontitis, were enrolled in this study. Each tooth was randomly assigned to 1 of the 2 experimental procedures. The test teeth were subjected to the irrigation of the subgingival area with HBX for 2 minutes, followed by SRP with hand and ultrasonic instruments for 14 minutes, and then extracted. The control teeth received only mechanical instrumentation before extraction. Residual biofilm was evaluated on photographs and measured as total area and percentage of root surface covered by remaining plaque (RP) or calculus (RC) after treatment. RESULTS The initial pocket depth (PD) and total subgingival root surface area were similar between the 2 treatment groups. After treatment, the total subgingival root area covered by RP and RC was statistically significantly larger ( P <0.001) in the control group than in the test group. The test teeth showed a lower percentage of RP, but a higher percentage of RC than the control teeth (both P <0.001). Complete calculus removal was achieved in 42% of the control teeth surfaces and in 25% of the test teeth surfaces for a PD of 4 mm. CONCLUSIONS The additional chemical cleansing with HBX resulted in a statistically significant improvement in bacterial plaque removal during SRP of deep pockets, but it was not effective in reducing calculus deposits.",2021,"Complete calculus removal was achieved in 42% of the control teeth surfaces and in 25% of the test teeth surfaces for a PD of 4 mm. ","['deep periodontal pockets', 'Fifty-six patients with 56 hopeless posterior teeth, scheduled for extraction due to severe periodontitis']","['chemical cleansing using a sulfonic/sulfuric acid gel solution (HBX', 'Chemical cleansing', 'mechanical instrumentation before extraction', 'HBX']","['initial pocket depth (PD) and total subgingival root surface area', 'Residual biofilm', 'Complete calculus removal', 'total area and percentage of root surface covered by remaining plaque (RP) or calculus (RC', 'calculus deposits', 'total subgingival root area covered by RP and RC', 'residual plaque and calculus', 'bacterial plaque removal']","[{'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0031094', 'cui_str': 'Periodontal pocket'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150041', 'cui_str': 'Feeling hopeless'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}]","[{'cui': 'C0220806', 'cui_str': 'Chemical'}, {'cui': 'C0038784', 'cui_str': 'Sulfuric acid'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0021632', 'cui_str': 'instrumentation'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}]","[{'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0595817', 'cui_str': 'Subgingival route'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0081786', 'cui_str': 'Biofilm'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0333562', 'cui_str': 'Deposition'}]",56.0,0.0570617,"Complete calculus removal was achieved in 42% of the control teeth surfaces and in 25% of the test teeth surfaces for a PD of 4 mm. ","[{'ForeName': 'Fahad', 'Initials': 'F', 'LastName': 'Zafar', 'Affiliation': 'Department of Surgical Sciences, University of Turin C.I.R. Dental School, Turin, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Romano', 'Affiliation': 'Department of Surgical Sciences, University of Turin C.I.R. Dental School, Turin, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Citterio', 'Affiliation': 'Department of Surgical Sciences, University of Turin C.I.R. Dental School, Turin, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Ferrarotti', 'Affiliation': 'Department of Surgical Sciences, University of Turin C.I.R. Dental School, Turin, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Dellavia', 'Affiliation': 'Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.'}, {'ForeName': 'Moontaek', 'Initials': 'M', 'LastName': 'Chang', 'Affiliation': 'Department of Surgical Sciences, University of Turin C.I.R. Dental School, Turin, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Aimetti', 'Affiliation': 'Department of Surgical Sciences, University of Turin C.I.R. Dental School, Turin, Italy.'}]",Journal of periodontal & implant science,['10.5051/jpis.2007080354'] 2874,34387038,Preventive effects of tamsulosin for postoperative urinary retention after lower limb arthroplasty: A randomized controlled study.,"PURPOSE This prospective, randomized, controlled study investigated the use of tamsulosin, a selective alpha-blocker, as a prophylactic medication to prevent postoperative urinary retention (POUR) following lower limb arthroplasty. MATERIALS AND METHODS The criterion for diagnosing POUR was used a postoperative bladder volume over 400 mL with incomplete emptying. Patients who underwent primary total hip or knee arthroplasty were randomly assigned at a 1:1 ratio to tamsulosin treatment and non-treatment groups at a single center from September 2018 to November 2018. The treatment group received 0.2 mg of tamsulosin orally once at night for 3 days starting on postoperative day 1. During this 3-day period, an indwelling Foley catheter was maintained. The incidence of POUR according to tamsulosin treatment following lower limb arthroplasty was the primary outcome. RESULTS In total, 100 patients were enrolled, of whom 5 discontinued participation. POUR was diagnosed in 20 of the remaining 95 patients (21.1%). The treatment group contained 48 patients, of whom 6 (12.5%) developed POUR, whereas POUR occurred in the 14 of the 47 patients (29.8%) in the non-treatment group. Tamsulosin treatment reduced the risk of POUR by two-thirds (odds ratio [OR], 0.337; 95% confidence interval [CI], 0.117-0.971; p=0.044). The risk reduction associated with tamsulosin treatment remained robust post-adjustment for potential covariates (OR, 0.250; 95% CI, 0.069-0.905; p=0.038). CONCLUSIONS Tamsulosin administration immediately after lower limb arthroplasty reduced the incidence of urinary retention and diminished the need for long-term catheterization.",2021,"Tamsulosin treatment reduced the risk of POUR by two-thirds (odds ratio [OR], 0.337; 95% confidence interval [CI], 0.117-0.971; p=0.044).","['postoperative urinary retention after lower limb arthroplasty', 'groups at a single center from September 2018 to November 2018', 'Patients who underwent primary total hip or knee arthroplasty', '100 patients were enrolled, of whom 5 discontinued participation']","['tamsulosin treatment and non-treatment', 'Tamsulosin', 'tamsulosin, a selective alpha-blocker', 'tamsulosin']","['risk of POUR', 'urinary retention', 'incidence of POUR', 'postoperative urinary retention (POUR', 'POUR']","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]","[{'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001641', 'cui_str': 'Alpha adrenergic receptor antagonist'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",100.0,0.0880895,"Tamsulosin treatment reduced the risk of POUR by two-thirds (odds ratio [OR], 0.337; 95% confidence interval [CI], 0.117-0.971; p=0.044).","[{'ForeName': 'Chang Il', 'Initials': 'CI', 'LastName': 'Choi', 'Affiliation': 'Department of Urology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.'}, {'ForeName': 'Jong Keun', 'Initials': 'JK', 'LastName': 'Kim', 'Affiliation': 'Department of Urology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.'}, {'ForeName': 'Min Soo', 'Initials': 'MS', 'LastName': 'Choo', 'Affiliation': 'Department of Urology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.'}, {'ForeName': 'Seong Ho', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Urology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.'}, {'ForeName': 'Jun Dong', 'Initials': 'JD', 'LastName': 'Chang', 'Affiliation': 'Department of Orthopaedic Surgery, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.'}, {'ForeName': 'Jun Hyun', 'Initials': 'JH', 'LastName': 'Han', 'Affiliation': 'Department of Urology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea. junuro@naver.com.'}]",Investigative and clinical urology,['10.4111/icu.20200523'] 2875,34386935,First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients.,"BACKGROUND The efficacy and safety of insulin sensitizer in Asians with non-alcoholic steatohepatitis (NASH) remain elusive. AIMS The double-blind, randomized, placebo-controlled trial was conducted aiming to investigate the efficacy and safety of pioglitazone in NASH patients. METHODS A total of 90 NASH patients (66 males, age = 44.1 ± 12.7 years) were prospectively randomized into oral pioglitazone 30 mg/day (Arm A) or placebo (Arm B) for 24 weeks. The primary endpoint was the efficacy of pioglitazone in reducing inflammation and liver fat at end-of-treatment (EOT). NASH resolution/improvement without fibrosis worsening was also evaluated. RESULTS At EOT, there was a significantly decline of alanine aminotransferase (86.9 ± 34.3 to 45.7 ± 35.8 IU/L, p = 0.003) level in Arm A patients. In intention-to-treat analysis among 66 patients who completed paired biopsies, The NAFLD activity score (NAS) of 30 Arm A patients significantly decreased from 4.27 ± 1.14 at baseline to 2.53 ± 1.63 at EOT (p < 0.0001), whereas there was no significant change in patients of Arm B (3.94 ± 1.41 vs 3.94 ± 1.51, p = 1.0). NASH improvement without worsening of fibrosis was achieved in 46.7% (14/30) patients in Arm A, compared to 11.1% (4/36) patients in Arm B (p = 0.002). Liver fat content reduced (20.2 ± 9.0 to 14.3 ± 6.9%, p < 0.0001) on MRI-PDFF in Arm A compared to their counterparts. No significant difference of adverse events occurred between groups. CONCLUSIONS A 24-week pioglitazone treatment was well-tolerated and effective in improving liver histology and reducing liver steatosis in Asian NASH patients. (ClinicalTrials.gov number: NCT01068444).",2021,"NASH improvement without worsening of fibrosis was achieved in 46.7% (14/30) patients in Arm A, compared to 11.1% (4/36) patients in Arm B (p = 0.002).","['90 NASH patients (66 males, age\u2009=\u200944.1\u2009±\u200912.7\xa0years', 'Asians with non-alcoholic steatohepatitis (NASH', 'Asian NASH patients', 'nonalcoholic steatohepatitis patients', 'NASH patients']","['pioglitazone', 'insulin sensitizer', 'placebo', 'oral pioglitazone']","['efficacy and safety', 'adverse events', 'alanine aminotransferase', 'inflammation and liver fat at end-of-treatment (EOT', 'Liver fat content', 'tolerated and effective in improving liver histology and reducing liver steatosis', 'NASH improvement without worsening of fibrosis', 'NASH resolution/improvement without fibrosis worsening', 'MRI-PDFF', 'NAFLD activity score (NAS']","[{'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517546', 'cui_str': '12.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}]","[{'cui': 'C0071097', 'cui_str': 'pioglitazone'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0015695', 'cui_str': 'Fatty Liver'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C4761214', 'cui_str': 'Magnetic resonance proton density fat fraction measurement'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",90.0,0.513018,"NASH improvement without worsening of fibrosis was achieved in 46.7% (14/30) patients in Arm A, compared to 11.1% (4/36) patients in Arm B (p = 0.002).","[{'ForeName': 'Jee-Fu', 'Initials': 'JF', 'LastName': 'Huang', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Chia-Yen', 'Initials': 'CY', 'LastName': 'Dai', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Chung-Feng', 'Initials': 'CF', 'LastName': 'Huang', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Pei-Chien', 'Initials': 'PC', 'LastName': 'Tsai', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Ming-Lun', 'Initials': 'ML', 'LastName': 'Yeh', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Po-Yau', 'Initials': 'PY', 'LastName': 'Hsu', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Shiu-Feng', 'Initials': 'SF', 'LastName': 'Huang', 'Affiliation': 'Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.'}, {'ForeName': 'Ming-Jong', 'Initials': 'MJ', 'LastName': 'Bair', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Taitung Mackay Memorial Hospital, Taitung, Taiwan.'}, {'ForeName': 'Nai-Jen', 'Initials': 'NJ', 'LastName': 'Hou', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Ching-I', 'Initials': 'CI', 'LastName': 'Huang', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Po-Cheng', 'Initials': 'PC', 'LastName': 'Liang', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Yi-Hung', 'Initials': 'YH', 'LastName': 'Lin', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Chih-Wen', 'Initials': 'CW', 'LastName': 'Wang', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Ming-Yen', 'Initials': 'MY', 'LastName': 'Hsieh', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Shinn-Chern', 'Initials': 'SC', 'LastName': 'Chen', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Zu-Yau', 'Initials': 'ZY', 'LastName': 'Lin', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan.'}, {'ForeName': 'Ming-Lung', 'Initials': 'ML', 'LastName': 'Yu', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan. fish6069@gmail.com.'}, {'ForeName': 'Wan-Long', 'Initials': 'WL', 'LastName': 'Chuang', 'Affiliation': 'Hepatobiliary Division and Hepatitis Center, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road, Kaohsiung, Taiwan. waloch@cc.kmu.edu.tw.'}]",Hepatology international,['10.1007/s12072-021-10242-2'] 2876,34386816,Increasing Vegetable Intake Decreases Urinary Acidity and Bone Resorption Marker in Overweight and Obese Adults: An 8-Week Randomized Controlled Trial.,"BACKGROUND Controlled intervention trials are needed to confirm a positive association from epidemiological studies between vegetable consumption and bone health. OBJECTIVE We investigated whether providing vegetables at the Dietary Guidelines for Americans (DGA) recommended amount affects excretion of acid and calcium in urine and bone turnover markers in serum in adults with low vegetable intake. METHODS In total, 102 adults (19 males and 83 females, age 18-65 y, BMI ≥25 kg/m2) consuming ≤1 serving of vegetables (128 g raw leafy or 64 g cooked vegetables) per d were recruited in a 2-arm, parallel, randomized, controlled, and community-based 8-wk feeding intervention trial. The 2 arms included a vegetable intervention (VI) during which participants received extra vegetables (∼270 g/d) and an attention control (CON) group that conducted only the testing visits. Measurements included nutrient intake, plasma carotenoids, and bone-related markers in serum and urine. Differences between CON and VI at week 8 were tested using the ANCOVA with baseline values as a covariate. RESULTS Compared with CON, carotenoid intake (mean ± SD) was higher (6.4 ± 3.4 compared with 2.0 ± 1.2 mg/d) (P < 0.01) and dietary potential renal acid load was lower (20 ± 13 compared with 3.4 ± 14 mEq/d) (P < 0.01) in VI. Compared with CON at week 8, urine titratable acid and Mg were 24 and 26% lower, respectively, while urine pH was 3% greater (P < 0.05) and serum C-terminal telopeptide of type I collagen (CTX) was 19% lower in VI. There were no group differences in serum concentrations of propeptide of type 1 procollagen and tartrate-resistant acid phosphatase or urinary excretion of deoxypyridinoline and CTX. CONCLUSIONS Consumption of vegetables at the DGA-recommended amount by adults with low vegetable intake potentially benefits bone health. This trial was registered at clinicaltrials.gov as NCT02585102.",2021,"There were no group differences in serum concentrations of propeptide of type 1 procollagen and tartrate-resistant acid phosphatase or urinary excretion of deoxypyridinoline and CTX. ","['Americans (DGA', 'adults with low vegetable intake', 'Overweight and Obese Adults', '102 adults (19 males and 83 females, age 18-65 y, BMI ≥25\xa0kg/m2) consuming ≤1 serving of vegetables (128\xa0g raw leafy or 64\xa0g cooked vegetables) per d']","['vegetable intervention (VI) during which participants received extra vegetables (∼270\xa0g/d) and an attention control (CON', 'Increasing Vegetable Intake', 'CON']","['serum concentrations of propeptide of type 1 procollagen and tartrate-resistant acid phosphatase or urinary excretion of deoxypyridinoline and CTX', 'urine pH', 'Urinary Acidity and Bone Resorption Marker', 'CON, carotenoid intake (mean\xa0±\xa0SD', 'dietary potential renal acid load', 'nutrient intake, plasma carotenoids, and bone-related markers in serum and urine', 'serum C-terminal telopeptide of type I collagen (CTX']","[{'cui': 'C3658297', 'cui_str': 'Dietary Guidelines'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0556223', 'cui_str': 'Vegetable intake'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0001884', 'cui_str': 'Airway Resistance'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}]","[{'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0556223', 'cui_str': 'Vegetable intake'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0033235', 'cui_str': 'Procollagen'}, {'cui': 'C0297331', 'cui_str': 'Acid phosphatase bone isoenzyme'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0057455', 'cui_str': 'Deoxypyridinoline'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0042044', 'cui_str': 'Urine pH test'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C1101784', 'cui_str': 'ICTP peptide'}]",102.0,0.149983,"There were no group differences in serum concentrations of propeptide of type 1 procollagen and tartrate-resistant acid phosphatase or urinary excretion of deoxypyridinoline and CTX. ","[{'ForeName': 'Jay J', 'Initials': 'JJ', 'LastName': 'Cao', 'Affiliation': 'USDA, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND, USA.'}, {'ForeName': 'James N', 'Initials': 'JN', 'LastName': 'Roemmich', 'Affiliation': 'USDA, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND, USA.'}, {'ForeName': 'Xiaoming', 'Initials': 'X', 'LastName': 'Sheng', 'Affiliation': 'Applied Statistics, University of Utah College of Nursing, Salt Lake City, UT, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Jahns', 'Affiliation': 'USDA, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND, USA.'}]",The Journal of nutrition,['10.1093/jn/nxab255'] 2877,34386769,"Evaluating a Topical Adjunctive Post Submental ATX-101 (Deoxycholic Acid) Injections for Improved Recovery: A Single-Center, Double-Blind, Randomized Controlled Pilot Study.","Background Optimizing postprocedural recovery and outcomes for patients is the aim for all physicians. TransFORM Body Treatment with TriHex Technology (TFB) is a topical product that aids in the elimination of fat particles created during procedures and the reduction of associated inflammation, thus speeding up postprocedure recovery time. Objectives Evaluation of postprocedural symptoms, signs, and healing following submental deoxycholic acid (DCA) injections in combination with TFB. Methods Participants received 2 treatments of submental DCA injections. Posttreatment 1, every participant received TFB to apply twice daily to the submental area. Follow-up visits included weeks 1, 2, and 4. After week 4, participants discontinued TFB for 30 days before the second treatment. At the second treatment visit, participants were randomized to receive either TFB or a bland moisturizer to apply twice daily with the same follow-up visits as posttreatment 1. Induration measurements, submental fullness grading, and standardized photography were captured at every visit. At all follow-up visits and before treatment 2, investigator assessments and participant assessments were completed. Results Posttreatment 2, investigator assessments of edema and induration decreased in participants using TFB at weeks 1 and 2 compared with the bland moisturizer. Induration measurements objectively showed a statistically significant reduction at week 2 (posttreatment 2) in participants using TFB compared with the bland moisturizer. Furthermore, participants reported less tenderness and soreness in the TFB group over the bland moisturizer. Conclusions Investigator assessments, participant query, and objective induration analyses have demonstrated that the use of TFB post DCA injections may reduce induration, edema, and discomfort associated with this procedure. Level of Evidence 2 ",2021,"Results Posttreatment 2, investigator assessments of edema and induration decreased in participants using TFB at weeks 1 and 2 compared with the bland moisturizer.",[],"['TFB', 'Topical Adjunctive Post Submental ATX-101 (Deoxycholic Acid', 'submental deoxycholic acid (DCA) injections', 'submental DCA injections', 'TriHex Technology (TFB', 'TFB post DCA injections']","['Recovery', 'edema and induration', 'Induration measurements, submental fullness grading, and standardized photography', 'induration, edema, and discomfort', 'tenderness and soreness']",[],"[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0011479', 'cui_str': 'deoxycholic acid'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C5198331', 'cui_str': 'trihex'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]","[{'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0332534', 'cui_str': 'Induration'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0439650', 'cui_str': 'Fullness'}, {'cui': 'C0031749', 'cui_str': 'Photography'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}]",,0.244348,"Results Posttreatment 2, investigator assessments of edema and induration decreased in participants using TFB at weeks 1 and 2 compared with the bland moisturizer.","[{'ForeName': 'Sachin M', 'Initials': 'SM', 'LastName': 'Shridharani', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, St. Louis, MO, USA.'}]",Aesthetic surgery journal. Open forum,['10.1093/asjof/ojab028'] 2878,34386749,Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP gen or combined TdaP gen vaccines.,"Background Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting antibody responses 2 and 3 years after booster vaccination with a new generation recombinant acellular pertussis vaccine. Methods Participants of a phase 2/3 randomised-controlled clinical trial with a monovalent pertussis vaccine containing genetically inactivated pertussis toxin (aP gen ) or its tetanus and diphtheria toxoids combination (TdaP gen ), or a chemically detoxified comparator vaccine (Tdap chem ), (originally conducted between July and August 2015) were invited to participate in observational studies of persisting antibody responses 2 and 3 years after vaccination. Serum IgG against pertussis toxin (PT-IgG) and filamentous hemagglutinin (FHA-IgG) were assessed by ELISA, and PT-neutralising antibodies (PT-Nab) by Chinese Hamster Ovary cell assay. Findings Waning of antibodies stabilised in aP gen and TdaP gen vaccinees 2 and 3 years after vaccination. Three years post-vaccination PT-neutralising antibodies remained 4·6-fold (95% Confidence Interval (CI) 2·6-8·1) and 3·7-fold (95% CI 2·2-6·1) higher, PT-IgG antibodies 3·0-fold (95% CI 2·2-4·1) and 2·5-fold (95% CI 1·9-3·3) higher, and FHA-IgG antibodies 1·8-fold (95% CI 1·3-2·5) and 1·6-fold (95% CI 1·2-2·1) higher than baseline in aP gen and TdaP gen recipients, respectively. In the Tdap chem group, PT-neutralising and PT-IgG and FHA-IgG antibodies were back at baseline levels 2 years post-vaccination. Three years post-vaccination seroconversion rates for PT-neutralising antibodies were 65·0% (95% CI 44·1-85·9) and 55·0% (95% CI 33·2-76·8) in aP gen and TdaP gen recipients, respectively. Interpretation Considering the persistence of elevated antibody responses 3 years post-booster vaccination, genetically detoxified monovalent aP gen and TdaP gen vaccines can be expected to induce longer-lasting protection than chemically inactivated Tdap vaccines. Funding BioNet-Asia.",2021,"Three years post-vaccination seroconversion rates for PT-neutralising antibodies were 65·0% (95% CI 44·1-85·9) and 55·0% (95% CI 33·2-76·8) in aP gen and TdaP gen recipients, respectively. ",[],"['monovalent pertussis vaccine containing genetically inactivated pertussis toxin (aP gen ) or its tetanus and diphtheria toxoids combination (TdaP gen ), or a chemically detoxified comparator vaccine (Tdap chem ']",['Serum IgG against pertussis toxin (PT-IgG) and filamentous hemagglutinin (FHA-IgG'],[],"[{'cui': 'C0031237', 'cui_str': 'Pertussis Vaccine'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0020731', 'cui_str': 'Pertussis toxin'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0012551', 'cui_str': 'diphtheria toxoid vaccine, inactivated'}, {'cui': 'C4521767', 'cui_str': 'US Military Commissioned Officer O10'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0201682', 'cui_str': 'Chemical procedure'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0020731', 'cui_str': 'Pertussis toxin'}, {'cui': 'C0018909', 'cui_str': 'Hemagglutinin'}, {'cui': 'C1704429', 'cui_str': 'Familial hypoalphalipoproteinemia'}]",,0.155361,"Three years post-vaccination seroconversion rates for PT-neutralising antibodies were 65·0% (95% CI 44·1-85·9) and 55·0% (95% CI 33·2-76·8) in aP gen and TdaP gen recipients, respectively. ","[{'ForeName': 'Punnee', 'Initials': 'P', 'LastName': 'Pitisuttithum', 'Affiliation': 'Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand.'}, {'ForeName': 'Jittima', 'Initials': 'J', 'LastName': 'Dhitavat', 'Affiliation': 'Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand.'}, {'ForeName': 'Chukiat', 'Initials': 'C', 'LastName': 'Sirivichayakul', 'Affiliation': 'Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand.'}, {'ForeName': 'Arom', 'Initials': 'A', 'LastName': 'Pitisuthitham', 'Affiliation': 'Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand.'}, {'ForeName': 'Yupa', 'Initials': 'Y', 'LastName': 'Sabmee', 'Affiliation': 'Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand.'}, {'ForeName': 'Pailinrut', 'Initials': 'P', 'LastName': 'Chinwangso', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Chawanee', 'Initials': 'C', 'LastName': 'Kerdsomboon', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Librada', 'Initials': 'L', 'LastName': 'Fortuna', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Spiegel', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Mukesh', 'Initials': 'M', 'LastName': 'Chauhan', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Indrajeet Kumar', 'Initials': 'IK', 'LastName': 'Poredi', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Anita H J', 'Initials': 'AHJ', 'LastName': 'van den Biggelaar', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Wassana', 'Initials': 'W', 'LastName': 'Wijagkanalan', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Simonetta', 'Initials': 'S', 'LastName': 'Viviani', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Souad', 'Initials': 'S', 'LastName': 'Mansouri', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}, {'ForeName': 'Hong Thai', 'Initials': 'HT', 'LastName': 'Pham', 'Affiliation': 'BioNet-Asia Co., Ltd., 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand.'}]",EClinicalMedicine,['10.1016/j.eclinm.2021.100976'] 2879,34386735,"Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial.","Background Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabetic kidney disease, possibly by reducing the proximal tubule transport workload with subsequent improvement of renal oxygenation. We aimed to test this hypothesis in individuals with type 1 diabetes and albuminuria. Methods A randomised, double-blind, placebo-controlled, crossover trial with a single 50 mg dose of the SGLT2 inhibitor dapagliflozin and placebo in random order, separated by a two-week washout period. Magnetic resonance imaging (MRI) was used to assess renal R 2 * (a low value corresponds to a high tissue oxygenation), renal perfusion (arterial spin labelling) and renal artery flow (phase contrast imaging) at baseline, three- and six hours from tablet ingestion. Exploratory outcomes, including baroreflex sensitivity, peripheral blood oxygen saturation, peripheral blood mononuclear cell mitochondrial oxygen consumption rate, and biomarkers of inflammation were evaluated at baseline and 12 h from medication. The study is registered in the EU Clinical Trials Register (EudraCT 2019-004,557-92), on ClinicalTrials.gov (NCT04193566), and is completed. Findings Between February 3, 2020 and October 23, 2020, 31 individuals were screened, and 19 eligible individuals were randomised. Three dropped out before receiving any of the interventions and one dropped out after receiving only placebo. We included 15 individuals (33% female) in the per-protocol analysis with a mean age of 58 (SD 14) years, median urinary albumin creatinine ratio of 46 [IQR 21-58] mg/g and an eGFR of 73 (32) ml/min/1·73m 2 . The mean changes in renal cortical R 2 * from baseline to six hours were for dapagliflozin -1·1 (SD 0·7) s -1 and for placebo +1·3 (0·7) s -1 , resulting in a difference between interventions of -2·3 s -1 [95% CI -4·0 to -0·6]; p  = 0·012. No between-intervention differences were found in any other MRI outcomes, physiological parameters or exploratory outcomes. There were no adverse events. Interpretation A single dose of 50 mg dapagliflozin acutely improved renal cortical R 2 * without changing renal perfusion or blood flow. This suggests improved renal cortical oxygenation due to a reduced tubular transport workload in the proximal tubules. Such improved oxygenation may in part explain the long-term beneficial renal effects seen with SGLT2 inhibitors, but it remains to be determined whether the observed effects can be achieved with lower doses, with chronic treatment and if they occur in type 2 diabetes as well.",2021,"Interpretation A single dose of 50 mg dapagliflozin acutely improved renal cortical R 2 * without changing renal perfusion or blood flow.","['individuals with type 1 diabetes and albuminuria', '0·7', 'Findings\n\n\nBetween February 3, 2020 and October 23, 2020, 31 individuals were screened, and 19 eligible individuals were randomised', 'type 1 diabetes with albuminuria', '15 individuals (33% female) in the per-protocol analysis with a mean age of 58 (SD 14) years, median urinary albumin creatinine ratio of 46']","['sodium-glucose cotransporter 2 (SGLT2', 'Magnetic resonance imaging (MRI', 'placebo +1·3', 'dapagliflozin', 'placebo', 'SGLT2 inhibitor dapagliflozin and placebo']","['renal R 2', 'renal perfusion (arterial spin labelling) and renal artery flow (phase contrast imaging', 'baroreflex sensitivity, peripheral blood oxygen saturation, peripheral blood mononuclear cell mitochondrial oxygen consumption rate, and biomarkers of inflammation', 'renal cortical oxygenation', 'renal oxygenation and perfusion', 'renal cortical R 2 * without changing renal perfusion or blood flow', 'MRI outcomes, physiological parameters or exploratory outcomes']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0486293', 'cui_str': 'Albumin/creatinine ratio measurement'}]","[{'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0194133', 'cui_str': 'Local perfusion of kidney'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0035065', 'cui_str': 'Structure of renal artery'}, {'cui': 'C0026024', 'cui_str': 'Phase contrast microscopy'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0206162', 'cui_str': 'Baroreceptor reflex'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",31.0,0.403461,"Interpretation A single dose of 50 mg dapagliflozin acutely improved renal cortical R 2 * without changing renal perfusion or blood flow.","[{'ForeName': 'Jens Christian', 'Initials': 'JC', 'LastName': 'Laursen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Søndergaard-Heinrich', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Joana Mendes Lopes', 'Initials': 'JML', 'LastName': 'de Melo', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Haddock', 'Affiliation': 'Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Denmark.'}, {'ForeName': 'Ida Kirstine Bull', 'Initials': 'IKB', 'LastName': 'Rasmussen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Safavimanesh', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Christian Stevns', 'Initials': 'CS', 'LastName': 'Hansen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Størling', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Henrik Bo Wiberg', 'Initials': 'HBW', 'LastName': 'Larsson', 'Affiliation': 'Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Denmark.'}, {'ForeName': 'Per-Henrik', 'Initials': 'PH', 'LastName': 'Groop', 'Affiliation': 'Folkhälsan Research Center, Helsinki, Finland.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Frimodt-Møller', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Ulrik Bjørn', 'Initials': 'UB', 'LastName': 'Andersen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rossing', 'Affiliation': 'Steno Diabetes Center Copenhagen, Denmark.'}]",EClinicalMedicine,['10.1016/j.eclinm.2021.100895'] 2880,34384459,Sleeping for two: study protocol for a randomized controlled trial of cognitive behavioral therapy for insomnia in pregnant women.,"BACKGROUND Insomnia and sleep disturbances are common in pregnancy and have potentially significant consequences for both maternal and infant health. There is limited research examining the effectiveness of cognitive behavioral therapy for insomnia (CBT-I) during pregnancy. With increased distress and limited access to services during the COVID-19 pandemic, there is also an unprecedented need for telehealth delivery of treatment programs for pregnant women. The aims of this trial are to evaluate the impact of the Sleeping for Two adaptation of CBT-I in pregnancy (in-person or telehealth) versus treatment as usual (TAU) in reducing symptoms of insomnia (primary outcome), as well as increasing gestational length and reducing symptoms of depression (secondary outcomes). METHODS A two-arm, single-blinded, parallel group randomized controlled trial (RCT) design with repeated measures will be used to evaluate the impact of CBT-I compared to TAU among a sample of 62 pregnant women, enrolled between 12 and 28 weeks of gestation, who self-identify as experiencing insomnia. Five weekly individual sessions of CBT-I will be delivered in person or via telehealth depending on physical distancing guidelines. Assessment of insomnia diagnosis by structured interview, self-reported insomnia symptom severity and sleep problems, and sleep quantity and quality as measured by a daily diary and actigraphy will occur at 12-28 weeks of pregnancy (T1), 1 week post-treatment (T2), and 6 months postpartum (T3). DISCUSSION CBT-I delivered in pregnancy has the potential to reduce symptoms of insomnia and depression and could lead to reduced risk of preterm birth, all of which can minimize risk of negative maternal and child health and developmental consequences in the short (e.g., infant death) and long terms (e.g., developmental delays). This RCT builds on a successful open pilot trial conducted by our team and will provide further evaluation of a novel evidence-based treatment for pregnancy-related insomnia, which can be widely disseminated and used to treat individuals that are most in need of intervention. Findings will enhance understanding of pregnancy-related sleep problems, as well as means by which to improve the health and sleep of mothers and their children. TRIAL REGISTRATION ClinicalTrials.gov NCT03918057. Registered on 17 April 2019.",2021,"DISCUSSION CBT-I delivered in pregnancy has the potential to reduce symptoms of insomnia and depression and could lead to reduced risk of preterm birth, all of which can minimize risk of negative maternal and child health and developmental consequences in the short (e.g., infant death) and long terms (e.g., developmental delays).","['pregnant women', '62 pregnant women, enrolled between 12 and 28 weeks of gestation, who self-identify as experiencing insomnia']","['usual (TAU', 'CBT-I compared to TAU', 'cognitive behavioral therapy']","['gestational length and reducing symptoms of depression (secondary outcomes', 'insomnia diagnosis by structured interview, self-reported insomnia symptom severity and sleep problems, and sleep quantity and quality as measured by a daily diary and actigraphy']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}]","[{'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}]",62.0,0.130865,"DISCUSSION CBT-I delivered in pregnancy has the potential to reduce symptoms of insomnia and depression and could lead to reduced risk of preterm birth, all of which can minimize risk of negative maternal and child health and developmental consequences in the short (e.g., infant death) and long terms (e.g., developmental delays).","[{'ForeName': 'Anna L', 'Initials': 'AL', 'LastName': 'MacKinnon', 'Affiliation': 'University of Calgary, Calgary, Canada.'}, {'ForeName': 'Joshua W', 'Initials': 'JW', 'LastName': 'Madsen', 'Affiliation': 'University of Calgary, Calgary, Canada.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Dhillon', 'Affiliation': 'University of Calgary, Calgary, Canada.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Keys', 'Affiliation': 'University of British Columbia, Okanagan Campus, Canada.'}, {'ForeName': 'Gerald F', 'Initials': 'GF', 'LastName': 'Giesbrecht', 'Affiliation': 'University of Calgary, Calgary, Canada.'}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Williamson', 'Affiliation': 'University of Calgary, Calgary, Canada.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Metcalfe', 'Affiliation': 'University of Calgary, Calgary, Canada.'}, {'ForeName': 'Tavis', 'Initials': 'T', 'LastName': 'Campbell', 'Affiliation': 'University of Calgary, Calgary, Canada.'}, {'ForeName': 'Kelly J', 'Initials': 'KJ', 'LastName': 'Mrklas', 'Affiliation': 'Alberta Health Services, Calgary, Canada.'}, {'ForeName': 'Lianne', 'Initials': 'L', 'LastName': 'Tomfohr-Madsen', 'Affiliation': 'University of Calgary, Calgary, Canada. ltomfohr@ucalgary.ca.'}]",Trials,['10.1186/s13063-021-05498-w'] 2881,34384458,Correction to: Intradermal acupuncture for rheumatoid arthritis: study protocol for a randomised controlled trial.,,2021,,['rheumatoid arthritis'],['Intradermal acupuncture'],[],"[{'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}]","[{'cui': 'C1522475', 'cui_str': 'Intradermal route'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]",[],,0.718335,,"[{'ForeName': 'Huifang', 'Initials': 'H', 'LastName': 'Luo', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Peng', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Ma', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Zhihua', 'Initials': 'Z', 'LastName': 'Wei', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Changsong', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Mingying', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Peiwu', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Department of Spleen and Stomach Diseases, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China. fau20@126.com.'}, {'ForeName': 'Xiangwei', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong Province, China. 1327758056@qq.com.'}]",Trials,['10.1186/s13063-021-05514-z'] 2882,34384427,Self-managed occupational therapy and physiotherapy for adults receiving inpatient rehabilitation ('My Therapy'): protocol for a stepped-wedge cluster randomised trial.,"BACKGROUND Ensuring patients receive an effective dose of therapeutic exercises and activities is a significant challenge for inpatient rehabilitation. My Therapy is a self-management program which encourages independent practice of occupational therapy and physiotherapy exercises and activities, outside of supervised therapy sessions. METHODS This implementation trial aims to determine both the clinical effectiveness of My Therapy on the outcomes of function and health-related quality of life, and cost-effectiveness per minimal clinically important difference (MCID) in functional independence achieved and per quality adjusted life year (QALY) gained, compared to usual care. Using a stepped-wedge cluster randomised design, My Therapy will be implemented across eight rehabilitation wards (inpatient and home-based) within two public and two private Australian health networks, over 54-weeks. We will include 2,160 patients aged 18 + years receiving rehabilitation for any diagnosis. Each ward will transition from the usual care condition (control group receiving usual care) to the experimental condition (intervention group receiving My Therapy in addition to usual care) sequentially at six-week intervals. The primary clinical outcome is achievement of a MCID in the Functional Independence Measure (FIM™) at discharge. Secondary outcomes include improvement in quality of life (EQ-5D-5L) at discharge, length of stay, 30-day re-admissions, discharge accommodation, follow-up rehabilitation services and adverse events (falls). The economic outcomes are the cost-effectiveness per MCID in functional independence (FIM™) achieved and per QALY gained, for My Therapy compared to usual care, from a health-care sector perspective. Cost of implementation will also be reported. Clinical outcomes will be analysed via mixed-effects linear or logistic regression models, and economic outcomes will be analysed via incremental cost-effectiveness ratios. DISCUSSION The My Therapy implementation trial will determine the effect of adding self-management within inpatient rehabilitation care. The results may influence health service models of rehabilitation including recommendations for systemic change to the inpatient rehabilitation model of care to include self-management. Findings have the potential to improve patient function and quality of life, and the ability to participate in self-management. Potential health service benefits include reduced hospital length of stay, improved access to rehabilitation and reduced health service costs. TRIAL REGISTRATION This study was prospectively registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12621000313831; registered 22/03/2021, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380828&isReview=true ).",2021,"Secondary outcomes include improvement in quality of life (EQ-5D-5L) at discharge, length of stay, 30-day re-admissions, discharge accommodation, follow-up rehabilitation services and adverse events (falls).","['2,160 patients aged 18\u2009+\u2009years receiving rehabilitation for any diagnosis', ""adults receiving inpatient rehabilitation ('My Therapy"", 'eight rehabilitation wards (inpatient and home-based) within two public and two private Australian health networks, over 54-weeks']","['My Therapy', 'Self-managed occupational therapy and physiotherapy', 'usual care condition (control group receiving usual care) to the experimental condition (intervention group receiving My Therapy']","['achievement of a MCID in the Functional Independence Measure (FIM™) at discharge', 'function and health-related quality of life, and cost-effectiveness per minimal clinically important difference (MCID) in functional independence achieved and per quality adjusted life year (QALY', 'quality of life (EQ-5D-5L) at discharge, length of stay, 30-day re-admissions, discharge accommodation, follow-up rehabilitation services and adverse events (falls', 'patient function and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C4277733', 'cui_str': 'Minimal Clinically Important Difference'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0587660', 'cui_str': 'Rehabilitation service'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",2160.0,0.0129987,"Secondary outcomes include improvement in quality of life (EQ-5D-5L) at discharge, length of stay, 30-day re-admissions, discharge accommodation, follow-up rehabilitation services and adverse events (falls).","[{'ForeName': 'Natasha K', 'Initials': 'NK', 'LastName': 'Brusco', 'Affiliation': 'Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Monash University, 47-49 Moorooduc Hwy, VIC, 3199, Frankston, Australia. natasha.brusco@monash.edu.'}, {'ForeName': 'Christina L', 'Initials': 'CL', 'LastName': 'Ekegren', 'Affiliation': 'Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Monash University, 47-49 Moorooduc Hwy, VIC, 3199, Frankston, Australia.'}, {'ForeName': 'Nicholas F', 'Initials': 'NF', 'LastName': 'Taylor', 'Affiliation': 'La Trobe University Centre for Sport and Exercise Medicine Research, Plenty Road & Kingsbury Drive, 3086, Bundoora, Australia.'}, {'ForeName': 'Keith D', 'Initials': 'KD', 'LastName': 'Hill', 'Affiliation': 'Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Monash University, 47-49 Moorooduc Hwy, VIC, 3199, Frankston, Australia.'}, {'ForeName': 'Annemarie L', 'Initials': 'AL', 'LastName': 'Lee', 'Affiliation': 'Cabrini Health, 154 Wattletree Rd, 3144, Malvern, Australia.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Somerville', 'Affiliation': 'La Trobe University Centre for Sport and Exercise Medicine Research, Plenty Road & Kingsbury Drive, 3086, Bundoora, Australia.'}, {'ForeName': 'Natasha A', 'Initials': 'NA', 'LastName': 'Lannin', 'Affiliation': 'La Trobe University Centre for Sport and Exercise Medicine Research, Plenty Road & Kingsbury Drive, 3086, Bundoora, Australia.'}, {'ForeName': 'Derick', 'Initials': 'D', 'LastName': 'Wade', 'Affiliation': 'Physiotherapy and Rehabilitation, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, OX3 0BP, Oxford, United Kingdom.'}, {'ForeName': 'Rania', 'Initials': 'R', 'LastName': 'Abdelmotaleb', 'Affiliation': 'Eastern Health, 5 Arnold St, 3128, Box Hill, Australia.'}, {'ForeName': 'Libby', 'Initials': 'L', 'LastName': 'Callaway', 'Affiliation': 'Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Monash University, 47-49 Moorooduc Hwy, VIC, 3199, Frankston, Australia.'}, {'ForeName': 'Sara L', 'Initials': 'SL', 'LastName': 'Whittaker', 'Affiliation': 'Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Monash University, 47-49 Moorooduc Hwy, VIC, 3199, Frankston, Australia.'}, {'ForeName': 'Meg E', 'Initials': 'ME', 'LastName': 'Morris', 'Affiliation': 'La Trobe University Centre for Sport and Exercise Medicine Research, Plenty Road & Kingsbury Drive, 3086, Bundoora, Australia.'}]",BMC health services research,['10.1186/s12913-021-06462-9'] 2883,34384282,"A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).","The CHARM-03 study was a randomized, open label, crossover Phase 1 safety and pharmacokinetic study of oral maraviroc and maraviroc 1% Gel. At a single site, healthy HIV-uninfected men and women were enrolled and randomized to an open label crossover sequence of eight consecutive daily exposures to MVC 300 mg dosed orally, MCV 1% gel dosed rectally, and MVC 1% gel dosed vaginally. Assessments were undertaken at baseline and following each eight-day period and included collection of plasma, rectal/cervical tissue, and rectal/endocervical/vaginal fluids. Eleven men and nine women were enrolled. Two participants withdrew from the study before receiving study product. There were 25 adverse events (AEs), of which 24 were Grade 1 (G1) and one was G2 (unrelated). After eight doses, MVC was quantifiable in all samples following oral, rectal, or vaginal product administration. The highest drug concentrations in plasma, rectal tissue, and cervical tissue were associated with oral, rectal, and vaginal drug delivery respectively. There were significant reductions in tissue drug concentrations when biopsies were incubated in media prior to tissue processing for PK (p<0.0001). Only oral MVC was associated with limited protection in the rectal explant HIV challenge model (p<0.05). There were no immunological changes in rectal tissue, and all products were acceptable to participants. In conclusion, all products were found to be safe and acceptable and did not induce local inflammation. The lack of ex vivo efficacy demonstrated in study samples may be due to rapid disassociation of MVC from the explant tissue.",2021,Only oral MVC was associated with limited protection in the rectal explant HIV challenge model (p<0.05).,"['healthy HIV-uninfected men and women', 'Eleven men and nine women were enrolled']","['oral maraviroc and maraviroc 1% Gel', 'Oral Maraviroc and Maraviroc 1% Gel', 'MVC 300 mg dosed orally, MCV 1% gel dosed rectally, and MVC 1% gel dosed vaginally']","['local inflammation', 'collection of plasma, rectal/cervical tissue, and rectal/endocervical/vaginal fluids', 'highest drug concentrations in plasma, rectal tissue, and cervical tissue', 'tissue drug concentrations']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1667052', 'cui_str': 'maraviroc'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0026394', 'cui_str': 'Molluscum contagiosum virus'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0205052', 'cui_str': 'Rectal'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0227837', 'cui_str': 'Endocervical structure'}, {'cui': 'C0392908', 'cui_str': 'Vaginal secretion'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",11.0,0.0830194,Only oral MVC was associated with limited protection in the rectal explant HIV challenge model (p<0.05).,"[{'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'McGowan', 'Affiliation': 'Orion Biotechnology Canada, Ottawa, Ontario, Canada.'}, {'ForeName': 'Sylvain', 'Initials': 'S', 'LastName': 'Chawki', 'Affiliation': 'INSERM, 27102, Unité U944, 16 rue de la grange aux belles, Paris, France, 75010; sylvain.chawki@gmail.com.'}, {'ForeName': 'Craig W', 'Initials': 'CW', 'LastName': 'Hendrix', 'Affiliation': 'Johns Hopkins University, 1466, Baltimore, Maryland, United States; cwhendrix@jhmi.edu.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Anton', 'Affiliation': 'UCLA Center for HIV Prevention Research, UCLA AIDS Institute, Dept. of Medicine, David Geffen School of Medicine at UCLA, MRL 2734, 675 Charles Young Dr. South, Los Angeles, California, United States, 90095; panton@mednet.ucla.edu.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Marzinke', 'Affiliation': 'The Johns Hopkins University, Medicine, Division of Clinical Pharmacology, 4940 Eastern Ave, Mason F Lord Tower, Rm 602, Baltimore, Maryland, United States, 21224; mmarzin1@jhmi.edu.'}, {'ForeName': 'Rhonda M', 'Initials': 'RM', 'LastName': 'Brand', 'Affiliation': 'University of Pittsburgh, Department of Medicine, Magee-Womens Research Institute, 204 Craft Ave, B607, Pittsburgh, United States, 15213; Rmb91@pitt.edu.'}, {'ForeName': 'Jarret C', 'Initials': 'JC', 'LastName': 'Engstrom', 'Affiliation': 'Orion Biotechnology, Ottawa, Ontario, Canada; j.engstrom@orionbiotechnology.com.'}, {'ForeName': 'Lisa C', 'Initials': 'LC', 'LastName': 'Rohan', 'Affiliation': 'University of Pittsburgh, Magee Womens Research Institute, Pittsburgh, Pennsylvania, United States; lrohan@mwri.magee.edu.'}, {'ForeName': 'Kaleab Z', 'Initials': 'KZ', 'LastName': 'Abebe', 'Affiliation': 'University of Pittsburgh, Medicine, 200 Meyran Ave, Suite 300, Pittsburgh, Pennsylvania, United States, 15213.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Richardson-Harman', 'Affiliation': 'Alpha StatConsult LLC, 25822 Bowman Acres Lane, Damascus, Maryland, United States, 20872; nicola@alphastatconsult.com.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Siegel', 'Affiliation': 'Magee-Womens Research Institute, 132197, Pittsburgh, Pennsylvania, United States; siegela@mwri.magee.edu.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Rinehart', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, North Carolina, United States; alex.r.rinehart@viivhealthcare.com.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Steytler', 'Affiliation': 'International Partnership for Microbicides, 160236, Silver Spring, Maryland, United States; jsteytler@ipmglobal.org.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Stall', 'Affiliation': 'University of Pittsburgh Graduate School of Public Health, 51303, Pittsburgh, Pennsylvania, United States; rstall@pitt.edu.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Spiegel', 'Affiliation': 'Henry Jackson Foundation for the Advancement of Military Medicine, HJF-DAIDS, 20817, Maryland, United States; hans.spiegel@nih.gov.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': 'Magee-Womens Hospital of UPMC, Ob/Gyn, Pittsburgh, United States; chenba@upmc.edu.'}, {'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Achilles', 'Affiliation': 'University of Pittsburgh, OB/Gyn/RS, 300 Halket St, Pittsburgh, Pennsylvania, United States, 15213; achisx@upmc.edu.'}, {'ForeName': 'Cindy E', 'Initials': 'CE', 'LastName': 'Jacobson', 'Affiliation': 'Microbicide Trials Network, Pittsburgh, United States; rosecj@mwri.magee.edu.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Khanukhova', 'Affiliation': 'David Geffen School of Medicine, 12222, Los Angeles, California, United States; ekhanukhova@gmail.com.'}, {'ForeName': 'Ross D', 'Initials': 'RD', 'LastName': 'Cranston', 'Affiliation': 'University of Barcelona, 16724, Medicine, Calle Villaroel, Barcelona, Spain, 08036; rdcranston@outlook.com.'}]",AIDS research and human retroviruses,['10.1089/AID.2021.0096'] 2884,34384273,The Impact of Multidisciplinary Collaborative Nursing Intervention on Arteriovenous Fistula in Patients Undergoing Hemodialysis.,"This study was conducted to evaluate the effect of multidisciplinary collaborative nursing intervention on AVF in patients with chronic kidney disease (CKD) undergoing hemodialysis. Patients ( n  = 84) with CKD who underwent the first autologous AVF were randomly divided into control group and multidisciplinary collaborative nursing intervention (MCNI) group and they received routine nursing procedure and multidisciplinary collaborative nursing intervention procedure, respectively. The natural blood flow and vessel diameter in MCNI group were higher than that in control group at the fourth week after surgery ( p  < .05). The vessel diameter in MCNI group at 2 and 4 weeks after operation was significantly larger than that in control group ( p  < .05).In conclusions, the implementation of multidisciplinary collaborative nursing intervention procedure can significantly promote the maturation of AVF, effectively increase the blood flow of AVF and promote the growth of vessel diameter.",2021,The natural blood flow and vessel diameter in MCNI group were higher than that in control group at the fourth week after surgery ( p  < .05).,"['patients with chronic kidney disease (CKD) undergoing hemodialysis', 'Patients Undergoing Hemodialysis', 'Patients ( n \u2009=\u200984) with CKD who underwent the first autologous AVF']","['Multidisciplinary Collaborative Nursing Intervention', 'multidisciplinary collaborative nursing intervention', 'control group and multidisciplinary collaborative nursing intervention (MCNI) group and they received routine nursing procedure and multidisciplinary collaborative nursing intervention procedure']","['natural blood flow and vessel diameter', 'blood flow of AVF and promote the growth of vessel diameter']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0449215', 'cui_str': 'aVF'}]","[{'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0204636', 'cui_str': 'Nursing procedure'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0449215', 'cui_str': 'aVF'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0018270', 'cui_str': 'Growth'}]",84.0,0.0130242,The natural blood flow and vessel diameter in MCNI group were higher than that in control group at the fourth week after surgery ( p  < .05).,"[{'ForeName': 'Danfeng', 'Initials': 'D', 'LastName': 'Zha', 'Affiliation': 'Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xionghao', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Nephrology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Shanghai Jiao Tong University, School of Nursing, Shanghai, China.'}, {'ForeName': 'Haifen', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Jin', 'Affiliation': 'Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}]",Clinical nursing research,['10.1177/10547738211037132'] 2885,34384228,Improving Outcomes After Stroke: From Stroke Units to Mobile Stroke Units.,"A proactive clinical approach to stroke care improved functional outcomes with implementation of specialized in-hospital stroke units, urgently delivered systemic thrombolysis, mechanical thrombectomy and most recently with mobile stroke units deployed in the field. An 18% absolute difference in outcomes as a shift across all modified Rankin Scale strata at 3 months in the recent Berlin study may not be explained by just 8.8% more patients treated within the golden hour for thrombolytic treatment from symptom onset. These findings parallel the findings in the largest controlled multi-center BEST-MSU trial (Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit) to date. A shortcoming in blinding of the investigators to the mode of transportation is similar to blinding to the endovascular treatment in PROBE (Prospective Randomized Open, Blinded End-Point) design used in thrombectomy trials. A faster access to stroke experts and brain imaging in the field for all patients suspect of stroke regardless symptom nature, severity, duration or resolution delivered by mobile stroke units is likely the reason for improved outcomes akin the impact observed in the initial multidisciplinary approach to in-hospital stroke units and reperfusion therapies delivery.",2021,"A proactive clinical approach to stroke care improved functional outcomes with implementation of specialized in-hospital stroke units, urgently delivered systemic thrombolysis, mechanical thrombectomy and most recently with mobile stroke units deployed in the field.",[],[],[],[],[],[],,0.0758772,"A proactive clinical approach to stroke care improved functional outcomes with implementation of specialized in-hospital stroke units, urgently delivered systemic thrombolysis, mechanical thrombectomy and most recently with mobile stroke units deployed in the field.","[{'ForeName': 'Andrei V', 'Initials': 'AV', 'LastName': 'Alexandrov', 'Affiliation': 'Department of Neurology, Mobile Stroke Unit and City-Wide Stroke Team, University of Tennessee Health Science Center, Memphis. (A.V.A.).'}, {'ForeName': 'Yongchai', 'Initials': 'Y', 'LastName': 'Nilanont', 'Affiliation': 'Department of Medicine, Siriraj Stroke Center, Siriraj Hospital, Mahidol University, Bangkok, Thailand (Y.N.).'}]",Stroke,['10.1161/STROKEAHA.121.034616'] 2886,34384109,Impact of Clomiphene Citrate on the Steroid Profile in Dysmetabolic Men with Low Testosterone Levels.,"Clomiphene citrate (CC) in male hypogonadism increases testosterone (T) and estrogen levels by stimulating pituitary gonadotropin release. Our group confirmed these hormonal changes in a randomized, cross-over, double-blind trial of CC versus placebo in addition to metformin, conducted in 21 obese dysmetabolic men with low T levels. However, we hypothesize that based on its mechanism of action, CC may directly or indirectly affect adrenal steroidogenesis. The aim of this sub-study was to better understand the changes in steroid levels and metabolism induced by CC treatment. We assessed 17α-hydroxypregnelone (17αOH-P5), dehydroepiandrosterone (DHEA), progesterone (P4), 17α-hydroxyprogesterone (17αOH-P4), androstenedione (A), T, dihydrotestosterone (DHT), estrone (E1), 17β-estradiol (E2), 11-deoxycortisol (11 S), cortisol (F), and cortisone (E) by LC-MS/MS, and corticosteroid binding globulin (CBG) by ELISA, before and after each treatment. In addition, free-F and steroid product/precursor ratios were calculated. We observed a significant change in serum levels induced by CC compared with placebo for 17αOH-P4, DHT, T, E2, E1, F, E, and CBG, but not free-F. In addition, compared to placebo, CC induced higher 17αOH-P4/P4, E2/E1, 17αOH-P4/17αOH-P5, A/17αOH-P4, T/A, E1/A, F/11 S, and F/E ratios. Therefore, besides the CC stimulating effect on testis steroidogenesis, our study showed increased F, E, but not free-F, levels, indicating changes in steroid metabolism rather than adrenal secretion stimulation. The steroid profiling also revealed the CC stimulation of the Δ5 rather than the Δ4 pathway, thus indicating considerable testicular involvement in the increased androgen secretion.",2021,"We observed a significant change in serum levels induced by CC compared with placebo for 17αOH-P4, DHT, T, E2, E1, F, E, and CBG, but not free-F.","['21 obese dysmetabolic men with low T levels', 'Dysmetabolic Men with Low Testosterone Levels', 'male hypogonadism increases']","['metformin', 'CC versus placebo', 'Clomiphene citrate (CC', 'Clomiphene Citrate', 'placebo', 'placebo, CC']","['17α-hydroxypregnelone (17αOH-P5), dehydroepiandrosterone (DHEA), progesterone (P4), 17α-hydroxyprogesterone (17αOH-P4), androstenedione (A), T, dihydrotestosterone (DHT), estrone (E1), 17β-estradiol (E2), 11-deoxycortisol (11\u2009S), cortisol (F), and cortisone (E) by LC-MS/MS, and corticosteroid binding globulin (CBG', 'testosterone (T) and estrogen levels', 'serum levels']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1295654', 'cui_str': 'Decreased testosterone level'}, {'cui': 'C0151721', 'cui_str': 'Male hypogonadism'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0546859', 'cui_str': 'Clomiphene citrate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C0020387', 'cui_str': 'Hydroxyprogesterone'}, {'cui': 'C0002860', 'cui_str': 'Androstenedione'}, {'cui': 'C0038148', 'cui_str': 'androstanolone'}, {'cui': 'C0014942', 'cui_str': 'Estrone'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0010139', 'cui_str': '11-deoxycortisol'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0010137', 'cui_str': 'Cortisone'}, {'cui': 'C0599748', 'cui_str': 'Mass Spectrometry-Mass Spectrometry'}, {'cui': 'C0040643', 'cui_str': 'Corticotropin binding globulin'}, {'cui': 'C2194257', 'cui_str': 'testosterone and estrogen'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",21.0,0.0573187,"We observed a significant change in serum levels induced by CC compared with placebo for 17αOH-P4, DHT, T, E2, E1, F, E, and CBG, but not free-F.","[{'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Pelusi', 'Affiliation': 'Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Flamina', 'Initials': 'F', 'LastName': 'Fanelli', 'Affiliation': 'Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Margherita', 'Initials': 'M', 'LastName': 'Baccini', 'Affiliation': 'Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'De Pergola', 'Affiliation': 'Nutrition Outpatient Clinic, Clinical Oncology Unit, University of Bari, Bari, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Triggiani', 'Affiliation': 'Interdisciplinary Department of Medicine, Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, University of Bari, Bari, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Mezzullo', 'Affiliation': 'Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Fazzini', 'Affiliation': 'Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Di Dalmazi', 'Affiliation': 'Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Biljana', 'Initials': 'B', 'LastName': 'Petrovic', 'Affiliation': 'Center for Applied Biomedical Research, Department of Medical & Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Paterini', 'Affiliation': 'Center for Applied Biomedical Research, Department of Medical & Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.'}, {'ForeName': 'Antonio Maria Morselli', 'Initials': 'AMM', 'LastName': 'Labate', 'Affiliation': 'Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Uberto', 'Initials': 'U', 'LastName': 'Pagotto', 'Affiliation': 'Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.'}, {'ForeName': 'Vito Angelo', 'Initials': 'VA', 'LastName': 'Giagulli', 'Affiliation': 'Interdisciplinary Department of Medicine, Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, University of Bari, Bari, Italy.'}]",Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,['10.1055/a-1542-8763'] 2887,34384079,Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton's Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction: Phase 1/2 Clinical Trial.,"BACKGROUND AND OBJECTIVES Stem cell therapy is a novel treatment with regenerative ability that can treat erectile dysfunction (ED). This phase 1/2 clinical trial (NCT02945449) using 2 consecutive intracavernous (IC) injections of allogeneic Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) was studied for the first time in the treatment of diabetic patients with ED. The primary outcome was to assess the safety and tolerability, and the secondary outcome was to assess the efficacy of 2 consecutive IC injections of allogeneic WJ-MSCs in diabetic ED. PATIENTS AND METHODS Twenty-two diabetic patients with refractory ED were included. Two consecutive IC injections of allogeneic WJ-MSCs were performed. Tolerability was assessed immediately, and at 24 h, safety was evaluated for 12 months. Efficacy was assessed using International Index of Erectile Function-5 (IIEF-5), Erection Hardness Score (EHS), and Color Duplex Doppler Ultrasound for 12 months. RESULTS The procedure was well-tolerated. Minimal and transient adverse events were redness and bruising at the site of injections. There were no patient-reported serious adverse effects. There were significant improvements in IIEF-5, EHS, peak systolic velocity (PSV) basal, and 20-min PSV, all over the follow-up time points in comparison to the baseline. CONCLUSION This is the first human study with proven tolerability, safety, and efficacy of IC injections of allogeneic WJ-MSCs for the treatment of diabetic patients with ED.",2021,"There were significant improvements in IIEF-5, EHS, peak systolic velocity (PSV) basal, and 20-min PSV, all over the follow-up time points in comparison to the baseline. ","['Diabetic Patients with Erectile Dysfunction', 'Twenty-two diabetic patients with refractory ED were included', 'diabetic patients with ED']","[""Allogeneic Wharton's Jelly-Derived Mesenchymal Stem Cells"", ""consecutive intracavernous (IC) injections of allogeneic Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs"", 'allogeneic WJ-MSCs']","['International Index of Erectile Function-5 (IIEF-5), Erection Hardness Score (EHS), and Color Duplex Doppler Ultrasound for 12 months', 'efficacy of 2 consecutive IC injections of allogeneic WJ-MSCs in diabetic ED', 'Tolerability', 'Safety and Efficacy', 'serious adverse effects', 'IIEF-5, EHS, peak systolic velocity (PSV) basal, and 20-min PSV', 'Efficacy', 'safety and tolerability']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242350', 'cui_str': 'Impotence'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0230987', 'cui_str': ""Structure of Wharton's jelly""}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0456267', 'cui_str': 'Intracavernous injection'}]","[{'cui': 'C2960541', 'cui_str': 'International index of erectile function'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030847', 'cui_str': 'Penile erection'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C2960554', 'cui_str': 'Erection hardness score'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0444916', 'cui_str': 'Duplex'}, {'cui': 'C0162481', 'cui_str': 'Doppler ultrasound'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0456267', 'cui_str': 'Intracavernous injection'}, {'cui': 'C0230987', 'cui_str': ""Structure of Wharton's jelly""}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0242350', 'cui_str': 'Impotence'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0439232', 'cui_str': 'min'}]",22.0,0.128154,"There were significant improvements in IIEF-5, EHS, peak systolic velocity (PSV) basal, and 20-min PSV, all over the follow-up time points in comparison to the baseline. ","[{'ForeName': 'Saddam', 'Initials': 'S', 'LastName': 'Al Demour', 'Affiliation': 'Division of Urology, Department of Special Surgery, School of Medicine, The University of Jordan, Amman, Jordan.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Adwan', 'Affiliation': 'Cell Therapy Center, The University of Jordan, Amman, Jordan.'}, {'ForeName': 'Hanan', 'Initials': 'H', 'LastName': 'Jafar', 'Affiliation': 'Cell Therapy Center, The University of Jordan, Amman, Jordan.'}, {'ForeName': 'Reem', 'Initials': 'R', 'LastName': 'Rahmeh', 'Affiliation': 'Cell Therapy Center, The University of Jordan, Amman, Jordan.'}, {'ForeName': 'Hussam', 'Initials': 'H', 'LastName': 'Alhawari', 'Affiliation': 'Department of Medicine, School of Medicine, The University of Jordan, Amman, Jordan.'}, {'ForeName': 'Abdalla', 'Initials': 'A', 'LastName': 'Awidi', 'Affiliation': 'Cell Therapy Center, The University of Jordan, Amman, Jordan.'}]",Urologia internationalis,['10.1159/000517364'] 2888,34383687,A Compassion-Focused Ecological Momentary Intervention for Enhancing Resilience in Help-Seeking Youth: Uncontrolled Pilot Study.,"BACKGROUND Digital interventions offer new avenues for low-threshold prevention and treatment in young people. Ecological momentary interventions (EMIs) represent a powerful approach that allows for adaptive, real-time, and real-world delivery of intervention components in daily life by real-time processing of ecological momentary assessment (EMA) data. Compassion-focused interventions (CFIs) may be particularly amenable to translation into an EMI to strengthen emotional resilience and modify putative risk mechanisms, such as stress sensitivity, in the daily lives of young help-seeking individuals. OBJECTIVE This study aims to investigate the feasibility, safety, and initial therapeutic effects of a novel, accessible, transdiagnostic, ecological momentary CFI for improving emotional resilience to stress (EMIcompass). METHODS In this uncontrolled pilot study, help-seeking youth with psychotic, depressive, or anxiety symptoms were offered the EMIcompass intervention in addition to treatment as usual. The EMIcompass intervention consisted of a 3-week EMI (including enhancing, consolidating, and EMA-informed interactive tasks) administered through a mobile health app and three face-to-face sessions with a trained psychologist intended to provide guidance and training on the CFI exercises presented in the app (ie, training session, follow-up booster session, and review session). RESULTS In total, 10 individuals (mean age 20.3 years, SD 3.8; range 14-25) were included in the study. Most (8/10, 80%) participants were satisfied and reported a low burden of app usage. No adverse events were observed. In approximately one-third of all EMAs, individuals scored high on stress, negative affect, or threat anticipation during the intervention period, resulting in real-time, interactive delivery of the CFI intervention components in addition to weekly enhancing and daily consolidating tasks. Although the findings should be interpreted with caution because of the small sample size, reduced stress sensitivity, momentary negative affect, and psychotic experiences, along with increased positive affect, were found at postintervention and the 4-week follow-up. Furthermore, reductions in psychotic, anxiety, and depressive symptoms were found (r=0.30-0.65). CONCLUSIONS Our findings provide evidence on the feasibility and safety of the EMIcompass intervention for help-seeking youth and lend initial support to beneficial effects on stress sensitivity and mental health outcomes. An exploratory randomized controlled trial is warranted to establish the feasibility and preliminary evidence of its efficacy.",2021,"Furthermore, reductions in psychotic, anxiety, and depressive symptoms were found (r=0.30-0.65). ","['help-seeking youth with psychotic, depressive, or anxiety symptoms', '10 individuals (mean age 20.3 years, SD 3.8; range 14-25) were included in the study', 'young people', 'Help-Seeking Youth']","['EMIcompass intervention', 'Compassion-focused interventions (CFIs', 'Compassion-Focused Ecological Momentary Intervention', 'novel, accessible, transdiagnostic, ecological momentary CFI', 'Ecological momentary interventions (EMIs', 'EMI (including enhancing, consolidating, and EMA-informed interactive tasks) administered through a mobile health app and three face-to-face sessions with a trained psychologist intended to provide guidance and training on the CFI exercises presented in the app (ie, training session, follow-up booster session, and review session']","['adverse events', 'psychotic, anxiety, and depressive symptoms']","[{'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0055288', 'cui_str': 'Chemotaxis factor inhibitor'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0033908', 'cui_str': 'Psychologist'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0020975', 'cui_str': 'Booster vaccination'}, {'cui': 'C0282443', 'cui_str': 'Review'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",,0.044521,"Furthermore, reductions in psychotic, anxiety, and depressive symptoms were found (r=0.30-0.65). ","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Rauschenberg', 'Affiliation': 'Department of Public Mental Health, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Boecking', 'Affiliation': 'Charité, Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Isabell', 'Initials': 'I', 'LastName': 'Paetzold', 'Affiliation': 'Department of Public Mental Health, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Schruers', 'Affiliation': 'Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Schick', 'Affiliation': 'Department of Public Mental Health, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.'}, {'ForeName': 'Thérèse', 'Initials': 'T', 'LastName': 'van Amelsvoort', 'Affiliation': 'Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Reininghaus', 'Affiliation': 'Department of Public Mental Health, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.'}]",JMIR mental health,['10.2196/25650'] 2889,34383681,Repeated Transcranial Magnetic Stimulation for Improving Cognition in Alzheimer Disease: Protocol for an Interim Analysis of a Randomized Controlled Trial.,"BACKGROUND Many clinical trials investigating treatment efficacy require an interim analysis. Recently we have been running a large, multisite, randomized, placebo-controlled, double-blind clinical trial investigating the effect of repetitive transcranial magnetic stimulation (rTMS) treatment for improving or stabilizing the cognition of patients diagnosed with Alzheimer disease. OBJECTIVE The objectives of this paper are to report on recruitment, adherence, and adverse events (AEs) to date, and to describe in detail the protocol for interim analysis of the clinical trial data. The protocol will investigate whether the trial is likely to reach its objectives if continued to the planned maximum sample size. METHODS The specific requirements of the analytic protocol are to (1) ensure the double-blind nature of the data while doing the analysis, (2) estimate the predictive probabilities of success (PPoSs), (3) estimate the numbers needed to treat, (4) re-estimate the initial required sample size. The initial estimate of sample size was 208. The interim analysis will be based on 150 patients who will be enrolled in the study and finish at least 8 weeks of the study. Our protocol for interim analysis, at the very first stage, is to determine the response rate for each participant to the treatment (either sham or active), while ensuring the double-blind nature of the data. The blinded data will be analyzed by a statistician to investigate the treatment efficacy. We will use Bayesian PPoS to predict the success rate and determine whether the study should continue. RESULTS The enrollment has been slowed significantly due to the COVID-19 pandemic and lockdown. Nevertheless, so far 133 participants have been enrolled, while 22 of these have been withdrawn or dropped out for various reasons. In general, rTMS has been found tolerable with no serious AE. Only 2 patients dropped out of the study due to their intolerability to rTMS pulses. CONCLUSIONS Overall, the study with the same protocol is going as expected with no serious AE or any major protocol deviation. TRIAL REGISTRATION ClinicalTrials.gov NCT02908815; https://clinicaltrials.gov/ct2/show/NCT02908815. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/31183.",2021,"In general, rTMS has been found tolerable with no serious AE.","['patients diagnosed with Alzheimer disease', '133 participants have been enrolled, while 22 of these have been withdrawn or dropped out for various reasons', 'Alzheimer Disease', '150 patients who will be enrolled in the study and finish at least 8 weeks of the study']","['rTMS', 'Transcranial Magnetic Stimulation', 'placebo', 'repetitive transcranial magnetic stimulation (rTMS']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1706059', 'cui_str': 'Finish'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.938111,"In general, rTMS has been found tolerable with no serious AE.","[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Moussavi', 'Affiliation': 'Biomedical Engineering Program, Faculty of Engineering, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Koski', 'Affiliation': 'McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Paul B', 'Initials': 'PB', 'LastName': 'Fitzgerald', 'Affiliation': 'Department of Psychiatry, Epworth Center for Innovation in Mental Health, Monash University, Melbourne, Australia.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Millikin', 'Affiliation': 'Department of Clinical Health Psychology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Lithgow', 'Affiliation': 'Biomedical Engineering Program, Faculty of Engineering, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Jafari-Jozani', 'Affiliation': 'Department of Statistics & Biomedical Engineering, Faculty of Science, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Xikui', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Warren Center for Actuarial Studies and Research, The Asper School of Business, University of Manitoba, Winnipeg, MB, Canada.'}]",JMIR research protocols,['10.2196/31183'] 2890,34383676,Implementing Exercise in Standard Cancer Care (Bizi Orain Hybrid Exercise Program): Protocol for a Randomized Controlled Trial.,"BACKGROUND Despite the established benefits of regular exercise for patients with cancer to counteract the deleterious effects of the disease itself and treatment-related adverse effects, most of them do not engage in sufficient levels of physical activity and there is a paucity of data on the integration of efficacious exercise programs that are accessible and generalizable to a large proportion of patients with cancer into routine cancer care. OBJECTIVE We intend to examine the effects attributable to the implementation of a community-based exercise program on cardiorespiratory functional capacity and quality of life for patients with cancer. METHODS This will be a hybrid study. In the first experimental phase, patients diagnosed with any type of cancer will be randomized into two parallel groups. One group immediately performs Bizi Orain, a 3-month supervised exercise program (3 times a week), in addition to behavioral counseling in a primary health care setting; the other is a reference group that starts the exercise program 3 months later (delayed treatment). In the second observational phase, the entire cohort of participants will be followed-up for 5 years. Any person diagnosed with cancer in the previous 2 years is eligible for the program. The program evaluation involves the uptake, safety, adherence, and effectiveness assessed after completion of the program and with follow-ups at 3, 6, 12, 24, 36, 48, and 60 months. The primary outcomes of the experimental study, to be compared between groups, are improved physical function and quality of life, whereas overall survival is the main objective of the prospective study. To analyze the association between changes in physical activity levels and overall survival, longitudinal mixed-effects models will be used for repeated follow-up measures. RESULTS A total of 265 patients have been enrolled into the study since January 2019, with 42 patients from the hematology service and 223 from the oncology service. CONCLUSIONS Bizi Orain is the first population-based exercise program in Spain that will offer more insight into the implementation of feasible, generalizable, and sustainable supportive care services involving structured exercise to extend survival of patients with cancer, improve their physical function and quality of life, and reverse the adverse effects of their disease and related treatments, thereby reducing the clinical burden. TRIAL REGISTRATION ClinicalTrials.gov NCT03819595; http://clinicaltrials.gov/ct2/show/NCT03819595. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/24835.",2021,"The primary outcomes of the experimental study, to be compared between groups, are improved physical function and quality of life, whereas overall survival is the main objective of the prospective study.","['265 patients have been enrolled into the study since January 2019, with 42 patients from the hematology service and 223 from the oncology service', 'patients diagnosed with any type of cancer', 'patients with cancer into routine cancer care', 'Standard Cancer Care', 'patients with cancer']","['regular exercise', 'community-based exercise program', 'Bizi Orain Hybrid Exercise Program', 'supervised exercise program (3 times a week), in addition to behavioral counseling']","['overall survival', 'cardiorespiratory functional capacity and quality of life', 'uptake, safety, adherence, and effectiveness', 'physical function and quality of life', 'physical activity levels and overall survival']","[{'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2030371', 'cui_str': 'Hematology service'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0582191', 'cui_str': 'Regular exercise'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4546207', 'cui_str': 'Behavioral counseling'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0582701,"The primary outcomes of the experimental study, to be compared between groups, are improved physical function and quality of life, whereas overall survival is the main objective of the prospective study.","[{'ForeName': 'Maria Soledad', 'Initials': 'MS', 'LastName': 'Arietaleanizbeaskoa', 'Affiliation': 'Biocruces Health Research Institute, Barakaldo, Spain.'}, {'ForeName': 'Erreka', 'Initials': 'E', 'LastName': 'Gil Rey', 'Affiliation': 'Deusto University, Bilbao, Spain.'}, {'ForeName': 'Nere', 'Initials': 'N', 'LastName': 'Mendizabal Gallastegui', 'Affiliation': 'Biocruces Health Research Institute, Barakaldo, Spain.'}, {'ForeName': 'Arturo', 'Initials': 'A', 'LastName': 'García-Álvarez', 'Affiliation': 'Biocruces Health Research Institute, Barakaldo, Spain.'}, {'ForeName': 'Ibon', 'Initials': 'I', 'LastName': 'De La Fuente', 'Affiliation': 'Biocruces Health Research Institute, Barakaldo, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Domínguez-Martinez', 'Affiliation': 'Biocruces Health Research Institute, Barakaldo, Spain.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Pablo', 'Affiliation': 'Biocruces Health Research Institute, Barakaldo, Spain.'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'Coca', 'Affiliation': 'Deusto University, Bilbao, Spain.'}, {'ForeName': 'Borja', 'Initials': 'B', 'LastName': 'Gutiérrez Santamaría', 'Affiliation': 'Deusto University, Bilbao, Spain.'}, {'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Grandes', 'Affiliation': 'Biocruces Health Research Institute, Barakaldo, Spain.'}]",JMIR research protocols,['10.2196/24835'] 2891,34383662,Feasibility and Effects of Virtual Reality Motor-Cognitive Training in Community-Dwelling Older People With Cognitive Frailty: Pilot Randomized Controlled Trial.,"BACKGROUND Cognitive frailty refers to the coexistence of physical frailty and cognitive impairment, and is associated with many adverse health outcomes. Although cognitive frailty is prevalent in older people, motor-cognitive training is effective at enhancing cognitive and physical function. We proposed a virtual reality (VR) simultaneous motor-cognitive training program, which allowed older people to perform daily activities in a virtual space mimicking real environments. OBJECTIVE We aimed to (1) explore the feasibility of offering VR simultaneous motor-cognitive training to older people with cognitive frailty and (2) compare its effects with an existing motor-cognitive training program in the community on the cognitive function and physical function of older people with cognitive frailty. METHODS A two-arm (1:1), assessor-blinded, parallel design, randomized controlled trial was employed. The eligibility criteria for participants were: (1) aged ≥60 years, (2) community dwelling, and (3) with cognitive frailty. Those in the intervention group received cognitive training (ie, cognitive games) and motor training (ie, cycling on an ergometer) simultaneously on a VR platform, mimicking the daily living activities of older people. Those in the control group received cognitive training (ie, cognitive games) on tablet computers and motor training (ie, cycling on the ergometer) sequentially on a non-VR platform. Both groups received a 30-minute session twice a week for 8 weeks. Feasibility was measured by adherence, adverse outcomes, and successful learning. The outcomes were cognitive function, physical frailty level, and walking speed. RESULTS Seventeen participants were recruited and randomized to either the control group (n=8) or intervention group (n=9). At baseline, the median age was 74.0 years (IQR 9.5) and the median Montreal Cognitive Assessment score was 20.0 (IQR 4.0). No significant between-group differences were found in baseline characteristics except in the number of chronic illnesses (P=.04). At postintervention, the intervention group (Z=-2.67, P=.01) showed a significantly larger improvement in cognitive function than the control group (Z=-1.19, P=.24). The reduction in physical frailty in the intervention group (Z=-1.73, P=.08) was similar to that in the control group (Z=-1.89, P=.06). Improvement in walking speed based on the Timed Up-and-Go test was moderate in the intervention group (Z=-0.16, P=.11) and greater in the control group (Z=-2.52, P=.01). The recruitment rate was acceptable (17/33, 52%). Both groups had a 100% attendance rate. The intervention group had a higher completion rate than the control group. Training was terminated for one participant (1/9, 11%) due to minimal VR sickness (Virtual Reality Sickness Questionnaire score=18.3/100). Two participants (2/8, 25%) in the control group withdrew due to moderate leg pain. No injuries were observed in either group. CONCLUSIONS This study provides preliminary evidence that the VR simultaneous motor-cognitive training is effective at enhancing the cognitive function of older people with cognitive frailty. The effect size on frailty was close to reaching a level of significance and was similar to that observed in the control group. VR training is feasible and safe for older people with cognitive frailty. TRIAL REGISTRATION ClinicalTrials.gov NCT04467216; https://clinicaltrials.gov/ct2/show/NCT04467216.",2021,"The reduction in physical frailty in the intervention group (Z=-1.73, P=.08) was similar to that in the control group (Z=-1.89, P=.06).","['older people with cognitive frailty and (2', 'Seventeen participants', 'participants were: (1) aged ≥60 years, (2) community dwelling, and (3) with cognitive frailty', 'Community-Dwelling Older People With Cognitive Frailty', 'older people with cognitive frailty']","['cognitive training (ie, cognitive games) on tablet computers and motor training (ie, cycling on the ergometer) sequentially on a non-VR platform', 'existing motor-cognitive training program', 'cognitive training (ie, cognitive games) and motor training (ie, cycling on an ergometer) simultaneously on a VR platform, mimicking the daily living activities of older people', 'VR training', 'VR simultaneous motor-cognitive training', 'virtual reality (VR) simultaneous motor-cognitive training program', 'Virtual Reality Motor-Cognitive Training']","['moderate leg pain', 'cognitive function', 'cognitive function, physical frailty level, and walking speed', 'completion rate', 'median Montreal Cognitive Assessment score', 'recruitment rate', 'walking speed based on the Timed Up-and-Go test', 'adherence, adverse outcomes, and successful learning', 'number of chronic illnesses', 'physical frailty']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C4045980', 'cui_str': 'Tablet Computers'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0023222', 'cui_str': 'Pain in lower limb'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}]",17.0,0.0187339,"The reduction in physical frailty in the intervention group (Z=-1.73, P=.08) was similar to that in the control group (Z=-1.89, P=.06).","[{'ForeName': 'Rick Yiu Cho', 'Initials': 'RYC', 'LastName': 'Kwan', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Justina Yat Wa', 'Initials': 'JYW', 'LastName': 'Liu', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Kenneth Nai Kuen', 'Initials': 'KNK', 'LastName': 'Fong', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Qin', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Philip Kwok-Yuen', 'Initials': 'PK', 'LastName': 'Leung', 'Affiliation': 'Mr. Kwok Hing Kwan Neighbour Elderly Centre, Pok Oi Hospital, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Olive Suk Kan', 'Initials': 'OSK', 'LastName': 'Sin', 'Affiliation': 'Mr. Kwok Hing Kwan Neighbour Elderly Centre, Pok Oi Hospital, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Pik Yuen', 'Initials': 'PY', 'LastName': 'Hon', 'Affiliation': 'Mr. Kwok Hing Kwan Neighbour Elderly Centre, Pok Oi Hospital, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Lydia W', 'Initials': 'LW', 'LastName': 'Suen', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Man-Kei', 'Initials': 'MK', 'LastName': 'Tse', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Claudia Ky', 'Initials': 'CK', 'LastName': 'Lai', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).'}]",JMIR serious games,['10.2196/28400'] 2892,34383536,A controlled trial of two mind-body interventions for grief in widows and widowers.,"Objective: Following bereavement, yearning and grief rumination are repetitive cognitive processes that can lead to disordered grief. Mindfulness training (MT) has been shown to reduce maladaptive repetitive thought. The current quasi-randomized controlled trial examined the feasibility, acceptability, and preliminary efficacy of MT for bereavement-related grief. Method: Ninety-five widow(er)s ( M age = 67.5, 79% women, 98% White) between 6 months to 4 years post-loss were assigned to a 6-week MT intervention or a progressive muscle relaxation (PMR) intervention, or a wait-list condition. Outcome measures were grief severity (Revised Inventory of Complicated Grief), yearning (Yearning in Situations of Loss), rumination (Utrecht Grief Rumination Scale), and decentering (Experiences Questionnaire-Decentering) assessed at baseline, Weeks 2 and 4 of intervention, post-intervention, and 1-month post-intervention. Growth curve analysis examined group differences in rates of improvement in outcomes through follow-up and associations with improvement in grief severity. Results: The MT and PMR groups showed significant rates of decline in grief severity and yearning, though only the PMR group showed a greater rate of decline in grief severity than wait-list. All groups showed significant rates of decline in grief rumination. The PMR and wait-list groups showed significant rates of increase in decentering compared to the MT group. Conclusions: Results support the feasibility and acceptability of MT and PMR for widow(er)s as well as the preliminary efficacy of PMR for improving grief severity in widow(er)s compared to a wait-list control condition. With replication, PMR could be a standalone intervention for non-disordered grief or a component of treatment for disordered grief. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"The MT and PMR groups showed significant rates of decline in grief severity and yearning, though only the PMR group showed a greater rate of decline in grief severity than wait-list.","['Method: Ninety-five widow(er)s', 'grief in widows and widowers', ' M age = 67.5, 79% women, 98% White) between 6 months to 4 years post-loss']","['PMR', 'MT', 'Mindfulness training (MT', 'MT intervention or a progressive muscle relaxation (PMR) intervention, or a wait-list condition']","['grief severity (Revised Inventory of Complicated Grief), yearning (Yearning in Situations of Loss), rumination (Utrecht Grief Rumination Scale), and decentering (Experiences Questionnaire-Decentering', 'grief rumination', 'grief severity']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517906', 'cui_str': '95'}, {'cui': 'C0206275', 'cui_str': 'Widow'}, {'cui': 'C0018235', 'cui_str': 'Normal grief reaction'}, {'cui': 'C0043174', 'cui_str': 'Widower'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C0032533', 'cui_str': 'Polymyalgia rheumatica'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0454043', 'cui_str': 'Jacobson technique'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0018235', 'cui_str': 'Normal grief reaction'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0426605,"The MT and PMR groups showed significant rates of decline in grief severity and yearning, though only the PMR group showed a greater rate of decline in grief severity than wait-list.","[{'ForeName': 'Lindsey M', 'Initials': 'LM', 'LastName': 'Knowles', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington School of Medicine.'}, {'ForeName': 'Krystal S', 'Initials': 'KS', 'LastName': 'Jovel', 'Affiliation': 'Department of Psychology, University of Arizona.'}, {'ForeName': 'Candace M', 'Initials': 'CM', 'LastName': 'Mayer', 'Affiliation': 'Department of Psychology, University of Arizona.'}, {'ForeName': 'Kenneth C', 'Initials': 'KC', 'LastName': 'Bottrill', 'Affiliation': 'Department of Psychology, University of Arizona.'}, {'ForeName': 'Alfred W', 'Initials': 'AW', 'LastName': 'Kaszniak', 'Affiliation': 'Department of Psychology, University of Arizona.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Sbarra', 'Affiliation': 'Department of Psychology, University of Arizona.'}, {'ForeName': 'Erika E', 'Initials': 'EE', 'LastName': 'Lawrence', 'Affiliation': 'Department of Psychology, University of Arizona.'}, {'ForeName': 'Mary-Frances', 'Initials': 'MF', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Psychology, University of Arizona.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000653'] 2893,34383535,A randomized trial comparing group mindfulness-based cognitive therapy with group supportive sex education and therapy for the treatment of female sexual interest/arousal disorder.,"Objective: Sexual interest/arousal disorder (SIAD) is the most prevalent sexual dysfunction in women. Our goal was to compare (a) group mindfulness-based cognitive therapy (MBCT) plus sex education with (b) group supportive sex education and therapy (STEP) for women with SIAD. Method: Eight-session treatments were delivered weekly and participants completed the measures of sexual desire and arousal, sexual distress, relationship satisfaction, rumination, and global impressions of change, at baseline, immediately posttreatment, and at 6- and 12-month posttreatment. Of 148 women who consented, 70 were randomized to MBCT (mean age 39.3 ± 13.2 years) and 78 were randomized to STEP (mean age 37.9 ± 12.2 years). Results: Sexual desire and arousal significantly improved at each time point relative to baseline, with large effect sizes ( d = -1.29 to -1.60), and similarly for MBCT and STEP. Sexual distress also improved at each time point with large effect sizes ( d = 0.83-1.17), and more so for MBCT relative to STEP. Relationship satisfaction significantly improved ( d = -0.17 to -0.20), and rumination about sex improved significantly in both arms, with medium effect sizes ( d = 0.42-0.69), with both outcomes responding more to MBCT. About half the participants across both treatments reported moderate or great improvements in global indicators of desire and overall sexuality. Conclusions: Results support the efficacy of both group MBCT and group supportive sex education for improving symptoms of SIAD with 12-month retention of improvements. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Sexual distress also improved at each time point with large effect sizes ( d = 0.83-1.17), and more so for MBCT relative to STEP.","['women with SIAD', '148 women who consented, 70 were randomized to MBCT (mean age 39.3 ± 13.2 years) and 78 were randomized to STEP (mean age 37.9 ± 12.2 years', 'female sexual interest/arousal disorder']","['mindfulness-based cognitive therapy (MBCT) plus sex education with (b) group supportive sex education and therapy (STEP', 'group mindfulness-based cognitive therapy with group supportive sex education and therapy']","['Sexual distress', 'Relationship satisfaction', 'global indicators of desire and overall sexuality', 'sexual desire and arousal, sexual distress, relationship satisfaction, rumination, and global impressions of change', 'rumination about sex', 'Sexual desire and arousal']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0424400', 'cui_str': 'Erotic interest'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0036879', 'cui_str': 'Sexuality education'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}]","[{'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0023618', 'cui_str': 'Libido'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}]",,0.026958,"Sexual distress also improved at each time point with large effect sizes ( d = 0.83-1.17), and more so for MBCT relative to STEP.","[{'ForeName': 'Lori A', 'Initials': 'LA', 'LastName': 'Brotto', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia.'}, {'ForeName': 'Bozena', 'Initials': 'B', 'LastName': 'Zdaniuk', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia.'}, {'ForeName': 'Meredith L', 'Initials': 'ML', 'LastName': 'Chivers', 'Affiliation': ""Department of Psychology, Queen's University.""}, {'ForeName': 'Faith', 'Initials': 'F', 'LastName': 'Jabs', 'Affiliation': 'Department of Psychology, University of British Columbia.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Grabovac', 'Affiliation': 'Department of Psychiatry, University of British Columbia.'}, {'ForeName': 'Martin L', 'Initials': 'ML', 'LastName': 'Lalumière', 'Affiliation': 'Department of Psychology, University of Ottawa.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Weinberg', 'Affiliation': 'Department of Cellular & Physiological Sciences, University of British Columbia.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Schonert-Reichl', 'Affiliation': 'Department of Educational and Counselling Psychology, University of British Columbia.'}, {'ForeName': 'Rosemary', 'Initials': 'R', 'LastName': 'Basson', 'Affiliation': 'Department of Psychiatry, University of British Columbia.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000661'] 2894,34383534,Effects of methylphenidate on cognitive functions in boys with attention deficit hyperactivity disorder: Does baseline performance matter?,"Objective: Although attention deficit hyperactivity disorder (ADHD) is associated with cognitive deficits, there is considerable heterogeneity and only a minority of individuals with the disorder demonstrate a deficit in any cognitive domain. Recent studies indicate that the relationships between ADHD symptoms and cognition are complex with a dissociation between medication responses across these two domains. Method: We examined whether methylphenidate (MPH) differentially impacts on cognition in those with and without pretreatment cognitive deficits in a 4-week randomized controlled crossover of high (0.6 mg/kg/dose) and low (0.3 mg/kg/dose) dose MPH and placebo in 75 medication-naive boys with ADHD. Cognition was assessed using tasks from the Cambridge Neuropsychological Test Automated Battery (CANTAB). Confirmatory factor analysis (CFA) was used to form latent cognitive factors of executive functioning, visual memory, and reaction time, as well as a general cognition factor. Results: Compared to placebo, both high and low MPH doses significantly improved performance on pattern recognition (PR), spatial recognition (SR), and simple reaction time. The low, but not the high, dose improved performance on the Stockings of Cambridge (SOC) and delayed matching-to-sample tasks. Both doses also significantly improved performance on the executive functioning, visual memory, reaction time skills, and general cognitive latent variables. There were however no differences in the effects of MPH on cognition between those with and without a baseline cognitive deficit, for either the observed task values or the latent cognitive factor scores. Conclusions: We conclude that MPH can enhance executive functioning, visual memory, reaction time, and general cognitive function in boys with ADHD. These improvements are not dependent on baseline cognitive performance. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Both doses also significantly improved performance on the executive functioning, visual memory, reaction time skills, and general cognitive latent variables.","['boys with ADHD', '75 medication-naive boys with ADHD', 'boys with attention deficit hyperactivity disorder']","['MPH', 'methylphenidate (MPH', 'MPH and placebo', 'methylphenidate', 'placebo']","['Stockings of Cambridge (SOC) and delayed matching-to-sample tasks', 'executive functioning, visual memory, reaction time skills, and general cognitive latent variables', 'performance on pattern recognition (PR), spatial recognition (SR), and simple reaction time', 'cognitive functions', 'baseline cognitive performance', 'executive functioning, visual memory, reaction time, and general cognitive function']","[{'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0445269', 'cui_str': 'Socks'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0542316', 'cui_str': 'Visual memory'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205275', 'cui_str': 'Latent'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",,0.0602251,"Both doses also significantly improved performance on the executive functioning, visual memory, reaction time skills, and general cognitive latent variables.","[{'ForeName': 'Iris Merith E', 'Initials': 'IME', 'LastName': 'Idema', 'Affiliation': 'Donders Center for Medical Neuroscience, Radboud University Nijmegen Medical Centre.'}, {'ForeName': 'Jonathan M', 'Initials': 'JM', 'LastName': 'Payne', 'Affiliation': ""Murdoch Children's Research Institute, Royal Children's Hospital.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Coghill', 'Affiliation': ""Murdoch Children's Research Institute, Royal Children's Hospital.""}]",Journal of consulting and clinical psychology,['10.1037/ccp0000662'] 2895,34383533,Main outcomes of M-bridge: A sequential multiple assignment randomized trial (SMART) for developing an adaptive preventive intervention for college drinking.,"Objective: The goal was to develop a universal and resource-efficient adaptive preventive intervention (API) for incoming first-year students as a bridge to indicated interventions to address alcohol-related risks. The aims were to examine: (a) API versus assessment-only control, (b) the different APIs (i.e., 4 intervention sequences) embedded in the study design, and (c) moderators of intervention effects on binge drinking. Method: A sequential multiple assignment randomized trial (SMART) included two randomizations: timing (summer before vs. first semester) of universal personalized normative feedback and biweekly self-monitoring and, for heavy drinkers, bridging strategy (resource email vs. health coaching invitation). Participants ( N = 891, 62.4% female, 76.8% White) were surveyed at the end of first and second semesters. The primary outcome was binge drinking frequency (4+/5+ drinks for females/males); secondary outcomes were alcohol consequences and health services utilization. Results: API (vs. control) was not significantly associated with outcomes. There were no differences between embedded APIs. Among heavy drinkers, the resource email (vs. health coach invitation) led to greater health services utilization. Moderator analyses suggested students intending to pledge into Greek life benefited more from any API (vs. control; 42% smaller increase from precollege in binge drinking frequency). Conclusions: Although overall effects were not significant, students at high risk (i.e., entering fraternities/sororities) did benefit more from the intervention. Furthermore, the resource email was effective for heavier drinkers. A technology-based strategy to deliver targeted resource-light interventions for heavy drinkers may be effective for reducing binge drinking during the transition to college. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Among heavy drinkers, the resource email (vs. health coach invitation) led to greater health services utilization.","['college drinking', 'Participants ( N = 891, 62.4% female, 76.8% White) were surveyed at the end of first and second semesters', 'heavy drinkers']","['universal personalized normative feedback and biweekly self-monitoring and, for heavy drinkers, bridging strategy (resource email vs. health coaching invitation', 'M-bridge']","['binge drinking frequency', 'alcohol consequences and health services utilization', 'binge drinking']","[{'cui': 'C4042862', 'cui_str': 'Alcohol Drinking, College Students'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0001969', 'cui_str': 'Alcohol intoxication'}]","[{'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0585332', 'cui_str': 'Biweekly'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0001969', 'cui_str': 'Alcohol intoxication'}, {'cui': 'C0221821', 'cui_str': 'Dental bridge'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0556346', 'cui_str': 'Drinking binge'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0030672', 'cui_str': 'Health Care Utilization'}]",,0.0306269,"Among heavy drinkers, the resource email (vs. health coach invitation) led to greater health services utilization.","[{'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Patrick', 'Affiliation': 'Survey Research Center, Institute for Social Research, University of Michigan.'}, {'ForeName': 'Grace R', 'Initials': 'GR', 'LastName': 'Lyden', 'Affiliation': 'Division of Biostatistics, University of Minnesota.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Morrell', 'Affiliation': 'Center for Applied Research and Educational Improvement, College of Education and Human Development, University of Minnesota.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Mehus', 'Affiliation': 'Center for Applied Research and Educational Improvement, College of Education and Human Development, University of Minnesota.'}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Gunlicks-Stoessel', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, University of Minnesota.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Center for the Study of Health and Risk Behaviors, University of Washington.'}, {'ForeName': 'Cheryl A', 'Initials': 'CA', 'LastName': 'King', 'Affiliation': 'Department of Psychiatry, University of Michigan.'}, {'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Bonar', 'Affiliation': ''}, {'ForeName': 'Inbal', 'Initials': 'I', 'LastName': 'Nahum-Shani', 'Affiliation': 'Survey Research Center, Institute for Social Research, University of Michigan.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Almirall', 'Affiliation': 'Survey Research Center, Institute for Social Research, University of Michigan.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Larimer', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Center for the Study of Health and Risk Behaviors, University of Washington.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Vock', 'Affiliation': 'Division of Biostatistics, University of Minnesota.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000663'] 2896,33825570,Very Early Exercise Rehabilitation After Intracerebral Hemorrhage Promotes Inflammation in the Brain.,"BACKGROUND Very early exercise has been reported to exacerbate motor dysfunction; however, its mechanism is largely unknown. OBJECTIVE This study examined the effect of very early exercise on motor recovery and associated brain damage following intracerebral hemorrhage (ICH) in rats. METHODS Collagenase solution was injected into the left striatum to induce ICH. Rats were randomly assigned to receive placebo surgery without exercise (SHAM) or ICH without (ICH) or with very early exercise within 24 hours of surgery (ICH+VET). We observed sensorimotor behaviors before surgery, and after surgery preexercise and postexercise. Postexercise brain tissue was collected 27 hours after surgery to investigate the hematoma area, brain edema, and Il1b , Tgfb1 , and Igf1 mRNA levels in the striatum and sensorimotor cortex using real-time reverse transcription polymerase chain reaction. NeuN, PSD95, and GFAP protein expression was analyzed by Western blotting. RESULTS We observed significantly increased skillful sensorimotor impairment in the horizontal ladder test and significantly higher Il1b mRNA levels in the striatum of the ICH+VET group compared with the ICH group. NeuN protein expression was significantly reduced in both brain regions of the ICH+VET group compared with the SHAM group. CONCLUSION Our results suggest that very early exercise may be associated with an exacerbation of motor dysfunction because of increased neuronal death and region-specific changes in inflammatory factors. These results indicate that implementing exercise within 24 hours after ICH should be performed with caution.",2021,We observed significantly increased skillful sensorimotor impairment in the horizontal ladder test and significantly higher Il1b mRNA levels in the striatum of the ICH+VET group compared with the ICH group.,['intracerebral hemorrhage (ICH) in rats'],"['Exercise Rehabilitation', 'ICH+VET', 'very early exercise', 'SHAM', 'placebo surgery without exercise (SHAM) or ICH without (ICH) or with very early exercise within 24 hours of surgery (ICH+VET']","['NeuN protein expression', 'skillful sensorimotor impairment', 'Postexercise brain tissue', 'NeuN, PSD95, and GFAP protein expression']","[{'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}]","[{'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0442111', 'cui_str': 'Intracerebral'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C0439584', 'cui_str': '24 hours'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0440746', 'cui_str': 'Brain tissue'}, {'cui': 'C0017626', 'cui_str': 'Glial fibrillary acidic protein'}]",,0.0717618,We observed significantly increased skillful sensorimotor impairment in the horizontal ladder test and significantly higher Il1b mRNA levels in the striatum of the ICH+VET group compared with the ICH group.,"[{'ForeName': 'Keigo', 'Initials': 'K', 'LastName': 'Tamakoshi', 'Affiliation': 'Niigata University of Health and Welfare, Japan.'}, {'ForeName': 'Madoka', 'Initials': 'M', 'LastName': 'Maeda', 'Affiliation': 'Kuwana Hospital, Niigata, Japan.'}, {'ForeName': 'Shinnosuke', 'Initials': 'S', 'LastName': 'Nakamura', 'Affiliation': 'Iwamuro Rehabilitation Hospital, Niigata, Japan.'}, {'ForeName': 'Nae', 'Initials': 'N', 'LastName': 'Murohashi', 'Affiliation': 'Niigata University of Health and Welfare, Japan.'}]",Neurorehabilitation and neural repair,['10.1177/15459683211006337'] 2897,34386658,"Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes.","Introduction Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes through mechanisms that are incompletely understood. In this exploratory post-hoc analysis of the VERTIS RENAL trial, we report the association between the SGLT2 inhibitor, ertugliflozin, and markers of kidney injury, inflammation, and fibrosis in participants with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD). Methods Participants were randomized to ertugliflozin (5 or 15 mg/d) or placebo, and plasma samples for biomarker analysis were collected at baseline, 26 weeks, and 52 weeks. Results Ertugliflozin-treated participants had lower plasma levels of kidney injury molecule-1 (KIM-1) at 26 weeks ( P  = 0.044) and 52 weeks ( P  = 0.007) and higher eotaxin-1 at 52 weeks ( P  = 0.007) postrandomization compared with placebo. The change in KIM-1 was not associated with the baseline urine albumin to creatinine ratio (UACR) or the estimated glomerular filtration rate (eGFR, P interaction > 0.05). Additionally, the change in KIM-1 was positively correlated with the change in UACR in participants treated with ertugliflozin ( P  = 0.0071). No other significant associations between ertugliflozin and changes in the markers of tubular injury, inflammation, fibrosis, oxidative stress, and endothelial dysfunction were observed. Conclusion In conclusion, in participants with T2D and stage 3 CKD, ertugliflozin was associated with a sustained lowering of the tubular injury marker KIM-1 regardless of baseline kidney function.",2021,"No other significant associations between ertugliflozin and changes in the markers of tubular injury, inflammation, fibrosis, oxidative stress, and endothelial dysfunction were observed. ","['Patients With CKD and Diabetes', 'participants with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD']","['ertugliflozin', 'placebo', 'Sodium-glucose cotransporter-2 (SGLT2) inhibitors']","['Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin', 'plasma levels of kidney injury molecule-1 (KIM-1', 'glomerular filtration rate (eGFR', 'baseline urine albumin to creatinine ratio (UACR', 'change in KIM-1', 'tubular injury, inflammation, fibrosis, oxidative stress, and endothelial dysfunction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C2316787', 'cui_str': 'Chronic kidney disease stage 3'}]","[{'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0160420', 'cui_str': 'Injury of kidney'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1313407', 'cui_str': 'HAVCR1 protein, human'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0042038', 'cui_str': 'Albumin urine'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0332208', 'cui_str': 'Tubular'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0856169', 'cui_str': 'Endothelial dysfunction'}]",,0.35404,"No other significant associations between ertugliflozin and changes in the markers of tubular injury, inflammation, fibrosis, oxidative stress, and endothelial dysfunction were observed. ","[{'ForeName': 'Hongyan', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Vikas S', 'Initials': 'VS', 'LastName': 'Sridhar', 'Affiliation': 'Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Leif Erik', 'Initials': 'LE', 'LastName': 'Lovblom', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.'}, {'ForeName': 'Yuliya', 'Initials': 'Y', 'LastName': 'Lytvyn', 'Affiliation': 'Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Dylan', 'Initials': 'D', 'LastName': 'Burger', 'Affiliation': 'Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, Kidney Research Centre, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Burns', 'Affiliation': 'Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, Kidney Research Centre, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Davor', 'Initials': 'D', 'LastName': 'Brinc', 'Affiliation': 'Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Patrick R', 'Initials': 'PR', 'LastName': 'Lawler', 'Affiliation': 'Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'David Z I', 'Initials': 'DZI', 'LastName': 'Cherney', 'Affiliation': 'Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.'}]",Kidney international reports,['10.1016/j.ekir.2021.05.022'] 2898,34383537,Correction to Lehavot et al. (2021).,"Reports an error in ""A randomized trial of an online, coach-assisted self-management PTSD intervention tailored for women veterans"" by Keren Lehavot, Steven P. Millard, Rachel M. Thomas, Konstantina Yantsides, Michelle Upham, Kerry Beckman, Alison B. Hamilton, Anne Sadler, Brett Litz and Tracy Simpson ( Journal of Consulting and Clinical Psychology , 2021[Feb], Vol 89[2], 134-142). In the article ""A Randomized Trial of an Online, Coach-Assisted Self-Management PTSD Intervention Tailored for Women Veterans"" by Keren Lehavot, Steven P. Millard, Rachel M. Thomas, Konstantina Yantsides, Michelle Upham, Kerry Beckman, Alison B. Hamilton, Anne Sadler, Brett Litz, and Tracy Simpson (Journal of Consulting and Clinical Psychology, 2021, 89(2), 134-141. https://doi.org/10 .1037/ccp0000556), due to production error, Figure 1 was not included. The online version of this article has been corrected. (The following abstract of the original article appeared in record 2021-24184-006.) Objective: Scalable, efficiently delivered treatments are needed to address the needs of women Veterans with PTSD. This randomized clinical trial compared an online, coach-assisted cognitive behavioral intervention tailored for women Veterans with PTSD to phone monitoring only. METHOD Women Veterans who met diagnostic criteria for PTSD were randomized to an 8-week web-based intervention, called DElivery of Self TRaining and Education for Stressful Situations (DESTRESS)-Women Veterans version (WV), or to phone monitoring only (N = 102). DESTRESS-WV consisted of online sessions and 15-min weekly phone calls from a study coach. Phone monitoring included 15-min weekly phone calls from a study coach to offer general support. PTSD symptom severity (PTSD Symptom-Checklist-Version 5 [PCL-5]) was evaluated pre and posttreatment, and at 3 and 6 months posttreatment. RESULTS More participants completed phone monitoring than DESTRESS-WV (96% vs. 76%, p = 0.01), although treatment satisfaction was significantly greater in the DESTRESS-WV condition. We failed to confirm the superiority of DESTRESS-WV in intent-to-treat slope changes in PTSD symptom severity. Both treatments were associated with significant reductions in PTSD symptom severity over time. However, post hoc analyses of treatment completers and of those with baseline PCL ≥ 33 revealed that the DESTRESS-WV group had greater improvement in PTSD symptom severity relative to phone monitoring with significant differences at the 3-month follow-up assessment. CONCLUSIONS Both DESTRESS-WV and phone monitoring resulted in significant improvements in women Veterans' PTSD symptoms. DESTRESS-WV may be an appropriate care model for women Veterans who can engage in the demands of the treatment and have higher baseline symptoms. Future research should explore characteristics of and the methods of reliably identifying women Veterans who are most likely to benefit. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"RESULTS More participants completed phone monitoring than DESTRESS-WV (96% vs. 76%, p = 0.01), although treatment satisfaction was significantly greater in the DESTRESS-WV condition.","['Women Veterans who met diagnostic criteria for PTSD', 'women Veterans with PTSD to phone monitoring only', 'women Veterans with PTSD', 'women Veterans who can engage in the demands of the treatment and have higher baseline symptoms', ""women Veterans' PTSD symptoms""]","['online, coach-assisted self-management PTSD intervention', 'online, coach-assisted cognitive behavioral intervention', '8-week web-based intervention, called DElivery of Self TRaining and Education for Stressful Situations (DESTRESS)-Women Veterans version (WV), or to phone monitoring only', 'Online, Coach-Assisted Self-Management PTSD Intervention']","['PTSD symptom severity', 'treatment satisfaction', 'PTSD symptom severity (PTSD Symptom-Checklist-Version 5 [PCL-5']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C3898714', 'cui_str': 'Internet Intervention'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0451524', 'cui_str': 'Symptom checklist'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C1704423', 'cui_str': 'Hereditary lymphedema'}]",,0.0267343,"RESULTS More participants completed phone monitoring than DESTRESS-WV (96% vs. 76%, p = 0.01), although treatment satisfaction was significantly greater in the DESTRESS-WV condition.",[],Journal of consulting and clinical psychology,['10.1037/ccp0000664'] 2899,34383532,Internet-delivered interpretation training reduces worry and anxiety in individuals with generalized anxiety disorder: A randomized controlled experiment.,"Objective: Generalized anxiety disorder (GAD) is a debilitating condition, characterized by negative interpretations about ambiguous situations. This study tested whether entirely internet-delivered interpretation training [cognitive bias modification (CBM)] versus control promotes positive interpretations and reduces worry and anxiety in individuals with GAD, with or without depression. Method: A two-arm (CBM; control) parallel-group randomized controlled experiment. Assessments were preintervention (T0), postintervention (T1), 1-month (T2) postintervention, and 3-month (T3) postintervention. Participants with GAD (with or without comorbid depression) were randomly allocated to either CBM ( n = 115) or control ( n = 115). Participants, but not researchers, were blind to allocated condition. Participants completed up to 10 online CBM or control sessions across 1 month. Interpretation bias [coprimary outcomes: scrambled sentence test (SST), recognition test (RT)], and number of negative thought intrusions during a breathing focus task were measured at T0 and T1. Self-reported levels of worry [Penn State Worry Questionnaire-trait (PSWQ trait); Penn State Worry Questionnaire-past week (PSWQ weekly)], anxiety [Generalized Anxiety Disorder scale (GAD-7)], depression [Patient Health Questionnaire (PHQ-9)], rumination [Ruminative Response Scale (RRS)], and repetitive negative thinking [RNT; Repetitive Thinking Questionnaire-trait (RTQ-trait)] were assessed at T0-T3. Results: The per-protocol analyses included N = 186 participants (CBM n = 94; control n = 92). As predicted, we found moderate-to-large training effects on the primary outcome of interpretation bias at T1. Secondary outcomes of negative thought intrusions at T1 and self-reported symptoms at T2 were all significantly lower in the CBM versus control condition. All but one effect (trait RNT) were sustained at T3. Conclusions: In this randomized controlled study, we found that fully online interpretation training ameliorated core features of GAD in individuals with or without comorbid depression up to 3 months posttraining. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,Secondary outcomes of negative thought intrusions at T1 and self-reported symptoms at T2 were all significantly lower in the CBM versus control condition.,"['individuals with GAD, with or without depression', 'individuals with or without comorbid depression up to 3 months posttraining', 'individuals with generalized anxiety disorder', 'N = 186 participants (CBM n = 94; control n = 92', 'Participants with GAD (with or without comorbid depression']","['fully online interpretation training', 'CBM', 'entirely internet-delivered interpretation training [cognitive bias modification (CBM', 'Internet-delivered interpretation training']","['Self-reported levels of worry', 'sentence test (SST), recognition test (RT)], and number of negative thought intrusions during a breathing focus task', 'Penn State Worry Questionnaire-trait (PSWQ trait); Penn State Worry Questionnaire-past week (PSWQ weekly)], anxiety [Generalized Anxiety Disorder scale (GAD-7)], depression [Patient Health Questionnaire (PHQ-9)], rumination [Ruminative Response Scale (RRS)], and repetitive negative thinking [RNT', 'negative thought intrusions at T1 and self-reported symptoms at T2', 'Repetitive Thinking Questionnaire-trait (RTQ-trait', 'preintervention (T0), postintervention (T1), 1-month (T2) postintervention, and 3-month (T3) postintervention']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0459471', 'cui_str': 'Interpretation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1142075', 'cui_str': 'Negative thoughts'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C2959752', 'cui_str': 'Penn State worry questionnaire'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3641330', 'cui_str': 'GAD-7'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0424134', 'cui_str': 'Pessimistic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",,0.049336,Secondary outcomes of negative thought intrusions at T1 and self-reported symptoms at T2 were all significantly lower in the CBM versus control condition.,"[{'ForeName': 'Colette R', 'Initials': 'CR', 'LastName': 'Hirsch', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Krahé', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Whyte', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Krzyzanowski', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Meeten', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Norton', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Mathews', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}]",Journal of consulting and clinical psychology,['10.1037/ccp0000660'] 2900,34383515,Investigating the effects of the Moms' Empowerment Program on 8-year traumatic stress symptom trajectories in women with histories of IPV.,"OBJECTIVE Intimate partner violence (IPV) is a pressing issue, affecting nearly one-third of women in the U.S. over their lifetimes, and has been linked with a number of deleterious outcomes, including the development of posttraumatic stress disorder (PTSD). Although IPV is often chronic, few studies have prospectively examined trajectories of PTSD symptoms (PTSS) in this population. The goal of the present study was to assess the effects of the Moms' Empowerment Program-an IPV-specific intervention; as well as trauma exposure, domestic violence (DV) shelter use, and depression symptoms on PTSS trajectories in women with histories of IPV. METHOD Data were drawn from a sample of 118 women who participated in a randomized controlled trial (RCT) of an intervention specifically designed for women and children experiencing IPV. Sixty-seven women from the original sample completed an assessment 8 years following the conclusion of the intervention. RESULTS On average, women's PTSS decreased over time. Intervention group assignment did not affect these trajectories; however, women who attended more sessions had significantly fewer PTSS at the 8-year follow-up. Greater IPV exposure, higher depression symptoms, and shelter use were all associated with higher PTSS over time, with some variation across PTSS subdomains. CONCLUSIONS These results provide preliminary evidence that brief intervention may have long-term effects. They also demonstrate how addressing ongoing IPV and concurrent symptoms of depression is likely an essential component of treating PTSS in this population. Finally, these results underscore the need for more research on relations between formal DV services and mental health. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Greater IPV exposure, higher depression symptoms, and shelter use were all associated with higher PTSS over time, with some variation across PTSS subdomains. ","['Sixty-seven women from the original sample completed an assessment 8 years following the conclusion of the intervention', 'women with histories of IPV', 'Intimate partner violence (IPV', 'Data were drawn from a sample of 118 women who participated in a randomized controlled trial (RCT) of an intervention specifically designed for women and children experiencing IPV']","[""Moms' Empowerment Program-an IPV-specific intervention"", ""Moms' Empowerment Program""]","['PTSS', '8-year traumatic stress symptom trajectories']","[{'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C1442163', 'cui_str': 'MoM'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}]",67.0,0.0360775,"Greater IPV exposure, higher depression symptoms, and shelter use were all associated with higher PTSS over time, with some variation across PTSS subdomains. ","[{'ForeName': 'Maria M', 'Initials': 'MM', 'LastName': 'Galano', 'Affiliation': 'Department of Psychological and Brain Sciences.'}, {'ForeName': 'Sara F', 'Initials': 'SF', 'LastName': 'Stein', 'Affiliation': 'School of Social Work.'}, {'ForeName': 'Andrew C', 'Initials': 'AC', 'LastName': 'Grogan-Kaylor', 'Affiliation': 'School of Social Work.'}, {'ForeName': 'Hannah M', 'Initials': 'HM', 'LastName': 'Clark', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Sandra A', 'Initials': 'SA', 'LastName': 'Graham-Bermann', 'Affiliation': 'Department of Psychology.'}]",The American journal of orthopsychiatry,['10.1037/ort0000577'] 2901,34383511,Building psychosocial safety climate in turbulent times: The case of COVID-19.,"Our theoretically driven cluster-randomized cohort control study sought to understand how psychosocial safety climate (PSC)-a climate to protect worker psychological health-could be built in different organizational change scenarios. We drew on event system theory to characterize change (planned vs. shock) as an event (observable, bounded in time and space, nonroutine) to understand how events connect and impact organizational behavior and features (e.g., job design, PSC). Event 1 was an 8-month planned intervention involving training middle managers to enact PSC in work units and reduce job stressors. Event 2 was the shock COVID-19 pandemic which occurred midintervention (at 4 months). Three waves (T1, 0 months; T2, 4 months; T3, 8 months) of data were collected from experimental (295T1, 224T2, 119T3) and control (236T1, 138T2, 83T3) employees across 22 work groups. Multilevel analysis showed in Event 1 (T1T2) a significant Group × Time effect where PSC (particularly management priority) significantly increased in the experimental versus control group. Under Event 2 (T2T3), PSC was maintained at higher levels in the experimental versus control group but both groups reported significantly increased PSC communication and commitment. Results suggest that middle management training increases PSC within 4 months. Event 2, COVID-19 was shocking and its novelty, disruption, criticality, and timing in Australian industrial history enabled a strong top management response, positively affecting the control group. PSC may be sustained and built in times of shock with top management will, the application of PSC principles, and a top-level pro-psychological health agenda. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Under Event 2 (T2T3), PSC was maintained at higher levels in the experimental versus control group but both groups reported significantly increased PSC communication and commitment.",[],[],['PSC communication and commitment'],[],[],"[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0008946', 'cui_str': 'Climate'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}]",,0.0413257,"Under Event 2 (T2T3), PSC was maintained at higher levels in the experimental versus control group but both groups reported significantly increased PSC communication and commitment.","[{'ForeName': 'Maureen F', 'Initials': 'MF', 'LastName': 'Dollard', 'Affiliation': 'PSC Global Observatory, Centre for Workplace Excellence, University of South Australia.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Bailey', 'Affiliation': 'School of Medicine, Nottingham University.'}]",The Journal of applied psychology,['10.1037/apl0000939'] 2902,34383416,"Clinical Effect of PRP with DPASB on Full-Thickness Rotator Cuff Tears and Its Role in VAS, SST, and Constant Scores of Patients.","BACKGROUND The aim of the study is to probe the effects of platelet-rich plasma (PRP) plus double-row anchor suture bridge (DRASB) under shoulder arthroscopy on the postoperative VAS, SST and Constant scores, rotator cuff tendonbone healing, and re-tear of patients with full-thickness rotator cuff tear (RCT). METHODS A total of 60 patients with full-thickness RCT treated in our institution from August 2019 to January 2020 were picked and assigned to either group A (n = 30) or group B (n = 30) on a voluntary basis. Group B received DRASB under shoulder arthroscopy, whereas group A underwent DRASB under shoulder arthroscopy plus PRP. We compared the curative effects of both groups. RESULTS Week 2, 4, 8, 12 after surgery and 6 months after surgery, VAS scores of patients in both groups declined saliently, whereas SST and Constant scores elevated, and the decrease/increase amplitude of patients in group A was sharply higher than that in group B (p < 0.05). At T2 and T3, abduction 90° external rotation, abduction 90° internal rotation, abduction and anteflexion in both groups increased strikingly, and group A harbored a brilliantly higher increase than group B (p < 0.05). At T2 and T3, serum NO and IL-6 contents were prominently dwindled in both groups, and group A held a plainly higher decrease than group B (p < 0.05). At T3, in comparison to group B, the rotator cuff tendonbone healing rate and quality of life scores in group A were higher (p < 0.05), whereas retear rate was dramatically lower (p < 0.05). CONCLUSIONS DRASB under shoulder arthroscopy plus PRP therapy can blatantly meliorate the curative effect of patients with full-thickness tear, improve the shoulder joint function and tendonbone healing rate, reduce the postoperative pain degree and the incidence of retear, and can be more broadly promoted and applied clinically.",2021,"At T3, in comparison to group B, the rotator cuff tendonbone healing rate and quality of life scores in group A were higher (p < 0.05), whereas retear rate was dramatically lower (p < 0.05). ","['patients with full-thickness rotator cuff tear (RCT', '60 patients with full-thickness RCT treated in our institution from August 2019 to January 2020']","['DRASB under shoulder arthroscopy plus PRP', 'DRASB under shoulder arthroscopy', 'PRP with DPASB', 'DRASB under shoulder arthroscopy plus PRP therapy', 'platelet-rich plasma (PRP) plus double-row anchor suture bridge (DRASB']","['postoperative VAS, SST and Constant scores, rotator cuff tendonbone healing, and re-tear', 'retear rate', 'Full-Thickness Rotator Cuff Tears', 'rotator cuff tendonbone healing rate and quality of life scores', 'VAS scores', 'serum NO and IL-6 contents', 'shoulder joint function and tendonbone healing rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0410017', 'cui_str': 'Full thickness rotator cuff tear'}, {'cui': 'C0263912', 'cui_str': 'Rotator cuff syndrome'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1293132', 'cui_str': 'Anchoring'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0221821', 'cui_str': 'Dental bridge'}, {'cui': 'C0559702', 'cui_str': 'Arthroscopy of shoulder'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C4727879', 'cui_str': 'Platelet rich plasma therapy'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0037659', 'cui_str': 'Somatostatin'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0085515', 'cui_str': 'Structure of rotator cuff including muscles and tendons'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0410017', 'cui_str': 'Full thickness rotator cuff tear'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0037009', 'cui_str': 'Joint structure of shoulder region'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",60.0,0.0129097,"At T3, in comparison to group B, the rotator cuff tendonbone healing rate and quality of life scores in group A were higher (p < 0.05), whereas retear rate was dramatically lower (p < 0.05). ","[{'ForeName': 'Yingbo', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Qingcai', 'Initials': 'Q', 'LastName': 'Meng', 'Affiliation': ''}]",Clinical laboratory,['10.7754/Clin.Lab.2020.201031'] 2903,34383414,"NF-kB Expression, Comparison of Intestinal Flora, Inflammation and Adiponectin and Clinical Significance in Prostate Cancer Patients.","BACKGROUND The aim was to compare the changes in nuclear factor kappa-B (NF-κB) expression, intestinal flora, inflammatory indexes, and adiponectin (ADPN) between prostate cancer patients complicated with metabolic syndrome (MS) and those without MS and to analyze their clinical significance. METHODS A total of 90 patients with prostate cancer diagnosed in our hospital from May 2018 to November 2019 were selected and divided into MS group (observation group, n = 45) and no MS group (control group, n = 45). Then the patients' general data, including age, body mass index (BMI), and blood pressure, were collected. Thereafter, the prostate volume was measured, blood triglyceride (TG), inflammatory indexes, fasting plasma glucose (FPG), fasting insulin (FINS), and ADPN were detected. In addition, the postoperative pathological Gleason score, pathological T (pT) stage, and pelvic lymph node metastasis were compared, and the relationship and influencing factors were explored. RESULTS There were no significant differences in age and blood pressure between the observation group and the control group. 1) The observation group had a significantly higher BMI, remarkably more TGs, and a notably larger prostate volume than the control group (p < 0.05). 2) The expression rate of NF-κB in the specimens in the observation group was markedly higher than that in the control group, and the difference was statistically signifi-cant (p < 0.05). 3) The total bacterial load in the observation group was obviously larger than that in the control group, in which the levels of Bifidobacteria and Lactobacilli (two types of probiotics) in the former were significantly lower than those in the latter, but the levels of Escherichia coli, Helicobacter pylori, Streptococci, and Staphylococci (harmful bacteria) in the former were evidently higher than those in the latter (p < 0.05). 4) The levels of inflammatory factors, including catabolite activator protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), in the peripheral blood in the observation group were markedly higher than those in control group (p < 0.05). 5) The observation group had distinctly higher levels of FINS and FPG and an evidently lower level of ADPN than the control group, showing statistically significant differences (p < 0.05). 6) The postoperative pathological Gleason score, the number of patients in pT3 - 4 stages, and the number of patients with pelvic lymph node metastasis in the observation group were remarkably higher and larger than those in the control group (p < 0.05). CONCLUSIONS The metabolic indexes such as blood lipid in prostate cancer patients complicated with MS are higher than those in prostate cancer patients without MS, and the degree of malignancy in the former is higher, suggesting that MS may promote the development of prostate cancer.",2021,"The expression rate of NF-κB in the specimens in the observation group was markedly higher than that in the control group, and the difference was statistically signifi-cant (p < 0.05).","['prostate cancer patients complicated with metabolic syndrome (MS', 'prostate cancer patients', 'Prostate Cancer Patients', '90 patients with prostate cancer diagnosed in our hospital from May 2018 to November 2019 were selected and divided into MS group (observation group, n = 45) and no MS group (control group, n = 45']",[],"['larger prostate volume', 'nuclear factor kappa-B (NF-κB) expression, intestinal flora, inflammatory indexes, and adiponectin (ADPN', 'postoperative pathological Gleason score', 'NF-kB Expression, Comparison of Intestinal Flora, Inflammation and Adiponectin and Clinical Significance', 'levels of Bifidobacteria and Lactobacilli', 'age and blood pressure', 'levels of inflammatory factors, including catabolite activator protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), in the peripheral blood', 'blood triglyceride (TG), inflammatory indexes, fasting plasma glucose (FPG), fasting insulin (FINS), and ADPN', 'total bacterial load', 'expression rate of NF-κB', 'BMI', 'levels of Escherichia coli, Helicobacter pylori, Streptococci, and Staphylococci (harmful bacteria', 'postoperative pathological Gleason score, pathological T (pT) stage, and pelvic lymph node metastasis', 'levels of FINS and FPG', 'level of ADPN', 'pelvic lymph node metastasis']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C0426732', 'cui_str': 'Large prostate'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0079904', 'cui_str': 'Immunoglobulin Enhancer-Binding Protein'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0332326', 'cui_str': 'Gleason grading system for prostatic cancer'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0007364', 'cui_str': 'Cyclic AMP Receptor Proteins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0518018', 'cui_str': 'Blood triglycerides'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2936404', 'cui_str': 'Bacterial Load'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0729595', 'cui_str': 'Pelvic lymph node group'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]",90.0,0.074648,"The expression rate of NF-κB in the specimens in the observation group was markedly higher than that in the control group, and the difference was statistically signifi-cant (p < 0.05).","[{'ForeName': 'Yongtao', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Hong', 'Affiliation': ''}]",Clinical laboratory,['10.7754/Clin.Lab.2020.200938'] 2904,34387964,"Participants with mild, moderate, or severe pain following total hip arthroplasty. A sub-study of the PANSAID trial on paracetamol and ibuprofen for postoperative pain treatment.","OBJECTIVES In this sub-study of the 'Paracetamol and Ibuprofen in Combination' (PANSAID) trial, in which participants were randomised to one of four different non-opioids analgesic regimen consisting of paracetamol, ibuprofen, or a combination of the two after planned primary total hip arthroplasty, our aims were to investigate the distribution of participants' pain (mild, moderate or severe), integrate opioid use and pain to a single score (Silverman Integrated Approach (SIA)-score), and identify preoperative risk factors for severe pain. METHODS We calculated the proportions of participants with mild (VAS 0-30 mm), moderate (VAS 31-60 mm) or severe (VAS 61-100 mm) pain and the SIA-scores (a sum of rank-based percentage differences from the mean rank in pain scores and opioid use, ranging from -200 to 200%). Using logistic regression with backwards elimination, we investigated the association between severe pain and easily obtainable preoperative patient characteristics. RESULTS Among 556 participants from the modified intention-to-treat population, 33% (95% CI: 26-42) (Group Paracetamol + Ibuprofen (PCM + IBU)), 28% (95% CI: 21-37) (Group Paracetamol (PCM)), 23% (95% CI: 17-31) (Group Ibuprofen (IBU)), and 19% (95% CI: 13-27) (Group Half Strength-Paracetamol + Ibuprofen (HS-PCM + IBU)) experienced mild pain 6 h postoperatively during mobilisation. Median SIA-scores during mobilisation were: Group PCM + IBU: -48% (IQR: -112 to 31), Group PCM: 40% (IQR: -31 to 97), Group IBU: -5% (IQR: -57 to 67), and Group HS-PCM + IBU: 6% (IQR: -70 to 74) (overall difference: p=0.0001). Use of analgesics before surgery was the only covariate associated with severe pain (non-opioid: OR 0.50, 95% CI: 0.29-0.82, weak opioid 0.56, 95% CI: 0.28-1.16, reference no analgesics before surgery, p=0.02). CONCLUSIONS Only one third of participants using paracetamol and ibuprofen experienced mild pain after total hip arthroplasty and even fewer experienced mild pain using each drug alone as basic non-opioid analgesic treatment. We were not able, in any clinically relevant way, to predict severe postoperative pain. A more extensive postoperative pain regimen than paracetamol, ibuprofen and opioids may be needed for a large proportion of patients having total hip arthroplasty. SIA-scores integrate pain scores and opioid use for the individual patient and may add valuable information in acute pain research.",2021,IBU: 6% (IQR: -70 to 74) (overall difference: p=0.0001).,"['patients having total hip arthroplasty', 'participants with mild (VAS 0-30\xa0mm), moderate (VAS 31-60\xa0mm) or severe (VAS 61-100\xa0mm) pain and the SIA-scores (a sum of rank-based percentage differences from the mean rank in pain scores and opioid use, ranging from\xa0-200 to 200', '556 participants from the modified intention-to-treat population, 33% (95% CI: 26-42) (Group', ""participants' pain (mild, moderate or severe"", 'Participants with mild, moderate, or severe pain following total hip arthroplasty']","['PCM\xa0', 'paracetamol, ibuprofen, or a combination of the two after planned primary total hip arthroplasty', 'Paracetamol\xa0+\xa0Ibuprofen', 'paracetamol and ibuprofen', 'Paracetamol and Ibuprofen', 'Strength-Paracetamol\xa0+\xa0Ibuprofen (HS-PCM\xa0+\xa0IBU', 'paracetamol, ibuprofen and opioids', 'Paracetamol (PCM']","['Median SIA-scores', 'mild pain 6', 'severe pain', 'mild pain', 'severe postoperative pain']","[{'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0450396', 'cui_str': '30mm'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4517811', 'cui_str': '556'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0278140', 'cui_str': 'Severe pain'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0033677', 'cui_str': 'Deficiency of macronutrients'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0721022', 'cui_str': 'Ibu'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0278138', 'cui_str': 'Mild pain'}, {'cui': 'C0278140', 'cui_str': 'Severe pain'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]",556.0,0.342414,IBU: 6% (IQR: -70 to 74) (overall difference: p=0.0001).,"[{'ForeName': 'Luma Mahmoud', 'Initials': 'LM', 'LastName': 'Issa', 'Affiliation': 'Department of Anaesthesiology, Centre for Anaesthesiological Research, Zealand University Hospital, Køge, Denmark.'}, {'ForeName': 'Kasper Højgaard', 'Initials': 'KH', 'LastName': 'Thybo', 'Affiliation': 'Department of Anaesthesiology, Centre for Anaesthesiological Research, Zealand University Hospital, Køge, Denmark.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Hägi-Pedersen', 'Affiliation': 'Department of Anaesthesiology, Head of Research, Næstved, Slagelse and Ringsted Hospitals, Næstved, Denmark.'}, {'ForeName': 'Jørn', 'Initials': 'J', 'LastName': 'Wetterslev', 'Affiliation': 'Copenhagen Trial\xa0Unit, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Janus Christian', 'Initials': 'JC', 'LastName': 'Jakobsen', 'Affiliation': 'Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Overgaard', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Orthopaedic Research Unit, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Mathiesen', 'Affiliation': 'Department of Anaesthesiology, Centre for Anaesthesiological Research, Zealand University Hospital, Køge, Denmark.'}]",Scandinavian journal of pain,['10.1515/sjpain-2020-0141'] 2905,34387949,The tolerance to stretch is linked with endogenous modulation of pain.,"OBJECTIVES The effect of stretching on joint range of motion is well documented, and although sensory perception has significance for changes in the tolerance to stretch following stretching the underlining mechanisms responsible for these changes is insufficiently understood. The aim of this study was to examine the influence of endogenous pain inhibitory mechanisms on stretch tolerance and to investigate the relationship between range of motion and changes in pain sensitivity. METHODS Nineteen healthy males participated in this randomized, repeated-measures crossover study, conducted on 2 separate days. Knee extension range of motion, passive resistive torque, and pressure pain thresholds were recorded before, after, and 10 min after each of four experimental conditions; (i) Exercise-induced hypoalgesia, (ii) two bouts of static stretching, (iii) resting, and (iv) a remote, painful stimulus induced by the cold pressor test. RESULTS Exercise-induced hypoalgesia and cold pressor test caused an increase in range of motion (p<0.034) and pressure pain thresholds (p<0.027). Moderate correlations in pressure pain thresholds were found between exercise-induced hypoalgesia and static stretch (Rho>0.507, p=0.01) and exercise-induced hypoalgesia and the cold pressor test (Rho=0.562, p=0.01). A weak correlation in pressure pain thresholds and changes in range of motion were found following the cold pressor test (Rho=0.460, p=0.047). However, a potential carryover hypoalgesic effect may have affected the results of the static stretch. CONCLUSIONS These results suggest that stretch tolerance may be linked with endogenous modulation of pain. Present results suggest, that stretch tolerance may merely be a marker for pain sensitivity which may have clinical significance given that stretching is often prescribed in the rehabilitation of different musculoskeletal pain conditions where reduced endogenous pain inhibition is frequently seen.",2021,"RESULTS Exercise-induced hypoalgesia and cold pressor test caused an increase in range of motion (p<0.034) and pressure pain thresholds (p<0.027).",['Nineteen healthy males'],"['i) Exercise-induced hypoalgesia, (ii) two bouts of static stretching, (iii) resting, and (iv) a remote, painful stimulus induced by the cold pressor test']","['range of motion (p<0.034) and pressure pain thresholds', 'hypoalgesia and cold pressor test', 'hypoalgesia and static stretch', 'exercise-induced hypoalgesia and the cold pressor test', 'pressure pain thresholds and changes in range of motion', 'Knee extension range of motion, passive resistive torque, and pressure pain thresholds', 'pressure pain thresholds']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0085625', 'cui_str': 'Hypoalgesia'}, {'cui': 'C1720875', 'cui_str': 'Static Stretching'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}]","[{'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0085625', 'cui_str': 'Hypoalgesia'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}]",19.0,0.0282158,"RESULTS Exercise-induced hypoalgesia and cold pressor test caused an increase in range of motion (p<0.034) and pressure pain thresholds (p<0.027).","[{'ForeName': 'Morten Pallisgaard', 'Initials': 'MP', 'LastName': 'Støve', 'Affiliation': 'Department of Physiotherapy, University College of Northern Denmark (UCN), Aalborg East, Denmark.'}, {'ForeName': 'Rogerio Pessoto', 'Initials': 'RP', 'LastName': 'Hirata', 'Affiliation': 'Department of Health Science and Technology, SMI®, Faculty of Medicine, Aalborg University, Aalborg East, Denmark.'}, {'ForeName': 'Thorvaldur Skuli', 'Initials': 'TS', 'LastName': 'Palsson', 'Affiliation': 'Department of Health Science and Technology, SMI®, Faculty of Medicine, Aalborg University, Aalborg East, Denmark.'}]",Scandinavian journal of pain,['10.1515/sjpain-2020-0010'] 2906,34387828,"Effectiveness and Safety of Acupoint Application of Guan Xin Su He Pill () for Patients with Chronic Stable Angina Pectoris: A Multi-Center, Randomized Controlled Trial.","OBJECTIVE To assess the clinical effectiveness of acupoint application (AP) of Guan Xin Su He Pill (, GXSHP) for patients with chronic stable angina pectoris (CSAP). METHODS This study was carried out in 3 local hospitals in Chengdu, China. After baseline evaluation, eligible patients were randomly assigned to the placebo application for acupoints (PAA) group or the herbal application for acupoints (HAA) group. Patients in the HAA group underwent AP with herbal powder, which was mainly GXSHP, and patients in the PAA group underwent AP with sham drugs. For each treatment session, unilateral acupoints including Neiguan (PC 6), Danzhong (RN 17), Xinshu (BL 15) and Jueyinshu (BL 14), were stimulated for both groups. AP was performed 3 times a week with a 2-day interval for 4 weeks. The primary outcome was the frequency of angina pectoris attacks per week, while the secondary outcomes included angina pain intensity measured by the Visual Analogue Scale (VAS), dose of rescue oral drugs (nitroglycerin), scores on the Seattle Angina Questionnaire (SAQ), Self-Rating Anxiety Scale scores (SAS) and Self-Rating Depression Scale scores (SDS). Clinical outcomes were measured at week 0, 4 and 8. The safety of AP of GXSHP treatment for CSAP were assessed. RESULTS A total of 121 patients were enrolled. Baseline characteristics were comparable across the 2 groups. After treatment, the angina attack numbers in the HAA group were significantly reduced from 11.00 to 4.81 (P<0.05). While, for PAA group, the angina frequency was not significantly improved (baseline 10.55; post-treatment 11.05). The HAA group had significantly fewer angina attacks than the PAA group (P<0.05). Pain intensity measured by VAS in HAA group was significantly reduced from 4.06 to 3.02 (P<0.05). While, for PAA group, the VAS was significantly increased (baseline 3.62; post-treatment 3.96; P<0.05). Clinical outcomes showed better improvement after treatment in the HAA group than in the PAA group in terms of oral administration of rescue drugs, SAS, SDS and SAQ scores (P<0.05). The adverse events were also reported. CONCLUSION AP of GXSHP is a safe and effective treatment for CSAP patients (Registration No. NCT02029118).",2021,"Clinical outcomes showed better improvement after treatment in the HAA group than in the PAA group in terms of oral administration of rescue drugs, SAS, SDS and SAQ scores (P<0.05).","['3 local hospitals in Chengdu, China', '121 patients were enrolled', 'Patients with Chronic Stable Angina Pectoris', 'patients with chronic stable angina pectoris (CSAP']","['HAA', 'acupoint application (AP) of Guan Xin Su', 'placebo application for acupoints (PAA) group or the herbal application for acupoints (HAA', 'PAA', 'He Pill (, GXSHP', 'Acupoint Application of Guan Xin Su', 'GXSHP', 'unilateral acupoints including Neiguan (PC 6), Danzhong (RN 17), Xinshu (BL 15) and Jueyinshu']","['rescue drugs, SAS, SDS and SAQ scores', 'angina frequency', 'VAS', 'Pain intensity', 'adverse events', 'frequency of angina pectoris attacks', 'angina pain intensity measured by the Visual Analogue Scale (VAS), dose of rescue oral drugs (nitroglycerin), scores on the Seattle Angina Questionnaire (SAQ), Self-Rating Anxiety Scale scores (SAS) and Self-Rating Depression Scale scores (SDS', 'angina attack numbers', 'angina attacks']","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0340288', 'cui_str': 'Stable angina'}]","[{'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0325602', 'cui_str': 'Guan'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3695257', 'cui_str': 'Frequency of angina'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0235462', 'cui_str': 'Anginal attack'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",121.0,0.0628573,"Clinical outcomes showed better improvement after treatment in the HAA group than in the PAA group in terms of oral administration of rescue drugs, SAS, SDS and SAQ scores (P<0.05).","[{'ForeName': 'De-Hua', 'Initials': 'DH', 'LastName': 'Li', 'Affiliation': 'Department of Acupuncture and Moxibustion, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Xie', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Yu-Lan', 'Initials': 'YL', 'LastName': 'Ren', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Yu-Lan', 'Initials': 'YL', 'LastName': 'Ren', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zheng', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Jun-Ling', 'Initials': 'JL', 'LastName': 'Lyu', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Jun-Yan', 'Initials': 'JY', 'LastName': 'Leng', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Ling-Lin', 'Initials': 'LL', 'LastName': 'Zhang', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Hai-Long', 'Initials': 'HL', 'LastName': 'Fan', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Fan-Rong', 'Initials': 'FR', 'LastName': 'Liang', 'Affiliation': 'Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China. acuresearch@126.com.'}]",Chinese journal of integrative medicine,['10.1007/s11655-021-2870-3'] 2907,34387827,Qishen Taohong Granule () as Adjuvant Therapy for Improving Cardiac Function and Quality of Life in Patients with Chronic Heart Failure: A Randomized Controlled Trial.,"OBJECTIVE To confirm the improvement of cardiac function and quality of life (QOL) in patients with chronic heart failure (CHF) via Chinese medicine (CM) Qishen Taohong Granule (, QTG). METHODS This study was a single-center, prospective, randomized, controlled clinical trial. Seventy-six patients from 27 to 84 years old diagnosed with CHF New York Heart Association (NYHA) class II or III in stage C were enrolled and randomly assigned at a 1:1 ratio to receive QTG or trimetazidine (TMZ), in addition to their standard medications for the treatment of CHF. The study period was 4 weeks. The primary outcomes included cardiac function evaluated by NYHA classification and left ventricular ejection fraction (LVEF), as well as QOL evaluated by CHF Integrated Chinese and Western Medicine Survival Scale (CHFQLS). The secondary outcomes included 6-min walking test (6MWT), CM syndrome score, symptom and sign scores and N-terminal pro-B-type natriuretic peptide (NT-proBNP). All indices were measured at baseline and the end of the trial. RESULTS At the 4-week follow-up period, the effective rate according to NYHA classification in the QTG group was better than that in the TMZ group (74.29% vs. 54.29%, P<0.05). But there was no significant difference in post-treatment level of LVEF between the two groups (P>0.05). The CHFQLS scores improved by 13.82±6.04 vs. 7.49±2.28 in the QTG and TMZ groups, respectively (P<0.05). Subgroup analysis of the CHFQLS results showed that physiological function, role limitation and vitality were significantly higher in the QTG group than in the TMZ group (15.76±7.85 vs. 7.40±3.36, P<0.05; 16.00±8.35 vs. 10.53±4.64, P<0.05; 15.31±8.09 vs. 7.89±4.60, P<0.05). Compared with TMZ group, treatment with QTG also demonstrated superior performance with respect to 6MWT, CM syndrome, shortness of breath, fatigue, gasping, general edema and NT-proBNP level. No significant adverse reactions or adverse cardiac events occurred during treatment in either group. CONCLUSION In addition to conventional treatments, the use of QTG as an adjuvant therapy significantly improved cardiac function and QOL in patients with CHF class II or III in stage C. [Registration No. ChiCTR1900022036 (retrospectively registered)].",2021,"Compared with TMZ group, treatment with QTG also demonstrated superior performance with respect to 6MWT, CM syndrome, shortness of breath, fatigue, gasping, general edema and NT-proBNP level.","['Seventy-six patients from 27 to 84 years old diagnosed with CHF New York Heart Association (NYHA) class II or III in stage C', 'patients with CHF class II or III in stage C', 'Patients with Chronic Heart Failure', 'patients with chronic heart failure (CHF) via Chinese medicine (CM) Qishen Taohong Granule (, QTG']","['TMZ', 'QTG', 'QTG or trimetazidine (TMZ', 'Qishen Taohong Granule () as Adjuvant Therapy', 'QTG and TMZ']","['Cardiac Function and Quality of Life', 'adverse reactions or adverse cardiac events', 'effective rate according to NYHA classification', 'superior performance with respect to 6MWT, CM syndrome, shortness of breath, fatigue, gasping, general edema and NT-proBNP level', 'cardiac function and quality of life (QOL', 'cardiac function evaluated by NYHA classification and left ventricular ejection fraction (LVEF), as well as QOL evaluated by CHF Integrated Chinese and Western Medicine Survival Scale (CHFQLS', 'CHFQLS scores', '6-min walking test (6MWT), CM syndrome score, symptom and sign scores and N-terminal pro-B-type natriuretic peptide (NT-proBNP', 'physiological function, role limitation and vitality', 'cardiac function and QOL']","[{'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441886', 'cui_str': 'Class 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0441785', 'cui_str': 'Stage C'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}]","[{'cui': 'C0041037', 'cui_str': 'Trimetazidine'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}]","[{'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1275491', 'cui_str': 'New York Heart Association Classification'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0425449', 'cui_str': 'Gasping for breath'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}]",76.0,0.0958308,"Compared with TMZ group, treatment with QTG also demonstrated superior performance with respect to 6MWT, CM syndrome, shortness of breath, fatigue, gasping, general edema and NT-proBNP level.","[{'ForeName': 'Xing-Xing', 'Initials': 'XX', 'LastName': 'Li', 'Affiliation': 'Department of Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.'}, {'ForeName': 'Zong-Jing', 'Initials': 'ZJ', 'LastName': 'Fan', 'Affiliation': 'Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Cui', 'Affiliation': 'Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.'}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Lin', 'Affiliation': 'Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Zhuang', 'Affiliation': 'Department of Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.'}, {'ForeName': 'Rong-Kun', 'Initials': 'RK', 'LastName': 'Yan', 'Affiliation': 'Department of Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Lin', 'Affiliation': 'Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China. 15801434320@163.com.'}]",Chinese journal of integrative medicine,['10.1007/s11655-021-2866-z'] 2908,34387740,Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C.,"OBJECTIVE To investigate the safety and efficacy of N-acetyl-L-leucine (NALL) on symptoms, functioning, and quality of life in pediatric (≥ 6 years) and adult Niemann-Pick disease type C (NPC) patients. METHODS In this multi-national, open-label, rater-blinded Phase II study, patients were assessed during a baseline period, a 6-week treatment period (orally administered NALL 4 g/day in patients ≥ 13 years, weight-tiered doses for patients 6-12 years), and a 6-week post-treatment washout period. The primary Clinical Impression of Change in Severity (CI-CS) endpoint (based on a 7-point Likert scale) was assessed by blinded, centralized raters who compared randomized video pairs of each patient performing a pre-defined primary anchor test (8-Meter Walk Test or 9-Hole Peg Test) during each study periods. Secondary outcomes included cerebellar functional rating scales, clinical global impression, and quality of life assessments. RESULTS 33 subjects aged 7-64 years with a confirmed diagnosis of NPC were enrolled. 32 patients were included in the primary modified intention-to-treat analysis. NALL met the CI-CS primary endpoint (mean difference 0.86, SD = 2.52, 90% CI 0.25, 1.75, p = 0.029), as well as secondary endpoints. No treatment-related serious adverse events occurred. CONCLUSIONS NALL demonstrated a statistically significant and clinical meaningfully improvement in symptoms, functioning, and quality of life in 6 weeks, the clinical effect of which was lost after the 6-week washout period. NALL was safe and well-tolerated, informing a favorable benefit-risk profile for the treatment of NPC. CLINICALTRIALS. GOV IDENTIFIER NCT03759639.",2021,"No treatment-related serious adverse events occurred. ","['33 subjects aged 7-64\xa0years with a confirmed diagnosis of NPC were enrolled', 'Niemann-Pick disease type C', '32 patients were included in the primary modified intention-to-treat analysis', 'pediatric (≥\u20096\xa0years) and adult Niemann-Pick disease type C (NPC) patients']","['N-acetyl-L-leucine', 'NALL', 'N-acetyl-L-leucine (NALL']","['Efficacy and safety', 'safe and well-tolerated', 'Change in Severity (CI-CS) endpoint (based on a 7-point Likert scale', 'cerebellar functional rating scales, clinical global impression, and quality of life assessments', 'symptoms, functioning, and quality of life']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0220756', 'cui_str': 'Niemann-Pick disease, type C'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C4547971', 'cui_str': 'N-acetyl-L-leucine'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0163299', 'cui_str': 'A 7'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C0007765', 'cui_str': 'Cerebellar structure'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",32.0,0.141941,"No treatment-related serious adverse events occurred. ","[{'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Bremova-Ertl', 'Affiliation': 'Department of Neurology, University Hospital Bern (Inselspital), 3010, Bern, Switzerland. Tatiana.Bremova-Ertl@insel.ch.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Claassen', 'Affiliation': 'Department of Neurology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Foltan', 'Affiliation': ""Department of Pediatric Neurology, National Institute of Children's Diseases, Comenius University in Bratislva, Bratislva, Slovak Republic.""}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Gascon-Bayarri', 'Affiliation': ""Department of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain.""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Gissen', 'Affiliation': 'NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London, UK.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hahn', 'Affiliation': 'Department of Child Neurology, Justus Liebig University, Giessen, Germany.'}, {'ForeName': 'Anhar', 'Initials': 'A', 'LastName': 'Hassan', 'Affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Hennig', 'Affiliation': 'Department of Neurology, Ludwig Maximilians University, Munich, Germany.'}, {'ForeName': 'Simon A', 'Initials': 'SA', 'LastName': 'Jones', 'Affiliation': ""Willink Unit, Manchester Centre for Genomic Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.""}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Kolnikova', 'Affiliation': ""Department of Pediatric Neurology, National Institute of Children's Diseases, Comenius University in Bratislva, Bratislva, Slovak Republic.""}, {'ForeName': 'Kyriakos', 'Initials': 'K', 'LastName': 'Martakis', 'Affiliation': 'Department of Child Neurology, Justus Liebig University, Giessen, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Raethjen', 'Affiliation': 'Neurology Outpatient Clinic, Kiel, Germany.'}, {'ForeName': 'Uma', 'Initials': 'U', 'LastName': 'Ramaswami', 'Affiliation': 'Lysosomal Storage Disorder Unit, Royal Free London NHS Foundation Trust, London, UK.'}, {'ForeName': 'Reena', 'Initials': 'R', 'LastName': 'Sharma', 'Affiliation': 'Department of Adult Metabolic Medicine, Salford Royal Foundation NHS Trust, Salford, UK.'}, {'ForeName': 'Susanne A', 'Initials': 'SA', 'LastName': 'Schneider', 'Affiliation': 'Department of Neurology, Ludwig Maximilians University, Munich, Germany.'}]",Journal of neurology,['10.1007/s00415-021-10717-0'] 2909,34387692,"Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.",,2021,,['adults with narcolepsy with cataplexy'],"['calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258']",[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0751362', 'cui_str': 'Cataplexy and narcolepsy'}]","[{'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0037537', 'cui_str': 'Sodium Oxybate'}, {'cui': 'C0012169', 'cui_str': 'Low sodium diet'}, {'cui': 'C0673093', 'cui_str': '4-hydroxybutyric acid'}]",[],,0.389058,,"[{'ForeName': 'Richard K', 'Initials': 'RK', 'LastName': 'Bogan', 'Affiliation': 'School of Medicine, University of South Carolina, Columbia, SC, United States.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Thorpy', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, United States.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Dauvilliers', 'Affiliation': 'Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France.'}, {'ForeName': 'Markku', 'Initials': 'M', 'LastName': 'Partinen', 'Affiliation': 'Helsinki Sleep Clinic, Vitalmed Research Center, Helsinki, Finland.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Del Rio Villegas', 'Affiliation': 'Neurophysiology and Sleep Disorders Unit, Hospital Vithas Nuestra Señora de America, Madrid, Spain.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Foldvary-Schaefer', 'Affiliation': 'Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, United States.'}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Skowronski', 'Affiliation': 'Global Clinical Development, Jazz Pharmaceuticals, Inc., Palo Alto, CA, United States.'}, {'ForeName': 'Lihua', 'Initials': 'L', 'LastName': 'Tang', 'Affiliation': 'Biostatistics, Jazz Pharmaceuticals, Inc., Palo Alto, CA, United States.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Skobieranda', 'Affiliation': 'Global Clinical Development, Jazz Pharmaceuticals, Inc., Palo Alto, CA, United States.'}, {'ForeName': 'Karel', 'Initials': 'K', 'LastName': 'Šonka', 'Affiliation': 'Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}]",Sleep,['10.1093/sleep/zsab188'] 2910,34387679,Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial.,"Importance Frontline health care professionals who work with patients with COVID-19 have an increased incidence of burnout symptoms. Cannabidiol (CBD) has anxiolytic and antidepressant properties and may be capable of reducing emotional exhaustion and burnout symptoms. Objective To investigate the safety and efficacy of CBD therapy for the reduction of emotional exhaustion and burnout symptoms among frontline health care professionals working with patients with COVID-19. Design, Setting, and Participants This prospective open-label single-site randomized clinical trial used a 1:1 block randomization design to examine emotional exhaustion and burnout symptoms among frontline health care professionals (physicians, nurses, and physical therapists) working with patients with COVID-19 at the Ribeirão Preto Medical School University Hospital in São Paulo, Brazil. Participants were enrolled between June 12 and November 12, 2020. A total of 214 health care professionals were recruited and assessed for eligibility, and 120 participants were randomized in a 1:1 ratio by a researcher who was not directly involved with data collection. Interventions Cannabidiol, 300 mg (150 mg twice per day), plus standard care or standard care alone for 28 days. Main Outcomes and Measures The primary outcome was emotional exhaustion and burnout symptoms, which were assessed for 28 days using the emotional exhaustion subscale of the Brazilian version of the Maslach Burnout Inventory-Human Services Survey for Medical Personnel. Results A total of 120 participants were randomized to receive either CBD, 300 mg, plus standard care (treatment arm; n = 61) or standard care alone (control arm; n = 59) for 28 days. Of those, 118 participants (59 participants in each arm; 79 women [66.9%]; mean age, 33.6 years [95% CI, 32.3-34.9 years]) received the intervention and were included in the efficacy analysis. In the treatment arm, scores on the emotional exhaustion subscale of the Maslach Burnout Inventory significantly decreased at day 14 (mean difference, 4.14 points; 95% CI, 1.47-6.80 points; partial eta squared [ηp2] = 0.08), day 21 (mean difference, 4.34 points; 95% CI, 0.94-7.73 points; ηp2 = 0.05), and day 28 (mean difference, 4.01 points; 95% CI, 0.43-7.59 points; ηp2 = 0.04). However, 5 participants, all of whom were in the treatment group, experienced serious adverse events: 4 cases of elevated liver enzymes (1 critical and 3 mild, with the mild elevations reported at the final 28-day assessment) and 1 case of severe pharmacodermia. In 2 of those cases (1 with critical elevation of liver enzymes and 1 with severe pharmacodermia), CBD therapy was discontinued, and the participants had a full recovery. Conclusions and Relevance In this study, CBD therapy reduced symptoms of burnout and emotional exhaustion among health care professionals working with patients during the COVID-19 pandemic. However, it is necessary to balance the benefits of CBD therapy with potential undesired or adverse effects. Future double-blind placebo-controlled clinical trials are needed to confirm the present findings. Trial Registration ClinicalTrials.gov Identifier: NCT04504877.",2021,"In the treatment arm, scores on the emotional exhaustion subscale of the Maslach Burnout Inventory significantly decreased at day 14 (mean difference, 4.14 points; 95% CI, 1.47-6.80 points; partial eta squared [ηp2] = 0.08), day 21 (mean difference, 4.34 points; 95% CI, 0.94-7.73 points; ηp2 = 0.05), and day 28 (mean difference, 4.01 points; 95% CI, 0.43-7.59 points; ηp2 = 0.04).","['frontline health care professionals working with patients with COVID-19', 'A total of 214 health care professionals were recruited and assessed for eligibility, and 120 participants were randomized in a 1:1 ratio by a researcher who was not directly involved with data collection', '120 participants', 'Participants were enrolled between June 12 and November 12, 2020', 'Frontline Health Care Workers During the COVID-19 Pandemic', '118 participants (59 participants in each arm; 79 women [66.9%]; mean age, 33.6 years [95% CI, 32.3-34.9 years', 'frontline health care professionals (physicians, nurses, and physical therapists) working with patients with COVID-19 at the Ribeirão Preto Medical School University Hospital in São Paulo, Brazil']","['plus standard care or standard care alone for 28 days', 'CBD therapy', 'Cannabidiol (CBD', 'CBD, 300 mg, plus standard care (treatment arm; n\u2009=\u200961) or standard care alone', 'placebo', 'Cannabidiol Plus Standard Care vs Standard Care Alone']","['Efficacy and Safety', 'symptoms of burnout and emotional exhaustion', 'serious adverse events', 'emotional exhaustion and burnout symptoms', 'emotional exhaustion subscale of the Maslach Burnout Inventory', 'emotional exhaustion subscale of the Brazilian version of the Maslach Burnout Inventory-Human Services Survey for Medical Personnel']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0036378', 'cui_str': 'Medical School'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]",120.0,0.412823,"In the treatment arm, scores on the emotional exhaustion subscale of the Maslach Burnout Inventory significantly decreased at day 14 (mean difference, 4.14 points; 95% CI, 1.47-6.80 points; partial eta squared [ηp2] = 0.08), day 21 (mean difference, 4.34 points; 95% CI, 0.94-7.73 points; ηp2 = 0.05), and day 28 (mean difference, 4.01 points; 95% CI, 0.43-7.59 points; ηp2 = 0.04).","[{'ForeName': 'José Alexandre S', 'Initials': 'JAS', 'LastName': 'Crippa', 'Affiliation': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Antonio W', 'Initials': 'AW', 'LastName': 'Zuardi', 'Affiliation': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Francisco S', 'Initials': 'FS', 'LastName': 'Guimarães', 'Affiliation': 'National Institute for Science and Technology-Translational Medicine, São Paulo, Brazil.'}, {'ForeName': 'Alline Cristina', 'Initials': 'AC', 'LastName': 'Campos', 'Affiliation': 'Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Flávia', 'Initials': 'F', 'LastName': 'de Lima Osório', 'Affiliation': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Sonia Regina', 'Initials': 'SR', 'LastName': 'Loureiro', 'Affiliation': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Rafael G', 'Initials': 'RG', 'LastName': 'Dos Santos', 'Affiliation': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'José Diogo S', 'Initials': 'JDS', 'LastName': 'Souza', 'Affiliation': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Juliana Mayumi', 'Initials': 'JM', 'LastName': 'Ushirohira', 'Affiliation': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Julia Cozar', 'Initials': 'JC', 'LastName': 'Pacheco', 'Affiliation': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Rafael Rinaldi', 'Initials': 'RR', 'LastName': 'Ferreira', 'Affiliation': 'Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Karla Cristinne', 'Initials': 'KC', 'LastName': 'Mancini Costa', 'Affiliation': 'Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Davi Silveira', 'Initials': 'DS', 'LastName': 'Scomparin', 'Affiliation': 'Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Franciele Franco', 'Initials': 'FF', 'LastName': 'Scarante', 'Affiliation': 'Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Isabela', 'Initials': 'I', 'LastName': 'Pires-Dos-Santos', 'Affiliation': 'Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Mechoulam', 'Affiliation': 'Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel.'}, {'ForeName': 'Flávio', 'Initials': 'F', 'LastName': 'Kapczinski', 'Affiliation': 'National Institute for Science and Technology-Translational Medicine, São Paulo, Brazil.'}, {'ForeName': 'Benedito A L', 'Initials': 'BAL', 'LastName': 'Fonseca', 'Affiliation': 'Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Danillo L A', 'Initials': 'DLA', 'LastName': 'Esposito', 'Affiliation': 'Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'Pereira-Lima', 'Affiliation': 'Department of Psychiatry, University of Michigan Medical School, Ann Arbor.'}, {'ForeName': 'Srijan', 'Initials': 'S', 'LastName': 'Sen', 'Affiliation': 'Department of Psychiatry, University of Michigan Medical School, Ann Arbor.'}, {'ForeName': 'Maristela Haddad', 'Initials': 'MH', 'LastName': 'Andraus', 'Affiliation': 'Chromatox Laboratory, São Paulo, Brazil.'}, {'ForeName': 'Jaime E C', 'Initials': 'JEC', 'LastName': 'Hallak', 'Affiliation': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA network open,['10.1001/jamanetworkopen.2021.20603'] 2911,34387678,Midcareer Medical School Research Faculty Perspectives on Vitality and Professionalism During the COVID-19 Pandemic.,"Importance As medical faculty have central roles during the COVID-19 pandemic, it is important to study the pandemic's association with the vitality and careers of medical school faculty. Objective To examine how the COVID-19 pandemic affected midcareer research faculty in academic medicine. Design, Setting, and Participants This qualitative study included medical school faculty who participated in the C-Change Mentoring and Leadership Institute. All US medical school faculty recipients of recent National Institutes of Health (NIH) RO1, RO1-equivalent, and K awards were invited to apply to the institute. The 99 applicants who met inclusion criteria were stratified by degree (MD or MD/PhD vs PhD), gender, and race/ethnicity. Enrollment was offered to applicants randomly selected for 40 spots, demographically balanced by sex, underrepresented in medicine minority (URMM) status, and degree. In April 2020, an inquiry was emailed to faculty enrolled in the institute requesting responses to questions about meaning in work, career choice, and values. A qualitative analysis of narrative data responses, using grounded theory, was undertaken to determine key themes. This study is part of a NIH-funded randomized trial to test the efficacy of a group peer mentoring course for midcareer faculty and study the course's mechanisms of action. Main Outcomes and Measures Key themes in data. Results Of 40 enrolled participants, 39 responded to the inquiry, for a response rate of 97%. The analytic sample included 39 faculty members; 19 (47%) were women, 20 (53%) identified as URMM, and 20 (53%) had an MD or MD with PhD vs 19 (47%) with PhD degrees. Key themes in the data that emerged describing faculty lived experience of the pandemic included increased meaningfulness of work; professionalism and moral responsibility; enhanced relationships with colleagues; reassertion of career choice; disrupted research; impact on clinical work; attention to health disparities, social justice and advocacy; increased family responsibilities; psychological stress; and focus on leadership. Conclusions and Relevance During the pandemic, diverse PhD and physician investigators reported increased meaningfulness in work and professionalism and enhanced relationships, all intrinsic motivators associated with vitality. Working during the pandemic appears to have produced intrinsic rewards positively associated with vitality, in addition to adverse mental health effects. These findings have implications for combatting burnout and retaining investigators in the future.",2021,"Working during the pandemic appears to have produced intrinsic rewards positively associated with vitality, in addition to adverse mental health effects.","['medical school faculty recipients of recent National Institutes of Health (NIH) RO1, RO1-equivalent, and K awards', '39 faculty members; 19 (47%) were women, 20 (53%) identified as URMM, and 20 (53%) had an MD or MD with PhD vs 19 (47%) with PhD degrees', 'Participants\n\n\nThis qualitative study included medical school faculty who participated in the C-Change Mentoring and Leadership Institute', '40 enrolled participants', '99 applicants who met inclusion criteria were stratified by degree (MD or MD/PhD vs PhD), gender, and race/ethnicity']",[],[],"[{'cui': 'C0036378', 'cui_str': 'Medical School'}, {'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0004446', 'cui_str': 'Awards'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C1739685', 'cui_str': 'PDC protein, human'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0949415', 'cui_str': 'Qualitative Research'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0023181', 'cui_str': 'Leadership'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}]",[],[],40.0,0.138937,"Working during the pandemic appears to have produced intrinsic rewards positively associated with vitality, in addition to adverse mental health effects.","[{'ForeName': 'Linda H', 'Initials': 'LH', 'LastName': 'Pololi', 'Affiliation': 'National Initiative on Gender, Culture and Leadership in Medicine: C-Change, Brandeis University, Waltham, Massachusetts.'}, {'ForeName': 'Vasilia', 'Initials': 'V', 'LastName': 'Vasiliou', 'Affiliation': 'School of Management, Clark University, Worcester, Massachusetts.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Bloom-Feshbach', 'Affiliation': 'Medicine, Section of Hospital Medicine, Division of General Internal Medicine, Weill Cornell Medicine, New York, New York.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.20642'] 2912,34387558,A Casual Video Game With Psychological Well-being Concepts for Young Adolescents: Protocol for an Acceptability and Feasibility Study.,"BACKGROUND Many face-to-face and digital therapeutic supports are designed for adolescents experiencing high levels of psychological distress. However, promoting psychological well-being among adolescents is often neglected despite significant short-term and long-term benefits. OBJECTIVE This research has 3 main objectives: (1) to assess the acceptability of Match Emoji, a casual video game with psychological well-being concepts among 13-15-year-old students in a New Zealand secondary school; (2) to identify the feasibility of the research process; and (3) to explore the preliminary well-being and therapeutic potential of Match Emoji. METHODS Approximately 40 participants aged 13-15 years from a local secondary college in Wellington, New Zealand, will be invited to download and play Match Emoji 3-4 times a week for 5-15 minutes over a 2-week period. Participants will complete 4 assessments at baseline, postintervention, and 3 weeks later to assess psychological well-being and therapeutic changes. Statistical analysis will be used to synthesize data from interviews and triangulated with assessment changes and game analytics. This synthesis will help to assess the acceptability and feasibility of the Match Emoji. RESULTS The key outputs from the project will include the acceptability, feasibility, and therapeutic potential of Match Emoji. It is anticipated that participants will have finished playing the recommended game play regimen by August 2021 with analysis of results completed by October 2021. CONCLUSIONS Data from the study are expected to inform future research on Match Emoji including a randomized controlled trial and further adjustments to the design and development of the game. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/31588.",2021,"Approximately 40 participants aged 13-15 years from a local secondary college in Wellington, New Zealand, will be invited to download and play Match Emoji 3-4 times a week for 5-15 minutes over a 2-week period.","['adolescents experiencing high levels of psychological distress', 'Approximately 40 participants aged 13-15 years from a local secondary college in Wellington, New Zealand', 'Young Adolescents', '13-15-year-old students in a New Zealand secondary school; (2']",['Casual Video Game With Psychological'],['psychological well-being and therapeutic changes'],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0453965', 'cui_str': 'Gum boots'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}]","[{'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}]","[{'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.190532,"Approximately 40 participants aged 13-15 years from a local secondary college in Wellington, New Zealand, will be invited to download and play Match Emoji 3-4 times a week for 5-15 minutes over a 2-week period.","[{'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Pine', 'Affiliation': 'School of Health, Victoria University of Wellington, Wellington, New Zealand.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Mbinta', 'Affiliation': 'School of Health, Victoria University of Wellington, Wellington, New Zealand.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Te Morenga', 'Affiliation': 'Research Centre for Hauora and Health, Massey University, Wellington, New Zealand.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Fleming', 'Affiliation': 'School of Health, Victoria University of Wellington, Wellington, New Zealand.'}]",JMIR research protocols,['10.2196/31588'] 2913,34387223,"Supramaximal Interval Running Prescription in Australian Rules Football Players: A Comparison Between Maximal Aerobic Speed, Anaerobic Speed Reserve, and the 30-15 Intermittent Fitness Test.","ABSTRACT Collison, J, Debenedictis, T, Fuller, JT, Gerschwitz, R, Ling, T, Gotch, L, Bishop, B, Sibley, L, Russell, J, Hobbs, A, and Bellenger, CR. Supramaximal interval running prescription in Australian Rules Football players: A comparison between maximal aerobic speed, anaerobic speed reserve and the 30-15 intermittent fitness test. J Strength Cond Res XX(X): 000-000, 2021-Accurate prescription of supramaximal interval running during Australian Rules Football (AF) preparatory periods is important to facilitate the specific targeting of physiological and neuromuscular adaptation. This study compared the variability in supramaximal interval running performance prescribed by proportion of maximal aerobic speed (MAS), anaerobic speed reserve (ASR), and 30-15 intermittent fitness test (30-15IFT) terminal speed. Seventeen male junior AF players first completed assessments of MAS, ASR, and 30-15IFT in a randomized order. They subsequently performed supramaximal interval running trials (15 seconds on: 15 seconds off until volitional exhaustion) at 120% MAS, 20% ASR, and 95% 30-15IFT in a randomized order. Variability in time to exhaustion (TTE) for each prescription method was calculated as the mean of the square root of the squared difference between the individual value and the mean value, and it was compared via repeated-measures analysis of variance with statistical significance set at p ≤ 0.05. Time to exhaustion during supramaximal interval running was not different between the prescription methods (p = 0.58). Time to exhaustion residuals were reduced when prescribed by ASR compared with MAS (standardized mean difference [SMD] = -0.47; 29%); however, confidence intervals about this reduction indicated that there was some uncertainty in this finding (SMD = -1.03 to 0.09; p = 0.09). Trivial differences in TTE residuals were present when prescribed by 30-15IFT compared with MAS (SMD = -0.05 ± 0.59; p = 0.86). Although there was some uncertainty about the reduction in supramaximal interval running performance variability when prescribed by ASR compared with MAS, the 29% reduction exceeds the inherent error in TTE efforts (i.e., ∼9-15%) and may thus be considered practically meaningful. Reducing supramaximal interval running performance variability ensures similar physiological demand across individuals, potentially facilitating similar degrees of physiological adaptation.",2021,Time to exhaustion during supramaximal interval running was not different between the prescription methods (p = 0.58).,"['Australian Rules Football players', 'Australian Rules Football Players', 'Seventeen male junior AF players']","['Supramaximal interval running prescription', 'J Strength Cond Res XX(X', 'supramaximal interval running during Australian Rules Football (AF) preparatory periods', 'Supramaximal Interval Running Prescription']","['Variability in time to exhaustion (TTE', 'supramaximal interval running performance variability', 'Time to exhaustion during supramaximal interval running', 'Time to exhaustion residuals', 'maximal aerobic speed (MAS), anaerobic speed reserve (ASR']","[{'cui': 'C1531722', 'cui_str': 'Australian rules football'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C1531722', 'cui_str': 'Australian rules football'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}]",17.0,0.14899,Time to exhaustion during supramaximal interval running was not different between the prescription methods (p = 0.58).,"[{'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Collison', 'Affiliation': 'North Adelaide Football Club, Adelaide, Australia; South Australian National Football League, Adelaide, Australia; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia; and Alliance for Research in Exercise, Nutrition and Activity (ARENA), Allied Health and Human Performance Unit, University of South Australia, Adelaide, Australia.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Debenedictis', 'Affiliation': ''}, {'ForeName': 'Joel T', 'Initials': 'JT', 'LastName': 'Fuller', 'Affiliation': ''}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Gerschwitz', 'Affiliation': ''}, {'ForeName': 'Tayla', 'Initials': 'T', 'LastName': 'Ling', 'Affiliation': ''}, {'ForeName': 'Lochlan', 'Initials': 'L', 'LastName': 'Gotch', 'Affiliation': ''}, {'ForeName': 'Brenden', 'Initials': 'B', 'LastName': 'Bishop', 'Affiliation': ''}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Sibley', 'Affiliation': ''}, {'ForeName': 'Jed', 'Initials': 'J', 'LastName': 'Russell', 'Affiliation': ''}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Hobbs', 'Affiliation': ''}, {'ForeName': 'Clint R', 'Initials': 'CR', 'LastName': 'Bellenger', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000004103'] 2914,34387216,The Effect of Facilitated Tucking on the Pain Intensity Induced by Chest Tube Removal in Infants.,"BACKGROUND Removal of a chest tube is a painful procedure for infants. Medications, including narcotics, are used to control pain, but nonpharmacologic interventions are also effective in reducing pain during this procedure and are not associated with adverse effects. PURPOSE To evaluate the additive effect of facilitated tucking to the use of morphine on infant pain associated at the time of chest tube removal. METHODS This was a prospective, randomized control study. Sixty infants were randomized into 2 equal groups utilizing a coin flip. All infants received 0.05-mg/kg morphine 20 minutes before chest tube removal. The intervention group received facilitated tucking and the control group received standard care. Infant pain was measured using the Neonatal Infant Pain Scale. Pain was assessed at 3 time points by 2 independent evaluators: 5 minutes before, during, and 5 minutes after removal of the chest tube. Mann-Whitney and Fisher's exact (Chi-square) tests were used to compare the intervention and control groups. RESULTS Pain scores were increased during chest tube removal for both the intervention and the control groups. Compared with the control group, pain scores for infants in the intervention group were less before, during, and after chest tube removal. IMPLICATIONS FOR PRACTICE Facilitated tucking combined with morphine administration can be an effective additive intervention for pain control in infants during chest tube removal. IMPLICATIONS FOR RESEARCH Evaluate the effect of the facilitated tucking on pain induced by chest tube removal in preterm infants. Preterm infants may respond differently to pain.",2021,"Compared with the control group, pain scores for infants in the intervention group were less before, during, and after chest tube removal. ","['preterm infants', 'Sixty infants', 'infants during chest tube removal', 'Preterm infants', 'infants', 'Infants']","['facilitated tucking and the control group received standard care', 'Facilitated Tucking', 'morphine']","['Pain', 'Pain scores', 'Neonatal Infant Pain Scale', 'Pain Intensity', 'Infant pain', 'pain scores']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C2224175', 'cui_str': 'Chest tube removal'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",60.0,0.00487059,"Compared with the control group, pain scores for infants in the intervention group were less before, during, and after chest tube removal. ","[{'ForeName': 'Batool', 'Initials': 'B', 'LastName': 'Pouraboli', 'Affiliation': ""School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran (Drs Pouraboli and Mirlashari); Department of OBGYN, Women's Health Research Institute, University of British Colombia, Vancouver, Canada (Dr Mirlashari); School of Public Health and Paraclinics, Qazvin University of Medical Sciences, Qazvin, Iran (Ms Safaiee Fakhr); Research Center for Mental Health, Iran University of Medical Sciences, Tehran, Iran (Dr Ranjbar); and Department of Pediatric and Neonatal Nursing, Tehran University of Medical Sciences, Tehran, Iran (Ms Ashtari).""}, {'ForeName': 'Jila', 'Initials': 'J', 'LastName': 'Mirlashari', 'Affiliation': ''}, {'ForeName': 'Aida Safaiee', 'Initials': 'AS', 'LastName': 'Fakhr', 'Affiliation': ''}, {'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Ranjbar', 'Affiliation': ''}, {'ForeName': 'Somayeh', 'Initials': 'S', 'LastName': 'Ashtari', 'Affiliation': ''}]",Advances in neonatal care : official journal of the National Association of Neonatal Nurses,['10.1097/ANC.0000000000000936'] 2915,34387126,Pacemaker-Based Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study.,"Background In prior unblinded studies, cardiac neuromodulation therapy (CNT) employing a sequence of variably timed short and longer atrioventricular intervals yielded sustained reductions of systolic blood pressure (SBP) in patients with hypertension. The effects of CNT on SBP were investigated in this double-blind randomized pilot study. Methods and Results Eligible patients had daytime ambulatory SBP (aSBP) ≥130 mm Hg and office SBP ≥140 mm Hg despite taking ≥1 antihypertensive medication, and an indication for a dual-chamber pacemaker. Patients underwent Moderato device implantation, which was programmed as a standard pacemaker during a 1-month run-in phase. Patients whose daytime aSBP was ≥125 mm Hg at the end of this period were randomized (1:1, double blind) to treatment (CNT) or control (CNT inactive). The primary efficacy end point was the between-group difference of the change in 24-hour aSBP at 6 months. Of 68 patients initially enrolled and who underwent implantation with the Moderato system, 47 met criteria for study continuation and were randomized (26 treatment, 21 control). The mean age was 74.0±8.7 years, 64% were men, left ventricular ejection fraction was 59.2%±5.7%, and aSBP averaged 141.0±10.8 mm Hg despite the use of 3.3±1.5 antihypertensive medications; 81% had isolated systolic hypertension. Six months after randomization, aSBP was 11.1±10.5 mm Hg (95% CI, -15.2 to -8.1 mm Hg) lower than prerandomization in the treatment group compared with 3.1±9.5 mm Hg (-7.4 to 1.2 mm Hg) lower in controls, yielding a net treatment effect of 8.1±10.1 mm Hg (-14.2 to -1.9 mm Hg) ( P =0.012). There were no Moderato device- or CNT-related adverse events. Conclusions CNT significantly reduced 24-hour aSBP in patients with hypertension with a clinical indication for a pacemaker. The majority of patients had isolated systolic hypertension, a particularly difficult group of patients to treat. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02837445.",2021,There were no Moderato device- or CNT-related adverse events.,"['patients with hypertension with a clinical indication for a pacemaker', 'patients with hypertension', '68 patients initially enrolled and who underwent implantation with the Moderato system, 47 met criteria for study continuation and were randomized (26 treatment, 21 control', 'Eligible patients had daytime ambulatory SBP (aSBP) ≥130\xa0mm', 'Patients With Hypertension']","['Moderato device implantation', 'CNT', 'cardiac neuromodulation therapy (CNT', 'treatment (CNT) or control (CNT inactive', 'Pacemaker-Based Cardiac Neuromodulation Therapy']","['daytime aSBP', 'Moderato device- or CNT-related adverse events', '24-hour aSBP', 'aSBP', 'left ventricular ejection fraction', 'systolic blood pressure (SBP', 'isolated systolic hypertension']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0030163', 'cui_str': 'Cardiac pacemaker'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0394674', 'cui_str': 'Neurostimulation/modulation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0030163', 'cui_str': 'Cardiac pacemaker'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0394674', 'cui_str': 'Neurostimulation/modulation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0745133', 'cui_str': 'Isolated systolic hypertension'}]",,0.165916,There were no Moderato device- or CNT-related adverse events.,"[{'ForeName': 'Zbigniew', 'Initials': 'Z', 'LastName': 'Kalarus', 'Affiliation': 'Department of Cardiology DMS in ZabrzeMedical University of Silesia Katowice Poland.'}, {'ForeName': 'Béla', 'Initials': 'B', 'LastName': 'Merkely', 'Affiliation': 'Heart and Vascular Center Semmelweis University Budapest Hungary.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Neužil', 'Affiliation': 'Department of Cardiology Na Homolce Hospital Prague Czech Republic.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Grabowski', 'Affiliation': '1st Chair and Department of Cardiology Medical University of Warsaw Poland.'}, {'ForeName': 'Przemysław', 'Initials': 'P', 'LastName': 'Mitkowski', 'Affiliation': '1st Department of Cardiology Karol Marcinkowski University of Medical Sciences Poznań Poland.'}, {'ForeName': 'Germanas', 'Initials': 'G', 'LastName': 'Marinskis', 'Affiliation': 'Department of Cardiovascular Diseases Centre for Cardiology and Angiology Vilnius University Vilnius Lithuania.'}, {'ForeName': 'Andrejs', 'Initials': 'A', 'LastName': 'Erglis', 'Affiliation': 'Pauls Stradins Clinical University Hospital University of Latvia Riga Latvia.'}, {'ForeName': 'Jarosław', 'Initials': 'J', 'LastName': 'Kaźmierczak', 'Affiliation': 'Department of Cardiology Pomeranian Medical University Szczecin Poland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Sturmberger', 'Affiliation': 'Interne 2 - Kardiologie, Angiologie & Interne Intensivmedizin Ordensklinikum Linz GmbH Elisabethinen Linz Austria.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Sokal', 'Affiliation': 'Department of Cardiology DMS in ZabrzeMedical University of Silesia Katowice Poland.'}, {'ForeName': 'Slawomir', 'Initials': 'S', 'LastName': 'Pluta', 'Affiliation': 'Department of Cardiology DMS in ZabrzeMedical University of Silesia Katowice Poland.'}, {'ForeName': 'László', 'Initials': 'L', 'LastName': 'Gellér', 'Affiliation': 'Heart and Vascular Center Semmelweis University Budapest Hungary.'}, {'ForeName': 'István', 'Initials': 'I', 'LastName': 'Osztheimer', 'Affiliation': 'Heart and Vascular Center Semmelweis University Budapest Hungary.'}, {'ForeName': 'Filip', 'Initials': 'F', 'LastName': 'Malek', 'Affiliation': 'Department of Cardiology Na Homolce Hospital Prague Czech Republic.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Kolodzińska', 'Affiliation': '1st Chair and Department of Cardiology Medical University of Warsaw Poland.'}, {'ForeName': 'Yuval', 'Initials': 'Y', 'LastName': 'Mika', 'Affiliation': 'Orchestra Biomed New York NY.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Evans', 'Affiliation': 'Orchestra Biomed New York NY.'}, {'ForeName': 'Harold M', 'Initials': 'HM', 'LastName': 'Hastings', 'Affiliation': ""Division of Science, Mathematics and Computing Bard College at Simon's Rock Great Barrington MA.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Burkhoff', 'Affiliation': 'Cardiovascular Research Foundation New York NY.'}, {'ForeName': 'Karl-Heinz', 'Initials': 'KH', 'LastName': 'Kuck', 'Affiliation': 'LANS Cardio Hamburg Germany.'}]",Journal of the American Heart Association,['10.1161/JAHA.120.020492'] 2916,34387557,"A Technological-Based Platform for Risk Assessment, Detection, and Prevention of Falls Among Home-Dwelling Older Adults: Protocol for a Quasi-Experimental Study.","BACKGROUND According to the United Nations, it is estimated that by 2050, the number of people aged 80 years and older will have increased by 3 times. Increased longevity is often accompanied by structural and functional changes that occur throughout an individual's lifespan. These changes are often aggravated by chronic comorbidities, adopted behaviors or lifestyles, and environmental exposure, among other factors. Some of the related outcomes are loss of muscle strength, decreased balance control, and mobility impairments, which are strongly associated with the occurrence of falls in the elderly. Despite the continued undervaluation of the importance of knowledge on fall prevention among the elderly population by primary care health professionals, several evidence-based (single or multifaceted) fall prevention programs such as the Otago Exercise Program (OEP) have demonstrated a significant reduction in the risk of falls and fall-related injuries in the elderly within community settings. Recent studies have strived to integrate technology into physical exercise programs, which is effective for adherence and overcoming barriers to exercise, as well as improving physical functioning. OBJECTIVE This study aims to assess the impact of the OEP on the functionality of home-dwelling elderly using a common technological platform. Particularly, the impact on muscle strength, balance, mobility, risk of falling, the perception of fear of falling, and the perception of the elderly regarding the ease of use of technology are being examined in this study. METHODS A quasi-experimental study (before and after; single group) will be conducted with male and female participants aged 65 years or older living at home in the district of Porto. Participants will be recruited through the network COLABORAR, with a minimum of 30 participants meeting the study inclusion and exclusion criteria. All participants will sign informed consent forms. The data collection instrument consists of sociodemographic and clinical variables (self-reported), functional evaluation variables, and environmental risk variables. The data collection tool integrates primary and secondary outcome variables. The primary outcome is gait (timed-up and go test; normal step). The secondary outcome variables are lower limb strength and muscle resistance (30-second chair stand test), balance (4-stage balance test), frequency of falls, functional capacity (Lawton and Brody - Portuguese version), fear of falling (Falls Efficacy Scale International - Portuguese version), usability of the technology (System Usability Scale - Portuguese version), and environmental risk variables (home fall prevention checklist for older adults). Technological solutions, such as the FallSensing Home application and Kallisto wearable device, will be used, which will allow the detection and prevention of falls. The intervention is characterized by conducting the OEP through a common technological platform 3 times a week for 8 weeks. Throughout these weeks, the participants will be followed up in person or by telephone contact by the rehabilitation nurse. Considering the COVID-19 outbreak, all guidelines from the National Health Service will be followed. The project was funded by InnoStars, in collaboration with the Local EIT Health Regional Innovation Scheme Hub of the University of Porto. RESULTS This study was approved on October 9, 2020 by the Ethics Committee of Escola Superior de Enfermagem do Porto (ESEP). The recruitment process was meant to start in October, but due to the COVID-19 pandemic, it was suspended. We expect to restart the study by the beginning of the third quarter of 2021. CONCLUSIONS The findings of this study protocol will contribute to the design and development of future robust studies for technological tests in a clinical context. TRIAL REGISTRATION ISRCTN 15895163; https://www.isrctn.com/ISRCTN15895163. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/25781.",2021,"Despite the continued undervaluation of the importance of knowledge on fall prevention among the elderly population by primary care health professionals, several evidence-based (single or multifaceted) fall prevention programs such as the Otago Exercise Program (OEP) have demonstrated a significant reduction in the risk of falls and fall-related injuries in the elderly within community settings.","['home-dwelling elderly', 'October 9, 2020 by the Ethics Committee of Escola Superior de Enfermagem do Porto (ESEP', 'male and female participants aged 65 years or older living at home in the district of Porto', 'Participants will be recruited through the network COLABORAR, with a minimum of 30 participants meeting the study inclusion and exclusion criteria', 'Home-Dwelling Older Adults']",['OEP'],"['gait (timed-up and go test; normal step', 'muscle strength, balance, mobility, risk of falling, the perception of fear of falling, and the perception of the elderly regarding the ease of use of technology', 'lower limb strength and muscle resistance (30-second chair stand test), balance (4-stage balance test), frequency of falls, functional capacity (Lawton and Brody - Portuguese version), fear of falling (Falls Efficacy Scale International - Portuguese version), usability of the technology (System Usability Scale - Portuguese version), and environmental risk variables (home fall prevention checklist for older adults']","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0085546', 'cui_str': 'Ethics Committees'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0877040', 'cui_str': 'Fear of falling'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0032730', 'cui_str': 'Portuguese'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}]",,0.0626562,"Despite the continued undervaluation of the importance of knowledge on fall prevention among the elderly population by primary care health professionals, several evidence-based (single or multifaceted) fall prevention programs such as the Otago Exercise Program (OEP) have demonstrated a significant reduction in the risk of falls and fall-related injuries in the elderly within community settings.","[{'ForeName': 'Fátima', 'Initials': 'F', 'LastName': 'Araújo', 'Affiliation': 'Escola Superior de Enfermagem do Porto (ESEP), Inovação e Desenvolvimento em Enfermagem, Centro de Investigação em Tecnologias e Serviços de Saúde, Porto, Portugal.'}, {'ForeName': 'Maria Nilza', 'Initials': 'MN', 'LastName': 'Nogueira', 'Affiliation': 'Escola Superior de Enfermagem do Porto (ESEP), Inovação e Desenvolvimento em Enfermagem, Centro de Investigação em Tecnologias e Serviços de Saúde, Porto, Portugal.'}, {'ForeName': 'Joana', 'Initials': 'J', 'LastName': 'Silva', 'Affiliation': 'Fraunhofer Portugal Research, Center for Assistive Information and Communication Solutions, Porto, Portugal.'}, {'ForeName': 'Sílvia', 'Initials': 'S', 'LastName': 'Rego', 'Affiliation': 'Fraunhofer Portugal Research, Center for Assistive Information and Communication Solutions, Porto, Portugal.'}]",JMIR research protocols,['10.2196/25781'] 2917,34387527,Fractional Erbium:YAG Laser (2940 nm) plus Topical Hydroquinone Compared to Intradermal Tranexamic Acid plus Topical Hydroquinone for the Treatment of Refractory Melasma: A Randomized Controlled Trial.,"OBJECTIVES Melasma is a chronic acquired condition characterized by grayish-brown macules and patches with a distinct border on the face. Although various treatments methods have been suggested for treating melasma, none has been completely successful. The aim of the study was to compare the efficiency of erbium: yttrium-aluminum-garnet (Er:YAG) laser and 4% hydroquinone (HQ) with the effects of intradermal tranexamic acid (TA) and 4% HQ for the treatment of refractory melasma. METHODS The study included 31 female patients with refractory melasma. The left or right side of the patient's face was chosen randomly to receive laser therapy with topical HQ on the one side (i.e., the laser side) and intradermal injection of TA plus topical HQ on the other side (i.e., the mesotherapy side). Digital photography was performed at baseline, at the end of the treatment, and three months after the treatment as follow-up. Two independent dermatologists evaluated the modified Melasma Area and Severity Index (mMASI) score according to the pictures. Overall, 27 patients completed the study and went through the clinical evaluation. RESULTS Treatment using HQ in combination with either Er:YAG laser therapy or intradermal injection of TA significantly improved the hemi-mMASI and resulted in higher patient satisfaction. While the improvement was not significantly different between the two regiments after the treatment and upon follow up and both were equally efficient in the treatment of refractory melasma (p = 1.308), recurrence rate was higher after treatment with Er:YAG laser than TA (12% vs 34%). CONCLUSION This study confirmed the comparable efficacy of TA plus topical HQ versus Er:YAG laser plus topical HQ for the treatment of refractory melasma. Both groups improved significantly and no subject left the treatment because of adverse effects.",2021,"While the improvement was not significantly different between the two regiments after the treatment and upon follow up and both were equally efficient in the treatment of refractory melasma (p = 1.308), recurrence rate was higher after treatment with Er:YAG laser than TA (12% vs 34%). ","['Refractory Melasma', 'refractory melasma', '27 patients completed the study and went through the clinical evaluation', '31 female patients with refractory melasma']","['Intradermal Tranexamic Acid plus Topical Hydroquinone', 'erbium: yttrium-aluminum-garnet (Er:YAG) laser and 4% hydroquinone (HQ', 'Fractional Erbium:YAG Laser (2940\u2009nm) plus Topical Hydroquinone', 'intradermal tranexamic acid (TA) and 4% HQ', 'TA plus topical HQ versus Er:YAG laser plus topical HQ', 'TA plus topical HQ', 'laser therapy with topical HQ']","['modified Melasma Area and Severity Index (mMASI) score', 'refractory melasma', 'adverse effects', 'recurrence rate', 'hemi-mMASI']","[{'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1522475', 'cui_str': 'Intradermal route'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0020306', 'cui_str': 'hydroquinone'}, {'cui': 'C0014688', 'cui_str': 'Erbium'}, {'cui': 'C1609285', 'cui_str': 'yttrium-aluminum-garnet'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0587723', 'cui_str': 'YAG - laser'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C1285521', 'cui_str': 'Hemi'}]",31.0,0.0580951,"While the improvement was not significantly different between the two regiments after the treatment and upon follow up and both were equally efficient in the treatment of refractory melasma (p = 1.308), recurrence rate was higher after treatment with Er:YAG laser than TA (12% vs 34%). ","[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Mokhtari', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Bahareh', 'Initials': 'B', 'LastName': 'Bahrami', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Gita', 'Initials': 'G', 'LastName': 'Faghihi', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Asilian', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Iraji', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",The Journal of dermatological treatment,['10.1080/09546634.2021.1968996'] 2918,34387520,A Randomized Double-Blind Placebo-Controlled Trial Evaluating the Efficacy of Oral Cholecalciferol in Improving Renal and Vascular Functions in Vitamin D-Deficient Patients With Type 2 Diabetes Mellitus.,"This study was performed to evaluate the efficacy of cholecalciferol in improving renal and vascular functions in vitamin D-deficient patients with type 2 diabetes mellitus (T2DM) along with chronic kidney disease (CKD). One hundred patients (18 - 65 years), having T2DM along with CKD (stage IIIA and IIIB) and hypovitaminosis D were randomized (1:1) to receive either oral cholecalciferol 60,000 IU (Group A) or placebo (Group B) weekly for 8 weeks along with standard background treatment. They were followed up for another 24 weeks. Various parameters of renal and vascular functions were compared. Except for serum calcium and phosphate levels which were significantly higher in Group A ( p  < 0.001), there was no significant difference in any of the biochemical or vascular parameters between the two groups at 8 weeks. There were comparable changes in urinary albumin-creatinine ratio and carotid-femoral pulse wave velocity in the two groups at 8 and 24 weeks. There was no improvement in any of the vascular parameters from the corresponding baseline values in the two groups at 8 and 32 weeks. No improvement in renal and vascular functions was observed following treatment with oral cholecalciferol in patients with T2DM and CKD.",2021,No improvement in renal and vascular functions was observed following treatment with oral cholecalciferol in patients with T2DM and CKD.,"['Vitamin D-Deficient Patients With Type 2 Diabetes Mellitus', 'One hundred patients (18\u2009-\u200965\u2009years), having T2DM along with CKD (stage IIIA and IIIB) and hypovitaminosis D', 'vitamin D-deficient patients with type 2 diabetes mellitus (T2DM) along with chronic kidney disease (CKD', 'patients with T2DM and CKD']","['cholecalciferol', 'oral cholecalciferol 60,000\u2009IU (Group A) or placebo', 'Placebo', 'Oral Cholecalciferol', 'oral cholecalciferol']","['renal and vascular functions', 'Renal and Vascular Functions', 'urinary albumin-creatinine ratio and carotid-femoral pulse wave velocity', 'vascular parameters', 'serum calcium and phosphate levels', 'biochemical or vascular parameters']","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0456598', 'cui_str': 'Stage 3A'}, {'cui': 'C0035579', 'cui_str': 'Rickets'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0486293', 'cui_str': 'Albumin/creatinine ratio measurement'}, {'cui': 'C5197774', 'cui_str': 'Carotid-Femoral Pulse Wave Velocities'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0523826', 'cui_str': 'Phosphate measurement'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}]",,0.217763,No improvement in renal and vascular functions was observed following treatment with oral cholecalciferol in patients with T2DM and CKD.,"[{'ForeName': 'Saibal', 'Initials': 'S', 'LastName': 'Das', 'Affiliation': 'Department of Clinical Pharmacology, JIPMER, Puducherry, India.'}, {'ForeName': 'Sandhiya', 'Initials': 'S', 'LastName': 'Selvarajan', 'Affiliation': 'Department of Clinical Pharmacology, JIPMER, Puducherry, India.'}, {'ForeName': 'Sadishkumar', 'Initials': 'S', 'LastName': 'Kamalanathan', 'Affiliation': 'Department of Endocrinology, JIPMER, Puducherry, India.'}, {'ForeName': 'Sreejith', 'Initials': 'S', 'LastName': 'Parameswaran', 'Affiliation': 'Department of Nephrology, JIPMER, Puducherry, India.'}, {'ForeName': 'Bobby', 'Initials': 'B', 'LastName': 'Zachariah', 'Affiliation': 'Department of Biochemistry, JIPMER, Puducherry, India.'}]",Journal of dietary supplements,['10.1080/19390211.2021.1958041'] 2919,34387411,DUAL II China: superior HbA 1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.,"AIMS In DUAL II China, the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (degludec) were assessed in Chinese people with type 2 diabetes (T2D) treated with basal insulin. MATERIALS AND METHODS In a randomized, double-blinded, multicentre, treat-to-target trial, Chinese adults with T2D and glycated haemoglobin (HbA 1c ) ≥7.5% on basal insulin and metformin, with or without other oral-antidiabetic drugs (OADs), were randomized 2:1 to 26 weeks' treatment with either IDegLira (max. Dose 50 U degludec/1.8 mg liraglutide) or degludec (max. 50 U/day), respectively, combined with metformin. At 26 weeks, superiority of IDegLira over degludec was assessed for change in HbA 1c (primary endpoint) and body weight and number of severe or blood glucose (BG)-confirmed hypoglycaemic episodes (confirmatory secondary endpoints). RESULTS Overall, 453 participants were randomized to IDegLira (n = 302) or degludec (n = 151). Superiority was confirmed for IDegLira over degludec in HbA 1c change (-1.9% versus -1.0%, respectively, estimated treatment difference (ETD) [95% confidence interval]: -0.92% [-1.09;-0.75], p < 0.0001), body weight change (-0.7 kg versus +0.4 kg, respectively, ETD [95% CI]: -1.08 kg [-1.63;-0.52], p = 0.0002) and severe or BG-confirmed hypoglycaemia (estimated rate ratio [95% CI]: 0.53 [0.30;0.94], p = 0.0297). The odds of achieving HbA 1c  < 7.0% without hypoglycaemia and/or weight gain were greater with IDegLira than degludec (p < 0.0001 for all). Daily insulin dose at 26 weeks was lower for IDegLira (34.3 U) than degludec (37.4 U), p = 0.0014. No unexpected safety signals were observed. CONCLUSIONS IDegLira may be an efficacious and well-tolerated treatment intensification option for Chinese people with T2D uncontrolled on basal insulin and OADs. DUAL™ II China; ClinicalTrials.gov Identifier: NCT03175120. This article is protected by copyright. All rights reserved.",2021,"Superiority was confirmed for IDegLira over degludec in HbA 1c change (-1.9% versus -1.0%, respectively, estimated treatment difference (ETD) [95% confidence interval]: -0.92% [-1.09;-0.75], p < 0.0001), body weight change (-0.7 kg versus +0.4 kg, respectively, ETD [95% CI]: -1.08 kg [-1.63;-0.52], p = 0.0002) and severe or BG-confirmed hypoglycaemia (estimated rate ratio [95% CI]: 0.53 [0.30;0.94], p = 0.0297).","['Chinese adults with T2D and glycated haemoglobin (HbA 1c ', 'Chinese people with type 2 diabetes (T2D) treated with basal insulin', '50', 'Chinese people with type 2 diabetes inadequately controlled on basal insulin', '453 participants were randomized to IDegLira (n\xa0=\xa0302) or degludec (n\xa0=\xa0151', 'Chinese people with T2D uncontrolled on basal insulin and OADs']","['basal insulin and metformin, with or without other oral-antidiabetic drugs (OADs', 'liraglutide (IDegLira', 'metformin', 'liraglutide', 'insulin degludec/liraglutide (IDegLira) versus insulin degludec (degludec']","['severe or BG-confirmed hypoglycaemia', 'hypoglycaemia and/or weight gain', 'body weight and number of severe or blood glucose (BG)-confirmed hypoglycaemic episodes', 'body weight change']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4059165', 'cui_str': 'insulin degludec and liraglutide'}, {'cui': 'C3491971', 'cui_str': 'insulin degludec'}]","[{'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0935929', 'cui_str': 'Antidiabetic agent'}, {'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C4059165', 'cui_str': 'insulin degludec and liraglutide'}, {'cui': 'C3491971', 'cui_str': 'insulin degludec'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0745153', 'cui_str': 'Hypoglycaemic episode'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",453.0,0.3126,"Superiority was confirmed for IDegLira over degludec in HbA 1c change (-1.9% versus -1.0%, respectively, estimated treatment difference (ETD) [95% confidence interval]: -0.92% [-1.09;-0.75], p < 0.0001), body weight change (-0.7 kg versus +0.4 kg, respectively, ETD [95% CI]: -1.08 kg [-1.63;-0.52], p = 0.0002) and severe or BG-confirmed hypoglycaemia (estimated rate ratio [95% CI]: 0.53 [0.30;0.94], p = 0.0297).","[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Pei', 'Affiliation': ""Chinese People's Liberation Army General Hospital, Beijing, China.""}, {'ForeName': 'Bue R', 'Initials': 'BR', 'LastName': 'Agner', 'Affiliation': 'Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Luo', 'Affiliation': 'Novo Nordisk China Pharmaceuticals, Beijing, China.'}, {'ForeName': 'Xiaolin', 'Initials': 'X', 'LastName': 'Dong', 'Affiliation': 'Jinan Central Hospital, Shandong University, Jinan, China.'}, {'ForeName': 'Dongmei', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': ""Inner Mongolia People's Hospital, Hohhot, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Fifth People's Hospital of Shanghai, Shanghai, China.""}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Tianjin Medical University General Hospital, Tianjin, China.'}, {'ForeName': 'Yibing', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Tomoyuki', 'Initials': 'T', 'LastName': 'Nishida', 'Affiliation': 'Novo Nordisk Pharma Ltd, Tokyo, Japan.'}, {'ForeName': 'Xiangjin', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Fuzhou General Hospital, Fuzhou, China.'}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Mu', 'Affiliation': ""Chinese People's Liberation Army General Hospital, Beijing, China.""}]","Diabetes, obesity & metabolism",['10.1111/dom.14522'] 2920,34387246,A Cognitive Aid Improves Adherence to Guidelines for Critical Endotracheal Intubation in the Resuscitation Room: A Randomized Controlled Trial With Manikin-Based In Situ Simulation.,"INTRODUCTION Emergency endotracheal intubation (ETI) is a high-risk procedure. Some of its adverse events are life-threatening, and guidelines emphasize the need to anticipate complications by thorough preparation. The emergency department (ED) can be an unpredictable environment, and we tested the hypothesis that a cognitive aid would help the emergency practitioners better follow guidelines. The main objective of this study was to determine whether the use of a cognitive aid focusing on both preintubation and postintubation items could improve ETI preparation and implementation in the ED resuscitation room regarding adherence to guidelines. The secondary objective was to measure and describe procedure times. METHODS We conducted a single-blind randomized controlled trial with manikin-based in situ simulation. The participants were not aware of the purpose of the study. The cognitive aid was developed using national guidelines and current scientific literature. The most relevant items were the preparation and implementation of a rapid sequence induction for ETI followed by mechanical ventilation. Emergency department physician-nurse pairs were randomized into a ""cognitive aid"" group and a ""control"" group. All pairs completed the same scenario that led to ETI in their own resuscitation room. An adherence to guidelines score of 30, derived from the 30 items of the cognitive aid (1 point per item), and preparation and intubation times were collected. RESULTS Seventeen pairs were included in each group. Adherence to guidelines scores were significantly higher in the cognitive aid group than in the control group (median = 28 of 30, interquartile range = 25-28, vs. median = 24 of 30, interquartile range = 21-26, respectively, P < 0.01). Preparation, intubation, and total procedure times were slightly longer in the cognitive aid group, but these results were not significant. CONCLUSIONS In an in situ simulation, a cognitive aid for the preparation and implementation of an emergency intubation procedure in the ED resuscitation room significantly improved adherence to guidelines without increasing procedure times. Further work is needed in a larger sample and in different settings to evaluate the optimal use of cognitive aids in critical situations.",2021,"Adherence to guidelines scores were significantly higher in the cognitive aid group than in the control group (median = 28 of 30, interquartile range = 25-28, vs. median = 24 of 30, interquartile range = 21-26, respectively, P < 0.01).","['Seventeen pairs were included in each group', 'Emergency department physician-nurse pairs']","['cognitive aid"" group and a ""control"" group', 'Manikin', 'Emergency endotracheal intubation (ETI']","['Adherence to guidelines scores', 'Preparation, intubation, and total procedure times']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0586803', 'cui_str': 'Emergency department physician'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}]","[{'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024722', 'cui_str': 'Mannequins'}, {'cui': 'C0189377', 'cui_str': 'Endotracheal intubation, emergency procedure'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",17.0,0.0637264,"Adherence to guidelines scores were significantly higher in the cognitive aid group than in the control group (median = 28 of 30, interquartile range = 25-28, vs. median = 24 of 30, interquartile range = 21-26, respectively, P < 0.01).","[{'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Ben-Haddour', 'Affiliation': 'From the Departments of Emergency Medicine (M.B.H., Z.D., M.R., L.-M.J.) and Emergency Medicine-SAMU 76A (M.B.H., A.L.-S.), Rouen University Hospital, F-76000 Rouen; Department of Emergency Medicine-SAMU 76B (M.C.), Le Havre Hospital, F-76600 Le Havre; Departments of Anesthesiology and Critical Care (A.L.-S.) and Biostatistics (A.G.), Rouen University Hospital; and Normandy University UNIROUEN (L.-M.J., M.R.), F-76000 Rouen, France.'}, {'ForeName': 'Mathilde', 'Initials': 'M', 'LastName': 'Colas', 'Affiliation': ''}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Lefevre-Scelles', 'Affiliation': ''}, {'ForeName': 'Zoé', 'Initials': 'Z', 'LastName': 'Durand', 'Affiliation': ''}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Gillibert', 'Affiliation': ''}, {'ForeName': 'Mélanie', 'Initials': 'M', 'LastName': 'Roussel', 'Affiliation': ''}, {'ForeName': 'Luc-Marie', 'Initials': 'LM', 'LastName': 'Joly', 'Affiliation': ''}]",Simulation in healthcare : journal of the Society for Simulation in Healthcare,['10.1097/SIH.0000000000000603'] 2921,34387244,The Development of an Assessment Rubric for the Core and Contingency Team Interaction Among Rapid Response Teams.,"INTRODUCTION Teamwork training is critical in the development of high-functioning rapid response teams (RRT). Rapid response teams involve interactions between a patient's core care team and a hospital contingency team, which can lead to disorganized and unsafe resuscitations, largely due to problems with communication and information dissemination. An extensive literature search found no assessment tools specific to the unique communicative challenges of an RRT, and thus, this study sought to develop an assessment rubric validated for training RRTs. METHODS This study elucidates the development, implementation, and testing of an RRT rubric based on Kane's framework for validating testing instruments. Twenty-four inpatient code teams underwent team training using a Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS) didactic, an online module on the TeamSTEPPS RRT program, and a subsequent presimulation and postsimulation experience. Two raters were randomized to give a bedside assessment for each team using the proposed RRT rubric. Simulation scores were assessed with Wilcoxon signed-rank tests. Interrater reliability was assessed using intraclass correlation coefficients. These analyses were then used to argue Kane's scoring, generalization, and extrapolation inferences. RESULTS All teams significantly improved from the presimulation to postsimulation scenarios across all TeamSTEPPS domains. Content validity was obtained from 5 resuscitation experts with a scale-level content validity index of 0.9, with individual content validity index of 0.8 to 1.0. Intraclass correlation coefficient for ""pre"" scores were 0.856 (n = 24, P < 0.001), ""post"" scores of 0.738 (n = 24, P < 0.001), and a total of 0.890 (n = 48, P < 0.001). CONCLUSIONS The authors argue for the validity of a new RRT rubric based off Kane's framework, with a specific focus on teamwork training to improve coordination and function of core and contingency teams. A follow-up study with longitudinal data along with external validation of this rubric is needed.",2021,"Twenty-four inpatient code teams underwent team training using a Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS) didactic, an online module on the TeamSTEPPS RRT program, and a subsequent presimulation and postsimulation experience.",[],"['team training using a Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS) didactic, an online module on the TeamSTEPPS RRT program, and a subsequent presimulation and postsimulation experience', 'Teamwork training']","['Intraclass correlation coefficient for ""pre"" scores', 'post"" scores', 'Interrater reliability', 'Content validity']",[],"[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C2718033', 'cui_str': 'Hospital Medical Emergency Team'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C0010101', 'cui_str': 'Correlation Studies'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0042283', 'cui_str': 'Validity (Epidemiology)'}]",2.0,0.0198339,"Twenty-four inpatient code teams underwent team training using a Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS) didactic, an online module on the TeamSTEPPS RRT program, and a subsequent presimulation and postsimulation experience.","[{'ForeName': 'Maninder', 'Initials': 'M', 'LastName': 'Singh', 'Affiliation': 'From the Department of Emergency Medicine (M.S.), Jacobi Medical Center; Department of Emergency Medicine (H.M.), Montefiore Medical Center; White Plains Hospital (G.M.T., S.B., B.A.), White Plains; Rutgers Robert Wood Johnson Medical School (N.B.D.), New Brunswick, NJ; and Departments of Emergency Medicine (D.M., J.S., F.N.J.) and Critical Care (K.E.), White Plains Hospital, White Plains, NY.'}, {'ForeName': 'Hillary', 'Initials': 'H', 'LastName': 'Moss', 'Affiliation': ''}, {'ForeName': 'Gifty M', 'Initials': 'GM', 'LastName': 'Thomas', 'Affiliation': ''}, {'ForeName': 'Nicholas B', 'Initials': 'NB', 'LastName': 'Dadario', 'Affiliation': ''}, {'ForeName': 'Doreen', 'Initials': 'D', 'LastName': 'Mirante', 'Affiliation': ''}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Ellsworth', 'Affiliation': ''}, {'ForeName': 'Jodi', 'Initials': 'J', 'LastName': 'Shulman', 'Affiliation': ''}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Bellido', 'Affiliation': ''}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Amicucci', 'Affiliation': ''}, {'ForeName': 'Farrukh N', 'Initials': 'FN', 'LastName': 'Jafri', 'Affiliation': ''}]",Simulation in healthcare : journal of the Society for Simulation in Healthcare,['10.1097/SIH.0000000000000602'] 2922,34387236,Effect of Reiki Therapy on Quality of Life and Fatigue Levels of Breast Cancer Patients Receiving Chemotherapy.,"BACKGROUND The quality of life of patients receiving chemotherapy decreases, and fatigue is one of the most common symptoms. Reiki is used for cancer patients as an energy-based complementary and alternative method. OBJECTIVE The aim of this study was to determine the effect of Reiki therapy on the quality of life and fatigue levels in breast cancer patients receiving chemotherapy. METHODS This was a pretest-posttest, quasi-experimental study with a control group: 70 patients enrolled with 35 participants in the experimental group and 35 in the control group. The experimental group received 6 sessions of Reiki therapy. The data were collected using a Patient Information Form, the Piper Fatigue Scale, and the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. RESULTS The mean scores on the general well-being subscale in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire increased in the experimental group and decreased in the control group, whereas the mean scores on the general function and general symptom subscales decreased in the experimental group and increased in the control group. The differences between the groups were statistically significant (P < .001). The mean Piper Fatigue Scale scores of the experimental group decreased, whereas that of the control group increased; the group differences were statistically significant (P < .001). CONCLUSION Reiki can reduce fatigue and increase the quality of life of breast cancer patients receiving chemotherapy. IMPLICATIONS FOR PRACTICE Reiki therapy can be used as a nursing intervention to increase the quality of life and reduce fatigue in breast cancer patients receiving chemotherapy.",2021,Reiki therapy can be used as a nursing intervention to increase the quality of life and reduce fatigue in breast cancer patients receiving chemotherapy.,"['breast cancer patients receiving chemotherapy', 'group: 70 patients enrolled with 35 participants in the experimental group and 35 in the control group', 'Breast Cancer Patients Receiving Chemotherapy']","['Reiki Therapy', 'control', 'Reiki therapy', '6 sessions of Reiki therapy']","['Quality of Life and Fatigue Levels', 'quality of life and reduce fatigue', 'quality of life and fatigue levels', 'general function and general symptom subscales', 'Cancer Quality of Life Questionnaire', 'quality of life', 'mean Piper Fatigue Scale scores']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0751715', 'cui_str': 'Reiki'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C2586108', 'cui_str': 'Level of fatigue'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0159028', 'cui_str': 'General symptom'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0330232', 'cui_str': 'Piper'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",70.0,0.0318097,Reiki therapy can be used as a nursing intervention to increase the quality of life and reduce fatigue in breast cancer patients receiving chemotherapy.,"[{'ForeName': 'Seda', 'Initials': 'S', 'LastName': 'Karaman', 'Affiliation': 'Author Affiliation: Department of Internal Medicine Nursing, Faculty of Nursing, Ataturk University, Erzurum, Turkey.'}, {'ForeName': 'Mehtap', 'Initials': 'M', 'LastName': 'Tan', 'Affiliation': ''}]",Cancer nursing,['10.1097/NCC.0000000000000970'] 2923,34387225,The effects of mindfulness-based stress reduction (MBSR) on the association between autonomic interoceptive signals and emotion regulation selection.,"OBJECTIVES The ability to select the most adaptive regulatory strategy as a function of the emotional context plays a pivotal role in psychological health. Recently, we showed that mindfulness-based interventions (MBIs) can improve the sensitivity of regulatory strategy selection to emotional intensity. Yet, the mechanisms underlying this improvement are unclear. In this study we tested the hypothesis that MBIs support adaptive regulatory selection by increasing sensitivity to interoceptive signals associated with the emotional stimuli. METHODS Participants (N = 84, mean ± SD age = 30.9 ± 8.3; 54% women) were randomized to either a Mindfulness-Based Stress Reduction (MBSR) program or a waitlist control condition. Before and after the MBSR program, physiological measures for autonomic nervous system activity were obtained and participants performed a task examining emotion regulation selections (reappraisal vs. distraction) when confronted with low or high negative intensity images. They also completed a battery of mindfulness, interoception and wellbeing self-report measures. A cross-classified model was employed for the main analyses. RESULTS The participants assigned to the MBSR were overall more likely to choose reappraisal than distraction (b = 0.26, posterior SD = 0.13, 95% CI [0.02, 0.52]) after the program. Interoceptive signals in response to negative images were associated with subsequent regulatory selections (b = 0.02, posterior SD = 0.01, 95% CI [0.01, 0.03]) in the MBSR group. Specifically, lower cardiac reactivity was associated with the choice to reappraise whereas higher cardiac reactivity was related to the choice to distract. Greater differences in cardiac reactivity between states that prompt reappraisal and states that prompt distraction were associated with higher wellbeing (Satisfaction with Life Scale, Pearson r (29) = .527, p = 0.003). CONCLUSION Mindfulness appears to increase the sensitivity of regulatory selections to interoceptive signals, and this is associated with subjective wellbeing. This may be a central pathway through which MBIs exert their positive effects on mental health and resilience.",2021,"Greater differences in cardiac reactivity between states that prompt reappraisal and states that prompt distraction were associated with higher wellbeing (Satisfaction with Life Scale, Pearson r (29) = .527, p = 0.003). ","['Participants (N = 84, mean ± SD age = 30.9 ± 8.3; 54% women']","['mindfulness-based stress reduction (MBSR', 'Mindfulness-Based Stress Reduction (MBSR) program or a waitlist control condition', 'mindfulness-based interventions (MBIs']","['lower cardiac reactivity', 'cardiac reactivity']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]",,0.0513549,"Greater differences in cardiac reactivity between states that prompt reappraisal and states that prompt distraction were associated with higher wellbeing (Satisfaction with Life Scale, Pearson r (29) = .527, p = 0.003). ","[{'ForeName': 'Ziv', 'Initials': 'Z', 'LastName': 'Ardi', 'Affiliation': 'Sagol Center for Brain and Mind, Baruch Ivcher School of Psychology, Interdisciplinary Center, Herzliya, Israel Department of Behavioral Sciences. Kinneret Academic College, Sea of Galilee, Israel. The School of Psychological Sciences, and Sagol School of Neuroscience, Tel Aviv University.'}, {'ForeName': 'Yulia', 'Initials': 'Y', 'LastName': 'Golland', 'Affiliation': ''}, {'ForeName': 'Roni', 'Initials': 'R', 'LastName': 'Shafir', 'Affiliation': ''}, {'ForeName': 'Gal', 'Initials': 'G', 'LastName': 'Sheppes', 'Affiliation': ''}, {'ForeName': 'Nava', 'Initials': 'N', 'LastName': 'Levit-Binnun', 'Affiliation': ''}]",Psychosomatic medicine,['10.1097/PSY.0000000000000994'] 2924,34386892,A Randomized Trial Comparing Polymer Versus Suture-Based Vascular Closure Devices for Arterial Closure Following Lower-Limb Arterial Endovascular Revascularization.,"PURPOSES The primary objective of this study (STEP trial) was to compare the efficacy of the polymer-based FemoSeal® vascular closure device (VCD) and the suture-based ProGlide® VCD in achieving hemostasis at the femoral access site after lower-limb arterial endovascular revascularization. MATERIALS AND METHODS STEP was a multicenter randomized clinical trial including patients undergoing lower-limb arterial endovascular revascularization. The primary endpoint was technical success 5 h after the VCD intervention, defined as achievement of hemostasis without the need for a follow-up intervention at the access site and without a 2-g/dL drop in hemoglobin. RESULTS Between December 2017 and April 2019, 113 patients were assigned to the FemoSeal® group (FS) and 117 to the ProGlide® group (PG). VCD interventions were technically successful for 90 FS patients (80%) and 58 PG patients (50%) (odds ratio, 3.98; 95% CI, 2.22 to 7.14; p < 0.0001). This difference in success rates between FS and PG is partly explained by more frequent recourse to manual compression (FS: n = 19; PG: n = 45) and an additional VCD (FS: n = 0; PG: n = 23) in the latter group. After 5 h, 87% of FS patients and 69% of PG patients resumed ambulation (odds ratio: 3.07; 95% CI: 1.93 to 6.15; p = 0.0016). CONCLUSIONS In patients undergoing lower-limb arterial endovascular revascularization, FemoSeal® was superior to ProGlide® in terms of technical success. CLINICAL TRIAL REGISTRATION Step trial was registered on http://ClinicalTrials.gov (NCT03192033).",2021,"In patients undergoing lower-limb arterial endovascular revascularization, FemoSeal® was superior to ProGlide® in terms of technical success. ","['patients undergoing lower-limb arterial endovascular revascularization', 'Arterial Closure', 'Between December 2017 and April 2019', '113 patients']","['FemoSeal®', 'ProGlide® group (PG', 'Polymer Versus Suture-Based Vascular Closure Devices', 'polymer-based FemoSeal® vascular closure device (VCD) and the suture-based ProGlide® VCD']","['ambulation', 'technical success 5']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3504161', 'cui_str': 'Vascular Closure Devices'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0449851', 'cui_str': 'Technique'}]",113.0,0.316126,"In patients undergoing lower-limb arterial endovascular revascularization, FemoSeal® was superior to ProGlide® in terms of technical success. ","[{'ForeName': 'Yann', 'Initials': 'Y', 'LastName': 'Gouëffic', 'Affiliation': 'Department of Vascular and Endovascular Surgery, Paris Saint Joseph Hospital, Paris, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Picquet', 'Affiliation': 'Department of Vascular Surgery, Angers University Hospital, Angers, France.'}, {'ForeName': 'Fabrice', 'Initials': 'F', 'LastName': 'Schneider', 'Affiliation': 'Department of Vascular Surgery, Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Adrien', 'Initials': 'A', 'LastName': 'Kaladji', 'Affiliation': 'Department of Cardiovascular and Thoracic Surgery, Rennes University Hospital, Rennes, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Marret', 'Affiliation': 'Department of Vascular Surgery, La Roche-sur-Yon Hospital, La Roche-sur-Yon, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Muller', 'Affiliation': 'Department of Vascular Surgery, Cholet Hospital, Cholet, France.'}, {'ForeName': 'Béatrice', 'Initials': 'B', 'LastName': ""Guyomarc'h"", 'Affiliation': 'Institut du Thorax, Nantes University Hospital/INSERM/CNRS/Nantes University, Nantes, France.'}, {'ForeName': 'Valéry-Pierre', 'Initials': 'VP', 'LastName': 'Riche', 'Affiliation': 'Division of Health Product Development and Economic Evaluation, Department of Partnerships and Innovation, Nantes University Hospital, Nantes, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Chaillou', 'Affiliation': 'Department of Vascular Surgery, Institut du Thorax, Nantes University Hospital, Nantes, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Guillou', 'Affiliation': 'Department of Vascular Surgery, Institut du Thorax, Nantes University Hospital, Nantes, France.'}, {'ForeName': 'Bahaa', 'Initials': 'B', 'LastName': 'Nasr', 'Affiliation': 'Department of Vascular Surgery, Brest University Hospital, Brest, France. nasr.bahaa@gmail.com.'}]",Cardiovascular and interventional radiology,['10.1007/s00270-021-02940-z'] 2925,34386885,Helping Us Heal: telephone versus in-person marital communication and support counseling for spouse caregivers of wives with breast cancer.,"PURPOSE (1) To test the short-term impact of Helping Us Heal (HUSH), a telephone-delivered counseling program for spouse caregivers of women with breast cancer. (2) To compare outcomes from HUSH with outcomes from a historical control group which received the same program in-person. METHODS Two-group quasi-experimental design using both within- and between-group analyses with 78 study participants, 26 in the within-group and 52 in the between-group analyses. Spouse caregivers were eligible if the wife was diagnosed within 8 months with stage 0-III breast cancer and were English-speaking. After obtaining signed informed consent and baseline data, 5 fully scripted telephone intervention sessions were delivered at 2-week intervals by patient educators. Spouses and diagnosed wives were assessed on standardized measures of adjustment at baseline and immediately after the final intervention session. RESULTS Within-group analyses revealed that spouses and wives in HUSH significantly improved on depressed mood and anxiety; spouses improved on self-efficacy and their skills in supporting their wife. Additionally, wives' appraisal of spousal support significantly improved. Between-group analyses revealed that outcomes from HUSH were comparable or larger in magnitude to outcomes achieved by the in-person delivered program. CONCLUSIONS A manualized telephone-delivered intervention given directly to spouse caregivers can potentially improve adjustment in both spouses and diagnosed wives but study outcomes must be interpreted with caution. Given the small samples in the pilot studies and the absence of randomization, further testing is needed with a more rigorous experimental design with a larger study sample.",2021,"RESULTS Within-group analyses revealed that spouses and wives in HUSH significantly improved on depressed mood and anxiety; spouses improved on self-efficacy and their skills in supporting their wife.","['Two-group quasi-experimental design using both within- and between-group analyses with 78 study participants, 26 in the within-group and 52 in the between-group analyses', 'spouse caregivers of women with breast cancer', 'spouse caregivers of wives with breast cancer', 'Spouse caregivers were eligible if the wife was diagnosed within 8\xa0months with stage 0-III breast cancer and were English-speaking']","['Heal: telephone versus in-person marital communication and support counseling', 'telephone-delivered counseling program', 'Helping Us Heal (HUSH']",['depressed mood and anxiety'],"[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0087015', 'cui_str': 'Spouse Caregivers'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0242665', 'cui_str': 'Wife'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0441763', 'cui_str': 'Stage 0'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0376245', 'cui_str': 'English language'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}]","[{'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",78.0,0.0565723,"RESULTS Within-group analyses revealed that spouses and wives in HUSH significantly improved on depressed mood and anxiety; spouses improved on self-efficacy and their skills in supporting their wife.","[{'ForeName': 'Frances Marcus', 'Initials': 'FM', 'LastName': 'Lewis', 'Affiliation': 'Department of Child, Family & Population Health, University of Washington, 1959 Pacific Street, Box 357262, Seattle, WA, 98195, USA. fmlewis@u.washington.edu.'}, {'ForeName': 'Kristin A', 'Initials': 'KA', 'LastName': 'Griffith', 'Affiliation': 'Department of Child, Family & Population Health, University of Washington, 1959 Pacific Street, Box 357262, Seattle, WA, 98195, USA.'}, {'ForeName': 'Kuan-Ching', 'Initials': 'KC', 'LastName': 'Wu', 'Affiliation': 'Department of Child, Family & Population Health, University of Washington, 1959 Pacific Street, Box 357262, Seattle, WA, 98195, USA.'}, {'ForeName': 'Mary Ellen', 'Initials': 'ME', 'LastName': 'Shands', 'Affiliation': 'Department of Child, Family & Population Health, University of Washington, 1959 Pacific Street, Box 357262, Seattle, WA, 98195, USA.'}, {'ForeName': 'Ellen H', 'Initials': 'EH', 'LastName': 'Zahlis', 'Affiliation': 'Department of Child, Family & Population Health, University of Washington, 1959 Pacific Street, Box 357262, Seattle, WA, 98195, USA.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-021-06439-8'] 2926,34386838,Changes in family involvement occasioned by FAMS mobile health intervention mediate changes in glycemic control over 12 months.,"Mobile phone-delivered interventions have proven effective in improving glycemic control (HbA1c) in the short term among adults with type 2 diabetes (T2D). Family systems theory suggests engaging family/friend in adults' diabetes self-care may enhance or sustain improvements. In secondary analysis from a randomized controlled trial (N = 506), we examined intervention effects on HbA1c via change in diabetes-specific helpful and harmful family/friend involvement. We compared a text messaging intervention that did not target family/friend involvement (REACH), REACH plus family-focused intervention components targeting helpful and harmful family/friend involvement (REACH + FAMS), and a control condition. Over 6 months, both intervention groups experienced improvement in HbA1c relative to control, but at 12 months neither did. However, REACH + FAMS showed an indirect effect on HbA1c via change in helpful family/friend involvement at both 6 and 12 months while REACH effects were not mediated by family/friend involvement. Consistent with family systems theory, improvements in HbA1c mediated by improved family/friend involvement were sustained.",2021,Mobile phone-delivered interventions have proven effective in improving glycemic control (HbA1c) in the short term among adults with type 2 diabetes (T2D).,['adults with type 2 diabetes (T2D'],"['text messaging intervention that did not target family/friend involvement (REACH), REACH plus family-focused intervention components targeting helpful and harmful family/friend involvement (REACH\u2009+\u2009FAMS', 'Mobile phone-delivered interventions']","['HbA1c relative', 'glycemic control']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0060056', 'cui_str': 'FAM protocol'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}]","[{'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0620148,Mobile phone-delivered interventions have proven effective in improving glycemic control (HbA1c) in the short term among adults with type 2 diabetes (T2D).,"[{'ForeName': 'McKenzie K', 'Initials': 'MK', 'LastName': 'Roddy', 'Affiliation': 'Quality Scholars Program, VA Tennessee Valley Healthcare System, US Department of Veteran Affairs, Nashville, TN, USA.'}, {'ForeName': 'Lyndsay A', 'Initials': 'LA', 'LastName': 'Nelson', 'Affiliation': 'Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Greevy', 'Affiliation': 'Deparment of Biostatistics, Vanderbilt University, Nashville, TN, USA.'}, {'ForeName': 'Lindsay S', 'Initials': 'LS', 'LastName': 'Mayberry', 'Affiliation': 'Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Lindsay.mayberry@vumc.org.'}]",Journal of behavioral medicine,['10.1007/s10865-021-00250-w'] 2927,34386824,"Open and closed surgical exposure of palatally displaced canines: a cost-minimization analysis of a multicentre, randomized controlled trial.","OBJECTIVE To evaluate the costs of open and closed surgical exposure and subsequent orthodontic treatment for the correction of palatally displaced canines (PDCs). TRIAL DESIGN A multicentre, two-arm parallel group randomized controlled trial. METHODS One hundred twenty adolescents between 9 and 16 years of age, from three orthodontic specialist centres, were randomized to one of the two surgical exposure interventions. The randomization was conducted according to a two-arm parallel group 1:1 allocation ratio, using computerized lists with block randomization. In both the surgical techniques, whole mucoperiosteal flaps were raised, and bone covering the PDCs was removed. In the open technique, glass ionomer was built up on the PDC crown - reaching above the mucosa through a hole punched in the flap - to allow the canine to erupt autonomously. After eruption, the canine was orthodontically moved above the mucosa. In the closed technique, an eyelet was bonded onto the PDC, the flap was repositioned and the canine was orthodontically moved beyond the mucosa. The trial ended when the PDC was successfully aligned in the dental arch.Cost analysis was performed including costs for surgery, orthodontic treatment, emergency visits, and material, as well as costs for transports and time spent in connection with every appointment. BLINDING Patients and caregivers could not be blinded due to obvious limitations of the clinical setting, while outcome assessors and data analysts were blinded. RESULTS A cost-minimization analysis was performed since both exposure groups succeeded equally well in terms of treatment effects. The two different surgical exposures and following orthodontic treatments did not differ significantly in terms of costs. GENERALIZABILITY AND LIMITATIONS Costs are estimated in the Swedish setting, which needs to be considered if applying the results in other settings. Calculations of total cost do not include finishing, debonding, retention, and follow-up. CONCLUSION There is no significant difference in costs between closed and open surgical exposure with following orthodontic treatments in PDCs. TRIAL REGISTRATION ClinicalTrials.gov, ID: NCT02186548.",2021,"The two different surgical exposures and following orthodontic treatments did not differ significantly in terms of costs. ","['palatally displaced canines (PDCs', 'One hundred twenty adolescents between 9 and 16 years of age, from three orthodontic specialist centres']","['open and closed surgical exposure and subsequent orthodontic treatment', 'Open and closed surgical exposure of palatally displaced canines']","['costs for surgery, orthodontic treatment, emergency visits, and material, as well as costs for transports and time spent', 'costs']","[{'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0204193', 'cui_str': 'Orthodontic procedure'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0204193', 'cui_str': 'Orthodontic procedure'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0005528', 'cui_str': 'Biological transport'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",120.0,0.218271,"The two different surgical exposures and following orthodontic treatments did not differ significantly in terms of costs. ","[{'ForeName': 'Margitha', 'Initials': 'M', 'LastName': 'Björksved', 'Affiliation': 'Department of Orthodontics, Public Dental Health Service, Eskilstuna, Sweden.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Ryen', 'Affiliation': 'University Health Care Research Center, Örebro University, SE-701 82, Sweden.'}, {'ForeName': 'Rune', 'Initials': 'R', 'LastName': 'Lindsten', 'Affiliation': 'The Institute for Postgraduate Dental Education, Department of Orthodontics, SE-551 11 Jönköping, Sweden.'}, {'ForeName': 'Farhan', 'Initials': 'F', 'LastName': 'Bazargani', 'Affiliation': 'Postgraduate Dental Education Center, Department of Orthodontics, SE-701 11 Örebro, Sweden.'}]",European journal of orthodontics,['10.1093/ejo/cjab052'] 2928,34386666,Tolvaptan in ADPKD Patients With Very Low Kidney Function.,"Introduction Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and REPRISE trials. Tolvaptan effects in subjects with eGFR 15 to 24 ml/min per 1.73 m 2 were not investigated. This post hoc analysis retrospectively investigated eGFR decline in REPRISE versus an open-label, phase 3b extension trial (open-label extension [OLE] NCT02251275) in subjects who received placebo in REPRISE and tolvaptan in OLE with eGFR 15 to 24 and 25 to 29 ml/min per 1.73 m 2 , respectively. Methods One data subset comprised subjects with OLE baseline eGFR 15 to 29 ml/min per 1.73 m 2 who had received placebo in REPRISE and began tolvaptan in OLE. The second comprised subjects who had received tolvaptan in REPRISE and were matched to REPRISE placebo-treated subjects for REPRISE baseline characteristics. Annualized eGFR slopes in REPRISE versus OLE were compared within the REPRISE placebo (i.e., placebo vs. tolvaptan treatment) and tolvaptan (i.e., 2 periods of tolvaptan treatment) subsets. Results Mean annualized eGFR slopes (ml/min per 1.73 m 2 ) during tolvaptan treatment in OLE versus placebo treatment in REPRISE were -3.4 versus -5.2 for subjects with OLE baseline eGFR 15 to 29 (difference, 1.7; P  < 0.001), -3.6 versus -5.4 with baseline eGFR 15 to 24 (difference, 1.8; P  < 0.001), and -3.3 versus -4.9 with baseline eGFR 25 to 29 (difference, 1.6; P  < 0.001). In REPRISE tolvaptan subjects who continued tolvaptan in OLE, treatment effect was maintained (no difference between mean annualized eGFR slopes). Conclusion Initiating or maintaining tolvaptan therapy significantly delayed eGFR decline in subjects with baseline eGFR 15 to 24 and 25 to 29 ml/min per 1.73 m 2 .",2021,Tolvaptan effects in subjects with eGFR 15 to 24 ml/min per 1.73 m 2 were not investigated.,"['subjects with eGFR 15 to 24 ml/min per 1.73 m 2 were not investigated', 'subjects with autosomal dominant polycystic kidney disease (ADPKD', 'ADPKD Patients With Very Low Kidney Function']","['Tolvaptan', 'placebo', 'tolvaptan therapy', 'REPRISE placebo']","['Annualized eGFR slopes', 'Tolvaptan effects', 'glomerular filtration rate (eGFR) decline', 'Mean annualized eGFR slopes', 'delayed eGFR decline']","[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0085413', 'cui_str': 'Autosomal dominant polycystic kidney disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442811', 'cui_str': 'Very low'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}]","[{'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.154342,Tolvaptan effects in subjects with eGFR 15 to 24 ml/min per 1.73 m 2 were not investigated.,"[{'ForeName': 'Vicente E', 'Initials': 'VE', 'LastName': 'Torres', 'Affiliation': 'Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Ron T', 'Initials': 'RT', 'LastName': 'Gansevoort', 'Affiliation': 'Division of Nephrology, Universitair Medisch Centrum Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Ronald D', 'Initials': 'RD', 'LastName': 'Perrone', 'Affiliation': 'Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Arlene B', 'Initials': 'AB', 'LastName': 'Chapman', 'Affiliation': 'Division of Nephrology, The University of Chicago, Chicago, Illinois, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Ouyang', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.'}, {'ForeName': 'Hina', 'Initials': 'H', 'LastName': 'Japes', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey, USA.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Nourbakhsh', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey, USA.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.'}]",Kidney international reports,['10.1016/j.ekir.2021.05.037'] 2929,34386665,Randomized Trial-PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis.,"Introduction Whether clinically implementable exercise interventions in people receiving hemodialysis (HD) therapy improve health-related quality of life (HRQoL) remains unknown. The PrEscription of intraDialytic exercise to improve quAlity of Life ( PEDAL) study evaluated the clinical benefit and cost-effectiveness of a 6-month intradialytic exercise program. Methods In a multicenter, single-blinded, randomized, controlled trial, people receiving HD were randomly assigned to (i) intradialytic exercise training (exercise intervention group [EX]) and (ii) usual care (control group [CON]). Primary outcome was change in Kidney Disease Quality of Life Short-Form Physical Component Summary (KDQOL-SF 1.3 PCS) from baseline to 6 months. Cost-effectiveness was determined using health economic analysis; physiological impairment was evaluated by peak oxygen uptake; and harms were recorded. Results We randomized 379 participants; 335 and 243 patients (EX n  = 127; CON n  = 116) completed baseline and 6-month assessments, respectively. Mean difference in change PCS from baseline to 6 months between EX and CON was 2.4 (95% confidence interval [CI]: -0.1 to 4.8) arbitrary units ( P  = 0.055); no improvements were observed in peak oxygen uptake or secondary outcome measures. Participants in the intervention group had poor compliance (47%) and poor adherence (18%) to the exercise prescription. Cost of delivering intervention ranged from US$598 to US$1092 per participant per year. The number of participants with harms was similar between EX ( n  = 69) and CON ( n  = 56). A primary limitation was the lack of an attention CON. Many patients also withdrew from the study or were too unwell to complete all physiological outcome assessments. Conclusions A 6-month intradialytic aerobic exercise program was not clinically beneficial in improving HRQoL as delivered to this cohort of deconditioned patients on HD.",2021,Participants in the intervention group had poor compliance (47%) and poor adherence (18%) to the exercise prescription.,"['379 participants; 335 and 243 patients (EX n \xa0= 127; CON n \xa0= 116', 'people receiving HD', 'Patients Receiving Hemodialysis', 'people receiving hemodialysis (HD']","['intradialytic exercise training (exercise intervention group [EX]) and (ii) usual care (control group [CON', 'intraDialytic exercise', 'intradialytic aerobic exercise program', 'implementable exercise interventions', 'intradialytic exercise program', 'CON']","['poor adherence', 'peak oxygen uptake', 'lack of an attention CON', 'Cost-effectiveness', 'change in Kidney Disease Quality of Life Short-Form Physical Component Summary (KDQOL-SF 1.3 PCS', 'quAlity of Life', 'health-related quality of life (HRQoL', 'poor compliance']","[{'cui': 'C4709307', 'cui_str': '335'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C1882368', 'cui_str': 'Dynamic Light Scattering'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",379.0,0.0945101,Participants in the intervention group had poor compliance (47%) and poor adherence (18%) to the exercise prescription.,"[{'ForeName': 'Sharlene A', 'Initials': 'SA', 'LastName': 'Greenwood', 'Affiliation': ""Renal Medicine, King's College Hospital NHS Trust, London, UK.""}, {'ForeName': 'Pelagia', 'Initials': 'P', 'LastName': 'Koufaki', 'Affiliation': 'School of Health Sciences, Queen Margaret University, Edinburgh, UK.'}, {'ForeName': 'Jamie H', 'Initials': 'JH', 'LastName': 'Macdonald', 'Affiliation': 'School of Sport, Health and Exercise Sciences, Bangor University, Wales, UK.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Bhandari', 'Affiliation': 'Renal Medicine, Hull University Teaching Hospitals NHS Trust, Hull, UK.'}, {'ForeName': 'James O', 'Initials': 'JO', 'LastName': 'Burton', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Indranil', 'Initials': 'I', 'LastName': 'Dasgupta', 'Affiliation': 'Renal Medicine, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Farrington', 'Affiliation': 'Renal Medicine, Lister Hospital, Stevenage, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Ford', 'Affiliation': 'Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Kalra', 'Affiliation': 'Renal Medicine, Salford Royal Hospital, Salford, UK.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Kean', 'Affiliation': 'Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Mick', 'Initials': 'M', 'LastName': 'Kumwenda', 'Affiliation': 'Renal Medicine, Glan Clwyd Hospital, Wales, UK.'}, {'ForeName': 'Iain C', 'Initials': 'IC', 'LastName': 'Macdougall', 'Affiliation': ""Renal Medicine, King's College Hospital NHS Trust, London, UK.""}, {'ForeName': 'Claudia-Martina', 'Initials': 'CM', 'LastName': 'Messow', 'Affiliation': 'Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Sandip', 'Initials': 'S', 'LastName': 'Mitra', 'Affiliation': 'Renal Medicine, Manchester University Hospitals, Manchester, UK.'}, {'ForeName': 'Chante', 'Initials': 'C', 'LastName': 'Reid', 'Affiliation': ""Renal Medicine, King's College Hospital NHS Trust, London, UK.""}, {'ForeName': 'Alice C', 'Initials': 'AC', 'LastName': 'Smith', 'Affiliation': 'Department of Health Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Maarten W', 'Initials': 'MW', 'LastName': 'Taal', 'Affiliation': 'Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Thomson', 'Affiliation': 'Renal Medicine, Queen Elizabeth University Hospital, Glasgow, UK.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Wheeler', 'Affiliation': 'Renal Medicine, University College London, London, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'White', 'Affiliation': ""Renal Medicine, King's College Hospital NHS Trust, London, UK.""}, {'ForeName': 'Magdi', 'Initials': 'M', 'LastName': 'Yaqoob', 'Affiliation': 'Renal Medicine, The Royal London Hospital, London, UK.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Mercer', 'Affiliation': 'School of Health Sciences, Queen Margaret University, Edinburgh, UK.'}]",Kidney international reports,['10.1016/j.ekir.2021.05.034'] 2930,34386661,Effect of Vancomycin on the Gut Microbiome and Plasma Concentrations of Gut-Derived Uremic Solutes.,"Introduction Declining renal function results in the accumulation of solutes normally excreted by healthy kidneys. Data suggest that some of the protein-bound solutes mediate accelerated cardiovascular disease. Many of the poorly dialyzable protein-bound uremic retention solutes are products of gut bacterial metabolism. Methods We performed a blinded-randomized controlled trial comparing the changes in plasma concentrations of a panel of protein-bound solutes and microbiome structure in response to the once-weekly oral administration of 250 mg of vancomycin or placebo over a period of 12 weeks in a cohort of stable patients with end-stage kidney disease. We also examined the pattern of recovery of the solutes and gut microbiome over 12 weeks of placebo administration following vancomycin. Results We enrolled 15 subjects. Ten subjects provided sufficient plasma and stool samples to permit us to examine the effect of vancomycin on plasma solute levels. We showed that a weekly dose of vancomycin resulted in a reduction in the plasma concentration of 7 colon-derived solutes. We described a significant effect of vancomycin on the microbiome structure with a decrease in alpha diversity and change in beta diversity. Multiple taxa decreased with vancomycin including genera Clostridium and Bacteroides . We demonstrated microbiome recovery after stopping vancomycin. However, recovery in the solutes was highly variable between subjects. Conclusions We demonstrated that microbiome suppression using vancomycin resulted in changes in multiple gut-derived uremic solutes. Future studies are needed to address whether reduction in those uremic solutes results in improvement of cardiovascular outcomes in ESKD patients.",2021,We showed that a weekly dose of vancomycin resulted in a reduction in the plasma concentration of 7 colon-derived solutes.,"['ESKD patients', 'stable patients with end-stage kidney disease', 'We enrolled 15 subjects']","['Vancomycin', 'placebo', 'vancomycin or placebo', 'vancomycin']","['Gut Microbiome and Plasma Concentrations of Gut-Derived Uremic Solutes', 'plasma concentration', 'alpha diversity and change in beta diversity', 'plasma solute levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}]","[{'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",15.0,0.0845162,We showed that a weekly dose of vancomycin resulted in a reduction in the plasma concentration of 7 colon-derived solutes.,"[{'ForeName': 'Lama', 'Initials': 'L', 'LastName': 'Nazzal', 'Affiliation': 'Department of Medicine, New York University School of Medicine, New York, New York, USA.'}, {'ForeName': 'Leland', 'Initials': 'L', 'LastName': 'Soiefer', 'Affiliation': 'Department of Medicine, New York-Presbyterian/Weill Cornell, New York, New York, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Chang', 'Affiliation': 'Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Tamizuddin', 'Affiliation': 'Department of Radiology, New York University School of Medicine, New York, New York, USA.'}, {'ForeName': 'Daria', 'Initials': 'D', 'LastName': 'Schatoff', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Cofer', 'Affiliation': 'Department of Medicine, New York University School of Medicine, New York, New York, USA.'}, {'ForeName': 'Maria E', 'Initials': 'ME', 'LastName': 'Aguero-Rosenfeld', 'Affiliation': 'Department of Pathology, New York University School of Medicine, New York, New York, USA.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Matalon', 'Affiliation': 'Department of Medicine, New York University School of Medicine, New York, New York, USA.'}, {'ForeName': 'Bjorn', 'Initials': 'B', 'LastName': 'Meijers', 'Affiliation': 'Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Holzman', 'Affiliation': 'Department of Medicine, New York University School of Medicine, New York, New York, USA.'}, {'ForeName': 'Jerome', 'Initials': 'J', 'LastName': 'Lowenstein', 'Affiliation': 'Department of Medicine, New York University School of Medicine, New York, New York, USA.'}]",Kidney international reports,['10.1016/j.ekir.2021.05.014'] 2931,33831327,"Topically applied mometasone furoate improves dysphagia in adult eosinophilic esophagitis - results from a double-blind, randomized, placebo-controlled trial.","OBJECTIVES Topical corticosteroids are considered a cornerstone in the treatment of patients with eosinophilic esophagitis. The aim of this study was to evaluate the benefit of using mometasone furoate spray versus placebo on dysphagia and health-related quality of life in these patients. MATERIAL AND METHODS Consecutive, newly diagnosed adult patients with eosinophilic esophagitis were randomized and treated with either 200 micrograms of orally administered topical mometasone furoate or placebo 4 times daily for 8 weeks. Symptoms and quality of life were evaluated using questionnaires including the Watson Dysphagia Scale, the European Organization for Research and Treatment of Cancer Quality of Life-Oesophageal Module 18 and the Short Form-36 before and after treatment. RESULTS In the intention-to-treat analysis ( n  = 36) the Watson Dysphagia Scale score after mometasone treatment was reduced by 6.5 (median, p  < .01) compared with 0 (median, ns) in the placebo group. The benefit of mometasone over placebo was significant ( p  < .05). In the per-protocol analysis ( n  = 33) the Watson Dysphagia Scale score was reduced by 5 (median, p  = .01) after mometasone treatment compared with 0 (median, ns) in the placebo group. The advantage of mometasone over the placebo was significant ( p  < .05). The benefit of using mometasoneas evaluated by the two quality of life questionnaires was, however, insignificant. CONCLUSIONS Our finding suggests that in adult patients with eosinophilic esophagitis, topical mometasone furoate exerts a beneficial effect compared with placebo regarding the main symptom, i.e., dysphagia. A corresponding benefit could not be verified regarding the various quality of life measurements. CLINICAL TRIAL REGISTRATION Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study ClinicalTrials.gov Identifier (NCT02113267).",2021,The advantage of mometasone over the placebo was significant ( p  < .05).,"['patients with eosinophilic esophagitis', 'adult eosinophilic esophagitis ', 'adult patients with eosinophilic esophagitis', 'Consecutive, newly diagnosed adult patients with eosinophilic esophagitis']","['mometasone', '200 micrograms of orally administered topical mometasone furoate or placebo', 'placebo', 'Placebo', 'mometasone furoate spray versus placebo', 'mometasone furoate', 'Mometasone-furoate']","['Watson Dysphagia Scale, the European Organization for Research and Treatment of Cancer Quality of Life-Oesophageal Module 18 and the Short Form-36', 'dysphagia', 'dysphagia and health-related quality of life', 'Symptoms and quality of life', 'Watson Dysphagia Scale score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0341106', 'cui_str': 'Eosinophilic esophagitis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0360564', 'cui_str': 'Mometasone'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439211', 'cui_str': 'mcg'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0066700', 'cui_str': 'Mometasone furoate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}]","[{'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.684913,The advantage of mometasone over the placebo was significant ( p  < .05).,"[{'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Tytor', 'Affiliation': 'Department of Otorhinolaryngology, NU Hospital Group, Trollhättan, Sweden.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Larsson', 'Affiliation': 'Department of Otorhinolaryngology, NU Hospital Group, Trollhättan, Sweden.'}, {'ForeName': 'Mogens', 'Initials': 'M', 'LastName': 'Bove', 'Affiliation': 'Department of Otorhinolaryngology, NU Hospital Group, Trollhättan, Sweden.'}, {'ForeName': 'Leif', 'Initials': 'L', 'LastName': 'Johansson', 'Affiliation': 'Department of Otorhinolaryngology, Skaraborg Hospital, Skövde, Sweden.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Bergquist', 'Affiliation': 'Department of ENT/H&N Surgery, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2021.1906314'] 2932,33834913,Evaluation of the Modified Atkins Diet for the Treatment of Epileptic Spasms Refractory to Hormonal Therapy: A Randomized Controlled Trial.,"OBJECTIVES We aimed to evaluate the efficacy of the modified Atkins diet in children with epileptic spasms who had failed hormonal therapy. METHODS Children aged 9 months to 3 years having daily epileptic spasms despite a trial of ACTH or oral prednisolone and 1 additional anticonvulsant medication were enrolled. Children were randomly assigned to receive the modified Atkins diet either immediately or after a delay of 4 weeks. The ongoing anticonvulsant medications were continued unchanged. The primary outcome variable was the proportion of children who achieved spasm freedom as per parental reports at 4 weeks. Secondary outcomes included time to spasm cessation, proportion of children with electroclinical remission, the proportion of children with >50% reduction of spasms at 4 weeks, and adverse effects of the diet. (ClinicalTrials.gov Identifier: NCT03807141). RESULTS A total of 91 children were enrolled in the study; 46 in the diet group and 45 in the control group. At the end of 4 weeks, 11 children in the diet group were spasm free compared with none in the control group ( P ≤ .001). The median time to achieve spasm cessation was 10 days (interquartile range 9-20). Nine of these had resolution of hypsarrhythmia on electroencephalography (EEG). Thirty (65.2%) in the diet group had >50% reduction in spasms, compared with none in the control group ( P < .001). The most common side effect was constipation, noted in 34.8% of the children. CONCLUSIONS The modified Atkins diet was found to be effective and well tolerated in children with epileptic spasms refractory to hormonal therapy.",2021,"had >50% reduction in spasms, compared with none in the control group ( P < .001).","['Children aged 9 months to 3 years having daily epileptic spasms despite a trial of', 'children with epileptic spasms refractory to hormonal therapy', 'children with epileptic spasms who had failed hormonal therapy', 'and 1 additional anticonvulsant medication were enrolled', 'Epileptic Spasms Refractory to Hormonal Therapy', '91 children were enrolled in the study; 46 in the diet group and 45 in the control group']","['ACTH or oral prednisolone', 'modified Atkins diet', 'Modified Atkins Diet']","['effective and well tolerated', 'spasms', 'proportion of children who achieved spasm freedom', 'median time to achieve spasm cessation', 'spasm free', 'resolution of hypsarrhythmia on electroencephalography (EEG', 'time to spasm cessation, proportion of children with electroclinical remission, the proportion of children with >50% reduction of spasms at 4 weeks, and adverse effects of the diet']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1527366', 'cui_str': 'Salaam Seizures'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0003286', 'cui_str': 'Anticonvulsant'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0358513', 'cui_str': 'Prednisolone-containing product in oral dose form'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0026821', 'cui_str': 'Cramp'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]",91.0,0.133798,"had >50% reduction in spasms, compared with none in the control group ( P < .001).","[{'ForeName': 'Suvasini', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': ""Department of Pediatrics, Division of Pediatric Neurology, 28856Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.""}, {'ForeName': 'Shaiphali', 'Initials': 'S', 'LastName': 'Goel', 'Affiliation': ""Department of Pediatrics, Division of Pediatric Neurology, 28856Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.""}, {'ForeName': 'Dipti', 'Initials': 'D', 'LastName': 'Kapoor', 'Affiliation': ""Department of Pediatrics, Division of Pediatric Neurology, 28856Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.""}, {'ForeName': 'Divyani', 'Initials': 'D', 'LastName': 'Garg', 'Affiliation': 'Department of Neurology, 28856Lady Hardinge Medical College and Associated Smt. Sucheta Kriplani Hospital, New Delhi, India.'}, {'ForeName': 'Isha', 'Initials': 'I', 'LastName': 'Panda', 'Affiliation': ""Department of Pediatrics, Division of Pediatric Neurology, 28856Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.""}, {'ForeName': 'Aman', 'Initials': 'A', 'LastName': 'Elwadhi', 'Affiliation': ""Department of Pediatrics, Division of Pediatric Neurology, 28856Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.""}, {'ForeName': 'Bijoy', 'Initials': 'B', 'LastName': 'Patra', 'Affiliation': ""Department of Pediatrics, 28856Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.""}, {'ForeName': 'Sharmila B', 'Initials': 'SB', 'LastName': 'Mukherjee', 'Affiliation': ""Department of Pediatrics, 28856Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.""}, {'ForeName': 'Harish', 'Initials': 'H', 'LastName': 'Pemde', 'Affiliation': ""Department of Pediatrics, 28856Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.""}]",Journal of child neurology,['10.1177/08830738211004747'] 2933,33823379,Efficacy of scenario simulation-based education in relieving parental anxiety about fever in children.,"PURPOSE This study was designed to evaluate the short- and long-term effects of a scenario simulation-based education intervention on parental anxiety about fever in their children. DESIGN AND METHODS This experimental research was conducted using a two-group pretest-posttest design. One hundred and sixty parents of 3-month to 5-year-old children enrolled in preschools and kindergartens with childcare services were recruited as participants using cluster random sampling. The participants were divided randomly into an experimental group (80) and a control group (80). The former participated in a scenario simulation-based education intervention and received a fever education booklet. The latter received the booklet only. Data were collected using the Children's Fever Anxiety Inventory at three time points: before the intervention (pretest, T1) and at six-month (T2) and 12-month (T3) posttests. RESULTS Significant intergroup differences in fever anxiety were found at both T2 and T3 (p < .001). For both groups, the scores at T2 and T3 were significantly lower than at T1 (p < .001) and the difference between T2 and T3 did not attain statistical significance (p > .05). Although both groups experienced reduced fever anxiety over time, this reduction was significantly greater in the experimental group than in the control group (p < .001). CONCLUSION Simulation-based education may be used in conjunction with the traditional fever education booklet to further reduce parent fever anxiety over time. PRACTICE IMPLICATIONS This simulation-based education approach significantly and positively impacts parental anxiety about fever in their children. Furthermore, the approach may be generalizable to other childhood healthcare settings.",2021,"RESULTS Significant intergroup differences in fever anxiety were found at both T2 and T3 (p < .001).","['parental anxiety about fever in children', 'parental anxiety about fever in their children', 'One hundred and sixty parents of 3-month to 5-year-old children enrolled in preschools and kindergartens with childcare services']","['scenario simulation-based education', 'scenario simulation-based education intervention', 'scenario simulation-based education intervention and received a fever education booklet']","['fever anxiety', ""Children's Fever Anxiety Inventory""]","[{'cui': 'C0577602', 'cui_str': 'Parental anxiety'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}]","[{'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",160.0,0.0167805,"RESULTS Significant intergroup differences in fever anxiety were found at both T2 and T3 (p < .001).","[{'ForeName': 'Li Chuan', 'Initials': 'LC', 'LastName': 'Chang', 'Affiliation': 'Department of Nursing, National Tainan Junior College of Nursing, Tainan, Taiwan. Electronic address: fabchuan@ntin.edu.tw.'}, {'ForeName': 'Mei Chih', 'Initials': 'MC', 'LastName': 'Huang', 'Affiliation': 'Department of Nursing, National Tainan Junior College of Nursing, Tainan, Taiwan; Department of Nursing, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: meay@mail.ncku.edu.tw.'}]",Journal of pediatric nursing,['10.1016/j.pedn.2021.03.024'] 2934,33823265,Lower Extremity Intermittent Negative Pressure for Intermittent Claudication. Follow-Up after 24 Weeks of Treatment.,"BACKGROUND Treatment with lower extremity intermittent negative pressure (INP) of -40 mm Hg for one hour twice daily for 12 weeks, increases walking capacity in patients with intermittent claudication (IC). However, the effects of INP treatment beyond 12 weeks have not been elucidated. The aim of the present study was to investigate the clinical effects of INP treatment after 24 weeks in patients with IC. METHODS This was a follow-up study after a randomized sham-controlled trial, where patients randomized to the active treatment group were offered to continue treatment for 12 additional weeks (24 weeks in total). Treatment with -40 mm Hg INP was applied in a pressure chamber sealed around the lower leg, and the patients were instructed to treat themselves at home one hour in the morning and one hour in the evening. Pain free walking distance (PWD), maximal walking distance (MWD), resting ankle-brachial index (ABI) and post exercise ABI were measured at baseline, after 12 and 24 weeks. RESULTS Ten out of 32 patients (31%) from the active treatment group in the initial trial were included in this follow-up study. At baseline, PWD was (mean ±SD) 151 ± 91 m and MWD was 362 ±159 m. There was a significant increase in both PWD and MWD after 24 weeks of treatment, compared to baseline (ANOVA; P= 0.006 and P= 0.012, respectively). Post hoc tests revealed that PWD increased significantly from baseline to 12 weeks (mean 81 m; 95% CI [6, 156]; P = 0.032), and that MWD increased significantly from 12 to 24 weeks (mean 145 m; 95% CI [22, 268]; P = 0.018). There were no significant changes in resting ABI or post exercise ABI during the 24-week treatment period (ANOVA; P= 0.157 and P= 0.450, respectively). CONCLUSION Both PWD and MWD improved after treatment with - 40 mm Hg INP for one hour twice daily for 24 weeks, compared to baseline. The main improvement in PWD occurred during the first 12 weeks of treatment, whereas the main improvement in MWD occurred between 12 and 24 weeks of treatment.",2021,"Both PWD and MWD improved after treatment with - 40 mmHg INP for one hour twice daily for 24 weeks, compared to baseline.","['patients with IC', 'Ten out of 32 patients (31%) from the active treatment group in the initial trial were included in this follow-up study', 'patients with intermittent claudication (IC']","['INP', 'Treatment with lower extremity intermittent negative pressure (INP) of -40 mmHg']","['PWD and MWD', 'PWD', 'Pain free walking distance (PWD), maximal walking distance (MWD), resting ankle-brachial index (ABI) and post exercise ABI', 'resting ABI or post exercise ABI', 'MWD', 'walking capacity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0016441', 'cui_str': 'Followup Studies'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}]","[{'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0908489', 'cui_str': 'Pain-Free'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C1328319', 'cui_str': 'Ankle brachial pressure index'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]",32.0,0.113944,"Both PWD and MWD improved after treatment with - 40 mmHg INP for one hour twice daily for 24 weeks, compared to baseline.","[{'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Hoel', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Vascular Surgery, Oslo University Hospital, Oslo, Norway; Otivio AS, Oslo, Norway. Electronic address: ho-hen@online.no.'}, {'ForeName': 'Erik Mulder', 'Initials': 'EM', 'LastName': 'Pettersen', 'Affiliation': 'Department of Surgery, Sørlandet Hospital, Kristiansand, Norway; Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Lars Øivind', 'Initials': 'LØ', 'LastName': 'Høiseth', 'Affiliation': 'Department of Anesthesiology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Iacob', 'Initials': 'I', 'LastName': 'Mathiesen', 'Affiliation': 'Otivio AS, Oslo, Norway.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Seternes', 'Affiliation': 'Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Section for Vascular Surgery, Department of Surgery, St. Olavs Hospital, Trondheim, Norway.'}, {'ForeName': 'Jonny', 'Initials': 'J', 'LastName': 'Hisdal', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Vascular Surgery, Oslo University Hospital, Oslo, Norway.'}]",Annals of vascular surgery,['10.1016/j.avsg.2021.03.016'] 2935,33823257,Automated Image Fusion Guidance during Endovascular Aorto-Iliac Procedures: A Randomized Controlled Pilot Study.,"BACKGROUND The benefits of imaging guidance using a new fully automated fusion process (CYDAR) have been demonstrated during endovascular aortic aneurysm repair, but little is known about its use during aorto-iliac occlusive disease endovascular revascularization. The aim of this study was to evaluate the influence of CYDAR image fusion guidance during endovascular treatment of symptomatic aorto-iliac occlusive lesions, compared with control patients treated using standard 2D fluoroscopy alone. METHODS This is a single-center randomized controlled pilot study that recruited patients undergoing aorto-iliac endovascular revascularization. RESULTS Between January 2019 and February 2020, 37 patients with symptomatic aorto-iliac lesions were enrolled: 18 were assigned to the fusion group and 19 to the control group. Patients and lesions characteristics were well balanced between both study groups. The technical success of the procedure was 100% in the Fusion group and 94% in the control group. All radiation-related parameters were lower in the fusion compared to the control group, including: median DAP 18.5 Gy.cm2 vs. 21.8 Gy.cm2; Air Kerma 0.10 Gy vs. 0.12 Gy; fluoroscopy dose 4.2 Gy.cm 2 vs. 5.1 Gy.cm 2 ; and number of DSA 7.5 vs. 8. The volume of iodinated contrast used was higher in the fusion group: 41 mL vs. 30 mL. The total procedure time was the same in both groups:60 min vs. 60 min. CONCLUSIONS The results of this pilot study suggest the use of fusion imaging in endovascular treatment of aorto-iliac disease results in reduction in radiation-related measured parameters with no change in procedure time and higher doses of iodinated contrast used. These results need to be further investigated in a larger, adequately powered study.",2021,"All radiation-related parameters were lower in the fusion compared to the control group, including: median DAP 18.5 Gy.cm2 vs 21.8 Gy.cm2; Air Kerma 0.10 Gy vs 0.12 Gy; fluoroscopy dose 4.2 Gy.cm 2 vs 5.1 Gy.cm 2 ; and number of DSA 7.5 vs 8.","['Between January 2019 and February 2020, 37 patients with symptomatic aorto-iliac lesions were enrolled: 18', 'recruited patients undergoing aorto-iliac endovascular revascularization']",['standard 2D fluoroscopy alone'],"['technical success', 'total procedure time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C1268307', 'cui_str': 'Aorta and iliac artery, CS'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}]","[{'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",37.0,0.0299227,"All radiation-related parameters were lower in the fusion compared to the control group, including: median DAP 18.5 Gy.cm2 vs 21.8 Gy.cm2; Air Kerma 0.10 Gy vs 0.12 Gy; fluoroscopy dose 4.2 Gy.cm 2 vs 5.1 Gy.cm 2 ; and number of DSA 7.5 vs 8.","[{'ForeName': 'Louis Marie', 'Initials': 'LM', 'LastName': 'De Beaufort', 'Affiliation': ""CHU Nantes, l'institut du thorax, service de chirurgie cardio-vasculaire, Nantes, France.""}, {'ForeName': 'Bahaa', 'Initials': 'B', 'LastName': 'Nasr', 'Affiliation': ""CHU Nantes, l'institut du thorax, service de chirurgie cardio-vasculaire, Nantes, France.""}, {'ForeName': 'Tom Le', 'Initials': 'TL', 'LastName': 'Corvec', 'Affiliation': ""CHU Nantes, l'institut du thorax, service de chirurgie cardio-vasculaire, Nantes, France.""}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Brisard', 'Affiliation': ""CHU Nantes, département d'anesthésie réanimation, Nantes, France.""}, {'ForeName': 'Béatrice', 'Initials': 'B', 'LastName': ""Guyomarc'h"", 'Affiliation': ""CHU Nantes, l'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.""}, {'ForeName': 'Imen', 'Initials': 'I', 'LastName': 'Fellah', 'Affiliation': ""CHU Nantes, l'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.""}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Postaire', 'Affiliation': ""CHU Nantes, l'institut du thorax, service de chirurgie cardio-vasculaire, Nantes, France.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Chaillou', 'Affiliation': ""CHU Nantes, l'institut du thorax, service de chirurgie cardio-vasculaire, Nantes, France.""}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Clough', 'Affiliation': ""School of Biomedical Engineering and Imaging Sciences, St Thomas' Hospital, King's College London.""}, {'ForeName': 'Blandine', 'Initials': 'B', 'LastName': 'Maurel', 'Affiliation': ""CHU Nantes, l'institut du thorax, service de chirurgie cardio-vasculaire, Nantes, France; Université de Nantes, Nantes, France. Electronic address: blandine.maurel@chu-nantes.fr.""}]",Annals of vascular surgery,['10.1016/j.avsg.2021.03.023'] 2936,33829651,The effect of pulmonary rehabilitation on smoking and health outcomes in COPD patients.,"OBJECTIVES Although several positive effects of pulmonary rehabilitation (PR) are known in COPD patients, the results of PR in smoker COPD patients are unclear. We aimed to compare the effect of PR on smoking behaviour and health outcomes between COPD patients who are smoker and ex-smoker. METHODS In our study; 62 COPD patients (31 of them active smoker and 31 of them were ex-smoker) who completed in an 8-week outpatient PR programme were included. Pulmonary function test, blood gas analysis, mMRC Dyspnoea Scale, 6-minute walk test, St. George's Respiratory Questionnaire, SF-36 Quality of Life Questionnaire and Hospital Anxiety Depression Scale were performed. Smoking behaviour and nicotine dependence of the study group was evaluated. RESULTS At baseline assessment; TLCO was found to be lower in the currently smoking group (p = 0.042) and significantly increased after PR (p = 0.012). FEV 1 , PaO 2 , arterial saturation, 6-min walk distance and quality of life improved in both groups (p < 0.05). Anxiety score decreased in both groups; depression score decreased only in the ex-smoker group. When comparing changes between groups; mMRC score was observed to be decreased more in the smoker group (p = 0.01). At the end of the programme, nicotine dependence score and the daily number of cigarettes were significantly decreased in the smoker group (p < 0.001), also 2 patients completely quit smoking. CONCLUSION Smoker COPD patients benefited from the PR programme at least as much as the patients who do not smoke. Furthermore, nicotine dependence and amount of cigarette decreased in smoker patients. Therefore, COPD patients who smoke should be referred to the PR programmes.",2021,"FEV 1 , PaO 2 , arterial saturation, 6-min walk distance and quality of life improved in both groups (p<0.05).","['COPD patients', 'Smoker COPD patients', '62 COPD patients (31 of them active smoker and 31 of them were ex-smoker) who completed in an 8-week outpatient PR program were included', 'COPD patients who are smoker and ex-smoker.\nMETHODS', 'smoker patients', 'COPD patients who are smoking should be referred to the PR programs', 'smoker COPD patients']","['pulmonary rehabilitation (PR', 'PR', 'Pulmonary Rehabılıtatıon']","['smoking behavior and health outcomes', 'mMRC score', 'FEV 1 , PaO 2 , arterial saturation, 6-min walk distance and quality of life', 'Smoking behavior and nicotine dependence', 'depression score', 'nicotine dependence score and the daily number of cigarettes', 'Anxiety score', ""Pulmonary function test, blood gas analysis, mMRC Dyspnea Scale, 6-minute walk test, St. George's Respiratory Questionnaire, SF-36 Quality Of Life Questionnaire, and Hospital Anxiety Depression Scale""]","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0337671', 'cui_str': 'Ex-smoker'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}]","[{'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}]","[{'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0028043', 'cui_str': 'Nicotine dependence'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0451107', 'cui_str': 'Depression anxiety scale'}]",62.0,0.00748732,"FEV 1 , PaO 2 , arterial saturation, 6-min walk distance and quality of life improved in both groups (p<0.05).","[{'ForeName': 'Hulya', 'Initials': 'H', 'LastName': 'Sahin', 'Affiliation': 'Pulmonary Rehabilitation Unit, Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Izmir, Turkey.'}, {'ForeName': 'Ilknur', 'Initials': 'I', 'LastName': 'Naz', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Izmir Katip Celebi University, Izmir, Turkey.'}]",The clinical respiratory journal,['10.1111/crj.13373'] 2937,33827788,Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.,"OBJECTIVES The differences of efficacy between each Janus kinase (JAK) inhibitors have not been clarified in the patients with rheumatoid arthritis (RA) in clinical practice. Here, we compared the efficacy between tofacitinib (TOFA) and baricitinib (BARI) in clinical practice. METHODS The efficacy of TOFA (n=156) in patients with RA was compared with BARI (n=138). Selection bias was reduced to a minimum using propensity score-based inverse probability of treatment weighting (IPTW). The Clinical Disease Activity Index (CDAI) trajectory for patients who started TOFA or BARI was analysed using growth mixture modelling (GMM). RESULTS No significant difference was observed in patient characteristics between the TOFA and BARI groups in after adjustment by propensity score-based IPTW. The BARI group had a significantly higher rate of CDAI remission at week 24 after the introduction of JAK inhibitors than the TOFA group. The treatment-resistant group defined by GMM, comprising patients who did not achieve low disease activity at week 24, was more likely to include those who had received many biological disease-modifying antirheumatic drugs (bDMARDs) before the introduction of JAK inhibitors and those who received TOFA. Among patients with RA who received TOFA, those who had received ≥4 bDMARDs before the introduction of TOFA were more likely to be classified into the treatment-resistant group. CONCLUSIONS BARI showed a similar safety profile and better clinical outcome when compared with TOFA after reduction to a minimum of selection bias. However, these were observed in a small population. Accordingly, further investigation is required in an accurately powered head-to-head trial.",2021,No significant difference was observed in patient characteristics between the TOFA and BARI groups in after adjustment by propensity score-based IPTW.,"['patients with rheumatoid arthritis (RA) in clinical practice', 'patients with rheumatoid arthritis in real clinical practice', 'patients with RA was compared with BARI (n=138']","['TOFA', 'tofacitinib (TOFA) and baricitinib (BARI', 'Janus kinase (JAK) inhibitors', 'tofacitinib versus baricitinib']","['Clinical Disease Activity Index (CDAI) trajectory', 'patient characteristics', 'rate of CDAI remission', 'low disease activity', 'Efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C4044947', 'cui_str': 'baricitinib'}]","[{'cui': 'C2930696', 'cui_str': 'tofacitinib'}, {'cui': 'C4044947', 'cui_str': 'baricitinib'}, {'cui': 'C0597721', 'cui_str': 'JAK Kinases'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.142813,No significant difference was observed in patient characteristics between the TOFA and BARI groups in after adjustment by propensity score-based IPTW.,"[{'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Miyazaki', 'Affiliation': 'The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.'}, {'ForeName': 'Kazuhisa', 'Initials': 'K', 'LastName': 'Nakano', 'Affiliation': 'The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.'}, {'ForeName': 'Shingo', 'Initials': 'S', 'LastName': 'Nakayamada', 'Affiliation': 'The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Kubo', 'Affiliation': 'The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.'}, {'ForeName': 'Yoshino', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.'}, {'ForeName': 'Yoshihisa', 'Initials': 'Y', 'LastName': 'Fujino', 'Affiliation': 'Department of Environmental Epidemiology, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.'}, {'ForeName': 'Yoshiya', 'Initials': 'Y', 'LastName': 'Tanaka', 'Affiliation': 'The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan tanaka@med.uoeh-u.ac.jp.'}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2020-219699'] 2938,33835175,Effectiveness of a Culturally Tailored HIV and Sexually Transmitted Infection Prevention Intervention for Black Women in Community Supervision Programs: A Randomized Clinical Trial.,"Importance Concentrated epidemics of HIV and sexually transmitted infections (STIs) have persisted among Black women in community supervision programs (CSPs) in the United States. Accumulating research has highlighted the effectiveness of culturally tailored HIV/STI interventions for Black women; however, there is a dearth of such interventions for the large number of Black women in CSPs. Objective To determine the effectiveness of a 5-session culturally tailored group-based intervention (Empowering African-American Women on the Road to Health [E-WORTH]) with individualized computerized modules and streamlined HIV testing in reducing STIs and condomless sex vs a 1-session streamlined HIV testing control condition. Design, Setting, and Participants This randomized clinical trial was conducted from November 18, 2015, (first recruitment) to August 20, 2019 (last 12-month follow-up). Black women mandated to probation, parole, or alternative-to-incarceration programs in New York City who had a history of drug use were recruited and randomized to receive either E-WORTH or a streamlined HIV testing control condition. Both conditions were delivered by Black female staff at a large CSP. The analysis took an intention-to-treat approach. Intervention E-WORTH included a 1-hour individual HIV testing and orientation session and 4 weekly 90-minute group sessions. The control condition included one 30-minute session of HIV testing and information. Main Outcomes and Measures Primary outcomes were incidence of any STI (biologically assayed chlamydia, gonorrhea, and Trichomonas vaginalis) at the 12-month assessment and the number of condomless acts of vaginal or anal intercourse in the past 90 days during the 12-month period. Results A total of 352 participants who identified as Black or African American were enrolled, including 79 (22.5%) who also identified as Latinx. The mean (SD) age was 32.4 (11.0) years. A total of 172 participants (48.9%) were assigned to the E-WORTH condition, and 180 (51.1%) were assigned to the control condition. Compared with control participants, participants assigned to the E-WORTH condition had 54% lower odds of testing positive for any STI at the 12-month follow-up (odds ratio, 0.46; 95% CI, 0.25-0.88; P = .01) and reported 38% fewer acts of condomless vaginal or anal intercourse during the 12-month period (incidence rate ratio, 0.62; 95% CI, 0.39-0.97; P = .04). Conclusions and Relevance The magnitudes of effects found across biological and behavioral outcomes in this randomized clinical trial indicate the feasibility and effectiveness of implementing E-WORTH in real-world CSPs. The findings lend further evidence to the promise of culturally tailored HIV/STI interventions for Black women. Trial Registration ClinicalTrials.gov Identifier: NCT02391233.",2021,"Importance Concentrated epidemics of HIV and sexually transmitted infections (STIs) have persisted among Black women in community supervision programs (CSPs) in the United States.","['November 18, 2015, (first recruitment) to August 20, 2019 (last 12-month follow-up', 'A total of 172 participants (48.9%) were assigned to the E-WORTH condition, and 180 (51.1', 'Black women in community supervision programs (CSPs) in the United States', '352 participants who identified as Black or African American were enrolled, including 79 (22.5%) who also identified as Latinx', 'Black women mandated to probation, parole, or alternative-to-incarceration programs in New York City who had a history of drug use', 'Black Women in Community Supervision Programs', 'Black women']","['Culturally Tailored HIV and Sexually Transmitted Infection Prevention Intervention', '5-session culturally tailored group-based intervention', 'E-WORTH', 'individualized computerized modules and streamlined HIV testing']","['condomless vaginal or anal intercourse', 'incidence of any STI (biologically assayed chlamydia, gonorrhea, and Trichomonas vaginalis) at the 12-month assessment and the number of condomless acts of vaginal or anal intercourse']","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517649', 'cui_str': '22.5'}, {'cui': 'C0205255', 'cui_str': 'Imprisonment'}, {'cui': 'C0027977', 'cui_str': 'New York City'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}]","[{'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}]","[{'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0556628', 'cui_str': 'Anal penetration'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0205460', 'cui_str': 'Biologic'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0040922', 'cui_str': 'Trichomonas vaginalis'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}]",352.0,0.213925,"Importance Concentrated epidemics of HIV and sexually transmitted infections (STIs) have persisted among Black women in community supervision programs (CSPs) in the United States.","[{'ForeName': 'Louisa', 'Initials': 'L', 'LastName': 'Gilbert', 'Affiliation': 'Social Intervention Group, Columbia University School of Social Work, New York, New York.'}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Goddard-Eckrich', 'Affiliation': 'Social Intervention Group, Columbia University School of Social Work, New York, New York.'}, {'ForeName': 'Mingway', 'Initials': 'M', 'LastName': 'Chang', 'Affiliation': 'Social Intervention Group, Columbia University School of Social Work, New York, New York.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Hunt', 'Affiliation': 'Social Intervention Group, Columbia University School of Social Work, New York, New York.'}, {'ForeName': 'Elwin', 'Initials': 'E', 'LastName': 'Wu', 'Affiliation': 'Social Intervention Group, Columbia University School of Social Work, New York, New York.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Johnson', 'Affiliation': 'University of Alabama School of Social Work, Tuscaloosa.'}, {'ForeName': 'Stanley', 'Initials': 'S', 'LastName': 'Richards', 'Affiliation': 'Fortune Society, Long Island City, New York.'}, {'ForeName': 'Sharun', 'Initials': 'S', 'LastName': 'Goodwin', 'Affiliation': 'New York City Department of Probation, New York, New York.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Tibbetts', 'Affiliation': 'New York City Department of Probation, New York, New York.'}, {'ForeName': 'Lisa R', 'Initials': 'LR', 'LastName': 'Metsch', 'Affiliation': 'Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York.'}, {'ForeName': 'Nabila', 'Initials': 'N', 'LastName': 'El-Bassel', 'Affiliation': 'Social Intervention Group, Columbia University School of Social Work, New York, New York.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.5226'] 2939,33833179,The Effect of Vibration on Pain During Intravenous Injection of Propofol: A Randomized Controlled Trial.,"PURPOSE Pain is a common side effect of intravenous injection of propofol. We conducted a randomized, prospective, single-blinded controlled trial to assess the efficacy of vibration analgesia on pain during propofol infusion in ambulatory surgery. METHODS After institutional review board approval, 100 patients undergoing elective ambulatory surgery with general anesthesia were randomized into 2 groups. A control group (n = 50) consisted of patients who received infusion of propofol without vibration analgesia. A treatment group (n = 50) consisted of patients who received infusion of propofol with vibration analgesia using the Buzzy device. Pain was assessed using a 4-point pain manifestation scale scored by 2 independent, blinded observers. RESULTS Participants in the treatment group with vibration analgesia were 0.47 times less likely (95% confidence interval, 0.24-0.94; P = 0.03) to experience any pain than the control group. The median summative pain score in the treatment group was significantly less than that of the control group [1 (interquartile range, 1-2) vs 2 (interquartile range, 2-4); P < 0.01] among participants who experienced any pain. Agreement between the 2 blinded observers regarding pain scores was excellent with κw = 0.82 (P < 0.001). Age, sex, body mass index, needle location or size, and medication doses did not differ significantly between the 2 groups. CONCLUSION Vibration analgesia is an effective, low-risk modality that reduces the pain of intravenous propofol injection in general anesthesia.",2021,Agreement between the 2 blinded observers regarding pain scores was excellent with κw = 0.82,['100 patients undergoing elective ambulatory surgery with general anesthesia'],"['Vibration', 'Vibration analgesia', 'propofol infusion', 'Propofol', 'propofol', 'propofol without vibration analgesia', 'propofol with vibration analgesia using the Buzzy device', 'vibration analgesia']","['pain', 'Pain', 'median summative pain score', 'pain scores', '4-point pain manifestation scale', 'vibration analgesia']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0002428', 'cui_str': 'Ambulatory surgery'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]",100.0,0.198721,Agreement between the 2 blinded observers regarding pain scores was excellent with κw = 0.82,"[{'ForeName': 'Lyahn K', 'Initials': 'LK', 'LastName': 'Hwang', 'Affiliation': 'From the Division of Plastic Surgery.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Nash', 'Affiliation': 'From the Division of Plastic Surgery.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Yedlin', 'Affiliation': 'Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Greige', 'Affiliation': 'From the Division of Plastic Surgery.'}, {'ForeName': 'Jessie', 'Initials': 'J', 'LastName': 'Larios-Valencia', 'Affiliation': 'From the Division of Plastic Surgery.'}, {'ForeName': 'Curtis', 'Initials': 'C', 'LastName': 'Choice', 'Affiliation': 'Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Aravind', 'Initials': 'A', 'LastName': 'Pothula', 'Affiliation': 'From the Division of Plastic Surgery.'}]",Annals of plastic surgery,['10.1097/SAP.0000000000002827'] 2940,33831623,Potential Efficacy of High-Dose Inhaled Salbutamol for the Treatment of Abdominal Pain During Oral Food Challenge.,"BACKGROUND Abdominal pain is a frequent symptom of IgE-mediated food allergy with limited therapeutic options. Visceral smooth muscle cell relaxation can be induced through beta-adrenergic stimulation. OBJECTIVE To evaluate the efficacy of inhaled salbutamol empirically used to relieve abdominal pain caused by IgE-mediated allergic reactions at 1 center. METHODS All double-blind placebo-controlled food challenges to peanut performed at 1 center between 2016 and 2021 were reviewed to identify patients who presented abdominal pain as part of their reaction. The primary outcome measure was the delay between the initiation of therapy and improvement of abdominal pain. It was compared between patients who had received inhaled salbutamol as part of their treatment and those who did not. Cox regression was performed to control for potential confounders. RESULTS During the study period, 186 positive double-blind placebo-controlled food challenges were performed, including 126 for peanut allergy. Of these, 77 were treated for abdominal pain and 57 met the criteria for inclusion in the study. Patients who received salbutamol improved significantly faster (median, 12.5 minutes) than those who did not (median, 65 minutes) (χ 2  = 45; P < .0001). In Cox regression, the administration of salbutamol and emesis were found to increase the rate of improvement by a hazard ratio of 11.35 (95% CI, 5.40-23.9; P < .0005) and 4.00-fold (95% CI, 1.90-8.42; P < .0005), respectively. CONCLUSIONS This retrospective study provides hypothesis-generating evidence for the use of salbutamol in the treatment of IgE-mediated abdominal pain. Further investigation in a double-blind randomized controlled trial is warranted.",2021,Patients that received salbutamol improved significantly faster (median 12.5 minutes) than those that did not (median 65 minutes) (χ 2 =45; p<0.0001).,"['IgE-mediated abdominal pain', '186 positive DBPCFCs were performed, including 126 for peanut allergy', 'abdominal pain during oral food challenge', 'controlled food challenges to peanut performed at on center between 2016 and 2021 were reviewed to identify patients that presented abdominal pain as part of their reaction', '77 were treated for abdominal pain and 57 met the criteria for inclusion in the study']","['placebo', 'salbutamol', 'inhaled salbutamol']","['abdominal pain', 'delay between the initiation of therapy and improvement of abdominal pain']","[{'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0559470', 'cui_str': 'Allergy to peanut'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C1269815', 'cui_str': 'Patient identification'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}]","[{'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",,0.668622,Patients that received salbutamol improved significantly faster (median 12.5 minutes) than those that did not (median 65 minutes) (χ 2 =45; p<0.0001).,"[{'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Frugier', 'Affiliation': 'Department of Pediatrics, Section of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Graham', 'Affiliation': ""Department of Pediatrics, Section of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada; Department of Medicine, Section of Allergy and Clinical Immunology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Samaan', 'Affiliation': 'Department of Pediatrics, Section of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Paradis', 'Affiliation': ""Department of Pediatrics, Section of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada; Department of Medicine, Section of Allergy and Clinical Immunology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Des Roches', 'Affiliation': 'Department of Pediatrics, Section of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Bégin', 'Affiliation': ""Department of Pediatrics, Section of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada; Department of Medicine, Section of Allergy and Clinical Immunology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada. Electronic address: philippe.begin.med@ssss.gouv.qc.ca.""}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2021.03.040'] 2941,33834505,"Effectiveness of a nurse-led, face-to-face health coaching intervention in enhancing activation and secondary outcomes of primary care users with chronic conditions.","Prevalence of chronic diseases and multimorbidity is rising, and it remains unclear what the best strategy is for activating people with chronic conditions in their self-care. We designed a two-group quasi-experimental time series trial to examine the effectiveness of a nurse-led, face-to-face, individually-tailored health coaching (HC) intervention in improving patient activation and secondary outcomes (self-efficacy, quality of life, anxiety and depression symptoms, medication adherence, hospitalization and emergency visits) among primary care users with chronic conditions. A total of 118 people with chronic conditions were recruited through a primary care center and allocated to either the intervention group (IG) (n = 58) or control group (CG) (n = 60). The IG received a nurse-led individually-tailored HC intervention involving 4-6 face-to-face multicomponent sessions covering six core activation topics. The CG received usual primary care. Data were collected at baseline, after the intervention (6 weeks after baseline for controls) and at 6 and 12 months from baseline. Compared with controls, the IG had significantly higher patient activation scores after the intervention (73.29 vs. 66.51, p = .006). However, this improvement was not maintained at follow-up and there were no significant differences in secondary outcomes across the study period. HC may be an effective strategy for achieving short-term improvements in the activation of primary care users with chronic conditions. Further studies with different methodological approaches are needed to elucidate how HC may improve and sustain changes in patient activation.",2021,"However, this improvement was not maintained at follow-up and there were no significant differences in secondary outcomes across the study period.","['118 people with chronic conditions', 'primary care users with chronic conditions']","['nurse-led individually-tailored HC intervention', 'nurse-led, face-to-face, individually-tailored health coaching (HC) intervention', 'intervention group (IG) (n\u2009=\u200958) or control group (CG', 'nurse-led, face-to-face health coaching intervention']","['patient activation scores', 'patient activation and secondary outcomes (self-efficacy, quality of life, anxiety and depression symptoms, medication adherence, hospitalization and emergency visits']","[{'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C3853034', 'cui_str': 'Patient Activation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}]",118.0,0.045282,"However, this improvement was not maintained at follow-up and there were no significant differences in secondary outcomes across the study period.","[{'ForeName': 'Cibeles', 'Initials': 'C', 'LastName': 'Moreno-Chico', 'Affiliation': 'Department of Nursing, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, Spain.'}, {'ForeName': 'Callista', 'Initials': 'C', 'LastName': 'Roy', 'Affiliation': ""Mount Saint Mary's University Los Angeles, Los Angeles, California, USA.""}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Monforte-Royo', 'Affiliation': 'Department of Nursing, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'González-De Paz', 'Affiliation': ""Les Corts Primary Healthcare Center, Consorci d'Atenció Primària de Salut Barcelona Esquerra, Barcelona, Spain.""}, {'ForeName': 'Maria D', 'Initials': 'MD', 'LastName': 'Navarro-Rubio', 'Affiliation': ""Patient and Family Empowerment, Sant Joan de Deu Children's Hospital, Barcelona, Spain.""}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Gallart Fernández-Puebla', 'Affiliation': 'Department of Nursing, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, Spain.'}]",Research in nursing & health,['10.1002/nur.22132'] 2942,34386602,"Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.","Background and Aim Ropeginterferon alfa-2b (P1101) is a novel long-acting mono-PEGylated recombinant proline interferon (IFN) conjugated to a 40 kDa branched polyethylene glycol (PEG) chain at its N-terminus, allowing every-two-week injection. It received European Medicines Agency and Taiwan marketing authorization for the treatment of polycythemia vera in 2019 and 2020, respectively. This phase 2 study aimed to evaluate the pharmacokinetics, safety, and preliminary efficacy of ropeginterferon alfa-2b as compared with PEG-IFN-α2a in patients with chronic hepatitis C virus genotype 1 infection. Methods One hundred six treatment naive patients were enrolled in this phase 2 study and randomized to four treatment groups: subcutaneous weekly PEG-IFN-α2a 180 μg (group 1), weekly ropeginterferon alfa-2b 180 μg (group 2), weekly ropeginterferon alfa-2b 270 μg (group 3), or biweekly ropeginterferon alfa-2b 450 μg (group 4) plus ribavirin for 48 weeks. Results After multiple weekly administration, serum exposure (AUC 0-τ ) in ropeginterferon alfa-2b 180 μg was approximately 41% greater and the accumulation ratio of 2-fold greater than PEG-IFN-α2a 180 μg. The incidences of flu-like symptoms were 66.7% (18/27), 53.3% (16/30), 55.0% (11/20), and 48.3% (14/29), anxiety were 14.8% (4/27), 6.7% (2/30), 0%, and 0%, and depression were 25.9% (7/27), 13.3% (4/30), 0%, and 3.4% (1/29), for groups 1-4, respectively. Two grade 2 of 3 depression were noted in PEG-IFN-α2a arm, but none in ropeginterferon arms. The SVR24 rates were 77.8% (21/27), 66.7% (20/30), 80% (16/20), and 69% (20/29), respectively. Conclusions Ropeginterferon alfa-2b showed longer effective half-life and superior safety profile than PEG-IFN-α2a. Biweekly injection of ropeginterferon alfa-2b will be studied in larger viral hepatitis patient population.",2021,"The SVR24 rates were 77.8% (21/27), 66.7% (20/30), 80% (16/20), and 69% (20/29), respectively. ","['patients with chronic hepatitis C virus genotype 1 infection', 'larger viral hepatitis patient population', 'patients with genotype 1 chronic hepatitis C', 'One hundred six treatment naive patients']","['PEG-IFN-α2a', 'subcutaneous weekly PEG-IFN-α2a 180\u2009μg (group 1), weekly ropeginterferon alfa-2b 180\u2009μg (group 2), weekly ropeginterferon alfa-2b 270\u2009μg (group 3), or biweekly ropeginterferon alfa-2b 450\u2009μg (group 4) plus ribavirin', 'ropeginterferon alfa-2b', 'Ropeginterferon alfa-2b', 'Ropeginterferon alfa-2b (P1101']","['SVR24 rates', 'anxiety', 'depression', 'accumulation ratio', 'incidences of flu-like symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3805156', 'cui_str': 'Chronic hepatitis C virus genotype 1'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0042721', 'cui_str': 'Viral hepatitis'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0524910', 'cui_str': 'Chronic hepatitis C'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0032483', 'cui_str': 'Polyethylene Glycols'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0585332', 'cui_str': 'Biweekly'}, {'cui': 'C3844104', 'cui_str': '450'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0035525', 'cui_str': 'Ribavirin'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0392171', 'cui_str': 'Influenza-like symptoms'}]",106.0,0.0586921,"The SVR24 rates were 77.8% (21/27), 66.7% (20/30), 80% (16/20), and 69% (20/29), respectively. ","[{'ForeName': 'Hsien-Hong', 'Initials': 'HH', 'LastName': 'Lin', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine Taipei Tzu Chi Hospital Taipei Taiwan.'}, {'ForeName': 'Shih-Jer', 'Initials': 'SJ', 'LastName': 'Hsu', 'Affiliation': 'Department of Internal Medicine National Taiwan University Hospital Yunlin Branch Douliu and Huwei Taiwan.'}, {'ForeName': 'Sheng-Nan', 'Initials': 'SN', 'LastName': 'Lu', 'Affiliation': 'Division of Hepatogastroenterology, Department of Internal Medicine Chia-Yi Chang Gung Memorial Hospital Puzi Taiwan.'}, {'ForeName': 'Wan-Long', 'Initials': 'WL', 'LastName': 'Chuang', 'Affiliation': 'Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung Taiwan.'}, {'ForeName': 'Chao-Wei', 'Initials': 'CW', 'LastName': 'Hsu', 'Affiliation': 'Division of Hepatology, Department of Gastroenterology and Hepatology Linkou Medical Center, Chang Gung Memorial Hospital Taoyuan Taiwan.'}, {'ForeName': 'Rong-Nan', 'Initials': 'RN', 'LastName': 'Chien', 'Affiliation': 'Division of Hepatology, Department of Gastroenterology and Hepatology Linkou Medical Center, Chang Gung Memorial Hospital Taoyuan Taiwan.'}, {'ForeName': 'Sien-Sing', 'Initials': 'SS', 'LastName': 'Yang', 'Affiliation': 'Liver Center, Department of Internal Medicine Cathay General Hospital Medical Center Taipei Taiwan.'}, {'ForeName': 'Wei-Wen', 'Initials': 'WW', 'LastName': 'Su', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine Changhua Christian Hospital Changhua Taiwan.'}, {'ForeName': 'Jaw-Ching', 'Initials': 'JC', 'LastName': 'Wu', 'Affiliation': 'Medical Research Department Taipei Veterans General Hospital Taipei Taiwan.'}, {'ForeName': 'Tzong-Hsi', 'Initials': 'TH', 'LastName': 'Lee', 'Affiliation': 'Division Gastroenterology, Department of Internal Medicine Far-Eastern Memorial Hospital New Taipei City Taiwan.'}, {'ForeName': 'Cheng-Yuan', 'Initials': 'CY', 'LastName': 'Peng', 'Affiliation': 'Center for Digestive Medicine, Department of Internal Medicine China Medical University Hospital, and School of Medicine, China Medical University Taichung Taiwan.'}, {'ForeName': 'Kuan-Chiao', 'Initials': 'KC', 'LastName': 'Tseng', 'Affiliation': 'Department of Medical Research PharmaEssentia Corp Taipei Taiwan.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Qin', 'Affiliation': 'Department of Medical Research PharmaEssentia Corp Taipei Taiwan.'}, {'ForeName': 'Yi-Wen', 'Initials': 'YW', 'LastName': 'Huang', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine Taipei Medical University Taipei Taiwan.'}, {'ForeName': 'Pei-Jer', 'Initials': 'PJ', 'LastName': 'Chen', 'Affiliation': 'Graduate Institute of Clinical Medicine National Taiwan University College of Medicine Taipei Taiwan.'}]",JGH open : an open access journal of gastroenterology and hepatology,['10.1002/jgh3.12613'] 2943,33829647,Sex-specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants-A substudy of the EINSTEIN-PE study.,"BACKGROUND It is unknown whether differences in clot structure and resolution contribute to the reported risk differences of recurrent venous thromboembolism (VTE) between men and women. PATIENTS/METHODS We used data from the EINSTEIN-PE study, a randomized, multicenter, non-inferiority study in which patients 18 years and older with acute symptomatic pulmonary embolism (PE) were randomized to rivaroxaban or enoxaparin followed by a vitamin K antagonist. PE was diagnosed by computed tomography pulmonary angiography scan or high-probability ventilation/perfusion scintigraphy. Three weeks after randomization a follow-up scan was performed. An independent adjudication committee assessed the degree of vascular obstruction. RESULTS AND CONCLUSIONS A total of 371 participants including 174 (46.9%) women and 197 (53.0%) men were included in the present analysis. At 3 weeks, there was no difference between men and women in complete clot resolution: 39.6% and 40.2%, respectively. The absolute reduction in pulmonary vascular obstruction at week 3 was also similar: 12.9% (95% confidence interval [CI]: 11.6-14.2) in men and 12.1% (95% CI: 10.4-13.7) in women, corresponding to a resolution ratio of 0.29 (95% CI: 0.24-0.33) and 0.35 (95% CI: 0.28-0.42), respectively. No differences in clot resolution were observed between men and women diagnosed with acute PE at 3 weeks after start of anticoagulant therapy. These findings suggest that the reported higher rate of VTE recurrence in men cannot be explained by decreased clot resolution.",2021,"At 3 weeks, there was no difference between men and women in complete clot resolution: 39.6% and 40.2%, respectively.","['patients of 18 years and older with acute symptomatic pulmonary embolism (PE', 'men and women', 'A total of 371 participants including 174 (46.9%) women and 197 (53.0%) men were included in the present analysis']","['vitamin K antagonist', 'rivaroxaban or enoxaparin', 'computed tomography pulmonary angiography scan or high-probability ventilation/perfusion scintigraphy']","['rate of VTE recurrence', 'complete clot resolution', 'pulmonary vascular obstruction', 'clot resolution']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0677490', 'cui_str': 'Angiogram pulmonary'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C2350394', 'cui_str': 'Perfusion Scintigraphy'}]","[{'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009074', 'cui_str': 'Clotrimazole'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C1096458', 'cui_str': 'Vascular occlusion'}]",371.0,0.279325,"At 3 weeks, there was no difference between men and women in complete clot resolution: 39.6% and 40.2%, respectively.","[{'ForeName': 'Hanke M G', 'Initials': 'HMG', 'LastName': 'Wiegers', 'Affiliation': 'Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Josien', 'Initials': 'J', 'LastName': 'van Es', 'Affiliation': 'Department of Pulmonology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Ákos F', 'Initials': 'ÁF', 'LastName': 'Pap', 'Affiliation': 'Bayer AG, Wuppertal, Germany.'}, {'ForeName': 'Anthonie W A', 'Initials': 'AWA', 'LastName': 'Lensing', 'Affiliation': 'Bayer AG, Wuppertal, Germany.'}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Middeldorp', 'Affiliation': 'Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Luuk J J', 'Initials': 'LJJ', 'LastName': 'Scheres', 'Affiliation': 'Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.15326'] 2944,33827781,Editor's Choice - Risk of Stroke before Revascularisation in Patients with Symptomatic Carotid Stenosis: A Pooled Analysis of Randomised Controlled Trials.,"OBJECTIVE Current guidelines recommending rapid revascularisation of symptomatic carotid stenosis are largely based on data from clinical trials performed at a time when best medical therapy was potentially less effective than today. The risk of stroke and its predictors among patients with symptomatic carotid stenosis awaiting revascularisation in recent randomised controlled trials (RCTs) and in medical arms of earlier RCTs was assessed. METHODS The pooled data of individual patients with symptomatic carotid stenosis randomised to stenting (CAS) or endarterectomy (CEA) in four recent RCTs, and of patients randomised to medical therapy in three earlier RCTs comparing CEA vs. medical therapy, were compared. The primary outcome event was any stroke occurring between randomisation and treatment by CAS or CEA, or within 120 days after randomisation. RESULTS A total of 4 754 patients from recent trials and 1 227 from earlier trials were included. In recent trials, patients were randomised a median of 18 (IQR 7, 50) days after the qualifying event (QE). Twenty-three suffered a stroke while waiting for revascularisation (cumulative 120 day risk 1.97%, 95% confidence interval [CI] 0.75 - 3.17). Shorter time from QE until randomisation increased stroke risk after randomisation (χ 2  = 6.58, p = .011). Sixty-one patients had a stroke within 120 days of randomisation in the medical arms of earlier trials (cumulative risk 5%, 95% CI 3.8 - 6.2). Stroke risk was lower in recent than earlier trials when adjusted for time between QE and randomisation, age, severity of QE, and degree of carotid stenosis (HR 0.47, 95% CI 0.25 - 0.88, p = .019). CONCLUSION Patients with symptomatic carotid stenosis enrolled in recent large RCTs had a lower risk of stroke after randomisation than historical controls. The added benefit of carotid revascularisation to modern medical care needs to be revisited in future studies. Until then, adhering to current recommendations for early revascularisation of patients with symptomatic carotid stenosis considered to require invasive treatment is advisable.",2021,"Shorter time from QE until randomisation increased stroke risk after randomisation (χ 2  = 6.58, p = .011).","['patients with symptomatic carotid stenosis awaiting revascularisation', 'Patients with symptomatic carotid stenosis', 'patients with symptomatic carotid stenosis', 'A total of 4 754 patients from recent trials and 1 227 from earlier trials were included', 'Patients with Symptomatic Carotid Stenosis', 'individual patients with symptomatic carotid stenosis randomised to']","['stenting (CAS) or endarterectomy (CEA', 'carotid revascularisation']","['stroke risk', 'severity of QE, and degree of carotid stenosis', 'Stroke risk', 'risk of stroke', 'stroke occurring between randomisation and treatment by CAS or CEA', 'stroke while waiting for revascularisation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0007282', 'cui_str': 'Carotid artery stenosis'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0007282', 'cui_str': 'Carotid artery stenosis'}, {'cui': 'C0014098', 'cui_str': 'Endarterectomy'}, {'cui': 'C0007082', 'cui_str': 'Carcinoembryonic antigen'}, {'cui': 'C3495793', 'cui_str': 'Carotid revascularisation'}]","[{'cui': 'C1277291', 'cui_str': 'Stroke risk'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0007282', 'cui_str': 'Carotid artery stenosis'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0007082', 'cui_str': 'Carcinoembryonic antigen'}, {'cui': 'C0542399', 'cui_str': 'Patient waiting for'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]",4754.0,0.417145,"Shorter time from QE until randomisation increased stroke risk after randomisation (χ 2  = 6.58, p = .011).","[{'ForeName': 'Urs', 'Initials': 'U', 'LastName': 'Fisch', 'Affiliation': 'Department of Neurology and Stroke Centre, Department of Clinical Research, University Hospital, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'von Felten', 'Affiliation': 'Clinical Trial Unit, Department of Clinical Research, University of Basel, Basel, Switzerland; Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Wiencierz', 'Affiliation': 'Clinical Trial Unit, Department of Clinical Research, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Olav', 'Initials': 'O', 'LastName': 'Jansen', 'Affiliation': 'Clinic for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Howard', 'Affiliation': 'Department of Biostatistics, UAB School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Hendrikse', 'Affiliation': 'Department of Radiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Halliday', 'Affiliation': 'Nuffield Department of Surgery University of Oxford, Oxford, UK.'}, {'ForeName': 'Gustav', 'Initials': 'G', 'LastName': 'Fraedrich', 'Affiliation': 'Department of Vascular Surgery, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Hans-Henning', 'Initials': 'HH', 'LastName': 'Eckstein', 'Affiliation': 'Department for Vascular and Endovascular Surgery-Vascular Centre, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Calvet', 'Affiliation': 'Department of Neurology, Hôpital Sainte-Anne, Université Paris-Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM U894, Paris, France.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Bulbulia', 'Affiliation': 'Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Becquemin', 'Affiliation': 'Vascular Institute of Paris East, Hôspital Paul D Egine, Champigny-sur-Marne, France.'}, {'ForeName': 'Ale', 'Initials': 'A', 'LastName': 'Algra', 'Affiliation': 'Department of Neurology and Neurosurgery, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rothwell', 'Affiliation': 'Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital and University of Oxford, Oxford, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Ringleb', 'Affiliation': 'Department of Neurology, University of Heidelberg Medical School, Heidelberg, Germany.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Mas', 'Affiliation': 'Department of Neurology, Hôpital Sainte-Anne, Université Paris-Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM U894, Paris, France.'}, {'ForeName': 'Martin M', 'Initials': 'MM', 'LastName': 'Brown', 'Affiliation': 'Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UK.'}, {'ForeName': 'Thomas G', 'Initials': 'TG', 'LastName': 'Brott', 'Affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Leo H', 'Initials': 'LH', 'LastName': 'Bonati', 'Affiliation': 'Department of Neurology and Stroke Centre, Department of Clinical Research, University Hospital, University of Basel, Basel, Switzerland; Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UK. Electronic address: leo.bonati@usb.ch.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,['10.1016/j.ejvs.2021.02.024'] 2945,33826418,Effect of Novel Breastfeeding Smartphone Applications on Breastfeeding Rates.,"Background: Low-income women are less likely to breastfeed than high-income women. Technology-based interventions demonstrate promise in decreasing health disparities. We assessed whether increased use of breastfeeding smartphone applications (apps) impacts breastfeeding rates for low-income women. Materials and Methods: This is a secondary analysis of a randomized control trial (RCT), including nulliparous, low-income women. Women were randomized to one of two novel apps: control app containing digital breastfeeding handouts and BreastFeeding Friend (BFF), an interactive app containing on-demand breastfeeding educational and video content. App usage was securely tracked. The highest quartile of BFF and control app users were combined and compared to the lowest quartile of app users. The primary outcome was breastfeeding initiation. Secondary outcomes included breastfeeding outcomes and resource preferences through 6 months. Results: In the RCT, BFF and control app median uses were 15 (interquartile range [IQR] 4-24) and 9 (IQR 5-19) ( p  = 0.1), respectively. Breastfeeding initiation did not differ with app usage (84.1% in highest quartile versus 78.2% for lowest quartile; p  = 0.5). Rates of sustained and exclusive breastfeeding through 6 months were similar between groups. Among both groups, smartphone apps were the most preferred breastfeeding resource at 6 weeks. Low quartile users also preferred alternative online breastfeeding resources: >50% of all users preferred technology-based breastfeeding resources. Conclusions: Increased usage of breastfeeding apps did not improve breastfeeding rates among low-income women. However, technology-based resources were the most preferred breastfeeding resource after hospital discharge, indicating ongoing development of technology-based interventions has potential to increase breastfeeding in this high-needs population. clinicaltrials.gov (NCT03167073).",2021,Breastfeeding initiation did not differ with app usage (84.1% in highest quartile versus 78.2% for lowest quartile; p  = 0.5).,"['low-income women', 'nulliparous, low-income women']","['control app containing digital breastfeeding handouts and BreastFeeding Friend (BFF), an interactive app containing on-demand breastfeeding educational and video content', 'breastfeeding smartphone applications', 'Novel Breastfeeding Smartphone Applications']","['Breastfeeding initiation', 'breastfeeding initiation', 'breastfeeding outcomes and resource preferences through 6 months', 'Breastfeeding Rates', 'breastfeeding rates']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",,0.0507374,Breastfeeding initiation did not differ with app usage (84.1% in highest quartile versus 78.2% for lowest quartile; p  = 0.5).,"[{'ForeName': 'Laurie B', 'Initials': 'LB', 'LastName': 'Griffin', 'Affiliation': 'Department of Obstetrics and Gynecology, Women and Infants Hospital, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.'}, {'ForeName': 'Julia D', 'Initials': 'JD', 'LastName': 'López', 'Affiliation': 'Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.'}, {'ForeName': 'Megan L', 'Initials': 'ML', 'LastName': 'Ranney', 'Affiliation': 'Department of Emergency Medicine, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Macones', 'Affiliation': ""Department of Women's Health, Dell Medical School, University of Texas at Austin, Austin, Texas, USA.""}, {'ForeName': 'Alison G', 'Initials': 'AG', 'LastName': 'Cahill', 'Affiliation': ""Department of Women's Health, Dell Medical School, University of Texas at Austin, Austin, Texas, USA.""}, {'ForeName': 'Adam K', 'Initials': 'AK', 'LastName': 'Lewkowitz', 'Affiliation': 'Department of Obstetrics and Gynecology, Women and Infants Hospital, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2021.0012'] 2946,33831566,Multiple-day high-dose beetroot juice supplementation does not improve pulmonary or muscle deoxygenation kinetics of well-trained cyclists in normoxia and hypoxia.,"Dietary nitrate (NO 3 - ) supplementation via beetroot juice (BR) has been reported to lower oxygen cost (i.e., increased exercise efficiency) and speed up oxygen uptake (VO 2 ) kinetics in untrained and moderately trained individuals, particularly during conditions of low oxygen availability (i.e., hypoxia). However, the effects of multiple-day, high dose (12.4 mmol NO 3- per day) BR supplementation on exercise efficiency and VO 2 kinetics during normoxia and hypoxia in well-trained individuals are not resolved. In a double-blinded, randomized crossover study, 12 well-trained cyclists (66.4 ± 5.3 ml min -1 ∙kg -1 ) completed three transitions from rest to moderate-intensity (~70% of gas exchange threshold) cycling in hypoxia and normoxia with supplementation of BR or nitrate-depleted BR as placebo. Continuous measures of VO 2 and muscle (vastus lateralis) deoxygenation (ΔHHb, using near-infrared spectroscopy) were acquired during all transitions. Kinetics of VO 2 and deoxygenation (ΔHHb) were modeled using mono-exponential functions. Our results showed that BR supplementation did not alter the primary time constant for VO 2 or ΔHHb during the transition from rest to moderate-intensity cycling. While BR supplementation lowered the amplitude of the VO 2 response (2.1%, p = 0.038), BR did not alter steady state VO 2 derived from the fit (p = 0.258), raw VO 2 data (p = 0.231), moderate intensity exercise efficiency (p = 0.333) nor steady state ΔHHb (p = 0.224). Altogether, these results demonstrate that multiple-day, high-dose BR supplementation does not alter exercise efficiency or oxygen uptake kinetics during normoxia and hypoxia in well-trained athletes.",2021,"While BR supplementation lowered the amplitude of the VO 2 response (2.1%, p=0.038), BR did not alter steady state VO 2 derived from the fit (p=0.258), raw VO 2 data (p=0.231), moderate intensity exercise efficiency (p=0.333) nor steady state ΔHHb (p=0.224).",['12 well-trained cyclists (66.4 ± 5.3 ml min -1 ∙kg -1 ) completed three'],"['Dietary nitrate (NO 3 - ) supplementation via beetroot juice (BR', 'transitions from rest to moderate-intensity (∼70% of gas exchange threshold) cycling in hypoxia and normoxia with supplementation of BR or nitrate-depleted BR as placebo', 'BR supplementation']","['exercise efficiency) and speed up oxygen uptake (VO 2 ) kinetics', 'Kinetics of VO 2 and deoxygenation (ΔHHb', 'pulmonary or muscle deoxygenation kinetics', 'exercise efficiency or oxygen uptake kinetics', 'moderate intensity exercise efficiency', 'VO 2 and muscle (vastus lateralis) deoxygenation (ΔHHb, using near-infrared spectroscopy', 'amplitude of the VO 2 response']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C1301862', 'cui_str': 'Min 1'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0376519', 'cui_str': 'Near-infrared spectroscopy'}]",12.0,0.160861,"While BR supplementation lowered the amplitude of the VO 2 response (2.1%, p=0.038), BR did not alter steady state VO 2 derived from the fit (p=0.258), raw VO 2 data (p=0.231), moderate intensity exercise efficiency (p=0.333) nor steady state ΔHHb (p=0.224).","[{'ForeName': 'Torben', 'Initials': 'T', 'LastName': 'Rokkedal-Lausch', 'Affiliation': 'Sport Sciences - Performance and Technology, Department of Health Science and Technology, Aalborg University, DK-9220, Aalborg, Denmark. Electronic address: torben@hst.aau.dk.'}, {'ForeName': 'Jesper', 'Initials': 'J', 'LastName': 'Franch', 'Affiliation': 'Sport Sciences - Performance and Technology, Department of Health Science and Technology, Aalborg University, DK-9220, Aalborg, Denmark.'}, {'ForeName': 'Mathias K', 'Initials': 'MK', 'LastName': 'Poulsen', 'Affiliation': 'Respiratory and Critical Care Group, Department of Health Science and Technology, Aalborg University, DK-9220, Aalborg, Denmark.'}, {'ForeName': 'Lars P', 'Initials': 'LP', 'LastName': 'Thomsen', 'Affiliation': 'Respiratory and Critical Care Group, Department of Health Science and Technology, Aalborg University, DK-9220, Aalborg, Denmark.'}, {'ForeName': 'Eddie', 'Initials': 'E', 'LastName': 'Weitzberg', 'Affiliation': 'Department of Physiology and Pharmacology, Karolinska Institutet, 171 77, Stockholm, Sweden.'}, {'ForeName': 'Ernest N', 'Initials': 'EN', 'LastName': 'Kamavuako', 'Affiliation': ""Center for Robotics Research, Department of Engineering, King's College London, London, United Kingdom.""}, {'ForeName': 'Dan S', 'Initials': 'DS', 'LastName': 'Karbing', 'Affiliation': 'Respiratory and Critical Care Group, Department of Health Science and Technology, Aalborg University, DK-9220, Aalborg, Denmark.'}, {'ForeName': 'Ryan G', 'Initials': 'RG', 'LastName': 'Larsen', 'Affiliation': 'Sport Sciences - Performance and Technology, Department of Health Science and Technology, Aalborg University, DK-9220, Aalborg, Denmark.'}]",Nitric oxide : biology and chemistry,['10.1016/j.niox.2021.03.006'] 2947,33831552,Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.,"OBJECTIVE Many patients with type 2 diabetes treated with premixed insulin gradually have inadequate glycemic control and switch to a basal-bolus regimen, which raises some concerns for weight gain and increased hypoglycemic risk. Switching to combination use of glp-1 agonist and basal insulin may be an alternative option. METHODS After a 12-week premixed human insulin 70/30 dosage optimization period, 200 patients with HbA1c of 7.0% to 10.0% were randomized into 24-week treatment groups with exenatide twice a day plus glargine or with aspart 70/30 twice a day. RESULTS After 24 weeks, the patients receiving exenatide plus glargine (n = 90) had improved HbA1c control compared with those receiving aspart 70/30 (n = 90) (least squares mean change: ‒0.59 vs ‒0.13%; difference [95% CI]: ‒0.45 [‒0.74 to ‒0.17]) in the full analysis set population. Weight decreased 3.5 kg with exenatide and decreased 0.4 kg with aspart 70/30 (P < .001). The insulin dose was reduced 10.7 units/day (95% CI, ‒12.2 to ‒9.2 units; P < .001) with exenatide, and increased 9.7 units/day (95% CI, 8.2 to 11.2 units; P < .001) with aspart 70/30. The most common adverse events were gastrointestinal adverse effects in the exenatide group (nausea [21%], vomiting [16%], diarrhea [13%]). The incidence of hypoglycemia was similar in 2 groups (27% for exenatide and 38% for aspart 70/30; P = .1). CONCLUSION In premixed human insulin‒treated patients with type 2 diabetes with inadequate glycemic control, switching to exenatide twice a day plus glargine was superior to aspart 70/30 twice a day for glycemic and weight control.",2021,"The incidence of hypoglycaemia was similar in two groups (27% for exenatide and 38% for aspart 70/30, respectively; P = 0.1). ","['200 patients with HbA1c of 7.0% to 10.0', 'type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and', '2 diabetic patients with inadequate glycaemic control']","['Exenatide twice daily plus glargine vs. aspart', 'premixed human insulin-treated type', 'exenatide BID plus glargine', 'exenatide BID plus glargine or with aspart 70/30 BID', 'premixed insulin', 'exenatide plus glargine', 'metformin', 'glp-1 agonist and basal insulin', 'premixed human insulin', 'exenatide']","['Weight', 'incidence of hypoglycaemia', 'nausea', 'diarrhea', 'vomiting', 'HbA1c control']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0795635', 'cui_str': 'Regular Insulin, Human'}]","[{'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C0123677', 'cui_str': 'Insulin, Aspart, Human'}, {'cui': 'C0795635', 'cui_str': 'Regular Insulin, Human'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0205112', 'cui_str': 'Basal'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",200.0,0.086415,"The incidence of hypoglycaemia was similar in two groups (27% for exenatide and 38% for aspart 70/30, respectively; P = 0.1). ","[{'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Division of Endocrinology, Branch of National Clinical Research Center for Metabolic Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Yongping', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Division of Endocrinology, Branch of National Clinical Research Center for Metabolic Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Division of Endocrinology, Branch of National Clinical Research Center for Metabolic Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Shiyin', 'Initials': 'S', 'LastName': 'Shao', 'Affiliation': 'Division of Endocrinology, Branch of National Clinical Research Center for Metabolic Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Yanran', 'Initials': 'Y', 'LastName': 'Duan', 'Affiliation': 'Department of Epidemiology and Health Statistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Peiwen', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Clinic of Peiwen Liu, Xinhua Hospital, Wuhan, China.'}, {'ForeName': 'Liya', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Wuhan Sixth Hospital, Wuhan, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Combine Traditional Chinese and Western Medicine Hospital, Wuhan, China.'}, {'ForeName': 'Jiaoe', 'Initials': 'J', 'LastName': 'Zeng', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Jingzhou Central Hospital, Jingzhou, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Wuhan PuAi Hospital, Wuhan, China.'}, {'ForeName': 'Shi', 'Initials': 'S', 'LastName': 'Zhao', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Wuhan Central Hospital, Wuhan, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Nanjing First Hospital, Nanjing, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhao', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Xiaogan Central Hospital, Xiaogan, China.'}, {'ForeName': 'Juping', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': ""Division of Endocrinology, Department of Internal Medicine, The Third People's Hospital of Hubei Province, Wuhan, China.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Liao', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, The Armed Police General Hospital, Chongqing, China.'}, {'ForeName': 'Xiaowen', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Huangshi Central Hospital, Huangshi, China.'}, {'ForeName': 'Shufang', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Hankou Railway Hospital. Wuhan, China.'}, {'ForeName': 'Yaoming', 'Initials': 'Y', 'LastName': 'Xue', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Nanfang Hospital, Southern Medical University. Guangzhou, China.'}, {'ForeName': 'Zhaoyang', 'Initials': 'Z', 'LastName': 'Zeng', 'Affiliation': 'Division of Endocrinology, Department of Internal Medicine, Yichang Central Hospital, Yichang, China.'}, {'ForeName': 'Wentao', 'Initials': 'W', 'LastName': 'He', 'Affiliation': 'Division of Endocrinology, Branch of National Clinical Research Center for Metabolic Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Zhelong', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Division of Endocrinology, Branch of National Clinical Research Center for Metabolic Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Wenjun', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Computer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Liegang', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Yin', 'Affiliation': 'Department of Epidemiology and Health Statistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Xuefeng', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': 'Division of Endocrinology, Branch of National Clinical Research Center for Metabolic Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: xfyu188@163.com.'}]",Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,['10.1016/j.eprac.2021.03.015'] 2948,33835051,Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora.,"Background We aimed to evaluate the therapeutic effect of additional ursodeoxycholic acid (UDCA) with mesalazine, compared to mesalazine alone in patients with ulcerative colitis (UC). The mechanism was evaluated by monitoring the changes of IL-23-IL-17 axis and the intestinal microflora. Methods In this prospective, single center study, patients with UC were randomly assigned to the Mesalazine group (n=20) or the UDCA + Mesalazine group (n=20). Mayo score and Inflammatory Bowel Disease Questionnaire (IBDQ), and fecal samples for 16S rRNA sequencing and blood samples for IL-23 and IL-17 ELISA were collected for analysis. Results Mayo scores and IBDQ score of the UDCA + Mesalazine group were significantly better than those of the Mesalazine group (P = 0.015 and P < 0.001, respectively). At post-treatment week 4, IL-23 and IL-17 levels were significantly lower in the UDCA + Mesalazine group compared to those in the Mesalazine group (both P < 0.038). In patients with UC after treatment, Firmicutes in the UDCA + Mesalazine group was higher than those in the Mesalazine group (P < 0.001). The UDCA + Mesalazine group showed lower percentage of Proteobacteria compared to those in the Mesalazine group (P < 0.001). Conclusion Additional UDCA could provide better therapeutic effects than mesalazine alone, possibly due to the change of IL-23 and IL-17 and the proportional distribution of intestinal microflora.",2021,"At post-treatment week 4, IL-23 and IL-17 levels were significantly lower in the UDCA + Mesalazine group compared to those in the Mesalazine group (both P < 0.038).","['patients with ulcerative colitis (UC', 'patients with UC', 'patients with ulcerative colitis']","['ursodeoxycholic acid (UDCA', 'UDCA', 'mesalazine', 'Mesalazine', 'UDCA + Mesalazine', 'ursodeoxycholic acid']","['percentage of Proteobacteria', 'Mayo score and Inflammatory Bowel Disease Questionnaire (IBDQ), and fecal samples for 16S rRNA sequencing and blood samples for IL-23 and IL-17 ELISA', 'Results\n\n\nMayo scores and IBDQ score', 'IL-23 and IL-17 levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}]","[{'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C0127615', 'cui_str': 'mesalamine'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0751985', 'cui_str': 'Proteobacteria'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0035702', 'cui_str': '16S Ribosomal RNA'}, {'cui': 'C0162801', 'cui_str': 'Analysis, Sequence'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0963088', 'cui_str': 'IL-23'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0533333,"At post-treatment week 4, IL-23 and IL-17 levels were significantly lower in the UDCA + Mesalazine group compared to those in the Mesalazine group (both P < 0.038).","[{'ForeName': 'Zhengjun', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology, The 900th Hospital of Joint Logistic Support Force, PLA, Fujian Medical University Fuzong Clinical College, Fuzhou, China.'}, {'ForeName': 'Jinhua', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Care, Union Hospital of Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Zhiping', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Gastroenterology, The 900th Hospital of Joint Logistic Support Force, PLA, Fujian Medical University Fuzong Clinical College, Fuzhou, China.'}, {'ForeName': 'Longke', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Department of Gastroenterology, The 900th Hospital of Joint Logistic Support Force, PLA, Fujian Medical University Fuzong Clinical College, Fuzhou, China.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology, The 900th Hospital of Joint Logistic Support Force, PLA, Fujian Medical University Fuzong Clinical College, Fuzhou, China.'}]",Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association,['10.4103/sjg.SJG_462_20'] 2949,33837509,Clinical effects of assessing electronic patient-reported outcomes monitoring symptomatic toxicities during breast cancer therapy: a nationwide and population-based study.,"The involvement of cancer patients in symptom reporting talks into our cultural narrative of empowerment and participation in decisions in health of both patients and professionals. Electronic patient-reported outcome (ePRO) is a tool applied for use in such interaction. Based on limited evidence and few empirical studies, health systems are rapidly implementing this instrument in managing patients in active treatment and in follow-up. In a cluster randomized trial of all Danish oncology departments treating breast cancer with adjuvant chemotherapy, we applied ePRO in 347 patients consecutively recruited. Our primary outcome, which was at least one treatment adjustment, was not significantly influenced using ePRO, 34% in the ePRO arm and 41% in the usual care arm received at least one treatment adjustment, p = 0.095. Number of hospitalizations and events of febrile neutropenia were not influenced by the intervention. We believe that one of the main reasons for this finding could be the application of PRO in a well-regulated treatment setting within a public health care system where the most impacting symptomatic toxicities are already taken care off.Trial registration: Clinicaltrials.gov identifier: NCT02996201, registered 19 Dec 2016, retrospectively registered.",2021,Number of hospitalizations and events of febrile neutropenia were not influenced by the intervention.,['347 patients consecutively recruited'],"['adjuvant chemotherapy', 'breast cancer therapy']",['Number of hospitalizations and events of febrile neutropenia'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}]",,0.225847,Number of hospitalizations and events of febrile neutropenia were not influenced by the intervention.,"[{'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Pappot', 'Affiliation': 'Documentation and Quality, Danish Cancer Society, Strandboulevarden 49, DK 2100, Copenhagen, Denmark. helle.pappot@regionh.dk.'}, {'ForeName': 'Christina W', 'Initials': 'CW', 'LastName': 'Baeksted', 'Affiliation': 'Documentation and Quality, Danish Cancer Society, Strandboulevarden 49, DK 2100, Copenhagen, Denmark.'}, {'ForeName': 'Aase', 'Initials': 'A', 'LastName': 'Nissen', 'Affiliation': 'Documentation and Quality, Danish Cancer Society, Strandboulevarden 49, DK 2100, Copenhagen, Denmark.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Knoop', 'Affiliation': 'Department of Oncology, Rigshospitalet, Blegdamsvej 9, DK 2100, Copenhagen, Denmark.'}, {'ForeName': 'Sandra A', 'Initials': 'SA', 'LastName': 'Mitchell', 'Affiliation': 'Outcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, 3 East Suite 448, Rockville, MD, 20850, USA.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Christensen', 'Affiliation': 'Documentation and Quality, Danish Cancer Society, Strandboulevarden 49, DK 2100, Copenhagen, Denmark.'}, {'ForeName': 'Niels Henrik', 'Initials': 'NH', 'LastName': 'Hjollund', 'Affiliation': 'Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus, Denmark.'}, {'ForeName': 'Christoffer', 'Initials': 'C', 'LastName': 'Johansen', 'Affiliation': 'Department of Oncology, Rigshospitalet, Blegdamsvej 9, DK 2100, Copenhagen, Denmark.'}]","Breast cancer (Tokyo, Japan)",['10.1007/s12282-021-01244-x'] 2950,33838159,A diagnostic randomised controlled trial to study the impact of rapid diagnostic tests in patients with Acute febrile illness when compared to conventional diagnostics (DRACO study).,,2021,,['patients with Acute febrile illness'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0743842', 'cui_str': 'Acute febrile illness'}]",[],[],,0.155193,,"[{'ForeName': 'Nitin', 'Initials': 'N', 'LastName': 'Gupta', 'Affiliation': 'Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India; Manipal Center for Infectious Diseases, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India. Electronic address: nityanitingupta@gmail.com.'}, {'ForeName': 'Sowmya', 'Initials': 'S', 'LastName': 'Joylin', 'Affiliation': 'Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.'}, {'ForeName': 'Prithvishree', 'Initials': 'P', 'LastName': 'Ravindra', 'Affiliation': 'Department of Emergency Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Wilson', 'Affiliation': 'Department of Emergency Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.'}, {'ForeName': 'Rachana', 'Initials': 'R', 'LastName': 'Bhat', 'Affiliation': 'Department of Emergency Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.'}, {'ForeName': 'Vasudev', 'Initials': 'V', 'LastName': 'Guddattu', 'Affiliation': 'Department of Statistics, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Neumayr', 'Affiliation': 'University of Basel, Basel, Switzerland; Department of Public Health and Tropical Medicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, Queensland, Australia.'}, {'ForeName': 'Chiranjay', 'Initials': 'C', 'LastName': 'Mukhopadhyay', 'Affiliation': 'Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India, 576104.'}, {'ForeName': 'Kavitha', 'Initials': 'K', 'LastName': 'Saravu', 'Affiliation': 'Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India; Manipal Center for Infectious Diseases, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.'}]",The Journal of infection,['10.1016/j.jinf.2021.04.001'] 2951,34386442,"The Effect of Pyridoxine Hydrochloride Supplementation on Leptin, Adiponectin, Glycemic Indices, and Anthropometric Indices in Obese and Overweight Women.","Obesity has reached epidemic proportions globally. Among several methods for treating obesity, the use of dietary supplements is common recently. One supplement that can help in this regard might be vitamin B6 in high doses. The objective of this study was to evaluate the effect of pyridoxine hydrochloride supplementation on anthropometric indices, body composition, visceral adiposity index (VAI), and metabolic status in obese and overweight women. In this randomized controlled clinical trial, 44 obese and overweight women aged 18-50 years were selected and divided randomly into 2 groups: an intervention group (receiving 80 mg pyridoxine hydrochloride supplement for 8 weeks) and a control group (receiving placebo for 8 weeks). In the pyridoxine hydrochloride group, weight (p = 0.03), body mass index (p = 0.023), fat mass (p = 0.003), waist circumference (p = 0.005), VAI (p = 0.001), fasting insulin, insulin resistance (homeostasis model assessment of insulin resistance; HOMA-IR), total cholesterol, low-density lipoprotein, triglycerides (TG) and leptin (p < 0.001) decreased whereas adiponectin (p < 0.001) increased in comparison to the baseline values. There was a significant difference in fat mass, VAI, fasting insulin, HOMA-IR, and TG between pyridoxine hydrochloride and control groups following intervention in adjusted models (p < 0.05). The findings suggest that vitamin B6 supplementation may be effective in reducing BMI and improving body composition and biochemical factors associated with obesity. Trial Registration Iranian Registry of Clinical Trials Identifier: IRCT20181002041206N1.",2021,"In the pyridoxine hydrochloride group, weight (p = 0.03), body mass index (p = 0.023), fat mass (p = 0.003), waist circumference (p = 0.005), VAI (p = 0.001), fasting insulin, insulin resistance (homeostasis model assessment of insulin resistance; HOMA-IR), total cholesterol, low-density lipoprotein, triglycerides (TG) and leptin (p < 0.001) decreased whereas adiponectin (p < 0.001) increased in comparison to the baseline values.","['obese and overweight women', '44 obese and overweight women aged 18-50 years', 'Obese and Overweight Women']","['Pyridoxine Hydrochloride Supplementation', 'vitamin B6 supplementation', 'intervention group (receiving 80 mg pyridoxine hydrochloride supplement', 'control group (receiving placebo', 'pyridoxine hydrochloride', 'pyridoxine hydrochloride supplementation']","['anthropometric indices, body composition, visceral adiposity index (VAI), and metabolic status', 'fat mass', 'VAI', 'body mass index', 'Leptin, Adiponectin, Glycemic Indices, and Anthropometric Indices', 'fasting insulin, insulin resistance (homeostasis model assessment of insulin resistance; HOMA-IR), total cholesterol, low-density lipoprotein, triglycerides (TG) and leptin', 'waist circumference', 'adiponectin', 'fat mass, VAI, fasting insulin, HOMA-IR, and TG']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0700496', 'cui_str': 'Pyridoxine hydrochloride'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C4524021', 'cui_str': 'Vitamin B6 supplementation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0626128', 'cui_str': ""5'-O-(6-O-malonylglucopyranosyl)pyridoxine""}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}]",44.0,0.0811476,"In the pyridoxine hydrochloride group, weight (p = 0.03), body mass index (p = 0.023), fat mass (p = 0.003), waist circumference (p = 0.005), VAI (p = 0.001), fasting insulin, insulin resistance (homeostasis model assessment of insulin resistance; HOMA-IR), total cholesterol, low-density lipoprotein, triglycerides (TG) and leptin (p < 0.001) decreased whereas adiponectin (p < 0.001) increased in comparison to the baseline values.","[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Haidari', 'Affiliation': 'Department of Nutrition, Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61357-15794, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Mohammadshahi', 'Affiliation': 'Department of Nutrition, Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61357-15794, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Zarei', 'Affiliation': 'Department of Food Hygiene, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz 61357-43337, Iran.'}, {'ForeName': 'Mohammad Hosein', 'Initials': 'MH', 'LastName': 'Haghighizadeh', 'Affiliation': 'Department of Statistics and Epidemiology, Faculty of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61357-15794, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Mirzaee', 'Affiliation': 'Department of Nutrition, Diabetes Research Center, Health Research Institute, Faculty of Paramedical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61357-15794, Iran.'}]",Clinical nutrition research,['10.7762/cnr.2021.10.3.230'] 2952,34386594,Naturally-occurring dietary salicylates in the genesis of functional gastrointestinal symptoms in patients with irritable bowel syndrome: Pilot study.,"Background and Aim An elimination-rechallenge dietary approach targeting naturally-occurring bioactive chemicals has been proposed to alleviate functional gastrointestinal symptoms. A major focus of this approach is salicylates. This study aimed to address the potential role of dietary salicylates in the induction of symptoms in patients with irritable bowel syndrome (IBS). Methods A pilot, double-blind, randomized, cross-over trial of 2-week low- versus high-salicylate diets (6.6 and 27.9 g/day salicylate, respectively) was undertaken. All foods were provided containing minimal quantities of other potential food triggers. Gastrointestinal and extraintestinal symptoms were measured daily using a 100-mm visual-analogue-scale. Results Ten participants with IBS completed the study, including one with known aspirin-sensitivity. Overall, no differences in symptoms were observed ( P  = 0.625; Friedman test). However, clear symptom provocation was seen in the aspirin-sensitive participant, with all abdominal symptoms and tiredness worsening during the high-salicylate diet. A similar trend was seen in another participant, where abdominal symptoms gradually worsened during the high-salicylate diet. Conclusions These results provide some evidence that food-related salicylates may influence the genesis of symptoms in a subset of patients with IBS. A larger cohort is needed to determine the incidence of salicylate-sensitivity and further evaluate the diet as a potential therapeutic target.The protocol was registered at www.anzctr.org.au (ACTRN12620001250921).",2021,"Overall, no differences in symptoms were observed ( P  = 0.625; Friedman test).","['patients with irritable bowel syndrome (IBS', 'patients with irritable bowel syndrome', 'Ten participants with IBS completed the study, including one with known aspirin-sensitivity']","['Naturally-occurring dietary salicylates', 'dietary salicylates', 'low- versus high-salicylate diets']","['functional gastrointestinal symptoms', 'clear symptom provocation', 'Gastrointestinal and extraintestinal symptoms', 'abdominal symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]","[{'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0036075', 'cui_str': 'Salicylate'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449428', 'cui_str': 'Provocation'}, {'cui': 'C0740651', 'cui_str': 'Abdominal symptom'}]",10.0,0.0808737,"Overall, no differences in symptoms were observed ( P  = 0.625; Friedman test).","[{'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Tuck', 'Affiliation': 'Department of Gastroenterology Alfred Hospital and Monash University Melbourne Victoria Australia.'}, {'ForeName': 'Sreepurna', 'Initials': 'S', 'LastName': 'Malakar', 'Affiliation': 'Department of Gastroenterology Alfred Hospital and Monash University Melbourne Victoria Australia.'}, {'ForeName': 'Jacqueline S', 'Initials': 'JS', 'LastName': 'Barrett', 'Affiliation': 'Department of Gastroenterology Alfred Hospital and Monash University Melbourne Victoria Australia.'}, {'ForeName': 'Jane G', 'Initials': 'JG', 'LastName': 'Muir', 'Affiliation': 'Department of Gastroenterology Alfred Hospital and Monash University Melbourne Victoria Australia.'}, {'ForeName': 'Peter R', 'Initials': 'PR', 'LastName': 'Gibson', 'Affiliation': 'Department of Gastroenterology Alfred Hospital and Monash University Melbourne Victoria Australia.'}]",JGH open : an open access journal of gastroenterology and hepatology,['10.1002/jgh3.12578'] 2953,34386535,Feasibility and Preliminary Effects of the BESMILE-HF Program on Chronic Heart Failure Patients: A Pilot Randomized Controlled Trial.,"Aims: The Baduanjin Eight-Silken-Movements wIth Self-Efficacy building for Heart Failure (BESMILE-HF) program is a contextually adapted cardiac rehabilitation program. It uses a traditional Chinese exercise, Baduanjin , to solve the unmet demand of exercise-based cardiac rehabilitation programs due to their scarcity and unaffordability in China. This pilot study assesses BESMILE-HF's feasibility and preliminary effects. Methods: Eighteen patients with chronic heart failure were included: 8 in a BESMILE-HF group (age: 67 ± 5 years, EF: 40.4 ± 13.6%) and 10 in a control group (age: 70 ± 13 years, EF: 42.9 ± 12.5%). Both received the usual medications, with the intervention group receiving additionally the BESMILE-HF program for 6 weeks. Feasibility was explored by participants' involvement in the intended intervention. Clinical outcome assessments were conducted at baseline and post-intervention, while adverse events were captured throughout the study period. Results: The BESMILE-HF program was well-received by patients, and adherence to the intervention was good. The intervention group completed all required home exercises and total home-practice time was correlated with baseline self-efficacy ( r = 0.831, p = 0.011). Moreover, after 6 weeks, self-efficacy increased in the BESMILE-HF group ( p = 0.028) and the change was higher than in the control [mean difference (MD): 3.2; 95% confidence interval (CI) 0.6-5.9, p = 0.004]. For the exercise capacity, the control group demonstrated a significant decline in peak oxygen consumption ( p =0.018) whereas, the BESMILE-HF group maintained their exercise capacity ( p = 0.063). Although the between-group difference was not statistically significance, there was clear clinical improvement in the BESMILE-HF group (1.5 mL/kg/min, 95% CI, -0.3 to 3.2 vs. minimal clinically important difference of 1 mL/kg/min). Throughout the study period, no adverse events related to the intervention were captured. Conclusions: BESMILE-HF is feasible for patients with chronic heart failure in Chinese settings. A larger sample size and a longer follow-up period is needed to confirm its benefit on clinical outcomes. Clinical Trial Registration: ClinicalTrials.gov: NCT03180320.",2021,"For the exercise capacity, the control group demonstrated a significant decline in peak oxygen consumption ( p =0.018) whereas, the BESMILE-HF group maintained their exercise capacity ( p = 0.063).","['Chronic Heart Failure Patients', 'Eighteen patients with chronic heart failure were included: 8 in a BESMILE-HF group (age: 67 ± 5 years, EF: 40.4 ± 13.6%) and 10 in a control group (age: 70 ± 13 years, EF: 42.9 ± 12.5', 'patients with chronic heart failure in Chinese settings']",['HF Program'],"['peak oxygen consumption', 'self-efficacy', 'adverse events']","[{'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517560', 'cui_str': '13.6'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517773', 'cui_str': '42.9'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",18.0,0.0600019,"For the exercise capacity, the control group demonstrated a significant decline in peak oxygen consumption ( p =0.018) whereas, the BESMILE-HF group maintained their exercise capacity ( p = 0.063).","[{'ForeName': 'Xiankun', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Health Systems and Policy, Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Olson', 'Affiliation': 'Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States.'}, {'ForeName': 'Cecilia Stålsby', 'Initials': 'CS', 'LastName': 'Lundborg', 'Affiliation': 'Health Systems and Policy, Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Zehuai', 'Initials': 'Z', 'LastName': 'Wen', 'Affiliation': 'Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Weihui', 'Initials': 'W', 'LastName': 'Lu', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Marrone', 'Affiliation': 'Health Systems and Policy, Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}]",Frontiers in cardiovascular medicine,['10.3389/fcvm.2021.715207'] 2954,33835174,Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.,"Importance The prevention of chemotherapy-induced nausea and vomiting has an important role in the overall management of cancer treatment. Objective To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk. Design, Setting, and Participants This phase 3, double-blind, placebo-controlled randomized clinical trial recruited young women (age ≤50 years) who drank little or no alcohol and had gastrointestinal cancer for which they received FOLFOX or FOLFIRI chemotherapy. A total of 248 women were enrolled and assigned in the ratio 1:1 to intervention and control groups from August 4, 2015, to March 31, 2020. Intention-to-treat analysis was used to evaluate patient baseline characteristics and efficacy. The analysis was conducted on October 30, 2020. Interventions Patients were randomly assigned to the aprepitant group (aprepitant, 125 mg, orally 60 minutes before initiation of chemotherapy on day 1 and 80 mg orally each morning of days 2 and 3; palonosetron, 0.25 mg, intravenously; and dexamethasone, 6 mg, orally 30 minutes before chemotherapy initiation on day 1) or the placebo group (placebo, 125 mg, orally 60 minutes before initiation of chemotherapy on day 1 and 80 mg orally on each morning of days 2 and 3; palonosetron, 0.25 mg, intravenously; and dexamethasone, 12 mg, orally 30 minutes before chemotherapy initiation on day 1). Main Outcomes and Measures The primary end point was the complete response (CR) rate, defined as the proportion of patients without emesis episodes or rescue medication use during the overall phase of the first cycle. Other efficacy indicators, such as no vomiting and no nausea, were measured as the secondary and exploratory end points. Results A total of 248 women from 4 clinical centers in China entered this study, and 243 patients (aprepitant regimen, 125 patients [51.4%]; placebo regimen, 118 patients [48.5%]) were evaluable for efficacy and safety; mean (SD) age of the total population was 40.1 (7.3) years. The CR rate was significantly higher in the aprepitant group vs the control group overall (107 [87.0%] vs 80 [66.7%]; P < .001) and in the acute (114 [92.7%] vs 91 [75.8%]; P = .001) and delayed (109 [88.6%] vs 84 [70.0%]; P = .001) phases of the trial. The incidence of adverse events was similar between the 2 groups (100 [80.0%] vs 96 [81.3%]; P = .79), and no grade 3 or 4 aprepitant treatment-related adverse events were observed. Multivariable analysis revealed that aprepitant use was the only independent factor associated with CR during the overall phase. Conclusions and Relevance The combination of aprepitant with palonosetron and dexamethasone provided increased antiemetic efficacy in the FOLFOX or FOLFIRI chemotherapy regimen and was well tolerated by younger women with gastrointestinal cancer who have a history of little or no alcohol consumption. Trial Registration ClinicalTrials.gov Identifier: NCT03674294.",2021,"The incidence of adverse events was similar between the 2 groups (100 [80.0%] vs 96 [81.3%]; P = .79), and no grade 3 or 4 aprepitant treatment-related adverse events were observed.","['Women', 'women with gastrointestinal cancer at higher risk', 'young women (age ≤50 years) who drank little or no alcohol and had gastrointestinal cancer for which they received', '248 women from 4 clinical centers in China entered this study, and 243 patients (aprepitant regimen, 125 patients [51.4', 'younger women with gastrointestinal cancer who have a history of little or no alcohol consumption', 'A total of 248 women were enrolled and assigned in the ratio 1:1 to intervention and control groups from August 4, 2015, to March 31, 2020', 'regimen, 118 patients [48.5%]) were evaluable for efficacy and safety; mean (SD) age of the total population was 40.1 (7.3) years']","['placebo group (placebo', 'FOLFOX or FOLFIRI chemotherapy', 'aprepitant group (aprepitant, 125 mg, orally 60 minutes before initiation of chemotherapy', 'placebo', 'palonosetron and dexamethasone', 'palonosetron, 0.25 mg, intravenously; and dexamethasone', 'FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens']","['antiemetic efficacy', 'vomiting and no nausea', 'incidence and severity of nausea and vomiting', 'CR rate', 'adverse events', 'nausea and vomiting', 'incidence of adverse events', 'complete response (CR) rate, defined as the proportion of patients without emesis episodes or rescue medication use during the overall phase of the first cycle', 'Nausea and Vomiting']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0685938', 'cui_str': 'Malignant neoplasm of gastrointestinal tract'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0023882', 'cui_str': 'Spastic diplegia'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1176306', 'cui_str': 'aprepitant'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1176306', 'cui_str': 'aprepitant'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0220578', 'cui_str': 'palonosetron'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}]","[{'cui': 'C0003297', 'cui_str': 'Antiemetic agent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0423584', 'cui_str': 'No nausea'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]",248.0,0.429539,"The incidence of adverse events was similar between the 2 groups (100 [80.0%] vs 96 [81.3%]; P = .79), and no grade 3 or 4 aprepitant treatment-related adverse events were observed.","[{'ForeName': 'De-Shen', 'Initials': 'DS', 'LastName': 'Wang', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Ming-Tao', 'Initials': 'MT', 'LastName': 'Hu', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Zhi-Qiang', 'Initials': 'ZQ', 'LastName': 'Wang', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Ren', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Miao-Zhen', 'Initials': 'MZ', 'LastName': 'Qiu', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Hui-Yan', 'Initials': 'HY', 'LastName': 'Luo', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Jin', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'William Pat', 'Initials': 'WP', 'LastName': 'Fong', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Shu-Bin', 'Initials': 'SB', 'LastName': 'Wang', 'Affiliation': ""Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, People's Republic of China.""}, {'ForeName': 'Jie-Wen', 'Initials': 'JW', 'LastName': 'Peng', 'Affiliation': ""Chemotherapy Department, Zhongshan People's Hospital, Zhongshan, Guangdong Province, People's Republic of China.""}, {'ForeName': 'Qing-Feng', 'Initials': 'QF', 'LastName': 'Zou', 'Affiliation': ""Section 3 of Internal Medicine, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.""}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Tan', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Feng-Hua', 'Initials': 'FH', 'LastName': 'Wang', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Yu-Hong', 'Initials': 'YH', 'LastName': 'Li', 'Affiliation': ""State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.""}]",JAMA network open,['10.1001/jamanetworkopen.2021.5250'] 2955,33836161,"New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.","BACKGROUND Current treatment for Chagas disease with the only available drugs, benznidazole or nifurtimox, has substantial limitations, including long treatment duration and safety and tolerability concerns. We aimed to evaluate the efficacy and safety of new benznidazole monotherapy regimens and combinations with fosravuconazole, in the treatment of Chagas disease. METHODS We did a double-blind, double-dummy, phase 2, multicentre, randomised trial in three outpatient units in Bolivia. Adults aged 18-50 years with chronic indeterminate Chagas disease, confirmed by serological testing and positive qualitative PCR results, were randomly assigned (1:1:1:1:1:1:1) to one of seven treatment groups using a balanced block randomisation scheme with an interactive response system. Participants were assigned to benznidazole 300 mg daily for 8 weeks, 4 weeks, or 2 weeks, benznidazole 150 mg daily for 4 weeks, benznidazole 150 mg daily for 4 weeks plus fosravuconazole, benznidazole 300 mg once per week for 8 weeks plus fosravuconazole, or placebo, with a 12-month follow-up period. The primary endpoints were sustained parasitological clearance at 6 months, defined as persistent negative qualitative PCR results from end of treatment, and incidence and severity of treatment-emergent adverse events, serious adverse events, and adverse events leading to treatment discontinuation. Primary efficacy analysis was based on the intention-to-treat and per-protocol populations and secondary efficacy analyses on the per-protocol population. Safety analyses were based on the as-treated population. Recruitment is now closed. This trial is registered with ClinicalTrials.gov, NCT03378661. FINDINGS Between Nov 30, 2016, and July 27, 2017, we screened 518 patients, and 210 were enrolled and randomised. 30 patients (14%) were assigned to each treatment group. All 210 randomised patients were included in the intention-to-treat population, and 190 (90%) were included in the per-protocol population. In the intention-to-treat analysis, only one (3%) of 30 patients in the placebo group had sustained parasitological clearance at 6 months of follow-up. Sustained parasitological clearance at 6 months was observed in 25 (89%) of 28 patients receiving benznidazole 300 mg daily for 8 weeks (rate difference vs placebo 86% [95% CI 73-99]), 25 (89%) of 28 receiving benznidazole 300 mg daily for 4 weeks (86% [73-99]), 24 (83%) of 29 receiving benznidazole 300 mg daily for 2 weeks (79% [64-95]), 25 (83%) of 30 receiving benznidazole 150 mg daily for 4 weeks (80% [65-95]), 23 (85%) of 28 receiving benznidazole 150 mg daily for 4 weeks plus fosravuconazole (82% [67-97]), and 24 (83%) of 29 receiving benznidazole 300 mg weekly for 8 weeks plus fosravuconazole (79% [64-95]; p<0·0001 for all group comparisons with placebo). Six patients (3%) had ten serious adverse events (leukopenia [n=3], neutropenia [n=2], pyrexia, maculopapular rash, acute cholecystitis, biliary polyp, and breast cancer), eight had 12 severe adverse events (defined as interfering substantially with the patient's usual functions; elevated alanine aminotransferase [n=4], elevated gamma-glutamyltransferase [n=2], elevated aspartate aminotransferase [n=1], neutropenia [n=3], leukopenia [n=1], and breast cancer [n=1]), and 15 (7%) had adverse events that led to treatment discontinuation (most of these were in the groups who received benznidazole 300 mg daily for 8 weeks, benznidazole 300 mg once per week for 8 weeks plus fosravuconazole, and benznidazole 150 mg daily for 4 weeks plus fosravuconazole). No adverse events leading to treatment discontinuation were observed in patients treated with benznidazole 300 mg daily for 2 weeks or placebo. There were no treatment-related deaths. INTERPRETATION Benznidazole induced effective antiparasitic response, regardless of treatment duration, dose, or combination with fosravuconazole, and was well tolerated in adult patients with chronic Chagas disease. Shorter or reduced regimens of benznidazole could substantially improve treatment tolerability and accessibility, but further studies are needed to confirm these results. FUNDING Drugs for Neglected Diseases initiative (DNDi). TRANSLATION For the Spanish translation of the abstract see Supplementary Materials section.",2021,"Sustained parasitological clearance at 6 months was observed in 25 (89%) of 28 patients receiving benznidazole 300 mg daily for 8 weeks (rate difference vs placebo 86% [95% CI 73-99]), 25 (89%) of 28 receiving benznidazole 300 mg daily for 4 weeks (86% [73-99]), 24 (83%) of 29 receiving benznidazole 300 mg daily for 2 weeks (79% [64-95]), 25 (83%) of 30 receiving benznidazole 150 mg daily for 4 weeks (80% [65-95]), 23 (85%) of 28 receiving benznidazole 150 mg daily for 4 weeks plus fosravuconazole (82% [67-97]), and 24 (83%) of 29 receiving benznidazole 300 mg weekly for 8 weeks plus fosravuconazole","['n=4], elevated gamma-glutamyltransferase [n=2], elevated aspartate aminotransferase [n=1], neutropenia [n=3], leukopenia [n=1], and breast cancer [n=1]), and 15 (7%) had adverse events that led to treatment discontinuation (most of these were in the groups who received', 'All 210 randomised patients were included in the intention-to-treat population, and 190 (90%) were included in the per-protocol population', 'adult patients with chronic Chagas disease', 'Between Nov 30, 2016, and July 27, 2017, we screened 518 patients, and 210 were enrolled and randomised', 'three outpatient units in Bolivia', '30 patients (14', 'Adults aged 18-50 years with chronic indeterminate Chagas disease, confirmed by serological testing and positive qualitative PCR results', 'Chagas disease']","['fosravuconazole', 'balanced block randomisation scheme with an interactive response system', 'benznidazole 150 mg daily for 4 weeks, benznidazole 150 mg daily for 4 weeks plus fosravuconazole, benznidazole 300 mg once per week for 8 weeks plus fosravuconazole, or placebo', 'benznidazole 300 mg daily for 8 weeks, benznidazole 300 mg once per week for 8 weeks plus fosravuconazole, and benznidazole 150 mg daily for 4 weeks plus fosravuconazole', 'placebo', 'benznidazole', 'benznidazole 300 mg weekly for 8 weeks plus fosravuconazole', 'benznidazole monotherapy and in combination with fosravuconazole', 'benznidazole 150 mg daily for 4 weeks plus fosravuconazole']","['serious adverse events (leukopenia [n=3], neutropenia [n=2], pyrexia, maculopapular rash, acute cholecystitis, biliary polyp, and breast cancer', 'efficacy and safety', 'alanine aminotransferase', 'Sustained parasitological clearance', 'sustained parasitological clearance', 'persistent negative qualitative PCR results from end of treatment, and incidence and severity of treatment-emergent adverse events, serious adverse events, and adverse events leading to treatment discontinuation', 'severe adverse events']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C4517622', 'cui_str': '190'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0343804', 'cui_str': ""Chronic Chagas' disease""}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0005918', 'cui_str': 'Bolivia'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205258', 'cui_str': 'Indeterminate'}, {'cui': 'C0041234', 'cui_str': 'Infection by Trypanosoma cruzi'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0205473', 'cui_str': 'Serologic'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]","[{'cui': 'C0205415', 'cui_str': 'Balanced'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0053230', 'cui_str': 'benznidazole'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0423791', 'cui_str': 'Maculopapular rash'}, {'cui': 'C0149520', 'cui_str': 'Acute cholecystitis'}, {'cui': 'C2363746', 'cui_str': 'Biliary polyp'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205468', 'cui_str': 'Parasitologic'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}]",,0.592577,"Sustained parasitological clearance at 6 months was observed in 25 (89%) of 28 patients receiving benznidazole 300 mg daily for 8 weeks (rate difference vs placebo 86% [95% CI 73-99]), 25 (89%) of 28 receiving benznidazole 300 mg daily for 4 weeks (86% [73-99]), 24 (83%) of 29 receiving benznidazole 300 mg daily for 2 weeks (79% [64-95]), 25 (83%) of 30 receiving benznidazole 150 mg daily for 4 weeks (80% [65-95]), 23 (85%) of 28 receiving benznidazole 150 mg daily for 4 weeks plus fosravuconazole (82% [67-97]), and 24 (83%) of 29 receiving benznidazole 300 mg weekly for 8 weeks plus fosravuconazole","[{'ForeName': 'Faustino', 'Initials': 'F', 'LastName': 'Torrico', 'Affiliation': 'Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES), Cochabamba, Bolivia; Universidad Mayor de San Simón, Cochabamba, Bolivia.'}, {'ForeName': 'Joaquim', 'Initials': 'J', 'LastName': 'Gascón', 'Affiliation': 'Barcelona Institute for Global Health, Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Barreira', 'Affiliation': 'DNDi Latin America, Rio de Janeiro, Brazil.'}, {'ForeName': 'Bethania', 'Initials': 'B', 'LastName': 'Blum', 'Affiliation': 'DNDi Latin America, Rio de Janeiro, Brazil.'}, {'ForeName': 'Igor C', 'Initials': 'IC', 'LastName': 'Almeida', 'Affiliation': 'University of Texas at El Paso, El Paso, TX, USA.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Alonso-Vega', 'Affiliation': 'Barcelona Institute for Global Health, Barcelona, Spain; DNDi Latin America, Rio de Janeiro, Brazil.'}, {'ForeName': 'Tayná', 'Initials': 'T', 'LastName': 'Barboza', 'Affiliation': 'DNDi Latin America, Rio de Janeiro, Brazil.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Bilbe', 'Affiliation': 'Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Correia', 'Affiliation': 'DNDi Latin America, Rio de Janeiro, Brazil.'}, {'ForeName': 'Wilson', 'Initials': 'W', 'LastName': 'Garcia', 'Affiliation': 'Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES), Cochabamba, Bolivia.'}, {'ForeName': 'Lourdes', 'Initials': 'L', 'LastName': 'Ortiz', 'Affiliation': 'Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES), Cochabamba, Bolivia; Juan Misael Saracho Autonomous University, Tarija, Bolivia.'}, {'ForeName': 'Rudy', 'Initials': 'R', 'LastName': 'Parrado', 'Affiliation': 'Universidad Mayor de San Simón, Cochabamba, Bolivia.'}, {'ForeName': 'Juan Carlos', 'Initials': 'JC', 'LastName': 'Ramirez', 'Affiliation': 'Instituto Nacional de Parasitología ""Dr Mario Fatala Chaben"" (INP-ANLIS), Buenos Aires, Argentina.'}, {'ForeName': 'Isabela', 'Initials': 'I', 'LastName': 'Ribeiro', 'Affiliation': 'Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Strub-Wourgaft', 'Affiliation': 'Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Vaillant', 'Affiliation': 'Luxembourg Institute of Health, Strassen, Luxembourg.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Sosa-Estani', 'Affiliation': 'DNDi Latin America, Rio de Janeiro, Brazil; Epidemiology and Public Health Research Centre, CONICET, Buenos Aires, Argentina. Electronic address: ssosa@dndi.org.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30844-6'] 2956,33835939,"Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study.","BACKGROUND AND OBJECTIVES In the CaLIPSO study, intravenous administration of SNF472 (300 or 600 mg) during hemodialysis significantly attenuated progression of coronary artery and aortic valve calcification. SNF472 selectively inhibits formation of hydroxyapatite, the final step in cardiovascular calcification. Because bone mineral is predominantly hydroxyapatite, we assessed changes in bone mineral density in CaLIPSO. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Patients with coronary artery calcification at screening (Agatston score of 100-3500 U) were randomized 1:1:1 to receive placebo, 300 mg SNF472, or 600 mg SNF472 as an intravenous infusion during hemodialysis three times weekly for 52 weeks. Dual-energy x-ray absorptiometry (DXA) scans were obtained at baseline (screening) and end of treatment, and between-group changes from baseline were compared using analysis of covariance. RESULTS Among 274 randomized patients, 202 had evaluable DXA scans at baseline and postrandomization (the DXA-modified intention-to-treat population). Mean (95% confidence interval) changes in total-hip bone mineral density from baseline to week 52 were -1.5% (-2.7% to -0.3%), -1.5% (-2.7% to -0.4%), and -2.5% (-3.8% to -1.2%) in the placebo, 300 mg SNF472, and 600 mg SNF472 groups, respectively. Mean (95% confidence interval) changes in femoral-neck bone mineral density from baseline to week 52 were -0.3% (-1.6% to 1.0%), -1.0% (-2.3% to 0.2%), and -2.6% (-4.0% to -1.3%), respectively. Regression analyses showed no correlation between change in coronary artery calcium volume and change in bone mineral density at either location. Changes in serum alkaline phosphatase, calcium, magnesium, phosphate, and intact parathyroid hormone levels were similar across treatment groups. Clinical fracture events were reported for four of 90, three of 92, and six of 91 patients in the placebo, 300 mg SNF472, and 600 mg SNF472 groups, respectively. CONCLUSIONS Bone mineral density decreased modestly in all groups over 1 year. In the 600 mg SNF472 group, the reduction appeared more pronounced. Reported fractures were infrequent in all groups. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD), NCT02966028.",2021,"Changes in serum alkaline phosphatase, calcium, magnesium, phosphate, and intact parathyroid hormone levels were similar across treatment groups.","['Patients with coronary artery calcification at screening (Agatston score of 100-3500 U', 'Patients Receiving Hemodialysis', '274 randomized patients, 202 had evaluable DXA scans at baseline and postrandomization (the DXA-modified intention-to-treat population']","['placebo, 300 mg SNF472, or 600 mg SNF472', 'Myo-inositol Hexaphosphate (SNF472', 'SNF472', 'placebo', 'Placebo']","['Bone mineral density', 'femoral-neck bone mineral density', 'coronary artery calcium volume and change in bone mineral density', 'serum alkaline phosphatase, calcium, magnesium, phosphate, and intact parathyroid hormone levels', 'Dual-energy x-ray absorptiometry (DXA) scans', 'Clinical fracture events', 'total-hip bone mineral density', 'bone mineral density', 'progression of coronary artery and aortic valve calcification', 'Bone Mineral Density']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1611184', 'cui_str': 'Calcification of coronary artery'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4517736', 'cui_str': '3500'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C5198328', 'cui_str': 'SNF472'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0021547', 'cui_str': 'Inositol'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C1562777', 'cui_str': 'Calcium volume'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0036776', 'cui_str': 'Serum alkaline phosphatase measurement'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}, {'cui': 'C0030520', 'cui_str': 'Parathyroid Hormone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030786', 'cui_str': 'Hip Bone'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0428791', 'cui_str': 'Aortic valve calcification'}]",274.0,0.198041,"Changes in serum alkaline phosphatase, calcium, magnesium, phosphate, and intact parathyroid hormone levels were similar across treatment groups.","[{'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Bushinsky', 'Affiliation': 'Department of Medicine, University of Rochester School of Medicine, Rochester, New York david_bushinsky@urmc.rochester.edu.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Raggi', 'Affiliation': 'Department of Medicine, Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Bover', 'Affiliation': 'Department of Nephrology, Puigvert Foundation/Autonoma University, Sant Pau Biomedical Research Institute, Red de Investigacion Renal (REDinREN), Barcelona, Spain.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Ketteler', 'Affiliation': 'Department of General Internal Medicine and Nephrology, Robert Bosch Hospital, Stuttgart, Germany.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Bellasi', 'Affiliation': 'Research, Innovation and Brand Reputation Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy.'}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Rodriguez', 'Affiliation': 'Nephrology Unit, Reina Sofia University Hospital, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Red de Investigacion Renal (REDinREN), Córdoba, Spain.'}, {'ForeName': 'Smeeta', 'Initials': 'S', 'LastName': 'Sinha', 'Affiliation': 'Department of Renal Medicine, Salford Royal National Health Service Foundation Trust, Salford, United Kingdom.'}, {'ForeName': 'Rekha', 'Initials': 'R', 'LastName': 'Garg', 'Affiliation': 'Research and Development, Sanifit Therapeutics, San Diego, California.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Perelló', 'Affiliation': 'Research and Development, Sanifit Therapeutics, Palma, Spain.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Gold', 'Affiliation': 'Research and Development, Sanifit Therapeutics, San Diego, California.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Chertow', 'Affiliation': 'Department of Medicine, Stanford University, Palo Alto, California.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.16931020'] 2957,33838870,Gonadotropin response to insulin and lipid infusion reproduces the reprometabolic syndrome of obesity in eumenorrheic lean women: a randomized crossover trial.,"OBJECTIVE To study the reprometabolic syndrome in normal-weight, eumenorrheic women by infusing a combination of insulin and lipid. Women with obesity have been shown to have reduced gonadotropins and impaired luteinizing hormone (LH) and follicle-stimulating hormone (FSH) response to gonadotropin-releasing hormone (GnRH). DESIGN Randomized crossover. SETTING Academic medical center. PARTICIPANT(S) Fifteen women, median age 32 (interquartile ranged [IQR] 26, 36) years and body mass index 21.9 (IQR 20.2, 22.9) kg/m 2 were recruited. INTERVENTION(S) Early follicular phase, 6-hour infusions of insulin (20-40 mU/m 2 per minute) and lipid (Intralipid)-insulin/lipid infusion; or saline infusion (controls). The first 4 hours of each study assessed endogenous gonadotropins; at 4 hours, GnRH (75 ng/kg) bolus was administered and sampling continued until 6 hours. MAIN OUTCOME MEASURE(S) Linear mixed model analysis was used to determine differences between insulin/lipid and saline influence on endogenous LH pulse amplitude (primary outcome), mean FSH, and area under the curve (AUC) response to GnRH (secondary outcomes). RESULT(S) Twelve women completed both intended studies and an additional 3 women completed only 1 of the 2 studies. LH pulse amplitude, mean FSH, and both AUC responses to GnRH were reduced by insulin/lipid, mean FSH and AUC for LH were at or near statistical significance. LH response to GnRH was significantly reduced when 1 participant with very high LH and antimullerian hormone levels was excluded. CONCLUSION(S) Acute infusion of insulin/lipid to eumenorrheic, normal-weight women recapitulated the reprometabolic syndrome of obesity. These findings imply that specific circulating factors in obese women contribute to their subfertility and thus may be amenable to discovery and treatment. CLINICAL TRIAL REGISTRATION NUMBER NCT02653092.",2021,"LH response to GnRH was significantly reduced when 1 participant with very high LH and antimullerian hormone levels was excluded. ","['obese women', 'eumenorrheic lean women', '\n\n\nFifteen women, median age 32 (interquartile ranged [IQR] 26, 36) years and body mass index 21.9 (IQR 20.2, 22.9) kg/m 2 were recruited', 'Women with obesity', 'Academic medical center', 'Twelve women completed both intended studies and an additional 3 women completed only 1 of the 2 studies']","['lipid (Intralipid)-insulin/lipid infusion; or saline infusion (controls', 'insulin and lipid', 'insulin and lipid infusion reproduces']","['LH pulse amplitude, mean FSH, and both AUC responses to GnRH', 'endogenous LH pulse amplitude (primary outcome), mean FSH, and area under the curve (AUC) response to GnRH (secondary outcomes', 'luteinizing hormone (LH) and follicle-stimulating hormone (FSH) response', 'Gonadotropin response', 'endogenous gonadotropins', 'LH response to GnRH']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517642', 'cui_str': '20.2'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0018120', 'cui_str': 'Ovarian follicle structure'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0202022', 'cui_str': 'Follicle stimulating hormone measurement'}, {'cui': 'C0018061', 'cui_str': 'Gonadotropin'}]",12.0,0.2955,"LH response to GnRH was significantly reduced when 1 participant with very high LH and antimullerian hormone levels was excluded. ","[{'ForeName': 'Nanette', 'Initials': 'N', 'LastName': 'Santoro', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: Nanette.Santoro@cuanschutz.edu.'}, {'ForeName': 'Irene E', 'Initials': 'IE', 'LastName': 'Schauer', 'Affiliation': 'Department of Medicine (Endocrinology), University of Colorado School of Medicine, Aurora, Colorado; Department of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Kuhn', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.'}, {'ForeName': 'Angela J', 'Initials': 'AJ', 'LastName': 'Fought', 'Affiliation': 'Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Babcock-Gilbert', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Bradford', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.'}]",Fertility and sterility,['10.1016/j.fertnstert.2021.03.005'] 2958,33852013,Diets Varying in Carbohydrate Content Differentially Alter Brain Activity in Homeostatic and Reward Regions in Adults.,"BACKGROUND Obesity has one of the highest refractory rates of all chronic diseases, in part because weight loss induced by calorie restriction, the first-line treatment for obesity, elicits biological adaptations that promote weight regain. Although acute feeding trials suggest a role for macronutrient composition in modifying brain activity related to hunger and satiety, relevance of these findings to weight-loss maintenance has not been studied. OBJECTIVES We investigated effects of weight-loss maintenance diets varying in macronutrient content on regional cerebral blood flow (rCBF) in brain regions involved in hunger and reward. METHODS In conjunction with a randomized controlled feeding trial, we investigated the effects of weight-loss maintenance diets varying in carbohydrate content [high, 60% of total energy: n = 20; 6 men/14 women; mean age: 32.5 y; mean BMI (in kg/m 2): 27.4; moderate, 40% of total energy: n = 22; 10 men/12 women; mean age: 32.5 y; mean BMI: 29.0; low, 20% of total energy: n = 28; 12 men/16 women; mean age: 33.2 y; mean BMI: 27.7] on rCBF in brain regions involved in hunger and reward preprandial and 4 h postprandial after 14-20 wk on the diets. The primary outcome was rCBF in the nucleus accumbens (NAcc) at 4 h postprandial; the secondary outcome was preprandial rCBF in the hypothalamus. RESULTS Consistent with a priori hypothesis, at 4 h postprandial, NAcc rCBF was 43% higher in adults assigned to the high- compared with low-carbohydrate diet {P[family-wise error (FWE)-corrected] < 0.05}. Preprandial hypothalamus rCBF was 41% higher on high-carbohydrate diet [P(FWE-corrected) < 0.001]. Exploratory analyses revealed that elevated rCBF on high-carbohydrate diet was not specific to prandial state: preprandial NAcc rCBF [P(FWE-corrected) < 0.001] and 4 h postprandial rCBF in hypothalamus [P(FWE-corrected) < 0.001]. Insulin secretion predicted differential postprandial activation of the NAcc by diet. CONCLUSIONS We report significant differences in rCBF in adults assigned to diets varying in carbohydrate content for several months, which appear to be partially associated with insulin secretion. These findings suggest that chronic intake of a high-carbohydrate diet may affect brain reward and homeostatic activity in ways that could impede weight-loss maintenance. This trial was registered at clinicaltrials.gov as NCT02300857.",2021,Exploratory analyses revealed that elevated rCBF on high-carbohydrate diet was not specific to prandial state: preprandial NAcc rCBF [P(FWE-corrected) < 0.001] and 4 h postprandial rCBF in hypothalamus [P(FWE-corrected) ,"['Adults', 'carbohydrate content [high, 60% of total energy: n\xa0=\xa020; 6 men/14 women; mean age: 32.5 y; mean BMI (in kg/m 2): 27.4; moderate, 40% of total energy: n\xa0=\xa022; 10 men/12 women; mean age: 32.5 y; mean BMI: 29.0; low, 20% of total energy: n\xa0=\xa028; 12 men/16 women; mean age: 33.2 y; mean BMI: 27.7] on rCBF in brain regions involved in hunger and reward preprandial and 4 h postprandial after 14-20 wk on the diets']","['weight-loss maintenance diets', 'carbohydrate diet']","['regional cerebral blood flow (rCBF', 'rCBF in the nucleus accumbens (NAcc', 'postprandial rCBF in hypothalamus [P(FWE-corrected', 'brain reward and homeostatic activity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439175', 'cui_str': '% of total'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517710', 'cui_str': '32.5'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C5192328', 'cui_str': '27.4'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C1273723', 'cui_str': 'Brain region'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C1550738', 'cui_str': 'Before food'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0301577', 'cui_str': 'Carbohydrate diet'}]","[{'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0007610', 'cui_str': 'Nucleus'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0020663', 'cui_str': 'Hypothalamic structure'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",,0.155153,Exploratory analyses revealed that elevated rCBF on high-carbohydrate diet was not specific to prandial state: preprandial NAcc rCBF [P(FWE-corrected) < 0.001] and 4 h postprandial rCBF in hypothalamus [P(FWE-corrected) ,"[{'ForeName': 'Laura M', 'Initials': 'LM', 'LastName': 'Holsen', 'Affiliation': ""Division of Women's Health and Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'W Scott', 'Initials': 'WS', 'LastName': 'Hoge', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Belinda S', 'Initials': 'BS', 'LastName': 'Lennerz', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Hilâl', 'Initials': 'H', 'LastName': 'Cerit', 'Affiliation': ""Division of Women's Health and Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Taryn', 'Initials': 'T', 'LastName': 'Hye', 'Affiliation': ""Division of Women's Health and Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Priyanka', 'Initials': 'P', 'LastName': 'Moondra', 'Affiliation': ""Division of Women's Health and Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Goldstein', 'Affiliation': ""Division of Women's Health and Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Cara B', 'Initials': 'CB', 'LastName': 'Ebbeling', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Ludwig', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxab090'] 2959,34386458,Oncologic comparison between nonradical management and total mesorectal excision in good responders after chemoradiotherapy in patients with mid-to-low rectal cancer.,"Purpose This study was performed to compare the oncologic outcomes between nonradical management and total mesorectal excision in good responders after chemoradiotherapy. Methods We analyzed 75 patients, who underwent 14 watch-and-wait, 30 local excision, and 31 total mesorectal excision, in ycT0-1N0M0 based on magnetic resonance imaging after chemoradiotherapy for advanced mid-to-low rectal cancer in 3 referral hospitals. The nonradical management group underwent surveillance with additional sigmoidoscopy and rectal magnetic resonance imaging every 3-6 months within the first 2 years. Results Nonradical management group had more low-lying tumors (P < 0.001) and less lymph node metastasis based on magnetic resonance imaging (P = 0.004). However, cT stage, ycT, and ycN stage were not different between the 2 groups. With a median follow-up period of 64.7 months, the 5-year locoregional failure rate was higher in the nonradical management group than in the total mesorectal excision group (16.7% vs. 0%, P = 0.013). However, the 5-year overall survival and disease-free survival rates of the nonradical management and total mesorectal excision groups were not different (95.2% vs. 93.5%, P = 0.467; 76.4% vs. 83.6%, P = 0.665; respectively). Conclusion This study shows that nonradical management for ycT0-1N0 mid-to-low rectal cancer may be an alternative treatment to total mesorectal excision under proper surveillance and management for oncologic events.",2021,"Results Nonradical management group had more low-lying tumors (P < 0.001) and less lymph node metastasis based on magnetic resonance imaging (P = 0.004).","['patients with mid-to-low rectal cancer', '75 patients, who underwent 14 watch-and-wait, 30 local excision, and 31 total mesorectal excision, in ycT0-1N0M0 based on magnetic resonance imaging after chemoradiotherapy for advanced mid-to-low rectal cancer in 3 referral hospitals']","['nonradical management group underwent surveillance with additional sigmoidoscopy and rectal magnetic resonance imaging', 'chemoradiotherapy', 'nonradical management and total mesorectal excision']","['5-year overall survival and disease-free survival rates', 'lymph node metastasis', '5-year locoregional failure rate', 'low-lying tumors']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0278259', 'cui_str': 'Local excision'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0037075', 'cui_str': 'Sigmoidoscopy'}, {'cui': 'C0205052', 'cui_str': 'Rectal'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0686619', 'cui_str': 'Secondary malignant neoplasm of lymph node'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0023668', 'cui_str': 'Liechtenstein'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]",75.0,0.102841,"Results Nonradical management group had more low-lying tumors (P < 0.001) and less lymph node metastasis based on magnetic resonance imaging (P = 0.004).","[{'ForeName': 'Ja Kyung', 'Initials': 'JK', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Jung Rae', 'Initials': 'JR', 'LastName': 'Cho', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Kwang-Seop', 'Initials': 'KS', 'LastName': 'Song', 'Affiliation': 'Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.'}, {'ForeName': 'Jae Hwan', 'Initials': 'JH', 'LastName': 'Oh', 'Affiliation': 'Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.'}, {'ForeName': 'Seung-Yong', 'Initials': 'SY', 'LastName': 'Jeong', 'Affiliation': 'Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Min Jung', 'Initials': 'MJ', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Jeehye', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Min Hyun', 'Initials': 'MH', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Heung-Kwon', 'Initials': 'HK', 'LastName': 'Oh', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Duck-Woo', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Sung-Bum', 'Initials': 'SB', 'LastName': 'Kang', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of surgical treatment and research,['10.4174/astr.2021.101.2.93'] 2960,33843296,The comparative effects of brief or multidisciplinary intervention on return to work at 1 year in employees on sick leave due to low back pain: A randomized controlled trial.,"OBJECTIVE To compare return to work (RTW) rates among patients with low back pain (LBP) and different job relations randomized to brief or multidisciplinary intervention. DESIGN A randomized controlled trial with 1-year follow-up. SETTING Silkeborg Regional Hospital, Denmark. SUBJECTS Four hundred seventy-six participants were divided into two groups concerning job relations: strong (influence on job and no fear of losing it) or weak (no influence on job and/or fear of losing it), and afterwards randomized to brief or multidisciplinary intervention. INTERVENTIONS Brief intervention included examination and advice by a rheumatologist and a physiotherapist. Multidisciplinary intervention included brief intervention plus coaching by a case manager making a plan for RTW with the patient. MAIN MEASURES Primary outcome was 1-year RTW rate. Secondary outcomes included pain intensity (LBP rating scale), disability (Roland Morris disability scale), and psychological measures (Common Mental Disorder Questionnaire, Major Depression Inventory, and EQ-5D-3L). RESULTS Mean (SD) age was 43.1 (9.8) years. Among 272 participants with strong job relations, RTW was achieved for 104/137 (76%) receiving brief intervention compared to 89/135 (66%) receiving multidisciplinary intervention, hazard ratio 0.73 (CI: 0.55-0.96). Corresponding results for 204 participants with weak job relations were 69/102 (68%) in both interventions, hazard ratio 1.07 (CI: 0.77-1.49). For patients with strong job relations, depressive symptoms and quality of life were more improved after brief intervention. CONCLUSION Brief intervention resulted in higher RTW rates than multidisciplinary intervention for employees with strong job relations. There were no differences in RTW rates between interventions for employees with weak job relations.",2021,"Corresponding results for 204 participants with weak job relations were 69/102 (68%) in both interventions, hazard ratio 1.07 (CI: 0.77-1.49).","['272 participants with strong job relations', '204 participants with weak job relations', 'employees on sick leave due to low back pain', 'Silkeborg Regional Hospital, Denmark', 'Four hundred seventy-six participants', 'patients with low back pain (LBP']","['intervention plus coaching by a case manager making a plan for RTW with the patient', 'job relations: strong (influence on job and no fear of losing it) or weak (no influence on job and/or fear of losing it), and afterwards randomized to brief or multidisciplinary intervention', 'Brief intervention included examination and advice by a rheumatologist and a physiotherapist', 'multidisciplinary intervention']","['return to work (RTW) rates', 'depressive symptoms and quality of life', 'RTW rates', 'higher RTW rates', 'pain intensity (LBP rating scale), disability (Roland Morris disability scale), and psychological measures (Common Mental Disorder Questionnaire, Major Depression Inventory, and EQ-5D-3L', '1-year RTW rate']","[{'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C1762617', 'cui_str': 'Weak'}, {'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0687694', 'cui_str': 'Case manager'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0425105', 'cui_str': 'Returned to work'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0334889', 'cui_str': 'Rheumatologist'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}]","[{'cui': 'C0425105', 'cui_str': 'Returned to work'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0439234', 'cui_str': 'year'}]",476.0,0.0840491,"Corresponding results for 204 participants with weak job relations were 69/102 (68%) in both interventions, hazard ratio 1.07 (CI: 0.77-1.49).","[{'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Langagergaard', 'Affiliation': 'Diagnostic Center, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.'}, {'ForeName': 'Ole Kudsk', 'Initials': 'OK', 'LastName': 'Jensen', 'Affiliation': 'Diagnostic Center, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.'}, {'ForeName': 'Claus Vinther', 'Initials': 'CV', 'LastName': 'Nielsen', 'Affiliation': 'Department of Clinical Social Medicine and Rehabilitation, Gødstrup Hospital, Herning, Denmark.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Jensen', 'Affiliation': 'Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Merete', 'Initials': 'M', 'LastName': 'Labriola', 'Affiliation': 'Norwegian Research Center A/S, Bergen, Norway.'}, {'ForeName': 'Vibeke Neergaard', 'Initials': 'VN', 'LastName': 'Sørensen', 'Affiliation': 'Diagnostic Center, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.'}, {'ForeName': 'Pernille', 'Initials': 'P', 'LastName': 'Pedersen', 'Affiliation': 'Section of Clinical Social Medicine and Rehabilitation, Department of Public Health, Aarhus University, Aarhus, Denmark.'}]",Clinical rehabilitation,['10.1177/02692155211005387'] 2961,33843086,Is a 20 gauge fenestrated intravenous catheter non-inferior to a 18 gauge standard catheter for apheresis procedures? A pilot study.,"BACKGROUND Peripheral venous access has been promoted as the safest, quickest, and most easily achievable route for performing apheresis procedures by the American Society for Apheresis' Choosing Wisely campaign. The current literature regarding catheter size and selection for both draw and return access is limited. Furthermore, the Infusion Nurses Society recommends using the smallest gauge catheter possible for the prescribed therapy in order to limit vein trauma and phlebitis. Since there is a lack of evidence to guide selection of catheter size for return access during therapeutic apheresis procedures (TAPs) for patients with chronic conditions, this pilot study seeks to compare the performance of a 20-gauge fenestrated (20G) catheter to a standard 18-gauge (18G) intravenous catheter. METHODS This non-inferiority pilot study randomized 26 subjects during 74 TAPs to either 20G fenestrated catheter or 18G standard catheter. RESULTS There were no statistically significant differences for variables associated with the efficiency of the TAPs comparing 20G to 18G catheter for inlet rate (P = .8666), return pressure (P = .9427), blood processed (P = .4318), or total procedure time (P = .3184). CONCLUSION The results from this pilot study suggest that 20G fenestrated catheter is non-inferior to 18G standard catheters. Additional studies with increased power are warranted to confirm these findings.",2021,"There were no statistically significant differences for variables associated with the efficiency of the TAPs comparing 20G to 18G catheter for inlet rate (P = .8666), return pressure (P = .9427), blood processed (P = .4318), or total procedure time (P = .3184). ","['26 subjects during 74 TAPs to either 20', 'patients with chronic conditions']",['G fenestrated catheter or 18G standard catheter'],"['return pressure', 'total procedure time']","[{'cui': 'C0005791', 'cui_str': 'Apheresis'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0456637', 'cui_str': '18G'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",26.0,0.0417274,"There were no statistically significant differences for variables associated with the efficiency of the TAPs comparing 20G to 18G catheter for inlet rate (P = .8666), return pressure (P = .9427), blood processed (P = .4318), or total procedure time (P = .3184). ","[{'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Armendariz', 'Affiliation': 'Apheresis Clinic, University of Texas Southwestern Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'West', 'Affiliation': 'Apheresis Clinic, University of Texas Southwestern Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'DaiWai M', 'Initials': 'DM', 'LastName': 'Olson', 'Affiliation': 'Apheresis Clinic, University of Texas Southwestern Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Sonja E', 'Initials': 'SE', 'LastName': 'Stutzman', 'Affiliation': 'Apheresis Clinic, University of Texas Southwestern Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'De Simone', 'Affiliation': 'Apheresis Clinic, University of Texas Southwestern Medical Center, Dallas, Texas, USA.'}]",Journal of clinical apheresis,['10.1002/jca.21900'] 2962,33839207,Establishment and validation of a prognostic nomogram to predict early metastasis in nasopharyngeal carcinoma patients within six months after radiotherapy and to guide intensive treatment.,"PURPOSE This study aimed to establish an effective prognostic nomogram to predict the risk of early metastasis (EM) in nasopharyngeal carcinoma (NPC) patients, as a guide for intensive treatment. MATERIALS AND METHODS A total of 9021 patients with biopsy-confirmed NPC at our institute were enrolled in this study between December 2006 to December 2016. We randomized these patients using a proportion of 2/3 and 1/3 and selected 6044 and 2977 patients as the training and validation cohorts, respectively. All patients received radiotherapy with or without chemotherapy. Univariate and multivariate logistical regressions were used to identify independent risk factors. The nomogram's predictive value was evaluated by concordance indexes (C-indexes), calibration curves, probability density functions (PDFs), and clinical utility curves (CUCs). ROC analysis using Delong test was used to compare efficiency between the nomogram and other risk factors. RESULTS In total, 174 (2.9%) and 81 (2.7%) patients in training and validation cohorts, respectively, had EM. Pretreatment plasma EBV DNA, N stage, LDH, ALP, BMI, and sex were independent predictive factors of EM. The C-indexes of nomogram were 0.756 (95% CI = 0.719-0.793) and 0.766 (95% CI = 0.720-0.813), in the training and validation cohorts, respectively. The C-index of the nomogram was significantly superior to any one of independent factors. According to the PDFs and CUCs and considering the balance of the true positive EM patients and true positive non-EM patients, we chose 5.0% as a threshold probability for clinical decision-making, which could distinguish about 85% and 48% of non-EM and EM patients, respectively. CONCLUSION Our nomogram had good accuracy in predicting EM incidence, and a 5.0% threshold was appropriate for clinical decision-making.",2021,"The nomogram's predictive value was evaluated by concordance indexes (C-indexes), calibration curves, probability density functions (PDFs), and clinical utility curves (CUCs).","['nasopharyngeal carcinoma (NPC) patients', 'nasopharyngeal carcinoma patients within six months after', 'patients using a proportion of 2/3 and 1/3 and selected 6044 and 2977 patients as the training and validation cohorts, respectively', '9021 patients with biopsy-confirmed NPC at our institute were enrolled in this study between December 2006 to December 2016']","['radiotherapy with or without chemotherapy', 'radiotherapy']","['Pretreatment plasma EBV DNA, N stage, LDH, ALP, BMI, and sex', 'concordance indexes (C-indexes), calibration curves, probability density functions (PDFs), and clinical utility curves (CUCs']","[{'cui': 'C2931822', 'cui_str': 'Nasopharyngeal carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0369169', 'cui_str': 'Epstein-Barr virus DNA'}, {'cui': 'C0456532', 'cui_str': 'N category'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0006751', 'cui_str': 'Calibration'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",9021.0,0.0161033,"The nomogram's predictive value was evaluated by concordance indexes (C-indexes), calibration curves, probability density functions (PDFs), and clinical utility curves (CUCs).","[{'ForeName': 'Zi-Jian', 'Initials': 'ZJ', 'LastName': 'Lu', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: luzj@sysucc.org.cn.'}, {'ForeName': 'Li-Ting', 'Initials': 'LT', 'LastName': 'Liu', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: liult@sysucc.org.cn.'}, {'ForeName': 'Xue-Song', 'Initials': 'XS', 'LastName': 'Sun', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: sunxs@sysucc.org.cn.'}, {'ForeName': 'Shan-Shan', 'Initials': 'SS', 'LastName': 'Guo', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: guoshsh@sysucc.org.cn.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Yang', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: yangqi@sysucc.org.cn.'}, {'ForeName': 'Sai-Lan', 'Initials': 'SL', 'LastName': 'Liu', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: liusl@sysucc.org.cn.'}, {'ForeName': 'Xiao-Yun', 'Initials': 'XY', 'LastName': 'Li', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: lixy1@sysucc.org.cn.'}, {'ForeName': 'Hui-Zhi', 'Initials': 'HZ', 'LastName': 'Qiu', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: qiuhz@sysucc.org.cn.'}, {'ForeName': 'Zhen-Chong', 'Initials': 'ZC', 'LastName': 'Yang', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: yangzc@sysucc.org.cn.'}, {'ForeName': 'Bei-Bei', 'Initials': 'BB', 'LastName': 'Xiao', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: xiaobb@sysucc.org.cn.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: linchao@sysucc.org.cn.'}, {'ForeName': 'Dong-Hua', 'Initials': 'DH', 'LastName': 'Luo', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: luodh@sysucc.org.cn.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Sun', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: sunrui@sysucc.org.cn.'}, {'ForeName': 'Huan-Xin', 'Initials': 'HX', 'LastName': 'Lin', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: linhx@sysucc.org.cn.'}, {'ForeName': 'Qiu-Yan', 'Initials': 'QY', 'LastName': 'Chen', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: chenqy@sysucc.org.cn.'}, {'ForeName': 'Lin-Quan', 'Initials': 'LQ', 'LastName': 'Tang', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: tanglq@sysucc.org.cn.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: guoling@sysucc.org.cn.'}, {'ForeName': 'Hai-Qiang', 'Initials': 'HQ', 'LastName': 'Mai', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: maihq@sysucc.org.cn.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2021.03.035'] 2963,33844262,Comparison of the effects of TENS stimulation and water immersion on relieving labour pain suffered byprimiparas.,"OBJECTIVES The aim of this study was to compare pain suffered by primiparas when delivering a child in a traditional way with deliveries where either TENS stimulation or water immersion was used. MATERIAL AND METHODS Primiparas were divided into 3 groups. In group 1 there were 45 women for whom TENS stimulation was applied during delivery. Group 2 consisted of 38 women who remained in the water during the actual birth of the baby. Group 3 served as the control group and was composed of 32 women. The intensity of pain during delivery was assessed by means of a numerical scale. During the first delivery period, pain was assessed three times at cervical dilation of 2, 3 and 4 fingers. RESULTS The analysis of pain suffered by primiparas at 2-finger widening showed no statistically significant differences between the groups. However, the analysis of pain experienced at 3-finger opening showed significant differences between the group of women using TENS stimulation in comparison with the control group. When comparing pain at 4-finger opening, statistically significant differences were found between the group of women who delivered in water in comparison to both the control group and the group using TENS stimulation. CONCLUSIONS TENS stimulation and water immersion are good methods to relieve labour pain; particularly helpful in the first period of labour. They are also safe, alternative, non-pharmacological methods of reducing labour pain.",2021,The analysis of pain suffered by primiparas at 2-finger widening showed no statistically significant differences between the groups.,"['labour pain suffered byprimiparas', '38 women who remained in the water during the actual birth of the baby', 'Primiparas were divided into 3 groups', 'pain suffered by primiparas when delivering a child in a traditional way with deliveries where either']","['TENS stimulation or water immersion', 'stimulation and water immersion']","['labour pain', 'intensity of pain during delivery']","[{'cui': 'C0474368', 'cui_str': 'Labor pain'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0033150', 'cui_str': 'Para 1'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]","[{'cui': 'C0014518', 'cui_str': 'Lyell syndrome'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0020940', 'cui_str': 'Immersion'}]","[{'cui': 'C0474368', 'cui_str': 'Labor pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]",45.0,0.0224602,The analysis of pain suffered by primiparas at 2-finger widening showed no statistically significant differences between the groups.,"[{'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Grymel-Kulesza', 'Affiliation': 'Gdansk Collage of Health, Poland.'}, {'ForeName': 'Katarzyna M', 'Initials': 'KM', 'LastName': 'Pawlowska', 'Affiliation': 'Department of Physiotherapy and Wellness, Institute of Health Sciences, Pomeranian University in Slupsk, Poland. pawlowskakatarzyna@interia.eu.'}, {'ForeName': 'Jakub', 'Initials': 'J', 'LastName': 'Pawlowski', 'Affiliation': 'Department of Physiotherapy and Wellness, Institute of Health Sciences, Pomeranian University in Slupsk, Poland.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Grochulska', 'Affiliation': 'Department of Physiotherapy and Wellness, Institute of Health Sciences, Pomeranian University in Slupsk, Poland.'}, {'ForeName': 'Marcelina', 'Initials': 'M', 'LastName': 'Belkius', 'Affiliation': 'Praxis Physiotherapie Jeske, Berlin, Germany.'}, {'ForeName': 'Izabela', 'Initials': 'I', 'LastName': 'Jerzak', 'Affiliation': 'Department of Pharmacology and Toxicology, University of Zielona Gora, Collegium Medicum, Poland.'}]",Ginekologia polska,['10.5603/GP.a2021.0026'] 2964,33844258,The effect of various pressure of pneumatic uterine bracket by using saccule sterine external stent on incidence of supine hypotensive syndrome.,"OBJECTIVES The saccule uterine external stent with a pneumatic uterine bracket reportedly prevents the incidence of supine hypotension syndrome (SHS) during cesarean section under combined spinal - epidural anesthesia (CSEA). However, the preventive effect is affected by the pressure within pneumatic uterine bracket. This study aims to explore the optimal pressure. MATERIAL AND METHODS One hundred forty-eight pregnant women were selected and randomly divided into three groups: Group A (the control group, n = 49), Group B (n = 49), and Group C (n = 50). The pressure within pneumatic uterine bracket was set at 240 mmHg, 260mmHg, and 280mmHg, respectively, during cesarean section under CSEA for participants in groups A, B and C. The intraoperative comfort rate and incidence of SHS were recorded. RESULTS No significant difference in the anesthetic efficacy was observed among the three groups (p > 0.05). However, there was a significant difference in the occurrence of SHS, with a reduction of 30 mmHg in blood pressure. The incidence of SHS belong the three groups showed significant differences (36.73% in Group A, 18.37% in Group B and 18.00% in Group C, p < 0.05). In addition, significant differences (p < 0.05) in the intraoperative comfort rate were also found among the three groups, with the comfort rate of 69.39% in group A, 91.84% in group B and 90.00% in Group C. CONCLUSIONS The optimal pressure within pneumatic uterine bracket for preventing SHS hypotension is about 260 mmHg. These findings might contribute to the prevention of SHS.",2021,"In addition, significant differences (p < 0.05) in the intraoperative comfort rate were also found among the three groups, with the comfort rate of 69.39% in group A, 91.84% in group B and 90.00% in Group C. ",['One hundred forty-eight pregnant women'],"['pneumatic uterine bracket', 'saccule sterine external stent', 'cesarean section under combined spinal - epidural anesthesia (CSEA']","['anesthetic efficacy', 'blood pressure', 'supine hypotension syndrome (SHS', 'intraoperative comfort rate', 'intraoperative comfort rate and incidence of SHS', 'incidence of supine hypotensive syndrome', 'incidence of SHS', 'occurrence of SHS', 'comfort rate']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]","[{'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0036029', 'cui_str': 'Saccule structure'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}]","[{'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C3267143', 'cui_str': 'Supine hypotension syndrome'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0341966', 'cui_str': 'Maternal hypotension syndrome'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}]",148.0,0.100706,"In addition, significant differences (p < 0.05) in the intraoperative comfort rate were also found among the three groups, with the comfort rate of 69.39% in group A, 91.84% in group B and 90.00% in Group C. ","[{'ForeName': 'Tianke', 'Initials': 'T', 'LastName': 'Xiao', 'Affiliation': 'Department of Anesthesiology, CNNC 416th Hospital, The Second Affiliated Hospital of Chengdu Medical College, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynecology, CNNC 416th Hospital, The Second Affiliated Hospital of Chengdu Medical College, China.'}, {'ForeName': 'Mingshuai', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'Department of Anesthesiology, CNNC 416th Hospital, The Second Affiliated Hospital of Chengdu Medical College, China.'}, {'ForeName': 'Xuehui', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Obstetrics and Gynecology, CNNC 416th Hospital, The Second Affiliated Hospital of Chengdu Medical College, China.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, CNNC 416th Hospital, The Second Affiliated Hospital of Chengdu Medical College, China. drzhangke@126.com.'}, {'ForeName': 'Jingyi', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Obstetrics and Gynecology, CNNC 416th Hospital, The Second Affiliated Hospital of Chengdu Medical College, China.'}]",Ginekologia polska,['10.5603/GP.a2021.0009'] 2965,34386391,Low-carb Diet in Hospitalized Late Pubertal Type 1 Diabetic Girls: A Short-Term CGM Study.,"Objective We conducted the present study to observe potential short-term benefits or risks of low-carb diet (LCD). Methods This is a prospective randomized cross-over study. Type 1 diabetic girls were hospitalized in ternary groups for 7 days and each group randomly started with LCD or regular diet. Continuous glucose monitoring (CGM) was performed between 0 and 168 h. Results Twenty-eight subjects completed the study. Total energy, protein, and fat consumption were high ( P < 0.001); carbohydrate consumption and rapidly acting insulin dose were low ( P < 0.001 and P = 0.002, respectively) during LCD. Morning postprandial, noon postprandial, and evening preprandial capillary blood sugar levels were lower during LCD ( P = 0.013, 0.018, and 0.048, respectively). Conclusion LCD may have the advantage of better glycemic control despite lower insulin dose which is a favorable outcome with regard to weight control and atherosclerosis prevention. No adverse events were observed.",2021,"Total energy, protein, and fat consumption were high ( P < 0.001); carbohydrate consumption and rapidly acting insulin dose were low ( P < 0.001 and P = 0.002, respectively) during LCD.","['Type 1 diabetic girls', 'Hospitalized Late Pubertal Type 1 Diabetic Girls', 'Results\n\n\nTwenty-eight subjects completed the study']","['low-carb diet (LCD', 'Continuous glucose monitoring (CGM', 'LCD or regular diet', 'Low-carb Diet']","['Morning postprandial, noon postprandial, and evening preprandial capillary blood sugar levels', 'adverse events', 'carbohydrate consumption and rapidly acting insulin dose', 'Total energy, protein, and fat consumption']","[{'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C1627769', 'cui_str': 'Pubertal'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0184625', 'cui_str': 'Normal diet'}]","[{'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0585020', 'cui_str': 'Noon'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C1550738', 'cui_str': 'Before food'}, {'cui': 'C0229666', 'cui_str': 'Capillary blood'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]",,0.0117667,"Total energy, protein, and fat consumption were high ( P < 0.001); carbohydrate consumption and rapidly acting insulin dose were low ( P < 0.001 and P = 0.002, respectively) during LCD.","[{'ForeName': 'Nefise Aribas', 'Initials': 'NA', 'LastName': 'Öz', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Duzce University, Konuralp, Duzce, Turkey.'}, {'ForeName': 'Ilknur', 'Initials': 'I', 'LastName': 'Arslanoglu', 'Affiliation': 'Department of Pediatric Endocrinology, Duzce University, Konuralp, Duzce, Turkey.'}, {'ForeName': 'Sengül', 'Initials': 'S', 'LastName': 'Cangür', 'Affiliation': 'Department of Biostatistics, Faculty of Medicine, Duzce University, Konuralp, Duzce, Turkey.'}, {'ForeName': 'Semih', 'Initials': 'S', 'LastName': 'Bolu', 'Affiliation': 'Department of Pediatric Endocrinology, Duzce University, Konuralp, Duzce, Turkey.'}, {'ForeName': 'Kenan', 'Initials': 'K', 'LastName': 'Kocabay', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Duzce University, Konuralp, Duzce, Turkey.'}]",Indian journal of endocrinology and metabolism,['10.4103/ijem.ijem_176_21'] 2966,34386365,Evaluation of the effect of shift cycle time on chest compression quality during cardiopulmonary resuscitation.,"Objective Considering the potential role of shift cycle time on chest compression quality during cardiopulmonary resuscitation (CPR) and the available contradictory results in this regard, the present study aimed at evaluating the effect of 1-min versus 2-min shift cycle time on the quality of CPR. Materials and Methods In this randomized crossover study, 80 rescuers performed CPR on a manikin in two scenarios with a rotation of 1 and 2-min cycles. The quality of CPR was evaluated and compared based on the information obtained regarding the chest compression depth, recoil, and rate of chest compression. In addition, rescuer fatigue was recorded in 1-min versus 2-min shift cycles. Results In the 1-min group, the number of chest compressions per minute, complete recoil, and good rate with the mean of 114.89 ± 3.62, 54.34 ± 3.86, and 76.06 ± 8.00 were significantly higher than those of the 2-min group with the mean of 113.78 ± 4.94, 53.49 ± 5.27, and 73.98 ± 7.87 ( P < 0.05), respectively. In addition, the quality of CPR provided by males was significantly higher than females in both groups. The score of rescuer fatigue was higher in the 2-min group as compared with the 1-min group ( P < 0.001). Conclusion According to the results of the present study, the difference in the quality of CPR in terms of the number of chest compressions, complete recoil, and good rate was higher in the 1-min group as compared with the 2-min group. In addition, the quality of CPR in terms of chest compression depth and number in both 1-and 2-min rotation cycles was higher for male rescuers than females. Furthermore, rescuer fatigue was higher in the 2-min group as compared with the 1-min group. The mentioned finding may be a factor in reducing, albeit slightly, the quality of CPR in the group with a longer time.",2021,"The score of rescuer fatigue was higher in the 2-min group as compared with the 1-min group ( P < 0.001). ",['cardiopulmonary resuscitation'],['cardiopulmonary resuscitation (CPR'],"['quality of CPR.\nMaterials and Methods', 'rescuer fatigue', 'chest compression quality', 'quality of CPR', 'score of rescuer fatigue', 'number of chest compressions, complete recoil, and good rate', 'number of chest compressions per minute, complete recoil, and good rate']","[{'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}]","[{'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0702093', 'cui_str': '/minute'}]",80.0,0.0155882,"The score of rescuer fatigue was higher in the 2-min group as compared with the 1-min group ( P < 0.001). ","[{'ForeName': 'Farhad', 'Initials': 'F', 'LastName': 'Heydari', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Kourosh', 'Initials': 'K', 'LastName': 'Eghdami', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Zamani', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Keihan', 'Initials': 'K', 'LastName': 'Golshani', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Masoumi', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Tzu chi medical journal,['10.4103/tcmj.tcmj_228_20'] 2967,34386286,Effect of Increasing Running Cadence on Peak Impact Force in an Outdoor Environment.,"Background An estimated 56% of recreational runners sustain a running-related injury related to the high impact forces in running. Increasing step frequency (cadence) while maintaining a consistent speed has been shown to be an effective way to lower impact forces which may reduce injury risk. Purpose To examine effects of increased cadence on peak impact force during running in an outdoor setting. It was hypothesized that as cadence increases, peak force would decrease. Study Design Repeated measures, quasi-experimental. Methods Peak force and cadence measurements were collected from 15 recreational runners (8 females, 7 males) during two 2.4-mile outdoor runs. Peak force was measured using an insole-based load measuring device. Baseline session run was completed at participant's naturally preferred cadence and cadence session run was completed at a cadence targeted to be 10% greater than baseline. Pace was monitored with a GPS watch. Cadence was cued by an auditory metronome and measured with both GPS watch and insoles. Repeated-measures ANOVA's examined the differences in average peak force, GPS-reported cadence, and insole-reported cadence between mile 1 and mile 2, and across the two cadence conditions. Results Cadence differences of 7.3% were observed between baseline and cadence sessions (p<0.001). A concurrent decrease in average peak force of 5.6% was demonstrated during the cadence run (p<0.05). Average cadences measured by GPS watch and insoles were found to be the same at both baseline (p=0.096) and during cadence (p=0.352) sessions. Conclusion Increasing cadence by an average of 7% in an outdoor setting resulted in a decrease in peak force at two different time points during a 2.4-mile run. Furthermore, using a metronome for in-field cadence manipulation led to a change in cadence. This suggests that a metronome may be an effective tool to manipulate cadence for the purpose of decreasing peak impact force in an outdoor setting. Level of evidence 3b.",2021,"Average cadences measured by GPS watch and insoles were found to be the same at both baseline (p=0.096) and during cadence (p=0.352) sessions. ","['an Outdoor Environment', '15 recreational runners (8 females, 7 males) during two 2.4-mile outdoor runs']",['Increasing Running Cadence'],"['average peak force, GPS-reported cadence, and insole-reported cadence', 'peak force', 'average peak force', 'Peak force']","[{'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517631', 'cui_str': '2.4'}, {'cui': 'C0331865', 'cui_str': 'miles'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]","[{'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0272302', 'cui_str': 'Gray platelet syndrome'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C3873740', 'cui_str': 'Insole'}]",,0.0699188,"Average cadences measured by GPS watch and insoles were found to be the same at both baseline (p=0.096) and during cadence (p=0.352) sessions. ","[{'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Musgjerd', 'Affiliation': 'University of Wisconsin-La Crosse.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Anason', 'Affiliation': 'University of Wisconsin-La Crosse.'}, {'ForeName': 'Drew', 'Initials': 'D', 'LastName': 'Rutherford', 'Affiliation': 'University of Wisconsin-La Crosse.'}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Kernozek', 'Affiliation': 'University of Wisconsin-La Crosse.'}]",International journal of sports physical therapy,['10.26603/001c.25166'] 2968,33847047,Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.,"AIMS Patients surviving an acute myocardial infarction (AMI) are at risk of developing symptomatic heart failure (HF) or premature death. We hypothesized that sacubitril/valsartan, effective in the treatment of chronic HF, prevents development of HF and reduces cardiovascular death following high-risk AMI compared to a proven angiotensin-converting enzyme (ACE) inhibitor. This paper describes the study design and baseline characteristics of patients enrolled in the Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI) trial. METHODS AND RESULTS PARADISE-MI, a multinational (41 countries), double-blind, active-controlled trial, randomized patients within 0.5-7 days of presentation with index AMI to sacubitril/valsartan or ramipril. Transient pulmonary congestion and/or left ventricular ejection fraction (LVEF) ≤40% and at least one additional factor augmenting risk of HF or death (age ≥70 years, estimated glomerular filtration rate <60 mL/min/1.73 m 2 , diabetes, prior myocardial infarction, atrial fibrillation, LVEF <30%, Killip class ≥III, ST-elevation myocardial infarction without reperfusion) were required for inclusion. PARADISE-MI was event-driven targeting 708 primary endpoints (cardiovascular death, HF hospitalization or outpatient development of HF). Randomization of 5669 patients occurred 4.3 ± 1.8 days from presentation with index AMI. The mean age was 64 ± 12 years, 24% were women. The majority (76%) qualified with ST-segment elevation myocardial infarction; acute percutaneous coronary intervention was performed in 88% and thrombolysis in 6%. LVEF was 37 ± 9% and 58% were in Killip class ≥II. CONCLUSIONS Baseline therapies in PARADISE-MI reflect advances in contemporary evidence-based care. With enrollment complete PARADISE-MI is poised to determine whether sacubitril/valsartan is more effective than a proven ACE inhibitor in preventing development of HF and cardiovascular death following AMI.",2021,The majority (76%) qualified with ST-segment elevation MI; acute percutaneous coronary intervention was performed in 88% and thrombolysis in 6%.,"['Patients surviving an acute myocardial infarction (AMI', 'The mean age was 64 ±\u200912\u2009years, 24% were women']","['sacubitril/valsartan or ramipril', 'sacubitril/valsartan', 'LVEF']","['heart failure', 'HF and CV death', 'cardiovascular (CV) death, HF hospitalization or outpatient development of HF', 'cardiovascular death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C4033631', 'cui_str': 'valsartan and sacubitril'}, {'cui': 'C0072973', 'cui_str': 'Ramipril'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}]","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}]",,0.223957,The majority (76%) qualified with ST-segment elevation MI; acute percutaneous coronary intervention was performed in 88% and thrombolysis in 6%.,"[{'ForeName': 'Karola S', 'Initials': 'KS', 'LastName': 'Jering', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Claggett', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Marc A', 'Initials': 'MA', 'LastName': 'Pfeffer', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Granger', 'Affiliation': 'Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Køber', 'Affiliation': 'Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Eldrin F', 'Initials': 'EF', 'LastName': 'Lewis', 'Affiliation': 'Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Aldo P', 'Initials': 'AP', 'LastName': 'Maggioni', 'Affiliation': 'ANMCO Research Center, Florence, Italy.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Mann', 'Affiliation': 'Washington University Medical Center, St Louis, MO, USA.'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Jean-Lucien', 'Initials': 'JL', 'LastName': 'Rouleau', 'Affiliation': 'Montreal Heart Institute, University of Montreal, Montreal, Canada.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Solomon', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Philippe G', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'Université de Paris, AP-HP (Assistance Publique-Hôpitaux de Paris), FACT (French Alliance for Cardiovascular Trials) and INSERM U-1148, Paris, France.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'van der Meer', 'Affiliation': 'Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Wernsing', 'Affiliation': 'Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Carter', 'Affiliation': 'Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Weinong', 'Initials': 'W', 'LastName': 'Guo', 'Affiliation': 'Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Yinong', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Lefkowitz', 'Affiliation': 'Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Jianjian', 'Initials': 'J', 'LastName': 'Gong', 'Affiliation': 'Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Bela', 'Initials': 'B', 'LastName': 'Merkely', 'Affiliation': 'Semmelweis University, Heart and Vascular Center, Budapest, Hungary.'}, {'ForeName': 'Stella M', 'Initials': 'SM', 'LastName': 'Macin', 'Affiliation': 'Instituto de Cardiología JF Cabral Corrientes, Corrientes, Argentina.'}, {'ForeName': 'Urmil', 'Initials': 'U', 'LastName': 'Shah', 'Affiliation': 'Care Institute of Medical Sciences, Ahmedabad, India.'}, {'ForeName': 'Jose C', 'Initials': 'JC', 'LastName': 'Nicolau', 'Affiliation': 'Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Braunwald', 'Affiliation': ""TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.""}]",European journal of heart failure,['10.1002/ejhf.2191'] 2969,33845211,Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.,"INTRODUCTION In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data. METHODS Patients with stage IIIB or IV or recurrent NSCLC with disease progression after platinum-doublet chemotherapy were randomized 1:1 to avelumab 10 mg/kg every 2 weeks or docetaxel 75 mg/m 2 every 3 weeks. The primary end point was OS in patients with PD-L1+ tumors (greater than or equal to 1% tumor cell expression; IHC 73-10 pharmDx assay). RESULTS Of 792 patients, 529 had PD-L1+ tumors (264 versus 265 in the avelumab versus docetaxel arms, respectively). As of March 4, 2019, median duration of follow-up for OS in the PD-L1+ population was 35.4 months in the avelumab arm and 34.7 months in the docetaxel arm; study treatment was ongoing in 25 (9.5%) versus 0 patients, respectively. In the PD-L1+ population, 2-year OS rates (95% confidence interval [CI]) with avelumab versus docetaxel were 29.9% (24.5%-35.5%) versus 20.5% (15.6%-25.8%); in greater than or equal to 50% PD-L1+ subgroups, 2-year OS rates were 36.4% (29.1%-43.7%) versus 17.7% (11.8%-24.7%) and in the greater than or equal to 80% subgroup were 40.2% (31.3%-49.0%) versus 20.3% (12.9%-28.8%), respectively. Median duration of response (investigator assessed) was 19.1 months (95% CI: 10.8-34.8) versus 5.7 months (95% CI: 4.1-8.3). Safety profiles for both arms were consistent with the primary analysis. CONCLUSIONS Although the JAVELIN Lung 200 primary analysis (reported previously) revealed that avelumab did not significantly prolong OS versus docetaxel in patients with platinum-treated PD-L1+ NSCLC, posthoc analyses at 2 years of follow-up revealed that 2-year OS rates were doubled with avelumab in subgroups with higher PD-L1 expression (greater than or equal to 50% and greater than or equal to 80%).",2021,Median duration of response (investigator assessed) was 19.1 months (95% CI: 10.8-34.8) vs 5.7 months (95% CI: 4.1-8.3).,"['patients with platinum-treated advanced non-small-cell lung cancer', 'Patients with stage IIIB/IV or recurrent NSCLC with disease progression following platinum-doublet chemotherapy', '792 patients', 'patients with platinum-treated PD-L1+ NSCLC']","['avelumab vs docetaxel', 'PD-L1', 'avelumab 10 mg/kg every 2 weeks or docetaxel', 'Avelumab vs docetaxel', 'docetaxel']","['Median duration of response', 'Safety profiles', '2-year OS rates', 'median duration of follow-up for OS', 'overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B'}, {'cui': 'C0278517', 'cui_str': 'Non-small cell lung cancer recurrent'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}]","[{'cui': 'C4055417', 'cui_str': 'avelumab'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0585332', 'cui_str': 'Biweekly'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.367026,Median duration of response (investigator assessed) was 19.1 months (95% CI: 10.8-34.8) vs 5.7 months (95% CI: 4.1-8.3).,"[{'ForeName': 'Keunchil', 'Initials': 'K', 'LastName': 'Park', 'Affiliation': 'Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Özgüroğlu', 'Affiliation': 'Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Vansteenkiste', 'Affiliation': 'Department of Respiratory Oncology, University Hospital KU Leuven, Leuven, Belgium.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Spigel', 'Affiliation': 'Sarah Cannon Research Institute, Nashville, Tennessee.'}, {'ForeName': 'James C H', 'Initials': 'JCH', 'LastName': 'Yang', 'Affiliation': 'Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.'}, {'ForeName': 'Hidenobu', 'Initials': 'H', 'LastName': 'Ishii', 'Affiliation': 'Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Garassino', 'Affiliation': 'Thoracic Oncology Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'de Marinis', 'Affiliation': 'Thoracic Oncology Division, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Szczesna', 'Affiliation': 'Department of Lung Diseases, Regional Lung Disease Hospital, Otwock, Poland.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Polychronis', 'Affiliation': 'Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom.'}, {'ForeName': 'Ruchan', 'Initials': 'R', 'LastName': 'Uslu', 'Affiliation': 'Department of Medical Oncology, Ege University Hospital, Izmir, Turkey.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Krzakowski', 'Affiliation': 'Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw, Poland.'}, {'ForeName': 'Jong-Seok', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.'}, {'ForeName': 'Luana', 'Initials': 'L', 'LastName': 'Calabrò', 'Affiliation': 'Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.'}, {'ForeName': 'Osvaldo', 'Initials': 'O', 'LastName': 'Arén Frontera', 'Affiliation': 'Instituto Nacional del Cáncer, Santiago, Chile.'}, {'ForeName': 'Huiling', 'Initials': 'H', 'LastName': 'Xiong', 'Affiliation': 'EMD Serono Research & Development Institute Inc., Billerica, Massachusetts; an affiliate of Merck KGaA, Darmstadt, Germany.'}, {'ForeName': 'Marcis', 'Initials': 'M', 'LastName': 'Bajars', 'Affiliation': 'EMD Serono Research & Development Institute Inc., Billerica, Massachusetts; an affiliate of Merck KGaA, Darmstadt, Germany.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Ruisi', 'Affiliation': 'EMD Serono Research & Development Institute Inc., Billerica, Massachusetts; an affiliate of Merck KGaA, Darmstadt, Germany.'}, {'ForeName': 'Fabrice', 'Initials': 'F', 'LastName': 'Barlesi', 'Affiliation': 'CRCM, INSERM, CNRS, Aix Marseille University, Marseille, France(∗); Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: Fabrice.BARLESI@gustaveroussy.fr.'}]",Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,['10.1016/j.jtho.2021.03.009'] 2970,34379922,Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.,"BACKGROUND Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection. METHODS We conducted a randomized, double-blind, double-dummy, noninferiority trial to compare long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI]) at a dose of 600 mg, given intramuscularly every 8 weeks, with daily oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for the prevention of HIV infection in at-risk cisgender men who have sex with men (MSM) and in at-risk transgender women who have sex with men. Participants were randomly assigned (1:1) to receive one of the two regimens and were followed for 153 weeks. HIV testing and safety evaluations were performed. The primary end point was incident HIV infection. RESULTS The intention-to-treat population included 4566 participants who underwent randomization; 570 (12.5%) identified as transgender women, and the median age was 26 years (interquartile range, 22 to 32). The trial was stopped early for efficacy on review of the results of the first preplanned interim end-point analysis. Among 1698 participants from the United States, 845 (49.8%) identified as Black. Incident HIV infection occurred in 52 participants: 13 in the cabotegravir group (incidence, 0.41 per 100 person-years) and 39 in the TDF-FTC group (incidence, 1.22 per 100 person-years) (hazard ratio, 0.34; 95% confidence interval, 0.18 to 0.62). The effect was consistent across prespecified subgroups. Injection-site reactions were reported in 81.4% of the participants in the cabotegravir group and in 31.3% of those in the TDF-FTC group. In the participants in whom HIV infection was diagnosed after exposure to CAB-LA, INSTI resistance and delays in the detection of HIV infection were noted. No safety concerns were identified. CONCLUSIONS CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women. Strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 083 ClinicalTrials.gov number, NCT02720094.).",2021,Injection-site reactions were reported in 81.4% of the participants in the cabotegravir group and in 31.3% of those in the TDF-FTC group.,"['4566 participants who underwent randomization; 570 (12.5%) identified as transgender women, and the median age was 26 years (interquartile range, 22 to 32', '1698 participants from the United States, 845 (49.8%) identified as Black', 'human immunodeficiency virus', 'Cisgender Men and Transgender Women', 'at-risk cisgender men who have sex with men (MSM) and in at-risk transgender women who have sex with men']","['long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI', 'tenofovir disoproxil fumarate-emtricitabine (TDF-FTC', 'TDF-FTC']","['Incident HIV infection', 'Injection-site reactions', 'incident HIV infection', 'HIV testing and safety evaluations']","[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1319927', 'cui_str': 'Male-to-female transsexual'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0376601', 'cui_str': 'Integrase strand transfer inhibitor-containing product'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0206682', 'cui_str': 'Follicular thyroid carcinoma'}]","[{'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]",4566.0,0.621575,Injection-site reactions were reported in 81.4% of the participants in the cabotegravir group and in 31.3% of those in the TDF-FTC group.,"[{'ForeName': 'Raphael J', 'Initials': 'RJ', 'LastName': 'Landovitz', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Donnell', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Meredith E', 'Initials': 'ME', 'LastName': 'Clement', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Brett', 'Initials': 'B', 'LastName': 'Hanscom', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Cottle', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Coelho', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Robinson', 'Initials': 'R', 'LastName': 'Cabello', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Suwat', 'Initials': 'S', 'LastName': 'Chariyalertsak', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Eileen F', 'Initials': 'EF', 'LastName': 'Dunne', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Frank', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Jorge A', 'Initials': 'JA', 'LastName': 'Gallardo-Cartagena', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Aditya H', 'Initials': 'AH', 'LastName': 'Gaur', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Gonzales', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Ha V', 'Initials': 'HV', 'LastName': 'Tran', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Juan C', 'Initials': 'JC', 'LastName': 'Hinojosa', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Esper G', 'Initials': 'EG', 'LastName': 'Kallas', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Colleen F', 'Initials': 'CF', 'LastName': 'Kelley', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Marcelo H', 'Initials': 'MH', 'LastName': 'Losso', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'J Valdez', 'Initials': 'JV', 'LastName': 'Madruga', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Keren', 'Initials': 'K', 'LastName': 'Middelkoop', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Nittaya', 'Initials': 'N', 'LastName': 'Phanuphak', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Breno', 'Initials': 'B', 'LastName': 'Santos', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Sued', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Valencia Huamaní', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Edgar T', 'Initials': 'ET', 'LastName': 'Overton', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Shobha', 'Initials': 'S', 'LastName': 'Swaminathan', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Del Rio', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Roy M', 'Initials': 'RM', 'LastName': 'Gulick', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Richardson', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Sullivan', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Estelle', 'Initials': 'E', 'LastName': 'Piwowar-Manning', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Marzinke', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Hendrix', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Maoji', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Marrazzo', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Daar', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Asmelash', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Todd T', 'Initials': 'TT', 'LastName': 'Brown', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Anderson', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Susan H', 'Initials': 'SH', 'LastName': 'Eshleman', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Bryan', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Blanchette', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Lucas', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Psaros', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Safren', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Sugarman', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Hyman', 'Initials': 'H', 'LastName': 'Scott', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Joseph J', 'Initials': 'JJ', 'LastName': 'Eron', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Sheldon D', 'Initials': 'SD', 'LastName': 'Fields', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Nirupama D', 'Initials': 'ND', 'LastName': 'Sista', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Kailazarid', 'Initials': 'K', 'LastName': 'Gomez-Feliciano', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Jennings', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Ryan M', 'Initials': 'RM', 'LastName': 'Kofron', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Timothy H', 'Initials': 'TH', 'LastName': 'Holtz', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Shin', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Rooney', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Kimberly Y', 'Initials': 'KY', 'LastName': 'Smith', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Spreen', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Margolis', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Rinehart', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Adeola', 'Initials': 'A', 'LastName': 'Adeyeye', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Myron S', 'Initials': 'MS', 'LastName': 'Cohen', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Marybeth', 'Initials': 'M', 'LastName': 'McCauley', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Grinsztejn', 'Affiliation': ""From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.),\xa0the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.),\xa0the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2101016'] 2971,34379917,Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.,,2021,,['Transplant Recipients'],['mRNA-1273 Vaccine'],[],"[{'cui': 'C0376387', 'cui_str': 'Recipient, Transplant'}]","[{'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",[],,0.112722,,"[{'ForeName': 'Victoria G', 'Initials': 'VG', 'LastName': 'Hall', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Victor H', 'Initials': 'VH', 'LastName': 'Ferreira', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Terrance', 'Initials': 'T', 'LastName': 'Ku', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Ierullo', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Beata', 'Initials': 'B', 'LastName': 'Majchrzak-Kita', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Chaparro', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Nazia', 'Initials': 'N', 'LastName': 'Selzner', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Schiff', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'McDonald', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Tomlinson', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Vathany', 'Initials': 'V', 'LastName': 'Kulasingam', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Deepali', 'Initials': 'D', 'LastName': 'Kumar', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Humar', 'Affiliation': 'University Health Network, Toronto, ON, Canada atul.humar@uhn.ca.'}]",The New England journal of medicine,['10.1056/NEJMc2111462'] 2972,34379916,A Monoclonal Antibody for Malaria Prevention.,"BACKGROUND Additional interventions are needed to reduce the morbidity and mortality caused by malaria. METHODS We conducted a two-part, phase 1 clinical trial to assess the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum . Part A of the trial assessed the safety, initial side-effect profile, and pharmacokinetics of CIS43LS in healthy adults who had never had malaria. Participants received CIS43LS subcutaneously or intravenously at one of three escalating dose levels. A subgroup of participants from Part A continued to Part B, and some received a second CIS43LS infusion. Additional participants were enrolled in Part B and received CIS43LS intravenously. To assess the protective efficacy of CIS43LS, some participants underwent controlled human malaria infection in which they were exposed to mosquitoes carrying P. falciparum sporozoites 4 to 36 weeks after administration of CIS43LS. RESULTS A total of 25 participants received CIS43LS at a dose of 5 mg per kilogram of body weight, 20 mg per kilogram, or 40 mg per kilogram, and 4 of the 25 participants received a second dose (20 mg per kilogram regardless of initial dose). No safety concerns were identified. We observed dose-dependent increases in CIS43LS serum concentrations, with a half-life of 56 days. None of the 9 participants who received CIS43LS, as compared with 5 of 6 control participants who did not receive CIS43LS, had parasitemia according to polymerase-chain-reaction testing through 21 days after controlled human malaria infection. Two participants who received 40 mg per kilogram of CIS43LS and underwent controlled human malaria infection approximately 36 weeks later had no parasitemia, with serum concentrations of CIS43LS of 46 and 57 μg per milliliter at the time of controlled human malaria infection. CONCLUSIONS Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection. (Funded by the National Institute of Allergy and Infectious Diseases; VRC 612 ClinicalTrials.gov number, NCT04206332.).",2021,No safety concerns were identified.,"['participants underwent controlled human malaria infection in which they were exposed to mosquitoes carrying P. falciparum sporozoites 4 to 36 weeks after administration of CIS43LS', 'adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection', 'healthy adults who had never had malaria']","['40 mg per kilogram of CIS43LS', 'CIS43LS', 'CIS43LS subcutaneously']",['CIS43LS serum concentrations'],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0562648', 'cui_str': 'Kingdom Protozoa sporozoite'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0439209', 'cui_str': 'kg'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",2.0,0.393783,No safety concerns were identified.,"[{'ForeName': 'Martin R', 'Initials': 'MR', 'LastName': 'Gaudinski', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Nina M', 'Initials': 'NM', 'LastName': 'Berkowitz', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Azza H', 'Initials': 'AH', 'LastName': 'Idris', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Emily E', 'Initials': 'EE', 'LastName': 'Coates', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'LaSonji A', 'Initials': 'LA', 'LastName': 'Holman', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Floreliz', 'Initials': 'F', 'LastName': 'Mendoza', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Ingelise J', 'Initials': 'IJ', 'LastName': 'Gordon', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Sarah H', 'Initials': 'SH', 'LastName': 'Plummer', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Trofymenko', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Zonghui', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Andrezza', 'Initials': 'A', 'LastName': 'Campos Chagas', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': ""O'Connell"", 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Manjula', 'Initials': 'M', 'LastName': 'Basappa', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Douek', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Sandeep R', 'Initials': 'SR', 'LastName': 'Narpala', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Barry', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Alicia T', 'Initials': 'AT', 'LastName': 'Widge', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Renunda', 'Initials': 'R', 'LastName': 'Hicks', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Seemal F', 'Initials': 'SF', 'LastName': 'Awan', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Richard L', 'Initials': 'RL', 'LastName': 'Wu', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Somia', 'Initials': 'S', 'LastName': 'Hickman', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Wycuff', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Judy A', 'Initials': 'JA', 'LastName': 'Stein', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Case', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Brian P', 'Initials': 'BP', 'LastName': 'Evans', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Carlton', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Jason G', 'Initials': 'JG', 'LastName': 'Gall', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Vazquez', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Britta', 'Initials': 'B', 'LastName': 'Flach', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Grace L', 'Initials': 'GL', 'LastName': 'Chen', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Joseph R', 'Initials': 'JR', 'LastName': 'Francica', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Flynn', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Neville K', 'Initials': 'NK', 'LastName': 'Kisalu', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Edmund V', 'Initials': 'EV', 'LastName': 'Capparelli', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'McDermott', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Mascola', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Ledgerwood', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Seder', 'Affiliation': 'From the Vaccine Research Center (M.R.G., N.M.B., A.H.I., E.E.C., L.A.H., F.M., I.J.G., S.H.P., O.T., S.O., M.B., N.D., S.R.N., C.R.B., A.T.W., R.H., S.F.A., R.L.W., S.H., D.W., J.A.S., K.C., J.G.G., S.V., B.F., G.L.C., J.R.F., B.J.F., N.K.K., A.M., J.R.M., J.E.L., R.A.S.) and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, the U.S. Public Health Service Commissioned Corps, Rockville (M.R.G.), the Entomology Branch, Walter Reed Army Institute of Research, Silver Spring (A.C.C., B.P.E.), and the Vaccine Clinical Materials Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (C.C.) - all in Maryland; and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego (E.V.C.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2034031'] 2973,33839602,Effectiveness of a one day self-compassion training for pediatric nurses' resilience.,"BACKGROUND Resilience is a critical skill for nurses and other healthcare professionals, especially during the COVID-19 pandemic, yet few nurses receive training that promotes emotional awareness and regulation, resilience, and self-compassion. PURPOSE The purpose of this study was to understand if attending a one-day workshop format of the Self Compassion for Healthcare Communities (SCHC) program would improve pediatric nurses' resilience, well-being, and professional quality of life. DESIGN AND METHODS Following a quasi-experimental design, pre, post, and follow-up surveys were acquired from 22 nurses who attended the training and 26 nurses who did not attend the training. In a linear mixed models regression analysis, changes in self-compassion, mindfulness, compassion, resilience, job engagement, professional quality of life (compassion satisfaction, burnout, and secondary traumatic stress), depression, anxiety and stress were analyzed between groups. RESULTS Participants in the intervention exhibited significant increases in self-compassion, mindfulness, compassion to others, resilience and compassion satisfaction, and significant decreases in burnout, anxiety, and stress compared to the non-intervention group. CONCLUSIONS A one-day SCHC training program provides nurses with knowledge and skills to increase their resilience and support their emotional well-being and professional quality of life. PRACTICE IMPLICATIONS Nurses' schedules may hamper their ability to attend lengthy resilience trainings, yet the skills needed for resilience are crucial to decreasing burnout, empathy fatigue, and turnover. Offering an effective, one-day training provides an accessible alternative for nurses to gain knowledge and skills that increase resilience.",2021,"RESULTS Participants in the intervention exhibited significant increases in self-compassion, mindfulness, compassion to others, resilience and compassion satisfaction, and significant decreases in burnout, anxiety, and stress compared to the non-intervention group. ","['22 nurses who attended the training and 26 nurses who did not attend the training', ""pediatric nurses' resilience"", 'attending a one-day workshop format of the Self Compassion for Healthcare Communities (SCHC) program']",['one day self-compassion training'],"['resilience and support their emotional well-being and professional quality of life', ""pediatric nurses' resilience, well-being, and professional quality of life"", 'self-compassion, mindfulness, compassion to others, resilience and compassion satisfaction', 'self-compassion, mindfulness, compassion, resilience, job engagement, professional quality of life (compassion satisfaction, burnout, and secondary traumatic stress), depression, anxiety and stress', 'burnout, anxiety, and stress']","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0559294', 'cui_str': 'Did not attend'}, {'cui': 'C0030753', 'cui_str': 'Nursing, Pediatric'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C1301627', 'cui_str': 'Format'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030753', 'cui_str': 'Nursing, Pediatric'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C4042834', 'cui_str': 'Vicarious Traumatization'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",,0.0147981,"RESULTS Participants in the intervention exhibited significant increases in self-compassion, mindfulness, compassion to others, resilience and compassion satisfaction, and significant decreases in burnout, anxiety, and stress compared to the non-intervention group. ","[{'ForeName': 'Phoebe Long', 'Initials': 'PL', 'LastName': 'Franco', 'Affiliation': ""Center for Resiliency, Dell Children's Medical Center, USA. Electronic address: phoebe.long@ascension.org.""}, {'ForeName': 'LeeAnn M', 'Initials': 'LM', 'LastName': 'Christie', 'Affiliation': ""Quality Improvement and Patient Safety, Dell Children's Medical Center, USA.""}]",Journal of pediatric nursing,['10.1016/j.pedn.2021.03.020'] 2974,33852752,Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine.,"BACKGROUND AND PURPOSE Fatigue in multiple sclerosis (MS) is common and disabling; medication efficacy is still not fully proven. The aim of this study was to investigate 4-week modifications of fatigue severity in 45 relapsing-remitting MS patients after different symptomatic treatments, and changes in concomitant resting state (RS) functional connectivity (FC). METHODS Patients were randomly, blindly assigned to treatment with fampridine (n = 15), amantadine (n = 15) or placebo (n = 15), and underwent clinical assessment and 3-Tesla RS functional magnetic resonance imaging at baseline (t0) and after 4 weeks (w4) of treatment. Fifteen healthy controls (HCs) were also studied. Changes in modified fatigue impact scale (MFIS) score and network RS FC were assessed. RESULTS In MS, abnormalities of network RS FC at t0 did not differ between treatment groups and correlated with fatigue severity. At w4, global scores and subscores on the MFIS decreased in all groups, with no time-by-treatment interaction. At w4, all patient groups had changes in RS FC in several networks, with significant time-by-treatment interactions in basal ganglia, sensorimotor and default-mode networks in fampridine-treated patients versus the other groups, and in frontoparietal network in amantadine-treated patients. In the fampridine group, RS FC changes correlated with concurrently decreased MFIS score (r range = -0.75 to 0.74, p range = 0.003-0.05). CONCLUSIONS Fatigue improved in all MS groups, independently of treatment. Concomitant RS FC modifications were located in sensorimotor, inferior frontal and subcortical regions for fampridine- and amantadine-treated patients, and in associative sensory cortices for placebo-treated patients.",2021,"Concomitant RS FC modifications were located in sensorimotor, inferior frontal and subcortical regions for fampridine and amantadine patients, and in associative sensory cortices for placebo patients.","['Patients', 'Fifteen healthy controls (HC', '45 relapsing-remitting MS patients']","['amantadine', 'fampridine', 'placebo', 'clinical/3T RS fMRI', 'fampridine and amantadine']","['MFIS', 'concomitant resting state (RS) functional connectivity (FC) changes', 'basal ganglia, sensorimotor and default-mode networks', 'RS FC changes', 'Concomitant RS FC modifications', 'fatigue severity', 'modified fatigue impact scale (MFIS) and network RS FC', 'MS, abnormalities of network RS FC', 'changes of RS FC', 'global and subscore MFISs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}]","[{'cui': 'C0002403', 'cui_str': 'Amantadine'}, {'cui': 'C0000477', 'cui_str': 'dalfampridine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2733557', 'cui_str': 'Fatigue impact scale'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0004781', 'cui_str': 'Basal ganglion structure'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}]",15.0,0.0654016,"Concomitant RS FC modifications were located in sensorimotor, inferior frontal and subcortical regions for fampridine and amantadine patients, and in associative sensory cortices for placebo patients.","[{'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Rocca', 'Affiliation': 'Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Valsasina', 'Affiliation': 'Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Colombo', 'Affiliation': 'Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Vittorio', 'Initials': 'V', 'LastName': 'Martinelli', 'Affiliation': 'Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Filippi', 'Affiliation': 'Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}]",European journal of neurology,['10.1111/ene.14867'] 2975,33858230,Educating caregivers of persons with cerebral palsy in night-time postural care: A randomized trial comparing two online training programs.,"OBJECTIVE Compare effectiveness of two differently formatted training programs in educating night-time postural care implementers. DESIGN Mixed-methods parallel-group double-blind design with random assignment. SETTING United States academic institution. PARTICIPANTS Thirty-eight adult caregivers/providers of children with cerebral palsy. INTERVENTIONS Both 2-hour online programs included content on night-time postural care evidence, risk-factor monitoring, sleep-system types, positioning methods, and assessments. Group A used interactive videos, Group B summary information with web-links. MAIN MEASURES We measured self-perceived competence via questionnaires (baseline, post-training, post-simulation) containing 4-point rating-scales of knowledge, ability, and confidence and measured positioning ability via a simulation observation instrument comprising 16 positioning-task ratings with space for describing performance. We recorded participant actions/statements using fieldnotes. RESULTS Thirty-eight completed training (19 per group). Group A (vs B) showed significantly greater self-perceived competence changes post-training (0.46 points (SE 0.17), P  = 0.008). Thirty-seven positioned a standardized ""client,"" with groups not differing significantly on total tasks completed correctly ( F (1, 92.32) = 1.91, P  = 0.17) averaging 11.85 (SE 0.83) and 12.60 (SE 0.84) of 16 tasks correct. Group A's post-positioning/simulation self-ratings were significantly associated with actual ability ( r  = 0.53, P  = 0.019). In both groups ⩾47% of caregivers incorrectly completed the tasks of placing head and neck in neutral and snugging up all [positioning] parts. CONCLUSION The sleep care positioning training program (interactive video-based format) is effective in building caregivers' self-perceived competence for night-time postural care. While the lesson was well-received by caregivers and considered a ""match [to their] learning style,"" the lesson did not lead to greater improvement in actual ability to position the ""client"" compared to control training.",2021,The sleep care positioning training program (interactive video-based format) is effective in building caregivers' self-perceived competence for night-time postural care.,"['Educating caregivers of persons with cerebral palsy in night-time postural care', 'United States academic institution', 'Thirty-eight adult caregivers/providers of children with cerebral palsy']","['sleep care positioning training program (interactive video-based format', 'interactive videos, Group B summary information with web-links']","['night-time postural care evidence, risk-factor monitoring, sleep-system types, positioning methods, and assessments', 'self-perceived competence changes post-training', 'self-perceived competence via questionnaires (baseline, post-training, post-simulation) containing 4-point rating-scales of knowledge, ability, and confidence and measured positioning ability via a simulation observation instrument comprising 16 positioning-task ratings with space for describing performance', 'actual ability']","[{'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0680063', 'cui_str': 'Child of'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1301627', 'cui_str': 'Format'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}]","[{'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}]",38.0,0.0140713,The sleep care positioning training program (interactive video-based format) is effective in building caregivers' self-perceived competence for night-time postural care.,"[{'ForeName': 'Jennifer Ann', 'Initials': 'JA', 'LastName': 'Hutson', 'Affiliation': 'Occupational Therapy, St. Catherine University, St. Paul, MN, USA.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Hodges', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'LeAnn', 'Initials': 'L', 'LastName': 'Snow', 'Affiliation': 'Division of Rehabilitation Science, Department of Rehabilitation Medicine, University of Minnesota, Minneapolis, MN, USA.'}]",Clinical rehabilitation,['10.1177/02692155211009484'] 2976,33849606,IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study.,"BACKGROUND Intraoperative radiotherapy with electrons (IOERT) boost could be not inferior to external beam radiotherapy (EBRT) boost in terms of local control and tissue tolerance. The aim of the study is to present the long-term follow-up results on local control, esthetic evaluation, and toxicity of a prospective study on early-stage breast cancer patients treated with breast-conserving surgery with an IOERT boost of 10 Gy (experimental group) versus 5 × 2 Gy EBRT boost (standard arm). Both arms received whole-breast irradiation (WBI) with 50 Gy (2 Gy single dose). METHODS A single-institution phase III randomized study to compare IOERT versus EBRT boost in early-stage breast cancer was conducted as a non-inferiority trial. Primary endpoints were the evaluation of in-breast true recurrences (IBTR) and out-field local recurrences (LR) as well as toxicity and cosmetic results. Secondary endpoints were overall survival (OS), disease-free survival (DFS), and patient's grade of satisfaction with cosmetic outcomes. RESULTS Between 1999 and 2004, 245 patients were randomized: 133 for IOERT and 112 for EBRT. The median follow-up was 12 years (range 10-16 years). The cumulative risk of IBTR at 5-10 years was 0.8% and 4.3% after IOERT, compared to 4.2% and 5.3% after EBRT boost (p = 0.709). The cumulative risk of out-field LR at 5-10 years was 4.7% and 7.9% for IOERT versus 5.2% and 10.3% for EBRT (p = 0.762). All of the IOERT arm recurrences were observed at > 100 months' follow-up, whereas the mean time to recurrence in the EBRT group was earlier (55.2 months) (p < 0.05). No late complications associated with IOERT were observed. The overall cosmetic results were scored as good or excellent in physician and patient evaluations for both IOERT and EBRT. There were significantly better scores for IOERT at all time points in physician and patient evaluations with the greatest difference at the end of EBRT (p = 0.006 objective and p = 0.0004 subjective) and most narrow difference at 12 months after the end of EBRT (p = 0.08 objective and p = 0.04 subjective analysis). CONCLUSION A 10-Gy IOERT boost during breast-conserving surgery provides high local control rates without significant morbidity. Although not significantly superior to external beam boosts, the median time to local recurrences after IOERT is prolonged by more than 4 years.",2021,"There were significantly better scores for IOERT at all time points in physician and patient evaluations with the greatest difference at the end of EBRT (p = 0.006 objective and p = 0.0004 subjective) and most narrow difference at 12 months after the end of EBRT (p = 0.08 objective and p = 0.04 subjective analysis). ","['245 patients were randomized: 133 for IOERT and 112 for EBRT', 'stage I/II breast cancer', 'early-stage breast cancer patients treated with', 'Between 1999 and 2004', 'early-stage breast cancer']","['IOERT versus external beam electrons', 'breast-conserving surgery with an IOERT boost of 10\u2009Gy (experimental group) versus 5\u2009×\u20092 Gy EBRT boost (standard arm', 'external beam radiotherapy (EBRT', 'Intraoperative radiotherapy with electrons (IOERT', 'IOERT versus EBRT', 'whole-breast irradiation (WBI) with 50 Gy (2 Gy single dose']","['cumulative risk of IBTR', 'mean time to recurrence', 'overall cosmetic results', 'median time to local recurrences', 'IOERT arm recurrences', 'local control, esthetic evaluation, and toxicity', 'evaluation of in-breast true recurrences (IBTR) and out-field local recurrences (LR) as well as toxicity and cosmetic results', ""overall survival (OS), disease-free survival (DFS), and patient's grade of satisfaction with cosmetic outcomes"", 'cumulative risk of out-field LR']","[{'cui': 'C4517661', 'cui_str': '245'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0338240', 'cui_str': 'Intraoperative radiation therapy'}, {'cui': 'C0013852', 'cui_str': 'Electron'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0419095', 'cui_str': 'Teleradiotherapy procedure'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0338240', 'cui_str': 'Intraoperative radiation therapy'}, {'cui': 'C0013852', 'cui_str': 'Electron'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0013840', 'cui_str': 'Electron beam'}, {'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0419095', 'cui_str': 'Teleradiotherapy procedure'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0457102', 'cui_str': 'Whole breast'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0205238', 'cui_str': 'True'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0338240', 'cui_str': 'Intraoperative radiation therapy'}, {'cui': 'C0013852', 'cui_str': 'Electron'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",245.0,0.0419014,"There were significantly better scores for IOERT at all time points in physician and patient evaluations with the greatest difference at the end of EBRT (p = 0.006 objective and p = 0.0004 subjective) and most narrow difference at 12 months after the end of EBRT (p = 0.08 objective and p = 0.04 subjective analysis). ","[{'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Ciabattoni', 'Affiliation': 'Department of Radiotherapy, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Gregucci', 'Affiliation': 'Department of Radiation Oncology, Miulli General Regional Hospital, Acquaviva delle Fonti, Bari, Italy. fabianagregucci@gmail.com.'}, {'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Fastner', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria.'}, {'ForeName': 'Silvio', 'Initials': 'S', 'LastName': 'Cavuto', 'Affiliation': 'Infrastructure Research and Statistics, Clinical Trials and Statistics Unit, AUSL-IRCCS, Reggio Emilia, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Spera', 'Affiliation': 'Department of Radiotherapy, San Giovanni di Dio Hospital, ASP Agrigento, Agrigento, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Drago', 'Affiliation': 'Department of Breast and Reconstructive Surgery, Sando Pertini Hospital, Rome, Italy.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Ziegler', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria.'}, {'ForeName': 'Maria Alessandra', 'Initials': 'MA', 'LastName': 'Mirri', 'Affiliation': 'Department of Radiotherapy, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Consorti', 'Affiliation': 'Medical Physics Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Sedlmayer', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria.'}]",Breast cancer research : BCR,['10.1186/s13058-021-01424-9'] 2977,33839465,Pilot assessment of omega-3 fatty acids and potassium thiocyanate in sickle cell anemia patients with conditional peak systolic cerebral artery blood velocity.,"OBJECTIVE The purpose of this pilot study was to explore the effect of omega-3 fatty acids and potassium thiocyanate on conditional peak systolic cerebral artery blood velocity in children with sickle cell anemia (SCA). METHODS Transcranial doppler ultrasonography (TCD) was done on 232 SCA children, and 21 found with conditional peak systolic blood velocity (PSV) of 200-249 cm/s in internal carotid, middle or anterior cerebral arteries. These were randomized to receive omega-3 fatty acids and potassium thiocyanate with standard treatment of SCA (test group, N = 14), or standard treatment only (control group, N = 7). After 3 months of treatment, PSV was measured again. RESULTS Right middle cerebral artery PSV was significantly reduced in the test relative to the control groups (p = 0.04). PSV returned to normal in 79% of the test versus 43% of the control group; and increased to abnormal in one member of the control group, but none of the test group. CONCLUSIONS The pilot data suggest that in SCA, omega-3 fatty acids and potassium thiocyanate might reduce conditional blood velocity to normal, or prevent progression to abnormal values. A larger, randomized, clinical trial is required to further address the current gap in management of conditional TCD blood velocity.",2021,Right middle cerebral artery PSV was significantly reduced in the test relative to the control groups (p = 0.04).,"['sickle cell anemia patients with conditional peak systolic cerebral artery blood velocity', 'children with sickle cell anemia (SCA', '232 SCA children, and 21 found with conditional peak systolic blood velocity (PSV) of 200-249\u202fcm/s in internal carotid, middle or anterior cerebral arteries']","['Transcranial doppler ultrasonography (TCD', 'omega-3 fatty acids and potassium thiocyanate', 'SCA, omega-3 fatty acids and potassium thiocyanate', 'omega-3 fatty acids and potassium thiocyanate with standard treatment of SCA']","['PSV', 'Right middle cerebral artery PSV', 'conditional peak systolic cerebral artery blood velocity']","[{'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic'}, {'cui': 'C0007770', 'cui_str': 'Structure of cerebral artery'}, {'cui': 'C1531610', 'cui_str': 'Blood velocity'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439392', 'cui_str': 'cm/s'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0149561', 'cui_str': 'Structure of anterior cerebral artery'}]","[{'cui': 'C0206077', 'cui_str': 'Transcranial doppler ultrasonography'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0071785', 'cui_str': 'Potassium thiocyanate'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0442710', 'cui_str': 'Peak systolic'}, {'cui': 'C1531610', 'cui_str': 'Blood velocity'}, {'cui': 'C0226213', 'cui_str': 'Structure of right middle cerebral artery'}, {'cui': 'C0007770', 'cui_str': 'Structure of cerebral artery'}]",232.0,0.150749,Right middle cerebral artery PSV was significantly reduced in the test relative to the control groups (p = 0.04).,"[{'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Ugwu', 'Affiliation': 'Department of Hematology, University of Nigeria College of Medicine, Enugu, Nigeria.'}, {'ForeName': 'Nneka', 'Initials': 'N', 'LastName': 'Iloanusi', 'Affiliation': 'Department of Radiation Medicine, University of Nigeria College of Medicine, Enugu, Nigeria.'}, {'ForeName': 'Ngozi', 'Initials': 'N', 'LastName': 'Ugwu', 'Affiliation': 'Department of Hematology, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria.'}, {'ForeName': 'Barth', 'Initials': 'B', 'LastName': 'Chukwu', 'Affiliation': 'Department of Pediatrics, University of Nigeria College of Medicine, Enugu, Nigeria.'}, {'ForeName': 'Osita', 'Initials': 'O', 'LastName': 'Ezenwosu', 'Affiliation': 'Department of Pediatrics, University of Nigeria College of Medicine, Enugu, Nigeria.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Modebe', 'Affiliation': 'Department of Radiation Medicine, University of Nigeria College of Medicine, Enugu, Nigeria.'}, {'ForeName': 'Augustine', 'Initials': 'A', 'LastName': 'Duru', 'Affiliation': 'Department of Hematology, University of Nigeria College of Medicine, Enugu, Nigeria.'}, {'ForeName': 'Anazoeze', 'Initials': 'A', 'LastName': 'Madu', 'Affiliation': 'Department of Hematology, University of Nigeria College of Medicine, Enugu, Nigeria.'}, {'ForeName': 'Ezinne', 'Initials': 'E', 'LastName': 'Chibueze', 'Affiliation': 'National Center for Child Health and Development, Tokyo, Japan.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Igboke', 'Affiliation': 'Department of Radiology, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria.'}, {'ForeName': 'Obiora', 'Initials': 'O', 'LastName': 'Ejiofor', 'Affiliation': 'Department of Pediatrics, Chukwuemeka Odumegwu Ojukwu University Teaching Hospital, Awka, Nigeria.'}, {'ForeName': 'Chilota', 'Initials': 'C', 'LastName': 'Efobi', 'Affiliation': 'Department of Hematology, Chukwuemeka Odumegwu Ojukwu University Teaching Hospital, Awka, Nigeria.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Uchendu', 'Affiliation': 'Department of Radiology, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria.'}, {'ForeName': 'Iheanyi', 'Initials': 'I', 'LastName': 'Okpala', 'Affiliation': 'Department of Hematology, University of Nigeria College of Medicine, Enugu, Nigeria. Electronic address: iheanyi.okpala@unn.edu.ng.'}]","Blood cells, molecules & diseases",['10.1016/j.bcmd.2021.102564'] 2978,33860592,"Effects of an Interprofessional Communication Approach on Support Needs, Quality of Life, and Mood of Patients with Advanced Lung Cancer: A Randomized Trial.","BACKGROUND To address the support needs of newly diagnosed patients with lung cancer with limited prognosis, the Milestone Communication Approach (MCA) was developed and implemented. The main elements of the MCA are situation-specific conversations along the disease trajectory conducted by an interprofessional tandem of physician and nurse. The aim of the study was to evaluate the effects of MCA on addressing support needs, quality of life, and mood as compared with standard oncological care. PATIENTS AND METHODS A randomized trial was conducted with baseline assessment and follow-up assessments at 3, 6, and 9 months in outpatients with newly diagnosed lung cancer stage IV at a German thoracic oncology hospital. The primary outcome was the Health System and Information Needs subscale of the Short Form Supportive Care Needs Survey (SCNS-SF34-G) at 3-month follow-up. Secondary outcomes included the other subscales of the SCNS-SF34-G, the Schedule for the Evaluation of Individual Quality of Life, the Functional Assessment of Cancer Therapy lung module, the Patient Health Questionnaire for Depression and Anxiety, and the Distress Thermometer. RESULTS At baseline, 174 patients were randomized, of whom 102 patients (MCA: n = 52; standard care: n = 50) provided data at 3-month follow-up. Patients of the MCA group reported lower information needs at 3-month follow-up (mean ± SD, 33.4 ± 27.5; standard care, 43.1 ± 29.9; p = .033). No effects were found for secondary outcomes. CONCLUSION MCA lowered patient-reported information needs but did not have other effects. MCA contributed to tailored communication because an adequate level of information and orientation set the basis for patient-centered care. IMPLICATIONS FOR PRACTICE By addressing relevant issues at predefined times, the Milestone Communication Approach provides individual patient-centered care facilitating the timely integration of palliative care for patients with a limited prognosis. The needs of patients with lung cancer must be assessed and addressed throughout the disease trajectory. Although specific topics may be relevant for all patients, such as information about the disease and associated health care, situations of individual patients and their families must be considered. Additionally, using the short form of the Supportive Care Needs Survey in clinical practice to identify patients' problems might support individually targeted communication and preference-sensitive care.",2021,"Patients of the MCA group reported lower information needs at 3-month follow-up (M=33.4, SD=27.5; standard care: M=43.1, SD=29.9, p=.033).","['lung cancer patients', '174 patients were randomized of whom 102 patients (MCA: n=52; standard care: n=50', 'newly diagnosed lung cancer patients with limited prognosis', 'patients with a limited prognosis', 'out-patients with newly diagnosed lung cancer stage IV at a German thoracic oncology hospital', 'advanced lung cancer patients']","['interprofessional communication approach', 'MCA']","['subscale Health System and Information Needs of the Short Form Supportive Care Needs Survey (SCNS-SF34-G', 'support needs, quality of life and mood', 'other subscales of the SCNS-SF34-G, the Schedule for the Evaluation of Individual Quality of Life (SEIQoL), the Functional Assessment of Chronic Illness Therapy (FACT-L), the Patient Health Questionnaire for Depression and Anxiety (PHQ-4) and the Distress Thermometer']","[{'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0855005', 'cui_str': 'Lung carcinoma cell type unspecified stage IV'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4524268', 'cui_str': 'Advanced lung cancer'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0344211', 'cui_str': 'Support'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0039818', 'cui_str': 'Thermometer'}]",174.0,0.16989,"Patients of the MCA group reported lower information needs at 3-month follow-up (M=33.4, SD=27.5; standard care: M=43.1, SD=29.9, p=.033).","[{'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Krug', 'Affiliation': 'Department of General Practice and Health Services Research, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Bossert', 'Affiliation': 'Department of General Practice and Health Services Research, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Deis', 'Affiliation': 'Thoracic Clinic, Department of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Krisam', 'Affiliation': 'Institute of Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Villalobos', 'Affiliation': 'Thoracic Clinic, Department of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Siegle', 'Affiliation': 'Thoracic Clinic, Department of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Corinna', 'Initials': 'C', 'LastName': 'Jung', 'Affiliation': 'Thoracic Clinic, Department of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Hagelskamp', 'Affiliation': 'Thoracic Clinic, Department of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Unsöld', 'Affiliation': 'Thoracic Clinic, Department of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Jünger', 'Affiliation': 'German National Institute for State Examinations in Medicine, Pharmacy, and Psychotherapy, Mainz, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Thomas', 'Affiliation': 'Thoracic Clinic, Department of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Wensing', 'Affiliation': 'Department of General Practice and Health Services Research, University Hospital Heidelberg, Heidelberg, Germany.'}]",The oncologist,['10.1002/onco.13790'] 2979,33852173,"The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism-A Randomized Crossover Study.","Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are gut hormones secreted postprandially. In healthy humans, both hormones decrease bone resorption accompanied by a rapid reduction in parathyroid hormone (PTH). The aim of this study was to investigate whether the changes in bone turnover after meal intake and after GIP- and GLP-2 injections, respectively, are mediated via a reduction in PTH secretion. This was tested in female patients with hypoparathyroidism given a standardized liquid mixed-meal test (n = 7) followed by a peptide injection test (n = 4) using a randomized crossover design. We observed that the meal- and GIP- but not the GLP-2-induced changes in bone turnover markers were preserved in the patients with hypoparathyroidism. To understand the underlying mechanisms, we examined the expression of the GIP receptor (GIPR) and the GLP-2 receptor (GLP-2R) in human osteoblasts and osteoclasts as well as in parathyroid tissue. The GIPR was expressed in both human osteoclasts and osteoblasts, whereas the GLP-2R was absent or only weakly expressed in osteoclasts. Furthermore, both GIPR and GLP-2R were expressed in parathyroid tissue. Our findings suggest that the GIP-induced effect on bone turnover may be mediated directly via GIPR expressed in osteoblasts and osteoclasts and that this may occur independent of PTH. In contrast, the effect of GLP-2 on bone turnover seems to depend on changes in PTH and may be mediated through GLP-2R in the parathyroid gland. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).",2021,"The GIPR was expressed in both human osteoclasts and osteoblasts, whereas the GLP-2R was absent or only weakly expressed in osteoclasts.","['female patients with hypoparathyroidism given a standardized liquid mixed-meal test (n\xa0=\xa07) followed by a', 'patients with hypoparathyroidism']","['GLP-2', 'GIP- and GLP-2 injections', 'Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2', 'peptide injection-test']",['bone turnover'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020626', 'cui_str': 'Hypoparathyroidism'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0912332', 'cui_str': 'Glucagon-like peptide 2'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0085268', 'cui_str': 'Bone remodeling'}]",,0.0243384,"The GIPR was expressed in both human osteoclasts and osteoblasts, whereas the GLP-2R was absent or only weakly expressed in osteoclasts.","[{'ForeName': 'Kirsa', 'Initials': 'K', 'LastName': 'Skov-Jeppesen', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Hepp', 'Affiliation': 'Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Jannika', 'Initials': 'J', 'LastName': 'Oeke', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Morten Steen', 'Initials': 'MS', 'LastName': 'Hansen', 'Affiliation': 'Molecular Endocrinology Unit (KMEB), Department of Endocrinology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Jafari', 'Affiliation': 'Department of Cellular and Molecular Medicine, Novo Nordisk Foundation Center for Stem Cell Biology (Danstem), University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Maria Saur', 'Initials': 'MS', 'LastName': 'Svane', 'Affiliation': 'Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Nariman', 'Initials': 'N', 'LastName': 'Balenga', 'Affiliation': 'Division of General and Oncologic Surgery, Department of Surgery, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Olson', 'Affiliation': 'Division of General and Oncologic Surgery, Department of Surgery, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Frost', 'Affiliation': 'Molecular Endocrinology Unit (KMEB), Department of Endocrinology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Moustapha', 'Initials': 'M', 'LastName': 'Kassem', 'Affiliation': 'Molecular Endocrinology Unit (KMEB), Department of Endocrinology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Sten', 'Initials': 'S', 'LastName': 'Madsbad', 'Affiliation': 'Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Jens-Erik', 'Initials': 'JE', 'LastName': 'Beck Jensen', 'Affiliation': 'Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Jens Juul', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mette Marie', 'Initials': 'MM', 'LastName': 'Rosenkilde', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Bolette', 'Initials': 'B', 'LastName': 'Hartmann', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.4308'] 2980,34386216,"Topical emollient therapy with sunflower seed oil alters the skin microbiota of young children with severe acute malnutrition in Bangladesh: A randomised, controlled study.","Background Topical emollient therapy with sunflower seed oil (SSO) reduces risk of sepsis and mortality in very preterm infants in low- or middle-income countries (LMICs). Proposed mechanisms include modulation of skin and possibly gut barrier function. The skin and gut microbiota play important roles in regulating barrier function, but the effects of emollient therapy on these microbiotas are poorly understood. Methods We characterised microbiota structure and diversity with 16S rRNA gene amplicon sequence data and ecological statistics in 20 children with severe acute malnutrition (SAM) aged 2-24 months, at four skin sites and in stool, during a randomised, controlled trial of emollient therapy with SSO in Bangladesh. Microbes associated with therapy were identified with tree-based sparse discriminant analysis. Results The skin microbiota of Bangladeshi children with SAM was highly diverse and displayed significant variation in structure as a function of physical distance between sites. Microbiota structure differed between the study groups ( P  = 0.005), was more diverse in emollient-treated subjects-including on the forehead which did not receive direct treatment-and changed with each day ( P  = 0.005) at all skin sites. Overall, Prevotellaceae were the most differentially affected by emollient treatment; several genera within this family became more abundant in the emollient group than in the controls across several skin sites. Gut microbiota structure was associated with sample day ( P  = 0.045) and subject age ( P  = 0.045), but was not significantly affected by emollient treatment ( P  = 0.060). Conclusions Emollient therapy altered the skin microbiota in a consistent and temporally coherent manner. We speculate that therapy with SSO enhances skin barrier function in part through alterations in the microbiota, and through systemic mechanisms. Strategies to strengthen skin and gut barrier function in populations at risk, such as children in LMICs like Bangladesh, might include deliberate manipulation of their skin microbiota. Trial registration ClinicalTrials.gov: NCT02616289.",2021,"Microbiota structure differed between the study groups ( P  = 0.005), was more diverse in emollient-treated subjects-including on the forehead which did not receive direct treatment-and changed with each day ( P  = 0.005) at all skin sites.","['20 children with severe acute malnutrition (SAM) aged 2-24 months, at four skin sites and in stool, during a randomised, controlled trial of emollient therapy with SSO in Bangladesh', 'very preterm infants in low- or middle-income countries (LMICs', 'young children with severe acute malnutrition in Bangladesh']","['Topical emollient therapy with sunflower seed oil', 'sunflower seed oil (SSO', 'SSO']","['Microbiota structure', 'skin barrier function', 'sepsis and mortality', 'skin microbiota', 'Gut microbiota structure']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4042945', 'cui_str': 'Severe Acute Malnutrition'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0013983', 'cui_str': 'Emollient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0947381', 'cui_str': 'Helianthus annuus'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0013983', 'cui_str': 'Emollient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0947381', 'cui_str': 'Helianthus annuus'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0028908', 'cui_str': 'Oil'}]","[{'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}]",20.0,0.0819452,"Microbiota structure differed between the study groups ( P  = 0.005), was more diverse in emollient-treated subjects-including on the forehead which did not receive direct treatment-and changed with each day ( P  = 0.005) at all skin sites.","[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Fischer', 'Affiliation': 'Division of Infectious Diseases & Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.'}, {'ForeName': 'Gary L', 'Initials': 'GL', 'LastName': 'Darmstadt', 'Affiliation': 'Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.'}, {'ForeName': 'K M', 'Initials': 'KM', 'LastName': 'Shahunja', 'Affiliation': 'Nutrition and Clinical Services Division, International Centre for Diarroheal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Jonathan M', 'Initials': 'JM', 'LastName': 'Crowther', 'Affiliation': 'JMC Scientific Consulting Ltd, Egham, Surrey, UK.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Kendall', 'Affiliation': 'GlaxoSmithKline R&D, Global Health Catalyst, Stevenage, UK.'}, {'ForeName': 'Rachel A', 'Initials': 'RA', 'LastName': 'Gibson', 'Affiliation': 'GlaxoSmithKline R&D, Global Health Catalyst, Stevenage, UK.'}, {'ForeName': 'Tahmeed', 'Initials': 'T', 'LastName': 'Ahmed', 'Affiliation': 'Nutrition and Clinical Services Division, International Centre for Diarroheal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Relman', 'Affiliation': 'Division of Infectious Diseases & Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.'}]",Journal of global health,['10.7189/jogh.11.04047'] 2981,34386186,Clinical and microbiological evaluation of 940-nm diode laser as an adjunct to modified Widman flap for the management of chronic periodontitis: A 6-month randomized split-mouth clinical trial.,"Background. The present randomized clinical trial aimed to determine the additive clinical and microbiological benefits of diode laser (DL) with modified Widman flap (MWF) to manage chronic periodontitis. Methods. Seventy-two sites in 36 healthy non-smoking patients diagnosed with chronic periodontitis were randomly assigned to the test group (MWF + active DL) or control group (MWF + sham DL). Clinical (probing pocket depth [PPD], clinical attachment level [CAL]) and microbiological (colony-forming units [CFUs]) measurements were recorded at baseline and 6- and 6-month postoperative intervals. Results. Compared to baseline, 6-month results showed significant changes in clinical and microbiological parameters in both groups. However, the intergroup comparison revealed significantly lower PPD (1.90±0.48 mm vs. 2.35±0.41 mm), CAL (4.43±0.57 mm vs. 4.93±0.58 mm), and CFUs for Porphyromonas gingivalis (6.32±0.18 vs. 8.88 ±1.88), Prevotella intermedia (7.62±1.86 vs. 8.12±1.78), and Aggregatibacter actinomycetemcomitans (6.43±1.44 vs. 7.24±1.22) in the test group after six months. Conclusion. Within the limitations, the present study confirmed the useful role of DL with MWF to manage chronic periodontitis.",2021,"However, the intergroup comparison revealed significantly lower PPD (1.90±0.48 mm vs. 2.35±0.41 mm), CAL (4.43±0.57 mm vs. 4.93±0.58 mm), and CFUs for Porphyromonas gingivalis (6.32±0.18 vs. 8.88 ±1.88), Prevotella intermedia (7.62±1.86 vs. 8.12±1.78), and Aggregatibacter actinomycetemcomitans (6.43±1.44 vs. 7.24±1.22) in the test group after six months. ","['Seventy-two sites in 36 healthy non-smoking patients diagnosed with chronic periodontitis', 'chronic periodontitis']","['test group (MWF + active DL) or control group (MWF + sham DL', '940-nm diode laser', 'diode laser (DL) with modified Widman flap (MWF', 'MWF']","['PPD', 'clinical and microbiological parameters', 'Clinical (probing pocket depth [PPD], clinical attachment level [CAL]) and microbiological (colony-forming units [CFUs]) measurements']","[{'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0266929', 'cui_str': 'Chronic periodontitis'}]","[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C4517905', 'cui_str': '940'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}, {'cui': 'C0398959', 'cui_str': 'Modified Widman flap'}]","[{'cui': 'C0034131', 'cui_str': 'Purified Protein Derivative of Tuberculin'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439158', 'cui_str': 'colonies'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",36.0,0.251413,"However, the intergroup comparison revealed significantly lower PPD (1.90±0.48 mm vs. 2.35±0.41 mm), CAL (4.43±0.57 mm vs. 4.93±0.58 mm), and CFUs for Porphyromonas gingivalis (6.32±0.18 vs. 8.88 ±1.88), Prevotella intermedia (7.62±1.86 vs. 8.12±1.78), and Aggregatibacter actinomycetemcomitans (6.43±1.44 vs. 7.24±1.22) in the test group after six months. ","[{'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Agarwal', 'Affiliation': 'Department of Periodontology and Implantology, Institute of Dental Sciences, Bareilly Uttar Pradesh, India.'}, {'ForeName': 'Anugrah', 'Initials': 'A', 'LastName': 'Saxena', 'Affiliation': 'Department of Periodontology and Implantology, Institute of Dental Sciences, Bareilly Uttar Pradesh, India.'}, {'ForeName': 'Shiva Shankar', 'Initials': 'SS', 'LastName': 'Gummaluri', 'Affiliation': 'Department of Periodontology and Implantology, Institute of Dental Sciences, Bareilly Uttar Pradesh, India.'}, {'ForeName': 'Bharti', 'Initials': 'B', 'LastName': 'Chaudhary', 'Affiliation': 'Department of Periodontology and Implantology, Institute of Dental Sciences, Bareilly Uttar Pradesh, India.'}, {'ForeName': 'Karthikeyan', 'Initials': 'K', 'LastName': 'Subramanyam S Sai', 'Affiliation': 'Department of Periodontology and Implantology, Institute of Dental Sciences, Bareilly Uttar Pradesh, India.'}, {'ForeName': 'Geetika', 'Initials': 'G', 'LastName': 'Kumar', 'Affiliation': 'Department of Periodontology and Implantology, Institute of Dental Sciences, Bareilly Uttar Pradesh, India.'}]","Journal of dental research, dental clinics, dental prospects",['10.34172/joddd.2021.023'] 2982,33857436,"Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial.","BACKGROUND Electronic nicotine delivery systems (ENDSs) are used by some smokers to reduce cigarette consumption, but their effectiveness is uncertain. We aimed to examine the extent to which ENDSs or a non-nicotine cigarette substitute influence tobacco-related toxicant exposure and cigarette consumption in smokers interested in smoking reduction. METHODS We did a four-arm, parallel-group, randomised controlled trial at two sites in the USA (Penn State University, Hershey, PA, and Virginia Commonwealth University, Richmond, VA). We enrolled adults aged 21-65 years who smoked more than nine cigarettes per day (for at least the past year), with exhaled CO of more than 9 parts per million at screening, who were not currently using an ENDS, and who were interested in reducing smoking but not quitting. Participants were randomised (site-specific with allocation concealment; 1:1:1:1) to receive either a cartomiser-based, pen-style ENDS (eGo-style) paired with 0, 8, or 36 mg/mL liquid nicotine (participants and researchers masked to concentration) or a non-ENDS cigarette-shaped plastic tube that delivered no nicotine or aerosol (cigarette substitute; unmasked) for 24 weeks. Conditions were chosen to reflect a range of nicotine delivery including none (cigarette substitute and 0 mg/mL ENDS), low (8 mg/mL), and cigarette-like (36 mg/mL), and all conditions were paired with smoking reduction instructions. The primary outcome was concentration of the tobacco-specific carcinogen metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL; urinary total) collected at randomisation and at 4, 12, and 24 weeks. Multiple imputation with and without covariate adjustment was used in addition to sensitivity analyses. This trial is registered with ClinicalTrials.gov, NCT02342795. FINDINGS Between July 22, 2015, and Nov 16, 2017, 684 individuals were screened and 520 (76%) were enrolled and randomised. 188 (36%) of 520 participants were lost to follow-up by week 24; attrition did not differ by study group (39 [30%] of 130 in the cigarette substitute group, 56 [43%] of 130 in the ENDS with 0 mg/mL nicotine group, 49 [38%] of 130 in the ENDS 8 mg/mL group, and 44 [34%] of 130 in the ENDS 36 mg/mL group). Urinary total NNAL at 24 weeks in the ENDS with 36 mg/mL nicotine group was 210·80 pg/mg creatinine (95% CI 163·03-274·42) compared with 346·09 pg/mg creatinine (265·00-455·32) in the cigarette substitute group (p=0·0061). No other significant differences between groups were observed for any time point for urinary total NNAL. Serious adverse event frequency was similar across groups (12 events in 12 participants [9%] in the ENDS with 36 mg/mL nicotine group, seven events in six participants [5%] in the 8 mg/mL group, 11 events in ten participants [8%] in the 0 mg/mL group, and 13 events in 13 participants [10%] in the cigarette substitute group), and all of these were deemed unrelated or unlikely to be related to study product use. There was one death between randomisation and 24 weeks (suicide; in the ENDS with 0 mg/mL nicotine group). INTERPRETATION Use of an ENDS with cigarette-like nicotine delivery can reduce exposure to a major pulmonary carcinogen, NNAL, even with concurrent smoking. Future ENDS trials should involve products with well characterised nicotine delivery, including those with nicotine delivery approaching that of a cigarette. FUNDING National Institutes of Health, US Food and Drug Administration.",2021,"Serious adverse event frequency was similar across groups (12 events in 12 participants [9%] in the ENDS with 36 mg/mL nicotine group, seven events in six participants [5%] in the 8 mg/mL group, 11 events in ten participants [8%] in the 0 mg/mL group, and 13 events in 13 participants [10%] in the cigarette substitute group), and all of these were deemed unrelated or unlikely to be related to study product use.","['smokers interested in smoking reduction', 'enrolled adults aged 21-65 years who smoked more than nine cigarettes per day (for at least the past year), with exhaled CO of more than 9 parts per million at screening, who were not currently using an ENDS, and who were interested in reducing smoking but not quitting', 'Between July 22, 2015, and Nov 16, 2017, 684 individuals were screened and 520 (76%) were enrolled and randomised']","['ENDSs or a non-nicotine cigarette substitute influence tobacco-related toxicant exposure and cigarette consumption', 'electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine', 'mL nicotine', 'cartomiser-based, pen-style ENDS (eGo-style) paired with 0, 8, or 36 mg/mL liquid nicotine (participants and researchers masked to concentration) or a non-ENDS cigarette-shaped plastic tube that delivered no nicotine or aerosol (cigarette substitute']","['concentration of the tobacco-specific carcinogen metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL; urinary total', 'Urinary total NNAL', 'time point for urinary total NNAL', 'Serious adverse event frequency']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C4505208', 'cui_str': 'Smoking Reduction'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0439187', 'cui_str': 'ppm'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4517803', 'cui_str': '520'}]","[{'cui': 'C3849993', 'cui_str': 'Electronic cigarette'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0459840', 'cui_str': 'Cigarette consumption'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0070220', 'cui_str': 'penclomedine'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0013712', 'cui_str': 'Ego'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0332479', 'cui_str': 'Shape finding'}, {'cui': 'C0336633', 'cui_str': 'Plastic tube'}, {'cui': 'C0001712', 'cui_str': 'Aerosol'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0007090', 'cui_str': 'Carcinogen'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0389836', 'cui_str': '4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",520.0,0.316752,"Serious adverse event frequency was similar across groups (12 events in 12 participants [9%] in the ENDS with 36 mg/mL nicotine group, seven events in six participants [5%] in the 8 mg/mL group, 11 events in ten participants [8%] in the 0 mg/mL group, and 13 events in 13 participants [10%] in the cigarette substitute group), and all of these were deemed unrelated or unlikely to be related to study product use.","[{'ForeName': 'Caroline O', 'Initials': 'CO', 'LastName': 'Cobb', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA; Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: cobbco@vcu.edu.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Foulds', 'Affiliation': 'Center for Research on Tobacco and Health, Penn State University College of Medicine, Hershey, PA, USA; Department of Public Health Sciences, Penn State University College of Medicine, Hershey, PA, USA.'}, {'ForeName': 'Miao-Shan', 'Initials': 'MS', 'LastName': 'Yen', 'Affiliation': 'Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA; Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Veldheer', 'Affiliation': 'Center for Research on Tobacco and Health, Penn State University College of Medicine, Hershey, PA, USA; Department of Public Health Sciences, Penn State University College of Medicine, Hershey, PA, USA; Department of Family and Community Medicine, Penn State University College of Medicine, Hershey, PA, USA.'}, {'ForeName': 'Alexa A', 'Initials': 'AA', 'LastName': 'Lopez', 'Affiliation': 'University of Wisconsin-Milwaukee, Milwaukee, WI, USA.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Yingst', 'Affiliation': 'Center for Research on Tobacco and Health, Penn State University College of Medicine, Hershey, PA, USA; Department of Public Health Sciences, Penn State University College of Medicine, Hershey, PA, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Bullen', 'Affiliation': 'University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Le', 'Initials': 'L', 'LastName': 'Kang', 'Affiliation': 'Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Eissenberg', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA; Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(21)00022-9'] 2983,33863665,Pulmonary Artery Proportional Pulse Pressure (PAPP) Index Identifies Patients With Improved Survival From the CardioMEMS Implantable Pulmonary Artery Pressure Monitor.,"BACKGROUND Pulmonary artery proportional pulse pressure (PAPP) was recently shown to have prognostic value in heart failure (HF) with reduced ejection fraction (HFrEF) and pulmonary hypertension. We tested the hypothesis that PAPP would be predictive of adverse outcomes in patients with implantable pulmonary artery pressure monitor (CardioMEMS™ HF System, St. Jude Medical [now Abbott], Atlanta, GA, USA). METHODS Survival analysis with Cox proportional hazards regression was used to evaluate all-cause deaths and HF hospitalisation (HFH) in CHAMPION trial 1 patients who received treatment with the CardioMEMS device based on the PAPP. RESULTS Among 550 randomised patients, 274 had PAPP ≤ the median value of 0.583 while 276 had PAPP>0.583. Patients with PAPP≤0.583 (versus PAPP>0.583) had an increased risk of HFH (HR 1.40, 95% CI 1.16-1.68, p=0.0004) and experienced a significant 46% reduction in annualised risk of death with CardioMEMS treatment (HR 0.54, 95% CI 0.31-0.92) during 2-3 years of follow-up. This survival benefit was attributable to the treatment benefit in patients with HFrEF and PAPP≤0.583 (HR 0.50, 95% CI 0.28-0.90, p<0.05). Patients with PAPP>0.583 or HF with preserved EF (HFpEF) had no significant survival benefit with treatment (p>0.05). CONCLUSION Lower PAPP in HFrEF patients with CardioMEMS constitutes a higher mortality risk status. More studies are needed to understand clinical applications of PAPP in implantable pulmonary artery pressure monitors.",2021,"Patients with PAPP≤0.583 (versus PAPP>0.583) had an increased risk of HFH (HR 1.40, 95% CI 1.16-1.68, p=0.0004) and experienced a significant 46% reduction in annualised risk of death with CardioMEMS treatment (HR 0.54, 95% CI 0.31-0.92) during 2-3 years of follow-up.","['patients with implantable pulmonary artery pressure monitor (CardioMEMS™ HF System, St. Jude Medical [now Abbott], Atlanta, GA, USA', 'patients who received treatment with the CardioMEMS device based on the PAPP', 'HFrEF patients with', '550 randomised patients, 274 had PAPP ≤ the median value of 0.583 while 276 had PAPP>0.583']","['PAPP', 'PAPP>0.583 or HF with preserved EF (HFpEF', 'CardioMEMS', 'Pulmonary artery proportional pulse pressure (PAPP']","['risk of HFH', 'survival benefit', 'annualised risk of death', 'Pulmonary Artery Proportional Pulse Pressure (PAPP', 'Survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0428642', 'cui_str': 'Pulmonary artery pressure'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205351', 'cui_str': 'Proportional'}, {'cui': 'C0949236', 'cui_str': 'Pulse Pressure'}, {'cui': 'C3844103', 'cui_str': '550'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}]","[{'cui': 'C0205351', 'cui_str': 'Proportional'}, {'cui': 'C0949236', 'cui_str': 'Pulse Pressure'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0034052', 'cui_str': 'Pulmonary artery structure'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0034052', 'cui_str': 'Pulmonary artery structure'}, {'cui': 'C0205351', 'cui_str': 'Proportional'}, {'cui': 'C0949236', 'cui_str': 'Pulse Pressure'}]",550.0,0.1863,"Patients with PAPP≤0.583 (versus PAPP>0.583) had an increased risk of HFH (HR 1.40, 95% CI 1.16-1.68, p=0.0004) and experienced a significant 46% reduction in annualised risk of death with CardioMEMS treatment (HR 0.54, 95% CI 0.31-0.92) during 2-3 years of follow-up.","[{'ForeName': 'Sula', 'Initials': 'S', 'LastName': 'Mazimba', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA. Electronic address: SM8SD@hscmail.mcc.virginia.edu.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Ginn', 'Affiliation': 'Global Research and Development, St. Jude Medical, Sylmar, CA, USA.'}, {'ForeName': 'Hunter', 'Initials': 'H', 'LastName': 'Mwansa', 'Affiliation': 'Case Western Reserve University/St Vincent Charity Medical Center, Cleveland, OH, USA.'}, {'ForeName': 'Olusola', 'Initials': 'O', 'LastName': 'Laja', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'Christiana', 'Initials': 'C', 'LastName': 'Jeukeng', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'Comfort', 'Initials': 'C', 'LastName': 'Elumogo', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'Brandy', 'Initials': 'B', 'LastName': 'Patterson', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'Jamie L W', 'Initials': 'JLW', 'LastName': 'Kennedy', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'Nishaki', 'Initials': 'N', 'LastName': 'Mehta', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Hossack', 'Affiliation': 'Department of Biomedical, Electrical and Computer Engineering, University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'Alex M', 'Initials': 'AM', 'LastName': 'Parker', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Mihalek', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Tallaj', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Nishtha', 'Initials': 'N', 'LastName': 'Sodhi', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}, {'ForeName': 'Younghoon', 'Initials': 'Y', 'LastName': 'Kwon', 'Affiliation': 'University of Washington Medical Center, Seattle, WA, USA.'}, {'ForeName': 'Salpy V', 'Initials': 'SV', 'LastName': 'Pamboukian', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Philip B', 'Initials': 'PB', 'LastName': 'Adamson', 'Affiliation': 'Global Research and Development, St. Jude Medical, Sylmar, CA, USA.'}, {'ForeName': 'Kenneth C', 'Initials': 'KC', 'LastName': 'Bilchick', 'Affiliation': 'University of Virginia Health System, Charlottesville, VA, USA.'}]","Heart, lung & circulation",['10.1016/j.hlc.2021.03.004'] 2984,34386281,"The Dynamic Innovative Balance System Improves Balance Ability: A Single Blind, Randomized Controlled Study.","Background Functional balance training is crucial for both rehabilitation and prevention. A Dynamic Innovative Balance System (DIBA) is readily available for utilization in both functional and postural control training in a wide variety of dynamic conditions. Purpose The purpose of this study was to compare the effectiveness of the DIBA and standard balance training tools on dynamic and static balance. Study Design Randomized controlled trial. Methods Thirty-six healthy males (18 to 32 years) were randomly assigned to group DIBA (n=18) or to the control group (n=18) who performed balance training using a balance board, a wobble board, the BOSU, or a soft cushion block for eight weeks. Each participant was assessed before training, at the end of the fourth and eighth week by using the Flamingo balance test (FBT) for assessing static balance ability and using Y-Balance Test (YBT) for dynamic balance ability. Results No significant differences were found in FBT and YBT between the DIBA and control groups at the end of fourth week (p>0.05). However, at the end of the eighth week, the DIBA group demonstrated statistically significantly better balance ability on the anterior component of YBT (p=0.001) and FBT (p=0.024) than controls. Conclusion The results of this study suggest that the DIBA was effective in both static and dynamic balance training and it may be used alongside other balance tools in a clinical setting. Further studies should include in lower extremity problems to confirm that DIBA training adaptations are transferred to clinical improvements in performance and balance qualities. Level of Evidence 2d.",2021,No significant differences were found in FBT and YBT between the DIBA and control groups at the end of fourth week (p>0.05).,['Methods\n\n\nThirty-six healthy males (18 to 32 years'],"['DIBA and standard balance training tools', 'control group (n=18) who performed balance training using a balance board, a wobble board, the BOSU, or a soft cushion block for eight weeks', '\n\n\nFunctional balance training', 'Flamingo balance test (FBT', 'Dynamic Innovative Balance System (DIBA']","['balance ability', 'Balance Ability', 'FBT and YBT']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C2721267', 'cui_str': 'Balance board'}, {'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0180249', 'cui_str': 'Cushion'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0325478', 'cui_str': 'Phoenicopteridae'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0560184', 'cui_str': 'Ability to balance'}, {'cui': 'C0325478', 'cui_str': 'Phoenicopteridae'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",36.0,0.0258209,No significant differences were found in FBT and YBT between the DIBA and control groups at the end of fourth week (p>0.05).,"[{'ForeName': 'Bunyamin', 'Initials': 'B', 'LastName': 'Haksever', 'Affiliation': 'Cyprus International University.'}, {'ForeName': 'Irem', 'Initials': 'I', 'LastName': 'Duzgun', 'Affiliation': 'Hacettepe University.'}, {'ForeName': 'Gul', 'Initials': 'G', 'LastName': 'Baltaci', 'Affiliation': 'Private Ankara Guven Hospital.'}]",International journal of sports physical therapy,['10.26603/001c.25756'] 2985,34386279,Safety and Effectiveness of a Perturbation-based Neuromuscular Training Program on Dynamic Balance in Adolescent Females: A Randomized Controlled Trial.,"Background Adolescent females are at much greater risk for ACL injury than their male counterparts when participating in the same sports. Preventative and pre-operative rehabilitation neuromuscular (NM) exercise programs are often recommended to improve knee function and reduce injury rates. The effectiveness of perturbation-based NM training program has been established in an adult population but has yet to be investigated in the at-risk adolescent female population. Purpose To determine the effectiveness of a perturbation-based NM exercise program in a group of physically active adolescent females. Study Design Prospective randomized trial. Methods Twenty-four healthy and an exploratory group of 10 ACL-injured females (ages 12-18) were equally randomized into a perturbation-based NM training or control group and evaluated before and after a five-week intervention period. The primary outcome of dynamic balance was measured using the Y-Balance test (YBT); secondary outcome measures included lower limb strength, proprioception, and flexibility. Results The perturbation-based NM training intervention was safely completed by all participants but had no significant effect on YBT scoring, lower limb strength, proprioception or flexibility in either the healthy or ACL-injured groups. Conclusions Perturbation-based NM training is safe, but may offer little preventative benefit for healthy or pre-operative rehabilitation benefit for ACL-injured adolescent females. Future research should examine whether the effectiveness of perturbation-based NM training is influenced by the length of the training intervention, training intensity, or when it is combined with other forms of prophylactic or pre-surgical rehabilitation frequently used with at-risk adolescent females who regularly participate in sport. Level of Evidence Level 3.",2021,"The perturbation-based NM training intervention was safely completed by all participants but had no significant effect on YBT scoring, lower limb strength, proprioception or flexibility in either the healthy or ACL-injured groups. ","['Methods\n\n\nTwenty-four healthy and an exploratory group of 10 ACL-injured females (ages 12-18', 'ACL-injured adolescent females', 'risk adolescent female population', '\n\n\nAdolescent females', 'risk adolescent females who regularly participate in sport', 'Adolescent Females', 'physically active adolescent females']","['perturbation-based NM exercise program', 'Perturbation-based Neuromuscular Training Program', 'Preventative and pre-operative rehabilitation neuromuscular (NM) exercise programs', 'perturbation-based NM training program', 'perturbation-based NM training intervention', 'perturbation-based NM training or control']","['YBT scoring, lower limb strength, proprioception or flexibility', 'Dynamic Balance', 'Safety and Effectiveness', 'dynamic balance', 'Y-Balance test (YBT); secondary outcome measures included lower limb strength, proprioception, and flexibility']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}]","[{'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",24.0,0.0153027,"The perturbation-based NM training intervention was safely completed by all participants but had no significant effect on YBT scoring, lower limb strength, proprioception or flexibility in either the healthy or ACL-injured groups. ","[{'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Bulow', 'Affiliation': 'University of Manitoba.'}, {'ForeName': 'Judith E', 'Initials': 'JE', 'LastName': 'Anderson', 'Affiliation': 'University of Manitoba.'}, {'ForeName': 'Jeff R S', 'Initials': 'JRS', 'LastName': 'Leiter', 'Affiliation': 'University of Manitoba.'}, {'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'MacDonald', 'Affiliation': 'Surgery, University of Manitoba; Pan Am Clinic.'}, {'ForeName': 'Jason D', 'Initials': 'JD', 'LastName': 'Peeler', 'Affiliation': 'Human Anatomy & Cell Science, University of Manitoba; Pan Am Clinic.'}]",International journal of sports physical therapy,['10.26603/001c.25685'] 2986,34386278,Accuracy of the SWAY Mobile Cognitive Assessment Application.,"Background Mobile electronic devices have become integral tools in addressing the need for portable assessment of cognitive function following neurocognitive/motor injury. SWAY Medical, Inc., has employed mobile device motion-based technology in the SWAY Cognitive Assessment (SWAY CA) application to assess cognitive function. Purpose The purpose of this study was to assess whether the SWAY CA application (reaction time, impulse control and inspective time) was able to reliably operate on different mobile devices and operating systems (iOS, Android). The study further sought to assess the validity of the SWAY CA application against the FDA approved ImPACT QT mobile device application. Study Design Original Research, observational study of validity. Methods 88 healthy, young adults, 18 to 48 years ( mean = 22.09 ± sd =4.47 years) completed four, randomized and counter-balanced, reaction time tests (2- SWAY RT, 2- ImPACT QT) using different operating systems (iOS, Android) of 4 randomly assigned mobile devices. Results ANOVAs reported the SWAY CA application (reaction time, impulse control, inspection time) operated reliably with iPhone 6S, Samsung Galaxy S9, and iPad Pro 5 mobile devices ( p > 0.05), respectively. Google Pixel 3 reliability with SWAY CA application remains undetermined. SWAY CA simple reaction motion measures were in agreement ( r = -0.46 to 0.22, p ≤ 0.05) with several ImPACT QT reaction time measures. SWAY CA impulse control and inspection time measures are weakly correlated ( r = -0.25 to -0.46, p ≤ 0.05) with five ImPACT QT reaction time measures. Conclusion The motion-based SWAY CA mobile device application appears to reliably operate when being administered on different mobile devices and software operating systems. Furthermore, the SWAY CA application appears to be comparable to the ImPACT QT and serve as a valid tool for assessing reaction time measures. Level of Evidence Level 2b (observational study of validity).",2021,"Results ANOVAs reported the SWAY CA application (reaction time, impulse control, inspection time) operated reliably with iPhone 6S, Samsung Galaxy S9, and iPad Pro 5 mobile devices ( p > 0.05), respectively.","['88 healthy, young adults, 18 to 48 years ( mean = 22.09 ± sd =4.47 years']","['SWAY CA application', 'counter-balanced, reaction time tests (2- SWAY RT, 2- ImPACT QT) using different operating systems (iOS, Android) of 4 randomly assigned mobile devices', 'SWAY Mobile Cognitive Assessment Application']","['SWAY CA impulse control and inspection time measures', 'SWAY CA application (reaction time, impulse control, inspection time) operated reliably with iPhone 6S, Samsung Galaxy S9, and iPad Pro 5 mobile devices', 'SWAY CA simple reaction motion measures', 'SWAY CA application (reaction time, impulse control and inspective time']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0677601', 'cui_str': 'Counter'}, {'cui': 'C0205415', 'cui_str': 'Balanced'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0242753', 'cui_str': 'Io'}, {'cui': 'C0336541', 'cui_str': 'Android'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0150632', 'cui_str': 'Self-control: impulsive behavior'}, {'cui': 'C0199219', 'cui_str': 'Inspection'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0282063', 'cui_str': 'Galaxy'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0026597', 'cui_str': 'Motion'}]",88.0,0.0810123,"Results ANOVAs reported the SWAY CA application (reaction time, impulse control, inspection time) operated reliably with iPhone 6S, Samsung Galaxy S9, and iPad Pro 5 mobile devices ( p > 0.05), respectively.","[{'ForeName': 'Heidi A', 'Initials': 'HA', 'LastName': 'VanRavenhorst-Bell', 'Affiliation': 'Wichita State University.'}, {'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Muzeau', 'Affiliation': 'Engineering and Ergonomics of Physical Activity, University Savoie Mont-Blanc; Sporttesting.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Luinstra', 'Affiliation': 'Wichita State University.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Goering', 'Affiliation': 'Wichita State University.'}, {'ForeName': 'Ryan Z', 'Initials': 'RZ', 'LastName': 'Amick', 'Affiliation': 'Independent Consultant.'}]",International journal of sports physical therapy,['10.26603/001c.24924'] 2987,33855883,Experiences of Military Veterans in a Therapeutic Horseback Riding Program.,"Posttraumatic stress disorder commonly occurs among U.S. military veterans. Therapeutic horseback riding (THR) has emerged as an adjunct therapy. We explored 20 veterans' perceived benefits, drawbacks and views of a 6-week THR program. Participants had confirmed diagnoses of posttraumatic stress disorder, traumatic brain injury, or both. Veterans rode the same horse weekly, the same day, at the same time. Data were collected as part of a randomized clinical trial testing the effects of THR on Post-Traumatic Stress Disorder. Veterans responded to an open-ended questionnaire. Content analysis was used for data analysis. Benefits were ""Connection to the Horse,"" ""Relaxing,"" ""180 Degree Change,"" and ""Meeting New People."" Drawbacks were ""None,"" ""Struggle to Get There,"" ""Pain,"" ""Too Short,"" and ""It is Structured."" Overall perceptions were ""I Absolutely Loved It,"" ""Feel Again,"" ""The Horse,"" ""The People,"" and ""No Worries."" Participants viewed THR as positive. Findings may elucidate why THR may be clinically beneficial.",2021,"Overall perceptions were ""I Absolutely Loved It,"" ""Feel Again,"" ""The Horse,"" ""The People,"" and ""No Worries.""","['20 veterans', 'Participants had confirmed diagnoses of posttraumatic stress disorder, traumatic brain injury, or both', 'U.S. military veterans', 'Experiences of Military Veterans in a Therapeutic Horseback Riding Program']","['THR', 'Therapeutic horseback riding (THR']",[],"[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0073361', 'cui_str': 'RID'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0336962', 'cui_str': 'Horseback riding'}]",[],,0.0949587,"Overall perceptions were ""I Absolutely Loved It,"" ""Feel Again,"" ""The Horse,"" ""The People,"" and ""No Worries.""","[{'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Johnson', 'Affiliation': 'University of Missouri, Columbia, USA.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Albright', 'Affiliation': 'The University of Alabama, Tuscaloosa, USA.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Marzolf', 'Affiliation': 'Whole Health Institute, Bentonville, AR.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Bibbo', 'Affiliation': 'Benjamin Rose Institute on Aging, Cleveland, OH, USA.'}, {'ForeName': 'Hayley D', 'Initials': 'HD', 'LastName': 'Yaglom', 'Affiliation': 'University of Missouri, Columbia, USA.'}, {'ForeName': 'Sandra M', 'Initials': 'SM', 'LastName': 'Crowder', 'Affiliation': 'Missouri Department of Vocational Rehabilitation, Jefferson City, MO.'}, {'ForeName': 'Gretchen M', 'Initials': 'GM', 'LastName': 'Carlisle', 'Affiliation': 'University of Missouri, Columbia, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Grindler', 'Affiliation': 'Cedar Creek Therapeutic Riding Center, Columbia, MO, USA.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Harms', 'Affiliation': 'TREE House of Greater St. Louis, Wentzville, MO, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Willard', 'Affiliation': 'TREE House of Greater St. Louis, Wentzville, MO, USA.'}, {'ForeName': 'Marita', 'Initials': 'M', 'LastName': 'Wassman', 'Affiliation': 'Ride On St. Louis, Kimmswick, MO, USA.'}, {'ForeName': 'Cynthia L', 'Initials': 'CL', 'LastName': 'Russell', 'Affiliation': 'University of Missouri-Kansas City, USA.'}]",Clinical nursing research,['10.1177/10547738211003580'] 2988,34386129,Rationale and design of the HINODE study: Heart failure indication and sudden cardiac death prevention trial Japan.,"Background Randomized trials in Western countries have provided evidence that prophylactic implantable cardioverter-defibrillator (ICD) therapy reduces mortality in heart failure (HF) patients with reduced left ventricular ejection fraction. However, the risk of life-threatening ventricular arrhythmias in Japanese HF patients sharing similar risk factors is still unknown. Methods The Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan trial (NCT03185832) is a prospective, multicenter registry designed to collect data on ventricular arrhythmia, HF events, and mortality in Japanese HF patients. Japanese patients with HF and 2-5 predefined risk factors who were indicated for cardiac device implantation based on European Society of Cardiology guidelines were enrolled in four treatment arms: implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D), HF pacing (PA; Pacemaker and cardiac resynchronization pacemaker), and nondevice (ND) cohorts and followed for a minimum of 12 months. Since it is anticipated that some baseline patient characteristics and risk factors will differ significantly from those reported in predominantly Western populations, event rates will be compared to a propensity-matched population from the MADIT RIT trial. Primary endpoints are composite rates of first appropriately treated ventricular arrhythmias (VA) or/and life-threatening VA symptoms for the ICD and CRT-D cohorts. For nondevice and PA cohorts, the primary outcome is all-cause mortality. Conclusions The Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan is a large prospective multicenter registry with defined device treatment cohorts and will provide data for risk stratification for cardiovascular events in Japanese HF patients.",2021,"The Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan trial (NCT03185832) is a prospective, multicenter registry designed to collect data on ventricular arrhythmia, HF events, and mortality in Japanese HF patients.","['Japanese patients with HF and 2-5 predefined risk factors who were indicated for cardiac device implantation based on European Society of Cardiology guidelines', 'Japanese HF patients', 'heart failure (HF) patients with reduced left ventricular ejection fraction']","['prophylactic implantable cardioverter-defibrillator (ICD) therapy', 'implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D), HF pacing (PA; Pacemaker and cardiac resynchronization pacemaker), and nondevice (ND']","['risk of life-threatening ventricular arrhythmias', 'composite rates of first appropriately treated ventricular arrhythmias (VA) or/and life-threatening VA symptoms']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0162589', 'cui_str': 'Implantable defibrillator'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1167956', 'cui_str': 'Cardiac resynchronisation therapy'}, {'cui': 'C0180307', 'cui_str': 'Defibrillator'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down'}, {'cui': 'C0030163', 'cui_str': 'Cardiac pacemaker'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0085612', 'cui_str': 'Ventricular arrhythmia'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.236125,"The Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan trial (NCT03185832) is a prospective, multicenter registry designed to collect data on ventricular arrhythmia, HF events, and mortality in Japanese HF patients.","[{'ForeName': 'Hiro', 'Initials': 'H', 'LastName': 'Yamasaki', 'Affiliation': 'Department of Cardiology Faculty of Medicine University of Tsukuba Ibaraki Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Ando', 'Affiliation': 'Department of Cardiology Kokura Memorial Hospital Fukuoka Japan.'}, {'ForeName': 'Takanori', 'Initials': 'T', 'LastName': 'Ikeda', 'Affiliation': 'Department of Cardiovascular Medicine Faculty of Medicine Toho University Tokyo Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Mitsuhashi', 'Affiliation': 'Department of Cardiology Hoshi General Hospital Fukushima Japan.'}, {'ForeName': 'Toyoaki', 'Initials': 'T', 'LastName': 'Murohara', 'Affiliation': 'Department of Cardiology Nagoya University Graduate School of Medicine Aichi Japan.'}, {'ForeName': 'Nobuhiro', 'Initials': 'N', 'LastName': 'Nishii', 'Affiliation': 'Department of Cardiovascular Therapeutics Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan.'}, {'ForeName': 'Akihiko', 'Initials': 'A', 'LastName': 'Nogami', 'Affiliation': 'Department of Cardiology Faculty of Medicine University of Tsukuba Ibaraki Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Sakata', 'Affiliation': 'Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.'}, {'ForeName': 'Wataru', 'Initials': 'W', 'LastName': 'Shimizu', 'Affiliation': 'Department of Cardiovascular Medicine Nippon Medical School Tokyo Japan.'}, {'ForeName': 'Torri', 'Initials': 'T', 'LastName': 'Simon', 'Affiliation': 'Department of Biostatistics Boston Scientific St Paul MN USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Beaudoint', 'Affiliation': 'Department Clinical Research Boston Scientific Diegem Belgium.'}, {'ForeName': 'Torsten', 'Initials': 'T', 'LastName': 'Kayser', 'Affiliation': 'Department Clinical Research Boston Scientific Diegem Belgium.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Kutyifa', 'Affiliation': 'University of Rochester Rochester NY USA.'}, {'ForeName': 'Kazutaka', 'Initials': 'K', 'LastName': 'Aonuma', 'Affiliation': 'Department of Cardiology Faculty of Medicine University of Tsukuba Ibaraki Japan.'}]",Journal of arrhythmia,['10.1002/joa3.12577'] 2989,34386048,Self-care training and informational support of patients with a mechanical heart valve on the international normalized ratio and bleeding complications.,"Aim The aim of the study was to determine the effect of self-care training and informational support of patients with a mechanical heart valve on the international normalized ratio (INR) and bleeding complications. Material and methods Design: A quasi-experimental study. Participants were recruited via convenience sampling and were randomly divided into two groups: control ( n = 80) and intervention ( n = 80). Participants in the control group received only routine training; in addition, the intervention group received 6 sessions of self-care training and 6 months of informational support. Monthly the level of INR and incidence of bleeding were determined. Data were analyzed using the independent t -test and χ 2 in SPSS16 software at a significance level of 0.05. Results During 6 months of follow-up, except for the third month, the frequency of INR levels in the therapeutic target range (2.5-3.5) in the intervention group was significantly higher than that in the control group ( p < 0.05). Also in the intervention group, the incidence of bleeding complications was lower than that in the control group, but this difference was not statistically significant ( p > 0.05). Conclusions Proper self-care training and informational support in patients with mechanical heart valve replacement have positive results. By maintaining self-care, the level of a therapeutic target range of INR can be maintained and the incidence of bleeding complications can be reduced.",2021,"Also in the intervention group, the incidence of bleeding complications was lower than that in the control group, but this difference was not statistically significant ( p > 0.05). ","['Participants were recruited via convenience sampling', 'patients with a mechanical heart valve on the international normalized ratio (INR) and bleeding complications', 'patients with mechanical heart valve replacement', 'patients with a mechanical heart valve on the international normalized ratio and bleeding complications']","['Self-care training', 'self-care training', 'routine training; in addition, the intervention group received 6 sessions of self-care training and 6 months of informational support']","['level of INR and incidence of bleeding', 'frequency of INR levels', 'incidence of bleeding complications']","[{'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018829', 'cui_str': 'Prosthetic heart'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C3697840', 'cui_str': 'Mechanical heart valve replacement'}]","[{'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.00817142,"Also in the intervention group, the incidence of bleeding complications was lower than that in the control group, but this difference was not statistically significant ( p > 0.05). ","[{'ForeName': 'Shirdel', 'Initials': 'S', 'LastName': 'Zandi', 'Affiliation': 'MS Student, Department of Operating Room, Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Behzad', 'Initials': 'B', 'LastName': 'Imani', 'Affiliation': 'Department of Operating Room, School of Paramedicine, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Safarpour', 'Initials': 'S', 'LastName': 'Gholamreza', 'Affiliation': 'Department of Heart Surgery, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.'}]",Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery,['10.5114/kitp.2021.107468'] 2990,34385955,The Effect of a Dilemma on the Relationship Between Ability to Identify the Criterion (ATIC) and Scores on a Validated Situational Interview.,"Four experiments were conducted to determine whether participants' awareness of the performance criterion on which they were being evaluated results in higher scores on a criterion valid situational interview (SI) where each question either contains or does not contain a dilemma. In the first experiment there was no significant difference between those who were or were not informed of the performance criterion that the SI questions predicted. Experiment 2 replicated this finding. In each instance the SI questions in these two experiments contained a dilemma. In a third experiment, participants were randomly assigned to a 2 (knowledge/no knowledge provided of the criterion) X 2 (SI dilemma/no dilemma) design. Knowledge of the criterion increased interview scores only when the questions did not contain a dilemma. The fourth experiment revealed that including a dilemma in a SI question attenuates the ATIC-SI relationship when participants must identify rather than be informed of the performance criterion that the SI has been developed to assess.",2021,In the first experiment there was no significant difference between those who were or were not informed of the performance criterion that the SI questions predicted.,[],[],['interview scores'],[],[],"[{'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",4.0,0.106066,In the first experiment there was no significant difference between those who were or were not informed of the performance criterion that the SI questions predicted.,"[{'ForeName': 'Gary P', 'Initials': 'GP', 'LastName': 'Latham', 'Affiliation': 'Rotman School of Management, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Itzchakov', 'Affiliation': 'Department of Human Services, University of Haifa, Haifa, Israel.'}]",Frontiers in psychology,['10.3389/fpsyg.2021.674815'] 2991,34385840,Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease.,"Objective To evaluate the long-term outcomes after drug-coated balloon (DCB) angioplasty dissection in patients with complex femoropopliteal artery disease. Methods Two hundred patients with femoropopliteal peripheral artery disease were enrolled in the AcoArt I trial and randomly assigned to either the DCB or percutaneous transluminal angioplasty (PTA) group. A total of 86 patients with post-balloon angioplasty dissection were reanalyzed. The primary endpoint was clinically driven target lesion revascularization (CD-TLR) over five years. Kaplan-Meier curve estimates were used to evaluate the association between the treatment and CD-TLR. Interaction and stratified analyses were also performed. Results Over five years, patients treated with DCB angioplasty demonstrated an acceptable effect with a numerically higher but not statistically significant rate of freedom from CD-TLR compared with those treated by PTA (Kaplan-Meier estimate of 77.6% vs 64.4%; log-rank P = 0.08). Among the patients who underwent TLR, the mean time from intervention to TLR in the DCB group was significantly prolonged compared to the PTA group (P < 0.001). The stratified analysis showed that the Rutherford classification played an interactive role in the association between the DCB angioplasty and low CD-TLR rate at five years. No significant difference in the all-cause mortality was found in the patients with post-balloon angioplasty dissection between the two treatment groups. Conclusion The five-year follow-up outcomes of the post-balloon angioplasty dissection in the AcoArt I trial demonstrated that DCB angioplasty is more trustworthy than PTA, with a higher rate of freedom than CD-TLR and sustained improvement in clinical symptoms. However, the all-cause mortality rate in patients with femoropopliteal lesions is similar after both DCB angioplasty and PTA. Clinical Trial Registration http://www.clinicaltrials.gov. Unique Identifier NCT01850056.",2021,"No significant difference in the all-cause mortality was found in the patients with post-balloon angioplasty dissection between the two treatment groups. ","['Two hundred patients with femoropopliteal peripheral artery disease', '86 patients with post-balloon angioplasty dissection were reanalyzed', 'patients with complex femoropopliteal artery disease', 'patients with femoropopliteal lesions', 'Complex Femoropopliteal Artery Disease']","['drug-coated balloon (DCB) angioplasty dissection', 'DCB angioplasty', 'DCB or percutaneous transluminal angioplasty (PTA', 'Post-Drug-Coated Balloon Angioplasty Dissection']","['clinically driven target lesion revascularization (CD-TLR', 'mortality rate', 'cause mortality', 'rate of freedom from CD-TLR', 'low CD-TLR rate']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0002996', 'cui_str': 'Balloon Angioplasty'}, {'cui': 'C0012737', 'cui_str': 'Dissection - action'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0852949', 'cui_str': 'Disorder of artery'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty of blood vessel'}, {'cui': 'C0012737', 'cui_str': 'Dissection - action'}, {'cui': 'C0002996', 'cui_str': 'Balloon Angioplasty'}, {'cui': 'C2936666', 'cui_str': 'Percutaneous transluminal angioplasty'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0014742', 'cui_str': 'Erythema multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",86.0,0.0254303,"No significant difference in the all-cause mortality was found in the patients with post-balloon angioplasty dissection between the two treatment groups. ","[{'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Ren', 'Affiliation': ""Medical School of Chinese PLA, Beijing, 100853, People's Republic of China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Medical School of Chinese PLA, Beijing, 100853, People's Republic of China.""}, {'ForeName': 'Jiwei', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Vascular Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200120, People's Republic of China.""}, {'ForeName': 'Baixi', 'Initials': 'B', 'LastName': 'Zhuang', 'Affiliation': ""Department of Vascular Surgery, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100080, People's Republic of China.""}, {'ForeName': 'Weiguo', 'Initials': 'W', 'LastName': 'Fu', 'Affiliation': ""Department of Vascular Surgery, Zhongshan Hospital Fudan University, Shanghai, 200032, People's Republic of China.""}, {'ForeName': 'Danming', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': ""Department of Vascular Surgery, The People's Hospital of Liaoning Province, Shenyang, 110016, People's Republic of China.""}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': ""Department of Interventional Therapy, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, People's Republic of China.""}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': ""Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400042, People's Republic of China.""}, {'ForeName': 'Pingfan', 'Initials': 'P', 'LastName': 'Guo', 'Affiliation': ""Department of Vascular Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Bi', 'Affiliation': ""Department of Vascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, 050073, People's Republic of China.""}, {'ForeName': 'Shenming', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': ""Department of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510055, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Guo', 'Affiliation': ""Medical School of Chinese PLA, Beijing, 100853, People's Republic of China.""}]",International journal of general medicine,['10.2147/IJGM.S316916'] 2992,33872051,Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.,"PURPOSE We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezūm™) for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia. MATERIALS AND METHODS A total of 197 subjects > 50 years of age with International Prostate Symptom Score ≥13, maximum flow rate ≤15 ml/second and prostate volume 30 to 80 cc were randomized and followed for 5 years. From the control arm of 61 subjects, a subset of 53 subjects requalified and after 3 months received treatment as part of the crossover group and were also followed for 5 years. The total number of vapor treatments to each lobe of the prostate was determined by length of prostatic urethra and included middle lobe treatment per physician discretion. RESULTS Significant improvement of lower urinary tract symptoms was observed at < 3 months post-thermal therapy, remaining durable through 5 years in the treatment group (International Prostate Symptom Score reduced 48%, quality of life increased 45%, maximum flow rate improved 44%, Benign Prostatic Hyperplasia Impact Index decreased 48%). Surgical re-treatment rate was 4.4% with no reports of device or procedure related sexual dysfunction or sustained de novo erectile dysfunction. Results within the crossover group were similar through 5 years. CONCLUSIONS Minimally invasive treatment with water vapor thermal therapy provides significant and durable symptom relief as well as flow rate improvements through 5 years, with low surgical re-treatment rates and without impacting sexual function. It is a versatile therapy, providing successful treatment to obstructive lateral and middle lobes.",2021,"Minimally invasive treatment with Rezum water vapor thermal therapy provides significant and durable symptom relief as well as flow rate improvements through 5 years, with low surgical retreatment rates and without impacting sexual function.","['moderate-to-severe LUTS due to BPH', 'Total of 197 subjects > 50 years of age, with IPSS ≥13, maximum flow rate (Qmax) ≤15 mL/s and prostate volume', 'Moderate-To-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia']","['Rezum water vapor therapy', 'Rezum water vapor thermal therapy', 'Rezūm Water Vapor Thermal Therapy']","['Surgical retreatment rate', 'sexual dysfunction', 'durable symptom relief', 'QOL', 'LUTS']","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0005001', 'cui_str': 'Hypertrophy, Benign Prostatic'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1504431', 'cui_str': 'Idiopathic pneumonia syndrome'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439390', 'cui_str': 'mL/s'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0574785', 'cui_str': 'Lower urinary tract symptoms'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}]","[{'cui': 'C2350022', 'cui_str': 'Water Vapor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0454527', 'cui_str': 'Thermal techniques'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}]",197.0,0.0475479,"Minimally invasive treatment with Rezum water vapor thermal therapy provides significant and durable symptom relief as well as flow rate improvements through 5 years, with low surgical retreatment rates and without impacting sexual function.","[{'ForeName': 'Kevin T', 'Initials': 'KT', 'LastName': 'McVary', 'Affiliation': 'Loyola University Medical Center, Maywood, Illinois.'}, {'ForeName': 'Marc C', 'Initials': 'MC', 'LastName': 'Gittelman', 'Affiliation': 'South Florida Medical Research, Aventura, Florida.'}, {'ForeName': 'Kenneth A', 'Initials': 'KA', 'LastName': 'Goldberg', 'Affiliation': 'University of Texas Southwestern, Lewisville, Texas.'}, {'ForeName': 'Kalpesh', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': 'Arizona Institute of Urology, Tucson, Arizona.'}, {'ForeName': 'Neal D', 'Initials': 'ND', 'LastName': 'Shore', 'Affiliation': 'Carolina Urologic Research Center, Myrtle Beach, South Carolina.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Levin', 'Affiliation': 'Chesapeake Urology Research Associates, Towson, Maryland.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Pliskin', 'Affiliation': 'The Urology Group, Cincinnati, Ohio.'}, {'ForeName': 'J Randolf', 'Initials': 'JR', 'LastName': 'Beahrs', 'Affiliation': 'Minnesota Urology, Woodbury, Minnesota.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Prall', 'Affiliation': 'Minnesota Urology, Woodbury, Minnesota.'}, {'ForeName': 'Jed', 'Initials': 'J', 'LastName': 'Kaminetsky', 'Affiliation': 'Manhattan Medical Research, New York, New York.'}, {'ForeName': 'Barrett E', 'Initials': 'BE', 'LastName': 'Cowan', 'Affiliation': 'Urology Associates of Denver, Englewood, Colorado.'}, {'ForeName': 'Christopher H', 'Initials': 'CH', 'LastName': 'Cantrill', 'Affiliation': 'Urology San Antonio Research, San Antonio, Texas.'}, {'ForeName': 'Lance A', 'Initials': 'LA', 'LastName': 'Mynderse', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Ulchaker', 'Affiliation': 'Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Nicholas N', 'Initials': 'NN', 'LastName': 'Tadros', 'Affiliation': 'Southern Illinois University, Springfield, Illinois.'}, {'ForeName': 'Steven N', 'Initials': 'SN', 'LastName': 'Gange', 'Affiliation': 'Western Urologic Clinic, Salt Lake City, Utah.'}, {'ForeName': 'Claus G', 'Initials': 'CG', 'LastName': 'Roehrborn', 'Affiliation': 'University of Texas Southwestern, Dallas, Texas.'}]",The Journal of urology,['10.1097/JU.0000000000001778'] 2993,33838657,"Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.","BACKGROUND Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. METHODS In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8). RESULTS There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 ± 3.64 and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). CONCLUSION In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone. TRIAL REGISTRATION The trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1 ).",2021,"The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). ","['86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran', 'hospitalized COVID-19 patients']","['dexamethasone', 'IRCT.IR', 'methylprednisolone', 'Methylprednisolone or dexamethasone']","['mean length of hospital stay', 'overall mean score', 'clinical status']","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449440', 'cui_str': 'Clinical status'}]",86.0,0.236146,"The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). ","[{'ForeName': 'Keivan', 'Initials': 'K', 'LastName': 'Ranjbar', 'Affiliation': 'Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Moghadami', 'Affiliation': 'Health Policy research center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. moghadami@sums.ac.ir.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Mirahmadizadeh', 'Affiliation': 'Health Policy research center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mohammad Javad', 'Initials': 'MJ', 'LastName': 'Fallahi', 'Affiliation': 'Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Khaloo', 'Affiliation': 'Ali Asghar hospital, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Shahriarirad', 'Affiliation': 'Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Amirhossein', 'Initials': 'A', 'LastName': 'Erfani', 'Affiliation': 'Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Zohre', 'Initials': 'Z', 'LastName': 'Khodamoradi', 'Affiliation': 'Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mohammad Hasan', 'Initials': 'MH', 'LastName': 'Gholampoor Saadi', 'Affiliation': 'Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",BMC infectious diseases,['10.1186/s12879-021-06045-3'] 2994,33840150,Two-minute tidal breathing methacholine bronchial challenge: Comparison of two jet nebulisers.,"BACKGROUND The American Thoracic Society (ATS) guideline for methacholine challenge testing (MCT) recommended using the English Wright (EW) nebuliser. However, other brands of nebulisers are also indicated to be acceptable for this technique, but further validation of nebuliser performance is recommended. OBJECTIVE To compare the methacholine provocation concentration causing a 20% fall in forced expiratory volume in 1 second (PC 20 -FEV 1 ) measured by using EW nebuliser and DV 646 nebuliser. METHODS Subjects were randomly assigned to undergo 2-min tidal breathing methacholine challenge with either EW or DV 646 nebuliser on two separate days, which were at least 24 hours but not more than 7 days apart. The above procedure was repeated for each subject in 1 month, but the nebulisers were selected in a reverse order. RESULTS The study includes 15 mild and stable asthmatic patients. The geometric means (SD) of methacholine PC 20 measured with using EW and DV 646 nebulisers were 1.82 (6.38) mg/mL versus 0.83 (1.82) mg/mL, respectively in the initial two visits and 2.56 (6.29) mg/mL versus 0.78 (1.40) mg/mL in the following two visits (both P < 0.05). There are well correlations between PC20-EW1 and PC20-EW2 (r = 0.99, P < 0.01), PC20-DV1 and PC20-DV2 (r = 0.88, P < 0.01), and between PC20-EW1 and PC20-DV1 (r = 0.91, P < 0.01), PC20-EW2 and PC20-DV2 (r = 0.78, P < 0.01). CONCLUSIONS PC 20 -FEV 1 measured by using the two conventional jet nebulisers was both repeatable and the results were highly correlated.",2021,mg/ml in the following two visits in asthma (both P < 0.05).,['Subjects'],"['tidal breathing methacholine challenge with either EW or DV 646 nebulizer', 'English Wright (EW) nebulizer']",['forced expiratory volume'],[],"[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0430567', 'cui_str': 'Methacholine challenge'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C1261259', 'cui_str': 'Wright stain'}, {'cui': 'C0027524', 'cui_str': 'Nebulizer'}]","[{'cui': 'C0016529', 'cui_str': 'Forced expired volume'}]",646.0,0.0321704,mg/ml in the following two visits in asthma (both P < 0.05).,"[{'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Zhu', 'Affiliation': 'Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Lab of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Hongyu', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Guangzhou Institute of Respiratory Health, State Key Lab of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Yanqing', 'Initials': 'Y', 'LastName': 'Xie', 'Affiliation': 'Guangzhou Institute of Respiratory Health, State Key Lab of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Jiaying', 'Initials': 'J', 'LastName': 'An', 'Affiliation': 'Guangzhou Institute of Respiratory Health, State Key Lab of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Lab of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Jinping', 'Initials': 'J', 'LastName': 'Zheng', 'Affiliation': 'Guangzhou Institute of Respiratory Health, State Key Lab of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}]",The clinical respiratory journal,['10.1111/crj.13374'] 2995,33858205,Comparison of the corticosteroid injection and hyaluronate in the treatment of chronic subacromial bursitis: A randomized controlled trial.,"OBJECTIVE To analyse the effectiveness of corticosteroid (CS) and hyaluronic acid (HA) subacromial - subdeltoid (SASD) injection compared with normal saline (NS) in patients with chronic subacromial bursitis (CSB). DESIGN A prospective three-arm double-blinded randomised controlled trial. SETTING Rehabilitation department of two teaching hospitals. SUBJECTS Patients with CSB ( N  = 186) divided into CS ( N  = 68), HA ( N  = 60), and NS ( N  = 58) groups. INTERVENTIONS Three SASD injections under ultrasound guidance: group A, 20 mg of triamcinolone; group B, 2.5 mL of HA; and group C, 2.5 mL of NS. OUTCOME MEASURES The primary outcome measures were the pain visual analogue scale (VAS) score at eight weeks. The secondary outcomes were scores on the Shoulder Pain and Disability Index (SPADI) and Shoulder Disability Questionnaire. RESULTS At eight weeks, the pain VAS scores during activity were 2.56 ± 2.29, 3.65 ± 2.50, and 4.71 ± 2.83 in the CS, HA, and NS groups, respectively (CS vs NS, P  < 0.001; HA vs NS, P  = 0.013; CS vs HA, P  = 0.010). SPADI scores were 40.83 ± 21.75, 36.92 ± 22.78, and 33.35 ± 23.38 in the CS, HA, and NS groups, respectively (CS vs NS, P  < 0.001; HA vs NS, P  = 0.197; CS vs HA, P  = 0.004). CONCLUSION Ultrasound-guided corticosteroid injection into the subacromial - subdeltoid bursa was proven to be effective and superior to hyaluronic acid and normal saline injection for treating CSB. Hyaluronic acid injection was only marginally more effective than normal saline injection. Trial Registration: ClinicalTrials.gov: NCT02702206.",2021,Hyaluronic acid injection was only marginally more effective than normal saline injection.,"['Patients with CSB ( N \u2009=\u2009186) divided into CS ( N \u2009=\u200968), HA ( N \u2009=\u200960), and NS ( N \u2009=\u200958) groups', 'chronic subacromial bursitis', 'patients with chronic subacromial bursitis (CSB', 'Rehabilitation department of two teaching hospitals']","['triamcinolone', 'corticosteroid (CS) and hyaluronic acid (HA) subacromial - subdeltoid (SASD) injection', 'corticosteroid injection and hyaluronate', 'Hyaluronic acid injection', 'HA', 'SASD injections under ultrasound guidance', 'normal saline (NS']","['Shoulder Pain and Disability Index (SPADI) and Shoulder Disability Questionnaire', 'pain visual analogue scale (VAS) score', 'pain VAS scores', 'SPADI scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751038', 'cui_str': 'Type II Cockayne Syndrome'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0546953', 'cui_str': 'Subacromial bursitis'}, {'cui': 'C0587478', 'cui_str': 'Rehabilitation department'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}]","[{'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0178695', 'cui_str': 'hyaluronate'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.276161,Hyaluronic acid injection was only marginally more effective than normal saline injection.,"[{'ForeName': 'Lin-Fen', 'Initials': 'LF', 'LastName': 'Hsieh', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, Shin Kong Wu Ho-Su Memorial Hospital, Taipei.'}, {'ForeName': 'Yi-Jia', 'Initials': 'YJ', 'LastName': 'Lin', 'Affiliation': 'Graduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei.'}, {'ForeName': 'Wei-Chun', 'Initials': 'WC', 'LastName': 'Hsu', 'Affiliation': 'Graduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei.'}, {'ForeName': 'Ying-Chen', 'Initials': 'YC', 'LastName': 'Kuo', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, Shin Kong Wu Ho-Su Memorial Hospital, Taipei.'}, {'ForeName': 'Yu-Chia', 'Initials': 'YC', 'LastName': 'Liu', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, Shin Kong Wu Ho-Su Memorial Hospital, Taipei.'}, {'ForeName': 'Yi-Pin', 'Initials': 'YP', 'LastName': 'Chiang', 'Affiliation': 'Department of Rehabilitation Medicine, MacKay Memorial Hospital, Taipei.'}, {'ForeName': 'Chun-Ping', 'Initials': 'CP', 'LastName': 'Wang', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, Shin Kong Wu Ho-Su Memorial Hospital, Taipei.'}]",Clinical rehabilitation,['10.1177/02692155211007799'] 2996,33861329,Loving-Kindness Meditation vs Cognitive Processing Therapy for Posttraumatic Stress Disorder Among Veterans: A Randomized Clinical Trial.,"Importance Additional options are needed for treatment of posttraumatic stress disorder (PTSD) among veterans. Objective To determine whether group loving-kindness meditation is noninferior to group cognitive processing therapy for treatment of PTSD. Design, Setting, and Participants This randomized clinical noninferiority trial assessed PTSD and depression at baseline, posttreatment, and 3- and 6-month follow-up. Veterans were recruited from September 24, 2014, to February 5, 2018, from a large Veternas Affairs medical center in Seattle, Washington. A total of 184 veteran volunteers who met Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) criteria for PTSD were randomized. Data collection was completed November 28, 2018, and data analyses were conducted from December 10, 2018, to November 5, 2019. Interventions Each intervention comprised 12 weekly 90-minute group sessions. Loving-kindness meditation (n = 91) involves silent repetition of phrases intended to elicit feelings of kindness for oneself and others. Cognitive processing therapy (n = 93) combines cognitive restructuring with emotional processing of trauma-related content. Main Outcomes and Measures Co-primary outcomes were change in PTSD and depression scores over 6-month follow-up, assessed by the Clinician-Administered PTSD Scale (CAPS-5; range, 0-80; higher is worse) and Patient-Reported Outcome Measurement Information System (PROMIS; reported as standardized T-score with mean [SD] of 50 [10] points; higher is worse) depression measures. Noninferiority margins were 5 points on the CAPS-5 and 4 points on the PROMIS depression measure. Results Among the 184 veterans (mean [SD] age, 57.1 [13.1] years; 153 men [83.2%]; 107 White participants [58.2%]) included in the study, 91 (49.5%) were randomized to the loving-kindness group, and 93 (50.5%) were randomized to the cognitive processing group. The mean (SD) baseline CAPS-5 score was 35.5 (11.8) and mean (SD) PROMIS depression score was 60.9 (7.9). A total of 121 veterans (66%) completed 6-month follow-up. At 6 months posttreatment, mean CAPS-5 scores were 28.02 (95% CI, 24.72-31.32) for cognitive processing therapy and 25.92 (95% CI, 22.62-29.23) for loving-kindness meditation (difference, 2.09; 95% CI, -2.59 to 6.78), and mean PROMIS depression scores were 61.22 (95% CI, 59.21-63.23) for cognitive processing therapy and 58.88 (95% CI, 56.86-60.91) for loving-kindness meditation (difference, 2.34; 95% CI, -0.52 to 5.19). In superiority analyses, there were no significant between-group differences in CAPS-5 scores, whereas for PROMIS depression scores, greater reductions were found for loving-kindness meditation vs cognitive processing therapy (for patients attending ≥6 visits, ≥4-point improvement was noted in 24 [39.3%] veterans receiving loving-kindness meditation vs 9 (18.0%) receiving cognitive processing therapy; P = .03). Conclusions and Relevance Among veterans with PTSD, loving-kindness meditation resulted in reductions in PTSD symptoms that were noninferior to group cognitive processing therapy. For both interventions, the magnitude of improvement in PTSD symptoms was modest. Change over time in depressive symptoms was greater for loving-kindness meditation than for cognitive processing therapy. Trial Registration Clinicaltrials.gov Identifier: NCT01962714.",2021,"At 6 months posttreatment, mean CAPS-5 scores were 28.02 (95% CI, 24.72-31.32) for cognitive processing therapy and 25.92 (95% CI, 22.62-29.23) for loving-kindness meditation (difference, 2.09; 95% CI, -2.59 to 6.78), and mean PROMIS depression scores were 61.22 (95% CI, 59.21-63.23) for cognitive processing therapy and 58.88","['posttraumatic stress disorder (PTSD) among veterans', 'Veterans were recruited from September 24, 2014, to February 5, 2018, from a large Veternas Affairs medical center in Seattle, Washington', '184 veterans (mean [SD] age, 57.1 [13.1] years; 153 men [83.2%]; 107 White participants [58.2%]) included in the study, 91 (49.5%) were randomized to the loving-kindness group, and 93 (50.5', '184 veteran volunteers who met Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) criteria for PTSD were randomized', 'Data collection was completed November 28, 2018, and data analyses were conducted from December 10, 2018, to November 5, 2019', '121 veterans (66%) completed 6-month follow-up', 'Posttraumatic Stress Disorder Among Veterans', 'veterans with PTSD']","['Loving-Kindness Meditation vs Cognitive Processing Therapy', 'Loving-kindness meditation', 'Cognitive processing therapy (n\u2009=\u200993) combines cognitive restructuring with emotional processing of trauma-related content', 'cognitive processing group']","['mean (SD) PROMIS depression score', 'mean PROMIS depression scores', 'CAPS-5 score', 'PROMIS depression measure', 'depressive symptoms', 'mean (SD) baseline', 'mean CAPS-5 scores', 'change in PTSD and depression scores over 6-month follow-up, assessed by the Clinician-Administered PTSD Scale', 'CAPS-5 scores', 'PROMIS depression scores', 'PTSD symptoms']","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0024028', 'cui_str': 'Love'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C1136324', 'cui_str': 'Diagnostic and Statistical Manual of Mental Disorders'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441792', 'cui_str': 'Editions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0024028', 'cui_str': 'Love'}, {'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0150173', 'cui_str': 'Cognitive restructuring'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0021428', 'cui_str': 'Information system'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",184.0,0.311297,"At 6 months posttreatment, mean CAPS-5 scores were 28.02 (95% CI, 24.72-31.32) for cognitive processing therapy and 25.92 (95% CI, 22.62-29.23) for loving-kindness meditation (difference, 2.09; 95% CI, -2.59 to 6.78), and mean PROMIS depression scores were 61.22 (95% CI, 59.21-63.23) for cognitive processing therapy and 58.88","[{'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Kearney', 'Affiliation': 'VA Puget Sound Health Care System, Seattle, Washington.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Malte', 'Affiliation': 'Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, Washington.'}, {'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'Storms', 'Affiliation': 'VA Research and Development, VA Puget Sound Health Care System, Seattle, Washington.'}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'Simpson', 'Affiliation': 'Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, Washington.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.6604'] 2997,33876525,Impact of structured curriculum with simulation on bronchoscopy.,"BACKGROUND AND OBJECTIVE Simulation enhances a physician's competency in procedural skills by accelerating ascent of the learning curve. Training programmes are moving away from the Halstedian model of 'see one, do one, teach one', also referred as medical apprenticeship. We aimed to determine if a 3-month structured bronchoscopy curriculum that incorporated simulator training could improve bronchoscopy competency among pulmonary medicine trainees. METHODS We prospectively recruited trainees from hospitals with accredited pulmonary medicine programmes. Trainees from hospitals (A, B and C) were assigned to control group (CG) where they received training by traditional apprenticeship while trainees from hospital D were assigned to intervention group (IG) where they underwent 3-month structured curriculum that incorporated training with the bronchoscopy simulator. Two patient bronchoscopy procedures per trainee were recorded on video and scored independently by two expert bronchoscopists using the modified Bronchoscopy Skills and Tasks Assessment Tool (BSTAT) forms. A 25 multiple choice questions (MCQ) test was administered to all participants at the end of 3 months. RESULTS Eighteen trainees participated; 10 in CG and eight in IG with equal female:male ratio. Competency assessed by modified BSTAT and MCQ tests was variable and not driven by volume as IG performed fewer patient bronchoscopies but demonstrated better BSTAT, airway anaesthesia and MCQ scores. Bronchoscopy simulator training was the only factor that correlated with better BSTAT (r = 0.80), MCQ (r = 0.85) and airway anaesthesia scores (r = 0.83), and accelerated the learning curve of IG trainees. CONCLUSION An intensive 3-month structured bronchoscopy curriculum that incorporated simulator training led to improved cognitive and technical skill performance as compared with apprenticeship training.",2021,An intensive 3-month structured bronchoscopy curriculum that incorporated simulator training led to improved cognitive and technical skill performance as compared with apprenticeship training.,"['recruited trainees from hospitals with accredited pulmonary medicine programmes', 'pulmonary medicine trainees', 'Eighteen trainees participated; 10 in CG and eight in IG with equal female:male ratio']","['apprenticeship training', 'simulator training', 'control group (CG) where they received training by traditional apprenticeship while trainees from hospital D were assigned to intervention group (IG) where they underwent 3-month structured curriculum that incorporated training with the bronchoscopy simulator', 'Bronchoscopy simulator training']","['airway anaesthesia scores', 'BSTAT, airway anaesthesia and MCQ scores', 'cognitive and technical skill performance', 'bronchoscopy competency']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0034060', 'cui_str': 'Pulmonary medicine'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0006290', 'cui_str': 'Bronchoscopy'}]","[{'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006290', 'cui_str': 'Bronchoscopy'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0086035', 'cui_str': 'Competence'}]",18.0,0.0258006,An intensive 3-month structured bronchoscopy curriculum that incorporated simulator training led to improved cognitive and technical skill performance as compared with apprenticeship training.,"[{'ForeName': 'Wen Ting', 'Initials': 'WT', 'LastName': 'Siow', 'Affiliation': 'Division of Respiratory and Critical Care Medicine, National University Hospital, Singapore.'}, {'ForeName': 'Gan-Liang', 'Initials': 'GL', 'LastName': 'Tan', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore.'}, {'ForeName': 'Chian-Min', 'Initials': 'CM', 'LastName': 'Loo', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore.'}, {'ForeName': 'Kay-Leong', 'Initials': 'KL', 'LastName': 'Khoo', 'Affiliation': 'Division of Respiratory and Critical Care Medicine, National University Hospital, Singapore.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Kee', 'Affiliation': 'Division of Respiratory and Critical Care Medicine, National University Hospital, Singapore.'}, {'ForeName': 'Augustine', 'Initials': 'A', 'LastName': 'Tee', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore.'}, {'ForeName': 'Imran', 'Initials': 'I', 'LastName': 'Bin Mohamed Noor', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore.'}, {'ForeName': 'Noel', 'Initials': 'N', 'LastName': 'Tay', 'Affiliation': 'Division of Respiratory and Critical Care Medicine, Ng Teng Fong Hospital, Singapore.'}, {'ForeName': 'Pyng', 'Initials': 'P', 'LastName': 'Lee', 'Affiliation': 'Division of Respiratory and Critical Care Medicine, National University Hospital, Singapore.'}]","Respirology (Carlton, Vic.)",['10.1111/resp.14054'] 2998,33875845,One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency.,"PURPOSE To assess olipudase alfa enzyme replacement therapy for non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in children. METHODS This phase 1/2, international, multicenter, open-label trial (ASCEND-Peds/NCT02292654) administered intravenous olipudase alfa every 2 weeks with intrapatient dose escalation to 3 mg/kg. Primary outcome was safety through week 64. Secondary outcomes included pharmacokinetics, spleen and liver volumes, lung diffusing capacity (DL CO ), lipid profiles, and height through week 52. RESULTS Twenty patients were enrolled: four adolescents (12-17 years), nine children (6-11 years), and seven infants/early child (1-5 years). Most adverse events were mild or moderate, including infusion-associated reactions (primarily urticaria, pyrexia, and/or vomiting) in 11 patients. Three patients had serious treatment-related events: one with transient asymptomatic alanine aminotransferase increases, another with urticaria and rash (antidrug antibody positive [ADA+]), and a third with an anaphylactic reaction (ADA+) who underwent desensitization and reached the 3 mg/kg maintenance dose. Mean splenomegaly and hepatomegaly improved by >40% (p < 0.0001). Mean % predicted DL CO improved by 32.9% (p = 0.0053) in patients able to perform the test. Lipid profiles and elevated liver transaminase levels normalized. Mean height Z-scores improved by 0.56 (p < 0.0001). CONCLUSION In this study in children with chronic ASMD, olipudase alfa was generally well-tolerated with significant, comprehensive improvements in disease pathology across a range of clinically relevant endpoints.",2021,Mean % predicted DL CO improved by 32.9% (p = 0.0053) in patients able to perform the test.,"['Twenty patients were enrolled: four adolescents (12-17 years), nine children (6-11 years), and seven infants/early child (1-5 years', 'children', 'Three patients had serious treatment-related events: one with transient asymptomatic alanine aminotransferase increases, another with urticaria and rash (antidrug antibody positive [ADA+]), and a third with an anaphylactic reaction (ADA+) who underwent desensitization and reached the 3\u2009mg/kg maintenance dose', 'children with chronic ASMD', 'pediatric patients with acid sphingomyelinase deficiency']",['olipudase alfa enzyme replacement therapy'],"['Mean splenomegaly and hepatomegaly', 'DL CO', 'infusion-associated reactions (primarily urticaria, pyrexia, and/or vomiting', 'Mean height Z-scores', 'pharmacokinetics, spleen and liver volumes, lung diffusing capacity (DL CO ), lipid profiles, and height through week 52']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0151905', 'cui_str': 'Alanine aminotransferase increased'}, {'cui': 'C0042109', 'cui_str': 'Urticaria'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0741132', 'cui_str': 'Antibody test positive'}, {'cui': 'C0002792', 'cui_str': 'Anaphylaxis'}, {'cui': 'C0178702', 'cui_str': 'Desensitization therapy'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C3714445', 'cui_str': 'Maintenance dose'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0037903', 'cui_str': 'Sphingomyelin phosphodiesterase'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}]","[{'cui': 'C4278198', 'cui_str': 'olipudase alfa'}, {'cui': 'C0598391', 'cui_str': 'Enzyme Replacement Therapy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038002', 'cui_str': 'Splenomegaly'}, {'cui': 'C0019209', 'cui_str': 'Large liver'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0042109', 'cui_str': 'Urticaria'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0037993', 'cui_str': 'Splenic structure'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0439230', 'cui_str': 'week'}]",20.0,0.135995,Mean % predicted DL CO improved by 32.9% (p = 0.0053) in patients able to perform the test.,"[{'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Diaz', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA. george.diaz@mssm.edu.'}, {'ForeName': 'Simon A', 'Initials': 'SA', 'LastName': 'Jones', 'Affiliation': ""St Mary's Hospital, Manchester University Foundation Trust, University of Manchester, Manchester, UK.""}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Scarpa', 'Affiliation': 'Regional Coordinating Center for Rare Diseases, University Hospital Udine, Udine, Italy.'}, {'ForeName': 'Karl Eugen', 'Initials': 'KE', 'LastName': 'Mengel', 'Affiliation': 'Clinical Science for LSD, SpinCS, Hochheim, Germany.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Giugliani', 'Affiliation': 'Dept Genetics, UFRGS, Medical Genetics Clinical Research Group, HCPA, and INAGEMP, Porto Alegre, Brazil.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Guffon', 'Affiliation': 'Reference Center for Inherited Metabolic Disorders, Femme Mère Enfant Hospital, Lyon, France.'}, {'ForeName': 'Isabela', 'Initials': 'I', 'LastName': 'Batsu', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Fraser', 'Affiliation': 'Sanofi Genzyme, Inc, Cambridge, MA, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Ortemann-Renon', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}]",Genetics in medicine : official journal of the American College of Medical Genetics,['10.1038/s41436-021-01156-3'] 2999,33863241,Randomized pilot study of a special education advocacy program for Latinx/minority parents of children with autism spectrum disorder.,"LAY ABSTRACT Persistent racial and ethnic disparities in obtaining an autism spectrum disorder diagnosis and services have been documented for Latinx children and other racial/ethnic minorities. This study reports on an educational intervention examining the effectiveness and feasibility of a low-intensity (i.e. three sessions), low-cost, parent advocacy for Latinx and other minority parents of children with autism. Results indicated significantly increased parental knowledge and in the immediate intervention group, but this knowledge did not lead to greater empowerment. While parents from low-income, racial/ethnic minority backgrounds, particularly Latinx parents, can significantly increase their advocacy skills with a low-intensity, low-cost program, they may need more support in changing their self-perceptions of empowerment and advocacy.",2021,"Results indicated significantly increased parental knowledge and in the immediate intervention group, but this knowledge did not lead to greater empowerment.","['Latinx/minority parents of children with autism spectrum disorder', 'minority parents of children with autism']","['educational intervention', 'special education advocacy program']","['advocacy skills', 'parental knowledge']","[{'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013649', 'cui_str': 'Special Education'}, {'cui': 'C0150446', 'cui_str': 'Advocacy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0150446', 'cui_str': 'Advocacy'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",,0.00660687,"Results indicated significantly increased parental knowledge and in the immediate intervention group, but this knowledge did not lead to greater empowerment.","[{'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Luelmo', 'Affiliation': 'San Diego State University, USA.'}, {'ForeName': 'Connie', 'Initials': 'C', 'LastName': 'Kasari', 'Affiliation': 'University of California, Los Angeles, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Fiesta Educativa, Inc., USA.'}]",Autism : the international journal of research and practice,['10.1177/1362361321998561'] 3000,33862624,Thalamic Deep Brain Stimulation for Spasmodic Dysphonia: A Phase I Prospective Randomized Double-Blind Crossover Trial.,"BACKGROUND Adductor spasmodic dysphonia (SD) is a dystonia of the vocal folds causing difficulty with speech. The current standard of care is repeated botulinum toxin injections to weaken the adductor muscles. We sought to ameliorate the underlying neurological cause of SD with a novel therapy-deep brain stimulation (DBS). OBJECTIVE To assess the safety of DBS in SD through phase I trial, and to quantify the magnitude of any benefit. METHODS Six patients had left ventral intermediate nucleus (Vim) thalamic DBS and were randomized to 3 mo blinded-DBS ""on"" or ""off"" followed by a crossover. Primary outcomes were quality of life and quality of voice during the blinded phase. Patients continued with open-DBS ""on."" Secondary outcomes were comparisons of pre- and 1-yr cognitive, mood, and quality of life. This trial was registered with ClinicalTrials.gov (NCT02558634). RESULTS There were no complications. Every patient reported an improvement in quality of life (P = .07) and had an improvement in quality of their voice (P = .06) when their blinded DBS was ""on"" versus ""off."" The trend did not reach statistical significance with the small sample size. Secondary outcomes showed no difference in cognition, an improvement in mood, and quality of life at 1 yr. CONCLUSION This phase I randomized controlled trial confirmed that DBS can be performed safely in patients with SD. Blinded DBS produced a strong trend toward improved quality of life and objective quality of voice despite the small sample size. The cerebellar circuit, not the pallidal circuit, appears to be crucial for motor control of the vocal folds.",2021,"Every patient reported an improvement in quality of life (P = .07) and had an improvement in quality of their voice (P = .06) when their blinded DBS was ""on"" versus ""off.""","['Six patients had left ventral intermediate nucleus (Vim) thalamic DBS', 'Spasmodic Dysphonia', 'patients with SD']","['DBS', 'novel therapy-deep brain stimulation (DBS', 'botulinum toxin injections']","['quality of life', 'pre- and 1-yr cognitive, mood, and quality of life', 'quality of life and objective quality of voice', 'quality of their voice', 'quality of life and quality of voice', 'cognition, an improvement in mood, and quality of life']","[{'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C1704448', 'cui_str': 'Ventral'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0007610', 'cui_str': 'Nucleus'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0264588', 'cui_str': 'Spastic dysphonia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1321035', 'cui_str': 'Injection of botulinum toxin'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0042943', 'cui_str': 'Vocal quality'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",6.0,0.600605,"Every patient reported an improvement in quality of life (P = .07) and had an improvement in quality of their voice (P = .06) when their blinded DBS was ""on"" versus ""off.""","[{'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Honey', 'Affiliation': 'Division of Neurosurgery, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Marie T', 'Initials': 'MT', 'LastName': 'Krüger', 'Affiliation': 'Department of Neurosurgery, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Timóteo', 'Initials': 'T', 'LastName': 'Almeida', 'Affiliation': 'Division of Neurosurgery, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Linda A', 'Initials': 'LA', 'LastName': 'Rammage', 'Affiliation': 'Division of Otolaryngology and School of Audiology and Speech Sciences, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Mandeep S', 'Initials': 'MS', 'LastName': 'Tamber', 'Affiliation': 'Division of Neurosurgery, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Murray D', 'Initials': 'MD', 'LastName': 'Morrison', 'Affiliation': 'Division of Otolaryngology, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Anujan', 'Initials': 'A', 'LastName': 'Poologaindran', 'Affiliation': 'Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Hu', 'Affiliation': 'Division of Otolaryngology, University of British Columbia, Vancouver, Canada.'}]",Neurosurgery,['10.1093/neuros/nyab095'] 3001,33876881,Clinical evaluation of the Hydra self-expanding transcatheter aortic valve: 6 month results from the GENESIS trial.,"OBJECTIVES To evaluate the safety and performance of the Hydra transcatheter aortic valve (THV) in the treatment of symptomatic severe aortic stenosis in patients at high or extreme surgical risk. BACKGROUND The Hydra THV (Vascular Innovations Co. Ltd., Nonthaburi, Thailand) is a novel flexible repositionable self-expanding system with supra-annular bovine pericardial leaflets, available in three sizes, covering aortic annuli between 17 and 27 mm. METHODS The GENESIS trial was a prospective, multi-center, single-arm, 6 month follow-up study conducted in India. The primary performance endpoint was device success defined as per VARC-II criteria at 30 days. The primary safety endpoint was all-cause mortality at 30 days. All endpoints were adjudicated by an independent clinical events committee. RESULTS Forty high-risk patients (74.5 ± 6.7 years, 60% men; STS Score:5.6 ± 4.2%) were enrolled in 11 centres. Device success was achieved in 92.5%. The effective orifice area improved from 0.7 ± 0.2 to 2.3 ± 0.6 cm 2 at 30 days and to 2.2 ± 0.7 cm 2 at 6 months (p < .0001). Mean aortic valve gradient decreased from 53.5 ± 18.1 to 8.9 ± 4.9 mmHg at 30 days and to 7.6 ± 2.7 mmHg at 6 months (p < .0001). The rate of new permanent pacemaker implantation was 7.5% at 30 days, and no patient had more than mild paravalvular leak at 6 months. The 30 days and 6 month all-cause mortality was 10.0 and 17.5%, cardiovascular mortality 7.5 and 7.5%, device-related mortality 5.0 and 5.0%, respectively. No patients had stroke up to 6 months. CONCLUSIONS The GENESIS trial demonstrated high efficacy of the self-expanding Hydra THV. The cardiovascular mortality rate of 7.5% may partly be explained by the inclusion of some centres with no or limited previous experience in transcatheter aortic valve implantation.",2021,"The 30 days and 6 month all-cause mortality was 10.0 and 17.5%, cardiovascular mortality 7.5 and 7.5%, device-related mortality 5.0 and 5.0%, respectively.","['symptomatic severe aortic stenosis in patients at high or extreme surgical risk', 'Forty high-risk patients (74.5\u2009±\u20096.7\u2009years, 60% men; STS Score:5.6\u2009±\u20094.2%) were enrolled in 11 centres']","['Hydra transcatheter aortic valve (THV', 'Hydra self-expanding transcatheter aortic valve']","['effective orifice area', 'Mean aortic valve gradient', 'Device success', 'rate of new permanent pacemaker implantation', 'cause mortality', 'device success defined as per VARC-II criteria', 'mild paravalvular leak', 'cardiovascular mortality', 'cardiovascular mortality rate']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003507', 'cui_str': 'Aortic valve stenosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205403', 'cui_str': 'Extreme'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0020222', 'cui_str': 'Genus Hydra'}, {'cui': 'C0442343', 'cui_str': 'Transcatheter approach'}, {'cui': 'C0003501', 'cui_str': 'Aortic valve structure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444567', 'cui_str': 'Ostium'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0428905', 'cui_str': 'Aortic valve ventriculoarterial gradient'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0030163', 'cui_str': 'Cardiac pacemaker'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C1709508', 'cui_str': 'Paravalvular leak'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",,0.105533,"The 30 days and 6 month all-cause mortality was 10.0 and 17.5%, cardiovascular mortality 7.5 and 7.5%, device-related mortality 5.0 and 5.0%, respectively.","[{'ForeName': 'Praveen', 'Initials': 'P', 'LastName': 'Chandra', 'Affiliation': 'Department of cardiology, Medanta Medicity Hospital, Gurgaon, India.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Jose', 'Affiliation': 'Department of cardiology- 2, Cardiac valve and structural heart disease clinic, Christian Medical College Hospital, Vellore, India.'}, {'ForeName': 'Shafeeq', 'Initials': 'S', 'LastName': 'Mattummal', 'Affiliation': 'Department of cardiology, Aster MIMS, Calicut, India.'}, {'ForeName': 'Ajaykumar U', 'Initials': 'AU', 'LastName': 'Mahajan', 'Affiliation': 'Department of cardiology, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, India.'}, {'ForeName': 'Sajeev C', 'Initials': 'SC', 'LastName': 'Govindan', 'Affiliation': 'Department of cardiology, Government Medical College, Kozhikode, India.'}, {'ForeName': 'Chandrashekhar N', 'Initials': 'CN', 'LastName': 'Makhale', 'Affiliation': 'Department of cardiology, Ruby Hall Clinic, Pune, India.'}, {'ForeName': 'Sharad', 'Initials': 'S', 'LastName': 'Chandra', 'Affiliation': ""Department of cardiology, King George's Medical University, Lucknow, India.""}, {'ForeName': 'Ranjan', 'Initials': 'R', 'LastName': 'Shetty', 'Affiliation': 'Department of cardiology, Manipal Hospital, Bengaluru, India.'}, {'ForeName': 'Sandeep', 'Initials': 'S', 'LastName': 'Mohanan', 'Affiliation': 'Department of cardiology, KMCT Medical College, Kozhikode, India.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'John', 'Affiliation': 'Department of cardiology, Baby Memorial Hospital, Calicut, India.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Mehrotra', 'Affiliation': 'Department of cardiology, Narayana Institute of Cardiac Sciences, Bengaluru, India.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Søndergaard', 'Affiliation': 'Department of cardiology, Rigshospitalet, Copenhagen, Denmark.'}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.29733'] 3002,33873267,"Impact of prolonged sitting and physical activity breaks on cognitive performance, perceivable benefits, and cardiometabolic health in overweight/obese adults: The role of meal composition.","BACKGROUND & AIMS Physical activity (PA) breaks may effectively attenuate the detrimental impact of prolonged sitting on acute cognitive performance, perceivable benefits (e.g. mood), vascular function, and metabolic health. To date, the impact of meal composition on the effects of sedentary behavior and/or PA breaks on health has been scarcely studied. Therefore, our aim was to investigate whether meal composition alters how sedentary behavior and PA breaks affect these acute health outcomes. METHODS A total of 24 overweight and obese, sedentary adults completed four conditions in randomized order in a cross-over design: [a] high-protein, low-fat breakfast (HPLF) + 4hrs uninterrupted sitting (SIT), [b] HPLF + 4hrs interrupted sitting (ACT; 5-min cycling every 30 min), [c] Western breakfast (WEST; higher in fats/simple sugars, lower in protein/fiber) + SIT, [d] WEST + ACT. WEST and HPLF were isocaloric. Linear mixed models were used to examine changes in cognitive performance (Test of Attentional Performance), perceivable benefits (Likert-scales, Profile of Mood States questionnaire), vascular health (carotid artery reactivity, blood pressure), and metabolic health (post-breakfast glucose, insulin, lipids). RESULTS Independent of meal composition, we did not observe any effect of PA breaks on cognitive performance, vascular health and post-breakfast lipid responses. PA breaks delayed post-breakfast mood and vigor decrements, as well as increases in fatigue and sleepiness (all p < 0.05), but effects were independent of meal composition (p > 0.05). WEST resulted in higher post-breakfast glucose levels compared to HPLF (p < 0.05), while PA breaks did not impact this response (p > 0.05). PA breaks reduced post-breakfast insulin (p < 0.05), which did not differ between meals (p > 0.05). CONCLUSIONS The acute impact of PA breaks and/or prolonged sitting on cognitive performance, perceivable benefits, and vascular and metabolic health was not altered by the composition of a single meal in overweight/obese, sedentary adults. Possibly, breaking up prolonged sitting, rather than meal composition, is a more potent strategy to impact acute health outcomes, such as perceivable benefits and insulin levels.",2021,"PA breaks delayed post-breakfast mood and vigor decrements, as well as increases in fatigue and sleepiness (all p < 0.05), but effects were independent of meal composition (p > 0.05).","['24 overweight and obese, sedentary adults', 'overweight/obese adults', 'overweight/obese, sedentary adults']","['high-protein, low-fat breakfast (HPLF)\xa0+\xa04hrs uninterrupted sitting (SIT), [b] HPLF\xa0+\xa04hrs interrupted sitting (ACT; 5-min cycling every 30\xa0min), [c] Western breakfast (WEST; higher in fats/simple sugars, lower in protein/fiber)\xa0+\xa0SIT, [d] WEST\xa0+\xa0ACT', 'prolonged sitting and physical activity breaks']","['PA breaks reduced post-breakfast insulin', 'fatigue and sleepiness', 'cognitive performance, perceivable benefits, and cardiometabolic health', 'cognitive performance, perceivable benefits, and vascular and metabolic health', 'PA breaks delayed post-breakfast mood and vigor decrements', 'cognitive performance (Test of Attentional Performance), perceivable benefits (Likert-scales, Profile of Mood States questionnaire), vascular health (carotid artery reactivity, blood pressure), and metabolic health (post-breakfast glucose, insulin, lipids', 'higher post-breakfast glucose levels', 'cognitive performance, vascular health and post-breakfast lipid responses']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0443239', 'cui_str': 'Interrupted'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0026492', 'cui_str': 'Monosaccharide'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0007272', 'cui_str': 'Carotid artery structure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}]",24.0,0.0288408,"PA breaks delayed post-breakfast mood and vigor decrements, as well as increases in fatigue and sleepiness (all p < 0.05), but effects were independent of meal composition (p > 0.05).","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Wanders', 'Affiliation': 'TiFN, P.O. Box 557, 6700 AN, Wageningen, the Netherlands; Radboud Institute for Health Sciences, Department of Physiology, Radboud university medical center, Radboudumc, Department of Physiology (392), P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands. Electronic address: Lisa.Wanders@radboudumc.nl.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Cuijpers', 'Affiliation': 'Radboud Institute for Health Sciences, Department of Physiology, Radboud university medical center, Radboudumc, Department of Physiology (392), P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands.'}, {'ForeName': 'Roy P C', 'Initials': 'RPC', 'LastName': 'Kessels', 'Affiliation': 'Department of Medical Psychology, Radboud university medical center, Radboudumc, Department of Medical Psychology (925), P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University, P.O. Box 9104, 6500 HE, Nijmegen, the Netherlands.'}, {'ForeName': 'Ondine', 'Initials': 'O', 'LastName': 'van de Rest', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University & Research, Division of Human Nutrition and Health (Bode 62), P.O. Box 17, 6700 AA, Wageningen, the Netherlands.'}, {'ForeName': 'Maria T E', 'Initials': 'MTE', 'LastName': 'Hopman', 'Affiliation': 'Radboud Institute for Health Sciences, Department of Physiology, Radboud university medical center, Radboudumc, Department of Physiology (392), P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands.'}, {'ForeName': 'Dick H J', 'Initials': 'DHJ', 'LastName': 'Thijssen', 'Affiliation': 'Radboud Institute for Health Sciences, Department of Physiology, Radboud university medical center, Radboudumc, Department of Physiology (392), P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands; Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Byrom Street, L3 3AF, Liverpool, United Kingdom.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.10.006'] 3003,33881579,Quality of Recovery of Patients Who Underwent Curative Pancreatectomy: Comparison of Total Intravenous Anesthesia Versus Inhalation Anesthesia Using the QOR-40 Questionnaire.,"BACKGROUND There has been increasing attention on the subjective recovery of patients undergoing cancer surgery. Total intravenous anesthesia (TIVA) and inhaled anesthesia with volatile anesthetics (INHA) are safe and common anesthetic techniques. Currently, TIVA and INHA have only been compared for less invasive and less complex surgeries. This prospective randomized trial aimed to compare the quality of recovery between TIVA and INHA in patients undergoing pancreatoduodenectomy (PD) or distal pancreatectomy (DP) using the Quality of Recovery (QOR)-40 questionnaire. METHODS We enrolled 132 patients who were randomly assigned to either the desflurane (DES) (INHA, balanced anesthesia with DES and remifentanil infusion) or TIVA (effect-site target-controlled infusion of propofol and remifentanil) groups and completed the QOR-40 questionnaire postoperatively. RESULTS The mean global QOR-40 score on postoperative day 3 was significantly higher in the TIVA group than in the DES group. In the PD group, the total QOR-40 score was significantly higher in the TIVA group than in the DES group. Moreover, the TIVA group had significantly higher scores in the physical comfort and psychological support QOR-40 dimensions than the DES group. CONCLUSION TIVA provides better quality of recovery scores on POD 3 for patients undergoing curative pancreatectomy. CLINICAL TRIAL REGISTRATION NUMBER NCT03447691.",2021,The mean global QOR-40 score on postoperative day 3 was significantly higher in the TIVA group than in the DES group.,"['patients undergoing curative pancreatectomy', '132 patients', 'patients undergoing pancreatoduodenectomy (PD) or distal pancreatectomy (DP', 'patients undergoing cancer surgery']","['TIVA and INHA', 'TIVA', 'Total Intravenous Anesthesia Versus Inhalation Anesthesia', 'Total intravenous anesthesia (TIVA) and inhaled anesthesia with volatile anesthetics (INHA', 'desflurane (DES) (INHA, balanced anesthesia with DES and remifentanil infusion) or TIVA (effect-site target-controlled infusion of propofol and remifentanil']","['mean global QOR-40 score', 'total QOR-40 score', 'physical comfort and psychological support QOR-40 dimensions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0030279', 'cui_str': 'Pancreatectomy'}, {'cui': 'C0085162', 'cui_str': 'Pancreaticoduodenectomy'}, {'cui': 'C0176940', 'cui_str': 'Distal subtotal pancreatectomy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0473965', 'cui_str': 'Total intravenous anesthesia'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0443769', 'cui_str': 'Volatile agent'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0002917', 'cui_str': 'Anesthesia, Inhalation'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C2936341', 'cui_str': 'Balanced Anesthesia'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0600015', 'cui_str': 'Emotional support'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}]",132.0,0.124014,The mean global QOR-40 score on postoperative day 3 was significantly higher in the TIVA group than in the DES group.,"[{'ForeName': 'Young-Eun', 'Initials': 'YE', 'LastName': 'Joe', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-Gu, Seoul, 03722, Korea.'}, {'ForeName': 'Chang Moo', 'Initials': 'CM', 'LastName': 'Kang', 'Affiliation': 'Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-Gu, Seoul, 03722, Korea.'}, {'ForeName': 'Hye-Mi', 'Initials': 'HM', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-Gu, Seoul, 03722, Korea.'}, {'ForeName': 'Ki-Jun', 'Initials': 'KJ', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-Gu, Seoul, 03722, Korea.'}, {'ForeName': 'Ho Kyoung', 'Initials': 'HK', 'LastName': 'Hwang', 'Affiliation': 'Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-Gu, Seoul, 03722, Korea. DRHHK@yuhs.ac.'}, {'ForeName': 'Jeong-Rim', 'Initials': 'JR', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-Gu, Seoul, 03722, Korea. leejeongrim@gmail.com.'}]",World journal of surgery,['10.1007/s00268-021-06117-0'] 3004,34385828,The Impact of the One-Day Clinic Diabetes Mellitus Management Model on Perinatal Outcomes in Patients with Gestational Diabetes Mellitus.,"Objective The aim of the present study was to explore the impact of the one-day clinic diabetes mellitus (DM) management model on perinatal outcomes in patients with gestational diabetes mellitus (GDM). Methods A total of 995 patients who underwent prenatal checkups at our hospital and were diagnosed with GDM by oral glucose tolerance test (OGTT) screening at 24-28 weeks of gestational age were enrolled between December 2018 and August 2020. The patients were randomly divided into a study group (541 cases) and a control group (454 cases). One-day clinic intervention for DM was conducted in the study group, while individualized dietary interventions and exercise instruction were given in the control group. The perinatal outcomes of patients were compared between the two groups. Results In the study group, maternal weight gain, fasting blood glucose before delivery, the incidence of abnormality in postpartum OGTT, and abnormality of pancreatic islet function were lower than in the control group, and the differences were statistically significant ( P < 0.05). The percentage of patients with insulin treatment in the study group was higher than in the control group, and the difference was statistically significant ( P < 0.05). The incidence of premature rupture of membranes, macrosomia, and neonatal jaundice was lower in the study group than in the control group, and the differences were statistically significant ( P < 0.05). Conclusion The one-day clinic DM management model can effectively control weight gain and blood glucose levels during pregnancy in patients with GDM, resulting in a higher recovery rate of blood glucose and islet function after delivery and a lower incidence of premature rupture of membranes, macrosomia, and neonatal jaundice. The one-day clinic DM management model could therefore have profound implications for reducing and delaying the onset of postpartum type 2 diabetes in patients with GDM.",2021,"The incidence of premature rupture of membranes, macrosomia, and neonatal jaundice was lower in the study group than in the control group, and the differences were statistically significant ( P < 0.05). ","['Patients with Gestational Diabetes Mellitus', '995 patients who underwent prenatal checkups at our hospital and were diagnosed with GDM by oral glucose tolerance test (OGTT) screening at 24-28 weeks of gestational age were enrolled between December 2018 and August 2020', 'patients with GDM', 'patients with gestational diabetes mellitus (GDM']","['one-day clinic diabetes mellitus (DM) management model', 'One-Day Clinic Diabetes Mellitus Management Model', 'individualized dietary interventions and exercise instruction']","['incidence of premature rupture of membranes, macrosomia, and neonatal jaundice', 'maternal weight gain, fasting blood glucose before delivery, the incidence of abnormality in postpartum OGTT, and abnormality of pancreatic islet function', 'control weight gain and blood glucose levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0948092', 'cui_str': 'Diabetes mellitus management'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0015944', 'cui_str': 'Premature rupture of membranes'}, {'cui': 'C0158915', 'cui_str': 'Exceptionally large at birth'}, {'cui': 'C0022353', 'cui_str': 'Neonatal jaundice'}, {'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0022131', 'cui_str': 'Endocrine pancreatic structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}]",995.0,0.0121337,"The incidence of premature rupture of membranes, macrosomia, and neonatal jaundice was lower in the study group than in the control group, and the differences were statistically significant ( P < 0.05). ","[{'ForeName': 'Yan-Min', 'Initials': 'YM', 'LastName': 'Cao', 'Affiliation': ""Department of Internal Medicine, The Fourth Hospital of Shijiazhuang (Maternal Hospital Affiliated to Hebei Medical University), Shijiazhuang, 050000, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""Department of Internal Medicine, The Fourth Hospital of Shijiazhuang (Maternal Hospital Affiliated to Hebei Medical University), Shijiazhuang, 050000, People's Republic of China.""}, {'ForeName': 'Na-Na', 'Initials': 'NN', 'LastName': 'Cai', 'Affiliation': ""Department of Internal Medicine, The Fourth Hospital of Shijiazhuang (Maternal Hospital Affiliated to Hebei Medical University), Shijiazhuang, 050000, People's Republic of China.""}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Ma', 'Affiliation': ""Department of Internal Medicine, The Fourth Hospital of Shijiazhuang (Maternal Hospital Affiliated to Hebei Medical University), Shijiazhuang, 050000, People's Republic of China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Department of Internal Medicine, The Fourth Hospital of Shijiazhuang (Maternal Hospital Affiliated to Hebei Medical University), Shijiazhuang, 050000, People's Republic of China.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': ""Department of Internal Medicine, The Fourth Hospital of Shijiazhuang (Maternal Hospital Affiliated to Hebei Medical University), Shijiazhuang, 050000, People's Republic of China.""}, {'ForeName': 'Lian', 'Initials': 'L', 'LastName': 'Xue', 'Affiliation': ""Department of Internal Medicine, The Fourth Hospital of Shijiazhuang (Maternal Hospital Affiliated to Hebei Medical University), Shijiazhuang, 050000, People's Republic of China.""}, {'ForeName': 'Yuan-Yuan', 'Initials': 'YY', 'LastName': 'Liu', 'Affiliation': ""Department of Internal Medicine, The Fourth Hospital of Shijiazhuang (Maternal Hospital Affiliated to Hebei Medical University), Shijiazhuang, 050000, People's Republic of China.""}]","Diabetes, metabolic syndrome and obesity : targets and therapy",['10.2147/DMSO.S316878'] 3005,34385827,The Combined Use of a Non-Invasive Skin-Stretching Device and the Negative-Pressure Wound Therapy Technique in the Treatment of Postoperative Diabetic Foot.,"Objective The present study explored the effectiveness of using a non-invasive skin-stretching device (NSSD) combined with negative-pressure wound therapy (NPWT) for the postoperative wound repair of diabetic foot (DF) gangrene. Methods The treatment group in this study involved 42 patients with Wagner grade 3-4 DF and undergone concomitant toe amputation or debridement, who were given NPWT combined with the use of a NSSD. The control group comprised 42 patients with similar trauma areas (±20%) that were matched at a ratio of 1:1. Following surgery, these patients received NPWT combined with the use of conventional dressings. A comparison was made of the postoperative wound healing rates and wound healing times of the two groups, with Kaplan-Meier survival analysis being used to compare the healing rate over time. Results The three-month wound healing rate was higher in the treatment group than in the control group (38 of 42 [90.5%] vs 25 of 42 [59.5%], p = 0.002), and the wound healing time was shorter in the treatment group (44 days [95% CI 40.0-48.0]) than that in the control group (76 days [95% CI 63.0-89.0], p = 0.000). Taking the end of the final NPWT as the starting point, the comparison of wound healing time revealed that this period was shorter in the treatment group than that in the control group and the difference was statistically significant (11 days [95% CI 9.0-13.0] vs 42 days [95% CI 23.0-ND], p = 0.000). Conclusion The use of the NPWT technique combined with a NSSD can shorten the wound healing time and improve the wound healing rate of DF gangrene patients during the postoperative wound repair period.",2021,The use of the NPWT technique combined with a NSSD can shorten the wound healing time and improve the wound healing rate of DF gangrene patients during the postoperative wound repair period.,"['42 patients with Wagner grade 3-4 DF and undergone concomitant toe amputation or debridement, who were given NPWT combined with the use of a NSSD', '42 patients with similar trauma areas (±20%) that were matched at a ratio of 1:1', 'Postoperative Diabetic Foot']","['NPWT technique combined with a NSSD', 'NPWT', 'Non-Invasive Skin-Stretching Device and the Negative-Pressure Wound Therapy Technique', 'non-invasive skin-stretching device (NSSD) combined with negative-pressure wound therapy (NPWT']","['healing rate over time', 'wound healing time', 'wound healing rate', 'postoperative wound healing rates and wound healing times']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0206172', 'cui_str': 'Diabetic foot'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0188602', 'cui_str': 'Amputation of toe'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0558242', 'cui_str': 'Stretched skin'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]","[{'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0558242', 'cui_str': 'Stretched skin'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",42.0,0.0139103,The use of the NPWT technique combined with a NSSD can shorten the wound healing time and improve the wound healing rate of DF gangrene patients during the postoperative wound repair period.,"[{'ForeName': 'Liangchen', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Department of Endocrinology, Air Force Medical Center, PLA, Beijing, 100142, People's Republic of China.""}, {'ForeName': 'Chenrui', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': ""Department of Endocrinology, Air Force Medical Center, PLA, Beijing, 100142, People's Republic of China.""}, {'ForeName': 'Hongmei', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': ""Department of Endocrinology, Air Force Medical Center, PLA, Beijing, 100142, People's Republic of China.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ""Department of Endocrinology, Air Force Medical Center, PLA, Beijing, 100142, People's Republic of China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""Department of Endocrinology, Air Force Medical Center, PLA, Beijing, 100142, People's Republic of China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Xiao', 'Affiliation': ""Department of Endocrinology, Air Force Medical Center, PLA, Beijing, 100142, People's Republic of China.""}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Zhu', 'Affiliation': ""Department of Endocrinology, Air Force Medical Center, PLA, Beijing, 100142, People's Republic of China.""}, {'ForeName': 'Caizhe', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': ""Department of Endocrinology, Air Force Medical Center, PLA, Beijing, 100142, People's Republic of China.""}]","Diabetes, metabolic syndrome and obesity : targets and therapy",['10.2147/DMSO.S322757'] 3006,33877707,The Effect of Bolus Vitamin D 3 Supplementation on Distal Radius Fracture Healing: A Randomized Controlled Trial Using HR-pQCT.,"Vitamin D is an important factor in bone metabolism. Animal studies have shown a positive effect of vitamin D 3 supplementation on fracture healing, but evidence from clinical trials is inconclusive. A randomized controlled trial was performed to assess the effects of vitamin D 3 supplementation on fracture healing using HR-pQCT-based outcome parameters. Thirty-two postmenopausal women with a conservatively treated distal radius fracture were included within 2 weeks postfracture and randomized to a low-dose (N = 10) and a high-dose (N = 11) vitamin D intervention group receiving a 6-week bolus dose, equivalent to 700 and 1800 IU vitamin D 3 supplementation per day, respectively, in addition to a control group (N = 11) receiving no supplementation. After the baseline visit 1-2 weeks postfracture, follow-up visits were scheduled at 3-4, 6-8, and 12 weeks postfracture. At each visit, HR-pQCT scans of the fractured radius were performed. Cortical and trabecular bone density and microarchitectural parameters and microfinite element analysis-derived torsion, compression, and bending stiffness were assessed. Additionally, serum markers of bone resorption (CTX) and bone formation (PINP) were measured. Baseline serum levels of 25OHD 3 were <50 nmol/L in 33% of all participants and <75 nmol/L in 70%. Compared with the control group, high-dose vitamin D 3 supplementation resulted in a decreased trabecular number (regression coefficient β: -0.22; p < 0.01) and lower compression stiffness (B: -3.63; p < 0.05, together with an increase in the bone resorption marker CTX (B: 0.062; p < 0.05). No statistically significant differences were observed between the control and low-dose intervention group. In conclusion, the bolus equivalent of 700 U/day vitamin D 3 supplementation in a Western postmenopausal population does not improve distal radius fracture healing and an equivalent dose of 1800 IU/day may be detrimental in restoring bone stiffness during the first 12 weeks of fracture healing. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).",2021,"Compared to the control group, high-dose vitamin D 3 supplementation resulted in a decreased trabecular number (regression coefficient B: -0.22; p < 0.01) and lower compression stiffness (B: -3.63; p < 0.05, together with an increase in the bone resorption marker CTX (B: 0.062; p < 0.05).","['Distal Radius Fracture Healing', 'Thirty-two postmenopausal women with a conservatively treated distal radius fracture']","['Vitamin D', 'vitamin D intervention group receiving a 6-week bolus dose, equivalent to 700 and 1,800\u2009IU vitamin D 3 supplementation per day respectively, in addition to a control group (N\xa0=\xa011) receiving no supplementation', 'Bolus Vitamin D 3 Supplementation', 'vitamin D 3 supplementation', 'HR-pQCT']","['bone resorption marker CTX', 'lower compression stiffness', 'fracture healing', 'serum markers of bone resorption (C-terminal telopeptide of type I collagen; CTX) and bone formation', 'restoring bone stiffness', 'Baseline serum levels of 25(OH)D3', 'trabecular number', 'distal radius fracture healing', 'Cortical and trabecular bone density and microarchitectural parameters and μFEA derived torsion, compression and bending stiffness']","[{'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C0152231', 'cui_str': 'Fracture, healed'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0152231', 'cui_str': 'Fracture, healed'}, {'cui': 'C0162491', 'cui_str': 'Marker, Serum'}, {'cui': 'C1101784', 'cui_str': 'ICTP peptide'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0222660', 'cui_str': 'Trabecular substance of bone'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0040480', 'cui_str': 'Torsion'}, {'cui': 'C0011119', 'cui_str': 'Bends'}]",32.0,0.151407,"Compared to the control group, high-dose vitamin D 3 supplementation resulted in a decreased trabecular number (regression coefficient B: -0.22; p < 0.01) and lower compression stiffness (B: -3.63; p < 0.05, together with an increase in the bone resorption marker CTX (B: 0.062; p < 0.05).","[{'ForeName': 'Frans L', 'Initials': 'FL', 'LastName': 'Heyer', 'Affiliation': 'NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Joost Ja', 'Initials': 'JJ', 'LastName': 'de Jong', 'Affiliation': 'MHeNs School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Willems', 'Affiliation': 'CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Jacobus J', 'Initials': 'JJ', 'LastName': 'Arts', 'Affiliation': 'CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Sandrine G P', 'Initials': 'SGP', 'LastName': 'Bours', 'Affiliation': 'CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Sander M J', 'Initials': 'SMJ', 'LastName': 'van Kuijk', 'Affiliation': 'Department of Clinical Epidemiology & Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Judith A P', 'Initials': 'JAP', 'LastName': 'Bons', 'Affiliation': 'Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Martijn', 'Initials': 'M', 'LastName': 'Poeze', 'Affiliation': 'NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Piet P', 'Initials': 'PP', 'LastName': 'Geusens', 'Affiliation': 'CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Bert', 'Initials': 'B', 'LastName': 'van Rietbergen', 'Affiliation': 'CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Joop P', 'Initials': 'JP', 'LastName': 'van den Bergh', 'Affiliation': 'NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.4311'] 3007,33877311,Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.,"Importance Elevated expression of AURKA adversely affects prognosis in estrogen receptor (ER)-positive and ERBB2 (formerly HER2)-negative and triple-negative breast cancer and is associated with resistance to taxanes. Objective To compare paclitaxel alone vs paclitaxel plus alisertib in patients with ER-positive and ERBB2-negative or triple-negative metastatic breast cancer (MBC). Design, Setting, and Participants In this randomized clinical trial conducted with the US Oncology Network, participants were randomized to intravenous (IV) paclitaxel 90 mg/m2 on days 1, 8, and 15 on a 28-day cycle or IV paclitaxel 60 mg/m2 on days 1, 8, and 15 plus oral alisertib 40 mg twice daily on days 1 to 3, 8 to 10, and 15 to 17 on a 28-day cycle. Stratification was by prior neo or adjuvant taxane and by line of metastatic therapy. Eligible patients were those who had undergone endocrine therapy, 0 or 1 prior chemotherapy regimens for MBC, more than 12 months treatment-free interval from neo or adjuvant taxane therapy, and with measurable or evaluable lytic bone-disease. Data were analyzed from March 2019 through May 2019. Main Outcomes and Measures The main outcome was progression-free survival (PFS) with secondary end points of overall survival (OS), overall response rate, clinical benefit rate, safety, and analysis of archival breast cancer tissues for molecular markers associated with benefit from alisertib. Results A total of 174 patients were randomized, including with 86 randomized to paclitaxel and 88 patients randomized to paclitaxel plus alisertib, and 169 patients received study treatment. The final cohort included 139 patients with a median (interquartile range [IQR]) age of 62 (27-84) years with ER-positive and ERBB2-negative MBC, with 70 randomized to paclitaxel and 69 randomized to paclitaxel plus alisertib. The TNBC cohort closed with only 35 patients enrolled due to slow accrual and were not included in efficacy analyses. The median (IQR) follow-up was 22 (10.6-25.1) months, and median (IQR) PFS was 10.2 (3.8-15.7) months with paclitaxel plus alisertib vs 7.1 (3.8-10.6) months with paclitaxel alone (HR, 0.56; 95% CI, 0.37-0.84; P = .005). Median (IQR) OS was 26.3 (12.4-37.2) months for patients who received paclitaxel plus alisertib vs 25.1 (11.0-31.4) months for paclitaxel alone (HR, 0.89; 95% CI, 0.58-1.38; P = .61). Grade 3 or 4 adverse events occurred in 56 patients (84.8%) receiving paclitaxel plus alisertib vs 34 patients (48.6%) receiving paclitaxel alone. The main grade 3 or 4 adverse events with paclitaxel plus alisertib vs paclitaxel alone were neutropenia (50 patients [59.5%] vs 14 patients [16.4%]), anemia (8 patients [9.5%] vs 1 patient [1.2%]), diarrhea (9 patients [10.7%] vs 0 patients), and stomatitis or oral mucositis (13 patients [15.5%] vs 0 patients). One patient receiving paclitaxel plus alisertib died of sepsis. Conclusions and Relevance This randomized clinical trial found that the addition of oral alisertib to a reduced dose of weekly paclitaxel significantly improved PFS compared with paclitaxel alone, and toxic effects with paclitaxel plus alisertib were manageable with alisertib dose reduction. These data support further evaluation of alisertib in patients with ER-positive, ERBB2-negative MBC. Trial Registration ClinicalTrials.gov Identifier: NCT02187991.",2021,Grade 3 or 4 adverse events occurred in 56 patients (84.8%) receiving paclitaxel plus alisertib vs 34 patients (48.6%) receiving paclitaxel alone.,"['patients with ER-positive, ERBB2-negative MBC', 'A total of 174 patients', 'Patients', ' and 169 patients received study treatment', 'With Metastatic Breast Cancer', 'Eligible patients were those who had undergone endocrine therapy, 0 or 1 prior chemotherapy regimens for MBC, more than 12 months treatment-free interval from neo or adjuvant taxane therapy, and with measurable or evaluable lytic bone-disease', '139 patients with a median (interquartile range [IQR]) age of 62 (27-84) years with ER-positive and ERBB2-negative MBC, with 70 randomized to', 'patients with ER-positive and ERBB2-negative or triple-negative metastatic breast cancer (MBC']","['paclitaxel', 'paclitaxel plus alisertib', 'Weekly Paclitaxel With or Without Oral Alisertib', 'paclitaxel alone vs paclitaxel plus alisertib', 'paclitaxel plus alisertib vs paclitaxel', 'intravenous (IV) paclitaxel']","['Median (IQR) OS', 'overall survival (OS), overall response rate, clinical benefit rate, safety, and analysis of archival breast cancer tissues for molecular markers associated with benefit from alisertib', 'Efficacy and Safety', 'stomatitis or oral mucositis', 'diarrhea', 'Grade 3 or 4 adverse events', 'PFS', 'anemia', 'neutropenia', 'median (IQR) PFS', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0279754', 'cui_str': 'ESR1 positive'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0215136', 'cui_str': 'taxane'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0024348', 'cui_str': 'Lysis'}, {'cui': 'C0005940', 'cui_str': 'Disorder of bone'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205174', 'cui_str': 'Triple'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0038362', 'cui_str': 'Stomatitis'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}]",139.0,0.596147,Grade 3 or 4 adverse events occurred in 56 patients (84.8%) receiving paclitaxel plus alisertib vs 34 patients (48.6%) receiving paclitaxel alone.,"[{'ForeName': 'Joyce', 'Initials': 'J', 'LastName': ""O'Shaughnessy"", 'Affiliation': 'Baylor University Medical Center, Dallas, Texas.'}, {'ForeName': 'Kristi', 'Initials': 'K', 'LastName': 'McIntyre', 'Affiliation': 'Texas Oncology, Dallas.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Wilks', 'Affiliation': 'Texas Oncology, Dallas.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Ma', 'Affiliation': 'US Oncology, Houston, Texas.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Block', 'Affiliation': 'US Oncology, Houston, Texas.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Andorsky', 'Affiliation': 'US Oncology, Houston, Texas.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Danso', 'Affiliation': 'US Oncology, Houston, Texas.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Locke', 'Affiliation': 'US Oncology, Houston, Texas.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Scales', 'Affiliation': 'US Oncology, Houston, Texas.'}, {'ForeName': 'Yunfei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'US Oncology, Houston, Texas.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.4103'] 3008,33868172,Obesity and Dietary Added Sugar Interact to Affect Postprandial GLP-1 and Its Relationship to Striatal Responses to Food Cues and Feeding Behavior.,"It has been hypothesized that the incretin hormone, glucagon-like peptide-1 (GLP-1), decreases overeating by influencing mesolimbic brain regions that process food-cues, including the dorsal striatum. We previously showed that habitual added sugar intake was associated with lower glucose-induced circulating GLP-1 and a greater striatal response to high calorie food cues in lean individuals. Less is known about how dietary added sugar and obesity may interact to affect postprandial GLP-1 and its relationship to striatal responses to food cues and feeding behavior. The current study aimed to expand upon previous research by assessing how circulating GLP-1 and striatal food cue reactivity are affected by acute glucose consumption in participants with varied BMIs and amounts of habitual consumption of added sugar. This analysis included 72 participants from the Brain Response to Sugar Study who completed two study visits where they consumed either plain water or 75g glucose dissolved in water (order randomized; both drinks were flavored with non-caloric cherry flavoring) and underwent repeated blood sampling, a functional magnetic resonance imaging (fMRI) based food-cue task, and an ad-libitum buffet meal. Correlations between circulating GLP-1 levels, striatal food-cue reactivity, and food intake were assessed, and interactions between obesity and added sugar on GLP-1 and striatal responses were examined. An interaction between BMI and dietary added sugar was associated with reduced post-glucose GLP-1 secretion. Participants who were obese and consumed high levels of added sugar had the smallest increase in plasma GLP-1 levels. Glucose-induced GLP-1 secretion was correlated with lower dorsal striatal reactivity to high-calorie versus low-calorie food-cues, driven by an increase in reactivity to low calorie food-cues. The increase in dorsal striatal reactivity to low calorie food-cues was negatively correlated with sugar consumed at the buffet. These findings suggest that an interaction between obesity and dietary added sugar intake is associated with additive reductions in postprandial GLP-1 secretion. Additionally, the results suggest that changes to dorsal striatal food cue reactivity through a combination of dietary added sugar and obesity may affect food consumption.",2021,"Glucose-induced GLP-1 secretion was correlated with lower dorsal striatal reactivity to high-calorie versus low-calorie food-cues, driven by an increase in reactivity to low calorie food-cues.","['72 participants from the Brain Response to Sugar Study who completed two study visits', 'participants with varied BMIs and amounts of habitual consumption of added sugar']","['plain water or 75g glucose dissolved in water (order randomized; both drinks were flavored with non-caloric cherry flavoring) and underwent repeated blood sampling, a functional magnetic resonance imaging (fMRI) based food-cue task, and an ad-libitum buffet meal']","['postprandial GLP-1 secretion', 'dorsal striatal reactivity', 'plasma GLP-1 levels', 'circulating GLP-1 levels, striatal food-cue reactivity, and food intake', 'Glucose-induced GLP-1 secretion']","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}]","[{'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C1549535', 'cui_str': 'Dissolve'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0682897', 'cui_str': 'Flavor Enhancers'}, {'cui': 'C0330657', 'cui_str': 'Prunus cerasus'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C1278023', 'cui_str': 'Plasma glucagon measurement'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]",72.0,0.0394612,"Glucose-induced GLP-1 secretion was correlated with lower dorsal striatal reactivity to high-calorie versus low-calorie food-cues, driven by an increase in reactivity to low calorie food-cues.","[{'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Jones', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Keck School of Medicine, University of Southern California, Los\xa0Angeles, CA, United States.'}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Luo', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Keck School of Medicine, University of Southern California, Los\xa0Angeles, CA, United States.'}, {'ForeName': 'Hilary M', 'Initials': 'HM', 'LastName': 'Dorton', 'Affiliation': 'Keck School of Medicine, Diabetes and Obesity Research Institute, University of Southern California, Los Angeles, CA, United States.'}, {'ForeName': 'Alexandra G', 'Initials': 'AG', 'LastName': 'Yunker', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Keck School of Medicine, University of Southern California, Los\xa0Angeles, CA, United States.'}, {'ForeName': 'Brendan', 'Initials': 'B', 'LastName': 'Angelo', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Keck School of Medicine, University of Southern California, Los\xa0Angeles, CA, United States.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Defendis', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Keck School of Medicine, University of Southern California, Los\xa0Angeles, CA, United States.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Monterosso', 'Affiliation': 'Department of Psychology, University of Southern California, Los Angeles, CA, United States.'}, {'ForeName': 'Kathleen A', 'Initials': 'KA', 'LastName': 'Page', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Keck School of Medicine, University of Southern California, Los\xa0Angeles, CA, United States.'}]",Frontiers in endocrinology,['10.3389/fendo.2021.638504'] 3009,34385825,Effects of Short-Term Dietary Fiber Intervention on Gut Microbiota in Young Healthy People.,"Gut microbiota are critical to many aspects of human health including immune and metabolic health. Long-term diet influences the community structure and activity of the trillions of microorganisms residing in the human gut, but it remains unclear how the human gut microbiome responds to short-term intervention with dietary fiber. This study explored the effects of mixed dietary fibers on gut microbiota in young, healthy people. Twelve healthy, young adults participated in a randomized, crossover trial comparing the effects of polyglucan, inulin and resistant malt dextrin on gut microbiota composition and bacterial abundances. During the study, the subjects followed their normal diets without any constraints. Microbial community profiles were determined by absolute quantification 16S rRNA gene amplicon sequencing. Mixed model analysis did not reveal an effect of dietary intervention on microbial community structure. At the genus level, dietary fiber intervention for 4 days significantly promoted the growth of Alloprevotella, Parabacteroides and Parasutterella and inhibited the growth of Adlercreutzia, Anaerovorax, Enterococcus, Intestinibacter and Ruminococcus 2 compared with the baseline. Addition of whey albumen powder for 4 days promoted the growth of Corynebacterium, Collinsella, Olsenella and Lactococcus but interfered with the growth of Megasphaera . Our results should be corroborated by randomized clinical trials with large sample size.",2021,"At the genus level, dietary fiber intervention for 4 days significantly promoted the growth of Alloprevotella, Parabacteroides and Parasutterella and inhibited the growth of Adlercreutzia, Anaerovorax, Enterococcus, Intestinibacter and Ruminococcus 2 compared with the baseline.","['Twelve healthy, young adults', 'young, healthy people', 'Young Healthy People']","['mixed dietary fibers', 'dietary intervention', 'polyglucan, inulin and resistant malt dextrin', 'whey albumen powder', 'Short-Term Dietary Fiber Intervention']","['growth of Alloprevotella, Parabacteroides and Parasutterella and inhibited the growth of Adlercreutzia, Anaerovorax, Enterococcus, Intestinibacter and Ruminococcus 2', 'Gut Microbiota', 'growth of Corynebacterium, Collinsella, Olsenella and Lactococcus', 'gut microbiota composition and bacterial abundances']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0024651', 'cui_str': 'Malt'}, {'cui': 'C0011808', 'cui_str': 'Dextrins'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C1927848', 'cui_str': 'Parabacteroides'}, {'cui': 'C2660976', 'cui_str': 'Parasutterella'}, {'cui': 'C2280992', 'cui_str': 'Adlercreutzia'}, {'cui': 'C1051340', 'cui_str': 'Anaerovorax'}, {'cui': 'C0085494', 'cui_str': 'Genus Enterococcus'}, {'cui': 'C0318074', 'cui_str': 'Ruminococcus'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0010148', 'cui_str': 'Corynebacterium'}, {'cui': 'C1047126', 'cui_str': 'Collinsella'}, {'cui': 'C1064749', 'cui_str': 'Olsenella'}, {'cui': 'C0085549', 'cui_str': 'Lactococcus'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}]",12.0,0.0263411,"At the genus level, dietary fiber intervention for 4 days significantly promoted the growth of Alloprevotella, Parabacteroides and Parasutterella and inhibited the growth of Adlercreutzia, Anaerovorax, Enterococcus, Intestinibacter and Ruminococcus 2 compared with the baseline.","[{'ForeName': 'Tian', 'Initials': 'T', 'LastName': 'Tian', 'Affiliation': ""Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, 830001, People's Republic of China.""}, {'ForeName': 'Xiaobo', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, 830001, People's Republic of China.""}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Luo', 'Affiliation': ""Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, 830001, People's Republic of China.""}, {'ForeName': 'Duolao', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, L35QAUK, UK.'}, {'ForeName': 'Yuping', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': ""School of Basic Medicine, Xinjiang Medical University, Urumqi, 830001, People's Republic of China.""}, {'ForeName': 'Jianghong', 'Initials': 'J', 'LastName': 'Dai', 'Affiliation': ""Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, 830001, People's Republic of China.""}]","Diabetes, metabolic syndrome and obesity : targets and therapy",['10.2147/DMSO.S313385'] 3010,31553134,"Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects.","Azilsartan (AZL), the active metabolite of azilsartan medoxomil, is the newest angiotensin receptor blocker that has been approved for the treatment of hypertension in 2012 in Japan. The present study aimed to evaluate the safety and pharmacokinetic properties of AZL in healthy Chinese subjects. We performed 2 phase 1 studies to investigate the pharmacokinetics and safety of AZL in healthy Chinese adults after a single dose (20 mg or 40 mg) or multiple doses of AZL (40 mg/d for 7 days; Study I) and after a single 40-mg dose under the fasted and fed conditions (Study II). Noncompartmental analysis and nonlinear mixed-effects modeling were used to analyze the pharmacokinetic properties of AZL. Twenty-seven healthy volunteers (14 men and 13 women) aged 20-32 years were enrolled and completed the study. During single dosing of AZL, the pharmacokinetics of AZL exhibited a linear profile between dosage and area under the concentration-time curve. There is no AZL accumulation after multiple doses. Food had no effect on the pharmacokinetic characteristics of AZL. AZL concentrations were best fit with a 2-compartment model, and the typical value of clearance was 1.63 L/h. Body weight had an impact on both the apparent clearance and peripheral volume of distribution. The pharmacokinetic parameters were consistent with previous studies in non-Chinese subjects. Model-based simulations indicated that a 45-kg subject would have approximately double the AZL exposure of a 90-kg subject. Whether the exposure difference has clinical significance needs to be confirmed in further studies among patients.",2020,Food had no effect on the pharmacokinetic characteristics of AZL.,"['Twenty-seven healthy volunteers (14 men and 13 women) aged 20-32\xa0years were enrolled and completed the study', 'hypertension in 2012 in Japan', 'Healthy Chinese Subjects', 'healthy Chinese adults', 'healthy Chinese subjects']","['AZL', 'Azilsartan', 'Azilsartan (AZL']","['AZL concentrations', 'Body weight', 'pharmacokinetic characteristics of AZL']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1958569', 'cui_str': 'azilsartan'}]","[{'cui': 'C1958569', 'cui_str': 'azilsartan'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",27.0,0.0156898,Food had no effect on the pharmacokinetic characteristics of AZL.,"[{'ForeName': 'Xiaojiao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Jingrui', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Changcheng', 'Initials': 'C', 'LastName': 'Sheng', 'Affiliation': 'Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Dongyang', 'Initials': 'D', 'LastName': 'Cui', 'Affiliation': 'Jiangsu Hengrui Medicine Co Ltd, Jiangsu, China.'}, {'ForeName': 'Guiling', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Xiaoxue', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Cuiyun', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Zhenwei', 'Initials': 'Z', 'LastName': 'Shen', 'Affiliation': 'First Hospital and Institute of Immunology, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Yingjie', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'School of Life Sciences, Jilin University, Jilin, China.'}, {'ForeName': 'Yanhua', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Jiao', 'Affiliation': 'Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.735'] 3011,31610101,A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV-0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers.,"Orally administered riluzole extends survival in patients with amyotrophic lateral sclerosis, although it has significant shortcomings (eg, adverse events, dysphagic patients) that limit its utility. BHV-0223 is a Zydis-based orally disintegrating formulation of riluzole designed for sublingual administration that addresses the limitations of conventional tablets. This study assessed the bioequivalence between 40-mg BHV-0223 and standard 50-mg oral riluzole tablets, and the food effect on BHV-0223 pharmacokinetics in healthy volunteers. Overall, 133 healthy subjects received BHV-0223 and riluzole tablets under fasted conditions. Geometric mean ratios for the area under the plasma concentration-time curve (AUC) from time zero to time of last nonzero concentration (AUC 0-t ) (89.9%; confidence interval [CI], 87.3%-92.5%), AUC from time zero to infinity (AUC 0-∞ ) (89.8%; CI, 87.3%-92.4%), and maximum observed concentration (112.7%; CI, 105.5%-120.4%) all met bioequivalence criteria (80%-125%). Subsequently, 67 subjects received BHV-0223 under fed conditions. The geometric mean ratios of AUC 0-t (91.2%; CI, 88.1-94.3%), and AUC 0-∞ (92.0%; CI, 89.0-95.1%) were similar, but maximum observed concentration ratios were not within bioequivalence criteria. BHV-0223 was well tolerated. This study demonstrated that 40-mg sublingual BHV-0223 is bioequivalent to 50-mg oral riluzole tablets.",2020,"The geometric mean ratios of AUC 0-t (91.2%; CI, 88.1-94.3%), and AUC 0-∞ (92.0%; CI, 89.0-95.1%) were similar, but maximum observed concentration ratios were not within bioequivalence criteria.","['133 healthy subjects received', 'Healthy Volunteers', 'patients with amyotrophic lateral sclerosis', 'healthy volunteers', '67 subjects received BHV-0223 under fed conditions']","['BHV-0223 and riluzole tablets', 'riluzole', 'Sublingual Riluzole (BHV-0223', '40-mg BHV-0223 and standard 50-mg oral riluzole tablets', 'Riluzole']","['concentration ratios', 'Geometric mean ratios for the area under the plasma concentration-time curve (AUC', 'geometric mean ratios of AUC 0-t', 'tolerated']","[{'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002736', 'cui_str': 'Amyotrophic lateral sclerosis'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C1247857', 'cui_str': 'Riluzole Oral Tablet'}, {'cui': 'C0073379', 'cui_str': 'Riluzole'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",133.0,0.145576,"The geometric mean ratios of AUC 0-t (91.2%; CI, 88.1-94.3%), and AUC 0-∞ (92.0%; CI, 89.0-95.1%) were similar, but maximum observed concentration ratios were not within bioequivalence criteria.","[{'ForeName': 'Irfan', 'Initials': 'I', 'LastName': 'Qureshi', 'Affiliation': 'Biohaven Pharmaceuticals, Inc., New Haven, Connecticut, USA.'}, {'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'Lovegren', 'Affiliation': 'Biohaven Pharmaceuticals, Inc., New Haven, Connecticut, USA.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Wirtz', 'Affiliation': 'Biohaven Pharmaceuticals, Inc., New Haven, Connecticut, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Larouche', 'Affiliation': 'Syneos Health Montréal, Quebec, Canada.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Tanguay', 'Affiliation': 'Syneos Health Montréal, Quebec, Canada.'}, {'ForeName': 'Matt S', 'Initials': 'MS', 'LastName': 'Anderson', 'Affiliation': 'Certara, Princeton, New Jersey, USA.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Hartmann', 'Affiliation': 'Certara, Princeton, New Jersey, USA.'}, {'ForeName': 'Vlad', 'Initials': 'V', 'LastName': 'Coric', 'Affiliation': 'Biohaven Pharmaceuticals, Inc., New Haven, Connecticut, USA.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Berman', 'Affiliation': 'Biohaven Pharmaceuticals, Inc., New Haven, Connecticut, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.747'] 3012,33884661,Effect of Neem (Azadirachta indica) versus 2.5% sodium hypochlorite as root canal irrigants on the intensity of post-operative pain and the amount of endotoxins in mandibular molars with necrotic pulps: a randomized controlled trial.,"AIM To assess the effect of Neem versus 2.5% NaOCl as root canal irrigants on the intensity of post-operative pain and amount of endotoxins following root canal treatment of mandibular molars with necrotic pulps. METHODOLOGY This parallel, prospective, double-blinded, randomized controlled trial with allocation ratio 1:1 was conducted in the out-patient clinic of the Endodontic Department, Faculty of Dentistry, Cairo University, Egypt. Fifty healthy patients with mandibular molars with necrotic pulps were randomly assigned into two equal groups using computer software. In the intervention group, root canals were irrigated using Neem; whilst 2.5% NaOCl was used in the control group. A standard root canal treatment was performed in two visits using ProTaper Next rotary files, with no intracanal medication. Pain intensity was assessed using a numerical rating scale (NRS) 6, 12, 24 and 48 h following instrumentation and canal filling. Endotoxin samples were collected using three paper points before and after canal instrumentation and a sandwich ELISA method was used to quantify the level of endotoxins. Demographic, baseline, and outcome data were collected and analysed using chi-square tests (for the comparisons of categorical variables), Mann-Whitney tests (for non-normally distributed variables) and Student's t tests (for normally distributed variables), A P-value < 0.05 was considered to be statistically significant. RESULTS The mean pain scores within the two groups decreased continually over time. The mean pain scores in the Neem group were lower than those in the 2.5% NaOCl group at 6, 12, 24 and 48 h following instrumentation and canal filling with no significant difference between them except at 24 h following instrumentation (P = 0.012). Both irrigants significantly reduced endotoxin levels compared to the pre-instrumentation samples (P < 0.001) by 8% for the NaOCL group and 18% for the Neem group. CONCLUSION Neem and 2.5% NaOCl were not significantly different in terms of reducing the intensity of post-operative pain during all follow-up periods except at 24 h following instrumentation where Neem was associated with lower pain intensity. Both irrigants significantly reduced endotoxin levels but were not effective in eliminating endotoxins completely from root canals of mandibular molars with necrotic pulps.",2021,Both irrigants significantly reduced endotoxin levels but were not effective in eliminating endotoxins completely from root canals of mandibular molars with necrotic pulps.,"['mandibular molars with necrotic pulps', 'out-patient clinic of the Endodontic Department, Faculty of Dentistry, Cairo University, Egypt', 'Fifty healthy patients with mandibular molars with necrotic pulps']","['Neem (Azadirachta indica) versus 2.5% sodium hypochlorite', 'NaOCL']","['intensity of postoperative pain', 'postoperative pain and amount of endotoxins', 'Pain intensity', 'mean pain scores', 'pain intensity', 'endotoxin levels']","[{'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0011407', 'cui_str': 'Necrosis of the pulp'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0332274', 'cui_str': 'Endodontic'}, {'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0011438', 'cui_str': 'Dentistry'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0013715', 'cui_str': 'Egypt'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1095052', 'cui_str': 'Melia azadirachta'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0037518', 'cui_str': 'sodium hypochlorite'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0014264', 'cui_str': 'Bacterial endotoxin'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",50.0,0.0594079,Both irrigants significantly reduced endotoxin levels but were not effective in eliminating endotoxins completely from root canals of mandibular molars with necrotic pulps.,"[{'ForeName': 'N S', 'Initials': 'NS', 'LastName': 'Hosny', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cairo University, Cairo, Egypt.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'El Khodary', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cairo University, Cairo, Egypt.'}, {'ForeName': 'R M', 'Initials': 'RM', 'LastName': 'El Boghdadi', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cairo University, Cairo, Egypt.'}, {'ForeName': 'O G', 'Initials': 'OG', 'LastName': 'Shaker', 'Affiliation': 'Department of Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt.'}]",International endodontic journal,['10.1111/iej.13532'] 3013,33875324,Walking Training Improves Systemic and Local Pathophysiological Processes in Intermittent Claudication.,"OBJECTIVE This study examined the impact of submaximal walking training (WT) on local and systemic nitric oxide (NO) bioavailability, inflammation, and oxidative stress in patients with intermittent claudication (IC). METHODS The study employed a randomised, controlled, parallel group design and was performed in a single centre. Thirty-two men with IC were randomly allocated to two groups: WT (n = 16, two sessions/week, 15 cycles of two minutes walking at an intensity corresponding to the heart rate obtained at the pain threshold interspersed by two minutes of upright rest) and control (CO, n = 16, two sessions/week, 30 minutes of stretching). NO bioavailability (blood NO and muscle nitric oxide synthase [eNOS]), redox homeostasis (catalase [CAT], superoxide dismutase [SOD], lipid peroxidation [LPO] measured in blood and muscle), and inflammation (interleukin-6 [IL-6], C-reactive protein [CRP], tumour necrosis factor α [TNF-α], intercellular adhesion molecules [ICAM], vascular adhesion molecules [VCAM] measured in blood and muscle) were assessed at baseline and after 12 weeks. RESULTS WT statistically significantly increased blood NO, muscle eNOS, blood SOD and CAT, and muscle SOD and abolished the increase in circulating and muscle LPO observed in the CO group. WT decreased blood CRP, ICAM, and VCAM and muscle IL-6 and CRP and eliminated the increase in blood TNF-α and muscle TNF-α, ICAM and VCAM observed in the CO group. CONCLUSION WT at an intensity of pain threshold improved NO bioavailability and decreased systemic and local oxidative stress and inflammation in patients with IC. The proposed WT protocol provides physiological adaptations that may contribute to cardiovascular health in these patients.",2021,"WT decreased blood CRP, ICAM, and VCAM and muscle IL-6 and CRP and eliminated the increase in blood TNF-α and muscle TNF-α, ICAM and VCAM observed in the CO group. ","['patients with IC', 'Thirty-two men with IC', 'patients with intermittent claudication (IC', 'Intermittent Claudication']","['Walking Training', 'submaximal walking training (WT']","['tumour necrosis factor α [TNF-α], intercellular adhesion molecules [ICAM], vascular adhesion molecules [VCAM] measured in blood and muscle', 'systemic and local oxidative stress and inflammation', 'blood TNF-α and muscle TNF-α, ICAM and VCAM', 'blood', 'NO, muscle eNOS, blood SOD and CAT, and muscle SOD', 'NO bioavailability (blood NO and muscle nitric oxide synthase [eNOS]), redox homeostasis (catalase [CAT], superoxide dismutase [SOD], lipid peroxidation [LPO] measured in blood and muscle), and inflammation (interleukin-6 [IL-6], C-reactive protein [CRP', 'local and systemic nitric oxide (NO) bioavailability, inflammation, and oxidative stress', 'circulating and muscle LPO', 'blood CRP, ICAM, and VCAM and muscle IL-6 and CRP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C1456820', 'cui_str': 'Tumor necrosis factor alpha'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0242565', 'cui_str': 'Intercellular Adhesion Molecules'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0007578', 'cui_str': 'Cell Adhesion Molecules'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0078056', 'cui_str': 'Lymphocyte antigen CD106'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0007366', 'cui_str': 'Catalan language'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0132555', 'cui_str': 'Nitric-oxide synthase'}, {'cui': 'C0030012', 'cui_str': 'Oxidation-reduction'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0007367', 'cui_str': 'CATALASE'}, {'cui': 'C0023775', 'cui_str': 'Lipid peroxidation'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0023776', 'cui_str': 'Fatty Acid Hydroperoxides'}]",32.0,0.035184,"WT decreased blood CRP, ICAM, and VCAM and muscle IL-6 and CRP and eliminated the increase in blood TNF-α and muscle TNF-α, ICAM and VCAM observed in the CO group. ","[{'ForeName': 'Aluisio', 'Initials': 'A', 'LastName': 'Andrade-Lima', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil. Electronic address: aluisiolima@live.com.'}, {'ForeName': 'Natan', 'Initials': 'N', 'LastName': 'Silva Junior', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Chehuen', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Miyasato', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Rodrigo W A', 'Initials': 'RWA', 'LastName': 'Souza', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Anthony S', 'Initials': 'AS', 'LastName': 'Leicht', 'Affiliation': 'Sport & Exercise Science, James Cook University, Townsville, Australia.'}, {'ForeName': 'Patricia C', 'Initials': 'PC', 'LastName': 'Brum', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Edilamar M', 'Initials': 'EM', 'LastName': 'de Oliveira', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Wolosker', 'Affiliation': 'Albert Einstein Israelite Hospital, São Paulo, Brazil.'}, {'ForeName': 'Claudia L M', 'Initials': 'CLM', 'LastName': 'Forjaz', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}]",European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,['10.1016/j.ejvs.2021.02.022'] 3014,33875320,"""It's Being Compassionate, Not Making Assumptions"": Transmasculine and Nonbinary Young Adults' Experiences of ""Women's"" Health Care Settings.","BACKGROUND Transgender and nonbinary (TNB) individuals assigned female sex at birth experience discrimination, misgendering, problems with insurance, and denial of services when accessing health care. This study aimed to understand the experiences of TNB young adults in accessing ""women's"" health care-a form of care that is structurally gendered that few studies have investigated. METHODS In 2015, we conducted in-depth interviews with 20 TNB young (ages 18-29) adults assigned female sex at birth. We thematically analyzed the data. RESULTS Participants described feelings of comfort and trust-and lack thereof-at every step of the health care-seeking process, including scheduling, checking in, waiting, and interactions with clinicians and other staff. Gendered language served as a constant stressor; participants-especially nonbinary participants-noted few opportunities to provide their correct pronouns and names. Participants relayed negative experiences associated with waiting rooms in ""women's"" health care spaces, where TNB patients are forced to disclose their identity simply through their presence or owing to actions of staff that out them. These concerns deterred some from seeking care, with most expressing discomfort or anxiety that caused them to feel unsafe. Participants described ""women's"" health care providers making assumptions about their anatomy, reproductive desires, sexual orientation, and sexual practices, as well as inappropriately and harmfully emphasizing their bodies and TNB identities during health care interactions. Clinician competence and humility engendered participants' feelings of safety and undergirded their interest in engaging with ""women's"" health care. CONCLUSIONS A lack of patient-centered, TNB-competent care in structurally gendered health settings exacerbates health care and health inequities for TNB young adults.",2021,"RESULTS Participants described feelings of comfort and trust-and lack thereof-at every step of the health care-seeking process, including scheduling, checking in, waiting, and interactions with clinicians and other staff.","['20 TNB young (ages 18-29) adults assigned female sex at birth', 'TNB young adults', 'Participants relayed negative experiences associated with waiting rooms in ""women\'s"" health care spaces, where TNB patients']",[],['feelings of comfort and trust-and lack thereof'],"[{'cui': 'C0558141', 'cui_str': 'Transsexual'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0086287', 'cui_str': 'Female'}, {'cui': 'C1744681', 'cui_str': 'Congenital'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}]",,0.101429,"RESULTS Participants described feelings of comfort and trust-and lack thereof-at every step of the health care-seeking process, including scheduling, checking in, waiting, and interactions with clinicians and other staff.","[{'ForeName': 'Anu Manchikanti', 'Initials': 'AM', 'LastName': 'Gomez', 'Affiliation': 'Sexual Health and Reproductive Equity Program, School of Social Welfare, University of California, Berkeley, Berkeley, California. Electronic address: anugomez@berkeley.edu.'}, {'ForeName': 'Noah', 'Initials': 'N', 'LastName': 'Hooker', 'Affiliation': 'Sexual Health and Reproductive Equity Program, School of Social Welfare, University of California, Berkeley, Berkeley, California.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Olip-Booth', 'Affiliation': 'Sexual Health and Reproductive Equity Program, School of Social Welfare, University of California, Berkeley, Berkeley, California.'}, {'ForeName': 'Phoebe', 'Initials': 'P', 'LastName': 'Woerner', 'Affiliation': 'Sexual Health and Reproductive Equity Program, School of Social Welfare, University of California, Berkeley, Berkeley, California.'}, {'ForeName': 'G Allen', 'Initials': 'GA', 'LastName': 'Ratliff', 'Affiliation': 'Sexual Health and Reproductive Equity Program, School of Social Welfare, University of California, Berkeley, Berkeley, California.'}]",Women's health issues : official publication of the Jacobs Institute of Women's Health,['10.1016/j.whi.2021.02.008'] 3015,33880833,Development and validation of a nomogram to predict intraoperative blood transfusion for gastric cancer surgery.,"OBJECTIVE To construct and validate a nomogram composed of preoperative variables to predict intraoperative blood transfusion for gastric cancer surgery. BACKGROUND Intraoperative transfusion for gastric cancer surgery is a common medical procedure that is associated with increased postoperative complications. METHODS A total of 999 patients who underwent gastrectomy between January 2010 and June 2019 were randomly allocated into the primary and validation cohorts in a 2:1 ratio. In the primary cohort, logistic analyses were performed to identify independent predictors for transfusion. Using the Akaike information criterion, selected variables were incorporated to construct a nomogram. Validations of the nomogram were performed in the primary and validation cohorts. The discrimination ability of the nomogram was assessed by the concordance index (C-index), and calibration was assessed by calibration curves and the Hosmer-Lemeshow goodness-of-fit test. RESULTS The following risk factors for transfusion were identified and used to construct the nomogram: ASA status (III-IV vs I-II: odds ratio [OR] 1.74), comorbidities (yes vs no: OR 1.57), tumour location (diffuse vs lower: OR 4.05), cTNM stage (III vs I: OR 1.95), and a preoperative haemoglobin level less than 80 g/L (vs over 120 g/L: OR 35.30). The C-index was 0.859 and 0.850 in the primary and validation cohorts, respectively, which both indicated good discrimination of the nomogram. Additionally, both calibration curves and Hosmer-Lemeshow tests (p-value 0.184 and 0.887, respectively) demonstrated high agreement between the predictions and actual outcomes. CONCLUSION A nomogram composed of preoperative variables to predict blood transfusion for gastric cancer surgery was effectively developed and validated. This nomogram could be used to improve the utilisation of red blood cells for gastrectomy.",2021,"The discrimination ability of the nomogram was assessed by the concordance index (C-index), and calibration was assessed by calibration curves and the Hosmer-Lemeshow goodness-of-fit test. ","['999 patients who underwent gastrectomy between January 2010 and June 2019', 'gastric cancer surgery']",[],"['concordance index (C-index), and calibration', 'preoperative haemoglobin level', 'calibration curves and Hosmer-Lemeshow tests', 'C-index']","[{'cui': 'C5191069', 'cui_str': '999'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",[],"[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0006751', 'cui_str': 'Calibration'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",999.0,0.168923,"The discrimination ability of the nomogram was assessed by the concordance index (C-index), and calibration was assessed by calibration curves and the Hosmer-Lemeshow goodness-of-fit test. ","[{'ForeName': 'Haoquan', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Minghui', 'Initials': 'M', 'LastName': 'Cao', 'Affiliation': 'Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.'}]","Transfusion medicine (Oxford, England)",['10.1111/tme.12777'] 3016,33881748,A Retrospective Analysis to Determine Whether Training-Induced Changes in Muscle Thickness Mediate Changes in Muscle Strength.,"OBJECTIVE To investigate the role of muscle thickness changes on changes in strength following 6 weeks of unaccustomed resistance training, via retrospective analysis. METHODS 151 participants completed 6 weeks of no intervention (CONTROL), one-repetition maximum training (1RM-TRAIN), or traditional resistance training (TRAD-TRAIN). Groups were assigned by covariate adaptive randomization. 1RM-TRAIN and TRAD-TRAIN performed elbow flexion exercise on the dominant arm 3 times/week. One-repetition maximum strength and muscle thickness (B-mode ultrasound at 50, 60, and 70% of the anterior upper arm) were assessed pre- and post-training. Direct and indirect effects on strength via each training modality were quantified relative to CONTROL using indicator-coded, change-score mediation analyses for each muscle thickness site. Values are presented as regression coefficients (95% CI). RESULTS The effect of 1RM-TRAIN on muscle thickness was greater than CONTROL for 60% [0.09 (0.01, 0.17) cm] and 70% [0.09 (0.01,0.18) cm] models. All muscle thickness changes for TRAD-TRAIN were greater than CONTROL: 50% [0.24 (0.16, 0.33) cm], 60% [0.25 (0.17, 0.33) cm], 70% [0.23 (0.14, 0.32) cm]. All direct effects on strength were greater for 1RM-TRAIN versus CONTROL: 50% [1.90 (1.21, 2.58) kg], 60% [1.89 (1.19, 2.58) kg], 70% [1.81 (1.12, 2.51) kg]; and TRAD-TRAIN versus CONTROL: 50% [2.04 (1.29, 2.80) kg], 60% [1.98 (1.22, 2.75) kg], 70% [1.79 (1.05, 2.53) kg]. Compared to CONTROL, there was no indication of an effect of 1RM-TRAIN on strength through muscle thickness (i.e., indirect effect) for 50% [- 0.03 (- 0.17, 0.10)], 60% [- 0.01 (- 0.17, 0.17)], or 70% [0.07 (- 0.09, 0.28)] sites, nor of TRAD-TRAIN for 50% [- 0.11 (- 0.48,0.29)], 60% [- 0.04 (- 0.42, 0.40)], and 70% sites [0.17 (- 0.23,0.58)]. CONCLUSION Training-induced changes in muscle thickness do not appear to appreciably mediate training-induced changes in the strength of untrained individuals during the first 6 weeks of training.",2021,"Compared to CONTROL, there was no indication of an effect of 1RM-TRAIN on strength through muscle thickness (i.e., indirect effect) for 50% [- 0.03 (- 0.17, 0.10)], 60% [- 0.01 (- 0.17, 0.17)], or 70% [0.07 (- 0.09, 0.28)] sites, nor of TRAD-TRAIN for 50% [- 0.11 (- 0.48,0.29)], 60% [- 0.04 (- 0.42, 0.40)], and 70% sites [0.17 (- 0.23,0.58)]. ",['151 participants completed 6\xa0weeks of'],"['no intervention (CONTROL), one-repetition maximum training (1RM-TRAIN), or traditional resistance training (TRAD-TRAIN', '1RM-TRAIN']","['All muscle thickness changes for TRAD-TRAIN', 'strength through muscle thickness', 'strength', 'muscle thickness']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]",151.0,0.0199021,"Compared to CONTROL, there was no indication of an effect of 1RM-TRAIN on strength through muscle thickness (i.e., indirect effect) for 50% [- 0.03 (- 0.17, 0.10)], 60% [- 0.01 (- 0.17, 0.17)], or 70% [0.07 (- 0.09, 0.28)] sites, nor of TRAD-TRAIN for 50% [- 0.11 (- 0.48,0.29)], 60% [- 0.04 (- 0.42, 0.40)], and 70% sites [0.17 (- 0.23,0.58)]. ","[{'ForeName': 'Matthew B', 'Initials': 'MB', 'LastName': 'Jessee', 'Affiliation': 'Applied Human Health and Physical Function Laboratory, Department of Health, Exercise, Science, and Recreation Management, The University of Mississippi, University, MS, USA.'}, {'ForeName': 'Scott J', 'Initials': 'SJ', 'LastName': 'Dankel', 'Affiliation': 'Exercise Physiology Laboratory, Department of Health and Exercise Science, Rowan University, Glassboro, NJ, USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Bentley', 'Affiliation': 'Department of Pharmacy Administration, The University of Mississippi, University, MS, USA.'}, {'ForeName': 'Jeremy P', 'Initials': 'JP', 'LastName': 'Loenneke', 'Affiliation': 'Kevser Ermin Applied Physiology Laboratory, Department of Health, Exercise, Science, and Recreation Management, The University of Mississippi, 231 Turner Center, University, MS, 38677, USA. jploenne@olemiss.edu.'}]","Sports medicine (Auckland, N.Z.)",['10.1007/s40279-021-01470-5'] 3017,33880558,Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.,"OBJECTIVES Two Phase 3, randomized, double-blind, active-controlled studies of initial HIV-1 treatment demonstrated that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was non-inferior to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC; Study 1489) or to DTG+F/TAF (Study 1490) through 144 weeks. In both studies, there was no emergent resistance to study drugs. Here, the 3 year resistance analysis and impact of baseline resistance substitutions on treatment response are described. METHODS Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. Retrospective baseline next generation sequencing of protease, RT and integrase (IN) was analysed at a ≥ 15% cutoff. Resistance analyses were performed on participants with confirmed viral rebound of HIV-1 RNA ≥200 copies/mL through Week 144 or last visit who did not resuppress to <50 copies/mL while on study drug. RESULTS Transmitted primary drug resistance substitutions were present in the following proportions of participants: integrase strand transfer inhibitor (INSTI) resistance (-R) in 1.3% (17/1270) of participants; NRTI-R in 2.7% (35/1274); NNRTI-R in 14.1% (179/1274); and PI-R in 3.5% (44/1274). These pre-existing resistance substitutions not associated with study drug did not affect treatment outcomes. One participant in the B/F/TAF group had pre-existing bictegravir and dolutegravir resistance substitutions (Q148H+G140S in integrase) at baseline and suppressed and maintained HIV-1 RNA <50 copies/mL through Week 144. In total, 21 participants qualified for resistance testing [1.3% (8/634) B/F/TAF; 1.9% (6/315) DTG/ABC/3TC; 2.2% (7/325) DTG+F/TAF]; none had emergent resistance to study drugs. CONCLUSIONS Treatment with B/F/TAF, DTG/ABC/3TC, or DTG+F/TAF achieved high, durable rates of virological suppression in HIV-1 treatment-naive participants. The presence of pre-existing resistance substitutions did not affect treatment outcomes, and there was no treatment-emergent resistance.",2021,"RESULTS Transmitted primary drug resistance substitutions were present in the following proportions of participants: integrase strand transfer inhibitor (INSTI) resistance (-R) in 1.3% (17/1270) of participants; NRTI-R in 2.7% (35/1274); NNRTI-R in 14.1% (179/1274); and PI-R in 3.5% (44/1274).","['Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening', 'HIV-1 treatment-naive participants']","['bictegravir/emtricitabine/tenofovir alafenamide', 'dolutegravir/abacavir/lamivudine (DTG/ABC/3TC', 'bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF', 'DTG+F/TAF']","['durable rates of virological suppression', 'integrase strand transfer inhibitor (INSTI) resistance (-R']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0162801', 'cui_str': 'Analysis, Sequence'}, {'cui': 'C0917721', 'cui_str': 'p16 protease, Human immunodeficiency virus 1'}, {'cui': 'C0035379', 'cui_str': 'RNA-directed DNA polymerase'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C4542162', 'cui_str': 'emtricitabine, tenofovir alafenamide and bictegravir'}, {'cui': 'C3253985', 'cui_str': 'dolutegravir'}, {'cui': 'C1613391', 'cui_str': 'lamivudine and abacavir'}, {'cui': 'C1450557', 'cui_str': 'IGFBP7 protein, human'}]","[{'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0376601', 'cui_str': 'Integrase strand transfer inhibitor-containing product'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]",1490.0,0.246809,"RESULTS Transmitted primary drug resistance substitutions were present in the following proportions of participants: integrase strand transfer inhibitor (INSTI) resistance (-R) in 1.3% (17/1270) of participants; NRTI-R in 2.7% (35/1274); NNRTI-R in 14.1% (179/1274); and PI-R in 3.5% (44/1274).","[{'ForeName': 'Rima K', 'Initials': 'RK', 'LastName': 'Acosta', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Grace Q', 'Initials': 'GQ', 'LastName': 'Chen', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Chang', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Martin', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Hailin', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Brainard', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Sean E', 'Initials': 'SE', 'LastName': 'Collins', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Hal', 'Initials': 'H', 'LastName': 'Martin', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Kirsten L', 'Initials': 'KL', 'LastName': 'White', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkab115'] 3018,33884633,Three-dimensional ultrasound imaging: An effective method to detect the effect of moderate intensity statin treatment in slowing carotid plaque progression.,"PURPOSE We aimed to evaluate the feasibility of three-dimensional ultrasound imaging (3DUS) in assessing the therapeutic effect of moderate-intensity statin therapy on carotid atherosclerotic plaques. METHODS Patients with carotid plaques were recruited to the study from January 2016 to September 2018, and were divided into two groups based on whether or not they were taking statins. All participants underwent 3DUS of their carotid plaques at baseline, then 3 months and 2 years after initial examination. The changes of the carotid plaques were compared between the two groups. RESULTS Were included 97 patients (57 males and 40 females), 65.26 ± 9.53 year-old with 67 into the statin group and 30 in the control group. The baseline levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were lower in the statin group than in the control group (3.79 ± 0.78 mmol/L vs 4.50 ± 1.12 mmol/L; 2.01 ± 0.62 mmol/L vs 2.58 ± 0.91 mmol/L, P < .05). There was no significant difference in the change of total plaque volume (TPV) detected by 3D-US between the statin (median [interquartile range]: 0 [-30-20] mm 3 ) and the control group (0 [-22.5-25] mm 3 ) at 3 months. Over 2 years, the TPV increased faster in the control group (+70 [25-150] mm 3 ), than in the statin group (15 [-57.5-90) mm 3 , P < .05). CONCLUSIONS 3DUS can be an effective tool to observe the development of carotid plaques and the effect of statin treatment.",2021,"The baseline levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were lower in the statin group than in the control group (3.79 ± 0.78 mmol/L vs 4.50 ± 1.12 mmol/L; 2.01 ± 0.62 mmol/L vs 2.58 ± 0.91 mmol/L, P < .05).","['Were included 97 patients (57 males and 40 females), 65.26\u2009±\u20099.53\u2009year-old with 67 into the statin group and 30 in the control group', 'Patients with carotid plaques were recruited to the study from January 2016 to September 2018']","['dimensional ultrasound imaging', 'dimensional ultrasound imaging (3DUS']","['baseline levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C', 'carotid plaques', 'TPV increased faster', 'change of total plaque volume (TPV']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",,0.0215058,"The baseline levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were lower in the statin group than in the control group (3.79 ± 0.78 mmol/L vs 4.50 ± 1.12 mmol/L; 2.01 ± 0.62 mmol/L vs 2.58 ± 0.91 mmol/L, P < .05).","[{'ForeName': 'Yuhui', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Neurology, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Haiying', 'Initials': 'H', 'LastName': 'Xing', 'Affiliation': 'Department of Neurology, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Jiexi', 'Initials': 'J', 'LastName': 'Wen', 'Affiliation': 'Department of Neurology, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Peng', 'Affiliation': 'Department of Neurology, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Ran', 'Initials': 'R', 'LastName': 'Liu', 'Affiliation': 'Department of Neurology, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': 'Department of Neurology, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Haiqiang', 'Initials': 'H', 'LastName': 'Jin', 'Affiliation': 'Department of Neurology, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Xu', 'Affiliation': 'Department of Neurology, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Yining', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Neurology, Peking University First Hospital, Beijing, China.'}]",Journal of clinical ultrasound : JCU,['10.1002/jcu.23013'] 3019,33888576,New forehead device in positional obstructive sleep apnoea: a randomised clinical trial.,"RATIONALE Approximately 60% of the patients with obstructive sleep apnoea suffer from a positional effect, and approximately 25% of these patients present events only in the supine position. OBJECTIVE To validate a new positional vibrating device and evaluate its efficacy in reducing the Apnoea-Hypopnoea Index and the total sleep time in the supine position without disturbing sleep. METHODS A total of 128 patients were recruited for this multicentre, prospective, parallel, randomised controlled trial and were distributed in three arms (general recommendations, inactive and active device). Full overnight polysomnography was performed at baseline and at 12 weeks. Anthropometric variables and sleep and quality of life questionnaires were collected at 4, 8 and 12 weeks. RESULTS The Apnoea-Hypopnoea Index decreased from 30.6 per hour to 20.4 per hour (p<0.001) in the active device (AD) group. In this group the reduction was 2.3-fold and 3.3-fold than the ones in the general recommendations (GR) and inactive device (ID) groups, respectively (p=0.014). Sleep time in supine position decreased 17.7%±26.3% in GR group (p<0.001), 13.0%±22.4% with ID group (p<0.001) and 21.0%±25.6% in the AD group (p<0.001). Furthermore, total sleep time increased significantly only in the AD group (22.1±57.5 min, p=0.016), with an increased percentage of time in the N3 (deep sleep) and N3+REM (rapid eye movement) stages, without sleep fragmentation. CONCLUSION The device was effective in reducing the Apnoea-Hypopnoea Index and time spent in the supine position also in improving sleep architecture. Therefore, the device could be a good option for the management of patients with positional obstructive sleep apnoea. TRIAL REGISTRATION DETAILS The trial was registered at www.clinicaltrials.gov (NCT03336515).",2021,The device was effective in reducing the Apnoea-Hypopnoea Index and time spent in the supine position also in improving sleep architecture.,"['patients with obstructive sleep apnoea', 'patients with positional obstructive sleep apnoea', 'positional obstructive sleep apnoea', 'A total of 128 patients']",['New forehead device'],"['Sleep time in supine position', 'Full overnight polysomnography', 'Anthropometric variables and sleep and quality of life questionnaires', 'percentage of time in the N3 (deep sleep) and N3+REM (rapid eye movement) stages, without sleep fragmentation', 'Apnoea-Hypopnoea Index and the total sleep time', 'total sleep time', 'Apnoea-Hypopnoea Index and time spent', 'Apnoea-Hypopnoea Index']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0016540', 'cui_str': 'Forehead structure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0015413', 'cui_str': 'Eye Movements'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0751507', 'cui_str': 'Sleep Fragmentation'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",128.0,0.0835657,The device was effective in reducing the Apnoea-Hypopnoea Index and time spent in the supine position also in improving sleep architecture.,"[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Hidalgo Armas', 'Affiliation': 'BioAraba, Osakidetza-Basque Health Service, Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Ingles', 'Affiliation': 'BioAraba, Osakidetza-Basque Health Service, Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Rafaela', 'Initials': 'R', 'LastName': 'Vaca', 'Affiliation': 'Respiratory Department, CIBERES, Madrid, Comunidad de Madrid, Spain.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Cordero-Guevara', 'Affiliation': 'Unidad de Metodología y Estadística, Osakidetza-Basque Health Service, Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Joaquin', 'Initials': 'J', 'LastName': 'Duran Carro', 'Affiliation': 'BioAraba, Osakidetza-Basque Health Service, Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Ullate', 'Affiliation': 'BioAraba, Osakidetza-Basque Health Service, Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Ferran', 'Initials': 'F', 'LastName': 'Barbé', 'Affiliation': 'Respiratory Department, CIBERES, Madrid, Comunidad de Madrid, Spain.'}, {'ForeName': 'Joaquin', 'Initials': 'J', 'LastName': 'Durán-Cantolla', 'Affiliation': 'BioAraba, Osakidetza-Basque Health Service, Vitoria-Gasteiz, Spain joaquin.durancantolla@gmail.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Thorax,['10.1136/thoraxjnl-2020-216167'] 3020,33888536,Targeting Sedentary Behavior in CKD: A Pilot and Feasibility Randomized Controlled Trial.,"BACKGROUND AND OBJECTIVES We tested the feasibility of reducing sedentary behavior common in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We carried out a Sit Less, Interact, Move More intervention in a 24-week parallel-group, randomized controlled trial in patients with stages 2-5 CKD. In the intervention group ( n =54), accelerometry performed at baseline and repeated every 4 weeks was used to develop and monitor adherence to individualized plans targeting sedentary and stepping durations. The control group ( n =52) was provided national physical activity recommendations; accelerometry was performed at baseline and every 8 weeks. Between-groups changes from baseline to the average follow-up values at weeks 8, 16, and 24 of the sedentary and stepping durations were the coprimary end points. RESULTS The mean age was 69±13 years. Fourteen percent were on dialysis or received a kidney transplant. Eight percent of the control group and 17% of the intervention group were lost to follow-up. Sedentary and stepping durations did not change in the control group. Within the intervention group, the maximum decrease in sedentary duration (-43; 95% confidence interval, -69 to -17 min/d) and increase in stepping duration (16; 95% confidence interval, 7 to 24 min/d) and the number of steps per day (1265; 95% confidence interval, 518 to 2012) were seen at week 20. These attenuated at week 24. In mixed effects models, overall treatment effects between groups on sedentary (-17; 95% confidence interval, -43 to 8 min/d) and stepping (6; 95% confidence interval, -3 to 15 min/d) durations and the number of steps per day, a secondary end point (652; 95% confidence interval, -146 to 1449), were not significantly different. The intervention significantly reduced secondary end points of body mass index (-1.1; 95% confidence interval, -1.9 to -0.3 kg/m 2 ) and body fat percentage (-2.1%; 95% confidence interval, -4.4% to -0.2%). CONCLUSIONS It is feasible to reduce sedentary duration and increase stepping duration in patients with CKD, but these were not sustained. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER National Health and Nutrition Examination Survey (NHANES), NCT02970123.",2021,"The intervention significantly reduced secondary end points of body mass index (-1.1; 95% confidence interval, -1.9 to -0.3 kg","['patients with CKD', 'Fourteen percent were on dialysis or received a kidney transplant', 'patients with stages 2-5 CKD']",[],"['sedentary duration and increase stepping duration', 'stepping duration', 'body fat percentage', 'body mass index', 'sedentary duration', 'Sedentary and stepping durations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}]",[],"[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",,0.442132,"The intervention significantly reduced secondary end points of body mass index (-1.1; 95% confidence interval, -1.9 to -0.3 kg","[{'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Lyden', 'Affiliation': 'Department of Kinesiology, University of Massachusetts, Amherst, Massachusetts.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Boucher', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': 'Guo', 'Initials': 'G', 'LastName': 'Wei', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhou', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Christensen', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Chertow', 'Affiliation': 'Division of Nephrology, Stanford University, Palo Alto, California.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Greene', 'Affiliation': 'Division of Biostatistics, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': 'Srinivasan', 'Initials': 'S', 'LastName': 'Beddhu', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah srinivasan.beddhu@hsc.utah.edu.'}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.12300720'] 3021,33884702,"Anti-nociceptive effects of oxytocin receptor modulation in healthy volunteers-A randomized, double-blinded, placebo-controlled study.","BACKGROUND There is increasing evidence for oxytocin as a neurotransmitter in spinal nociceptive processes. Hypothalamic oxytocinergic neurons project to the spinal dorsal horn, where they activate GABA-ergic inhibitory interneurons. The present study tested whether the long-acting oxytocin-analogue carbetocin has anti-nociceptive effects in multi-modal experimental pain in humans. METHODS Twenty-five male volunteers received carbetocin 100 mcg and placebo (0.9% NaCl) on two different sessions in a randomized, double-blinded, cross-over design. Multi-modal quantitative sensory testing (QST) including a model of capsaicin-induced hyperalgesia and allodynia were performed at baseline and at 10, 60 and 120 min after drug administration. QST data were analysed using mixed linear and logistic regression models. Carbetocin plasma concentrations and oxytocin receptor genotypes were quantified and assessed in an exploratory fashion. RESULTS An anti-nociceptive effect of carbetocin was observed on intramuscular electrical temporal summation (estimated difference: 1.26 mA, 95% CI 1.01 to 1.56 mA, p = .04) and single-stimulus electrical pain thresholds (estimated difference: 1.21 mA, 95% CI 1.0 to 1.47 mA, p = .05). Furthermore, the area of capsaicin-induced allodynia was reduced after carbetocin compared to placebo (estimated difference: -6.5 cm 2 , 95% CI -9.8 to -3.2 cm 2 , p < .001). CONCLUSIONS This study provides evidence of an anti-nociceptive effect of carbetocin on experimental pain in humans. SIGNIFICANCE This study provides evidence of the anti-nociceptive effect of intravenous administration of the oxytocin agonist carbetocin in healthy male volunteers.",2021,"Furthermore, the area of capsaicin-induced allodynia was reduced after carbetocin compared to placebo (estimated difference: -6.5 cm 2 , 95%-CI -9.8 to -3.2 cm 2 , p < 0.001). ","['Healthy Volunteers ', 'Twenty-five male volunteers received', 'humans', 'multi-modal experimental pain in humans']","['Multi-modal quantitative sensory testing (QST', 'Oxytocin Receptor Modulation', 'placebo', 'Placebo', 'carbetocin 100 mcg and placebo (0.9% NaCl', 'oxytocin', 'carbetocin', 'oxytocin-analogue carbetocin']","['area of capsaicin-induced allodynia', 'intramuscular electrical temporal summation', 'Carbetocin plasma concentrations and oxytocin receptor genotypes', 'single-stimulus electrical pain thresholds', 'hyperalgesia and allodynia']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0430838', 'cui_str': 'Quantitative sensory test'}, {'cui': 'C0069841', 'cui_str': 'Oxytocin Receptor'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0054670', 'cui_str': 'carbetocin'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439211', 'cui_str': 'mcg'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0006931', 'cui_str': 'Capsaicin'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0458247', 'cui_str': 'Allodynia'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0234110', 'cui_str': 'Temporal summation'}, {'cui': 'C0054670', 'cui_str': 'carbetocin'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0069841', 'cui_str': 'Oxytocin Receptor'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesia'}]",25.0,0.597716,"Furthermore, the area of capsaicin-induced allodynia was reduced after carbetocin compared to placebo (estimated difference: -6.5 cm 2 , 95%-CI -9.8 to -3.2 cm 2 , p < 0.001). ","[{'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'Biurrun Manresa', 'Affiliation': 'Center for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Jürg', 'Initials': 'J', 'LastName': 'Schliessbach', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Pascal H', 'Initials': 'PH', 'LastName': 'Vuilleumier', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Müller', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Musshoff', 'Affiliation': 'Forensic Toxicological Center (FTC), Munich, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Stamer', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Stüber', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Arendt-Nielsen', 'Affiliation': 'Center for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Curatolo', 'Affiliation': 'Center for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.'}]","European journal of pain (London, England)",['10.1002/ejp.1781'] 3022,33881530,Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial.,"Importance Female gender is a major risk factor for dementia; however, gender has not yet been adequately addressed by clinical trials. A recent study demonstrated that sodium benzoate, a D-amino acid oxidase inhibitor, improved cognitive function in early-phase Alzheimer disease. Objective To examine the potential gender difference in the effects of benzoate treatment on the behavioral and psychological symptoms of dementia (BPSD). Design, Setting, and Participants This post hoc secondary analysis used data from a randomized, double-masked, placebo-controlled trial conducted in 3 major medical centers in Taiwan and enrolled 97 patients with BPSD. Data were analyzed between February 2014 and November 2017. Interventions Six weeks of treatment of 250 to 1500 mg/d of sodium benzoate or placebo. Main Outcomes and Measures The primary outcome measures were Alzheimer disease assessment scale-cognitive subscale (ADAS-cog) and Behavioral Pathology in Alzheimer Disease Rating Scale (BEHAVE-AD) scores. Results Among 97 total participants (62 [64%] women; mean [SD] age, 75.4 [7.7] years), 49 patients (30 women and 19 men) were randomized to sodium benzoate, and 48 (32 women and 16 men) were randomized to placebo. Among 62 women, 6-week benzoate treatment significantly surpassed placebo in the effects on ADAS-cog performance (mean [SD] difference in score between baseline and end point, -3.1 [6.4] points vs 0 [4.5] points; Cohen d = 0.56; P = .04) but not BEHAVE-AD performance. In contrast, among 35 men, the 2 treatment groups did not differ significantly in both ADAS-cog and BEHAVE-AD scores. Compared with placebo, benzoate treatment also increased estradiol to follicle-stimulating hormone ratios among women (mean [SD] difference between baseline and end point, 0 [0.2] vs -0.1 [0.3]; P = .03). Conclusions and Relevance These findings suggest that benzoate treatment may improve cognitive function in women with later-phase dementia. In the future, longer dose-finding trials are warranted to further clarify the efficacy of benzoate for later-phase dementia and investigate the role of sex hormones and other factors in the pathogenesis of dementia. Trial Registration ClinicalTrials.gov Identifier: NCT02103673.",2021,"Among 62 women, 6-week benzoate treatment significantly surpassed placebo in the effects on ADAS-cog performance (mean [SD] difference in score between baseline and end point, -3.1 [6.4] points vs 0","['Patients With Behavioral and Psychological Symptoms of Dementia', '62 women', '97 total participants (62 [64%] women; mean [SD] age, 75.4 [7.7] years), 49 patients (30 women and 19 men', 'women with later-phase dementia', '3 major medical centers in Taiwan and enrolled 97 patients with BPSD', ' and 48 (32 women and 16 men', 'Data were analyzed between February 2014 and November 2017']","['sodium benzoate', 'placebo', 'sodium benzoate or placebo', 'sodium benzoate, a D-amino acid oxidase inhibitor', 'Sodium Benzoate', 'benzoate treatment']","['Alzheimer disease assessment scale-cognitive subscale (ADAS-cog) and Behavioral Pathology in Alzheimer Disease Rating Scale (BEHAVE-AD) scores', 'behavioral and psychological symptoms of dementia (BPSD', 'Cognitive Function', 'estradiol to follicle-stimulating hormone ratios', 'ADAS-cog performance', 'cognitive function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517860', 'cui_str': '7.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}]","[{'cui': 'C0142805', 'cui_str': 'sodium benzoate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0010895', 'cui_str': 'D-amino-acid oxidase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0005058', 'cui_str': 'Benzoates'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0202022', 'cui_str': 'Follicle stimulating hormone measurement'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",97.0,0.87676,"Among 62 women, 6-week benzoate treatment significantly surpassed placebo in the effects on ADAS-cog performance (mean [SD] difference in score between baseline and end point, -3.1 [6.4] points vs 0","[{'ForeName': 'Chieh-Hsin', 'Initials': 'CH', 'LastName': 'Lin', 'Affiliation': 'Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.'}, {'ForeName': 'Ping-Kun', 'Initials': 'PK', 'LastName': 'Chen', 'Affiliation': 'School of Medicine, China Medical University, Taichung, Taiwan.'}, {'ForeName': 'Shi-Heng', 'Initials': 'SH', 'LastName': 'Wang', 'Affiliation': 'Department of Occupational Safety and Health, China Medical University, Taichung, Taiwan.'}, {'ForeName': 'Hsien-Yuan', 'Initials': 'HY', 'LastName': 'Lane', 'Affiliation': 'Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.6156'] 3023,33887400,Younger age is associated with higher levels of self-reported affective and cognitive sequelae six months post-cardiac arrest.,"BACKGROUND Affective and cognitive sequelae are frequently reported in cardiac arrest survivors; however, little is known about the risk factors. We assessed the hypothesis that self-reported affective and cognitive sequelae six months after OHCA may be associated with demography, acute care and cerebral outcome. METHODS This is a sub-study of the multicentre ""Target Temperature Management for 48 vs. 24 h and Neurologic Outcome after Out-of-Hospital Cardiac Arrest: A Randomised Clinical Trial"" (the TTH48 trial) investigating the effect of prolonged TTM at 33 ± 1 °C. We invited patients with good outcome on the Cerebral Performances Categories (CPC score ≤ 2) to answer questionnaires on anxiety, depression, emotional distress, perceived stress and cognitive failures six months post OHCA. RESULTS In total 79 of 111 eligible patients were included in the analysis. There were no significant differences in baseline characteristics between the included group and the group lost to follow-up. Younger age was a negative predictor across all self-reported outcomes, even when controlling for gender, ROSC time, treatment allocation, cognitive impairment and global outcome (CPC 1 or 2). Female gender was a predictor of anxiety, though this should be interpreted cautiously as only eight women participated. A CPC score of 2 score was a negative predictor of self-reported affective outcomes, albeit not for self-reported cognitive failures. CONCLUSION Younger age was associated with higher levels of self-reported affective and cognitive sequelae six months post OHCA. Female gender may be associated with self-reported anxiety. A higher CPC score may be a proxy for self-reported affective sequelae.",2021,Younger age was associated with higher levels of self-reported affective and cognitive sequelae six months post OHCA.,"['48 vs. 24hours and Neurologic Outcome after Out-of-Hospital Cardiac Arrest', 'In total 79 of 107 eligible patients were included in the analysis']",['prolonged TTM'],"['Cerebral Performances Categories (CPC score≤2)to answer questionnaires on anxiety, depression, emotional distress, perceived stress and cognitive failures six months post OHCA']","[{'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C2936490', 'cui_str': 'Out-of-Hospital Heart Arrest'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0040953', 'cui_str': 'Trichotillomania'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0056911', 'cui_str': ""cytidylyl-(3'-5')-cytidine""}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0687676', 'cui_str': 'After values'}]",107.0,0.137081,Younger age was associated with higher levels of self-reported affective and cognitive sequelae six months post OHCA.,"[{'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Evald', 'Affiliation': 'Hammel Neurorehabilitation Clinic and University Research Centre, Hammel, Denmark. Electronic address: lars.evald@midt.rm.dk.'}, {'ForeName': 'Kolbjørn', 'Initials': 'K', 'LastName': 'Brønnick', 'Affiliation': 'Department of Psychiatry, Stavanger University Hospital, Stavanger, Norway.'}, {'ForeName': 'Christophe Henri Valdemar', 'Initials': 'CHV', 'LastName': 'Duez', 'Affiliation': 'Research Centre for Emergency Medicine and Department of Intensive Care Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Anders Morten', 'Initials': 'AM', 'LastName': 'Grejs', 'Affiliation': 'Research Centre for Emergency Medicine and Department of Intensive Care Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Anni Nørgaard', 'Initials': 'AN', 'LastName': 'Jeppesen', 'Affiliation': 'Research Centre for Emergency Medicine and Department of Intensive Care Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Eldar', 'Initials': 'E', 'LastName': 'Søreide', 'Affiliation': 'Critical Care and Anaesthesiology Research Group, Stavanger University Hospital, Stavanger, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Kirkegaard', 'Affiliation': 'Research Centre for Emergency Medicine and Department of Intensive Care Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Jørgen Feldbæk', 'Initials': 'JF', 'LastName': 'Nielsen', 'Affiliation': 'Hammel Neurorehabilitation Clinic and University Research Centre, Hammel, Denmark.'}]",Resuscitation,['10.1016/j.resuscitation.2021.04.009'] 3024,33888362,A Pilot Study Examining the Efficacy of Delivering Colorectal Cancer Screening Messages via Virtual Health Assistants.,"INTRODUCTION Patients are more likely to complete colorectal cancer screening when recommended by a race-concordant healthcare provider. Leveraging virtual healthcare assistants to deliver tailored screening interventions may promote adherence to colorectal cancer screening guidelines among diverse patient populations. The purpose of this pilot study is to determine the efficacy of the Agent Leveraging Empathy for eXams virtual healthcare assistant intervention to increase patient intentions to talk to their doctor about colorectal cancer screening. It also examines the influence of animation and race concordance on intentions to complete colorectal cancer screening. METHODS White and Black adults (N=1,363) aged 50-73 years and not adherent to colorectal cancer screening guidelines were recruited from Qualtrics Panels in 2018 to participate in a 3-arm (animated virtual healthcare assistant, static virtual healthcare assistant, attention control) message design experiment. In 2020, a probit regression model was used to identify the intervention effects. RESULTS Participants assigned to the animated virtual healthcare assistant (p<0.01) reported higher intentions to talk to their doctor about colorectal cancer screening than participants assigned to the other conditions. There was a significant effect of race concordance on colorectal cancer screening intentions but only in the static virtual healthcare assistant condition (p=0.04). Participant race, age, trust in healthcare providers, health literacy, and cancer information overload were also significant predictors of colorectal cancer screening intentions. CONCLUSIONS Animated virtual healthcare assistants were efficacious compared with the static virtual healthcare assistant and attention control conditions. The influence of race concordance between source and participant was inconsistent across conditions. This warrants additional investigation in future studies given the potential for virtual healthcare assistant‒assisted interventions to promote colorectal cancer screening within guidelines.",2021,"RESULTS Participants assigned to the animated virtual healthcare assistant (p<0.01) reported higher intentions to talk to their doctor about colorectal cancer screening than participants assigned to the other conditions.","['White and Black adults (N=1,363) aged 50-73 years and not adherent to colorectal cancer screening guidelines were recruited from Qualtrics Panels in 2018 to participate in a 3-arm (animated virtual healthcare assistant, static virtual healthcare assistant, attention control) message design experiment', 'diverse patient populations']","['Agent Leveraging Empathy for eXams virtual healthcare assistant intervention', 'animated virtual healthcare assistant']","['higher intentions to talk to their doctor about colorectal cancer screening', 'colorectal cancer screening intentions']","[{'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0557545', 'cui_str': 'Healthcare assistant'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0557545', 'cui_str': 'Healthcare assistant'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]",,0.0509032,"RESULTS Participants assigned to the animated virtual healthcare assistant (p<0.01) reported higher intentions to talk to their doctor about colorectal cancer screening than participants assigned to the other conditions.","[{'ForeName': 'Janice L', 'Initials': 'JL', 'LastName': 'Krieger', 'Affiliation': 'STEM Translational Communication Center, College of Journalism and Communication, University of Florida, Gainesville, Florida. Electronic address: janicekrieger@ufl.edu.'}, {'ForeName': 'Jordan M', 'Initials': 'JM', 'LastName': 'Neil', 'Affiliation': 'Massachusetts General Hospital, Harvard University, Boston, Massachusetts.'}, {'ForeName': 'Kyle A', 'Initials': 'KA', 'LastName': 'Duke', 'Affiliation': 'Department of Statistical Science, Duke University, Raleigh, North Carolina.'}, {'ForeName': 'Mohan S', 'Initials': 'MS', 'LastName': 'Zalake', 'Affiliation': 'Department of Computer & Information Science & Engineering, College of Engineering, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Tavassoli', 'Affiliation': 'Department of Computer & Information Science & Engineering, College of Engineering, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Vilaro', 'Affiliation': 'STEM Translational Communication Center, College of Journalism and Communication, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Danyell S', 'Initials': 'DS', 'LastName': 'Wilson-Howard', 'Affiliation': 'Department of Chemistry, Bethune-Cookman University, Daytona, Florida.'}, {'ForeName': 'Sarah Y', 'Initials': 'SY', 'LastName': 'Chavez', 'Affiliation': 'STEM Translational Communication Center, College of Journalism and Communication, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Eric B', 'Initials': 'EB', 'LastName': 'Laber', 'Affiliation': 'Department of Statistical Science, Duke University, Raleigh, North Carolina.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Davidian', 'Affiliation': 'Department of Statistical Science, Duke University, Raleigh, North Carolina.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'George', 'Affiliation': 'Division of Hematology & Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida.'}, {'ForeName': 'François P', 'Initials': 'FP', 'LastName': 'Modave', 'Affiliation': 'Department of Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Folakemi T', 'Initials': 'FT', 'LastName': 'Odedina', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Benjamin C', 'Initials': 'BC', 'LastName': 'Lok', 'Affiliation': 'Department of Computer & Information Science & Engineering, College of Engineering, University of Florida, Gainesville, Florida.'}]",American journal of preventive medicine,['10.1016/j.amepre.2021.01.014'] 3025,33874955,The effect of chiropractic care on infantile colic: results from a single-blind randomised controlled trial.,"BACKGROUND Chiropractic care is commonly used to treat infantile colic. However large trials with parental blinding are missing. Therefore, the purpose of this study is to evaluate the effect of chiropractic care on infantile colic. METHOD This is a multicenter, single-blind randomized controlled trial conducted in four Danish chiropractic clinics, 2015-2019. Information was distributed in the maternity wards and by maternal and child health nurses. Children aged 2-14 weeks with unexplained excessive crying were recruited through home visits and randomized (1:1) to either chiropractic care or control group. Both groups attended the chiropractic clinic twice a week for 2 weeks. The intervention group received chiropractic care, while the control group was not treated. The parents were not present in the treatment room and unaware of their child's allocation. The primary outcome was change in daily hours of crying before and after treatment. Secondary outcomes were changes in hours of sleep, hours being awake and content, gastrointestinal symptoms, colic status and satisfaction. All outcomes were based on parental diaries and a final questionnaire. RESULTS Of 200 recruited children, 185 completed the trial (treatment group n = 96; control group n = 89). Duration of crying in the treatment group was reduced by 1.5 h compared with 1 h in the control group (mean difference - 0.6, 95% CI - 1.1 to - 0.1; P = 0.026), but when adjusted for baseline hours of crying, age and chiropractic clinic, the difference was not significant (P = 0.066). The proportion obtaining a clinically important reduction of 1 h of crying was 63% in the treatment group and 47% in the control group (p = 0.037), and NNT was 6.5. We found no effect on any of the secondary outcomes. CONCLUSION Excessive crying was reduced by half an hour in favor of the group receiving chiropractic care compared with the control group, but not at a statistically significant level after adjustments. From a clinical perspective, the mean difference between the groups was small, but there were large individual differences, which emphasizes the need to investigate if subgroups of children, e.g. those with musculoskeletal problems, benefit more than others from chiropractic care. TRIAL REGISTRATION Clinical Trials NCT02595515 , registered 2 November 2015.",2021,"Duration of crying in the treatment group was reduced by 1.5 h compared with 1 h in the control group (mean difference - 0.6, 95% CI - 1.1 to - 0.1; P = 0.026), but when adjusted for baseline hours of crying, age and chiropractic clinic, the difference was not significant (P = 0.066).","['200 recruited children', 'four Danish chiropractic clinics, 2015-2019', 'Children aged 2-14\u2009weeks with unexplained excessive crying', 'infantile colic']","['chiropractic care or control group', 'chiropractic care']","['changes in hours of sleep, hours being awake and content, gastrointestinal symptoms, colic status and satisfaction', 'Duration of crying', 'Excessive crying', 'change in daily hours of crying', 'proportion obtaining a clinically important reduction of 1 h of crying']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0010969', 'cui_str': 'Danish language'}, {'cui': 'C0008138', 'cui_str': 'Chiropractic'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0438697', 'cui_str': 'Crying, excessive'}, {'cui': 'C0266836', 'cui_str': 'Infantile colic'}]","[{'cui': 'C0008138', 'cui_str': 'Chiropractic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0232488', 'cui_str': 'Abdominal colic'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0438697', 'cui_str': 'Crying, excessive'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0700308', 'cui_str': 'Protium'}]",200.0,0.363215,"Duration of crying in the treatment group was reduced by 1.5 h compared with 1 h in the control group (mean difference - 0.6, 95% CI - 1.1 to - 0.1; P = 0.026), but when adjusted for baseline hours of crying, age and chiropractic clinic, the difference was not significant (P = 0.066).","[{'ForeName': 'Lise Vilstrup', 'Initials': 'LV', 'LastName': 'Holm', 'Affiliation': 'The Chiropractic Knowledge Hub, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark.'}, {'ForeName': 'Dorte Ejg', 'Initials': 'DE', 'LastName': 'Jarbøl', 'Affiliation': 'Research Unit of General Practice, Department of Public Health, University of Southern Denmark, J.B. Winsløws vej 9A, DK-5000, Odense C, Denmark.'}, {'ForeName': 'Henrik Wulff', 'Initials': 'HW', 'LastName': 'Christensen', 'Affiliation': 'The Chiropractic Knowledge Hub, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Søndergaard', 'Affiliation': 'Research Unit of General Practice, Department of Public Health, University of Southern Denmark, J.B. Winsløws vej 9A, DK-5000, Odense C, Denmark.'}, {'ForeName': 'Lise', 'Initials': 'L', 'LastName': 'Hestbæk', 'Affiliation': 'The Chiropractic Knowledge Hub, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark. l.hestbaek@nikkb.dk.'}]",Chiropractic & manual therapies,['10.1186/s12998-021-00371-8'] 3026,33885776,Effect of Community-Initiated Kangaroo Mother Care on Postpartum Depressive Symptoms and Stress Among Mothers of Low-Birth-Weight Infants: A Randomized Clinical Trial.,"Importance Approximately 1 in 5 women in low- and middle-income countries experience postpartum depression, and the risk is higher among mothers of low-birth-weight (LBW) infants. Kangaroo mother care (KMC) is effective in improving survival among LBW infants, but the benefits of KMC for mothers are not well described. Objective To estimate the effects of community-initiated KMC (ciKMC) on maternal risk of moderate-to-severe postpartum depressive symptoms and on salivary cortisol concentration, a biomarker of stress. Design, Setting, and Participants This was an unmasked, parallel-group, individually randomized clinical trial. Participants included 1950 mothers of stable LBW infants (weighing 1500-2250 g) in rural and semiurban low-income populations in North India enrolled between April 2017 and March 2018. Data analysis was performed from January to July 2020. Interventions Eligible participants were randomly assigned to the intervention or control group by block randomization. The mothers in the intervention group were supported to practice ciKMC until 28 days after birth or until the infant wriggled out of the KMC position (ie, was no longer staying in the KMC position). The intervention included promotion and support of skin-to-skin contact and exclusive breastfeeding through home visits. Main Outcomes and Measures Postpartum depressive symptoms at the end of the neonatal period were measured using the Patient Health Questionnaire-9, with a score of 10 or higher used to identify moderate-to-severe depressive symptoms. Salivary cortisol concentration was measured in a subsample of 550 mothers before and after breastfeeding on day 28 after birth. Results Of the 1950 participants (mean [SD] age, 23 [3.5] years), outcome assessment was completed for 974 of 1047 participants (93%) in the intervention group and 852 of 903 participants (94%) in the control group. Sixty-four percent of participants (1175 of 1826 participants) belonged to the lowest 3 wealth quintiles. The proportion of mothers with moderate-to-severe postpartum depressive symptoms was 10.8% (95% CI, 8.9%-12.9%; 105 of 974 mothers) in the intervention group vs 13.6% (95% CI, 11.4%-16.1%; 116 of 852 mothers) in the control group. The adjusted relative risk of moderate-to-severe maternal postpartum depressive symptoms was 0.75 (95% CI, 0.59-0.96), or an efficacy of 25%. There was no difference in day-28 salivary cortisol concentration between the ciKMC and control group mothers before or after breastfeeding. The analysis estimated that supporting 36 mothers to perform KMC at home would prevent 1 mother from experiencing moderate-to-severe postpartum depressive symptoms. Conclusions and Relevance These findings suggest that ciKMC practice may substantially reduce the risk of moderate-to-severe maternal postpartum depressive symptoms. This evidence supports KMC as an intervention to be incorporated in essential newborn care programs in low- and middle-income settings. Trial Registration Clinical Trials Registry-India Identifier: CTRI/2017/04/008430.",2021,There was no difference in day-28 salivary cortisol concentration between the ciKMC and control group mothers before or after breastfeeding.,"['Participants included 1950 mothers of stable LBW infants (weighing 1500-2250 g) in rural and semiurban low-income populations in North India enrolled between April 2017 and March 2018', '1950 participants (mean [SD] age, 23 [3.5] years', 'Mothers of Low-Birth-Weight Infants', '550 mothers before and after breastfeeding on day 28 after birth']","['KMC', 'practice ciKMC', 'Community-Initiated Kangaroo Mother Care', 'promotion and support of skin-to-skin contact and exclusive breastfeeding through home visits', 'community-initiated KMC (ciKMC', 'Kangaroo mother care (KMC', 'intervention or control group by block randomization']","['risk of moderate-to-severe maternal postpartum depressive symptoms', 'day-28 salivary cortisol concentration', 'Patient Health Questionnaire-9, with a score of 10 or higher used to identify moderate-to-severe depressive symptoms', 'adjusted relative risk of moderate-to-severe maternal postpartum depressive symptoms', 'Postpartum Depressive Symptoms and Stress', 'Salivary cortisol concentration', 'proportion of mothers with moderate-to-severe postpartum depressive symptoms', 'Main Outcomes and Measures\n\n\nPostpartum depressive symptoms', 'maternal risk of moderate-to-severe postpartum depressive symptoms']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0024045', 'cui_str': 'Low Income Population'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021288', 'cui_str': 'Low birth weight infant'}, {'cui': 'C3844103', 'cui_str': '550'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1257803', 'cui_str': 'Kangaroo-Mother Care'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0242205', 'cui_str': 'Breastfeeding, Exclusive'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0976874,There was no difference in day-28 salivary cortisol concentration between the ciKMC and control group mothers before or after breastfeeding.,"[{'ForeName': 'Bireshwar', 'Initials': 'B', 'LastName': 'Sinha', 'Affiliation': 'Centre for Health Research and Development, Society for Applied Studies, New Delhi, India.'}, {'ForeName': 'Halvor', 'Initials': 'H', 'LastName': 'Sommerfelt', 'Affiliation': 'Centre for Intervention Science in Maternal and Child Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Ashorn', 'Affiliation': 'Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University Hospital, Tampere University, Tampere, Finland.'}, {'ForeName': 'Sarmila', 'Initials': 'S', 'LastName': 'Mazumder', 'Affiliation': 'Centre for Health Research and Development, Society for Applied Studies, New Delhi, India.'}, {'ForeName': 'Sunita', 'Initials': 'S', 'LastName': 'Taneja', 'Affiliation': 'Centre for Health Research and Development, Society for Applied Studies, New Delhi, India.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'More', 'Affiliation': 'Clinical and Research Laboratories, Society for Applied Studies, New Delhi, India.'}, {'ForeName': 'Rajiv', 'Initials': 'R', 'LastName': 'Bahl', 'Affiliation': 'Department of Maternal, Newborn, Child and Adolescent Health, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Nita', 'Initials': 'N', 'LastName': 'Bhandari', 'Affiliation': 'Centre for Health Research and Development, Society for Applied Studies, New Delhi, India.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.6040'] 3027,33885773,Effect of Changing Electronic Health Record Opioid Analgesic Dispense Quantity Defaults on the Quantity Prescribed: A Cluster Randomized Clinical Trial.,"Importance Interventions to improve judicious prescribing of opioid analgesics for acute pain are needed owing to the risks of diversion, misuse, and overdose. Objective To assess the effect of modifying opioid analgesic prescribing defaults in the electronic health record (EHR) on prescribing and health service use. Design, Setting, and Participants A cluster randomized clinical trial with 2 parallel arms was conducted between June 13, 2016, and June 13, 2018, in a large urban health care system comprising 32 primary care and 4 emergency department (ED) sites in the Bronx, New York. Data were analyzed using a difference-in-differences method from 6 months before implementation through 18 months after implementation. Data were analyzed from January 2019 to February 2020. Interventions A default dispense quantity for new opioid analgesic prescriptions of 10 tablets (intervention) vs no change (control) in the EHR. Main Outcomes and Measures The primary outcome was the quantity of opioid analgesics prescribed with the new default prescription. Secondary outcomes were opioid analgesic reorders and health service use within 30 days after the new prescription. Intention-to-treat analysis was conducted. Results Overall, 21 331 patients received a new opioid analgesic prescription from 490 prescribers. Comparing the intervention and control arms, site, prescriber, and patient characteristics were similar. For the new prescription, compared with the control arm, patients in the intervention arm had significantly more prescriptions for 10 tablets or fewer (7.6 percentage points; 95% CI, 6.1-9.2 percentage points), a lower number of tablets prescribed (-2.1 tablets; 95% CI, -3.3 to -0.9 tablets), and lower morphine milligram equivalents (MME) prescribed (-14.6 MME; 95% CI, -22.6 to -6.6 MME). Within 30 days after the new prescription, significant differences remained in the number of tablets prescribed (-2.7 tablets; 95% CI, -4.8 to -0.6 tablets), but not MME (-15.8 MME; 95% CI, -33.8 to 2.2 MME). Within this 30-day period, there were no significant differences between the arms in health service use. Conclusions and Relevance In this study, implementation of a uniform reduced default dispense quantity of 10 tablets for opioid analgesic prescriptions led to a modest reduction in the quantity prescribed initially, without significantly increasing health service use. However, during 30 days after implementation, the influence on prescribing was mixed. Reducing EHR default dispense quantities for opioid analgesics is a feasible strategy that can be widely disseminated and may modestly reduce prescribing. Trial Registration ClinicalTrials.gov Identifier: NCT03003832.",2021,"For the new prescription, compared with the control arm, patients in the intervention arm had significantly more prescriptions for 10 tablets or fewer (7.6 percentage points; 95% CI, 6.1-9.2 percentage points), a lower number of tablets prescribed (-2.1 tablets; 95% CI, -3.3 to -0.9 tablets), and lower morphine milligram equivalents (MME) prescribed (-14.6 MME; 95% CI, -22.6 to -6.6 MME).","['Data were analyzed from January 2019 to February 2020', 'Participants\n\n\nA cluster randomized clinical trial with 2 parallel arms was conducted between June 13, 2016, and June 13, 2018, in a large urban health care system comprising 32 primary care and 4 emergency department (ED) sites in the Bronx, New York']","['new opioid analgesic prescription', 'Changing Electronic Health Record Opioid Analgesic Dispense Quantity Defaults']","['morphine milligram equivalents (MME', 'quantity of opioid analgesics prescribed with the new default prescription', 'number of tablets prescribed', 'opioid analgesic reorders and health service use within 30 days after the new prescription']","[{'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0041933', 'cui_str': 'Urban Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0027976', 'cui_str': 'New York'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0439210', 'cui_str': 'mg'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0066662', 'cui_str': '1,2,3,4,9,9-hexachloro-1,4,4a,5,8,8a-hexahydro-6- methyl-6,7-epoxy-1,4-methanonaphthalene'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",32.0,0.374711,"For the new prescription, compared with the control arm, patients in the intervention arm had significantly more prescriptions for 10 tablets or fewer (7.6 percentage points; 95% CI, 6.1-9.2 percentage points), a lower number of tablets prescribed (-2.1 tablets; 95% CI, -3.3 to -0.9 tablets), and lower morphine milligram equivalents (MME) prescribed (-14.6 MME; 95% CI, -22.6 to -6.6 MME).","[{'ForeName': 'Marcus A', 'Initials': 'MA', 'LastName': 'Bachhuber', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Nash', 'Affiliation': 'Institute for Implementation Science in Population Health, City University of New York, New York.'}, {'ForeName': 'William N', 'Initials': 'WN', 'LastName': 'Southern', 'Affiliation': 'Division of Hospital Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Moonseong', 'Initials': 'M', 'LastName': 'Heo', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Berger', 'Affiliation': 'Montefiore Information Technology, Montefiore Medical Center, Bronx, New York.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Schepis', 'Affiliation': 'Montefiore Information Technology, Montefiore Medical Center, Bronx, New York.'}, {'ForeName': 'Manu', 'Initials': 'M', 'LastName': 'Thakral', 'Affiliation': 'College of Nursing and Health Sciences, University of Massachusetts Boston, Boston.'}, {'ForeName': 'Chinazo O', 'Initials': 'CO', 'LastName': 'Cunningham', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.7481'] 3028,33866656,"Relationship between symptoms, barriers to care and healthcare utilisation among children under five in rural Mali.","OBJECTIVES To identify social and structural barriers to timely utilisation of qualified providers among children under five years in a high-mortality setting, rural Mali and to analyse how utilisation varies by symptom manifestation. METHODS Using baseline household survey data from a cluster-randomised trial, we assessed symptom patterns and healthcare trajectories of 5117 children whose mothers reported fever, diarrhoea, bloody stools, cough and/or fast breathing in the preceding two weeks. We examine associations between socio-demographic factors, symptoms and utilisation outcomes in mixed-effect logistic regressions. RESULTS Almost half of recently ill children reported multiple symptoms (46.2%). Over half (55.9%) received any treatment, while less than one-quarter (21.7%) received care from a doctor, nurse, midwife, trained community health worker or pharmacist within 24 h of symptom onset. Distance to primary health facility, household wealth and maternal education were consistently associated with better utilisation outcomes. While children with potentially more severe symptoms such as fever and cough with fast breathing or diarrhoea with bloody stools were more likely to receive any care, they were no more likely than children with fever to receive timely care with a qualified provider. CONCLUSIONS Even distances as short as 2-5 km significantly reduced children's likelihood of utilising healthcare relative to those within 2 km of a facility. While children with symptoms indicative of pneumonia and malaria were more likely to receive any care, suggesting mothers and caregivers recognised potentially severe illness, multiple barriers to care contributed to delays and low utilisation of qualified providers, illustrating the need for improved consideration of barriers.",2021,"Distance to primary health facility, household wealth, and maternal education were consistently associated with better utilization outcomes.","['qualified providers among children under five years in a high-mortality setting, rural Mali', '5,117 children whose mothers reported fever, diarrhea, bloody stools, cough, and/or fast breathing in the preceding two weeks', 'children under five in rural Mali']",[],"['fever and cough with fast breathing or diarrhea', 'multiple symptoms']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0024581', 'cui_str': 'Mali'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0018932', 'cui_str': 'Hematochezia'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0231835', 'cui_str': 'Tachypnea'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C4082118', 'cui_str': 'Two weeks'}]",[],"[{'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0231835', 'cui_str': 'Tachypnea'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0231217', 'cui_str': 'Multiple symptoms'}]",5117.0,0.0804657,"Distance to primary health facility, household wealth, and maternal education were consistently associated with better utilization outcomes.","[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Treleaven', 'Affiliation': 'Institute for Social Research, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Whidden', 'Affiliation': 'Muso, Bamako, Mali.'}, {'ForeName': 'Faith', 'Initials': 'F', 'LastName': 'Cole', 'Affiliation': 'Institute for Social Research, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Kassoum', 'Initials': 'K', 'LastName': 'Kayentao', 'Affiliation': 'Muso, Bamako, Mali.'}, {'ForeName': 'Mohamed Bana', 'Initials': 'MB', 'LastName': 'Traoré', 'Affiliation': 'Muso, Bamako, Mali.'}, {'ForeName': 'Djoumé', 'Initials': 'D', 'LastName': 'Diakité', 'Affiliation': 'Muso, Bamako, Mali.'}, {'ForeName': 'Seydou', 'Initials': 'S', 'LastName': 'Sidibé', 'Affiliation': 'Muso, Bamako, Mali.'}, {'ForeName': 'Tracy Kuo', 'Initials': 'TK', 'LastName': 'Lin', 'Affiliation': 'Institute for Health & Aging, University of California, San Francisco, CA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Boettiger', 'Affiliation': 'Institute for Health & Aging, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Souleymane', 'Initials': 'S', 'LastName': 'Cissouma', 'Affiliation': 'Mali Regional Health Directorate, Bankass, Mali.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Sanogo', 'Affiliation': 'Division of Prevention and Case Management, National Malaria Control Programme, Bamako, Mali.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Padian', 'Affiliation': 'Institute for Health & Aging, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Ari', 'Initials': 'A', 'LastName': 'Johnson', 'Affiliation': 'Muso, Bamako, Mali.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Institute for Health & Aging, University of California, San Francisco, CA, USA.'}]",Tropical medicine & international health : TM & IH,['10.1111/tmi.13592'] 3029,33906908,"Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.","BACKGROUND AND OBJECTIVES CKD and type 2 diabetes mellitus interact to increase the risk of major adverse cardiovascular events ( i.e. , cardiovascular death, nonfatal myocardial infarction, or stroke) and congestive heart failure. A maladaptive epigenetic response may be a cardiovascular risk driver and amenable to modification with apabetalone, a selective modulator of the bromodomain and extraterminal domain transcription system. We examined this question in a prespecified analysis of BETonMACE, a phase 3 trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS BETonMACE was an event-driven, randomized, double-blind, placebo-controlled trial comparing effects of apabetalone versus placebo on major adverse cardiovascular events and heart failure hospitalizations in 2425 participants with type 2 diabetes and a recent acute coronary syndrome, including 288 participants with CKD with eGFR <60 ml/min per 1.73 m 2 at baseline. The primary end point in BETonMACE was the time to the first major adverse cardiovascular event, with a secondary end point of time to hospitalization for heart failure. RESULTS Median follow-up was 27 months (interquartile range, 20-32 months). In participants with CKD, apabetalone compared with placebo was associated with fewer major adverse cardiovascular events (13 events in 124 patients [11%] versus 35 events in 164 patients [21%]; hazard ratio, 0.50; 95% confidence interval, 0.26 to 0.96) and fewer heart failure-related hospitalizations (three hospitalizations in 124 patients [3%] versus 14 hospitalizations in 164 patients [9%]; hazard ratio, 0.48; 95% confidence interval, 0.26 to 0.86). In the non-CKD group, the corresponding hazard ratio values were 0.96 (95% confidence interval, 0.74 to 1.24) for major adverse cardiovascular events, and 0.76 (95% confidence interval, 0.46 to 1.27) for heart failure-related hospitalization. Interaction of CKD on treatment effect was P =0.03 for major adverse cardiovascular events, and P =0.12 for heart failure-related hospitalization. Participants with CKD showed similar numbers of adverse events, regardless of randomization to apabetalone or placebo (119 [73%] versus 88 [71%] patients), and there were fewer serious adverse events (29% versus 43%; P =0.02) in the apabetalone group. CONCLUSIONS Apabetalone may reduce the incidence of major adverse cardiovascular events in patients with CKD and type 2 diabetes who have a high burden of cardiovascular disease.",2021,"In the non-CKD group, the corresponding hazard ratio values were 0.96 (95% confidence interval, 0.74 to 1.24) for major adverse cardiovascular events, and 0.76 (95% confidence interval, 0.46 to 1.27) for heart failure-related hospitalization.","['Diabetes, CKD, and Recent Acute Coronary Syndrome', '2425 participants with type 2 diabetes and a recent acute coronary syndrome, including 288 participants with CKD with eGFR <60 ml/min per 1.73 m 2 at baseline', 'patients with CKD and type 2 diabetes who have a high burden of cardiovascular disease']","['CKD', 'placebo', 'apabetalone versus placebo', 'Apabetalone']","['risk of major adverse cardiovascular events ( i.e. , cardiovascular death, nonfatal myocardial infarction, or stroke) and congestive heart failure', 'hazard ratio values', 'major adverse cardiovascular events', 'heart failure-related hospitalizations', 'time to the first major adverse cardiovascular event, with a secondary end point of time to hospitalization for heart failure', 'Cardiovascular Events', 'heart failure-related hospitalization', 'adverse events', 'serious adverse events', 'incidence of major adverse cardiovascular events', 'major adverse cardiovascular events and heart failure hospitalizations']","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C1097282', 'cui_str': '2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4520219', 'cui_str': 'apabetalone'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C1532109', 'cui_str': 'Ratio value'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",2425.0,0.642888,"In the non-CKD group, the corresponding hazard ratio values were 0.96 (95% confidence interval, 0.74 to 1.24) for major adverse cardiovascular events, and 0.76 (95% confidence interval, 0.46 to 1.27) for heart failure-related hospitalization.","[{'ForeName': 'Kamyar', 'Initials': 'K', 'LastName': 'Kalantar-Zadeh', 'Affiliation': 'Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Orange, California kkz@uci.edu.'}, {'ForeName': 'Gregory G', 'Initials': 'GG', 'LastName': 'Schwartz', 'Affiliation': 'Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Nicholls', 'Affiliation': 'Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia.'}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Buhr', 'Affiliation': 'Statistical Data Analysis Center, University of Wisconsin, Madison, Wisconsin.'}, {'ForeName': 'Henry N', 'Initials': 'HN', 'LastName': 'Ginsberg', 'Affiliation': 'Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.'}, {'ForeName': 'Jan O', 'Initials': 'JO', 'LastName': 'Johansson', 'Affiliation': 'Resverlogix Corporation, Calgary, Alberta, Canada.'}, {'ForeName': 'Ewelina', 'Initials': 'E', 'LastName': 'Kulikowski', 'Affiliation': 'Resverlogix Corporation, Calgary, Alberta, Canada.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Lebioda', 'Affiliation': 'Resverlogix Corporation, Calgary, Alberta, Canada.'}, {'ForeName': 'Peter P', 'Initials': 'PP', 'LastName': 'Toth', 'Affiliation': 'CGH Medical Center Sterling, Sterling, Illinois.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Wong', 'Affiliation': 'Resverlogix Corporation, Calgary, Alberta, Canada.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sweeney', 'Affiliation': 'Resverlogix Corporation, Calgary, Alberta, Canada.'}, {'ForeName': 'Kausik K', 'Initials': 'KK', 'LastName': 'Ray', 'Affiliation': 'Imperial Centre for Cardiovascular Disease Prevention, Imperial College, London, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.16751020'] 3030,32800319,Comparison effectiveness of acute coronary syndrome treatments on geriatric function.,"OBJECTIVES The study objectives were to compare short time complications, mortality, and effectiveness of primary Percutaneous Coronary Intervention (PCI) with optimal medical therapy in older adults with acute coronary syndromes (ACS). METHODS A prospective cohort study, which patients 60 years old and over with ACS were collecting by face to face interview and assessment of the electronic document, in two educational hospitals of Tehran medical university from May 2018 to Jan. 2019. Patients were evaluated in two groups (primary PCI and medical) in terms of complications, mortality and effectiveness, 24hours and 30 days after treatment. Initially, 312 patients were enrolled in the study that 192 were excluded for different reasons. In the final, 120 patients have met all inclusion criteria. RESULTS One hundred and twenty patients were collected with mean age 71.2±8.2 years old. In both groups every 1 point increase in Instrumental Activity Daily Living (IADL), the Major Adverse Cardiac Effect (MACE) was significantly reduced up to 88% (P=0.007). Short-term mortality was significantly higher in the optimal medical therapy group (P=0.006). In comparison complications 24hours between two groups, atrial fibrillation was significantly higher in the medical group which risk increased 11 times (OR=10.93, CI95%=1.38-87.04, P=0.02). CONCLUSIONS Notwithstanding, primary PCI reduced poor outcomes, and improve quality of life, but a lesser option for older adult patients. Primary PCI in older adult patients could maintain independence in functional daily living that results in reduced mortality and MACE considerably.",2020,Short-term mortality was significantly higher in the optimal medical therapy group (P=0.006).,"['312 patients were enrolled in the study that 192 were excluded for different reasons', 'One hundred and twenty patients were collected with mean age 71.2±8.2 years old', '120 patients have met all inclusion criteria', 'older adults with acute coronary syndromes (ACS', 'older adult patients', 'patients 60 years old and over with ACS were collecting by face to face interview and assessment of the electronic document, in two educational hospitals of Tehran medical university from May 2018 to Jan. 2019']","['acute coronary syndrome treatments', 'primary Percutaneous Coronary Intervention (PCI) with optimal medical therapy']","['short time complications, mortality, and effectiveness', 'Short-term mortality', 'geriatric function', 'quality of life', 'Instrumental Activity Daily Living (IADL), the Major Adverse Cardiac Effect (MACE', 'atrial fibrillation']","[{'cui': 'C4517706', 'cui_str': '312'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]",312.0,0.0242517,Short-term mortality was significantly higher in the optimal medical therapy group (P=0.006).,"[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Hekmat', 'Affiliation': 'Department of Cardiology, Ziaeian Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Sadat Mirzadeh', 'Affiliation': 'DDepartment of Geriatric Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, opposite the municipality of the region 17, Abouzar Street, Tehran, Iran. Electronic address: Fatima_mirzadeh@yahoo.com.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Sharifi', 'Affiliation': 'Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Raeesi', 'Affiliation': 'Department of Geriatric Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Ashraf', 'Affiliation': 'Cardiac Primary Prevention Research Center (CPPRC), Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran; Research Development Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}]",Annales de cardiologie et d'angeiologie,['10.1016/j.ancard.2020.07.014'] 3031,32893741,Comparison of two different cooling systems in alleviating thermal and physiological strain during prolonged exercise in the heat.,"This study compared the efficacy of an ice vest comprising of water (WATER) or a water-carbon (CARBON) emulsion on thermophysiological responses to strenuous exercise in the heat. Twelve male cyclists completed three 50-minute constant workload trials (55% of peak power output, ambient temperature 30.4 ± 0.6°C) with WATER, CARBON, and without ice vest (CONTROL), respectively. The increase in core body temperature (Tcore) was lower in WATER at 40 (-0.49 ± 0.34 °C) and 50 minutes (-0.48 ± 0.48 °C) and in CARBON at 30 (-0.41 ± 0.48 °C), 40 (-0.54 ± 0.51 °C), and 50 minutes (-0.67 ± 0.62 °C) as compared to CONTROL ( p  < 0.05, ES > 0.8). While heart rate and blood lactate kinetics did not differ between the conditions, statistical main effects in favour of both WATER and CARBON were found for thermal sensation (condition p  < 0.001 and interaction p  < 0.01) and rating of perceived exertion (condition p  < 0.05). Per-cooling with CARBON and WATER similarly reduced Tcore but not physiological strain during prolonged exercise in the heat. Practitioner Summary: Exercise in the heat is characterised by increases in thermophysiological strain. Both per-cooling with a novel carbon-based and a conventional water-based ice vest were shown to reduce core temperature significantly. However, due to its lower mass, the carbon-based system may be recommended especially for weight-bearing sports.",2021,The increase in core body temperature (Tcore) was lower in WATER at 40 (-0.49 ± 0.34 °C) and 50 minutes (-0.48 ± 0.48,['Twelve male cyclists'],['ice vest comprising of water (WATER) or a water-carbon (CARBON) emulsion'],"['heart rate and blood lactate kinetics', 'core body temperature (Tcore', 'alleviating thermal and physiological strain', 'rating of perceived exertion', 'thermal sensation ']","[{'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0020746', 'cui_str': 'Ice'}, {'cui': 'C0453884', 'cui_str': 'Vest'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0007009', 'cui_str': 'Carbon'}, {'cui': 'C0014020', 'cui_str': 'Emulsions'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0456240', 'cui_str': 'Core body temperature'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0039478', 'cui_str': 'Thermal sensation, function'}]",12.0,0.0279354,The increase in core body temperature (Tcore) was lower in WATER at 40 (-0.49 ± 0.34 °C) and 50 minutes (-0.48 ± 0.48,"[{'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Keller', 'Affiliation': 'Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Kohne', 'Affiliation': 'Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Wilhelm', 'Initials': 'W', 'LastName': 'Bloch', 'Affiliation': 'Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Schumann', 'Affiliation': 'Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.'}]",Ergonomics,['10.1080/00140139.2020.1818835'] 3032,34320223,Early resistance training-mediated stimulation of daily muscle protein synthetic responses to higher habitual protein intake in middle-aged adults.,"KEY POINTS The ingestion of protein potentiates the stimulation of myofibrillar protein synthesis rates after an acute bout of resistance exercise. Protein supplementation (eating above the protein Recommended Dietary Allowance) during resistance training has been shown to maximize lean mass and strength gains in healthy young and older adults. Here, contractile, oxidative, and structural protein synthesis were assessed in skeletal muscle in response to a moderate or higher protein diet during the early adaptive phase of resistance training in middle-aged adults. The stimulation of myofibrillar, mitochondrial or collagen protein synthesis rates during 0-3 weeks of resistance training is not further enhanced by a higher protein diet. These results show that moderate protein diets are sufficient to support the skeletal muscle adaptive response during the early phase of a resistance training programme. ABSTRACT Protein ingestion augments muscle protein synthesis (MPS) rates acutely after resistance exercise and can offset age-related loss in muscle mass. Skeletal muscle contains a variety of protein pools, such as myofibrillar (contractile), mitochondrial (substrate oxidation), and collagen (structural support) proteins, and the sensitivity to nutrition and exercise seems to be dependent on the major protein fraction studied. However, it is unknown how free-living conditions with high dietary protein density and habitual resistance exercise mediates muscle protein subfraction synthesis. Therefore, we investigated the effect of moderate (MOD: 1.06 ± 0.22 g kg -1  day -1 ) or high (HIGH: 1.55 ± 0.25 g kg -1  day -1 ) protein intake on daily MPS rates within the myofibrillar (MyoPS), mitochondrial (MitoPS) and collagen (CPS) protein fractions in middle-aged men and women (n = 20, 47 ± 1 years, BMI 28 ± 1 kg m -2 ) during the early phase (0-3 weeks) of a dietary counselling-controlled resistance training programme. Participants were loaded with deuterated water, followed by daily maintenance doses throughout the intervention. Muscle biopsies were collected at baseline and after weeks 1, 2 and 3. MyoPS in the HIGH condition remained constant (P = 1.000), but MOD decreased over time (P = 0.023). MitoPS decreased after 0-3 weeks when compared to 0-1 week (P = 0.010) with no effects of protein intake (P = 0.827). A similar decline with no difference between groups (P = 0.323) was also observed for CPS (P = 0.007). Our results demonstrated that additional protein intake above moderate amounts does not potentiate the stimulation of longer-term MPS responses during the early stage of resistance training adaptations in middle-aged adults.",2021,MitoPS decreased after 0-3 weeks when compared to 0-1 week (P = 0.010) with no effects of protein intake (P = 0.827).,"['middle-aged adults', 'in middle-aged men and women (n\xa0=\xa020, 47\xa0±\xa01\xa0years, BMI 28\xa0±\xa01\xa0kg', 'healthy young and older adults']","['high (HIGH: 1.55\xa0±\xa00.25\xa0g\xa0kg -1 \xa0day -1 ) protein intake on daily MPS rates within the myofibrillar (MyoPS), mitochondrial (MitoPS) and collagen (CPS) protein fractions', 'Early resistance training-mediated stimulation of daily muscle protein synthetic responses', 'Protein supplementation (eating above the protein Recommended Dietary Allowance', 'dietary counselling-controlled resistance training programme']","['skeletal muscle adaptive response', 'Muscle biopsies', 'MOD', 'MitoPS', 'stimulation of myofibrillar, mitochondrial or collagen protein synthesis rates']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0026832', 'cui_str': 'Muscle Protein'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0770246', 'cui_str': 'Protein supplementation'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0524787', 'cui_str': 'Recommended Dietary Allowance'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0185283', 'cui_str': 'Biopsy of muscle'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0597295', 'cui_str': 'Genetic translation'}]",,0.00783044,MitoPS decreased after 0-3 weeks when compared to 0-1 week (P = 0.010) with no effects of protein intake (P = 0.827).,"[{'ForeName': 'Amadeo F', 'Initials': 'AF', 'LastName': 'Salvador', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Colleen F', 'Initials': 'CF', 'LastName': 'McKenna', 'Affiliation': 'Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Kevin J M', 'Initials': 'KJM', 'LastName': 'Paulussen', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Alexander R', 'Initials': 'AR', 'LastName': 'Keeble', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Andrew T', 'Initials': 'AT', 'LastName': 'Askow', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Hsin-Yu', 'Initials': 'HY', 'LastName': 'Fang', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Zhong', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Roy J. Carver Biotechnology Center, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Alexander V', 'Initials': 'AV', 'LastName': 'Ulanov', 'Affiliation': 'Roy J. Carver Biotechnology Center, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Paluska', 'Affiliation': 'Department of Family Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Daniel R', 'Initials': 'DR', 'LastName': 'Moore', 'Affiliation': 'Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Burd', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}]",The Journal of physiology,['10.1113/JP281907'] 3033,33891718,The Use of a Brief Family Intervention to Reduce Dropout Among Veterans in Individual Trauma-Focused Treatment: A Randomized Controlled Trial.,"Dropout from trauma-focused treatment for posttraumatic stress disorder (PTSD) represents a daunting challenge for the field, particularly among military and veteran samples. Family involvement may help to increase the effectiveness of PTSD treatment while also improving retention. We tested a two-session brief family intervention (BFI) protocol delivered as an adjunct to individual trauma-focused treatment among a sample of 20 veteran-family member dyads (N = 40). Willingness to participate in the family-inclusive protocol was high, with over 85% of veterans and family members who were screened agreeing to take part. All enrolled veterans were beginning a course of either cognitive processing therapy (CPT) or prolonged exposure (PE), delivered in outpatient Veterans Affairs clinics. Family members were randomized to either receive or not receive the BFI from study clinicians. In the BFI condition, 20.0% of veterans dropped out of CPT/PE before the 16-week study end; the remainder were either still attending on-protocol sessions or had completed the full protocol. In the control condition, 40.0% of veterans dropped out of CPT/PE before the end of the study. Observed significant, large-magnitude decreases in PTSD symptoms over time did not differ by condition, ESsg range = -1.12 to -2.04. Accommodation did not significantly decrease over time in either condition, ESsg range = 0.18 to -0.98. The BFI represents a promising option for veterans, family members, and clinicians who are seeking a brief, feasible, narrowly focused method for incorporating families into veterans' individual trauma-focused therapy and potentially reducing the rate of dropout.",2021,"Accommodation did not significantly decrease over time in either condition, ESsg range = 0.18 to -0.98.",['Family members'],"['Brief Family Intervention', 'cognitive processing therapy (CPT) or prolonged exposure (PE']",['PTSD symptoms'],"[{'cui': 'C0086282', 'cui_str': 'Person in the family'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0325483,"Accommodation did not significantly decrease over time in either condition, ESsg range = 0.18 to -0.98.","[{'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Thompson-Hollands', 'Affiliation': 'National Center for PTSD at VA Boston Healthcare System, Behavioral Science Division, Boston, Massachusetts, United States.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Lee', 'Affiliation': 'National Center for PTSD at VA Boston Healthcare System, Behavioral Science Division, Boston, Massachusetts, United States.'}, {'ForeName': 'Denise M', 'Initials': 'DM', 'LastName': 'Sloan', 'Affiliation': 'National Center for PTSD at VA Boston Healthcare System, Behavioral Science Division, Boston, Massachusetts, United States.'}]",Journal of traumatic stress,['10.1002/jts.22680'] 3034,33893671,"The effect of curcumin and zinc co-supplementation on glycemic parameters in overweight or obese prediabetic subjects: A phase 2 randomized, placebo-controlled trial with a multi-arm, parallel-group design.","Management of prediabetes is a critical step to prevent type-2 diabetes. Curcumin and zinc have been studied as an antioxidant, antiinflammatory, and antidiabetic agents. In this clinical trial, 84 subjects were randomized into curcumin (500 mg), zinc (30 mg), zinc and curcumin, and placebo groups for 90 days. At the baseline and the end of the study, the outcomes (fasting plasma glucose (FPG), 2-hour postprandial glucose (2hpp), HbA 1 C, insulin, insulin sensitivity (IS), insulin resistance (IR), β-cell function (BCF), weight, body mass index (BMI), dietary intake, and physical activity (PA)) were measured. A hypocaloric diet and PA were recommended for all subjects. In total, 82 subjects completed the study. After the intervention, dietary intake, PA, weight, and BCF% did not show a significant difference among the groups. However, subjects taking only zinc and zinc and curcumin groups experienced decreased BMI compared to the placebo (p = .01 and .007, respectively). The three treated groups had improved FPG (p = .01), 2hpp (p = .003), HbA1C (p = .004), insulin (p = .001), IS% (p = .001), and IR (p < .001) compared to the placebo. Based on these results, zinc and curcumin supplementation exerted a beneficial effect on several key glycemic parameters.",2021,"The three treated groups had improved FPG (p = .01), 2hpp (p = .003), HbA1C (p = .004), insulin (p = .001), IS% (p = .001), and IR (p < .001) compared to the placebo.","['82 subjects completed the study', 'overweight or obese prediabetic subjects', '84 subjects']","['curcumin and zinc co-supplementation', 'placebo', 'zinc (30\u2009mg), zinc and curcumin, and placebo', 'curcumin', 'zinc and curcumin supplementation']","['FPG', 'glycemic parameters', 'BMI', 'dietary intake, PA, weight, and BCF', 'outcomes (fasting plasma glucose (FPG), 2-hour postprandial glucose (2hpp), HbA 1 C, insulin, insulin sensitivity (IS), insulin resistance (IR), β-cell function (BCF), weight, body mass index (BMI), dietary intake, and physical activity (PA']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0007613', 'cui_str': 'Physiology, Cell'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",84.0,0.0979466,"The three treated groups had improved FPG (p = .01), 2hpp (p = .003), HbA1C (p = .004), insulin (p = .001), IS% (p = .001), and IR (p < .001) compared to the placebo.","[{'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Karandish', 'Affiliation': 'Nutrition and Metabolic Diseases Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Mozaffari-Khosravi', 'Affiliation': 'Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.'}, {'ForeName': 'Seyed Mohammad', 'Initials': 'SM', 'LastName': 'Mohammadi', 'Affiliation': 'Endocrinology & Metabolism, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.'}, {'ForeName': 'Bahman', 'Initials': 'B', 'LastName': 'Cheraghian', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Health Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Azhdari', 'Affiliation': 'Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.7136'] 3035,33894832,"Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial.","BACKGROUND Long-term loss of arm function after ischaemic stroke is common and might be improved by vagus nerve stimulation paired with rehabilitation. We aimed to determine whether this strategy is a safe and effective treatment for improving arm function after stroke. METHODS In this pivotal, randomised, triple-blind, sham-controlled trial, done in 19 stroke rehabilitation services in the UK and the USA, participants with moderate-to-severe arm weakness, at least 9 months after ischaemic stroke, were randomly assigned (1:1) to either rehabilitation paired with active vagus nerve stimulation (VNS group) or rehabilitation paired with sham stimulation (control group). Randomisation was done by ResearchPoint Global (Austin, TX, USA) using SAS PROC PLAN (SAS Institute Software, Cary, NC, USA), with stratification by region (USA vs UK), age (≤30 years vs >30 years), and baseline Fugl-Meyer Assessment-Upper Extremity (FMA-UE) score (20-35 vs 36-50). Participants, outcomes assessors, and treating therapists were masked to group assignment. All participants were implanted with a vagus nerve stimulation device. The VNS group received 0·8 mA, 100 μs, 30 Hz stimulation pulses, lasting 0·5 s. The control group received 0 mA pulses. Participants received 6 weeks of in-clinic therapy (three times per week; total of 18 sessions) followed by a home exercise programme. The primary outcome was the change in impairment measured by the FMA-UE score on the first day after completion of in-clinic therapy. FMA-UE response rates were also assessed at 90 days after in-clinic therapy (secondary endpoint). All analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, NCT03131960. FINDINGS Between Oct 2, 2017, and Sept 12, 2019, 108 participants were randomly assigned to treatment (53 to the VNS group and 55 to the control group). 106 completed the study (one patient for each group did not complete the study). On the first day after completion of in-clinic therapy, the mean FMA-UE score increased by 5·0 points (SD 4·4) in the VNS group and by 2·4 points (3·8) in the control group (between group difference 2·6, 95% CI 1·0-4·2, p=0·0014). 90 days after in-clinic therapy, a clinically meaningful response on the FMA-UE score was achieved in 23 (47%) of 53 patients in the VNS group versus 13 (24%) of 55 patients in the control group (between group difference 24%, 6-41; p=0·0098). There was one serious adverse event related to surgery (vocal cord paresis) in the control group. INTERPRETATION Vagus nerve stimulation paired with rehabilitation is a novel potential treatment option for people with long-term moderate-to-severe arm impairment after ischaemic stroke. FUNDING MicroTransponder.",2021,"There was one serious adverse event related to surgery (vocal cord paresis) in the control group. ","['108 participants', 'people with long-term moderate-to-severe arm impairment after ischaemic stroke', '19 stroke rehabilitation services in the UK and the USA, participants with moderate-to-severe arm weakness, at least 9 months after ischaemic stroke']","['home exercise programme', 'rehabilitation paired with active vagus nerve stimulation (VNS group) or rehabilitation paired with sham stimulation (control group', 'vagus nerve stimulation device', '0 mA pulses', 'Vagus nerve stimulation paired with rehabilitation', '0·8 mA, 100 μs, 30 Hz stimulation pulses, lasting 0·5']","['baseline Fugl-Meyer Assessment-Upper Extremity (FMA-UE) score', 'FMA-UE score', 'mean FMA-UE score', 'FMA-UE response rates', 'change in impairment measured by the FMA-UE score']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0204097', 'cui_str': 'Stroke rehabilitation'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0751409', 'cui_str': 'Monoparesis - arm'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0475647', 'cui_str': 'Home exercise program'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",108.0,0.122065,"There was one serious adverse event related to surgery (vocal cord paresis) in the control group. ","[{'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Dawson', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Electronic address: jesse.dawson@glasgow.ac.uk.'}, {'ForeName': 'Charles Y', 'Initials': 'CY', 'LastName': 'Liu', 'Affiliation': 'USC Neurorestoration Center and Department of Neurological Surgery, USC Keck School of Medicine, Los Angeles, CA, USA; Rancho Los Amigos National Rehabilitation Center, Downey, CA, USA.'}, {'ForeName': 'Gerard E', 'Initials': 'GE', 'LastName': 'Francisco', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, The University of Texas Health Science Center McGovern Medical School, Houston, TX, USA; The Institute for Rehabilitation and Research (TIRR) Memorial Hermann Hospital, Houston, Texas, USA.'}, {'ForeName': 'Steven C', 'Initials': 'SC', 'LastName': 'Cramer', 'Affiliation': 'Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; California Rehabilitation Institute, Los Angeles, CA, USA.'}, {'ForeName': 'Steven L', 'Initials': 'SL', 'LastName': 'Wolf', 'Affiliation': 'Department of Rehabilitation Medicine, Division of Physical Therapy, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Dixit', 'Affiliation': 'Stroke Service, The Newcastle Upon Tyne Hospitals National Health Service Foundation Trust, Newcastle, UK.'}, {'ForeName': 'Jen', 'Initials': 'J', 'LastName': 'Alexander', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Rushna', 'Initials': 'R', 'LastName': 'Ali', 'Affiliation': 'Department of Neurosciences, Spectrum Health, Grand Rapids, MI, USA.'}, {'ForeName': 'Benjamin L', 'Initials': 'BL', 'LastName': 'Brown', 'Affiliation': 'Department of Neurosurgery, Ochsner Neuroscience Institute, Covington, LA, USA.'}, {'ForeName': 'Wuwei', 'Initials': 'W', 'LastName': 'Feng', 'Affiliation': 'Department of Neurology, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'DeMark', 'Affiliation': 'Brooks Rehabilitation, Jacksonville, FL, USA.'}, {'ForeName': 'Leigh R', 'Initials': 'LR', 'LastName': 'Hochberg', 'Affiliation': 'Department of Neurology, Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; School of Engineering and Carney Institute for Brain Science, Brown University, Providence, RI, USA; VA RR&D Center for Neurorestoration and Neurotechnology, VA Medical Center, Providence, RI, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Kautz', 'Affiliation': 'Ralph H Johnson VA Medical Center, Charleston, SC, USA; Department of Health Sciences and Research, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Arshad', 'Initials': 'A', 'LastName': 'Majid', 'Affiliation': 'Sheffield Institute for Neurological Sciences (SITraN), University of Sheffield, Sheffield, UK; Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, UK.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': ""O'Dell"", 'Affiliation': 'Clinical Rehabilitation Medicine, Weill Cornell Medicine, New York City, NY, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Pierce', 'Affiliation': 'MicroTransponder, Austin, TX, USA.'}, {'ForeName': 'Cecília N', 'Initials': 'CN', 'LastName': 'Prudente', 'Affiliation': 'MicroTransponder, Austin, TX, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Redgrave', 'Affiliation': 'Sheffield Institute for Neurological Sciences (SITraN), University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Duncan L', 'Initials': 'DL', 'LastName': 'Turner', 'Affiliation': 'School of Health, Sport and Bioscience, University of East London, London, UK.'}, {'ForeName': 'Navzer D', 'Initials': 'ND', 'LastName': 'Engineer', 'Affiliation': 'MicroTransponder, Austin, TX, USA.'}, {'ForeName': 'Teresa J', 'Initials': 'TJ', 'LastName': 'Kimberley', 'Affiliation': 'Department of Neurology, Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Physical Therapy, MGH Institute of Health Professions, Boston, MA, USA.'}]","Lancet (London, England)",['10.1016/S0140-6736(21)00475-X'] 3036,33899268,Oral health-related quality of life during supportive periodontal therapy: results from a randomized clinical trial.,"AIM Assessment of Oral Health Impact Profile (OHIP-14) during a randomized controlled trial of supportive periodontal therapy (SPT) consisting of oral prophylaxis with oral hygiene instructions only (test) or in conjunction with subgingival instrumentation (control). METHODS OHIP-14 was assessed at baseline, 6, 12, 18 and 24 months. Data from 62 participants (50.97 ± 9.26 years, 24 smokers) were analysed by GEE and Logistic regression. OHIP-14 means, effect size, floor and ceiling effect and minimal important difference were calculated. Sum of OHIP-14 (severity), numbers of responses (extent) ""fairly often"" (FO) or ""very often"" (VO) and percentage of people (prevalence) reporting FO or VO were computed. RESULTS At baseline, low scores of OHIP-14 were observed for test (7.67 ± 9.27) and control (6.51 ± 7.47) with a decreasing trend during SPT, without differences between or intra-groups over time. At 6 months, a difference was observed in the OHIP-14 prevalence (p = .03), without differences in severity and extent. Smoking status and plaque >15% (moderate oral hygiene) at 24 months were associated with higher OHIP-14 prevalence scores at that point of time (p = .038 and p = .034, respectively). CONCLUSION Patients submitted to two different modalities of SPT maintained low OHIP-14 scores over 2 years of care.",2021,"At 6 months a difference was observed in the OHIP-14 prevalence (p=0.03), without differences in severity and extent.","['62 participants (50.97 ± 9.26 years, 24 smokers']","['supportive periodontal therapy (SPT) consisting of oral prophylaxis with oral hygiene instructions only (test) or in conjunction with subgingival instrumentation (control', 'Oral Health Impact Profile (OHIP-14', 'supportive periodontal therapy']","['Smoking status and plaque', 'OHIP-14 prevalence scores', 'OHIP-14 prevalence', 'low OHIP-14 scores', 'low scores of OHIP-14', 'Oral health-related quality of life', ""Sum of OHIP-14 (severity), numbers of responses (extent) 'fairly often' (FO) or 'very often' (VO) and percentage of people (prevalence) reporting FO or VO"", 'OHIP-14 means, effect size, floor and ceiling effect and minimal important difference']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0204131', 'cui_str': 'Oral hygiene education'}, {'cui': 'C0595817', 'cui_str': 'Subgingival route'}, {'cui': 'C0021632', 'cui_str': 'instrumentation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]","[{'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0016249', 'cui_str': 'Walking surface of room'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}]",62.0,0.159516,"At 6 months a difference was observed in the OHIP-14 prevalence (p=0.03), without differences in severity and extent.","[{'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Mendez', 'Affiliation': 'Private clinic, Porto Alegre, Brazil.'}, {'ForeName': 'Patricia Daniela Melchiors', 'Initials': 'PDM', 'LastName': 'Angst', 'Affiliation': 'Conservative Dentistry Department, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Rui Vicente', 'Initials': 'RV', 'LastName': 'Oppermann', 'Affiliation': 'Conservative Dentistry Department, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Ubele', 'Initials': 'U', 'LastName': 'van der Velden', 'Affiliation': 'Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Sabrina Carvalho', 'Initials': 'SC', 'LastName': 'Gomes', 'Affiliation': 'Conservative Dentistry Department, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.'}]",Journal of clinical periodontology,['10.1111/jcpe.13473'] 3037,33896706,SMARTphone Based Cardiovascular Risk Reduction in BREAST Cancer Patients (SMART-BREAST): A Randomised Controlled Trial Protocol.,"INTRODUCTION Breast cancer survivors are at greater risk for cardiovascular-related mortality compared to women without breast cancer. Accordingly, attention to reducing the risk of cardiovascular disease must be a priority in the long-term management of these patients. With the exponential rise in cancer survivors, there is a need for innovative cardio-oncology programs. This paper describes the study design of a randomised controlled trial assessing the effectiveness of a smartphone-based cardiovascular risk reduction program in improving physical activity and cardiovascular health in patients undergoing treatment for breast cancer. METHODS AND ANALYSIS The aim of this study is to assess the efficacy and usability of a smartphone-based model of care for exercise promotion, cardiovascular risk reduction and community engagement in women undergoing treatment for breast cancer. This will be achieved by testing our personalised smartphone application ""BreastMate"", as an adjunct to standard care in a single-blinded, parallel, randomised controlled trial. The primary outcome of the trial is change in exercise capacity, as measured by the 6-minute walk test distance at 12 months compared to baseline. Secondary endpoints include improvements in cardiovascular risk factor status and quality of life, received dose intensity of chemotherapy and major adverse cardiovascular events. ETHICS Multicentre ethical approval has been granted by the Austin Hospital (HREC/47081/Austin/2018). DISSEMINATION OF RESULTS The analysed results will be published in a peer reviewed journal on completion of the clinical trial. REGISTRATION DETAILS SMART-BREAST has been prospectively registered with the Australia and New Zealand Clinical Trials Registry (ANZCTR12620000007932).",2021,"This will be achieved by testing our personalised smartphone application ""BreastMate"", as an adjunct to standard care in a single-blinded, parallel, randomised controlled trial.","['patients undergoing treatment for breast cancer', 'women undergoing treatment for breast cancer', 'cancer survivors', 'BREAST Cancer Patients (SMART-BREAST']","['SMARTphone', 'smartphone-based model of care for exercise promotion, cardiovascular risk reduction and community engagement', 'smartphone-based cardiovascular risk reduction program']","['physical activity and cardiovascular health', 'Cardiovascular Risk Reduction', 'change in exercise capacity, as measured by the 6-minute walk test distance', 'cardiovascular risk factor status and quality of life, received dose intensity of chemotherapy and major adverse cardiovascular events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0582434', 'cui_str': 'Giving encouragement to exercise'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",,0.455594,"This will be achieved by testing our personalised smartphone application ""BreastMate"", as an adjunct to standard care in a single-blinded, parallel, randomised controlled trial.","[{'ForeName': 'Alexandra C', 'Initials': 'AC', 'LastName': 'Murphy', 'Affiliation': 'Department of Cardiology, Austin Health, Melbourne, Vic, Australia; Department of Medicine, University of Melbourne, Vic, Australia; Department of Oncology, The Olivia Newton John Cancer and Wellness Centre, Melbourne, Vic, Australia; Department of Cardiology, Epworth HealthCare, Melbourne, Vic, Australia.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Farouque', 'Affiliation': 'Department of Cardiology, Austin Health, Melbourne, Vic, Australia; Department of Medicine, University of Melbourne, Vic, Australia.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Yeo', 'Affiliation': 'Department of Oncology, The Olivia Newton John Cancer and Wellness Centre, Melbourne, Vic, Australia.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Dick', 'Affiliation': 'Department of Cardiology, Epworth HealthCare, Melbourne, Vic, Australia.'}, {'ForeName': 'Anoop N', 'Initials': 'AN', 'LastName': 'Koshy', 'Affiliation': 'Department of Cardiology, Austin Health, Melbourne, Vic, Australia; Department of Medicine, University of Melbourne, Vic, Australia.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Roccisano', 'Affiliation': 'Department of Cardiology, Austin Health, Melbourne, Vic, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Reid', 'Affiliation': 'School of Public Health, Curtin University, Perth, WA, Australia.'}, {'ForeName': 'Jaishankar', 'Initials': 'J', 'LastName': 'Raman', 'Affiliation': 'Department of Cardiology, Austin Health, Melbourne, Vic, Australia; Department of Medicine, University of Melbourne, Vic, Australia; Department of Medicine, Deakin University, Geelong, Vic, Australia; Department of Medicine, The University of Illinois, Champaign, IL, USA.'}, {'ForeName': 'Leighton', 'Initials': 'L', 'LastName': 'Kearney', 'Affiliation': 'Department of Cardiology, Austin Health, Melbourne, Vic, Australia; Department of Medicine, University of Melbourne, Vic, Australia.'}, {'ForeName': 'Matias B', 'Initials': 'MB', 'LastName': 'Yudi', 'Affiliation': 'Department of Cardiology, Austin Health, Melbourne, Vic, Australia; Department of Medicine, University of Melbourne, Vic, Australia; Department of Cardiology, Epworth HealthCare, Melbourne, Vic, Australia. Electronic address: matiasyudi@gmail.com.'}]","Heart, lung & circulation",['10.1016/j.hlc.2021.03.271'] 3038,33896622,Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges.,"BACKGROUND Although a number of neuroimaging biomarkers for response have been proposed, none have been tested prospectively for direct effects on treatment outcomes. To the best of our knowledge, this is the first prospective test of the clinical utility of the use of an imaging biomarker to select treatment for patients with major depressive disorder. METHODS Eligible participants (n = 60) had a primary diagnosis of major depressive disorder and were assigned to either escitalopram or cognitive behavioral therapy based on fluorodeoxyglucose positron emission tomography activity in the right anterior insula. The overall study remission rate after 12 weeks of treatment, based on the end point Hamilton Depression Rating Scale score, was then examined for futility and benefit of the strategy. RESULTS Remission rates demonstrated lack of futility at the end of stage 1 (37%, 10/27), and the study proceeded to stage 2. After adjustment for the change in stage 2 sample size, the complete remission rate did not demonstrate evidence of benefit (37.7%, 95% confidence interval, 26.3%-51.4%, p = .38). However, total remission rates (complete and partial remission) did reach significance in post hoc analysis (49.1%, 95% confidence interval, 37.6%-60.7%, p = .020). CONCLUSIONS The study shows some evidence for a role of the right anterior insula in the clinical choice of major depressive disorder monotherapy. The effect size, however, is insufficient for the use of insula activity as a sole predictive biomarker of remission. The study also demonstrates the logistical difficulties in establishing clinical utility of biomarkers.",2021,"However, total remission rates (complete and partial remission) did reach significance in post hoc analysis (49.1%, 95% confidence interval, 37.6%-60.7%, p = .020). ","['Major Depressive Disorder', 'patients with major depressive disorder', 'Eligible participants (n\xa0= 60) had a primary diagnosis of major depressive disorder']",['escitalopram or cognitive behavioral therapy based on fluorodeoxyglucose positron emission tomography activity'],"['overall study remission rate', 'total remission rates', 'Hamilton Depression Rating Scale score', 'complete remission rate']","[{'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332137', 'cui_str': 'Principal diagnosis'}]","[{'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3641247', 'cui_str': 'FDG PET scan'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}]",,0.141152,"However, total remission rates (complete and partial remission) did reach significance in post hoc analysis (49.1%, 95% confidence interval, 37.6%-60.7%, p = .020). ","[{'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Kelley', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia. Electronic address: mekelle@emory.edu.'}, {'ForeName': 'Ki Sueng', 'Initials': 'KS', 'LastName': 'Choi', 'Affiliation': 'Center for Advanced Circuit Therapeutics, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Justin K', 'Initials': 'JK', 'LastName': 'Rajendra', 'Affiliation': 'Scientific and Statistical Computing Core, National Institute of Mental Health/National Institutes of Health/U.S. Department of Health and Human Services, Bethesda, Maryland.'}, {'ForeName': 'W Edward', 'Initials': 'WE', 'LastName': 'Craighead', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia; Department of Psychology, Emory University, Atlanta, Georgia.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Rakofsky', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Boadie W', 'Initials': 'BW', 'LastName': 'Dunlop', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Helen S', 'Initials': 'HS', 'LastName': 'Mayberg', 'Affiliation': 'Center for Advanced Circuit Therapeutics, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.'}]",Biological psychiatry,['10.1016/j.biopsych.2021.02.966'] 3039,33904798,"The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial.","PURPOSE Prophylactic antibiotics are routinely given at the time of catheter removal post-radical prostatectomy (RP). The low rate of infectious complications entails that large sample sizes are required for randomized controlled trials, a challenge given the cost of standard randomized controlled trials. We evaluated infectious complications associated with 1 vs 3 days of prophylactic antibiotics at the time of catheter removal post-RP using a novel, clinically integrated trial with randomization at the surgeon level. MATERIALS AND METHODS Surgeons were cluster randomized for periods of 3 months to prescribe 1-day vs 3-day regimen of prophylactic antibiotics at the time of catheter removal. The primary end point was an infectious complication as routinely captured by nursing phone call within 10 days of catheter removal and defined as positive urine cultures (≥10 5 CFU) and at least 1 of the following symptoms: fever (>38°C), urgency, frequency, dysuria or suprapubic tenderness. RESULTS A total of 824 patients were consented and underwent RP with, respectively, 389 and 435 allocated to 1-day and 3-day antibiotics, predominantly ciprofloxacin. Accrual was achieved within 3 years: 95% vs 88% of patients received the allocated 3-day vs 1-day antibiotic regimen. There were 0 urinary tract infections (0%) in the 1-day regimen and 3 urinary tract infections (0.7%) in the 3-day regimen, meeting our prespecified criterion for declaring the 1-day regimen to be noninferior. CONCLUSIONS A clinically integrated trial using cluster randomization accrued rapidly with no important logistical problems and negligible burden on surgeons. If surgeons choose to prescribe empiric prophylactic antibiotics after catheter removal following RP, then the duration should not exceed 1 day.",2021,"There was 0 UTI (0%) in the 1-day regimen and 3 UTIs (0.7%) in the 3-day regimen, meeting our prespecified criterion for declaring the 1-day regimen to be non-inferior. CONCLUSION A clinically integrated trial using cluster randomization accrued rapidly with no important logistical problems and negligible burden on surgeons.","['Surgeons', '824 patients were consented and underwent RP, with respectively, 389 and 435 allocated to 1-and 3-day antibiotics, predominately']","['ciprofloxacin', 'catheter removal post radical prostatectomy (RP', 'prescribe 1-day versus 3-day regimen of prophylactic antibiotics']","['infectious complication as routinely captured by nursing phone call within 10 days of catheter removal and defined as: positive urine cultures (≥10 5 CFU) and at least 1 of the following symptoms: fever (>38C), urgency, frequency, dysuria or suprapubic tenderness']","[{'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C4517752', 'cui_str': '389'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0332251', 'cui_str': 'Predominate'}]","[{'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0394884', 'cui_str': 'Removal of catheter'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0362063', 'cui_str': 'Other prophylactic chemotherapy'}]","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0394884', 'cui_str': 'Removal of catheter'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0430404', 'cui_str': 'Urine culture'}, {'cui': 'C0553561', 'cui_str': 'colony-forming unit'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0013428', 'cui_str': 'Dysuria'}, {'cui': 'C0205498', 'cui_str': 'Suprapubic approach'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}]",824.0,0.110133,"There was 0 UTI (0%) in the 1-day regimen and 3 UTIs (0.7%) in the 3-day regimen, meeting our prespecified criterion for declaring the 1-day regimen to be non-inferior. CONCLUSION A clinically integrated trial using cluster randomization accrued rapidly with no important logistical problems and negligible burden on surgeons.","[{'ForeName': 'Behfar', 'Initials': 'B', 'LastName': 'Ehdaie', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Ghalib', 'Initials': 'G', 'LastName': 'Jibara', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Sjoberg', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Laudone', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Eastham', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Touijer', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Scardino', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Donahue', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Alvin', 'Initials': 'A', 'LastName': 'Goh', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Vickers', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.'}]",The Journal of urology,['10.1097/JU.0000000000001845'] 3040,33915463,A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.,"PURPOSE To determine the safety of tipifarnib in combination with escalating doses of bortezomib and to determine the maximum tolerated dose in patients with untreated high-risk MDS and oligoblastic acute myeloid leukemia, who were not eligible for intensive therapy. EXPERIMENTAL DESIGN In a ""3 + 3″ design, patients received fixed doses of tipifarnib 200 mg bid (days 1-21) and escalating doses of bortezomib (days 8, 15, 22) every 4 weeks in 4-6 cycles. RESULTS The combination was tolerated well by the 11 patients in this study without reaching the maximum tolerated dose. Myelosuppression was the most frequent side effect, but usually of short duration. Interestingly a complete response with or without complete count recovery was observed in three patients and three additional patients had stable disease. The median duration of overall survival was 449 days. Two patients were still alive at 4.0 and 4.3 years, including one patient in continuing CR. CONCLUSIONS The combination of tipifarnib and bortezomib was tolerated well and appeared to have clinical activity in patients with high-risk MDS and AML with low counts of marrow blasts. Our results warrant further evaluation in a phase II study.",2021,The combination of tipifarnib and bortezomib was tolerated well and appeared to have clinical activity in patients with high-risk MDS and AML with low counts of marrow blasts.,"['patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia', 'patients with high-risk MDS and AML with low counts of marrow blasts', 'patients with untreated high-risk MDS and oligoblastic acute myeloid leukemia, who were not eligible for intensive therapy']","['tipifarnib', 'bortezomib', 'tipifarnib and bortezomib', 'tipifarnib combined with bortezomib']","['Myelosuppression', 'median duration of overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C2347761', 'cui_str': 'Childhood myelodysplastic syndrome'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C0337026', 'cui_str': 'Blast'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C1176289', 'cui_str': 'tipifarnib'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0854467', 'cui_str': 'Myelosuppression'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",2.0,0.0239646,The combination of tipifarnib and bortezomib was tolerated well and appeared to have clinical activity in patients with high-risk MDS and AML with low counts of marrow blasts.,"[{'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Muus', 'Affiliation': 'Dept. of Hematology, Radboudumc, Nijmegen, the Netherlands; Dept. of Haematology, Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, UK. Electronic address: P.Muus@KPNplanet.nl.'}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Langemeijer', 'Affiliation': 'Dept. of Hematology, Radboudumc, Nijmegen, the Netherlands.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'van Bijnen', 'Affiliation': 'Dept. of Hematology, Radboudumc, Nijmegen, the Netherlands; Dept. Rheumatology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Blijlevens', 'Affiliation': 'Dept. of Hematology, Radboudumc, Nijmegen, the Netherlands.'}, {'ForeName': 'Theo', 'Initials': 'T', 'LastName': 'de Witte', 'Affiliation': 'Dept. of Hematology, Radboudumc, Nijmegen, the Netherlands; Dept. of Tumor Immunology, Radboudumc, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.'}]",Leukemia research,['10.1016/j.leukres.2021.106573'] 3041,33874964,Identifying potential treatment effect modifiers of the effectiveness of chiropractic care to infants with colic through prespecified secondary analyses of a randomised controlled trial.,"BACKGROUND A recent trial identified large variation in effect of chiropractic care for infantile colic. Thus, identification of possible effect modifiers could potentially enhance the clinical reasoning to select infants with excessive crying for chiropractic care. Therefore, the aim of this study is to identify potential treatment effect modifiers which might influence the effect of chiropractic care for excessive crying in infancy. METHODS Design: Prespecified secondary analyses of data from a randomised controlled trial. The analyses are partly confirmative and partly exploratory. SETTING Four chiropractic clinics in Denmark. PARTICIPANTS Infants aged 2-14 weeks with unexplained excessive crying. Of the 200 infants randomised (1:1), 103 were assigned to a chiropractic care group and 97 to a control group. INTERVENTION Infants in the intervention group received chiropractic care for 2 weeks, while the control group was not treated. Main analyses: The outcome was change in daily hours of crying. Fifteen baseline variables and 6 general variables were selected as potential effect modifiers, and indices based on these were constructed. Factor analyses, latent class analyses and prognosis were used to construct other potentially modifying variables. Finally, an attempt at defining a new index aiming at optimal prediction of the treatment effect was made. The predictive value for all resulting variables were examined by considering the difference in mean change in crying time between the two treatment groups, stratified by the values of the candidate variables, i.e. interaction analyses. RESULTS None of the predefined items or indices were shown to be useful in identifying colicky infants with potentially larger gain from manual therapy. However, more baseline hours of crying (p = 0.029), short duration of symptoms (p = 0.061) and young age (p = 0.089) were all associated with an increased effect on the outcome of hours of crying. CONCLUSION Musculoskeletal indicators were not shown to be predictive of an increased benefit for colicky infants from chiropractic treatment. However, increased benefit was associated with early treatment and a high level of baseline crying, suggesting that the most severely affected infants have the greatest potential of benefiting from manual therapy. This finding requires validation by future studies. TRIAL REGISTRATION Clinical Trials NCT02595515 , registered 2 November 2015.",2021,None of the predefined items or indices were shown to be useful in identifying colicky infants with potentially larger gain from manual therapy.,"['infants with excessive crying for chiropractic care', 'infants with colic', 'infantile colic', 'Four chiropractic clinics in Denmark', '200 infants randomised (1:1), 103 were assigned to a', 'Design', 'Infants aged 2-14\u2009weeks with unexplained excessive crying']","['chiropractic care group and 97 to a control group', 'chiropractic care']","['outcome of hours of crying', 'crying time', 'change in daily hours of crying', 'baseline hours of crying', 'short duration of symptoms']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0438697', 'cui_str': 'Crying, excessive'}, {'cui': 'C0008138', 'cui_str': 'Chiropractic'}, {'cui': 'C0232488', 'cui_str': 'Abdominal colic'}, {'cui': 'C0266836', 'cui_str': 'Infantile colic'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0008138', 'cui_str': 'Chiropractic'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439593', 'cui_str': 'Short duration'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.280983,None of the predefined items or indices were shown to be useful in identifying colicky infants with potentially larger gain from manual therapy.,"[{'ForeName': 'Lise Vilstrup', 'Initials': 'LV', 'LastName': 'Holm', 'Affiliation': 'Nordic Institute of Chiropractic and Clinical Biomechanics, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Vach', 'Affiliation': 'Nordic Institute of Chiropractic and Clinical Biomechanics, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark.'}, {'ForeName': 'Dorte Ejg', 'Initials': 'DE', 'LastName': 'Jarbøl', 'Affiliation': 'Research Unit of General Practice in Odense, Department of Public Health, University of Southern Denmark, J.B. Winsløws vej 9A, DK-5000, Odense C, Denmark.'}, {'ForeName': 'Henrik Wulff', 'Initials': 'HW', 'LastName': 'Christensen', 'Affiliation': 'Nordic Institute of Chiropractic and Clinical Biomechanics, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Søndergaard', 'Affiliation': 'Research Unit of General Practice in Odense, Department of Public Health, University of Southern Denmark, J.B. Winsløws vej 9A, DK-5000, Odense C, Denmark.'}, {'ForeName': 'Lise', 'Initials': 'L', 'LastName': 'Hestbæk', 'Affiliation': 'Nordic Institute of Chiropractic and Clinical Biomechanics, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark. l.hestbaek@nikkb.dk.'}]",Chiropractic & manual therapies,['10.1186/s12998-021-00373-6'] 3042,33909330,High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT).,"BACKGROUND Spironolactone (SPL) is a reversible mineralocorticoid receptor (MR) and androgen receptor (AR) antagonist which attracts pharmacotherapeutic interest not only because of its beneficial effects in heart failure but also because of the pathogenetic roles of MR and AR activities in neuropsychiatric diseases. Recently, beneficial and rapid-onset effects of SPL have been documented in a case series of women with fibromyalgia syndrome (FMS). To reaffirm this observation, we performed a double-blind placebo-controlled randomized clinical trial (RCT). METHODS A total of 69 patients were screened, 56 patients were eligible and randomized to SPL or placebo (each n = 28). Forty-three patients completed the clinical trial to the last visit (n = 21 and n = 22). After a run-in phase of 50 and 100 mg/day, 200 mg/day SPL or placebo were applied between days 7 and 28. Primary outcome was the change in the FIQ-G score (Fibromyalgia Impact Questionnaire, German version). Secondary outcome parameters were the changes in pain (numeric rating scale, NRS), mood (ADS), quality of life (SF-36) and change in FIQ scores 14 days after the end of the medication. RESULTS SPL of 200 mg/day did not change significantly either the primary or the secondary end points. SPL evoked a transient rise in serum potassium and a transient fall in GFR maximal after 2 weeks, but without clinical relevance. CONCLUSIONS SPL at 200 mg/day does not improve symptoms in women with FMS, but was considered not to cause harm. SIGNIFICANCE The mineralocorticoid receptor and androgen receptor antagonist spironolactone is repeatedly tested for its therapeutic effectivity against neuropsychiatric disorders. The present RCT demonstrated that 200 mg spironolactone does not change the symptoms of the fibromyalgia syndrome (FMS) in adult women. Between 2 and 4 weeks, spironolactone evokes a transient decrease in GFR and increase in serum potassium. Spironolactone cannot be recommended for the treatment of FMS.",2021,"SPL evoked a transient rise in serum potassium and a transient fall in GFR maximal after 2 weeks, but without clinical relevance. ","['fibromyalgia (RCT', 'women with fibromyalgia syndrome (FMS', '43 patients completed the clinical trial to the last visit (n = 21 and n = 22', '69 patients were screened, 56 patients were eligible and randomized to']","['Spironolactone (SPL', 'placebo', 'spironolactone', 'SPL or placebo']","['changes of pain (numeric rating scala, NRS); mood (ADS); quality of life (SF-36); and change of FIQ-scores', 'serum potassium', 'GFR maximal', 'change of the FIQ-G-score (Fibromyalgia Impact Questionnaire, German version']","[{'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0037982', 'cui_str': 'Spironolactone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0302353', 'cui_str': 'Serum potassium measurement'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C2607870', 'cui_str': 'Version'}]",56.0,0.440662,"SPL evoked a transient rise in serum potassium and a transient fall in GFR maximal after 2 weeks, but without clinical relevance. ","[{'ForeName': 'Ruwen', 'Initials': 'R', 'LastName': 'Böhm', 'Affiliation': 'Institute for Experimental and Clinical Pharmacology, University Medical Center Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Westermann', 'Affiliation': 'Clinic for Anesthesiology, University Medical Center Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Gleim', 'Affiliation': 'Clinic for Anesthesiology, University Medical Center Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Ingolf', 'Initials': 'I', 'LastName': 'Cascorbi', 'Affiliation': 'Institute for Experimental and Clinical Pharmacology, University Medical Center Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Gruenewald', 'Affiliation': 'Institute for Experimental and Clinical Pharmacology, University Medical Center Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Herdegen', 'Affiliation': 'Institute for Experimental and Clinical Pharmacology, University Medical Center Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Ohnesorge', 'Affiliation': 'Clinic for Anesthesiology, University Medical Center Schleswig-Holstein, Kiel, Germany.'}]","European journal of pain (London, England)",['10.1002/ejp.1784'] 3043,33914047,Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.,"Importance Accumulating evidence indicates that higher blood pressure (BP) variability from one physician office visit to the next (hereafter referred to as visit-to-visit BP variability) is associated with poor outcomes. Short-term measurement (throughout 1 year) of visit-to-visit BP variability in high-risk older patients may help identify patients at increased risk of death. Objective To evaluate whether short-term visit-to-visit BP variability is associated with increased long-term mortality risk. Design, Setting, and Participants The US cohort of the International Verapamil SR-Trandolapril Study (INVEST), a randomized clinical trial of 16 688 patients aged 50 years or older with hypertension and coronary artery disease, was conducted between September 2, 1997, and December 15, 2000, with in-trial follow-up through February 14, 2003. The study evaluated a calcium antagonist (sustained-release verapamil plus trandolapril) vs β-blocker (atenolol plus hydrochlorothiazide) treatment strategy. Blood pressure measurement visits were scheduled every 6 weeks for the first 6 months and biannually thereafter. Statistical analysis was performed from September 2, 1997, to May 1, 2014. Exposures Visit-to-visit systolic BP (SBP) and diastolic BP variability during the first year of enrollment using 4 different BP variability measures: standard deviation, coefficient of variation, average real variability, and variability independent of the mean. Main Outcomes and Measures All-cause death, assessed via the US National Death Index, beginning after the exposure assessment period through May 1, 2014. Results For the present post hoc analysis, long-term mortality data were available on 16 688 patients (9001 women [54%]; mean [SD] age, 66.5 [9.9] years; 45% White patients, 16% Black patients, and 37% Hispanic patients). During a mean (SD) follow-up of 10.9 (4.2) years, 5058 patients (30%) died. All 4 variability measures for SBP were significantly associated with long-term mortality after adjustment for baseline demographic characteristics and comorbidities. After comparison of lowest vs highest variability measure quintiles, the magnitude of the association with death remained statistically significant even after adjustment for baseline demographic characteristics and comorbidities (average real variability: adjusted hazard ratio [aHR], 1.18; 95% CI, 1.08-1.30; standard deviation: aHR, 1.14; 95% CI, 1.04-1.24; coefficient of variation: aHR, 1.15; 95% CI, 1.06-1.26; variability independent of the mean: aHR, 1.15; 95% CI, 1.05-1.25). The signal was stronger in women compared with men. Associations of diastolic BP variability measures with death were weaker than for SBP and were not significant after adjustment. Conclusions and Relevance This study suggests that, in a large population of older patients with hypertension and coronary artery disease, short-term visit-to-visit SBP variability was associated with excess long-term mortality, especially for women. Efforts to identify and minimize visit-to-visit SBP variability may be important in reducing excess mortality later in life. Trial Registration ClinicalTrials.gov Identifier: NCT00133692.",2021,"Short-term measurement (throughout 1 year) of visit-to-visit BP variability in high-risk older patients may help identify patients at increased risk of death. ","['older patients with hypertension and coronary artery disease, short-term visit-to-visit SBP variability', 'Adults With Coronary Artery Disease', '688 patients (9001 women [54', '16\u202f688 patients aged 50 years or older with hypertension and coronary artery disease, was conducted between September 2, 1997, and December 15, 2000, with in-trial follow-up through February 14, 2003']","['calcium antagonist (sustained-release verapamil plus trandolapril) vs β-blocker (atenolol plus hydrochlorothiazide', 'Verapamil SR-Trandolapril']","['1-Year Blood Pressure Variability With Long-term Mortality', 'blood pressure (BP) variability', 'Exposures\n\n\nVisit-to-visit systolic BP (SBP) and diastolic BP variability', 'Measures\n\n\nAll-cause death, assessed via the US National Death Index, beginning after the exposure assessment period through May 1, 2014', 'diastolic BP variability measures with death', 'Blood pressure measurement visits', 'BP variability measures: standard deviation, coefficient of variation, average real variability, and variability independent of the mean', 'SBP']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0730225', 'cui_str': '1997'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0006684', 'cui_str': 'Calcium channel blocker'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0042523', 'cui_str': 'Verapamil'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0076891', 'cui_str': 'trandolapril'}, {'cui': 'C0004147', 'cui_str': 'Atenolol'}, {'cui': 'C0020261', 'cui_str': 'Hydrochlorothiazide'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0332291', 'cui_str': 'Independent of'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",16688.0,0.215663,"Short-term measurement (throughout 1 year) of visit-to-visit BP variability in high-risk older patients may help identify patients at increased risk of death. ","[{'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Dasa', 'Affiliation': 'Department of Internal Medicine and Epidemiology, College of Public Health and Health Professions, College of Medicine, University of Florida, Gainesville.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Smith', 'Affiliation': 'Center for Integrative Cardiovascular and Metabolic Diseases, University of Florida, Gainesville.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Howard', 'Affiliation': 'Department of Biostatistics, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Rhonda M', 'Initials': 'RM', 'LastName': 'Cooper-DeHoff', 'Affiliation': 'Center for Integrative Cardiovascular and Metabolic Diseases, University of Florida, Gainesville.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Gong', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Handberg', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville.'}, {'ForeName': 'Carl J', 'Initials': 'CJ', 'LastName': 'Pepine', 'Affiliation': 'Center for Integrative Cardiovascular and Metabolic Diseases, University of Florida, Gainesville.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.8418'] 3044,33892089,Key concepts in clinical epidemiology: Stepped wedge trials.,"A stepped wedge trial evaluates an intervention that is implemented over a number of time periods according to a staggered timetable. Stepped wedge trials are usually cluster randomized, the intervention being delivered at some geographical, service or other cluster level. There is considerable variety in the design and conduct of stepped wedge trials in practice. The analysis of a stepped wedge trial often assumes that the effect of the intervention is maintained at a constant level once it has been implemented. It is important when estimating this effect to adjust for a period effect or underlying secular trend, since time is confounded with intervention, and to account for the clustering of outcomes. The advantage often cited for a stepped wedge design is that every cluster ends up getting the intervention, though in any trial design we can offer the intervention preferentially to control clusters after the trial has finished. The real advantage of a stepped wedge design is likely to be practicality or statistical efficiency.",2021,"The advantage often cited for a stepped wedge design is that every cluster ends up getting the intervention, though in any trial design we can offer the intervention preferentially to control clusters after the trial has finished.",['clinical epidemiology'],[],[],"[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0014507', 'cui_str': 'Epidemiology'}]",[],[],,0.0952518,"The advantage often cited for a stepped wedge design is that every cluster ends up getting the intervention, though in any trial design we can offer the intervention preferentially to control clusters after the trial has finished.","[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Hooper', 'Affiliation': 'Institute of Population Health Sciences, Queen Mary University of London, London, UK. Electronic address: r.l.hooper@qmul.ac.uk.'}]",Journal of clinical epidemiology,['10.1016/j.jclinepi.2021.04.003'] 3045,33893865,Prospective trial of a 2940 nm Er:YAG laser for the treatment of meibomian gland dysfunction.,"PURPOSE The primary objective was to evaluate the efficacy and safety of Er:YAG laser treatment for meibomian gland dysfunction (MGD) in a prospective study. METHODS A total of 128 eyes from 64 patients with MGD were enrolled to receive either three Er:YAG laser treatments with meibomian gland expression (MGX) or MGX-alone treatment sessions at 3-week intervals. The Standard Patient Evaluation of Eye Dryness (SPEED) validated questionnaire; fluorescein breakup time of the tear film (FBUT); corneal fluorescein staining (CFS); lid margin abnormalities; meibomian gland morphology (meiboscore); lower tear meniscus height (TMH); and assessment of 15 meibomian glands in the lower eyelids, including total meibomian gland secretion quality (TMGS), the number of glands secreting any liquid (GSAL), and the number of glands yielding optimal clear liquid secretion (GYCL), were assessed at day (D)0, D21, D42, and D63 for the Er:YAG-MGX group and D0 and D63 for the MGX group. RESULTS At D63, significant decreases in SPEED scores and lid margin abnormalities as well as significant increases in FBUT, TMGS, and GSAL were observed in both groups (all p < 0.05). The Er:YAG-MGX group showed a significantly better improvement in SPEED scores, TMGS, and GYCL than the MGX group (all p < 0.05). CONCLUSION Although preliminary, the study results of Er:YAG laser treatment for dry eye syndrome caused by MGD are promising. Er:YAG laser treatment may be a new direction for managing MGD. TRIAL REGISTRATION The study was registered at www.chictr.org.cn : ChiCTR1900026004.",2021,"The Er:YAG-MGX group showed a significantly better improvement in SPEED scores, TMGS, and GYCL than the MGX group (all p < 0.05). ","['A total of 128 eyes from 64 patients with MGD', 'meibomian gland dysfunction', 'meibomian gland dysfunction (MGD']","['MGX', '2940\xa0nm Er:YAG laser', 'Er:YAG laser treatment', 'three Er:YAG laser treatments with meibomian gland expression (MGX) or MGX-alone treatment sessions']","['Eye Dryness (SPEED) validated questionnaire; fluorescein breakup time of the tear film (FBUT); corneal fluorescein staining (CFS); lid margin abnormalities; meibomian gland morphology (meiboscore); lower tear meniscus height (TMH); and assessment of 15 meibomian glands in the lower eyelids, including total meibomian gland secretion quality (TMGS), the number of glands secreting any liquid (GSAL), and the number of glands yielding optimal clear liquid secretion (GYCL', 'efficacy and safety', 'FBUT, TMGS, and GSAL', 'SPEED scores, TMGS, and GYCL', 'SPEED scores and lid margin abnormalities']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1275684', 'cui_str': 'Meibomian gland dysfunction'}]","[{'cui': 'C0025181', 'cui_str': 'Structure of meibomian gland'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0457903', 'cui_str': 'Erbium:YAG laser device'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0314719', 'cui_str': 'Dry eyes'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0016314', 'cui_str': 'Fluoresceins'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0444582', 'cui_str': 'Structure of free margin of eyelid'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0025181', 'cui_str': 'Structure of meibomian gland'}, {'cui': 'C0332437', 'cui_str': 'Associated morphology'}, {'cui': 'C1828397', 'cui_str': 'Low tear meniscus'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C1827565', 'cui_str': 'Tear meniscus height'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0229258', 'cui_str': 'Lower eyelid structure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1285092', 'cui_str': 'Gland structure'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",128.0,0.0380205,"The Er:YAG-MGX group showed a significantly better improvement in SPEED scores, TMGS, and GYCL than the MGX group (all p < 0.05). ","[{'ForeName': 'Yana', 'Initials': 'Y', 'LastName': 'Fu', 'Affiliation': 'Eye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Xiang', 'Affiliation': 'Eye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Renjian', 'Initials': 'R', 'LastName': 'Hu', 'Affiliation': 'Eye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Xiaodan', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Eye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Lin', 'Affiliation': 'Eye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'XiuMing', 'Initials': 'X', 'LastName': 'Jin', 'Affiliation': 'Eye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. lzyjxm@zju.edu.cn.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-021-05170-8'] 3046,33894465,Effects of orthopedic insoles on postural balance in patients with chronic stroke: A randomized crossover study.,"BACKGROUND Orthopedic insoles (OIs) with medial arch support and heel cushion are widely used to manage lower extremity injuries, but their effects on postural balance in patients with chronic stroke have not been adequately explored. METHODS Design: Double-blinded, sham-controlled, randomized crossover trial. PARTICIPANTS A total of 32 ambulatory patients (20 men and 12 women, aged between 30 and 76 years) with more than 6 months since stroke onset. INTERVENTIONS All participants received one assessment session wearing OIs and one session wearing sham insole (SI) in a random order with a 1-day interval. OUTCOMES Our primary outcome was the Berg Balance Scale score. Secondary outcomes included the Functional Reach Test, Timed Up and Go test, and computerized posturography. All were performed in both sessions. Subgroup analyses regarding demographic and functional variables were conducted to identify potential responders. RESULTS Significant between-insole differences favoring OIs were seen in all clinical tests (P < 0.05), but were seen only in the static medial-lateral sway in computerized posturography assessment (P = 0.04). An approximate 2-point difference in the BBS score favoring OIs was observed in all subgroups, not reaching the minimal clinically important difference. CONCLUSION The use of OIs generated small but significant positive effects on improving postural balance among patients with chronic stroke. Additional biomechanical and clinical studies are required to evaluate their potential for routine clinical use. TRIAL REGISTRATION NCT03194282.",2021,"RESULTS Significant between-insole differences favoring OIs were seen in all clinical tests (P < 0.05), but were seen only in the static medial-lateral sway in computerized posturography assessment (P = 0.04).","['A total of 32 ambulatory patients (20 men and 12 women, aged between 30 and 76 years) with more than 6 months since stroke onset', 'patients with chronic stroke']","['assessment session wearing OIs and one session wearing sham insole (SI', 'orthopedic insoles']","['BBS score favoring OIs', 'static medial-lateral sway in computerized posturography assessment', 'Functional Reach Test, Timed Up and Go test, and computerized posturography', 'postural balance', 'Berg Balance Scale score']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C3873740', 'cui_str': 'Insole'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0398791', 'cui_str': 'Microcephaly, normal intelligence and immunodeficiency'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C3873740', 'cui_str': 'Insole'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0919611', 'cui_str': 'Posturography'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1998271', 'cui_str': 'Functional reach test'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1256755', 'cui_str': 'Postural balance'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}]",32.0,0.290879,"RESULTS Significant between-insole differences favoring OIs were seen in all clinical tests (P < 0.05), but were seen only in the static medial-lateral sway in computerized posturography assessment (P = 0.04).","[{'ForeName': 'Yen-Ting', 'Initials': 'YT', 'LastName': 'Liu', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Wang Fang Hospital, Taipei Medical University, Taipei, Taiwan. Electronic address: 95175@w.tmu.edu.tw.'}, {'ForeName': 'Han-Ting', 'Initials': 'HT', 'LastName': 'Tsai', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Wang Fang Hospital, Taipei Medical University, Taipei, Taiwan. Electronic address: 97463@w.tmu.edu.tw.'}, {'ForeName': 'Chih-Yang', 'Initials': 'CY', 'LastName': 'Hsu', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Wang Fang Hospital, Taipei Medical University, Taipei, Taiwan. Electronic address: hsumacher@icloud.com.'}, {'ForeName': 'Yen-Nung', 'Initials': 'YN', 'LastName': 'Lin', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Wang Fang Hospital, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Injury Prevention and Control, Taipei Medical University, Taipei, Taiwan. Electronic address: semitune@gmail.com.'}]",Gait & posture,['10.1016/j.gaitpost.2021.04.014'] 3047,33894422,Women's self-estimates of body size are more accurate and precise when made with three-quarter view than front-view stimuli.,"Recently, Cornelissen, Cornelissen, Groves, McCarty and Tovée (2018) asked which image orientations (e.g. front-, side-, or three-quarter view) are most appropriate for tasks which are used for self-estimates of body size and shape. Based on psychophysical measurements, they showed that front view stimuli showed substantially poorer content validity compared to side- and three-quarter view stimuli. Here, we tested the real-world consequences of Cornelissen et al.'s (2018) findings. We carried out a body size self-estimation task in a sample of healthy adult women, once with front view stimuli, and once with three-quarter view stimuli. The order in which front- and three-quarter view tasks were carried out was randomized across participants. Compared to three-quarter view stimuli, we found that: a) the precision of participants' judgements was worse with front view stimuli, and b) that front view stimuli led to over-estimation of body size by ∼1.7 BMI units. While these results need to be replicated, they do suggest that careful consideration needs to be given to stimulus orientation in future studies.",2021,"Compared to three-quarter view stimuli, we found that: a) the precision of participants' judgements was worse with front view stimuli, and b) that front view stimuli led to over-estimation of body size by ∼1.7 BMI units.",['healthy adult women'],[],[],"[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],[],,0.0477278,"Compared to three-quarter view stimuli, we found that: a) the precision of participants' judgements was worse with front view stimuli, and b) that front view stimuli led to over-estimation of body size by ∼1.7 BMI units.","[{'ForeName': 'Piers L', 'Initials': 'PL', 'LastName': 'Cornelissen', 'Affiliation': 'Department of Psychology, Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne, NE1 8ST, UK. Electronic address: piers.cornelissen@northumbria.ac.uk.'}, {'ForeName': 'Lise Gulli', 'Initials': 'LG', 'LastName': 'Brokjøb', 'Affiliation': 'Department of Psychology, Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne, NE1 8ST, UK.'}, {'ForeName': 'Jiří', 'Initials': 'J', 'LastName': 'Gumančík', 'Affiliation': 'Department of Psychology, Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne, NE1 8ST, UK.'}, {'ForeName': 'Katri K', 'Initials': 'KK', 'LastName': 'Cornelissen', 'Affiliation': 'Department of Psychology, Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne, NE1 8ST, UK.'}]",Body image,['10.1016/j.bodyim.2021.04.003'] 3048,33891348,Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.,"OBJECTIVE To evaluate the efficacy of fremanezumab in patients with chronic migraine (CM) and moderate to severe depression. BACKGROUND Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, has been approved for the preventive treatment of migraine in adults. CM and depression are highly comorbid. METHODS The 12-week, Phase 3 HALO trial randomized patients with CM to fremanezumab quarterly (675 mg/placebo/placebo), fremanezumab monthly (675/225/225 mg), or placebo. Post hoc analyses evaluated the effects of fremanezumab in patients with moderate to severe depression (baseline 9-item Patient Health Questionnaire sum score ≥10) on monthly number of headache days of at least moderate severity; monthly migraine days; Patient Global Impression of Change (PGIC); 6-item Headache Impact Test (HIT-6) scores; and depression. RESULTS For the 219/1121 (19.5%) patients with moderate to severe depression at baseline, fremanezumab was associated with a significant reduction in monthly number of headache days of at least moderate severity for active treatment versus placebo (least-squares mean change ± standard error for quarterly dosing: -5.3 ± 0.77; for monthly dosing: -5.5 ± 0.72; and for placebo: -2.2 ± 0.81; both p < 0.001). More patients achieved a ≥50% reduction in headache days of at least moderate severity with fremanezumab (quarterly: 31/78 [39.7%]; monthly: 39/96 [40.6%]) than placebo (9/67 [13.4%]; both p < 0.001). Compared with placebo, fremanezumab improved PGIC and HIT-6 scores. CONCLUSIONS Fremanezumab demonstrated efficacy in the preventive treatment of CM and reduced headache impact in patients with comorbid depression.",2021,"Compared with placebo, fremanezumab improved PGIC and HIT-6 scores. ","['patients with comorbid depression', 'patients with moderate to', 'patients with chronic migraine and comorbid depression', 'patients with chronic migraine (CM']","['placebo/placebo), fremanezumab', 'fremanezumab', 'placebo', 'placebo, fremanezumab', 'CM to fremanezumab']","['severe depression', 'headache days', 'severe depression (baseline 9-item Patient Health Questionnaire sum score ≥10) on monthly number of headache days of at least moderate severity; monthly migraine days; Patient Global Impression of Change (PGIC); 6-item Headache Impact Test (HIT-6) scores; and depression', 'PGIC and HIT-6 scores', 'headache impact']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C1960870', 'cui_str': 'Transformed migraine'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4549503', 'cui_str': 'fremanezumab'}, {'cui': 'C1960870', 'cui_str': 'Transformed migraine'}]","[{'cui': 'C0588008', 'cui_str': 'Severe depression'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",,0.301453,"Compared with placebo, fremanezumab improved PGIC and HIT-6 scores. ","[{'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Cohen', 'Affiliation': 'Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Galic', 'Affiliation': 'Global Medical Affairs, Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Seminerio', 'Affiliation': 'North America Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Paul P', 'Initials': 'PP', 'LastName': 'Yeung', 'Affiliation': 'Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Ernesto', 'Initials': 'E', 'LastName': 'Aycardi', 'Affiliation': 'Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Marcelo E', 'Initials': 'ME', 'LastName': 'Bigal', 'Affiliation': 'Research and Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Bibeau', 'Affiliation': 'Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.'}, {'ForeName': 'Dawn C', 'Initials': 'DC', 'LastName': 'Buse', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.'}]",Headache,['10.1111/head.14097'] 3049,33900585,Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.,"BACKGROUND We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. METHODS We calculated costs and quality-adjusted life-years from the UK National Health Service and Personal Social Services perspective. We performed a within-trial analysis using the efficacy, safety, resource use and health utility data from a randomised controlled trial (LEAVO) over 100 weeks. We built a discrete event simulation to model long-term outcomes. We estimated utilities using the Visual-Functioning Questionnaire-Utility Index, EQ-5D and EQ-5D with an additional vision question. We used standard UK costs sources for 2018/19 and a cost of £28 per bevacizumab injection. We discounted costs and quality-adjusted life-years at 3.5% annually. RESULTS Bevacizumab was the least costly intervention followed by ranibizumab and aflibercept in both the within-trial analysis (bevacizumab: £6292, ranibizumab: £13,014, aflibercept: £14,328) and long-term model (bevacizumab: £18,353, ranibizumab: £30,226, aflibercept: £35,026). Although LEAVO did not demonstrate bevacizumab to be non-inferior for the visual acuity primary outcome, the three interventions generated similar quality-adjusted life-years in both analyses. Bevacizumab was always the most cost-effective intervention at a threshold of £30,000 per quality-adjusted life-year, even using the list price of £243 per injection. CONCLUSIONS Wider adoption of bevacizumab for the treatment of macular oedema due to central retinal vein occlusion could result in substantial savings to healthcare systems and deliver similar health-related quality of life. However, patients, funders and ophthalmologists should be fully aware that LEAVO could not demonstrate that bevacizumab is non-inferior to the licensed agents.",2021,"RESULTS Bevacizumab was the least costly intervention followed by ranibizumab and aflibercept in both the within-trial analysis (bevacizumab: £6292, ranibizumab: £13,014, aflibercept: £14,328) and long-term model (bevacizumab: £18,353, ranibizumab: £30,226, aflibercept: £35,026).","['macular oedema due to central retinal vein occlusion', 'Macular Oedema Due to Central Retinal Vein Occlusion']","['ranibizumab and aflibercept', 'Bevacizumab', 'bevacizumab injection', 'long-term model (bevacizumab', 'ranibizumab', 'LEAVO', 'bevacizumab', 'Ranibizumab vs Aflibercept vs Bevacizumab', 'intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin']","['Cost Effectiveness', 'efficacy, safety, resource use and health utility data', 'Visual-Functioning Questionnaire-Utility Index, EQ-5D and EQ-5D with an additional vision question']","[{'cui': 'C0271051', 'cui_str': 'Macular retinal edema'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0154841', 'cui_str': 'Central retinal vein occlusion'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C4019040', 'cui_str': 'bevacizumab Injection'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C1135130', 'cui_str': 'Avastin'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.123285,"RESULTS Bevacizumab was the least costly intervention followed by ranibizumab and aflibercept in both the within-trial analysis (bevacizumab: £6292, ranibizumab: £13,014, aflibercept: £14,328) and long-term model (bevacizumab: £18,353, ranibizumab: £30,226, aflibercept: £35,026).","[{'ForeName': 'Becky', 'Initials': 'B', 'LastName': 'Pennington', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, UK. b.pennington@sheffield.ac.uk.'}, {'ForeName': 'Abualbishr', 'Initials': 'A', 'LastName': 'Alshreef', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Flight', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Metry', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Edith', 'Initials': 'E', 'LastName': 'Poku', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Hykin', 'Affiliation': 'NIHR Moorfields Biomedical Research Centre, London, UK.'}, {'ForeName': 'Sobha', 'Initials': 'S', 'LastName': 'Sivaprasad', 'Affiliation': 'NIHR Moorfields Biomedical Research Centre, London, UK.'}, {'ForeName': 'A Toby', 'Initials': 'AT', 'LastName': 'Prevost', 'Affiliation': ""Nightingale-Saunders Clinical Trials and Epidemiology Unit at King's Clinical Trials Unit, King's College London, London, UK.""}, {'ForeName': 'Joana C', 'Initials': 'JC', 'LastName': 'Vasconcelos', 'Affiliation': ""Nightingale-Saunders Clinical Trials and Epidemiology Unit at King's Clinical Trials Unit, King's College London, London, UK.""}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Murphy', 'Affiliation': ""King's Clinical Trials Unit at King's Health Partners, King's College London, London, UK.""}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Kelly', 'Affiliation': ""King's Clinical Trials Unit at King's Health Partners, King's College London, London, UK.""}, {'ForeName': 'Yit', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Wolverhampton Eye Infirmary, Wolverhampton, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Lotery', 'Affiliation': 'Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Williams', 'Affiliation': ""Centre for Medical Education, Queen's University of Belfast, Belfast, UK.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Brazier', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, UK.'}]",PharmacoEconomics,['10.1007/s40273-021-01026-5'] 3050,33896847,Contribution of Basal Ganglia to the Sense of Upright: A Double-Blind Within-Person Randomized Trial of Subthalamic Stimulation in Parkinson's Disease with Pisa Syndrome.,"BACKGROUND Verticality perception is frequently altered in Parkinson's disease (PD) with Pisa syndrome (PS). Is it the cause or the consequence of the PS? OBJECTIVE We tested the hypothesis that both scenarios coexist. METHODS We performed a double-blind within-person randomized trial (NCT02704910) in 18 individuals (median age 63.5 years) with PD evolving for a median of 17.5 years and PS for 2.5 years and treated with bilateral stimulation of the subthalamus nuclei (STN-DBS) for 6.5 years. We analyzed whether head and trunk orientations were congruent with the visual (VV) and postural (PV) vertical, and whether switching on one or both sides of the STN-DBS could modulate trunk orientation via verticality representation. RESULTS The tilted verticality perception could explain the PS in 6/18 (33%) patients, overall in three right-handers (17%) who showed net and congruent leftward trunk and PV tilts. Two of the 18 (11%) had an outstanding clinical picture associating leftward: predominant parkinsonian symptoms, whole-body tilt (head -11°, trunk -8°) and transmodal tilt in verticality perception (PV -10°, VV -8.9°). Trunk orientation or VV were not modulated by STN-DBS, whereas PV tilts were attenuated by unilateral or bilateral stimulations if it was applied on the opposite STN. CONCLUSION In most cases of PS, verticality perception is altered by the body deformity. In some cases, PS seems secondary to a biased internal model of verticality, and DBS on the side of the most denervated STN attenuated PV tilts with a quasi-immediate effect. This is an interesting track for further clinical studies.",2021,"Trunk orientation or VV were not modulated by STN-DBS, whereas PV tilts were attenuated by unilateral or bilateral stimulations if it was applied on the opposite STN. ","[""Parkinson's Disease with Pisa Syndrome"", ""Parkinson's disease (PD) with Pisa syndrome (PS"", '18 individuals (median age 63.5 years) with PD evolving for a median of 17.5 years and PS for 2.5 years and treated with bilateral stimulation of the subthalamus nuclei (STN-DBS) for 6.5 years']",['Subthalamic Stimulation'],['Trunk orientation or VV'],"[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0920233', 'cui_str': 'Pisa syndrome'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332253', 'cui_str': 'Evolving'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0152349', 'cui_str': 'Subthalamic structure'}, {'cui': 'C0007610', 'cui_str': 'Nucleus'}, {'cui': 'C0038427', 'cui_str': 'Bruneomycin'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C3844007', 'cui_str': '6.5'}]","[{'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}]",,0.270471,"Trunk orientation or VV were not modulated by STN-DBS, whereas PV tilts were attenuated by unilateral or bilateral stimulations if it was applied on the opposite STN. ","[{'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Piscicelli', 'Affiliation': 'Department of NeuroRehabilitation, Grenoble-Alpes University Hospital, Grenoble, France.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Castrioto', 'Affiliation': 'Grenoble Institute Neurosciences (GIN), Grenoble-Alpes University Hospital, University Grenoble-Alpes, Inserm, U1216, Grenoble, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Jaeger', 'Affiliation': 'Department of NeuroRehabilitation, Grenoble-Alpes University Hospital, Grenoble, France.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Fraix', 'Affiliation': 'Grenoble Institute Neurosciences (GIN), Grenoble-Alpes University Hospital, University Grenoble-Alpes, Inserm, U1216, Grenoble, France.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Chabardes', 'Affiliation': 'Department of Neurosurgery, Grenoble-Alpes University Hospital, Grenoble, France.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Moro', 'Affiliation': 'Grenoble Institute Neurosciences (GIN), Grenoble-Alpes University Hospital, University Grenoble-Alpes, Inserm, U1216, Grenoble, France.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Krack', 'Affiliation': 'Movement Disorders Center, Department of Neurology, University Hospital (Inselspital) and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Debû', 'Affiliation': 'Grenoble Institute Neurosciences (GIN), Grenoble-Alpes University Hospital, University Grenoble-Alpes, Inserm, U1216, Grenoble, France.'}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Pérennou', 'Affiliation': 'Department of NeuroRehabilitation, Grenoble-Alpes University Hospital, Grenoble, France.'}]",Journal of Parkinson's disease,['10.3233/JPD-202388'] 3051,32896447,No association between preoperative impaired glucose control and postoperative adverse events following hip fracture surgery - A single-centre observational cohort study.,"RATIONALE Observational studies have shown an association between hyperglycaemia and increased complications in orthopaedic patients. The aim of the study was to investigate if impaired preoperative glycaemic control, reflected by elevated HbA1c, was associated with adverse postoperative events in hip fracture patients. METHODS 160 patients (116 women and 44 men; age 80 ± 10 and BMI 24 ± 4; mean ± SD) with hip fractures were included in a prospective observational cohort study. The patients were divided into two groups, normal glycaemic control (NGC) and impaired glycaemic control (IGC) HbA1c ≥ 42 mmol/mol. The patients were also characterized according to BMI and nutritional status using MNA-SF (Minimal Nutritional Assessment Short Form). Complications within 30 days of surgery were classified according to Clavien-Dindo and 1-year mortality was compared between the groups. RESULTS Out of 160 patients, 18 had diabetes and 4 more had likely occult diabetes (HbA1c ≥ 48). Impaired glycaemic control (IGC) was seen in 29 patients (18.1%) and normal glycaemic control (NGC) in 131 (81.9%). In patients with NGC and IGC, no postoperative complications (Clavien-Dindo Grade 0) were seen in 64/131 vs. 14/29 (48.9 vs. 48.3%), Grade 1-3a in 54/131 vs. 14/29 (41.2 vs. 48.3%) and Grade 3b-5 in 13/131 vs. 1/29 (9.9 vs. 3.4%) respectively, p = NS. There were no differences in 30-day complications (p = 0.55) or 1-year mortality (p = 0.35) between the groups. CONCLUSION Elevated HbA1c at admission is not associated with increased complications or mortality after hip fracture surgery.",2021,"In patients with NGC and IGC, no postoperative complications (Clavien-Dindo Grade 0) were seen in 64/131 vs. 14/29 (48.9 vs. 48.3%), Grade 1-3a in 54/131 vs. 14/29 (41.2 vs. 48.3%) and Grade 3b-5 in 13/131 vs. 1/29 (9.9 vs. 3.4%) respectively, p = NS.","['160 patients, 18 had diabetes and 4 more had likely occult diabetes (HbA1c', 'hip fracture patients', 'orthopaedic patients', '160 patients (116 women and 44 men; age 80\xa0±\xa010 and BMI 24\xa0±\xa04; mean\xa0±\xa0SD) with hip fractures']",['normal glycaemic control (NGC) and impaired glycaemic control '],"['complications or mortality', '30-day complications', 'Clavien-Dindo and 1-year mortality', 'postoperative complications', 'normal glycaemic control (NGC', '1-year mortality', 'preoperative impaired glucose control and postoperative adverse events', 'Impaired glycaemic control (IGC', 'Complications']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0028794', 'cui_str': 'Occultism'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",160.0,0.0459893,"In patients with NGC and IGC, no postoperative complications (Clavien-Dindo Grade 0) were seen in 64/131 vs. 14/29 (48.9 vs. 48.3%), Grade 1-3a in 54/131 vs. 14/29 (41.2 vs. 48.3%) and Grade 3b-5 in 13/131 vs. 1/29 (9.9 vs. 3.4%) respectively, p = NS.","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Thörling', 'Affiliation': 'Department of Emergency Medicine, Karolinska University Hospital, Sweden; Department of Clinical Science, Intervention and Technology, (CLINTEC), Karolinska Institutet, Stockholm, Sweden. Electronic address: john.thorling@ki.se.'}, {'ForeName': 'Olle', 'Initials': 'O', 'LastName': 'Ljungqvist', 'Affiliation': 'Faculty of Medicine and Health, School of Health and Medical Sciences, Department of Surgery, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Olof', 'Initials': 'O', 'LastName': 'Sköldenberg', 'Affiliation': 'Karolinska Institutet, Department of Clinical Sciences at Danderyd Hospital, Division of Orthopaedics, Sweden; Danderyd University Hospital Corp., Department of Orthopaedics, Stockholm, Sweden.'}, {'ForeName': 'Folke', 'Initials': 'F', 'LastName': 'Hammarqvist', 'Affiliation': 'Department of Emergency Surgery and Trauma, Karolinska University Hospital, Sweden; Department of Clinical Science, Intervention and Technology, (CLINTEC), Karolinska Institutet, Stockholm, Sweden.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.023'] 3052,34389022,Comparing the effects of self-selected MUsic versus predetermined music on patient ANXiety prior to gynaecological surgery: the MUANX randomized controlled trial.,"BACKGROUND Anxiety is frequently observed in the preoperative setting. The negative impact of preoperative anxiety is well known. In the context of gynaecological surgery, anxiety is exacerbated by the fact that the intervention can have catastrophic repercussions on a woman's body image, sexuality, and psycho-affective well-being. Music listening is increasingly used as an alternative therapy for minimizing preoperative anxiety. Personal preferences, familiarity, and popularity may be key elements for an optimal relaxation response to music. This study aimed to determine whether listening to self-selected music decreases preoperative anxiety in women scheduled to undergo gynaecologic surgery compared with predetermined music from an application (MUSIC CARE®). METHODS The MUANX study was a single-blind, monocentric, parallel, superiority, randomized controlled trial. A total of 174 women were included and randomized in two groups between August 2017 and September 2018. Patients in the intervention group listened to the personal music playlist that they had created before being hospitalized. Patients in the control group listened to the predetermined playlist on the MUSIC CARE® application. All patients received standard nursing care and listened to 20 min of music 1 h before surgery. Anxiety scores were assessed before and after the music session using Spielberger's State-Trait Anxiety Inventory (STAI). RESULTS The mean age of the 171 evaluated patients was 41.5 years (SD = 10.0 years). Before the music session, the STAI state anxiety score was similar in the control group (M = 38.8, SD = 11.9) and the intervention group (M = 39.0, SD = 13.1). After the music session, this score had significantly decreased in both the control group (M = -7.2, SD = 9.0) and the intervention group (M = -5.5, SD = 6.6), with no significant difference in score reduction between groups. Physiological parameters were unchanged after the music session. No significant differences in postoperative measurements (pain intensity, hospitalization duration) were observed between the two groups. CONCLUSION Self-selected music is as effective as predetermined music for reducing patient anxiety before gynaecological surgery. As it has no side effects and is easily applicable in gynaecological surgical services, this non-drug intervention may be proposed by healthcare professionals in the management of preoperative anxiety. TRIAL REGISTRATION The MUANX trial (MUsic therapy on ANXiety) is registered at the US National Institutes of Health ( ClinicalTrials.gov ) #NCT03226834. Registered on 24 July 2017. https://clinicaltrials.gov/ct2/show/NCT03226834?term=muanx&draw=2&rank=1.",2021,"No significant differences in postoperative measurements (pain intensity, hospitalization duration) were observed between the two groups. ","['women scheduled to undergo gynaecologic surgery compared with predetermined music from an application (MUSIC CARE®', 'The mean age of the 171 evaluated patients was 41.5\u2009years (SD = 10.0\u2009years', 'patient ANXiety prior to gynaecological surgery', 'A total of 174 women were included and randomized in two groups between August 2017 and September 2018']","['personal music playlist', 'MUSIC CARE® application', 'listening to self-selected music', 'standard nursing care and listened to 20\u2009min of music 1\u2009h before surgery', 'self-selected MUsic versus predetermined music', 'Music listening', 'Self-selected music']","['postoperative measurements (pain intensity, hospitalization duration', 'Anxiety scores', 'STAI state anxiety score', 'score reduction']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0028678', 'cui_str': 'nursing'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",174.0,0.0405901,"No significant differences in postoperative measurements (pain intensity, hospitalization duration) were observed between the two groups. ","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Reynaud', 'Affiliation': 'Direction des Soins Infirmiers, de Rééducation et MédicoTechniques (Site Sud), CHU de la Réunion, 97410, Saint-Pierre, France. danielle.reynaud@chu-reunion.fr.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Bouscaren', 'Affiliation': 'Inserm CIC1410, CHU de la Réunion, Saint-Pierre, France.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Lenclume', 'Affiliation': 'Inserm CIC1410, CHU de la Réunion, Saint-Pierre, France.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Boukerrou', 'Affiliation': 'Service de Gynécologie Obstétrique, PFME, CHU SUD de la Réunion, 350 97448, Saint-Pierre, BP, France.'}]",Trials,['10.1186/s13063-021-05511-2'] 3053,34389017,Cost-effectiveness of a stepped care program to prevent depression among primary care patients with diabetes mellitus type 2 and/or coronary heart disease and subthreshold depression in comparison with usual care.,"BACKGROUND Patients with diabetes mellitus type 2 (DM2) and/or coronary heart disease (CHD) are at high risk to develop major depression. Preventing incident major depression may be an important tool in reducing the personal and societal burden of depression. The aim of the current study was to assess the cost-effectiveness of a stepped care program to prevent major depression (Step-Dep) in diabetes mellitus type 2 and/or coronary heart disease patients with subthreshold depression in comparison with usual care. METHODS An economic evaluation with 12 months follow-up was conducted alongside a pragmatic cluster-randomized controlled trial from a societal perspective. Participants received care as usual (n = 140) or Step-Dep (n = 96) which consisted of four sequential treatment steps: watchful waiting, guided self-help, problem solving treatment and referral to a general practitioner. Primary outcomes were quality-adjusted life years (QALYs) and cumulative incidence of major depression. Costs were measured every 3 months. Missing data was imputed using multiple imputation. Uncertainty around cost-effectiveness outcomes was estimated using bootstrapping and presented in cost-effectiveness planes and acceptability curves. RESULTS There were no significant differences in QALYs or depression incidence between treatment groups. Secondary care costs (mean difference €1644, 95% CI €344; €3370) and informal care costs (mean difference €1930, 95% CI €528; €4089) were significantly higher in the Step-Dep group than in the usual care group. The difference in total societal costs (€1001, 95% CI €-3975; €6409) was not statistically significant. The probability of the Step-Dep intervention being cost-effective was low, with a maximum of 0.41 at a ceiling ratio of €30,000 per QALY gained and 0.32 at a ceiling ratio of €0 per prevented case of major depression. CONCLUSIONS The Step-Dep intervention is not cost-effective compared to usual care in a population of patients with DM2/CHD and subthreshold depression. Therefore, widespread implementation cannot be recommended. TRIAL REGISTRATION The trial was registered in the Netherlands Trial Register ( NTR3715 ).",2021,The Step-Dep intervention is not cost-effective compared to usual care in a population of patients with DM2/CHD and subthreshold depression.,"['primary care patients with diabetes mellitus type 2 and/or coronary heart disease and subthreshold depression in comparison with usual care', 'diabetes mellitus type 2 and/or coronary heart disease patients with subthreshold depression in comparison with usual care', 'Patients with diabetes mellitus type 2 (DM2) and/or coronary heart disease (CHD']","['stepped care program to prevent major depression (Step-Dep', 'stepped care program', 'care as usual (n\xa0=\u2009140) or Step-Dep (n\xa0=\u200996) which consisted of four sequential treatment steps: watchful waiting, guided self-help, problem solving treatment and referral to a general practitioner']","['informal care costs', 'QALYs or depression incidence', 'cost-effectiveness', 'total societal costs', 'quality-adjusted life years (QALYs) and cumulative incidence of major depression', 'cost-effectiveness planes and acceptability curves', 'Costs', 'Cost-effectiveness']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0700325', 'cui_str': 'Patient status observation'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0017319', 'cui_str': 'General physician'}]","[{'cui': 'C3494177', 'cui_str': 'Informal care'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",4.0,0.04198,The Step-Dep intervention is not cost-effective compared to usual care in a population of patients with DM2/CHD and subthreshold depression.,"[{'ForeName': 'S E M', 'Initials': 'SEM', 'LastName': 'van Dijk', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, De Boelelaan 1085, 1081, HV, Amsterdam, the Netherlands.'}, {'ForeName': 'A D', 'Initials': 'AD', 'LastName': 'Pols', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, De Boelelaan 1085, 1081, HV, Amsterdam, the Netherlands.'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Adriaanse', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, De Boelelaan 1085, 1081, HV, Amsterdam, the Netherlands.'}, {'ForeName': 'H W J', 'Initials': 'HWJ', 'LastName': 'van Marwijk', 'Affiliation': 'Department of General Practice and Elderly Medicine and the Amsterdam Public Health research institute, VU University Medical Centre, Amsterdam, The Netherlands.'}, {'ForeName': 'M W', 'Initials': 'MW', 'LastName': 'van Tulder', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, De Boelelaan 1085, 1081, HV, Amsterdam, the Netherlands.'}, {'ForeName': 'J E', 'Initials': 'JE', 'LastName': 'Bosmans', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, De Boelelaan 1085, 1081, HV, Amsterdam, the Netherlands. j.e.bosmans@vu.nl.'}]",BMC psychiatry,['10.1186/s12888-021-03367-z'] 3054,33929612,A biomechanical comparison of a cement-augmented odontoid screw with a posterior-instrumented fusion in geriatric patients with an odontoid fracture type IIb.,"PURPOSE Possible surgical therapies for odontoid fracture type IIb include odontoid screw osteosynthesis (OG) with preservation of mobility or dorsal C1/2 fusion with restriction of cervical rotation. In order to reduce material loosening in odontoid screw osteosynthesis in patients with low bone density, augmentation at the base of the axis using bone cement has been established as a suitable alternative. In this study, we compared cement-augmented OG and C1/2 fusion according to Harms (HG). METHODS Body donor preparations of the 1st and 2nd cervical vertebrae were randomized in 2 groups (OG vs. HG). The range of motion (ROM) was determined in 3 principle motion plains. Subsequently, a cyclic loading test was performed. The decrease in height of the specimen and the double amplitude height were determined as absolute values as an indication of screw loosening. Afterward, the ROM was determined again and loosening of the screws was measured in a computed tomography. RESULTS A total of 16 were included. Two groups of 8 specimens (OG vs. HG) from patients with a median age of 80 (interquartile range (IQ) 73.5-85) years and a reduced bone density of 87.2 (IQ 71.2-104.5) mg/cc dipotassium hydrogen phosphate were examined for their biomechanical properties. Before and after exposure, the OG preparations were significantly more mobile. At the time of loading, the OG had similar loading properties to HG decrease in height of the specimen and the double amplitude height. Computed tomography revealed similar outcomes with regard to the screw loosening rate (62.5 vs. 87.5%, p = 0.586). CONCLUSION In patients with an odontoid fracture type IIb and reduced bone density, cement-augmented odontoid screw yielded similar properties in the loading tests compared to the HG. It may, therefore, be considered as a primary alternative to preserve cervical mobility in these patients.",2021,"Computed tomography revealed similar outcomes with regard to the screw loosening rate (62.5 vs. 87.5%, p = 0.586). ","['A total of 16 were included', 'Body donor preparations of the 1st and 2nd cervical vertebrae', 'patients with low bone density', 'Two groups of 8 specimens (OG vs. HG) from patients with a median age of 80 (interquartile range (IQ) 73.5-85) years and a reduced bone density of 87.2 (IQ 71.2-104.5) mg/cc dipotassium hydrogen phosphate were examined for their biomechanical properties', 'geriatric patients with an odontoid fracture type IIb']","['odontoid screw osteosynthesis', 'odontoid screw osteosynthesis (OG) with preservation of mobility or dorsal C1/2 fusion with restriction of cervical rotation', 'cement-augmented odontoid screw with a posterior-instrumented fusion']","['height of the specimen and the double amplitude height', 'range of motion (ROM', 'screw loosening rate']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0205435', 'cui_str': 'First'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0728985', 'cui_str': 'Structure of cervical vertebral column'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0138037', 'cui_str': 'Dibasic potassium phosphate'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0559777', 'cui_str': 'Fracture of odontoid process'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}]","[{'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0410830', 'cui_str': 'Loosening of screw'}]",3.0,0.0392296,"Computed tomography revealed similar outcomes with regard to the screw loosening rate (62.5 vs. 87.5%, p = 0.586). ","[{'ForeName': 'Falko', 'Initials': 'F', 'LastName': 'Schwarz', 'Affiliation': 'Department of Neurosurgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Liebsch', 'Affiliation': 'Trauma Research Centre Ulm, Institute of Orthopaedic Research and Biomechanics, Ulm University, Ulm, Germany.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Berger-Roscher', 'Affiliation': 'Trauma Research Centre Ulm, Institute of Orthopaedic Research and Biomechanics, Ulm University, Ulm, Germany.'}, {'ForeName': 'Hans-Joachim', 'Initials': 'HJ', 'LastName': 'Wilke', 'Affiliation': 'Trauma Research Centre Ulm, Institute of Orthopaedic Research and Biomechanics, Ulm University, Ulm, Germany. hans-joachim.wilke@uni-ulm.de.'}, {'ForeName': 'Yasser', 'Initials': 'Y', 'LastName': 'Sakr', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Kalff', 'Affiliation': 'Department of Neurosurgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.'}, {'ForeName': 'Albrecht', 'Initials': 'A', 'LastName': 'Waschke', 'Affiliation': 'Department of Neurosurgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-021-06848-7'] 3055,33929523,Effects of Hospital-Based Comprehensive Medication Reviews Including Postdischarge Follow-up on Older Patients' Use of Health Care: A Cluster Randomized Clinical Trial.,"Importance Suboptimal use of medications is a leading cause of health care-related harm. Medication reviews improve medication use, but evidence of the possible benefit of inpatient medication review for hard clinical outcomes after discharge is scarce. Objective To study the effects of hospital-based comprehensive medication reviews (CMRs), including postdischarge follow-up of older patients' use of health care resources, compared with only hospital-based reviews and usual care. Design, Setting, and Participants The Medication Reviews Bridging Healthcare trial is a cluster randomized crossover trial that was conducted in 8 wards with multiprofessional teams at 4 hospitals in Sweden from February 6, 2017, to October 19, 2018, with 12 months of follow-up completed December 6, 2019. The study was prespecified in the trial protocol. Outcome assessors were blinded to treatment allocation. In total, 2644 patients aged 65 years or older who had been admitted to 1 of the study wards for at least 1 day were included. Data from the modified intention-to-treat population were analyzed from December 10, 2019, to September 9, 2020. Interventions Each ward participated in the trial for 6 consecutive 8-week periods. The wards were randomized to provide 1 of 3 treatments during each period: CMR, CMR plus postdischarge follow-up, and usual care without a clinical pharmacist. Main Outcomes and Measures The primary outcome measure was the incidence of unplanned hospital visits (admissions plus emergency department visits) within 12 months. Secondary outcomes included medication-related admissions, visits with primary care clinicians, time to first unplanned hospital visit, mortality, and costs of hospital-based care. Results Of the 2644 participants, 7 withdrew after inclusion, leaving 2637 for analysis (1357 female [51.5%]; median age, 81 [interquartile range, 74-87] years; median number of medications, 9 [interquartile range, 5-13]). In the modified intention-to-treat analysis, 922 patients received CMR, 823 received CMR plus postdischarge follow-up, and 892 received usual care. The crude incidence rate of unplanned hospital visits was 1.77 per patient-year in the total study population. The primary outcome did not differ between the intervention groups and usual care (adjusted rate ratio, 1.04 [95% CI, 0.89-1.22] for CMR and 1.15 [95% CI, 0.98-1.34] for CMR plus postdischarge follow-up). However, CMR plus postdischarge follow-up was associated with an increased incidence of emergency department visits within 12 months (adjusted rate ratio, 1.29; 95% CI, 1.05-1.59) compared with usual care. There were no differences between treatment groups regarding other secondary outcomes. Conclusions and Relevance In this study of older hospitalized patients, CMR plus postdischarge follow-up did not decrease the incidence of unplanned hospital visits. The findings do not support the performance of hospital-based CMRs as conducted in this trial. Alternative forms of medication reviews that aim to improve older patients' health outcomes should be considered and subjected to randomized clinical trials. Trial Registration ClinicalTrials.gov Identifier: NCT02986425.",2021,"The primary outcome did not differ between the intervention groups and usual care (adjusted rate ratio, 1.04 [95% CI, 0.89-1.22] for CMR and 1.15 [95% CI, 0.98-1.34] for CMR plus postdischarge follow-up).","['8 wards with multiprofessional teams at 4 hospitals in Sweden from February 6, 2017, to October 19, 2018, with 12 months of follow-up completed December 6, 2019', '2644 patients aged 65 years or older who had been admitted to 1 of the study wards for at least 1 day were included', ""older patients' health outcomes"", 'older hospitalized patients', ""Older Patients' Use of Health Care"", '2644 participants, 7 withdrew after inclusion, leaving 2637 for analysis (1357 female [51.5%]; median age, 81 [interquartile range, 74-87] years; median number of medications, 9 [interquartile range, 5-13']","['Hospital-Based Comprehensive Medication', 'hospital-based comprehensive medication reviews (CMRs', 'CMR, CMR plus postdischarge follow-up, and usual care without a clinical pharmacist']","['incidence of emergency department visits', 'usual care', 'incidence of unplanned hospital visits', 'incidence of unplanned hospital visits (admissions plus emergency department visits', 'medication-related admissions, visits with primary care clinicians, time to first unplanned hospital visit, mortality, and costs of hospital-based care', 'crude incidence rate of unplanned hospital visits']","[{'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0560023', 'cui_str': 'Review of medication'}, {'cui': 'C0006802', 'cui_str': 'Cameroon'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1449564', 'cui_str': 'Clinical pharmacist'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]",2644.0,0.350834,"The primary outcome did not differ between the intervention groups and usual care (adjusted rate ratio, 1.04 [95% CI, 0.89-1.22] for CMR and 1.15 [95% CI, 0.98-1.34] for CMR plus postdischarge follow-up).","[{'ForeName': 'Thomas G H', 'Initials': 'TGH', 'LastName': 'Kempen', 'Affiliation': 'Hospital Pharmacy Department, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Bertilsson', 'Affiliation': 'Uppsala Clinical Research Center, Uppsala, Sweden.'}, {'ForeName': 'Nermin', 'Initials': 'N', 'LastName': 'Hadziosmanovic', 'Affiliation': 'Uppsala Clinical Research Center, Uppsala, Sweden.'}, {'ForeName': 'Karl-Johan', 'Initials': 'KJ', 'LastName': 'Lindner', 'Affiliation': 'Pharmacy Department, Region Västmanland, Västerås, Sweden.'}, {'ForeName': 'Håkan', 'Initials': 'H', 'LastName': 'Melhus', 'Affiliation': 'Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Elisabet I', 'Initials': 'EI', 'LastName': 'Nielsen', 'Affiliation': 'Department of Pharmacy, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Sulku', 'Affiliation': 'Pharmacy Department, Region Gävleborg, Gävle, Sweden.'}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Gillespie', 'Affiliation': 'Hospital Pharmacy Department, Uppsala University Hospital, Uppsala, Sweden.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.6303'] 3056,33926922,Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial.,"OBJECTIVES Although causality remains to be established, targeting dysbiosis of the intestinal microbiota by faecal microbiota transplantation (FMT) has been proposed as a novel treatment for inflammatory diseases. In this exploratory, proof-of-concept study, we evaluated the safety and efficacy of FMT in psoriatic arthritis (PsA). METHODS In this double-blind, parallel-group, placebo-controlled, superiority trial, we randomly allocated (1:1) adults with active peripheral PsA (≥3 swollen joints) despite ongoing treatment with methotrexate to one gastroscopic-guided FMT or sham transplantation into the duodenum. Safety was monitored throughout the trial. The primary efficacy endpoint was the proportion of participants experiencing treatment failure (ie, needing treatment intensification) through 26 weeks. Key secondary endpoints were change in Health Assessment Questionnaire Disability Index (HAQ-DI) and American College of Rheumatology (ACR20) response at week 26. RESULTS Of 97 screened, 31 (32%) underwent randomisation (15 allocated to FMT) and 30 (97%) completed the 26-week clinical evaluation. No serious adverse events were observed. Treatment failure occurred more frequently in the FMT group than in the sham group (9 (60%) vs 3 (19%); risk ratio, 3.20; 95% CI 1.06 to 9.62; p=0.018). Improvement in HAQ-DI differed between groups (0.07 vs 0.30) by 0.23 points (95% CI 0.02 to 0.44; p=0.031) in favour of sham. There was no difference in the proportion of ACR20 responders between groups (7 of 15 (47%) vs 8 of 16 (50%)). CONCLUSIONS In this first preliminary, interventional randomised controlled trial of FMT in immune-mediated arthritis, we did not observe any serious adverse events. Overall, FMT appeared to be inferior to sham in treating active peripheral PsA. TRIAL REGISTRATION NUMBER NCT03058900.",2021,Improvement in HAQ-DI differed between groups (0.07 vs 0.30) by 0.23 points (95% CI 0.02 to 0.44; p=0.031) in favour of sham.,"['Of 97 screened, 31 (32%) underwent randomisation (15 allocated to FMT) and 30 (97%) completed the 26-week clinical evaluation', 'active peripheral psoriatic arthritis', 'randomly allocated (1:1) adults with active peripheral PsA (≥3 swollen joints) despite ongoing treatment with', 'psoriatic arthritis (PsA']","['faecal microbiota transplantation', 'placebo', 'FMT', 'methotrexate to one gastroscopic-guided FMT or sham transplantation into the duodenum']","['Treatment failure', 'change in Health Assessment Questionnaire Disability Index (HAQ-DI) and American College of Rheumatology (ACR20) response', 'safety and efficacy', 'HAQ-DI', 'Safety and efficacy', 'proportion of participants experiencing treatment failure (ie, needing treatment intensification', 'Safety', 'serious adverse events', 'proportion of ACR20 responders']","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C2242628', 'cui_str': 'Fecal microbiota transplantation'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0003872', 'cui_str': 'Psoriatic arthritis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0152031', 'cui_str': 'Joint swelling'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C2242628', 'cui_str': 'Fecal microbiota transplantation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0013303', 'cui_str': 'Duodenal'}]","[{'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.527477,Improvement in HAQ-DI differed between groups (0.07 vs 0.30) by 0.23 points (95% CI 0.02 to 0.44; p=0.031) in favour of sham.,"[{'ForeName': 'Maja Skov', 'Initials': 'MS', 'LastName': 'Kragsnaes', 'Affiliation': 'Rheumatology Research Unit, Department of Rheumatology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Kjeldsen', 'Affiliation': 'Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Hans Christian', 'Initials': 'HC', 'LastName': 'Horn', 'Affiliation': 'Rheumatology Research Unit, Department of Rheumatology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Heidi Lausten', 'Initials': 'HL', 'LastName': 'Munk', 'Affiliation': 'Rheumatology Research Unit, Department of Rheumatology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Jens Kristian', 'Initials': 'JK', 'LastName': 'Pedersen', 'Affiliation': 'Section of Rheumatology, Department of Medicine, Svendborg Hospital, Svendborg, Denmark.'}, {'ForeName': 'Søren Andreas', 'Initials': 'SA', 'LastName': 'Just', 'Affiliation': 'Section of Rheumatology, Department of Medicine, Svendborg Hospital, Svendborg, Denmark.'}, {'ForeName': 'Palle', 'Initials': 'P', 'LastName': 'Ahlquist', 'Affiliation': 'Reumaklinik Fyn, Odense, Denmark.'}, {'ForeName': 'Finn Moeller', 'Initials': 'FM', 'LastName': 'Pedersen', 'Affiliation': 'Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Maarten', 'Initials': 'M', 'LastName': 'de Wit', 'Affiliation': 'Patient Research Partner, Amsterdam, The Netherlands.'}, {'ForeName': 'Sören', 'Initials': 'S', 'LastName': 'Möller', 'Affiliation': 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Vibeke', 'Initials': 'V', 'LastName': 'Andersen', 'Affiliation': 'IRS-Center Sønderjylland, University Hospital of Southern Denmark, Aabenraa, Denmark.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Kristiansen', 'Affiliation': 'Laboratory of Genomics and Molecular Biomedicine, Department of Biology, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Dorte', 'Initials': 'D', 'LastName': 'Kinggaard Holm', 'Affiliation': 'Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Hanne Marie', 'Initials': 'HM', 'LastName': 'Holt', 'Affiliation': 'Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Christensen', 'Affiliation': 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Torkell', 'Initials': 'T', 'LastName': 'Ellingsen', 'Affiliation': 'Rheumatology Research Unit, Department of Rheumatology, Odense University Hospital, Odense, Denmark torkell.ellingsen@rsyd.dk.'}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2020-219511'] 3057,34388698,Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.,"OBJECTIVE In the PALOMA-2 trial, palbociclib in combination with letrozole prolonged progression-free survival (PFS) and exhibited an acceptable safety profile in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). This post hoc analysis of PALOMA-2 evaluated the efficacy and safety of palbociclib plus letrozole in patients with preexisting conditions grouped by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC). METHODS Postmenopausal patients without prior treatment for ABC were randomized 2:1 to receive palbociclib (125 mg/d on a 3 weeks on/1 week off schedule) plus letrozole (2.5 mg/d, continuous) or placebo plus letrozole. Patients were grouped by the following MedDRA SOC preexisting conditions: gastrointestinal, musculoskeletal, metabolic, and vascular/cardiac. Median PFS was estimated by the Kaplan-Meier method, and treatment emergent adverse events (AEs) were compared between treatment arms within each preexisting condition subgroup. RESULTS At baseline, 276 (41.4 %) patients had preexisting gastrointestinal disorders, 390 (58.6 %) had musculoskeletal disorders, 259 (38.9 %) had metabolic disorders, and 382 (57.4 %) had vascular/cardiac disorders. Baseline characteristics were similar between subgroups and between each arm within subgroups. Regardless of baseline preexisting condition, palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole. Treatment-emergent AEs associated with palbociclib plus letrozole and dose modifications due to AEs were similar across preexisting condition subgroups. CONCLUSION This post hoc analysis of PALOMA-2 demonstrated a favorable effect of palbociclib on PFS and a safety profile consistent with previous observations, regardless of underlying preexisting condition. Pfizer Inc (NCT01740427).",2021,"Treatment-emergent AEs associated with palbociclib plus letrozole and dose modifications due to AEs were similar across preexisting condition subgroups. ","['patients with preexisting conditions grouped by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC', 'patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC', 'Patients were grouped by the following MedDRA SOC preexisting conditions: gastrointestinal, musculoskeletal, metabolic, and vascular/cardiac', 'Postmenopausal patients without prior treatment for ABC', 'patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions']","['palbociclib plus letrozole', 'letrozole', 'placebo plus letrozole', 'palbociclib']","['Median PFS', 'vascular/cardiac disorders', 'Efficacy and safety', 'preexisting gastrointestinal disorders', 'musculoskeletal disorders', 'metabolic disorders', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0012113', 'cui_str': 'Dictionary, Medical'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0460002', 'cui_str': 'Body system structure'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0279754', 'cui_str': 'ESR1 positive'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0521987', 'cui_str': 'Pre-existing condition'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0017178', 'cui_str': 'Disorder of gastrointestinal tract'}, {'cui': 'C0026857', 'cui_str': 'Disorder of musculoskeletal system'}, {'cui': 'C0025517', 'cui_str': 'Metabolic disease'}]",,0.0955949,"Treatment-emergent AEs associated with palbociclib plus letrozole and dose modifications due to AEs were similar across preexisting condition subgroups. ","[{'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Gelmon', 'Affiliation': 'British Columbia Cancer Agency, Vancouver, BC, Canada. Electronic address: kgelmon@bccancer.bc.ca.'}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Walshe', 'Affiliation': 'Cancer Trials Ireland, Dublin, Ireland.'}, {'ForeName': 'Reshma', 'Initials': 'R', 'LastName': 'Mahtani', 'Affiliation': 'Sylvester Cancer Center, University of Miami, Deerfield Beach, FL, USA.'}, {'ForeName': 'Anil A', 'Initials': 'AA', 'LastName': 'Joy', 'Affiliation': 'Cross Cancer Institute, Edmonton, AB, Canada.'}, {'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'Karuturi', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Neven', 'Affiliation': 'Breast Centre, UZ Leuven, Leuven, Belgium.'}, {'ForeName': 'Dongrui Ray', 'Initials': 'DR', 'LastName': 'Lu', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Sindy', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Schnell', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Eustratios', 'Initials': 'E', 'LastName': 'Bananis', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Schwartzberg', 'Affiliation': 'West Cancer Center, Germantown, TN, USA.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2021.07.017'] 3058,34388424,"A comparison of the effectiveness of splinting, exercise and electrotherapy in women patients with hallux valgus: A randomized clinical trial.","BACKGROUND Hallux valgus (HV) is a very common foot deformity involving lateral deviation of the hallux and medial deviation of the first metatarsal head. OBJECTIVES To investigate the effects of HV night splinting, exercise and electrotherapy on the HV angle, and foot-specific health-related quality of life. METHODS Sixty women (120 feet) with bilateral HV deformity were randomly assigned to one of three groups - an HV night splint (SP) group, an exercise (EX) group, and a high-voltage galvanic stimulation (HVPGS) (EL) group. The patients in SP group used the HV night splints while resting or sleeping for at least 8 h a day and the patients in the EX group performed exercises 3-4 times a day with 10 repetitions for the duration of the one-month treatment period. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks in EL group. Angular degrees (hallux interphalangeal angle (HIPA), HV angle (HVA), and intermetatarsal angle (IMA)) were determined before (t0) and three months after treatment (t2). Foot-specific quality of life was assessed using the Manchester-Oxford Foot Questionnaire (MOFQ) at t0, after one month (t1), and at t2. RESULTS All groups exhibited significant changes in the HIPA, HVA, and IMA angles and outcome measures (p ≤ 0.001). Decreases in the HIPA and IMA angles, and MOFQ-Pain subscale scores, were higher in the SP group than in the other two groups (p < 0.05). IMA angle at t2, MOFQ-Walking score at t1 and t2 and MOFQ-Pain subscale score at t1 were lower in the SP group (p < 0.05). CONCLUSION The SP group exhibited more positive effects in the parameters measured than the other two groups. A combination of these conservative treatment approaches may be more beneficial to improve HV symptoms with longer follow-up periods. CLINICALTRIALS. GOV IDENTIFIER NCT04393545.",2021,"Decreases in the HIPA and IMA angles, and MOFQ-Pain subscale scores, were higher in the SP group than in the other two groups (p < 0.05).","['women patients with hallux valgus', 'Sixty women (120 feet) with bilateral HV deformity']","['HV night splint (SP) group, an exercise (EX) group, and a high-voltage galvanic stimulation (HVPGS) (EL) group', 'HV night splinting, exercise and electrotherapy', 'splinting, exercise and electrotherapy']","['HV angle, and foot-specific health-related quality of life', 'MOFQ-Pain subscale score', 'Manchester-Oxford Foot Questionnaire (MOFQ', 'IMA angle at t2, MOFQ-Walking score', 'Foot-specific quality of life', 'HV night splints while resting or sleeping', 'Angular degrees (hallux interphalangeal angle (HIPA), HV angle (HVA), and intermetatarsal angle (IMA', 'HV symptoms', 'HIPA and IMA angles, and MOFQ-Pain subscale scores', 'HIPA, HVA, and IMA angles and outcome measures']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018536', 'cui_str': 'Hallux valgus'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}]","[{'cui': 'C0018536', 'cui_str': 'Hallux valgus'}, {'cui': 'C0556894', 'cui_str': 'Night splinting'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0013787', 'cui_str': 'Electrotherapy'}, {'cui': 'C0038009', 'cui_str': 'Splint'}]","[{'cui': 'C0018536', 'cui_str': 'Hallux valgus'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0459443', 'cui_str': 'Subscale score'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0556894', 'cui_str': 'Night splinting'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0456574', 'cui_str': 'Angular degrees'}, {'cui': 'C0018534', 'cui_str': 'Hallux structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0178681', 'cui_str': 'Homovanillate'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}]",60.0,0.0153638,"Decreases in the HIPA and IMA angles, and MOFQ-Pain subscale scores, were higher in the SP group than in the other two groups (p < 0.05).","[{'ForeName': 'Bahar Anaforoğlu', 'Initials': 'BA', 'LastName': 'Külünkoğlu', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Ankara Yildirim Beyazit University, Ankara, Turkey. Electronic address: banaforoglu@ybu.edu.tr.'}, {'ForeName': 'Yasemin', 'Initials': 'Y', 'LastName': 'Akkubak', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Necmettin Erbakan University, Konya, Turkey.'}, {'ForeName': 'Derya', 'Initials': 'D', 'LastName': 'Çelik', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Afra', 'Initials': 'A', 'LastName': 'Alkan', 'Affiliation': 'Department of Biostatistics and Medical Informatics, Institute of Health Sciences, Ankara Yıldırım Beyazıt University, Ankara, Turkey.'}]","Foot (Edinburgh, Scotland)",['10.1016/j.foot.2021.101828'] 3059,34388414,A multicenter randomized clinical trial of pharmacological vitamin B1 administration to critically ill patients who develop hypophosphatemia during enteral nutrition (The THIAMINE 4 HYPOPHOSPHATEMIA trial).,"BACKGROUND Hypophosphatemia may be a useful biomarker to identify thiamine deficiency in critically ill enterally-fed patients. The objective was to determine whether intravenous thiamine affects blood lactate, biochemical and clinical outcomes in this group. METHOD This randomized clinical trial was conducted across 5 Intensive Care Units. Ninety critically ill adult patients with a serum phosphate ≤0.65 mmol/L within 72 h of commencing enteral nutrition were randomized to intravenous thiamine (200 mg every 12 h for up to 14 doses) or usual care (control). The primary outcome was blood lactate over time and data are median [IQR] unless specified. RESULTS Baseline variables were well balanced (thiamine: lactate 1.2 [1.0, 1.6] mmol/L, phosphate 0.56 [0.44, 0.64] mmol/L vs. control: lactate 1.0 [0.8, 1.3], phosphate 0.54 [0.44, 0.61]). Patients randomized to the intervention received a median of 11 [7.5, 13.5] doses for a total of 2200 [1500, 2700] mg of thiamine. Blood lactate over the entire 7 days of treatment was similar between groups (mean difference = -0.1 (95 % CI -0.2 to 0.1) mmol/L; P = 0.55). The percentage change from lactate pre-randomization to T = 24 h was not statistically different (thiamine: -32 (-39, -26) vs. control: -24 (-31, -16) percent, P = 0.09). Clinical outcomes were not statistically different (days of vasopressor administration: thiamine 2 [1, 4] vs. control 2 [0, 5.5] days; P = 0.37, and deaths 9 (21 %) vs. 5 (11 %); P = 0.25). CONCLUSIONS In critically ill enterally-fed patients who developed hypophosphatemia, intravenous thiamine did not cause measurable differences in blood lactate or clinical outcomes. TRIAL REGISTRATION Australian and New Zealand Clinical Trials Registry (ACTRN12619000121167).",2021,"24 h was not statistically different (thiamine: -32 (-39, -26) vs. control: -24","['critically ill enterally-fed patients', 'critically ill patients who develop hypophosphatemia during enteral nutrition (The THIAMINE 4 HYPOPHOSPHATEMIA trial', '5 Intensive Care Units', 'Ninety critically ill adult patients with a serum phosphate ≤0.65\xa0mmol/L within 72\xa0h of commencing enteral nutrition']","['pharmacological vitamin B1', 'intravenous thiamine', 'thiamine', 'usual care (control']","['blood lactate, biochemical and clinical outcomes', 'Blood lactate', 'blood lactate or clinical outcomes', 'blood lactate over time and data are median [IQR] unless specified']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085682', 'cui_str': 'Hypophosphatemia'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0039840', 'cui_str': 'Thiamine'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036820', 'cui_str': 'Serum phosphate'}, {'cui': 'C1532563', 'cui_str': 'mmol/L'}]","[{'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0039840', 'cui_str': 'Thiamine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205369', 'cui_str': 'Specific'}]",90.0,0.244506,"24 h was not statistically different (thiamine: -32 (-39, -26) vs. control: -24","[{'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Deane', 'Affiliation': 'The University of Melbourne, Department of Critical Care, Melbourne Medical School, Melbourne, Australia; Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia. Electronic address: adam.deane@mh.org.au.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Jiang', 'Affiliation': 'Monash University, Department of Epidemiology and Preventive Medicine, Australian and New Zealand Intensive Care Research Centre, Melbourne, Australia.'}, {'ForeName': 'Brianna', 'Initials': 'B', 'LastName': 'Tascone', 'Affiliation': 'Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'Annabelle', 'Initials': 'A', 'LastName': 'Clancy', 'Affiliation': 'Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Finnis', 'Affiliation': 'The University of Melbourne, Department of Critical Care, Melbourne Medical School, Melbourne, Australia; Monash University, Department of Epidemiology and Preventive Medicine, Australian and New Zealand Intensive Care Research Centre, Melbourne, Australia; The University of Adelaide, Discipline of Acute Care Medicine, Adelaide, Australia.'}, {'ForeName': 'Jake T', 'Initials': 'JT', 'LastName': 'Collie', 'Affiliation': 'RMIT University, School of Health and Biomedical Sciences, Melbourne, Australia.'}, {'ForeName': 'Ronda', 'Initials': 'R', 'LastName': 'Greaves', 'Affiliation': ""RMIT University, School of Health and Biomedical Sciences, Melbourne, Australia; Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne, Australia.""}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Byrne', 'Affiliation': 'Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Fujii', 'Affiliation': 'Monash University, Department of Epidemiology and Preventive Medicine, Australian and New Zealand Intensive Care Research Centre, Melbourne, Australia; Intensive Care Unit, Jikei University Hospital, Tokyo, Japan.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Douglas', 'Affiliation': 'Department of Intensive Care, Western Health, Melbourne, Australia.'}, {'ForeName': 'Alistair', 'Initials': 'A', 'LastName': 'Nichol', 'Affiliation': 'Monash University, Department of Epidemiology and Preventive Medicine, Australian and New Zealand Intensive Care Research Centre, Melbourne, Australia; School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland; Department of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Australia.'}, {'ForeName': 'Andrew A', 'Initials': 'AA', 'LastName': 'Udy', 'Affiliation': 'Monash University, Department of Epidemiology and Preventive Medicine, Australian and New Zealand Intensive Care Research Centre, Melbourne, Australia; Department of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Australia.'}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Young', 'Affiliation': 'Department of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Australia.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Russo', 'Affiliation': 'Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Fetterplace', 'Affiliation': 'The University of Melbourne, Department of Critical Care, Melbourne Medical School, Melbourne, Australia; Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Maiden', 'Affiliation': 'The University of Adelaide, Discipline of Acute Care Medicine, Adelaide, Australia; Intensive Care Unit, Barwon Health, Geelong, Australia.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Plummer', 'Affiliation': 'The University of Melbourne, Department of Critical Care, Melbourne Medical School, Melbourne, Australia; Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'Fumitaka', 'Initials': 'F', 'LastName': 'Yanase', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'The University of Melbourne, Department of Critical Care, Melbourne Medical School, Melbourne, Australia; Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}, {'ForeName': 'Yasmine', 'Initials': 'Y', 'LastName': 'Ali Abdelhamid', 'Affiliation': 'The University of Melbourne, Department of Critical Care, Melbourne Medical School, Melbourne, Australia; Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2021.07.024'] 3060,33865797,Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial.,"BACKGROUND Pelvic lymph node dissection (PLND) is the most reliable procedure for lymph node staging. However, the therapeutic benefit remains unproven; although most radical prostatectomies at academic centers are accompanied by PLND, there is no consensus regarding the optimal anatomical extent of PLND. OBJECTIVE To evaluate whether extended PLND results in a lower biochemical recurrence rate. DESIGN, SETTING, AND PARTICIPANTS We conducted a single-center randomized trial. Patients, enrolled between October 2011 and March 2017, were scheduled to undergo radical prostatectomy and PLND. Patients were assigned to limited or extended PLND by cluster randomization. Specifically, surgeons were randomized to perform limited or extended PLND for 3-mo periods. INTERVENTION Randomization to limited (external iliac nodes) or extended (external iliac, obturator fossa and hypogastric nodes) PLND. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary endpoint was the rate of biochemical recurrence. RESULTS AND LIMITATIONS Of 1440 patients included in the final analysis, 700 were randomized to limited PLND and 740 to extended PLND. The median number of nodes retrieved was 12 (interquartile range [IQR] 8-17) for limited PLND and 14 (IQR 10-20) extended PLND; the corresponding rate of positive nodes was 12% and 14% (difference -1.9%, 95% confidence interval [CI] -5.4% to 1.5%; p = 0.3). With median follow-up of 3.1 yr, there was no significant difference in the rate of biochemical recurrence between the groups (hazard ratio 1.04, 95% CI 0.93-1.15; p = 0.5). Rates for grade 2 and 3 complications were similar at 7.3% for limited versus 6.4% for extended PLND; there were no grade 4 or 5 complications. CONCLUSIONS Extended PLND did not improve freedom from biochemical recurrence over limited PLND for men with clinically localized prostate cancer. However, there were smaller than expected differences in nodal count and the rate of positive nodes between the two templates. A randomized trial comparing PLND to no node dissection is warranted. PATIENT SUMMARY In this clinical trial we did not find a difference in the rate of biochemical recurrence of prostate cancer between limited and extended dissection of lymph nodes in the pelvis. This study is registered on ClinicalTrials.gov as NCT01407263.",2021,In this clinical trial we did not find a difference in the rate of biochemical recurrence of prostate cancer between limited and extended dissection of lymph nodes in the pelvis.,"['men with clinically localized prostate cancer', 'Patients, enrolled between October 2011 and March 2017, were scheduled to undergo', '1440 patients included in the final analysis, 700 were randomized to limited PLND and 740 to extended PLND', 'Prostate Cancer']","['Randomization to limited (external iliac nodes) or extended (external iliac, obturator fossa and hypogastric nodes) PLND', 'radical prostatectomy and PLND', 'PLND']","['rate of biochemical recurrence of prostate cancer', 'median number of nodes', 'rate of biochemical recurrence', 'Rates for grade 2 and 3 complications', 'rate of positive nodes', 'nodal count and the rate of positive nodes']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0392752', 'cui_str': 'Localized'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C4517576', 'cui_str': '1440'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0193883', 'cui_str': 'Pelvic lymphadenectomy'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0229815', 'cui_str': 'External iliac lymph node group'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0020889', 'cui_str': 'Bone structure of ilium'}, {'cui': 'C0230192', 'cui_str': 'Obturator fossa'}, {'cui': 'C0447192', 'cui_str': 'Internal iliac node'}, {'cui': 'C0193883', 'cui_str': 'Pelvic lymphadenectomy'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}]","[{'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0443268', 'cui_str': 'Nodal'}, {'cui': 'C0439157', 'cui_str': 'counts'}]",700.0,0.590472,In this clinical trial we did not find a difference in the rate of biochemical recurrence of prostate cancer between limited and extended dissection of lymph nodes in the pelvis.,"[{'ForeName': 'Karim A', 'Initials': 'KA', 'LastName': 'Touijer', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: touijerk@mskcc.org.'}, {'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Sjoberg', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Benfante', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Vincent P', 'Initials': 'VP', 'LastName': 'Laudone', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Behfar', 'Initials': 'B', 'LastName': 'Ehdaie', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Eastham', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Peter T', 'Initials': 'PT', 'LastName': 'Scardino', 'Affiliation': 'Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Vickers', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}]",European urology oncology,['10.1016/j.euo.2021.03.006'] 3061,33871742,The Effect of Intensive Implementation Support on Fidelity for Four Evidence-Based Psychosis Treatments: A Cluster Randomized Trial.,"PURPOSE Service providers need effective strategies to implement evidence-based practices (EBPs) with high fidelity. This study aimed to evaluate an intensive implementation support strategy to increase fidelity to EBP standards in treatment of patients with psychosis. METHODS The study used a cluster randomized design with pairwise assignment of practices within each of 39 Norwegian mental health clinics. Each site chose two of four practices for implementation: physical health care, antipsychotic medication management, family psychoeducation, illness management and recovery. One practice was assigned to the experimental condition (toolkits, clinical training, implementation facilitation, data-based feedback) and the other to the control condition (manual only). The outcome measure was fidelity to the EBP, measured at baseline and after 6, 12, and 18 months, analyzed using linear mixed models and effect sizes. RESULTS The increase in fidelity scores (within a range 1-5) from baseline to 18 months was significantly greater for experimental sites than for control sites for the combined four practices, with mean difference in change of 0.86 with 95% CI (0.21; 1.50), p = 0.009). Effect sizes for increase in group difference of mean fidelity scores were 2.24 for illness management and recovery, 0.68 for physical health care, 0.71 for antipsychotic medication management, and 0.27 for family psychoeducation. Most improvements occurred during the first 12 months. CONCLUSIONS Intensive implementation strategies (toolkits, clinical training, implementation facilitation, data-based feedback) over 12 months can facilitate the implementation of EBPs for psychosis treatment. The approach may be more effective for some practices than for others.",2021,"The increase in fidelity scores (within a range 1-5) from baseline to 18 months was significantly greater for experimental sites than for control sites for the combined four practices, with mean difference in change of 0.86 with 95% CI (0.21; 1.50), p = 0.009).","['patients with psychosis', '39 Norwegian mental health clinics']",['Intensive Implementation Support'],"['mean fidelity scores', 'fidelity to the EBP', 'fidelity scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}, {'cui': 'C3839912', 'cui_str': 'Mental health clinic'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0290918,"The increase in fidelity scores (within a range 1-5) from baseline to 18 months was significantly greater for experimental sites than for control sites for the combined four practices, with mean difference in change of 0.86 with 95% CI (0.21; 1.50), p = 0.009).","[{'ForeName': 'Torleif', 'Initials': 'T', 'LastName': 'Ruud', 'Affiliation': 'Division of Mental Health Services, Akershus University Hospital, Lørenskog, Norway. torleif.ruud@medisin.uio.no.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Drake', 'Affiliation': 'Westat, Lebanon, NH, USA.'}, {'ForeName': 'Jūratė', 'Initials': 'J', 'LastName': 'Šaltytė Benth', 'Affiliation': 'Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Drivenes', 'Affiliation': 'Division of Mental Health, Sørlandet Hospital, Kristiansand, Norway.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Hartveit', 'Affiliation': 'Section of Research and Innovation, Helse Fonna Health Trust, Haugesund, Norway.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Heiervang', 'Affiliation': 'Division of Mental Health Services, Akershus University Hospital, Lørenskog, Norway.'}, {'ForeName': 'Tordis S', 'Initials': 'TS', 'LastName': 'Høifødt', 'Affiliation': 'University Hospital of Northern Norway, Tromsø, Norway.'}, {'ForeName': 'Vegard Ø', 'Initials': 'VØ', 'LastName': 'Haaland', 'Affiliation': 'Division of Mental Health, Sørlandet Hospital, Kristiansand, Norway.'}, {'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'Joa', 'Affiliation': 'TIPS Centre for Clinical Research in Psychosis, Psychiatric Division, Stavanger University Hospital, Stavanger, Norway.'}, {'ForeName': 'Jan Olav', 'Initials': 'JO', 'LastName': 'Johannessen', 'Affiliation': 'TIPS Centre for Clinical Research in Psychosis, Psychiatric Division, Stavanger University Hospital, Stavanger, Norway.'}, {'ForeName': 'Karl Johan', 'Initials': 'KJ', 'LastName': 'Johansen', 'Affiliation': 'Mental Health Norway, Oslo, Norway.'}, {'ForeName': 'Bjørn', 'Initials': 'B', 'LastName': 'Stensrud', 'Affiliation': 'Division of Mental Health, Innlandet Hospital Trust, Brumunddal, Norway.'}, {'ForeName': 'Espen', 'Initials': 'E', 'LastName': 'Woldsengen Haugom', 'Affiliation': 'Division of Mental Health, Innlandet Hospital Trust, Brumunddal, Norway.'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Clausen', 'Affiliation': 'Division of Mental Health Services, Akershus University Hospital, Lørenskog, Norway.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Biringer', 'Affiliation': 'Section of Research and Innovation, Helse Fonna Health Trust, Haugesund, Norway.'}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Bond', 'Affiliation': 'Westat, Lebanon, NH, USA.'}]",Administration and policy in mental health,['10.1007/s10488-021-01136-4'] 3062,33906089,Impact of destination-based visual cues on gait characteristics among adults over 75 years old: A pilot study.,"BACKGROUND Visual information is a contributing factor affecting human gait and balance, especially in low lit environments. To mitigate the adverse effects of poor lighting conditions and help older adults perceive their positions in a community-dwelling setting, destination-based visual perceptual cues were designed as a specific lighting intervention and the effectiveness of the lighting intervention was tested in this study. RESEARCH QUESTIONS 1) Does the designed lighting intervention improve older adults' walking performance? 2) Does the designed lighting intervention change older adults' walking strategy? METHODS Fifteen community-dwelling older adults (165.5 ± 9.3 cm, 6 males, 9 females) were recruited. Participants were instructed to walk from their bed to the bathroom repeatedly in two lighting conditions, their usual nightlight condition and a novel LED strip lighting condition. Human motion patterns, including walking performance, lower-limb kinematics, and trunk motions, were recorded and analyzed. To investigate the effect of visual cues on walking behaviors, one-way analysis of variance (ANOVA) were performed with lighting conditions as the within-subject factor. RESULTS Destination-based visual perceptual cues induced less walking time among adults over 75 years old, compared to the usual nightlight condition. The decrease in walking time was accompanied by changes in other walking behaviors, including decreased hip flexion, increased ankle flexion, larger trunk planar acceleration RMS, and smoother trunk log dimensionless jerk. SIGNIFICANCE This study demonstrated the effectiveness of the designed lighting intervention upon the changes in older adults' walking performance and strategies. With the help of destination-based visual perceptual cues, the older adults spent a shorter period of time walking to their destination (i.e., walking faster), with an improvement in their walking strategies, such as mitigated lower-body biomechanical plasticity and smoother trunk movement.",2021,"RESULTS Destination-based visual perceptual cues induced less walking time among adults over 75 years old, compared to the usual nightlight condition.","['1', 'adults over 75 years old', 'Fifteen community-dwelling older adults (165.5 ± 9.3 cm, 6 males, 9 females', ""older adults' walking performance and strategies""]","['lighting intervention', 'destination-based visual cues', 'visual cues']","['decreased hip flexion, increased ankle flexion, larger trunk planar acceleration RMS, and smoother trunk log dimensionless jerk', 'walking performance, lower-limb kinematics, and trunk motions', 'walking time']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0010439', 'cui_str': 'Cues'}]","[{'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}, {'cui': 'C0205357', 'cui_str': 'Smooth'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.0124556,"RESULTS Destination-based visual perceptual cues induced less walking time among adults over 75 years old, compared to the usual nightlight condition.","[{'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': 'Department of Industrial and Systems Engineering, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Xiaojie', 'Initials': 'X', 'LastName': 'Lu', 'Affiliation': 'Shimberg Center for Housing Studies, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Sherry', 'Initials': 'S', 'LastName': 'Ahrentzen', 'Affiliation': 'Shimberg Center for Housing Studies, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Boyi', 'Initials': 'B', 'LastName': 'Hu', 'Affiliation': 'Department of Industrial and Systems Engineering, University of Florida, Gainesville, FL, USA. Electronic address: boyihu@ise.ufl.edu.'}]",Gait & posture,['10.1016/j.gaitpost.2021.04.030'] 3063,33901759,A randomized control trial of a child abuse mandated reporter training: Knowledge and attitudes.,"BACKGROUND Despite being well-positioned to identify maltreatment in the children that they provide care for and being legally required to report suspected child maltreatment, early childhood professionals (ECPs) make a limited proportion of reports to child protective services. It is critical to identify evidence-based interventions to improve the reporting practices of this group of mandated reporters allowing for the better protection of children from maltreatment. OBJECTIVE The goal of the present study was to determine if iLookOut, an online child abuse identification and reporting training for ECPs, results in differential gains in knowledge and attitudes towards child abuse and its reporting among ECPs, as compared to an online standard training. PARTICIPANTS AND SETTING Both interventions were completed online by participants recruited from licensed child care programs in Southern Maine from October 2017 to January 2020. Eligibility criteria included being at least 18 years of age, English-speaking, and working as paid or volunteer staff at a licensed child care program taking care of children 5 years of age or younger. Of the 1152 enrolled individuals, 1094 provided complete pre- and post-intervention data. METHODS A randomized controlled trial comparing iLookOut with an online standard training. RESULTS ECPs who completed iLookOut significantly outperformed those who completed Standard mandated reporter training in terms of both knowledge (d=1.09 vs. 0.67) and attitudes (d=0.67 vs. 0.54) relative to pre-test scores. CONCLUSIONS iLookOut is a promising candidate for widespread use in meeting the need for evidence-based training on child abuse and its reporting.",2021,"RESULTS ECPs who completed iLookOut significantly outperformed those who completed Standard mandated reporter training in terms of both knowledge (d=1.09 vs. 0.67) and attitudes (d=0.67 vs. 0.54) relative to pre-test scores. ","['1152 enrolled individuals, 1094 provided complete pre- and post-intervention data', 'Eligibility criteria included being at least 18 years of age, English-speaking, and working as paid or volunteer staff at a licensed child care program taking care of children 5 years of age or younger', 'Both interventions were completed online by participants recruited from licensed child care programs in Southern Maine from October 2017 to January 2020']","['iLookOut with an online standard training', 'child abuse mandated reporter training']",[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0008067', 'cui_str': 'Puericulture'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0024497', 'cui_str': 'Maine'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0008060', 'cui_str': 'Child abuse'}, {'cui': 'C0335038', 'cui_str': 'Reporter'}]",[],1152.0,0.0276078,"RESULTS ECPs who completed iLookOut significantly outperformed those who completed Standard mandated reporter training in terms of both knowledge (d=1.09 vs. 0.67) and attitudes (d=0.67 vs. 0.54) relative to pre-test scores. ","[{'ForeName': 'Kathryn L', 'Initials': 'KL', 'LastName': 'Humphreys', 'Affiliation': 'Vanderbilt University, Nashville, TN, United States. Electronic address: k.humphreys@vanderbilt.edu.'}, {'ForeName': 'Hannah A', 'Initials': 'HA', 'LastName': 'Piersiak', 'Affiliation': 'Vanderbilt University, Nashville, TN, United States.'}, {'ForeName': 'Carlomagno C', 'Initials': 'CC', 'LastName': 'Panlilio', 'Affiliation': 'Pennsylvania State University, Hershey, PA, United States.'}, {'ForeName': 'Erik B', 'Initials': 'EB', 'LastName': 'Lehman', 'Affiliation': 'Pennsylvania State College of Medicine, Hershey, PA, United States.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Verdiglione', 'Affiliation': 'Pennsylvania State College of Medicine, Hershey, PA, United States.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Dore', 'Affiliation': 'Pennsylvania State College of Medicine, Hershey, PA, United States.'}, {'ForeName': 'Benjamin H', 'Initials': 'BH', 'LastName': 'Levi', 'Affiliation': 'Pennsylvania State College of Medicine, Hershey, PA, United States.'}]",Child abuse & neglect,['10.1016/j.chiabu.2021.105033'] 3064,32948350,Simultaneous assessment of intestinal permeability and lactase activity in human-milk-fed preterm infants by sugar absorption test: Clinical implementation and analytical method.,"BACKGROUND & AIMS Experimental (nutritional) interventions in preterm infants frequently focus on intestinal maturation, as improving tolerance to enteral nutrition is a major goal. Intestinal permeability and lactase activity serve as markers for intestinal maturation. We aimed to develop a protocol for the simultaneous assessment of both markers in human-milk-fed preterm infants by a sugar absorption test. In addition, we developed a new gas chromatography-mass spectrometry (GC-MS) method for the analysis of lactulose, lactose, and mannitol in urine and milk collected during the sugar absorption test. METHODS The sugar absorption test was performed on days 4, 7, and 14 postpartum in 12 preterm infants (gestational age of 26-32 weeks). Human milk was collected, pooled, and divided into equal portions to provide a stable lactose intake for 24 h. Urine was collected in the last 6 h of this 24 h period, after administration of a bolus test sugar solution. Samples were analyzed by GC-MS after derivatization by oxime formation combined with acetylation. RESULTS The GC-MS method was validated and used for the accurate measurement of lactulose, lactose, and mannitol concentrations. The urinary lactulose/mannitol ratio declined with time, suggesting a decreased intestinal permeability. The urine-to-milk-lactulose/lactose ratio increased as a result of increased lactase activity with time. CONCLUSIONS The developed protocol for simultaneous assessment of intestinal permeability and lactase activity can be used to monitor the effect of experimental (nutritional) interventions in human-milk-fed preterm infants. Urine and milk samples obtained during the sugar absorption test can be accurately analyzed by GC-MS.",2021,"The GC-MS method was validated and used for the accurate measurement of lactulose, lactose, and mannitol concentrations.","['preterm infants', '12 preterm infants (gestational age of 26-32 weeks', 'human-milk-fed preterm infants', 'human-milk-fed preterm infants by a sugar absorption test']",[],"['intestinal permeability and lactase activity', 'urine-to-milk-lactulose/lactose ratio', 'lactase activity', 'urinary lactulose/mannitol ratio', 'Intestinal permeability and lactase activity', 'intestinal permeability']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0026140', 'cui_str': 'Breast milk'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",[],"[{'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C0005220', 'cui_str': 'Beta-galactosidase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0022957', 'cui_str': 'Lactulose'}, {'cui': 'C0022949', 'cui_str': 'Lactose'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0024730', 'cui_str': 'Mannitol'}]",12.0,0.0487618,"The GC-MS method was validated and used for the accurate measurement of lactulose, lactose, and mannitol concentrations.","[{'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Mank', 'Affiliation': ""Amsterdam UMC, University of Amsterdam, Vrije Universiteit, Emma Children's Hospital, Department of Neonatology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.""}, {'ForeName': 'Dewi', 'Initials': 'D', 'LastName': 'van Harskamp', 'Affiliation': ""Amsterdam UMC, University of Amsterdam, Vrije Universiteit, Emma Children's Hospital, Department of Neonatology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands; Amsterdam UMC, University of Amsterdam, Vrije Universiteit, Stable Isotope Research Laboratory, Endocrinology, Amsterdam Gastroenterology Endocrinology and Metabolism, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.""}, {'ForeName': 'Letty', 'Initials': 'L', 'LastName': 'van Toledo', 'Affiliation': ""Amsterdam UMC, University of Amsterdam, Vrije Universiteit, Emma Children's Hospital, Department of Neonatology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.""}, {'ForeName': 'Johannes B', 'Initials': 'JB', 'LastName': 'van Goudoever', 'Affiliation': ""Amsterdam UMC, University of Amsterdam, Vrije Universiteit, Emma Children's Hospital, Department of Neonatology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. Electronic address: h.vangoudoever@amsterdamumc.nl.""}, {'ForeName': 'Henk', 'Initials': 'H', 'LastName': 'Schierbeek', 'Affiliation': ""Amsterdam UMC, University of Amsterdam, Vrije Universiteit, Emma Children's Hospital, Department of Neonatology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands; Amsterdam UMC, University of Amsterdam, Vrije Universiteit, Stable Isotope Research Laboratory, Endocrinology, Amsterdam Gastroenterology Endocrinology and Metabolism, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.""}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.08.034'] 3065,33913497,Letter: Randomized Trial of Unilateral Focused Ultrasound Subthalamotomy for Parkinson Disease.,,2021,,"['Letter', 'Parkinson Disease']",['Unilateral Focused Ultrasound Subthalamotomy'],[],"[{'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]",[],,0.117373,,"[{'ForeName': 'Ron L', 'Initials': 'RL', 'LastName': 'Alterman', 'Affiliation': 'Beth Israel Deaconess Medical Center Boston, Massachusetts, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schulder', 'Affiliation': 'Zucker School of Medicine at Hofstra/Northwell Manhasset, New York, USA.'}]",Neurosurgery,['10.1093/neuros/nyab140'] 3066,33894918,"Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.","BACKGROUND Laparoscopic surgery has been widely used for rectal cancer; however, its long-term outcomes remain controversial. This study aimed to assess the long-term oncological safety of laparoscopic surgery for rectal cancer using 10-year follow-up data of the Comparison of Open versus laparoscopic surgery for mid or low REctal cancer After Neoadjuvant chemoradiotherapy (COREAN) trial. METHODS The COREAN trial is a, open-label, non-inferiority, randomised controlled trial. Eligible participants were aged 18-80 years, had cT3N0-2M0 middle or low rectal cancer with lesions located within 9 cm of the anal verge, and had been treated with preoperative chemoradiotherapy. Patients were randomly assigned (1:1) to open or laparoscopic surgery with a computer-generated random allocation sequence with a random permuted block design. Neither patients nor clinicians were masked to treatment assignment. Open or laparoscopic total mesorectal excision was done 6-8 weeks after the administration of preoperative concurrent chemoradiotherapy (fluoropyrimidines alone, doublet therapy, or triplet therapy) at a dose of 50·5 Gy over 5·5 weeks. Postoperative adjuvant chemotherapy was administered for 4 months. The primary endpoint of 3-year disease-free survival was published previously. Here, we report 10-year overall survival, disease-free survival, and local recurrence. Analyses were done in the modified intention-to-treat population of all participants who were randomly assigned and provided follow-up data. This study is registered with ClinicalTrials.gov, NCT00470951. FINDINGS Of the 340 patients enrolled in the COREAN trial between April 4, 2006, and Aug 26, 2009 (170 patients in each group), two patients in the laparoscopic surgery group moved abroad and were lost to follow-up, so were not included in this 10-year analysis. The median duration of follow-up was 143 months (IQR 122-156). No differences were observed in 10-year overall survival (74·1% [95% CI 66·8-80·0] in the open surgery group vs 76·8% [69·6-82·5] in the laparoscopic surgery group; p=0·44), 10-year disease-free survival (59·3% [51·1-66·5] vs 64·3% [56·0-71·5]; p=0·20), or 10-year local recurrence (8·9% [5·2-15·0] vs 3·4% [1·4-7·9]; p=0·050) between the open surgery and laparoscopic surgery groups at 10 years after surgery. The stratified hazard ratios, adjusted for ypT and ypN classification and tumour regression grade, for open surgery versus laparoscopic surgery were 0·94 (95% CI 0·63-1·43) for overall survival, 1·05 (0·74-1·49) for disease-free survival, and 2·22 (0·78-6·34) for local recurrence. INTERPRETATION The 10-year follow-up of the COREAN trial confirms the long-term oncological safety of laparoscopic surgery in patients with rectal cancer treated with preoperative chemoradiotherapy. Similar to open surgery, laparoscopic surgery does not compromise long-term survival outcomes in rectal cancer when performed by well trained surgeons. FUNDING National Cancer Center, Goyang, South Korea.",2021,"No differences were observed in 10-year overall survival (74·1% [95% CI 66·8-80·0] in the open surgery group vs 76·8% [69·6-82·5] in the laparoscopic surgery group; p=0·44), 10-year disease-free survival (59·3% [51·1-66·5] vs 64·3% [56·0-71·5]; p=0·20), or 10-year local recurrence (8·9% [5·2-15·0] vs 3·4% [1·4-7·9]; p=0·050) between the open surgery and laparoscopic surgery groups at 10 years after surgery.","['Eligible participants were aged 18-80 years, had cT3N0-2M0 middle or low rectal cancer with lesions located within 9 cm of the anal verge, and had been treated with preoperative chemoradiotherapy', 'mid or low REctal cancer', '340 patients enrolled in the COREAN trial between April 4, 2006, and Aug 26, 2009 (170 patients in each group), two patients in the', 'for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial', 'patients with rectal cancer treated with']","['laparoscopic surgery', 'Laparoscopic surgery', 'Open versus laparoscopic surgery', 'Postoperative adjuvant chemotherapy', 'preoperative chemoradiotherapy', 'Neoadjuvant chemoradiotherapy', 'laparoscopic total mesorectal excision', 'open or laparoscopic surgery with a computer-generated random allocation sequence with a random permuted block design', 'preoperative concurrent chemoradiotherapy (fluoropyrimidines alone, doublet therapy, or triplet therapy']","['10-year overall survival', '10-year disease-free survival', 'median duration', 'compromise long-term survival outcomes', '10-year local recurrence', '10-year overall survival, disease-free survival, and local recurrence', '3-year disease-free survival']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0227423', 'cui_str': 'Structure of transition zone of anal mucous membrane'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C4517730', 'cui_str': '340'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}]","[{'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0041095', 'cui_str': 'Triplets'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",340.0,0.800245,"No differences were observed in 10-year overall survival (74·1% [95% CI 66·8-80·0] in the open surgery group vs 76·8% [69·6-82·5] in the laparoscopic surgery group; p=0·44), 10-year disease-free survival (59·3% [51·1-66·5] vs 64·3% [56·0-71·5]; p=0·20), or 10-year local recurrence (8·9% [5·2-15·0] vs 3·4% [1·4-7·9]; p=0·050) between the open surgery and laparoscopic surgery groups at 10 years after surgery.","[{'ForeName': 'Ji Won', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Sung-Bum', 'Initials': 'SB', 'LastName': 'Kang', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Hao', 'Affiliation': 'Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Seok-Byung', 'Initials': 'SB', 'LastName': 'Lim', 'Affiliation': 'Department of Colon and Rectal Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hyo Seong', 'Initials': 'HS', 'LastName': 'Choi', 'Affiliation': 'Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Duck-Woo', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Hee Jin', 'Initials': 'HJ', 'LastName': 'Chang', 'Affiliation': 'Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Dae Yong', 'Initials': 'DY', 'LastName': 'Kim', 'Affiliation': 'Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Kyung Hae', 'Initials': 'KH', 'LastName': 'Jung', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Tae-You', 'Initials': 'TY', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Gyeong Hoon', 'Initials': 'GH', 'LastName': 'Kang', 'Affiliation': 'Department of Pathology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Eui Kyu', 'Initials': 'EK', 'LastName': 'Chie', 'Affiliation': 'Department of Radiation Oncology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Sun Young', 'Initials': 'SY', 'LastName': 'Kim', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Dae Kyung', 'Initials': 'DK', 'LastName': 'Sohn', 'Affiliation': 'Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Jae-Sung', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Department of Radiation Oncology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Hye Seung', 'Initials': 'HS', 'LastName': 'Lee', 'Affiliation': 'Department of Pathology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea.'}, {'ForeName': 'Jee Hyun', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Seung-Yong', 'Initials': 'SY', 'LastName': 'Jeong', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University, Seoul, South Korea. Electronic address: syjeong@snu.ac.kr.'}, {'ForeName': 'Jae Hwan', 'Initials': 'JH', 'LastName': 'Oh', 'Affiliation': 'Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(21)00094-7'] 3067,33894856,Comparison of three sitting positions for combined spinal - epidural anesthesia: a multicenter randomized controlled trial.,"BACKGROUND AND OBJECTIVES The aim of this prospective, multi-centered and multi-arm parallel randomized trial was to test the hypothesis that modified sitting positions including hamstring stretch position (HSP) and squatting position (SP) would reduce needle - bone contact events and increase the success rate of combined spinal - epidural anesthesia (CSEA) compared to traditional sitting position (TSP) in patients undergoing total knee or hip arthroplasty. PATIENTS AND METHODS Three hundred and sixty American Society of Anesthesiologists (ASA) I-III patients, aged between 45-85 years were randomly allocated to one of three groups using computer-generated simple randomization: group TSP (n = 120), group HSP (n = 120), and group SP (n = 120). Primary outcome measures were the number of needle-bone contact and success rates. Secondary outcome measure was the ease of interspinous space identification. RESULTS Seven patients in group SP and four of HSP could not tolerate their position and were excluded. Number of needle-bone contact, success rates, and grade of interspinous space identification were similar between groups (p = 1.000). Independent of positioning, the success rates were higher in patients whose interspinous space was graded as easy compared to difficult or impossible (p < 0.001). Success rates reduced, interspinous space identification became more challenging, and number of needle - bone contact increased as patient's body mass index (BMI) increased (p < 0.001). CONCLUSION SP and HSP may be used as alternatives to the TSP. BMI and ease of interspinous space identification may be considered important determinants for CSEA success.",2021,"Independent of positioning, the success rates were higher in patients whose interspinous space was graded as easy compared to difficult or impossible (p < 0.001).","['I-III patients, aged between 45-85 years', 'Three hundred and sixty American Society of Anesthesiologists (ASA', 'patients undergoing total knee or hip arthroplasty']","['combined spinal - epidural anesthesia', 'combined spinal - epidural anesthesia (CSEA', 'computer-generated simple randomization: group TSP', 'HSP', 'modified sitting positions including hamstring stretch position (HSP) and squatting position (SP', 'traditional sitting position (TSP']","[""number of needle - bone contact increased as patient's body mass index (BMI"", 'number of needle-bone contact and success rates', 'success rates', 'Number of needle-bone contact, success rates, and grade of interspinous space identification', 'ease of interspinous space identification']","[{'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0186193', 'cui_str': 'Repair of hip'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0076560', 'cui_str': 'Thrombospondin'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}]",360.0,0.0551044,"Independent of positioning, the success rates were higher in patients whose interspinous space was graded as easy compared to difficult or impossible (p < 0.001).","[{'ForeName': 'Mehmet Özgür', 'Initials': 'MÖ', 'LastName': 'Özhan', 'Affiliation': 'Private Çankaya Hospital, Department of Anesthesiology and Reanimation, Ankara, Turkey.'}, {'ForeName': 'Ceyda Özhan', 'Initials': 'CÖ', 'LastName': 'Çaparlar', 'Affiliation': 'University of Medical Sciences Yildirim Beyazit Training and Research Hospital, Department of Anesthesiology and Reanimation, Ankara, Turkey.'}, {'ForeName': 'Mehmet Anıl', 'Initials': 'MA', 'LastName': 'Süzer', 'Affiliation': 'Private Çankaya Hospital, Department of Anesthesiology and Reanimation, Ankara, Turkey.'}, {'ForeName': 'Mehmet Burak', 'Initials': 'MB', 'LastName': 'Eskin', 'Affiliation': 'University of Medical Sciences Gulhane Training and Research Hospital, Department of Anesthesiology and Reanimation, Ankara, Turkey.'}, {'ForeName': 'Bülent', 'Initials': 'B', 'LastName': 'Atik', 'Affiliation': 'Balikesir University Medical Faculty Health Practice and Research Hospital, Department of Anesthesiology and Reanimation, Balikesir, Turkey. Electronic address: bulent_atik@yahoo.com.'}]",Brazilian journal of anesthesiology (Elsevier),['10.1016/j.bjane.2020.12.012'] 3068,33896803,Spectral analysis of blood flow oscillations to assess the plantar skin blood flow regulation in response to preconditioning local vibrations.,"BACKGROUND Local vibration has shown promise in improving skin blood flow and wound healing. However, the underlying mechanism of local vibration as a preconditioning intervention to alter plantar skin blood flow after walking is unclear. OBJECTIVE The objective was to use wavelet analysis of skin blood flow oscillations to investigate the effect of preconditioning local vibration on plantar tissues after walking. METHODS A double-blind, repeated measures design was tested in 10 healthy participants. The protocol included 10-min baseline, 10-min local vibrations (100 Hz or sham), 10-min walking, and 10-min recovery periods. Skin blood flow was measured over the first metatarsal head of the right foot during the baseline and recovery periods. Wavelet amplitudes after walking were expressed as the ratio of the wavelet amplitude before walking. RESULTS The results showed the significant difference in the metabolic (vibration 10.06 ± 1.97, sham 5.78 ± 1.53, p < 0.01) and neurogenic (vibration 7.45 ± 1.54, sham 4.78 ± 1.22, p < 0.01) controls. There were no significant differences in the myogenic, respiratory and cardiac controls between the preconditioning local vibration and sham conditions. CONCLUSIONS Our results showed that preconditioning local vibration altered the normalization rates of plantar skin blood flow after walking by stimulating the metabolic and neurogenic controls.",2021,"The results showed the significant difference in the metabolic (vibration 10.06 ± 1.97, sham 5.78 ± 1.53, p < 0.01) and neurogenic (vibration 7.45 ± 1.54, sham 4.78 ± 1.22, p < 0.01) controls.",['10 healthy participants'],"['preconditioning local vibration', '10-min local vibrations (100Hz or sham), 10-min walking, and 10-min recovery periods']","['skin blood flow and wound healing', 'normalization rates of plantar skin blood flow', 'myogenic, respiratory and cardiac controls', 'Skin blood flow', 'plantar skin blood flow']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1709632', 'cui_str': 'Precondition'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",10.0,0.101676,"The results showed the significant difference in the metabolic (vibration 10.06 ± 1.97, sham 5.78 ± 1.53, p < 0.01) and neurogenic (vibration 7.45 ± 1.54, sham 4.78 ± 1.22, p < 0.01) controls.","[{'ForeName': 'Xiaotong', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Champaign, IL, USA.'}, {'ForeName': 'Keying', 'Initials': 'K', 'LastName': 'Zhang', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Champaign, IL, USA.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'He', 'Affiliation': 'College of Physical Education and Sports, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Fuyuan', 'Initials': 'F', 'LastName': 'Liao', 'Affiliation': ""Department of Biomedical Engineering, Xi'an Technological University, Xi'an, China.""}, {'ForeName': 'Yuanchun', 'Initials': 'Y', 'LastName': 'Ren', 'Affiliation': 'College of Physical Education and Sports, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Yih-Kuen', 'Initials': 'YK', 'LastName': 'Jan', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Champaign, IL, USA.'}]",Biorheology,['10.3233/BIR-201011'] 3069,33905100,"Clinical, radiological and HRQoL outcomes after selective thoracic fusion with minimum 15-year follow-up.","INTRODUCTION The purpose of the study was to provide a 15-year natural history evaluation of the radiographic appearance of uninstrumented compensatory lumbar curves in patients who had undergone selective thoracic fusion (STF) for scoliosis, measure any changes in health-related quality of life scores (HRQoL) and compare them with controls matched for age, gender and body-mass index (BMI). METHODS STF group included 43 female adolescent idiopathic scoliosis (AIS) patients who underwent STF with mean age 33(27-42) years and a mean follow-up of 18.7 (15-28) years, mean BMI 22(18-29). Preop, early postop and follow-up radiographs were reviewed for behavior of lumbar curves. Control group included a random selection of healthy volunteers with no history of back pain and with mean age 33(27-41), and mean BMI 22(17-33). HRQoL scores were compared between two groups in latest f/up. Radiographs including low dose biplanar imaging with EOS were used to measure disc heights and assess for radiographic evidence of degenerative changes. Various parameters were statistically compared. RESULTS Posterior fusion was performed in all 43, with all pedicle screws used in 41 and all-hook constructs in 2. Main thoracic curve correction was improved from pre-op to early-post-op and maintained at latest f/up (55.6°-16.1°-16.9°). Spontaneous lumbar curve correction (SLCC) was also maintained beyond 15 years (39.9°-16.6°-17.1°). Two patients developed coronal decompensation following surgery, but improved with time and were well compensated at final follow-up. Mean HRQoL scores, self-image and mental health scores were higher in STF group than control group (p < 0.05). SRS-22r pain and function, Oswestry Disability Index and Numeric Rating Scale, marital status, number of children were similar between the groups(p > 0.05). All disc heights except L5-S1 were significantly lower in STF group (p < 0.05). There was no significant difference between the groups for degenerative changes in the latest radiographs. CONCLUSION In this group of patients, the uninstrumented lumbar curve spontaneously corrected and the correction was maintained after 18 years following surgery using STF. Mild degenerative changes were seen radiographically and HRQoL scores suggest that the psychological-functional well-being are quite good in the long term in AIS patients who have undergone STF when compared with an age-gender-BMI-matched population.",2021,All disc heights except L5-S1 were significantly lower in STF group (p < 0.05).,"['STF group included 43 female adolescent idiopathic scoliosis (AIS) patients who underwent STF with mean age 33(27-42) years and a mean follow-up of 18.7 (15-28) years, mean BMI 22(18-29', 'healthy volunteers with no history of back pain and with mean age 33(27-41), and mean BMI 22(17-33', 'patients who had undergone selective thoracic fusion (STF) for scoliosis']",[],"['Main thoracic curve correction', 'Mean HRQoL scores, self-image and mental health scores', 'HRQoL scores', 'Spontaneous lumbar curve correction (SLCC', 'SRS-22r pain and function, Oswestry Disability Index and Numeric Rating Scale, marital status, number of children', 'coronal decompensation', 'degenerative changes', 'All disc heights except L5-S1']","[{'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0595995', 'cui_str': 'Idiopathic scoliosis'}, {'cui': 'C0410702', 'cui_str': 'Adolescent idiopathic scoliosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332122', 'cui_str': 'No history of'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0036439', 'cui_str': 'Scoliosis deformity of spine'}]",[],"[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0242498', 'cui_str': 'Self-image'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0175693', 'cui_str': 'Russell-Silver syndrome'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0024819', 'cui_str': 'Marital status'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0231187', 'cui_str': 'Decompensation'}, {'cui': 'C0011164', 'cui_str': 'Degeneration'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}]",43.0,0.0131711,All disc heights except L5-S1 were significantly lower in STF group (p < 0.05).,"[{'ForeName': 'Azmi', 'Initials': 'A', 'LastName': 'Hamzaoglu', 'Affiliation': 'Istanbul Spine Center at Florence Nightingale Hospital, Abide-i Hurriyet Cad. No:164 Sisli, 34381, Istanbul, Turkey.'}, {'ForeName': 'Selhan', 'Initials': 'S', 'LastName': 'Karadereler', 'Affiliation': 'Istanbul Spine Center at Florence Nightingale Hospital, Abide-i Hurriyet Cad. No:164 Sisli, 34381, Istanbul, Turkey.'}, {'ForeName': 'Sinan', 'Initials': 'S', 'LastName': 'Kahraman', 'Affiliation': 'Department of Orthopaedics and Traumatology, Faculty of Medicine, Istanbul Bilim University, Abide-i Hurriyet Cad. No:166 Sisli, 34381, Istanbul, Turkey. kahramansin@gmail.com.'}, {'ForeName': 'Yunus Emre', 'Initials': 'YE', 'LastName': 'Akman', 'Affiliation': 'Department of Orthopaedics and Traumatology, Faculty of Medicine, Istanbul Bilim University, Abide-i Hurriyet Cad. No:166 Sisli, 34381, Istanbul, Turkey.'}, {'ForeName': 'Ayhan', 'Initials': 'A', 'LastName': 'Mutlu', 'Affiliation': 'Department of Radiology, Istanbul Florence Nightingale Hospital, Abide-i Hurriyet Cad. No:166 Sisli, 34381, Istanbul, Turkey.'}, {'ForeName': 'Okan', 'Initials': 'O', 'LastName': 'Aslanturk', 'Affiliation': 'Malatya Education Ve Research Hospital, Özalper mah. Turgut Özal Bulvarı No:4, Malatya, Turkey.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Elsadig', 'Affiliation': 'Istanbul Spine Center at Florence Nightingale Hospital, Abide-i Hurriyet Cad. No:164 Sisli, 34381, Istanbul, Turkey.'}, {'ForeName': 'Tunay', 'Initials': 'T', 'LastName': 'Sanli', 'Affiliation': 'Istanbul Spine Center at Florence Nightingale Hospital, Abide-i Hurriyet Cad. No:164 Sisli, 34381, Istanbul, Turkey.'}, {'ForeName': 'Meric', 'Initials': 'M', 'LastName': 'Enercan', 'Affiliation': 'Istanbul Spine Center at Florence Nightingale Hospital, Abide-i Hurriyet Cad. No:164 Sisli, 34381, Istanbul, Turkey.'}]",Spine deformity,['10.1007/s43390-021-00350-2'] 3070,33915252,"Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.","INTRODUCTION ZL-2306-005 is a randomized, double-blind, multicenter phase 3 study evaluating the efficacy and safety of niraparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, as first-line maintenance therapy in Chinese patients with platinum-responsive, extensive-stage SCLC (ES-SCLC). METHODS Patients with complete response (CR) or partial response (PR) to standardized, platinum-based first-line chemotherapy were randomized 2:1 to receive niraparib or placebo (300 mg [baseline body weight ≥ 77 kg, platelet count ≥ 150,000/μL] or 200 mg) once daily until progression or unacceptable toxicity. Primary end points were progression-free survival (PFS) (blinded independent central review) and overall survival (sample size planned: 591 patients). Secondary end points included investigator-evaluated PFS and safety. RESULTS ZL-2306-005 was terminated early owing to ES-SCLC treatment landscape changes (data cutoff: March 20, 2020). During July 2018-February 2020, a total of 185 of 272 patients screened were randomized (niraparib: n = 125 [CR = 1, PR = 124]; placebo: n = 60 [CR = 1, PR = 59]). Median (95% confidence interval [CI]) PFS (blinded independent central review) was 1.54 months (1.41-2.69, niraparib) and 1.36 months (1.31-1.48, placebo); hazard ratio (HR) = 0.66 (95% CI: 0.46-0.95, p = 0.0242). Median overall survival was 9.92 months (9.33-13.54, niraparib) and 11.43 months (9.53-not estimable, placebo); HR = 1.03 (95% CI: 0.62-1.73, p = 0.9052). Median investigator-evaluated PFS was 1.48 months (1.41-2.56, niraparib) and 1.41 months (1.31-2.00, placebo); HR = 0.88 (95% CI: 0.61-1.26; p = 0.4653). Grade greater than or equal to 3 adverse events occurred in 34.4% (niraparib) and 25.0% (placebo) of patients. CONCLUSIONS ZL-2306-005 did not reach primary end points. Nevertheless, niraparib as maintenance therapy modestly improved PFS in patients with platinum-responsive ES-SCLC, with acceptable tolerability profile and no new safety signal.",2021,"PFS (BICR) was 1.54 months (1.41-2.69, niraparib) and 1.36 months (1.31-1.48, placebo); hazard ratio [","['Chinese patients with platinum-responsive, extensive-stage small cell lung cancer (ES-SCLC', 'During July 2018-February 2020, 185 of 272 patients screened were randomized (niraparib: n=125 [CR=1, PR=124', 'sample size planned: 591 patients', 'Patients with complete/partial response (CR/PR) to standardized, platinum-based first-line chemotherapy', 'Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy']","['niraparib, a poly(ADP-ribose) polymerase inhibitor', 'Niraparib', 'niraparib or placebo', 'placebo']","['progression-free survival (PFS) (blinded independent central review, BICR) and overall survival (OS) ', 'Efficacy and Safety', 'Median OS', 'PFS', 'Median investigator-assessed PFS', 'Grade ≥3 adverse events', 'investigator-assessed PFS and safety', 'PFS (BICR']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0205342', 'cui_str': 'Responsive'}, {'cui': 'C0278726', 'cui_str': 'Small cell lung cancer extensive stage'}, {'cui': 'C4517617', 'cui_str': '185'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C2744440', 'cui_str': 'niraparib'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C2744440', 'cui_str': 'niraparib'}, {'cui': 'C1882413', 'cui_str': 'Nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor-containing product'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.790288,"PFS (BICR) was 1.54 months (1.41-2.69, niraparib) and 1.36 months (1.31-1.48, placebo); hazard ratio [","[{'ForeName': 'Xinghao', 'Initials': 'X', 'LastName': 'Ai', 'Affiliation': ""Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.""}, {'ForeName': 'Yueyin', 'Initials': 'Y', 'LastName': 'Pan', 'Affiliation': ""Department of Chemotherapy, Anhui Provincial Hospital, Hefei, People's Republic of China.""}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': ""Department of Medical Oncology, Linyi Cancer Hospital, Linyi, People's Republic of China.""}, {'ForeName': 'Nong', 'Initials': 'N', 'LastName': 'Yang', 'Affiliation': ""Lung & Gastrointestinal Oncology Department, Hunan Cancer Hospital, Changsha, People's Republic of China.""}, {'ForeName': 'Chunling', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': ""Department of Pulmonary Medicine, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, People's Republic of China.""}, {'ForeName': 'Jianying', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': ""Department of Respiratory Medicine, First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.""}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Medical Oncology, Nantong Tumor Hospital, Nantong, People's Republic of China.""}, {'ForeName': 'Xiaorong', 'Initials': 'X', 'LastName': 'Dong', 'Affiliation': ""Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.""}, {'ForeName': 'Jianxing', 'Initials': 'J', 'LastName': 'He', 'Affiliation': ""Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.""}, {'ForeName': 'Xiaoling', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ""Department of Thoracic Medicine, Liaoning Cancer Hospital & Institute, Shenyang, People's Republic of China.""}, {'ForeName': 'Gongyan', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': ""Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.""}, {'ForeName': 'Xingya', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ""Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.""}, {'ForeName': 'Helong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': ""Department of Oncology, Tangdu Hospital, Xi'an, People's Republic of China.""}, {'ForeName': 'Wangjun', 'Initials': 'W', 'LastName': 'Liao', 'Affiliation': ""Department of Oncology, Nanfang Hospital, Guangzhou, People's Republic of China.""}, {'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.""}, {'ForeName': 'Zhiyong', 'Initials': 'Z', 'LastName': 'Ma', 'Affiliation': ""Department of Respiratory Medicine, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, People's Republic of China.""}, {'ForeName': 'Liyan', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': ""Department of Respiration, Shanghai Chest Hospital, Shanghai, People's Republic of China.""}, {'ForeName': 'Jiuwei', 'Initials': 'J', 'LastName': 'Cui', 'Affiliation': ""Department of Oncology, The First Bethune Hospital of Jilin University, Changchun, People's Republic of China.""}, {'ForeName': 'Chunhong', 'Initials': 'C', 'LastName': 'Hu', 'Affiliation': ""Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""Department of Oncology, Jinzhou Central Hospital, Jinzhou, People's Republic of China.""}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': ""Department of Oncology, Fujian Cancer Hospital, Fuzhou, People's Republic of China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': ""Department of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.""}, {'ForeName': 'Cuimin', 'Initials': 'C', 'LastName': 'Ding', 'Affiliation': ""Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, Shijiazhuang, People's Republic of China.""}, {'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': ""Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.""}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': ""Department of Respiratory Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China.""}, {'ForeName': 'Beili', 'Initials': 'B', 'LastName': 'Gao', 'Affiliation': ""Department of Respiratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': ""Department of Respiratory Medicine, Nanjing General Hospital of Nanjing Military Command, Nanjing, People's Republic of China.""}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': ""Department of Pulmonary Oncology, The 307th Hospital of the Chinese People's Liberation Army, Beijing, People's Republic of China.""}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Xiong', 'Affiliation': ""Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.""}, {'ForeName': 'Anwen', 'Initials': 'A', 'LastName': 'Liu', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.""}, {'ForeName': 'Junling', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""Department of Internal Medicine, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, People's Republic of China.""}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ""Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.""}, {'ForeName': 'Yinyin', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""Department of Oncology, Shenyang the Tenth People's Hospital, Shenyang, People's Republic of China.""}, {'ForeName': 'Mengzhao', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': ""Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, People's Republic of China.""}, {'ForeName': 'Biao', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': ""R&D Department, Zai Lab (Shanghai) Co., Ltd., Shanghai, People's Republic of China.""}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': ""R&D Department, Zai Lab (Shanghai) Co., Ltd., Shanghai, People's Republic of China.""}, {'ForeName': 'Shun', 'Initials': 'S', 'LastName': 'Lu', 'Affiliation': ""Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China. Electronic address: shunlu@sjtu.edu.cn.""}]",Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,['10.1016/j.jtho.2021.04.001'] 3071,33928486,"Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.","BACKGROUND We aimed to assess the safety and efficacy of combination treatment with panitumumab plus trifluridine/tipiracil (FTD/TPI) in patients with wild-type RAS metastatic colorectal cancer (mCRC) who were refractory/intolerant to standard therapies other than anti-epidermal growth factor receptor therapy. METHODS APOLLON was an open-label, multicentre, phase 1/2 trial. In the phase 1 part, 3 + 3 de-escalation design was used to investigate the recommended phase 2 dose (RP2D); all patients in the phase 2 part received the RP2D. The primary endpoint was investigator-assessed progression-free survival (PFS) rate at 6 months. Secondary endpoints included PFS, overall survival (OS), overall response rate (ORR), disease control rate (DCR), time to treatment failure (TTF), and safety. RESULTS Fifty-six patients were enrolled (phase 1, n = 7; phase 2, n = 49) at 25 Japanese centres. No dose-limiting toxicities were observed in patients receiving panitumumab (6 mg/kg every 2 weeks) plus FTD/TPI (35 mg/m 2 twice daily; days 1-5 and 8-12 in a 28-day cycle), which became RP2D. PFS rate at 6 months was 33.3% (90% confidence interval [CI] 22.8-45.3). Median PFS, OS, ORR, DCR, and TTF were 5.8 months (95% CI 4.5-6.5), 14.1 months (95% CI 12.2-19.3), 37.0% (95% CI 24.3-51.3), 81.5% (95% CI 68.6-90.8), and 5.8 months (95% CI 4.29-6.21), respectively. Neutrophil count decreased (47.3%) was the most common Grade 3/4 treatment-emergent adverse event. No treatment-related deaths occurred. CONCLUSION Panitumumab plus FTD/TPI exhibited favourable anti-tumour activity with a manageable safety profile and may be a therapeutic option for pre-treated mCRC patients.",2021,"Median PFS, OS, ORR, DCR, and TTF were 5.8 months (95% CI 4.5-6.5), 14.1 months (95% CI 12.2-19.3), 37.0% (95% CI 24.3-51.3), 81.5% (95% CI 68.6-90.8), and 5.8 months (95% CI 4.29-6.21), respectively.","['Fifty-six patients were enrolled (phase 1, n\u2009=\u20097; phase 2, n\u2009=\u200949) at 25 Japanese centres', 'pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS', 'patients with wild-type RAS metastatic colorectal cancer (mCRC) who were refractory/intolerant to standard therapies other than anti-epidermal growth factor receptor therapy']","['Panitumumab plus FTD/TPI', 'trifluridine/tipiracil', 'RP2D', 'panitumumab', 'panitumumab plus trifluridine/tipiracil (FTD/TPI']","['safety and efficacy', 'No dose-limiting toxicities', 'Safety and efficacy', 'Median PFS, OS, ORR, DCR, and TTF', 'investigator-assessed progression-free survival (PFS) rate', 'PFS, overall survival (OS), overall response rate (ORR), disease control rate (DCR), time to treatment failure (TTF), and safety', 'RP2D. PFS rate', 'Neutrophil count']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439559', 'cui_str': 'Phase 1'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0879427', 'cui_str': 'panitumumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0338451', 'cui_str': 'Frontotemporal dementia'}, {'cui': 'C4055631', 'cui_str': 'Tipiracil- and trifluridine-containing product'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C3494202', 'cui_str': 'Time to Treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0200633', 'cui_str': 'Neutrophil count'}]",56.0,0.181978,"Median PFS, OS, ORR, DCR, and TTF were 5.8 months (95% CI 4.5-6.5), 14.1 months (95% CI 12.2-19.3), 37.0% (95% CI 24.3-51.3), 81.5% (95% CI 68.6-90.8), and 5.8 months (95% CI 4.29-6.21), respectively.","[{'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kato', 'Affiliation': 'National Hospital Organization Osaka National Hospital, 2 Chome-1-14 Hoenzaka, Chuo Ward, Osaka, 540-0006, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Kagawa', 'Affiliation': 'Kansai Rosai Hospital, 3 Chome-1-69 Inabaso, Amagasaki, Hyogo, 660-8511, Japan.'}, {'ForeName': 'Yasutoshi', 'Initials': 'Y', 'LastName': 'Kuboki', 'Affiliation': 'National Cancer Center Hospital East, 6 Chome-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.'}, {'ForeName': 'Makio', 'Initials': 'M', 'LastName': 'Gamoh', 'Affiliation': 'Osaki Citizen Hospital, Furukawa Honami, 3 Chome, Osaki, 989-6183, Japan.'}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Komatsu', 'Affiliation': 'Hokkaido University Hospital, 5 Chome Kita 14 Jonishi, Kita Ward, Sapporo, Hokkaido, 060-8648, Japan.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Yasui', 'Affiliation': 'Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto District, Shizuoka, 411-0934, Japan.'}, {'ForeName': 'Hironaga', 'Initials': 'H', 'LastName': 'Satake', 'Affiliation': 'Kobe City Medical Center General Hospital, 2 Chome-1-1 Minatojima Minamimachi, Chuo Ward, Kobe, Hyogo, 650-0047, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Oki', 'Affiliation': 'Kyushu University, Maidashi 3 Chome-1-3, Higashi Ward, Fukuoka, 812-0053, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Tanioka', 'Affiliation': 'Okayama Rosai Hospital, 1 Chome-10-25 Chikkomidorimachi, Minami Ward, Okayama, 702-8055, Japan.'}, {'ForeName': 'Masahito', 'Initials': 'M', 'LastName': 'Kotaka', 'Affiliation': 'Sano Hospital, 2 Chome-5-1 Shimizugaoka, Tarumi Ward, Kobe, Hyogo, 655-0031, Japan.'}, {'ForeName': 'Akitaka', 'Initials': 'A', 'LastName': 'Makiyama', 'Affiliation': 'Japan Community Healthcare Organization Kyushu Hospital, 1 Chome-8-1 Kishinoura, Yahatanishi Ward, Kitakyushu, Fukuoka, 806-8501, Japan.'}, {'ForeName': 'Tadamichi', 'Initials': 'T', 'LastName': 'Denda', 'Affiliation': 'Chiba Cancer Center, 666-2 Nitona-cho, Chuo Ward, Chiba, 260-8717, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Goto', 'Affiliation': 'Osaka Medical College Hospital, 2-7 Daigakumachi, Takatsuki, Osaka, 569-0096, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yoshino', 'Affiliation': 'National Cancer Center Hospital East, 6 Chome-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Yamazaki', 'Affiliation': 'Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto District, Shizuoka, 411-0934, Japan.'}, {'ForeName': 'Junpei', 'Initials': 'J', 'LastName': 'Soeda', 'Affiliation': 'Takeda Pharmaceutical Company, Ltd, Nihonbashi-Honcho 2 Chome-1-1, Chuo Ward, Tokyo, 103-8668, Japan.'}, {'ForeName': 'Kazunori', 'Initials': 'K', 'LastName': 'Shibuya', 'Affiliation': 'Takeda Pharmaceutical Company, Ltd, Nihonbashi-Honcho 2 Chome-1-1, Chuo Ward, Tokyo, 103-8668, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Iwata', 'Affiliation': 'Takeda Pharmaceutical Company, Ltd, Nihonbashi-Honcho 2 Chome-1-1, Chuo Ward, Tokyo, 103-8668, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Oba', 'Affiliation': 'University of Tokyo, 7 Chome-3-1 Hongo, Bunkyo, Tokyo, 113-8654, Japan.'}, {'ForeName': 'Kensei', 'Initials': 'K', 'LastName': 'Yamaguchi', 'Affiliation': 'Gastroenterological Chemotherapy Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3 Chome-8-31, Ariake, Koto, Tokyo, 135-8550, Japan. kensei.yamaguchi@jfcr.or.jp.'}]",International journal of clinical oncology,['10.1007/s10147-021-01902-2'] 3072,34389012,Flexible e-learning video approach to improve fundus examination skills for medical students: a mixed-methods study.,"BACKGROUND Training for the fundus examination using traditional teaching is challenging, resulting in low generalist physicians' confidence in performing the funduscopic examination. There is growing evidence suggesting a flexible e-learning video approach's value in teaching physical examination procedures. However, whether the flexible e-learning video approach is superior to the traditional, face-to-face (F2F) lecture-based teaching for the funduscopic exam and the cognitive processes supporting its effectiveness has not yet been determined. METHODS We conducted a sequential explanatory mixed-method study to compare the flexible e-learning video approach's effectiveness versus the F2F lecture-based approach for teaching the funduscopic exam to medical students at Chiba University in Japan. Medical students were randomly assigned to either a flexible e-learning video approach group or a F2F lecture approach group. We then quantitatively measured the diagnostic accuracy of funduscopic findings before and after attending the specific classrooms. Next, we conducted student focus groups to explore the students' thinking processes in the flexible e-learning video approach vs. the F2F lecture-based teaching of fundus examination. The qualitative data were analyzed using the qualitative content analysis method. RESULTS The mean diagnostic accuracy scores in the post-test significantly increased from pre-test in the intervention group (36.6 to 63.4%, p < 0.001). Post-post comparisons across the two groups revealed a significant difference (intervention group 63.4% vs. control group 34.6%, p < 0.001). Six semi-structured focused group interviews were conducted (n = 36). In the flexible e-learning video approach group, we identified ten categories corresponding to four levels of the revised Bloom's taxonomy: remember, understand, apply, analyze. Five categories were identified in the traditional F2F lecture approach group corresponding to three revised Bloom's taxonomy levels: understand, apply, analyze. Interrater reliability was substantial (Cohen's kappa = 0.81). CONCLUSIONS Teaching medical students funduscopic examination using the flexible e-learning video approach leads to improved diagnostic accuracy of funduscopic examinations. The flexible e-learning video teaching method enabled higher cognitive activity levels than the traditional, lecture-based classroom, as assessed using the revised Bloom's taxonomy. TRIAL REGISTRATION This study was registered with the University Hospital Medical Information Network Clinical Trials Registry on 08/02/2020 (Unique trial number: UMIN 000039434 ).",2021,"Post-post comparisons across the two groups revealed a significant difference (intervention group 63.4% vs. control group 34.6%, p < 0.001).","['Medical students', 'medical students', 'medical students at Chiba University in Japan']","['Flexible e-learning video approach', 'F2F lecture-based approach', 'flexible e-learning video approach vs. the F2F lecture-based teaching of fundus examination', 'flexible e-learning video approach group or a F2F lecture approach group']","['cognitive activity levels', 'fundus examination skills', 'mean diagnostic accuracy scores', 'Interrater reliability']","[{'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0443220', 'cui_str': 'Flexible'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0376683', 'cui_str': 'Lectures'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0016823', 'cui_str': 'Structure of fundus of eye'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0016823', 'cui_str': 'Structure of fundus of eye'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}]",,0.0178978,"Post-post comparisons across the two groups revealed a significant difference (intervention group 63.4% vs. control group 34.6%, p < 0.001).","[{'ForeName': 'Kiyoshi', 'Initials': 'K', 'LastName': 'Shikino', 'Affiliation': 'Department of General Medicine, Chiba University Hospital, Chiba, Japan. kshikino@gmail.com.'}, {'ForeName': 'Claudia A', 'Initials': 'CA', 'LastName': 'Rosu', 'Affiliation': 'Health Professions Education Program, MGH Institute of Health Professions, Boston, MA, USA.'}, {'ForeName': 'Daiki', 'Initials': 'D', 'LastName': 'Yokokawa', 'Affiliation': 'Department of General Medicine, Chiba University Hospital, Chiba, Japan.'}, {'ForeName': 'Shingo', 'Initials': 'S', 'LastName': 'Suzuki', 'Affiliation': 'Department of General Medicine, Chiba University Hospital, Chiba, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Hirota', 'Affiliation': 'Department of General Medicine, Chiba University Hospital, Chiba, Japan.'}, {'ForeName': 'Katsumi', 'Initials': 'K', 'LastName': 'Nishiya', 'Affiliation': 'Center for Medical Education, Kansai Medical University, Hirakata, Japan.'}, {'ForeName': 'Masatomi', 'Initials': 'M', 'LastName': 'Ikusaka', 'Affiliation': 'Department of General Medicine, Chiba University Hospital, Chiba, Japan.'}]",BMC medical education,['10.1186/s12909-021-02857-8'] 3073,34388972,A cluster randomized trial of interferon ß-1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19).,"BACKGROUND SARS-CoV-2 infection rapidly spreads in populations due to the high rates of community transmission. Interrupting the shedding of SARS-CoV-2 may reduce the incidence of Coronavirus Disease 19 (COVID-19). Herein we provide a protocol for a cluster randomized trial that will examine the effectiveness of treatment with interferon (IFN) ß-1a compared to standard of care in limiting the transmission of SARS-CoV-2. Co-primary objectives are to determine whether IFN therapy reduces (a) the proportion of infected cases shedding SARS-CoV-2 at day 11 post randomization and (b) the incidence of transmission of SARS-CoV-2 infection from index cases to treatment-eligible household post-exposure contacts at day 11 after randomization. Secondary objectives include assessing the impact of IFN treatment on duration of viral clearance, hospitalizations and fatalities, and evaluating the safety of IFN treatment. METHODS Three hundred and ten households, each including an index case with a recent COVID-19 diagnosis and at least one asymptomatic treatment-eligible household contact, will be randomized to receive 3 doses of 125 μg IFN ß-1a by subcutaneous administration (days 1, 6, and 11), or standard of care. All participants will be followed until day 29. DISCUSSION The results from this trial will identify whether IFN ß treatment of mild or moderate COVID-19 cases accelerates viral clearance and prevents disease progression and whether IFN ß treatment of post-exposure contacts of COVID-19 cases reduces transmission of infection. TRIAL REGISTRATION This trial is registered at ClinicalTrials.gov NCT04552379; date of registration September 17, 2020.",2021,Interrupting the shedding of SARS-CoV-2 may reduce the incidence of Coronavirus Disease 19 (COVID-19).,"['Three hundred and ten households, each including an index case with a recent COVID-19 diagnosis and at least one asymptomatic treatment-eligible household contact']","['interferon (IFN) ß-1a', 'IFN therapy', 'interferon ß-1a']","['duration of viral clearance, hospitalizations and fatalities, and evaluating the safety of IFN treatment', 'viral clearance']","[{'cui': 'C5191352', 'cui_str': '310'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}]","[{'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0279030', 'cui_str': 'Interferon therapy'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",310.0,0.382033,Interrupting the shedding of SARS-CoV-2 may reduce the incidence of Coronavirus Disease 19 (COVID-19).,"[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Iturriaga', 'Affiliation': 'School of Medicine, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4686, Macul, Santiago, Chile.'}, {'ForeName': 'Nat', 'Initials': 'N', 'LastName': 'Eiffler', 'Affiliation': 'Telethon Kids Institute, Perth, Australia.'}, {'ForeName': 'Rad', 'Initials': 'R', 'LastName': 'Aniba', 'Affiliation': 'Telethon Kids Institute, Perth, Australia.'}, {'ForeName': 'Rym', 'Initials': 'R', 'LastName': 'Ben-Othman', 'Affiliation': 'Telethon Kids Institute, Perth, Australia.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Perez-Mateluna', 'Affiliation': 'School of Medicine, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4686, Macul, Santiago, Chile.'}, {'ForeName': 'Jessica K V', 'Initials': 'JKV', 'LastName': 'Meyer', 'Affiliation': 'School of Medicine, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4686, Macul, Santiago, Chile.'}, {'ForeName': 'Eleanor N', 'Initials': 'EN', 'LastName': 'Fish', 'Affiliation': 'Toronto & Department of Immunology, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Tobias R', 'Initials': 'TR', 'LastName': 'Kollmann', 'Affiliation': 'Telethon Kids Institute, Perth, Australia.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Severino', 'Affiliation': 'School of Medicine, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4686, Macul, Santiago, Chile.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Stick', 'Affiliation': 'Telethon Kids Institute, Perth, Australia.'}, {'ForeName': 'Arturo', 'Initials': 'A', 'LastName': 'Borzutzky', 'Affiliation': 'School of Medicine, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4686, Macul, Santiago, Chile.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Perret', 'Affiliation': 'School of Medicine, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4686, Macul, Santiago, Chile.'}, {'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'Castro-Rodriguez', 'Affiliation': 'School of Medicine, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4686, Macul, Santiago, Chile.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Garcia-Huidobro', 'Affiliation': 'School of Medicine, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4686, Macul, Santiago, Chile. dgarciah@med.puc.cl.'}]",BMC infectious diseases,['10.1186/s12879-021-06519-4'] 3074,34388395,"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.","BACKGROUND A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community. METHODS PRINCIPLE is a multicentre, open-label, multi-arm, randomised, controlled, adaptive platform trial done remotely from a central trial site and at primary care centres in the UK. Eligible participants were aged 65 years or older or 50 years or older with comorbidities, and unwell for up to 14 days with suspected COVID-19 but not admitted to hospital. Participants were randomly assigned to usual care, usual care plus inhaled budesonide (800 μg twice daily for 14 days), or usual care plus other interventions, and followed up for 28 days. Participants were aware of group assignment. The coprimary endpoints are time to first self-reported recovery and hospital admission or death related to COVID-19, within 28 days, analysed using Bayesian models. The primary analysis population included all eligible SARS-CoV-2-positive participants randomly assigned to budesonide, usual care, and other interventions, from the start of the platform trial until the budesonide group was closed. This trial is registered at the ISRCTN registry (ISRCTN86534580) and is ongoing. FINDINGS The trial began enrolment on April 2, 2020, with randomisation to budesonide from Nov 27, 2020, until March 31, 2021, when the prespecified time to recovery superiority criterion was met. 4700 participants were randomly assigned to budesonide (n=1073), usual care alone (n=1988), or other treatments (n=1639). The primary analysis model includes 2530 SARS-CoV-2-positive participants, with 787 in the budesonide group, 1069 in the usual care group, and 974 receiving other treatments. There was a benefit in time to first self-reported recovery of an estimated 2·94 days (95% Bayesian credible interval [BCI] 1·19 to 5·12) in the budesonide group versus the usual care group (11·8 days [95% BCI 10·0 to 14·1] vs 14·7 days [12·3 to 18·0]; hazard ratio 1·21 [95% BCI 1·08 to 1·36]), with a probability of superiority greater than 0·999, meeting the prespecified superiority threshold of 0·99. For the hospital admission or death outcome, the estimated rate was 6·8% (95% BCI 4·1 to 10·2) in the budesonide group versus 8·8% (5·5 to 12·7) in the usual care group (estimated absolute difference 2·0% [95% BCI -0·2 to 4·5]; odds ratio 0·75 [95% BCI 0·55 to 1·03]), with a probability of superiority 0·963, below the prespecified superiority threshold of 0·975. Two participants in the budesonide group and four in the usual care group had serious adverse events (hospital admissions unrelated to COVID-19). INTERPRETATION Inhaled budesonide improves time to recovery, with a chance of also reducing hospital admissions or deaths (although our results did not meet the superiority threshold), in people with COVID-19 in the community who are at higher risk of complications. FUNDING National Institute of Health Research and United Kingdom Research Innovation.",2021,"Two participants in the budesonide group and four in the usual care group had serious adverse events (hospital admissions unrelated to COVID-19). ","['2530 SARS-CoV-2-positive participants, with 787 in the budesonide group, 1069 in the usual care group, and 974 receiving other treatments', 'Eligible participants were aged 65 years or older or 50 years or older with comorbidities, and unwell for up to 14 days with suspected COVID-19 but not admitted to hospital', '4700 participants', 'people at high risk of complications in the community in the UK (PRINCIPLE', 'patients not admitted to hospital', 'people at high risk of complications in the community']","['usual care, usual care plus inhaled budesonide ', 'usual care alone', 'budesonide, usual care, and other interventions', 'inhaled budesonide', 'Inhaled budesonide', 'budesonide']","['serious adverse events (hospital admissions unrelated to COVID-19', 'time to first self-reported recovery and hospital admission or death related to COVID-19, within 28 days, analysed using Bayesian models', 'hospital admission or death outcome', 'hospital admissions or deaths']","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0857256', 'cui_str': 'Unwell'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0445356', 'cui_str': 'Unrelated'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",4700.0,0.253973,"Two participants in the budesonide group and four in the usual care group had serious adverse events (hospital admissions unrelated to COVID-19). ","[{'ForeName': 'Ly-Mee', 'Initials': 'LM', 'LastName': 'Yu', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Bafadhel', 'Affiliation': 'Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Jienchi', 'Initials': 'J', 'LastName': 'Dorward', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Hayward', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Benjamin R', 'Initials': 'BR', 'LastName': 'Saville', 'Affiliation': 'Berry Consultants, Austin, TX, USA; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Oghenekome', 'Initials': 'O', 'LastName': 'Gbinigie', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Van Hecke', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Ogburn', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Philip H', 'Initials': 'PH', 'LastName': 'Evans', 'Affiliation': 'College of Medicine and Health, University of Exeter, Exeter, UK; National Institute for Health Research Clinical Research Network, National Institute for Health Research, London, UK.'}, {'ForeName': 'Nicholas P B', 'Initials': 'NPB', 'LastName': 'Thomas', 'Affiliation': 'National Institute for Health Research Clinical Research Network, National Institute for Health Research, London, UK; Royal College of General Practitioners, London, UK.'}, {'ForeName': 'Mahendra G', 'Initials': 'MG', 'LastName': 'Patel', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Richards', 'Affiliation': 'Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, UK.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Berry', 'Affiliation': 'Berry Consultants, Austin, TX, USA.'}, {'ForeName': 'Michelle A', 'Initials': 'MA', 'LastName': 'Detry', 'Affiliation': 'Berry Consultants, Austin, TX, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Saunders', 'Affiliation': 'Berry Consultants, Austin, TX, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Fitzgerald', 'Affiliation': 'Berry Consultants, Austin, TX, USA.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Harris', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Milensu', 'Initials': 'M', 'LastName': 'Shanyinde', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'de Lusignan', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Monique I', 'Initials': 'MI', 'LastName': 'Andersson', 'Affiliation': 'Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Barnes', 'Affiliation': 'National Heart and Lung Institute, Imperial College, London, UK.'}, {'ForeName': 'Richard E K', 'Initials': 'REK', 'LastName': 'Russell', 'Affiliation': 'Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Dan V', 'Initials': 'DV', 'LastName': 'Nicolau', 'Affiliation': 'Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; UQ Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Ramakrishnan', 'Affiliation': 'National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'F D Richard', 'Initials': 'FDR', 'LastName': 'Hobbs', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: richard.hobbs@phc.ox.ac.uk.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Butler', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: christopher.butler@phc.ox.ac.uk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(21)01744-X'] 3075,34388379,ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.,"The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations.",2021,"The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation.",['patients with brain metastases and EGFR L858R mutation'],"['VEGF inhibitor bevacizumab', 'EGFR inhibitor erlotinib']",['progression-free survival'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}]","[{'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C1443775', 'cui_str': 'Epidermal growth factor receptor antagonist-containing product'}, {'cui': 'C1135135', 'cui_str': 'erlotinib'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.124246,"The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation.","[{'ForeName': 'Xiuning', 'Initials': 'X', 'LastName': 'Le', 'Affiliation': 'Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Monique B', 'Initials': 'MB', 'LastName': 'Nilsson', 'Affiliation': 'Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Jacqulyne P', 'Initials': 'JP', 'LastName': 'Robichaux', 'Affiliation': 'Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'John V', 'Initials': 'JV', 'LastName': 'Heymach', 'Affiliation': 'Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: jheymach@mdanderson.org.'}]",Cancer cell,['10.1016/j.ccell.2021.07.017'] 3076,34388360,"Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.","BACKGROUND BI 695501 is a biosimilar that has demonstrated similar efficacy, safety, and immunogenicity to adalimumab reference product in patients with rheumatoid arthritis and chronic plaque psoriasis. The VOLTAIRE-CD study aimed to compare the efficacy and safety of BI 695501 with adalimumab reference product in patients with Crohn's disease. METHODS This phase 3, randomised, double-blind study was done at 92 centres in 12 countries across Europe and the USA in patients aged 18-80 years with moderately to severely active Crohn's disease (Crohn's Disease Activity Index [CDAI] score 220-450). Patients were randomly assigned 1:1 using an interactive response technology system to the BI 695501 group or adalimumab reference product group, stratified by previous exposure to infliximab (yes vs no) and simple endoscopic score for Crohn's disease at screening (<16 vs ≥16). All investigators involved in trial assessments or procedures and all patients were masked to treatment allocation until week 24. Patients received BI 695501 (40 mg/0·8 mL formulation) or adalimumab reference product (either 40 mg/0·4 mL citrate-free or 40 mg/0·8 mL) 160 mg on day 1 and 80 mg on day 15, followed by 40 mg every 2 weeks, via subcutaneous injection. The primary endpoint was the proportion of patients with clinical response (CDAI decrease ≥70 points) at week 4, with an exploratory non-inferiority margin of 0·76 for the lower limit of the two-sided 90% CI of the risk ratio (RR). The primary analysis was done in a modified full analysis set of all patients who received at least one dose of study medication and had a baseline and at least one post-baseline CDAI assessment. Safety was assessed in all patients who received at least one dose of study medication. After week 4, responders were treated until week 46; those randomly assigned to adalimumab reference product switched to BI 695501 at week 24. This study is registered at ClinicalTrials.gov (NCT02871635) and EudraCT (2016-000612-14). FINDINGS Between Jan 4, 2017, and April 5, 2018, 147 patients were enrolled and randomly assigned to BI 695501 (n=72) or adalimumab reference product (n=75). At week 4, 61 (90%) of 68 patients in the BI 695501 group and 68 (94%) of 72 in the adalimumab reference product group had a clinical response (adjusted RR 0·945 [90% CI 0·870-1·028]). In the safety analysis set, 45 (63%) of 72 patients in the BI 695501 group and 42 (56%) of 75 in the adalimumab reference product group had an adverse event during weeks 0-24; 31 (43%) and 34 (45%) had adverse events during weeks 24-56. The most common drug-related treatment-emergent adverse events during weeks 0-24 were weight increase (three [4%] patients in the BI 695501 group) and injection-site erythema and upper respiratory tract infection (three [4%] patients for each event) in the adalimumab reference product group. The only drug-related TEAEs reported in two or more patients during weeks 24-56 were weight increase and increased γ-glutamyltransferase, which occured in two (3%) patients each in the BI 695501 group. No drug-related TEAEs were reported in two or more patients during weeks 24-56 in the adalimumab reference product followed by BI 699501 group. Serious adverse events occurred in six (8%) patients in the BI 695501 group and eight (11%) in the adalimumab reference group between weeks 0-24, and two (3%) and nine (12%) patients between weeks 24-56. Adverse events of special interest occurred in two (3%) patients in each treatment group during weeks 0-24 (acute sinusitis and pulmonary tuberculosis in the BI 695501 group and anal abscess and postoperative wound infection in the adalimumab reference product group) and two (3%) patients in each group during weeks 24-56 (psoas abscess and hypersensitivity in the BI 695501 group and pulmonary tuberculosis and erythematous rash in the adalimumab reference product followed by BI 699501 group). INTERPRETATION Safety and efficacy were similar in patients with Crohn's disease treated with BI 695501 or adalimumab reference product. Treatment benefits were maintained in patients receiving adalimumab reference product who switched to BI 695501. These results further support the existing licensure of BI 695501 as an alternative to adalimumab reference product for patients with Crohn's disease, as well as the other indications for which BI 695501 is approved. FUNDING Boehringer Ingelheim.",2021,No drug-related TEAEs were reported in two or more patients during weeks 24-56 in the adalimumab reference product followed by BI 699501 group.,"[""patients with Crohn's disease treated with BI 695501 or adalimumab reference product"", ""patients with advanced Crohn's disease (VOLTAIRE-CD"", ""patients with Crohn's disease"", 'Between Jan 4, 2017, and April 5, 2018, 147 patients were enrolled and randomly assigned to BI 695501 (n=72) or', 'patients with rheumatoid arthritis and chronic plaque psoriasis', ""92 centres in 12 countries across Europe and the USA in patients aged 18-80 years with moderately to severely active Crohn's disease (Crohn's Disease Activity Index [CDAI] score 220-450""]","['BI 695501 versus adalimumab', 'EudraCT', 'adalimumab reference product', 'adalimumab', ""interactive response technology system to the BI 695501 group or adalimumab reference product group, stratified by previous exposure to infliximab (yes vs no) and simple endoscopic score for Crohn's disease at screening"", 'adalimumab reference product (either 40 mg/0·4 mL citrate-free or 40', 'mL']","['pulmonary tuberculosis and erythematous rash', 'efficacy and safety', 'proportion of patients with clinical response', 'Serious adverse events', 'Adverse events of special interest', 'adverse events', 'Safety and efficacy', 'clinical response', 'injection-site erythema and upper respiratory tract infection', 'adverse event', 'anal abscess and postoperative wound infection', 'Safety', 'weight increase and increased γ-glutamyltransferase']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C5198301', 'cui_str': 'BI 695501'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0451071', 'cui_str': ""Crohn's disease activity index""}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C3844104', 'cui_str': '450'}]","[{'cui': 'C5198301', 'cui_str': 'BI 695501'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C1298907', 'cui_str': 'Yes'}, {'cui': 'C1298908', 'cui_str': 'No'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008857', 'cui_str': 'Citrates'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]","[{'cui': 'C0041327', 'cui_str': 'Pulmonary tuberculosis'}, {'cui': 'C0234913', 'cui_str': 'Rash erythematous'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0852625', 'cui_str': 'Injection site erythema'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0281778', 'cui_str': 'Anal abscess'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0678107', 'cui_str': 'Glutamyl transferase'}]",147.0,0.23847,No drug-related TEAEs were reported in two or more patients during weeks 24-56 in the adalimumab reference product followed by BI 699501 group.,"[{'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Hanauer', 'Affiliation': 'Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Electronic address: shanauer@northwestern.edu.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Liedert', 'Affiliation': 'Sandoz Biopharmaceuticals, Holzkirchen, Germany.'}, {'ForeName': 'Sigrid', 'Initials': 'S', 'LastName': 'Balser', 'Affiliation': 'Boehringer Ingelheim Pharma, Biberach an der Riss, Germany.'}, {'ForeName': 'Ekkehard', 'Initials': 'E', 'LastName': 'Brockstedt', 'Affiliation': 'Boehringer Ingelheim Pharma, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Viktoria', 'Initials': 'V', 'LastName': 'Moschetti', 'Affiliation': 'Boehringer Ingelheim Pharma, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schreiber', 'Affiliation': 'Klinik für Innere Medizin I, Universitaetsklinikum Schleswig-Holstein, Kiel University, Kiel, Germany.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(21)00252-1'] 3077,33945964,Effects of bi-axial ankle strengthening on muscle co-contraction during gait in chronic stroke patients: A randomized controlled pilot study.,"INTRODUCTION Ankle dysfunction in patients with stroke is a common but serious cause of balance and gait impairments. However, comprehensive paretic ankle training seldom exists. Thus, we investigated the effects of a bi-axial ankle muscle training program using visual feedback as a means to improve ankle strength and performance of functional activities in patients with stroke. METHODS This study was a randomized controlled pilot trial with concealed allocation and assessor blinding and intention-to-treat analysis. Twenty-five patients with stroke and difficulty in walking (e.g., foot drop) or ankle muscle weakness receiving inpatient rehabilitation were included. The experimental group underwent ankle muscle training consisting of passive stretching, control of ankle muscles, and active-resistive strengthening using visual feedback for 40 min per day, 5 times per week for 4 weeks. The control group underwent ankle-related physical therapy, including ankle range-of-motion exercises. The amount of time for training was equal between the two groups. The outcome measurements were isometric ankle contraction force to assess the strength of ankle muscles, ankle proprioception, Fugl-Meyer lower extremity score, Berg balance scale score, walking speed, and ankle co-contraction index to assess muscle efficiency during gait. RESULTS The analysis revealed significant between-group differences in the ankle muscle strength in each direction (P < 0.05), Fugl-Meyer score (P < 0.01), and stance-phase co-contraction index (P < 0.05). After training, the experimental group displayed significant within-group differences in the strength of the ankle muscles in each direction (P < 0.01), ankle proprioception (P < 0.05), and walking speed (P < 0.05). CONCLUSIONS Our findings demonstrate the significant short-term effects of ankle muscle training on strength, walking speed, and muscle efficiency in patients with chronic stroke.",2021,"The analysis revealed significant between-group differences in the ankle muscle strength in each direction (P < 0.05), Fugl-Meyer score (P < 0.01), and stance-phase co-contraction index (P < 0.05).","['Twenty-five patients with stroke and difficulty in walking (e.g., foot drop) or ankle muscle weakness receiving inpatient rehabilitation were included', 'patients with stroke', 'chronic stroke patients', 'patients with chronic stroke']","['ankle-related physical therapy, including ankle range-of-motion exercises', 'bi-axial ankle muscle training program', 'ankle muscle training consisting of passive stretching, control of ankle muscles, and active-resistive strengthening using visual feedback', 'bi-axial ankle strengthening']","['isometric ankle contraction force to assess the strength of ankle muscles, ankle proprioception, Fugl-Meyer lower extremity score, Berg balance scale score, walking speed, and ankle co-contraction index to assess muscle efficiency during gait', 'ankle strength and performance of functional activities', 'strength of the ankle muscles in each direction', 'ankle proprioception', 'strength, walking speed, and muscle efficiency', 'Fugl-Meyer score', 'stance-phase co-contraction index', 'ankle muscle strength', 'amount of time for training', 'walking speed']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0085684', 'cui_str': 'Foot-drop'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0030552', 'cui_str': 'Paresis'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}]","[{'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0576183', 'cui_str': 'Ankle joint - range of movement'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205131', 'cui_str': 'Axial'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C1720871', 'cui_str': 'Static-Passive Stretching'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}]","[{'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439755', 'cui_str': 'Directions'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",25.0,0.0112013,"The analysis revealed significant between-group differences in the ankle muscle strength in each direction (P < 0.05), Fugl-Meyer score (P < 0.01), and stance-phase co-contraction index (P < 0.05).","[{'ForeName': 'Ji-Eun', 'Initials': 'JE', 'LastName': 'Cho', 'Affiliation': 'National Rehabilitation Research Institute, National Rehabilitation Center, Seoul, South Korea.'}, {'ForeName': 'Wan-Hee', 'Initials': 'WH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, Sahmyook University College of Health Science, Seoul, South Korea.'}, {'ForeName': 'Joon-Ho', 'Initials': 'JH', 'LastName': 'Shin', 'Affiliation': 'National Rehabilitation Hospital, National Rehabilitation Center, Seoul, South Korea.'}, {'ForeName': 'Hogene', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'National Rehabilitation Research Institute, National Rehabilitation Center, Seoul, South Korea. Electronic address: hogenekim@korea.kr.'}]",Gait & posture,['10.1016/j.gaitpost.2021.04.011'] 3078,33949215,Theoretical Mediators of Diabetes Risk and Quality of Life Following a Diabetes Prevention Program for Latino Youth With Obesity.,"PURPOSE This study tested self-efficacy and social support for activity and dietary changes as mediators of changes in type 2 diabetes related outcomes following a lifestyle intervention among Latino youth. SETTING AND INTERVENTION Latino adolescents (14-16 years) with obesity (BMI% = 98.1 ± 1.4) were randomized to a 3-month intervention (n = 67) that fostered self-efficacy and social support through weekly, family-centered sessions or a comparison condition (n = 69). MEASURES Primary outcomes included insulin sensitivity and weight specific quality of life. Mediators included self-efficacy, friend, and family social support for health behaviors. Data was collected at baseline, 3-months, 6-months, and 12-months. ANALYSIS Sequential path analysis was used to examine mediators as mechanisms by which the intervention influenced primary outcomes. RESULTS The intervention had a direct effect on family (β = 0.33, P < .01) and friend social support (β = 0.22, P < .001) immediately following the intervention (3-months). Increased family social support mediated the intervention's effect on self-efficacy at 6-months (β = 0.09, P < .01). However, social support and self-efficacy did not mediate long-term changes in primary outcomes ( P > .05) at 12-months. CONCLUSIONS Family social support may improve self-efficacy for health behaviors in high-risk Latino youth, highlighting the important role of family diabetes prevention. Fostering family social support is a critical intervention target and more research is needed to understand family-level factors that have the potential to lead to long-term metabolic and psychosocial outcome in vulnerable youth.",2021,"The intervention had a direct effect on family (β = 0.33, P < .01) and friend social support (β = 0.22, P < .001) immediately following the intervention (3-months).","['high-risk Latino youth', 'Latino youth', 'Latino adolescents (14-16 years) with obesity (BMI% = 98.1 ± 1.4', 'Latino Youth With Obesity']","['fostered self-efficacy and social support through weekly, family-centered sessions or a comparison condition']","['Diabetes Risk and Quality of Life', 'self-efficacy', 'insulin sensitivity and weight specific quality of life', 'friend social support', 'social support and self-efficacy', 'self-efficacy, friend, and family social support for health behaviors']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4517503', 'cui_str': '1.4'}]","[{'cui': 'C0242298', 'cui_str': 'Fostering'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",69.0,0.0246227,"The intervention had a direct effect on family (β = 0.33, P < .01) and friend social support (β = 0.22, P < .001) immediately following the intervention (3-months).","[{'ForeName': 'Erica G', 'Initials': 'EG', 'LastName': 'Soltero', 'Affiliation': ""Children's Nutrition Research Center, Department of Pediatrics, 3989Baylor College of Medicine, Houston, TX, USA.""}, {'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Ayers', 'Affiliation': 'Southwest Interdisciplinary Research Center, 7864Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Marvyn A', 'Initials': 'MA', 'LastName': 'Avalos', 'Affiliation': 'Southwest Interdisciplinary Research Center, 7864Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'Peña', 'Affiliation': 'Center for Health Promotion and Disease Prevention, 7864Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Allison N', 'Initials': 'AN', 'LastName': 'Williams', 'Affiliation': 'Center for Health Promotion and Disease Prevention, 7864Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Micah L', 'Initials': 'ML', 'LastName': 'Olson', 'Affiliation': 'Center for Health Promotion and Disease Prevention, 7864Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Yolanda P', 'Initials': 'YP', 'LastName': 'Konopken', 'Affiliation': 'Family Wellness Program, St. Vincent De Paul Medical and Dental Clinic, Phoenix, AZ, USA.'}, {'ForeName': 'Felipe G', 'Initials': 'FG', 'LastName': 'Castro', 'Affiliation': 'Center for Health Promotion and Disease Prevention, 7864Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Kimberly J', 'Initials': 'KJ', 'LastName': 'Arcoleo', 'Affiliation': 'School of Nursing, 6927University of Rochester, Rochester, NY, USA.'}, {'ForeName': 'Colleen S', 'Initials': 'CS', 'LastName': 'Keller', 'Affiliation': 'Center for Health Promotion and Disease Prevention, 7864Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Donald L', 'Initials': 'DL', 'LastName': 'Patrick', 'Affiliation': 'Department of Health Services, 49462School of Public Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Jager', 'Affiliation': 'Southwest Interdisciplinary Research Center, 7864Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Gabriel Q', 'Initials': 'GQ', 'LastName': 'Shaibi', 'Affiliation': 'Center for Health Promotion and Disease Prevention, 7864Arizona State University, Phoenix, AZ, USA.'}]",American journal of health promotion : AJHP,['10.1177/08901171211012951'] 3079,33948805,CRP-Guided Antibiotic Therapy for Acute COPD Exacerbation: a Randomized Control Trial.,,2021,,['Acute COPD Exacerbation'],['CRP-Guided Antibiotic Therapy'],[],"[{'cui': 'C0340044', 'cui_str': 'Acute exacerbation of chronic obstructive airways disease'}]","[{'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}]",[],,0.0781647,,"[{'ForeName': 'Jocelyn A', 'Initials': 'JA', 'LastName': 'Carter', 'Affiliation': 'Harvard Medical School , Massachusetts General Hospital, Boston, MA, USA. jcarter0@mgh.harvard.edu.'}, {'ForeName': 'Harry B', 'Initials': 'HB', 'LastName': 'Burke', 'Affiliation': 'Uniformed Services University of the Health Sciences, Bethesda, MD, USA.'}]",Journal of general internal medicine,['10.1007/s11606-020-06053-0'] 3080,33947627,Parent Website Engagement and Health Equity Implications in a Child Care-Based Wellness Intervention.,"OBJECTIVE To evaluate demographic differences in parent website engagement in a child care-based wellness intervention. DESIGN Parent-reported demographic characteristics and observed website engagement were averaged by child care centers participating in the web-based intervention arm of a cluster randomized controlled trial of wellness interventions. SETTING AND PARTICIPANTS Parents of preschoolers in 17 Maryland child care centers. MAIN OUTCOME MEASURES Website engagement: (1) webpage views, (2) average time on webpage, and (3) intervention activity completion. INTERVENTION Parents received access to a website containing content on wellness-promoting topics (eg, parenting, nutrition, physical activity) and their child care center's activities. ANALYSIS Cross-sectional differences in website engagement by demographic characteristics were assessed using ANOVA. RESULTS Centers with a high proportion of parents who identified as other than non-Hispanic White and had less than a bachelor's degree had significantly fewer webpage views, and completed significantly fewer intervention activities compared with centers with parents who were predominantly non-Hispanic White and had more than a bachelor's degree. CONCLUSIONS AND IMPLICATIONS Demographic differences in parents' child care center website engagement represent disparities that could contribute to health inequities in parents' access to wellness-promoting material. Future efforts could identify factors that eliminate demographic disparities in parent engagement in web-based interventions.",2021,"DESIGN Parent-reported demographic characteristics and observed website engagement were averaged by child care centers participating in the web-based intervention arm of a cluster randomized controlled trial of wellness interventions. ",['Parents of preschoolers in 17 Maryland child care centers'],"['wellness interventions', ""Parents received access to a website containing content on wellness-promoting topics (eg, parenting, nutrition, physical activity) and their child care center's activities""]",['intervention activities'],"[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0024858', 'cui_str': 'Maryland'}, {'cui': 'C0008070', 'cui_str': 'Child day care center'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0008070', 'cui_str': 'Child day care center'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",,0.0431924,"DESIGN Parent-reported demographic characteristics and observed website engagement were averaged by child care centers participating in the web-based intervention arm of a cluster randomized controlled trial of wellness interventions. ","[{'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Ezran', 'Affiliation': 'Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD.'}, {'ForeName': 'Angela C B', 'Initials': 'ACB', 'LastName': 'Trude', 'Affiliation': 'Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD.'}, {'ForeName': 'Allison D', 'Initials': 'AD', 'LastName': 'Hepworth', 'Affiliation': 'Department of Nutritional Sciences, Oklahoma State University, Stillwater, OK.'}, {'ForeName': 'Maureen M', 'Initials': 'MM', 'LastName': 'Black', 'Affiliation': 'Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD; RTI International, Research Triangle Park, NC. Electronic address: mblack@som.umaryland.edu.'}]",Journal of nutrition education and behavior,['10.1016/j.jneb.2021.03.003'] 3081,33947516,Effects of a health-belief-model-based osteoporosis- and fall-prevention program on women at early old age.,"BACKGROUND Elderly women are at high risk of osteoporosis and falls. Lifestyle modifications and regular check-ups are strongly recommended to promote their bone health. However, elderly women tend to perform low preventive behaviors due to physiological changes associated with aging. Education facilitating healthy behaviors is essential for older women. Therefore, the purpose of this study was to determine whether a Health Belief Model (HBM)-based osteoporosis- and fall-prevention program could improve osteoporosis- and fall-prevention knowledge, self-efficacy, and health behaviors among women aged 65 to 74 years. METHODS This study included an untreated control group with a pretest-posttest design. Women (n = 47) in the intervention group received four sessions of an HBM-based program within a 2-month period. Participants (n = 47) in the control group attended usual education sessions. RESULTS Women in the intervention group exhibited greater knowledge in exercise and diet for osteoporosis-prevention (t = 5.473, p < 0.001; t = 6.895, p < 0.001, respectively), fall-prevention knowledge (t = 2.354, p = 0.021), self-efficacy in exercise for osteoporosis-prevention (t = 2.736, p = 0.008), osteoporosis-prevention behavior of exercise, diet, and routine follow-ups (t = 3.019, p = 0.003; t = 2.705, p = 0.008; t = 2.368, p = 0.020, respectively), and fall-prevention behavior (t = 3.879, p < 0.001). CONCLUSION HBM-based osteoporosis- and fall-prevention program exhibited outstanding effectiveness in promoting osteoporosis and fall prevention among women at early old age. Further studies with more rigorous designs are needed to provide further evidence that supports this finding.",2021,"RESULTS Women in the intervention group exhibited greater knowledge in exercise and diet for osteoporosis-prevention (t = 5.473, p < 0.001; t = 6.895, p < 0.001, respectively), fall-prevention knowledge (","['Elderly women', 'women at early old age', 'women aged 65 to 74 years', 'older women', 'elderly women']","['control group attended usual education sessions', 'health-belief-model-based osteoporosis- and fall-prevention program', 'Health Belief Model (HBM)-based osteoporosis- and fall-prevention program', 'HBM-based osteoporosis- and fall-prevention']","['knowledge in exercise and diet for osteoporosis-prevention', 'self-efficacy', 'fall-prevention behavior', 'fall-prevention knowledge ', 'osteoporosis- and fall-prevention knowledge, self-efficacy, and health behaviors']","[{'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0231337', 'cui_str': 'Senility'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C3714363', 'cui_str': 'Health belief model'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C3650929', 'cui_str': 'Prevention of osteoporosis'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C1321116', 'cui_str': 'Fall prevention behavior'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.00928609,"RESULTS Women in the intervention group exhibited greater knowledge in exercise and diet for osteoporosis-prevention (t = 5.473, p < 0.001; t = 6.895, p < 0.001, respectively), fall-prevention knowledge (","[{'ForeName': 'Sukhee', 'Initials': 'S', 'LastName': 'Ahn', 'Affiliation': 'Chungnam National University, College of Nursing, 266 Munhwa-ro, Jung-gu, Daejeon 35015, South Korea. Electronic address: sukheeahn@cnu.ac.kr.'}, {'ForeName': 'Jiwon', 'Initials': 'J', 'LastName': 'Oh', 'Affiliation': 'Chungnam National University, College of Nursing, 266 Munhwa-ro, Jung-gu, Daejeon 35015, South Korea. Electronic address: ohjw@cnu.ac.kr.'}]",Applied nursing research : ANR,['10.1016/j.apnr.2021.151430'] 3082,33890242,"Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY.","INTRODUCTION As a result of limited clinical data, guidelines do not recommend the use of non-vitamin K antagonist oral anticoagulants in patients who weigh > 120 kg or have a body mass index (BMI) > 40 kg/m 2 . METHODS This post hoc analysis of the AMPLIFY trial evaluated the efficacy (venous thromboembolism [VTE]/VTE-related death), safety (major and composite of major and clinically relevant non-major [CRNM] bleeding), and exposure of apixaban compared with enoxaparin followed by warfarin for the treatment of VTE by body weight (≤ 60, > 60 to < 100, ≥ 100 to < 120, ≥ 120 kg) and BMI (≤ 25, > 25 to 30, > 30 to 35, > 35 to 40, > 40 kg/m 2 ). RESULTS Among the AMPLIFY safety population, 5384 and 5359 patients had recorded body weight (range 28.9 to 222.0 kg; ≥ 120 kg, n = 290) and BMI (range 12.5-71.8 kg/m 2 ; > 40 kg/m 2 , n = 263), respectively. The rates of recurrent VTE/VTE-related death for apixaban versus enoxaparin/warfarin were similar across body weight subgroups: relative risks (RR; 95% confidence intervals [CI]) were 0.63 (0.23, 1.72), 0.99 (0.65, 1.50), 0.77 (0.34, 1.72), and 0.20 (0.02, 1.72) for the ≤ 60, > 60 to < 100, ≥ 100 to < 120, and ≥ 120 kg groups, respectively (P interaction  = 0.44). The rates of major bleeding were lower with apixaban versus enoxaparin/warfarin; RRs (95% CI) were 0.15 (0.02, 1.15), 0.41 (0.21, 0.77), not estimable, and 0.34 (0.04, 3.22), respectively (P interaction  = not estimable). The rates of major/CRNM bleeding were significantly lower for apixaban versus enoxaparin/warfarin; RRs (95% CI) were 0.46 (0.24, 0.89), 0.49 (0.38, 0.63), 0.30 (0.16, 0.58), and 0.28 (0.12, 0.66), respectively (P interaction  = 0.36). Similar trends were seen in the BMI subgroups. There was a modest, not clinically meaningful, decrease (< 30%) in the median predicted exposure with increasing body weight (n = 281). CONCLUSIONS The findings of this post hoc analysis support the use of apixaban in patients with body weight ≥ 120 kg or BMI > 40 kg/m 2 . TRIAL REGISTRATION NUMBER NCT00643201.",2021,"The rates of recurrent VTE/VTE-related death for apixaban versus enoxaparin/warfarin were similar across body weight subgroups: relative risks (RR; 95% confidence intervals [CI]) were 0.63 (0.23, 1.72), 0.99 (0.65, 1.50), 0.77 (0.34, 1.72), and 0.20 (0.02, 1.72) for the ≤ 60, > 60 to < 100, ≥ 100 to < 120, and ≥ 120 kg groups, respectively (P interaction  = 0.44).","['VTE by body weight (≤\u200960, >\u200960 to <\u2009100, ≥\u2009100 to <\u2009120, ≥\u2009120\xa0kg) and BMI (≤\u200925, >\u200925 to 30, >\u200930 to 35, >\u200935 to 40, ', 'patients with body weight ≥\u2009120\xa0kg or BMI\u2009>\u200940\xa0kg/m 2 ', '5384 and 5359 patients had recorded body weight (range 28.9 to 222.0\xa0kg; ≥\u2009120\xa0kg, n\u2009=\u2009290) and BMI (range 12.5-71.8\xa0kg/m 2 ; >\u200940\xa0kg/m 2 , n\u2009=\u2009263), respectively', 'Patients with High Body Weight or Obesity and Venous Thromboembolism', '40\xa0kg', 'patients who weigh >\u2009120\xa0kg or have a body mass index (BMI']","['enoxaparin/warfarin', 'apixaban', 'enoxaparin followed by warfarin']","['rates of major/CRNM bleeding', 'Efficacy, Safety, and Exposure of Apixaban', 'rates of recurrent VTE/VTE-related death', 'efficacy (venous thromboembolism [VTE]/VTE-related death), safety (major and composite of major and clinically relevant non-major [CRNM] bleeding), and exposure of apixaban', 'rates of major bleeding']","[{'cui': 'C0630906', 'cui_str': 'vinyltriethoxysilane'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C5191218', 'cui_str': '290'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C4517671', 'cui_str': '263'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}]","[{'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0630906', 'cui_str': 'vinyltriethoxysilane'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0205199', 'cui_str': 'Composite'}]",,0.167665,"The rates of recurrent VTE/VTE-related death for apixaban versus enoxaparin/warfarin were similar across body weight subgroups: relative risks (RR; 95% confidence intervals [CI]) were 0.63 (0.23, 1.72), 0.99 (0.65, 1.50), 0.77 (0.34, 1.72), and 0.20 (0.02, 1.72) for the ≤ 60, > 60 to < 100, ≥ 100 to < 120, and ≥ 120 kg groups, respectively (P interaction  = 0.44).","[{'ForeName': 'Alexander T', 'Initials': 'AT', 'LastName': 'Cohen', 'Affiliation': ""Guy's and St Thomas' Hospitals, Westminster Bridge Road, London, UK. alexander.cohen@kcl.ac.uk.""}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Pan', 'Affiliation': 'Pfizer, New York, USA.'}, {'ForeName': 'Wonkyung', 'Initials': 'W', 'LastName': 'Byon', 'Affiliation': 'Pfizer, New York, USA.'}, {'ForeName': 'Bushra S', 'Initials': 'BS', 'LastName': 'Ilyas', 'Affiliation': 'Pfizer, New York, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Taylor', 'Affiliation': ""Guy's and St Thomas' Hospitals, Westminster Bridge Road, London, UK.""}, {'ForeName': 'Theodore C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': 'Pfizer, New York, USA.'}]",Advances in therapy,['10.1007/s12325-021-01716-8'] 3083,33870956,"Self-Efficacy, Outcome Expectations, Group Social Support, and Adherence to Physical Activity in African American Women.","BACKGROUND African American women have lower levels of leisure time physical activity compared to White American women. Interventions to improve physical activity have mixed benefits for African American women, even when guided by theory. Understanding how theoretical constructs used in physical activity interventions relate to changing behavior may provide direction for more successful interventions. OBJECTIVE The study aimed to examine the relationships among social cognitive constructs (self-efficacy, social support from group behavioral meetings, outcome expectations/realizations), and change in physical activity from baseline to 48 weeks in African American women participating in a lifestyle physical activity program. METHODS A secondary data analysis of longitudinal data using a correlational design was conducted using data from a 48-week physical activity randomized controlled trial (RCT). The RCT included a group behavioral meeting component with one of three telephone intervention conditions (no calls, personal motivation calls, or automated motivational calls) randomly assigned across six community healthcare sites. The participants were 260 sedentary, midlife African American women with no major signs or symptoms of cardiovascular disease who completed baseline and 48-week assessments of the RCT. Measures included self-efficacy for change in overcoming barriers to physical activity at 24 weeks, physical and psychological outcome realizations at 24 weeks, social support from group behavioral meetings at 24 weeks, and physical activity (self-report and device-measured) change from baseline to 48 weeks. RESULTS In a hierarchical regression model predicting change in self-reported time spent in weekly moderate-vigorous physical activity at 48 weeks, psychological outcome realizations at 24 weeks were significant positive predictors. In a hierarchical regression model for change in device-measured daily steps at 48 weeks, a self-efficacy change at 24 weeks was a significant positive predictor. DISCUSSION Attention should be given to increasing self-efficacy to overcome physical activity barriers and achieve self-identified physical and psychological outcomes in physical activity programs.",2021,"In a hierarchical regression model predicting change in self-reported time spent in weekly moderate-vigorous physical activity (MVPA) at 48 weeks, psychological-outcome realizations at 24 weeks were significant positive predictors.","['African American women', 'African American women participating in a lifestyle physical activity program', 'African American Women', 'participants were 260 sedentary, midlife African American women with no major signs or symptoms of cardiovascular disease who completed baseline and 48-week assessments of the RTC']","['telephone intervention conditions (no calls, personal motivation calls, or automated motivational calls) randomly assigned across six community health care sites']","['self-efficacy for change in overcoming barriers change at 24 weeks, physical and psychological-outcome realizations at 24 weeks, social support from group behavioral meetings at 24 weeks, and physical activity (self-report and device-measured) change', 'Self-Efficacy, Outcome Expectations, Group Social Support, and Adherence to Physical Activity']","[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4517669', 'cui_str': '260'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0026062', 'cui_str': 'Middle-age'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0520942', 'cui_str': 'Personal motivation'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0086034', 'cui_str': 'Community Healthcare'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",260.0,0.0348388,"In a hierarchical regression model predicting change in self-reported time spent in weekly moderate-vigorous physical activity (MVPA) at 48 weeks, psychological-outcome realizations at 24 weeks were significant positive predictors.","[{'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'Garland', 'Affiliation': ''}, {'ForeName': 'JoEllen', 'Initials': 'J', 'LastName': 'Wilbur', 'Affiliation': ''}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Fogg', 'Affiliation': ''}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Halloway', 'Affiliation': ''}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Braun', 'Affiliation': ''}, {'ForeName': 'Arlene', 'Initials': 'A', 'LastName': 'Miller', 'Affiliation': ''}]",Nursing research,['10.1097/NNR.0000000000000516'] 3084,33871619,Development and Validation of a Machine Learning Model to Estimate Bacterial Sepsis Among Immunocompromised Recipients of Stem Cell Transplant.,"Importance Sepsis disproportionately affects recipients of allogeneic hematopoietic cell transplant (allo-HCT), and timely detection is crucial. However, the atypical presentation of sepsis within this population makes detection challenging, and existing clinical sepsis tools have limited prognostic value among this high-risk population. Objective To develop a full risk factor (demographic, transplant, clinical, and laboratory factors) and clinical factor-specific automated bacterial sepsis decision support tool for recipients of allo-HCT with potential bloodstream infections (PBIs). Design, Setting, and Participants This prognostic study used data from adult recipients of allo-HCT transplanted at the Fred Hutchinson Cancer Research Center, Seattle, Washington, between June 2010 and June 2019 randomly divided into 70% modeling and 30% validation data sets. Tools were developed using the area under the curve (AUC) optimized SuperLearner, and their performance was compared with existing clinical sepsis tools: National Early Warning Score (NEWS), quick Sequential Organ Failure Assessment (qSOFA), and Systemic Inflammatory Response Syndrome (SIRS), using the validation data set. Data were analyzed between January and October of 2020. Main Outcomes and Measures The primary outcome was high-sepsis risk bacteremia (culture confirmed gram-negative species, Staphylococcus aureus, or Streptococcus spp bacteremia), and the secondary outcomes were 10- and 28-day mortality. Tool discrimination and calibration were examined using accuracy metrics and expected vs observed probabilities. Results Between June 2010 and June 2019, 1943 recipients of allo-HCT received their first transplant, and 1594 recipients (median [interquartile range] age at transplant, 54 [43-63] years; 911 [57.2%] men; 1242 individuals [77.9%] identifying as White) experienced at least 1 PBI. Of 8131 observed PBIs, 238 (2.9%) were high-sepsis risk bacteremia. Compared with high-sepsis risk bacteremia, the full decision support tool had the highest AUC (0.85; 95% CI, 0.81-0.89), followed by the clinical factor-specific tool (0.72; 95% CI, 0.66-0.78). SIRS had the highest AUC of existing tools (0.64; 95% CI, 0.57-0.71). The full decision support tool had the highest AUCs for PBIs identified in inpatient (0.82; 95% CI, 0.76-0.89) and outpatient (0.82; 95% CI, 0.75-0.89) settings and for 10-day (0.85; 95% CI, 0.79-0.91) and 28-day (0.80; 95% CI, 0.75-0.84) mortality. Conclusions and Relevance These findings suggest that compared with existing tools and the clinical factor-specific tool, the full decision support tool had superior prognostic accuracy for the primary (high-sepsis risk bacteremia) and secondary (short-term mortality) outcomes in inpatient and outpatient settings. If used at the time of culture collection, the full decision support tool may inform more timely sepsis detection among recipients of allo-HCT.",2021,"SIRS had the highest AUC of existing tools (0.64; 95% CI, 0.57-0.71).","['Immunocompromised Recipients of Stem Cell Transplant', '1943 recipients of allo-HCT received their first transplant, and 1594 recipients (median [interquartile range] age at transplant, 54 [43-63] years; 911 [57.2%] men; 1242 individuals [77.9%] identifying as White) experienced at least 1 PBI', 'adult recipients of allo-HCT transplanted at the Fred Hutchinson Cancer Research Center, Seattle, Washington, between June 2010 and June 2019 randomly divided into 70% modeling and 30% validation data sets', 'recipients of allo-HCT with potential bloodstream infections (PBIs', 'Importance\n\n\nSepsis disproportionately affects recipients of allogeneic hematopoietic cell transplant (allo-HCT']",['Machine Learning Model'],"['Bacterial Sepsis', 'high-sepsis risk bacteremia (culture confirmed gram-negative species, Staphylococcus aureus, or Streptococcus spp bacteremia), and the secondary outcomes were 10- and 28-day mortality', 'high-sepsis risk bacteremia']","[{'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0206152', 'cui_str': 'Cell Transplants'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0607251', 'cui_str': '43-63'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0001721', 'cui_str': 'Affect'}]","[{'cui': 'C0376284', 'cui_str': 'Machine Learning'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0684256', 'cui_str': 'Bacterial sepsis'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.180532,"SIRS had the highest AUC of existing tools (0.64; 95% CI, 0.57-0.71).","[{'ForeName': 'Margaret L', 'Initials': 'ML', 'LastName': 'Lind', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Mooney', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Carone', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Benjamin M', 'Initials': 'BM', 'LastName': 'Althouse', 'Affiliation': 'Institute for Disease Modeling, Bellevue, Washington.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle.'}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Evans', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle.'}, {'ForeName': 'Phuong T', 'Initials': 'PT', 'LastName': 'Vo', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Pergam', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Amanda I', 'Initials': 'AI', 'LastName': 'Phipps', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle.'}]",JAMA network open,['10.1001/jamanetworkopen.2021.4514'] 3085,33908312,Selective attention to emotional stimuli and emotion recognition in patients with major depression: The role of mineralocorticoid and glutamatergic NMDA receptors.,"BACKGROUND Mineralocorticoid receptors (MR) are highly expressed in limbic brain areas and prefrontal cortex, which are closely related to selective attention to emotional stimuli and emotion recognition. Patients with major depressive disorder (MDD) show alterations in MR functioning and both cognitive processes. MR stimulation improves cognitive processes in MDD and leads to glutamate release that binds upon N-methyl-D-aspartate receptors (NMDA-R). AIMS We examined (1) whether MR stimulation has beneficial effects on selective attention to emotional stimuli and on emotion recognition and (2) whether these advantageous effects can be improved by simultaneous NMDA-R stimulation. METHODS We examined 116 MDD patients and 116 healthy controls matched for age ( M  = 34 years), sex (78% women), and education in the following conditions: no pharmacological stimulation (placebo), MR stimulation (0.4 mg fludrocortisone + placebo), NMDA-R stimulation (placebo + 250 mg D-cycloserine (DCS)), MR + NMDA-R stimulation (fludrocortisone + DCS). An emotional dot probe task and a facial emotion recognition task were used to measure selective attention to emotional stimuli and emotion recognition. RESULTS Patients with MDD and healthy individuals did not differ in task performance. MR stimulation had no effect on both cognitive processes in both groups. Across groups, NMDA-R stimulation had no effect on selective attention but showed a small effect on emotion recognition by increasing accuracy to recognize angry faces. CONCLUSIONS Relatively young unmedicated MDD patients showed no depression-related cognitive deficits compared with healthy controls. Separate MR and simultaneous MR and NMDA-R stimulation revealed no advantageous effects on cognition, but NMDA-R might be involved in emotion recognition.",2021,"Across groups, NMDA-R stimulation had no effect on selective attention but showed a small effect on emotion recognition by increasing accuracy to recognize angry faces. ","['patients with major depression', 'Patients with MDD and healthy individuals', '116 MDD patients and 116 healthy controls matched for age ( M \u2009=\u200934\u2009years), sex (78% women), and education in the following conditions: no', 'Patients with major depressive disorder (MDD']","['pharmacological stimulation (placebo), MR stimulation (0.4\u2009mg fludrocortisone\u2009+\u2009placebo), NMDA-R stimulation (placebo\u2009+\u2009250\u2009mg D-cycloserine (DCS)), MR\u2009+\u2009NMDA-R stimulation (fludrocortisone\u2009+\u2009DCS', 'Selective attention to emotional stimuli and emotion recognition', 'MR stimulation']","['cognitive processes', 'selective attention to emotional stimuli and emotion recognition', 'task performance', 'emotion recognition', 'depression-related cognitive deficits']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0441694', 'cui_str': 'Pharmacological stimulation'}, {'cui': 'C0066563', 'cui_str': 'Mineralocorticoid Receptor'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0016280', 'cui_str': 'Fludrocortisone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0080093', 'cui_str': 'N-Methyl-D-Aspartate Receptors'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}]","[{'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0009241', 'cui_str': 'Cognitive disorder'}]",116.0,0.0366595,"Across groups, NMDA-R stimulation had no effect on selective attention but showed a small effect on emotion recognition by increasing accuracy to recognize angry faces. ","[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Nowacki', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Wingenfeld', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kaczmarczyk', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Woo Ri', 'Initials': 'WR', 'LastName': 'Chae', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Salchow', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Christian Eric', 'Initials': 'CE', 'LastName': 'Deuter', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Piber', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Otte', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/02698811211009797'] 3086,33913347,Effects of Data-Based Decision-Making on Low-Performing Readers in General Education Classrooms: Cumulative Evidence From Six Intervention Studies.,"In most general education classrooms in Germany, students with and without special educational needs are taught together. To support teachers in adapting instruction to these heterogeneous classrooms, we have developed learning progress assessment (LPA) and reading instructional materials, the Reading Sportsman (RS), in line with the theoretical framework of data-based decision-making, which has led to beneficial effects in several studies. However, data from these studies have not been analyzed to examine effects for low-performing readers. Data within and across six quasi-experimental studies conducted by our team in Grades 2 to 4 were reanalyzed to examine the effects of LPA on students whose reading fluency scores were at or below the 25th percentile ( n = 1,346 students from 264 classes). In each study, students had been assigned to a control group (with business-as-usual instruction), an LPA group only, or an LPA-RS group (i.e., with teachers provided with LPA and the RS). Separate multilevel regression results were integrated by means of meta-analytical methods to investigate the consistency of results. Overall, findings from the single studies indicated no positive effects of LPA with or without the RS compared with the control group. The integrated analyses showed small positive effect trends on reading fluency and intrinsic reading motivation.",2021,"Overall, findings from the single studies indicated no positive effects of LPA with or without the RS compared with the control group.",['Low-Performing Readers in General Education Classrooms'],"['control group (with business-as-usual instruction', 'Data-Based Decision-Making', 'LPA group only, or an LPA-RS', 'LPA']","['reading fluency and intrinsic reading motivation', 'reading fluency scores']","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0085936', 'cui_str': 'Business'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",1346.0,0.049684,"Overall, findings from the single studies indicated no positive effects of LPA with or without the RS compared with the control group.","[{'ForeName': 'Martin T', 'Initials': 'MT', 'LastName': 'Peters', 'Affiliation': 'University of Münster, Germany.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Förster', 'Affiliation': 'University of Münster, Germany.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Hebbecker', 'Affiliation': 'University of Münster, Germany.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Forthmann', 'Affiliation': 'University of Münster, Germany.'}, {'ForeName': 'Elmar', 'Initials': 'E', 'LastName': 'Souvignier', 'Affiliation': 'University of Münster, Germany.'}]",Journal of learning disabilities,['10.1177/00222194211011580'] 3087,33912470,Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer.,"Background Induction with four cycles of platinum-based chemotherapy was the standard of care for metastatic non-small cell lung cancer (NSCLC) until the approval of immune checkpoint blockade (ICB) in the first-line setting. Switch maintenance therapy has shown promise in improving survival by exposing patients to novel, non-cross-resistant agents earlier in their treatment course. Methods We performed this open-label, three-arm, randomized phase II study (NCT02684461) to evaluate three sequences of consolidation with pembrolizumab and nab-paclitaxel in patients without progressive disease post induction chemotherapy. Consolidation was either sequential with pembrolizumab for four cycles followed by nab-paclitaxel for four cycles (P→A), nab-paclitaxel followed by pembrolizumab (A→P), or concurrent nab-paclitaxel and pembrolizumab for four cycles (AP). Results Twenty patients were randomized before the study was closed early due to the approval of first-line checkpoint inhibitors. We found that consolidation is feasible and well tolerated, with 30% of patients experiencing grade 3 toxicity. The median progression-free survival and OS in months (95% CI) in P→A were 10.1 (1.5-NR), 27.6 (1.7-NR); 8.4 (1.2-9.0), 12.7 (4.4-NR) in A→P; and 10.2 (5.1-NR), NR. Quality of life as measured by FACT-L improved in the majority of patients during the course of the study. Conclusion Sequential and concurrent consolidation regimens are well tolerated and have encouraging overall survival in patients with metastatic NSCLC.",2021,"The median progression-free survival and OS in months (95% CI) in P→A were 10.1 (1.5-NR), 27.6 (1.7-NR); 8.4 (1.2-9.0), 12.7 (4.4-NR) in A→P; and 10.2 (5.1-NR), NR.","['Twenty patients', 'Advanced Non-Small Cell Lung Cancer', 'patients without progressive disease post induction chemotherapy', 'patients with metastatic NSCLC']","['Induction Platinum-Based Chemotherapy', 'pembrolizumab and nab-paclitaxel', 'nab-paclitaxel followed by pembrolizumab (A→P), or concurrent nab-paclitaxel and pembrolizumab', 'Pembrolizumab and Nab-Paclitaxel', 'pembrolizumab', 'platinum-based chemotherapy']","['feasible and well tolerated', 'median progression-free survival and OS', 'Quality of life', 'overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C3179010', 'cui_str': 'Induction chemotherapy'}, {'cui': 'C0278987', 'cui_str': 'Metastatic non-small cell lung cancer'}]","[{'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",20.0,0.163458,"The median progression-free survival and OS in months (95% CI) in P→A were 10.1 (1.5-NR), 27.6 (1.7-NR); 8.4 (1.2-9.0), 12.7 (4.4-NR) in A→P; and 10.2 (5.1-NR), NR.","[{'ForeName': 'Shetal A', 'Initials': 'SA', 'LastName': 'Patel', 'Affiliation': 'Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Gerber', 'Affiliation': 'Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Deal', 'Affiliation': 'Department of Biostatistics, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Kathe', 'Initials': 'K', 'LastName': 'Douglas', 'Affiliation': 'Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Chad V', 'Initials': 'CV', 'LastName': 'Pecot', 'Affiliation': 'Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Carrie', 'Initials': 'C', 'LastName': 'Lee', 'Affiliation': 'Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Schiller', 'Affiliation': 'Department of Medicine, University of Virginia, Charlottesville, VA, United States.'}, {'ForeName': 'Nirav', 'Initials': 'N', 'LastName': 'Dhruva', 'Affiliation': 'UNC REX Healthcare, Raleigh, NC, United States.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Weiss', 'Affiliation': 'Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}]",Frontiers in oncology,['10.3389/fonc.2021.666691'] 3088,33893867,Grading reliability of the tear film viscosity examination.,"PURPOSE To assess the reliability of a tear film (TF) viscosity video grading system. METHODS Thirty-four dynamic TF viscosity videos were obtained by a clinically available TF analyzer and objectively sorted according to the movement speed of three arbitrary reflective light particles. A 4-grade system was constructed on a specially designed window for simultaneous comparison with the three standard videos. Two masked graders were invited to grade these videos under a randomized procedure. Observer reliabilities were determined by Spearman's correlation analysis and Bland-Altman agreement analysis. RESULTS For this four-grade system, the intra-observer correlation was very strong in the two graders (ρ = 0.96 and 0.82; both P < 0.0001). However, the inter-observer correlation showed moderate strength in normal playback speed (ρ = 0.53, P = 0.002 and ρ = 0.52, P = 0.003 for 1st and 2nd gradings, respectively). In slower playback videos, the inter-observer correlation of the two graders was higher (ρ = 0.70 and P < 0.0001) when reduced to 0.8-times playback speed. Moreover, the 0.8-times mode was also significantly better than normal playback mode (P = 0.0204) in terms of inter-observer agreement. CONCLUSIONS The dynamic 4-grade system has an excellent intra-observer reliability and a good inter-observer reliability under 0.8-times playback speed. The grading system established in this study provides a promising solution for rapidly determining the level of TF viscosity.",2021,"Moreover, the 0.8-times mode was also significantly better than normal playback mode (P = 0.0204) in terms of inter-observer agreement. ",['Thirty-four dynamic TF viscosity videos were obtained by a clinically available TF analyzer and objectively sorted according to the movement speed of three arbitrary reflective light particles'],[],"['Observer reliabilities', 'moderate strength in normal playback speed', 'reliability of a tear film (TF) viscosity video grading system']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0179038', 'cui_str': 'Analyzer'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C1264693', 'cui_str': 'Arbitrary'}, {'cui': 'C0023693', 'cui_str': 'Light'}]",[],"[{'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",34.0,0.0514155,"Moreover, the 0.8-times mode was also significantly better than normal playback mode (P = 0.0204) in terms of inter-observer agreement. ","[{'ForeName': 'Hung-Yin', 'Initials': 'HY', 'LastName': 'Lai', 'Affiliation': 'Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, No.123, Dapi Rd., Niaosong Dist., Kaohsiung, 83301, Taiwan, Republic of China.'}, {'ForeName': 'Po-Chiung', 'Initials': 'PC', 'LastName': 'Fang', 'Affiliation': 'Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, No.123, Dapi Rd., Niaosong Dist., Kaohsiung, 83301, Taiwan, Republic of China.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Chen', 'Affiliation': 'Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, No.123, Dapi Rd., Niaosong Dist., Kaohsiung, 83301, Taiwan, Republic of China.'}, {'ForeName': 'Ming-Tse', 'Initials': 'MT', 'LastName': 'Kuo', 'Affiliation': 'Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, No.123, Dapi Rd., Niaosong Dist., Kaohsiung, 83301, Taiwan, Republic of China. mingtse@cgmh.org.tw.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-021-05176-2'] 3089,33895362,Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma.,"BACKGROUND Medication adherence is challenging for adolescents. In mild asthma, as-needed budesonide-formoterol (BUD-FORM) reduces severe exacerbations compared with as-needed short-acting beta 2 -agonists, similar to the reduction with maintenance budesonide. OBJECTIVE This post hoc pooled analysis of Symbicort Given as-needed in Mild Asthma (SYGMA) 1 and 2 assessed the efficacy and safety of as-needed BUD-FORM in adolescents. METHODS SYGMA 1 and 2 were 52-week, double-blind studies (NCT022149199; NCT02224157) in patients 12 years or older with mild asthma. Patients were randomized to twice-daily placebo + as-needed BUD-FORM 200/6 μg, twice-daily BUD 200 μg + as-needed terbutaline (BUD maintenance), or twice-daily placebo + as-needed terbutaline 0.5 mg (SYGMA 1 only). Annualized severe exacerbation rates, maintenance treatment adherence, and safety (including change in height) were compared between treatment groups in adolescents (aged ≥12 to <18 years). RESULTS Severe exacerbation rate was similar with as-needed BUD-FORM and BUD maintenance (pooled analysis: 0.08 vs 0.07/y; P = .634), and was significantly lower with as-needed BUD-FORM versus as-needed terbutaline (SYGMA 1: 0.04 vs 0.17/y; P = .005). Median adherence was 73% in SYGMA 1 and 51% in SYGMA 2. Change in height from baseline in adolescents aged ≥12 years to <14 years was significantly greater with as-needed BUD-FORM (4.8 cm) versus BUD maintenance (3.9 cm) (pooled: P < .046), and was similar between as-needed BUD-FORM (4.5 cm) and as-needed terbutaline (4.1 cm) (SYGMA 1: P = .500). No new or unexpected safety concerns were identified. CONCLUSIONS In adolescents with mild asthma, as-needed BUD-FORM was superior to as-needed terbutaline for severe exacerbation reduction, with similar efficacy to BUD maintenance. As-needed BUD-FORM provides an alternative treatment option for adolescents with mild asthma, without needing daily treatment.",2021,"RESULTS Severe exacerbation rate was similar with as-needed BUD-FORM and BUD maintenance (pooled analysis: 0.08 vs 0.07/year, p=0.634), and was significantly lower with as-needed BUD-FORM versus as-needed terbutaline (SYGMA 1: 0.04 vs 0.17/year, p=0.005).","['adolescents with mild asthma', 'patients ≥12 years with mild asthma', 'adolescents', 'adolescents aged ≥12-<14 years']","['placebo', 'budesonide-formoterol (BUD-FORM', 'budesonide-formoterol', 'placebo ']","['efficacy and safety', 'Annualized severe exacerbation rates, maintenance treatment adherence and safety (including change in height', 'Severe exacerbation rate', 'Median adherence', 'Efficacy and safety']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0581124', 'cui_str': 'Mild asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1276807', 'cui_str': 'formoterol and budesonide'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C4505265', 'cui_str': 'Therapeutic Adherence'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",,0.114763,"RESULTS Severe exacerbation rate was similar with as-needed BUD-FORM and BUD maintenance (pooled analysis: 0.08 vs 0.07/year, p=0.634), and was significantly lower with as-needed BUD-FORM versus as-needed terbutaline (SYGMA 1: 0.04 vs 0.17/year, p=0.005).","[{'ForeName': 'Helen K', 'Initials': 'HK', 'LastName': 'Reddel', 'Affiliation': 'The Woolcock Institute of Medical Research, The University of Sydney, Sydney, NSW, Australia. Electronic address: helen.reddel@sydney.edu.au.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': ""O'Byrne"", 'Affiliation': ""Firestone Institute for Respiratory Health, St Joseph's Healthcare and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.""}, {'ForeName': 'J Mark', 'Initials': 'JM', 'LastName': 'FitzGerald', 'Affiliation': 'The Centre for Lung Health, Vancouver Coastal Health Research Institute and the University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Barnes', 'Affiliation': 'Airway Disease Section, National Heart and Lung Institute, Imperial College, London, United Kingdom.'}, {'ForeName': 'Jinping', 'Initials': 'J', 'LastName': 'Zheng', 'Affiliation': 'State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Ivanov', 'Affiliation': 'AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Lamarca', 'Affiliation': 'AstraZeneca, Barcelona, Spain.'}, {'ForeName': 'Margareta', 'Initials': 'M', 'LastName': 'Puu', 'Affiliation': 'AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Vijay K T', 'Initials': 'VKT', 'LastName': 'Alagappan', 'Affiliation': 'AstraZeneca, Gaithersburg, Md.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Bateman', 'Affiliation': 'Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2021.04.016'] 3090,33899259,A tissue-engineered biocomplex for periodontal reconstruction. A proof-of-principle randomized clinical study.,"AIM To assess the safety/efficacy of a tissue-engineered biocomplex in periodontal reconstruction. METHODS Twenty-seven intrabony defects were block-randomized across three treatment groups: Group-A (N A  = 9) received autologous clinical-grade alveolar bone marrow mesenchymal stem cells (a-BMMSCs), seeded into collagen scaffolds, enriched with autologous fibrin/platelet lysate (aFPL). In Group-B (N B  = 10), the collagen scaffold/aFPL devoid of a-BMMSCs filled the osseous defect. Group-C (N C  = 8) received Minimal Access Flap surgery retaining the soft tissue wall of defects identically with Groups-A/-B. Subjects were clinically/radiographically assessed before anaesthesia (baseline) and repeatedly over 12 months. RESULTS Quality controls were satisfied before biocomplex transplantation. There were no adverse healing events. All approaches led to significant clinical improvements (p < .001) with no inter-group differences. At 12 months, the estimated marginal means for all groups were as follows: 3.0 (95% CI: 1.9-4.1) mm for attachment gain; 3.7 (2.7-4.8) mm for probing pocket depth reduction; 0.7 (0.2-1.3) mm increase in recession. An overall greater mean reduction in the radiographic Cemento-Enamel Junction to Bottom Defect (CEJ-BD) distance was found for Groups-A/-C over Group-B (p < .023). CONCLUSION Radiographic evidence of bone fill was less pronounced in Group-B, although clinical improvements were similar across groups. All approaches aimed to trigger the innate healing potential of tissues. Cell-based therapy is justified for periodontal reconstruction and remains promising in selected cases.",2021,All approaches led to significant clinical improvements (p<0.001) with no inter-group differences.,['Twenty-seven intrabony defects'],"['tissue-engineered biocomplex', 'Cell-based therapy', 'Minimal Access Flap surgery retaining the soft-tissue-wall of defects identically with Groups-A/-B. Subjects were clinically/radiographically assessed before anaesthesia (baseline) and repeatedly over 12-months', 'autologous clinical-grade alveolar Bone-Marrow Mesenchymal-Stem-Cells (a-BMMSCs), seeded into collagen scaffolds, enriched with autologous fibrin/platelet lysate (aFPL']","['adverse healing events', 'safety/efficacy', 'Radiographic evidence of bone fill']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0243067', 'cui_str': 'defects'}]","[{'cui': 'C0596171', 'cui_str': 'Tissue Engineering'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C4704952', 'cui_str': 'Bone Marrow Mesenchymal Stem Cells'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0337143', 'cui_str': 'Scaffold'}, {'cui': 'C0015982', 'cui_str': 'Fibrin'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}]",,0.0914605,All approaches led to significant clinical improvements (p<0.001) with no inter-group differences.,"[{'ForeName': 'Danae A', 'Initials': 'DA', 'LastName': 'Apatzidou', 'Affiliation': 'Department of Preventive Dentistry, Periodontology and Implant Biology, School of Dentistry, Faculty of Health Sciences (FHS), Aristotle University of Thessaloniki (AUTh), Thessaloniki, Greece.'}, {'ForeName': 'Athina A', 'Initials': 'AA', 'LastName': 'Bakopoulou', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Faculty of Health Sciences (FHS), Aristotle University of Thessaloniki (AUTh), Thessaloniki, Greece.'}, {'ForeName': 'Kokkona', 'Initials': 'K', 'LastName': 'Kouzi-Koliakou', 'Affiliation': 'Biohellenika SA, Biotechnology Company, Thessaloniki, Greece.'}, {'ForeName': 'Vassilis', 'Initials': 'V', 'LastName': 'Karagiannis', 'Affiliation': 'School of Mathematics, Aristotle University of Thessaloniki, AUTh, Thessaloniki, Greece.'}, {'ForeName': 'Antonis', 'Initials': 'A', 'LastName': 'Konstantinidis', 'Affiliation': 'Department of Preventive Dentistry, Periodontology and Implant Biology, School of Dentistry, Faculty of Health Sciences (FHS), Aristotle University of Thessaloniki (AUTh), Thessaloniki, Greece.'}]",Journal of clinical periodontology,['10.1111/jcpe.13474'] 3091,33901103,Using Novel Approaches to Evaluate Behavioral Interventions: Overlooked Significant HIV Prevention Effects in the HPTN 015 Project EXPLORE.,"BACKGROUND Mediated and moderated processes that lead to intervention efficacy may underlie results of trials ruled as nonefficacious. The overall purpose of this study was to examine such processes to explain the findings of one of the largest, rigorously conducted behavioral intervention randomized controlled trials, EXPLORE. METHODS Four thousand two hundred ninety-five HIV-negative men who have sex with men (MSM) in the United States were randomized in a 2-armed trial. Participants completed follow-up and an HIV test every 6 months up to 48 months. We used multiple and causal mediation analyses to test 5 mediators, including safer sex self-efficacy and condomless receptive anal sex with HIV-positive or status-unknown partners on our primary outcome (HIV seroconversion). We also examined whether intervention effects on the mediators would be moderated by robust correlates of HIV among MSM, including stimulant use. RESULTS There were significant effects of the intervention on all hypothesized mediators. Stimulant use moderated the effect on condomless receptive anal sex In stratified multiple mediation models, we found that among MSM with low stimulant use, the intervention significantly prevented HIV by reducing condomless receptive anal sex with HIV-positive or status-unknown partners. Among MSM with higher stimulant use, there were no indirect effects of the intervention on HIV through any of the hypothesized mediators. CONCLUSION The results suggest that the null effect found in the original EXPLORE trial might have occurred as a function of previously unexplored mediated and moderated processes. This study illustrates the value of testing mediated and moderated pathways in randomized trials, even in trials ruled out as nonefficacious.",2021,"Among MSM with higher stimulant use, there were no indirect effects of the intervention on HIV through any of the hypothesized mediators. ","['4,295 HIV-negative MSM in the U.S']",[],['condomless receptive anal sex'],"[{'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C0058231', 'cui_str': 'methylsulfonylmethane'}]",[],"[{'cui': 'C0282347', 'cui_str': 'Anal sex'}]",4295.0,0.0906401,"Among MSM with higher stimulant use, there were no indirect effects of the intervention on HIV through any of the hypothesized mediators. ","[{'ForeName': 'Eileen V', 'Initials': 'EV', 'LastName': 'Pitpitan', 'Affiliation': 'School of Social Work, San Diego State University, San Diego, CA.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'MacKinnon', 'Affiliation': 'Department of Psychology, Arizona State University, Tempe, AZ.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Eaton', 'Affiliation': 'Department of Human, Development and Family Sciences, University of Connecticut, Storrs, CT; and.'}, {'ForeName': 'Laramie R', 'Initials': 'LR', 'LastName': 'Smith', 'Affiliation': 'Departments of Medicine, and Psychiatry University of California San Diego, San Diego, CA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Wagman', 'Affiliation': 'Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Patterson', 'Affiliation': 'Departments of Medicine, and Psychiatry University of California San Diego, San Diego, CA.'}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002711'] 3092,33904178,Improving the donation experience and reducing venipuncture pain by addressing fears among whole-blood and plasma donors.,"BACKGROUND Fear of blood donation is implicated in vasovagal reactions, donor recruitment, and retention. This study examined the extent to which fear among donors is associated with various donor outcomes in an Australian sample, and whether fear can be addressed on-site to reduce adverse reactions and improve the donation experience. STUDY DESIGN AND METHODS Six hundred and sixty-four donors (age M = 33.4, SD = 12.7; 55% female) participated in a two-center, pragmatic, parallel group, individually randomized controlled trial. Following donor registration and consent, whole-blood (n = 539) and plasma (n = 125) donors were assigned to one of four Conditions: control; fear assessment; fear assessment + brochure; fear assessment + brochure + tailored conversation focused on any self-reported fear and coping strategies. Post-donation questionnaires assessed the donors' experience including positive support, donor self-efficacy, anxiety, fear, venipuncture pain, and vasovagal reactions. RESULTS Fear among donors predicted higher venipuncture pain, post-donation anxiety, and vasovagal reactions and remained significant after controlling for other established predictors (i.e., total estimated blood volume, age, sex, and donation experience). Mediational analyses showed that exposure to brochures (with or without the tailored conversation) was associated with less pain, with this effect mediated by donor perceptions of more positive support. Venipuncture pain was also associated with vasovagal reactions, reduced likelihood of return within 6 months, and less satisfaction with the donation experience. CONCLUSION The current results underline the importance of interventions to address fear among both whole-blood and plasma donors to secure the safety and well-being of donors and the blood supply.",2021,"Mediational analyses showed that exposure to brochures (with or without the tailored conversation) was associated with less pain, with this effect mediated by donor perceptions of more positive support.","['Six hundred and sixty-four donors (age M = 33.4, SD = 12.7; 55% female']",['control; fear assessment; fear assessment + brochure; fear assessment + brochure + tailored conversation focused on any self-reported fear and coping strategies'],"['venipuncture pain', 'venipuncture pain, post-donation anxiety, and vasovagal reactions', 'positive support, donor self-efficacy, anxiety, fear, venipuncture pain, and vasovagal reactions', 'vasovagal reactions', 'Venipuncture pain']","[{'cui': 'C4517845', 'cui_str': '660'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0221134', 'cui_str': 'Blood group antigen M'}, {'cui': 'C4517546', 'cui_str': '12.7'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}]","[{'cui': 'C0190979', 'cui_str': 'Phlebotomy'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C4049936', 'cui_str': 'Patient status determination, deceased and body donated'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0042420', 'cui_str': 'Vasovagal syncope'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0015726', 'cui_str': 'Fear'}]",664.0,0.100332,"Mediational analyses showed that exposure to brochures (with or without the tailored conversation) was associated with less pain, with this effect mediated by donor perceptions of more positive support.","[{'ForeName': 'Philippe T', 'Initials': 'PT', 'LastName': 'Gilchrist', 'Affiliation': 'Department of Psychology, Macquarie University, North Ryde, New South Wales, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Thijsen', 'Affiliation': 'Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia.'}, {'ForeName': 'Barbara M', 'Initials': 'BM', 'LastName': 'Masser', 'Affiliation': 'Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'France', 'Affiliation': 'Department of Psychology, Ohio University, Athens, Ohio, USA.'}, {'ForeName': 'Tanya E', 'Initials': 'TE', 'LastName': 'Davison', 'Affiliation': 'Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia.'}]",Transfusion,['10.1111/trf.16407'] 3093,33909607,Effectiveness of a primary care-based integrated mobile health intervention for stroke management in rural China (SINEMA): A cluster-randomized controlled trial.,"BACKGROUND Managing noncommunicable diseases through primary healthcare has been identified as the key strategy to achieve universal health coverage but is challenging in most low- and middle-income countries. Stroke is the leading cause of death and disability in rural China. This study aims to determine whether a primary care-based integrated mobile health intervention (SINEMA intervention) could improve stroke management in rural China. METHODS AND FINDINGS Based on extensive barrier analyses, contextual research, and feasibility studies, we conducted a community-based, two-arm cluster-randomized controlled trial with blinded outcome assessment in Hebei Province, rural Northern China including 1,299 stroke patients (mean age: 65.7 [SD:8.2], 42.6% females, 71.2% received education below primary school) recruited from 50 villages between June 23 and July 21, 2017. Villages were randomly assigned (1:1) to either the intervention or control arm (usual care). In the intervention arm, village doctors who were government-sponsored primary healthcare providers received training, conducted monthly follow-up visits supported by an Android-based mobile application, and received performance-based payments. Participants received monthly doctor visits and automatically dispatched daily voice messages. The primary outcome was the 12-month change in systolic blood pressure (BP). Secondary outcomes were predefined, including diastolic BP, health-related quality of life, physical activity level, self-reported medication adherence (antiplatelet, statin, and antihypertensive), and performance in ""timed up and go"" test. Analyses were conducted in the intention-to-treat framework at the individual level with clusters and stratified design accounted for by following the prepublished statistical analysis plan. All villages completed the 12-month follow-up, and 611 (intervention) and 615 (control) patients were successfully followed (3.4% lost to follow-up among survivors). The program was implemented with high fidelity, and the annual program delivery cost per capita was US$24.3. There was a significant reduction in systolic BP in the intervention as compared with the control group with an adjusted mean difference: -2.8 mm Hg (95% CI -4.8, -0.9; p = 0.005). The intervention was significantly associated with improvements in 6 out of 7 secondary outcomes in diastolic BP reduction (p < 0.001), health-related quality of life (p = 0.008), physical activity level (p < 0.001), adherence in statin (p = 0.003) and antihypertensive medicines (p = 0.039), and performance in ""timed up and go"" test (p = 0.022). We observed reductions in all exploratory outcomes, including stroke recurrence (4.4% versus 9.3%; risk ratio [RR] = 0.46, 95% CI 0.32, 0.66; risk difference [RD] = 4.9 percentage points [pp]), hospitalization (4.4% versus 9.3%; RR = 0.45, 95% CI 0.32, 0.62; RD = 4.9 pp), disability (20.9% versus 30.2%; RR = 0.65, 95% CI 0.53, 0.79; RD = 9.3 pp), and death (1.8% versus 3.1%; RR = 0.52, 95% CI 0.28, 0.96; RD = 1.3 pp). Limitations include the relatively short study duration of only 1 year and the generalizability of our findings beyond the study setting. CONCLUSIONS In this study, a primary care-based mobile health intervention integrating provider-centered and patient-facing technology was effective in reducing BP and improving stroke secondary prevention in a resource-limited rural setting in China. TRIAL REGISTRATION ClinicalTrials.gov NCT03185858.",2021,"The intervention was significantly associated with improvements in 6 out of 7 secondary outcomes in diastolic BP reduction (p < 0.001), health-related quality of life (p = 0.008), physical activity level (p < 0.001), adherence in statin (p = 0.003) and antihypertensive medicines (p = 0.039), and performance in ""timed up and go"" test (p = 0.022).","['rural China', 'village doctors who were government-sponsored primary healthcare providers received', 'Hebei Province, rural Northern China including 1,299 stroke patients (mean age: 65.7 [SD:8.2], 42.6% females, 71.2% received education below primary school) recruited from 50 villages between June 23 and July 21, 2017', 'stroke management in rural China (SINEMA']","['monthly doctor visits and automatically dispatched daily voice messages', 'primary care-based integrated mobile health intervention (SINEMA intervention', 'primary care-based integrated mobile health intervention', 'training, conducted monthly follow-up visits supported by an Android-based mobile application, and received performance-based payments']","['adherence in statin', 'disability', 'health-related quality of life', 'diastolic BP reduction', 'diastolic BP, health-related quality of life, physical activity level, self-reported medication adherence (antiplatelet, statin, and antihypertensive), and performance in ""timed up and go"" test', 'performance in ""timed up and go"" test', 'stroke recurrence', 'hospitalization', 'antihypertensive medicines', '12-month change in systolic blood pressure (BP', 'physical activity level', 'death', 'systolic BP']","[{'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0589121', 'cui_str': 'Follow-up visit'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0336541', 'cui_str': 'Android'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0220808', 'cui_str': 'Compensation'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.387774,"The intervention was significantly associated with improvements in 6 out of 7 secondary outcomes in diastolic BP reduction (p < 0.001), health-related quality of life (p = 0.008), physical activity level (p < 0.001), adherence in statin (p = 0.003) and antihypertensive medicines (p = 0.039), and performance in ""timed up and go"" test (p = 0.022).","[{'ForeName': 'Lijing L', 'Initials': 'LL', 'LastName': 'Yan', 'Affiliation': 'Global Health Research Center, Duke Kunshan University, Jiangsu, China.'}, {'ForeName': 'Enying', 'Initials': 'E', 'LastName': 'Gong', 'Affiliation': 'Global Health Research Center, Duke Kunshan University, Jiangsu, China.'}, {'ForeName': 'Wanbing', 'Initials': 'W', 'LastName': 'Gu', 'Affiliation': 'Global Health Research Center, Duke Kunshan University, Jiangsu, China.'}, {'ForeName': 'Elizabeth L', 'Initials': 'EL', 'LastName': 'Turner', 'Affiliation': 'Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Gallis', 'Affiliation': 'Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Zixiao', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Kara E', 'Initials': 'KE', 'LastName': 'McCormack', 'Affiliation': 'Department of Biostatistics & Bioinformatics, Duke University, Durham North Carolina, United States.'}, {'ForeName': 'Li-Qun', 'Initials': 'LQ', 'LastName': 'Xu', 'Affiliation': 'China Mobile Industry Institute, Chengdu, China.'}, {'ForeName': 'Janet P', 'Initials': 'JP', 'LastName': 'Bettger', 'Affiliation': 'Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America.'}, {'ForeName': 'Shenglan', 'Initials': 'S', 'LastName': 'Tang', 'Affiliation': 'Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America.'}, {'ForeName': 'Yilong', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Oldenburg', 'Affiliation': 'Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.'}]",PLoS medicine,['10.1371/journal.pmed.1003582'] 3094,33914729,"Efficacy of live attenuated and inactivated influenza vaccines among children in rural India: A 2-year, randomized, triple-blind, placebo-controlled trial.","BACKGROUND Influenza is a cause of febrile acute respiratory infection (FARI) in India; however, few influenza vaccine trials have been conducted in India. We assessed absolute and relative efficacy of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) among children aged 2 to 10 years in rural India through a randomized, triple-blind, placebo-controlled trial conducted over 2 years. METHODS AND FINDINGS In June 2015, children were randomly allocated to LAIV, IIV, intranasal placebo, or inactivated polio vaccine (IPV) in a 2:2:1:1 ratio. In June 2016, vaccination was repeated per original allocation. Overall, 3,041 children received LAIV (n = 1,015), IIV (n = 1,010), nasal placebo (n = 507), or IPV (n = 509). Mean age of children was 6.5 years with 20% aged 9 to 10 years. Through weekly home visits, nasal and throat swabs were collected from children with FARI and tested for influenza virus by polymerase chain reaction. The primary outcome was laboratory-confirmed influenza-associated FARI; vaccine efficacy (VE) was calculated using modified intention-to-treat (mITT) analysis by Cox proportional hazards model (PH) for each year. In Year 1, VE was 40.0% (95% confidence interval (CI) 25.2 to 51.9) for LAIV and 59.0% (95% CI 47.8 to 67.9) for IIV compared with controls; relative efficacy of LAIV compared with IIV was -46.2% (95% CI -88.9 to -13.1). In Year 2, VE was 51.9% (95% CI 42.0 to 60.1) for LAIV and 49.9% (95% CI 39.2 to 58.7) for IIV; relative efficacy of LAIV compared with IIV was 4.2% (95% CI -19.9 to 23.5). No serious adverse vaccine-attributable events were reported. Study limitations include differing dosage requirements for children between nasal and injectable vaccines (single dose of LAIV versus 2 doses of IIV) in Year 1 and the fact that immunogenicity studies were not conducted. CONCLUSIONS In this study, we found that LAIV and IIV vaccines were safe and moderately efficacious against influenza virus infection among Indian children. TRIAL REGISTRATION Clinical Trials Registry of India CTRI/2015/06/005902.",2021,"In Year 1, VE was 40.0% (95% confidence interval (CI) 25.2 to 51.9) for LAIV and 59.0% (95% CI 47.8 to 67.9) for IIV compared with controls; relative efficacy of LAIV compared with IIV was -46.2% (95% CI -88.9 to -13.1).","['children aged 2 to 10 years in rural India', 'children in rural India', 'Indian children', '3,041 children received', 'Mean age of children was 6.5 years with 20% aged 9 to 10 years']","['live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV', 'live attenuated and inactivated influenza vaccines', 'LAIV', 'LAIV, IIV, intranasal placebo, or inactivated polio vaccine (IPV', 'placebo', 'nasal placebo', 'LAIV and IIV vaccines']","['laboratory-confirmed influenza-associated FARI; vaccine efficacy (VE', 'modified intention-to-treat (mITT) analysis by Cox proportional hazards model (PH', 'efficacy of LAIV']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C3844007', 'cui_str': '6.5'}]","[{'cui': 'C3652556', 'cui_str': 'influenza, live attenuated'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0718003', 'cui_str': 'Inactivated Poliovirus vaccine'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}]","[{'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0238990', 'cui_str': 'Acute lower respiratory tract infection'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0010235', 'cui_str': 'Cox Proportional Hazards Models'}, {'cui': 'C0033489', 'cui_str': 'Proportional Hazard Models'}, {'cui': 'C3652556', 'cui_str': 'influenza, live attenuated'}]",3041.0,0.56396,"In Year 1, VE was 40.0% (95% confidence interval (CI) 25.2 to 51.9) for LAIV and 59.0% (95% CI 47.8 to 67.9) for IIV compared with controls; relative efficacy of LAIV compared with IIV was -46.2% (95% CI -88.9 to -13.1).","[{'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Krishnan', 'Affiliation': 'Centre for Community Medicine, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Lalit', 'Initials': 'L', 'LastName': 'Dar', 'Affiliation': 'Microbiology Department, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Siddhartha', 'Initials': 'S', 'LastName': 'Saha', 'Affiliation': 'Influenza Program, Centers for Disease Control and Prevention, New Delhi, India.'}, {'ForeName': 'Venkatesh Vinayak', 'Initials': 'VV', 'LastName': 'Narayan', 'Affiliation': 'Influenza Program, Centers for Disease Control and Prevention, New Delhi, India.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Kumar', 'Affiliation': 'Centre for Community Medicine, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Ramesh', 'Initials': 'R', 'LastName': 'Kumar', 'Affiliation': 'Microbiology Department, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Ritvik', 'Initials': 'R', 'LastName': 'Amarchand', 'Affiliation': 'Centre for Community Medicine, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Shivram', 'Initials': 'S', 'LastName': 'Dhakad', 'Affiliation': 'Microbiology Department, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Reshmi', 'Initials': 'R', 'LastName': 'Chokker', 'Affiliation': 'Centre for Community Medicine, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Avinash', 'Initials': 'A', 'LastName': 'Choudekar', 'Affiliation': 'Microbiology Department, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Giridara', 'Initials': 'G', 'LastName': 'Gopal', 'Affiliation': 'Centre for Community Medicine, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Aashish', 'Initials': 'A', 'LastName': 'Choudhary', 'Affiliation': 'Microbiology Department, All India Institute of Medical Sciences, Delhi, India.'}, {'ForeName': 'Varsha', 'Initials': 'V', 'LastName': 'Potdar', 'Affiliation': 'National Institute of Virology, Pune, India.'}, {'ForeName': 'Mandeep', 'Initials': 'M', 'LastName': 'Chadha', 'Affiliation': 'National Institute of Virology, Pune, India.'}, {'ForeName': 'Kathryn E', 'Initials': 'KE', 'LastName': 'Lafond', 'Affiliation': 'Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Lindstrom', 'Affiliation': 'Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Marc-Alain', 'Initials': 'MA', 'LastName': 'Widdowson', 'Affiliation': 'Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Jain', 'Affiliation': 'Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.'}]",PLoS medicine,['10.1371/journal.pmed.1003609'] 3095,33914660,Acute preexercise supplementation of combined carnosine and anserine enhances initial maximal power of Wingate tests in humans.,"Classic in vitro experiments (Severin's phenomenon) demonstrated that acute carnosine supplementation may potentiate muscle contractility. However, upon oral ingestion, carnosine is readily degraded in human plasma by the highly active serum carnosinase-1 (CN1). We developed a novel strategy to circumvent CN1 by preexercise ingestion of combined carnosine (CARN) and anserine (ANS), the methylated analog with similar biochemical properties but more resistant to CN1. First, in vitro hydrolysis was tested by adding carnosine and anserine to human plasma, alone or in combination. Second, five subjects were supplemented with 25 mg/kg anserine or 25 mg/kg of each anserine and carnosine to test in vivo bioavailability. Third, two double-blind, placebo-controlled, crossover studies investigated the effect of preexercise ANS + CARN (20 mg/kg body wt of each) supplementation on performance during a single all-out Wingate test following 6-min high-intensity cycling ( study A ) or three repeated Wingate tests ( study B ). In vitro experiments demonstrated slower degradation of anserine versus carnosine, which was further slowed by simultaneously adding carnosine. In vivo bioavailability of plasma anserine was more prominent [2.5-fold increased area under the curve (AUC)] when ANS + CARN versus ANS was ingested. Study A showed significantly higher (+6% ± 11%; P = 0.04) power in the first 5 s of the Wingate test following ANS + CARN (12.8 ± 2.4 W/kg) versus placebo (12.1 ± 2.2 W/kg). Study B demonstrated increased peak power (+3%) throughout three consecutive Wingate tests (ANS + CARN 10.5 ± 0.6 W/kg vs. placebo 10.2 ± 9.9 W/kg). These experiments reveal a novel acute nutritional method to effectively raise plasma anserine and carnosine by high-dose combined supplementation. This approach led to improved initial cycling power, revealing a new nutritional strategy to increase exercise performance. NEW & NOTEWORTHY Current results reveal that carnosine and anserine competitively bind to the highly active carnosinase enzyme in human plasma. Acute combined carnosine and anserine supplementation is therefore described as novel strategy to raise plasma anserine and carnosine. We report that indices of maximal exercise/muscle power during the initial stage of a Wingate test were significantly improved by preexercise 20-25mg/kg body wt anserine and carnosine supplementation, pointing toward a novel acute nutritional strategy to improve high-intensity exercise performance.",2021,Study A showed significantly higher (+6±11%; p=0.04) power in the first 5s of the Wingate test following ANS+CARN (12.8±2.4W/kg) vs placebo (12.1±2.2W/kg).,['humans'],"['CN1 by pre-exercise ingestion of combined carnosine (CARN) and anserine (ANS', 'combined carnosine and anserine', 'placebo', 'pre-exercise ANS+CARN (20mg/kg BW of each) supplementation']",['peak power'],"[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0051615', 'cui_str': 'Aminoacyl-histidine dipeptidase'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0007267', 'cui_str': 'Carnosine'}, {'cui': 'C0003134', 'cui_str': 'Anserine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}]",5.0,0.155788,Study A showed significantly higher (+6±11%; p=0.04) power in the first 5s of the Wingate test following ANS+CARN (12.8±2.4W/kg) vs placebo (12.1±2.2W/kg).,"[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Blancquaert', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Everaert', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Baguet', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Bex', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Barbaresi', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'de Jager', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Lievens', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Stautemas', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'De Smet', 'Affiliation': 'Laboratory for Animal Nutrition and Animal Product Quality, Ghent University, Ghent, Belgium.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Baron', 'Affiliation': 'Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Gilardoni', 'Affiliation': 'Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Regazzoni', 'Affiliation': 'Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Aldini', 'Affiliation': 'Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Derave', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00602.2020'] 3096,33951124,"Comparison of Four Bowel Cleansing Agents for Colonoscopy and the Factors Affecting their Efficacy. A Prospective, Randomized Study.","BACKGROUND AND AIMS Adequate bowel preparation is essential for successful and effective colonoscopy. Several types of cleansing agents are currently available including low-volume solutions. The aim of this study was to compare the efficacy of four different bowel cleansing agents. METHODS A single-center, prospective, randomized, and single-blind study was performed. Consecutive patients referred for colonoscopy were enrolled and randomized into one of the following types of laxatives: polyethylenglycol 4L (PEG), oral sulfate solution (OSS), 2L polyethylenglycol + ascorbate (2L-PEG/Asc), or magnesium citrate + sodium picosulfate (MCSP). The primary outcome was quality of bowel cleansing evaluated according to the Boston Bowel Preparation Scale (BBPS). Secondary outcomes were polyp detection rate (PDR) and tolerability. RESULTS Final analysis was performed on 431 patients. The number of patients with adequate bowel preparation (BBPS total scores ≥6 and sub scores ≥2 in each segment) was not significantly different throughout all groups (95.4% PEG; 94.6% OSS; 96.3% 2L-PEG/Asc; 96.2% MCSP; p=0.955). Excellent bowel preparation (BBPS total scores ≥ 8) was associated with younger age (p=0.007). The groups did not have significantly different PDRs (49.5% PEG; 49.1% OSS; 38% 2L-PEG/Asc; 40.4% MCSP; p=0.201). The strongest predictors of pathology identification were age and male gender. The best-tolerated solution was MCSP (palatability: p<0.001; nausea: p=0.024).",2021,Excellent bowel preparation (BBPS total scores ≥ 8) was associated with younger age (p=0.007).,"['431 patients', 'Consecutive patients referred for colonoscopy']","['laxatives: polyethylenglycol 4L (PEG), oral sulfate solution (OSS), 2L polyethylenglycol + ascorbate (2L-PEG/Asc), or magnesium citrate + sodium picosulfate (MCSP']","['quality of bowel cleansing evaluated according to the Boston Bowel Preparation Scale (BBPS', 'polyp detection rate (PDR) and tolerability', 'Excellent bowel preparation (BBPS total scores ≥ 8', 'number of patients with adequate bowel preparation (BBPS total scores ≥6 and sub scores ≥2', 'PDRs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}]","[{'cui': 'C0282090', 'cui_str': 'Laxative'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0038720', 'cui_str': 'Inorganic sulfate'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0178487', 'cui_str': 'Ascorbate'}, {'cui': 'C3710940', 'cui_str': 'STS protein, human'}, {'cui': 'C0126774', 'cui_str': 'magnesium citrate'}, {'cui': 'C0071042', 'cui_str': 'sodium picosulfate'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C4302285', 'cui_str': 'BBPS - Boston bowel preparation scale'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}]",431.0,0.00802594,Excellent bowel preparation (BBPS total scores ≥ 8) was associated with younger age (p=0.007).,"[{'ForeName': 'Klara', 'Initials': 'K', 'LastName': 'Kmochova', 'Affiliation': 'Department of Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic. . klara.kmochova@uvn.cz.'}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Grega', 'Affiliation': 'Department of Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic. tomas.grega@uvn.cz.'}, {'ForeName': 'Ondrej', 'Initials': 'O', 'LastName': 'Ngo', 'Affiliation': 'Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. ngo@iba.muni.cz.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Vojtechova', 'Affiliation': 'Department of Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic. gabriela.vojtechova@uvn.cz.'}, {'ForeName': 'Ondrej', 'Initials': 'O', 'LastName': 'Majek', 'Affiliation': 'Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. majek@iba.muni.cz.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Urbanek', 'Affiliation': 'Department of Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic. petr.urbanek@uvn.cz.'}, {'ForeName': 'Miroslav', 'Initials': 'M', 'LastName': 'Zavoral', 'Affiliation': 'Department of Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic. miroslav.zavoral@uvn.cz.'}, {'ForeName': 'Stepan', 'Initials': 'S', 'LastName': 'Suchanek', 'Affiliation': 'Department of Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic. stepan.suchanek@uvn.cz.'}]",Journal of gastrointestinal and liver diseases : JGLD,['10.15403/jgld-3401'] 3097,33955079,Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction.,"BACKGROUND This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV 1 in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary analysis was performed. STUDY DESIGN AND METHODS Subjects from 10 lung transplant centres were assigned to ECP treatment or to observation based on spirometric criteria, with potential crossover for those under observation. The primary endpoint of this study was to assess response to ECP (i.e., greater than a 50% decrease in the rate of FEV 1 decline) before and 6 months after initiation of ECP. Mortality was also evaluated 6 and 12 months after enrolment as a secondary endpoint. RESULTS Of 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non-random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV 1 decline that were reduced by 93% in evaluable ECP-treated patients. Mortality rates (percentages) at 6 and 12 months after enrolment was 32% and 41%, respectively. The most common (92%) primary cause of death was respiratory or graft failure. Significantly (p = 0.002) higher rates of FEV 1 decline were observed in the non-survivors (-212 ± 177 ml/month) when compared to the survivors (-95 ± 117 ml/month) 12 months after enrolment. In addition, 18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6 months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment. CONCLUSIONS These analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP.",2021,Significantly (p = 0.002) higher rates of FEV 1 decline were observed in the non-survivors (-212 ± 177 ml/month) when compared to the survivors (-95 ± 117 ml/month) 12 months after enrolment.,"['18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6\u2009months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment', 'Subjects from 10 lung transplant centres', '44 enrolled subjects', 'lung transplant recipients with refractory bronchiolitis obliterans']","['extracorporeal photopheresis (ECP', 'specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP', 'ECP', 'Extracorporeal photopheresis']","['rate of FEV 1 decline', 'response to ECP', 'death was respiratory or graft failure', 'Mortality rates', 'Mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006272', 'cui_str': 'Obliterative bronchiolitis'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0024128', 'cui_str': 'Transplant of lung'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}]","[{'cui': 'C0206373', 'cui_str': 'Extracorporeal photopheresis'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}]","[{'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0206373', 'cui_str': 'Extracorporeal photopheresis'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1262018', 'cui_str': 'Transplant failure'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",44.0,0.189855,Significantly (p = 0.002) higher rates of FEV 1 decline were observed in the non-survivors (-212 ± 177 ml/month) when compared to the survivors (-95 ± 117 ml/month) 12 months after enrolment.,"[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Chadi A', 'Initials': 'CA', 'LastName': 'Hage', 'Affiliation': 'Department of Medicine, Division of Pulmonology, Indiana University, Bloomington, Indiana, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Klesney-Tait', 'Affiliation': 'Department of Medicine, Division of Pulmonology, University of Iowa, Iowa City, Iowa, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Wille', 'Affiliation': 'Department of Medicine, Division of Pulmonology, University of Alabama, Tuscaloosa, Alabama, USA.'}, {'ForeName': 'Selim', 'Initials': 'S', 'LastName': 'Arcasoy', 'Affiliation': 'Department of Medicine, Division of Pulmonology, Columbia University of Alabama, Orange Beach, Alabama, USA.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Yung', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, California, USA.'}, {'ForeName': 'Marshall', 'Initials': 'M', 'LastName': 'Hertz', 'Affiliation': 'Department of Medicine, Division of Pulmonology, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Chan', 'Affiliation': 'Department of Medicine, Division of Pulmonology, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Morrell', 'Affiliation': 'Department of Medicine, Division of Pulmonology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Hilary', 'Initials': 'H', 'LastName': 'Goldberg', 'Affiliation': ""Harvard Medical School, Department of Medicine, Division of Pulmonology, Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Vedantham', 'Affiliation': 'Clinical Coordinating Center, Washington University School of Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri, USA.'}, {'ForeName': 'Mary Clare', 'Initials': 'MC', 'LastName': 'Derfler', 'Affiliation': 'Clinical Coordinating Center, Washington University School of Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Commean', 'Affiliation': 'Data Coordinating Center, Washington University School of Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Berman', 'Affiliation': 'Health Research Associates, Mountlake Terrace, Washington, USA.'}, {'ForeName': 'Ed', 'Initials': 'E', 'LastName': 'Spitznagel', 'Affiliation': 'Department of Mathematics, Washington University, St. Louis, Missouri, USA.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Atkinson', 'Affiliation': 'Department of Internal Medicine, Division of Pulmonary Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Despotis', 'Affiliation': 'Department of Pathology & Immunology, Division of Laboratory & Genomic Medicine, Department of Anesthesiology, Division of Cardiothoracic Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.'}]","Transfusion medicine (Oxford, England)",['10.1111/tme.12779'] 3098,33870752,Psychosocial Correlates of Meeting National Guidelines for Muscle-Strengthening Activities in Latinas.,"BACKGROUND Performing regular muscle-strengthening activity has numerous health benefits, including improvements in blood pressure, hemoglobin A1c, and lean body mass. Despite the disproportionate prevalence of lifestyle-related chronic disease in Latinas (diabetes, hypertension, obesity), most do not report meeting the national guidelines for muscle-strengthening activity. Existing physical activity (PA) research in Latinas has focused almost exclusively on aerobic PA. Our study examined Latinas' sociodemographic and psychosocial correlates of meeting muscle-strengthening PA guidelines that can inform future PA interventions. METHOD A cross-sectional study of participants ( N = 436) enrolled in a randomized controlled trial promoting PA and cancer screening in Latinas was conducted, and t tests examined the associations between sociodemographic and psychosocial factors with self-reported muscle-strengthening activities. Hierarchical regression was conducted in separate blocks guided by the socioecological model (sociodemographic, individual, and interpersonal factors) to examine the independent contribution of each block to the outcome of meeting national guidelines for muscle-strengthening PA. RESULTS Participants who met the national PA guidelines of ≥2 days/week of muscle-strengthening activities reported significantly higher social support for PA ( p < .001), greater use of behavioral strategies for PA ( p < .001), and lower barriers to PA ( p < .03) than those who did not meet the guidelines. Hierarchical binary logistic regression indicated behavioral strategies for PA was the only significant correlate of meeting the national guidelines for muscle-strengthening PA (odds ratio = 1.39, 95% confidence interval [1.18, 1.65], p < .001). DISCUSSION/CONCLUSION Results support a hypothesis that instructing Latinas to use behavior change strategies could help them increase muscle-strengthening PA.",2021,"Hierarchical binary logistic regression indicated behavioral strategies for PA was the only significant correlate of meeting the national guidelines for muscle-strengthening PA (odds ratio = 1.39, 95% confidence interval [1.18, 1.65], p < .001). ","['Latinas', 'A cross-sectional study of participants ( N = 436']",[],"['blood pressure, hemoglobin A1c, and lean body mass', 'social support for PA']","[{'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}]",[],"[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",436.0,0.0625249,"Hierarchical binary logistic regression indicated behavioral strategies for PA was the only significant correlate of meeting the national guidelines for muscle-strengthening PA (odds ratio = 1.39, 95% confidence interval [1.18, 1.65], p < .001). ","[{'ForeName': 'Tanya J', 'Initials': 'TJ', 'LastName': 'Benitez', 'Affiliation': 'Brown University, Providence, RI, USA.'}, {'ForeName': 'Nanette', 'Initials': 'N', 'LastName': 'Lopez', 'Affiliation': 'Northern Arizona University, Flagstaff, AZ, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Haughton', 'Affiliation': 'San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Bess H', 'Initials': 'BH', 'LastName': 'Marcus', 'Affiliation': 'Brown University, Providence, RI, USA.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Sallis', 'Affiliation': 'University of California, San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Noe', 'Initials': 'N', 'LastName': 'Crespo', 'Affiliation': 'San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Lilian G', 'Initials': 'LG', 'LastName': 'Perez', 'Affiliation': 'RAND Corporation, Santa Monica, CA, USA.'}, {'ForeName': 'Elva M', 'Initials': 'EM', 'LastName': 'Arredondo', 'Affiliation': 'San Diego State University, San Diego, CA, USA.'}]",Health education & behavior : the official publication of the Society for Public Health Education,['10.1177/10901981211005342'] 3099,33908636,Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease.,"Patients in the GEMINI 1 or 2 study (NCT00790933; Eudra CT2008-002784-14) with ulcerative colitis or Crohn disease had low immunogenicity rates after vedolizumab treatment for up to 52 weeks. We report immunogenicity rates from the GEMINI long-term safety (LTS) study using a new drug-tolerant electrochemiluminescence assay, including analyses in patients who received continuous vedolizumab induction and maintenance in GEMINI 1 or 2 and long term safety, or vedolizumab induction and placebo maintenance in GEMINI 1 or 2 followed by re-treatment in long term safety (treatment interruption). Patients were enrolled in GEMINI long term safety from GEMINI 1, 2, or 3, or as de novo vedolizumab-treated patients; all received vedolizumab 300 mg intravenously every 4 weeks. Vedolizumab antidrug antibody (ADA) status was determined by electrochemiluminescence assay; ADA-positive samples were characterized by neutralizing activity. Vedolizumab ADA data were available for 1753 patients: 1513 continuously treated with vedolizumab before/during GEMINI long term safety, 240 re-treated after treatment interruption. Among continuously treated patients, 36 (2.4%) were ADA positive (15 persistently, 20 neutralizing ADA positive). Among re-treated patients, 53 (22.1%) were ADA positive (42 persistently, 40 neutralizing ADA positive). Longitudinal immunogenicity rates increased during placebo maintenance (19.4% at week 52), then decreased in GEMINI long term safety to rates (0 at the final visit) similar to continuously treated patients. ADA positivity was 1.1% vs 2.5% (continuous treatment) and 23.1% vs 22.0% (re-treatment) among patients with and without infusion-related reactions, respectively. Long-term vedolizumab treatment was associated with generally low immunogenicity rates; vedolizumab-re-treated patients had higher rates during placebo maintenance, which decreased during re-treatment. No relationship was observed between immunogenicity and infusion-related reactions.",2021,"ADA positivity was 1.1% versus 2.5% (continuous treatment) and 23.1% versus 22.0% (retreatment) among patients with and without infusion-related reactions, respectively.","['patients who received continuous vedolizumab induction and maintenance in GEMINI 1 or 2 and LTS, or vedolizumab induction and placebo maintenance in GEMINI 1 or 2 then retreatment in LTS (treatment interruption', '1753 patients: 1513 continuously treated with', 'Patients With Inflammatory Bowel Disease', ""002784-14) with ulcerative colitis or Crohn's disease had low immunogenicity rates after vedolizumab treatment for up to 52 weeks""]","['vedolizumab 300 mg intravenously every 4 weeks', 'vedolizumab', 'new drug-tolerant electrochemiluminescence (ECL) assay']","['immunogenicity and infusion-related reactions', 'Vedolizumab antidrug antibody (ADA) status', 'immunogenicity rates', 'ADA-positive', 'Longitudinal immunogenicity rates', 'ADA positivity', 'Vedolizumab Immunogenicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C2742797', 'cui_str': 'vedolizumab'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C4033760', 'cui_str': 'vedolizumab 300 MG [Entyvio]'}, {'cui': 'C1275555', 'cui_str': 'Every four weeks'}, {'cui': 'C2742797', 'cui_str': 'vedolizumab'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}]","[{'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C2742797', 'cui_str': 'vedolizumab'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0741132', 'cui_str': 'Antibody test positive'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}]",,0.0978244,"ADA positivity was 1.1% versus 2.5% (continuous treatment) and 23.1% versus 22.0% (retreatment) among patients with and without infusion-related reactions, respectively.","[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Wyant', 'Affiliation': 'Takeda Development Center Americas Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Takeda Pharmaceuticals International Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Lirio', 'Affiliation': 'Takeda Development Center Americas Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Rosario', 'Affiliation': 'Takeda Development Center Americas Inc., Cambridge, Massachusetts, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1877'] 3100,33908425,Prospective randomized trial of continuous femoral nerve block with posterior capsular injection versus periarticular injection for analgesia in primary total knee arthroplasty.,"Background Femoral nerve block (NB) and periarticular injection (PI) are 2 common options for pain control after total knee arthroplasty (TKA). We performed a prospective triple-blinded randomized trial comparing continuous femoral NB to PI, with follow-up to 1 year. Methods Patients younger than 70 years of age who were scheduled to undergo elective primary TKA under spinal anesthesia between 2009 and 2010 were randomly allocated to receive either continuous femoral NB or PI. Patients in the NB group received ropivacaine through an NB catheter and a sham saline PI. The PI group received a PI of ropivacaine, morphine, ketorolac and epinephrine, and a sham saline infusion via an NB catheter. Both groups had standardized oral analgesia preoperatively, spinal anesthesia and sedation, and postoperative analgesia. Surgeons, anesthesiologists, patients and assessors were blinded to group assignment. Pain was measured twice daily on postoperative days 1 and 2, at rest and with motion, with a numeric rating scale. Patient satisfaction, pain (Oxford Knee Score) and range of motion were assessed at 1 year. Results There were 39 participants in the NB group and 35 participants in the PI group. There were no statistically significant differences between the groups at baseline. Statistically but nonclinically significant reductions in pain scores on postoperative day 2 and in narcotic need on the day of surgery were found in the PI group. Patient-reported satisfaction did not differ at any time point. At 1 year, knee flexion was significantly greater in the NB group than in the PI group (mean range of motion 120° v. 110°, p = 0.03). Conclusion There was no demonstrated improvement in pain control with the use of an NB versus PI when used with multimodal analgesia. Clinicians should opt for the modality that has the best efficiency for their surgical environment. ClinicalTrials.gov # NCT00869037",2021,"At 1 year, knee flexion was significantly greater in the NB group than in the PI group (mean range of motion 120° v. 110°, p = 0.03). ","['Patients younger than 70 years of age who were scheduled to undergo elective primary TKA under spinal anesthesia between 2009 and 2010', 'primary total knee arthroplasty', '39 participants in the NB group and 35 participants in the PI group', 'pain control after total knee arthroplasty (TKA']","['ropivacaine, morphine, ketorolac and epinephrine, and a sham saline infusion via an NB catheter', '\n\n\nFemoral nerve block (NB) and periarticular injection (PI', 'continuous femoral nerve block with posterior capsular injection versus periarticular injection', 'ropivacaine through an NB catheter and a sham saline PI', 'continuous femoral NB or PI', 'continuous femoral NB']","['pain control', 'Pain', 'knee flexion', 'pain scores', 'Patient satisfaction, pain (Oxford Knee Score) and range of motion', 'standardized oral analgesia preoperatively, spinal anesthesia and sedation, and postoperative analgesia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0595695', 'cui_str': 'Periarticular route'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0394739', 'cui_str': 'Local anesthetic femoral nerve block'}, {'cui': 'C0595695', 'cui_str': 'Periarticular route'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0205151', 'cui_str': 'Capsular'}]","[{'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C1997265', 'cui_str': 'Oxford knee score'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}]",,0.133454,"At 1 year, knee flexion was significantly greater in the NB group than in the PI group (mean range of motion 120° v. 110°, p = 0.03). ","[{'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Aragola', 'Affiliation': 'From the Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Turgeon, Bohm); and the Department of Anesthesiology, Perioperative and Pain Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Aragola, Arenson, Tenenbein, Jacobsohn).'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Arenson', 'Affiliation': 'From the Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Turgeon, Bohm); and the Department of Anesthesiology, Perioperative and Pain Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Aragola, Arenson, Tenenbein, Jacobsohn).'}, {'ForeName': 'Marshall', 'Initials': 'M', 'LastName': 'Tenenbein', 'Affiliation': 'From the Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Turgeon, Bohm); and the Department of Anesthesiology, Perioperative and Pain Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Aragola, Arenson, Tenenbein, Jacobsohn).'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Bohm', 'Affiliation': 'From the Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Turgeon, Bohm); and the Department of Anesthesiology, Perioperative and Pain Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Aragola, Arenson, Tenenbein, Jacobsohn).'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Jacobsohn', 'Affiliation': 'From the Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Turgeon, Bohm); and the Department of Anesthesiology, Perioperative and Pain Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Aragola, Arenson, Tenenbein, Jacobsohn).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Turgeon', 'Affiliation': 'From the Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Turgeon, Bohm); and the Department of Anesthesiology, Perioperative and Pain Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Man. (Aragola, Arenson, Tenenbein, Jacobsohn).'}]",Canadian journal of surgery. Journal canadien de chirurgie,['10.1503/cjs.020519'] 3101,33239135,Ginsenoside regulates Treg/Th17 cell ratio and inhibits inflammation to treat COPD.,"Objective: Several studies have suggested an involvement of the immune system in the occurrence and development of chronic obstructive pulmonary disease (COPD), but the mechanism is still unclear. The aim of this study was to explore the mechanism of ginsenoside in inhibiting inflammation by regulating FOXP3 in COPD. Methods : Eighty COPD patients were selected and 35 healthy people were enrolled in the study to determine clinical efficacy, observation index, and SGRQ scores. Percentage of Treg and Th17 cells were detected by flow cytometry; HE staining was used to detect the effect of ginsenoside therapy on pathological changes of COPD in mice. Additionally, we transfected FOXP3 inhibitor; RT-PCR and western blot were used to detect the inflammation related genes and proteins. Results: The basic information of the patients were comparable. The clinical outcome in the treatment group was better than that in the control group, which indicated that ginsenoside has a certain therapeutic effect on COPD patients. The lung function and 6MWT distance results indicated that ginsenoside could stabilize the clinical symptoms of COPD patients and improve their quality of life. Flow cytometry results showed that ginsenoside can increase Treg expression while reducing Th17 cell expression. RT-PCR and western blot results showed that the expression of TNF-α and IL-17 in the model group was significantly increased after treatment, obviously caused by an increased expression of FOXP3. Conclusion: Ginsenoside can inhibit inflammation in COPD by up-regulating FOXP3.",2020,"RT-PCR and western blot results showed that the expression of TNF-α and IL-17 in the model group was significantly increased after treatment, obviously caused by an increased expression of FOXP3. ",['Eighty COPD patients were selected and 35 healthy people'],['ginsenoside therapy'],"['expression of TNF-α and IL-17', 'quality of life', 'clinical efficacy, observation index, and SGRQ scores', 'expression of FOXP3']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0061278', 'cui_str': 'Panaxosides'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",80.0,0.0402632,"RT-PCR and western blot results showed that the expression of TNF-α and IL-17 in the model group was significantly increased after treatment, obviously caused by an increased expression of FOXP3. ","[{'ForeName': 'Yan-Qiu', 'Initials': 'YQ', 'LastName': 'Xu', 'Affiliation': 'The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China; Department of Pneumology, Jiangning District Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Lv', 'Affiliation': 'Department of Pneumology, Jiangning District Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.'}, {'ForeName': 'Hong-Juan', 'Initials': 'HJ', 'LastName': 'Wu', 'Affiliation': 'Department of Pneumology, Jiangning District Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.'}, {'ForeName': 'Suo -Fang', 'Initials': 'S-', 'LastName': 'Shi', 'Affiliation': 'Department of Pneumology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China;, Email: jssssf2006@163.com.'}]",Die Pharmazie,['10.1691/ph.2020.0696'] 3102,33910604,Correction to: IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study.,,2021,,['stage I/II breast cancer'],['IOERT versus external beam electrons'],[],"[{'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0013840', 'cui_str': 'Electron beam'}]",[],,0.0610461,,"[{'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Ciabattoni', 'Affiliation': 'Department of Radiotherapy, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Gregucci', 'Affiliation': 'Department of Radiation Oncology, Miulli General Regional Hospital, Acquaviva delle Fonti, Bari, Italy. fabianagregucci@gmail.com.'}, {'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Fastner', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria.'}, {'ForeName': 'Silvio', 'Initials': 'S', 'LastName': 'Cavuto', 'Affiliation': 'Infrastructure Research and Statistics, Clinical Trials and Statistics Unit, AUSL-IRCCS, Reggio Emilia, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Spera', 'Affiliation': 'Department of Radiotherapy, San Giovanni di Dio Hospital, ASP Agrigento, Agrigento, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Drago', 'Affiliation': 'Department of Breast and Reconstructive Surgery, Sando Pertini Hospital, Rome, Italy.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Ziegler', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria.'}, {'ForeName': 'Maria Alessandra', 'Initials': 'MA', 'LastName': 'Mirri', 'Affiliation': 'Department of Radiotherapy, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Consorti', 'Affiliation': 'Medical Physics Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Sedlmayer', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria.'}]",Breast cancer research : BCR,['10.1186/s13058-021-01432-9'] 3103,32233043,Parental Wartime Deployment and Socioemotional Adjustment in Early Childhood: The Critical Role of Military Parents' Perceived Threat During Deployment.,"Infants, toddlers, and preschool-aged children have unique developmental needs that render them vulnerable to challenges associated with parental military service. We used a sample of military-connected families with 3-6-year-old children (N = 104) to examine associations among children's socioemotional development and fathers' trauma-related deployment experiences, including perceived threat during deployment and exposure to combat and the aftermath of battle. Of these potential stressors, only paternal perceived threat during deployment was significantly associated with measures of mother-reported child adjustment. Fathers' perceived threat during deployment was associated with child behavior problems even after accounting for demographic variables and current paternal symptoms of posttraumatic stress, depression, and anxiety, β = .36, p = .007. The association between fathers' perceived threat during deployment and child behavior problems was mediated by several family processes related to emotion socialization, including father-reported sensitive parenting, indirect effect (IE) B = 0.106, 95% CI [0.009, 0.236]; parent-child dysfunctional interaction, IE B = 0.119, 95% CI [0.014, 0.252]; and mother-reported family emotional responsiveness, IE B = 0.119, 95% CI [0.011, 0.258]. Implications for future research on the intergenerational transmission of traumatic stress as well as prevention and intervention efforts for military-connected families with young children are discussed.",2020,"The association between fathers' perceived threat during deployment and child behavior problems was mediated by several family processes related to emotion socialization, including father-reported sensitive parenting, indirect effect (IE) B = 0.106, 95% CI [0.009, 0.236]; parent-child dysfunctional interaction, IE B = 0.119, 95% CI [0.014, 0.252]; and mother-reported family emotional responsiveness, IE B = 0.119, 95% CI [0.011, 0.258].","[""sample of military-connected families with 3-6-year-old children (N = 104) to examine associations among children's socioemotional development and fathers' trauma-related deployment experiences, including perceived threat during deployment and exposure to combat and the aftermath of battle"", 'Infants, toddlers, and preschool-aged children', 'military-connected families with young children', 'Early Childhood']",[],[],"[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0442759', 'cui_str': '3/6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0015671', 'cui_str': 'Father'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0557345', 'cui_str': 'Exposure to combat'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0557118', 'cui_str': 'Family with young children'}, {'cui': 'C0599196', 'cui_str': 'Early childhood'}]",[],[],,0.0917886,"The association between fathers' perceived threat during deployment and child behavior problems was mediated by several family processes related to emotion socialization, including father-reported sensitive parenting, indirect effect (IE) B = 0.106, 95% CI [0.009, 0.236]; parent-child dysfunctional interaction, IE B = 0.119, 95% CI [0.014, 0.252]; and mother-reported family emotional responsiveness, IE B = 0.119, 95% CI [0.011, 0.258].","[{'ForeName': 'Nastassia J', 'Initials': 'NJ', 'LastName': 'Hajal', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Jane and Terry , Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Hilary J', 'Initials': 'HJ', 'LastName': 'Aralis', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Jane and Terry , Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Cara J', 'Initials': 'CJ', 'LastName': 'Kiff', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Jane and Terry , Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Melissa M', 'Initials': 'MM', 'LastName': 'Wasserman', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Jane and Terry , Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Blair', 'Initials': 'B', 'LastName': 'Paley', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Jane and Terry , Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Norweeta G', 'Initials': 'NG', 'LastName': 'Milburn', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Jane and Terry , Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Mogil', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Jane and Terry , Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Lester', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Jane and Terry , Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.'}]",Journal of traumatic stress,['10.1002/jts.22475'] 3104,33914991,Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.,"BACKGROUND Abemaciclib is a CDK4/6 inhibitor used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The prognostic value of patient-reported outcomes (PROs) has been minimally explored for treatment outcomes with CDK4/6 inhibitors. The performance of PROs compared with Eastern Cooperative Oncology Group performance status (ECOG-PS) is unknown. MATERIALS AND METHODS This study pooled data from single-arm trial, MONARCH 1, and randomized trials, MONARCH 2 and 3. In total, 900 patients initiated abemaciclib and 384 comparator therapy. Pretreatment PRO association with progression-free survival (PFS) was modeled using Cox proportional hazards regression. Prediction performance was assessed via the C-statistic (c). PROs were recorded via the European Organisation for Research and Treatment of Cancer QLQ-C30. RESULTS Patient-reported physical function, pain, role function, fatigue, and appetite loss were associated with PFS on univariable and adjusted analysis (p < .05). Physical function (c = 0.55) was most predictive, superior to ECOG-PS (c = 0.54), with multivariable analysis indicating both provide independent information (p < .02). In the pooled randomized arms of MONARCH 2 and 3, the PFS treatment benefit (hazard ratio [95% confidence interval]) of abemaciclib (vs. comparators) was 0.75 (0.57-1.0) for low physical function, compared with 0.48 (0.40-0.59) for intermediate/high (p[interaction] = .01). CONCLUSION PROs were identified as prognostic factors for PFS in patients initiating abemaciclib, with patient-reported physical function containing independent predictive information beyond ECOG-PS. Low physical function was associated with a decrease in the magnitude of PFS benefit from abemaciclib. PROs should be explored as prognostic, predictive, and stratification factors for clinical use and research trials of CDK4/6 inhibitors. IMPLICATIONS FOR PRACTICE For the first time, pretreatment patient-reported outcomes have been shown to be independent prognostic markers for progression-free survival (PFS) in patients diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer treated with abemaciclib. Importantly, patients with low physical function had a smaller PFS benefit from abemaciclib (vs. comparator) than patients with intermediate/high physical function. The present study demonstrates patient-reported outcomes as a simple, effective, inexpensive, and independent prognostic marker for patients with HR+/HER2- advanced breast cancer treated with abemaciclib.",2021,"RESULTS Patient-reported physical function, pain, role function, fatigue and appetite loss were associated with PFS on univariable and adjusted analysis (P<0.05).","['patients diagnosed with HR+/HER2- advanced breast cancer treated with abemaciclib', '900 patients initiated abemaciclib and 384 comparator therapy', 'HR+/HER2- ABC patients treated with abemaciclib', 'patients with advanced breast cancer treated with abemaciclib']",['MONARCH'],"['Low physical function', 'Pre-treatment PRO association with progression-free survival (PFS', 'Physical function', 'physical function, pain, role function, fatigue and appetite loss']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C3852841', 'cui_str': 'abemaciclib'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],"[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}]",900.0,0.128322,"RESULTS Patient-reported physical function, pain, role function, fatigue and appetite loss were associated with PFS on univariable and adjusted analysis (P<0.05).","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Badaoui', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, Australia.'}, {'ForeName': 'Ganessan', 'Initials': 'G', 'LastName': 'Kichenadasse', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Rowland', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, Australia.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Sorich', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, Australia.'}, {'ForeName': 'Ashley M', 'Initials': 'AM', 'LastName': 'Hopkins', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, Australia.'}]",The oncologist,['10.1002/onco.13806'] 3105,33929522,Effects of a Technology-Assisted Integrated Diabetes Care Program on Cardiometabolic Risk Factors Among Patients With Type 2 Diabetes in the Asia-Pacific Region: The JADE Program Randomized Clinical Trial.,"Importance Many health care systems lack the efficiency, preparedness, or resources needed to address the increasing number of patients with type 2 diabetes, especially in low- and middle-income countries. Objective To examine the effects of a quality improvement intervention comprising information and communications technology and contact with nonphysician personnel on the care and cardiometabolic risk factors of patients with type 2 diabetes in 8 Asia-Pacific countries. Design, Setting, and Participants This 12-month multinational open-label randomized clinical trial was conducted from June 28, 2012, to April 28, 2016, at 50 primary care or hospital-based diabetes centers in 8 Asia-Pacific countries (India, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam). Six countries were low and middle income, and 2 countries were high income. The study was conducted in 2 phases; phase 1 enrolled 7537 participants, and phase 2 enrolled 13 297 participants. Participants in both phases were randomized on a 1:1 ratio to intervention or control groups. Data were analyzed by intention to treat and per protocol from July 3, 2019, to July 21, 2020. Interventions In both phases, the intervention group received 3 care components: a nurse-led Joint Asia Diabetes Evaluation (JADE) technology-guided structured evaluation, automated personalized reports to encourage patient empowerment, and 2 or more telephone or face-to-face contacts by nurses to increase patient engagement. In phase 1, the control group received the JADE technology-guided structured evaluation and automated personalized reports. In phase 2, the control group received the JADE technology-guided structured evaluation only. Main Outcomes and Measures The primary outcome was the incidence of a composite of diabetes-associated end points, including cardiovascular disease, chronic kidney disease, visual impairment or eye surgery, lower extremity amputation or foot ulcers requiring hospitalization, all-site cancers, and death. The secondary outcomes were the attainment of 2 or more primary diabetes-associated targets (glycated hemoglobin A1c <7.0%, blood pressure <130/80 mm Hg, and low-density lipoprotein cholesterol <100 mg/dL) and/or 2 or more key performance indices (reduction in glycated hemoglobin A1c≥0.5%, reduction in systolic blood pressure ≥5 mm Hg, reduction in low-density lipoprotein cholesterol ≥19 mg/dL, and reduction in body weight ≥3.0%). Results A total of 20 834 patients with type 2 diabetes were randomized in phases 1 and 2. In phase 1, 7537 participants (mean [SD] age, 60.0 [11.3] years; 3914 men [51.9%]; 4855 patients [64.4%] from low- and middle-income countries) were randomized, with 3732 patients allocated to the intervention group and 3805 patients allocated to the control group. In phase 2, 13 297 participants (mean [SD] age, 54.0 [11.1] years; 7754 men [58.3%]; 13 297 patients [100%] from low- and middle-income countries) were randomized, with 6645 patients allocated to the intervention group and 6652 patients allocated to the control group. In phase 1, compared with the control group, the intervention group had a similar risk of experiencing any of the primary outcomes (odds ratio [OR], 0.94; 95% CI, 0.74-1.21) but had an increased likelihood of attaining 2 or more primary targets (OR, 1.34; 95% CI, 1.21-1.49) and 2 or more key performance indices (OR, 1.18; 95% CI, 1.04-1.34). In phase 2, the intervention group also had a similar risk of experiencing any of the primary outcomes (OR, 1.02; 95% CI, 0.83-1.25) and had a greater likelihood of attaining 2 or more primary targets (OR, 1.25; 95% CI, 1.14-1.37) and 2 or more key performance indices (OR, 1.50; 95% CI, 1.33-1.68) compared with the control group. For attainment of 2 or more primary targets, larger effects were observed among patients in low- and middle-income countries (OR, 1.50; 95% CI, 1.29-1.74) compared with high-income countries (OR, 1.20; 95% CI, 1.03-1.39) (P = .04). Conclusions and Relevance In this 12-month clinical trial, the use of information and communications technology and nurses to empower and engage patients did not change the number of clinical events but did reduce cardiometabolic risk factors among patients with type 2 diabetes, especially those in low- and middle-income countries in the Asia-Pacific region. Trial Registration ClinicalTrials.gov Identifier: NCT01631084.",2021,"For attainment of 2 or more primary targets, larger effects were observed among patients in low- and middle-income countries (OR, 1.50; 95% CI, 1.29-1.74) compared with high-income countries (OR, 1.20; 95% CI, 1.03-1.39) (P = .04). ","['7537 participants (mean [SD] age, 60.0 [11.3] years; 3914 men [51.9%]; 4855 patients [64.4%] from low- and middle-income countries) were randomized, with 3732 patients allocated to the intervention group and 3805 patients allocated to the control group', 'June 28, 2012, to April 28, 2016, at 50 primary care or hospital-based diabetes centers in 8 Asia-Pacific countries (India, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam', '13 297 participants (mean [SD] age, 54.0 [11.1] years; 7754 men [58.3%]; 13 297 patients [100%] from low- and middle-income countries) were randomized, with 6645 patients allocated to the intervention group and 6652 patients allocated to the control group', 'A total of 20\u202f834 patients with type 2 diabetes', 'patients with type 2 diabetes, especially those in low- and middle-income countries in the Asia-Pacific region', 'patients with type 2 diabetes in 8 Asia-Pacific countries', 'Patients With Type 2 Diabetes in the Asia-Pacific Region', '2 phases; phase 1 enrolled 7537 participants, and phase 2 enrolled 13 297 participants']","['JADE technology-guided structured evaluation and automated personalized reports', 'Technology-Assisted Integrated Diabetes Care Program', 'JADE technology-guided structured evaluation only', 'quality improvement intervention comprising information and communications technology and contact with nonphysician personnel', '3 care components: a nurse-led Joint Asia Diabetes Evaluation (JADE) technology-guided structured evaluation, automated personalized reports to encourage patient empowerment, and 2 or more telephone or face-to-face contacts by nurses to increase patient engagement']","['attainment of 2 or more primary diabetes-associated targets (glycated hemoglobin A1c <7.0%, blood pressure <130/80 mm Hg, and low-density lipoprotein cholesterol', 'systolic blood pressure ≥5 mm Hg, reduction in low-density lipoprotein cholesterol ≥19 mg/dL, and reduction in body weight ≥3.0', 'cardiometabolic risk factors', 'incidence of a composite of diabetes-associated end points, including cardiovascular disease, chronic kidney disease, visual impairment or eye surgery, lower extremity amputation or foot ulcers requiring hospitalization, all-site cancers, and death', 'Cardiometabolic Risk Factors']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}, {'cui': 'C0042658', 'cui_str': 'Vietnam'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439560', 'cui_str': 'Phase 2'}, {'cui': 'C0439559', 'cui_str': 'Phase 1'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}]","[{'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C2936612', 'cui_str': 'Quality Improvement'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0683867', 'cui_str': 'Information Technology'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C3853035', 'cui_str': 'Patient Empowerment'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C3508152', 'cui_str': 'Patient Engagement'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0042798', 'cui_str': 'Dim vision'}, {'cui': 'C0038901', 'cui_str': 'Ophthalmologic Surgical Procedure'}, {'cui': 'C0337308', 'cui_str': 'Amputation of lower limb'}, {'cui': 'C0085119', 'cui_str': 'Ulcer of foot'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",20834.0,0.189233,"For attainment of 2 or more primary targets, larger effects were observed among patients in low- and middle-income countries (OR, 1.50; 95% CI, 1.29-1.74) compared with high-income countries (OR, 1.20; 95% CI, 1.03-1.39) (P = .04). ","[{'ForeName': 'Lee-Ling', 'Initials': 'LL', 'LastName': 'Lim', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Eric S H', 'Initials': 'ESH', 'LastName': 'Lau', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Amy W C', 'Initials': 'AWC', 'LastName': 'Fu', 'Affiliation': 'Asia Diabetes Foundation, Shatin, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Subir', 'Initials': 'S', 'LastName': 'Ray', 'Affiliation': 'Relief Polyclinic, Hoogly, India.'}, {'ForeName': 'Yi-Jen', 'Initials': 'YJ', 'LastName': 'Hung', 'Affiliation': 'Tri-Service General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Alexander T B', 'Initials': 'ATB', 'LastName': 'Tan', 'Affiliation': 'Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Parinya', 'Initials': 'P', 'LastName': 'Chamnan', 'Affiliation': 'Sanpasitthiprasong Hospital, Ubon Ratchathani, Thailand.'}, {'ForeName': 'Wayne H H', 'Initials': 'WHH', 'LastName': 'Sheu', 'Affiliation': 'Taichung Veterans General Hospital, Taichung, Taiwan.'}, {'ForeName': 'Manoj S', 'Initials': 'MS', 'LastName': 'Chawla', 'Affiliation': 'Lina Diabetes Care Centre, Mumbai, India.'}, {'ForeName': 'Yook-Chin', 'Initials': 'YC', 'LastName': 'Chia', 'Affiliation': 'Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Lee-Ming', 'Initials': 'LM', 'LastName': 'Chuang', 'Affiliation': 'National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Duc-Cong', 'Initials': 'DC', 'LastName': 'Nguyen', 'Affiliation': 'Thong Nhat Hospital, Ho Chi Minh, Vietnam.'}, {'ForeName': 'Aravind', 'Initials': 'A', 'LastName': 'Sosale', 'Affiliation': 'Diacon Hospital, Bangalore, India.'}, {'ForeName': 'Banshi D', 'Initials': 'BD', 'LastName': 'Saboo', 'Affiliation': 'Dia Care-Diabetes Care and Hormone Clinic, Gujarat, India.'}, {'ForeName': 'Uday', 'Initials': 'U', 'LastName': 'Phadke', 'Affiliation': 'Instride, Pune, India.'}, {'ForeName': 'Jothydev', 'Initials': 'J', 'LastName': 'Kesavadev', 'Affiliation': ""Jothydev's Diabetes and Research Center, Kerala, India.""}, {'ForeName': 'Su-Yen', 'Initials': 'SY', 'LastName': 'Goh', 'Affiliation': 'Department of Endocrinology, Singapore General Hospital, Outram Road, Singapore.'}, {'ForeName': 'Neeru', 'Initials': 'N', 'LastName': 'Gera', 'Affiliation': 'Max Healthcare Institute, New Delhi, India.'}, {'ForeName': 'Thi Thanh', 'Initials': 'TT', 'LastName': 'Huyen Vu', 'Affiliation': 'Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam.'}, {'ForeName': 'Ronald C W', 'Initials': 'RCW', 'LastName': 'Ma', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Lau', 'Affiliation': 'Asia Diabetes Foundation, Shatin, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Andrea O Y', 'Initials': 'AOY', 'LastName': 'Luk', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Alice P S', 'Initials': 'APS', 'LastName': 'Kong', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Juliana C N', 'Initials': 'JCN', 'LastName': 'Chan', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA network open,['10.1001/jamanetworkopen.2021.7557'] 3106,33927638,Effects of Whole Body Electrostimulation Associated With Body Weight Training on Functional Capacity and Body Composition in Inactive Older People.,"Objective: To analyze the effects of whole body electrostimulation (WB-EMS) with body weight training on functional fitness and body composition of older men. Methods: Twenty physically inactive older men were randomized into: Control group (control), performed the body weight exercise training wearing electrostimulation clothing, but without receiving electrical current stimuli ( n = 10), and body weight associated with whole body electrostimulation group (BW+WB-EMS), performed the body weight exercise training wearing electrostimulation clothing plus whole body electrostimulation ( n = 10). The training sessions were performed twice a week for 6 weeks and included eight exercises using body weight, performed in two sets of eight repetitions. Physical function was assessed using a battery composed of seven tests, six derived from the Senior fitness test and a handgrip strength test. We also measured the muscle thickness (MT) of the biceps and triceps brachii and vastus lateralis. Results: The BW+WB-EMS group presented increased ( p < 0.05) performance in the 30-s chair stand test (10.2 ± 3.3 vs. 13.8 ± 5.0 reps), arm curl (16.6 ± 3.9 vs. 19.9 ± 6.1 reps), 6-min walk test (402 ± 96 vs. 500 ± 104 m), and handgrip strength test (30 ± 11 vs. 32 ± 11 kgf). The BW+WB-EMS group also presented increased MT ( p < 0.05) in the biceps brachii (17.7 ± 3.0 vs. 21.4 ± 3.4 mm), triceps brachial (14.7 ± 3.6 vs. 17.5 ± 4.1 mm), and vastus lateralis muscles (15.1 ± 2.6 vs. 18.6 ± 4.3 mm). Moderate correlations were found in arm curl ( p = 0.011, r = 0.552) but not handgrip strength ( p = 0.053, r = 0.439) with changes in the biceps MT. Moderate changes in the 6-min walk distance were significantly correlated with changes in vastus lateralis MT ( p = 0.036, r = 0.471). There was a moderate correlation between the changes in the 30-s chair stand test ( p = 0.006, r = 0.589) and changes in the vastus lateralis MT. Furthermore, although a moderate correlation ( r = 0.438) was found between triceps MT and handgrip strength no significant difference ( p = 0.053) was reported. Additionally, there were no statistical differences in any parameters for the control group. Conclusion: WB-EMS with body weight training increased functional fitness and MT in physically inactive older men.",2021,"There was a moderate correlation between the changes in the 30-s chair stand test ( p = 0.006, r = 0.589) and changes in the vastus lateralis MT.","['Inactive Older People', 'physically inactive older men', 'Twenty physically inactive older men', 'older men']","['Whole Body Electrostimulation', 'Body Weight Training', 'WB-EMS with body weight training', 'whole body electrostimulation (WB-EMS) with body weight training', 'Control group (control), performed the body weight exercise training wearing electrostimulation clothing, but without receiving electrical current stimuli ( n = 10), and body weight associated with whole body electrostimulation group (BW+WB-EMS), performed the body weight exercise training wearing electrostimulation clothing plus whole body electrostimulation']","['functional fitness and body composition', 'muscle thickness (MT) of the biceps and triceps brachii and vastus lateralis', 'triceps MT and handgrip strength', 'handgrip strength', '6-min walk distance', 'functional fitness and MT', 'Physical function', 'Functional Capacity and Body Composition']","[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0009072', 'cui_str': 'Garments'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}]",20.0,0.00542058,"There was a moderate correlation between the changes in the 30-s chair stand test ( p = 0.006, r = 0.589) and changes in the vastus lateralis MT.","[{'ForeName': 'Alexandre Lopes', 'Initials': 'AL', 'LastName': 'Evangelista', 'Affiliation': 'Laboratório de Fisiologia e Bioquímica Experimental, Centro de Educação Física e Esporte, Universidade Federal do Espirito Santo, Vitoria, Brazil.'}, {'ForeName': 'Angelica Castilho', 'Initials': 'AC', 'LastName': 'Alonso', 'Affiliation': 'Programa de Mestrado Ciências do Envelhecimento, Universidade São Judas Tadeu, São Paulo, Brazil.'}, {'ForeName': 'Raphael M', 'Initials': 'RM', 'LastName': 'Ritti-Dias', 'Affiliation': 'Programa de Pós-graduação em ciências da reabilitação, Universidade Nove de Julho, São Paulo, Brazil.'}, {'ForeName': 'Bruna Massaroto', 'Initials': 'BM', 'LastName': 'Barros', 'Affiliation': 'Programa de Pós-graduação em ciências da reabilitação, Universidade Nove de Julho, São Paulo, Brazil.'}, {'ForeName': 'Cleison Rodrigues', 'Initials': 'CR', 'LastName': 'de Souza', 'Affiliation': 'Laboratório de Fisiologia e Bioquímica Experimental, Centro de Educação Física e Esporte, Universidade Federal do Espirito Santo, Vitoria, Brazil.'}, {'ForeName': 'Tiago Volpi', 'Initials': 'TV', 'LastName': 'Braz', 'Affiliation': 'Laboratório de Avaliação do Movimento Humano, Universidade Metodista de Piracicaba, Piracicaba, Brazil.'}, {'ForeName': 'Danilo Sales', 'Initials': 'DS', 'LastName': 'Bocalini', 'Affiliation': 'Laboratório de Fisiologia e Bioquímica Experimental, Centro de Educação Física e Esporte, Universidade Federal do Espirito Santo, Vitoria, Brazil.'}, {'ForeName': ""Julia Maria D'andréa"", 'Initials': 'JMD', 'LastName': 'Greve', 'Affiliation': 'Departamento de Ortopedia e Traumatologia, Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil.'}]",Frontiers in physiology,['10.3389/fphys.2021.638936'] 3107,33932507,"A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.","BACKGROUND The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced soft tissue sarcoma (STS). PATIENTS AND METHODS This randomized, multicenter, open-label, phase III study included adults with STS who progressed after 1-3 prior treatment lines. Patients were randomized (1 : 1) to receive trabectedin 1.5 mg/m 2 every 3 weeks or BSC, stratified into L-STS (liposarcoma/leiomyosarcoma) and non-L-STS groups (other histotypes). Patients from the BSC arm were allowed to cross over to trabectedin at progression. The primary efficacy endpoint was progression-free survival (PFS) confirmed by blinded central review and analyzed in the intention-to-treat population. RESULTS Between 26 January 2015 and 5 November 2015, 103 heavily pre-treated patients (60.2% with L-STS) from 16 French centers were allocated to receive trabectedin (n = 52) or BSC (n = 51). Median PFS was 3.1 months [95% confidence interval (CI) 1.8-5.9 months] in the trabectedin arm versus 1.5 months (0.9-2.6 months) in the BSC arm (hazard ratio = 0.39, 95% CI 0.24-0.64, P < 0.001) with benefits observed across almost all analyzed subgroups, but particularly in patients with L-STS (5.1 versus 1.4 months, P = 0.0001). Seven patients (13.7%) in the trabectedin arm (all with L-STS) achieved a partial response, while no objective responses were observed in the BSC arm (P = 0.004). The most common grade 3/4 adverse events were neutropenia (44.2% of patients), leukopenia (34.6%), and transaminase increase (32.7%). Health-related 30-item core European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire evidenced no statistical differences between the arms for any domain and at any time point. After progression, 91.8% of patients crossed over from BSC to trabectedin. CONCLUSION Trabectedin demonstrates superior disease control to BSC without impairing QoL in patients with recurrent STS of multiple histologies, with greater impact in patients with L-STS.",2021,Health-related EORTC QLQ-C30 QoL questionnaires evidenced no statistical differences between the arms for any domain and at any time point.,"['Between Jan 26, 2015, and Nov 5, 2015, 103 heavily pretreated patients (60.2% with L-STS) from 16 French centers', 'patients with advanced soft-tissue sarcoma (STS', 'patients with pre-treated soft tissue sarcoma', 'adults with STS who progressed after 1-3 prior treatment lines']","['trabectedin', 'trabectedin 1.5 mg/m 2 every three weeks or BSC, stratified into L-STS (lipo/leiomyosarcoma) and non-L-STS groups (other histotypes', 'BSC']","['Health-related EORTC QLQ-C30 QoL questionnaires', 'leukopenia', 'intention-to-treat population', 'progression-free survival (PFS', 'efficacy, safety, and quality of life (QoL) of trabectedin vs best supportive care (BSC', 'partial response', 'Median PFS', 'neutropenia']","[{'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1261473', 'cui_str': 'Sarcoma'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205132', 'cui_str': 'Linear'}]","[{'cui': 'C1311070', 'cui_str': 'trabectedin'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0585333', 'cui_str': 'Triweekly'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0344211', 'cui_str': 'Support'}, {'cui': 'C1261473', 'cui_str': 'Sarcoma'}, {'cui': 'C0122111', 'cui_str': 'HMGI-C Protein'}, {'cui': 'C0023269', 'cui_str': 'Leiomyosarcoma'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449574', 'cui_str': 'Histologic type'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1311070', 'cui_str': 'trabectedin'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0344211', 'cui_str': 'Support'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}]",103.0,0.0873214,Health-related EORTC QLQ-C30 QoL questionnaires evidenced no statistical differences between the arms for any domain and at any time point.,"[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Le Cesne', 'Affiliation': 'Medical Oncology Department, Gustave Roussy, Villejuif, France. Electronic address: axel.lecesne@gustaveroussy.fr.'}, {'ForeName': 'J-Y', 'Initials': 'JY', 'LastName': 'Blay', 'Affiliation': 'Medical Oncology Department, Centre Léon Bérard and Claude Bernard University, Lyon, France.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cupissol', 'Affiliation': ""Medical Oncology Department, Centre Val d'Aurelle, Montpellier, France.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Italiano', 'Affiliation': 'Medical Oncology Department, Institut Bergonié, Bordeaux, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Delcambre', 'Affiliation': 'Medical Oncology Department, Centre François Baclesse, Caen, France.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Penel', 'Affiliation': 'Medical Oncology Department, Centre Oscar Lambret and Lille University, Lille, France.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Isambert', 'Affiliation': 'Medical Oncology Department, Centre Georges-François Leclerc, Dijon, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Chevreau', 'Affiliation': 'Medical Oncology Department, Institut Claudius Regaud, Toulouse, France.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Bompas', 'Affiliation': 'Medical Oncology Department, Centre René Gauduchau, Nantes, France.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Bertucci', 'Affiliation': 'Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Chaigneau', 'Affiliation': 'Medical Oncology Department, Hôpital Jean Minjoz, Besancon, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Piperno-Neumann', 'Affiliation': 'Medical Oncology Department, Insitut Curie, Paris, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Salas', 'Affiliation': 'Medical Oncology Department, Hôpital La Timone, Marseille, France.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rios', 'Affiliation': 'Medical Oncology Department, Institut de Cancerologie de Lorraine, Nancy, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Guillemet', 'Affiliation': 'Medical Oncology Department, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'J-O', 'Initials': 'JO', 'LastName': 'Bay', 'Affiliation': 'Medical Oncology Department, Centre Jean Perrin, Clermont Ferrand, France.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Ray-Coquard', 'Affiliation': 'Medical Oncology Department, Centre Léon Bérard and Claude Bernard University, Lyon, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Haddag', 'Affiliation': 'Department of Radiology, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bonastre', 'Affiliation': 'Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Kapso', 'Affiliation': 'Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Fraslin', 'Affiliation': 'Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Bouvet', 'Affiliation': 'Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Mir', 'Affiliation': 'Medical Oncology Department, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Foulon', 'Affiliation': 'Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.04.014'] 3108,33932503,Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.,"BACKGROUND In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recurrence or death with adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab. Here, we present additional exploratory safety and efficacy analyses. PATIENTS AND METHODS KATHERINE enrolled HER2-positive EBC patients with residual invasive disease in the breast/axilla at surgery after NACT containing a taxane (± anthracycline, ± platinum) and trastuzumab (± pertuzumab). Patients were randomized to adjuvant T-DM1 (n = 743) or trastuzumab (n = 743) for 14 cycles. The primary endpoint was invasive disease-free survival (IDFS). RESULTS The incidence of peripheral neuropathy (PN) was similar regardless of neoadjuvant taxane type. Irrespective of treatment arm, baseline PN was associated with longer PN duration (median, 105-109 days longer) and lower resolution rate (∼65% versus ∼82%). Prior platinum therapy was associated with more grade 3-4 thrombocytopenia in the T-DM1 arm (13.5% versus 3.8%), but there was no grade ≥3 hemorrhage in these patients. Risk of recurrence or death was decreased with T-DM1 versus trastuzumab in patients who received anthracycline-based NACT [hazard ratio (HR) = 0.51; 95% confidence interval (CI): 0.38-0.67], non-anthracycline-based NACT (HR = 0.43; 95% CI: 0.22-0.82), presented with cT1, cN0 tumors (0 versus 6 IDFS events), or had particularly high-risk tumors (HRs ranged from 0.43 to 0.72). The central nervous system (CNS) was more often the site of first recurrence in the T-DM1 arm (5.9% versus 4.3%), but T-DM1 was not associated with a difference in overall risk of CNS recurrence. CONCLUSIONS T-DM1 provides clinical benefit across patient subgroups, including small tumors and particularly high-risk tumors and does not increase the overall risk of CNS recurrence. NACT type had a minimal impact on safety.",2021,"Irrespective of treatment arm, baseline peripheral neuropathy was associated with longer peripheral neuropathy duration (median, 105-109 days longer) and lower resolution rate (∼65% versus ∼82%).","['Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer', 'enrolled HER2-positive EBC patients with residual invasive disease in the breast/axilla at surgery after NACT containing a', 'patients with residual invasive early breast cancer (EBC) after']","['taxane (±anthracycline, ±platinum) and trastuzumab (±pertuzumab', 'trastuzumab', 'Adjuvant T-DM1 versus Trastuzumab', 'anthracycline-based NACT', 'neoadjuvant chemotherapy (NACT) plus HER2-targeted therapy', 'adjuvant T-DM1']","['Risk of recurrence or death', 'grade ≥3 hemorrhage', 'incidence of peripheral neuropathy', 'safety', 'invasive disease-free survival (IDFS', 'resolution rate', 'risk of recurrence or death', 'overall risk of CNS recurrence', 'grade 3-4 thrombocytopenia', 'peripheral neuropathy duration', 'central nervous system (CNS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C1960398', 'cui_str': 'HER2-positive carcinoma of breast'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0004454', 'cui_str': 'Axillary'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0215136', 'cui_str': 'taxane'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C2935436', 'cui_str': 'ado-trastuzumab emtansine'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",,0.190662,"Irrespective of treatment arm, baseline peripheral neuropathy was associated with longer peripheral neuropathy duration (median, 105-109 days longer) and lower resolution rate (∼65% versus ∼82%).","[{'ForeName': 'E P', 'Initials': 'EP', 'LastName': 'Mamounas', 'Affiliation': 'NSABP Foundation and; Department of Surgery, Orlando Health UF Health Cancer Center, Orlando, USA. Electronic address: terry.mamounas@orlandohealth.com.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Untch', 'Affiliation': 'AGO-B and Department of Gynecologic Oncology, HELIOS Klinikum Berlin Buch, Berlin, Germany.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Mano', 'Affiliation': 'Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'C-S', 'Initials': 'CS', 'LastName': 'Huang', 'Affiliation': 'Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'C E', 'Initials': 'CE', 'LastName': 'Geyer', 'Affiliation': 'NSABP Foundation and; NSABP Foundation and Department of Internal Medicine, Division of Hematology and Medical Oncology, Houston Methodist Cancer Center, Houston, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'von Minckwitz', 'Affiliation': 'GBG, Neu-Isenburg, Germany.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Wolmark', 'Affiliation': 'NSABP Foundation and; NSABP Foundation and Department of Surgery, The University of Pittsburgh, Pittsburgh, USA.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Pivot', 'Affiliation': 'ICANS, Strasbourg, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kuemmel', 'Affiliation': 'Breast Unit Kliniken Essen-Mitte, Essen, Germany; Klinik für Gynäkologie mit Brustzentrum Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'M P', 'Initials': 'MP', 'LastName': 'DiGiovanna', 'Affiliation': 'Yale University School of Medicine, Yale Cancer Center and Smilow Cancer Hospital, New Haven, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Kaufman', 'Affiliation': 'Oncology Division, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Kunz', 'Affiliation': 'GBG, Neu-Isenburg, Germany; St. Johannes Hospital Dortmund, Dortmund, Germany.'}, {'ForeName': 'A K', 'Initials': 'AK', 'LastName': 'Conlin', 'Affiliation': 'NSABP Foundation and; NSABP Foundation and Department of Medical Oncology, Providence Cancer Institute, Portland, USA.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Alcedo', 'Affiliation': 'Department of Clinical Oncology, Centro Hemato Oncologico, Panama City, Panama.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Kuehn', 'Affiliation': 'AGO-B and Klinikum Esslingen, Esslingen, Germany.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Wapnir', 'Affiliation': 'NSABP Foundation and; NSABP Foundation and Stanford University School of Medicine, Stanford, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Fontana', 'Affiliation': 'Division of Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hackmann', 'Affiliation': 'GBG, Neu-Isenburg, Germany; Marien-Hospital Witten, SEG, Witten, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Polikoff', 'Affiliation': 'NSABP Foundation and; NSABP Foundation and Department of Hematology/Oncology, Kaiser Permanente, San Diego, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Saghatchian', 'Affiliation': 'Breast Cancer Department, Institut Gustave Roussy, Villejuif, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Brufsky', 'Affiliation': 'NSABP Foundation and; NSABP Foundation and Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Division of Hematology-Oncolog, Taichung Veterans General Hospital and School of Medicine, China Medical University, Taichung City, Taiwan.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Zimovjanova', 'Affiliation': 'Department of Oncology, Charles University and General University Hospital, Prague, Czech Republic.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Boulet', 'Affiliation': 'Department of Biostatistics, F. Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Product Development Safety, Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Tesarowski', 'Affiliation': 'Product Development Oncology, Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'L H', 'Initials': 'LH', 'LastName': 'Lam', 'Affiliation': 'Product Development Oncology, Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Song', 'Affiliation': 'Product Development Oncology, Genentech, Inc., South San Francisco, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Smitt', 'Affiliation': 'Product Development Oncology, Genentech, Inc., South San Francisco, USA; Seattle Genetics, South San Francisco, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loibl', 'Affiliation': 'GBG, Neu-Isenburg, Germany; Center for Haematology and Oncology Bethanien, Frankfurt, Germany.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.04.011'] 3109,33938307,A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression.,"BACKGROUND Pharmacotherapies for depression are often ineffective and treatment-resistant depression (TRD) is common across bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Patient genetic information can be used to predict treatment outcomes. Prospective studies indicate that pharmacogenetic (PGX) tests have utility in the treatment of depression. However, few studies have examined the utility of PGX in other diagnoses typified by depression, or in veterans, a cohort with high rates of medical comorbidity, social stress, and suicide. AIM To determine the efficacy of genetically guided pharmacological treatment of TRD. METHODS We conducted an 8-week, prospective, multisite, single-blind study in 182 veterans with TRD including patients with BD, MDD, and PTSD. Subjects were randomly assigned to PGX-guided treatment in which the clinician incorporated PGX information into decision-making, or treatment as usual (TAU). RESULTS Overall, the PGX group improved marginally faster compared to TAU, but the difference was not statistically significant. Secondary analyses revealed that only PTSD patients showed a potential benefit from PGX testing. Patients predicted by PGX testing to have moderate levels of genetic risk showed a significant benefit from the PGX-guided treatment, whereas other risk groups demonstrated no benefit. Clinicians generally found the PGX test was useful, particularly in more depressed patients and/or those with more warnings for significant or serious adverse outcomes. Clinicians more often used the results to select a drug, but only rarely to adjust dosing. CONCLUSIONS The data reveal possible group differences in the utility of PGX testing in veterans with TRD.ClinicalTrials.gov Identifier: NCT04469322.",2021,"Clinicians generally found the PGX test was useful, particularly in more depressed patients and/or those with more warnings for significant or serious adverse outcomes.","['veterans with treatment-resistant depression', '182 veterans with TRD including patients with BD, MDD, and PTSD']","['PGX', 'PGX-guided treatment in which the clinician incorporated PGX information into decision-making, or treatment as usual (TAU']",[],"[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}]","[{'cui': 'C0033567', 'cui_str': 'Epoprostenol'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}]",[],182.0,0.0311018,"Clinicians generally found the PGX test was useful, particularly in more depressed patients and/or those with more warnings for significant or serious adverse outcomes.","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'McCarthy', 'Affiliation': 'Mental Health Service, VA San Diego Healthcare System, San Diego, CA, USA.'}, {'ForeName': 'Yucui', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Psychiatry, UC San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Demodena', 'Affiliation': 'Mental Health Service, VA San Diego Healthcare System, San Diego, CA, USA.'}, {'ForeName': 'Susan G', 'Initials': 'SG', 'LastName': 'Leckband', 'Affiliation': 'Mental Health Service, VA San Diego Healthcare System, San Diego, CA, USA.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Fischer', 'Affiliation': 'VA Palo Alto Healthcare System, Palo Alto, CA, USA.'}, {'ForeName': 'Shahrokh', 'Initials': 'S', 'LastName': 'Golshan', 'Affiliation': 'Mental Health Service, VA San Diego Healthcare System, San Diego, CA, USA.'}, {'ForeName': 'Trisha', 'Initials': 'T', 'LastName': 'Suppes', 'Affiliation': 'VA Palo Alto Healthcare System, Palo Alto, CA, USA.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Kelsoe', 'Affiliation': 'Mental Health Service, VA San Diego Healthcare System, San Diego, CA, USA.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/02698811211015224'] 3110,33940625,Sleep Deprivation Impairs Binding of Information with Its Context.,"Binding information to its context in long-term memory is critical for many tasks, including memory tasks and decision making. Failure to associate information to its context could be an important aspect of sleep deprivation effects on cognition, but little is known about binding problems from being sleep-deprived at the time of encoding. We studied how sleep deprivation affects binding using a well-established paradigm testing the ability to remember auditorily presented words (items) and their speakers (source context). In a laboratory study, 68 healthy young adults were randomly assigned to total sleep deprivation or a well-rested control condition. Participants completed an affective item and source memory task twice: once after 7h awake during baseline and again 24h later, after nearly 31h awake in the total sleep deprivation condition or 7h awake in the control condition. Participants listened to negative, positive, and neutral words presented by a male or female speaker and were immediately tested for recognition of the words and their respective speakers. Recognition of items declined during sleep deprivation, but even when items were recognized accurately, recognition of their associated sources also declined. Negative items were less bound with their sources than positive or neutral items,but sleep deprivation did not significantly affect this pattern.Our findings indicate that learning while sleep-deprived disrupts the binding of information to its context independent of item valence. Such binding failures may contribute to sleep deprivation effects on tasks requiring the ability to bind new information together in memory.",2021,"Negative items were less bound with their sources than positive or neutral items,but sleep deprivation did not significantly affect this pattern.","['Participants listened to negative, positive, and neutral words presented by a male or female speaker', '68 healthy young adults']",['total sleep deprivation or a well-rested control condition'],['sleep deprivation'],"[{'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}]",68.0,0.0260723,"Negative items were less bound with their sources than positive or neutral items,but sleep deprivation did not significantly affect this pattern.","[{'ForeName': 'Courtney A', 'Initials': 'CA', 'LastName': 'Kurinec', 'Affiliation': 'Department of Psychology, Washington State University, Pullman, WA, United States.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Whitney', 'Affiliation': 'Department of Psychology, Washington State University, Pullman, WA, United States.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Hinson', 'Affiliation': 'Department of Psychology, Washington State University, Pullman, WA, United States.'}, {'ForeName': 'Devon A', 'Initials': 'DA', 'LastName': 'Hansen', 'Affiliation': 'Sleep and Performance Research Center, Washington State University, Spokane, WA, United States.'}, {'ForeName': 'Hans P A', 'Initials': 'HPA', 'LastName': 'Van Dongen', 'Affiliation': 'Sleep and Performance Research Center, Washington State University, Spokane, WA, United States.'}]",Sleep,['10.1093/sleep/zsab113'] 3111,33940550,Self-compassion and dissonance-based interventions for body image distress in young adult women.,"Self-compassion interventions have been suggested as a potentially more acceptable way to address body image distress compared to interventions that emphasize challenging (often firmly entrenched) thin-ideals. In the current randomized controlled trial, young adult women endorsing body image concerns were randomized to a self-compassion (SC) intervention consisting of one in-person session plus one week of self-guided practice (n = 50), a similarly-structured dissonance-based (DB) intervention (n = 50), or a waitlist (WL) control (n = 51). Both brief interventions were acceptable and were more effective than WL. The two interventions did not differ significantly from each other in reducing the global measure of body dissatisfaction, improving body appreciation, or reducing appearance-contingent self-worth. The DB intervention alone decreased thin-ideal internalization, but only among participants with initially high scores. More participants initially expressed a preference for the SC rationale, and at post-test SC participants reported a higher likelihood of recommending the intervention they had received to others. Change in self-compassion emerged as a possible mechanism of action within both interventions, suggesting it may be useful to integrate aspects of both approaches to enhance acceptability and provide the greatest benefits.",2021,"The two interventions did not differ significantly from each other in reducing the global measure of body dissatisfaction, improving body appreciation, or reducing appearance-contingent self-worth.","['young adult women endorsing body image concerns', 'young adult women']","['self-compassion (SC) intervention consisting of one in-person session plus one week of self-guided practice (n = 50), a similarly-structured dissonance-based (DB) intervention (n = 50), or a waitlist (WL) control', 'Self-compassion and dissonance-based interventions']","['global measure of body dissatisfaction, improving body appreciation, or reducing appearance-contingent self-worth']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005891', 'cui_str': 'Body image'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0009242', 'cui_str': 'Cognitive Dissonance'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C2732632', 'cui_str': 'Dissatisfaction with body image'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0036588', 'cui_str': 'Self'}]",51.0,0.0324494,"The two interventions did not differ significantly from each other in reducing the global measure of body dissatisfaction, improving body appreciation, or reducing appearance-contingent self-worth.","[{'ForeName': 'Aubrey M', 'Initials': 'AM', 'LastName': 'Toole', 'Affiliation': 'Emory University, Department of Psychology, 36 Eagle Row, Atlanta, GA, 30322, USA. Electronic address: drtoole@stanford.edu.'}, {'ForeName': 'Devon', 'Initials': 'D', 'LastName': 'LoParo', 'Affiliation': 'Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, 12 Executive Park Drive NE, Suite 200, Atlanta, GA, 30329, USA. Electronic address: devon.loparo@emory.edu.'}, {'ForeName': 'Linda W', 'Initials': 'LW', 'LastName': 'Craighead', 'Affiliation': 'Emory University, Department of Psychology, 36 Eagle Row, Atlanta, GA, 30322, USA. Electronic address: lcraigh@emory.edu.'}]",Body image,['10.1016/j.bodyim.2021.04.001'] 3112,34389016,Comparative study of suction drainage placement in cementless hip replacement among patients undergoing extended thromboprophylaxis: a prospective randomized study.,"BACKGROUND The use of drains reportedly does not improve surgical outcomes after hip replacement. There is still a lack of strict recommendations for drain placement after primary hip replacement. This study aimed to assess the safety of not using suction drainage after primary hip replacement in a population of patients undergoing extended thromboprophylaxis. METHODS In this prospective randomized study, all patients were qualified for primary hip replacement and were divided into two groups: with and without drainage. The inclusion criterion was idiopathic hip osteoarthritis. The exclusion criteria were secondary coxarthrosis, autoimmune disease, coagulopathy, venous/arterial thrombosis, hepatic/renal insufficiency, cement, or hybrid endoprostheses. We performed an intention-to-treat analysis. Clinical, laboratory, and radiographic parameters were measured for the first three days after surgery. Hematoma collection, due to extended thromboprophylaxis, in the joint and soft tissues was evaluated precisely. The patients underwent follow-up for 30 days. RESULTS The final analysis included a total of 100 patients. We did not find any significant statistical differences between groups in terms of hip fluid collection (9.76 vs. 10.33 mm, with and without drainage, respectively; mean difference, 0.6 mm; 95 % confidence interval [CI] -2.8 to 3.9; p = 0.653), estimated blood loss (1126 vs. 1224 ml; mean difference, 97.1 ml; 95 % CI -84.1 to 278.2; p = 0.59), and hemoglobin levels on postoperative day 3 (11.05 vs. 10.85 g/dl; mean difference, 0.2; 95 % CI -2.1 to 2.5; p = 0.53). In addition, the other parameters did not show significant differences between groups. Notably, two cases of early infections were observed in the no-drainage group, whereas there were no such complications in the drainage group. CONCLUSIONS We conclude that the use of closed suction drainage after primary hip replacement is a safe procedure in patients undergoing extended thromboprophylaxis. Further research is warranted to validate these findings. TRIAL REGISTRATION The study was successfully registered retrospectively at Clinicaltrial.gov with the identification number NCT04333264  03 April 2020.",2021,"We did not find any significant statistical differences between groups in terms of hip fluid collection (9.76 vs. 10.33 mm, with and without drainage, respectively; mean difference, 0.6 mm; 95 % confidence interval [CI] -2.8 to 3.9; p = 0.653), estimated blood loss (1126 vs. 1224 ml; mean difference, 97.1 ml; 95 % CI -84.1 to 278.2; p = 0.59), and hemoglobin levels on postoperative day 3 (11.05 vs. 10.85 g/dl; mean difference, 0.2; 95 % CI -2.1 to 2.5; p = 0.53).","['patients undergoing extended thromboprophylaxis', 'all patients were qualified for primary hip replacement', 'cementless hip replacement among patients undergoing extended thromboprophylaxis']","['suction drainage', 'suction drainage placement', 'closed suction drainage']","['Clinical, laboratory, and radiographic parameters', 'estimated blood loss', 'hip fluid collection', 'hemoglobin levels', 'surgical outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0392806', 'cui_str': 'Insertion of hip prosthesis'}]","[{'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0587267', 'cui_str': 'Closed'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",100.0,0.071359,"We did not find any significant statistical differences between groups in terms of hip fluid collection (9.76 vs. 10.33 mm, with and without drainage, respectively; mean difference, 0.6 mm; 95 % confidence interval [CI] -2.8 to 3.9; p = 0.653), estimated blood loss (1126 vs. 1224 ml; mean difference, 97.1 ml; 95 % CI -84.1 to 278.2; p = 0.59), and hemoglobin levels on postoperative day 3 (11.05 vs. 10.85 g/dl; mean difference, 0.2; 95 % CI -2.1 to 2.5; p = 0.53).","[{'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Bartosz', 'Affiliation': 'Orthopedic Department, Centre of Postgraduate Medical Education, Konarskiego 13, Kosciuszki 3/10B, 05-400, Otwock, Poland. pbartosz@vp.pl.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Marczyński', 'Affiliation': 'Orthopedic Department, Centre of Postgraduate Medical Education, Konarskiego 13, Kosciuszki 3/10B, 05-400, Otwock, Poland.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Para', 'Affiliation': 'Orthopedic Department, Centre of Postgraduate Medical Education, Konarskiego 13, Kosciuszki 3/10B, 05-400, Otwock, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Kogut', 'Affiliation': 'Orthopedic Department, Centre of Postgraduate Medical Education, Konarskiego 13, Kosciuszki 3/10B, 05-400, Otwock, Poland.'}, {'ForeName': 'Jerzy', 'Initials': 'J', 'LastName': 'Białecki', 'Affiliation': 'Orthopedic Department, Centre of Postgraduate Medical Education, Konarskiego 13, Kosciuszki 3/10B, 05-400, Otwock, Poland.'}]",BMC musculoskeletal disorders,['10.1186/s12891-021-04583-0'] 3113,33931979,Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC-guided dosing in nonsmall cell lung cancer.,,2021,,['nonsmall cell lung cancer'],['docetaxel'],[],"[{'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}]",[],,0.36571,,"[{'ForeName': 'Yuxiang', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'BGI-Shenzhen, Shenzhen, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Qingguang', 'Initials': 'Q', 'LastName': 'Lin', 'Affiliation': 'State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yuehao', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': 'State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Salvatore J', 'Initials': 'SJ', 'LastName': 'Salamone', 'Affiliation': 'Saladax Biomedical Inc., Bethlehem, Pennsylvania, USA.'}, {'ForeName': 'Xinlan', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'BGI-Shenzhen, Shenzhen, China.'}, {'ForeName': 'Changzheng', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'BGI-Shenzhen, Shenzhen, China.'}, {'ForeName': 'Weiting', 'Initials': 'W', 'LastName': 'Liang', 'Affiliation': 'State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Hongyun', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Kui', 'Initials': 'K', 'LastName': 'Wu', 'Affiliation': 'BGI-Shenzhen, Shenzhen, China.'}, {'ForeName': 'Yunpeng', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.'}]",Clinical and translational medicine,['10.1002/ctm2.354'] 3114,33931415,Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety: A Randomized Controlled Clinical Trial.,"BACKGROUND AND OBJECTIVES Medication safety events are predominant contributors to suboptimal graft outcomes in kidney transplant recipients. The goal of this study was to examine the efficacy of improving medication safety through a pharmacist-led, mobile health-based intervention. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This was a 12-month, single-center, prospective, parallel, two-arm, single-blind, randomized controlled trial. Adult kidney recipients 6-36 months post-transplant were eligible. Participants randomized to intervention received supplemental clinical pharmacist-led medication therapy monitoring and management via a mobile health-based application, integrated with risk-guided televisits and home-based BP and glucose monitoring. The application provided an accurate medication regimen, timely reminders, and side effect surveys. Both the control and intervention arms received usual care, including serial laboratory monitoring and regular clinic visits. The coprimary outcomes were to assess the incidence and severity of medication errors and adverse events. RESULTS In total, 136 kidney transplant recipients were included, 68 in each arm. The mean age was 51 years, 57% were male, and 64% were Black individuals. Participants receiving the intervention experienced a significant reduction in medication errors (61% reduction in the risk rate; incident risk ratio, 0.39; 95% confidence interval, 0.28 to 0.55; P <0.001) and a significantly lower incidence risk of Grade 3 or higher adverse events (incident risk ratio, 0.55, 95% confidence interval, 0.30 to 0.99; P =0.05). For the secondary outcome of hospitalizations, the intervention arm demonstrated significantly lower rates of hospitalizations (incident risk ratio, 0.46; 95% confidence interval, 0.27 to 0.77; P =0.005). CONCLUSIONS We demonstrated a significant reduction in medication errors, adverse events, and hospitalizations using a pharmacist-led, mobile health-based intervention.",2021,"Participants receiving the intervention experienced a significant reduction in medication errors (61% reduction in the risk rate; incident risk ratio, 0.39; 95% confidence interval, 0.28 to 0.55; P <0.001) and a significantly lower incidence risk of Grade 3 or higher adverse events (incident risk ratio, 0.55, 95% confidence interval, 0.30 to 0.99; P =0.05).","['The mean age was 51 years, 57% were male, and 64% were Black individuals', '136 kidney transplant recipients were included, 68 in each arm', 'Adult kidney recipients 6-36 months post-transplant were eligible', 'kidney transplant recipients']","['supplemental clinical pharmacist-led medication therapy monitoring and management via a mobile health-based application, integrated with risk-guided televisits and home-based BP and glucose monitoring', 'usual care, including serial laboratory monitoring and regular clinic visits', 'Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety']","['rates of hospitalizations', 'medication errors', 'incidence and severity of medication errors and adverse events', 'medication errors, adverse events, and hospitalizations using a pharmacist-led, mobile health-based intervention']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}]","[{'cui': 'C1449564', 'cui_str': 'Clinical pharmacist'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0025115', 'cui_str': 'Medication error'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",136.0,0.306425,"Participants receiving the intervention experienced a significant reduction in medication errors (61% reduction in the risk rate; incident risk ratio, 0.39; 95% confidence interval, 0.28 to 0.55; P <0.001) and a significantly lower incidence risk of Grade 3 or higher adverse events (incident risk ratio, 0.55, 95% confidence interval, 0.30 to 0.99; P =0.05).","[{'ForeName': 'Haley M', 'Initials': 'HM', 'LastName': 'Gonzales', 'Affiliation': 'Department of Surgery, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'James N', 'Initials': 'JN', 'LastName': 'Fleming', 'Affiliation': 'Department of Surgery, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Mulugeta', 'Initials': 'M', 'LastName': 'Gebregziabher', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Maria Aurora', 'Initials': 'MA', 'LastName': 'Posadas-Salas', 'Affiliation': 'Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Zemin', 'Initials': 'Z', 'LastName': 'Su', 'Affiliation': 'Department of Medicine, Medical University of South Carolina, Charleston, South Carolina taberd@musc.edu.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'McGillicuddy', 'Affiliation': 'Department of Surgery, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Taber', 'Affiliation': 'Department of Surgery, Medical University of South Carolina, Charleston, South Carolina taberd@musc.edu.'}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.15911020'] 3115,33931405,A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care.,"The 2019 report of a randomized, placebo-controlled clinical trial demonstrating that immune therapy can delay the onset of clinical type 1 diabetes (T1D) in antibody-positive relatives by a median of 2 years stands out as a landmark in the decades-long effort to prevent T1D. With this important step achieved, it is now time to consider what is needed to bring disease-modifying therapy for prevention or delay of T1D to clinical use from this point. Long considered a chicken and egg problem (why screen for T1D risk when we have no therapy, and how can we develop therapies without more screening), we now have the opportunity to break this impasse. The purpose of this article is to place this clinical trial result in context, highlighting key foundational studies leading to this accomplishment, addressing the current gaps, and suggesting that a key next step for prevention of T1D is to screen and monitor relatives for T1D risk in the context of clinical care.",2021,"The 2019 report of a randomized, placebo-controlled clinical trial demonstrating that immune therapy can delay the onset of clinical type 1 diabetes (T1D) in antibody-positive relatives by a median of 2 years stands out as a landmark in the decades-long effort to prevent T1D. With this important step achieved, it is now time to consider what is needed to bring disease-modifying therapy for prevention or delay of T1D to clinical use from this point.",[],"['placebo', 'immune therapy']",[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],,0.186696,"The 2019 report of a randomized, placebo-controlled clinical trial demonstrating that immune therapy can delay the onset of clinical type 1 diabetes (T1D) in antibody-positive relatives by a median of 2 years stands out as a landmark in the decades-long effort to prevent T1D. With this important step achieved, it is now time to consider what is needed to bring disease-modifying therapy for prevention or delay of T1D to clinical use from this point.","[{'ForeName': 'Carla J', 'Initials': 'CJ', 'LastName': 'Greenbaum', 'Affiliation': 'Benaroya Research Institute, Seattle, WA cjgreen@benaroyaresearch.org.'}]",Diabetes,['10.2337/db20-1112'] 3116,34388615,Responding to a simulated disaster in the virtual or live classroom: Is there a difference in BSN student learning?,"AIM This study aim was to investigate if prelicensure baccalaureate nursing students gained more knowledge from a live or virtual disaster simulation. The study goal was to inform the use of e-learning or traditional textbooks in undergraduate nursing population health courses. BACKGROUND Weather-related disasters have increased in frequency and severity in the past ten years, with 2020 being the most active storm season ever seen (National Oceanographic and Atmospheric Administration, 2021.) Even with advances in early warning systems and mitigation efforts, educating student nurses in disaster response remains a priority. Due to the impact of Covid-19 quarantine policies, many in-person student learning labs and clinical experiences were cancelled. However, virtual simulation offers an alternative to developing nursing student skills and clinical reasoning ability (Aebersold, 2018; Fogg et al., 2020). DESIGN A randomized quasi-experimental, repeated measures 2 × 2 crossover design (Kim, 2018) was applied, which allowed students to participate in both the live and virtual simulations. METHODS Analysis was conducted using paired samples t-test to evaluate knowledge gains. To measure students' self-assessment of knowledge, Unver et al. (2018) 12-item survey was administered. To explore students' own perceptions about the disaster simulations, semi-structured interview questions were offered through private Wiki postings. The responses were analyzed using Saldaña's in vivo coding (2015) and thematic analysis. RESULTS Students retained more empirical knowledge following the virtual assignment as compared to the disaster simulation, except in two items addressing triage. Neither age, years of education, or GPA impacted test results. However, students' own assessment of learning did not differ between live and virtual simulations. In all but three items, students perceived a significant increase (p < .05) in their learning following the simulation, regardless whether it was live or virtual. In narrative responses, students overwhelmingly cited the benefit of an in-person simulation. However, they did not believe that they were prepared adequately for the live simulation. They also expressed that they would be more prepared if the simulation was repeated. Students expressed discomfort, even distress, regarding not being able to care adequately for everyone, even though it was a simulation (See Table 5). This highlighted that live simulations can affect students emotionally, and follow-up debriefing is essential to help in both acknowledging and processing student feelings. CONCLUSION These findings, which support the use of virtual disaster training in nursing education, are especially important in the light of Covid-19 and increasing threat of storm disasters.",2021,"In all but three items, students perceived a significant increase (p < .05) in their learning following the simulation, regardless whether it was live or virtual.","['past ten years, with 2020 being the most active storm season ever seen (National Oceanographic and Atmospheric Administration, 2021', 'prelicensure baccalaureate nursing students', 'undergraduate nursing population health courses']","['virtual disaster training', 'e-learning or traditional textbooks']",['empirical knowledge'],"[{'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C3242284', 'cui_str': 'Population Health'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0012618', 'cui_str': 'Disasters'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0039712', 'cui_str': 'Textbooks'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}]",,0.0361191,"In all but three items, students perceived a significant increase (p < .05) in their learning following the simulation, regardless whether it was live or virtual.","[{'ForeName': 'Lisa Kirk', 'Initials': 'LK', 'LastName': 'Wiese', 'Affiliation': 'C.E. Lynn College of Nursing, Florida Atlantic University, BC84, #333, 777 Glades Road, Boca Raton, FL 33431, USA. Electronic address: lwiese@health.fau.edu.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Love', 'Affiliation': 'C.E. Lynn College of Nursing, Florida Atlantic University, BC84, 777 Glades Road, Boca Raton, FL 33431, USA. Electronic address: lovet@health.fau.edu.'}, {'ForeName': 'Rhonda', 'Initials': 'R', 'LastName': 'Goodman', 'Affiliation': 'C.E. Lynn College of Nursing, Florida Atlantic University, BC84, #325, 777 Glades Road, Boca Raton, FL 33431, USA. Electronic address: rgoodm10@health.fau.edu.'}]",Nurse education in practice,['10.1016/j.nepr.2021.103170'] 3117,34388561,"Additive effects of acupuncture in alleviating anxiety: A double-blind, three-arm, randomized clinical trial.","BACKGROUND In this trial, additive effects of acupuncture to selective serotonin reuptake inhibitors (SSRIs) treatment for reducing anxiety, were investigated. METHODS 112 patients with anxiety disorder were randomly divided into three groups including SSRIs alone (drug group), SSRIs with sham acupuncture (control group) and SSRI with acupuncture (acupuncture group), and treated for 4 weeks. At the beginning of the study and on day 28, Spielberger State-Trait Anxiety Inventory (STAI) questionnaire was completed and serum levels of cortisol were measured. RESULTS 105 patients completed the treatment period. STAI score showed significant differences among the three groups at the end of the study; importantly, changes in STAI score in the acupuncture group were significantly larger than the other groups. A decrease in cortisol levels was observed in all groups; though statistically non-significant, this decrease in the acupuncture group was larger. CONCLUSION Acupuncture combined with SSRIs can significantly improve anxiety state compared to anti-anxiety therapy using SSRIs alone.",2021,"A decrease in cortisol levels was observed in all groups; though statistically non-significant, this decrease in the acupuncture group was larger. ","['112 patients with anxiety disorder', '105 patients completed the treatment period']","['acupuncture', 'Acupuncture combined with SSRIs', 'acupuncture to selective serotonin reuptake inhibitors (SSRIs', 'SSRIs alone (drug group), SSRIs with sham acupuncture (control group) and SSRI with acupuncture (acupuncture group']","['Spielberger State-Trait Anxiety Inventory (STAI) questionnaire', 'alleviating anxiety', 'cortisol levels', 'STAI score', 'anxiety state']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0451497', 'cui_str': 'Spielberger state-trait anxiety inventory'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0150135', 'cui_str': 'Alleviating anxiety'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}]",112.0,0.0813888,"A decrease in cortisol levels was observed in all groups; though statistically non-significant, this decrease in the acupuncture group was larger. ","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Sabbagh Gol', 'Affiliation': 'Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Rezaei Ardani', 'Affiliation': 'Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Seyed Kazem', 'Initials': 'SK', 'LastName': 'Farahmand', 'Affiliation': 'Department of Complementary and Chinese Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Malihe', 'Initials': 'M', 'LastName': 'Dadgarmoghaddam', 'Affiliation': 'Community Medicine Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Vahideh', 'Initials': 'V', 'LastName': 'Ghorani', 'Affiliation': 'Clinical Research Unit, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Shima', 'Initials': 'S', 'LastName': 'Rezaei', 'Affiliation': 'Clinic of Acupuncture and Chinese Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Khorsand', 'Affiliation': 'Department of Complementary and Chinese Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: Khorsanda@mums.ac.ir.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2021.101466'] 3118,34388515,Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).,"BACKGROUND The REGOMA trial showed that regorafenib significantly improved overall survival in patients with recurrent glioblastoma compared with lomustine. Patients treated with regorafenib experienced a higher occurrence of grade 3-4 drug-related adverse events than those receiving the standard treatment. Because this safety profile was expected, it was considered of great importance to assess the patient point of view regarding the disease and treatment impact on different aspects of life and patient well-being. We here report the final results of the health-related quality of life (HRQoL) assessment, a secondary end-point of the study. This trial is registered with ClinicalTrials.gov, NCT02926222. METHODS Patient-reported outcomes were assessed, within a prospective, randomised, multicentre, open-label phase II trial, by the European Organisation for Research and Treatment of Cancer core questionnaire and brain module at baseline and every 8-weekly neuroradiological assessment till disease progression. Mixed-effect linear models were fitted for each of the HRQoL domain to examine the change over progression-free time within and between arms. Furthermore, differences were also classified as clinically meaningful changes. To correct for multiple comparisons and avoid type I errors, the level of significance was set at P = 0.01 (2-sided). RESULTS Of 119 enrolled patients, 56/59 (95%) patients and 58/60 (97%) patients treated with regorafenib and lomustime completed questionnaires at baseline, respectively. No significant differences were observed in any generic or cancer-specific domain during treatment in both arms, or between the two arms, except for the appetite loss and diarrhoea scales which were significantly worse in patients treated with regorafenib. The rate of patients with a clinically meaningful worsening for appetite loss, diarrhoea and for any other domain was not statistically different between the two arms. CONCLUSIONS Regorafenib did not negatively affect HRQoL in patients with recurrent glioblastoma. These data combined with the survival benefit shown in the REGOMA trial support the use of regorafenib as a treatment option for these patients.",2021,"No significant differences were observed in any generic or cancer-specific domain during treatment in both arms, or between the two arms, except for the appetite loss and diarrhoea scales which were significantly worse in patients treated with regorafenib.","['patients with recurrent glioblastoma', 'Of 119 enrolled patients, 56/59 (95%) patients and 58/60 (97', 'patients with relapsed glioblastoma (the REGOMA trial']","['Regorafenib', 'regorafenib', 'lomustine']","['overall survival', 'higher occurrence of grade 3-4 drug-related adverse events', 'generic or cancer-specific domain', 'appetite loss and diarrhoea scales', 'appetite loss, diarrhoea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0017636', 'cui_str': 'Glioblastoma'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C0023972', 'cui_str': 'Lomustine'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",119.0,0.204682,"No significant differences were observed in any generic or cancer-specific domain during treatment in both arms, or between the two arms, except for the appetite loss and diarrhoea scales which were significantly worse in patients treated with regorafenib.","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Lombardi', 'Affiliation': 'Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Del Bianco', 'Affiliation': 'Clinical Research Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.'}, {'ForeName': 'Alba A', 'Initials': 'AA', 'LastName': 'Brandes', 'Affiliation': 'Medical Oncology Department, AUSL/IRCCS, Neurological Science Institute, Bologna, Italy.'}, {'ForeName': 'Marica', 'Initials': 'M', 'LastName': 'Eoli', 'Affiliation': 'Molecolar Neuro-Oncology Unit, IRCCS Foundation, ""Carlo Besta"" Neurological Institute, Milan, Italy.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Rudà', 'Affiliation': 'Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Turin, Italy.'}, {'ForeName': 'Toni', 'Initials': 'T', 'LastName': 'Ibrahim', 'Affiliation': 'Osteoncology and Rare Tumors Center, IRST-IRCCS ""Dino Amadori"", Meldola, Italy.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Lolli', 'Affiliation': 'Medical Oncology Unit, IRCCS Saverio de Bellis Hospital, Castellana Grotte, Bari, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Rizzato', 'Affiliation': 'Department of Oncology, Santa Maria della Misericordia University Hospital, Udine, Italy.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Daniele', 'Affiliation': 'Oncology Unit, Ospedale del Mare, Napoli, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Pace', 'Affiliation': 'Neuroncology Unit, IRCCS Regina Elena Cancer Institute, Roma, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Pasqualetti', 'Affiliation': 'Radiotherapy Unit, University Hospital S. Chiara, Pisa, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Caccesse', 'Affiliation': 'Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Bergo', 'Affiliation': 'Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Magni', 'Affiliation': 'Clinical Research Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.'}, {'ForeName': 'Gian Luca', 'Initials': 'GL', 'LastName': 'De Salvo', 'Affiliation': 'Clinical Research Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Electronic address: gianluca.desalvo@iov.veneto.it.'}, {'ForeName': 'Vittorina', 'Initials': 'V', 'LastName': 'Zagonel', 'Affiliation': 'Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2021.06.055'] 3119,33935094,"Paraoxonase 1, B Vitamins Supplementation, and Mild Cognitive Impairment.","BACKGROUND Identification of modifiable risk factors that affect cognitive decline is important for the development of preventive and treatment strategies. Status of paraoxonase 1 (PON1), a high-density lipoprotein-associated enzyme, may play a role in the development of neurological diseases, including Alzheimer's disease. OBJECTIVE We tested a hypothesis that PON1 status predicts cognition in individuals with mild cognitive impairment (MCI). METHODS Individuals with MCI (n = 196, 76.8-years-old, 60% women) participating in a randomized, double-blind placebo-controlled trial (VITACOG) were assigned to receive a daily dose of folic acid (0.8 mg), vitamin B12 (0.5 mg) and B6 (20 mg) (n = 95) or placebo (n = 101) for 2 years. Cognition was analyzed by neuropsychological tests. Brain atrophy was quantified in a subset of participants (n = 168) by MRI. PON1 status, including PON1 Q192R genotype, was determined by quantifying enzymatic activity of PON1 using paraoxon and phenyl acetate as substrates. RESULTS In the placebo group, baseline phenylacetate hydrolase (PhAcase) activity of PON1 (but not paraoxonase activity or PON1 Q192R genotype) was significantly associated with global cognition (Mini-Mental State Examination, MMSE; Telephone Inventory for Cognitive Status-modified, TICS-m), verbal episodic memory (Hopkins Verbal Learning Test-revised: Total Recall, HVLT-TR; Delayed Recall, HVLT-DR), and attention/processing speed (Trail Making A and Symbol Digits Modalities Test, SDMT) at the end of study. In addition to PhAcase, baseline iron and triglycerides predicted MMSE, baseline fatty acids predicted SDMT, baseline anti-N-Hcy-protein autoantibodies predicted TICS-m, SDMT, Trail Making A, while BDNF V66M genotype predicted HVLT-TR and HVLT-DR scores at the end of study. B-vitamins abrogated associations of PON1 and other variables with cognition. CONCLUSION PON1 is a new factor associated with impaired cognition that can be ameliorated by B-vitamins in individuals with MCI.",2021,"In the placebo group, baseline phenylacetate hydrolase (PhAcase) activity of PON1 (but not paraoxonase activity or PON1 Q192R genotype) was significantly associated with global cognition (Mini-Mental State Examination, MMSE; Telephone Inventory for Cognitive Status-modified, TICS-m), verbal episodic memory (Hopkins Verbal Learning Test-revised: Total Recall, HVLT-TR; Delayed Recall, HVLT-DR), and attention/processing speed (Trail Making A and Symbol Digits Modalities Test, SDMT) at the end of study.","['Individuals with MCI (n\u200a=\u200a196, 76.8-years-old, 60% women) participating', 'individuals with MCI', 'individuals with mild cognitive impairment (MCI']","['folic acid', 'placebo', 'vitamin B12']","['baseline phenylacetate hydrolase (PhAcase) activity of PON1', 'PhAcase, baseline iron and triglycerides predicted MMSE, baseline fatty acids predicted SDMT, baseline anti-N-Hcy-protein autoantibodies predicted TICS-m, SDMT, Trail Making A, while BDNF V66M genotype predicted HVLT-TR and HVLT-DR scores', 'Mild Cognitive Impairment', 'global cognition (Mini-Mental State Examination, MMSE; Telephone Inventory for Cognitive Status-modified, TICS-m), verbal episodic memory (Hopkins Verbal Learning Test-revised: Total Recall, HVLT-TR; Delayed Recall, HVLT-DR), and attention/processing speed (Trail Making A and Symbol Digits Modalities Test, SDMT', 'Brain atrophy']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031452', 'cui_str': 'Benzeneacetates'}, {'cui': 'C0020289', 'cui_str': 'Hydrolase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1121571', 'cui_str': 'Paraoxonase 1'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0432633', 'cui_str': 'Blood group antibody N'}, {'cui': 'C0019878', 'cui_str': 'Homocysteine'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0004358', 'cui_str': 'Autoantibody'}, {'cui': 'C0040188', 'cui_str': 'Tic disorder'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0042531', 'cui_str': 'Verbal learning'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}, {'cui': 'C0451522', 'cui_str': 'Symbol digit modalities test'}, {'cui': 'C0235946', 'cui_str': 'Cerebral atrophy'}]",,0.611436,"In the placebo group, baseline phenylacetate hydrolase (PhAcase) activity of PON1 (but not paraoxonase activity or PON1 Q192R genotype) was significantly associated with global cognition (Mini-Mental State Examination, MMSE; Telephone Inventory for Cognitive Status-modified, TICS-m), verbal episodic memory (Hopkins Verbal Learning Test-revised: Total Recall, HVLT-TR; Delayed Recall, HVLT-DR), and attention/processing speed (Trail Making A and Symbol Digits Modalities Test, SDMT) at the end of study.","[{'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Perła-Kaján', 'Affiliation': 'Department of Biochemistry and Biotechnology, Poznań University of Life Sciences, Poznań, Poland.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Włoczkowska', 'Affiliation': 'Department of Biochemistry and Biotechnology, Poznań University of Life Sciences, Poznań, Poland.'}, {'ForeName': 'Anetta', 'Initials': 'A', 'LastName': 'Zioła-Frankowska', 'Affiliation': 'Department of Analytical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Poznań, Poland.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Frankowski', 'Affiliation': 'Department of Analytical and Environmental Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Poznań, Poland.'}, {'ForeName': 'A David', 'Initials': 'AD', 'LastName': 'Smith', 'Affiliation': 'OPTIMA, Department of Pharmacology, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Celeste A', 'Initials': 'CA', 'LastName': 'de Jager', 'Affiliation': 'OPTIMA, Department of Pharmacology, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Refsum', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Hieronim', 'Initials': 'H', 'LastName': 'Jakubowski', 'Affiliation': 'Department of Biochemistry and Biotechnology, Poznań University of Life Sciences, Poznań, Poland.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-210137'] 3120,33935089,Verbal Fluency in Mild Alzheimer's Disease: Transcranial Direct Current Stimulation over the Dorsolateral Prefrontal Cortex.,"BACKGROUND Recent studies showed that in healthy controls and in aphasic patients, inhibitory trains of repetitive transcranial magnetic stimulation (rTMS) over the right prefrontal cortex can improve phonemic fluency performance, while anodal transcranial direct current stimulation (tDCS) over the left prefrontal cortex can improve performance in naming and semantic fluency tasks. OBJECTIVE This study aimed at investigating the effects of cathodal tDCS over the left or the right dorsolateral prefrontal cortex (DLPFC) on verbal fluency tasks (VFT) in patients with mild Alzheimer's disease (AD). METHODS Forty mild AD patients participated in the study (mean age 73.17±5.61 years). All participants underwent cognitive baseline tasks and a VFT twice. Twenty patients randomly received cathodal tDCS to the left or the right DLPFC, and twenty patients were assigned to a control group in which only the two measures of VFT were taken, without the administration of the tDCS. RESULTS A significant improvement of performance on the VFT in AD patients was present after tDCS over the right DLPFC (p = 0.001). Instead, no difference was detected between the two VFTs sessions after tDCS over the left DLPFC (p = 0.42). Furthermore, these results cannot be related to task learning effects, since no significant difference was found between the two VFT sessions in the control group (p = 0.73). CONCLUSION These data suggest that tDCS over DLPFC can improve VFT performance in AD patients. A hypothesis is that tDCS enhances adaptive patterns of brain activity between functionally connected areas.",2021,"Furthermore, these results cannot be related to task learning effects, since no significant difference was found between the two VFT sessions in the control group (p = 0.73). ","[""patients with mild Alzheimer's disease (AD"", 'AD patients', 'Twenty patients randomly received', 'Forty mild AD patients participated in the study (mean age 73.17±5.61 years', ""Mild Alzheimer's Disease""]","['anodal transcranial direct current stimulation (tDCS', 'cathodal tDCS', 'tDCS', 'Transcranial Direct Current Stimulation', 'repetitive transcranial magnetic stimulation (rTMS', 'tDCS over DLPFC']","['Verbal Fluency', 'brain activity', 'VFT performance', 'phonemic fluency performance', 'verbal fluency tasks (VFT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}]","[{'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}]",40.0,0.102491,"Furthermore, these results cannot be related to task learning effects, since no significant difference was found between the two VFT sessions in the control group (p = 0.73). ","[{'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Smirni', 'Affiliation': 'Department of Psychology, Educational Science and Human Movement, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Massimiliano', 'Initials': 'M', 'LastName': 'Oliveri', 'Affiliation': 'Department of Psychology, Educational Science and Human Movement, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Eliana', 'Initials': 'E', 'LastName': 'Misuraca', 'Affiliation': 'NeuroTeam Life and Science, Palermo, Italy.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Catania', 'Affiliation': 'NeuroTeam Life and Science, Palermo, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Vernuccio', 'Affiliation': 'Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Picciolo', 'Affiliation': 'Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Flora', 'Initials': 'F', 'LastName': 'Inzerillo', 'Affiliation': 'Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Barbagallo', 'Affiliation': 'Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Cipolotti', 'Affiliation': 'Department of Neuropsychology, National Hospital for Neurology and Neurosurgery, London, UK.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Turriziani', 'Affiliation': 'Department of Psychology, Educational Science and Human Movement, University of Palermo, Palermo, Italy.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-210003'] 3121,33935080,"Interventional Study to Evaluate the Clinical Effects and Safety of the Nutraceutical Compound BrainUp-10® in a Cohort of Patients with Alzheimer's Disease: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial.","BACKGROUND Clinically-evaluated nutraceuticals are candidates for Alzheimer's disease (AD) prevention and treatment. Phase I studies showed biological safety of the nutraceutical BrainUp-10®, while a pilot trial demonstrated efficacy for treatment. Cell studies demonstrated neuroprotection. BrainUp-10® blocks tau self-assembly. Apathy is the most common of behavioral alterations. OBJECTIVE The aim was to explore efficacy of BrainUp-10® in mitigating cognitive and behavioral symptoms and in providing life quality, in a cohort of Chilean patients with mild to moderate AD. METHODS The was a multicenter, randomized, double blind, placebo-controlled phase II clinical study in mild to moderate AD patients treated with BrainUp-10® daily, while controls received a placebo. Primary endpoint was Apathy (AES scale), while secondary endpoints included Mini-Mental State Examination (MMSE), Trail Making Test (TMT A and TMT B), and Neuropsychiatry Index (NPI). AD blood biomarkers were analyzed. Laboratory tests were applied to all subjects. RESULTS 82 patients were enrolled. The MMSE score improved significantly at week 24 compared to baseline with tendency to increase, which met the pre-defined superiority criteria. NPI scores improved, the same for caregiver distress at 12th week (p = 0.0557), and the alimentary response (p = 0.0333). Apathy tests showed a statistically significant decrease in group treated with BrainUp-10®, with p = 0.0321 at week 4 and p = 0.0480 at week 12 treatment. A marked decrease in homocysteine was shown with BrainUp-10® (p = 0.0222). CONCLUSION Data show that BrainUp-10® produces a statistically significant improvement in apathy, ameliorating neuropsychiatric distress of patients. There were no compound-related adverse events. BrainUp-10® technology may enable patients to receive the benefits for their cognitive and behavioral problems.",2021,"NPI scores improved, the same for caregiver distress at 12th week (p = 0.0557), and the alimentary response (p = 0.0333).","[""Patients with Alzheimer's Disease"", '82 patients were enrolled', 'Chilean patients with mild to moderate AD', 'mild to moderate AD patients treated with']","['BrainUp-10® daily', 'Placebo', 'BrainUp-10®', 'placebo', 'Nutraceutical Compound BrainUp-10®']","['NPI scores', 'AD blood biomarkers', 'biological safety', 'Apathy (AES scale), while secondary endpoints included Mini-Mental State Examination (MMSE), Trail Making Test (TMT A and TMT B), and Neuropsychiatry Index (NPI', 'alimentary response', 'apathy, ameliorating neuropsychiatric distress', 'MMSE score', 'caregiver distress', 'homocysteine']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1518478', 'cui_str': 'Nutriceuticals'}, {'cui': 'C0205198', 'cui_str': 'Compound'}]","[{'cui': 'C0870956', 'cui_str': 'Neuropsychiatry'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0085632', 'cui_str': 'Indifference'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0040604', 'cui_str': 'Trail making test'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0019878', 'cui_str': 'Homocysteine'}]",82.0,0.544013,"NPI scores improved, the same for caregiver distress at 12th week (p = 0.0557), and the alimentary response (p = 0.0333).","[{'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Guzman-Martinez', 'Affiliation': 'Laboratory of Neuroscience and Functional Medicine, Faculty of Sciences, International Center for Biomedicine (ICC), University of Chile, Santiago, Chile.'}, {'ForeName': 'Gonzalo A', 'Initials': 'GA', 'LastName': 'Farías', 'Affiliation': 'Department of Neurology, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'José P', 'Initials': 'JP', 'LastName': 'Tapia', 'Affiliation': 'Laboratory of Neuroscience and Functional Medicine, Faculty of Sciences, International Center for Biomedicine (ICC), University of Chile, Santiago, Chile.'}, {'ForeName': 'María P', 'Initials': 'MP', 'LastName': 'Sánchez', 'Affiliation': 'Faculty of Chemistry and Biology, University of Santiago of Chile, Santiago, Chile.'}, {'ForeName': 'Patricio', 'Initials': 'P', 'LastName': 'Fuentes', 'Affiliation': 'Department of Neurology, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Gloger', 'Affiliation': 'Biomedica Research Group, Santiago, Chile.'}, {'ForeName': 'Ricardo B', 'Initials': 'RB', 'LastName': 'Maccioni', 'Affiliation': 'Laboratory of Neuroscience and Functional Medicine, Faculty of Sciences, International Center for Biomedicine (ICC), University of Chile, Santiago, Chile.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201501'] 3122,33935074,Effects of Acupuncture on Vascular Cognitive Impairment with No Dementia: A Randomized Controlled Trial.,"BACKGROUND Acupuncture has been used for treating vascular cognitive impairment, but evidence for its effectiveness remains limited. OBJECTIVE This single-center, patient-accessor blinded, randomized controlled trial was designed to assess whether acupuncture could improve the cognitive function of patients with vascular cognitive impairment with no dementia (VCIND). METHODS 120 VCIND patients were randomly assigned to the electro-acupuncture (EA) or sham acupuncture (SA) group at a 1 : 1 ratio, with treatment conducted thrice weekly for 8 weeks. The primary outcome was the changes of cognitive function measured by the Montreal Cognitive Assessment (MoCA) from baseline to week 8. The secondary outcomes included the scores of the Mini-Mental State Examination (MMSE), the Modified Barthel Index (MBI) and the Self-rating Depression Scale (SDS). Follow-up assessments were performed with MoCA and MMSE at week 16 and 32. Linear mixed-effects models were used for analysis and all statistical tests were two-sided. RESULTS The results showed that patients in the EA group had a significantly greater improvement in MoCA score (23.85±4.18) than those in the SA group (21.48±4.44) at week 8 (95% CI = 0.80, 3.92, p = 0.04), as well as higher MoCA scores over time (p < 0.001 for interaction). Patients who received EA showed a greater increase in MMSE scores (26.41±3.47) than those who received SA (24.40±3.85) along 8 weeks (95% CI = 0.69, 3.34, p = 0.004). However, results diminished over time. No serious adverse events occurred during the trial. CONCLUSION EA is a safe and effective technique to improve cognition over the short term of 8 weeks in VCIND patients.",2021,"Patients who received EA showed a greater increase in MMSE scores (26.42±3.47) than those who received SA (24.40±3.85) along 8 weeks (95% CI = 0.69, 3.34, p = 0.0036).","['Vascular Cognitive Impairment with No Dementia', 'patients with vascular cognitive impairment with no dementia (VCIND', '120 VCIND patients']","['Acupuncture', 'electro-acupuncture (EA) or sham acupuncture (SA', 'acupuncture', 'EA']","['changes of cognitive function measured by the Montreal Cognitive Assessment (MoCA', 'scores of the Mini-Mental State Examination (MMSE), the Modified Barthel Index (MBI) and the Self-rating Depression Scale (SDS', 'MoCA score', 'MoCA scores', 'serious adverse events', 'MMSE scores', 'cognitive function']","[{'cui': 'C3805043', 'cui_str': 'Vascular cognitive impairment'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}]",120.0,0.412137,"Patients who received EA showed a greater increase in MMSE scores (26.42±3.47) than those who received SA (24.40±3.85) along 8 weeks (95% CI = 0.69, 3.34, p = 0.0036).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Yin', 'Affiliation': 'Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Shanghai Medical College, Fudan University, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': 'Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Yueqi', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Lixing', 'Initials': 'L', 'LastName': 'Lao', 'Affiliation': 'Virginia University of Integrative Medicine, Fairfax, VA, USA.'}, {'ForeName': 'Zhangjin', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'School of Chinese Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong.'}, {'ForeName': 'Yiqun', 'Initials': 'Y', 'LastName': 'Mi', 'Affiliation': 'Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Shifen', 'Initials': 'S', 'LastName': 'Xu', 'Affiliation': 'Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201353'] 3123,33939245,A low exhaled nitric oxide level excludes a short-term benefit from inhaled corticosteroids in suspected asthma: A randomized placebo-controlled trial.,"BACKGROUND AND OBJECTIVE Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker that reflects IL-4/IL-13 production and therefore represents T2 allergic inflammation. FeNO has previously been used to guide inhaled corticosteroid (ICS) treatment in asthma. The purpose of this study was to determine if a low FeNO (≤27 ppb) could be used to reliably identify patients with symptoms suggestive of asthma who would not benefit from initiating treatment with an ICS. METHODS A total of 180 steroid-naïve adults with healthcare professional suspected asthma and an FeNO of ≤27 ppb were randomized to receive either 400 mcg of budesonide or placebo daily for 3 months. The primary outcome was the difference in the Asthma Control Questionnaire 7 (ACQ7) between treatment groups and the study was powered to determine equivalence. Secondary outcomes were the difference in FEV 1 , Medical Research Council and Leicester Cough Questionnaire scores. RESULTS One hundred and thirty-four patients (68 budesonide and 66 placebo) completed the study and were included in the analysis. The between-group mean difference in ACQ7 from baseline to the end of the study was -0.25 and the 95% CI around this difference was -0.004 to 0.495 confirming equivalence (p < 0.05). Differences in forced expiratory volume over 1 s and other secondary outcomes were also small and clinically unimportant. CONCLUSION The results of this study suggest that steroid-naïve patients with symptoms suggestive of asthma and an FeNO ≤ 27 ppb are unlikely to benefit from initiating treatment with an ICS over 3 months. However, further research is recommended to confirm these findings before withholding ICS treatment.",2021,The between-group mean difference in ACQ7 from baseline to the end of the study was -0.25 and the 95% CI around this difference was -0.004 to 0.495 confirming equivalence (p < 0.05).,"['suspected asthma', 'One hundred and thirty-four patients (68', '180 steroid-naïve adults with healthcare professional suspected asthma and an FeNO of ≤27\u2009ppb', 'patients with symptoms suggestive of asthma who would not benefit from initiating treatment with an ICS', 'naïve patients with symptoms suggestive of asthma']","['budesonide and 66 placebo', '400\u2009mcg of budesonide or placebo', 'corticosteroid (ICS', 'inhaled corticosteroids', 'steroid', 'placebo']","['FEV 1 , Medical Research Council and Leicester Cough Questionnaire scores', 'Asthma Control Questionnaire 7 (ACQ7', 'ACQ7', 'forced expiratory volume']","[{'cui': 'C1271086', 'cui_str': 'Suspected asthma'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0032441', 'cui_str': 'Polybrominated biphenyl'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]","[{'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0439211', 'cui_str': 'mcg'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}]","[{'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}]",,0.532935,The between-group mean difference in ACQ7 from baseline to the end of the study was -0.25 and the 95% CI around this difference was -0.004 to 0.495 confirming equivalence (p < 0.05).,"[{'ForeName': 'Lissa', 'Initials': 'L', 'LastName': 'Sutherland', 'Affiliation': 'School of Life Sciences, NIHR BRC University of Nottingham, University of Nottingham, Nottingham City Hospital, Nottingham, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Shaw', 'Affiliation': 'School of Medicine, NIHR BRC University of Nottingham, University of Nottingham, Nottingham City Hospital, Nottingham, UK.'}, {'ForeName': 'Clair', 'Initials': 'C', 'LastName': 'Parrish', 'Affiliation': 'School of Medicine, NIHR BRC University of Nottingham, University of Nottingham, Nottingham City Hospital, Nottingham, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Singleton', 'Affiliation': 'School of Medicine, NIHR BRC University of Nottingham, University of Nottingham, Nottingham City Hospital, Nottingham, UK.'}, {'ForeName': 'Tricia M', 'Initials': 'TM', 'LastName': 'McKeever', 'Affiliation': 'School of Medicine, NIHR BRC University of Nottingham, University of Nottingham, Nottingham City Hospital, Nottingham, UK.'}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Stewart', 'Affiliation': 'School of Medicine, NIHR BRC University of Nottingham, University of Nottingham, Nottingham City Hospital, Nottingham, UK.'}, {'ForeName': 'Dominick', 'Initials': 'D', 'LastName': 'Shaw', 'Affiliation': 'School of Medicine, NIHR BRC University of Nottingham, University of Nottingham, Nottingham City Hospital, Nottingham, UK.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Martin', 'Affiliation': 'School of Medicine, NIHR BRC University of Nottingham, University of Nottingham, Nottingham City Hospital, Nottingham, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Harrison', 'Affiliation': 'School of Medicine, NIHR BRC University of Nottingham, University of Nottingham, Nottingham City Hospital, Nottingham, UK.'}]","Respirology (Carlton, Vic.)",['10.1111/resp.14055'] 3124,33938094,Public health interventions for preventing re-infection of Opisthorchis viverrini: application of the self-efficacy theory and group process in high-prevalent areas of Thailand.,"OBJECTIVE To study the effectiveness of public health interventions in preventing Opisthorchis viverrini (OV) re-infection in high-prevalence areas of Thailand. METHODS 68 people from Sisaket, the province with the second-highest prevalence in Thailand, who tested positive for OV eggs in faeces and took praziquantel before the start of the study, participated. 34 participants were allocated to the experimental group, which received a 12-week public health intervention based on the self-efficacy theory and group process between July and October 2018. The control group received the usual services. Data were collected using a questionnaire with a reliability of 0.84. Faecal examinations using the formalin-ether concentration technique were conducted before and after the experiment. The re-infection rate was analysed after the experimental 12 weeks and after one year. Descriptive and inferential statistics, including paired t-test and independent t-test, were employed for data analysis. RESULTS After the experiment, the mean scores of knowledge, perceived self-efficacy, self-efficacy expectation and OV prevention behaviour of the experimental group were significantly higher than before the experiment and also higher than scores of the control group (P < 0.05). CONCLUSION The public health intervention is useful. It educated the experimental group about OV, perceived self-efficacy and self-efficacy expectation in changing behaviour to prevent OV re-infection. As a result, no re-infections were observed after the 12-week intervention nor at the one-year follow-up. Public health benefits will be evident if the results are extended to other high-prevalence areas.",2021,"After the experiment, the mean scores of knowledge, perceived self-efficacy, self-efficacy expectation, and OV prevention behavior of the experimental group were signifivcantly higher than before the experiment and also higher than scores of the control group (p<0.05). ","['68 people from Sisaket, the province with the second-highest prevalence in Thailand, who tested positive for OV eggs in feces and took praziquantel before the start of the study, participated', '34 participants', 'high-prevalent areas of Thailand']","['public health interventions', 'public health intervention', 'usual services', 'Opisthorchis viverrini']","['mean scores of knowledge, perceived self-efficacy, self-efficacy expectation, and OV prevention behavior', 'Opisthorchis viverrini (OV', 're-infection rate']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0029111', 'cui_str': 'Opisthorchis viverrini'}, {'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0032911', 'cui_str': 'Praziquantel'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0029111', 'cui_str': 'Opisthorchis viverrini'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0029111', 'cui_str': 'Opisthorchis viverrini'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",34.0,0.0349741,"After the experiment, the mean scores of knowledge, perceived self-efficacy, self-efficacy expectation, and OV prevention behavior of the experimental group were signifivcantly higher than before the experiment and also higher than scores of the control group (p<0.05). ","[{'ForeName': 'Nopparat', 'Initials': 'N', 'LastName': 'Songserm', 'Affiliation': 'Faculty of Public Health, Ubon Ratchathani Rajabhat University, Ubon Ratchathani, Thailand.'}, {'ForeName': 'Worawut', 'Initials': 'W', 'LastName': 'Namwong', 'Affiliation': 'Hua Chang Sub-District Health Promoting Hospital, Uthumphon Phisai District, Sisaket, Thailand.'}, {'ForeName': 'Somkiattiyos', 'Initials': 'S', 'LastName': 'Woradet', 'Affiliation': 'Faculty of Health and Sports Science, Thaksin University, Phatthalung, Thailand.'}, {'ForeName': 'Banchob', 'Initials': 'B', 'LastName': 'Sripa', 'Affiliation': 'Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Akhtar', 'Initials': 'A', 'LastName': 'Ali', 'Affiliation': 'Department of Biological Science, The University of Tulsa, Tulsa, OK, USA.'}]",Tropical medicine & international health : TM & IH,['10.1111/tmi.13598'] 3125,33938088,Patent foramen ovale closure in stroke patients with migraine in the CLOSE trial. The CLOSE-MIG study.,"BACKGROUND AND PURPOSE The efficacy of patent foramen ovale (PFO) closure to reduce the frequency of migraine attacks remains controversial. METHODS This was a planned sub-study in migraine patients enrolled in a randomized, clinical trial designed to assess the superiority of PFO closure plus antiplatelet therapy over antiplatelet therapy alone to prevent stroke recurrence in patients younger than 60 years with a PFO-associated cryptogenic ischaemic stroke. The main outcome was the mean annual number of migraine attacks in migraine patients with aura and in those without aura, as recorded at each follow-up visit by study neurologists. RESULTS Of 473 patients randomized to PFO closure or antiplatelet therapy, 145 (mean age 41.9 years; women 58.6%) had migraine (75 with aura and 70 without aura). Sixty-seven patients were randomized to PFO closure and 78 to antiplatelet therapy. During a mean follow-up of about 5 years, there were no differences between antiplatelet-only and PFO closure groups in the mean annual number of migraine attacks, both in migraine patients with aura (9.2 [11.9] vs. 12.0 [19.1], p = 0.81) and in those without aura (12.1 [16.1] vs. 11.8 [18.4], p > 0.999). There were no differences between treatment groups regarding cessation of migraine attacks, migraine-related disability at 2 years and use of migraine-preventive drugs during follow-up. CONCLUSIONS In young and middle-aged adults with PFO-associated cryptogenic stroke and migraine, PFO closure plus antiplatelet therapy did not reduce the mean annual number of migraine attacks compared to antiplatelet therapy alone, in migraine patients both with and without aura.",2021,"During a mean follow-up of about 5 years, there were no differences between antiplatelet-only and PFO closure groups in the mean annual number of migraine attacks, both in migraine patients with aura (9.2 [11.9] vs 12.0 [19.1], p = 0.81) and in those without aura (12.1 [16.1] vs 11.8 [18.4], p > 0.999).","['Sixty-seven patients', 'Stroke Patients With Migraine', 'Planned sub-study in migraine patients enrolled', 'young and middle-aged adults with PFO-associated cryptogenic stroke and migraine', 'patients younger than 60 years with a PFO-associated cryptogenic ischemic stroke', '473 patients randomized to PFO closure or antiplatelet therapy, 145 (mean age, 41.9 years; women 58.6%) had migraine (75 with aura and 70 without aura']","['PFO closure', 'Patent Foramen Ovale Closure', 'patent foramen ovale (PFO) closure', 'PFO closure plus antiplatelet therapy', 'PFO closure plus antiplatelet therapy over antiplatelet therapy alone', 'antiplatelet therapy']","['cessation of migraine attacks, migraine-related disability', 'migraine attacks', 'mean annual number of migraine attacks', 'stroke recurrence']","[{'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0016522', 'cui_str': 'Patent foramen ovale'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C4518466', 'cui_str': 'Stroke co-occurrent with migraine'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0189967', 'cui_str': 'Closure of patent foramen ovale'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0236018', 'cui_str': 'Aura'}]","[{'cui': 'C0189967', 'cui_str': 'Closure of patent foramen ovale'}, {'cui': 'C0016522', 'cui_str': 'Patent foramen ovale'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}]","[{'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",473.0,0.0519172,"During a mean follow-up of about 5 years, there were no differences between antiplatelet-only and PFO closure groups in the mean annual number of migraine attacks, both in migraine patients with aura (9.2 [11.9] vs 12.0 [19.1], p = 0.81) and in those without aura (12.1 [16.1] vs 11.8 [18.4], p > 0.999).","[{'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Mas', 'Affiliation': 'Stroke Unit, Department of Neurology, Sainte-Anne Hospital, Paris Descartes University, INSERM 1226, Paris, France.'}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Guillon', 'Affiliation': 'Stroke Unit, Department of Neurology, University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Anaïs', 'Initials': 'A', 'LastName': 'Charles-Nelson', 'Affiliation': ""Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges-Pompidou, Unité de Recherche Clinique, Centre d'Investigations Cliniques 1418 (CIC1418), Paris, France.""}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Domigo', 'Affiliation': 'Stroke Unit, Department of Neurology, Sainte-Anne Hospital, Paris Descartes University, INSERM 1226, Paris, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Derex', 'Affiliation': 'Stroke Unit, Department of Neurology, Hospices Civils de Lyon, EA 7425 HESPER, Claude Bernard Lyon 1 University, Lyon, France.'}, {'ForeName': 'Evelyne', 'Initials': 'E', 'LastName': 'Massardier', 'Affiliation': 'Stroke Unit, Department of Neurology, CHU Rouen, Rouen, France.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Arquizan', 'Affiliation': 'Department of Neurology, Gui de Chauliac Hospital, INSERM 1226, Montpellier, France.'}, {'ForeName': 'Fabrice', 'Initials': 'F', 'LastName': 'Vuillier', 'Affiliation': 'Stroke Unit, Department of Neurology, CHU Besançon, Besançon, France.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Timsit', 'Affiliation': 'Stroke Unit, Department of Neurology, CHRU Brest, Bretagne Occidentale University, INSERM 1028, Brest, France.'}, {'ForeName': 'Yannick', 'Initials': 'Y', 'LastName': 'Béjot', 'Affiliation': 'Stroke Unit, Department of Neurology, Dijon Stroke Registry, CHU Dijon, EA7460 Pathophysiology and Epidemiology of Cerebro-Cardiovascular diseases (PEC2), University of Burgundy, Dijon, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Detante', 'Affiliation': 'Stroke Unit, CHU Grenoble, INSERM 836-UJF-CEA-CHU, Grenoble, France.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Sablot', 'Affiliation': 'Stroke Unit, Department of Neurology, Perpignan Hospital, Perpignan, France.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Guidoux', 'Affiliation': 'Stroke Unit, Department of Neurology, Bichat Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Sibon', 'Affiliation': 'Stroke Unit, Department of Neurology, University Hospital, Bordeaux University, CNRS 5287, Bordeaux, France.'}, {'ForeName': 'Nelly', 'Initials': 'N', 'LastName': 'Dequatre-Ponchelle', 'Affiliation': 'Stroke Unit, Department of Neurology, Univ-Lille, INSERM U1171, CHU Lille, Lille, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Touzé', 'Affiliation': 'Normandie Université, Université Caen Normandie, CHU Caen Normandie, INSERM U1237, Caen, France.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Canaple', 'Affiliation': 'Stroke Unit, Department of Neurology, Laboratoire de Neurosciences Fonctionnelles et Pathologies, Centre Hospitalier Régional et Universitaire, Amiens, France.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Alamowitch', 'Affiliation': 'Service de Neurologie, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM, UMRS 938, Paris, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Aubry', 'Affiliation': 'Department of Cardiology, Bichat Hospital, Paris, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Teiger', 'Affiliation': 'Department of Cardiology, Henri Mondor Hospital, AP-HP, UPEC, Créteil, France.'}, {'ForeName': 'Geneviève', 'Initials': 'G', 'LastName': 'Derumeaux', 'Affiliation': 'Department of Physiology, Henri Mondor Hospital, APHP, INSERM U955, Créteil, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Chatellier', 'Affiliation': ""Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges-Pompidou, Unité de Recherche Clinique, Centre d'Investigations Cliniques 1418 (CIC1418), Paris, France.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of neurology,['10.1111/ene.14892'] 3126,33967047,Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial.,"BACKGROUND The plasma fraction GRF6019 shows multiple benefits on brain aging in mice, including enhanced cognition, neurogenesis, and synaptic density, as well as reduced neuroinflammation. OBJECTIVE To evaluate the safety, tolerability, and preliminary efficacy of GRF6019 in patients with severe Alzheimer's disease (AD). METHODS A phase II, double-blind, placebo-controlled study in patients with severe AD (Mini-Mental State Examination score 0-10). Patients were randomized 2 : 1 to GRF6019 (N = 18) or placebo (N = 8) and received daily 250 mL intravenous infusions over 5 days. The primary endpoints were the rates of adverse events (AEs) and the tolerability of GRF6019 as assessed by the number of patients completing the study. Change from baseline in cognitive and functional assessments was also evaluated. RESULTS All patients completed 100%of study visits and infusions. The rate of AEs was similar in the GRF6019 (8/18 patients [44.4%]) and placebo (3/8 patients [37.5%]) groups, and there were no deaths or serious AEs. The most common AEs considered related to treatment were mild, transient changes in blood pressure in the GRF6019 group (hypotension: 2 patients [11.1%]; hypertension: 1 patient [5.6%]); there were no related AEs in the placebo group. The trial was not powered to detect statistically significant differences between treatment groups. At the end of the study, patients in both treatment groups remained stable or improved on all cognitive and functional endpoints. CONCLUSION GRF6019 demonstrated excellent safety, feasibility, and tolerability. Future trials designed to characterize the potential functional benefits of GRF6019 and related plasma fractions in severe AD are warranted.",2021,"The most common AEs considered related to treatment were mild, transient changes in blood pressure in the GRF6021 group (hypotension: 2 patients [11.1%]; hypertension: 1 patient [5.6%]); there were no related AEs in the placebo group.","[""patients with severe Alzheimer's disease (AD"", 'patients with severe AD (Mini-Mental State Examination score 0-10', ""Severe Alzheimer's Disease""]","['Placebo', 'GRF6019', 'GRF6019 Infusions', 'placebo']","['excellent safety, feasibility, and tolerability', 'rate of AEs', 'Safety and Tolerability', 'rates of adverse events (AEs) and the tolerability of GRF6019', 'deaths or serious AEs', 'blood pressure', 'safety, tolerability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",,0.664615,"The most common AEs considered related to treatment were mild, transient changes in blood pressure in the GRF6021 group (hypotension: 2 patients [11.1%]; hypertension: 1 patient [5.6%]); there were no related AEs in the placebo group.","[{'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Hannestad', 'Affiliation': 'Alkahest Inc., San Carlos, CA, USA.'}, {'ForeName': 'Tiffanie', 'Initials': 'T', 'LastName': 'Duclos', 'Affiliation': 'Alkahest Inc., San Carlos, CA, USA.'}, {'ForeName': 'Whitney', 'Initials': 'W', 'LastName': 'Chao', 'Affiliation': 'Alkahest Inc., San Carlos, CA, USA.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Koborsi', 'Affiliation': 'Alkahest Inc., San Carlos, CA, USA.'}, {'ForeName': 'Vicki', 'Initials': 'V', 'LastName': 'Klutzaritz', 'Affiliation': 'Alkahest Inc., San Carlos, CA, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Beck', 'Affiliation': 'CCT Research, Scottsdale, Arizona, USA.'}, {'ForeName': 'Ashok K', 'Initials': 'AK', 'LastName': 'Patel', 'Affiliation': 'Bio Behavioral Health, Toms River, NJ, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Scott', 'Affiliation': 'Riverside Clinical Research, Edgewater, FL, USA.'}, {'ForeName': 'Stephen G', 'Initials': 'SG', 'LastName': 'Thein', 'Affiliation': 'Pacific Research Network -an ERG Portfolio Company, San Diego, CA, USA.'}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Cummings', 'Affiliation': 'Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Kay', 'Affiliation': 'Cognitive Research Corporation, St. Petersburg, FL, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Braithwaite', 'Affiliation': 'Alkahest Inc., San Carlos, CA, USA.'}, {'ForeName': 'Karoly', 'Initials': 'K', 'LastName': 'Nikolich', 'Affiliation': 'Alkahest Inc., San Carlos, CA, USA.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-210011'] 3127,34388409,Effect of 10 consecutive days of remote ischemic preconditioning on local neuromuscular performance.,"BACKGROUND Most studies focus on the effects of a single remote ischemic preconditioning (RIPC) session on performance. However, the training-like effect of repeat RIPC sessions performed on consecutive days could potentially be even more beneficial to neuromuscular performance than a single RIPC session. Therefore, aim of the study was to assess the impact of 10 days of RIPC on local neuromuscular performance. METHODS Thirty-seven male participants performed 10 days of either RIPC or sham-controlled condition. Before and after procedure, the maximal voluntary contraction and muscle fatigue were assessed by dynamometry and surface electromyography (EMG) of the isometric extension of the knee joint. The following neuromuscular outcomes were investigated: peak torque (PKTQ); rate of force development (RTD); time to failure; and the slope of median frequency of power spectrum (MDF) and EMG amplitude. RESULTS After RIPC, while there was no change in PKTQ and time to failure, the late RTD and MDF slope were significantly affected. The RTD at 0-100 and 0-200 ms showed 24 and 16% increase, respectively, while the MDF slope showed 24% decrease in rectus femoris. CONCLUSIONS 10 days of RIPC induced neuromuscular performance changes in the quadriceps muscle. Even though there were no changes in task to failure performance, RIPC showed EMG changes limited to rectus femoris and increased late RTD in MVC task.",2021,"Even though there were no changes in task to failure performance, RIPC showed EMG changes limited to rectus femoris and increased late RTD in MVC task.",['Thirty-seven male participants performed 10\xa0days of either'],"['single remote ischemic preconditioning (RIPC) session', 'RIPC', 'RIPC or sham-controlled condition', 'remote ischemic preconditioning']","['dynamometry and surface electromyography (EMG) of the isometric extension of the knee joint', 'maximal voluntary contraction and muscle fatigue', 'neuromuscular performance changes', 'peak torque (PKTQ); rate of force development (RTD); time to failure; and the slope of median frequency of power spectrum (MDF) and EMG amplitude', 'local neuromuscular performance', 'MDF slope', 'rectus femoris', 'PKTQ and time to failure, the late RTD and MDF slope']","[{'cui': 'C4319569', 'cui_str': '37'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0376466', 'cui_str': 'Ischemic Pre-Conditioning'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0430815', 'cui_str': 'Surface EMG'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0242979', 'cui_str': 'Muscle fatigue'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0429340', 'cui_str': 'EMG amplitude'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205087', 'cui_str': 'Late'}]",37.0,0.144413,"Even though there were no changes in task to failure performance, RIPC showed EMG changes limited to rectus femoris and increased late RTD in MVC task.","[{'ForeName': 'Bartłomiej', 'Initials': 'B', 'LastName': 'Niespodziński', 'Affiliation': 'Department of Human Biology, Institute of Physical Education, Kazimierz Wielki University, Bydgoszcz, Poland. Electronic address: bar.niespodzinski@wp.pl.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Mieszkowski', 'Affiliation': 'Department of Gymnastics and Dance, Gdansk University of Physical Education and Sport, Gdańsk, Poland.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Kochanowicz', 'Affiliation': 'Department of Physiotherapy, The Faculty of Health Sciences with the Institute of Maritime and Tropical Medicine, Medical University of Gdańsk, Gdańsk, Poland.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Kochanowicz', 'Affiliation': 'Department of Gymnastics and Dance, Gdansk University of Physical Education and Sport, Gdańsk, Poland.'}, {'ForeName': 'Jędrzej', 'Initials': 'J', 'LastName': 'Antosiewicz', 'Affiliation': 'Department of Bioenergetics and Physiology of Exercise, Medical University of Gdańsk, Gdańsk, Poland.'}]",Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology,['10.1016/j.jelekin.2021.102584'] 3128,34388407,The relation between task-relatedness of anxiety and metacognitive performance.,"It is well established that anxiety influences a range of cognitive processes such as cognitive control or decision-making. What is less known is how anxiety influences the metacognitive evaluations individuals make about their own performance. The present study explored the importance of task-relatedness in the relation between anxiety and metacognitive awareness. More specifically, we hypothesized that induced anxiety would affect metacognitive performance in opposite directions depending solely on whether the threat is perceived as related or unrelated to the performance. We conducted two experiments to test this hypothesis. In both studies, electric shocks were administered randomly, regardless of participant's performance. In experiment 1, participants were informed that the shocks would be administered randomly, unrelated to performance. In experiment 2, participants were told that their metacognitive performance would influence the administration of the electric shocks (i.e. fewer electric shocks with better metacognitive performance). Our predictions were confirmed. Threat perceived as unrelated to metacognitive performance (Experiment 1) decreased metacognitive performance. Threat believed to be related to metacognitive performance resulted in improved performance (Experiment 2). These findings confirm that induced anxiety exerts a strong influence on metacognitive awareness while sparing first-order task performance. We furthermore demonstrate that the perceived relatedness of the anxiety determines whether metacognitive performance decreases or improves performance under threat.",2021,Threat believed to be related to metacognitive performance resulted in improved performance (Experiment 2).,[],[],"['metacognitive performance', 'metacognitive awareness']",[],[],"[{'cui': 'C4046092', 'cui_str': 'Meta-cognitive Awareness'}]",,0.0361106,Threat believed to be related to metacognitive performance resulted in improved performance (Experiment 2).,"[{'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Culot', 'Affiliation': 'Center for Research in Cognition and Neurosciences (CRCN) - Université Libre de Bruxelles (ULB), Brussels, Belgium; Neurosciences Institute (UNI), Université Libre de Bruxelles (ULB), Brussels, Belgium. Electronic address: cculot@ulb.be.'}, {'ForeName': 'Gaia', 'Initials': 'G', 'LastName': 'Corlazzoli', 'Affiliation': 'Center for Research in Cognition and Neurosciences (CRCN) - Université Libre de Bruxelles (ULB), Brussels, Belgium; Neurosciences Institute (UNI), Université Libre de Bruxelles (ULB), Brussels, Belgium.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Fantini-Hauwel', 'Affiliation': 'Research center for experiMEntAl & clinical cogNitive psychopatholoGy (MEANING), Université Libre de Bruxelles (ULB), Brussels, Belgium.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Gevers', 'Affiliation': 'Center for Research in Cognition and Neurosciences (CRCN) - Université Libre de Bruxelles (ULB), Brussels, Belgium; Neurosciences Institute (UNI), Université Libre de Bruxelles (ULB), Brussels, Belgium.'}]",Consciousness and cognition,['10.1016/j.concog.2021.103191'] 3129,33940308,Biomechanical measures of balance after balance-based exergaming training dedicated for patients with Parkinson's disease.,"INTRODUCTION Although previous studies have contributed to our understanding of the effects of implementing the virtual reality as a rehabilitation tool in patients with Parkinson's disease (PD), additional research is needed to examine the effects of applying balance-based exergaming training on quantitative biomechanical measures of balance. RESEARCH QUESTION To investigate the effects of balance-based conventional and exergaming training on posture parameters. METHODS The study involved 24 patients with PD (Hoehn and Yahr stages II-III).Participants underwent twelve training sessions during the 4-week training period. The experimental group (n=12) was trained with a custom-made exergaming balance based training system, the control group (n=12) underwent a conventional balance training. All objective outcomes were measured before intervention and the day after completion of training program. Postural stability was assessed using the quiet standing test, dynamic balance was assessed using limits of stability (LOS) and functional balance (FBT) tests. RESULTS After training, participants in both groups showed significantly better results in static balance performance. However, only exergaming training significantly improved LOS performance (higher values of Range of forward lean (p = 0.039, d z = 0.67) and leaning rate (p=0.007, d z =0.96). Also FBT test improved significantly only in experimental group (decrease in time to target hit (p=0.02, d z =0.76) and significant increase of average COP velocity (p=0.008, d z =0.93). CONCLUSION This study found that exergaming training created for patients with PD enhanced static and dynamic balance whereas conventional balance training improved static balance. Posturography is sensitive enough to reveal differential effects of training for both groups. These findings support the inclusion of our exergaming training in the exercise program for participants with PD.",2021,"Also FBT test improved significantly only in experimental group (decrease in time to target hit (p=0.02, d z =0.76) and significant increase of average COP velocity (p=0.008, d z =0.93). ","[""patients with Parkinson's disease"", '24 patients with PD (Hoehn and Yahr stages II-III).Participants underwent twelve training sessions during the 4-week training period', 'participants with PD', ""patients with Parkinson's disease (PD""]","['conventional balance training', 'custom-made exergaming balance based training system, the control group (n=12) underwent a conventional balance training', 'balance-based conventional and exergaming training']","['time to target hit', 'static balance', 'limits of stability (LOS) and functional balance (FBT) tests', 'average COP velocity', 'leaning rate', 'LOS performance', 'quiet standing test, dynamic balance', 'Postural stability', 'static balance performance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0162343', 'cui_str': 'Customs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0056471', 'cui_str': 'creatinolfosfate'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0439654', 'cui_str': 'Quiet'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0205278', 'cui_str': 'Postural'}]",24.0,0.00558813,"Also FBT test improved significantly only in experimental group (decrease in time to target hit (p=0.02, d z =0.76) and significant increase of average COP velocity (p=0.008, d z =0.93). ","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Brachman', 'Affiliation': 'Institute of Sport Sciences, Department of Biomechanics, The Jerzy Kukuczka Academy of Physical Education, 72a Mikolowska, 40-065 Katowice, Poland. Electronic address: a.brachman@awf.katowice.pl.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Marszałek', 'Affiliation': 'Institute of Sport Sciences, Department of Human Motor Behavior, The Jerzy Kukuczka Academy of Physical Education, 72a Mikolowska, 40-065 Katowice, Poland. Electronic address: w.marszalek@awf.katowice.pl.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Kamieniarz', 'Affiliation': 'Institute of Sport Sciences, Department of Human Motor Behavior, The Jerzy Kukuczka Academy of Physical Education, 72a Mikolowska, 40-065 Katowice, Poland. Electronic address: a.kamieniarz@awf.katowice.pl.'}, {'ForeName': 'Justyna', 'Initials': 'J', 'LastName': 'Michalska', 'Affiliation': 'Institute of Sport Sciences, Department of Human Motor Behavior, The Jerzy Kukuczka Academy of Physical Education, 72a Mikolowska, 40-065 Katowice, Poland. Electronic address: j.michalska@awf.katowice.pl.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Pawłowski', 'Affiliation': 'Institute of Sport Sciences, Department of Human Motor Behavior, The Jerzy Kukuczka Academy of Physical Education, 72a Mikolowska, 40-065 Katowice, Poland. Electronic address: m.pawlowski@awf.katowice.pl.'}, {'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Juras', 'Affiliation': 'Institute of Sport Sciences, Department of Human Motor Behavior, The Jerzy Kukuczka Academy of Physical Education, 72a Mikolowska, 40-065 Katowice, Poland. Electronic address: g.juras@awf.katowice.pl.'}]",Gait & posture,['10.1016/j.gaitpost.2021.04.036'] 3130,33939383,Moderate-Intensity Aerobic vs Resistance Exercise and Dietary Modification in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial.,"INTRODUCTION This randomized trial aimed to compare the effects of moderate-intensity aerobic vs resistance exercise with dietary modification in patients with nonalcoholic fatty liver disease (NAFLD). METHODS Patients with NAFLD were randomly assigned (1:1) to a 12-week supervised training program of moderate-intensity aerobic or resistance exercise with dietary intervention consisting of monthly individual nutritional counseling by a dietician. Transient elastography, anthropometry, body composition, cardiorespiratory fitness, biochemistries, and glucose tolerance were measured at baseline and 12 weeks. RESULTS Eighteen subjects exercised for an average of 3.35 ± 0.30 sessions a week in the aerobic group, and 17 subjects exercised an average of 3.39 ± 0.28 sessions a week in the resistance group. After completion of the training program, hepatic fat content was similarly reduced in both groups (P < 0.001). The mean relative reduction from baseline in the aerobic group was -10.3% (95% confidence interval -18.2 to -2.40) and the resistance group was -12.6% (-20.5 to -4.69). Liver steatosis (defined as controlled attenuation parameter >248 dB/m) disappeared in 9 (50%) of the aerobic group and in 9 (53%) of the resistance group. Whole-body and muscle insulin sensitivity indexes were improved, and waist circumference was reduced comparably in both exercise groups. The number of exercise sessions per week was correlated with the absolute reduction in hepatic fat content (r = 0.52; P = 0.001). Weekly exercise training ≥3 sessions substantially attenuates liver fat accumulation independent of weight loss. DISCUSSION Moderate-intensity aerobic training and resistance training with dietary modification are equally effective for reducing intrahepatic fat and improving underlying insulin resistance among patients with NAFLD.",2021,"After completion of the training program, hepatic fat content was similarly reduced in both groups (P < 0.001).","['patients with NAFLD', 'Patients With Nonalcoholic Fatty Liver Disease', 'patients with nonalcoholic fatty liver disease (NAFLD', 'Patients with NAFLD']","['supervised training program of moderate-intensity aerobic or resistance exercise with dietary intervention consisting of monthly individual nutritional counseling by a dietician', 'moderate-intensity aerobic vs resistance exercise with dietary modification', 'Moderate-Intensity Aerobic vs Resistance Exercise and Dietary Modification']","['liver fat accumulation independent of weight loss', 'waist circumference', 'Transient elastography, anthropometry, body composition, cardiorespiratory fitness, biochemistries, and glucose tolerance', 'hepatic fat content', 'Whole-body and muscle insulin sensitivity indexes', 'Liver steatosis', 'mean relative reduction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C3536818', 'cui_str': 'Dietitian'}]","[{'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0332291', 'cui_str': 'Independent of'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C2748260', 'cui_str': 'Transient elastography'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0015695', 'cui_str': 'Fatty Liver'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",18.0,0.00941012,"After completion of the training program, hepatic fat content was similarly reduced in both groups (P < 0.001).","[{'ForeName': 'Phunchai', 'Initials': 'P', 'LastName': 'Charatcharoenwitthaya', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.'}, {'ForeName': 'Kraisingh', 'Initials': 'K', 'LastName': 'Kuljiratitikal', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.'}, {'ForeName': 'Ophas', 'Initials': 'O', 'LastName': 'Aksornchanya', 'Affiliation': 'Department of Health Promotion, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.'}, {'ForeName': 'Kusuma', 'Initials': 'K', 'LastName': 'Chaiyasoot', 'Affiliation': 'Division of Clinical Nutrition, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.'}, {'ForeName': 'Wimolrak', 'Initials': 'W', 'LastName': 'Bandidniyamanon', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.'}, {'ForeName': 'Natthinee', 'Initials': 'N', 'LastName': 'Charatcharoenwitthaya', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Thammasat University, Thailand.'}]",Clinical and translational gastroenterology,['10.14309/ctg.0000000000000316'] 3131,33945820,Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.,"PURPOSE To assess the post-acute activity and clinical utility of reproxalap, a novel reactive aldehyde species (RASP) inhibitor, versus vehicle in patients with seasonal allergic conjunctivitis. DESIGN Parallel-group, double-masked, randomized Phase 3 trial. METHODS Two topical ocular reproxalap concentrations (0.25% and 0.5%) were evaluated versus vehicle in patients with allergic conjunctivitis randomized 1:1:1 and treated with test article 10 minutes prior to conjunctival seasonal allergen challenge. The primary endpoint was area under the post-acute ocular itching score (range = 0-4) curve from 10 to 60 minutes after challenge. The key secondary endpoint was the proportion of subjects with ≥2 points improvement from their peak ocular itching score at baseline. RESULTS A total of 318 patients were randomized at 11 US sites. Both concentrations of reproxalap (0.25% and 0.5%) achieved the primary endpoint (P < .0001 and P = .003, respectively) and the key secondary endpoint (P = .0005 and P = .02, respectively). Time to complete resolution of ocular itching was statistically faster for both reproxalap concentrations than for vehicle (P < .0001 and P = .001, respectively). No safety or tolerability concerns were noted. The most common adverse event was mild and transient instillation site irritation. CONCLUSION Reproxalap was effective at reducing ocular itching in patients with allergic conjunctivitis. Reproxalap activity was clinically relevant, as assessed by responder-based and distributional analyses. ALLEVIATE represents one of the first allergic conjunctivitis Phase 3 trials of a novel mechanism of action in decades, and is unique among conjunctival allergen challenge trials in assessing clinical relevance with standard and validated techniques.",2021,"Time to complete resolution of ocular itching was statistically faster for both reproxalap concentrations than for vehicle (P < .0001 and P = .001, respectively).","['patients with allergic conjunctivitis', 'Allergic Conjunctivitis', '318 patients', 'patients with seasonal allergic conjunctivitis']","['Reproxalap', 'reproxalap, a novel reactive aldehyde species (RASP) inhibitor']","['area under the post-acute ocular itching score', 'Reproxalap activity', 'proportion of subjects with ≥2 points improvement from their peak ocular itching score', 'Time to complete resolution of ocular itching', 'safety or tolerability concerns']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009766', 'cui_str': 'Allergic conjunctivitis'}, {'cui': 'C0339164', 'cui_str': 'Seasonal allergic conjunctivitis'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0001992', 'cui_str': 'Aldehyde'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0022281', 'cui_str': 'Itching of eye'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",318.0,0.296781,"Time to complete resolution of ocular itching was statistically faster for both reproxalap concentrations than for vehicle (P < .0001 and P = .001, respectively).","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Clark', 'Affiliation': 'From Aldeyra Therapeutics, Lexington, MA (D.C, B.C, T.C.B), Adelphi Values, Boston, MA (A.L.S), Kentucky Eye Institute, Lexington, KY (P.K), Virginia Eye Consultants, Norfolk, VA, USA (J.S).'}, {'ForeName': 'Bill', 'Initials': 'B', 'LastName': 'Cavanagh', 'Affiliation': 'From Aldeyra Therapeutics, Lexington, MA (D.C, B.C, T.C.B), Adelphi Values, Boston, MA (A.L.S), Kentucky Eye Institute, Lexington, KY (P.K), Virginia Eye Consultants, Norfolk, VA, USA (J.S).'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Shields', 'Affiliation': 'From Aldeyra Therapeutics, Lexington, MA (D.C, B.C, T.C.B), Adelphi Values, Boston, MA (A.L.S), Kentucky Eye Institute, Lexington, KY (P.K), Virginia Eye Consultants, Norfolk, VA, USA (J.S).'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Karpecki', 'Affiliation': 'From Aldeyra Therapeutics, Lexington, MA (D.C, B.C, T.C.B), Adelphi Values, Boston, MA (A.L.S), Kentucky Eye Institute, Lexington, KY (P.K), Virginia Eye Consultants, Norfolk, VA, USA (J.S).'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Sheppard', 'Affiliation': 'From Aldeyra Therapeutics, Lexington, MA (D.C, B.C, T.C.B), Adelphi Values, Boston, MA (A.L.S), Kentucky Eye Institute, Lexington, KY (P.K), Virginia Eye Consultants, Norfolk, VA, USA (J.S).'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Brady', 'Affiliation': 'From Aldeyra Therapeutics, Lexington, MA (D.C, B.C, T.C.B), Adelphi Values, Boston, MA (A.L.S), Kentucky Eye Institute, Lexington, KY (P.K), Virginia Eye Consultants, Norfolk, VA, USA (J.S). Electronic address: tbrady@aldeyra.com.'}]",American journal of ophthalmology,['10.1016/j.ajo.2021.04.023'] 3132,33949126,Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes trial: A post-hoc analysis.,,2021,"In people with type 1 or 2 diabetes, cardiovascular autonomic neuropathy (CAN) is associated with the development of atherosclerotic cardiovascular disease (CVD) and with a high risk of lethal arrhythmias and sudden death.",[],['Intensive Risk Factor Management'],"['risk of total death', 'death or hospitalization due to heart failure', 'orthostatic hypotension (OH']",[],"[{'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0020651', 'cui_str': 'Orthostatic hypotension'}]",,0.237588,"In people with type 1 or 2 diabetes, cardiovascular autonomic neuropathy (CAN) is associated with the development of atherosclerotic cardiovascular disease (CVD) and with a high risk of lethal arrhythmias and sudden death.","[{'ForeName': 'Yoshimasa', 'Initials': 'Y', 'LastName': 'Aso', 'Affiliation': 'Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Japan.'}]",Journal of diabetes investigation,['10.1111/jdi.13565'] 3133,33949051,The efficacy of an educational movie to improve pain and dysfunctional behavior in school children: A randomized controlled trial.,"BACKGROUND Chronic pain in children is a serious issue, therefore calling for effective prevention/intervention measures. This study aimed to evaluate the efficacy of an educational movie on pain knowledge in school children in general and on pain-related behaviours and pain intensity in those who are affected by chronic pain. Regarding those affected, the association between pain knowledge and intensity, as well as the potential mediating effect of pain-related behaviours, were investigated. METHODS Recruited from four schools, N = 381 students (51.7% female; M age  = 11.4, SD = 0.95) participated, of which n = 108 reported chronic pain. Each school was randomly allocated to the intervention or control group (cluster-randomization). At two time points spaced 4-5 weeks apart, students provided information on their pain knowledge, pain-related behaviour (passive pain coping, pain-related disability, missed school days, medication use) and pain intensity. After the first assessment, students in the intervention group watched an educational movie. Multilevel linear models for all outcomes were calculated as well as a mediation analysis. RESULTS Pain knowledge increased significantly in the intervention group (β = 2.76 [95% CI 2.20, 3.31]). However, no significant time-by-group interactions were found for pain-related behaviour or pain intensity. The mediation model identified that the indirect effect of pain knowledge on pain intensity was mediated by pain-related behaviour (β = -0.18, p = 0.014 and β = 0.38, p < 0.001, respectively). CONCLUSIONS Educational movies may be an effective tool for educating students about pain management. However, the knowledge gained may not be sufficient to improve pain behaviour and intensity overall. SIGNIFICANCE A 10-min educational movie on chronic pain management was tested in school children (N = 381). Following the intervention, knowledge of chronic pain concepts was statistically greater in the intervention group compared to the control group not watching the movie. Furthermore, a mediation model theoretically determined whether an association between pain knowledge and pain intensity exists, and whether this is explained by level of dysfunctional pain-related behaviorisms. Full mediation was confirmed.",2021,"Following the intervention, knowledge of chronic pain concepts was statistically greater in the intervention group compared to the control group not watching the movie.","['Recruited from four schools, N\xa0', 'school children in general and on pain-related behaviours and pain intensity in those who are affected by chronic pain', 'school children (N\xa0=\xa0381', 'school children', '381 students (51.7% female; M age \xa0=\xa011.4, SD\xa0=\xa00.95) participated, of which n\xa0=\xa0108 reported chronic pain']",['educational movie'],"['pain-related behaviour or pain intensity', 'pain knowledge, pain-related behaviour (passive pain coping, pain-related disability, missed school days, medication use) and pain intensity', 'Pain knowledge', 'pain behaviour and intensity overall', 'pain intensity', 'chronic pain management', 'knowledge of chronic pain concepts', 'pain knowledge', 'pain and dysfunctional behavior']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0260267', 'cui_str': 'School child'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C4708787', 'cui_str': '381'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C0681495', 'cui_str': 'Movies'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]",381.0,0.0507506,"Following the intervention, knowledge of chronic pain concepts was statistically greater in the intervention group compared to the control group not watching the movie.","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Kisling', 'Affiliation': ""Department of Children's Pain Therapy and Paediatric Palliative Care, Faculty of Health, School of Medicine, Witten/Herdecke University, Witten, Germany.""}, {'ForeName': 'Benedikt B', 'Initials': 'BB', 'LastName': 'Claus', 'Affiliation': 'Pedscience Research Institute, Datteln, Germany.'}, {'ForeName': 'Lorin', 'Initials': 'L', 'LastName': 'Stahlschmidt', 'Affiliation': ""German Paediatric Pain Centre, Children's and Adolescents' Hospital, Datteln, Germany.""}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Wager', 'Affiliation': ""Department of Children's Pain Therapy and Paediatric Palliative Care, Faculty of Health, School of Medicine, Witten/Herdecke University, Witten, Germany.""}]","European journal of pain (London, England)",['10.1002/ejp.1777'] 3134,34388288,Inhibitory Control Moderates the Intervention Effects of a Preventive Parenting Program on Posttraumatic Stress Disorder Symptoms Among Male Service Members.,"Military servicemembers face substantial challenges due to war-related trauma exposure, including posttraumatic stress disorder (PTSD). Individuals with deficits in inhibitory control (IC) may have an increased risk of developing PTSD due to a reduced ability to regulate their cognitive responses to and disengage from trauma-related stimuli. After Deployment, Adaptive Parenting Tools (ADAPT) is a mindfulness-infused parenting program for military families that has also been found to have crossover effects on parental mental health. The present study examined whether fathers' IC at baseline affected their response to this emotional skills-focused intervention and further influenced their PTSD symptoms 1 year later. The sample included 282 male National Guard and Reserve (NG/R) service members who had recently been deployed to Iraq or Afghanistan. Fathers were randomly assigned to either the ADAPT program or a control condition, with IC measured at baseline and PTSD symptoms measured at baseline and 1-year follow-up. Intent-to-treat analyses revealed no significant main effect of the intervention on fathers' PTSD symptoms. However, fathers' IC moderated intervention effects on PTSD symptoms, f 2 = 0.03. The intervention had more beneficial effects on reducing fathers' PTSD symptoms for participants with low IC at baseline. These findings are consistent with compensatory effects in the risk moderation hypothesis, which suggests that prevention or intervention programs are more effective for high-risk subgroups.",2021,Intent-to-treat analyses revealed no significant main effect of the intervention on fathers' PTSD symptoms.,"['Male Service Members', '282 male National Guard and Reserve (NG/R) service members who had recently been deployed to Iraq or Afghanistan', 'Individuals with deficits in inhibitory control (IC']","['ADAPT program or a control condition, with IC', 'Preventive Parenting Program', 'Adaptive Parenting Tools (ADAPT']","['Posttraumatic Stress Disorder Symptoms', ""fathers' PTSD symptoms""]","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0278253', 'cui_str': 'Guarded prognosis'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0022066', 'cui_str': 'Iraq'}, {'cui': 'C0001732', 'cui_str': 'Afghanistan'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015671', 'cui_str': 'Father'}]",282.0,0.0240167,Intent-to-treat analyses revealed no significant main effect of the intervention on fathers' PTSD symptoms.,"[{'ForeName': 'Jingchen', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Family Social Science, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Gretchen J R', 'Initials': 'GJR', 'LastName': 'Buchanan', 'Affiliation': 'Department of Family Social Science, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Amy R', 'Initials': 'AR', 'LastName': 'Monn', 'Affiliation': 'Green Hills Family Psych, Nashville, Tennessee, USA.'}, {'ForeName': 'Abigail H', 'Initials': 'AH', 'LastName': 'Gewirtz', 'Affiliation': 'Department of Family Social Science and Institute of Child Development, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA.'}]",Journal of traumatic stress,['10.1002/jts.22724'] 3135,34388256,Short-term skeletal and dentoalveolar effects of overexpansion.,"OBJECTIVES To evaluate whether the amount of rapid maxillary expansion differentially affects the skeletal and dentoalveolar changes that occur. MATERIALS AND METHODS This randomized controlled trial included 23 patients who had rapid maxillary expansion (RME). Subjects were randomly assigned to a conventional expansion control group (n = 12) or an overexpansion group (n = 11), who started treatment at 13.2 ± 1.5 and 13.8 ± 1 years of age, respectively. Cone beam computed tomography scans (11 cm) were obtained prior to rapid maxillary expander (RME) delivery and approximately 3.7 months later. Initial hand-wrist radiographs were used to determine the participants' skeletal maturity. RESULTS The RME screws were activated 5.6 ± 1.2 mm and 10.1 ± 0.6 mm in the conventional and overexpansion groups, respectively. Overexpansion produced significantly greater expansion of the nasal cavity (2.1X-2.5X), maxillary base (2.3X), buccal alveolar crest (1.4X), and greater palatine foramina (1.9X). Significantly greater intermolar width increases (1.8X) and molar inclination (2.8X) changes were also produced. The nasal cavity and maxillary base expanded 23%-32% as much as the screws were activated. Skeletal expansion was positively correlated with RME screw activation (R = 0.61 to 0.70) and negatively correlated (R = -0.56 to -0.64) with the patients' skeletal maturation indicators (SMIs). Together, screw activation and the patients' SMI scores explained 48%-66% of the variation in skeletal expansion. CONCLUSIONS This pilot study shows that overexpansion produces greater changes than conventional expansion, with greater skeletal effects among less mature patients.",2021,"Overexpansion produced significantly greater expansion of the nasal cavity (2.1X-2.5X), maxillary base (2.3X), buccal alveolar crest (1.4X), and greater palatine foramina (1.9X).",['23 patients who had rapid maxillary expansion (RME'],"['overexpansion', 'Cone beam computed tomography scans', 'conventional expansion control group', 'Overexpansion']","['expansion of the nasal cavity (2.1X-2.5X), maxillary base (2.3X), buccal alveolar crest (1.4X), and greater palatine foramina (1.9X', 'intermolar width increases (1.8X) and molar inclination (2.8X) changes', 'skeletal effects', 'RME screw activation', 'Skeletal expansion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0600288', 'cui_str': 'Maxillary Expansion'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}]","[{'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0027423', 'cui_str': 'Nasal cavity structure'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0206138', 'cui_str': 'CREST syndrome'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}]",23.0,0.0371379,"Overexpansion produced significantly greater expansion of the nasal cavity (2.1X-2.5X), maxillary base (2.3X), buccal alveolar crest (1.4X), and greater palatine foramina (1.9X).","[{'ForeName': 'Arun K', 'Initials': 'AK', 'LastName': 'Bala', 'Affiliation': ''}, {'ForeName': 'Phillip M', 'Initials': 'PM', 'LastName': 'Campbell', 'Affiliation': ''}, {'ForeName': 'Larry P', 'Initials': 'LP', 'LastName': 'Tadlock', 'Affiliation': ''}, {'ForeName': 'Emet D', 'Initials': 'ED', 'LastName': 'Schneiderman', 'Affiliation': ''}, {'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': 'Buschang', 'Affiliation': ''}]",The Angle orthodontist,['10.2319/032921-243.1'] 3136,34388182,Rapport building and witness memory: Actions may 'speak' louder than words.,"Building rapport during police interviews is argued as important for improving on the completeness and accuracy of information provided by witnesses and victims. However, little experimental research has clearly operationalised rapport and investigated the impact of rapport behaviours on episodic memory. Eighty adults watched a video of a mock crime event and 24-hours later were randomly allocated to an interview condition where verbal and/or behavioural (non-verbal) rapport techniques were manipulated. Memorial performance measures revealed significantly more correct information, without a concomitant increase in errors, was elicited when behavioural rapport was present, a superiority effect found in both the free and probed recall phase of interviews. The presence of verbal rapport was found to reduce recall accuracy in the free recall phase of interviews. Post-interview feedback revealed significant multivariate effects for the presence of behavioural (only) rapport and combined (behavioural + verbal) rapport. Participants rated their interview experience far more positively when these types of rapport were present compared to when verbal (only) rapport or no rapport was present. These findings add weight to the importance of rapport in supporting eyewitness cognition, highlighting the potential consequences of impoverished social behaviours for building rapport during dyadic interactions, suggesting 'doing' rather than simply 'saying' may be more beneficial.",2021,"Memorial performance measures revealed significantly more correct information, without a concomitant increase in errors, was elicited when behavioural rapport was present, a superiority effect found in both the free and probed recall phase of interviews.",['Eighty adults watched a video of a mock crime event and 24-hours later'],"['Rapport building and witness memory', 'interview condition where verbal and/or behavioural (non-verbal) rapport techniques']","['recall accuracy', 'behavioural (only) rapport and combined (behavioural + verbal) rapport']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0562577', 'cui_str': 'Mocking'}, {'cui': 'C0010325', 'cui_str': 'Crime'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0205087', 'cui_str': 'Late'}]","[{'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}]",80.0,0.032282,"Memorial performance measures revealed significantly more correct information, without a concomitant increase in errors, was elicited when behavioural rapport was present, a superiority effect found in both the free and probed recall phase of interviews.","[{'ForeName': 'Zacharia', 'Initials': 'Z', 'LastName': 'Nahouli', 'Affiliation': 'Department of Psychology, University of Westminster, London, United Kingdom.'}, {'ForeName': 'Coral J', 'Initials': 'CJ', 'LastName': 'Dando', 'Affiliation': 'Department of Psychology, University of Westminster, London, United Kingdom.'}, {'ForeName': 'Jay-Marie', 'Initials': 'JM', 'LastName': 'Mackenzie', 'Affiliation': 'Department of Psychology, University of Westminster, London, United Kingdom.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Aresti', 'Affiliation': 'Department of Criminology, University of Westminster, London, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0256084'] 3137,33951361,"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.","BACKGROUND Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, -4.1 kg (95% confidence interval [CI], -7.8 to -0.4; P = 0.03); in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001); and in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004) but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P = 0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.).",2021,"Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness.","['enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes', 'persons with obesity']","['Exercise, Liraglutide, or Both Combined', 'liraglutide', 'liraglutide therapy', 'moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo', 'placebo']","['glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness', 'weight loss', 'change in body weight', 'body-fat percentage', 'heart rate and cholelithiasis', 'body weight', 'healthy weight loss maintenance']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439209', 'cui_str': 'kg'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0008350', 'cui_str': 'Biliary calculus'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]",,0.0915866,"Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness.","[{'ForeName': 'Julie R', 'Initials': 'JR', 'LastName': 'Lundgren', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Janus', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Simon B K', 'Initials': 'SBK', 'LastName': 'Jensen', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Christian R', 'Initials': 'CR', 'LastName': 'Juhl', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Olsen', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Rasmus M', 'Initials': 'RM', 'LastName': 'Christensen', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Maria S', 'Initials': 'MS', 'LastName': 'Svane', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bandholm', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Kirstine N', 'Initials': 'KN', 'LastName': 'Bojsen-Møller', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Martin B', 'Initials': 'MB', 'LastName': 'Blond', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Jens-Erik B', 'Initials': 'JB', 'LastName': 'Jensen', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Bente M', 'Initials': 'BM', 'LastName': 'Stallknecht', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Sten', 'Initials': 'S', 'LastName': 'Madsbad', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}, {'ForeName': 'Signe S', 'Initials': 'SS', 'LastName': 'Torekov', 'Affiliation': 'From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) - all in Denmark.'}]",The New England journal of medicine,['10.1056/NEJMoa2028198'] 3138,33955262,"Exercise modality, but not exercise training, alters the acute effect of exercise on endothelial function in healthy men.","We used a within-subject crossover design to examine the impact of exercise modality, i.e., resistance (RT) and endurance (END), on the acute impact of exercise on endothelial function. Then, we examined whether a 4-wk period of chronic exercise training altered the acute exercise-induced change in endothelial function in healthy individuals. Thirty-four healthy, young men (21 ± 2 yr) reported to our laboratory and completed assessment of endothelial function [using the brachial artery flow-mediated dilation test (FMD)] before and immediately after a single bout of RT (leg-extension) or END (cycling). Subsequently, participants completed a 4-wk period of training (12 sessions), followed by evaluation of the FMD before and after a single bout of exercise. Following a 3-wk washout, participants repeated these experiments with the different exercise modality (in a balanced crossover design). An exercise × modality interaction effect was found ( P < 0.001). Post hoc pairwise analyses revealed a decrease in FMD after END ( P < 0.001) but not after RT ( P = 0.06). Four weeks of exercise training improved resting FMD after END and RT ( P = 0.04) but did not alter the acute effect of exercise on FMD (exercise × modality × training effect: P = 0.63), an effect independent of the modality of exercise (exercise × training interaction: P = 0.46 and P = 0.11 in RT and END, respectively). These distinct changes in FMD following acute exercise may relate to the different prolonged physiological responses induced by endurance versus resistance exercise. Specifically, endurance exercise, but not resistance exercise, causes a decrease in brachial artery endothelial function, which was unaffected by 4 wk of chronic exercise training. NEW & NOTEWORTHY We found that resistance and endurance exercise modalities lead to different endothelial function responses after a single bout of exercise. Endothelial function increased after an acute bout of resistance exercise, whereas it decreased after an acute bout of endurance exercise. Four weeks of chronic exercise training did not affect the acute endothelial function response.",2021,"An Exercise*Modality-interaction effect was found (P=0.003), with post-hoc analysis revealing a decrease in FMD after END (P=0.03 and P<0.001, pre and post training respectively), but no change in FMD after RT (P=0.06 and P=0.39, before and after the training intervention respectively).","['healthy subjects', 'Forty young healthy men (21±2 years) reported to our laboratory to complete assessment of endothelial function (using the brachial artery flow-mediated dilation test [FMD]) before and immediately after a single bout of RT (leg-extension) or END (cycling', 'healthy individuals']","['acute exercise', 'exercise training', '4-week exercise training']","['endothelial function', 'brachial artery endothelial function', 'FMD after END', 'FMD after RT']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0016052', 'cui_str': 'Fibromuscular dysplasia'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]",40.0,0.00377937,"An Exercise*Modality-interaction effect was found (P=0.003), with post-hoc analysis revealing a decrease in FMD after END (P=0.03 and P<0.001, pre and post training respectively), but no change in FMD after RT (P=0.06 and P=0.39, before and after the training intervention respectively).","[{'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Boidin', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Erskine', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Dick H J', 'Initials': 'DHJ', 'LastName': 'Thijssen', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Ellen Adele', 'Initials': 'EA', 'LastName': 'Dawson', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00004.2021'] 3139,33957371,A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.,"BACKGROUND Rasburicase can markedly and rapidly decrease uric acid (UA) levels, thereby preventing and treating tumor lysis syndrome. However, rasburicase is expensive, especially when used as per the manufacturer's recommended dosage of 0.2 mg/kg/day for up to 5 days. Numerous reports have shown that lower, and even single doses are effective in lowering UA levels but prospective randomized studies comparing low doses have not been performed. OBJECTIVES To prospectively determine the efficacy and safety of two single low doses of rasburicase in adult patients (pts) with acute leukemia and elevated plasma UA. METHODS Eligible pts aged ≥ 18 years old with acute leukemia and UA ≥ 7.5 mg/dL were randomized to receive an initial single dose of rasburicase 1.5 mg (Arm A) or 3 mg (Arm B) on day 1 in an unblinded fashion. All pts received allopurinol 300 mg daily on days 1-6. RESULTS Twenty-four pts (median age 69 years; 14 males and 10 females) were enrolled in this phase 2 study (12 on each arm). Twenty pts had acute myeloid leukemia while 3 had acute lymphoblastic leukemia, and 1 had acute promyelocytic leukemia. Median initial UA level was 9.8 mg/dL. Eighty-three percent of pts in both arms achieved UA < 7.5 mg/dL by 24 h after therapy. Five pts (21 %; 2 from Arm A and 3 from Arm B) required additional doses of rasburicase. The majority (23/24) of pts achieved UA goals after 1-2 doses of rasburicase. None had worsening renal function. Both doses were well tolerated, and no treatment related adverse events were reported. CONCLUSIONS Single doses of rasburicase (as low as 1.5-3 mg) used in addition to allopurinol were well tolerated and highly efficacious (83 % response rate) in decreasing UA levels within 24 h of administration in adult acute leukemia pts with hyperuricemia.",2021,Five pts (21 %; 2 from Arm A and 3 from Arm B) required additional doses of rasburicase.,"['Eligible pts aged ≥ 18 years old with acute leukemia and UA ≥ 7.5 mg/dL', 'adult patients (pts) with acute leukemia and elevated plasma UA', 'adult acute leukemia pts with hyperuricemia', 'Twenty pts had acute myeloid leukemia while 3 had acute lymphoblastic leukemia, and 1 had acute promyelocytic leukemia', 'Twenty-four pts (median age 69 years; 14 males and 10 females', 'adult patients with acute leukemia']","['rasburicase', 'allopurinol']","['uric acid (UA) levels', 'efficacy and safety', 'Median initial UA level', 'tolerated and highly efficacious', 'adverse events', 'UA levels', 'worsening renal function', 'UA goals']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0085669', 'cui_str': 'Acute leukemia'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0857451', 'cui_str': 'Plasma uric acid'}, {'cui': 'C0740394', 'cui_str': 'Hyperuricemia'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C0023487', 'cui_str': 'Acute promyelocytic leukemia'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0937932', 'cui_str': 'Rasburicase'}, {'cui': 'C0002144', 'cui_str': 'Allopurinol'}]","[{'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0202239', 'cui_str': 'Uric acid measurement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]",,0.0618056,Five pts (21 %; 2 from Arm A and 3 from Arm B) required additional doses of rasburicase.,"[{'ForeName': 'Pankit', 'Initials': 'P', 'LastName': 'Vachhani', 'Affiliation': 'Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA. Electronic address: pvachhani@uabmc.edu.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Baron', 'Affiliation': 'Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.'}, {'ForeName': 'Craig W', 'Initials': 'CW', 'LastName': 'Freyer', 'Affiliation': 'Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Austin', 'Initials': 'A', 'LastName': 'Miller', 'Affiliation': 'Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.'}, {'ForeName': 'Meir', 'Initials': 'M', 'LastName': 'Wetzler', 'Affiliation': 'Section of Leukemia, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.'}, {'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Thompson', 'Affiliation': 'Section of Leukemia, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Griffiths', 'Affiliation': 'Section of Leukemia, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.'}, {'ForeName': 'Eunice S', 'Initials': 'ES', 'LastName': 'Wang', 'Affiliation': 'Section of Leukemia, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.'}]",Leukemia research,['10.1016/j.leukres.2021.106588'] 3140,33959986,Novel application of a discrete time-to-event model for randomized oral immunotherapy clinical trials with repeat food challenges.,"The evaluation of double-blind, placebo-controlled food challenges (DBPCFC) generally focuses on a participant passing a challenge at a predetermined dose, and does not consider the dose of reaction for those who fail or are censored due to study discontinuation. Further, a number of food allergy trials have incorporated multiple DBPCFCs throughout the duration of the study in order to evaluate changes in reaction over time including sustained unresponsiveness from treatment. Outcomes arising from these trials are commonly modeled using Chi-squared or Fisher's exact tests at each time point. We propose applying time-to-event methodology to food allergy trials in order to exploit the inherent granularity of challenge outcomes that additionally accommodates repeated DBPCFCs. Specifically, we consider dose-to-failure for each study challenge and extend the cumulative tolerated dose across challenges to result in a dose-time axis. A discrete time-to-event framework is applied to the dose-time outcome to assess the efficacy of treatment across the entire study period. We illustrate ideas with data from the Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery (POISED) trial, conducted at Stanford University, which evaluated the efficacy of oral immunotherapy on desensitization and sustained unresponsiveness in peanut allergic children and adults. We demonstrate the advantages of time-to-event approaches for assessing the efficacy of treatment over time and incorporating information for those who failed or were lost to follow up. Further, we introduce a dose-time outcome that is interpretable to clinicians and allows for examination of such outcomes over time.",2021,"We illustrate ideas with data from the Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery (POISED) trial, conducted at Stanford University, which evaluated the efficacy of oral immunotherapy on desensitization and sustained unresponsiveness in peanut allergic children and adults.",['peanut allergic children and adults'],"['oral immunotherapy', 'placebo-controlled food challenges (DBPCFC']",[],"[{'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}]",[],,0.11329,"We illustrate ideas with data from the Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery (POISED) trial, conducted at Stanford University, which evaluated the efficacy of oral immunotherapy on desensitization and sustained unresponsiveness in peanut allergic children and adults.","[{'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Purington', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, California, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Andorf', 'Affiliation': 'Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, California, USA.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Bunning', 'Affiliation': 'Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, California, USA.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Chinthrajah', 'Affiliation': 'Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, California, USA.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Nadeau', 'Affiliation': 'Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, California, USA.'}, {'ForeName': 'Manisha', 'Initials': 'M', 'LastName': 'Desai', 'Affiliation': 'Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, California, USA.'}]",Statistics in medicine,['10.1002/sim.9019'] 3141,33978187,"Baseline Hemoglobin, Hepcidin, Ferritin, and Total Body Iron Stores are Equally Strong Diagnostic Predictors of a Hemoglobin Response to 12 Weeks of Daily Iron Supplementation in Cambodian Women.","BACKGROUND The WHO recommends daily iron supplementation for all women in areas where the population-level anemia prevalence is ≥40%, despite the fact that hemoglobin (Hb) concentration is generally considered to be a poor prognostic indicator of iron status. OBJECTIVES In this secondary analysis, we investigated the predictive power of ten baseline hematological biomarkers towards a 12-week Hb response to iron supplementation. METHODS Data were obtained from a randomized controlled trial of daily iron supplementation in 407 nonpregnant Cambodian women (18-45 years) who received 60 mg elemental iron as ferrous sulfate for 12 weeks. Ten baseline biomarkers were included: Hb, measured with both a hematology analyzer and a HemoCue; inflammation-adjusted ferritin; soluble transferrin receptor; reticulocyte Hb; hepcidin; mean corpuscular volume; inflammation-adjusted total body iron stores (TBIS); total iron binding capacity; and transferrin saturation. Receiver operating characteristic (ROC) curves from fitted logistic regression models were used to make discrimination comparisons and variable selection methods were used to construct a multibiomarker prognostic model. RESULTS Only 25% (n = 95/383) of women who completed the trial experienced a 12-week Hb response ≥10 g/L. The strongest univariate predictors of a Hb response were Hb as measured with a hematology analyzer, inflammation-adjusted ferritin, hepcidin, and inflammation-adjusted TBIS (AUCROC = 0.81, 0.83, 0.82, and 0.82, respectively), and the optimal cutoffs to identify women who were likely to experience a Hb response were 117 g/L, 17.3 μg/L, 1.98 nmol/L, and 1.95 mg/kg, respectively. Hb as measured with a hematology analyzer, inflammation-adjusted ferritin, and hepcidin had the best combined predictive ability (AUCROC=0.86). Hb measured with the HemoCue had poor discrimination ability (AUCROC = 0.65). CONCLUSIONS Baseline Hb as measured with a hematology analyzer was as strong a predictor of Hb response to iron supplementation as inflammation-adjusted ferritin, hepcidin, and inflammation-adjusted TBIS. This is positive given that the WHO currently uses the population-level anemia prevalence to guide recommendations for untargeted iron supplementation.",2021,"Hb as measured with a hematology analyzer, inflammation-adjusted ferritin, and hepcidin had the best combined predictive ability (AUCROC=0.86).","['Ten baseline biomarkers were included', 'Cambodian Women', 'Only 25% (n\xa0=\xa095/383) of women who completed the trial experienced a 12-week Hb response ≥10', '407 nonpregnant Cambodian women (18-45 years']","['60\xa0mg elemental iron as ferrous sulfate', 'daily iron supplementation']","['hematology analyzer, inflammation-adjusted ferritin, hepcidin, and inflammation-adjusted TBIS', 'Baseline Hemoglobin, Hepcidin, Ferritin, and Total Body Iron Stores', 'total body iron stores (TBIS); total iron binding capacity; and transferrin saturation']","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1553323', 'cui_str': 'Cambodians'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0302583', 'cui_str': 'Iron'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}]","[{'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0179038', 'cui_str': 'Analyzer'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0450235', 'cui_str': 'Evaluation of iron stores'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0700379', 'cui_str': 'Total iron binding capacity'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}]",,0.180786,"Hb as measured with a hematology analyzer, inflammation-adjusted ferritin, and hepcidin had the best combined predictive ability (AUCROC=0.86).","[{'ForeName': 'Lulu X', 'Initials': 'LX', 'LastName': 'Pei', 'Affiliation': 'Department of Biostatistics, The University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Hou', 'Initials': 'H', 'LastName': 'Kroeun', 'Affiliation': 'Helen Keller International, Phnom Penh, Cambodia.'}, {'ForeName': 'Suzanne M', 'Initials': 'SM', 'LastName': 'Vercauteren', 'Affiliation': 'Division of Hematopathology, The University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Susan I', 'Initials': 'SI', 'LastName': 'Barr', 'Affiliation': 'Department of Food, Nutrition and Health, The University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Tim J', 'Initials': 'TJ', 'LastName': 'Green', 'Affiliation': 'South Australian Health and Medical Research Institute, Adelaide, Australia.'}, {'ForeName': 'Arianne Y', 'Initials': 'AY', 'LastName': 'Albert', 'Affiliation': ""Department of Biostatistics, Women's Health Research Institute, Vancouver, Canada.""}, {'ForeName': 'Crystal D', 'Initials': 'CD', 'LastName': 'Karakochuk', 'Affiliation': ""BC Children's Hospital Research Institute, Vancouver, Canada.""}]",The Journal of nutrition,['10.1093/jn/nxab108'] 3142,33978167,The Inclusion of Folic Acid in Weekly Iron-Folic Acid Supplements Confers no Additional Benefit on Anemia Reduction in Nonpregnant Women: A Randomized Controlled Trial in Malaysia.,"BACKGROUND Weekly iron-folic acid (IFA) supplements are recommended for all menstruating women in countries where anemia prevalence is ≥20%; however, it is unknown whether the inclusion of folic acid in weekly IFA supplements reduces anemia. OBJECTIVES We examined whether the inclusion of folic acid in weekly IFA supplements conferred any benefit on hemoglobin (Hb) concentration, anemia reduction, or iron status [ferritin and soluble transferrin receptor (sTfR)], over iron alone. METHODS In this secondary analysis of a randomized controlled trial in Malaysia, n = 311 nonpregnant women (18-45 y old) received 60 mg Fe with either 0, 0.4, or 2.8 mg folic acid once-weekly for 16 wk. Fasting blood was collected at baseline and 16 wk. A generalized linear model (normal distribution with identity link) was used to assess Hb concentration at 16 wk (primary outcome). RESULTS At baseline, 84% of women had low folate status (plasma folate < 14 nmol/L). At 16 wk, marginal mean (95% CI) Hb was 131 (130, 133), 131 (129, 132), and 132 (130, 133) g/L; ferritin was 58.2 (53.9, 62.5), 56.5 (52.2, 60.9), and 58.0 (53.7, 62.3) μg/L; and sTfR was 5.8 (5.5, 6.1), 5.8 (5.5, 6.1), and 5.9 (5.6, 6.2) mg/L in the 0, 0.4, and 2.8 mg/wk groups, respectively, with no differences between groups (P > 0.05). Baseline plasma folate concentration did not modify the effect of treatment on Hb concentration at 16 wk. Among all women, the risks of anemia [risk ratio (RR): 0.65; 95% CI: 0.45, 0.96; P = 0.03] and iron deficiency based on ferritin (RR: 0.30; 95% CI: 0.20, 0.44; P < 0.001) were lower at 16 wk than at baseline. CONCLUSIONS Despite the low folate status among these nonpregnant Malaysian women, the inclusion of folic acid in weekly IFA supplements did not reduce anemia or improve iron status, over iron alone. However, the benefits of folic acid for neural tube defect prevention still warrant its retention in weekly IFA supplements.This trial was registered at www.anzctr.org.au as ACTRN12619000818134.",2021,"Among all women, the risks of anemia [risk ratio (RR): 0.65; 95% CI: 0.45, 0.96; P = 0.03] and iron deficiency based on ferritin (RR: 0.30; 95% CI: 0.20, 0.44; P < 0.001) were lower at 16 wk than at baseline. ","['menstruating women in countries', 'Malaysia, n\xa0=\xa0311 nonpregnant women (18-45 y old', 'Nonpregnant Women', 'nonpregnant Malaysian women']","['60\xa0mg Fe with either 0, 0.4, or 2.8\xa0mg folic acid', 'folic acid', 'Weekly iron-folic acid (IFA) supplements']","['Fasting blood', 'Anemia Reduction', 'Baseline plasma folate concentration', 'risks of anemia [risk ratio', 'sTfR', 'hemoglobin (Hb) concentration, anemia reduction, or iron status [ferritin and soluble transferrin receptor']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0357067', 'cui_str': 'Folic acid- and iron-containing product'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C1116139', 'cui_str': 'Transferrin receptor, soluble'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}]",311.0,0.413736,"Among all women, the risks of anemia [risk ratio (RR): 0.65; 95% CI: 0.45, 0.96; P = 0.03] and iron deficiency based on ferritin (RR: 0.30; 95% CI: 0.20, 0.44; P < 0.001) were lower at 16 wk than at baseline. ","[{'ForeName': 'Kaitlyn L I', 'Initials': 'KLI', 'LastName': 'Samson', 'Affiliation': 'Food, Nutrition, and Health, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Su Peng', 'Initials': 'SP', 'LastName': 'Loh', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.'}, {'ForeName': 'Siew Siew', 'Initials': 'SS', 'LastName': 'Lee', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.'}, {'ForeName': 'Dian C', 'Initials': 'DC', 'LastName': 'Sulistyoningrum', 'Affiliation': 'SAHMRI Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.'}, {'ForeName': 'Geok Lin', 'Initials': 'GL', 'LastName': 'Khor', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.'}, {'ForeName': 'Zalilah Binti', 'Initials': 'ZB', 'LastName': 'Mohd Shariff', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.'}, {'ForeName': 'Irmi Zarina', 'Initials': 'IZ', 'LastName': 'Ismai', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Makrides', 'Affiliation': 'SAHMRI Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Hutcheon', 'Affiliation': ""BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.""}, {'ForeName': 'Marion L', 'Initials': 'ML', 'LastName': 'Roche', 'Affiliation': 'Nutrition International, Ottawa, Ontario, Canada.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Green', 'Affiliation': 'SAHMRI Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.'}, {'ForeName': 'Crystal D', 'Initials': 'CD', 'LastName': 'Karakochuk', 'Affiliation': 'Food, Nutrition, and Health, University of British Columbia, Vancouver, British Columbia, Canada.'}]",The Journal of nutrition,['10.1093/jn/nxab115'] 3143,33978160,Biomarkers and Fatty Fish Intake: A Randomized Controlled Trial in Norwegian Preschool Children.,"BACKGROUND Biomarkers such as omega-3 (n-3) PUFAs, urinary iodine concentration (UIC), 1-methylhistidine (1-MH), and trimethylamine N-oxide (TMAO) have been associated with fish intake in observational studies, but data from children in randomized controlled trials are limited. OBJECTIVES The objective of this exploratory analysis was to investigate the effects of fatty fish intake compared with meat intake on various biomarkers in preschool children. METHODS We randomly allocated (1:1) 232 children, aged 4 to 6 y, from 13 kindergartens. The children received lunch meals of either fatty fish (herring/mackerel) or meat (chicken/lamb/beef) 3 times a week for 16 wk. We analyzed 86 biomarkers in plasma (n = 207), serum (n = 195), RBCs (n = 211), urine (n = 200), and hair samples (n = 210). We measured the effects of the intervention on the normalized biomarker concentrations in linear mixed-effect regression models taking the clustering within the kindergartens into account. The results are presented as standardized effect sizes. RESULTS We found significant effects of the intervention on the following biomarkers: RBC EPA (20:5n-3), 0.61 (95% CI: 0.36, 0.86); DHA (22:6n-3), 0.43 (95% CI: 0.21, 0.66); total n-3 PUFAs, 0.41 (95% CI: 0.20, 0.64); n-3/n-6 ratio, 0.48 (95% CI: 0.24, 0.71); adrenic acid (22:4n-6, -0.65 (95% CI: -0.91, -0.40), arachidonic acid (20:4n-6), -0.54 (95% CI: -0.79, -0.28); total n-6 PUFAs, -0.31 (95% CI: -0.56, -0.06); UIC, 0.32 (95% CI: 0.052, 0.59); hair mercury, 0.83 (95% CI: 0.05, 1.05); and plasma 1-MH, -0.35 (95% CI: -0.61, -0.094). CONCLUSIONS Of the 86 biomarkers, the strongest effect of fatty fish intake was on n-3 PUFAs, UIC, hair mercury, and plasma 1-MH. We observed no or limited effects on biomarkers related to micronutrient status, inflammation, or essential amino acid, choline oxidation, and tryptophan pathways.The trial was registered at clinicaltrials.gov (NCT02331667).",2021,"We found significant effects of the intervention on the following biomarkers: RBC EPA (20:5n-3), 0.61 (95% CI: 0.36, 0.86); DHA (22:6n-3), 0.43 (95% CI: 0.21, 0.66); total n-3 PUFAs, 0.41 (95% CI: 0.20, 0.64); n-3/n-6 ratio, 0.48","['232 children, aged 4 to 6 y, from 13 kindergartens', '86 biomarkers in plasma (n\xa0=\xa0207), serum (n\xa0=\xa0195), RBCs (n\xa0=\xa0211), urine (n\xa0=\xa0200), and hair samples (n\xa0=\xa0210', 'Norwegian Preschool Children', 'preschool children']","['omega-3 (n-3) PUFAs, urinary iodine concentration (UIC), 1-methylhistidine (1-MH), and trimethylamine N-oxide (TMAO', 'fatty fish intake compared with meat intake', 'lunch meals of either fatty fish (herring/mackerel) or meat (chicken/lamb/beef']","['adrenic acid', 'total n-6 PUFAs', 'arachidonic acid', 'Biomarkers and Fatty Fish Intake', 'n-3 PUFAs, UIC, hair mercury, and plasma 1-MH', 'total n-3 PUFAs']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0014792', 'cui_str': 'erythrocytes'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0444095', 'cui_str': 'Hair specimen'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated fatty acid'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0044470', 'cui_str': '1-methyl histidine'}, {'cui': 'C0077194', 'cui_str': 'trimethyloxamine'}, {'cui': 'C0556218', 'cui_str': 'Fatty fish intake'}, {'cui': 'C0556201', 'cui_str': 'Meat intake'}, {'cui': 'C2697949', 'cui_str': 'Lunch'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0453017', 'cui_str': 'Fatty fish'}, {'cui': 'C0446375', 'cui_str': 'Family Clupeidae - herring'}, {'cui': 'C0010342', 'cui_str': 'Family Scombridae - mackerel'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0008051', 'cui_str': 'Gallus gallus'}, {'cui': 'C0406810', 'cui_str': 'Carney complex'}, {'cui': 'C0452849', 'cui_str': 'Beef'}]","[{'cui': 'C0050877', 'cui_str': 'adrenic acid'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated fatty acid'}, {'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0556218', 'cui_str': 'Fatty fish intake'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1168378', 'cui_str': 'Hair mercury'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0044470', 'cui_str': '1-methyl histidine'}]",232.0,0.447868,"We found significant effects of the intervention on the following biomarkers: RBC EPA (20:5n-3), 0.61 (95% CI: 0.36, 0.86); DHA (22:6n-3), 0.43 (95% CI: 0.21, 0.66); total n-3 PUFAs, 0.41 (95% CI: 0.20, 0.64); n-3/n-6 ratio, 0.48","[{'ForeName': 'Beate S', 'Initials': 'BS', 'LastName': 'Solvik', 'Affiliation': 'Innlandet Hospital Trust, Lillehammer, Norway.'}, {'ForeName': 'Jannike', 'Initials': 'J', 'LastName': 'Øyen', 'Affiliation': 'Institute of Marine Research, Bergen, Norway.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Kvestad', 'Affiliation': 'Regional Center for Child and Youth Mental Health and Child Welfare, NORCE Norwegian Research Centre, Bergen, Norway.'}, {'ForeName': 'Maria W', 'Initials': 'MW', 'LastName': 'Markhus', 'Affiliation': 'Institute of Marine Research, Bergen, Norway.'}, {'ForeName': 'Per M', 'Initials': 'PM', 'LastName': 'Ueland', 'Affiliation': 'Bevital AS, Bergen, Norway.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'McCann', 'Affiliation': 'Bevital AS, Bergen, Norway.'}, {'ForeName': 'Tor A', 'Initials': 'TA', 'LastName': 'Strand', 'Affiliation': 'Innlandet Hospital Trust, Lillehammer, Norway.'}]",The Journal of nutrition,['10.1093/jn/nxab112'] 3144,34390392,Allopurinol attenuates postoperative pain and modulates the purinergic system in patients undergoing abdominal hysterectomy: a randomized controlled trial.,"PURPOSE Allopurinol is a potent inhibitor of the enzyme xanthine oxidase used primarily in the treatment of hyperuricemia and gout. The aim of this study was to compare the analgesic efficacy of preanesthetic allopurinol versus placebo on postoperative pain and anxiety in patients undergoing abdominal hysterectomy. METHODS This is a prospective, double-blinded, placebo-controlled, randomized clinical trial. We investigated 54 patients scheduled to undergo elective abdominal hysterectomy. Patients were randomly assigned to receive either oral allopurinol 300 mg (n = 27) or placebo (n = 27) the night before and 1 h before surgery. Patients were submitted to evaluation of pain and anxiety before the treatment, for 24 h postoperatively, 30 and 90 days after surgery. Cerebrospinal fluid was collected at the time of the spinal anesthesia to perform the measurement of the central levels of purines. RESULTS Preoperative administration of allopurinol was effective in reducing postoperative pain 2 h after surgery. Allopurinol caused a reduction of approximately 40% in pain scores measured by the visual analogue pain scale after surgery (p < 0.05). No differences were found between groups in anxiety scores after surgery. There was a significant change in the cerebrospinal fluid concentrations of xanthine and uric acid before surgery (p < 0.01). CONCLUSION This study showed a short-term benefit of the use of allopurinol as a preanesthetic medication since it was related to a reduction on pain scores 2 h after surgery. The purinergic system is a potential target for new analgesic drugs. New studies investigating more selective purine derivatives in the management of pain should be performed. TRIAL NUMBER REGISTRATION Brazilian Registry of Clinical Trials-ReBEC #RBR-9pw58p.",2021,"There was a significant change in the cerebrospinal fluid concentrations of xanthine and uric acid before surgery (p < 0.01). ","['patients undergoing abdominal hysterectomy', '54 patients scheduled to undergo elective abdominal hysterectomy']","['oral allopurinol 300\xa0mg (n\u2009=\u200927) or placebo', 'preanesthetic allopurinol', 'Allopurinol', 'placebo', 'allopurinol']","['cerebrospinal fluid concentrations of xanthine and uric acid', 'analgesic efficacy', 'pain and anxiety', 'postoperative pain and anxiety', 'postoperative pain', 'anxiety scores', 'visual analogue pain scale', 'pain scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0404077', 'cui_str': 'Abdominal hysterectomy'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0983479', 'cui_str': 'Allopurinol 300 MG'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002144', 'cui_str': 'Allopurinol'}]","[{'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0043314', 'cui_str': 'xanthine'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",54.0,0.595076,"There was a significant change in the cerebrospinal fluid concentrations of xanthine and uric acid before surgery (p < 0.01). ","[{'ForeName': 'André P', 'Initials': 'AP', 'LastName': 'Schmidt', 'Affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde (ICBS), Universidade Federal Do Rio Grande Do Sul (UFRGS), Avenida Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil. aschmidt@ufrgs.br.'}, {'ForeName': 'Enderson D', 'Initials': 'ED', 'LastName': 'de Oliveira', 'Affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde (ICBS), Universidade Federal Do Rio Grande Do Sul (UFRGS), Avenida Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil.'}, {'ForeName': 'Aécio C', 'Initials': 'AC', 'LastName': 'Fagundes', 'Affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde (ICBS), Universidade Federal Do Rio Grande Do Sul (UFRGS), Avenida Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil.'}, {'ForeName': 'Gisele', 'Initials': 'G', 'LastName': 'Hansel', 'Affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde (ICBS), Universidade Federal Do Rio Grande Do Sul (UFRGS), Avenida Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil.'}, {'ForeName': 'Renata O', 'Initials': 'RO', 'LastName': 'Pedrini', 'Affiliation': 'Department of Anesthesia, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Valdameri', 'Affiliation': 'Department of Anesthesia, Hospital Universitário de Santa Maria, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil.'}, {'ForeName': 'Eduarda S', 'Initials': 'ES', 'LastName': 'Martinelli', 'Affiliation': 'Department of Anesthesia, Hospital Nossa Senhora da Conceição, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Sérgio R G', 'Initials': 'SRG', 'LastName': 'Schmidt', 'Affiliation': 'Pain S.O.S., Pain Relief Center, Medical Center of Hospital Mãe de Deus, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Cristiano F', 'Initials': 'CF', 'LastName': 'Andrade', 'Affiliation': 'Postgraduate Program in Pneumological Sciences, UFRGS, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Diogo R', 'Initials': 'DR', 'LastName': 'Lara', 'Affiliation': 'Cingulo Mental Health App, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Diogo O', 'Initials': 'DO', 'LastName': 'Souza', 'Affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde (ICBS), Universidade Federal Do Rio Grande Do Sul (UFRGS), Avenida Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil.'}]",Journal of anesthesia,['10.1007/s00540-021-02983-z'] 3145,34390300,"Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.","Disrupted brain gamma-aminobutyric acid (GABA)/glutamate homeostasis is a promising target for pharmacological intervention in co-occurring bipolar disorder (BD) and cannabis use disorder (CUD). Gabapentin is a safe and well-tolerated medication, FDA-approved to treat other neurological diseases, that restores GABA/glutamate homeostasis, with treatment studies supporting efficacy in treating CUD, as well as anxiety and sleep disorders that are common to both BD and CUD. The present manuscript represents the primary report of a randomized, double-blind, placebo-controlled, crossover (1-week/condition), multimodal-MRI (proton-MR spectroscopy, functional MRI) pilot study of gabapentin (1200 mg/day) in BD + CUD (n = 22). Primary analyses revealed that (1) gabapentin was well tolerated and adherence and retention were high, (2) gabapentin increased dorsal anterior cingulate cortex (dACC) and right basal ganglia (rBG) glutamate levels and (3) gabapentin increased activation to visual cannabis cues in the posterior midcingulate cortex (pMCC, a region involved in response inhibition to rewarding stimuli). Exploratory evaluation of clinical outcomes further found that in participants taking gabapentin versus placebo, (1) elevations of dACC GABA levels were associated with lower manic/mixed and depressive symptoms and (2) elevations of rBG glutamate levels and pMCC activation to cannabis cues were associated with lower cannabis use. Though promising, the findings from this study should be interpreted with caution due to observed randomization order effects on dACC glutamate levels and identification of statistical moderators that differed by randomization order (i.e. cigarette-smoking status on rBG glutamate levels and pMCC cue activation). Nonetheless, they provide the necessary foundation for a more robustly designed (urn-randomized, parallel-group) future study of adjuvant gabapentin for BD + CUD.",2021,"Exploratory evaluation of clinical outcomes further found that in participants taking gabapentin versus placebo, (1) elevations of dACC GABA levels were associated with lower manic/mixed and depressive symptoms and (2) elevations of rBG glutamate levels and pMCC activation to cannabis cues were associated with lower cannabis use.",['for co-occurring bipolar and cannabis use disorders'],"['gabapentin', 'gabapentin versus placebo', 'placebo', 'Gabapentin']","['tolerated and adherence and retention', 'dorsal anterior cingulate cortex (dACC) and right basal ganglia (rBG) glutamate levels', 'dACC GABA levels']","[{'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0004781', 'cui_str': 'Basal ganglion structure'}, {'cui': 'C0017789', 'cui_str': 'Glutamates'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0016904', 'cui_str': 'Gamma-aminobutyric acid'}]",,0.193868,"Exploratory evaluation of clinical outcomes further found that in participants taking gabapentin versus placebo, (1) elevations of dACC GABA levels were associated with lower manic/mixed and depressive symptoms and (2) elevations of rBG glutamate levels and pMCC activation to cannabis cues were associated with lower cannabis use.","[{'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Prisciandaro', 'Affiliation': 'Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Mellick', 'Affiliation': 'Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.'}, {'ForeName': 'Lindsay M', 'Initials': 'LM', 'LastName': 'Squeglia', 'Affiliation': 'Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Hix', 'Affiliation': 'Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Arnold', 'Affiliation': 'Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.'}, {'ForeName': 'Bryan K', 'Initials': 'BK', 'LastName': 'Tolliver', 'Affiliation': 'Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.'}]",Addiction biology,['10.1111/adb.13085'] 3146,34390283,Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.,"BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating adverse effect of neurotoxic chemotherapy that significantly worsens cancer survivors' quality of life. MATERIALS AND METHODS Solid tumor survivors with persistent moderate-to-severe CIPN defined as numbness, tingling, or pain rated ≥4 on an 11-point numeric rating scale (NRS) were randomized in a 1:1:1 ratio to eight weeks of real acupuncture (RA) versus sham acupuncture (SA) versus usual care (UC). We previously reported the primary endpoint (NRS); here we report health-related quality of life endpoints: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), and Brief Fatigue Inventory (BFI). For each endpoint, the mean changes from baseline and 95% confidence intervals were estimated within each arm and compared between arms using linear mixed models. RESULTS We enrolled 75 solid tumor survivors with moderate to severe CIPN into the study. Compared to baseline, at week 8, FACT/GOG-Ntx, HADS anxiety, and ISI scores significantly improved in RA and SA, but not in UC. Compared to UC, at week 8, FACT/GOG-Ntx scores significantly increased in RA and SA arms indicating improved CIPN-related symptoms and quality of life (p=0.001 and p=0.01). There was no statistically significant difference between RA and SA. There was no difference in HADS depression or BFI among RA, SA, and UC at weeks 8 and 12. CONCLUSION Acupuncture may improve CIPN-related symptoms and quality of life in cancer survivors with persistent CIPN. Further large sample size studies are needed to delineate placebo effects. TRIAL REGISTRATION ClinicalTrials.gov (NCT03183037) IMPLICATIONS FOR PRACTICE: We conducted a randomized sham acupuncture- and usual care-controlled clinical trial to evaluate the impact of acupuncture on health-related quality of life outcomes in solid tumor patients with chemotherapy-induced peripheral neuropathy (CIPN). Statistically significant improvements in quality of life, anxiety, insomnia, and fatigue were achieved with eight weeks of real acupuncture when compared to baseline, without statistically significant differences between real and sham acupuncture. These findings suggest that acupuncture may be effective for improving CIPN-related symptoms and quality of life and reducing anxiety and insomnia in cancer survivors with persistent CIPN, with further study needed to delineate placebo effects.",2021,"There was no difference in HADS depression or BFI among RA, SA, and UC at weeks 8 and 12. CONCLUSION Acupuncture may improve CIPN-related symptoms and quality of life in cancer survivors with persistent CIPN.","['solid tumor patients with chemotherapy-induced peripheral neuropathy (CIPN', 'Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy', 'enrolled 75 solid tumor survivors with moderate to severe CIPN into the study', 'cancer survivors with persistent CIPN', 'Solid tumor survivors with persistent moderate-to-severe CIPN defined as numbness, tingling, or pain rated ≥4 on an 11-point numeric rating scale (NRS']","['acupuncture', 'Acupuncture', 'real acupuncture (RA) versus sham acupuncture (SA) versus usual care (UC', 'neurotoxic chemotherapy']","['health-related quality of life endpoints: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity', 'FACT/GOG-Ntx), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), and Brief Fatigue Inventory (BFI', 'FACT/GOG-Ntx scores', 'HADS depression or BFI', 'quality of life, anxiety, insomnia, and fatigue', 'FACT/GOG-Ntx, HADS anxiety, and ISI scores', 'CIPN-related symptoms and quality of life', 'health-related quality of life outcomes']","[{'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3873567', 'cui_str': 'Peripheral neuropathy due to and following chemotherapy'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0020580', 'cui_str': 'Hypesthesia'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1321164', 'cui_str': 'Gynecological oncology'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0235032', 'cui_str': 'Neurotoxicity'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C4706228', 'cui_str': 'ISI (Insomnia Severity Index) score'}, {'cui': 'C3873567', 'cui_str': 'Peripheral neuropathy due to and following chemotherapy'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",75.0,0.138446,"There was no difference in HADS depression or BFI among RA, SA, and UC at weeks 8 and 12. CONCLUSION Acupuncture may improve CIPN-related symptoms and quality of life in cancer survivors with persistent CIPN.","[{'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Bao', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Baser', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY, 10017, USA.'}, {'ForeName': 'Connie', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Medicine, NYU Winthrop Hospital, 259 1st St, Mineola, NY, 11501, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Weitzman', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.'}, {'ForeName': 'Yi Lily', 'Initials': 'YL', 'LastName': 'Zhang', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Seluzicki', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.'}, {'ForeName': 'Qing Susan', 'Initials': 'QS', 'LastName': 'Li', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Piulson', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.'}, {'ForeName': 'W Iris', 'Initials': 'WI', 'LastName': 'Zhi', 'Affiliation': 'Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 650 Commack Road, Commack, NY, 11725, USA.'}]",The oncologist,['10.1002/onco.13933'] 3147,34390228,"Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: A randomized, double-blind, controlled trial.","BACKGROUND The stability of hemodynamics during anesthesia induction in patients undergoing valve replacement surgery is particularly important. Remimazolam is a new type of benzodiazepine drug, with supposed advantages of rapid induction, rapid recovery, stable hemodynamics, and mild respiratory inhibition. AIM To evaluate the effect of remimazolam anesthesia induction on hemodynamics in patients undergoing valve replacement surgery. METHODS This randomized, double-blind, controlled trial enrolled consecutive patients undergoing mitral valve replacement (MVR)/aortic valve replacement (AVR)/double-valve replacement (DVR) surgery on cardiopulmonary bypass (CPB). The study was conducted according to the Consolidated Standards of Reporting Trials statement. Participants were randomly assigned to receive either remimazolam or propofol induction of 30 patients each. All patients, data collectors, and data analyzers were blinded to the group allocation. The primary outcomes were the fluctuations in hemodynamic parameters (the difference of maximum or minimum heart rate to baseline, ▲HR, the difference of maximum or minimum mean arterial pressure to baseline, ▲MAP), the occurrence of cardiovascular events (hypotension, severe bradycardia), and the cumulative norepinephrine doses used per patient, averaged per group during induction. The secondary outcomes were hemodynamic parameters (heart rate, HR, mean arterial pressure, MAP, bispectral index, BIS, plasma lactic acid, Lac, and blood glucose, Glu values). RESULTS A total of 60 patients with heart valve replacement were included in the final analysis, with 30 patients in each group. The ▲MAP was significantly lower in the remimazolam group than in the propofol group during induction (p < .05). The incidences of hypotension and the cumulative norepinephrine doses used per patient, averaged per group during induction were significantly lower in the remimazolam group than in the propofol group (p < .05). CONCLUSION Remimazolam may be safe and effective for induction and may as an alternative to propofol during anesthesia induction in patients undergoing valve replacement surgery.",2021,The ▲MAP was significantly lower in the remimazolam group than in the propofol group during induction (p < .05).,"['60 patients with heart valve replacement were included in the final analysis, with 30 patients in each group', 'consecutive patients undergoing', 'patients undergoing valve replacement surgery']","['benzodiazepine', 'remimazolam induction', 'remimazolam anesthesia induction', 'propofol', 'mitral valve replacement (MVR)/aortic valve replacement (AVR)/double-valve replacement (DVR) surgery on cardiopulmonary bypass (CPB', 'remimazolam', 'Remimazolam', 'remimazolam or propofol']","['incidences of hypotension and the cumulative norepinephrine doses', 'fluctuations in hemodynamic parameters (the difference of maximum or minimum heart rate to baseline, ▲HR, the difference of maximum or minimum mean arterial pressure to baseline, ▲MAP), the occurrence of cardiovascular events (hypotension, severe bradycardia), and the cumulative norepinephrine doses', 'hemodynamic parameters (heart rate, HR, mean arterial pressure, MAP, bispectral index, BIS, plasma lactic acid, Lac, and blood glucose, Glu values', '▲MAP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0190173', 'cui_str': 'Heart valve replacement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C3179470', 'cui_str': 'remimazolam'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0473960', 'cui_str': 'Induction of general anesthesia'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0026268', 'cui_str': 'Replacement of mitral valve'}, {'cui': 'C0026264', 'cui_str': 'Mitral valve structure'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0190170', 'cui_str': 'Double valve replacement'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C0053723', 'cui_str': 'bis(cyclohexylammonium)'}, {'cui': 'C0858132', 'cui_str': 'Plasma lactic acid'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0061055', 'cui_str': 'gamma-glutamyl-alpha-aminobutyrate'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",60.0,0.432725,The ▲MAP was significantly lower in the remimazolam group than in the propofol group during induction (p < .05).,"[{'ForeName': 'Tianxiao', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Lai', 'Affiliation': 'Department of Anesthesiology, Cardiovascular Institute, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.'}, {'ForeName': 'Yizhi', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, Cardiovascular Institute, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'He', 'Affiliation': 'Department of Anesthesiology, Cardiovascular Institute, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.'}, {'ForeName': 'Yanhua', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Cardiovascular Institute, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.'}, {'ForeName': 'Yubo', 'Initials': 'Y', 'LastName': 'Xie', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.'}]",Pharmacology research & perspectives,['10.1002/prp2.851'] 3148,33980116,Obesity decreases the EC50 of epidural ropivacaine when combined with dexmedetomidine for labor analgesia.,"OBJECTIVES This study aims to estimate the EC50 of ropivacaine when co-administered with dexmedetomidine for epidural labor analgesia in antepartum obese and non-obese parturients. METHODS Sixty parturients scheduled for epidural labor analgesia were enrolled and divided into antepartum obesity (AO) and control (CON) groups, according to their body mass index at labor. Both groups received 0.5 µg/mL dexmedetomidine with ropivacaine as anesthetics. The concentration of ropivacaine was initially set at 0.125% and varied by 0.01% according to the up-and-down rule for sequential allocation. Hemodynamic parameters were monitored and pain intensity was assessed using a visual analog scale. RESULTS When co-administered with dexmedetomidine, the EC50 of ropivacaine was 0.095% (95% confidence interval [CI]: 0.090-0.100%) and 0.070% (95% CI: 0.062-0.076%) in CON and AO groups, respectively. There was a significant difference between the two groups ( P < 0.001). EC95 values of ropivacaine were 0.084% (95% CI: 0.077-0.122%) and 0.106% (95% CI: 0.101-0.128%) in AO and CON groups, respectively. CONCLUSION Patients with antepartum obese may require decreased ropivacaine concentration for epidural labor analgesia when co-administered with 0.5 µg/mL dexmedetomidine.",2021,"EC95 values of ropivacaine were 0.084% (95% CI: 0.077-0.122%) and 0.106% (95% CI: 0.101-0.128 %) in AO and CON groups, respectively. ","['antepartum obese and non-obese parturients', 'Patients with antepartum obese', 'Sixty parturients scheduled for epidural labor analgesia were enrolled and divided into antepartum obesity (AO) and control (CON) groups, according to their body mass index at labor']","['ropivacaine', 'dexmedetomidine']","['ropivacaine concentration', 'pain intensity', 'EC95 values']","[{'cui': 'C0456336', 'cui_str': 'Antepartum'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C1301740', 'cui_str': 'Analgesia in labor'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0022864', 'cui_str': 'Labor'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.263913,"EC95 values of ropivacaine were 0.084% (95% CI: 0.077-0.122%) and 0.106% (95% CI: 0.101-0.128 %) in AO and CON groups, respectively. ","[{'ForeName': 'Xiaojun', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Chongqing Health Center for Women and Children, Yubei District. Chongqing, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Cai', 'Affiliation': 'Department of Anesthesiology, Chongqing Health Center for Women and Children, Yubei District. Chongqing, China.'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Lei', 'Affiliation': 'Department of Anesthesiology, Chongqing Health Center for Women and Children, Yubei District. Chongqing, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Department of Anesthesiology, Chongqing Health Center for Women and Children, Yubei District. Chongqing, China.'}]",Expert review of clinical pharmacology,['10.1080/17512433.2021.1929924'] 3149,34390084,Effects of endotracheal tube fixation methods on haemodynamic parameters during endotracheal suction: A single-blind non-randomized clinical trial study.,"AIM This study aimed to determine the effect of the methods used in endotracheal tube fixation on haemodynamic parameters (systolic and diastolic blood pressure, heart rate and oxygen saturation) during endotracheal suction. METHODS The sample of this prospective, parallel two-armed, single-blind non-randomized clinical trial study included 86 intubated patients treated in the cardiovascular surgery intensive care unit between September 2016 and December 2017. The endotracheal tube was fixed with tube holders in the intervention group (n = 43), whereas the endotracheal tube was fixed with plasters in the control group (n = 43). The patients' haemodynamic parameters were measured before, during, at the end of suction, and 5 and 15 min after suction. RESULTS In comparison with the patients with plasters, patients with tube holders had significantly lower systolic blood pressure 15 min after endotracheal suction and significantly lower diastolic blood pressure during and at the end of endotracheal suction. Oxygen saturation of the patients with tube holder during, at the end, and following 5 min after endotracheal suction were higher than patients with plaster. Heart rate was not affected during endotracheal suction in both groups. CONCLUSION The study showed the tube holder affected the haemodynamic parameters during endotracheal suction less than the plaster.",2021,"In comparison with the patients with plasters, patients with tube holders had significantly lower systolic blood pressure 15 min after endotracheal suction and significantly lower diastolic blood pressure during and at the end of endotracheal suction.",['86 intubated patients treated in the cardiovascular surgery intensive care unit between September 2016 and December 2017'],"['endotracheal tube fixation methods', 'endotracheal tube fixation', 'endotracheal suction']","['haemodynamic parameters', 'systolic blood pressure', 'diastolic blood pressure', 'haemodynamic parameters (systolic and diastolic blood pressure, heart rate and oxygen saturation', 'Oxygen saturation', 'Heart rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0038897', 'cui_str': 'Cardiovascular surgical procedure'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]","[{'cui': 'C0336630', 'cui_str': 'Endotracheal tube'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}]",86.0,0.0351524,"In comparison with the patients with plasters, patients with tube holders had significantly lower systolic blood pressure 15 min after endotracheal suction and significantly lower diastolic blood pressure during and at the end of endotracheal suction.","[{'ForeName': 'Tuğba', 'Initials': 'T', 'LastName': 'Çam Yanık', 'Affiliation': 'Faculty of Nursing, Department of Surgical Nursing, Mersin University, Mersin, Turkey.'}, {'ForeName': 'Gülay', 'Initials': 'G', 'LastName': 'Altun Uğraş', 'Affiliation': 'Faculty of Nursing, Department of Surgical Nursing, Mersin University, Mersin, Turkey.'}]",International journal of nursing practice,['10.1111/ijn.13007'] 3150,34390083,Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection.,"BACKGROUND The Maastricht V/Florence Consensus Report recommends amoxicillin-fluoroquinolone triple or quadruple therapy as a second-line treatment for Helicobacter pylori infection. An important caveat of amoxicillin-fluoroquinolone rescue therapy is poor eradication efficacy in the presence of fluoroquinolone resistance. The study aimed to investigate the efficacies of tetracycline-levofloxacin (TL) quadruple therapy and amoxicillin-levofloxacin (AL) quadruple therapy in the second-line treatment of H. pylori infection. METHODS Consecutive H. pylori-infected subjects after the failure of first-line therapies were randomly allocated to receive either TL quadruple therapy (tetracycline 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, and tripotassium dicitrato bismuthate 300 mg QID) or AL quadruple therapy (amoxicillin 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, and tripotassium dicitrato bismuthate 300 mg QID) for 10 days. Post-treatment H. pylori status was assessed 6 weeks after the end of therapy. RESULTS The study was early terminated after an interim analysis. In the TL quadruple group, 50 out of 56 patients (89.3%) had successful eradication of H. pylori infection. Cure of H. pylori infection was achieved only in 39 of 52 patients (69.6%) receiving AL quadruple therapy. Intention-to-treat analysis showed that TL quadruple therapy achieved a markedly higher eradication rate than AL quadruple therapy (95% confidence interval: 4.8% to 34.6%; p = 0.010). Further analysis revealed that TL quadruple therapy had a high eradication rate for both levofloxacin-susceptible and resistant strains (100% and 88.9%). In contrast, AL quadruple therapy yielded a high eradication for levofloxacin-susceptible strains (90.9%) but a poor eradication efficacy for levofloxacin-resistant strains (50.0%). The two therapies exhibited comparable frequencies of adverse events (37.5% vs 21.4%) and drug adherence (98.2% vs 94.6%). CONCLUSIONS Ten-day TL quadruple therapy is more effective than AL quadruple therapy in the second-line treatment of H. pylori infection in a population with high levofloxacin resistance.",2021,Intention-to-treat analysis showed that TL quadruple therapy achieved a markedly higher eradication rate than AL quadruple therapy (95% confidence interval: 4.8% to 34.6%; p = 0.010).,"['Consecutive H. pylori-infected subjects after the failure of first-line therapies', 'Helicobacter pylori infection']","['TL quadruple therapy (tetracycline 500\xa0mg QID, levofloxacin 500\xa0mg QD, esomeprazole 40\xa0mg BID, and tripotassium dicitrato bismuthate 300\xa0mg QID) or AL quadruple therapy (amoxicillin 500\xa0mg QID, levofloxacin 500\xa0mg QD, esomeprazole 40\xa0mg BID, and tripotassium dicitrato bismuthate 300\xa0mg QID', 'amoxicillin-fluoroquinolone rescue therapy', 'levofloxacin', 'TL quadruple therapy', 'Tetracycline-levofloxacin versus amoxicillin-levofloxacin', 'tetracycline-levofloxacin (TL) quadruple therapy and amoxicillin-levofloxacin (AL) quadruple therapy', 'amoxicillin-fluoroquinolone triple or quadruple therapy']","['successful eradication of H.\xa0pylori infection', 'frequencies of adverse events', 'drug adherence', 'Cure of H.\xa0pylori infection', 'eradication efficacy', 'eradication rate']","[{'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}, {'cui': 'C0850666', 'cui_str': 'Infection caused by Helicobacter pylori'}]","[{'cui': 'C0039644', 'cui_str': 'Tetracycline'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0205175', 'cui_str': 'Quadruple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0585291', 'cui_str': 'Four times daily'}, {'cui': 'C0992502', 'cui_str': 'Levofloxacin 500 MG'}, {'cui': 'C1127610', 'cui_str': 'Esomeprazole 40 MG'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}, {'cui': 'C0106556', 'cui_str': 'bismuth subcitrate'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0993263', 'cui_str': 'Amoxicillin 500 MG'}, {'cui': 'C0949665', 'cui_str': 'Fluoroquinolones'}, {'cui': 'C0205174', 'cui_str': 'Triple'}]","[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0850666', 'cui_str': 'Infection caused by Helicobacter pylori'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",56.0,0.0525924,Intention-to-treat analysis showed that TL quadruple therapy achieved a markedly higher eradication rate than AL quadruple therapy (95% confidence interval: 4.8% to 34.6%; p = 0.010).,"[{'ForeName': 'Ping-I', 'Initials': 'PI', 'LastName': 'Hsu', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.'}, {'ForeName': 'Feng-Woei', 'Initials': 'FW', 'LastName': 'Tsay', 'Affiliation': 'Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan.'}, {'ForeName': 'John Y', 'Initials': 'JY', 'LastName': 'Kao', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Nan-Jing', 'Initials': 'NJ', 'LastName': 'Peng', 'Affiliation': 'Department of Nuclear Medicine, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Yan-Hua', 'Initials': 'YH', 'LastName': 'Chen', 'Affiliation': 'Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan.'}, {'ForeName': 'Sheng-Yeh', 'Initials': 'SY', 'LastName': 'Tang', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.'}, {'ForeName': 'Chao-Hung', 'Initials': 'CH', 'LastName': 'Kuo', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.'}, {'ForeName': 'Sung-Shuo', 'Initials': 'SS', 'LastName': 'Kao', 'Affiliation': 'Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan.'}, {'ForeName': 'Huay-Min', 'Initials': 'HM', 'LastName': 'Wang', 'Affiliation': 'Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan.'}, {'ForeName': 'I-Ting', 'Initials': 'IT', 'LastName': 'Wu', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.'}, {'ForeName': 'Chang-Bih', 'Initials': 'CB', 'LastName': 'Shie', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.'}, {'ForeName': 'Seng-Kee', 'Initials': 'SK', 'LastName': 'Chuah', 'Affiliation': 'Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.'}, {'ForeName': 'Deng-Chyang', 'Initials': 'DC', 'LastName': 'Wu', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Helicobacter,['10.1111/hel.12840'] 3151,34390049,Predictors of Intimate Partner Violence Victimization by Multiple Partners Over a Period of 8 Years.,"Intimate partner violence (IPV) is a pervasive social issue with broad physical and mental health implications. Although 35%-56% of women report IPV victimization with more than one violent partner, few studies have identified factors that increase the risk of experiencing IPV across multiple partners (i.e., IPV reengagement). In the current study, multilevel modeling was used to examine the roles of trauma exposure, mental health, and sociodemographic factors in the risk for reengagement in a sample of women (N = 120) with IPV victimization. Participants were drawn from a randomized control trial of an intervention for mothers who had experienced IPV. The results revealed that more psychological but less sexual IPV was associated with increased reengagement. Higher degrees of posttraumatic reexperiencing symptoms were associated with less reengagement. Depressive symptoms were also significantly associated with reengagement such that lower levels of positive affect and increased somatic symptoms were associated with increased reengagement. Higher income levels and less housing instability were associated with more reengagement, β range = -.13-.16. Finally, compared to the control condition, participation in the intervention program was significantly associated with lower levels of reengagement at 8-year follow-up, β = -.75, p = .001. These findings suggest that it is not what happened (i.e., experiences of abuse) but rather a woman's posttraumatic experience (i.e., posttraumatic stress and depressive symptoms) that creates risk for reengagement. The findings support the long-term effectiveness of a brief intervention in reducing reengagement.",2021,"Finally, compared to the control condition, participation in the intervention program was significantly associated with lower levels of reengagement at 8-year follow-up, β = -.75, p = .001.","['Intimate partner violence (IPV', 'women (N = 120) with IPV victimization', 'mothers who had experienced IPV']",[],"['housing instability', 'Depressive symptoms', 'somatic symptoms', 'posttraumatic reexperiencing symptoms', 'sexual IPV']","[{'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0376695', 'cui_str': 'Victimization'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",[],"[{'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C3839861', 'cui_str': 'Medically unexplained symptom'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}]",120.0,0.0129423,"Finally, compared to the control condition, participation in the intervention program was significantly associated with lower levels of reengagement at 8-year follow-up, β = -.75, p = .001.","[{'ForeName': 'Sara F', 'Initials': 'SF', 'LastName': 'Stein', 'Affiliation': 'Department of Psychology, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Maria M', 'Initials': 'MM', 'LastName': 'Galano', 'Affiliation': 'Department of Psychological and Brain Sciences, University of Massachusetts, Amherst, Massachusetts, USA.'}, {'ForeName': 'Andrew C', 'Initials': 'AC', 'LastName': 'Grogan-Kaylor', 'Affiliation': 'School of Social Work, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Hannah M', 'Initials': 'HM', 'LastName': 'Clark', 'Affiliation': 'Department of Psychology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.'}, {'ForeName': 'Julie M', 'Initials': 'JM', 'LastName': 'Ribaudo', 'Affiliation': 'School of Social Work, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Sandra A', 'Initials': 'SA', 'LastName': 'Graham-Bermann', 'Affiliation': 'Department of Psychology, University of Michigan, Ann Arbor, Michigan, USA.'}]",Journal of traumatic stress,['10.1002/jts.22723'] 3152,34388179,Repeated anodal high-definition transcranial direct current stimulation over the left dorsolateral prefrontal cortex in mild cognitive impairment patients increased regional homogeneity in multiple brain regions.,"Transcranial direct current stimulation (tDCS) can improve cognitive function. However, it is not clear how high-definition tDCS (HD-tDCS) regulates the cognitive function and its neural mechanism, especially in individuals with mild cognitive impairment (MCI). This study aimed to examine whether HD-tDCS can modulate cognitive function in individuals with MCI and to determine whether the potential variety is related to spontaneous brain activity changes recorded by resting-state functional magnetic resonance imaging (rs-fMRI). Forty-three individuals with MCI were randomly assigned to receive either 10 HD-tDCS sessions or 10 sham sessions to the left dorsolateral prefrontal cortex (L-DLPFC). The fractional amplitude of low-frequency fluctuation (fALFF) and the regional homogeneity (ReHo) was computed using rs-fMRI data from all participants. The results showed that the fALFF and ReHo values changed in multiple areas following HD-tDCS. Brain regions with significant decreases in fALFF values include the Insula R, Precuneus R, Thalamus L, and Parietal Sup R, while the Temporal Inf R, Fusiform L, Occipital Sup L, Calcarine R, and Angular R showed significantly increased in their fALFF values. The brain regions with significant increases in ReHo values include the Temporal Inf R, Putamen L, Frontal Mid L, Precentral R, Frontal Sup Medial L, Frontal Sup R, and Precentral L. We found that HD-tDCS can alter the intensity and synchrony of brain activity, and our results indicate that fALFF and ReHo analysis are sensitive indicators for the detection of HD-tDCS during spontaneous brain activity. Interestingly, HD-tDCS increases the ReHo values of multiple brain regions, which may be related to the underlying mechanism of its clinical effects, these may also be related to a potential compensation mechanism involving the mobilization of more regions to complete a function following a functional decline.",2021,"The brain regions with significant increases in ReHo values include the Temporal Inf R, Putamen L, Frontal Mid L, Precentral R, Frontal Sup Medial L, Frontal Sup R, and Precentral L.","['Forty-three individuals with MCI', 'mild cognitive impairment patients', 'individuals with MCI', 'individuals with mild cognitive impairment (MCI']","['Repeated anodal high-definition transcranial direct current stimulation', '10 HD-tDCS sessions or 10 sham sessions to the left dorsolateral prefrontal cortex (L-DLPFC', 'Transcranial direct current stimulation (tDCS', 'HD-tDCS']","['intensity and synchrony of brain activity', 'ReHo values include the Temporal Inf R, Putamen L, Frontal Mid L, Precentral R, Frontal Sup Medial L, Frontal Sup R, and Precentral L', 'fractional amplitude of low-frequency fluctuation (fALFF) and the regional homogeneity (ReHo', 'fALFF and ReHo values', 'fALFF values include the Insula R, Precuneus R, Thalamus L, and Parietal Sup R, while the Temporal Inf R, Fusiform L, Occipital Sup L, Calcarine R, and Angular R']","[{'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0450424', 'cui_str': 'To the left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C1451765', 'cui_str': 'SNAP25 protein, human'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0442030', 'cui_str': 'Parietal'}, {'cui': 'C0332493', 'cui_str': 'Fusiform shape'}, {'cui': 'C0205143', 'cui_str': 'Angular'}]",43.0,0.056203,"The brain regions with significant increases in ReHo values include the Temporal Inf R, Putamen L, Frontal Mid L, Precentral R, Frontal Sup Medial L, Frontal Sup R, and Precentral L.","[{'ForeName': 'Fangmei', 'Initials': 'F', 'LastName': 'He', 'Affiliation': ""The Key Laboratory of Biomedical Information Engineering of Ministry of Education, The Key Laboratory of Neuro-informatics and Rehabilitation Engineering of Ministry of Civil Affairs, and Institute of Health and Rehabilitation Science, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.""}, {'ForeName': 'Youjun', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""The Key Laboratory of Biomedical Information Engineering of Ministry of Education, The Key Laboratory of Neuro-informatics and Rehabilitation Engineering of Ministry of Civil Affairs, and Institute of Health and Rehabilitation Science, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.""}, {'ForeName': 'Chenxi', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': ""The Key Laboratory of Biomedical Information Engineering of Ministry of Education, The Key Laboratory of Neuro-informatics and Rehabilitation Engineering of Ministry of Civil Affairs, and Institute of Health and Rehabilitation Science, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.""}, {'ForeName': 'Liming', 'Initials': 'L', 'LastName': 'Fan', 'Affiliation': ""The Key Laboratory of Biomedical Information Engineering of Ministry of Education, The Key Laboratory of Neuro-informatics and Rehabilitation Engineering of Ministry of Civil Affairs, and Institute of Health and Rehabilitation Science, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.""}, {'ForeName': 'Tian', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': ""The Key Laboratory of Biomedical Information Engineering of Ministry of Education, The Key Laboratory of Neuro-informatics and Rehabilitation Engineering of Ministry of Civil Affairs, and Institute of Health and Rehabilitation Science, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.""}, {'ForeName': 'Jue', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""The Key Laboratory of Biomedical Information Engineering of Ministry of Education, The Key Laboratory of Neuro-informatics and Rehabilitation Engineering of Ministry of Civil Affairs, and Institute of Health and Rehabilitation Science, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.""}]",PloS one,['10.1371/journal.pone.0256100'] 3153,33951448,Laser in Glaucoma and Ocular Hypertension Trial (LIGHT) in China - A Randomized Controlled Trial: Design and Baseline Characteristics.,"PURPOSE To describe the baseline characteristics of a trial to evaluate whether selective laser trabeculoplasty (SLT), as a first-line treatment, provides superior economic and health-related quality of life outcomes to medical treatment in China. DESIGN The LiGHT China trial is an unmasked, single-center, pragmatic, randomized controlled trial. METHODS A total of 771 previously undiagnosed patients with primary open angle glaucoma (POAG, 622 patients) or ocular hypertension (OHT, 149 patients) at Zhongshan Ophthalmic Center were recruited from March 2015 to January 2019. Subjects were randomized to SLT-1st (followed by medication then surgery when required) or Medicine-1st (medication followed by surgery when required). The primary outcome was health-related quality of life (HRQL). The secondary outcomes were clinical outcomes, cost, cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, visual function, and safety. RESULTS The mean age of POAG patients was 49.8 years and 38.8 years for OHT. The median intraocular pressure was 20 mm Hg for the 1,105 POAG eyes and 24 mm Hg for the 271 OHT eyes. POAG eyes had thinner central cornea thickness (CCT, 536 µm) than OHT eyes (545 µm). Median mean deviation of the visual field in POAG eyes was -4.2 dB. Median refractive error was -1.5 D for OHT eyes and -1.25 D for POAG eyes. There was no difference between POAG and OHT patients on baseline scores of GUI, GSS and VF-14. The difference between OHT and POAG on the EQ-5D-5L was 0.024. CONCLUSIONS Compared with participants in the LiGHT UK trial, participants in this trial were younger, more myopic and had more severe visual field defects.",2021,"There was no difference between POAG and OHT patients on baseline scores of GUI, GSS and VF-14.","['771', 'previously undiagnosed patients with primary open angle glaucoma (POAG, 622 patients) or ocular hypertension (OHT, 149 patients) at Zhongshan Ophthalmic Center were recruited from March 2015 to January 2019', 'mean age of POAG patients was 49.8 years and 38.8 years for OHT', 'China']","['selective laser trabeculoplasty (SLT', 'SLT-1st']","['OHT and POAG', 'median intraocular pressure', 'Median mean deviation of visual-field', 'baseline scores of GUI, GSS and VF-14', 'clinical outcomes, cost, cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, visual function and safety', 'health-related quality of life (HRQoL', 'thinner central cornea thickness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0339573', 'cui_str': 'Primary open angle glaucoma'}, {'cui': 'C0028840', 'cui_str': 'Ocular hypertension'}, {'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C1271447', 'cui_str': 'Selective laser trabeculoplasty'}, {'cui': 'C0205435', 'cui_str': 'First'}]","[{'cui': 'C0339573', 'cui_str': 'Primary open angle glaucoma'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C1828170', 'cui_str': 'Mean deviation'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0017495', 'cui_str': 'Gerstmann-Straussler-Scheinker syndrome'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205168', 'cui_str': 'Thin'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0010031', 'cui_str': 'Corneal structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",771.0,0.359205,"There was no difference between POAG and OHT patients on baseline scores of GUI, GSS and VF-14.","[{'ForeName': 'Yangfan', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, PRC.'}, {'ForeName': 'Yuzhen', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Ophthalmology, University College London, London, UK.'}, {'ForeName': 'Shitong', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, PRC.'}, {'ForeName': 'Xinyi', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, PRC.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Nathwani', 'Affiliation': 'NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Mingkai', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': 'From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, PRC.'}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, PRC.'}, {'ForeName': 'Xiulan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, PRC.'}, {'ForeName': 'Yanmei', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': 'From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, PRC.'}, {'ForeName': 'Jiangang', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, PRC.'}, {'ForeName': 'Gus', 'Initials': 'G', 'LastName': 'Gazzard', 'Affiliation': 'NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Ophthalmology, University College London, London, UK. Electronic address: g.gazzard@nhs.net.'}, {'ForeName': 'Minbin', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, PRC. Electronic address: yuminbin@mail.sysu.edu.cn.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of ophthalmology,['10.1016/j.ajo.2021.04.020'] 3154,33955547,Effects of vegetarian versus Mediterranean diet on kidney function: Findings from the CARDIVEG study.,"BACKGROUND The aim of the present study was to assess the effects of a lacto-ovo-vegetarian diet (VD), compared to a Mediterranean diet (MD), on kidney function in a group of subjects with medium-to-low cardiovascular risk profile. METHODS We analysed 107 subjects (82 women, 25 men; median age 52) who followed a VD (n = 54) and a MD (n = 53) for 3 months in the CARDIVEG study, a randomized, open, crossover trial that compared the effects of these 2 diets on cardiovascular disease risk. RESULTS The effect of the two diets on kidney function markers was evaluated by conducting a general linear model for repeated measurements adjusted for possible confounding factors such as age, sex, physical activity, alcohol, smoking, hypertension, LDL cholesterol, glucose and body weight change. A significant reduction in creatinine (-5.3%; P < .001), urea nitrogen levels (-9%; P = .001), blood urea nitrogen (BUN) (-8.7%; P = .001) and BUN/creatinine ratio (-5.8%; P < .001), and an increase in estimated glomerular filtration rate (eGFR) (+3.5%; P = .001) was observed during the VD period. On the contrary, no significant changes were noted in the MD group. Variations obtained in the two dietary interventions were significantly different (P < .0001) for creatinine levels, BUN/creatinine and eGFR, for which opposite trends were observed in the VD and MD groups. CONCLUSIONS In a selected group of subjects with medium-to-low cardiovascular risk profile, a 3 month VD period determined significant improvements in kidney function markers. Further trials are needed to confirm these results.",2021,"Variations obtained in the two dietary interventions were significantly different (P < .0001) for creatinine levels, BUN/creatinine and eGFR, for which opposite trends were observed in the VD and MD groups. ","['subjects with medium-to-low cardiovascular risk profile', '107 subjects (82 women, 25 men; median age 52) who followed a VD (n\xa0=\xa054) and a MD (n\xa0=\xa053) for 3\xa0months in the CARDIVEG study']","['vegetarian versus Mediterranean diet', 'lacto-ovo-vegetarian diet (VD', 'Mediterranean diet (MD']","['blood urea nitrogen (BUN', 'urea nitrogen levels', 'BUN/creatinine ratio', 'cardiovascular disease risk', 'creatinine', 'creatinine levels, BUN/creatinine and eGFR', 'estimated glomerular filtration rate (eGFR', 'kidney function', 'kidney function markers', 'physical activity, alcohol, smoking, hypertension, LDL cholesterol, glucose and body weight change']","[{'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0311164', 'cui_str': 'Vegetarian diet'}, {'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0042441', 'cui_str': 'Vegetarian'}, {'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C0311165', 'cui_str': 'Lacto-ovo-vegetarian diet'}, {'cui': 'C0311164', 'cui_str': 'Vegetarian diet'}]","[{'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}, {'cui': 'C0600137', 'cui_str': 'Blood urea nitrogen'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0201922', 'cui_str': 'BUN/Creatinine ratio'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0201975', 'cui_str': 'Creatinine measurement'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",107.0,0.0143651,"Variations obtained in the two dietary interventions were significantly different (P < .0001) for creatinine levels, BUN/creatinine and eGFR, for which opposite trends were observed in the VD and MD groups. ","[{'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Dinu', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Colombini', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Giuditta', 'Initials': 'G', 'LastName': 'Pagliai', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Giangrandi', 'Affiliation': 'Clinical Nutrition Unit, Careggi University Hospital, Florence, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Cesari', 'Affiliation': 'Atherohtombotic Diseases Unit, Careggi University Hospital, Florence, Italy.'}, {'ForeName': 'Annamaria', 'Initials': 'A', 'LastName': 'Gori', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Betti', 'Initials': 'B', 'LastName': 'Giusti', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Rossella', 'Initials': 'R', 'LastName': 'Marcucci', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Sofi', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}]",European journal of clinical investigation,['10.1111/eci.13576'] 3155,33952426,Long versus short biliopancreatic limb in Roux-en-Y gastric bypass: short-term results of a randomized clinical trial.,"BACKGROUND The Roux-en-Y gastric bypass continues to be one of the most performed bariatric surgeries because of its adequate balance of outcomes, complications, and durability. Recently, the role of the biliopancreatic limb on weight loss and co-morbidity control has gained attention because it seems to have a positive impact based on limb length. OBJECTIVE To compare results at 12 months of a ""standard"" (group 1) versus a long (group 2) biliopancreatic limb bypass. Biliopancreatic limbs were 50 cm and 200 cm, and alimentary limbs were 150 cm and 50 cm, respectively. SETTING Academic Referal Center; Mexico City; Public Seeting. METHODS Randomized study with patients undergoing both types of surgeries at a single academic center from 2016 to 2018. The analysis included weight loss, co-morbidity control (diabetes and hypertension), biochemical panel, operative outcomes, and complications. RESULTS Two-hundred ten patients were included (105 in each group). Almost all data were homogenous at baseline. Female sex comprised 86.1% of cases, with a mean body mass index of 43.5 kg/m 2 . Excess weight loss (77.6 ± 15.7% versus 83.6 ± 16.7%; P = .011) and total weight loss (33.5 ± 6.4% versus 37.1 ± 7.1%; P < .001) was higher in group 2; better HbA1C levels were also observed. Co-morbidity outcomes, operative data, and complications were similar between groups. CONCLUSION The Roux-en-Y gastric bypass with 200 cm of biliopancreatic limb length induces more weight loss at 12 months than a 50 cm limb length. Better HbA1C levels were also observed, but similar effects on co-morbidities and complications were noted.",2021,Excess weight loss (77.6 ± 15.7% versus 83.6 ± 16.7%; P = .011) and total weight loss (33.5 ± 6.4% versus 37.1 ± 7.1%; P < .001) was higher in group 2; better HbA1C levels were also observed.,"['patients undergoing both types of surgeries at a single academic center from 2016 to 2018', 'Two-hundred ten patients were included (105 in each group', 'Academic Referal Center; Mexico City; Public Seeting']","['Long versus short biliopancreatic limb in Roux-en-Y gastric bypass', 'standard"" (group 1) versus a long (group 2) biliopancreatic limb bypass', 'Roux-en-Y gastric bypass with 200 cm of biliopancreatic limb length']","['weight loss', 'weight loss, co-morbidity control (diabetes and hypertension), biochemical panel, operative outcomes, and complications', 'co-morbidities and complications', 'Co-morbidity outcomes, operative data, and complications', 'total weight loss', 'Excess weight loss', 'Better HbA1C levels', 'HbA1C levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0008848', 'cui_str': 'Cities'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0399839', 'cui_str': 'Bypass gastrojejunostomy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0741847', 'cui_str': 'Bypass'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1261315', 'cui_str': 'Limb length'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",210.0,0.0780987,Excess weight loss (77.6 ± 15.7% versus 83.6 ± 16.7%; P = .011) and total weight loss (33.5 ± 6.4% versus 37.1 ± 7.1%; P < .001) was higher in group 2; better HbA1C levels were also observed.,"[{'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Zerrweck', 'Affiliation': 'The Obesity Clinic at Hospital General Tláhuac, Mexico City, Mexico. Electronic address: zerrweck@yahoo.com.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Herrera', 'Affiliation': 'The Obesity Clinic at Hospital General Tláhuac, Mexico City, Mexico.'}, {'ForeName': 'Elisa M', 'Initials': 'EM', 'LastName': 'Sepúlveda', 'Affiliation': 'The Obesity Clinic at Hospital General Tláhuac, Mexico City, Mexico.'}, {'ForeName': 'Fátima M', 'Initials': 'FM', 'LastName': 'Rodríguez', 'Affiliation': 'The Obesity Clinic at Hospital General Tláhuac, Mexico City, Mexico.'}, {'ForeName': 'Lizbeth', 'Initials': 'L', 'LastName': 'Guilbert', 'Affiliation': 'The Obesity Clinic at Hospital General Tláhuac, Mexico City, Mexico.'}]",Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery,['10.1016/j.soard.2021.03.030'] 3156,34388110,Evaluating the role of Approach-Avoidance Training on action-tendencies in individuals with skin-picking disorder: A preliminary randomized experiment.,"Background and aims Pathological skin-picking (PSP) or excoriation disorder is a destructive behavior that affects 1-2% of the general population. The purpose of this pilot study was to evaluate the effect of a computerized behavior modification task on action-tendencies (i.e., approach or avoidance) in adults with PSP. We aimed to modify these action-tendencies by having participants with PSP complete the Approach-Avoidance Training (AAT) task, using a joystick to simulate an approach (=pull) or avoidance (=push) response. Method Forty-five participants diagnosed with PSP were randomized to one of three training conditions: (1) Avoidance Training (AvT; n = 15), (2) Approach Training (ApT; n = 15), or (3) Placebo Training (PT; n = 15). We hypothesized that after training, those in the AvT would have the greatest reduction in behavioral approach (i.e., their overall reaction time [RT] to approach pictures of irregular skin stimuli). Results Results of the pre-training assessment task revealed a positive correlation between behavioral approach to irregular skin stimuli and skin-picking severity as assessed by the Skin Picking Scale-Revised (SPS-R). After training, a lower behavioral approach and urges to pick were found in the AvT and PT groups, while those in the ApT reported higher behavioral approach and urges to pick. At two-week follow-up, no significant changes on the SPS-R were reported between groups. Discussion Our preliminary data suggest that the AAT is a promising avenue of research to develop as a cognitive intervention to address an excessive behavioral approach tendency that characterizes skin-picking problems.",2021,"After training, a lower behavioral approach and urges to pick were found in the AvT and PT groups, while those in the ApT reported higher behavioral approach and urges to pick.","['Method\n\n\nForty-five participants diagnosed with PSP', 'adults with PSP', 'individuals with skin-picking disorder']","['Placebo Training', 'Approach-Avoidance Training', 'computerized behavior modification task', 'Approach-Avoidance Training (AAT) task, using a joystick to simulate an approach (=pull) or avoidance (=push) response']","['Skin Picking Scale-Revised (SPS-R', 'action-tendencies', 'SPS-R', 'irregular skin stimuli and skin-picking severity']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C1696701', 'cui_str': 'Dermatillomania'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0580846', 'cui_str': 'Does pull'}, {'cui': 'C0580841', 'cui_str': 'Does push'}]","[{'cui': 'C1696701', 'cui_str': 'Dermatillomania'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0205271', 'cui_str': 'Irregular'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",45.0,0.00467179,"After training, a lower behavioral approach and urges to pick were found in the AvT and PT groups, while those in the ApT reported higher behavioral approach and urges to pick.","[{'ForeName': 'Abel S', 'Initials': 'AS', 'LastName': 'Mathew', 'Affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Madeline A', 'Initials': 'MA', 'LastName': 'Rech', 'Affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Han-Joo', 'Initials': 'HJ', 'LastName': 'Lee', 'Affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.'}]",Journal of behavioral addictions,['10.1556/2006.2021.00031'] 3157,34388107,"Topical tranexamic acid in hip fractures: a randomized, placebo-controlled double-blinded study.","BACKGROUND Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in elective orthopedic surgery. The safety of intravenous TXA in nonelective hip fracture surgery is uncertain. The purpose of this study was to evaluate the efficacy and safety of topical TXA in hip fracture surgery. METHODS Adult patients presenting to a community hospital with a hip fracture requiring surgery were randomly assigned to receive topical TXA or placebo. Hemoglobin and troponin I levels were measured preoperatively and on postoperative days 1, 2 and 3. All postoperative blood transfusions were recorded. Complications, including acute coronary syndrome (ACS), venous thromboembolism (VTE), cerebrovascular accidents (CVA), surgical site infections (SSI) and 90-day mortality, were recorded. RESULTS Data were analyzed for 65 patients (31 in the TXA group, 34 in the control group). Hemogloblin level was significantly higher on postoperative days 1 and 2 in the TXA group than in the control group. The difference in hemoglobin level between the groups was not statistically significant by postoperative day 3. Significantly fewer units of packed red blood cells were transfused in the TXA group (2 units v. 8 units); however, 2 of the units in the control group were given intraoperatively, and when these were excluded the difference was not significant. The incidence of ACS, CVA, VTE, SSI, transfusion and all-cause mortality at 90 days did not differ significantly between the groups. CONCLUSION Topical TXA reduces early postoperative blood loss after hip fracture surgery without increased patient risk. TRIAL REGISTRATION Clinicaltrials.gov, no. NCT02993341.",2021,Hemogloblin level was significantly higher on postoperative days 1 and 2 in the TXA group than in the control group.,"['65 patients (31 in the TXA group, 34 in the control group', 'hip fracture surgery', 'hip fractures', 'after hip fracture surgery without increased patient risk', 'Adult patients presenting to a community hospital with a hip fracture requiring surgery', 'elective orthopedic surgery']","['topical TXA', 'topical TXA or placebo', 'Tranexamic acid (TXA', 'TXA', 'Topical tranexamic acid', 'Topical TXA', 'placebo']","['postoperative blood loss', 'efficacy and safety', 'All postoperative blood transfusions', 'Hemogloblin level', 'incidence of ACS, CVA, VTE, SSI, transfusion and all-cause mortality', 'Hemoglobin and troponin I levels', 'hemoglobin level', 'packed red blood cells', 'perioperative blood loss', 'acute coronary syndrome (ACS), venous thromboembolism (VTE), cerebrovascular accidents (CVA), surgical site infections (SSI) and 90-day mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0020003', 'cui_str': 'Community hospital'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032788', 'cui_str': 'Postoperative hemorrhage'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0077401', 'cui_str': 'Troponin I'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C2316467', 'cui_str': 'Packed red blood cells'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",,0.346352,Hemogloblin level was significantly higher on postoperative days 1 and 2 in the TXA group than in the control group.,"[{'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Costain', 'Affiliation': 'From the Northern Ontario School of Medicine, Sault Ste. Marie, Ont. (Costain, Elder, Kelly, Cheong, Fera); and the Sault Area Hospital, Sault Ste. Marie, Ont. (Costain, Elder, Fraser, Slagel, Kelly, Cheong, Fera). dcostain@gmail.com.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Elder', 'Affiliation': 'From the Northern Ontario School of Medicine, Sault Ste. Marie, Ont. (Costain, Elder, Kelly, Cheong, Fera); and the Sault Area Hospital, Sault Ste. Marie, Ont. (Costain, Elder, Fraser, Slagel, Kelly, Cheong, Fera).'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Fraser', 'Affiliation': 'From the Northern Ontario School of Medicine, Sault Ste. Marie, Ont. (Costain, Elder, Kelly, Cheong, Fera); and the Sault Area Hospital, Sault Ste. Marie, Ont. (Costain, Elder, Fraser, Slagel, Kelly, Cheong, Fera).'}, {'ForeName': 'Brad', 'Initials': 'B', 'LastName': 'Slagel', 'Affiliation': 'From the Northern Ontario School of Medicine, Sault Ste. Marie, Ont. (Costain, Elder, Kelly, Cheong, Fera); and the Sault Area Hospital, Sault Ste. Marie, Ont. (Costain, Elder, Fraser, Slagel, Kelly, Cheong, Fera).'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Kelly', 'Affiliation': 'From the Northern Ontario School of Medicine, Sault Ste. Marie, Ont. (Costain, Elder, Kelly, Cheong, Fera); and the Sault Area Hospital, Sault Ste. Marie, Ont. (Costain, Elder, Fraser, Slagel, Kelly, Cheong, Fera).'}, {'ForeName': 'Yifun', 'Initials': 'Y', 'LastName': 'Cheong', 'Affiliation': 'From the Northern Ontario School of Medicine, Sault Ste. Marie, Ont. (Costain, Elder, Kelly, Cheong, Fera); and the Sault Area Hospital, Sault Ste. Marie, Ont. (Costain, Elder, Fraser, Slagel, Kelly, Cheong, Fera).'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Fera', 'Affiliation': 'From the Northern Ontario School of Medicine, Sault Ste. Marie, Ont. (Costain, Elder, Kelly, Cheong, Fera); and the Sault Area Hospital, Sault Ste. Marie, Ont. (Costain, Elder, Fraser, Slagel, Kelly, Cheong, Fera).'}]",Canadian journal of surgery. Journal canadien de chirurgie,['10.1503/cjs.014220'] 3158,33957292,Transcranial direct current stimulation as an adjunct to cognitive training for older adults with mild cognitive impairment: A randomized controlled trial.,"BACKGROUND Cognitive training (CT) for individuals with mild cognitive impairment (MCI) may not be optimal for enhancing cognitive functioning. Coupling CT with transcranial direct current stimulation (tDCS) may maximize the strength of transmission across synaptic circuits in pathways that are stimulated by CT. The synergistic effects arising from this combination could be superior to those with administration of CT alone. OBJECTIVES To investigate whether the receiving tDCS combined with CT is superior to CT alone on domain-specific and task-specific cognitive outcomes in older adults with MCI. METHODS This double-blind, sham-controlled randomized trial included 67 older adults with MCI assigned to 3 groups: 1) tDCS combined with CT (tDCS+CT), 2) sham tDCS combined with CT (sham tDCS+CT) and 3) CT alone. Nine sessions of computerized CT were administered to the 3 groups for 3 weeks. In addition, tDCS and sham tDCS was delivered to the left dorsolateral prefrontal cortex to the tDCS+CT and sham tDCS+CT groups, respectively, simultaneously with CT. Standardized cognitive assessments were performed at baseline, post-intervention, and at 6-week follow-up. Participants' performance in the CT tasks was rated every session. RESULTS The 3 groups showed improvements in global cognition and everyday memory (P<0.017) after the intervention and at follow-up, with larger effect sizes in the tDCS+CT than other groups (d>0.94) but with no significant differences between groups. Regarding CT outcomes, the groups showed significant differences in favour of the tDCS+CT group in decreasing the completion and reaction times of working memory and attention activities (P<0.017). CONCLUSIONS tDCS combined with CT was not superior to sham tDCS with CT and CT alone in its effects on domain-specific cognitive outcomes, but it did provide comparatively larger effect sizes and improve the processing speed of task-specific outcomes. CLINICALTRIALS.GOV: NCT03441152.",2021,"The 3 groups showed improvements in global cognition and everyday memory (p < 0.017) after the intervention and at follow-up, with larger effect sizes in the tDCS+CT than other groups (d > 0.94) but with no significant differences between groups.","['67 older adults with MCI assigned to 3 groups: 1', 'older adults with mild cognitive impairment', 'individuals with mild cognitive impairment (MCI', 'older adults with MCI']","['cognitive training', 'computerized CT', 'tDCS combined with CT', 'tDCS combined with CT (tDCS+CT), 2) sham tDCS combined with CT (sham tDCS+CT) and 3) CT alone', 'Transcranial direct current stimulation', 'tDCS+CT and sham tDCS+CT', 'tDCS+CT', 'Cognitive training (CT', 'CT alone', 'tDCS and sham tDCS', 'CT and CT', 'Coupling CT with transcranial direct current stimulation (tDCS', 'CT']","['global cognition and everyday memory', 'completion and reaction times of working memory and attention activities', 'processing speed of task-specific outcomes', 'Standardized cognitive assessments']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach'}, {'cui': 'C0442831', 'cui_str': 'Direct current'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0010222', 'cui_str': 'Couples'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",67.0,0.129658,"The 3 groups showed improvements in global cognition and everyday memory (p < 0.017) after the intervention and at follow-up, with larger effect sizes in the tDCS+CT than other groups (d > 0.94) but with no significant differences between groups.","[{'ForeName': 'Pablo Cruz', 'Initials': 'PC', 'LastName': 'Gonzalez', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.'}, {'ForeName': 'Kenneth N K', 'Initials': 'KNK', 'LastName': 'Fong', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR. Electronic address: rsnkfong@polyu.edu.hk.'}, {'ForeName': 'Ted', 'Initials': 'T', 'LastName': 'Brown', 'Affiliation': 'Department of Occupational Therapy, Monash University-Peninsula Campus, Frankston, 3199 Victoria, Australia.'}]",Annals of physical and rehabilitation medicine,['10.1016/j.rehab.2021.101536'] 3159,33957004,"A randomized, double-blind, placebo-controlled, clinical trial to evaluate the benefits of Nigella sativa seeds oil in reducing cardiovascular risks in hypertensive patients.","The efficacy, safety, and utility of Nigella sativa seeds oil as a complementary treatment for hypertension, glucose control, and lipid metabolism were evaluated. Hypertensive patients in the intervention (n = 26) and placebo (n = 29) groups received 2.5 ml of N. sativa seeds oil and sunflower oil twice daily for 8 weeks, respectively. The levels of systolic and diastolic blood pressure (SBP, DBP), blood lipid profile, and fasting blood sugar (FBS), at different stages of the treatment period (0, 3, 6, 8 weeks), and malondialdehyde (MDA) and glutathione reductase (GR), at the baseline and end of the study, were assessed. SBP level in the intervention group was significantly reduced, compared with the baseline values (p < .001) and the placebo group (p < .05). A significant decline was observed in the levels of DBP, total cholesterols, and low density lipoprotein (LDL) (p < .000), MDA, and FBS (p < .001); also, a significant increase was observed in the levels of high density lipoprotein (HDL) and GR (p < .001). The use of N. sativa seeds oil as an adjunct to common medications exhibited additional antihypertensive effects as well as beneficial effects on glucose control and lipid metabolism in hypertensive patients with no renal, hepatic, and patient-reported adverse events.",2021,"SBP level in the intervention group was significantly reduced, compared with the baseline values (p < .001) and the placebo group (p < .05).","['hypertensive patients with no renal, hepatic, and patient-reported adverse events', 'Hypertensive patients in the intervention (n = 26) and', 'hypertensive patients']","['2.5 ml of N. sativa seeds oil and sunflower oil', 'placebo', 'Nigella sativa seeds oil']","['levels of high density lipoprotein (HDL) and GR', 'cardiovascular risks', 'levels of systolic and diastolic blood pressure (SBP, DBP), blood lipid profile, and fasting blood sugar (FBS), at different stages of the treatment period (0, 3, 6, 8 weeks), and malondialdehyde (MDA) and glutathione reductase (GR', 'levels of DBP, total cholesterols, and low density lipoprotein (LDL', 'glucose control and lipid metabolism', 'hypertension, glucose control, and lipid metabolism', 'MDA, and FBS', 'SBP level']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0947381', 'cui_str': 'Helianthus annuus'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3651714', 'cui_str': 'NIGELLA SATIVA SEED OIL'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0017824', 'cui_str': 'Glutathione reductase (NAD(P)H)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",,0.172794,"SBP level in the intervention group was significantly reduced, compared with the baseline values (p < .001) and the placebo group (p < .05).","[{'ForeName': 'Parisa', 'Initials': 'P', 'LastName': 'Shoaei-Hagh', 'Affiliation': 'Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Kamelan Kafi', 'Affiliation': 'Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Najafi', 'Affiliation': 'Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mansoureh', 'Initials': 'M', 'LastName': 'Zamanzadeh', 'Affiliation': 'Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Heidari Bakavoli', 'Affiliation': 'Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Ramezani', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Samira', 'Initials': 'S', 'LastName': 'Soltanian', 'Affiliation': 'Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Asili', 'Affiliation': 'Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Hosseinzadeh', 'Affiliation': 'Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Saeid', 'Initials': 'S', 'LastName': 'Eslami', 'Affiliation': 'Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Zhila', 'Initials': 'Z', 'LastName': 'Taherzadeh', 'Affiliation': 'Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.7140'] 3160,34388099,Integrated Clinical and CT based Artificial Intelligence nomogram for predicting severity and need for ventilator support in COVID-19 patients: A multi-site study.,"Almost 25% of COVID-19 patients end up in ICU needing critical mechanical ventilation support. There is currently no validated objective way to predict which patients will end up needing ventilator support, when the disease is mild and not progressed. N=869 patients from two sites (D1: N=822, D2: N=47) with baseline clinical characteristics and chest CT scans were considered for this study. The entire dataset was randomly divided into 70% training, D1 train (N=606) and 30% test-set (D test : D1 test (N=216) + D2 (N=47)). An expert radiologist delineated ground-glass-opacities (GGOs) and consolidation regions on a subset of D1 train, (D1 train_sub, N=88). These regions were automatically segmented and used along with their corresponding CT volumes to train an imaging AI predictor (AIP) on D1 train to predict the need of mechanical ventilators for COVID-19 patients. Finally, top five prognostic clinical factors selected using univariate analysis were integrated with AIP to construct an integrated clinical and AI imaging nomogram (ClAIN). Univariate analysis identified lactate dehydrogenase, prothrombin time, aspartate aminotransferase, %lymphocytes, albumin as top five prognostic clinical features. AIP yielded an AUC of 0.81 on D test and was independently prognostic irrespective of other clinical parameters on multivariable analysis (p<0.001). ClAIN improved the performance over AIP yielding an AUC of 0.84 (p=0.04) on D test. ClAIN outperformed AIP in predicting which COVID-19 patients ended up needing a ventilator. Our results across multiple sites suggest that ClAIN could help identify COVID-19 with severe disease more precisely and likely to end up on a life-saving mechanical ventilation.",2021,ClAIN improved the performance over AIP yielding an AUC of 0.84 (p=0.04) on D test.,"['patients from two sites (D1: N=822, D2: N=47) with baseline clinical characteristics and chest CT scans', 'COVID-19 patients']","['Integrated Clinical and CT based Artificial Intelligence nomogram', 'D1 train ']","['lactate dehydrogenase, prothrombin time, aspartate aminotransferase, %lymphocytes, albumin as top five prognostic clinical features']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0202823', 'cui_str': 'CT of chest'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}, {'cui': 'C1450294', 'cui_str': 'Nomogram chart'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}]","[{'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement'}, {'cui': 'C0033707', 'cui_str': 'Prothrombin time'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",869.0,0.0921237,ClAIN improved the performance over AIP yielding an AUC of 0.84 (p=0.04) on D test.,"[{'ForeName': 'Amogh', 'Initials': 'A', 'LastName': 'Hiremath', 'Affiliation': ''}, {'ForeName': 'Kaustav', 'Initials': 'K', 'LastName': 'Bera', 'Affiliation': ''}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Yuan', 'Affiliation': ''}, {'ForeName': 'Pranjal', 'Initials': 'P', 'LastName': 'Vaidya', 'Affiliation': ''}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Alilou', 'Affiliation': ''}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Furin', 'Affiliation': ''}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Armitage', 'Affiliation': ''}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Gilkeson', 'Affiliation': ''}, {'ForeName': 'Mengyao', 'Initials': 'M', 'LastName': 'Ji', 'Affiliation': ''}, {'ForeName': 'Pingfu', 'Initials': 'P', 'LastName': 'Fu', 'Affiliation': ''}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Gupta', 'Affiliation': ''}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Anant', 'Initials': 'A', 'LastName': 'Madabushi', 'Affiliation': ''}]",IEEE journal of biomedical and health informatics,['10.1109/JBHI.2021.3103389'] 3161,34388037,Meaning-Centered Pain Coping Skills Training: A Pilot Feasibility Trial of a Psychosocial Pain Management Intervention for Patients with Advanced Cancer.,"Background: Pain from advanced cancer can greatly reduce patients' physical, emotional, and spiritual well-being. Objective: To examine the feasibility and acceptability of a behavioral pain management intervention, Meaning-Centered Pain Coping Skills Training (MCPC). Design: This trial used a single-arm feasibility design. Setting/Subjects: Thirty participants with stage IV solid tumor cancer, moderate-to-severe pain, and clinically elevated distress were enrolled from a tertiary cancer center in the United States. The manualized protocol was delivered across four 45- to 60-minute videoconference sessions. Measurements: Feasibility and acceptability were assessed through accrual, session/assessment completion, intervention satisfaction, and coping skills usage. Participants completed validated measures of primary outcomes (i.e., pain severity, pain interference, and spiritual well-being) and secondary outcomes at baseline, post-intervention, and four-week follow-up. Results: Eighty-eight percent (38/43) of patients who completed screening met inclusion criteria, and 79% (30/38) consented and completed baseline assessment. Sixty-seven percent (20/30) of participants were female (mean age = 57). Most participants were White/Caucasian (77%; 23/30) or Black/African American (17%; 5/30) with at least some college education (90%; 27/30). Completion rates for intervention sessions and both post-intervention assessments were 90% (27/30), 87% (26/30), and 77% (23/30), respectively. At the post-intervention assessment, participants reported a high degree of intervention satisfaction (mean = 3.53/4.00; SD = 0.46), and 81% (21/26) reported weekly use of coping skills that they learned. Participants also showed improvement from baseline on all primary outcomes and nearly all secondary outcomes at both post-intervention assessments. Conclusions: MCPC demonstrated strong feasibility and acceptability. Findings warrant further evaluation of MCPC in a randomized controlled trial. ClinicalTrials.gov Identifier: NCT03207360.",2021,"At the post-intervention assessment, participants reported a high degree of intervention satisfaction (mean = 3.53/4.00; SD = 0.46), and 81% (21/26) reported weekly use of coping skills that they learned.","['Patients with Advanced Cancer', 'Results: Eighty-eight percent (38/43) of patients who completed screening met inclusion criteria, and 79% (30/38) consented and completed baseline assessment', 'Sixty-seven percent (20/30) of participants were female (mean age\u2009=\u200957', 'Thirty participants with stage IV solid tumor cancer, moderate-to-severe pain, and clinically elevated distress were enrolled from a tertiary cancer center in the United States', 'Most participants were White/Caucasian (77%; 23/30) or Black/African American (17%; 5/30) with at least some college education (90%; 27/30']","['Psychosocial Pain Management Intervention', 'behavioral pain management intervention, Meaning-Centered Pain Coping Skills Training (MCPC', 'Meaning-Centered Pain Coping Skills Training']","['accrual, session/assessment completion, intervention satisfaction, and coping skills usage', 'pain severity, pain interference, and spiritual well-being) and secondary outcomes', 'high degree of intervention satisfaction', 'Feasibility and acceptability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0442751', 'cui_str': 'Distance vision 6/9'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0043157', 'cui_str': 'Caucasian'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0242936', 'cui_str': 'Pain clinic'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0086059', 'cui_str': 'Coping Skills'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",30.0,0.19202,"At the post-intervention assessment, participants reported a high degree of intervention satisfaction (mean = 3.53/4.00; SD = 0.46), and 81% (21/26) reported weekly use of coping skills that they learned.","[{'ForeName': 'Joseph G', 'Initials': 'JG', 'LastName': 'Winger', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Ramos', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Kelleher', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA.'}, {'ForeName': 'Tamara J', 'Initials': 'TJ', 'LastName': 'Somers', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA.'}, {'ForeName': 'Karen E', 'Initials': 'KE', 'LastName': 'Steinhauser', 'Affiliation': 'Center for the Study of Human Aging and Development, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Laura S', 'Initials': 'LS', 'LastName': 'Porter', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA.'}, {'ForeName': 'Arif H', 'Initials': 'AH', 'LastName': 'Kamal', 'Affiliation': 'Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.'}, {'ForeName': 'William S', 'Initials': 'WS', 'LastName': 'Breitbart', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Francis J', 'Initials': 'FJ', 'LastName': 'Keefe', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA.'}]",Journal of palliative medicine,['10.1089/jpm.2021.0081'] 3162,33964566,The effects of self-disclaimer Instagram captions on young women's mood and body image: The moderating effect of participants' own photo manipulation practices.,"The current experiment investigated the impact of attaching self-disclaimer captions (i.e., captions about whether photos had been edited) to thin-ideal Instagram photos on young women's body image and mood. Participants were 311 undergraduate students aged 18-25 years. Participants were randomly assigned to view images of a thin woman on Instagram with no captions, or with a generic, specific, or warning self-disclaimer caption, and completed pre and post measures of body image and mood and a questionnaire about their own photo-editing practices. Across all conditions, exposure to the images resulted in decreased body satisfaction, likelihood to compare one's body to another's, happiness, confidence, and anxiety. There was no significant effect of disclaimer type on body image or mood, and therefore no type of self-disclaimer had an ameliorating effect. However, specific disclaimers were superior to the other disclaimers at reducing likelihood to compare one's body to another's, for women high on photo manipulation. Future research should be conducted in adolescent girls and men.",2021,"Across all conditions, exposure to the images resulted in decreased body satisfaction, likelihood to compare one's body to another's, happiness, confidence, and anxiety.","['Participants were 311 undergraduate students aged 18-25 years', ""young women's mood and body image"", 'adolescent girls and men']","['self-disclaimer Instagram captions', 'view images of a thin woman on Instagram with no captions, or with a generic, specific, or warning self-disclaimer caption, and completed pre and post measures of body image and mood and a questionnaire about their own photo-editing practices']","[""body satisfaction, likelihood to compare one's body to another's, happiness, confidence, and anxiety""]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0450335', 'cui_str': '18/25'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0205168', 'cui_str': 'Thin'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",311.0,0.0139625,"Across all conditions, exposure to the images resulted in decreased body satisfaction, likelihood to compare one's body to another's, happiness, confidence, and anxiety.","[{'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'McComb', 'Affiliation': 'Department of Psychology, York University, 4700 Keele St, Toronto, ON, M3J 1P3, Canada. Electronic address: mccombs@yorku.ca.'}, {'ForeName': 'Keisha C', 'Initials': 'KC', 'LastName': 'Gobin', 'Affiliation': 'Department of Psychology, York University, 4700 Keele St, Toronto, ON, M3J 1P3, Canada. Electronic address: kgobin@yorku.ca.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Mills', 'Affiliation': 'Department of Psychology, York University, 4700 Keele St, Toronto, ON, M3J 1P3, Canada. Electronic address: jsmills@yorku.ca.'}]",Body image,['10.1016/j.bodyim.2021.04.011'] 3163,33964555,Urinary metabolites of polycyclic aromatic hydrocarbons after short-term fine particulate matter exposure: A randomized crossover trial of air filtration.,"Research on the relationship between short-term exposure to fine particulate matter (PM 2.5 ) and urinary metabolites of polycyclic aromatic hydrocarbons (PAHs) is sparse in the nonoccupationally exposed populations. A quasi-experimental observation of haze events nested within a randomized crossover trial of alternative 1-week real or sham indoor air filtration was conducted to evaluate the associations of urinary monohydroxy-PAHs (OH-PAHs) with short-term exposure to PM 2.5 and PM 2.5 -bound PAHs. The study was conducted among 57 healthy college students in Beijing, China. PM 2.5 -bound PAHs and urinary OH-PAHs were quantified using gas chromatography coupled with a triple-quadrupole tandem mass spectrometer. Linear mixed-effect models were applied to evaluate the association of urinary OH-PAHs with time-weighted personal PM 2.5 and PM 2.5 -bound PAHs, controlling for potentially confounding variables. The results demonstrated that air filtration could markedly reduce external exposure to PM 2.5 and PM 2.5 -bound parent, nitrated, and oxygenated PAHs. In the intervention trial, the urinary concentrations of 2-hydroxyfluorene (2-OH-FLU) and 9-hydroxyphenanthrene (9-OH-PHE) were elevated significantly by 16.5% (95% CI, 2.1%, 33.1%) and 37.9% (95% CI, 8.4%, 75.4%), respectively, in association with a doubling increase in personal PM 2.5 exposure. Urinary 9-OH-PHE was also significantly positively associated with the increase in the sum of PM 2.5 -bound parent PAHs. Furthermore, the levels of urinary OH-PAHs such as 2-OH-FLU and 9-OH-PHE in the haze events were elevated by 31.1% (95% CI, 8.7%, 53.4%) and 73.5% (95% CI, 16.0%, 131.0%), respectively, in association with a doubling increase in personal PM 2.5 exposure. The findings indicated that urinary 2-OH-FLU and 9-OH-PHE could serve as potential internal exposure biomarkers for assessing short-term PM 2.5 exposure in nonoccupational populations.",2021,"In the intervention trial, the urinary concentrations of 2-hydroxyfluorene (2-OH-FLU) and 9-hydroxyphenanthrene (9-OH-PHE) were elevated significantly by 16.5% (95% CI, 2.1%, 33.1%) and 37.9% (95% CI, 8.4%, 75.4%), respectively, in association with a doubling increase in personal PM 2.5 exposure.","['polycyclic aromatic hydrocarbons after short-term fine particulate matter exposure', '57 healthy college students in Beijing, China']",['alternative 1-week real or sham indoor air filtration'],"['PM 2.5 -bound PAHs and urinary OH-PAHs', 'levels of urinary OH-PAHs such as 2-OH-FLU and 9-OH-PHE in the haze events', 'Urinary 9-OH-PHE', 'urinary concentrations of 2-hydroxyfluorene (2-OH-FLU) and 9-hydroxyphenanthrene (9-OH-PHE', 'urinary OH-PAHs']","[{'cui': 'C0032458', 'cui_str': 'Polycyclic Hydrocarbons, Aromatic'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C1720884', 'cui_str': 'Particulate Matter'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0016107', 'cui_str': 'Filtration'}]","[{'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0032458', 'cui_str': 'Polycyclic Hydrocarbons, Aromatic'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0104281', 'cui_str': 'AS 2'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0031453', 'cui_str': 'Phenylalanine'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0232827', 'cui_str': 'Urinary concentration'}, {'cui': 'C1312051', 'cui_str': '2-hydroxyfluorene'}, {'cui': 'C0292873', 'cui_str': '9-phenanthrol'}]",57.0,0.103093,"In the intervention trial, the urinary concentrations of 2-hydroxyfluorene (2-OH-FLU) and 9-hydroxyphenanthrene (9-OH-PHE) were elevated significantly by 16.5% (95% CI, 2.1%, 33.1%) and 37.9% (95% CI, 8.4%, 75.4%), respectively, in association with a doubling increase in personal PM 2.5 exposure.","[{'ForeName': 'Jiazhang', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing, PR China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing, PR China.'}, {'ForeName': 'Lijun', 'Initials': 'L', 'LastName': 'Xue', 'Affiliation': 'Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing, PR China.'}, {'ForeName': 'Guoxing', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing, PR China.'}, {'ForeName': 'Shaowei', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': ""Department of Occupational and Environmental Health, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, PR China.""}, {'ForeName': 'Xinbiao', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing, PR China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Institute of Reproductive and Child Health, Peking University, Beijing, PR China; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, PR China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing, PR China. Electronic address: jing_huang@bjmu.edu.cn.'}]","Environmental pollution (Barking, Essex : 1987)",['10.1016/j.envpol.2021.117258'] 3164,33966335,Comparison of transcutaneous tibial nerve stimulation (TTNS) protocols for women with refractory overactive bladder (OAB): A prospective randomised trial.,"OBJECTIVES Transcutaneous tibial nerve stimulation (TTNS) is a noninvasive method used in OAB treatment. Purpose of this study is to compare the effectiveness of the TTNS procedure applied once a week and three times a week in women diagnosed with wet type refractory OAB. METHODS A total of 60 patients diagnosed with wet type OAB that was refractory to medical treatment were included in the study. Participants were equally and randomly divided into two groups: TTNS treatment was performed with a duration of 30 minutes for 12 weeks, once a week to Group I and three times a week to Group II. Pretreatment and posttreatment OAB-V8/ICIQ-SF scores and voiding frequencies recorded in the bladder diary were compared between groups. RESULTS Four patients in Group 1 and eight in Group 2 left the study without completing the treatment. TTNS was performed in both groups for 12 weeks. There was a significant decrease in the voiding frequency, OAB-V8, ICIQ-SF scores in both group 1 and group 2 (P < .001). A significant decrease in the OAB-V8 score was observed in the 5th week in Group 1, and in the 3rd week in Group 2. Complete response was observed in 6 patients (23.1%) in Group 1 after 12 weeks of TTNS procedure. In Group 2, 10 patients (45.5%) had a complete response. After the 12-week TTNS procedure, no significant difference was observed between the groups in terms of treatment response. CONCLUSION TTNS can be safely used before invasive treatments in resistant OAB. TTNS procedure three times a week seems more effective than performing it once a week. What's known TTNS is one of the effective alternative treatments in resistant OAB treatment. What's new As the number of sessions is increased in TTNS treatment, the success of the treatment can increase.",2021,"There was a significant decrease in the voiding frequency, OAB-V8, ICIQ-SF scores in both group-1 and group-2 (p<0.001).","['60 patients diagnosed with wet type OAB that was refractory to medical treatment were included in the study', 'women diagnosed with wet type refractory OAB', 'Women with Refractory Overactive Bladder (OAB']","['TTNS procedure', 'Transcutaneous Tibial Nerve Stimulation (TTNS) Protocols', 'TTNS', 'Transcutaneous Tibial Nerve Stimulation (TTNS']","['voiding frequency, OAB-V8, ICIQ-SF scores', 'OAB-V8 score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205381', 'cui_str': 'Wet'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}]","[{'cui': 'C0040186', 'cui_str': 'Structure of tibial nerve'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",60.0,0.00260676,"There was a significant decrease in the voiding frequency, OAB-V8, ICIQ-SF scores in both group-1 and group-2 (p<0.001).","[{'ForeName': 'Okan', 'Initials': 'O', 'LastName': 'Alkis', 'Affiliation': 'Department of Urology, Faculty of Medicine, Kütahya University of Health Sciences, Kutahya, Turkey.'}, {'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Sevim', 'Affiliation': 'Department of Urology, Faculty of Medicine, Kütahya University of Health Sciences, Kutahya, Turkey.'}, {'ForeName': 'İbrahim', 'Initials': 'İ', 'LastName': 'Güven Kartal', 'Affiliation': 'Department of Urology, Faculty of Medicine, Kütahya University of Health Sciences, Kutahya, Turkey.'}, {'ForeName': 'Aykut', 'Initials': 'A', 'LastName': 'Baser', 'Affiliation': 'Department of Urology, Faculty of Medicine, Hitit University, Çorum, Turkey.'}, {'ForeName': 'Halil', 'Initials': 'H', 'LastName': 'İbrahim İvelik', 'Affiliation': 'Department of Urology, Faculty of Medicine, Kütahya University of Health Sciences, Kutahya, Turkey.'}, {'ForeName': 'Bekir', 'Initials': 'B', 'LastName': 'Aras', 'Affiliation': 'Department of Urology, Faculty of Medicine, Kütahya University of Health Sciences, Kutahya, Turkey.'}]",International journal of clinical practice,['10.1111/ijcp.14342'] 3165,33978490,Sympathetic activation due to limb venous distension is preserved during muscle metaboreceptor stimulation.,"Venous saline infusions in an arterially occluded forearm evoke reflex increases in muscle sympathetic nerve activity (MSNA) and blood pressure (BP) in humans (venous distension reflex). It is unclear if the inputs from metabolically sensitive skeletal muscle afferents (i.e., muscle metaboreflex) would modify the venous distension reflex. We hypothesized that muscle metaboreceptor stimulation might augment the venous distension reflex. BP (Finapres), heart rate (ECG), and MSNA (microneurography) were assessed in 18 young healthy subjects. In trial A , saline (5% forearm volume) was infused into the veins of an arterially occluded arm (nonhandgrip trial). In trial B , subjects performed 2-min static handgrip followed by postexercise circulatory occlusion (PECO) of the arm. During PECO, saline was infused into the veins of the arm (handgrip trial). In trial A , the infusion increased MSNA and BP as expected (both P < 0.001). In trial B , handgrip significantly raised MSNA, BP, and venous lactic acid concentrations. Venous saline infusion during PECO further raised MSNA and BP (both P < 0.001). The changes in MSNA (Δ8.6 ± 1.5 to Δ10.6 ± 1.8 bursts/min, P = 0.258) and mean arterial pressure ( P = 0.844) evoked by the infusion during PECO were not significantly different from those in the nonhandgrip trial. These observations indicate that venous distension reflex responses are preserved during sympathetic activation mediated by the muscle metaboreflex.",2021,Venous saline infusion during PECO further raised MSNA and BP (both P < 0.001).,"['18 young healthy subjects', 'humans (venous distension reflex']","['saline', 'PECO, saline', 'static handgrip followed by post exercise circulatory occlusion (PECO']","['MSNA and BP', 'mean arterial pressure', 'BP (Finapres), heart rate (ECG), and MSNA (microneurography', 'MSNA, BP and venous lactic acid concentrations', 'muscle sympathetic nerve activity (MSNA) and blood pressure (BP']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0034929', 'cui_str': 'Reflex'}]","[{'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0459521', 'cui_str': 'Sympathetic nerve structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0064582', 'cui_str': 'lactic acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",18.0,0.104906,Venous saline infusion during PECO further raised MSNA and BP (both P < 0.001).,"[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Cui', 'Affiliation': 'Penn State Hershey Heart and Vascular Institute, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Blaha', 'Affiliation': 'Penn State Hershey Heart and Vascular Institute, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'Urs A', 'Initials': 'UA', 'LastName': 'Leuenberger', 'Affiliation': 'Penn State Hershey Heart and Vascular Institute, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'Lawrence I', 'Initials': 'LI', 'LastName': 'Sinoway', 'Affiliation': 'Penn State Hershey Heart and Vascular Institute, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00305.2020'] 3166,34389772,Early decompressive hemicraniectomy in thrombolyzed acute ischemic stroke patients from the international ENCHANTED trial.,"Decompressive hemicraniectomy (DHC) can improve outcomes for patients with severe forms of acute ischemic stroke (AIS), but the evidence is mainly derived from non-thrombolyzed patients. We aimed to determine the characteristics and outcomes of early DHC in thrombolyzed AIS participants of the international Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED). Post-hoc analyses of ENCHANTED, an international, partial-factorial, open, blinded outcome-assessed, controlled trial in 4557 thrombolysis-eligible AIS patients randomized to low- versus standard-dose intravenous alteplase (Arm A, n = 2350), intensive versus guideline-recommended blood pressure control (Arm B, n = 1280), or both (Arms A + B, n = 947). Logistic regression models were used to identify baseline variables associated with DHC, with inverse probability of treatment weights employed to eliminate baseline imbalances between those with and without DHC. Logistic regression was also used to determine associations of DHC and clinical outcomes of death/disability, major disability, and death (defined by scores 2-6, 3-5, and 6, respectively, on the modified Rankin scale) at 90 days post-randomization. There were 95 (2.1%) thrombolyzed AIS patients who underwent DHC, who were significantly younger, of non-Asian ethnicity, and more likely to have had prior lipid-lowering treatment and severe neurological impairment from large vessel occlusion than other patients. DHC patients were more likely to receive other management interventions and have poor functional outcomes than non-DHC patients, with no relation to different doses of intravenous alteplase. Compared to other thrombolyzed AIS patients, those who received DHC had a poor prognosis from more severe disease despite intensive in-hospital management.",2021,"DHC patients were more likely to receive other management interventions and have poor functional outcomes than non-DHC patients, with no relation to different doses of intravenous alteplase.","['thrombolyzed acute ischemic stroke patients', 'thrombolyzed AIS participants of the international Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED', 'DHC patients', '4557 thrombolysis-eligible AIS patients randomized to', 'patients with severe forms of acute ischemic stroke (AIS']","['decompressive hemicraniectomy', 'DHC', 'Decompressive hemicraniectomy (DHC', 'low- versus standard-dose intravenous alteplase (Arm A, n\u2009=\u20092350), intensive versus guideline-recommended blood pressure control']","['death/disability, major disability, and death']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205431', 'cui_str': 'Formed'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",4557.0,0.0387256,"DHC patients were more likely to receive other management interventions and have poor functional outcomes than non-DHC patients, with no relation to different doses of intravenous alteplase.","[{'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Xia', 'Affiliation': ""Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.""}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Richard I', 'Initials': 'RI', 'LastName': 'Lindley', 'Affiliation': 'Westmead Applied Research Centre, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Candice', 'Initials': 'C', 'LastName': 'Delcourt', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Zien', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Guo', 'Affiliation': ""Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.""}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Carcel', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'Malavera', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Zeljka', 'Initials': 'Z', 'LastName': 'Calic', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Grant', 'Initials': 'G', 'LastName': 'Mair', 'Affiliation': 'Division of Neuroimaging Sciences, Edinburgh Imaging and Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Joanna M', 'Initials': 'JM', 'LastName': 'Wardlaw', 'Affiliation': 'Division of Neuroimaging Sciences, Edinburgh Imaging and Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Thompson G', 'Initials': 'TG', 'LastName': 'Robinson', 'Affiliation': 'Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.'}, {'ForeName': 'Craig S', 'Initials': 'CS', 'LastName': 'Anderson', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. canderson@georgeinstitute.org.au.'}]",Scientific reports,['10.1038/s41598-021-96087-z'] 3167,34389753,"Relative absorption of silicon from different formulations of dietary supplements: a pilot randomized, double-blind, crossover post-prandial study.","The purpose of the present study was to compare the relative absorption of a new powder presentation of silicon (Si) as orthosilicic acid with maltodextrin (Orgono Powder) compared to usual Si liquid presentations as orthosilicic acid with Equisetum arvense and Rosmarinus officinalis (G5 Siliplant) and orthosilicic acid with aloe vera (G7 Aloe). All dietary supplements were administered at the same Si oral dose (21.6 mg) in a randomized, double-blind, crossover post-prandial study conducted in 5 healthy men. Urine was collected at baseline and over the 6-h post-dose period in 2 separate 3-h collections for the analysis of Si concentration, which was conducted by inductively coupled plasma optical emission spectrometry as the gold standard method. No significant differences in total urinary Si excretion were found after the intake of these 3 dietary supplements; 34.6%, 32.4% and 27.2% of the ingested Si from G7 Aloe, G5 Siliplant and Orgono Powder, respectively, was excreted in urine over the 6-h follow-up period. The 3 different oral Si formulations tested, in powder and liquid presentations, provide highly bioavailable Si and present an equivalent relative absorption in healthy humans.",2021,"No significant differences in total urinary Si excretion were found after the intake of these 3 dietary supplements; 34.6%, 32.4% and 27.2% of the ingested Si from G7 Aloe, G5 Siliplant and Orgono Powder, respectively, was excreted in urine over the 6-h follow-up period.","['5 healthy men', 'healthy humans']","['silicon (Si) as orthosilicic acid with maltodextrin (Orgono Powder', 'dietary supplements', 'orthosilicic acid with aloe vera (G7 Aloe']",['total urinary Si excretion'],"[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0037107', 'cui_str': 'Silicon'}, {'cui': 'C4020396', 'cui_str': 'orthosilicic acid'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0718405', 'cui_str': 'Aloe vera'}, {'cui': 'C0002168', 'cui_str': 'Aloe'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037107', 'cui_str': 'Silicon'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}]",5.0,0.268521,"No significant differences in total urinary Si excretion were found after the intake of these 3 dietary supplements; 34.6%, 32.4% and 27.2% of the ingested Si from G7 Aloe, G5 Siliplant and Orgono Powder, respectively, was excreted in urine over the 6-h follow-up period.","[{'ForeName': 'N', 'Initials': 'N', 'LastName': 'Boqué', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició I Salut, Av. de La Universitat, 43204, Reus, Spain.'}, {'ForeName': 'R M', 'Initials': 'RM', 'LastName': 'Valls', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició I Salut, Av. de La Universitat, 43204, Reus, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pedret', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició I Salut, Av. de La Universitat, 43204, Reus, Spain. anna.pedret@eurecat.org.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Puiggrós', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició I Salut, Av. de La Universitat, 43204, Reus, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Arola', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició I Salut, Av. de La Universitat, 43204, Reus, Spain.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Solà', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició I Salut, Av. de La Universitat, 43204, Reus, Spain.'}]",Scientific reports,['10.1038/s41598-021-95220-2'] 3168,33993302,Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).,"BACKGROUND To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the pharmacokinetics of raltegravir and lamivudine in genital tissue against ex vivo tissue infection with HIV-1. METHODS Open-label trial of 36 HIV-negative females and males randomized to 7 days raltegravir 400 mg twice daily and 7 days raltegravir 400 mg+lamivudine 150 mg twice daily (after washout), or vice versa. Blood, saliva, rectal fluid, rectal tissue, vaginal fluid and vaginal tissue were sampled at baseline and on and off PrEP during a total of 12 days, for pharmacokinetics and antiviral activity via ex vivo HIV-1BaL challenge. Ex vivo infectivity was compared with baseline. The trial has been registered in https://clinicaltrials.gov/ with the identifier NCT03205566. RESULTS Steady state for both drugs was reached by day 4. Dosing with raltegravir alone provided modest ex vivo HIV protection with higher drug levels in rectal tissue and vaginal tissue than in plasma on and off PrEP. Off PrEP, plasma and vaginal concentrations declined rapidly, while persisting in the rectum. On PrEP, the highest lamivudine concentrations were in the rectum, followed by vaginal tissue then plasma. Lamivudine washout was rapid in plasma, while persisting in the rectum and vagina. Raltegravir/lamivudine increased ex vivo protection on and off PrEP compared with raltegravir alone, reaching maximum protection at day 2 in rectal tissue and at day 8 in vaginal tissue. CONCLUSIONS Raltegravir 400 mg+lamivudine 150 mg showed high levels of ex vivo HIV protection, associated with high drug concentrations persisting after discontinuation in vaginal and rectal compartments, supporting further investigation of these agents for PrEP.",2021,Dosing with raltegravir alone provided modest ex vivo HIV protection with higher drug levels in rectal tissue and vaginal tissue than in plasma on and off PrEP.,['36 HIV-negative females and males randomized to 7\u2009days'],"['Raltegravir/lamivudine', 'raltegravir with or without lamivudine', 'Lamivudine', 'raltegravir and lamivudine', 'raltegravir 400\u2009mg twice daily and 7\u2009days raltegravir 400\u2009mg+lamivudine 150', 'raltegravir']","['rectal tissue and vaginal tissue', 'pharmacokinetics and antiviral activity via ex vivo HIV-1BaL challenge', 'modest ex vivo HIV protection', 'Off PrEP, plasma and vaginal concentrations', 'levels of ex vivo HIV protection', 'Blood, saliva, rectal fluid, rectal tissue, vaginal fluid and vaginal tissue']","[{'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C1871526', 'cui_str': 'raltegravir'}, {'cui': 'C0209738', 'cui_str': 'Lamivudine'}, {'cui': 'C1967561', 'cui_str': 'raltegravir 400 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C4321486', 'cui_str': '150'}]","[{'cui': 'C0205052', 'cui_str': 'Rectal'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0003451', 'cui_str': 'Antiviral'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0392908', 'cui_str': 'Vaginal secretion'}]",36.0,0.0794055,Dosing with raltegravir alone provided modest ex vivo HIV protection with higher drug levels in rectal tissue and vaginal tissue than in plasma on and off PrEP.,"[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Herrera', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Julianne', 'Initials': 'J', 'LastName': 'Lwanga', 'Affiliation': ""Guys and St Thomas' NHS Foundation Trust and King's College London, London, UK.""}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': ""Guys and St Thomas' NHS Foundation Trust and King's College London, London, UK.""}, {'ForeName': 'Suna', 'Initials': 'S', 'LastName': 'Mantori', 'Affiliation': ""Guys and St Thomas' NHS Foundation Trust and King's College London, London, UK.""}, {'ForeName': 'Alieu', 'Initials': 'A', 'LastName': 'Amara', 'Affiliation': 'Department of Pharmacology, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Else', 'Affiliation': 'Department of Pharmacology, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Sujan Dilly', 'Initials': 'SD', 'LastName': 'Penchala', 'Affiliation': 'Department of Pharmacology, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Deirdre', 'Initials': 'D', 'LastName': 'Egan', 'Affiliation': 'Department of Pharmacology, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Challenger', 'Affiliation': 'Department of Pharmacology, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Dickinson', 'Affiliation': 'Department of Pharmacology, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Boffito', 'Affiliation': 'Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Shattock', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Saye', 'Initials': 'S', 'LastName': 'Khoo', 'Affiliation': 'Department of Pharmacology, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Fox', 'Affiliation': ""Guys and St Thomas' NHS Foundation Trust and King's College London, London, UK.""}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkab136'] 3169,33993295,Is a randomized controlled design sufficient for a trial to be valuable?,,2021,,[],[],[],[],[],[],,0.244053,,"[{'ForeName': 'Filippo Maria', 'Initials': 'FM', 'LastName': 'Ubaldi', 'Affiliation': 'GeneraLife IVF, Clinica Valle Giulia, Rome, Italy.'}, {'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'Cimadomo', 'Affiliation': 'GeneraLife IVF, Clinica Valle Giulia, Rome, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Vaiarelli', 'Affiliation': 'GeneraLife IVF, Clinica Valle Giulia, Rome, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Rienzi', 'Affiliation': 'GeneraLife IVF, Clinica Valle Giulia, Rome, Italy.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/deab114'] 3170,33993250,Is the 'freeze-all' strategy really inferior to a 'fresh embryo transfer' strategy? Critical assessment of a randomized controlled trial.,,2021,,[],[],[],[],[],[],,0.120675,,"[{'ForeName': 'B', 'Initials': 'B', 'LastName': 'Lawrenz', 'Affiliation': 'IVF Department, ART Fertility Clinic, Abu Dhabi, United Arab Emirates.'}, {'ForeName': 'H M', 'Initials': 'HM', 'LastName': 'Fatemi', 'Affiliation': 'IVF Department, ART Fertility Clinic, Abu Dhabi, United Arab Emirates.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/deab116'] 3171,33999544,Physical Rehabilitation for Older Patients Hospitalized for Heart Failure.,"BACKGROUND Older patients who are hospitalized for acute decompensated heart failure have high rates of physical frailty, poor quality of life, delayed recovery, and frequent rehospitalizations. Interventions to address physical frailty in this population are not well established. METHODS We conducted a multicenter, randomized, controlled trial to evaluate a transitional, tailored, progressive rehabilitation intervention that included four physical-function domains (strength, balance, mobility, and endurance). The intervention was initiated during, or early after, hospitalization for heart failure and was continued after discharge for 36 outpatient sessions. The primary outcome was the score on the Short Physical Performance Battery (total scores range from 0 to 12, with lower scores indicating more severe physical dysfunction) at 3 months. The secondary outcome was the 6-month rate of rehospitalization for any cause. RESULTS A total of 349 patients underwent randomization; 175 were assigned to the rehabilitation intervention and 174 to usual care (control). At baseline, patients in each group had markedly impaired physical function, and 97% were frail or prefrail; the mean number of coexisting conditions was five in each group. Patient retention in the intervention group was 82%, and adherence to the intervention sessions was 67%. After adjustment for baseline Short Physical Performance Battery score and other baseline characteristics, the least-squares mean (±SE) score on the Short Physical Performance Battery at 3 months was 8.3±0.2 in the intervention group and 6.9±0.2 in the control group (mean between-group difference, 1.5; 95% confidence interval [CI], 0.9 to 2.0; P<0.001). At 6 months, the rates of rehospitalization for any cause were 1.18 in the intervention group and 1.28 in the control group (rate ratio, 0.93; 95% CI, 0.66 to 1.19). There were 21 deaths (15 from cardiovascular causes) in the intervention group and 16 deaths (8 from cardiovascular causes) in the control group. The rates of death from any cause were 0.13 and 0.10, respectively (rate ratio, 1.17; 95% CI, 0.61 to 2.27). CONCLUSIONS In a diverse population of older patients who were hospitalized for acute decompensated heart failure, an early, transitional, tailored, progressive rehabilitation intervention that included multiple physical-function domains resulted in greater improvement in physical function than usual care. (Funded by the National Institutes of Health and others; REHAB-HF ClinicalTrials.gov number, NCT02196038.).",2021,There were 21 deaths (15 from cardiovascular causes) in the intervention group and 16 deaths (8 from cardiovascular causes) in the control group.,"['Older patients who are hospitalized for acute decompensated heart failure', '349 patients underwent randomization; 175 were assigned to the', 'older patients who were hospitalized for acute decompensated heart failure, an early, transitional, tailored, progressive rehabilitation intervention that included multiple physical-function domains', 'Older Patients Hospitalized for Heart Failure']","['rehabilitation intervention and 174 to usual care (control', 'progressive rehabilitation intervention', 'Physical Rehabilitation']","['frail or prefrail; the mean number of coexisting conditions', 'score on the Short Physical Performance Battery (total scores range', 'rates of death', 'severe physical dysfunction', '6-month rate of rehospitalization for any cause', 'Patient retention', 'least-squares mean (±SE) score on the Short Physical Performance Battery', 'physical function', 'physical-function domains (strength, balance, mobility, and endurance', 'rates of rehospitalization']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]","[{'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}]",349.0,0.114272,There were 21 deaths (15 from cardiovascular causes) in the intervention group and 16 deaths (8 from cardiovascular causes) in the control group.,"[{'ForeName': 'Dalane W', 'Initials': 'DW', 'LastName': 'Kitzman', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Whellan', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Duncan', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'Amy M', 'Initials': 'AM', 'LastName': 'Pastva', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mentz', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'Gordon R', 'Initials': 'GR', 'LastName': 'Reeves', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'M Benjamin', 'Initials': 'MB', 'LastName': 'Nelson', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'Haiying', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'Bharathi', 'Initials': 'B', 'LastName': 'Upadhya', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'Shelby D', 'Initials': 'SD', 'LastName': 'Reed', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Espeland', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'LeighAnn', 'Initials': 'L', 'LastName': 'Hewston', 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': ""O'Connor"", 'Affiliation': 'From the Department of Internal Medicine, Sections of Cardiovascular Medicine (D.W.K., M.B.N., B.U.) and Gerontology and Geriatric Medicine (D.W.K.,\xa0M.A.E.), and the Departments of Neurology (P.D.) and Biostatistics and Data Science (H.C., M.A.E.), Wake Forest School of Medicine, Winston-Salem, the Department of Orthopedic Surgery, Doctor of Physical Therapy Division (A.M.P.), the Department of Medicine, Division of Cardiology (R.J.M.), and the Department of Population Health Sciences (S.D.R.), Duke University School of Medicine, Durham, and Novant Health Heart and Vascular Institute, Charlotte (G.R.R.) - all in North Carolina; the Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University (D.J.W.), and the Department of Physical Therapy, Jefferson College of Rehabilitation Sciences at Thomas Jefferson University (L.A.H.) - both in Philadelphia; and Inova Heart and Vascular Institute, Fairfax, VA (C.M.O.).'}]",The New England journal of medicine,['10.1056/NEJMoa2026141'] 3172,33998561,Effect of home-based rehabilitation of purposeful activity-based electrical stimulation therapy for chronic stroke survivors: a crossover randomized controlled trial.,"BACKGROUND In this trial we combined the effect of purposeful activity and electrical stimulation therapy (PA-EST) to promote transition of severely hemiparetic upper limb to auxiliary upper limb in chronic stroke survivors in a single-case study. OBJECTIVE The purpose of this study was to examine the effect of PA-EST on the upper limb motor function in a crossover randomized controlled trial. METHODS The study included eight stroke survivors (age: 63.1±10.9 years) who were receiving home-based visiting occupational therapy. The average time since stroke onset was 8.8±5.6 years. All participants had severely hemiparetic upper limb, with the Fugl-Meyer Assessment upper extremity (FMA-U) score of 21.3±8.5. Participants were randomly assigned to group A or B. Group A received PA-EST for 3 months (phase 1), followed by standard stretching and exercise for 3 months (phase 2), whereas group B had the inverse order of treatments. To avoid carry-over effect, 1-month washout period was provided between the phase 1 and 2. Two-way analysis of variance (ANOVA) with repeated measures was used for the analysis. The primary outcome was FMA-U, and the secondary outcomes were, Motor Activity Log (MAL; amount of use [AOU] and quality of movement [QOM]), and Goal attainment scale-light (GAS-light). RESULTS Repeated measures-ANOVA revealed a significant interaction between type of intervention and time for FMA-U (F = 16.303, P = 0.005), MAL AOU (F = 7.966, P = 0.026) and QOM (F = 6.408, P = 0.039), and GAS-light (F = 6.905, P = 0.034), where PA-EST was associated with significantly improved motor function and goal achievement compared with standard stretching. CONCLUSIONS The PA-EST may have greater effects than stretch/exercise in the recovery of hand function as reflected in FMA-U, MAL, and GAS-light. Our results suggest that PA-EST is an important and useful home-based rehabilitation program for promoting the use of the severely hemiparetic upper limb in chronic stroke survivors.",2021,"RESULTS Repeated measures-ANOVA revealed a significant interaction between type of intervention and time for FMA-U","['eight stroke survivors (age: 63.1±10.9 years) who were receiving home-based visiting occupational therapy', 'All participants had severely hemiparetic upper limb, with the Fugl-Meyer Assessment upper extremity (FMA-U) score of 21.3±8.5', 'chronic stroke survivors']","['PA-EST', 'home-based rehabilitation of purposeful activity-based electrical stimulation therapy', 'purposeful activity and electrical stimulation therapy (PA-EST']","['MAL AOU', 'FMA-U, and the secondary outcomes were, Motor Activity Log (MAL; amount of use [AOU] and quality of movement [QOM]), and Goal attainment scale-light (GAS-light', 'average time since stroke onset', 'QOM', 'FMA-U', 'motor function and goal achievement']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0013787', 'cui_str': 'Electrotherapy'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C4749296', 'cui_str': 'GAS-Light - Goal Attainment Scaling-Light'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}]",8.0,0.027482,"RESULTS Repeated measures-ANOVA revealed a significant interaction between type of intervention and time for FMA-U","[{'ForeName': 'Seigo', 'Initials': 'S', 'LastName': 'Minami', 'Affiliation': 'Department of Occupational Therapy, Osaka Kawasaki Rehabilitation University, Mizuma, Kaizuka City, Osaka, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Fukumoto', 'Affiliation': 'Graduate School of Medicine, Kyoto University, Shogoinkawaracho, Sakyou-ku, Kyoto City, Kyoto Japan.'}, {'ForeName': 'Ryuji', 'Initials': 'R', 'LastName': 'Kobayashi', 'Affiliation': 'Graduate School of Human Health Sciences, Tokyo Metropolitan University, Higashi-Ogu, Arakawa City, Tokyo, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Aoki', 'Affiliation': 'Graduate School of Medicine, Wakayama Medical University, Kimiidera, Wakayama City, Wakayama, Japan.'}, {'ForeName': 'Tomoki', 'Initials': 'T', 'LastName': 'Aoyama', 'Affiliation': 'Graduate School of Medicine, Kyoto University, Shogoinkawaracho, Sakyou-ku, Kyoto City, Kyoto Japan.'}]",Restorative neurology and neuroscience,['10.3233/RNN-211157'] 3173,33998292,Exercise effect on insulin-dependent and insulin-independent glucose utilization in healthy individuals and individuals with type 1 diabetes: a modeling study.,"Exercise effects (EE) on whole body glucose rate of disappearance (Rd) occur through insulin-independent (IIRd) and insulin-dependent (IDRd) mechanisms. Quantifying these processes in vivo would allow a better understanding of the physiology of glucose regulation. This is of particular importance in individuals with type 1 diabetes (T1D) since such a knowledge may help to improve glucose management. However, such a model is still lacking. Here, we analyzed data from six T1D and six nondiabetic (ND) subjects undergoing a labeled glucose clamp study during, before, and after a 60-min exercise session at 65% V̇o 2max on three randomized visits: euglycemia-low insulin, euglycemia-high insulin, and hyperglycemia-low insulin. We tested a set of models, all sharing a single-compartment description of glucose kinetics, but differing in how exercise is assumed to modulate glucose disposal. Model selection was based on parsimony criteria. The best model assumed an exercise-induced immediate effect on IIRd and a delayed effect on IDRd. It predicted that exercise increases IIRd, compared with rest, by 66%-82% and 67%-97% in T1D and ND, respectively, not significantly different between the two groups. Conversely, the exercise effect on IDRd ranged between 81% and 155% in T1D and it was significantly higher than ND, which ranged between 10% and 40%. The exaggerated effect observed in IDRd can explain the higher hypoglycemia risk related to individuals with T1D. This novel exercise model could help in informing safe and effective glucose management during and after exercise in individuals with T1D. NEW & NOTEWORTHY Here, we present a new mathematical model describing the effect of moderate physical activity on insulin-mediated and noninsulin-mediated glucose disposal in subjects with and without diabetes. We believe that this represents a step-forward in the knowledge of type 1 diabetes pathophysiology, and an useful tool to design safe and effective insulin-therapies.",2021,"It predicted that exercise increases IIRd, compared to rest, by 66% - 82% and 67% - 97% in T1D and ND, respectively, not significantly different between the two groups.","['individuals with type 1 diabetes (T1D', '6 T1D and 6 nondiabetic (ND) subjects undergoing a labeled glucose clamp study during, before and after a 60 min exercise session at 65% VO 2 max on three randomized visits', 'Healthy and Type 1 Diabetes Individuals', 'T1D individuals']","['euglycemia-low insulin, euglycemia-high insulin and hyperglycemia-low insulin', 'Insulin-Dependent and Insulin-Independent Glucose Utilization']","['Exercise effects (EE) on whole body glucose rate of disappearance (Rd) occur through insulin- independent (IIRd) and insulin-dependent (IDRd) mechanisms', 'IDRd']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0015159', 'cui_str': 'Euglycemic Clamping'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}]","[{'cui': 'C0861023', 'cui_str': 'Insulin low'}, {'cui': 'C0020459', 'cui_str': 'Hyperinsulinism'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}]",,0.012794,"It predicted that exercise increases IIRd, compared to rest, by 66% - 82% and 67% - 97% in T1D and ND, respectively, not significantly different between the two groups.","[{'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Romeres', 'Affiliation': 'Department of Information Engineering, University of Padova, Padova, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Schiavon', 'Affiliation': 'Department of Information Engineering, University of Padova, Padova, Italy.'}, {'ForeName': 'Ananda', 'Initials': 'A', 'LastName': 'Basu', 'Affiliation': 'Division of Endocrinology, University of Virginia School of Medicine, Charlottesville, Virginia.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Cobelli', 'Affiliation': ""Department of Woman and Child's Health, University of Padova, Padova, Italy.""}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Basu', 'Affiliation': 'Division of Endocrinology, University of Virginia School of Medicine, Charlottesville, Virginia.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Dalla Man', 'Affiliation': 'Department of Information Engineering, University of Padova, Padova, Italy.'}]",American journal of physiology. Endocrinology and metabolism,['10.1152/ajpendo.00084.2021'] 3174,33997903,Perceptions of event notification following discharge to improve geriatric care: qualitative interviews of care team members from a 2-site cluster randomized trial.,"OBJECTIVE To assess primary care teams' perceptions of a health information exchange (HIE) event notification intervention for geriatric patients in 2 Veterans Health Administration (VHA) medical centers. MATERIALS AND METHODS We conducted a qualitative evaluation of an event notification alerting primary care teams to non-VHA hospital admissions and emergency department visits. Data were collected through semistructured interviews (n = 23) of primary care team physicians, nurses and medical assistants. Study design and analysis were guided by the Consolidated Framework for Implementation Research (CFIR). RESULTS Team members found the alerts necessary, helpful for filling information gaps, and effective in supporting timely follow-up care, although some expressed concern over scheduling capacity and distinguishing alerts from other VHA notices. Participants also suggested improvements including additional data on patients' diagnosis and discharge instructions, timing alerts to patients' discharge (including clear next steps), including additional team members to ensure alerts were acted upon, and implementing a single sign-on. DISCUSSION Primary care team members perceived timely event notification of non-VHA emergency department visits and hospital admissions as potentially improving post-discharge follow-up and patient outcomes. However, they were sometimes unsure of next steps and suggested the alerts and platform could be streamlined for easier use. CONCLUSIONS Event notifications may be a valuable tool in coordinating care for high-risk older patients. Future intervention research should explore the optimal amount and types of information and delivery method across sites and test the integration of alerts into broader care coordination efforts.",2021,"RESULTS Team members found the alerts necessary, helpful for filling information gaps, and effective in supporting timely follow-up care, although some expressed concern over scheduling capacity and distinguishing alerts from other VHA notices.","['high-risk older patients', 'geriatric patients in 2 Veterans Health Administration (VHA) medical centers', 'We conducted a qualitative evaluation of an event notification alerting primary care teams to non-VHA hospital admissions and emergency department visits']",['health information exchange (HIE) event notification intervention'],"[""additional data on patients' diagnosis and discharge instructions, timing alerts to patients' discharge""]","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0178672', 'cui_str': 'Health administration'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0034375', 'cui_str': 'Qualitative Evaluation'}, {'cui': 'C0422202', 'cui_str': 'Notifications'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}]","[{'cui': 'C3849995', 'cui_str': 'Medical Information Exchange'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0422202', 'cui_str': 'Notifications'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0449243', 'cui_str': 'Timing'}]",,0.145301,"RESULTS Team members found the alerts necessary, helpful for filling information gaps, and effective in supporting timely follow-up care, although some expressed concern over scheduling capacity and distinguishing alerts from other VHA notices.","[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Franzosa', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, James J. Peters VA Medical Center, Bronx, New York, USA.'}, {'ForeName': 'Morgan', 'Initials': 'M', 'LastName': 'Traylor', 'Affiliation': 'Department of Veterans Affairs, Health Services Research & Development Service, Center for Health Information and Communication, Indianapolis, Indiana, USA.'}, {'ForeName': 'Kimberly M', 'Initials': 'KM', 'LastName': 'Judon', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, James J. Peters VA Medical Center, Bronx, New York, USA.'}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Guerrero Aquino', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, James J. Peters VA Medical Center, Bronx, New York, USA.'}, {'ForeName': 'Ashley L', 'Initials': 'AL', 'LastName': 'Schwartzkopf', 'Affiliation': 'Department of Veterans Affairs, Health Services Research & Development Service, Center for Health Information and Communication, Indianapolis, Indiana, USA.'}, {'ForeName': 'Kenneth S', 'Initials': 'KS', 'LastName': 'Boockvar', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, James J. Peters VA Medical Center, Bronx, New York, USA.'}, {'ForeName': 'Brian E', 'Initials': 'BE', 'LastName': 'Dixon', 'Affiliation': 'Department of Veterans Affairs, Health Services Research & Development Service, Center for Health Information and Communication, Indianapolis, Indiana, USA.'}]",Journal of the American Medical Informatics Association : JAMIA,['10.1093/jamia/ocab074'] 3175,33389817,Diurnal variation of corneal elasticity in healthy young human using air-puff optical coherence elastography.,"Due to the disruption of intraocular pressure (IOP) and central corneal thickness (CCT), diurnal variation in normal young human corneal elasticity is not clear. Using the custom-built air-puff optical coherence elastography, one eye of 21 normal subjects is enrolled randomly to measure the central corneal elasticity, IOP, and CCT in different time points within a day. Based on the multi-level model, the corneal elastic modulus is found to have a linear positive relation with IOP (P < .01) but not CCT (P = .175) and time point (P = .174-.686). A new indicator, corneal elasticity change rate, is proposed to present the magnitude of corneal elasticity change caused by 1 mmHg IOP, which can correct the interference effect of IOP. The results show that the corneal elasticity in the normal young human does not have the characteristics of diurnal variation under IOP control. Furthermore, IOP plays an important role in the corneal elasticity, and corneal elasticity change rate can increase the comparability of results between individuals.",2021,The results show that the corneal elasticity in the normal young human does not have the characteristics of diurnal variation under IOP control.,"['healthy young human using air-puff optical coherence elastography', '21 normal subjects']",[],"['Diurnal variation of corneal elasticity', 'corneal elasticity', 'intraocular pressure (IOP) and central corneal thickness (CCT), diurnal variation']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C1533107', 'cui_str': 'Puff - unit of product usage'}, {'cui': 'C1955928', 'cui_str': 'Tissue Elasticity Imaging'}, {'cui': 'C0205307', 'cui_str': 'Normal'}]",[],"[{'cui': 'C0008810', 'cui_str': 'Circadian rhythm'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C1720164', 'cui_str': 'Central corneal thickness'}]",21.0,0.0406191,The results show that the corneal elasticity in the normal young human does not have the characteristics of diurnal variation under IOP control.,"[{'ForeName': 'Sisi', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Zi', 'Initials': 'Z', 'LastName': 'Jin', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Gu', 'Initials': 'G', 'LastName': 'Zheng', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Shuling', 'Initials': 'S', 'LastName': 'Ye', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Yiyi', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Weicheng', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Dexi', 'Initials': 'D', 'LastName': 'Zhu', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Meixiao', 'Initials': 'M', 'LastName': 'Shen', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Lu', 'Affiliation': 'School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.'}]",Journal of biophotonics,['10.1002/jbio.202000440'] 3176,34003568,"A prospective, randomised clinical study comparing triple therapy regimen to hydrocortisone monotherapy in reducing mortality in septic shock patients.","OBJECTIVES This prospective, comparative and randomised clinical study evaluated the effectiveness of triple therapy regimen (hydrocortisone, thiamine and vitamin C) versus hydrocortisone alone in reducing the mortality rate and preventing progressive organ dysfunction in septic shock patients. METHODS A total of 94 patients were randomly assigned to one of two groups: the first group received hydrocortisone 50 mg/6-h IV for 7 days or till intensive care unit (ICU) discharge, if sooner, followed by tapering. The second group received hydrocortisone 50 mg/6-h IV for 7 days or ICU discharge followed by tapering, vitamin C 1.5 g/6-h IV for 4 days or till ICU discharge and thiamine 200 mg/12-h IV for 4 days or till ICU discharge. RESULTS The triple therapy regimen showed a non-significant reduction in 28-day mortality compared to hydrocortisone alone (17 [36.2%] vs. 21 [44.7%]; P = .4005), but it was significantly lower than the control group regarding shock time and the duration of vasopressor use in days (4.000 [3.000-7.000]; 5.000 [4.000-8.000], [P = .0100]). The patients in the control group were likely to get 0.59 more in SCr level than those in the intervention group by a linear regression model which was significant (P < .05). Also, the number of patients who developed a fever after 216 hours was significantly higher in the control group (P value = .0299). CONCLUSION Vitamin C, thiamine, and hydrocortisone regimen for septic shock management showed non-significant efficacy in decreasing 28-day mortality when compared to hydrocortisone monotherapy. On the other hand, it showed significant efficacy in decreasing the shock time and duration on vasopressors.",2021,"The triple therapy regimen showed a non-significant reduction in 28- day mortality compared to hydrocortisone alone [17 (36.2%) vs. 21 (44.7%); P = 0.4005], but it was significantly lower than the control group regarding shock time and the duration of vasopressor use in days [4.000, (3000-7.000); 5.000, (4.000-8000), (p=0.0100)].",['septic shock patients'],"['hydrocortisone 50 mg/6-hour IV for seven-day or till ICU-discharge, if sooner, followed by tapering', 'triple therapy regimen (hydrocortisone, thiamine, vitamin c', 'hydrocortisone 50 mg/6-hour IV for seven-day or ICU-discharge followed by tapering, vitamin C 1.5 gm/6-hour IV for 4-day or till ICU-discharge and thiamine 200 mg/12-hour IV for 4-day or till ICU-discharge', 'hydrocortisone monotherapy', 'hydrocortisone', 'Vitamin C, thiamine, and hydrocortisone']","['SCr level', 'number of patients who developed a fever', 'shock time and duration on vasopressors', 'mortality rate', 'shock time and the duration of vasopressor use', 'progressive organ dysfunction', '28- day mortality']","[{'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0441640', 'cui_str': 'Tapering - action'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0039840', 'cui_str': 'Thiamine'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",,0.105257,"The triple therapy regimen showed a non-significant reduction in 28- day mortality compared to hydrocortisone alone [17 (36.2%) vs. 21 (44.7%); P = 0.4005], but it was significantly lower than the control group regarding shock time and the duration of vasopressor use in days [4.000, (3000-7.000); 5.000, (4.000-8000), (p=0.0100)].","[{'ForeName': 'Abdelrhman A', 'Initials': 'AA', 'LastName': 'Hussein', 'Affiliation': 'Clinical Pharmacy department, Air Force Specialized Hospital, Cairo, Egypt.'}, {'ForeName': 'Nirmeen A', 'Initials': 'NA', 'LastName': 'Sabry', 'Affiliation': 'Clinical pharmacy department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Maged S', 'Initials': 'MS', 'LastName': 'Abdalla', 'Affiliation': 'Anaesthesia and Critical Care department, Faculty of Medicine (Kasr-el Ainy), Cairo University, Cairo, Egypt.'}, {'ForeName': 'Samar F', 'Initials': 'SF', 'LastName': 'Farid', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}]",International journal of clinical practice,['10.1111/ijcp.14376'] 3177,34002406,Bibliotherapy for improving caregiving appraisal of informal caregivers of people with dementia: A pilot randomized controlled trial.,"Caregiving appraisal is a key driver to moderating caregiving outcomes. The caregiving appraisal of informal caregivers of people with dementia requires increased attention. This study aimed to explore the feasibility and acceptability of an evidence-based bibliotherapy protocol, and test the efficacy on improving caregiving appraisal. A two-arm pilot randomized controlled trial was adopted. Sixty informal caregivers were randomized to either the intervention group, receiving eight weekly professional-guided bibliotherapy sessions in addition to usual care; or the usual care group. The professional-guided bibliotherapy sessions were weekly sessions in which caregivers self-read the designated chapter and then received telephone coaching. Caregiving appraisal, coping, psychological well-being, positive aspects of caregiving, knowledge of dementia, and attitude toward dementia were assessed both at baseline and immediately after the intervention. Assessors were blinded to group allocation. Individual interviews among 10 participants from the intervention group were conducted to explorecaregivers' acceptance of the intervention. Descriptive statistics, χ 2 test, Mann-Whitney U test, independent t test, generalized estimating equation, and content analysis were used for data analysis. This study pioneered the use of bibliotherapy among informal caregivers of people with dementia. The participant recruitment rate was 69.8%. The attrition rate of the intervention group was 20%. Bibliotherapy had a significant time-by-group interaction effect on caregiving appraisal (p < 0.001), coping (p = 0.003), positive aspects of caregiving (p = 0.001), knowledge of dementia (p = 0.017), and attitude toward dementia (p < 0.001). The effect on psychological well-being, however, was only significant on the personal growth subscale (p = 0.025). The acceptability was also confirmed. No adverse event was documented.",2021,"Bibliotherapy had a significant time-by-group interaction effect on caregiving appraisal (p < 0.001), coping (p = 0.003), positive aspects of caregiving (p = 0.001), knowledge of dementia (p = 0.017), and attitude toward dementia (p < 0.001).","['informal caregivers of people with dementia', '10 participants from the intervention group', 'Sixty informal caregivers']","['Bibliotherapy', 'telephone coaching', 'bibliotherapy', 'intervention group, receiving eight weekly professional-guided bibliotherapy sessions in addition to usual care; or the usual care group']","['attitude toward dementia', 'attrition rate', 'caregiving appraisal', 'positive aspects of caregiving', 'personal growth subscale', 'knowledge of dementia', 'Caregiving appraisal, coping, psychological well-being, positive aspects of caregiving, knowledge of dementia, and attitude toward dementia', 'feasibility and acceptability']","[{'cui': 'C1319882', 'cui_str': 'Informal caregiver'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0005365', 'cui_str': 'Bibliotherapy'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",60.0,0.0926018,"Bibliotherapy had a significant time-by-group interaction effect on caregiving appraisal (p < 0.001), coping (p = 0.003), positive aspects of caregiving (p = 0.001), knowledge of dementia (p = 0.017), and attitude toward dementia (p < 0.001).","[{'ForeName': 'Shanshan', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'School of Nursing and Health, Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Daphne Sze Ki', 'Initials': 'DSK', 'LastName': 'Cheung', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China.'}, {'ForeName': 'Angela Yee Man', 'Initials': 'AYM', 'LastName': 'Leung', 'Affiliation': 'WHO Collaborating Center for Community Health Services, School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China.'}, {'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Davidson', 'Affiliation': 'School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.'}]",Research in nursing & health,['10.1002/nur.22143'] 3178,34002326,Blood flow restriction in the presence or absence of muscle contractions does not preserve vasculature structure and function following 14-days of limb immobilization.,"PURPOSE Limb immobilization causes local vasculature to experience detrimental adaptations. Simple strategies to increase blood flow (heating, fidgeting) successfully prevent acute (≤ 1 day) impairments; however, none have leveraged the hyperemic response over prolonged periods (weeks) mirroring injury rehabilitation. Throughout a 14-day unilateral limb immobilization, we sought to preserve vascular structure and responsiveness by repeatedly activating a reactive hyperemic response via blood flow restriction (BFR) and amplifying this stimulus by combining BFR with electric muscle stimulation (EMS). METHODS Young healthy adults (M:F = 14:17, age = 22.4 ± 3.7 years) were randomly assigned to control, BFR, or BFR + EMS groups. BFR and BFR + EMS groups were treated for 30 min twice daily (3 × 10 min ischemia-reperfusion cycles; 15% maximal voluntary contraction EMS), 5 days/week (20 total sessions). Before and after immobilization, artery diameter, flow-mediated dilation (FMD) and blood flow measures were collected in the superficial femoral artery (SFA). RESULTS Following immobilization, there was less retrograde blood velocity (+ 1.8 ± 3.6 cm s -1 , P = 0.01), but not retrograde shear (P = 0.097). All groups displayed reduced baseline and peak SFA diameter following immobilization (- 0.46 ± 0.41 mm and - 0.43 ± 0.39 mm, P < 0.01); however, there were no differences by group or across time for FMD (% diameter change, shear-corrected, or allometrically scaled) nor microvascular function assessed by peak flow capacity. CONCLUSION Following immobilization, our results reveal (1) neither BFR nor BFR + EMS mitigate artery structure impairments, (2) intervention-induced shear stress did not affect vascular function assessed by FMD, and (3) retrograde blood velocity is reduced at rest offering potential insight to mechanisms of flow regulation. In conclusion, BFR appears insufficient as a treatment strategy for preventing macrovascular dysfunction during limb immobilization.",2021,"All groups displayed reduced baseline and peak SFA diameter following immobilization (- 0.46 ± 0.41 mm and - 0.43 ± 0.39 mm, P < 0.01); however, there were no differences by group or across time for FMD (% diameter change, shear-corrected, or allometrically scaled) nor microvascular function assessed by peak flow capacity. ","['Young healthy adults (M:F\u2009=\u200914:17, age\u2009=\u200922.4\u2009±', '3.7\xa0years']",[],"['time for FMD (% diameter change, shear-corrected, or allometrically scaled) nor microvascular function assessed by peak flow capacity', 'vascular function assessed by FMD, and (3) retrograde blood velocity', 'peak SFA diameter', 'retrograde blood velocity', 'retrograde shear', 'artery diameter, flow-mediated dilation (FMD) and blood flow measures']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517696', 'cui_str': '3.7'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],"[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0175735', 'cui_str': 'Scissors'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0857465', 'cui_str': 'Peak flow'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0439784', 'cui_str': 'Retrograde direction'}, {'cui': 'C1531610', 'cui_str': 'Blood velocity'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0447106', 'cui_str': 'Superficial femoral artery'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.014654,"All groups displayed reduced baseline and peak SFA diameter following immobilization (- 0.46 ± 0.41 mm and - 0.43 ± 0.39 mm, P < 0.01); however, there were no differences by group or across time for FMD (% diameter change, shear-corrected, or allometrically scaled) nor microvascular function assessed by peak flow capacity. ","[{'ForeName': 'Jeremy N', 'Initials': 'JN', 'LastName': 'Cohen', 'Affiliation': 'Human Health and Nutritional Sciences, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada.'}, {'ForeName': 'Joshua T', 'Initials': 'JT', 'LastName': 'Slysz', 'Affiliation': 'Human Health and Nutritional Sciences, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada.'}, {'ForeName': 'Trevor J', 'Initials': 'TJ', 'LastName': 'King', 'Affiliation': 'Human Health and Nutritional Sciences, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada.'}, {'ForeName': 'Alexandra M', 'Initials': 'AM', 'LastName': 'Coates', 'Affiliation': 'Human Health and Nutritional Sciences, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'King', 'Affiliation': 'Human Health and Nutritional Sciences, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada.'}, {'ForeName': 'Jamie F', 'Initials': 'JF', 'LastName': 'Burr', 'Affiliation': 'Human Health and Nutritional Sciences, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada. burrj@uoguelph.ca.'}]",European journal of applied physiology,['10.1007/s00421-021-04715-3'] 3179,32329651,The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.,"BACKGROUND Larotrectinib and entrectinib are FDA-approved therapies for patients with non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase gene fusion (TRK fusion-positive) whose cancer has metastasized and progressed. Early evidence indicates that these targeted therapies may offer dramatic survival benefits versus traditional cytotoxic regimens, but it remains uncertain how larotrectinib and entrectinib compare with each other. OBJECTIVE To simulate and compare expected life-years and quality-adjusted life-years (QALYs) for both TRK inhibitors. METHODS We developed a partitioned survival model to project the long-term comparative effectiveness of larotrectinib versus entrectinib in second-line treatment of metastatic NSCLC. Larotrectinib survival data were derived from a 13-month follow-up of 12 patients with TRK fusion-positive NSCLC in the NCT02122913 (phase 1) and NCT02576431 (NAVIGATE) trials. Entrectinib survival data were derived from a 13-month follow-up of 10 patients with TRK fusion-positive NSCLC in the ALKA-372-001, STARTRK-1, and STARTRK-2 trials. For larotrectinib and entrectinib progression-free survival and overall survival (OS), in-trial survival was extrapolated using parametric curve fits. Exponential fits were selected for all survival models based on minimal Bayesian information criteria and clinical plausibility. Lifetime survival curves were used to estimate expected mean/median survival. QALYs were estimated by applying preprogression and postprogression health state utilities derived from the literature. RESULTS In the base case, treatment with larotrectinib and entrectinib resulted in 5.4 and 1.2 median preprogression life-years and 7.0 and 1.8 median total life-years, respectively. Mean preprogression life-years (QALYs) were 7.5 (5.0) and 1.9 (1.2), and mean total life-years (QALYs) were 9.2 (5.8) and 4.4 (2.4), respectively. CONCLUSIONS Among TRK inhibitors for metastatic NSCLC, larotrectinib is estimated to provide improved life-year and QALY outcomes versus entrectinib based on parametric extrapolations of in-trial survival data. Our analysis is limited by lack of NSCLC-specific data on entrectinib OS, the small samples of patients with NSCLC in the trials, and a cross-trial comparison. Future studies should re-evaluate the comparative effectiveness of larotrectinib versus entrectinib as more patients are treated and as long-term survival data mature. DISCLOSURES Funding for this study was contributed by Bayer Healthcare, which reviewed the manuscript drafts, and employees contributed to the manuscript as coauthors. Xia and Williamson are employees of Bayer Healthcare. Roth, Carlson, and Sullivan are consultants to Bayer Healthcare and retain rights to all final revisions to the manuscript. Carlson also reports fees from Adaptive Biotechnologies, unrelated to this work. Roth reports consulting fees from BMS, unrelated to this work.",2020,"For larotrectinib and entrectinib progression-free survival and overall survival (OS), in-trial survival was extrapolated using parametric curve fits.","['patients with non-small cell lung cancer (NSCLC', 'TRK Fusion-Positive Metastatic Lung Cancer', 'metastatic NSCLC']","['Larotrectinib and Entrectinib', 'TRK inhibitors']","['Lifetime survival curves', 'Larotrectinib survival data', 'For larotrectinib and entrectinib progression-free survival and overall survival (OS), in-trial survival', 'mean total life-years (QALYs', 'Mean preprogression life-years (QALYs', 'Entrectinib survival data']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0206364', 'cui_str': 'Receptor Protein-Tyrosine Kinase'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0153676', 'cui_str': 'Secondary malignant neoplasm of lung'}, {'cui': 'C0278987', 'cui_str': 'Metastatic non-small cell lung cancer'}]","[{'cui': 'C4524315', 'cui_str': 'larotrectinib'}, {'cui': 'C4086264', 'cui_str': 'entrectinib'}, {'cui': 'C0206364', 'cui_str': 'Receptor Protein-Tyrosine Kinase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C4524315', 'cui_str': 'larotrectinib'}, {'cui': 'C4086264', 'cui_str': 'entrectinib'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}]",12.0,0.192124,"For larotrectinib and entrectinib progression-free survival and overall survival (OS), in-trial survival was extrapolated using parametric curve fits.","[{'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Roth', 'Affiliation': 'Hutchinson Institute for Cancer Outcomes Research and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Josh J', 'Initials': 'JJ', 'LastName': 'Carlson', 'Affiliation': 'CHOICE Institute, School of Pharmacy, University of Washington, Seattle.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Xia', 'Affiliation': 'Bayer Healthcare, Parsippany, New Jersey.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Williamson', 'Affiliation': 'Bayer Healthcare, Parsippany, New Jersey.'}, {'ForeName': 'Sean D', 'Initials': 'SD', 'LastName': 'Sullivan', 'Affiliation': 'Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, and CHOICE Institute, School of Pharmacy, University of Washington, Seattle.'}]",Journal of managed care & specialty pharmacy,['10.18553/jmcp.2020.20045'] 3180,33963594,Neurotoxicity prevention with a multimodal program (ATENTO) prior to cancer treatment versus throughout cancer treatment in women newly diagnosed for breast cancer: Protocol for a randomized clinical trial.,"A current challenge in breast cancer (BC) patients is how to reduce the side effects of cancer and cancer treatments and prevent a decrease in quality of life (QoL). Neurotoxic side effects, especially from chemotherapy, are present in up to 75% of women with BC, which implies a large impact on QoL. There is a special interest in the preventive possibilities of therapeutic exercise (TE) for these neurological sequelae, and the benefits of TE could be improved when it is combined with vagal activation techniques (VATs). This superiority randomized controlled trial aims to examine the feasibility and efficacy of an 8-week multimodal intervention (ATENTO) based on moderate-vigorous intensity and individualized TE (aerobic and strength exercises) and VAT (myofascial and breathing exercises), on neurotoxicity prevention in women with BC before starting adjuvant chemotherapy (ATENTO-B) versus throughout adjuvant chemotherapy (ATENTO-T). A sample of 56 women newly diagnosed with BC, as calculated with a power of 85%, will be randomly allocated into these two groups. This study could provide an impetus for the introduction of early multimodal intervention methods to prevent neurotoxicity and consequently avoid the QoL deterioration that BC patients presently suffer throughout their treatments.",2021,"This superiority randomized controlled trial aims to examine the feasibility and efficacy of an 8-week multimodal intervention (ATENTO) based on moderate-vigorous intensity and individualized TE (aerobic and strength exercises) and VAT (myofascial and breathing exercises), on neurotoxicity prevention in women with BC before starting adjuvant chemotherapy (ATENTO-B) versus throughout adjuvant chemotherapy (ATENTO-T).","['women newly diagnosed for breast cancer', '56 women newly diagnosed with BC, as calculated with a power of 85', 'women with BC before starting', 'breast cancer (BC) patients']","['multimodal intervention (ATENTO) based on moderate-vigorous intensity and individualized TE (aerobic and strength exercises) and VAT (myofascial and breathing exercises', 'multimodal program (ATENTO) prior to cancer treatment versus throughout cancer treatment', 'adjuvant chemotherapy']","['quality of life (QoL', 'Neurotoxic side effects']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0042427', 'cui_str': 'Vatican City'}, {'cui': 'C0006155', 'cui_str': 'Physiotherapeutic breathing exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",56.0,0.170672,"This superiority randomized controlled trial aims to examine the feasibility and efficacy of an 8-week multimodal intervention (ATENTO) based on moderate-vigorous intensity and individualized TE (aerobic and strength exercises) and VAT (myofascial and breathing exercises), on neurotoxicity prevention in women with BC before starting adjuvant chemotherapy (ATENTO-B) versus throughout adjuvant chemotherapy (ATENTO-T).","[{'ForeName': 'Ángela', 'Initials': 'Á', 'LastName': 'González-Santos', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Postigo-Martin', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Gallart-Aragón', 'Affiliation': 'Hospital Universitario San Cecilio, Granada, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Esteban-Cornejo', 'Affiliation': 'Sport and Health University Research Institute (iMUDS), University of Granada, Granada, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lopez-Garzon', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Noelia', 'Initials': 'N', 'LastName': 'Galiano-Castillo', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Arroyo-Morales', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Rebeca', 'Initials': 'R', 'LastName': 'Illescas-Montes', 'Affiliation': 'Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Artacho-Cordón', 'Affiliation': 'Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Martín-Martín', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Forneiro-Pérez', 'Affiliation': 'Hospital Universitario San Cecilio, Granada, Spain.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Lozano-Lozano', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Fernández-Lao', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Ruiz-Vozmediano', 'Affiliation': 'Hospital Universitario Virgen de las Nieves, Granada, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Sánchez-Salgado', 'Affiliation': 'Hospital Universitario Virgen de las Nieves, Granada, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Cantarero-Villanueva', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}]",Research in nursing & health,['10.1002/nur.22136'] 3181,33962686,The promotion of healthy breakfast and snacks based on the social marketing model: a mixed-methods study.,"BACKGROUND Skipping breakfast and replacing it with non-nutritious snacks are progressively increasing among adolescents. This study aimed to develop an educational intervention based on the Social Marketing Model and evaluate its effects on healthy breakfast and snack consumption among female adolescent students. METHODS This mixed-methods study was conducted in 2016-2019 in two phases. In the first phase, a qualitative study was conducted through directed content analysis in guidance schools in Khorramabad, Isfahan, and Tehran, Iran, to explore factors affecting breakfast consumption. The results of this phase were set in the benchmarks of the Social Marketing Model. In the second phase, a randomized controlled trial was conducted based on the benchmarks of the Social Marketing Model on 94 students randomly recruited from guidance schools in Khorramabad, Iran. RESULTS The findings of the qualitative phase were categorized into the benchmarks of the Social Marketing Model, namely the social marketing mix, the intended behavior, internal and external competing factors for behavior modification, theoretical concepts related to the behavior, and the role of supporters. In the quantitative phase, the univariate analysis showed significant between-group differences concerning the product, price, promotion, and behavior (p < 0.05). CONCLUSION Healthy breakfast and snack consumption can be promoted through making acceptable the tastes, costs, preparations, and consumption places of breakfast and snack. TRIAL REGISTRATION The trial was registered in the Iranian Registry of Clinical Trials (code: IRCT20170201032347N1 ). The trial was registered in 11/07/2018 and is accessible on the Iranian Clinical Trial Registration website.",2021,"In the quantitative phase, the univariate analysis showed significant between-group differences concerning the product, price, promotion, and behavior (p < 0.05). ","['94 students randomly recruited from guidance schools in Khorramabad, Iran', 'female adolescent students', '2016-2019 in two phases']",[],"['product, price, promotion, and behavior']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]",[],"[{'cui': 'C0080045', 'cui_str': 'Prices'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",94.0,0.063,"In the quantitative phase, the univariate analysis showed significant between-group differences concerning the product, price, promotion, and behavior (p < 0.05). ","[{'ForeName': 'Firoozeh', 'Initials': 'F', 'LastName': 'Mostafavi', 'Affiliation': 'Department of Health Education and Promotion, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Zamani-Alavijeh', 'Affiliation': 'Department of Health Education and Promotion, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Marjan', 'Initials': 'M', 'LastName': 'Mansourian', 'Affiliation': 'Department of Epidemiology and Biostatistic, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Bastami', 'Affiliation': 'Department of Public Health, School of Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran. fatemeh2011bastami@gmail.com.'}]","Journal of health, population, and nutrition",['10.1186/s41043-021-00245-y'] 3182,33962515,Education With Therapeutic Alliance Did Not Improve Symptoms in Patients With Chronic Low Back Pain and Low Risk of Poor Prognosis Compared to Education Without Therapeutic Alliance: A Randomized Controlled Trial.,"OBJECTIVES To compare the effectiveness of an education intervention with or without the addition of the therapeutic alliance to no education intervention in patients with nonspecific chronic low back pain (LBP) and low risk of poor prognosis. DESIGN Randomized controlled trial. Randomization was performed using randomly generated numbers. METHODS Two hundred twenty-two patients with nonspecific chronic LBP and low risk of poor prognosis from 2 university physical therapy services in Taubaté, Brazil were randomized into 3 groups: education plus therapeutic alliance, education only, and no education. Primary outcomes were pain (measured with the numeric pain-rating scale) and patient-specific disability (measured with the Patient-Specific Functional Scale), assessed 1 month after randomization. The patients, therapists, and assessors were not blinded due to the nature of the intervention and self-reported outcomes. RESULTS Patients were recruited between November 2015 and February 2017. There was a loss of 17 (7.6%) follow-up assessments at 1 month, 28 (12.6%) at 6 months, and 31 (13.9%) at 12 months after randomization, and intention-to-treat analyses were conducted. There were no significant differences in pain between groups. However, there was a significant improvement in patient-specific disability for the education-plus-therapeutic alliance and education-only groups compared to no education after 1 month (mean difference, -1.41; 95% confidence interval: -2.31, -0.51 and -0.95; 95% confidence interval: -1.85, -0.04, respectively). CONCLUSION An education intervention did not provide clinically relevant improvements in patient-specific disability and did not influence pain in patients with nonspecific chronic LBP and low risk of poor prognosis. Additionally, there was no difference between interventions with or without emphasis on the therapeutic alliance. J Orthop Sports Phys Ther 2021;51(8):392-400. Epub 7 May 2021. doi:10.2519/jospt.2021.9636 .",2021,"CONCLUSION Educational intervention did not confer clinically-relevant improvements in patient-specific disability, and did not influence pain in patients with nonspecific chronic LBP and low risk of poor prognosis.","['patients with nonspecific chronic low back pain (LBP) and low risk of poor prognosis', '222 patients with nonspecific chronic LBP and low risk of poor prognosis from two university physical therapy services in Taubaté, São Paulo', 'Patients were recruited between November 2015 and February 2017']","['education plus therapeutic alliance, education only, no education', 'Educational intervention', 'educational intervention']","['pain', 'patient-specific disability', 'pain (measured with the Pain Numerical Rating Scale) and patient-specific disability (measured with the Patient-Specific Functional Scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0278252', 'cui_str': 'Prognosis bad'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0587629', 'cui_str': 'Physiotherapy service'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0814487', 'cui_str': 'Therapeutic Alliance'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4304943', 'cui_str': 'Patient-Specific Functional Scale'}]",222.0,0.10923,"CONCLUSION Educational intervention did not confer clinically-relevant improvements in patient-specific disability, and did not influence pain in patients with nonspecific chronic LBP and low risk of poor prognosis.","[{'ForeName': 'Gisela Cristiane', 'Initials': 'GC', 'LastName': 'Miyamoto', 'Affiliation': ''}, {'ForeName': 'Felipe Ribeiro Cabral', 'Initials': 'FRC', 'LastName': 'Fagundes', 'Affiliation': ''}, {'ForeName': 'Caique', 'Initials': 'C', 'LastName': 'de Melo do Espírito Santo', 'Affiliation': ''}, {'ForeName': 'Francine Mendonça', 'Initials': 'FM', 'LastName': 'de Luna Teixeira', 'Affiliation': ''}, {'ForeName': 'Thaís Vanelli', 'Initials': 'TV', 'LastName': 'Tonini', 'Affiliation': ''}, {'ForeName': 'Flavio Turina', 'Initials': 'FT', 'LastName': 'Prado', 'Affiliation': ''}, {'ForeName': 'Cristina Maria Nunes', 'Initials': 'CMN', 'LastName': 'Cabral', 'Affiliation': ''}]",The Journal of orthopaedic and sports physical therapy,['10.2519/jospt.2021.9636'] 3183,34388007,Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.,"PURPOSE The contemporary management of early-stage Hodgkin lymphoma (ES-HL) involves balancing the risk of late adverse effects of radiotherapy against the increased risk of relapse if radiotherapy is omitted. This study provides information on the risk of radiation-related cardiovascular disease to help personalize the delivery of radiotherapy in ES-HL. METHODS We predicted 30-year absolute cardiovascular risk from chemotherapy and involved field radiotherapy in patients who were positron emission tomography (PET)-negative following three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy within a UK randomized trial of PET-directed therapy for ES-HL. Cardiac and carotid radiation doses and chemotherapy exposure were combined with established dose-response relationships and population-based mortality and incidence rates. RESULTS Average mean heart dose was 4.0 Gy (range 0.1-24.0 Gy) and average bilateral common carotid artery dose was 21.5 Gy (range 0.6-38.1 Gy), based on individualized cardiovascular dosimetry for 144 PET-negative patients receiving involved field radiotherapy. The average predicted 30-year radiation-related absolute excess overall cardiovascular mortality was 0.56% (range 0.01%-6.79%; < 0.5% in 67% of patients and > 1% in 15%), whereas average predicted 30-year excess incidence was 6.24% (range 0.31%-31.09%; < 5% in 58% of patients and > 10% in 24%). For cardiac disease, the average predicted 30-year radiation-related absolute excess mortality was 0.42% (0.79% with mediastinal involvement and 0.05% without) and for stroke, it was 0.14%. CONCLUSION Predicted excess cardiovascular risk is small for most patients, so radiotherapy may provide net benefit. However, for a minority of patients receiving high doses of radiation to cardiovascular structures, it may be preferable to consider advanced radiotherapy techniques to reduce doses or to omit radiotherapy and accept the increased relapse risk. Individual assessment of cardiovascular and other risks before treatment would allow personalized decision making about radiotherapy in ES-HL.",2021,"For cardiac disease, the average predicted 30-year radiation-related absolute excess mortality was 0.42% (0.79% with mediastinal involvement and 0.05% without) and for stroke, it was 0.14%. ","['early-stage Hodgkin lymphoma (ES-HL', 'patients who were positron emission tomography (PET)-negative following three cycles of', '144 PET-negative patients receiving involved', 'Early-Stage Hodgkin Lymphoma']","['radiotherapy', 'Chemotherapy and Radiotherapy', 'doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy', 'field radiotherapy', 'Positron Emission Tomography-Directed Therapy', 'chemotherapy and involved field radiotherapy']","['relapse risk', 'cardiovascular mortality']","[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0019829', 'cui_str': 'Hodgkin lymphoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0005740', 'cui_str': 'Bleomycin'}, {'cui': 'C0042670', 'cui_str': 'Vinblastine'}, {'cui': 'C0010927', 'cui_str': 'Dacarbazine'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0439851', 'cui_str': 'Direct'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.0620259,"For cardiac disease, the average predicted 30-year radiation-related absolute excess mortality was 0.42% (0.79% with mediastinal involvement and 0.05% without) and for stroke, it was 0.14%. ","[{'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Cutter', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Ramroth', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Diez', 'Affiliation': 'National Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, Northwood, United Kingdom.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Buckle', 'Affiliation': 'Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, United Kingdom.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Ntentas', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Bilyana', 'Initials': 'B', 'LastName': 'Popova', 'Affiliation': 'Cancer Research UK, UCL Cancer Trials Centre, London, United Kingdom.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Clifton-Hadley', 'Affiliation': 'Cancer Research UK, UCL Cancer Trials Centre, London, United Kingdom.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Hoskin', 'Affiliation': 'National Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, Northwood, United Kingdom.'}, {'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Darby', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Radford', 'Affiliation': 'Manchester Academic Health Science Centre, Manchester Cancer Research Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Illidge', 'Affiliation': 'Manchester Academic Health Science Centre, Manchester Cancer Research Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.21.00408'] 3184,34390504,Low-dose Thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.,"Despite the proven efficacy of anti-T-cell or antithymocyte globulin (ATG) for chronic graft-versus-host disease (GVHD) prevention in transplantation from an unrelated donor, dosing protocols and the effects of ATG on relapse and infection remain controversial. In the setting of transplantation from an HLA-matched sibling (MSD-T), few randomized studies have been conducted. We conducted a prospective, single-center, open-label, randomized study of low-dose Thymoglobulin (2.5 mg/kg) for chronic GVHD prevention. A total of 120 patients with acute leukemia were randomly assigned in a 1:1 ratio. After a median follow-up of 27 months, the cumulative incidence of chronic GVHD in the ATG and non-ATG groups was 25.0% and 65.4% (P<0.001), respectively. The ATG group had an increased relapse rate compared with the non-ATG-group (20.0% vs 9.3%; P=0.055), with risks that differed according to cytogenetic subgroup (high-risk, 29.6% vs. 9.3%, P=0.042; non-high-risk, 12.2% vs. 9.2%, P=0.596). Chronic GVHD-free and relapse-free survival (cGRFS) was higher in the ATG group (46.7% vs. 19.4%; P=0.070), and the difference was significant in a cytogenetic non-high-risk subgroup (45.5% vs. 0%; P=0.038). No differences were observed in other survival outcomes. Improved physical components in quality-of-life scores were observed in the ATG group at 12 months after transplantation. A higher rate of Epstein-Barr virus reactivation was observed in the ATG group (21.8% vs. 5.1%; P=0.013), whereas no between-group differences for other complications. In conclusion, the low-dose Thymoglobulin effectively prevented chronic GVHD in MSD-T, resulting in improvement in quality-of-life and cGRFS, whereas the necessity of caution for high-risk acute leukemia. This article is protected by copyright. All rights reserved.",2021,"Chronic GVHD-free and relapse-free survival (cGRFS) was higher in the ATG group (46.7% vs. 19.4%; P=0.070), and the difference was significant in a cytogenetic non-high-risk subgroup (45.5% vs. 0%; P=0.038).",['120 patients with acute leukemia'],"['low-dose Thymoglobulin', 'Low-dose Thymoglobulin', 'anti-T-cell or antithymocyte globulin (ATG']","['quality-of-life and cGRFS', 'Chronic GVHD-free and relapse-free survival (cGRFS', 'Improved physical components in quality-of-life scores', 'chronic GVHD', 'survival outcomes', 'rate of Epstein-Barr virus reactivation', 'cumulative incidence of chronic GVHD', 'relapse rate']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085669', 'cui_str': 'Acute leukemia'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0730920', 'cui_str': 'Thymoglobulin'}, {'cui': 'C0076533', 'cui_str': 'Thomsen-Friedenreich antibodies'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0003442', 'cui_str': 'Lymphocyte Immune Globulin, Anti-Thymocyte Globulin'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0867389', 'cui_str': 'Chronic graft-versus-host disease'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0014644', 'cui_str': 'Epstein-Barr Virus'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",120.0,0.145535,"Chronic GVHD-free and relapse-free survival (cGRFS) was higher in the ATG group (46.7% vs. 19.4%; P=0.070), and the difference was significant in a cytogenetic non-high-risk subgroup (45.5% vs. 0%; P=0.038).","[{'ForeName': 'Byung-Sik', 'Initials': 'BS', 'LastName': 'Cho', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Gi-June', 'Initials': 'GJ', 'LastName': 'Min', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Sung-Soo', 'Initials': 'SS', 'LastName': 'Park', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Seok Yoon', 'Initials': 'SY', 'LastName': 'Yoon', 'Affiliation': 'Department of Hematology, Soon Chun Hyang University Hospital, College of Medicine, Soon Chun Hyang University of Korea, Seoul, Republic of Korea.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Young-Woo', 'Initials': 'YW', 'LastName': 'Jeon', 'Affiliation': ""Department of Hematology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Seung-Hwan', 'Initials': 'SH', 'LastName': 'Shin', 'Affiliation': ""Department of Hematology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Seung-Ah', 'Initials': 'SA', 'LastName': 'Yahng', 'Affiliation': ""Department of Hematology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Jae-Ho', 'Initials': 'JH', 'LastName': 'Yoon', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Sung-Eun', 'Initials': 'SE', 'LastName': 'Lee', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Ki-Seong', 'Initials': 'KS', 'LastName': 'Eom', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Yoo-Jin', 'Initials': 'YJ', 'LastName': 'Kim', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Chang-Ki', 'Initials': 'CK', 'LastName': 'Min', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Seok-Goo', 'Initials': 'SG', 'LastName': 'Cho', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Dong-Wook', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Jong Wook', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Hee-Je', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Seok', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}]",American journal of hematology,['10.1002/ajh.26320'] 3185,33969554,The effect of Cornus mas extract consumption on bone biomarkers and inflammation in postmenopausal women: A randomized clinical trial.,"The drastic decrease in estrogen levels in menopausal women can elevate bone resorption and osteoporosis. Cornus mas extract (C. mas extract) is a potential candidate for treating menopausal-related bone complications because of its phytoestrogen and anti-inflammatory contents. It was an interventional double-blind placebo-controlled randomized study. Eighty-four women aged 45-60 years old were randomly allocated to either the extract group receiving 3 capsules of 300 mg C. mas extract or the placebo group receiving 3 capsules of 300 mg of starch powder per day for 8 weeks. Then, venous blood was used to measure bone-specific alkaline phosphatase (BAP), osteocalcin (OC), C-terminal telopeptide (TC) as well as serum levels of PTH and hsCRP. Our results indicated the decrease in alkaline phosphatase, PTH, and as an inflammation biomarker, hsCRP, between two groups at the end of the study. No statistically significant difference was observed in telopeptide C, osteocalcin, and calcium between the placebo and extract groups after 8 weeks of intervention. In conclusion, the results indicate that the C. mas extract supplement of 900 mg/day may decrease levels of BAP, PTH, and hsCRP. However, this intervention had no beneficial effect on OC and TC in healthy postmenopausal women.",2021,"No statistically significant difference was observed in telopeptide C, osteocalcin, and calcium between the placebo and extract groups after 8 weeks of intervention.","['healthy postmenopausal women', 'menopausal women', 'Eighty-four women aged 45-60\u2009years old', 'postmenopausal women']","['placebo', 'extract group receiving 3 capsules of 300\u2009mg C. mas extract or the placebo group receiving 3 capsules of 300\u2009mg of starch powder', 'Cornus mas extract consumption', 'Cornus mas extract (C. mas extract']","['estrogen levels', 'telopeptide C, osteocalcin, and calcium', 'levels of BAP, PTH, and hsCRP', 'alkaline phosphatase, PTH, and as an inflammation biomarker, hsCRP', 'bone-specific alkaline phosphatase (BAP), osteocalcin (OC), C-terminal telopeptide (TC', 'bone biomarkers and inflammation', 'OC and TC', 'serum levels of PTH and hsCRP']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0025048', 'cui_str': 'Meconium aspiration syndrome'}, {'cui': 'C0301424', 'cui_str': 'Starch powder'}, {'cui': 'C0950010', 'cui_str': 'Cornus'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029419', 'cui_str': 'Osteocalcin'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0312399', 'cui_str': 'Alkaline phosphatase isoenzyme, bone fraction'}, {'cui': 'C0020063', 'cui_str': 'PTH protein, human'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",84.0,0.0678631,"No statistically significant difference was observed in telopeptide C, osteocalcin, and calcium between the placebo and extract groups after 8 weeks of intervention.","[{'ForeName': 'Naheed', 'Initials': 'N', 'LastName': 'Aryaeian', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Fatemehsadat', 'Initials': 'F', 'LastName': 'Amiri', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seyedeh Tayebeh', 'Initials': 'ST', 'LastName': 'Rahideh', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Jamileh', 'Initials': 'J', 'LastName': 'Abolghasemi', 'Affiliation': 'Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shima', 'Initials': 'S', 'LastName': 'Jazayeri', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Afsaneh', 'Initials': 'A', 'LastName': 'Gholamrezayi', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Manijeh', 'Initials': 'M', 'LastName': 'Motevalian', 'Affiliation': 'Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Solaymani-Dodaran', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Taghizadeh', 'Affiliation': 'Kashan University of Medical Sciences and Health Services, Kashan, Iran.'}, {'ForeName': 'Elaheh', 'Initials': 'E', 'LastName': 'Heshmati', 'Affiliation': 'Alborz University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shahnaz', 'Initials': 'S', 'LastName': 'Rimaz', 'Affiliation': 'Radiation Biology Research Center, Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.7143'] 3186,33965944,Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema.,"BACKGROUND Bronchoscopic lung volume reduction using endobronchial coils is a new treatment for patients with severe emphysema. To date, the benefits have been modest and have been suggested to be much larger in patients with severe hyperinflation and nonmulti-comorbidity. OBJECTIVE We aimed to evaluate the efficacy and safety of endobronchial coil treatment in a randomized multicenter clinical trial using optimized patient selection. METHOD Patients with severe emphysema on HRCT scan with severe hyperinflation (residual volume [RV] ≥200% predicted and RV/total lung capacity [TLC] >55%) were randomized to coil treatment or control. Primary outcome measures were differences in the forced expiratory volume in 1 s (FEV1) and St George's Respiratory Questionnaire (SGRQ) total score at 6 months. RESULTS Due to premature study termination, a total of 120 patients (age 63 ± 7 years, FEV1 29 ± 7% predicted, RV 251 ± 41% predicted, RV/TLC 67 ± 6%, and SGRQ 58 ± 13 points), instead of 210 patients, were randomized. At study termination, 91 patients (57 coil and 34 control) had 6-month results available. Analyses showed significantly greater improvements in favor of the coil group. The increase in FEV1 was greater in the coil group than that in the control group by + 10.3 [+4.7 to +16.0] % and in SGRQ by -10.6 [-15.9 to -5.4] points. At study termination, there were 5 (6.8%) deaths in the coil cohort reported. CONCLUSION Despite early study termination, coil treatment compared to control results in a significant improvement in the lung function and quality of life benefits for up to 6 months in patients with emphysema and severe hyperinflation. These improvements were of clinical importance but were associated with a higher likelihood of serious adverse events.",2021,The increase in FEV1 was greater in the coil group than that in the control group by + 10.3 [+4.7 to +16.0] % and in SGRQ by -10.6 [-15.9 to -5.4] points.,"['120 patients (age 63 ± 7 years, FEV1 29 ± 7% predicted, RV 251 ± 41% predicted, RV/TLC 67 ± 6%, and SGRQ 58 ± 13 points), instead of 210 patients', 'patients with severe emphysema', '91 patients (57 coil and 34 control) had 6-month results available', 'patients with severe hyperinflation and nonmulti-comorbidity', 'patients with emphysema and severe hyperinflation', 'Patients with severe emphysema on HRCT scan with severe hyperinflation (residual volume [RV] ≥200% predicted and RV/total lung capacity [TLC] >55', 'Subjects with Severe Emphysema']","['endobronchial coils', 'Endobronchial Coil System versus Standard-of-Care Medical Management', 'endobronchial coil treatment', 'coil treatment or control']","['FEV1', 'lung function and quality of life benefits', 'efficacy and safety', ""forced expiratory volume in 1 s (FEV1) and St George's Respiratory Questionnaire (SGRQ) total score at 6 months""]","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0008569', 'cui_str': 'Thin Layer Chromatography'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0013990', 'cui_str': 'Emphysema'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0020449', 'cui_str': 'Hyperdistention'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0035190', 'cui_str': 'Residual respiratory volume'}, {'cui': 'C0040509', 'cui_str': 'Total lung capacity'}]","[{'cui': 'C0444471', 'cui_str': 'Endobronchial'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",120.0,0.0337753,The increase in FEV1 was greater in the coil group than that in the control group by + 10.3 [+4.7 to +16.0] % and in SGRQ by -10.6 [-15.9 to -5.4] points.,"[{'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Klooster', 'Affiliation': 'Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Arschang', 'Initials': 'A', 'LastName': 'Valipour', 'Affiliation': 'Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Floridsdorf, Austria.'}, {'ForeName': 'Charles-Hugo', 'Initials': 'CH', 'LastName': 'Marquette', 'Affiliation': ""Université Côte d'Azur, FHU OncoAge, CHU de Nice, Nice, France.""}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Boutros', 'Affiliation': ""Université Côte d'Azur, FHU OncoAge, CHU de Nice, Nice, France.""}, {'ForeName': 'Hervé', 'Initials': 'H', 'LastName': 'Mal', 'Affiliation': 'Hôpital Bichat - Claude Bernard, Paris, France.'}, {'ForeName': 'Armelle', 'Initials': 'A', 'LastName': 'Marceau', 'Affiliation': 'Hôpital Bichat - Claude Bernard, Paris, France.'}, {'ForeName': 'Pallav L', 'Initials': 'PL', 'LastName': 'Shah', 'Affiliation': 'Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Conway', 'Affiliation': 'Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom.'}, {'ForeName': 'Gaëtan', 'Initials': 'G', 'LastName': 'Deslée', 'Affiliation': 'CHU de Reims, Reims, France.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Bourdin', 'Affiliation': 'CHU de Montpellier, Montpellier, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Pison', 'Affiliation': 'CHU de Grenoble, Grenoble, France.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Grah', 'Affiliation': 'Gemeinschaftskrankenhaus Havelhöhe GmbH, Berlin, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hetzel', 'Affiliation': 'Krankenhaus vom Roten Kreuz Bad Cannstatt GmbH, Stuttgart, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schumann', 'Affiliation': 'Klinikverbund Allgäu, Immenstadt, Immenstadt, Germany.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Kessler', 'Affiliation': 'Nouvel Hôpital Civil, Strasbourg, France.'}, {'ForeName': 'Ralf-Harto', 'Initials': 'RH', 'LastName': 'Huebner', 'Affiliation': 'Charité Berlin, Berlin, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Skowasch', 'Affiliation': 'Universitätsklinkum Bonn, Bonn, Germany.'}, {'ForeName': 'Kaid', 'Initials': 'K', 'LastName': 'Darwiche', 'Affiliation': 'Department for Interventional Pneumology, Ruhrlandklinik - University Medicine Essen, Essen, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hammerl', 'Affiliation': 'Lungenfachklinik Immenhausen, Immenhausen, Germany.'}, {'ForeName': 'Franz', 'Initials': 'F', 'LastName': 'Stanzel', 'Affiliation': 'Lungenklinik Hemer, Hemer, Germany.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Bezzi', 'Affiliation': 'ASST Spedali Civili di Brescia, Brescia, Italy.'}, {'ForeName': 'Hervé', 'Initials': 'H', 'LastName': 'Dutau', 'Affiliation': 'Hôpital Nord - APHM, Marseille, France.'}, {'ForeName': 'Felix J F', 'Initials': 'FJF', 'LastName': 'Herth', 'Affiliation': 'Department of Internal Medicine, Pulmonary and Critical Care Medicine Thoraxklinik and Translational Lung Research Center Heidelberg University Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Dirk-Jan', 'Initials': 'DJ', 'LastName': 'Slebos', 'Affiliation': 'Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}]",Respiration; international review of thoracic diseases,['10.1159/000515744'] 3187,33972795,"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.","Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. After psychiatric medication washout, participants (n = 90) were randomized 1:1 to receive manualized therapy with MDMA or with placebo, combined with three preparatory and nine integrative therapy sessions. PTSD symptoms, measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5, the primary endpoint), and functional impairment, measured with the Sheehan Disability Scale (SDS, the secondary endpoint) were assessed at baseline and at 2 months after the last experimental session. Adverse events and suicidality were tracked throughout the study. MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43). The mean change in CAPS-5 scores in participants completing treatment was -24.4 (s.d. 11.6) in the MDMA group and -13.9 (s.d. 11.5) in the placebo group. MDMA did not induce adverse events of abuse potential, suicidality or QT prolongation. These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities. We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation.",2021,"MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43).","['patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma', 'Post-traumatic stress disorder (PTSD', 'After psychiatric medication washout, participants (n\u2009=\u200990', 'severe PTSD']","['inactive placebo, MDMA-assisted therapy', 'MDMA-assisted therapy', 'MDMA', 'manualized therapy with MDMA or with placebo, combined with three preparatory and nine integrative therapy sessions', 'placebo', '3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy']","['mean change in CAPS-5 scores', 'SDS total score', 'functional impairment, measured with the Sheehan Disability Scale (SDS, the secondary endpoint', 'adverse events of abuse potential, suicidality or QT prolongation', 'CAPS-5 score', 'PTSD symptoms, measured with the Clinician-Administered PTSD Scale for DSM-5', 'Adverse events and suicidality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0086168', 'cui_str': 'Dissociation - mental defense mechanism'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0115471', 'cui_str': 'Methylenedioxymethamphetamine'}, {'cui': 'C0557035', 'cui_str': 'Assisting with therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4720840', 'cui_str': 'Sheehan disability scale'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0151878', 'cui_str': 'Prolonged QT interval'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}]",90.0,0.262122,"MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43).","[{'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Mitchell', 'Affiliation': 'Department of Neurology, University of California San Francisco, San Francisco, CA, USA. jennifer.mitchell@ucsf.edu.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bogenschutz', 'Affiliation': 'Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Alia', 'Initials': 'A', 'LastName': 'Lilienstein', 'Affiliation': 'Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Harrison', 'Affiliation': 'MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Kleiman', 'Affiliation': 'Kleiman Consulting and Psychological Services, Sayreville, NJ, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Parker-Guilbert', 'Affiliation': 'KPG Psychological Services LLC, Brunswick, ME, USA.'}, {'ForeName': 'Marcela', 'Initials': 'M', 'LastName': ""Ot'alora G"", 'Affiliation': 'Aguazul-Bluewater Inc., Boulder, CO, USA.'}, {'ForeName': 'Wael', 'Initials': 'W', 'LastName': 'Garas', 'Affiliation': 'Aguazul-Bluewater Inc., Boulder, CO, USA.'}, {'ForeName': 'Casey', 'Initials': 'C', 'LastName': 'Paleos', 'Affiliation': 'Nautilus Sanctuary, New York, NY, USA.'}, {'ForeName': 'Ingmar', 'Initials': 'I', 'LastName': 'Gorman', 'Affiliation': 'Fluence, Woodstock, NY, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Nicholas', 'Affiliation': 'Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Mithoefer', 'Affiliation': 'MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Carlin', 'Affiliation': 'MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Poulter', 'Affiliation': 'Aguazul-Bluewater Inc., Boulder, CO, USA.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Mithoefer', 'Affiliation': 'MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA.'}, {'ForeName': 'Sylvestre', 'Initials': 'S', 'LastName': 'Quevedo', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Wells', 'Affiliation': 'San Francisco Insight and Integration Center, San Francisco, CA, USA.'}, {'ForeName': 'Sukhpreet S', 'Initials': 'SS', 'LastName': 'Klaire', 'Affiliation': 'British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Bessel', 'Initials': 'B', 'LastName': 'van der Kolk', 'Affiliation': 'Boston University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Keren', 'Initials': 'K', 'LastName': 'Tzarfaty', 'Affiliation': 'MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA.'}, {'ForeName': 'Revital', 'Initials': 'R', 'LastName': 'Amiaz', 'Affiliation': 'Chaim Sheba Medical Center, Tel HaShomer, Israel.'}, {'ForeName': 'Ray', 'Initials': 'R', 'LastName': 'Worthy', 'Affiliation': 'Ray Worthy Psychiatry LLC, New Orleans, LA, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Shannon', 'Affiliation': 'Wholeness Center, Fort Collins, CO, USA.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Woolley', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Cole', 'Initials': 'C', 'LastName': 'Marta', 'Affiliation': 'New School Research LLC, North Hollywood, CA, USA.'}, {'ForeName': 'Yevgeniy', 'Initials': 'Y', 'LastName': 'Gelfand', 'Affiliation': 'Zen Therapeutic Solutions, Mt Pleasant, SC, USA.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hapke', 'Affiliation': 'University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Amar', 'Affiliation': 'Dr Simon Amar Inc., Montreal, Quebec, Canada.'}, {'ForeName': 'Yair', 'Initials': 'Y', 'LastName': 'Wallach', 'Affiliation': ""Be'er Ya'akov Ness Ziona Mental Health Center, Be'er Ya'akov, Israel.""}, {'ForeName': 'Randall', 'Initials': 'R', 'LastName': 'Brown', 'Affiliation': 'Fluence, Woodstock, NY, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Hamilton', 'Affiliation': 'Stanford School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Julie B', 'Initials': 'JB', 'LastName': 'Wang', 'Affiliation': 'MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Coker', 'Affiliation': 'Department of Neurology, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Matthews', 'Affiliation': 'MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.'}, {'ForeName': 'Alberdina', 'Initials': 'A', 'LastName': 'de Boer', 'Affiliation': 'MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.'}, {'ForeName': 'Berra', 'Initials': 'B', 'LastName': 'Yazar-Klosinski', 'Affiliation': 'Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Emerson', 'Affiliation': 'MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.'}, {'ForeName': 'Rick', 'Initials': 'R', 'LastName': 'Doblin', 'Affiliation': 'Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA.'}]",Nature medicine,['10.1038/s41591-021-01336-3'] 3188,34390461,Sclerostin and bone turnover markers response to cycling and running at the same moderate-to-vigorous exercise intensity in healthy men.,"BACKGROUND Recreational cycling is a popular activity which stimulates and improves cardiovascular fitness. The corresponding benefits for bone are unclear. PURPOSE This study examined the effect of running (high-impact) vs. cycling (low-impact), at the same moderate-to-vigorous exercise intensity, on markers of bone formation (N-terminal propeptide of type I collagen, PINP) and bone resorption (C-telopeptide of type I collagen, CTX-1), a non-collagenous bone remodeling marker (osteocalcin), as well as bone-modulating factors, including parathyroid hormone (PTH), irisin (myokine) and sclerostin (osteokine). METHODS Thirteen healthy men (23.7 ± 1.0 y) performed two progressive exercise tests to exhaustion (peak VO 2 ) on a cycle ergometer (CE) and on a treadmill (TM). On subsequent separate days, in randomized order, participants performed 30-min continuous running or cycling at 70% heart rate reserve (HRR). Blood was drawn before, immediately post- and 1 h into recovery. RESULTS PTH transiently increased (CE, 51.7%; TM, 50.6%) immediately after exercise in both exercise modes. Sclerostin levels increased following running only (27.7%). Irisin increased following both running and cycling. In both exercise modes, CTX-1 decreased immediately after exercise, with no significant change in PINP and osteocalcin. CONCLUSION At the same moderate-to-vigorous exercise intensity, running appears to result in a greater transient sclerostin response compared with cycling, while the responses of bone markers, PTH and irisin are similar. The longer-term implications of this differential bone response need to be further examined.",2021,"In both exercise modes, CTX-1 decreased immediately after exercise, with no significant change in PINP and osteocalcin. ","['healthy men', 'Thirteen healthy men (23.7 ± 1.0 y']","['progressive exercise tests to exhaustion (peak VO 2 ) on a cycle ergometer (CE) and on a treadmill (TM', 'running (high-impact) vs. cycling (low-impact']","['Irisin', 'cardiovascular fitness', 'PINP and osteocalcin', 'PTH', 'parathyroid hormone (PTH), irisin (myokine) and sclerostin (osteokine', 'bone formation (N-terminal propeptide of type I collagen, PINP) and bone resorption (C-telopeptide of type', 'Sclerostin levels']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C3715149', 'cui_str': '13'}]","[{'cui': 'C0430513', 'cui_str': 'Progressive exercise test'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0205251', 'cui_str': 'Low'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0072053', 'cui_str': 'Procollagen peptide, type 1 N-terminal'}, {'cui': 'C0029419', 'cui_str': 'Osteocalcin'}, {'cui': 'C0020063', 'cui_str': 'PTH protein, human'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0631180', 'cui_str': 'C-telopeptide'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",13.0,0.0110776,"In both exercise modes, CTX-1 decreased immediately after exercise, with no significant change in PINP and osteocalcin. ","[{'ForeName': 'N', 'Initials': 'N', 'LastName': 'Dror', 'Affiliation': 'Pediatric Exercise and Genomics Research Center, Department of Pediatrics, School of Medicine, University of California Irvine, 101 Academy, Suite 150, Irvine, CA, 92617, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Carbone', 'Affiliation': 'Pediatric Exercise and Genomics Research Center, Department of Pediatrics, School of Medicine, University of California Irvine, 101 Academy, Suite 150, Irvine, CA, 92617, USA.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Haddad', 'Affiliation': 'Pediatric Exercise and Genomics Research Center, Department of Pediatrics, School of Medicine, University of California Irvine, 101 Academy, Suite 150, Irvine, CA, 92617, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Falk', 'Affiliation': 'Department of Kinesiology, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Klentrou', 'Affiliation': 'Department of Kinesiology, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Radom-Aizik', 'Affiliation': 'Pediatric Exercise and Genomics Research Center, Department of Pediatrics, School of Medicine, University of California Irvine, 101 Academy, Suite 150, Irvine, CA, 92617, USA. saizik@uci.edu.'}]",Journal of endocrinological investigation,['10.1007/s40618-021-01659-5'] 3189,34390436,Evaluation of pedometer use in men with lower urinary tract symptoms: a randomized clinical trial.,"PURPOSE To assess the effect of a pedometer use in men aged between 50 and 59 years presenting lower urinary tract symptoms (LUTS). METHODS A single-center, not blind clinical trial with two parallel groups and equal randomization was performed with 38 men aged 50-59 years with LUTS. All patients received guidance and encouragement to physical activity practice. Only the intervention group received a Pedometer with a goal of 10,000 steps/day. After a period of 12 weeks, the groups were compared through the following variables: number of steps/day, IPSS score, flexibility, anthropometric values and Maximum Oxygen Consumption (VO2max). RESULTS The number of steps per day in the intervention group was 9753 ± 1549 compared to 6212 ± 1152 in the control group (p = 0.004). Pedometer use efficacy was a 50% risk reduction of not achieve the goal of 10,000 steps per day. Regarding IPSS score, the intervention group achieved lower scores (6.95 ± 2.85 vs. 10.16 ± 3.23, p = 0.007). Pedometer use efficacy was a 94% risk reduction of not achieve more than 30% reduction in IPSS score. In VO2max, the intervention group performed better than the control group (34.84 ± 3.25 vs. 32.58 ± 6.89; p = 0.011). There was no difference in flexibility and anthropometric values between the groups. CONCLUSIONS The use of pedometer in LUTS patients provided an increase in the number of steps/day, a decrease in LUTS score and an improvement in VO2max measure. CLINICAL TRIAL REGISTRATION Trial url: www.ensaiosclinicos.gov.br/rg/RBR-4vynk5/ . Register Number: RBR-4vynk5 .",2021,"In VO2max, the intervention group performed better than the control group (34.84 ± 3.25 vs. 32.58 ± 6.89; p = 0.011).","['men with lower urinary tract symptoms', '38 men aged 50-59\xa0years with LUTS', 'men aged between 50 and 59\xa0years presenting lower urinary tract symptoms (LUTS']",[],"['flexibility and anthropometric values', 'VO2max measure', 'IPSS score', 'LUTS score', 'IPSS score, flexibility, anthropometric values and Maximum Oxygen Consumption (VO2max']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0574785', 'cui_str': 'Lower urinary tract symptoms'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0150312', 'cui_str': 'Present'}]",[],"[{'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1504431', 'cui_str': 'Idiopathic pneumonia syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0574785', 'cui_str': 'Lower urinary tract symptoms'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}]",38.0,0.116358,"In VO2max, the intervention group performed better than the control group (34.84 ± 3.25 vs. 32.58 ± 6.89; p = 0.011).","[{'ForeName': 'Lucas Cortes Machado', 'Initials': 'LCM', 'LastName': 'Agostini', 'Affiliation': 'NIPU - Núcleo Interdisciplnar de Pesquisa em Urologia, Federal University of Juiz de Fora, Avenida Barão do Rio Branco, 5141, Apto 1606, Juiz de Fora, MG, 36026-500, Brazil.'}, {'ForeName': 'Christiano Silva', 'Initials': 'CS', 'LastName': 'Brum', 'Affiliation': 'NIPU - Núcleo Interdisciplnar de Pesquisa em Urologia, Federal University of Juiz de Fora, Avenida Barão do Rio Branco, 5141, Apto 1606, Juiz de Fora, MG, 36026-500, Brazil.'}, {'ForeName': 'Humberto Elias', 'Initials': 'HE', 'LastName': 'Lopes', 'Affiliation': 'NIPU - Núcleo Interdisciplnar de Pesquisa em Urologia, Federal University of Juiz de Fora, Avenida Barão do Rio Branco, 5141, Apto 1606, Juiz de Fora, MG, 36026-500, Brazil.'}, {'ForeName': 'José Murillo Bastos', 'Initials': 'JMB', 'LastName': 'Netto', 'Affiliation': 'NIPU - Núcleo Interdisciplnar de Pesquisa em Urologia, Federal University of Juiz de Fora, Avenida Barão do Rio Branco, 5141, Apto 1606, Juiz de Fora, MG, 36026-500, Brazil.'}, {'ForeName': 'André Avarese', 'Initials': 'AA', 'LastName': 'Figueiredo', 'Affiliation': 'NIPU - Núcleo Interdisciplnar de Pesquisa em Urologia, Federal University of Juiz de Fora, Avenida Barão do Rio Branco, 5141, Apto 1606, Juiz de Fora, MG, 36026-500, Brazil. andreavaresef@gmail.com.'}]",International urology and nephrology,['10.1007/s11255-021-02970-z'] 3190,33976751,Effects of Continuous Positive Airway Pressure on Sleep EEG Characteristics in Patients with Primary Central Sleep Apnea Syndrome.,"This study aimed to investigate the effects of continuous positive airway pressure (CPAP) on the electroencephalographic (EEG) characteristics of patients with primary central sleep apnea syndrome (CSAS). Nine patients with primary CSAS were enrolled in this study. The raw sleep EEG data were analyzed based on two main factors: fractal dimension (FD) and zero-crossing rate of detrended FD. Additionally, conventional EEG spectral analysis in the delta, theta, alpha, and beta bands was conducted using a fast Fourier transform. The FD in patients with primary CSAS who underwent CPAP treatment was significantly decreased during nonrapid eye movement (NREM) sleep but increased during rapid eye movement (REM) sleep ( p < 0.05). Regarding the EEG spectral analysis, the alpha power increased, while the delta/alpha ratio decreased during REM sleep in patients with CSAS ( p < 0.05). In conclusion, CPAP treatment can reduce FD in NREM sleep and increase FD during REM sleep in patients with primary CSAS. FD may be used as a new biomarker of EEG stability and improvement in brain function after CPAP treatment for primary CSAS.",2021,"Regarding the EEG spectral analysis, the alpha power increased, while the delta/alpha ratio decreased during REM sleep in patients with CSAS ( p < 0.05).","['patients with primary CSAS', 'Nine patients with primary CSAS', 'patients with primary central sleep apnea syndrome (CSAS', 'Patients with Primary Central Sleep Apnea Syndrome']","['Continuous Positive Airway Pressure', 'continuous positive airway pressure (CPAP', 'CPAP']","['nonrapid eye movement (NREM) sleep', 'brain function', 'delta/alpha ratio decreased during REM sleep', 'rapid eye movement (REM) sleep', 'Sleep EEG Characteristics', 'fractal dimension (FD) and zero-crossing rate of detrended FD', 'FD in NREM sleep and increase FD during REM sleep']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751762', 'cui_str': 'Primary central sleep apnea'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0520680', 'cui_str': 'Apnea, Central Sleep'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}]","[{'cui': 'C0015413', 'cui_str': 'Eye Movements'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0037322', 'cui_str': 'Rapid eye movement sleep'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0206163', 'cui_str': 'Fractals'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",9.0,0.0281587,"Regarding the EEG spectral analysis, the alpha power increased, while the delta/alpha ratio decreased during REM sleep in patients with CSAS ( p < 0.05).","[{'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Chen', 'Affiliation': 'Academy of Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.'}, {'ForeName': 'Guangfa', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China.'}, {'ForeName': 'Jue', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Academy of Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China.'}]",Canadian respiratory journal,['10.1155/2021/6657724'] 3191,34000236,"Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial.","BACKGROUND We sought to clarify the benefit of cytokine adsorption in patients with COVID-19 supported with venovenous extracorporeal membrane oxygenation (ECMO). METHODS We did a single-centre, open-label, randomised, controlled trial to investigate cytokine adsorption in adult patients with severe COVID-19 pneumonia requiring ECMO. Patients with COVID-19 selected for ECMO at the Freiburg University Medical Center (Freiburg, Germany) were randomly assigned (1:1) to receive cytokine adsorption using the CytoSorb device or not. Randomisation was computer-generated, allocation was concealed by opaque, sequentially numbered sealed envelopes. The CytoSorb device was incorporated into the ECMO circuit before connection to the patient circuit, replaced every 24 h, and removed after 72 h. The primary endpoint was serum interleukin-6 (IL-6) concentration 72 h after initiation of ECMO analysed by intention to treat. Secondary endpoints included 30-day survival. The trial is registered with ClinicalTrials.gov (NCT04324528) and the German Clinical Trials Register (DRKS00021300) and is closed. FINDINGS From March 29, 2020, to Dec 29, 2020, of 34 patients assessed for eligibility, 17 (50%) were treated with cytokine adsorption and 17 (50%) without. Median IL-6 decreased from 357·0 pg/mL to 98·6 pg/mL in patients randomly assigned to cytokine adsorption and from 289·0 pg/mL to 112·0 pg/mL in the control group after 72 h. One patient in each group died before 72 h. Adjusted mean log IL-6 concentrations after 72 h were 0·30 higher in the cytokine adsorption group (95% CI -0·70 to 1·30, p=0·54). Survival after 30 days was three (18%) of 17 with cytokine adsorption and 13 (76%) of 17 without cytokine adsorption (p=0·0016). INTERPRETATION Early initiation of cytokine adsorption in patients with severe COVID-19 and venovenous ECMO did not reduce serum IL-6 and had a negative effect on survival. Cytokine adsorption should not be used during the first days of ECMO support in COVID-19. FUNDING None.",2021,"Survival after 30 days was three (18%) of 17 with cytokine adsorption and 13 (76%) of 17 without cytokine adsorption (p=0·0016). ","['patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV', 'patients with COVID-19 supported with venovenous extracorporeal membrane oxygenation (ECMO', 'From March 29, 2020, to Dec 29, 2020, of 34 patients assessed for eligibility, 17 (50%) were treated with cytokine adsorption and 17 (50%) without', 'Patients with COVID-19 selected for ECMO at the Freiburg University Medical Center (Freiburg, Germany', 'adult patients with severe COVID-19 pneumonia requiring ECMO']",['cytokine adsorption using the CytoSorb device or not'],"['30-day survival', 'mean log IL-6 concentrations', 'serum interleukin-6 (IL-6) concentration', 'survival', 'Cytokine adsorption', 'Survival', 'Median IL-6']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0015357', 'cui_str': 'Extracorporeal membrane oxygenation'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C5192099', 'cui_str': 'Venovenous extracorporeal membrane oxygenation'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0001674', 'cui_str': 'Adsorption'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0001674', 'cui_str': 'Adsorption'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0001674', 'cui_str': 'Adsorption'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.402627,"Survival after 30 days was three (18%) of 17 with cytokine adsorption and 13 (76%) of 17 without cytokine adsorption (p=0·0016). ","[{'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Supady', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany; Heidelberg Institute of Global Health, University of Heidelberg, Germany. Electronic address: alexander.supady@uniklinik-freiburg.de.'}, {'ForeName': 'Enya', 'Initials': 'E', 'LastName': 'Weber', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Medical Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Rieder', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Achim', 'Initials': 'A', 'LastName': 'Lother', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Niklaus', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Timm', 'Initials': 'T', 'LastName': 'Zahn', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Frech', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Sissi', 'Initials': 'S', 'LastName': 'Müller', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Kuhl', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Benk', 'Affiliation': 'Department of Cardiovascular Surgery, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Maier', 'Affiliation': 'Department of Cardiovascular Surgery, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Trummer', 'Affiliation': 'Department of Cardiovascular Surgery, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Annabelle', 'Initials': 'A', 'LastName': 'Flügler', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Krüger', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Asieb', 'Initials': 'A', 'LastName': 'Sekandarzad', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Stachon', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Viviane', 'Initials': 'V', 'LastName': 'Zotzmann', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Bode', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Biever', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Dawid', 'Initials': 'D', 'LastName': 'Staudacher', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Wengenmayer', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Graf', 'Affiliation': 'Institute of Medical Biometry and Statistics, Faculty of Medicine, University of Freiburg, Germany; Medical Center, Faculty of Medicine, University of Freiburg, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Duerschmied', 'Affiliation': 'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(21)00177-6'] 3192,34000004,A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial.,"AIMS The REFLECT I trial investigated the safety and effectiveness of the TriGuard™ HDH (TG) cerebral embolic deflection device in patients undergoing transcatheter aortic valve replacement (TAVR). METHODS AND RESULTS This prospective, multicentre, single-blind, 2:1 randomized (TG vs. no TG) study aimed to enrol up to 375 patients, including up to 90 roll-in patients. The primary combined safety endpoint (VARC-2 defined early safety) at 30 days was compared with a performance goal. The primary efficacy endpoint was a hierarchical composite of (i) all-cause mortality or any stroke at 30 days, (ii) National Institutes of Health Stroke Scale (NIHSS) worsening at 2-5 days or Montreal Cognitive Assessment worsening at 30 days, and (iii) total volume of cerebral ischaemic lesions detected by diffusion-weighted magnetic resonance imaging at 2-5 days. Cumulative scores were compared between treatment groups using the Finkelstein-Schoenfeld method. A total of 258 of the planned, 375 patients (68.8%) were enrolled (54 roll-in and 204 randomized). The primary safety outcome was met compared with the performance goal (21.8% vs. 35%, P < 0.0001). The primary hierarchical efficacy endpoint was not met (mean efficacy score, higher is better: -5.3 ± 99.8 TG vs. 11.8 ± 96.4 control, P = 0.31). Covert central nervous system injury was numerically lower with TG both in-hospital (46.1% vs. 60.3%, P = 0.0698) and at 5 days (61.7 vs. 76.2%, P = 0.054) compared with controls. CONCLUSION REFLECT I demonstrated that TG cerebral protection during TAVR was safe in comparison with historical TAVR data but did not meet the predefined effectiveness endpoint compared with unprotected TAVR controls.",2021,"Covert central nervous system injury was numerically lower with TG both in-hospital (46.1% vs. 60.3%, P = 0.0698) and at 5 days (61.7 vs. 76.2%, P = 0.054) compared with controls. ","['375 patients, including up to 90 roll-in patients', 'patients undergoing transcatheter aortic valve replacement (TAVR', 'A total of 258 of the planned, 375 patients (68.8%) were enrolled (54 roll-in and 204 randomized']","['TriGuard™ HDH cerebral embolic protection device', 'TriGuard™ HDH (TG) cerebral embolic deflection device', 'TransCatheter Aortic Valve ImplanTation']","['Cumulative scores', 'hierarchical composite of (i) all-cause mortality or any stroke at 30\u2009days, (ii) National Institutes of Health Stroke Scale (NIHSS) worsening at 2-5\u2009days or Montreal Cognitive Assessment worsening at 30\u2009days, and (iii) total volume of cerebral ischaemic lesions', 'Cerebral Embolic LEsions', 'safety endpoint (VARC-2 defined early safety']","[{'cui': 'C4517745', 'cui_str': '375'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C2936200', 'cui_str': 'Embolism Protection Devices'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1279919', 'cui_str': 'Early'}]",375.0,0.128344,"Covert central nervous system injury was numerically lower with TG both in-hospital (46.1% vs. 60.3%, P = 0.0698) and at 5 days (61.7 vs. 76.2%, P = 0.054) compared with controls. ","[{'ForeName': 'Alexandra J', 'Initials': 'AJ', 'LastName': 'Lansky', 'Affiliation': 'Division of Cardiology, Yale School of Medicine, 135 College Street, Suite 101, New Haven, CT 06510, USA.'}, {'ForeName': 'Rajendra', 'Initials': 'R', 'LastName': 'Makkar', 'Affiliation': 'Cedar Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Tamim', 'Initials': 'T', 'LastName': 'Nazif', 'Affiliation': 'College of Physicians and Surgeons, Columbia University, New York, NY, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Messé', 'Affiliation': 'Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Forrest', 'Affiliation': 'Division of Cardiology, Yale School of Medicine, 135 College Street, Suite 101, New Haven, CT 06510, USA.'}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Sharma', 'Affiliation': 'Division of Cardiology, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Schofer', 'Affiliation': 'Hamburg University Cardiovascular Center, Hamburg, DE.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Linke', 'Affiliation': 'University Hospital Dresden Heart Center, Dresden,DE.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Brown', 'Affiliation': 'Heart Hospital Baylor, Plano, TX, USA.'}, {'ForeName': 'Abhijeet', 'Initials': 'A', 'LastName': 'Dhoble', 'Affiliation': 'University of Texas Health Science Center, Houston, TX, USA.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Horwitz', 'Affiliation': 'University of Iowa Carver College of Medicine, Iowa City, IA, USA.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Zang', 'Affiliation': 'Swedish Medical Center, Seattle, WA, USA.'}, {'ForeName': 'Frederico', 'Initials': 'F', 'LastName': 'DeMarco', 'Affiliation': 'San Donato, Milan, Italy.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Rajagopal', 'Affiliation': 'Piedmont Heart Institute, Atlanta, GA, USA.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Dwyer', 'Affiliation': 'Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Zivadinov', 'Affiliation': 'Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Stella', 'Affiliation': 'Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Rovin', 'Affiliation': 'BayCare Health System, Clearwater, FL, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Parise', 'Affiliation': 'Division of Cardiology, Yale School of Medicine, 135 College Street, Suite 101, New Haven, CT 06510, USA.'}, {'ForeName': 'Susheel', 'Initials': 'S', 'LastName': 'Kodali', 'Affiliation': 'College of Physicians and Surgeons, Columbia University, New York, NY, USA.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Baumbach', 'Affiliation': 'Division of Cardiology, Yale School of Medicine, 135 College Street, Suite 101, New Haven, CT 06510, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Moses', 'Affiliation': 'College of Physicians and Surgeons, Columbia University, New York, NY, USA.'}]",European heart journal,['10.1093/eurheartj/ehab213'] 3193,34389579,Evaluation of the effectiveness and cost effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) model in Myanmar: protocol for an open stepped-wedge cluster-randomised controlled trial.,"INTRODUCTION In the Greater Mekong Subregion, community health workers, known as malaria volunteers, have played a key role in reducing malaria in the control phase, providing essential malaria services in areas with limited formal healthcare. However, the motivation and social role of malaria volunteers, and testing rates, have declined with decreasing malaria burden and reorientation of malaria programmes from control to elimination. Provision of additional interventions for common health concerns could help sustain the effectiveness of volunteers and maintain malaria testing rates required for malaria elimination accreditation by the WHO. METHODS AND ANALYSIS The Community-delivered Integrated Malaria Elimination (CIME) volunteer model, integrating interventions for malaria, dengue, tuberculosis, childhood diarrhoea and malaria Rapid Diagnostic Test (RDT)-negative fever, was developed based on global evidence and extensive stakeholder consultations. An open stepped-wedge cluster-randomised controlled trial, randomised at the volunteer level, will be conducted over 6 months to evaluate the effectiveness of the CIME model in Myanmar. One hundred and forty Integrated Community Malaria Volunteers (ICMVs, current model of care) providing malaria services in 140 villages will be retrained as CIME volunteers (intervention). These 140 ICMVs/villages will be grouped into 10 blocks of 14 villages, with blocks transitioned from control (ICMV) to intervention states (CIME), fortnightly, in random order, following a 1-week training and transition period. The primary outcome of the trial is blood examination rate determined by the number of malaria RDTs performed weekly. Difference in rates will be estimated across village intervention and control states using a generalised linear mixed modelling analytical approach with maximum likelihood estimation. ETHICS AND DISSEMINATION The study was approved by Institutional Review Board, Myanmar Department of Medical Research (Ethics/DMR/2020/111) and Alfred Hospital Ethics Review Committee, Australia (241/20). Findings will be disseminated in peer-review journals, conferences and regional, national and local stakeholder meetings. TRIAL REGISTRATION NUMBER NCT04695886.",2021,"Provision of additional interventions for common health concerns could help sustain the effectiveness of volunteers and maintain malaria testing rates required for malaria elimination accreditation by the WHO. ","['One hundred and forty Integrated Community Malaria Volunteers (ICMVs, current model of care) providing malaria services in 140 villages will be retrained as CIME volunteers (intervention', 'Myanmar']",['Community-delivered Integrated Malaria Elimination (CIME) model'],['blood examination rate'],"[{'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0006416', 'cui_str': 'Burma'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",140.0,0.10468,"Provision of additional interventions for common health concerns could help sustain the effectiveness of volunteers and maintain malaria testing rates required for malaria elimination accreditation by the WHO. ","[{'ForeName': 'Win Han', 'Initials': 'WH', 'LastName': 'Oo', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Aung', 'Initials': 'A', 'LastName': 'Thi', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Win', 'Initials': 'W', 'LastName': 'Htike', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Agius', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Julia C', 'Initials': 'JC', 'LastName': 'Cutts', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Kyawt Mon', 'Initials': 'KM', 'LastName': 'Win', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Nay Yi', 'Initials': 'NY', 'LastName': 'Yi Linn', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Wint Phyo', 'Initials': 'WP', 'LastName': 'Than', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Galau Naw', 'Initials': 'GN', 'LastName': 'Hkawng', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Kaung Myat', 'Initials': 'KM', 'LastName': 'Thu', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'May Chan', 'Initials': 'MC', 'LastName': 'Oo', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': ""O'Flaherty"", 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Kearney', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Scott', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Pwint Phyu', 'Initials': 'PP', 'LastName': 'Phyu', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Aung Thu', 'Initials': 'AT', 'LastName': 'Htet', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Ohnmar', 'Initials': 'O', 'LastName': 'Myint', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Lwin', 'Initials': 'L', 'LastName': 'Lwin Yee', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Zay Phyo', 'Initials': 'ZP', 'LastName': 'Thant', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Aung', 'Initials': 'A', 'LastName': 'Mon', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Soe', 'Initials': 'S', 'LastName': 'Htike', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Thet Pan', 'Initials': 'TP', 'LastName': 'Hnin', 'Affiliation': 'Department of Public Health, Myanmar Ministry of Health and Sports Myanmar, Nay Pyi Taw, Myanmar.'}, {'ForeName': 'Freya J I', 'Initials': 'FJI', 'LastName': 'Fowkes', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia freya.fowkes@burnet.edu.au.'}]",BMJ open,['10.1136/bmjopen-2021-050400'] 3194,34009725,"No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed-loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial.","A post hoc analysis of the Diabeloop WP7 multicentre, randomized controlled trial was performed to investigate the efficacy of the Diabeloop Generation-1 (DBLG1) closed-loop system in controlling the hypoglycaemia induced by physical activity (PA) in real-life conditions. Glycaemic outcomes were compared between days with and without PA in 56 patients with type 1 diabetes (T1D) using DBLG1 for 12 weeks. After the patient announces a PA, DBLG1 reduces insulin delivery and, if necessary, calculates the amount of preventive carbohydrates (CHO). Daily time spent in the interstitial glucose range less than 70 mg/dL was not significantly different between days with and without PA (2.0% ± 1.5% vs. 2.2% ± 1.1%), regardless of the intensity or duration of the PA. Preventive CHO intake recommended by the system was significantly higher in days with PA (41.1 ± 35.5 vs. 21.8 ± 28.5 g/day; P < .0001), and insulin delivery was significantly lower (31.5 ± 10.5 vs. 34.0 ± 10.5 U/day; P < .0001). The time spent in hyperglycaemia and the glycaemic variation coefficient increased significantly on days with PA. In real-life conditions, the use of DBLG1 avoids PA-induced hypoglycaemia. Insulin adjustments and preventive CHO recommendation may explain this therapeutic benefit.",2021,"RESULTS Daily time spent in the interstitial glucose range <70 mg/dL was not significantly different between days with and without PA (2.0 ± 1.5% versus 2.2 ± 1.1%) and this regardless of the intensity or duration of the PA.",['56 patients with type 1 diabetes (T1D'],['Diabeloop Generation-1 (DBLG1) closed-loop system'],"['time spent in hyperglycaemia and the glycaemic variation coefficient', 'insulin delivery', 'hypoglycaemia', 'Preventive CHO intake', 'Glycaemic outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}]","[{'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0443183', 'cui_str': 'Closed loop'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0054889', 'cui_str': 'CAV protocol'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",56.0,0.0682588,"RESULTS Daily time spent in the interstitial glucose range <70 mg/dL was not significantly different between days with and without PA (2.0 ± 1.5% versus 2.2 ± 1.1%) and this regardless of the intensity or duration of the PA.","[{'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Franc', 'Affiliation': 'Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France.'}, {'ForeName': 'Pierre-Yves', 'Initials': 'PY', 'LastName': 'Benhamou', 'Affiliation': 'Department of Diabetology, University Hospital Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Borot', 'Affiliation': 'Department of Endocrinology, Metabolism, Diabetes and Nutrition, Centre Hospitalier Universitaire Jean Minjoz, Besançon, France.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Chaillous', 'Affiliation': 'CHU de Nantes - Hospital Laennec, Saint-Herblain, France.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Delemer', 'Affiliation': 'Department of Endocrinology, Diabetes and Nutrition, Reims University Hospital, Reims, France.'}, {'ForeName': 'Maeva', 'Initials': 'M', 'LastName': 'Doron', 'Affiliation': ""Université Grenoble Alpes, Commissariat à l'Energie Atomique, Laboratoire d'électronique et de technologie de l'information, Département micro Technologies pour la Biologie et la Santé, Grenoble, France.""}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Guerci', 'Affiliation': 'Endocrinology-Diabetes Care Unit, University of Lorraine, Vandoeuvre Lès Nancy, France.'}, {'ForeName': 'Hélène', 'Initials': 'H', 'LastName': 'Hanaire', 'Affiliation': 'Department of Diabetology, Metabolic Diseases and Nutrition, CHU Toulouse, University of Toulouse, Toulouse, France.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Huneker', 'Affiliation': 'Diabeloop S.A., Paris, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Jeandidier', 'Affiliation': 'Department of Endocrinology, Diabetes and Nutrition, CHRU of Strasbourg (UDS), Strasbourg, France.'}, {'ForeName': 'Coralie', 'Initials': 'C', 'LastName': 'Amadou', 'Affiliation': 'Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Renard', 'Affiliation': 'Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital, and Institute of Functional Genomics, CNRS, INSERM, University of Montpellier, Montpellier, France.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Reznik', 'Affiliation': 'Department of Endocrinology, University of Caen Côte de Nacre Regional Hospital Center, Caen, France.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Schaepelynck', 'Affiliation': 'Department of Nutrition-Endocrinology-Metabolic Disorders, Marseille University Hospital, Sainte Marguerite Hospital, Marseille, France.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Simon', 'Affiliation': 'Department of Endocrinology, Diabetes and Nutrition, Centre Hospitalier Lyon Sud, Lyon, France.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Thivolet', 'Affiliation': 'Center for Diabetes, Lyon University Hospital, Lyon, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Thomas', 'Affiliation': ""Laboratoire de Biologie de l'Exercice pour la Performance et la Santé, Université Evry Val d'Essonne, Institut de Recherches Biomédicales des Armées, Université Paris Saclay, Evry, France.""}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Hannaert', 'Affiliation': ""School of Medicine and Pharmacy of Poitiers, Ischémie Reperfusion en Transplantation d'Organes Mécanismes et Innovations Thérapeutiques, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1082, Poitiers, France.""}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Charpentier', 'Affiliation': ""Centre d'Etude et de Recherche pour l'Intensification du Traitement du Diabète (CERITD), Evry, France.""}]","Diabetes, obesity & metabolism",['10.1111/dom.14442'] 3195,34009239,Errors in Numbers in the Text and Tables in a Secondary Analysis of the ISCHEMIA Randomized Clinical Trial.,,2021,,[],[],[],[],[],[],,0.458104,,"[{'ForeName': 'Harmony R', 'Initials': 'HR', 'LastName': 'Reynolds', 'Affiliation': 'NYU Grossman School of Medicine, New York, New York.'}]",JAMA cardiology,['10.1001/jamacardio.2021.1481'] 3196,34006923,Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women's Health Initiative (WHI) randomised trial.,"BACKGROUND In the Women's Health Initiative (WHI) dietary modification (DM) randomised trial, the low-fat dietary intervention reduced deaths from breast cancer (P = 0.02). Extending these findings, secondary analysis examined dietary intervention influence on breast cancer mortality by metabolic syndrome (MS) components. METHODS In total, 48,835 postmenopausal women with no prior breast cancer were randomised to a low-fat dietary intervention or comparison groups. Four MS components were determined at entry in 45,833 participants: (1) high waist circumference, (2) high blood pressure, (3) high cholesterol and (4) diabetes history. Forest plots of hazard ratios (HRs) were generated with P-values for interaction between randomisation groups and MS component score. Primary outcome was death from breast cancer by metabolic syndrome score. RESULTS HRs and 95% confidence intervals (CI) for dietary intervention influence on death from breast cancer were with no MS components (n = 10,639), HR 1.09, 95% CI 0.63-1.87; with 1-2 MS components (n = 30,948), HR 0.80, 95% CI 0.62-1.02; with 3-4 MS components (n = 4,246), HR 0.31, 95% CI 0.14-0.69 (interaction P = 0.01). CONCLUSIONS While postmenopausal women with 3-4 MS components were at higher risk of death from breast cancer, those randomised to a low-fat dietary intervention more likely had reduction in this risk. REGISTRY ClinicalTrials.gov (NCT00000611).",2021,"RESULTS HRs and 95% confidence intervals (CI) for dietary intervention influence on death from breast cancer were with no MS components (n = 10,639), HR 1.09, 95% CI 0.63-1.87; with 1-2 MS components (n = 30,948), HR 0.80, 95% CI 0.62-1.02; with 3-4 MS components (n = 4,246), HR 0.31, 95% CI 0.14-0.69 (interaction P = 0.01). ","['45,833 participants: (1) high waist circumference, (2) high blood pressure, (3) high cholesterol and (4) diabetes history', '48,835 postmenopausal women with no prior breast cancer']",['low-fat dietary intervention'],"['death from breast cancer by metabolic syndrome score', 'hazard ratios (HRs', 'breast cancer mortality by metabolic syndrome (MS) components', 'death from breast cancer']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0020443', 'cui_str': 'Hypercholesterolemia'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",48835.0,0.404433,"RESULTS HRs and 95% confidence intervals (CI) for dietary intervention influence on death from breast cancer were with no MS components (n = 10,639), HR 1.09, 95% CI 0.63-1.87; with 1-2 MS components (n = 30,948), HR 0.80, 95% CI 0.62-1.02; with 3-4 MS components (n = 4,246), HR 0.31, 95% CI 0.14-0.69 (interaction P = 0.01). ","[{'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Pan', 'Affiliation': 'Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA. kathyjpan@gmail.com.'}, {'ForeName': 'Aaron K', 'Initials': 'AK', 'LastName': 'Aragaki', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Marian L', 'Initials': 'ML', 'LastName': 'Neuhouser', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Simon', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Juhua', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': 'University of Indiana, Bloomington, IN, USA.'}, {'ForeName': 'Bette', 'Initials': 'B', 'LastName': 'Caan', 'Affiliation': 'Kaiser Permanente Northern California Division of Research, Oakland, CA, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Snetselaar', 'Affiliation': 'University of Iowa, Bloomington, IN, USA.'}, {'ForeName': 'Joanne E', 'Initials': 'JE', 'LastName': 'Mortimer', 'Affiliation': 'City of Hope National Medical Center, Duarte, CA, USA.'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Candyce', 'Initials': 'C', 'LastName': 'Kroenke', 'Affiliation': 'Kaiser Permanente Northern California Division of Research, Oakland, CA, USA.'}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Lane', 'Affiliation': 'State University of New York at Stony Brook, Stony Brook, NY, USA.'}, {'ForeName': 'Kerryn', 'Initials': 'K', 'LastName': 'Reding', 'Affiliation': 'Fred Hutchinson Cancer Research Center & University of Washington, School of Nursing, Seattle, WA, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Rohan', 'Affiliation': 'Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Rowan T', 'Initials': 'RT', 'LastName': 'Chlebowski', 'Affiliation': 'Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.'}]",British journal of cancer,['10.1038/s41416-021-01379-w'] 3197,34389577,Study protocol for the TRUSt trial: a pragmatic randomised controlled trial comparing the standard of care with a transitional pain service for patients at risk of chronic postsurgical pain undergoing surgery.,"INTRODUCTION Patients with either surgery-related or patient-related risk factors are at an increased risk of acute and chronic postsurgical pain (CPSP) and long-term opioid use. To improve recovery, prevent CPSP and decrease opioid use, we need to identify these patients before surgery and provide a multidisciplinary pain management strategy throughout hospital admission and follow-up in the postdischarge period. We hypothesise that a multidisciplinary transitional pain service (TPS) improves quality of recovery and reduce the incidence of CPSP and opioid consumption. METHODS AND ANALYSIS We aim to investigate the effectiveness of implementation of a TPS for patients at risk of developing CPSP. The trial design is a pragmatic, open-label, randomised controlled trial (RCT). After stratification for sex, patients are randomly assigned to the TPS or standard of care (SOC) group. Our primary outcome is the quality of recovery, measured at the morning of the third postoperative day, employing the quality of recovery (QoR)-15 questionnaire. Secondary outcomes are the incidence of CPSP, opioid consumption and patient-reported outcome measures at 3 and 6 months postoperatively. We need to enrol 176 patients to detect a minimal clinical important difference of 8 points on the QoR-15 score. ETHICS AND DISSEMINATION Ethics approval was obtained by the accredited medical research ethics committee of the Academic Medical Center in Amsterdam (2020_211) on 15 October 2020. Protocol version 3.2 was approved on 25 January 2020. The trial is registered with the Netherlands Trial Register, NL9115. The results will be disseminated by open access publication in a peer-reviewed journal. Trial registration number NL9115.",2021,"Secondary outcomes are the incidence of CPSP, opioid consumption and patient-reported outcome measures at 3 and 6 months postoperatively.","['patients at risk of developing CPSP', 'patients at risk of chronic postsurgical pain undergoing surgery']","['standard of care with a transitional pain service', 'TPS or standard of care (SOC', 'TPS']","['QoR-15 score', 'incidence of CPSP, opioid consumption and patient-reported outcome measures', 'quality of recovery, measured at the morning of the third postoperative day, employing the quality of recovery (QoR)-15 questionnaire']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.478381,"Secondary outcomes are the incidence of CPSP, opioid consumption and patient-reported outcome measures at 3 and 6 months postoperatively.","[{'ForeName': 'Manouk', 'Initials': 'M', 'LastName': 'Admiraal', 'Affiliation': 'Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Hermanns', 'Affiliation': 'Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Hermanides', 'Affiliation': 'Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands j.hermanides@amsterdamumc.nl.'}, {'ForeName': 'Carin G C L', 'Initials': 'CGCL', 'LastName': 'Wensing', 'Affiliation': 'Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Soe L', 'Initials': 'SL', 'LastName': 'Meinsma', 'Affiliation': 'Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Hans C H', 'Initials': 'HCH', 'LastName': 'Wartenberg', 'Affiliation': 'Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Martin V H', 'Initials': 'MVH', 'LastName': 'Rutten', 'Affiliation': 'Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Vivian M C', 'Initials': 'VMC', 'LastName': 'Ward-van der Stam', 'Affiliation': 'Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Markus W', 'Initials': 'MW', 'LastName': 'Hollmann', 'Affiliation': 'Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands.'}]",BMJ open,['10.1136/bmjopen-2021-049676'] 3198,34389570,Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol).,"INTRODUCTION Pregnancy in sickle cell disease is fraught with many complications including pre-eclampsia (PE) and intrauterine growth restriction (IUGR). Previously, we found an abnormality in prostacyclin-thromboxane ratio in sickle cell pregnant women, a situation that is also found in non-sickle pregnancies with PE and unexplained IUGR. Low-dose aspirin (LDA) has been shown to reduce the incidence of PE and IUGR in high-risk women by reducing the vasoconstrictor thromboxane while sparing prostacyclin, in effect 'correcting' the ratio. It has been found to be safe for use in pregnancy but has not been tested in sickle cell pregnancy. We hypothesise that LDA will reduce the incidence of IUGR and PE in pregnant haemoglobin SS (HbSS) and haemoglobin SC (HbSC) women. METHODS AND ANALYSIS This is a multisite, double blind, randomised controlled trial, comparing a daily dose of 100 mg aspirin to placebo, from 12 to 16 weeks' gestation until 36 weeks, in Lagos state, Nigeria. Four hundred and seventy-six eligible pregnant HbSS and HbSC women will be recruited consecutively, randomly assigned to either group and followed from recruitment until delivery. The primary outcome will be the incidence of birth weight below 10th centile for gestational age on INTERGROWTH 21 birth weight charts, or incidence of miscarriage or perinatal death. Secondary outcomes will include PE, maternal death, preterm delivery, perinatal death, number of crises, need for blood transfusion and complications such as infections and placental abruption. Analysis will be by intention to treat and the main treatment effects will be quantified by relative risk with 95% CI, at a 5% significance level. ETHICAL APPROVAL Ethical approval has been granted by the Health Research and Ethics committees of the recruiting hospitals and the National Health Research and Ethics Committee. Study findings will be presented at conferences and published appropriately. TRAIL REGISTRATION NUMBER PACTR202001787519553; Pre-results.",2021,"We hypothesise that LDA will reduce the incidence of IUGR and PE in pregnant haemoglobin SS (HbSS) and haemoglobin SC (HbSC) women. ","['Four hundred and seventy-six eligible pregnant HbSS and HbSC women', 'sickle cell pregnant women', 'sickle cell pregnancy (PIPSICKLE']","['aspirin (LDA', 'aspirin to placebo', 'Low-dose aspirin']","['incidence of birth weight below 10th centile for gestational age on INTERGROWTH 21 birth weight charts, or incidence of miscarriage or perinatal death', 'PE, maternal death, preterm delivery, perinatal death, number of crises, need for blood transfusion and complications such as infections and placental abruption', 'prostacyclin-thromboxane ratio']","[{'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0019043', 'cui_str': 'Hemoglobin S'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0221283', 'cui_str': 'Drepanocyte'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0701826', 'cui_str': 'Perinatal death'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0024923', 'cui_str': 'Maternal death'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0231224', 'cui_str': 'Crisis'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0000832', 'cui_str': 'Placental abruption'}, {'cui': 'C0033567', 'cui_str': 'Epoprostenol'}, {'cui': 'C0040061', 'cui_str': 'Thromboxane'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",476.0,0.7937,"We hypothesise that LDA will reduce the incidence of IUGR and PE in pregnant haemoglobin SS (HbSS) and haemoglobin SC (HbSC) women. ","[{'ForeName': 'Bosede Bukola', 'Initials': 'BB', 'LastName': 'Afolabi', 'Affiliation': 'Obstetrics and Gynaecology, University of Lagos College of Medicine, Idi-Araba, Lagos, Nigeria bbafolabi@unilag.edu.ng.'}, {'ForeName': 'Ochuwa Adiketu', 'Initials': 'OA', 'LastName': 'Babah', 'Affiliation': 'Obstetrics and Gynaecology, University of Lagos College of Medicine, Idi-Araba, Lagos, Nigeria.'}, {'ForeName': 'Titilope Adenike', 'Initials': 'TA', 'LastName': 'Adeyemo', 'Affiliation': 'Haematology and Blood Transfusion, University of Lagos College of Medicine, Idi-Araba, Lagos, Nigeria.'}, {'ForeName': 'Oluwakemi Ololade', 'Initials': 'OO', 'LastName': 'Odukoya', 'Affiliation': 'Community Health and Primary Care, University of Lagos, Idi-Araba, Lagos, Nigeria.'}, {'ForeName': 'Chinyere Veronica', 'Initials': 'CV', 'LastName': 'Ezeaka', 'Affiliation': 'Paediatrics, University of Lagos College of Medicine, Idi-Araba, Lagos, Nigeria.'}, {'ForeName': 'Obinyo', 'Initials': 'O', 'LastName': 'Nwaiwu', 'Affiliation': 'Pharmacology, University of Lagos College of Medicine, Idi-Araba, Lagos, Nigeria.'}, {'ForeName': 'Yusuf Abisowo', 'Initials': 'YA', 'LastName': 'Oshodi', 'Affiliation': 'Obstetrics & Gynaecology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria.'}, {'ForeName': 'Babatunde A', 'Initials': 'BA', 'LastName': 'Ogunnaike', 'Affiliation': 'Chemical Engineering, University of Delaware, Newark, Delaware, USA.'}]",BMJ open,['10.1136/bmjopen-2020-047949'] 3199,34389552,Cardiorespiratory fitness in breast cancer survivors: a randomised controlled trial of home-based smartphone supported high intensity interval training.,"BACKGROUND A strategy for maintaining and/or improving cardiorespiratory fitness (CRF) in the growing population of cancer survivors is of major clinical importance, especially in the COVID-19 era. The effect of unsupervised high-intensity interval training (HIIT) on increasing CRF in breast cancer survivors is unknown. PURPOSE The purpose of this study was to determine whether the newly developed habit-B programme, which involves home-based smartphone-supported HIIT using body weight exercises, improves CRF in early-stage breast cancer survivors. METHODS This single-centre, 12-week, parallel-group, single-blind, randomised controlled trial involved 50 women with stage I-IIa breast cancer, aged 20-59 years, who had completed initial treatment except for hormone therapy. Participants were randomised to either the exercise or control group. The primary outcome was the 12-week change in peak oxygen uptake [Formula: see text]. Other outcomes included muscle strength, 6 min walk test, resting heart rate, physical activity, fatigue, safety and quality of life. RESULTS The change in [Formula: see text] and leg strength increased significantly in the exercise group compared with the control group (p<0.01). Changes in other outcomes were not significantly different between the groups. CONCLUSION A home-based HIIT intervention can lead to improve CRF and muscle strength in early-stage breast cancer survivors.",2021,The change in [Formula: see text] and leg strength increased significantly in the exercise group compared with the control group (p<0.01).,"['50\u2009women with stage I-IIa breast cancer, aged 20-59 years, who had completed initial treatment except for hormone therapy', 'early-stage breast cancer survivors', 'breast cancer survivors']","['unsupervised high-intensity interval training (HIIT', 'exercise or control group', 'home-based smartphone supported high intensity interval training', 'smartphone-supported HIIT using body weight exercises']","['peak oxygen uptake', 'Cardiorespiratory fitness', 'leg strength', 'CRF and muscle strength', 'muscle strength, 6\u2009min walk test, resting heart rate, physical activity, fatigue, safety and quality of life']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332300', 'cui_str': 'Except for'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",50.0,0.144076,The change in [Formula: see text] and leg strength increased significantly in the exercise group compared with the control group (p<0.01).,"[{'ForeName': 'Eisuke', 'Initials': 'E', 'LastName': 'Ochi', 'Affiliation': 'Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan matsuoka-psy@umin.ac.jp ochi@hosei.ac.jp.'}, {'ForeName': 'Katsunori', 'Initials': 'K', 'LastName': 'Tsuji', 'Affiliation': 'Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Tomomi', 'Initials': 'T', 'LastName': 'Narisawa', 'Affiliation': 'Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Shimizu', 'Affiliation': 'Division of Nursing, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Kuchiba', 'Affiliation': 'Biostatistics Division, Center for Research Administration and Support, National Cancer Center Japan, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Akihiko', 'Initials': 'A', 'LastName': 'Suto', 'Affiliation': 'Division of Breast Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Kenjiro', 'Initials': 'K', 'LastName': 'Jimbo', 'Affiliation': 'Division of Breast Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Takayama', 'Affiliation': 'Division of Breast Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Taro', 'Initials': 'T', 'LastName': 'Ueno', 'Affiliation': 'SUSMED Inc, Chuo-ku, Tokyo, Japan.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Sakurai', 'Affiliation': 'Cancer Solutions, Chiyoda-ku, Tokyo, Japan.'}, {'ForeName': 'Yutaka', 'Initials': 'Y', 'LastName': 'Matsuoka', 'Affiliation': 'Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan matsuoka-psy@umin.ac.jp ochi@hosei.ac.jp.'}]",BMJ supportive & palliative care,['10.1136/bmjspcare-2021-003141'] 3200,34014402,Twelve weeks of sprint interval training increases peak cardiac output in previously untrained individuals.,"INTRODUCTION Sprint interval training (SIT), characterized by brief bouts of 'supramaximal' exercise interspersed with recovery periods, increases peak oxygen uptake ([Formula: see text]) despite a low total exercise volume. Per the Fick principle, increased [Formula: see text] is attributable to increased peak cardiac output ([Formula: see text]) and/or peak arterio-venous oxygen difference (a-vO 2diff ). There are limited and equivocal data regarding the physiological basis for SIT-induced increases in [Formula: see text], with most studies lasting ≤ 6 weeks. PURPOSE To determine the effect of 12 weeks of SIT on [Formula: see text], measured using inert gas rebreathing, and the relationship between changes in [Formula: see text] and [Formula: see text]. METHODS 15 healthy untrained adults [6 males, 9 females; 21 ± 2 y (mean ± SD)] performed 28 ± 3 training sessions. Each session involved a 2-min warm-up at 50 W, 3 × 20-s 'all-out' cycling bouts (581 ± 221 W) interspersed with 2-min of recovery, and a 3-min cool-down at 50 W. RESULTS Measurements performed before and after training showed that 12 weeks of SIT increased [Formula: see text] (17.0 ± 3.7 vs 18.1 ± 4.6 L/min, p = 0.01, partial η 2  = 0.28) and [Formula: see text] (2.63 ± 0.78 vs 3.18 ± 1.1 L/min, p < 0.01, partial η 2  = 0.58). The changes in these two variables were correlated (r 2  = 0.46, p < 0.01). Calculated peak a-vO 2diff also increased after training (154 ± 22 vs 174 ± 23 ml O 2 /L; p < 0.01) and was correlated with the change in [Formula: see text] (r 2  = 0.33, p = 0.03). Exploratory analyses revealed an interaction (p < 0.01) such that [Formula: see text] increased in male (+ 10%, p < 0.01) but not female participants (+ 0.6%, p = 0.96), suggesting potential sex-specific differences. CONCLUSION Twelve weeks of SIT increased [Formula: see text] by 6% in previously untrained participants and the change was correlated with the larger 21% increase in [Formula: see text].",2021,Calculated peak a-vO 2diff also increased after training (154 ± 22 vs 174 ± 23 ml O 2 /L; p < 0.01) and was correlated with the change in [Formula: see text],"['15 healthy untrained adults [6 males, 9 females; 21\u2009±\u20092 y (mean\u2009±\u2009SD)] performed 28\u2009±\u20093 training sessions', 'previously untrained individuals']","['sprint interval training', 'Sprint interval training (SIT']","['peak oxygen uptake', 'Calculated peak a-vO 2diff', 'SIT increased [Formula: see text', 'peak cardiac output']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C4279979', 'cui_str': 'Sprint Interval Training'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C4279979', 'cui_str': 'Sprint Interval Training'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}]",15.0,0.02965,Calculated peak a-vO 2diff also increased after training (154 ± 22 vs 174 ± 23 ml O 2 /L; p < 0.01) and was correlated with the change in [Formula: see text],"[{'ForeName': 'William', 'Initials': 'W', 'LastName': 'Bostad', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, L8S 4K1, Canada.'}, {'ForeName': 'Sydney E', 'Initials': 'SE', 'LastName': 'Valentino', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, L8S 4K1, Canada.'}, {'ForeName': 'Devin G', 'Initials': 'DG', 'LastName': 'McCarthy', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, L8S 4K1, Canada.'}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Richards', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'MacInnis', 'Affiliation': 'Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Maureen J', 'Initials': 'MJ', 'LastName': 'MacDonald', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, L8S 4K1, Canada.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'Gibala', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, L8S 4K1, Canada. gibalam@mcmaster.ca.'}]",European journal of applied physiology,['10.1007/s00421-021-04714-4'] 3201,34013747,No additive effect of acetaminophen when co-ingested with caffeine on cycling performance in well-trained young men.,"We investigated the effect of caffeine and acetaminophen on power output during a 6-min performance test, peripheral fatigue, and muscle protein kinase A (PKA) substrate phosphorylation. Fourteen men [age (means ± SD): 26 ± 6 yr; V̇o 2max : 63.9 ± 5.0 mL·min -1 ·kg -1 ] completed four randomized trials with acetaminophen (1,500 mg), caffeine (5 mg·kg body wt -1 ), combined caffeine and acetaminophen (caffeine + acetaminophen), or placebo. Mean power output during the 6-min performance test (placebo mean: 312 ± 41 W) was higher with caffeine (+5 W; 95% CI: 1 to 9; P = 0.017) and caffeine + acetaminophen (+6 W; 95% CI: 0 to 12; P = 0.049) than placebo, but not with acetaminophen (+1 W; 95% CI: -4 to 7; P = 0.529). Decline in quadriceps maximal isometric voluntary torque immediately after the performance test was lower (treatment × time; P = 0.035) with acetaminophen (-40 N·m; 95% CI: -53 to -30; P < 0.001) and caffeine + acetaminophen (-44 N·m; 95% CI: -58 to -30; P < 0.001) than placebo (-53 N·m; 95% CI: -71 to -39; P < 0.001) but was similar with caffeine (-54 N·m; 95% CI: -69 to -38; P < 0.001). Muscle phosphocreatine content decreased more during the performance test (treatment × time; P = 0.036) with caffeine + acetaminophen (-55 mmol·kg dry wt -1 ; 95% CI: -65 to -46; P < 0.001) than placebo (-40 mmol·kg dry wt -1 ; 95% CI: -52 to -24; P < 0.001). Muscle net lactate accumulation was not different from placebo (+85 mmol·kg dry wt -1 ; 95% CI: 60 to 110; P < 0.001) for any treatment (treatment × time; P = 0.066), being +75 mmol·kg dry wt -1 (95% CI: 51 to 99; P < 0.001) with caffeine, +76 mmol·kg dry wt -1 (95% CI: 58 to 96; P < 0.001) with acetaminophen, and +103 mmol·kg dry wt -1 (95% CI: 89 to 115; P < 0.001) with caffeine + acetaminophen. Decline in muscle ATP and glycogen content and increase in PKA substrate phosphorylation was not different between treatments (treatment × time; P > 0.1). Thus, acetaminophen provides no additive performance enhancing effect to caffeine during 6-min maximal cycling. In addition, change in PKA activity is likely not a major mechanism of performance improvement with caffeine. NEW & NOTEWORTHY Here, we show that acetaminophen does not provide additive performance improvement to caffeine during a 6-min cycling ergometer performance test, and that acetaminophen does not improve performance on its own. Neither substance affects peripheral fatigue, muscle glycolytic energy production, or phosphorylation of muscle proteins of importance for ion handling. In contrast to previous suggestions, increased epinephrine action on muscle cells does not appear to be a major contributor to the performance enhancement with caffeine.",2021,Muscle phosphocreatine content decreased more during the performance-test (treatment×time;P=0.036) with caffeine+acetaminophen (-55,"['Fourteen men (age(mean±SD): 26±6 years; V̇O 2max : 63.9±5.0 mL∙min -1 ∙kg -1 ', 'well-trained young men', '53']","['caffeine (5 mg∙kgbw -1 ), combined caffeine and acetaminophen (caffeine+acetaminophen) or placebo', 'placebo ', 'caffeine and acetaminophen', 'mmol∙kgdw -1 ', 'caffeine+acetaminophen (-55', 'caffeine', 'acetaminophen, and +103 mmol∙kgdw -1 (95%CI: 89 to 115;P<0.001) with caffeine+acetaminophen', 'acetaminophen', 'placebo', 'placebo (-40 mmol∙kgdw -1', 'caffeine ']","['power output during a 6-min performance-test, peripheral fatigue, and muscle protein kinase A (PKA) substrate-phosphorylation', 'cycling performance', 'Muscle phosphocreatine content', 'quadriceps maximal isometric voluntary torque', 'Muscle net lactate accumulation', 'Mean power output', 'muscle ATP and glycogen content and increase in PKA substrate-phosphorylation']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4517526', 'cui_str': '103'}]","[{'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026832', 'cui_str': 'Muscle Protein'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}, {'cui': 'C0010531', 'cui_str': 'Cyclic AMP-Dependent Protein Kinase'}, {'cui': 'C0031715', 'cui_str': 'Phosphorylation'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0031634', 'cui_str': 'fosfocreatine'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001480', 'cui_str': 'Adenosine Triphosphate'}, {'cui': 'C0017911', 'cui_str': 'Glycogen'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",,0.342914,Muscle phosphocreatine content decreased more during the performance-test (treatment×time;P=0.036) with caffeine+acetaminophen (-55,"[{'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Jessen', 'Affiliation': 'Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Eibye', 'Affiliation': 'Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Peter Møller', 'Initials': 'PM', 'LastName': 'Christensen', 'Affiliation': 'Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Hostrup', 'Affiliation': 'Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Bangsbo', 'Affiliation': 'Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00108.2021'] 3202,34013615,Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.,"OBJECTIVE To compare the safety and outcomes between green-light laser en bloc resection and transurethral resection of bladder tumor. METHODS A single-center, randomized controlled trial was carried out from August 2014 to September 2018. Patients with initial non-muscle-invasive bladder cancer were randomized to green-light laser en bloc resection or transurethral resection of bladder tumor. The primary outcomes were pathological findings and perioperative events. The secondary outcome was tumor recurrence. RESULTS A total of 233 patients were randomized to the transurethral resection of bladder tumor group (117 patients) and the green-light laser en bloc resection group (116 patients). The resection time was longer in the green-light laser en bloc resection group (P = 0.022); however, no differences were identified in overall operative time (P = 0.255). Nine patients (7.7%) had an obturator nerve reflex during transurethral resection of bladder tumor. The estimated volume of blood loss was significantly lower in the green-light laser en bloc resection group (P = 0.012). The green-light laser en bloc resection group had a higher rate of T1 bladder cancer (P = 0.031). A total of 104 patients (89.7%) treated with green-light laser en bloc resection had detrusor muscle presence in the specimen, whereas 37 (31.9%) patients had the presence of muscularis mucosae, which was significantly higher than the corresponding number of transurethral resection of bladder tumor patients (P = 0.005 and 0.002, respectively). After a median follow-up period of 48 months, just five patients had tumor recurrence (three in the transurethral resection of bladder tumor group and two in the green-light laser en bloc resection group), and there was no difference between these two groups. CONCLUSIONS Compared with transurethral resection of bladder tumor, green-light laser en bloc resection is more effective due to less obturator nerve reflex and the same recurrence rate. Most importantly, green-light laser en bloc resection can provide better tumor specimens for pathological examinations.",2021,"The resection time was longer in the green-light laser en bloc resection group (P = 0.022); however, no differences were identified in overall operative time (P = 0.255).","['233 patients', 'Patients with initial non-muscle-invasive bladder cancer', 'group (116 patients', 'August 2014 to September 2018', 'initial non-muscle-invasive bladder cancer']","['green-light laser en bloc resection or transurethral resection of bladder tumor', 'green-light laser en bloc resection and transurethral resection', 'Green-light laser en bloc resection versus conventional transurethral resection', 'transurethral resection of bladder tumor group (117 patients) and the green-light laser en bloc resection', 'green-light laser en bloc resection', 'transurethral resection of bladder tumor, green-light laser en bloc resection']","['pathological findings and perioperative events', 'rate of T1 bladder cancer', 'overall operative time', 'estimated volume of blood loss', 'transurethral resection of bladder tumor patients', 'tumor recurrence', 'obturator nerve reflex', 'resection time', 'detrusor muscle presence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517541', 'cui_str': '116'}]","[{'cui': 'C1306567', 'cui_str': 'Green light'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0401496', 'cui_str': 'Transurethral resection of bladder neoplasm'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0401496', 'cui_str': 'Transurethral resection of bladder neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521158', 'cui_str': 'Recurrent tumor'}, {'cui': 'C0028783', 'cui_str': 'Structure of obturator nerve'}, {'cui': 'C0034929', 'cui_str': 'Reflex'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0150312', 'cui_str': 'Present'}]",233.0,0.0728461,"The resection time was longer in the green-light laser en bloc resection group (P = 0.022); however, no differences were identified in overall operative time (P = 0.255).","[{'ForeName': 'Jinhai', 'Initials': 'J', 'LastName': 'Fan', 'Affiliation': ""Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Kaijie', 'Initials': 'K', 'LastName': 'Wu', 'Affiliation': ""Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': ""Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Yang', 'Affiliation': ""Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Liu', 'Affiliation': ""Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Yumei', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': ""Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Xiaojing', 'Initials': 'X', 'LastName': 'Bai', 'Affiliation': ""Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Xinyang', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Dalin', 'Initials': 'D', 'LastName': 'He', 'Affiliation': ""Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.""}]",International journal of urology : official journal of the Japanese Urological Association,['10.1111/iju.14592'] 3203,33967056,Six-Month Community-Based Brisk Walking and Balance Exercise Alleviates Motor Symptoms and Promotes Functions in People with Parkinson's Disease: A Randomized Controlled Trial.,"BACKGROUND In Parkinson's disease (PD), sustained aerobic exercise is a promising therapy in delaying motor disability. Brisk walking is a moderate intensity aerobic training, which could be translated to community practice at low cost, but its effects on motor symptoms remains unclear. OBJECTIVE To determine the effectiveness of a six-month brisk walking and balance program in alleviating motor symptoms, and promoting functional, gait, and balance performance in people with PD. METHODS Seventy individuals with mild to moderate PD were randomly assigned to a brisk walking (BW) group or an active control (CON) group. BW group received ten 90-minute supervised brisk walking and balance exercise for six months (weeks 1-6: once/week, weeks 7-26: once/month). CON group received upper limb training. Both groups performed 2-3 self-practice sessions weekly. Primary outcome was Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score. Secondary outcomes were fast gait speed (FGS), timed-up-and-go (TUG) time, six-minute walk distance (6MWD), and Mini-Balance Evaluation Systems Test (Mini-BEST) score. RESULTS Sixty-four participants (33 BW/31 CON) completed training. BW group showed greater significant decreases from baseline than CON group in MDS-UPDRS motor score after six weeks (-5.5 vs -1.6, p < 0.001) and 6 months (-6.0 vs -1.4, p < 0.001) of training. BW group also showed greater significant improvement from the baseline than CON group for TUG time, FGS, 6MWD, and mini-BEST score (all p < 0.05). CONCLUSION The six-month brisk walking and balance program alleviates motor symptoms, promotes functional and gait performance, walking capacity, and dynamic balance in people with mild to moderate PD.",2021,"BW group also showed greater significant improvement from the baseline than CON group for TUG time, FGS, 6MWD, and mini-BEST score (all p <  0.05). ","[""People with Parkinson's Disease"", 'people with mild to moderate PD', 'Seventy individuals with mild to moderate PD', 'people with PD']","['upper limb training', 'six-month brisk walking and balance program', '90-minute supervised brisk walking and balance exercise', 'Six-Month Community-Based Brisk Walking and Balance Exercise', 'Brisk walking', 'brisk walking (BW) group or an active control (CON', 'CON']","['fast gait speed (FGS), timed-up-and-go (TUG) time, six-minute walk distance (6MWD), and Mini-Balance Evaluation Systems Test (Mini-BEST) score', 'TUG time, FGS, 6MWD, and mini-BEST score', 'alleviating motor symptoms, and promoting functional, gait, and balance performance', ""Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score"", 'functional and gait performance, walking capacity, and dynamic balance', 'MDS-UPDRS motor score']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C3816957', 'cui_str': '70'}]","[{'cui': 'C0556501', 'cui_str': 'Upper limb training'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0150219', 'cui_str': 'Balance exercises'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}]",70.0,0.0351583,"BW group also showed greater significant improvement from the baseline than CON group for TUG time, FGS, 6MWD, and mini-BEST score (all p <  0.05). ","[{'ForeName': 'Margaret K Y', 'Initials': 'MKY', 'LastName': 'Mak', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China.'}, {'ForeName': 'Irene S K', 'Initials': 'ISK', 'LastName': 'Wong-Yu', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China.'}]",Journal of Parkinson's disease,['10.3233/JPD-202503'] 3204,33967049,A Novel Cognitive Function Scale Using Functional Near-Infrared Spectroscopy for Evaluating Cognitive Dysfunction.,"BACKGROUND Maintaining cognitive function is integral to a healthy social life in the aged. Although neuropsychological tests and brain imaging methods can assess cognitive dysfunction, these techniques are subjective, psychologically burdensome, and cannot be conducted easily. OBJECTIVE We sought to develop an objective, low-burden novel cognitive function scale based on functional near-infrared spectroscopy (fNIRS) of hemodynamic changes in the cerebral cortex during daily task performance. METHODS A total of 63 participants (aged 60-80 years) identified as non-dementia controls (NDC) or with mild cognitive impairment (MCI) were recruited and randomly assigned to training and test data sets. Explanatory variables were hemodynamic responses during low-burden sensory and simple tasks without higher-order brain functioning. RESULTS A logistic regression analysis of the fNIRS index in NDCs and MCI patients revealed area under the curve, sensitivity, specificity, and holdout results of 0.98, 94%, 88%, and 62% respectively. Correlation between fNIRS index and MCI odds showed positive linearity (R2 = 0.96). CONCLUSION Positive correlation between the fNIRS index and MCI odds indicated effectiveness of this fNIRS measurement. Although additional experiments are necessary, the fNIRS index representing degree of cognitive decline can be an onsite monitoring tool to assess cognitive status.",2021,"A logistic regression analysis of the fNIRS index in NDCs and MCI patients revealed area under the curve, sensitivity, specificity, and holdout results of 0.98, 94%, 88%, and 62% respectively.",['63 participants (aged 60-80 years) identified as non-dementia controls (NDC) or with mild cognitive impairment (MCI'],[],[],"[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}]",[],[],63.0,0.0886378,"A logistic regression analysis of the fNIRS index in NDCs and MCI patients revealed area under the curve, sensitivity, specificity, and holdout results of 0.98, 94%, 88%, and 62% respectively.","[{'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Nakamura', 'Affiliation': 'Analytical & Measuring Instruments Division, Shimadzu Corp., Kyoto, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Yomota', 'Affiliation': 'Analytical & Measuring Instruments Division, Shimadzu Corp., Kyoto, Japan.'}, {'ForeName': 'Hitomi', 'Initials': 'H', 'LastName': 'Ito', 'Affiliation': 'Research Division, MCBI Inc., Ibaraki, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Akinaga', 'Affiliation': 'Analytical & Measuring Instruments Division, Shimadzu Corp., Kyoto, Japan.'}, {'ForeName': 'Ayaka', 'Initials': 'A', 'LastName': 'Hori', 'Affiliation': 'Analytical & Measuring Instruments Division, Shimadzu Corp., Kyoto, Japan.'}, {'ForeName': 'Kenta', 'Initials': 'K', 'LastName': 'Chinomi', 'Affiliation': 'Technology Research Laboratory, Shimadzu Corp., Kyoto, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Suzuki', 'Affiliation': 'Research Division, MCBI Inc., Ibaraki, Japan.'}, {'ForeName': 'Kazuhiko', 'Initials': 'K', 'LastName': 'Uchida', 'Affiliation': 'Research Division, MCBI Inc., Ibaraki, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Asada', 'Affiliation': 'Medical Corporation Association Sochikai, Memory Clinic Ochanomizu, Tokyo, Japan.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-210072'] 3205,33971141,"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.","BACKGROUND Inhibition of vascular endothelial growth factor receptor (VEGFR) has shown antitumour activity in advanced hepatocellular carcinoma, but few studies of VEGFR inhibitors have been done in populations with a high prevalence of hepatitis B virus infection. The aim of this study was to evaluate the efficacy and safety of apatinib in patients with pretreated advanced hepatocellular carcinoma. METHODS AHELP was a randomised, double-blind, placebo-controlled, phase 3 trial done at 31 hospitals in China, in patients (aged ≥18 years) with advanced hepatocellular carcinoma who had previously been refractory or intolerant to at least one line of systemic chemotherapy or targeted therapy. Patients were randomly assigned (2:1) to receive apatinib 750 mg or placebo orally once daily in 28-day treatment cycles. Group allocation was done with a central randomisation system, with a block size of six, and was stratified by Eastern Cooperative Oncology Group performance status, previous sorafenib treatment, and presence of vascular invasion or extrahepatic metastasis. The primary endpoint was overall survival, which was defined as time from randomisation to death from any cause, and was analysed in patients who were randomly assigned and received at least one dose of the study drug. Safety analyses were done in patients who received at least one dose of the study treatment and had post-dose safety assessments. This trial is registered with ClinicalTrials.gov, NCT02329860. FINDINGS Between April 1, 2014, and May 3, 2017, 400 eligible patients were randomly assigned to receive apatinib (n=267) or placebo (n=133). Seven patients (six in the apatinib group and one in the placebo group) did not receive study treatment and were excluded from efficacy analyses. Overall survival was significantly improved in the apatinib group compared with the placebo group (median 8·7 months [95% CI 7·5‒9·8] vs 6·8 months [5·7‒9·1]; hazard ratio 0·785 [95% CI 0·617‒0·998], p=0·048). 387 patients (257 in the apatinib group and 130 in the placebo group) had a safety assessment after study treatment and were included in safety analyses. The most common treatment-related adverse events of grade 3 or 4 were hypertension (71 [28%] patients in the apatinib group vs three [2%] in the placebo group), hand-foot syndrome (46 [18%] vs none), and decreased platelet count (34 [13%] vs one [1%]). 24 (9%) patients in the apatinib group and 13 (10%) in the placebo group died due to adverse events, but none of these deaths were deemed to be related to treatment by investigators. INTERPRETATION Apatinib significantly improved overall survival in patients with pretreated advanced hepatocellular carcinoma compared with placebo, with a manageable safety profile. FUNDING Jiangsu Hengrui Medicine.",2021,"Overall survival was significantly improved in the apatinib group compared with the placebo group (median 8·7 months [95% CI 7·5‒9·8] vs 6·8 months [5·7‒9·1]; hazard ratio 0·785 [95% CI 0·617‒0·998], p=0·048).","['Between April 1, 2014, and May 3, 2017, 400 eligible patients', 'patients with advanced hepatocellular carcinoma (AHELP', 'patients with pretreated advanced hepatocellular carcinoma', 'advanced hepatocellular carcinoma', '31 hospitals in China, in patients (aged ≥18 years) with advanced hepatocellular carcinoma who had previously been refractory or intolerant to at least one line of systemic chemotherapy or targeted therapy', '387 patients (257 in the apatinib group and 130 in the']","['vascular endothelial growth factor receptor (VEGFR', 'placebo', 'apatinib 750 mg or placebo']","['overall survival', 'efficacy and safety', 'platelet count', 'hand-foot syndrome', 'adverse events', 'Overall survival']","[{'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C2346836', 'cui_str': 'apatinib'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319552', 'cui_str': '130'}]","[{'cui': 'C0148199', 'cui_str': 'Vascular Endothelial Growth Factor Receptor'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2346836', 'cui_str': 'apatinib'}, {'cui': 'C4517868', 'cui_str': '750'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",400.0,0.812042,"Overall survival was significantly improved in the apatinib group compared with the placebo group (median 8·7 months [95% CI 7·5‒9·8] vs 6·8 months [5·7‒9·1]; hazard ratio 0·785 [95% CI 0·617‒0·998], p=0·048).","[{'ForeName': 'Shukui', 'Initials': 'S', 'LastName': 'Qin', 'Affiliation': 'Department of Medical Oncology, Cancer Center of Bayi Hospital, Nanjing Chinese Medicine University, Nanjing, China. Electronic address: qinsk@csco.org.cn.'}, {'ForeName': 'Qiu', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Cancer Center, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Shanzhi', 'Initials': 'S', 'LastName': 'Gu', 'Affiliation': 'Department of Intervention, Hunan Cancer Hospital, Changsha, China.'}, {'ForeName': 'Xiaoming', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': ""Department of Invasive Technology, Guangdong Provincial People's Hospital, Guangzhou, China.""}, {'ForeName': 'Lizhu', 'Initials': 'L', 'LastName': 'Lin', 'Affiliation': 'Cancer Center, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Zishu', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.'}, {'ForeName': 'Aibing', 'Initials': 'A', 'LastName': 'Xu', 'Affiliation': 'Department of Interventional Therapy, Nantong Tumor Hospital, Nantong, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Oncology, The 900th Hospital of Joint Logistics Support Force, Fuzhou, China.'}, {'ForeName': 'Cuncai', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': 'Department of Hepatobiliary Interventional, Jiangxi Cancer Hospital, Nanchang, China.'}, {'ForeName': 'Zhenggang', 'Initials': 'Z', 'LastName': 'Ren', 'Affiliation': 'Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yuxian', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': 'Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Hongming', 'Initials': 'H', 'LastName': 'Pan', 'Affiliation': 'Department of Oncology, Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Bangwei', 'Initials': 'B', 'LastName': 'Cao', 'Affiliation': 'Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Weijia', 'Initials': 'W', 'LastName': 'Fang', 'Affiliation': 'Department of Oncology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': ""Department of Hepatopathy, The Sixth People's Hospital of Shenyang, Shenyang, China.""}, {'ForeName': 'Ge', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': 'Department of Internal Medicine-Oncology, Jilin Cancer Hospital, Changchun, China.'}, {'ForeName': 'Zhuang', 'Initials': 'Z', 'LastName': 'Yu', 'Affiliation': 'Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Department of Interventional Therapy Unit, Beijing Cancer Hospital, Beijing, China.'}, {'ForeName': 'Da', 'Initials': 'D', 'LastName': 'Jiang', 'Affiliation': 'Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.'}, {'ForeName': 'Yinying', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Comprehensive Liver Cancer Centre, The Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Huaming', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Interventional Therapy, The Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Jianming', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Digestive Oncology, The Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Bai', 'Affiliation': 'Department of Oncology, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Yunpeng', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Oncology, The First Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Hailan', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': 'Department of Intervention, Fujian Cancer Hospital, Fuzhou, China.'}, {'ForeName': 'Changping', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': ""Department of Medical Oncology, The First People's Hospital of Changzhou, Changzhou, China.""}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Yan', 'Affiliation': 'Clinical Research and Development, Jiangsu Hengrui Medicine, Shanghai, China.'}, {'ForeName': 'Chunlei', 'Initials': 'C', 'LastName': 'Jin', 'Affiliation': 'Clinical Research and Development, Jiangsu Hengrui Medicine, Shanghai, China.'}, {'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Zou', 'Affiliation': 'Clinical Research and Development, Jiangsu Hengrui Medicine, Shanghai, China.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(21)00109-6'] 3206,33978188,"Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","BACKGROUND Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. However, few studies have investigated its effect in healthy older populations. OBJECTIVE The objective of this study was to investigate the effects of citicoline (Cognizin®), on memory in healthy elderly populations with age-associated memory impairment (AAMI). METHODS A total of 100 healthy men and women aged between 50 and 85 y with AAMI participated in this randomized, double-blind, placebo-controlled trial. Participants were randomized to receive placebo (n = 51) or citicoline (n = 49; 500 mg/d) for 12 wk. Memory function was assessed at baseline and end of the intervention (12 wk) using computerized tests (Cambridge Brain Sciences, Ontario, Canada). Safety measurements included adverse events query, body weight, blood pressure, and hematology and metabolic panel. Intent-to-treat analysis was conducted using ANCOVA for the primary and secondary outcome variables with Bonferroni correction for multiple comparisons. RESULTS A total of 99 out of 100 participants completed the study in its entirety. After the 12-wk intervention, participants supplemented with citicoline showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025). Composite memory (secondary outcome), calculated using the scores of 4 memory tests, also significantly improved to a greater extent following citicoline supplementation (mean: 3.78) compared with placebo (mean: 0.72, P = 0.0052). CONCLUSIONS Dietary supplementation of citicoline for 12 wk improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI. The findings suggest that regular consumption of citicoline may be safe and potentially beneficial against memory loss due to aging. This trial was registered at clinicaltrials.gov as NCT03369925.",2021,"After the 12-wk intervention, participants supplemented with citicoline showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025).","['healthy elderly populations with age-associated memory impairment (AAMI', 'healthy older males and females with AAMI', 'healthy older populations', 'A total of 99 out of 100 participants completed the study in its entirety', 'Healthy Older Adults', '12', '100 healthy men and women aged between 50 and 85\xa0y with AAMI participated']","['Citicoline and Memory Function', 'citicoline (Cognizin®', 'citicoline', 'Placebo', 'citicoline (CDP-choline', 'placebo']","['secondary outcomes of episodic memory', 'adverse events query, body weight, blood pressure, and hematology and metabolic panel', 'Memory function', 'overall memory performance, especially episodic memory']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0338657', 'cui_str': 'Age-associated memory impairment'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0233794', 'cui_str': 'Memory impairment'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0303591', 'cui_str': 'Yttrium-85'}]","[{'cui': 'C0010725', 'cui_str': 'Citicoline'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3543841', 'cui_str': 'Query'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1285654', 'cui_str': 'Memory performance'}]",100.0,0.797291,"After the 12-wk intervention, participants supplemented with citicoline showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025).","[{'ForeName': 'Eri', 'Initials': 'E', 'LastName': 'Nakazaki', 'Affiliation': 'Research & Innovation Center, Kyowa Hakko Bio Co., Ltd, Tsukuba, Ibaraki, 305-0841, Japan.'}, {'ForeName': 'Eunice', 'Initials': 'E', 'LastName': 'Mah', 'Affiliation': 'Biofortis Innovation Services, Addison, IL 60101, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Sanoshy', 'Affiliation': 'Biofortis Innovation Services, Addison, IL 60101, USA.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Citrolo', 'Affiliation': 'Scientific and Regulatory Affairs, Kyowa Hakko USA Inc., New York, NY 10016, USA.'}, {'ForeName': 'Fumiko', 'Initials': 'F', 'LastName': 'Watanabe', 'Affiliation': 'Research & Innovation Center, Kyowa Hakko Bio Co., Ltd, Tsukuba, Ibaraki, 305-0841, Japan.'}]",The Journal of nutrition,['10.1093/jn/nxab119'] 3207,33977571,Implants sites with concomitant bone regeneration using a resorbable or non-resorbable membrane result in stable marginal bone levels and similar profilometric outcomes over 5 years.,"OBJECTIVES To assess clinical and radiographic outcomes as well as the profilometric contour alterations of peri-implant hard and soft tissues around single implants treated with simultaneous guided bone regeneration (GBR) at 5 years. MATERIALS AND METHODS Twenty-seven patients presenting with a single tooth gap in the esthetic zone received a two-piece implant. GBR was randomly performed using a resorbable (RES) or a non-resorbable membrane (N-RES) combined with a bone substitute material. Follow-up examinations were performed at baseline (BL = crown insertion), 1 year (FU-1), 3 years (FU-3), and at 5 years (FU-5) including clinical and radiographic parameters as well as profilometric changes. Statistics were performed by means of parametric and nonparametric tests. RESULTS At 5 years, 20 out of 27 patients (9 RES, 11 N-RES) were re-examined. Median values for probing depth changed insignificantly between BL and FU-5 in both groups. The median marginal bone levels were located 0.23 mm (0.06; 0.46; RES) and 0.17 mm (0.13;0.28; N-RES) below the implant shoulder at FU-5 (changes over time p < .05). The calculated median profilometric change between BL and FU-5 was -0.28 mm (-0.53;-0.20; RES; p = .016) and -0.24 mm (-0.43;0.08; N-RES; p = .102; intergroup p = .380). The horizontal bone thickness decreased significantly between re-entry and FU-5 for group RES at all measured levels (p < .05) measuring 0.87 mm (0.0; 2.05) at the implant shoulder, whereas the decrease for group N-RES was insignificant (p = .031) with 0 mm (0; 0.84) at the implant shoulder at 5 years. CONCLUSIONS Implants sites with concomitant GBR using a resorbable or non-resorbable membrane revealed stable marginal bone levels and clinical outcomes. Profilometric changes were clinically negligible over 5 years. The observed change in hard tissue thickness was partially compensated by an increase in soft tissue thickness.",2021,"The horizontal bone thickness decreased significantly between re-entry and FU-5 for group RES at all measured levels (p<0.05 ) measuring 0.87mm (0.0;2.05) at the implant shoulder, whereas the decrease for group N-RES was insignificant (p=0.031) with 0mm (0; 0.84) at the implant shoulder at 5 years. ",['Twenty-seven patients presenting with a single tooth gap in the esthetic zone received a two-piece implant'],"['GBR was randomly performed using a resorbable (RES) or a non-resorbable membrane (N-RES) combined with a bone substitute material', 'simultaneous guided bone regeneration (GBR']","['hard tissue thickness', 'Median values for probing depth', 'soft tissue thickness', 'calculated median profilometric change between BL and FU-5', 'median marginal bone levels', 'horizontal bone thickness']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0005972', 'cui_str': 'Bone Regeneration'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0243003', 'cui_str': 'Bone Substitute'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}]","[{'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205126', 'cui_str': 'Horizontal'}]",27.0,0.0196232,"The horizontal bone thickness decreased significantly between re-entry and FU-5 for group RES at all measured levels (p<0.05 ) measuring 0.87mm (0.0;2.05) at the implant shoulder, whereas the decrease for group N-RES was insignificant (p=0.031) with 0mm (0; 0.84) at the implant shoulder at 5 years. ","[{'ForeName': 'Nadja', 'Initials': 'N', 'LastName': 'Naenni', 'Affiliation': 'Clinic of Reconstructive Dentistry, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Stucki', 'Affiliation': 'Clinic of Reconstructive Dentistry, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Jürg', 'Initials': 'J', 'LastName': 'Hüsler', 'Affiliation': 'Clinic of Reconstructive Dentistry, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Schneider', 'Affiliation': 'Clinic of Reconstructive Dentistry, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Christoph H F', 'Initials': 'CHF', 'LastName': 'Hämmerle', 'Affiliation': 'Clinic of Reconstructive Dentistry, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Ronald E', 'Initials': 'RE', 'LastName': 'Jung', 'Affiliation': 'Clinic of Reconstructive Dentistry, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Thoma', 'Affiliation': 'Clinic of Reconstructive Dentistry, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}]",Clinical oral implants research,['10.1111/clr.13764'] 3208,33974725,"Effects of garlic powder supplementation on metabolic syndrome components, insulin resistance, fatty liver index, and appetite in subjects with metabolic syndrome: A randomized clinical trial.","The prevalence of metabolic syndrome (MetS) is increasing. It is closely linked to nonalcoholic fatty liver disease. Garlic consumption as a strategy for the management of MetS has been suggested. We investigated the effect of garlic supplementation on MetS components, insulin resistance, fatty liver index (FLI), and appetite in subjects with MetS. Ninety subjects were assigned to receive 1,600 mg/d garlic powder or placebo for 3 months. The primary outcomes included MetS components. The secondary outcomes included insulin resistance, FLI, and appetite. Garlic supplementation compared with the placebo led to a significant increase in high density lipoprotein-cholesterol (4.5 vs. -1.8, p < .001) and a significant reduction in waist circumference (-1.3 vs. 0.0, p = .001), diastolic blood pressure (-6.7 vs. 0.0, p < .001), systolic blood pressure (-7.7 vs. 0.5, p < .001), triglyceride (-40.0 vs. 0.1, p < .001), γ-glutamyl transferase (-3.2 vs. 0.6, p = .01), FLI (-5.5 vs. 0.1, p < .001), insulin (-2.9 vs. -1.1, p < .001), homeostatic model of assessment for insulin resistance (-0.5 vs. -0.3, p < .001) and appetite (hunger: -11.7 vs. 1.7, p < .001; fullness: 10.0 vs. 0.3, p = .001; desire to eat: -6.7 vs. 2.1, p < .001; and ability to eat: -11.5 vs. -1.0, p < .001). Garlic improves MetS components, insulin resistance, FLI, and appetite.",2021,"Garlic supplementation compared with the placebo led to a significant increase in high density lipoprotein-cholesterol (4.5 vs. -1.8, p < .001) and a significant reduction in waist circumference (-1.3 vs. 0.0, p = .001), diastolic blood pressure (-6.7 vs. 0.0, p < .001), systolic blood pressure (-7.7 vs. 0.5, p < .001), triglyceride (-40.0 vs. 0.1, p < .001), γ-glutamyl transferase (-3.2 vs. 0.6, p = .01), FLI (-5.5 vs. 0.1, p < .001), insulin (-2.9 vs. -1.1, p < .001), homeostatic model of assessment for insulin resistance (-0.5 vs. -0.3, p < .001) and appetite (hunger: -11.7 vs. 1.7, p < .001; fullness: 10.0 vs. 0.3, p = .001; desire to eat: -6.7 vs. 2.1, p < .001; and ability to eat: -11.5 vs. -1.0, p < .001).","['subjects with metabolic syndrome', 'subjects with MetS. Ninety subjects']","['garlic powder or placebo', 'Garlic consumption', 'garlic powder supplementation', 'Garlic', 'Garlic supplementation', 'placebo', 'garlic supplementation']","['insulin resistance, FLI, and appetite', 'homeostatic model of assessment for insulin resistance', 'MetS components, insulin resistance, fatty liver index (FLI), and appetite', 'systolic blood pressure', 'high density lipoprotein-cholesterol', 'metabolic syndrome components, insulin resistance, fatty liver index, and appetite', 'diastolic blood pressure', 'waist circumference', 'γ-glutamyl transferase', 'appetite', 'MetS components', 'MetS components, insulin resistance, FLI, and appetite', 'FLI', 'triglyceride']","[{'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C3816959', 'cui_str': '90'}]","[{'cui': 'C1119842', 'cui_str': 'GARLIC POWDER'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0331590', 'cui_str': 'Allium ameloprasum'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0015695', 'cui_str': 'Fatty Liver'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0678107', 'cui_str': 'Glutamyl transferase'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",90.0,0.411871,"Garlic supplementation compared with the placebo led to a significant increase in high density lipoprotein-cholesterol (4.5 vs. -1.8, p < .001) and a significant reduction in waist circumference (-1.3 vs. 0.0, p = .001), diastolic blood pressure (-6.7 vs. 0.0, p < .001), systolic blood pressure (-7.7 vs. 0.5, p < .001), triglyceride (-40.0 vs. 0.1, p < .001), γ-glutamyl transferase (-3.2 vs. 0.6, p = .01), FLI (-5.5 vs. 0.1, p < .001), insulin (-2.9 vs. -1.1, p < .001), homeostatic model of assessment for insulin resistance (-0.5 vs. -0.3, p < .001) and appetite (hunger: -11.7 vs. 1.7, p < .001; fullness: 10.0 vs. 0.3, p = .001; desire to eat: -6.7 vs. 2.1, p < .001; and ability to eat: -11.5 vs. -1.0, p < .001).","[{'ForeName': 'Abbas Ali', 'Initials': 'AA', 'LastName': 'Sangouni', 'Affiliation': 'Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Alizadeh', 'Affiliation': 'Department of Nutrition, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Atena', 'Initials': 'A', 'LastName': 'Jamalzehi', 'Affiliation': 'Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Parastouei', 'Affiliation': 'Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.7146'] 3209,33974712,"Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial.","BACKGROUND Studying the differential impact of aspirin and other nonsteroidal anti-inflammatory drugs across the stages of colorectal neoplasia from early adenoma to cancer is critical for understanding the benefits of these widely used drugs. METHODS With 13 years of follow-up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. With multivariable-adjusted models, odds ratio (ORs) and 95% confidence intervals (CIs) for adenoma incidence and recurrence and hazard ratios (HRs) and 95% CIs for incident CRC were determined. RESULTS The authors observed a significantly reduced risk of incident adenoma with ibuprofen use (≥30 vs <4 pills per month: OR, 0.76 [95% CI, 0.60-0.95]; P trend = .04), particularly advanced adenoma (OR, 0.48 [95% CI, 0.28-0.83]; P trend = .005). Among those with a previous adenoma detected through screening, aspirin use was associated with a decreased risk of advanced recurrent adenoma (≥30 vs <4 pills per month: OR, 0.56 [95% CI, 0.36-0.87]; P trend = 0.006). Both aspirin (HR, 0.88 [95% CI, 0.81-0.96]; P trend <.0001) and ibuprofen use (HR, 0.81 [95% CI, 0.70-0.93); P trend = 0.003) ≥30 versus <4 pills per month were significantly associated with reduced CRC risk. CONCLUSIONS In this large prospective study with long-term follow-up, a beneficial role for not only aspirin, but also ibuprofen, in preventing advanced adenoma and curbing progression to recurrence and cancer among older adults was observed.",2021,"Among those with a previous adenoma detected through screening, aspirin use was associated with a decreased risk of advanced recurrent adenoma (≥30 vs <4 pills per month: OR, 0.56 [95% CI, 0.36-0.87]; P trend = 0.006).","['With 13 years of follow-up', 'incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial']","['ibuprofen', 'aspirin', 'Aspirin, ibuprofen', 'aspirin and ibuprofen']","['reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer', 'risk of advanced recurrent adenoma', 'adenoma incidence and recurrence and hazard ratios (HRs', 'risk of incident adenoma', 'particularly advanced adenoma']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1302401', 'cui_str': 'Adenoma of large intestine'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.105214,"Among those with a previous adenoma detected through screening, aspirin use was associated with a decreased risk of advanced recurrent adenoma (≥30 vs <4 pills per month: OR, 0.56 [95% CI, 0.36-0.87]; P trend = 0.006).","[{'ForeName': 'Kenechukwu', 'Initials': 'K', 'LastName': 'Chudy-Onwugaje', 'Affiliation': 'Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Wen-Yi', 'Initials': 'WY', 'LastName': 'Huang', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'L Joseph', 'Initials': 'LJ', 'LastName': 'Su', 'Affiliation': 'Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Purdue', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Christine C', 'Initials': 'CC', 'LastName': 'Johnson', 'Affiliation': 'Department of Public Health Sciences, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.'}, {'ForeName': 'Lingxiao', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Hormuzd A', 'Initials': 'HA', 'LastName': 'Katki', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Kathryn Hughes', 'Initials': 'KH', 'LastName': 'Barry', 'Affiliation': 'Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Sonja I', 'Initials': 'SI', 'LastName': 'Berndt', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.'}]",Cancer,['10.1002/cncr.33623'] 3210,33979464,"Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial.","Xiyanping (XYP) is a Chinese herbal medicine used in the clinic to treat respiratory infection and pneumonia. Recent evidence identified XYP as a potential inhibitor of severe acute respiratory syndrome coronavirus 2, implying XYP as a possible treatment for the coronavirus disease 2019 (COVID-19). Here, we conducted a prospective, multicenter, open-label and randomized controlled trial to evaluate the safety and effectiveness of XYP injection in patients with mild to moderate COVID-19. We consecutively recruited 130 COVID-19 patients with mild to moderate symptoms from five study sites, and randomized them in 1:1 ratio to receive XYP injection in combination with standard therapy or receive standard supportive therapy alone. We found that XYP injection significantly reduced the time to cough relief, fever resolution and virus clearance. Less patients receiving XYP injection experienced disease progression to the severe stage during the treatment process. No severe adverse events were reported during the study. Taken together, XYP injection is safe and effective in improving the recovery of patients with mild to moderate COVID-19. However, further studies are warranted to evaluate the efficacy of XYP in an expanded cohort comprising COVID-19 patients at different disease stages.",2021,No severe adverse events were reported during the study.,"['COVID-19', '130 COVID-19 patients with mild to moderate symptoms from five study sites', 'patients with mild to moderate COVID-19']","['Xiyanping injection', 'Xiyanping (XYP', 'XYP injection in combination with standard therapy or receive standard supportive therapy alone', 'XYP injection']","['disease progression', 'safety and effectiveness', 'severe adverse events', 'Efficacy and safety', 'time to cough relief, fever resolution and virus clearance']","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0344211', 'cui_str': 'Support'}]","[{'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}]",,0.0663282,No severe adverse events were reported during the study.,"[{'ForeName': 'Xin-Yi', 'Initials': 'XY', 'LastName': 'Zhang', 'Affiliation': 'Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Lang', 'Initials': 'L', 'LastName': 'Lv', 'Affiliation': 'Department of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China.'}, {'ForeName': 'Yu-Long', 'Initials': 'YL', 'LastName': 'Zhou', 'Affiliation': 'Department of Respiratory Diseases, The Ninth Hospital of Nanchang, Nanchang, China.'}, {'ForeName': 'Liang-Dong', 'Initials': 'LD', 'LastName': 'Xie', 'Affiliation': ""Department of Critical Care Medicine, The Fifth People's Hospital of Ganzhou, Ganzhou, China.""}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Xu', 'Affiliation': ""Department of Respiratory Diseases, Fengcheng People's Hospital, Fengcheng, China.""}, {'ForeName': 'Xiao-Fan', 'Initials': 'XF', 'LastName': 'Zou', 'Affiliation': ""Department of Respiratory Diseases, Ji'an Central People's Hospital, Ji'an, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Department of Respiratory Diseases, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Tian', 'Affiliation': 'Department of Respiratory Diseases, The Ninth Hospital of Nanchang, Nanchang, China.'}, {'ForeName': 'Jia-Liang', 'Initials': 'JL', 'LastName': 'Fan', 'Affiliation': ""Department of Respiratory Diseases, Ji'an Central People's Hospital, Ji'an, China.""}, {'ForeName': 'Hai-Wei', 'Initials': 'HW', 'LastName': 'Fan', 'Affiliation': 'Department of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China.'}, {'ForeName': 'Yi-Xi', 'Initials': 'YX', 'LastName': 'Yang', 'Affiliation': 'Department of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China.'}, {'ForeName': 'Xiao-Qun', 'Initials': 'XQ', 'LastName': 'Ye', 'Affiliation': 'Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.'}]",Phytotherapy research : PTR,['10.1002/ptr.7141'] 3211,33982320,Autogenous Mineralized Dentin versus Xenograft granules in Ridge Preservation for Delayed Implantation in Post-extraction Sites: A Randomized controlled clinical trial with an 18 months follow-up.,"OBJECTIVES To test primary stability of delayed implants placed in post-extraction ridges preserved with autogenous mineralized dentin matrix (MDM) versus xenograft granules. Clinical, histological and pain experience outcomes were further assessed. MATERIAL AND METHODS From March 2018 to July 2020, patients requiring ridge preservation in preparation for delayed implant placement in post-extraction sites were included. Participants were randomly allocated to either the test (MDM) or control group (xenograft granules) prior to ridge preservation. Visual analogue scale and analgesic consumption were measured every day for a week. Six months after preservation, trephine cores were harvested for histomorphometry prior to implant placement. Implants were then placed, and implant stability was measured immediately as well as two months after placement. Marginal bone loss and presence of mucositis/peri-implantitis were registered up to 18 months after prosthetic loading. RESULTS Fifty-two patients (66 implants) completed the study. MDM and xenograft groups presented similar primary (77.1 ± 6.9 versus. 77.0 versus. 5.9) and secondary (81.8 ± 5.1 versus. 80.1 ± 3.8) implant stabilities. The percentage of newly formed bone in MDM (47.3%) was significantly higher than xenograft (34.9%) (p < .001), and the proportion of residual graft was significantly lower (12.2% in MDM and 22.1% in xenograft) (p < .001). No significant differences were found as far as clinical, radiographic and patient-related outcomes. CONCLUSIONS Implants placed in sites preserved with MDM had similar primary stability in comparison to xenograft granules. MDM showed a significantly higher quantity of newly formed bone and lower amount of residual graft in histomorphometry results and equal clinical and patient-related outcomes.",2021,MDM showed a significantly higher quantity of newly formed bone and lower amount of residual graft in histomorphometry results and equal clinical and patient-related outcomes.,"['Delayed Implantation in Postextraction Sites', 'Fifty-two patients (66 implants) completed the study', 'From March 2018 to July 2020, patients requiring ridge preservation in preparation for delayed implant placement in post-extraction sites were included']","['Autogenous Mineralized Dentin versus Xenograft granules', 'autogenous mineralized dentin matrix (MDM) versus xenograft granules', 'MDM', 'xenograft', 'test (MDM) or control group (xenograft granules) prior to ridge preservation']","['proportion of residual graft', 'Visual analogue scale and analgesic consumption', 'percentage of newly formed bone in MDM', 'Marginal bone loss, and presence of mucositis/peri-implantitis']","[{'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0332243', 'cui_str': 'Ridging'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0443145', 'cui_str': 'Autogenous'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0520484', 'cui_str': 'Xenogeneic transplantation'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0332243', 'cui_str': 'Ridging'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}]","[{'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}, {'cui': 'C2936258', 'cui_str': 'Dental peri-implantitis'}]",,0.104966,MDM showed a significantly higher quantity of newly formed bone and lower amount of residual graft in histomorphometry results and equal clinical and patient-related outcomes.,"[{'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Santos', 'Affiliation': 'Periodontology Department, Clinical Research Unit (CRU), Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz (IUEM), Caparica, Portugal.'}, {'ForeName': 'João', 'Initials': 'J', 'LastName': 'Botelho', 'Affiliation': 'Periodontology Department, Clinical Research Unit (CRU), Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz (IUEM), Caparica, Portugal.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Machado', 'Affiliation': 'Periodontology Department, Clinical Research Unit (CRU), Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz (IUEM), Caparica, Portugal.'}, {'ForeName': 'Gonçalo', 'Initials': 'G', 'LastName': 'Borrecho', 'Affiliation': 'Clinical Research Unit (CRU), CiiEM, IUEM, Caparica, Portugal.'}, {'ForeName': 'Luís', 'Initials': 'L', 'LastName': 'Proença', 'Affiliation': 'Quantitative Methods for Health Research (MQIS), CiiEM, IUEM, Caparica, Portugal.'}, {'ForeName': 'José João', 'Initials': 'JJ', 'LastName': 'Mendes', 'Affiliation': 'Clinical Research Unit (CRU), CiiEM, IUEM, Caparica, Portugal.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Mascarenhas', 'Affiliation': 'Oral and Biomedical Sciences Research Unit, Faculty of Dental Medicine, University of Lisbon, Lisbon, Portugal.'}, {'ForeName': 'Gil', 'Initials': 'G', 'LastName': 'Alcoforado', 'Affiliation': 'Periodontology Department, Clinical Research Unit (CRU), Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz (IUEM), Caparica, Portugal.'}]",Clinical oral implants research,['10.1111/clr.13765'] 3212,33979838,"Maternal Overweight and Obesity during Pregnancy Are Associated with Neonatal, but Not Maternal, Hepcidin Concentrations.","BACKGROUND Overweight or obesity among pregnant women may compromise maternal and neonatal iron status by upregulating hepcidin. OBJECTIVES This study determined the association of 1) maternal and neonatal iron status with maternal and neonatal hepcidin concentrations, and 2) maternal prepregnancy weight status with maternal and neonatal hepcidin concentrations. METHODS We examined hematologic data from 405 pregnant women and their infants from the placebo treatment group of a pregnancy iron supplementation trial in rural China. We measured hepcidin, serum ferritin (SF), soluble transferrin receptor (sTfR), and high-sensitivity C-reactive protein in maternal blood samples at mid-pregnancy and in cord blood at delivery. We used regression analysis to examine the association of maternal prepregnancy overweight or obese status with maternal hepcidin concentration in mid-pregnancy and cord hepcidin concentrations. We also used path analysis to examine mediation of the association of maternal prepregnancy overweight or obese status with maternal iron status by maternal hepcidin, as well as with neonatal hepcidin by neonatal iron status. RESULTS Maternal iron status was positively correlated with maternal hepcidin at mid-pregnancy (SF: r = 0.63, P < 0.001; sTfR: r = -0.37, P < 0.001). Neonatal iron status was also positively correlated with cord hepcidin (SF: r = 0.61, P < 0.001; sTfR: r = -0.39, P < 0.001). In multiple linear regression models, maternal prepregnancy overweight or obese status was not associated with maternal hepcidin at mid-pregnancy but was associated with lower cord hepcidin (coefficient = -0.21, P = 0.004). Using path analysis, we observed a significant indirect effect of maternal prepregnancy overweight or obese status on cord hepcidin, mediated by neonatal iron status. CONCLUSIONS In both pregnant women and neonates, hepcidin was responsive to iron status. Maternal prepregnancy overweight status, with or without including obese women, was associated with lower cord blood hepcidin, likely driven by lower iron status among the neonates of these mothers.",2021,Neonatal iron status was also positively correlated with cord hepcidin,"['Overweight or obesity among pregnant women', '405 pregnant women and their infants from the placebo treatment group of a pregnancy iron supplementation trial in rural China', 'maternal prepregnancy overweight or obese status with maternal iron status by maternal hepcidin, as well as with neonatal hepcidin by neonatal iron status', 'maternal prepregnancy overweight or obese status with maternal hepcidin concentration in mid-pregnancy and cord hepcidin concentrations']",['sTfR'],"['maternal hepcidin', 'Maternal iron status', 'cord hepcidin', 'hepcidin, serum ferritin (SF), soluble transferrin receptor (sTfR), and high-sensitivity C-reactive protein in maternal blood samples at mid-pregnancy and in cord blood at delivery', 'Neonatal iron status', 'Maternal Overweight and Obesity during Pregnancy']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C4517768', 'cui_str': '405'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}]","[{'cui': 'C1116139', 'cui_str': 'Transferrin receptor, soluble'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C0696113', 'cui_str': 'Serum ferritin measurement'}, {'cui': 'C1116139', 'cui_str': 'Transferrin receptor, soluble'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0162371', 'cui_str': 'Cord blood'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]",405.0,0.13342,Neonatal iron status was also positively correlated with cord hepcidin,"[{'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Jones', 'Affiliation': 'Department of Nutritional Sciences, School of Public Health, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Shi', 'Affiliation': 'Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Nathalie J', 'Initials': 'NJ', 'LastName': 'Lambrecht', 'Affiliation': 'Department of Nutritional Sciences, School of Public Health, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Yaping', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Jingmin', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Margit', 'Initials': 'M', 'LastName': 'Burmeister', 'Affiliation': 'Department of Computational Medicine & Bioinformatics, Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Betsy', 'Initials': 'B', 'LastName': 'Lozoff', 'Affiliation': 'Department of Pediatrics, Medical School, University of Michigan, Ann Arbor, MI, USA.'}]",The Journal of nutrition,['10.1093/jn/nxab133'] 3213,33985942,"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.","OBJECTIVES To evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA). METHODS In this randomised, double-blind, placebo-controlled, phase IIb study, patients with active PsA were randomised 1:1:1:1:1 to tildrakizumab 200 mg every 4 weeks (Q4W); tildrakizumab 200, 100 or 20 mg Q12W; or placebo Q4W. Patients receiving tildrakizumab 20 mg or placebo switched to tildrakizumab 200 mg Q12W at W24; treatment continued to W52. The primary efficacy endpoint was proportion of patients with ACR20 response (≥20% improvement by American College of Rheumatology criteria) at W24. Secondary efficacy endpoints were assessed without adjustment for multiplicity. Safety was evaluated from treatment-emergent adverse events (TEAEs). RESULTS 391/500 patients screened were randomised and treated. At W24, 71.4%-79.5% of tildrakizumab-treated versus 50.6% of placebo-treated patients achieved ACR20 (all p<0.01). Patients receiving tildrakizumab versus placebo generally achieved higher rates of ACR50, Disease Activity Score in 28 joints with C reactive protein <3.2, minimal disease activity and 75%/90%/100% improvement from baseline Psoriasis Area and Severity Index responses at W24 and through W52. Improvement in dactylitis and enthesitis was not observed; results were mixed for other outcomes. Responses in patients switched to tildrakizumab 200 mg at W24 were consistent with treatment from baseline. TEAEs and serious TEAEs occurred in 64.5% and 3.3%, respectively, of all patients through W52 and were comparable among treatment arms. CONCLUSIONS Tildrakizumab treatment significantly improved joint and skin manifestations of PsA other than dactylitis and enthesitis. Treatment was generally well tolerated through W52. Clinicaltrials.gov NCT02980692.",2021,"Patients receiving tildrakizumab versus placebo generally achieved higher rates of ACR50, Disease Activity Score in 28 joints with C reactive protein <3.2, minimal disease activity and 75%/90%/100% improvement from baseline Psoriasis Area and Severity Index responses at W24 and through W52.","['391/500 patients screened were randomised and treated', 'patients with active psoriatic arthritis', 'patients with active PsA', 'patients with psoriatic arthritis (PsA']","['tildrakizumab', 'tildrakizumab 200 mg Q12W at W24; treatment continued to W52', 'anti-interleukin-23p19 monoclonal antibody tildrakizumab', 'tildrakizumab 200 mg every 4 weeks (Q4W); tildrakizumab', 'Tildrakizumab', 'placebo', 'placebo Q4W. Patients receiving tildrakizumab 20 mg or placebo', 'tildrakizumab versus placebo']","['efficacy and safety', 'proportion of patients with ACR20 response', 'Efficacy and safety', 'dactylitis and enthesitis', 'rates of ACR50, Disease Activity Score', 'joint and skin manifestations', 'baseline Psoriasis Area and Severity Index responses', 'TEAEs and serious TEAEs', 'Safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0003872', 'cui_str': 'Psoriatic arthritis'}]","[{'cui': 'C4043954', 'cui_str': 'tildrakizumab'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}, {'cui': 'C1275555', 'cui_str': 'Every four weeks'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0239161', 'cui_str': 'Dactylitis'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0037285', 'cui_str': 'Skin Manifestations'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.285548,"Patients receiving tildrakizumab versus placebo generally achieved higher rates of ACR50, Disease Activity Score in 28 joints with C reactive protein <3.2, minimal disease activity and 75%/90%/100% improvement from baseline Psoriasis Area and Severity Index responses at W24 and through W52.","[{'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Mease', 'Affiliation': 'Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA pmease@philipmease.com.'}, {'ForeName': 'Saima', 'Initials': 'S', 'LastName': 'Chohan', 'Affiliation': 'Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, Arizona, USA.'}, {'ForeName': 'Ferran J Garcia', 'Initials': 'FJG', 'LastName': 'Fructuoso', 'Affiliation': 'Hospital CIMA Sanitas, Barcelona, Spain.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Luggen', 'Affiliation': 'Cincinnati Rheumatic Disease Study Group, Cincinnati, Ohio, USA.'}, {'ForeName': 'Proton', 'Initials': 'P', 'LastName': 'Rahman', 'Affiliation': 'Medicine, Eastern Health and Memorial University, St. Johns, Newfoundland, Canada.'}, {'ForeName': 'Siba P', 'Initials': 'SP', 'LastName': 'Raychaudhuri', 'Affiliation': 'Division of Rheumatology, Allergy and Clinical Immunology, University of California School of Medicine, Davis, California, USA.'}, {'ForeName': 'Richard C', 'Initials': 'RC', 'LastName': 'Chou', 'Affiliation': 'Division of Allergy, Immunology and Rheumatology, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York, USA.'}, {'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Mendelsohn', 'Affiliation': 'Sun Pharmaceutical Industries, Princeton, New Jersey, USA.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Rozzo', 'Affiliation': 'Sun Pharmaceutical Industries, Princeton, New Jersey, USA.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Gottlieb', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2020-219014'] 3214,33983844,MOSES™ Technology for Holmium Laser Enucleation of the Prostate: A Prospective Double-Blind Randomized Control Trial. Letter.,,2021,,['of the Prostate'],['Holmium Laser Enucleation'],[],"[{'cui': 'C0033572', 'cui_str': 'Prostatic'}]","[{'cui': 'C0441085', 'cui_str': 'Holmium:YAG laser device'}, {'cui': 'C0014392', 'cui_str': 'Enucleation'}]",[],,0.422213,,"[{'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Yuan', 'Affiliation': 'Department of Urology, the third Medical Center, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Shengfeng', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Banggao', 'Initials': 'B', 'LastName': 'Huang', 'Affiliation': ""Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China.""}, {'ForeName': 'Zhihui', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': ""Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China.""}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Department of Urology, Tongji Hospital, Shanghai, China.'}, {'ForeName': 'Jianxing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Urology, Beijing Tsinghua Changgung Hospital, School of Medicine, Tsinghua University, Beijing, China.'}, {'ForeName': 'Weijun', 'Initials': 'W', 'LastName': 'Fu', 'Affiliation': 'Department of Urology, the third Medical Center, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Urology, the third Medical Center, Chinese PLA General Hospital, Beijing, China.'}]",The Journal of urology,['10.1097/JU.0000000000001881'] 3215,33983843,MOSES™ Technology for Holmium Laser Enucleation of the Prostate: A Prospective Double-Blind Randomized Control Trial. Reply.,,2021,,['of the Prostate'],['Holmium Laser Enucleation'],[],"[{'cui': 'C0033572', 'cui_str': 'Prostatic'}]","[{'cui': 'C0441085', 'cui_str': 'Holmium:YAG laser device'}, {'cui': 'C0014392', 'cui_str': 'Enucleation'}]",[],,0.392886,,"[{'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Kavoussi', 'Affiliation': 'Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Miller', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, Tennessee.'}]",The Journal of urology,['10.1097/JU.0000000000001882'] 3216,33983840,The Effects of Early Oropharyngeal Administration of Microdosed Colostrum on Feeding Status in Ventilated Extremely Low-Birth-Weight Infants.,"Background: For extremely low-birth-weight infants (ELBWIs), mechanical ventilation and total parenteral nutrition are generally required in the early stages and lose the protective effect of early gastrointestinal nutrition of colostrum. We conducted a prospective randomized controlled trial to explore the effectiveness of early colostrum oropharyngeal administration on the feeding status of ELBWIs on mechanical ventilation. Materials and Methods: We randomly divided mechanically ventilated ELBWIs into an intervention group and a control group. In the intervention group, we provided oropharyngeal administration of colostrum during mechanical ventilation. The first colostrum oropharyngeal administration ended within 24 hours of birth. In the control group, we gave colostrum only for gastrointestinal nutrition, and other interventions were the same as for the intervention group. We collected the 1st and 6th day of life airway secretions and urine specimens from both groups. We recorded feeding status, including corrected gestational age at onset of enteral nutrition, corrected gestational age of no gastric retention during feeding, corrected gestational age of full enteral nutrition, corrected gestational age of sucking began, and corrected gestational age of per oral feeding. We also recorded growth of body mass, the incidence of feeding intolerance, and necrotizing enterocolitis (NEC). Results: On the 6th day of life, concentrations of secretory immunoglobulin A, and lactoferrin in airway secretions and urine of the intervention group were significantly higher than those of the control group ( p  < 0.05). The intervention group showed younger corrected gestational age of no gastric retention during feeding, corrected gestational age of full enteral nutrition, the corrected gestational age of sucking began and per oral feeding than those in the control group ( p  < 0.05). The day of recovery to birth weight was earlier than those in the control group ( p  < 0.05). The rate of feeding intolerance and NEC incidence in the intervention group was significantly lower than in the control group ( p  < 0.05). Conclusions: Early oropharyngeal administration of colostrum improves immune function of the gastrointestinal tract and the systemic anti-infective capability in ELBWI on mechanical ventilation, promoting the maturity of gastrointestinal function, improving feeding condition, and reducing the risk of feeding intolerance and NEC.",2021,The rate of feeding intolerance and NEC incidence in the intervention group was significantly lower than in the control group ( p  < 0.05). ,"['Ventilated Extremely Low-Birth-Weight Infants', 'corrected gestational age at onset of enteral nutrition, corrected gestational age of no gastric retention during feeding, corrected gestational age of full enteral nutrition, corrected gestational age of sucking began, and corrected gestational age of per oral feeding']",['Microdosed Colostrum'],"['rate of feeding intolerance and NEC incidence', 'younger corrected gestational age of no gastric retention during feeding, corrected gestational age of full enteral nutrition, the corrected gestational age of sucking began and per oral feeding', 'recovery to birth weight', 'life, concentrations of secretory immunoglobulin A, and lactoferrin in airway secretions and urine', 'growth of body mass, the incidence of feeding intolerance, and necrotizing enterocolitis (NEC']","[{'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0456065', 'cui_str': 'Extremely low birth weight infant'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0585136', 'cui_str': 'Gastric retention'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}]","[{'cui': 'C0009413', 'cui_str': 'Colostrum'}]","[{'cui': 'C1820738', 'cui_str': 'Feeding intolerance'}, {'cui': 'C0206695', 'cui_str': 'Neuroendocrine carcinoma'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0585136', 'cui_str': 'Gastric retention'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0233927', 'cui_str': 'Sucking'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0020838', 'cui_str': 'Immunoglobulin A secretory'}, {'cui': 'C0022942', 'cui_str': 'Lactoferrin'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0231199', 'cui_str': 'Intolerance'}, {'cui': 'C0014356', 'cui_str': 'Enterocolitis'}]",,0.0206383,The rate of feeding intolerance and NEC incidence in the intervention group was significantly lower than in the control group ( p  < 0.05). ,"[{'ForeName': 'Xiao-Chun', 'Initials': 'XC', 'LastName': 'Chen', 'Affiliation': ""Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.""}, {'ForeName': 'Yan-Fen', 'Initials': 'YF', 'LastName': 'Tong', 'Affiliation': ""Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.""}, {'ForeName': 'Zi-Min', 'Initials': 'ZM', 'LastName': 'Han', 'Affiliation': ""Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.""}, {'ForeName': 'Zhen-Lang', 'Initials': 'ZL', 'LastName': 'Lin', 'Affiliation': ""Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.""}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0244'] 3217,33990951,Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.,"OBJECTIVE To evaluate the efficacy and safety of lasmiditan in Japanese adults with migraine. BACKGROUND Global clinical studies have demonstrated the efficacy and safety of lasmiditan in the acute treatment of migraine. METHODS This was a multicenter, randomized, double-blind, placebo-controlled, phase 2 study in Japan (NCT03962738), which enrolled adults with migraine with or without aura. Participants were randomized 7:3:7:6 to placebo, lasmiditan 50 mg, 100 mg, or 200 mg to be self-administered orally within 4 h of onset of a single moderate-to-severe migraine attack. Participants recorded their response to treatment prior to dosing and for 48 h postdose. The primary endpoint was headache pain freedom at 2 h postdose. RESULTS Participants (N = 846) were randomized and treated (N = 691, safety; N = 682, modified intent-to-treat). At 2 h postdose, a significantly higher proportion of participants were headache pain-free in the lasmiditan 200 mg (40.8%, 73/179; odds ratio 3.46 [95% confidence interval 2.17 to 5.54]; p < 0.001; primary objective) and 100 mg groups (32.4%, 67/207; odds ratio 2.41 [1.51 to 3.83]; p < 0.001) compared with the placebo group (16.6%, 35/211), whereas the lasmiditan 50 mg group had a numerically higher proportion of participants headache pain-free (23.5%, 20/85; odds ratio 1.55 [0.83 to 2.87]; p = 0.167) compared with placebo. A statistically significant linear dose-response relationship for pain freedom was achieved at 2 h by a Cochran-Armitage trend test (p < 0.001). Lasmiditan treatment was also associated with headache pain relief, most bothersome symptom freedom, and improvement on disability and Patient Global Impression of Change outcomes. The majority of treatment-emergent adverse events were mild and of short duration, the most common of which were dizziness (39.4%; 188/477), somnolence (19.3%; 92/477), and malaise (10.5%; 50/477) in all lasmiditan groups, with no serious adverse events reported. CONCLUSIONS Lasmiditan was well tolerated and effective for the acute treatment of Japanese patients with migraine, consistent with global phase 3 studies.",2021,"Lasmiditan treatment was also associated with headache pain relief, most bothersome symptom freedom, and improvement on disability and Patient Global Impression of Change outcomes.","['Japan (NCT03962738), which enrolled adults with migraine with or without aura', 'Japanese adults with migraine', 'Japanese patients', 'Participants (N\xa0=\xa0846', 'Japanese patients with migraine']","['lasmiditan', 'placebo', 'placebo, lasmiditan 50\xa0mg, 100\xa0mg, or 200\xa0mg to be self-administered orally within 4\xa0h of onset of a single moderate-to-severe migraine attack']","['efficacy and safety', 'malaise', 'disability and Patient Global Impression of Change outcomes', 'tolerated and effective', 'somnolence', 'headache pain-free', 'pain freedom', 'headache pain freedom', 'headache pain relief', 'dizziness']","[{'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0236018', 'cui_str': 'Aura'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0004063', 'cui_str': 'Assault'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0908489', 'cui_str': 'Pain-Free'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}]",846.0,0.65857,"Lasmiditan treatment was also associated with headache pain relief, most bothersome symptom freedom, and improvement on disability and Patient Global Impression of Change outcomes.","[{'ForeName': 'Fumihiko', 'Initials': 'F', 'LastName': 'Sakai', 'Affiliation': 'Saitama International Headache Center, Saitama Neuropsychiatric Institute, Saitama, Japan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Takeshima', 'Affiliation': 'Department of Neurology, Tominaga Hospital, Kyoto, Japan.'}, {'ForeName': 'Gosuke', 'Initials': 'G', 'LastName': 'Homma', 'Affiliation': 'Eli Lilly Japan K.K., Kobe, Japan.'}, {'ForeName': 'Yuka', 'Initials': 'Y', 'LastName': 'Tanji', 'Affiliation': 'Eli Lilly Japan K.K., Kobe, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Katagiri', 'Affiliation': 'Eli Lilly Japan K.K., Kobe, Japan.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Komori', 'Affiliation': 'Eli Lilly Japan K.K., Kobe, Japan.'}]",Headache,['10.1111/head.14122'] 3218,34011161,Home-based exercise program for older adults with Motoric Cognitive Risk syndrome: feasibility study.,"Aim: We developed a home-based goal-directed exercise program with telephonic coaching to overcome barriers to exercise participation in cognitively impaired older adults. Methods: Six patients with Motoric Cognitive Risk syndrome at high risk for dementia were enrolled, three assigned to goal-directed exercises and three to stretching exercises. All participants underwent an in-person training session followed by a session at home with a telephonic coach. Sessions were supervised by a physiatrist, and exercise programs were personalized. Results: In-person training and remote telephonic coaching support promoted adherence. There were no adverse effects and interventions were rated highly. Participant and logistical barriers were identified that can inform design of home-based clinical trials. Conclusion: Home-based exercises are safe and feasible in older adults with Motoric Cognitive Risk.",2021,There were no adverse effects and interventions were rated highly.,"['older adults with Motoric Cognitive Risk', 'cognitively impaired older adults', 'older adults with Motoric Cognitive Risk syndrome', 'Six patients with Motoric Cognitive Risk\xa0syndrome at high risk for dementia']","['home-based goal-directed exercise program with telephonic coaching', 'Home-based exercises', 'stretching exercises', 'Home-based exercise program', 'person training and remote telephonic coaching support']",[],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0183683', 'cui_str': 'Support'}]",[],6.0,0.033038,There were no adverse effects and interventions were rated highly.,"[{'ForeName': 'Anne Felicia', 'Initials': 'AF', 'LastName': 'Ambrose', 'Affiliation': 'Departments of Rehabilitation Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Gulley', 'Affiliation': 'Departments of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Verghese', 'Affiliation': 'Albert Einstein College of Medicine Medical School, Bronx, NY 10461, USA.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Verghese', 'Affiliation': 'Departments of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.'}]",Neurodegenerative disease management,['10.2217/nmt-2020-0064'] 3219,34389547,Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland).,"OBJECTIVE To determine whether the addition of placental growth factor (PlGF) measurement to current clinical assessment of women with suspected pre-eclampsia before 37 weeks' gestation would reduce maternal morbidity without increasing neonatal morbidity. DESIGN Stepped wedge cluster randomised control trial from 29 June 2017 to 26 April 2019. SETTING National multisite trial in seven maternity hospitals throughout the island of Ireland PARTICIPANTS: Women with a singleton pregnancy between 20 +0 to 36 +6 weeks' gestation, with signs or symptoms suggestive of evolving pre-eclampsia. Of the 5718 women screened, 2583 were eligible and 2313 elected to participate. INTERVENTION Participants were assigned randomly to either usual care or to usual care plus the addition of point-of-care PlGF testing based on the randomisation status of their maternity hospital at the time point of enrolment. MAIN OUTCOMES MEASURES Co-primary outcomes of composite maternal morbidity and composite neonatal morbidity. Analysis was on an individual participant level using mixed-effects Poisson regression adjusted for time effects (with robust standard errors) by intention-to-treat. RESULTS Of the 4000 anticipated recruitment target, 2313 eligible participants (57%) were enrolled, of whom 2219 (96%) were included in the primary analysis. Of these, 1202 (54%) participants were assigned to the usual care group, and 1017 (46%) were assigned the intervention of additional point-of-care PlGF testing. The results demonstrate that the integration of point-of-care PlGF testing resulted in no evidence of a difference in maternal morbidity-457/1202 (38%) of women in the control group versus 330/1017 (32%) of women in the intervention group (adjusted risk ratio (RR) 1.01 (95% CI 0.76 to 1.36), P=0.92)-or in neonatal morbidity-527/1202 (43%) of neonates in the control group versus 484/1017 (47%) in the intervention group (adjusted RR 1.03 (0.89 to 1.21), P=0.67). CONCLUSIONS This was a pragmatic evaluation of an interventional diagnostic test, conducted nationally across multiple sites. These results do not support the incorporation of PlGF testing into routine clinical investigations for women presenting with suspected preterm pre-eclampsia, but nor do they exclude its potential benefit. TRIAL REGISTRATION ClinicalTrials.gov NCT02881073.",2021,The results demonstrate that the integration of point-of-care PlGF testing resulted in no evidence of a difference in maternal morbidity-457/1202 (38%) of women in the control group versus 330/1017 (32%) of women in the intervention group (adjusted risk ratio (RR) 1.01,"['1202 (54%) participants were assigned to the usual care group, and 1017 (46', '29 June 2017 to 26 April 2019', ""Women with a singleton pregnancy between 20 +0 to 36 +6 weeks' gestation, with signs or symptoms suggestive of evolving pre-eclampsia"", 'women with suspected pre-eclampsia', '5718 women screened, 2583 were eligible and 2313 elected to participate', ""women with suspected pre-eclampsia before 37 weeks' gestation"", '2313 eligible participants (57%) were enrolled, of whom 2219 (96%) were included in the primary analysis', 'National multisite trial in seven maternity hospitals throughout the island of Ireland PARTICIPANTS', 'women presenting with suspected preterm pre-eclampsia']","['placental growth factor (PlGF) measurement', 'usual care or to usual care plus the addition of point-of-care PlGF testing']","['composite maternal morbidity and composite neonatal morbidity', 'maternal morbidity']","[{'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of'}, {'cui': 'C0332253', 'cui_str': 'Evolving'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0020010', 'cui_str': 'Maternity Hospitals'}, {'cui': 'C0022130', 'cui_str': 'Island'}, {'cui': 'C0022067', 'cui_str': 'Republic of Ireland'}, {'cui': 'C0150312', 'cui_str': 'Present'}]","[{'cui': 'C0138514', 'cui_str': 'Placenta Growth Factor'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}]",2313.0,0.195095,The results demonstrate that the integration of point-of-care PlGF testing resulted in no evidence of a difference in maternal morbidity-457/1202 (38%) of women in the control group versus 330/1017 (32%) of women in the intervention group (adjusted risk ratio (RR) 1.01,"[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Hayes-Ryan', 'Affiliation': 'Irish Centre for Maternal and Child Health Research (INFANT), University College Cork, Cork, Ireland Deirdre.hayesryan@ucc.ie.'}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Khashan', 'Affiliation': 'Irish Centre for Maternal and Child Health Research (INFANT), University College Cork, Cork, Ireland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Hemming', 'Affiliation': 'University of Birmingham, United Kingdom.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Easter', 'Affiliation': 'University of Birmingham, United Kingdom.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Devane', 'Affiliation': 'Irish Centre for Maternal and Child Health Research (INFANT), University College Cork, Cork, Ireland.'}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Murphy', 'Affiliation': 'Trinity College Dublin & Coombe Women & Infants University Hospital Dublin 8, Republic of Ireland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hunter', 'Affiliation': 'Royal Jubilee Maternity Hospital, Belfast, Northern Ireland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Cotter', 'Affiliation': 'University Maternity Hospital Limerick & University of Limerick.'}, {'ForeName': 'F M', 'Initials': 'FM', 'LastName': 'McAuliffe', 'Affiliation': 'UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Morrison', 'Affiliation': 'Department of Obstetrics & Gynaecology, National University of Ireland Galway.'}, {'ForeName': 'F M', 'Initials': 'FM', 'LastName': 'Breathnach', 'Affiliation': 'Royal College of Surgeons in Ireland, Rotunda Hospital, Parnell Square W, Dublin 1, Ireland.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Dempsey', 'Affiliation': 'Irish Centre for Maternal and Child Health Research (INFANT), University College Cork, Cork, Ireland.'}, {'ForeName': 'L C', 'Initials': 'LC', 'LastName': 'Kenny', 'Affiliation': ""Department of Women's and Children's Health, Liverpool Women's Hospital, University of Liverpool, UK.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': ""O'Donoghue"", 'Affiliation': 'Irish Centre for Maternal and Child Health Research (INFANT), University College Cork, Cork, Ireland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ (Clinical research ed.),['10.1136/bmj.n1857'] 3220,34389522,Effectiveness and Safety of Continuous Infusion Regional Anesthesia Pumps for Pain after Thoracopelvic Fusion Surgeries for Persistent Spinal Pain Syndrome.,"INTRODUCTION Postoperative pain after complex revision spine surgeries, especially for the treatment of persistent spinal pain syndrome (PSPS), is frequently severe and can be debilitating, requiring the use of intravenous and oral opioids. This is the first study aimed at evaluating the effectiveness and safety of continuous infusion regional anesthesia pumps placed after thoracopelvic fusions for the treatment of PSPS. METHODS This is a retrospective comparative study of consecutive patients who underwent thoracopelvic fusion for PSPS. The patients included in this study either had a continuous infusion regional anesthesia pump placed during surgery or not (control). Demographics, use of preoperative and postoperative opioids, postoperative adverse events, length of hospital stay, and 90-days readmission were recorded. RESULTS Patients in the pump group (n=14) used less opioids during their hospital stay than the control group (n=12) (p=0.6). This difference was greater during the first 2 days (p=0.3 and p=0.2, respectively). There was no significant difference in opioid utilization during the first 14 days after surgery (p=0.8) and at the 3-month postoperative follow-up evaluation (p=0.8). Furthermore, there was no significant difference between groups in terms of postoperative complications. The pump group had a 1.4-day shorter hospital stay (p=0.7). The control group had more 90-day readmissions than the pump group (p=0.2). CONCLUSION Despite showing a trend towards less utilization of opioids during the first 2 days after surgery and a shorter hospital stay with no increased complications in the pump group, the study data failed to demonstrate a statistically significant difference between groups.",2021,"a shorter hospital stay with no increased complications in the pump group, the study data failed to demonstrate a statistically significant difference between groups.","['persistent spinal pain syndrome (PSPS', 'consecutive patients who underwent thoracopelvic fusion for PSPS', 'Pain after Thoracopelvic Fusion Surgeries for Persistent Spinal Pain Syndrome']","['Continuous Infusion Regional Anesthesia Pumps', 'continuous infusion regional anesthesia pump placed during surgery or not (control']","['opioid utilization', 'utilization of opioids', 'complications', 'opioids during their hospital stay', 'postoperative complications', 'Demographics, use of preoperative and postoperative opioids, postoperative adverse events, length of hospital stay, and 90-days readmission', '90-day readmissions', 'hospital stay', '1.4-day shorter hospital stay']","[{'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0423673', 'cui_str': 'Pain in spine'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0444889', 'cui_str': 'Continuous infusion'}, {'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C4517503', 'cui_str': '1.4'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}]",,0.0131635,"a shorter hospital stay with no increased complications in the pump group, the study data failed to demonstrate a statistically significant difference between groups.","[{'ForeName': 'Mohamed A R', 'Initials': 'MAR', 'LastName': 'Soliman', 'Affiliation': 'Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Buffalo General Medical Center, Kaleida Health, Buffalo, New York, USA; Department of Neurosurgery, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Asham', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': 'Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Buffalo General Medical Center, Kaleida Health, Buffalo, New York, USA.'}, {'ForeName': 'Alexander O', 'Initials': 'AO', 'LastName': 'Aguirre', 'Affiliation': 'Jacobs School of Medicine, University at Buffalo, Buffalo New York, USA.'}, {'ForeName': 'Nicco', 'Initials': 'N', 'LastName': 'Ruggiero', 'Affiliation': 'Jacobs School of Medicine, University at Buffalo, Buffalo New York, USA.'}, {'ForeName': 'Bennett R', 'Initials': 'BR', 'LastName': 'Levy', 'Affiliation': 'George Washington University, School of Medicine and Health Sciences, Washington DC, USA.'}, {'ForeName': 'Brandon L', 'Initials': 'BL', 'LastName': 'Mariotti', 'Affiliation': 'Jacobs School of Medicine, University at Buffalo, Buffalo New York, USA.'}, {'ForeName': 'Patrick K', 'Initials': 'PK', 'LastName': 'Jowdy', 'Affiliation': 'Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Buffalo General Medical Center, Kaleida Health, Buffalo, New York, USA.'}, {'ForeName': 'Kenan R', 'Initials': 'KR', 'LastName': 'Rajjoub', 'Affiliation': 'Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Buffalo General Medical Center, Kaleida Health, Buffalo, New York, USA.'}, {'ForeName': 'Ryan M', 'Initials': 'RM', 'LastName': 'Hess', 'Affiliation': 'Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Buffalo General Medical Center, Kaleida Health, Buffalo, New York, USA.'}, {'ForeName': 'Qazi', 'Initials': 'Q', 'LastName': 'Zeeshan', 'Affiliation': 'Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Buffalo General Medical Center, Kaleida Health, Buffalo, New York, USA.'}, {'ForeName': 'Robert V', 'Initials': 'RV', 'LastName': 'Starling', 'Affiliation': 'Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Buffalo General Medical Center, Kaleida Health, Buffalo, New York, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Pollina', 'Affiliation': 'Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Buffalo General Medical Center, Kaleida Health, Buffalo, New York, USA.'}, {'ForeName': 'Jeffrey P', 'Initials': 'JP', 'LastName': 'Mullin', 'Affiliation': 'Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Buffalo General Medical Center, Kaleida Health, Buffalo, New York, USA. Electronic address: Jmullin@ubns.com.'}]",World neurosurgery,['10.1016/j.wneu.2021.08.013'] 3221,34389519,Implementing family-based behavioral treatment in the pediatric primary care setting: Design of the PLAN study.,"Family-based behavioral treatment (FBT) is an evidence-based treatment for pediatric obesity. FBT has primarily been implemented in specialty clinics, with highly trained interventionists. The goal of this study is to assess effectiveness of FBT implemented in pediatric primary care settings using newly trained interventionists who might implement FBT in pediatric practices. The goal is to randomize 528 families with a child with overweight/obesity (≥85th BMI percentile) and parent with overweight/obesity (BMI ≥ 25) across four sites (Buffalo and Rochester, New York; Columbus, Ohio; St. Louis, Missouri) to FBT or usual care and obtain assessments at 6-month intervals over 24 months of treatment. FBT is implemented using a mastery model, which provides quantity of treatment tailored to family progress and following the United States Preventive Services Task Force recommendations for effective dose and duration of treatment. The primary outcome of the trial is change in relative weight for children, and secondarily, for parents and siblings who are overweight/obese. Between group differences in the tendency to prefer small immediate rewards over larger, delayed rewards (delay discounting) and how this is related to treatment outcome is also evaluated. Challenges in translation of group-based interventions to individualized treatments in primary care settings, and in study implementation that arose due to the COVID-19 pandemic are discussed. It is hypothesized that the FBT intervention will be associated with better changes in relative weight for children, parents, and siblings than usual care. The results of this study can inform future dissemination and implementation of FBT into primary care settings.",2021,"Between group differences in the tendency to prefer small immediate rewards over larger, delayed rewards (delay discounting) and how this is related to treatment outcome is also evaluated.","['pediatric primary care settings using newly trained interventionists who might implement FBT in pediatric practices', '528 families with a child with overweight/obesity (≥85th BMI percentile) and parent with overweight/obesity (BMI\u202f≥\u202f25']","['FBT', 'Family-based behavioral treatment (FBT', 'FBT intervention']","['relative weight for children, and secondarily, for parents and siblings who are overweight/obese']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]",528.0,0.0491251,"Between group differences in the tendency to prefer small immediate rewards over larger, delayed rewards (delay discounting) and how this is related to treatment outcome is also evaluated.","[{'ForeName': 'Leonard H', 'Initials': 'LH', 'LastName': 'Epstein', 'Affiliation': 'Department of Pediatrics, Jacobs School of Medicine, and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. Electronic address: lhenet@buffalo.edu.'}, {'ForeName': 'Kenneth B', 'Initials': 'KB', 'LastName': 'Schechtman', 'Affiliation': 'Department of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Kilanowski', 'Affiliation': 'Department of Pediatrics, Jacobs School of Medicine, and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Ramel', 'Affiliation': 'Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Nasreen A', 'Initials': 'NA', 'LastName': 'Moursi', 'Affiliation': 'Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Quattrin', 'Affiliation': 'Department of Pediatrics, Jacobs School of Medicine, and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Cook', 'Affiliation': 'Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Ihouma U', 'Initials': 'IU', 'LastName': 'Eneli', 'Affiliation': ""Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Pratt', 'Affiliation': 'National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Geller', 'Affiliation': 'National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Campo', 'Affiliation': 'National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Daphne', 'Initials': 'D', 'LastName': 'Lew', 'Affiliation': 'Department of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Denise E', 'Initials': 'DE', 'LastName': 'Wilfley', 'Affiliation': 'Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2021.106497'] 3222,34389506,Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study.,"BACKGROUND A double-blind, placebo-controlled Phase III study (200622) showed that mepolizumab reduces disease flares for patients with uncontrolled FIP1L1-PDGFRA-negative hypereosinophilic syndrome (HES) and ≥2 flares in the previous year. OBJECTIVES To further characterize the safety, clinical benefit, and pharmacodynamics of mepolizumab. METHODS Eligible patients from both treatment arms of the double-blind study could enter an open-label extension (OLE) study (205203; NCT03306043) to receive 4-weekly mepolizumab (300 mg subcutaneously) plus background therapy for 20 weeks. Primary endpoints were safety-based; other endpoints included flare rates and changes from baseline in mean daily oral corticosteroid (OCS) dose and blood eosinophil count (BEC). RESULTS Of 104 patients who completed the double-blind study, 98% (previous placebo n=52; previous mepolizumab n=50) enrolled in the OLE. Overall, 66 (65%) patients reported adverse events (AEs); 15 (15%) reported treatment-related AEs and 9 (9%) reported serious AEs. No events were fatal. The annualized flare rate (95% confidence interval) in the previous placebo and previous mepolizumab groups was 0.37 (0.16, 0.86) and 0.14 (0.04, 0.49) events/year, respectively. Of 72 patients receiving OCS during Weeks 0-4, 20 (28%; previous placebo, n=14; previous mepolizumab, n=6) achieved ≥50% reductions in mean daily dose during Weeks 16-20. At Week 20, BEC was reduced by 89% in patients previously receiving placebo and remained reduced for those previously receiving mepolizumab. CONCLUSION Extended mepolizumab treatment was associated with a positive benefit:risk profile. Continued control of disease flares and blood eosinophil counts, plus reductions in OCS use, were observed with mepolizumab in patients with FIP1L1-PDGFRA-negative HES.",2021,"At Week 20, BEC was reduced by 89% in patients previously receiving placebo and remained reduced for those previously receiving mepolizumab. ","['72 patients receiving', 'patients with uncontrolled FIP1L1-PDGFRA-negative hypereosinophilic syndrome (HES) and ≥2 flares in the previous year', 'Eligible patients from both treatment arms of the double-blind study could enter an open-label extension (OLE) study (205203; NCT03306043) to', 'patients with FIP1L1-PDGFRA-negative HES', '104 patients who completed the double-blind study, 98% (previous placebo n=52; previous mepolizumab n=50) enrolled in the OLE', 'hypereosinophilic syndrome']","['OCS', 'placebo', 'receive 4-weekly mepolizumab (300 mg subcutaneously) plus background therapy', 'mepolizumab']","['annualized flare rate', 'dose and blood eosinophil count (BEC', 'adverse events', 'Safety and efficacy', 'safety-based; other endpoints included flare rates and changes from baseline in mean daily oral corticosteroid (OCS', 'serious AEs', 'BEC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0206141', 'cui_str': 'Idiopathic hypereosinophilic syndrome'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0969324', 'cui_str': 'mepolizumab'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0969324', 'cui_str': 'mepolizumab'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]",205203.0,0.654908,"At Week 20, BEC was reduced by 89% in patients previously receiving placebo and remained reduced for those previously receiving mepolizumab. ","[{'ForeName': 'Gerald J', 'Initials': 'GJ', 'LastName': 'Gleich', 'Affiliation': 'Departments of Dermatology and Medicine, School of Medicine, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Roufosse', 'Affiliation': 'Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: froufoss@ulb.ac.be.'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Chupp', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Stanislas', 'Initials': 'S', 'LastName': 'Faguer', 'Affiliation': ""Département de Néphrologie et Transplantation d'Organes, CHU de Toulouse, Toulouse, France.""}, {'ForeName': 'Bastian', 'Initials': 'B', 'LastName': 'Walz', 'Affiliation': 'Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim-Teck, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Reiter', 'Affiliation': 'Department of Hematology and Oncology, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.'}, {'ForeName': 'Steven W', 'Initials': 'SW', 'LastName': 'Yancey', 'Affiliation': 'Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.'}, {'ForeName': 'Jane H', 'Initials': 'JH', 'LastName': 'Bentley', 'Affiliation': 'Clinical Statistics, GSK, Brentford, Middlesex, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Steinfeld', 'Affiliation': 'Respiratory Research & Development, GSK, Collegeville, PA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2021.07.050'] 3223,34018624,Randomization-based inference for a marginal treatment effect in stepped wedge cluster randomized trials.,"In a cross-sectional stepped wedge cluster randomized trial (SWT), clusters are randomized to crossover from control to intervention at different time periods and outcomes are assessed for a different set of individuals in each cluster-period. Randomization-based inference is an attractive analysis strategy for SWTs because it does not require full parametric specification of the outcome distribution or correlation structure and its validity does not rely on having a large number of clusters. Existing randomization-based approaches for SWTs, however, either focus on hypothesis testing and omit technical details on confidence interval (CI) calculation with noncontinuous outcomes, or employ weighted cluster-period summary statistics for p-value and CI calculation, which can result in suboptimal efficiency if weights do not incorporate information on varying cluster-period sizes. In this article, we propose a framework for calculating randomization-based p-values and CIs for a marginal treatment effect in SWTs by using test statistics derived from individual-level generalized linear models. We also investigate how study design features, such as stratified randomization, subsequently impact various SWT analysis methods including the proposed approach. Data from the XpertMTB/RIF tuberculosis trial are reanalyzed to illustrate our method and compare it to alternatives.",2021,Randomization-based inference is an attractive analysis strategy for SWTs because it does not require full parametric specification of the outcome distribution or correlation structure and its validity does not rely on having a large number of clusters.,[],[],[],[],[],[],,0.0868377,Randomization-based inference is an attractive analysis strategy for SWTs because it does not require full parametric specification of the outcome distribution or correlation structure and its validity does not rely on having a large number of clusters.,"[{'ForeName': 'Dustin J', 'Initials': 'DJ', 'LastName': 'Rabideau', 'Affiliation': 'Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts.'}]",Statistics in medicine,['10.1002/sim.9040'] 3224,34018333,"Contribution of the right temporoparietal junction and ventromedial prefrontal cortex to theory of mind in autism: A randomized, sham-controlled tDCS study.","Theory of mind (ToM) is the ability to attribute subjective mental states to oneself and others and is significantly impaired in autism spectrum disorder (ASD). A frontal-posterior network of regions including the ventromedial prefrontal cortex (vmPFC) and temporoparietal junction (TPJ) is involved in ToM. Previous studies show an underactivation of these regions in ASD. Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation method for causally investigating brain-behavior relationships via induction of cortical excitability alterations. tDCS, mostly over the dorsolateral prefrontal cortex, has been increasingly applied for improving behavioral problems in ASD leaving other potentially interesting regions untouched. Here we investigated contribution of the vmPFC and right TPJ in ToM abilities of ASD children via tDCS in a pilot study. Sixteen children with ASD (mean age = 10.7 ± 1.9) underwent three tDCS sessions (1 mA, 20 min) in a randomized, sham-controlled design. Stimulation protocols included: (a) anodal vmPFC tDCS, (b) anodal r-TPJ tDCS, and (c) sham tDCS. ToM abilities were explored during tDCS using the theory of mind test (TOMT). Our results show that activation of the vmPFC with anodal tDCS significantly improved ToM in children with ASD compared with both, r-TPJ tDCS, and sham stimulation. Specifically, precursors of ToM (e.g., emotion recognition, perception, and imitation) and elementary ToM skills (e.g., first-order mental state reasoning) were significantly improved by anodal vmPFC tDCS. Based on these results, the vmPFC could be a potential target region for the reduction of ASD symptoms via noninvasive brain stimulation, which should be examined in larger detail in future studies. LAY SUMMARY: Theory of mind (ToM) is the ability to infer mental states of oneself and others, which is impaired in autism. Brain imaging studies have shown involvement of two brain regions in ToM (ventromedial prefrontal cortex, temporoparietal junction) which are underactivated in autism. We increased activation of these regions via noninvasive brain stimulation in this experiment to see how it would affect ToM abilities in autism. We found that increased activation of the ventromedial prefrontal cortex improved ToM abilities in children with autism.",2021,"Our results show that activation of the vmPFC with anodal tDCS significantly improved ToM in children with ASD compared with both, r-TPJ tDCS, and sham stimulation.","['ASD children via tDCS', 'Sixteen children with ASD (mean age\xa0=\xa010.7\xa0±\u20091.9) underwent three', 'autism', 'children with autism', 'children with ASD']","['tDCS sessions', 'Transcranial direct current stimulation (tDCS', 'vmPFC and right TPJ', 'vmPFC with anodal tDCS', 'anodal vmPFC tDCS, (b) anodal r-TPJ tDCS, and (c) sham tDCS']","['precursors of ToM (e.g., emotion recognition, perception, and imitation) and elementary ToM skills (e.g., first-order mental state reasoning', 'ToM abilities']","[{'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191365', 'cui_str': '10.7'}, {'cui': 'C4517517', 'cui_str': '1.9'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C3850122', 'cui_str': 'Ventral Medial Prefrontal Cortex'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0935573', 'cui_str': 'Theory of Mind'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",16.0,0.0649875,"Our results show that activation of the vmPFC with anodal tDCS significantly improved ToM in children with ASD compared with both, r-TPJ tDCS, and sham stimulation.","[{'ForeName': 'Mohammad Ali', 'Initials': 'MA', 'LastName': 'Salehinejad', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, Dortmund, Germany.'}, {'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Paknia', 'Affiliation': 'Department of Rehabilitation Counseling, University of Social Welfare and Rehabilitation Science, Tehran, Iran.'}, {'ForeName': 'Amir Hossein', 'Initials': 'AH', 'LastName': 'Hosseinpour', 'Affiliation': 'Department of Rehabilitation Counseling, University of Social Welfare and Rehabilitation Science, Tehran, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Yavari', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, Dortmund, Germany.'}, {'ForeName': 'Carmelo M', 'Initials': 'CM', 'LastName': 'Vicario', 'Affiliation': ""Dipartimento di Scienze Cognitive, Psicologiche, Pedagogiche e degli studi culturali, Universita' di Messina, Messina, Italy.""}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Nitsche', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, Dortmund, Germany.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Nejati', 'Affiliation': 'Department of Psychology, Shahid Beheshti University, Tehran, Iran.'}]",Autism research : official journal of the International Society for Autism Research,['10.1002/aur.2538'] 3225,34016554,"The influence of preoperative carbohydrate loading on postoperative outcomes in bariatric surgery patients: a randomized, controlled trial.","BACKGROUND Preoperative carbohydrate loading is a component of Enhanced Recovery After Surgery (ERAS) protocols, but there is limited literature in bariatric surgery patients. OBJECTIVES The objective of this study was to characterize the impact of preoperative carbohydrate loading on postoperative bariatric surgery outcomes. SETTING University Hospital. METHODS Patients undergoing a primary minimally invasive Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2018 and 2020 were randomized to standard management or intervention. Standard management patients were nothing by mouth (NPO) after midnight prior to surgery. Intervention patients consumed 2 carbohydrate drinks: 1 the night before and another 3 hours prior to surgery. Primary outcomes analyzed included postoperative nausea and vomiting (PONV), length of stay, and overall complications. RESULTS In total, 134 patients were analyzed: 64 intervention (47.8%) and 70 (52.2%) standard. In the end, 7% and 15% of patients were lost to follow-up at 6-weeks and 3-months, respectively. There was no statistically significant difference in length of stay (2.0 ± 1.2 vs 2.1 ± .9 d; P = .65) or postoperative outcomes between the 2 groups. There were no episodes of aspiration among the intervention group. Among RYGB patients, intervention patients had a shorter duration of nausea compared with standard patients. There was no significant difference in glycemic control among patients with and without diabetes. CONCLUSIONS Preoperative carbohydrate drinks can be administered to bariatric surgery patients without significant risks. Carbohydrate loading preoperatively can decrease the duration of PONV in RYGB patients. Carbohydrate drinks can be safely included in bariatric ERAS protocols for patients with and without diabetes, although the benefits remain unknown.",2021,There were no episodes of aspiration among the intervention group.,"['patients with and without diabetes', 'Patients undergoing a primary minimally invasive Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2018 and 2020 were randomized to', '134 patients were analyzed: 64 intervention (47.8%) and 70 (52.2%) standard', 'bariatric surgery patients', 'University Hospital']","['standard management or intervention', 'preoperative carbohydrate loading', 'Preoperative carbohydrate drinks', 'Carbohydrate drinks', 'carbohydrate drinks']","['length of stay', 'postoperative outcomes', 'glycemic control', 'postoperative nausea and vomiting (PONV), length of stay, and overall complications', 'shorter duration of nausea', 'duration of PONV']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0399839', 'cui_str': 'Bypass gastrojejunostomy'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4517801', 'cui_str': '52.2'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C4277655', 'cui_str': 'Carbohydrate Loading Diet'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0452428', 'cui_str': 'Drink'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439593', 'cui_str': 'Short duration'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",134.0,0.0973776,There were no episodes of aspiration among the intervention group.,"[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Suh', 'Affiliation': 'Department of Surgery, Division of General Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Hetzel', 'Affiliation': 'Department of Surgery, Division of General Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Alter-Troilo', 'Affiliation': 'Department of Surgery, Division of General Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Lak', 'Affiliation': 'Department of Surgery, Division of General Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Jon C', 'Initials': 'JC', 'LastName': 'Gould', 'Affiliation': 'Department of Surgery, Division of General Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Tammy L', 'Initials': 'TL', 'LastName': 'Kindel', 'Affiliation': 'Department of Surgery, Division of General Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Rana M', 'Initials': 'RM', 'LastName': 'Higgins', 'Affiliation': 'Department of Surgery, Division of General Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: rhiggins@mcw.edu.'}]",Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery,['10.1016/j.soard.2021.04.014'] 3226,34016004,Time-of-day effects on the postural control and symptoms in women with rheumatoid arthritis.,"The present study was designed to assess time-of-day effects on postural balance and symptoms of rheumatoid arthritis (RA) patients. A total of 15 American College of Rheumatology functional class I and II RA patients and 15 healthy controls aged between 45 and 55 (mean age: 50  ±  3) years of age voluntarily participated. We conducted a case-control, repeated-measures in design study. Postural balance, axillary temperature, pain intensity, fatigue, and sleepiness were measured during five test sessions at 06:00, 10:00, 14:00, 18:00, and 22:00 h. Participants were randomized to the order of test sessions, and each session was separated by >36 hours to minimize/eliminate learning effects. Center of pressure area (CoP area) ( p < .001), pain ( p < .01), and sleepiness ( p < .05) values were significantly higher at 06:00 and 22:00 h compared to 10:00, 14:00, and 18:00 h in the RA group. Fatigue significantly increased ( p < .05) at 22:00 h in comparison to 10:00, 14:00, and 18:00 h in the RA group. Axillary temperature was significantly ( p < .001) lower at 06:00 and at 22:00 h compared to 10:00, 14:00, and 18:00 h in the RA group. In the control group, there were no significant time-of-day difference in fatigue, but axillary temperature was significantly lower ( p < .01) at 06:00 h compared to 10:00 h, 14:00, 18:00, and 22:00 h, sleepiness values were significantly higher ( p < .05) at 06:00 and 22:00 h compared to 10:00, 14:00, and 18:00 h, and revealed CoP area values were significantly ( p < .05) higher at 06:00 h compared to 14:00 h. Finally, in the RA group, significant correlations were found between values of CoP area and pain (r = 0.47; p < .001), sleepiness (r = 0.39; p < .01), fatigue (r = -0.46; p < .001), and also axillary temperature (r = -0.35; p < .001). Multiple linear regression analysis further indicated that in the RA group, time-of-day variation in postural balance was predicted collectively by that in pain and fatigue (30.7%) (R2 = 0.307; F = 11.53; p < .001). Our results first suggest that time-of-day significantly affects postural balance, axillary temperature, pain intensity, fatigue, and sleepiness in RA patients and second that the temporal variation observed in pain, fatigue, and somnolence are concomitant with that observed in postural balance. Abbreviations : RA: Rheumatoid arthritis; H&O questionnaire: Horne and Ostberg questionnaire; PSQI: Pittsburgh sleep quality index; HAQ: Health assessment questionnaire; SF-36: the short form-36; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; CoP: The Center of foot Pressure; CoP area : The Center of foot Pressure area; VAS: The Visual Analogue Scale; KSS: Karolinska Sleepiness Scale.",2021,"Center of pressure area (CoP area) ( p < .001), pain ( p < .01), and sleepiness ( p < .05) values were significantly higher at 06:00 and 22:00 h compared to 10:00, 14:00, and 18:00 h in the RA group.","['rheumatoid arthritis (RA) patients', '15 American College of Rheumatology functional class', 'women with rheumatoid arthritis', 'arthritis', 'I and II RA patients and 15 healthy controls aged between 45 and 55 (mean age: 50\xa0 ± \xa03) years of age voluntarily participated']",['Ostberg questionnaire; PSQI'],"['postural balance, axillary temperature, pain intensity, fatigue, and sleepiness', 'axillary temperature', 'postural control and symptoms', 'time-of-day variation in postural balance', 'Axillary temperature', 'Postural balance, axillary temperature, pain intensity, fatigue, and sleepiness', 'sleepiness values', 'pain and fatigue', 'pain, fatigue, and somnolence', 'sleepiness', 'Fatigue', 'fatigue', 'CoP area values', 'pain', 'time-of-day difference in fatigue, but axillary temperature', 'values of CoP area and pain']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0003864', 'cui_str': 'Arthritis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}]","[{'cui': 'C1256755', 'cui_str': 'Postural balance'}, {'cui': 'C1531924', 'cui_str': 'Axillary temperature'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439548', 'cui_str': 'Temporal periods of day'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0056471', 'cui_str': 'creatinolfosfate'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]",,0.0922031,"Center of pressure area (CoP area) ( p < .001), pain ( p < .01), and sleepiness ( p < .05) values were significantly higher at 06:00 and 22:00 h compared to 10:00, 14:00, and 18:00 h in the RA group.","[{'ForeName': 'Fatma', 'Initials': 'F', 'LastName': 'Bouchaala', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport Et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Sfax, Tunisia.'}, {'ForeName': 'Rabeb', 'Initials': 'R', 'LastName': 'Laatar', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport Et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Sfax, Tunisia.'}, {'ForeName': 'Mariam', 'Initials': 'M', 'LastName': 'Lahiani', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport Et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Sfax, Tunisia.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Vuillerme', 'Affiliation': 'University of Grenoble Alpes, AGEIS, Grenoble, France.'}, {'ForeName': 'Amira', 'Initials': 'A', 'LastName': 'Zouabi', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport Et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Sfax, Tunisia.'}, {'ForeName': 'Rihab', 'Initials': 'R', 'LastName': 'Borji', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport Et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Sfax, Tunisia.'}, {'ForeName': 'Haithem', 'Initials': 'H', 'LastName': 'Rebai', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport Et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Sfax, Tunisia.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Sahli', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport Et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Sfax, Tunisia.'}]",Chronobiology international,['10.1080/07420528.2021.1927069'] 3227,34015580,"The intraperitoneal ondansetron for postoperative pain management following laparoscopic cholecystectomy: A proof-of-concept, double-blind, placebo-controlled trial.","BACKGROUND Pain after laparoscopic cholecystectomy remains a major challenge. Ondansetron blocks sodium channels and may have local anesthetic properties. AIMS To investigate the effect of intraperitoneal administration of ondansetron for postoperative pain management as an adjuvant to intravenous acetaminophen in patients undergoing laparoscopic cholecystectomy. METHODS Patients scheduled for elective laparoscopic cholecystectomy were randomized into two groups (n = 25 each) to receive either intraperitoneal ondansetron or saline injected in the gall bladder bed at the end of the procedure. The primary outcome was the difference in pain from baseline to 24-h post-operative assessed by comparing the area under the curve of visual analog score between the two groups. RESULTS The derived area under response curve of visual analog scores in the ondansetron group (735.8 ± 418.3) was 33.97% lower than (p = 0.005) that calculated for the control group (1114.4 ± 423.9). The need for rescue analgesia was significantly lower in the ondansetron (16%) versus in the control group (54.17%) (p = 0.005), indicating better pain control. The correlation between the time for unassisted mobilization and the area under response curve of visual analog scores signified the positive analgesic influence of ondansetron (r s =0.315, p = 0.028). The frequency of nausea and vomiting was significantly lower in patients who received ondansetron than that reported in the control group (p = 0.023 (8 h), and 0.016 (24 h) respectively). CONCLUSIONS The added positive impact of ondansetron on postoperative pain control alongside its anti-emetic effect made it a unique novel option for patients undergoing laparoscopic cholecystectomy.",2021,"The need for rescue analgesia was significantly lower in the ondansetron (16%) versus in the control group (54.17%) (p = 0.005), indicating better pain control.","['Patients scheduled for elective laparoscopic cholecystectomy', 'patients undergoing laparoscopic cholecystectomy']","['Ondansetron', 'intraperitoneal ondansetron or saline', 'intraperitoneal ondansetron', 'laparoscopic cholecystectomy', 'ondansetron', 'acetaminophen', 'placebo']","['pain from baseline to 24-h post-operative assessed by comparing the area under the curve of visual analog score', 'frequency of nausea and vomiting', 'visual analog scores', 'postoperative pain management', 'need for rescue analgesia', 'pain control']","[{'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0442120', 'cui_str': 'Intraperitoneal'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]",,0.301526,"The need for rescue analgesia was significantly lower in the ondansetron (16%) versus in the control group (54.17%) (p = 0.005), indicating better pain control.","[{'ForeName': 'Doaa H', 'Initials': 'DH', 'LastName': 'Abdelaziz', 'Affiliation': 'Department of Clinical Pharmacy, The National Hepatology and Tropical Medicine Research Institute, Egypt; Pharmacy Practice & Clinical Pharmacy Department, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt. Electronic address: Doaa.yousef@fue.edu.eg.'}, {'ForeName': 'Sherif', 'Initials': 'S', 'LastName': 'Boraii', 'Affiliation': 'Department of Hepatobiliary Pancreatic Surgery, The National Hepatology and Tropical Medicine Research Institute, Egypt. Electronic address: Sherifbm@yahoo.com.'}, {'ForeName': 'Ejaz', 'Initials': 'E', 'LastName': 'Cheema', 'Affiliation': 'School of Pharmacy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: E.Cheema@bham.ac.uk.'}, {'ForeName': 'Mohamed Hassan', 'Initials': 'MH', 'LastName': 'Elnaem', 'Affiliation': 'Department of Pharmacy Practice, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia; Quality Use of Medicines Research Group, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia. Electronic address: drmelnaem@iium.edu.my.'}, {'ForeName': 'Tamer', 'Initials': 'T', 'LastName': 'Omar', 'Affiliation': 'Department of Anesthesia, The National Hepatology and Tropical Medicine Research Institute, Egypt. Electronic address: dromar30@yahoo.com.'}, {'ForeName': 'Amr', 'Initials': 'A', 'LastName': 'Abdelraouf', 'Affiliation': 'Department of Hepatobiliary Pancreatic Surgery, The National Hepatology and Tropical Medicine Research Institute, Egypt. Electronic address: Abdelraoufamr@gmail.com.'}, {'ForeName': 'Noha O', 'Initials': 'NO', 'LastName': 'Mansour', 'Affiliation': 'Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Egypt. Electronic address: dr.nohamansour@gmail.com.'}]",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,['10.1016/j.biopha.2021.111725'] 3228,34015555,"A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.","AIM A combination of olanzapine and samidorphan (OLZ/SAM) is in development for the treatment of patients with schizophrenia or bipolar I disorder and is intended to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. This 52-week open-label extension (NCT02873208; ENLIGHTEN-2-EXT) assessed the long-term safety and tolerability of OLZ/SAM in patients with schizophrenia. METHODS Patients completing the 24-week randomized, double-blind, phase 3 ENLIGHTEN-2 study (NCT02694328) comparing weight change from baseline to week 24 with OLZ/SAM versus olanzapine were eligible to enroll in the 52-week ENLIGHTEN-2-EXT study. Assessments included adverse events (AEs; each visit), weight/waist circumference (every other week for the first 8 weeks, then every 4 weeks thereafter), metabolic laboratory parameters (weeks 4, 12, 24, 36, and 52), Positive and Negative Syndrome Scale (PANSS) scores (weeks 2, 4, 8, 12, 24, 36, and 52), and Clinical Global Impression-Severity (CGI-S) scores (weeks 2 and 4, then every 4 weeks thereafter through week 48, and at week 52). Analyses were based on observed results using descriptive statistics. Baseline was relative to the first OLZ/SAM dose in the extension study. RESULTS In total, 265 patients were enrolled and received at least 1 dose of OLZ/SAM; 167 (63.0%) completed the 52-week extension study. Common AEs (≥5%) were weight decreased (n = 23; 8.7%), extra dose administered (n = 21; 7.9%), headache (n = 18; 6.8%), and weight increased (n = 16; 6.0%). At week 52, the mean (SD) change from baseline for weight and waist circumference was -0.03 (6.17) kg and - 0.35 (6.12) cm, respectively. Changes in fasting lipid and glycemic parameters were generally small and remained stable over 52 weeks. During the extension, PANSS total scores remained stable, and at week 52, 81.3% of patients had CGI-S scores of 3 or less, reflecting mild illness severity. CONCLUSIONS OLZ/SAM was generally well tolerated over 52 weeks. Weight, waist circumference, metabolic laboratory parameters, and schizophrenia symptoms remained stable throughout the study.",2021,"Common AEs (≥5%) were weight decreased (n = 23; 8.7%), extra dose administered (n = 21; 7.9%), headache (n = 18; 6.8%), and weight increased (n = 16; 6.0%).","['patients with schizophrenia', '265 patients were enrolled and received at least 1 dose of', 'patients with schizophrenia or bipolar I disorder']","['olanzapine and samidorphan', 'OLZ/SAM versus olanzapine', 'olanzapine', 'OLZ/SAM', 'olanzapine and samidorphan (OLZ/SAM']","['fasting lipid and glycemic parameters', 'Weight, waist circumference, metabolic laboratory parameters, and schizophrenia symptoms', 'metabolic laboratory parameters', 'Clinical Global Impression-Severity (CGI-S) scores', '1-year safety and tolerability', 'Positive and Negative Syndrome Scale (PANSS) scores', 'headache', 'adverse events (AEs; each visit), weight/waist circumference', 'mean (SD) change from baseline for weight and waist circumference', 'weight']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0853193', 'cui_str': 'Bipolar I disorder'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C4277369', 'cui_str': '3-carboxamido-4-hydroxynaltrexone'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",265.0,0.149808,"Common AEs (≥5%) were weight decreased (n = 23; 8.7%), extra dose administered (n = 21; 7.9%), headache (n = 18; 6.8%), and weight increased (n = 16; 6.0%).","[{'ForeName': 'René S', 'Initials': 'RS', 'LastName': 'Kahn', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: rene.kahn@mssm.edu.'}, {'ForeName': 'Bernard L', 'Initials': 'BL', 'LastName': 'Silverman', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'DiPetrillo', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Graham', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Jiani', 'Initials': 'J', 'LastName': 'Yin', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Simmons', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Vasudev', 'Initials': 'V', 'LastName': 'Bhupathi', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Yu', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Yagoda', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Hopkinson', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'McDonnell', 'Affiliation': 'Alkermes Pharma Ireland Limited, Dublin, Ireland.'}]",Schizophrenia research,['10.1016/j.schres.2021.04.009'] 3229,34021752,Improving outcomes and antibiotic stewardship (IOAS) for patients with Gram-positive bloodstream infections through use of rapid testing: a quasi-experimental multicentre study of the Accelerate PhenoTest™ BC Kit.,"BACKGROUND Data from the Improving Outcomes and Antibiotic Stewardship for Patients with Bloodstream Infections: Accelerate PhenoTest™ BC Kit (AXDX) Registry Study were analysed to determine the impact of rapid organism identification and antimicrobial susceptibility testing (AST) for Gram-positive bacteraemia. PATIENTS AND METHODS This multicentre, quasi-experimental study evaluated clinical and antimicrobial stewardship metrics following the implementation of AXDX. Data from hospitalized patients with bacteraemia were compared between groups, one that underwent testing on AXDX (post-AXDX) and one that underwent traditional identification and AST (pre-AXDX). An analysis of patients with Gram-positive bacteraemia was performed. The primary outcome was time to optimal therapy (TTOT). Secondary outcomes included time to first antibiotic modification (overall and Gram-positive), duration of unnecessary MRSA coverage, incidence of adverse events, length of stay and mortality. RESULTS A total of 219 (109 pre-AXDX, 110 post-AXDX) patients with Gram-positive bacteraemia were included. Median TTOT was 36.3 h (IQR, 16.9-56.7) in the pre-AXDX group and 20.4 h (IQR, 7.5-36.7) in the post-AXDX group (P = 0.01). Compared with pre-AXDX, median time to first antibiotic modification (29.1 versus 15.9 h; P = 0.002), time to first Gram-positive antibiotic modification (33.2 versus 17.2 h; P = 0.003) and median duration of unnecessary MRSA coverage (58.4 versus 29.7 h; P = 0.04) were reduced post-AXDX. A trend towards decreased acute kidney injury (24% versus 13%; P = 0.06) was observed in the post-AXDX group. Groups did not differ in other secondary outcomes. CONCLUSIONS Implementation of AXDX testing for patients with Gram-positive bacteraemia shortened the TTOT and reduced unnecessary antibiotic exposure due to faster antibiotic modifications.",2021,A trend towards decreased acute kidney injury (24% versus 13%; P = 0.06) was observed in the post-AXDX group.,"['A total of 219 (109 pre-AXDX, 110 post-AXDX) patients with Gram-positive bacteraemia were included', 'hospitalized patients with bacteraemia', 'Patients with Bloodstream Infections', 'patients with Gram-positive bloodstream infections']","['BC Kit (AXDX', 'antibiotic stewardship (IOAS']","['median duration of unnecessary MRSA coverage', 'acute kidney injury', 'Median TTOT', 'median time to first antibiotic modification', 'time to first antibiotic modification (overall and Gram-positive), duration of unnecessary MRSA coverage, incidence of adverse events, length of stay and mortality', 'time to optimal therapy (TTOT', 'time to first Gram-positive antibiotic modification']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517648', 'cui_str': '219'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0744474', 'cui_str': 'Gram-positive bacteremia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C4505100', 'cui_str': 'Antibiotic Stewardship'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0343401', 'cui_str': 'Methicillin resistant Staphylococcus aureus infection'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.115852,A trend towards decreased acute kidney injury (24% versus 13%; P = 0.06) was observed in the post-AXDX group.,"[{'ForeName': 'Shawn H', 'Initials': 'SH', 'LastName': 'MacVane', 'Affiliation': 'Accelerate Diagnostics, Inc, Tucson, AZ, USA.'}, {'ForeName': 'Amira A', 'Initials': 'AA', 'LastName': 'Bhalodi', 'Affiliation': 'Accelerate Diagnostics, Inc, Tucson, AZ, USA.'}, {'ForeName': 'Ryan K', 'Initials': 'RK', 'LastName': 'Dare', 'Affiliation': 'Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Eric R', 'Initials': 'ER', 'LastName': 'Rosenbaum', 'Affiliation': 'Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Kaleb', 'Initials': 'K', 'LastName': 'Wolfe', 'Affiliation': 'Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Ford', 'Affiliation': 'Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Dilek', 'Initials': 'D', 'LastName': 'Ince', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Kinn', 'Affiliation': 'Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Kelly M', 'Initials': 'KM', 'LastName': 'Percival', 'Affiliation': 'Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Romney M', 'Initials': 'RM', 'LastName': 'Humphries', 'Affiliation': 'Accelerate Diagnostics, Inc, Tucson, AZ, USA.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkab165'] 3230,34021097,The Impact of Low Energy Availability on Nonexercise Activity Thermogenesis and Physical Activity Behavior in Recreationally Trained Adults.,"Energy availability describes the amount of dietary energy remaining for physiological functionality after the energy cost of exercise is deducted. The physiological and hormonal consequences of low energy availability (LEA) are well established, but the impact of LEA on physical activity behavior outside of exercise and, specifically, nonexercise activity thermogenesis (NEAT) has not been systematically examined. The authors conducted a secondary analysis of a repeated-measures crossover study in which recreationally trained young men (n = 6, 25 ± 1.0 years) underwent two 4-day conditions of LEA (15 kcal·kg fat-free mass-1 ·day-1) with and without endurance exercise (LEA + EX and LEA EX) and two energy-balanced control conditions (CON + EX and CON EX). The duration and intensity of physical activity outside of prescribed exercise were assessed using the SenseWear Pro3 armband. LEA did not alter NEAT (p = .41), nor time spent in moderate to vigorous (p = .20) and low-intensity physical activity (p = .17). However, time spent in low-intensity physical activity was lower in LEA + EX than LEA - EX (13.7 ± 0.3 vs. 15.2 ± 0.3 hr/day; p = .002). Short-term LEA does not seem to impact NEAT per se, but the way it is attained may impact physical activity behavior outside of exercise. As the participants expended similar amounts of energy during NEAT (900-1,300 kcal/day = 12.5-18.0 kcal·kg fat-free mass-1·day-1) and prescribed exercise bouts (15.0 kcal·kg fat-free mass-1·day-1), excluding it as a component of energy expenditure may skew the true energy available for physiological functionality in active populations.",2021,"LEA did not alter NEAT (p = .41), nor time spent in moderate to vigorous (p = .20) and low-intensity physical activity (p = .17).","['Recreationally Trained Adults', 'recreationally trained young men (n = 6, 25 ± 1.0\xa0years']","['LEA', 'LEA (15\xa0kcal·kg fat-free mass-1 ·day-1) with and without endurance exercise (LEA + EX and LEA EX) and two energy-balanced control conditions (CON + EX and CON EX', 'low energy availability (LEA']","['time spent in low-intensity physical activity', 'Nonexercise Activity Thermogenesis and Physical Activity Behavior', 'low-intensity physical activity', 'time spent in moderate to vigorous', 'duration and intensity of physical activity outside of prescribed exercise']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0018841', 'cui_str': 'Heat Production'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205101', 'cui_str': 'External'}]",,0.0186534,"LEA did not alter NEAT (p = .41), nor time spent in moderate to vigorous (p = .20) and low-intensity physical activity (p = .17).","[{'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'Technical University of Munich.'}, {'ForeName': 'Hande', 'Initials': 'H', 'LastName': 'Hofmann', 'Affiliation': 'Technical University of Munich.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'Drenowatz', 'Affiliation': 'University of Education Upper Austria.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Wallmann-Sperlich', 'Affiliation': 'University of Würzburg.'}, {'ForeName': 'Billy', 'Initials': 'B', 'LastName': 'Sperlich', 'Affiliation': 'University of Würzburg.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Koehler', 'Affiliation': 'Technical University of Munich.'}]",International journal of sport nutrition and exercise metabolism,['10.1123/ijsnem.2021-0029'] 3231,34020931,Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).,"BACKGROUND No standard of care exists for patients with high-risk biochemical recurrence (BCR) after prostatectomy. OBJECTIVE To evaluate whether addition of docetaxel to androgen deprivation therapy (ADT) improved progression-free survival (PFS) in high-risk BCR patients. DESIGN, SETTING, AND PARTICIPANTS TAX3503 was a multicenter phase 3 trial that randomized patients with high-risk BCR to ADT for 18 mo ± docetaxel (75 mg/m 2 q3w for ten cycles). Eligibility included prostate-specific antigen (PSA) ≥1.0 ng/ml after prostatectomy alone or after postoperative radiation therapy, PSA doubling time ≤9 mo, and absence of metastases on computed tomography and bone scintigraphy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary endpoint was PFS following testosterone recovery to noncastrate levels (testosterone >50 ng/dl). Secondary endpoints included time to testosterone recovery, overall survival (OS), quality of life, and safety. RESULTS AND LIMITATIONS Between September 2007 and May 2011, 413 patients were assigned to ADT ± docetaxel. In 2012, following completion of accrual and treatment, the sponsor withdrew support of the study, and in 2013, a registry was created to secure the primary endpoint. The final analysis included data from the original trial and registry. At a median follow-up of 33.6 mo, 260 patients demonstrated testosterone recovery, which occurred similarly between groups. ADT plus docetaxel trended toward a nonclinically meaningful improvement in PFS (median 26.2 vs 24.7 mo) for the testosterone-recovered population (218 events, hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.61-1.04) and in OS for the intention-to-treat population (medians not reached, HR 0.51, 95% CI 0.23-1.10). Grade ≥3 adverse events occurred more frequently in the ADT plus docetaxel group (48.0% vs 10.8%). CONCLUSIONS TAX3503 did not demonstrate a meaningful benefit of adding docetaxel to ADT in patients with high-risk BCR. Testosterone recovery was unaffected by addition of docetaxel to ADT. PATIENT SUMMARY Addition of docetaxel to androgen deprivation therapy did not meaningfully improve outcomes for men with high-risk biochemically recurrent prostate cancer.",2021,Addition of docetaxel to androgen deprivation therapy did not meaningfully improve outcomes for men with high-risk biochemically recurrent prostate cancer.,"['high-risk BCR patients', 'TAX3503 was a multicenter phase 3 trial that randomized patients with high-risk BCR to ADT for 18 mo\xa0±', '75\xa0mg/m 2 q3w for ten cycles', 'High-risk Biochemically Recurrent Prostate Cancer', 'men with high-risk biochemically recurrent prostate cancer', 'patients with high-risk BCR', 'patients with high-risk biochemical recurrence (BCR) after prostatectomy', 'Between September 2007 and May 2011, 413 patients were assigned to ADT\xa0±']","['docetaxel to androgen deprivation therapy', 'Androgen Deprivation Therapy with or Without Docetaxel', 'docetaxel', 'ADT plus docetaxel', 'docetaxel to androgen deprivation therapy (ADT', 'TAX3503']","['testosterone recovery', 'time to testosterone recovery, overall survival (OS), quality of life, and safety', 'Grade ≥3 adverse events', 'PSA doubling time', 'PFS', 'PFS following testosterone recovery to noncastrate levels (testosterone ', 'progression-free survival (PFS', 'Testosterone recovery']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C4759295', 'cui_str': 'Non-metastatic prostate cancer'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0033573', 'cui_str': 'Prostatectomy'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",413.0,0.497545,Addition of docetaxel to androgen deprivation therapy did not meaningfully improve outcomes for men with high-risk biochemically recurrent prostate cancer.,"[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Morris', 'Affiliation': 'Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: morrism@mskcc.org.'}, {'ForeName': 'Jose Mauricio', 'Initials': 'JM', 'LastName': 'Mota', 'Affiliation': 'Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Lacuna', 'Affiliation': 'Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Hilden', 'Affiliation': 'Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Gleave', 'Affiliation': 'Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Carducci', 'Affiliation': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Saad', 'Affiliation': 'Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.'}, {'ForeName': 'Erica D', 'Initials': 'ED', 'LastName': 'Cohn', 'Affiliation': 'Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Filipenko', 'Affiliation': 'Prostate Cancer Clinical Trials Consortium, New York, NY, USA.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Heller', 'Affiliation': 'Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Shore', 'Affiliation': 'Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Armstrong', 'Affiliation': 'Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery at the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Howard I', 'Initials': 'HI', 'LastName': 'Scher', 'Affiliation': 'Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}]",European urology oncology,['10.1016/j.euo.2021.04.008'] 3232,33972256,"Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread rapidly worldwide. This study is the first to report the tolerability, safety, pharmacokinetics (PK), and immunogenicity of a recombinant human anti-SARS-CoV-2 monoclonal antibody, etesevimab (CB6, JS016, LY3832479, or LY-CoV016), in healthy adults. This paper describes a randomized, double-blind, placebo-controlled, phase 1 study. A total of 40 participants were enrolled to receive a single intravenous dose of either etesevimab or placebo in one of four sequential ascending intravenous dose cohorts. All 40 participants completed the study. Seventeen (42.5%) participants experienced 22 treatment emergent adverse events (TEAEs) that were drug-related, and the rates of these TEAEs among different dose cohorts were numerically comparable. No difference was observed between the combined etesevimab group and the placebo group. The exposure after etesevimab infusion increased in an approximately proportional manner as the dose increased from 2.5 to 50 mg/kg. The elimination half-life ( t 1/2 ) value did not differ among different dose cohorts and was estimated to be around 4 weeks. Etesevimab was well tolerated after administration of a single dose at a range of 2.5 mg/kg to 50 mg/kg in healthy Chinese adults. The PK profiles of etesevimab in healthy volunteers showed typical monoclonal antibody distribution and elimination characteristics. (This study has been registered at ClinicalTrials.gov under identifier NCT04441918.).",2021,"Seventeen (42.5%) participants experienced 22 treatment emergent adverse events (TEAEs) that were drug-related, and the rates of these TEAEs among different dose cohorts were numerically comparable.","['All 40 participants completed the study', 'A total of 40 participants', 'healthy Chinese adults', 'Chinese Healthy Adults', 'healthy volunteers', 'healthy adults']","['Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab', 'Placebo', 'recombinant human anti-SARS-CoV-2 monoclonal antibody, etesevimab (CB6, JS016, LY3832479 or LY-CoV016', 'placebo', 'etesevimab or a placebo']","['tolerability, safety, pharmacokinetics (PK), and immunogenicity', 'Tolerability, Safety, Pharmacokinetics, and Immunogenicity', 'tolerated']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0282682', 'cui_str': 'Blocking antibody'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0003250', 'cui_str': 'Monoclonal antibody'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",40.0,0.374423,"Seventeen (42.5%) participants experienced 22 treatment emergent adverse events (TEAEs) that were drug-related, and the rates of these TEAEs among different dose cohorts were numerically comparable.","[{'ForeName': 'Xiaojie', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Nanyang', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Guoqin', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.'}, {'ForeName': 'Jicheng', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Guoying', 'Initials': 'G', 'LastName': 'Cao', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yuancheng', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.'}, {'ForeName': 'Jufang', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Haijing', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Xiaomeng', 'Initials': 'X', 'LastName': 'Mao', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jinjie', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yiqi', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Qiu', 'Affiliation': 'Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.'}, {'ForeName': 'Sheng', 'Initials': 'S', 'LastName': 'Yao', 'Affiliation': 'Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Feng', 'Affiliation': 'Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.'}, {'ForeName': 'Jinghua', 'Initials': 'J', 'LastName': 'Yan', 'Affiliation': 'CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Wenhong', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00350-21'] 3233,33972248,Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.,"Higher doses of intravenous rifampicin may improve outcomes in tuberculous meningitis but are impractical in high-burden settings. We hypothesized that plasma rifampicin exposures would be similar between oral dosing of 35 mg/kg of body weight and intravenous dosing of 20 mg/kg, which has been proposed for efficacy trials in tuberculous meningitis. We performed a randomized parallel-group pharmacokinetic study nested within a clinical trial of intensified antimicrobial therapy for tuberculous meningitis. HIV-positive participants with tuberculous meningitis were recruited from South African hospitals and randomized to one of three rifampicin dosing groups: standard (oral 10 mg/kg), high dose (oral 35 mg/kg), and intravenous (20 mg/kg). Intensive pharmacokinetic sampling was done on day 3. Data were described using noncompartmental analysis, and exposures were compared by geometric mean ratios (GMRs). Forty-six participants underwent pharmacokinetic sampling (standard dose, n  = 17; high-dose oral, n = 15; intravenous, n  = 14). The median CD4 count was 130 cells/mm 3 (interquartile range [IQR], 66 to 253 cells/mm 3 ). The rifampicin geometric mean area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) values were 42.9 μg · h/ml (95% confidence interval [CI], 24.5 to 75.0 μg · h/ml) for the standard dose, 295.2 μg · h/ml (95% CI, 189.9 to 458.8 μg · h/ml) for the high oral dose, and 206.5 μg · h/ml (95% CI, 154.6 to 275.8 μg · h/ml) for intravenous administration. The rifampicin AUC 0-24 GMR was 1.44 (90% CI, 0.84 to 2.21) and the maximal concentration of drug in serum ( C max ) GMR was 0.89 (90% CI, 0.63 to 1.23) for high-dose oral administration with respect to intravenous dosing. The plasma rifampicin AUC 0-24 was higher after an oral 35-mg/kg dose than with intravenous administration at a 20-mg/kg dose over the first few days of tuberculosis (TB) treatment. The findings support oral rifampicin dosing in future tuberculous meningitis trials.",2021,"Rifampicin geometric mean AUC 0-24 was 42.9 μg·h/mL (95% CI, 24.5 - 75.0) for standard dose; 295.2 μg·h/mL (95% CI, 189.9 - 458.8) for high dose oral; and 206.5 μg·h/mL (95% CI, 154.6 - 275.8) for intravenous administration.","['patients with tuberculous meningitis', 'tuberculous meningitis', 'HIV-positive participants with tuberculous meningitis were recruited from South African hospitals']","['intravenous rifampicin', 'Rifampicin', 'Rifampicin AUC', 'intensified antimicrobial therapy', 'rifampicin']","['Median CD4 count', 'Plasma pharmacokinetics']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041318', 'cui_str': 'Tuberculosis of meninges'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0035608', 'cui_str': 'Rifampin'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Cell Counts'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",46.0,0.303739,"Rifampicin geometric mean AUC 0-24 was 42.9 μg·h/mL (95% CI, 24.5 - 75.0) for standard dose; 295.2 μg·h/mL (95% CI, 189.9 - 458.8) for high dose oral; and 206.5 μg·h/mL (95% CI, 154.6 - 275.8) for intravenous administration.","[{'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Wasserman', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Angharad', 'Initials': 'A', 'LastName': 'Davis', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Cari', 'Initials': 'C', 'LastName': 'Stek', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Maxwell', 'Initials': 'M', 'LastName': 'Chirehwa', 'Affiliation': 'Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Stephani', 'Initials': 'S', 'LastName': 'Botha', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Remy', 'Initials': 'R', 'LastName': 'Daroowala', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Marise', 'Initials': 'M', 'LastName': 'Bremer', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Mpumi', 'Initials': 'M', 'LastName': 'Maxebengula', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Sonya', 'Initials': 'S', 'LastName': 'Koekemoer', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Rene', 'Initials': 'R', 'LastName': 'Goliath', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Jackson', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Crede', 'Affiliation': 'Department of Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Naude', 'Affiliation': 'Department of Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Patryk', 'Initials': 'P', 'LastName': 'Szymanski', 'Affiliation': 'Department of Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Yakoob', 'Initials': 'Y', 'LastName': 'Vallie', 'Affiliation': 'Department of Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Muhammed S', 'Initials': 'MS', 'LastName': 'Moosa', 'Affiliation': 'Department of Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Lubbe', 'Initials': 'L', 'LastName': 'Wiesner', 'Affiliation': 'Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Black', 'Affiliation': 'Livingstone Hospital Complex, Eastern Cape Department of Health, Port Elizabeth, South Africa.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Meintjes', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Maartens', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Wilkinson', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00140-21'] 3234,34390109,The effectiveness of weight-loss lifestyle interventions for improving fertility in women and men with overweight or obesity and infertility: A systematic review update of evidence from randomized controlled trials.,"Being overweight or obese can have a negative impact on fertility outcomes. This systematic review updates randomized controlled trial (RCT) findings on the effectiveness of weight loss interventions in reducing weight and improving reproductive outcomes of women and men with overweight or obesity and infertility. Eligible studies, published since the last review, were identified by searching databases from March 20, 2016 until March 31, 2020. RCTs involving any type of lifestyle intervention were considered. Eight RCTs were identified and aggregated with seven RCTs included in our previous review. Meta-analyses revealed that women randomized to a combined diet and exercise intervention were more likely to become pregnant, risk ratio (RR) = 1.87 (95% CI 1.20, 2.93) and achieve a live birth RR = 2.20 (95% CI 1.23, 3.94), compared to women in control groups who received no or minimal intervention. This pattern was not replicated in trials where control groups received immediate access to assisted reproductive technology (ART). No eligible randomized trials involving men were identified. Data were largely obtained from small scale studies. Better designed, adequately powered, robust randomized trials are needed to better understand the effect of weight loss interventions on reproductive outcomes in both women and men.",2021,"(95% CI 1.23, 3.94), compared to women in control groups who received no or minimal intervention.","['women and men', 'women and men with overweight or obesity and infertility']","['weight-loss lifestyle interventions', 'combined diet and exercise intervention', 'weight loss interventions', 'immediate access to assisted reproductive technology (ART']",[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0035157', 'cui_str': 'Reproductive Technologies'}, {'cui': 'C0872104', 'cui_str': 'Assisted reproductive technology'}]",[],,0.170428,"(95% CI 1.23, 3.94), compared to women in control groups who received no or minimal intervention.","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hunter', 'Affiliation': 'Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Avenell', 'Affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'Abha', 'Initials': 'A', 'LastName': 'Maheshwari', 'Affiliation': 'Aberdeen Fertility Centre, Aberdeen Maternity Hospital, Aberdeen, UK.'}, {'ForeName': 'Gertraud', 'Initials': 'G', 'LastName': 'Stadler', 'Affiliation': 'Institute of Gender in Medicine, Charité University Berlin, Germany & Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'Damian', 'Initials': 'D', 'LastName': 'Best', 'Affiliation': 'Faculty of Medical Sciences, University of the West Indies, Bridgetown, Barbados.'}]",Obesity reviews : an official journal of the International Association for the Study of Obesity,['10.1111/obr.13325'] 3235,33982590,Neuromuscular electrical stimulation resistance training enhances oxygen uptake and ventilatory efficiency independent of mitochondrial complexes after spinal cord injury: a randomized clinical trial.,"The purpose of the study was to determine whether neuromuscular electrical stimulation resistance training (NMES-RT)-evoked muscle hypertrophy is accompanied by increased V̇o 2 peak, ventilatory efficiency, and mitochondrial respiration in individuals with chronic spinal cord injury (SCI). Thirty-three men and women with chronic, predominantly traumatic SCI were randomized to either NMES-RT ( n = 20) or passive movement training (PMT; n = 13). Functional electrical stimulation-lower extremity cycling (FES-LEC) was used to test the leg V̇o 2 peak, V̇E/V̇co 2 ratio, and substrate utilization pre- and postintervention. Magnetic resonance imaging was used to measure muscle cross-sectional area (CSA). Finally, muscle biopsy was performed to measure mitochondrial complexes and respiration. The NMES-RT group showed a significant increase in postintervention V̇o 2 peak compared with baseline (ΔV̇o 2 = 14%, P < 0.01) with no changes in the PMT group (ΔV̇o 2 = 1.6%, P = 0.47). Similarly, thigh (ΔCSA thigh = 19%) and knee extensor (ΔCSA knee = 30.4%, P < 0.01) CSAs increased following NMES-RT but not after PMT. The changes in thigh and knee extensor muscle CSAs were positively related with the change in V̇o 2 peak. Neither NMES-RT nor PMT changed mitochondrial complex tissue levels; however, changes in peak V̇o 2 were related to complex I. In conclusion, in persons with SCI, NMES-RT-induced skeletal muscle hypertrophy was accompanied by increased peak V̇o 2 consumption which may partially be explained by enhanced activity of mitochondrial complex I. NEW & NOTEWORTHY Leg oxygen uptake (V̇o 2 ) and ventilatory efficiency (V̇E/V̇co 2 ratio) were measured during functional electrical stimulation cycling testing following 12-16 wk of either electrically evoked resistance training or passive movement training, and the respiration of mitochondrial complexes. Resistance training increased thigh muscle area and leg V̇o 2 peak but decreased V̇E/V̇co 2 ratio without changes in mitochondrial complex levels. Leg V̇o 2 peak was associated with muscle hypertrophy and mitochondrial respiration of complex I following training.",2021,"The NMES-RT group showed a significant increase in post-intervention VO 2 peak compared to baseline (∆ VO 2 = 14%, P < 0.01) with no changes in the PMT group (∆ VO 2 = 1.6%, P= 0.47).","['Thirty-three men and women with chronic, predominantly traumatic, SCI', 'individuals with chronic spinal cord injury (SCI']","['neuromuscular electrical stimulation resistance training (NMES-RT', 'passive movement training', 'Functional electrical stimulation-lower extremity cycling (FES-LEC', 'NMES-RT', 'NMES-Resistance Training', 'Magnetic resonance imaging']","['changes in thigh and knee extensor muscle CSAs', 'Oxygen Uptake and Ventilatory Efficiency', 'knee extensor', 'post-intervention VO 2 peak']","[{'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0079991', 'cui_str': 'Passive movement'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0525959', 'cui_str': '16-fluoroestradiol, (16alpha, 17beta)-isomer, (18F)-labeled'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}]",33.0,0.0232198,"The NMES-RT group showed a significant increase in post-intervention VO 2 peak compared to baseline (∆ VO 2 = 14%, P < 0.01) with no changes in the PMT group (∆ VO 2 = 1.6%, P= 0.47).","[{'ForeName': 'Ashraf S', 'Initials': 'AS', 'LastName': 'Gorgey', 'Affiliation': 'Spinal Cord Injury and Disorders Hunter Holmes McGuire VA Medical Center, Richmond, Virginia.'}, {'ForeName': 'Raymond E', 'Initials': 'RE', 'LastName': 'Lai', 'Affiliation': 'Spinal Cord Injury and Disorders Hunter Holmes McGuire VA Medical Center, Richmond, Virginia.'}, {'ForeName': 'Refka E', 'Initials': 'RE', 'LastName': 'Khalil', 'Affiliation': 'Spinal Cord Injury and Disorders Hunter Holmes McGuire VA Medical Center, Richmond, Virginia.'}, {'ForeName': 'Jeannie', 'Initials': 'J', 'LastName': 'Rivers', 'Affiliation': 'Surgical Service, Hunter Holmes McGuire VA Medical Center, Richmond, Virginia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Cardozo', 'Affiliation': 'National Center for the Medical Consequences of Spinal Cord Injury and Medical and Surgical Service, James J Peters VA Medical Center, Bronx, New York.'}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Medical Service, Hunter Holmes McGuire VA Medical Center, Richmond, Virginia.'}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Lesnefsky', 'Affiliation': 'Medical Service, Hunter Holmes McGuire VA Medical Center, Richmond, Virginia.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.01029.2020'] 3236,33980033,Effect of botulinum toxin on quality of life of patients with chronic myofascial pain.,"Aim: This prospective controlled clinical study aimed to evaluate the effect of botulinum toxin Type A (BTX-A) on pain control and quality of life (QoL) in patients with chronic myofascial pain. Materials & methods: Patients with chronic myofascial pain were randomly divided into two groups (n = 20): counseling and self-care and Michigan-type occlusal splint (MOS) (CG-control group) or BTX-A injection (BTX-AG). The pain was evaluated with visual analogue scale and QoL with the oral health impact profile-14 (OHIP-14) questionnaire. Results: In both groups, the pain was reduced, and QoL improved after 30 days. The results of social disability and handicap were better for patients treated with counseling and self-care and MOS. Conclusion: Minimally invasive strategies and BTX-A application improved QoL and alleviated myofascial pain.",2021,The results of social disability and handicap were better for patients treated with counseling and self-care and MOS. ,"['patients with chronic myofascial pain', 'Patients with chronic myofascial pain']","['botulinum toxin', 'counseling and self-care\xa0and Michigan-type occlusal splint\xa0(MOS', 'BTX-A injection (BTX-AG', 'botulinum toxin Type\xa0A (BTX-A']","['QoL and alleviated myofascial pain', 'pain control and quality of life (QoL', 'pain', 'social disability and handicap', 'QoL', 'quality of life', 'visual analogue scale\xa0and QoL with the oral health impact profile-14 (OHIP-14) questionnaire']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0553642', 'cui_str': 'Myofascial pain'}]","[{'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0025939', 'cui_str': 'Michigan'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0162528', 'cui_str': 'Occlusal appliance'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0553642', 'cui_str': 'Myofascial pain'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0109276,The results of social disability and handicap were better for patients treated with counseling and self-care and MOS. ,"[{'ForeName': 'Edivaldo', 'Initials': 'E', 'LastName': 'Miotto', 'Affiliation': 'Department of Orthodontics, Ingá University Center UNINGÁ, Maringá, Brazil.'}, {'ForeName': 'Karina Maria', 'Initials': 'KM', 'LastName': 'Salvatore Freitas', 'Affiliation': 'Department of Orthodontics, Ingá University Center UNINGÁ, Maringá, Brazil.'}, {'ForeName': 'Aline Akemi', 'Initials': 'AA', 'LastName': 'Mori', 'Affiliation': 'Department of Orthodontics, Ingá University Center UNINGÁ, Maringá, Brazil.'}, {'ForeName': 'Fabricio Pinelli', 'Initials': 'FP', 'LastName': 'Valarelli', 'Affiliation': 'Department of Orthodontics, Ingá University Center UNINGÁ, Maringá, Brazil.'}, {'ForeName': 'Ricardo Cesar', 'Initials': 'RC', 'LastName': 'Gobbi de Oliveira', 'Affiliation': 'Department of Orthodontics, Ingá University Center UNINGÁ, Maringá, Brazil.'}, {'ForeName': 'Renata Cristina', 'Initials': 'RC', 'LastName': 'Oliveira', 'Affiliation': 'Department of Orthodontics, Ingá University Center UNINGÁ, Maringá, Brazil.'}]",Pain management,['10.2217/pmt-2020-0045'] 3237,33988886,Cross-sectional study on patients' understanding and views of the informed consent procedure of a secondary stroke prevention trial.,"BACKGROUND AND PURPOSE Improving understanding of study contents and procedures might enhance recruitment into studies and retention during follow-up. However, data in stroke patients on understanding of the informed consent (IC) procedure are sparse. METHODS We conducted a cross-sectional study among ischemic stroke patients taking part in the IC procedure of an ongoing cluster-randomized secondary prevention trial. All aspects of the IC procedure were assessed in an interview using a standardized 20-item questionnaire. Responses were collected within 72 h after the IC procedure and analyzed quantitatively and qualitatively. Participants were also asked their main reasons for participation. RESULTS A total of 146 stroke patients (65 ± 12 years old, 38% female) were enrolled. On average, patients recalled 66.4% (95% confidence interval = 65.2%-67.5%) of the content of the IC procedure. Most patients understood that participation was voluntary (99.3%) and that they had the right to withdraw consent (97.1%); 79.1% of the patients recalled the study duration and 56.1% the goal. Only 40.3% could clearly state a benefit of participation, and 28.8% knew their group allocation. Younger age, higher graduation, and allocation to the intervention group were associated with better understanding. Of all patients, 53% exclusively stated a personal and 22% an altruistic reason for participation. CONCLUSIONS Whereas understanding of patient rights was high, many patients were unable to recall other important aspects of study content and procedures. Increased attention to older and less educated patients may help to enhance understanding in this patient population. Actual recruitment and retention benefit of an improved IC procedure remains to be tested in a randomized trial.",2021,"On average, patients recalled 66.4% (95% CI 65.2%-67.5%) of the content of the IC procedure.","['146 stroke patients (65±12 years, 38% female) were enrolled', 'ischemic stroke patients taking part in the IC procedure of an ongoing cluster-randomized secondary prevention trial']",[],[],"[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0679699', 'cui_str': 'Secondary prevention'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],[],146.0,0.0921106,"On average, patients recalled 66.4% (95% CI 65.2%-67.5%) of the content of the IC procedure.","[{'ForeName': 'Felizitas A', 'Initials': 'FA', 'LastName': 'Eichner', 'Affiliation': 'Institute for Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.'}, {'ForeName': 'Joschua M', 'Initials': 'JM', 'LastName': 'Reis', 'Affiliation': 'Institute for Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.'}, {'ForeName': 'Joaquim', 'Initials': 'J', 'LastName': 'Dores', 'Affiliation': 'Department of Neurology, Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen, Germany.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Pavlovic', 'Affiliation': 'Neurological Clinic, Leopoldina Krankenhaus Schweinfurt, Schweinfurt, Germany.'}, {'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Kreß', 'Affiliation': 'Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany.'}, {'ForeName': 'Naeimeh', 'Initials': 'N', 'LastName': 'Daneshkhah', 'Affiliation': 'Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany.'}, {'ForeName': 'Renate', 'Initials': 'R', 'LastName': 'Weinhardt', 'Affiliation': 'Neurological Clinic, Rhön-Klinikum Campus Bad Neustadt an der Saale, Bad Neustadt, Germany.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Grau', 'Affiliation': 'Department of Neurology, Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Mühler', 'Affiliation': 'Neurological Clinic, Leopoldina Krankenhaus Schweinfurt, Schweinfurt, Germany.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Soda', 'Affiliation': 'Neurological Clinic, Rhön-Klinikum Campus Bad Neustadt an der Saale, Bad Neustadt, Germany.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Schwarzbach', 'Affiliation': 'Department of Neurology, Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schuler', 'Affiliation': 'Institute for Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.'}, {'ForeName': 'Karl Georg', 'Initials': 'KG', 'LastName': 'Häusler', 'Affiliation': 'Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany.'}, {'ForeName': 'Peter U', 'Initials': 'PU', 'LastName': 'Heuschmann', 'Affiliation': 'Institute for Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.'}]",European journal of neurology,['10.1111/ene.14917'] 3238,33987881,Pain referral area is reduced by remote pain.,"BACKGROUND Endogenous pain inhibitory mechanisms are known to reduce pain intensity, but whether they influence the size and distribution of pain referral is unclear. This study aimed to determine if referred pain is reduced by applying a remote, conditioning painful stimulus. METHODS Twenty-four healthy men participated in this randomized, crossover study with a control and conditioning session. Referred pain was induced from the infraspinatus muscle (dominant side) by a painful pressure for 60 s. When applying pressure, the intensity was adjusted to a local pain intensity of 7/10 on a numerical rating scale. In the conditioning session, tonic painful pressure was simultaneously applied to the non-dominant leg during induction of referred pain. The area of referred pain was drawn onto a digital body chart and size extracted for data analysis. RESULTS For the total group and in a subgroup with distinct patterns of referred pain (n = 15/24), the pain area perceived in the back and front+back was smaller during the conditioning compared with the control (p < 0.05). No significant difference was found between sessions in a subgroup only demonstrating local pain (n = 9/24). CONCLUSIONS Engaging the descending noxious inhibitory control reduced the size of pain areas predominately when distinct pain referral was present. Assuming a conditioning effect of descending inhibitory control acting on dorsal horn neurons, these findings may indicate that mechanisms underlying pain referral can be modulated by endogenous control. The findings may indicate that referred pain may be a useful proxy to evaluate sensitivity of central pain mechanisms as previously suggested. SIGNIFICANCE The current results indicate a link between endogenous inhibition and pain referral. Descending inhibitory control effects on pain referral support a spinal mechanism involved in pain referral. Future studies should investigate whether the spatial characteristics of referred pain (e.g. size, frequency of affected body regions and distribution away from the primary nociceptive stimulus) can useful to evaluate the efficiency of endogenous pain modulation.",2021,"No significant difference was found between sessions in a subgroup only demonstrating local pain (n=9/24). ",['Twenty-four healthy men'],['control and conditioning session'],"['tonic painful pressure', 'Pain referral area', 'Referred pain', 'local pain', 'size of pain areas', 'pain area']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C3543842', 'cui_str': 'TONICS'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0234250', 'cui_str': 'Referred pain'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",24.0,0.101462,"No significant difference was found between sessions in a subgroup only demonstrating local pain (n=9/24). ","[{'ForeName': 'Thorvaldur S', 'Initials': 'TS', 'LastName': 'Palsson', 'Affiliation': 'Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Doménech-García', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, Universidad San Jorge, Villanueva de Gállego, Zaragoza, Spain.'}, {'ForeName': 'Shellie S', 'Initials': 'SS', 'LastName': 'Boudreau', 'Affiliation': 'Center For Neuroplasticity and Pain (CNAP), Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Graven-Nielsen', 'Affiliation': 'Center For Neuroplasticity and Pain (CNAP), Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.'}]","European journal of pain (London, England)",['10.1002/ejp.1792'] 3239,34390076,Does Treatment Preference Affect Outcome in a Randomized Trial of a Mindfulness Intervention versus Cognitive Behaviour Therapy for Social Anxiety Disorder?,"Research suggests that treatment preference may affect outcome of randomized clinical trials, but few studies have assessed treatment preference in trials comparing different types of psychosocial interventions. This study used secondary data analysis to evaluate the impact of treatment preference in a randomized trial of a mindfulness-based intervention adapted for social anxiety disorder (MBI-SAD) versus cognitive behaviour group therapy (CBGT). Ninety-seven participants who met DSM-5 criteria for SAD were randomized. Prior to randomization, twice as many participants expressed a preference for the MBI-SAD over CBGT. However, being allocated or not to one's preferred treatment had no impact on treatment response. Additionally, with the exception of perception of treatment credibility, treatment matching had no impact on treatment-related variables, including treatment initiation, session attendance, homework compliance, satisfaction with treatment, and perception that treatment met expectations. In sum, despite the greater preference for the mindfulness intervention in this sample of participants with SAD, we found little evidence of preference effects on our study outcomes. Findings should be viewed as preliminary and require replication.",2021,"Additionally, with the exception of perception of treatment credibility, treatment matching had no impact on treatment-related variables, including treatment initiation, session attendance, homework compliance, satisfaction with treatment, and perception that treatment met expectations.",['Ninety-seven participants who met DSM-5 criteria for SAD were randomized'],"['Mindfulness Intervention versus Cognitive Behaviour Therapy', 'mindfulness-based intervention adapted for social anxiety disorder (MBI-SAD) versus cognitive behaviour group therapy (CBGT']","['treatment initiation, session attendance, homework compliance, satisfaction with treatment, and perception that treatment met expectations']","[{'cui': 'C0439073', 'cui_str': '97'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0033971', 'cui_str': 'Group psychotherapy'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0589414', 'cui_str': 'Homework'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}]",97.0,0.0604323,"Additionally, with the exception of perception of treatment credibility, treatment matching had no impact on treatment-related variables, including treatment initiation, session attendance, homework compliance, satisfaction with treatment, and perception that treatment met expectations.","[{'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Koszycki', 'Affiliation': 'University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Ilton', 'Affiliation': 'University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Dowell', 'Affiliation': 'University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Bradwejn', 'Affiliation': 'University of Ottawa, Ottawa, Ontario, Canada.'}]",Clinical psychology & psychotherapy,['10.1002/cpp.2658'] 3240,34389983,FDA Breakthrough Therapy Designation-Trial Design and More - Commentary.,,2021,,[],[],[],[],[],[],,0.13841,,"[{'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Corrigan-Curay', 'Affiliation': 'Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Stein', 'Affiliation': 'Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.2378'] 3241,33989780,"Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).","INTRODUCTION We aimed to evaluate the efficacy and safety of intrathecal pemetrexed (IP) for treating EGFR-mutant leptomeningeal metastases (LMs) from EGFR-mutant NSCLC. METHODS Patients with EGFR-mutant NSCLC with LM who had failed tyrosine kinase inhibitors were recruited. The dose of IP was escalated from 15 mg to 80 mg using an accelerated titration design in a phase 1 study. The recommended dose (RD) determined in phase 1 was used in the phase 2 study. The primary end point was treatment efficacy measured as the clinical response rate. Overall survival and adverse events (AEs) were evaluated as secondary end points. RESULTS The RD observed in the phase 1 study was 50 mg pemetrexed. A total of 30 cases of LM-NSCLC were enrolled in the phase 2 study, including 14 males and 16 females. Four patients did not survive for 4 weeks and could not be evaluated for efficacy. The clinical response rate was 84.6% (22 of 26). The median overall survival of all patients was 9.0 months (n = 30, 95% confidence interval: 6.6-11.4 mo). Most AEs were mild, and the most frequent AE of any grade was myelosuppression (n = 9, 30%), which returned to normal after symptomatic treatment. CONCLUSIONS This study revealed that 50 mg pemetrexed is the RD which results in few AEs and a good response rate. IP is an effective treatment for patients with EGFR-mutant NSCLC-LM who had failed on tyrosine kinase inhibitor.",2021,"The median OS of all patients was 9.0 months (n=30, 95%CI, 6.6-11.4 months).","['EGFR-mutant NSCLC patients with LM who had failed tyrosine-kinase inhibitors (TKIs) were recruited', 'A total of 30 cases of LM-NSCLC were enrolled in the Phase II study, including 14 males and 16 females']","['Intrathecal pemetrexed', 'intrathecal pemetrexed (IP', 'Intrathecal Pemetrexed Combined with Dexamethasone']","['efficacy and safety', 'Efficacy and Safety', 'Overall survival (OS) and adverse events (AEs', 'treatment efficacy', 'clinical response rate', 'median OS', 'myelosuppression']","[{'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948840', 'cui_str': 'Meningeal leukemia'}, {'cui': 'C1268567', 'cui_str': 'Protein-tyrosine kinase inhibitor'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0854467', 'cui_str': 'Myelosuppression'}]",,0.0437843,"The median OS of all patients was 9.0 months (n=30, 95%CI, 6.6-11.4 months).","[{'ForeName': 'Chengjuan', 'Initials': 'C', 'LastName': 'Fan', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Qiuyu', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Weixi', 'Initials': 'W', 'LastName': 'Shen', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Du', 'Affiliation': ""Department of Oncology, The Second Tumor Hospital of Heilongjiang Province, Harbin, People's Republic of China.""}, {'ForeName': 'Chong', 'Initials': 'C', 'LastName': 'Teng', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Gao', 'Affiliation': ""Department of Oncology, The Second Tumor Hospital of Heilongjiang Province, Harbin, People's Republic of China.""}, {'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Song', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Qiuying', 'Initials': 'Q', 'LastName': 'Jiang', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Dayong', 'Initials': 'D', 'LastName': 'Huang', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Yinghua', 'Initials': 'Y', 'LastName': 'Jin', 'Affiliation': ""Department of Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Yanju', 'Initials': 'Y', 'LastName': 'Lv', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Lingxiao', 'Initials': 'L', 'LastName': 'Wei', 'Affiliation': ""Department of Oncology, Yunnan Cancer Hospital, Kunming, People's Republic of China.""}, {'ForeName': 'Tengfei', 'Initials': 'T', 'LastName': 'Shi', 'Affiliation': ""Department of Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Naisheng', 'Initials': 'N', 'LastName': 'Gao', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Zhengjun', 'Initials': 'Z', 'LastName': 'Jiang', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Xin', 'Affiliation': ""Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. Electronic address: xintao1234@263.net.""}]",Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,['10.1016/j.jtho.2021.04.018'] 3242,34389923,Cost Effectiveness of a Cultural Physical Activity Intervention to Reduce Blood Pressure Among Native Hawaiians with Hypertension.,"OBJECTIVE The aim of this study was to calculate the costs and assess whether a culturally grounded physical activity intervention offered through community-based organizations is cost effective in reducing blood pressure among Native Hawaiian adults with hypertension. METHODS Six community-based organizations in Hawai'i completed a randomized controlled trial between 2015 and 2019. Overall, 263 Native Hawaiian adults with uncontrolled hypertension (≥ 140 mmHg systolic, ≥ 90 mmHg diastolic) were randomized to either a 12-month intervention group of hula (traditional Hawaiian dance) lessons and self-regulation classes, or to an education-only waitlist control group. The primary outcome was change in systolic blood pressure collected at baseline and 3, 6, and 12 months for the intervention compared with the control group. Incremental cost-effectiveness ratios (ICERs) were calculated for primary and secondary outcomes. Non-parametric bootstrapping and sensitivity analyses evaluated uncertainty in parameters and outcomes. RESULTS The mean intervention cost was US$361/person, and the 6-month ICER was US$103/mmHg reduction in systolic blood pressure and US$95/mmHg in diastolic blood pressure. At 12 months, the intervention group maintained reductions in blood pressure, which exceeded reductions for usual care based on blood pressure outcomes. The change in blood pressure at 12 months resulted in ICERs of US$100/mmHg reduction in systolic blood pressure and US$93/mmHg in diastolic blood pressure. Sensitivity analyses suggested that at the estimated intervention cost, the probability that the program would lower systolic blood pressure by 5 mmHg was 67 and 2.5% at 6 and 12 months, respectively. CONCLUSION The 6-month Ola Hou program may be cost effective for low-resource community-based organizations. Maintenance of blood pressure reductions at 6 and 12 months in the intervention group contributed to potential cost effectiveness. Future studies should further evaluate the cost effectiveness of indigenous physical activity programs in similar settings and by modeling lifetime costs and quality-adjusted life-years. TRIAL REGISTRATION NUMBER NCT02620709.",2021,"At 12 months, the intervention group maintained reductions in blood pressure, which exceeded reductions for usual care based on blood pressure outcomes.","['Native Hawaiian adults with hypertension', '263 Native Hawaiian adults with uncontrolled hypertension (≥\u2009140\xa0mmHg systolic, ≥\u200990', ""Six community-based organizations in Hawai'i completed a randomized controlled trial between 2015 and 2019"", 'Native Hawaiians with Hypertension']","['intervention group of hula (traditional Hawaiian dance) lessons and self-regulation classes, or to an education-only waitlist control group', 'Cultural Physical Activity Intervention', 'culturally grounded physical activity intervention']","['mmHg diastolic', 'blood pressure reductions', 'Blood Pressure', 'blood pressure outcomes', 'systolic blood pressure', 'potential cost effectiveness', 'Incremental cost-effectiveness ratios (ICERs', 'mean intervention cost', 'systolic blood pressure and US$95/mmHg in diastolic blood pressure', 'systolic blood pressure and US$93/mmHg in diastolic blood pressure', 'blood pressure']","[{'cui': 'C0337920', 'cui_str': 'Hawaiians'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C4517671', 'cui_str': '263'}, {'cui': 'C1868885', 'cui_str': 'Uncontrolled hypertension'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0018619', 'cui_str': 'Hawaii state'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0162878', 'cui_str': 'Hawaiian language'}, {'cui': 'C0010963', 'cui_str': 'Dance'}, {'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",,0.0557552,"At 12 months, the intervention group maintained reductions in blood pressure, which exceeded reductions for usual care based on blood pressure outcomes.","[{'ForeName': 'Ashley F', 'Initials': 'AF', 'LastName': 'Railey', 'Affiliation': 'Institute for Research and Education to Advance Community Health (IREACH), Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA. arailey@iu.edu.'}, {'ForeName': 'Clemma', 'Initials': 'C', 'LastName': 'Muller', 'Affiliation': 'Institute for Research and Education to Advance Community Health (IREACH), Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Noonan', 'Affiliation': 'Institute for Research and Education to Advance Community Health (IREACH), Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Schmitter-Edgecombe', 'Affiliation': 'Department of Psychology, Washington State University, Pullman, WA, USA.'}, {'ForeName': 'Ka Imi', 'Initials': 'KI', 'LastName': 'Sinclair', 'Affiliation': 'Institute for Research and Education to Advance Community Health (IREACH), Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.'}, {'ForeName': 'Corin', 'Initials': 'C', 'LastName': 'Kim', 'Affiliation': ""Kilohana, University of Hawai'i at Hilo, Hilo, HI, USA.""}, {'ForeName': 'Mele', 'Initials': 'M', 'LastName': 'Look', 'Affiliation': ""Department of Native Health, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Mānoa, HI, USA.""}, {'ForeName': ""J Keawe'aimoku"", 'Initials': 'JK', 'LastName': 'Kaholokula', 'Affiliation': ""Department of Native Health, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Mānoa, HI, USA.""}]",PharmacoEconomics - open,['10.1007/s41669-021-00291-6'] 3243,34389850,Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials.,"Randomized clinical trials are the gold standard for new drugs development. Clinical trials became increasingly complex, in particular in the field of inflammatory bowel diseases. For this reason, a new study design called ""cluster randomized trial"" has been introduced. Cluster randomized trials randomly assign groups of individuals within a population of interest, such as people in a particular research site, clinic, or hospital, and measure the effects of an intervention at the individual level. In contrast to individual randomization, cluster randomization permits the evaluation of a cluster-level intervention, may be logistically simpler and less expensive than a conventional randomized trial, and can help reduce the effect of treatment contamination. An important aspect requiring special attention in cluster randomized trials is the risk for imbalance of covariates at baseline which decreases statistical power and precision of the results, and reduces face validity and credibility of the trial results. A variety of restricted randomization methods have been proposed to minimize risk of imbalance. Our aim is to clarify the advantages and drawbacks of cluster randomized trials in order to properly interpret study results and to identify their role in upcoming inflammatory bowel disease trials.",2021,"In contrast to individual randomization, cluster randomization permits the evaluation of a cluster-level intervention, may be logistically simpler and less expensive than a conventional randomized trial, and can help reduce the effect of treatment contamination.","['individuals within a population of interest, such as people in a particular research site, clinic, or hospital']",[],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]",[],[],,0.102167,"In contrast to individual randomization, cluster randomization permits the evaluation of a cluster-level intervention, may be logistically simpler and less expensive than a conventional randomized trial, and can help reduce the effect of treatment contamination.","[{'ForeName': 'Bénédicte', 'Initials': 'B', 'LastName': 'Caron', 'Affiliation': 'Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, 54500 Vandoeuvre-lès-Nancy, France.'}, {'ForeName': 'Ferdinando', 'Initials': 'F', 'LastName': ""D'Amico"", 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy.'}, {'ForeName': 'Silvio', 'Initials': 'S', 'LastName': 'Danese', 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Peyrin-Biroulet', 'Affiliation': 'Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, 54500 Vandoeuvre-lès-Nancy, France.'}]",Journal of Crohn's & colitis,['10.1093/ecco-jcc/jjab149'] 3244,34389780,Effect of adding hydrochlorothiazide to usual treatment of patients with acute decompensated heart failure: a randomized clinical trial.,"Acute decompensated heart failure (ADHF) is the leading cause of hospitalization in patients aged 65 years or older, and most of them present with congestion. The use of hydrochlorothiazide (HCTZ) may increase the response to loop diuretics. To evaluate the effect of adding HCTZ to furosemide on congestion and symptoms in patients with ADHF. This randomized clinical trial compared HCTZ 50 mg versus placebo for 3 days in patients with ADHF and signs of congestion. The primary outcome of the study was daily weight reduction. Secondary outcomes were change in creatinine, need for vasoactive drugs, change in natriuretic peptides, congestion score, dyspnea, thirst, and length of stay. Fifty-one patients were randomized-26 to the HCTZ group and 25 to the placebo group. There was an increment of 0.73 kg/day towards additional weight reduction in the HCTZ group (HCTZ: - 1.78 ± 1.08 kg/day vs placebo: - 1.05 ± 1.51 kg/day; p = 0.062). In post hoc analysis, the HCTZ group demonstrated significant weight reduction for every 40 mg of intravenous furosemide (HCTZ: - 0.74 ± 0.47 kg/40 mg vs placebo: - 0.33 ± 0.80 kg/40 mg; p = 0.032). There was a trend to increase in creatinine in the HCTZ group (HCTZ: 0.50 ± 0.37 vs placebo: 0.27 ± 0.40; p = 0.05) but no significant difference in onset of acute renal failure (HCTZ: 58% vs placebo: 41%; p = 0.38). No differences were found in the remaining outcomes. Adding hydrochlorothiazide to usual treatment of patients with acute decompensated heart failure did not cause significant difference in daily body weight reduction compared to placebo. In analysis adjusted to the dose of intravenous furosemide, adding HCTZ 50 mg to furosemide resulted in a significant synergistic effect on weight loss.Trial registration: The Brazilian Clinical Trials Registry (ReBEC), a publically accessible primary register that participates in the World Health Organization International Clinical Trial Registry Platform; number RBR-5qkn8h. Registered in 23/07/2019 (retrospectively), http://www.ensaiosclinicos.gov.br/rg/RBR-5qkn8h/ .",2021,Adding hydrochlorothiazide to usual treatment of patients with acute decompensated heart failure did not cause significant difference in daily body weight reduction compared to placebo.,"['Acute decompensated heart failure (ADHF', 'patients aged 65\xa0years or older', 'patients with ADHF', 'patients with acute decompensated heart failure', 'patients with ADHF and signs of congestion']","['hydrochlorothiazide (HCTZ', 'HCTZ', 'hydrochlorothiazide', 'furosemide (HCTZ', 'furosemide', 'placebo']","['additional weight reduction', 'daily weight reduction', 'creatinine', 'weight loss', 'acute renal failure', 'change in creatinine, need for vasoactive drugs, change in natriuretic peptides, congestion score, dyspnea, thirst, and length of stay', 'daily body weight reduction', 'congestion and symptoms', 'weight reduction']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0700148', 'cui_str': 'Congestion'}]","[{'cui': 'C0020261', 'cui_str': 'Hydrochlorothiazide'}, {'cui': 'C0016860', 'cui_str': 'Furosemide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1144709', 'cui_str': 'Natriuretic Peptide Hormones'}, {'cui': 'C0700148', 'cui_str': 'Congestion'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0039971', 'cui_str': 'Thirst'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",51.0,0.535272,Adding hydrochlorothiazide to usual treatment of patients with acute decompensated heart failure did not cause significant difference in daily body weight reduction compared to placebo.,"[{'ForeName': 'Diogo Silva', 'Initials': 'DS', 'LastName': 'Piardi', 'Affiliation': 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Maurício', 'Initials': 'M', 'LastName': 'Butzke', 'Affiliation': 'Serviço de Cardiologia, Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, 2350, Porto Alegre, 90035-003, Brazil.'}, {'ForeName': 'Ana Carolina Martins', 'Initials': 'ACM', 'LastName': 'Mazzuca', 'Affiliation': 'Serviço de Cardiologia, Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, 2350, Porto Alegre, 90035-003, Brazil.'}, {'ForeName': 'Bruna Sessim', 'Initials': 'BS', 'LastName': 'Gomes', 'Affiliation': 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Sofia Giusti', 'Initials': 'SG', 'LastName': 'Alves', 'Affiliation': 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Bruno Jaskulski', 'Initials': 'BJ', 'LastName': 'Kotzian', 'Affiliation': 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Eduarda Chiesa', 'Initials': 'EC', 'LastName': 'Ghisleni', 'Affiliation': 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Giaretta', 'Affiliation': 'Serviço de Cardiologia, Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, 2350, Porto Alegre, 90035-003, Brazil.'}, {'ForeName': 'Priscila', 'Initials': 'P', 'LastName': 'Bellaver', 'Affiliation': 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Gabrielle Aguiar', 'Initials': 'GA', 'LastName': 'Varaschin', 'Affiliation': 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Arthur Pereira', 'Initials': 'AP', 'LastName': 'Garbin', 'Affiliation': 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Luís', 'Initials': 'L', 'LastName': 'Beck-da-Silva', 'Affiliation': 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. lbneto@hcpa.edu.br.'}]",Scientific reports,['10.1038/s41598-021-96002-6'] 3245,33994294,Postoperative pain and edema control following different protocols of preemptive analgesia in the surgical removal of impacted third molars: A triple-blind parallel randomized placebo-controlled clinical trial.,"This randomized controlled clinical trial aimed to evaluate the preemptive effects of acetaminophen, ibuprofen, ketoprofen, nimesulide or dexamethasone on postoperative pain and edema in the surgical removal of impacted third molars. Participants underwent bilateral surgeries at 2 different times and were randomly given the test drug or placebo (split-mouth). Postoperative pain, edema and rescue medication were evaluated at different times. Study power was >80% for the observed effect size in the crossover repeated measures design. Differences between test drug and placebo were the response variable. Generalized Estimation Equation models were adjusted for each outcome. Sample comprised 5 groups (n = 20 each). Ibuprofen and nimesulide showed higher overall effects on pain scores over time, with no differences between them (p = 0.557). Acetaminophen showed significantly lower overall effects in edema control over time, when compared to other test drugs, that showed similar effects. Lower quantity of rescue medication were also observed for ibuprofen and nimesulide, with no differences between them (p = 0.999). Ibuprofen and nimesulide showed beneficial overall preemptive effects. Hence, in the decision-making process for preemptive analgesia in impacted third molar surgeries, ibuprofen and nimesulide should be considered on a case-by-case basis as the drugs of choice.",2021,"Acetaminophen showed significantly lower overall effects in edema control over time, when compared to other test drugs, that showed similar effects.","['surgical removal of impacted third molars', 'impacted third molars']","['Acetaminophen', 'Ibuprofen and nimesulide', 'ibuprofen and nimesulide', 'acetaminophen, ibuprofen, ketoprofen, nimesulide or dexamethasone', 'ibuprofen', 'preemptive analgesia', 'placebo']","['Lower quantity of rescue medication', 'Postoperative pain, edema and rescue medication', 'beneficial overall preemptive effects', 'postoperative pain and edema', 'Postoperative pain and edema control', 'pain scores']","[{'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}]","[{'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0132515', 'cui_str': 'nimesulide'}, {'cui': 'C0022635', 'cui_str': 'Ketoprofen'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0150561', 'cui_str': 'Edema control'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",,0.158932,"Acetaminophen showed significantly lower overall effects in edema control over time, when compared to other test drugs, that showed similar effects.","[{'ForeName': 'Bianca Fernanda Espósito', 'Initials': 'BFE', 'LastName': 'Santos', 'Affiliation': 'School of Dentistry, Department of Dental Clinics, Oral Pathology and Oral Surgery, Periodontology Division, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Fernando Oliveira', 'Initials': 'FO', 'LastName': 'Costa', 'Affiliation': 'School of Dentistry, Department of Dental Clinics, Oral Pathology and Oral Surgery, Periodontology Division, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Aécio Abner Campos', 'Initials': 'AAC', 'LastName': 'Pinto Júnior', 'Affiliation': 'Centro Universitário de Belo Horizonte, Department of Dentistry, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'André Vitor Alves', 'Initials': 'AVA', 'LastName': 'Araújo', 'Affiliation': 'Private Dental Clinic, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Renata Magalhães', 'Initials': 'RM', 'LastName': 'Cyrino', 'Affiliation': 'School of Dentistry, Department of Dental Clinics, Oral Pathology and Oral Surgery, Periodontology Division, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Luís Otávio Miranda', 'Initials': 'LOM', 'LastName': 'Cota', 'Affiliation': 'School of Dentistry, Department of Dental Clinics, Oral Pathology and Oral Surgery, Periodontology Division, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address: luiscota@ufmg.br.'}]",Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,['10.1016/j.jcms.2021.01.002'] 3246,34022425,Promoting Early Literacy Using Digital Devices: A Pilot Randomized Controlled Trial.,"OBJECTIVE To determine feasibility and explore effects of literacy promotion using e-books versus board books on the home reading environment, book reading, television use, and child development. METHODS Randomized controlled trial comparing digital literacy promotion (DLP) using e-books to standard literacy promotion (SLP) using board books among Medicaid-eligible infants. DLP participants received e-books on home digital devices, while SLP participants received board books at well visits between 6 and 12 months of age. Differences in StimQ Read Subscale (StimQ-Read) scores, parent-reported reading and television use, and Bayley Scales of Infant Development-3rd Edition (Bayley-3) scores between groups were assessed using intention-to-treat analysis. RESULTS A total of 104 Medicaid-eligible infants were enrolled and randomized from 3 pediatric practices. There were no differences in sociodemographic characteristics between groups at baseline. Children in the DLP group initially had lower StimQ-Read scores but showed similar increases in StimQ-Read scores over time as children in the SLP group. Parents in the DLP group reported greater use of digital devices to read or engage their child (65% vs 23%, P < .001) but similar board book reading and television viewing. There were no differences between groups in cognitive or motor scale scores, but DLP participants had marginally lower language scales scores (DLP 85.7 vs SLP 89.7; P = .10) at the 6-month follow-up. CONCLUSIONS/DISCUSSION Literacy promotion using e-books was feasible and associated with greater e-book usage but no difference in board book reading, television viewing, or home reading environment scores. A potential adverse impact of e-books on language development should be confirmed in future study.",2021,"There were no differences between groups in cognitive or motor scale scores, but DLP participants had marginally lower language scales scores (DLP 85.7 vs. SLP 89.7; p=0.10) at the 6-month follow-up. ","['104 Medicaid-eligible infants', 'Medicaid-eligible infants']","['digital literacy promotion (DLP) using e-books to standard literacy promotion (SLP', 'DLP']","['cognitive or motor scale scores', 'socio-demographic characteristics', 'board book reading, television viewing, or home reading environment scores', 'StimQ Read Subscale (StimQ-Read) scores, parent-reported reading and television use, and Bayley Scales of Infant Development-3 rd Edition (Bayley-3) scores', 'StimQ-Read scores', 'digital devices to read or engage their child', 'language scales scores']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0025071', 'cui_str': 'Medicaid coverage'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0006002', 'cui_str': 'Book'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0006002', 'cui_str': 'Book'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0039461', 'cui_str': 'Television'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0451021', 'cui_str': 'Bayley scale of infant development'}, {'cui': 'C0441792', 'cui_str': 'Editions'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023008', 'cui_str': 'Language'}]",104.0,0.166938,"There were no differences between groups in cognitive or motor scale scores, but DLP participants had marginally lower language scales scores (DLP 85.7 vs. SLP 89.7; p=0.10) at the 6-month follow-up. ","[{'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Guevara', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at Penn, Roberts Center for Pediatric Research (JP Guevara, D Erkoboni, and M Gerdes), Philadelphia, Pa. Electronic address: guevara@email.chop.edu.""}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Erkoboni', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at Penn, Roberts Center for Pediatric Research (JP Guevara, D Erkoboni, and M Gerdes), Philadelphia, Pa.""}, {'ForeName': 'Marsha', 'Initials': 'M', 'LastName': 'Gerdes', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at Penn, Roberts Center for Pediatric Research (JP Guevara, D Erkoboni, and M Gerdes), Philadelphia, Pa.""}, {'ForeName': 'Sherry', 'Initials': 'S', 'LastName': 'Winston', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, Roberts Center for Pediatric Research (S Winston and D Sands), Philadelphia, Pa.""}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Sands', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, Roberts Center for Pediatric Research (S Winston and D Sands), Philadelphia, Pa.""}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Rogers', 'Affiliation': ""Reach Out and Read Greater Philadelphia, Children's Hospital of Philadelphia, Roberts Center for Pediatric Research (K Rogers), Philadelphia, Pa.""}, {'ForeName': 'Trude', 'Initials': 'T', 'LastName': 'Haecker', 'Affiliation': ""Department of Pediatrics, Reach Out and Read Greater Philadelphia, Children's Hospital of Philadelphia, Roberts Center for Pediatric Research (T Haecker), Philadelphia, Pa.""}, {'ForeName': 'Manuel E', 'Initials': 'ME', 'LastName': 'Jimenez', 'Affiliation': 'Department of Pediatrics, Robert Wood Johnson Medical School, Rutgers University, Child Health Institute of New Jersey (ME Jimenez), New Brunswick, NJ.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Mendelsohn', 'Affiliation': 'Departments of Pediatrics and Population Health, New York University School of Medicine (AL Mendelsohn), New York, NY.'}]",Academic pediatrics,['10.1016/j.acap.2021.05.013'] 3247,34022376,Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial.,"BACKGROUND Nutritional support in patients with cancer aims at improving quality of life. Whether use of nutritional support is also effective in improving clinical outcomes requires further study. PATIENTS AND METHODS In this preplanned secondary analysis of patients with cancer included in a prospective, randomized-controlled, Swiss, multicenter trial (EFFORT), we compared protocol-guided individualized nutritional support (intervention group) to standard hospital food (control group) regarding mortality at 30-day (primary endpoint) and other clinical outcomes. RESULTS We analyzed 506 patients with a main admission diagnosis of cancer, including lung cancer (n = 113), gastrointestinal tumors (n = 84), hematological malignancies (n = 108) and other types of cancer (n = 201). Nutritional risk based on Nutritional Risk Screening (NRS 2002) was an independent predictor for mortality over 180 days with an (age-, sex-, center-, type of cancer-, tumor activity- and treatment-) adjusted hazard ratio of 1.29 (95% CI 1.09-1.54; P = 0.004) per point increase in NRS. In the 30-day follow-up period, 50 patients (19.9%) died in the control group compared to 36 (14.1%) in the intervention group resulting in an adjusted odds ratio of 0.57 (95% CI 0.35-0.94; P = 0.027). Interaction tests did not show significant differences in mortality across the cancer type subgroups. Nutritional support also significantly improved functional outcomes and quality of life measures. CONCLUSIONS Compared to usual hospital nutrition without nutrition support, individualized nutritional support reduced the risk of mortality and improved functional and quality of life outcomes in cancer patients with increased nutritional risk. These data further support the inclusion of nutritional care in cancer management guidelines.",2021,"Compared to usual hospital nutrition without nutrition support, individualized nutritional support reduced the risk for mortality and improved functional and quality of life outcomes in cancer patients with increased nutritional risk.","['patients with different types of cancers', 'cancer patients with increased nutritional risk', '506 patients with a main admission diagnosis of cancer, including lung cancer (n=113), gastrointestinal tumors (n=84), hematological malignancies (n=108) and other types of cancer (n=201', 'patients with cancer']",['protocol-guided individualized nutritional support (intervention group) to standard hospital food (control group'],"['mortality', 'risk for mortality and improved functional and quality of life outcomes', 'functional outcomes and quality of life measures']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0017185', 'cui_str': 'Neoplasm of gastrointestinal tract'}, {'cui': 'C0376545', 'cui_str': 'Hematologic neoplasm'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",506.0,0.0822852,"Compared to usual hospital nutrition without nutrition support, individualized nutritional support reduced the risk for mortality and improved functional and quality of life outcomes in cancer patients with increased nutritional risk.","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Bargetzi', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Brack', 'Affiliation': 'Medical Faculty of the University of Basel, Basel, Switzerland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Herrmann', 'Affiliation': 'Medical Faculty of the University of Basel, Basel, Switzerland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bargetzi', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Hersberger', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bargetzi', 'Affiliation': 'Medical Faculty of the University of Basel, Basel, Switzerland; Division of Oncology, Hematology and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Kaegi-Braun', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Tribolet', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Gomes', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; The New York Academy of Sciences, New York, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Hoess', 'Affiliation': 'Internal Medicine, Kantonsspital Muensterlingen, Muensterlingen, Switzerland.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Pavlicek', 'Affiliation': 'Internal Medicine, Kantonsspital Muensterlingen, Muensterlingen, Switzerland.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bilz', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, St.Gallen, Switzerland.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sigrist', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, St.Gallen, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Brändle', 'Affiliation': 'Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, St.Gallen, Switzerland.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Henzen', 'Affiliation': 'Internal Medicine, Kantonsspital Luzern, Luzern, Switzerland.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Thomann', 'Affiliation': 'Internal Medicine, Buergerspital Solothurn, Solothurn, Switzerland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Rutishauser', 'Affiliation': 'Internal Medicine, Kantonsspital Baselland, Liestal, Switzerland.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Aujesky', 'Affiliation': 'Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Rodondi', 'Affiliation': 'Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Donzé', 'Affiliation': ""Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Division of General Internal Medicine, Brigham and Women's Hospital, Boston, USA.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Laviano', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Stanga', 'Affiliation': 'Division of Diabetes, Endocrinology, Nutritional Medicine & Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Mueller', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Schuetz', 'Affiliation': 'Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland. Electronic address: schuetzph@gmail.com.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.05.793'] 3248,34389984,Intervention effects on self-control decrease speed of biological aging mediated by changes in substance use: A longitudinal study of African American youth.,"Biological aging is a common root for multiple diseases causing morbidity and mortality, and trajectories of aging may start early in life. This study was designed to examine whether a universal family-based substance use preventive intervention to enhance self-control and reduce substance use would also result in reductions in biological aging among Black youth from the rural South. The Adults in the Making (AIM) program is a randomized controlled trial with six 2-h sessions for Black youth. The 216 youths agreeing to provide blood at age 22 included 114 who had received the AIM intervention and 102 who assigned to the control group. We examined accelerated DNA methylation (DNAm)-based aging using a recently developed measure, ""GrimAge,"" that has been shown to predict the risk of early mortality and that is known to be more strongly affected by substance use than other DNAm-based aging indices. Relative to those randomly assigned to the control group, those receiving the intervention demonstrated significantly enhanced self-control, slower increases in substance use, and reduced Grim aging at age 22. Using a bootstrapping method with 1000 replications, we found a significant indirect effect of AIM on reduced Grim aging through its effect on self-control and substance use. Sensitivity analyses examined effects using other indices of DNAm-based aging. These findings suggest that a family-based program designed to enhance rural Black youth's self-control can have beneficial effects on self-control, enhancing young adult health and health behavior, and ultimately decreased mortality risk.",2021,"Relative to those randomly assigned to the control group, those receiving the intervention demonstrated significantly enhanced self-control, slower increases in substance use, and reduced Grim aging at age 22.","['Black youth from the rural South', '216 youths agreeing to provide blood at age 22 included 114 who had received the AIM intervention and 102 who assigned to the control group', 'African American youth', 'Black youth']",['universal family-based substance use preventive intervention'],['enhanced self-control'],"[{'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C4708905', 'cui_str': '216'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0085756', 'cui_str': 'African American'}]","[{'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0684274', 'cui_str': 'Self-control'}]",,0.00974223,"Relative to those randomly assigned to the control group, those receiving the intervention demonstrated significantly enhanced self-control, slower increases in substance use, and reduced Grim aging at age 22.","[{'ForeName': 'Man-Kit', 'Initials': 'MK', 'LastName': 'Lei', 'Affiliation': 'Department of Sociology, University of Georgia, Athens, Georgia, USA.'}, {'ForeName': 'Gene H', 'Initials': 'GH', 'LastName': 'Brody', 'Affiliation': 'Center for Family Research, University of Georgia, Athens, Georgia, USA.'}, {'ForeName': 'Steven R H', 'Initials': 'SRH', 'LastName': 'Beach', 'Affiliation': 'Department of Psychology and Center for Family Research, University of Georgia, Athens, Georgia, USA.'}]",Family process,['10.1111/famp.12715'] 3249,33992687,Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.,"Baek et al. 1 investigated the duration of COVID-19 virus shedding in infected patients and demonstrated that even in patients demonstrating prolonged viral clearance, the virus was no longer viable after 15 days post onset of symptoms. Our study aimed to measure whether nitric oxide nasal spray (NONS) further accelerates this reduction in SARS-CoV-2 RNA load versus a control arm with saline spray. Our study recruited 80 participants who were divided into a NONS treatment arm or a placebo arm to test the efficacy of NONS as a treatment for mild COVID-19 infection.",2021,Our study aimed to measure whether nitric oxide nasal spray (NONS) further accelerates this reduction in SARS-CoV-2 RNA load versus a control arm with saline spray.,"['80 participants who were divided into a NONS treatment arm or a', 'Mild COVID-19 Infection']","['NONS', 'placebo', 'nitric oxide nasal spray (NONS', 'Nitric Oxide Nasal Spray (NONS']",['duration of COVID-19 virus shedding'],"[{'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0461725', 'cui_str': 'Nasal spray'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0162633', 'cui_str': 'Viral Shedding'}]",80.0,0.120408,Our study aimed to measure whether nitric oxide nasal spray (NONS) further accelerates this reduction in SARS-CoV-2 RNA load versus a control arm with saline spray.,"[{'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Winchester', 'Affiliation': 'Consultant Medical Virologist, Frimley Health NHS Foundation Trust, Portsmouth Road, Camberley, Surrey GU16 7UJ, United Kingdom. Electronic address: s.winchester@nhs.net.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'John', 'Affiliation': 'Medical Student, University of Cambridge School of Clinical Medicine, Box 111 Cambridge Biomedical Campus, Cambridge CB2 0SP, United Kingdom.'}, {'ForeName': 'Kashif', 'Initials': 'K', 'LastName': 'Jabbar', 'Affiliation': ""Clinical Researcher, Ashford and St Peter's Hospitals NHS Foundation Trust, St Peters Hospital, Guildford Road, Chertsey, Surrey, KT16 0PZ, United Kingdom.""}, {'ForeName': 'Isaac', 'Initials': 'I', 'LastName': 'John', 'Affiliation': ""Honorary Senior Lecturer, Royal Holloway University of London, Egham, Surrey, TW20 OEX, United Kingdom; Deputy Director of Research & Development, Ashford and St Peter's Hospitals NHS Foundation Trust, St Peters Hospital, Guildford Road, Chertsey, Surrey, KT16 0PZ, United Kingdom.""}]",The Journal of infection,['10.1016/j.jinf.2021.05.009'] 3250,33992615,"Effects of Lipiflow Treatment Prior to Cataract Surgery: A Prospective, Randomized, Controlled Study.","To investigate the effects of preoperative Lipiflow (Johnson & Johnson, Jacksonville, FL, USA) treatment before cataract surgery on meibomian gland dysfunction (MGD) and dry eye induced by surgery. DESIGN Prospective, randomized controlled study. METHODS This study comprised 124 eyes of 124 patients with planned surgery for senile cataract. Participants were randomly allocated into control and Lipiflow groups based on administration of Lipiflow treatment 3 weeks before cataract surgery. For meibomian gland (MG) evaluation, MG atrophy, degree of gland expressibility, and quality of gland secretions were examined at the baseline visit and 1 and 3 months postoperatively. Ocular surface parameters of tear film break-up time, Oxford corneal staining score, and tear film lipid layer thickness were measured at each visit. Ocular Surface Disease Index and Dry Eye Questionnaire were also assessed. RESULTS The control group exhibited a significant decrease in MG expressibility, worsened meibum quality, decreased lipid layer thickness, and worsened corneal staining after cataract surgery. Also, dry eye symptom showed significant worsening. Conversely, the Lipiflow group showed significantly improved MG patency and meibum quality, increased tear film break-up time, and reduced corneal staining, and presented improved subjective outcomes reported on both Ocular Surface Disease Index and Dry Eye Questionnaire. The improvement of each parameter in the Lipiflow group showed a linear correlation with baseline MGD grade. In addition, patients without baseline MGD showed less worsening or improvement of MGD and dry eye induced by surgery, with preoperative Lipiflow treatment. CONCLUSIONS Preoperative Lipiflow treatment conducted before cataract surgery may be a safe and effective intervention for relieving MGD and dry eye induced by surgery. It might be recommended not only for the patients with preoperative MGD but also for those without baseline MGD, to prevent the development of MGD and dry eye induced by ocular surgeries.",2021,"Ocular surface parameters of tear film break-up time (TBUT), Oxford corneal staining score, and tear film lipid layer thickness (LLT) were measured at each visit.","['Cataract Surgery', '124 eyes of 124 patients with planned surgery for senile cataract']","['Lipiflow treatment three weeks prior to cataract surgery', 'preoperative Lipiflow (Johnson & Johnson, USA) treatment prior to cataract surgery', 'Lipiflow', 'Lipiflow prior to cataract surgery']","['worsening or improvement of MGD and dry eye', 'MG patency and meibum quality, increased TBUT, and reduced corneal staining', 'Ocular surface parameters of tear film break-up time (TBUT), Oxford corneal staining score, and tear film lipid layer thickness (LLT', 'MG expressibility, worsened meibum quality, decreased LLT, and worsened corneal staining', 'MG atrophy, degree of gland expressibility, and quality of gland secretions', 'meibomian gland dysfunction (MGD', 'Ocular Surface Disease Index (OSDI) and Dry Eye Questionnaire (DEQ']","[{'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0036646', 'cui_str': 'Senile cataract'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4082109', 'cui_str': 'Three weeks'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C1275684', 'cui_str': 'Meibomian gland dysfunction'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0025181', 'cui_str': 'Structure of meibomian gland'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C5197842', 'cui_str': 'Meibomian Lipids'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0429495', 'cui_str': 'Tear film break-up time'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0423232', 'cui_str': 'Corneal epithelial staining pattern'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0038128', 'cui_str': 'Stain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0026846', 'cui_str': 'Muscle atrophy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1285092', 'cui_str': 'Gland structure'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",124.0,0.0248149,"Ocular surface parameters of tear film break-up time (TBUT), Oxford corneal staining score, and tear film lipid layer thickness (LLT) were measured at each visit.","[{'ForeName': 'Jongyeop', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': ""From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (J.P., Y.-S.Y., K.S., G.H., D.H.L., T.-Y.C.), Department of Ophthalmology, Dongguk University Gyeongju Hospital, Dongguk University School of Medicine, Gyeongju, Gyeongsangbuk-do (J.P.), Department of Ophthalmology, Uijeongbu St. Mary's Hospital, the Catholic University of Korea, Uijeongbu-si (Y.-S.Y.), Department of Ophthalmology, Seongnam Citizens Medical Center, Seongnam-si (K.S.), Gyeonggi-do, Republic of Korea, Department of Ophthalmology, Itoh Clinic, Saitama, Japan (R.A.), and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea (D.H.L.).""}, {'ForeName': 'Young-Sik', 'Initials': 'YS', 'LastName': 'Yoo', 'Affiliation': ""From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (J.P., Y.-S.Y., K.S., G.H., D.H.L., T.-Y.C.), Department of Ophthalmology, Dongguk University Gyeongju Hospital, Dongguk University School of Medicine, Gyeongju, Gyeongsangbuk-do (J.P.), Department of Ophthalmology, Uijeongbu St. Mary's Hospital, the Catholic University of Korea, Uijeongbu-si (Y.-S.Y.), Department of Ophthalmology, Seongnam Citizens Medical Center, Seongnam-si (K.S.), Gyeonggi-do, Republic of Korea, Department of Ophthalmology, Itoh Clinic, Saitama, Japan (R.A.), and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea (D.H.L.).""}, {'ForeName': 'Kyungyoon', 'Initials': 'K', 'LastName': 'Shin', 'Affiliation': ""From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (J.P., Y.-S.Y., K.S., G.H., D.H.L., T.-Y.C.), Department of Ophthalmology, Dongguk University Gyeongju Hospital, Dongguk University School of Medicine, Gyeongju, Gyeongsangbuk-do (J.P.), Department of Ophthalmology, Uijeongbu St. Mary's Hospital, the Catholic University of Korea, Uijeongbu-si (Y.-S.Y.), Department of Ophthalmology, Seongnam Citizens Medical Center, Seongnam-si (K.S.), Gyeonggi-do, Republic of Korea, Department of Ophthalmology, Itoh Clinic, Saitama, Japan (R.A.), and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea (D.H.L.).""}, {'ForeName': 'Gyule', 'Initials': 'G', 'LastName': 'Han', 'Affiliation': ""From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (J.P., Y.-S.Y., K.S., G.H., D.H.L., T.-Y.C.), Department of Ophthalmology, Dongguk University Gyeongju Hospital, Dongguk University School of Medicine, Gyeongju, Gyeongsangbuk-do (J.P.), Department of Ophthalmology, Uijeongbu St. Mary's Hospital, the Catholic University of Korea, Uijeongbu-si (Y.-S.Y.), Department of Ophthalmology, Seongnam Citizens Medical Center, Seongnam-si (K.S.), Gyeonggi-do, Republic of Korea, Department of Ophthalmology, Itoh Clinic, Saitama, Japan (R.A.), and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea (D.H.L.).""}, {'ForeName': 'Reiko', 'Initials': 'R', 'LastName': 'Arita', 'Affiliation': ""From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (J.P., Y.-S.Y., K.S., G.H., D.H.L., T.-Y.C.), Department of Ophthalmology, Dongguk University Gyeongju Hospital, Dongguk University School of Medicine, Gyeongju, Gyeongsangbuk-do (J.P.), Department of Ophthalmology, Uijeongbu St. Mary's Hospital, the Catholic University of Korea, Uijeongbu-si (Y.-S.Y.), Department of Ophthalmology, Seongnam Citizens Medical Center, Seongnam-si (K.S.), Gyeonggi-do, Republic of Korea, Department of Ophthalmology, Itoh Clinic, Saitama, Japan (R.A.), and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea (D.H.L.).""}, {'ForeName': 'Dong H', 'Initials': 'DH', 'LastName': 'Lim', 'Affiliation': ""From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (J.P., Y.-S.Y., K.S., G.H., D.H.L., T.-Y.C.), Department of Ophthalmology, Dongguk University Gyeongju Hospital, Dongguk University School of Medicine, Gyeongju, Gyeongsangbuk-do (J.P.), Department of Ophthalmology, Uijeongbu St. Mary's Hospital, the Catholic University of Korea, Uijeongbu-si (Y.-S.Y.), Department of Ophthalmology, Seongnam Citizens Medical Center, Seongnam-si (K.S.), Gyeonggi-do, Republic of Korea, Department of Ophthalmology, Itoh Clinic, Saitama, Japan (R.A.), and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea (D.H.L.). Electronic address: donghui.lim@samsung.com.""}, {'ForeName': 'Tae-Young', 'Initials': 'TY', 'LastName': 'Chung', 'Affiliation': ""From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (J.P., Y.-S.Y., K.S., G.H., D.H.L., T.-Y.C.), Department of Ophthalmology, Dongguk University Gyeongju Hospital, Dongguk University School of Medicine, Gyeongju, Gyeongsangbuk-do (J.P.), Department of Ophthalmology, Uijeongbu St. Mary's Hospital, the Catholic University of Korea, Uijeongbu-si (Y.-S.Y.), Department of Ophthalmology, Seongnam Citizens Medical Center, Seongnam-si (K.S.), Gyeonggi-do, Republic of Korea, Department of Ophthalmology, Itoh Clinic, Saitama, Japan (R.A.), and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea (D.H.L.). Electronic address: tychung@skku.edu.""}]",American journal of ophthalmology,['10.1016/j.ajo.2021.04.031'] 3251,33993064,Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone.,"Men with obesity and/or type 2 diabetes (T2D) have a high prevalence of testosterone deficiency (TD). Similarly, men with TD have an increased risk of developing obesity and/or T2D, and further body fat accumulation and deterioration of glycemic control create a vicious cycle. The landmark testosterone for diabetes mellitus trial, the largest randomized controlled trial of testosterone therapy (TTh) to date, confirms the beneficial effects of TTh on fat loss and gain in muscle mass, and that TTh for 2 years significantly reduces the risk of incident T2D, and may also reverse T2D. The testosterone for diabetes mellitus trial suggests that TTh reduces the risk of T2D and results in greater improvement in sexual function and wellbeing, beyond lifestyle intervention alone.",2021,"The landmark testosterone for diabetes mellitus trial, the largest randomized controlled trial of testosterone therapy (TTh) to date, confirms the beneficial effects of TTh on fat loss and gain in muscle mass, and that TTh for 2 years significantly reduces the risk of incident T2D, and may also reverse T2D.","['Men with obesity and/or type 2 diabetes (T2D', 'men with low testosterone']","['Testosterone therapy', 'testosterone therapy (TTh']","['fat loss and gain in muscle mass', 'risk of developing obesity and/or T2D']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C1295654', 'cui_str': 'Decreased testosterone level'}]","[{'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]",,0.0724447,"The landmark testosterone for diabetes mellitus trial, the largest randomized controlled trial of testosterone therapy (TTh) to date, confirms the beneficial effects of TTh on fat loss and gain in muscle mass, and that TTh for 2 years significantly reduces the risk of incident T2D, and may also reverse T2D.","[{'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Caliber', 'Affiliation': 'American Medical Writers Association (AMWA), Rockville, MD, USA; International Society for Medical Publication Professionals (ISMPP), Fort Lauderdale, FL, USA.'}, {'ForeName': 'Farid', 'Initials': 'F', 'LastName': 'Saad', 'Affiliation': 'Consultant Medical Affairs, Bayer AG, Hamburg, Germany. Electronic address: farid.saad@bayer.com.'}]",Current opinion in pharmacology,['10.1016/j.coph.2021.04.002'] 3252,33992897,Effects of analgesic and surgical modality on immune response in colorectal cancer surgery.,"BACKGROUND AND OBJECTIVE Different surgical methods, anesthesia, and analgesia are known to modify the surgical stress response, especially in patients with malignancy. We compared the impact of patient-controlled intravenous (PCA) versus epidural analgesia (EDA) on tumor-related mucosal immune response in patients undergoing open or laparoscopic surgery for colorectal cancer. METHODS In a University Hospital subgroup (n = 43) of a larger cohort (n = 235) of patients undergoing open or laparoscopic surgery for colorectal carcinoma randomized to PCA or EDA, colorectal tissues were stained for interleukin-10 (IL-10), tumor necrosis factor (TNF), and mast cell tryptase and then examined by immunofluorescence microscopy. RESULTS More IL-10 + -cells were found in patients undergoing open compared to laparoscopic surgery in the PCA (P < 0.05) and EDA group (P < 0.0005), respectively, and numbers of TNF + -cells were higher in the open surgery group who received PCA (P < 0.05). No differences in IL-10 or TNF expressions were detected between EDA/PCA within the open or laparoscopic surgery groups, respectively. Fewer mast cells were observed in patients undergoing laparoscopic compared to open surgery combined with PCA (P < 0.05). Within the open surgery group, EDA resulted in fewer mucosal mast cells compared to the PCA group (P < 0.05). CONCLUSIONS The surgical method, rather than type of analgesia, may have higher impact on peri-operative inflammation. Laparoscopic surgery when combined with EDA for colorectal cancer caused a decrease in the TNF and IL-10 expression and mast cells. EDA seems to have an anti-inflammatory effect on cancer-related inflammation during open surgery.",2021,"No differences in IL-10 or TNF expressions were detected between EDA/PCA within the open or laparoscopic surgery groups, respectively.","['patients with malignancy', 'In a University Hospital subgroup (n\xa0=\xa043) of a larger cohort (n\xa0=\xa0235) of patients undergoing', 'patients undergoing open or laparoscopic surgery for colorectal cancer', 'colorectal cancer surgery']","['EDA', 'Laparoscopic surgery', 'analgesic and surgical modality', 'open or laparoscopic surgery', 'patient-controlled intravenous (PCA) versus epidural analgesia (EDA']","['IL-10 + -cells', 'mast cells', 'IL-10 or TNF expressions', 'TNF and IL-10 expression and mast cells', 'numbers of TNF + -cells', 'mucosal mast cells']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0024880', 'cui_str': 'Mast cell'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0475450', 'cui_str': 'Number of tumors'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}]",,0.118143,"No differences in IL-10 or TNF expressions were detected between EDA/PCA within the open or laparoscopic surgery groups, respectively.","[{'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Faisal', 'Affiliation': 'Department of Surgery, Surgical Oncology Unit, Faculty of Medicine, Suez Canal University, Egypt; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Christopher Niels', 'Initials': 'CN', 'LastName': 'Schäfer', 'Affiliation': 'Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Anesthesia, Operation and Intensive Care, Norrlands University Hospital, Umeå, Sweden.'}, {'ForeName': 'Pär', 'Initials': 'P', 'LastName': 'Myrelid', 'Affiliation': 'Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Surgery, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Martin E', 'Initials': 'ME', 'LastName': 'Winberg', 'Affiliation': 'Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Johan D', 'Initials': 'JD', 'LastName': 'Söderholm', 'Affiliation': 'Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Surgery, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Åsa V', 'Initials': 'ÅV', 'LastName': 'Keita', 'Affiliation': 'Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. Electronic address: asa.keita@liu.se.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Eintrei', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Linköping University Hospital, Linköping, Sweden.'}]",Surgical oncology,['10.1016/j.suronc.2021.101602'] 3253,34000958,"The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study.","BACKGROUND Irritable bowel syndrome (IBS) is associated with intestinal dysbiosis. Therefore, faecal microbiota transplantation (FMT) has been hypothesised to have a positive effect in patients with IBS. In this study, we analysed previously unexamined data from our randomised, double-blind, placebo-controlled study (trial registration number NCT02788071). The objective was to evaluate the effect of FMT on abdominal pain, stool frequency, and stool form. METHOD The study included 52 adult patients with moderate-to-severe IBS assigned randomly to treatment with FMT capsules or placebo capsules (1:1) for 12 days. The patients were followed for a total of six months, during which they kept a daily symptom diary tracking their abdominal pain on a scale from 0-10 and their bowel movements using the Bristol Stool Form Scale (BSFS). Diary data were not collected before treatment start. RESULTS A statistically significant improvement in stool frequency was found in the FMT group from during treatment to post-treatment and 1 month. No statistically significant differences were found between groups at any time during the study for any of abdominal pain, stool frequency, and stool form (as measured by weighted stool score). CONCLUSION In this analysis of results from a randomised, double-blind, placebo-controlled study, we found no clinically beneficial effect of FMT on abdominal pain, stool frequency, or stool form. However, since the current literature on the potential role of FMT in treating IBS shows conflicting results, further studies are required. To assess treatment efficacy, we recommend future studies to include daily symptom diaries both before and after treatment intervention.",2021,"No statistically significant differences were found between groups at any time during the study for any of abdominal pain, stool frequency, and stool form (as measured by weighted stool score). ","['patients with IBS', 'patients with moderate-to-severe irritable bowel syndrome', '52 adult patients with moderate-to-severe IBS']","['placebo', 'FMT capsules or placebo capsules', 'FMT', 'faecal microbiota transplantation']","['Bristol Stool Form Scale (BSFS', 'abdominal pain, stool frequency, and stool form (as measured by weighted stool score', 'abdominal pain, stool frequency, and stool form', 'stool frequency', 'abdominal pain, stool frequency, and stool', 'abdominal pain, stool frequency, or stool form']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2242628', 'cui_str': 'Fecal microbiota transplantation'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C1997606', 'cui_str': 'Bristol stool form scale'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",52.0,0.360423,"No statistically significant differences were found between groups at any time during the study for any of abdominal pain, stool frequency, and stool form (as measured by weighted stool score). ","[{'ForeName': 'Anna Maria Alcasid', 'Initials': 'AMA', 'LastName': 'Madsen', 'Affiliation': 'Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark.'}, {'ForeName': 'Sofie Ingdam', 'Initials': 'SI', 'LastName': 'Halkjær', 'Affiliation': 'Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark.'}, {'ForeName': 'Alice Højer', 'Initials': 'AH', 'LastName': 'Christensen', 'Affiliation': 'Department of Gastroenterology, Aleris-Hamlet Hospitals Copenhagen, Soborg, Denmark.'}, {'ForeName': 'Stig', 'Initials': 'S', 'LastName': 'Günther', 'Affiliation': 'Department of Gastroenterology, Aleris-Hamlet Hospitals Copenhagen, Soborg, Denmark.'}, {'ForeName': 'Patrick Denis', 'Initials': 'PD', 'LastName': 'Browne', 'Affiliation': 'Department of Plant and Environmental Sciences, University of Copenhagen, Frederiksberg, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kallemose', 'Affiliation': 'Clinical Research Department, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.'}, {'ForeName': 'Lars Hestbjerg', 'Initials': 'LH', 'LastName': 'Hansen', 'Affiliation': 'Department of Plant and Environmental Sciences, University of Copenhagen, Frederiksberg, Denmark.'}, {'ForeName': 'Andreas Munk', 'Initials': 'AM', 'LastName': 'Petersen', 'Affiliation': 'Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2021.1915375'] 3254,34000949,Botulinum toxin type-A infiltration of the external anal sphincter to treat outlet constipation in motor incomplete spinal cord injury: pilot cohort study.,"BACKGROUND Outlet constipation is a major problem in spinal cord injury (SCI) patients. We aimed to study the efficacy of external anal sphincter (EAS) infiltration with type-A botulinum toxin (BTX-A) in motor incomplete SCI patients with outlet constipation. METHODS Double blind, randomized, placebo controlled, comparative study in 16 motor incomplete SCI subjects. Patients were randomly assigned toreceive100 UI of BTX-A ( n  = 9) or physiologic serum infiltration ( n  = 7) in the EAS under electromyographic guidance. Outcome measures included a questionnaire for clinical bowel function evaluation, colonic transit time and anorectal manometry. All assessments were done at baseline, 1 and 3 months after treatment. RESULTS Fourteen patients completed the study. In the BTX-A group we observed an improvement of subjective perception of bowel function ( p  = 0.01), constipation ( p  = 0.02) and neurogenic bowel dysfunction score ( p  = 0.02). The anorectal manometry revealed are duction of EAS voluntary contraction pressure ( p  = 0.01). No changes were observed in the placebo group. No significant side effects were observed in none of the groups. CONCLUSION BTX-A infiltration of the EAS is a safe technique that in motor incomplete SCI, decreases the EAS contraction and the anal canal pressure during straining, and improves outlet constipation symptoms. Future studies in larger populations are needed.",2021,"In the BTX-A group we observed an improvement of subjective perception of bowel function ( p  = 0.01), constipation ( p  = 0.02) and neurogenic bowel dysfunction score ( p  = 0.02).","['spinal cord injury (SCI) patients', 'motor incomplete spinal cord injury', '16 motor incomplete SCI subjects', 'motor incomplete SCI patients with outlet constipation', 'Fourteen patients completed the study']","['external anal sphincter', 'external anal sphincter (EAS) infiltration with type-A botulinum toxin (BTX-A', 'placebo', 'Botulinum toxin type']","['constipation', 'neurogenic bowel dysfunction score', 'EAS contraction and the anal canal pressure', 'subjective perception of bowel function', 'outlet constipation symptoms', 'duction of EAS voluntary contraction pressure', 'side effects', 'questionnaire for clinical bowel function evaluation, colonic transit time and anorectal manometry']","[{'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4545488', 'cui_str': 'Incomplete spinal cord injury'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0224395', 'cui_str': 'External anal sphincter structure'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0695242', 'cui_str': 'Neurogenic bowel'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0224395', 'cui_str': 'External anal sphincter structure'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0227411', 'cui_str': 'Anal canal structure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C1301827', 'cui_str': 'In transit'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0374190', 'cui_str': 'Anorectal manometry'}]",16.0,0.0822887,"In the BTX-A group we observed an improvement of subjective perception of bowel function ( p  = 0.01), constipation ( p  = 0.02) and neurogenic bowel dysfunction score ( p  = 0.02).","[{'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Vallès', 'Affiliation': 'Unit of Functional Digestive Rehabilitation, Institut Guttmann, University of Barcelona, Badalona, Spain.'}, {'ForeName': 'Sergiu', 'Initials': 'S', 'LastName': 'Albu', 'Affiliation': 'Spinal Cord Injury Unit, Institut Guttmann, University of Barcelona, Badalona, Spain.'}, {'ForeName': 'Hatice', 'Initials': 'H', 'LastName': 'Kumru', 'Affiliation': 'Spinal Cord Injury Unit, Institut Guttmann, University of Barcelona, Badalona, Spain.'}, {'ForeName': 'Fermín', 'Initials': 'F', 'LastName': 'Mearin', 'Affiliation': 'Unit of Functional Digestive Rehabilitation, Institut Guttmann, University of Barcelona, Badalona, Spain.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2021.1921255'] 3255,34000834,Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign.,"BACKGROUND AND PURPOSE The computed tomography angiography or contrast-enhanced computed tomography based spot sign has been proposed as a biomarker for identifying on-going hematoma expansion in patients with acute intracerebral hemorrhage. We investigated, if spot-sign positive participants benefit more from tranexamic acid versus placebo as compared to spot-sign negative participants. METHODS TICH-2 trial (Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage) was a randomized, placebo-controlled clinical trial recruiting acutely hospitalized participants with intracerebral hemorrhage within 8 hours after symptom onset. Local investigators randomized participants to 2 grams of intravenous tranexamic acid or matching placebo (1:1). All participants underwent computed tomography scan on admission and on day 2 (24±12 hours) after randomization. In this sub group analysis, we included all participants from the main trial population with imaging allowing adjudication of spot sign status. RESULTS Of the 2325 TICH-2 participants, 254 (10.9%) had imaging allowing for spot-sign adjudication. Of these participants, 64 (25.2%) were spot-sign positive. Median (interquartile range) time from symptom onset to administration of the intervention was 225.0 (169.0 to 310.0) minutes. The adjusted percent difference in absolute day-2 hematoma volume between participants allocated to tranexamic versus placebo was 3.7% (95% CI, -12.8% to 23.4%) for spot-sign positive and 1.7% (95% CI, -8.4% to 12.8%) for spot-sign negative participants ( P heterogenity =0.85). No difference was observed in significant hematoma progression (dichotomous composite outcome) between participants allocated to tranexamic versus placebo among spot-sign positive (odds ratio, 0.85 [95% CI, 0.29 to 2.46]) and negative (odds ratio, 0.77 [95% CI, 0.41 to 1.45]) participants ( P heterogenity =0.88). CONCLUSIONS Data from the TICH-2 trial do not support that admission spot sign status modifies the treatment effect of tranexamic acid versus placebo in patients with acute intracerebral hemorrhage. The results might have been affected by low statistical power as well as treatment delay. Registration: URL: http://www.controlled-trials.com; Unique identifier: ISRCTN93732214.",2021,"No difference was observed in significant hematoma progression (dichotomous composite outcome) between participants allocated to tranexamic versus placebo among spot-sign positive (odds ratio, 0.85","['patients with acute intracerebral hemorrhage', 'participants from the main trial population with imaging allowing adjudication of spot sign status', 'Intracerebral Hemorrhage Patients With or Without Spot Sign', 'Hyperacute Primary Intracerebral Haemorrhage', 'acutely hospitalized participants with intracerebral hemorrhage within 8 hours after symptom onset']","['computed tomography scan', 'Tranexamic Acid', 'tranexamic', 'computed tomography angiography or contrast-enhanced computed tomography based spot sign', 'intravenous tranexamic acid or matching placebo (1:1', 'tranexamic acid versus placebo', 'placebo']","['absolute day-2 hematoma volume', 'significant hematoma progression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C1292429', 'cui_str': '8 hours'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}]","[{'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",2325.0,0.719949,"No difference was observed in significant hematoma progression (dichotomous composite outcome) between participants allocated to tranexamic versus placebo among spot-sign positive (odds ratio, 0.85","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ovesen', 'Affiliation': 'Department of Neurology, Bispebjerg Hospital (C.O., L.M.C., H.C.), Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Janus Christian', 'Initials': 'JC', 'LastName': 'Jakobsen', 'Affiliation': 'The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet (C.O., J.C.J., C.G.), Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Gluud', 'Affiliation': 'The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet (C.O., J.C.J., C.G.), Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Thorsten', 'Initials': 'T', 'LastName': 'Steiner', 'Affiliation': 'Department of Neurology, Klinikum Frankfurt Höchst, Germany (T.S.).'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Law', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, United Kingdom (Z.L., K.F., P.M.B., N.S.).'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Flaherty', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, United Kingdom (Z.L., K.F., P.M.B., N.S.).'}, {'ForeName': 'Rob A', 'Initials': 'RA', 'LastName': 'Dineen', 'Affiliation': ""Radiological Sciences, Division of Clinical Neuroscience, University of Nottingham, Queen's Medical Centre, United Kingdom (R.A.D.).""}, {'ForeName': 'Louisa M', 'Initials': 'LM', 'LastName': 'Christensen', 'Affiliation': 'Department of Neurology, Bispebjerg Hospital (C.O., L.M.C., H.C.), Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Overgaard', 'Affiliation': 'Department of Neurology, Herlev Hospital (K.O., R.S.R.), Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Rune S', 'Initials': 'RS', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Neurology, Herlev Hospital (K.O., R.S.R.), Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Bath', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, United Kingdom (Z.L., K.F., P.M.B., N.S.).'}, {'ForeName': 'Nikola', 'Initials': 'N', 'LastName': 'Sprigg', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, United Kingdom (Z.L., K.F., P.M.B., N.S.).'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Christensen', 'Affiliation': 'Department of Neurology, Bispebjerg Hospital (C.O., L.M.C., H.C.), Copenhagen University Hospital, Copenhagen, Denmark.'}]",Stroke,['10.1161/STROKEAHA.120.032426'] 3256,34000245,"Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.","BACKGROUND The CATNON trial investigated the addition of concurrent, adjuvant, and both current and adjuvant temozolomide to radiotherapy in adults with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas. The benefit of concurrent temozolomide chemotherapy and relevance of mutations in the IDH1 and IDH2 genes remain unclear. METHODS This randomised, open-label, phase 3 study done in 137 institutions across Australia, Europe, and North America included patients aged 18 years or older with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas and a WHO performance status of 0-2. Patients were randomly assigned (1:1:1:1) centrally using a minimisation technique to radiotherapy alone (59·4 Gy in 33 fractions; three-dimensional conformal radiotherapy or intensity-modulated radiotherapy), radiotherapy with concurrent oral temozolomide (75 mg/m 2 per day), radiotherapy with adjuvant oral temozolomide (12 4-week cycles of 150-200 mg/m 2 temozolomide given on days 1-5), or radiotherapy with both concurrent and adjuvant temozolomide. Patients were stratified by institution, WHO performance status score, age, 1p loss of heterozygosity, the presence of oligodendroglial elements on microscopy, and MGMT promoter methylation status. The primary endpoint was overall survival adjusted by stratification factors at randomisation in the intention-to-treat population. A second interim analysis requested by the independent data monitoring committee was planned when two-thirds of total required events were observed to test superiority or futility of concurrent temozolomide. This study is registered with ClinicalTrials.gov, NCT00626990. FINDINGS Between Dec 4, 2007, and Sept 11, 2015, 751 patients were randomly assigned (189 to radiotherapy alone, 188 to radiotherapy with concurrent temozolomide, 186 to radiotherapy and adjuvant temozolomide, and 188 to radiotherapy with concurrent and adjuvant temozolomide). Median follow-up was 55·7 months (IQR 41·0-77·3). The second interim analysis declared futility of concurrent temozolomide (median overall survival was 66·9 months [95% CI 45·7-82·3] with concurrent temozolomide vs 60·4 months [45·7-71·5] without concurrent temozolomide; hazard ratio [HR] 0·97 [99·1% CI 0·73-1·28], p=0·76). By contrast, adjuvant temozolomide improved overall survival compared with no adjuvant temozolomide (median overall survival 82·3 months [95% CI 67·2-116·6] vs 46·9 months [37·9-56·9]; HR 0·64 [95% CI 0·52-0·79], p<0·0001). The most frequent grade 3 and 4 toxicities were haematological, occurring in no patients in the radiotherapy only group, 16 (9%) of 185 patients in the concurrent temozolomide group, and 55 (15%) of 368 patients in both groups with adjuvant temozolomide. No treatment-related deaths were reported. INTERPRETATION Adjuvant temozolomide chemotherapy, but not concurrent temozolomide chemotherapy, was associated with a survival benefit in patients with 1p/19q non-co-deleted anaplastic glioma. Clinical benefit was dependent on IDH1 and IDH2 mutational status. FUNDING Merck Sharpe & Dohme.",2021,Median follow-up was 55·7 months,"['patients with 1p/19q non-co-deleted anaplastic glioma', '137 institutions across Australia, Europe, and North America included patients aged 18 years or older with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas and a WHO performance status of 0-2', 'adults with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas', 'Patients were stratified by institution, WHO performance status score, age, 1p loss of heterozygosity, the presence of oligodendroglial elements on microscopy, and MGMT promoter methylation status']","['Adjuvant and concurrent temozolomide', 'temozolomide to radiotherapy', 'radiotherapy with both concurrent and adjuvant temozolomide', 'minimisation technique to radiotherapy alone (59·4 Gy in 33 fractions; three-dimensional conformal radiotherapy or intensity-modulated radiotherapy), radiotherapy with concurrent oral temozolomide', 'temozolomide chemotherapy', 'temozolomide', 'radiotherapy with concurrent temozolomide, 186 to radiotherapy and adjuvant temozolomide, and 188 to radiotherapy with concurrent and adjuvant temozolomide', 'radiotherapy', 'radiotherapy with adjuvant oral temozolomide', 'Adjuvant temozolomide chemotherapy']","['overall survival', 'survival benefit']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205618', 'cui_str': 'Undifferentiated'}, {'cui': 'C0017638', 'cui_str': 'Glioma'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0524869', 'cui_str': 'Heterozygosity, Loss of'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0013879', 'cui_str': 'Chemical element'}, {'cui': 'C0026018', 'cui_str': 'Microscopy'}, {'cui': 'C0069197', 'cui_str': 'Methylated-DNA-protein-cysteine methyltransferase'}, {'cui': 'C0025723', 'cui_str': 'Methylation'}]","[{'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0076080', 'cui_str': 'temozolomide'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0600521', 'cui_str': 'Conformal radiotherapy'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",751.0,0.296586,Median follow-up was 55·7 months,"[{'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'van den Bent', 'Affiliation': 'Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.'}, {'ForeName': 'C Mircea S', 'Initials': 'CMS', 'LastName': 'Tesileanu', 'Affiliation': 'Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Wick', 'Affiliation': 'Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen Universitätsklinik Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Sanson', 'Affiliation': 'Sorbonne Universités, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM AP-HP, Paris, France; Hôpital Univeristaires Pitié-salpêtrière -Chales Foix, service de Neurologie 2-Mazarin, Paris, France.'}, {'ForeName': 'Alba Ariela', 'Initials': 'AA', 'LastName': 'Brandes', 'Affiliation': 'Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Clement', 'Affiliation': 'Department of Oncology, KU Leuven and Department of General Medical Oncology, UZ Leuven, Leuven Cancer Institute, Leuven, Belgium.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Erridge', 'Affiliation': 'Edinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Vogelbaum', 'Affiliation': 'Department of NeuroOncology, Moffitt Cancer Center, Tampa, FL, USA.'}, {'ForeName': 'Anna K', 'Initials': 'AK', 'LastName': 'Nowak', 'Affiliation': 'Medical School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia; CoOperative Group for NeuroOncology, University of Sydney, Camperdown, NSW, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.'}, {'ForeName': 'Jean Français', 'Initials': 'JF', 'LastName': 'Baurain', 'Affiliation': 'Medical Oncology Department, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Warren P', 'Initials': 'WP', 'LastName': 'Mason', 'Affiliation': 'Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Wheeler', 'Affiliation': 'Northern Sydney Cancer Centre, St Leonards, Sydney, NSW, Australia.'}, {'ForeName': 'Olivier L', 'Initials': 'OL', 'LastName': 'Chinot', 'Affiliation': 'Aix-Marseille University, AP-HM, Neuro-Oncology division, Marseille, France.'}, {'ForeName': 'Sanjeev', 'Initials': 'S', 'LastName': 'Gill', 'Affiliation': 'Department of Medical Oncology, Alfred Hospital, Melbourne, QLD, Australia.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Griffin', 'Affiliation': 'Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Leland', 'Initials': 'L', 'LastName': 'Rogers', 'Affiliation': 'Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Taal', 'Affiliation': 'Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Rudà', 'Affiliation': 'Department of Neuro-Oncology, City of Health and Science Hospital and University of Turin, Turin, Italy.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Weller', 'Affiliation': 'Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'McBain', 'Affiliation': 'Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Jaap', 'Initials': 'J', 'LastName': 'Reijneveld', 'Affiliation': 'Brain Tumor Center Amsterdam and Department of Neurology, VU University Medical Center, Amsterdam, Netherlands; Department of Neurology, Academic Medical Center, Amsterdam, Netherlands.'}, {'ForeName': 'Roelien H', 'Initials': 'RH', 'LastName': 'Enting', 'Affiliation': 'Department of Neurology, UMCG, University of Groningen, Groningen, Netherlands.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Caparrotti', 'Affiliation': 'Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Lesimple', 'Affiliation': 'Department of Clinical Oncology, Comprehensive Cancer Center Eugène Marquis, Rennes, France.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Clenton', 'Affiliation': 'Weston Park Hospital, Sheffield, UK.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Gijtenbeek', 'Affiliation': 'Department of Neurology, Radboud University Medical Centre, Nijmegen, Netherlands.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Lim', 'Affiliation': 'Department of Clinical Oncology, Plymouth Hospitals NHS Trust, Plymouth, UK.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Herrlinger', 'Affiliation': 'Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hau', 'Affiliation': 'Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital, Regensburg, Regensburg, Germany.'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Dhermain', 'Affiliation': 'Radiotherapy Department, Gustave Roussy University Hospital, Villejuif, Cedex, France.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'de Heer', 'Affiliation': 'Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Aldape', 'Affiliation': 'Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.'}, {'ForeName': 'Robert B', 'Initials': 'RB', 'LastName': 'Jenkins', 'Affiliation': 'Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN, USA.'}, {'ForeName': 'Hendrikus Jan', 'Initials': 'HJ', 'LastName': 'Dubbink', 'Affiliation': 'Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.'}, {'ForeName': 'Johan M', 'Initials': 'JM', 'LastName': 'Kros', 'Affiliation': 'Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Wesseling', 'Affiliation': 'Department of Pathology, Amsterdam University Medical Centers, Amsterdam, Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Nuyens', 'Affiliation': 'EORTC, Brussels, Belgium.'}, {'ForeName': 'Vassilis', 'Initials': 'V', 'LastName': 'Golfinopoulos', 'Affiliation': 'EORTC, Brussels, Belgium.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Gorlia', 'Affiliation': 'EORTC, Brussels, Belgium.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'French', 'Affiliation': 'Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.'}, {'ForeName': 'Brigitta G', 'Initials': 'BG', 'LastName': 'Baumert', 'Affiliation': 'Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Center (MUMC) GROW (School for Oncology), Maastricht, Netherlands; Institute of Radiation-Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.'}]",The Lancet. Oncology,['10.1016/S1470-2045(21)00090-5'] 3257,34389701,"The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes.","BACKGROUND Some evidence suggests indirect ameliorating effects of vitamin D in diabetes via adiponectin and sirtuins. This study aimed to evaluate the effects of daily intake of vitamin D-fortified yogurt drink, either with or without added calcium, on serum adiponectin, sirtuins (SIRT)1 and 6. METHODS Briefly, 75 adults aged 30-60 years from both sexes with type 2 diabetes were randomly allocated to one of the three groups: (i) D-fortified-yogurt drink (DY; containing 1000 IU vitamin D and 300 mg calcium), (ii) Ca+D-fortified-yogurt drink (CDY; containing 1000 IU vitamin D and 500 mg calcium) and (iii) plain yogurt drink (PY; containing no detectable vitamin D and 300 mg calcium). All assessments were performed initially and after 12 weeks. RESULTS A significant within-group increment in serum adiponectin concentrations was observed in both DY and CDY groups (+60.4 ± 8.6, +57.5 ± 6.4 µg/L, respectively; p < 0.001 for both). The concentrations of SIRT1 and SIRT6 had a significant within-group increment only in the CDY group (p = 0.003, p = 0.001 respectively). Being in CDY group was more favorable predictor of improvement in SIRT6 concentrations. Changes of 25(OH)D were a significant predictor of changes of adiponectin. However, this association disappeared following adjustment for changes of SIRT1. In contrast, the association between changes of 25(OH)D and HbA1c remained significant even after adjustment for SIRT1. CONCLUSIONS Daily consumption of vitamin D-fortified yogurt drink for 12 weeks resulted in an increase in circulating concentrations of SIRT1 and SIRT6 in T2D subjects and D+Ca-fortified yogurt drink was more in favor of SIRT6 increment.",2021,"The concentrations of SIRT1 and SIRT6 had a significant within-group increment only in the CDY group (p = 0.003, p = 0.001 respectively).","['75 adults aged 30-60\u2009years from both sexes with type 2 diabetes', 'adult subjects with type 2 diabetes']","['vitamin D-fortified yogurt drink, either with or without added calcium', 'vitamin D', 'vitamin D-fortified yogurt drink, with and without added calcium', 'D-fortified-yogurt drink (DY; containing 1000 IU vitamin D and 300\u2009mg calcium), (ii) Ca+D-fortified-yogurt drink (CDY; containing 1000 IU vitamin D and 500\u2009mg calcium) and (iii) plain yogurt drink (PY; containing no detectable vitamin D and 300\u2009mg calcium']","['concentrations of SIRT1 and SIRT6', 'SIRT6 concentrations', 'serum adiponectin concentrations', 'adiponectin', 'circulating concentrations of SIRT1 and SIRT6']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0043419', 'cui_str': 'Yogurt'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C3816747', 'cui_str': '500'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2720167', 'cui_str': 'Sirt1'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}]",75.0,0.12669,"The concentrations of SIRT1 and SIRT6 had a significant within-group increment only in the CDY group (p = 0.003, p = 0.001 respectively).","[{'ForeName': 'Bahareh', 'Initials': 'B', 'LastName': 'Nikooyeh', 'Affiliation': 'Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Bruce W', 'Initials': 'BW', 'LastName': 'Hollis', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Tirang R', 'Initials': 'TR', 'LastName': 'Neyestani', 'Affiliation': 'Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. t.neyestani@sbmu.ac.ir.'}]",Nutrition & diabetes,['10.1038/s41387-021-00168-x'] 3258,34389633,"A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.","OBJECTIVE Tumour necrosis factor signalling via the receptor-interacting protein kinase 1 (RIPK1) pathway regulates colonic inflammation suggesting that RIPK1 inhibition may be a potential therapeutic target in ulcerative colitis (UC). This phase IIa, randomised, double-blind experimental medicine study investigated the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of the RIPK1 inhibitor GSK2982772 in patients with active UC. DESIGN In part A, prior to a protocol amendment, one patient was randomised to receive GSK2982772 60 mg twice daily for 42 days. After the amendment, patients were randomised 2:1 to receive GSK2982772 60 mg or placebo three times daily for 42 days. In part B, all patients switched to open-label GSK2982772 60 mg three times daily for 42 days. Safety, PK, PD biomarkers, histological disease activity, clinical efficacy and quality of life were assessed at days 43 and 85. RESULTS Thirty-six patients were randomised (n=12, placebo/open-label GSK2982772; n=24, GSK2982772/open-label GSK2982772). Most adverse events were mild, with headache reported the most frequently across groups (placebo/open-label GSK2982772, n=2 (17%); GSK2982772/open-label GSK2982772, n=8 (33%)). GSK2982772 was well distributed into colonic tissue, with generally higher concentrations in colonic biopsy samples versus plasma. No apparent differences between treatment groups were observed for PD, histological disease activity, clinical disease activity or quality-of-life measures. At screening, all patients had Mayo endoscopic scores of 2 or 3. At day 43, no patients in the placebo/open-label GSK2982772 group achieved Mayo endoscopic scores of 0 or 1 vs 3/24 (13%) for GSK2982772/open-label GSK2982772. At day 85, 1/9 (11%) achieved scores of 0 or one for placebo/open-label GSK2982772 vs 3/22 (14%) for GSK2982772/open-label GSK2982772. CONCLUSION GSK2982772 was generally well tolerated, with no treatment-related safety concerns identified. However, no significant differences in efficacy were observed between treatment groups, suggesting that GSK2982772 as monotherapy is not a promising treatment for patients with active UC. TRIAL REGISTRATION NUMBER NCT02903966.",2021,"At day 43, no patients in the placebo/open-label GSK2982772 group achieved Mayo endoscopic scores of 0 or 1 vs 3/24 (13%) for GSK2982772/open-label GSK2982772.","['patients with active ulcerative colitis', 'Thirty-six patients', 'patients with active UC']","['RIPK1 inhibitor GSK2982772', 'placebo', 'placebo/open-label GSK2982772', 'GSK2982772 60\u2009mg or placebo']","['Safety, PK, PD biomarkers, histological disease activity, clinical efficacy and quality of life', 'efficacy', 'Mayo endoscopic scores', 'PD, histological disease activity, clinical disease activity or quality-of-life measures', 'safety, pharmacokinetics (PK), pharmacodynamics (PD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C4319606', 'cui_str': '36'}]","[{'cui': 'C0297981', 'cui_str': 'RIPK1 protein, human'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",36.0,0.0543272,"At day 43, no patients in the placebo/open-label GSK2982772 group achieved Mayo endoscopic scores of 0 or 1 vs 3/24 (13%) for GSK2982772/open-label GSK2982772.","[{'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Weisel', 'Affiliation': 'Immunology and Inflammation, GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Scott', 'Affiliation': 'Biostatistics, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, UK.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Berger', 'Affiliation': 'Immunology and Inflammation, GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Immunology and Inflammation, GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Brown', 'Affiliation': 'Immunology and Inflammation, GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Marcy', 'Initials': 'M', 'LastName': 'Powell', 'Affiliation': 'Safety and Medical Governance, GlaxoSmithKline, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Matthijs', 'Initials': 'M', 'LastName': 'Broer', 'Affiliation': 'Global Clinical Development, GlaxoSmithKline, Van Asch van Wijckstraat, LP Amersfoort, The Netherlands.'}, {'ForeName': 'Clarissa', 'Initials': 'C', 'LastName': 'Watts', 'Affiliation': 'Global Clinical Sciences and Delivery, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, UK.'}, {'ForeName': 'Debra J', 'Initials': 'DJ', 'LastName': 'Tompson', 'Affiliation': 'Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, UK.'}, {'ForeName': 'Susan W', 'Initials': 'SW', 'LastName': 'Burriss', 'Affiliation': 'Global Clinical Sciences and Delivery, GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Hawkins', 'Affiliation': 'Global Clinical Sciences and Delivery, GlaxoSmithKline, Brentford, Middlesex, UK.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Abbott-Banner', 'Affiliation': 'Discovery Medicine, GlaxoSmithKline, Brentford, Middlesex, UK kathy.x.abbott-banner@gsk.com.'}, {'ForeName': 'Paul Peter', 'Initials': 'PP', 'LastName': 'Tak', 'Affiliation': 'Pharmaceuticals Research and Development, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, UK.'}]",BMJ open gastroenterology,['10.1136/bmjgast-2021-000680'] 3259,34389605,Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment.,"OBJECTIVES Fatigue is a frequent symptom in rheumatoid arthritis (RA) and has high impact on quality of life. We explored associations between disease activity and fatigue in patients with early RA during the initial 24 months of modern treat-to-target therapy and predictors of fatigue after 24 months of follow-up. METHODS Data were obtained from the treat-to-target, tight control Aiming for Remission in Rheumatoid Arthritis: a Randomised Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regime (ARCTIC) trial. Fatigue was measured on a visual analogue scale (VAS) from 0 to 100 mm and defined as clinically relevant if VAS was ≥20 mm. Baseline predictors of fatigue at 24 months were analysed by multivariable logistic regression. RESULTS 205 patients with fatigue data at baseline and 24 months were included. Median (25th, 75th percentiles) symptom duration was 5.4 months (2.8, 10.4), fatigue VAS 37.0 mm (13.0, 62.0) and mean Disease Activity Score (DAS) 3.4 (SD 1.1) at baseline. Prevalence of fatigue declined from 69% at baseline to 38% at 24 months. Fewer swollen joints (OR 0.92, 95% CI 0.87 to 0.98, p=0.006), lower power Doppler ultrasound score (OR 0.95, 95% CI 0.90 to 0.99, p=0.027) and higher patient global assessment (PGA) (OR 1.03, 95% CI 1.01 to 1.04, p<0.001) increased the risk of clinically relevant fatigue at 24 months. Not achieving remission at 6 months was associated with a higher risk of reporting fatigue at 24 months. CONCLUSIONS Fatigue in patients with early RA was prevalent at disease onset, with a rapid and sustained reduction during treatment. Low objective disease activity and high PGA at baseline were predictors of clinically relevant fatigue at 24 months.",2021,"Fewer swollen joints (OR 0.92, 95% CI 0.87 to 0.98, p=0.006), lower power Doppler ultrasound score (OR 0.95, 95% CI 0.90 to 0.99, p=0.027) and higher patient global assessment (PGA) (","['205 patients with fatigue data at baseline and 24 months were included', 'Rheumatoid Arthritis', 'patients with early rheumatoid arthritis undergoing treat-to-target therapy', 'patients with early RA during the initial 24 months of modern treat-to-target therapy and predictors of fatigue after 24 months of follow-up']",[],"['disease activity and fatigue', 'patient global assessment (PGA) ', 'risk of clinically relevant fatigue', 'swollen joints', 'Fatigue', 'mean Disease Activity Score', 'visual analogue scale (VAS', 'symptom duration', 'fatigue VAS', 'Prevalence of fatigue', 'lower power Doppler ultrasound score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",[],"[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0152031', 'cui_str': 'Joint swelling'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1960437', 'cui_str': 'Power doppler ultrasound'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",205.0,0.602805,"Fewer swollen joints (OR 0.92, 95% CI 0.87 to 0.98, p=0.006), lower power Doppler ultrasound score (OR 0.95, 95% CI 0.90 to 0.99, p=0.027) and higher patient global assessment (PGA) (","[{'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Holten', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway karenholten@gmail.com.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Paulshus Sundlisater', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Siri', 'Initials': 'S', 'LastName': 'Lillegraven', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Sexton', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Lena Bugge', 'Initials': 'LB', 'LastName': 'Nordberg', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Moholt', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Hilde Berner', 'Initials': 'HB', 'LastName': 'Hammer', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Till', 'Initials': 'T', 'LastName': 'Uhlig', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Tore K', 'Initials': 'TK', 'LastName': 'Kvien', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Espen A', 'Initials': 'EA', 'LastName': 'Haavardsholm', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}, {'ForeName': 'Anna-Birgitte', 'Initials': 'AB', 'LastName': 'Aga', 'Affiliation': 'Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.'}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2021-220750'] 3260,34009291,Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.,"Importance To date, no randomized clinical trials have investigated perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metastases (CPM). Objective To assess the feasibility and safety of perioperative systemic therapy in patients with resectable CPM and the response of CPM to neoadjuvant treatment. Design, Setting, and Participants An open-label, parallel-group phase 2 randomized clinical trial in all 9 Dutch tertiary centers for the surgical treatment of CPM enrolled participants between June 15, 2017, and January 9, 2019. Participants were patients with pathologically proven isolated resectable CPM who did not receive systemic therapy within 6 months before enrollment. Interventions Randomization to perioperative systemic therapy or CRS-HIPEC alone. Perioperative systemic therapy comprised either four 3-week neoadjuvant and adjuvant cycles of CAPOX (capecitabine and oxaliplatin), six 2-week neoadjuvant and adjuvant cycles of FOLFOX (fluorouracil, leucovorin, and oxaliplatin), or six 2-week neoadjuvant cycles of FOLFIRI (fluorouracil, leucovorin, and irinotecan) and either four 3-week adjuvant cycles of capecitabine or six 2-week adjuvant cycles of fluorouracil with leucovorin. Bevacizumab was added to the first 3 (CAPOX) or 4 (FOLFOX/FOLFIRI) neoadjuvant cycles. Main Outcomes and Measures Proportions of macroscopic complete CRS-HIPEC and Clavien-Dindo grade 3 or higher postoperative morbidity. Key secondary outcomes were centrally assessed rates of objective radiologic and major pathologic response of CPM to neoadjuvant treatment. Analyses were done modified intention-to-treat in patients starting neoadjuvant treatment (experimental arm) or undergoing upfront surgery (control arm). Results In 79 patients included in the analysis (43 [54%] men; mean [SD] age, 62 [10] years), experimental (n = 37) and control (n = 42) arms did not differ significantly regarding the proportions of macroscopic complete CRS-HIPEC (33 of 37 [89%] vs 36 of 42 [86%] patients; risk ratio, 1.04; 95% CI, 0.88-1.23; P = .74) and Clavien-Dindo grade 3 or higher postoperative morbidity (8 of 37 [22%] vs 14 of 42 [33%] patients; risk ratio, 0.65; 95% CI, 0.31-1.37; P = .25). No treatment-related deaths occurred. Objective radiologic and major pathologic response rates of CPM to neoadjuvant treatment were 28% (9 of 32 evaluable patients) and 38% (13 of 34 evaluable patients), respectively. Conclusions and Relevance In this randomized phase 2 trial in patients diagnosed with resectable CPM, perioperative systemic therapy seemed feasible, safe, and able to induce response of CPM, justifying a phase 3 trial. Trial Registration ClinicalTrials.gov Identifier: NCT02758951.",2021,"Objective radiologic and major pathologic response rates of CPM to neoadjuvant treatment were 28% (9 of 32 evaluable patients) and 38% (13 of 34 evaluable patients), respectively. ","['Participants were patients with pathologically proven isolated resectable CPM who did not receive systemic therapy within 6 months before enrollment', '9 Dutch tertiary centers for the surgical treatment of CPM enrolled participants between June 15, 2017, and January 9, 2019', 'patients diagnosed with resectable CPM', 'patients with resectable CPM and the response of CPM to neoadjuvant treatment', 'Resectable Colorectal Peritoneal Metastases', 'resectable colorectal peritoneal metastases (CPM']","['capecitabine', 'Bevacizumab', 'perioperative systemic therapy', 'neoadjuvant treatment (experimental arm) or undergoing upfront surgery (control arm', 'FOLFIRI (fluorouracil, leucovorin, and irinotecan', 'fluorouracil with leucovorin', 'Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone', 'CAPOX (capecitabine and oxaliplatin', 'FOLFOX (fluorouracil, leucovorin, and oxaliplatin', 'cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC', 'CRS-HIPEC alone']","['feasibility and safety', 'Measures\n\n\nProportions of macroscopic complete CRS-HIPEC and Clavien-Dindo grade 3 or higher postoperative morbidity', 'rates of objective radiologic and major pathologic response of CPM to neoadjuvant treatment', 'proportions of macroscopic complete CRS-HIPEC', 'Objective radiologic and major pathologic response rates', 'postoperative morbidity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0346989', 'cui_str': 'Secondary malignant neoplasm of peritoneum'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}]","[{'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive surgery'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive surgery'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0034599', 'cui_str': 'Radiology - specialty'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0346989', 'cui_str': 'Secondary malignant neoplasm of peritoneum'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}]",,0.258345,"Objective radiologic and major pathologic response rates of CPM to neoadjuvant treatment were 28% (9 of 32 evaluable patients) and 38% (13 of 34 evaluable patients), respectively. ","[{'ForeName': 'Koen P', 'Initials': 'KP', 'LastName': 'Rovers', 'Affiliation': 'Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.'}, {'ForeName': 'Checca', 'Initials': 'C', 'LastName': 'Bakkers', 'Affiliation': 'Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.'}, {'ForeName': 'Simon W', 'Initials': 'SW', 'LastName': 'Nienhuijs', 'Affiliation': 'Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.'}, {'ForeName': 'Jacobus W A', 'Initials': 'JWA', 'LastName': 'Burger', 'Affiliation': 'Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.'}, {'ForeName': 'Geert-Jan M', 'Initials': 'GM', 'LastName': 'Creemers', 'Affiliation': 'Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands.'}, {'ForeName': 'Anna M J', 'Initials': 'AMJ', 'LastName': 'Thijs', 'Affiliation': 'Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands.'}, {'ForeName': 'Alexandra R M', 'Initials': 'ARM', 'LastName': 'Brandt-Kerkhof', 'Affiliation': 'Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Eva V E', 'Initials': 'EVE', 'LastName': 'Madsen', 'Affiliation': 'Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'van Meerten', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Jurriaan B', 'Initials': 'JB', 'LastName': 'Tuynman', 'Affiliation': 'Department of Surgery, Amsterdam University Medical Centers, location VUMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Miranda', 'Initials': 'M', 'LastName': 'Kusters', 'Affiliation': 'Department of Surgery, Amsterdam University Medical Centers, location VUMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Kathelijn S', 'Initials': 'KS', 'LastName': 'Versteeg', 'Affiliation': 'Department of Medical Oncology, Amsterdam University Medical Centers, location VUMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Arend G J', 'Initials': 'AGJ', 'LastName': 'Aalbers', 'Affiliation': 'Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Niels F M', 'Initials': 'NFM', 'LastName': 'Kok', 'Affiliation': 'Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Tineke E', 'Initials': 'TE', 'LastName': 'Buffart', 'Affiliation': 'Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Marinus J', 'Initials': 'MJ', 'LastName': 'Wiezer', 'Affiliation': 'Department of Surgery, Sint Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Djamila', 'Initials': 'D', 'LastName': 'Boerma', 'Affiliation': 'Department of Surgery, Sint Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Maartje', 'Initials': 'M', 'LastName': 'Los', 'Affiliation': 'Department of Medical Oncology, Sint Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Philip R', 'Initials': 'PR', 'LastName': 'de Reuver', 'Affiliation': 'Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Andreas J A', 'Initials': 'AJA', 'LastName': 'Bremers', 'Affiliation': 'Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Henk M W', 'Initials': 'HMW', 'LastName': 'Verheul', 'Affiliation': 'Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Schelto', 'Initials': 'S', 'LastName': 'Kruijff', 'Affiliation': 'Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Derk Jan A', 'Initials': 'DJA', 'LastName': 'de Groot', 'Affiliation': 'Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Arjen J', 'Initials': 'AJ', 'LastName': 'Witkamp', 'Affiliation': 'Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Wilhelmina M U', 'Initials': 'WMU', 'LastName': 'van Grevenstein', 'Affiliation': 'Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Koopman', 'Affiliation': 'Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Nederend', 'Affiliation': 'Department of Radiology, Catharina Cancer Institute, Eindhoven, the Netherlands.'}, {'ForeName': 'Max J', 'Initials': 'MJ', 'LastName': 'Lahaye', 'Affiliation': 'Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Onno', 'Initials': 'O', 'LastName': 'Kranenburg', 'Affiliation': 'Cancer Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Remond J A', 'Initials': 'RJA', 'LastName': 'Fijneman', 'Affiliation': 'Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': ""van 't Erve"", 'Affiliation': 'Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Petur', 'Initials': 'P', 'LastName': 'Snaebjornsson', 'Affiliation': 'Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Patrick H J', 'Initials': 'PHJ', 'LastName': 'Hemmer', 'Affiliation': 'Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Marcel G W', 'Initials': 'MGW', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Epidemiology and Data Science, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Cornelis J A', 'Initials': 'CJA', 'LastName': 'Punt', 'Affiliation': 'Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Pieter J', 'Initials': 'PJ', 'LastName': 'Tanis', 'Affiliation': 'Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Ignace H J T', 'Initials': 'IHJT', 'LastName': 'de Hingh', 'Affiliation': 'Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA surgery,['10.1001/jamasurg.2021.1642'] 3261,34010807,Habitual Caffeine Consumption Does Not Interfere With the Acute Caffeine Supplementation Effects on Strength Endurance and Jumping Performance in Trained Individuals.,"The long-standing caffeine habituation paradigm was never investigated in strength endurance and jumping exercise performance through a straightforward methodology. The authors examined if habitual caffeine consumption would influence the caffeine ergogenic effects on strength endurance and jumping performance as well as perceptual responses. Thirty-six strength-trained individuals were mathematically allocated into tertiles according to their habitual caffeine consumption: low (20 ± 11 mg/day), moderate (88 ± 33 mg/day), and high consumers (281 ± 167 mg/day). Then, in a double-blind, crossover, counterbalanced fashion, they performed a countermovement vertical jump test and a strength endurance test either after caffeine (6 mg/kg) and placebo supplementation or after no supplementation (control). Perceptual responses such as ratings of perceived exertion and pain were measured at the termination of the exercises. Acute caffeine supplementation improved countermovement vertical jump performance (p = .001) and total repetitions (p = .004), regardless of caffeine habituation. Accordingly, analysis of absolute change from the control session showed that caffeine promoted a significantly greater improvement in both countermovement vertical jump performance (p = .004) and total repetitions (p = .0001) compared with placebo. Caffeine did not affect the rating of perceived exertion and pain in any exercise tests, irrespective of tertiles (for all comparisons, p > .05 for both measures). Caffeine side effects were similar in low, moderate, and high caffeine consumers. These results show that habitual caffeine consumption does not influence the potential of caffeine as an ergogenic aid in strength endurance and jumping exercise performance, thus challenging recommendations to withdraw from the habitual caffeine consumption before supplementing with caffeine.",2021,"Acute caffeine supplementation improved countermovement vertical jump performance (p = .001) and total repetitions (p = .004), regardless of caffeine habituation.","['Trained Individuals', 'Thirty-six strength-trained individuals']","['Caffeine', 'placebo', 'placebo supplementation or after no supplementation (control', 'caffeine']","['strength endurance and jumping exercise performance', 'Strength Endurance and Jumping Performance', 'total repetitions', 'Caffeine side effects', 'rating of perceived exertion and pain', 'countermovement vertical jump performance', 'strength endurance and jumping performance', 'Perceptual responses such as ratings of perceived exertion and pain']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}]","[{'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}]",,0.0504442,"Acute caffeine supplementation improved countermovement vertical jump performance (p = .001) and total repetitions (p = .004), regardless of caffeine habituation.","[{'ForeName': 'Vitor', 'Initials': 'V', 'LastName': 'de Salles Painelli', 'Affiliation': 'University of São Paulo.'}, {'ForeName': 'Emerson L', 'Initials': 'EL', 'LastName': 'Teixeira', 'Affiliation': 'Paulista University.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Tardone', 'Affiliation': 'Paulista University.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Moreno', 'Affiliation': 'Paulista University.'}, {'ForeName': 'Jonatas', 'Initials': 'J', 'LastName': 'Morandini', 'Affiliation': 'Paulista University.'}, {'ForeName': 'Victória H', 'Initials': 'VH', 'LastName': 'Larrain', 'Affiliation': 'University of São Paulo.'}, {'ForeName': 'Flávio O', 'Initials': 'FO', 'LastName': 'Pires', 'Affiliation': 'University of São Paulo.'}]",International journal of sport nutrition and exercise metabolism,['10.1123/ijsnem.2020-0363'] 3262,34014063,Impact of the acute care surgery model on resident operative experience in emergency general surgery.,"Background The acute care surgery (ACS) model has been shown to improve patient, hospital and surgeon-specific outcomes. To date, however, little has been published on its impact on residency training. Our study compared the emergency general surgery (EGS) operative experiences of residents assigned to ACS versus elective surgical rotations. Methods Resident-reported EGS case logs were prospectively collected over a 9-month period across 3 teaching hospitals. Descriptive statistics were tabulated and group comparisons were made using χ2 statistics for categorical data and t tests for continuous data. Results Overall, 1061 cases were reported. Resident participation exceeded 90%). Appendiceal and biliary disease accounted for 49.7% of EGS cases. Residents on ACS rotations reported participating in twice as many EGS cases per block as residents on elective rotations (12.64 v. 6.30 cases, p < 0.01). Most cases occurred after hours while residents were on call rather than during daytime ACS hours (78.8% v. 21.1%, p < 0.01). Senior residents were more likely than junior residents to report having a primary operator role (71.3% v. 32.0%, p < 0.01). Although the timing of cases made no difference in the operative role of senior residents, junior residents assumed the primary operator role more often during the daytime than after hours (50.0% v. 33.1%, p = 0.01). Conclusion Despite implementation of the ACS model, residents in our program obtained most of their EGS operative experience after hours while on call. Although further research is needed, our study suggests that improved daytime access to the operating room may represent an opportunity to improve the quantity and quality of the EGS operative experience at our academic network.",2021,"Senior residents were more likely than junior residents to report having a primary operator role (71.3% v. 32.0%, p < 0.01).","['emergency general surgery', 'emergency general surgery (EGS) operative experiences of residents assigned to ACS versus elective surgical rotations']",['ACS model'],"['elective rotations', 'Appendiceal and biliary disease']","[{'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C1274039', 'cui_str': 'General surgery'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0016977', 'cui_str': 'Disorder of gallbladder'}]",1061.0,0.0361001,"Senior residents were more likely than junior residents to report having a primary operator role (71.3% v. 32.0%, p < 0.01).","[{'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Meschino', 'Affiliation': 'From the Department of Surgery, McMaster University, Hamilton, Ont. (Meschino, Giles, Engels, Rice, Nenshi, Maraccio).'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Giles', 'Affiliation': 'From the Department of Surgery, McMaster University, Hamilton, Ont. (Meschino, Giles, Engels, Rice, Nenshi, Maraccio).'}, {'ForeName': 'Paul T', 'Initials': 'PT', 'LastName': 'Engels', 'Affiliation': 'From the Department of Surgery, McMaster University, Hamilton, Ont. (Meschino, Giles, Engels, Rice, Nenshi, Maraccio).'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Rice', 'Affiliation': 'From the Department of Surgery, McMaster University, Hamilton, Ont. (Meschino, Giles, Engels, Rice, Nenshi, Maraccio).'}, {'ForeName': 'Rahima', 'Initials': 'R', 'LastName': 'Nenshi', 'Affiliation': 'From the Department of Surgery, McMaster University, Hamilton, Ont. (Meschino, Giles, Engels, Rice, Nenshi, Maraccio).'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Marcaccio', 'Affiliation': 'From the Department of Surgery, McMaster University, Hamilton, Ont. (Meschino, Giles, Engels, Rice, Nenshi, Maraccio).'}]",Canadian journal of surgery. Journal canadien de chirurgie,['10.1503/cjs.019619'] 3263,34013992,Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.,"OBJECTIVES To describe the methodology and implications of the patient-identified most bothersome symptom (PI-MBS) measure used in the phase 3, multicenter, randomized, double-blind, placebo-controlled, and parallel-group PROMISE-2 trial and to evaluate the contribution of this measure to the assessment of the preventive migraine benefits of treatment. BACKGROUND Although freedom from MBS is a coprimary endpoint in acute migraine treatment trials, its evaluation in preventive migraine trials is limited. The PROMISE-2 study assessed a unique PI-MBS measure as a secondary endpoint. METHODS This was a secondary analysis of data from the PROMISE-2 study. Adults with chronic migraine (CM) were randomized to receive intravenous (IV) eptinezumab 100 mg, eptinezumab 300 mg, or placebo, administered on day 0 and every 12 weeks. At the screening visit, patients were asked to verbally describe the MBS associated with their CM; the question format was open ended. At subsequent visits, patients were asked to rate the overall change in severity of their MBS from study inception to that time point, using a 7-point ordinal scale ranging from ""very much worse"" (-3) to ""very much improved"" (+3). Patients completed the Patient Global Impression of Change (PGIC) assessment during the same visits, using an identical rating scale and recall period. Endpoints were summarized descriptively; post hoc correlations using the methodologies of Pearson and Spearman were calculated to evaluate relationships between PGIC and PI-MBS and between PGIC and mean monthly migraine days (MMDs; primary efficacy endpoint in PROMISE-2). RESULTS Altogether, 1072 patients received treatment (eptinezumab 100 mg, n = 356; eptinezumab 300 mg, n = 350; placebo, n = 366) and were included in the analysis. There were 23 unique MBS identified; those reported by ≥10 patients included light sensitivity (18.7%), nausea/vomiting (15.1%), pain with activity (13.7%), pain (12.4%), headache (11.2%), sound sensitivity (7.3%), throbbing/pulsating pain (4.7%), cognitive disruption (4.1%), fatigue (2.4%), mood changes (1.5%), and sensitivity to smell (0.9%). Four weeks after the first dose (week 4), the rates of much or very much improvement in PI-MBS were higher with eptinezumab 100 mg (45%) and 300 mg (57%) than with placebo (29%). Four weeks after the second dose (week 16), the proportions with much or very much improvement in PI-MBS had increased to 58%, 65%, and 36%, respectively. At each time point, the percentages of patients with PGIC ratings of much or very much improved were similar to those for patient-reported improvement in PI-MBS. Patient ratings of changes in PI-MBS and PGIC correlated strongly across time points (Pearson, r range, 0.83-0.88; Spearman, r range, 0.83-0.89); the absolute value of the correlations was greater than the correlation among changes in MMDs and PGIC (Pearson, r range, -0.49 to -0.52; Spearman, r range, -0.49 to -0.52). CONCLUSIONS Among patients with CM in the PROMISE-2 study, a broad range of PI-MBS was reported at baseline. Throughout the study, patients treated with eptinezumab reported greater improvement in their PI-MBS severity compared with placebo recipients, and this improvement correlated strongly with PGIC findings. Collectively, these results indicate that PI-MBS is a promising and novel outcome measure for preventive trials of CM and thus may provide a unique patient-centered approach for identifying and measuring the burden of migraine symptoms that matter most to each patient, as well as the benefits of treatment.",2021,"Four weeks after the first dose (week 4), the rates of much or very much improvement in PI-MBS were higher with eptinezumab 100 mg (45%) and 300 mg (57%) than with placebo (29%).","['Adults with chronic migraine (CM', '1072 patients received']","['intravenous (IV) eptinezumab 100\xa0mg, eptinezumab 300\xa0mg, or placebo', 'placebo', 'treatment (eptinezumab 100\xa0mg, n\xa0=\xa0356; eptinezumab 300\xa0mg, n\xa0=\xa0350; placebo', 'eptinezumab']","['Patient Global Impression of Change (PGIC) assessment', 'cognitive disruption', 'MMDs and PGIC', 'throbbing/pulsating pain', 'sound sensitivity', 'pain with activity', 'nausea/vomiting', 'Patient ratings of changes in PI-MBS and PGIC', 'light sensitivity', 'PI-MBS severity', 'pain', 'headache', 'mood changes', 'sensitivity to smell', 'fatigue', 'PI-MBS', 'PGIC and PI-MBS and between PGIC and mean monthly migraine days (MMDs; primary efficacy endpoint in PROMISE-2']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1960870', 'cui_str': 'Transformed migraine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C4694272', 'cui_str': 'eptinezumab'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517735', 'cui_str': '350'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439606', 'cui_str': 'Pulsatile'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0085636', 'cui_str': 'Photophobia'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",1072.0,0.260126,"Four weeks after the first dose (week 4), the rates of much or very much improvement in PI-MBS were higher with eptinezumab 100 mg (45%) and 300 mg (57%) than with placebo (29%).","[{'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Dodick', 'Affiliation': 'Department of Neurology, Mayo Clinic, Phoenix, AZ, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Ailani', 'Affiliation': 'Department of Neurology, Medstar Georgetown University Hospital, Washington, DC, USA.'}, {'ForeName': 'Lora', 'Initials': 'L', 'LastName': 'McGill', 'Affiliation': 'CNS HealthCare, Memphis, TN, USA.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Hirman', 'Affiliation': 'Pacific Northwest Statistical Consulting, Woodinville, WA, USA.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Cady', 'Affiliation': 'Lundbeck La Jolla Research Center, San Diego, CA, USA.'}]",Headache,['10.1111/head.14120'] 3264,34013755,One-year aerobic exercise altered cerebral vasomotor reactivity in mild cognitive impairment.,"The purpose of this study was to test the hypothesis that changes in cerebral vasomotor reactivity (CVMR) after 1-yr aerobic exercise training (AET) are associated with cognitive performances in individuals with amnestic mild cognitive impairment (MCI). Seventy sedentary patients with amnestic MCI were randomized to 1-yr moderate-to-vigorous intensity AET or stretching and toning (SAT) interventions. Cerebral blood flow velocity (CBFV) with transcranial Doppler, mean arterial pressure (MAP) with finapres plethysmograph, and EtCO 2 with capnography were measured during hyperventilation (hypocapnia) and a modified rebreathing protocol (hypercapnia) to assess CVMR. Cerebrovascular conductance index (CVCi) was calculated by CBFV/MAP, and CVMR by ΔCBFV/ΔEtCO 2 and ΔCVCi/ΔEtCO 2 . Episodic memory and executive function were assessed using standard neuropsychological tests (CVLT-II and D-KEFS). Cardiorespiratory fitness was assessed by peak oxygen uptake (V̇o 2peak ). A total of 37 patients (19 in SAT and 18 in AET) completed 1-yr interventions and CVMR assessments. AET improved V̇o 2peak , increased hypocapnic CVMR, but decreased hypercapnic CVMR. The effects of AET on cognitive performance were minimal when compared with SAT. Across both groups, there was a negative correlation between changes in hypocapnic and hypercapnic CVMRs in CBFV% and CVCi% ( r = -0.741, r = -0.725, P < 0.001). Attenuated hypercapnic CVMR, but not increased hypocapnic CVMR, was associated with improved cognitive test scores in the AET group. In conclusion, 1-yr AET increased hypocapnic CVMR and attenuated hypercapnic CVMR which is associated cognitive performance in patients with amnestic MCI. NEW & NOTEWORTHY One-year moderate-to-vigorous intensity aerobic exercise training (AET) improved cardiorespiratory fitness (V̇o 2peak ), increased hypocapnic cerebral vasomotor reactivity (CVMR), whereas it decreased hypercapnic CVMR when compared with stretching and toning in patients with amnestic mild cognitive impairment (MCI). Furthermore, changes in hypercapnic CVMR with AET were correlated with improved memory and executive function. These findings indicate that AET has an impact on cerebrovascular function which may benefit cognitive performance in older adults who have high risk of Alzheimer's disease.",2021,"Attenuated hypercapnic CVMR, but not increased hypocapnic CVRM, was associated with improved cognitive test scores in the AET group.","['Mild Cognitive Impairment', 'Seventy sedentary patients with amnestic MCI', 'patients with amnestic MCI', '37 patients (19 in SAT and 18 in AET) completed one-year interventions and CVMR assessments', 'individuals with amnestic mild cognitive impairment (MCI']","['vigorous intensity AET or stretching and toning (SAT) interventions', 'aerobic exercise training (AET']","['VO 2peak , increased hypocapnic CVMR', 'Cerebrovascular conductance index (CVCi', 'cerebral vasomotor reactivity (CVMR', 'Cerebral blood flow velocity (CBFV) with transcranial Doppler, mean arterial pressure (MAP) with finapres plethysmograph, and EtCO 2 with capnography', 'cognitive test scores', 'peak oxygen uptake (VO 2peak ', 'Cerebral Vasomotor Reactivity', 'Cardiorespiratory fitness', 'Episodic memory and executive function', 'hypercapnic CVMR', 'cognitive performance', 'hypocapnic CVMR', 'hypo- and hypercapnic CVMRs in CBFV% and CVCi', 'hypocapnic CVRM']","[{'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0085383', 'cui_str': 'Hypocapnia'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0206077', 'cui_str': 'Transcranial doppler ultrasonography'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0182319', 'cui_str': 'Plethysmograph'}, {'cui': 'C0376529', 'cui_str': 'Capnography'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0020440', 'cui_str': 'Hypercapnia'}]",70.0,0.0504111,"Attenuated hypercapnic CVMR, but not increased hypocapnic CVRM, was associated with improved cognitive test scores in the AET group.","[{'ForeName': 'Tsubasa', 'Initials': 'T', 'LastName': 'Tomoto', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Tarumi', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}, {'ForeName': 'Jason N', 'Initials': 'JN', 'LastName': 'Chen', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}, {'ForeName': 'Linda S', 'Initials': 'LS', 'LastName': 'Hynan', 'Affiliation': 'Department of Population and Data Sciences (Biostatistics), University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'C Munro', 'Initials': 'CM', 'LastName': 'Cullum', 'Affiliation': 'Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00158.2021'] 3265,34013549,Editorial Comment to Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.,,2021,,['initial non-muscle-invasive bladder cancer'],"['Editorial Comment to Green-light laser en bloc resection', 'conventional transurethral resection']",[],"[{'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}]","[{'cui': 'C0282411', 'cui_str': 'Editorial Comment'}, {'cui': 'C1306567', 'cui_str': 'Green light'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach'}]",[],,0.247047,,"[{'ForeName': 'Yasuyoshi', 'Initials': 'Y', 'LastName': 'Miyata', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Matsuo', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Sakai', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.'}]",International journal of urology : official journal of the Japanese Urological Association,['10.1111/iju.14607'] 3266,34038529,"Strengthening Nutrition Interventions in Antenatal Care Services Affects Dietary Intake, Micronutrient Intake, Gestational Weight Gain, and Breastfeeding in Uttar Pradesh, India: Results of a Cluster-Randomized Program Evaluation.","BACKGROUND Maternal nutrition interventions are inadequately integrated into antenatal care (ANC). Alive & Thrive aimed to strengthen delivery of micronutrient supplements and intensify interpersonal counseling and community mobilization through government ANC services. OBJECTIVES We compared nutrition-intensified ANC (I-ANC) with standard ANC (S-ANC) on coverage of nutrition interventions and maternal nutrition practices. METHODS We used a cluster-randomized design with cross-sectional baseline (2017) and endline (2019) surveys (n ∼660 pregnant and 1800 recently delivered women per survey) and a repeated-measures longitudinal study in 2018-2019 (n = 400). We derived difference-in-difference effect estimates (DIDs) for diet diversity, consumption of micronutrient supplements, weight monitoring, and early breastfeeding practices. RESULTS Despite substantial secular improvements in service coverage from India's national nutrition program, women in the I-ANC arm received more home visits [DID: 7-14 percentage points (pp)] and counseling on core nutrition messages (DID: 10-23 pp) than in the S-ANC arm. One-third of women got ≥3 home visits and one-fourth received ≥4 ANC check-ups in the I-ANC arm. Improvements were greater in the I-ANC arm than in the S-ANC arm for any receipt and consumption of iron-folic acid (DID: 7.5 pp and 9.5 pp, respectively) and calcium supplements (DID: 14.1 pp and 11.5 pp, respectively). Exclusive breastfeeding improved (DID: 7.5 pp) but early initiation of breastfeeding did not. Maternal food group consumption (∼4 food groups) and probability of adequacy of micronutrients (∼20%) remained low in both arms. Repeated-measures longitudinal analyses showed similar results, with additional impact on consumption of vitamin A-rich foods (10 pp, 11 g/d), other vegetables and fruits (22-29 g/d), and gestational weight gain (0.4 kg). CONCLUSIONS Intensifying nutrition in government ANC services improved maternal nutrition practices even with strong secular trends in service coverage. Dietary diversity, supplement consumption, and breastfeeding practices remained suboptimal. Achieving greater behavior changes will require strengthening the delivery and use of maternal nutrition services integrated into ANC services in the health system. This trial was registered at clinicaltrials.gov as NCT03378141.",2021,"Improvements were greater in the I-ANC arm than in the S-ANC arm for any receipt and consumption of iron-folic acid (DID: 7.5 pp and 9.5 pp, respectively) and calcium supplements (DID:",['2019) surveys (n ∼660 pregnant and 1800 recently delivered women per survey) and a repeated-measures longitudinal study in 2018-2019 (n\xa0=\xa0400'],"['cross-sectional baseline (2017) and endline', 'calcium supplements (DID', 'nutrition-intensified ANC (I-ANC) with standard ANC (S-ANC', 'Strengthening Nutrition Interventions']","['Dietary Intake, Micronutrient Intake, Gestational Weight Gain, and Breastfeeding in Uttar Pradesh, India', 'maternal nutrition practices', 'gestational weight gain']","[{'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C3816746', 'cui_str': '400'}]","[{'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C3540037', 'cui_str': 'Calcium supplement'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C1720845', 'cui_str': 'Maternal Nutritional Physiological Phenomenon'}]",,0.0257279,"Improvements were greater in the I-ANC arm than in the S-ANC arm for any receipt and consumption of iron-folic acid (DID: 7.5 pp and 9.5 pp, respectively) and calcium supplements (DID:","[{'ForeName': 'Phuong H', 'Initials': 'PH', 'LastName': 'Nguyen', 'Affiliation': 'International Food Policy Research Institute, Washington, DC, USA.'}, {'ForeName': 'Shivani', 'Initials': 'S', 'LastName': 'Kachwaha', 'Affiliation': 'International Food Policy Research Institute, Washington, DC, USA.'}, {'ForeName': 'Lan M', 'Initials': 'LM', 'LastName': 'Tran', 'Affiliation': 'FHI Solutions, Washington, DC, USA.'}, {'ForeName': 'Rasmi', 'Initials': 'R', 'LastName': 'Avula', 'Affiliation': 'International Food Policy Research Institute, Washington, DC, USA.'}, {'ForeName': 'Melissa F', 'Initials': 'MF', 'LastName': 'Young', 'Affiliation': 'Hubert Department of Global Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Sebanti', 'Initials': 'S', 'LastName': 'Ghosh', 'Affiliation': 'FHI Solutions, Washington, DC, USA.'}, {'ForeName': 'Praveen K', 'Initials': 'PK', 'LastName': 'Sharma', 'Affiliation': 'FHI Solutions, Washington, DC, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Escobar-Alegria', 'Affiliation': 'FHI Solutions, Washington, DC, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Forissier', 'Affiliation': 'FHI Solutions, Washington, DC, USA.'}, {'ForeName': 'Sumeet', 'Initials': 'S', 'LastName': 'Patil', 'Affiliation': 'Network for Engineering, Economics, Research and Management (NEERMAN), Delhi, India.'}, {'ForeName': 'Edward A', 'Initials': 'EA', 'LastName': 'Frongillo', 'Affiliation': 'Health Department of Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.'}, {'ForeName': 'Purnima', 'Initials': 'P', 'LastName': 'Menon', 'Affiliation': 'International Food Policy Research Institute, Washington, DC, USA.'}]",The Journal of nutrition,['10.1093/jn/nxab131'] 3267,34014688,Day-level shifts in social contexts during youth cannabis use treatment.,"OBJECTIVE Social context plays a critical role in youth cannabis use. Yet few studies have examined if and when social contexts shift during cannabis use treatment. This study examined daily shifts in youths' social contexts with the goal of characterizing how specific social contexts (e.g., time with cannabis-using friends or siblings) relate to cannabis craving and use during cannabis treatment. METHOD Participants were 65 cannabis users (51% male), ages 15-24 years, who participated in a double-blind randomized clinical trial that tested the effects of motivational enhancement and cognitive behavioral therapies plus either adjunctive pharmacotherapy or placebo on cannabis craving and use. Ecological momentary assessment (EMA) data, collected from a pre-randomization period through the completion of the six-week intervention, assessed youths' social contexts, cannabis use, and craving. RESULTS Time-varying effects models identified shifts in social contexts during treatment. Overall, time spent with cannabis-using friends and siblings decreased, where time spent with non-using friends or alone increased across the trial. Time with parents or non-using siblings was unchanged. Comparing the relative associations of social contexts with same-day craving and use, more time with cannabis-using friends and with siblings was uniquely associated with greater craving and use. CONCLUSIONS Social context is an important factor in youth substance-use treatment. While time spent with cannabis-using friends and siblings decreased over treatment for all participants, those who continued to spend time with using individuals reported greater craving and use. This research supports increased attention to shifting youths' social contexts to enhance treatment success. (PsycInfo Database Record (c) 2021 APA, all rights reserved).",2021,"Overall, time spent with cannabis-using friends and siblings decreased, where time spent with non-using friends or alone increased across the trial.","['Participants were 65 cannabis users (51% male), ages 15-24 years', ""youths' social contexts with the goal of characterizing how specific social contexts (e.g., time with cannabis-using friends or siblings""]",['motivational enhancement and cognitive behavioral therapies plus either adjunctive pharmacotherapy or placebo'],"['time spent with non-using friends or alone', 'Ecological momentary assessment (EMA) data', 'Overall, time spent with cannabis-using friends and siblings', ""youths' social contexts, cannabis use, and craving""]","[{'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0037414', 'cui_str': 'Social context'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}]","[{'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0037414', 'cui_str': 'Social context'}, {'cui': 'C0870371', 'cui_str': 'Craving'}]",,0.0248681,"Overall, time spent with cannabis-using friends and siblings decreased, where time spent with non-using friends or alone increased across the trial.","[{'ForeName': 'Samuel N', 'Initials': 'SN', 'LastName': 'Meisel', 'Affiliation': 'Center for Alcohol and Addiction Studies.'}, {'ForeName': 'Ryan W', 'Initials': 'RW', 'LastName': 'Carpenter', 'Affiliation': 'University of Missouri.'}, {'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'Treloar Padovano', 'Affiliation': 'Center for Alcohol and Addiction Studies.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Miranda', 'Affiliation': 'Center for Alcohol and Addiction Studies.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000647'] 3268,34389505,Long-term benefit of Probiotic Peanut Oral Immunotherapy (PPOIT) on quality of life in a randomised trial.,,2021,,[],['Probiotic Peanut Oral Immunotherapy (PPOIT'],['quality of life'],[],"[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.128733,,"[{'ForeName': 'Audrey Dunn', 'Initials': 'AD', 'LastName': 'Galvin', 'Affiliation': 'School of Applied Psychology, University College Cork, Ireland.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Lloyd', 'Affiliation': ""Allergy Immunology, Murdoch Children's Research Institute, Melbourne, Australia.""}, {'ForeName': 'Kuang-Chih', 'Initials': 'KC', 'LastName': 'Hsiao', 'Affiliation': ""Department of Immunology, Starship Children's Hospital, Auckland, New Zealand; Department of Paediatrics, University of Auckland, Auckland, New Zealand; Allergy Immunology, Murdoch Children's Research Institute, Melbourne, Australia.""}, {'ForeName': 'Mimi Lk', 'Initials': 'ML', 'LastName': 'Tang', 'Affiliation': ""Allergy Immunology, Murdoch Children's Research Institute; Department of Paediatrics, University of Melbourne; and Department of Allergy and Immunology, The Royal Children's Hospital; Melbourne, VIC, Australia. Electronic address: mimi.tang@rch.org.au.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2021.07.047'] 3269,34018042,Laparoscopic Versus Open Incisional Hernia Repair: Long-Term Follow-up Results of a Randomized Clinical Trial.,"PURPOSE Long-term extension of a previous randomized controlled clinical trial comparing open (OVHR) vs. laparoscopic (LVHR) ventral hernia repair, assessing recurrence, reoperation, mesh-related complications and self-reported quality of life with 10 years of follow-up. METHODS Eighty-five patients were followed up to assess recurrence (main endpoint), reoperation, mesh complications and death, from the date of index until recurrence, death or study completion, whichever was first. Recurrence, reoperation rates and death were estimated by intention to treat. Mesh-related complications were only assessed in the LVHR group, excluding conversions (intraperitoneal onlay; n = 40). Quality of life, using the European Hernia Society Quality of Life score, was assessed in surviving non-reoperated patients (n = 47). RESULTS The incidence rates with 10 person-years of follow-up were 21.01% (CI 13.24-33.36) for recurrence, 11.92% (CI: 6.60-21.53) for reoperation and 24.88% (CI 16.81-36.82) for death. Sixty-two percent of recurrences occurred within the first 2 years of follow-up. No significant differences between arms were found in any of the outcomes analyzed. Incidence rate of intraperitoneal mesh complications with 10 person-years of follow-up was 6.15% (CI 1.99-19.09). The mean EuraHS-QoL score with 13.8 years of mean follow-up for living non-reoperated patients was 6.63 (CI 4.50-8.78) over 90 possible points with no significant differences between arms. CONCLUSION In incisional ventral hernias with wall defects up to 15 cm wide, laparoscopic repair seems to be as safe and effective as open techniques, with no long-term differences in recurrence and reoperation rates or global quality of life, although lack of statistical power does not allow definitive conclusions on equivalence between alternatives. TRIAL REGISTRATION NUMBER ClinicalTrial.gov (NCT04192838).",2021,"Quality of life, using the European Hernia Society Quality of Life score, was assessed in surviving non-reoperated patients (n = 47). ",['Eighty-five patients'],"['Laparoscopic Versus Open Incisional Hernia Repair', 'open (OVHR) vs. laparoscopic (LVHR) ventral hernia repair']","['mean EuraHS-QoL score', 'Mesh-related complications', 'Quality of life, using the European Hernia Society Quality of Life score', 'recurrence (main endpoint), reoperation, mesh complications and death, from the date of index until recurrence, death or study completion', 'incidence rates', 'Recurrence, reoperation rates and death', 'Incidence rate of intraperitoneal mesh complications']","[{'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0342971', 'cui_str': 'Repair of incisional hernia'}, {'cui': 'C0019334', 'cui_str': 'Repair of ventral hernia'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0442120', 'cui_str': 'Intraperitoneal'}]",85.0,0.280724,"Quality of life, using the European Hernia Society Quality of Life score, was assessed in surviving non-reoperated patients (n = 47). ","[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Asencio', 'Affiliation': 'Department of Surgery, Arnau de Vilanova University Hospital, SanClemente 12, 46015, Valencia, Spain. f.asencio@comv.es.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Carbó', 'Affiliation': 'Research Department, Arnau de Vilanova University Hospital, Valencia, Spain.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Ferri', 'Affiliation': 'Research Department, Arnau de Vilanova University Hospital, Valencia, Spain.'}, {'ForeName': 'Salvador', 'Initials': 'S', 'LastName': 'Peiró', 'Affiliation': 'Research Department, Arnau de Vilanova University Hospital, Valencia, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Aguiló', 'Affiliation': 'Research Department, Arnau de Vilanova University Hospital, Valencia, Spain.'}, {'ForeName': 'Inmaculada', 'Initials': 'I', 'LastName': 'Torrijo', 'Affiliation': 'Department of Surgery, Arnau de Vilanova University Hospital, SanClemente 12, 46015, Valencia, Spain.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Barber', 'Affiliation': 'Research Department, Arnau de Vilanova University Hospital, Valencia, Spain.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Canovas', 'Affiliation': 'Department of Surgery, Arnau de Vilanova University Hospital, SanClemente 12, 46015, Valencia, Spain.'}, {'ForeName': 'Juan Carlos', 'Initials': 'JC', 'LastName': 'Andreu-Ballester', 'Affiliation': 'Department of Surgery, Arnau de Vilanova University Hospital, SanClemente 12, 46015, Valencia, Spain.'}]",World journal of surgery,['10.1007/s00268-021-06164-7'] 3270,34015940,Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration.,"BACKGROUND AND PURPOSE The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. METHODS AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. RESULTS Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76-1.14]; P =0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. CONCLUSIONS Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. Registration: URL: http://www.anzctr.org.au/; Unique identifier: ACTRN12611000774921.",2021,"Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. ","['adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019']","['fluoxetine', 'Fluoxetine', 'placebo', 'oral fluoxetine 20 mg once daily (n=642) or matching placebo']","['falls', 'lower rate of recurrent ischemic stroke', 'functional outcome, falls, bone fractures, or seizures', 'recurrent ischemic strokes', 'bone fractures', 'modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months', 'functional outcome', 'function, measured by the modified Rankin Scale', 'Functional Recovery', 'distribution of modified Rankin Scale categories', 'risk of falls, bone fractures, and seizures', 'seizures']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0587502', 'cui_str': 'Stroke unit'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0042658', 'cui_str': 'Vietnam'}]","[{'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0986112', 'cui_str': 'Fluoxetine 20 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0599766', 'cui_str': 'Recovery of Function'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",10.0,0.198989,"Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. ","[{'ForeName': 'Graeme J', 'Initials': 'GJ', 'LastName': 'Hankey', 'Affiliation': 'Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Western Australia, Australia (G.J.H., O.P.A., L.F.).'}, {'ForeName': 'Maree L', 'Initials': 'ML', 'LastName': 'Hackett', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia (M.L.H., S.J., T.L., C.S.A.).'}, {'ForeName': 'Osvaldo P', 'Initials': 'OP', 'LastName': 'Almeida', 'Affiliation': 'Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Western Australia, Australia (G.J.H., O.P.A., L.F.).'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Flicker', 'Affiliation': 'Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Western Australia, Australia (G.J.H., O.P.A., L.F.).'}, {'ForeName': 'Gillian E', 'Initials': 'GE', 'LastName': 'Mead', 'Affiliation': 'University of Edinburgh, Royal Infirmary, Scotland (G.E.M., M.S.D.).'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Dennis', 'Affiliation': 'University of Edinburgh, Royal Infirmary, Scotland (G.E.M., M.S.D.).'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Etherton-Beer', 'Affiliation': 'The University of Western Australia, Perth, Western Australia, Australia (C.E.-B., A.H.F.).'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Ford', 'Affiliation': 'The University of Western Australia, Perth, Western Australia, Australia (C.E.-B., A.H.F.).'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Billot', 'Affiliation': 'Statistics Division, The George Institute for Global Health, Sydney, New South Wales, Australia (L.B.).'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Jan', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia (M.L.H., S.J., T.L., C.S.A.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lung', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia (M.L.H., S.J., T.L., C.S.A.).'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Lundström', 'Affiliation': 'Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden (E.L.).'}, {'ForeName': 'Katharina S', 'Initials': 'KS', 'LastName': 'Sunnerhagen', 'Affiliation': 'Institute of Neuroscience and Physiology-Clinical Neuroscience, The Sahlgrenska Academy, University of Gothenburg, Sweden (K.S.S.).'}, {'ForeName': 'Craig S', 'Initials': 'CS', 'LastName': 'Anderson', 'Affiliation': 'The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia (M.L.H., S.J., T.L., C.S.A.).'}, {'ForeName': 'Huy', 'Initials': 'H', 'LastName': 'Thang-Nguyen', 'Affiliation': 'The George Institute for Global Health at Peking University Health Science Center, Beijing, China (C.S.A.).'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gommans', 'Affiliation': ""Department of Neurology, The People's Hospital 115, Ho Chi Minh city, Vietnam (H.T.-N.).""}, {'ForeName': 'Qilong', 'Initials': 'Q', 'LastName': 'Yi', 'Affiliation': ""Hawke's Bay Hospital, Hastings, New Zealand (J.G.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Stroke,['10.1161/STROKEAHA.120.033070'] 3271,34389407,Involved-Field Radiotherapy prevents recurrences in the early stages of Hodgkin's lymphoma in PET-negative patients after ABVD Chemotherapy Relapse Analysis of GHSG Phase III HD16 Trial.,"PURPOSE The HD16 trial of the GHSG (xxxxxxxx) demonstrated that radiotherapy in early-stage Hodgkin's lymphoma without risk factors (ESHL) cannot be safely omitted and therefore combined modality therapy (CMT) remains the standard treatment. To demonstrate the local effect of consolidating involved-field radiotherapy (IF-RT) we performed an analysis of the recurrence pattern of PET-negative HD16 patients. METHOD AND MATERIALS Between 2009 and 2015 1150 patients with ESHL were randomly assigned to PET guided to 20 Gy IFRT after 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy in the HD16 study of the German Hodgkin Study Group. The study was designed as a prospective randomized controlled trial. We now correlated the localization of recurrence with the panel-based IF-RT plan, which was drawn up for all patients prospectively, blinded to treatment #allocation. Accordingly, we were able to identify recurrences that occurred at least in part inside or outside of the (potential) radiation field (""in-field"", ""out-field""). RESULTS There were 328 and 300 PET-negative patients assigned to CMT and PET-guided treatment (i.e. chemotherapy alone), respectively. Within 47 months median follow-up, disease progression or recurrence was documented for 15 and 29 patients treated with and without IF-RT, respectively. Relapse localization was unknown in 1 CMT patient. Without IF-RT, 5-year incidence of in-field relapses was 10.5% (95% CI 6.5-14.6) compared to 2.4% (0,5-4.3) with CMT (p=0.0008). There were no relevant differences in out-field recurrences (5-year incidence 4.1% [1.7-6.6] vs. 6.6% [3.0-10.3], p=0.54). There was no grade 4 toxicity observed during IF-RT and incidence of second primary malignancies was similar in both groups. CONCLUSIONS PET-negative patients of the HD16 study showed no significant toxicity after 20 Gy IF-RT and we demonstrated that omission of IF-RT resulted in more, particularly local recurrences. Therefore, consolidation IF-RT should still be considered as standard therapy in this setting.",2021,"There were no relevant differences in out-field recurrences (5-year incidence 4.1% [1.7-6.6] vs. 6.6% [3.0-10.3], p=0.54).","[""early-stage Hodgkin's lymphoma without risk factors (ESHL"", 'Between 2009 and 2015 1150 patients with ESHL']","['radiotherapy', 'consolidating involved-field radiotherapy (IF-RT', 'PET guided to 20 Gy IFRT', 'ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy', 'RT', 'GHSG (xxxxxxxx']","['Relapse localization', 'toxicity', 'grade 4 toxicity', 'disease progression or recurrence', '5-year incidence of in-field relapses']","[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0019829', 'cui_str': 'Hodgkin lymphoma'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0050380', 'cui_str': 'ABVD-I protocol'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0005740', 'cui_str': 'Bleomycin'}, {'cui': 'C0042670', 'cui_str': 'Vinblastine'}, {'cui': 'C0010927', 'cui_str': 'Dacarbazine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0037710', 'cui_str': 'Auditory localization'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}]",,0.0449633,"There were no relevant differences in out-field recurrences (5-year incidence 4.1% [1.7-6.6] vs. 6.6% [3.0-10.3], p=0.54).","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Baues', 'Affiliation': 'Department of Radiooncology, Radiotherapy and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany; German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany. Electronic address: christian.baues@uk-koeln.de.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Goergen', 'Affiliation': 'German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany. Electronic address: helen.goergen@uk-koeln.de.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Fuchs', 'Affiliation': 'German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.'}, {'ForeName': 'Dr Johannes', 'Initials': 'DJ', 'LastName': 'Rosenbrock', 'Affiliation': 'Department of Radiooncology, Radiotherapy and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany; German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.'}, {'ForeName': 'Eren', 'Initials': 'E', 'LastName': 'Celik', 'Affiliation': 'Department of Radiooncology, Radiotherapy and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Eich', 'Affiliation': 'German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany; Department of Radiotherapy, University Hospital of Muenster, Muenster, Germany.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Kobe', 'Affiliation': 'German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.'}, {'ForeName': 'Conrad-Amadeus', 'Initials': 'CA', 'LastName': 'Voltin', 'Affiliation': 'Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Engert', 'Affiliation': 'German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Borchmann', 'Affiliation': 'German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Marnitz', 'Affiliation': 'Department of Radiooncology, Radiotherapy and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany; German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2021.07.1697'] 3272,34389374,Increasing vegetables purchase with a descriptive-norm message: A cluster randomized controlled intervention in two university canteens.,"Exposure to social norms is a popular way to foster healthy food behavior. Testing the robustness of this effect, we report a field study assessing the impact of a vegetable-related descriptive norm message on vegetables purchase. The first contribution was to rely on a cluster randomized crossover design: Two canteens were randomly selected to display either a vegetable-related or a neutral-behavior norm message. After a first period of data collection, the displays were reversed for a second period: The number of vegetable portions on the main plate were recorded before, during and after the message display (N = 12.994). The second contribution was to test the impact of a message describing vegetables as the normative choice beyond the mere selection of vegetables, on the quantity of vegetables purchased in lunches containing some. Results indicated that the vegetable-related norm message led to a sustained probability of choosing vegetables, contrary to a decrease observed in the control condition. Moreover, students who ordered vegetables ordered a higher quantity when exposed to a vegetable-related message than before whereas quantity declined in the control condition. By treating both canteens as experimental and control and by analyzing both the presence and the amount of vegetables, these results extend and strengthen those previously observed, bringing support for the effectiveness of a descriptive norm message in eliciting healthier food behavior.",2021,"Results indicated that the vegetable-related norm message led to a sustained probability of choosing vegetables, contrary to a decrease observed in the control condition.",['two university canteens'],['vegetable-related or a neutral-behavior norm message'],"['number of vegetable portions on the main plate', 'sustained probability of choosing vegetables']","[{'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",2.0,0.00618368,"Results indicated that the vegetable-related norm message led to a sustained probability of choosing vegetables, contrary to a decrease observed in the control condition.","[{'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Guichard', 'Affiliation': ""Centre de Recherches sur la Cognition et l'Apprentissage (CeRCA, UMR CNRS 7295), Université de Poitiers, Poitiers, France; MSHS - Bâtiment A5, Université de Poitiers, 5 rue Théodore Lefebvre, TSA 21103, F-86073, Poitiers Cedex 9, France. Electronic address: emilie.guichard@univ-poitiers.fr.""}, {'ForeName': 'Frédérique', 'Initials': 'F', 'LastName': 'Autin', 'Affiliation': ""Centre de Recherches sur la Cognition et l'Apprentissage (CeRCA, UMR CNRS 7295), Université de Poitiers, Poitiers, France; MSHS - Bâtiment A5, Université de Poitiers, 5 rue Théodore Lefebvre, TSA 21103, F-86073, Poitiers Cedex 9, France. Electronic address: frederique.autin@univ-poitiers.fr.""}, {'ForeName': 'Jean-Claude', 'Initials': 'JC', 'LastName': 'Croizet', 'Affiliation': 'LAboratoire de Psychologie Sociale et COgnitive (LAPSCO, UMR UCA-CNRS 6024), Université Clermont Auvergne, Clermont-Ferrand, 34 av. Carnot, 63037, Clermont-Ferrand Cedex, France. Electronic address: j-claude.croizet@uca.fr.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Jouffre', 'Affiliation': ""Centre de Recherches sur la Cognition et l'Apprentissage (CeRCA, UMR CNRS 7295), Université de Poitiers, Poitiers, France; MSHS - Bâtiment A5, Université de Poitiers, 5 rue Théodore Lefebvre, TSA 21103, F-86073, Poitiers Cedex 9, France. Electronic address: stephane.jouffre@univ-poitiers.fr.""}]",Appetite,['10.1016/j.appet.2021.105624'] 3273,34021264,Healthy eating and lifestyle in pregnancy (HELP): a cluster randomised trial to evaluate the effectiveness of a weight management intervention for pregnant women with obesity on weight at 12 months postpartum.,"OBJECTIVE To assess whether a weight management intervention for pregnant women with obesity was effective in reducing body mass index (BMI) 12 months after giving birth. METHODS Pragmatic, cluster randomised controlled trial (RCT) with embedded cost-effectiveness analysis. 598 women with a BMI of ≥30 kg/m 2 (between 12 and 20 weeks gestation) were recruited from 20 secondary care maternity units in England and Wales. BMI at 12 months postpartum was the primary outcome. A range of clinical and behavioural secondary outcomes were examined. INTERVENTIONS Women attending maternity units randomised to intervention were invited to a weekly weight management group, which combined expertise from a commercial weight loss programme with clinical advice from midwives. Both intervention and control participants received usual care and leaflets on diet and physical activity in pregnancy. RESULTS Mean (SD) BMI at 12 months postpartum was 36.0 kg/m 2 (5.2) in the control group, and 37.5 kg/m 2 (6.7) in the intervention group. After adjustment for baseline BMI, the intervention effect was -0.02 (95% CI -0.04 to 0.01). The intervention group had an improved healthy eating score (3.08, 95% CI 0.16 to 6.00, p < 0.04), improved fibre score (3.22, 1.07 to 5.37, p < 0.01) and lower levels of risky drinking at 12 months postpartum compared to the control group (OR 0.45, 0.27 to 0.74, p < 0.002). The net incremental monetary benefit was not statistically significantly different between arms, although the probability of the intervention being cost-effective was above 60%, at policy-relevant thresholds. CONCLUSIONS There was no significant difference between groups on the primary outcome of BMI at 12 months. Analyses of secondary outcomes indicated improved healthy eating and lower levels of risky drinking. TRIAL REGISTRATION Current Controlled Trials ISRCTN25260464.",2021,"The net incremental monetary benefit was not statistically significantly different between arms, although the probability of the intervention being cost-effective was above 60%, at policy-relevant thresholds. ","['pregnant women with obesity on weight at 12 months postpartum', '598 women with a BMI of ≥30\u2009kg/m 2 (between 12 and 20 weeks gestation) were recruited from 20 secondary care maternity units in England and Wales', 'Healthy eating and lifestyle in pregnancy (HELP', 'pregnant women with obesity', 'Women attending maternity units']","['weight management group, which combined expertise from a commercial weight loss programme with clinical advice from midwives', 'weight management intervention', 'usual care and leaflets on diet and physical activity in pregnancy']","['lower levels of risky drinking', 'healthy eating and lower levels of risky drinking', 'net incremental monetary benefit', 'Mean (SD) BMI', 'fibre score', 'BMI', 'healthy eating score']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C3494402', 'cui_str': 'Secondary Care'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C1456498', 'cui_str': 'Attended'}]","[{'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0026083', 'cui_str': 'Professional midwife'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}]",598.0,0.139653,"The net incremental monetary benefit was not statistically significantly different between arms, although the probability of the intervention being cost-effective was above 60%, at policy-relevant thresholds. ","[{'ForeName': 'Sharon A', 'Initials': 'SA', 'LastName': 'Simpson', 'Affiliation': 'MRC/CSO Social and Public Health Sciences Unit, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK. sharon.simpson@glasgow.ac.uk.'}, {'ForeName': 'Elinor', 'Initials': 'E', 'LastName': 'Coulman', 'Affiliation': 'Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Dunla', 'Initials': 'D', 'LastName': 'Gallagher', 'Affiliation': ""Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Jewell', 'Affiliation': 'Office of the Chief Nursing Officer, Welsh Government, Cardiff, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cohen', 'Affiliation': 'Faculty of Life Sciences and Education, University of South Wales, Newport, UK.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Newcombe', 'Affiliation': 'Institute of Primary Care and Public Health, School of Medicine, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': 'Hull York Medical School, University of Hull, Hull, UK.'}, {'ForeName': 'Jose Antonio', 'Initials': 'JA', 'LastName': 'Robles', 'Affiliation': 'Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Busse', 'Affiliation': 'Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Eleri', 'Initials': 'E', 'LastName': 'Owen-Jones', 'Affiliation': 'Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Duncan', 'Affiliation': 'Abertawe Bro Morgannwg University Health Board, Swansea, UK.'}, {'ForeName': 'Nefyn', 'Initials': 'N', 'LastName': 'Williams', 'Affiliation': 'Department of Health Services Research, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Stanton', 'Affiliation': 'Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Avery', 'Affiliation': 'School of Biosciences, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'McIntosh', 'Affiliation': 'Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Playle', 'Affiliation': 'Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, UK.'}]",International journal of obesity (2005),['10.1038/s41366-021-00835-0'] 3274,34020105,Sex Differences in Maternal Restrictive Feeding Practices in the Intervention Nurses Start Infants Growing on Healthy Trajectories Study.,"BACKGROUND Intervention Nurses Start Infants Growing on Healthy Trajectories tested an early life responsive parenting (RP) intervention designed for obesity prevention. Body mass index z-score at age 3 years was lower for the RP group versus controls with a larger effect for girls than boys. We sought to determine if child sex was associated with differing maternal feeding practices and whether sex moderated intervention effects on feeding. DESIGN/METHODS Mothers (N = 279) completed the Infant Feeding Styles Questionnaire (IFSQ) at 28 weeks, the Structure and Control in Parent Feeding (SCPF) at 1, 2, and 3 years, and the Child Feeding Questionnaire (CFQ) at 3 years. Study aims were tested using 2-way analysis of variance and repeated measures. RESULTS Mothers reported greater restriction (limiting food quantity) for boys at 28 weeks (IFSQ: 3.0 ± 1.1 vs 2.8 ± 1.0, P = .07) and across annual measurements from age 1 to 3 years (SCPF: P = .04). At age 3, the intervention group effect on restriction differed by sex (CFQ: P = .047) such that higher restriction was reported by RP group mothers of boys versus girls (3.4 ± 0.7 vs 3.0 ± 0.9, P = .002) with no control group sex difference (3.4 ± 0.8 vs 3.3 ± 0.9, P = .79). There were no sex differences or sex by intervention group interactions in other reported feeding practices at any assessment (ie, structure-based feeding, pressure). CONCLUSIONS Mothers of boys used more restrictive feeding through age 3. These findings may be partially explained by previously reported better self-soothing and self-regulation abilities of participating girls.",2021,"At age 3, the intervention group effect on restriction differed by sex (CFQ: P = .047) such that higher restriction was reported by RP group mothers of boys versus girls (3.4 ± 0.7 vs. 3.0 ± 0.9, P = .002) with no control group sex difference (3.4 ± 0.8 vs. 3.3 ± 0.9, P = .79).","['Mothers (N=279) completed the', 'Mothers of boys used more restrictive feeding through age 3']","['Infant Feeding Styles Questionnaire (IFSQ) at 28 weeks, the Structure and Control in Parent Feeding (SCPF']","['greater restriction (limiting food quantity', 'BMIz']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}]",,0.0139381,"At age 3, the intervention group effect on restriction differed by sex (CFQ: P = .047) such that higher restriction was reported by RP group mothers of boys versus girls (3.4 ± 0.7 vs. 3.0 ± 0.9, P = .002) with no control group sex difference (3.4 ± 0.8 vs. 3.3 ± 0.9, P = .79).","[{'ForeName': 'Alexis V', 'Initials': 'AV', 'LastName': 'Hyczko', 'Affiliation': 'Penn State College of Medicine (AV Hyczko and IM Paul), Hershey, Pa.'}, {'ForeName': 'Cara F', 'Initials': 'CF', 'LastName': 'Ruggiero', 'Affiliation': 'Center for Childhood Obesity Research, 129 Noll Laboratory, Penn State University (CF Ruggiero, EE Hohman, and JS Savage), University Park, Pa.'}, {'ForeName': 'Emily E', 'Initials': 'EE', 'LastName': 'Hohman', 'Affiliation': 'Center for Childhood Obesity Research, 129 Noll Laboratory, Penn State University (CF Ruggiero, EE Hohman, and JS Savage), University Park, Pa.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Anzman-Frasca', 'Affiliation': 'Department of Pediatrics, University at Buffalo (S Anzman-Frasca), Buffalo, NY.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Savage', 'Affiliation': 'Center for Childhood Obesity Research, 129 Noll Laboratory, Penn State University (CF Ruggiero, EE Hohman, and JS Savage), University Park, Pa.'}, {'ForeName': 'Leann L', 'Initials': 'LL', 'LastName': 'Birch', 'Affiliation': 'Department of Foods and Nutrition, University of Georgia (LL Birch), Athens, Ga.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Paul', 'Affiliation': 'Penn State College of Medicine (AV Hyczko and IM Paul), Hershey, Pa; Departments of Pediatrics & Public Health Sciences, Penn State College of Medicine (IM Paul), Hershey, Pa. Electronic address: ipaul@psu.edu.'}]",Academic pediatrics,['10.1016/j.acap.2021.05.002'] 3275,34020099,Randomized Trial of a Mobile App Introduced During Well-Visits to Enhance Guidance for Reading With Young Children.,"OBJECTIVE To estimate feasibility, usability and efficacy of a mobile parenting app (Rx for Success; RxS) to enhance reading guidance provided to parents of young children during well-visits. METHODS This trial was conducted at a clinic serving primarily families of Hispanic ethnicity and low-socioeconomic status (SES) where Reach Out and Read (ROR) is standard practice. It involved 252 parent-child dyads in 2 age groups (~6-months old, ~18-months old) randomized during well-visits to receive RxS or a children's book modeling alternatives to screen time (Control) by research coordinators. RxS involves videos, activities and ""push"" messages. Follow-up assessments were conducted approximately 6 months later, including impression and use, shared reading behaviors, child language and screen time. RESULTS A total of 217 dyads completed both visits (110 RxS, 107 Control). Time to introduce RxS was under 3 minutes and 32% of parents experienced largely minor performance issues. Parent impression of RxS was favorable for both age groups at baseline and follow-up, though use was infrequent, attributable to a desire for more relevant and updated content. Significant findings favoring RxS included shared reading as a favorite activity, more frequent shared reading reported at 12 months and higher language scores at 24 months. Screen time was equivalent between cohorts, exceeding American Academy of Pediatrics guidelines. CONCLUSIONS A mobile app introduced to parents of young children from low-SES backgrounds was feasible during well-visits, rated as helpful, and effective to enhance shared reading at younger and language at older ages. While a potentially impactful enhancement to ROR, features needing improvement were identified.",2021,"Parent impression of RxS was favorable for both age groups at baseline and follow-up, though use was infrequent, attributable to a desire for more relevant and updated content.","['217 dyads completed both visits (110 RxS, 107 Control', '252 parent-child dyads in two age groups (∼6-months-old, ∼18-months-old) randomized during well-visits to receive', 'parents of young children during well-visits', 'clinic serving primarily families of Hispanic ethnicity and low-socioeconomic status (SES']","['mobile parenting app (Rx for Success; RxS', ""RxS or a children's book modeling alternatives to screen time (Control) by research coordinators""]","['impression and use, shared reading behaviors, child language and screen time']","[{'cui': 'C4517646', 'cui_str': '217'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}]","[{'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0006002', 'cui_str': 'Book'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C4704787', 'cui_str': 'Screen Time'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}]","[{'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0008081', 'cui_str': 'Child Language'}, {'cui': 'C4704787', 'cui_str': 'Screen Time'}]",217.0,0.0769667,"Parent impression of RxS was favorable for both age groups at baseline and follow-up, though use was infrequent, attributable to a desire for more relevant and updated content.","[{'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Hutton', 'Affiliation': ""Division of General and Community Pediatrics, Cincinnati Children's Hospital Medical Center (JS Hutton and T DeWitt), Cincinnati, Ohio; Reading and Literacy Discovery Center, Cincinnati Children's Hospital Medical Center (JS Hutton and T DeWitt), Cincinnati, Ohio. Electronic address: John1.Hutton@cchmc.org.""}, {'ForeName': 'Guixia', 'Initials': 'G', 'LastName': 'Huang', 'Affiliation': ""Division of Biostatistics and Epidemiology, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center (G Huang and RF Ittenbach), Cincinnati, Ohio.""}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Wiley', 'Affiliation': ""Community Health Center at Connecticut Children's Hospital (C Wiley), Hartford, Conn.""}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'DeWitt', 'Affiliation': ""Division of General and Community Pediatrics, Cincinnati Children's Hospital Medical Center (JS Hutton and T DeWitt), Cincinnati, Ohio; Reading and Literacy Discovery Center, Cincinnati Children's Hospital Medical Center (JS Hutton and T DeWitt), Cincinnati, Ohio.""}, {'ForeName': 'Richard F', 'Initials': 'RF', 'LastName': 'Ittenbach', 'Affiliation': ""Division of Biostatistics and Epidemiology, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center (G Huang and RF Ittenbach), Cincinnati, Ohio.""}]",Academic pediatrics,['10.1016/j.acap.2021.05.005'] 3276,34389340,Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma.,"BACKGROUND & AIMS Surgery is the standard of care for T1bN0M0 esophageal squamous cell carcinoma (ESCC), while chemoradiotherapy (CRT) is a treatment option. This trial aimed to investigate the non-inferiority of CRT relative to surgery for T1bN0M0 ESCC. METHODS Clinical T1bN0M0 ESCC patients were eligible for enrollment in this prospective non-randomized controlled study of surgery versus CRT. The primary endpoint was overall survival (OS), which was determined using inverse probability weighting with propensity scoring. Surgery consisted of an esophagectomy with two- or three-field lymph node dissection. CRT consisted of two courses of 5-FU (700 mg/m 2 ) on days 1-4 and cisplatin (70 mg/m 2 ) on day 1 every 4 weeks with concurrent radiation (60 Gy). RESULTS From December 20, 2006, to February 5, 2013, a total of 368 patients were enrolled in the non-randomized portion of the study. The patient characteristics in surgery arm and CRT arm, respectively, were as follows: median age, 62 and 65 years; proportion of males, 82.8% and 88.1%; and proportion of PS 0, 99.5% and 98.1%. Comparisons were made using the non-randomized groups. The 5-year OS was 86.5% in surgery arm and 85.5% in CRT arm (adjusted hazard ratio, 1.05; 95% CI, 0.67-1.64 [<1.78]). The complete response rate in CRT arm was 87.3% (95% CI, 81.1-92.1). The 5-year PFS was 81.7% in surgery arm and 71.6% in CRT arm. Treatment-related deaths occurred in two patients in surgery arm and none in CRT arm. CONCLUSIONS CRT is non-inferior to surgery and should be considered for the treatment of T1bN0M0 ESCC.",2021,"The 5-year OS was 86.5% in surgery arm and 85.5% in CRT arm (adjusted hazard ratio, 1.05; 95% CI, 0.67-1.64 [<1.78]).","['From December 20, 2006, to February 5, 2013', 'patients with stage I esophageal squamous cell carcinoma', 'Clinical T1bN0M0 ESCC patients', '368 patients were enrolled in the non-randomized portion of the study', 'T1bN0M0 esophageal squamous cell carcinoma (ESCC']","['surgery versus CRT', '5-FU', 'cisplatin', 'chemoradiotherapy (CRT', 'esophagectomy with two- or three-field lymph node dissection', 'surgery versus chemoradiotherapy']","['complete response rate', 'deaths', '5-year PFS', 'overall survival (OS', '5-year OS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0854771', 'cui_str': 'Oesophageal squamous cell carcinoma stage I'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0279626', 'cui_str': 'Squamous cell carcinoma of esophagus'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0085198', 'cui_str': 'Esophagectomy'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0024203', 'cui_str': 'Excision of lymph node'}]","[{'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",368.0,0.170341,"The 5-year OS was 86.5% in surgery arm and 85.5% in CRT arm (adjusted hazard ratio, 1.05; 95% CI, 0.67-1.64 [<1.78]).","[{'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Kato', 'Affiliation': 'Department of Esophageal Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo, Japan;. Electronic address: kenkato@ncc.go.jp.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Ito', 'Affiliation': 'Department of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Isao', 'Initials': 'I', 'LastName': 'Nozaki', 'Affiliation': 'Department of Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Daiko', 'Affiliation': 'Esophageal Surgery Division, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kojima', 'Affiliation': 'Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Yano', 'Affiliation': 'Department of Surgery, Osaka International Cancer Center, Osaka, Japan.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Ueno', 'Affiliation': 'Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan.'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Nakagawa', 'Affiliation': 'Department of Surgery, Niigata Cancer Center Hospital, Niigata, Japan.'}, {'ForeName': 'Masakazu', 'Initials': 'M', 'LastName': 'Takagi', 'Affiliation': 'Department of Surgery, Shizuoka General Hospital, Shizuoka, Japan.'}, {'ForeName': 'Shigeru', 'Initials': 'S', 'LastName': 'Tsunoda', 'Affiliation': 'Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Abe', 'Affiliation': 'Department of Gastrointestinal Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Tetsu', 'Initials': 'T', 'LastName': 'Nakamura', 'Affiliation': 'Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Morihito', 'Initials': 'M', 'LastName': 'Okada', 'Affiliation': 'Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Toh', 'Affiliation': 'Department of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Shibuya', 'Affiliation': 'Department of Surgery, Kochi Health Sciences Center, Kochi, Japan.'}, {'ForeName': 'Seiichiro', 'Initials': 'S', 'LastName': 'Yamamoto', 'Affiliation': 'Japan Clinical Oncology Group Data Center/ Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Katayama', 'Affiliation': 'Japan Clinical Oncology Group Data Center/ Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Nakamura', 'Affiliation': 'Japan Clinical Oncology Group Data Center/ Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Kitagawa', 'Affiliation': 'Department of Surgery, Keio University, School of Medicine, Tokyo, Japan.'}]",Gastroenterology,['10.1053/j.gastro.2021.08.007'] 3277,34389292,A randomized controlled trial of low-dose aspirin for the prevention of pre-eclampsia in women at high-risk in China (the APPEC study).,"BACKGROUND Low-dose aspirin has been the most widely studied preventive drug for pre-eclampsia. However, guidelines differ considerably from country to country regarding the prophylactic use of aspirin for pre-eclampsia. There is limited evidence from large trials to determine the effect of 100mg aspirin for pre-eclampsia in high-risk pregnant women screening based on maternal risk factors and to guide the use of low-dose aspirin in pre-eclampsia prevention in China. OBJECTIVE The low-dose Aspirin in the Prevention of Pre-Eclampsia in China (APPEC) study was designed to evaluate the effect of 100mg aspirin in preventing pre-eclampsia among high-risk pregnant women screened with maternal risk factors in China, where pre-eclampsia is highly prevalent, and the status of low-dose aspirin supply is commonly suboptimal. STUDY DESIGN We conducted a multicenter randomized controlled trial at 13 tertiary hospitals from 11 provinces in China between 2016 and 2019. We assumed that the relative reduction in the incidence of pre-eclampsia was at least 20%, namely, from 20% in the control group to 16% in the aspirin group. Therefore, the targeted recruitment number was 1000 participants. Women were randomly assigned to the aspirin or control group in a 1:1 allocation ratio. Statistical analyses were performed according to an intention-to-treat basis. The primary outcome was the incidence of pre-eclampsia, diagnosed with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg developing after 20 weeks of gestation with previously normal blood pressure (SBP < 140 mmHg and DBP < 90 mmHg), and complicated by proteinuria. The secondary outcomes included maternal and neonatal outcomes. Logistic regression analysis was used to determine the significance of difference of pre-eclampsia incidence between the groups for both the primary and secondary outcomes. Interaction analysis was also performed. RESULTS One thousand eligible women were recruited between December 2016 and March 2019, of which final 898 patients were analyzed (464 participants in the aspirin group, 434 participants in the control group) on an intention-to-treat basis. Pre-eclampsia incidence did not show a significant difference between the aspirin group (16.8% (78/464)) and the control group (17.1% (74/434), RR 0.986, 95% CI 0.738-1.317, p=0.924). Likewise, adverse maternal and neonatal outcomes did not differ significantly between the two groups. Meanwhile, the incidence of postpartum hemorrhage between the two groups was similar (6.5% (30/464) in the aspirin group and 5.3% (23/434) in the control group, RR 1.220, 95% CI 0.720-2.066, p=0.459). We did not find any significant differences in pre-eclampsia incidence between the two groups in the subgroup analysis of the different risk factors. CONCLUSIONS A dose of 100mg of aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation, did not reduce the incidence of pre-eclampsia in pregnant women with high-risk factors in China.",2021,"eclampsia incidence did not show a significant difference between the aspirin group (16.8% (78/464)) and the control group (17.1% (74/434), RR 0.986, 95% CI 0.738-1.317, p=0.924).","['women at high-risk in China (the APPEC study', 'high-risk pregnant women screened with maternal risk factors in China, where pre-eclampsia', 'pregnant women with high-risk factors in China', 'Pre-Eclampsia in China (APPEC', 'One thousand eligible women were recruited between December 2016 and March 2019, of which final 898 patients were analyzed (464 participants in the aspirin group, 434 participants in the control group) on an intention-to-treat basis', '13 tertiary hospitals from 11 provinces in China between 2016 and 2019']","['Aspirin', 'aspirin']","['maternal and neonatal outcomes', 'pre-eclampsia incidence', 'incidence of postpartum hemorrhage', 'eclampsia incidence', 'incidence of pre-eclampsia', 'incidence of pre-eclampsia, diagnosed with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg developing after 20 weeks of gestation with previously normal blood pressure', 'Likewise, adverse maternal and neonatal outcomes']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0013537', 'cui_str': 'Eclampsia'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure'}]",1000.0,0.185129,"eclampsia incidence did not show a significant difference between the aspirin group (16.8% (78/464)) and the control group (17.1% (74/434), RR 0.986, 95% CI 0.738-1.317, p=0.924).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Lin', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Huai', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China.'}, {'ForeName': 'Boya', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China.'}, {'ForeName': 'Yuchun', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Juan', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China.'}, {'ForeName': 'Meihua', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Obstetrics and Gynecology, Maternal and Child Health Hospital of Taiyuan, Shanxi, China.'}, {'ForeName': 'Shihong', 'Initials': 'S', 'LastName': 'Cui', 'Affiliation': 'Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Henan, China.'}, {'ForeName': 'Xianlan', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Henan, China.'}, {'ForeName': 'Yuyan', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Shandong, China.'}, {'ForeName': 'Yangyu', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Mi', 'Affiliation': 'Department of Obstetrics and Gynecology, Shaanxi Maternity and Child Health Care Hospital, Shaanxi, China.'}, {'ForeName': 'Hongjuan', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': 'Department of Obstetrics and Gynecology, Nanjing Maternity and Child Health Care Hospital, Jiangsu, China.'}, {'ForeName': 'Dunjin', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangdong, China.'}, {'ForeName': 'Weishe', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Obstetrics and Gynecology, Xiangya Hospital of Central South University, Hunan, China.'}, {'ForeName': 'Hongbo', 'Initials': 'H', 'LastName': 'Qi', 'Affiliation': 'Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Xiaotian', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'Guanlin', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China.'}, {'ForeName': 'Jiahui', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China.'}, {'ForeName': 'Huijing', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China.'}, {'ForeName': 'Mengting', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China.'}, {'ForeName': 'Xiaotong', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': 'Department of Obstetrics and Gynecology, Gansu Province Hospital, Gansu, China.'}, {'ForeName': 'Huixia', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China. Electronic address: yanghuixia@bjmu.edu.cn.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2021.08.004'] 3278,34389257,The feasibility and acceptability of a pilot randomized controlled trial testing pharmacy-based HPV vaccine completion.,"OBJECTIVE Immunizing pharmacists can administer vaccines; however, they are less likely to administer adolescent vaccines such as vaccines that protect against human papillomavirus (HPV). Although past research has recommended incorporating pharmacists to increase adolescent vaccination, few intervention studies have tested healthcare delivery models that incorporate pharmacists to aid in vaccine series completion. This research explored the feasibility and acceptability of an intervention in which pharmacists administered booster doses of the HPV vaccine series. METHODS Between April 2019 and February 2020, the research team recruited participants for a pilot randomized controlled trial hosted in one federally qualified health center (FQHC) clinic. Researchers asked intervention group participants to complete the HPV vaccine series with their community pharmacists and control group participants to complete the series at their FQHC. We conducted a pre- and post-intervention surveys and in-depth interviews with both intervention and control group participants. RESULTS A total of 33 parents of children who received the first dose of the HPV vaccine enrolled in the study of whom 8 intervention and 11 control group participants completed post-intervention data collection. Although there were no statistically significant changes in vaccine completion and in psychometric variables, we did find that pharmacist-delivered HPV vaccination was acceptable, due, primarily, to convenience. Barriers to receiving pharmacist-administered vaccines included pharmacies' lack of stocking the vaccine and insurance-related barriers to care. CONCLUSION Although a promising and acceptable healthcare delivery approach, there are still barriers for caregivers to have their children vaccinated against HPV at their community pharmacies.",2021,"Although there were no statistically significant changes in vaccine completion and in psychometric variables, we did find that pharmacist-delivered HPV vaccination was acceptable, due, primarily, to convenience.","['33 parents of children who received the first dose of the HPV vaccine enrolled in the study of whom 8 intervention and 11 control group participants completed post-intervention data collection', 'Between April 2019 and February 2020, the research team recruited participants for a pilot randomized controlled trial hosted in one federally qualified health center (FQHC) clinic']","['pharmacy-based HPV vaccine completion', 'HPV vaccine series with their community pharmacists and control group participants to complete the series at their FQHC']",['vaccine completion'],"[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1512511', 'cui_str': 'Human papillomavirus vaccine'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1512511', 'cui_str': 'Human papillomavirus vaccine'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205549', 'cui_str': 'Series'}, {'cui': 'C0402003', 'cui_str': 'Community pharmacist'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0475309', 'cui_str': 'Health center'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",,0.139445,"Although there were no statistically significant changes in vaccine completion and in psychometric variables, we did find that pharmacist-delivered HPV vaccination was acceptable, due, primarily, to convenience.","[{'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Koskan', 'Affiliation': 'Arizona State University College of Health Solutions, mail: 425 N 5th Street, Phoenix, AZ, 85004, USA. Electronic address: alexis.koskan@asu.edu.'}, {'ForeName': 'Morgan E', 'Initials': 'ME', 'LastName': 'Zittel', 'Affiliation': 'Arizona State University, USA. Electronic address: mzittel@asu.edu.'}, {'ForeName': 'Chong', 'Initials': 'C', 'LastName': 'Lee', 'Affiliation': 'Arizona State University College of Health Solutions, USA. Electronic address: chong.lee@asu.edu.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Sanchez', 'Affiliation': 'Arizona State University, USA. Electronic address: osanche31@gmail.com.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Alvarez', 'Affiliation': 'Arizona State University, USA. Electronic address: Lindaa3430@yahoo.com.'}, {'ForeName': 'Deborah L', 'Initials': 'DL', 'LastName': 'Helitzer', 'Affiliation': 'Arizona State University College of Health Solutions, USA. Electronic address: deborah.helitzer@asu.edu.'}]",Research in social & administrative pharmacy : RSAP,['10.1016/j.sapharm.2021.08.002'] 3279,34043983,Prediction of vaginal birth after cesarean delivery in term gestations: a calculator without race and ethnicity.,"BACKGROUND Investigators have attempted to derive tools that could provide clinicians with an easily obtainable estimate of the chance of vaginal birth after cesarean delivery for those who undertake trial of labor after cesarean delivery. One tool that has been validated externally was derived from data from the Maternal-Fetal Medicine Units Cesarean Registry. However, concern has been raised that this tool includes the socially constructed variables of race and ethnicity. OBJECTIVE This study aimed to develop an accurate tool to predict vaginal birth after cesarean delivery, using data easily obtainable early in pregnancy, without the inclusion of race and ethnicity. STUDY DESIGN This was a secondary analysis of the Cesarean Registry of the Maternal-Fetal Medicine Units Network. The approach to the current analysis is similar to that of the analysis in which the previous vaginal birth after cesarean delivery prediction tool was derived. Specifically, individuals were included in this analysis if they were delivered on or after 37 0/7 weeks' gestation with a live singleton cephalic fetus at the time of labor and delivery admission, had a trial of labor after cesarean delivery, and had a history of 1 previous low-transverse cesarean delivery. Information was only considered for inclusion in the model if it was ascertainable at an initial prenatal visit. Model selection and internal validation were performed using a cross-validation procedure, with the dataset randomly and equally divided into a training set and a test set. The training set was used to identify factors associated with vaginal birth after cesarean delivery and build the logistic regression predictive model using stepwise backward elimination. A final model was generated that included all variables found to be significant (P<.05). The accuracy of the model to predict vaginal birth after cesarean delivery was assessed using the concordance index. The independent test set was used to estimate classification errors and validate the model that had been developed from the training set, and calibration was assessed. The final model was then applied to the overall analytical population. RESULTS Of the 11,687 individuals who met the inclusion criteria for this secondary analysis, 8636 (74%) experienced vaginal birth after cesarean delivery. The backward elimination variable selection yielded a model from the training set that included maternal age, prepregnancy weight, height, indication for previous cesarean delivery, obstetrical history, and chronic hypertension. Vaginal birth after cesarean delivery was significantly more likely for women who were taller and had a previous vaginal birth, particularly if that vaginal birth had occurred after a previous cesarean delivery. Conversely, vaginal birth after cesarean delivery was significantly less likely for women whose age was older, whose weight was heavier, whose indication for previous cesarean delivery was arrest of dilation or descent, and who had a history of medication-treated chronic hypertension. The model had excellent calibration between predicted and empirical probabilities and, when applied to the overall analytical population, an area under the receiver operating characteristic curve of 0.75 (95% confidence interval, 0.74-0.77), which is similar to the area under the receiver operating characteristic curve of the previous model (0.75) that included race and ethnicity. CONCLUSION We successfully derived an accurate model (available at https://mfmunetwork.bsc.gwu.edu/web/mfmunetwork/vaginal-birth-after-cesarean-calculator), which did not include race or ethnicity, for the estimation of the probability of vaginal birth after cesarean delivery.",2021,"Conversely, VBAC was significantly less likely among those whose age was older, whose weight was heavier, whose indication for prior cesarean was arrest of dilation or descent, and who had a history of medication-treated chronic hypertension.","['11,687 individuals who met inclusion criteria for this secondary analysis']",[],"['VBAC', 'vaginal birth']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",[],"[{'cui': 'C0080301', 'cui_str': 'Vaginal Birth after Cesareans'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]",11687.0,0.0318498,"Conversely, VBAC was significantly less likely among those whose age was older, whose weight was heavier, whose indication for prior cesarean was arrest of dilation or descent, and who had a history of medication-treated chronic hypertension.","[{'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Grobman', 'Affiliation': 'Department of Obstetrics and Gynecology, Northwestern University, Chicago, IL. Electronic address: w-grobman@northwestern.edu.'}, {'ForeName': 'Grecio', 'Initials': 'G', 'LastName': 'Sandoval', 'Affiliation': 'Department of Obstetrics and Gynecology, George Washington University Biostatistics Center, Washington, DC.'}, {'ForeName': 'Madeline Murguia', 'Initials': 'MM', 'LastName': 'Rice', 'Affiliation': 'Department of Obstetrics and Gynecology, George Washington University Biostatistics Center, Washington, DC.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Bailit', 'Affiliation': 'Department of Obstetrics and Gynecology, Case Western Reserve University, Cleveland, OH.'}, {'ForeName': 'Suneet P', 'Initials': 'SP', 'LastName': 'Chauhan', 'Affiliation': ""Department of Obstetrics and Gynecology, University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston, TX.""}, {'ForeName': 'Maged M', 'Initials': 'MM', 'LastName': 'Costantine', 'Affiliation': 'Department of Obstetrics and Gynecology, Ohio State University, Columbus, OH.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Gyamfi-Bannerman', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University, New York, NY.'}, {'ForeName': 'Torri D', 'Initials': 'TD', 'LastName': 'Metz', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Parry', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Dwight J', 'Initials': 'DJ', 'LastName': 'Rouse', 'Affiliation': 'Department of Obstetrics and Gynecology, Brown University, Providence, RI.'}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Saade', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX.'}, {'ForeName': 'Hyagriv N', 'Initials': 'HN', 'LastName': 'Simhan', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Thorp', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'Alan T N', 'Initials': 'ATN', 'LastName': 'Tita', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Longo', 'Affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD.'}, {'ForeName': 'Mark B', 'Initials': 'MB', 'LastName': 'Landon', 'Affiliation': 'Department of Obstetrics and Gynecology, Ohio State University, Columbus, OH.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2021.05.021'] 3280,34048286,Arthroscopic Matrix-Assisted Autologous Chondrocyte Transplantation Versus Microfracture: A 6-Year Follow-up of a Prospective Randomized Trial.,"BACKGROUND Few randomized controlled trials with a midterm follow-up have compared matrix-assisted autologous chondrocyte transplantation (MACT) with microfracture (MFx) for knee cartilage lesions. PURPOSE To compare the structural, clinical, and safety outcomes at midterm follow-up of MACT versus MFx for treating symptomatic knee cartilage lesions. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS A total of 48 patients aged between 18 and 50 years, with 1- to 4-cm 2 International Cartilage Repair Society (ICRS) grade III to IV knee chondral lesions, were randomized in a 1:1 ratio to the MACT and MFx treatment groups. A sequential prospective evaluation was performed using magnetic resonance imaging (MRI) T2 mapping, the MOCART (magnetic resonance observation of cartilage repair tissue) score, second-look arthroscopic surgery, patient-reported outcome measures, the responder rate (based on achieving the minimal clinically important difference for the Knee injury and Osteoarthritis Outcome Score [KOOS] pain and KOOS Sport/Recreation), adverse events, and treatment failure (defined as a reoperation because of symptoms caused by the primary defect and the detachment or absence of >50% of the repaired tissue during revision surgery). RESULTS Overall, 35 patients (18 MACT and 17 MFx) with a mean chondral lesion size of 1.8 ± 0.8 cm 2 (range, 1-4 cm 2 ) were followed up to a mean of 6 years postoperatively (range, 4-9 years). MACT demonstrated significantly better structural outcomes than MFx at 1 to 6 years postoperatively. At final follow-up, the MRI T2 mapping values of the repaired tissue were 37.7 ± 8.5 ms for MACT versus 46.4 ± 8.5 ms for MFx ( P = .003), while the MOCART scores were 59.4 ± 17.3 and 42.4 ± 16.3, respectively ( P = .006). More than 50% defect filling was seen in 95% of patients at 2 years and 82% at 6 years in the MACT group and in 67% at 2 years and 53% at 6 years in the MFx group. The second-look ICRS scores at 1 year were 10.7 ± 1.3 for MACT and 9.0 ± 1.8 for MFx ( P = .001). Both groups showed significant clinical improvements at 6 years postoperatively compared with their preoperative status. Significant differences favoring the MACT group were observed at 2 years on the KOOS Activities of Daily Living ( P = .043), at 4 years on all KOOS subscales (except Symptoms; P < .05) and the Tegner scale ( P = .008), and at 6 years on the Tegner scale ( P = .010). The responder rates at 6 years were 53% and 77% for MFx and MACT, respectively. There were no reported treatment failures after MACT; the failure rate was 8.3% in the MFx group. Neither group had serious adverse events related to treatment. CONCLUSION Patients who underwent MACT had better structural outcomes than those who underwent MFx at 1 to 6 years postoperatively. Both groups of patients showed significant clinical improvements at final follow-up compared with their preoperative status. MACT showed superiority at 4 years for the majority of the KOOS subscales and for the Tegner scale at 4 to 6 years. The MACT group also had a higher responder rate and lower failure rate at final follow-up. REGISTRATION NCT01947374 (ClinicalTrials.gov identifier).",2021,MACT showed superiority at 4 years for the majority of the KOOS subscales and for the Tegner scale at 4 to 6 years.,"['48 patients aged between 18 and 50 years, with 1- to 4-cm 2 International Cartilage Repair Society (ICRS) grade III to IV knee chondral lesions', '35 patients (18 MACT and 17 MFx) with a mean chondral lesion size of 1.8 ± 0.8 cm 2 (range, 1-4 cm 2 ']","['MACT', 'MACT and MFx', 'Arthroscopic Matrix-Assisted Autologous Chondrocyte Transplantation Versus Microfracture', 'magnetic resonance imaging (MRI) T2 mapping, the MOCART', 'matrix-assisted autologous chondrocyte transplantation (MACT) with microfracture (MFx', 'MACT versus MFx']","['Tegner scale', 'Knee injury and Osteoarthritis Outcome Score [KOOS] pain and KOOS Sport/Recreation), adverse events, and treatment failure', 'serious adverse events', 'MRI T2 mapping values of the repaired tissue', 'KOOS Activities of Daily Living', 'structural outcomes', 'second-look ICRS scores', 'failure rate', 'responder rate and lower failure rate', 'responder rates', 'KOOS subscales', 'MOCART scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1112785', 'cui_str': 'Cartilage repair'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0442012', 'cui_str': 'Chondral'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C3652916', 'cui_str': 'chondrocytes, autologous'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449453', 'cui_str': 'Lesion size'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]","[{'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C3652916', 'cui_str': 'chondrocytes, autologous'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C1265651', 'cui_str': 'Microfracture'}, {'cui': 'C3472340', 'cui_str': 'Magnetic resonance imaging T2 mapping'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3476088', 'cui_str': 'Knee Injury and Osteoarthritis Outcome Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0034872', 'cui_str': 'Recreation'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1283195', 'cui_str': 'Mapping - action'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0949626', 'cui_str': 'Incision and reexploration for second look'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",48.0,0.155543,MACT showed superiority at 4 years for the majority of the KOOS subscales and for the Tegner scale at 4 to 6 years.,"[{'ForeName': 'Clemente', 'Initials': 'C', 'LastName': 'Ibarra', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Villalobos', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Madrazo-Ibarra', 'Affiliation': 'School of Medicine, Universidad Panamericana, Mexico City, Mexico.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Velasquillo', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Valentin', 'Initials': 'V', 'LastName': 'Martinez-Lopez', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Aldo', 'Initials': 'A', 'LastName': 'Izaguirre', 'Affiliation': 'Facultad de Medicina de Tampico ""Dr. Alberto Romo Caballero,"" Universidad Autonoma de Tamaulipas, Victoria, Mexico.'}, {'ForeName': 'Anell', 'Initials': 'A', 'LastName': 'Olivos-Meza', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Socorro', 'Initials': 'S', 'LastName': 'Cortes-Gonzalez', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Francisco Javier', 'Initials': 'FJ', 'LastName': 'Perez-Jimenez', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Vargas-Ramirez', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Gilberto', 'Initials': 'G', 'LastName': 'Franco-Sanchez', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Luis Guillermo', 'Initials': 'LG', 'LastName': 'Ibarra-Ibarra', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Sierra-Suarez', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Arturo', 'Initials': 'A', 'LastName': 'Almazan', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Carmina', 'Initials': 'C', 'LastName': 'Ortega-Sanchez', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Cesareo', 'Initials': 'C', 'LastName': 'Trueba', 'Affiliation': 'Hospital Español, Mexico City, Mexico.'}, {'ForeName': 'Fernando Barbosa', 'Initials': 'FB', 'LastName': 'Martin', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}, {'ForeName': 'Reynaldo', 'Initials': 'R', 'LastName': 'Arredondo-Valdes', 'Affiliation': 'Hospital Regional ""1 de Octubre,"" Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Chavez-Arias', 'Affiliation': 'Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.'}]",The American journal of sports medicine,['10.1177/03635465211010487'] 3281,34043898,Video-based cognitive-behavioral intervention for COVID-19 anxiety: a randomized controlled trial.,"OBJECTIVE Cognitive-behavioral interventions can be effective for relieving anxiety associated with coronavirus disease 2019 (COVID-19), but complications such as social distancing, quarantine, a shortage of experts, and delayed care provisions have made it difficult to access face-to-face therapeutic interventions. The purpose of this study was to investigate the efficacy of a video-based cognitive-behavioral intervention for reducing COVID-19 anxiety. METHOD In the present randomized controlled trial, 150 college students with severe COVID-19 anxiety were randomly assigned to either an intervention (n = 75) or a waiting list control (n = 75) group. The intervention group participated in a video-based cognitive-behavioral program consisting of nine 15-20-minute sessions (three days a week for three weeks). Dependent measures included the COVID-19 Anxiety Questionnaire, Short Health Anxiety Inventory, Anxiety Sensitivity Index-3, Somatosensory Amplification Scale, Experience of Parasocial Interaction Scale, and Source Credibility Scale. RESULTS Participants who were randomly assigned to the cognitive-behavioral program reported high parasocial interaction, source credibility, and satisfaction with the intervention. Eighty percent reported that the video-based intervention was a beneficial alternative to traditional face-to-face therapeutic intervention. At post-treatment evaluation, the video-based cognitive-behavioral intervention group showed a significant reduction in COVID-19 anxiety, health anxiety, anxiety sensitivity, and somatosensory amplification when compared to the wait-listed control group. CONCLUSIONS This study suggests that video-based cognitive-behavioral interventions can be an affordable, feasible, and effective method to reduce anxiety during a large-scale pandemic.",2021,"At post-treatment evaluation, the video-based cognitive-behavioral intervention group showed a significant reduction in COVID-19 anxiety, health anxiety, anxiety sensitivity, and somatosensory amplification when compared to the wait-listed control group. ","['150 college students with severe COVID-19 anxiety', 'COVID-19 anxiety']","['video-based cognitive-behavioral program consisting of nine 15-20-minute sessions', 'waiting list control', 'video-based cognitive-behavioral intervention', 'Video-based cognitive-behavioral intervention', 'Cognitive-behavioral interventions', 'video-based cognitive-behavioral interventions']","['parasocial interaction, source credibility, and satisfaction', 'COVID-19 Anxiety Questionnaire, Short Health Anxiety Inventory, Anxiety Sensitivity Index-3, Somatosensory Amplification Scale, Experience of Parasocial Interaction Scale, and Source Credibility Scale', 'COVID-19 anxiety, health anxiety, anxiety sensitivity, and somatosensory amplification']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2959402', 'cui_str': 'Short health anxiety inventory'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",150.0,0.00944598,"At post-treatment evaluation, the video-based cognitive-behavioral intervention group showed a significant reduction in COVID-19 anxiety, health anxiety, anxiety sensitivity, and somatosensory amplification when compared to the wait-listed control group. ","[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Shabahang', 'Affiliation': 'University of Tehran, Tehran, Iran.'}, {'ForeName': 'Mara S', 'Initials': 'MS', 'LastName': 'Aruguete', 'Affiliation': 'Lincoln University, Jefferson City, MO, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'McCutcheon', 'Affiliation': 'North American Journal of Psychology, Winter Garden, FL, USA.'}]",Trends in psychiatry and psychotherapy,['10.47626/2237-6089-2020-0056'] 3282,34043878,"Comment on ""Analgesic effect of music during wound care among patients with diaphyseal tibial fractures: Randomized controlled trial"".",,2021,"The authors performed a randomized controlled trial (RCT) and concluded that ""Listening to music is effective for relieving acute procedural pain during the first post-operative tibial fracture dressing change.",['patients with diaphyseal tibial fractures'],['Listening to music'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040185', 'cui_str': 'Fracture of tibia'}]","[{'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0026867', 'cui_str': 'Music'}]",[],,0.0784401,"The authors performed a randomized controlled trial (RCT) and concluded that ""Listening to music is effective for relieving acute procedural pain during the first post-operative tibial fracture dressing change.","[{'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Jin', 'Affiliation': 'Department of Psychiatry, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Shanghai Changning Mental Health, Shanghai, China.'}, {'ForeName': 'Meiduo', 'Initials': 'M', 'LastName': 'He', 'Affiliation': 'Department of Psychiatry, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Xu', 'Affiliation': 'Shanghai Changning Mental Health, Shanghai, China.'}, {'ForeName': 'Guozhen', 'Initials': 'G', 'LastName': 'Lin', 'Affiliation': 'Department of Psychiatry, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}]","European journal of pain (London, England)",['10.1002/ejp.1812'] 3283,34019439,Beach Chair Versus Lateral Decubitus Position: Differences in Suture Anchor Position and Number During Arthroscopic Anterior Shoulder Stabilization.,"BACKGROUND Arthroscopic shoulder capsulolabral repair using glenoid-based suture anchor fixation provides consistently favorable outcomes for patients with anterior glenohumeral instability. To optimize outcomes, inferior anchor position, especially at the 6-o'clock position, has been emphasized. Proponents of both the beach-chair (BC) and lateral decubitus (LD) positions advocate that this anchor location can be consistently achieved in both positions. HYPOTHESIS Patient positioning would be associated with the surgeon-reported labral tear length, total number of anchors used, number of anchors in the inferior glenoid, and placement of an anchor at the 6-o'clock position. STUDY DESIGN Cross-sectional study; Level of evidence, 3. METHODS This study was a cross-sectional analysis of a prospective multicenter cohort of patients undergoing primary arthroscopic anterior capsulolabral repair. Patient positioning in the BC versus LD position was determined by the operating surgeon and was not randomized. At the time of operative intervention, surgeon-reported labral tear length, total anchor number, anchor number in the inferior glenoid, and anchor placement at the 6-o'clock position were evaluated between BC and LD cohorts. Descriptive statistics and between-group differences (continuous: t test [normal distributions], Wilcoxon rank sum test [nonnormal distributions], and chi-square test [categorical]) were assessed. RESULTS In total, 714 patients underwent arthroscopic anterior capsulolabral repair (BC vs LD, 406 [56.9%] vs 308 [43.1%]). The surgeon-reported labral tear length was greater for patients having surgery in the LD position (BC vs LD [mean ± SD], 123.5°± 49° vs 132.3°± 44°; P = .012). The LD position was associated with more anchors placed in the inferior glenoid and more frequent placement of anchors at the 6-o'clock (BC vs LD, 22.4% vs 51.6%; P < .001). The LD position was more frequently associated with utilization of ≥4 total anchors (BC vs LD, 33.5% vs 46.1%; P < .001). CONCLUSION Surgeons utilizing the LD position for arthroscopic capsulolabral repair in patients with anterior shoulder instability more frequently placed anchors in the inferior glenoid and at the 6-o'clock position. Additionally, surgeon-reported labral tear length was longer when utilizing the LD position. These results suggest that patient positioning may influence the total number of anchors used, the number of anchors used in the inferior glenoid, and the frequency of anchor placement at the 6 o'clock position during arthroscopic capsulolabral repair for anterior shoulder instability. How these findings affect clinical outcomes warrants further study. REGISTRATION NCT02075775 (ClinicalTrials.gov identifier).",2021,"The LD position was associated with more anchors placed in the inferior glenoid and more frequent placement of anchors at the 6-o'clock (BC vs LD, 22.4% vs 51.6%; P < .001).","['patients undergoing primary arthroscopic anterior capsulolabral repair', '714 patients underwent', 'patients with anterior glenohumeral instability']","['Arthroscopic shoulder capsulolabral repair using glenoid-based suture anchor fixation', 'arthroscopic anterior capsulolabral repair']","[""labral tear length, total anchor number, anchor number in the inferior glenoid, and anchor placement at the 6-o'clock position"", 'Wilcoxon rank sum test [nonnormal distributions], and chi-square test [categorical', 'labral tear length']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}]","[{'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1720977', 'cui_str': 'Suture Anchors'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}]","[{'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1293132', 'cui_str': 'Anchoring'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0442321', 'cui_str': ""6 o'clock position""}, {'cui': 'C0242928', 'cui_str': 'Rank-Sum Tests'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0008041', 'cui_str': 'Chi-Square Test'}]",714.0,0.108874,"The LD position was associated with more anchors placed in the inferior glenoid and more frequent placement of anchors at the 6-o'clock (BC vs LD, 22.4% vs 51.6%; P < .001).","[{'ForeName': 'Jacqueline E', 'Initials': 'JE', 'LastName': 'Baron', 'Affiliation': 'University of Iowa, UI Sports Medicine, Iowa City, Iowa, USA.'}, {'ForeName': 'Kyle R', 'Initials': 'KR', 'LastName': 'Duchman', 'Affiliation': 'University of Iowa, UI Sports Medicine, Iowa City, Iowa, USA.'}, {'ForeName': 'Carolyn M', 'Initials': 'CM', 'LastName': 'Hettrich', 'Affiliation': ""Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Natalie A', 'Initials': 'NA', 'LastName': 'Glass', 'Affiliation': 'University of Iowa, UI Sports Medicine, Iowa City, Iowa, USA.'}, {'ForeName': 'Shannon F', 'Initials': 'SF', 'LastName': 'Ortiz', 'Affiliation': 'University of Iowa, UI Sports Medicine, Iowa City, Iowa, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Investigation performed at University of Iowa, Iowa City, Iowa, USA.'}, {'ForeName': 'Keith M', 'Initials': 'KM', 'LastName': 'Baumgarten', 'Affiliation': 'Orthopedic Institute, Sioux Falls, South Dakota, USA.'}, {'ForeName': 'Julie Y', 'Initials': 'JY', 'LastName': 'Bishop', 'Affiliation': 'The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Bollier', 'Affiliation': 'University of Iowa, Iowa City, Iowa, USA.'}, {'ForeName': 'Jonathan T', 'Initials': 'JT', 'LastName': 'Bravman', 'Affiliation': 'University of Colorado, Aurora, Colorado, USA.'}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Brophy', 'Affiliation': 'Washington University, St. Louis, Missouri, USA.'}, {'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Carpenter', 'Affiliation': 'University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Charles L', 'Initials': 'CL', 'LastName': 'Cox', 'Affiliation': 'Vanderbilt University, Nashville, Tennessee, USA.'}, {'ForeName': 'Brian T', 'Initials': 'BT', 'LastName': 'Feeley', 'Affiliation': 'University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Rachel M', 'Initials': 'RM', 'LastName': 'Frank', 'Affiliation': 'University of Colorado, Denver, Denver, Colorado, USA.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Grant', 'Affiliation': 'University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Grant L', 'Initials': 'GL', 'LastName': 'Jones', 'Affiliation': 'The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Kuhn', 'Affiliation': 'Vanderbilt University, Nashville, Tennessee, USA.'}, {'ForeName': 'Drew A', 'Initials': 'DA', 'LastName': 'Lansdown', 'Affiliation': 'University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Benjamin Ma', 'Affiliation': 'University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Marx', 'Affiliation': 'Hospital for Special Surgery, New York, New York, USA.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'McCarty', 'Affiliation': 'University of Colorado, Aurora, Colorado, USA.'}, {'ForeName': 'Bruce S', 'Initials': 'BS', 'LastName': 'Miller', 'Affiliation': 'University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Andres S', 'Initials': 'AS', 'LastName': 'Neviaser', 'Affiliation': 'The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Adam J', 'Initials': 'AJ', 'LastName': 'Seidl', 'Affiliation': 'University of Colorado, Aurora, Colorado, USA.'}, {'ForeName': 'Matthew V', 'Initials': 'MV', 'LastName': 'Smith', 'Affiliation': 'Washington University, St. Louis, Missouri, USA.'}, {'ForeName': 'Rick W', 'Initials': 'RW', 'LastName': 'Wright', 'Affiliation': 'Vanderbilt University, Nashville, Tennessee, USA.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Zhang', 'Affiliation': 'University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Brian R', 'Initials': 'BR', 'LastName': 'Wolf', 'Affiliation': 'University of Iowa, UI Sports Medicine, Iowa City, Iowa, USA.'}]",The American journal of sports medicine,['10.1177/03635465211013709'] 3284,34027969,Corrigendum to: A Randomized Comparative Trial of Targeted Steroid Injection via Epidural Catheter vs Standard Transforaminal Epidural Injection for the Treatment of Unilateral Cervical Radicular Pain: Six-Month Results.,,2021,,['Unilateral Cervical Radicular Pain'],['Steroid Injection via Epidural Catheter vs Standard Transforaminal Epidural Injection'],[],"[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C4552559', 'cui_str': 'Cervical radicular pain'}]","[{'cui': 'C1261311', 'cui_str': 'Injection of steroid'}, {'cui': 'C0179751', 'cui_str': 'Epidural catheter'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0021486', 'cui_str': 'Injections, Peridural'}]",[],,0.0745955,,"[{'ForeName': 'Zachary L', 'Initials': 'ZL', 'LastName': 'McCormick', 'Affiliation': ''}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Conger', 'Affiliation': ''}, {'ForeName': 'Beau P', 'Initials': 'BP', 'LastName': 'Sperry', 'Affiliation': ''}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Teramoto', 'Affiliation': ''}, {'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Petersen', 'Affiliation': ''}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Salazar', 'Affiliation': ''}, {'ForeName': 'Shellie', 'Initials': 'S', 'LastName': 'Cunningham', 'Affiliation': ''}, {'ForeName': 'A Michael', 'Initials': 'AM', 'LastName': 'Henrie', 'Affiliation': ''}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Bisson', 'Affiliation': ''}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kendall', 'Affiliation': ''}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnab111'] 3285,34391006,The long-term effect of repetitive transcranial magnetic stimulation in the treatment of intractable insomnia.,"OBJECTIVE To explore the differences in clinical efficacy of different courses of repetitive transcranial magnetic stimulation (rTMS) in the treatment of intractable insomnia and the duration of clinical efficacy after cessation of treatment. METHOD 70 patients with intractable insomnia were randomly divided into 1 treatment course group and 2 treatment courses group. The rTMS course consisted of daily sessions of 1200 stimuli for the r-DLPFC at a frequency of 1 Hz and 800 stimuli for parietal lobe (CPZ) at a frequency of 1 Hz. The pitchburg sleep index (PSQI), Hamilton depression scale (HAMD), Hamilton anxiety scale (HAMA), and cardiopulmonary coupled sleep (CPC) were assessed for 35 patients in each group at baseline, at 2 weeks, and at 1 and 3 months after treatment. RESULT The scores of PSQI, HAMD and HAMA in the 2 groups were significantly improved after 1 month of follow-up after rTMS treatment (p < 0.01). The long-term effect of different treatment courses is different. After 2 consecutive courses of treatment, there was still a significant difference between the 3-month follow-up and the pre-treatment period (p < 0.05). However, there was no statistical difference between the 3-month follow-up of one course of treatment and the pre-treatment period. The results of CPC test showed that the improvement of total sleep time (TST), and deep sleep time (DST) was basically consistent with the assessment of PSQI, HAMD and HAMA that the clinical efficacy of the 3-month follow-up was better than that of one course of treatment after 2 consecutive courses of treatment. CONCLUSION The treatment of refractory insomnia by rTMS is effective, and the duration of the curative effect is related to the course of treatment. 2 consecutive courses of treatment still have a certain effect after 3 months, which is worthy of clinical promotion.",2021,"The scores of PSQI, HAMD and HAMA in the 2 groups were significantly improved after 1 month of follow-up after rTMS treatment (p < 0.01).","['70 patients with intractable insomnia', 'intractable insomnia']","['rTMS', 'repetitive transcranial magnetic stimulation', 'repetitive transcranial magnetic stimulation (rTMS']","['pitchburg sleep index (PSQI), Hamilton depression scale (HAMD), Hamilton anxiety scale (HAMA), and cardiopulmonary coupled sleep (CPC', 'scores of PSQI, HAMD and HAMA', 'total sleep time (TST), and deep sleep time (DST']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}]",70.0,0.0134811,"The scores of PSQI, HAMD and HAMA in the 2 groups were significantly improved after 1 month of follow-up after rTMS treatment (p < 0.01).","[{'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Department of Neurology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Lv', 'Affiliation': 'Department of Neurology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.'}, {'ForeName': 'Minfen', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Department of Neurology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Neurology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.'}, {'ForeName': 'Yanzhou', 'Initials': 'Y', 'LastName': 'Qu', 'Affiliation': 'Department of Neurology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.'}, {'ForeName': 'Liqun', 'Initials': 'L', 'LastName': 'Ji', 'Affiliation': 'Department of Neurology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.'}, {'ForeName': 'Likang', 'Initials': 'L', 'LastName': 'Lan', 'Affiliation': 'Department of Neurology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China. Electronic address: lsllk67@163.com.'}]",Sleep medicine,['10.1016/j.sleep.2021.07.018'] 3286,34038185,Altered Knee Laxity and Stiffness in Response to a Soccer Match Simulation in Players Returning to Sport Within 12 Months After Anterior Cruciate Ligament Reconstruction.,"BACKGROUND The acute effects of exercise on anterior knee laxity (AKL) and anterior knee stiffness (AKS) have been documented in healthy participants, but only limited evidence has been provided for athletes cleared to return to sports after anterior cruciate ligament (ACL) reconstruction (ACLR). PURPOSE/HYPOTHESIS The purpose was to determine if 45 minutes of a soccer match simulation lead to acute changes in AKL and AKS in soccer players returning to sport within 12 months after ACLR. We hypothesized that the reconstructed knee of the ACLR group would exhibit an altered response to sport-specific exercise. STUDY DESIGN Controlled laboratory study. METHODS A total of 13 soccer players cleared to return to sport after ACLR and 13 healthy control soccer players matched for age, physical activity level, limb dominance, and anthropometric characteristics were recruited. To assess the effects of a standardized soccer match simulation (Soccer Aerobic Field Test [SAFT45]) on AKL and AKS, an arthrometric evaluation was carried out bilaterally before and immediately after SAFT45. To conduct a comprehensive examination of the force-displacement curve, the absolute and side-to-side difference (SSD) values of both AKL and AKS were extracted at 67, 134, and 200 N. RESULTS The ACLR and control groups showed similar AKL and AKS at baseline ( P > .05). In response to SAFT45, laxity increased bilaterally at all force levels by 14% to 17% only in the control group ( P < .025). Similarly, AKS at 134 and 200 N decreased in response to SAFT45 only in the control group (10.5% and 20.5%, respectively; P < .025). After SAFT45, the ACLR group had 1.9 and 2.5 times higher SSDs of AKS at 67 and 134 N compared with the control group, respectively ( P < .025), as well as a 1.9 times higher SSD of AKS at 134 N compared with baseline ( P = .014). CONCLUSION Soccer players at the time of return to sport after ACLR showed an altered mechanical response to a sport-specific match simulation consisting of bilaterally unchanged AKL and AKS. CLINICAL RELEVANCE Soccer players showing altered AKL and AKS in response to exercise after ACLR may not be ready to sustain their preinjury levels of sport, thus potentially increasing the risk of second ACL injuries.",2021,"In response to SAFT45, laxity increased bilaterally at all force levels by 14% to 17% only in the control group ( P < .025).","['After Anterior Cruciate Ligament Reconstruction', '13 soccer players cleared to return to sport after ACLR and 13 healthy control soccer players matched for age, physical activity level, limb dominance, and anthropometric characteristics were recruited', 'soccer players returning to sport within 12 months after ACLR', 'healthy participants', 'Soccer players', 'Players Returning to Sport Within 12 Months']","['standardized soccer match simulation (Soccer Aerobic Field Test [SAFT45', 'exercise']","['SSDs of AKS', 'response to SAFT45']","[{'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C4042817', 'cui_str': 'Return to Play'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C1287621', 'cui_str': 'Eye dominance - finding'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0723179', 'cui_str': 'SSD'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0240129', 'cui_str': 'Knee stiff'}]",,0.0686504,"In response to SAFT45, laxity increased bilaterally at all force levels by 14% to 17% only in the control group ( P < .025).","[{'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Nuccio', 'Affiliation': 'Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Rome, Italy.'}, {'ForeName': 'Luciana', 'Initials': 'L', 'LastName': 'Labanca', 'Affiliation': 'Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Rome, Italy.'}, {'ForeName': 'Jacopo Emanuele', 'Initials': 'JE', 'LastName': 'Rocchi', 'Affiliation': 'Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Rome, Italy.'}, {'ForeName': 'Pier Paolo', 'Initials': 'PP', 'LastName': 'Mariani', 'Affiliation': 'Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Rome, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Sbriccoli', 'Affiliation': 'Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Rome, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Macaluso', 'Affiliation': 'Department of Movement, Human and Health Sciences, University of Rome ""Foro Italico"", Rome, Italy.'}]",The American journal of sports medicine,['10.1177/03635465211013020'] 3287,34032204,Bioequivalence of daclatasvir hydrochloride tablets in healthy Chinese subjects.,"OBJECTIVE The aim of the present study was to evaluate the bioequivalence and safety of two types of daclatasvir hydrochloride tablets administered to healthy Chinese subjects under fasting and postprandial conditions. MATERIALS AND METHODS A total of 72 healthy Chinese subjects were randomly divided into two groups: the fasting group (n = 36) and the postprandial group (n = 36). A dose of 60 mg of both the test and reference preparations of the daclatasvir hydrochloride tablets was taken orally under fasting and postprandial conditions. RESULTS The main plasma pharmacokinetic parameters of the test and reference preparations in the fasting group were as follows: T 1/2 was 9.82 ± 1.00 and 9.67 ± 0.99 hours, respectively; t max was 1.00 hour in both; C max was 1,528.25 ± 428.80 and 1,504.25 ± 414.50 ng/mL -1 , respectively; AUC 0-t was 14,553.04 ± 4,013.26 and 14,391.97 ± 4,078.18 h/ng/mL -1 , respectively; the AUC 0-∞ was 14,660.80 ± 4,018.37 and 14,494.85 ± 4,095.57 ng/mL -1 , respectively. Meanwhile, the main plasma pharmacokinetic parameters of the test and reference preparations in the postprandial group were as follows: T 1/2 was 10.18 ± 1.38 and 10.18 ± 1.69 hours, respectively; t max was 2.00 and 1.75 hours, respectively; C max was 974.92 ± 248.50 and 981.44 ± 237.11 ng/mL -1 , respectively; AUC 0-t was 9,597.00 ± 3,094.28 and 9,982.83 ± 3,512.07 h/ng/mL -1 , respectively; AUC 0-∞ was 9,712.92 ± 3,130.43 and 10,113.97 ± 3,593.47 ng/mL -1 , respectively. CONCLUSION Both types of daclatasvir hydrochloride tablets demonstrated good safety levels in healthy Chinese subjects under both fasting and postprandial conditions. Moreover, the two preparations were bioequivalent.",2021,Both types of daclatasvir hydrochloride tablets demonstrated good safety levels in healthy Chinese subjects under both fasting and postprandial conditions.,"['72 healthy Chinese subjects', 'healthy Chinese subjects under both fasting and postprandial conditions', 'healthy Chinese subjects', 'healthy Chinese subjects under fasting and postprandial conditions']",['daclatasvir hydrochloride tablets'],['good safety levels'],"[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C3252090', 'cui_str': 'daclatasvir'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",72.0,0.0773688,Both types of daclatasvir hydrochloride tablets demonstrated good safety levels in healthy Chinese subjects under both fasting and postprandial conditions.,"[{'ForeName': 'Li-Ping', 'Initials': 'LP', 'LastName': 'Shi', 'Affiliation': ''}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Jun-Gang', 'Initials': 'JG', 'LastName': 'Yin', 'Affiliation': ''}, {'ForeName': 'Jing-Mei', 'Initials': 'JM', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Chong', 'Initials': 'C', 'LastName': 'Zou', 'Affiliation': ''}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Jiang', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203895'] 3288,34042206,The relationship between working alliance with peer mentors and eating psychopathology in a digital 6-week guided self-help intervention for anorexia nervosa.,"OBJECTIVE The quality of working alliance (WA) is associated with treatment outcomes across several types of psychiatric disorders and psychological interventions. This study examined the role of WA with peer mentors (people with lived experience of illness) and student mentors (graduated psychology students) in a 6-week, digital, guided self-help (GSH) intervention for anorexia nervosa. METHOD Ninety-nine patients rated weekly, for 6 weeks: (a) eating psychopathology using the short version of the Eating Disorder Examination Questionnaire (EDE-QS) and (b) WA with a student mentor (n = 14) or a peer mentor (n = 10). WA was assessed by asking patients the extent to which they felt comfortable working with their mentor and the extent to which they agreed with them on the goals for support. WA with mentors and the association with eating psychopathology change were measured on a session-by-session basis. The analysis involved a random intercepts cross-lagged panel model. RESULTS WA with peer mentors was slightly higher than WA with students (ES = 0.3). Peer mentors' WA in the previous session was significantly associated with eating psychopathology ratings in the next session. No significant relationship was found between the previous session's EDE-QS scores and peer mentor alliance in the following session. In the student mentor group, there were no session-by-session associations between WA and eating psychopathology. However, greater WA with the student mentor across sessions was associated with less eating psychopathology. DISCUSSION These findings suggest that clinical outcomes are in part associated with the characteristics of the mentor delivering guidance in an online GSH for eating disorders.",2021,No significant relationship was found between the previous session's EDE-QS scores and peer mentor alliance in the following session.,"['WA with peer mentors (people with lived experience of illness) and student mentors (graduated psychology students', 'anorexia nervosa', 'Ninety-nine patients rated weekly, for 6\u2009weeks: (a) eating psychopathology using the short version of the Eating Disorder Examination Questionnaire (EDE-QS) and (b) WA with a student mentor (n\xa0=\u200914) or a peer mentor (n\xa0=\u200910']","['digital, guided self-help (GSH) intervention', 'digital 6-week guided self-help intervention']","['eating psychopathology', ""previous session's EDE-QS scores and peer mentor alliance"", 'eating psychopathology ratings', 'eating psychopathology change']","[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0025369', 'cui_str': 'Mentors'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0588053', 'cui_str': 'Graduate'}, {'cui': 'C0033909', 'cui_str': 'Psychology'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}, {'cui': 'C3828813', 'cui_str': '99'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C2960501', 'cui_str': 'Eating disorder examination questionnaire'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C2959667', 'cui_str': 'Eating disorder examination questionnaire score'}, {'cui': 'C0025369', 'cui_str': 'Mentors'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.0351183,No significant relationship was found between the previous session's EDE-QS scores and peer mentor alliance in the following session.,"[{'ForeName': 'Gaia', 'Initials': 'G', 'LastName': 'Albano', 'Affiliation': 'Department of Psychology, Educational Science and Human Movement, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Cardi', 'Affiliation': 'Department of Psychological Medicine, Kings College London, London, UK.'}, {'ForeName': 'Dennis M', 'Initials': 'DM', 'LastName': 'Kivlighan', 'Affiliation': 'Department of Counseling, Higher Education and Special Education, University of Maryland, College Park, Maryland, USA.'}, {'ForeName': 'Suman', 'Initials': 'S', 'LastName': 'Ambwani', 'Affiliation': 'Department of Psychology, Dickinson College, Carlisle, Pennsylvania, USA.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Treasure', 'Affiliation': 'Department of Psychological Medicine, Kings College London, London, UK.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Lo Coco', 'Affiliation': 'Department of Psychology, Educational Science and Human Movement, University of Palermo, Palermo, Italy.'}]",The International journal of eating disorders,['10.1002/eat.23559'] 3289,34044580,PRESERVE: Randomized Trial of Intensive Versus Standard Blood Pressure Control in Small Vessel Disease.,[Figure: see text].,2021,"CONCLUSIONS Intensive blood pressure lowering in severe cerebral small vessel disease was not associated with progression of white matter damage on diffusion tensor imaging or magnetic resonance imaging.","['One hundred eleven participants with magnetic resonance imaging confirmed symptomatic lacunar infarct and confluent white matter hyperintensities', 'Patients were mean 68 years and 60% male', 'Small Vessel Disease']","['standard (systolic=130-140 mmHg) (N=56) or intensive (systolic<125 mmHg) (N=55) blood pressure targets', 'multimodal diffusion tensor imaging-magnetic resonance imaging', 'Intensive Versus Standard Blood Pressure Control']","['Mean (SD) blood pressure', 'change in diffusion tensor imaging white matter mean diffusivity peak height', 'magnetic resonance imaging markers and cognition', 'cognition']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0333559', 'cui_str': 'Lacunar infarction'}, {'cui': 'C0205200', 'cui_str': 'Confluent'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0225988', 'cui_str': 'Structure of small blood vessel (organ)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",111.0,0.440229,"CONCLUSIONS Intensive blood pressure lowering in severe cerebral small vessel disease was not associated with progression of white matter damage on diffusion tensor imaging or magnetic resonance imaging.","[{'ForeName': 'Hugh S', 'Initials': 'HS', 'LastName': 'Markus', 'Affiliation': 'Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge (H.S.M., M.E., I.D.C., H.S., D.J.T.).'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Egle', 'Affiliation': 'Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge (H.S.M., M.E., I.D.C., H.S., D.J.T.).'}, {'ForeName': 'Iain D', 'Initials': 'ID', 'LastName': 'Croall', 'Affiliation': 'Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge (H.S.M., M.E., I.D.C., H.S., D.J.T.).'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Sari', 'Affiliation': 'Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge (H.S.M., M.E., I.D.C., H.S., D.J.T.).'}, {'ForeName': 'Usman', 'Initials': 'U', 'LastName': 'Khan', 'Affiliation': 'Atkinson Morley Neuroscience Centre, St. Georges NHS Healthcare Trust (U.K., A.M.).'}, {'ForeName': 'Ahamad', 'Initials': 'A', 'LastName': 'Hassan', 'Affiliation': 'Leeds Teaching Hospitals NHS Trust (A.H.).'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'Harkness', 'Affiliation': 'Sheffield Teaching Hospital NHS Foundation Trust (K.H.).'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'MacKinnon', 'Affiliation': 'Atkinson Morley Neuroscience Centre, St. Georges NHS Healthcare Trust (U.K., A.M.).'}, {'ForeName': 'John T', 'Initials': 'JT', 'LastName': ""O'Brien"", 'Affiliation': 'Department of Psychiatry, University of Cambridge (J.T.O.).'}, {'ForeName': 'Robin G', 'Initials': 'RG', 'LastName': 'Morris', 'Affiliation': 'Kings College Institute of Psychiatry, Psychology and Neurosciences, London, United Kingdom (R.G.M.).'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Barrick', 'Affiliation': ""Neurosciences Research Centre, Molecular and Clinical Science Research Institute, St George's University of London, United Kingdom (T.R.B.).""}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Blamire', 'Affiliation': 'Magnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, United Kingdom (A.M.B.).'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Tozer', 'Affiliation': 'Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge (H.S.M., M.E., I.D.C., H.S., D.J.T.).'}, {'ForeName': 'Gary A', 'Initials': 'GA', 'LastName': 'Ford', 'Affiliation': 'Oxford University Hospitals NHS Foundation Trust, University of Oxford (G.A.F.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Stroke,['10.1161/STROKEAHA.120.032054'] 3290,34043475,"Arterial stiffness responses to prolonged sitting combined with a high-glycemic-index meal: a double-blind, randomized crossover trial.","Regular exposure to uninterrupted prolonged sitting and the consumption of high-glycemic-index (HGI) meals is independently associated with increased cardiovascular disease risk. Sitting for as little as 1 h can impair the health of both peripheral and central arteries. However, it is currently unknown whether combined acute exposure to uninterrupted prolonged sitting and an HGI meal is more detrimental to global (peripheral and central) vascular health. The purpose of this study was to investigate the effect of prolonged sitting (3 h), following the consumption of an HGI or a low-glycemic-index (LGI) meal, on global pulse wave velocity (G-PWV). Eighteen healthy participants [70% female, mean (standard deviation, SD) age = 22.6 (3.1) yr, body mass index (BMI) = 25.5 (6.1) kg/m 2 ] sat for 3 h after consuming an HGI or LGI meal. G-PWV was assessed by incorporating three PWV measures (carotid-femoral, brachial-femoral, and femoral-ankle). The effects of time (PRE vs. POST) and condition (LGI vs. HGI) were analyzed using linear mixed models. Following prolonged sitting, G-PWV increased by 0.29 m/s (i.e., PRE vs. POST). However, the condition ( P = 0.987) and time × condition ( P = 0.954) effects were nonsignificant. The current findings support previous research showing an increase in arterial stiffness with prolonged sitting. However, in young and healthy adults, the arterial stiffness response was not worsened through HGI meal consumption. NEW & NOTEWORTHY We used novel statistical techniques and study design characteristics to examine how the cardiovascular disruptions due to prolonged sitting are changed after the consumption of low- and high-glycemic-index meals. The current study indicates that changes in arterial stiffness due to prolonged sitting are not worsened in young, healthy adults after the consumption of a high-glycemic-index meal.",2021,"RESULTS Following prolonged sitting","['Eighteen healthy participants (70% female, mean standard deviation [SD] age: 22.6 [3.1] years old, BMI: 25.5 [6.1] kg/m 2 ) sat for 3 hours after consuming a HGI or LGI meal', 'young and healthy adults']","['time (PRE vs. POST) and condition (LGI vs. HGI', 'HGI or low glycemic index (LGI) meal', 'Prolonged Sitting', 'prolonged sitting', 'High Glycemic Index Meal', 'Regular exposure to uninterrupted prolonged sitting and the consumption of high glycemic meals (HGI']","['global pulse wave velocity (G-PWV', 'arterial stiffness', 'arterial stiffness response', 'G-PWV']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517683', 'cui_str': '3.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517663', 'cui_str': '25.5'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}]",18.0,0.0380642,"RESULTS Following prolonged sitting","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Kelsch', 'Affiliation': 'Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Jake C', 'Initials': 'JC', 'LastName': 'Diana', 'Affiliation': 'Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Burnet', 'Affiliation': 'Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Erik D', 'Initials': 'ED', 'LastName': 'Hanson', 'Affiliation': 'Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Simon F', 'Initials': 'SF', 'LastName': 'Fryer', 'Affiliation': 'School of Sport and Exercise, University of Gloucestershire, Gloucester, United Kingdom.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': 'Credeur', 'Affiliation': 'School of Kinesiology and Nutrition, The University of Southern Mississippi, Hattiesburg, Mississippi.'}, {'ForeName': 'Keeron J', 'Initials': 'KJ', 'LastName': 'Stone', 'Affiliation': 'School of Sport and Exercise, University of Gloucestershire, Gloucester, United Kingdom.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Stoner', 'Affiliation': 'Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00030.2021'] 3291,34030999,Effect of opaque eye coverage on anxiety in candidates for surgical removal of impacted third molars: a randomized clinical trial.,"OBJECTIVE To assess the effects of opaque eye coverage on anxiety in candidates for surgical removal of impacted third molars. STUDY DESIGN This randomized clinical trial was conducted in candidates for surgical extraction of bilateral, vertical, class IC impacted maxillary third molars or bilateral, mesioangular class IC impacted mandibular third molars. Patients with moderate anxiety (dental anxiety scale range, 9-14) were selected. Surgical extraction of the bilateral third molars was performed in 2 separate visits with and without covering the eyes using surgical drapes. Pulse rate (PR), systolic and diastolic blood pressure (BP), and respiratory rate (RR) were measured immediately after surgery. Moreover, after surgery, the patients were asked to rate their dental anxiety on a visual analog scale (VAS) from 0 to 10. The collected data were used for statistical analysis. RESULTS Sixty patients with a mean age of 21.31 years participated in the study. PR, systolic BP, RR, and VAS were significantly higher with eye coverage (P < .001). Diastolic BP was not significantly different between the 2 surgical sessions (with or without eye coverage) (P = .157). CONCLUSION In patients with moderate dental anxiety, covering the eyes during surgical extraction of third molars may contribute to the increase of dental anxiety.",2021,"Diastolic BP was not significantly different between the 2 surgical sessions (with or without eye coverage) (P = .157). ","['candidates for surgical removal of impacted third molars', 'Patients with moderate anxiety (dental anxiety scale range, 9-14) were selected', 'candidates for surgical extraction of bilateral, vertical, class IC impacted maxillary third molars or bilateral, mesioangular class IC impacted mandibular third molars', 'Sixty patients with a mean age of 21.31 years participated in the study']",['opaque eye coverage'],"['anxiety', 'Diastolic BP', 'rate their dental anxiety on a visual analog scale (VAS', 'PR, systolic BP, RR, and VAS', 'dental anxiety', 'Pulse rate (PR), systolic and diastolic blood pressure (BP), and respiratory rate (RR']","[{'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231402', 'cui_str': 'Moderate anxiety'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1293139', 'cui_str': 'Surgical extraction'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0029053', 'cui_str': 'Decreased translucency'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",60.0,0.044919,"Diastolic BP was not significantly different between the 2 surgical sessions (with or without eye coverage) (P = .157). ","[{'ForeName': 'Amirhossein', 'Initials': 'A', 'LastName': 'Moaddabi', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Dariush', 'Initials': 'D', 'LastName': 'Hasheminia', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Dental Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Sheida', 'Initials': 'S', 'LastName': 'Bagheri', 'Affiliation': ""Dental Students' Research Committee, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.""}, {'ForeName': 'Parisa', 'Initials': 'P', 'LastName': 'Soltani', 'Affiliation': 'Department of Oral and Maxillofacial Radiology, Dental Implants Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: p.soltani@dnt.mui.ac.ir.'}, {'ForeName': 'Romeo', 'Initials': 'R', 'LastName': 'Patini', 'Affiliation': 'Department of Head, Neck and Sense Organs, School of Dentistry, ""Agostino Gemelli"" Teaching Hospital Foundation, Istituto di Ricovero e Cura a Carattere Scientifico, Catholic University of the Sacred Heart, Rome, Italy.'}]","Oral surgery, oral medicine, oral pathology and oral radiology",['10.1016/j.oooo.2021.03.019'] 3292,34028126,Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.,"BACKGROUND Neratinib has efficacy in central nervous system (CNS) metastases from HER2-positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capecitabine (N + C) versus lapatinib plus capecitabine (L + C). MATERIALS AND METHODS NALA was a randomized, active-controlled trial in patients who received two or more previous HER2-directed regimens for HER2-positive MBC. Patients with asymptomatic/stable brain metastases (treated or untreated) were eligible. Patients were assigned to N + C (neratinib 240 mg per day, capecitabine 750 mg/m 2 twice daily) or L + C (lapatinib 1,250 mg per day, capecitabine 1,000 mg/m 2 twice daily) orally. Independently adjudicated progression-free survival (PFS), overall survival (OS), and CNS endpoints were considered. RESULTS Of 621 patients enrolled, 101 (16.3%) had known CNS metastases at baseline (N + C, n = 51; L + C, n = 50); 81 had received prior CNS-directed radiotherapy and/or surgery. In the CNS subgroup, mean PFS through 24 months was 7.8 months with N + C versus 5.5 months with L + C (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.41-1.05), and mean OS through 48 months was 16.4 versus 15.4 months (HR, 0.90; 95% CI, 0.59-1.38). At 12 months, cumulative incidence of interventions for CNS disease was 25.5% for N + C versus 36.0% for L + C, and cumulative incidence of progressive CNS disease was 26.2% versus 41.6%, respectively. In patients with target CNS lesions at baseline (n = 32), confirmed intracranial objective response rates were 26.3% and 15.4%, respectively. No new safety signals were observed. CONCLUSION These analyses suggest improved PFS and CNS outcomes with N + C versus L + C in patients with CNS metastases from HER2-positive MBC. IMPLICATIONS FOR PRACTICE In a subgroup of patients with central nervous system (CNS) metastases from HER2-positive breast cancer after two or more previous HER2-directed regimens, the combination of neratinib plus capecitabine was associated with improved progression-free survival and CNS outcomes compared with lapatinib plus capecitabine. These findings build on previous phase II and III studies describing efficacy of neratinib in the prevention and treatment of CNS metastases, and support a role for neratinib as a systemic treatment option in the management of patients with HER2-positive brain metastases following antibody-based HER2-directed therapies.",2021,"In the CNS subgroup, mean PFS through 24 months was 7.8 months with N + C versus 5.5 months with L + C (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.41-1.05), and mean OS through 48 months was 16.4 versus 15.4 months (HR, 0.90; 95% CI, 0.59-1.38).","['Patients with asymptomatic/stable brain metastases (treated or untreated) were eligible', 'HER2-positive metastatic breast cancer (MBC', 'patients with CNS metastases from HER2-positive MBC', '621 patients enrolled, 101 (16.3%) had known CNS metastases at baseline', 'patients with central nervous system (CNS) metastases from HER2-positive breast cancer', 'patients with HER2-positive brain metastases following antibody-based HER2-directed therapies', 'patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus', 'Subgroup of Patients with CNS Involvement from the NALA Trial', 'patients who received two or more previous HER2-directed regimens for HER2-positive MBC']","['capecitabine', 'CNS-directed radiotherapy and/or surgery', 'lapatinib plus capecitabine', 'Neratinib Plus Capecitabine', 'capecitabine 750 mg/m 2 twice daily) or L\xa0+\xa0C (lapatinib 1,250 mg per day, capecitabine']","['cumulative incidence of interventions for CNS disease', 'progression-free survival and CNS outcomes', 'intracranial objective response rates', 'cumulative incidence of progressive CNS disease', 'PFS and CNS outcomes', 'adjudicated progression-free survival (PFS), overall survival (OS), and CNS endpoints']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C4721209', 'cui_str': 'Metastatic human epidermal growth factor 2 positive carcinoma of breast'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0279130', 'cui_str': 'CNS metastases'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C1960398', 'cui_str': 'HER2-positive carcinoma of breast'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C2713008', 'cui_str': 'neratinib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1506770', 'cui_str': 'lapatinib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2713008', 'cui_str': 'neratinib'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0439505', 'cui_str': '/day'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0007682', 'cui_str': 'Disorder of the central nervous system'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",621.0,0.423703,"In the CNS subgroup, mean PFS through 24 months was 7.8 months with N + C versus 5.5 months with L + C (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.41-1.05), and mean OS through 48 months was 16.4 versus 15.4 months (HR, 0.90; 95% CI, 0.59-1.38).","[{'ForeName': 'Sara A', 'Initials': 'SA', 'LastName': 'Hurvitz', 'Affiliation': 'University of California Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, California, USA.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Saura', 'Affiliation': ""Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.""}, {'ForeName': 'Mafalda', 'Initials': 'M', 'LastName': 'Oliveira', 'Affiliation': ""Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.""}, {'ForeName': 'Maureen E', 'Initials': 'ME', 'LastName': 'Trudeau', 'Affiliation': 'Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Beverly', 'Initials': 'B', 'LastName': 'Moy', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Suzette', 'Initials': 'S', 'LastName': 'Delaloge', 'Affiliation': 'Gustave Roussy, Villejuif, France.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Gradishar', 'Affiliation': 'Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.'}, {'ForeName': 'Sung-Bae', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Haley', 'Affiliation': 'University of Texas Southwestern, Dallas, Texas, USA.'}, {'ForeName': 'Larisa', 'Initials': 'L', 'LastName': 'Ryvo', 'Affiliation': 'Sourasky Medical Center (Ichilov), Tel Aviv, Israel.'}, {'ForeName': 'Ming-Shen', 'Initials': 'MS', 'LastName': 'Dai', 'Affiliation': 'Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Milovanov', 'Affiliation': 'Tambov Regional Oncology Center, Tambov, Russia.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Alarcón', 'Affiliation': 'Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.'}, {'ForeName': 'Sujith', 'Initials': 'S', 'LastName': 'Kalmadi', 'Affiliation': 'Ironwood Cancer and Research Centers, Chandler, Arizona, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Cronemberger', 'Affiliation': 'Centro Regional Integrado de Oncologia, Fortaleza, Ceará, Brazil.'}, {'ForeName': 'Cristiano', 'Initials': 'C', 'LastName': 'Souza', 'Affiliation': 'Hospital de Câncer de Barretos, Barretos, São Paulo, Brazil.'}, {'ForeName': 'Luciana', 'Initials': 'L', 'LastName': 'Landeiro', 'Affiliation': 'Nucleo de Oncologia Da Bahia, Ondina, Bahia, Brazil.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Bose', 'Affiliation': 'Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Bebchuk', 'Affiliation': 'Puma Biotechnology, Inc., Los Angeles, California, USA.'}, {'ForeName': 'Fairooz', 'Initials': 'F', 'LastName': 'Kabbinavar', 'Affiliation': 'Puma Biotechnology, Inc., Los Angeles, California, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Bryce', 'Affiliation': 'Puma Biotechnology, Inc., Los Angeles, California, USA.'}, {'ForeName': 'Kiana', 'Initials': 'K', 'LastName': 'Keyvanjah', 'Affiliation': 'Puma Biotechnology, Inc., Los Angeles, California, USA.'}, {'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Brufsky', 'Affiliation': 'Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, USA.'}]",The oncologist,['10.1002/onco.13830'] 3293,34024791,Navigated perilesional transcranial magnetic stimulation can improve post-stroke visual field defect: A double-blind sham-controlled study.,"BACKGROUND Visual field defects (VFD) usually do not show improvement beyond 12 weeks from their onset. It has been shown that repetitive presentation of a stimulus to areas of residual vision in cases of visual field defect can improve vision. The counterpart of these areas in the brain are the partially damaged brain regions at the perilesional areas where plasticity can be enhanced. OBJECTIVE We aimed to study the effect of navigated repetitive transcranial magnetic stimulation (rTMS) applied to perilesional areas on the recovery of patients with cortical VFD. METHODS Thirty-two patients with cortical VFD secondary to stroke of more than 3 months duration received 16 sessions of either active or sham high frequency navigated perilesional rTMS. Automated perimetry and visual functioning questionnaire (VFQ-25) were performed at baseline and after completion of the sessions. RESULTS The active group showed significant improvement after intervention, compared to the sham group, in both mean deviation (MD), visual field index (VFI) and in the VFQ-25 scores. CONCLUSIONS Navigated rTMS is a new treatment option for post-stroke VFD as it can selectively stimulate areas of residual vision around the infarcted tissue, improving the threshold of visual stimulus detection which could be used alone or in combination with existing therapies.",2021,"The active group showed significant improvement after intervention, compared to the sham group, in both mean deviation (MD), visual field index (VFI) and in the VFQ-25 scores. ","['Thirty-two patients with cortical VFD secondary to stroke of more than 3 months duration received 16 sessions of either', 'patients with cortical VFD']","['Navigated perilesional transcranial magnetic stimulation', 'navigated repetitive transcranial magnetic stimulation (rTMS', 'Navigated rTMS', 'active or sham high frequency navigated perilesional rTMS']","['Automated perimetry and visual functioning questionnaire (VFQ-25', 'mean deviation (MD), visual field index (VFI) and in the VFQ-25 scores']","[{'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C3887875', 'cui_str': 'Visual field defect'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]","[{'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}]","[{'cui': 'C4760939', 'cui_str': 'Automated perimetry'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1828170', 'cui_str': 'Mean deviation'}, {'cui': 'C1720706', 'cui_str': 'Visual field index'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",32.0,0.0687937,"The active group showed significant improvement after intervention, compared to the sham group, in both mean deviation (MD), visual field index (VFI) and in the VFQ-25 scores. ","[{'ForeName': 'Nevine', 'Initials': 'N', 'LastName': 'El Nahas', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Elbokl', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Eman Hamid', 'Initials': 'EH', 'LastName': 'Abd Eldayem', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Tamer M', 'Initials': 'TM', 'LastName': 'Roushdy', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Randa M', 'Initials': 'RM', 'LastName': 'Amin', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Shahinaz M', 'Initials': 'SM', 'LastName': 'Helmy', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Ahmed Zaki', 'Initials': 'AZ', 'LastName': 'Akl', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Aya Ahmed', 'Initials': 'AA', 'LastName': 'Ashour', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Shady', 'Initials': 'S', 'LastName': 'Samy', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Alaa', 'Initials': 'A', 'LastName': 'Amgad', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Tamer H', 'Initials': 'TH', 'LastName': 'Emara', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Nowara', 'Affiliation': 'Al-Mashreq Eye Center, Cairo, Egypt.'}, {'ForeName': 'Fatma Fathalla', 'Initials': 'FF', 'LastName': 'Kenawy', 'Affiliation': 'Ain Shams Neuromodulation Research Lab, Neurology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}]",Restorative neurology and neuroscience,['10.3233/RNN-211181'] 3294,34389234,"A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol.","AIM SGLT2 inhibitors have been shown to reduce cardiovascular and renal complications in type 2 diabetes (T2D) patients at high cardiovascular risk. Metformin is currently widely used as initial monotherapy in T2D but lacks convincing data to show that it reduces risk of complications. We aim to compare the SGLT2 inhibitor dapagliflozin and metformin as first-line T2D medication with regard to development of complications in a registry-based randomised controlled trial. METHODS The SGLT2 inhibitor or metformin as standard treatment of early stage type 2 diabetes (SMARTEST) trial will enrol 4300 subjects at 30-40 study sites in Sweden who will be randomised 1:1 to either metformin or dapagliflozin. Participants must have T2D duration <4 years, no prior cardiovascular disease, and be either drug-naïve or on monotherapy for T2D. RESULTS The primary endpoint is a composite of all-cause death, major adverse cardiovascular events and occurrence or progression of microvascular complications (retinopathy, nephropathy, diabetic foot lesions). Secondary endpoints include individual components of the primary endpoint, start of insulin therapy, risk factor biomarkers, patient-reported outcome measures, and cost-effectiveness analysis. Outcomes will primarily be assessed using nationwide healthcare registries. CONCLUSIONS The SMARTEST trial will investigate whether dapagliflozin is superior to metformin in preventing complications in early stage T2D. (Clinicaltrials.gov identifier NCT03982381, EudraCT 2019-001046-17).",2021,"The primary endpoint is a composite of all-cause death, major adverse cardiovascular events and occurrence or progression of microvascular complications (retinopathy, nephropathy, diabetic foot lesions).","['Participants must have T2D duration <4\xa0years, no prior cardiovascular disease, and be either drug-naïve or on monotherapy for T2D', 'early stage type 2 diabetes (SMARTEST', 'type 2 diabetes (T2D) patients at high cardiovascular risk', 'early stage type 2 diabetes (SMARTEST) trial will enrol 4300 subjects at 30-40 study sites in Sweden who will be randomised 1:1 to either']","['metformin', 'Metformin', 'metformin or dapagliflozin', 'SGLT2 inhibitor dapagliflozin and metformin', 'dapagliflozin', 'SGLT2 inhibitor and metformin', 'SGLT2 inhibitor or metformin']","['cardiovascular and renal complications', 'individual components of the primary endpoint, start of insulin therapy, risk factor biomarkers, patient-reported outcome measures, and cost-effectiveness analysis', 'composite of all-cause death, major adverse cardiovascular events and occurrence or progression of microvascular complications (retinopathy, nephropathy, diabetic foot lesions']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C3273807', 'cui_str': 'SGLT2 Inhibitors'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C1511536', 'cui_str': 'Cost-Effectiveness Analysis'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0035309', 'cui_str': 'Retinal disorder'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0206172', 'cui_str': 'Diabetic foot'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",4300.0,0.298913,"The primary endpoint is a composite of all-cause death, major adverse cardiovascular events and occurrence or progression of microvascular complications (retinopathy, nephropathy, diabetic foot lesions).","[{'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Sundström', 'Affiliation': 'Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala, Sweden; The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Kristófi', 'Affiliation': 'Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Ollie', 'Initials': 'O', 'LastName': 'Östlund', 'Affiliation': 'Uppsala Clinical Research Center, Uppsala, Sweden.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Bennet', 'Affiliation': 'Department of Clinical Sciences, Lund University, Malmö, Sweden.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Eliasson', 'Affiliation': 'Institute of Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Jansson', 'Affiliation': 'Institution of Medical Sciences, University Health Care Research Center, Örebro University, Örebro, Sweden; Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Janeth', 'Initials': 'J', 'LastName': 'Leksell', 'Affiliation': 'Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Almby', 'Affiliation': 'Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Lundqvist', 'Affiliation': 'Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Jan W', 'Initials': 'JW', 'LastName': 'Eriksson', 'Affiliation': 'Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden. Electronic address: jan.eriksson@medsci.uu.se.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of diabetes and its complications,['10.1016/j.jdiacomp.2021.107996'] 3295,34389170,Lifting the lid on perioperative goal-directed therapy.,The complex cellular interactions that underlie pathologies related to reduced oxygen delivery after surgery are poorly defined and difficult to measure. Heywood and colleagues explored the patterns of protein expression in skin biopsies taken from a subgroup of patients enrolled in a randomised trial designed to evaluate perioperative goal-directed therapy. One of their key findings was that a failure of participants to maintain preoperative systemic oxygen delivery was associated with an upregulation of intracellular proteins involved in counteracting oxidative stress. Their study highlights the importance of oxidative stress in the perioperative setting and suggests that maintenance of baseline oxygen delivery might be an important regulator of redox balance.,2021,One of their key findings was that a failure of participants to maintain preoperative systemic oxygen delivery was associated with an upregulation of intracellular proteins involved in counteracting oxidative stress.,[],[],[],[],[],[],,0.18048,One of their key findings was that a failure of participants to maintain preoperative systemic oxygen delivery was associated with an upregulation of intracellular proteins involved in counteracting oxidative stress.,"[{'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Martin', 'Affiliation': 'Peninsula Medical School, University of Plymouth, Plymouth, UK. Electronic address: daniel.martin@plymouth.ac.uk.'}]",British journal of anaesthesia,['10.1016/j.bja.2021.07.009'] 3296,34389168,Goal-directed fluid therapy in emergency abdominal surgery: a randomised multicentre trial.,"BACKGROUND More than 50% of patients have a major complication after emergency gastrointestinal surgery. Intravenous (i.v.) fluid therapy is a life-saving part of treatment, but evidence to guide what i.v. fluid strategy results in the best outcome is lacking. We hypothesised that goal-directed fluid therapy during surgery (GDT group) reduces the risk of major complications or death in patients undergoing major emergency gastrointestinal surgery compared with standard i.v. fluid therapy (STD group). METHODS In a randomised, assessor-blinded, two-arm, multicentre trial, we included 312 adult patients with gastrointestinal obstruction or perforation. Patients in the GDT group received i.v. fluid to near-maximal stroke volume. Patients in the STD group received i.v. fluid following best clinical practice. Postoperative target was 0-2 L fluid balance. The primary outcome was a composite of major complications or death within 90 days. Secondary outcomes were time in intensive care, time on ventilator, time in dialysis, hospital stay, and minor complications. RESULTS In a modified intention-to-treat analysis, we found no difference in the primary outcome between groups: 45 (30%) (GDT group) vs 39 (25%) (STD group) (odds ratio=1.24; 95% confidence interval, 0.75-2.05; P=0.40). Hospital stay was longer in the GDT group: median (inter-quartile range), 7 (4-12) vs 6 days (4-8.5) (P=0.04); no other differences were found. CONCLUSION Compared with pressure-guided i.v. fluid therapy (STD group), flow-guided fluid therapy to near-maximal stroke volume (GDT group) did not improve the outcome after surgery for bowel obstruction or gastrointestinal perforation but may have prolonged hospital stay. CLINICAL TRIAL REGISTRATION EudraCT number 2015-000563-14; the Danish Scientific Ethics Committee and the Danish Data Protection Agency (REG-18-2015).",2021,"Hospital stay was longer in the GDT group: median (inter-quartile range), 7 (4-12) vs 6 days (4-8.5) (P=0.04); no other differences were found. ","['312 adult patients with gastrointestinal obstruction or perforation', 'patients undergoing major emergency gastrointestinal surgery', 'emergency abdominal surgery']","['Goal-directed fluid therapy', 'goal-directed fluid therapy during surgery (GDT group', 'fluid therapy (STD group), flow-guided fluid therapy to near-maximal stroke volume (GDT group', 'GDT', 'Intravenous (i.v.) fluid therapy']","['risk of major complications or death', 'Hospital stay', 'composite of major complications or death within 90 days', 'time in intensive care, time on ventilator, time in dialysis, hospital stay, and minor complications']","[{'cui': 'C4517706', 'cui_str': '312'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0236124', 'cui_str': 'Gastrointestinal obstruction'}, {'cui': 'C0549099', 'cui_str': 'Perforation'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0524722', 'cui_str': 'Gastrointestinal surgery'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0016286', 'cui_str': 'Therapy, Fluid'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2603364', 'cui_str': 'On ventilator'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0026193', 'cui_str': 'Minor'}]",312.0,0.659272,"Hospital stay was longer in the GDT group: median (inter-quartile range), 7 (4-12) vs 6 days (4-8.5) (P=0.04); no other differences were found. ","[{'ForeName': 'Anne A', 'Initials': 'AA', 'LastName': 'Aaen', 'Affiliation': 'Department of Anaesthesia, Holbæk Hospital, Part of Copenhagen University Hospitals, Holbaek, Denmark. Electronic address: aaaa@regionsjaelland.dk.'}, {'ForeName': 'Anders W', 'Initials': 'AW', 'LastName': 'Voldby', 'Affiliation': 'Department of Surgery, Holbæk Hospital, Part of Copenhagen University Hospitals, Holbaek, Denmark.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Storm', 'Affiliation': 'Department of Surgery, Herlev University Hospital, Herlev, Denmark.'}, {'ForeName': 'Jeppe', 'Initials': 'J', 'LastName': 'Kildsig', 'Affiliation': 'Department of Surgery, Herlev University Hospital, Herlev, Denmark.'}, {'ForeName': 'Egon G', 'Initials': 'EG', 'LastName': 'Hansen', 'Affiliation': 'Department of Anaesthesia, Herlev University Hospital, Herlev, Denmark.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Zimmermann-Nielsen', 'Affiliation': 'Department of Surgery, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Kenneth M', 'Initials': 'KM', 'LastName': 'Jensen', 'Affiliation': 'Department of Anaesthesia, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Pernille', 'Initials': 'P', 'LastName': 'Tibæk', 'Affiliation': 'Department of Surgery, Slagelse Hospital, Part of Copenhagen University Hospitals, Slagelse, Zealand, Denmark.'}, {'ForeName': 'Anette', 'Initials': 'A', 'LastName': 'Mortensen', 'Affiliation': 'Department of Anaesthesia, Slagelse Hospital, Part of Copenhagen University Hospitals, Slagelse, Zealand, Denmark.'}, {'ForeName': 'Ann M', 'Initials': 'AM', 'LastName': 'Møller', 'Affiliation': 'Department of Anaesthesia, Herlev University Hospital, Herlev, Denmark.'}, {'ForeName': 'Birgitte', 'Initials': 'B', 'LastName': 'Brandstrup', 'Affiliation': 'Department of Surgery, Holbæk Hospital, Part of Copenhagen University Hospitals, Holbaek, Denmark.'}]",British journal of anaesthesia,['10.1016/j.bja.2021.06.031'] 3297,34039025,Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: COAPT Trial.,"BACKGROUND In the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation), among 614 patients with heart failure with 3+ or 4+ secondary mitral regurgitation (MR), transcatheter mitral valve repair (TMVr) with the MitraClip reduced MR, heart failure hospitalizations, and mortality and improved quality of life compared with guideline-directed medical therapy (GDMT) alone. We aimed to examine the prognostic relationship between MR reduction and outcomes after TMVr and GDMT alone. METHODS Outcomes in COAPT between 30 days and 2 years were examined on the basis of the severity of residual MR at 30 days. RESULTS TMVr-treated patients had less severe residual MR at 30 days than GDMT-treated patients (0/1+, 2+, and 3+/4+: 72.9%, 19.9%, and 7.2% versus 8.2%, 26.1%, and 65.8%, respectively [ P <0.0001]). The rate of composite death or heart failure hospitalizations between 30 days and 2 years was lower in patients with 30-day residual MR of 0/1+ and 2+ compared with patients with 30-day residual MR of 3+/4+ (37.7% versus 49.5% versus 72.2%, respectively [ P <0.0001]). This relationship was consistent in the TMVr and GDMT arms ( P interaction =0.92). The improvement in Kansas City Cardiomyopathy Questionnaire score from baseline to 30 days was maintained between 30 days and 2 years in patients with 30-day MR ≤2+ but deteriorated in those with 30-day MR 3+/4+ (-0.3±1.7 versus -9.4±4.6 [ P =0.0008]) consistently in both groups ( P interaction =0.95). CONCLUSIONS In the COAPT trial, reduced MR at 30 days was associated with greater freedom from death or heart failure hospitalizations and improved quality of life through 2-year follow-up whether the MR reduction was achieved by TMVr or GDMT. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01626079.",2021,"The rate of composite death or HFH between 30 days and 2 years was lower in patients with 30-day residual MR of 0/1+ and 2+ compared with 3+/4+ (37.7% versus 49.5% versus 72.2%, respectively, P<0.0001).","['Heart Failure', '614 heart failure (HF) patients with 3+ or 4+ secondary mitral regurgitation (MR), transcatheter mitral valve repair (TMVr) with the MitraClip reduced']","['guideline-directed medical therapy (GDMT) alone', 'TMVr and GDMT alone']","['MR, HF hospitalizations (HFH), and mortality and improved quality of life', 'freedom from death or HFH and improved quality of life', 'Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes', 'severe residual MR', 'KCCQ score', 'rate of composite death or HFH']","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3179739', 'cui_str': 'lanthanum citrate'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0026266', 'cui_str': 'Mitral valve regurgitation'}, {'cui': 'C2921039', 'cui_str': 'Transcatheter mitral valve repair'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]","[{'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0026266', 'cui_str': 'Mitral valve regurgitation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205199', 'cui_str': 'Composite'}]",,0.262604,"The rate of composite death or HFH between 30 days and 2 years was lower in patients with 30-day residual MR of 0/1+ and 2+ compared with 3+/4+ (37.7% versus 49.5% versus 72.2%, respectively, P<0.0001).","[{'ForeName': 'Saibal', 'Initials': 'S', 'LastName': 'Kar', 'Affiliation': 'Los Robles Regional Medical Center, Thousand Oaks, CA (S.K.).'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Mack', 'Affiliation': 'Baylor Scott & White Heart Hospital Plano, TX (M.J.M.).'}, {'ForeName': 'JoAnn', 'Initials': 'J', 'LastName': 'Lindenfeld', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplantation Section, Vanderbilt Heart and Vascular Institute, Nashville, TN (J.L.).'}, {'ForeName': 'William T', 'Initials': 'WT', 'LastName': 'Abraham', 'Affiliation': 'Division of Cardiovascular Medicine, The Ohio State University, Columbus (W.T.A.).'}, {'ForeName': 'Federico M', 'Initials': 'FM', 'LastName': 'Asch', 'Affiliation': 'MedStar Health Research Institute, Washington, DC (F.M.A., N.J.W.).'}, {'ForeName': 'Neil J', 'Initials': 'NJ', 'LastName': 'Weissman', 'Affiliation': 'MedStar Health Research Institute, Washington, DC (F.M.A., N.J.W.).'}, {'ForeName': 'Maurice', 'Initials': 'M', 'LastName': 'Enriquez-Sarano', 'Affiliation': 'Mayo Clinic, Rochester, MN (M.E.-S.).'}, {'ForeName': 'D Scott', 'Initials': 'DS', 'LastName': 'Lim', 'Affiliation': 'Division of Cardiology, University of Virginia, Charlottesville (D.S.L.).'}, {'ForeName': 'Jacob M', 'Initials': 'JM', 'LastName': 'Mishell', 'Affiliation': 'Kaiser Permanente-San Francisco Hospital, CA (J.M.M.).'}, {'ForeName': 'Brian K', 'Initials': 'BK', 'LastName': 'Whisenant', 'Affiliation': 'Intermountain Heart Center, Salt Lake City, UT (B.K.W.).'}, {'ForeName': 'Jason H', 'Initials': 'JH', 'LastName': 'Rogers', 'Affiliation': 'University of California Davis Medical Center, Sacramento (J.H.R.).'}, {'ForeName': 'Suzanne V', 'Initials': 'SV', 'LastName': 'Arnold', 'Affiliation': ""Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A.).""}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Cohen', 'Affiliation': 'University of Missouri-Kansas City School of Medicine (S.V.A.).'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Grayburn', 'Affiliation': 'Baylor University Medical Center, Baylor Heart and Vascular Institute, Dallas, TX (P.A.G.).'}, {'ForeName': 'Gregg W', 'Initials': 'GW', 'LastName': 'Stone', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (D.J.C., G.W.S.).'}]",Circulation,['10.1161/CIRCULATIONAHA.120.053061'] 3298,34023513,Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19.,"BACKGROUND AND AIM Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of tofacitinib in the management of this complication. METHODS The retrospective study included COVID-19 patients with C-reactive protein (CRP) levels of 60-150 mg/L. RESULTS Thirty-two patients who received tofacitinib (TOF group) and 30 patients who did not receive any anti-cytokine drugs (control [CON] group) were enrolled. Mortality and the incidence of admission to the intensive care unit were lower in the TOF group than in the CON group (16.6% vs. 40.0%, p = 0.009; and 15.6% vs. 50.0%, p = 0.004). There was a significant decrease in the volume of the affected part of the lungs (p = 0.022) and a significant increase in oxygen saturation (p = 0.012) in the TOF group than in the CON group 7-10 days after the beginning tofacitinib administration. CRP level was lower in the TOF group than in the CON group (7 [3-22] vs. 20 [5-52] mg/L; p = 0.048) 7-10 days after the start of the administration of tofacitinib. During this period, the number of patients requiring mechanical ventilation or those in the prone position increased in the CON group compared to those in the TOF group (26.7% vs. 0.0%, p = 0.002; 33.3% vs. 6.7%, p = 0.020). There was no significant difference in the development of secondary infections, liver or kidney injury, and cytopenia between the two groups. CONCLUSION Tofacitinib was effective and safe for managing the cytokine release syndrome in COVID-19. Randomized controlled double-blind trials with tofacitinib with and without the simultaneous use of glucocorticoids are required to confirm our findings.",2021,There was a significant decrease in the volume of the affected part of the lungs (p = 0.022) and a significant increase in oxygen saturation (p = 0.012) in the TOF group than in the CON group 7-10 days after the beginning tofacitinib administration.,"['COVID-19 patients with C-reactive protein (CRP) levels of 60-150\xa0mg/L.\nRESULTS\n\n\nThirty-two patients who received', 'group) and 30 patients who did not receive any anti-cytokine drugs (control [CON] group) were enrolled']","['tofacitinib (TOF', 'glucocorticoids', 'tofacitinib', 'Tofacitinib', 'CON']","['Mortality and the incidence of admission to the intensive care unit', 'efficacy and safety', 'volume of the affected part of the lungs', 'number of patients requiring mechanical ventilation', 'oxygen saturation', 'CRP level', 'development of secondary infections, liver or kidney injury, and cytopenia']","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2930696', 'cui_str': 'tofacitinib'}, {'cui': 'C0039685', 'cui_str': 'Tetralogy of Fallot'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0442886', 'cui_str': 'Secondary infection'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0160420', 'cui_str': 'Injury of kidney'}, {'cui': 'C0010828', 'cui_str': 'Cytopenia'}]",32.0,0.0847868,There was a significant decrease in the volume of the affected part of the lungs (p = 0.022) and a significant increase in oxygen saturation (p = 0.012) in the TOF group than in the CON group 7-10 days after the beginning tofacitinib administration.,"[{'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Maslennikov', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation. Electronic address: mmmm00@yandex.ru.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Ivashkin', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Ekaterina', 'Initials': 'E', 'LastName': 'Vasilieva', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Maxim', 'Initials': 'M', 'LastName': 'Chipurik', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Polina', 'Initials': 'P', 'LastName': 'Semikova', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Semenets', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Tatyana', 'Initials': 'T', 'LastName': 'Russkova', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Levshina', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Grigoriadis', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Shamil', 'Initials': 'S', 'LastName': 'Magomedov', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Efremova', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}, {'ForeName': 'Natiya', 'Initials': 'N', 'LastName': 'Dzhakhaya', 'Affiliation': 'Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow, 119435, Russian Federation.'}]",Pulmonary pharmacology & therapeutics,['10.1016/j.pupt.2021.102039'] 3299,34390930,Training detection of camouflaged targets in natural scenes: Backgrounds and targets both matter.,"As target-background similarity increases, search performance declines, but this pattern can be attenuated with training. In the present study we (1) characterized training and transfer effects in visual search for camouflaged targets in naturalistic scenes, (2) evaluated whether transfer effects are preserved 3 months after training, (3) tested the suitability of the perceptual learning hypothesis (i.e., using learned scene statistics to aid camouflaged target detection) for explaining camouflage search improvements over training, and (4) provide guidance for camouflage detection training in practice. Participants were assigned to one of three training groups: adaptive camouflage (difficulty varied by performance), massed camouflage (difficulty increased over time), or an active control (no camouflage), and trained over 14 sessions. Additional sessions measured transfer (immediately post training) and retention of training benefits (10 days and 3 months post training). Both the adaptive and massed training groups showed improved camouflaged target detection up to 3 months following training, relative to the control. These benefits were observed only with backgrounds and targets that were similar to those experienced during training and are broadly consistent with the perceptual learning hypothesis. In practice, training interventions should utilize stimuli similar to the operational environment in which detection is expected to occur.",2021,"Both the adaptive and massed training groups showed improved camouflaged target detection up to 3 months following training, relative to the control.",['natural scenes'],"['adaptive camouflage (difficulty varied by performance), massed camouflage (difficulty increased over time), or an active control (no camouflage), and trained over 14 sessions']","['camouflaged target detection', 'retention of training benefits']","[{'cui': 'C0205296', 'cui_str': 'Natural'}]","[{'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",1.0,0.00938032,"Both the adaptive and massed training groups showed improved camouflaged target detection up to 3 months following training, relative to the control.","[{'ForeName': 'Mark B', 'Initials': 'MB', 'LastName': 'Neider', 'Affiliation': 'University of Central Florida, United States of America. Electronic address: mark.neider@ucf.edu.'}, {'ForeName': 'Dawn M', 'Initials': 'DM', 'LastName': 'Sarno', 'Affiliation': 'Clemson University, United States of America.'}, {'ForeName': 'Joanna E', 'Initials': 'JE', 'LastName': 'Lewis', 'Affiliation': 'University of Northern Colorado, United States of America.'}, {'ForeName': 'Ada D', 'Initials': 'AD', 'LastName': 'Mishler', 'Affiliation': 'Naval Air Warfare Center Training Systems Division, United States of America.'}, {'ForeName': 'Alyssa S', 'Initials': 'AS', 'LastName': 'Hess', 'Affiliation': 'Expedia Group, United States of America.'}, {'ForeName': 'Corey J', 'Initials': 'CJ', 'LastName': 'Bohil', 'Affiliation': 'University of Central Florida, United States of America.'}, {'ForeName': 'Arthur F', 'Initials': 'AF', 'LastName': 'Kramer', 'Affiliation': 'Northeastern University, United States of America; University of Illinois, United States of America.'}]",Acta psychologica,['10.1016/j.actpsy.2021.103394'] 3300,34041932,"COVID-19 vaccine trials: The potential for ""hybrid"" analyses.","BACKGROUND Although several COVID-19 vaccines have been found to be effective in rigorous evaluation and have emerging availability in parts of the world, their supply will be inadequate to meet international needs for a considerable period of time. There also will be continued interest in vaccines that are more effective or have improved scalability to facilitate mass vaccination campaigns. Ongoing clinical testing of new vaccines also will be needed as variant strains continue to emerge that may elude some aspects of immunity induced by current vaccines. Randomized clinical trials meaningfully enhance the efficiency and reliability of such clinical testing. In clinical settings with limited or no access to known effective vaccines, placebo-controlled randomized trials of new vaccines remain a preferred approach to maximize the reliability, efficiency and interpretability of results. When emerging availability of licensed vaccines makes it no longer possible to use a placebo control, randomized active comparator non-inferiority trials may enable reliable insights. METHODS In this article, ""hybrid"" methods are proposed to address settings where, during the conduct of a placebo-controlled trial, a judgment is made to replace the placebo arm by a licensed COVID-19 vaccine due to emerging availability of effective vaccines in regions participating in that trial. These hybrid methods are based on proposed statistics that aggregate evidence to formally test as well as to estimate the efficacy of the experimental vaccine, by combining placebo-controlled data during the first period of trial conduct with active-controlled data during the second period. RESULTS Application of the proposed methods is illustrated in two important scenarios where the active control vaccine would become available in regions engaging in the experimental vaccine's placebo-controlled trial: in the first, the active comparator's vaccine efficacy would have been established to be 50%-70% for the 4- to 6-month duration of follow-up of its placebo-controlled trial; in the second, the active comparator's vaccine efficacy would have been established to be 90%-95% during that duration. These two scenarios approximate what has been seen with adenovirus vaccines or mRNA vaccines, respectively, assuming the early estimates of vaccine efficacy for those vaccines would hold over longer-term follow-up. CONCLUSION The proposed hybrid methods could readily play an important role in the near future in the design, conduct and analysis of randomized clinical trials performed to address the need for multiple additional vaccines reliably established to be safe and have worthwhile efficacy in reducing the risk of symptomatic disease from SARS-CoV-2 infections.",2021,"RESULTS Application of the proposed methods is illustrated in two important scenarios where the active control vaccine would become available in regions engaging in the experimental vaccine's placebo-controlled trial: in the first, the active comparator's vaccine efficacy would have been established to be 50%-70% for the 4- to 6-month duration of follow-up of its placebo-controlled trial; in the second, the active comparator's vaccine efficacy would have been established to be 90%-95% during that duration.",[],['placebo'],[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.612625,"RESULTS Application of the proposed methods is illustrated in two important scenarios where the active control vaccine would become available in regions engaging in the experimental vaccine's placebo-controlled trial: in the first, the active comparator's vaccine efficacy would have been established to be 50%-70% for the 4- to 6-month duration of follow-up of its placebo-controlled trial; in the second, the active comparator's vaccine efficacy would have been established to be 90%-95% during that duration.","[{'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Fleming', 'Affiliation': 'Department of Biostatistics, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Nason', 'Affiliation': 'Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases (NIAID/NIH), Bethesda, MD, USA.'}, {'ForeName': 'Philip R', 'Initials': 'PR', 'LastName': 'Krause', 'Affiliation': 'Office of Vaccines Research and Review, FDA/CBER, Silver Spring, MD, USA.'}, {'ForeName': 'Ira M', 'Initials': 'IM', 'LastName': 'Longini', 'Affiliation': 'Department of Biostatistics, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Ana-Maria', 'Initials': 'AM', 'LastName': 'Henao-Restrepo', 'Affiliation': 'World Health Organization, Geneva, Switzerland.'}]","Clinical trials (London, England)",['10.1177/17407745211018613'] 3301,34390874,Enhancing dopamine tone modulates global and local cortical perfusion as a function of COMT val158met genotype.,"The cognitive effects of pharmacologically enhancing cortical dopamine (DA) tone are variable across healthy human adults. It has been postulated that individual differences in drug responses are linked to baseline cortical DA activity according to an inverted-U-shaped function. To better understand the effect of divergent starting points along this curve on DA drug responses, researchers have leveraged a common polymorphism (rs4680) in the gene encoding the enzyme catechol-O-methyltransferase (COMT) that gives rise to greater (Met allele) or lesser (Val allele) extracellular levels of cortical DA. Here we examined the extent to which changes in resting cortical perfusion following the administration of two mechanistically-distinct dopaminergic drugs vary by COMT genotype, and thereby track predictions of the inverted-U model. Using arterial spin labeling (ASL) and a double-blind, within-subject design, perfusion was measured in 75 healthy, genotyped participants once each after administration of tolcapone (a COMT inhibitor), bromocriptine (a DA D2/3 agonist), and placebo. COMT genotype and drug interacted such that COMT Val homozygotes exhibited increased prefusion in response to both drugs, whereas Met homozygotes did not. Additionally, tolcapone-related perfusion changes in the right inferior frontal gyrus correlated with altered performance on a task of executive function. No comparable effects were found for a genetic polymorphism (rs1800497) affecting striatal DA system function. Together, these results indicate that both the directionality and magnitude of drug-induced perfusion change provide meaningful information about individual differences in response to enhanced cortical DA tone.",2021,"COMT genotype and drug interacted such that COMT Val homozygotes exhibited increased prefusion in response to both drugs, whereas Met homozygotes did not.","['75 healthy, genotyped participants once each after administration of', 'healthy human adults']","['placebo', 'pharmacologically enhancing cortical dopamine (DA', 'tolcapone (a COMT inhibitor), bromocriptine', 'arterial spin labeling (ASL']",['genetic polymorphism (rs1800497) affecting striatal DA system function'],"[{'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0246330', 'cui_str': 'tolcapone'}, {'cui': 'C0595267', 'cui_str': 'Catechol-O-methyltransferase inhibitor'}, {'cui': 'C0006230', 'cui_str': 'Bromocriptine'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}]","[{'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",75.0,0.088536,"COMT genotype and drug interacted such that COMT Val homozygotes exhibited increased prefusion in response to both drugs, whereas Met homozygotes did not.","[{'ForeName': 'Daniella J', 'Initials': 'DJ', 'LastName': 'Furman', 'Affiliation': 'Department of Neurology, University of California, San Francisco, CA; Helen Wills Neuroscience Institute, University of California, Berkeley, CA. Electronic address: Daniella.Furman@ucsf.edu.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Pappas', 'Affiliation': 'Helen Wills Neuroscience Institute, University of California, Berkeley, CA; Division of Neurology, VA Northern California Health Care System. Electronic address: ioannis.p.pappas@gmail.com.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'White', 'Affiliation': 'Department of Neurology, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'Kayser', 'Affiliation': 'Department of Neurology, University of California, San Francisco, CA; Helen Wills Neuroscience Institute, University of California, Berkeley, CA; Division of Neurology, VA Northern California Health Care System.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': ""D'Esposito"", 'Affiliation': 'Helen Wills Neuroscience Institute, University of California, Berkeley, CA; Division of Neurology, VA Northern California Health Care System.'}]",NeuroImage,['10.1016/j.neuroimage.2021.118472'] 3302,34044454,Evaluation of Hypoglycemia in Neonates of Women at Risk for Late Preterm Delivery: An Antenatal Late Preterm Steroids Trial Cohort Study.,"OBJECTIVE In the antenatal late preterm steroids (ALPS) trial betamethasone significantly decreased short-term neonatal respiratory morbidity but increased the risk of neonatal hypoglycemia, diagnosed only categorically (<40 mg/dL). We sought to better characterize the nature, duration, and treatment for hypoglycemia. STUDY DESIGN Secondary analysis of infants from ALPS, a multicenter trial randomizing women at risk for late preterm delivery to betamethasone or placebo. This study was a reabstraction of all available charts from the parent trial, all of which were requested. Unreviewed charts included those lost to follow-up or from sites not participating in the reabstraction. Duration of hypoglycemia (<40 mg/dL), lowest value and treatment, if any, were assessed by group. Measures of association and regression models were used where appropriate. RESULTS Of 2,831 randomized, 2,609 (92.2%) were included. There were 387 (29.3%) and 223 (17.3%) with hypoglycemia in the betamethasone and placebo groups, respectively (relative risk [RR]: 1.69, 95% confidence interval [CI]: 1.46-1.96). Hypoglycemia generally occurred in the first 24 hours in both groups: 374/385 (97.1%) in the betamethasone group and 214/222 (96.4%) in the placebo group ( p  = 0.63). Of 387 neonates with hypoglycemia in the betamethasone group, 132 (34.1%) received treatment, while 73/223 (32.7%) received treatment in placebo group ( p  = 0.73). The lowest recorded blood sugar was similar between groups. Most hypoglycemia resolved by 24 hours in both (93.0 vs. 89.3% in the betamethasone and placebo groups, respectively, p  = 0.18). Among infants with hypoglycemia in the first 24 hours, the time to resolution was shorter in the betamethasone group (2.80 [interquartile range: 2.03-7.03) vs. 3.74 (interquartile range: 2.15-15.08) hours; p  = 0.002]. Persistence for >72 hours was rare and similar in both groups, nine (2.4%, betamethasone) and four (1.9%, placebo, p  = 0.18). CONCLUSION In this cohort, hypoglycemia was transient and most received no treatment, with a quicker resolution in the betamethasone group. Prolonged hypoglycemia was uncommon irrespective of steroid exposure. KEY POINTS · Hypoglycemia was transient and approximately two-thirds received no treatment.. · Neonates in the ALPS trial who received betamethasone had a shorter time to resolution than those with hypoglycemia in the placebo group.. · Prolonged hypoglycemia occurred in approximately 2 out of 100 late preterm newborns, irrespective of antenatal steroid exposure..",2021,"Among infants with hypoglycemia in the first 24 hours, the time to resolution was shorter in the betamethasone group (2.80 [interquartile range: 2.03-7.03) vs. 3.74 (interquartile range: 2.15-15.08) hours; p  = 0.002].","['387 neonates with hypoglycemia in the', 'Of 2,831 randomized, 2,609 (92.2%) were included', 'Neonates of Women at Risk for Late Preterm Delivery', 'Secondary analysis of infants from ALPS, a multicenter trial randomizing women at risk for late preterm delivery to', '100 late preterm newborns']","['betamethasone', 'placebo', 'betamethasone or placebo']","['shorter time to resolution', 'Duration of hypoglycemia', 'short-term neonatal respiratory morbidity', 'blood sugar', 'time to resolution', 'Prolonged hypoglycemia', 'Hypoglycemia', 'Most hypoglycemia', 'hypoglycemia']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0206012', 'cui_str': 'Multicentre Trials'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}]","[{'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1301752', 'cui_str': 'Respiratory morbidity'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]",100.0,0.354137,"Among infants with hypoglycemia in the first 24 hours, the time to resolution was shorter in the betamethasone group (2.80 [interquartile range: 2.03-7.03) vs. 3.74 (interquartile range: 2.15-15.08) hours; p  = 0.002].","[{'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Gyamfi-Bannerman', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University, New York City, New York.'}, {'ForeName': 'Kathleen A', 'Initials': 'KA', 'LastName': 'Jablonski', 'Affiliation': 'Department of Epidemiology, George Washington University Biostatistics Center, Washington, District of Columbia.'}, {'ForeName': 'Sean C', 'Initials': 'SC', 'LastName': 'Blackwell', 'Affiliation': ""Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Texas Health Science Center, Children's Memorial Hermann Hospital, Houston, Texas.""}, {'ForeName': 'Alan T N', 'Initials': 'ATN', 'LastName': 'Tita', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Uma M', 'Initials': 'UM', 'LastName': 'Reddy', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.'}, {'ForeName': 'Lucky', 'Initials': 'L', 'LastName': 'Jain', 'Affiliation': 'Department of Pediatrics, Emory University, Atlanta, Georgia.'}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Saade', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas.'}, {'ForeName': 'Dwight J', 'Initials': 'DJ', 'LastName': 'Rouse', 'Affiliation': 'Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Erin A S', 'Initials': 'EAS', 'LastName': 'Clark', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Thorp', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Edward K', 'Initials': 'EK', 'LastName': 'Chien', 'Affiliation': 'Department of Obstetrics and Gynecology Specialists, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.'}, {'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Peaceman', 'Affiliation': 'Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Ronald S', 'Initials': 'RS', 'LastName': 'Gibbs', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado.'}, {'ForeName': 'Geeta K', 'Initials': 'GK', 'LastName': 'Swamy', 'Affiliation': 'Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Norton', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, Stanford University, Stanford, California.'}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Casey', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Steve N', 'Initials': 'SN', 'LastName': 'Caritis', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Jorge E', 'Initials': 'JE', 'LastName': 'Tolosa', 'Affiliation': 'Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon.'}, {'ForeName': 'Yoram', 'Initials': 'Y', 'LastName': 'Sorokin', 'Affiliation': 'Department of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan.'}, {'ForeName': 'J Peter', 'Initials': 'JP', 'LastName': 'VanDorsten', 'Affiliation': 'Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of perinatology,['10.1055/s-0041-1729561'] 3303,34044407,Efficacy and Safety of Divaza for the Correction of Oxidative Disturbances in Patients with Cerebral Atherosclerosis: A Randomized Controlled Trial.,"OBJECTIVE The objective of this study was to determine if Divaza, a drug with nootropic and antioxidant effects, was safe and effective for the correction of oxidative disturbances and to stabilize cognitive impairment in patients with cerebral atherosclerosis. STUDY DESIGN The study design consisted of a 12-week multicenter, randomized, double-blind, placebo-controlled, prospective trial in parallel groups. SETTING The setting in which the study was conducted comprised 10 clinical centers across the Russian Federation. INTERVENTIONS Patients were randomized into 2 groups and instructed to take either 2 tablets of the study drug or a placebo 3 times per day in conjunction with basic therapy. OUTCOMES The primary outcome was a change in the average endogenous antioxidant potential after the completion of the study. The blood indicators of the oxidative stress (OS) were analyzed at the baseline and then after 12 weeks of therapy using iron-induced chemiluminescence analysis. The Montreal cognitive assessment test was used as a secondary outcome measure to evaluate cognitive impairment at the end of the study. RESULTS 124 outpatients with a mean age of 60.7 ± 7.6 years were enrolled and randomly assigned to receive Divaza (n = 65) or a placebo (n = 59). An improvement of cognitive function was observed in all patients of the Divaza group at the end of the treatment; this was significantly better than the placebo group (100 [100] vs. 89.5 [89.1]%, respectively, p = 0.0272 [p = 0.0128]). The administration of Divaza restored the activity of the endogenous antioxidant system. The change in the average level of lipoprotein resistance to oxidation after 12 weeks of therapy, compared to the baseline, was significantly higher in the Divaza group (14.8 ± 14.7 [14.8 ± 14.7] seconds latent period vs. 6.4 ± 16.9 [6.9 ± 16.7] seconds in the placebo group (p = 0.007 [p = 0.0107]). CONCLUSIONS Divaza is a safe and effective therapeutic option for attenuating OS and recovery of cognitive impairment in patients with cerebral atherosclerosis.",2021,"An improvement of cognitive function was observed in all patients of the Divaza group at the end of the treatment; this was significantly better than the placebo group (100 [100] vs. 89.5 [89.1]%, respectively, p = 0.0272 [p = 0.0128]).","['Patients with Cerebral Atherosclerosis', 'patients with cerebral atherosclerosis', '124 outpatients with a mean age of 60.7 ± 7.6 years', 'The setting in which the study was conducted comprised 10 clinical centers across the Russian Federation']","['Divaza', 'placebo', 'placebo 3 times per day in conjunction with basic therapy']","['Efficacy and Safety', 'average endogenous antioxidant potential', 'cognitive function', 'blood indicators of the oxidative stress (OS', 'average level of lipoprotein resistance to oxidation', 'Oxidative Disturbances']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007775', 'cui_str': 'Cerebral atherosclerosis'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0035970', 'cui_str': 'Russian federation - Europe'}]","[{'cui': 'C4309853', 'cui_str': 'divaza'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0556984', 'cui_str': 'Three times daily'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}]",124.0,0.469407,"An improvement of cognitive function was observed in all patients of the Divaza group at the end of the treatment; this was significantly better than the placebo group (100 [100] vs. 89.5 [89.1]%, respectively, p = 0.0272 [p = 0.0128]).","[{'ForeName': 'Nataliia U', 'Initials': 'NU', 'LastName': 'Lashch', 'Affiliation': 'Pirogov Russian National Research Medical University, Moscow, Russian Federation.'}, {'ForeName': 'Pavel R', 'Initials': 'PR', 'LastName': 'Kamchatnov', 'Affiliation': 'Pirogov Russian National Research Medical University, Moscow, Russian Federation.'}, {'ForeName': 'Tatiana N', 'Initials': 'TN', 'LastName': 'Fedorova', 'Affiliation': 'Research Center of Neurology, Moscow, Russian Federation.'}, {'ForeName': 'Olga A', 'Initials': 'OA', 'LastName': 'Muzychuk', 'Affiliation': 'Research Center of Neurology, Moscow, Russian Federation.'}, {'ForeName': 'Kristina K', 'Initials': 'KK', 'LastName': 'Khacheva', 'Affiliation': 'Research Center of Neurology, Moscow, Russian Federation.'}, {'ForeName': 'Nataliya V', 'Initials': 'NV', 'LastName': 'Pizova', 'Affiliation': 'Yaroslavl State Medical University, Yaroslavl, Russian Federation.'}, {'ForeName': 'Alexander U', 'Initials': 'AU', 'LastName': 'Malygin', 'Affiliation': 'Clinical Hospital, Yaroslavl, Russian Federation.'}, {'ForeName': 'Olga A', 'Initials': 'OA', 'LastName': 'Shavlovskaya', 'Affiliation': 'Autonomous Nonprofit Organization of Higher Education «International University of Restorative Medicine», Moscow, Russian Federation.'}, {'ForeName': 'Victoria V', 'Initials': 'VV', 'LastName': 'Fateeva', 'Affiliation': 'Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation.'}, {'ForeName': 'Kseniya V', 'Initials': 'KV', 'LastName': 'Nikulina', 'Affiliation': 'Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation.'}, {'ForeName': 'Аlbert V', 'Initials': 'АV', 'LastName': 'Abrosimov', 'Affiliation': 'Regional Clinic Hospital, Yaroslavl, Russian Federation.'}, {'ForeName': 'Yulia A', 'Initials': 'YA', 'LastName': 'Gerasimova', 'Affiliation': 'Regional Clinic Hospital, Vladimir, Russian Federation.'}, {'ForeName': 'Konstantin S', 'Initials': 'KS', 'LastName': 'Glushkov', 'Affiliation': 'Family Clinic, Korolev, Russian Federation.'}, {'ForeName': 'Anna V', 'Initials': 'AV', 'LastName': 'Lebedeva', 'Affiliation': 'Scientific Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, State-Financed Institution of Moscow City, Moscow, Russian Federation.'}]","Cerebrovascular diseases (Basel, Switzerland)",['10.1159/000515233'] 3304,34031968,Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.,"AIMS Loop diuretics (LD) relieve symptoms and signs of congestion due to heart failure (HF), but many patients prescribed LD do not have such a diagnosis. We studied the relationship between HF diagnosis, use of LD, and outcomes in patients with type 2 diabetes mellitus (T2DM) enrolled in the EMPA-REG OUTCOME trial. METHODS AND RESULTS The relationship between HF diagnosis, use of LD, and outcomes was evaluated in four patient subgroups with T2DM: (i) investigator-reported HF on LD, (ii) investigator-reported HF not on LD, (iii) no HF on LD, and (iv) no HF and not on LD, and we assessed their risk of cardiovascular events. Of 7020 participants, 706 (10%) had a diagnosis of HF at baseline, of whom 334 were prescribed LD. However, 755 (11%) patients who did not have a diagnosis of HF were prescribed LD. Compared to those with neither HF nor prescribed LD (reference group; placebo), those with both HF and receiving LD had the highest rates for all-cause [hazard ratio (HR) (95% confidence interval) 3.19 (2.03-5.01)] and cardiovascular mortality [3.83 [(2.28-6.44)], and HF hospitalizations [9.51 (5.61-16.14)]. Patients without HF but prescribed LD had higher rates for all three outcomes [1.62 (1.10-2.39); 1.97 (1.26-3.08); 3.20 (1.90-5.39)], which were similar to patients with HF who were not receiving LD [1.42 (0.78-2.57); 1.56 (0.78-3.11); 3.00 (1.40-6.40)]. Empagliflozin had similar benefits regardless of subgroup (P for interaction >0.1 for all outcomes). CONCLUSION Patients with T2DM prescribed LD are at greater risk of cardiovascular events even if they are not reported to have HF; this might reflect under-diagnosis. Empagliflozin was similarly effective in all subgroups investigated.",2021,"Empagliflozin had similar benefits regardless of subgroup (p for interaction >0.1 for all outcomes). ","['Of 7,020 participants, at baseline, 706 (10%) had a diagnosis of HF, of whom 334 were prescribed LD', 'patients with type', 'four patient subgroups with type-2 diabetes mellitus (T2DM) in EMPA-REG OUTCOME']","['placebo', 'Empagliflozin', 'Loop diuretics (LD']","['LD, iii] no HF on LD, and iv) no HF and not on LD', 'CV mortality', 'risk of CV events']","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C4517729', 'cui_str': '334'}, {'cui': 'C0354100', 'cui_str': 'Loop diuretic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0208940', 'cui_str': 'REG1A protein, human'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0354100', 'cui_str': 'Loop diuretic'}]","[{'cui': 'C0354100', 'cui_str': 'Loop diuretic'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",7020.0,0.302651,"Empagliflozin had similar benefits regardless of subgroup (p for interaction >0.1 for all outcomes). ","[{'ForeName': 'Pierpaolo', 'Initials': 'P', 'LastName': 'Pellicori', 'Affiliation': 'Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fitchett', 'Affiliation': ""St. Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Canada.""}, {'ForeName': 'Mikhail N', 'Initials': 'MN', 'LastName': 'Kosiborod', 'Affiliation': ""Saint Luke's Mid America Heart Institute.""}, {'ForeName': 'Anne P', 'Initials': 'AP', 'LastName': 'Ofstad', 'Affiliation': 'Boehringer Ingelheim Norway KS, Asker, Norway.'}, {'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Seman', 'Affiliation': 'Boehringer Ingelheim Pharmaceuticals Incorporated, Ridgefield, CT, USA.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Zwiener', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Wanner', 'Affiliation': 'Department of Medicine, Wuerzburg University Clinic, Wuerzburg, Germany.'}, {'ForeName': 'Jyothis', 'Initials': 'J', 'LastName': 'George', 'Affiliation': 'Boehringer Ingelheim International GmbH & Co KG, Ingelheim, Germany.'}, {'ForeName': 'Silvio E', 'Initials': 'SE', 'LastName': 'Inzucchi', 'Affiliation': 'Section of Endocrinology, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Testani', 'Affiliation': 'Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'John G F', 'Initials': 'JGF', 'LastName': 'Cleland', 'Affiliation': 'Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.'}]",European journal of heart failure,['10.1002/ejhf.2220'] 3305,34031921,Reduced fracture load of dental implants after implantoplasty with different instrumentation sequences. An in vitro study.,"OBJECTIVES To assess the mechanical stability of implants after implantoplasty and thermocyclic loading, the residual thickness of the instrumented areas and neighbouring tooth injury due to implantoplasty. MATERIALS AND METHODS Using a phantom head simulator and maxillary model implants were subjected to an implantoplasty procedure. Thirty implants were randomly assigned to receive one of three instrumentation sequences. After instrumentation, injury on neighbouring teeth was assessed. Instrumented implants and non-instrumented controls were subjected to 1.2 million cycles of thermo-mechanical loading in a chewing machine. Afterwards, maximum fracture load for all implants and an additional five pristine control implants was tested. RESULTS Generally, damage of neighbour teeth was a frequent finding (33 ± 56% of all cases) with considerable inter-group differences. No considerable inter-group difference for the residual implant thickness was found for different areas assessed. No implant fractured during cyclic loading. Fracture load was reduced after cyclic loading of uninstrumented implants from 2,724 ± 70 N to 2,299 ± 127 N, and after implantoplasty to 1,737 ± 165 N, while no effect by the instrumentation sequence could be observed. CONCLUSIONS Both implantoplasty and cyclic loading were shown to reduce the implants' maximum bending strength. Cyclic loading in a laboratory masticator, simulating a five-year equivalent of chewing, did not result in fractured implants. Since neighbouring tooth injury was assessed often, care should be taken with the selection of suitable instruments.",2021,No considerable inter-group difference for the residual implant thickness was found for different areas assessed.,['Thirty implants'],"['Instrumented implants and non-instrumented controls were subjected to 1.2 million cycles of thermo-mechanical loading in a chewing-machine', 'phantom head simulator and maxillary model implants']","['fracture load of dental implants', 'damage of neighbour teeth', 'Fracture load', 'residual implant thickness']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]","[{'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C1881839', 'cui_str': '1000000'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0024888', 'cui_str': 'Mastication'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0282611', 'cui_str': 'Phantom'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0011370', 'cui_str': 'Dental implantation'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C1553702', 'cui_str': 'Neighbor'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",,0.103774,No considerable inter-group difference for the residual implant thickness was found for different areas assessed.,"[{'ForeName': 'Isabelle C', 'Initials': 'IC', 'LastName': 'Jorio', 'Affiliation': 'Clinic of Conservative and Preventive Dentistry Periodontology and Cariology, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Bogna', 'Initials': 'B', 'LastName': 'Stawarczyk', 'Affiliation': 'Department of Prosthetic Dentistry, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Attin', 'Affiliation': 'Clinic of Conservative and Preventive Dentistry Periodontology and Cariology, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Patrick R', 'Initials': 'PR', 'LastName': 'Schmidlin', 'Affiliation': 'Clinic of Conservative and Preventive Dentistry Periodontology and Cariology, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Sahrmann', 'Affiliation': 'Clinic of Conservative and Preventive Dentistry Periodontology and Cariology, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.'}]",Clinical oral implants research,['10.1111/clr.13754'] 3306,34036692,Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.,"Pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) with manageable safety compared with placebo plus pemetrexed-platinum in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the global, randomized, double-blind, phase 3 KEYNOTE-189 study. We present results of Japanese patients enrolled in the KEYNOTE-189 global and Japan extension studies. Patients were randomized 2:1 to intravenous pembrolizumab 200 mg or placebo every 3 weeks (Q3W) for up to 35 cycles. All patients received pemetrexed 500 mg/m 2 plus the investigator's choice of cisplatin or carboplatin Q3W for four cycles, followed by maintenance pemetrexed 500 mg/m 2 Q3W (all intravenous). Co-primary endpoints were OS and PFS. Forty Japanese patients enrolled (pembrolizumab, n = 25; placebo, n = 15). At data cutoff (20 May 2019; median time from randomization to data cutoff, 18.5 [range, 14.7-38.2] months), the median OS was not reached in the pembrolizumab plus pemetrexed-platinum arm; the median OS was 25.9 (95% confidence interval [CI], 11.9-29.0) months in the placebo plus pemetrexed-platinum arm (hazard ratio [HR] .29; 95% CI, .07-1.15). The median (95% CI) PFS was 16.5 (8.8-21.1) compared with 7.1 (4.7-21.4) months (HR, .62; 95% CI, .27-1.42), respectively. There were no grade 5 adverse events (AE). Grade 3/4 AE occurred in 72% vs 60% of patients in the pembrolizumab vs placebo arms; 40% vs 20% had immune-mediated AE, and 4% vs 0% had infusion reactions. Efficacy and safety outcomes were similar to those from the global study and support first-line therapy with pembrolizumab plus pemetrexed-platinum in Japanese patients with nonsquamous NSCLC without EGFR/ALK alterations.",2021,There were no grade 5 adverse events (AEs).,"['Japanese patients enrolled in the KEYNOTE-189 global and Japan extension studies', 'Forty Japanese patients enrolled (pembrolizumab, n=25; placebo, n=15', 'patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC', 'Metastatic Nonsquamous Non-Small-Cell Lung Cancer', 'Japanese patients with nonsquamous NSCLC without EGFR/ALK alterations']","[""pemetrexed 500 mg/m 2 plus investigator's choice of cisplatin or carboplatin Q3W"", 'intravenous pembrolizumab 200 mg or placebo', 'Pembrolizumab plus pemetrexed-platinum', 'Pembrolizumab Plus Pemetrexed-Platinum', 'pembrolizumab plus pemetrexed-platinum', 'placebo', 'placebo plus pemetrexed-platinum']","['overall survival (OS) and progression-free survival (PFS', 'Efficacy and safety outcomes', 'Grade 3/4 AEs', 'median OS']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C1663627', 'cui_str': 'ALK protein, human'}]","[{'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",40.0,0.506126,There were no grade 5 adverse events (AEs).,"[{'ForeName': 'Hidehito', 'Initials': 'H', 'LastName': 'Horinouchi', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Naoyuki', 'Initials': 'N', 'LastName': 'Nogami', 'Affiliation': 'Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Saka', 'Affiliation': 'Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Nishio', 'Affiliation': 'Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.'}, {'ForeName': 'Takaaki', 'Initials': 'T', 'LastName': 'Tokito', 'Affiliation': 'Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Takahashi', 'Affiliation': 'Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Kasahara', 'Affiliation': 'Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Hattori', 'Affiliation': 'Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan.'}, {'ForeName': 'Eiki', 'Initials': 'E', 'LastName': 'Ichihara', 'Affiliation': 'Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.'}, {'ForeName': 'Noriaki', 'Initials': 'N', 'LastName': 'Adachi', 'Affiliation': 'MSD K.K, Tokyo, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Noguchi', 'Affiliation': 'MSD K.K, Tokyo, Japan.'}, {'ForeName': 'Fabricio', 'Initials': 'F', 'LastName': 'Souza', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Takayasu', 'Initials': 'T', 'LastName': 'Kurata', 'Affiliation': 'Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.'}]",Cancer science,['10.1111/cas.14980'] 3307,34034288,Telephone-based assessment of walking confidence in older people.,"To validate the telephone-based application of the modified Gait Efficacy Scale (mGES) for the assessment of walking confidence in older people. Participants answered the mGES-Brazil on two randomized occasions, face-to-face and by telephone. The mean difference (MD) between the interviews was reported. Intraclass correlation coefficient (ICC3,1) was used to investigate the levels of agreement between the two occasions for total mGES-Brazil scores and for the individual items. A total of 78 individuals were included. There was no significant difference in the MD obtained between applications of the mGES (1 point, 95% confidence interval -6 to 7). A very high level of agreement was found between the mGES total scores during face-to-face and telephone applications (ICC = 0.98; 95% CI 0.97-0.99). All items, except one (item 3), had a very high agreement between the two applications. The mGES showed to be reliable to be applied for telephone assessments of walking confidence in older people.",2021,A very high level of agreement was found between the mGES total scores during face-to-face and telephone applications (ICC = 0.98; 95% CI 0.97-0.99).,"['older people', 'A total of 78 individuals were included']","['Telephone-based assessment of walking confidence', 'telephone-based application of the modified Gait Efficacy Scale (mGES']","['MD', 'mean difference (MD', 'total mGES-Brazil scores']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",78.0,0.052351,A very high level of agreement was found between the mGES total scores during face-to-face and telephone applications (ICC = 0.98; 95% CI 0.97-0.99).,"[{'ForeName': 'Kênia K P', 'Initials': 'KKP', 'LastName': 'Menezes', 'Affiliation': 'NeuroGroup, Department of Physical Therapy, Universidade Federal de Minas Gerais, Belo Horizonte.'}, {'ForeName': 'Patrick R', 'Initials': 'PR', 'LastName': 'Avelino', 'Affiliation': 'NeuroGroup, Department of Physical Therapy, Universidade Federal de Minas Gerais, Belo Horizonte.'}, {'ForeName': 'Gabriela Azevedo', 'Initials': 'GA', 'LastName': 'Costa', 'Affiliation': 'Department of Physical Therapy, Fundação Comunitária de Ensino Superior de Itabira, Itabira.'}, {'ForeName': 'Jhonniter Bragança', 'Initials': 'JB', 'LastName': 'Viana', 'Affiliation': 'Department of Physical Therapy, Fundação Comunitária de Ensino Superior de Itabira, Itabira.'}, {'ForeName': 'Wanda Lucia', 'Initials': 'WL', 'LastName': 'Gomes', 'Affiliation': 'Department of Physical Therapy, Fundação Comunitária de Ensino Superior de Itabira, Itabira.'}, {'ForeName': 'Lucas R', 'Initials': 'LR', 'LastName': 'Nascimento', 'Affiliation': 'NeuroGroup, Department of Physical Therapy, Universidade Federal de Minas Gerais, Belo Horizonte.'}]",International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation,['10.1097/MRR.0000000000000472'] 3308,34390923,Concentric not eccentric cycling sprint intervals acutely impair balance and jump performance in healthy active young adults: A randomized controlled cross-over study.,"INTRODUCTION Moderate aerobic, high-intensity and sprint running or cycling training can transiently impair postural control. However, the acute effects of modified sprint interval training (mSIT) at different muscle working modes have not yet been examined. Thus, this study aimed at investigating acute effects of time-matched eccentric (ECC) versus concentric mSIT cycling session (CON) on jumping and functional balance performance. METHODS Twenty-five healthy and active males (30.0 ± 6.0 years; 80.1 ± 9.1 kg; V̇O 2max : 64.2 ± 7.9 mL kg -1  min -1 ) were enrolled in this acute randomized controlled crossover trial. Counter-Movement-Jump (CMJ) and functional balance testing (Y-Balance-Test composite score [YBT CS ]; Posturomed total distance: Posturomed TD ) were assessed as primary outcomes before, and immediately after cessation of ECC and CON (10 × 10 s maximum sprints and 50 s of active recovery). RESULTS A significant mode × time interaction effect for CMJ (F = 9.620, p = 0.005, η p 2  = 0.29) was observed. Subsequent post-hoc testing revealed significant moderate reductions in jumping height after CON (0.31 ± 0.06 vs. 0.27 ± 0.06m; p = 0.004, SMD = 0.59), whilst ECC remained unchanged. YBT CS (mode × time interaction: F = 6.880, p = 0.015, η p 2  = 0.22) showed small but significant balance impairments after CON (0.964 ± 0.068 vs. 0.960 ± 0.063 AU; p = 0.009, SMD = 0.28) and did not significantly change after ECC. Although large significant interaction effects (p = 0.029, η p 2  = 0.18) were observed for Posturomed TD , follow up post-hoc testing did not reveal relevant pre-post differences, neither for ECC nor CON. CONCLUSION Both functional balance and jumping performance are deteriorated after acute concentric but not eccentric mSIT cycling. Although higher pedal forces at lower perceived efforts and heart rates during eccentric mSIT were observed, it seems that the cardiocirculatory demanding CON session elicited more pronounced balance and jump performance impairments than eccentric cycling.",2021,"A significant mode × time interaction effect for CMJ (F = 9.620, p = 0.005, η p 2  = 0.29) was observed.","['Twenty-five healthy and active males (30.0\u2009±\u20096.0 years; 80.1\u2009±\u20099.1\u2009kg; V̇O 2max : 64.2\u2009±\u20097.9\u2009mL\u2009kg -1 \u2009min -1 ', 'healthy active young adults']","['modified sprint interval training (mSIT', 'Counter-Movement-Jump (CMJ) and functional balance testing (Y-Balance-Test composite score [YBT CS ', 'Concentric not eccentric cycling sprint', 'Moderate aerobic, high-intensity and sprint running or cycling training', 'time-matched eccentric (ECC) versus concentric mSIT cycling session (CON']",[],"[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1301862', 'cui_str': 'Min 1'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4279979', 'cui_str': 'Sprint Interval Training'}, {'cui': 'C0677601', 'cui_str': 'Counter'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]",[],25.0,0.0826088,"A significant mode × time interaction effect for CMJ (F = 9.620, p = 0.005, η p 2  = 0.29) was observed.","[{'ForeName': 'Ludwig', 'Initials': 'L', 'LastName': 'Rappelt', 'Affiliation': 'Intervention Research in Exercise Training, German Sports University Cologne, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Held', 'Affiliation': 'Intervention Research in Exercise Training, German Sports University Cologne, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Donath', 'Affiliation': 'Intervention Research in Exercise Training, German Sports University Cologne, Germany. Electronic address: l.donath@dshs-koeln.de.'}]",Gait & posture,['10.1016/j.gaitpost.2021.08.006'] 3309,34045164,Comment on: Long versus short biliopancreatic limb in Roux-en-Y gastric bypass: short-term results of a randomized clinical trial.,,2021,,['Roux-en-Y gastric bypass'],['biliopancreatic limb'],[],"[{'cui': 'C0399839', 'cui_str': 'Bypass gastrojejunostomy'}]","[{'cui': 'C0015385', 'cui_str': 'Limb structure'}]",[],,0.180485,,"[{'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Topart', 'Affiliation': ""Clinique de l'Anjou, Société de Chirurgie Viscérale, Angers, France.""}]",Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery,['10.1016/j.soard.2021.05.007'] 3310,34044625,The Effect of the Web-Based Communication between a Nurse and a Family Member on the Perceived Stress of the Family Member of Patients with Suspected or Confirmed COVID-19: A Parallel Randomized Clinical Trial.,"The aim of this study was to identify the effect of web-based communication between a nurse and a family member of a patient with COVID-19 on his/her perceived stress. In this multicenter parallel randomized controlled trial, 67 family members of COVID-19 patients admitted to the Intensive Care Unit (ICU) were investigated. In the intervention group, web-based communication was performed for four consecutive days for 10 to 15 minutes. The Perceived Stress Scale (PSS-14) were completed in both groups before and after the intervention. Mean and standard deviation of perceived stress scores in the two groups were not significantly different ( p  = 0.26) before the intervention; however, after the intervention, the mean PSS-14 in the intervention group was significantly lower than that of the control group ( p  < 0.001). Due to the need to follow the physical and social distancing to protect against Coronavirus disease, the use of web-based communication recommended in future studies.",2021,"Mean and standard deviation of perceived stress scores in the two groups were not significantly different ( p  = 0.26) before the intervention; however, after the intervention, the mean PSS-14 in the intervention group was significantly lower than that of the control group ( p  < 0.001).","['67 family members of COVID-19 patients admitted to the Intensive Care Unit (ICU) were investigated', 'Family Member of Patients with Suspected or Confirmed COVID-19']",[],"['mean PSS-14', 'Perceived Stress Scale (PSS-14', 'Mean and standard deviation of perceived stress scores']","[{'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",67.0,0.0353986,"Mean and standard deviation of perceived stress scores in the two groups were not significantly different ( p  = 0.26) before the intervention; however, after the intervention, the mean PSS-14 in the intervention group was significantly lower than that of the control group ( p  < 0.001).","[{'ForeName': 'Esmail', 'Initials': 'E', 'LastName': 'Shariati', 'Affiliation': 'The Student Research Committee, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Dadgari', 'Affiliation': 'School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Seyedeh Solmaz', 'Initials': 'SS', 'LastName': 'Talebi', 'Affiliation': 'Department of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Gholam Reza', 'Initials': 'GR', 'LastName': 'Mahmoodi Shan', 'Affiliation': 'Nursing Research Center, Golestan University of Medical Sciences, Gorgan, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Ebrahimi', 'Affiliation': 'Center for Health-Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran.'}]",Clinical nursing research,['10.1177/10547738211017688'] 3311,34031220,"Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 12-month results.","INTRODUCTION Vertebral endplates, innervated by the basivertebral nerve (BVN), are a source of chronic low back pain correlated with Modic changes. A randomized trial comparing BVN ablation to standard care (SC) recently reported results of an interim analysis. Here, we report the results of the full randomized trial, including the 3-month and 6-month between-arm comparisons, 12-month treatment arm results, and 6-month outcomes of BVN ablation in the former SC arm. METHODS Prospective, open label, 1:1 randomized controlled trial of BVN ablation versus SC in 23 US sites with follow-up at 6 weeks, 3, 6, 9, and 12 months. SC patients were re-baselined and followed up for 6 months post BVN ablation. The primary endpoint was the between-arm comparison of mean Oswestry Disability Index (ODI) change from baseline. Secondary endpoints were Visual Analog Scale (VAS), Short Form (SF-36), EuroQual Group 5 Dimension 5-Level Quality of Life (EQ-5D-5L), responder rates, and rates of continued opioid use. RESULTS 140 were randomized. Results from BVN ablation (n=66) were superior to SC (n=74) at 3 months for the primary endpoint (mean ODI reduction, difference between arms of -20.3 (CI -25.9 to -14.7 points; p<0.001)), VAS pain improvement (difference of -2.5 cm between arms (CI -3.37 to -1.64, p<0.001)) and quality of life outcomes. At 12 months, basivertebral ablation demonstrated a 25.7±18.5 point reduction in mean ODI (p<0.001), and a 3.8±2.7 cm VAS reduction (p<0.001) from baseline, with 64% demonstrating ≥50% reduction and 29% pain free. Similarly, the former SC patients who elected BVN ablation (92%) demonstrated a 25.9±15.5 point mean ODI reduction (p<0.001) from baseline. The proportion of opioid use did not change in either group (p=0.56). DISCUSSION/CONCLUSION BVN ablation demonstrates significant improvements in pain and function over SC, with treatment results sustained through 12 months in patients with chronic low back pain of vertebrogenic origin.",2021,"Results from BVN ablation (n=66) were superior to SC (n=74) at 3 months for the primary endpoint (mean ODI reduction, difference between arms of -20.3 (CI -25.9 to -14.7 points; p<0.001)), VAS pain improvement (difference of -2.5 cm between arms (CI -3.37 to -1.64, p<0.001)) and quality of life outcomes.","['patients with chronic low back pain of vertebrogenic origin', '23 US sites with follow-up at 6 weeks, 3, 6, 9, and 12 months', 'chronic low back pain']","['BVN ablation', 'intraosseous basivertebral nerve ablation', 'BVN ablation versus SC', 'BVN ablation to standard care (SC']","['VAS pain improvement', 'pain and function', 'Visual Analog Scale (VAS), Short Form (SF-36), EuroQual Group 5 Dimension 5-Level Quality of Life (EQ-5D-5L), responder rates, and rates of continued opioid use', 'mean ODI reduction', 'mean ODI', 'proportion of opioid use', 'BVN ablation', 'elected BVN ablation', 'quality of life outcomes', 'mean Oswestry Disability Index (ODI) change']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0595613', 'cui_str': 'Intraosseous route'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",140.0,0.117048,"Results from BVN ablation (n=66) were superior to SC (n=74) at 3 months for the primary endpoint (mean ODI reduction, difference between arms of -20.3 (CI -25.9 to -14.7 points; p<0.001)), VAS pain improvement (difference of -2.5 cm between arms (CI -3.37 to -1.64, p<0.001)) and quality of life outcomes.","[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Smuck', 'Affiliation': 'Physical Medicine & Rehabilitation Division, Stanford University, Redwood City, California, USA msmuck@stanford.edu.'}, {'ForeName': 'Jad', 'Initials': 'J', 'LastName': 'Khalil', 'Affiliation': 'Orthopaedic Surgery, William Beaumont Hospital, Royal Oak, Michigan, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Barrette', 'Affiliation': 'Neurological Surgery, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Joshua Adam', 'Initials': 'JA', 'LastName': 'Hirsch', 'Affiliation': 'Department of Neurointerventional Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Kreiner', 'Affiliation': 'Neurophysiatry, Barrow Neurological Institute, Phoenix, Arizona, USA.'}, {'ForeName': 'Theodore', 'Initials': 'T', 'LastName': 'Koreckij', 'Affiliation': ""Orthopaedic Surgery Spine, St Luke's Hospital, Kansas, Missouri, USA.""}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Garfin', 'Affiliation': 'Orthopaedic Surgery, University of California San Diego, La Jolla, California, USA.'}, {'ForeName': 'Nagy', 'Initials': 'N', 'LastName': 'Mekhail', 'Affiliation': 'Anesthesiology, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Regional anesthesia and pain medicine,['10.1136/rapm-2020-102259'] 3312,34036644,Soft tissue integration of different abutment surfaces: An experimental study with histological analysis.,"OBJECTIVE To evaluate whether abutment surface and surface bio-activation have an effect on soft tissue morphogenesis. MATERIALS AND METHODS 36 patients (36 implants) were included. Abutments were randomly divided into 4 groups (n = 9): Smooth Surface-MAChined (MAC), Ultrathin Threaded Microsurface (UTM), MAC Plasma of Argon activated (Plasma-MAC), and UTM Plasma of Argon activated (Plasma-UTM). After 2 months of healing, soft tissue samples were collected and prepared for histological analysis. The margin of the peri-implant mucosa (PM), the apical extension of the barrier epithelium (aJE), and the apical location of the abutment (AM) were identified. Significances of differences among groups were tested by means of the Kruskal-Wallis test and between pairs of results by means of the Mann-Whitney test. RESULTS The mean (SD) vertical dimension of the mucosa was 2.5mm (1.0), including a connective tissue portion (CTP) of 0.8mm (0.8) in the MAC group; 3.6mm (0.2) with a CTP of 1.6mm (0.4) in the Plasma-MAC group; 3.2mm (1.0), with a CPT of 0.5mm (0.6) in the UTM; and 3.3mm (0.8), with a CPT of 0.9mm (0.7) in the Plasma-UTM group. Statistically significant differences were observed in the aJE-AM height and PM-aJE profile among the four experimental groups (p = .042 and p = .039, respectively). The Mann-Whitney test indicated differences between the Plasma-abutments and the untreated abutments both for PM-AM (p = .025) and AjE-AM (p = .021). The differences appeared more evident when the preoperative soft tissue thickness was ≤2mm. CONCLUSIONS Within its limits, the study demonstrated a favorable effect of the plasma treatment on the connective tissue portion tissues. Plasma-MAC group highlighted the best performance. This behavior appeared strictly correlated with the soft tissue thickness.",2021,"Statistically significant differences were observed in the aJE-AM height and PM-aJE profile among the four experimental groups (P=0.042 and P=0.039, respectively).",['36 patients (36 implants) were included'],"['Smooth Surface - MAChined (MAC), Ultrathin Threaded Microsurface (UTM), MAC Plasma of Argon activated (Plasma MAC), UTM Plasma of Argon activated (Plasma UTM']","['mean (SD) vertical dimension of the mucosa', 'preoperative soft tissue thickness', 'margin of the peri-implant mucosa (PM), the apical extension of the barrier epithelium (aJE), the apical location of the abutment (AM', 'aJE-AM height and PM-aJE profile']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0205357', 'cui_str': 'Smooth'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0009545', 'cui_str': 'Active C5b6789'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003781', 'cui_str': 'Argon'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042569', 'cui_str': 'Vertical Dimension'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205111', 'cui_str': 'Apical'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0014609', 'cui_str': 'Epithelium'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}]",36.0,0.0219837,"Statistically significant differences were observed in the aJE-AM height and PM-aJE profile among the four experimental groups (P=0.042 and P=0.039, respectively).","[{'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Canullo', 'Affiliation': 'Department of Oral Surgery and Implants, University of Valencia, Valencia, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Penarrocha Oltra', 'Affiliation': 'Department of Oral Surgery and Implants, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Pesce', 'Affiliation': 'Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Zarauz', 'Affiliation': 'Department of Fixed Prosthodontics, University of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Rossano', 'Initials': 'R', 'LastName': 'Lattanzio', 'Affiliation': ""Department of Innovative Technologies in Medicine & Dentistry, Center for Advanced Studies and Technology (CAST), 'G. d'Annunzio' University of Chieti-Pescara, Chieti, Italy.""}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Penarrocha Diago', 'Affiliation': 'Department of Oral Surgery and Implants, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Iezzi', 'Affiliation': ""Department of Medical, Oral and Biotechnological Sciences, 'G. d'Annunzio' University of Chieti-Pescara, Chieti, Italy.""}]",Clinical oral implants research,['10.1111/clr.13782'] 3313,34034341,Effects of Tinnitus Sound Therapy Determined Using Subjective Measurements.,"BACKGROUND Sound therapy is generally considered as an effective method for relieving tinnitus. There have been various reports on the effects of tinnitus interventions involving sound therapy as a component; however, there have been only a small number of reports on the effects of sound therapy itself on tinnitus. PURPOSE The aim of the study is to elucidate whether sound therapy significantly improves tinnitus as determined by subjective measurements. RESEARCH DESIGN Prospective study involves within-subject (baseline, 3-month, 6-month) measurements. STUDY SAMPLE This includes 16 adults with subjective and sensorineural tinnitus. INTERVENTION Participants undertook sound therapy for 3 hours a day for 6 months. The level of stimulus for sound therapy was set to the mixing point of each participant. No counseling was provided. DATA COLLECTION AND ANALYSIS Participants rated the visual analog scale for loudness and annoyance using a numeric 0 to 100 point scale and completed the Korean version of the Tinnitus Primary Function Questionnaire at the baseline, 3-month, and 6-month time points. RESULTS Sound therapy led to significant improvements of tinnitus in participants in all subjective measurements. Significant effects were found not only between the baseline and 3-month but also between the 3-month and 6-month follow-ups. CONCLUSION Results of the present study showed that the sound therapy alone led to significant improvements of tinnitus in participants as assessed by subjective measurements. To improve the effects of sound therapy, consistent sound therapy may be required for a certain period of time such as 3 hours a day over a 6-month period.",2021,"Significant effects were found not only between the baseline and 3-month but also between the 3-month and 6-month follow-ups. ",['16 adults with subjective and sensorineural tinnitus'],['Tinnitus Sound Therapy Determined Using Subjective Measurements'],['tinnitus'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}]","[{'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]","[{'cui': 'C0040264', 'cui_str': 'Tinnitus'}]",,0.0326475,"Significant effects were found not only between the baseline and 3-month but also between the 3-month and 6-month follow-ups. ","[{'ForeName': 'In-Ki', 'Initials': 'IK', 'LastName': 'Jin', 'Affiliation': 'Division of Speech Pathology and Audiology, Research Institute of Audiology and Speech Pathology, College of Natural Sciences, Hallym University, Chuncheon, South Korea.'}, {'ForeName': 'Soon-Je', 'Initials': 'SJ', 'LastName': 'Choi', 'Affiliation': 'Department of Speech Pathology and Audiology, Graduate School, Hallym University, Chuncheon, South Korea.'}, {'ForeName': 'Jeeun', 'Initials': 'J', 'LastName': 'Yoo', 'Affiliation': 'Department of Speech Pathology and Audiology, Graduate School, Hallym University, Chuncheon, South Korea.'}, {'ForeName': 'Seungyeop', 'Initials': 'S', 'LastName': 'Jeong', 'Affiliation': 'Department of Speech Pathology and Audiology, Graduate School, Hallym University, Chuncheon, South Korea.'}, {'ForeName': 'Sohee', 'Initials': 'S', 'LastName': 'Heo', 'Affiliation': 'Department of Speech Pathology and Audiology, Graduate School, Hallym University, Chuncheon, South Korea.'}, {'ForeName': 'Hongyeop', 'Initials': 'H', 'LastName': 'Oh', 'Affiliation': 'Department of Speech Pathology and Audiology, Graduate School, Hallym University, Chuncheon, South Korea.'}]",Journal of the American Academy of Audiology,['10.1055/s-0041-1722984'] 3314,34031053,Bioavailability of Single-Dose SUBA-Itraconazole Compared to Conventional Itraconazole under Fasted and Fed Conditions.,"Conventional itraconazole (C-ITZ) suffers from absorption variability. SUBA-itraconazole (S-ITZ) is more bioavailable than C-ITZ at steady state in a fed condition, but there are no data comparing the two under a fasted state. An open-label, single-dose, randomized, bioequivalence study was performed comparing S-ITZ to C-ITZ capsules under fasted and fed conditions in healthy adults measuring itraconazole and hydroxyitraconazole plasma levels. This study demonstrated less variability of S-ITZ compared to C-ITZ capsules under fasted conditions.",2021,"SUBA-itraconazole (S-ITZ) is more bioavailable than C-ITZ at steady-state in a fed condition, but there is no data comparing them under a fasted state.",['healthy adults measuring'],"['itraconazole', 'Single-Dose SUBA-itraconazole', 'Conventional Itraconazole', 'SUBA-itraconazole (S-ITZ', 'Conventional itraconazole (C-ITZ']",['Bioavailability'],"[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]","[{'cui': 'C0064113', 'cui_str': 'Itraconazole'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0005508', 'cui_str': 'Availability, Biological'}]",,0.0681511,"SUBA-itraconazole (S-ITZ) is more bioavailable than C-ITZ at steady-state in a fed condition, but there is no data comparing them under a fasted state.","[{'ForeName': 'Adriana M', 'Initials': 'AM', 'LastName': 'Rauseo', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis, St Louis, Missouri, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Mazi', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis, St Louis, Missouri, USA.'}, {'ForeName': 'Phoebe', 'Initials': 'P', 'LastName': 'Lewis', 'Affiliation': 'Mayne Pharma, Medical Affairs, Raleigh, North Carolina, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Burnett', 'Affiliation': 'Mayne Pharma, Medical Affairs, Raleigh, North Carolina, USA.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Mudge', 'Affiliation': 'Mayne Pharma, Medical Affairs, Raleigh, North Carolina, USA.'}, {'ForeName': 'Andrej', 'Initials': 'A', 'LastName': 'Spec', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis, St Louis, Missouri, USA.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00134-21'] 3315,34029163,The endocrine effects of bitter tastant administration in the gastrointestinal system: intragastric versus intraduodenal administration.,"Bitter tastants are recently introduced as potential hunger-suppressive compounds, the so-called ""Bitter pill."" However, the literature about bitter administration lacks consistency in methods and findings. We want to test whether hunger ratings and hormone plasma levels are affected by: 1 ) the site of administration: intragastrically (IG) or intraduodenally (ID), 2 ) the bitter tastant itself, quinine hydrochloride (QHCl) or denatonium benzoate (DB), and 3 ) the timing of infusion. Therefore, 14 healthy, female volunteers participated in a randomized, placebo-controlled six-visit crossover study. After an overnight fast, DB (1 µmol/kg), QHCl (10 µmol/kg), or placebo were given IG or ID via a nasogastric feeding tube. Blood samples were taken 10 min before administration and every 10 min after administration for a period of 2 h. Hunger was rated at the same time points on a visual analogue scale. ID bitter administration did not affect hunger sensations, motilin, or acyl-ghrelin release compared with its placebo infusion. IG QHCl infusion tended to suppress hunger increase, especially between 50 and 70 min after infusion, simultaneously with reduced motilin values. Here, acyl-ghrelin was not affected. IG DB did not affect hunger or motilin, however acyl-ghrelin levels were reduced 50-70 minutes after infusion. Plasma values of glucagon-like peptide 1 and cholecystokinin were too low to be properly detected or to have any physiological relevance. In conclusion, bitter tastants should be infused into the stomach to reduce hunger sensations and orexigenic gut peptides. QHCl has the best potential to reduce hunger sensations, and it should be infused 60 min before food intake. NEW & NOTEWORTHY Bitter tastants are a potential new weight-loss treatment. This is a noninvasive, easy approach, which should be received with considerable enthusiasm by the public. However, literature about bitter administration lacks consistency in methods and findings. We summarize how the compound should be given based on: the site of administration, the best bitter compound to use, and at what timing in respect to the meal. This paper is therefore a fundamental step to continue research toward the further development of the ""bitter pill.""",2021,"ID bitter administration did not affect hunger sensations, motilin or acyl-ghrelin release compared with its PLC infusion.","['14 healthy, female volunteers']","['QHCl', 'IG DB', 'placebo', 'bitter tastant itself, quinine hydrochloride (QHCl) or denatonium benzoate (DB', 'IG QHCl']","['Hunger', 'hunger or motilin, however acyl-ghrelin levels', 'hunger ratings and hormone plasma levels', 'hunger sensations, motilin or acyl-ghrelin release', 'visual analogue scale (VAS', 'motilin values', 'hunger sensations']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0235290', 'cui_str': 'Taste bitter'}, {'cui': 'C0034421', 'cui_str': 'Quinine hydrochloride'}, {'cui': 'C0057380', 'cui_str': 'denatonium benzoate'}]","[{'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0026594', 'cui_str': 'Motilin'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.115016,"ID bitter administration did not affect hunger sensations, motilin or acyl-ghrelin release compared with its PLC infusion.","[{'ForeName': 'Wout', 'Initials': 'W', 'LastName': 'Verbeure', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Eveline', 'Initials': 'E', 'LastName': 'Deloose', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Joran', 'Initials': 'J', 'LastName': 'Tóth', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Jens F', 'Initials': 'JF', 'LastName': 'Rehfeld', 'Affiliation': 'Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Van Oudenhove', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'Depoortere', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Tack', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.'}]",American journal of physiology. Endocrinology and metabolism,['10.1152/ajpendo.00636.2020'] 3316,34034287,Efficacy and safety of a simple home-based resistance exercise program for older adults with low muscle mass: a prospective longitudinal clinical trial.,"Low muscle mass is a common condition among older adults that adversely affects strength, physical performance and quality of life. This study aimed to investigate the efficacy and safety of a simple home-based resistance exercise program for older adults with low muscle mass, which was defined as appendicular skeletal mass (ASM) measured by bioimpedance analysis lower than 5.7 kg/m2 in females, and lower than 7.0 kg/m2 in males. This home-based resistance exercise program targets 10 muscles with a frequency of 3-5 days/week for 24 weeks. ASM, grip strength, gait speed and functional reach were measured at baseline, 3 and 6 months. The same four outcomes were then remeasured at 9 months to assess long-term effects. A total of 112 participants (average age: 70 years) were recruited. The mean difference between baseline and 6 months was statistically significant for all outcomes, including ASM [0.12 kg/m2: 95% confidence interval (CI), 0.05-0.18; P = 0.001], gait speed (0.19 meter/s: 95% CI, 0.14-0.25; P < 0.001), grip strength (2.06 kg: 95% CI, 1.32-2.80; P < 0.001), and functional reach distance (4.18 cm: 95% CI, 3.18-5.18; P < 0.001). Change over time for all main outcomes from baseline to 9 months also showed statistically significant improvement. The most commonly reported adverse events were muscle pain, joint pain and fatigue. The majority of participants (90-93%) had good exercise compliance, even at the end of the study. In conclusion, this 24-week simple home-based resistance exercise program significantly improved all main outcomes with low adverse events, and most participants continued the program after the end of the intervention.",2021,"In conclusion, this 24-week simple home-based resistance exercise program significantly improved all main outcomes with low adverse events, and most participants continued the program after the end of the intervention.","['112 participants (average age: 70\u2009years) were recruited', 'older adults with low muscle mass', 'older adults', 'older adults with low muscle mass, which was defined as appendicular skeletal mass (ASM) measured by bioimpedance analysis lower than 5.7 kg/m2 in females, and lower than 7.0 kg/m2 in males']",['simple home-based resistance exercise program'],"['strength, physical performance and quality of life', 'efficacy and safety', 'muscle pain, joint pain and fatigue', 'ASM, grip strength, gait speed and functional reach', 'functional reach distance', 'Efficacy and safety', 'gait speed', 'good exercise compliance', 'grip strength']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517795', 'cui_str': '5.7'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C1321055', 'cui_str': 'Functional reach'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",112.0,0.189745,"In conclusion, this 24-week simple home-based resistance exercise program significantly improved all main outcomes with low adverse events, and most participants continued the program after the end of the intervention.","[{'ForeName': 'Vilai', 'Initials': 'V', 'LastName': 'Kuptniratsaikul', 'Affiliation': 'Department of Rehabilitation Medicine.'}, {'ForeName': 'Thanitta', 'Initials': 'T', 'LastName': 'Thanakiatpinyo', 'Affiliation': 'Department of Rehabilitation Medicine.'}, {'ForeName': 'Rinlada', 'Initials': 'R', 'LastName': 'Pongratanakul', 'Affiliation': 'Department of Rehabilitation Medicine.'}, {'ForeName': 'Pornsiri', 'Initials': 'P', 'LastName': 'Chinsawangwattanakul', 'Affiliation': 'Research Group and Research Network Division, Research Department.'}, {'ForeName': 'Ananya', 'Initials': 'A', 'LastName': 'Srisomnuek', 'Affiliation': 'Research Group and Research Network Division, Research Department.'}, {'ForeName': 'Suwicha', 'Initials': 'S', 'LastName': 'Inthibal', 'Affiliation': 'Division of Surgical Nursing, Department of Nursing, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}]",International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation,['10.1097/MRR.0000000000000479'] 3317,34033580,Mobile Delivery of Mindfulness-Based Smoking Cessation Treatment Among Low-Income Adults During the COVID-19 Pandemic: Pilot Randomized Controlled Trial.,"BACKGROUND Smoking is the leading cause of premature death, and low-income adults experience disproportionate burden from tobacco. Mindfulness interventions show promise for improving smoking cessation. A text messaging program ""iQuit Mindfully"" was developed to deliver just-in-time support for quitting smoking among low-income adults. A pilot study of iQuit Mindfully was conducted in spring 2020, during the COVID-19 pandemic, among low-income and predominantly African American smokers. OBJECTIVE This pilot study examined the acceptability and feasibility of delivering Mindfulness-Based Addiction Treatment via mHealth during the COVID-19 pandemic. METHODS Participants were adult cigarette smokers (n=23), of whom 8 (34.8%) were female, 19 (82.6%) were African American, and 18 (78.3%) had an annual income of .05). Within the limitations of this study, it can be concluded that PDT was efficient in decreasing pain in teeth presenting with SAP. There was no difference observed after 72 hours and there was no impact on the intake of pain relief medication.",2021,The PG resulted in lower pain levels after the 24-hour interval (median 0) than the CG (median 2); there was no difference between both groups at 72-h and 1-week intervals.,"['posterior teeth presenting symptomatic apical periodontitis (SAP', 'Only patients who registered moderate or severe pain were included', 'Seventy patients', 'Posterior Teeth with Symptomatic Apical Periodontitis']","['control group (CG) without the PDT application and an intervention group with PDT application (PG', 'photodynamic therapy (PDT', 'Photodynamic Therapy', 'root canal preparation', '150 µM methylene blue (MB', 'PDT']","['lower pain levels', 'mean number of tablets taken for pain relief', 'Postoperative Pain', 'intake of pain relief medication', 'A visual analog scale (VAS', 'pain', 'pain perception', 'number of tablets taken for pain relief', 'pain relief']","[{'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0457755', 'cui_str': 'Tooth presence - finding'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0031030', 'cui_str': 'Apical periodontitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0278140', 'cui_str': 'Severe pain'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0282543', 'cui_str': 'Root canal preparation'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0025746', 'cui_str': 'Methylene blue'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",70.0,0.0708129,The PG resulted in lower pain levels after the 24-hour interval (median 0) than the CG (median 2); there was no difference between both groups at 72-h and 1-week intervals.,"[{'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Vilas-Boas', 'Affiliation': 'São Leopoldo Mandic School of Dentistry, Rua Emilio Ribas 776 sala 13, Campinas, SP, 13025-141, Brazil.'}, {'ForeName': 'Viviany', 'Initials': 'V', 'LastName': 'Cozer', 'Affiliation': 'Universidade Federal Fluminense - UFF, School of Dentistry, Department of Endodontics, Niterói, RJ , Brazil.'}, {'ForeName': 'Peter Z', 'Initials': 'PZ', 'LastName': 'Tawil', 'Affiliation': 'UNC Adams School of Dentistry, Brazil.'}, {'ForeName': 'Marcelo Santos', 'Initials': 'MS', 'LastName': 'Coelho', 'Affiliation': 'São Leopoldo Mandic School of Dentistry, Rua Emilio Ribas 776 sala 13, Campinas, SP, 13025-141, Brazil. Electronic address: coelho_marcelo@yahoo.com.br.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102348'] 3324,34033934,"Clinical, bacterial, and inflammatory outcomes of indocyanine green-mediated photodynamic therapy for treating periimplantitis among diabetic patients: A randomized controlled clinical trial.","Background This 6-months randomized controlled clinical trial aimed to assess the efficacy of indocyanine green mediated photodynamic therapy (ICG-PDT) as an adjunct to peri‑implant manual debridement (PIMD) versus PIMD alone among Diabetes Mellitus (DM) patients in the treatment of peri‑implantitis. Methods A total of 48 DM patients having 64 implants were treated with either ICG-PDT + PIMD (n = 35 implants) or PIMD alone (n = 29 implants). Clinical (probing depth [PD], bleeding on probing [BOP], and plaque index [PI]) and radiographic (peri‑implant crestal bone loss [PCBL]) peri‑implant variables were recorded. Bacterial species including Porphyromonas gingivalis and Treponema denticola were evaluated from peri‑implant plaque biofilms. Levels of interleukin (IL)-1β and IL-6 were assessed after the collection of peri‑implant sulcular fluid. All the evaluations were carried out at baseline, 3- and 6-months. The significance level was set to p < 0.05. Results All clinical parameters significantly reduced within both treatment groups (P<0.05). Intra-group comparison indicates that there was statistically significant reduction in PD and suppuration for ICG-PDT group (P<0.05). There was a statistically significant difference in the BOP between ICG-PDT and PIMD groups at both follow-up periods (P<0.001). However, there was a significant difference for PD (P = 0.001), suppuration (P = 0.01), and PCBL (P = 0.04) on 6 months follow-up between ICG-PDT and PIMD groups, respectively. Only ICG-PDT showed a significant reduction in P. gingivalis and T. denticola on both 3 months and 6 months follow-up compared to baseline. PIMD showed a statistically significant reduction only on 3 months follow-up compared to baseline. This reduction was maintained for both the species when dental implants were treated with ICG-PDT. However, PIMD failed to maintain this reduction until 6 months. Only at 3 months assessment that both treatment groups showed statistically significant reduction in IL-1β and IL-6 with no significant difference between the groups. Both biomarkers failed to maintain the reduction in both groups and significantly increased levels for IL-1β was noted at 6 months follow up Conclusion Multiple application of indocyanine-green mediated photodynamic therapy resulted in improved clinical and microbial parameters among type 2 DM subjects in the treatment of peri‑implantitis. This clinical trial was registered in the ClinicalTrials.gov Protocol Registration and Results System with registration record number: NCT04833569.",2021,Only ICG-PDT showed a significant reduction in P. gingivalis and T. denticola on both 3 months and 6 months follow-up compared to baseline.,"['DM patients in the treatment of peri-implantitis', '48 DM patients having 64 implants', 'diabetic patients']","['indocyanine green-mediated photodynamic therapy', 'PIMD alone', 'ICG-PDT', 'indocyanine green mediated photodynamic therapy (ICG-PDT', 'ICG-PDT\u202f+\u202fPIMD', 'indocyanine-green mediated photodynamic therapy']","['IL-1β and IL-6', 'Clinical (probing depth [PD], bleeding on probing [BOP], and plaque index [PI]) and radiographic (peri-implant crestal bone loss [PCBL', 'PCBL', 'BOP', 'clinical and microbial parameters', 'PD and suppuration', 'PD', 'P. gingivalis and T. denticola', 'Levels of interleukin (IL)-1β and IL-6', 'suppuration', 'levels for IL-1β']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C2936258', 'cui_str': 'Dental peri-implantitis'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}]","[{'cui': 'C0021234', 'cui_str': 'Indocyanine Green'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}]","[{'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0796232', 'cui_str': 'Bohring Opitz syndrome'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0038862', 'cui_str': 'Suppurative inflammation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",48.0,0.167094,Only ICG-PDT showed a significant reduction in P. gingivalis and T. denticola on both 3 months and 6 months follow-up compared to baseline.,"[{'ForeName': 'Nawaf', 'Initials': 'N', 'LastName': 'Labban', 'Affiliation': 'Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia. Electronic address: nalabban@ksu.edu.sa.'}, {'ForeName': 'Nouf Al', 'Initials': 'NA', 'LastName': 'Shibani', 'Affiliation': 'Department of Periodontics and Community Dentistry, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia.'}, {'ForeName': 'Reem', 'Initials': 'R', 'LastName': 'Al-Kattan', 'Affiliation': 'Department of Periodontics and Community Dentistry, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia.'}, {'ForeName': 'Afnan F', 'Initials': 'AF', 'LastName': 'Alfouzan', 'Affiliation': 'Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia.'}, {'ForeName': 'Abdulaziz', 'Initials': 'A', 'LastName': 'Binrayes', 'Affiliation': 'Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia.'}, {'ForeName': 'Mansour K', 'Initials': 'MK', 'LastName': 'Assery', 'Affiliation': 'Department of Prosthodontics, Riyadh Elm University, Riyadh, Saudi Arabia.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102350'] 3325,34037768,Educating outdoor workers using tailored and financial messages to encourage safe-sun behaviors.,"Excessive and unsafe sun exposure represents a concerning hazard to the health of individuals. Of particular interest are those who are most susceptible to sun exposure, such as outdoor workers. The current study used a 3 × 2 between-subjects design to investigate the effectiveness of messages that varied the extent of personalization (i.e. generic message; occupation targeted message; individual tailored message) and the inclusion of content regarding financial consequences of skin cancer. Participants (N = 304) were recruited from the USA through Amazon's Mechanical Turk and randomly assigned to view a generic message, occupation targeted message, or individual tailored message. Additionally, participants were randomly assigned to view messages in which financial information was either present or not. Participants responded to questions assessing pre- and post-test sun protection behaviors. Individual tailored messaging was as effective as occupation targeted messaging, with both being more effective than generic messaging. This finding indicates that some degree of personalization is necessary when promoting safe-sun practices to outdoor workers, but that tailoring to individuals may not always be necessary. Inclusion of financial content in messaging resulted in greater intentions to practice sun protection behaviors. Results provide insight into effective methods for promoting sun protection.",2021,"Individual tailored messaging was as effective as occupation targeted messaging, with both being more effective than generic messaging.","[""Participants (N\u2009=\u2009304) were recruited from the USA through Amazon's Mechanical Turk and randomly assigned to""]","['view a generic message, occupation targeted message, or individual tailored message']",[],"[{'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0337911', 'cui_str': 'Turks'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",[],304.0,0.0290776,"Individual tailored messaging was as effective as occupation targeted messaging, with both being more effective than generic messaging.","[{'ForeName': 'Aaron C', 'Initials': 'AC', 'LastName': 'Entringer', 'Affiliation': 'Department of Psychological Sciences, Kansas State University, Manhattan, KS, USA.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Brannon', 'Affiliation': 'Department of Psychological Sciences, Kansas State University, Manhattan, KS, USA.'}, {'ForeName': 'Whitney K', 'Initials': 'WK', 'LastName': 'Whitaker', 'Affiliation': 'Department of Psychology, Fort Hays State University, Hays, KS, USA.'}]",Health education research,['10.1093/her/cyab008'] 3326,34047449,Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies.,"AIM To assess whether a FiASP-and-pramlintide closed-loop system has the potential to replace carbohydrate counting with a simple meal announcement (SMA) strategy (meal priming bolus without carbohydrate counting) without degrading glycaemic control compared with a FiASP closed-loop system. MATERIALS AND METHODS We conducted a 24-hour feasibility study comparing a FiASP system with full carbohydrate counting (FCC) with a FiASP-and-pramlintide system with SMA. We conducted a subsequent 12-day outpatient pilot study comparing a FiASP-and-placebo system with FCC, a FiASP-and-pramlintide system with SMA, and a FiASP-and-placebo system with SMA. Basal-bolus FiASP-and-pramlintide were delivered at a fixed ratio (1 U:10 μg). Glycaemic outcomes were measured, surveys evaluated gastrointestinal symptoms and diabetes distress, and participant interviews helped establish a preliminary coding framework to assess user experience. RESULTS Seven participants were included in the feasibility analysis. Time spent in 3.9-10 mmol/L was similar between both interventions (81%-84%). Four participants were included in the pilot analysis. Time spent in 3.9-10 mmol/L was similar between the FiASP-and-placebo with FCC and FiASP-and-pramlintide with SMA interventions (70%), but was lower in the FiASP-and-placebo with SMA intervention (60%). Time less than 3.9 mmol/L and gastrointestinal symptoms were similar across all interventions. Emotional distress was moderate at baseline, after the FiASP-and-placebo with FCC and SMA interventions, and fell after the FiASP-and-pramlintide with SMA intervention. SMA reportedly afforded participants flexibility and reduced mealtime concerns. CONCLUSIONS The FiASP-and-pramlintide system has the potential to substitute carbohydrate counting with SMA without degrading glucose control.",2021,Time spent between 3.9-10 mmol/L was similar between both interventions (81%-84%).,"['Seven participants were included in the feasibility analysis', 'Four participants were included in the pilot analysis']","['FiASP closed-loop system', 'FiASP-plus-Pramlintide Closed-Loop Delivery System (Artificial Pancreas', 'FiASP-and-placebo system with FCC, (ii) a FiASP-and-pramlintide system with SMA, and (iii) a FiASP-and-placebo system with SMA', 'FiASP system with full carbohydrate counting (FCC) to (ii) a FiASP-and-pramlintide system with simple meal announcement (SMA', 'SMA', 'FiASP-and-pramlintide closed-loop system']","['gastrointestinal symptoms', 'gastrointestinal symptoms and diabetes distress, and participant interviews helped establish a preliminary coding framework to assess user experience', 'Time spent', 'Emotional distress', 'Glycemic outcomes']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}]","[{'cui': 'C4529885', 'cui_str': 'Fiasp'}, {'cui': 'C0443183', 'cui_str': 'Closed loop'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0537551', 'cui_str': 'Pramlintide'}, {'cui': 'C0449914', 'cui_str': 'Delivery system'}, {'cui': 'C2004457', 'cui_str': 'Artificial'}, {'cui': 'C0771711', 'cui_str': 'Pancreas extract'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1562940', 'cui_str': 'Carbohydrate counting'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0439611', 'cui_str': 'Preliminary'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",4.0,0.113547,Time spent between 3.9-10 mmol/L was similar between both interventions (81%-84%).,"[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Tsoukas', 'Affiliation': 'Division of Endocrinology, McGill University Health Centre, Montreal, Canada.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Cohen', 'Affiliation': 'Division of Experimental Medicine, McGill University, Montreal, Canada.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Legault', 'Affiliation': 'The Research Institute of McGill University Health Centre, Montreal, Canada.'}, {'ForeName': 'Julia E', 'Initials': 'JE', 'LastName': 'von Oettingen', 'Affiliation': 'The Research Institute of McGill University Health Centre, Montreal, Canada.'}, {'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Yale', 'Affiliation': 'Division of Endocrinology, McGill University Health Centre, Montreal, Canada.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Vallis', 'Affiliation': 'Department of Family Medicine, Dalhousie University, Halifax, Canada.'}, {'ForeName': 'Madison', 'Initials': 'M', 'LastName': 'Odabassian', 'Affiliation': 'Department of Biomedical Engineering, McGill University, Montreal, Canada.'}, {'ForeName': 'Anas', 'Initials': 'A', 'LastName': 'El Fathi', 'Affiliation': 'Department of Biomedical Engineering, McGill University, Montreal, Canada.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Rutkowski', 'Affiliation': 'Department of Biomedical Engineering, McGill University, Montreal, Canada.'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Jafar', 'Affiliation': 'Department of Biomedical Engineering, McGill University, Montreal, Canada.'}, {'ForeName': 'Milad', 'Initials': 'M', 'LastName': 'Ghanbari', 'Affiliation': 'Department of Biomedical Engineering, McGill University, Montreal, Canada.'}, {'ForeName': 'Nikita', 'Initials': 'N', 'LastName': 'Gouchie-Provencher', 'Affiliation': 'The Research Institute of McGill University Health Centre, Montreal, Canada.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'René', 'Affiliation': 'The Research Institute of McGill University Health Centre, Montreal, Canada.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Palisaitis', 'Affiliation': 'Department of Biomedical Engineering, McGill University, Montreal, Canada.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Haidar', 'Affiliation': 'The Research Institute of McGill University Health Centre, Montreal, Canada.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14447'] 3327,34048358,Guided Relaxation-Based Virtual Reality for Acute Postoperative Pain and Anxiety in a Pediatric Population: Pilot Observational Study.,"BACKGROUND Distraction-based therapies, such as virtual reality (VR), have been used to reduce pain during acutely painful procedures. However, distraction alone cannot produce prolonged pain reduction to manage sustained postoperative pain. Therefore, the integration of VR with other pain-reducing therapies, like guided relaxation, may enhance its clinical impact. OBJECTIVE The goal of this pilot study was to assess the impact of a single guided relaxation-based VR (VR-GR) session on postoperative pain and anxiety reduction in children. We also explored the influence of pain catastrophizing and anxiety sensitivity on this association. METHODS A total of 51 children and adolescents (7-21 years) with postoperative pain and followed by the Acute Pain Service at Cincinnati Children's Hospital were recruited over an 8-month period to undergo a single VR-GR session. Prior to VR, the patients completed 2 questionnaires: Pain Catastrophizing Scale for Children (PCS-C) and the Child Anxiety Sensitivity Index (CASI). The primary outcome was a change in pain intensity following the VR-GR session (immediately, 15 minutes, and 30 minutes). The secondary outcomes included changes in pain unpleasantness and anxiety. RESULTS The VR-GR decreased pain intensity immediately (P<.001) and at 30 minutes (P=.04) after the VR session, but not at 15 minutes (P=.16) postsession. Reductions in pain unpleasantness were observed at all time intervals (P<.001 at all intervals). Anxiety was reduced immediately (P=.02) but not at 15 minutes (P=.08) or 30 minutes (P=.30) following VR-GR. Patients with higher CASI scores reported greater reductions in pain intensity (P=.04) and unpleasantness (P=.01) following VR-GR. Pain catastrophizing was not associated with changes in pain and anxiety. CONCLUSIONS A single, short VR-GR session showed transient reductions in pain intensity, pain unpleasantness, and anxiety in children and adolescents with acute postoperative pain. The results call for a future randomized controlled trial to assess the efficacy of VR-GR. TRIAL REGISTRATION ClinicalTrials.gov NCT04556747; https://clinicaltrials.gov/ct2/show/NCT04556747.",2021,Patients with higher CASI reported greater reductions in pain intensity (p = 0.04) and unpleasantness (p = 0.01) following VR-GR.,"['children', 'Pediatric Population', 'children and adolescents with acute postoperative pain', 'Acute Postoperative Pain and Anxiety', ""51 children and adolescents (7-21 years) with postoperative pain followed by the Acute Pain Service at Cincinnati Children's Hospital were recruited over an 8-month period to undergo a single VR-GR session""]","['single guided relaxation-based VR (VR-GR) session', 'Guided Relaxation-Based Virtual Reality']","['pain catastrophizing and anxiety sensitivity', 'pain and anxiety', 'pain intensity', 'Anxiety', 'postoperative pain and anxiety', 'pain catastrophizing (PCS-C) and anxiety sensitivity (CASI) questionnaires', 'pain unpleasantness and anxiety', 'Pain catastrophizing', 'pain intensity, pain unpleasantness, and anxiety', 'pain unpleasantness', 'prolonged pain reduction', 'unpleasantness']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C2215257', 'cui_str': 'Acute postoperative pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0242934', 'cui_str': 'Acute pain service'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]","[{'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C1882368', 'cui_str': 'Dynamic Light Scattering'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",51.0,0.108751,Patients with higher CASI reported greater reductions in pain intensity (p = 0.04) and unpleasantness (p = 0.01) following VR-GR.,"[{'ForeName': 'Vanessa A', 'Initials': 'VA', 'LastName': 'Olbrecht', 'Affiliation': ""Center for Understanding Pediatric Pain, Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Keith T', 'Initials': 'KT', 'LastName': ""O'Conor"", 'Affiliation': ""Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Sara E', 'Initials': 'SE', 'LastName': 'Williams', 'Affiliation': ""Center for Understanding Pediatric Pain, Division of Behavioral Medicine and Clinical Psychology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Chloe O', 'Initials': 'CO', 'LastName': 'Boehmer', 'Affiliation': ""Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Gilbert W', 'Initials': 'GW', 'LastName': 'Marchant', 'Affiliation': ""Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Glynn', 'Affiliation': ""Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Kristie J', 'Initials': 'KJ', 'LastName': 'Geisler', 'Affiliation': ""Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Ding', 'Affiliation': ""Division of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': ""Division of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'King', 'Affiliation': ""Center for Understanding Pediatric Pain, Division of Behavioral Medicine and Clinical Psychology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}]",Journal of medical Internet research,['10.2196/26328'] 3328,34050972,"Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.","Chronic lymphocytic leukemia (CLL)-related symptoms impair the well-being of patients, making improvement of health-related quality of life (QoL) a goal of treatment. The CLL14 trial demonstrated higher efficacy of fixed-duration venetoclax-obinutuzumab (Ven-Obi) compared to chlorambucil-obinutuzumab (Clb-Obi) in patients with previously untreated CLL. To assess patients' QoL, the following patient-reported outcomes (PRO) measures were assessed: the M.D. Anderson Symptom Inventory (MDASI) core instrument and CLL module and the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). At treatment start, physical functioning (mean 75.9 [standard deviation (SD) ± 20.1] in the Clb-Obi arm and 76.9 [±19.4] in the Ven-Obi arm), role functioning (73.6 [±27.86] and 72.6 [±26.9]) and GHS/QoL (63.6 [±21.0] and 60.3 [±20.5]) were comparable between treatment arms per EORTC QLQ-C30 scale scores. Baseline levels of physical and role functioning were maintained throughout treatment and follow-up, with no relevant improvement or deterioration. On average, patients treated with Ven-Obi showed a meaningful improvement of GHS/QoL during treatment and follow-up by at least eight points at cycle three, whereas improvement was delayed until cycle eight with Clb-Obi. According to MDASI scores, CLL symptoms (1.5 [±1.2] and 1.6 [±1.3]), core cancer symptoms (1.5 [±1.4] and 1.8 [±1.7]) and symptom interference (2.1 [±2.3] and 2.3 [±2.3]) were generally low and comparable between treatment arms at baseline and were maintained throughout treatment and follow-up. This analysis demonstrates that the higher efficacy of Ven-Obi is not associated with QoL impairment and that Ven-Obi achieves early relief of CLL-related symptoms in elderly unfit patients.",2021,"On average, patients treated with Ven-Obi showed a meaningful improvement of GHS/QoL during treatment and follow-up by at least 8 points at cycle 3, whereas improvement was delayed until cycle 8 with Clb-Obi.","['previously untreated chronic lymphocytic leukemia', 'patients with previously untreated CLL', 'elderly unfit patients']","['fixed-duration venetoclax-obinutuzumab', 'chlorambucil-obinutuzumab']","['per EORTC QLQ-C30 scale scores', 'symptom interference', 'role functioning', 'GHS/QoL', 'MDASI scores, CLL symptoms', 'Baseline levels of physical and role functioning', 'Chronic lymphocytic leukemia (CLL)-related symptoms', 'meaningful improvement of GHS/QoL', 'M.D. Anderson Symptom Inventory (MDASI) core instrument and CLL module and the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30', 'physical functioning', 'core cancer symptoms']","[{'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0023434', 'cui_str': 'Chronic lymphocytic leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C4079830', 'cui_str': 'venetoclax'}, {'cui': 'C2742503', 'cui_str': 'obinutuzumab'}, {'cui': 'C0008163', 'cui_str': 'Chlorambucil'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0023434', 'cui_str': 'Chronic lymphocytic leukemia'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0451149', 'cui_str': 'EORTC - Quality of life questionnaire'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]",,0.0508934,"On average, patients treated with Ven-Obi showed a meaningful improvement of GHS/QoL during treatment and follow-up by at least 8 points at cycle 3, whereas improvement was delayed until cycle 8 with Clb-Obi.","[{'ForeName': 'Othman', 'Initials': 'O', 'LastName': 'Al-Sawaf', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Gentile', 'Affiliation': 'Genentech Inc, South San Francisco, California, USA.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Devine', 'Affiliation': 'Genentech Inc, South San Francisco, California, USA.'}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Kavita', 'Initials': 'K', 'LastName': 'Sail', 'Affiliation': 'AbbVie Inc., North Chicago, Illinois, USA.'}, {'ForeName': 'Maneesh', 'Initials': 'M', 'LastName': 'Tandon', 'Affiliation': 'Roche Products Limited, Welwyn Garden City, UK.'}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Fink', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Kutsch', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Clemens-Martin', 'Initials': 'CM', 'LastName': 'Wendtner', 'Affiliation': 'Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Eichhorst', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Fischer', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany.'}]",American journal of hematology,['10.1002/ajh.26260'] 3329,34033212,Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.,"AIMS To assess the efficacy, safety and tolerability of ipragliflozin 50 mg once daily added to sitagliptin 50 mg once daily monotherapy in Japanese patients with type 2 diabetes (T2D). MATERIALS AND METHODS The results of two clinical trials are reported. In both trials, patients had glycated haemoglobin (HbA1c) levels of 7.0% to 10.0% on sitagliptin 50 mg once daily 2 weeks prior to addition of ipragliflozin or placebo. In one trial (Trial 843), patients were randomized 1:1 to addition of blinded ipragliflozin 50 mg once daily (n = 73) or placebo (n = 70) for 24 weeks; the primary endpoint was efficacy (change in HbA1c at Week 24). In the other trial (Trial 849), open-label ipragliflozin 50 mg once daily was added for 52 weeks (n = 77); the primary objective was to assess safety/tolerability. RESULTS In Trial 843, baseline characteristics were similar between groups (mean age 60.5 years, HbA1c 8.0%); after 24 weeks, adding ipragliflozin provided significantly greater reduction in HbA1c compared to placebo: least squares mean difference -0.77% (95% confidence interval -0.98, -0.57; P <0.001). In Trial 843, the incidences of adverse events (AEs) overall and prespecified AEs of clinical interest (symptomatic hypoglycaemia, urinary tract infection, genital infection, hypovolaemia, and polyuria/pollakiuria) were similar between groups. In Trial 849, specific AEs with incidence ≥5% were nasopharyngitis, pollakiuria, back pain, thirst, constipation, influenza and arthralgia; drug-related AEs reported in ≥2 patients were pollakiuria, thirst and constipation. CONCLUSIONS Ipragliflozin 50 mg once daily added on to sitagliptin 50 mg once daily monotherapy provided significant improvement in glycaemic control and was generally well tolerated in Japanese patients with T2D. ClinicalTrials.gov: NCT02577003, NCT02564211.",2021,"CONCLUSIONS Ipragliflozin","['Japanese patients', 'Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control on Sitagliptin', 'Japanese patients with type 2 diabetes (T2D']","['blinded ipragliflozin 50 mg q.d', 'ipragliflozin', 'ipragliflozin or placebo', 'sitagliptin', 'monotherapy', 'Ipragliflozin', 'placebo', 'open-label ipragliflozin', 'sitagliptin 50 mg q.d']","['incidences of adverse events (AEs) overall and prespecified AEs of clinical interest (symptomatic hypoglycemia, urinary tract infection, genital infection, hypovolemia, and polyuria/pollakiuria', 'Efficacy and Safety', 'safety/tolerability', 'glycemic control', 'nasopharyngitis, pollakiuria, back pain, thirst, constipation, influenza, and arthralgia; drug-related AEs', 'efficacy, safety, and tolerability']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C3492889', 'cui_str': 'ipragliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1812990', 'cui_str': 'sitagliptin 50 MG'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0729552', 'cui_str': 'Genital infection'}, {'cui': 'C0546884', 'cui_str': 'Hypovolemia'}, {'cui': 'C0032617', 'cui_str': 'Polyuria'}, {'cui': 'C0042023', 'cui_str': 'Increased frequency of urination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0039971', 'cui_str': 'Thirst'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",849.0,0.487545,"CONCLUSIONS Ipragliflozin","[{'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Kaku', 'Affiliation': 'Kawasaki Medical School, Okayama, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kadowaki', 'Affiliation': 'Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Yutaka', 'Initials': 'Y', 'LastName': 'Seino', 'Affiliation': 'Kansai Electric Power Hospital, Osaka, Japan.'}, {'ForeName': 'Taro', 'Initials': 'T', 'LastName': 'Okamoto', 'Affiliation': 'Japan Development, MSD K.K, Tokyo, Japan.'}, {'ForeName': 'Masayoshi', 'Initials': 'M', 'LastName': 'Shirakawa', 'Affiliation': 'Japan Development, MSD K.K, Tokyo, Japan.'}, {'ForeName': 'Asako', 'Initials': 'A', 'LastName': 'Sato', 'Affiliation': 'Japan Development, MSD K.K, Tokyo, Japan.'}, {'ForeName': 'Edward A', 'Initials': 'EA', 'LastName': ""O'Neill"", 'Affiliation': 'Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Samuel S', 'Initials': 'SS', 'LastName': 'Engel', 'Affiliation': 'Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Keith D', 'Initials': 'KD', 'LastName': 'Kaufman', 'Affiliation': 'Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14448'] 3330,34047220,The impact of emotion regulation therapy on emotion differentiation in psychologically distressed caregivers of cancer patients.,"BACKGROUND AND OBJECTIVES Emotion differentiation is considered adaptive because differentiated emotional experiences are believed to promote access to the information that emotions carry, enabling context-appropriate emotion regulation. In the present study, secondary analyses from a recent randomized controlled trial (O'Toole et al., 2019) were conducted to investigate whether emotion differentiation can improve as a result of psychotherapy and whether improvements in emotion differentiation are associated with reduced distress. DESIGN AND METHODS A total of 81 distressed caregivers of cancer patients were randomized to Emotion Regulation Therapy (ERT), an intervention aimed at improving emotion differentiation and facilitating healthy emotion regulation, or a waitlist condition. Emotion differentiation scores could be calculated for 54 caregivers. RESULTS Repeated measures ANOVAs revealed that ERT led to significant improvements in negative ( η 2   = 0.21, p  = .012), but not positive emotion differentiation ( η 2  = <0.01, p  = .973). Correlation analyses showed that improvements in negative emotion differentiation were not associated with changes in distress. CONCLUSIONS The results suggest that negative emotion differentiation can improve as a result of psychotherapy. Further research is needed to clarify how improvements in emotion differentiation following therapeutic interventions relate to treatment outcomes such as distress. Trial registration: ClinicalTrials.gov identifier: NCT02322905.",2021,"RESULTS Repeated measures ANOVAs revealed that ERT led to significant improvements in negative ( η 2   = 0.21, ","['psychologically distressed caregivers of cancer patients', '81 distressed caregivers of cancer patients']","['ERT', 'Emotion Regulation Therapy (ERT), an intervention aimed at improving emotion differentiation and facilitating healthy emotion regulation, or a waitlist condition', 'emotion regulation therapy']","['Emotion differentiation scores', 'positive emotion differentiation', 'negative emotion differentiation']","[{'cui': 'C3887804', 'cui_str': 'Feeling upset'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0007589', 'cui_str': 'Differentiation, Cell'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0007589', 'cui_str': 'Differentiation, Cell'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}]",81.0,0.132188,"RESULTS Repeated measures ANOVAs revealed that ERT led to significant improvements in negative ( η 2   = 0.21, ","[{'ForeName': 'Mai B', 'Initials': 'MB', 'LastName': 'Mikkelsen', 'Affiliation': 'Department of Psychology and Behavioural Sciences, Aarhus University, Denmark.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Elkjær', 'Affiliation': 'Department of Psychology and Behavioural Sciences, Aarhus University, Denmark.'}, {'ForeName': 'Douglas S', 'Initials': 'DS', 'LastName': 'Mennin', 'Affiliation': 'Department of Psychology, Teachers College, Columbia University, New York, NY, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Fresco', 'Affiliation': 'Department of Psychiatry, Research Professor, Institute for Social Research, University of Michigan, Ann Arbor, MI, US.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Zachariae', 'Affiliation': 'Department of Psychology and Behavioural Sciences, Aarhus University, Denmark.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Applebaum', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Mia S', 'Initials': 'MS', 'LastName': ""O'Toole"", 'Affiliation': 'Department of Psychology and Behavioural Sciences, Aarhus University, Denmark.'}]","Anxiety, stress, and coping",['10.1080/10615806.2021.1929934'] 3331,33999548,Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.,"BACKGROUND The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy. METHODS Using an open-label, pragmatic design, we randomly assigned patients with established atherosclerotic cardiovascular disease to a strategy of 81 mg or 325 mg of aspirin per day. The primary effectiveness outcome was a composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis. The primary safety outcome was hospitalization for major bleeding, also assessed in a time-to-event analysis. RESULTS A total of 15,076 patients were followed for a median of 26.2 months (interquartile range [IQR], 19.0 to 34.9). Before randomization, 13,537 (96.0% of those with available information on previous aspirin use) were already taking aspirin, and 85.3% of these patients were previously taking 81 mg of daily aspirin. Death, hospitalization for myocardial infarction, or hospitalization for stroke occurred in 590 patients (estimated percentage, 7.28%) in the 81-mg group and 569 patients (estimated percentage, 7.51%) in the 325-mg group (hazard ratio, 1.02; 95% confidence interval [CI], 0.91 to 1.14). Hospitalization for major bleeding occurred in 53 patients (estimated percentage, 0.63%) in the 81-mg group and 44 patients (estimated percentage, 0.60%) in the 325-mg group (hazard ratio, 1.18; 95% CI, 0.79 to 1.77). Patients assigned to 325 mg had a higher incidence of dose switching than those assigned to 81 mg (41.6% vs. 7.1%) and fewer median days of exposure to the assigned dose (434 days [IQR, 139 to 737] vs. 650 days [IQR, 415 to 922]). CONCLUSIONS In this pragmatic trial involving patients with established cardiovascular disease, there was substantial dose switching to 81 mg of daily aspirin and no significant differences in cardiovascular events or major bleeding between patients assigned to 81 mg and those assigned to 325 mg of aspirin daily. (Funded by the Patient-Centered Outcomes Research Institute; ADAPTABLE ClinicalTrials.gov number, NCT02697916.).",2021,"Hospitalization for major bleeding occurred in 53 patients (estimated percentage, 0.63%) in the 81-mg group and 44 patients (estimated percentage, 0.60%) in the 325-mg group (hazard ratio, 1.18; 95% CI, 0.79 to 1.77).","['patients with established atherosclerotic cardiovascular disease', 'patients with established cardiovascular disease', 'Cardiovascular Disease']","['aspirin', 'Aspirin']","['cardiovascular events or major bleeding', 'Death, hospitalization for myocardial infarction, or hospitalization for stroke', 'hospitalization for major bleeding, also assessed in a time-to-event analysis', 'Hospitalization for major bleeding', 'composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205199', 'cui_str': 'Composite'}]",15076.0,0.237885,"Hospitalization for major bleeding occurred in 53 patients (estimated percentage, 0.63%) in the 81-mg group and 44 patients (estimated percentage, 0.60%) in the 325-mg group (hazard ratio, 1.18; 95% CI, 0.79 to 1.77).","[{'ForeName': 'W Schuyler', 'Initials': 'WS', 'LastName': 'Jones', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Hillary', 'Initials': 'H', 'LastName': 'Mulder', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Wruck', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Pencina', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Kripalani', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Muñoz', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Crenshaw', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Mark B', 'Initials': 'MB', 'LastName': 'Effron', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Richard N', 'Initials': 'RN', 'LastName': 'Re', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Kamal', 'Initials': 'K', 'LastName': 'Gupta', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'R David', 'Initials': 'RD', 'LastName': 'Anderson', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Carl J', 'Initials': 'CJ', 'LastName': 'Pepine', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': 'Handberg', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Brittney R', 'Initials': 'BR', 'LastName': 'Manning', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Sandeep K', 'Initials': 'SK', 'LastName': 'Jain', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Saket', 'Initials': 'S', 'LastName': 'Girotra', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Riley', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Darren A', 'Initials': 'DA', 'LastName': 'DeWalt', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Whittle', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Ythan H', 'Initials': 'YH', 'LastName': 'Goldberg', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Veronique L', 'Initials': 'VL', 'LastName': 'Roger', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Hess', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Catherine P', 'Initials': 'CP', 'LastName': 'Benziger', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Farrehi', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhou', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Ford', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Haynes', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'VanWormer', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Kirk U', 'Initials': 'KU', 'LastName': 'Knowlton', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Kraschnewski', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Tamar S', 'Initials': 'TS', 'LastName': 'Polonsky', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Dan J', 'Initials': 'DJ', 'LastName': 'Fintel', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Faraz S', 'Initials': 'FS', 'LastName': 'Ahmad', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'McClay', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Campbell', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Douglas S', 'Initials': 'DS', 'LastName': 'Bell', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Gregg C', 'Initials': 'GC', 'LastName': 'Fonarow', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Bradley', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Anuradha', 'Initials': 'A', 'LastName': 'Paranjape', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Roe', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Holly R', 'Initials': 'HR', 'LastName': 'Robertson', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Lesley H', 'Initials': 'LH', 'LastName': 'Curtis', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Amber G', 'Initials': 'AG', 'LastName': 'Sharlow', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Lisa G', 'Initials': 'LG', 'LastName': 'Berdan', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Bradley G', 'Initials': 'BG', 'LastName': 'Hammill', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Debra F', 'Initials': 'DF', 'LastName': 'Harris', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Laura G', 'Initials': 'LG', 'LastName': 'Qualls', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Marquis-Gravel', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Madelaine F', 'Initials': 'MF', 'LastName': 'Modrow', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Gregory M', 'Initials': 'GM', 'LastName': 'Marcus', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Carton', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Nauman', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Lemuel R', 'Initials': 'LR', 'LastName': 'Waitman', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Abel N', 'Initials': 'AN', 'LastName': 'Kho', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Shenkman', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'McTigue', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Rainu', 'Initials': 'R', 'LastName': 'Kaushal', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Frederick A', 'Initials': 'FA', 'LastName': 'Masoudi', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Elliott M', 'Initials': 'EM', 'LastName': 'Antman', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Desiree R', 'Initials': 'DR', 'LastName': 'Davidson', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Edgley', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Merritt', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Linda S', 'Initials': 'LS', 'LastName': 'Brown', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Doris N', 'Initials': 'DN', 'LastName': 'Zemon', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'McCormick', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Jacqueline D', 'Initials': 'JD', 'LastName': 'Alikhaani', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Kenneth C', 'Initials': 'KC', 'LastName': 'Gregoire', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Russell L', 'Initials': 'RL', 'LastName': 'Rothman', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Harrington', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': 'Adrian F', 'Initials': 'AF', 'LastName': 'Hernandez', 'Affiliation': ""From Duke Clinical Research Institute, Duke University, Durham (W.S.J., H.M., L.M.W., M.J.P., M.T.R., H.R.R., L.H.C., A.G.S., L.G.B., B.G.H., D.F.H., L.G.Q., G.M.-G., A.F.H.), University of North Carolina at Chapel Hill, Chapel Hill (D.A.D.), and Wake Forest University School of Medicine, Winston-Salem (L.Z.) - all in North Carolina; Vanderbilt University Medical Center, Nashville (S.K., D.M., D.L.C., R.L.R.); Ochsner Health (M.B.E., R.N.R.) and Louisiana Public Health Institute (T.W.C., E.N.) - both in New Orleans; University of Kansas Medical Center, Kansas City (K.G.); University of Florida, Gainesville (R.D.A., C.J.P., E.M.H., B.R.M., E.A.S.); University of Pittsburgh Medical Center, Pittsburgh (S.K.J., K.M.M.), Penn State College of Medicine, Hershey (J.L.K.), and Temple University, Philadelphia (A.P.) - all in Pennsylvania; University of Iowa, Iowa City (S.G., D.R.); Medical College of Wisconsin, Milwaukee (J.W.), and Marshfield Clinic Research Institute, Marshfield (J.J.V.) - both in Wisconsin; Albert Einstein College of Medicine, Bronx (Y.H.G.), and Weill Cornell Medicine and New York-Presbyterian Hospital, New York (R.K.) - both in New York; Mayo Clinic, Rochester (V.L.R.), Essentia Health Heart and Vascular Center, Duluth (C.P.B.), and Allina Health and Minneapolis Heart Institute, Minneapolis (S.M.B.) - all in Minnesota; University of Utah School of Medicine (R.H.) and Intermountain Medical Center Heart Institute (K.U.K.) - both in Salt Lake City; University of Michigan, Ann Arbor (P.F.); Johns Hopkins University School of Medicine, Baltimore (D.E.F.); HealthCore, Wilmington, DE (K.H.); University of Chicago Medicine (T.S.P.) and Northwestern University Feinberg School of Medicine (D.J.F., F.S.A., A.M.K.) - both in Chicago; University of Nebraska Medical Center, Omaha (J.C.M., J.R.C.); University of California, Los Angeles, Los Angeles (D.S.B., G.C.F.), University of California, San Francisco, San Francisco (M.F.M., G.M.M.), and Stanford University School of Medicine, Stanford (R.A.H.) - all in California; University of Missouri School of Medicine, Columbia (L.R.W.); University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (F.A.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.M.A.); Chicago (D.R.D.); St. Joseph, MO (K.E.); Brighton, MI (J.G.M.); Columbia, TN (L.S.B.); Alachua, FL (D.N.Z.); Columbia, MD (T.E.M.); North Hills, CA (J.D.A.); and Metairie, LA (K.C.G.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2102137'] 3332,34037323,Effect of open versus closed endotracheal suctioning on intracranial pressure in severe brain-injured children: Study protocol for a randomized controlled trial.,"AIM To compare the effects and safety of open and closed endotracheal suction in children with severe brain injury. DESIGN A single-blinding, single-centre randomized controlled trial (RCT). METHODS The children with severe brain injury admitted to the intensive care unit (ICU) from 1 September 2020-31 August 2022 will be included. And a total of 172 children with severe brain injury are expected to be included. The intracranial pressure, SpO 2 and heart rate before suctioning, at the end of suction, and at 5 and 10 min after suction, the estimated sputum volume for each suction, the incidence of ventilator-associated pneumonia, the duration of mechanical ventilation and the length of ICU stay will be analysed. RESULTS This present RCT has been prospectively registered in China Clinical Trial Registry (http://www.chictr.org.cn, ChiCTR2000030963). This present study is expected to provide reliable evidence to the airway management in children with severe brain injury.",2021,"The intracranial pressure, SpO 2 and heart rate before suctioning, at the end of suction, and at 5 and 10 min after suction, the estimated sputum volume for each suction, the incidence of ventilator-associated pneumonia, the duration of mechanical ventilation and the length of ICU stay will be analysed. ","['172 children with severe brain injury', 'severe brain-injured children', 'children with severe brain injury admitted to the intensive care unit (ICU) from 1 September 2020-31 August 2022 will be included', 'children with severe brain injury']","['open and closed endotracheal suction', 'open versus closed endotracheal suctioning']","['intracranial pressure', 'duration of mechanical ventilation and the length of ICU stay', 'intracranial pressure, SpO 2 and heart rate']","[{'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}]","[{'cui': 'C0021880', 'cui_str': 'Intracranial pressure'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",172.0,0.114583,"The intracranial pressure, SpO 2 and heart rate before suctioning, at the end of suction, and at 5 and 10 min after suction, the estimated sputum volume for each suction, the incidence of ventilator-associated pneumonia, the duration of mechanical ventilation and the length of ICU stay will be analysed. ","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""SICU, Children's Hospital of Nanjing Medical University, Nanjing City, China.""}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ""SICU, Children's Hospital of Nanjing Medical University, Nanjing City, China.""}, {'ForeName': 'Zunjia', 'Initials': 'Z', 'LastName': 'Wen', 'Affiliation': ""SICU, Children's Hospital of Nanjing Medical University, Nanjing City, China.""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""SICU, Children's Hospital of Nanjing Medical University, Nanjing City, China.""}, {'ForeName': 'Yingfei', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""SICU, Children's Hospital of Nanjing Medical University, Nanjing City, China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wei', 'Affiliation': ""SICU, Children's Hospital of Nanjing Medical University, Nanjing City, China.""}]",Nursing open,['10.1002/nop2.656'] 3333,34037282,Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.,"BACKGROUND This analysis investigated whether baseline characteristics affect the survival benefit derived from palbociclib-fulvestrant and the optimal timing of cyclin-dependent kinase 4/6 inhibitor therapy for advanced breast cancer (ABC) in patients from PALOMA-3. PATIENTS AND METHODS In total, 521 patients were randomized 2:1 to receive palbociclib (125 mg/day, 3/1 schedule)-fulvestrant (500 mg, intramuscular injection, on days 1 and 15 of cycle 1, and then day 1 of each subsequent cycle) or matching placebo-fulvestrant. Median overall survival (OS) and progression-free survival were estimated using the Kaplan-Meier method. RESULTS Multivariable analysis identified endocrine sensitivity, nonvisceral disease, no prior chemotherapy for ABC, and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 as significant prognostic factors for OS. Patients without chemotherapy for ABC had fewer prior lines of treatment in any setting and in the ABC setting versus patients with prior chemotherapy for ABC (two or fewer prior systemic therapies: 69% vs. 42%; no more than one prior line for ABC: 82% vs. 33%, respectively). Median OS was prolonged with palbociclib-fulvestrant in patients without prior chemotherapy for ABC (39.7 vs. 29.5 months; hazard ratio, 0.75; 95% confidence interval [CI]: 0.56-1.01) and was similar in patients with prior chemotherapy for ABC (25.6 vs. 26.2 months; hazard ratio, 0.91 [95% CI: 0.63-1.32]) versus placebo-fulvestrant. CONCLUSION Prognostic factors for OS included endocrine sensitivity, nonvisceral disease, ECOG PS of 0, and no prior chemotherapy for ABC. Exploratory analyses suggest improved OS with palbociclib-fulvestrant versus placebo-fulvestrant in patients with no prior chemotherapy for ABC, prior endocrine sensitivity, and fewer prior regimens of systemic therapy. (Clinical trial identification number: NCT01942135). IMPLICATIONS FOR PRACTICE Prognostic factors for overall survival in HR+/HER2- advanced breast cancer (ABC) include the absence of prior chemotherapy in the advanced setting, endocrine sensitivity, nonvisceral disease, and an ECOG performance status of 0. Improved overall survival benefit was observed with palbociclib-fulvestrant versus placebo-fulvestrant in patients (regardless of menopausal status or visceral involvement) with no prior chemotherapy for ABC, with prior endocrine sensitivity, and fewer prior regimens of systemic therapy. Progression-free survival was prolonged with palbociclib across subgroups (regardless of chemotherapy exposure in ABC). These exploratory findings suggest that patients may receive greater clinical benefit from palbociclib-fulvestrant if they receive the combination before chemotherapy in the advanced setting.",2021,"Exploratory analyses suggest improved OS with palbociclib-fulvestrant versus placebo-fulvestrant in patients with no prior chemotherapy for ABC, prior endocrine sensitivity, and fewer prior regimens of systemic therapy.","['patients (regardless of menopausal status or visceral involvement) with no prior chemotherapy for advanced breast cancer', 'patients with no prior chemotherapy for ABC, prior endocrine sensitivity, and fewer prior regimens of systemic therapy', 'advanced breast cancer (ABC) in patients from PALOMA-3', 'Patients With Hormone Receptor-Positive Advanced Breast Cancer', '521 patients']","['palbociclib', 'placebo-fulvestrant', 'palbociclib-fulvestrant', 'placebo plus fulvestrant']","['Median overall survival (OS) and progression-free survival (PFS', 'Median OS', 'overall survival benefit', 'Progression-free survival', 'Overall Survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",521.0,0.301802,"Exploratory analyses suggest improved OS with palbociclib-fulvestrant versus placebo-fulvestrant in patients with no prior chemotherapy for ABC, prior endocrine sensitivity, and fewer prior regimens of systemic therapy.","[{'ForeName': 'Hope S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'Department of Medicine (Hematology/Oncology), University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Cristofanilli', 'Affiliation': 'Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Sybille', 'Initials': 'S', 'LastName': 'Loibl', 'Affiliation': 'Department of Medicine and Research, German Breast Group, Neu-Isenburg, Germany.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Harbeck', 'Affiliation': 'Department of Obstetrics and Gynecology, Breast Center, University of Munich, Munich, Germany.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'DeMichele', 'Affiliation': 'Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Hiroji', 'Initials': 'H', 'LastName': 'Iwata', 'Affiliation': 'Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Yoon Hee', 'Initials': 'YH', 'LastName': 'Park', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Brufsky', 'Affiliation': 'Division of Hematology/Oncology, Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Kathy Puyana', 'Initials': 'KP', 'LastName': 'Theall', 'Affiliation': 'Oncology Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Biostatistics, Pfizer Inc, San Diego, California, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'McRoy', 'Affiliation': 'U.S. Medical Affairs, Pfizer Inc, New York, New York, USA.'}, {'ForeName': 'Eustratios', 'Initials': 'E', 'LastName': 'Bananis', 'Affiliation': 'U.S. Medical Affairs, Pfizer Inc, New York, New York, USA.'}, {'ForeName': 'Nicholas C', 'Initials': 'NC', 'LastName': 'Turner', 'Affiliation': 'Department of Molecular Oncology, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.'}]",The oncologist,['10.1002/onco.13833'] 3334,34023739,Managing the experience of breathlessness with Tai Chi: A qualitative analysis from a randomized controlled trial in COPD.,"PURPOSE Chronic obstructive pulmonary disease (COPD) is associated with dyspnea, decreased physical activity, and reduced quality-of-life. While pulmonary rehabilitation is helpful, maintenance of physical activity afterwards is problematic. We sought to explore qualitatively the multi-dimensional, biopsychosocial experience of patients with COPD who participated in Tai Chi (TC) vs. group walking to facilitate physical activity after pulmonary rehabilitation). METHODS We analyzed semi-structured qualitative exit interviews (N = 81) from a randomized controlled trial comparing 6-months TC with a time-matched group walking intervention and usual care control (UC). Transcripts were reviewed by at least 2 independent reviewers utilizing a social constructivist framework and theoretical sampling approach. An in-depth analysis of an exemplar subset was performed to thematic saturation and captured emergent themes within and between groups. RESULTS Focused analysis was conducted on 54 transcripts (N = 21 TC, N = 16 Walking, N = 17 UC). Participants were characterized by mean age 68.5 (±8.3) years, GOLD Stage = 3.0 (IQR 2.0-3.0), baseline FEV 1 percent predicted 48.8% (±16.4), and 48.2% female. We identified predominant themes of breathlessness, and associated fear and embarrassment that limited physical activity across all groups. In both TC and walking, participants reported improvements in energy and endurance. Those in TC additionally shared improvements in breathing, mobility, and capacity for daily activities facilitated by body and breath awareness, emotional control and regulation of breathing, and an adaptive reframing of breathlessness. CONCLUSION TC promoted physical and mental wellbeing by diminishing fear and embarrassment associated with breathlessness. Results highlight the multimodal characteristics of TC that may facilitate continued physical activity and improvement in quality of life.",2021,"We identified predominant themes of breathlessness, and associated fear and embarrassment that limited physical activity across all groups.","['Participants were characterized by mean age 68.5 (±8.3) years, GOLD Stage\xa0=\xa03.0 (IQR 2.0-3.0), baseline FEV 1 percent predicted 48.8% (±16.4), and 48.2% female', 'Chronic obstructive pulmonary disease (COPD', 'patients with COPD who participated in']","['6-months TC with a time-matched group walking intervention and usual care control (UC', 'Tai Chi (TC) vs. group walking to facilitate physical activity after pulmonary rehabilitation']","['energy and endurance', 'quality of life', 'physical and mental wellbeing', 'breathing, mobility, and capacity for daily activities facilitated by body and breath awareness, emotional control and regulation of breathing, and an adaptive reframing of breathlessness']","[{'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C5191314', 'cui_str': '48.2'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0024908', 'cui_str': 'Matched Groups'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376403', 'cui_str': 'Tai-chi'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}]","[{'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}]",81.0,0.0590043,"We identified predominant themes of breathlessness, and associated fear and embarrassment that limited physical activity across all groups.","[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Gilliam', 'Affiliation': 'Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA, USA. Electronic address: egilliam@bidmc.harvard.edu.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Kilgore', 'Affiliation': 'School of Special Education, School Psychology, and Early Childhood Studies, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Yuchen', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Bernier', 'Affiliation': 'Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA, USA.'}, {'ForeName': 'Shana', 'Initials': 'S', 'LastName': 'Criscitiello', 'Affiliation': 'Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Litrownik', 'Affiliation': ""Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA, USA; Osher Center for Integrative Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Wayne', 'Affiliation': ""Osher Center for Integrative Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Marilyn L', 'Initials': 'ML', 'LastName': 'Moy', 'Affiliation': 'Pulmonary and Critical Care Medicine Section, Department of Medicine, Veterans Administration Boston Healthcare System, Boston, MA, USA and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Gloria Y', 'Initials': 'GY', 'LastName': 'Yeh', 'Affiliation': ""Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA, USA; Osher Center for Integrative Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}]",Respiratory medicine,['10.1016/j.rmed.2021.106463'] 3335,34058423,Randomized controlled trial of single-use negative-pressure wound therapy dressings in morbidly obese patients undergoing cesarean delivery.,"BACKGROUND The single-use negative-pressure wound therapy dressings are designed to use over a closed surgical wound. Early prospective studies suggested that these dressings may be of potential benefit in reducing cesarean wound complications. OBJECTIVE This study aimed to test the hypothesis that incisional negative-pressure wound therapy decreases postoperative wound morbidity compared with standard surgical dressing in patients with class III obesity undergoing cesarean delivery. STUDY DESIGN In a single-site, parallel, randomized controlled trial, participants with class III obesity (body mass index ≥40 kg/m 2 ) were recruited to participate in the study. Patients were consented in the ambulatory obstetrical units, on admission to the antepartum service, and on labor and delivery before active labor. Patients who had a cesarean delivery were randomized to either the standard surgical dressing or a prophylactic negative-pressure wound therapy device. The randomization was achieved using permuted blocks of 4, 6, and 8 in a 1:1 allocation ratio. The primary outcome was a composite outcome of wound complications. The planned enrollment of 242 subjects was based on the power to detect a 50% decrease in the composite wound outcome, assuming a 30% baseline wound morbidity rate for this population. The outcomes were assessed by study staff blinded to the patient's treatment arm. RESULTS An unplanned interim analysis was performed because of the slow enrollment and publication of larger trials showing no benefit of the negative-pressure wound therapy. Of 411 eligible patients during the study period, 212 participants with class III obesity were enrolled. Of these, 110 underwent cesarean delivery and were subsequently randomized (55 to standard dressing and 55 to prophylactic negative-pressure wound therapy device). The primary outcome occurred in 29.1% in the standard surgical dressing compared with 20% in the negative-pressure wound therapy group (risk difference, 9.1%; 95% confidence interval, -8.3 to 25.8%; P=.38). The study was stopped early because of a low enrollment rate and lower likelihood of seeing a clinically significant benefit. CONCLUSION The trial was stopped after an unplanned, interim analysis showed the use of a prophylactic negative-pressure wound therapy device used for cesarean delivery did not reduce wound complications compared with a standard surgical dressing.",2021,"The primary outcome occurred in 29.1% in the standard surgical dressing compared with 20.0% in the negative pressure wound therapy group (risk difference 9.1%, 95% confidence interval -8.3 to 25.8%, p = 0.38).","['110 underwent cesarean delivery', 'Patients who had a cesarean delivery', 'patients with class III obesity undergoing cesarean delivery', 'participants with class III obesity (body mass index 40 kg/m 2 or higher) were recruited to participate in the study', 'Morbidly Obese Patients Undergoing Cesarean Delivery', 'Patients were consented in the ambulatory obstetric units, on admission to the antepartum service, and on labor and delivery prior to active labor', '411 eligible patients during the study period, 212 participants with class III obesity were enrolled', '242 subjects']","['incisional negative pressure wound therapy', 'standard surgical dressing', 'standard surgical dressing or a prophylactic negative pressure wound therapy device', 'standard dressing and 55 to prophylactic negative pressure wound therapy device', 'Single-Use Negative Pressure Wound Therapy Dressings']","['standard surgical dressing', 'wound complications', 'wound morbidity rate', 'postoperative wound morbidity', 'composite outcome of wound complications']","[{'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0457453', 'cui_str': 'On admission'}, {'cui': 'C0456336', 'cui_str': 'Antepartum'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0233081', 'cui_str': 'Normal labor'}]","[{'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3653515', 'cui_str': 'SURGICAL DRESSINGS'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3653515', 'cui_str': 'SURGICAL DRESSINGS'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",212.0,0.12175,"The primary outcome occurred in 29.1% in the standard surgical dressing compared with 20.0% in the negative pressure wound therapy group (risk difference 9.1%, 95% confidence interval -8.3 to 25.8%, p = 0.38).","[{'ForeName': 'Ashley T', 'Initials': 'AT', 'LastName': 'Peterson', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA (Drs Peterson, Bakaysa and House). Electronic address: apeterson@tuftsmedicalcenter.org.'}, {'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Bakaysa', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA (Drs Peterson, Bakaysa and House); Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Hartford Hospital, Hartford, CT (Dr Bakaysa).'}, {'ForeName': 'Janelle M', 'Initials': 'JM', 'LastName': 'Driscoll', 'Affiliation': 'Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA (Dr Driscoll and Ms Kalyanaraman).'}, {'ForeName': 'Rajeshwari', 'Initials': 'R', 'LastName': 'Kalyanaraman', 'Affiliation': 'Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA (Dr Driscoll and Ms Kalyanaraman); Department of Obstetrics and Gynecology, Saint Francis Hospital and Medical Center, Hartford, CT (Ms Kalyanaraman).'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'House', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA (Drs Peterson, Bakaysa and House); Mother Infant Research Institute, Tufts Medical Center, Boston, MA (Dr House).'}]",American journal of obstetrics & gynecology MFM,['10.1016/j.ajogmf.2021.100410'] 3336,34058419,Race and neonatal respiratory morbidity in the late preterm period.,"BACKGROUND Prematurity is one of the leading causes of perinatal morbidity and mortality. Some studies suggest that respiratory disease may differ by race in early preterm infants. However, the role of race in late preterm neonatal morbidity is not yet established. OBJECTIVE The objective of our study was to determine whether neonatal respiratory morbidity differs by race in neonates born late preterm. STUDY DESIGN This was a secondary analysis of a randomized trial of women at high risk for late preterm delivery (Antenatal Late Preterm Steroids). Our study was limited to women with nonanomalous, singleton gestations, delivering between 34+0 to 36+6 weeks. Women were categorized into 4 groups by race: Black, White, Asian, or other/mixed. The primary outcome was a neonatal composite of treatment in the first 72 hours (continuous positive airway pressure or high-flow nasal cannula >2 hours, oxygen >4 hours, extracorporeal membrane oxygenation or mechanical ventilation) or stillbirth or neonatal death before 72 hours. The secondary outcomes included severe respiratory morbidity (the primary outcome extending continuous positive airway pressure or high-flow nasal cannula to >12 continuous hours and oxygen to at least 24 continuous hours), respiratory distress syndrome, transient tachypnea of the newborn, apnea, neonatal intensive care unit admission, bronchopulmonary dysplasia, and surfactant administration. The primary and secondary outcomes were assessed in the active (steroid) and placebo groups separately. We fit a logistic regression model to adjust for confounders related to respiratory morbidity. RESULTS Of a total of 2331 included women, 26.9% (n=627) were Black/African American, 57.1% (n=1333) White, 3.56% (n=83) Asian, and 12.36% (n=288) were other/mixed. In the placebo group, the rate of the primary outcome was significantly higher in Whites (18.6%) and Asians (22.8%) compared with the African American/Black group (12.3%) (P=.03). Adjusting for confounders, the primary outcome was not significant between the groups. The primary predictor for respiratory morbidity was a prior pregnancy with neonatal respiratory morbidity. Findings were similar in the steroid group, but severe respiratory morbidity was less common in Black infants compared with White infants (adjusted odds ratio, 0.45; 95% confidence interval, 0.24-0.83). However, a prior pregnancy with neonatal respiratory complications was no longer associated with respiratory morbidity after receipt of betamethasone. CONCLUSION Late preterm respiratory morbidity was similar between racial groups. Although a history of pregnancy with previous neonatal respiratory disease is the strongest risk factor for recurrence, this risk factor is mitigated by the receipt of steroids.",2021,"However, a prior pregnancy with neonatal respiratory complications was no longer associated with respiratory morbidity after receipt of betamethasone. ","['women with non-anomalous, singleton gestations delivering between 34+0 to 36+6 weeks', 'neonates born late preterm', 'early preterm infants', 'Women were categorized into four groups by race: Black, White, Asian, or other/mixed', 'women at high risk for late preterm delivery (Antenatal Late Preterm Steroids, ALPS', 'White (n=1333), 3.56% Asian (n=83) and 12.36% (n=288) were other/mixed', 'Of a total of 2,331 included women, 26.9% (n= 627) were Black/African American, 57.1']","['betamethasone', 'placebo']","['oxygen >4 hours, ECMO or mechanical ventilation) or stillbirth or neonatal death', 'Race and neonatal respiratory morbidity', 'severe respiratory morbidity', 'Late term respiratory morbidity', 'severe respiratory morbidity (SRM, the primary outcome extending CPAP or high-flow nasal cannula to >12 continuous hours and oxygen to at least 24 continuous hours), respiratory distress syndrome, transient tachypnea of the newborn, apnea, neonatal intensive care unit admission, bronchopulmonary dysplasia and surfactant administration', 'neonatal composite of treatment in the first 72 hours (CPAP or high flow nasal cannula >2 hours', 'respiratory morbidity', 'neonatal respiratory morbidity']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0085756', 'cui_str': 'African American'}]","[{'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1292426', 'cui_str': '4 hours'}, {'cui': 'C0015357', 'cui_str': 'Extracorporeal membrane oxygenation'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0410916', 'cui_str': 'Newborn death'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1301752', 'cui_str': 'Respiratory morbidity'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0035220', 'cui_str': 'Respiratory distress syndrome in the newborn'}, {'cui': 'C0158940', 'cui_str': 'Transitory tachypnea of newborn'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C1292425', 'cui_str': '2 hours'}]",2331.0,0.212813,"However, a prior pregnancy with neonatal respiratory complications was no longer associated with respiratory morbidity after receipt of betamethasone. ","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Andrikopoulou', 'Affiliation': 'Columbia University Irving Medical Center, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine. Electronic address: ma3659@cumc.columbia.edu.'}, {'ForeName': 'Ukachi N', 'Initials': 'UN', 'LastName': 'Emeruwa', 'Affiliation': 'Columbia University Irving Medical Center, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Ludwig', 'Affiliation': 'Columbia University Irving Medical Center, Department of Obstetrics and Gynecology.'}, {'ForeName': 'Eve', 'Initials': 'E', 'LastName': 'Overton', 'Affiliation': 'Columbia University Irving Medical Center, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Gyamfi-Bannerman', 'Affiliation': 'Cynthia Gyamfi-Bannerman, MD, Msc, University of California San Diego, Department of Obstetrics, Gynecology and Reproductive Sciences.'}]",American journal of obstetrics & gynecology MFM,['10.1016/j.ajogmf.2021.100408'] 3337,34047001,Advanced counselling using training device and smartphone application on inhalation technique from metered-dose inhaler with spacer equipped with different interfaces in asthmatic children.,"BACKGROUND Spacers are equipped with either facemask or mouthpiece as an interface through which patient inhale their dose. The present study aimed to evaluate the effect of advanced counselling using training devices and smartphone applications on inhalation techniques from the metered-dose inhaler (MDI) with a spacer equipped with different interfaces. METHODS 100 paediatric asthmatic children (8-18 years) were divided into two groups. Group one was a spacer with a mouthpiece (n = 50) and group two was a spacer with a facemask group (n = 50). Both groups had three visits one month apart. At each visit, patients were asked to show the investigator their inhalation technique using MDI with spacer, and mistakes were recorded and then patients were trained on the proper inhalation technique of using MDI with a spacer. In the spacer with mouthpiece group, Flo-Tone was attached to the mouthpiece to allow the Trainhaler smartphone application to detect the duration of inhalation. In the spacer with facemask group, there was no need to use the Flo-Tone training device since the facemask was equipped with a built-in whistle detected by the Trainhaler smartphone application. RESULTS The total number of mistakes in the inhalation technique decreased significantly (P < .05) in visits 2 and 3 for both groups. Duration of inhalation increased significantly (P < .05) in the mouthpiece group at visit 2 and in the facemask group at visit 3. Achieving 5 seconds of slow deep inhalation, breath-holding for 5 seconds after inhalation and the tight fit of facemask represented the major obstacles in most children especially the youngest subjects. Breath out as far as comfortable had the highest number of mistakes in the first visit in both groups. CONCLUSION The Flo-Tone with its positive reinforcement whistle and the Trainhaler smartphone application significantly improved the inhalation technique by decreasing the total number of mistakes especially in important steps eg, shaking MDI, maintaining slow inhalation rate, breath-holding after inhalation and appropriate facemask fitting. Also, they increased the duration of inhalation of asthmatic children from MDI with a spacer. Both spacer interfaces are easy to handle once taught well.",2021,The total number of mistakes in the inhalation technique decreased significantly (p<0.05) in visits 2 and 3 for both groups.,"['100 pediatric asthmatic children (8-18 years', 'asthmatic children']",[],"['Duration of inhalation', 'total number of mistakes in the inhalation technique', 'duration of inhalation of asthmatic children']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],"[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1998547', 'cui_str': 'Inhalation technique'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",100.0,0.0104653,The total number of mistakes in the inhalation technique decreased significantly (p<0.05) in visits 2 and 3 for both groups.,"[{'ForeName': 'Sara M', 'Initials': 'SM', 'LastName': 'Tony', 'Affiliation': 'Clinical pharmacy department, Beni-Suef Specialized Hospital, Beni-Suef, Egypt.'}, {'ForeName': 'Mona A', 'Initials': 'MA', 'LastName': 'Abdelrahman', 'Affiliation': 'Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.'}, {'ForeName': 'Hasnaa', 'Initials': 'H', 'LastName': 'Osama', 'Affiliation': 'Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.'}, {'ForeName': 'Mohamed E A', 'Initials': 'MEA', 'LastName': 'Abdelrahim', 'Affiliation': 'Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.'}]",International journal of clinical practice,['10.1111/ijcp.14413'] 3338,34023695,Long-term follow-up of facilitated subcutaneous immunoglobulin therapy in multifocal motor neuropathy.,"OBJECTIVE To assess the feasibility, efficacy and patient satisfaction of long-term facilitated subcutaneous immunoglobulin therapy (fSCIG) in multifocal motor neuropathy (MMN). METHODS Twelve patients previously participating in a randomized trial investigating the short-term efficacy of fSCIG were offered to switch to fSCIG maintenance therapy following a variable interval on conventional subcutaneous immunoglobulin. RESULTS Eight patients were switched to fSCIG maintenance therapy, seven of whom were invited for a follow-up assessment after 18 months (range 13-23 months) of treatment. The age at follow-up was 57 years (range 45-70 years) and patients received a median weekly dose immunoglobulin G of 32.5 g (range 20.0-50.0 g), the dose being unaltered compared to baseline values following completion of the fSCIG trial. In five patients the infusion was biweekly, whereas two patients were infused weekly. The follow-up mean isometric strength normalized to pre-trial values was 107.7% (95% CI 86.4-129.0%) being non-inferior to baseline values (104.7%, 95% CI 97.6-111.8%, P = 0.015). The mean ODSS was 2.0 (95% CI 0.8-3.2) which is identical to the baseline score following completion of the fSCIG trial, the P-value for non-inferiority being <0.0001. The secondary variables of impairment, function and quality of life at follow-up all were non-inferior to baseline values (P ≤ 0.046). CONCLUSION fSCIG seems feasible and effective for long-term maintenance treatment in patients with MMN.",2021,"The secondary variables of impairment, function and quality of life at follow-up all were non-inferior to baseline values (P ≤ 0.046). ","['Twelve patients previously participating', 'multifocal motor neuropathy', 'patients with MMN', 'multifocal motor neuropathy (MMN']","['fSCIG maintenance therapy', 'fSCIG', 'subcutaneous immunoglobulin therapy', 'long-term facilitated subcutaneous immunoglobulin therapy (fSCIG']","['mean ODSS', 'mean isometric strength normalized to pre-trial values', 'impairment, function and quality of life', 'feasibility, efficacy and patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0393847', 'cui_str': 'Motor neuropathy with multiple conduction block'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0021022', 'cui_str': 'Immunoglobulin therapy'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",8.0,0.32599,"The secondary variables of impairment, function and quality of life at follow-up all were non-inferior to baseline values (P ≤ 0.046). ","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Al-Zuhairy', 'Affiliation': 'Department of Neurology, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark. Electronic address: ali.al-zuhairy@regionh.dk.'}, {'ForeName': 'Søren H', 'Initials': 'SH', 'LastName': 'Sindrup', 'Affiliation': 'Department of Neurology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Jakobsen', 'Affiliation': 'Department of Neurology, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.'}]",Journal of the neurological sciences,['10.1016/j.jns.2021.117495'] 3339,34023556,Comparing the effects of mobile-based education and booklet-based education on Iranian mothers' perception on antibiotics: a quasi-experimental study.,"PURPOSE The aim of this study was to investigate the effect of mobile-based education in comparison with booklet-based education on mothers' perception on antibiotics. DESIGN AND METHODS This quasi-experimental study was performed on 160 mothers of children aged 1 to 6 years (80 in the experimental group and 80 in the control group) who referred to the urban community health centers in Iran. Both groups were taught about the proper use of antibiotics. The experimental group was taught using a mobile application and the control group was taught using a booklet. The Parental Perception on Antibiotics (PAPA) scale was used to collect data at the beginning and two to four weeks after the educational intervention. The data were analyzed using SPSS version 19. RESULTS The results showed that 91.9% of mothers used the knowledge of nurses or other health care providers and 86.3% used their previous experience as the source of information about antibiotics. Also, mothers' perceptions about antibiotics in the subscales of knowledge and beliefs, behaviors, adherence and awareness about antibiotics resistance in the experimental group improved significantly compared to the control group (p < 0.05). CONCLUSIONS Mobile-based education was more effective in improving mothers' perception on antibiotics than booklet-based education. PRACTICE IMPLICATIONS Health care providers can use mobile-based educational method for different groups of society to promote health in various fields.",2021,"Also, mothers' perceptions about antibiotics in the subscales of knowledge and beliefs, behaviors, adherence and awareness about antibiotics resistance in the experimental group improved significantly compared to the control group (p < 0.05). ","[""Iranian mothers' perception on antibiotics"", ""mothers' perception on antibiotics"", '160 mothers of children aged 1 to 6 years (80 in the experimental group and 80 in the control group) who referred to the urban community health centers in Iran']","['mobile-based education and booklet-based education', 'mobile-based education in comparison with booklet-based education']","['knowledge and beliefs, behaviors, adherence and awareness about antibiotics resistance', 'Parental Perception on Antibiotics (PAPA) scale']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0009469', 'cui_str': 'Satellite Centers'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0949285', 'cui_str': 'Antibiotic Resistance'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",160.0,0.00536903,"Also, mothers' perceptions about antibiotics in the subscales of knowledge and beliefs, behaviors, adherence and awareness about antibiotics resistance in the experimental group improved significantly compared to the control group (p < 0.05). ","[{'ForeName': 'Niloofar Taghva', 'Initials': 'NT', 'LastName': 'Salimi', 'Affiliation': 'Nursing and Midwifery School of Shahid Beheshti, Guilan University of Medical Sciences, Rasht, Iran. Electronic address: niloofartaghva@gmail.com.'}, {'ForeName': 'Zahra Taheri', 'Initials': 'ZT', 'LastName': 'Ezbarami', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery-Guilan University of Medical Sciences, Rasht, Iran. Electronic address: zahra_taheri@gums.ac.ir.'}, {'ForeName': 'Rasoul', 'Initials': 'R', 'LastName': 'Tabari-Khomeiran', 'Affiliation': 'Social Determinants of Health Research Center, Guilan University of Medical Sciences, Rasht, Iran. Electronic address: rasooltabari@gmail.com.'}, {'ForeName': 'Zahra Atrkar', 'Initials': 'ZA', 'LastName': 'Roushan', 'Affiliation': 'Department of Biostatistics, School of medicine, Guilan University of Medical Sciences, Rasht, Iran. Electronic address: atrkarroushan@gmail.com.'}, {'ForeName': 'Houman', 'Initials': 'H', 'LastName': 'Hashemian', 'Affiliation': 'Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. Electronic address: hashemian@gums.ac.ir.'}, {'ForeName': 'Hamid Khordadi', 'Initials': 'HK', 'LastName': 'Astaneh', 'Affiliation': 'Guilan University of Medical Science, Rasht, Iran. Electronic address: hashemian@gums.ac.ir.'}]",Journal of pediatric nursing,['10.1016/j.pedn.2021.04.034'] 3340,34039435,Impact of emollient therapy for preterm infants in the neonatal period on child neurodevelopment in Bangladesh: an observational cohort study.,"BACKGROUND Topical treatment with sunflower seed oil (SSO) or Aquaphor® reduced sepsis and neonatal mortality in hospitalized preterm infants <33 weeks' gestational age in Bangladesh. We sought to determine whether the emollient treatments improved neurodevelopmental outcomes during early childhood. METHODS 497 infants were randomized to receive SSO, Aquaphor®, or neither through the neonatal period or hospital discharge. 159 infant survivors were enrolled in the longitudinal follow-up study using a validated Rapid Neurodevelopmental Assessment tool and the Bayley Scales of Infant Development II (BSID II) administered at three-monthly intervals for the first year and thereafter at six-monthly intervals. Lowess smoothing was used to display neurodevelopmental status across multiple domains by age and treatment group, and Generalized Estimating Equations (GEE) were used to compare treatment groups across age points. RESULTS 123 children completed at least one follow-up visit. Lowess graphs suggest that lower proportions of children who received massage with either SSO or Aquaphor® had neurodevelopmental delays than control infants in a composite outcome of disabilities. In GEE analysis, infants receiving SSO showed a significant protective effect on the development of fine motor skills [odds ratio (OR) 0.92, 95% confidence interval (CI) 0.86-0.98, p=0.006]. The Psychomotor Development Index (PDI) in the BSID II showed significantly lower disability rates in the Aquaphor group (23.6%) compared to the control (55.2%) (OR 0.21, 95% CI 0.06-0.72, p=0.004). CONCLUSIONS Emollient massage of very preterm, hospitalized newborn infants improved some child neurodevelopmental outcomes over the first 2 years of follow-up. Findings warrant further confirmatory research. TRIAL REGISTRATION ClinicalTrials.gov (98-04-21-03-2) under weblink https://clinicaltrials.gov/ct2/show/NCT00162747.",2021,"The Psychomotor Development Index (PDI) in the BSID II showed significantly lower disability rates in the Aquaphor group (23.6%) compared to the control (55.2%) (OR 0.21, 95% CI 0.06-0.72, p=0.004). ","['preterm infants in the neonatal period on child neurodevelopment in Bangladesh', '497 infants', ""hospitalized preterm infants <33 weeks' gestational age in Bangladesh"", '123 children completed at least one follow-up visit', '159 infant survivors']","['emollient therapy', 'SSO or Aquaphor®', 'SSO, Aquaphor®, or neither through the neonatal period or hospital discharge', 'sunflower seed oil (SSO) or Aquaphor®']","['neurodevelopmental outcomes', 'development of fine motor skills', 'neurodevelopmental delays', 'Psychomotor Development Index (PDI', 'validated Rapid Neurodevelopmental Assessment tool and the Bayley Scales of Infant Development II (BSID II', 'sepsis and neonatal mortality', 'disability rates', 'child neurodevelopmental outcomes']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589121', 'cui_str': 'Follow-up visit'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0013983', 'cui_str': 'Emollient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0947381', 'cui_str': 'Helianthus annuus'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0718635', 'cui_str': 'Aquaphor'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0392358', 'cui_str': 'Psychomotor development'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0451021', 'cui_str': 'Bayley scale of infant development'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",497.0,0.17629,"The Psychomotor Development Index (PDI) in the BSID II showed significantly lower disability rates in the Aquaphor group (23.6%) compared to the control (55.2%) (OR 0.21, 95% CI 0.06-0.72, p=0.004). ","[{'ForeName': 'Gary L', 'Initials': 'GL', 'LastName': 'Darmstadt', 'Affiliation': 'Prematurity Research Center, Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, 1701 Page Mill Road, Palo Alto, CA, 94304, USA. gdarmsta@stanford.edu.'}, {'ForeName': 'Naila Z', 'Initials': 'NZ', 'LastName': 'Khan', 'Affiliation': 'Clinical Neurosciences Center, Bangladesh Protibondhi Foundation, Dhaka, Bangladesh.'}, {'ForeName': 'Summer', 'Initials': 'S', 'LastName': 'Rosenstock', 'Affiliation': 'Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Humaira', 'Initials': 'H', 'LastName': 'Muslima', 'Affiliation': 'Clinical Neurosciences Center, Bangladesh Protibondhi Foundation, Dhaka, Bangladesh.'}, {'ForeName': 'Monowara', 'Initials': 'M', 'LastName': 'Parveen', 'Affiliation': 'Clinical Neurosciences Center, Bangladesh Protibondhi Foundation, Dhaka, Bangladesh.'}, {'ForeName': 'Wajeeha', 'Initials': 'W', 'LastName': 'Mahmood', 'Affiliation': 'Prematurity Research Center, Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, 1701 Page Mill Road, Palo Alto, CA, 94304, USA.'}, {'ForeName': 'A S M Nawshad Uddin', 'Initials': 'ASMNU', 'LastName': 'Ahmed', 'Affiliation': 'Department of Neonatology, Bangladesh Institute of Child Health, Dhaka Shishu Hospital, Dhaka, Bangladesh.'}, {'ForeName': 'M A K Azad', 'Initials': 'MAKA', 'LastName': 'Chowdhury', 'Affiliation': 'Department of Neonatology, Bangladesh Institute of Child Health, Dhaka Shishu Hospital, Dhaka, Bangladesh.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Zeger', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Samir K', 'Initials': 'SK', 'LastName': 'Saha', 'Affiliation': 'Department of Microbiology, Bangladesh Institute of Child Health, Dhaka Shishu Hospital, Dhaka, Bangladesh.'}]","Journal of health, population, and nutrition",['10.1186/s41043-021-00248-9'] 3341,34058256,The Influence of Patient-Provider Language Concordance in Cancer Care: Results of the Hispanic Outcomes by Language Approach (HOLA) Randomized Trial.,"PURPOSE Delivering linguistically competent care is critical to serving patients who have limited English proficiency (LEP) and represents a key national strategy to help reduce health disparities. Current acceptable standards of communication with patients who have LEP include providers communicating through professional interpretive services or bilingual providers speaking the patients' preferred language directly. This randomized clinical trial tests the effect of patient-provider language concordance on patient satisfaction. METHODS AND MATERIALS Eighty-three adult Spanish-speaking patients with cancer were randomly assigned to receive care from either (1) 1 of 2 bilingual physicians speaking to the patient directly in Spanish or (2) the same physicians speaking English and using a professional interpreter service. Validated questionnaires were administered to assess patient-reported satisfaction with both provider communication and overall care. Transcripts of initial consultations were analyzed for content variations. RESULTS Compared with patients receiving care through professional interpretive services, patients cared for in direct Spanish reported significantly improved general satisfaction, technical quality of care (mean composite score [MCS], 4.41 vs 4.06; P = .005), care team interpersonal manner (MCS, 4.37 vs 3.88; P = .004), communication (MCS, 4.50 vs 4.25; P = .018), and time spent with patient,(MCS, 4.30 vs 3.92; P = .028). Specific to physician communication, patients rated direct-Spanish care more highly in perceived opportunity to disclose concerns (MCS 4.91 vs 4.62; P = .001), physician empathy (MCS, 4.94 vs 4.59; P <.001), confidence in physician abilities (MCS, 4.84 vs 4.51; P = .001), and general satisfaction with their physician (MCS, 4.88 vs 4.59; P <.001). Analyzing the content of consultation encounters revealed differences between study arms, with the direct-Spanish arm having more physician speech related to patient history verification (mean number of utterances, 13 vs 9; P = .01) and partnering activities (mean utterances, 16 vs 5; P <.001). Additionally, patients in the direct-Spanish arm were more likely to initiate unprompted speech (mean utterances, 11 vs 3; P <.001) and asked their providers more questions (mean utterances, 11 vs 4; P = .007). CONCLUSIONS This study shows improved patient-reported satisfaction among patients with cancer who had LEP and were cared for in direct Spanish compared with interpreter-based communication. Further research into interventions to mitigate the patient-provider language barrier is necessary to optimize care for this population.",2021,"Specific to physician communication, patients rated direct Spanish care more highly in perceived opportunity to disclose concerns (MCS 4.91 vs 4.62, p=0.001), physician empathy (MCS 4.94 vs 4.59, p<0.001), confidence in physician abilities (MCS 4.84 vs 4.51, p=0.001), and general satisfaction with their physician (MCS 4.88 vs 4.59, p<0.001).","['patient-provider language concordance in cancer care', 'Eighty-three adult Spanish-speaking cancer patients', 'patient-provider language concordance on patient satisfaction']",['bilingual physician speaking to the patient directly in Spanish or 2) the same physicians speaking English and using a professional interpreter service'],"['care team interpersonal manner', 'partnering activities', 'general satisfaction', 'general satisfaction, technical quality of care', 'physician empathy', 'initiate unprompted speech', 'confidence in physician abilities', 'time spent']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]","[{'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0150646', 'cui_str': 'Interpreter'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",83.0,0.149638,"Specific to physician communication, patients rated direct Spanish care more highly in perceived opportunity to disclose concerns (MCS 4.91 vs 4.62, p=0.001), physician empathy (MCS 4.94 vs 4.59, p<0.001), confidence in physician abilities (MCS 4.84 vs 4.51, p=0.001), and general satisfaction with their physician (MCS 4.88 vs 4.59, p<0.001).","[{'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Seible', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California, San Diego, California.'}, {'ForeName': 'Souma', 'Initials': 'S', 'LastName': 'Kundu', 'Affiliation': 'School of Medicine, University of California, San Diego, California.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'Azuara', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California, San Diego, California.'}, {'ForeName': 'Daniel R', 'Initials': 'DR', 'LastName': 'Cherry', 'Affiliation': 'School of Medicine, University of California, San Diego, California.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Arias', 'Affiliation': 'School of Medicine, University of California, San Diego, California.'}, {'ForeName': 'Vinit V', 'Initials': 'VV', 'LastName': 'Nalawade', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California, San Diego, California.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Cruz', 'Affiliation': 'School of Medicine, University of California, San Diego, California.'}, {'ForeName': 'Rolando', 'Initials': 'R', 'LastName': 'Arreola', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California, San Diego, California.'}, {'ForeName': 'Maria Elena', 'Initials': 'ME', 'LastName': 'Martinez', 'Affiliation': 'Department of Family and Preventive Medicine, University of California, San Diego, California.'}, {'ForeName': 'Jesse N', 'Initials': 'JN', 'LastName': 'Nodora', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, California.'}, {'ForeName': 'Douglas A', 'Initials': 'DA', 'LastName': 'Rahn', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California, San Diego, California.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Murphy', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California, San Diego, California. Electronic address: j2murphy@ucsd.edu.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2021.05.122'] 3342,34046894,Minimally invasive ultrasound-guided vs open release for carpal tunnel syndrome in working population: A randomized controlled trial.,"PURPOSE To compare the clinical effectiveness of minimally invasive ultrasound (US)-guided vs open release for carpal tunnel syndrome. METHODS In an open randomized controlled trial, 47 employed patients were allocated to US-guided carpal tunnel release (USCTR) and 42 to an open carpal tunnel release (OCTR) procedure. The main outcome was symptom severity measured by the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ-S). Secondary outcomes were hand functionality (BCTQ-F), nerve conduction, two-point discrimination, handgrip and pinch strength, pain (visual analog scale), work leave and complications. For BCTQ-S and BCTQ-F, minimal clinically important differences (MCID) were also considered. Follow-up duration was 12 months. RESULTS Mixed model analyses detected no significant differences between the two treatment arms in BCTQ-S (P = .098) while BCTQ-F scores were significantly better in the USCTR group (P = .007). This benefit was, however, not supported by the MCID data. Remaining variables were similar in the two groups except pain which was lower in USCTR at 3 months follow-up. All variables but two-point discrimination showed significant improvement after 3 months. CONCLUSIONS Our findings reveal similar symptom relief benefits following OCTR or USCTR in these patients. The patients in our USCTR group, however, reported better hand functional status and less pain.",2021,Remaining variables were similar in the two groups except pain which was lower in USCTR at 3 months follow-up.,"['carpal tunnel syndrome in working population', 'carpal tunnel syndrome', '47 employed patients were allocated to']","['minimally invasive ultrasound (US)-guided', 'US-guided carpal tunnel release (USCTR) and 42 to an open carpal tunnel release (OCTR) procedure', 'Minimally invasive ultrasound-guided vs open release']","['hand functionality (BCTQ-F), nerve conduction, two-point discrimination, handgrip and pinch strength, pain (visual analog scale), work leave and complications', 'BCTQ-F scores', 'BCTQ-S', 'symptom severity measured by the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ-S', 'better hand functional status and less pain']","[{'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0196576', 'cui_str': 'Decompression of median nerve'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}]","[{'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0027788', 'cui_str': 'Nerve conduction'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C1720876', 'cui_str': 'Pinch Strength'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",47.0,0.0751129,Remaining variables were similar in the two groups except pain which was lower in USCTR at 3 months follow-up.,"[{'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'de la Fuente', 'Affiliation': 'Department of Orthopedic Surgery, Clínica Pakea-Mutualia, San Sebastián, Spain.'}, {'ForeName': 'Jose F', 'Initials': 'JF', 'LastName': 'Aramendi', 'Affiliation': 'Primary Care Department, Clínica Pakea-Mutualia, San Sebastián, Spain.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Ibañez', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Clínica Pakea-Mutualia, San Sebastián, Spain.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Blasi', 'Affiliation': 'Plastic Surgery Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Vazquez', 'Affiliation': 'Department of Occupational Medicine, Clínica Pakea-Mutualia, San Sebastián, Spain.'}, {'ForeName': 'Juan J', 'Initials': 'JJ', 'LastName': 'Aurrekoetxea', 'Affiliation': 'Public Health Department, Basque Government, Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Dávila', 'Affiliation': 'Department of Orthopedic Surgery, Clínica Pakea-Mutualia, San Sebastián, Spain.'}]",Journal of clinical ultrasound : JCU,['10.1002/jcu.23019'] 3343,34048643,Short-term effects of the orthodontic removable traction appliance in the treatment of skeletal Class III malocclusion: A randomized controlled trial.,"BACKGROUND The orthodontic removable traction appliance (ORTA) was introduced as an intraoral removable appliance to treat Class III patients, but the pure treatment effects of ORTA have not been established yet. OBJECTIVES The aim of the study was to evaluate the skeletal, dental and soft tissue changes following the use of ORTA in treating Class III growing patients, and to compare these changes with those observed in an untreated control group (UCG). MATERIAL AND METHODS Forty-two patients with Class III malocclusion (mean age: 9.04 ±0.84 years) were randomly allocated to either the intervention group (ORTA) or UCG with a 1:1 allocation ratio. The patients in the ORTA group were treated until a positive overjet was achieved, whereas those in UCG were observed for an average of 6 months. Lateral cephalograms were obtained before (T1) and at the end of the treatment or observation period (T2). Twenty-six variables were used to evaluate treatment changes. The paired and independent t tests were used to detect significant differences within and between the groups, respectively. RESULTS Forty-two patients who met the inclusion criteria were included primarily. Two patients in UCG dropped out of the study. Therefore, 40 patients were included in the statistical analyses (ORTA: 21; UCG: 19). The orthodontic removable traction appliance was able to correct Class III malocclusion in a mean treatment time of 4.34 ±2.02 months. The maxilla moved forward by a mean of 1.31°, which was significantly greater than in the case of UCG (i.e., a mean difference of 1.02°). The mandible moved significantly backward in the ORTA group (the mean change in SNB: -1.85°) and significantly forward in UCG (the mean change in SNB: 0.97°), leaving the overall sagittal skeletal change significantly greater in the ORTA group as compared to UCG (the mean change in ANB: 3.81°) (p < 0.001). CONCLUSIONS In the short term, ORTA seemed to be an effective intraoral removable appliance in the treatment of growing Class III patients.",2021,The orthodontic removable traction appliance was able to correct Class III malocclusion in a mean treatment time of 4.34 ±2.02 months.,"['Forty-two patients who met the inclusion criteria were included primarily', 'Forty-two patients with Class III malocclusion (mean age: 9.04 ±0.84 years', '40 patients were included in the statistical analyses (ORTA: 21; UCG: 19', 'skeletal Class III malocclusion']","['intervention group (ORTA) or UCG', 'orthodontic removable traction appliance', 'SNB', 'orthodontic removable traction appliance (ORTA']",['overall sagittal skeletal change'],"[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0399526', 'cui_str': 'Malocclusion, Angle class III'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0040597', 'cui_str': 'Traction'}, {'cui': 'C1542418', 'cui_str': 'Appliance'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0040597', 'cui_str': 'Traction'}, {'cui': 'C1542418', 'cui_str': 'Appliance'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0796693', 'cui_str': 'Sentinel lymph node biopsy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205129', 'cui_str': 'Sagittal'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",42.0,0.04759,The orthodontic removable traction appliance was able to correct Class III malocclusion in a mean treatment time of 4.34 ±2.02 months.,"[{'ForeName': 'Batool Ahmad', 'Initials': 'BA', 'LastName': 'Alzabibi', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, University of Damascus, Syria.'}, {'ForeName': 'Ahmad Sharafeddin', 'Initials': 'AS', 'LastName': 'Burhan', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, University of Damascus, Syria.'}, {'ForeName': 'Mohammad Younis', 'Initials': 'MY', 'LastName': 'Hajeer', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, University of Damascus, Syria.'}, {'ForeName': 'Fehmieh Rafik', 'Initials': 'FR', 'LastName': 'Nawaya', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dentistry, Syrian Private University, Damascus, Syria.'}]",Dental and medical problems,['10.17219/dmp/126304'] 3344,34049396,"Higher Carbohydrate Amount and Lower Glycemic Index Increase Hunger, Diet Satisfaction, and Heartburn in Overweight and Obese Adults in the OmniCarb Randomized Clinical Trial.","BACKGROUND The Dietary Approaches to Stop Hypertension (DASH) diet, a high-carbohydrate diet, is highly recommended based on its cardiovascular risk benefits, yet adherence remains persistently low. How subjective impressions of this diet contribute to adherence has not been thoroughly explored. The OmniCarb trial, which compared DASH-style diets varying in glycemic index (GI) and carbohydrate amount, surveyed subjective impressions of such diets. OBJECTIVES We examined the effects of GI and carbohydrate amount on qualitative aspects of diet acceptability through secondary outcomes in the OmniCarb trial. METHODS OmniCarb was a randomized, crossover trial of 4 DASH-style diets varying by GI (≥65 compared with ≤45) and carbohydrate amount (40% compared with 58% kcal) in overweight or obese (BMI ≥25 kg/m2) adults (n = 163). Participants consumed each diet in random order over 5-wk periods, separated by 2-wk washouts. At baseline and the end of each feeding period, participants rated hunger, diet satisfaction, and gastrointestinal symptoms (diarrhea/loose stools, constipation, bloating, nausea, and heartburn). RESULTS Participant mean age was 52 y, with 52% women, 51% non-Hispanic black, and 56% obese (BMI ≥30). Compared with baseline, all intervention diets decreased heartburn, increased diarrhea/loose stools, and increased bloating, but did not significantly affect constipation or nausea. Compared with lower carbohydrate diets, higher carbohydrate diets increased hunger (RR: 1.16; 95% CI: 1.04, 1.30), increased diet satisfaction (RR: 1.10; 95% CI: 1.01, 1.20), and increased heartburn (RR: 1.49; 95% CI: 1.09, 2.04). Compared with lower GI diets, higher GI diets did not affect hunger (RR: 0.92; 95% CI: 0.83, 1.02), decreased diet satisfaction (RR: 0.83; 95% CI: 0.75, 0.92), and did not affect heartburn (RR: 0.89; 95% CI: 0.70, 1.13). There were no between-diet differences for diarrhea/loose stools, constipation, bloating, and nausea. CONCLUSIONS Although a higher carbohydrate amount in DASH-style diets can increase diet satisfaction, it can also decrease satiety and increase heartburn in adults with overweight or obesity.This trial is registered at clinicaltrials.gov as NCT00608049.",2021,"Compared with baseline, all intervention diets decreased heartburn, increased diarrhea/loose stools, and increased bloating, but did not significantly affect constipation or nausea.","['adults with overweight or obesity', 'Overweight and Obese Adults', 'overweight or obese', 'Participant mean age was 52']","['4 DASH-style diets varying by GI (≥65\xa0compared with\xa0≤45) and carbohydrate amount (40% compared with 58%\xa0kcal', 'GI and carbohydrate']","['rated hunger, diet satisfaction, and gastrointestinal symptoms (diarrhea/loose stools, constipation, bloating, nausea, and heartburn', 'constipation or nausea', 'glycemic index (GI) and carbohydrate amount, surveyed subjective impressions of such diets', 'satiety and increase heartburn', 'heartburn', 'diarrhea/loose stools, constipation, bloating, and nausea', 'Higher Carbohydrate Amount and Lower Glycemic Index Increase Hunger, Diet Satisfaction, and Heartburn', 'diet satisfaction', 'heartburn, increased diarrhea/loose stools, and increased bloating']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0439259', 'cui_str': 'kcal'}]","[{'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018834', 'cui_str': 'Heartburn'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0232461', 'cui_str': 'Increased appetite'}]",163.0,0.217029,"Compared with baseline, all intervention diets decreased heartburn, increased diarrhea/loose stools, and increased bloating, but did not significantly affect constipation or nausea.","[{'ForeName': 'Yingfei', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Medicine, New York University Langone Health, New York, NY, USA.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Juraschek', 'Affiliation': 'Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Jiun-Ruey', 'Initials': 'JR', 'LastName': 'Hu', 'Affiliation': 'Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Noel T', 'Initials': 'NT', 'LastName': 'Mueller', 'Affiliation': 'Welch Center for Epidemiology, Prevention, and Clinical Research, Johns Hopkins University School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Appel', 'Affiliation': 'Welch Center for Epidemiology, Prevention, and Clinical Research, Johns Hopkins University School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Cheryl A M', 'Initials': 'CAM', 'LastName': 'Anderson', 'Affiliation': 'Herbert Wertheim School of Public Health, University of California San Diego, San Diego, CA, USA.'}, {'ForeName': 'Edgar R', 'Initials': 'ER', 'LastName': 'Miller', 'Affiliation': 'Welch Center for Epidemiology, Prevention, and Clinical Research, Johns Hopkins University School of Public Health, Baltimore, MD, USA.'}]",The Journal of nutrition,['10.1093/jn/nxab128'] 3345,34029936,Effectiveness of the manual diaphragmatic stretching technique on respiratory function in cerebral palsy: A randomised controlled trial.,"BACKGROUND Respiratory failure resulting from diaphragmatic muscle weakness is a major cause of long-term hospitalization in children with cerebral palsy (CP). Manual diaphragmatic stretching technique (MDST) can be directly applied to stretch diaphragmatic muscle and has been reported to improve respiratory function in patients with asthma and COPD. However, there have been no studies among CP. This study aimed to examine the effects of a six-week MDST course on respiratory function among CP. METHODS Fifty-three children with spastic CP were randomly assigned to experimental (n = 27) and control (n = 26) groups. The experimental group received MDST on non-consecutive days, three days per week for six weeks alongside standard physiotherapy (SDPT), while the control group received only SDPT. The outcome variables were diaphragmatic mobility, pulmonary function and chest wall expansion. RESULTS MDST significantly improved diaphragmatic mobility on both sides of the body, with a between-group difference of 0.97 cm (95% CI 0.55-1.39 cm, p < 0.001) for the right side and 0.82 cm (95% CI 0.35-1.29 cm, p = 0.001) for the left side. MDST significantly improved chest wall expansion at the xiphoid process and umbilical levels, with between-group differences of 0.57 cm (95% CI 0.12-1.20 cm, p = 0.013) and 0.87 cm (95% CI 0.31-1.43 cm, p = 0.003), respectively. There was no significant difference in pulmonary function testing between the groups. CONCLUSION MDST could significantly improve diaphragmatic mobility, and lower and abdominal chest wall expansion, among children with CP. Therefore, MDST could be considered as an additional technique for physiotherapy programmes, to improve diaphragmatic function in spastic CP.",2021,"MDST significantly improved chest wall expansion at the xiphoid process and umbilical levels, with between-group differences of 0.57 cm (95% CI 0.12-1.20 cm, p = 0.013) and 0.87 cm (95% CI 0.31-1.43 cm, p = 0.003), respectively.","['patients with asthma and COPD', 'Fifty-three children with spastic CP', 'cerebral palsy', 'children with CP', 'children with cerebral palsy (CP']","['manual diaphragmatic stretching technique', 'six-week MDST', 'standard physiotherapy (SDPT), while the control group received only SDPT', 'MDST', 'Manual diaphragmatic stretching technique (MDST']","['diaphragmatic function', 'diaphragmatic mobility', 'pulmonary function testing', 'umbilical levels', 'respiratory function', 'chest wall expansion', 'diaphragmatic mobility, pulmonary function and chest wall expansion', 'diaphragmatic mobility, and lower and abdominal chest wall expansion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}]","[{'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0041638', 'cui_str': 'Umbilical structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0205076', 'cui_str': 'Chest wall structure'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}]",53.0,0.114967,"MDST significantly improved chest wall expansion at the xiphoid process and umbilical levels, with between-group differences of 0.57 cm (95% CI 0.12-1.20 cm, p = 0.013) and 0.87 cm (95% CI 0.31-1.43 cm, p = 0.003), respectively.","[{'ForeName': 'Surussawadi', 'Initials': 'S', 'LastName': 'Bennett', 'Affiliation': 'Research Centre in Back, Neck, Other Joint Pain and Human Performance, Khon Kaen University, Khon Kaen, 40002, Thailand; Division of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, 40002, Thailand. Electronic address: surmac@kku.ac.th.'}, {'ForeName': 'Wantana', 'Initials': 'W', 'LastName': 'Siritaratiwat', 'Affiliation': 'Research Centre in Back, Neck, Other Joint Pain and Human Performance, Khon Kaen University, Khon Kaen, 40002, Thailand; Division of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, 40002, Thailand. Electronic address: wantana.siritaratiwat@gmail.com.'}, {'ForeName': 'Nittaya', 'Initials': 'N', 'LastName': 'Tanrangka', 'Affiliation': 'Research Centre in Back, Neck, Other Joint Pain and Human Performance, Khon Kaen University, Khon Kaen, 40002, Thailand; Division of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, 40002, Thailand. Electronic address: fai.cooper@gmail.com.'}, {'ForeName': 'Michael John', 'Initials': 'MJ', 'LastName': 'Bennett', 'Affiliation': 'Faculty of Medicine, University of Southampton, SO17 1BJ, United Kingdom; National Institute for Health Research, Southampton Respiratory and Critical Care Biomedical Research Centre, Mailpoint 218, D Level, West Wing, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, United Kingdom. Electronic address: Michael.bennett@soton.ac.uk.'}, {'ForeName': 'Jaturat', 'Initials': 'J', 'LastName': 'Kanpittaya', 'Affiliation': 'Department of Radiology, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand. Electronic address: jatkan@kku.ac.th.'}]",Respiratory medicine,['10.1016/j.rmed.2021.106443'] 3346,34051124,Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.,"AIMS Sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally developed as glucose-lowering agents, have been shown to reduce heart failure hospitalizations in patients with type 2 diabetes without established heart failure, and in patients with heart failure with and without diabetes. Their role in patients with heart failure with preserved and mildly reduced ejection fraction remains unknown. METHODS Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER) is an international, multicentre, parallel group, event-driven, randomized, double-blind trial in patients with chronic heart failure and left ventricular ejection fraction (LVEF) >40%, comparing the effect of dapagliflozin 10 mg once daily, vs. placebo, in addition to standard of care. Patients with or without diabetes, with signs and symptoms of heart failure, a LVEF >40%, elevation in natriuretic peptides and evidence of structural heart disease are eligible. The primary endpoint is time-to-first cardiovascular death or worsening heart failure event (heart failure hospitalization or urgent heart failure visit), and will be assessed in dual primary analyses - the full population and in those with LVEF <60%. The study is event-driven and will target 1117 primary events. A total of 6263 patients have been randomized. CONCLUSIONS DELIVER will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy, in patients with heart failure and preserved and mildly reduced ejection fraction.",2021,"The primary endpoint is time to first cardiovascular death or worsening heart failure event (heart failure hospitalization or urgent heart failure visit), and will be assessed in dual primary analyses - the full population and in those with LVEF < 60%.","['patients with heart failure and preserved and mildly reduced ejection fraction', 'patients with type 2 diabetes without established heart failure, and in patients with heart failure with and without diabetes', 'patients with chronic heart failure and left ventricular ejection fraction (LVEF) greater than 40', 'Heart Failure with Preserved and Mildly Reduced Ejection Fraction', 'patients with heart failure with preserved and mildly reduced ejection fraction remains unknown', '6263 patients have been randomized', 'Patients with or without diabetes, with signs and symptoms of heart failure, a left ventricular ejection fraction']","['Sodium glucose co-transporter type 2 (SGLT2) inhibitors', 'dapagliflozin', 'Dapagliflozin', 'placebo']","['efficacy and safety', 'time to first cardiovascular death or worsening heart failure event (heart failure hospitalization or urgent heart failure visit), and will be assessed in dual primary analyses - the full population']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C2945599', 'cui_str': 'Mild'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}]","[{'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598849', 'cui_str': 'Co-Transporters'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",6263.0,0.31864,"The primary endpoint is time to first cardiovascular death or worsening heart failure event (heart failure hospitalization or urgent heart failure visit), and will be assessed in dual primary analyses - the full population and in those with LVEF < 60%.","[{'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Solomon', 'Affiliation': ""Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Rudolf A', 'Initials': 'RA', 'LastName': 'de Boer', 'Affiliation': 'University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'DeMets', 'Affiliation': 'University of Wisconsin, Madison, WI, USA.'}, {'ForeName': 'Adrian F', 'Initials': 'AF', 'LastName': 'Hernandez', 'Affiliation': 'Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Silvio E', 'Initials': 'SE', 'LastName': 'Inzucchi', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Mikhail N', 'Initials': 'MN', 'LastName': 'Kosiborod', 'Affiliation': ""Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.""}, {'ForeName': 'Carolyn S P', 'Initials': 'CSP', 'LastName': 'Lam', 'Affiliation': 'University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Martinez', 'Affiliation': 'University of Cordoba, Cordoba, Argentina.'}, {'ForeName': 'Sanjiv J', 'Initials': 'SJ', 'LastName': 'Shah', 'Affiliation': 'Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lindholm', 'Affiliation': 'AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Ulrica', 'Initials': 'U', 'LastName': 'Wilderäng', 'Affiliation': 'AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Öhrn', 'Affiliation': 'AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Claggett', 'Affiliation': ""Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Anna Maria', 'Initials': 'AM', 'LastName': 'Langkilde', 'Affiliation': 'AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Petersson', 'Affiliation': 'AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'University of Glasgow, Glasgow, UK.'}]",European journal of heart failure,['10.1002/ejhf.2249'] 3347,34390797,"Effectiveness of crocin of saffron (Crocus sativus L.) against chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial.","ETHNOPHARMACOLOGICAL RELEVANCE Chemotherapy-induced peripheral neuropathy (CIPN) is one of the complications vexes patients treated with anti-cancer agents. Saffron has been demonstrated to attenuate symptoms of peripheral neuropathy in animal models. Also, there is a published clinical trial that investigated the pain relieving effect of saffron following nationally accepted rules and concluded that saffron was successful in alleviating pain symptoms in patients suffering from fibromyalgia. AIM OF THE STUDY We aimed to determine the efficacy of crocin as a constituent of saffron in CIPN as the first report. MATERIALS AND METHODS One hundred and seventy-seven enrolled eligible patients (between December 2018 and March 2020) for study entry were cases demonstrating mild to severe symptomatic CIPN for at least a month. These cases were randomly assigned to two main groups including 15 mg crocin tablet, bid (30 mg total daily target dose) and placebo tablet for 8 weeks. A crossover study was performed with a 2-week washout period. Patient outcomes were measured once a week for 8 consecutive weeks. RESULTS Grade of sensory, motor and neuropathic pain decreased considerably and significantly in the crocin group compared with placebo (P < 0.05). Observed toxicities were mild and adverse effects had no significant differences between the two groups (P > 0.05). CONCLUSIONS Crocin considerably seems to be effective for relieving symptoms of CIPN in cancer patients receiving chemotherapy agents. However, further studies are needed about crocin with its beneficial neuropharmacological effects and lower adverse effects than the chemical agents such as antidepressants, lamotrigine, and gabapentin.",2021,"RESULTS Grade of sensory, motor and neuropathic pain decreased considerably and significantly in the crocin group compared with placebo (P < 0.05).","['induced peripheral neuropathy', 'Chemotherapy-induced peripheral neuropathy (CIPN', 'patients suffering from fibromyalgia', 'One hundred and seventy-seven enrolled eligible patients (between December 2018 and March 2020) for study entry were cases demonstrating mild to severe symptomatic CIPN for at least a month', 'vexes patients treated with anti-cancer agents', 'cancer patients receiving chemotherapy agents']","['gabapentin', 'crocin of saffron (Crocus sativus L.) against chemotherapy', 'placebo']","['pain symptoms', 'Grade of sensory, motor and neuropathic pain', 'Observed toxicities']","[{'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C3873567', 'cui_str': 'Peripheral neuropathy due to and following chemotherapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0003392', 'cui_str': 'Antineoplastic agent'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0450442', 'cui_str': 'Agent'}]","[{'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0056503', 'cui_str': 'crocin'}, {'cui': 'C0162753', 'cui_str': 'Saffron Stain'}, {'cui': 'C0946614', 'cui_str': 'Saffron Crocus'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",177.0,0.0551426,"RESULTS Grade of sensory, motor and neuropathic pain decreased considerably and significantly in the crocin group compared with placebo (P < 0.05).","[{'ForeName': 'Hooman', 'Initials': 'H', 'LastName': 'Bozorgi', 'Affiliation': 'Department of Pharmacology, Research Center of Physiology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran. Electronic address: hoomanbozorgi@semums.ac.ir.'}, {'ForeName': 'Farahnaz', 'Initials': 'F', 'LastName': 'Ghahremanfard', 'Affiliation': 'Department of Internal Medicine, Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.'}, {'ForeName': 'Ehsan', 'Initials': 'E', 'LastName': 'Motaghi', 'Affiliation': 'Department of Physiology and Pharmacology, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Zamaemifard', 'Affiliation': 'Kosar Hospital, Semnan, Iran.'}, {'ForeName': 'Melika', 'Initials': 'M', 'LastName': 'Zamani', 'Affiliation': 'Panzdah-e-Khordad Hospital, Semnan, Iran.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Izadi', 'Affiliation': 'School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2021.114511'] 3348,34390762,Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.,"AIMS To date, no clinical studies have compared once-weekly dipeptidyl peptidase 4 (DPP-4) inhibitors with once-daily DPP-4 inhibitors in terms of glucose variability (GV) and oxidative stress (OS). METHODS Thirty-six patients with type 2 diabetes mellitus (T2DM) treated with once-daily DPP-4 inhibitors for at least 12 weeks were randomized to either continue once-daily DPP-4 inhibitors or receive omarigliptin, a once-weekly DPP-4 inhibitor, for 24 weeks. The primary end points were changes in the diacron-reactive oxygen metabolite (d-ROMs) test, a marker of OS, and GV using flash glucose monitoring. The secondary end point was changes in the diabetes treatment satisfaction questionnaire (DTSQ) scores. RESULTS There were no significant group differences in d-ROMs and DTSQ scores after 24 weeks of treatments. However, omarigliptin was superior to once-daily DPP-4 inhibitors in controlling fasting plasma glucose (FPG) and time in range (TIR). Although FPG and TIR were unchanged at 24 weeks after switching to omarigliptin, these parameters increased in the group receiving maintenance therapy with once-daily DPP-4 inhibitors. No statistically significant changes in hemoglobin A1c were observed between the two groups. CONCLUSIONS Our findings suggest that switching from once-daily DPP-4 inhibitors to omarigliptin may be efficacious for maintaining FPG and TIR in T2DM patients.",2021,There were no significant group differences in d-ROMs and DTSQ scores after 24 weeks of treatments.,"['T2DM patients', 'type 2 diabetes patients', 'Thirty-six patients with type 2 diabetes mellitus (T2DM) treated with once-daily DPP-4 inhibitors for at least 12 weeks']","['continue once-daily DPP-4 inhibitors or receive omarigliptin, a once-weekly DPP-4 inhibitor', 'omarigliptin']","['diabetes treatment satisfaction questionnaire (DTSQ) scores', 'glucose variability and oxidative stress', 'd-ROMs and DTSQ scores', 'hemoglobin A1c', 'glucose variability (GV) and oxidative stress (OS', 'FPG and TIR', 'fasting plasma glucose (FPG) and time in range (TIR', 'diacron-reactive oxygen metabolite (d-ROMs) test, a marker of OS, and GV using flash glucose monitoring']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl peptidase IV inhibitor'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl peptidase IV inhibitor'}, {'cui': 'C4279587', 'cui_str': 'Omarigliptin'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}]","[{'cui': 'C0451116', 'cui_str': 'Diabetes treatment satisfaction questionnaire'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0948106', 'cui_str': 'Amniorrhexis'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0460094', 'cui_str': 'Within reference range'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0085635', 'cui_str': 'Photopsia'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]",36.0,0.0949723,There were no significant group differences in d-ROMs and DTSQ scores after 24 weeks of treatments.,"[{'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Ohara', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. Electronic address: s6018@nms.ac.jp.'}, {'ForeName': 'Hiroe', 'Initials': 'H', 'LastName': 'Nagaike', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Tomoki', 'Initials': 'T', 'LastName': 'Fujikawa', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yo', 'Initials': 'Y', 'LastName': 'Kohata', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Maiho', 'Initials': 'M', 'LastName': 'Ogawa', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takemasa', 'Initials': 'T', 'LastName': 'Omachi', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Risa', 'Initials': 'R', 'LastName': 'Sasajima', 'Affiliation': 'Department of Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Japan.'}, {'ForeName': 'Hirotoshi', 'Initials': 'H', 'LastName': 'Chiba', 'Affiliation': 'Department of Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Japan.'}, {'ForeName': 'Toshimasa', 'Initials': 'T', 'LastName': 'Ara', 'Affiliation': 'Department of Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Japan.'}, {'ForeName': 'Ayuka', 'Initials': 'A', 'LastName': 'Sugawara', 'Affiliation': 'Department of Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Japan.'}, {'ForeName': 'Munenori', 'Initials': 'M', 'LastName': 'Hiromura', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Michishige', 'Initials': 'M', 'LastName': 'Terasaki', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yusaku', 'Initials': 'Y', 'LastName': 'Mori', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Anti-glycation Research Section, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Tomoyasu', 'Initials': 'T', 'LastName': 'Fukui', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Tsutomu', 'Initials': 'T', 'LastName': 'Hirano', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan; Diabetes Center, Ebina General Hospital, Kanagawa, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Yokoyama', 'Affiliation': 'Department of Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Japan.'}, {'ForeName': 'Sho-Ichi', 'Initials': 'SI', 'LastName': 'Yamagishi', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}]",Diabetes research and clinical practice,['10.1016/j.diabres.2021.108999'] 3349,34071868,The Effect of a Multi-Ingredient Pre-Workout Supplement on Time to Fatigue in NCAA Division I Cross-Country Athletes.,"This investigation aimed to determine the effect of a multi-ingredient pre-workout supplement (MIPS) on heart rate (HR), perceived exertion (RPE), lactate concentration, and time to fatigue (TTF) during a running task to volitional exhaustion. Eleven NCAA Division I cross-country runners (20 ± 2 year; height: 171 ± 14 cm; weight: 63.5 ± 9.1 kg) participated in this randomized, double-blind, placebo-controlled cross-over study. Bayesian statistical methods were utilized, and parameter estimates were interpreted as statistically significant if the 95% highest-density intervals (HDIs) did not include zero. TTF was increased in the MIPS condition with a posterior Mean diff = 154 ± 4.2 s (95% HDI: -167, 465) and a 0.84 posterior probability that the supplement would increase TTF relative to PL. Blood lactate concentration immediately post-exercise was also higher in the MIPS condition compared to PL with an estimated posterior Mean diff = 3.99 ± 2.1 mmol (95% HDI: -0.16, 7.68). There were no differences in HR or RPE between trials. These findings suggest that a MIPS ingested prior to sustained running at lactate threshold has an 84% chance of increasing TTF in highly trained runners and may allow athletes to handle a higher level of circulating lactate before reaching exhaustion.",2021,"Blood lactate concentration immediately post-exercise was also higher in the MIPS condition compared to PL with an estimated posterior Mean diff = 3.99 ± 2.1 mmol (95% HDI: -0.16, 7.68).",['Eleven NCAA Division I cross-country runners (20 ± 2 year; height: 171 ± 14 cm; weight: 63.5 ± 9.1 kg'],"['placebo', 'multi-ingredient pre-workout supplement (MIPS', 'Multi-Ingredient Pre-Workout Supplement']","['heart rate (HR), perceived exertion (RPE), lactate concentration, and time to fatigue (TTF', 'Blood lactate concentration', 'TTF relative to PL', 'TTF', 'Time to Fatigue in NCAA Division', 'HR or RPE']","[{'cui': 'C1293097', 'cui_str': 'Division'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C1293097', 'cui_str': 'Division'}]",,0.0607281,"Blood lactate concentration immediately post-exercise was also higher in the MIPS condition compared to PL with an estimated posterior Mean diff = 3.99 ± 2.1 mmol (95% HDI: -0.16, 7.68).","[{'ForeName': 'Haley', 'Initials': 'H', 'LastName': 'Fye', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, NE 68178, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Pass', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, NE 68178, USA.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Dickman', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, NE 68178, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Bredahl', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, NE 68178, USA.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Eckerson', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, NE 68178, USA.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Siedlik', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, NE 68178, USA.'}]",Nutrients,['10.3390/nu13061823'] 3350,34076333,Monotherapy treatment with chlorthalidone or amlodipine in the systolic blood pressure intervention trial (SPRINT).,"This post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) examined the performance of chlorthalidone (C) versus amlodipine (A) monotherapies. ANOVA was used to analyze the differences in systolic blood pressure (SBP) response between C and A. Logistic regression was used to examine monotherapy failure (adding a second antihypertensive agent or switching to a different antihypertensive agent) rates. Four hundred ninety-one participants were treated with C monotherapy (n = 210, mean dose = 22 mg/day) or A monotherapy (n = 281, mean dose = 7 mg/day). There was a significant difference in mean SBP reduction between the C and A monotherapies at the third visit (higher reduction with A, adjusted p = .018). Unadjusted analysis showed a higher failure with C in the standard treatment group. Although the average SBP at failure was higher and above the 140 mm Hg cutoff that indicated monotherapy failure with A (142.60) compared with C (138.40), more participants on C failed despite having SBP below the 140 cutoff. This was probably due to decisions made by the investigative teams to change the antihypertensive regimen, because, in their opinion, the clinical picture required it. After adjusting for baseline characteristics, C had higher failure than A only in the standard treatment group (1.64 odds ratio [OR], 95% CI 1.06-2.56, p = .028). A sub-analysis including participants who had never used antihypertensive treatment before randomization had similar results (2.57 OR, 95% CI 1.34-5.02, p = .004). Overall, in SPRINT chlorthalidone was associated with higher monotherapy failure than amlodipine in the standard treatment group because of decisions of the investigative teams.",2021,"Overall, in SPRINT chlorthalidone was associated with higher monotherapy failure than amlodipine in the standard treatment group because of decisions of the investigative teams.","['Four hundred ninety-one participants were treated with C monotherapy (n\xa0=\xa0210, mean']","['amlodipine', 'SPRINT chlorthalidone', 'chlorthalidone or amlodipine', 'monotherapy', 'chlorthalidone (C) versus amlodipine (A) monotherapies']","['systolic blood pressure (SBP) response', 'average SBP at failure', 'mean SBP reduction']","[{'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]","[{'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008294', 'cui_str': 'Chlorthalidone'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C1282151', 'cui_str': 'Average systolic blood pressure'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",491.0,0.154242,"Overall, in SPRINT chlorthalidone was associated with higher monotherapy failure than amlodipine in the standard treatment group because of decisions of the investigative teams.","[{'ForeName': 'Deep', 'Initials': 'D', 'LastName': 'Vakil', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Zinonos', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Kostis', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Jeanne M', 'Initials': 'JM', 'LastName': 'Dobrzynski', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Nora M', 'Initials': 'NM', 'LastName': 'Cosgrove', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Abel E', 'Initials': 'AE', 'LastName': 'Moreyra', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Kostis', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}]","Journal of clinical hypertension (Greenwich, Conn.)",['10.1111/jch.14296'] 3351,34073610,Strong and Bitter Vegetables from Traditional Cultivars and Cropping Methods Improve the Health Status of Type 2 Diabetics: A Randomized Control Trial.,"Vegetables rich in bitter-tasting phytochemicals may exert enhanced beneficial effects against key factors associated with type two diabetes (T2D). This study investigates whether selected cultivars of bitter and strong-tasting (BST) Brassica and root vegetables exert greater health benefits on T2D patients compared to equivalent modern mild and sweet tasting (MST) vegetables. A 12-week randomized, controlled, parallel intervention study involved 92 T2D patients, who were allocated three different diets: (1) 500 g daily of bitter and strong-tasting (BST) vegetables; (2) 500 g daily of mild and sweet-tasting (MST) vegetables; (3) 120 g daily MST normal diet (control). Both vegetable diets contained root vegetables and cabbages selected based on sensory differences and content of phytochemicals. Prior to and after the study, all participants underwent an oral glucose tolerance test (OGTT), 24 h blood pressure measurements, DEXA scans, and fasted blood samples. Both diets high in vegetables significantly reduced the participants' BMI, total body fat mass, and HbA1c levels compared to control, but in the BST group, significant differences were also found regarding incremental area under the curve glucose 240 min (OGTT) and fasting glucose levels. A high daily intake of root vegetables and cabbages showed significant health improvements in both vegetable groups. BST vegetables had the greatest impact on insulin sensitivity, body fat mass, and blood pressure compared to control; moreover, they further improved glycemic control compared to MST vegetables.",2021,"BST vegetables had the greatest impact on insulin sensitivity, body fat mass, and blood pressure compared to control; moreover, they further improved glycemic control compared to MST vegetables.","['92 T2D patients', 'T2D patients compared to equivalent modern mild and sweet tasting (MST) vegetables', 'Type 2 Diabetics']","['bitter and strong-tasting (BST) Brassica and root vegetables', 'oral glucose tolerance test (OGTT', 'diets: (1) 500 g daily of bitter and strong-tasting (BST) vegetables; (2) 500 g daily of mild and sweet-tasting (MST) vegetables; (3) 120 g daily MST normal diet (control']","['blood pressure measurements, DEXA scans, and fasted blood samples', 'insulin sensitivity, body fat mass, and blood pressure', 'health improvements', ""participants' BMI, total body fat mass, and HbA1c levels"", 'incremental area under the curve glucose 240 min (OGTT) and fasting glucose levels']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}]","[{'cui': 'C0235290', 'cui_str': 'Taste bitter'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0006135', 'cui_str': 'Brassica'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C1834582', 'cui_str': 'Transient abnormal myelopoiesis'}, {'cui': 'C0184625', 'cui_str': 'Normal diet'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0424677', 'cui_str': 'Total body fat'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}]",92.0,0.0239466,"BST vegetables had the greatest impact on insulin sensitivity, body fat mass, and blood pressure compared to control; moreover, they further improved glycemic control compared to MST vegetables.","[{'ForeName': 'Anne Cathrine', 'Initials': 'AC', 'LastName': 'Thorup', 'Affiliation': 'Department of Clinical Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Hanne Lakkenborg', 'Initials': 'HL', 'LastName': 'Kristensen', 'Affiliation': 'Department of Food Science, Faculty of Technical Sciences, Aarhus University, Agro Food Park 48, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Ulla', 'Initials': 'U', 'LastName': 'Kidmose', 'Affiliation': 'Department of Food Science, Faculty of Technical Sciences, Aarhus University, Agro Food Park 48, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Max Norman Tandrup', 'Initials': 'MNT', 'LastName': 'Lambert', 'Affiliation': 'Department of Clinical Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Lars Porskjær', 'Initials': 'LP', 'LastName': 'Christensen', 'Affiliation': 'Department of Green Technology, Faculty of Engineering, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Fretté', 'Affiliation': 'Department of Green Technology, Faculty of Engineering, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.'}, {'ForeName': 'Morten Rahr', 'Initials': 'MR', 'LastName': 'Clausen', 'Affiliation': 'Department of Food Science, Faculty of Technical Sciences, Aarhus University, Agro Food Park 48, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Steen Møller', 'Initials': 'SM', 'LastName': 'Hansen', 'Affiliation': 'Center for Clinical Research, Vendsyssel Hospital, Aalborg University, Bispensgade 37, 9800 Hjoerring, Denmark.'}, {'ForeName': 'Per Bendix', 'Initials': 'PB', 'LastName': 'Jeppesen', 'Affiliation': 'Department of Clinical Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, 8200 Aarhus N, Denmark.'}]",Nutrients,['10.3390/nu13061813'] 3352,34073587,"Adiponectin Gene Variant rs3774261, Effects on Lipid Profile and Adiponectin Levels after a High Polyunsaturated Fat Hypocaloric Diet with Mediterranean Pattern.","The role of ADIPOQ gene variants on metabolic improvements after weight change secondary to different hypocaloric diets remained unclear. We evaluate the effect of rs3774261 of ADIPOQ gene polymorphism on biochemical improvements and weight change after high polyunsaturated fat hypocaloric diet with a Mediterranean dietary pattern for 12 weeks. A population of 361 obese subjects was enrolled in an intervention trial with a calorie restriction of 500 calories over the usual intake and 45.7% of carbohydrates, 34.4% of fats, and 19.9% of proteins. The percentages of different fats was; 21.8% of monounsaturated fats, 55.5% of saturated fats, and 22.7% of polyunsaturated fats. Before and after intervention, an anthropometric study, an evaluation of nutritional intake and a biochemical evaluation were realized. All patients lost weight regardless of genotype and diet used. After 12 weeks with a similar improvement in weight loss (AA vs. AG vs. GG); total cholesterol (delta: -28.1 ± 2.1 mg/dL vs. -14.2 ± 4.1 mg/dL vs. -11.0 ± 3.9 mg/dL; p = 0.02), LDL cholesterol (delta: -17.1 ± 2.1 mg/dL vs. -6.1 ± 1.9 mg/dL vs. -6.0 ± 2.3 mg/dL; p = 0.01), triglyceride levels (delta: -35.0 ± 3.6 mg/dL vs. 10.1 ± 3.2 mg/dL vs. -9.7 ± 3.1 mg/dL; p = 0.02), C reactive protein (CRP) (delta: -2.3 ± 0.1 mg/dL vs. -0.2 ± 0.1 mg/dL vs. -0.2 ± 0.1 mg/dL; p = 0.02), serum adiponectin (delta: 11.6 ± 2.9 ng/dL vs. 2.1 ± 1.3 ng/dL vs. 3.3 ± 1.1 ng/dL; p = 0.02) and adiponectin/leptin ratio (delta: 1.5 ± 0.1 ng/dL vs. 0.3 ± 0.2 ng/dL vs. 0.4 ± 0.3 ng/dL; p = 0.03), improved only in AA group. AA genotype of ADIPOQ variant (rs3774261) is related with a significant increase in serum levels of adiponectin and ratio adiponectin/leptin and decrease on lipid profile and C-reactive protein (CRP).",2021,AA genotype of ADIPOQ variant (rs3774261) is related with a significant increase in serum levels of adiponectin and ratio adiponectin/leptin and decrease on lipid profile and C-reactive protein (CRP).,['361 obese subjects'],"['calorie restriction of 500 calories over the usual intake and 45.7% of carbohydrates, 34.4% of fats']","['weight loss', 'Lipid Profile and Adiponectin Levels', 'serum levels of adiponectin and ratio adiponectin/leptin and decrease on lipid profile and C-reactive protein (CRP', 'adiponectin/leptin ratio', 'LDL cholesterol', 'serum adiponectin', 'C reactive protein (CRP', 'triglyceride levels']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}]",361.0,0.0353916,AA genotype of ADIPOQ variant (rs3774261) is related with a significant increase in serum levels of adiponectin and ratio adiponectin/leptin and decrease on lipid profile and C-reactive protein (CRP).,"[{'ForeName': 'Daniel Antonio', 'Initials': 'DA', 'LastName': 'de Luis Roman', 'Affiliation': 'Center of Investigation of Endocrinology and Nutrition, Department of Endocrinology and Investigation, Medicine School, Hospital Clinico Universitario, University of Valladolid, 47005 Valladolid, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Primo', 'Affiliation': 'Center of Investigation of Endocrinology and Nutrition, Department of Endocrinology and Investigation, Medicine School, Hospital Clinico Universitario, University of Valladolid, 47005 Valladolid, Spain.'}, {'ForeName': 'Olatz', 'Initials': 'O', 'LastName': 'IZaola', 'Affiliation': 'Center of Investigation of Endocrinology and Nutrition, Department of Endocrinology and Investigation, Medicine School, Hospital Clinico Universitario, University of Valladolid, 47005 Valladolid, Spain.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Gómez', 'Affiliation': 'Center of Investigation of Endocrinology and Nutrition, Department of Endocrinology and Investigation, Medicine School, Hospital Clinico Universitario, University of Valladolid, 47005 Valladolid, Spain.'}, {'ForeName': 'Juan Jose', 'Initials': 'JJ', 'LastName': 'López', 'Affiliation': 'Center of Investigation of Endocrinology and Nutrition, Department of Endocrinology and Investigation, Medicine School, Hospital Clinico Universitario, University of Valladolid, 47005 Valladolid, Spain.'}]",Nutrients,['10.3390/nu13061811'] 3353,34051877,"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.","BACKGROUND Evidence suggests a role for excessive inflammation in COVID-19 complications. Colchicine is an oral anti-inflammatory medication beneficial in gout, pericarditis, and coronary disease. We aimed to investigate the effect of colchicine on the composite of COVID-19-related death or hospital admission. METHODS The present study is a phase 3, randomised, double-blind, adaptive, placebo-controlled, multicentre trial. The study was done in Brazil, Canada, Greece, South Africa, Spain, and the USA, and was led by the Montreal Heart Institute. Patients with COVID-19 diagnosed by PCR testing or clinical criteria who were not being treated in hospital were eligible if they were at least 40 years old and had at least one high-risk characteristic. The randomisation list was computer-generated by an unmasked biostatistician, and masked randomisation was centralised and done electronically through an automated interactive web-response system. The allocation sequence was unstratified and used a 1:1 ratio with a blocking schema and block sizes of six. Patients were randomly assigned to receive orally administered colchicine (0·5 mg twice per day for 3 days and then once per day for 27 days thereafter) or matching placebo. The primary efficacy endpoint was the composite of death or hospital admission for COVID-19. Vital status at the end of the study was available for 97·9% of patients. The analyses were done according to the intention-to-treat principle. The COLCORONA trial is registered with ClinicalTrials.gov (NCT04322682) and is now closed to new participants. FINDINGS Trial enrolment began in March 23, 2020, and was completed in Dec 22, 2020. A total of 4488 patients (53·9% women; median age 54·0 years, IQR 47·0-61·0) were enrolled and 2235 patients were randomly assigned to colchicine and 2253 to placebo. The primary endpoint occurred in 104 (4·7%) of 2235 patients in the colchicine group and 131 (5·8%) of 2253 patients in the placebo group (odds ratio [OR] 0·79, 95·1% CI 0·61-1·03; p=0·081). Among the 4159 patients with PCR-confirmed COVID-19, the primary endpoint occurred in 96 (4·6%) of 2075 patients in the colchicine group and 126 (6·0%) of 2084 patients in the placebo group (OR 0·75, 0·57-0·99; p=0·042). Serious adverse events were reported in 108 (4·9%) of 2195 patients in the colchicine group and 139 (6·3%) of 2217 patients in the placebo group (p=0·051); pneumonia occurred in 63 (2·9%) of 2195 patients in the colchicine group and 92 (4·1%) of 2217 patients in the placebo group (p=0·021). Diarrhoea was reported in 300 (13·7%) of 2195 patients in the colchicine group and 161 (7·3%) of 2217 patients in the placebo group (p<0·0001). INTERPRETATION In community-treated patients including those without a mandatory diagnostic test, the effect of colchicine on COVID-19-related clinical events was not statistically significant. Among patients with PCR-confirmed COVID-19, colchicine led to a lower rate of the composite of death or hospital admission than placebo. Given the absence of orally administered therapies to prevent COVID-19 complications in community-treated patients and the benefit of colchicine in patients with PCR-proven COVID-19, this safe and inexpensive anti-inflammatory agent could be considered for use in those at risk of complications. Notwithstanding these considerations, replication in other studies of PCR-positive community-treated patients is recommended. FUNDING The Government of Quebec, the Bill & Melinda Gates Foundation, the National Heart, Lung, and Blood Institute of the US National Institutes of Health, the Montreal Heart Institute Foundation, the NYU Grossman School of Medicine, the Rudin Family Foundation, and philanthropist Sophie Desmarais.",2021,Serious adverse events were reported in 108 (4·9%) of 2195 patients in the colchicine group and 139 (6·3%) of 2217 patients in the placebo group (p=0·051); pneumonia occurred in 63 (2·9%) of 2195 patients in the colchicine group and 92 (4·1%) of 2217 patients in the placebo group (p=0·021).,"['4159 patients with PCR', 'Trial enrolment began in March 23, 2020, and was completed in Dec 22, 2020', '0·79', 'Patients with COVID-19 diagnosed by PCR testing or clinical criteria who were not being treated in hospital were eligible if they were at least 40 years old and had at least one high-risk characteristic', '4488 patients (53·9% women; median age 54·0 years, IQR 47·0-61·0) were enrolled and 2235 patients', 'community-treated patients with COVID-19 (COLCORONA']","['colchicine', 'placebo', 'Colchicine']","['composite of death or hospital admission', 'COVID-19 complications', 'pneumonia', 'Diarrhoea', 'Serious adverse events', 'composite of death or hospital admission for COVID-19', 'COVID-19-related clinical events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0009262', 'cui_str': 'Colchicine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",4488.0,0.72654,Serious adverse events were reported in 108 (4·9%) of 2195 patients in the colchicine group and 139 (6·3%) of 2217 patients in the placebo group (p=0·051); pneumonia occurred in 63 (2·9%) of 2195 patients in the colchicine group and 92 (4·1%) of 2217 patients in the placebo group (p=0·021).,"[{'ForeName': 'Jean-Claude', 'Initials': 'JC', 'LastName': 'Tardif', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada. Electronic address: jean-claude.tardif@icm-mhi.org.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Bouabdallaoui', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Philippe L', 'Initials': 'PL', 'LastName': ""L'Allier"", 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Gaudet', 'Affiliation': 'Ecogene-21, Université de Montréal, Montreal, QC, Canada; Department of Medicine, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Binita', 'Initials': 'B', 'LastName': 'Shah', 'Affiliation': 'New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Pillinger', 'Affiliation': 'New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lopez-Sendon', 'Affiliation': 'H La Paz, IdiPaz, UAM, Ciber-CV, Madrid, Spain.'}, {'ForeName': 'Protasio', 'Initials': 'P', 'LastName': 'da Luz', 'Affiliation': 'Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil.'}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Verret', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Audet', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Jocelyn', 'Initials': 'J', 'LastName': 'Dupuis', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Denault', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Pelletier', 'Affiliation': 'Centre Hospitalier Universitaire de Québec, Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'Philippe A', 'Initials': 'PA', 'LastName': 'Tessier', 'Affiliation': 'Centre Hospitalier Universitaire de Québec, Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Samson', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Fortin', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Jean-Daniel', 'Initials': 'JD', 'LastName': 'Tardif', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Busseuil', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Goulet', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Lacoste', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Anick', 'Initials': 'A', 'LastName': 'Dubois', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Avni Y', 'Initials': 'AY', 'LastName': 'Joshi', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Waters', 'Affiliation': 'San Francisco General Hospital, San Francisco, CA, USA.'}, {'ForeName': 'Priscilla', 'Initials': 'P', 'LastName': 'Hsue', 'Affiliation': 'San Francisco General Hospital, San Francisco, CA, USA.'}, {'ForeName': 'Norman E', 'Initials': 'NE', 'LastName': 'Lepor', 'Affiliation': 'Cedars-Sinai Heart Institute, Geffen School of Medicine-UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Lesage', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Sainturet', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Eve', 'Initials': 'E', 'LastName': 'Roy-Clavel', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Zohar', 'Initials': 'Z', 'LastName': 'Bassevitch', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Orfanos', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Stamatescu', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'Grégoire', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Lambert', 'Initials': 'L', 'LastName': 'Busque', 'Affiliation': 'Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Lavallée', 'Affiliation': 'Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Pierre-Olivier', 'Initials': 'PO', 'LastName': 'Hétu', 'Affiliation': ""Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Jean-Sébastien', 'Initials': 'JS', 'LastName': 'Paquette', 'Affiliation': 'Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'Spyridon G', 'Initials': 'SG', 'LastName': 'Deftereos', 'Affiliation': 'Second Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Levesque', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Mariève', 'Initials': 'M', 'LastName': 'Cossette', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Nozza', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Malorie', 'Initials': 'M', 'LastName': 'Chabot-Blanchet', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Marie-Pierre', 'Initials': 'MP', 'LastName': 'Dubé', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Guertin', 'Affiliation': 'Montréal Health Innovations Coordinating Center, Montreal, QC, Canada.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Boivin', 'Affiliation': 'Centre Hospitalier Universitaire de Québec, Université Laval, Quebec City, QC, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(21)00222-8'] 3354,34059149,Development and double cross-validation of new spot urine sodium equation to predict 24-h urine sodium in the Malaysian population.,"BACKGROUND Monitoring sodium intake through 24-h urine collection sample is recommended, but the implementation of this method can be difficult. The objective of this study was to develop and validate an equation using spot urine concentration to predict 24-h sodium excretion in the Malaysian population. METHODS This was a Malaysian Community Salt Study (MyCoSS) sub-study, which was conducted from October 2017 to March 2018. Out of 798 participants in the MyCoSS study who completed 24-h urine collection, 768 of them have collected one-time spot urine the following morning. They were randomly assigned into two groups to form separate spot urine equations. The final spot urine equation was derived from the entire data set after confirming the stability of the equation by double cross-validation in both study groups. Newly derived spot urine equation was developed using the coefficients from the multiple linear regression test. A Bland-Altman plot was used to measure the mean bias and limits of agreement between estimated and measured 24-h urine sodium. The estimation of sodium intake using the new equation was compared with other established equations, namely Tanaka and INTERSALT. RESULTS The new equation showed the least mean bias between measured and predicted sodium, - 0.35 (- 72.26, 71.56) mg/day compared to Tanaka, 629.83 (532.19, 727.47) mg/day and INTERSALT, and 360.82 (284.34, 437.29) mg/day. Predicted sodium measured from the new equation showed greater correlation with measured sodium (r = 0.50) compared to Tanaka (r =0.24) and INTERSALT (r = 0.44), P < 0.05. CONCLUSION Our newly developed equation from spot urine can predict least mean bias of sodium intake among the Malaysian population when 24-h urine sodium collection is not feasible.",2021,"Predicted sodium measured from the new equation showed greater correlation with measured sodium (r = 0.50) compared to Tanaka (r =0.24) and INTERSALT (r = 0.44), P < 0.05. ","['798 participants in the MyCoSS study who completed 24-h urine collection, 768 of them have collected one-time spot urine the following morning', 'Malaysian population']",[],['mean bias and limits of agreement between estimated and measured 24-h urine sodium'],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0200354', 'cui_str': 'Urine specimen collection'}, {'cui': 'C0205447', 'cui_str': '1'}, {'cui': 'C0457208', 'cui_str': 'Spot urine sample'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1256585', 'cui_str': 'Sodium measurement, urine'}]",798.0,0.10729,"Predicted sodium measured from the new equation showed greater correlation with measured sodium (r = 0.50) compared to Tanaka (r =0.24) and INTERSALT (r = 0.44), P < 0.05. ","[{'ForeName': 'Fatimah', 'Initials': 'F', 'LastName': 'Othman', 'Affiliation': 'Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia. fatimah.oth@moh.gov.my.'}, {'ForeName': 'Rashidah', 'Initials': 'R', 'LastName': 'Ambak', 'Affiliation': 'Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia.'}, {'ForeName': 'Mohd Azahadi', 'Initials': 'MA', 'LastName': 'Omar', 'Affiliation': 'Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia.'}, {'ForeName': 'Suzana', 'Initials': 'S', 'LastName': 'Shahar', 'Affiliation': 'Centre of Healthy Ageing and Wellness, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Noor Safiza Mohd', 'Initials': 'NSM', 'LastName': 'Nor', 'Affiliation': 'Policy and Strategic Planning Section, Allied Health Science Division, Ministry of Health Malaysia, Putrajaya, Malaysia.'}, {'ForeName': 'Mohamad Hasnan', 'Initials': 'MH', 'LastName': 'Ahmad', 'Affiliation': 'Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia.'}, {'ForeName': 'Muhammad Fadhli Mohd', 'Initials': 'MFM', 'LastName': 'Yusoff', 'Affiliation': 'Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia.'}, {'ForeName': 'Hasnah', 'Initials': 'H', 'LastName': 'Haron', 'Affiliation': 'Centre of Healthy Ageing and Wellness, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Mohd Fairulnizal Md', 'Initials': 'MFM', 'LastName': 'Noh', 'Affiliation': 'Diabetes & Endocrine Unit, Institute for Medical Research, National Institute for Health, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Tahir', 'Initials': 'T', 'LastName': 'Aris', 'Affiliation': 'Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia.'}]","Journal of health, population, and nutrition",['10.1186/s41043-021-00232-3'] 3355,34058023,Plasma trial: Pilot randomized clinical trial to determine safety and efficacy of plasma transfusions.,"BACKGROUND Plasma is frequently administered to patients with prolonged INR prior to invasive procedures. However, there is limited evidence evaluating efficacy and safety. STUDY DESIGN AND METHODS We performed a pilot trial in hospitalized patients with INR between 1.5 and 2.5 undergoing procedures conducted outside the operating room. We excluded patients undergoing procedures proximal to the central nervous system, platelet counts <40,000/μl, or congenital or acquired coagulation disorders unresponsive to plasma. We randomly allocated patients stratified by hospital and history of cirrhosis to receive plasma transfusion (10-15 cc/kg) or no transfusion. The primary outcome was change in hemoglobin concentration within 2 days of procedure. RESULTS We enrolled 57 patients, mean age 56.0, 34 (59.6%) with cirrhosis, and mean INR 1.92 (SD = 0.27). In the intention to treat analysis, there were 10 of 27 (38.5%) participants in the plasma arm with a post procedure INR <1.5 and one of 30 (3.6%) in the no treatment arm (p < .01). The mean INR after receiving plasma transfusion was -0.24 (SD 0.26) lower than baseline. The change from pre-procedure hemoglobin level to lowest level within 2 days was -0.6 (SD = 1.0) in the plasma transfusion arm and -0.4 (SD = 0.6) in the no transfusion arm (p = .29). Adverse outcomes were uncommon. DISCUSSION We found no differences in change in hemoglobin concentration in those treated with plasma compared to no treatment. The change in INR was small and corrected to less than 1.5 in minority of patients. Large trials are required to establish if plasma is safe and efficacious.",2021,The mean INR after receiving plasma transfusion was -0.24,"['We enrolled 57 patients, mean age 56.0, 34 (59.6%) with cirrhosis, and mean INR 1.92 (SD\xa0=\xa00.27', 'patients undergoing procedures proximal to the central nervous system, platelet counts <40,000/μl, or congenital or acquired coagulation disorders unresponsive to plasma', 'hospitalized patients with INR between 1.5 and 2.5 undergoing procedures conducted outside the operating room', 'patients with prolonged INR prior to invasive procedures']","['plasma transfusions', 'plasma transfusion (10-15\u2009cc/kg) or no transfusion']","['hemoglobin concentration', 'change in INR', 'mean INR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0009678', 'cui_str': 'congenital'}, {'cui': 'C0398622', 'cui_str': 'Acquired coagulation disorder'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0278347', 'cui_str': 'Transfusion of plasma'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}]","[{'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",57.0,0.320934,The mean INR after receiving plasma transfusion was -0.24,"[{'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Carson', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Ness', 'Affiliation': 'Division of Transfusion Medicine, Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, USA.'}, {'ForeName': 'Monica B', 'Initials': 'MB', 'LastName': 'Pagano', 'Affiliation': 'Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Claire S', 'Initials': 'CS', 'LastName': 'Philipp', 'Affiliation': 'Division of Hematology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.'}, {'ForeName': 'Arthur W', 'Initials': 'AW', 'LastName': 'Bracey', 'Affiliation': 'Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Maria Mori', 'Initials': 'MM', 'LastName': 'Brooks', 'Affiliation': 'Department of Epidemiology and Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'John L', 'Initials': 'JL', 'LastName': 'Nosher', 'Affiliation': 'Department of Radiology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Hogshire', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.'}, {'ForeName': 'Helaine', 'Initials': 'H', 'LastName': 'Noveck', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.'}, {'ForeName': 'Darrell J', 'Initials': 'DJ', 'LastName': 'Triulzi', 'Affiliation': 'Division of Transfusion Medicine, Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}]",Transfusion,['10.1111/trf.16508'] 3356,34062004,"Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.","In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1-3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone (Vd). Compared with Vd, XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy, with trends in overall survival (OS) favoring XVd. In BOSTON, 141 (35.1%) patients had MM with high-risk (presence of del[17p], t[4;14], t[14;16], or ≥4 copies of amp1q21) cytogenetics (XVd, n = 70; Vd, n = 71), and 261 (64.9%) exhibited standard-risk cytogenetics (XVd, n = 125; Vd, n = 136). Among patients with high-risk MM, median PFS was 12.91 months for XVd and 8.61 months for Vd (HR, 0.73 [95% CI, (0.4673, 1.1406)], p = 0.082), and ORRs were 78.6% and 57.7%, respectively (OR 2.68; p = 0.004). In the standard-risk subgroup, median PFS was 16.62 months for XVd and 9.46 months for Vd (HR 0.61; p = 0.004), and ORRs were 75.2% and 64.7%, respectively (OR 1.65; p = 0.033). The safety profiles of XVd and Vd in both subgroups were consistent with the overall population. These data suggest that selinexor can confer benefits to patients with MM regardless of cytogenetic risk. ClinicalTrials.gov identifier: NCT03110562.",2021,"Compared with Vd, XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy, with trends in overall survival (OS) favoring XVd.","['patients with multiple myeloma (MM) after 1-3 prior regimens', '141 (35.1%) patients had MM with high-risk (presence of del[17p], t[4;14], t[14;16], or ≥4 copies of amp1q21) cytogenetics (XVd, n=70; Vd, n=71), and 261 (64.9%) exhibited standard-risk cytogenetics (XVd, n=125; Vd, n=136', 'previously treated multiple myeloma']","['Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone', 'selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone (Vd', 'selinexor']","['ORRs', 'median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy', 'median PFS', 'overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0008628', 'cui_str': 'Chromosomal deletion'}, {'cui': 'C0010802', 'cui_str': 'Cytogenetics'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C3852671', 'cui_str': 'Selinexor'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0210793', 'cui_str': 'exportin 1 protein'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.170404,"Compared with Vd, XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy, with trends in overall survival (OS) favoring XVd.","[{'ForeName': 'Shambavi', 'Initials': 'S', 'LastName': 'Richard', 'Affiliation': 'Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA.'}, {'ForeName': 'Ajai', 'Initials': 'A', 'LastName': 'Chari', 'Affiliation': 'Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA.'}, {'ForeName': 'Sosana', 'Initials': 'S', 'LastName': 'Delimpasi', 'Affiliation': 'General Hospital Evangelismos, Athens, Greece.'}, {'ForeName': 'Maryana', 'Initials': 'M', 'LastName': 'Simonova', 'Affiliation': 'Institute of Blood Pathology & Transfusion Medicine of National Academy of Medical Sciences of Ukraine, Lviv, Ukraine.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Spicka', 'Affiliation': 'Charles University and General Hospital, Prague, Czech Republic.'}, {'ForeName': 'Ludek', 'Initials': 'L', 'LastName': 'Pour', 'Affiliation': 'Clinic of Internal Medicine -Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.'}, {'ForeName': 'Iryna', 'Initials': 'I', 'LastName': 'Kriachok', 'Affiliation': 'National Cancer Institute Ukraine, Kiev, Ukraine.'}, {'ForeName': 'Meletios A', 'Initials': 'MA', 'LastName': 'Dimopoulos', 'Affiliation': 'School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.'}, {'ForeName': 'Halyna', 'Initials': 'H', 'LastName': 'Pylypenko', 'Affiliation': 'Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.'}, {'ForeName': 'Holger W', 'Initials': 'HW', 'LastName': 'Auner', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Leleu', 'Affiliation': 'Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.'}, {'ForeName': 'Ganna', 'Initials': 'G', 'LastName': 'Usenko', 'Affiliation': 'City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine.'}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Hajek', 'Affiliation': 'Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.'}, {'ForeName': 'Reuben', 'Initials': 'R', 'LastName': 'Benjamin', 'Affiliation': 'Kings College Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Tuphan Kanti', 'Initials': 'TK', 'LastName': 'Dolai', 'Affiliation': 'Nil Ratan Sircar Medical College and Hospital, Kolkata, India.'}, {'ForeName': 'Dinesh Kumar', 'Initials': 'DK', 'LastName': 'Sinha', 'Affiliation': 'State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Venner', 'Affiliation': 'Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Mamta', 'Initials': 'M', 'LastName': 'Garg', 'Affiliation': 'University Hospitals of Leicester NHS Trust, Leicester, UK.'}, {'ForeName': 'Don Ambrose', 'Initials': 'DA', 'LastName': 'Stevens', 'Affiliation': 'Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, USA.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Quach', 'Affiliation': ""University of Melbourne, St. Vincent's Hospital, Melbourne, Victoria, Australia.""}, {'ForeName': 'Sundar', 'Initials': 'S', 'LastName': 'Jagannath', 'Affiliation': 'Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA.'}, {'ForeName': 'Phillipe', 'Initials': 'P', 'LastName': 'Moreau', 'Affiliation': 'University Hospital, Hotel-Dieu, Nantes, France.'}, {'ForeName': 'Moshe', 'Initials': 'M', 'LastName': 'Levy', 'Affiliation': 'Baylor University Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Badros', 'Affiliation': 'University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.'}, {'ForeName': 'Larry D', 'Initials': 'LD', 'LastName': 'Anderson', 'Affiliation': 'Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Nizar J', 'Initials': 'NJ', 'LastName': 'Bahlis', 'Affiliation': 'University of Calgary, Charbonneau Cancer Research Institute, Calgary, Alberta, Canada.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Facon', 'Affiliation': 'CHU Lille Service des Maladies du Sang F-59000, Lille, France.'}, {'ForeName': 'Maria Victoria', 'Initials': 'MV', 'LastName': 'Mateos', 'Affiliation': 'Hospital Universitario de Salamanca, Salamanca, Spain.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Cavo', 'Affiliation': 'Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Chang', 'Affiliation': 'Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.'}, {'ForeName': 'Yosef', 'Initials': 'Y', 'LastName': 'Landesman', 'Affiliation': 'Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Chai', 'Affiliation': 'Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.'}, {'ForeName': 'Melina', 'Initials': 'M', 'LastName': 'Arazy', 'Affiliation': 'Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.'}, {'ForeName': 'Jatin', 'Initials': 'J', 'LastName': 'Shah', 'Affiliation': 'Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Shacham', 'Affiliation': 'Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Kauffman', 'Affiliation': 'Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Grosicki', 'Affiliation': 'Medical University of Silesia, Katowice, Poland.'}, {'ForeName': 'Paul G', 'Initials': 'PG', 'LastName': 'Richardson', 'Affiliation': 'Dana Farber Cancer Institute, Boston, Massachusetts, USA.'}]",American journal of hematology,['10.1002/ajh.26261'] 3357,34076382,"An in vivo, randomized, controlled comparative evaluation of efficacy, hemodynamic changes, and postoperative complications of 4% articaine using buccal infiltration and 2% lidocaine using inferior alveolar nerve block in mandibular primary molars of children aged 6 to 8 years.","OBJECTIVE To compare and evaluate the efficacy, hemodynamic changes, and postoperative complications of 4% articaine using buccal infiltration and 2% lidocaine using inferior alveolar nerve block in mandibular primary molars of children aged 6 to 8 years. METHOD AND MATERIALS 100 participants were randomly distributed to receive either 4% articaine using infiltration anesthesia or 2% lidocaine using inferior alveolar nerve block on each side of the mandibular arch, in two different appointments, after a 1-week interval. The pain perception was evaluated using visual analog scale (VAS) and Wong-Baker Faces pain rating scale (WBFPRS). In both the appointments, the efficacy and onset of anesthesia were evaluated using an electric pulp tester. Hemodynamic parameters, which included pulse rate and oxygen saturation levels, were evaluated using a pulse oximeter. Postoperative complications were evaluated at 24-hour follow-up. RESULTS Pain score recorded with block was more painful compared to infiltration (P < .05). Anesthetic success was observed with both the local anesthetic agents, with no significant differences (P > .05). Shorter onset of action was observed with articaine (P < .05). Statistically significant differences between groups were noted with regard to heart rate (P < .05). Oxygen saturation levels did not show significant differences (P > .05). When postoperative complications were evaluated with either 4% articaine or 2% lidocaine, very few adverse effects were recorded (P > .05). CONCLUSION Buccal infiltration using 4% articaine has the potential to replace 2% lidocaine using inferior alveolar nerve block in children.",2021,"RESULTS Pain score recorded with block was more painful compared to infiltration (P < .05).","['100 participants', 'children', 'mandibular primary molars of children aged 6 to 8 years']","['articaine', 'articaine using infiltration anesthesia or 2% lidocaine', 'lidocaine']","['Pain score', 'efficacy and onset of anesthesia', 'heart rate', 'Postoperative complications', 'postoperative complications', 'Oxygen saturation levels', 'visual analog scale (VAS) and Wong-Baker Faces pain rating scale (WBFPRS', 'adverse effects', 'Shorter onset of action', 'pain perception', 'efficacy, hemodynamic changes, and postoperative complications', 'pulse rate and oxygen saturation levels', 'Anesthetic success']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1608295', 'cui_str': 'Articaine'}, {'cui': 'C0234945', 'cui_str': 'Infiltration anaesthesia'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0238749', 'cui_str': 'Baker, general'}, {'cui': 'C0015468', 'cui_str': 'Pain in face'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}]",100.0,0.0195423,"RESULTS Pain score recorded with block was more painful compared to infiltration (P < .05).","[{'ForeName': 'Suhani R', 'Initials': 'SR', 'LastName': 'Khanna', 'Affiliation': ''}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Rao', 'Affiliation': ''}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Panwar', 'Affiliation': ''}, {'ForeName': 'Safna', 'Initials': 'S', 'LastName': 'Ameen', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.b1492247'] 3358,34076381,Influence of PRGF and PRF on postextractive alveolus regeneration: a randomised controlled trial.,"OBJECTIVES Healing of postextraction alveolus is a complex process that involves soft and hard tissue regeneration. Pain, swelling, difficulty in opening the mouth, delayed bone tissue healing, alveolitis, and horizontal or vertical resorption of bone tissue are the main problems that impact on consequent treatment. Blood concentrates PRGF (plasma rich in growth factors) and PRF (platelet-rich fibrin), which are rich in growth factors, create better conditions for postextraction alveolus healing, enhance quality of soft tissues and bone regeneration, and decrease pain. The study objective was to compare physiologic healing of the postextraction zone with PRF- and PRGF-induced changes. METHOD AND MATERIALS In total, 43 patients were randomly divided into three groups: control group (mandibular molar extraction and filling of postextraction alveolus with hemostatic sponge containing gentamicin), group 2 (postextraction alveolus filled with PRGF), and group 3 (postextraction alveolus filled with PRF). Bone regeneration was evaluated in CBCT scans after 1 month. Pain was evaluated using the visual analog scale (VAS). RESULTS After evaluating VAS results 1 day after surgery the lowest pain score was in the PRGF group. Tooth alveolus vertical and diagonal dimensions in the control group were significantly (P = .017) smaller than in the PRGF group. The vertical dimension of the alveolar ridge did not change significantly (P = .859) in the PRGF group; however, it was significantly reduced (P = .04) in the PRF group. One month after surgery the age of the control group was inversely proportionally correlated with the height and diagonal dimension of callus. CONCLUSION Both blood concentrates had great anti-inflammatory properties, but PRGF had better osteoblastic properties and resulted in lower postoperative pain.",2021,"The vertical dimension of the alveolar ridge did not change significantly (P = .859) in the PRGF group; however, it was significantly reduced (P = .04) in the PRF group.",['43 patients'],"['PRGF', 'control group (mandibular molar extraction and filling of postextraction alveolus with hemostatic sponge containing gentamicin), group 2 (postextraction alveolus filled with PRGF), and group 3 (postextraction alveolus filled with PRF', 'PRGF and PRF']","['visual analog scale (VAS', 'Tooth alveolus vertical and diagonal dimensions', 'Pain', 'vertical dimension of the alveolar ridge', 'postextractive alveolus regeneration', 'Pain, swelling, difficulty in opening the mouth, delayed bone tissue healing, alveolitis, and horizontal or vertical resorption of bone tissue', 'height and diagonal dimension of callus', 'postoperative pain', 'Bone regeneration', 'lowest pain score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0227130', 'cui_str': 'Structure of alveolus dentalis'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0032699', 'cui_str': 'Phylum Porifera'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0017436', 'cui_str': 'Gentamycins'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0033374', 'cui_str': 'Prolactin releasing factor'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0227130', 'cui_str': 'Structure of alveolus dentalis'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0443198', 'cui_str': 'Diagonal'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042569', 'cui_str': 'Vertical Dimension'}, {'cui': 'C0447411', 'cui_str': 'Alveolar ridge structure'}, {'cui': 'C0034963', 'cui_str': 'Regeneration'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0391978', 'cui_str': 'Bone (tissue) structure'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0549493', 'cui_str': 'Alveolitis'}, {'cui': 'C0205126', 'cui_str': 'Horizontal'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0006767', 'cui_str': 'Callus of bone'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0005972', 'cui_str': 'Bone Regeneration'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",43.0,0.0110196,"The vertical dimension of the alveolar ridge did not change significantly (P = .859) in the PRGF group; however, it was significantly reduced (P = .04) in the PRF group.","[{'ForeName': 'Valdonė', 'Initials': 'V', 'LastName': 'Brazdeikytė', 'Affiliation': ''}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Baliutavičiūtė', 'Affiliation': ''}, {'ForeName': 'Jan Pavel', 'Initials': 'JP', 'LastName': 'Rokicki', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.b1492237'] 3359,34076379,"Assessment of Passiflora incarnata L for conscious sedation of patients during the extraction of mandibular third molars: a randomized, split-mouth, double-blind, crossover study.","OBJECTIVE The aim of the present study was to evaluate the efficacy of Passiflora incarnata L for the control of anxiety during third mandibular molar extraction and compare it to midazolam, the most used benzodiazepine in dentistry. METHOD AND MATERIALS The investigators implemented a prospective, randomized, double-blind, split-mouth study. The degree of anxiety of the patients was assessed before the surgical procedure. The surgeries took place in two sessions: one on each side of the hemi-mandible and, on each of them, the patient received one of the drugs, crosswise. Anxiety control was measured through physical parameters, at the following periods during the surgery: (1) immediately administration of anxiolytic medication, (2) 30 minutes after anxiolytic medication, (3) after extraoral antisepsis, (4) after local anesthesia, (5) during incision, (6) during osteotomy, (7) between osteotomy and odontosection, (8) during odontosection, (9) during surgical store curettage, (10) during suture, and (11) immediately after postoperative care guidelines. Lastly, the volunteers received a self-assessment form in order to report their experience. Statistical analysis was performed using the Wilcoxon test. RESULTS The final sample was composed of 20 patients, with a mean age of 22.5 years. The results of the physical parameters showed statistically significant differences (P < .05) for certain times and physical parameters, especially heart rate (P = .036), which showed the highest control for Passiflora at time point (3). The undesirable effects reported by patients such as drowsiness, muscle relaxation, and dizziness were greater with benzodiazepine. CONCLUSION The results of this study suggest that Passiflora may be considered as an alternative to midazolam in controlling anxiety in dentistry. Future studies will focus on other benzodiazepines and herbal medicines.",2021,"The results of the physical parameters showed statistically significant differences (P < .05) for certain times and physical parameters, especially heart rate (P = .036), which showed the highest control for Passiflora at time point (3).","['patients during the extraction of mandibular third molars', '20 patients, with a mean age of 22.5 years']","['benzodiazepine', 'benzodiazepines', 'Passiflora incarnata L', 'midazolam']","['degree of anxiety', 'certain times and physical parameters, especially heart rate', 'Anxiety control', 'drowsiness, muscle relaxation, and dizziness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517649', 'cui_str': '22.5'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C2919980', 'cui_str': 'passiflora incarnata flowering top extract'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205423', 'cui_str': 'Certain'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0026836', 'cui_str': 'Muscle relaxation'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}]",,0.0165929,"The results of the physical parameters showed statistically significant differences (P < .05) for certain times and physical parameters, especially heart rate (P = .036), which showed the highest control for Passiflora at time point (3).","[{'ForeName': 'Marcelly Tupan', 'Initials': 'MT', 'LastName': 'Christoffoli', 'Affiliation': ''}, {'ForeName': 'Andressa Bolognesi', 'Initials': 'AB', 'LastName': 'Bachesk', 'Affiliation': ''}, {'ForeName': 'Gustavo Jacobucci', 'Initials': 'GJ', 'LastName': 'Farah', 'Affiliation': ''}, {'ForeName': 'Gustavo Zanna', 'Initials': 'GZ', 'LastName': 'Ferreira', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.b1492199'] 3360,34390625,The effect of total compression time and rate (slope) of compression on the incidence of symptomatic Eustachian tube dysfunction and middle ear barotrauma: a Phase II prospective study.,"Eustachian tube dysfunction (ETD) and middle ear barotrauma (MEB) are common reported complications during hyperbaric oxygen treatment. Our Phase I study data was the first to demonstrate a statistically significant decrease in the occurrence of symptomatic ETD and MEB. The Phase I Trial suggested the total time interval and rate (slope) of compression (ROC) may be a determining factor in ETD and MEB. This Phase II study investigates an optimal rate of compression to reduce ETD and MEB when considering each multiplace treatment (with multiple patients) as the unit of observation as a group, rather than for each individual patient. Data were collected prospectively on 1,244 group patient-treatment exposures, collectively including 5,072 individual patient-treatment/exposures. We randomly assigned patient-treatment group exposures to four different time interval and rate (slope) of compression. These compression rates and slopes were identical to those used in the Phase I trial. All patients experiencing symptoms of MEB requiring compression stops were evaluated post treatment for the presence of ETD and MEB using the O'Neill Grading System (OGS) for ETD. Data were analyzed using the IBM-SPSS statistical software program. A statistically significant decrease in the number of compression holds was observed in the 15-minute compression schedule, correlating to the results observed in the Phase I trial. The 15-minute linear compression profile continues to demonstrate the decreased need for patient symptomatic compression stops (as in the Phase I trial) using a USN TT9 during elective hyperbaric oxygen treatments in a Class A multiplace hyperbaric chamber. Trial Registration: ClinicalTrials.gov Identifier: NCT04776967.",2021,All patients experiencing symptoms of MEB requiring compression stops were evaluated post treatment for the presence of ETD and MEB using the O'Neill Grading System (OGS) for ETD.,"['a Class A multiplace hyperbaric chamber', '1,244 group patient-treatment exposures, collectively including 5,072 individual patient-treatment/exposures', 'symptomatic Eustachian tube dysfunction and middle ear barotrauma']","['USN TT9', 'total compression time and rate (slope) of compression']","['total time interval and rate (slope) of compression (ROC', 'occurrence of symptomatic ETD and MEB', 'number of compression holds', 'Eustachian tube dysfunction (ETD) and middle ear barotrauma (MEB']","[{'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0175726', 'cui_str': 'Hyperbaric chamber'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0271468', 'cui_str': 'Eustachian tube disorder'}, {'cui': 'C0013455', 'cui_str': 'Middle ear structure'}, {'cui': 'C0004760', 'cui_str': 'Accident due to extremes of atmospheric pressure and to sudden changes in atmospheric pressure'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0040223', 'cui_str': 'Time'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0271468', 'cui_str': 'Eustachian tube disorder'}, {'cui': 'C0013455', 'cui_str': 'Middle ear structure'}, {'cui': 'C0004760', 'cui_str': 'Accident due to extremes of atmospheric pressure and to sudden changes in atmospheric pressure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}]",,0.0316223,All patients experiencing symptoms of MEB requiring compression stops were evaluated post treatment for the presence of ETD and MEB using the O'Neill Grading System (OGS) for ETD.,"[{'ForeName': 'Owen J', 'Initials': 'OJ', 'LastName': ""O'Neill"", 'Affiliation': 'Department of Surgery, Division of Undersea and Hyperbaric Medicine, Phelps Hospital Northwell Health.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Dayya', 'Affiliation': 'Department of Surgery, Division of Undersea and Hyperbaric Medicine, Phelps Hospital Northwell Health.'}, {'ForeName': 'Lince', 'Initials': 'L', 'LastName': 'Varughese', 'Affiliation': 'Department of Hyperbaric and Wound Medicine, Baylor, Scott and White Medical Center Rowlett.'}, {'ForeName': 'Jo Anne', 'Initials': 'JA', 'LastName': 'Marker', 'Affiliation': 'Department of Surgery, Division of Undersea and Hyperbaric Medicine, Phelps Hospital Northwell Health.'}, {'ForeName': 'Lubiha', 'Initials': 'L', 'LastName': 'Perez', 'Affiliation': 'Department of Surgery, Division of Undersea and Hyperbaric Medicine, Phelps Hospital Northwell Health.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Dayya', 'Affiliation': 'Department of Engineering, University of Connecticut.'}]","Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc",[] 3361,34075811,Impact of acute antioxidant supplementation on vascular function and autonomic nervous system modulation in young adults with PTSD.,"Posttraumatic stress disorder (PTSD) has been associated with an increase in risk of cardiovascular disease (CVD). The goal of this study was to determine if peripheral vascular dysfunction, a precursor to CVD, was present in young adults with PTSD, and if an acute antioxidant (AO) supplementation could modify this potential PTSD-induced vascular dysfunction. Thirteen individuals with PTSD were recruited for this investigation and were compared with 35 age- and sex-matched controls (CTRL). The PTSD group participated in two visits, consuming either a placebo (PTSD-PL) or antioxidants (PTSD-AO; vitamins C and E; α-lipoic acid) before their visits, whereas the CTRL subjects only participated in one visit. Upper and lower limb vascular functions were assessed via flow-mediated dilation and passive leg movement technique. Heart rate variability was utilized to assess autonomic nervous system modulation. The PTSD-PL condition, when compared with the CTRL group, reported lower arm and leg microvascular function as well as sympathetic nervous system (SNS) predominance. After acute AO supplementation, arm, but not leg, microvascular function was improved and SNS predominance was lowered to which the prior difference between PTSD group and CTRL was no longer significant. Young individuals with PTSD demonstrated lower arm and leg microvascular function as well as greater SNS predominance when compared with age- and sex-matched controls. Furthermore, this lower vascular/autonomic function was augmented by an acute AO supplementation to the level of the healthy controls, potentially implicating oxidative stress as a contributor to this blunted vascular/autonomic function.",2021,"The PTSD-PL condition, when compared to the CTRL group, reported lower arm and leg microvascular function as well as sympathetic nervous system (SNS) predominance.","['Young Adults with PTSD', 'Young individuals with', 'Posttraumatic stress disorder (PTSD', 'young adults with PTSD', 'Thirteen individuals with PTSD were recruited for this investigation and were compared to 35 age- and sex-matched controls (CTRL']","['PTSD', 'placebo (PTSD-PL) or antioxidants (PTSD-AO; Vitamins C and E; Alpha Lipoic Acid', 'Acute Antioxidant Supplementation']","['lower vascular/autonomic function', 'Upper and lower limb vascular function', 'Vascular Function and Autonomic Nervous System Modulation', 'SNS predominance', 'leg microvascular function', 'leg, microvascular function']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0023791', 'cui_str': 'thioctic acid'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0039044', 'cui_str': 'Sympathetic nervous system structure'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}]",13.0,0.0560469,"The PTSD-PL condition, when compared to the CTRL group, reported lower arm and leg microvascular function as well as sympathetic nervous system (SNS) predominance.","[{'ForeName': 'Jennifer B', 'Initials': 'JB', 'LastName': 'Weggen', 'Affiliation': 'Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, Virginia.'}, {'ForeName': 'Ashley M', 'Initials': 'AM', 'LastName': 'Darling', 'Affiliation': 'Department of Kinesiology, University of Texas at Arlington, Arlington, Texas.'}, {'ForeName': 'Aaron S', 'Initials': 'AS', 'LastName': 'Autler', 'Affiliation': 'Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, Virginia.'}, {'ForeName': 'Austin C', 'Initials': 'AC', 'LastName': 'Hogwood', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Kevin P', 'Initials': 'KP', 'LastName': 'Decker', 'Affiliation': 'Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, Virginia.'}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Imthurn', 'Affiliation': 'Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, Virginia.'}, {'ForeName': 'Gina M', 'Initials': 'GM', 'LastName': 'Tuzzolo', 'Affiliation': 'Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, Virginia.'}, {'ForeName': 'Ryan S', 'Initials': 'RS', 'LastName': 'Garten', 'Affiliation': 'Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, Virginia.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00054.2021'] 3362,34081408,"Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double-Blind, Dose Escalation, Placebo- and Positive-Controlled, Phase 1/2 Trial.","Tetanus is a fatal but vaccine-preventable disease. The currently available tetanus vaccines are tetanus toxoid (TT)-based. Although these vaccines are generally effective, challenges in vaccine development and access remain. A randomized, double-blind, dose escalation, placebo- and positive-controlled, phase 1/2 trial (ChiCTR1800015865) is performed to evaluate the safety and immunogenicity of an alternative recombinant tetanus vaccine based on the Hc domain of tetanus neurotoxin (TeNT-Hc) in healthy adult volunteers. The primary outcome is the safety profile of the recombinant tetanus vaccine, and immunogenicity is the secondary outcome. 150 eligible participants were enrolled and randomly assigned to receive one of the three doses of recombinant tetanus vaccine (TeNT-Hc 10/20/30 µg), TT vaccine, or placebo. The recombinant tetanus vaccine shows a good safety profile. The frequency of any solicited and unsolicited adverse events after each vaccination does not differ across the vaccine and placebo recipients. No serious treatment-related adverse events occur. The recombinant tetanus vaccine shows strong immune responses (seroconversion rates, geometric mean titer, and antigen-specific CD4+/CD8+ T-cell responses), which are roughly comparable to those of the TT vaccine. In conclusion, the findings from this study support that recombinant tetanus vaccine is safe and immunogenic; thereby, it represents a novel vaccine candidate against tetanus.",2021,"The recombinant tetanus vaccine shows strong immune responses (seroconversion rates, geometric mean titer, and antigen-specific CD4+/CD8+ T-cell responses), which are roughly comparable to those of the TT vaccine.","['Healthy Adults in China', 'healthy adult volunteers', '150 eligible participants']","['Placebo', 'Recombinant Tetanus Vaccine', 'recombinant tetanus vaccine', 'placebo', 'recombinant tetanus vaccine (TeNT-Hc 10/20/30\xa0µg), TT vaccine, or placebo', 'tetanus neurotoxin (TeNT-Hc']","['immune responses (seroconversion rates, geometric mean titer, and antigen-specific CD4+/CD8+ T-cell responses', 'safety profile of the recombinant tetanus vaccine, and immunogenicity', 'safety and immunogenicity', 'Safety and Immunogenicity', 'frequency of any solicited and unsolicited adverse events']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C4321486', 'cui_str': '150'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039620', 'cui_str': 'Tetanus vaccine'}, {'cui': 'C0677506', 'cui_str': 'Tent'}, {'cui': 'C0305062', 'cui_str': 'tetanus toxoid vaccine, inactivated'}, {'cui': 'C0076205', 'cui_str': 'Tetanospasmin'}]","[{'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0456981', 'cui_str': 'Specific antigen'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0039620', 'cui_str': 'Tetanus vaccine'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",150.0,0.698983,"The recombinant tetanus vaccine shows strong immune responses (seroconversion rates, geometric mean titer, and antigen-specific CD4+/CD8+ T-cell responses), which are roughly comparable to those of the TT vaccine.","[{'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Yu', 'Affiliation': 'Beijing Institute of Biotechnology, Beijing, 100071, China.'}, {'ForeName': 'Lanlan', 'Initials': 'L', 'LastName': 'Xiao', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Meihong', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Junjie', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Beijing Institute of Biotechnology, Beijing, 100071, China.'}, {'ForeName': 'Yajun', 'Initials': 'Y', 'LastName': 'Tan', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing, 102629, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing, 102629, China.'}, {'ForeName': 'Xiaoxin', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Jiangshan', 'Initials': 'J', 'LastName': 'Lian', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Kaizhou', 'Initials': 'K', 'LastName': 'Huang', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Xiaoxi', 'Initials': 'X', 'LastName': 'Ouyang', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Sheng', 'Initials': 'S', 'LastName': 'Bi', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Shipo', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': 'Beijing Institute of Biotechnology, Beijing, 100071, China.'}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Jiandi', 'Initials': 'J', 'LastName': 'Jin', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Yu', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Huafen', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Wei', 'Affiliation': 'Sichuan Zihao Times Pharmaceutical Co., Ltd, Meishan, Sichuan Province, 610000, China.'}, {'ForeName': 'Jinfa', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Sichuan Zihao Times Pharmaceutical Co., Ltd, Meishan, Sichuan Province, 610000, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Beijing Institute of Biotechnology, Beijing, 100071, China.'}, {'ForeName': 'Lanjuan', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.'}]","Advanced science (Weinheim, Baden-Wurttemberg, Germany)",['10.1002/advs.202002751'] 3363,34081385,"The impact of postbariatric hypoglycaemia on driving performance: A randomized, single-blind, two-period, crossover study in a driving simulator.","Postbariatric hypoglycaemia (PBH) is an increasingly recognized complication of bariatric surgery, but its effect on daily functioning remains unclear. In this randomized, single-blind, crossover trial we assessed driving performance in patients with PBH. Ten active drivers with PBH (eight females, age 38.2 ± 14.7 years, body mass index 27.2 ± 4.6 kg/m 2 ) received 75 g glucose to induce PBH in the late postprandial period and aspartame to leave glycaemia unchanged, on two different occasions. A simulator was driven during 10 minutes before (D0) and 20 (D1), 80 (D2), 125 (D3) and 140 minutes (D4) after the glucose/aspartame ingestion, reflecting the expected blood glucose (BG) increase (D1), decrease (D2) and hypoglycaemia (D3, D4). Seven driving features indicating impaired driving were integrated in a Bayesian hierarchical regression model to assess the difference in driving performance after glucose/aspartame ingestion. Mean ± standard deviation peak and nadir BG after glucose were 182 ± 24 and 47 ± 14 mg/dL, while BG was stable after aspartame (85 ± 4 mg/dL). Despite the lack of a difference in symptom perception, driving performance was significantly impaired after glucose versus aspartame during D4 (posterior probability 98.2%). Our findings suggest that PBH negatively affects driving performance.",2021,"Despite the lack of a difference in symptom perception, driving performance was significantly impaired after glucose vs. aspartame during D4 (posterior probability 98.2%).","['patients with PBH', 'Ten active drivers with PBH (8 females, age 38.2\u2009±\u200914.7\u2009years, BMI 27.2\u2009±\u20094.6\u2009kg/m 2 ) received']","['75\u2009g glucose to induce PBH', 'postbariatric hypoglycemia']","['symptom perception, driving performance', 'Mean\u2009±\u2009standard deviation peak and nadir BG', 'blood glucose (BG) increase (D1), decrease (D2), and hypoglycemia (D3, D4', 'Postbariatric hypoglycemia (PBH']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C5191357', 'cui_str': '27.2'}, {'cui': 'C4517764', 'cui_str': '4.6'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0595877', 'cui_str': 'Blood glucose increased'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}]",,0.091514,"Despite the lack of a difference in symptom perception, driving performance was significantly impaired after glucose vs. aspartame during D4 (posterior probability 98.2%).","[{'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Lehmann', 'Affiliation': 'Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Afroditi', 'Initials': 'A', 'LastName': 'Tripyla', 'Affiliation': 'Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Herzig', 'Affiliation': 'Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Meier', 'Affiliation': 'Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Banholzer', 'Affiliation': 'Department of Management, Technology, and Economics, ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Maritsch', 'Affiliation': 'Department of Management, Technology, and Economics, ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Zehetner', 'Affiliation': 'Department of Visceral Surgery, Hirslanden Clinic Beau-Site, Bern, Switzerland.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Giachino', 'Affiliation': 'Department of Visceral Surgery, Lindenhofspital, Bern, Switzerland.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Nett', 'Affiliation': 'Department of Visceral Surgery and Medicine, Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Feuerriegel', 'Affiliation': 'Department of Management, Technology, and Economics, ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Wortmann', 'Affiliation': 'Institute of Technology Management, University of St. Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Bally', 'Affiliation': 'Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14456'] 3364,34083234,Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.,"PURPOSE Cross-resistance renders multiple lines of androgen receptor (AR) signaling inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We sought to determine acquired genomic contributors to cross-resistance. EXPERIMENTAL DESIGN We collected 458 serial plasma cell-free DNA samples at baseline and progression timepoints from 202 patients with mCRPC receiving sequential AR signaling inhibitors (abiraterone and enzalutamide) in a randomized phase II clinical trial (NCT02125357). We utilized deep targeted and whole-exome sequencing to compare baseline and posttreatment somatic genomic profiles in circulating tumor DNA (ctDNA). RESULTS Patient ctDNA abundance was correlated across plasma collections and independently prognostic for sequential therapy response and overall survival. Most driver alterations in established prostate cancer genes were consistently detected in ctDNA over time. However, shifts in somatic populations after treatment were identified in 53% of patients, particularly after strong treatment responses. Treatment-associated changes converged upon the AR gene, with an average 50% increase in AR copy number, changes in AR mutation frequencies, and a 2.5-fold increase in the proportion of patients carrying AR ligand binding domain truncating rearrangements. CONCLUSIONS Our data show that the dominant AR genotype continues to evolve during sequential lines of AR inhibition and drives acquired resistance in patients with mCRPC.",2021,"Treatment-associated changes converged upon the AR gene, with an average 50% increase in AR copy number, changes in AR mutation frequencies, and a 2.5-fold increase in the proportion of patients carrying AR ligand binding domain truncating rearrangements. ","['202 mCRPC patients receiving', 'metastatic castration-resistant prostate cancer (mCRPC', 'patients with mCRPC']",['sequential AR signaling inhibitors (abiraterone and enzalutamide'],['sequential therapy response and overall survival'],"[{'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0034786', 'cui_str': 'Androgen receptor'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0754011', 'cui_str': 'abiraterone'}, {'cui': 'C3496793', 'cui_str': 'enzalutamide'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",458.0,0.128633,"Treatment-associated changes converged upon the AR gene, with an average 50% increase in AR copy number, changes in AR mutation frequencies, and a 2.5-fold increase in the proportion of patients carrying AR ligand binding domain truncating rearrangements. ","[{'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Annala', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.'}, {'ForeName': 'Sinja', 'Initials': 'S', 'LastName': 'Taavitsainen', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Khalaf', 'Affiliation': 'BC Cancer, Vancouver Centre, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Vandekerkhove', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Beja', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.'}, {'ForeName': 'Joonatan', 'Initials': 'J', 'LastName': 'Sipola', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland.'}, {'ForeName': 'Evan W', 'Initials': 'EW', 'LastName': 'Warner', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.'}, {'ForeName': 'Cameron', 'Initials': 'C', 'LastName': 'Herberts', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Fu', 'Affiliation': 'BC Cancer, Vancouver Centre, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Daygen L', 'Initials': 'DL', 'LastName': 'Finch', 'Affiliation': 'BC Cancer, Southern Interior Centre, Kelowna, British Columbia, Canada.'}, {'ForeName': 'Conrad D', 'Initials': 'CD', 'LastName': 'Oja', 'Affiliation': 'BC Cancer, Fraser Valley Centre, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Vergidis', 'Affiliation': 'BC Cancer, Vancouver Island Centre, Victoria, British Columbia, Canada.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Zulfiqar', 'Affiliation': 'BC Cancer, Abbotsford Centre, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Bernhard J', 'Initials': 'BJ', 'LastName': 'Eigl', 'Affiliation': 'BC Cancer, Vancouver Centre, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Christian K', 'Initials': 'CK', 'LastName': 'Kollmansberger', 'Affiliation': 'BC Cancer, Vancouver Centre, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Nykter', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland.'}, {'ForeName': 'Martin E', 'Initials': 'ME', 'LastName': 'Gleave', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.'}, {'ForeName': 'Kim N', 'Initials': 'KN', 'LastName': 'Chi', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada. awwyatt@mail.ubc.ca kchi@bccancer.bc.ca.'}, {'ForeName': 'Alexander W', 'Initials': 'AW', 'LastName': 'Wyatt', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada. awwyatt@mail.ubc.ca kchi@bccancer.bc.ca.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-21-1625'] 3365,34081779,Learning the full impact of migraine through patient voices: A qualitative study.,"OBJECTIVE To better characterize the ways that migraine affects multiple domains of life. BACKGROUND Further understanding of migraine burden is needed. METHODS Adults with migraine randomized to mindfulness-based stress reduction or headache education arms (n = 81) in two separate randomized clinical trials participated in semistructured in-person qualitative interviews conducted after the interventions. Interviews queried participants on migraine impact on life and were audio-recorded, transcribed, and summarized into a framework matrix. A master codebook was created until meaning saturation was reached and magnitude coding established code frequency. Themes and subthemes were identified using a constructivist grounded theory approach. RESULTS Despite most participants being treated with acute and/or prophylactic medications, 90% (73/81) reported migraine had a negative impact on overall life, with 68% (55/81) endorsing specific domains of life impacted and 52% (42/81) describing impact on emotional health. Six main themes of migraine impact emerged: (1) global negative impact on overall life; (2) impact on emotional health; (3) impact on cognitive function; (4) impact on specific domains of life (work/career, family, social); (5) fear and avoidance (pain catastrophizing and anticipatory anxiety); and (6) internalized and externalized stigma. Participants reported how migraine (a) controls life, (b) makes life difficult, and (c) causes disability during attacks, with participants (d) experiencing a lack of control and/or (e) attempting to push through despite migraine. Emotional health was affected through (a) isolation, (b) anxiety, (c) frustration/anger, (d) guilt, (e) mood changes/irritability, and (f) depression/hopelessness. Cognitive function was affected through concentration and communication difficulties. CONCLUSIONS Migraine has a global negative impact on overall life, cognitive and emotional health, work, family, and social life. Migraine contributes to isolation, frustration, guilt, fear, avoidance behavior, and stigma. A greater understanding of the deep burden of this chronic neurological disease is needed to effectively target and treat what is most important to those living with migraine.",2021,"Emotional health was affected through (a) isolation, (b) anxiety, (c) frustration/anger, (d) guilt, (e) mood changes/irritability, and (f) depression/hopelessness.","['Participants reported how migraine (a) controls life, (b) makes life difficult, and (c) causes disability during attacks, with participants (d) experiencing a lack of control and/or (e) attempting to push through despite migraine', 'Adults with migraine randomized to mindfulness-based stress reduction or headache education arms (n\xa0=\xa081']",[],"['emotional health', 'Cognitive function', 'overall life; (2) impact on emotional health; (3) impact on cognitive function; (4) impact on specific domains of life (work/career, family, social); (5) fear and avoidance (pain catastrophizing and anticipatory anxiety); and (6) internalized and externalized stigma', 'overall life, cognitive and emotional health, work, family, and social life', 'overall life', 'Emotional health was affected through (a) isolation, (b) anxiety, (c) frustration/anger, (d) guilt, (e) mood changes/irritability, and (f) depression/hopelessness']","[{'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0332218', 'cui_str': 'Difficult'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}, {'cui': 'C0580841', 'cui_str': 'Does push'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]",[],"[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0231397', 'cui_str': 'Anticipatory anxiety'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0016770', 'cui_str': 'Feeling frustrated'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0018379', 'cui_str': 'Feeling guilt'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0022107', 'cui_str': 'Feeling irritable'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0150041', 'cui_str': 'Feeling hopeless'}]",,0.0978229,"Emotional health was affected through (a) isolation, (b) anxiety, (c) frustration/anger, (d) guilt, (e) mood changes/irritability, and (f) depression/hopelessness.","[{'ForeName': 'Paige M', 'Initials': 'PM', 'LastName': 'Estave', 'Affiliation': 'Department of Physiology and Pharmacology, Wake Forest Baptist Health, Winston-Salem, NC, USA.'}, {'ForeName': 'Summerlyn', 'Initials': 'S', 'LastName': 'Beeghly', 'Affiliation': 'Department of Neurology, Wake Forest Baptist Health, Winston-Salem, NC, USA.'}, {'ForeName': 'Reid', 'Initials': 'R', 'LastName': 'Anderson', 'Affiliation': 'Department of Neurology, Wake Forest Baptist Health, Winston-Salem, NC, USA.'}, {'ForeName': 'Caitlyn', 'Initials': 'C', 'LastName': 'Margol', 'Affiliation': 'Department of Neurology, Wake Forest Baptist Health, Winston-Salem, NC, USA.'}, {'ForeName': 'Mariam', 'Initials': 'M', 'LastName': 'Shakir', 'Affiliation': 'Department of Neurology, Wake Forest Baptist Health, Winston-Salem, NC, USA.'}, {'ForeName': 'Geena', 'Initials': 'G', 'LastName': 'George', 'Affiliation': 'Department of Neurology, Wake Forest Baptist Health, Winston-Salem, NC, USA.'}, {'ForeName': 'Anissa', 'Initials': 'A', 'LastName': 'Berger', 'Affiliation': 'Department of Neurology, Wake Forest Baptist Health, Winston-Salem, NC, USA.'}, {'ForeName': 'Nathaniel', 'Initials': 'N', 'LastName': ""O'Connell"", 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest Baptist Health, Winston-Salem, NC, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Burch', 'Affiliation': ""Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Niina', 'Initials': 'N', 'LastName': 'Haas', 'Affiliation': 'BrightOutcome, Inc., Buffalo Grove, IL, USA.'}, {'ForeName': 'Scott W', 'Initials': 'SW', 'LastName': 'Powers', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cinncinati Children's Hospital Medical Center, Cinncinati, OH, USA.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Seng', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, New York, NY, USA.'}, {'ForeName': 'Dawn C', 'Initials': 'DC', 'LastName': 'Buse', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, New York, NY, USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, New York, NY, USA.'}, {'ForeName': 'Rebecca Erwin', 'Initials': 'RE', 'LastName': 'Wells', 'Affiliation': 'Department of Neurology, Wake Forest Baptist Health, Winston-Salem, NC, USA.'}]",Headache,['10.1111/head.14151'] 3366,34051345,Bleaching and microstructural effects of low concentration hydrogen peroxide photoactivated with LED/laser system on bovine enamel.,"BACKGROUND Tooth whitening protocols with low concentration hydrogen peroxide (HP) appear to minimize the microstructural effect on teeth. In addition, light sources have been used to enhance bleaching efficiency. This study evaluated the color change and microhardness of a protocol with 6% HP photoactivated by LED/laser in comparison with 35% HP. METHODS Twenty bovine incisors were randomized in two groups: 6% HP + LED/laser and 35% HP (n=10). Teeth were submitted to staining using dark tea. Three whitening sessions were carried out according to the manufacturer's instructions. Enamel microhardness (VHN) and color change evaluation (∆L*, ∆a*, ∆b*, ∆E 00 [CIEDE2000], and WI D ) before 24 hours and 7 days after the last whitening session were performed. Two-way repeated ANOVA and Bonferroni post-test was used (α = 0.05). RESULTS Both groups showed perceptible color changes, being more pronounce for 35% HP. Differences were observed for ∆a*, ∆b* and ∆E 00 (p≤0.027), except for ∆L* (p>0.05). Differences were also found in the comparison among the evaluation times within the same group (p≤0.027), except for ∆a* results (p>0.05). WI D showed that 35% HP exhibited high whiteness values. Regarding microhardness, the groups did not show significant differences (p>0.05). However, 35% HP showed decreased values after 7 days of the last whitening session compared to the baseline (p≤0.027). CONCLUSIONS 6% HP + LED/laser promoted perceptible color change, but not comparable with 35% HP. No differences on enamel microhardness were observed between the whitening protocols. However, 35% HP showed decreased hardness after 7 days of whitening compared to baseline.",2021,"Differences were also found in the comparison among the evaluation times within the same group (p≤0.027), except for ∆a","['Twenty bovine incisors', 'bovine enamel']","['HP photoactivated by LED/laser', 'low concentration hydrogen peroxide (HP', 'HP\u202f+\u202fLED/laser and 35% HP', 'low concentration hydrogen peroxide photoactivated with LED/laser system']","['enamel microhardness', 'Enamel microhardness (VHN) and color change evaluation (∆L*, ∆a', 'hardness']","[{'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}, {'cui': 'C0011350', 'cui_str': 'Enamel structure'}]","[{'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C3873738', 'cui_str': 'Laser system'}]","[{'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C0475330', 'cui_str': 'Color change'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0018599', 'cui_str': 'Hard'}]",20.0,0.0221957,"Differences were also found in the comparison among the evaluation times within the same group (p≤0.027), except for ∆a","[{'ForeName': 'Joatan Lucas de Sousa Gomes', 'Initials': 'JLSG', 'LastName': 'Costa', 'Affiliation': 'Department of Restorative Dentistry, School of Dentistry, Araraquara, São Paulo State University - UNESP, Araraquara, São Paulo 14801-903, Brazil. Electronic address: joatan_costa@hotmail.com.'}, {'ForeName': 'João Felipe', 'Initials': 'JF', 'LastName': 'Besegato', 'Affiliation': 'Department of Restorative Dentistry, School of Dentistry, Araraquara, São Paulo State University - UNESP, Araraquara, São Paulo 14801-903, Brazil. Electronic address: besegato@outlook.com.'}, {'ForeName': 'Milton Carlos', 'Initials': 'MC', 'LastName': 'Kuga', 'Affiliation': 'Department of Restorative Dentistry, School of Dentistry, Araraquara, São Paulo State University - UNESP, Araraquara, São Paulo 14801-903, Brazil. Electronic address: milton.kuga@unesp.br.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102352'] 3367,34057096,Short Pulse and Conventional Deep Brain Stimulation Equally Improve the Parkinsonian Gait Disorder.,"BACKGROUND Gait disturbances and balance remain challenging issues in Parkinsonian patients (PD) with deep brain stimulation (DBS). Short pulse deep brain stimulation (spDBS) increases the therapeutic window in PD patients, yet the effect on gait and postural symptoms remains unknown. OBJECTIVE We assessed the efficacy of spDBS compared to conventional DBS (cDBS) within the subthalamic nucleus (STN) on Parkinsonian gait. METHODS The study was a single-centre, randomized, double-blind, clinical short-term trial. 20 PD patients were studied postoperatively in three different conditions (DBS stimulation switched off (off DBS), spDBS with 40μs pulse width, cDBS with 60μs pulse width) on regular medication. The primary endpoint was the relative difference of gait velocity at self-paced speed during quantitative gait analysis between stimulation conditions. Secondary endpoints were changes of further measures of quantitative gait analysis, Ziegler course, Berg balance scale, FOG questionnaire, MDS-UPDRS, PDQ-39, and HADS. Mixed-model analysis and post-hoc t-tests were performed. RESULTS Both spDBS and cDBS improved gait velocity at self-paced speed compared to off DBS, however, there was no significant difference between both stimulation modes. Still, 40% of the patients preferred spDBS over cDBS subjectively. Both stimulation modes were equally effective in improving secondary endpoints of gait, balance, motor and non-motor performances. CONCLUSION The use of spDBS and cDBS is equally effective in improving gait and balance in PD and might be beneficial in specified cohorts of PD patients.",2021,"Both spDBS and cDBS improved gait velocity at self-paced speed compared to off DBS, however, there was no significant difference between both stimulation modes.","['20 PD patients', 'PD patients', 'Parkinsonian patients (PD) with deep brain stimulation (DBS']","['conventional DBS (cDBS', 'Short Pulse and Conventional Deep Brain Stimulation', 'Short pulse deep brain stimulation (spDBS', 'spDBS']","['gait velocity at self-paced speed during quantitative gait analysis between stimulation conditions', 'changes of further measures of quantitative gait analysis, Ziegler course, Berg balance scale, FOG questionnaire, MDS-UPDRS, PDQ-39, and HADS', 'gait velocity', 'Parkinsonian Gait Disorder', 'secondary endpoints of gait, balance, motor and non-motor performances']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0558820', 'cui_str': 'Examination of gait'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0450030', 'cui_str': 'Fog'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0427160', 'cui_str': 'Extrapyramidal gait'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",20.0,0.185326,"Both spDBS and cDBS improved gait velocity at self-paced speed compared to off DBS, however, there was no significant difference between both stimulation modes.","[{'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Seger', 'Affiliation': 'Department of Neurology, Hamburg, University Medical Center Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Gulberti', 'Affiliation': 'Department of Neurology, Hamburg, University Medical Center Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Eik', 'Initials': 'E', 'LastName': 'Vettorazzi', 'Affiliation': 'Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Braa', 'Affiliation': 'Department of Neurology, Hamburg, University Medical Center Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Buhmann', 'Affiliation': 'Department of Neurology, Hamburg, University Medical Center Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Gerloff', 'Affiliation': 'Department of Neurology, Hamburg, University Medical Center Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Hamel', 'Affiliation': 'Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Christian K E', 'Initials': 'CKE', 'LastName': 'Moll', 'Affiliation': 'Department of Neurophysiology and Pathophysiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Pötter-Nerger', 'Affiliation': 'Department of Neurology, Hamburg, University Medical Center Hamburg-Eppendorf, Germany.'}]",Journal of Parkinson's disease,['10.3233/JPD-202492'] 3368,34052421,Effect of ultrasonic scaling with adjunctive photodynamic therapy on the treatment of gingival inflammation among diabetic patients undergoing fixed orthodontic treatment.,"BACKGROUND The aim of the present clinical trial was to evaluate the effect of methylene blue-mediated antimicrobial photodynamic therapy (aPDT) on the gingival and immunological parameters in diabetic adolescent patients undergoing fixed orthodontic treatment. METHODS The selected 40 participants were randomized equally into two groups; Group I (ultrasonic scaling + oral hygiene instructions) and Group II (ultrasonic scaling/oral hygiene instructions + aPDT). Serum HbA1c levels was assessed for all the participants at chairside. Plaque index (Pi), and bleeding on probing (BOP) were analyzed. Moreover, the assessment of crevicular fluid matrix metalloproteinase 8 (MMP-8) and macrophage inflammatory protein 1 alpha (MIP-1α) was performed using enzyme-linked immunosorbent assay technique. All measurements were recorded at baseline, 6 weeks, and 12 weeks follow-up periods, respectively. Intergroup comparisons for p-value were computed using Mann-Whitney test and Wilcoxon singed ranks test to compute p-value for intra-group comparisons. Stepwise logistic regression analysis was used to identify explanatory variables for reduction in plaque scores and bleeding on probing, after controlling for the effects of other covariates. Odds ratios and 95% confidence intervals were used to assess the direction and strength for associations. Significance level was set at 5% for all analyses. RESULTS All 40 individuals completed the clinical trial. There was a statistically significant reduction in Pi and BOP in both Group I and Group II from baseline to 12 weeks of follow up (P<0.05). However, there was slight reduction in the plaque scores in Group-II as compared to Group-I at 12 weeks visit (P<0.05). There was also a statistically significant difference for BOP when Group-I was compared with Group-II on 12 weeks follow up assessment (P<0.05). HbA1c assessment indicated no statistically significant difference either within or between groups at any time point (P>0.05). Both MMP-8 and MIP-1α reported a significant decrease for both Groups I and II at 6 weeks and 12 weeks follow-up periods in comparison to baseline (P<0.05). Inter-group comparison indicated a statistically significant difference noted at both 6 weeks follow up that was maintained at 12 weeks follow up (P<0.05). The logistic regression analysis revealed that even after controlling the mean BMI as a predictor, the change of biomarker levels along with the improvement in plaque scores and bleeding on probing was not significant (p> 0.05). CONCLUSION aPDT significantly improved bleeding on probing and proinflammatory biomarkers among diabetic adolescent patients undergoing fixed orthodontic therapy.",2021,There was a statistically significant reduction in Pi and BOP in both Group I and Group II from baseline to 12 weeks of follow up (P<0.05).,"['diabetic patients undergoing fixed orthodontic treatment', 'diabetic adolescent patients undergoing fixed orthodontic therapy', 'All 40 individuals completed the clinical trial', 'diabetic adolescent patients undergoing fixed orthodontic treatment', '40 participants']","['Group I (ultrasonic scaling\u202f+\u202foral hygiene instructions) and Group II (ultrasonic scaling/oral hygiene instructions\u202f+\u202faPDT', 'aPDT', 'ultrasonic scaling with adjunctive photodynamic therapy', 'methylene blue-mediated antimicrobial photodynamic therapy (aPDT']","['crevicular fluid matrix metalloproteinase 8 (MMP-8) and macrophage inflammatory protein 1 alpha (MIP-1α', 'Plaque index (Pi), and bleeding on probing (BOP', 'Serum HbA1c levels', 'BOP', 'bleeding on probing and proinflammatory biomarkers', 'plaque scores', 'Pi and BOP', 'plaque scores and bleeding on probing', 'gingival inflammation']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0204193', 'cui_str': 'Orthodontic procedure'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0441843', 'cui_str': 'Group I'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0204131', 'cui_str': 'Oral hygiene education'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0025746', 'cui_str': 'Methylene blue'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}]","[{'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0172956', 'cui_str': 'Neutrophil collagenase'}, {'cui': 'C0623362', 'cui_str': 'MMPs'}, {'cui': 'C0128546', 'cui_str': 'Small Inducible Cytokine A3'}, {'cui': 'C0376579', 'cui_str': 'Macrophage Inflammatory Proteins'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0017574', 'cui_str': 'Gingivitis'}]",40.0,0.0326452,There was a statistically significant reduction in Pi and BOP in both Group I and Group II from baseline to 12 weeks of follow up (P<0.05).,"[{'ForeName': 'Master Luqman', 'Initials': 'ML', 'LastName': 'Mannakandath', 'Affiliation': 'Department of Oral Diagnosis and Oral Biology, College of Dentistry, King Khalid University, Abha, Saudi Arabia.'}, {'ForeName': 'Muhammad Abdullah', 'Initials': 'MA', 'LastName': 'Kamran', 'Affiliation': 'Department of Pediatric and Orthodontic Sciences, College of Dentistry, King Khalid University, Abha, Saudi Arabia. Electronic address: mmuhammad@kku.edu.sa.'}, {'ForeName': 'Samuel Ebele', 'Initials': 'SE', 'LastName': 'Udeabor', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, College of Dentistry, King Khalid University, Abha, Saudi Arabia.'}, {'ForeName': 'Mohammad Shahul', 'Initials': 'MS', 'LastName': 'Hameed', 'Affiliation': 'Department of Diagnostic Sciences and Oral Biology, College of Dentistry, King Khalid University, Abha, Saudi Arabia.'}, {'ForeName': 'Muhammed', 'Initials': 'M', 'LastName': 'Ajmal', 'Affiliation': 'Department of Diagnostic Sciences and Oral Biology, College of Dentistry, King Khalid University, Abha, Saudi Arabia.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Alshahrani', 'Affiliation': 'Department of Pediatric and Orthodontic Sciences, College of Dentistry, King Khalid University, Abha, Saudi Arabia.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102360'] 3369,34058682,Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.,"OBJECTIVES To examine the safety and efficacy of omadacycline by body mass index (BMI) in adults with community-acquired bacterial pneumonia (CABP) from a Phase III trial. METHODS Patients hospitalized for suspected CABP were randomized 1:1 to receive intravenous omadacycline or moxifloxacin, with an optional transition to oral, for a total of 7-14 days. Early clinical response (ECR) was assessed 72-120 h after receipt of the first dose, and clinical success was assessed 5-10 days after the last dose (post-treatment evaluation [PTE]). ECR was defined as improvement in at least two CABP symptoms with no worsening of other symptoms or use of rescue antibacterial treatment; success at PTE was defined as resolution of signs and symptoms to the extent that further antibacterial therapy was unnecessary. Safety evaluations included treatment-emergent adverse events and laboratory measures. Between-treatment comparisons were made by World Health Organization BMI categories and by diabetes history. RESULTS Distribution of patients in the normal weight, overweight, and obese subgroups was fairly even. Clinical success for omadacycline-treated patients at ECR were similar across ascending BMI groups (OMC: 82.9%, 80.5%, 76.9%; MOX: 88.6%, 80.7%, 76.9%). Outcomes by diabetes status were generally similar in omadacycline- and moxifloxacin-treated patients. Patients who had clinical success or clinical stability at ECR generally showed continued clinical success at PTE. Safety profiles for omadacycline and moxifloxacin were largely similar across BMI subgroups and by diabetes history. CONCLUSION The omadacycline fixed-dosing strategy showed consistent safety and efficacy in patients with CABP of different body sizes.",2021,"Safety profiles for omadacycline and moxifloxacin were largely similar across BMI subgroups and by diabetes history. ","['adults with community-acquired bacterial pneumonia (CABP', 'Patients hospitalized for suspected CABP', 'patients with CABP of different body sizes', 'patients with community-acquired bacterial pneumonia']","['omadacycline and moxifloxacin', 'intravenous omadacycline or moxifloxacin', 'omadacycline', 'moxifloxacin']","['Clinical success', 'Early clinical response (ECR', 'safety and efficacy', 'Safety and efficacy', 'clinical success', 'ECR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0456394', 'cui_str': 'Community acquired'}, {'cui': 'C0004626', 'cui_str': 'Bacterial pneumonia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0005901', 'cui_str': 'Body Size'}]","[{'cui': 'C2983838', 'cui_str': 'omadacycline'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0665868,"Safety profiles for omadacycline and moxifloxacin were largely similar across BMI subgroups and by diabetes history. ","[{'ForeName': 'Manjunath P', 'Initials': 'MP', 'LastName': 'Pai', 'Affiliation': 'Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, 428 Church St, Rm 3569, Ann Arbor, MI, 48109, USA. Electronic address: amitpai@med.umich.edu.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Wilcox', 'Affiliation': 'University of Leeds & Leeds Teaching Hospitals, Woodhouse, Leeds, LS2 9JT, UK.'}, {'ForeName': 'Surya', 'Initials': 'S', 'LastName': 'Chitra', 'Affiliation': 'Paratek Pharmaceuticals, Inc., 1000 First Avenue, Suite 200, King of Prussia, PA, 19406, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'McGovern', 'Affiliation': 'Paratek Pharmaceuticals, Inc., 1000 First Avenue, Suite 200, King of Prussia, PA, 19406, USA.'}]",Respiratory medicine,['10.1016/j.rmed.2021.106442'] 3370,34061402,Titanium vs ceramic single dental implants in the anterior maxilla: A 12-month randomized clinical trial.,"OBJECTIVE The aim of this randomized clinical trial was to compare ceramic and titanium implants with respect to the esthetic and clinical parameters, and patient-reported outcome measures (PROMs). MATERIAL AND METHODS Thirty patients received thirty implants (8-12 mm in length, 3.3 mm diameter, and a tissue level design) to replace single teeth in the anterior maxilla. Patients were randomly allocated to receive a ceramic or a titanium implant. Esthetic, clinical parameters, and PROMs were evaluated 18 months after surgery. RESULTS At 12 months post-final loading, there were no significant differences between groups with respect to esthetics. Mean Index Crown Aesthetic score was 6.31 (95% C.I. 4.59-8.04) and 6.07 (95% C.I. 4.21-7.93) for ceramic and titanium implants, respectively. The pink esthetic score (PES) was 7.81 (95% C.I. 6.90-8.73) for ceramic implants and 7.86 (95% C.I. 7.11-8.60) for titanium implants, with no significant differences between groups. No statistically significant differences were found for any of the other clinical parameters and PROMs. CONCLUSIONS Monotype ceramic implants have proven to be a good treatment option in the upper anterior sector, showing favorable esthetic results, being comparable to titanium implants. This clinical trial has been registered in clinical trials with the identifier CI_RCT_US16 and registration number NCT04707677. A retrospective registration of the clinical trial was carried out since registration was not mandatory on the date the study began.",2021,"Mean Index Crown Aesthetic score was 6.31 (95% C.I. 4.59-8.04) and 6.07 (95% C.I. 4.21-7.93) for ceramic and titanium implants, respectively.","['Thirty patients received thirty implants (8-12 mm in length, 3.3 mm diameter and a tissue level design) to replace single teeth in the anterior maxilla', 'anterior maxilla']","['Titanium vs ceramic single dental implants', 'ceramic or a titanium implant']","['Pink Esthetic Score (PES', 'Mean Index Crown Aesthetic score']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C4517688', 'cui_str': '3.3'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0459697', 'cui_str': 'Anterior segment of maxilla'}]","[{'cui': 'C0040302', 'cui_str': 'Titanium'}, {'cui': 'C0007742', 'cui_str': 'Ceramic'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0011370', 'cui_str': 'Dental implantation'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]","[{'cui': 'C0332585', 'cui_str': 'Pink color'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0010384', 'cui_str': 'Crown'}]",,0.319098,"Mean Index Crown Aesthetic score was 6.31 (95% C.I. 4.59-8.04) and 6.07 (95% C.I. 4.21-7.93) for ceramic and titanium implants, respectively.","[{'ForeName': 'Paula Andrea', 'Initials': 'PA', 'LastName': 'Ruiz Henao', 'Affiliation': 'Periodontology Unit, School of Medicine and Dentistry, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Leticia', 'Initials': 'L', 'LastName': 'Caneiro Queija', 'Affiliation': 'Periodontology Unit, School of Medicine and Dentistry, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Mareque', 'Affiliation': 'Periodontology Unit, School of Medicine and Dentistry, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Almudena', 'Initials': 'A', 'LastName': 'Tasende Pereira', 'Affiliation': 'Periodontology Unit, School of Medicine and Dentistry, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Liñares González', 'Affiliation': 'Periodontology Unit, School of Medicine and Dentistry, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Blanco Carrión', 'Affiliation': 'Periodontology Unit, School of Medicine and Dentistry, University of Santiago de Compostela, Santiago de Compostela, Spain.'}]",Clinical oral implants research,['10.1111/clr.13788'] 3371,34060901,Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso.,"A recent randomized controlled trial, the WANECAM (West African Network for Clinical Trials of Antimalarial Drugs) trial, conducted at seven centers in West Africa, found that artemether-lumefantrine, artesunate-amodiaquine, pyronaridine-artesunate, and dihydroartemisinin-piperaquine all displayed good efficacy. However, artemether-lumefantrine was associated with a shorter interval between clinical episodes than the other regimens. In a further comparison of these therapies, we identified cases of persisting submicroscopic parasitemia by quantitative PCR (qPCR) at 72 h posttreatment among WANECAM participants from 5 sites in Mali and Burkina Faso, and we compared treatment outcomes for this group to those with complete parasite clearance by 72 h. Among 552 evaluable patients, 17.7% had qPCR-detectable parasitemia at 72 h during their first treatment episode. This proportion varied among sites, reflecting differences in malaria transmission intensity, but did not differ among pooled drug treatment groups. However, patients who received artemether-lumefantrine and were qPCR positive at 72 h were significantly more likely to have microscopically detectable recurrent Plasmodium falciparum parasitemia by day 42 than those receiving other regimens and experienced, on average, a shorter interval before the next clinical episode. Haplotypes of pfcrt and pfmdr1 were also evaluated in persisting parasites. These data identify a possible threat to the parasitological efficacy of artemether-lumefantrine in West Africa, over a decade since it was first introduced on a large scale.",2021,"However, artemether-lumefantrine was associated with a shorter interval between clinical episodes than the other regimens.","['seven centres in West Africa, found that artemether']","['lumefantrine, artesunate-amodiaquine, pyronaridine-artesunate and dihydroartemisinin-piperaquine', 'artemether-lumefantrine']","['qPCR positive', 'qPCR-detectable parasitaemia', 'malaria transmission intensity']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0001747', 'cui_str': 'Western Africa'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0052429', 'cui_str': 'artemether'}]","[{'cui': 'C0531104', 'cui_str': 'lumefantrine'}, {'cui': 'C0052432', 'cui_str': 'artesunate'}, {'cui': 'C0002641', 'cui_str': 'Amodiaquine'}, {'cui': 'C0072768', 'cui_str': 'pyronaridine'}, {'cui': 'C0058108', 'cui_str': 'dihydroartemisinin'}, {'cui': 'C0071105', 'cui_str': 'piperaquine'}, {'cui': 'C0936150', 'cui_str': 'artemether and lumefantrine'}]","[{'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",547.0,0.0679777,"However, artemether-lumefantrine was associated with a shorter interval between clinical episodes than the other regimens.","[{'ForeName': 'Khalid B', 'Initials': 'KB', 'LastName': 'Beshir', 'Affiliation': 'Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Nouhoum', 'Initials': 'N', 'LastName': 'Diallo', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Fabrice A', 'Initials': 'FA', 'LastName': 'Somé', 'Affiliation': ""Institut de Recherche en Sciences de la Santé Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.""}, {'ForeName': 'Salif', 'Initials': 'S', 'LastName': 'Sombie', 'Affiliation': 'Centre National de Recherche et de Formation sur le Paludisme, Ougadougou, Burkina Faso.'}, {'ForeName': 'Issaka', 'Initials': 'I', 'LastName': 'Zongo', 'Affiliation': ""Institut de Recherche en Sciences de la Santé Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.""}, {'ForeName': 'Bakary', 'Initials': 'B', 'LastName': 'Fofana', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Aliou', 'Initials': 'A', 'LastName': 'Traore', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Souleymane', 'Initials': 'S', 'LastName': 'Dama', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Amadou', 'Initials': 'A', 'LastName': 'Bamadio', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Oumar B', 'Initials': 'OB', 'LastName': 'Traore', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Sam A', 'Initials': 'SA', 'LastName': 'Coulibaly', 'Affiliation': 'Centre National de Recherche et de Formation sur le Paludisme, Ougadougou, Burkina Faso.'}, {'ForeName': 'Ouattara S', 'Initials': 'OS', 'LastName': 'Maurice', 'Affiliation': 'Groupe de Recherche Action en Santé, Ougadougou, Burkina Faso.'}, {'ForeName': 'Amidou', 'Initials': 'A', 'LastName': 'Diarra', 'Affiliation': 'Groupe de Recherche Action en Santé, Ougadougou, Burkina Faso.'}, {'ForeName': 'Jean Moise', 'Initials': 'JM', 'LastName': 'Kaboré', 'Affiliation': 'Groupe de Recherche Action en Santé, Ougadougou, Burkina Faso.'}, {'ForeName': 'Aly', 'Initials': 'A', 'LastName': 'Kodio', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Amadou Hamidou', 'Initials': 'AH', 'LastName': 'Togo', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Niawanlou', 'Initials': 'N', 'LastName': 'Dara', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Moctar', 'Initials': 'M', 'LastName': 'Coulibaly', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Dao', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Nikiema', 'Affiliation': ""Institut de Recherche en Sciences de la Santé Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.""}, {'ForeName': 'Yves D', 'Initials': 'YD', 'LastName': 'Compaore', 'Affiliation': ""Institut de Recherche en Sciences de la Santé Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.""}, {'ForeName': 'Naomie T', 'Initials': 'NT', 'LastName': 'Kabore', 'Affiliation': ""Institut de Recherche en Sciences de la Santé Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.""}, {'ForeName': 'Nouhoun', 'Initials': 'N', 'LastName': 'Barry', 'Affiliation': ""Institut de Recherche en Sciences de la Santé Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.""}, {'ForeName': 'Issiaka', 'Initials': 'I', 'LastName': 'Soulama', 'Affiliation': 'Centre National de Recherche et de Formation sur le Paludisme, Ougadougou, Burkina Faso.'}, {'ForeName': 'Issaka', 'Initials': 'I', 'LastName': 'Sagara', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Sodiomon B', 'Initials': 'SB', 'LastName': 'Sirima', 'Affiliation': 'Groupe de Recherche Action en Santé, Ougadougou, Burkina Faso.'}, {'ForeName': 'Jean-Bosco', 'Initials': 'JB', 'LastName': 'Ouédraogo', 'Affiliation': ""Institut de Recherche en Sciences de la Santé Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.""}, {'ForeName': 'Abdoulaye', 'Initials': 'A', 'LastName': 'Djimde', 'Affiliation': 'Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.'}, {'ForeName': 'Colin J', 'Initials': 'CJ', 'LastName': 'Sutherland', 'Affiliation': 'Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00873-21'] 3372,34062261,"The influence of a 16-week exercise program, APOE status, and age on executive function task performance: A randomized trial.","Previous research has shown beneficial cognitive changes following exercise training in older adults. However, the work on the potential moderating effects of Apoliprotein E (APOE) ε4 carrier status has been mixed, and the role of exercise intensity remains largely unexplored. The present study sought to examine the influence of APOE ε4 status and exercise intensity on measures of cognitive performance in a group of older adults. Cross-sectional comparisons between a group of younger inactive adults (n = 44, age = 28.86 ± 0.473 SD, 60.5% female) and a group of older inactive adults (n = 142, age = 67.8 ± 5.4, 62.7% female) were made on baseline measurements of APOE ε4 status, VO 2 peak, and cognitive performance in the domain of executive functioning. The older adults also participated in a randomized controlled exercise trial, exercising three times per week for 16-weeks in either a low-intensity continuous training (LICT) group or a moderate-intensity continuous training plus interval training (MICT+IT) group at the Center for Health and Neuroscience, Genes, and Environment (CUChange) Exercise Laboratory. Follow-up measurements of VO 2 peak and cognitive performance were collected on the older adults after the exercise intervention. Cross-sectional comparisons between the older and younger adults demonstrated significant impairments among older adults in Stroop effect on error and time, Category Switch mixing effects, and Keep Track task. This impairment was not moderated by APOE ε4 carrier status. Improvements from pre- to post-exercise intervention were observed in both exercise groups in Stroop effect on error ([F (1, 256) = 9.381, p < 0.01, η 2  = 0.031]) and Category Switch switching effect reaction time ([F(1, 274) = 4.442, p < 0.05, η 2  = 0.020]), with no difference between exercise groups. The moderating effects of APOE ε4 carrier status were mixed. Exercise did not improve the Stroop effect on error among ε4 carriers assigned to MICT+IT when improvements were seen in all other groups. Further research is needed to examine the mechanisms of action by which exercise impacts cognitive task performance, and possible moderators such as genetic variability and exercise intensity.",2021,"Cross-sectional comparisons between the older and younger adults demonstrated significant impairments among older adults in Stroop effect on error and time, Category Switch mixing effects, and Keep Track task.","['younger inactive adults (n\u202f=\u202f44, age\u202f=\u202f28.86\u202f±\u202f0.473 SD, 60.5% female) and a group of older inactive adults (n\u202f=\u202f142, age\u202f=\u202f67.8\u202f±\u202f5.4, 62.7% female', 'older adults', 'a group of older adults']","['exercise training', 'Apoliprotein E (APOE', 'low-intensity continuous training (LICT) group or a moderate-intensity continuous training plus interval training (MICT+IT) group at the Center for Health and Neuroscience, Genes, and Environment (CUChange) Exercise Laboratory']","['error and time, Category Switch mixing effects, and Keep Track task', 'cognitive performance', 'Category Switch switching effect reaction time']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517792', 'cui_str': '5.4'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0027910', 'cui_str': 'Neurosciences'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",,0.0118932,"Cross-sectional comparisons between the older and younger adults demonstrated significant impairments among older adults in Stroop effect on error and time, Category Switch mixing effects, and Keep Track task.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Martin-Willett', 'Affiliation': 'The University of Colorado Boulder, Boulder, CO, United States of America. Electronic address: renee.martinwillett@colorado.edu.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Morris', 'Affiliation': 'The University of Colorado Boulder, Boulder, CO, United States of America.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Wilcox', 'Affiliation': 'The University of Illinois, Champaign, IL, United States of America.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Giordano', 'Affiliation': 'The University of Colorado Boulder, Boulder, CO, United States of America.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Andrews-Hanna', 'Affiliation': 'The University of Arizona, Tucson, AZ, United States of America.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Banich', 'Affiliation': 'The University of Colorado Boulder, Boulder, CO, United States of America.'}, {'ForeName': 'A B', 'Initials': 'AB', 'LastName': 'Bryan', 'Affiliation': 'The University of Colorado Boulder, Boulder, CO, United States of America.'}]",Experimental gerontology,['10.1016/j.exger.2021.111431'] 3373,34071782,Lifestyle and Treatment Adherence Intervention after a Coronary Event Based on an Interactive Web Application (EVITE): Randomized Controlled Clinical Trial Protocol.,"Coronary heart disease is one of the main causes of morbimortality around the world. Patients that survive a coronary event suffer a high risk of readmission, relapse and mortality, attributed to the sub-optimal control of cardiovascular risk factors (CVRF), which highlights the need to improve secondary prevention strategies aimed at improving their lifestyle and adherence to treatment. Through a randomized controlled clinical trial, this study aims to evaluate the effect of an intervention involving an online health application supported by a mobile telephone or tablet (mHealth) on lifestyle (diet, physical activity, and tobacco consumption) and treatment adherence among people with coronary heart disease after percutaneous coronary intervention. The sample will comprise 240 subjects (120 in each arm: intervention and usual care). They are assessed immediately and nine months after their hospital discharge about sociodemographic, clinical, CVRF, lifestyle, and treatment adherence characteristics. The educative intervention, involving a follow-up and self-monitoring, will be performed using an online mHealth tool consisting of an application for mobile phones and tablets. The quantitative primary outcomes from the two groups will be compared using an analysis of covariance (ANCOVA) adjusted for age and gender. A multivariate analysis will be performed to examine the association of the intervention with lifestyle habits, the control of CVRFs, and outcomes after discharge in terms of the use of health services, emergency visits, cardiovascular events and readmissions.",2021,"A multivariate analysis will be performed to examine the association of the intervention with lifestyle habits, the control of CVRFs, and outcomes after discharge in terms of the use of health services, emergency visits, cardiovascular events and readmissions.","['240 subjects (120 in each arm: intervention and usual care', 'people with coronary heart disease after percutaneous coronary intervention']","['mobile telephone or tablet (mHealth) on lifestyle (diet, physical activity, and tobacco consumption', 'Interactive Web Application (EVITE']",[],"[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0543414', 'cui_str': 'Tobacco Chewing'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0185125', 'cui_str': 'Application'}]",[],240.0,0.0369899,"A multivariate analysis will be performed to examine the association of the intervention with lifestyle habits, the control of CVRFs, and outcomes after discharge in terms of the use of health services, emergency visits, cardiovascular events and readmissions.","[{'ForeName': 'María Ángeles', 'Initials': 'MÁ', 'LastName': 'Bernal-Jiménez', 'Affiliation': 'Faculty of Nursing and Physiotherapy, University of Cádiz, 11009 Cádiz, Spain.'}, {'ForeName': 'Germán', 'Initials': 'G', 'LastName': 'Calle-Pérez', 'Affiliation': 'Institute of Biomedical Research and Innovation of Cádiz (INiBICA), 11009 Cádiz, Spain.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Gutiérrez-Barrios', 'Affiliation': 'Institute of Biomedical Research and Innovation of Cádiz (INiBICA), 11009 Cádiz, Spain.'}, {'ForeName': 'Livia', 'Initials': 'L', 'LastName': 'Gheorghe', 'Affiliation': 'Institute of Biomedical Research and Innovation of Cádiz (INiBICA), 11009 Cádiz, Spain.'}, {'ForeName': 'Ana María', 'Initials': 'AM', 'LastName': 'Solano-Mulero', 'Affiliation': 'Cardiology Unit, Puerta del Mar Hospital, 11009 Cadiz, Spain.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Rodríguez-Martín', 'Affiliation': 'Faculty of Nursing and Physiotherapy, University of Cádiz, 11009 Cádiz, Spain.'}, {'ForeName': 'Josep A', 'Initials': 'JA', 'LastName': 'Tur', 'Affiliation': 'Research Group on Community Nutrition & Oxidative Stress, University of the Balearic Islands, IDISBA & CIBEROBN, 07122 Palma de Mallorca, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Vázquez-García', 'Affiliation': 'Institute of Biomedical Research and Innovation of Cádiz (INiBICA), 11009 Cádiz, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Santi-Cano', 'Affiliation': 'Faculty of Nursing and Physiotherapy, University of Cádiz, 11009 Cádiz, Spain.'}]",Nutrients,['10.3390/nu13061818'] 3374,34071781,Efficacy of Vitamin D Supplementation in Addition to Aerobic Exercise Training in Obese Women with Perceived Myalgia: A Single-Blinded Randomized Controlled Clinical Trial.,"Obese women were more susceptible to myalgia because of their significantly lower vitamin D concentrations; the present study investigated the efficacy of vitamin D in addition to an aerobic interval training in the management of obese women with myalgia. Forty-five obese women with vitamin D deficiency and myalgia (30 to 40 years old) were assigned randomly into three equal groups. Group A received an aerobic interval training with vitamin D supplementation, Group B received vitamin D supplementation only, and Group C received aerobic interval training only; participants in all groups were on calorie deficient diets. The study outcomes were the Visual Analog Scale (VAS) for Pain Evaluation, serum vitamin D level, and Cooper 12-Minute Walk Test for Functional Capacity Evaluation, while the Short-Form Health Survey (SF) was used for assessment of quality of life. We detected a significant improvement in pain intensity level, serum vitamin D level, and quality of life in all groups with significant difference between Group A and groups B and C. We also detected a significant improvement in functional capacity in groups A and C, with no significant change in Group B. Aerobic interval training with vitamin D supplementation was more effective for the management of obese women with perceived myalgia.",2021,"We detected a significant improvement in pain intensity level, serum vitamin D level, and quality of life in all groups with significant difference between Group A and groups B and C.","['Forty-five obese women with vitamin D deficiency and myalgia (30 to 40 years old', 'Obese women', 'obese women with myalgia', 'Obese Women with Perceived Myalgia', 'obese women with perceived myalgia']","['vitamin D supplementation', 'vitamin D', 'aerobic interval training with vitamin D supplementation, Group B received vitamin D supplementation', 'Aerobic Exercise Training', 'aerobic interval training', 'Vitamin D Supplementation', 'aerobic interval training only; participants in all groups were on calorie deficient diets']","['quality of life', 'pain intensity level, serum vitamin D level, and quality of life', 'Visual Analog Scale (VAS) for Pain Evaluation, serum vitamin D level, and Cooper 12-Minute Walk Test for Functional Capacity Evaluation, while the Short-Form Health Survey (SF', 'functional capacity']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042870', 'cui_str': 'Vitamin D deficiency'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0428586', 'cui_str': 'Serum vitamin D measurement'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0335912', 'cui_str': 'Cooper'}, {'cui': 'C0430516', 'cui_str': '12-minute walk test'}, {'cui': 'C2732531', 'cui_str': 'Functional capacity evaluation'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}]",45.0,0.0522496,"We detected a significant improvement in pain intensity level, serum vitamin D level, and quality of life in all groups with significant difference between Group A and groups B and C.","[{'ForeName': 'Heba Ahmed Ali', 'Initials': 'HAA', 'LastName': 'Abdeen', 'Affiliation': 'Department of Physical Therapy for Cardiovascular/Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Ad Doqi, Giza District, Giza Governorate 11432, Egypt.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rodriguez-Sanz', 'Affiliation': 'Faculty of Nursing, Physical Therapy and Podiatry, Universidad Complutense de Madrid, 28040 Madrid, Spain.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Ewidea', 'Affiliation': 'Department of Basic Science for Physical Therapy, Faculty of Physical Therapy, Kafr Elshiekh University, Kafr Elsheikh Government 33511, Egypt.'}, {'ForeName': 'Dina Mohamed Ali', 'Initials': 'DMA', 'LastName': 'Al-Hamaky', 'Affiliation': 'Department of Physical Therapy for Musculoskeletal Disorders and Its Surgery, Faculty of Physical Therapy, Cairo University, Ad Doqi, Giza District, Giza Governorate 11432, Egypt.'}, {'ForeName': 'Marwa Abd El-Rahman', 'Initials': 'MAE', 'LastName': 'Mohamed', 'Affiliation': 'Department of Physical Therapy for Women Health, Faculty of Physical Therapy, Cairo University, Ad Doqi, Giza District, Giza Governorate 11432, Egypt.'}, {'ForeName': 'Ahmed Ebrahim', 'Initials': 'AE', 'LastName': 'Elerian', 'Affiliation': 'Department of Basic Science for Physical Therapy, Faculty of Physical Therapy, Cairo University, Ad Doqi, Giza District, Giza Governorate 11432, Egypt.'}]",Nutrients,['10.3390/nu13061819'] 3375,34390604,The Impact of Enriched Resistant Starch Type-2 Cookies on the Gut Microbiome in Hemodialysis Patients: A Randomized Controlled Trial.,"SCOPE Resistant starch type-2 (RS2), can mitigate inflammation and oxidative stress in hemodialysis (HD) patients. However, there is still a lack of knowledge on the impact of the RS2 on the gut microbiota community in these patients. Thus, this study aimed to evaluate the effects of enriched RS2 cookies on the gut microbiome in HD patients. METHODS AND RESULTS This comprised a randomized, double-blind, placebo-controlled trial of age-, sex-, and BMI-matched patients and controls. The RS2 group received enriched RS2 cookies (16 g/d of Hi-Maize® 260, Ingredion) for four weeks, while the placebo group received cookies made with manioc flour. Fecal microbiota composition was evaluated by the 16S ribosomal RNA gene. Analysis of the microbiota revealed that Pielou's evenness was significantly decreased after RS2 supplementation. Notably, we observed that RS2 intervention upregulated significantly 8 Amplicon Sequencing Variants (ASV's), including Roseburia and Ruminococcus gauvreauii, which are short-chain fatty acids (SCFA) producers. Furthermore, it was associated with the downregulation of 11 ASV's, such as the pro-inflammatory Dialister. CONCLUSIONS RS2 intervention for four weeks in HD patients effectively altered SCFA producers in the gut microbiota, suggesting that it could be a good nutritional strategy for patients with CKD on HD. This article is protected by copyright. All rights reserved.",2021,"SCOPE Resistant starch type-2 (RS2), can mitigate inflammation and oxidative stress in hemodialysis (HD) patients.","['hemodialysis (HD) patients', 'HD patients', 'controlled trial of age-, sex-, and BMI-matched patients and controls', 'Hemodialysis Patients', 'patients with CKD on HD']","['Enriched Resistant Starch Type-2 Cookies', 'RS2 intervention', 'SCOPE\n\n\nResistant starch type-2 (RS2', 'placebo', 'cookies made with manioc flour', 'RS2 cookies']","[""Pielou's evenness"", 'Fecal microbiota composition']","[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}]","[{'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C3853210', 'cui_str': 'Cookie'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0007335', 'cui_str': 'Manihot esculenta'}, {'cui': 'C0016260', 'cui_str': 'Flour'}]","[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}]",,0.160275,"SCOPE Resistant starch type-2 (RS2), can mitigate inflammation and oxidative stress in hemodialysis (HD) patients.","[{'ForeName': 'Julie Ann', 'Initials': 'JA', 'LastName': 'Kemp', 'Affiliation': 'Graduate Program in Cardiovascular Sciences, Fluminense Federal University (UFF), Niterói, RJ, Brazil.'}, {'ForeName': 'Bruna Regis', 'Initials': 'BR', 'LastName': 'de Paiva', 'Affiliation': 'Graduate Program in Cardiovascular Sciences, Fluminense Federal University (UFF), Niterói, RJ, Brazil.'}, {'ForeName': 'Henrique Fragoso', 'Initials': 'HF', 'LastName': 'Dos Santos', 'Affiliation': 'Department of Marine Biology, Fluminense Federal University (UFF), Niterói, RJ, Brazil.'}, {'ForeName': 'Hugo Emiliano', 'Initials': 'HE', 'LastName': 'de Jesus', 'Affiliation': 'Department of Marine Biology, Fluminense Federal University (UFF), Niterói, RJ, Brazil.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Craven', 'Affiliation': 'Wolfson Wohl Translational Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, UK.'}, {'ForeName': 'Umer Z', 'Initials': 'UZ', 'LastName': 'Ijaz', 'Affiliation': 'School of Engineering University of Glasgow, UK.'}, {'ForeName': 'Natalia Alvarenga', 'Initials': 'NA', 'LastName': 'Borges', 'Affiliation': 'Graduate Program in Cardiovascular Sciences, Fluminense Federal University (UFF), Niterói, RJ, Brazil.'}, {'ForeName': 'Paul G', 'Initials': 'PG', 'LastName': 'Shiels', 'Affiliation': 'Wolfson Wohl Translational Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, UK.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Mafra', 'Affiliation': 'Graduate Program in Cardiovascular Sciences, Fluminense Federal University (UFF), Niterói, RJ, Brazil.'}]",Molecular nutrition & food research,['10.1002/mnfr.202100374'] 3376,34080441,Acupuncture for chronic pain in adults with sickle cell disease: a mixed-methods pilot study.,"OBJECTIVE Chronic pain is a common symptom experienced among patients with sickle cell disease (SCD). Our aims were to assess the feasibility and acceptability of performing acupuncture for the treatment of chronic pain in adults with SCD. METHODS This was a single-arm, prospective pilot study of six adults with SCD. Participants reported ⩾ 3 months of chronic pain and were > 18 years of age. Per protocol, acupuncture was to be administered twice per week for 5 weeks, for 30 min per session. All treatments were performed in the acupuncture treatment laboratory at the University of Illinois Chicago College of Nursing. Pain intensity, pain interference, and other symptoms were measured at baseline and after the intervention. Participants completed a semi-structured interview and a protocol acceptability questionnaire after the acupuncture intervention. RESULTS Six participants (mean age 52.5 years, six Black) were enrolled. Although the study was suspended due to COVID-19 and not all participants completed the 10-session protocol, completion rates were high with no missed appointments. One participant did not complete the study due to hospitalization unrelated to acupuncture. No adverse events were reported. At completion of the intervention at 4-5 weeks post-baseline, all participants had reduced pain intensity and pain interference. The mean acceptability score on the protocol acceptability questionnaire was 82%. CONCLUSION It was feasible and acceptable to implement acupuncture in adults with SCD. This study can be used to guide a larger randomized controlled trial to evaluate the effect of acupuncture on reducing chronic pain in adults with SCD. Trial registration number: NCT04156399 (ClinicalTrials.gov).",2021,"At completion of the intervention at 4-5 weeks post-baseline, all participants had reduced pain intensity and pain interference.","['adults with SCD', 'adults with sickle cell disease', 'six adults with SCD', 'patients with sickle cell disease (SCD', 'Six participants (mean age 52.5 years, six Black) were enrolled', 'Participants reported ⩾ 3\u2009months of chronic pain and were > 18\u2009years of age']","['acupuncture', 'Acupuncture', 'acupuncture intervention']","['Pain intensity, pain interference, and other symptoms', 'mean acceptability score', 'adverse events', 'pain intensity and pain interference', 'chronic pain', 'feasibility and acceptability']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517802', 'cui_str': '52.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}]",6.0,0.581158,"At completion of the intervention at 4-5 weeks post-baseline, all participants had reduced pain intensity and pain interference.","[{'ForeName': 'Hongjin', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Biobehavioral Nursing Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Crystal L', 'Initials': 'CL', 'LastName': 'Patil', 'Affiliation': 'Department of Human Development Nursing Science, College of Nursing, University of Illinois Chicago, Chicago, IL, USA.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Molokie', 'Affiliation': 'Department of Hematology/Oncology, College of Medicine, University of Illinois Chicago, Chicago, IL, USA.'}, {'ForeName': 'Franklin', 'Initials': 'F', 'LastName': 'Njoku', 'Affiliation': 'Department of Hematology/Oncology, College of Medicine, University of Illinois Chicago, Chicago, IL, USA.'}, {'ForeName': 'Alana D', 'Initials': 'AD', 'LastName': 'Steffen', 'Affiliation': 'Department of Population Health Nursing Science, College of Nursing, University of Illinois Chicago, Chicago, IL, USA.'}, {'ForeName': 'Ardith Z', 'Initials': 'AZ', 'LastName': 'Doorenbos', 'Affiliation': 'Department of Biobehavioral Nursing Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Judith M', 'Initials': 'JM', 'LastName': 'Schlaeger', 'Affiliation': 'Department of Human Development Nursing Science, College of Nursing, University of Illinois Chicago, Chicago, IL, USA.'}]",Acupuncture in medicine : journal of the British Medical Acupuncture Society,['10.1177/09645284211017303'] 3377,34082279,A randomized controlled trial evaluating the efficacy of a brief computerized anxiety sensitivity reduction intervention for health anxiety.,"It is estimated that individuals with severe health anxiety (HA) utilize 41 %-78 % more healthcare resources than individuals with identified medical diagnoses. Thus, identifying targets for intervention and prevention efforts for HA that are appropriate for primary care or specialty clinic settings is imperative. The aim of the present investigation was to evaluate the effect of a single-session, computerized anxiety sensitivity (AS) intervention on AS and HA. Participants were 68 university students (79.4 % female; M age = 19.68) with elevated levels of AS and HA. Participants were randomized to either the AS intervention condition or an active control condition and completed self-report and behavioral follow-up assessments at post-intervention, 1-week follow-up, and 1-month follow-up. Results indicated a significant Time x Condition interaction for ASI-3 at each follow-up assessment (all ps < .001), such that individuals in the active condition exhibited greater reductions in AS compared to the control condition. There was no significant Time x Condition interaction for HA at any follow-up. Mediation analyses revealed a significant indirect effect of Condition on changes in HA through changes in AS. No significant effects were observed for behavioral outcomes. Findings suggest that this intervention successfully reduces AS among those who are high in HA and AS and may indirectly contribute to reductions in HA over time through reductions in AS.",2021,"Results indicated a significant Time x Condition interaction for ASI-3 at each follow-up assessment (all ps < .001), such that individuals in the active condition exhibited greater reductions in AS compared to the control condition.","['Participants were 68 university students (79.4 % female; M age = 19.68) with elevated levels of AS and HA', 'health anxiety', 'individuals with severe health anxiety (HA']","['AS intervention condition or an active control condition and completed self-report and behavioral follow-up assessments at post-intervention, 1-week follow-up, and 1-month follow-up', 'single-session, computerized anxiety sensitivity (AS) intervention', 'computerized anxiety sensitivity reduction intervention']","['Time x Condition interaction for HA', 'behavioral outcomes', 'Time x Condition interaction for ASI-3']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0450981', 'cui_str': 'Addiction severity index'}]",,0.0213746,"Results indicated a significant Time x Condition interaction for ASI-3 at each follow-up assessment (all ps < .001), such that individuals in the active condition exhibited greater reductions in AS compared to the control condition.","[{'ForeName': 'Emily M', 'Initials': 'EM', 'LastName': ""O'Bryan"", 'Affiliation': ""Department of Psychology, University of Cincinnati, USA; Anxiety Disorders Center, Hartford Hospital/Institute of Living, USA. Electronic address: Emily.O'Bryan@hhchealth.org.""}, {'ForeName': 'Alison C', 'Initials': 'AC', 'LastName': 'McLeish', 'Affiliation': 'University of Louisville, USA.'}, {'ForeName': 'Aaron M', 'Initials': 'AM', 'LastName': 'Norr', 'Affiliation': 'VA VISN 20 Northwest Network Mental Illness Research, Education and Clinical Center (MIRECC), USA; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Ely', 'Affiliation': 'Department of Psychology, University of Cincinnati, USA.'}, {'ForeName': 'Zoey', 'Initials': 'Z', 'LastName': 'Bass', 'Affiliation': 'Department of Psychology, University of Cincinnati, USA.'}, {'ForeName': 'Carolyn D', 'Initials': 'CD', 'LastName': 'Davies', 'Affiliation': 'Anxiety Disorders Center, Hartford Hospital/Institute of Living, USA; Department of Psychological and Brain Sciences, University of Massachusetts Amherst, USA.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Capron', 'Affiliation': 'School of Psychology, University of Southern Mississippi, USA.'}, {'ForeName': 'Norman B', 'Initials': 'NB', 'LastName': 'Schmidt', 'Affiliation': 'Department of Psychology, Florida State University, USA.'}, {'ForeName': 'Kristen E Jastrowski', 'Initials': 'KEJ', 'LastName': 'Mano', 'Affiliation': 'Department of Psychology, University of Cincinnati, USA.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2021.102425'] 3378,34082300,"Adherence with blood pressure self-monitoring in women with pregnancy hypertension, and comparisons to clinic readings: A secondary analysis of OPTIMUM-BP.","OBJECTIVES To assess adherence to self-monitoring of blood pressure (SMBP), and differences between SMBP and clinic readings, in a self-monitoring intervention for managing pregnancy hypertension. STUDY DESIGN OPTIMUM-BP was an unmasked randomised controlled clinical trial. 154 women with pregnancy hypertension from four maternity units in England were recruited and randomised to SMBP or usual care. This secondary analysis included 91 women randomised to self-monitoring who provided BP readings. Trial instructions were for daily SMBP. MAIN OUTCOME MEASURES Adherence was calculated as proportion of days on which SMBP readings were taken. Proportion of weeks in which at least 4 and at least 2 SMBP readings were taken was also calculated. Mean differences between clinic and SMBP measurements were calculated. RESULTS Self-monitored BP data were available for 49 women with chronic hypertension and 42 women with gestational hypertension. Median percentage of days with SMBP readings was 77% (IQR 51, 89) in the chronic hypertension group and 85% (IQR 52, 95) in the gestational hypertension group. Adherence did not vary by different socio-demographic groups. Mean difference (95% CI) between clinic and SMBP for systolic BP was 0.99 mmHg (-1.44, 3.41; chronic hypertension) and 3.76 mmHg (0.75, 6.78; gestational hypertension) and for diastolic BP was 3.03 mmHg (0.93, 5.12; chronic hypertension) and 3.27 mmHg (0.56, 5.98; gestational hypertension). CONCLUSIONS Adherence to self-monitoring was good and differences between SMBP and clinic readings were small. These findings offer reassurance about the use of self-monitoring at a time when it is being increasingly implemented in maternity settings.",2021,"Median percentage of days with SMBP readings was 77% (IQR 51, 89) in the chronic hypertension group and 85% (IQR 52, 95) in the gestational hypertension group.","['154 women with pregnancy hypertension from four maternity units in England', '49 women with chronic hypertension and 42 women with gestational hypertension', '91 women randomised to self-monitoring who provided BP readings', 'women with pregnancy hypertension']","['SMBP or usual care', 'blood pressure self-monitoring']","['systolic BP', 'Adherence', 'Median percentage of days with SMBP readings', 'diastolic BP', 'blood pressure (SMBP']","[{'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0565599', 'cui_str': 'Maternal hypertension'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0341934', 'cui_str': 'Transient hypertension of pregnancy'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0034754', 'cui_str': 'Reading'}]","[{'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",154.0,0.0543717,"Median percentage of days with SMBP readings was 77% (IQR 51, 89) in the chronic hypertension group and 85% (IQR 52, 95) in the gestational hypertension group.","[{'ForeName': 'Liza', 'Initials': 'L', 'LastName': 'Bowen', 'Affiliation': ""Department of Population Health Sciences, King's College London, London, UK.""}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Pealing', 'Affiliation': 'Department of Primary Care, Health Sciences, University of Oxford, UK.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Tucker', 'Affiliation': 'Department of Primary Care, Health Sciences, University of Oxford, UK.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'McManus', 'Affiliation': 'Department of Primary Care, Health Sciences, University of Oxford, UK.'}, {'ForeName': 'Lucy C', 'Initials': 'LC', 'LastName': 'Chappell', 'Affiliation': ""Women and Children's Health, School of Life Course Sciences, King's College London, London, UK. Electronic address: lucy.chappell@kcl.ac.uk.""}]",Pregnancy hypertension,['10.1016/j.preghy.2021.05.016'] 3379,34085324,Evaluation of respiratory and peripheral muscle training in individuals undergoing myocardial revascularization.,"OBJECTIVES To investigate the effect of peripheral muscle strength training (PMT) and respiratory muscle strength training (RMT) muscle strength training associated with conventional physical therapy on the respiratory muscle strength, functional capacity, and quality of life in the immediate postoperative period of patients undergoing coronary artery bypass graft (CABG). METHODS This was a randomized controlled trial. Eighty-three patients undergoing CABG were divided into two groups: Intervention group, patients that received PMT and RMT associated with conventional physical therapy, one session a day for 5 days; control group, patients that received conventional physical therapy, one session a day for 5 days. All patients had respiratory muscle strength, peripheral muscle strength, functional capacity, and quality of life evaluated by manovacuometry, dynamometry, 6-min walking test, and 36-item Short-Form Health Survey Questionnaire, respectively, before and 5 days after CABG. RESULTS Both groups showed a significantly reduced respiratory muscle strength after CABG; however, in the intervention group, the inspiratory muscle strength reduction was lower (confidence interval [CI] 95%: 2.29 [1.9; 27.54]). The quality of live domains for pain (CI 95%: 3.08 [5.21; 24.97]) and vitality perception (CI 95%: 2.51 [2.12; 19.53]) worsened in the control and improved in the intervention group (pain: CI 95%: 1.19 [-3.38; 13.09]; vitality CI 95%: 0.07 [-6.55; 7.04]). Both groups showed reduced functional capacity and expiratory muscle strength after CABG. CONCLUSION Conventional physical therapy combined with PMT and RMT may reduce inspiratory muscle strength loss and improve pain and vitality perception in the immediate postoperative period after CABG.",2021,The quality of live domains for pain (CI 95%: 3.08 [5.21; 24.97]) and vitality perception (CI 95%: 2.51 [2.12; 19.53]) worsened in the control and improved in the intervention group (pain: CI 95%: 1.19 [-3.38; 13.09]; vitality CI 95%: 0.07,"['individuals undergoing myocardial revascularization', 'Eighty-three patients undergoing CABG', 'patients undergoing coronary artery bypass graft (CABG']","['peripheral muscle strength training (PMT) and respiratory muscle strength training (RMT) muscle strength training', 'PMT and RMT associated with conventional physical therapy', 'respiratory and peripheral muscle training', 'conventional physical therapy', 'Conventional physical therapy combined with PMT and RMT']","['quality of live domains for pain', 'inspiratory muscle strength loss and improve pain and vitality perception', 'inspiratory muscle strength reduction', 'respiratory muscle strength, peripheral muscle strength, functional capacity, and quality of life evaluated by manovacuometry, dynamometry, 6-min\xa0walking test, and 36-item Short-Form Health Survey Questionnaire', 'functional capacity and expiratory muscle strength', 'respiratory muscle strength', 'respiratory muscle strength, functional capacity, and quality of life', 'and vitality perception']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0027056', 'cui_str': 'Myocardial revascularization'}, {'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}]",83.0,0.0143742,The quality of live domains for pain (CI 95%: 3.08 [5.21; 24.97]) and vitality perception (CI 95%: 2.51 [2.12; 19.53]) worsened in the control and improved in the intervention group (pain: CI 95%: 1.19 [-3.38; 13.09]; vitality CI 95%: 0.07,"[{'ForeName': 'Tarcísio Nema', 'Initials': 'TN', 'LastName': 'de Aquino', 'Affiliation': 'Department of Motricity Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'de Faria Rosseto', 'Affiliation': 'Department of Motricity Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.'}, {'ForeName': 'Jaqueline', 'Initials': 'J', 'LastName': 'Lúcio Vaz', 'Affiliation': 'Department of Motricity Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.'}, {'ForeName': 'Carolline', 'Initials': 'C', 'LastName': 'de Faria Cordeiro Alves', 'Affiliation': 'Department of Rehabilitation and Cardiology of Hospital Santa Lucia, Poços de Caldas, Minas Gerais, Brazil.'}, {'ForeName': 'Fernanda de Carvalho', 'Initials': 'FC', 'LastName': 'Vidigal', 'Affiliation': 'Department of Nutrition, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.'}, {'ForeName': 'Giovane', 'Initials': 'G', 'LastName': 'Galdino', 'Affiliation': 'Department of Motricity Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.'}]",Journal of cardiac surgery,['10.1111/jocs.15698'] 3380,34062603,Hearing Health Care Utilization Following Automated Hearing Screening.,"BACKGROUND The study examined follow-up rates for pursuing hearing health care (HHC) 6 to 8 months after participants self-administered one of three hearing screening methods: an automated method for testing of auditory sensitivity (AMTAS), a four-frequency pure-tone screener (FFS), or a digits-in-noise test (DIN), with and without the presentation of a 2-minute educational video about hearing. PURPOSE The study aims to determine if the type of self-administered hearing screening method (with or without an educational video) affects HHC follow-up rates. RESEARCH DESIGN The study is a randomized controlled trial of three automated hearing screening methods, plus control group, with and without an educational video. The control group completed questionnaires and provided follow-up data but did not undergo a hearing screening test. STUDY SAMPLE The study sample includes 1,665 participants (mean age 50.8 years; 935 males) at two VA Medical Centers and at university and community centers in Portland, OR; Bay Pines, FL; Minneapolis, MN; Mauston, WI; and Columbus, OH. DATA COLLECTION AND ANALYSIS HHC follow-up data at 6 to 8 months were obtained by contacting participants by phone or mail. Screening methods and participant characteristics were compared in relation to the probability of participants pursuing HHC during the follow-up period. RESULTS The 2-minute educational video did not have a significant effect on HHC follow-up rates. When all participants who provided follow-up data are considered ( n  = 1012), the FFS was the only test that resulted in a significantly greater percentage of HHC follow-up (24.6%) compared with the control group (16.8%); p  = 0.03. However, for participants who failed a hearing screening ( n  = 467), follow-up results for all screening methods were significantly greater than for controls. The FFS resulted in a greater probability for HHC follow-up overall than the other two screening methods. Moreover, veterans had higher follow-up rates for all screening methods than non-veterans. CONCLUSION The FFS resulted in a greater HHC follow-up rate compared with the other screening methods. This self-administered test may be more motivational for HHC follow-up because participants who fail the screening are aware of sounds they could not hear which does not occur with adaptive assessments like AMTAS or the DIN test. It is likely that access to and reduced personal cost of audiological services for veterans contributed to higher HHC follow-up rates in this group compared with non-veteran participants.",2021,The 2-minute educational video did not have a significant effect on HHC follow-up rates.,"['1,665 participants (mean age 50.8 years; 935 males) at two VA Medical Centers and at university and community centers in Portland, OR; Bay Pines, FL; Minneapolis, MN; Mauston, WI; and Columbus, OH']","['control group completed questionnaires and provided follow-up data but did not undergo a hearing screening test', 'hearing screening method (with or without an educational video', 'automated hearing screening methods, plus control group, with and without an educational video', 'hearing screening methods: an automated method for testing of auditory sensitivity (AMTAS), a four-frequency pure-tone screener (FFS), or a digits-in-noise test (DIN), with and without the presentation of a 2-minute educational video about hearing', 'Automated Hearing Screening']",['percentage of HHC follow'],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C3203003', 'cui_str': 'Bays'}, {'cui': 'C0330186', 'cui_str': 'Pinus'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0439232', 'cui_str': 'min'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]",3.0,0.111204,The 2-minute educational video did not have a significant effect on HHC follow-up rates.,"[{'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Folmer', 'Affiliation': 'VA National Center for Rehabilitative Auditory Research, VA Portland Medical Center, Portland, Oregon.'}, {'ForeName': 'Gabrielle H', 'Initials': 'GH', 'LastName': 'Saunders', 'Affiliation': 'VA National Center for Rehabilitative Auditory Research, VA Portland Medical Center, Portland, Oregon.'}, {'ForeName': 'Jay J', 'Initials': 'JJ', 'LastName': 'Vachhani', 'Affiliation': 'VA National Center for Rehabilitative Auditory Research, VA Portland Medical Center, Portland, Oregon.'}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Margolis', 'Affiliation': 'Audiology Incorporated, Arden Hills, Minnesota.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Saly', 'Affiliation': 'Audiology Incorporated, Arden Hills, Minnesota.'}, {'ForeName': 'Bevan', 'Initials': 'B', 'LastName': 'Yueh', 'Affiliation': 'Department of Otolaryngology/Head & Neck Surgery, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Rachel A', 'Initials': 'RA', 'LastName': 'McArdle', 'Affiliation': 'Office of Patient Care Services, Veterans Health Administration, Washington, DC.'}, {'ForeName': 'Lawrence L', 'Initials': 'LL', 'LastName': 'Feth', 'Affiliation': 'Department of Speech and Hearing Science, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Roup', 'Affiliation': 'Department of Speech and Hearing Science, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'M Patrick', 'Initials': 'MP', 'LastName': 'Feeney', 'Affiliation': 'VA National Center for Rehabilitative Auditory Research, VA Portland Medical Center, Portland, Oregon.'}]",Journal of the American Academy of Audiology,['10.1055/s-0041-1723041'] 3381,34390676,"Breastfeeding Outcomes, Self-Efficacy, and Satisfaction Among Low-Income Women With Late-Preterm, Early-Term, and Full-Term Infants.","OBJECTIVE To assess breastfeeding exclusivity and rate of breastfeeding, breastfeeding self-efficacy, and satisfaction with breastfeeding after hospital discharge among low-income women with late-preterm and early-term infants compared with women with full-term infants. DESIGN Prospective, comparative, with repeated measures. SETTING Four Midwestern U.S. Special Supplemental Nutrition Program for Women, Infants, and Children offices. PARTICIPANTS Participants included 270 mother-infant dyads. METHODS We assessed breastfeeding exclusivity, rate of breastfeeding, and breastfeeding self-efficacy at 2 weeks, 2 months, and 5 months and satisfaction with breastfeeding at 5 months after birth or when participants stopped breastfeeding. RESULTS More than 50% of women in each subgroup were non-Hispanic White. Late-preterm and early-term infants had lower breastfeeding exclusivity rates than full-term infants across the three time points (40%, 51%, and 65% at 2 weeks, p = .029; 22.5%, 34%, and 58% at 2 months, p = .000; and 7%, 15%, and 28.46% at 5 months, p = .000, respectively). The overall exclusive breastfeeding rate for all groups was 55.93% at 2 weeks, 44.07% at 2 months, and 20.37% at 5 months; 55.56% continued any breastfeeding at 5 months. Breastfeeding self-efficacy during the first 5 months after birth, satisfaction with breastfeeding, level of education, and attending breastfeeding classes were positively correlated with breastfeeding exclusivity. We found significantly less exclusive breastfeeding, lower breastfeeding self-efficacy, and lower satisfaction with breastfeeding among participants with late-preterm and early-term infants compared to those with full-term infants. CONCLUSION Ongoing professional breastfeeding support for women is needed to improve and promote breastfeeding exclusivity and continuation among their late-preterm and early-term infants.",2021,"Late-preterm and early-term infants had lower breastfeeding exclusivity rates than full-term infants across the three time points (40%, 51%, and 65% at 2 weeks, p = .029; 22.5%, 34%, and 58% at 2 months, p = .000; and 7%, 15%, and 28.46% at 5 months, p = .000, respectively).","['low-income women with late-preterm and early-term infants compared with women with full-term infants', 'Four Midwestern U.S. Special Supplemental Nutrition Program for Women, Infants, and Children offices', 'Participants included 270 mother-infant dyads']",[],"['exclusive breastfeeding, lower breastfeeding self-efficacy, and lower satisfaction with breastfeeding', 'Breastfeeding self-efficacy', 'overall exclusive breastfeeding rate', 'satisfaction with breastfeeding, level of education, and attending breastfeeding classes', 'breastfeeding exclusivity rates', 'Breastfeeding Outcomes, Self-Efficacy, and Satisfaction Among Low-Income Women', 'breastfeeding exclusivity and rate of breastfeeding, breastfeeding self-efficacy, and satisfaction', 'breastfeeding exclusivity, rate of breastfeeding, and breastfeeding self-efficacy']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0456128', 'cui_str': 'Term infant'}, {'cui': 'C4551581', 'cui_str': 'Term baby'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]",[],"[{'cui': 'C0242205', 'cui_str': 'Breastfeeding, Exclusive'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",270.0,0.0682287,"Late-preterm and early-term infants had lower breastfeeding exclusivity rates than full-term infants across the three time points (40%, 51%, and 65% at 2 weeks, p = .029; 22.5%, 34%, and 58% at 2 months, p = .000; and 7%, 15%, and 28.46% at 5 months, p = .000, respectively).","[{'ForeName': 'Azza H', 'Initials': 'AH', 'LastName': 'Ahmed', 'Affiliation': ''}, {'ForeName': 'Wilaiporn', 'Initials': 'W', 'LastName': 'Rojjanasrirat', 'Affiliation': ''}]","Journal of obstetric, gynecologic, and neonatal nursing : JOGNN",['10.1016/j.jogn.2021.06.010'] 3382,34080266,The impact of clinical pharmacy services on patients with hypertension.,"AIMS Globally, hypertension is a major concern in all health care systems. The role of clinical pharmacists in managing hypertension is essential not only in dispensing drugs but also in actively participating in managing treatment regimens. The goal of this study was to support the role of clinical pharmacists in managing patient hypertension therapy. METHODS This study was designed as a pragmatic, prospective, quasi-experimental study. In this study, 160 patients were enrolled, but seven patients withdrew from the study. The effects of the intervention were studied on the remaining 153 participants. Blood pressure, MINICHAL score, and DAI-10 score were measured at the beginning and at the end of the study. The patients received different medication counselling sessions that included medication education. The counselling sessions were conducted three times, with each session 4 months apart from the previous session. The first session was conducted at the beginning of the study following the enrolment of the patients. Only the first session was carried out in person for all the participants, while the other two sessions were conducted either in person or via a phone call. RESULTS Ninety-three male participants (60.8%) and 60 female participants were included (39.2%), and the mean age was 44.18 (±8.385). Most patients enrolled in the study were diagnosed with hypertension within the previous 12 months from the beginning of the study. The mean changes in SBP and DBP between the baseline and final readings were 13.1 and 5.4 mmHg, respectively P < .001). In addition, the DAI-10 positive score improved from 33.3% of the study population at the beginning of the study to 86.3% of the population at the end of the study. CONCLUSION The interventions of clinical pharmacists were found to be significantly important in improving the outcomes of hypertensive patients. Therefore, legislation making clinical pharmacy services compulsory in Middle Eastern health care systems, and particularly the UAE, is needed to expand the roles of pharmacists within the health care system.",2021,"The mean changes in SBP and DBP between the baseline and final readings were 13.1 and 5.4 mmHg, respectively (p<0.001).","['160 patients were enrolled, but 7 patients withdrew from the study', 'Ninety-three male participants (60.8%) and 60 female participants were included (39.2%), and the mean age was 44.18 (±8.385', 'Most patients enrolled in the study were diagnosed with hypertension within the previous 12 months from the beginning of the study', 'hypertensive patients', 'remaining 153 participants', 'Patients with Hypertension']",[],"['DAI-10 positive score', 'mean changes in SBP and DBP', 'Blood pressure, MINICHAL score, and DAI-10 score']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}]",[],"[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",160.0,0.0698203,"The mean changes in SBP and DBP between the baseline and final readings were 13.1 and 5.4 mmHg, respectively (p<0.001).","[{'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Houjazi', 'Affiliation': 'College of Pharmacy, Al Ain University, Al Ain, UAE.'}, {'ForeName': 'Faris', 'Initials': 'F', 'LastName': 'El-Dahiyat', 'Affiliation': 'College of Pharmacy, Al Ain University, Al Ain, UAE.'}, {'ForeName': 'Kishore Gnana', 'Initials': 'KG', 'LastName': 'Sam', 'Affiliation': 'College of Pharmacy, Gulf Medical University, Ajman, UAE.'}]",International journal of clinical practice,['10.1111/ijcp.14433'] 3383,34080258,A calorie-restricted diet with nuts favourably raises plasma high-density lipoprotein-cholesterol in overweight and obese patients with stable coronary heart disease: A randomised controlled trial.,"BACKGROUND Weight loss and consumption of nuts may both improve plasma lipids and lipoproteins. However, their effects in patients with coronary artery disease (CAD) who are under treatment with statins remain unclear. This study was conducted to determine plasma lipid and lipoprotein responses to a low-calorie (25% of energy deficit) nuts containing diet (NELCD) compared with a nut-free energy-restricted diet (NFLCD) in stable CAD patients who were overweight or obese (n = 67). METHODS Plasma lipids and lipoproteins and ATP-binding cassette (ABC) A1 and ABCG1 mRNA expressions in peripheral blood mononuclear cells (PBMCs) isolated from patients were assessed at baseline and after 8 weeks. RESULTS Plasma high-density lipoprotein (HDL) cholesterol and apoA1 increased significantly in the NELCD group at the end of Week 8 compared with those in NFLCD group (in NELCD group, mean change and 95% confidence interval (CI) were 1.17 [-1.31, 3.66] mg/dL, P = 0.012, and 2.55 [-2.10, 7.20] mg/dL, P = 0.011, for HDL cholesterol and apoA1, respectively). In both groups, the concentrations of total cholesterol, low-density lipoprotein cholesterol and triglyceride reduced significantly at Week 8 compared with those in baseline with no significant difference between the two groups. ABCA1 and ABCG1 mRNA expressions non-significantly decreased in both groups. CONCLUSION This study indicates that inclusion of nuts as part of a calorie-restricted diet improves the concentrations of HDL cholesterol and apoA-1 in patients with stable, established CHD receiving statins.",2021,"In both groups, the concentrations of total cholesterol, low-density lipoprotein cholesterol and triglyceride reduced significantly at week 8 compared to baseline with no significant difference between the two groups.","['patients with stable, established CHD receiving statins', 'stable CAD patients who were overweight or obese (n=67', 'overweight and obese patients with stable coronary heart disease', 'patients with coronary artery disease (CAD']","['nut-free energy-restricted diet (NFLCD', 'low-calorie [25% of energy deficit] nuts containing diet (NELCD', 'NFLCD', 'NELCD', 'calorie-restricted diet with nuts favorably raises plasma high density lipoprotein-cholesterol']","['ABCA1 and ABCG1 mRNA expressions non', 'concentrations of HDL cholesterol and apoA-1', 'plasma lipid and lipoprotein responses', 'concentrations of total cholesterol, low-density lipoprotein cholesterol and triglyceride', 'Plasma high-density lipoprotein (HDL) cholesterol and apoA1', 'Plasma lipids and lipoproteins and ATP-binding cassette (ABC) A1 and ABCG1 mRNA expressions in peripheral blood mononuclear cells (PBMCs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0028723', 'cui_str': 'Nut'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C2930544', 'cui_str': 'Calorie restricted diet'}, {'cui': 'C0442818', 'cui_str': 'Raised'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}]","[{'cui': 'C3711161', 'cui_str': 'ABCA1 protein, human'}, {'cui': 'C0963751', 'cui_str': 'ABCG1 protein, human'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0085201', 'cui_str': 'Apolipoprotein A-I'}, {'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C1677784', 'cui_str': 'APOA1 protein, human'}, {'cui': 'C0001480', 'cui_str': 'Adenosine Triphosphate'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0450240', 'cui_str': 'Cassette'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}]",,0.0706426,"In both groups, the concentrations of total cholesterol, low-density lipoprotein cholesterol and triglyceride reduced significantly at week 8 compared to baseline with no significant difference between the two groups.","[{'ForeName': 'Matin', 'Initials': 'M', 'LastName': 'Ghanavati', 'Affiliation': 'Department of Clinical Nutrition & Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Alipour Parsa', 'Affiliation': 'Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Nasrollahzadeh', 'Affiliation': 'Department of Clinical Nutrition & Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",International journal of clinical practice,['10.1111/ijcp.14431'] 3384,34080237,Effects of curcuminoids on inflammatory and oxidative stress biomarkers and clinical outcomes in critically ill patients: A randomized double-blind placebo-controlled trial.,"Experimental studies have suggested the beneficial effects of curcuminoids as natural polyphenols against traumatic brain injury (TBI). The aim of this study was to investigate the effects of supplementation with curcuminoids on inflammatory and oxidative stress biomarkers, clinical outcomes and nutritional status in critically ill patients with TBI. A total of 62 ICU-admitted adult patients with TBI were randomly allocated to receive either a daily dose of 500 mg curcuminoids or matched placebo via enteral nutrition for 7 consecutive days based on stratified block randomization by age and sex. Inflammatory and oxidative stress as well as clinical outcomes and nutritional status of the patients were measured at baseline and at the end of the study. There were no overall group effects regarding to all dependent variables. Compared with baseline, serum levels of IL-6, TNF-α, MCP-1 and CRP were significantly reduced in patients receiving curcuminoids (p < .05) without any significant changes in placebo group; however, changes in the activities of GPx and SOD in serum were not significant between two groups. Moreover, APACHEII and NUTRIC score were significantly improved following curcuminoids consumption in comparison with placebo (p < .05). The findings of this study suggest that short-term supplementation with curcuminoids may have beneficial effects on inflammation, clinical outcomes and nutritional status of critically ill patients with TBI.",2021,"Compared with baseline, serum levels of IL-6, TNF-α, MCP-1 and CRP were significantly reduced in patients receiving curcuminoids (p < .05) without any significant changes in placebo group; however, changes in the activities of GPx and SOD in serum were not significant between two groups.","['A total of 62 ICU-admitted adult patients with TBI', 'critically ill patients with TBI', 'critically ill patients']","['500\u2009mg curcuminoids or matched placebo via enteral nutrition', 'curcuminoids', 'placebo']","['inflammatory and oxidative stress biomarkers and clinical outcomes', 'Inflammatory and oxidative stress', 'serum levels of IL-6, TNF-α, MCP-1 and CRP', 'activities of GPx and SOD in serum']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}]","[{'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}]","[{'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}]",,0.423876,"Compared with baseline, serum levels of IL-6, TNF-α, MCP-1 and CRP were significantly reduced in patients receiving curcuminoids (p < .05) without any significant changes in placebo group; however, changes in the activities of GPx and SOD in serum were not significant between two groups.","[{'ForeName': 'Hoda', 'Initials': 'H', 'LastName': 'Zahedi', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Javad', 'Initials': 'MJ', 'LastName': 'Hosseinzadeh-Attar', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Shadnoush', 'Affiliation': 'Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.'}, {'ForeName': 'Amirhossein', 'Initials': 'A', 'LastName': 'Sahebkar', 'Affiliation': 'Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Bahareh', 'Initials': 'B', 'LastName': 'Barkhidarian', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Sadeghi', 'Affiliation': 'Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Atabak', 'Initials': 'A', 'LastName': 'Najafi', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Hosseini', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Qorbani', 'Affiliation': 'Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.'}, {'ForeName': 'Arezoo', 'Initials': 'A', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seyed Hossein', 'Initials': 'SH', 'LastName': 'Ardehali', 'Affiliation': 'Department of Anesthesiology and Critical Care, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Abdolreza', 'Initials': 'A', 'LastName': 'Norouzy', 'Affiliation': 'Department of Nutrition, Mashhad University of Medical Sciences, Mahshad, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.7179'] 3385,34077644,Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers.,"BACKGROUND Neisseria meningitidis serogroups A, B, C, W, X, and Y cause outbreaks of meningococcal disease. Quadrivalent conjugate vaccines targeting the A, C, W, and Y serogroups are available. A pentavalent vaccine that also includes serogroup X (NmCV-5) is under development. METHODS We conducted a phase 2, observer-blinded, randomized, controlled trial involving Malian children 12 to 16 months of age. Participants were assigned in a 2:2:1 ratio to receive nonadjuvanted NmCV-5, alum-adjuvanted NmCV-5, or the quadrivalent vaccine MenACWY-D, administered intramuscularly in two doses 12 weeks apart. Participants were followed for safety for 169 days. Immunogenicity was assessed with an assay for serum bactericidal antibody (SBA) with rabbit complement on days 0, 28, 84, and 112. RESULTS A total of 376 participants underwent randomization, with 150 assigned to each NmCV-5 group and 76 to the MenACWY-D group; 362 participants received both doses of vaccine. A total of 1% of the participants in the nonadjuvanted NmCV-5 group, 1% of those in the adjuvanted NmCV-5 group, and 4% of those in the MenACWY-D group reported local solicited adverse events; 6%, 5%, and 7% of the participants, respectively, reported systemic solicited adverse events. An SBA titer of at least 128 was seen in 91 to 100% (for all five serotypes) of the participants in the NmCV-5 groups and in 36 to 99% (excluding serogroup X) of those in the MenACWY-D group at day 84 (before the second dose); the same threshold was met in 99 to 100% (for all five serotypes) of the participants in the NmCV-5 groups and in 92 to 100% (excluding serogroup X) of those in the MenACWY-D group at day 112. Immune responses to the nonadjuvanted and adjuvanted NmCV-5 formulations were similar. CONCLUSIONS No safety concerns were identified with two doses of NmCV-5. A single dose of NmCV-5 elicited immune responses that were similar to those observed with two doses of MenACWY-D. Adjuvanted NmCV-5 provided no discernible benefit over nonadjuvanted NmCV-5. (Funded by the U.K. Foreign, Commonwealth, and Development Office; ClinicalTrials.gov number, NCT03295318.).",2021,A single dose of NmCV-5 elicited immune responses that were similar to those observed with two doses of MenACWY-D. Adjuvanted NmCV-5 provided no discernible benefit over nonadjuvanted NmCV-5.,"['376 participants underwent randomization, with 150 assigned to each NmCV-5 group and 76 to the MenACWY-D group; 362 participants received both doses of', 'Malian Toddlers', 'Malian children 12 to 16 months of age']","['Meningococcal Serogroup ACWYX Conjugate Vaccine', 'nonadjuvanted NmCV-5, alum-adjuvanted NmCV-5, or the quadrivalent vaccine MenACWY-D', 'vaccine']","['systemic solicited adverse events', 'Immune responses', 'local solicited adverse events', 'Immunogenicity', 'SBA titer']","[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2003457', 'cui_str': 'MenACWY'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0127526', 'cui_str': 'Meningococcal polysaccharide vaccine'}, {'cui': 'C0449543', 'cui_str': 'Serogroup'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0002371', 'cui_str': 'Aluminum Hydroxide'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C2003457', 'cui_str': 'MenACWY'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0474643', 'cui_str': 'Antibody titer measurement'}]",376.0,0.488606,A single dose of NmCV-5 elicited immune responses that were similar to those observed with two doses of MenACWY-D. Adjuvanted NmCV-5 provided no discernible benefit over nonadjuvanted NmCV-5.,"[{'ForeName': 'Milagritos D', 'Initials': 'MD', 'LastName': 'Tapia', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Samba O', 'Initials': 'SO', 'LastName': 'Sow', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Abdi', 'Initials': 'A', 'LastName': 'Naficy', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Fatoumata', 'Initials': 'F', 'LastName': 'Diallo', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Fadima C', 'Initials': 'FC', 'LastName': 'Haidara', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Amol', 'Initials': 'A', 'LastName': 'Chaudhari', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Lionel', 'Initials': 'L', 'LastName': 'Martellet', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Awa', 'Initials': 'A', 'LastName': 'Traore', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Townsend-Payne', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Ray', 'Initials': 'R', 'LastName': 'Borrow', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Hosken', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Smolenov', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Sambhaji S', 'Initials': 'SS', 'LastName': 'Pisal', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'F Marc', 'Initials': 'FM', 'LastName': 'LaForce', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Rajeev M', 'Initials': 'RM', 'LastName': 'Dhere', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Dhananjay', 'Initials': 'D', 'LastName': 'Kapse', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Yuxiao', 'Initials': 'Y', 'LastName': 'Tang', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Alderson', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}, {'ForeName': 'Prasad S', 'Initials': 'PS', 'LastName': 'Kulkarni', 'Affiliation': 'From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).'}]",The New England journal of medicine,['10.1056/NEJMoa2013615'] 3386,34085092,Efficacy of Splenectomy for Proximal Gastric Cancer with Greater Curvature Invasion or Type 4 Tumor: a Propensity Score Analysis of a Multi-Institutional Dataset.,"BACKGROUND Splenectomy for proximal gastric cancer was found to have no survival benefit in a randomized trial clarifying the role of splenectomy (JCOG0110 study). However, since tumor with invasion to the greater curvature and Type 4 tumor were excluded in JCOG0110, the benefit of splenectomy for these tumors is not known. METHODS A multicenter dataset of patients with gastric cancer who underwent gastrectomy between 2010 and 2014 was created. From the dataset, 114 eligible patients with proximal advanced gastric cancer with invasion to the greater curvature or Type 4 tumor were enrolled. There were 60 patients in the gastrectomy with splenectomy (Spx) group and 54 patients in the spleen-preserving (Prs) group. To balance the essential variables, propensity score analysis was performed, estimating the propensity score with a logistic regression model. Adjusted overall survival (OS) and adjusted disease-free survival (DFS) were estimated using the inverse probability of treatment weighting (IPTW) method. RESULTS There were significant differences in age, performance status, comorbidity, macroscopic type, and clinical T stage between the Spx and Prs groups. The model for estimating the propensity score was well adapted (c-statistic: 0.830, 95%CI: 0.754-0.906). Adjusted OS was identical between the two groups (HR = 1.089, 95%CI: 0.759-1.563; p = 0.644). The DFS curve of Prs group was consistently tended to be lower than Spx, but the difference was not significant (HR = 0.813, 95%CI: 0.572-1.156; p = 0.249). CONCLUSIONS The efficacy of splenectomy was minimal for proximal advanced gastric cancer even with invasion to the greater curvature or Type 4 tumor.",2021,"Adjusted OS was identical between the two groups (HR = 1.089, 95%CI: 0.759-1.563; p = 0.644).","['proximal advanced gastric cancer', '60 patients in the gastrectomy with splenectomy (Spx) group and 54 patients in the spleen-preserving (Prs) group', 'proximal gastric cancer', '114 eligible patients with proximal advanced gastric cancer with invasion to the greater curvature or Type 4 tumor were enrolled', 'Proximal Gastric Cancer with Greater Curvature Invasion or Type 4 Tumor', 'patients with gastric cancer who underwent gastrectomy between 2010 and 2014 was created']","['splenectomy', 'Splenectomy']","['DFS curve', 'Adjusted OS', 'age, performance status, comorbidity, macroscopic type, and clinical T stage', 'Adjusted overall survival (OS) and adjusted disease-free survival (DFS']","[{'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}, {'cui': 'C0037995', 'cui_str': 'Splenectomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0037993', 'cui_str': 'Splenic structure'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C1269955', 'cui_str': 'Tumour invasion'}, {'cui': 'C0227223', 'cui_str': 'Structure of greater curvature of stomach'}, {'cui': 'C0441732', 'cui_str': 'Type 4'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]","[{'cui': 'C0037995', 'cui_str': 'Splenectomy'}]","[{'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0475455', 'cui_str': 'T - Tumor stage'}]",114.0,0.148906,"Adjusted OS was identical between the two groups (HR = 1.089, 95%CI: 0.759-1.563; p = 0.644).","[{'ForeName': 'Seiji', 'Initials': 'S', 'LastName': 'Ito', 'Affiliation': 'Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. seito@aichi-cc.jp.'}, {'ForeName': 'Mitsuro', 'Initials': 'M', 'LastName': 'Kanda', 'Affiliation': 'Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Yoshinari', 'Initials': 'Y', 'LastName': 'Mochizuki', 'Affiliation': 'Department of Surgery, Komaki Municipal Hospital, Komaki, Japan.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Teramoto', 'Affiliation': 'Department of Surgery, Yokkaichi Municipal Hospital, Yokkaichi, Japan.'}, {'ForeName': 'Kiyoshi', 'Initials': 'K', 'LastName': 'Ishigure', 'Affiliation': 'Department of Surgery, Konan Kosei Hospital, Konan, Japan.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Murai', 'Affiliation': 'Department of Surgery, Ichinomiya Municipal Hospital, Ichinomiya, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Asada', 'Affiliation': 'Department of Surgery, Gifu Prefectural Tajimi Hospital, Tajimi, Japan.'}, {'ForeName': 'Akiharu', 'Initials': 'A', 'LastName': 'Ishiyama', 'Affiliation': 'Department of Surgery, Okazaki City Hospital, Okazaki, Japan.'}, {'ForeName': 'Hidenobu', 'Initials': 'H', 'LastName': 'Matsushita', 'Affiliation': 'Department of Surgery, Tosei General Hospital, Seto, Japan.'}, {'ForeName': 'Chie', 'Initials': 'C', 'LastName': 'Tanaka', 'Affiliation': 'Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Surgery, Komaki Municipal Hospital, Komaki, Japan.'}, {'ForeName': 'Michitaka', 'Initials': 'M', 'LastName': 'Fujiwara', 'Affiliation': 'Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Kenta', 'Initials': 'K', 'LastName': 'Murotani', 'Affiliation': 'Biostatistics Center, Graduate School of Medicine, Kurume University, Kurume, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Kodera', 'Affiliation': 'Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.'}]",World journal of surgery,['10.1007/s00268-021-06173-6'] 3387,34087466,Indocyanine-mediated antimicrobial photodynamic therapy promotes superior clinical effects in stage III and grade C chronic periodontitis among controlled and uncontrolled diabetes mellitus: A randomized controlled clinical trial.,"BACKGROUND The aim of this randomized controlled clinical trial was to evaluate the efficacy of indocyanine-green mediated antimicrobial photodynamic therapy (ICG-aPDT) in the treatment of stage III grade C periodontitis in terms of clinical, microbiological, and immune-inflammatory parameters in patients with well-controlled and poorly-controlled form of type-2 diabetes mellitus (T2DM). MATERIALS AND METHODS Subjects with a diagnosis of chronic periodontitis according to the new classification and case definition of periodontitis [probing depth (PD): ≥6 mm, interdental clinical attachment loss (CAL): ≥5 mm and bone loss extending to mid-third of root and beyond (≥3 mm)] were recruited. Subjects were grouped on the basis of well-controlled and poorly-controlled diabetic status. Two subgroups were made according to the treatment modality (RSD versus ICG-aPDT/RSD) in each group. A split-mouth design was used in which one site was designated for control (RSD alone treatment) while the other contralateral site was chosen for test treatment (ICG-aPDT/RSD) in all the patients. Periodontal parameters included the measurement of plaque score (PS), bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL) and alveolar bone levels (ABL). Identification of Porphyromonas gingivalis and Tannarella forsythia through PCR was executed using species specific primers. Gingival crevicular fluid samples were then analyzed using enzyme-linked immunosorbent assay for the quantification of interleukin (IL)-17 and interferon (IFN)-γ. All the clinical, microbiological, and immunological parameters were assessed using repeated measure ANOVA for intra and inter-group comparisons. The p-value significance was set at 0.05. RESULTS The mean age of the 50 patients was 44.7 ± 7.4 years. Systemic parameters suggest no significant change between the times in either HbA1c or serum CRP levels in any of the groups. A statistically significant reduction for BOP was noted for ICG-aPDT group for non-diabetic subjects at 3 months follow up only, while a significant reduction was seen at both 3 months and 6 months among well-controlled and poorly-controlled T2DM subjects (p<0.05). For PD and CAL, a significant improvement was seen for ICG-aPDT group among non-diabetic and well-controlled T2DM subjects at both 3- and 6-months follow up, while a significant reduction was seen at only 3 months among poorly-controlled T2DM subjects. A significant reduction was seen for ICG-aPDT group compared to RSD group for both bacteria in all the three groups at 6 months follow up (p<0.05). CONCLUSION ICG-aPDT significantly improved clinical and antimicrobial parameters in well-controlled and poorly-controlled T2DM having stage III and grade C periodontitis. Glycemic status did not have negative impact in the reduction of periodontal parameters in either types of T2DM. TRIAL REGISTRATION The present RCT was registered in the clinicaltrials.gov under the identifier: NCT04857346.",2021,Systemic parameters suggest no significant change between the times in either HbA1c or serum CRP levels in any of the groups.,"['stage III grade C periodontitis', 'stage III and grade C chronic periodontitis among controlled and uncontrolled diabetes mellitus', 'patients with well-controlled and poorly-controlled form of type-2 diabetes mellitus (T2DM', 'The mean age of the 50 patients was 44.7 ± 7.4 years', 'Subjects with a diagnosis of chronic periodontitis according to the new classification and case definition of periodontitis [probing depth (PD): ≥6mm, interdental clinical attachment loss (CAL): ≥5 mm and bone loss extending to mid-third of root and beyond (≥3 mm)] were recruited']","['RSD', 'Indocyanine-mediated antimicrobial photodynamic therapy', 'ICG-aPDT', 'indocyanine-green mediated antimicrobial photodynamic therapy (ICG-aPDT']","['BOP', 'plaque score (PS), bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL) and alveolar bone levels (ABL', 'Gingival crevicular fluid samples', 'serum CRP levels']","[{'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0441807', 'cui_str': 'Grade C'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0266929', 'cui_str': 'Chronic periodontitis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3853142', 'cui_str': 'Well controlled'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517858', 'cui_str': '7.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0442104', 'cui_str': 'Interdental'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}]","[{'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0021234', 'cui_str': 'Indocyanine Green'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0017564', 'cui_str': 'Gingival Exudate'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",50.0,0.0410468,Systemic parameters suggest no significant change between the times in either HbA1c or serum CRP levels in any of the groups.,"[{'ForeName': 'Mohammed Mahmoud', 'Initials': 'MM', 'LastName': 'Al-Momani', 'Affiliation': 'Department of Community Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia. Electronic address: malmomani@ksu.edu.sa.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102379'] 3388,34390648,Correction to Lancet Respir Med 2021; published online June 18. https://doi.org/10.1016/S2213-2600(21)00089-8.,,2021,,[],[],[],[],[],[],,0.113774,,[],The Lancet. Respiratory medicine,['10.1016/S2213-2600(21)00371-4'] 3389,34077287,Peak and Per-Step Tibial Bone Stress During Walking and Running in Female and Male Recreational Runners.,"BACKGROUND Athletes, especially female athletes, experience high rates of tibial bone stress injuries (BSIs). Knowledge of tibial loads during walking and running is needed to understand injury mechanisms and design safe running progression programs. PURPOSE To examine tibial loads as a function of gait speed in male and female runners. STUDY DESIGN Controlled laboratory study. METHODS Kinematic and kinetic data were collected on 40 recreational runners (20 female, 20 male) during 4 instrumented gait speed conditions on a treadmill (walk, preferred run, slow run, fast run). Musculoskeletal modeling, using participant-specific magnetic resonance imaging and motion data, was used to estimate tibial stress. Peak tibial stress and stress-time impulse were analyzed using 2-factor multivariate analyses of variance (speed*sex) and post hoc comparisons (α = .05). Bone geometry and tibial forces and moments were examined. RESULTS Peak compression was influenced by speed ( P < .001); increasing speed generally increased tibial compression in both sexes. Women displayed greater increases in peak tension ( P = .001) and shear ( P < .001) than men when transitioning from walking to running. Further, women displayed greater peak tibial stress overall ( P < .001). Compressive and tensile stress-time impulse varied by speed ( P < .001) and sex ( P = .006); impulse was lower during running than walking and greater in women. A shear stress-time impulse interaction ( P < .001) indicated that women displayed greater impulse relative to men when changing from a walk to a run. Compared with men, women displayed smaller tibiae ( P < .001) and disproportionately lower tibial forces ( P ≤ .001-.035). CONCLUSION Peak tibial stress increased with gait speed, with a 2-fold increase in running relative to walking. Women displayed greater tibial stress than men and greater increases in stress when shifting from walking to running. Sex differences appear to be the result of smaller bone geometry in women and tibial forces that were not proportionately lower, given the womens' smaller stature and lower mass relative to men. CLINICAL RELEVANCE These results may inform interventions to regulate running-related training loads and highlight a need to increase bone strength in women. Lower relative bone strength in women may contribute to a sex bias in tibial BSIs, and female runners may benefit from a slower progression when initiating a running program.",2021,Women displayed greater increases in peak tension ( P = .001) and shear ( P < .001) than men when transitioning from walking to running.,"['Athletes, especially female athletes, experience high rates of tibial bone stress injuries (BSIs', 'male and female runners', '40 recreational runners (20 female, 20 male) during 4', 'Female and Male Recreational Runners']","['Peak and Per-Step Tibial Bone Stress During Walking and Running', 'instrumented gait speed conditions on a treadmill (walk, preferred run, slow run, fast run']","['peak tibial stress overall', 'Compressive and tensile stress-time impulse varied by speed', 'tibial forces', 'bone strength', 'tibial compression', 'Peak tibial stress and stress-time impulse', 'Peak compression', 'peak tension', 'Peak tibial stress increased with gait speed', 'tibial stress', 'running relative to walking']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443235', 'cui_str': 'Impulse'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]",40.0,0.049259,Women displayed greater increases in peak tension ( P = .001) and shear ( P < .001) than men when transitioning from walking to running.,"[{'ForeName': 'Stacey A', 'Initials': 'SA', 'LastName': 'Meardon', 'Affiliation': 'Department of Physical Therapy, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Timothy R', 'Initials': 'TR', 'LastName': 'Derrick', 'Affiliation': 'Department of Kinesiology, Iowa State University, Ames, Iowa, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Willson', 'Affiliation': 'Department of Physical Therapy, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Baggaley', 'Affiliation': 'Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'C Ryan', 'Initials': 'CR', 'LastName': 'Steinbaker', 'Affiliation': 'Eastern Radiologists, Greenville, North Carolina, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Marshall', 'Affiliation': 'Department of Physical Therapy, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Willy', 'Affiliation': 'School of Physical Therapy and Rehabilitation Science, University of Montana, Missoula, Montana, USA.'}]",The American journal of sports medicine,['10.1177/03635465211014854'] 3390,34390601,"Clinical, radiographic, and immunological evaluation of angulated screw-retained and cemented single-implant crowns in the esthetic region: A 1-year randomized controlled clinical trial.","BACKGROUND Screw-retained implant crowns are considered more biologically compatible than cemented crowns due to the absence of excess cement. However, traditional screw-retained implant crowns are not viable when the access hole of the screw channel would need to be located in an esthetic area, which would compromise the esthetic outcome of the treatment. PURPOSE To evaluate the clinical, radiographic, and immunological outcomes of angulated screw-retained and cemented single-implant crowns in the esthetic region. MATERIALS AND METHODS The study was a single-center, open-label, randomized controlled clinical trial. Eligible patients were randomly placed in two groups: angulated screw-retained group (AG) and cemented group (CG). Implant survival rate, bleeding on probing rate (BOP%), probing depth (PD), modified plaque index (mPI), marginal bone loss (MBL), concentrations of pro-inflammatory cytokines (TNF-α, IL-6) in peri-implant crevicular fluid (PICF), mechanical complications, and pink esthetic score/white esthetic score (PES/WES) were evaluated. RESULTS Fifty-six patients (AG: 29, CG: 27) attended the 1-year examination. The drop-out rate was 6.67%. No implant failure was found in both groups during the observation period. BOP% was significantly lower in the AG than that in the CG (mean, 21.84% ± 19.97% vs. 37.04% ± 26.28%, p = 0.018). The concentration of TNF-α in PICF was significantly higher in the AG than that in the CG (median, 13.54 vs. 4.62, p = 0.019). No significant difference of PD, mPI, MBL, IL-6, or mechanical complication rates was found between the two groups. Mean scores for PES/WES were 21.71 and 21.64 in the AG and CG, respectively. CONCLUSION Based on the present results, both treatment options showed acceptable clinical outcomes in the short term. Angulated screw-retained crowns might benefit the peri-implant soft tissue. However, studies with long-term follow-up are needed to confirm whether the higher concentration of TNF-α will compromise the long-term outcomes of treatment.",2021,"Implant survival rate, bleeding on probing rate (BOP%), probing depth (PD), modified plaque index (mPI), marginal bone loss (MBL), concentrations of pro-inflammatory cytokines (TNF-α, IL-6) in peri-implant crevicular fluid (PICF), mechanical complications, and pink esthetic score/white esthetic score (PES/WES) were evaluated. ","['Fifty-six patients (AG: 29, CG: 27) attended the 1-year examination', 'Eligible patients']","['Angulated screw-retained crowns', 'angulated screw-retained group (AG) and cemented group (CG', 'angulated screw-retained and cemented single-implant crowns']","['Mean scores for PES/WES', 'concentration of TNF-α in PICF', 'Implant survival rate, bleeding on probing rate (BOP%), probing depth (PD), modified plaque index (mPI), marginal bone loss (MBL), concentrations of pro-inflammatory cytokines (TNF-α, IL-6) in peri-implant crevicular fluid (PICF), mechanical complications, and pink esthetic score/white esthetic score (PES/WES', 'BOP', 'implant failure', 'PD, mPI, MBL, IL-6, or mechanical complication rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0333179', 'cui_str': 'Angulated'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0333179', 'cui_str': 'Angulated'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0010384', 'cui_str': 'Crown'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332585', 'cui_str': 'Pink color'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0796232', 'cui_str': 'Bohring Opitz syndrome'}, {'cui': 'C0854676', 'cui_str': 'Failure of implant'}]",56.0,0.241798,"Implant survival rate, bleeding on probing rate (BOP%), probing depth (PD), modified plaque index (mPI), marginal bone loss (MBL), concentrations of pro-inflammatory cytokines (TNF-α, IL-6) in peri-implant crevicular fluid (PICF), mechanical complications, and pink esthetic score/white esthetic score (PES/WES) were evaluated. ","[{'ForeName': 'Xiao-Lei', 'Initials': 'XL', 'LastName': 'Lv', 'Affiliation': ""Department of Oral and Maxillo-facial Implantology, Shanghai Key Laboratory of Stomatology, National Clinical Research Center for Stomatology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.""}, {'ForeName': 'Shu-Jiao', 'Initials': 'SJ', 'LastName': 'Qian', 'Affiliation': ""Department of Oral and Maxillo-facial Implantology, Shanghai Key Laboratory of Stomatology, National Clinical Research Center for Stomatology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.""}, {'ForeName': 'Shi-Chong', 'Initials': 'SC', 'LastName': 'Qiao', 'Affiliation': ""Department of Oral and Maxillo-facial Implantology, Shanghai Key Laboratory of Stomatology, National Clinical Research Center for Stomatology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.""}, {'ForeName': 'Ying-Xin', 'Initials': 'YX', 'LastName': 'Gu', 'Affiliation': ""Department of Oral and Maxillo-facial Implantology, Shanghai Key Laboratory of Stomatology, National Clinical Research Center for Stomatology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.""}, {'ForeName': 'Hong-Chang', 'Initials': 'HC', 'LastName': 'Lai', 'Affiliation': ""Department of Oral and Maxillo-facial Implantology, Shanghai Key Laboratory of Stomatology, National Clinical Research Center for Stomatology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.""}, {'ForeName': 'Jun-Yu', 'Initials': 'JY', 'LastName': 'Shi', 'Affiliation': ""Department of Oral and Maxillo-facial Implantology, Shanghai Key Laboratory of Stomatology, National Clinical Research Center for Stomatology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.""}]",Clinical implant dentistry and related research,['10.1111/cid.13035'] 3391,34080238,Randomized Clinical Trial comparing clinical adjustment times of CAD/CAM screw-retained posterior crowns on ti-base abutments created with digital or conventional impressions. One-year follow-up.,"OBJECTIVES The purpose of this randomized clinical trial was to compare the required time of potential clinical adjustments of posterior screw-retained monolithic zirconia implant retained crowns based on intraoral optical scanning (IOS) or conventional impressions. MATERIALS AND METHODS Patients with posterior tissue level implants (Straumann RN) replacing solitary teeth were recruited. Of all patients, impressions were taken with both an IOS (3M ™ TDS) and a conventional (polyether) pick-up impression. Randomization was performed after impression taking and patients were to receive either a crown based on the digital or the conventional impression. The time required for adjustments at placement was recorded. Additionally, restoration survival and mechanical complications with a follow-up of one year were documented. RESULTS Thirty two patients with 45 implants were included: 23 restorations in the test (IOS) and 22 in the control (conventional) group. The average adjustment time was 3.35 min (SD ± 3.38, range: 0-11 min) for the digital versus 6.09 min (SD ± 4.63, range: 0-18 min) for the conventional impressions (p = .039). A proper fit (no adjustments required) was achieved 39,1% in the digital and 18,2% conventional group respectively. All 45 restorations could be placed within the two planned appointments and only two minor mechanical complications occurred during the first year of function. CONCLUSIONS The use of IOS resulted in shorter adjustment times at try-in than conventional impressions for solitary CAD/CAM implant restorations. Screw-retained solitary monolithic zirconia restorations on ti-base abutments show low complication- and survival rates in the short term.",2021,The use of IOS resulted in shorter adjustment times at try-in than conventional impressions for solitary CAD/CAM implant restorations.,"['32 Patients with 45 implants were included: 23 restorations in the test (IOS) and 22 in the control (conventional) group', 'Patients with posterior tissue level implants (Straumann RN) replacing solitary teeth were recruited']","['posterior screw-retained monolithic zirconia implant retained crowns', 'CAD/CAM screw-retained posterior crowns']","['restoration survival and mechanical complications', 'average adjustment time', 'mechanical complications', 'survival rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0442119', 'cui_str': 'Intraoral approach'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0205171', 'cui_str': 'Singular'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}]","[{'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0078814', 'cui_str': 'zirconium oxide'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0010384', 'cui_str': 'Crown'}, {'cui': 'C0011905', 'cui_str': 'Computer-Assisted Diagnosis'}, {'cui': 'C0002346', 'cui_str': 'Medicine, Alternative'}]","[{'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",32.0,0.123598,The use of IOS resulted in shorter adjustment times at try-in than conventional impressions for solitary CAD/CAM implant restorations.,"[{'ForeName': 'Wiebe', 'Initials': 'W', 'LastName': 'Derksen', 'Affiliation': 'Section of Oral Implantology and Prosthetic Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), Amsterdam, The Netherlands.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Tahmaseb', 'Affiliation': 'Section of Oral Implantology and Prosthetic Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), Amsterdam, The Netherlands.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Wismeijer', 'Affiliation': 'Section of Oral Implantology and Prosthetic Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), Amsterdam, The Netherlands.'}]",Clinical oral implants research,['10.1111/clr.13790'] 3392,34080077,Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial.,"This study aimed to illustrate how a new methodology to assess clinical trial outcome measures using a longitudinal item response theory-based model (IRM) could serve as an alternative to mixed model repeated measures (MMRM). Data from the EXACT (Exacerbation of chronic pulmonary disease tool) which is used to capture frequency, severity, and duration of exacerbations in COPD were analyzed using an IRM. The IRM included a graded response model characterizing item parameters and functions describing symptom-time course. Total scores were simulated (month 12) using uncertainty in parameter estimates. The 50th (2.5th, 97.5th) percentiles of the resulting simulated differences in average total score (drug minus placebo) represented the estimated drug effect (95%CI), which was compared with published MMRM results. Furthermore, differences in sample size, sensitivity, specificity, and type I and II errors between approaches were explored. Patients received either oral danirixin 75 mg twice daily (n = 45) or placebo (n = 48) on top of standard of care over 52 weeks. A step function best described the COPD symptoms-time course in both trial arms. The IRM improved precision of the estimated drug effect compared to MMRM, resulting in a sample size of 2.5 times larger for the MMRM analysis to achieve the IRM precision. The IRM showed a higher probability of a positive predictive value (34%) than MMRM (22%). An item model-based analysis data gave more precise estimates of drug effect than MMRM analysis for the same endpoint in this one case study.",2021,The IRM showed a higher probability of a positive predictive value (34%) than MMRM (22%).,[],"['longitudinal item response theory-based model (IRM', 'oral danirixin 75\xa0mg twice daily (n\u2009=\u200945) or placebo']","['COPD symptoms-time course', 'Total scores', 'sample size, sensitivity, specificity, and type I and II errors']",[],"[{'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4519256', 'cui_str': 'danirixin'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449247', 'cui_str': 'Time course'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}]",,0.184354,The IRM showed a higher probability of a positive predictive value (34%) than MMRM (22%).,"[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Llanos-Paez', 'Affiliation': 'Department of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Ambery', 'Affiliation': 'Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline plc, London, UK.'}, {'ForeName': 'Shuying', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline plc, London, UK.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Tabberer', 'Affiliation': 'Patient Centred Outcomes: Value Evidence and Outcomes, GlaxoSmithKline plc, Brentford, Middlesex, UK.'}, {'ForeName': 'Misba', 'Initials': 'M', 'LastName': 'Beerahee', 'Affiliation': 'Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline plc, London, UK.'}, {'ForeName': 'Elodie L', 'Initials': 'EL', 'LastName': 'Plan', 'Affiliation': 'Department of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden.'}, {'ForeName': 'Mats O', 'Initials': 'MO', 'LastName': 'Karlsson', 'Affiliation': 'Department of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden. mats.karlsson@farmaci.uu.se.'}]",The AAPS journal,['10.1208/s12248-021-00600-1'] 3393,34080920,Mirtazapine reduces susceptibility to hypocapnic central sleep apnea in males with sleep-disordered breathing: a pilot study.,"Studies in humans and animal models with spinal cord injury (SCI) have demonstrated that medications targeting serotonin receptors may decrease the susceptibility to central sleep-disordered breathing (SDB). We hypothesized that mirtazapine would decrease the propensity to develop hypocapnic central sleep apnea (CSA) during sleep. We performed a single-blind pilot study on a total of 10 men with SDB (7 with chronic SCI and 3 noninjured) aged 52.0 ± 11.2 yr. Participants were randomly assigned to either mirtazapine (15 mg at bedtime) or a placebo for at least 1 wk, followed by a 7-day washout period before crossing over to the other intervention. Split-night studies included polysomnography and induction of hypocapnic CSA using a noninvasive ventilation (NIV) protocol. The primary outcome was CO 2 reserve, defined as the difference between eupneic and end of NIV end-tidal CO 2 ([Formula: see text]) preceding induced hypocapneic CSA. Secondary outcomes included controller gain (CG), other ventilatory parameters, and SDB severity. CG was defined as the ratio of change in minute ventilation (V̇e) between control and hypopnea to the change in CO 2 during sleep. CO 2 reserve was significantly widened on mirtazapine than placebo (-3.8 ± 1.2 vs. -2.0 ± 1.5 mmHg; P = 0.015). CG was significantly decreased on mirtazapine compared with placebo [2.2 ± 0.7 vs. 3.5 ± 1.9 L/(mmHg × min); P = 0.023]. There were no significant differences for other ventilatory parameters assessed or SDB severity between mirtazapine and placebo trials. These findings suggest that the administration of mirtazapine can decrease the susceptibility to central apnea by reducing chemosensitivity and increasing CO 2 reserve; however, considering the lack of changes in apnea-hypopnea index (AHI), further research is required to understand the significance of this finding. NEW & NOTEWORTHY To our knowledge, this research study is novel as it is the first study in humans assessing the effect of mirtazapine on CO 2 reserve and chemosensitivity in individuals with severe sleep-disordered breathing. This is also the first study to determine the potential therapeutic effects of mirtazapine on sleep parameters in individuals with a spinal cord injury.",2021,There were no significant differences for other ventilatory parameters assessed or SDB severity between mirtazapine and placebo trials.,"['those with spinal cord injury (SCI', '10 men with SDB (seven with chronic SCI and three non-injured) aged 52.0±11.2 years', 'Males with Sleep Disordered Breathing ']","['hypocapnic CSA using a non-invasive ventilation (NIV) protocol', 'placebo', 'mirtazapine', 'Mirtazapine']","['CO 2 reserve', 'CG', 'hypocapnic central sleep apnea (CSA', 'CO 2 reserve, defined as the difference between eupneic and end of NIV P ET CO 2 preceding induced hypocapneic CSA', 'controller gain (CG), other ventilatory parameters, and SDB severity', 'SDB severity', 'Hypocapnic Central Sleep Apnea']","[{'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0085383', 'cui_str': 'Hypocapnia'}, {'cui': 'C0520680', 'cui_str': 'Apnea, Central Sleep'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0049506', 'cui_str': 'Mirtazapine'}]","[{'cui': 'C0085383', 'cui_str': 'Hypocapnia'}, {'cui': 'C0520680', 'cui_str': 'Apnea, Central Sleep'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",10.0,0.0682784,There were no significant differences for other ventilatory parameters assessed or SDB severity between mirtazapine and placebo trials.,"[{'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Prowting', 'Affiliation': 'Sleep Research Laboratory, John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Maresh', 'Affiliation': 'Sleep Research Laboratory, John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Vaughan', 'Affiliation': 'Sleep Research Laboratory, John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Kruppe', 'Affiliation': 'Sleep Research Laboratory, John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.'}, {'ForeName': 'Bander', 'Initials': 'B', 'LastName': 'Alsabri', 'Affiliation': 'Sleep Research Laboratory, John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.'}, {'ForeName': 'M Safwan', 'Initials': 'MS', 'LastName': 'Badr', 'Affiliation': 'Sleep Research Laboratory, John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.'}, {'ForeName': 'Abdulghani', 'Initials': 'A', 'LastName': 'Sankari', 'Affiliation': 'Sleep Research Laboratory, John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00838.2020'] 3394,34066784,Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study).,"BACKGROUND Relevant improvement in first-line treatment of metastatic pancreatic cancer (mPC) was provided by FOLFIRINOX and by gemcitabine (gem) plus nab-paclitaxel (Nab-p) regimens. Regardless of the first-line treatment survival benefit, most patients survive less than 1 year. AIM The objectives of this multicenter phase I/II study were to evaluate as first-line chemotherapy (CT) two modified regimens of FOLFIRINOX, replacing either oxaliplatin (Oxa) or irinotecan with Nab-p, in patients with mPC. METHODS The primary objectives of phase 1 were the definition of the dose limit binations, while for phase II they were the characterization of safety and activity of Nab-FOLFIRI and Nab-FOLFOX in mPC. RESULTS Sixty-three patients received Nab-FOLFIRI or Nab-FOLFOX in phase I. We defined MTD at 120 mg/m 2 for Nab-p with FOLFIRI and 160 mg/m 2 with FOLFOX. In phase II, we randomized 42 patients for each arm with the following results: (1) overall response rate (ORR) was 31% for both schedules; (2) a clinical benefit rate (CBR) of 69% and 71%; (3) 1-year survival was 41% and 50%; (4) progression free survival (PFS) was 6 months and 5.6 months; (5) median overall survival (OS) was 10.2 and 10.4 months for Nab-FOLFIRI and Nab-FOLFOX, respectively. (6) Neutropenia was the most common grade ≥3 adverse event in our regimens, significantly lower than that reported for the FOLFIRINOX triplet. CONCLUSION Nab-FOLFIRI and Nab-FOLFOX might be hopeful first-line CT options for mPC patients, with promising activity and a good safety profile.",2021,(3) 1-year survival was 41% and 50%; (4) progression free survival (PFS) was 6 months and 5.6 months;,"['metastatic pancreatic cancer (mPC', 'metastatic Pancreatic Cancer (NabucCO Study', 'patients with mPC']","['line chemotherapy (CT) two modified regimens of FOLFIRINOX, replacing either oxaliplatin (Oxa) or irinotecan with Nab-p', 'Nab-FOLFIRI or Nab-FOLFOX', 'NAB-FOLFIRI and NAB-FOLFOX', 'gemcitabine (gem) plus nab-paclitaxel', 'FOLFOX']","['clinical benefit rate (CBR', 'overall response rate (ORR', 'median overall survival (OS', '1-year survival', 'characterization of safety and activity of Nab-FOLFIRI and Nab-FOLFOX in mPC', 'progression free survival (PFS']","[{'cui': 'C0346976', 'cui_str': 'Secondary malignant neoplasm of pancreas'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C4742253', 'cui_str': 'folfirinox'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0346976', 'cui_str': 'Secondary malignant neoplasm of pancreas'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",42.0,0.0706636,(3) 1-year survival was 41% and 50%; (4) progression free survival (PFS) was 6 months and 5.6 months;,"[{'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Giommoni', 'Affiliation': 'Medical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy.'}, {'ForeName': 'Evaristo', 'Initials': 'E', 'LastName': 'Maiello', 'Affiliation': 'Medical Oncology Unit, IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.'}, {'ForeName': 'Vanja', 'Initials': 'V', 'LastName': 'Vaccaro', 'Affiliation': 'Medical Oncology Unit, Istituto Nazionale Tumori Regina Elena, 00144 Roma, Italy.'}, {'ForeName': 'Ermanno', 'Initials': 'E', 'LastName': 'Rondini', 'Affiliation': 'Oncology Unit, Ospedale Santa Maria Nuova-IRCCS, 42100 Reggio Emilia, Italy.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Vivaldi', 'Affiliation': 'Medical Oncology Unit 2, Azienda Ospedaliero Universitaria Pisana, 56126 Pisa, Italy.'}, {'ForeName': 'Giampaolo', 'Initials': 'G', 'LastName': 'Tortora', 'Affiliation': 'Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, 37134 Verona, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Toppo', 'Affiliation': 'Medical Oncology Unit, ASST Cremona, 26100 Cremona, Italy.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Giordano', 'Affiliation': 'Oncology Unit, Ospedale ""Sacro Cuore di Gesù"" Fatebenefratelli, 82100 Benevento, Italy.'}, {'ForeName': 'Tiziana Pia', 'Initials': 'TP', 'LastName': 'Latiano', 'Affiliation': 'Medical Oncology Unit, IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Lamperini', 'Affiliation': 'Medical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy.'}, {'ForeName': 'Serena', 'Initials': 'S', 'LastName': 'Pillozzi', 'Affiliation': 'Medical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Boni', 'Affiliation': 'Clinical Trial Coordinating Center, Careggi University Hospital, 50134 Florence, Italy.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Antonuzzo', 'Affiliation': 'Medical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Di Costanzo', 'Affiliation': 'Medical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy.'}]","Current oncology (Toronto, Ont.)",['10.3390/curroncol28030164'] 3395,34077237,Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.,"PURPOSE To evaluate the use of early assessment of chemotherapy responsiveness by positron emission tomography (PET) imaging to tailor therapy in patients with esophageal and esophagogastric junction adenocarcinoma. METHODS After baseline PET, patients were randomly assigned to an induction chemotherapy regimen: modified oxaliplatin, leucovorin, and fluorouracil (FOLFOX) or carboplatin-paclitaxel (CP). Repeat PET was performed after induction; change in maximum standardized uptake value (SUV) from baseline was assessed. PET nonresponders (< 35% decrease in SUV) crossed over to the alternative chemotherapy during chemoradiation (50.4 Gy/28 fractions). PET responders (≥ 35% decrease in SUV) continued on the same chemotherapy during chemoradiation. Patients underwent surgery at 6 weeks postchemoradiation. Primary end point was pathologic complete response (pCR) rate in nonresponders after switching chemotherapy. RESULTS Two hundred forty-one eligible patients received Protocol treatment, of whom 225 had an evaluable repeat PET. The pCR rates for PET nonresponders after induction FOLFOX who crossed over to CP (n = 39) or after induction CP who changed to FOLFOX (n = 50) was 18.0% (95% CI, 7.5 to 33.5) and 20% (95% CI, 10 to 33.7), respectively. The pCR rate in responders who received induction FOLFOX was 40.3% (95% CI, 28.9 to 52.5) and 14.1% (95% CI, 6.6 to 25.0) in responders to CP. With a median follow-up of 5.2 years, median overall survival was 48.8 months (95% CI, 33.2 months to not estimable) for PET responders and 27.4 months (95% CI, 19.4 months to not estimable) for nonresponders. For induction FOLFOX patients who were PET responders, median survival was not reached. CONCLUSION Early response assessment using PET imaging as a biomarker to individualize therapy for patients with esophageal and esophagogastric junction adenocarcinoma was effective, improving pCR rates in PET nonresponders. PET responders to induction FOLFOX who continued on FOLFOX during chemoradiation achieved a promising 5-year overall survival of 53%.",2021,PET responders to induction FOLFOX who continued on FOLFOX during chemoradiation achieved a promising 5-year overall survival of 53%.,"['Two hundred forty-one eligible patients received Protocol treatment, of whom 225 had an evaluable repeat PET', 'patients with esophageal and esophagogastric junction adenocarcinoma', 'Esophageal Cancer']","['induction FOLFOX', 'induction chemotherapy regimen: modified oxaliplatin, leucovorin, and fluorouracil (FOLFOX) or carboplatin-paclitaxel (CP', 'positron emission tomography (PET) imaging to tailor therapy', 'PET Response-Adapted Combined Modality Therapy', 'FOLFOX']","['maximum standardized uptake value (SUV', '5-year overall survival', 'pCR rate', 'SUV', 'median survival', 'pCR rates', 'pathologic complete response (pCR) rate', 'median overall survival']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C4517652', 'cui_str': '225'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}, {'cui': 'C0014859', 'cui_str': 'Neoplasm of esophagus'}]","[{'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C3179010', 'cui_str': 'Induction chemotherapy'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",241.0,0.167795,PET responders to induction FOLFOX who continued on FOLFOX during chemoradiation achieved a promising 5-year overall survival of 53%.,"[{'ForeName': 'Karyn A', 'Initials': 'KA', 'LastName': 'Goodman', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Fang-Shu', 'Initials': 'FS', 'LastName': 'Ou', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Nathan C', 'Initials': 'NC', 'LastName': 'Hall', 'Affiliation': 'Hospital of the University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Tanios', 'Initials': 'T', 'LastName': 'Bekaii-Saab', 'Affiliation': 'Mayo Clinic Cancer Center, Scottsdale, AZ.'}, {'ForeName': 'Briant', 'Initials': 'B', 'LastName': 'Fruth', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Twohy', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Michael O', 'Initials': 'MO', 'LastName': 'Meyers', 'Affiliation': 'University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Boffa', 'Affiliation': 'Yale University, New Haven, CT.'}, {'ForeName': 'Kisha', 'Initials': 'K', 'LastName': 'Mitchell', 'Affiliation': 'Greenwich Hospital, Greenwich, CT.'}, {'ForeName': 'Wendy L', 'Initials': 'WL', 'LastName': 'Frankel', 'Affiliation': 'The Ohio State University Wexner Medical Center, Columbus, OH.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Niedzwiecki', 'Affiliation': 'Duke University, Durham, NC.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Noonan', 'Affiliation': 'The Ohio State University Wexner Medical Center, Columbus, OH.'}, {'ForeName': 'Yelena Y', 'Initials': 'YY', 'LastName': 'Janjigian', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Thurmes', 'Affiliation': 'Metro Minnesota Community Oncology Research Consortium, Minneapolis, MN.'}, {'ForeName': 'Alan P', 'Initials': 'AP', 'LastName': 'Venook', 'Affiliation': 'Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Meyerhardt', 'Affiliation': 'Dana Farber/Partners CancerCare, Boston, MA.'}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Ilson', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.03611'] 3396,34080764,Effectiveness of kinesiotaping in pregnant women with sacroiliac joint pain: A randomised controlled study.,"AIM Sacroiliac joint (SIJ) dysfunction is an especially common cause of pain during pregnancy. Treatment options during pregnancy are very limited in order to reduce pain and increase the quality of life. We aimed to determine the efficacy of kinesiotaping (KT) in the treatment of SIJ pain in pregnant women. METHODS A total of 50 pregnant women with SIJ pain were included in the study. Patients were randomised into two groups as KT and sham KT groups. Women in the KT group underwent a total of 5 weeks of KT once per week; the sham KT group also underwent 5 weeks of KT applications, but without tension in the kinesiotape. Patients were assessed before and 5 weeks after the treatment with a visual analogue scale (VAS) for pain and the Roland-Morris Disability Questionnaire (RMDQ) and Pelvic Girdle Questionnaire (PGQ) for disability and quality of life. RESULTS The KT and sham KT groups were similar in terms of age, parity, gravidas, gestational week and body mass index. At the beginning of the study, there were no statistically significant differences between the two groups in their VAS, RMDQ or PGQ scores. Five weeks later, the KT group showed significant improvement in all parameters, but no significant differences were observed for the sham KT group in terms of VAS, RMDQ or PGQ. CONCLUSIONS KT treatment improved the pain levels, functioning and quality of life among pregnant women with SIJ pain.",2021,"At the beginning of the study, there were no statistically significant differences between the two groups in their VAS, RMDQ, or PGQ scores.","['pregnant women', 'pregnant women with sacroiliac joint pain', 'Pregnant Women with Sacroiliac Joint Pain', '50 pregnant women with sacroiliac joint pain']","['Kinesiotaping', 'kinesiotaping (KT']","['VAS, RMDQ, or PGQ', 'VAS, RMDQ, or PGQ scores', 'visual analogue scale (VAS) for pain and the Roland-Morris Disability Questionnaire (RMDQ) and Pelvic Girdle Questionnaire (PGQ) for disability and quality of life', 'pain levels, functioning, and quality of life', 'quality of life']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0458232', 'cui_str': 'Sacroiliac joint pain'}]",[],"[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0684083', 'cui_str': 'Structure of pelvic girdle'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",50.0,0.0518999,"At the beginning of the study, there were no statistically significant differences between the two groups in their VAS, RMDQ, or PGQ scores.","[{'ForeName': 'Banu', 'Initials': 'B', 'LastName': 'Ordahan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Meram Medical School, Necmettin Erbakan University, Konya, Turkey.'}, {'ForeName': 'Jule', 'Initials': 'J', 'LastName': 'Eriç Horasanlı', 'Affiliation': 'Department of Gynecology and Obstetrics, Meram Medical School, Necmettin Erbakan University, Konya, Turkey.'}]",International journal of clinical practice,['10.1111/ijcp.14432'] 3397,34080761,The implementation of reciprocal imitation training in a Part C early intervention setting: A stepped-wedge pragmatic trial.,"Despite the development of several evidence-based Naturalistic Developmental Behavioral Interventions (NDBIs), very few have been adapted for use in community-based settings. This study examines the implementation of Reciprocal Imitation Training (RIT)-an NDBI-by community Early Intervention (EI; IDEA Part C) providers serving toddlers from birth to 3 years. Of the 87 EI providers enrolled from 9 agencies in 4 counties across Washington State, 66 were included in the current sample. A stepped-wedge design was used to randomly assign counties to the timing of RIT training workshops. Self-report measures of practice and self-efficacy regarding ASD care were collected at baseline (T1, T2) and 6-months and 12-months post-training (T3, T4). At T3 and T4, providers reported on RIT adoption and rated items about RIT feasibility and perceived RIT effectiveness; at T4, they also reported on child characteristics that led to RIT use and modifications. From pre-training to post-training, there were significant increases in providers' self-efficacy in providing services to children with ASD or suspected ASD. At T3 and T4, provider ratings indicated high levels of RIT adoption, feasibility, and perceived RIT effectiveness. At T4, providers indicated that they most commonly: (a) initiated RIT when there were social-communication or motor imitation delays, or an ASD diagnosis; and (b) made modifications to RIT by repeating elements, blending it with other therapies, and loosening its structure. While additional research is needed, RIT may help families get an early start on accessing specialized treatment within an established infrastructure available across the United States. LAY SUMMARY: Reciprocal imitation training (RIT) is an evidence-based treatment for ASD that might be a good fit for use by intervention providers in widely accessible community-based settings. After attending an educational workshop on RIT, providers reported feeling more comfortable providing services to families with ASD concerns, used RIT with over 400 families, and believed that RIT improved important social communication behaviors.",2021,"From pre-training to post-training, there were significant increases in providers' self-efficacy in providing services to children with ASD or suspected ASD.","['87 EI providers enrolled from 9 agencies in 4 counties across Washington State, 66 were included in the current sample', 'providers serving toddlers from birth to 3\u2009years']","['reciprocal imitation training', 'Reciprocal imitation training (RIT', 'Reciprocal Imitation Training (RIT)-an NDBI-by community Early Intervention (EI; IDEA Part C']","[""providers' self-efficacy"", 'levels of RIT adoption, feasibility, and perceived RIT effectiveness', 'RIT adoption and rated items about RIT feasibility and perceived RIT effectiveness', 'important social communication behaviors', 'social-communication or motor imitation delays']","[{'cui': 'C0242687', 'cui_str': 'Provision of early intervention service for child'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0242687', 'cui_str': 'Provision of early intervention service for child'}, {'cui': 'C0459920', 'cui_str': 'Ability to think abstractly'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0172527,"From pre-training to post-training, there were significant increases in providers' self-efficacy in providing services to children with ASD or suspected ASD.","[{'ForeName': 'Lisa V', 'Initials': 'LV', 'LastName': 'Ibañez', 'Affiliation': 'Department of Psychology, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Scott', 'Affiliation': 'Department of Psychology, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Wendy L', 'Initials': 'WL', 'LastName': 'Stone', 'Affiliation': 'Department of Psychology, University of Washington, Seattle, Washington, USA.'}]",Autism research : official journal of the International Society for Autism Research,['10.1002/aur.2522'] 3398,34082090,Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.,"OBJECTIVES In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority. Accordingly, we tested co-administration of Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) and yellow fever (YF) vaccines. METHODS We conducted a randomized, double-blind, and controlled, phase 2 trial in Ouagadougou, Burkina Faso. Healthy children aged 9-11 months were randomized 1:1 to receive TCV (Group 1) or control vaccine (inactivated polio vaccine (IPV), Group 2). Vaccines were administered intramuscularly with routine MR and YF vaccines. Safety was assessed by (1) local and systemic reactions on days 0, 3, and 7; (2) unsolicited adverse events within 28 days; and (3) serious adverse events (SAEs) within six months after immunization. RESULTS We enrolled, randomized, and vaccinated 100 eligible children (49 Group 1 and 51 Group 2). Safety outcomes occurred with similar frequency in both groups: local/solicited reactions (Group 1: 1/49, Group 2: 3/50), systemic/solicited reactions (Group 1: 4/49, Group 2: 9/50), unsolicited adverse events (Group 1: 26/49, Group 2: 33/51), and SAEs (Group 1: 2/49, Group 2: 3/51). TCV conferred robust immunogenicity without interference with MR or YF vaccines. CONCLUSION TCV can be safely co-administered with MR and YF vaccines to children at the 9-month vaccination visit.",2021,"Safety outcomes occurred with similar frequency in both groups: local/solicited reactions (Group 1: 1/49, Group 2: 3/50), systemic/solicited reactions (Group 1: 4/49, Group 2: 9/50), unsolicited adverse events (Group 1: 26/49, Group 2: 33/51), and SAEs (Group 1: 2/49, Group 2: 3/51).","['Healthy children aged 9-11 months', '100 eligible children (49 Group 1 and 51 Group 2', 'Burkina Faso']","['typhoid conjugate vaccine (TCV', 'TCV', 'control vaccine (inactivated polio vaccine (IPV', 'Vi-typhoid conjugate vaccine co-administration', 'routine MR and YF vaccines', 'Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) and yellow fever (YF) vaccines']","['1) local and systemic reactions on days 0, 3, and 7; 2) unsolicited adverse events within 28 days; and 3) serious adverse events (SAEs', 'Safety and immunogenicity', 'systemic/solicited reactions', 'unsolicited adverse events']","[{'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0006409', 'cui_str': 'Burkina Faso'}]","[{'cui': 'C0041466', 'cui_str': 'Typhoid fever'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0718003', 'cui_str': 'Inactivated Poliovirus vaccine'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0035920', 'cui_str': 'Rubella'}, {'cui': 'C0301508', 'cui_str': 'Yellow Fever Vaccine'}, {'cui': 'C0025007', 'cui_str': 'Measles'}, {'cui': 'C0043395', 'cui_str': 'Yellow fever'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",100.0,0.3668,"Safety outcomes occurred with similar frequency in both groups: local/solicited reactions (Group 1: 1/49, Group 2: 3/50), systemic/solicited reactions (Group 1: 4/49, Group 2: 9/50), unsolicited adverse events (Group 1: 26/49, Group 2: 33/51), and SAEs (Group 1: 2/49, Group 2: 3/51).","[{'ForeName': 'Sodiomon B', 'Initials': 'SB', 'LastName': 'Sirima', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Alphonse', 'Initials': 'A', 'LastName': 'Ouedraogo', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Nouhoun', 'Initials': 'N', 'LastName': 'Barry', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Mohamadou', 'Initials': 'M', 'LastName': 'Siribie', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Alfred', 'Initials': 'A', 'LastName': 'Tiono', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Issa', 'Initials': 'I', 'LastName': 'Nébié', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Amadou', 'Initials': 'A', 'LastName': 'Konaté', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Gloria Damoaliga', 'Initials': 'GD', 'LastName': 'Berges', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Amidou', 'Initials': 'A', 'LastName': 'Diarra', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Moussa', 'Initials': 'M', 'LastName': 'Ouedraogo', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Edith C', 'Initials': 'EC', 'LastName': 'Bougouma', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Issiaka', 'Initials': 'I', 'LastName': 'Soulama', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Alimatou', 'Initials': 'A', 'LastName': 'Hema', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Shrimati', 'Initials': 'S', 'LastName': 'Datta', 'Affiliation': 'Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Elizabeth T', 'Initials': 'ET', 'LastName': 'Rotrosen', 'Affiliation': 'Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'J Kathleen', 'Initials': 'JK', 'LastName': 'Tracy', 'Affiliation': 'Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Leslie P', 'Initials': 'LP', 'LastName': 'Jamka', 'Affiliation': 'Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Jennifer J', 'Initials': 'JJ', 'LastName': 'Oshinsky', 'Affiliation': 'Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Marcela F', 'Initials': 'MF', 'LastName': 'Pasetti', 'Affiliation': 'Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Neuzil', 'Affiliation': 'Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Matthew B', 'Initials': 'MB', 'LastName': 'Laurens', 'Affiliation': 'Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: mlaurens@som.umaryland.edu.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2021.05.061'] 3399,34391318,Recovery profiles of eccentric hamstring strength in response to cooling and compression.,"INTRODUCTION The effectiveness of different forms of cryotherapy and combined compression (cryo-compression) commonly used in sport to enhance recovery following exercise are not fully understood. Therefore, the exploration of protocols that use contemporary cryo-compression is warranted. The purpose of the study was to investigate the effectiveness of using a cryo-compression device to recover hamstrings eccentric strength following a fatiguing exercise. METHODS Eighteen healthy male adult footballers were randomly allocated to receive cryo-compression or rest following a lower limb fatiguing protocol. Cryo-compression was applied for 15-min, target temperature of 10 °C, and high intermittent pressure (5-75 mm Hg) using the Game Ready® device. Rest consisted of 15-min in a prone position on a plinth. To induce hamstring fatigue, participants performed the Yo-Yo intermittent fatigue test (IFT). Skin surface temperature (T sk ) and hamstring eccentric strength measures were taken at three time points; pre-IFT, immediately post-fatigue test (IPFT), and immediately post-intervention (IPI) (rest or Game Ready®). Participants returned one week later and performed the Yo-Yo IFT again and were exposed to the opposite intervention and data collection. RESULTS Significant decreases in T sk over the posterior thigh were reported for all timepoints compared to pre cryo-compression temperatures (p=<0.05). Overall data displayed no significant main effects for timepoint or condition for PT or AvT (p=<0.05). There was no timepoint × condition interaction for PT or AvT (p=<0.05). Collapse of the data by condition (CC/R) demonstrated no significant effect for time for PT or AvT (p=>0.05). CONCLUSIONS No significant changes in HES occurred after exposure to cryo-compression or rest applied immediately following the Yo-Yo IFT. Further investigations to maximise beneficial application of contemporary cryo-compression applications in sport are required. Multiple measures of performance over rewarming periods, within competitive training schedules after sport-specific training are required to develop optimal cooling protocols for recovery.",2021,No significant changes in HES occurred after exposure to cryo-compression or rest applied immediately following the Yo-Yo IFT.,['Eighteen healthy male adult footballers'],"['Cryo-compression', 'cryo-compression device', 'cryo-compression or rest following a lower limb fatiguing protocol', 'cryotherapy and combined compression (cryo-compression']","['HES', 'hamstring fatigue', 'Skin surface temperature (T sk ) and hamstring eccentric strength measures', 'T sk']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0686751', 'cui_str': 'Well male adult'}]","[{'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",18.0,0.0174026,No significant changes in HES occurred after exposure to cryo-compression or rest applied immediately following the Yo-Yo IFT.,"[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Alexander', 'Affiliation': 'Sport, Nutrition and Clinical Sciences, School of Sport & Health Sciences, University of Central Lancashire, Preston, UK. Electronic address: JAlexander3@uclan.ac.uk.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Jeffery', 'Affiliation': 'Everton Football Club, Finch Farm, Merseyside, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Rhodes', 'Affiliation': 'Institute of Coaching and Performance (ICaP), School of Sport & Health Sciences, University of Central Lancashire, Preston, UK.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.010'] 3400,34086067,"A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.","PURPOSE To compare the pharmacokinetic profiles, safety and immunogenicity of proposed bevacizumab biosimilar HLX04 with reference bevacizumab in healthy Chinese males. METHODS In this double-blind Phase 1 study, healthy volunteers (N = 208) were randomized 1:1:1:1 to a single 3 mg/kg intravenous infusion of HLX04 or reference bevacizumab sourced from the United States (bevacizumab-US), the European Union (bevacizumab-EU) or China (bevacizumab-CN). Co-primary endpoints were area under the serum concentration-time profile (AUC) from time zero extrapolated to infinity (AUC 0-inf ) and from zero to last quantifiable concentration (AUC last ). Secondary endpoint was the maximum serum drug concentration (C max ). Study participants were monitored for treatment-emergent adverse events (TEAEs) and samples were collected for anti-drug antibody (ADA) testing throughout the study. RESULTS Pharmacokinetic parameters were similar across groups. The respective geometric least-squares mean ratios (GLSMR) of AUC 0-inf , AUC last and C max were: 95.7%, 96.0% and 101.8% for HLX04 versus bevacizumab-US; 94.3%, 94.6% and 100.5% for HLX04 versus bevacizumab-EU; and 90.0%, 90.4% and 98.2% for HLX04 versus bevacizumab-CN. For all test-to-reference comparisons, two-sided 90% confidence intervals of GLSMR for AUC 0-inf , AUC last and C max fell in the pre-specified bioequivalence range (80-125%). There were no notable differences in the frequency, nature and/or grade of TEAEs. No deaths were reported and no ADAs were detected during the study. CONCLUSION HLX04 had similar safety and pharmacokinetic profiles to reference bevacizumab in healthy Chinese males, supporting the confirmatory Phase 3 study investigating the efficacy and safety equivalence between HLX04 and bevacizumab in patients with metastatic colorectal cancer (NCT03511963). CLINICAL TRIAL REGISTRATION The study was registered with Clinicaltrials.gov, NCT03483649.",2021,AUC last and C max fell in the pre-specified bioequivalence range (80-125%).,"['healthy volunteers (N\u2009=\u2009208', 'patients with metastatic colorectal cancer (NCT03511963', 'healthy Chinese males', 'healthy Chinese male volunteers']","['HLX04', 'bevacizumab-CN', 'HLX04 and bevacizumab', 'bevacizumab', 'HLX04 to reference bevacizumab', 'bevacizumab-EU', 'HLX04 or reference bevacizumab sourced from the United States (bevacizumab-US), the European Union (bevacizumab-EU) or China (bevacizumab-CN', 'bevacizumab biosimilar HLX04 with reference bevacizumab']","['AUC last and C max fell', 'frequency, nature and/or grade of TEAEs', 'safety and pharmacokinetic profiles', 'respective geometric least-squares mean ratios (GLSMR) of AUC 0-inf , AUC last and C max', 'area under the serum concentration-time profile (AUC) from time zero extrapolated to infinity (AUC 0-inf ) and from zero to last quantifiable concentration (AUC last ', 'pharmacokinetic profiles, safety and immunogenicity', 'maximum serum drug concentration (C max ', 'efficacy and safety equivalence']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0015179', 'cui_str': 'European Community'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",208.0,0.102627,AUC last and C max fell in the pre-specified bioequivalence range (80-125%).,"[{'ForeName': 'Xiaoxue', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'The First Hospital of Jilin University, No. 1 Xinmin Street, Chaoyang District, Changchun, Jilin, China.'}, {'ForeName': 'Hongjie', 'Initials': 'H', 'LastName': 'Qian', 'Affiliation': 'Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, China.'}, {'ForeName': 'Jixuan', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'The First Hospital of Jilin University, No. 1 Xinmin Street, Chaoyang District, Changchun, Jilin, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'The First Hospital of Jilin University, No. 1 Xinmin Street, Chaoyang District, Changchun, Jilin, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, China.'}, {'ForeName': 'Yanhua', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'The First Hospital of Jilin University, No. 1 Xinmin Street, Chaoyang District, Changchun, Jilin, China.'}, {'ForeName': 'Xiaodi', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Shanghai Henlius Biotech, Inc., Shanghai, China.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Chai', 'Affiliation': 'Shanghai Henlius Biotech, Inc., Shanghai, China.'}, {'ForeName': 'Xiaojiao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'The First Hospital of Jilin University, No. 1 Xinmin Street, Chaoyang District, Changchun, Jilin, China. xiaojiaoli@jlu.edu.cn.'}]",Cancer chemotherapy and pharmacology,['10.1007/s00280-021-04297-z'] 3401,34087690,Modifying insecure attachment style with cognitive bias modification.,"BACKGROUND AND OBJECTIVES Attachment theory suggests that internal working models developed from early experiences with attachment figures biases cognitive appraisals a person makes of themselves and others. The current paper investigates whether attachment-related interpretative biases can be altered using Cognitive Bias Modification (CBM-I). METHODS Eighty anxiously attached participants were randomly assigned to receive either secure or insecure CBM-I training. To measure training effects on attachment-related interpretation bias, participants read scenarios involving attachment figures whereby the availability of the attachment figure was undetermined, followed by test sentences that assigned an attachment-secure or -insecure interpretation to the situations. Participants rated the similarity of these sentences to the previously read ambiguous situations. RESULTS Participants who received secure CBM-I training ascribed higher similarity ratings to secure sentence interpretations of ambiguous scenarios compared to insecure sentence interpretations. Attachment anxiety increased after CBM-I training for those who received insecure training, but did not differ for those who received secure training. LIMITATIONS This study was limited to healthy participants and did not include clinical participants. These findings need to be replicated by assessing the effects of CBM-I over an extended period. CONCLUSIONS CBM-I training may provide a viable means of modulating attachment anxiety. If validated with more potent strategies for secure attachment training, this approach could have significant implications for the treatment of affective disorders characterized by insecure attachments.",2021,"Attachment anxiety increased after CBM-I training for those who received insecure training, but did not differ for those who received secure training. ","['Eighty anxiously attached participants', 'healthy participants and did not include clinical participants']","['secure or insecure CBM-I training', 'secure CBM-I training']",['Attachment anxiety'],"[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]","[{'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",80.0,0.0402135,"Attachment anxiety increased after CBM-I training for those who received insecure training, but did not differ for those who received secure training. ","[{'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Doolan', 'Affiliation': 'University of New South Wales, Australia.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Bryant', 'Affiliation': 'University of New South Wales, Australia. Electronic address: r.bryant@unsw.edu.au.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2021.101664'] 3402,34087542,"The impact of different responses to negative body talk on body satisfaction, shame, and future negative body talk likelihood: A UK sample.","A recent online experiment found that, following a negative body talk induction task, receiving a response of ignoring the comment, compared with reassuring, reciprocating, and challenging, led to worse body satisfaction and socio-emotional outcomes for Australian women. The current online study aimed to replicate and extend this study by examining the effects of these four negative body talk responses on body satisfaction, shame, and future negative body talk likelihood in UK-based women. Participants (N = 156, M age = 25.29, SD age = 5.64, range age = 18-40) recalled a scenario in which they engaged in negative body talk and were randomly assigned to receive one of four responses. Contrary to hypotheses, there were no significant differences in body satisfaction, shame, or future negative body talk likelihood across the four groups. Preferred negative body talk response data were mixed, with challenge and reassurance responses preferred at comparable rates, and just under a quarter of participants preferring a response outside of the original four. Possible explanations, including that the responses used in the original Australasian study may not perfectly correspond with UK women's experiences of social interactions and heterogeneous motivations for engaging in negative body talk necessitate more nuanced and sophisticated responses, are explored.",2021,"Contrary to hypotheses, there were no significant differences in body satisfaction, shame, or future negative body talk likelihood across the four groups.","['Australian women', 'UK-based women', 'Participants (N = 156, M age = 25.29, SD age = 5.64, range age = 18-40) recalled a scenario in which they engaged in negative body talk']",[],"['body satisfaction, shame, or future negative body talk likelihood']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0037817', 'cui_str': 'Speech'}]",[],"[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0036938', 'cui_str': 'Shame'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",,0.0150003,"Contrary to hypotheses, there were no significant differences in body satisfaction, shame, or future negative body talk likelihood across the four groups.","[{'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Mills', 'Affiliation': 'School of Psychology, Faculty of Health, Deakin University, Australia. Electronic address: jacqueline.mills@deakin.edu.au.'}, {'ForeName': 'Adrienn', 'Initials': 'A', 'LastName': 'Mata', 'Affiliation': 'School of Psychology, Counselling, and Psychotherapy, The Cairnmillar Institute, Australia.'}, {'ForeName': 'Mathew', 'Initials': 'M', 'LastName': 'Ling', 'Affiliation': 'School of Psychology, Faculty of Health, Deakin University, Australia. Electronic address: mathew.ling@deakin.edu.au.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Trawley', 'Affiliation': 'School of Psychology, Counselling, and Psychotherapy, The Cairnmillar Institute, Australia. Electronic address: steven.trawley@cairnmillar.edu.au.'}]",Body image,['10.1016/j.bodyim.2021.05.007'] 3403,34087468,Efficacy of Rose Bengal and Curcumin mediated photodynamic therapy for the treatment of denture stomatitis in patients with habitual cigarette smoking: A randomized controlled clinical trial.,"BACKGROUND Cigarette smoking in conjugation with bad oral hygiene is considered a typical predisposing factor for many oral diseases including denture stomatitis. This study investigated the effect of Rose Bengal (RB)-and Curcumin (CUR)-mediated photodynamic therapy (PDT) in comparison with nystatin therapy in the intervention of denture stomatitis in cigarette smokers. METHODS Overall, 45 habitual cigarette smokers aged ~58 years having denture stomatitis were categorized into three groups: Group-I - RB-mediated PDT, Group-II - CUR-mediated PDT, and Group-III - Nystatin therapy. The primary outcome of the interest was: counts of Candida colony from denture surface and palatal mucosa, calculated as CFU/mL, whereas the prevalence of Candida species determined in 3 research groups comprised the secondary outcome. Oral swab specimens were gathered from the denture surfaces and palatal mucosa. All clinical assessments were performed at baseline, 6 weeks, and 12 weeks. RESULTS C. albicans was the most prevalent yeast identified on both denture surfaces and palatal mucosa, followed by C. tropicalis and C. glabrata. A considerable decrease in the CFU/mL scores were observed in Group-I and Group-II at the end of the interventions and on the 12-week follow-up (p<0.05). Group-I, II, and III demonstrated clinical efficacy rates of 53%, 51%, and 49%, respectively. CONCLUSION CUR-and RB-mediated PDT was found to be as effective as topical Nystatin therapy for the intervention of denture stomatitis among cigarette smokers.",2021,"RESULTS C. albicans was the most prevalent yeast identified on both denture surfaces and palatal mucosa, followed by C. tropicalis and C. glabrata.","['cigarette smokers', 'patients with habitual cigarette smokers', 'denture stomatitis in cigarette smokers', '45 habitual cigarette smokers aged ∼58 years having denture stomatitis']","['topical Nystatin therapy', 'Rose Bengal (RB)-and Curcumin (CUR)-mediated photodynamic therapy (PDT', 'Rose Bengal and Curcumin mediated photodynamic therapy', 'nystatin therapy', 'Nystatin therapy']","['clinical efficacy rates', 'counts of Candida colony from denture surface and palatal mucosa, calculated as CFU/mL, whereas the prevalence of Candida species', 'CFU/mL scores']","[{'cui': 'C0337667', 'cui_str': 'Cigarette smoker'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0011394', 'cui_str': 'Denture'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}]","[{'cui': 'C0360358', 'cui_str': 'Nystatin-containing product in cutaneous dose form'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0444826', 'cui_str': 'Bengal'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0028741', 'cui_str': 'Nystatin'}]","[{'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0006836', 'cui_str': 'Candida'}, {'cui': 'C0439158', 'cui_str': 'colonies'}, {'cui': 'C0457711', 'cui_str': 'Denture surface finding'}, {'cui': 'C0700374', 'cui_str': 'Palatal'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0439361', 'cui_str': 'cfu/mL'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0546636,"RESULTS C. albicans was the most prevalent yeast identified on both denture surfaces and palatal mucosa, followed by C. tropicalis and C. glabrata.","[{'ForeName': 'Nawaf', 'Initials': 'N', 'LastName': 'Labban', 'Affiliation': 'Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia. Electronic address: nalabban@ksu.edu.sa.'}, {'ForeName': 'Sara Mohammad Al', 'Initials': 'SMA', 'LastName': 'Taweel', 'Affiliation': 'Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia.'}, {'ForeName': 'Mohammed A', 'Initials': 'MA', 'LastName': 'ALRabiah', 'Affiliation': 'Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia.'}, {'ForeName': 'Afnan F', 'Initials': 'AF', 'LastName': 'Alfouzan', 'Affiliation': 'Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia.'}, {'ForeName': 'Ibraheem F', 'Initials': 'IF', 'LastName': 'Alshiddi', 'Affiliation': 'Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University. P. O. Box 60169, Riyadh 11545, Saudi Arabia.'}, {'ForeName': 'Mansour K', 'Initials': 'MK', 'LastName': 'Assery', 'Affiliation': 'Department of Prosthodontics, Riyadh Elm University, Riyadh, Saudi Arabia.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102380'] 3404,34096066,Correct response negativity may reflect subjective value of reaction time under regulatory fit in a speed-rewarded task.,"Error-related negativity (ERN), an electroencephalogram (EEG) component following an erroneous response, has been associated with the subjective motivational relevance of error commission. A smaller EEG event, the correct response negativity (CRN), occurs after a correct response. It is unclear why correct behavior evokes a neural response similar to error commission. CRN might reflect suboptimal performance: in tasks where speed is motivationally relevant (i.e., incentivized), a correct but slow response may be experienced as a minor error. The literature is mixed on the relationship between CRN and response time (RT), possibly due to different motivational structures, tasks, or individual traits. We examined ERN and CRN in a go/no-go task where correctness and speed were encouraged using a points-based feedback system. A key individual trait, regulatory focus, describes a person's tendency to seek gains (promotion focus) and avoid losses (prevention focus). Trait regulatory focus was measured, and participants were randomly assigned to one of three conditions: points gain, points loss, and informative-only feedback. Participants committed too few errors to reliably model ERN effects. CRN amplitude related to RT in all feedback conditions, with slower responses having larger CRN. Participants with stronger promotion focus had a more exaggerated RT/CRN relationship in the point gain condition, suggesting that regulatory fit influences the motivational relevance of speed and thus the negative subjective experience and CRN for slower responses. These findings are consistent with the claim that CRN reflects RT when RT is motivationally relevant and that the CRN/RT relationship reflects the degree of subjective motivational relevance.",2021,"CRN amplitude related to RT in all feedback conditions, with slower responses having larger CRN.",[],['CRN'],"['CRN and response time (RT', 'correct response negativity (CRN', 'exaggerated RT/CRN relationship', 'Error-related negativity (ERN), an electroencephalogram (EEG) component']",[],"[{'cui': 'C0205202', 'cui_str': 'Corrected'}]","[{'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0442801', 'cui_str': 'Exaggerated'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",,0.0182179,"CRN amplitude related to RT in all feedback conditions, with slower responses having larger CRN.","[{'ForeName': 'Benjamin T', 'Initials': 'BT', 'LastName': 'Files', 'Affiliation': 'US Army Combat Capabilities Development Command Army Research Laboratory, Los Angeles, CA, USA.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Pollard', 'Affiliation': 'US Army Combat Capabilities Development Command Army Research Laboratory, Los Angeles, CA, USA.'}, {'ForeName': 'Ashley H', 'Initials': 'AH', 'LastName': 'Oiknine', 'Affiliation': 'DCS Corporation, Los Angeles, CA, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Khooshabeh', 'Affiliation': 'US Army Combat Capabilities Development Command Army Research Laboratory, Los Angeles, CA, USA.'}, {'ForeName': 'Antony D', 'Initials': 'AD', 'LastName': 'Passaro', 'Affiliation': 'US Army Combat Capabilities Development Command Army Research Laboratory, Los Angeles, CA, USA.'}]",Psychophysiology,['10.1111/psyp.13856'] 3405,34092002,Efficacy and safety of ultrasound-guided quadratus lumborum block in patients receiving percutaneous nephrolithotomy under general anaesthesia.,"PURPOSE The aim of this study was to explore the overall efficacy and safety of ultrasound-guided quadratus lumborum block combined with general anaesthesia in patients undergoing percutaneous nephrolithotomy (PCNL). METHODS The study included 76 patients who underwent PCNL at our hospital between October 2018 and October 2019. The patients were randomly divided into the study group (ultrasound-guided quadratus lumborum block combined with general anaesthesia, 38 cases) and the control group (general anaesthesia, 38 cases). The intra-operative estimated blood loss, operative time and intra-operative anaesthetic usage were recorded. Moreover, the effective pressing times of the posterior cerebral artery (PCA) and the dosage of sufentanil in patient-controlled intravenous analgesia (PCIA) were observed within 48 hours after operation. RESULTS The dosage of propofol and remifentanil, the time of intestinal exhaust recovery time and the hospital study in the study group were lower than those in the control group. The HR and MAP of the two groups, with a trend towards gradual decrease at T0 and T1, were lower than those at T0. At 2, 6, 8 and 24 hours after operation, the visual analogue scale/score (VAS) of the study group was lower than that of the control group. The analgesic rescue rate, the dosage of sufentanil and the effective PCA compression times in the study group were lower than those in the control group. The total incidence of adverse reactions in postanaesthesia care unit in the study group was significantly lower than that in the control group (8/38 vs 18/38). CONCLUSION The combination of ultrasound-guided quadratus lumborum block and general anaesthesia effectively exerts beneficial outcomes in terms of validly reducing the dose of tranquilisers and anaesthetic analgesics during PCNL, which is able to treat patients with anaesthetic mode of low opioids.",2021,"The total incidence of adverse reactions in postanesthesia care unit (PACU) in the study group was significantly lower than that in the control group (8/38 vs. 18/38). ","['patients receiving percutaneous nephrolithotomy under general anesthesia', 'patients with anesthetic mode of low opioids', 'patients undergoing percutaneous nephrolithotomy (PCNL', '76 patients who underwent PCNL at our hospital between October 2018 and October 2019']","['sufentanil', 'propofol and remifentanil', 'ultrasound-guided quadratus lumborum block', 'ultrasound-guided quadratus lumborum block combined with general anesthesia', 'study group (ultrasound-guided quadratus lumborum block combined with general anesthesia', 'ultrasound-guided quadratus lumborum block and general anesthesia']","['analgesic rescue rate', 'overall efficacy and safety', 'effective PCA compression times', 'Efficacy and safety', 'time of intestinal exhaust recovery time', 'visual analogue scale/score (VAS) score', 'total incidence of adverse reactions in postanesthesia care unit (PACU', 'intraoperative estimated blood loss, operative time and intraoperative anesthetic usage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0224380', 'cui_str': 'Structure of quadratus lumborum muscle'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0149576', 'cui_str': 'Structure of posterior cerebral artery'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0262723', 'cui_str': 'Postanesthesia care'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0457083', 'cui_str': 'Usage'}]",76.0,0.0326387,"The total incidence of adverse reactions in postanesthesia care unit (PACU) in the study group was significantly lower than that in the control group (8/38 vs. 18/38). ","[{'ForeName': 'Xing-Da', 'Initials': 'XD', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Linyi Central Hospital, Linyi, Shandong, China.'}, {'ForeName': 'Yu-Jian', 'Initials': 'YJ', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Linyi Central Hospital, Linyi, Shandong, China.'}, {'ForeName': 'Cheng-Yun', 'Initials': 'CY', 'LastName': 'Fan', 'Affiliation': 'Department of Anesthesiology, Linyi Central Hospital, Linyi, Shandong, China.'}]",International journal of clinical practice,['10.1111/ijcp.14439'] 3406,34390556,Stress management and In Vitro Fertilization (IVF): A pilot randomized controlled trial.,"The objective of the study was to evaluate the psychological effect of an intervention of 8 stress-management sessions in women undergoing in vitro fertilization (IVF). Moreover, the overall IVF success was assessed against the fluctuation of the participants' stress levels. A total of 144 women participated in the study with 74 of them in the intervention group and 70 women in the control group. Demographics and medical history of all participants were recorded. The intervention group only underwent 8 weekly stress management sessions. During the 1st and 8th week of the study, both groups completed the Depression, Anxiety, Stress Scale 21 (DASS-21), the Perceived Stress Scale 14 (PSS-14) and the Fertility Problem Inventory (FPI). Following the intervention, the outcome of the IVF cycles, as defined by clinical pregnancy rates, were recorded. Our results indicated that total stress in the intervention group declined significantly (p<0.001) in respect to all the parameters of the PSS-14, DASS-21 and FPI scales, with the exception of the need for parenthood dimension that did not change significantly in the intervention group (p=0.002), while significantly increased in the control group (p<0.001). The difference of stress levels between the two groups for each scale as well as in total was also significant. There were no significant differences in the demographic data, lifestyle and medical history of the participants and their spouses between the two groups. The IVF success rate was found to be related to the levels of perceived stress on the PSS-14 scale (p=0.029) but not to any of the dimensions of DASS-21(p=0.197) and FPI (p=0.611) scales. Definitive factors affecting the IVF success were the participants' age (p=0.046), which was negatively correlated to IVF success, and the spouses' medical history of cryptorchidism (undescended testicles) (p=0.05). The high significance of these variables probably limited the effect of the intervention for stress relief on IVF success. This pilot study revealed encouraging results regarding the positive effect of interventions for stress management in women undergoing fertility treatment, however the possible contribution of such interventions to overall IVF success rates requires further investigation.",2021,"Our results indicated that total stress in the intervention group declined significantly (p<0.001) in respect to all the parameters of the PSS-14, DASS-21 and FPI scales, with the exception of the need for parenthood dimension that did not change significantly in the intervention group (p=0.002), while significantly increased in the control group (p<0.001).","['women undergoing in vitro fertilization (IVF', '144 women participated in the study with 74 of them in the intervention group and 70 women in the control group', 'women undergoing fertility treatment']","['Vitro Fertilization (IVF', '8 stress-management sessions', '8 weekly stress management sessions']","['overall IVF success', 'PSS-14, DASS-21 and FPI scales', 'clinical pregnancy rates', 'levels of perceived stress on the PSS-14 scale', 'demographic data, lifestyle and medical history', 'IVF success', 'Depression, Anxiety, Stress Scale 21 (DASS-21), the Perceived Stress Scale 14 (PSS-14) and the Fertility Problem Inventory (FPI', 'IVF success rate', 'total stress', 'stress levels']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0015914', 'cui_str': 'Fertilization'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0278048', 'cui_str': 'Fertility problem'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}]",144.0,0.0179351,"Our results indicated that total stress in the intervention group declined significantly (p<0.001) in respect to all the parameters of the PSS-14, DASS-21 and FPI scales, with the exception of the need for parenthood dimension that did not change significantly in the intervention group (p=0.002), while significantly increased in the control group (p<0.001).","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Koumparou', 'Affiliation': 'Second Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.'}, {'ForeName': 'Panagiotis', 'Initials': 'P', 'LastName': 'Bakas', 'Affiliation': 'Second Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Pantos', 'Affiliation': 'IVF Unit at Genesis Athens Clinic, Athens, Greece.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Economou', 'Affiliation': 'First Department of Psychiatry, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Chrousos', 'Affiliation': 'University Research Institute of Maternal and Child Health and Precision Medicine, National and Kapodistrian University of Athens, Medical School.'}]",Psychiatrike = Psychiatriki,['10.22365/jpsych.2021.029'] 3407,34083744,Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.,"BACKGROUND Extended-release naltrexone/bupropion (NB) is indicated for chronic weight management. Incretin agents are recommended for patients with type 2 diabetes. This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents. METHODS This was a post-hoc analysis of NB vs. placebo (PL) among subjects with type 2 diabetes stable on an incretin agent prior to randomization in a double-blind, PL-controlled cardiovascular outcome trial (N = 1317). RESULTS Over 1 year, mean weight loss was significantly greater among NB patients vs. PL among those taking DPP-4i (mean absolute difference 4.6% [p < 0.0001]) and those taking GLP-1RAs (mean absolute difference 5.2%, p < 0.0001). Proportions of subjects achieving 5% weight loss were significantly greater for NB vs. PL at weeks 26 and 52 among those taking DPP-4is or GLP-1RAs. There were no significant differences in effectiveness observed between NB + DPP-4i and NB + GLP-1RA or between PL + DPP-4i and PL + GLP-1RA in any of the analyses. Serious adverse events were reported by 9.1% and 11.1% for PL + DPP-4i and PL + GLP-1RA, respectively, and 13.3% and 12.4% of NB + DPP-4i and NB + GLP-1RA, respectively. CONCLUSION NB appears to be effective in reducing weight in patients with T2DM and obesity/overweight who are taking DPP-4ihibitors or GLP-1RA. The SAE rates in all arms of this analysis were lower than have been reported in other cardiovascular outcome trials in type 2 diabetes.",2021,There were no significant differences in effectiveness observed between NB + DPP-4i and NB + GLP-1RA or between PL + DPP-4i and PL + GLP-1RA in any of the analyses.,"['subjects with type 2 diabetes already taking incretin agents', 'patients with type 2 diabetes', 'subjects with type 2 diabetes stable on an incretin agent prior to randomization in a double-blind, PL-controlled cardiovascular outcome trial (N\u2009=\u20091317', 'patients with T2DM and obesity/overweight who are taking DPP-4ihibitors or GLP-1RA']","['NB', 'NB vs. placebo (PL', 'naltrexone/bupropion', 'naltrexone/bupropion (NB']","['mean weight loss', 'weight loss', 'SAE rates', 'Serious adverse events']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1562292', 'cui_str': 'Incretin'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0018301', 'cui_str': 'Guadeloupe island'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0085208', 'cui_str': 'Bupropion'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.201015,There were no significant differences in effectiveness observed between NB + DPP-4i and NB + GLP-1RA or between PL + DPP-4i and PL + GLP-1RA in any of the analyses.,"[{'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Wharton', 'Affiliation': 'The Wharton Medical Clinic, Toronto, ON, Canada. sean@whartonmedicalclinic.com.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Yin', 'Affiliation': 'Bausch Health, Laval, QC, Canada.'}, {'ForeName': 'Melonie', 'Initials': 'M', 'LastName': 'Burrows', 'Affiliation': 'Bausch Health, Laval, QC, Canada.'}, {'ForeName': 'Errol', 'Initials': 'E', 'LastName': 'Gould', 'Affiliation': 'Currax Pharmaceuticals LLC, Morristown, NJ, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Blavignac', 'Affiliation': 'Bausch Health, Laval, QC, Canada.'}, {'ForeName': 'Rebecca A G', 'Initials': 'RAG', 'LastName': 'Christensen', 'Affiliation': 'The Wharton Medical Clinic, Toronto, ON, Canada.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Kamran', 'Affiliation': 'The Wharton Medical Clinic, Toronto, ON, Canada.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Camacho', 'Affiliation': 'Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Barakat', 'Affiliation': 'Bausch Health, Laval, QC, Canada.'}]",International journal of obesity (2005),['10.1038/s41366-021-00831-4'] 3408,34089210,"Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.","INTRODUCTION SCT800 is a recombinant human B-domain-deleted coagulation factor VIII (BDDrFVIII) developed in China. AIM To evaluate the repeat pharmacokinetics (PKs), efficacy, and safety of SCT800 in previously treated Chinese adolescent and adult patients with severe haemophilia A. METHODS A phase III, multicentre, prospective, open-label, single-arm trial was conducted at 12 medical centres. Subjects received treatment for 24 weeks. PKs were assessed at the initial and repeated dosing 24 weeks later. The primary endpoint was annualized bleeding rate (ABR). Breakthrough bleeding episodes and inhibitor development were assessed. RESULTS A total of 71 of 73 patients completed the study, and 18 were enrolled for the repeat PK investigation. Total exposure was 5643 exposure days. Overall, SCT800 showed comparable repeat PK profiles. The total ABR was 2.82 (95% confidence interval 2.01-3.96). During prophylaxis, 43.8% of patients had no bleeding episodes. The majority (89.4%) of bleeding episodes were controlled with 1-2 injections of SCT800, the success rate (defined as 'excellent' or 'good' haemostatic response) for the treatment of bleeding episodes was 92.6%. The incidence of treatment-related adverse events was 53.4%. Drug-related AE incidence was 4.1%. The observed AEs were similar to those of other coagulation factor VIII, but lower in frequency. No subject developed an inhibitor, and no other safety concerns were identified. CONCLUSIONS SCT800 has robust PK characteristics, and is safe and efficacious for the prophylaxis and treatment of bleeding episodes in previously treated adolescent and adult patients with severe haemophilia A.",2021,"CONCLUSIONS SCT800 has robust PK characteristics, and is safe and efficacious for the prophylaxis and treatment of bleeding episodes in previously treated adolescent and adult patients with severe haemophilia A.","['previously treated Chinese adolescent and adult patients with severe haemophilia A', 'adolescent and adult patients with severe haemophilia A', 'A total of 71 of 73 patients completed the study, and 18 were enrolled for the repeat PK investigation', 'previously treated adolescent and adult patients with severe haemophilia A']","['B-domain-deleted recombinant FVIII (SCT800', 'SCT800']","[""success rate (defined as 'excellent' or 'good' haemostatic response"", 'repeat pharmacokinetics (PKs), efficacy, and safety', 'annualized bleeding rate (ABR', 'bleeding episodes', 'total ABR', 'incidence of treatment-related adverse events', 'Pharmacokinetic, efficacy and safety evaluation']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0272322', 'cui_str': 'Severe hereditary factor VIII deficiency disease'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}]","[{'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C2732002', 'cui_str': 'Antihemophilic Factor, Human Recombinant'}]","[{'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]",,0.0722672,"CONCLUSIONS SCT800 has robust PK characteristics, and is safe and efficacious for the prophylaxis and treatment of bleeding episodes in previously treated adolescent and adult patients with severe haemophilia A.","[{'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Xue', 'Affiliation': 'State Key Laboratory of Experimental Hematology, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, China.'}, {'ForeName': 'Xielan', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Hematology, Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Department of Hematology, Nanfang Hospital, Nanfang Medial University, Guangzhou, China.'}, {'ForeName': 'Xiaojing', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': 'Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.'}, {'ForeName': 'Fenge', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': 'Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Xu', 'Affiliation': ""Pediatric Hematology& Oncology, Chengdu Women's & Children's Central Hospital, Chengdu, China.""}, {'ForeName': 'Ziqiang', 'Initials': 'Z', 'LastName': 'Yu', 'Affiliation': 'Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.'}, {'ForeName': 'Weiying', 'Initials': 'W', 'LastName': 'Gu', 'Affiliation': ""Department of Hematology, The First People's Hospital of Changzhou, Changzhou, China.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Feng', 'Affiliation': 'Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Wenqian', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': ""Department of Hematology & Rheumatology, Qinghai Provincial People's Hospital, Qinghai, China.""}, {'ForeName': 'Changcheng', 'Initials': 'C', 'LastName': 'Zheng', 'Affiliation': 'Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Bi', 'Affiliation': 'Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Liangzhi', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China.'}, {'ForeName': 'Wenlin', 'Initials': 'W', 'LastName': 'Gai', 'Affiliation': 'Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China.'}, {'ForeName': 'Renchi', 'Initials': 'R', 'LastName': 'Yang', 'Affiliation': 'State Key Laboratory of Experimental Hematology, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, China.'}]",Haemophilia : the official journal of the World Federation of Hemophilia,['10.1111/hae.14350'] 3409,34076901,Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.,"Researchers around the world are working at record speed to find the best ways to treat and prevent coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID-19 infected patients. This was a randomized open-label controlled study that included 164 patients with COVID-19. Patients were randomized into two groups where Group 1 (Ivermectin group) included patients who received ivermectin 12 mg once daily for 3 days with standard care and Group 2 (control group) included patients who received standard protocol of treatment alone for 14 days. The main outcomes were mortality, the length of hospital stay, and the need for mechanical ventilation. All patients were followed up for 1 month. Overall, 82 individuals were randomized to receive ivermectin plus standard of care and 82 to receive standard of care alone. Patients in the ivermectin group had a shorter length of hospital stay (8.82 ± 4.94 days) than the control group (10.97 ± 5.28 days), but this was not statistically significant (p = 0.085). Three patients (3.7%) in each group required mechanical ventilation (p = 1.00). The death rate was three patients in the ivermectin group (3.7%) versus four patients (4.9%) in the control group without any significant difference between the two groups (p = 1.00). Although there was no statistically significant difference in any endpoints by ivermectin doses (12 mg/day for 3 days); there was an observed trend to reducing hospital stay in the ivermectin-treated group.",2021,Although there was no statistically significant difference in any endpoints by ivermectin doses (12 mg/day for 3 days); there was an observed trend to reducing hospital stay in the ivermectin-treated group.,"['164 patients with COVID-19', '82 individuals', 'hospitalized mild to moderate COVID-19 infected patients']","['ivermectin 12\u2009mg once daily for 3 days with standard care and Group 2 (control group) included patients who received standard protocol of treatment alone', 'ivermectin plus standard of care and 82 to receive standard of care alone', 'Ivermectin', 'ivermectin']","['shorter length of hospital stay', 'mechanical ventilation', 'death rate', 'hospital stay', 'mortality, the length of hospital stay, and the need for mechanical ventilation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0022322', 'cui_str': 'Ivermectin'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}]",164.0,0.0619101,Although there was no statistically significant difference in any endpoints by ivermectin doses (12 mg/day for 3 days); there was an observed trend to reducing hospital stay in the ivermectin-treated group.,"[{'ForeName': 'Sherief', 'Initials': 'S', 'LastName': 'Abd-Elsalam', 'Affiliation': 'Department of Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Rasha A', 'Initials': 'RA', 'LastName': 'Noor', 'Affiliation': 'Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Rehab', 'Initials': 'R', 'LastName': 'Badawi', 'Affiliation': 'Department of Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Mai', 'Initials': 'M', 'LastName': 'Khalaf', 'Affiliation': 'Department of Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Eslam S', 'Initials': 'ES', 'LastName': 'Esmail', 'Affiliation': 'Department of Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Shaimaa', 'Initials': 'S', 'LastName': 'Soliman', 'Affiliation': 'Department of Public health and Community Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Mohamed S', 'Initials': 'MS', 'LastName': 'Abd El Ghafar', 'Affiliation': 'Department of Anesthesia, Surgical Intensive Care, and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Elbahnasawy', 'Affiliation': 'Department of Emergency Medicine and traumatology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Ehab F', 'Initials': 'EF', 'LastName': 'Moustafa', 'Affiliation': 'Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Sahar M', 'Initials': 'SM', 'LastName': 'Hassany', 'Affiliation': 'Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Mohammed A', 'Initials': 'MA', 'LastName': 'Medhat', 'Affiliation': 'Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Haidi Karam-Allah', 'Initials': 'HK', 'LastName': 'Ramadan', 'Affiliation': 'Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Maii A S', 'Initials': 'MAS', 'LastName': 'Eldeen', 'Affiliation': 'Department of Microbiology and Immunology, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Alboraie', 'Affiliation': 'Department of Internal Medicine, Al-Azhar University, Cairo, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Cordie', 'Affiliation': 'Department of Endemic Medicine, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Gamal', 'Initials': 'G', 'LastName': 'Esmat', 'Affiliation': 'Department of Endemic Medicine, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.'}]",Journal of medical virology,['10.1002/jmv.27122'] 3410,34092654,"Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.","BACKGROUND Immunotherapies targeting α-synuclein aim to limit its extracellular spread in the brain and prevent progression of pathology in Parkinson's disease (PD). PD03A is a specific active immunotherapy (SAIT) involving immunization with a short peptide formulation. OBJECTIVE This phase 1 study characterized the safety and tolerability of PD03A in patients with early PD. A key secondary objective was to evaluate immunological activity following immunization. METHODS This was a phase 1 study of two different doses of PD03A versus placebo in PD patients. Patients were randomized (1:1:1) to receive four priming plus one booster vaccination of PD03A 15μg, PD03A 75μg or placebo and were followed for 52 weeks. RESULTS Overall, 36 patients were randomized, of which 35 received five immunizations and completed the study. All patients experienced at least one adverse event. Transient local injection site reactions affected all but two patients; otherwise most AEs were considered unrelated to study treatment. A substantial IgG antibody response against PD03 was observed with a maximum titer achieved at Week-12. Differences in titers between both active groups versus placebo were statistically significant from the second immunization at Week-8 until Week-52. CONCLUSION The safety profile and positive antibody response of PD03A supports the further development of active immunotherapeutic approaches for the treatment of PD.",2021,"Differences in titers between both active groups versus placebo were statistically significant from the second immunization at Week-8 until Week-52. ","['36 patients', 'patients with early PD', ""Parkinson's disease (PD"", ""Patients with Early Parkinson's Disease"", 'PD patients']","['PD03A', 'PD03A versus placebo', 'four priming plus one booster vaccination of PD03A 15μg, PD03A 75μg or placebo', 'Placebo', 'Active Immunotherapy Targeting α-Synuclein with PD03A', 'placebo']","['immunological activity', 'Safety and Tolerability', 'Transient local injection site reactions', 'safety and tolerability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0331021', 'cui_str': 'Ligustrum vulgare'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0020975', 'cui_str': 'Booster vaccination'}, {'cui': 'C0079612', 'cui_str': 'Active Immunotherapy'}, {'cui': 'C0165073', 'cui_str': 'Synuclein'}]","[{'cui': 'C0205470', 'cui_str': 'Immunologic'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}]",36.0,0.137661,"Differences in titers between both active groups versus placebo were statistically significant from the second immunization at Week-8 until Week-52. ","[{'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Poewe', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Dieter', 'Initials': 'D', 'LastName': 'Volc', 'Affiliation': 'PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Seppi', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Rossella', 'Initials': 'R', 'LastName': 'Medori', 'Affiliation': 'AFFiRiS AG, Vienna, Austria.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Lührs', 'Affiliation': 'AFFiRiS AG, Vienna, Austria.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Kutzelnigg', 'Affiliation': 'AFFiRiS AG, Vienna, Austria.'}, {'ForeName': 'Atbin', 'Initials': 'A', 'LastName': 'Djamshidian', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Thun-Hohenstein', 'Affiliation': 'PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria.'}, {'ForeName': 'Wassilios G', 'Initials': 'WG', 'LastName': 'Meissner', 'Affiliation': 'Service de Neurologie, CRMR Atrophie Multisystématisée, CHU Bordeaux and Université Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Rascol', 'Affiliation': ""Toulouse Parkinson Expert Center, Departments of Neurosciences and Clinical Pharmacology, Centre d'Investigation Clinique de Toulouse CIC1436, NS-Park/FCRIN Network, and NeuroToul COEN Center, University Hospital of Toulouse, INSERM, University of Toulouse, Toulouse, France.""}, {'ForeName': 'Achim', 'Initials': 'A', 'LastName': 'Schneeberger', 'Affiliation': 'AFFiRiS AG, Vienna, Austria.'}, {'ForeName': 'Günther', 'Initials': 'G', 'LastName': 'Staffler', 'Affiliation': 'AFFiRiS AG, Vienna, Austria.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Poewe', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Seppi', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Atbin', 'Initials': 'A', 'LastName': 'Djamshidian', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'deMarzi', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Heim', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Mangesius', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Raphaela', 'Initials': 'R', 'LastName': 'Stolz', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Wachowicz', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Dieter', 'Initials': 'D', 'LastName': 'Volc', 'Affiliation': 'PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Thun-Hohenstein', 'Affiliation': 'PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria.'}, {'ForeName': 'Constanze', 'Initials': 'C', 'LastName': 'Riha', 'Affiliation': 'PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria.'}, {'ForeName': 'Achim', 'Initials': 'A', 'LastName': 'Schneeberger', 'Affiliation': 'AFFiRiS AG, Vienna, Austria.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Bürger', 'Affiliation': 'AFFiRiS AG, Vienna, Austria.'}, {'ForeName': 'Gergana', 'Initials': 'G', 'LastName': 'Galabova', 'Affiliation': 'AFFiRiS AG, Vienna, Austria.'}]",Journal of Parkinson's disease,['10.3233/JPD-212594'] 3411,34092635,"Effects of Aerobic, Resistance, or Combined Exercise Training Among Older Adults with Subjective Memory Complaints: A Randomized Controlled Trial.","BACKGROUND Physical exercise is suggested to be effective for preventing cognitive decline in older adults, but the relative efficacy of different types of exercise have yet to be clarified. OBJECTIVE This single-blinded randomized controlled trial was designed to investigate the differential effects of aerobic exercise training (AT), resistance exercise training (RT), and combined exercise training (CT) on cognition in older adults with subjective memory complaints (SMC). METHODS Community-dwelling older adults with SMC (n = 415; mean age = 72.3 years old) were randomly assigned to one of the four groups: AT, RT, CT, or control group. The study consisted of two phases: a 26-week intervention and a 26-week follow-up. The participants were evaluated at baseline, 26 weeks (postintervention), and 52 weeks (follow-up). The primary outcome of this study was memory function, which was assessed using the Logical Memory II subtest of the Wechsler Memory Scale-Revised (WMS-R) score. The secondary outcomes included global cognitive function, verbal fluency, working memory, processing speed, and executive functions. RESULTS Intention-to-treat analysis by a mixed-effect model repeated measure showed that the AT group had significantly improved performance on the WMS-R Logical Memory II test (2.74 [1.82-3.66] points) than the control group (1.36 [0.44-2.28] points) at the postintervention assessment (p = 0.037). The effect was more pronounced in those without amnesia than those with amnesia. No significant improvement was observed in the RT and CT groups. CONCLUSION This study suggests that AT intervention can improve delayed memory in community-dwelling older adults, particularly in individuals without objective memory decline.",2021,"No significant improvement was observed in the RT and CT groups. ","['Older Adults with Subjective Memory Complaints', 'older adults with subjective memory complaints (SMC', 'Community-dwelling older adults with SMC (n\u200a=\u200a415; mean age\u200a=\u200a72.3 years old', 'community-dwelling older adults', 'older adults']","['Aerobic, Resistance, or Combined Exercise Training', 'aerobic exercise training (AT), resistance exercise training (RT), and combined exercise training (CT', 'AT intervention']","['global cognitive function, verbal fluency, working memory, processing speed, and executive functions', 'performance on the WMS-R Logical Memory II test', 'delayed memory', 'Logical Memory II subtest of the Wechsler Memory Scale-Revised (WMS-R) score']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C4517772', 'cui_str': '415'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0451575', 'cui_str': 'Wechsler memory scale'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0376364', 'cui_str': 'Delayed Memory'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0390828,"No significant improvement was observed in the RT and CT groups. ","[{'ForeName': 'Taeko', 'Initials': 'T', 'LastName': 'Makino', 'Affiliation': 'Department of Rehabilitation and Care, Seijoh University, Tokai, Aichi, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Umegaki', 'Affiliation': 'Department of Community Healthcare and Geriatrics, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Ando', 'Affiliation': 'Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Aichi, Japan.'}, {'ForeName': 'Xian Wu', 'Initials': 'XW', 'LastName': 'Cheng', 'Affiliation': 'Institute of Innovation for Future Society, Nagoya University, Nagoya, Aichi, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Ishida', 'Affiliation': 'Research Center of Health, Physical Fitness & Sports, Nagoya University, Nagoya, Aichi, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Akima', 'Affiliation': 'Research Center of Health, Physical Fitness & Sports, Nagoya University, Nagoya, Aichi, Japan.'}, {'ForeName': 'Yoshiharu', 'Initials': 'Y', 'LastName': 'Oshida', 'Affiliation': 'Research Center of Health, Physical Fitness & Sports, Nagoya University, Nagoya, Aichi, Japan.'}, {'ForeName': 'Yasuko', 'Initials': 'Y', 'LastName': 'Yoshida', 'Affiliation': 'Innovative Research Center for Preventive Medical Engineering, Nagoya University, Nagoya, Aichi, Japan.'}, {'ForeName': 'Kazuki', 'Initials': 'K', 'LastName': 'Uemura', 'Affiliation': 'Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Shimada', 'Affiliation': 'Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Kuzuya', 'Affiliation': 'Institute of Innovation for Future Society, Nagoya University, Nagoya, Aichi, Japan.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-210047'] 3412,34096661,"Efficacy of cranial microcurrent stimulation in patients with tension-type headache: A prospective, randomised, double-blinded, sham-controlled clinical trial.","OBJECTIVE To investigate the therapeutic effect of cranial microcurrent stimulation (CMS) in patients with tension-type headaches (TTH). METHODS This study was designed as a prospective, randomised, double-blinded and sham-controlled trial. A total of 22 patients with tension-type headache were selected as our study participants and randomly assigned into two groups: CMS group (n = 11) and Sham group (n = 11). To each of the participants, a sham or a true portable CMS stimulation device (CMS; intensity, 25 μA; frequency, 8 Hz) to wear was distributed, and 20-minute daily treatment was provided using the device for 2 weeks. In CMS group, treatment was given by means of electrodes clipped to the ear, whereas, in Sham group, sham treatment was provided by CMS without current. The measurements of Visual Analogue Scale (VAS), Headache Impact Test-6 (HIT6), Patient Health Questionnaire-9 (PHQ9), Generalised Anxiety Disorder 7-item (GAD7) and Hospital Anxiety and Depression Scale (HADS) were performed at pre-treatment (baseline), week 1 and 2 of treatment and two weeks post-treatment. RESULTS In CMS group, VAS of maximal headache and VAS of current headache, HIT6, PHQ9 and GAD7 significantly decreased by two weeks post-CMS therapy, but not in Sham group (P < .05). Scores of HADS-A (anxiety), HADS-D (depression) and HADS-T (total) significantly decreased by 2 weeks post-CMS therapy in CMS group, but not in Sham group (P < .05). Changes in scores of PHQ9 and GAD7, HADS-A, HADS-D and HADS-T in CMS group were significantly greater than in Sham group by 2 weeks post-CMS therapy (P < .05). CONCLUSION The results indicate that CMS, as an adjunctive treatment for patients with TTH, is safe and analgesic as well as reducing depression or anxiety.",2021,"The measurements of Visual Analogue Scale (VAS), Headache Impact Test-6","['A total of twenty-two patients with tension type headache', 'patients with tension type headaches (TTH', 'patients with tension-type headache']","['cranial microcurrent stimulation (CMS', 'cranial microcurrent stimulation', 'CMS']","['scores of PHQ9 and GAD7, HADS-A, HADS-D, and HADS-T', 'Scores of HADS-A (anxiety), HADS-D (depression), and HADS-T (total', 'depression or anxiety', 'HIT6), Patient Health Questionnaire-9 (PHQ9), Generalized Anxiety Disorder 7-item (GAD7), and Hospital Anxiety and Depression Scale (HADS', 'Visual Analogue Scale (VAS), Headache Impact Test-6', 'VAS of maximal headache and VAS of current headache, HIT6, PHQ9, and GAD7']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033893', 'cui_str': 'Psychogenic headache'}]","[{'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0521116', 'cui_str': 'Current'}]",22.0,0.169011,"The measurements of Visual Analogue Scale (VAS), Headache Impact Test-6","[{'ForeName': 'Jin Kuk', 'Initials': 'JK', 'LastName': 'Do', 'Affiliation': 'Department of Neurology, Catholic University of Daegu School of Medicine, Daegu, South Korea.'}, {'ForeName': 'Dong Rak', 'Initials': 'DR', 'LastName': 'Kwon', 'Affiliation': 'Department of Rehabilitation Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea.'}]",International journal of clinical practice,['10.1111/ijcp.14437'] 3413,34100711,Acute Tolerance to the Analgesic Effects of Alcohol.,"OBJECTIVE The goal of this study was to determine whether the acute analgesic effects of alcohol intake are moderated by acute alcohol tolerance, characterized by differing subjective and neurobehavioral effects of a given blood alcohol concentration (BAC) depending on whether BAC is rising or falling. METHOD Twenty-nine healthy drinkers (20 women) completed two laboratory sessions in which they consumed a study beverage: active alcohol (target BAC= .08 g/dl) and placebo. Acute alcohol tolerance was assessed by examining the main and interactive effects of beverage condition and assessment limb (ascending vs. descending) on quantitative sensory testing measures collected using slowly ramping heat stimuli and perceived relief ratings at comparable breath alcohol concentrations on the ascending and descending limbs. RESULTS BAC limb moderated the effect of condition on pain threshold, such that the threshold was significantly elevated in the alcohol condition on the ascending limb. The alcohol condition produced greater ratings of perceived pain relief than the placebo condition, and pain relief ratings were greater on the ascending versus descending limb of the BAC curve. Alcohol intake did not significantly affect pain tolerance or aftersensation ratings on either BAC limb. CONCLUSIONS This study provides initial experimental evidence that alcohol's analgesic and pain-relieving effects are subject to acute tolerance following acute alcohol intake. These findings suggest that self-medicating pain via alcohol intake may be associated with high-risk drinking topography, increasing the risk for alcohol-related consequences. Further research is needed to determine if these effects extend to the context of clinical and chronic pain.",2021,"The alcohol condition produced greater ratings of perceived pain relief than the placebo condition, and pain relief ratings were greater on the ascending versus descending limb of the BAC curve.",['Twenty-nine healthy drinkers (20 women) completed two'],"['Alcohol', 'blood alcohol concentration (BAC', 'laboratory sessions in which they consumed a study beverage: active alcohol (target BAC= .08 g/dl) and placebo']","['pain tolerance or aftersensation ratings', 'ratings of perceived pain relief', 'Acute alcohol tolerance', 'pain relief ratings']","[{'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0684262', 'cui_str': 'Blood Alcohol Concentration'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1167994', 'cui_str': 'Blood alcohol'}, {'cui': 'C0439267', 'cui_str': 'g/dL'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0556369', 'cui_str': 'Tolerance to alcohol'}]",29.0,0.00552983,"The alcohol condition produced greater ratings of perceived pain relief than the placebo condition, and pain relief ratings were greater on the ascending versus descending limb of the BAC curve.","[{'ForeName': 'Michelle K', 'Initials': 'MK', 'LastName': 'Williams', 'Affiliation': 'Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Darya', 'Initials': 'D', 'LastName': 'Vitus', 'Affiliation': 'Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Ferguson', 'Affiliation': 'Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Stennett', 'Affiliation': 'Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Robinson', 'Affiliation': 'Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Boissoneault', 'Affiliation': 'Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida.'}]",Journal of studies on alcohol and drugs,[] 3414,34089122,Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.,"BACKGROUND Autosomal dominant polycystic kidney disease (ADPKD) is a progressive condition that eventually leads to end-stage renal disease. A phase 3 trial of tolvaptan (TEMPO 3:4; NCT00428948) and its open-label extension (TEMPO Extension Japan: TEMPO-EXTJ; NCT01280721) were conducted in patients with ADPKD. In this post hoc analysis, effects on renal function and the safety profile of tolvaptan were assessed over a long-term period that included the 3-year TEMPO 3:4 and the approximately 3-year TEMPO-EXTJ trials. METHODS Patients from Japanese trial sites who completed TEMPO 3:4 were offered participation in TEMPO-EXTJ. Patients whose efficacy parameters were measured at year 2 in TEMPO-EXTJ for efficacy evaluation were included. The annual slope of the estimated glomerular filtration rate (eGFR) and growth in total kidney volume (TKV) were analyzed. RESULTS In patients who received tolvaptan in TEMPO 3:4 and TEMPO-EXTJ, the annual slope of eGFR (mL/min/1.73 m 2 ) was - 3.480 in TEMPO 3:4 and - 3.417 in TEMPO-EXTJ, with no apparent effect of an approximately 3.6-month off-treatment interval between the two trials. In patients who received a placebo in TEMPO 3:4 before initiating tolvaptan in TEMPO-EXTJ, the slope of eGFR was significantly less steep from TEMPO 3:4 (- 4.287) to TEMPO-EXTJ (- 3.364), a difference of 0.923 (P = 0.0441). CONCLUSION The TEMPO-EXTJ trial supports a sustained beneficial effect of tolvaptan on eGFR. In patients who received a placebo in TEMPO 3:4, initiation of tolvaptan in TEMPO-EXTJ was associated with a significant slowing of eGFR decline.",2021,"The annual slope of the estimated glomerular filtration rate (eGFR) and growth in total kidney volume (TKV) were analyzed. ","['patients with ADPKD', 'Japanese patients with autosomal dominant polycystic kidney disease', 'Patients from Japanese trial sites who completed TEMPO 3:4 were offered participation in TEMPO-EXTJ']","['placebo', 'tolvaptan', 'open-label extension (TEMPO Extension Japan']","['eGFR decline', 'glomerular filtration rate (eGFR) and growth in total kidney volume (TKV', 'renal function and the safety profile of tolvaptan', 'slope of eGFR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085413', 'cui_str': 'Autosomal dominant polycystic kidney disease'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0076084', 'cui_str': '2,2,6,6-tetramethyl-4-piperidine-N-oxide'}, {'cui': 'C1444648', 'cui_str': 'Offered'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0076084', 'cui_str': '2,2,6,6-tetramethyl-4-piperidine-N-oxide'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1176308', 'cui_str': 'tolvaptan'}]",,0.0559278,"The annual slope of the estimated glomerular filtration rate (eGFR) and growth in total kidney volume (TKV) were analyzed. ","[{'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Muto', 'Affiliation': 'Department of Advanced Informatics for Genetic Disease, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo, 113-8421, Japan. s-muto@juntendo.ac.jp.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Okada', 'Affiliation': 'Department of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Shibasaki', 'Affiliation': 'Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Tatsuki', 'Initials': 'T', 'LastName': 'Ibuki', 'Affiliation': 'Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Shigeo', 'Initials': 'S', 'LastName': 'Horie', 'Affiliation': 'Department of Advanced Informatics for Genetic Disease, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo, 113-8421, Japan.'}]",Clinical and experimental nephrology,['10.1007/s10157-021-02083-y'] 3415,34089698,Experience of 300 cases of prenatal fetoscopic open spina bifida repair: report of the International Fetoscopic Neural Tube Defect Repair Consortium.,"BACKGROUND The multicenter randomized controlled trial Management of Myelomeningocele Study demonstrated that prenatal repair of open spina bifida by hysterotomy, compared with postnatal repair, decreases the need for ventriculoperitoneal shunting and increases the chances of independent ambulation. However, the hysterotomy approach is associated with risks that are inherent to the uterine incision. Fetal surgeons from around the world embarked on fetoscopic open spina bifida repair aiming to reduce maternal and fetal/neonatal risks while preserving the neurologic benefits of in utero surgery to the child. OBJECTIVE This study aimed to report the main obstetrical, perinatal, and neurosurgical outcomes in the first 12 months of life of children undergoing prenatal fetoscopic repair of open spina bifida included in an international registry and to compare these with the results reported in the Management of Myelomeningocele Study and in a subsequent large cohort of patients who received an open fetal surgery repair. STUDY DESIGN All known centers performing fetoscopic spina bifida repair were contacted and invited to participate in a Fetoscopic Myelomeningocele Repair Consortium and enroll their patients in a registry. Patient data entered into this fetoscopic registry were analyzed for this report. Fisher exact test was performed for comparison of categorical variables in the registry with both the Management of Myelomeningocele Study and a post-Management of Myelomeningocele Study cohort. Binary logistic regression analyses were used to assess the registry data for predictors of preterm birth at <30 weeks' gestation, preterm premature rupture of membranes, and need for postnatal cerebrospinal fluid diversion in the fetoscopic registry. RESULTS There were 300 patients in the fetoscopic registry, 78 in the Management of Myelomeningocele Study, and 100 in the post-Management of Myelomeningocele Study cohort. The 3 data sets showed similar anatomic levels of the spinal lesion, mean gestational age at delivery, distribution of motor function compared with upper anatomic level of the lesion in the neonates, and perinatal death. In the Management of Myelomeningocele Study (26.16±1.6 weeks) and post-Management of Myelomeningocele Study cohort (23.3 [20.2-25.6] weeks), compared with the fetoscopic registry group (23.6±1.4 weeks), the gestational age at surgery was lower (comparing fetoscopic repair group with the Management of Myelomeningocele Study; P<.01). After open fetal surgery, all patients were delivered by cesarean delivery, whereas in the fetoscopic registry approximately one-third were delivered vaginally (P<.01). At cesarean delivery, areas of dehiscence or thinning in the scar were observed in 34% of cases in the Management of Myelomeningocele Study, in 49% in the post-Management of Myelomeningocele Study cohort, and in 0% in the fetoscopic registry (P<.01 for both comparisons). At 12 months of age, there was no significant difference in the number of patients requiring treatment for hydrocephalus between those in the fetoscopic registry and the Management of Myelomeningocele Study. CONCLUSION Prenatal and postnatal outcomes up to 12 months of age after prenatal fetoscopic and open fetal surgery repair of open spina bifida are similar. Fetoscopic repair allows for having a vaginal delivery and eliminates the risk of uterine scar dehiscence, therefore protecting subsequent pregnancies of unnecessary maternal and fetal risks.",2021,Fetoscopic repair allows for having a vaginal delivery and eliminates the risk of uterine scar dehiscence therefore protecting subsequent pregnancies of unnecessary maternal and fetal risks.,"['children undergoing prenatal fetoscopic repair of open spina bifida', '300 cases of prenatal fetoscopic open spina bifida repair', 'All known centers performing fetoscopic spina bifida repair were contacted and invited to participate in a Fetoscopic Myelomeningocele Repair Consortium and enroll their patients in a registry', '300 patients in the fetoscopic registry, 78 in the MOMS trial and 100 in the post MOMS cohort']","['Myelomeningocele Study (MOMS', 'prenatal fetoscopic and open fetal surgery repair', 'Fetoscopic repair', 'open fetal surgery repair', 'International Fetoscopic Neural Tube Defect Repair Consortium']","['dehiscence or thinning in the scar', 'number of patients requiring treatment for hydrocephalus', 'anatomic levels of the spinal lesion, mean gestational age at delivery, distribution of motor function', 'preterm prelabor rupture of membranes (PPROM) and need for postnatal cerebrospinal fluid (CSF) diversion']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0917813', 'cui_str': 'Spina Bifida, Open'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0196472', 'cui_str': 'Repair of spina bifida'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0025312', 'cui_str': 'Meningomyelocele'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0025312', 'cui_str': 'Meningomyelocele'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1261465', 'cui_str': 'Operation on fetus'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0027794', 'cui_str': 'Neural tube defect'}]","[{'cui': 'C0149663', 'cui_str': 'Dehiscence'}, {'cui': 'C0205168', 'cui_str': 'Thin'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0020255', 'cui_str': 'Hydrocephalus'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0015944', 'cui_str': 'Premature rupture of membranes'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0185033', 'cui_str': 'Diversion procedure'}]",300.0,0.158933,Fetoscopic repair allows for having a vaginal delivery and eliminates the risk of uterine scar dehiscence therefore protecting subsequent pregnancies of unnecessary maternal and fetal risks.,"[{'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Sanz Cortes', 'Affiliation': ""Department of Obstetrics and Gynecology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX. Electronic address: Magdalec@bcm.edu.""}, {'ForeName': 'Ramen H', 'Initials': 'RH', 'LastName': 'Chmait', 'Affiliation': 'Department of Obstetrics and Gynecology, Los Angeles Fetal Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA.'}, {'ForeName': 'Denise A', 'Initials': 'DA', 'LastName': 'Lapa', 'Affiliation': 'Fetal Therapy Program, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Belfort', 'Affiliation': ""Department of Obstetrics and Gynecology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; Department of Neurosurgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Carreras', 'Affiliation': ""Department of Obstetrics and Gynecology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Jena L', 'Initials': 'JL', 'LastName': 'Miller', 'Affiliation': 'Department of Gynecology and Obstetrics, Johns Hopkins Center for Fetal Therapy, Baltimore, MD.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Brawura Biskupski Samaha', 'Affiliation': 'First Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland.'}, {'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Sepulveda Gonzalez', 'Affiliation': 'Medicina Perinatal Alta Especialidad, Hospital Christus Muguerza Alta Especialidad, Monterrey, NL, Mexico.'}, {'ForeName': 'Yuval', 'Initials': 'Y', 'LastName': 'Gielchinsky', 'Affiliation': 'Department of Obstetrics and Gynecology, Rabin Medical Center, Petah Tikva, Israel.'}, {'ForeName': 'Masami', 'Initials': 'M', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Obstetrics and Gynecology, Clinica Universidad de los Andes, Santiago, Chile.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Persico', 'Affiliation': ""Fetal Medicine and Surgery Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Clinical Science and Community Health, University of Milan, Milan, Italy.""}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Santorum', 'Affiliation': ""Fetal Medicine Research Institute, King's College Hospital, London, United Kingdom.""}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Otaño', 'Affiliation': 'Obstetrics Division, Department of Obstetrics and Gynecology, Instituto Universitario, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.'}, {'ForeName': 'Ermos', 'Initials': 'E', 'LastName': 'Nicolaou', 'Affiliation': 'Division of Maternal and Fetal Medicine, Department of Obstetrics and Gynecology, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Yoav', 'Initials': 'Y', 'LastName': 'Yinon', 'Affiliation': 'Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Faig-Leite', 'Affiliation': 'Department of Perinatology, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Reynaldo', 'Initials': 'R', 'LastName': 'Brandt', 'Affiliation': 'Department of Perinatology, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Whitehead', 'Affiliation': ""Department of Neurosurgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.""}, {'ForeName': 'Nerea', 'Initials': 'N', 'LastName': 'Maiz', 'Affiliation': ""Department of Obstetrics and Gynecology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Baschat', 'Affiliation': 'Department of Gynecology and Obstetrics, Johns Hopkins Center for Fetal Therapy, Baltimore, MD.'}, {'ForeName': 'Przemyslaw', 'Initials': 'P', 'LastName': 'Kosinski', 'Affiliation': 'First Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Nieto-Sanjuanero', 'Affiliation': 'Medicina Perinatal Alta Especialidad, Hospital Christus Muguerza Alta Especialidad, Monterrey, NL, Mexico.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Chu', 'Affiliation': ""Department of Neurosurgery, Los Angeles Fetal Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA; Department of Neurosurgery, Keck School of Medicine, University of Southern California, Children's Hospital Los Angeles, Los Angeles, CA.""}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Kershenovich', 'Affiliation': ""Division of Pediatric Neurosurgery, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.""}, {'ForeName': 'Kypros H', 'Initials': 'KH', 'LastName': 'Nicolaides', 'Affiliation': 'Fetal Medicine Foundation, London, United Kingdom.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2021.05.044'] 3416,34097130,Effect of hypoxia and nitrate supplementation on different high-intensity interval-training sessions.,"PURPOSE To test the hypothesis that interval-training (IHT) would be impaired by hypoxia to a larger extent than repeated-sprint training (RSH) and that dietary nitrate (NO 3 - ) would mitigate the detrimental effect of hypoxia to a larger extent during IHT than RSH. METHODS Thirty endurance-trained male participants performed IHT (6 × 1 min at 90%∆ with 1 min active recovery) and RSH (2 sets of 6 × 10 s ""all-out"" efforts with 20 s active recovery) on a cycle ergometer, allocated in one of three groups: normobaric hypoxia (~ 13% F i O 2 ) + NO 3 -  - HNO, n = 10; normobaric hypoxia + placebo - HPL, n = 10; normoxia (20.9% F i O 2 ) + placebo - CON, n = 10. Submaximal oxygen uptake ([Formula: see text]O 2 ), time spent above 90% of maximal [Formula: see text]O 2 (≥ 90 [Formula: see text]O 2 max) and heart rate (≥ 90 HRmax) were compared between IHT and RSH sessions and groups. Additionally, mean power output (MPO), decrement score and % of power associated with [Formula: see text]O 2 max (%p[Formula: see text]O 2 max) in RSH sessions were analyzed. RESULTS [Formula: see text]O 2 at sub-maximal intensities did not differ between training protocols and groups (~ 27 ml kg -1  min -1 ).  ≥ 90 HRmax was significantly higher in IHT compared to RSH session (39 ± 8 vs. 30 ± 8%, p = 0.03) but only in HNO group. MPO (range 360-490 W) and decrement score (10-13%) were similar between groups although %p[Formula: see text]O 2 max was significantly higher (p = 0.04) in CON (166 ± 16 W) compared with both HPL (147 ± 15 W) and HNO (144 ± 10 W) groups. CONCLUSION IHT responses were neither more impaired by hypoxia than RSH ones. Moreover, dietary NO 3 - supplementation impacted equally IHT and RSH training responses' differences between hypoxia and normoxia.",2021,"MPO (range 360-490 W) and decrement score (10-13%) were similar between groups although %p[Formula: see text]O 2 max was significantly higher (p = 0.04) in CON (166 ± 16 W) compared with both HPL (147 ± 15 W) and HNO (144 ± 10 W) groups. ",['Thirty endurance-trained male participants performed'],"['normobaric hypoxia (~\u200913% F', 'IHT (6\u2009×\u20091\xa0min at 90%∆ with 1\xa0min active recovery) and RSH (2 sets of 6\u2009×\u200910\xa0s ""all-out"" efforts with 20\xa0s active recovery', '\u2009placebo', 'interval-training (IHT', 'hypoxia and nitrate supplementation', 'normobaric hypoxia\u2009+\u2009placebo\xa0-\xa0HPL, n\u2009=\u200910; normoxia (20.9% F']","['heart rate (≥\u200990 HRmax', 'Submaximal oxygen uptake', 'mean power output (MPO', 'MPO']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032052', 'cui_str': 'Human placental lactogen'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0027021', 'cui_str': 'Peroxidase'}]",,0.0570018,"MPO (range 360-490 W) and decrement score (10-13%) were similar between groups although %p[Formula: see text]O 2 max was significantly higher (p = 0.04) in CON (166 ± 16 W) compared with both HPL (147 ± 15 W) and HNO (144 ± 10 W) groups. ","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sousa', 'Affiliation': 'Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, University of Trás-Os-Montes and Alto Douro, Vila Real, Portugal. sousa.acm@gmail.com.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Viana', 'Affiliation': 'Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, University Institute of Maia, ISMAI, Maia, Portugal.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Milheiro', 'Affiliation': 'CMEP Exercise Medical Center & SPA, Porto, Portugal.'}, {'ForeName': 'V M', 'Initials': 'VM', 'LastName': 'Reis', 'Affiliation': 'Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, University of Trás-Os-Montes and Alto Douro, Vila Real, Portugal.'}, {'ForeName': 'G P', 'Initials': 'GP', 'LastName': 'Millet', 'Affiliation': 'ISSUL, Institute of Sport Sciences and Physical Education (ISSEP), University of Lausanne, Lausanne, Switzerland.'}]",European journal of applied physiology,['10.1007/s00421-021-04726-0'] 3417,34092633,"Multidomain Intervention for Reversal of Cognitive Frailty, Towards a Personalized Approach (AGELESS Trial): Study Design.","BACKGROUND Cognitive frailty (CF) is identified as one of the main precursors of dementia. Multidomain intervention has been found to delay or prevent the onset of CF. OBJECTIVE The aim of our present study is to determine the effectiveness of a comprehensive, multidomain intervention on CF; to evaluate its cost effectiveness and the factors influencing adherence toward this intensive intervention. METHODS A total of 1,000 community dwelling older adults, aged 60 years and above will be screened for CF. This randomized controlled trial involves recruitment of 330 older adults with CF from urban, semi-urban, and rural areas in Malaysia. Multidomain intervention comprised of physical, nutritional, cognitive, and psychosocial aspects will be provided to participants in the experimental group (n = 165). The control group (n = 165) will continue their usual care with their physician. Primary outcomes include CF status, physical function, psychosocial and nutritional status as well as cognitive performance. Vascular health and gut microbiome will be assessed using blood and stool samples. A 24-month intensive intervention will be prescribed to the participants and its sustainability will be assessed for the following 12 months. The effective intervention strategies will be integrated as a personalized telerehabilitation package for the reversal of CF for future use. RESULTS The multidomain intervention developed from this trial is expected to be cost effective compared to usual care as well as able is to reverse CF. CONCLUSION This project will be part of the World-Wide FINGERS (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) Network, of which common identifiable data will be shared and harmonized among the consortia.",2021,"The effective intervention strategies will be integrated as a personalized telerehabilitation package for the reversal of CF for future use. ","['327 older adults with CF from urban, semi-urban, and rural areas in Malaysia', 'Reversal of Cognitive Frailty', 'A total of 1,000 community dwelling older adults, aged 60 years and above will be screened for CF']","['multidomain intervention', 'Multidomain intervention', 'comprehensive, multidomain intervention', 'Multidomain Intervention']","['CF status, physical function, psychosocial and nutritional status as well as cognitive performance']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}]",1000.0,0.0482374,"The effective intervention strategies will be integrated as a personalized telerehabilitation package for the reversal of CF for future use. ","[{'ForeName': 'Pavapriya', 'Initials': 'P', 'LastName': 'Ponvel', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Suzana', 'Initials': 'S', 'LastName': 'Shahar', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Devinder Kaur Ajit', 'Initials': 'DKA', 'LastName': 'Singh', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Arimi Fitri Mat', 'Initials': 'AFM', 'LastName': 'Ludin', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Roslee', 'Initials': 'R', 'LastName': 'Rajikan', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Nor Fadilah', 'Initials': 'NF', 'LastName': 'Rajab', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Chin', 'Initials': 'C', 'LastName': 'Ai-Vyrn', 'Affiliation': 'Geriatric Division, Faculty of Medicine, University Malaya Medical Center, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Normah Che', 'Initials': 'NC', 'LastName': 'Din', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Norhayati', 'Initials': 'N', 'LastName': 'Ibrahim', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Ponnusamy', 'Initials': 'P', 'LastName': 'Subramaniam', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Hasnah', 'Initials': 'H', 'LastName': 'Haron', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Aniza', 'Initials': 'A', 'LastName': 'Ismail', 'Affiliation': 'Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Razinah', 'Initials': 'R', 'LastName': 'Sharif', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Kalavathy', 'Initials': 'K', 'LastName': 'Ramasamy', 'Affiliation': 'Faculty of Pharmacy, Universiti Teknologi Mara, Shah Alam, Malaysia.'}, {'ForeName': 'Abu Bakar Abdul', 'Initials': 'ABA', 'LastName': 'Majeed', 'Affiliation': 'Faculty of Pharmacy, Universiti Teknologi Mara, Shah Alam, Malaysia.'}, {'ForeName': 'Nazlena Mohamad', 'Initials': 'NM', 'LastName': 'Ali', 'Affiliation': 'Institute of IR4.0 (IIR4.0), Universiti Kebangsaan Malaysia, Malaysia.'}, {'ForeName': 'Mazlyfarina', 'Initials': 'M', 'LastName': 'Mohamad', 'Affiliation': 'Centre for Diagnostic, Therapeutic & Investigative Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Shahrul Azman Mohd', 'Initials': 'SAM', 'LastName': 'Noah', 'Affiliation': 'Centre for Artificial Intelligence Technology, Faculty of Information Science and Technology, Universiti Kebangsaan Malaysia, Malaysia.'}, {'ForeName': 'Azianah Mohd', 'Initials': 'AM', 'LastName': 'Ibrahim', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Aisyah Mohd', 'Initials': 'AM', 'LastName': 'Safien', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Norhayati Mustafa', 'Initials': 'NM', 'LastName': 'Khalid', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Nurul Hidayah Md', 'Initials': 'NHM', 'LastName': 'Fadzil', 'Affiliation': 'Centre for Healthy Ageing and Wellness (HCARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Mangialasche', 'Affiliation': 'Division of Clinical Geriatrics, Alzheimer Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.'}, {'ForeName': 'Miia', 'Initials': 'M', 'LastName': 'Kivipelto', 'Affiliation': 'Division of Clinical Geriatrics, Alzheimer Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201607'] 3418,34092631,Acute Exercise and Cognitive Function in Alzheimer's Disease.,"BACKGROUND Many studies have shown the impact of acute aerobic exercises (AAE) on cognition in healthy adults or at a pre-dementia stage. Few studies, however, have explored the positive effects of AAE in moderate Alzheimer's disease (ADM) patients. OBJECTIVE Evaluating the effect of AAE on cognitive functions in ADM patients. METHODS Overall, 79 (age: 69.62±0.99) ADM patients were recruited. Participants were divided into three groups according to the task: aerobic exercises done alone or combined with cognitive games presented on a screen, and a control group who performed a reading task. The aerobic exercise protocol consisted of a 20-min cycling exercise of moderate intensity, corresponding to 60%of the individual target maximal heart rate recorded in a 6-minute walking test. The participants' cognition was monitored before and after the intervention using the Tower of Hanoi, Digit Span, and Stroop tasks. RESULTS After the exercise, the participants' attention in both the physical and combined groups improved for the Stroop, the forward and backward Digit Span tasks, as well as the time taken to solve the Tower of Hanoi, although no significant differences were found in the number of moves taken in the latter. By contrast, the control group did not show any significant improvement for most of the cognitive tasks after the reading session. CONCLUSION Current evidence suggests that AAE may help to improve cognitive functions in ADM patients. This improvement is enhanced when the exercise is combined with cognitive games. Safe and progressive types of exercises should be promoted among ADM patients.",2021,"After the exercise, the participants' attention in both the physical and combined groups improved for the Stroop, the forward and backward Digit Span tasks, as well as the time taken to solve the Tower of Hanoi, although no significant differences were found in the number of moves taken in the latter.","['ADM patients', 'healthy adults or at a pre-dementia stage', ""Alzheimer's Disease"", ""moderate Alzheimer's disease (ADM) patients"", 'Overall, 79 (age: 69.62±0.99) ADM patients were recruited']","['aerobic exercises done alone or combined with cognitive games presented on a screen, and a control group who performed a reading task', 'acute aerobic exercises (AAE', 'AAE']","['cognitive functions', 'cognitive tasks']","[{'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.0535823,"After the exercise, the participants' attention in both the physical and combined groups improved for the Stroop, the forward and backward Digit Span tasks, as well as the time taken to solve the Tower of Hanoi, although no significant differences were found in the number of moves taken in the latter.","[{'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Ben Ayed', 'Affiliation': 'Laboratory of Physiology and Functional Explorations, Laboratory of Exercise Physiology and Physiopathology (LR19ES09), Faculty of Medicine of Sousse, Sousse, Tunisia.'}, {'ForeName': 'Naomie', 'Initials': 'N', 'LastName': 'Castor-Guyonvarch', 'Affiliation': 'Laboratory of Human and Artificial Cognition (EA 4004), Psychology UFR, University of Vincennes/Saint-Denis, Paris, France.'}, {'ForeName': 'Souad', 'Initials': 'S', 'LastName': 'Amimour', 'Affiliation': 'Laboratory of Human and Artificial Cognition (EA 4004), Psychology UFR, University of Vincennes/Saint-Denis, Paris, France.'}, {'ForeName': 'Salma', 'Initials': 'S', 'LastName': 'Naija', 'Affiliation': 'Neurology Department, University Hospital Sahloul Sousse, Sahloul, Sousse, Tunisia.'}, {'ForeName': 'Chirine', 'Initials': 'C', 'LastName': 'Aouichaoui', 'Affiliation': 'Laboratory of Physiology and Functional Explorations, Laboratory of Exercise Physiology and Physiopathology (LR19ES09), Faculty of Medicine of Sousse, Sousse, Tunisia.'}, {'ForeName': 'Sana', 'Initials': 'S', 'LastName': 'Ben Omor', 'Affiliation': 'Neurology Department, University Hospital Sahloul Sousse, Sahloul, Sousse, Tunisia.'}, {'ForeName': 'Zouhair', 'Initials': 'Z', 'LastName': 'Tabka', 'Affiliation': 'Laboratory of Physiology and Functional Explorations, Laboratory of Exercise Physiology and Physiopathology (LR19ES09), Faculty of Medicine of Sousse, Sousse, Tunisia.'}, {'ForeName': 'Farid', 'Initials': 'F', 'LastName': 'El Massioui', 'Affiliation': 'Laboratory of Human and Artificial Cognition (EA 4004), Psychology UFR, University of Vincennes/Saint-Denis, Paris, France.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-201317'] 3419,34101212,Thiamine supplementation holds neurocognitive benefits for breastfed infants during the first year of life.,"Women reliant on mostly rice-based diets can have inadequate thiamine intake, placing breastfed infants at risk of thiamine deficiency and, in turn, physical and cognitive impairments. We investigated the impact of maternal thiamine supplementation doses on infants' cognitive, motor, and language development across the first year. In this double-blind, four-parallel-arm, randomized controlled trial, healthy mothers of exclusively breastfed newborn infants were recruited in Kampong Thom, Cambodia. At 2 weeks postnatal, women (n = 335) were randomized to one of four treatment groups to consume one capsule/day with varying amounts of thiamine for 22 weeks: 0, 1.2, 2.4, and 10 mg. At 2, 12, 24, and 52 weeks of age, infants were assessed with the Mullen Scales of Early Learning (MSEL) and the Caregiver Reported Early Development Instrument (CREDI). Multiple regression and mixed effects modeling suggest that by 6 months of age, the highest maternal thiamine dose (10 mg/day) held significant benefits for infants' language development, but generally not for motor or visual reception development. Despite having achieved standardized scores on the MSEL that approximated U.S. norms by 6 months, infants showed a significant drop relative to these norms in both language domains following trial completion, indicating that nutritional interventions beyond 6 months may be necessary.",2021,"Despite having achieved standardized scores on the MSEL that approximated U.S. norms by 6 months, infants showed a significant drop relative to these norms in both language domains following trial completion, indicating that nutritional interventions beyond 6 months may be necessary.","['At 2 weeks postnatal, women (n\xa0=\xa0335', ""infants' cognitive, motor, and language development across the first year"", 'breastfed infants during the first year of life', 'healthy mothers of exclusively breastfed newborn infants were recruited in Kampong Thom, Cambodia']","['Thiamine supplementation', 'maternal thiamine supplementation']","['Mullen Scales of Early Learning (MSEL) and the Caregiver', 'neurocognitive benefits']","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4709307', 'cui_str': '335'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0023013', 'cui_str': 'Language Development'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0006797', 'cui_str': 'Cambodia'}]","[{'cui': 'C4524016', 'cui_str': 'Thiamin supplementation'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}]",335.0,0.220199,"Despite having achieved standardized scores on the MSEL that approximated U.S. norms by 6 months, infants showed a significant drop relative to these norms in both language domains following trial completion, indicating that nutritional interventions beyond 6 months may be necessary.","[{'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Measelle', 'Affiliation': 'Department of Psychology, University of Oregon, Eugene, Oregon.'}, {'ForeName': 'Dare A', 'Initials': 'DA', 'LastName': 'Baldwin', 'Affiliation': 'Department of Psychology, University of Oregon, Eugene, Oregon.'}, {'ForeName': 'Jelisa', 'Initials': 'J', 'LastName': 'Gallant', 'Affiliation': 'Department of Applied Human Nutrition, Mount Saint Vincent University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Chan', 'Affiliation': 'Department of Applied Human Nutrition, Mount Saint Vincent University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Tim J', 'Initials': 'TJ', 'LastName': 'Green', 'Affiliation': 'South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.'}, {'ForeName': 'Frank T', 'Initials': 'FT', 'LastName': 'Wieringa', 'Affiliation': 'UMR-204, Institut de recherche pour le développement, Montpellier, France.'}, {'ForeName': 'Mam', 'Initials': 'M', 'LastName': 'Borath', 'Affiliation': 'National Sub-Committee for Food Fortification, Cambodia Ministry of Planning, Phnom Penh, Cambodia.'}, {'ForeName': 'Sophonneary', 'Initials': 'S', 'LastName': 'Prak', 'Affiliation': 'National Nutrition Programme, Maternal and Child Health Centre, Cambodia Ministry of Health, Phnom Penh, Cambodia.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Hampel', 'Affiliation': 'USDA/ARS Western Human Nutrition Research Center, Davis, California.'}, {'ForeName': 'Setareh', 'Initials': 'S', 'LastName': 'Shahab-Ferdows', 'Affiliation': 'USDA/ARS Western Human Nutrition Research Center, Davis, California.'}, {'ForeName': 'Lindsay H', 'Initials': 'LH', 'LastName': 'Allen', 'Affiliation': 'USDA/ARS Western Human Nutrition Research Center, Davis, California.'}, {'ForeName': 'Hou', 'Initials': 'H', 'LastName': 'Kroeun', 'Affiliation': 'Helen Keller International Cambodia, Phnom Penh, Cambodia.'}, {'ForeName': 'Kyly C', 'Initials': 'KC', 'LastName': 'Whitfield', 'Affiliation': 'Department of Applied Human Nutrition, Mount Saint Vincent University, Halifax, Nova Scotia, Canada.'}]",Annals of the New York Academy of Sciences,['10.1111/nyas.14610'] 3420,34062418,Metformin has no impact on nitric oxide production in patients with pre-diabetes.,"AIMS/INTRODUCTION The authors evaluated the impact of different dose of metformin on NO (nitric oxide) production in subjects with pre-diabetes. MATERIALS AND METHODS The metformin-naïve patients from one Diabetic Center with newly diagnosed pre-diabetes, without cardio-vascular diseases, were randomized (based on the identification number, individual for each inhabitant in the country) for treatment with different doses of metformin (group A 3 × 500 mg, group B 3 × 1000 mg) for 12 weeks. Then, the subjects from group B were switched to dose 3 × 500 for the last 3 weeks. The wide panel of L-arginine/NO pathway metabolites concentrations was assessed using the liquid chromatography-mass spectrometry technique. RESULTS Between October 2017 and December 2018, 36 individuals were initially randomized to intervention groups. The study was completed with 25 subjects: 14 patients in group A, 11 in group B; also 11 healthy volunteers were recruited. There was no difference between participants with pre-diabetes and healthy volunteers as regards the baseline characteristics except for fasting glucose and fatty liver. The decrease of L-citrulline concentration only was reported for treatment groups during the intervention period, with no change for the other NO-production related substances. CONCLUSION It was the first study on the in vivo release of NO in humans with different metformin doses in patients with pre-diabetes. Metformin did not seem to increase NO production measured by the citrulline plasma levels, irrespective of the dose. The citrulline concentration change might indicate the drug impact on the condition of the enterocytes.",2021,There was no difference between participants with pre-diabetes and healthy volunteers as regards the baseline characteristics except for fasting glucose and fatty liver.,"['patients with pre-diabetes', 'participants with pre-diabetes and healthy volunteers', '36 individuals', 'Between October 2017 and December 2018', '25 subjects: 14 patients in group A, 11 in group B; also 11 healthy volunteers were recruited', 'subjects with pre-diabetes', 'naïve patients from one Diabetic Center with newly diagnosed pre-diabetes, without cardio-vascular diseases']","['metformin', 'Metformin']","['L-citrulline concentration', 'fasting glucose and fatty liver', 'NO (nitric oxide) production', 'citrulline plasma levels', 'nitric oxide production']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0042373', 'cui_str': 'Vascular disorder'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0008864', 'cui_str': 'Citrulline'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0015695', 'cui_str': 'Fatty Liver'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",11.0,0.00795338,There was no difference between participants with pre-diabetes and healthy volunteers as regards the baseline characteristics except for fasting glucose and fatty liver.,"[{'ForeName': 'Edyta', 'Initials': 'E', 'LastName': 'Sutkowska', 'Affiliation': 'Department and Division of Medical Rehabilitation, Wroclaw Medical University, Wroclaw, Poland. Electronic address: edyta.sutkowska@umed.wroc.pl.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Fortuna', 'Affiliation': 'Department of Medical Biochemistry, Wroclaw Medical University, Wroclaw, Poland. Electronic address: paulina.fortuna@umed.wroc.pl.'}, {'ForeName': 'Bernadetta', 'Initials': 'B', 'LastName': 'Kałuża', 'Affiliation': 'Department of Internal Medicine, Endocrinology and Diabetology, Central Clinical Hospital of the Ministry of the Interior, Warsaw, Poland. Electronic address: bernadettta@o2.pl.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Sutkowska', 'Affiliation': 'Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. Electronic address: karolina.sutkowska@student.umed.wroc.pl.'}, {'ForeName': 'Jerzy', 'Initials': 'J', 'LastName': 'Wiśniewski', 'Affiliation': 'Central Laboratory of Instrumental Analysis, Wroclaw University of Science and Technology, Wybrzeże Wyspiańskiego 27, 50-370 Wroclaw, Poland. Electronic address: jerzy.wisniewski@pwr.edu.pl.'}, {'ForeName': 'Andrzej Gamian', 'Initials': 'AG', 'LastName': 'Prof', 'Affiliation': 'Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Science, Weigla 12, 53-114 Wroclaw, Poland. Electronic address: andrzej.gamian@hirszweld.pl.'}]",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,['10.1016/j.biopha.2021.111773'] 3421,34092548,Artificial Intelligence-Based Chatbot for Anxiety and Depression in University Students: Pilot Randomized Controlled Trial.,"BACKGROUND Artificial intelligence-based chatbots are emerging as instruments of psychological intervention; however, no relevant studies have been reported in Latin America. OBJECTIVE The objective of the present study was to evaluate the viability, acceptability, and potential impact of using Tess, a chatbot, for examining symptoms of depression and anxiety in university students. METHODS This was a pilot randomized controlled trial. The experimental condition used Tess for 8 weeks, and the control condition was assigned to a psychoeducation book on depression. Comparisons were conducted using Mann-Whitney U and Wilcoxon tests for depressive symptoms, and independent and paired sample t tests to analyze anxiety symptoms. RESULTS The initial sample consisted of 181 Argentinian college students (158, 87.2% female) aged 18 to 33. Data at week 8 were provided by 39 out of the 99 (39%) participants in the experimental condition and 34 out of the 82 (41%) in the control group. On an average, 472 (SD 249.52) messages were exchanged, with 116 (SD 73.87) of the messages sent from the users in response to Tess. A higher number of messages exchanged with Tess was associated with positive feedback (F 2,36 =4.37; P=.02). No significant differences between the experimental and control groups were found from the baseline to week 8 for depressive and anxiety symptoms. However, significant intragroup differences demonstrated that the experimental group showed a significant decrease in anxiety symptoms; no such differences were observed for the control group. Further, no significant intragroup differences were found for depressive symptoms. CONCLUSIONS The students spent a considerable amount of time exchanging messages with Tess and positive feedback was associated with a higher number of messages exchanged. The initial results show promising evidence for the usability and acceptability of Tess in the Argentinian population. Research on chatbots is still in its initial stages and further research is needed.",2021,No significant intergroup differences from baseline to week eight between the experimental group and the control group were found for depression and anxiety symptoms.,"['University Students', '181 Argentinian college students (87.2% female) ages 18 to 33', 'university students']",['Artificial Intelligence Chatbot'],"['anxiety symptoms', 'depressive symptoms', 'depression and anxiety symptoms']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}]","[{'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",,0.108105,No significant intergroup differences from baseline to week eight between the experimental group and the control group were found for depression and anxiety symptoms.,"[{'ForeName': 'Maria Carolina', 'Initials': 'MC', 'LastName': 'Klos', 'Affiliation': 'Interdisciplinary Center for Research in Health and Behavioral Sciences (CIICSAC), Universidad Adventista del Plata (UAP)., National Scientific and Technical Research Council (CONICET)., Libertador San Martín, Entre Ríos, Argentina.'}, {'ForeName': 'Milagros', 'Initials': 'M', 'LastName': 'Escoredo', 'Affiliation': 'X2AI inc., San Francisco, CA, United States.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Joerin', 'Affiliation': 'X2AI inc., San Francisco, CA, United States.'}, {'ForeName': 'Viviana Noemí', 'Initials': 'VN', 'LastName': 'Lemos', 'Affiliation': 'Interdisciplinary Center for Research in Health and Behavioral Sciences (CIICSAC), Universidad Adventista del Plata (UAP)., National Scientific and Technical Research Council (CONICET)., Libertador San Martín, Entre Ríos, Argentina.'}, {'ForeName': 'Michiel', 'Initials': 'M', 'LastName': 'Rauws', 'Affiliation': 'X2AI inc., San Francisco, CA, United States.'}, {'ForeName': 'Eduardo L', 'Initials': 'EL', 'LastName': 'Bunge', 'Affiliation': 'Department of Psychology, Palo Alto University, Palo Alto, CA, United States.'}]",JMIR formative research,['10.2196/20678'] 3422,34391315,Effects of Pilates training VS. Suspension training on quality of life in women with knee osteoarthritis: A randomized controlled trial.,"INTRODUCTION Osteoarthritis is the most common synovial joint disease and is characterized by progressive destruction of the articular cartilage. This study aimed to compare the effect of Pilates and suspension training in patients with knee Osteoarthritis. METHODS The participants in this randomized trial study were patients with knee Osteoarthritis. In this study, 30 females (61.40 ± 4.85 years) were divided into three groups of suspension training, Pilates, and control group. Participants were randomly assigned to 8-week (3x/week, 1 h/session) Pilates and suspension training program groups. The static and dynamic balance, range of motion, and knee function were respectively measured by The Stork stand balance test, Y balance test, Goniometers, and The WOMAC performance disability questionnaire. To analyze the findings, a dependent sample t-test, covariance test, and Bonferroni's post hoc test were used (P ≤ 0.05). RESULTS Dynamic and static balance in the suspension training and Pilates training caused a significant increase (P ≤ 0.05) compared to the control group. Also, the range of motion and motor performance in the suspension training and Pilates training showed a significant decrease (P ≤ 0.05) compared to the control group. The suspension training compared to the Pilates training was more effective on dynamic and static balance (P ≤ 0.05). Also, the suspension training compared to the Pilates training had more effect on Range of motion and Motor performance (P ≤ 0.05). CONCLUSION It seems that Pilates and suspension training can be used in medical centers as a complementary rehabilitation method among female patients with knee Osteoarthritis to improve the dynamic and static balance, range of motion, and performance.",2021,The suspension training compared to the Pilates training was more effective on dynamic and static balance (P ≤ 0.05).,"['women with knee osteoarthritis', '30 females (61.40\xa0±\xa04.85 years', 'patients with knee Osteoarthritis', 'female patients with knee Osteoarthritis']","['suspension training program groups', 'suspension training, Pilates, and control group', 'Pilates training VS', 'suspension training', 'Suspension training', 'suspension training and Pilates training', 'Pilates and suspension training']","['dynamic and static balance', 'static and dynamic balance, range of motion, and knee function', 'Range of motion and Motor performance', 'Dynamic and static balance', 'range of motion and motor performance', 'quality of life', 'Stork stand balance test, Y balance test, Goniometers, and The WOMAC performance disability questionnaire']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0325459', 'cui_str': 'Stork'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",30.0,0.00625197,The suspension training compared to the Pilates training was more effective on dynamic and static balance (P ≤ 0.05).,"[{'ForeName': 'Nahid', 'Initials': 'N', 'LastName': 'Karimi', 'Affiliation': 'Department of Physical Education and Sport Sciences, Faculty of Sport Sciences, Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, Iran. Electronic address: nahidkarimi4877@gmail.com.'}, {'ForeName': 'Khosro Jalali', 'Initials': 'KJ', 'LastName': 'Dehkordi', 'Affiliation': 'Department of Sport Sciences, Isfahan (Khorasgan) Branch, Isfahan Azad University, Isfahan, Iran. Electronic address: Khosrojalali@gmail.com.'}, {'ForeName': 'Rezvan Mirsafaei', 'Initials': 'RM', 'LastName': 'Rizi', 'Affiliation': 'Department of Sport Sciences, Isfahan (Khorasgan) Branch, Isfahan Azad University, Isfahan, Iran.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.002'] 3423,34391310,Comparative study of combination therapy with non-steroidal anti inflammatory drugs and different doses of low level laser therapy in acute low back pain.,"According to various side effects of medication in low back pain, respecting conservative therapy, owing to the widespread use of laser therapy in recent decades, related therapeutic outcomes were different and contradictory. The current study aimed at comparing the effect of non-steroidal drugs and laser therapy with different doses in patients with acute low back pain. METHODS The current randomized, placebo-controlled study was conducted on 65 patients randomly assigned to four groups. In group 1(N = 20), only drug therapy and in group 2(N = 15), laser therapy (3 J/cm 2 ) in addition to medication was administrated to the patients. For group 3(N = 15), a therapeutic plan similar to that of group 2 was given; however, the laser dose was 6 J/cm 2 . Finally, drug therapy plus placebo laser therapy was applied to group 4(N = 15). Pain was compared among the groups using visual analogue scale and Oswestry low back pain disability questionnaire. RESULTS Significant difference between baseline pain scores and those of the weeks 1, 2, 3, and 4 of laser therapy in all intervention groups. Also, the results of the intergroup analyses showed a significant difference between group 1 compared with groups 2 and 3. There was a significant ODI difference between the groups after laser therapy. CONCLUSION Findings showed that laser therapy plus drug therapy in comparison with drug therapy alone was a more effective method to relieve pain and disability in patient with acute low back pain; however, evidence to support this finding is still inadequate.",2021,"Findings showed that laser therapy plus drug therapy in comparison with drug therapy alone was a more effective method to relieve pain and disability in patient with acute low back pain; however, evidence to support this finding is still inadequate.","['patient with acute low back pain', 'patients with acute low back pain', 'acute low back pain', '65 patients randomly assigned to four groups']","['laser therapy', 'laser therapy plus drug therapy', 'non-steroidal drugs and laser therapy', 'low level laser therapy', 'placebo', 'placebo laser therapy']","['Pain', 'pain and disability', 'ODI difference', 'baseline pain scores', 'visual analogue scale and Oswestry low back pain disability questionnaire']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457950', 'cui_str': 'Acute low back pain'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",65.0,0.0253332,"Findings showed that laser therapy plus drug therapy in comparison with drug therapy alone was a more effective method to relieve pain and disability in patient with acute low back pain; however, evidence to support this finding is still inadequate.","[{'ForeName': 'Hosein Mozhdehi', 'Initials': 'HM', 'LastName': 'Panah', 'Affiliation': 'Neurology, Clinical Research Development Unit, Buali Hospital, Qazvin University of Medical Sciences, Qazvin, Iran.'}, {'ForeName': 'Mahnaz', 'Initials': 'M', 'LastName': 'Abbasi', 'Affiliation': 'Professor of Rheumatology, Metabolic Diseases Research Center, Metabolic Disease Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.'}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Yazdi', 'Affiliation': 'Occupational Medicine, Social Determinant of Health Center, Qazvin University of Medical Sciences, Qazvin, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Hayati', 'Affiliation': 'Tehran University of Medical Sciences, Tehran, Iran. Electronic address: m-hayati@razi.tums.ac.ir.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.05.015'] 3424,34391309,Effect of whole-body vibration on obstacle clearance and stair negotiation time in chronic stroke patients; A randomized controlled trial.,"OBJECTIVE To assess the effect of Whole-Body Vibration (WBV) and Routine Physiotherapy (RP) on obstacle crossing and stair negotiation time in chronic stroke patients. METHODS The current study was randomized, parallel-group, assessor-blinded, clinical trial conducted in Physiotherapy Department of Lahore General Hospital, involving 64 patients with chronic stroke. Patients were randomly allocated to 2 groups, i.e., the WBV group (n = 32) and the RP group (n = 32). The WBV group was given additional twelve sessions of vibration therapy (amplitude of 3 mm and frequency of 20 Hz), 6 days/week for 2 weeks. The outcome measures were change in score of height and depth of obstacles cleared, i.e., 6, 8, 10 & 12 inches height and 6, 8, 10 & 12 inches depth and stair negotiation time, i.e., Stair-Climb Test. Chi square test, Independent sample t-test and Paired sample t-test were used to analyze the data. RESULTS Results show that higher number of patients improved in crossing the maximum height and maximum depth of obstacles in the WBV group but improvement was significant only in height, i.e., (p < 0.05). In the WBV group, Stair Negotiation Time decreased significantly as compared to the RP group, i.e., (p < 0.05). CONCLUSIONS The present study concluded that both study groups, i.e., RP and WBV, improved despite better results for the latter. Speed of stair climbing and capacity to cross obstacles improved with the WBV therapy in chronic stroke survivors. TRIAL REGISTRATION IRCT, IRCT20190328043131N1. Registered 03 august 2019 - Retrospectively registered, https://www.irct.ir/user/trial/38832/view.",2021,"RESULTS Results show that higher number of patients improved in crossing the maximum height and maximum depth of obstacles in the WBV group but improvement was significant only in height, i.e., (p < 0.05).","['chronic stroke patients', 'chronic stroke survivors', 'Registered 03 august 2019 - Retrospectively registered, https://www.irct.ir/user/trial/38832/view', '64 patients with chronic stroke']","['whole-body vibration', 'vibration therapy', 'WBV therapy', 'Whole-Body Vibration (WBV) and Routine Physiotherapy (RP']","['maximum height and maximum depth of obstacles', 'Stair Negotiation Time', 'obstacle clearance and stair negotiation time', 'obstacle crossing and stair negotiation time', 'RP and WBV', 'change in score of height and depth of obstacles cleared, i.e., 6, 8, 10 & 12 inches height and 6, 8, 10 & 12 inches depth and stair negotiation time, i.e., Stair-Climb Test']","[{'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0600375', 'cui_str': 'Registers'}]","[{'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0680727', 'cui_str': 'Mediation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0439204', 'cui_str': 'in - inch'}, {'cui': 'C0432601', 'cui_str': 'Stairs climbed'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",64.0,0.074669,"RESULTS Results show that higher number of patients improved in crossing the maximum height and maximum depth of obstacles in the WBV group but improvement was significant only in height, i.e., (p < 0.05).","[{'ForeName': 'Hafiz Syed Ijaz', 'Initials': 'HSI', 'LastName': 'Ahmed Burq', 'Affiliation': 'University Institute of Physical Therapy, Faculty of Allied Health Sciences, University of Lahore, Lahore, Pakistan. Electronic address: burq802@yahoo.com.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Karimi', 'Affiliation': 'University Institute of Physical Therapy, Faculty of Allied Health Sciences, University of Lahore, Lahore, Pakistan. Electronic address: hossein.karimi@queensu.ca.'}, {'ForeName': 'Ashfaq', 'Initials': 'A', 'LastName': 'Ahmad', 'Affiliation': 'University Institute of Physical Therapy, Faculty of Allied Health Sciences, University of Lahore, Lahore, Pakistan. Electronic address: ashfaq.ahmad@uipt.uol.edu.pk.'}, {'ForeName': 'Syed Amir', 'Initials': 'SA', 'LastName': 'Gilani', 'Affiliation': 'Dean Faculty of Allied Health Sciences, Faculty of Allied Health Sciences, University of Lahore, Lahore, Pakistan. Electronic address: profgilani@gmail.com.'}, {'ForeName': 'Asif', 'Initials': 'A', 'LastName': 'Hanif', 'Affiliation': 'University Institute of Public Health, Faculty of Allied Health Sciences, University of Lahore, Lahore, Pakistan. Electronic address: mebiostatistician@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.05.012'] 3425,34391308,Role of yoga therapy in improving digestive health and quality of sleep in an elderly population: A randomized controlled trial.,"INTRODUCTION Constipation and sleep disturbances commonly affect elderly population results in compromised physical and mental health. Mind-body interventions like yoga not only address the mental and physical health but also promote healthy ageing. This study evaluates the effect of 3 months yoga intervention on the sleep and constipation related quality of life (QoL) among the elderly. MATERIALS AND METHODS Ninety six participants aged between 60 and 75 who did not had any history of yoga practice for past 1 year and having a zubrod score of 0-2 were randomized in to yoga (n = 48) or waitlisted control (n = 48). The yoga group received yoga interventions at a frequency of 3 sessions per week for 3 months. Pittsburg Sleep Quality Index (PSQI) and Patient Assessment of Constipation QoL (PAC-QOL) were used to assess the improvement. Intention to treat analysis method was used to include the drop-out participants. RESULTS Eighty one participants (Yoga = 48, waitlisted control = 33) completed the study. Wilcoxon's sign rank test has shown that the yoga group had statistically significant changes in most of the parameters in PSQI and PAC-QOL (P ≤ 0.05). Mann Whitney test revealed that yoga group has better improvement in the sleep quality and constipation related QOL (P ≤ 0.05) compared to the controls. DISCUSSION The results signify yoga can ease old age related issues like constipation and insomnia. This is encouraging for inclusion of yoga as a daily practice regimen to improve the constipation and sleep related quality of life in elderly population.",2021,"Mann Whitney test revealed that yoga group has better improvement in the sleep quality and constipation related QOL (P ≤ 0.05) compared to the controls. ","['elderly population', 'one participants (Yoga\xa0=\xa048, waitlisted control\xa0=\xa033) completed the study', 'Eighty', 'Ninety six participants aged between 60 and 75 who did not had any history of yoga practice for past 1 year and having a zubrod score of 0-2']","['waitlisted control', 'yoga intervention', 'yoga therapy', 'yoga interventions']","['Pittsburg Sleep Quality Index (PSQI) and Patient Assessment of Constipation QoL (PAC-QOL', 'digestive health and quality of sleep', 'sleep and constipation related quality of life (QoL', 'sleep quality and constipation related QOL', 'PSQI and PAC-QOL']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0012238', 'cui_str': 'Digestive system function'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",96.0,0.0222693,"Mann Whitney test revealed that yoga group has better improvement in the sleep quality and constipation related QOL (P ≤ 0.05) compared to the controls. ","[{'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Shree Ganesh', 'Affiliation': 'Swami Vivekananda Yoga AnusandhanaSamsthana, Bengaluru, India.'}, {'ForeName': 'Pailoor', 'Initials': 'P', 'LastName': 'Subramanya', 'Affiliation': 'Department of Yoga Studies, Central University of Kerala, Kasaragod, Kerala, India. Electronic address: pailoors@cukerala.ac.in.'}, {'ForeName': 'Raghavendra', 'Initials': 'R', 'LastName': 'Rao M', 'Affiliation': 'Central Council for Research in Yoga and Naturopathy, New Delhi, India.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Udupa', 'Affiliation': 'SarvaKshema Hospital and Research Foundation, Saligrama, Udupi, Karnataka, India.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.012'] 3426,34391303,A comparison between whole-body vibration and conventional training on pain and performance in athletes with patellofemoral pain.,"INTRODUCTION Patellofemoral pain (PFP) is the most common cause of anterior knee pain in athletes, which affects their performance especially during single leg activities. The aim of this study was to compare the effects of whole-body vibration training (WBVT) and conventional training (CT) on pain and performance in athletes with PFP. METHODS 30 athletes with unilateral PFP were randomly assigned to the WBVT (6 women, 9 men) or CT (7 women, 8 men) group. All participants received training for 4 weeks in 12 sessions. The outcomes of pain and performance were measured at three points in time: baseline, immediately after training and 2 weeks after training. Pain was assessed with the Numeric Pain Rating Scale (NPRS). Performance was measured with the leg-press test and the Kujala Patellofemoral Score (KPS). RESULTS In both groups, pain intensity decreased significantly (p < 0.001) and the KPS and number of leg presses increased significantly (p < 0.001) with time. There was no significant difference between groups for changes in the pain score (p = 0.896), KPS (p = 0.463) or leg press (p = 0.796) results. CONCLUSION Whole-body vibration training had the same effect as exercise therapy on pain reduction and on improvements in performance in athletes with PFP.",2021,"In both groups, pain intensity decreased significantly (p < 0.001) and the KPS and number of leg presses increased significantly (p < 0.001) with time.","['6 women, 9 men) or CT (7 women, 8 men) group', 'athletes with patellofemoral pain', 'athletes with PFP', '30 athletes with unilateral PFP']","['whole-body vibration training (WBVT) and conventional training (CT', 'WBVT', 'exercise therapy', 'Whole-body vibration training', 'whole-body vibration and conventional training']","['Pain', 'pain intensity', 'pain and performance', 'leg-press test and the Kujala Patellofemoral Score (KPS', 'Numeric Pain Rating Scale (NPRS', 'KPS and number of leg presses', 'pain reduction', 'pain score']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}]","[{'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",30.0,0.020007,"In both groups, pain intensity decreased significantly (p < 0.001) and the KPS and number of leg presses increased significantly (p < 0.001) with time.","[{'ForeName': 'Najmeh', 'Initials': 'N', 'LastName': 'Shadloo', 'Affiliation': 'Physical Therapy Department, School of Rehabilitation Sciences, Shiraz University of Medical Sciences, Shiraz, Iran; Student Research Committee, School of Rehabilitation Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Fahimeh', 'Initials': 'F', 'LastName': 'Kamali', 'Affiliation': 'Physical Therapy Department, School of Rehabilitation Sciences, Shiraz University of Medical Sciences, Shiraz, Iran; Rehabilitation Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: fahimehkamali@hotmail.com.'}, {'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Salehi Dehno', 'Affiliation': 'Physical Therapy Department, School of Rehabilitation Sciences, Shiraz University of Medical Sciences, Shiraz, Iran; Student Research Committee, School of Rehabilitation Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.03.003'] 3427,34096673,"Comparison of the fracture strength of endodontically treated teeth restored with polyether ether ketone, zirconia and glass-fibre post-core systems.","PURPOSE This study aimed to compare the fracture resistance and fracture mode of maxillary central incisors restored with four different sizes and three different post-core systems. MATERIALS AND METHODS One hundred and twenty maxillary incisors were endodontically treated and randomly divided into three groups (12 subgroups). Post cavities for the narrow subgroups were prepared with 1.4-mm-diameter drills in lengths of 7.5 mm (SN) and 10 mm (LN). Post cavities for the wide subgroups were prepared with 1.6-mm-diameter drills in lengths of 7.5 mm (SW) and 10 mm (LW) (n = 10). Group F was restored with glass-fibre post and composite resin core, Group P was restored with custom PEEK post-core and Group Z was restored with custom zirconia post-core. All posts were cemented with a dual-cure resin cement. Zirconia copings were cemented. Specimens were loaded on the palatal surface with a universal testing machine, and the fracture strengths of the teeth were statistically analysed using ANOVA and post hoc Tukey tests. RESULTS Statistically significant differences existed between the fracture strengths of the post materials. The highest fracture strength was in Group F, and the lowest was in Group P. Evaluation of the fracture strengths of the post lengths and diameters demonstrated that the short-narrow group of Group Z had the lowest fracture strength (P < .05). The long-wide group of Group F showed the highest fracture resistance. In Group P, no statistically significant difference existed between the post-cores of different dimensions (P > .05). Irreparable fractures were observed mostly in Group Z, and decementation was more common in Group P. CONCLUSIONS PEEK post-cores showed sufficient fracture strength for the anterior region, similar to the other two post-core materials. PEEK post-cores showed more decementation and repairable fractures at lower forces, while restoration failure was mostly catastrophic for glass-fibre and zirconia posts.",2021,"In Group P, no statistically significant difference existed between the post-cores of different dimensions (p > 0.05).",['One hundred and twenty maxillary incisors'],"['polyether ether ketone, zirconia and glass-fiber post-core systems']","['lowest fracture strength', 'fracture strengths', 'fracture strength', 'highest fracture resistance', 'highest fracture strength', 'fracture resistance and fracture mode of maxillary central incisors']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}]","[{'cui': 'C0014994', 'cui_str': 'ethyl ether'}, {'cui': 'C0022634', 'cui_str': 'Ketone'}, {'cui': 'C0078814', 'cui_str': 'zirconium oxide'}, {'cui': 'C0060317', 'cui_str': 'Fiberglass'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4704755', 'cui_str': 'Fracture Strength'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}]",120.0,0.0209193,"In Group P, no statistically significant difference existed between the post-cores of different dimensions (p > 0.05).","[{'ForeName': 'Merve', 'Initials': 'M', 'LastName': 'Özarslan', 'Affiliation': 'Department of Prosthetic Dentistry, Faculty of Dentistry, Akdeniz University, Antalya, Turkey.'}, {'ForeName': 'Ulviye Şebnem', 'Initials': 'UŞ', 'LastName': 'Büyükkaplan', 'Affiliation': 'Department of Prosthetic Dentistry, Faculty of Dentistry, Akdeniz University, Antalya, Turkey.'}, {'ForeName': 'Mehmet Mustafa', 'Initials': 'MM', 'LastName': 'Özarslan', 'Affiliation': 'Department of Prosthetic Dentistry, Faculty of Dentistry, Akdeniz University, Antalya, Turkey.'}]",International journal of clinical practice,['10.1111/ijcp.14440'] 3428,34098033,"CPR compression strategy 30:2 is difficult to adhere to, but has better survival than continuous chest compressions when done correctly.","BACKGROUND A large, randomized trial showed no significant difference in survival to discharge between cardiopulmonary resuscitation (CPR) strategies of 30 compressions with pause for 2 ventilations per cycle (30:2) and continuous chest compression with asynchronous ventilations (CCC). Data from the same trial suggested that adherence to the intended CPR strategy was associated with significantly greater survival. We sought to determine the adherence rate with intended strategy and then explore the association of adherence with survival to discharge in the Resuscitation Outcomes Consortium (ROC). METHODS This secondary analysis of data from the ROC included three interventional trials and a prospective registry. We modified an automated software algorithm that classified care as 30:2 or CCC before intubation based on compression segment length (defined as the elapsed time from start of compressions to subsequent pause of ≥2 s), number of pauses per minute ≥2 s in length and chest compression fraction. Intended CPR strategy for individual agencies was based on study randomization (during trial phase) or local standard of care (during registry phase). We defined CPR delivered as adherent when its classification matched the intended strategy. We characterized adherence with intended strategy across trial and registry periods. We examined its association with survival to hospital discharge using multivariate logistic regression after adjustment for Utstein and other potential confounders. Effect modification with intended strategy was assessed through a multiplicative interaction term. RESULTS Included were 26,810 adults with out of hospital cardiac arrest, of which 10,942 had an intended strategy of 30:2 and 15,868 an intended strategy of CCC. The automated algorithm classified 12,276 cases as CCC, 7037 as 30:2 and left 7497 as unclassified. Adherence to intended strategy was 54.4%; this differed by intended strategy (58.6% for CCC vs 48.3% for 30:2). Overall adherence was less during the registry phase as compared to during the trial phase(s). The association between adherence and survival was modified by treatment arm (CCC OR: 0.72, 95% CI: 0.64-0.81 vs 30:2 OR: 1.05, 95% CI: 0.90-1.22; interaction p-value<0.01) after adjustment for known confounders. CONCLUSION For intended strategy CCC, survival was significantly lower, OR (95%CI) = 0.72 (0.64, 0.81), when adhered to while for intended strategy 30:2, survival was higher, OR (95%CI) = 1.05 (0.90, 1.22), when adhered to. Intended strategy of 30:2 had lower adherence rates than CCC possibly a result of being a more difficult strategy to administer.",2021,Adherence to intended strategy was 54.4%; this differed by intended strategy (58.6% for CCC vs 48.3% for 30:2).,"['26,810 adults with out of hospital cardiac arrest, of which 10,942 had an intended strategy of 30:2 and 15,868 an intended strategy of CCC']","['continuous chest compression with asynchronous ventilations (CCC', 'CCC', 'For intended strategy CCC']","['adherence rate', 'Overall adherence', 'adherence rates', 'survival', 'adherence and survival']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2936490', 'cui_str': 'Out-of-Hospital Heart Arrest'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0439581', 'cui_str': 'Asynchronous'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0439581', 'cui_str': 'Asynchronous'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",26810.0,0.0850772,Adherence to intended strategy was 54.4%; this differed by intended strategy (58.6% for CCC vs 48.3% for 30:2).,"[{'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Schmicker', 'Affiliation': 'Center for Biomedical Statistics, University of Washington, Seattle, WA United States. Electronic address: rschmick@uw.edu.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Nichol', 'Affiliation': 'University of Washington-Harborview Center for Prehospital Emergency Care, Seattle, WA United States.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kudenchuk', 'Affiliation': 'Department of Medicine, Division of Cardiology, University of Washington, Seattle, WA, United States; King County Emergency Medical Services, Public Health, Seattle & King County, WA, United States.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Christenson', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Canada; Center for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, British Columbia, Canada.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Vaillancourt', 'Affiliation': 'Department of Emergency Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Henry E', 'Initials': 'HE', 'LastName': 'Wang', 'Affiliation': 'Department of Emergency Medicine, The Ohio State University, Columbus, OH, United States.'}, {'ForeName': 'Tom P', 'Initials': 'TP', 'LastName': 'Aufderheide', 'Affiliation': 'Department of Emergency Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.'}, {'ForeName': 'Ahamed H', 'Initials': 'AH', 'LastName': 'Idris', 'Affiliation': 'Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, TX United States.'}, {'ForeName': 'Mohamud R', 'Initials': 'MR', 'LastName': 'Daya', 'Affiliation': 'Department of Emergency Medicine, Oregon Health & Science University, Portland, OR United States.'}]",Resuscitation,['10.1016/j.resuscitation.2021.05.027'] 3429,34102075,"Arthroscopic Versus Open Anterior Shoulder Stabilization: A Prospective Randomized Clinical Trial With 15-Year Follow-up With an Assessment of the Glenoid Being ""On-Track"" and ""Off-Track"" as a Predictor of Failure.","BACKGROUND Recent studies have demonstrated equivalent short-term results when comparing arthroscopic versus open anterior shoulder stabilization. However, none have evaluated the long-term clinical outcomes of patients after arthroscopic or open anterior shoulder stabilization, with inclusion of an assessment of preoperative glenoid tracking. PURPOSE To compare long-term clinical outcomes of patients with recurrent anterior shoulder instability randomized to open and arthroscopic stabilization groups. Additionally, preoperative magnetic resonance imaging (MRI) studies were used to assess whether the shoulders were ""on-track"" or ""off-track"" to ascertain a prediction of increased failure risk. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS A consecutive series of 64 patients with recurrent anterior shoulder instability were randomized to receive either arthroscopic or open stabilization by a single surgeon. Follow-up assessments were performed at minimum 15-year follow-up using established postoperative evaluations. Clinical failure was defined as any recurrent dislocation postoperatively or subjective instability. Preoperative MRI scans were obtained to calculate the glenoid track and designate shoulders as on-track or off-track. These results were then correlated with the patients' clinical results at their latest follow-up. RESULTS Of 64 patients, 60 (28 arthroscopic and 32 open) were contacted or examined for follow-up (range, 15-17 years). The mean age at the time of surgery was 25 years (range, 19-42 years), while the mean age at the time of this assessment was 40 years (range, 34-57 years). The rates of arthroscopic and open long-term failure were 14.3% (4/28) and 12.5% (4/32), respectively. There were no differences in subjective shoulder outcome scores between the treatment groups. Of the 56 shoulders, with available MRI studies, 8 (14.3%) were determined to be off-track. Of these 8 shoulders, there were 2 surgical failures (25.0%; 1 treated arthroscopically, 1 treated open). In the on-track group, 6 of 48 had failed surgery (12.5%; 3 open, 3 arthroscopic [ P = .280]). CONCLUSION Long-term clinical outcomes were comparable at 15 years postoperatively between the arthroscopic and open stabilization groups. The presence of an off-track lesion may be associated with a higher rate of recurrent instability in both cohorts at long-term follow-up; however, this study was underpowered to verify this situation.",2021,"The rates of arthroscopic and open long-term failure were 14.3% (4/28) and 12.5% (4/32), respectively.","['64 patients, 60 (28 arthroscopic and 32 open', 'The mean age at the time of surgery was 25 years (range, 19-42 years), while the mean age at the time of this assessment was 40 years (range, 34-57 years', '64 patients with recurrent anterior shoulder instability', 'patients with recurrent anterior shoulder instability randomized to open and arthroscopic stabilization groups']","['arthroscopic or open stabilization by a single surgeon', 'Arthroscopic Versus Open Anterior Shoulder Stabilization', 'preoperative magnetic resonance imaging (MRI']","['subjective shoulder outcome scores', 'rates of arthroscopic and open long-term failure', 'Preoperative MRI scans', 'surgical failures']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0575624', 'cui_str': 'Shoulder joint unstable'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1868733', 'cui_str': 'Surgical failure'}]",64.0,0.0294611,"The rates of arthroscopic and open long-term failure were 14.3% (4/28) and 12.5% (4/32), respectively.","[{'ForeName': 'Craig R', 'Initials': 'CR', 'LastName': 'Bottoni', 'Affiliation': 'Department of Orthopaedic Surgery, Tripler Army Medical Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Johnson', 'Affiliation': 'Department of Orthopaedic Surgery, Tripler Army Medical Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Zhou', 'Affiliation': 'Department of Orthopaedic Surgery, Tripler Army Medical Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'Sarah G', 'Initials': 'SG', 'LastName': 'Raybin', 'Affiliation': 'Department of Orthopaedic Surgery, Tripler Army Medical Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Shaha', 'Affiliation': 'Department of Orthopaedic Surgery, Tripler Army Medical Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'Christian A', 'Initials': 'CA', 'LastName': 'Cruz', 'Affiliation': 'Department of Orthopaedic Surgery, Tripler Army Medical Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'Kenneth K', 'Initials': 'KK', 'LastName': 'Lindell', 'Affiliation': 'Department of Orthopaedic Surgery, Tripler Army Medical Center, Honolulu, Hawaii, USA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Thoma', 'Affiliation': 'Department of Orthopaedic Surgery, Tripler Army Medical Center, Honolulu, Hawaii, USA.'}]",The American journal of sports medicine,['10.1177/03635465211018212'] 3430,34102253,"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.","BACKGROUND Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). Here we present a new landmark in survival follow-up for a phase III cyclin-dependent kinases 4 and 6 inhibitor clinical trial in patients with ABC (median, 56.3 months). PATIENTS AND METHODS This phase III, randomized, double-blind, placebo-controlled trial was conducted at 174 sites (30 countries). Patients were men and postmenopausal women (age ≥18 years) with histologically/cytologically confirmed HR+/HER2- ABC. Patients could have received ≤1 line of endocrine therapy (ET) but no chemotherapy for ABC. Patients, assigned 2:1, were stratified by the presence/absence of liver/lung metastases and previous ET. Patients received intramuscular fulvestrant (500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1) with oral ribociclib (600 mg/day, 3 weeks on, 1 week off) or placebo. Efficacy analyses were by intention to treat. Safety was assessed in patients receiving ≥1 dose study treatment. OS was a secondary endpoint. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615; no longer enrolling). RESULTS Between 18 June 2015 and 10 June 2016, 726 patients were randomly assigned (484, ribociclib; 242, placebo). At data cut-off (30 October 2020), median OS (mOS) was 53.7 months (ribociclib) versus 41.5 months (placebo) [hazard ratio (HR), 0.73; 95% confidence interval (CI) 0.59-0.90]. Subgroup analyses were consistent with overall population. In the first-line setting, most patients in the ribociclib arm (∼60%) lived longer than median follow-up; mOS was 51.8 months in the placebo arm (HR, 0.64; 95% CI 0.46-0.88). In the second-line setting, mOS was 39.7 months (ribociclib) versus 33.7 months (placebo) (HR, 0.78; 95% CI 0.59-1.04). No apparent drug-drug interaction between ribociclib and fulvestrant or new safety signals were observed. CONCLUSIONS This analysis reported extended OS follow-up in MONALEESA-3. mOS was ∼12 months longer in patients with HR+/HER2- ABC treated with ribociclib plus fulvestrant compared with fulvestrant monotherapy.",2021,"No apparent drug-drug interaction between ribociclib and fulvestrant or new safety signals were observed. ","['patients with ABC (median [m], 56.3 months', '726 patients were randomly assigned (484, ribociclib; 242', 'postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer', '174 sites (30 countries', 'Between June 18, 2015 and June 10, 2016', 'Patients were me and postmenopausal women (age ≥18 years) with histologically/cytologically confirmed HR+/HER2- ABC', 'patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC']","['oral ribociclib', 'ribociclib plus fulvestrant', 'Ribociclib plus fulvestrant', 'fulvestrant monotherapy', 'intramuscular fulvestrant', 'placebo', '≤1-line endocrine therapy (ET']","['Safety', 'progression-free survival (PFS) and overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C4045494', 'cui_str': 'ribociclib'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4045494', 'cui_str': 'ribociclib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",726.0,0.655658,"No apparent drug-drug interaction between ribociclib and fulvestrant or new safety signals were observed. ","[{'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Slamon', 'Affiliation': 'David Geffen School of Medicine at UCLA, Los Angeles, USA. Electronic address: dslamon@mednet.ucla.edu.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Neven', 'Affiliation': 'Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chia', 'Affiliation': 'British Columbia Cancer Agency, Vancouver, Canada.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Jerusalem', 'Affiliation': 'CHU Liege and Liège University, Liège, Belgium.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'De Laurentiis', 'Affiliation': ""Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Im', 'Affiliation': 'Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Petrakova', 'Affiliation': 'Masaryk Memorial Cancer Institute, Brno, Czech Republic.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Valeria Bianchi', 'Affiliation': 'Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Martín', 'Affiliation': 'Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Nusch', 'Affiliation': 'Practice for Hematology and Internal Oncology, Velbert, Germany.'}, {'ForeName': 'G S', 'Initials': 'GS', 'LastName': 'Sonke', 'Affiliation': 'Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'De la Cruz-Merino', 'Affiliation': 'Hospital Universitario Virgen Macarena, Seville, Spain.'}, {'ForeName': 'J T', 'Initials': 'JT', 'LastName': 'Beck', 'Affiliation': 'Highlands Oncology Group, Fayetteville, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Ji', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Deore', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Chakravartty', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, USA.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Zarate', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Taran', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'Fasching', 'Affiliation': 'Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Erlangen, Germany.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2021.05.353'] 3431,34098301,"Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.","AIM This report examined naturalistic opioid use outcomes and utilization of medications for opioid use disorder (MOUD) 36 weeks post-randomization in the National Drug Abuse Treatment Clinical Trials Network (CTN) Extended-Release Naltrexone (XR-NTX) versus Buprenorphine-Naloxone (BUP-NX) for Opioid Treatment trial (CTN-0051, X:BOT). DESIGN X:BOT was a multisite, randomized, 24-week comparative effectiveness trial of BUP-NX (N = 287) and XR-NTX (N = 283). Study medications were discontinued following treatment completion, relapse, or dropout. Participants were encouraged to continue MOUD. This report examined opioid use outcomes in 428 (75%) of the 570 participants who attended the 36-week follow-up visit. SETTING AND PARTICIPANTS Adults with opioid use disorder recruited from 8 community treatment programs across the United States. MEASUREMENTS Outcomes included medication status (on/off MOUD), type of MOUD (BUP-NX, XR-NTX, or methadone), abstinence from non-prescribed opioids, opioid use days, relapse, and other substance use 30 days prior to the 36-week visit. Relapse was defined as opioid use for 4 consecutive weeks or 7 consecutive days in the past month. Baseline and clinical variables included opioid use severity, intravenous drug use, study medication assignment, and induction status. FINDINGS Of the 428 participants who completed the 36-week visit, 225 (53%) of participants were receiving MOUD and 203 (47%) were not. Compared to those off medication, participants on medication had fewer opioid use days (4.4 days (SD 9.0) versus 9.8 days (SD 12.1)), fewer met relapse criteria (37 (16.4%) versus 79 (38.9%)), and reported less stimulant use (34 (15.2%) versus 56 (27.7%)) and sedative use (14 (6.3%) versus 31 (15.3%)). There was no difference in abstinence rates between those on or off MOUD. A greater proportion of participants on XR-NTX (47 (53.4%) of 88 participants) were abstinent from non-prescribed opioids compared to those on buprenorphine (28 (23.3%) of 120 participants). CONCLUSIONS Naturalistic outcomes data showed that despite potential barriers to continuing treatment in the community, about half of individuals were on opioid use disorder pharmacotherapy at follow-up and those on medication generally had better outcomes. Future research should explore barriers and facilitators to treatment retention in community settings; and developing interventions tailored to improve treatment engagement and adherence.",2021,"Compared to those off medication, participants on medication had fewer opioid use days (4.4 days (SD 9.0) versus 9.8 days (SD 12.1)), fewer met relapse criteria (37 (16.4%) versus 79 (38.9%)), and reported less stimulant use (34 (15.2%) versus 56 (27.7%)) and sedative use (14 (6.3%) versus 31 (15.3%)).","['Adults with opioid use disorder recruited from 8 community treatment programs across the United States', '428 (75%) of the 570 participants who attended the 36-week follow-up visit', '428 participants who completed the 36-week visit, 225 (53%) of participants were receiving MOUD and 203 (47%) were not']","['Naltrexone (XR-NTX) versus Buprenorphine-Naloxone (BUP-NX', 'buprenorphine', 'BUP-NX']","['Relapse', 'met relapse criteria', 'abstinence rates', 'opioid use disorder (MOUD', 'sedative use', 'opioid use severity, intravenous drug use, study medication assignment, and induction status', 'medication status (on/off MOUD), type of MOUD (BUP-NX, XR-NTX, or methadone), abstinence from non-prescribed opioids, opioid use days, relapse, and other substance use 30\xa0days prior to the 36-week visit']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C4517775', 'cui_str': '428'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0589121', 'cui_str': 'Follow-up visit'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4517652', 'cui_str': '225'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C1169989', 'cui_str': 'Buprenorphine- and naloxone-containing product'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0020592', 'cui_str': 'HYPNOTICS AND SEDATIVES'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0242566', 'cui_str': 'Intravenous drug user'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1169989', 'cui_str': 'Buprenorphine- and naloxone-containing product'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0439230', 'cui_str': 'week'}]",570.0,0.162223,"Compared to those off medication, participants on medication had fewer opioid use days (4.4 days (SD 9.0) versus 9.8 days (SD 12.1)), fewer met relapse criteria (37 (16.4%) versus 79 (38.9%)), and reported less stimulant use (34 (15.2%) versus 56 (27.7%)) and sedative use (14 (6.3%) versus 31 (15.3%)).","[{'ForeName': 'Miranda G', 'Initials': 'MG', 'LastName': 'Greiner', 'Affiliation': 'New York State Psychiatric Institute and Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: miranda.greiner@nyspi.columbia.edu.'}, {'ForeName': 'Matisyahu', 'Initials': 'M', 'LastName': 'Shulman', 'Affiliation': 'New York State Psychiatric Institute and Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: matisyahu.shulman@nyspi.columbia.edu.'}, {'ForeName': 'Tse-Hwei', 'Initials': 'TH', 'LastName': 'Choo', 'Affiliation': 'New York State Psychiatric Institute and Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: tse.hwei@nyspi.columbia.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Scodes', 'Affiliation': 'New York State Psychiatric Institute and Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: jennifer.scodes@nyspi.columbia.edu.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Pavlicova', 'Affiliation': 'Columbia University Mailman School of Public Health, 722 West 168th Street, New York, NY 10032, United States of America. Electronic address: mp2370@columbia.edu.'}, {'ForeName': 'Aimee N C', 'Initials': 'ANC', 'LastName': 'Campbell', 'Affiliation': 'New York State Psychiatric Institute and Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: anc2002@cumc.columbia.edu.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Novo', 'Affiliation': 'New York University Grossman School of Medicine, 550 First Avenue, New York, NY 10016, United States of America. Electronic address: patricia.novo@nyulangone.org.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Fishman', 'Affiliation': 'Johns Hopkins University School of Medicine and Maryland Treatment Centers, 3800 Frederick Ave, Baltimore, MD 21229, United States of America.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Lee', 'Affiliation': 'New York University Grossman School of Medicine, 550 First Avenue, New York, NY 10016, United States of America. Electronic address: joshua.lee@nyulangone.org.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rotrosen', 'Affiliation': 'New York University Grossman School of Medicine, 550 First Avenue, New York, NY 10016, United States of America. Electronic address: john.rotrosen@nyulangone.org.'}, {'ForeName': 'Edward V', 'Initials': 'EV', 'LastName': 'Nunes', 'Affiliation': 'New York State Psychiatric Institute and Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: edward.nunes@nyspi.columbia.edu.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2021.108447'] 3432,34102017,Severe loss of mechanical efficiency in COVID-19 patients.,"BACKGROUND There is limited information about the impact of coronavirus disease (COVID-19) on the muscular dysfunction, despite the generalized weakness and fatigue that patients report after overcoming the acute phase of the infection. This study aimed to detect impaired muscle efficiency by evaluating delta efficiency (DE) in patients with COVID-19 compared with subjects with chronic obstructive pulmonary disease (COPD), ischaemic heart disease (IHD), and control group (CG). METHODS A total of 60 participants were assigned to four experimental groups: COVID-19, COPD, IHD, and CG (n = 15 each group). Incremental exercise tests in a cycle ergometer were performed to obtain peak oxygen uptake (VO 2 peak). DE was obtained from the end of the first workload to the power output where the respiratory exchange ratio was 1. RESULTS A lower DE was detected in patients with COVID-19 and COPD compared with those in CG (P ≤ 0.033). However, no significant differences were observed among the experimental groups with diseases (P > 0.05). Lower VO 2 peak, peak ventilation, peak power output, and total exercise time were observed in the groups with diseases than in the CG (P < 0.05). A higher VO 2 , ventilation, and power output were detected in the CG compared with those in the groups with diseases at the first and second ventilatory threshold (P < 0.05). A higher power output was detected in the IHD group compared with those in the COVID-19 and COPD groups (P < 0.05) at the first and second ventilatory thresholds and when the respiratory exchange ratio was 1. A significant correlation (P < 0.001) was found between the VO 2 peak and DE and between the peak power output and DE (P < 0.001). CONCLUSIONS Patients with COVID-19 showed marked mechanical inefficiency similar to that observed in COPD and IHD patients. Patients with COVID-19 and COPD showed a significant decrease in power output compared to IHD during pedalling despite having similar response in VO 2 at each intensity. Resistance training should be considered during the early phase of rehabilitation.",2021,"Lower VO 2 peak, peak ventilation, peak power output, and total exercise time were observed in the groups with diseases than in the CG (P ","['A total of 60 participants', 'patients with COVID-19 compared with subjects with chronic obstructive pulmonary disease (COPD), ischaemic heart disease (IHD), and control group (CG', 'COVID-19 patients']","['COVID-19, COPD, IHD, and CG', 'Resistance training']","['Severe loss of mechanical efficiency', 'power output', 'Lower VO 2 peak, peak ventilation, peak power output, and total exercise time', 'peak oxygen uptake', 'VO 2 , ventilation, and power output', 'marked mechanical inefficiency', 'peak power output and DE']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0429931', 'cui_str': 'Total exercise time'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0231184', 'cui_str': 'Inefficiency'}, {'cui': 'C0439097', 'cui_str': 'Delta'}]",60.0,0.0607746,"Lower VO 2 peak, peak ventilation, peak power output, and total exercise time were observed in the groups with diseases than in the CG (P ","[{'ForeName': 'Eulogio', 'Initials': 'E', 'LastName': 'Pleguezuelos', 'Affiliation': 'Physical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Del Carmen', 'Affiliation': 'Physical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Llorensi', 'Affiliation': 'Physical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Carcole', 'Affiliation': 'Physical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Casarramona', 'Affiliation': 'Physical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Moreno', 'Affiliation': ""Physical Medicine and Rehabilitation Department, Hospitalet General Hospital, L'Hospitalet de Llobregat, Spain.""}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Ortega', 'Affiliation': 'Pneumology Department, Hospital de Mataró, Mataró, Spain.'}, {'ForeName': 'Mateo', 'Initials': 'M', 'LastName': 'Serra-Prat', 'Affiliation': 'Research Unit, Consorci Sanitari del Maresme, Mataró, Spain.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'Palomera', 'Affiliation': 'Research Unit, Consorci Sanitari del Maresme, Mataró, Spain.'}, {'ForeName': 'Marc M', 'Initials': 'MM', 'LastName': 'Miravitlles', 'Affiliation': ""Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.""}, {'ForeName': 'Joan Carles', 'Initials': 'JC', 'LastName': 'Yebenes', 'Affiliation': 'Critical Care Department, Hospital de Mataró, Mataró, Spain.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Boixeda', 'Affiliation': 'Department of Internal Medicine, Hospital de Mataró, CSDM, Mataró, Spain.'}, {'ForeName': 'Lluis', 'Initials': 'L', 'LastName': 'Campins', 'Affiliation': 'Department of Pharmacy, Hospital de Mataró, CSdM, Mataró, Spain.'}, {'ForeName': 'Koldo', 'Initials': 'K', 'LastName': 'Villelabeitia-Jaureguizar', 'Affiliation': 'Physical Medicine and Rehabilitation Department, Infanta Elena University Hospital, Valdemoro, Spain.'}, {'ForeName': 'Manuel Vicente', 'Initials': 'MV', 'LastName': 'Garnacho-Castaño', 'Affiliation': 'GRI-AFIRS, School of Health Sciences, TecnoCampus, Universitat Pompeu Fabra, Mataró, Spain.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12739'] 3433,34105866,"The efficacy of alpha-lipoic acid in improving oxidative, inflammatory, and mood status in women with episodic migraine in a randomised, double-blind, placebo-controlled clinical trial.","AIM Migraine is a common neurovascular disorder, which is associated with severe to moderate disabling headaches. Oxidative stress and inflammation might play a role in migraine pathogenesis and the mood disorders. Considering the antioxidant and anti-inflammatory properties of alpha-lipoic acid (ALA), this study was designed to investigate its effect on oxidative, inflammatory, and mood conditions in women with episodic migraine. METHODS In total, 92 women with episodic migraine participated in the study. The patients were randomly divided into two groups, receiving a 300-mg capsule of ALA or placebo twice daily for 3 months. To assess the oxidative and inflammatory status, the serum levels of total antioxidant capacity (TAC), total oxidant status (TOS), glutathione (GSH), malondialdehyde (MDA), oxidative stress index (OSI), and C-reactive protein (CRP) were determined at the beginning and at the end of the intervention. A depression, anxiety, stress scale (DASS-21-items) questionnaire was used to evaluate mood status. RESULTS Finally, 79 patients reached the final analysis stage. At the end of the intervention, a significant decrease in the serum levels of MDA (means difference [MD]: -0.83, 95% confidence intervals (CI): -1.04, -0.62 nmol/mL vs MD: -0.32, CI: -0.48, -0.15 nmol/mL; P < .001) and CRP (MD: -0.78, CI: -1.17, -0.39 mg/L vs MD: -0.63, CI: -1.80, 0.52 mg/L; P < .001) was observed in the ALA as compared with the placebo group, but changes in serum GSH (P = .086), TAC (P = .068), TOS (P = .225), and OSI (P = .404) were not statistically significant. In addition, depression, anxiety, and stress (with P < .001, in all cases) had significantly decreased in the intervention as compared with the control group. CONCLUSION The results of this study suggest that ALA supplementation for 3 months has beneficial effects on improving the oxidative, inflammatory, and mood conditions of patients suffering from episodic migraine.",2021,"But changes in serum GSH (P=0.086), TAC (P=0.068), TOS (P=0.225), and OSI (P=0.404) were not statistically significant.","['79 patients reached the final analysis stage', 'patients suffering from episodic migraine', 'women with episodic migraine', 'In total 92 women with episodic migraine participated in the study']","['alpha-lipoic acid (ALA', 'receiving a 300 mg capsule of ALA or placebo', 'Alpha-Lipoic Acid', 'ALA supplementation', 'placebo']","['TOS', 'oxidative, inflammatory and mood conditions', 'OSI', 'serum GSH', 'CRP', 'depression, anxiety, and stress', 'oxidative, inflammatory and mood status', 'oxidative and inflammatory status, the serum levels of total antioxidant capacity (TAC), total oxidant status (TOS), glutathione (GSH), malondialdehyde (MDA), oxidative stress index (OSI) and C - reactive protein (CRP', 'A depression, anxiety, stress scale (DASS-21-items) questionnaire', 'serum levels of MDA (means difference (MD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0023791', 'cui_str': 'thioctic acid'}, {'cui': 'C0100700', 'cui_str': 'A 300'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0085403', 'cui_str': 'Oxidizing Agents'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1832594', 'cui_str': 'Verloes Bourguignon syndrome'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",92.0,0.258854,"But changes in serum GSH (P=0.086), TAC (P=0.068), TOS (P=0.225), and OSI (P=0.404) were not statistically significant.","[{'ForeName': 'Mahnaz', 'Initials': 'M', 'LastName': 'Rezaei Kelishadi', 'Affiliation': 'Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Amirmansour', 'Initials': 'A', 'LastName': 'Alavi Naeini', 'Affiliation': 'Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Gholamreza', 'Initials': 'G', 'LastName': 'Askari', 'Affiliation': 'Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Fariborz', 'Initials': 'F', 'LastName': 'Khorvash', 'Affiliation': 'Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Heidari', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",International journal of clinical practice,['10.1111/ijcp.14455'] 3434,34102418,Paired inhibitory stimulation and gait training modulates supplemental motor area connectivity in freezing of gait.,"INTRODUCTION Freezing of gait (FOG) is a debilitating feature of Parkinson's disease (PD). Evidence suggests patients with FOG have increased cortical control of gait. The supplementary motor area (SMA) may be a key structure due to its connectivity with locomotor and cognitive networks. The objectives of this study were to determine (1) if SMA connectivity is disrupted in patients with FOG and (2) if ""inhibitory"" repetitive transcranial magnetic stimulation can decrease maladaptive SMA connectivity. METHODS Two experiments were performed. In experiment 1 resting-state (T2* BOLD imaging) was compared between 38 PD freezers and 17 PD controls. In experiment 2, twenty PD patients with FOG were randomized to either 10 sessions of real or sham rTMS to the SMA (1 Hz, 110% motor threshold, 1200 pulses/session) combined with daily gait training. RESULTS (Experiment 1) Freezers had increased connectivity between the left SMA and the vermis of the cerebellum and decreased connectivity between the SMA and the orbitofrontal cortex (p FDR-corr <0.05). (Experiment 2) 10 sessions of active TMS reduced SMA connectivity with the anterior cingulate, angular gyrus and the medial temporal cortex, whereas sham TMS did not reduce SMA connectivity. From a behavioral perspective, both groups showed nFOG-Q improvements (F(4, 25.7) = 3.87, p = 0.014). CONCLUSIONS The SMA in freezers is hyper-connected to the cerebellum, a key locomotor region which may represent maladaptive compensation. In this preliminary study, 1 Hz rTMS reduced SMA connectivity however, this was not specific to the locomotor regions. Intervention outcomes may be improved with subject specific targeting of SMA.",2021,"(Experiment 2) 10 sessions of active TMS reduced SMA connectivity with the anterior cingulate, angular gyrus and the medial temporal cortex, whereas sham TMS did not reduce SMA connectivity.","['twenty PD patients with FOG', 'freezing of gait', 'patients with FOG and (2) if']","['10 sessions of real or sham rTMS to the SMA (1\xa0Hz, 110% motor threshold, 1200 pulses/session) combined with daily gait training', 'Freezing of gait (FOG', 'Paired inhibitory stimulation and gait training', 'inhibitory"" repetitive transcranial magnetic stimulation']","['nFOG-Q improvements', 'SMA connectivity', 'subject specific targeting of SMA', 'cortical control of gait']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0016928', 'cui_str': 'Gait'}]","[{'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C3496174', 'cui_str': 'Supplementary Motor Area'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C4517548', 'cui_str': '1200'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C3496174', 'cui_str': 'Supplementary Motor Area'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0016928', 'cui_str': 'Gait'}]",2.0,0.041826,"(Experiment 2) 10 sessions of active TMS reduced SMA connectivity with the anterior cingulate, angular gyrus and the medial temporal cortex, whereas sham TMS did not reduce SMA connectivity.","[{'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Lench', 'Affiliation': 'Department of Neurology, Medical University of South Carlina, Charleston, SC, USA.'}, {'ForeName': 'Will', 'Initials': 'W', 'LastName': 'DeVries', 'Affiliation': 'Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Tonisha E', 'Initials': 'TE', 'LastName': 'Kearney-Ramos', 'Affiliation': 'Division on Substance Use Disorders, Columbia University Irving Medical Center, New York, NY, USA.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Chesnutt', 'Affiliation': 'Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Monsch', 'Affiliation': 'Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Aaron E', 'Initials': 'AE', 'LastName': 'Embry', 'Affiliation': 'Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Jade D', 'Initials': 'JD', 'LastName': 'Doolittle', 'Affiliation': 'Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Kautz', 'Affiliation': 'Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.'}, {'ForeName': 'Colleen A', 'Initials': 'CA', 'LastName': 'Hanlon', 'Affiliation': 'Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Gonzalo J', 'Initials': 'GJ', 'LastName': 'Revuelta', 'Affiliation': 'Department of Neurology, Medical University of South Carlina, Charleston, SC, USA. Electronic address: revuelta@musc.edu.'}]",Parkinsonism & related disorders,['10.1016/j.parkreldis.2021.05.028'] 3435,34105256,Four weeks of electromyostimulation improves muscle function and strength in sarcopenic patients: a three-arm parallel randomized trial.,"BACKGROUND Sarcopenia, defined as loss of muscle mass, quality, and function, is associated with reduced quality of life and adverse health outcomes including disability and mortality. Electromyostimulation (EMS) has been suggested to attenuate the loss of muscle mass and function in elderly, sedentary individuals. This study aimed to investigate the effects of EMS on muscle strength and function during 4 weeks of inpatient medical rehabilitation. METHODS Patients receiving 4 weeks of inpatient medical rehabilitation diagnosed with sarcopenia using bioimpedance analysis were eligible to participate. One hundred and thirty-four patients (55.7 ± 7.9 years, 25.4% female) were randomly assigned to three groups: whole-body (WB) EMS (n = 48): stimulation of major muscle groups (pectoral muscles, latissimus, trapezius, abdominals, upper arm and leg, lower back muscles, gluteal muscles, and thighs); part-body (PB) EMS (n = 42): stimulation of leg muscles including gluteal muscles and thighs; and control group (CG, n = 44). All participants performed six 20 min training sessions including dynamic movements (squats, lunges, biceps curl, chest press, butterfly reverse, reverse lunges, standing diagonal crunches, etc.) with superimposed (WB-, PB-) EMS or without EMS (CG) in addition to the standard rehabilitation programme. Primary outcome variables included muscle function assessed by chair rise test and 6 min walking test as well as muscle strength (isometric grip strength, leg, arm, and back extension). RESULTS Primary outcome variables chair rise test and leg extension improved significantly (P = 0.001, η 2  = 0.06 and P = 0.008, η 2  = 0.06; EMS vs. CG) in that chair rise test results increased in WB-EMS from 5 (4; 7) to 7 (5; 9), in PB-EMS from 5 (5; 7) to 7 (6; 8), and in CG from 6 (4; 7) to 7 (5; 8) repetitions. Knee extension increased in WB-EMS from 692.3 ± 248.6 to 831.7 ± 298.7 N, in PB-EMS from 682.8 ± 257.8 to 790.2 ± 270.2 N, and in CG from 638.5 ± 236.9 to 703.2 ± 218.6 N. No adverse events or side effects occurred. CONCLUSIONS We conclude that EMS might be an additional training option to improve muscle function and strength in sarcopenic patients during a 4 week rehabilitation programme. EMS provides greater functional and strength improvements compared with standard treatment with additional potential health benefits for sarcopenic cardiac and orthopaedic patients.",2021,"Primary outcome variables chair rise test and leg extension improved significantly (P = 0.001, η 2  = 0.06 and P = 0.008, η 2  = 0.06; EMS vs. CG) in that chair rise test results increased in WB-EMS from 5 (4; 7) to 7 (5; 9), in PB-EMS from 5 (5; 7) to 7 (6; 8), and in CG from 6 (4; 7) to 7 (5; 8) repetitions.","['sarcopenic cardiac and orthopaedic patients', 'elderly, sedentary individuals', 'One hundred and thirty-four patients (55.7\xa0±\xa07.9\xa0years, 25.4% female', 'Patients receiving 4\xa0weeks of inpatient medical rehabilitation diagnosed with sarcopenia using bioimpedance analysis were eligible to participate', 'sarcopenic patients']","['electromyostimulation', 'EMS', 'Electromyostimulation (EMS', 'six 20\xa0min training sessions including dynamic movements (squats, lunges, biceps curl, chest press, butterfly reverse, reverse lunges, standing diagonal crunches, etc.) with superimposed (WB-, PB-) EMS or without EMS (CG) in addition to the standard rehabilitation programme', 'whole-body (WB) EMS (n\xa0=\xa048): stimulation of major muscle groups (pectoral muscles, latissimus, trapezius, abdominals, upper arm and leg, lower back muscles, gluteal muscles, and thighs); part-body (PB) EMS (n\xa0=\xa042): stimulation of leg muscles including gluteal muscles and thighs; and control group (CG, n\xa0=\xa044']","['chair rise test and leg extension', 'muscle strength and function', 'Knee extension', 'muscle function and strength', 'muscle function assessed by chair rise test and 6\xa0min walking test as well as muscle strength (isometric grip strength, leg, arm, and back extension', 'chair rise test results increased in WB-EMS']","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0010474', 'cui_str': ""Curling's ulcers""}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0006496', 'cui_str': 'Butterfly'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0443198', 'cui_str': 'Diagonal'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030747', 'cui_str': 'Pectoral muscle structure'}, {'cui': 'C0224361', 'cui_str': 'Structure of trapezius muscle'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0230348', 'cui_str': 'Both upper arms'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0224334', 'cui_str': 'Skeletal muscle structure of back'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0224456', 'cui_str': 'Skeletal muscle structure of lower leg'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}]",,0.0294873,"Primary outcome variables chair rise test and leg extension improved significantly (P = 0.001, η 2  = 0.06 and P = 0.008, η 2  = 0.06; EMS vs. CG) in that chair rise test results increased in WB-EMS from 5 (4; 7) to 7 (5; 9), in PB-EMS from 5 (5; 7) to 7 (6; 8), and in CG from 6 (4; 7) to 7 (5; 8) repetitions.","[{'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Teschler', 'Affiliation': 'Department of Rehabilitation Sciences, Faculty of Health, University of Witten/Herdecke, Witten, Germany.'}, {'ForeName': 'Melina', 'Initials': 'M', 'LastName': 'Heimer', 'Affiliation': 'Department of Rehabilitation Sciences, Faculty of Health, University of Witten/Herdecke, Witten, Germany.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Schmitz', 'Affiliation': 'Department of Rehabilitation Sciences, Faculty of Health, University of Witten/Herdecke, Witten, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Kemmler', 'Affiliation': 'Institute of Medical Physics, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Frank C', 'Initials': 'FC', 'LastName': 'Mooren', 'Affiliation': 'Department of Rehabilitation Sciences, Faculty of Health, University of Witten/Herdecke, Witten, Germany.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12717'] 3436,34103179,Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.,"BACKGROUND Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and circulating tumour DNA (ctDNA). Low-pass whole-genome sequencing (lpWGS) of ctDNA can provide information on mCRPC behaviour. OBJECTIVE To validate and clinically qualify plasma lpWGS for mCRPC. DESIGN, SETTING, AND PARTICIPANTS Plasma lpWGS data were obtained for mCRPC patients consenting to optional substudies of two prospective phase 3 trials (FIRSTANA and PROSELICA). In FIRSTANA, chemotherapy-naïve patients were randomised to treatment with docetaxel (75 mg/m 2 ) or cabazitaxel (20 or 25 mg/m 2 ). In PROSELICA, patients previously treated with docetaxel were randomised to 20 or 25 mg/m 2 cabazitaxel. lpWGS data were generated from 540 samples from 188 mCRPC patients acquired at four different time points (screening, cycle 1, cycle 4, and end of study). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: lpWGS data for ctDNA were evaluated for prognostic, response, and tumour genomic measures. Associations with response and survival data were determined for tumour fraction. Genomic biomarkers including large-scale transition (LST) scores were explored in the context of prior treatments. RESULTS AND LIMITATIONS Plasma tumour fraction was prognostic for overall survival in univariable and stratified multivariable analyses (hazard ratio 1.75, 95% confidence interval 1.08-2.85; p = 0.024) and offered added value compared to existing biomarkers (C index 0.722 vs 0.709; p = 0.021). Longitudinal changes were associated with drug response. PROSELICA samples were enriched for LSTs (p = 0.029) indicating genomic instability, and this enrichment was associated with prior abiraterone and enzalutamide treatment but not taxane or radiation therapy. Higher LSTs were correlated with losses of RB1/RNASEH2B, independent of BRCA2 loss. CONCLUSIONS Plasma lpWGS of ctDNA describes CRPC behaviour, providing prognostic and response data of clinical relevance. The added prognostic value of the ctDNA fraction over established biomarkers should be studied further. PATIENT SUMMARY We studied tumour DNA in blood samples from patients with prostate cancer. We found that levels of tumour DNA in blood were indicative of disease prognosis, and that changes after treatment could be detected. We also observed a ""genetic scar"" in the results that was associated with certain previous treatments. This test allows an assessment of tumour activity that can complement existing tests, offer insights into drug response, and detect clinically relevant genetic changes.",2021,"PROSELICA samples were enriched for LSTs (p = 0.029) indicating genomic instability, and this enrichment was associated with prior abiraterone and enzalutamide treatment but not taxane or radiation therapy.","['naïve patients', 'patients previously treated with', 'patients with prostate cancer', 'mCRPC patients consenting to optional substudies of two prospective phase 3 trials', 'metastatic castration-resistant prostate cancer (mCRPC', '188 mCRPC patients']","['Low-pass whole-genome sequencing (lpWGS) of ctDNA', 'docetaxel', 'taxane or radiation therapy', 'cabazitaxel', 'chemotherapy']","['prognostic, response, and tumour genomic measures', 'Plasma cell-free DNA (cfDNA) comprises normal and circulating tumour DNA (ctDNA', 'large-scale transition (LST) scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C3640076', 'cui_str': 'Whole genome sequencing'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0215136', 'cui_str': 'taxane'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C2830183', 'cui_str': 'cabazitaxel'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0032112', 'cui_str': 'Plasma cell'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C4289789', 'cui_str': 'Cell free DNA'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0924215,"PROSELICA samples were enriched for LSTs (p = 0.029) indicating genomic instability, and this enrichment was associated with prior abiraterone and enzalutamide treatment but not taxane or radiation therapy.","[{'ForeName': 'Semini', 'Initials': 'S', 'LastName': 'Sumanasuriya', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK; The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Seed', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Parr', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Rossitza', 'Initials': 'R', 'LastName': 'Christova', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Pope', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Bertan', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Diletta', 'Initials': 'D', 'LastName': 'Bianchini', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK; The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Pasquale', 'Initials': 'P', 'LastName': 'Rescigno', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK; The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Figueiredo', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Goodall', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Fowler', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Penelope', 'Initials': 'P', 'LastName': 'Flohr', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Niven', 'Initials': 'N', 'LastName': 'Mehra', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK; The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Antje', 'Initials': 'A', 'LastName': 'Neeb', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Rekowski', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Eisenberger', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Sartor', 'Affiliation': 'Tulane Medical School, New Orleans, LA, USA.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Oudard', 'Affiliation': 'Hôpital Européen Georges Pompidou and Université de Paris, Paris, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Geffriaud-Ricouard', 'Affiliation': 'Sanofi-Genzyme, Paris, France.'}, {'ForeName': 'Ayse', 'Initials': 'A', 'LastName': 'Ozatilgan', 'Affiliation': 'Sanofi-Genzyme, Paris, France.'}, {'ForeName': 'Mustapha', 'Initials': 'M', 'LastName': 'Chadjaa', 'Affiliation': 'Sanofi-Genzyme, Paris, France.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Macé', 'Affiliation': 'Sanofi-Genzyme, Paris, France.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Lord', 'Affiliation': 'The CRUK Gene Function Laboratory and Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Baxter', 'Affiliation': 'The CRUK Gene Function Laboratory and Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Pettitt', 'Affiliation': 'The CRUK Gene Function Laboratory and Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Maryou', 'Initials': 'M', 'LastName': 'Lambros', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK; The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Sharp', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK; The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Joaquin', 'Initials': 'J', 'LastName': 'Mateo', 'Affiliation': ""Vall d'Hebron Institute of Oncology, Barcelona, Spain.""}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Carreira', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK; The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Yuan', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK; The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Johann S', 'Initials': 'JS', 'LastName': 'de Bono', 'Affiliation': 'The Institute of Cancer Research, University of London, London, UK; The Royal Marsden Hospital, London, UK. Electronic address: johann.de-bono@icr.ac.uk.'}]",European urology,['10.1016/j.eururo.2021.05.030'] 3437,34108180,Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.,"PURPOSE Although patients with unresectable or metastatic melanoma can experience long-term survival with BRAF- and MEK-targeted agents or immune checkpoint inhibitors over 5 years, resistance develops in most patients. There is a distinct lack of pretherapeutic biomarkers to identify which patients are likely to benefit from each therapy type. Most research has focused on the predictive role of T cells in antitumor responses as opposed to B cells. PATIENTS AND METHODS We conducted prespecified exploratory biomarker analysis using gene expression profiling and digital pathology in 146 patients with previously untreated BRAF V600-mutant metastatic melanoma from the randomized, phase III COMBI-v trial and treated with dabrafenib plus trametinib who had available tumor specimens from screening. RESULTS Baseline cell-cycle gene expression signature was associated with progression-free survival ( P = 0.007). Patients with high T-cell/low B-cell gene signatures had improved median overall survival (not reached [95% confidence interval (CI), 33.8 months-not reached]) compared with patients with high T-cell/high B-cell signatures (19.1 months; 95% CI, 13.4-38.6 months). Patients with high B-cell signatures had high B-cell infiltration into the tumor compartment, corresponding with decreased MAPK activity and increased expression of immunosuppressive markers. CONCLUSIONS B cells may serve as a potential biomarker to predict clinical outcome in patients with advanced melanoma treated with dabrafenib plus trametinib. As separate studies have shown an opposite effect for B-cell levels and response to immunotherapy, B cells may serve as a potential biomarker to facilitate treatment selection. Further validation in a larger patient cohort is needed.",2021,"Patients with high T-cell/low B-cell gene signatures had improved median overall survival (not reached [95% confidence interval (CI), 33.8 months-not reached]) compared with patients with high T-cell/high B-cell signatures (19.1 months [95% CI, 13.4-38.6 months]).","['patients with advanced melanoma treated with dabrafenib plus trametinib', 'Patients with Melanoma Treated With Dabrafenib Plus Trametinib', 'patients with unresectable or metastatic melanoma', '146 patients with previously untreated BRAF V600-mutant metastatic melanoma from the randomized, phase III COMBI-v trial and treated with dabrafenib plus trametinib who had available tumor specimens from screening']",[],"['median overall survival', 'progression-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C3467876', 'cui_str': 'dabrafenib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2697961', 'cui_str': 'trametinib'}, {'cui': 'C0278883', 'cui_str': 'Metastatic melanoma'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C1259929', 'cui_str': 'BRAF protein, human'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]",[],"[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",146.0,0.411426,"Patients with high T-cell/low B-cell gene signatures had improved median overall survival (not reached [95% confidence interval (CI), 33.8 months-not reached]) compared with patients with high T-cell/high B-cell signatures (19.1 months [95% CI, 13.4-38.6 months]).","[{'ForeName': 'Jan C', 'Initials': 'JC', 'LastName': 'Brase', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Robert F H', 'Initials': 'RFH', 'LastName': 'Walter', 'Affiliation': 'Department of Pathology, University Hospital Essen, Essen, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Savchenko', 'Affiliation': 'Oncology Precision Medicine, Novartis, Cambridge, Massachusetts.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Gusenleitner', 'Affiliation': 'Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Garrett', 'Affiliation': 'Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Schimming', 'Affiliation': 'Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Varaljai', 'Affiliation': 'Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Castelletti', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Ju', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Navigate BioPharma Services, Inc. (a Novartis subsidiary), Carlsbad, California.'}, {'ForeName': 'Naveen', 'Initials': 'N', 'LastName': 'Dakappagari', 'Affiliation': 'Navigate BioPharma Services, Inc. (a Novartis subsidiary), Carlsbad, California.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Schultz', 'Affiliation': 'Oncology Precision Medicine, Novartis, Cambridge, Massachusetts.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Robert', 'Affiliation': 'Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France.'}, {'ForeName': 'Georgina V', 'Initials': 'GV', 'LastName': 'Long', 'Affiliation': 'Melanoma Institute Australia and Sydney Medical School, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Nathan', 'Affiliation': 'Mount Vernon Cancer Centre, Northwood, United Kingdom.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Ribas', 'Affiliation': 'Department of Medicine, University of California-Los Angeles, Los Angeles, California.'}, {'ForeName': 'Keith T', 'Initials': 'KT', 'LastName': 'Flaherty', 'Affiliation': 'Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Boguslawa', 'Initials': 'B', 'LastName': 'Karaszewska', 'Affiliation': 'Przychodnia Lekarska Komed, Konin, Poland.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Schachter', 'Affiliation': 'The Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, and Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Antje', 'Initials': 'A', 'LastName': 'Sucker', 'Affiliation': 'Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Kurt W', 'Initials': 'KW', 'LastName': 'Schmid', 'Affiliation': 'Department of Pathology, University Hospital Essen, Essen, Germany.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Zimmer', 'Affiliation': 'Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Livingstone', 'Affiliation': 'Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Gasal', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Schadendorf', 'Affiliation': 'Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Roesch', 'Affiliation': 'Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. alexander.roesch@uk-essen.de.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-3586'] 3438,34105083,Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.,"BACKGROUND The MONALEESA-3 trial demonstrated the efficacy and safety of ribociclib plus fulvestrant versus placebo plus fulvestrant for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). This analysis evaluated the cost effectiveness of ribociclib plus fulvestrant versus fulvestrant in patients with HR+/HER2- ABC from a Canadian healthcare payer perspective. METHODS The incremental cost-effectiveness ratio (ICER), expressed as incremental costs per quality-adjusted life-year (QALY) gained for ribociclib plus fulvestrant versus fulvestrant, was estimated using a semi-Markov cohort model developed in Microsoft Excel, with states for progression-free, post-progression, and dead. A 15-year time horizon was used. Survival distributions for progression-free survival (PFS), post-progression survival (PPS), and time to discontinuation (TTD) were based on parametric survival distributions fit to data from MONALEESA-3. Health-state utilities were estimated using EQ-5D index values collected in MONALEESA-3. Direct costs of ABC treatment (medication and administration costs, follow-up and monitoring, adverse events, subsequent treatments) were based on Canadian-specific values from published sources. Costs (2019 CAN$) and QALYs were discounted at 1.5% annually. RESULTS In the base case, ribociclib plus fulvestrant was estimated to result in gains of 1.19 life-years and 0.96 QALYs versus fulvestrant, at an incremental cost of $151,371. The ICER of ribociclib plus fulvestrant versus fulvestrant was $157,343 per QALY gained based on the mean of probabilistic analyses. Results were sensitive to parametric distributions used for projecting long-term TTD, PFS, and PPS. CONCLUSIONS For patients with HR+/HER2- ABC, ribociclib plus fulvestrant is projected to result in substantial gains in QALYs compared with fulvestrant. At its current list price, ribociclib used in combination with fulvestrant is likely to be cost effective in these patients at a threshold ICER of $157,343. These results may be useful in deliberations regarding reimbursement and access to this treatment.",2021,"Results were sensitive to parametric distributions used for projecting long-term TTD, PFS, and PPS. ","['patients with HR+/HER2- ABC from a Canadian healthcare payer perspective', 'patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC', 'Postmenopausal Women with HR+/HER2- Advanced Breast Cancer']","['ribociclib plus fulvestrant versus fulvestrant', 'placebo plus fulvestrant', 'ribociclib plus fulvestrant', 'fulvestrant', 'Ribociclib', 'Fulvestrant']","['Costs (2019 CAN$) and QALYs', 'Survival distributions for progression-free survival (PFS), post-progression survival (PPS), and time to discontinuation (TTD', 'incremental cost-effectiveness ratio (ICER', 'Direct costs of ABC treatment (medication and administration costs, follow-up and monitoring, adverse events, subsequent treatments', 'Health-state utilities', 'EQ-5D index values', 'incremental costs per quality-adjusted life-year (QALY', 'Cost Effectiveness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C2348942', 'cui_str': 'Healthcare payer'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C4045494', 'cui_str': 'ribociclib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0984044,"Results were sensitive to parametric distributions used for projecting long-term TTD, PFS, and PPS. ","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Stellato', 'Affiliation': 'Policy Analysis Inc. (PAI), 822 Boylston Street, Suite 206, Chestnut Hill, MA, 02467, USA.'}, {'ForeName': 'Marroon E', 'Initials': 'ME', 'LastName': 'Thabane', 'Affiliation': 'Novartis Pharmaceuticals Corp., East Hanover, NJ, USA.'}, {'ForeName': 'Jinhee', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Novartis Pharmaceuticals Corp., East Hanover, NJ, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Chandiwana', 'Affiliation': 'Novartis Pharmaceuticals Corp., East Hanover, NJ, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Delea', 'Affiliation': 'Policy Analysis Inc. (PAI), 822 Boylston Street, Suite 206, Chestnut Hill, MA, 02467, USA. tdelea@pai2.com.'}]",PharmacoEconomics,['10.1007/s40273-021-01027-4'] 3439,34103345,Diffusion-weighted imaging lesions and risk of recurrent stroke after intracerebral haemorrhage.,"OBJECTIVE To determine whether the presence of diffusion-weighted imaging-positive (DWI+) lesions is associated with recurrent stroke after intracerebral haemorrhage (ICH). METHODS The REstart or STop Antithrombotics Randomised Trial (RESTART) assessed the effect of restarting versus avoiding antiplatelet therapy after ICH on major vascular events for up to 5 years. We rated DWI sequences of MRI done before randomisation for DWI+ lesion presence, masked to outcome and antiplatelet use. Cox proportional hazards regression models were used to quantify associations. RESULTS Of 537 participants in RESTART, 247 (median (IQR) age 75.7 (69.6-81.1) years; 170 men (68.8%); 120 started vs 127 avoided antiplatelet therapy) had DWI sequences on brain MRI at a median of 57 days (IQR 19-103) after ICH, of whom 73 (30%) had one or more DWI+ lesion. During a median follow-up of 2 years (1-3), 18 participants had recurrent ICH and 21 had ischaemic stroke. DWI+ lesion presence was associated with all stroke, (adjusted HR 2.2 (95% CI 1.1 to 4.2)) and recurrent ICH (4.8 (95% CI 1.8 to 13.2)), but not ischaemic stroke (0.9 (95% CI 0.3 to 2.5)). DWI+ lesion presence (0.5 (95% CI 0.2 to 1.3)) vs absence (0.6 (95% CI 0.3 to 1.5), p interaction =0.66) did not modify the effect of antiplatelet therapy on a composite outcome of recurrent stroke. CONCLUSIONS DWI+ lesion presence in ICH survivors is associated with recurrent ICH, but not with ischaemic stroke. We found no evidence of modification of effects of antiplatelet therapy on recurrent stroke after ICH by DWI+ lesion presence. These findings provide a new perspective on the significance of DWI+ lesions, which may be markers of microvascular mechanisms associated with recurrent ICH. TRIAL REGISTRATION NUMBER ISRCTN71907627.",2021,"vs absence (0.6 (95% CI 0.3 to 1.5), p interaction =0.66) did not modify the effect of antiplatelet therapy on a composite outcome of recurrent stroke. ","['18 participants had recurrent ICH and 21 had ischaemic stroke', 'recurrent stroke after ICH by DWI+ lesion presence', 'recurrent stroke after intracerebral haemorrhage', '537 participants in RESTART, 247 (median (IQR', 'age 75.7 (69.6-81.1) years; 170 men (68.8%); 120 started vs 127 avoided antiplatelet therapy) had DWI sequences on brain MRI at a median of 57 days (IQR 19-103) after ICH, of whom 73 (30%) had one or more DWI+ lesion', 'recurrent stroke after intracerebral haemorrhage (ICH']","['diffusion-weighted imaging-positive (DWI+) lesions', 'antiplatelet therapy']","['ischaemic stroke', 'DWI+ lesion presence', 'recurrent ICH']","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C1836785', 'cui_str': 'Recurrent stroke'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0598801', 'cui_str': 'Diffusion weighted magnetic resonance imaging'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C4028269', 'cui_str': 'Nuclear magnetic resonance imaging brain'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4517526', 'cui_str': '103'}]","[{'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}]","[{'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}]",537.0,0.118883,"vs absence (0.6 (95% CI 0.3 to 1.5), p interaction =0.66) did not modify the effect of antiplatelet therapy on a composite outcome of recurrent stroke. ","[{'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Wiegertjes', 'Affiliation': 'Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Dinsmore', 'Affiliation': 'Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Drever', 'Affiliation': 'Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Aidan', 'Initials': 'A', 'LastName': 'Hutchison', 'Affiliation': 'Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Stephen', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Valdés Hernández', 'Affiliation': 'Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Priya', 'Initials': 'P', 'LastName': 'Bhatnagar', 'Affiliation': 'Department of Neuroradiology, Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle-upon-Tyne, UK.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Minks', 'Affiliation': 'Department of Neuroradiology, Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle-upon-Tyne, UK.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Rodrigues', 'Affiliation': 'Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Werring', 'Affiliation': 'Stroke Research Centre, Queen Square Institute of Neurology, University College London, London, UK.'}, {'ForeName': 'Frank-Erik', 'Initials': 'FE', 'LastName': 'de Leeuw', 'Affiliation': 'Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Catharina Jm', 'Initials': 'CJ', 'LastName': 'Klijn', 'Affiliation': 'Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Rustam', 'Initials': 'R', 'LastName': 'Al-Shahi Salman', 'Affiliation': 'Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK rustam.al-shahi@ed.ac.uk.'}, {'ForeName': 'Phillip M', 'Initials': 'PM', 'LastName': 'White', 'Affiliation': 'Translational and Clinical Research Institute, The University of Newcastle, Newcastle-upon-Tyne, UK.'}, {'ForeName': 'Joanna M', 'Initials': 'JM', 'LastName': 'Wardlaw', 'Affiliation': 'Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.'}]","Journal of neurology, neurosurgery, and psychiatry",['10.1136/jnnp-2021-326116'] 3440,34104574,Acupuncture Intervention Protocol: Consensus Process for a Pragmatic Randomized Controlled Trial of Acupuncture for Management of Chronic Low Back Pain in Older Adults: An NIH HEAL Initiative Funded Project.,"Objective The aim of this article is to describe the consensus process used to develop an acupuncture intervention protocol for an NIH-funded pragmatic randomized controlled trial (PRCT) of acupuncture for the management of chronic low back (cLBP) in older adults (BackInAction). Background CLBP is among leading causes of disability worldwide: almost 33% of US adults 65 and older experience LBP. Acupuncture is effective for cLBP but there is no specific data on older adults. The National Institutes for Health (NIH) funded a PRCT of acupuncture needling for this population. An essential trial milestone was development of a consensus intervention protocol. Methods An Acupuncture Advisory Panel (AAP) was formed with nine members: two physician-acupuncturists, six licensed acupuncturists representing diverse work backgrounds, and an acupuncture researcher. We used a modified Delphi process that included provision of acupuncture trial data, survey data describing how each expert treats cLBP, three conference calls, and between-call email discussion. Results Lively and professional discussions led to a consensus intervention protocol for the BackInAction trial that included steps/staging of care, recommendations for parameters of care session length, number of needle insertion sites, insertion depths, needle retention times, recommended types of needles, both local and distal areas of the body to be treated, acupuncture point options, auricular point options, self-care options, and minimum number of sessions considered ideal. Conclusion Using a modified Delphi process, an expert AAP created a consensus intervention protocol for the PRCT of acupuncture needling for cLBP in patients 65 and older.",2021,"Conclusion Using a modified Delphi process, an expert AAP created a consensus intervention protocol for the PRCT of acupuncture needling for cLBP in patients 65 and older.","['older adults (BackInAction', 'patients 65 and older', 'older adults', 'Older Adults']","['acupuncture', 'Acupuncture Advisory Panel (AAP', 'acupuncture needling', 'acupuncture intervention protocol', 'acupuncture needling for cLBP', 'Acupuncture']",['chronic low back (cLBP'],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0181956', 'cui_str': 'Acupuncture needle'}]","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",65.0,0.203562,"Conclusion Using a modified Delphi process, an expert AAP created a consensus intervention protocol for the PRCT of acupuncture needling for cLBP in patients 65 and older.","[{'ForeName': 'Arya', 'Initials': 'A', 'LastName': 'Nielsen', 'Affiliation': 'Department of Family Medicine & Community Health, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ocker', 'Affiliation': 'Multnomah County, Integrated Clinical Services, Portland, Oregon.'}, {'ForeName': 'Iman', 'Initials': 'I', 'LastName': 'Majd', 'Affiliation': 'Department of Family Medicine, University of Washington, Seattle, Washington.'}, {'ForeName': 'Jeff A', 'Initials': 'JA', 'LastName': 'Draisin', 'Affiliation': 'Institute for Health and Healing, San Francisco, California.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Taromina', 'Affiliation': 'Seattle Institute of East Asian Medicine, Seattle, Washington.'}, {'ForeName': 'Marjorie T', 'Initials': 'MT', 'LastName': 'Maggenti', 'Affiliation': 'The Permanente Medical Group, Oakland, California.'}, {'ForeName': 'Jaimie', 'Initials': 'J', 'LastName': 'Long', 'Affiliation': 'Private Practice, Oakland, California.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Nolting', 'Affiliation': 'Tivity Health, Edmonds, Washington.'}, {'ForeName': 'Karen J', 'Initials': 'KJ', 'LastName': 'Sherman', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute; Department of Epidemiology, University of Washington, Seattle, Washington.'}]",Global advances in health and medicine,['10.1177/21649561211007091'] 3441,34110230,Short-term intensified training temporarily impairs mitochondrial respiratory capacity in elite endurance athletes.,"The maintenance of healthy and functional mitochondria is the result of a complex mitochondrial turnover and herein quality-control program that includes both mitochondrial biogenesis and autophagy of mitochondria. The aim of this study was to examine the effect of an intensified training load on skeletal muscle mitochondrial quality control in relation to changes in mitochondrial oxidative capacity, maximal oxygen consumption, and performance in highly trained endurance athletes. Elite endurance athletes ( n = 27) performed high-intensity interval exercise followed by moderate-intensity continuous exercise 3 days per week for 4 wk in addition to their usual volume of training. Mitochondrial oxidative capacity, abundance of mitochondrial proteins, markers of autophagy, and antioxidant capacity of skeletal muscle were assessed in skeletal muscle biopsies before and after the intensified training period. The intensified training period increased several autophagy markers suggesting an increased turnover of mitochondrial and cytosolic proteins. In permeabilized muscle fibers, mitochondrial respiration was ∼20% lower after training although some markers of mitochondrial density increased by 5%-50%, indicative of a reduced mitochondrial quality by the intensified training intervention. The antioxidative proteins UCP3, ANT1, and SOD2 were increased after training, whereas we found an inactivation of aconitase. In agreement with the lower aconitase activity, the amount of mitochondrial LON protease that selectively degrades oxidized aconitase was doubled. Together, this suggests that mitochondrial respiratory function is impaired during the initial recovery from a period of intensified endurance training whereas mitochondrial quality control is slightly activated in highly trained skeletal muscle. NEW & NOTEWORTHY We show that mitochondrial respiration is temporarily impaired after a period of intensified exercise training in elite athletes. In parallel, proteins involved in the antioxidative response including SOD2, UCP3, and ANT2 were upregulated, whereas mitochondrial biogenesis was slightly activated. Despite the mitochondrial respiratory impairments, physical performance was improved a few days after the intense training period.",2021,"In permeabilized muscle fibers, mitochondrial respiration was ~20 % lower after training although some markers of mitochondrial density increased by 5-50%, indicative of a reduced mitochondrial quality by the intensified training intervention.","['elite endurance athletes', 'highly trained endurance athletes', '27 elite endurance athletes performed']","['high intensity interval exercise followed by moderate intensity continuous exercise 3 days per week for 4 weeks in addition to their usual volume of training', 'intensified training load']","['mitochondrial respiratory capacity', 'mitochondrial respiration', 'mitochondrial density', 'Mitochondrial oxidative capacity, abundance of mitochondrial proteins, markers of autophagy and antioxidant capacity of skeletal muscle', 'turnover of mitochondrial and cytosolic proteins', 'mitochondrial quality', 'antioxidative proteins UCP3, ANT1, and SOD2']","[{'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0677547', 'cui_str': 'days/week'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0949610', 'cui_str': 'Mitochondrial Protein'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0004391', 'cui_str': 'Autophagocytosis'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0031227', 'cui_str': 'Employee Turnover'}, {'cui': 'C1383501', 'cui_str': 'Cytoplasmic matrix'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1442881', 'cui_str': 'SLC25A4 protein, human'}]",27.0,0.0164487,"In permeabilized muscle fibers, mitochondrial respiration was ~20 % lower after training although some markers of mitochondrial density increased by 5-50%, indicative of a reduced mitochondrial quality by the intensified training intervention.","[{'ForeName': 'Daniele A', 'Initials': 'DA', 'LastName': 'Cardinale', 'Affiliation': 'Åstrand Laboratory, Department of Physiology, Nutrition, and Biomechanics, The Swedish School of Sport and Health Sciences (GIH), Stockholm, Sweden.'}, {'ForeName': 'Kasper D', 'Initials': 'KD', 'LastName': 'Gejl', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Kristine G', 'Initials': 'KG', 'LastName': 'Petersen', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Nielsen', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Ørtenblad', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Filip J', 'Initials': 'FJ', 'LastName': 'Larsen', 'Affiliation': 'Åstrand Laboratory, Department of Physiology, Nutrition, and Biomechanics, The Swedish School of Sport and Health Sciences (GIH), Stockholm, Sweden.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00829.2020'] 3442,34107152,Comparison of serum dynamic thiol/disulphide homeostasis and nitric oxide levels of total intravenous vs inhaled anaesthesia in endoscopic transsphenoidal pituitary surgery.,"BACKGROUND Transsphenoidal pituitary surgery (TPS) is traditionally performed under general anaesthesia. This study aimed to compare the effects of total intravenous anaesthesia (TIVA) or sevoflurane, an inhalation anaesthetic, on thiol-disulphide homeostasis in patients undergoing endoscopic endonasal TPS. METHODS In this study, 84 patients scheduled for TPS were randomly categorised into two groups: propofol (n = 42, the TIVA group) or sevoflurane (n = 42, the SEVO group). Blood samples were taken before induction of general anaesthesia and at the 30 minutes of postoperation. Serum native thiol and total thiol levels were detected, and the number of dynamic disulphide bonds and related ratios were calculated from these values. Serum nitric oxide (NO) levels were measured using a chemiluminescence method. RESULTS Although native thiol levels in TIVA postoperation group were markedly increased (P < .05), total thiol levels in SEVO postoperation group were significantly decreased (P < .01). Disulphide levels were declined in both groups (P < .05 for TIVA and P = .001 for SEVO groups). Disulphide/native thiol (P < .05 for both groups) and disulphide/total thiol ratios (P < .05 for TIVA and P < .01 for SEVO groups) were depressed in postoperation groups. We found a marked elevation in native thiol/total thiol ratio in both groups (P < .05 for TIVA and P < .01 for SEVO groups). There was significant augmentation in serum NO levels in the SEVO postoperation group (P < .05). CONCLUSION These results are the first to show that both TIVA and sevoflurane showed similar antioxidant effect with reduced disulphide levels, but sevoflurane may offer more robust oxidative stress protection and augmented NO production than TIVA during TPS. However, the clinical effect is needed to further investigate.",2021,Disulfide levels were declined in both groups (P<0.05 for TIVA and P=0.001 for SEVO groups).,"['endoscopic transsphenoidal pituitary surgery', '84 patients scheduled for TPS', 'patients undergoing endoscopic endonasal TPS']","['Transsphenoidal pituitary surgery (TPS', 'propofol', 'total intravenous versus inhaled anesthesia', 'Disulfide/native thiol', 'sevoflurane', 'total intravenous anesthesia (TIVA) or sevoflurane']","['disulfide/total thiol ratios', 'Disulfide levels', 'marked elevation in native thiol/total thiol ratio', 'serum', 'number of dynamic disulfide bonds and related ratios', 'Serum nitric oxide (NO) levels', 'total thiol levels', 'Serum native thiol and total thiol levels']","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0205508', 'cui_str': 'Transsphenoidal approach'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0225425', 'cui_str': 'Internal nose structure'}]","[{'cui': 'C0205508', 'cui_str': 'Transsphenoidal approach'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0012771', 'cui_str': 'Disulfides'}, {'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0038734', 'cui_str': 'Sulfhydryls'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0473965', 'cui_str': 'Total intravenous anesthesia'}]","[{'cui': 'C0012771', 'cui_str': 'Disulfides'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038734', 'cui_str': 'Sulfhydryls'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}]",84.0,0.0167356,Disulfide levels were declined in both groups (P<0.05 for TIVA and P=0.001 for SEVO groups).,"[{'ForeName': 'Berna', 'Initials': 'B', 'LastName': 'Kaya-Ugur', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Erkutlu', 'Affiliation': 'Department of Neurosurgery, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Saracaloglu', 'Affiliation': 'Department of Medical Pharmacology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.'}, {'ForeName': 'Abidin M', 'Initials': 'AM', 'LastName': 'Geyik', 'Affiliation': 'Department of Neurosurgery, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.'}, {'ForeName': 'Seniz', 'Initials': 'S', 'LastName': 'Demiryürek', 'Affiliation': 'Department of Physiology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.'}, {'ForeName': 'Abdullah T', 'Initials': 'AT', 'LastName': 'Demiryürek', 'Affiliation': 'Department of Medical Pharmacology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.'}]",International journal of clinical practice,['10.1111/ijcp.14485'] 3443,34114250,Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.,"Sleep disturbances (SDs) are among the most distressing and commonly reported symptoms in posttraumatic stress disorder (PTSD). Despite increased attention on sleep in clinical PTSD research, SDs remain difficult to treat. In Phase 2 trials, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has been shown to greatly improve PTSD symptoms. We hypothesized that MDMA-assisted psychotherapy would improve self-reported sleep quality (SQ) in individuals with PTSD and be associated with declining PTSD symptoms. Participants in four studies (n = 63) were randomized to receive 2-3 sessions of active MDMA (75-125 mg; n = 47) or placebo/control MDMA (0-40 mg, n = 16) during all-day psychotherapy sessions. The PSQI was used to assess change in SQ from baseline to the primary endpoint, 1-2 months after the blinded sessions. Additionally, PSQI scores were measured at treatment exit (TE) and 12-month follow-up. Symptoms of PTSD were measured using the CAPS-IV. At the primary endpoint, CAPS-IV total severity scores dropped more after active MDMA than after placebo/control (-34.0 vs. -12.4), p = .003. Participants in the active dose group showed more improvement in SQ compared to those in the control group (PSQI total score ΔM = -3.5 vs. 0.6), p = .003. Compared to baseline, SQ had improved at TE, p < .001, with further significant gains reported at 12-month follow-up (TE to 12-months ΔM = -1.0), p = .030. Data from these randomized controlled double-blind studies provide evidence for the beneficial effects of MDMA-assisted psychotherapy in treating SDs in individuals with PTSD.",2021,"Participants in the active dose group showed more improvement in SQ compared to those in the control group (PSQI total score ΔM = -3.5 vs. 0.6), p = .003.","['individuals with PTSD', 'Participants in four studies (n = 63', 'Posttraumatic Stress Disorder']","['3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy', 'placebo/control MDMA', 'MDMA-assisted psychotherapy', 'active MDMA', 'MDMA-Assisted Psychotherapy']","['Sleep disturbances (SDs', 'CAPS-IV total severity scores', 'PTSD symptoms', 'Symptoms of PTSD', 'PSQI scores', 'self-reported sleep quality (SQ', 'improvement in SQ', 'Sleep Quality Improvements']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0115471', 'cui_str': 'Methylenedioxymethamphetamine'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",63.0,0.270758,"Participants in the active dose group showed more improvement in SQ compared to those in the control group (PSQI total score ΔM = -3.5 vs. 0.6), p = .003.","[{'ForeName': 'Linnae', 'Initials': 'L', 'LastName': 'Ponte', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Jerome', 'Affiliation': 'MAPS Public Benefit Corporation, San Jose, California, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Hamilton', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, California, USA.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Mithoefer', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.'}, {'ForeName': 'Berra B', 'Initials': 'BB', 'LastName': 'Yazar-Klosinski', 'Affiliation': 'MAPS Public Benefit Corporation, San Jose, California, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vermetten', 'Affiliation': 'Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Allison A', 'Initials': 'AA', 'LastName': 'Feduccia', 'Affiliation': 'Psychedelic Support, Santa Cruz, California, USA.'}]",Journal of traumatic stress,['10.1002/jts.22696'] 3444,34114246,"Enhanced access to healthcare utilization data through medical record review: Lessons learned from a community-based, multi-site project.","Collecting accurate healthcare utilization (HCU) data on community-based interventions is essential to establishing their clinical effectiveness and cost-related impact. Strategies used to enhance receiving medical records for HCU data extraction in a multi-site longitudinal randomized control trial with urban adolescents are presented. Successful strategies included timely assessment of procedures and practice preferences for access to electronic health records and hardcopy medical charts. Repeated outreach to clinical practice sites to identify and accommodate their preferred procedure for medical record release and flexibility in obtaining chart information helped achieve a 75% success rate in this study. Maintaining participant contact, updating provider information, and continuously evaluating site-specific personnel needs are recommended.",2021,Collecting accurate healthcare utilization (HCU) data on community-based interventions is essential to establishing their clinical effectiveness and cost-related impact.,['urban adolescents'],[],[],"[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]",[],[],,0.0500824,Collecting accurate healthcare utilization (HCU) data on community-based interventions is essential to establishing their clinical effectiveness and cost-related impact.,"[{'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Grape', 'Affiliation': 'Department of Social Work, SUNY Brockport, Brockport, New York, USA.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Wicks', 'Affiliation': 'College of Nursing, University of Tennessee Health Science Center, Memphis, Tennessee, USA.'}, {'ForeName': 'Laurene', 'Initials': 'L', 'LastName': 'Tumiel-Berhalter', 'Affiliation': 'Department of Family Medicine, State University of New York at Buffalo, Buffalo, New York, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Sloand', 'Affiliation': 'School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.'}, {'ForeName': 'Hyekyun', 'Initials': 'H', 'LastName': 'Rhee', 'Affiliation': 'School of Nursing, University of Rochester, Rochester, New York, USA.'}]",Research in nursing & health,['10.1002/nur.22160'] 3445,34109630,Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.,"Chemotherapy-induced myelosuppression is an acute, dose-limiting toxicity of chemotherapy regimens used in the treatment of extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib protects haematopoietic stem and progenitor cells from chemotherapy-induced damage (myeloprotection). To assess the totality of the myeloprotective benefits of trilaciclib, including analysis of several clinically relevant but low-frequency events, an exploratory composite endpoint comprising five major adverse haematological events (MAHE) was prospectively defined: all-cause hospitalisations, all-cause chemotherapy dose reductions, febrile neutropenia (FN), prolonged severe neutropenia (SN) and red blood cell (RBC) transfusions on/after Week 5. MAHE and its individual components were assessed in three randomised, double-blind, placebo-controlled Phase 2 trials in patients receiving a platinum/etoposide or topotecan-containing chemotherapy regimen for ES-SCLC and in data pooled from the three trials. A total of 242 patients were randomised across the three trials (trilaciclib, n = 123; placebo, n = 119). In the individual trials and the pooled analysis, administering trilaciclib prior to chemotherapy resulted in a statistically significant reduction in the cumulative incidence of MAHE compared to placebo. In the pooled analysis, the cumulative incidences of all-cause chemotherapy dose reductions, FN, prolonged SN and RBC transfusions on/after Week 5 were significantly reduced with trilaciclib vs placebo; however, no significant difference was observed in rates of all-cause hospitalisations. Additionally, compared to placebo, trilaciclib significantly extended the amount of time patients remained free of MAHE. These data support the myeloprotective benefits of trilaciclib and its ability to improve the overall safety profile of myelosuppressive chemotherapy regimens used to treat patients with ES-SCLC.",2021,"In the pooled analysis, the cumulative incidences of all-cause chemotherapy dose reductions, FN, prolonged SN and RBC transfusions on/after week 5 were significantly reduced with trilaciclib versus placebo; however, no significant difference was observed in rates of all-cause hospitalisations.","['patients with small cell lung cancer', 'patients with ES-SCLC', 'A total of 242 patients', 'patients receiving a platinum/etoposide or topotecan-containing chemotherapy regimen for ES-SCLC, and in data pooled from the three trials']","['Chemotherapy-induced myelosuppression', 'placebo', 'trilaciclib']","['rates of all-cause hospitalisations', 'febrile neutropenia (FN), prolonged severe neutropenia (SN) and red blood cell (RBC) transfusions', 'cumulative incidence of MAHE', 'free of MAHE', 'cumulative incidences of all-cause chemotherapy dose reductions, FN, prolonged SN and RBC transfusions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0149925', 'cui_str': 'Small cell carcinoma of lung'}, {'cui': 'C0278726', 'cui_str': 'Small cell lung cancer extensive stage'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0146224', 'cui_str': 'Topotecan'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0920317', 'cui_str': 'Clinical Trial Overviews'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0854467', 'cui_str': 'Myelosuppression'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0086252', 'cui_str': 'Transfusion of red blood cells'}]",242.0,0.390627,"In the pooled analysis, the cumulative incidences of all-cause chemotherapy dose reductions, FN, prolonged SN and RBC transfusions on/after week 5 were significantly reduced with trilaciclib versus placebo; however, no significant difference was observed in rates of all-cause hospitalisations.","[{'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Dómine Gómez', 'Affiliation': 'Medical Oncology Department, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain.'}, {'ForeName': 'Tibor', 'Initials': 'T', 'LastName': 'Csőszi', 'Affiliation': 'County Oncology Centre, Hetenyi Geza Korhaz, Szolnok, Hungary.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Jaal', 'Affiliation': 'Institute of Clinical Medicine, Department of Hematology and Oncology, University of Tartu, Tartu, Estonia.'}, {'ForeName': 'Iveta', 'Initials': 'I', 'LastName': 'Kudaba', 'Affiliation': 'Chemotherapy and Haematology Clinic, Riga East Clinical University-Latvian Oncology Center, Riga, Latvia.'}, {'ForeName': 'Krasimir', 'Initials': 'K', 'LastName': 'Nikolov', 'Affiliation': 'Department of Medical Oncology, Complex Oncology Center, Burgas, Bulgaria.'}, {'ForeName': 'Davorin', 'Initials': 'D', 'LastName': 'Radosavljevic', 'Affiliation': 'Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Xiao', 'Affiliation': 'Clinical Development, G1 Therapeutics, Inc., Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Janet K', 'Initials': 'JK', 'LastName': 'Horton', 'Affiliation': 'Clinical Development, G1 Therapeutics, Inc., Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Rajesh K', 'Initials': 'RK', 'LastName': 'Malik', 'Affiliation': 'Clinical Development, G1 Therapeutics, Inc., Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Janakiraman', 'Initials': 'J', 'LastName': 'Subramanian', 'Affiliation': ""Division of Oncology, Saint Luke's Cancer Institute, University of Missouri, Kansas City, Missouri, USA.""}]",International journal of cancer,['10.1002/ijc.33705'] 3446,34107336,The effective group size for teaching cardiopulmonary resuscitation skills - A randomized controlled simulation trial.,"AIM OF THE STUDY The ideal group size for effective teaching of cardiopulmonary resuscitation is currently under debate. The upper limit is reached when instructors are unable to correct participants' errors during skills practice. This simulation study aimed to define this limit during cardiopulmonary resuscitation teaching. METHODS Medical students acting as simulated Basic Life Support course participants were instructed to make three different pre-defined Basic Life Support quality errors (e.g., chest compression too fast) in 7 min. Basic Life Support instructors were randomized to groups of 3-10 participants. Instructors were asked to observe the Basic Life Support skills and to correct performance errors. Primary outcome was the maximum group size at which the percentage of correctly identified participants' errors drops below 80%. RESULTS Sixty-four instructors participated, eight for each group size. Their average age was 41 ± 9 years and 33% were female, with a median [25th percentile; 75th percentile] teaching experience of 6 [2;11] years. Instructors had taught 3 [1;5] cardiopulmonary resuscitation courses in the year before the study. A logistic binominal regression model showed that the predicted mean percentage of correctly identified participants' errors dropped below 80% for group sizes larger than six. CONCLUSION This randomized controlled simulation trial reveals decreased ability of instructors to detect Basic Life Support performance errors with increased group size. The maximum group size enabling Basic Life Support instructors to correct more than 80% of errors is six. We therefore recommend a maximum instructor-to-participant ratio of 1:6 for cardiopulmonary resuscitation courses.",2021,"A logistic binominal regression model showed that the predicted mean percentage of correctly identified participants' errors dropped below 80% for group sizes larger than six. ","['Their average age was 41\u2009±\u20099 years and 33% were female, with a median [25 th percentile; 75 th percentile] teaching experience of 6 [2;11] years', 'Medical students acting as simulated Basic Life Support course participants']",[],"[""maximum group size at which the percentage of correctly identified participants' errors drops below 80""]","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0085873', 'cui_str': 'Basic life support'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]",[],"[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}]",64.0,0.126954,"A logistic binominal regression model showed that the predicted mean percentage of correctly identified participants' errors dropped below 80% for group sizes larger than six. ","[{'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Nabecker', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Anesthesia and Pain Management, Sinai Health System, University of Toronto, Toronto, Canada; ERC ResearchNET. Electronic address: sabine.nabecker@insel.ch.'}, {'ForeName': 'Sören', 'Initials': 'S', 'LastName': 'Huwendiek', 'Affiliation': 'Department for Assessment and Evaluation, Institute for Medical Education, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Lorenz', 'Initials': 'L', 'LastName': 'Theiler', 'Affiliation': 'Department of Anaesthesia, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Huber', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland; Statistical Unit, Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Petrowski', 'Affiliation': 'Department for Medical Psychology and Medical Sociology, University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Greif', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland; ERC ResearchNET; School of Medicine, Sigmund Freud University Vienna, Vienna, Austria.'}]",Resuscitation,['10.1016/j.resuscitation.2021.05.034'] 3447,34110580,"Balanced Salt Solution Versus Normal Saline in Resuscitation of Pediatric Sepsis: A Randomized, Controlled Trial.","Current evidences in resuscitation of adult sepsis have pointed to the importance of types of crystalloid fluid-related complications on resuscitation outcomes, but evidences are lacking in pediatric populations. In this study, the authors aimed to compare outcomes of pediatric sepsis resuscitation with different types of crystalloid. They randomly assigned pediatric sepsis patients requiring fluid bolus into three groups to receive either normal saline solution (NSS), Ringer lactate solution (RLS), or Sterofundin as fluid bolus therapy. Forty-two patients were included in the study. Median age was 29 mo and, weight 13 kg. After fluid bolus, the complications were not different among groups. However, in the RLS group, the patients who received large dose of the fluid showed significant reduction in urinary neutrophil gelatinase-associated lipocalin (uNGAL) level. It is concluded that fluid bolus therapy with different types of crystalloid solution did not result in different outcomes but large dose of RLS was associated with greater reduction of uNGAL level, compared to other fluids.Trial Registration: Thai Clinical Trial Registry (TCTR) identification number TCTR20170605001 (retrospectively registered on 1st June 2017). https://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task20=search&task2=view1&id=2576.",2021,"After fluid bolus, the complications were not different among groups.","['Pediatric Sepsis', 'Forty-two patients were included in the study', 'Median age was 29 mo and, weight 13\xa0kg']","['Balanced Salt Solution Versus Normal Saline', 'crystalloid', 'normal saline solution (NSS), Ringer lactate solution (RLS), or Sterofundin as fluid bolus therapy']","['uNGAL level', 'urinary neutrophil gelatinase-associated lipocalin (uNGAL) level']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0205415', 'cui_str': 'Balanced'}, {'cui': 'C3653289', 'cui_str': 'Salt solutions'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0056562', 'cui_str': 'Crystalloid'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0073385', 'cui_str': ""Lactated Ringer's Solution""}, {'cui': 'C0630627', 'cui_str': 'sterofundin'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0206528', 'cui_str': 'Gelatinase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",42.0,0.337826,"After fluid bolus, the complications were not different among groups.","[{'ForeName': 'Sirawut', 'Initials': 'S', 'LastName': 'Trepatchayakorn', 'Affiliation': 'Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd, Pathum Wan, Bangkok, 10330, Thailand. sirawut.t@chula.ac.th.'}, {'ForeName': 'Manee', 'Initials': 'M', 'LastName': 'Sakunpunphuk', 'Affiliation': 'Department of Nursing, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.'}, {'ForeName': 'Rujipat', 'Initials': 'R', 'LastName': 'Samransamruajkit', 'Affiliation': 'Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd, Pathum Wan, Bangkok, 10330, Thailand.'}]",Indian journal of pediatrics,['10.1007/s12098-021-03808-3'] 3448,34391302,A comparison of mobilization and mobilization with movement on pain and range of motion in people with lateral ankle sprain: A randomized clinical trial.,"BACKGROUND Maitland and Mulligan mobilization techniques are two manual therapy methods to increase the range of motion following immobility treatment. The present study was conducted to compare two therapeutic methods, namely mobilization and mobilization with movement (MWM), on the pain and range of motion in people with lateral ankle sprain. METHODS A total of 40 individuals with grade two lateral ankle sprain were randomly divided into two groups, including the Maitland's mobilization intervention group, and the Mulligan's mobilization intervention group. Both groups underwent treatment every other day for two consecutive weeks. The pain intensity was measured using the Visual Analogue Scale (VAS), and the ankle dorsiflexion movement range using the Weight Bearing Lunge Test (WBLT) before and one day after the intervention. RESULTS There were no significant differences between the two groups in terms of pain (P = 0.297) and range of motion (P = 0.294) before the intervention. Meanwhile, after the intervention, a significant change was observed in both groups in terms of these variables, which indicates the effectiveness of both interventions (P < 0.001) and the greater effect of the mobilization with movement in reducing pain (P = 0.037) and increasing the range of motion (P = 0.021). CONCLUSIONS Both techniques significantly improved the range of motion and reduced pain in people with lateral ankle sprain, but Mulligan's technique was significantly more effective among the two, perhaps due to joining active and passive mobilizing tensile forces as well as interaction of afferents and efferents in the reflex arc.",2021,There were no significant differences between the two groups in terms of pain (P = 0.297) and range of motion (P = 0.294) before the intervention.,"['40 individuals with grade two lateral ankle sprain', 'people with lateral ankle sprain']","[""Maitland's mobilization intervention group, and the Mulligan's mobilization intervention group"", 'namely mobilization and mobilization with movement (MWM', 'mobilization and mobilization with movement']","['pain and range of motion', 'pain intensity', 'range of motion and reduced pain', 'Visual Analogue Scale (VAS), and the ankle dorsiflexion movement range using the Weight Bearing Lunge Test (WBLT', 'pain', 'range of motion']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0160087', 'cui_str': 'Sprain of ankle'}]","[{'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0231770', 'cui_str': 'Dorsiflexion of foot'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0085086', 'cui_str': 'Weight-bearing'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",40.0,0.0404063,There were no significant differences between the two groups in terms of pain (P = 0.297) and range of motion (P = 0.294) before the intervention.,"[{'ForeName': 'Adeleh', 'Initials': 'A', 'LastName': 'Norouzi', 'Affiliation': 'Department of Physiotherapy, Rehabilitation Faculty, Semnan University of Medical Sciences, Semnan, Iran. Electronic address: ad_norouzi@yahoo.com.'}, {'ForeName': 'Cyrus Taghizadeh', 'Initials': 'CT', 'LastName': 'Delkhoush', 'Affiliation': 'Neuromuscular Rehabilitation Research Center, Semnan University of Medical Sciences, Semnan, Iran. Electronic address: cyrustaghizadeh@yahoo.com.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Mirmohammadkhani', 'Affiliation': 'Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran. Electronic address: majidmirmohammadkhani@yahoo.com.'}, {'ForeName': 'Rasool', 'Initials': 'R', 'LastName': 'Bagheri', 'Affiliation': 'Neuromuscular Rehabilitation Research Center, Semnan University of Medical Sciences, Semnan, Iran. Electronic address: rasool.bagheri@yahoo.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.05.006'] 3449,34113095,"Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.","Background Management of acute exacerbations of chronic obstructive pulmonary disease (COPD) is sometimes inadequate leading to either prolonged duration and/or an increased risk of recurrent exacerbations in the period following the initial event. Objective To evaluate the safety and efficacy of inhaled nemiralisib, a phosphoinositide 3-kinase δ inhibitor, in patients experiencing an acute exacerbation of COPD. Patients and Methods In this double-blind, placebo-controlled study, COPD patients (40-80 years, ≥10 pack-year smoking history, current moderate/severe acute exacerbation of COPD requiring standard-of-care treatment) were randomized to placebo or nemiralisib 12.5 µg, 50 µg, 100 µg, 250 µg, 500 µg, or 750 µg (ratio of 3:1:1:1:1:1:3; N=938) for 12 weeks with an exploratory 12-week follow-up period. The primary endpoint was change from baseline in post-bronchodilator FEV 1 at week 12. Key secondary endpoints were rate of re-exacerbations, patient-reported outcomes (Exacerbations of Chronic Pulmonary Disease Tool, COPD Assessment Test, St George's Respiratory Questionnaire-COPD), plasma pharmacokinetics (PK) and safety/tolerability. Results There was no difference in change from baseline FEV 1 at week 12 between the nemiralisib and placebo treatment groups (posterior adjusted median difference, nemiralisib 750 µg and placebo: -0.004L (95% CrI: -0.051L to 0.042L)). Overall, there were also no differences between nemiralisib and placebo in secondary endpoints, including re-exacerbations. Plasma PK increased in a dose proportional manner. The most common adverse event for nemiralisib was post-inhalation cough which appeared to be dose-related. Conclusion The addition of nemiralisib to standard-of-care treatment for 12 weeks did not improve lung function or re-exacerbations in patients with, and following an acute exacerbation of COPD. However, this study demonstrated that large clinical trials recruiting acutely exacerbating patients can successfully be conducted.",2021,"There was no difference in change from baseline FEV 1 at week 12 between the nemiralisib and placebo treatment groups (posterior adjusted median difference, nemiralisib 750 µg and placebo: -0.004L","['COPD patients (40-80 years, ≥10 pack-year smoking history, current moderate/severe acute exacerbation of COPD requiring standard-of-care treatment', 'patients with, and following an acute exacerbation of COPD', 'chronic obstructive pulmonary disease (COPD', 'patients experiencing an acute exacerbation of COPD', 'Patients with an Acute Exacerbation of COPD']",['placebo'],"['safety and efficacy', 're-exacerbations', 'lung function or re-exacerbations', 'Plasma PK', ""rate of re-exacerbations, patient-reported outcomes (Exacerbations of Chronic Pulmonary Disease Tool, COPD Assessment Test, St George's Respiratory Questionnaire-COPD), plasma pharmacokinetics (PK) and safety/tolerability""]","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1277691', 'cui_str': 'Pack years'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0340044', 'cui_str': 'Acute exacerbation of chronic obstructive airways disease'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0024115', 'cui_str': 'Disorder of lung'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C4284282', 'cui_str': 'COPD assessment test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",,0.625908,"There was no difference in change from baseline FEV 1 at week 12 between the nemiralisib and placebo treatment groups (posterior adjusted median difference, nemiralisib 750 µg and placebo: -0.004L","[{'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Fahy', 'Affiliation': 'Discovery Medicine, GlaxoSmithKline R&D, GSK House, Brentford, UK.'}, {'ForeName': 'Farshid', 'Initials': 'F', 'LastName': 'Homayoun-Valiani', 'Affiliation': 'Global Clinical Operations, GlaxoSmithKline, GSK House, Brentford, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Cahn', 'Affiliation': 'Discovery Medicine, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Robertson', 'Affiliation': 'Biostatistics, GlaxoSmithKline R&D, Stevenage, UK.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Templeton', 'Affiliation': 'Biostatistics, GlaxoSmithKline R&D, Stevenage, UK.'}, {'ForeName': 'Wilhelmine H', 'Initials': 'WH', 'LastName': 'Meeraus', 'Affiliation': 'Respiratory Epidemiology, Value Evidence and Outcomes, GlaxoSmithKline R&D, GSK House, Brentford, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Wilson', 'Affiliation': 'Discovery Medicine, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Lowings', 'Affiliation': 'Regulatory Affairs, GlaxoSmithKline, GSK House, Brentford, UK.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Marotti', 'Affiliation': 'Safety and Medical Governance, GlaxoSmithKline R&D, GSK House, Brentford, UK.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'West', 'Affiliation': 'Global Clinical Operations, GlaxoSmithKline, GSK House, Brentford, UK.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Tabberer', 'Affiliation': 'Value Evidence and Outcomes, GlaxoSmithKline R&D, GSK House, Brentford, UK.'}, {'ForeName': 'Edith M', 'Initials': 'EM', 'LastName': 'Hessel', 'Affiliation': 'Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.'}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S309320'] 3450,34110614,Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects.,"BACKGROUND AND OBJECTIVE Omecamtiv mecarbil (OM) is a cardiac myosin activator under clinical development for the treatment of heart failure. Two modified-release (MR) novel OM minitablet formulations were developed to support the planned investigation of chronic heart failure in pediatric patients. The primary objective of this study was to determine the bioavailability of the minitablets relative to the adult matrix MR formulation tablets. METHODS In a randomized, 5-period, crossover study, 20 healthy subjects received each of the following treatments orally: one 25-mg adult matrix MR tablet, 25 1-mg slow-release minitablets, 25 1-mg fast-release minitablets, six 1-mg slow-release minitablets, or six 1-mg fast-release minitablets after an overnight fast of at least 10 h with a minimum washout of 7 days between treatments. Blood samples were collected for up to 168 h. OM pharmacokinetic parameters were estimated using non-compartmental methods. RESULTS When OM was administered as 25 1-mg OM slow-release minitablets, AUC last , AUC inf , and C max were 0.998-, 1.00-, and 1.29-fold of a single 25-mg OM matrix MR tablet, respectively. When OM was administered as 25 1-mg OM fast-release minitablets, AUC last , AUC inf , and C max were 1.26-, 1.25-, and 2.21-fold of a single 25-mg OM matrix MR tablet, respectively. The slow- and fast-release minitablets display approximately dose-proportional pharmacokinetics. There were no serious adverse events or treatment-emergent adverse events leading to discontinuation from the study. CONCLUSIONS Relative bioavailability of slow-release minitablets was demonstrated to be similar to the adult matrix MR formulation.",2021,"There were no serious adverse events or treatment-emergent adverse events leading to discontinuation from the study. ","['pediatric patients', '20 healthy subjects', 'Healthy Adult Subjects', 'heart failure']","['Omecamtiv Mecarbil Pediatric Minitablet Formulations', '25-mg adult matrix MR tablet', 'OM']","['Blood samples', 'AUC last , AUC inf , and C max', 'OM pharmacokinetic parameters', 'serious adverse events', 'bioavailability']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}]","[{'cui': 'C2932035', 'cui_str': 'omecamtiv mecarbil'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C1273646', 'cui_str': 'Modified-release oral tablet'}]","[{'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C2932035', 'cui_str': 'omecamtiv mecarbil'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}]",20.0,0.102118,"There were no serious adverse events or treatment-emergent adverse events leading to discontinuation from the study. ","[{'ForeName': 'Ashit', 'Initials': 'A', 'LastName': 'Trivedi', 'Affiliation': 'Amgen, Inc, 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA. ashitt@amgen.com.'}, {'ForeName': 'Mia', 'Initials': 'M', 'LastName': 'Mackowski', 'Affiliation': 'Amgen, Inc, 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.'}, {'ForeName': 'Pegah', 'Initials': 'P', 'LastName': 'Jafarinasabian', 'Affiliation': 'Amgen, Inc, 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.'}, {'ForeName': 'Hanze', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Amgen, Inc, 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Flach', 'Affiliation': 'Covance Inc, Madison, WI, USA.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Terminello', 'Affiliation': 'Amgen, Inc, 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.'}, {'ForeName': 'Ajay', 'Initials': 'A', 'LastName': 'Bhatia', 'Affiliation': 'Amgen, Inc, 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.'}, {'ForeName': 'Sandeep', 'Initials': 'S', 'LastName': 'Dutta', 'Affiliation': 'Amgen, Inc, 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Lee', 'Affiliation': 'Amgen, Inc, 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.'}]",Clinical drug investigation,['10.1007/s40261-021-01052-3'] 3451,34114077,The effect of acute aerobic exercise on the consolidation of motor memories.,"Acute aerobic exercise performed prior to training may assist with motor skill acquisition through enhancement of motor cortical plasticity. In addition, high-intensity exercise performed after training improves retention, although the mechanisms of this are unclear. We hypothesized that acute continuous moderate-intensity exercise performed post-motor training would also assist with motor skill retention and that this behavioral change would be positively correlated with neural markers of training-related cortical adaptation. Participants [n = 33; assigned to an exercise (EXE) or control (CON) group] completed a single visuomotor training session using bilateral wrist movements while movement-related cortical potentials (MRCPs) were collected. After motor training, the EXE group exercised for 20 min [70% of heart rate reserve (HRR)] and the CON group read for the same amount of time. Both groups completed two post-training tests after exercise/rest: 10 min and ~ 30 min once heart rate returned to resting level in EXE. Retention and transfer tests were both completed 1 and 7 days later. MRCPs measured training-related neural adaptations during the first visit and motor performance was assessed as time and trajectory to the target. The EXE group had better performance than CON at retention (significant 7 days post-training). MRCP amplitudes increased from early to late motor training and this amplitude change was correlated with motor performance at retention. Results suggest that moderate-intensity exercise post-motor training helps motor skill retention and that there may be a relationship with motor training-related cortical adaptations that is enhanced with post-motor training exercise.",2021,The EXE group had better performance than CON at retention (significant 7 days post-training).,['Participants [n\u2009=\u200933; assigned to an'],"['acute aerobic exercise', 'CON', 'EXE', 'exercise (EXE) or control (CON) group] completed a single visuomotor training session using bilateral wrist movements while movement-related cortical potentials (MRCPs']","['MRCP amplitudes', 'MRCPs measured training-related neural adaptations', 'consolidation of motor memories', 'Retention and transfer tests']","[{'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}]","[{'cui': 'C0994163', 'cui_str': 'Magnetic resonance cholangiopancreatography'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0521530', 'cui_str': 'Lung consolidation'}, {'cui': 'C0561782', 'cui_str': 'Procedural memory'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",,0.00472279,The EXE group had better performance than CON at retention (significant 7 days post-training).,"[{'ForeName': 'Sarah R', 'Initials': 'SR', 'LastName': 'Holman', 'Affiliation': 'Department of Kinesiology, University of Waterloo, 200 University Ave. W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'W Richard', 'Initials': 'WR', 'LastName': 'Staines', 'Affiliation': 'Department of Kinesiology, University of Waterloo, 200 University Ave. W, Waterloo, ON, N2L 3G1, Canada. rstaines@uwaterloo.ca.'}]",Experimental brain research,['10.1007/s00221-021-06148-y'] 3452,34113094,"Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials.","Background Inhibition of phosphoinositide 3-kinase δ (PI3Kδ) exerts corrective effects on the dysregulated migration characteristics of neutrophils isolated from patients with chronic obstructive pulmonary disease (COPD). Objective To develop novel, induced sputum endpoints to demonstrate changes in neutrophil phenotype in the lung by administering nemiralisib, a potent and selective inhaled PI3Kδ inhibitor, to patients with stable COPD or patients with acute exacerbation (AE) of COPD. Methods In two randomized, double-blind, placebo-controlled clinical trials patients with A) stable COPD (N=28, randomized 3:1) or B) AECOPD (N=44, randomized 1:1) received treatment with inhaled nemiralisib (1mg). Endpoints included induced sputum at various time points before and during treatment for the measurement of transcriptomics (primary endpoint), inflammatory mediators, functional respiratory imaging (FRI), and spirometry. Results In stable COPD patients, the use of nemiralisib was associated with alterations in sputum neutrophil transcriptomics suggestive of an improvement in migration phenotype; however, the same nemiralisib-evoked effects were not observed in AECOPD. Inhibition of sputum inflammatory mediators was also observed in stable but not AECOPD patients. In contrast, a placebo-corrected improvement in forced expiratory volume in 1 sec of 136 mL (95% Credible Intervals -46, 315mL) with a probability that the true treatment ratio was >0% (Pr(θ>0)) of 93% was observed in AECOPD. However, FRI endpoints remained unchanged. Conclusion We provide evidence for nemiralisib-evoked changes in neutrophil migration phenotype in stable COPD but not AECOPD, despite improving lung function in the latter group. We conclude that induced sputum can be used for measuring evidence of alteration of neutrophil phenotype in stable patients, and our study provides a data set of the sputum transcriptomic changes during recovery from AECOPD.",2021,"In contrast, a placebo-corrected improvement in forced expiratory volume in 1 sec of 136 mL (95% Credible Intervals -46, 315mL) with a probability that the true treatment ratio was >0% (Pr(θ>0)) of 93% was observed in AECOPD.","['controlled clinical trials patients with A) stable COPD (N=28, randomized 3:1) or B) AECOPD ', 'patients with chronic obstructive pulmonary disease (COPD', 'patients with stable COPD or patients with acute exacerbation (AE) of COPD']","['inhaled nemiralisib', 'placebo', 'phosphoinositide 3-kinase δ (PI3Kδ']","['lung function', 'forced expiratory volume', 'FRI endpoints', 'Inhibition of sputum inflammatory mediators', 'induced sputum at various time points before and during treatment for the measurement of transcriptomics (primary endpoint), inflammatory mediators, functional respiratory imaging (FRI), and spirometry']","[{'cui': 'C0936233', 'cui_str': 'Controlled Clinical Trial'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C5197976', 'cui_str': 'Nemiralisib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0044602', 'cui_str': '1-phosphatidylinositol 3-kinase'}]","[{'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}]",,0.184355,"In contrast, a placebo-corrected improvement in forced expiratory volume in 1 sec of 136 mL (95% Credible Intervals -46, 315mL) with a probability that the true treatment ratio was >0% (Pr(θ>0)) of 93% was observed in AECOPD.","[{'ForeName': 'Malcolm', 'Initials': 'M', 'LastName': 'Begg', 'Affiliation': 'Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'J Nicole', 'Initials': 'JN', 'LastName': 'Hamblin', 'Affiliation': 'Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Jarvis', 'Affiliation': 'Biostatistics, GlaxoSmithKline R&D, Stevenage, UK.'}, {'ForeName': 'Glyn', 'Initials': 'G', 'LastName': 'Bradley', 'Affiliation': 'Computational Biology, Medicinal Science and Technology, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Mark', 'Affiliation': 'Study Management, Clinical Development, GlaxoSmithKline, Mississauga, ON, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Michalovich', 'Affiliation': 'Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Lennon', 'Affiliation': 'Nonclinical and Translational Statistics, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Hannah E', 'Initials': 'HE', 'LastName': 'Wajdner', 'Affiliation': 'Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Augustin', 'Initials': 'A', 'LastName': 'Amour', 'Affiliation': 'Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Wilson', 'Affiliation': 'Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Saunders', 'Affiliation': 'Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Rikako', 'Initials': 'R', 'LastName': 'Tanaka', 'Affiliation': 'Data Management & Strategy, Clinical Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Saki', 'Initials': 'S', 'LastName': 'Arai', 'Affiliation': 'Data Management & Strategy, Clinical Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Tang', 'Affiliation': 'Pharma Safety, Clinical Development, GlaxoSmithKline, Brentford, Middlesex, UK.'}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Van Holsbeke', 'Affiliation': 'FLUIDDA nv, Kontich, 2550, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'De Backer', 'Affiliation': 'FLUIDDA nv, Kontich, 2550, Belgium.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Vos', 'Affiliation': 'FLUIDDA nv, Kontich, 2550, Belgium.'}, {'ForeName': 'Ingrid L', 'Initials': 'IL', 'LastName': 'Titlestad', 'Affiliation': 'Department of Respiratory Medicine, Odense University Hospital and University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'J Mark', 'Initials': 'JM', 'LastName': 'FitzGerald', 'Affiliation': 'Centre for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': 'Killian', 'Affiliation': 'Cardiorespiratory Research Laboratory, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Bourbeau', 'Affiliation': 'Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Claude', 'Initials': 'C', 'LastName': 'Poirier', 'Affiliation': 'Department of Medicine, Respiratory Medicine Division, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Maltais', 'Affiliation': 'Institut Universitaire de Cardiologie et de Pneumologie de Québe, Université Laval, Quebec City, QC, Canada.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Cahn', 'Affiliation': 'Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Edith M', 'Initials': 'EM', 'LastName': 'Hessel', 'Affiliation': 'Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.'}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S309303'] 3453,34113093,An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial.,"Purpose This study evaluated the safety and efficacy of inhaled nemiralisib, a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor, in patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods In this double-blind, placebo-controlled study, 126 patients (40-80 years with a post-bronchodilator forced expiratory volume in 1 sec (FEV 1 ) ≤80% of predicted (previously documented)) were randomized 1:1 to once daily inhaled nemiralisib (1 mg) or placebo for 84 days, added to standard of care. The primary endpoint was specific imaging airway volume (siVaw) after 28 treatment days and was analyzed using a Bayesian repeated measures model (clintrials.gov: NCT02294734). Results A total of 126 patients were randomized to treatment; 55 on active treatment and 49 on placebo completed the study. When comparing nemiralisib and placebo-treated patients, an 18% placebo-corrected increase from baseline in distal siVaw (95% credible intervals (Cr I) (-1%, 42%)) was observed on Day 28. The probability that the true treatment ratio was >0% (Pr(θ>0)) was 96%, suggestive of a real treatment effect. Improvements were observed across all lung lobes. Patients treated with nemiralisib experienced a 107.3 mL improvement in posterior median FEV 1 (change from baseline, 95% Cr I (-2.1, 215.5)) at day 84, compared with placebo. Adverse events were reported by 41 patients on placebo and 49 on nemiralisib, the most common being post-inhalation cough on nemiralisib (35%) vs placebo (3%). Conclusion These data show that addition of nemiralisib to usual care delivers more effective recovery from an acute exacerbation and improves lung function parameters including siVaw and FEV 1 . Although post-inhalation cough was identified, nemiralisib was otherwise well tolerated, providing a promising novel therapy for this acutely ill patient group.",2021,"Patients treated with nemiralisib experienced a 107.3 mL improvement in posterior median FEV 1 (change from baseline, 95%","['Acutely Exacerbating COPD Patients', '126 patients were randomized to treatment; 55 on active treatment and 49 on', '126 patients (40-80 years with a post-bronchodilator forced expiratory volume in 1 sec (FEV 1 ) ≤80% of predicted (previously documented', 'patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD']","['placebo', 'daily inhaled nemiralisib (1 mg) or placebo', 'inhaled nemiralisib, a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor', 'Inhaled PI3Kδ Inhibitor']","['specific imaging airway volume (siVaw', 'posterior median FEV', 'distal siVaw', 'Adverse events']","[{'cui': 'C0436331', 'cui_str': 'Symptom aggravating factors'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0006280', 'cui_str': 'Bronchodilator agent'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0059387', 'cui_str': 'staphylococcal enterotoxin C'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0340044', 'cui_str': 'Acute exacerbation of chronic obstructive airways disease'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C5197976', 'cui_str': 'Nemiralisib'}, {'cui': 'C0044602', 'cui_str': '1-phosphatidylinositol 3-kinase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",126.0,0.359001,"Patients treated with nemiralisib experienced a 107.3 mL improvement in posterior median FEV 1 (change from baseline, 95%","[{'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Cahn', 'Affiliation': 'Discovery Medicine, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'J Nicole', 'Initials': 'JN', 'LastName': 'Hamblin', 'Affiliation': 'Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Robertson', 'Affiliation': 'Biostatistics, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Malcolm', 'Initials': 'M', 'LastName': 'Begg', 'Affiliation': 'Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Jarvis', 'Affiliation': 'Biostatistics, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Wilson', 'Affiliation': 'Discovery Medicine, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Dear', 'Affiliation': 'Mechanistic Safety & Disposition, GlaxoSmithKline, Ware, UK.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Leemereise', 'Affiliation': 'Global Clinical Sciences & Delivery, GlaxoSmithKline, Amersfoort, the Netherlands.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Cui', 'Affiliation': 'Pharma Safety, GlaxoSmithKline, Brentford, Middlesex, UK.'}, {'ForeName': 'Maki', 'Initials': 'M', 'LastName': 'Mizuma', 'Affiliation': 'Data Management & Strategy, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Mickael', 'Initials': 'M', 'LastName': 'Montembault', 'Affiliation': 'Global Clinical Sciences & Delivery, GlaxoSmithKline, Brentford, Middlesex, UK.'}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Van Holsbeke', 'Affiliation': 'FLUIDDA nv, Kontich, 2550, Belgium.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Vos', 'Affiliation': 'FLUIDDA nv, Kontich, 2550, Belgium.'}, {'ForeName': 'Wilfried', 'Initials': 'W', 'LastName': 'De Backer', 'Affiliation': 'Pulmonary Medicine & Pulmonary Rehabilitation, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'De Backer', 'Affiliation': 'FLUIDDA nv, Kontich, 2550, Belgium.'}, {'ForeName': 'Edith M', 'Initials': 'EM', 'LastName': 'Hessel', 'Affiliation': 'Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.'}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S309129'] 3454,34112710,Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.,"PURPOSE In the placebo-controlled SPARTAN study, apalutamide added to androgen-deprivation therapy (ADT) improved metastasis-free survival, second progression-free survival (PFS2), and overall survival (OS) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Mechanisms of resistance to apalutamide in nmCRPC require evaluation. PATIENTS AND METHODS In a subset of patients from SPARTAN, aberrations were assessed at baseline and end of study treatment (EOST) using targeted next-generation sequencing or qRT-PCR. Circulating-tumor DNA (ctDNA) levels were assessed qualitatively. Select aberrations in androgen receptor (AR) and other common PC-driving genes were detected and summarized by the treatment group; genomic aberrations were summarized in ctDNA-positive samples. Association between detection of aberrations in all patients and outcomes was assessed using Cox proportional-hazards models and multivariate analysis. RESULTS In 247 patients, the overall prevalence of ctDNA, AR aberrations, and TP53 inactivation increased from baseline (40.6%, 13.6%, and 22.2%) to EOST (57.1%, 25.4%, and 35.0%) and was comparable between treatment groups at EOST. In patients who received subsequent androgen signaling inhibition after study treatment, detectable biomarkers at EOST were significantly associated with poor outcomes: ctDNA with PFS2 or OS (HR, 2.01 or 2.17, respectively; P < 0.0001 for both), any AR aberration with PFS2 (1.74; P = 0.024), and TP53 or BRCA2 inactivation with OS (2.06; P = 0.003; or 3.1; P < 0.0001). CONCLUSIONS Apalutamide plus ADT did not increase detectable AR/non-AR aberrations over ADT alone. Detectable ctDNA, AR aberrations, and TP53/BRCA2 inactivation at EOST were associated with poor outcomes in patients treated with first subsequent androgen signaling inhibitor.",2021,"Detectable ctDNA, AR aberrations, and TP53/BRCA2 inactivation at EOST were associated with poor outcomes in patients treated with first subsequent androgen signaling inhibitor.","['patients with nonmetastatic castration-resistant prostate cancer (nmCRPC', 'Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with']","['Apalutamide and Androgen-Deprivation Therapy', 'placebo', 'PFS2']","['Circulating tumor (ct)DNA levels', 'TP53 or BRCA2 inactivation', 'Blood Biomarker Landscape', 'overall prevalence of ctDNA, AR aberrations, and TP53 inactivation', 'metastasis-free survival, second progression-free survival, and overall survival (OS', 'Detectable ctDNA, AR aberrations, and TP53/BRCA2 inactivation at EOST', 'detectable AR/non-AR aberrations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1328504', 'cui_str': 'Hormone refractory prostate cancer'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C4329353', 'cui_str': 'apalutamide'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0079419', 'cui_str': 'Genes, TP53'}, {'cui': 'C2973986', 'cui_str': 'BRCA2 protein, human'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C3827014', 'cui_str': 'Cell-Free Tumor DNA'}, {'cui': 'C0034786', 'cui_str': 'Androgen receptor'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",247.0,0.110818,"Detectable ctDNA, AR aberrations, and TP53/BRCA2 inactivation at EOST were associated with poor outcomes in patients treated with first subsequent androgen signaling inhibitor.","[{'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Smith', 'Affiliation': 'Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts. MRSMITH@mgh.harvard.edu.'}, {'ForeName': 'Shibu', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': 'Janssen Research & Development, Spring House, Pennsylvania.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gormley', 'Affiliation': 'Janssen Research & Development, Spring House, Pennsylvania.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Chowdhury', 'Affiliation': ""Guy's, King's and St. Thomas' Hospitals, Great Maze Pond, London, United Kingdom.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Olmos', 'Affiliation': 'Spanish National Cancer Research Center (CNIO), and Hospital Universitario Virgen de la Victoria y Regional de Málaga, Madrid, Spain.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Oudard', 'Affiliation': 'Oncology Department, Georges Pompidou Hospital, University of Paris, Paris, France.'}, {'ForeName': 'Felix Y', 'Initials': 'FY', 'LastName': 'Feng', 'Affiliation': 'Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Yashoda', 'Initials': 'Y', 'LastName': 'Rajpurohit', 'Affiliation': 'Janssen Research & Development, Spring House, Pennsylvania.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Urtishak', 'Affiliation': 'Janssen Research & Development, Spring House, Pennsylvania.'}, {'ForeName': 'Deborah S', 'Initials': 'DS', 'LastName': 'Ricci', 'Affiliation': 'Janssen Research & Development, Spring House, Pennsylvania.'}, {'ForeName': 'Brendan', 'Initials': 'B', 'LastName': 'Rooney', 'Affiliation': 'Janssen Research & Development, High Wycombe, United Kingdom.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Lopez-Gitlitz', 'Affiliation': 'Janssen Research & Development, Los Angeles, California.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'Janssen Research & Development, Los Angeles, California.'}, {'ForeName': 'Alexander W', 'Initials': 'AW', 'LastName': 'Wyatt', 'Affiliation': 'The University of British Columbia, Vancouver Prostate Centre, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Resolution Bioscience, Kirkland, Washington.'}, {'ForeName': 'Gerhardt', 'Initials': 'G', 'LastName': 'Attard', 'Affiliation': 'University College London Cancer Institute, London, United Kingdom.'}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Small', 'Affiliation': 'Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-21-0358'] 3455,34114354,Effects of preserving the bronchial artery on cough after thoracoscopic lobectomy.,"BACKGROUND The purpose of this prospective study was to explore the influence of both preoperative three-dimensional (3D) reconstruction and intraoperative preservation of the bronchial artery (BA) on postoperative cough after thoracoscopic lobectomy. METHODS A total of 60 patients who had received a combination of thoracoscopic lobectomy and systematic lymph node dissection were included in this study. They were divided into two groups, namely the BA preservation group (Group A), and conventional surgical treatment group (Group B). In group A, we used Exoview software for 3D reconstruction of the BA before the operation and the BA was preserved during the operation. 3D reconstruction of the BA was not performed before surgery in group B. The incidence of postoperative cough, the Mandarin Chinese version of the Leicester cough questionnaire (LCQ-MC), physiological, psychological and social dimensions and total score of the two groups were compared and analyzed. RESULTS The scores and total scores of LCQ-MC in group B were lower than those in group A one and two months after surgery. There were significant differences between the two groups in physiological and psychological dimensions and total scores (p < 0.05), but there was no significant difference in social dimension between the two groups (p > 0.05). The incidence of postoperative cough in group A (16.7%) was lower than that in group B (30%), while the difference was not statistically significant (p = 0.222). CONCLUSIONS Preoperative 3D reconstruction and intraoperative preservation of the BA can reduce the severity of postoperative cough.",2021,"There were significant differences between the two groups in physiological and psychological dimensions and total scores (p < 0.05), but there was no significant difference in social dimension between the two groups (p > 0.05).","['60 patients who had received a combination of thoracoscopic lobectomy and systematic lymph node dissection', 'cough after thoracoscopic lobectomy']","['conventional surgical treatment', 'preoperative three-dimensional (3D) reconstruction and intraoperative preservation of the bronchial artery (BA']","['social dimension', 'incidence of postoperative cough', 'incidence of postoperative cough, the Mandarin Chinese version of the Leicester cough questionnaire (LCQ-MC), physiological, psychological and social dimensions and total score', 'postoperative cough', 'severity of postoperative cough', 'physiological and psychological dimensions and total scores', 'scores and total scores of LCQ-MC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023928', 'cui_str': 'Lobectomy'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0024203', 'cui_str': 'Excision of lymph node'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0006257', 'cui_str': 'Structure of bronchial artery'}]","[{'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",60.0,0.0357983,"There were significant differences between the two groups in physiological and psychological dimensions and total scores (p < 0.05), but there was no significant difference in social dimension between the two groups (p > 0.05).","[{'ForeName': 'Liuying', 'Initials': 'L', 'LastName': 'Pan', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Department of Radiology, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Chun', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Ding', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Xinyu', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, China.'}]",Thoracic cancer,['10.1111/1759-7714.14012'] 3456,34111367,"ActionHealthNYC: Effectiveness of a Health Care Access Program for the Uninsured, 2016-2017.","Objectives. To evaluate the effectiveness of a novel health care access program (ActionHealthNYC) for uninsured immigrants. Methods. The evaluation was conducted as a randomized controlled trial in New York City from May 2016 through June 2017. Using baseline and follow-up survey data, we assessed health care access, patient experience, and health status. Results. At baseline, 25% of participants had a regular source of care; two thirds had visited a doctor in the past year and reported 2.5 visits in the past 12 months, on average. Nine to 12 months later, intervention participants were 1.2 times more likely to report having a primary care provider (58% vs 46%), were 1.2 times more likely to have seen a doctor in the past 9 months (91% vs 77%), and had 1.5 times more health care visits (4.1 vs 2.9) compared with control participants. Conclusions. ActionHealthNYC increased health care access among program participants. Public Health Implications . State and local policymakers should build on the progress that has been made over the last decade to expand and improve access to health care for uninsured immigrants.",2021,"Nine to 12 months later, intervention participants were 1.2 times more likely to report having a primary care provider (58% vs 46%), were 1.2 times more likely to have seen a doctor in the past 9 months (91% vs 77%), and had 1.5 times more health care visits (4.1 vs 2.9) compared with control participants. ","['New York City from May 2016 through June 2017', 'program participants', 'uninsured immigrants']","['Health Care Access Program', 'ActionHealthNYC', 'novel health care access program (ActionHealthNYC']","['times more likely to report having a primary care provider', 'health care access, patient experience, and health status', 'regular source of care', 'health care visits', 'health care access']","[{'cui': 'C0027977', 'cui_str': 'New York City'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0087134', 'cui_str': 'Uninsured'}, {'cui': 'C0282163', 'cui_str': 'Immigrant'}]","[{'cui': 'C0018748', 'cui_str': 'Accessibility of Health Services'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C0018748', 'cui_str': 'Accessibility of Health Services'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}]",,0.12914,"Nine to 12 months later, intervention participants were 1.2 times more likely to report having a primary care provider (58% vs 46%), were 1.2 times more likely to have seen a doctor in the past 9 months (91% vs 77%), and had 1.5 times more health care visits (4.1 vs 2.9) compared with control participants. ","[{'ForeName': 'Rishi K', 'Initials': 'RK', 'LastName': 'Sood', 'Affiliation': 'Rishi K. Sood is with the Bureau of Equitable Health Systems, New York City Department of Health and Mental Hygiene, Queens, NY. Jin Yung Bae and Caroline Heindrichs were with the Bureau of Primary Care Access and Planning, New York City Department of Health and Mental Hygiene. Adrienne Sabety was with the Interfaculty Initiative in Health Policy at Harvard University, Cambridge, MA. Pui Ying Chan is with the Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene.'}, {'ForeName': 'Jin Yung', 'Initials': 'JY', 'LastName': 'Bae', 'Affiliation': 'Rishi K. Sood is with the Bureau of Equitable Health Systems, New York City Department of Health and Mental Hygiene, Queens, NY. Jin Yung Bae and Caroline Heindrichs were with the Bureau of Primary Care Access and Planning, New York City Department of Health and Mental Hygiene. Adrienne Sabety was with the Interfaculty Initiative in Health Policy at Harvard University, Cambridge, MA. Pui Ying Chan is with the Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Sabety', 'Affiliation': 'Rishi K. Sood is with the Bureau of Equitable Health Systems, New York City Department of Health and Mental Hygiene, Queens, NY. Jin Yung Bae and Caroline Heindrichs were with the Bureau of Primary Care Access and Planning, New York City Department of Health and Mental Hygiene. Adrienne Sabety was with the Interfaculty Initiative in Health Policy at Harvard University, Cambridge, MA. Pui Ying Chan is with the Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene.'}, {'ForeName': 'Pui Ying', 'Initials': 'PY', 'LastName': 'Chan', 'Affiliation': 'Rishi K. Sood is with the Bureau of Equitable Health Systems, New York City Department of Health and Mental Hygiene, Queens, NY. Jin Yung Bae and Caroline Heindrichs were with the Bureau of Primary Care Access and Planning, New York City Department of Health and Mental Hygiene. Adrienne Sabety was with the Interfaculty Initiative in Health Policy at Harvard University, Cambridge, MA. Pui Ying Chan is with the Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Heindrichs', 'Affiliation': 'Rishi K. Sood is with the Bureau of Equitable Health Systems, New York City Department of Health and Mental Hygiene, Queens, NY. Jin Yung Bae and Caroline Heindrichs were with the Bureau of Primary Care Access and Planning, New York City Department of Health and Mental Hygiene. Adrienne Sabety was with the Interfaculty Initiative in Health Policy at Harvard University, Cambridge, MA. Pui Ying Chan is with the Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene.'}]",American journal of public health,['10.2105/AJPH.2021.306271'] 3457,34117798,Smoking and obesity negatively affect the favourable outcome of varicocelectomy in sub-fertile men.,"We assessed the effect of smoking and/or obesity on semen parameters and testosterone/oestradiol (T/E) ratio among sub-fertile men treated with sub-inguinal varicocelectomy. In this prospective, controlled, clinical study, 80 sub-fertile men with clinical varicocele who were subjected to sub-inguinal varicocelectomy were assigned into four equal groups (n = 20/each), group A: obese and smokers, group B: obese and nonsmokers, group C: smokers and nonobese and group D: nonsmokers and nonobese. Semen parameters, serum testosterone, oestradiol, follicle-stimulating hormone, luteinising hormone, prolactin and calculation of T/E ratio were assessed at baseline and 6 months post-varicocelectomy. The mean age ± SD of the study population was 26.1 ± 4.55. No statistical difference was detected among the study groups regarding age, residence, education, marital status and occupation (p > 0.05 for each). Post-operatively, significant improvements in semen parameters were detected in all groups. There was a significant difference between groups A and B versus C and D (obese versus nonobese groups) and between groups A and C versus B and D (smokers versus nonsmokers; p < 0.05 for each) regarding semen parameters, testosterone level and T/E ratio. Smoking and/or obesity negatively affect(s) the favourable outcome of varicocelectomy, specifically improvement of semen parameters and hormonal pattern in sub-fertile men with varicocele.",2021,"There was a significant difference between groups A and B versus C and D (obese versus nonobese groups) and between groups A and C versus B and D (smokers versus nonsmokers; p < 0.05 for each) regarding semen parameters, testosterone level and T/E ratio.","['sub-fertile men treated with sub-inguinal varicocelectomy', 'sub-fertile men', '80 sub-fertile men with clinical varicocele who were subjected to sub-inguinal varicocelectomy were assigned into four equal groups (n\xa0=\xa020/each), group A: obese and smokers, group B: obese and nonsmokers, group C: smokers and nonobese and group D: nonsmokers and nonobese', 'sub-fertile men with varicocele']",['varicocelectomy'],"['semen parameters', 'semen parameters and testosterone/oestradiol (T/E) ratio', 'semen parameters, testosterone level and T/E ratio', 'Semen parameters, serum testosterone, oestradiol, follicle-stimulating hormone, luteinising hormone, prolactin and calculation of T/E ratio']","[{'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0018246', 'cui_str': 'Inguinal'}, {'cui': 'C0194985', 'cui_str': 'Excision of varicocele'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0042341', 'cui_str': 'Varicocele'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0337672', 'cui_str': 'Non-smoker'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0441838', 'cui_str': 'Group D'}]","[{'cui': 'C0194985', 'cui_str': 'Excision of varicocele'}]","[{'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement'}, {'cui': 'C0428413', 'cui_str': 'Serum testosterone measurement'}, {'cui': 'C0018120', 'cui_str': 'Ovarian follicle structure'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0033371', 'cui_str': 'Prolactin'}, {'cui': 'C1441506', 'cui_str': 'Calculation technique'}]",80.0,0.0641963,"There was a significant difference between groups A and B versus C and D (obese versus nonobese groups) and between groups A and C versus B and D (smokers versus nonsmokers; p < 0.05 for each) regarding semen parameters, testosterone level and T/E ratio.","[{'ForeName': 'Mohamed A', 'Initials': 'MA', 'LastName': 'El-Dighidy', 'Affiliation': 'Department of Urology, Suez Canal University, Ismailia, Egypt.'}, {'ForeName': 'Mahmoud H', 'Initials': 'MH', 'LastName': 'Sherief', 'Affiliation': 'Department of Urology, Suez Canal University, Ismailia, Egypt.'}, {'ForeName': 'Mostafa A', 'Initials': 'MA', 'LastName': 'Shamaa', 'Affiliation': 'Department of Urology, Suez Canal University, Ismailia, Egypt.'}, {'ForeName': 'Ahmed I', 'Initials': 'AI', 'LastName': 'El-Sakka', 'Affiliation': 'Department of Urology, Suez Canal University, Ismailia, Egypt.'}]",Andrologia,['10.1111/and.14131'] 3458,34111898,Comparison of Acceptance and Knowledge Transfer in Patient Information Before an MRI Exam Administered by Humanoid Robot Versus a Tablet Computer: A Randomized Controlled Study.,"PURPOSE To investigate whether a humanoid robot in a clinical radiological setting is accepted as a source of information in conversations before MRI examinations of patients. In addition, the usability and the information transfer were compared with a tablet. METHODS Patients were randomly assigned to a robot or tablet group with their consent prior to MRI. The usability of both devices was compared with the extended System Usability Scale (SUS) and the information transfer with a knowledge query. Reasons for refusal were collected by a non-responder questionnaire. RESULTS At the University Hospital Halle 117 patients were included for participation. There was no statistically significant difference in gender and age. Of 18 non-responders, 4 refused to participate partly because of the robot; for another 3 the reason could not be clarified. The usability according to SUS score was different with statistical significance between the groups in the mean comparison and was one step higher for the tablet on the adjective scale. There was no statistically significant difference in knowledge transfer. On average, 8.41 of 9 questions were answered correctly. CONCLUSION This study is the first application, in a clinical radiological setting, of a humanoid robot interacting with patients. Tablet and robot are suitable for information transfer in the context of MRI. In comparison to studies in which the willingness to interact with a robot in the health care sector was investigated, the willingness is significantly higher in the present study. This could be explained by the fact that it was a concrete use case that was understandable to the participants and not a hypothetical scenario. Thus, potentially high acceptance for further specific areas of application of robots in radiology can be assumed. The higher level of usability perceived in the tablet group can be explained by the fact that here the interface represents a form of operation that has been established for years in all population groups. More frequent exposure to robots could also improve the response in the future. KEY POINTS · patients accept humanoid robots in clinical radiologic situations. · at present they can only convey information as well as an inexpensive tablet. · future systems can relieve the burden on personnel.. CITATION FORMAT · Stoevesandt D, Jahn P, Watzke S et al. Comparison of Acceptance and Knowledge Transfer in Patient Information Before an MRI Exam Administered by Humanoid Robot Versus a Tablet Computer: A Randomized Controlled Study. Fortschr Röntgenstr 2021; 193: 947 - 954.",2021,The usability according to SUS score was different with statistical significance between the groups in the mean comparison and was one step higher for the tablet on the adjective scale.,"['Patients', 'At the University Hospital Halle 117 patients were included for participation']","['Humanoid Robot', 'robot or tablet group with their consent prior to MRI', 'Tablet Computer', 'humanoid robot']","['SUS score', 'knowledge transfer']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C4045980', 'cui_str': 'Tablet Computers'}]","[{'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}]",117.0,0.0167905,The usability according to SUS score was different with statistical significance between the groups in the mean comparison and was one step higher for the tablet on the adjective scale.,"[{'ForeName': 'Dietrich', 'Initials': 'D', 'LastName': 'Stoevesandt', 'Affiliation': 'Dorothea Erxleben Skills and Simulation Centre, Martin\xa0Luther University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Jahn', 'Affiliation': 'Health service research group, Martin Luther University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Watzke', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Martin Luther University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Walter A', 'Initials': 'WA', 'LastName': 'Wohlgemuth', 'Affiliation': 'Department of Radiology, Martin Luther University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Behr', 'Affiliation': 'Dorothea Erxleben Skills and Simulation Centre, Martin\xa0Luther University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Buhtz', 'Affiliation': 'Dorothea Erxleben Skills and Simulation Centre, Martin\xa0Luther University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Faber', 'Affiliation': 'Dorothea Erxleben Skills and Simulation Centre, Martin\xa0Luther University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Enger', 'Affiliation': 'Department of Radiology, Martin Luther University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Schwarz', 'Affiliation': 'Dorothea Erxleben Skills and Simulation Centre, Martin\xa0Luther University Halle-Wittenberg, Halle, Germany.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Brill', 'Affiliation': 'Department of Radiology, Martin Luther University Halle-Wittenberg, Halle, Germany.'}]",RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,['10.1055/a-1382-8482'] 3459,34117493,Feeling better on hemodialysis: user-centered design requirements for promoting patient involvement in the prevention of treatment complications.,"OBJECTIVE Hemodialysis patients frequently experience dialysis therapy sessions complicated by intradialytic hypotension (IDH), a major patient safety concern. We investigate user-centered design requirements for a theory-informed, peer mentoring-based, informatics intervention to activate patients toward IDH prevention. METHODS We conducted observations (156 hours) and interviews (n = 28) with patients in 3 hemodialysis clinics, followed by 9 focus groups (including participatory design activities) with patients (n = 17). Inductive and deductive analyses resulted in themes and design principles linked to constructs from social, cognitive, and self-determination theories. RESULTS Hemodialysis patients want an informatics intervention for IDH prevention that collapses distance between patients, peers, and family; harnesses patients' strength of character and resolve in all parts of their life; respects and supports patients' individual needs, preferences, and choices; and links ""feeling better on dialysis"" to becoming more involved in IDH prevention. Related design principles included designing for: depth of interpersonal connections; positivity; individual choice and initiative; and comprehension of connections and possible actions. DISCUSSION Findings advance the design of informatics interventions by presenting design requirements for outpatient safety and addressing key design opportunities for informatics to support patient involvement; these include incorporation of behavior change theories. Results also demonstrate the meaning of design choices for hemodialysis patients in the context of their experiences; this may have applicability to other populations with serious illnesses. CONCLUSION The resulting patient-facing informatics intervention will be evaluated in a pragmatic cluster-randomized controlled trial in 28 hemodialysis facilities in 4 US regions.",2021,"Inductive and deductive analyses resulted in themes and design principles linked to constructs from social, cognitive, and self-determination theories. ","['Hemodialysis patients frequently experience dialysis therapy sessions complicated by intradialytic hypotension (IDH', 'Hemodialysis patients', '28 hemodialysis facilities in 4 US regions']",[],[],"[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0011946', 'cui_str': 'Dialysis procedure'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]",[],[],28.0,0.0509717,"Inductive and deductive analyses resulted in themes and design principles linked to constructs from social, cognitive, and self-determination theories. ","[{'ForeName': 'Matthew A', 'Initials': 'MA', 'LastName': 'Willis', 'Affiliation': 'School of Information, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Leah Brand', 'Initials': 'LB', 'LastName': 'Hein', 'Affiliation': 'School of Information, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Zhaoxian', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': 'School of Information and Computer Sciences, University of California, Irvine, California, USA.'}, {'ForeName': 'Rajiv', 'Initials': 'R', 'LastName': 'Saran', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Marissa', 'Initials': 'M', 'LastName': 'Argentina', 'Affiliation': 'National Kidney Foundation, New York City, New York, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Bragg-Gresham', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Krein', 'Affiliation': 'Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Gillespie', 'Affiliation': 'Department of Biostatistics, Consulting for Statistics, Computing and Analytics Research, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Zheng', 'Affiliation': 'School of Information and Computer Sciences, University of California, Irvine, California, USA.'}, {'ForeName': 'Tiffany C', 'Initials': 'TC', 'LastName': 'Veinot', 'Affiliation': 'School of Information, University of Michigan, Ann Arbor, Michigan, USA.'}]",Journal of the American Medical Informatics Association : JAMIA,['10.1093/jamia/ocab033'] 3460,34111838,The effect of training on neonatal nurses' knowledge about transitioning preterm infants to oral feeding.,"BACKGROUND Neonatal nurses require knowledge of evidence-based interventions that can be utilized for supporting oral feeding skills in preterm infants. Little is known about the impact of education/training programs on neonatal nurses' knowledge of this topic. PURPOSE This study was conducted to determine the effect of a training program about evidence-based interventions for the transition to and support of oral feeding in preterm infants on the knowledge levels of neonatal nurses. METHODS We conducted a pretest-posttest studywith 73 neonatal nurses in a research and training hospital. Participants completed a demographic information form and their knowledge about oral feeding in preterm infants was assessed before and after a 240-min training about the transition to oral feeding and evidence-based therapeutic interventions to promote preterm infants' oral feeding skills. RESULTS Posttest scores evaluated at 1 week (81.6 ± 6.8) and 1 month (79.5 ± 6.5) after the training were significantly higher than pre-test scores (66.8 ± 6.9) (p < 0.001). CONCLUSION Neonatal nurses showed higher levels of knowledge about evidence-based interventions for supporting oral feeding skills in preterm infants at 1 week and 1 month after the training program compared to their knowledge before training. IMPLICATIONS FOR PRACTICE Providing training to neonatal intensive care nurses on the transition to oral feeding in preterm infants will increase their level of knowledge and ensure that oral feeding interventions for preterm infants can be implemented using evidence-based therapeutic methods.",2021,"Neonatal nurses showed higher levels of knowledge about evidence-based interventions for supporting oral feeding skills in preterm infants at 1 week and 1 month after the training program compared to their knowledge before training. ","['73 neonatal nurses in a research and training hospital', 'neonatal intensive care nurses', 'preterm infants', 'transitioning preterm infants to oral feeding', 'preterm infants on the knowledge levels of neonatal nurses']","['training program about evidence-based interventions', ""240-min training about the transition to oral feeding and evidence-based therapeutic interventions to promote preterm infants' oral feeding skills""]",[],"[{'cui': 'C0600089', 'cui_str': 'Neonatal nurse'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0021711', 'cui_str': 'Neonatal Intensive Care'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0871796', 'cui_str': 'Knowledge level'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]",[],,0.00460869,"Neonatal nurses showed higher levels of knowledge about evidence-based interventions for supporting oral feeding skills in preterm infants at 1 week and 1 month after the training program compared to their knowledge before training. ","[{'ForeName': 'Burcu', 'Initials': 'B', 'LastName': 'Aykanat Girgin', 'Affiliation': 'University of Health Sciences-Turkey, Hamidiye Faculty of Nursing, Department of Pediatric Nursing, İstanbul, Turkey. Electronic address: aykanat_87@hotmail.com.'}, {'ForeName': 'Duygu', 'Initials': 'D', 'LastName': 'Gözen', 'Affiliation': 'İstanbul University-Cerrahpaşa, Florence Nightingale Faculty of Nursing, Pediatric Nursing Department, İstanbul, Turkey.'}, {'ForeName': 'Ebru', 'Initials': 'E', 'LastName': 'Temizsoy', 'Affiliation': 'Zeynep Kamil Maternity and Children Diseases Training and Research Hospital, Neonatal Intensive Care Unit, İstanbul, Turkey.'}]",Journal of pediatric nursing,['10.1016/j.pedn.2021.05.019'] 3461,34110960,Blood Flow Restriction Training for the Shoulder: A Case for Proximal Benefit.,"BACKGROUND Although blood flow restriction (BFR) is becoming increasingly popular in physical therapy and athletic training settings, little is known about the effects of BFR combined with low-intensity exercise (LIX) on muscles proximal to the site of occlusion. HYPOTHESIS/PURPOSE Determine whether LIX combined with BFR applied distally to the shoulder on the brachial region of the arm (BFR-LIX) promotes greater increases in shoulder lean mass, rotator cuff strength, endurance, and acute increases in shoulder muscle activation compared with LIX alone. We hypothesized that BFR-LIX would elicit greater increases in rotator cuff strength, endurance, and muscle mass. We also hypothesized that the application of BFR would increase EMG amplitude in the shoulder muscles during acute exercise. STUDY DESIGN Controlled laboratory study. METHODS 32 healthy adults were randomized into 2 groups (BFR group, 13 men, 3 women; No-BFR group, 10 men, 6 women) who performed 8 weeks of shoulder LIX (2 times per week; 4 sets [30/15/15/fatigue]; 20% maximum) using common rotator cuff exercises (cable external rotation [ER], cable internal rotation [IR], dumbbell scaption, and side-lying dumbbell ER). The BFR group also trained with an automated tourniquet placed at the proximal arm (50% occlusion). Regional lean mass (dual-energy x-ray absorptiometry), isometric strength, and muscular endurance (repetitions to fatigue [RTF]; 20% maximum; with and without 50% occlusion) were measured before and after training. Electromyographic amplitude (EMGa) was recorded from target shoulder muscles during endurance testing. A mixed-model analysis of covariance (covaried on baseline measures) was used to detect within-group and between-group differences in primary outcome measures (α = .05). RESULTS The BFR group had greater increases in lean mass in the arm (mean ± 95% CI: BFR, 175 ± 54 g; No BFR, -17 ± 77 g; P < .01) and shoulder (mean ± 95% CI: BFR, 278 ± 90 g; No BFR, 96 ± 61 g; P < .01), isometric IR strength (mean ± 95% CI: BFR, 2.9 ± 1.3 kg; No BFR, 0.1 ± 1.3 kg; P < .01), single-set RTF volume (repetitions × resistance) for IR (~1.7- to 2.1-fold higher; P < .01), and weekly training volume (weeks 4, 6-8, ~5%-22%; P < .05). Acute occlusion (independent of group or timepoint) yielded increases in EMGa during RTF (~10%-20%; P < .05). CONCLUSION Combined BFR-LIX may yield greater increases in shoulder and arm lean mass, strength, and muscular endurance compared with fatiguing LIX alone during rotator cuff exercises. These findings may be due, in part, to a greater activation of shoulder muscles while using BFR. CLINICAL RELEVANCE The present study demonstrates that BFR-LIX may be a suitable candidate for augmenting preventive training or rehabilitation outcomes for the shoulder.",2021,"The BFR group had greater increases in lean mass in the arm (mean ± 95% CI: BFR, 175 ± 54 g; No BFR, -17 ± 77 g; P < .01) and shoulder (mean ± 95% CI: BFR, 278 ± 90 g; No BFR, 96 ± 61 g; P < .01), isometric IR strength (mean ± 95% CI: BFR, 2.9 ± 1.3 kg; No BFR, 0.1 ± 1.3 kg; P < .01), single-set RTF volume (repetitions × resistance) for IR (~1.7- to 2.1-fold higher; P < .01), and weekly training volume (weeks 4, 6-8, ~5%-22%; P < .05).","['32 healthy adults were randomized into 2 groups (BFR group, 13 men, 3 women; No-BFR group, 10 men, 6 women) who performed 8 weeks of', 'Shoulder']","['BFR combined with low-intensity exercise (LIX', 'blood flow restriction (BFR', 'Blood Flow Restriction Training', 'shoulder LIX (2 times per week; 4 sets [30/15/15/fatigue]; 20% maximum) using common rotator cuff exercises (cable external rotation [ER], cable internal rotation [IR], dumbbell scaption, and side-lying dumbbell ER', 'Combined BFR-LIX', 'LIX combined with BFR', 'BFR-LIX']","['Electromyographic amplitude (EMGa', 'shoulder lean mass, rotator cuff strength, endurance, and acute increases in shoulder muscle activation', 'single-set RTF volume', 'shoulder and arm lean mass, strength, and muscular endurance', 'Regional lean mass (dual-energy x-ray absorptiometry), isometric strength, and muscular endurance', 'lean mass', 'rotator cuff strength, endurance, and muscle mass', 'Acute occlusion', 'isometric IR strength', 'EMG amplitude', 'EMGa during RTF']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}]","[{'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0085515', 'cui_str': 'Structure of rotator cuff including muscles and tendons'}, {'cui': 'C0231462', 'cui_str': 'External rotation'}, {'cui': 'C0231459', 'cui_str': 'Internal rotation'}, {'cui': 'C0023668', 'cui_str': 'Liechtenstein'}]","[{'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0085515', 'cui_str': 'Structure of rotator cuff including muscles and tendons'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0687023', 'cui_str': 'Structure of skeletal muscle of shoulder'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0429340', 'cui_str': 'EMG amplitude'}]",32.0,0.0321242,"The BFR group had greater increases in lean mass in the arm (mean ± 95% CI: BFR, 175 ± 54 g; No BFR, -17 ± 77 g; P < .01) and shoulder (mean ± 95% CI: BFR, 278 ± 90 g; No BFR, 96 ± 61 g; P < .01), isometric IR strength (mean ± 95% CI: BFR, 2.9 ± 1.3 kg; No BFR, 0.1 ± 1.3 kg; P < .01), single-set RTF volume (repetitions × resistance) for IR (~1.7- to 2.1-fold higher; P < .01), and weekly training volume (weeks 4, 6-8, ~5%-22%; P < .05).","[{'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Lambert', 'Affiliation': 'Orthopedic Biomechanics Research Laboratory, Department of Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, Texas, USA.'}, {'ForeName': 'Corbin', 'Initials': 'C', 'LastName': 'Hedt', 'Affiliation': 'Orthopedic Biomechanics Research Laboratory, Department of Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, Texas, USA.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Daum', 'Affiliation': 'Orthopedic Biomechanics Research Laboratory, Department of Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, Texas, USA.'}, {'ForeName': 'Carter', 'Initials': 'C', 'LastName': 'Taft', 'Affiliation': 'Department of Kinesiology, Rice University, Houston, Texas, USA.'}, {'ForeName': 'Kalyan', 'Initials': 'K', 'LastName': 'Chaliki', 'Affiliation': 'Department of Kinesiology, Rice University, Houston, Texas, USA.'}, {'ForeName': 'Eden', 'Initials': 'E', 'LastName': 'Epner', 'Affiliation': 'Orthopedic Biomechanics Research Laboratory, Department of Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, Texas, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'McCulloch', 'Affiliation': 'Orthopedic Biomechanics Research Laboratory, Department of Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, Texas, USA.'}]",The American journal of sports medicine,['10.1177/03635465211017524'] 3462,34113090,Feasibility of a 6-Month Home-Based Fall Prevention Exercise Program in Older Adults with COPD.,"Purpose Older adults with chronic obstructive pulmonary disease (COPD) have a high risk and rate of falls. Home-based fall prevention exercise programs reduce falls in older adults and may be an alternative approach for people with COPD without access to hospital-based rehabilitation. Therefore, we aimed to determine the feasibility of a home-based fall prevention exercise program in older adults with COPD and to examine the effect of the program on fall-related outcomes at baseline, 3 and 6 months. Patients and Methods Adults ≥60 years with COPD at risk for falls participated in a single group study. The intervention was a 6-month home-based fall prevention program which included 40 minutes of independent exercise three times per week, four physiotherapist home visits, bimonthly phone calls, and an optional booster session post-exacerbation. An independent assessor collected outcome measures at home at baseline, 3- and 6-months. Primary feasibility criteria were recruitment and retention rates (≥70%) and exercise adherence (≥60%). Functional outcomes included the Berg Balance Scale (BBS), the Balance Evaluation Systems Test (BESTest), the Activities-Specific Balance Confidence (ABC) scale, the repeated chair-stand test, self-reported function, and fall history. Results Thirty-six patients (female 63.8%, mean age 74.4 ± 6.1 years; mean FEV 1 45.0 ± 13.8% predicted) were enrolled. The recruitment rate was 46.8%, participant retention rate was 69.4%, and exercise adherence rate was 73.6%. Repeated measures ANOVA showed improvements at 3- and 6-months compared to baseline in the BBS ( p= 0.001) and the BESTest total scores and sub-scores ( p= 0.001). Conclusion The home-based fall prevention exercise program met one of the three pre-specified feasibility criteria (exercise adherence), and improved balance-related measures of fall risk in older adults with COPD. Our findings highlight important opportunities for refinement of the study design prior to undertaking a full-scale trial.",2021,"Repeated measures ANOVA showed improvements at 3- and 6-months compared to baseline in the BBS ( p= 0.001) and the BESTest total scores and sub-scores ( p= 0.001). ","['Older Adults with COPD', 'Thirty-six patients (female 63.8%, mean age 74.4 ± 6.1 years; mean FEV 1 45.0 ± 13.8% predicted) were enrolled', 'people with COPD without access to hospital-based rehabilitation', 'older adults with COPD', 'Patients and Methods\n\n\nAdults ≥60 years with COPD at risk for falls participated in a single group study', 'older adults', 'Older adults with chronic obstructive pulmonary disease (COPD']","['6-month home-based fall prevention program which included 40 minutes of independent exercise three times per week, four physiotherapist home visits, bimonthly phone calls', 'home-based fall prevention exercise program', 'Home-based fall prevention exercise programs', '6-Month Home-Based Fall Prevention Exercise Program']","['Berg Balance Scale (BBS), the Balance Evaluation Systems Test (BESTest), the Activities-Specific Balance Confidence (ABC) scale, the repeated chair-stand test, self-reported function, and fall history', 'recruitment and retention rates', 'recruitment rate', 'participant retention rate', 'exercise adherence', 'exercise adherence rate', 'BESTest total scores and sub-scores']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C4517561', 'cui_str': '13.8'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1268740', 'cui_str': 'At risk for falls'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0585337', 'cui_str': 'Bimonthly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C2733457', 'cui_str': 'Activities specific balance confidence scale'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}]",,0.0310059,"Repeated measures ANOVA showed improvements at 3- and 6-months compared to baseline in the BBS ( p= 0.001) and the BESTest total scores and sub-scores ( p= 0.001). ","[{'ForeName': 'Marla K', 'Initials': 'MK', 'LastName': 'Beauchamp', 'Affiliation': 'School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Ellerton', 'Affiliation': 'School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Kirkwood', 'Affiliation': 'School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Brooks', 'Affiliation': 'School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Richardson', 'Affiliation': 'School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Roger S', 'Initials': 'RS', 'LastName': 'Goldstein', 'Affiliation': 'Respiratory Rehabilitation, West Park Healthcare Centre, Toronto, ON, Canada.'}, {'ForeName': 'Stewart', 'Initials': 'S', 'LastName': 'Pugsley', 'Affiliation': ""Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, ON, Canada.""}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Hatzoglou', 'Affiliation': ""Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, ON, Canada.""}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S309537'] 3463,34391301,A comparative study of Thai massage and muscle energy technique for chronic neck pain: A single-blinded randomized clinical trial.,"BACKGROUND Myofascial pain syndrome (MPS) is the most common form of muscle disorders. Traditional Thai massage (TM) and muscle energy (ME) technique have been used to treat patients with MPS for long time but head-to-head comparisons of these interventions have not been established. AIM The aim of the current study was to compare the effects of TM and the ME technique on pain intensity (PI), pressure pain threshold (PPT), neck disability (ND), and neck flexion range of motion (NFROM) in patients with chronic neck pain associated with myofascial trigger points (MTrPs). DESIGN A randomized, single-blinded clinical trial. SETTING Department of Physical Therapy, School of Integrative Medicine, Mae Fah Luang University. POPULATION Forty-five patients with chronic neck pain associated with MTrPs were recruited. METHODS The patients were randomly allocated to the TM, ME, or control groups, with each having eight treatment sessions over a period of two weeks. PI, PPT, ND, and NFROM were assessed before, immediately after the first treatment session, and one day after the last treatment session. RESULTS Based on the results, both TM and the ME technique resulted in a significant improvement in all parameters (p < 0.05) compared to the control group. Additionally, no significant difference was observed between TM and the ME technique in all parameters. CONCLUSIONS The application of TM or the ME technique can be a practical alternative approach for the treatment of chronic neck pain associated with MTrPs.",2021,"Based on the results, both TM and the ME technique resulted in a significant improvement in all parameters (p < 0.05) compared to the control group.","['Forty-five patients with chronic neck pain associated with MTrPs were recruited', 'patients with chronic neck pain associated with myofascial trigger points (MTrPs', 'Department of Physical Therapy, School of Integrative Medicine, Mae Fah Luang University', 'Myofascial pain syndrome (MPS', 'chronic neck pain']","['Traditional Thai massage (TM) and muscle energy (ME) technique', 'Thai massage and muscle energy technique', 'TM and the ME technique', 'TM, ME']","['PI, PPT, ND, and NFROM', 'pain intensity (PI), pressure pain threshold (PPT), neck disability (ND), and neck flexion range of motion (NFROM']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C2350258', 'cui_str': 'Integrative Medicine'}, {'cui': 'C0286540', 'cui_str': 'MAV protocol'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0039724', 'cui_str': 'Thai language'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C1562466', 'cui_str': 'Muscle energy technique'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0445088', 'cui_str': 'Neck flexion'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}]",45.0,0.0426434,"Based on the results, both TM and the ME technique resulted in a significant improvement in all parameters (p < 0.05) compared to the control group.","[{'ForeName': 'Vitsarut', 'Initials': 'V', 'LastName': 'Buttagat', 'Affiliation': 'Department of Physical Therapy, School of Integrative Medicine, Mae Fah Luang University, Chiang Rai, Thailand. Electronic address: vitsarutbut@hotmail.com.'}, {'ForeName': 'Kanokwan', 'Initials': 'K', 'LastName': 'Muenpan', 'Affiliation': 'Department of Physical Therapy, School of Integrative Medicine, Mae Fah Luang University, Chiang Rai, Thailand.'}, {'ForeName': 'Witawit', 'Initials': 'W', 'LastName': 'Wiriyasakunphan', 'Affiliation': 'Department of Physical Therapy, School of Integrative Medicine, Mae Fah Luang University, Chiang Rai, Thailand.'}, {'ForeName': 'Saowalak', 'Initials': 'S', 'LastName': 'Pomsuwan', 'Affiliation': 'Department of Physical Therapy, School of Integrative Medicine, Mae Fah Luang University, Chiang Rai, Thailand.'}, {'ForeName': 'Sujittra', 'Initials': 'S', 'LastName': 'Kluayhomthong', 'Affiliation': 'Department of Physical Therapy, School of Integrative Medicine, Mae Fah Luang University, Chiang Rai, Thailand.'}, {'ForeName': 'Pattanasin', 'Initials': 'P', 'LastName': 'Areeudomwong', 'Affiliation': 'Department of Physical Therapy, School of Integrative Medicine, Mae Fah Luang University, Chiang Rai, Thailand.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.05.007'] 3464,34391298,Dual-task intervention based on trail making test: Effects on Parkinson's disease.,"OBJECTIVE To evaluate the effectiveness of an intervention with dual task based on trail making test on gait, cognition and daily activities execution in individuals with Parkinson's disease. DESIGN Randomized controlled trial. METHODOLOGY 10 individuals with Parkinson's Disease (PD) were divided into dual task group (DTG) and control group (CG). Were realized 16 dual task (DT) training sessions based on the Trail Making Test (TMT) for DTG and a conventional training protocol for CG. Pre and post intervention assessments used the 6 minute walk test (T6), TMT, Katz Index and Falls Efficacy Scale (FES). RESULTS Comparing the difference between pre and post intervention values between groups, there was no significant difference for T6 (p=0,36). In TMT there was a significant difference (p=0,03), showing shorter times for DTG. The tests used for time values in the Katz index tasks showed an important difference for the DTG (P=0,02). As for the results of the FES, they did not show pre and post changes in the DTG (0,45) and in the CG (p= 0,29) and not even between the groups (p=0,45). CONCLUSION The proposed intervention was able to promote improvements in the performance of daily life activities, learning adaptations and retention of motor and cognitive aspects, which may reflect positively in the daily lives of patients with PD and, consequently, greater autonomy to perform these types of activities.",2021,"The proposed intervention was able to promote improvements in the performance of daily life activities, learning adaptations and retention of motor and cognitive aspects, which may reflect positively in the daily lives of patients with PD and, consequently, greater autonomy to perform these types of activities.","[""individuals with Parkinson's disease"", ""10 individuals with Parkinson's Disease (PD""]","['Dual-task intervention based on trail making test', 'realized 16 dual task (DT) training sessions based on the Trail Making Test (TMT) for DTG and a conventional training protocol for CG', 'dual task group (DTG) and control group (CG']","['gait, cognition and daily activities execution', 'performance of daily life activities, learning adaptations and retention of motor and cognitive aspects', '6 minute walk test (T6), TMT, Katz Index and Falls Efficacy Scale (FES']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C1278561', 'cui_str': 'Judicial execution'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0243151', 'cui_str': 'cognitive aspects'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0040604', 'cui_str': 'Trail making test'}, {'cui': 'C0451239', 'cui_str': 'Katz activities of daily living'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",10.0,0.0461199,"The proposed intervention was able to promote improvements in the performance of daily life activities, learning adaptations and retention of motor and cognitive aspects, which may reflect positively in the daily lives of patients with PD and, consequently, greater autonomy to perform these types of activities.","[{'ForeName': 'Renata do Nascimento', 'Initials': 'RDN', 'LastName': 'Silva', 'Affiliation': 'Residente Pelo Programa de Residência Integrada Multiprofissional e em Área Profissional da Saúde, Universidade Federal do Triângulo Mineiro (UFTM), Brazil.'}, {'ForeName': 'Sabrina Vilela', 'Initials': 'SV', 'LastName': 'Afonso', 'Affiliation': 'Mestranda Pelo Programa de Pós-graduação em Fisioterapia, Universidade Federal do Triângulo Mineiro (UFTM), Brazil.'}, {'ForeName': 'Luana Rosseto', 'Initials': 'LR', 'LastName': 'Felipe', 'Affiliation': 'Residente Pelo Programa de Residência Integrada Multiprofissional e em Área Profissional da Saúde, Universidade Federal do Triângulo Mineiro (UFTM), Brazil.'}, {'ForeName': 'Rafael Almeida', 'Initials': 'RA', 'LastName': 'Oliveira', 'Affiliation': 'Mestre Pelo Programa de Pós-graduação em Educação Física, Universidade Federal do Triângulo Mineiro (UFTM), Brazil.'}, {'ForeName': 'Lislei Jorge', 'Initials': 'LJ', 'LastName': 'Patrizzi Martins', 'Affiliation': 'Docente do Departamento de Fisioterapia Aplicada da Universidade Federal do Triângulo Mineiro (UFTM), Brazil.'}, {'ForeName': 'Luciane Aparecida', 'Initials': 'LA', 'LastName': 'Pascucci Sande de Souza', 'Affiliation': 'Docente do Departamento de Fisioterapia Aplicada da Universidade Federal do Triângulo Mineiro (UFTM), Brazil. Electronic address: lucianesande@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.013'] 3465,34391297,The effect of core stability-based corrective exercises on gait parameters in elite soccer players diagnosed with Middle Crossed Syndrome.,"BACKGROUND/AIMS The aim of this study was to investigate the effect of eight weeks of core stability-based corrective exercises, on gait parameters in elite soccer players diagnosed with middle crossed syndrome. METHODS 15 male elite soccer players (aged 18-28) were enrolled in a same-subject intervention trial to assess if the middle crossed syndrome could be influenced through core stability exercise. Core stability-based corrective exercises were completed 3 times per week for 8 weeks and changes in gait parameters (pre- and post- intervention) were measured. RESULTS The results showed that most gait parameters including stride length (p = 0.025), gait speed (p = 0.023), number of strides (p = 0.007), length of shots (p = 0.003), and also soccer players' height (p = 0.011) improved significantly in post-intervention in comparison to pre-intervention. Stride width in post-intervention did not show changes in comparison with pre-intervention (p = 0.083). CONCLUSION The results indicate the significant effectiveness of core stability-based corrective exercises on gait parameters in those with middle crossed syndrome. By doing corrective exercises based on core stability during the study period, gait parameters in the post-intervention surpass the results in the pre-intervention in most parameters. Therefore, it is proposed that corrective exercises based on core stability is a safe and useful method for improving function in those with middle crossed syndrome and it could be used as a therapy to help players identified with this finding. In this regard, it is suggested to researchers and coaches to correct imbalances in order to achieve better results in training programs.",2021,"Stride width in post-intervention did not show changes in comparison with pre-intervention (p = 0.083). ","['elite soccer players diagnosed with middle crossed syndrome', '15 male elite soccer players (aged 18-28', 'elite soccer players diagnosed with Middle Crossed Syndrome']",['core stability-based corrective exercises'],"['number of strides', 'length of shots', ""soccer players' height"", 'gait parameters', 'Stride width', 'gait speed', 'stride length']","[{'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0268496', 'cui_str': 'Oculocerebral syndrome with hypopigmentation'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}]",15.0,0.0188564,"Stride width in post-intervention did not show changes in comparison with pre-intervention (p = 0.083). ","[{'ForeName': 'Nima', 'Initials': 'N', 'LastName': 'Nakisa', 'Affiliation': 'Department of Physical Education, Islamic Azad University, Karaj, Iran. Electronic address: nimanakisa1354@yahoo.com.'}, {'ForeName': 'Mahboobeh', 'Initials': 'M', 'LastName': 'Ghasemzadeh Rahbardar', 'Affiliation': 'Mashhad University of Medical Sciences, MUMS, Mashhad, Iran. Electronic address: ghasemzadeh_mahboobeh@yahoo.com.'}, {'ForeName': 'Yahya', 'Initials': 'Y', 'LastName': 'Sokhangouei', 'Affiliation': 'University of Welfare & Rehabilitation Silences, Tehran, Iran. Electronic address: yahya0102@yahoo.com.'}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Afsharmand', 'Affiliation': 'Department of Physical Education and Sport Sciences, Islamshahr Branch, Islamic Azad University, Tehran, Iran. Electronic address: afsharmand_ro@yahoo.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.016'] 3466,34351722,Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.,"BACKGROUND Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19. METHODS In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. RESULTS The trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio <1.2], 99.9%). The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% and 64.5%, respectively; adjusted odds ratio, 0.84; 95% credible interval, 0.64 to 1.11). Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis. CONCLUSIONS In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis. (REMAP-CAP, ACTIV-4a, and ATTACC ClinicalTrials.gov numbers, NCT02735707, NCT04505774, NCT04359277, and NCT04372589.).",2021,"Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis. ","['critically ill patients with Covid-19', 'Critically Ill Patients with Covid-19', 'patients with coronavirus disease 2019 (Covid-19', 'critically ill patients with severe Covid-19', '1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis', 'critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with']","['Heparin', 'therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis', 'heparin']","['median value for organ support-free days', 'probability of survival to hospital discharge', 'organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support', 'Major bleeding', 'percentage of patients who survived to hospital discharge']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205265', 'cui_str': 'Initial'}]","[{'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",,0.172624,"Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis. ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Ewan C', 'Initials': 'EC', 'LastName': 'Goligher', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Charlotte A', 'Initials': 'CA', 'LastName': 'Bradbury', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Bryan J', 'Initials': 'BJ', 'LastName': 'McVerry', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Patrick R', 'Initials': 'PR', 'LastName': 'Lawler', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Berger', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Michelle N', 'Initials': 'MN', 'LastName': 'Gong', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Carrier', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Harmony R', 'Initials': 'HR', 'LastName': 'Reynolds', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Alexis F', 'Initials': 'AF', 'LastName': 'Turgeon', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lucy Z', 'Initials': 'LZ', 'LastName': 'Kornblith', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Kahn', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Marshall', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Keri S', 'Initials': 'KS', 'LastName': 'Kim', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Brett L', 'Initials': 'BL', 'LastName': 'Houston', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lennie P G', 'Initials': 'LPG', 'LastName': 'Derde', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Cushman', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Tritschler', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Derek C', 'Initials': 'DC', 'LastName': 'Angus', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lucas C', 'Initials': 'LC', 'LastName': 'Godoy', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'McQuilten', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Bridget-Anne', 'Initials': 'BA', 'LastName': 'Kirwan', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Farkouh', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Maria M', 'Initials': 'MM', 'LastName': 'Brooks', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Roger J', 'Initials': 'RJ', 'LastName': 'Lewis', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lindsay R', 'Initials': 'LR', 'LastName': 'Berry', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Lorenzi', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Anthony C', 'Initials': 'AC', 'LastName': 'Gordon', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Ahuja', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Al-Beidh', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Djillali', 'Initials': 'D', 'LastName': 'Annane', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Yaseen M', 'Initials': 'YM', 'LastName': 'Arabi', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Diptesh', 'Initials': 'D', 'LastName': 'Aryal', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Baumann Kreuziger', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Abi', 'Initials': 'A', 'LastName': 'Beane', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Bhimani', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Shailesh', 'Initials': 'S', 'LastName': 'Bihari', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Henny H', 'Initials': 'HH', 'LastName': 'Billett', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Bond', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Bonten', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Brunkhorst', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Buxton', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Buzgau', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lana A', 'Initials': 'LA', 'LastName': 'Castellucci', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Sweta', 'Initials': 'S', 'LastName': 'Chekuri', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jen-Ting', 'Initials': 'JT', 'LastName': 'Chen', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Allen C', 'Initials': 'AC', 'LastName': 'Cheng', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Tamta', 'Initials': 'T', 'LastName': 'Chkhikvadze', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Coiffard', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Aira', 'Initials': 'A', 'LastName': 'Contreras', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Todd W', 'Initials': 'TW', 'LastName': 'Costantini', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'de Brouwer', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Michelle A', 'Initials': 'MA', 'LastName': 'Detry', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Abhijit', 'Initials': 'A', 'LastName': 'Duggal', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Vladimír', 'Initials': 'V', 'LastName': 'Džavík', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Mark B', 'Initials': 'MB', 'LastName': 'Effron', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Heather F', 'Initials': 'HF', 'LastName': 'Eng', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Escobedo', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lise J', 'Initials': 'LJ', 'LastName': 'Estcourt', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Brendan M', 'Initials': 'BM', 'LastName': 'Everett', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Dean A', 'Initials': 'DA', 'LastName': 'Fergusson', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Fitzgerald', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Fowler', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Froess', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Zhuxuan', 'Initials': 'Z', 'LastName': 'Fu', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jean P', 'Initials': 'JP', 'LastName': 'Galanaud', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Benjamin T', 'Initials': 'BT', 'LastName': 'Galen', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Sheetal', 'Initials': 'S', 'LastName': 'Gandotra', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Girard', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Andrew L', 'Initials': 'AL', 'LastName': 'Goodman', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Herman', 'Initials': 'H', 'LastName': 'Goossens', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Cameron', 'Initials': 'C', 'LastName': 'Green', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Yonatan Y', 'Initials': 'YY', 'LastName': 'Greenstein', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Gross', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Rashan', 'Initials': 'R', 'LastName': 'Haniffa', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Sheila M', 'Initials': 'SM', 'LastName': 'Hegde', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Carolyn M', 'Initials': 'CM', 'LastName': 'Hendrickson', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Alisa M', 'Initials': 'AM', 'LastName': 'Higgins', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Alexander A', 'Initials': 'AA', 'LastName': 'Hindenburg', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Aluko A', 'Initials': 'AA', 'LastName': 'Hope', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Horowitz', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Horvat', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Huang', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Hudock', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Beverley J', 'Initials': 'BJ', 'LastName': 'Hunt', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Mansoor', 'Initials': 'M', 'LastName': 'Husain', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Hyzy', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Jacobson', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Devachandran', 'Initials': 'D', 'LastName': 'Jayakumar', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Norma M', 'Initials': 'NM', 'LastName': 'Keller', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Akram', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Yuri', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Andrei', 'Initials': 'A', 'LastName': 'Kindzelski', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'King', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'M Margaret', 'Initials': 'MM', 'LastName': 'Knudson', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Aaron E', 'Initials': 'AE', 'LastName': 'Kornblith', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Matthew E', 'Initials': 'ME', 'LastName': 'Kutcher', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Laffan', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Lamontagne', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Grégoire', 'Initials': 'G', 'LastName': 'Le Gal', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Leeper', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Eric S', 'Initials': 'ES', 'LastName': 'Leifer', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Lim', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Gallego Lima', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Linstrum', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Litton', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lopez-Sendon', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marten', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Andréa', 'Initials': 'A', 'LastName': 'Saud Marinez', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Martinez', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Mateos Garcia', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Stavroula', 'Initials': 'S', 'LastName': 'Mavromichalis', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'McAuley', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'McGlothlin', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Shay P', 'Initials': 'SP', 'LastName': 'McGuinness', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Middeldorp', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Stephanie K', 'Initials': 'SK', 'LastName': 'Montgomery', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Paul R', 'Initials': 'PR', 'LastName': 'Mouncey', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Srinivas', 'Initials': 'S', 'LastName': 'Murthy', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Girish B', 'Initials': 'GB', 'LastName': 'Nair', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Nair', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Alistair D', 'Initials': 'AD', 'LastName': 'Nichol', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jose C', 'Initials': 'JC', 'LastName': 'Nicolau', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Nunez-Garcia', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Park', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Pauline K', 'Initials': 'PK', 'LastName': 'Park', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Rachael L', 'Initials': 'RL', 'LastName': 'Parke', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jane C', 'Initials': 'JC', 'LastName': 'Parker', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Parnia', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Paul', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Mauricio', 'Initials': 'M', 'LastName': 'Pompilio', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Quigley', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Rosenson', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Natalia S', 'Initials': 'NS', 'LastName': 'Rost', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Rowan', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Fernanda O', 'Initials': 'FO', 'LastName': 'Santos', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Marlene', 'Initials': 'M', 'LastName': 'Santos', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Mayler O', 'Initials': 'MO', 'LastName': 'Santos', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lewis', 'Initials': 'L', 'LastName': 'Satterwhite', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Christina T', 'Initials': 'CT', 'LastName': 'Saunders', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jake', 'Initials': 'J', 'LastName': 'Schreiber', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Roger E G', 'Initials': 'REG', 'LastName': 'Schutgens', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Christopher W', 'Initials': 'CW', 'LastName': 'Seymour', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Deborah M', 'Initials': 'DM', 'LastName': 'Siegal', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Delcio G', 'Initials': 'DG', 'LastName': 'Silva', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Aneesh B', 'Initials': 'AB', 'LastName': 'Singhal', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Arthur S', 'Initials': 'AS', 'LastName': 'Slutsky', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Dayna', 'Initials': 'D', 'LastName': 'Solvason', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Stanworth', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Turner', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Wilma', 'Initials': 'W', 'LastName': 'van Bentum-Puijk', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Frank L', 'Initials': 'FL', 'LastName': 'van de Veerdonk', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'van Diepen', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Vazquez-Grande', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Lana', 'Initials': 'L', 'LastName': 'Wahid', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Wareham', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'R Jay', 'Initials': 'RJ', 'LastName': 'Widmer', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Jennifer G', 'Initials': 'JG', 'LastName': 'Wilson', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Yuriditsky', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Yongqi', 'Initials': 'Y', 'LastName': 'Zhong', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Berry', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Colin J', 'Initials': 'CJ', 'LastName': 'McArthur', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Neal', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Hochman', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Webb', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': ""From the University of Toronto (E.C.G., P.R.L., L.C.G., M.E.F., V.D., R.A.F., J.P.G., M.H., A.S.S.), University Health Network (E.C.G., M.H.), Peter Munk Cardiac Centre at University Health Network (P.R.L., L.C.G., M.E.F., V.D.), Ozmosis Research (L.B., V.W.), Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (M. Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, the University of Manitoba (A. Kumar, B.L.H., R.Z., S.A.L., D.S., G.V.-G.) and CancerCare Manitoba (B.L.H., R.Z.), Winnipeg, Université Laval and Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Quebec, QC (A.F.T.), McGill University, Montreal (S.R.K., E.G.M.), St. Michael's Hospital Unity Health, Toronto (J.C.M., Z.B., M.S., A.S.S.), McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (P.L.G.) Université de Sherbrooke, Sherbrooke, QC (F.L.), St. Boniface Hospital, Winnipeg, MB (N.M.), the University of British Columbia, Vancouver (S. Murthy), and the University of Alberta, Edmonton (S.D.) - all in Canada; University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol (C.A.B.), the London School of Hygiene and Tropical Medicine (B.-A.K.), Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), and Intensive Care National Audit and Research Centre (ICNARC) (P.R.M., K.R.), London, Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.), and Oxford University (A. Beane, L.J.E., S.J.S.) and NHS Blood and Transplant (L.J.E., S. Mavromichalis, S.J.S.), Oxford - all in the United Kingdom; the University of Pittsburgh (B.J.M., D.C.A., M.M.B., M.D.N., H.F.E., J.D.F., Z.F., D.T.H., A.J.K., C.M.L., K.L., M.M., S.K.M., C.W.S., Y.Z.), University of Pittsburgh Medical Center (B.J.M., D.C.A., M.D.N., K.L.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (C.M. Horvat) - all in Pittsburgh; New York University (NYU) Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., A.C., N.M.K., S. Mavromichalis, S.P.), NYU Langone Health, NYU Langone Hospital (T.A., T.C., A.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), Icahn School of Medicine at Mount Sinai (R.S.R.), and Mount Sinai Heart (R.S.R.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.-T.C., A.A. Hope, R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A.A. Hope), Bronx, and NYU Langone Long Island, Mineola (A.A. Hindenburg) - all in New York; Zuckerberg San Francisco General Hospital-University of California, San Francisco (L.Z.K., C.M. Hendrickson, M.M.K., A.E.K., B.N.-G., J.J.P.), Harbor-UCLA Medical Center, Torrance (R.J.L.), Global Coalition for Adaptive Research (M. Buxton) and the University of California, Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; the University of Illinois (K.S.K., J.R.J., J.G.Q.), the University of Chicago (J.D.P.), and the Chartis Group (J.S.) - all in Chicago; University Medical Center Utrecht, Utrecht University (L.P.G.D., M. Bonten, R.E.G.S., W.B.-P.), and Utrecht University (R.E.G.S.), Utrecht, and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - all in the Netherlands; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Inselspital, Bern University Hospital, University of Bern, Bern (T.T.), and SOCAR Research, Nyon (B.-A.K., S. Brouwer) - both in Switzerland; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (L.C.G., F.G.L., J.C.N.), Avanti Pesquisa Clínica (A.S.M.), and Hospital 9 de Julho (F.O.S.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul (M.P.), the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.), and Hospital Unimed Campo Grande (D.G.S.), Campo Grande, and Instituto Goiano de Oncologia e Hematologia, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; the Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., C.J.M., S.A.W., A. Buzgau, C.G., A.M.H., S.P.M., A.D.N., J.C.P.), Monash University (A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital, Subiaco, WA (S.A.W., E. Litton), Flinders University, Bedford Park, SA (S. Bihari), and Fiona Stanley Hospital, Perth, WA (E. Litton) - all in Australia; Berry Consultants, Austin (R.J.L., L.R.B., E. Lorenzi, S.M.B., M.A.D., M.F., A.M., C.T.S.), and Baylor Scott and White Health, Temple (R.J.W.) - both in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Fédération Hospitalo-Universitaire Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis (FHU-SEPSIS), Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur (D. Aryal), and the Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Versiti Blood Research Institute, Milwaukee (L.B.K.); National Intensive Care Surveillance (NICS)-Mahidol Oxford Tropical Medicine Research Unit (MORU), Colombo, Sri Lanka (A. Beane); Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic, Cleveland (A.D.), and the University of Cincinnati, Cincinnati (K.H.) - both in Ohio; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Instituto Mexicano del Seguro Social, Mexico City (J.E., E.M.G.); Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Massachusetts General Hospital (N.S.R., A.B.S.), and Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S.) - all in Boston; University of Alabama, Birmingham (S.G.); TriStar Centennial Medical Center, Nashville (A.L.G.); University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark, New Jersey (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); the University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak (G.B.N.), and Oakland University William Beaumont School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Apollo Speciality Hospital OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A. Kindzelski, E.S.L.); University of Mississippi Medical Center, Jackson (M.E.K.); IdiPaz Research Institute, Universidad Autonoma, Madrid (J.L.-S.); University College Dublin, Dublin (A.D.N.); the University of Kansas School of Medicine, Kansas City (L.S.); and Duke University Hospital, Durham, North Carolina (L.W.).""}]",The New England journal of medicine,['10.1056/NEJMoa2103417'] 3467,34391295,Immediate decrease of muscle biomechanical stiffness following dry needling in asymptomatic participants.,"BACKGROUND Biomechanical muscle stiffness has been linked to musculoskeletal disorders. Assessing changes in muscle stiffness following DN may help elucidate a physiologic mechanism of DN. This study characterizes the effects of dry needling (DN) to the infraspinatus, erector spinae, and gastrocnemius muscles on biomechanical muscle stiffness. METHOD 60 healthy participants were randomized into infraspinatus, erector spinae, or gastrocnemius groups. One session of DN was applied to the muscle in standardized location. Stiffness was assessed using a MyotonPRO at baseline, immediately post DN, and 24 h later. The presence of a localized twitch response (LTR) during DN was used to subgroup participants. RESULTS A statistically significant decrease in stiffness was observed in the gastrocnemius, the LTR gastrocnemius, and the LTR erector spinae group immediately following DN treatment. However, stiffness increased after 24 h. No significant change was found in the infraspinatus group. CONCLUSIONS DN may cause an immediate, yet transitory change in local muscle stiffness. It is unknown whether these effects are present in a symptomatic population or related to improvements in clinical outcomes. Future studies are necessary to determine if a decrease in biomechanical stiffness is related to improvement in symptomatic individuals.",2021,"A statistically significant decrease in stiffness was observed in the gastrocnemius, the LTR gastrocnemius, and the LTR erector spinae group immediately following DN treatment.","['asymptomatic participants', '60 healthy participants']",['dry needling (DN'],"['muscle biomechanical stiffness', 'localized twitch response (LTR', 'biomechanical stiffness', 'stiffness']","[{'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0392752', 'cui_str': 'Localized'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}]",60.0,0.0728495,"A statistically significant decrease in stiffness was observed in the gastrocnemius, the LTR gastrocnemius, and the LTR erector spinae group immediately following DN treatment.","[{'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Kelly', 'Affiliation': 'Bradley University, Peoria, IL, United States. Electronic address: jpkelly@fsmail.bradley.edu.'}, {'ForeName': 'Shane L', 'Initials': 'SL', 'LastName': 'Koppenhaver', 'Affiliation': 'Baylor University, Waco, TX, United States.'}, {'ForeName': 'Lori A', 'Initials': 'LA', 'LastName': 'Michener', 'Affiliation': 'Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, CA, United States.'}, {'ForeName': 'Morey J', 'Initials': 'MJ', 'LastName': 'Kolber', 'Affiliation': 'Nova Southeastern University, Fort Lauderdale, Florida, United States.'}, {'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Cleland', 'Affiliation': 'Tufts University School of Medicine, MA, United States.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2021.04.014'] 3468,34116249,Clinical evaluation of in-office tooth whitening with violet LED (405 nm): A double-blind randomized controlled clinical trial.,"BACKGROUND Although there is little evidence showing the effectiveness of violet LED on in-office tooth whitening, there are some studies which have reported satisfactory results. This double-blind randomized controlled clinical trial aimed to evaluate the effect of a violet light emission diode (LED) (405 nm) system, used in-office, on tooth whitening, sensitivity, use of medication after whitening and quality of life. METHODS Eight patients were randomized into 4 groups (n = 20): G1 - violet LED, G2 - 35% carbamide peroxide (CP) and violet LED, G3 only CP 35% and G4 35% hydrogen peroxide (HP). The color was measured using a spectrophotometer at the following times: baseline, 15 and 180days. The colorimetric changes were analyzed using measurements from the CieLab System ΔE (ΔL, Δa and Δb) and the WID (Whiteness Index for Dentistry) for the 4 groups. Tooth sensitivity was recorded via a visual analog scale (VAS). Additionally, the Psychosocial Impact of Dental. Aesthetics Questionnaire (PIDAQ) was used to evaluate quality of life. RESULTS For the analysis of ΔL, G4 and G2 presented more brightness than G1 and G3 (p<0.05), implying that G2 is at least as good as G4 (p>0.05). For measure of Δa, G4 presented better results, standing out from the other groups. (p<0.05). For Δb, both G4 and G2 showed a greater tendency for blue color than groups G1 and G3 (p <0.05). When analyzing ∆E at the 180-day follow up, G4 produced the highest ∆E, while G3 showed the lowest ∆E. The other 2 whitening groups produced intermediate ∆E values. For ∆W, G1 and G3 significantly differed from G2 and G3. When analyzing the 180-day follow up, G2 produced the highest ∆W, while G3 showed the lowest ∆W. The other two whitening treatments produced intermediate ∆W values. As for sensitivity, only G4 patients showed dental sensitivity within 24 h of the bleaching, with pain ceasing after 48 h. For G4, 33% of the patients needed to take analgesics within the first 24 h after the first 3 whitening sessions. For PIDAQ, there was no overall decrease in score over time for any of the groups and there was no difference between them (p>0.05). CONCLUSION Our results showed that violet LED was not able to whiten teeth at the same intensity, when used alone, as it was when associated with 35% CP, contrary to our initial hypothesis. However, given that pain was not consistently reported in G2, one could suggest that treatment with LED + 35% CP is quite similar to that of 35% HP when used for tooth whitening, but with better pain outcomes. All treatments suggested an improvement in quality of life.Clinical Trial Registry: This trial is registered at ClinicalTrials.gov; the registration number is NCT03192852 https://clinicaltrials.gov/ct2/show/NCT03192852.",2021,"For PIDAQ, there was no overall decrease in score over time for any of the groups and there was no difference between them (p>0.05). ",['Eight patients were randomized into 4 groups (n\u202f=\u202f20'],"['G1 - violet LED, G2 - 35% carbamide peroxide (CP) and violet LED, G3 only CP 35% and G4 35% hydrogen peroxide (HP', 'violet light emission diode (LED) (405nm) system', 'violet LED (405 nm']","['visual analog scale (VAS', 'Aesthetics Questionnaire (PIDAQ', 'dental sensitivity', 'Tooth sensitivity', 'quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}]","[{'cui': 'C0330463', 'cui_str': 'Viola'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0233929', 'cui_str': 'Emission'}, {'cui': 'C0108342', 'cui_str': 'carbamide peroxide'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C4517768', 'cui_str': '405'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0011432', 'cui_str': 'Sensitive dentin'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",8.0,0.192295,"For PIDAQ, there was no overall decrease in score over time for any of the groups and there was no difference between them (p>0.05). ","[{'ForeName': 'Ana Eliza Castanho Garrini', 'Initials': 'AECG', 'LastName': 'Santos', 'Affiliation': 'Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil. Electronic address: anaelizagarrini@gmail.com.'}, {'ForeName': 'Sandra Kalil', 'Initials': 'SK', 'LastName': 'Bussadori', 'Affiliation': 'Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil; Postgraduate Program in Rehabilitation Sciences, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil. Electronic address: sandrakalil@uni9.pro.br.'}, {'ForeName': 'Marcelo Mendes', 'Initials': 'MM', 'LastName': 'Pinto', 'Affiliation': 'School of Dentistry, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil. Electronic address: mmpdent@uni9.pro.br.'}, {'ForeName': 'Aldo Jr', 'Initials': 'AJ', 'LastName': 'Brugnera', 'Affiliation': 'Invited professor and Associate Researcher of Nacional Institute of Science, IFSC-USP, São Carlos, Brazil.'}, {'ForeName': 'Fátima Antonia Aparecida', 'Initials': 'FAA', 'LastName': 'Zanin', 'Affiliation': 'Director of Biophotonic Center of Institute Brugnera and Zanin, São Paulo, Brazil.'}, {'ForeName': 'Tamiris', 'Initials': 'T', 'LastName': 'Silva', 'Affiliation': 'Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil. Electronic address: tamiris.slv@uni9.edu.br.'}, {'ForeName': 'Ana Luiza Cabrera', 'Initials': 'ALC', 'LastName': 'Martinbianco', 'Affiliation': 'Universidade Metropolitana de Santos, UNIMES, Santos, São Paulo, Brasil. Electronic address: ana.martimbianco@unimes.br.'}, {'ForeName': 'Dacio Antônio', 'Initials': 'DA', 'LastName': 'Pantano Junior', 'Affiliation': 'School of Dentistry, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil. Electronic address: daciopan@uni9.pro.br.'}, {'ForeName': 'Maria Fernanda Setúbal Dextro', 'Initials': 'MFSD', 'LastName': 'Rodrigues', 'Affiliation': 'Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil. Electronic address: fernandarodrigues@uni9.pro.br.'}, {'ForeName': 'Hilana Paula Carrillo', 'Initials': 'HPC', 'LastName': 'Artese', 'Affiliation': 'School of Dentistry, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil.'}, {'ForeName': 'Alessandro Melo', 'Initials': 'AM', 'LastName': 'Deana', 'Affiliation': 'Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil. Electronic address: amdeana@uni9.pro.br.'}, {'ForeName': 'Lara Jansiski', 'Initials': 'LJ', 'LastName': 'Motta', 'Affiliation': 'Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil. Electronic address: larajmotta@uni9.pro.br.'}, {'ForeName': 'Anna Carolina Ratto Tempestini', 'Initials': 'ACRT', 'LastName': 'Horliana', 'Affiliation': 'Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de Julho, UNINOVE, São Paulo, Brazil. Electronic address: acrth@uni9.pro.br.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2021.102385'] 3469,31310839,How to improve the clinical experience for dermatology patients requiring a genital examination: A randomized trial of deodorizing wipes versus standard of care.,,2020,,['Dermatology Patients Requiring a Genital Examination'],['Deodorizing Wipes versus Standard of Care'],[],"[{'cui': 'C0011627', 'cui_str': 'Dermatology'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}]","[{'cui': 'C2936643', 'cui_str': 'Standard of Care'}]",[],,0.02847,,"[{'ForeName': 'Susruthi', 'Initials': 'S', 'LastName': 'Rajanala', 'Affiliation': 'Department of Dermatology, Boston University School of Medicine, Boston, Masschusetts.'}, {'ForeName': 'Lauren K', 'Initials': 'LK', 'LastName': 'Burdine', 'Affiliation': 'Department of Dermatology, Boston University School of Medicine, Boston, Masschusetts.'}, {'ForeName': 'Mayra B C', 'Initials': 'MBC', 'LastName': 'Maymone', 'Affiliation': 'Department of Dermatology, Boston University School of Medicine, Boston, Masschusetts.'}, {'ForeName': 'Neelam A', 'Initials': 'NA', 'LastName': 'Vashi', 'Affiliation': 'Department of Dermatology, Boston University School of Medicine, Boston, Masschusetts; US Department of Veterans Affairs, Boston Health Care System, Boston, Massachusetts. Electronic address: nvashi@bu.edu.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.07.026'] 3470,29489608,The Impact of a Displayed Checklist on Simulated Pediatric Trauma Resuscitations.,"BACKGROUND Advanced Trauma Life Support resuscitation follows a strict protocolized approach to the initial trauma evaluation. Despite this structure, elements of the primary and secondary assessments can still be omitted. The aim of this study is to determine if a cognitive aid checklist reduces omissions and speeds the time to assessment completion. We additionally investigated if a displayed checklist improved performance further. METHODS A series of 131 simulated trauma resuscitations were performed. Teams were randomized to 1 of 3 arms (no checklist, handheld checklist, or displayed). The scenarios were recorded and analyzed to determine time to completion and absolute completion of tasks of the primary and secondary survey. The workload of individual team members was assessed via NASA-TLX. RESULTS There was no difference in time to completion of surveys among the 3 arms. In the primary survey, there was a nonsignificant increase in the number of completed tasks with the use of the displayed checklist. In the secondary survey, there was a significant improvement in task completion with the displayed checklists with improved evaluation of the pelvis (P = 0.011), lower extremities (P = 0.048), and covering the patient (P = 0.046). There was a significant improvement in performance in those reported among nurse documenters with use of the displayed checklist. CONCLUSIONS Despite a structured approach to trauma resuscitations, omissions still occur. The use of a displayed checklist improves performance and reduces omissions without delaying assessment. Better compliance with Advanced Trauma Life Support protocols may improve patient outcomes.",2021,"In the primary survey, there was a nonsignificant increase in the number of completed tasks with the use of the displayed checklist.",['131 simulated trauma resuscitations'],[],"['task completion', 'performance', 'number of completed tasks', 'lower extremities']","[{'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}]",,0.0629294,"In the primary survey, there was a nonsignificant increase in the number of completed tasks with the use of the displayed checklist.","[{'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Hulfish', 'Affiliation': ""From the Stony Brook Children's Hospital, Stony Brook University, Stony Brook, NY.""}, {'ForeName': 'Maria Carmen G', 'Initials': 'MCG', 'LastName': 'Diaz', 'Affiliation': 'Nemours/AI duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Feick', 'Affiliation': 'Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Messina', 'Affiliation': 'Deparment of Family, Population, and Preventive Medicine, Stony Brook University, Stony Brook, NY.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Stryjewski', 'Affiliation': 'Inpatient Medical Director, Pediatric Intensive Care Unit, Alaska Native Medical Center, Anchorage, AK.'}]",Pediatric emergency care,['10.1097/PEC.0000000000001439'] 3471,31987770,Bias in the evaluation of psychology studies: A comparison of parapsychology versus neuroscience.,"Research suggests that scientists display confirmation biases with regard to the evaluation of research studies, in that they evaluate results as being stronger when a study confirms their prior expectations. These biases may influence the peer review process, particularly for studies that present controversial findings. The purpose of the current study was to compare the evaluation of a parapsychology study versus a neuroscience study. One hundred participants with a background in psychology were randomly assigned to read and evaluate one of two virtually identical study abstracts (50 participants per group). One of the abstracts described the findings as if they were from a parapsychology study, whereas the other abstract described the findings as if they were from a neuroscience study. The results revealed that participants rated the neuroscience abstract as having stronger findings and as being more valid and reliable than the parapsychology abstract, despite the fact that the two abstracts were identical. Participants also displayed confirmation bias in their ratings of the parapsychology abstract, in that their ratings were correlated with their scores on transcendentalism (a measure of beliefs and experiences related to parapsychology, consciousness and reality). Specifically, higher transcendentalism was associated with more favorable ratings of the parapsychology abstract, whereas lower transcendentalism was associated with less favorable ratings. The findings suggest that individuals with a background in psychology need to be vigilant about potential biases that could impact their evaluations of parapsychology research during the peer review process.",2020,"Participants also displayed confirmation bias in their ratings of the parapsychology abstract, in that their ratings were correlated with their scores on transcendentalism (a measure of beliefs and experiences related to parapsychology, consciousness and reality).",['One hundred participants with a background in psychology'],['parapsychology versus neuroscience'],[],"[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0033909', 'cui_str': 'Psychology'}]","[{'cui': 'C0030492', 'cui_str': 'Parapsychology'}, {'cui': 'C0027910', 'cui_str': 'Neurosciences'}]",[],100.0,0.0264862,"Participants also displayed confirmation bias in their ratings of the parapsychology abstract, in that their ratings were correlated with their scores on transcendentalism (a measure of beliefs and experiences related to parapsychology, consciousness and reality).","[{'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Butzer', 'Affiliation': 'School of Psychology, University of New York in Prague, Londýnská 41, Prague 2 12000, Czech Republic. Electronic address: bbutzer@faculty.unyp.cz.'}]","Explore (New York, N.Y.)",['10.1016/j.explore.2019.12.010'] 3472,31669438,"A comparison of the efficacy of ablative fractional laser-assisted photodynamic therapy according to the density of the ablative laser channel in the treatment of actinic keratosis: A prospective, randomized, controlled trial.",,2021,,['Actinic Keratosis'],['Ablative Fractional Laser-assisted Photodynamic Therapy'],[],"[{'cui': 'C0022602', 'cui_str': 'Senile keratoma (disorder)'}]","[{'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0031740', 'cui_str': 'Photodynamic Therapy'}]",[],,0.027242,,"[{'ForeName': 'Yeo-Rye', 'Initials': 'YR', 'LastName': 'Cho', 'Affiliation': 'Department of Dermatology, College of Medicine, Dong-A University, Republic of Korea.'}, {'ForeName': 'Jeong-Wan', 'Initials': 'JW', 'LastName': 'Seo', 'Affiliation': 'Department of Dermatology, College of Medicine, Dong-A University, Republic of Korea.'}, {'ForeName': 'Ho-Jin', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, College of Medicine, Dong-A University, Republic of Korea.'}, {'ForeName': 'Ki-Hoon', 'Initials': 'KH', 'LastName': 'Song', 'Affiliation': 'Department of Dermatology, National Cancer Center, Republic of Korea. Electronic address: khsong@ncc.re.kr.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.10.037'] 3473,31694484,"Speech perception, real-ear measurements and self-perceived hearing impairment after remote and face-to-face programming of hearing aids: A randomized single-blind agreement study.","INTRODUCTION Current literature does not provide strong evidence that remote programming of hearing aids is effective, despite its increasing use by audiologists. We tested speech perception outcomes, real-ear insertion gain, and changes in self-perceived hearing impairment after face-to-face and remote programming of hearing aids in a randomized multicentre, single-blind crossover study. METHODS Adult experienced hearing aid users were enrolled during routine follow-up visits to audiology clinics. Hearing aids were programmed both face to face and remotely, then participants randomly received either the face-to-face or remote settings in a blinded manner and were evaluated 5 weeks later. Participants then received the other settings and were evaluated 5 weeks later. RESULTS Data from 52 out of 60 participants were analysed. We found excellent concordance in performance of hearing aids programmed face to face and remotely for speech understanding in quiet (phonetically balanced kindergarten test - intraclass correlation coefficient of 0.92 (95% confidence interval: 0.87-0.95)), and good concordance in performance for speech understanding in noise (phonetically balanced kindergarten +5 dB signal-to-noise ratio - intraclass correlation coefficient of 0.71 (95% confidence interval: 0.55-0.82)). Face-to-face and remote programming took 10 minutes (±2.9) and 10 minutes (±2.8), respectively. Real-ear insertion gains were highly correlated for input sound at 50, 65 and 80 dB sound pressure levels. The programming type did not affect the abbreviated profile of hearing aid questionnaire scores. CONCLUSIONS In experienced hearing aid users, face-to-face and remote programming of hearing aids give similar results in terms of speech perception, with no increase in the time spent on patients' care and no difference in self-reported hearing benefit. CLINICALTRIALS.GOV IDENTIFIER NCT02589561.",2021,,['hearing aids'],[],"['Speech perception, real-ear measurements and self-perceived hearing impairment']",[],[],"[{'cui': 'C0037826', 'cui_str': 'Speech Perception'}, {'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}]",,0.0178994,,"[{'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Venail', 'Affiliation': 'ENT and Audiology Department, University Hospital Gui de Chauliac, France.'}, {'ForeName': 'Marie C', 'Initials': 'MC', 'LastName': 'Picot', 'Affiliation': 'Biostatistics & Clinical Research Unit, University Montpellier, France.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Marin', 'Affiliation': 'Biostatistics & Clinical Research Unit, University Montpellier, France.'}, {'ForeName': 'Sylvain', 'Initials': 'S', 'LastName': 'Falinower', 'Affiliation': 'AudioProConnect Company, France.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Samson', 'Affiliation': 'AudioProConnect Company, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Cizeron', 'Affiliation': 'AudioProConnect Company, France.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Balcon', 'Affiliation': 'ENT and Audiology Department, University Hospital Gui de Chauliac, France.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Blanc', 'Affiliation': 'Audition Conseil, Nîmes, France.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Bricaud', 'Affiliation': 'Audition Conseil, Perpignan, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Lorenzi', 'Affiliation': 'ENT and Audiology Department, University Hospital Gui de Chauliac, France.'}, {'ForeName': 'Jean-Charles', 'Initials': 'JC', 'LastName': 'Ceccato', 'Affiliation': 'Auditory Disorders, Institute for Neurosciences of Montpellier, INSERM, France.'}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Puel', 'Affiliation': 'Auditory Disorders, Institute for Neurosciences of Montpellier, INSERM, France.'}]",Journal of telemedicine and telecare,['10.1177/1357633X19883543'] 3474,31610100,Comparing the Pharmacokinetics of 2 Novel Intravenous Tramadol Dosing Regimens to Oral Tramadol: A Randomized 3-Arm Crossover Study.,"Tramadol is a dual-mechanism (opiate and monoamine reuptake inhibition) analgesic. Intravenous (IV) tramadol has been widely prescribed outside the United States. However, there have not been studies comparing the pharmacokinetics (PK) of IV dosing regimens to that of oral tramadol. In this phase 1, open-label, single investigational center, 3-treatment, 3-period, multidose crossover study, we compared 2 novel IV dosing regimens (IV tramadol 75 mg and IV tramadol 50 mg) to oral tramadol 100 mg given every 6 hours (the highest approved oral dosage in the United States) Compared to the oral regimen, IV tramadol 50 mg administered at hours 0, 2, and 4 and every 4 hours thereafter reached initial tramadol peak serum concentration (C max ) more rapidly, while resulting in similar overall steady-state C max and area under the plasma concentration-time curve. IV tramadol 75 mg administered at hours 0, 3, and 6 and every 6 hours thereafter had higher C max and greater fluctuation in peak to trough tramadol concentration. The primary metabolite M1 (a potent μ agonist) had lower area under the plasma concentration-time curve and C max for both IV regimens than for the oral regimen. IV tramadol at both doses was well tolerated, with adverse event profiles consistent with the known pharmacological effects of tramadol. IV tramadol 50 mg is now in phase 3 development in patients with postsurgical pain.",2020,The primary metabolite M1 (a potent µ agonist) had lower area under the plasma concentration-time curve and C max for both IV regimens than for the oral regimen.,['patients with postsurgical pain'],"['tramadol', 'Intravenous (IV) tramadol', 'IV tramadol', 'Tramadol', 'tramadol 75\xa0mg and IV tramadol 50\xa0mg) to oral tramadol']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]",[],,0.0214376,The primary metabolite M1 (a potent µ agonist) had lower area under the plasma concentration-time curve and C max for both IV regimens than for the oral regimen.,"[{'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Avenue Therapeutics, Inc., New York, New York, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ryan', 'Affiliation': 'Avenue Therapeutics, Inc., New York, New York, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Harnett', 'Affiliation': 'Avenue Therapeutics, Inc., New York, New York, USA.'}, {'ForeName': 'George J', 'Initials': 'GJ', 'LastName': 'Atiee', 'Affiliation': 'Worldwide Clinical Trials, San Antonio, Texas, USA.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Reines', 'Affiliation': 'Avenue Therapeutics, Inc., New York, New York, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.746'] 3475,31530065,Cost-effectiveness of telerehabilitation versus traditional care after total hip replacement: A trial-based economic evaluation.,"INTRODUCTION Physical rehabilitation for total hip replacement patients following hospital discharge is beneficial; however, accessing rehabilitation is often challenging. Telerehabilitation helps negate access issues and is efficacious in total knee and hip replacement patients. This study aims to compare the cost-effectiveness of a telerehabilitation programme delivered remotely into patients' homes versus traditional care for total hip replacement patients following hospital discharge. METHODS A cost-effectiveness (cost-utility) analysis was conducted from the perspective of a health service alongside a two-arm randomised controlled trial comparing telerehabilitation ( n =35) with in-person care ( n =35) following hospital discharge after total hip replacement. The primary analysis used an Incremental Cost-Effectiveness Ratio to compare the cost per Quality Adjusted Life Year (QALY) accrued in the telerehabilitation group versus in-person control using costs and effects data from the randomised trial. A secondary analysis was conducted whereby the time accrued by patients attending rehabilitation sessions (including travel time) was considered the ""cost"" (i.e. a time burden), rather than cost from the health service perspective. RESULTS Estimated mean differences in healthcare costs and QALYs gained were detected but were not significant. The estimated mean (95%CI) difference in cost of telerehabilitation versus in-person was -$28.90 (-$96.37 to $40.45), favouring the telerehabilitation group. The estimated mean (95%CI) difference in QALYs gained from telerehabilitation versus in-person was -0.0025 (-0.0227 to 0.0217). The estimated mean (95%CI) difference in time burden favoured less time burden for the telerehabilitation group (-4.21 (-4.69 to -3.74) hours). DISCUSSION Telerehabilitation in the total hip replacement population incurred similar costs and yielded similar effects to traditional in-person care. Telerehabilitation significantly reduced the time burden for patients and carers. These findings are valuable for healthcare providers seeking to implement accessible patient-centred rehabilitation services.",2021,,[],['telerehabilitation versus traditional care after total hip replacement'],[],[],"[{'cui': 'C4042802', 'cui_str': 'Tele-rehabilitation'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0040508', 'cui_str': 'Hip Replacement, Total'}]",[],,0.0178466,,"[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Nelson', 'Affiliation': 'QEII Jubilee Hospital, Metro South Hospital and Health Service, Brisbane, Australia.'}, {'ForeName': 'Trevor', 'Initials': 'T', 'LastName': 'Russell', 'Affiliation': 'Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Crossley', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, College of Science, Health and Engineering, Melbourne, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bourke', 'Affiliation': 'Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'McPhail', 'Affiliation': 'Queensland University of Technology, Institute of Health and Biomedical Innovation and School of Public Health & Social Work, Brisbane, Australia.'}]",Journal of telemedicine and telecare,['10.1177/1357633X19869796'] 3476,32129681,Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.,"COMPASS study demonstrated efficacy of dual pathway inhibition with 2.5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the underlying mechanism of which is not clearly understood. In this Phase IV, prospective, open-label and randomized study, we hypothesize that treatment with rivaroxaban is associated with a reduction in platelet activation and aggregation, inflammation and coagulation markers. 30 patients will be randomly treated with aspirin (81 mg q.d.) or aspirin plus rivaroxaban (2.5 mg b.i.d.) for 12 weeks. Platelet aggregation, platelet activation and inflammation markers, thrombin generation kinetics and tissue factor-induced platelet-fibrin clot strength will be measured at baseline, and 4 and 12 weeks after randomization. Trial registration number: NCT04059679.",2020,"Platelet aggregation, platelet activation and inflammation markers, thrombin generation kinetics and tissue factor-induced platelet-fibrin clot strength will be measured at baseline, and 4 and 12 weeks after randomization. ","['Thirty patients', 'patients with coronary artery disease and peripheral artery disease on aspirin therapy', 'patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both']","['aspirin', 'aspirin plus rivaroxaban', 'dual pathway inhibition with 2.5\xa0mg twice daily rivaroxaban and aspirin', 'rivaroxaban']","['platelet activation and aggregation, inflammation and coagulation markers', 'inflammation and coagulation biomarkers', 'Platelet aggregation, platelet activation and inflammation markers, thrombin generation kinetics and tissue factor-induced platelet-fibrin clot strength']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Artery Disease'}, {'cui': 'C4303556', 'cui_str': 'Aspirin therapy'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0032173', 'cui_str': 'Platelet Activation'}, {'cui': 'C0332621', 'cui_str': 'Aggregation (finding)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0677599', 'cui_str': 'Platelet aggregation'}, {'cui': 'C0863178', 'cui_str': 'Thrombin'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0040048', 'cui_str': 'Prothrombinase'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0015982', 'cui_str': 'Fibrin'}, {'cui': 'C0302148', 'cui_str': 'Blood coagulum'}]",30.0,0.0407357,"Platelet aggregation, platelet activation and inflammation markers, thrombin generation kinetics and tissue factor-induced platelet-fibrin clot strength will be measured at baseline, and 4 and 12 weeks after randomization. ","[{'ForeName': 'Udaya', 'Initials': 'U', 'LastName': 'Tantry', 'Affiliation': 'Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Cummings', 'Affiliation': 'Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Mackrell', 'Affiliation': 'Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Gonze', 'Affiliation': 'Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Ulloa', 'Affiliation': 'Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Bafford', 'Affiliation': 'Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Rout', 'Affiliation': 'Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.'}, {'ForeName': 'Ajaypaul', 'Initials': 'A', 'LastName': 'Sukhi', 'Affiliation': 'Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Gurbel', 'Affiliation': 'Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.'}]",Future cardiology,['10.2217/fca-2019-0091'] 3477,32195655,A Qualitative Study of Increased Pediatric Reutilization After a Postdischarge Home Nurse Visit.,"BACKGROUND The Hospital to Home Outcomes (H2O) trial was a 2-arm, randomized controlled trial that assessed the effects of a nurse home visit after a pediatric hospital discharge. Children randomized to the intervention had higher 30-day postdischarge reutilization rates compared with those with standard discharge. We sought to understand perspectives on why postdischarge home nurse visits resulted in higher reutilization rates and to elicit suggestions on how to improve future interventions. METHODS We sought qualitative input using focus groups and interviews from stakeholder groups: parents, primary care physicians (PCP), hospital medicine physicians, and home care registered nurses (RNs). A multidisciplinary team coded and analyzed transcripts using an inductive, iterative approach. RESULTS Thirty-three parents participated in interviews. Three focus groups were completed with PCPs (n = 7), 2 with hospital medicine physicians (n = 12), and 2 with RNs (n = 10). Major themes in the explanation of increased reutilization included: appropriateness of patient reutilization; impact of red flags/warning sign instructions on family's reutilization decisions; hospital-affiliated RNs ""directing traffic"" back to hospital; and home visit RNs had a low threshold for escalating care. Major themes for improving design of the intervention included: need for improved postdischarge communication; individualizing home visits-one size does not fit all; and providing context and framing of red flags. CONCLUSION Stakeholders questioned whether hospital reutilization was appropriate and whether the intervention unintentionally directed patients back to the hospital. Future interventions could individualize the visit to specific needs or diagnoses, enhance postdischarge communication, and better connect patients and home nurses to primary care.",2020,Children randomized to the intervention had higher 30-day postdischarge reutilization rates compared with those with standard discharge.,"['Thirty-three parents participated in interviews', 'n = 7), 2 with hospital medicine physicians (n = 12), and 2 with RNs (n = 10', 'stakeholder groups: parents, primary care physicians (PCP), hospital medicine physicians, and home care registered nurses (RNs']",['PCPs'],['30-day postdischarge reutilization rates'],"[{'cui': 'C0450358', 'cui_str': '33 (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C3658340', 'cui_str': 'Hospital Medicine'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0033131', 'cui_str': 'Primary Care Physicians'}, {'cui': 'C0204977', 'cui_str': 'Home Care'}, {'cui': 'C0687673', 'cui_str': 'Registered nurse (occupation)'}]",[],"[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",33.0,0.0821655,Children randomized to the intervention had higher 30-day postdischarge reutilization rates compared with those with standard discharge.,"[{'ForeName': 'Sarah W', 'Initials': 'SW', 'LastName': 'Riddle', 'Affiliation': ""Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Susan N', 'Initials': 'SN', 'LastName': 'Sherman', 'Affiliation': 'SNS Research, Cincinnati, Ohio.'}, {'ForeName': 'Margo J', 'Initials': 'MJ', 'LastName': 'Moore', 'Affiliation': ""Division of Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Allison M', 'Initials': 'AM', 'LastName': 'Loechtenfeldt', 'Affiliation': ""Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Tubbs-Cooley', 'Affiliation': 'College of Nursing, Martha S. Pitzer Center for Women, Children and Youth, Columbus, Ohio.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Gold', 'Affiliation': ""Division of Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Wade-Murphy', 'Affiliation': ""Division of Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Andrew F', 'Initials': 'AF', 'LastName': 'Beck', 'Affiliation': ""Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Statile', 'Affiliation': ""Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Samir S', 'Initials': 'SS', 'LastName': 'Shah', 'Affiliation': ""Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Simmons', 'Affiliation': ""Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Auger', 'Affiliation': ""Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of hospital medicine,['10.12788/jhm.3370'] 3478,3552020,Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring.,"A double-blind controlled trial of oral hydroxychloroquine (HC) treatment in polymorphic light eruption (PLE) was completed in 13 patients on active treatment and 15 on placebo during June, July and August 1982. HC dose was 400 mg daily for the first month and 200 mg daily thereafter. Exposure to ambient solar ultraviolet radiation (UVR) was monitored throughout the trial by polysulphone film lapel badges. Patients scored their symptoms on a visual analogue scale. Drug concentration was monitored in plasma and hair, and oculotoxicity was assessed by visual contrast sensitivity. Moderate clinical improvement occurred, associated with a statistically significant improvement in skin rash (P less than 0.01).",1987,"Moderate clinical improvement occurred, associated with a statistically significant improvement in skin rash (P less than 0.01).","['13 patients on active treatment and 15 on placebo during June, July and August 1982', 'polymorphic light eruption', 'polymorphic light eruption (PLE']","['ambient solar ultraviolet radiation (UVR', 'oral hydroxychloroquine (HC', 'Hydroxychloroquine']","['Drug concentration', 'skin rash', 'plasma and hair, and oculotoxicity', 'visual analogue scale']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0456590', 'cui_str': '1982 (qualifier value)'}, {'cui': 'C0031736', 'cui_str': 'Polymorphic light eruption (disorder)'}, {'cui': 'C0449200', 'cui_str': 'PLE (body structure)'}]","[{'cui': 'C4319812', 'cui_str': 'Ultraviolet Radiation'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0018494', 'cui_str': 'Hair'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",,0.0850209,"Moderate clinical improvement occurred, associated with a statistically significant improvement in skin rash (P less than 0.01).","[{'ForeName': 'G M', 'Initials': 'GM', 'LastName': 'Murphy', 'Affiliation': ''}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Hawk', 'Affiliation': ''}, {'ForeName': 'I A', 'Initials': 'IA', 'LastName': 'Magnus', 'Affiliation': ''}]",The British journal of dermatology,[] 3479,32037127,Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort.,"Some, but not all, studies have found longer duration of untreated psychosis (DUP) to be associated with poor response to treatment and more severe negative symptoms in schizophrenia. The aim of the current analysis was to investigate these parameters in a large cohort of patients in their first psychotic episode. The OPTiMiSE cohort included 446 patients with DUP up to two years, who were administered amisulpride for 4 weeks (Phase I). Patients who did not meet Andreasen remission criteria were randomized to double-blind continuation of amisulpride or olanzapine for 6 additional weeks in a blinded study (Phase II). Analyses showed that shorter DUP was associated with lower baseline CGI scores (p<0.001, r = 0.184), PANSS total (p = 0.025, r = 0.106) and PANSS negative subscale scores (p = 0.023, r = 0.107). Remitters had a significantly shorter mean DUP compared to non-remitters both in Phase I (24.5 weeks ±24.3 vs. 35 weeks ± 32.2, p = 0.01, t=-2.521) and in Phase II (24.3 weeks ± 26.4 vs. 38.3 weeks ± 31.3, p = 0.031, t=-2.194). Logistic regression analyses showed a significant effect of DUP on treatment response both in phase I (p = 0.008) and phase II (p = 0.041). Linear regression analyses found that DUP significantly affects PANSS Total change at the end of phase I (p = 0.028) but not at the end of phase II (p = 0.236). Based on these findings, it is possible to conclude that shorter DUP is associated with better response to treatment, particularly during the first weeks after treatment initiation. These findings highlight the need for early identification of the first psychotic episode.",2020,Remitters had a significantly shorter mean DUP compared to non-remitters both in Phase,"['Patients who did not meet Andreasen remission criteria', '446 patients with DUP up to two years, who were administered', 'large cohort of patients in their first psychotic episode']","['amisulpride or olanzapine', 'amisulpride']","['baseline CGI scores', 'mean DUP', 'PANSS negative subscale scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0338614'}]","[{'cui': 'C0103045', 'cui_str': 'Amisulpride'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0459443', 'cui_str': 'Subscale score (qualifier value)'}]",446.0,0.0316464,Remitters had a significantly shorter mean DUP compared to non-remitters both in Phase,"[{'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Levi', 'Affiliation': 'Psychiatry Department, Sheba Medical Center, Tel-Hashomer, 52621 Ramat Gan, Israel.'}, {'ForeName': 'Mor', 'Initials': 'M', 'LastName': 'Bar Haim', 'Affiliation': 'Psychiatry Department, Sheba Medical Center, Tel-Hashomer, 52621 Ramat Gan, Israel.'}, {'ForeName': 'Shimon', 'Initials': 'S', 'LastName': 'Burshtein', 'Affiliation': 'Psychiatry Department, Sheba Medical Center, Tel-Hashomer, 52621 Ramat Gan, Israel.'}, {'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'Winter-Van Rossum', 'Affiliation': 'Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Heres', 'Affiliation': 'Psychiatry Department, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Davidson', 'Affiliation': 'Psychiatry Department, Sheba Medical Center, Tel-Hashomer, 52621 Ramat Gan, Israel; Nicosia School of Medicine, Cyprus.'}, {'ForeName': 'Geva', 'Initials': 'G', 'LastName': 'Shenkman', 'Affiliation': 'Psychology Department, Interdisciplinary Center Hertzelya, Hertzelya, Israel.'}, {'ForeName': 'René S', 'Initials': 'RS', 'LastName': 'Kahn', 'Affiliation': 'Department of Psychiatry, Icahn School of Medicine, Mount Sinai, New York, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Weiser', 'Affiliation': 'Psychiatry Department, Sheba Medical Center, Tel-Hashomer, 52621 Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: mweiser@netvision.net.il.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2020.01.007'] 3480,31403668,A Web-Based HIV/STD Prevention Intervention for Divorced or Separated Older Women.,"BACKGROUND AND OBJECTIVE Sexually transmitted diseases (STDs) are increasing among older adults concomitant with a rise in divorce after the age of 50 years. The objective of this study was to examine the effectiveness of a web-based human immunodeficiency virus (HIV)/STD risk reduction intervention for divorced and separated women aged more than 50 years. RESEARCH DESIGN AND METHODS Two hundred nineteen divorced or separated women, aged 50 years and older, participated in 60-day randomized pre-post control group study. Recruitment occurred via health agencies in Boston and Columbia, SC, and Craigslist advertisements placed in Boston, Columbia, Charleston, New York City, Washington DC, Baltimore, Chicago, Atlanta, Orlando, and Miami. RESULTS Intervention group reported greater intention to practice safe sex compared to the control group (B = .55, p = .03). Intention to practice safe sex differed by perceived stress (B = .15, p = .005), with no difference between control and intervention groups for those with low levels of stress. For high levels of stress, intervention group reported greater intention to practice safe sex compared to controls. Sexual risk was reduced by 6.10 points (SD: 1.10), and self-efficacy for sexual discussion was increased by 2.65 points (SD: 0.56) in the intervention group. DISCUSSION AND IMPLICATIONS A web-based intervention represents a promising tool to reduce HIV/STD risk among older women. Offering HIV/STD education in the context of other topics of interest to at-risk older women, such as divorce, may solve the problem of at-risk older women not seeking out prevention information due to lack of awareness of their heightened risk.",2020,Intention to practice safe sex differed by perceived stress,"['Two hundred nineteen divorced or separated women, aged 50 years and older, participated in 60-day randomized pre-post control group study', 'older adults concomitant with a rise in divorce after the age of 50 years', 'Divorced or Separated Older Women', 'older women', 'divorced and separated women aged more than 50 years']","['STD Prevention Intervention', 'web-based human immunodeficiency virus (HIV)/STD risk reduction intervention']","['Sexual risk', 'self-efficacy for sexual discussion', 'greater intention to practice safe sex']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C0086170', 'cui_str': 'Divorced'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0521999', 'cui_str': 'Age more than 50 years (finding)'}]","[{'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0597728', 'cui_str': 'Responsible Sex'}]",,0.0513786,Intention to practice safe sex differed by perceived stress,"[{'ForeName': 'Patricia Flynn', 'Initials': 'PF', 'LastName': 'Weitzman', 'Affiliation': 'Environment and Health Group, Cambridge, Massachusetts.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Environment and Health Group, Cambridge, Massachusetts.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Kogelman', 'Affiliation': ""Infectious Diseases Clinic, Traveler's Health Service, Tufts University School of Medicine, Boston, Massachusetts.""}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Mack', 'Affiliation': 'Environment and Health Group, Cambridge, Massachusetts.'}, {'ForeName': 'Jie Yang', 'Initials': 'JY', 'LastName': 'Sharir', 'Affiliation': 'Environment and Health Group, Cambridge, Massachusetts.'}, {'ForeName': 'Sara Romero', 'Initials': 'SR', 'LastName': 'Vicente', 'Affiliation': 'Environment and Health Group, Cambridge, Massachusetts.'}, {'ForeName': 'Sue E', 'Initials': 'SE', 'LastName': 'Levkoff', 'Affiliation': 'Environment and Health Group, Cambridge, Massachusetts.'}]",The Gerontologist,['10.1093/geront/gnz098'] 3481,32104104,A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants.,"Purpose The burden of hepatitis C virus infection is particularly high in Asian countries, and new treatments are urgently needed. The purpose of this study was to characterize the pharmacokinetics (PK) and safety of the fixed-dose combination tablet of elbasvir/grazoprevir in healthy Chinese participants. Patient and Methods In this Phase I, single-site, open-label, 3-period study in healthy Chinese adults, participants received a single tablet of elbasvir 50 mg/grazoprevir 100 mg, followed by blood sampling for up to 96 hrs (http://www.chinadrugtrials.org.cn/ CTR20160034; Protocol PN071). Participants then received 1 tablet daily for 10 days, followed by a minimum 10-day washout, after which participants received a single dose of 2 tablets (elbasvir 100 mg/grazoprevir 200 mg). Elbasvir and grazoprevir PK were assessed following single and multiple doses. Safety and tolerability were also evaluated. Results Twelve participants (50% male) were enrolled in and completed the study. Following single-dose oral administration of elbasvir 50 mg/grazoprevir 100 mg or elbasvir 100 mg/grazoprevir 200 mg, the median T max was 3-4 hrs and elimination half-life was 18 hrs (elbasvir) and 30 hrs (grazoprevir). Multiple-dose administration resulted in AUC 0-24 accumulation ratios of 1.58 (elbasvir) and 2.35 (grazoprevir). Both elbasvir 50 mg/grazoprevir 100 mg and 100 mg/200 mg regimens were generally well tolerated. Conclusion Single-dose administration of elbasvir 50 mg/grazoprevir 100 mg or 100 mg/200 mg and once-daily administration of elbasvir 50 mg/grazoprevir 100 mg for 10 days has been adequately characterized, with PK values within the expected range, and was generally well tolerated in healthy Chinese male and female participants.",2020,"Both elbasvir 50 mg/grazoprevir 100 mg and 100 mg/200 mg regimens were generally well tolerated. ","['Healthy Chinese Participants', 'Twelve participants (50% male) were enrolled in and completed the study', 'healthy Chinese male and female participants', 'healthy Chinese participants', 'healthy Chinese adults, participants received a']","['elbasvir/grazoprevir', 'single tablet of elbasvir 50 mg/grazoprevir', 'elbasvir 50 mg/grazoprevir', 'Fixed-Dose Grazoprevir/Elbasvir', 'elbasvir 50 mg/grazoprevir 100 mg or elbasvir 100 mg/grazoprevir', 'single dose of 2 tablets (elbasvir 100 mg/grazoprevir']","['Safety and tolerability', 'tolerated', 'pharmacokinetics (PK) and safety', 'Elbasvir and grazoprevir PK']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C4080453', 'cui_str': 'elbasvir / grazoprevir'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C4080448', 'cui_str': 'elbasvir 50 MG'}, {'cui': 'C4080053', 'cui_str': 'grazoprevir'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4080052', 'cui_str': 'elbasvir'}, {'cui': 'C4080456', 'cui_str': 'elbasvir 50 MG / grazoprevir 100 MG [Zepatier]'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C4080453', 'cui_str': 'elbasvir / grazoprevir'}]",,0.0888417,"Both elbasvir 50 mg/grazoprevir 100 mg and 100 mg/200 mg regimens were generally well tolerated. ","[{'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': ""Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.""}, {'ForeName': 'Zhenhua', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': ""Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.""}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': ""Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.""}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': ""Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.""}, {'ForeName': 'Yudong', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': ""Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': ""Department of Infectious Diseases, MSD (China) R&D, Beijing, People's Republic of China.""}, {'ForeName': 'Luzelena', 'Initials': 'L', 'LastName': 'Caro', 'Affiliation': 'Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Hwa-Ping', 'Initials': 'HP', 'LastName': 'Feng', 'Affiliation': 'Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Jacqueline B', 'Initials': 'JB', 'LastName': 'McCrea', 'Affiliation': 'Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': ""Department of Infectious Diseases, MSD (China) R&D, Beijing, People's Republic of China.""}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Xie', 'Affiliation': ""Department of Infectious Diseases, MSD (China) R&D, Beijing, People's Republic of China.""}, {'ForeName': 'Jiangdian', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Infectious Diseases, MSD (China) R&D, Beijing, People's Republic of China.""}, {'ForeName': 'Xu Min', 'Initials': 'XM', 'LastName': 'Zhao', 'Affiliation': ""Department of Infectious Diseases, MSD (China) R&D, Beijing, People's Republic of China.""}, {'ForeName': 'Shengmei', 'Initials': 'S', 'LastName': 'Mu', 'Affiliation': ""Department of Infectious Diseases, MSD (China) R&D, Beijing, People's Republic of China.""}]",Clinical pharmacology : advances and applications,['10.2147/CPAA.S224662'] 3482,32048274,"DEX-2-TKA - DEXamethasone twice for pain treatment after Total Knee Arthroplasty: Detailed statistical analysis plan for a randomized, blinded, three-group multicentre clinical trial.","BACKGROUND Optimization of post-operative pain treatment is of upmost importance. Multimodal analgesia is the main post-operative pain treatment principle, but the evidence on optimal analgesic combinations is unclear. With the ""DEXamethasone twice for pain treatment after TKA"" trial, we aim to investigate the role of one or two doses of glucocorticoid for post-operative pain treatment after total knee arthroplasty. To ensure transparency and minimization of bias, we present this article with a detailed statistical analysis plan, to be published before the last participant is enrolled. METHODS ""DEXamethasone twice for pain treatment after TKA"" (DEX-2-TKA) is a randomized, blinded, three-group multicentre clinical trial. Participants will be randomized to one of three intervention groups: single dose of iv dexamethasone 24 mg, two consecutive doses of iv dexamethasone 24 mg or matching iv placebo. All three intervention groups will receive paracetamol, NSAID (ibuprofen) and local infiltration analgesia. Participants, treatment providers, outcome assessors, data managers, statisticians and conclusion drawers will be blinded to the allocated intervention. The primary outcome is total opioid consumption (iv morphine milligram equivalents) 0-48 hours post-operatively. Secondary outcomes are (1) visual analogue scale pain levels: (a) during active 45 degrees flexion of the knee at 24 and 48 hours post-operatively, (b) at rest at 24 and 48 hours post-operatively, and (c) during 0-24 hours (highest score) and 24-48 hours post-operatively (highest score); and (2) the proportion of participants with one or more adverse events within 48 hours post-operatively. DISCUSSION The DEX-2-TKA trial will provide high quality data regarding benefits and harms of adding one or two high-doses of dexamethasone to a multimodal analgesic regimen. TRIAL REGISTRATION EudraCT: 2018-001099-39 (08/06-18); ClinicalTrials.gov: NCT03506789 (24/04-2019).",2020,The primary outcome is total opioid consumption (intravenous morphine milligram equivalents) 0,"['twice for pain treatment after Total Knee Arthroplasty', 'postoperative pain treatment after total knee arthroplasty', ""twice for pain treatment after TKA' (DEX-2-TKA""]","['dexamethasone', 'paracetamol, ibuprofen, and local infiltration analgesia', 'intravenous 24 mg dexamethasone, or matching intravenous placebo', 'DEXamethasone', 'DEX-2-TKA - DEXamethasone', 'glucocorticoid']","['1) visual analogue scale pain levels: a) during active 45 degrees flexion of the knee at 24 and 48 hours postoperatively, b) at rest', 'proportion of participants with one or more adverse events', 'total opioid consumption (intravenous morphine milligram equivalents) 0']","[{'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C3669041', 'cui_str': 'Spread by direct extension (qualifier value)'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}]","[{'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0439586', 'cui_str': '48 hours (qualifier value)'}, {'cui': 'C0443144', 'cui_str': 'At rest (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0439210', 'cui_str': 'milligram'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}]",,0.433772,The primary outcome is total opioid consumption (intravenous morphine milligram equivalents) 0,"[{'ForeName': 'Kasper S', 'Initials': 'KS', 'LastName': 'Gasbjerg', 'Affiliation': 'Department of Anaesthesiology, Naestved-Slagelse-Ringsted Hospitals, Naestved, Denmark.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Hägi-Pedersen', 'Affiliation': 'Department of Anaesthesiology, Naestved-Slagelse-Ringsted Hospitals, Naestved, Denmark.'}, {'ForeName': 'Troels H', 'Initials': 'TH', 'LastName': 'Lunn', 'Affiliation': 'Department of Anaesthesiology, Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Overgaard', 'Affiliation': 'Orthopedic Research Unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Niels Anker', 'Initials': 'NA', 'LastName': 'Pedersen', 'Affiliation': 'Department of Anaesthesia, Gildhøj Private Hospital, Brøndby, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Bagger', 'Affiliation': 'Department of Orthopaedics, Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Lindholm', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Stig', 'Initials': 'S', 'LastName': 'Brorson', 'Affiliation': 'Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark.'}, {'ForeName': 'Henrik M', 'Initials': 'HM', 'LastName': 'Schrøder', 'Affiliation': 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Kasper H', 'Initials': 'KH', 'LastName': 'Thybo', 'Affiliation': 'Department of Anaesthesiology, Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Mathiesen', 'Affiliation': 'Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark.'}, {'ForeName': 'Janus C', 'Initials': 'JC', 'LastName': 'Jakobsen', 'Affiliation': 'Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13560'] 3483,32100161,Effects of vascular morphological features and ultrasound-guided vascular cannulation techniques on the success of femoral artery catheterisation in newborns.,"Ultrasound-guided vascular access is a technique that can increase safety as well as technical and procedural success when performing invasive cardiovascular procedures. The aim of this study was to evaluate the effects of two cannulation techniques and vascular morphological properties on the success of femoral artery catheterisation in neonatal patients. We recruited 65 consecutive patients requiring femoral artery catheterisation and randomly divided them into two groups: Group 1, in-plane technique (n = 31) and Group 2, out-of-plane technique (n = 34). We compared the preparation duration, puncture duration, number of punctures, number of arterial punctures, number of unsuccessful interventions, hematoma incidence and vascular morphological characteristics between the groups. The mean age of Group 1 was 17.16 ± 7.04 days, and the mean age of Group 2 was 17.20 ± 7.40 days, with no difference observed between the groups (p > 0.05). Four patients in Group 1 and nine patients in Group 2 developed hematoma (p = 0.172). Hematoma was strongly correlated with the number of venous punctures (r = 0.632; p = 0.001) and the number of needle advancements (r = 0.415; p = 0.001). In terms of artery-vein position, patients whose artery overlapped the vein by > 50% required clearly longer artery cannulation durations than the other patients (p < 0.001). Although the in-plane technique has a steep learning curve, it was found superior in terms of procedure-related factors such as the number of trials, the incidence of hematoma and arterial puncture counts, as it offers advantages such as the ability to evaluate the lumen and a better control of the needle advancement direction.",2020,"Although the in-plane technique has a steep learning curve, it was found superior in terms of procedure-related factors such as the number of trials, the incidence of hematoma and arterial puncture counts, as it offers advantages such as the ability to evaluate the lumen and a better control of the needle advancement direction.","['neonatal patients', '65 consecutive patients requiring femoral artery catheterisation', 'newborns']","['cannulation techniques and vascular morphological properties', 'plane technique (n\u2009=\u200931) and Group 2, out-of-plane technique', 'vascular morphological features and ultrasound-guided vascular cannulation techniques']","['hematoma', 'preparation duration, puncture duration, number of punctures, number of arterial punctures, number of unsuccessful interventions, hematoma incidence and vascular morphological characteristics', 'Hematoma', 'number of needle advancements', 'number of venous punctures', 'artery cannulation durations', 'femoral artery catheterisation']","[{'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0015801', 'cui_str': 'Femoral Artery'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}]","[{'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}]","[{'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0189586', 'cui_str': 'Puncture of artery'}, {'cui': 'C1272705', 'cui_str': 'Unsuccessful'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0441478', 'cui_str': 'Surgical advancement - action'}, {'cui': 'C0340778', 'cui_str': 'Venous puncture (disorder)'}, {'cui': 'C0003842', 'cui_str': 'Arteries'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0015801', 'cui_str': 'Femoral Artery'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}]",65.0,0.0309259,"Although the in-plane technique has a steep learning curve, it was found superior in terms of procedure-related factors such as the number of trials, the incidence of hematoma and arterial puncture counts, as it offers advantages such as the ability to evaluate the lumen and a better control of the needle advancement direction.","[{'ForeName': 'Omer Faruk', 'Initials': 'OF', 'LastName': 'Boran', 'Affiliation': 'Department of Anesthesiology and Reanimation, Sütçü Imam University School of Medicine, C Blok Kat 5, Daire 11, 46100, Kahramanmaraş, Turkey. ofboran@ksu.edu.tr.'}, {'ForeName': 'Aykut', 'Initials': 'A', 'LastName': 'Urfalıoglu', 'Affiliation': 'Department of Anesthesiology and Reanimation, Sütçü Imam University School of Medicine, C Blok Kat 5, Daire 11, 46100, Kahramanmaraş, Turkey.'}, {'ForeName': 'Mahmut', 'Initials': 'M', 'LastName': 'Arslan', 'Affiliation': 'Department of Anesthesiology and Reanimation, Sütçü Imam University School of Medicine, C Blok Kat 5, Daire 11, 46100, Kahramanmaraş, Turkey.'}, {'ForeName': 'Fatih Mehmet', 'Initials': 'FM', 'LastName': 'Yazar', 'Affiliation': 'Department of General Surgery, Sütçü Imam University School of Medicine, Kahramanmaraş, Turkey.'}, {'ForeName': 'Bora', 'Initials': 'B', 'LastName': 'Bilal', 'Affiliation': 'Department of Anesthesiology and Reanimation, Sütçü Imam University School of Medicine, C Blok Kat 5, Daire 11, 46100, Kahramanmaraş, Turkey.'}, {'ForeName': 'Yavuz', 'Initials': 'Y', 'LastName': 'Orak', 'Affiliation': 'Department of Anesthesiology and Reanimation, Sütçü Imam University School of Medicine, C Blok Kat 5, Daire 11, 46100, Kahramanmaraş, Turkey.'}, {'ForeName': 'Erdinç', 'Initials': 'E', 'LastName': 'Eroğlu', 'Affiliation': 'Department of Cardiovascular Surgery, Sütçü Imam University School of Medicine, Kahramanmaraş, Turkey.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-020-00490-2'] 3484,32087001,Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects.,"Cenobamate (YKP3089) is an antiepileptic drug recently approved by the Food and Drug Administration for the treatment of focal (partial-onset) seizures in adults. The objectives of a first-in-human single-ascending-dose study and 3 multiple-ascending-dose studies were to characterize the pharmacokinetics, safety, and tolerability of cenobamate after single-dose and multiple-dose administration in healthy subjects. The 4 randomized, placebo-controlled, double-blind studies were conducted in 210 healthy subjects receiving single (5 to 750 mg) or multiple (50 to 600 mg/day) oral doses of cenobamate or placebo using capsule formulation. Safety assessments included treatment-emergent adverse events (TEAEs) and laboratory evaluations. Maximum plasma concentrations of cenobamate were observed between 0.8 and 4.0 hours after oral administration. C max increased in a dose-proportional manner for single- and multiple-dose administration across all tested doses. Although the AUC of cenobamate increased in a more than dose-proportional manner after single-dose administration, a dose-proportional increase in cenobamate AUC τ was observed after multiple dosing from 50 to 500 mg/day. Cenobamate exhibited low oral clearance (decreasing from approximately 1.4 to 0.50 L/h with dose increase) and long terminal half-life (range, approximately 30 to 76 hours with increasing dose). Steady-state was attained after approximately 2 weeks, and the accumulation ratio was approximately 5 over the 50 to 300 mg/day range. The pharmacokinetic characteristics of cenobamate are consistent with once-daily dosing. Most TEAEs were mild in severity, 2 serious TEAEs were reported, and no deaths occurred across all studies. Except for multiple daily doses of 600 mg, all doses were generally well tolerated.",2020,"Cenobamate exhibited low oral clearance (decreasing from approximately 1.4 to 0.50 L/h with dose increase) and long terminal half-life (range, approximately 30 to 76 hours with increasing dose).","['Healthy Subjects', 'focal (partial-onset) seizures in adults', '210 healthy subjects receiving single (5\xa0to 750\xa0mg) or multiple (50\xa0to 600\xa0mg/day) oral doses of', 'healthy subjects']","['placebo', 'Cenobamate (YKP3089', 'cenobamate or placebo', 'Cenobamate']","['cenobamate AUC τ', 'Steady-state', 'low oral clearance', 'tolerated', 'pharmacokinetics, safety, and tolerability of cenobamate', 'Maximum plasma concentrations of cenobamate', 'Safety assessments included treatment-emergent adverse events (TEAEs) and laboratory evaluations', 'C max', 'accumulation ratio']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205234', 'cui_str': 'Focal (qualifier value)'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4517868', 'cui_str': '750 (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",210.0,0.0923336,"Cenobamate exhibited low oral clearance (decreasing from approximately 1.4 to 0.50 L/h with dose increase) and long terminal half-life (range, approximately 30 to 76 hours with increasing dose).","[{'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Vernillet', 'Affiliation': 'SK Life Science, Inc., Paramus, New Jersey, USA.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Greene', 'Affiliation': 'SK Life Science, Inc., Paramus, New Jersey, USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Kamin', 'Affiliation': 'SK Life Science, Inc., Paramus, New Jersey, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.769'] 3485,32074652,The Effects of Tourniquet Application in Total Knee Arthroplasty on the Recovery of Thigh Muscle Strength and Clinical Outcomes.,"The present randomized controlled study aims to evaluate whether tourniquet application during total knee arthroplasty (TKA) has an effect on (1) thigh muscle strength (quadriceps and hamstring muscle strength) and (2) clinical outcomes (postoperative knee range of motion [ROM], postoperative pain level, and Knee Society Score [KSS]). The effects of tourniquet application during TKA were investigated in 65 patients randomly allocated to one of two groups: TKA with a tourniquet and TKA without a tourniquet. Patients in both groups were comparable in terms of the demographic and clinical data ( p  > 0.05 for age, number of patients, sex, radiographic gonarthrosis grade, American Society of Anesthesiologists [ASA] classification, and body mass index [BMI]). All patients in both groups were operated by the same surgeon using one type of prosthesis. Isokinetic muscle strength (peak torque and total work) of knee extensors (quadriceps) and flexors (hamstrings) was measured in Newton meters (Nm) using a CYBEX 350 isokinetic dynamometer (HUMAC/CYBEX 2009, Stoughton, MA). The combined KSS (knee score + function score), visual analog scale (VAS), and knee ROM were measured preoperatively and at 1 and 3 months postoperatively to evaluate clinical outcomes. There were no significant differences between the two groups in preoperative and postoperative values of isokinetic muscle strength (peak torque and total work) and aforementioned clinical outcomes ( p  < 0.05). The present study has shown that quadriceps strength and clinical outcomes were not improved in the early postoperative period (3 months) when a tourniquet was not used during TKA.",2021,There were no significant differences between the two groups in preoperative and postoperative values of isokinetic muscle strength (peak torque and total work) and aforementioned clinical outcomes ( p  < 0.05).,"['Total Knee Arthroplasty', '65 patients randomly allocated to one of two groups']","['Tourniquet Application', 'tourniquet application during TKA', 'tourniquet application', 'TKA with a tourniquet and TKA without a tourniquet', 'total knee arthroplasty (TKA']","['combined KSS (knee score\u2009+\u2009function score), visual analog scale (VAS), and knee ROM', 'quadriceps strength and clinical outcomes', 'Recovery of Thigh Muscle Strength and Clinical Outcomes', 'Isokinetic muscle strength (peak torque and total work) of knee extensors (quadriceps) and flexors (hamstrings', 'preoperative and postoperative values of isokinetic muscle strength (peak torque and total work) and aforementioned clinical outcomes', 'thigh muscle strength (quadriceps and hamstring muscle strength) and (2) clinical outcomes (postoperative knee range of motion [ROM], postoperative pain level, and Knee Society Score [KSS']","[{'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0204731', 'cui_str': 'Application of tourniquet (procedure)'}, {'cui': 'C0040519', 'cui_str': 'Tourniquets'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0039866', 'cui_str': 'Thigh'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0584895', 'cui_str': 'Hamstring Muscles'}, {'cui': 'C0576094', 'cui_str': 'Knee range of motion'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}]",65.0,0.048839,There were no significant differences between the two groups in preoperative and postoperative values of isokinetic muscle strength (peak torque and total work) and aforementioned clinical outcomes ( p  < 0.05).,"[{'ForeName': 'Omer', 'Initials': 'O', 'LastName': 'Ayik', 'Affiliation': 'Department of Orthopaedics and Traumatology, Istanbul University, Istanbul School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Demirel', 'Affiliation': 'Department of Orthopaedics and Traumatology, Istanbul University, Istanbul School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Fevzi', 'Initials': 'F', 'LastName': 'Birisik', 'Affiliation': 'Department of Orthopaedics Surgery and Traumatology, University of Health Sciences, Faculty of Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ersen', 'Affiliation': 'Department of Orthopaedics and Traumatology, Istanbul University, Istanbul School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Halil I', 'Initials': 'HI', 'LastName': 'Balci', 'Affiliation': 'Department of Orthopaedics and Traumatology, Istanbul University, Istanbul School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Turker', 'Initials': 'T', 'LastName': 'Sahinkaya', 'Affiliation': 'Department of Sports Medicine, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Sefa Giray', 'Initials': 'SG', 'LastName': 'Batibay', 'Affiliation': 'Department of Orthopaedics Surgery and Traumatology, University of Health Sciences, Faculty of Medicine, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Irfan', 'Initials': 'I', 'LastName': 'Ozturk', 'Affiliation': 'Department of Orthopaedics and Traumatology, Istanbul University, Istanbul School of Medicine, Istanbul, Turkey.'}]",The journal of knee surgery,['10.1055/s-0040-1701454'] 3486,32061718,Characteristics of Chinese fish-allergic patients: Findings from double-blind placebo-controlled food challenges.,,2020,,['Chinese fish-allergic patients'],['placebo'],[],"[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0016163', 'cui_str': 'Fishes'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.3927,,"[{'ForeName': 'Agnes Sze Yin', 'Initials': 'ASY', 'LastName': 'Leung', 'Affiliation': 'Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Nicki Yat Hin', 'Initials': 'NYH', 'LastName': 'Leung', 'Affiliation': 'Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Christine Yee Yan', 'Initials': 'CYY', 'LastName': 'Wai', 'Affiliation': 'Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong; Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Kary Jia Ying', 'Initials': 'KJY', 'LastName': 'Xu', 'Affiliation': 'Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Maco Cheuk Yin', 'Initials': 'MCY', 'LastName': 'Lam', 'Affiliation': 'Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Yuki Yuk', 'Initials': 'YY', 'LastName': 'Shum', 'Affiliation': 'Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Tak Hong', 'Initials': 'TH', 'LastName': 'Lee', 'Affiliation': 'Allergy Centre, Hong Kong Sanatorium and Hospital, Hong Kong.'}, {'ForeName': 'Marco Hok Kung', 'Initials': 'MHK', 'LastName': 'Ho', 'Affiliation': 'Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong.'}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Sou Da Rosa Duque', 'Affiliation': 'Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong.'}, {'ForeName': 'Gilbert T', 'Initials': 'GT', 'LastName': 'Chua', 'Affiliation': 'Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong.'}, {'ForeName': 'Yat Sun', 'Initials': 'YS', 'LastName': 'Yau', 'Affiliation': 'Department of Paediatrics, Queen Elizabeth Hospital, Kowloon, Hong Kong.'}, {'ForeName': 'Wai Hung', 'Initials': 'WH', 'LastName': 'Chan', 'Affiliation': 'Department of Paediatrics, Queen Elizabeth Hospital, Kowloon, Hong Kong.'}, {'ForeName': 'Po Ki', 'Initials': 'PK', 'LastName': 'Ho', 'Affiliation': 'Department of Paediatrics, Queen Elizabeth Hospital, Kowloon, Hong Kong.'}, {'ForeName': 'Gary Wing Kin', 'Initials': 'GWK', 'LastName': 'Wong', 'Affiliation': 'Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Ting Fan', 'Initials': 'TF', 'LastName': 'Leung', 'Affiliation': 'Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong; Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong. Electronic address: tfleung@cuhk.edu.hk.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2020.02.002'] 3487,32074665,"Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.","BACKGROUND Fixed-dose combination of calcipotriol (50 μg/g; Cal) and betamethasone dipropionate (0.5 mg/g; BD) foam is approved for plaque psoriasis treatment in adults, with a paucity of data supporting use in adolescents. OBJECTIVES To evaluate safety of 4 weeks' treatment with Cal/BD foam in adolescent patients with psoriasis, and additional safety outcomes in patients with more severe disease (HPA-axis cohort). Primary objectives included treatment-emergent adverse events (TEAEs) and systemic calcium levels in the overall population, and HPA-axis function, change in calcium excretion and the calcium:creatinine ratio in the HPA-axis cohort. Secondary objectives included exploratory efficacy endpoints [treatment success: change in Psoriasis Area and Severity Index (PASI)]. Systemic exposure to Cal/BD was also assessed. METHODS A phase II, open-label, study (NCT02387853) in patients (12 to <17 years) with at least mild psoriasis, to evaluate Cal/BD foam applied once daily for ≤4 weeks. RESULTS In patients assigned to treatment (n = 106), 32 TEAEs occurred in 22 patients (20.8%). All but two TEAEs were mild; none led to study withdrawal or death. Changes (0-4 weeks) in albumin-corrected serum calcium (overall population) and urinary calcium excretion (HPA-axis cohort) were small, transient and not considered clinically relevant. In the HPA-axis cohort, no change in urinary calcium:creatinine ratio was observed and responses to adrenocorticotropic-hormone (ACTH) challenge did not suggest disruption of the HPA-axis. Prespecified treatment success on the body and scalp was achieved by 71.8% and 75.7% of the overall population, respectively. Mean PASI decreased by 82.0% vs. baseline at Week 4. Systemic exposure to Cal/BD was minimal. CONCLUSIONS Cal/BD foam was well tolerated in adolescent patients with body/scalp psoriasis. There was no evidence for dysregulation of the HPA-axis nor calcium homoeostasis in patients with more severe disease. Exploratory efficacy data in the overall population were encouraging.",2020,Mean PASI decreased by 82.0% vs. baseline at Week 4.,"['adolescent patients (aged 12 to <17\xa0years) with plaque psoriasis', 'adolescent patients with body/scalp psoriasis', 'patients with more severe disease', 'adolescent patients with psoriasis, and additional safety outcomes in patients with more severe disease (HPA-axis cohort', 'patients (12 to <17\xa0years) with at least mild psoriasis, to evaluate Cal/BD foam applied once daily for ≤4\xa0weeks']","['betamethasone dipropionate', 'Cal/BD foam', 'fixed-dose combination calcipotriol', 'calcipotriol']","['Mean PASI', 'body and scalp', 'mild; none led to study withdrawal or death', 'treatment-emergent adverse events (TEAEs) and systemic calcium levels in the overall population, and HPA-axis function, change in calcium excretion and the calcium:creatinine ratio', 'exploratory efficacy endpoints [treatment success: change in Psoriasis Area and Severity Index (PASI', 'albumin-corrected serum calcium (overall population) and urinary calcium excretion (HPA-axis cohort', 'urinary calcium:creatinine ratio', 'Safety and efficacy']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0406317', 'cui_str': 'Plaque psoriasis (disorder)'}, {'cui': 'C0406326', 'cui_str': 'Scalp psoriasis (disorder)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0966198', 'cui_str': ""P(1)-(6-hydroxymethylpterin)-P(4)-(5'-adenosyl)tetraphosphate""}, {'cui': 'C0004457', 'cui_str': 'C2 Vertebra'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0991510', 'cui_str': 'Foam (basic dose form)'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0053523', 'cui_str': 'betamethasone dipropionate'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0991510', 'cui_str': 'Foam (basic dose form)'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C3653162', 'cui_str': 'calcipotriol, combinations'}, {'cui': 'C0065767', 'cui_str': 'calcipotriol'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0036270', 'cui_str': 'Scalp'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0201925', 'cui_str': 'Calcium measurement (procedure)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0966198', 'cui_str': ""P(1)-(6-hydroxymethylpterin)-P(4)-(5'-adenosyl)tetraphosphate""}, {'cui': 'C0004457', 'cui_str': 'C2 Vertebra'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.1012,Mean PASI decreased by 82.0% vs. baseline at Week 4.,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Seyger', 'Affiliation': 'Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Abramovits', 'Affiliation': 'Dermatology Treatment & Research Centre, Dallas, TX, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Liljedahl', 'Affiliation': 'Medical Department, LEO Pharma A/S, Ballerup, Denmark.'}, {'ForeName': 'M N', 'Initials': 'MN', 'LastName': 'Hoejen', 'Affiliation': 'Biostatistics, LEO Pharma A/S, Ballerup, Denmark.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Teng', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.'}]",Journal of the European Academy of Dermatology and Venereology : JEADV,['10.1111/jdv.16233'] 3488,32057088,Titration of sevoflurane anesthesia to optimize the time to regain airway reflexes in patients undergoing elective surgery: A randomized clinical trial comparing desflurane and sevoflurane anesthesia.,"BACKGROUND Desflurane has adverse environmental effects, but has clinical advantages to speed emergence and return of protective airway reflexes compared with sevoflurane. We hypothesized that weaning of the inspired sevoflurane during the final 15 minutes of surgery would eliminate differences in airway reflex recovery between these agents. METHODS After obtaining IRB approval and informed consent, 40 patients undergoing elective surgery (≥1-hour) randomly received desflurane or sevoflurane. Patients swallowed 20 mL of water without drooling or coughing, and then received sedation and PONV pre-medication. Anesthesia was induced using propofol and fentanyl and maintained with desflurane or sevoflurane through a laryngeal mask airway maintaining a bispectral index of 45-50 and 50-60 during the final 15 minutes before surgery end. Cardiorespiratory variables and age-adjusted minimal alveolar concentration were recorded. The duration between anesthetic discontinuation and first appropriate response to command was measured; the laryngeal mask airway was removed. Two minutes after responding to command, patients were positioned semi-upright and attempted to swallow water. If successful swallowing was not achieved, the test was repeated every 4 minutes after each failure until successful swallowing was achieved. RESULTS Average anesthetic concentration and bispectral index was similar in patients receiving desflurane vs sevoflurane. Response times after discontinuation of anesthetics were similar. There were no differences in the recovery of swallowing ability between desflurane and sevoflurane groups. CONCLUSION Weaning of sevoflurane during the final 15 minutes of surgery eliminates clinical advantages of the more rapid return of airway reflexes with desflurane.",2020,"There were no differences in the recovery of swallowing ability between desflurane and sevoflurane groups. ","['Patients swallowed 20 ml of water without drooling or coughing, and then received sedation and PONV premedication', 'After obtaining IRB approval and informed consent', 'patients undergoing elective surgery', '40 patients undergoing elective surgery (≥1-hour) randomly received']","['desflurane or sevoflurane', 'propofol and fentanyl and maintained with desflurane or sevoflurane', 'desflurane', 'Desflurane', 'sevoflurane anesthesia', 'sevoflurane']","['Cardiorespiratory variables and age-adjusted minimal alveolar concentration', 'airway reflex recovery', 'recovery of swallowing ability', 'anesthetic concentration and bispectral index']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0013132', 'cui_str': 'Drooling'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0520909', 'cui_str': 'PONV'}, {'cui': 'C0033045', 'cui_str': 'Premedication'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0086911', 'cui_str': 'Institutional Review Boards'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0206058', 'cui_str': 'Elective Surgical Procedures'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}]","[{'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}]","[{'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0034929', 'cui_str': 'Reflex'}, {'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0002930', 'cui_str': 'Anesthesiology'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}]",40.0,0.0590172,"There were no differences in the recovery of swallowing ability between desflurane and sevoflurane groups. ","[{'ForeName': 'Shahbaz R', 'Initials': 'SR', 'LastName': 'Arain', 'Affiliation': 'Anesthesia Service, The Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, USA.'}, {'ForeName': 'Sherman', 'Initials': 'S', 'LastName': 'Yu', 'Affiliation': 'Anesthesia Service, The Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Dugan', 'Affiliation': 'Anesthesia Service, The Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, USA.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Pagel', 'Affiliation': 'Anesthesia Service, The Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Ebert', 'Affiliation': 'Anesthesia Service, The Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, USA.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13565'] 3489,32065514,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study.","PF-05221304 is a liver-targeted inhibitor of acetyl-CoA carboxylase, an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL). This first-in-human study investigated safety/tolerability and pharmacokinetics of single and multiple ascending oral PF-05221304 doses, and fructose-stimulated DNL inhibition with repeated oral doses. Healthy subjects (n = 96) received single (1-240 mg) or repeated (2-200 mg daily) doses for 14 days or single 100-mg doses with and without food. PF-05221304 was well tolerated at all doses. Repeated PF-05221304 doses inhibited hepatic DNL in a dose-dependent manner, with near-complete inhibition seen at higher doses. With doses yielding ≥90% DNL inhibition, asymptomatic increases in fasting/postprandial serum triglyceride levels (≥40 mg/day) and declines in platelet count (≥60 mg/day) occurred; these were not observed at ≤80% DNL inhibition. Steady-state pharmacokinetics generally increased dose-proportionally, with a half-life of 14-18 hours and a minimal food effect on plasma exposure. The observed safety and tolerability, pharmacokinetics, and pharmacodynamics support the continued evaluation of PF-05221304 for the treatment of nonalcoholic steatohepatitis.",2020,"Repeated PF-05221304 doses inhibited hepatic DNL in a dose-dependent manner, with near-complete inhibition seen at higher doses.",['Healthy subjects (n\xa0=\xa096'],['Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304'],"['tolerated', 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics', 'safety and tolerability, pharmacokinetics, and pharmacodynamics', 'fasting/postprandial serum triglyceride levels', 'platelet count']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0001022', 'cui_str': 'Acetyl Coenzyme A Carboxylase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C1287267', 'cui_str': 'Finding of platelet count (finding)'}]",,0.0259406,"Repeated PF-05221304 doses inhibited hepatic DNL in a dose-dependent manner, with near-complete inhibition seen at higher doses.","[{'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Bergman', 'Affiliation': 'Pfizer Inc, Early Clinical Development, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Santos', 'Initials': 'S', 'LastName': 'Carvajal-Gonzalez', 'Affiliation': 'Pfizer Inc, Early Clinical Development, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Sanela', 'Initials': 'S', 'LastName': 'Tarabar', 'Affiliation': 'Pfizer Inc, Clinical Research Unit, New Haven, Connecticut, USA.'}, {'ForeName': 'Aditi R', 'Initials': 'AR', 'LastName': 'Saxena', 'Affiliation': 'Pfizer Inc, Internal Medicine Research Unit, Cambridge, Massachusetts, USA.'}, {'ForeName': 'William P', 'Initials': 'WP', 'LastName': 'Esler', 'Affiliation': 'Pfizer Inc, Internal Medicine Research Unit, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Neeta B', 'Initials': 'NB', 'LastName': 'Amin', 'Affiliation': 'Pfizer Inc, Internal Medicine Research Unit, Cambridge, Massachusetts, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.782'] 3490,32018065,Schema modes as a common mechanism of change in personality pathology and functioning: Results from a randomized controlled trial.,"OBJECTIVE We aimed to empirically test whether schema modes are central to the change process in schema therapy, clarification-oriented psychotherapy, and treatment as usual, i.e., predictive of personality pathology, and global and social-occupational functioning. METHOD A multicenter randomized controlled trial was conducted (N = 139 men, N = 181 women) over the course of three years. Repeated assessments of schema modes, personality disorder (PD) severity and functioning (controlled for concurrent PD-pathology) were analyzed using a multilevel autoregressive model. Variables were person-centered to ensure that within-person changes were analyzed. Through a process of backward elimination, the schema modes predictive of the dependent variable (i.e., PD-severity and functioning) at a later point in time were identified while controlling for concurrent dependent variable levels. Bidirectionality was tested by assessing whether dependent variables predicted later schema modes. RESULTS The Healthy Adult, Vulnerable Child, Impulsive Child, and Avoidant Protector predicted later personality pathology, with no bidirectionality observed for the first two. The Healthy Adult and Self-Aggrandizer predicted functioning at a later point in time, with no bidirectionality for Self-Aggrandizer. There was no moderation by treatment type for PD symptomatology, except for Self-Aggrandizer, which predicted functioning only in schema therapy. CONCLUSIONS The Healthy Adult and Vulnerable Child are central to the change process and appear to reflect common mechanisms of change. The Self-Aggrandizer might reflect a change mechanism specific for schema therapy. Our findings support the recent emphasis on these modes in schema therapy.",2020,"There was no moderation by treatment type for PD symptomatology, except for Self-Aggrandizer, which predicted functioning only in schema therapy. ","['N\xa0=\xa0139 men, N\xa0=\xa0181 women) over the course of three years']",[],"['schema modes, personality disorder (PD) severity and functioning (controlled for concurrent PD-pathology']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",[],"[{'cui': 'C0031212', 'cui_str': 'Personality Disorders'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}]",181.0,0.0749117,"There was no moderation by treatment type for PD symptomatology, except for Self-Aggrandizer, which predicted functioning only in schema therapy. ","[{'ForeName': 'Duygu', 'Initials': 'D', 'LastName': 'Yakın', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam, the Netherlands.'}, {'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Grasman', 'Affiliation': 'Department of Psychological Methods, University of Amsterdam, the Netherlands.'}, {'ForeName': 'Arnoud', 'Initials': 'A', 'LastName': 'Arntz', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam, the Netherlands. Electronic address: A.R.Arntz@uva.nl.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103553'] 3491,32061002,"Low-Dose, Contrast-Enhanced Mammography Compared to Contrast-Enhanced Breast MRI: A Feasibility Study.","Contrast-enhanced MRI (CE-MRI) is the most sensitive technique for breast cancer detection. Contrast-enhanced mammography (CEM) is emerging as a possible alternative to CE-MRI. PURPOSE To evaluate the diagnostic performance of a low radiation dose contrast-enhanced mammography (L-CEM) in women with suspicious findings on conventional imaging compared to CE-MRI of the breast. STUDY TYPE Prospective, single center. POPULATION Women with suspicious findings on mammography, tomosynthesis, or ultrasound, and no contraindications for L-CEM or CE-MRI. Eighty women were included. FIELD STRENGTH/SEQUENCE 1.5 and 3T CE-MRI, standard protocol for breast, with dedicated coils, according to international guidelines. L-CEM was performed using a dedicated prototype. ASSESSMENT Three, off-site, blinded readers evaluated the images according to the BI-RADS lexicon in a randomized order, each in two separate reading sessions. Histology served as a gold standard. STATISTICAL TEST Lesion detection rate, sensitivity, specificity, and negative and positive predictive values (NPV, PPV) were calculated and compared with multivariate statistics. RESULTS Included were 80 women (mean age, 54.3 years ±11.2 standard deviation) with 93 lesions (32 benign, 61 malignant). The detection rate was significantly higher with CE-MRI (92.5-94.6%; L-CEM 79.6-91.4%, P = 0.014). Sensitivity (L-CEM 65.6-90.2%; CE-MRI 83.6-93.4%, P = 0.086) and NPV (L-CEM 59.6-71.4%; CE-MRI 63.0-76.5%, P = 0.780) did not differ between the modalities. Specificity (L-CEM 46.9-96.9%; CE-MRI 37.5-53.1%, P = 0.001) and PPV (L-CEM 76.4-97.6%; CE-MRI 73.3-77.3%, P = 0.007) were significantly higher with L-CEM. Variations between readers were significant for sensitivity and NPV. The accuracy of L-CEM was as good as CE-MRI (75.3-76.3% vs. 72.0-75.3%, P = 0.514). DATA CONCLUSION L-CEM showed a high sensitivity and accuracy in women with suspicious findings on conventional imaging. Compared to CE-MRI, L-CEM has the potential to increase specificity and PPV. L-CEM might help to reduce false-positive biopsies while obtaining sensitivity comparable to that of CE-MRI LEVEL OF EVIDENCE: 1 TECHNICAL EFFICACY STAGE: 2 J. Magn. Reson. Imaging 2020;52:589-595.",2020,"The detection rate was significantly higher with CE-MRI (92.5-94.6%; L-CEM 79.6-91.4%, P = 0.014).","['Women with suspicious findings on mammography, tomosynthesis, or ultrasound, and no contraindications for L-CEM or CE-MRI', 'women with suspicious findings on conventional imaging compared to CE-MRI of the breast', '80 women (mean age, 54.3\u2009years ±11.2 standard deviation) with 93 lesions (32 benign, 61 malignant', 'Eighty women were included']","['L-CEM', 'low radiation dose contrast-enhanced mammography (L-CEM', 'Contrast-enhanced mammography (CEM', 'Low-Dose, Contrast-Enhanced Mammography', 'Contrast-enhanced MRI (CE-MRI']","['accuracy of L-CEM', 'sensitivity and accuracy', 'detection rate', 'PPV', 'diagnostic performance', 'sensitivity and NPV', 'Specificity', 'Sensitivity', 'Lesion detection rate, sensitivity, specificity, and negative and positive predictive values (NPV, PPV']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C1301624', 'cui_str': 'Contraindications'}, {'cui': 'C0378574', 'cui_str': 'CEMS'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205183', 'cui_str': 'Benign (qualifier value)'}, {'cui': 'C0205282', 'cui_str': 'Malignant (qualifier value)'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0378574', 'cui_str': 'CEMS'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}]","[{'cui': 'C0378574', 'cui_str': 'CEMS'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",80.0,0.0348892,"The detection rate was significantly higher with CE-MRI (92.5-94.6%; L-CEM 79.6-91.4%, P = 0.014).","[{'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Clauser', 'Affiliation': 'Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Pascal A T', 'Initials': 'PAT', 'LastName': 'Baltzer', 'Affiliation': 'Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Panagiotis', 'Initials': 'P', 'LastName': 'Kapetas', 'Affiliation': 'Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Hoernig', 'Affiliation': 'Diagnostic Imaging, Siemens Healthcare GmbH, Forchheim, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Weber', 'Affiliation': 'Department of Biomedical Imaging and Image-Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Leone', 'Affiliation': 'ASST Fatebenefratelli-Sacco, Ospedale Fatebenefrateli e Oftalmico, Milan, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Bernathova', 'Affiliation': 'Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Helbich', 'Affiliation': 'Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.'}]",Journal of magnetic resonance imaging : JMRI,['10.1002/jmri.27079'] 3492,32067132,The effects of strategy training on spatial memory in diencephalic amnesia: a randomized controlled study.,"Alcoholic Korsakoff's syndrome is characterized by severe amnesia, also affecting spatial memory. To date, research on cognitive rehabilitation in these patients is scarce. Aim of the present study is to examine the efficacy of a mnemonic strategy training in patients with Korsakoff's syndrome. A randomized controlled exploratory study was performed. A convenience sample of 14 patients with amnesia due to alcoholic Korsakoff's syndrome was included and randomized into a mnemonic strategy training group (n = 7) and a control group (n = 7). The training group completed a 3-day 45-60 min mnemonic strategy training that focused on specific strategies to encode and retrieve information about specific objects and their locations in virtual rooms, using labeling, verbal reasoning and mental imagery. The control group only received care as usual. Outcome measure was an object-location memory task consisting of novel, untrained object locations administered 1 day before the intervention, as well as 1 day and 1 week after completing the intervention. Patients in the intervention group were able to acquire and use the strategies, but no significant differences were found between the intervention group and the control group, and no significant change in performance was demonstrated compared to baseline 1 day and 1 week after the intervention. To conclude, the mnemonic strategy training in KS patients did not result in a better spatial memory performance 1 day or 1 week after training completion compared to participation in the regular non-cognitive treatment program that focused on occupational therapy, music therapy and exercise.",2020,"Patients in the intervention group were able to acquire and use the strategies, but no significant differences were found between the intervention group and the control group, and no significant change in performance was demonstrated compared to baseline 1 day and 1 week after the intervention.","['diencephalic amnesia', ""patients with Korsakoff's syndrome"", ""14 patients with amnesia due to alcoholic Korsakoff's syndrome""]","['strategy training', 'mnemonic strategy training', '3-day 45-60\xa0min mnemonic strategy training that focused on specific strategies to encode and retrieve information about specific objects and their locations in virtual rooms, using labeling, verbal reasoning and mental imagery']","['spatial memory performance', 'object-location memory task consisting of novel, untrained object locations']","[{'cui': 'C0002622', 'cui_str': 'Amnesia-Memory Loss'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0349464', 'cui_str': 'Wernicke-Korsakoff Syndrome'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1704427', 'cui_str': 'Alcoholic Wernicke-Korsakoff Syndrome'}]","[{'cui': 'C0589105', 'cui_str': 'Strategy training (regime/therapy)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0150627', 'cui_str': 'Imagery'}]","[{'cui': 'C0814087', 'cui_str': 'Spatial Memory'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}]",14.0,0.0323846,"Patients in the intervention group were able to acquire and use the strategies, but no significant differences were found between the intervention group and the control group, and no significant change in performance was demonstrated compared to baseline 1 day and 1 week after the intervention.","[{'ForeName': 'Roy P C', 'Initials': 'RPC', 'LastName': 'Kessels', 'Affiliation': 'Neuropsychology and Rehabilitation Psychology, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Montessorilaan 3, 6525 HR, Nijmegen, The Netherlands. r.kessels@donders.ru.nl.'}, {'ForeName': 'Sjoerd', 'Initials': 'S', 'LastName': 'Murk', 'Affiliation': 'Centre of Excellence for Korsakoff and Alcohol-Related Cognitive Disorders, Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands.'}, {'ForeName': 'Serge J W', 'Initials': 'SJW', 'LastName': 'Walvoort', 'Affiliation': 'Centre of Excellence for Korsakoff and Alcohol-Related Cognitive Disorders, Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands.'}, {'ForeName': 'Benjamin M', 'Initials': 'BM', 'LastName': 'Hampstead', 'Affiliation': 'Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.'}]",Cognitive processing,['10.1007/s10339-020-00961-z'] 3493,32067836,Effect of blood pressure control on sudden death risk score in the SPRINT trial.,"BACKGROUND Recent data suggest that population screening for risk of sudden cardiac death (SCD) may be feasible with risk scores that can be implemented in the electronic health record. But, there are no established therapeutic strategies to target lowering risk for SCD in the general population. Our aim was to evaluate the effect of the Systolic Blood Pressure Intervention Trial (SPRINT) intensive blood pressure intervention on SCD risk and cardiovascular (CV) outcomes. METHODS We conducted a prospective cohort study within the SPRINT trial including all participants who had information required to calculate a SCD score. We classified SPRINT participants at baseline by randomized arm into high, intermediate and low SCD risk and followed them for a period of 12 months. We determined changes in SCD risk by comparing the baseline SCD risk score with the 12-month recalculated SCD risk score and determined the incidence of the primary SPRINT outcome and all-cause mortality. We used both linear regression and Cox proportional models to evaluate outcomes adjusted for CV risk, prevalent CV diseases, and randomization site. RESULTS We included 8052 SPRINT participants who met our inclusion criteria. The median baseline SCD score was 2.7% SCD per 10 years; 95% CI 1.6 to 4.7 for both randomized arms. At 12-month follow-up, the median SCD score for the intensive group was 5.5 (2.0-20) while the standard group was 6.8 (2.4-26) p<0.01. Over a follow-up period of 3.8 years, in the intensive arm, the HR for those who had a reduction in SCD risk score was 0.80; 95% CI 0.62-0.98 for the primary event while the HR for the standard arm was 1.01; 95% CI 0.81-1.26. The changes in SCD risk were mediated by decreases in blood pressure and an increase in diabetes incidence as well as age. CONCLUSIONS SCD risk changed in SPRINT because of intensive blood pressure control and those who changed their score had fewer cardiovascular events. Future studies should target comprehensive interventions targeting all modifiable risk factors.",2020,The median baseline SCD score was 2.7% SCD per 10 years; 95% CI 1.6 to 4.7 for both randomized arms.,"['participants who had information required to calculate a SCD score', '8052 SPRINT participants who met our inclusion criteria']","['blood pressure control', 'Systolic Blood Pressure Intervention Trial (SPRINT) intensive blood pressure intervention']","['SCD risk and cardiovascular (CV) outcomes', 'SCD risk', 'median baseline SCD score', 'blood pressure', 'sudden death risk score', 'SCD risk score', 'diabetes incidence', 'median SCD score', 'cardiovascular events']","[{'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}, {'cui': 'C0964695', 'cui_str': 's(7)(beta)CD'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}]","[{'cui': 'C0964695', 'cui_str': 's(7)(beta)CD'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0011071', 'cui_str': 'Sudden death (event)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",8052.0,0.162061,The median baseline SCD score was 2.7% SCD per 10 years; 95% CI 1.6 to 4.7 for both randomized arms.,"[{'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Tamariz', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America; Department of Medicine Veterans Affairs Medical Center, Miami, FL, United States of America. Electronic address: ltamariz@med.miami.edu.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Palacio', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America; Department of Medicine Veterans Affairs Medical Center, Miami, FL, United States of America.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Contreras', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Myerburg', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America.'}, {'ForeName': 'Juhani', 'Initials': 'J', 'LastName': 'Junttila', 'Affiliation': 'Department of Medicine Oulu University Hospital and University of Oulu, Oulu, Finland.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Olarte', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Goldberger', 'Affiliation': 'Department of Medicine Division of Cardiology, United States of America.'}]",International journal of cardiology,['10.1016/j.ijcard.2020.01.060'] 3494,32051002,Evaluating a couple-based intervention addressing sexual concerns for breast cancer survivors: study protocol for a randomized controlled trial.,"BACKGROUND Sexual concerns are distressing for breast cancer survivors and interfere with their intimate relationships. This study evaluates the efficacy of a four-session couple-based intervention delivered via telephone, called Intimacy Enhancement (IE). The IE intervention is grounded in social cognitive theory and integrates evidence-based techniques from cognitive behavioral couple therapy and sex therapy to address survivors' sexual concerns and enhance their and their partners' sexual, relationship, and psychological outcomes. METHODS This trial is designed to evaluate the efficacy of the IE intervention in improving survivors' sexual function, the primary study outcome. Secondary outcomes include survivors' sexual distress, partners' sexual function, and survivors' and partners' relationship intimacy and quality as well as psychological distress (depressive symptoms and anxiety symptoms). Additional aims are to examine whether treatment effects on patient sexual function are mediated by sexual communication and self-efficacy for coping with sexual concerns and to explore whether survivor age and race/ethnicity moderate intervention effects on survivors' sexual function. Eligible adult female breast cancer survivors reporting sexual concerns and their intimate partners are recruited from two academic sites in the USA and are randomized to either the IE intervention or to a control condition of equal length offering education and support around breast cancer-related health topics (Living Healthy Together). The target sample size is 120 couples. Self-report outcome measures are administered to participants in both conditions at baseline (T1), post-treatment (T2), 3 months post-treatment (T3), and 6 months post-treatment (T4). DISCUSSION Evidence-based interventions are needed to address sexual concerns for breast cancer survivors and to enhance their and their intimate partners' sexual, relationship, and psychological well-being. This randomized controlled trial will allow us to examine the efficacy of a novel couple-based intervention delivered via telephone for breast cancer survivors experiencing sexual concerns and their intimate partners, in comparison with an attention control. Findings of this study could influence clinical care for women with breast cancer and inform theory guiding cancer-related sexual rehabilitation. TRIAL REGISTRATION ClinicalTrials.gov, NCT03930797. Registered on 24 April 2019.",2020,Additional aims are to examine whether treatment effects on patient sexual function are mediated by sexual communication and self-efficacy for coping with sexual concerns and to explore whether survivor age and race/ethnicity moderate intervention effects on survivors' sexual function.,"['120 couples', 'breast cancer survivors experiencing sexual concerns and their intimate partners', 'breast cancer survivors', 'women with breast cancer', 'Eligible adult female breast cancer survivors reporting sexual concerns and their intimate partners']","['four-session couple-based intervention delivered via telephone, called Intimacy Enhancement (IE', 'social cognitive theory and integrates evidence-based techniques from cognitive behavioral couple therapy and sex therapy', 'novel couple-based intervention delivered via telephone', 'couple-based intervention addressing sexual concerns', 'IE intervention or to a control condition of equal length offering education and support around breast cancer-related health topics (Living Healthy Together', 'IE intervention']","[""survivors' sexual distress, partners' sexual function, and survivors' and partners' relationship intimacy and quality as well as psychological distress (depressive symptoms and anxiety symptoms""]","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0235653', 'cui_str': 'Malignant neoplasm of female breast (disorder)'}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0302822', 'cui_str': 'Couples Therapy'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0376649', 'cui_str': 'Address'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0278092', 'cui_str': 'Sexual function (observable entity)'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}]",,0.0479534,Additional aims are to examine whether treatment effects on patient sexual function are mediated by sexual communication and self-efficacy for coping with sexual concerns and to explore whether survivor age and race/ethnicity moderate intervention effects on survivors' sexual function.,"[{'ForeName': 'Jennifer Barsky', 'Initials': 'JB', 'LastName': 'Reese', 'Affiliation': 'Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA. Jennifer.Reese@fccc.edu.'}, {'ForeName': 'Lauren A', 'Initials': 'LA', 'LastName': 'Zimmaro', 'Affiliation': 'Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Lepore', 'Affiliation': 'Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.'}, {'ForeName': 'Kristen A', 'Initials': 'KA', 'LastName': 'Sorice', 'Affiliation': 'Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Handorf', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.'}, {'ForeName': 'Mary B', 'Initials': 'MB', 'LastName': 'Daly', 'Affiliation': 'Department of Clinical Genetics, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.'}, {'ForeName': 'Leslie R', 'Initials': 'LR', 'LastName': 'Schover', 'Affiliation': 'Will2Love LLC, 1333 Old Spanish Trail, Suite G, #134, Houston, TX, 77054, USA.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Kashy', 'Affiliation': 'Department of Psychology, Michigan State University, 316 Physics Road, Room 262, East Lansing, MI, 48824, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Westbrook', 'Affiliation': 'Department of Medicine-Oncology, Duke University Medical Center, DUMC 3459, Durham, NC, 27710, USA.'}, {'ForeName': 'Laura S', 'Initials': 'LS', 'LastName': 'Porter', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Duke University Medical Center, DUMC 90399, Durham, NC, 27708, USA.'}]",Trials,['10.1186/s13063-019-3975-2'] 3495,31981802,Test of an Anxiety Sensitivity Amelioration Program for at-risk youth (ASAP-Y).,"OBJECTIVE Adult research supports the efficacy of targeting the malleable risk factor of anxiety sensitivity (AS) in preventing anxiety and related psychopathology. However, very little work has evaluated the impact of AS reduction among youth, which is unfortunate given adolescence is a ""core risk"" period in terms of disorder onset. METHOD The primary project aim was to test the effects of an Anxiety Sensitivity Amelioration Program for Youth (ASAP-Y) among a sample of 88 youth aged 10-14 years with elevated AS. High AS youth and a parent were randomly assigned to either the ASAP-Y, which consisted of psychoeducation and experimenter-led and parent-led exposures, or a general health information control condition. RESULTS Youth in the intervention condition sustained low AS levels across the intervention period, and although AS levels in both conditions decreased from baseline to the one-month assessment, this decrease was more pronounced at one-month for youth in the intervention condition. Further, significant indirect effects of condition on one-month anxiety and depression symptoms via reduced AS were detected. Homework compliance rates and self-report data support the acceptability of the ASAP-Y. Contrary to hypotheses, differences between conditions in emotional reactivity elicited using experimental psychopathology methods were not observed. CONCLUSIONS The current findings offer preliminary support for the ASAP-Y as an acceptable selective preventive intervention for at-risk youth, with specific anxiety- and depression-related effects through reduced AS.",2020,"The current findings offer preliminary support for the ASAP-Y as an acceptable selective preventive intervention for at-risk youth, with specific anxiety- and depression-related effects through reduced AS.","['Youth (ASAP-Y) among a sample of 88 youth aged 10-14 years with elevated AS', 'at-risk youth (ASAP-Y']","['ASAP-Y, which consisted of psychoeducation and experimenter-led and parent-led exposures, or a general health information control condition', 'Anxiety Sensitivity Amelioration Program']",[],"[{'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}]","[{'cui': 'C0871175', 'cui_str': 'Psycho-education'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",[],88.0,0.0345051,"The current findings offer preliminary support for the ASAP-Y as an acceptable selective preventive intervention for at-risk youth, with specific anxiety- and depression-related effects through reduced AS.","[{'ForeName': 'Ashley A', 'Initials': 'AA', 'LastName': 'Knapp', 'Affiliation': 'Center for Behavioral Intervention Technologies, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, 750 N. Lake Shore Dr. 10th Floor, Chicago, IL, 60611, USA; Anxiety Research Program, Department of Psychological Science, University of Arkansas, 216 Memorial Hall, University of Arkansas, Fayetteville, AR, 72701, USA. Electronic address: ashley.knapp@northwestern.edu.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Feldner', 'Affiliation': 'Anxiety Research Program, Department of Psychological Science, University of Arkansas, 216 Memorial Hall, University of Arkansas, Fayetteville, AR, 72701, USA. Electronic address: mfeldne@gmail.com.'}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Allan', 'Affiliation': 'Factors of Emotional/Affective Risk Laboratory, Department of Psychology, Ohio University, Porter Hall 209, Athens, OH, 45701, USA. Electronic address: allan@ohio.edu.'}, {'ForeName': 'Norman B', 'Initials': 'NB', 'LastName': 'Schmidt', 'Affiliation': 'Anxiety and Behavioral Health Clinic, Department of Psychology, Florida State University, 1107 West Call Street, Tallahassee, FL, 32306, USA. Electronic address: schmidt@psy.fsu.edu.'}, {'ForeName': 'Meghan E', 'Initials': 'ME', 'LastName': 'Keough', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington, 1959 NE Pacific Street Box 356560, Seattle, WA, 98195, USA. Electronic address: meghankeough@gmail.com.'}, {'ForeName': 'Ellen W', 'Initials': 'EW', 'LastName': 'Leen-Feldner', 'Affiliation': 'Anxiety Research Program, Department of Psychological Science, University of Arkansas, 216 Memorial Hall, University of Arkansas, Fayetteville, AR, 72701, USA. Electronic address: eleenfe@uark.edu.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103544'] 3496,32052925,"A Two-Sequence, Four-Period, Crossover, Replicate Study to Demonstrate Bioequivalence of Warfarin Sodium Tablet in Healthy Chinese Subjects Under Fasting and Fed Conditions.","Warfarin is a narrow therapeutic index anticoagulant drug, and several generic formulations have been approved worldwide. However, there has been no report evaluating the bioequivalence of warfarin sodium according to US Food and Drug Administration draft guidance. We designed a 2-sequence and 4-period crossover study to compare the pharmacokinetic profile and assess bioequivalence between the test warfarin sodium tablet and reference product Coumadin (2.5 mg) in 56 healthy Chinese subjects under fasting and fed conditions. The plasma concentration of warfarin was analyzed by a validated liquid chromatography-tandem mass spectrometry assay, and the reference-scaled procedure was used to determine bioequivalence for the pharmacokinetics parameters. The results showed that the point estimate of geometric mean ratios of C max and AUC 0-t for warfarin were 103.21% and 99.31%, respectively, in the fasting condition and 100.62% and 98.98%, respectively, in the fed condition, and the 90% confidence intervals were all within the range of 90.00%-111.11%. The upper limit of the 90% confidence interval of estimated within-subject variation ratios of the test and reference products was 1.33 for C max and 2.22 for AUC 0-t under the fasting condition and 1.68 for C max and 2.15 for AUC 0-t under the fed condition. Overall, bioequivalence of the 2 warfarin sodium products was demonstrated.",2020,"Overall, bioequivalence of the 2 warfarin sodium products was demonstrated.","['Healthy Chinese Subjects Under Fasting and Fed Conditions', '56 healthy Chinese subjects under fasting and fed conditions']","['Warfarin Sodium Tablet', 'warfarin sodium tablet and reference product Coumadin', 'Warfarin', 'warfarin sodium']","['geometric mean ratios of C max and AUC 0-t for warfarin', 'plasma concentration of warfarin']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0376218', 'cui_str': 'Warfarin Sodium'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0699129', 'cui_str': 'Coumadin'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",56.0,0.0243494,"Overall, bioequivalence of the 2 warfarin sodium products was demonstrated.","[{'ForeName': 'Chaoying', 'Initials': 'C', 'LastName': 'Hu', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Unit, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Unit, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Zirun', 'Initials': 'Z', 'LastName': 'Zhao', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Unit, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Gao', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Unit, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Shili', 'Initials': 'S', 'LastName': 'Gong', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Unit, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Lizhi', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Qilu Pharmaceutical Co., Ltd., Jinan, China.'}, {'ForeName': 'Yongpeng', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Qilu Pharmaceutical Co., Ltd., Jinan, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Unit, Xuanwu Hospital Capital Medical University, Beijing, China.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Pharmacy, Phase I Clinical Trial Unit, Xuanwu Hospital Capital Medical University, Beijing, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.783'] 3497,32045540,Developing and validating equations to predict V ˙ O 2 peak from the 6MWT in Childhood ALL Survivors.,"INTRODUCTION The 6-Minute Walking Test (6MWT) is a safe, standardized and well utilized method to assess the functional capacity. Recently, it was reported that the published prediction equations cannot accurately predict a valid maximal oxygen consumption (V̇O 2 peak) value in cancer survivors. Thus, the aim of this study was to establish and to validate a new equation based on the 6MWT to predict V̇O 2 peak in childhood acute lymphoblastic leukemia (ALL) survivors. METHODS A total of 200 childhood ALL survivors were enrolled in this study, among which 168 participants underwent a cardiopulmonary exercise test and a 6MWT to assess their functional capacity and their cardiorespiratory fitness. In addition, participants completed a physical activity questionnaire. Participants were randomly divided in two groups to establish the equations ( n  = 118 (70%)) and to validate it ( n  = 50 (30%)). Multiple linear regression analyses were used to determine a new prediction equation for V̇O 2 peak from 6MWT using clinical and specific variables related to the disease. The accuracy in between V̇O 2 peak measured and V̇O 2 peak predicted were assessed using the Bland and Altman method. RESULTS The new establish clinical V̇O 2 peak equation is: V̇O 2 peak (mL.kg -1 .min -1 ) = (-0.283*age(years)) - (0.099*weight(kg)) + (0.071*6MWD(meters)) -(0.135*HR end(bpm)) + 22.789 with a mean bias of 2.67 mL.kg -1 .min -1 (95% CI (-9.64 to 14.98)). The new establish disease-specific V̇O 2 peak equation is: V̇O 2 peak (mL.kg -1 .min -1 ) = (-0.236*age(years)) - (0.094*weight(kg)) -(0.120*HR end(bpm)) + (0.067*6MWD(meters)) + (0.065*MVLPA(min/day)) - (0.204*DT(years)) + 25.145 with a mean bias of 2.51 mL.kg -1 .min -1 (95% CI (-9.98 to 15.01)). CONCLUSION This is the first study that predicted V̇O 2 peak from a 6MWT using clinical and specific variables related to the disease of childhood ALL survivors. The availability of these newly established V̇O 2 peak equations makes them an accurate tool to provide a better follow-up and better adapted physical training for survivors. We invite researchers to use our assessment procedures for their further studies.IMPLICATIONS FOR REHABILITATIONIt is critical to understand the cardiorespiratory fitness of the childhood ALL survivorsThe maximal oxygen consumption (i.e., V̇O 2 peak) is recognized as the gold standard to measure the patient's cardiorespiratory fitness in the field of exercise physiologyThis study is novel and reports the validation of two new VO 2 peak equations, from 6MWT, by using clinical and disease-specific variables of childhood ALL survivorsThe availability of such validated equations can better facilitate the follow-up of survivors' cardiorespiratory fitness, by relevant health care professionals and exercise physiologists.",2020,(0.071*6MWD(meters)),"['168 participants underwent a', 'childhood acute lymphoblastic leukemia (ALL) survivors', '200 childhood ALL survivors']","['0.135*HR end(bpm', 'cardiopulmonary exercise test and a 6MWT', ' (0.065*MVLPA(min/day', '0.120*HR end(bpm']","['physical activity questionnaire', '6-Minute Walking Test (6MWT']","[{'cui': 'C4319556', 'cui_str': 'One hundred and sixty-eight'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C1961102', 'cui_str': 'Lymphocytic Leukemia, Acute'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0023452', 'cui_str': 'Lymphoblastic Leukemia, Acute, L1'}]","[{'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",168.0,0.0264598,(0.071*6MWD(meters)),"[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Labonté', 'Affiliation': 'Laboratory of Pathophysiology of EXercise (LPEX), School of Kinesiology and Physical Activity Sciences, Faculty of Medicine, University of Montreal, Montreal, Canada.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Caru', 'Affiliation': 'Laboratory of Pathophysiology of EXercise (LPEX), School of Kinesiology and Physical Activity Sciences, Faculty of Medicine, University of Montreal, Montreal, Canada.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Lemay', 'Affiliation': 'Laboratory of Pathophysiology of EXercise (LPEX), School of Kinesiology and Physical Activity Sciences, Faculty of Medicine, University of Montreal, Montreal, Canada.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Alos', 'Affiliation': 'Research Center, Sainte-Justine University Health Center, Montreal, Canada.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Drouin', 'Affiliation': 'Research Center, Sainte-Justine University Health Center, Montreal, Canada.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Bertout', 'Affiliation': 'Research Center, Sainte-Justine University Health Center, Montreal, Canada.'}, {'ForeName': 'Gregor', 'Initials': 'G', 'LastName': 'Andelfinger', 'Affiliation': 'Research Center, Sainte-Justine University Health Center, Montreal, Canada.'}, {'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Krajinovic', 'Affiliation': 'Research Center, Sainte-Justine University Health Center, Montreal, Canada.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Laverdière', 'Affiliation': 'Research Center, Sainte-Justine University Health Center, Montreal, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Sinnett', 'Affiliation': 'Research Center, Sainte-Justine University Health Center, Montreal, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Curnier', 'Affiliation': 'Laboratory of Pathophysiology of EXercise (LPEX), School of Kinesiology and Physical Activity Sciences, Faculty of Medicine, University of Montreal, Montreal, Canada.'}]",Disability and rehabilitation,['10.1080/09638288.2020.1725159'] 3498,32030636,The effectiveness of cognitive rehabilitation in improving visual and auditory attention in ischemic stroke patients.,"The present study aimed to investigate the effectiveness of a cognitive rehabilitation program in improving the visual and auditory attention performance in stroke patients. The research method was quasi-experimental with a pre-intervention, post-intervention and follow-up design and control group. Twenty ischemic stroke patients with attention disorder were randomly classified into experimental and control groups. Cognitive evaluation of patients, including pre-intervention, immediately and 6 weeks after the intervention, was performed by the IVA + Plus (Integrated Visual and Auditory Continuous Performance Test). The experimental group received a cognitive rehabilitation program as 1-h sessions per week for 8 weeks, but the control group received no intervention. The results indicated significant effects of a cognitive rehabilitation program on the auditory (p = 0.002) and visual (p = 0.009) attention as well as the 6-week follow-up after the intervention, and it improved visual and auditory attention in stroke patients in the experimental group. The effectiveness of a cognitive rehabilitation program improved attention performance in stroke patients and had a positive effect on visual and auditory attention performance in ischemic stroke patients.",2021,The effectiveness of a cognitive rehabilitation program improved attention performance in stroke patients and had a positive effect on visual and auditory attention performance in ischemic stroke patients.,"['ischemic stroke patients', 'Twenty ischemic stroke patients with attention disorder', 'stroke patients']","['control group received no intervention', 'cognitive rehabilitation program', 'cognitive rehabilitation']","['attention performance', 'visual and auditory attention', 'visual and auditory attention performance']","[{'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}]",,0.0139689,The effectiveness of a cognitive rehabilitation program improved attention performance in stroke patients and had a positive effect on visual and auditory attention performance in ischemic stroke patients.,"[{'ForeName': 'Samira', 'Initials': 'S', 'LastName': 'Hasanzadeh Pashang', 'Affiliation': 'Department of Psychology, Payame Noor University, PO BOX 19395-4697, Tehran, Iran. shasanzadehp@gmail.com.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Zare', 'Affiliation': 'Department of Psychology, Payame Noor University, PO BOX 19395-4697, Tehran, Iran.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Alipour', 'Affiliation': 'Department of Psychology, Payame Noor University, PO BOX 19395-4697, Tehran, Iran.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Sharif-Alhoseini', 'Affiliation': 'Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}]",Acta neurologica Belgica,['10.1007/s13760-020-01288-4'] 3499,32022904,Protocol and statistical analysis plan for the REstricted fluid therapy VERsus Standard trEatment in Acute Kidney Injury-REVERSE-AKI randomized controlled pilot trial.,"BACKGROUND Fluid accumulation frequently coexists with acute kidney injury (AKI) and is associated with increased risk for AKI progression and mortality. Among septic shock patients, restricted use of resuscitation fluid has been reported to reduce the risk of worsening of AKI. Restrictive fluid therapy, however, has not been studied in the setting of established AKI. Here, we present the protocol and statistical analysis plan of the REstricted fluid therapy VERsus Standard trEatment in Acute Kidney Injury-the REVERSE-AKI trial that compares a restrictive fluid therapy regimen to standard therapy in critically ill patients with AKI. METHODS REVERSE-AKI is an investigator-initiated, multinational, open-label, randomized, controlled, feasibility pilot trial conducted in seven ICUs in five countries. We aim to randomize 100 critically ill patients with AKI to a restrictive fluid treatment regimen vs standard management. In the restrictive fluid therapy regimen, the daily fluid balance target is neutral or negative. The primary outcome is the cumulative fluid balance assessed after 72 hours from randomization. Secondary outcomes include safety, feasibility, duration, and severity of AKI, and outcome at 90 days (mortality and dialysis dependence). CONCLUSIONS This is the first multinational trial investigating the feasibility and safety of a restrictive fluid therapy regimen in critically ill patients with AKI. TRIAL REGISTRATION clinical.trials.gov NCT03251131.",2020,"Secondary outcomes include safety, feasibility, duration and severity of AKI, and outcome at 90 days (mortality and dialysis dependence). ","['Acute Kidney Injury', '100 critically ill patients with AKI to a restrictive fluid treatment regimen versus standard management', 'septic shock patients', '7 ICUs in 5 countries', 'critically ill patients with AKI']",['restrictive fluid therapy regimen'],"['safety, feasibility, duration and severity of AKI, and outcome at 90 days (mortality and dialysis dependence', 'cumulative fluid balance']","[{'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0036983', 'cui_str': 'Septic Shock'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}]","[{'cui': 'C0016286', 'cui_str': 'Fluid Therapy'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}, {'cui': 'C0439857', 'cui_str': 'Patient dependence on (contextual qualifier) (qualifier value)'}, {'cui': 'C0016284', 'cui_str': 'Fluid Balance'}]",100.0,0.24103,"Secondary outcomes include safety, feasibility, duration and severity of AKI, and outcome at 90 days (mortality and dialysis dependence). ","[{'ForeName': 'Suvi T', 'Initials': 'ST', 'LastName': 'Vaara', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Marlies', 'Initials': 'M', 'LastName': 'Ostermann', 'Affiliation': ""Department of Critical Care, King's College London, Guy's and St Thomas' Hospital, London, UK.""}, {'ForeName': 'Tuomas', 'Initials': 'T', 'LastName': 'Selander', 'Affiliation': 'Science Service Center, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Bitker', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Schneider', 'Affiliation': 'Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'Elettra', 'Initials': 'E', 'LastName': 'Poli', 'Affiliation': 'Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Hoste', 'Affiliation': 'Intensive Care Unit, Ghent University Hospital, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Joannidis', 'Affiliation': 'Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Zarbock', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'van Haren', 'Affiliation': 'Australian National University Medical School, Canberra, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Prowle', 'Affiliation': 'Critical Care and Preoperative Medicine Research Group, Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, Queen Mary University of London, London, UK.'}, {'ForeName': 'Ville', 'Initials': 'V', 'LastName': 'Pettilä', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13557'] 3500,32014692,A randomized dismantling trial of the open and engaged components of acceptance and commitment therapy in an online intervention for distressed college students.,"This dismantling trial compared the effects of a full online Acceptance and Commitment Therapy (ACT) intervention to the isolated effects of the Open (i.e., acceptance, cognitive defusion) and Engaged (i.e., values, committed action) components of ACT. A sample of 181 distressed college students were randomized to one of four conditions: a 12-session full ACT website (Full), a version targeting the Open components (Open), a version targeting the Engaged components (Engaged), or waitlist. Participants in active conditions were also randomized to receive phone coaching or just email prompts to increase program adherence. All three ACT conditions significantly improved over time relative to the waitlist condition on the primary outcome of mental health symptoms. The Engaged and Full conditions had greater rates of reliable change on the primary outcome relative to waitlist, but not the Open condition. Similarly, only Engaged and Full conditions improved on positive mental health relative to waitlist. The Full condition had greater improvements on a few ACT process measures relative to Engaged and Open conditions, particularly cognitive fusion. Overall, results indicate targeting only the Open components of ACT was somewhat less effective, and that including both the Open and Engaged components led to greater decreases in cognitive fusion.",2020,"The Engaged and Full conditions had greater rates of reliable change on the primary outcome relative to waitlist, but not the Open condition.","['181 distressed college students', 'distressed college students', 'Participants in active conditions']","['12-session full ACT website (Full), a version targeting the Open components (Open), a version targeting the Engaged components (Engaged), or waitlist', 'open and engaged components of acceptance and commitment therapy', 'full online Acceptance and Commitment Therapy (ACT) intervention', 'phone coaching or just email prompts to increase program adherence']","['cognitive fusion', 'mental health symptoms', 'positive mental health']","[{'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and Commitment Therapy'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C1293131', 'cui_str': 'Fusion procedure (procedure)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}]",181.0,0.0550397,"The Engaged and Full conditions had greater rates of reliable change on the primary outcome relative to waitlist, but not the Open condition.","[{'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Levin', 'Affiliation': 'Utah State University, Department of Psychology, 2810 Old Main Hill, Logan, UT 84322, USA. Electronic address: Michael.Levin@usu.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Krafft', 'Affiliation': 'Utah State University, Department of Psychology, 2810 Old Main Hill, Logan, UT 84322, USA.'}, {'ForeName': 'Elizabeth T', 'Initials': 'ET', 'LastName': 'Hicks', 'Affiliation': 'Utah State University, Department of Psychology, 2810 Old Main Hill, Logan, UT 84322, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Pierce', 'Affiliation': 'Utah State University, Department of Psychology, 2810 Old Main Hill, Logan, UT 84322, USA.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Twohig', 'Affiliation': 'Utah State University, Department of Psychology, 2810 Old Main Hill, Logan, UT 84322, USA.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103557'] 3501,32348036,"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.","Dupilumab is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases, including atopic dermatitis and asthma. Six phase 1 studies investigated the pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy subjects. Two randomized, double-blind, placebo-controlled, sequential studies assessed safety and tolerability of single escalating dupilumab doses administered intravenously or subcutaneously (one included various racial groups, and one included exclusively Japanese subjects); 3 randomized, parallel-group, single-dose studies compared the pharmacokinetic profiles of different dupilumab products and formulations after single subcutaneous doses; and one study assessed dupilumab administered as fast versus slow subcutaneous injections. Dupilumab concentrations in serum were measured in all studies, and total immunoglobulin E (IgE) and thymus- and activation-regulated chemokine (TARC) concentrations were measured in 2 studies as pharmacodynamic markers. Across the phase 1 studies, dupilumab exhibited target-mediated pharmacokinetics consisting of parallel linear and nonlinear elimination, with the target-mediated phase highly dominated by nonlinearity at lower drug concentrations. Systemic exposure and tolerability of dupilumab were consistent irrespective of differences in product, formulation, or racial background. Dupilumab reduced circulating concentrations of total IgE and TARC, indicating blockade of IL-4Rα-mediated signaling. Dupilumab had a favorable safety profile across the wide range of doses administered. Together, these findings support the continued development and use of dupilumab in treatment of type 2 diseases.",2020,"Dupilumab reduced circulating concentrations of total IgE and TARC, indicating blockade of IL-4Rα-mediated signaling.","['various racial groups, and one included exclusively Japanese subjects', 'healthy subjects', 'Healthy Adult Subjects']","['α subunit (IL-4Rα) of IL-4 heterodimeric type', 'dupilumab administered as fast versus slow subcutaneous injections', 'placebo']","['circulating concentrations of total IgE and TARC', 'total immunoglobulin E (IgE) and thymus- and activation-regulated chemokine (TARC) concentrations', 'Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab', 'safety and tolerability', 'Systemic exposure and tolerability of dupilumab', 'pharmacokinetics, pharmacodynamics, safety, and tolerability', 'Dupilumab concentrations in serum']","[{'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0599220', 'cui_str': 'Protein Subunit'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous injection'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0428539', 'cui_str': 'Total immunoglobulin measurement'}, {'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0539535', 'cui_str': 'CCL17 protein, human'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.158021,"Dupilumab reduced circulating concentrations of total IgE and TARC, indicating blockade of IL-4Rα-mediated signaling.","[{'ForeName': 'Zhaoyang', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Sanofi Genzyme, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Radin', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Jennifer D', 'Initials': 'JD', 'LastName': 'Hamilton', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Miyuki', 'Initials': 'M', 'LastName': 'Kajiwara', 'Affiliation': 'Sanofi KK, Tokyo, Japan.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Davis', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Takahashi', 'Affiliation': 'Sanofi KK, Tokyo, Japan.'}, {'ForeName': 'Setsuo', 'Initials': 'S', 'LastName': 'Hasegawa', 'Affiliation': 'Sekino Clinical Pharmacology Clinic, Tokyo, Japan.'}, {'ForeName': 'Jeffrey E', 'Initials': 'JE', 'LastName': 'Ming', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'A Thomas', 'Initials': 'AT', 'LastName': 'DiCioccio', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Yongtao', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Kovalenko', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Lu', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Ortemann-Renon', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Ardeleanu', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Brian N', 'Initials': 'BN', 'LastName': 'Swanson', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.798'] 3502,30876827,"Unconjugated and secondary bile acid profiles in response to higher-fat, lower-carbohydrate diet and associated with related gut microbiota: A 6-month randomized controlled-feeding trial.","BACKGROUND & AIMS Observational studies have shown that diets high in fat and low in dietary fiber, might have an unfavorable impact on bile acid (BA) profiles, which might further affect host cardiometabolic health. In the current study, we aimed to evaluate the effects of dietary fat content on BA profiles and associated gut microbiota, and their correlates with cardiometabolic risk factors. METHODS In a randomized controlled-feeding trial, healthy young adults were assigned to one of the three diets: a lower-fat diet (fat 20%, carbohydrate 66% and protein 14%), a moderate-fat diet (fat 30%, carbohydrate 56% and protein 14%) and a higher-fat diet (fat 40%, carbohydrate 46% and protein 14%) for 6 months. All the foods were provided during the entire intervention period. The BA profiles, associated gut microbiota and markers of cardiometabolic risk factors were determined before and after intervention. RESULTS The higher-fat diet resulted in an elevated concentration of total BAs (p < 0.001), and unconjugated BAs (p = 0.03) compared with lower-fat diet. Secondary BAs, such as deoxycholic acid (DCA), taurodeoxycholic acid (TDCA), 12ketolithocholic acid (12keto-LCA), 3β-DCA and taurolithocholic acid (TLCA) (p < 0.05 after FDR correction) were significantly increased in the higher-fat diet group after the 6-month intervention. Consistently, the abundances of gut bacteria (Bacteroides, Clostridium, Bifidobacterium and Lactobacillus) which affect bile salt hydrolase gene expression were significantly increased after higher-fat consumption. The change of DCA was positively associated with the relative abundance of Bacteroides (r = 0.31, p = 0.08 after FDR correction). In addition, the changes of fecal concentrations of DCA and 12keto-LCA were positively associated with serum total cholesterol (r > 0.3, p = 0.02 and p = 0.008 after FDR correction, respectively). In line with these findings, serum fibroblast growth factor 19 (FGF19) was marginally significantly elevated in the higher-fat group after intervention (p = 0.05). CONCLUSIONS The higher-fat diet resulted in an alteration of BAs, especially unconjugated BAs and secondary BAs, most likely through actions of gut microbiota. These alterations might confer potentially unfavorable impacts on colonic and host cardiometabolic health in healthy young adults. Clinical trial registry number: NCT02355795 listed on NIH website: ClinicalTrials.gov.",2020,"The higher-fat diet resulted in an elevated concentration of total BAs (p < 0.001), and unconjugated BAs (p = 0.03) compared with lower-fat diet.",['healthy young adults'],"['lower-fat diet (fat 20%, carbohydrate 66% and protein 14%), a moderate-fat diet (fat 30%, carbohydrate 56% and protein 14%) and a higher-fat diet']","['abundances of gut bacteria (Bacteroides, Clostridium, Bifidobacterium and Lactobacillus) which affect bile salt hydrolase gene expression', 'relative abundance of Bacteroides', 'serum fibroblast growth factor 19 (FGF19', 'Secondary BAs, such as deoxycholic acid (DCA), taurodeoxycholic acid (TDCA), 12ketolithocholic acid (12keto-LCA), 3β-DCA and taurolithocholic acid (TLCA', 'fecal concentrations of DCA and 12keto-LCA', 'BA profiles, associated gut microbiota and markers of cardiometabolic risk factors', 'serum total cholesterol', 'BA profiles and associated gut microbiota', 'elevated concentration of total BAs', 'unconjugated BAs']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0242970', 'cui_str': 'Fat-Restricted Diet'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0301585', 'cui_str': 'Fat diet (finding)'}, {'cui': 'C0521974', 'cui_str': 'Diet, High-Fat'}]","[{'cui': 'C1510439', 'cui_str': 'bacteria'}, {'cui': 'C0004661', 'cui_str': 'Bacteroides'}, {'cui': 'C0009054', 'cui_str': 'Clostridium'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0055580', 'cui_str': 'glycocholic acid hydrolase'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0016026', 'cui_str': 'DNA Synthesis Factor'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0011479', 'cui_str': 'Deoxycholic Acid'}, {'cui': 'C0039360', 'cui_str': 'Deoxycholyltaurine'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C0600203', 'cui_str': 'DCA'}, {'cui': 'C0039362', 'cui_str': 'Lithocholyltaurine'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C4018878', 'cui_str': 'Gastrointestinal Microbial Community'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}]",,0.0218642,"The higher-fat diet resulted in an elevated concentration of total BAs (p < 0.001), and unconjugated BAs (p = 0.03) compared with lower-fat diet.","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Wan', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University, Hangzhou, 310058, China.'}, {'ForeName': 'Jihong', 'Initials': 'J', 'LastName': 'Yuan', 'Affiliation': ""No. 1 Department of Nutrition, Chinese People's Liberation Army General Hospital, Beijing, China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""No. 1 Department of Nutrition, Chinese People's Liberation Army General Hospital, Beijing, China.""}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University, Hangzhou, 310058, China.'}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310058, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University, Hangzhou, 310058, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Ni', 'Affiliation': ""The Children's Hospital, School of Medicine, Zhejiang University, Hangzhou 310024, China.""}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Huang', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, China.'}, {'ForeName': 'Fenglei', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University, Hangzhou, 310058, China; Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhao', 'Affiliation': 'Institute of Nutrition and Health, Qingdao University, Qingdao, 266071, China. Electronic address: fengzhao21c@126.com.'}, {'ForeName': 'Duo', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University, Hangzhou, 310058, China; Institute of Nutrition and Health, Qingdao University, Qingdao, 266071, China. Electronic address: duoli@qdu.edu.cn.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.02.037'] 3503,31345107,Comparative effects of enalapril versus perindopril on serum levels of leptin and adiponectin in hypertensive patients.,"Introduction: Abnormal adipokine levels affect blood pressure (BP) regulation. Hypo-adiponectinaemia and hyperleptinaemia were reported in hypertension, little is known about how antihypertensive therapy affects these alterations. This study aimed to evaluate the effects of perindopril versus enalapril on plasma adiponectin, tumour necrosis alpha (TNF-α) and leptin levels in hypertensive individuals. Methods: In the present study, we analysed the samples obtained from 93 treatment-naıve, adult hypertensive patients, randomised to treatement with enalapril (10 mg/d, n  = 31), perindopril (5 mg/d, n  = 31), or maintained on life style modification ( n  = 31). Plasma levels of leptin, adiponectin, TNF-α and lipid profile were determined at baseline, and after 3 months. Results: Compared to subjects maintained on lifestyle modification ( n  = 31), enalapril or perindopril treatment was associated with a significant decrease in BP. Administration of perindopril or enalapril resulted in an increase in plasma adiponectin and a reduction in plasma leptin. No significant changes in lipid profile were observed after treatment. Conclusions: Our results indicate that perindopril is superior to enalapril when it comes to its effect on the human adipose-tissue-derived hormones. This suggests that angiotensin-converting enzyme inhibitors improves the adipokine profile, possibly allowing beneficial effects to hypertensive individuals.",2020,Administration of perindopril or enalapril resulted in an increase in plasma adiponectin and a reduction in plasma leptin.,"['hypertensive patients', 'hypertensive individuals', '93 treatment-naıve, adult hypertensive patients']","['angiotensin-converting enzyme inhibitors', 'perindopril', 'enalapril or perindopril', 'enalapril', 'perindopril versus enalapril', 'perindopril or enalapril']","['Plasma levels of leptin, adiponectin, TNF-α and lipid profile', 'plasma adiponectin, tumour necrosis alpha (TNF-α) and leptin levels', 'serum levels of leptin and adiponectin', 'plasma leptin', 'plasma adiponectin', 'lipid profile', 'blood pressure (BP) regulation', 'BP']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0003015', 'cui_str': 'ACE Inhibitors'}, {'cui': 'C0136123', 'cui_str': 'Perindopril'}, {'cui': 'C0014025', 'cui_str': 'Enalapril'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0333516', 'cui_str': 'Tumor necrosis (morphologic abnormality)'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0220905', 'cui_str': 'regulations'}]",93.0,0.0260195,Administration of perindopril or enalapril resulted in an increase in plasma adiponectin and a reduction in plasma leptin.,"[{'ForeName': 'Rehab', 'Initials': 'R', 'LastName': 'Werida', 'Affiliation': 'Clinical Pharmacy Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.'}, {'ForeName': 'Ibtsam', 'Initials': 'I', 'LastName': 'Khairat', 'Affiliation': 'Cardiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Lamiaa', 'Initials': 'L', 'LastName': 'Khedr', 'Affiliation': 'Cardiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Alaa El-Din', 'Initials': 'AE', 'LastName': 'El-Sisi', 'Affiliation': 'Pharmacology & Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.'}]",Acta cardiologica,['10.1080/00015385.2019.1636533'] 3504,32101872,"The Combined Effect of Polygenic Risk from FTO and ADRB2 Gene Variants, Odds of Obesity, and Post-Hipcref Diet Differences.","BACKGROUND Computing polygenic risk scores (PRS) to predict the degree of risk for obesity may contribute to weight management programs strategically. OBJECTIVES To investigate the combined effect of FTO rs9930501, rs9930506, and rs9932754 and ADRB2 rs1042713 and rs1042714 using PRS on (1) the odds of obesity and (2) post-intervention differences in dietary, anthropometric, and cardiometabolic parameters in response to high-protein calorie-restricted, high-vitamin E, high-fiber (Hipcref) diet intervention in Malaysian adults. METHODS Both a cross-sectional study (n = 178) and a randomized controlled trial (RCT) (n = 128) were conducted to test the aforementioned objectives. PRS was computed as the weighted sum of the risk alleles possessed by each individual participant. Participants were stratified into first (PRS 0-0.64), second (PRS 0.65-3.59), and third (PRS 3.60-8.18) tertiles. RESULTS The third tertile of PRS was associated with significantly higher odds of obesity: 2.29 (95% CI = 1.11-4.72, adjusted p = 0.025) compared to the first tertile. Indians (3.9 ± 0.3) had significantly higher PRS compared to Chinese (2.1 ± 0.4) (p = 0.010). In the RCT, a greater reduction in high-sensitivity C-reactive protein (hsCRP) levels was found in second and third tertiles after Hipcref diet intervention compared to the control diet (p interaction = 0.048). CONCLUSION Higher PRS was significantly associated with increased odds of obesity. Individuals with higher PRS had a significantly greater reduction in hsCRP levels after Hipcref diet compared to the control diet.",2020,Individuals with higher PRS had a significantly greater reduction in hsCRP levels after Hipcref diet compared to the control diet.,"['Malaysian adults', 'Both a cross-sectional study (n = 178) and a randomized controlled trial (RCT) (n = 128']","['high-protein calorie-restricted, high-vitamin E, high-fiber (Hipcref) diet intervention']","['high-sensitivity C-reactive protein (hsCRP) levels', 'hsCRP levels', 'obesity', 'odds of obesity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0010362', 'cui_str': 'Disease Frequency Surveys'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0443288', 'cui_str': 'Restricted (qualifier value)'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0301568', 'cui_str': 'High residue diet (finding)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]",128.0,0.0178011,Individuals with higher PRS had a significantly greater reduction in hsCRP levels after Hipcref diet compared to the control diet.,"[{'ForeName': 'Pui Yee', 'Initials': 'PY', 'LastName': 'Tan', 'Affiliation': 'School of Biosciences, Faculty of Science and Engineering, University of Nottingham Malaysia, Semenyih, Malaysia.'}, {'ForeName': 'Soma Roy', 'Initials': 'SR', 'LastName': 'Mitra', 'Affiliation': 'School of Biosciences, Faculty of Science and Engineering, University of Nottingham Malaysia, Semenyih, Malaysia, soma.mitra@nottingham.edu.my.'}]",Lifestyle genomics,['10.1159/000505662'] 3505,31785201,Overcoming cultural barriers to implementing oral HIV self-testing with high fidelity among Tanzanian youth.,"Tanzanian youth have high levels of HIV risk and poor access to HIV-testing. Oral self-implemented testing (Oral-SIT) provides an alternative that reduces barriers to HIV-testing. We examined adaptations to Oral-SIT training components in a randomized experiment to evaluate a ""train-the-trainer"" strategy for improving comprehension of graphic training materials. Participants (N = 257, age = 14-19 years) were randomly assigned to one of two self-training conditions: graphic instruction book (GIB) or Video-GIB. Outcomes included behavioral performance fidelity, self-reported comprehension, and intentions to seek treatment. Video-GIB participants, relative to GIB-only participants, had higher performance fidelity scores, made fewer performance errors, had better instruction comprehension, and were more likely to intend to seek treatment. Oral-SIT timing errors were significantly more common among GIB-only participants. Graphic training materials in conjunction with a ""train-the-trainer"" video has significant potential for increasing Oral-SIT's reach by overcoming technological and literacy barriers.",2021,"Video-GIB participants, relative to GIB-only participants, had higher performance fidelity scores, made fewer performance errors, had better instruction comprehension, and were more likely to intend to seek treatment.","['Participants (N = 257, age = 14-19 years', 'Tanzanian youth']","['Oral self-implemented testing (Oral-SIT', 'self-training conditions: graphic instruction book (GIB) or Video-GIB']","['behavioral performance fidelity, self-reported comprehension, and intentions to seek treatment']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0087178', 'cui_str': 'Youth'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0006002', 'cui_str': 'Books'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",,0.0188192,"Video-GIB participants, relative to GIB-only participants, had higher performance fidelity scores, made fewer performance errors, had better instruction comprehension, and were more likely to intend to seek treatment.","[{'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Catania', 'Affiliation': 'Hallie E. Ford Center, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Cassidy', 'Initials': 'C', 'LastName': 'Huun', 'Affiliation': 'Oregon Health Sciences University, Portland, OR, USA.'}, {'ForeName': 'M Margaret', 'Initials': 'MM', 'LastName': 'Dolcini', 'Affiliation': 'Hallie E. Ford Center, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Angelmary Joel', 'Initials': 'AJ', 'LastName': 'Urban', 'Affiliation': 'Hallie E. Ford Center, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Fleury', 'Affiliation': 'Hallie E. Ford Center, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Clinton', 'Initials': 'C', 'LastName': 'Ndyetabula', 'Affiliation': 'FASDO, Yatima Group Fund, Tanzania.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Singh', 'Affiliation': 'Hallie E. Ford Center, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Amy W', 'Initials': 'AW', 'LastName': 'Young', 'Affiliation': 'Hallie E. Ford Center, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Donaldson F', 'Initials': 'DF', 'LastName': 'Conserve', 'Affiliation': 'University of South Carolina, Columbia, SC, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Lace', 'Affiliation': 'FASDO, Yatima Group Fund, Tanzania.'}, {'ForeName': 'Joyce Samweli', 'Initials': 'JS', 'LastName': 'Msigwa', 'Affiliation': 'FASDO, Yatima Group Fund, Tanzania.'}]",Translational behavioral medicine,['10.1093/tbm/ibz157'] 3506,31970931,Anterior chamber granuloma: conservative treatment versus surgical intervention.,"PURPOSE A distinct pattern of granulomatous anterior uveitis, with white anterior chamber (AC) granuloma, has been reported in certain endemic areas. The aim of this work was to compare the outcome of conservative treatment to surgical intervention for the treatment of large AC granulomas presenting with moderate-severe anterior uveitis. The secondary outcome is ultrasound biomicroscopy (UBM) characterization of AC granulomas. METHODS This is a prospective randomized interventional study including 41 eyes of 39 patients with active AC granuloma ≥3 mm (flare & cells ≥ +2). Patients were randomly assigned to either conservative treatment in the form of topical prednisolone and cycloplegic drops with orbital floor (transseptal) injection of Triamcinolone acetonide (20 eyes) or surgery in the form of granuloma excision and AC wash (21 eyes). As a perioperative care, topical steroids and cycloplegic drops were given few days before surgery and tapered gradually over 6 weeks. Patients were followed up at first day, 2 weeks, 1 and 3 months. RESULTS Thirty-seven patients were males, and 2 were females (13.0 ± 3.5 years). After 2 weeks, disappearance/healing of granuloma was achieved in 20 eyes in the surgical group versus 2 eyes in the conservative group (p < 0.0001). This effect was maintained throughout the follow-up period, for the surgical group and reached up to 70%, for the medical group. At every follow-up, BCVA was better in the surgical group, but this was only statistically significant at 1 and 3 months. The granuloma appeared as a homogenous hyperreflective lesion in examined eyes (16 eyes of 15 patients). CONCLUSION Surgical treatment of large granulomas leads to a more complete and rapid resolution of inflammation.",2020,"At every follow-up, BCVA was better in the surgical group, but this was only statistically significant at 1 and 3 months.","['Thirty-seven patients were males, and 2 were females (13.0\xa0±\xa03.5\xa0years', 'large AC granulomas presenting with moderate-severe anterior uveitis', '41 eyes of 39 patients with active AC granuloma ≥3\xa0mm (flare & cells\xa0≥\xa0+2']","['surgical intervention', 'topical prednisolone and cycloplegic drops with orbital floor (transseptal) injection of Triamcinolone acetonide (20 eyes) or surgery in the form of granuloma excision and AC']","['ultrasound biomicroscopy (UBM) characterization of AC granulomas', 'disappearance/healing of granuloma']","[{'cui': 'C4319569', 'cui_str': '37 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0018188', 'cui_str': 'Granuloma'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0042165', 'cui_str': 'Anterior uveitis (disorder)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]","[{'cui': 'C0549433', 'cui_str': 'Surgical intervention'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0010586', 'cui_str': 'Cycloplegics'}, {'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}, {'cui': 'C0230060', 'cui_str': 'Structure of inferior wall of orbit'}, {'cui': 'C1960581', 'cui_str': 'Injection of triamcinolone'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018188', 'cui_str': 'Granuloma'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}]","[{'cui': 'C1301497', 'cui_str': 'Ultrasound Biomicroscopy'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0018188', 'cui_str': 'Granuloma'}]",39.0,0.0240447,"At every follow-up, BCVA was better in the surgical group, but this was only statistically significant at 1 and 3 months.","[{'ForeName': 'Sherin Hassan', 'Initials': 'SH', 'LastName': 'Sadek', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.'}, {'ForeName': 'Mahmoud Naguib', 'Initials': 'MN', 'LastName': 'Ahmed', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.'}, {'ForeName': 'Mahmoud Ahmed', 'Initials': 'MA', 'LastName': 'Kamal', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.'}, {'ForeName': 'Maha Mohamed', 'Initials': 'MM', 'LastName': 'Youssef', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}]",Acta ophthalmologica,['10.1111/aos.14355'] 3507,32144884,Racial Differences in Pain and Function Following Knee Arthroplasty: A Secondary Analysis From a Multicenter Randomized Clinical Trial.,"OBJECTIVE The assessment of racial differences in pain and function outcome following knee arthroplasty (KA) has received little attention despite very substantial literature exploring a variety of other prognostic factors. The present study was undertaken to determine whether race was associated with KA outcome after accounting for potential confounding factors. METHODS We conducted a secondary analysis of a randomized clinical trial of 384 participants with moderate-to-high pain catastrophizing who underwent KA. Preoperative measures included race/ethnicity status as well as a variety of potential confounders, including socioeconomic status, comorbidity, and bodily pain. Outcome measures were Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scales as well as performance measures. Linear mixed-effects models compared outcomes over a 1-year follow-up period for African American versus non-African American participants. RESULTS WOMAC pain scores differences for African American versus non-African American participants averaged ~2 points in unadjusted analyses and 1-1.5 points in adjusted analyses. In adjusted analyses, follow-up WOMAC function scores differed by 6 points for African Americans compared to non-African Americans (P = 0.002). CONCLUSION African Americans generally had worse pain, function, and performance prior to KA and worse scores after surgery, but differences were small and attenuated by ~25-50% after adjustment for potential confounding. Only WOMAC function scores showed clinically important postsurgical differences in adjusted analyses. Clinicians should be aware that after adjustment for potential confounders, African Americans have approximately equivalent outcomes compared to others, with the exception of WOMAC function score.",2021,"RESULTS WOMAC Pain scores differences for African Americans versus non-African Americans averaged approximately 2 points in unadjusted analyses and 1 to 1.5 points in adjusted analyses.","['384 participants with moderate to high pain catastrophizing who underwent knee arthroplasty', 'African Americans versus the non-African Americans', 'knee arthroplasty', 'African Americans versus non-African Americans']",[],"['socioeconomic status, comorbidity and bodily pain', 'pain and function', 'Western Ontario and McMaster Universities Osteoarthritis Index', 'WOMAC) Pain and Function Scales', 'WOMAC Function scores']","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}]",[],"[{'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C3472647', 'cui_str': 'WOMAC index'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",384.0,0.21899,"RESULTS WOMAC Pain scores differences for African Americans versus non-African Americans averaged approximately 2 points in unadjusted analyses and 1 to 1.5 points in adjusted analyses.","[{'ForeName': 'Daniel L', 'Initials': 'DL', 'LastName': 'Riddle', 'Affiliation': 'Virginia Commonwealth University, Richmond.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Slover', 'Affiliation': 'New York University Medical Center, New York, New York.'}, {'ForeName': 'Francis J', 'Initials': 'FJ', 'LastName': 'Keefe', 'Affiliation': 'Duke University, Durham, North Carolina.'}, {'ForeName': 'Dennis C', 'Initials': 'DC', 'LastName': 'Ang', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Levent', 'Initials': 'L', 'LastName': 'Dumenci', 'Affiliation': 'Temple University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Perera', 'Affiliation': 'Virginia Commonwealth University, Richmond.'}]",Arthritis care & research,['10.1002/acr.24177'] 3508,32064530,Generativity and Social Well-Being in Older Women: Expectations Regarding Aging Matter.,"OBJECTIVES Beliefs about aging can contribute to health and well-being in older adults. Feeling generative, or that one is caring for and contributing to the well-being of others, can also impact health and well-being. In this study, we hypothesized that those with more positive expectations regarding aging (ERA) in the mental health domain would report greater levels of perceived social support (PSS) and lower levels of loneliness in response to a generativity intervention (vs control condition). METHOD Participants in this study (n = 73, 100% female) were randomly assigned to a 6-week generativity condition, which involved writing about life experiences and sharing advice with others, or to a control condition, which involved writing about neutral topics. Pre- and postintervention, PSS, and feelings of loneliness were measured. RESULTS Those in the generativity condition with more positive ERA in the mental health domain reported greater PSS and lower loneliness postintervention. DISCUSSION These results highlight the importance of psychological factors, such as ERA, in moderating the efficacy of interventions to promote social well-being in older adults.",2021,"Those in the generativity condition with more positive ERA in the mental health domain reported greater PSS and lower loneliness post-intervention. ","['Older Women', 'older adults', 'Participants in this study (n=73, 100% female']","['6-week generativity condition, which involved writing about life experiences and sharing advice with others, or to a control condition, which involved writing about neutral topics']",['PSS and feelings of loneliness'],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0023974', 'cui_str': 'Loneliness'}]",,0.026759,"Those in the generativity condition with more positive ERA in the mental health domain reported greater PSS and lower loneliness post-intervention. ","[{'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Moieni', 'Affiliation': 'Department of Psychology, University of California, Los Angeles.'}, {'ForeName': 'Teresa E', 'Initials': 'TE', 'LastName': 'Seeman', 'Affiliation': 'Department of Medicine, Division of Geriatrics, David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Theodore F', 'Initials': 'TF', 'LastName': 'Robles', 'Affiliation': 'Department of Psychology, University of California, Los Angeles.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Lieberman', 'Affiliation': 'Department of Psychology, University of California, Los Angeles.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Okimoto', 'Affiliation': 'UCLA Clinical and Translational Research Center, David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Lengacher', 'Affiliation': 'Department of Psychology, University of California, Los Angeles.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Irwin', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior, Cousins Center for Psychoneuroimmunology, University of California, Los Angeles.'}, {'ForeName': 'Naomi I', 'Initials': 'NI', 'LastName': 'Eisenberger', 'Affiliation': 'Department of Psychology, University of California, Los Angeles.'}]","The journals of gerontology. Series B, Psychological sciences and social sciences",['10.1093/geronb/gbaa022'] 3509,31901794,Family network satisfaction moderates treatment effects among homeless youth experiencing suicidal ideation.,"OBJECTIVE Limited research has evaluated the efficacy of suicide prevention interventions among homeless youth, especially considering how their connectedness with their family would impact treatment outcomes. METHOD Suicidal homeless youth (N = 150) between the ages of 18-24 years were recruited from a local drop-in center. Youth were randomly assigned to Cognitive Therapy for Suicide Prevention (CTSP) + Treatment as Usual (TAU) or Treatment as Usual alone. Youth reported their family network satisfaction at the baseline assessment, whereas their suicidal ideation, perceived burdensomeness and thwarted belongingness were assessed at baseline and three additional times during a nine-month period. RESULTS A multiple-group autoregressive cross-lagged model suggests that CTSP was associated with lower suicidal ideation and lower thwarted belongingness only among those with high family network satisfaction. Among both groups, perceived burdensomeness predicted higher suicidal ideation, which in turn predicted lower perceived burdensomeness and thwarted belongingness. Additionally, only among youth with low family network satisfaction, thwarted belongingness predicted lower suicidal ideation. CONCLUSIONS Findings suggest that family network satisfaction may be an important factor when considering cognitive interventions with homeless youth, with implications to improve treatment efforts and to reduce premature mortality, hospitalization and loss of human capital in a very high-risk population.",2020,"Among both groups, perceived burdensomeness predicted higher suicidal ideation, which in turn predicted lower perceived burdensomeness and thwarted belongingness.","['homeless youth experiencing suicidal ideation', 'homeless youth', 'Suicidal homeless youth (N\xa0=\xa0150) between the ages of 18-24 years were recruited from a local drop-in center']","['Cognitive Therapy for Suicide Prevention (CTSP)\xa0+\xa0Treatment as Usual (TAU) or Treatment as Usual alone', 'CTSP']","['suicidal ideation, perceived burdensomeness and thwarted belongingness', 'family network satisfaction', 'suicidal ideation']","[{'cui': 'C0242663', 'cui_str': 'Homeless Children'}, {'cui': 'C0424000', 'cui_str': 'Suicidal Ideation'}, {'cui': 'C0438696', 'cui_str': 'Suicidal (finding)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0204732', 'cui_str': 'Suicide prevention (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0424000', 'cui_str': 'Suicidal Ideation'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0390458,"Among both groups, perceived burdensomeness predicted higher suicidal ideation, which in turn predicted lower perceived burdensomeness and thwarted belongingness.","[{'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Wu', 'Affiliation': 'Department of Family and Child Sciences, College of Human Sciences, Florida State University, 322 Sandels Building, 120 Convocation Way, Tallahassee, FL, 32306, USA. Electronic address: qwu3@fsu.edu.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Human Development and Family Studies, School of Lifespan Development and Educational Sciences, Kent State University, 406G White Hall, 150 Terrace Drive, P.O. Box 5190, Kent, OH, 44242, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Walsh', 'Affiliation': 'Department of Human Sciences, College of Education and Human Ecology, The Ohio State University, Campbell Hall Room 135, 1787 Neil Ave., Columbus, OH, 43210, USA.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Slesnick', 'Affiliation': 'Department of Human Sciences, College of Education and Human Ecology, The Ohio State University, Campbell Hall Room 135, 1787 Neil Ave., Columbus, OH, 43210, USA.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103548'] 3510,30954363,Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: The randomized controlled NUTRAIN trial.,"BACKGROUND AND AIMS The efficacy of nutritional intervention to enhance short- and long-term outcomes of pulmonary rehabilitation in COPD is still unclear, hence this paper aims to investigate the clinical outcome and cost-effectiveness of a 12-month nutritional intervention strategy in muscle-wasted COPD patients. METHODS Prior to a 4-month pulmonary rehabilitation programme, 81 muscle-wasted COPD patients (51% males, aged 62.5 ± 0.9 years) with moderate airflow obstruction (FEV 1 55.1 ± 2.2% predicted) and impaired exercise capacity (W max 63.5 ± 2.4% predicted) were randomized to 3 portions of nutritional supplementation per day (enriched with leucine, vitamin D and polyunsaturated fatty acids) [NUTRITION] or PLACEBO (phase 1). In the unblinded 8-month maintenance phase (phase 2), both groups received structured feedback on their physical activity level assessed by accelerometry. NUTRITION additionally received 1 portion of supplemental nutrition per day and motivational interviewing-based nutritional counselling. A 3-month follow-up (phase 3) was included. RESULTS After 12 months, physical capacity measured by quadriceps muscle strength and cycle endurance time were not different, but physical activity was higher in NUTRITION than in PLACEBO (Δ1030 steps/day, p = 0.025). Plasma levels of the enriched nutrients (p < 0.001) were higher in NUTRITION than PLACEBO. Trends towards weight gain in NUTRITION and weight loss in PLACEBO led to a significant between-group difference after 12 months (Δ1.54 kg, p = 0.041). The HADS anxiety and depression scores improved in NUTRITION only (Δ-1.92 points, p = 0.037). Generic quality of life (EQ-5D) was decreased in PLACEBO but not in NUTRITION (between-group difference after 15 months 0.072 points, p = 0.009). Overall motivation towards exercising and healthy eating was high and did not change significantly after 12 months; only amotivation towards healthy eating yielded a significant between-group difference (Δ1.022 points, p = 0.015). The cost per quality-adjusted life-year after 15 months was EUR 16,750. CONCLUSIONS Nutritional intervention in muscle-wasted patients with moderate COPD does not enhance long-term outcome of exercise training on physical capacity but ameliorates plasma levels of the supplemented nutrients, total body weight, physical activity and generic health status, at an acceptable increase of costs for patients with high disease burden.",2020,"Overall motivation towards exercising and healthy eating was high and did not change significantly after 12 months; only amotivation towards healthy eating yielded a significant between-group difference (Δ1.022 points, p = 0.015).","['patients with high disease burden', 'muscle-wasted patients with moderate COPD', 'COPD patients with low muscle mass', 'muscle-wasted COPD patients', '81 muscle-wasted COPD patients (51% males, aged 62.5\xa0±\xa00.9 years) with moderate airflow obstruction (FEV 1 55.1\xa0±\xa02.2% predicted) and impaired exercise capacity (W max 63.5\xa0±\xa02.4% predicted']","['nutritional intervention programme', 'supplemental nutrition per day and motivational interviewing-based nutritional counselling', 'exercise training', 'nutritional supplementation per day (enriched with leucine, vitamin D and polyunsaturated fatty acids) [NUTRITION] or PLACEBO', 'nutritional intervention', 'structured feedback on their physical activity level assessed by accelerometry']","['physical capacity measured by quadriceps muscle strength and cycle endurance time', 'total body weight, physical activity and generic health status', 'HADS anxiety and depression scores', 'weight gain in NUTRITION and weight loss', 'Generic quality of life (EQ-5D', 'Plasma levels', 'Clinical outcome and cost-effectiveness', 'physical activity', 'Overall motivation towards exercising and healthy eating']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0856558', 'cui_str': 'Muscle wasting (disuse)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle (finding)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C4517836', 'cui_str': '62.5'}, {'cui': 'C4068881', 'cui_str': 'Zero point nine'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0231999', 'cui_str': 'Airflow, function (observable entity)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C4517631', 'cui_str': '2.4 (qualifier value)'}]","[{'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplement'}, {'cui': 'C0023401', 'cui_str': 'L-leucine'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated Fatty Acids'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0441677', 'cui_str': 'Accelerometry'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0034380'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0452415', 'cui_str': 'Healthy Diet'}]",,0.110496,"Overall motivation towards exercising and healthy eating was high and did not change significantly after 12 months; only amotivation towards healthy eating yielded a significant between-group difference (Δ1.022 points, p = 0.015).","[{'ForeName': 'Martijn', 'Initials': 'M', 'LastName': 'van Beers', 'Affiliation': 'Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Maureen P M H', 'Initials': 'MPMH', 'LastName': 'Rutten-van Mölken', 'Affiliation': 'Institute of Health Care Policy and Management/Institute of Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, the Netherlands.'}, {'ForeName': 'Coby', 'Initials': 'C', 'LastName': 'van de Bool', 'Affiliation': 'Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Melinde', 'Initials': 'M', 'LastName': 'Boland', 'Affiliation': 'Institute of Health Care Policy and Management/Institute of Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, the Netherlands.'}, {'ForeName': 'Stef P J', 'Initials': 'SPJ', 'LastName': 'Kremers', 'Affiliation': 'Department of Health Promotion, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Frits M E', 'Initials': 'FME', 'LastName': 'Franssen', 'Affiliation': 'Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands; CIRO, Center of Expertise for Chronic Organ Failure, Horn, the Netherlands.'}, {'ForeName': 'Ardy', 'Initials': 'A', 'LastName': 'van Helvoort', 'Affiliation': 'Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands; Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, the Netherlands.'}, {'ForeName': 'Harry R', 'Initials': 'HR', 'LastName': 'Gosker', 'Affiliation': 'Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Emiel F', 'Initials': 'EF', 'LastName': 'Wouters', 'Affiliation': 'Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands; CIRO, Center of Expertise for Chronic Organ Failure, Horn, the Netherlands.'}, {'ForeName': 'Annemie M W J', 'Initials': 'AMWJ', 'LastName': 'Schols', 'Affiliation': 'Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands. Electronic address: a.schols@maastrichtuniversity.nl.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.03.001'] 3511,29945955,Preterm Neuroimaging and School-Age Cognitive Outcomes.,"BACKGROUND AND OBJECTIVES Children born extremely preterm are at risk for cognitive difficulties and disability. The relative prognostic value of neonatal brain MRI and cranial ultrasound (CUS) for school-age outcomes remains unclear. Our objectives were to relate near-term conventional brain MRI and early and late CUS to cognitive impairment and disability at 6 to 7 years among children born extremely preterm and assess prognostic value. METHODS A prospective study of adverse early and late CUS and near-term conventional MRI findings to predict outcomes at 6 to 7 years including a full-scale IQ (FSIQ) <70 and disability (FSIQ <70, moderate-to-severe cerebral palsy, or severe vision or hearing impairment) in a subgroup of Surfactant Positive Airway Pressure and Pulse Oximetry Randomized Trial enrollees. Stepwise logistic regression evaluated associations of neuroimaging with outcomes, adjusting for perinatal-neonatal factors. RESULTS A total of 386 children had follow-up. In unadjusted analyses, severity of white matter abnormality and cerebellar lesions on MRI and adverse CUS findings were associated with outcomes. In full regression models, both adverse late CUS findings (odds ratio [OR] 27.9; 95% confidence interval [CI] 6.0-129) and significant cerebellar lesions on MRI (OR 2.71; 95% CI 1.1-6.7) remained associated with disability, but only adverse late CUS findings (OR 20.1; 95% CI 3.6-111) were associated with FSIQ <70. Predictive accuracy of stepwise models was not substantially improved with the addition of neuroimaging. CONCLUSIONS Severe but rare adverse late CUS findings were most strongly associated with cognitive impairment and disability at school age, and significant cerebellar lesions on MRI were associated with disability. Near-term conventional MRI did not substantively enhance prediction of severe early school-age outcomes.",2018,Near-term conventional MRI did not substantively enhance prediction of severe early school-age outcomes.,"['Children born extremely preterm', '6 to 7 years including a full-scale IQ (FSIQ) <70 and disability', '386 children had follow-up']",['neonatal brain MRI and cranial ultrasound (CUS'],"['cerebellar lesions on MRI', 'Preterm Neuroimaging and School-Age Cognitive Outcomes', 'severity of white matter abnormality and cerebellar lesions on MRI and adverse CUS findings', 'severe vision or hearing impairment']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0205403', 'cui_str': 'Extreme (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C3163632', 'cui_str': 'Cranial'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0056599', 'cui_str': 'cpd with unspecified MF of cupric sulfide'}]","[{'cui': 'C0742035', 'cui_str': 'Cerebellar lesion NOS'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0682708'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0056599', 'cui_str': 'cpd with unspecified MF of cupric sulfide'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}]",386.0,0.138485,Near-term conventional MRI did not substantively enhance prediction of severe early school-age outcomes.,"[{'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Hintz', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, School of Medicine, Stanford University and Lucile Packard Children's Hospital, Palo Alto, California; srhintz@stanford.edu.""}, {'ForeName': 'Betty R', 'Initials': 'BR', 'LastName': 'Vohr', 'Affiliation': 'Department of Pediatrics, Women and Infants Hospital and Brown University, Providence, Rhode Island.'}, {'ForeName': 'Carla M', 'Initials': 'CM', 'LastName': 'Bann', 'Affiliation': 'Social, Statistical, and Environmental Sciences Unit, Research Triangle Institute International, Research Triangle Park, North Carolina.'}, {'ForeName': 'H Gerry', 'Initials': 'HG', 'LastName': 'Taylor', 'Affiliation': ""Department of Pediatrics, Rainbow Babies and Children's Hospital and Case Western Reserve University, Cleveland, Ohio.""}, {'ForeName': 'Abhik', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'Social, Statistical, and Environmental Sciences Unit, Research Triangle Institute International, Rockville, Maryland.'}, {'ForeName': 'Kathryn E', 'Initials': 'KE', 'LastName': 'Gustafson', 'Affiliation': 'Department of Pediatrics, Duke University, Durham, North Carolina.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Yolton', 'Affiliation': ""Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Victoria E', 'Initials': 'VE', 'LastName': 'Watson', 'Affiliation': 'Department of Pediatrics, Women and Infants Hospital and Brown University, Providence, Rhode Island.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Lowe', 'Affiliation': 'Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.'}, {'ForeName': 'Maria Elena', 'Initials': 'ME', 'LastName': 'DeAnda', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, School of Medicine, Stanford University and Lucile Packard Children's Hospital, Palo Alto, California.""}, {'ForeName': 'M Bethany', 'Initials': 'MB', 'LastName': 'Ball', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, School of Medicine, Stanford University and Lucile Packard Children's Hospital, Palo Alto, California.""}, {'ForeName': 'Neil N', 'Initials': 'NN', 'LastName': 'Finer', 'Affiliation': 'Department of Pediatrics, University of California at San Diego, San Diego, California.'}, {'ForeName': 'Krisa P', 'Initials': 'KP', 'LastName': 'Van Meurs', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, School of Medicine, Stanford University and Lucile Packard Children's Hospital, Palo Alto, California.""}, {'ForeName': 'Seetha', 'Initials': 'S', 'LastName': 'Shankaran', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Athina', 'Initials': 'A', 'LastName': 'Pappas', 'Affiliation': 'Department of Pediatrics, Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Patrick D', 'Initials': 'PD', 'LastName': 'Barnes', 'Affiliation': ""Division of Neonatal and Developmental Medicine, Department of Pediatrics, School of Medicine, Stanford University and Lucile Packard Children's Hospital, Palo Alto, California.""}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Bulas', 'Affiliation': ""Department of Diagnostic Imaging and Radiology, Children's National Medical Center, Washington, District of Columbia.""}, {'ForeName': 'Jamie E', 'Initials': 'JE', 'LastName': 'Newman', 'Affiliation': 'Social, Statistical, and Environmental Sciences Unit, Research Triangle Institute International, Research Triangle Park, North Carolina.'}, {'ForeName': 'Deanne E', 'Initials': 'DE', 'LastName': 'Wilson-Costello', 'Affiliation': ""Department of Pediatrics, Rainbow Babies and Children's Hospital and Case Western Reserve University, Cleveland, Ohio.""}, {'ForeName': 'Roy J', 'Initials': 'RJ', 'LastName': 'Heyne', 'Affiliation': 'Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Heidi M', 'Initials': 'HM', 'LastName': 'Harmon', 'Affiliation': 'Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, Indiana.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Peralta-Carcelen', 'Affiliation': 'Division of Neonatology, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Adams-Chapman', 'Affiliation': ""Department of Pediatrics, School of Medicine, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia.""}, {'ForeName': 'Andrea Freeman', 'Initials': 'AF', 'LastName': 'Duncan', 'Affiliation': 'Department of Pediatrics, McGovern Medical School, University of Texas at Houston, Houston, Texas.'}, {'ForeName': 'Janell', 'Initials': 'J', 'LastName': 'Fuller', 'Affiliation': 'Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.'}, {'ForeName': 'Yvonne E', 'Initials': 'YE', 'LastName': 'Vaucher', 'Affiliation': 'Department of Pediatrics, University of California at San Diego, San Diego, California.'}, {'ForeName': 'Tarah T', 'Initials': 'TT', 'LastName': 'Colaizy', 'Affiliation': 'Department of Pediatrics, University of Iowa, Iowa City, Iowa.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Winter', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, Utah.'}, {'ForeName': 'Elisabeth C', 'Initials': 'EC', 'LastName': 'McGowan', 'Affiliation': 'Department of Pediatrics, Women and Infants Hospital and Brown University, Providence, Rhode Island.'}, {'ForeName': 'Ricki F', 'Initials': 'RF', 'LastName': 'Goldstein', 'Affiliation': 'Department of Pediatrics, Duke University, Durham, North Carolina.'}, {'ForeName': 'Rosemary D', 'Initials': 'RD', 'LastName': 'Higgins', 'Affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pediatrics,['10.1542/peds.2017-4058'] 3512,30852029,"Prediabetes diagnosis criteria, type 2 diabetes risk and dietary modulation: The CORDIOPREV study.","AIM Our objective was to investigate the role of two healthy diets in modulating the risk of type 2 diabetes (T2DM) development associated with each prediabetes diagnosis criteria in coronary heart disease patients. Additionally, we explored the pathophysiological characteristics and the risk of developing T2DM in patients with different prediabetes criteria. METHODS We included 462 patients from the CORDIOPREV study without T2DM at baseline: 213 had prediabetes defined by impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) (PreDM-IFG/IGT); 180 had prediabetes by isolated hemoglobin glycated plasma levels (PreDM-isolated-HbA1c), and 69 were not prediabetics (non-PreDM), according to the American Diabetes Association criteria. Patients were randomized to consume either a Mediterranean or a low-fat diet. We performed a COX proportional hazards regression analysis to determine the T2DM risk according to diet and the prediabetes criteria after a median follow-up of 60 months. RESULTS We found higher T2DM risk (HR: 2.98; 95% CI 1.27-6.98) in PreDM-IFG/IGT than in PreDM-isolated-HbA1c (HR: 2.31; 95% CI 0.97-5.49) compared with non-PreDM. Long-term consumption of a low-fat diet was associated with a lower risk of T2DM when compared to the Mediterranean diet in the PreDM-IFG/IGT group (HR: 3.20; 95% CI 0.75-13.69 versus HR: 4.70; 95% CI 1.12-19.67, respectively). Moreover, we found the highest risk of T2DM development associated with patients who had both IFG and IGT (HR: 2.15; 95% CI 1.11-4.16). Patients who had both IFG and IGT and consumed a low-fat diet had a lower T2DM risk than those who consumed a Mediterranean diet (HR: 1.53; 95% CI 0.53-4.39 versus HR: 3.33; 95% CI 1.34-8.30, respectively). CONCLUSION Our results suggest that the type of diet consumed may modulate the risk of T2DM development according to the prediabetes diagnosis criteria. Specifically, our study showed that the consumption of a low-fat diet was more beneficial than a Mediterranean diet in patients with IFG and IGT. CLINICAL TRIAL REGISTRATION NUMBER ClinicalTrials.govNCT00924937.",2020,"Long-term consumption of a low-fat diet was associated with a lower risk of T2DM when compared to the Mediterranean diet in the PreDM-IFG/IGT group (HR: 3.20; 95% CI 0.75-13.69 versus HR: 4.70; 95% CI 1.12-19.67, respectively).","['coronary heart disease patients', '462 patients from the CORDIOPREV study without T2DM at baseline', '180 had prediabetes by isolated hemoglobin glycated plasma levels (PreDM-isolated-HbA1c), and 69 were not prediabetics (non-PreDM), according to the American Diabetes Association criteria', 'patients with different prediabetes criteria', 'Prediabetes diagnosis criteria, type 2 diabetes risk and dietary modulation']","['Mediterranean or a low-fat diet', 'healthy diets', 'PreDM-IFG/IGT']","['lower risk of T2DM', 'impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT', 'risk of T2DM development', 'T2DM risk', 'highest risk of T2DM development']","[{'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C3666909', 'cui_str': 'Glycate'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C0242970', 'cui_str': 'Fat-Restricted Diet'}, {'cui': 'C0452415', 'cui_str': 'Healthy Diet'}]","[{'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}]",462.0,0.048523,"Long-term consumption of a low-fat diet was associated with a lower risk of T2DM when compared to the Mediterranean diet in the PreDM-IFG/IGT group (HR: 3.20; 95% CI 0.75-13.69 versus HR: 4.70; 95% CI 1.12-19.67, respectively).","[{'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Roncero-Ramos', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Alcala-Diaz', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Oriol A', 'Initials': 'OA', 'LastName': 'Rangel-Zuñiga', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Gomez-Delgado', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Jimenez-Lucena', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'García-Rios', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Vals-Delgado', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Romero-Baldonado', 'Affiliation': 'Biochemical Laboratory, Reina Sofia University Hospital, Córdoba, Spain.'}, {'ForeName': 'Raul M', 'Initials': 'RM', 'LastName': 'Luque', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain; Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Reina Sofía University Hospital, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Ordovas', 'Affiliation': 'Nutrition and Genomics Laboratory, J.M.-US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, Spain; IMDEA Alimentacion, Madrid, Spain; CNIC, Madrid, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Perez-Martinez', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Camargo', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lopez-Miranda', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain. Electronic address: jlopezmir@uco.es.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.02.027'] 3513,31990615,Treatment for Borderline Personality Disorder and Secondary Effects on Somatization.,"Borderline personality disorder (BPD) is often accompanied by other diagnoses. Some comorbidities have received a good deal of attention, but others, including somatization, have not. As effective treatments for BPD are identified, the secondary effects of these treatments on BPD comorbidities are of clinical relevance. Secondary data were used from a randomized clinical trial of dialectical behavior therapy (DBT) and community treatment by experts among 101 women with BPD in order to characterize change in somatization with treatment for BPD, and to examine emotional avoidance as a mediator. Somatization decreased significantly over time, which did not differ by treatment condition. DBT had an indirect effect on somatization through less emotional avoidance. These results suggest that the comorbid presence of significant somatization should be evaluated among those with BPD, especially in the context of emotional avoidance; treatments could be enhanced by addressing emotion regulation skills.",2021,"Somatization decreased significantly over time, which did not differ by treatment condition.","['Borderline personality disorder (BPD', '101 women with BPD']","['dialectical behavior therapy (DBT', 'DBT']",['Somatization'],"[{'cui': 'C0006012', 'cui_str': 'Borderline Personality Disorder'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C1321145', 'cui_str': 'Dialectical Behavior Therapy'}]",[],101.0,0.0211455,"Somatization decreased significantly over time, which did not differ by treatment condition.","[{'ForeName': 'Karen B', 'Initials': 'KB', 'LastName': 'Schmaling', 'Affiliation': 'Department of Psychology, Washington State University, Vancouver, Washington.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Fales', 'Affiliation': 'Department of Psychology, Washington State University, Vancouver, Washington.'}, {'ForeName': 'Marsha M', 'Initials': 'MM', 'LastName': 'Linehan', 'Affiliation': 'Department of Psychology, University of Washington, Seattle, Washington.'}]",Journal of personality disorders,['10.1521/pedi_2020_34_469'] 3514,32202155,A Promotor -Led Pilot Study to Increase Colorectal Cancer Screening in Latinos: The Juntos Contra El Cáncer Program.,"Background. Latinos have lower colorectal cancer (CRC) screening rates compared to other racial/ethnic groups in the United States, despite an overall increase in CRC screening over the past 10 years. To address this disparity, we implemented a promotor -led intervention to increase CRC screening test adherence in community-based settings, connecting community members with a partnering federally qualified health center. Purpose . To evaluate the Juntos Contra el Cáncer /Together Against Cancer (JUNTOS) intervention, by assessing pre-post changes in (1) CRC screening test adherence and (2) CRC knowledge and perceived barriers to CRC screening. We also assessed the feasibility and acceptability of program activities. Method . JUNTOS was a group-based intervention, delivered by promotores (community health workers), to promote CRC screening test adherence among Latino adults. The intervention consisted of a culturally tailored 2½-hour interactive workshop followed by an appointment scheduling assistance from a promotor. Workshop participants were Latino adults (males and females) aged 50 to 75 years who were not up-to-date with CRC screening guidelines. We conducted interviews before and 6 to 9 months after the workshop to assess program outcomes. Results . Of the 177 participants included, 118 reported completing the CRC screening test (66.7%) by 6 to 9 months postintervention. We observed baseline to 6- to 9-month increase in CRC knowledge and lower perceived barriers to obtaining CRC screening. Furthermore, the intervention was found to be feasible and acceptable. Conclusion . Results suggest that JUNTOS can be feasibly implemented in partnership with a federally qualified health center. The current study supports group-based CRC interventions in community and clinic settings.",2021,"Of the 177 participants included, 118 reported completing the CRC screening test (66.7%) by 6 to 9 months postintervention.","['community-based settings, connecting community members with a partnering federally qualified health center', 'among Latino adults', 'Latinos', '177 participants included, 118 reported completing the CRC screening test (66.7%) by 6 to 9 months postintervention', 'Workshop participants were Latino adults (males and females) aged 50 to 75 years who were not up-to-date with CRC screening guidelines']","['CRC screening test adherence', 'culturally tailored 2½-hour interactive workshop followed by an appointment scheduling assistance from a promotor']","['CRC screening', 'CRC knowledge', 'colorectal cancer (CRC) screening rates']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C4517843', 'cui_str': '66.7 (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0011008', 'cui_str': 'Dates'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}]","[{'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C1446911', 'cui_str': 'Scheduling'}]","[{'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}]",177.0,0.0135493,"Of the 177 participants included, 118 reported completing the CRC screening test (66.7%) by 6 to 9 months postintervention.","[{'ForeName': 'Elva M', 'Initials': 'EM', 'LastName': 'Arredondo', 'Affiliation': 'San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Dumbauld', 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Milla', 'Affiliation': 'San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Hala', 'Initials': 'H', 'LastName': 'Madanat', 'Affiliation': 'San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Gloria D', 'Initials': 'GD', 'LastName': 'Coronado', 'Affiliation': 'Kaiser Permanente Center for Health Research, Portland, OR, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Haughton', 'Affiliation': 'San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Garcia-Bigley', 'Affiliation': 'Family Health Centers of San Diego, San Diego, CA, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ramers', 'Affiliation': 'Family Health Centers of San Diego, San Diego, CA, USA.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Nodora', 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Balambal', 'Initials': 'B', 'LastName': 'Bharti', 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Lopez', 'Affiliation': 'Family Health Centers of San Diego, San Diego, CA, USA.'}, {'ForeName': 'Mirna', 'Initials': 'M', 'LastName': 'Diaz', 'Affiliation': 'Family Health Centers of San Diego, San Diego, CA, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Marquez', 'Affiliation': 'Family Health Centers of San Diego, San Diego, CA, USA.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Gupta', 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}]",Health promotion practice,['10.1177/1524839920912240'] 3515,34351721,Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.,"BACKGROUND Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19. METHODS In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level. RESULTS The trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis. CONCLUSIONS In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT02735707, and NCT04359277.).",2021,"Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis. ","['noncritically ill patients with Covid-19', 'patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either', '2219 patients', 'patients with coronavirus disease 2019 (Covid-19', 'Noncritically Ill Patients with Covid-19', 'noncritically ill patients who are hospitalized with Covid-19']","['Heparin', 'therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis', 'heparin']","['probability that therapeutic-dose anticoagulation increased organ support-free days', 'probability of survival to hospital discharge', 'organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support', 'survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation', 'Major bleeding']","[{'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",2219.0,0.0773447,"Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis. ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Patrick R', 'Initials': 'PR', 'LastName': 'Lawler', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Ewan C', 'Initials': 'EC', 'LastName': 'Goligher', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Berger', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Neal', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Bryan J', 'Initials': 'BJ', 'LastName': 'McVerry', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jose C', 'Initials': 'JC', 'LastName': 'Nicolau', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Michelle N', 'Initials': 'MN', 'LastName': 'Gong', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Carrier', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Rosenson', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Harmony R', 'Initials': 'HR', 'LastName': 'Reynolds', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Alexis F', 'Initials': 'AF', 'LastName': 'Turgeon', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Escobedo', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Huang', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Charlotte A', 'Initials': 'CA', 'LastName': 'Bradbury', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Brett L', 'Initials': 'BL', 'LastName': 'Houston', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lucy Z', 'Initials': 'LZ', 'LastName': 'Kornblith', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Kahn', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Cushman', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'McQuilten', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Arthur S', 'Initials': 'AS', 'LastName': 'Slutsky', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Keri S', 'Initials': 'KS', 'LastName': 'Kim', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Anthony C', 'Initials': 'AC', 'LastName': 'Gordon', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Bridget-Anne', 'Initials': 'BA', 'LastName': 'Kirwan', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Maria M', 'Initials': 'MM', 'LastName': 'Brooks', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Alisa M', 'Initials': 'AM', 'LastName': 'Higgins', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Roger J', 'Initials': 'RJ', 'LastName': 'Lewis', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Lorenzi', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Berry', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lindsay R', 'Initials': 'LR', 'LastName': 'Berry', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Aaron W', 'Initials': 'AW', 'LastName': 'Aday', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Al-Beidh', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Djillali', 'Initials': 'D', 'LastName': 'Annane', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Yaseen M', 'Initials': 'YM', 'LastName': 'Arabi', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Diptesh', 'Initials': 'D', 'LastName': 'Aryal', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Baumann Kreuziger', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Abi', 'Initials': 'A', 'LastName': 'Beane', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Bhimani', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Shailesh', 'Initials': 'S', 'LastName': 'Bihari', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Henny H', 'Initials': 'HH', 'LastName': 'Billett', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Bond', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Bonten', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Brunkhorst', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Buxton', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Buzgau', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lana A', 'Initials': 'LA', 'LastName': 'Castellucci', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Sweta', 'Initials': 'S', 'LastName': 'Chekuri', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jen-Ting', 'Initials': 'JT', 'LastName': 'Chen', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Allen C', 'Initials': 'AC', 'LastName': 'Cheng', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Tamta', 'Initials': 'T', 'LastName': 'Chkhikvadze', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Coiffard', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Todd W', 'Initials': 'TW', 'LastName': 'Costantini', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'de Brouwer', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lennie P G', 'Initials': 'LPG', 'LastName': 'Derde', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Michelle A', 'Initials': 'MA', 'LastName': 'Detry', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Abhijit', 'Initials': 'A', 'LastName': 'Duggal', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Vladimír', 'Initials': 'V', 'LastName': 'Džavík', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Mark B', 'Initials': 'MB', 'LastName': 'Effron', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lise J', 'Initials': 'LJ', 'LastName': 'Estcourt', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Brendan M', 'Initials': 'BM', 'LastName': 'Everett', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Dean A', 'Initials': 'DA', 'LastName': 'Fergusson', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Fitzgerald', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Fowler', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jean P', 'Initials': 'JP', 'LastName': 'Galanaud', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Benjamin T', 'Initials': 'BT', 'LastName': 'Galen', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Sheetal', 'Initials': 'S', 'LastName': 'Gandotra', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'García-Madrona', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Girard', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lucas C', 'Initials': 'LC', 'LastName': 'Godoy', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Andrew L', 'Initials': 'AL', 'LastName': 'Goodman', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Herman', 'Initials': 'H', 'LastName': 'Goossens', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Cameron', 'Initials': 'C', 'LastName': 'Green', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Yonatan Y', 'Initials': 'YY', 'LastName': 'Greenstein', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Gross', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Naomi M', 'Initials': 'NM', 'LastName': 'Hamburg', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Rashan', 'Initials': 'R', 'LastName': 'Haniffa', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Hanna', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Hanna', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Sheila M', 'Initials': 'SM', 'LastName': 'Hegde', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Carolyn M', 'Initials': 'CM', 'LastName': 'Hendrickson', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'R Duncan', 'Initials': 'RD', 'LastName': 'Hite', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Alexander A', 'Initials': 'AA', 'LastName': 'Hindenburg', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Aluko A', 'Initials': 'AA', 'LastName': 'Hope', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Horowitz', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Horvat', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Hudock', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Beverley J', 'Initials': 'BJ', 'LastName': 'Hunt', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Mansoor', 'Initials': 'M', 'LastName': 'Husain', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Hyzy', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Vivek N', 'Initials': 'VN', 'LastName': 'Iyer', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Jacobson', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Devachandran', 'Initials': 'D', 'LastName': 'Jayakumar', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Norma M', 'Initials': 'NM', 'LastName': 'Keller', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Akram', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Yuri', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Andrei L', 'Initials': 'AL', 'LastName': 'Kindzelski', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'King', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'M Margaret', 'Initials': 'MM', 'LastName': 'Knudson', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Aaron E', 'Initials': 'AE', 'LastName': 'Kornblith', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Vidya', 'Initials': 'V', 'LastName': 'Krishnan', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Matthew E', 'Initials': 'ME', 'LastName': 'Kutcher', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Laffan', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Lamontagne', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Grégoire', 'Initials': 'G', 'LastName': 'Le Gal', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Leeper', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Eric S', 'Initials': 'ES', 'LastName': 'Leifer', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Lim', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Felipe Gallego', 'Initials': 'FG', 'LastName': 'Lima', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Linstrum', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Litton', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lopez-Sendon', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jose L', 'Initials': 'JL', 'LastName': 'Lopez-Sendon Moreno', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Saurabh', 'Initials': 'S', 'LastName': 'Malhotra', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Marcos', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Andréa', 'Initials': 'A', 'LastName': 'Saud Marinez', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Marshall', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marten', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Matthay', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'McAuley', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'McGlothlin', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Shay P', 'Initials': 'SP', 'LastName': 'McGuinness', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Middeldorp', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Stephanie K', 'Initials': 'SK', 'LastName': 'Montgomery', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Steven C', 'Initials': 'SC', 'LastName': 'Moore', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Morillo Guerrero', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Paul R', 'Initials': 'PR', 'LastName': 'Mouncey', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Srinivas', 'Initials': 'S', 'LastName': 'Murthy', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Girish B', 'Initials': 'GB', 'LastName': 'Nair', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Nair', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Alistair D', 'Initials': 'AD', 'LastName': 'Nichol', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Nunez-Garcia', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Ambarish', 'Initials': 'A', 'LastName': 'Pandey', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Pauline K', 'Initials': 'PK', 'LastName': 'Park', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Rachael L', 'Initials': 'RL', 'LastName': 'Parke', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jane C', 'Initials': 'JC', 'LastName': 'Parker', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Parnia', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Paul', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Yessica S', 'Initials': 'YS', 'LastName': 'Pérez González', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Mauricio', 'Initials': 'M', 'LastName': 'Pompilio', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Matthew E', 'Initials': 'ME', 'LastName': 'Prekker', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Quigley', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Natalia S', 'Initials': 'NS', 'LastName': 'Rost', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Rowan', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Fernanda O', 'Initials': 'FO', 'LastName': 'Santos', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Marlene', 'Initials': 'M', 'LastName': 'Santos', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Mayler', 'Initials': 'M', 'LastName': 'Olombrada Santos', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lewis', 'Initials': 'L', 'LastName': 'Satterwhite', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Christina T', 'Initials': 'CT', 'LastName': 'Saunders', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Roger E G', 'Initials': 'REG', 'LastName': 'Schutgens', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Christopher W', 'Initials': 'CW', 'LastName': 'Seymour', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Deborah M', 'Initials': 'DM', 'LastName': 'Siegal', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Delcio G', 'Initials': 'DG', 'LastName': 'Silva', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Manu', 'Initials': 'M', 'LastName': 'Shankar-Hari', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Sheehan', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Aneesh B', 'Initials': 'AB', 'LastName': 'Singhal', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Dayna', 'Initials': 'D', 'LastName': 'Solvason', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Stanworth', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Tritschler', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Turner', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Wilma', 'Initials': 'W', 'LastName': 'van Bentum-Puijk', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Frank L', 'Initials': 'FL', 'LastName': 'van de Veerdonk', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'van Diepen', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Vazquez-Grande', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Lana', 'Initials': 'L', 'LastName': 'Wahid', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Wareham', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Bryan J', 'Initials': 'BJ', 'LastName': 'Wells', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'R Jay', 'Initials': 'RJ', 'LastName': 'Widmer', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Jennifer G', 'Initials': 'JG', 'LastName': 'Wilson', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Yuriditsky', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Fernando G', 'Initials': 'FG', 'LastName': 'Zampieri', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Derek C', 'Initials': 'DC', 'LastName': 'Angus', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Colin J', 'Initials': 'CJ', 'LastName': 'McArthur', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Webb', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Farkouh', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Hochman', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': ""From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michael's Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, Université Laval (A.F.T.) and CHU de Québec-Université Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, Université de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) - all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) - all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Children's Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) - all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa Clínica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do Coração de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital Universitário Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, Goiânia (M.O.S.) - all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Mary's Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guy's and St. Thomas' NHS Foundation Trust (M.S.-H.), and King's College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queen's University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) - all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), Harbor-UCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) - all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) - all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) - all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern - all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) - all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) - all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) - both in Nashville; Fédération Hospitalo Universitaire, Raymond Poincaré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) - both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) - both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care Surveillance-Mahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) - both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) - both in Cleveland; Ochsner Medical Center, University of Queensland-Ochsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Women's Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) - all in Boston; University of Alabama, Birmingham (S.G.); Hospital Ramón y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of Salamanca-University of Salamanca-IBSAL, Salamanca (M.M.) - all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) - all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) - both in Minnesota; Apollo Speciality Hospital-OMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).""}]",The New England journal of medicine,['10.1056/NEJMoa2105911'] 3516,34351693,"Efficacy and safety of intralesional tuberculin purified protein derivative versus cryotherapy in the treatment of warts: An assessor-blinded, randomized controlled trial.","Cryotherapy is a standard treatment for warts. Tuberculin immunotherapy is a novel therapeutic option. We compared the efficacy and safety of cryotherapy versus tuberculin immunotherapy in a randomized, assessor-blinded study. 15 patients were treated with intralesional tuberculin and 15 patients received cryotherapy every 2 weeks until complete wart resolution or a maximum of six sessions. Wart diameter, total number of warts and adverse effects were documented. Complete clearance of treated warts was achieved in 13(86.7%) and 11(73.3%) of patients with immunotherapy and cryotherapy respectively. Immunotherapy showed greater wart size reduction (51.88 ± 89.36 mm) than cryotherapy (32.99 ± 36.19 mm), (p = 0.46). Immunotherapy resulted in 64% reduction in total number of warts compared to 23.2% with cryotherapy, p < 0.01. More blisters developed with cryotherapy (46.7%) than immunotherapy (6.7%), (p = 0.01). Compartment syndrome-like features complicate immunotherapy in 1 patient. Tuberculin immunotherapy and cryotherapy are equally effective in treating warts. Immunotherapy has added benefit with resolution of distant warts. Safety profiles were similar except for blisters which were more common with cryotherapy.",2021,"Immunotherapy showed greater wart size reduction (51.88±89.36mm) than cryotherapy (32.99±36.19mm), (p= 0.46).","['warts', 'Fifteen patients were treated with']","['cryotherapy', 'Tuberculin immunotherapy and cryotherapy', 'Cryotherapy', 'intralesional tuberculin purified protein derivative versus cryotherapy', 'Tuberculin immunotherapy', 'Immunotherapy', 'intralesional tuberculin', 'cryotherapy versus tuberculin immunotherapy']","['Wart diameter, total number of warts and adverse effects', 'efficacy and safety', 'Efficacy and safety', 'total number of warts', 'greater wart size reduction', 'Complete clearance of treated warts']","[{'cui': 'C0043037', 'cui_str': 'Verruca'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C0041289', 'cui_str': 'Tuberculin'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C1512955', 'cui_str': 'Intralesional route'}, {'cui': 'C0034131', 'cui_str': 'Purified Protein Derivative of Tuberculin'}]","[{'cui': 'C0043037', 'cui_str': 'Verruca'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0445137', 'cui_str': 'Number of warts'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0445306', 'cui_str': 'Wart size'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]",15.0,0.0339845,"Immunotherapy showed greater wart size reduction (51.88±89.36mm) than cryotherapy (32.99±36.19mm), (p= 0.46).","[{'ForeName': 'Wan Syazween Lyana', 'Initials': 'WSL', 'LastName': 'Wan Ahmad Kammal', 'Affiliation': 'Dermatology Unit, Internal Medicine Department, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang, Malaysia.'}, {'ForeName': 'Adawiyah', 'Initials': 'A', 'LastName': 'Jamil', 'Affiliation': 'Dermatology Unit, Department of Medicine, Universiti Kebangsaan Malaysia (UKM) Medical Centre, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Norazirah', 'Initials': 'N', 'LastName': 'Md Nor', 'Affiliation': 'Dermatology Unit, Department of Medicine, Universiti Kebangsaan Malaysia (UKM) Medical Centre, Kuala Lumpur, Malaysia.'}]",Dermatologic therapy,['10.1111/dth.15080']